cancer_type	qtl_type	tag_SNP	LD	SNP_id	gene_id	gene_symbol	t-stat	p-value	FDR	beta	r	Traits	SNP_position	Gene_position
PRAD	cis	rs2882667	0.69	rs851278	ENSG00000253404.1	AC034243.1	-36.12	9.89e-136	3.21e-129	-1.19	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138767577	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.654	rs700617	ENSG00000253404.1	AC034243.1	-36.12	1e-135	3.21e-129	-1.19	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138752290	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs700618	ENSG00000253404.1	AC034243.1	-36.12	1e-135	3.21e-129	-1.19	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138752429	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs700625	ENSG00000253404.1	AC034243.1	-36.12	1e-135	3.21e-129	-1.19	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138763908	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.654	rs2940595	ENSG00000253404.1	AC034243.1	-36.12	1e-135	3.21e-129	-1.19	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138765348	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.589	rs825770	ENSG00000253404.1	AC034243.1	-36.12	1e-135	3.21e-129	-1.19	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138779530	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs825769	ENSG00000253404.1	AC034243.1	-36.12	1e-135	3.21e-129	-1.19	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138779666	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs700627	ENSG00000253404.1	AC034243.1	-36.12	1e-135	3.21e-129	-1.19	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138783711	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs825758	ENSG00000253404.1	AC034243.1	-36.12	1e-135	3.21e-129	-1.19	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138791288	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs10038162	ENSG00000253404.1	AC034243.1	-36.08	1.4e-135	4.12e-129	-1.18	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138901066	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs6860780	ENSG00000253404.1	AC034243.1	-35.99	3.33e-135	7.5e-129	-1.19	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138824367	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs6884198	ENSG00000253404.1	AC034243.1	-35.99	3.33e-135	7.5e-129	-1.19	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138828618	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs4835706	ENSG00000253404.1	AC034243.1	-35.99	3.33e-135	7.5e-129	-1.19	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138829037	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs1039788	ENSG00000253404.1	AC034243.1	-35.89	8.66e-135	1.75e-128	-1.18	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138835812	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs1828188	ENSG00000253404.1	AC034243.1	-35.89	8.66e-135	1.75e-128	-1.18	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138836307	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs825754	ENSG00000253404.1	AC034243.1	-35.88	9.13e-135	1.75e-128	-1.19	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138796200	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs1627698	ENSG00000253404.1	AC034243.1	-35.73	4e-134	6.66e-128	-1.18	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138741777	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.654	rs160406	ENSG00000253404.1	AC034243.1	-35.73	4e-134	6.66e-128	-1.18	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748032	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs4835707	ENSG00000253404.1	AC034243.1	-35.65	8.47e-134	1.05e-127	-1.18	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138838831	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs12656942	ENSG00000253404.1	AC034243.1	-35.65	8.47e-134	1.05e-127	-1.18	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138840769	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.686	rs62381196	ENSG00000253404.1	AC034243.1	-35.65	8.47e-134	1.05e-127	-1.18	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138841000	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs1976568	ENSG00000253404.1	AC034243.1	-35.65	8.47e-134	1.05e-127	-1.18	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844627	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs6880786	ENSG00000253404.1	AC034243.1	-35.65	8.47e-134	1.05e-127	-1.18	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138845874	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs9327826	ENSG00000253404.1	AC034243.1	-35.65	8.47e-134	1.05e-127	-1.18	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846318	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.654	rs1972072	ENSG00000253404.1	AC034243.1	-35.65	8.47e-134	1.05e-127	-1.18	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138849604	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs700616	ENSG00000253404.1	AC034243.1	-35.61	1.25e-133	1.49e-127	-1.18	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138752184	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.587	rs288015	ENSG00000253404.1	AC034243.1	-35.59	1.44e-133	1.62e-127	-1.18	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138859528	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs288025	ENSG00000253404.1	AC034243.1	35.59	1.44e-133	1.62e-127	1.18	0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138887944	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs495638	ENSG00000253404.1	AC034243.1	-35.51	2.99e-133	3.01e-127	-1.18	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138865253	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs288042	ENSG00000253404.1	AC034243.1	35.51	2.99e-133	3.01e-127	1.18	0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138867345	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs288030	ENSG00000253404.1	AC034243.1	35.51	2.99e-133	3.01e-127	1.18	0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138880594	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs160405	ENSG00000253404.1	AC034243.1	35.51	3.07e-133	3.02e-127	1.17	0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748387	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs700624	ENSG00000253404.1	AC034243.1	-35.42	7.07e-133	6.01e-127	-1.17	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138763332	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.587	rs2174972	ENSG00000253404.1	AC034243.1	-35.42	7.07e-133	6.01e-127	-1.17	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138766229	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs2693963	ENSG00000253404.1	AC034243.1	-35.42	7.07e-133	6.01e-127	-1.17	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138770637	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs1567313	ENSG00000253404.1	AC034243.1	-35.42	7.07e-133	6.01e-127	-1.17	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138775013	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs17207772	ENSG00000253404.1	AC034243.1	35.41	8.07e-133	6.72e-127	1.19	0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138906131	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs2662543	ENSG00000253404.1	AC034243.1	35.31	1.94e-132	1.58e-126	1.19	0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138898441	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs4835705	ENSG00000253404.1	AC034243.1	-35.29	2.36e-132	1.88e-126	-1.17	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138827887	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs288016	ENSG00000253404.1	AC034243.1	-35.29	2.53e-132	1.97e-126	-1.18	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138859299	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs6421921	ENSG00000253404.1	AC034243.1	-35.18	6.7e-132	4.93e-126	-1.17	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138831581	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs1039789	ENSG00000253404.1	AC034243.1	-35.18	6.7e-132	4.93e-126	-1.17	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138835734	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.591	rs56322405	ENSG00000253404.1	AC034243.1	-35.18	6.7e-132	4.93e-126	-1.17	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138837693	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.621	rs55901834	ENSG00000253404.1	AC034243.1	-35.17	7.54e-132	5.35e-126	-1.17	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844094	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs1828187	ENSG00000253404.1	AC034243.1	34.99	4.37e-131	2.99e-125	1.16	0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138836531	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs6887841	ENSG00000253404.1	AC034243.1	-34.95	6.1e-131	3.83e-125	-1.17	-0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138840221	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.72	rs56044552	ENSG00000253404.1	AC034243.1	-34.95	6.1e-131	3.83e-125	-1.17	-0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138841265	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs7710288	ENSG00000253404.1	AC034243.1	-34.95	6.1e-131	3.83e-125	-1.17	-0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844049	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.654	rs6863054	ENSG00000253404.1	AC034243.1	-34.95	6.1e-131	3.83e-125	-1.17	-0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138853166	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs288013	ENSG00000253404.1	AC034243.1	-34.92	8.42e-131	4.67e-125	-1.17	-0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860128	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs176381	ENSG00000253404.1	AC034243.1	-34.92	8.42e-131	4.67e-125	-1.17	-0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138861042	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs288011	ENSG00000253404.1	AC034243.1	-34.92	8.42e-131	4.67e-125	-1.17	-0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138864250	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs288010	ENSG00000253404.1	AC034243.1	-34.92	8.42e-131	4.67e-125	-1.17	-0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138864340	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs288041	ENSG00000253404.1	AC034243.1	34.92	8.42e-131	4.67e-125	1.17	0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138868322	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs288039	ENSG00000253404.1	AC034243.1	34.92	8.42e-131	4.67e-125	1.17	0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138870511	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs288038	ENSG00000253404.1	AC034243.1	34.92	8.42e-131	4.67e-125	1.17	0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138871844	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.654	rs288019	ENSG00000253404.1	AC034243.1	-34.87	1.3e-130	7.03e-125	-1.17	-0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138855704	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.654	rs1703211	ENSG00000253404.1	AC034243.1	-34.84	1.73e-130	9.19e-125	-1.17	-0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138740587	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs288031	ENSG00000253404.1	AC034243.1	34.81	2.26e-130	1.17e-124	1.17	0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138880377	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs288023	ENSG00000253404.1	AC034243.1	34.81	2.26e-130	1.17e-124	1.17	0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888359	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs10043478	ENSG00000253404.1	AC034243.1	34.68	7.96e-130	4.07e-124	1.16	0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138853022	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs13172507	ENSG00000253404.1	AC034243.1	34.52	3.8e-129	1.89e-123	1.17	0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138907409	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs1725335	ENSG00000253404.1	AC034243.1	-34.51	3.94e-129	1.94e-123	-1.18	-0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138745541	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs825669	ENSG00000253404.1	AC034243.1	-34.46	6.48e-129	3.14e-123	-1.16	-0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138731258	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.599	rs288008	ENSG00000253404.1	AC034243.1	34.43	8.56e-129	4e-123	1.17	0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138893632	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs288004	ENSG00000253404.1	AC034243.1	34.43	8.56e-129	4e-123	1.17	0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138895956	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs176382	ENSG00000253404.1	AC034243.1	34.3	2.99e-128	1.38e-122	1.16	0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138891078	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs6872423	ENSG00000253404.1	AC034243.1	34.14	1.34e-127	5.96e-122	1.18	0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138911089	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs6873425	ENSG00000253404.1	AC034243.1	-33.94	9.9e-127	4.36e-121	-1.17	-0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138819556	chr5:138744434~138753309:-
PRAD	cis	rs9322193	0.962	rs12175575	ENSG00000231760.4	RP11-350J20.5	33.84	2.41e-126	8.18e-121	1.15	0.85	Lung cancer;	chr6:149763351	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.962	rs4869966	ENSG00000231760.4	RP11-350J20.5	33.84	2.41e-126	8.18e-121	1.15	0.85	Lung cancer;	chr6:149763714	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.962	rs1112730	ENSG00000231760.4	RP11-350J20.5	33.84	2.41e-126	8.18e-121	1.15	0.85	Lung cancer;	chr6:149766383	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs1112729	ENSG00000231760.4	RP11-350J20.5	33.84	2.41e-126	8.18e-121	1.15	0.85	Lung cancer;	chr6:149766491	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.962	rs10452626	ENSG00000231760.4	RP11-350J20.5	33.84	2.41e-126	8.18e-121	1.15	0.85	Lung cancer;	chr6:149767481	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs62441303	ENSG00000231760.4	RP11-350J20.5	33.84	2.41e-126	8.18e-121	1.15	0.85	Lung cancer;	chr6:149767547	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.962	rs9765929	ENSG00000231760.4	RP11-350J20.5	33.84	2.41e-126	8.18e-121	1.15	0.85	Lung cancer;	chr6:149769680	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.962	rs3805748	ENSG00000231760.4	RP11-350J20.5	33.84	2.41e-126	8.18e-121	1.15	0.85	Lung cancer;	chr6:149772542	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.736	rs10457851	ENSG00000231760.4	RP11-350J20.5	33.84	2.41e-126	8.18e-121	1.15	0.85	Lung cancer;	chr6:149775216	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.886	rs10872652	ENSG00000231760.4	RP11-350J20.5	33.84	2.41e-126	8.18e-121	1.15	0.85	Lung cancer;	chr6:149775303	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.886	rs12525871	ENSG00000231760.4	RP11-350J20.5	33.84	2.41e-126	8.18e-121	1.15	0.85	Lung cancer;	chr6:149775882	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.886	rs17672976	ENSG00000231760.4	RP11-350J20.5	33.84	2.41e-126	8.18e-121	1.15	0.85	Lung cancer;	chr6:149776207	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs2184369	ENSG00000231760.4	RP11-350J20.5	33.84	2.41e-126	8.18e-121	1.15	0.85	Lung cancer;	chr6:149776681	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.962	rs2342861	ENSG00000231760.4	RP11-350J20.5	33.84	2.41e-126	8.18e-121	1.15	0.85	Lung cancer;	chr6:149777561	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.926	rs2342860	ENSG00000231760.4	RP11-350J20.5	33.84	2.41e-126	8.18e-121	1.15	0.85	Lung cancer;	chr6:149777641	chr6:149796151~149826294:-
PRAD	cis	rs2882667	0.722	rs825751	ENSG00000253404.1	AC034243.1	-33.83	2.79e-126	9.38e-121	-1.17	-0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138798180	chr5:138744434~138753309:-
PRAD	cis	rs9322193	0.962	rs4869730	ENSG00000231760.4	RP11-350J20.5	33.82	2.92e-126	9.65e-121	1.15	0.85	Lung cancer;	chr6:149808187	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs2151913	ENSG00000231760.4	RP11-350J20.5	33.82	2.92e-126	9.65e-121	1.15	0.85	Lung cancer;	chr6:149809506	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.962	rs7818	ENSG00000231760.4	RP11-350J20.5	33.75	5.72e-126	1.87e-120	1.14	0.85	Lung cancer;	chr6:149810956	chr6:149796151~149826294:-
PRAD	cis	rs2882667	0.69	rs160399	ENSG00000253404.1	AC034243.1	33.71	8.8e-126	2.83e-120	1.14	0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727552	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs13181762	ENSG00000253404.1	AC034243.1	33.67	1.23e-125	3.39e-120	1.16	0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138914417	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs825748	ENSG00000253404.1	AC034243.1	-33.67	1.23e-125	3.39e-120	-1.18	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800378	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs825746	ENSG00000253404.1	AC034243.1	-33.67	1.23e-125	3.39e-120	-1.18	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800930	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs825762	ENSG00000253404.1	AC034243.1	-33.67	1.23e-125	3.39e-120	-1.18	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138801981	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs825761	ENSG00000253404.1	AC034243.1	-33.67	1.23e-125	3.39e-120	-1.18	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138802318	chr5:138744434~138753309:-
PRAD	cis	rs9322193	0.962	rs10872653	ENSG00000231760.4	RP11-350J20.5	33.67	1.27e-125	3.39e-120	1.14	0.84	Lung cancer;	chr6:149778907	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs11155683	ENSG00000231760.4	RP11-350J20.5	33.67	1.27e-125	3.39e-120	1.14	0.84	Lung cancer;	chr6:149779341	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs9372044	ENSG00000231760.4	RP11-350J20.5	33.67	1.27e-125	3.39e-120	1.14	0.84	Lung cancer;	chr6:149780867	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.962	rs11155685	ENSG00000231760.4	RP11-350J20.5	33.67	1.27e-125	3.39e-120	1.14	0.84	Lung cancer;	chr6:149781649	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.962	rs9689269	ENSG00000231760.4	RP11-350J20.5	33.67	1.27e-125	3.39e-120	1.14	0.84	Lung cancer;	chr6:149791861	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.962	rs62441335	ENSG00000231760.4	RP11-350J20.5	33.67	1.27e-125	3.39e-120	1.14	0.84	Lung cancer;	chr6:149792658	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.962	rs4816	ENSG00000231760.4	RP11-350J20.5	33.67	1.27e-125	3.39e-120	1.14	0.84	Lung cancer;	chr6:149793609	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.926	rs952166	ENSG00000231760.4	RP11-350J20.5	33.67	1.27e-125	3.39e-120	1.14	0.84	Lung cancer;	chr6:149798774	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.962	rs952165	ENSG00000231760.4	RP11-350J20.5	33.67	1.27e-125	3.39e-120	1.14	0.84	Lung cancer;	chr6:149798900	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.926	rs9285525	ENSG00000231760.4	RP11-350J20.5	33.67	1.27e-125	3.39e-120	1.14	0.84	Lung cancer;	chr6:149801253	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.962	rs6914319	ENSG00000231760.4	RP11-350J20.5	33.67	1.27e-125	3.39e-120	1.14	0.84	Lung cancer;	chr6:149806304	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.884	rs2095375	ENSG00000231760.4	RP11-350J20.5	33.67	1.27e-125	3.39e-120	1.14	0.84	Lung cancer;	chr6:149807037	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.962	rs3805753	ENSG00000231760.4	RP11-350J20.5	33.65	1.5e-125	3.98e-120	1.14	0.84	Lung cancer;	chr6:149795662	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.884	rs11155689	ENSG00000231760.4	RP11-350J20.5	33.64	1.79e-125	4.58e-120	1.15	0.84	Lung cancer;	chr6:149808470	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs2342857	ENSG00000231760.4	RP11-350J20.5	33.64	1.79e-125	4.58e-120	1.15	0.84	Lung cancer;	chr6:149809537	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.884	rs933055	ENSG00000231760.4	RP11-350J20.5	33.64	1.79e-125	4.58e-120	1.15	0.84	Lung cancer;	chr6:149809701	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.962	rs4869731	ENSG00000231760.4	RP11-350J20.5	33.64	1.79e-125	4.58e-120	1.15	0.84	Lung cancer;	chr6:149810072	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs9479810	ENSG00000231760.4	RP11-350J20.5	33.61	2.38e-125	6e-120	1.14	0.84	Lung cancer;	chr6:149751359	chr6:149796151~149826294:-
PRAD	cis	rs2882667	0.654	rs12517514	ENSG00000253404.1	AC034243.1	-33.56	3.82e-125	9.56e-120	-1.17	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138814430	chr5:138744434~138753309:-
PRAD	cis	rs9322193	0.962	rs4552	ENSG00000231760.4	RP11-350J20.5	33.49	7.42e-125	1.85e-119	1.15	0.84	Lung cancer;	chr6:149811183	chr6:149796151~149826294:-
PRAD	cis	rs2882667	0.722	rs4835649	ENSG00000253404.1	AC034243.1	-33.47	8.86e-125	2.16e-119	-1.17	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138810534	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs13177415	ENSG00000253404.1	AC034243.1	33.4	1.74e-124	4.21e-119	1.16	0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138914251	chr5:138744434~138753309:-
PRAD	cis	rs9322193	0.962	rs6899661	ENSG00000231760.4	RP11-350J20.5	33.39	1.83e-124	4.42e-119	1.14	0.84	Lung cancer;	chr6:149818093	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.884	rs2342858	ENSG00000231760.4	RP11-350J20.5	33.39	1.85e-124	4.42e-119	1.14	0.84	Lung cancer;	chr6:149805967	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs12211511	ENSG00000231760.4	RP11-350J20.5	33.37	2.39e-124	5.69e-119	1.14	0.84	Lung cancer;	chr6:149745206	chr6:149796151~149826294:-
PRAD	cis	rs2882667	0.69	rs13178601	ENSG00000253404.1	AC034243.1	33.36	2.68e-124	6.23e-119	1.16	0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138931688	chr5:138744434~138753309:-
PRAD	cis	rs9322193	0.962	rs9322220	ENSG00000231760.4	RP11-350J20.5	33.31	4.13e-124	8.84e-119	1.15	0.84	Lung cancer;	chr6:149782897	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.962	rs10214845	ENSG00000231760.4	RP11-350J20.5	33.31	4.13e-124	8.84e-119	1.15	0.84	Lung cancer;	chr6:149783124	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.962	rs9767122	ENSG00000231760.4	RP11-350J20.5	33.31	4.13e-124	8.84e-119	1.15	0.84	Lung cancer;	chr6:149783553	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs1413654	ENSG00000231760.4	RP11-350J20.5	33.31	4.13e-124	8.84e-119	1.15	0.84	Lung cancer;	chr6:149783956	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.683	rs113281309	ENSG00000231760.4	RP11-350J20.5	33.31	4.13e-124	8.84e-119	1.15	0.84	Lung cancer;	chr6:149787289	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.962	rs9688809	ENSG00000231760.4	RP11-350J20.5	33.31	4.13e-124	8.84e-119	1.15	0.84	Lung cancer;	chr6:149787920	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.962	rs9689242	ENSG00000231760.4	RP11-350J20.5	33.31	4.13e-124	8.84e-119	1.15	0.84	Lung cancer;	chr6:149787970	chr6:149796151~149826294:-
PRAD	cis	rs9322193	1	rs9767077	ENSG00000231760.4	RP11-350J20.5	33.31	4.13e-124	8.84e-119	1.15	0.84	Lung cancer;	chr6:149788479	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs9688938	ENSG00000231760.4	RP11-350J20.5	33.31	4.13e-124	8.84e-119	1.15	0.84	Lung cancer;	chr6:149788941	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.962	rs9688940	ENSG00000231760.4	RP11-350J20.5	33.31	4.13e-124	8.84e-119	1.15	0.84	Lung cancer;	chr6:149788977	chr6:149796151~149826294:-
PRAD	cis	rs2882667	0.69	rs7714455	ENSG00000253404.1	AC034243.1	-33.31	4.37e-124	9.3e-119	-1.17	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138818281	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs2351463	ENSG00000253404.1	AC034243.1	33.3	4.65e-124	9.79e-119	1.15	0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138923113	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.654	rs884470	ENSG00000253404.1	AC034243.1	-33.27	6.06e-124	1.26e-118	-1.16	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138820236	chr5:138744434~138753309:-
PRAD	cis	rs9322193	0.926	rs3805751	ENSG00000231760.4	RP11-350J20.5	33.25	7.48e-124	1.53e-118	1.14	0.84	Lung cancer;	chr6:149791193	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.962	rs10872656	ENSG00000231760.4	RP11-350J20.5	33.25	7.48e-124	1.53e-118	1.14	0.84	Lung cancer;	chr6:149799444	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs10872645	ENSG00000231760.4	RP11-350J20.5	33.23	9.18e-124	1.87e-118	1.14	0.84	Lung cancer;	chr6:149742840	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.632	rs3828700	ENSG00000231760.4	RP11-350J20.5	33.19	1.4e-123	2.81e-118	1.15	0.84	Lung cancer;	chr6:149791033	chr6:149796151~149826294:-
PRAD	cis	rs2882667	0.62	rs3789151	ENSG00000253404.1	AC034243.1	-33.18	1.52e-123	3.03e-118	-1.16	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138809771	chr5:138744434~138753309:-
PRAD	cis	rs9322193	0.962	rs9689447	ENSG00000231760.4	RP11-350J20.5	33.14	2.07e-123	4.11e-118	1.14	0.84	Lung cancer;	chr6:149789350	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.962	rs9688412	ENSG00000231760.4	RP11-350J20.5	-33.08	3.84e-123	7.5e-118	-1.13	-0.84	Lung cancer;	chr6:149803147	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.926	rs9766562	ENSG00000231760.4	RP11-350J20.5	33.03	6.23e-123	1.19e-117	1.15	0.84	Lung cancer;	chr6:149788709	chr6:149796151~149826294:-
PRAD	cis	rs2882667	0.628	rs3749663	ENSG00000253404.1	AC034243.1	33.02	6.76e-123	1.28e-117	1.15	0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935498	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs3749664	ENSG00000253404.1	AC034243.1	33.02	6.76e-123	1.28e-117	1.15	0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935732	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs160398	ENSG00000253404.1	AC034243.1	32.96	1.25e-122	2.3e-117	1.17	0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727750	chr5:138744434~138753309:-
PRAD	cis	rs9322193	0.923	rs14314	ENSG00000231760.4	RP11-350J20.5	32.96	1.28e-122	2.35e-117	1.13	0.84	Lung cancer;	chr6:149820395	chr6:149796151~149826294:-
PRAD	cis	rs2739330	0.929	rs5751777	ENSG00000273295.1	AP000350.5	32.95	1.39e-122	2.54e-117	1.02	0.84	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23901432~23907068:-
PRAD	cis	rs2882667	0.587	rs6596450	ENSG00000253404.1	AC034243.1	-32.84	4.06e-122	7.23e-117	-1.16	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138810831	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.658	rs311592	ENSG00000253404.1	AC034243.1	32.84	4.14e-122	7.32e-117	1.17	0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138734506	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs891996	ENSG00000253404.1	AC034243.1	32.83	4.51e-122	7.92e-117	1.14	0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138932127	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs160402	ENSG00000253404.1	AC034243.1	32.78	6.9e-122	1.2e-116	1.17	0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138723599	chr5:138744434~138753309:-
PRAD	cis	rs9322193	0.962	rs2151912	ENSG00000231760.4	RP11-350J20.5	32.73	1.14e-121	1.94e-116	1.13	0.84	Lung cancer;	chr6:149831772	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.962	rs2065664	ENSG00000231760.4	RP11-350J20.5	32.66	2.29e-121	3.86e-116	1.12	0.84	Lung cancer;	chr6:149762485	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.926	rs9383546	ENSG00000231760.4	RP11-350J20.5	32.66	2.39e-121	3.97e-116	1.13	0.84	Lung cancer;	chr6:149822743	chr6:149796151~149826294:-
PRAD	cis	rs2882667	0.69	rs1651032	ENSG00000253404.1	AC034243.1	-32.52	9.36e-121	1.51e-115	-1.15	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138743151	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs10068280	ENSG00000253404.1	AC034243.1	32.5	1.17e-120	1.86e-115	1.15	0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138931394	chr5:138744434~138753309:-
PRAD	cis	rs9322193	0.962	rs1413655	ENSG00000231760.4	RP11-350J20.5	32.49	1.22e-120	1.93e-115	1.12	0.84	Lung cancer;	chr6:149821815	chr6:149796151~149826294:-
PRAD	cis	rs2882667	0.69	rs1059110	ENSG00000253404.1	AC034243.1	32.49	1.25e-120	1.97e-115	1.14	0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138930857	chr5:138744434~138753309:-
PRAD	cis	rs9322193	0.962	rs17673294	ENSG00000231760.4	RP11-350J20.5	32.48	1.43e-120	2.25e-115	1.14	0.84	Lung cancer;	chr6:149813857	chr6:149796151~149826294:-
PRAD	cis	rs2882667	0.69	rs6877187	ENSG00000253404.1	AC034243.1	-32.41	2.69e-120	4e-115	-1.14	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138823655	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs3804199	ENSG00000253404.1	AC034243.1	-32.41	2.75e-120	4e-115	-1.14	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138826440	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.654	rs1095374	ENSG00000253404.1	AC034243.1	-32.41	2.77e-120	4e-115	-1.14	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138759517	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs700620	ENSG00000253404.1	AC034243.1	-32.41	2.77e-120	4e-115	-1.14	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762247	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.659	rs700621	ENSG00000253404.1	AC034243.1	-32.41	2.77e-120	4e-115	-1.14	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762741	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs700629	ENSG00000253404.1	AC034243.1	-32.41	2.78e-120	4e-115	-1.13	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138788305	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs9327827	ENSG00000253404.1	AC034243.1	32.39	3.14e-120	4.5e-115	1.15	0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846639	chr5:138744434~138753309:-
PRAD	cis	rs2739330	0.892	rs5751776	ENSG00000273295.1	AP000350.5	32.29	8.89e-120	1.23e-114	1	0.83	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23901432~23907068:-
PRAD	cis	rs2882667	0.69	rs700623	ENSG00000253404.1	AC034243.1	-32.29	8.92e-120	1.23e-114	-1.13	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762993	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs160401	ENSG00000253404.1	AC034243.1	-32.27	1.03e-119	1.42e-114	-1.16	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138725652	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.722	rs2011462	ENSG00000253404.1	AC034243.1	-32.24	1.38e-119	1.86e-114	-1.13	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138827083	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs10515504	ENSG00000253404.1	AC034243.1	-32.22	1.69e-119	2.27e-114	-1.16	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138887305	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs1703212	ENSG00000253404.1	AC034243.1	-32.21	1.88e-119	2.52e-114	-1.13	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138742863	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs311596	ENSG00000253404.1	AC034243.1	-32.2	2.15e-119	2.86e-114	-1.16	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138736393	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.659	rs311595	ENSG00000253404.1	AC034243.1	32.15	3.46e-119	4.57e-114	1.13	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138736183	chr5:138744434~138753309:-
PRAD	cis	rs9322193	0.962	rs3763162	ENSG00000231760.4	RP11-350J20.5	-32.1	5.71e-119	7.5e-114	-1.12	-0.83	Lung cancer;	chr6:149819674	chr6:149796151~149826294:-
PRAD	cis	rs2882667	0.69	rs4835708	ENSG00000253404.1	AC034243.1	-32.09	6.57e-119	8.39e-114	-1.13	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844204	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.587	rs1848506	ENSG00000253404.1	AC034243.1	-32.09	6.57e-119	8.39e-114	-1.13	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846768	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs1848505	ENSG00000253404.1	AC034243.1	-32.09	6.57e-119	8.39e-114	-1.13	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846841	chr5:138744434~138753309:-
PRAD	cis	rs9322193	0.962	rs2275046	ENSG00000231760.4	RP11-350J20.5	32.06	8.43e-119	1.07e-113	1.13	0.83	Lung cancer;	chr6:149835865	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs12175504	ENSG00000231760.4	RP11-350J20.5	32.03	1.1e-118	1.37e-113	1.13	0.83	Lung cancer;	chr6:149664079	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.962	rs62439843	ENSG00000231760.4	RP11-350J20.5	32.03	1.1e-118	1.37e-113	1.13	0.83	Lung cancer;	chr6:149676521	chr6:149796151~149826294:-
PRAD	cis	rs2882667	0.69	rs160403	ENSG00000253404.1	AC034243.1	32.02	1.24e-118	1.53e-113	1.14	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138722793	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.654	rs884469	ENSG00000253404.1	AC034243.1	-31.94	2.8e-118	3.24e-113	-1.14	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138820270	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs274119	ENSG00000253404.1	AC034243.1	31.92	3.35e-118	3.82e-113	1.13	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138728530	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs274118	ENSG00000253404.1	AC034243.1	31.92	3.35e-118	3.82e-113	1.13	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138729198	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs274117	ENSG00000253404.1	AC034243.1	31.92	3.35e-118	3.82e-113	1.13	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138729359	chr5:138744434~138753309:-
PRAD	cis	rs9322193	0.962	rs9505974	ENSG00000231760.4	RP11-350J20.5	31.89	4.29e-118	4.76e-113	1.11	0.83	Lung cancer;	chr6:149779294	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.926	rs9689036	ENSG00000231760.4	RP11-350J20.5	31.89	4.29e-118	4.76e-113	1.11	0.83	Lung cancer;	chr6:149780563	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.962	rs9322218	ENSG00000231760.4	RP11-350J20.5	31.89	4.29e-118	4.76e-113	1.11	0.83	Lung cancer;	chr6:149782183	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.962	rs9322219	ENSG00000231760.4	RP11-350J20.5	31.89	4.29e-118	4.76e-113	1.11	0.83	Lung cancer;	chr6:149782263	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.962	rs9322223	ENSG00000231760.4	RP11-350J20.5	31.89	4.29e-118	4.76e-113	1.11	0.83	Lung cancer;	chr6:149801509	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs7753812	ENSG00000231760.4	RP11-350J20.5	31.87	5.23e-118	5.74e-113	1.12	0.83	Lung cancer;	chr6:149690150	chr6:149796151~149826294:-
PRAD	cis	rs2882667	0.69	rs288012	ENSG00000253404.1	AC034243.1	-31.86	6.08e-118	6.64e-113	-1.13	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860584	chr5:138744434~138753309:-
PRAD	cis	rs9322193	0.923	rs12195866	ENSG00000231760.4	RP11-350J20.5	31.85	6.46e-118	7.02e-113	1.12	0.83	Lung cancer;	chr6:149693334	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs9285524	ENSG00000231760.4	RP11-350J20.5	31.85	6.46e-118	7.02e-113	1.12	0.83	Lung cancer;	chr6:149694122	chr6:149796151~149826294:-
PRAD	cis	rs2882667	0.69	rs6596456	ENSG00000253404.1	AC034243.1	-31.83	8.3e-118	8.71e-113	-1.13	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138831808	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs288014	ENSG00000253404.1	AC034243.1	-31.81	1.02e-117	1.07e-112	-1.13	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860104	chr5:138744434~138753309:-
PRAD	cis	rs9322193	0.962	rs13215691	ENSG00000231760.4	RP11-350J20.5	31.79	1.26e-117	1.31e-112	1.11	0.83	Lung cancer;	chr6:149792666	chr6:149796151~149826294:-
PRAD	cis	rs2882667	0.69	rs311597	ENSG00000253404.1	AC034243.1	31.76	1.63e-117	1.68e-112	1.17	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138720212	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs825749	ENSG00000253404.1	AC034243.1	-31.73	2.17e-117	2.23e-112	-1.15	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800232	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs288022	ENSG00000253404.1	AC034243.1	31.72	2.32e-117	2.37e-112	1.13	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888586	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.598	rs288020	ENSG00000253404.1	AC034243.1	31.72	2.32e-117	2.37e-112	1.13	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888609	chr5:138744434~138753309:-
PRAD	cis	rs9322193	0.962	rs35031906	ENSG00000231760.4	RP11-350J20.5	31.72	2.42e-117	2.47e-112	1.13	0.83	Lung cancer;	chr6:149677438	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.736	rs3828701	ENSG00000231760.4	RP11-350J20.5	31.71	2.59e-117	2.62e-112	1.13	0.83	Lung cancer;	chr6:149791063	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.736	rs3805750	ENSG00000231760.4	RP11-350J20.5	31.71	2.59e-117	2.62e-112	1.13	0.83	Lung cancer;	chr6:149791065	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.962	rs9397022	ENSG00000231760.4	RP11-350J20.5	31.68	3.65e-117	3.67e-112	1.11	0.83	Lung cancer;	chr6:149812052	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.962	rs9397357	ENSG00000231760.4	RP11-350J20.5	31.68	3.65e-117	3.67e-112	1.11	0.83	Lung cancer;	chr6:149812465	chr6:149796151~149826294:-
PRAD	cis	rs2882667	0.69	rs288033	ENSG00000253404.1	AC034243.1	31.62	6.3e-117	6.31e-112	1.12	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138878405	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs311599	ENSG00000253404.1	AC034243.1	31.59	8.55e-117	8.51e-112	1.17	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138718994	chr5:138744434~138753309:-
PRAD	cis	rs9322193	0.962	rs7745915	ENSG00000231760.4	RP11-350J20.5	31.59	8.65e-117	8.59e-112	1.13	0.83	Lung cancer;	chr6:149834111	chr6:149796151~149826294:-
PRAD	cis	rs2739330	0.929	rs5751775	ENSG00000273295.1	AP000350.5	31.58	9.49e-117	9.39e-112	1.01	0.83	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23901432~23907068:-
PRAD	cis	rs2882667	0.659	rs12719515	ENSG00000253404.1	AC034243.1	31.49	2.29e-116	2.24e-111	1.13	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138905629	chr5:138744434~138753309:-
PRAD	cis	rs9322193	0.962	rs9478848	ENSG00000231760.4	RP11-350J20.5	31.41	5.23e-116	5.06e-111	1.1	0.83	Lung cancer;	chr6:149825080	chr6:149796151~149826294:-
PRAD	cis	rs2882667	0.69	rs906695	ENSG00000253404.1	AC034243.1	31.4	5.95e-116	5.74e-111	1.14	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138803588	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs7446631	ENSG00000253404.1	AC034243.1	31.34	1.06e-115	1.01e-110	1.12	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138891376	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs160404	ENSG00000253404.1	AC034243.1	31.33	1.16e-115	1.1e-110	1.14	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748580	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs1651358	ENSG00000253404.1	AC034243.1	-31.19	4.63e-115	4.39e-110	-1.15	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138745318	chr5:138744434~138753309:-
PRAD	cis	rs9322193	0.962	rs3763163	ENSG00000231760.4	RP11-350J20.5	31.15	7.03e-115	6.65e-110	1.09	0.83	Lung cancer;	chr6:149819770	chr6:149796151~149826294:-
PRAD	cis	rs2882667	0.654	rs700626	ENSG00000253404.1	AC034243.1	-31.15	7.07e-115	6.67e-110	-1.16	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138782249	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs9327829	ENSG00000253404.1	AC034243.1	-31.13	8.31e-115	7.81e-110	-1.16	-0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138925982	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs423469	ENSG00000253404.1	AC034243.1	31.11	9.96e-115	9.33e-110	1.13	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138898427	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.598	rs10078179	ENSG00000253404.1	AC034243.1	31.03	2.25e-114	2.09e-109	1.12	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920410	chr5:138744434~138753309:-
PRAD	cis	rs858239	0.6	rs10235786	ENSG00000230658.1	KLHL7-AS1	31.02	2.49e-114	2.3e-109	1	0.82	Cerebrospinal fluid biomarker levels;	chr7:23100321	chr7:23101228~23105703:-
PRAD	cis	rs9322193	0.962	rs1889473	ENSG00000231760.4	RP11-350J20.5	31.02	2.58e-114	2.38e-109	1.09	0.82	Lung cancer;	chr6:149825485	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs1984111	ENSG00000231760.4	RP11-350J20.5	31.02	2.59e-114	2.39e-109	1.09	0.82	Lung cancer;	chr6:149831720	chr6:149796151~149826294:-
PRAD	cis	rs858239	0.6	rs10233039	ENSG00000230658.1	KLHL7-AS1	30.98	3.67e-114	3.34e-109	1	0.82	Cerebrospinal fluid biomarker levels;	chr7:23103494	chr7:23101228~23105703:-
PRAD	cis	rs9322193	0.923	rs12174035	ENSG00000231760.4	RP11-350J20.5	30.97	3.97e-114	3.59e-109	1.11	0.82	Lung cancer;	chr6:149763311	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.962	rs9688750	ENSG00000231760.4	RP11-350J20.5	30.95	5.23e-114	4.72e-109	1.12	0.82	Lung cancer;	chr6:149657633	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.962	rs9322206	ENSG00000231760.4	RP11-350J20.5	30.91	7.61e-114	6.84e-109	1.13	0.82	Lung cancer;	chr6:149641481	chr6:149796151~149826294:-
PRAD	cis	rs858239	0.6	rs10256524	ENSG00000230658.1	KLHL7-AS1	30.9	8.14e-114	7.3e-109	0.99	0.82	Cerebrospinal fluid biomarker levels;	chr7:23105328	chr7:23101228~23105703:-
PRAD	cis	rs2882667	0.69	rs2016720	ENSG00000253404.1	AC034243.1	30.88	1.01e-113	9.05e-109	1.12	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138928369	chr5:138744434~138753309:-
PRAD	cis	rs9322193	0.962	rs6903998	ENSG00000231760.4	RP11-350J20.5	30.71	5.52e-113	4.89e-108	1.09	0.82	Lung cancer;	chr6:149831357	chr6:149796151~149826294:-
PRAD	cis	rs2882667	0.69	rs160400	ENSG00000253404.1	AC034243.1	-30.71	5.65e-113	5e-108	-1.12	-0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727330	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs3763016	ENSG00000253404.1	AC034243.1	30.7	5.95e-113	5.25e-108	1.13	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935043	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.659	rs10056014	ENSG00000253404.1	AC034243.1	30.7	6.04e-113	5.32e-108	1.12	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920329	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.658	rs172664	ENSG00000253404.1	AC034243.1	30.69	7.12e-113	6.26e-108	1.13	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138720617	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs13158360	ENSG00000253404.1	AC034243.1	30.68	7.76e-113	6.77e-108	1.12	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138922488	chr5:138744434~138753309:-
PRAD	cis	rs858239	0.6	rs28646184	ENSG00000230658.1	KLHL7-AS1	30.63	1.21e-112	1.05e-107	0.99	0.82	Cerebrospinal fluid biomarker levels;	chr7:23099976	chr7:23101228~23105703:-
PRAD	cis	rs2882667	0.69	rs311602	ENSG00000253404.1	AC034243.1	30.55	2.8e-112	2.39e-107	1.13	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717370	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs930063	ENSG00000253404.1	AC034243.1	30.55	2.8e-112	2.39e-107	1.13	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717929	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs930062	ENSG00000253404.1	AC034243.1	30.55	2.8e-112	2.39e-107	1.13	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717934	chr5:138744434~138753309:-
PRAD	cis	rs858239	0.6	rs10256361	ENSG00000230658.1	KLHL7-AS1	30.42	1.01e-111	8.5e-107	1	0.82	Cerebrospinal fluid biomarker levels;	chr7:23084266	chr7:23101228~23105703:-
PRAD	cis	rs9322193	0.962	rs35443312	ENSG00000231760.4	RP11-350J20.5	30.38	1.58e-111	1.33e-106	1.11	0.82	Lung cancer;	chr6:149670625	chr6:149796151~149826294:-
PRAD	cis	rs858239	0.6	rs2014768	ENSG00000230658.1	KLHL7-AS1	30.35	2.15e-111	1.79e-106	0.99	0.82	Cerebrospinal fluid biomarker levels;	chr7:23082821	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.6	rs6978827	ENSG00000230658.1	KLHL7-AS1	30.35	2.15e-111	1.79e-106	0.99	0.82	Cerebrospinal fluid biomarker levels;	chr7:23085925	chr7:23101228~23105703:-
PRAD	cis	rs2882667	0.69	rs13174008	ENSG00000253404.1	AC034243.1	30.33	2.44e-111	2.03e-106	1.12	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138922220	chr5:138744434~138753309:-
PRAD	cis	rs858239	0.6	rs7790157	ENSG00000230658.1	KLHL7-AS1	30.3	3.44e-111	2.84e-106	0.99	0.82	Cerebrospinal fluid biomarker levels;	chr7:23087379	chr7:23101228~23105703:-
PRAD	cis	rs9322193	0.923	rs9322197	ENSG00000231760.4	RP11-350J20.5	30.26	5.03e-111	4.11e-106	1.12	0.82	Lung cancer;	chr6:149622577	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.884	rs9688858	ENSG00000231760.4	RP11-350J20.5	30.26	5.03e-111	4.11e-106	1.12	0.82	Lung cancer;	chr6:149637911	chr6:149796151~149826294:-
PRAD	cis	rs2882667	0.69	rs6890932	ENSG00000253404.1	AC034243.1	30.25	5.87e-111	4.78e-106	1.12	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138910639	chr5:138744434~138753309:-
PRAD	cis	rs858239	0.601	rs73272048	ENSG00000230658.1	KLHL7-AS1	30.19	9.77e-111	7.94e-106	0.99	0.82	Cerebrospinal fluid biomarker levels;	chr7:23113034	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.6	rs6960001	ENSG00000230658.1	KLHL7-AS1	30.19	1.04e-110	8.37e-106	0.99	0.82	Cerebrospinal fluid biomarker levels;	chr7:23091257	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.6	rs10237755	ENSG00000230658.1	KLHL7-AS1	30.19	1.04e-110	8.37e-106	0.99	0.82	Cerebrospinal fluid biomarker levels;	chr7:23091945	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.6	rs6961131	ENSG00000230658.1	KLHL7-AS1	30.19	1.04e-110	8.37e-106	0.99	0.82	Cerebrospinal fluid biomarker levels;	chr7:23095171	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.6	rs7785842	ENSG00000230658.1	KLHL7-AS1	30.07	3.37e-110	2.61e-105	0.99	0.82	Cerebrospinal fluid biomarker levels;	chr7:23102087	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.6	rs7456915	ENSG00000230658.1	KLHL7-AS1	30.07	3.37e-110	2.61e-105	0.99	0.82	Cerebrospinal fluid biomarker levels;	chr7:23103430	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.6	rs13438179	ENSG00000230658.1	KLHL7-AS1	30.07	3.37e-110	2.61e-105	0.99	0.82	Cerebrospinal fluid biomarker levels;	chr7:23104232	chr7:23101228~23105703:-
PRAD	cis	rs801193	1	rs2659909	ENSG00000226824.5	RP4-756H11.3	-30.02	5.57e-110	4.29e-105	-1.08	-0.82	Aortic root size;	chr7:66695292	chr7:66654538~66669855:+
PRAD	cis	rs858239	0.601	rs1034963	ENSG00000230658.1	KLHL7-AS1	30.01	5.98e-110	4.6e-105	0.99	0.82	Cerebrospinal fluid biomarker levels;	chr7:23108854	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.6	rs9691762	ENSG00000230658.1	KLHL7-AS1	30.01	6.12e-110	4.7e-105	0.99	0.82	Cerebrospinal fluid biomarker levels;	chr7:23086303	chr7:23101228~23105703:-
PRAD	cis	rs2882667	0.69	rs9327830	ENSG00000253404.1	AC034243.1	30	6.9e-110	5.29e-105	1.11	0.81	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936560	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.628	rs311605	ENSG00000253404.1	AC034243.1	29.99	7.38e-110	5.63e-105	1.17	0.81	Age-related hearing impairment (SNP x SNP interaction);	chr5:138710150	chr5:138744434~138753309:-
PRAD	cis	rs858239	0.6	rs1115941	ENSG00000230658.1	KLHL7-AS1	29.87	2.61e-109	1.96e-104	0.99	0.81	Cerebrospinal fluid biomarker levels;	chr7:23097569	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.601	rs6461693	ENSG00000230658.1	KLHL7-AS1	-29.8	5.17e-109	3.77e-104	-0.99	-0.81	Cerebrospinal fluid biomarker levels;	chr7:23120514	chr7:23101228~23105703:-
PRAD	cis	rs2882667	0.69	rs11750163	ENSG00000253404.1	AC034243.1	29.56	6.22e-108	4.26e-103	1.11	0.81	Age-related hearing impairment (SNP x SNP interaction);	chr5:138705920	chr5:138744434~138753309:-
PRAD	cis	rs858239	0.601	rs1558313	ENSG00000230658.1	KLHL7-AS1	29.55	6.29e-108	4.28e-103	0.99	0.81	Cerebrospinal fluid biomarker levels;	chr7:23116460	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.601	rs6962526	ENSG00000230658.1	KLHL7-AS1	29.55	6.29e-108	4.28e-103	0.99	0.81	Cerebrospinal fluid biomarker levels;	chr7:23118614	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.539	rs6971673	ENSG00000230658.1	KLHL7-AS1	29.55	6.29e-108	4.28e-103	0.99	0.81	Cerebrospinal fluid biomarker levels;	chr7:23119904	chr7:23101228~23105703:-
PRAD	cis	rs2739330	0.892	rs5751776	ENSG00000218537.1	MIF-AS1	29.55	6.5e-108	4.41e-103	1.08	0.81	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23894426~23898930:-
PRAD	cis	rs858239	0.601	rs6980224	ENSG00000230658.1	KLHL7-AS1	29.55	6.92e-108	4.68e-103	0.99	0.81	Cerebrospinal fluid biomarker levels;	chr7:23109518	chr7:23101228~23105703:-
PRAD	cis	rs2882667	0.69	rs9327831	ENSG00000253404.1	AC034243.1	29.54	7.35e-108	4.96e-103	1.12	0.81	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936597	chr5:138744434~138753309:-
PRAD	cis	rs858239	0.6	rs2072368	ENSG00000230658.1	KLHL7-AS1	29.52	9.34e-108	6.25e-103	0.99	0.81	Cerebrospinal fluid biomarker levels;	chr7:23106493	chr7:23101228~23105703:-
PRAD	cis	rs2882667	0.654	rs6862845	ENSG00000253404.1	AC034243.1	29.45	1.76e-107	1.17e-102	1.12	0.81	Age-related hearing impairment (SNP x SNP interaction);	chr5:138937456	chr5:138744434~138753309:-
PRAD	cis	rs858239	0.6	rs2072369	ENSG00000230658.1	KLHL7-AS1	29.43	2.28e-107	1.52e-102	0.99	0.81	Cerebrospinal fluid biomarker levels;	chr7:23106570	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.601	rs15775	ENSG00000230658.1	KLHL7-AS1	29.43	2.29e-107	1.52e-102	0.99	0.81	Cerebrospinal fluid biomarker levels;	chr7:23125082	chr7:23101228~23105703:-
PRAD	cis	rs2882667	0.628	rs311606	ENSG00000253404.1	AC034243.1	29.41	2.68e-107	1.78e-102	1.14	0.81	Age-related hearing impairment (SNP x SNP interaction);	chr5:138709551	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.728	rs10037071	ENSG00000253404.1	AC034243.1	29.4	3.05e-107	2.02e-102	1.14	0.81	Age-related hearing impairment (SNP x SNP interaction);	chr5:138942158	chr5:138744434~138753309:-
PRAD	cis	rs858239	0.6	rs7787110	ENSG00000230658.1	KLHL7-AS1	29.38	3.65e-107	2.41e-102	0.98	0.81	Cerebrospinal fluid biomarker levels;	chr7:23098855	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.6	rs13438188	ENSG00000230658.1	KLHL7-AS1	-29.37	4e-107	2.64e-102	-0.99	-0.81	Cerebrospinal fluid biomarker levels;	chr7:23104578	chr7:23101228~23105703:-
PRAD	cis	rs2882667	0.69	rs7709789	ENSG00000253404.1	AC034243.1	29.34	5.57e-107	3.66e-102	1.12	0.81	Age-related hearing impairment (SNP x SNP interaction);	chr5:138938762	chr5:138744434~138753309:-
PRAD	cis	rs858239	0.57	rs10235467	ENSG00000230658.1	KLHL7-AS1	29.3	8.5e-107	5.55e-102	0.99	0.81	Cerebrospinal fluid biomarker levels;	chr7:23109189	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.601	rs10278700	ENSG00000230658.1	KLHL7-AS1	29.29	8.89e-107	5.77e-102	0.99	0.81	Cerebrospinal fluid biomarker levels;	chr7:23120910	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.601	rs10263110	ENSG00000230658.1	KLHL7-AS1	29.29	8.89e-107	5.77e-102	0.99	0.81	Cerebrospinal fluid biomarker levels;	chr7:23120932	chr7:23101228~23105703:-
PRAD	cis	rs9322193	0.962	rs4870048	ENSG00000231760.4	RP11-350J20.5	29.28	9.69e-107	6.28e-102	1.09	0.81	Lung cancer;	chr6:149834324	chr6:149796151~149826294:-
PRAD	cis	rs858239	0.57	rs10271613	ENSG00000230658.1	KLHL7-AS1	29.25	1.36e-106	8.61e-102	0.98	0.81	Cerebrospinal fluid biomarker levels;	chr7:23122967	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.57	rs10242166	ENSG00000230658.1	KLHL7-AS1	29.25	1.36e-106	8.61e-102	0.98	0.81	Cerebrospinal fluid biomarker levels;	chr7:23123180	chr7:23101228~23105703:-
PRAD	cis	rs2882667	0.69	rs9942422	ENSG00000253404.1	AC034243.1	29.21	2.06e-106	1.29e-101	1.1	0.81	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936847	chr5:138744434~138753309:-
PRAD	cis	rs858239	0.632	rs13438452	ENSG00000230658.1	KLHL7-AS1	29.2	2.35e-106	1.47e-101	0.99	0.81	Cerebrospinal fluid biomarker levels;	chr7:23134563	chr7:23101228~23105703:-
PRAD	cis	rs2882667	0.658	rs10076442	ENSG00000253404.1	AC034243.1	29.18	2.81e-106	1.76e-101	1.14	0.81	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941090	chr5:138744434~138753309:-
PRAD	cis	rs858239	0.601	rs4599714	ENSG00000230658.1	KLHL7-AS1	29.12	5.25e-106	3.26e-101	0.99	0.81	Cerebrospinal fluid biomarker levels;	chr7:23129182	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.601	rs10278776	ENSG00000230658.1	KLHL7-AS1	29.12	5.25e-106	3.26e-101	0.99	0.81	Cerebrospinal fluid biomarker levels;	chr7:23130140	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.601	rs3735228	ENSG00000230658.1	KLHL7-AS1	29.08	7.74e-106	4.79e-101	0.98	0.81	Cerebrospinal fluid biomarker levels;	chr7:23130808	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.601	rs11982002	ENSG00000230658.1	KLHL7-AS1	29.07	8.27e-106	5.11e-101	0.99	0.81	Cerebrospinal fluid biomarker levels;	chr7:23123651	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.601	rs10255228	ENSG00000230658.1	KLHL7-AS1	29.01	1.52e-105	9.28e-101	0.98	0.81	Cerebrospinal fluid biomarker levels;	chr7:23119244	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.601	rs929507	ENSG00000230658.1	KLHL7-AS1	28.99	2.02e-105	1.22e-100	0.98	0.81	Cerebrospinal fluid biomarker levels;	chr7:23127045	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.601	rs929508	ENSG00000230658.1	KLHL7-AS1	28.99	2.02e-105	1.22e-100	0.98	0.81	Cerebrospinal fluid biomarker levels;	chr7:23127090	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.601	rs987257	ENSG00000230658.1	KLHL7-AS1	28.96	2.63e-105	1.58e-100	0.98	0.81	Cerebrospinal fluid biomarker levels;	chr7:23108221	chr7:23101228~23105703:-
PRAD	cis	rs801193	1	rs2420824	ENSG00000226824.5	RP4-756H11.3	28.96	2.66e-105	1.6e-100	1.07	0.81	Aortic root size;	chr7:66666129	chr7:66654538~66669855:+
PRAD	cis	rs2739330	0.929	rs5751777	ENSG00000218537.1	MIF-AS1	28.94	3.2e-105	1.92e-100	1.08	0.8	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23894426~23898930:-
PRAD	cis	rs858239	0.601	rs4140959	ENSG00000230658.1	KLHL7-AS1	28.9	4.67e-105	2.79e-100	0.99	0.8	Cerebrospinal fluid biomarker levels;	chr7:23131157	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.601	rs6948469	ENSG00000230658.1	KLHL7-AS1	28.86	7e-105	4.17e-100	0.99	0.8	Cerebrospinal fluid biomarker levels;	chr7:23135147	chr7:23101228~23105703:-
PRAD	cis	rs9322193	1	rs9322193	ENSG00000231760.4	RP11-350J20.5	28.86	7.44e-105	4.41e-100	1.09	0.8	Lung cancer;	chr6:149598007	chr6:149796151~149826294:-
PRAD	cis	rs801193	0.904	rs4718405	ENSG00000226824.5	RP4-756H11.3	-28.86	7.61e-105	4.5e-100	-1.05	-0.8	Aortic root size;	chr7:66789659	chr7:66654538~66669855:+
PRAD	cis	rs858239	0.6	rs1468592	ENSG00000230658.1	KLHL7-AS1	-28.84	9.13e-105	5.36e-100	-0.98	-0.8	Cerebrospinal fluid biomarker levels;	chr7:23101028	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.541	rs4624924	ENSG00000230658.1	KLHL7-AS1	28.79	1.43e-104	8.34e-100	0.99	0.8	Cerebrospinal fluid biomarker levels;	chr7:23129224	chr7:23101228~23105703:-
PRAD	cis	rs9322193	1	rs9377229	ENSG00000231760.4	RP11-350J20.5	28.76	2.09e-104	1.21e-99	1.09	0.8	Lung cancer;	chr6:149607655	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.886	rs4039600	ENSG00000231760.4	RP11-350J20.5	28.74	2.52e-104	1.46e-99	1.11	0.8	Lung cancer;	chr6:149576319	chr6:149796151~149826294:-
PRAD	cis	rs858239	0.57	rs6968242	ENSG00000230658.1	KLHL7-AS1	28.69	4.36e-104	2.49e-99	0.98	0.8	Cerebrospinal fluid biomarker levels;	chr7:23127792	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.601	rs1981665	ENSG00000230658.1	KLHL7-AS1	28.69	4.36e-104	2.49e-99	0.98	0.8	Cerebrospinal fluid biomarker levels;	chr7:23128350	chr7:23101228~23105703:-
PRAD	cis	rs916888	0.773	rs199448	ENSG00000214401.4	KANSL1-AS1	28.68	4.54e-104	2.59e-99	1.35	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46193576~46196723:+
PRAD	cis	rs858239	0.6	rs7776649	ENSG00000230658.1	KLHL7-AS1	28.67	5.11e-104	2.91e-99	0.98	0.8	Cerebrospinal fluid biomarker levels;	chr7:23079698	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.6	rs10241208	ENSG00000230658.1	KLHL7-AS1	28.61	9.17e-104	5.19e-99	0.99	0.8	Cerebrospinal fluid biomarker levels;	chr7:23105295	chr7:23101228~23105703:-
PRAD	cis	rs2882667	0.728	rs7722413	ENSG00000253404.1	AC034243.1	28.59	1.2e-103	6.76e-99	1.13	0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138942562	chr5:138744434~138753309:-
PRAD	cis	rs916888	0.773	rs199447	ENSG00000214401.4	KANSL1-AS1	28.56	1.5e-103	8.44e-99	1.35	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46193576~46196723:+
PRAD	cis	rs9322193	0.961	rs9027	ENSG00000231760.4	RP11-350J20.5	28.53	2.14e-103	1.19e-98	1.09	0.8	Lung cancer;	chr6:149594921	chr6:149796151~149826294:-
PRAD	cis	rs9326248	0.906	rs171052	ENSG00000254851.1	RP11-109L13.1	28.46	4.47e-103	2.47e-98	1.11	0.8	Blood protein levels;	chr11:117211047	chr11:117135528~117138582:+
PRAD	cis	rs858239	0.601	rs6971002	ENSG00000230658.1	KLHL7-AS1	28.42	6.61e-103	3.64e-98	0.99	0.8	Cerebrospinal fluid biomarker levels;	chr7:23132685	chr7:23101228~23105703:-
PRAD	cis	rs9326248	0.953	rs488962	ENSG00000254851.1	RP11-109L13.1	28.42	6.82e-103	3.74e-98	1.12	0.8	Blood protein levels;	chr11:117201809	chr11:117135528~117138582:+
PRAD	cis	rs916888	0.773	rs199447	ENSG00000262539.1	RP11-259G18.3	28.4	8.21e-103	4.49e-98	1.37	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46259551~46260606:-
PRAD	cis	rs916888	0.773	rs199534	ENSG00000262539.1	RP11-259G18.3	28.39	9.02e-103	4.93e-98	1.37	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46259551~46260606:-
PRAD	cis	rs9326248	0.953	rs634960	ENSG00000254851.1	RP11-109L13.1	28.37	1.06e-102	5.76e-98	1.11	0.8	Blood protein levels;	chr11:117202247	chr11:117135528~117138582:+
PRAD	cis	rs858239	0.6	rs6461691	ENSG00000230658.1	KLHL7-AS1	28.37	1.13e-102	6.18e-98	0.99	0.8	Cerebrospinal fluid biomarker levels;	chr7:23099726	chr7:23101228~23105703:-
PRAD	cis	rs916888	0.773	rs199448	ENSG00000262539.1	RP11-259G18.3	28.32	1.77e-102	9.58e-98	1.37	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46259551~46260606:-
PRAD	cis	rs916888	0.773	rs199457	ENSG00000214401.4	KANSL1-AS1	28.3	2.18e-102	1.17e-97	1.32	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46193576~46196723:+
PRAD	cis	rs916888	0.687	rs199456	ENSG00000214401.4	KANSL1-AS1	28.3	2.18e-102	1.17e-97	1.32	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46193576~46196723:+
PRAD	cis	rs916888	0.773	rs199451	ENSG00000214401.4	KANSL1-AS1	28.3	2.18e-102	1.17e-97	1.32	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46193576~46196723:+
PRAD	cis	rs9322193	0.923	rs10872649	ENSG00000231760.4	RP11-350J20.5	28.3	2.26e-102	1.21e-97	1.08	0.8	Lung cancer;	chr6:149759454	chr6:149796151~149826294:-
PRAD	cis	rs2882667	0.69	rs311608	ENSG00000253404.1	AC034243.1	28.28	2.72e-102	1.45e-97	1.12	0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138708000	chr5:138744434~138753309:-
PRAD	cis	rs916888	0.773	rs199533	ENSG00000262539.1	RP11-259G18.3	28.28	2.89e-102	1.54e-97	1.36	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46259551~46260606:-
PRAD	cis	rs9322193	0.923	rs10872650	ENSG00000231760.4	RP11-350J20.5	28.24	4.21e-102	2.22e-97	1.08	0.8	Lung cancer;	chr6:149760959	chr6:149796151~149826294:-
PRAD	cis	rs858239	0.6	rs7341483	ENSG00000230658.1	KLHL7-AS1	-28.18	7.68e-102	4.04e-97	-0.98	-0.8	Cerebrospinal fluid biomarker levels;	chr7:23088038	chr7:23101228~23105703:-
PRAD	cis	rs9326248	1	rs664922	ENSG00000254851.1	RP11-109L13.1	-28.16	9.35e-102	4.9e-97	-1.11	-0.8	Blood protein levels;	chr11:117200179	chr11:117135528~117138582:+
PRAD	cis	rs9326248	1	rs664082	ENSG00000254851.1	RP11-109L13.1	-28.16	9.35e-102	4.9e-97	-1.11	-0.8	Blood protein levels;	chr11:117200354	chr11:117135528~117138582:+
PRAD	cis	rs916888	0.773	rs199457	ENSG00000262539.1	RP11-259G18.3	28.15	1.02e-101	5.32e-97	1.34	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46259551~46260606:-
PRAD	cis	rs916888	0.687	rs199456	ENSG00000262539.1	RP11-259G18.3	28.15	1.02e-101	5.32e-97	1.34	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46259551~46260606:-
PRAD	cis	rs916888	0.773	rs199451	ENSG00000262539.1	RP11-259G18.3	28.15	1.02e-101	5.32e-97	1.34	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46259551~46260606:-
PRAD	cis	rs9322193	0.884	rs10872646	ENSG00000231760.4	RP11-350J20.5	28.15	1.05e-101	5.45e-97	1.08	0.8	Lung cancer;	chr6:149746539	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.884	rs12528279	ENSG00000231760.4	RP11-350J20.5	28.15	1.05e-101	5.45e-97	1.08	0.8	Lung cancer;	chr6:149750892	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.809	rs9479808	ENSG00000231760.4	RP11-350J20.5	28.15	1.05e-101	5.45e-97	1.08	0.8	Lung cancer;	chr6:149751328	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs10782316	ENSG00000231760.4	RP11-350J20.5	28.15	1.05e-101	5.45e-97	1.08	0.8	Lung cancer;	chr6:149752755	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs11155677	ENSG00000231760.4	RP11-350J20.5	28.14	1.14e-101	5.85e-97	1.08	0.8	Lung cancer;	chr6:149756953	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.884	rs9480009	ENSG00000231760.4	RP11-350J20.5	28.14	1.14e-101	5.85e-97	1.08	0.8	Lung cancer;	chr6:149758502	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs9480031	ENSG00000231760.4	RP11-350J20.5	28.14	1.14e-101	5.85e-97	1.08	0.8	Lung cancer;	chr6:149758875	chr6:149796151~149826294:-
PRAD	cis	rs2882667	0.69	rs10071381	ENSG00000253404.1	AC034243.1	28.13	1.29e-101	6.62e-97	1.11	0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138937159	chr5:138744434~138753309:-
PRAD	cis	rs858239	0.632	rs7811903	ENSG00000230658.1	KLHL7-AS1	28.11	1.62e-101	8.3e-97	0.98	0.8	Cerebrospinal fluid biomarker levels;	chr7:23079437	chr7:23101228~23105703:-
PRAD	cis	rs9322193	0.923	rs62441284	ENSG00000231760.4	RP11-350J20.5	28.1	1.77e-101	9.07e-97	1.08	0.8	Lung cancer;	chr6:149751542	chr6:149796151~149826294:-
PRAD	cis	rs875971	0.66	rs2013222	ENSG00000226824.5	RP4-756H11.3	28.05	3.1e-101	1.59e-96	1.03	0.8	Aortic root size;	chr7:66570949	chr7:66654538~66669855:+
PRAD	cis	rs916888	0.773	rs199534	ENSG00000214401.4	KANSL1-AS1	28.03	3.78e-101	1.92e-96	1.34	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46193576~46196723:+
PRAD	cis	rs858239	0.6	rs10266123	ENSG00000230658.1	KLHL7-AS1	28	4.83e-101	2.45e-96	0.99	0.8	Cerebrospinal fluid biomarker levels;	chr7:23096868	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.6	rs28483572	ENSG00000230658.1	KLHL7-AS1	28	5.21e-101	2.63e-96	0.97	0.8	Cerebrospinal fluid biomarker levels;	chr7:23092166	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.6	rs6961406	ENSG00000230658.1	KLHL7-AS1	28	5.21e-101	2.63e-96	0.97	0.8	Cerebrospinal fluid biomarker levels;	chr7:23095272	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.6	rs6461690	ENSG00000230658.1	KLHL7-AS1	28	5.21e-101	2.63e-96	0.97	0.8	Cerebrospinal fluid biomarker levels;	chr7:23095915	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.6	rs6967419	ENSG00000230658.1	KLHL7-AS1	28	5.21e-101	2.63e-96	0.97	0.8	Cerebrospinal fluid biomarker levels;	chr7:23096691	chr7:23101228~23105703:-
PRAD	cis	rs2882667	0.69	rs825759	ENSG00000253404.1	AC034243.1	-27.97	7.04e-101	3.54e-96	-1.13	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138790250	chr5:138744434~138753309:-
PRAD	cis	rs801193	1	rs3778909	ENSG00000226824.5	RP4-756H11.3	-27.96	7.52e-101	3.77e-96	-1.04	-0.8	Aortic root size;	chr7:66790659	chr7:66654538~66669855:+
PRAD	cis	rs2739330	0.929	rs5751775	ENSG00000218537.1	MIF-AS1	27.95	8.68e-101	4.35e-96	1.07	0.79	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23894426~23898930:-
PRAD	cis	rs10256972	0.552	rs2960830	ENSG00000229043.2	AC091729.9	-27.95	8.72e-101	4.36e-96	-0.96	-0.79	Endometriosis;Longevity;	chr7:1161005	chr7:1160374~1165267:+
PRAD	cis	rs10256972	0.552	rs2960831	ENSG00000229043.2	AC091729.9	-27.95	8.72e-101	4.36e-96	-0.96	-0.79	Endometriosis;Longevity;	chr7:1161556	chr7:1160374~1165267:+
PRAD	cis	rs801193	0.844	rs7779971	ENSG00000226824.5	RP4-756H11.3	-27.92	1.12e-100	5.56e-96	-1.04	-0.79	Aortic root size;	chr7:66696803	chr7:66654538~66669855:+
PRAD	cis	rs801193	1	rs2659906	ENSG00000226824.5	RP4-756H11.3	-27.92	1.12e-100	5.56e-96	-1.04	-0.79	Aortic root size;	chr7:66700323	chr7:66654538~66669855:+
PRAD	cis	rs801193	1	rs2707836	ENSG00000226824.5	RP4-756H11.3	-27.92	1.14e-100	5.66e-96	-1.04	-0.79	Aortic root size;	chr7:66695448	chr7:66654538~66669855:+
PRAD	cis	rs2882667	0.69	rs1976562	ENSG00000253404.1	AC034243.1	-27.88	1.65e-100	8.05e-96	-1.12	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138774905	chr5:138744434~138753309:-
PRAD	cis	rs858239	0.6	rs10256359	ENSG00000230658.1	KLHL7-AS1	27.86	2.09e-100	1.02e-95	0.98	0.79	Cerebrospinal fluid biomarker levels;	chr7:23084258	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.6	rs4628176	ENSG00000230658.1	KLHL7-AS1	27.85	2.26e-100	1.1e-95	0.99	0.79	Cerebrospinal fluid biomarker levels;	chr7:23102947	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.6	rs10488077	ENSG00000230658.1	KLHL7-AS1	27.85	2.26e-100	1.1e-95	0.99	0.79	Cerebrospinal fluid biomarker levels;	chr7:23104563	chr7:23101228~23105703:-
PRAD	cis	rs2882667	0.69	rs700619	ENSG00000253404.1	AC034243.1	-27.85	2.35e-100	1.14e-95	-1.12	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138753060	chr5:138744434~138753309:-
PRAD	cis	rs9322193	0.923	rs9479494	ENSG00000231760.4	RP11-350J20.5	27.85	2.38e-100	1.15e-95	1.07	0.79	Lung cancer;	chr6:149739108	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs9800806	ENSG00000231760.4	RP11-350J20.5	27.85	2.38e-100	1.15e-95	1.07	0.79	Lung cancer;	chr6:149740350	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs9688517	ENSG00000231760.4	RP11-350J20.5	27.85	2.38e-100	1.15e-95	1.07	0.79	Lung cancer;	chr6:149740655	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs1572229	ENSG00000231760.4	RP11-350J20.5	27.85	2.38e-100	1.15e-95	1.07	0.79	Lung cancer;	chr6:149743841	chr6:149796151~149826294:-
PRAD	cis	rs801193	1	rs4717310	ENSG00000226824.5	RP4-756H11.3	-27.81	3.64e-100	1.73e-95	-1.04	-0.79	Aortic root size;	chr7:66696020	chr7:66654538~66669855:+
PRAD	cis	rs858239	0.6	rs2003555	ENSG00000230658.1	KLHL7-AS1	27.8	3.9e-100	1.85e-95	0.97	0.79	Cerebrospinal fluid biomarker levels;	chr7:23083296	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.6	rs7784929	ENSG00000230658.1	KLHL7-AS1	27.8	3.9e-100	1.85e-95	0.97	0.79	Cerebrospinal fluid biomarker levels;	chr7:23084658	chr7:23101228~23105703:-
PRAD	cis	rs9326248	0.954	rs10790177	ENSG00000254851.1	RP11-109L13.1	-27.74	7.07e-100	3.32e-95	-1.12	-0.79	Blood protein levels;	chr11:117177701	chr11:117135528~117138582:+
PRAD	cis	rs858239	0.6	rs7799422	ENSG00000230658.1	KLHL7-AS1	27.74	7.46e-100	3.5e-95	0.97	0.79	Cerebrospinal fluid biomarker levels;	chr7:23088794	chr7:23101228~23105703:-
PRAD	cis	rs916888	0.773	rs199533	ENSG00000214401.4	KANSL1-AS1	27.74	7.53e-100	3.53e-95	1.33	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46193576~46196723:+
PRAD	cis	rs507080	0.922	rs625513	ENSG00000255239.1	AP002954.6	27.72	8.86e-100	4.14e-95	1.09	0.79	Serum metabolite levels;	chr11:118685010	chr11:118688039~118690600:-
PRAD	cis	rs801193	1	rs2707856	ENSG00000226824.5	RP4-756H11.3	-27.72	8.98e-100	4.19e-95	-1.04	-0.79	Aortic root size;	chr7:66746023	chr7:66654538~66669855:+
PRAD	cis	rs507080	0.885	rs533144	ENSG00000255239.1	AP002954.6	27.71	9.89e-100	4.6e-95	1.08	0.79	Serum metabolite levels;	chr11:118688538	chr11:118688039~118690600:-
PRAD	cis	rs507080	0.883	rs12798453	ENSG00000255239.1	AP002954.6	27.71	9.89e-100	4.6e-95	1.08	0.79	Serum metabolite levels;	chr11:118690701	chr11:118688039~118690600:-
PRAD	cis	rs801193	1	rs3800812	ENSG00000226824.5	RP4-756H11.3	-27.71	1.02e-99	4.73e-95	-1.04	-0.79	Aortic root size;	chr7:66758474	chr7:66654538~66669855:+
PRAD	cis	rs801193	1	rs4279493	ENSG00000226824.5	RP4-756H11.3	-27.71	1.02e-99	4.73e-95	-1.04	-0.79	Aortic root size;	chr7:66761633	chr7:66654538~66669855:+
PRAD	cis	rs801193	0.761	rs2659888	ENSG00000226824.5	RP4-756H11.3	-27.71	1.02e-99	4.73e-95	-1.04	-0.79	Aortic root size;	chr7:66765184	chr7:66654538~66669855:+
PRAD	cis	rs801193	0.904	rs4718403	ENSG00000226824.5	RP4-756H11.3	-27.7	1.05e-99	4.87e-95	-1.04	-0.79	Aortic root size;	chr7:66777742	chr7:66654538~66669855:+
PRAD	cis	rs801193	1	rs2707845	ENSG00000226824.5	RP4-756H11.3	-27.7	1.12e-99	5.13e-95	-1.04	-0.79	Aortic root size;	chr7:66733811	chr7:66654538~66669855:+
PRAD	cis	rs801193	1	rs2707850	ENSG00000226824.5	RP4-756H11.3	-27.7	1.12e-99	5.13e-95	-1.04	-0.79	Aortic root size;	chr7:66738883	chr7:66654538~66669855:+
PRAD	cis	rs801193	0.967	rs1110414	ENSG00000226824.5	RP4-756H11.3	-27.7	1.12e-99	5.13e-95	-1.04	-0.79	Aortic root size;	chr7:66740595	chr7:66654538~66669855:+
PRAD	cis	rs801193	1	rs7783924	ENSG00000226824.5	RP4-756H11.3	-27.7	1.12e-99	5.13e-95	-1.04	-0.79	Aortic root size;	chr7:66744070	chr7:66654538~66669855:+
PRAD	cis	rs801193	1	rs7789184	ENSG00000226824.5	RP4-756H11.3	-27.7	1.12e-99	5.13e-95	-1.04	-0.79	Aortic root size;	chr7:66745208	chr7:66654538~66669855:+
PRAD	cis	rs801193	1	rs2707854	ENSG00000226824.5	RP4-756H11.3	-27.7	1.12e-99	5.13e-95	-1.04	-0.79	Aortic root size;	chr7:66747610	chr7:66654538~66669855:+
PRAD	cis	rs801193	1	rs4717319	ENSG00000226824.5	RP4-756H11.3	-27.7	1.13e-99	5.14e-95	-1.04	-0.79	Aortic root size;	chr7:66777606	chr7:66654538~66669855:+
PRAD	cis	rs801193	1	rs62466793	ENSG00000226824.5	RP4-756H11.3	-27.69	1.23e-99	5.6e-95	-1.04	-0.79	Aortic root size;	chr7:66726530	chr7:66654538~66669855:+
PRAD	cis	rs507080	0.922	rs585039	ENSG00000255239.1	AP002954.6	27.69	1.25e-99	5.66e-95	1.09	0.79	Serum metabolite levels;	chr11:118692672	chr11:118688039~118690600:-
PRAD	cis	rs9326248	1	rs585849	ENSG00000254851.1	RP11-109L13.1	-27.69	1.26e-99	5.73e-95	-1.11	-0.79	Blood protein levels;	chr11:117198345	chr11:117135528~117138582:+
PRAD	cis	rs801193	1	rs1553610	ENSG00000226824.5	RP4-756H11.3	-27.68	1.35e-99	6.11e-95	-1.04	-0.79	Aortic root size;	chr7:66732246	chr7:66654538~66669855:+
PRAD	cis	rs801193	0.967	rs2707853	ENSG00000226824.5	RP4-756H11.3	-27.68	1.35e-99	6.11e-95	-1.04	-0.79	Aortic root size;	chr7:66749023	chr7:66654538~66669855:+
PRAD	cis	rs10256972	0.577	rs6962809	ENSG00000229043.2	AC091729.9	-27.65	1.75e-99	7.87e-95	-0.96	-0.79	Endometriosis;Longevity;	chr7:1169253	chr7:1160374~1165267:+
PRAD	cis	rs507080	0.922	rs558781	ENSG00000255239.1	AP002954.6	27.63	2.19e-99	9.85e-95	1.09	0.79	Serum metabolite levels;	chr11:118693688	chr11:118688039~118690600:-
PRAD	cis	rs801193	0.935	rs2659916	ENSG00000226824.5	RP4-756H11.3	-27.63	2.25e-99	1.01e-94	-1.04	-0.79	Aortic root size;	chr7:66686365	chr7:66654538~66669855:+
PRAD	cis	rs801193	1	rs10234018	ENSG00000226824.5	RP4-756H11.3	27.62	2.43e-99	1.09e-94	1.02	0.79	Aortic root size;	chr7:66681297	chr7:66654538~66669855:+
PRAD	cis	rs9326248	1	rs3736120	ENSG00000254851.1	RP11-109L13.1	-27.62	2.46e-99	1.1e-94	-1.12	-0.79	Blood protein levels;	chr11:117161409	chr11:117135528~117138582:+
PRAD	cis	rs9326248	1	rs10790175	ENSG00000254851.1	RP11-109L13.1	-27.6	2.94e-99	1.31e-94	-1.12	-0.79	Blood protein levels;	chr11:117164013	chr11:117135528~117138582:+
PRAD	cis	rs2882667	0.69	rs825677	ENSG00000253404.1	AC034243.1	-27.6	3.01e-99	1.34e-94	-1.12	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138769081	chr5:138744434~138753309:-
PRAD	cis	rs801193	1	rs2659889	ENSG00000226824.5	RP4-756H11.3	-27.59	3.33e-99	1.48e-94	-1.04	-0.79	Aortic root size;	chr7:66752125	chr7:66654538~66669855:+
PRAD	cis	rs858239	0.511	rs10256996	ENSG00000230658.1	KLHL7-AS1	-27.59	3.56e-99	1.58e-94	-0.97	-0.79	Cerebrospinal fluid biomarker levels;	chr7:23105676	chr7:23101228~23105703:-
PRAD	cis	rs801193	1	rs62466794	ENSG00000226824.5	RP4-756H11.3	-27.58	3.91e-99	1.71e-94	-1.04	-0.79	Aortic root size;	chr7:66726592	chr7:66654538~66669855:+
PRAD	cis	rs507080	0.885	rs693037	ENSG00000255239.1	AP002954.6	27.58	3.93e-99	1.71e-94	1.09	0.79	Serum metabolite levels;	chr11:118682617	chr11:118688039~118690600:-
PRAD	cis	rs507080	0.922	rs546890	ENSG00000255239.1	AP002954.6	27.58	3.93e-99	1.71e-94	1.09	0.79	Serum metabolite levels;	chr11:118686489	chr11:118688039~118690600:-
PRAD	cis	rs507080	0.883	rs693306	ENSG00000255239.1	AP002954.6	27.58	3.93e-99	1.71e-94	1.09	0.79	Serum metabolite levels;	chr11:118687624	chr11:118688039~118690600:-
PRAD	cis	rs507080	0.922	rs561845	ENSG00000255239.1	AP002954.6	27.58	3.93e-99	1.71e-94	1.09	0.79	Serum metabolite levels;	chr11:118688118	chr11:118688039~118690600:-
PRAD	cis	rs507080	0.922	rs638805	ENSG00000255239.1	AP002954.6	27.58	3.93e-99	1.71e-94	1.09	0.79	Serum metabolite levels;	chr11:118688180	chr11:118688039~118690600:-
PRAD	cis	rs507080	0.845	rs510408	ENSG00000255239.1	AP002954.6	27.58	3.93e-99	1.71e-94	1.09	0.79	Serum metabolite levels;	chr11:118688192	chr11:118688039~118690600:-
PRAD	cis	rs507080	0.845	rs509641	ENSG00000255239.1	AP002954.6	27.58	3.93e-99	1.71e-94	1.09	0.79	Serum metabolite levels;	chr11:118688243	chr11:118688039~118690600:-
PRAD	cis	rs507080	0.883	rs563549	ENSG00000255239.1	AP002954.6	27.58	3.93e-99	1.71e-94	1.09	0.79	Serum metabolite levels;	chr11:118688244	chr11:118688039~118690600:-
PRAD	cis	rs507080	0.922	rs582630	ENSG00000255239.1	AP002954.6	27.57	3.98e-99	1.73e-94	1.08	0.79	Serum metabolite levels;	chr11:118692090	chr11:118688039~118690600:-
PRAD	cis	rs507080	0.883	rs527475	ENSG00000255239.1	AP002954.6	27.57	3.98e-99	1.73e-94	1.08	0.79	Serum metabolite levels;	chr11:118692530	chr11:118688039~118690600:-
PRAD	cis	rs801193	0.935	rs2659899	ENSG00000226824.5	RP4-756H11.3	-27.57	4.25e-99	1.84e-94	-1.04	-0.79	Aortic root size;	chr7:66721734	chr7:66654538~66669855:+
PRAD	cis	rs801193	1	rs1553609	ENSG00000226824.5	RP4-756H11.3	-27.57	4.25e-99	1.84e-94	-1.04	-0.79	Aortic root size;	chr7:66732152	chr7:66654538~66669855:+
PRAD	cis	rs9326248	1	rs664971	ENSG00000254851.1	RP11-109L13.1	27.56	4.44e-99	1.93e-94	1.11	0.79	Blood protein levels;	chr11:117200141	chr11:117135528~117138582:+
PRAD	cis	rs801193	0.935	rs11772264	ENSG00000226824.5	RP4-756H11.3	-27.56	4.61e-99	1.99e-94	-1.05	-0.79	Aortic root size;	chr7:66711400	chr7:66654538~66669855:+
PRAD	cis	rs858239	0.632	rs1985769	ENSG00000230658.1	KLHL7-AS1	27.56	4.86e-99	2.09e-94	0.97	0.79	Cerebrospinal fluid biomarker levels;	chr7:23082887	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.6	rs28499396	ENSG00000230658.1	KLHL7-AS1	27.56	4.86e-99	2.09e-94	0.97	0.79	Cerebrospinal fluid biomarker levels;	chr7:23084479	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.6	rs7789237	ENSG00000230658.1	KLHL7-AS1	27.56	4.86e-99	2.09e-94	0.97	0.79	Cerebrospinal fluid biomarker levels;	chr7:23085094	chr7:23101228~23105703:-
PRAD	cis	rs9326248	0.954	rs8521	ENSG00000254851.1	RP11-109L13.1	-27.53	6.56e-99	2.82e-94	-1.11	-0.79	Blood protein levels;	chr11:117196983	chr11:117135528~117138582:+
PRAD	cis	rs507080	0.922	rs642662	ENSG00000255239.1	AP002954.6	27.52	7.2e-99	3.08e-94	1.09	0.79	Serum metabolite levels;	chr11:118696311	chr11:118688039~118690600:-
PRAD	cis	rs9326248	0.954	rs4938349	ENSG00000254851.1	RP11-109L13.1	-27.51	8.07e-99	3.45e-94	-1.11	-0.79	Blood protein levels;	chr11:117151207	chr11:117135528~117138582:+
PRAD	cis	rs2882667	0.69	rs825672	ENSG00000253404.1	AC034243.1	-27.49	9.96e-99	4.24e-94	-1.11	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138759954	chr5:138744434~138753309:-
PRAD	cis	rs9322193	0.923	rs10782317	ENSG00000231760.4	RP11-350J20.5	-27.48	1.06e-98	4.5e-94	-1.07	-0.79	Lung cancer;	chr6:149753911	chr6:149796151~149826294:-
PRAD	cis	rs801193	1	rs6958520	ENSG00000226824.5	RP4-756H11.3	-27.47	1.19e-98	4.95e-94	-1.04	-0.79	Aortic root size;	chr7:66686466	chr7:66654538~66669855:+
PRAD	cis	rs801193	0.967	rs2707849	ENSG00000226824.5	RP4-756H11.3	-27.47	1.19e-98	4.95e-94	-1.04	-0.79	Aortic root size;	chr7:66687725	chr7:66654538~66669855:+
PRAD	cis	rs801193	1	rs7788576	ENSG00000226824.5	RP4-756H11.3	27.47	1.19e-98	4.95e-94	1.04	0.79	Aortic root size;	chr7:66683315	chr7:66654538~66669855:+
PRAD	cis	rs507080	0.922	rs508640	ENSG00000255239.1	AP002954.6	27.47	1.2e-98	5.02e-94	1.09	0.79	Serum metabolite levels;	chr11:118693704	chr11:118688039~118690600:-
PRAD	cis	rs801193	1	rs11773829	ENSG00000226824.5	RP4-756H11.3	27.47	1.2e-98	5.02e-94	1.04	0.79	Aortic root size;	chr7:66676087	chr7:66654538~66669855:+
PRAD	cis	rs9322193	0.923	rs10872644	ENSG00000231760.4	RP11-350J20.5	27.45	1.45e-98	6.05e-94	1.07	0.79	Lung cancer;	chr6:149741819	chr6:149796151~149826294:-
PRAD	cis	rs801193	1	rs7782320	ENSG00000226824.5	RP4-756H11.3	-27.45	1.46e-98	6.08e-94	-1.05	-0.79	Aortic root size;	chr7:66712111	chr7:66654538~66669855:+
PRAD	cis	rs2882667	0.69	rs6596455	ENSG00000253404.1	AC034243.1	-27.44	1.61e-98	6.65e-94	-1.11	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138831416	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs995177	ENSG00000253404.1	AC034243.1	-27.44	1.61e-98	6.65e-94	-1.11	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138833874	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.654	rs7710300	ENSG00000253404.1	AC034243.1	-27.44	1.61e-98	6.65e-94	-1.11	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138834793	chr5:138744434~138753309:-
PRAD	cis	rs10256972	0.552	rs6978842	ENSG00000229043.2	AC091729.9	-27.44	1.68e-98	6.88e-94	-0.95	-0.79	Endometriosis;Longevity;	chr7:1164963	chr7:1160374~1165267:+
PRAD	cis	rs507080	0.922	rs555356	ENSG00000255239.1	AP002954.6	27.43	1.87e-98	7.65e-94	1.08	0.79	Serum metabolite levels;	chr11:118687369	chr11:118688039~118690600:-
PRAD	cis	rs2739330	0.892	rs4822455	ENSG00000273295.1	AP000350.5	27.42	2.02e-98	8.08e-94	0.96	0.79	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23901432~23907068:-
PRAD	cis	rs9322193	0.923	rs9766004	ENSG00000231760.4	RP11-350J20.5	27.41	2.11e-98	8.45e-94	1.07	0.79	Lung cancer;	chr6:149754363	chr6:149796151~149826294:-
PRAD	cis	rs916888	0.779	rs199528	ENSG00000262539.1	RP11-259G18.3	27.41	2.19e-98	8.74e-94	1.37	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46259551~46260606:-
PRAD	cis	rs916888	0.821	rs199525	ENSG00000262539.1	RP11-259G18.3	27.41	2.19e-98	8.74e-94	1.37	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46259551~46260606:-
PRAD	cis	rs507080	0.922	rs471227	ENSG00000255239.1	AP002954.6	27.36	3.61e-98	1.43e-93	1.08	0.79	Serum metabolite levels;	chr11:118693892	chr11:118688039~118690600:-
PRAD	cis	rs507080	0.922	rs516153	ENSG00000255239.1	AP002954.6	27.36	3.61e-98	1.43e-93	1.08	0.79	Serum metabolite levels;	chr11:118694053	chr11:118688039~118690600:-
PRAD	cis	rs507080	0.922	rs518028	ENSG00000255239.1	AP002954.6	27.36	3.61e-98	1.43e-93	1.08	0.79	Serum metabolite levels;	chr11:118694273	chr11:118688039~118690600:-
PRAD	cis	rs507080	0.922	rs519982	ENSG00000255239.1	AP002954.6	27.36	3.61e-98	1.43e-93	1.08	0.79	Serum metabolite levels;	chr11:118694522	chr11:118688039~118690600:-
PRAD	cis	rs507080	0.922	rs502601	ENSG00000255239.1	AP002954.6	27.36	3.61e-98	1.43e-93	1.08	0.79	Serum metabolite levels;	chr11:118694970	chr11:118688039~118690600:-
PRAD	cis	rs801193	0.935	rs3800820	ENSG00000226824.5	RP4-756H11.3	27.36	3.84e-98	1.52e-93	1.03	0.79	Aortic root size;	chr7:66682191	chr7:66654538~66669855:+
PRAD	cis	rs801193	1	rs2003301	ENSG00000226824.5	RP4-756H11.3	27.36	3.84e-98	1.52e-93	1.03	0.79	Aortic root size;	chr7:66682669	chr7:66654538~66669855:+
PRAD	cis	rs801193	1	rs7785213	ENSG00000226824.5	RP4-756H11.3	27.35	3.89e-98	1.53e-93	1.03	0.79	Aortic root size;	chr7:66673991	chr7:66654538~66669855:+
PRAD	cis	rs801193	0.967	rs2707841	ENSG00000226824.5	RP4-756H11.3	-27.35	3.89e-98	1.53e-93	-1.03	-0.79	Aortic root size;	chr7:66692033	chr7:66654538~66669855:+
PRAD	cis	rs2882667	0.728	rs10068766	ENSG00000253404.1	AC034243.1	27.35	3.94e-98	1.55e-93	1.12	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941095	chr5:138744434~138753309:-
PRAD	cis	rs507080	0.961	rs34413584	ENSG00000255239.1	AP002954.6	27.35	4.04e-98	1.59e-93	1.08	0.79	Serum metabolite levels;	chr11:118675072	chr11:118688039~118690600:-
PRAD	cis	rs916888	0.773	rs199445	ENSG00000262539.1	RP11-259G18.3	27.34	4.62e-98	1.81e-93	1.33	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46259551~46260606:-
PRAD	cis	rs916888	0.773	rs199443	ENSG00000262539.1	RP11-259G18.3	27.34	4.62e-98	1.81e-93	1.33	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46259551~46260606:-
PRAD	cis	rs507080	0.922	rs514143	ENSG00000255239.1	AP002954.6	27.33	5.27e-98	2.07e-93	1.09	0.79	Serum metabolite levels;	chr11:118687740	chr11:118688039~118690600:-
PRAD	cis	rs858239	0.6	rs6461692	ENSG00000230658.1	KLHL7-AS1	27.32	5.45e-98	2.13e-93	0.97	0.79	Cerebrospinal fluid biomarker levels;	chr7:23100076	chr7:23101228~23105703:-
PRAD	cis	rs507080	0.885	rs4938530	ENSG00000255239.1	AP002954.6	27.31	5.91e-98	2.3e-93	1.08	0.79	Serum metabolite levels;	chr11:118689861	chr11:118688039~118690600:-
PRAD	cis	rs2882667	0.654	rs2351247	ENSG00000253404.1	AC034243.1	-27.3	6.8e-98	2.61e-93	-1.11	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138849456	chr5:138744434~138753309:-
PRAD	cis	rs507080	0.845	rs613377	ENSG00000255239.1	AP002954.6	27.29	7.31e-98	2.8e-93	1.08	0.79	Serum metabolite levels;	chr11:118685375	chr11:118688039~118690600:-
PRAD	cis	rs507080	0.922	rs7114458	ENSG00000255239.1	AP002954.6	27.29	7.74e-98	2.94e-93	1.09	0.79	Serum metabolite levels;	chr11:118695466	chr11:118688039~118690600:-
PRAD	cis	rs507080	0.922	rs7114216	ENSG00000255239.1	AP002954.6	27.29	7.74e-98	2.94e-93	1.09	0.79	Serum metabolite levels;	chr11:118695525	chr11:118688039~118690600:-
PRAD	cis	rs507080	0.922	rs533646	ENSG00000255239.1	AP002954.6	27.29	7.74e-98	2.94e-93	1.09	0.79	Serum metabolite levels;	chr11:118696037	chr11:118688039~118690600:-
PRAD	cis	rs507080	0.922	rs478371	ENSG00000255239.1	AP002954.6	27.27	9.15e-98	3.46e-93	1.08	0.79	Serum metabolite levels;	chr11:118694627	chr11:118688039~118690600:-
PRAD	cis	rs801193	1	rs2659912	ENSG00000226824.5	RP4-756H11.3	-27.26	1.01e-97	3.79e-93	-1.04	-0.79	Aortic root size;	chr7:66693012	chr7:66654538~66669855:+
PRAD	cis	rs2882667	0.652	rs700622	ENSG00000253404.1	AC034243.1	-27.24	1.34e-97	4.95e-93	-1.11	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762862	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs7722965	ENSG00000253404.1	AC034243.1	-27.24	1.34e-97	4.95e-93	-1.11	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138764766	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs167009	ENSG00000253404.1	AC034243.1	-27.22	1.54e-97	5.68e-93	-1.11	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138864768	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs288040	ENSG00000253404.1	AC034243.1	27.22	1.54e-97	5.68e-93	1.11	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138869205	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.659	rs288037	ENSG00000253404.1	AC034243.1	27.22	1.54e-97	5.68e-93	1.11	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138872752	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs288036	ENSG00000253404.1	AC034243.1	27.22	1.54e-97	5.68e-93	1.11	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138875206	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs288035	ENSG00000253404.1	AC034243.1	27.22	1.54e-97	5.68e-93	1.11	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138876728	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs288032	ENSG00000253404.1	AC034243.1	27.22	1.54e-97	5.68e-93	1.11	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138879639	chr5:138744434~138753309:-
PRAD	cis	rs9322193	0.923	rs4870529	ENSG00000231760.4	RP11-350J20.5	27.22	1.65e-97	6.04e-93	1.06	0.79	Lung cancer;	chr6:149716436	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs9767309	ENSG00000231760.4	RP11-350J20.5	27.22	1.65e-97	6.04e-93	1.06	0.79	Lung cancer;	chr6:149716807	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs17745062	ENSG00000231760.4	RP11-350J20.5	27.22	1.65e-97	6.04e-93	1.06	0.79	Lung cancer;	chr6:149721079	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs62441279	ENSG00000231760.4	RP11-350J20.5	27.22	1.65e-97	6.04e-93	1.06	0.79	Lung cancer;	chr6:149721194	chr6:149796151~149826294:-
PRAD	cis	rs2882667	0.69	rs288026	ENSG00000253404.1	AC034243.1	27.21	1.83e-97	6.66e-93	1.11	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138886905	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs288024	ENSG00000253404.1	AC034243.1	27.21	1.83e-97	6.66e-93	1.11	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888103	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs288021	ENSG00000253404.1	AC034243.1	27.21	1.83e-97	6.66e-93	1.11	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888594	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs288017	ENSG00000253404.1	AC034243.1	-27.21	1.83e-97	6.66e-93	-1.11	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138857826	chr5:138744434~138753309:-
PRAD	cis	rs507080	0.922	rs558907	ENSG00000255239.1	AP002954.6	27.19	2.15e-97	7.62e-93	1.08	0.79	Serum metabolite levels;	chr11:118687746	chr11:118688039~118690600:-
PRAD	cis	rs9326248	0.954	rs521171	ENSG00000254851.1	RP11-109L13.1	-27.18	2.34e-97	8.25e-93	-1.11	-0.79	Blood protein levels;	chr11:117193977	chr11:117135528~117138582:+
PRAD	cis	rs507080	0.922	rs525485	ENSG00000255239.1	AP002954.6	27.17	2.68e-97	9.39e-93	1.09	0.79	Serum metabolite levels;	chr11:118685045	chr11:118688039~118690600:-
PRAD	cis	rs858239	0.6	rs59073109	ENSG00000230658.1	KLHL7-AS1	27.17	2.71e-97	9.45e-93	0.96	0.79	Cerebrospinal fluid biomarker levels;	chr7:23093607	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.6	rs7788821	ENSG00000230658.1	KLHL7-AS1	27.17	2.71e-97	9.45e-93	0.96	0.79	Cerebrospinal fluid biomarker levels;	chr7:23094026	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.6	rs6956595	ENSG00000230658.1	KLHL7-AS1	27.17	2.71e-97	9.45e-93	0.96	0.79	Cerebrospinal fluid biomarker levels;	chr7:23094637	chr7:23101228~23105703:-
PRAD	cis	rs9322193	0.923	rs9478291	ENSG00000231760.4	RP11-350J20.5	27.16	2.81e-97	9.75e-93	1.06	0.79	Lung cancer;	chr6:149729434	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs2185352	ENSG00000231760.4	RP11-350J20.5	27.16	2.81e-97	9.75e-93	1.06	0.79	Lung cancer;	chr6:149714640	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs12174349	ENSG00000231760.4	RP11-350J20.5	27.16	2.81e-97	9.75e-93	1.06	0.79	Lung cancer;	chr6:149718012	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs2297932	ENSG00000231760.4	RP11-350J20.5	27.16	2.81e-97	9.75e-93	1.06	0.79	Lung cancer;	chr6:149718225	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs2297930	ENSG00000231760.4	RP11-350J20.5	27.16	2.81e-97	9.75e-93	1.06	0.79	Lung cancer;	chr6:149718360	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs9479094	ENSG00000231760.4	RP11-350J20.5	27.16	2.81e-97	9.75e-93	1.06	0.79	Lung cancer;	chr6:149725083	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs2297928	ENSG00000231760.4	RP11-350J20.5	27.16	2.84e-97	9.86e-93	1.06	0.79	Lung cancer;	chr6:149718584	chr6:149796151~149826294:-
PRAD	cis	rs507080	0.883	rs558593	ENSG00000255239.1	AP002954.6	27.16	3.05e-97	1.05e-92	1.07	0.79	Serum metabolite levels;	chr11:118691811	chr11:118688039~118690600:-
PRAD	cis	rs858239	0.601	rs10239760	ENSG00000230658.1	KLHL7-AS1	27.13	3.84e-97	1.32e-92	0.98	0.79	Cerebrospinal fluid biomarker levels;	chr7:23110331	chr7:23101228~23105703:-
PRAD	cis	rs9326248	1	rs7946257	ENSG00000254851.1	RP11-109L13.1	-27.13	4.02e-97	1.38e-92	-1.11	-0.79	Blood protein levels;	chr11:117182449	chr11:117135528~117138582:+
PRAD	cis	rs507080	0.922	rs4938524	ENSG00000255239.1	AP002954.6	27.13	4.03e-97	1.39e-92	1.08	0.79	Serum metabolite levels;	chr11:118681365	chr11:118688039~118690600:-
PRAD	cis	rs9322193	0.923	rs10747276	ENSG00000231760.4	RP11-350J20.5	27.13	4.08e-97	1.4e-92	1.05	0.79	Lung cancer;	chr6:149758739	chr6:149796151~149826294:-
PRAD	cis	rs2882667	0.628	rs10076629	ENSG00000253404.1	AC034243.1	27.12	4.63e-97	1.58e-92	1.11	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920272	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.659	rs11750067	ENSG00000253404.1	AC034243.1	27.12	4.63e-97	1.58e-92	1.11	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920589	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs10054682	ENSG00000253404.1	AC034243.1	27.12	4.63e-97	1.58e-92	1.11	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138923754	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs11953339	ENSG00000253404.1	AC034243.1	27.12	4.63e-97	1.58e-92	1.11	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138923853	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs9327828	ENSG00000253404.1	AC034243.1	27.12	4.63e-97	1.58e-92	1.11	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138925859	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs288007	ENSG00000253404.1	AC034243.1	27.1	5.24e-97	1.79e-92	1.1	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138894939	chr5:138744434~138753309:-
PRAD	cis	rs507080	0.961	rs642497	ENSG00000255239.1	AP002954.6	27.06	7.91e-97	2.68e-92	1.06	0.79	Serum metabolite levels;	chr11:118680075	chr11:118688039~118690600:-
PRAD	cis	rs507080	0.845	rs667982	ENSG00000255239.1	AP002954.6	27.04	9.89e-97	3.33e-92	1.06	0.79	Serum metabolite levels;	chr11:118692058	chr11:118688039~118690600:-
PRAD	cis	rs858239	0.539	rs6945510	ENSG00000230658.1	KLHL7-AS1	27.04	1.01e-96	3.41e-92	0.97	0.79	Cerebrospinal fluid biomarker levels;	chr7:23152621	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.601	rs11984129	ENSG00000230658.1	KLHL7-AS1	27.03	1.08e-96	3.63e-92	0.96	0.79	Cerebrospinal fluid biomarker levels;	chr7:23113058	chr7:23101228~23105703:-
PRAD	cis	rs9322193	0.923	rs4870267	ENSG00000231760.4	RP11-350J20.5	27.02	1.19e-96	3.99e-92	1.06	0.78	Lung cancer;	chr6:149671572	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs1934534	ENSG00000231760.4	RP11-350J20.5	27.02	1.3e-96	4.36e-92	1.06	0.78	Lung cancer;	chr6:149711896	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs9767123	ENSG00000231760.4	RP11-350J20.5	27.01	1.4e-96	4.67e-92	1.06	0.78	Lung cancer;	chr6:149660323	chr6:149796151~149826294:-
PRAD	cis	rs2882667	0.619	rs6861556	ENSG00000253404.1	AC034243.1	-27.01	1.41e-96	4.71e-92	-1.11	-0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138852351	chr5:138744434~138753309:-
PRAD	cis	rs9326248	0.817	rs1242127	ENSG00000254851.1	RP11-109L13.1	27	1.56e-96	5.2e-92	1.09	0.78	Blood protein levels;	chr11:117205848	chr11:117135528~117138582:+
PRAD	cis	rs2882667	0.69	rs12186373	ENSG00000253404.1	AC034243.1	27	1.61e-96	5.36e-92	1.11	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138912885	chr5:138744434~138753309:-
PRAD	cis	rs858239	0.6	rs4321896	ENSG00000230658.1	KLHL7-AS1	26.99	1.77e-96	5.88e-92	0.97	0.78	Cerebrospinal fluid biomarker levels;	chr7:23088437	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.601	rs7805206	ENSG00000230658.1	KLHL7-AS1	26.99	1.77e-96	5.89e-92	0.96	0.78	Cerebrospinal fluid biomarker levels;	chr7:23120591	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.509	rs57611130	ENSG00000230658.1	KLHL7-AS1	26.98	1.84e-96	6.12e-92	0.98	0.78	Cerebrospinal fluid biomarker levels;	chr7:23144933	chr7:23101228~23105703:-
PRAD	cis	rs2882667	0.69	rs10155636	ENSG00000253404.1	AC034243.1	26.98	1.91e-96	6.34e-92	1.11	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138926301	chr5:138744434~138753309:-
PRAD	cis	rs9322193	0.923	rs3924871	ENSG00000231760.4	RP11-350J20.5	26.97	2.01e-96	6.67e-92	1.06	0.78	Lung cancer;	chr6:149662080	chr6:149796151~149826294:-
PRAD	cis	rs858239	0.571	rs2390755	ENSG00000230658.1	KLHL7-AS1	26.95	2.47e-96	8.1e-92	0.97	0.78	Cerebrospinal fluid biomarker levels;	chr7:23151097	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.539	rs4365988	ENSG00000230658.1	KLHL7-AS1	26.95	2.47e-96	8.1e-92	0.97	0.78	Cerebrospinal fluid biomarker levels;	chr7:23151252	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.539	rs10279194	ENSG00000230658.1	KLHL7-AS1	26.95	2.47e-96	8.1e-92	0.97	0.78	Cerebrospinal fluid biomarker levels;	chr7:23151464	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.539	rs3950345	ENSG00000230658.1	KLHL7-AS1	26.95	2.47e-96	8.1e-92	0.97	0.78	Cerebrospinal fluid biomarker levels;	chr7:23151495	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.539	rs2178139	ENSG00000230658.1	KLHL7-AS1	26.95	2.47e-96	8.1e-92	0.97	0.78	Cerebrospinal fluid biomarker levels;	chr7:23152017	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.539	rs2141306	ENSG00000230658.1	KLHL7-AS1	26.95	2.47e-96	8.1e-92	0.97	0.78	Cerebrospinal fluid biomarker levels;	chr7:23152045	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.539	rs2141305	ENSG00000230658.1	KLHL7-AS1	26.95	2.47e-96	8.1e-92	0.97	0.78	Cerebrospinal fluid biomarker levels;	chr7:23152280	chr7:23101228~23105703:-
PRAD	cis	rs2882667	0.69	rs288009	ENSG00000253404.1	AC034243.1	26.95	2.54e-96	8.27e-92	1.11	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138892973	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs185956	ENSG00000253404.1	AC034243.1	26.95	2.54e-96	8.27e-92	1.11	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138894574	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.658	rs288003	ENSG00000253404.1	AC034243.1	26.95	2.54e-96	8.27e-92	1.11	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138896266	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs288002	ENSG00000253404.1	AC034243.1	26.95	2.54e-96	8.27e-92	1.11	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138896398	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs10044401	ENSG00000253404.1	AC034243.1	26.95	2.54e-96	8.27e-92	1.11	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138901868	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs10067361	ENSG00000253404.1	AC034243.1	26.95	2.54e-96	8.27e-92	1.11	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138905185	chr5:138744434~138753309:-
PRAD	cis	rs507080	0.922	rs644867	ENSG00000255239.1	AP002954.6	26.95	2.73e-96	8.86e-92	1.08	0.78	Serum metabolite levels;	chr11:118696836	chr11:118688039~118690600:-
PRAD	cis	rs507080	0.883	rs692750	ENSG00000255239.1	AP002954.6	26.94	2.75e-96	8.94e-92	1.08	0.78	Serum metabolite levels;	chr11:118667599	chr11:118688039~118690600:-
PRAD	cis	rs9322193	0.923	rs11155674	ENSG00000231760.4	RP11-350J20.5	26.94	2.99e-96	9.67e-92	1.06	0.78	Lung cancer;	chr6:149711111	chr6:149796151~149826294:-
PRAD	cis	rs858239	0.6	rs61292332	ENSG00000230658.1	KLHL7-AS1	26.93	3.24e-96	1.04e-91	0.96	0.78	Cerebrospinal fluid biomarker levels;	chr7:23092243	chr7:23101228~23105703:-
PRAD	cis	rs9322193	0.962	rs4380763	ENSG00000231760.4	RP11-350J20.5	26.92	3.37e-96	1.08e-91	1.07	0.78	Lung cancer;	chr6:149678086	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.884	rs62439836	ENSG00000231760.4	RP11-350J20.5	26.92	3.61e-96	1.16e-91	1.07	0.78	Lung cancer;	chr6:149669173	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs4869812	ENSG00000231760.4	RP11-350J20.5	26.92	3.61e-96	1.16e-91	1.07	0.78	Lung cancer;	chr6:149669447	chr6:149796151~149826294:-
PRAD	cis	rs2882667	0.69	rs288018	ENSG00000253404.1	AC034243.1	-26.91	3.81e-96	1.22e-91	-1.1	-0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138856727	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.628	rs311607	ENSG00000253404.1	AC034243.1	26.91	4.03e-96	1.29e-91	1.11	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138709231	chr5:138744434~138753309:-
PRAD	cis	rs9322193	0.923	rs56397000	ENSG00000231760.4	RP11-350J20.5	26.89	4.97e-96	1.59e-91	1.05	0.78	Lung cancer;	chr6:149739347	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.884	rs9689702	ENSG00000231760.4	RP11-350J20.5	26.89	4.97e-96	1.59e-91	1.05	0.78	Lung cancer;	chr6:149740720	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs10782315	ENSG00000231760.4	RP11-350J20.5	26.89	4.97e-96	1.59e-91	1.05	0.78	Lung cancer;	chr6:149743093	chr6:149796151~149826294:-
PRAD	cis	rs916888	0.773	rs199445	ENSG00000214401.4	KANSL1-AS1	26.89	4.98e-96	1.59e-91	1.3	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46193576~46196723:+
PRAD	cis	rs916888	0.773	rs199443	ENSG00000214401.4	KANSL1-AS1	26.89	4.98e-96	1.59e-91	1.3	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46193576~46196723:+
PRAD	cis	rs9326248	1	rs4938354	ENSG00000254851.1	RP11-109L13.1	-26.89	5.02e-96	1.6e-91	-1.12	-0.78	Blood protein levels;	chr11:117180449	chr11:117135528~117138582:+
PRAD	cis	rs801193	0.967	rs34356500	ENSG00000226824.5	RP4-756H11.3	-26.89	5.03e-96	1.6e-91	-1.02	-0.78	Aortic root size;	chr7:66771620	chr7:66654538~66669855:+
PRAD	cis	rs9322193	0.923	rs35830138	ENSG00000231760.4	RP11-350J20.5	26.88	5.39e-96	1.7e-91	1.06	0.78	Lung cancer;	chr6:149668635	chr6:149796151~149826294:-
PRAD	cis	rs2882667	0.554	rs1368425	ENSG00000253404.1	AC034243.1	26.88	5.4e-96	1.7e-91	1.11	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138944528	chr5:138744434~138753309:-
PRAD	cis	rs801193	1	rs6975195	ENSG00000226824.5	RP4-756H11.3	26.88	5.47e-96	1.71e-91	1.03	0.78	Aortic root size;	chr7:66659787	chr7:66654538~66669855:+
PRAD	cis	rs801193	1	rs3857688	ENSG00000226824.5	RP4-756H11.3	26.88	5.47e-96	1.71e-91	1.03	0.78	Aortic root size;	chr7:66662819	chr7:66654538~66669855:+
PRAD	cis	rs801193	1	rs2286684	ENSG00000226824.5	RP4-756H11.3	26.88	5.47e-96	1.71e-91	1.03	0.78	Aortic root size;	chr7:66664843	chr7:66654538~66669855:+
PRAD	cis	rs801193	0.935	rs2286683	ENSG00000226824.5	RP4-756H11.3	26.88	5.47e-96	1.71e-91	1.03	0.78	Aortic root size;	chr7:66664856	chr7:66654538~66669855:+
PRAD	cis	rs801193	1	rs10274773	ENSG00000226824.5	RP4-756H11.3	26.88	5.47e-96	1.71e-91	1.03	0.78	Aortic root size;	chr7:66668591	chr7:66654538~66669855:+
PRAD	cis	rs9322193	0.923	rs35961297	ENSG00000231760.4	RP11-350J20.5	26.88	5.5e-96	1.72e-91	1.06	0.78	Lung cancer;	chr6:149667929	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs35967444	ENSG00000231760.4	RP11-350J20.5	26.88	5.5e-96	1.72e-91	1.06	0.78	Lung cancer;	chr6:149675588	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs62439842	ENSG00000231760.4	RP11-350J20.5	26.88	5.5e-96	1.72e-91	1.06	0.78	Lung cancer;	chr6:149675847	chr6:149796151~149826294:-
PRAD	cis	rs858239	0.539	rs10280815	ENSG00000230658.1	KLHL7-AS1	26.87	5.91e-96	1.84e-91	0.97	0.78	Cerebrospinal fluid biomarker levels;	chr7:23148751	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.539	rs10225608	ENSG00000230658.1	KLHL7-AS1	26.87	5.91e-96	1.84e-91	0.97	0.78	Cerebrospinal fluid biomarker levels;	chr7:23149289	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.539	rs28624974	ENSG00000230658.1	KLHL7-AS1	26.87	5.91e-96	1.84e-91	0.97	0.78	Cerebrospinal fluid biomarker levels;	chr7:23149317	chr7:23101228~23105703:-
PRAD	cis	rs5850	0.557	rs10270788	ENSG00000230658.1	KLHL7-AS1	26.87	5.91e-96	1.84e-91	0.97	0.78	Blood protein levels;	chr7:23149381	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.539	rs28716381	ENSG00000230658.1	KLHL7-AS1	26.87	5.91e-96	1.84e-91	0.97	0.78	Cerebrospinal fluid biomarker levels;	chr7:23149396	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.539	rs1358442	ENSG00000230658.1	KLHL7-AS1	26.87	5.91e-96	1.84e-91	0.97	0.78	Cerebrospinal fluid biomarker levels;	chr7:23150120	chr7:23101228~23105703:-
PRAD	cis	rs507080	0.922	rs12788848	ENSG00000255239.1	AP002954.6	26.86	6.52e-96	2.01e-91	1.06	0.78	Serum metabolite levels;	chr11:118683079	chr11:118688039~118690600:-
PRAD	cis	rs507080	0.922	rs4474473	ENSG00000255239.1	AP002954.6	26.86	6.52e-96	2.01e-91	1.06	0.78	Serum metabolite levels;	chr11:118683180	chr11:118688039~118690600:-
PRAD	cis	rs507080	0.922	rs12796373	ENSG00000255239.1	AP002954.6	26.86	6.52e-96	2.01e-91	1.06	0.78	Serum metabolite levels;	chr11:118684230	chr11:118688039~118690600:-
PRAD	cis	rs875971	0.638	rs7793569	ENSG00000226824.5	RP4-756H11.3	26.85	7.58e-96	2.33e-91	1.03	0.78	Aortic root size;	chr7:66651646	chr7:66654538~66669855:+
PRAD	cis	rs507080	0.922	rs478296	ENSG00000255239.1	AP002954.6	26.85	7.6e-96	2.33e-91	1.08	0.78	Serum metabolite levels;	chr11:118696666	chr11:118688039~118690600:-
PRAD	cis	rs507080	0.922	rs493834	ENSG00000255239.1	AP002954.6	26.85	7.6e-96	2.33e-91	1.08	0.78	Serum metabolite levels;	chr11:118696735	chr11:118688039~118690600:-
PRAD	cis	rs507080	0.922	rs644498	ENSG00000255239.1	AP002954.6	26.85	7.6e-96	2.33e-91	1.08	0.78	Serum metabolite levels;	chr11:118696777	chr11:118688039~118690600:-
PRAD	cis	rs9322193	0.923	rs4354168	ENSG00000231760.4	RP11-350J20.5	26.83	9.44e-96	2.88e-91	1.06	0.78	Lung cancer;	chr6:149696642	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs4455682	ENSG00000231760.4	RP11-350J20.5	26.83	9.44e-96	2.88e-91	1.06	0.78	Lung cancer;	chr6:149700161	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs12660304	ENSG00000231760.4	RP11-350J20.5	26.82	9.74e-96	2.97e-91	1.04	0.78	Lung cancer;	chr6:149739647	chr6:149796151~149826294:-
PRAD	cis	rs507080	0.922	rs4589335	ENSG00000255239.1	AP002954.6	26.81	1.14e-95	3.47e-91	1.07	0.78	Serum metabolite levels;	chr11:118668431	chr11:118688039~118690600:-
PRAD	cis	rs9322193	0.923	rs9800736	ENSG00000231760.4	RP11-350J20.5	26.8	1.22e-95	3.7e-91	1.05	0.78	Lung cancer;	chr6:149661281	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs7767622	ENSG00000231760.4	RP11-350J20.5	26.79	1.31e-95	3.97e-91	1.05	0.78	Lung cancer;	chr6:149681766	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs4421206	ENSG00000231760.4	RP11-350J20.5	26.79	1.31e-95	3.97e-91	1.05	0.78	Lung cancer;	chr6:149682891	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs3798761	ENSG00000231760.4	RP11-350J20.5	26.79	1.31e-95	3.97e-91	1.05	0.78	Lung cancer;	chr6:149683643	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs9322209	ENSG00000231760.4	RP11-350J20.5	26.79	1.31e-95	3.97e-91	1.05	0.78	Lung cancer;	chr6:149691226	chr6:149796151~149826294:-
PRAD	cis	rs507080	0.922	rs519848	ENSG00000255239.1	AP002954.6	26.78	1.46e-95	4.41e-91	1.06	0.78	Serum metabolite levels;	chr11:118682006	chr11:118688039~118690600:-
PRAD	cis	rs9322193	0.923	rs9968911	ENSG00000231760.4	RP11-350J20.5	26.77	1.62e-95	4.9e-91	1.07	0.78	Lung cancer;	chr6:149657419	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.884	rs9322210	ENSG00000231760.4	RP11-350J20.5	26.77	1.76e-95	5.26e-91	1.05	0.78	Lung cancer;	chr6:149695440	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs9688350	ENSG00000231760.4	RP11-350J20.5	26.75	2.14e-95	6.39e-91	1.05	0.78	Lung cancer;	chr6:149730977	chr6:149796151~149826294:-
PRAD	cis	rs916888	0.773	rs199535	ENSG00000262539.1	RP11-259G18.3	26.73	2.52e-95	7.51e-91	1.32	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46259551~46260606:-
PRAD	cis	rs858239	0.601	rs10224327	ENSG00000230658.1	KLHL7-AS1	26.73	2.52e-95	7.52e-91	0.98	0.78	Cerebrospinal fluid biomarker levels;	chr7:23122201	chr7:23101228~23105703:-
PRAD	cis	rs507080	0.961	rs673770	ENSG00000255239.1	AP002954.6	26.73	2.6e-95	7.74e-91	1.06	0.78	Serum metabolite levels;	chr11:118679892	chr11:118688039~118690600:-
PRAD	cis	rs9322193	0.923	rs9689723	ENSG00000231760.4	RP11-350J20.5	26.73	2.63e-95	7.82e-91	1.06	0.78	Lung cancer;	chr6:149655935	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs11155671	ENSG00000231760.4	RP11-350J20.5	26.72	2.93e-95	8.72e-91	1.07	0.78	Lung cancer;	chr6:149650996	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs9689716	ENSG00000231760.4	RP11-350J20.5	26.71	3.18e-95	9.41e-91	1.06	0.78	Lung cancer;	chr6:149655662	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs9322207	ENSG00000231760.4	RP11-350J20.5	26.71	3.18e-95	9.41e-91	1.06	0.78	Lung cancer;	chr6:149657185	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs9322208	ENSG00000231760.4	RP11-350J20.5	26.71	3.18e-95	9.41e-91	1.06	0.78	Lung cancer;	chr6:149658547	chr6:149796151~149826294:-
PRAD	cis	rs507080	0.885	rs7926959	ENSG00000255239.1	AP002954.6	26.71	3.25e-95	9.6e-91	1.08	0.78	Serum metabolite levels;	chr11:118689157	chr11:118688039~118690600:-
PRAD	cis	rs507080	0.663	rs7926970	ENSG00000255239.1	AP002954.6	26.71	3.25e-95	9.6e-91	1.08	0.78	Serum metabolite levels;	chr11:118689172	chr11:118688039~118690600:-
PRAD	cis	rs507080	0.961	rs4457789	ENSG00000255239.1	AP002954.6	26.69	3.71e-95	1.09e-90	1.08	0.78	Serum metabolite levels;	chr11:118668461	chr11:118688039~118690600:-
PRAD	cis	rs858239	0.539	rs2178140	ENSG00000230658.1	KLHL7-AS1	26.69	3.72e-95	1.1e-90	0.97	0.78	Cerebrospinal fluid biomarker levels;	chr7:23152006	chr7:23101228~23105703:-
PRAD	cis	rs2882667	0.69	rs7736925	ENSG00000253404.1	AC034243.1	-26.69	3.94e-95	1.16e-90	-1.1	-0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138818841	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.654	rs883333	ENSG00000253404.1	AC034243.1	-26.69	3.94e-95	1.16e-90	-1.1	-0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138819781	chr5:138744434~138753309:-
PRAD	cis	rs9322193	0.923	rs9800871	ENSG00000231760.4	RP11-350J20.5	26.68	4.52e-95	1.33e-90	1.06	0.78	Lung cancer;	chr6:149644540	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs9767652	ENSG00000231760.4	RP11-350J20.5	26.67	4.73e-95	1.38e-90	1.05	0.78	Lung cancer;	chr6:149734502	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs10782314	ENSG00000231760.4	RP11-350J20.5	26.67	4.73e-95	1.38e-90	1.05	0.78	Lung cancer;	chr6:149735527	chr6:149796151~149826294:-
PRAD	cis	rs507080	0.961	rs600969	ENSG00000255239.1	AP002954.6	26.65	5.98e-95	1.74e-90	1.06	0.78	Serum metabolite levels;	chr11:118675087	chr11:118688039~118690600:-
PRAD	cis	rs2882667	0.69	rs288028	ENSG00000253404.1	AC034243.1	26.63	6.91e-95	2.01e-90	1.1	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138886300	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.654	rs7709770	ENSG00000253404.1	AC034243.1	-26.61	8.92e-95	2.59e-90	-1.11	-0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138813650	chr5:138744434~138753309:-
PRAD	cis	rs9322193	0.886	rs4870049	ENSG00000231760.4	RP11-350J20.5	26.61	9.24e-95	2.67e-90	1.06	0.78	Lung cancer;	chr6:149837058	chr6:149796151~149826294:-
PRAD	cis	rs507080	0.961	rs520543	ENSG00000255239.1	AP002954.6	26.6	9.98e-95	2.88e-90	1.07	0.78	Serum metabolite levels;	chr11:118667448	chr11:118688039~118690600:-
PRAD	cis	rs9322193	0.923	rs12529698	ENSG00000231760.4	RP11-350J20.5	26.6	1.01e-94	2.93e-90	1.06	0.78	Lung cancer;	chr6:149650951	chr6:149796151~149826294:-
PRAD	cis	rs2882667	0.622	rs34645817	ENSG00000253404.1	AC034243.1	-26.58	1.18e-94	3.4e-90	-1.11	-0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138816944	chr5:138744434~138753309:-
PRAD	cis	rs858239	0.601	rs764534	ENSG00000230658.1	KLHL7-AS1	26.58	1.28e-94	3.67e-90	0.97	0.78	Cerebrospinal fluid biomarker levels;	chr7:23114316	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.601	rs2068459	ENSG00000230658.1	KLHL7-AS1	26.58	1.28e-94	3.67e-90	0.97	0.78	Cerebrospinal fluid biomarker levels;	chr7:23114694	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.601	rs73272053	ENSG00000230658.1	KLHL7-AS1	26.58	1.28e-94	3.67e-90	0.97	0.78	Cerebrospinal fluid biomarker levels;	chr7:23115906	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.6	rs6967475	ENSG00000230658.1	KLHL7-AS1	26.57	1.3e-94	3.71e-90	0.96	0.78	Cerebrospinal fluid biomarker levels;	chr7:23089363	chr7:23101228~23105703:-
PRAD	cis	rs916888	0.779	rs199528	ENSG00000214401.4	KANSL1-AS1	26.55	1.64e-94	4.7e-90	1.34	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46193576~46196723:+
PRAD	cis	rs916888	0.821	rs199525	ENSG00000214401.4	KANSL1-AS1	26.55	1.64e-94	4.7e-90	1.34	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46193576~46196723:+
PRAD	cis	rs9322193	0.923	rs9800614	ENSG00000231760.4	RP11-350J20.5	26.54	1.91e-94	5.45e-90	1.06	0.78	Lung cancer;	chr6:149644604	chr6:149796151~149826294:-
PRAD	cis	rs2882667	0.69	rs17031	ENSG00000253404.1	AC034243.1	26.52	2.22e-94	6.31e-90	1.09	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138934853	chr5:138744434~138753309:-
PRAD	cis	rs9322193	0.923	rs9383812	ENSG00000231760.4	RP11-350J20.5	26.48	3.33e-94	9.11e-90	1.04	0.78	Lung cancer;	chr6:149712355	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.847	rs9383844	ENSG00000231760.4	RP11-350J20.5	26.48	3.33e-94	9.11e-90	1.04	0.78	Lung cancer;	chr6:149716268	chr6:149796151~149826294:-
PRAD	cis	rs507080	0.922	rs592280	ENSG00000255239.1	AP002954.6	26.48	3.5e-94	9.58e-90	1.06	0.78	Serum metabolite levels;	chr11:118682509	chr11:118688039~118690600:-
PRAD	cis	rs858239	0.539	rs6965833	ENSG00000230658.1	KLHL7-AS1	26.47	3.91e-94	1.07e-89	0.97	0.78	Cerebrospinal fluid biomarker levels;	chr7:23152747	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.539	rs6949363	ENSG00000230658.1	KLHL7-AS1	26.47	3.91e-94	1.07e-89	0.97	0.78	Cerebrospinal fluid biomarker levels;	chr7:23152775	chr7:23101228~23105703:-
PRAD	cis	rs2882667	0.587	rs825674	ENSG00000253404.1	AC034243.1	-26.46	4.41e-94	1.2e-89	-1.12	-0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138767031	chr5:138744434~138753309:-
PRAD	cis	rs10256972	0.552	rs2960837	ENSG00000229043.2	AC091729.9	-26.45	4.95e-94	1.35e-89	-0.94	-0.78	Endometriosis;Longevity;	chr7:1164321	chr7:1160374~1165267:+
PRAD	cis	rs507080	0.961	rs1784298	ENSG00000255239.1	AP002954.6	26.44	5.02e-94	1.36e-89	1.06	0.78	Serum metabolite levels;	chr11:118677956	chr11:118688039~118690600:-
PRAD	cis	rs507080	0.961	rs4938522	ENSG00000255239.1	AP002954.6	26.44	5.02e-94	1.36e-89	1.06	0.78	Serum metabolite levels;	chr11:118677962	chr11:118688039~118690600:-
PRAD	cis	rs507080	1	rs659969	ENSG00000255239.1	AP002954.6	26.44	5.02e-94	1.36e-89	1.06	0.78	Serum metabolite levels;	chr11:118679094	chr11:118688039~118690600:-
PRAD	cis	rs10256972	0.577	rs2949179	ENSG00000229043.2	AC091729.9	-26.42	6.34e-94	1.72e-89	-0.95	-0.78	Endometriosis;Longevity;	chr7:1170249	chr7:1160374~1165267:+
PRAD	cis	rs10256972	0.504	rs2949178	ENSG00000229043.2	AC091729.9	-26.42	6.34e-94	1.72e-89	-0.95	-0.78	Endometriosis;Longevity;	chr7:1170289	chr7:1160374~1165267:+
PRAD	cis	rs916888	0.773	rs169201	ENSG00000214401.4	KANSL1-AS1	26.42	6.58e-94	1.78e-89	1.32	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46193576~46196723:+
PRAD	cis	rs875971	0.619	rs12533585	ENSG00000226824.5	RP4-756H11.3	-26.41	7.27e-94	1.96e-89	-0.99	-0.78	Aortic root size;	chr7:66519618	chr7:66654538~66669855:+
PRAD	cis	rs507080	0.961	rs642530	ENSG00000255239.1	AP002954.6	26.4	7.93e-94	2.13e-89	1.05	0.78	Serum metabolite levels;	chr11:118680047	chr11:118688039~118690600:-
PRAD	cis	rs9322193	0.923	rs9377230	ENSG00000231760.4	RP11-350J20.5	26.4	8.22e-94	2.21e-89	1.05	0.78	Lung cancer;	chr6:149613607	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs9767105	ENSG00000231760.4	RP11-350J20.5	26.38	9.96e-94	2.67e-89	1.06	0.78	Lung cancer;	chr6:149659591	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs11155670	ENSG00000231760.4	RP11-350J20.5	26.38	1.03e-93	2.76e-89	1.06	0.78	Lung cancer;	chr6:149644992	chr6:149796151~149826294:-
PRAD	cis	rs507080	1	rs507080	ENSG00000255239.1	AP002954.6	26.37	1.12e-93	2.99e-89	1.05	0.78	Serum metabolite levels;	chr11:118678873	chr11:118688039~118690600:-
PRAD	cis	rs875971	0.522	rs1968127	ENSG00000226824.5	RP4-756H11.3	26.34	1.43e-93	3.82e-89	1	0.78	Aortic root size;	chr7:66591816	chr7:66654538~66669855:+
PRAD	cis	rs2882667	0.69	rs10078079	ENSG00000253404.1	AC034243.1	26.34	1.49e-93	3.95e-89	1.12	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920450	chr5:138744434~138753309:-
PRAD	cis	rs858239	0.601	rs12539331	ENSG00000230658.1	KLHL7-AS1	26.34	1.54e-93	4.09e-89	0.97	0.78	Cerebrospinal fluid biomarker levels;	chr7:23111711	chr7:23101228~23105703:-
PRAD	cis	rs507080	0.807	rs7926944	ENSG00000255239.1	AP002954.6	26.32	1.84e-93	4.89e-89	1.08	0.78	Serum metabolite levels;	chr11:118689119	chr11:118688039~118690600:-
PRAD	cis	rs858239	0.6	rs7776644	ENSG00000230658.1	KLHL7-AS1	26.31	1.96e-93	5.19e-89	0.96	0.78	Cerebrospinal fluid biomarker levels;	chr7:23079688	chr7:23101228~23105703:-
PRAD	cis	rs507080	0.961	rs543413	ENSG00000255239.1	AP002954.6	26.31	2.02e-93	5.33e-89	1.05	0.78	Serum metabolite levels;	chr11:118679308	chr11:118688039~118690600:-
PRAD	cis	rs875971	0.638	rs801216	ENSG00000226824.5	RP4-756H11.3	26.31	2.02e-93	5.33e-89	0.99	0.78	Aortic root size;	chr7:66546680	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.66	rs801211	ENSG00000226824.5	RP4-756H11.3	26.31	2.02e-93	5.33e-89	0.99	0.78	Aortic root size;	chr7:66550702	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.66	rs12698534	ENSG00000226824.5	RP4-756H11.3	-26.31	2.02e-93	5.33e-89	-0.99	-0.78	Aortic root size;	chr7:66521858	chr7:66654538~66669855:+
PRAD	cis	rs9322193	0.923	rs4870050	ENSG00000231760.4	RP11-350J20.5	26.31	2.05e-93	5.4e-89	1.06	0.78	Lung cancer;	chr6:149838917	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.962	rs7752089	ENSG00000231760.4	RP11-350J20.5	26.31	2.05e-93	5.4e-89	1.06	0.78	Lung cancer;	chr6:149839298	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs4242279	ENSG00000231760.4	RP11-350J20.5	26.31	2.05e-93	5.4e-89	1.06	0.78	Lung cancer;	chr6:149839815	chr6:149796151~149826294:-
PRAD	cis	rs801193	1	rs2659915	ENSG00000226824.5	RP4-756H11.3	-26.28	2.87e-93	7.54e-89	-1.01	-0.78	Aortic root size;	chr7:66688114	chr7:66654538~66669855:+
PRAD	cis	rs2882667	0.654	rs825760	ENSG00000253404.1	AC034243.1	-26.27	3.15e-93	8.27e-89	-1.11	-0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138804285	chr5:138744434~138753309:-
PRAD	cis	rs507080	0.922	rs12577485	ENSG00000255239.1	AP002954.6	26.26	3.46e-93	9.07e-89	1.05	0.78	Serum metabolite levels;	chr11:118676793	chr11:118688039~118690600:-
PRAD	cis	rs507080	0.961	rs4938523	ENSG00000255239.1	AP002954.6	26.24	4.19e-93	1.1e-88	1.05	0.78	Serum metabolite levels;	chr11:118678129	chr11:118688039~118690600:-
PRAD	cis	rs507080	0.883	rs656575	ENSG00000255239.1	AP002954.6	26.23	4.95e-93	1.29e-88	1.06	0.78	Serum metabolite levels;	chr11:118679199	chr11:118688039~118690600:-
PRAD	cis	rs507080	0.961	rs656505	ENSG00000255239.1	AP002954.6	26.23	4.95e-93	1.29e-88	1.06	0.78	Serum metabolite levels;	chr11:118679245	chr11:118688039~118690600:-
PRAD	cis	rs507080	0.961	rs660489	ENSG00000255239.1	AP002954.6	26.23	4.95e-93	1.29e-88	1.06	0.78	Serum metabolite levels;	chr11:118679255	chr11:118688039~118690600:-
PRAD	cis	rs507080	0.961	rs543327	ENSG00000255239.1	AP002954.6	26.23	4.95e-93	1.29e-88	1.06	0.78	Serum metabolite levels;	chr11:118679276	chr11:118688039~118690600:-
PRAD	cis	rs9322193	0.884	rs7450246	ENSG00000231760.4	RP11-350J20.5	26.22	5.03e-93	1.31e-88	1.04	0.78	Lung cancer;	chr6:149702517	chr6:149796151~149826294:-
PRAD	cis	rs858239	0.571	rs6953020	ENSG00000230658.1	KLHL7-AS1	26.22	5.26e-93	1.37e-88	0.96	0.78	Cerebrospinal fluid biomarker levels;	chr7:23132513	chr7:23101228~23105703:-
PRAD	cis	rs2882667	0.69	rs10463975	ENSG00000253404.1	AC034243.1	26.21	5.58e-93	1.45e-88	1.12	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138927560	chr5:138744434~138753309:-
PRAD	cis	rs858239	0.539	rs57864591	ENSG00000230658.1	KLHL7-AS1	26.21	5.85e-93	1.51e-88	0.97	0.78	Cerebrospinal fluid biomarker levels;	chr7:23144805	chr7:23101228~23105703:-
PRAD	cis	rs875971	0.66	rs28698552	ENSG00000226824.5	RP4-756H11.3	-26.21	5.99e-93	1.55e-88	-0.99	-0.78	Aortic root size;	chr7:66540031	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.638	rs6460305	ENSG00000226824.5	RP4-756H11.3	26.2	6.3e-93	1.63e-88	1	0.78	Aortic root size;	chr7:66595421	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.66	rs10272357	ENSG00000226824.5	RP4-756H11.3	26.2	6.3e-93	1.63e-88	1	0.78	Aortic root size;	chr7:66598087	chr7:66654538~66669855:+
PRAD	cis	rs858239	0.601	rs764533	ENSG00000230658.1	KLHL7-AS1	26.2	6.49e-93	1.68e-88	0.95	0.78	Cerebrospinal fluid biomarker levels;	chr7:23114256	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.539	rs4294098	ENSG00000230658.1	KLHL7-AS1	26.17	8.48e-93	2.18e-88	0.97	0.78	Cerebrospinal fluid biomarker levels;	chr7:23146376	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.539	rs4504540	ENSG00000230658.1	KLHL7-AS1	26.17	8.48e-93	2.18e-88	0.97	0.78	Cerebrospinal fluid biomarker levels;	chr7:23146579	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.509	rs6975524	ENSG00000230658.1	KLHL7-AS1	26.17	8.48e-93	2.18e-88	0.97	0.78	Cerebrospinal fluid biomarker levels;	chr7:23146833	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.539	rs6955726	ENSG00000230658.1	KLHL7-AS1	26.17	8.48e-93	2.18e-88	0.97	0.78	Cerebrospinal fluid biomarker levels;	chr7:23147072	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.539	rs6976957	ENSG00000230658.1	KLHL7-AS1	26.17	8.48e-93	2.18e-88	0.97	0.78	Cerebrospinal fluid biomarker levels;	chr7:23147714	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.539	rs6956828	ENSG00000230658.1	KLHL7-AS1	26.17	8.48e-93	2.18e-88	0.97	0.78	Cerebrospinal fluid biomarker levels;	chr7:23147728	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.601	rs6969733	ENSG00000230658.1	KLHL7-AS1	26.17	8.55e-93	2.19e-88	0.96	0.78	Cerebrospinal fluid biomarker levels;	chr7:23128758	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.601	rs4440529	ENSG00000230658.1	KLHL7-AS1	26.17	8.55e-93	2.19e-88	0.96	0.78	Cerebrospinal fluid biomarker levels;	chr7:23129132	chr7:23101228~23105703:-
PRAD	cis	rs916888	0.773	rs1378358	ENSG00000214401.4	KANSL1-AS1	26.17	8.75e-93	2.24e-88	1.3	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46193576~46196723:+
PRAD	cis	rs2882667	0.69	rs825747	ENSG00000253404.1	AC034243.1	-26.16	9.38e-93	2.4e-88	-1.1	-0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800896	chr5:138744434~138753309:-
PRAD	cis	rs916888	0.773	rs199535	ENSG00000214401.4	KANSL1-AS1	26.15	1.04e-92	2.67e-88	1.29	0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46193576~46196723:+
PRAD	cis	rs858239	0.6	rs4409314	ENSG00000230658.1	KLHL7-AS1	26.14	1.23e-92	3.15e-88	0.95	0.77	Cerebrospinal fluid biomarker levels;	chr7:23088333	chr7:23101228~23105703:-
PRAD	cis	rs875971	0.66	rs62465434	ENSG00000226824.5	RP4-756H11.3	-26.1	1.89e-92	4.81e-88	-0.98	-0.77	Aortic root size;	chr7:66540165	chr7:66654538~66669855:+
PRAD	cis	rs2882667	0.69	rs4835703	ENSG00000253404.1	AC034243.1	-26.09	2e-92	5.08e-88	-1.09	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138815048	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.654	rs4835704	ENSG00000253404.1	AC034243.1	-26.09	2e-92	5.08e-88	-1.09	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138815636	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.69	rs6596453	ENSG00000253404.1	AC034243.1	-26.09	2e-92	5.08e-88	-1.09	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138816202	chr5:138744434~138753309:-
PRAD	cis	rs858239	0.539	rs6955969	ENSG00000230658.1	KLHL7-AS1	26.07	2.63e-92	6.65e-88	0.97	0.77	Cerebrospinal fluid biomarker levels;	chr7:23147080	chr7:23101228~23105703:-
PRAD	cis	rs9322193	0.923	rs12174716	ENSG00000231760.4	RP11-350J20.5	26.06	2.75e-92	6.94e-88	1.06	0.77	Lung cancer;	chr6:149644487	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.962	rs3805749	ENSG00000231760.4	RP11-350J20.5	26.04	3.43e-92	8.63e-88	1.05	0.77	Lung cancer;	chr6:149772546	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs2342765	ENSG00000231760.4	RP11-350J20.5	26.04	3.48e-92	8.76e-88	1.05	0.77	Lung cancer;	chr6:149858873	chr6:149796151~149826294:-
PRAD	cis	rs801193	1	rs2055682	ENSG00000226824.5	RP4-756H11.3	-26.03	3.67e-92	9.24e-88	-1.02	-0.77	Aortic root size;	chr7:66795302	chr7:66654538~66669855:+
PRAD	cis	rs916888	0.773	rs169201	ENSG00000262539.1	RP11-259G18.3	26.02	4.12e-92	1.03e-87	1.33	0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46259551~46260606:-
PRAD	cis	rs875971	0.66	rs801192	ENSG00000226824.5	RP4-756H11.3	26.02	4.13e-92	1.04e-87	0.99	0.77	Aortic root size;	chr7:66566965	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.66	rs801190	ENSG00000226824.5	RP4-756H11.3	26.02	4.13e-92	1.04e-87	0.99	0.77	Aortic root size;	chr7:66568046	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.66	rs3857686	ENSG00000226824.5	RP4-756H11.3	26.02	4.13e-92	1.04e-87	0.99	0.77	Aortic root size;	chr7:66571204	chr7:66654538~66669855:+
PRAD	cis	rs10256972	0.552	rs2949192	ENSG00000229043.2	AC091729.9	-26.01	4.94e-92	1.24e-87	-0.94	-0.77	Endometriosis;Longevity;	chr7:1164205	chr7:1160374~1165267:+
PRAD	cis	rs10256972	0.567	rs2949185	ENSG00000229043.2	AC091729.9	-26	5.34e-92	1.34e-87	-0.95	-0.77	Endometriosis;Longevity;	chr7:1169377	chr7:1160374~1165267:+
PRAD	cis	rs1577917	0.655	rs12203963	ENSG00000203875.9	SNHG5	25.99	5.91e-92	1.47e-87	0.83	0.77	Response to antipsychotic treatment;	chr6:85513598	chr6:85660950~85678736:-
PRAD	cis	rs10256972	0.552	rs2949195	ENSG00000229043.2	AC091729.9	-25.98	6.18e-92	1.54e-87	-0.94	-0.77	Endometriosis;Longevity;	chr7:1163069	chr7:1160374~1165267:+
PRAD	cis	rs858239	0.632	rs6952947	ENSG00000230658.1	KLHL7-AS1	-25.98	6.28e-92	1.56e-87	-0.96	-0.77	Cerebrospinal fluid biomarker levels;	chr7:23081423	chr7:23101228~23105703:-
PRAD	cis	rs9322193	0.847	rs9505972	ENSG00000231760.4	RP11-350J20.5	25.97	6.83e-92	1.7e-87	1.05	0.77	Lung cancer;	chr6:149775255	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.962	rs3805752	ENSG00000231760.4	RP11-350J20.5	25.96	8.07e-92	2.01e-87	1.05	0.77	Lung cancer;	chr6:149795490	chr6:149796151~149826294:-
PRAD	cis	rs875971	0.66	rs10215132	ENSG00000226824.5	RP4-756H11.3	25.96	8.35e-92	2.07e-87	1	0.77	Aortic root size;	chr7:66589419	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.66	rs13224319	ENSG00000226824.5	RP4-756H11.3	-25.95	8.57e-92	2.13e-87	-0.99	-0.77	Aortic root size;	chr7:66542376	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.66	rs801217	ENSG00000226824.5	RP4-756H11.3	25.95	8.57e-92	2.13e-87	0.99	0.77	Aortic root size;	chr7:66545590	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.66	rs10281080	ENSG00000226824.5	RP4-756H11.3	25.95	8.78e-92	2.17e-87	1	0.77	Aortic root size;	chr7:66577454	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.66	rs10950044	ENSG00000226824.5	RP4-756H11.3	25.95	8.78e-92	2.17e-87	1	0.77	Aortic root size;	chr7:66577989	chr7:66654538~66669855:+
PRAD	cis	rs9322193	0.847	rs56103941	ENSG00000231760.4	RP11-350J20.5	25.94	9.38e-92	2.31e-87	1.05	0.77	Lung cancer;	chr6:149816095	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.847	rs12210605	ENSG00000231760.4	RP11-350J20.5	25.94	9.38e-92	2.31e-87	1.05	0.77	Lung cancer;	chr6:149817267	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs9371199	ENSG00000231760.4	RP11-350J20.5	25.94	9.38e-92	2.31e-87	1.05	0.77	Lung cancer;	chr6:149817526	chr6:149796151~149826294:-
PRAD	cis	rs875971	0.638	rs801205	ENSG00000226824.5	RP4-756H11.3	25.93	1.14e-91	2.81e-87	0.99	0.77	Aortic root size;	chr7:66557157	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.617	rs810400	ENSG00000226824.5	RP4-756H11.3	25.93	1.14e-91	2.81e-87	0.99	0.77	Aortic root size;	chr7:66557902	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.638	rs3898855	ENSG00000226824.5	RP4-756H11.3	25.93	1.14e-91	2.81e-87	0.99	0.77	Aortic root size;	chr7:66571411	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.638	rs10278816	ENSG00000226824.5	RP4-756H11.3	25.93	1.14e-91	2.81e-87	0.99	0.77	Aortic root size;	chr7:66572000	chr7:66654538~66669855:+
PRAD	cis	rs9322193	0.923	rs12205092	ENSG00000231760.4	RP11-350J20.5	25.92	1.22e-91	2.98e-87	1.05	0.77	Lung cancer;	chr6:149761375	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs10872651	ENSG00000231760.4	RP11-350J20.5	25.92	1.22e-91	2.98e-87	1.05	0.77	Lung cancer;	chr6:149768273	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs66516768	ENSG00000231760.4	RP11-350J20.5	25.91	1.34e-91	3.29e-87	1.04	0.77	Lung cancer;	chr6:149671999	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.886	rs9485408	ENSG00000231760.4	RP11-350J20.5	25.9	1.45e-91	3.53e-87	1.04	0.77	Lung cancer;	chr6:149618888	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.962	rs2275045	ENSG00000231760.4	RP11-350J20.5	25.9	1.49e-91	3.62e-87	1.05	0.77	Lung cancer;	chr6:149842775	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.884	rs9688699	ENSG00000231760.4	RP11-350J20.5	25.89	1.63e-91	3.96e-87	1.04	0.77	Lung cancer;	chr6:149733680	chr6:149796151~149826294:-
PRAD	cis	rs916888	0.821	rs70600	ENSG00000262539.1	RP11-259G18.3	25.89	1.64e-91	3.99e-87	1.34	0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46259551~46260606:-
PRAD	cis	rs9322193	0.923	rs9505982	ENSG00000231760.4	RP11-350J20.5	25.88	1.8e-91	4.38e-87	1.05	0.77	Lung cancer;	chr6:149618465	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs9322196	ENSG00000231760.4	RP11-350J20.5	25.88	1.8e-91	4.38e-87	1.05	0.77	Lung cancer;	chr6:149619645	chr6:149796151~149826294:-
PRAD	cis	rs858239	0.539	rs870476	ENSG00000230658.1	KLHL7-AS1	25.87	2.03e-91	4.93e-87	0.96	0.77	Cerebrospinal fluid biomarker levels;	chr7:23153652	chr7:23101228~23105703:-
PRAD	cis	rs916888	0.773	rs1378358	ENSG00000262539.1	RP11-259G18.3	25.87	2.13e-91	5.15e-87	1.32	0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46259551~46260606:-
PRAD	cis	rs875971	0.638	rs10249404	ENSG00000226824.5	RP4-756H11.3	25.84	2.84e-91	6.82e-87	1	0.77	Aortic root size;	chr7:66581737	chr7:66654538~66669855:+
PRAD	cis	rs507080	0.961	rs607527	ENSG00000255239.1	AP002954.6	-25.83	3.02e-91	7.25e-87	-1.03	-0.77	Serum metabolite levels;	chr11:118667478	chr11:118688039~118690600:-
PRAD	cis	rs10256972	0.552	rs7805591	ENSG00000229043.2	AC091729.9	-25.82	3.39e-91	8.1e-87	-0.95	-0.77	Endometriosis;Longevity;	chr7:1171109	chr7:1160374~1165267:+
PRAD	cis	rs9322193	0.923	rs9688861	ENSG00000231760.4	RP11-350J20.5	25.81	3.93e-91	9.37e-87	1.04	0.77	Lung cancer;	chr6:149637924	chr6:149796151~149826294:-
PRAD	cis	rs858239	0.601	rs2141307	ENSG00000230658.1	KLHL7-AS1	25.8	4.06e-91	9.67e-87	0.97	0.77	Cerebrospinal fluid biomarker levels;	chr7:23151805	chr7:23101228~23105703:-
PRAD	cis	rs9322193	0.923	rs9404048	ENSG00000231760.4	RP11-350J20.5	25.78	5.12e-91	1.21e-86	1.05	0.77	Lung cancer;	chr6:149616188	chr6:149796151~149826294:-
PRAD	cis	rs875971	0.66	rs7807944	ENSG00000226824.5	RP4-756H11.3	25.78	5.38e-91	1.27e-86	1	0.77	Aortic root size;	chr7:66622208	chr7:66654538~66669855:+
PRAD	cis	rs9322193	0.923	rs9505823	ENSG00000231760.4	RP11-350J20.5	25.77	5.89e-91	1.39e-86	1.04	0.77	Lung cancer;	chr6:149628899	chr6:149796151~149826294:-
PRAD	cis	rs875971	0.66	rs79009421	ENSG00000226824.5	RP4-756H11.3	25.77	6.11e-91	1.44e-86	0.99	0.77	Aortic root size;	chr7:66603522	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.66	rs6460308	ENSG00000226824.5	RP4-756H11.3	25.77	6.11e-91	1.44e-86	0.99	0.77	Aortic root size;	chr7:66619753	chr7:66654538~66669855:+
PRAD	cis	rs801193	1	rs17566701	ENSG00000226824.5	RP4-756H11.3	-25.75	7.09e-91	1.66e-86	-1.03	-0.77	Aortic root size;	chr7:66728196	chr7:66654538~66669855:+
PRAD	cis	rs801193	0.967	rs2420827	ENSG00000226824.5	RP4-756H11.3	25.75	7.21e-91	1.69e-86	1.02	0.77	Aortic root size;	chr7:66682114	chr7:66654538~66669855:+
PRAD	cis	rs9322193	0.886	rs4870055	ENSG00000231760.4	RP11-350J20.5	25.73	8.71e-91	2.03e-86	1.04	0.77	Lung cancer;	chr6:149848433	chr6:149796151~149826294:-
PRAD	cis	rs916888	0.821	rs70600	ENSG00000214401.4	KANSL1-AS1	25.72	9.48e-91	2.21e-86	1.32	0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46193576~46196723:+
PRAD	cis	rs916888	0.773	rs538628	ENSG00000262539.1	RP11-259G18.3	25.72	9.51e-91	2.21e-86	1.29	0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:46259551~46260606:-
PRAD	cis	rs875971	0.619	rs10278371	ENSG00000226824.5	RP4-756H11.3	25.7	1.26e-90	2.93e-86	0.99	0.77	Aortic root size;	chr7:66586553	chr7:66654538~66669855:+
PRAD	cis	rs9322193	0.923	rs2184370	ENSG00000231760.4	RP11-350J20.5	25.69	1.33e-90	3.07e-86	1.05	0.77	Lung cancer;	chr6:149843242	chr6:149796151~149826294:-
PRAD	cis	rs875971	0.66	rs7807930	ENSG00000226824.5	RP4-756H11.3	25.69	1.34e-90	3.1e-86	0.99	0.77	Aortic root size;	chr7:66622178	chr7:66654538~66669855:+
PRAD	cis	rs9322193	0.847	rs62439808	ENSG00000231760.4	RP11-350J20.5	25.66	1.92e-90	4.41e-86	1.04	0.77	Lung cancer;	chr6:149629690	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs1080670	ENSG00000231760.4	RP11-350J20.5	25.65	2.01e-90	4.63e-86	1.04	0.77	Lung cancer;	chr6:149620161	chr6:149796151~149826294:-
PRAD	cis	rs8013143	1	rs941718	ENSG00000279656.1	RP11-298I3.6	-25.65	2.07e-90	4.76e-86	-1.05	-0.77	Reticulocyte fraction of red cells;Reticulocyte count;Red cell distribution width;	chr14:23025839	chr14:23023083~23024217:-
PRAD	cis	rs801193	0.967	rs3800823	ENSG00000226824.5	RP4-756H11.3	25.64	2.19e-90	5.02e-86	1.02	0.77	Aortic root size;	chr7:66682123	chr7:66654538~66669855:+
PRAD	cis	rs2882667	0.69	rs10045605	ENSG00000253404.1	AC034243.1	25.64	2.31e-90	5.31e-86	1.1	0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936458	chr5:138744434~138753309:-
PRAD	cis	rs10256972	0.552	rs6953538	ENSG00000229043.2	AC091729.9	-25.64	2.32e-90	5.32e-86	-0.94	-0.77	Endometriosis;Longevity;	chr7:1157338	chr7:1160374~1165267:+
PRAD	cis	rs858239	0.602	rs6953996	ENSG00000230658.1	KLHL7-AS1	25.63	2.65e-90	6.08e-86	0.97	0.77	Cerebrospinal fluid biomarker levels;	chr7:23136327	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.539	rs7791200	ENSG00000230658.1	KLHL7-AS1	25.62	2.81e-90	6.44e-86	0.97	0.77	Cerebrospinal fluid biomarker levels;	chr7:23142502	chr7:23101228~23105703:-
PRAD	cis	rs875971	0.66	rs801193	ENSG00000226824.5	RP4-756H11.3	25.62	2.82e-90	6.46e-86	0.99	0.77	Aortic root size;	chr7:66565625	chr7:66654538~66669855:+
PRAD	cis	rs9326248	0.911	rs474339	ENSG00000254851.1	RP11-109L13.1	-25.61	3.19e-90	7.31e-86	-1.09	-0.77	Blood protein levels;	chr11:117188836	chr11:117135528~117138582:+
PRAD	cis	rs916888	0.773	rs538628	ENSG00000214401.4	KANSL1-AS1	25.57	4.78e-90	1.09e-85	1.27	0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:46193576~46196723:+
PRAD	cis	rs9322193	0.884	rs10782312	ENSG00000231760.4	RP11-350J20.5	25.56	5.21e-90	1.18e-85	1.04	0.77	Lung cancer;	chr6:149622669	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.886	rs9322198	ENSG00000231760.4	RP11-350J20.5	25.56	5.21e-90	1.18e-85	1.04	0.77	Lung cancer;	chr6:149623772	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs9689599	ENSG00000231760.4	RP11-350J20.5	25.56	5.21e-90	1.18e-85	1.04	0.77	Lung cancer;	chr6:149631973	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs9800580	ENSG00000231760.4	RP11-350J20.5	25.56	5.21e-90	1.18e-85	1.04	0.77	Lung cancer;	chr6:149632845	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.884	rs11155669	ENSG00000231760.4	RP11-350J20.5	25.56	5.21e-90	1.18e-85	1.04	0.77	Lung cancer;	chr6:149633501	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.887	rs9505824	ENSG00000231760.4	RP11-350J20.5	25.56	5.21e-90	1.18e-85	1.04	0.77	Lung cancer;	chr6:149633663	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs9766886	ENSG00000231760.4	RP11-350J20.5	25.56	5.21e-90	1.18e-85	1.04	0.77	Lung cancer;	chr6:149637048	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs7740278	ENSG00000231760.4	RP11-350J20.5	25.56	5.21e-90	1.18e-85	1.04	0.77	Lung cancer;	chr6:149640116	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs10747275	ENSG00000231760.4	RP11-350J20.5	25.54	6.76e-90	1.53e-85	1.05	0.77	Lung cancer;	chr6:149622782	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.884	rs9688794	ENSG00000231760.4	RP11-350J20.5	25.54	6.76e-90	1.53e-85	1.05	0.77	Lung cancer;	chr6:149632121	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs9689084	ENSG00000231760.4	RP11-350J20.5	25.54	6.76e-90	1.53e-85	1.05	0.77	Lung cancer;	chr6:149639648	chr6:149796151~149826294:-
PRAD	cis	rs6952407	1	rs6952407	ENSG00000226824.5	RP4-756H11.3	25.53	7.15e-90	1.62e-85	1	0.77	Cotinine glucuronidation;	chr7:66580525	chr7:66654538~66669855:+
PRAD	cis	rs9322193	0.923	rs10782310	ENSG00000231760.4	RP11-350J20.5	25.53	7.44e-90	1.66e-85	1.04	0.77	Lung cancer;	chr6:149622458	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs10782311	ENSG00000231760.4	RP11-350J20.5	25.53	7.44e-90	1.66e-85	1.04	0.77	Lung cancer;	chr6:149622592	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs9322200	ENSG00000231760.4	RP11-350J20.5	25.53	7.44e-90	1.66e-85	1.04	0.77	Lung cancer;	chr6:149630078	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs9322204	ENSG00000231760.4	RP11-350J20.5	25.53	7.44e-90	1.66e-85	1.04	0.77	Lung cancer;	chr6:149636047	chr6:149796151~149826294:-
PRAD	cis	rs1577917	0.655	rs1059307	ENSG00000203875.9	SNHG5	25.52	7.9e-90	1.76e-85	0.84	0.77	Response to antipsychotic treatment;	chr6:85678170	chr6:85660950~85678736:-
PRAD	cis	rs9322193	0.847	rs12234128	ENSG00000231760.4	RP11-350J20.5	25.52	7.93e-90	1.77e-85	1.04	0.77	Lung cancer;	chr6:149627553	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs57012784	ENSG00000231760.4	RP11-350J20.5	25.52	7.93e-90	1.77e-85	1.04	0.77	Lung cancer;	chr6:149627691	chr6:149796151~149826294:-
PRAD	cis	rs2882667	0.69	rs288029	ENSG00000253404.1	AC034243.1	25.51	9.01e-90	2.01e-85	1.1	0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138881616	chr5:138744434~138753309:-
PRAD	cis	rs2739330	0.892	rs4822455	ENSG00000218537.1	MIF-AS1	25.5	9.86e-90	2.19e-85	1.03	0.77	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23894426~23898930:-
PRAD	cis	rs875971	0.638	rs35986979	ENSG00000226824.5	RP4-756H11.3	25.5	1.01e-89	2.25e-85	1	0.77	Aortic root size;	chr7:66624003	chr7:66654538~66669855:+
PRAD	cis	rs1577917	0.681	rs4707211	ENSG00000203875.9	SNHG5	25.49	1.07e-89	2.37e-85	0.82	0.77	Response to antipsychotic treatment;	chr6:85522992	chr6:85660950~85678736:-
PRAD	cis	rs10256972	0.539	rs2949174	ENSG00000229043.2	AC091729.9	-25.45	1.6e-89	3.54e-85	-0.95	-0.77	Endometriosis;Longevity;	chr7:1174287	chr7:1160374~1165267:+
PRAD	cis	rs10256972	0.577	rs4999286	ENSG00000229043.2	AC091729.9	-25.45	1.76e-89	3.89e-85	-0.92	-0.77	Endometriosis;Longevity;	chr7:1159870	chr7:1160374~1165267:+
PRAD	cis	rs9322193	0.962	rs7740784	ENSG00000231760.4	RP11-350J20.5	25.44	1.8e-89	3.98e-85	1.03	0.77	Lung cancer;	chr6:149833364	chr6:149796151~149826294:-
PRAD	cis	rs8013143	1	rs8013143	ENSG00000279656.1	RP11-298I3.6	-25.43	2.1e-89	4.64e-85	-1.04	-0.77	Reticulocyte fraction of red cells;Reticulocyte count;Red cell distribution width;	chr14:23025068	chr14:23023083~23024217:-
PRAD	cis	rs9322193	0.923	rs10782318	ENSG00000231760.4	RP11-350J20.5	25.43	2.13e-89	4.71e-85	1.03	0.77	Lung cancer;	chr6:149754137	chr6:149796151~149826294:-
PRAD	cis	rs875971	0.638	rs6960778	ENSG00000226824.5	RP4-756H11.3	25.41	2.51e-89	5.53e-85	1	0.77	Aortic root size;	chr7:66606610	chr7:66654538~66669855:+
PRAD	cis	rs9322193	0.923	rs55993747	ENSG00000231760.4	RP11-350J20.5	25.41	2.68e-89	5.9e-85	1.03	0.77	Lung cancer;	chr6:149622016	chr6:149796151~149826294:-
PRAD	cis	rs2882667	0.728	rs10068786	ENSG00000253404.1	AC034243.1	25.4	2.75e-89	6.06e-85	1.11	0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941255	chr5:138744434~138753309:-
PRAD	cis	rs9322193	0.886	rs2065663	ENSG00000231760.4	RP11-350J20.5	25.4	2.78e-89	6.12e-85	1.04	0.77	Lung cancer;	chr6:149760331	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.887	rs9767113	ENSG00000231760.4	RP11-350J20.5	25.4	2.89e-89	6.37e-85	1.03	0.77	Lung cancer;	chr6:149718157	chr6:149796151~149826294:-
PRAD	cis	rs801193	1	rs13239306	ENSG00000226824.5	RP4-756H11.3	25.38	3.35e-89	7.36e-85	1.02	0.77	Aortic root size;	chr7:66671030	chr7:66654538~66669855:+
PRAD	cis	rs9322193	0.923	rs12526675	ENSG00000231760.4	RP11-350J20.5	-25.36	4.35e-89	9.54e-85	-1.02	-0.77	Lung cancer;	chr6:149729540	chr6:149796151~149826294:-
PRAD	cis	rs2882667	0.69	rs311601	ENSG00000253404.1	AC034243.1	25.35	4.78e-89	1.05e-84	1.11	0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717697	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.628	rs13171173	ENSG00000253404.1	AC034243.1	-25.33	5.65e-89	1.24e-84	-1.1	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138706775	chr5:138744434~138753309:-
PRAD	cis	rs9322193	0.847	rs12191643	ENSG00000231760.4	RP11-350J20.5	25.33	6.1e-89	1.33e-84	1.03	0.76	Lung cancer;	chr6:149628912	chr6:149796151~149826294:-
PRAD	cis	rs858239	0.539	rs4295546	ENSG00000230658.1	KLHL7-AS1	25.3	7.77e-89	1.7e-84	0.96	0.76	Cerebrospinal fluid biomarker levels;	chr7:23151402	chr7:23101228~23105703:-
PRAD	cis	rs9322193	0.962	rs2342764	ENSG00000231760.4	RP11-350J20.5	25.3	7.79e-89	1.7e-84	1.03	0.76	Lung cancer;	chr6:149835068	chr6:149796151~149826294:-
PRAD	cis	rs2882667	0.654	rs10044432	ENSG00000253404.1	AC034243.1	25.3	8.47e-89	1.85e-84	1.09	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138939207	chr5:138744434~138753309:-
PRAD	cis	rs9322193	0.923	rs9688452	ENSG00000231760.4	RP11-350J20.5	25.27	1.14e-88	2.48e-84	1.05	0.76	Lung cancer;	chr6:149658764	chr6:149796151~149826294:-
PRAD	cis	rs875971	0.642	rs35526611	ENSG00000226824.5	RP4-756H11.3	25.26	1.21e-88	2.62e-84	0.99	0.76	Aortic root size;	chr7:66629021	chr7:66654538~66669855:+
PRAD	cis	rs9322193	0.923	rs9505826	ENSG00000231760.4	RP11-350J20.5	25.26	1.26e-88	2.73e-84	1.04	0.76	Lung cancer;	chr6:149633912	chr6:149796151~149826294:-
PRAD	cis	rs1577917	0.56	rs12193777	ENSG00000203875.9	SNHG5	25.26	1.28e-88	2.77e-84	0.82	0.76	Response to antipsychotic treatment;	chr6:85536991	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.655	rs9444351	ENSG00000203875.9	SNHG5	25.26	1.28e-88	2.77e-84	0.82	0.76	Response to antipsychotic treatment;	chr6:85538081	chr6:85660950~85678736:-
PRAD	cis	rs8013143	0.961	rs7147308	ENSG00000279656.1	RP11-298I3.6	-25.23	1.67e-88	3.61e-84	-1.04	-0.76	Reticulocyte fraction of red cells;Reticulocyte count;Red cell distribution width;	chr14:23028420	chr14:23023083~23024217:-
PRAD	cis	rs9322193	0.886	rs9718079	ENSG00000231760.4	RP11-350J20.5	25.22	1.8e-88	3.89e-84	1.05	0.76	Lung cancer;	chr6:149645947	chr6:149796151~149826294:-
PRAD	cis	rs2283792	0.812	rs94194	ENSG00000224086.5	LL22NC03-86G7.1	-25.21	2.16e-88	4.65e-84	-0.89	-0.76	Multiple sclerosis;	chr22:21933937	chr22:21938293~21977632:+
PRAD	cis	rs2283792	0.812	rs5995269	ENSG00000224086.5	LL22NC03-86G7.1	-25.21	2.16e-88	4.65e-84	-0.89	-0.76	Multiple sclerosis;	chr22:21935025	chr22:21938293~21977632:+
PRAD	cis	rs9322193	0.923	rs9767554	ENSG00000231760.4	RP11-350J20.5	25.2	2.36e-88	5.07e-84	1.03	0.76	Lung cancer;	chr6:149616860	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs4869750	ENSG00000231760.4	RP11-350J20.5	25.16	3.4e-88	7.26e-84	1.03	0.76	Lung cancer;	chr6:149855996	chr6:149796151~149826294:-
PRAD	cis	rs916888	0.821	rs199505	ENSG00000262539.1	RP11-259G18.3	-25.16	3.45e-88	7.36e-84	-1.29	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:46259551~46260606:-
PRAD	cis	rs916888	0.821	rs70602	ENSG00000262539.1	RP11-259G18.3	-25.16	3.45e-88	7.36e-84	-1.29	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:46259551~46260606:-
PRAD	cis	rs916888	0.773	rs199439	ENSG00000262539.1	RP11-259G18.3	25.16	3.57e-88	7.62e-84	1.29	0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:46259551~46260606:-
PRAD	cis	rs1577917	0.629	rs6927475	ENSG00000203875.9	SNHG5	25.13	4.83e-88	1.03e-83	0.82	0.76	Response to antipsychotic treatment;	chr6:85497055	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.629	rs9450285	ENSG00000203875.9	SNHG5	25.13	4.83e-88	1.03e-83	0.82	0.76	Response to antipsychotic treatment;	chr6:85498378	chr6:85660950~85678736:-
PRAD	cis	rs9322193	0.924	rs9322189	ENSG00000231760.4	RP11-350J20.5	25.1	6.85e-88	1.45e-83	1.05	0.76	Lung cancer;	chr6:149588797	chr6:149796151~149826294:-
PRAD	cis	rs2882667	0.652	rs874115	ENSG00000253404.1	AC034243.1	25.06	1.03e-87	2.18e-83	1.07	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138944367	chr5:138744434~138753309:-
PRAD	cis	rs875971	0.628	rs6974355	ENSG00000226824.5	RP4-756H11.3	-25.05	1.13e-87	2.38e-83	-1	-0.76	Aortic root size;	chr7:66376994	chr7:66654538~66669855:+
PRAD	cis	rs858239	0.539	rs2390757	ENSG00000230658.1	KLHL7-AS1	25.03	1.43e-87	3e-83	0.96	0.76	Cerebrospinal fluid biomarker levels;	chr7:23151873	chr7:23101228~23105703:-
PRAD	cis	rs916888	0.773	rs199439	ENSG00000214401.4	KANSL1-AS1	25	1.91e-87	4e-83	1.26	0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:46193576~46196723:+
PRAD	cis	rs507080	0.845	rs481903	ENSG00000255239.1	AP002954.6	25	2e-87	4.2e-83	1.05	0.76	Serum metabolite levels;	chr11:118697024	chr11:118688039~118690600:-
PRAD	cis	rs9322193	0.923	rs4870509	ENSG00000231760.4	RP11-350J20.5	24.99	2.19e-87	4.58e-83	1.03	0.76	Lung cancer;	chr6:149702212	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs9322214	ENSG00000231760.4	RP11-350J20.5	24.99	2.19e-87	4.58e-83	1.03	0.76	Lung cancer;	chr6:149703986	chr6:149796151~149826294:-
PRAD	cis	rs1577917	0.655	rs7766485	ENSG00000203875.9	SNHG5	24.98	2.41e-87	5.01e-83	0.82	0.76	Response to antipsychotic treatment;	chr6:85553837	chr6:85660950~85678736:-
PRAD	cis	rs9326248	0.911	rs11216284	ENSG00000254851.1	RP11-109L13.1	-24.97	2.7e-87	5.6e-83	-1.07	-0.76	Blood protein levels;	chr11:117132344	chr11:117135528~117138582:+
PRAD	cis	rs916888	0.821	rs199514	ENSG00000262539.1	RP11-259G18.3	-24.95	3.2e-87	6.62e-83	-1.28	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:46259551~46260606:-
PRAD	cis	rs113525195	1	rs113525195	ENSG00000279656.1	RP11-298I3.6	-24.95	3.42e-87	7.07e-83	-1.04	-0.76	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Mean corpuscular hemoglobin;	chr14:23030112	chr14:23023083~23024217:-
PRAD	cis	rs858239	0.699	rs858260	ENSG00000230658.1	KLHL7-AS1	24.93	4.04e-87	8.32e-83	0.96	0.76	Cerebrospinal fluid biomarker levels;	chr7:23173315	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.669	rs12539467	ENSG00000230658.1	KLHL7-AS1	24.92	4.27e-87	8.79e-83	0.96	0.76	Cerebrospinal fluid biomarker levels;	chr7:23076240	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.508	rs2390754	ENSG00000230658.1	KLHL7-AS1	24.92	4.41e-87	9.06e-83	0.96	0.76	Cerebrospinal fluid biomarker levels;	chr7:23150875	chr7:23101228~23105703:-
PRAD	cis	rs9322193	0.923	rs9766037	ENSG00000231760.4	RP11-350J20.5	24.91	5.02e-87	1.03e-82	1.04	0.76	Lung cancer;	chr6:149616921	chr6:149796151~149826294:-
PRAD	cis	rs916888	0.821	rs415430	ENSG00000262539.1	RP11-259G18.3	-24.86	8.46e-87	1.73e-82	-1.29	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:46259551~46260606:-
PRAD	cis	rs916888	0.779	rs430685	ENSG00000262539.1	RP11-259G18.3	-24.86	8.46e-87	1.73e-82	-1.29	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:46259551~46260606:-
PRAD	cis	rs1577917	0.655	rs2842605	ENSG00000203875.9	SNHG5	-24.8	1.6e-86	3.26e-82	-0.82	-0.76	Response to antipsychotic treatment;	chr6:85625432	chr6:85660950~85678736:-
PRAD	cis	rs9322193	1	rs9377228	ENSG00000231760.4	RP11-350J20.5	24.8	1.62e-86	3.29e-82	1.03	0.76	Lung cancer;	chr6:149600862	chr6:149796151~149826294:-
PRAD	cis	rs2882667	0.728	rs13181830	ENSG00000253404.1	AC034243.1	-24.8	1.64e-86	3.33e-82	-1.04	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138944727	chr5:138744434~138753309:-
PRAD	cis	rs2739330	0.828	rs5751770	ENSG00000273295.1	AP000350.5	24.79	1.7e-86	3.46e-82	0.92	0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23901432~23907068:-
PRAD	cis	rs916888	0.821	rs199513	ENSG00000262539.1	RP11-259G18.3	-24.78	1.91e-86	3.87e-82	-1.28	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46259551~46260606:-
PRAD	cis	rs1577917	0.561	rs3087978	ENSG00000203875.9	SNHG5	24.76	2.43e-86	4.91e-82	0.82	0.76	Response to antipsychotic treatment;	chr6:85678505	chr6:85660950~85678736:-
PRAD	cis	rs875971	0.666	rs13242072	ENSG00000226824.5	RP4-756H11.3	24.74	2.95e-86	5.96e-82	0.99	0.76	Aortic root size;	chr7:66301001	chr7:66654538~66669855:+
PRAD	cis	rs4423214	1	rs12785878	ENSG00000254682.1	RP11-660L16.2	24.74	2.97e-86	5.99e-82	0.99	0.76	Vitamin D levels;	chr11:71456403	chr11:71448674~71452157:+
PRAD	cis	rs916888	0.821	rs199506	ENSG00000262539.1	RP11-259G18.3	-24.74	3.05e-86	6.15e-82	-1.28	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:46259551~46260606:-
PRAD	cis	rs10256972	0.567	rs2960835	ENSG00000229043.2	AC091729.9	-24.73	3.25e-86	6.56e-82	-0.92	-0.76	Endometriosis;Longevity;	chr7:1163327	chr7:1160374~1165267:+
PRAD	cis	rs916888	0.697	rs199516	ENSG00000262539.1	RP11-259G18.3	-24.73	3.37e-86	6.77e-82	-1.28	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:46259551~46260606:-
PRAD	cis	rs916888	0.821	rs199512	ENSG00000262539.1	RP11-259G18.3	-24.73	3.37e-86	6.77e-82	-1.28	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:46259551~46260606:-
PRAD	cis	rs916888	0.821	rs199509	ENSG00000262539.1	RP11-259G18.3	-24.73	3.37e-86	6.77e-82	-1.28	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:46259551~46260606:-
PRAD	cis	rs916888	0.821	rs199507	ENSG00000262539.1	RP11-259G18.3	-24.73	3.37e-86	6.77e-82	-1.28	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:46259551~46260606:-
PRAD	cis	rs858239	0.539	rs4559148	ENSG00000230658.1	KLHL7-AS1	24.7	4.42e-86	8.85e-82	0.95	0.76	Cerebrospinal fluid biomarker levels;	chr7:23146348	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.539	rs4377861	ENSG00000230658.1	KLHL7-AS1	24.7	4.42e-86	8.85e-82	0.95	0.76	Cerebrospinal fluid biomarker levels;	chr7:23146350	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.539	rs10247268	ENSG00000230658.1	KLHL7-AS1	24.7	4.42e-86	8.85e-82	0.95	0.76	Cerebrospinal fluid biomarker levels;	chr7:23147560	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.539	rs6461694	ENSG00000230658.1	KLHL7-AS1	24.7	4.42e-86	8.85e-82	0.95	0.76	Cerebrospinal fluid biomarker levels;	chr7:23148160	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.508	rs7805071	ENSG00000230658.1	KLHL7-AS1	24.7	4.42e-86	8.85e-82	0.95	0.76	Cerebrospinal fluid biomarker levels;	chr7:23150593	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.508	rs7805085	ENSG00000230658.1	KLHL7-AS1	24.7	4.42e-86	8.85e-82	0.95	0.76	Cerebrospinal fluid biomarker levels;	chr7:23150624	chr7:23101228~23105703:-
PRAD	cis	rs1577917	0.655	rs9444354	ENSG00000203875.9	SNHG5	24.7	4.58e-86	9.16e-82	0.81	0.76	Response to antipsychotic treatment;	chr6:85582217	chr6:85660950~85678736:-
PRAD	cis	rs916888	0.821	rs199504	ENSG00000262539.1	RP11-259G18.3	-24.69	4.95e-86	9.9e-82	-1.28	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:46259551~46260606:-
PRAD	cis	rs1577917	0.655	rs6454472	ENSG00000203875.9	SNHG5	24.69	5.25e-86	1.05e-81	0.81	0.76	Response to antipsychotic treatment;	chr6:85514335	chr6:85660950~85678736:-
PRAD	cis	rs2486288	0.656	rs12911861	ENSG00000259520.4	CTD-2651B20.3	24.67	6.4e-86	1.27e-81	0.95	0.76	Glomerular filtration rate;	chr15:45274520	chr15:45251580~45279251:-
PRAD	cis	rs9322193	0.961	rs2064520	ENSG00000231760.4	RP11-350J20.5	24.66	7.04e-86	1.4e-81	1.02	0.76	Lung cancer;	chr6:149603650	chr6:149796151~149826294:-
PRAD	cis	rs875971	0.66	rs3764903	ENSG00000226824.5	RP4-756H11.3	24.64	8.28e-86	1.64e-81	0.96	0.76	Aortic root size;	chr7:66633495	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.66	rs1860470	ENSG00000226824.5	RP4-756H11.3	24.64	8.39e-86	1.66e-81	0.97	0.76	Aortic root size;	chr7:66638707	chr7:66654538~66669855:+
PRAD	cis	rs9322193	1	rs58189451	ENSG00000231760.4	RP11-350J20.5	24.64	8.7e-86	1.72e-81	1.03	0.76	Lung cancer;	chr6:149600252	chr6:149796151~149826294:-
PRAD	cis	rs875971	0.577	rs35072105	ENSG00000226824.5	RP4-756H11.3	24.62	1.02e-85	2e-81	0.99	0.76	Aortic root size;	chr7:66144830	chr7:66654538~66669855:+
PRAD	cis	rs9326248	0.798	rs10892079	ENSG00000254851.1	RP11-109L13.1	-24.62	1.11e-85	2.17e-81	-1.08	-0.76	Blood protein levels;	chr11:117146108	chr11:117135528~117138582:+
PRAD	cis	rs2486288	0.586	rs12909625	ENSG00000259520.4	CTD-2651B20.3	24.59	1.44e-85	2.82e-81	0.95	0.76	Glomerular filtration rate;	chr15:45279855	chr15:45251580~45279251:-
PRAD	cis	rs2486288	0.586	rs12909883	ENSG00000259520.4	CTD-2651B20.3	24.59	1.44e-85	2.82e-81	0.95	0.76	Glomerular filtration rate;	chr15:45279856	chr15:45251580~45279251:-
PRAD	cis	rs9322193	1	rs9399693	ENSG00000231760.4	RP11-350J20.5	24.59	1.53e-85	2.99e-81	1.03	0.76	Lung cancer;	chr6:149612718	chr6:149796151~149826294:-
PRAD	cis	rs875971	0.706	rs1643374	ENSG00000226824.5	RP4-756H11.3	-24.57	1.85e-85	3.58e-81	-0.98	-0.76	Aortic root size;	chr7:66407695	chr7:66654538~66669855:+
PRAD	cis	rs9322193	0.923	rs62439840	ENSG00000231760.4	RP11-350J20.5	24.56	1.96e-85	3.79e-81	1.02	0.76	Lung cancer;	chr6:149674639	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.962	rs9393175	ENSG00000231760.4	RP11-350J20.5	24.56	1.96e-85	3.79e-81	1.02	0.76	Lung cancer;	chr6:149677587	chr6:149796151~149826294:-
PRAD	cis	rs2739330	0.828	rs2877178	ENSG00000273295.1	AP000350.5	24.56	2.01e-85	3.89e-81	0.91	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23901432~23907068:-
PRAD	cis	rs2739330	0.828	rs2154593	ENSG00000273295.1	AP000350.5	24.56	2.01e-85	3.89e-81	0.91	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23901432~23907068:-
PRAD	cis	rs2283792	0.812	rs240066	ENSG00000224086.5	LL22NC03-86G7.1	24.56	2.07e-85	3.99e-81	0.91	0.75	Multiple sclerosis;	chr22:21938623	chr22:21938293~21977632:+
PRAD	cis	rs9322193	0.884	rs62439837	ENSG00000231760.4	RP11-350J20.5	24.56	2.09e-85	4.02e-81	1.03	0.75	Lung cancer;	chr6:149670380	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.924	rs9498382	ENSG00000231760.4	RP11-350J20.5	24.55	2.23e-85	4.3e-81	1.02	0.75	Lung cancer;	chr6:149610982	chr6:149796151~149826294:-
PRAD	cis	rs2486288	0.656	rs12908818	ENSG00000259520.4	CTD-2651B20.3	24.54	2.39e-85	4.59e-81	0.95	0.75	Glomerular filtration rate;	chr15:45279470	chr15:45251580~45279251:-
PRAD	cis	rs2486288	0.656	rs12910009	ENSG00000259520.4	CTD-2651B20.3	24.54	2.39e-85	4.59e-81	0.95	0.75	Glomerular filtration rate;	chr15:45280210	chr15:45251580~45279251:-
PRAD	cis	rs2739330	0.828	rs5760108	ENSG00000273295.1	AP000350.5	24.54	2.53e-85	4.85e-81	0.91	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23901432~23907068:-
PRAD	cis	rs858239	0.539	rs6975852	ENSG00000230658.1	KLHL7-AS1	24.52	2.94e-85	5.61e-81	0.95	0.75	Cerebrospinal fluid biomarker levels;	chr7:23147035	chr7:23101228~23105703:-
PRAD	cis	rs9322193	0.884	rs2064521	ENSG00000231760.4	RP11-350J20.5	-24.51	3.59e-85	6.84e-81	-1.03	-0.75	Lung cancer;	chr6:149625336	chr6:149796151~149826294:-
PRAD	cis	rs916888	0.738	rs199515	ENSG00000262539.1	RP11-259G18.3	-24.5	3.85e-85	7.3e-81	-1.27	-0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:46259551~46260606:-
PRAD	cis	rs1577917	0.655	rs9450311	ENSG00000203875.9	SNHG5	24.5	3.86e-85	7.31e-81	0.82	0.75	Response to antipsychotic treatment;	chr6:85666868	chr6:85660950~85678736:-
PRAD	cis	rs9322193	0.923	rs12176034	ENSG00000231760.4	RP11-350J20.5	24.49	4.33e-85	8.19e-81	1.03	0.75	Lung cancer;	chr6:149800557	chr6:149796151~149826294:-
PRAD	cis	rs875971	0.558	rs4433015	ENSG00000226824.5	RP4-756H11.3	24.49	4.34e-85	8.2e-81	0.98	0.75	Aortic root size;	chr7:66174736	chr7:66654538~66669855:+
PRAD	cis	rs2486288	0.656	rs62026703	ENSG00000259520.4	CTD-2651B20.3	24.48	4.54e-85	8.56e-81	0.95	0.75	Glomerular filtration rate;	chr15:45277731	chr15:45251580~45279251:-
PRAD	cis	rs2486288	0.656	rs7165039	ENSG00000259520.4	CTD-2651B20.3	24.48	4.54e-85	8.56e-81	0.95	0.75	Glomerular filtration rate;	chr15:45278215	chr15:45251580~45279251:-
PRAD	cis	rs2486288	0.656	rs7166580	ENSG00000259520.4	CTD-2651B20.3	24.48	4.54e-85	8.56e-81	0.95	0.75	Glomerular filtration rate;	chr15:45279011	chr15:45251580~45279251:-
PRAD	cis	rs801193	1	rs10252765	ENSG00000226824.5	RP4-756H11.3	-24.44	6.89e-85	1.29e-80	-1	-0.75	Aortic root size;	chr7:66763745	chr7:66654538~66669855:+
PRAD	cis	rs9322193	0.923	rs6913486	ENSG00000231760.4	RP11-350J20.5	-24.4	1.12e-84	2.07e-80	-1.01	-0.75	Lung cancer;	chr6:149705060	chr6:149796151~149826294:-
PRAD	cis	rs916888	0.821	rs199505	ENSG00000214401.4	KANSL1-AS1	-24.4	1.15e-84	2.12e-80	-1.26	-0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:46193576~46196723:+
PRAD	cis	rs916888	0.821	rs70602	ENSG00000214401.4	KANSL1-AS1	-24.4	1.15e-84	2.12e-80	-1.26	-0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:46193576~46196723:+
PRAD	cis	rs875971	0.619	rs2302918	ENSG00000226824.5	RP4-756H11.3	-24.38	1.32e-84	2.43e-80	-0.96	-0.75	Aortic root size;	chr7:66535945	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.54	rs35510581	ENSG00000226824.5	RP4-756H11.3	24.37	1.43e-84	2.62e-80	0.98	0.75	Aortic root size;	chr7:66113790	chr7:66654538~66669855:+
PRAD	cis	rs9322193	0.961	rs4870144	ENSG00000231760.4	RP11-350J20.5	24.33	2.3e-84	4.22e-80	1.04	0.75	Lung cancer;	chr6:149575540	chr6:149796151~149826294:-
PRAD	cis	rs4423214	1	rs11600860	ENSG00000254682.1	RP11-660L16.2	24.32	2.42e-84	4.43e-80	0.98	0.75	Vitamin D levels;	chr11:71452973	chr11:71448674~71452157:+
PRAD	cis	rs4423214	0.959	rs11606611	ENSG00000254682.1	RP11-660L16.2	24.32	2.42e-84	4.43e-80	0.98	0.75	Vitamin D levels;	chr11:71453000	chr11:71448674~71452157:+
PRAD	cis	rs4423214	1	rs11606612	ENSG00000254682.1	RP11-660L16.2	24.32	2.42e-84	4.43e-80	0.98	0.75	Vitamin D levels;	chr11:71453001	chr11:71448674~71452157:+
PRAD	cis	rs4423214	1	rs12791871	ENSG00000254682.1	RP11-660L16.2	24.32	2.42e-84	4.43e-80	0.98	0.75	Vitamin D levels;	chr11:71453498	chr11:71448674~71452157:+
PRAD	cis	rs9322193	0.923	rs4870052	ENSG00000231760.4	RP11-350J20.5	24.32	2.55e-84	4.67e-80	1.02	0.75	Lung cancer;	chr6:149839978	chr6:149796151~149826294:-
PRAD	cis	rs4423214	1	rs7944926	ENSG00000254682.1	RP11-660L16.2	24.31	2.83e-84	5.17e-80	0.98	0.75	Vitamin D levels;	chr11:71454579	chr11:71448674~71452157:+
PRAD	cis	rs2882667	0.69	rs11954103	ENSG00000253404.1	AC034243.1	24.3	3.32e-84	6.05e-80	1.09	0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138933459	chr5:138744434~138753309:-
PRAD	cis	rs875971	0.66	rs1860468	ENSG00000226824.5	RP4-756H11.3	24.28	3.7e-84	6.74e-80	0.96	0.75	Aortic root size;	chr7:66642265	chr7:66654538~66669855:+
PRAD	cis	rs7847628	0.55	rs12343516	ENSG00000226752.6	PSMD5-AS1	-24.25	5.34e-84	9.67e-80	-0.87	-0.75	Birth weight;	chr9:120841191	chr9:120824828~120854385:+
PRAD	cis	rs2486288	0.656	rs6493145	ENSG00000259520.4	CTD-2651B20.3	24.25	5.52e-84	9.99e-80	0.95	0.75	Glomerular filtration rate;	chr15:45281664	chr15:45251580~45279251:-
PRAD	cis	rs1577917	0.655	rs2758848	ENSG00000203875.9	SNHG5	-24.24	5.9e-84	1.07e-79	-0.81	-0.75	Response to antipsychotic treatment;	chr6:85637887	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.727	rs9344539	ENSG00000203875.9	SNHG5	-24.24	6.11e-84	1.1e-79	-0.81	-0.75	Response to antipsychotic treatment;	chr6:85643903	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.771	rs9362232	ENSG00000203875.9	SNHG5	-24.24	6.11e-84	1.1e-79	-0.81	-0.75	Response to antipsychotic treatment;	chr6:85643904	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.61	rs11752795	ENSG00000203875.9	SNHG5	24.23	6.73e-84	1.21e-79	0.8	0.75	Response to antipsychotic treatment;	chr6:85577411	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.566	rs2842611	ENSG00000203875.9	SNHG5	-24.23	6.73e-84	1.21e-79	-0.8	-0.75	Response to antipsychotic treatment;	chr6:85592316	chr6:85660950~85678736:-
PRAD	cis	rs2739330	0.753	rs4822452	ENSG00000273295.1	AP000350.5	24.22	7.07e-84	1.27e-79	0.91	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23901432~23907068:-
PRAD	cis	rs801193	0.901	rs4273746	ENSG00000226824.5	RP4-756H11.3	24.2	9.45e-84	1.68e-79	1	0.75	Aortic root size;	chr7:66836124	chr7:66654538~66669855:+
PRAD	cis	rs2486288	0.656	rs2413771	ENSG00000259520.4	CTD-2651B20.3	24.17	1.28e-83	2.28e-79	0.93	0.75	Glomerular filtration rate;	chr15:45260942	chr15:45251580~45279251:-
PRAD	cis	rs2739330	0.892	rs5751776	ENSG00000225282.1	AP000350.6	24.14	1.72e-83	3.05e-79	0.97	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23926900~23929574:+
PRAD	cis	rs2739330	0.828	rs4822454	ENSG00000273295.1	AP000350.5	24.14	1.72e-83	3.05e-79	0.92	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23901432~23907068:-
PRAD	cis	rs2486288	0.656	rs6493144	ENSG00000259520.4	CTD-2651B20.3	-24.12	2.04e-83	3.62e-79	-0.95	-0.75	Glomerular filtration rate;	chr15:45281291	chr15:45251580~45279251:-
PRAD	cis	rs7847628	0.587	rs3793638	ENSG00000226752.6	PSMD5-AS1	-24.11	2.46e-83	4.36e-79	-0.87	-0.75	Birth weight;	chr9:120820419	chr9:120824828~120854385:+
PRAD	cis	rs7847628	0.587	rs1060817	ENSG00000226752.6	PSMD5-AS1	-24.1	2.54e-83	4.49e-79	-0.87	-0.75	Birth weight;	chr9:120820914	chr9:120824828~120854385:+
PRAD	cis	rs7847628	0.587	rs10760117	ENSG00000226752.6	PSMD5-AS1	-24.1	2.72e-83	4.8e-79	-0.87	-0.75	Birth weight;	chr9:120824459	chr9:120824828~120854385:+
PRAD	cis	rs1577917	0.655	rs2842600	ENSG00000203875.9	SNHG5	-24.06	3.93e-83	6.92e-79	-0.8	-0.75	Response to antipsychotic treatment;	chr6:85615914	chr6:85660950~85678736:-
PRAD	cis	rs2739330	0.828	rs2186366	ENSG00000273295.1	AP000350.5	-24.05	4.41e-83	7.75e-79	-0.91	-0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23901432~23907068:-
PRAD	cis	rs4423214	1	rs12790010	ENSG00000254682.1	RP11-660L16.2	24.05	4.67e-83	8.17e-79	0.97	0.75	Vitamin D levels;	chr11:71459607	chr11:71448674~71452157:+
PRAD	cis	rs4423214	1	rs12806844	ENSG00000254682.1	RP11-660L16.2	24.05	4.67e-83	8.17e-79	0.97	0.75	Vitamin D levels;	chr11:71459724	chr11:71448674~71452157:+
PRAD	cis	rs4423214	1	rs12790558	ENSG00000254682.1	RP11-660L16.2	24.05	4.67e-83	8.17e-79	0.97	0.75	Vitamin D levels;	chr11:71459859	chr11:71448674~71452157:+
PRAD	cis	rs4423214	0.959	rs11233747	ENSG00000254682.1	RP11-660L16.2	24.05	4.67e-83	8.17e-79	0.97	0.75	Vitamin D levels;	chr11:71460596	chr11:71448674~71452157:+
PRAD	cis	rs9322193	0.923	rs57938011	ENSG00000231760.4	RP11-350J20.5	24.03	5.73e-83	9.99e-79	1.02	0.75	Lung cancer;	chr6:149642969	chr6:149796151~149826294:-
PRAD	cis	rs4423214	1	rs2002063	ENSG00000254682.1	RP11-660L16.2	24.02	6.02e-83	1.05e-78	0.98	0.75	Vitamin D levels;	chr11:71452430	chr11:71448674~71452157:+
PRAD	cis	rs8013143	1	rs11846575	ENSG00000279656.1	RP11-298I3.6	-24.02	6.38e-83	1.11e-78	-1.03	-0.75	Reticulocyte fraction of red cells;Reticulocyte count;Red cell distribution width;	chr14:23022075	chr14:23023083~23024217:-
PRAD	cis	rs4423214	0.959	rs12793224	ENSG00000254682.1	RP11-660L16.2	24.01	7.11e-83	1.23e-78	0.97	0.75	Vitamin D levels;	chr11:71457664	chr11:71448674~71452157:+
PRAD	cis	rs4423214	0.959	rs12794668	ENSG00000254682.1	RP11-660L16.2	24.01	7.11e-83	1.23e-78	0.97	0.75	Vitamin D levels;	chr11:71457669	chr11:71448674~71452157:+
PRAD	cis	rs507080	0.922	rs4936433	ENSG00000255239.1	AP002954.6	-23.99	8.21e-83	1.42e-78	-1.03	-0.75	Serum metabolite levels;	chr11:118681711	chr11:118688039~118690600:-
PRAD	cis	rs1577917	0.655	rs2758849	ENSG00000203875.9	SNHG5	-23.97	1.02e-82	1.76e-78	-0.81	-0.75	Response to antipsychotic treatment;	chr6:85634578	chr6:85660950~85678736:-
PRAD	cis	rs7847628	0.587	rs12684934	ENSG00000226752.6	PSMD5-AS1	-23.95	1.27e-82	2.19e-78	-0.87	-0.75	Birth weight;	chr9:120830881	chr9:120824828~120854385:+
PRAD	cis	rs7847628	0.551	rs10818476	ENSG00000226752.6	PSMD5-AS1	-23.94	1.37e-82	2.35e-78	-0.88	-0.75	Birth weight;	chr9:120809760	chr9:120824828~120854385:+
PRAD	cis	rs1799949	1	rs8176126	ENSG00000198496.9	NBR2	23.94	1.37e-82	2.36e-78	0.95	0.75	Menopause (age at onset);	chr17:43107032	chr17:43125610~43153671:+
PRAD	cis	rs2739330	0.929	rs5751777	ENSG00000225282.1	AP000350.6	23.94	1.49e-82	2.56e-78	0.98	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23926900~23929574:+
PRAD	cis	rs2739330	0.828	rs2330635	ENSG00000273295.1	AP000350.5	23.89	2.33e-82	3.99e-78	0.92	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23901432~23907068:-
PRAD	cis	rs1577917	0.559	rs1173418	ENSG00000203875.9	SNHG5	23.88	2.73e-82	4.68e-78	0.81	0.75	Response to antipsychotic treatment;	chr6:85693198	chr6:85660950~85678736:-
PRAD	cis	rs2283792	0.812	rs240064	ENSG00000224086.5	LL22NC03-86G7.1	23.88	2.85e-82	4.87e-78	0.86	0.75	Multiple sclerosis;	chr22:21927265	chr22:21938293~21977632:+
PRAD	cis	rs2739330	0.828	rs5760107	ENSG00000273295.1	AP000350.5	23.87	2.99e-82	5.11e-78	0.91	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23901432~23907068:-
PRAD	cis	rs2739330	0.789	rs5760109	ENSG00000273295.1	AP000350.5	23.87	2.99e-82	5.11e-78	0.91	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23901432~23907068:-
PRAD	cis	rs858239	0.509	rs6962213	ENSG00000230658.1	KLHL7-AS1	23.85	3.82e-82	6.5e-78	0.94	0.75	Cerebrospinal fluid biomarker levels;	chr7:23148490	chr7:23101228~23105703:-
PRAD	cis	rs9322193	0.923	rs7769101	ENSG00000231760.4	RP11-350J20.5	23.78	7.82e-82	1.33e-77	1.02	0.74	Lung cancer;	chr6:149848768	chr6:149796151~149826294:-
PRAD	cis	rs916888	0.821	rs199506	ENSG00000214401.4	KANSL1-AS1	-23.78	8.05e-82	1.36e-77	-1.24	-0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:46193576~46196723:+
PRAD	cis	rs9326248	1	rs7107152	ENSG00000254851.1	RP11-109L13.1	23.75	1.03e-81	1.74e-77	1.04	0.74	Blood protein levels;	chr11:117185364	chr11:117135528~117138582:+
PRAD	cis	rs7847628	0.587	rs4837796	ENSG00000226752.6	PSMD5-AS1	23.73	1.31e-81	2.21e-77	0.86	0.74	Birth weight;	chr9:120848010	chr9:120824828~120854385:+
PRAD	cis	rs10256972	0.528	rs7784607	ENSG00000229043.2	AC091729.9	-23.71	1.65e-81	2.78e-77	-0.94	-0.74	Endometriosis;Longevity;	chr7:1139058	chr7:1160374~1165267:+
PRAD	cis	rs858239	0.665	rs6964665	ENSG00000230658.1	KLHL7-AS1	23.71	1.7e-81	2.86e-77	0.95	0.74	Cerebrospinal fluid biomarker levels;	chr7:23171733	chr7:23101228~23105703:-
PRAD	cis	rs9322193	0.923	rs55849538	ENSG00000231760.4	RP11-350J20.5	23.68	2.24e-81	3.76e-77	1.01	0.74	Lung cancer;	chr6:149635330	chr6:149796151~149826294:-
PRAD	cis	rs4423214	0.921	rs12807827	ENSG00000254682.1	RP11-660L16.2	23.68	2.33e-81	3.91e-77	0.98	0.74	Vitamin D levels;	chr11:71492744	chr11:71448674~71452157:+
PRAD	cis	rs2283792	0.718	rs239918	ENSG00000224086.5	LL22NC03-86G7.1	-23.67	2.61e-81	4.36e-77	-0.86	-0.74	Multiple sclerosis;	chr22:21959457	chr22:21938293~21977632:+
PRAD	cis	rs2739330	0.796	rs2154594	ENSG00000273295.1	AP000350.5	-23.66	2.69e-81	4.49e-77	-0.91	-0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23901432~23907068:-
PRAD	cis	rs2283792	0.687	rs381849	ENSG00000224086.5	LL22NC03-86G7.1	-23.65	3.02e-81	5.05e-77	-0.85	-0.74	Multiple sclerosis;	chr22:21951341	chr22:21938293~21977632:+
PRAD	cis	rs916888	0.821	rs199514	ENSG00000214401.4	KANSL1-AS1	-23.62	4.48e-81	7.46e-77	-1.23	-0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:46193576~46196723:+
PRAD	cis	rs10256972	0.527	rs28671326	ENSG00000229043.2	AC091729.9	-23.6	5.53e-81	9.21e-77	-0.93	-0.74	Endometriosis;Longevity;	chr7:1135337	chr7:1160374~1165267:+
PRAD	cis	rs4423214	1	rs11606631	ENSG00000254682.1	RP11-660L16.2	23.59	5.7e-81	9.48e-77	0.97	0.74	Vitamin D levels;	chr11:71453075	chr11:71448674~71452157:+
PRAD	cis	rs4423214	1	rs12789751	ENSG00000254682.1	RP11-660L16.2	23.59	5.7e-81	9.48e-77	0.97	0.74	Vitamin D levels;	chr11:71453425	chr11:71448674~71452157:+
PRAD	cis	rs916888	0.821	rs415430	ENSG00000214401.4	KANSL1-AS1	-23.59	5.94e-81	9.87e-77	-1.24	-0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:46193576~46196723:+
PRAD	cis	rs916888	0.779	rs430685	ENSG00000214401.4	KANSL1-AS1	-23.59	5.94e-81	9.87e-77	-1.24	-0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:46193576~46196723:+
PRAD	cis	rs9322193	0.923	rs9800686	ENSG00000231760.4	RP11-350J20.5	23.51	1.31e-80	2.16e-76	1	0.74	Lung cancer;	chr6:149634464	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.81	rs62439811	ENSG00000231760.4	RP11-350J20.5	23.51	1.31e-80	2.16e-76	1	0.74	Lung cancer;	chr6:149640416	chr6:149796151~149826294:-
PRAD	cis	rs1577917	0.681	rs4348284	ENSG00000203875.9	SNHG5	-23.48	1.8e-80	2.96e-76	-0.8	-0.74	Response to antipsychotic treatment;	chr6:85640676	chr6:85660950~85678736:-
PRAD	cis	rs875971	0.66	rs10263935	ENSG00000226824.5	RP4-756H11.3	-23.45	2.66e-80	4.36e-76	-0.94	-0.74	Aortic root size;	chr7:66631041	chr7:66654538~66669855:+
PRAD	cis	rs7188445	0.556	rs7194711	ENSG00000261390.4	RP11-345M22.2	-23.44	3.07e-80	5.02e-76	-0.85	-0.74	Urate levels;	chr16:79715134	chr16:79715232~79770563:-
PRAD	cis	rs9322193	0.886	rs9767555	ENSG00000231760.4	RP11-350J20.5	23.42	3.78e-80	6.19e-76	1.01	0.74	Lung cancer;	chr6:149647022	chr6:149796151~149826294:-
PRAD	cis	rs2283792	0.792	rs151680	ENSG00000224086.5	LL22NC03-86G7.1	-23.4	4.32e-80	7.04e-76	-0.86	-0.74	Multiple sclerosis;	chr22:21918869	chr22:21938293~21977632:+
PRAD	cis	rs2739330	0.828	rs4820572	ENSG00000273295.1	AP000350.5	23.38	5.47e-80	8.91e-76	0.9	0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23901432~23907068:-
PRAD	cis	rs507080	0.733	rs4486664	ENSG00000255239.1	AP002954.6	23.38	5.79e-80	9.42e-76	1	0.74	Serum metabolite levels;	chr11:118698358	chr11:118688039~118690600:-
PRAD	cis	rs875971	0.577	rs34888281	ENSG00000226824.5	RP4-756H11.3	23.37	5.85e-80	9.51e-76	0.97	0.74	Aortic root size;	chr7:66120784	chr7:66654538~66669855:+
PRAD	cis	rs858239	0.539	rs10254544	ENSG00000230658.1	KLHL7-AS1	23.37	6.18e-80	1e-75	0.94	0.74	Cerebrospinal fluid biomarker levels;	chr7:23180616	chr7:23101228~23105703:-
PRAD	cis	rs916888	0.821	rs199504	ENSG00000214401.4	KANSL1-AS1	-23.36	7.07e-80	1.15e-75	-1.23	-0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:46193576~46196723:+
PRAD	cis	rs916888	0.697	rs199516	ENSG00000214401.4	KANSL1-AS1	-23.33	9.38e-80	1.52e-75	-1.23	-0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:46193576~46196723:+
PRAD	cis	rs916888	0.821	rs199512	ENSG00000214401.4	KANSL1-AS1	-23.33	9.38e-80	1.52e-75	-1.23	-0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:46193576~46196723:+
PRAD	cis	rs916888	0.821	rs199509	ENSG00000214401.4	KANSL1-AS1	-23.33	9.38e-80	1.52e-75	-1.23	-0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:46193576~46196723:+
PRAD	cis	rs916888	0.821	rs199507	ENSG00000214401.4	KANSL1-AS1	-23.33	9.38e-80	1.52e-75	-1.23	-0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:46193576~46196723:+
PRAD	cis	rs916888	0.773	rs9896243	ENSG00000214401.4	KANSL1-AS1	23.32	9.9e-80	1.6e-75	1.2	0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46193576~46196723:+
PRAD	cis	rs9322193	0.887	rs3777949	ENSG00000231760.4	RP11-350J20.5	23.32	1e-79	1.62e-75	1.02	0.74	Lung cancer;	chr6:149596021	chr6:149796151~149826294:-
PRAD	cis	rs4423214	1	rs12808368	ENSG00000254682.1	RP11-660L16.2	23.28	1.65e-79	2.66e-75	0.95	0.74	Vitamin D levels;	chr11:71459771	chr11:71448674~71452157:+
PRAD	cis	rs916888	0.738	rs199515	ENSG00000214401.4	KANSL1-AS1	-23.27	1.74e-79	2.79e-75	-1.22	-0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:46193576~46196723:+
PRAD	cis	rs7188445	0.592	rs4404082	ENSG00000261390.4	RP11-345M22.2	23.27	1.77e-79	2.84e-75	0.84	0.74	Urate levels;	chr16:79716615	chr16:79715232~79770563:-
PRAD	cis	rs858239	0.539	rs6461695	ENSG00000230658.1	KLHL7-AS1	23.26	2.07e-79	3.32e-75	0.92	0.74	Cerebrospinal fluid biomarker levels;	chr7:23158165	chr7:23101228~23105703:-
PRAD	cis	rs507080	0.663	rs523793	ENSG00000255239.1	AP002954.6	23.25	2.09e-79	3.34e-75	1	0.74	Serum metabolite levels;	chr11:118699988	chr11:118688039~118690600:-
PRAD	cis	rs507080	0.736	rs659564	ENSG00000255239.1	AP002954.6	23.25	2.09e-79	3.34e-75	1	0.74	Serum metabolite levels;	chr11:118700205	chr11:118688039~118690600:-
PRAD	cis	rs507080	0.736	rs642224	ENSG00000255239.1	AP002954.6	23.25	2.09e-79	3.34e-75	1	0.74	Serum metabolite levels;	chr11:118700210	chr11:118688039~118690600:-
PRAD	cis	rs507080	0.733	rs541631	ENSG00000255239.1	AP002954.6	23.25	2.09e-79	3.34e-75	1	0.74	Serum metabolite levels;	chr11:118700314	chr11:118688039~118690600:-
PRAD	cis	rs507080	0.736	rs658676	ENSG00000255239.1	AP002954.6	23.25	2.09e-79	3.34e-75	1	0.74	Serum metabolite levels;	chr11:118700414	chr11:118688039~118690600:-
PRAD	cis	rs507080	0.733	rs488141	ENSG00000255239.1	AP002954.6	23.25	2.09e-79	3.34e-75	1	0.74	Serum metabolite levels;	chr11:118700459	chr11:118688039~118690600:-
PRAD	cis	rs507080	0.733	rs657769	ENSG00000255239.1	AP002954.6	23.25	2.09e-79	3.34e-75	1	0.74	Serum metabolite levels;	chr11:118700607	chr11:118688039~118690600:-
PRAD	cis	rs507080	0.733	rs544452	ENSG00000255239.1	AP002954.6	23.25	2.09e-79	3.34e-75	1	0.74	Serum metabolite levels;	chr11:118700648	chr11:118688039~118690600:-
PRAD	cis	rs507080	0.697	rs656287	ENSG00000255239.1	AP002954.6	23.25	2.09e-79	3.34e-75	1	0.74	Serum metabolite levels;	chr11:118701081	chr11:118688039~118690600:-
PRAD	cis	rs507080	0.733	rs570949	ENSG00000255239.1	AP002954.6	23.25	2.09e-79	3.34e-75	1	0.74	Serum metabolite levels;	chr11:118701202	chr11:118688039~118690600:-
PRAD	cis	rs507080	0.733	rs611733	ENSG00000255239.1	AP002954.6	23.25	2.09e-79	3.34e-75	1	0.74	Serum metabolite levels;	chr11:118702051	chr11:118688039~118690600:-
PRAD	cis	rs858239	0.539	rs2103281	ENSG00000230658.1	KLHL7-AS1	23.25	2.18e-79	3.47e-75	0.92	0.74	Cerebrospinal fluid biomarker levels;	chr7:23154612	chr7:23101228~23105703:-
PRAD	cis	rs507080	0.733	rs4393358	ENSG00000255239.1	AP002954.6	23.25	2.19e-79	3.5e-75	0.99	0.74	Serum metabolite levels;	chr11:118698388	chr11:118688039~118690600:-
PRAD	cis	rs9322193	0.961	rs9285521	ENSG00000231760.4	RP11-350J20.5	23.24	2.45e-79	3.91e-75	1.01	0.74	Lung cancer;	chr6:149585576	chr6:149796151~149826294:-
PRAD	cis	rs507080	0.769	rs7389	ENSG00000255239.1	AP002954.6	-23.23	2.69e-79	4.29e-75	-1.01	-0.74	Serum metabolite levels;	chr11:118657756	chr11:118688039~118690600:-
PRAD	cis	rs7188445	0.556	rs7203910	ENSG00000261390.4	RP11-345M22.2	-23.23	2.74e-79	4.36e-75	-0.85	-0.74	Urate levels;	chr16:79711722	chr16:79715232~79770563:-
PRAD	cis	rs507080	0.733	rs7108144	ENSG00000255239.1	AP002954.6	23.22	3.04e-79	4.83e-75	1	0.74	Serum metabolite levels;	chr11:118698985	chr11:118688039~118690600:-
PRAD	cis	rs507080	0.733	rs552079	ENSG00000255239.1	AP002954.6	23.21	3.23e-79	5.13e-75	1	0.74	Serum metabolite levels;	chr11:118702313	chr11:118688039~118690600:-
PRAD	cis	rs507080	0.733	rs673547	ENSG00000255239.1	AP002954.6	23.21	3.23e-79	5.13e-75	1	0.74	Serum metabolite levels;	chr11:118702630	chr11:118688039~118690600:-
PRAD	cis	rs2739330	0.828	rs5760098	ENSG00000273295.1	AP000350.5	23.17	5.29e-79	8.36e-75	0.89	0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23901432~23907068:-
PRAD	cis	rs2739330	0.828	rs5760102	ENSG00000273295.1	AP000350.5	23.16	5.97e-79	9.43e-75	0.89	0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23901432~23907068:-
PRAD	cis	rs7188445	0.615	rs4340340	ENSG00000261390.4	RP11-345M22.2	-23.12	9.1e-79	1.43e-74	-0.85	-0.73	Urate levels;	chr16:79716720	chr16:79715232~79770563:-
PRAD	cis	rs916888	0.773	rs9896243	ENSG00000262539.1	RP11-259G18.3	23.11	9.45e-79	1.48e-74	1.22	0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46259551~46260606:-
PRAD	cis	rs507080	0.769	rs745663	ENSG00000255239.1	AP002954.6	23.09	1.17e-78	1.84e-74	1	0.73	Serum metabolite levels;	chr11:118658886	chr11:118688039~118690600:-
PRAD	cis	rs507080	0.733	rs517445	ENSG00000255239.1	AP002954.6	23.07	1.55e-78	2.42e-74	1	0.73	Serum metabolite levels;	chr11:118702826	chr11:118688039~118690600:-
PRAD	cis	rs507080	0.771	rs687664	ENSG00000255239.1	AP002954.6	23.07	1.55e-78	2.42e-74	1	0.73	Serum metabolite levels;	chr11:118703476	chr11:118688039~118690600:-
PRAD	cis	rs507080	0.771	rs523715	ENSG00000255239.1	AP002954.6	23.07	1.55e-78	2.42e-74	1	0.73	Serum metabolite levels;	chr11:118703479	chr11:118688039~118690600:-
PRAD	cis	rs4423214	0.879	rs4945008	ENSG00000254682.1	RP11-660L16.2	23.04	2.16e-78	3.37e-74	0.95	0.73	Vitamin D levels;	chr11:71510202	chr11:71448674~71452157:+
PRAD	cis	rs1799949	0.896	rs8176098	ENSG00000198496.9	NBR2	-23.03	2.38e-78	3.69e-74	-0.95	-0.73	Menopause (age at onset);	chr17:43116189	chr17:43125610~43153671:+
PRAD	cis	rs9326248	1	rs4938344	ENSG00000254851.1	RP11-109L13.1	-23.02	2.62e-78	4.06e-74	-1.07	-0.73	Blood protein levels;	chr11:117133033	chr11:117135528~117138582:+
PRAD	cis	rs2882667	0.69	rs11749163	ENSG00000253404.1	AC034243.1	23.01	2.78e-78	4.3e-74	1	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138926981	chr5:138744434~138753309:-
PRAD	cis	rs1799949	1	rs8176109	ENSG00000198496.9	NBR2	-23	3.04e-78	4.7e-74	-0.95	-0.73	Menopause (age at onset);	chr17:43113759	chr17:43125610~43153671:+
PRAD	cis	rs4423214	1	rs11600569	ENSG00000254682.1	RP11-660L16.2	23	3.16e-78	4.88e-74	0.95	0.73	Vitamin D levels;	chr11:71462701	chr11:71448674~71452157:+
PRAD	cis	rs10256972	0.567	rs2960850	ENSG00000229043.2	AC091729.9	-23	3.2e-78	4.94e-74	-0.93	-0.73	Endometriosis;Longevity;	chr7:1172013	chr7:1160374~1165267:+
PRAD	cis	rs916888	0.821	rs199513	ENSG00000214401.4	KANSL1-AS1	-22.97	4.51e-78	6.96e-74	-1.22	-0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46193576~46196723:+
PRAD	cis	rs1577917	0.655	rs9444352	ENSG00000203875.9	SNHG5	22.96	4.63e-78	7.14e-74	0.79	0.73	Response to antipsychotic treatment;	chr6:85547817	chr6:85660950~85678736:-
PRAD	cis	rs7188445	0.592	rs17767281	ENSG00000261390.4	RP11-345M22.2	-22.94	5.78e-78	8.91e-74	-0.85	-0.73	Urate levels;	chr16:79708544	chr16:79715232~79770563:-
PRAD	cis	rs2739330	0.796	rs5760097	ENSG00000273295.1	AP000350.5	22.93	6.41e-78	9.87e-74	0.9	0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23901432~23907068:-
PRAD	cis	rs9322193	0.961	rs9767713	ENSG00000231760.4	RP11-350J20.5	22.92	7.66e-78	1.18e-73	1.01	0.73	Lung cancer;	chr6:149588241	chr6:149796151~149826294:-
PRAD	cis	rs858239	0.508	rs10242104	ENSG00000230658.1	KLHL7-AS1	22.91	8.63e-78	1.32e-73	0.93	0.73	Cerebrospinal fluid biomarker levels;	chr7:23180831	chr7:23101228~23105703:-
PRAD	cis	rs9322193	0.887	rs3734295	ENSG00000231760.4	RP11-350J20.5	22.89	9.99e-78	1.53e-73	1.02	0.73	Lung cancer;	chr6:149593917	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.851	rs9322194	ENSG00000231760.4	RP11-350J20.5	22.88	1.09e-77	1.66e-73	1.01	0.73	Lung cancer;	chr6:149599113	chr6:149796151~149826294:-
PRAD	cis	rs4423214	1	rs4944958	ENSG00000254682.1	RP11-660L16.2	22.87	1.23e-77	1.88e-73	0.95	0.73	Vitamin D levels;	chr11:71457027	chr11:71448674~71452157:+
PRAD	cis	rs1799949	1	rs35668327	ENSG00000198496.9	NBR2	-22.87	1.28e-77	1.95e-73	-0.94	-0.73	Menopause (age at onset);	chr17:43121078	chr17:43125610~43153671:+
PRAD	cis	rs2739330	0.929	rs5751775	ENSG00000225282.1	AP000350.6	22.86	1.36e-77	2.07e-73	0.96	0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23926900~23929574:+
PRAD	cis	rs4423214	1	rs732934	ENSG00000254682.1	RP11-660L16.2	22.85	1.61e-77	2.45e-73	0.95	0.73	Vitamin D levels;	chr11:71475430	chr11:71448674~71452157:+
PRAD	cis	rs4423214	1	rs7935125	ENSG00000254682.1	RP11-660L16.2	22.84	1.74e-77	2.65e-73	0.95	0.73	Vitamin D levels;	chr11:71473144	chr11:71448674~71452157:+
PRAD	cis	rs4423214	1	rs3794060	ENSG00000254682.1	RP11-660L16.2	22.84	1.74e-77	2.65e-73	0.95	0.73	Vitamin D levels;	chr11:71476633	chr11:71448674~71452157:+
PRAD	cis	rs1799949	0.929	rs12937015	ENSG00000198496.9	NBR2	-22.81	2.3e-77	3.49e-73	-0.95	-0.73	Menopause (age at onset);	chr17:43155456	chr17:43125610~43153671:+
PRAD	cis	rs9322193	0.772	rs7738696	ENSG00000231760.4	RP11-350J20.5	22.8	2.74e-77	4.16e-73	0.97	0.73	Lung cancer;	chr6:149848985	chr6:149796151~149826294:-
PRAD	cis	rs1799949	0.965	rs8176130	ENSG00000198496.9	NBR2	-22.78	3.4e-77	5.14e-73	-0.94	-0.73	Menopause (age at onset);	chr17:43106026	chr17:43125610~43153671:+
PRAD	cis	rs1799949	1	rs8176120	ENSG00000198496.9	NBR2	-22.78	3.4e-77	5.14e-73	-0.94	-0.73	Menopause (age at onset);	chr17:43109216	chr17:43125610~43153671:+
PRAD	cis	rs507080	0.769	rs645637	ENSG00000255239.1	AP002954.6	22.77	3.55e-77	5.37e-73	1	0.73	Serum metabolite levels;	chr11:118634373	chr11:118688039~118690600:-
PRAD	cis	rs1799949	1	rs4340367	ENSG00000198496.9	NBR2	-22.76	4.18e-77	6.3e-73	-0.95	-0.73	Menopause (age at onset);	chr17:43155755	chr17:43125610~43153671:+
PRAD	cis	rs1799949	1	rs4792981	ENSG00000198496.9	NBR2	-22.76	4.18e-77	6.3e-73	-0.95	-0.73	Menopause (age at onset);	chr17:43156257	chr17:43125610~43153671:+
PRAD	cis	rs507080	0.769	rs483283	ENSG00000255239.1	AP002954.6	22.69	8.77e-77	1.31e-72	1	0.73	Serum metabolite levels;	chr11:118635684	chr11:118688039~118690600:-
PRAD	cis	rs1799949	0.965	rs35521261	ENSG00000198496.9	NBR2	-22.68	9.52e-77	1.42e-72	-0.95	-0.73	Menopause (age at onset);	chr17:43161595	chr17:43125610~43153671:+
PRAD	cis	rs1799949	0.896	rs33933393	ENSG00000198496.9	NBR2	-22.68	9.52e-77	1.42e-72	-0.95	-0.73	Menopause (age at onset);	chr17:43165415	chr17:43125610~43153671:+
PRAD	cis	rs1799949	1	rs33946455	ENSG00000198496.9	NBR2	-22.68	9.52e-77	1.42e-72	-0.95	-0.73	Menopause (age at onset);	chr17:43169829	chr17:43125610~43153671:+
PRAD	cis	rs507080	0.769	rs570952	ENSG00000255239.1	AP002954.6	22.67	1.02e-76	1.53e-72	0.99	0.73	Serum metabolite levels;	chr11:118629477	chr11:118688039~118690600:-
PRAD	cis	rs507080	0.733	rs489126	ENSG00000255239.1	AP002954.6	22.66	1.14e-76	1.7e-72	0.98	0.73	Serum metabolite levels;	chr11:118702038	chr11:118688039~118690600:-
PRAD	cis	rs507080	0.769	rs570836	ENSG00000255239.1	AP002954.6	22.66	1.17e-76	1.74e-72	1	0.73	Serum metabolite levels;	chr11:118641444	chr11:118688039~118690600:-
PRAD	cis	rs507080	0.769	rs571001	ENSG00000255239.1	AP002954.6	22.63	1.6e-76	2.38e-72	0.99	0.73	Serum metabolite levels;	chr11:118629457	chr11:118688039~118690600:-
PRAD	cis	rs1799949	0.965	rs12950779	ENSG00000198496.9	NBR2	-22.62	1.74e-76	2.58e-72	-0.95	-0.73	Menopause (age at onset);	chr17:43154506	chr17:43125610~43153671:+
PRAD	cis	rs507080	0.769	rs2077173	ENSG00000255239.1	AP002954.6	22.62	1.9e-76	2.83e-72	0.99	0.73	Serum metabolite levels;	chr11:118621876	chr11:118688039~118690600:-
PRAD	cis	rs2739330	0.828	rs5760099	ENSG00000273295.1	AP000350.5	22.61	2.09e-76	3.1e-72	0.89	0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23901432~23907068:-
PRAD	cis	rs2486288	0.656	rs7167146	ENSG00000259520.4	CTD-2651B20.3	-22.6	2.34e-76	3.47e-72	-0.94	-0.73	Glomerular filtration rate;	chr15:45279188	chr15:45251580~45279251:-
PRAD	cis	rs2739330	0.828	rs4822451	ENSG00000273295.1	AP000350.5	22.59	2.41e-76	3.57e-72	0.89	0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23901432~23907068:-
PRAD	cis	rs507080	0.769	rs11603616	ENSG00000255239.1	AP002954.6	22.59	2.57e-76	3.8e-72	0.99	0.73	Serum metabolite levels;	chr11:118625350	chr11:118688039~118690600:-
PRAD	cis	rs2739330	0.796	rs5760106	ENSG00000273295.1	AP000350.5	-22.57	3e-76	4.43e-72	-0.89	-0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23901432~23907068:-
PRAD	cis	rs9322193	0.884	rs10872647	ENSG00000231760.4	RP11-350J20.5	22.57	3.13e-76	4.62e-72	0.99	0.73	Lung cancer;	chr6:149758687	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.884	rs10872648	ENSG00000231760.4	RP11-350J20.5	22.56	3.49e-76	5.15e-72	0.99	0.73	Lung cancer;	chr6:149758699	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.884	rs11155679	ENSG00000231760.4	RP11-350J20.5	22.56	3.49e-76	5.15e-72	0.99	0.73	Lung cancer;	chr6:149758881	chr6:149796151~149826294:-
PRAD	cis	rs7188445	0.592	rs7196490	ENSG00000261390.4	RP11-345M22.2	-22.52	5.07e-76	7.46e-72	-0.84	-0.73	Urate levels;	chr16:79718572	chr16:79715232~79770563:-
PRAD	cis	rs7188445	0.614	rs62043313	ENSG00000261390.4	RP11-345M22.2	-22.49	7.5e-76	1.1e-71	-0.82	-0.73	Urate levels;	chr16:79710237	chr16:79715232~79770563:-
PRAD	cis	rs1799949	1	rs1960605	ENSG00000198496.9	NBR2	-22.46	1.01e-75	1.48e-71	-0.94	-0.73	Menopause (age at onset);	chr17:43153380	chr17:43125610~43153671:+
PRAD	cis	rs1799949	1	rs2037076	ENSG00000198496.9	NBR2	-22.46	1.01e-75	1.48e-71	-0.94	-0.73	Menopause (age at onset);	chr17:43153866	chr17:43125610~43153671:+
PRAD	cis	rs2739330	0.892	rs4822455	ENSG00000225282.1	AP000350.6	22.44	1.24e-75	1.81e-71	0.96	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23926900~23929574:+
PRAD	cis	rs1799949	1	rs8176103	ENSG00000198496.9	NBR2	-22.44	1.28e-75	1.87e-71	-0.94	-0.72	Menopause (age at onset);	chr17:43115033	chr17:43125610~43153671:+
PRAD	cis	rs9326248	1	rs9326248	ENSG00000254851.1	RP11-109L13.1	-22.43	1.39e-75	2.02e-71	-1.06	-0.72	Blood protein levels;	chr11:117128509	chr11:117135528~117138582:+
PRAD	cis	rs1799949	1	rs33926631	ENSG00000198496.9	NBR2	-22.41	1.72e-75	2.5e-71	-0.94	-0.72	Menopause (age at onset);	chr17:43152446	chr17:43125610~43153671:+
PRAD	cis	rs4853012	0.838	rs60705299	ENSG00000217702.2	RP11-287D1.4	22.38	2.44e-75	3.54e-71	1.1	0.72	Gestational age at birth (maternal effect);	chr2:74118243	chr2:74130583~74135395:+
PRAD	cis	rs9322193	0.884	rs11155675	ENSG00000231760.4	RP11-350J20.5	22.36	3.04e-75	4.41e-71	0.99	0.72	Lung cancer;	chr6:149742883	chr6:149796151~149826294:-
PRAD	cis	rs507080	0.769	rs527290	ENSG00000255239.1	AP002954.6	22.34	3.44e-75	5e-71	1.01	0.72	Serum metabolite levels;	chr11:118644898	chr11:118688039~118690600:-
PRAD	cis	rs2486288	0.656	rs7171312	ENSG00000259520.4	CTD-2651B20.3	22.32	4.55e-75	6.6e-71	0.91	0.72	Glomerular filtration rate;	chr15:45278027	chr15:45251580~45279251:-
PRAD	cis	rs2486288	0.656	rs6493143	ENSG00000259520.4	CTD-2651B20.3	22.32	4.55e-75	6.6e-71	0.91	0.72	Glomerular filtration rate;	chr15:45278583	chr15:45251580~45279251:-
PRAD	cis	rs4853012	0.838	rs4452177	ENSG00000217702.2	RP11-287D1.4	22.29	6.41e-75	9.27e-71	1.1	0.72	Gestational age at birth (maternal effect);	chr2:74118079	chr2:74130583~74135395:+
PRAD	cis	rs9322193	0.884	rs9371201	ENSG00000231760.4	RP11-350J20.5	22.23	1.13e-74	1.62e-70	0.99	0.72	Lung cancer;	chr6:149823865	chr6:149796151~149826294:-
PRAD	cis	rs2283792	0.745	rs5756306	ENSG00000224086.5	LL22NC03-86G7.1	22.21	1.4e-74	2.01e-70	0.83	0.72	Multiple sclerosis;	chr22:21978846	chr22:21938293~21977632:+
PRAD	cis	rs9322193	0.923	rs9371486	ENSG00000231760.4	RP11-350J20.5	22.2	1.58e-74	2.26e-70	0.98	0.72	Lung cancer;	chr6:149832090	chr6:149796151~149826294:-
PRAD	cis	rs1799949	1	rs2271574	ENSG00000198496.9	NBR2	-22.19	1.69e-74	2.41e-70	-0.94	-0.72	Menopause (age at onset);	chr17:43175631	chr17:43125610~43153671:+
PRAD	cis	rs1799949	1	rs33920795	ENSG00000198496.9	NBR2	-22.19	1.69e-74	2.41e-70	-0.94	-0.72	Menopause (age at onset);	chr17:43176993	chr17:43125610~43153671:+
PRAD	cis	rs1799949	1	rs33918839	ENSG00000198496.9	NBR2	-22.19	1.69e-74	2.41e-70	-0.94	-0.72	Menopause (age at onset);	chr17:43177155	chr17:43125610~43153671:+
PRAD	cis	rs9322193	0.887	rs4870139	ENSG00000231760.4	RP11-350J20.5	22.18	2.08e-74	2.97e-70	1	0.72	Lung cancer;	chr6:149575182	chr6:149796151~149826294:-
PRAD	cis	rs1799949	1	rs33994002	ENSG00000198496.9	NBR2	-22.16	2.44e-74	3.48e-70	-0.94	-0.72	Menopause (age at onset);	chr17:43176801	chr17:43125610~43153671:+
PRAD	cis	rs507080	0.769	rs12290522	ENSG00000255239.1	AP002954.6	22.15	2.66e-74	3.78e-70	1	0.72	Serum metabolite levels;	chr11:118615610	chr11:118688039~118690600:-
PRAD	cis	rs2739330	0.828	rs5751770	ENSG00000218537.1	MIF-AS1	22.14	3.05e-74	4.34e-70	0.96	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23894426~23898930:-
PRAD	cis	rs2486288	0.656	rs8024620	ENSG00000259520.4	CTD-2651B20.3	22.11	4.07e-74	5.78e-70	0.9	0.72	Glomerular filtration rate;	chr15:45282131	chr15:45251580~45279251:-
PRAD	cis	rs1799949	1	rs11653231	ENSG00000198496.9	NBR2	-22.1	4.52e-74	6.41e-70	-0.94	-0.72	Menopause (age at onset);	chr17:43179443	chr17:43125610~43153671:+
PRAD	cis	rs1799949	0.965	rs35954893	ENSG00000198496.9	NBR2	-22.1	4.52e-74	6.41e-70	-0.94	-0.72	Menopause (age at onset);	chr17:43181769	chr17:43125610~43153671:+
PRAD	cis	rs858239	0.537	rs10279691	ENSG00000230658.1	KLHL7-AS1	22.1	4.56e-74	6.47e-70	0.91	0.72	Cerebrospinal fluid biomarker levels;	chr7:23188768	chr7:23101228~23105703:-
PRAD	cis	rs4853012	0.838	rs72915068	ENSG00000217702.2	RP11-287D1.4	22.09	5.01e-74	7.1e-70	1.13	0.72	Gestational age at birth (maternal effect);	chr2:74129058	chr2:74130583~74135395:+
PRAD	cis	rs858239	0.537	rs2286272	ENSG00000230658.1	KLHL7-AS1	22.09	5.04e-74	7.14e-70	0.91	0.72	Cerebrospinal fluid biomarker levels;	chr7:23184748	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.537	rs6955115	ENSG00000230658.1	KLHL7-AS1	22.09	5.04e-74	7.14e-70	0.91	0.72	Cerebrospinal fluid biomarker levels;	chr7:23187525	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.539	rs10270695	ENSG00000230658.1	KLHL7-AS1	-22.09	5.2e-74	7.35e-70	-0.9	-0.72	Cerebrospinal fluid biomarker levels;	chr7:23149369	chr7:23101228~23105703:-
PRAD	cis	rs875971	0.522	rs781144	ENSG00000226824.5	RP4-756H11.3	-22.07	6.33e-74	8.95e-70	-0.91	-0.72	Aortic root size;	chr7:65975357	chr7:66654538~66669855:+
PRAD	cis	rs4423214	1	rs4944946	ENSG00000254682.1	RP11-660L16.2	22.07	6.71e-74	9.48e-70	0.94	0.72	Vitamin D levels;	chr11:71448383	chr11:71448674~71452157:+
PRAD	cis	rs1799949	1	rs1399323	ENSG00000198496.9	NBR2	-22.05	8.29e-74	1.17e-69	-0.94	-0.72	Menopause (age at onset);	chr17:43180313	chr17:43125610~43153671:+
PRAD	cis	rs4423214	1	rs28364617	ENSG00000254682.1	RP11-660L16.2	22.04	8.69e-74	1.22e-69	0.94	0.72	Vitamin D levels;	chr11:71448718	chr11:71448674~71452157:+
PRAD	cis	rs875971	0.522	rs1880556	ENSG00000226824.5	RP4-756H11.3	-22.04	8.95e-74	1.26e-69	-0.91	-0.72	Aortic root size;	chr7:65967557	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.505	rs2462573	ENSG00000226824.5	RP4-756H11.3	22	1.32e-73	1.84e-69	0.9	0.72	Aortic root size;	chr7:66042405	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.505	rs1167386	ENSG00000226824.5	RP4-756H11.3	22	1.32e-73	1.84e-69	0.9	0.72	Aortic root size;	chr7:66048109	chr7:66654538~66669855:+
PRAD	cis	rs1799949	1	rs1973646	ENSG00000198496.9	NBR2	-21.97	1.92e-73	2.65e-69	-0.95	-0.72	Menopause (age at onset);	chr17:43158478	chr17:43125610~43153671:+
PRAD	cis	rs1799949	1	rs8074136	ENSG00000198496.9	NBR2	-21.95	2.26e-73	3.12e-69	-0.94	-0.72	Menopause (age at onset);	chr17:43190296	chr17:43125610~43153671:+
PRAD	cis	rs1799949	0.93	rs4445938	ENSG00000198496.9	NBR2	-21.95	2.29e-73	3.16e-69	-0.94	-0.72	Menopause (age at onset);	chr17:43185883	chr17:43125610~43153671:+
PRAD	cis	rs4853012	0.838	rs59570457	ENSG00000217702.2	RP11-287D1.4	21.95	2.31e-73	3.18e-69	1.11	0.72	Gestational age at birth (maternal effect);	chr2:74117155	chr2:74130583~74135395:+
PRAD	cis	rs1799949	0.965	rs8176087	ENSG00000198496.9	NBR2	-21.93	2.74e-73	3.78e-69	-0.93	-0.72	Menopause (age at onset);	chr17:43118649	chr17:43125610~43153671:+
PRAD	cis	rs858239	0.899	rs5850	ENSG00000230658.1	KLHL7-AS1	21.93	2.77e-73	3.81e-69	0.9	0.72	Cerebrospinal fluid biomarker levels;	chr7:23274928	chr7:23101228~23105703:-
PRAD	cis	rs1799949	1	rs34942571	ENSG00000198496.9	NBR2	-21.92	3.04e-73	4.18e-69	-0.93	-0.72	Menopause (age at onset);	chr17:43121362	chr17:43125610~43153671:+
PRAD	cis	rs2739330	0.828	rs2877178	ENSG00000218537.1	MIF-AS1	21.89	4.47e-73	6.13e-69	0.96	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23894426~23898930:-
PRAD	cis	rs2739330	0.828	rs2154593	ENSG00000218537.1	MIF-AS1	21.89	4.47e-73	6.13e-69	0.96	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23894426~23898930:-
PRAD	cis	rs916888	0.773	rs199447	ENSG00000262500.1	RP11-259G18.2	21.88	4.63e-73	6.34e-69	1.13	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46243606~46245044:+
PRAD	cis	rs2739330	0.828	rs5760108	ENSG00000218537.1	MIF-AS1	21.88	5.08e-73	6.95e-69	0.96	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23894426~23898930:-
PRAD	cis	rs9322193	0.884	rs7744105	ENSG00000231760.4	RP11-350J20.5	21.88	5.09e-73	6.97e-69	0.95	0.72	Lung cancer;	chr6:149849308	chr6:149796151~149826294:-
PRAD	cis	rs4423214	1	rs4944959	ENSG00000254682.1	RP11-660L16.2	-21.87	5.22e-73	7.14e-69	-0.93	-0.72	Vitamin D levels;	chr11:71457188	chr11:71448674~71452157:+
PRAD	cis	rs9322193	0.884	rs7743823	ENSG00000231760.4	RP11-350J20.5	21.86	6.05e-73	8.27e-69	0.95	0.72	Lung cancer;	chr6:149849744	chr6:149796151~149826294:-
PRAD	cis	rs916888	0.773	rs199448	ENSG00000262500.1	RP11-259G18.2	21.86	6.32e-73	8.63e-69	1.13	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46243606~46245044:+
PRAD	cis	rs916888	0.773	rs199534	ENSG00000262500.1	RP11-259G18.2	21.84	7.43e-73	1.01e-68	1.13	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46243606~46245044:+
PRAD	cis	rs4853012	0.838	rs72911122	ENSG00000217702.2	RP11-287D1.4	21.83	8.04e-73	1.1e-68	1.11	0.72	Gestational age at birth (maternal effect);	chr2:74116992	chr2:74130583~74135395:+
PRAD	cis	rs2486288	0.656	rs11631021	ENSG00000259520.4	CTD-2651B20.3	21.83	8.28e-73	1.13e-68	0.91	0.72	Glomerular filtration rate;	chr15:45264631	chr15:45251580~45279251:-
PRAD	cis	rs916888	0.773	rs199533	ENSG00000262500.1	RP11-259G18.2	21.83	8.28e-73	1.13e-68	1.13	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46243606~46245044:+
PRAD	cis	rs1799949	1	rs11653460	ENSG00000198496.9	NBR2	-21.82	8.8e-73	1.2e-68	-0.95	-0.72	Menopause (age at onset);	chr17:43179289	chr17:43125610~43153671:+
PRAD	cis	rs9322193	0.884	rs9383865	ENSG00000231760.4	RP11-350J20.5	21.82	8.91e-73	1.21e-68	0.95	0.72	Lung cancer;	chr6:149852043	chr6:149796151~149826294:-
PRAD	cis	rs2486288	0.656	rs1706768	ENSG00000259520.4	CTD-2651B20.3	21.82	9.5e-73	1.29e-68	0.91	0.72	Glomerular filtration rate;	chr15:45277245	chr15:45251580~45279251:-
PRAD	cis	rs875971	0.505	rs1723275	ENSG00000226824.5	RP4-756H11.3	21.78	1.48e-72	2.01e-68	0.9	0.71	Aortic root size;	chr7:66039646	chr7:66654538~66669855:+
PRAD	cis	rs1577917	0.56	rs9450288	ENSG00000203875.9	SNHG5	21.75	1.88e-72	2.54e-68	0.78	0.71	Response to antipsychotic treatment;	chr6:85511868	chr6:85660950~85678736:-
PRAD	cis	rs2486288	0.656	rs11639349	ENSG00000259520.4	CTD-2651B20.3	21.75	1.95e-72	2.64e-68	0.91	0.71	Glomerular filtration rate;	chr15:45276062	chr15:45251580~45279251:-
PRAD	cis	rs2486288	0.656	rs12440356	ENSG00000259520.4	CTD-2651B20.3	-21.75	2e-72	2.71e-68	-0.91	-0.71	Glomerular filtration rate;	chr15:45275331	chr15:45251580~45279251:-
PRAD	cis	rs4853012	0.838	rs12619982	ENSG00000217702.2	RP11-287D1.4	21.71	2.97e-72	3.99e-68	1.15	0.71	Gestational age at birth (maternal effect);	chr2:74128895	chr2:74130583~74135395:+
PRAD	cis	rs916888	0.773	rs199457	ENSG00000262500.1	RP11-259G18.2	21.71	3.01e-72	4.04e-68	1.11	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46243606~46245044:+
PRAD	cis	rs916888	0.687	rs199456	ENSG00000262500.1	RP11-259G18.2	21.71	3.01e-72	4.04e-68	1.11	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46243606~46245044:+
PRAD	cis	rs916888	0.773	rs199451	ENSG00000262500.1	RP11-259G18.2	21.71	3.01e-72	4.04e-68	1.11	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46243606~46245044:+
PRAD	cis	rs4853012	0.838	rs6707729	ENSG00000217702.2	RP11-287D1.4	21.7	3.18e-72	4.25e-68	1.09	0.71	Gestational age at birth (maternal effect);	chr2:74117558	chr2:74130583~74135395:+
PRAD	cis	rs858239	0.669	rs10950940	ENSG00000230658.1	KLHL7-AS1	-21.7	3.2e-72	4.28e-68	-0.9	-0.71	Cerebrospinal fluid biomarker levels;	chr7:23157197	chr7:23101228~23105703:-
PRAD	cis	rs2486288	0.656	rs2461705	ENSG00000259520.4	CTD-2651B20.3	21.7	3.39e-72	4.52e-68	0.91	0.71	Glomerular filtration rate;	chr15:45278043	chr15:45251580~45279251:-
PRAD	cis	rs9322193	0.884	rs7769115	ENSG00000231760.4	RP11-350J20.5	21.7	3.44e-72	4.58e-68	0.95	0.71	Lung cancer;	chr6:149848796	chr6:149796151~149826294:-
PRAD	cis	rs1799949	1	rs4793229	ENSG00000198496.9	NBR2	21.69	3.76e-72	5.01e-68	0.93	0.71	Menopause (age at onset);	chr17:43340966	chr17:43125610~43153671:+
PRAD	cis	rs1799949	1	rs8176220	ENSG00000198496.9	NBR2	-21.68	3.97e-72	5.28e-68	-0.94	-0.71	Menopause (age at onset);	chr17:43070445	chr17:43125610~43153671:+
PRAD	cis	rs1799949	1	rs1799966	ENSG00000198496.9	NBR2	-21.68	3.97e-72	5.28e-68	-0.94	-0.71	Menopause (age at onset);	chr17:43071077	chr17:43125610~43153671:+
PRAD	cis	rs2486288	0.656	rs1719232	ENSG00000259520.4	CTD-2651B20.3	21.67	4.49e-72	5.97e-68	0.91	0.71	Glomerular filtration rate;	chr15:45279874	chr15:45251580~45279251:-
PRAD	cis	rs4423214	1	rs2852853	ENSG00000254682.1	RP11-660L16.2	21.67	4.5e-72	5.98e-68	0.91	0.71	Vitamin D levels;	chr11:71439171	chr11:71448674~71452157:+
PRAD	cis	rs1799949	1	rs4793215	ENSG00000198496.9	NBR2	-21.65	5.46e-72	7.25e-68	-0.95	-0.71	Menopause (age at onset);	chr17:43166915	chr17:43125610~43153671:+
PRAD	cis	rs2486288	0.656	rs1706770	ENSG00000259520.4	CTD-2651B20.3	21.63	6.78e-72	8.97e-68	0.91	0.71	Glomerular filtration rate;	chr15:45282864	chr15:45251580~45279251:-
PRAD	cis	rs858239	0.899	rs10262243	ENSG00000230658.1	KLHL7-AS1	21.63	7.12e-72	9.41e-68	0.88	0.71	Cerebrospinal fluid biomarker levels;	chr7:23251368	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.899	rs1881203	ENSG00000230658.1	KLHL7-AS1	21.63	7.12e-72	9.41e-68	0.88	0.71	Cerebrospinal fluid biomarker levels;	chr7:23253189	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.568	rs6970694	ENSG00000230658.1	KLHL7-AS1	21.63	7.33e-72	9.69e-68	0.91	0.71	Cerebrospinal fluid biomarker levels;	chr7:23211209	chr7:23101228~23105703:-
PRAD	cis	rs875971	0.505	rs1167385	ENSG00000226824.5	RP4-756H11.3	21.62	7.54e-72	9.95e-68	0.9	0.71	Aortic root size;	chr7:66048321	chr7:66654538~66669855:+
PRAD	cis	rs858239	0.899	rs2268747	ENSG00000230658.1	KLHL7-AS1	21.6	9.25e-72	1.22e-67	0.9	0.71	Cerebrospinal fluid biomarker levels;	chr7:23273843	chr7:23101228~23105703:-
PRAD	cis	rs507080	0.697	rs653008	ENSG00000255239.1	AP002954.6	21.58	1.15e-71	1.51e-67	0.97	0.71	Serum metabolite levels;	chr11:118649775	chr11:118688039~118690600:-
PRAD	cis	rs1799949	0.965	rs8176161	ENSG00000198496.9	NBR2	-21.58	1.22e-71	1.6e-67	-0.93	-0.71	Menopause (age at onset);	chr17:43089373	chr17:43125610~43153671:+
PRAD	cis	rs1799949	0.894	rs8176160	ENSG00000198496.9	NBR2	-21.58	1.22e-71	1.6e-67	-0.93	-0.71	Menopause (age at onset);	chr17:43089486	chr17:43125610~43153671:+
PRAD	cis	rs10256972	0.591	rs6968988	ENSG00000229043.2	AC091729.9	-21.56	1.44e-71	1.89e-67	-0.88	-0.71	Endometriosis;Longevity;	chr7:1129983	chr7:1160374~1165267:+
PRAD	cis	rs9322193	0.884	rs1125	ENSG00000231760.4	RP11-350J20.5	21.56	1.51e-71	1.98e-67	0.98	0.71	Lung cancer;	chr6:149658280	chr6:149796151~149826294:-
PRAD	cis	rs507080	0.733	rs601318	ENSG00000255239.1	AP002954.6	21.55	1.59e-71	2.08e-67	0.97	0.71	Serum metabolite levels;	chr11:118648845	chr11:118688039~118690600:-
PRAD	cis	rs858239	0.867	rs10250602	ENSG00000230658.1	KLHL7-AS1	21.54	1.82e-71	2.38e-67	0.9	0.71	Cerebrospinal fluid biomarker levels;	chr7:23264082	chr7:23101228~23105703:-
PRAD	cis	rs2486288	0.656	rs8039352	ENSG00000259520.4	CTD-2651B20.3	21.54	1.92e-71	2.51e-67	0.9	0.71	Glomerular filtration rate;	chr15:45259592	chr15:45251580~45279251:-
PRAD	cis	rs858239	0.537	rs6942981	ENSG00000230658.1	KLHL7-AS1	21.53	2.16e-71	2.82e-67	0.9	0.71	Cerebrospinal fluid biomarker levels;	chr7:23191929	chr7:23101228~23105703:-
PRAD	cis	rs1799949	1	rs2037075	ENSG00000198496.9	NBR2	-21.52	2.17e-71	2.84e-67	-0.93	-0.71	Menopause (age at onset);	chr17:43153809	chr17:43125610~43153671:+
PRAD	cis	rs10256972	0.553	rs4236381	ENSG00000229043.2	AC091729.9	-21.52	2.24e-71	2.93e-67	-0.88	-0.71	Endometriosis;Longevity;	chr7:1126087	chr7:1160374~1165267:+
PRAD	cis	rs1799949	0.965	rs11658499	ENSG00000198496.9	NBR2	-21.51	2.68e-71	3.5e-67	-0.94	-0.71	Menopause (age at onset);	chr17:43182732	chr17:43125610~43153671:+
PRAD	cis	rs858239	0.669	rs1618339	ENSG00000230658.1	KLHL7-AS1	21.5	2.8e-71	3.66e-67	0.9	0.71	Cerebrospinal fluid biomarker levels;	chr7:23190155	chr7:23101228~23105703:-
PRAD	cis	rs4423214	1	rs12422045	ENSG00000254682.1	RP11-660L16.2	21.5	2.91e-71	3.79e-67	0.91	0.71	Vitamin D levels;	chr11:71443774	chr11:71448674~71452157:+
PRAD	cis	rs1799949	0.965	rs8176193	ENSG00000198496.9	NBR2	-21.5	2.91e-71	3.8e-67	-0.93	-0.71	Menopause (age at onset);	chr17:43079499	chr17:43125610~43153671:+
PRAD	cis	rs9322193	0.887	rs11155662	ENSG00000231760.4	RP11-350J20.5	21.47	3.9e-71	5.02e-67	0.99	0.71	Lung cancer;	chr6:149592731	chr6:149796151~149826294:-
PRAD	cis	rs858239	0.699	rs955187	ENSG00000230658.1	KLHL7-AS1	-21.45	5.06e-71	6.5e-67	-0.87	-0.71	Cerebrospinal fluid biomarker levels;	chr7:23154986	chr7:23101228~23105703:-
PRAD	cis	rs1799949	1	rs3950989	ENSG00000198496.9	NBR2	-21.44	5.39e-71	6.91e-67	-0.93	-0.71	Menopause (age at onset);	chr17:43085936	chr17:43125610~43153671:+
PRAD	cis	rs1799949	1	rs2070834	ENSG00000198496.9	NBR2	-21.44	5.39e-71	6.91e-67	-0.93	-0.71	Menopause (age at onset);	chr17:43090268	chr17:43125610~43153671:+
PRAD	cis	rs9322193	0.884	rs9397036	ENSG00000231760.4	RP11-350J20.5	21.41	7.11e-71	9.1e-67	0.94	0.71	Lung cancer;	chr6:149851787	chr6:149796151~149826294:-
PRAD	cis	rs1799949	1	rs11649954	ENSG00000198496.9	NBR2	-21.41	7.16e-71	9.16e-67	-0.93	-0.71	Menopause (age at onset);	chr17:43342667	chr17:43125610~43153671:+
PRAD	cis	rs1799949	1	rs1824889	ENSG00000198496.9	NBR2	-21.41	7.16e-71	9.16e-67	-0.93	-0.71	Menopause (age at onset);	chr17:43344508	chr17:43125610~43153671:+
PRAD	cis	rs4853012	0.838	rs6715351	ENSG00000217702.2	RP11-287D1.4	21.41	7.54e-71	9.63e-67	1.08	0.71	Gestational age at birth (maternal effect);	chr2:74118992	chr2:74130583~74135395:+
PRAD	cis	rs4853012	0.838	rs61521879	ENSG00000217702.2	RP11-287D1.4	21.41	7.54e-71	9.63e-67	1.08	0.71	Gestational age at birth (maternal effect);	chr2:74119081	chr2:74130583~74135395:+
PRAD	cis	rs4853012	0.941	rs60291089	ENSG00000217702.2	RP11-287D1.4	21.4	8.11e-71	1.03e-66	1.09	0.71	Gestational age at birth (maternal effect);	chr2:74117763	chr2:74130583~74135395:+
PRAD	cis	rs4853012	0.838	rs58759652	ENSG00000217702.2	RP11-287D1.4	21.4	8.11e-71	1.03e-66	1.09	0.71	Gestational age at birth (maternal effect);	chr2:74117775	chr2:74130583~74135395:+
PRAD	cis	rs1799949	0.965	rs11650913	ENSG00000198496.9	NBR2	-21.4	8.55e-71	1.09e-66	-0.94	-0.71	Menopause (age at onset);	chr17:43179580	chr17:43125610~43153671:+
PRAD	cis	rs1799949	1	rs12936831	ENSG00000198496.9	NBR2	-21.4	8.55e-71	1.09e-66	-0.94	-0.71	Menopause (age at onset);	chr17:43179799	chr17:43125610~43153671:+
PRAD	cis	rs2739330	0.828	rs4822454	ENSG00000218537.1	MIF-AS1	21.38	9.89e-71	1.26e-66	0.96	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23894426~23898930:-
PRAD	cis	rs1799949	1	rs16942	ENSG00000198496.9	NBR2	-21.38	1.02e-70	1.3e-66	-0.93	-0.71	Menopause (age at onset);	chr17:43091983	chr17:43125610~43153671:+
PRAD	cis	rs10256972	0.591	rs11766651	ENSG00000229043.2	AC091729.9	-21.36	1.25e-70	1.6e-66	-0.87	-0.71	Endometriosis;Longevity;	chr7:1122010	chr7:1160374~1165267:+
PRAD	cis	rs1577917	0.655	rs9342045	ENSG00000203875.9	SNHG5	21.35	1.46e-70	1.86e-66	0.78	0.71	Response to antipsychotic treatment;	chr6:85715430	chr6:85660950~85678736:-
PRAD	cis	rs9322193	0.884	rs9383864	ENSG00000231760.4	RP11-350J20.5	21.32	1.91e-70	2.42e-66	0.94	0.71	Lung cancer;	chr6:149851969	chr6:149796151~149826294:-
PRAD	cis	rs916888	0.821	rs199499	ENSG00000262539.1	RP11-259G18.3	21.31	2.21e-70	2.8e-66	1.29	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788132	chr17:46259551~46260606:-
PRAD	cis	rs858239	0.899	rs7794684	ENSG00000230658.1	KLHL7-AS1	21.3	2.28e-70	2.89e-66	0.9	0.71	Cerebrospinal fluid biomarker levels;	chr7:23271186	chr7:23101228~23105703:-
PRAD	cis	rs916888	0.773	rs199445	ENSG00000262500.1	RP11-259G18.2	21.3	2.33e-70	2.95e-66	1.1	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46243606~46245044:+
PRAD	cis	rs916888	0.773	rs199443	ENSG00000262500.1	RP11-259G18.2	21.3	2.33e-70	2.95e-66	1.1	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46243606~46245044:+
PRAD	cis	rs1799949	1	rs8176234	ENSG00000198496.9	NBR2	-21.3	2.4e-70	3.03e-66	-0.93	-0.71	Menopause (age at onset);	chr17:43067763	chr17:43125610~43153671:+
PRAD	cis	rs1799949	1	rs8176233	ENSG00000198496.9	NBR2	-21.3	2.4e-70	3.03e-66	-0.93	-0.71	Menopause (age at onset);	chr17:43067787	chr17:43125610~43153671:+
PRAD	cis	rs1799949	1	rs4793197	ENSG00000198496.9	NBR2	-21.29	2.56e-70	3.24e-66	-0.93	-0.71	Menopause (age at onset);	chr17:43079885	chr17:43125610~43153671:+
PRAD	cis	rs858239	0.601	rs6461702	ENSG00000230658.1	KLHL7-AS1	21.27	3.43e-70	4.32e-66	0.9	0.71	Cerebrospinal fluid biomarker levels;	chr7:23209654	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.899	rs28458177	ENSG00000230658.1	KLHL7-AS1	21.27	3.47e-70	4.37e-66	0.88	0.71	Cerebrospinal fluid biomarker levels;	chr7:23255253	chr7:23101228~23105703:-
PRAD	cis	rs1799949	1	rs35956818	ENSG00000198496.9	NBR2	-21.26	3.5e-70	4.41e-66	-0.93	-0.71	Menopause (age at onset);	chr17:43345617	chr17:43125610~43153671:+
PRAD	cis	rs12439619	0.846	rs28470877	ENSG00000278603.1	RP13-608F4.5	21.26	3.83e-70	4.81e-66	1.1	0.71	Intelligence (multi-trait analysis);	chr15:82245797	chr15:82472203~82472426:+
PRAD	cis	rs916888	0.61	rs199529	ENSG00000262539.1	RP11-259G18.3	21.25	4.1e-70	5.15e-66	1.13	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:46259551~46260606:-
PRAD	cis	rs916888	0.773	rs199535	ENSG00000262500.1	RP11-259G18.2	21.25	4.28e-70	5.37e-66	1.1	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46243606~46245044:+
PRAD	cis	rs2739330	0.828	rs2186366	ENSG00000218537.1	MIF-AS1	-21.24	4.54e-70	5.7e-66	-0.95	-0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23894426~23898930:-
PRAD	cis	rs4423214	1	rs12797951	ENSG00000254682.1	RP11-660L16.2	-21.23	5.03e-70	6.3e-66	-0.9	-0.71	Vitamin D levels;	chr11:71432220	chr11:71448674~71452157:+
PRAD	cis	rs1799949	0.93	rs4584865	ENSG00000198496.9	NBR2	-21.21	6.02e-70	7.53e-66	-0.93	-0.71	Menopause (age at onset);	chr17:43347551	chr17:43125610~43153671:+
PRAD	cis	rs1799949	1	rs4793194	ENSG00000198496.9	NBR2	-21.21	6.05e-70	7.57e-66	-0.93	-0.71	Menopause (age at onset);	chr17:43066316	chr17:43125610~43153671:+
PRAD	cis	rs1799949	1	rs2271573	ENSG00000198496.9	NBR2	-21.21	6.32e-70	7.9e-66	-0.93	-0.71	Menopause (age at onset);	chr17:43175604	chr17:43125610~43153671:+
PRAD	cis	rs1799949	1	rs11654731	ENSG00000198496.9	NBR2	-21.2	7.36e-70	9.16e-66	-0.93	-0.7	Menopause (age at onset);	chr17:43174923	chr17:43125610~43153671:+
PRAD	cis	rs1799949	0.965	rs11651623	ENSG00000198496.9	NBR2	-21.2	7.36e-70	9.16e-66	-0.93	-0.7	Menopause (age at onset);	chr17:43177830	chr17:43125610~43153671:+
PRAD	cis	rs1799949	0.965	rs11657883	ENSG00000198496.9	NBR2	-21.2	7.36e-70	9.16e-66	-0.93	-0.7	Menopause (age at onset);	chr17:43178007	chr17:43125610~43153671:+
PRAD	cis	rs1799949	0.965	rs11656945	ENSG00000198496.9	NBR2	-21.2	7.36e-70	9.16e-66	-0.93	-0.7	Menopause (age at onset);	chr17:43178248	chr17:43125610~43153671:+
PRAD	cis	rs1799949	1	rs12944430	ENSG00000198496.9	NBR2	-21.2	7.36e-70	9.16e-66	-0.93	-0.7	Menopause (age at onset);	chr17:43178803	chr17:43125610~43153671:+
PRAD	cis	rs875971	0.522	rs709604	ENSG00000226824.5	RP4-756H11.3	21.19	7.75e-70	9.63e-66	0.88	0.7	Aortic root size;	chr7:66032447	chr7:66654538~66669855:+
PRAD	cis	rs1799949	0.965	rs11650132	ENSG00000198496.9	NBR2	-21.18	8.86e-70	1.1e-65	-0.93	-0.7	Menopause (age at onset);	chr17:43174070	chr17:43125610~43153671:+
PRAD	cis	rs858239	0.899	rs28635122	ENSG00000230658.1	KLHL7-AS1	21.17	9.45e-70	1.17e-65	0.89	0.7	Cerebrospinal fluid biomarker levels;	chr7:23270562	chr7:23101228~23105703:-
PRAD	cis	rs12439619	0.846	rs62013464	ENSG00000278603.1	RP13-608F4.5	21.17	9.5e-70	1.18e-65	1.1	0.7	Intelligence (multi-trait analysis);	chr15:82288250	chr15:82472203~82472426:+
PRAD	cis	rs5850	0.602	rs1005786	ENSG00000230658.1	KLHL7-AS1	21.17	9.97e-70	1.23e-65	0.88	0.7	Blood protein levels;	chr7:23106218	chr7:23101228~23105703:-
PRAD	cis	rs9322193	0.923	rs2880436	ENSG00000231760.4	RP11-350J20.5	21.17	1.01e-69	1.24e-65	0.95	0.7	Lung cancer;	chr6:149859123	chr6:149796151~149826294:-
PRAD	cis	rs1799949	0.896	rs35908185	ENSG00000198496.9	NBR2	-21.16	1.02e-69	1.26e-65	-0.92	-0.7	Menopause (age at onset);	chr17:43103094	chr17:43125610~43153671:+
PRAD	cis	rs1799949	0.93	rs33968979	ENSG00000198496.9	NBR2	-21.16	1.04e-69	1.28e-65	-0.92	-0.7	Menopause (age at onset);	chr17:43145975	chr17:43125610~43153671:+
PRAD	cis	rs1799949	1	rs12952790	ENSG00000198496.9	NBR2	-21.16	1.04e-69	1.28e-65	-0.92	-0.7	Menopause (age at onset);	chr17:43147590	chr17:43125610~43153671:+
PRAD	cis	rs1799949	1	rs12950607	ENSG00000198496.9	NBR2	-21.16	1.04e-69	1.28e-65	-0.92	-0.7	Menopause (age at onset);	chr17:43147911	chr17:43125610~43153671:+
PRAD	cis	rs1799949	1	rs11079056	ENSG00000198496.9	NBR2	-21.16	1.04e-69	1.28e-65	-0.92	-0.7	Menopause (age at onset);	chr17:43148782	chr17:43125610~43153671:+
PRAD	cis	rs1799949	1	rs12936816	ENSG00000198496.9	NBR2	-21.16	1.04e-69	1.28e-65	-0.92	-0.7	Menopause (age at onset);	chr17:43149692	chr17:43125610~43153671:+
PRAD	cis	rs10256972	0.567	rs7782651	ENSG00000229043.2	AC091729.9	-21.16	1.07e-69	1.31e-65	-0.87	-0.7	Endometriosis;Longevity;	chr7:1120259	chr7:1160374~1165267:+
PRAD	cis	rs1799949	0.864	rs60309406	ENSG00000198496.9	NBR2	-21.16	1.07e-69	1.31e-65	-0.93	-0.7	Menopause (age at onset);	chr17:43358297	chr17:43125610~43153671:+
PRAD	cis	rs4423214	1	rs2282621	ENSG00000254682.1	RP11-660L16.2	21.15	1.18e-69	1.43e-65	0.91	0.7	Vitamin D levels;	chr11:71472428	chr11:71448674~71452157:+
PRAD	cis	rs4423214	1	rs2282620	ENSG00000254682.1	RP11-660L16.2	21.15	1.18e-69	1.43e-65	0.91	0.7	Vitamin D levels;	chr11:71472431	chr11:71448674~71452157:+
PRAD	cis	rs1799949	0.93	rs35292991	ENSG00000198496.9	NBR2	-21.15	1.25e-69	1.5e-65	-0.93	-0.7	Menopause (age at onset);	chr17:43181999	chr17:43125610~43153671:+
PRAD	cis	rs1799949	0.896	rs8176086	ENSG00000198496.9	NBR2	-21.15	1.25e-69	1.5e-65	-0.92	-0.7	Menopause (age at onset);	chr17:43122761	chr17:43125610~43153671:+
PRAD	cis	rs1799949	0.93	rs3765640	ENSG00000198496.9	NBR2	-21.15	1.25e-69	1.5e-65	-0.92	-0.7	Menopause (age at onset);	chr17:43124230	chr17:43125610~43153671:+
PRAD	cis	rs1799949	1	rs8176077	ENSG00000198496.9	NBR2	-21.15	1.25e-69	1.5e-65	-0.92	-0.7	Menopause (age at onset);	chr17:43124331	chr17:43125610~43153671:+
PRAD	cis	rs1799949	1	rs11655505	ENSG00000198496.9	NBR2	-21.15	1.25e-69	1.5e-65	-0.92	-0.7	Menopause (age at onset);	chr17:43126360	chr17:43125610~43153671:+
PRAD	cis	rs1799949	0.965	rs4793204	ENSG00000198496.9	NBR2	-21.15	1.25e-69	1.5e-65	-0.92	-0.7	Menopause (age at onset);	chr17:43127281	chr17:43125610~43153671:+
PRAD	cis	rs1799949	0.965	rs12947782	ENSG00000198496.9	NBR2	-21.15	1.25e-69	1.5e-65	-0.92	-0.7	Menopause (age at onset);	chr17:43127865	chr17:43125610~43153671:+
PRAD	cis	rs1799949	1	rs33945274	ENSG00000198496.9	NBR2	-21.15	1.25e-69	1.5e-65	-0.92	-0.7	Menopause (age at onset);	chr17:43128056	chr17:43125610~43153671:+
PRAD	cis	rs1799949	1	rs11653069	ENSG00000198496.9	NBR2	-21.15	1.25e-69	1.5e-65	-0.92	-0.7	Menopause (age at onset);	chr17:43131360	chr17:43125610~43153671:+
PRAD	cis	rs1799949	0.965	rs33988650	ENSG00000198496.9	NBR2	-21.15	1.25e-69	1.5e-65	-0.92	-0.7	Menopause (age at onset);	chr17:43135863	chr17:43125610~43153671:+
PRAD	cis	rs1799949	1	rs11656097	ENSG00000198496.9	NBR2	-21.15	1.25e-69	1.5e-65	-0.92	-0.7	Menopause (age at onset);	chr17:43138596	chr17:43125610~43153671:+
PRAD	cis	rs1799949	1	rs11658754	ENSG00000198496.9	NBR2	-21.15	1.25e-69	1.5e-65	-0.92	-0.7	Menopause (age at onset);	chr17:43140722	chr17:43125610~43153671:+
PRAD	cis	rs2739330	0.753	rs4822452	ENSG00000218537.1	MIF-AS1	21.14	1.28e-69	1.53e-65	0.94	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23894426~23898930:-
PRAD	cis	rs2739330	0.828	rs2330635	ENSG00000218537.1	MIF-AS1	21.14	1.32e-69	1.58e-65	0.96	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23894426~23898930:-
PRAD	cis	rs2739330	0.796	rs2154594	ENSG00000218537.1	MIF-AS1	-21.13	1.42e-69	1.69e-65	-0.95	-0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23894426~23898930:-
PRAD	cis	rs2739330	0.828	rs5760107	ENSG00000218537.1	MIF-AS1	21.13	1.51e-69	1.8e-65	0.96	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23894426~23898930:-
PRAD	cis	rs2739330	0.789	rs5760109	ENSG00000218537.1	MIF-AS1	21.13	1.51e-69	1.8e-65	0.96	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23894426~23898930:-
PRAD	cis	rs1799949	1	rs2292595	ENSG00000198496.9	NBR2	-21.12	1.67e-69	1.98e-65	-0.92	-0.7	Menopause (age at onset);	chr17:43138657	chr17:43125610~43153671:+
PRAD	cis	rs9322193	0.847	rs868375	ENSG00000231760.4	RP11-350J20.5	21.11	1.76e-69	2.09e-65	0.94	0.7	Lung cancer;	chr6:149844905	chr6:149796151~149826294:-
PRAD	cis	rs1799949	1	rs11651341	ENSG00000198496.9	NBR2	-21.11	1.77e-69	2.09e-65	-0.92	-0.7	Menopause (age at onset);	chr17:43350693	chr17:43125610~43153671:+
PRAD	cis	rs1799949	1	rs34572725	ENSG00000198496.9	NBR2	-21.11	1.77e-69	2.09e-65	-0.92	-0.7	Menopause (age at onset);	chr17:43351298	chr17:43125610~43153671:+
PRAD	cis	rs1799949	1	rs4534897	ENSG00000198496.9	NBR2	-21.11	1.77e-69	2.09e-65	-0.92	-0.7	Menopause (age at onset);	chr17:43354440	chr17:43125610~43153671:+
PRAD	cis	rs4853012	0.793	rs6707619	ENSG00000217702.2	RP11-287D1.4	21.1	1.99e-69	2.36e-65	1.08	0.7	Gestational age at birth (maternal effect);	chr2:74117529	chr2:74130583~74135395:+
PRAD	cis	rs4423214	1	rs909217	ENSG00000254682.1	RP11-660L16.2	21.1	2.13e-69	2.52e-65	0.9	0.7	Vitamin D levels;	chr11:71435531	chr11:71448674~71452157:+
PRAD	cis	rs1799949	0.965	rs4793233	ENSG00000198496.9	NBR2	-21.09	2.33e-69	2.75e-65	-0.93	-0.7	Menopause (age at onset);	chr17:43358069	chr17:43125610~43153671:+
PRAD	cis	rs1799949	0.965	rs4793234	ENSG00000198496.9	NBR2	-21.09	2.33e-69	2.75e-65	-0.93	-0.7	Menopause (age at onset);	chr17:43358815	chr17:43125610~43153671:+
PRAD	cis	rs12439619	0.846	rs7496227	ENSG00000278603.1	RP13-608F4.5	21.09	2.34e-69	2.76e-65	1.1	0.7	Intelligence (multi-trait analysis);	chr15:82275241	chr15:82472203~82472426:+
PRAD	cis	rs1799949	1	rs2175957	ENSG00000198496.9	NBR2	-21.08	2.55e-69	3.02e-65	-0.92	-0.7	Menopause (age at onset);	chr17:43134805	chr17:43125610~43153671:+
PRAD	cis	rs9322193	0.923	rs9371207	ENSG00000231760.4	RP11-350J20.5	21.07	2.76e-69	3.26e-65	0.95	0.7	Lung cancer;	chr6:149858087	chr6:149796151~149826294:-
PRAD	cis	rs1799949	0.965	rs33925201	ENSG00000198496.9	NBR2	-21.06	3.21e-69	3.78e-65	-0.91	-0.7	Menopause (age at onset);	chr17:43128665	chr17:43125610~43153671:+
PRAD	cis	rs12439619	0.846	rs28697264	ENSG00000278603.1	RP13-608F4.5	21.04	3.98e-69	4.68e-65	1.1	0.7	Intelligence (multi-trait analysis);	chr15:82265559	chr15:82472203~82472426:+
PRAD	cis	rs10256972	0.616	rs4585652	ENSG00000229043.2	AC091729.9	-21.01	5.23e-69	6.13e-65	-0.86	-0.7	Endometriosis;Longevity;	chr7:1105760	chr7:1160374~1165267:+
PRAD	cis	rs9322193	0.651	rs9322188	ENSG00000231760.4	RP11-350J20.5	-20.98	7.25e-69	8.5e-65	-0.96	-0.7	Lung cancer;	chr6:149588355	chr6:149796151~149826294:-
PRAD	cis	rs12439619	0.774	rs2867649	ENSG00000278603.1	RP13-608F4.5	20.98	7.34e-69	8.59e-65	1.1	0.7	Intelligence (multi-trait analysis);	chr15:82262331	chr15:82472203~82472426:+
PRAD	cis	rs1799949	1	rs8176145	ENSG00000198496.9	NBR2	-20.97	8.48e-69	9.9e-65	-0.92	-0.7	Menopause (age at onset);	chr17:43097077	chr17:43125610~43153671:+
PRAD	cis	rs1799949	0.965	rs8176140	ENSG00000198496.9	NBR2	-20.97	8.48e-69	9.9e-65	-0.92	-0.7	Menopause (age at onset);	chr17:43099629	chr17:43125610~43153671:+
PRAD	cis	rs858239	0.899	rs10085838	ENSG00000230658.1	KLHL7-AS1	20.96	9.25e-69	1.08e-64	0.88	0.7	Cerebrospinal fluid biomarker levels;	chr7:23258796	chr7:23101228~23105703:-
PRAD	cis	rs1799949	1	rs3092994	ENSG00000198496.9	NBR2	-20.96	9.59e-69	1.12e-64	-0.93	-0.7	Menopause (age at onset);	chr17:43063808	chr17:43125610~43153671:+
PRAD	cis	rs2486288	0.656	rs11637364	ENSG00000259520.4	CTD-2651B20.3	20.95	1.03e-68	1.2e-64	0.9	0.7	Glomerular filtration rate;	chr15:45287040	chr15:45251580~45279251:-
PRAD	cis	rs4423214	1	rs12278461	ENSG00000254682.1	RP11-660L16.2	20.94	1.1e-68	1.28e-64	0.91	0.7	Vitamin D levels;	chr11:71471139	chr11:71448674~71452157:+
PRAD	cis	rs858239	0.601	rs28673077	ENSG00000230658.1	KLHL7-AS1	20.93	1.22e-68	1.42e-64	0.9	0.7	Cerebrospinal fluid biomarker levels;	chr7:23211235	chr7:23101228~23105703:-
PRAD	cis	rs1799949	0.501	rs2343819	ENSG00000198496.9	NBR2	-20.92	1.4e-68	1.62e-64	-0.93	-0.7	Menopause (age at onset);	chr17:43332285	chr17:43125610~43153671:+
PRAD	cis	rs1799949	0.501	rs35399157	ENSG00000198496.9	NBR2	-20.92	1.4e-68	1.62e-64	-0.93	-0.7	Menopause (age at onset);	chr17:43334234	chr17:43125610~43153671:+
PRAD	cis	rs1799949	0.602	rs4600503	ENSG00000198496.9	NBR2	-20.92	1.4e-68	1.62e-64	-0.93	-0.7	Menopause (age at onset);	chr17:43336956	chr17:43125610~43153671:+
PRAD	cis	rs1799949	0.501	rs9675035	ENSG00000198496.9	NBR2	-20.92	1.4e-68	1.62e-64	-0.93	-0.7	Menopause (age at onset);	chr17:43337648	chr17:43125610~43153671:+
PRAD	cis	rs2739330	0.828	rs4820572	ENSG00000218537.1	MIF-AS1	20.92	1.41e-68	1.64e-64	0.95	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23894426~23898930:-
PRAD	cis	rs7188445	0.592	rs7199794	ENSG00000261390.4	RP11-345M22.2	20.92	1.41e-68	1.64e-64	0.82	0.7	Urate levels;	chr16:79708296	chr16:79715232~79770563:-
PRAD	cis	rs875971	0.522	rs9530	ENSG00000226824.5	RP4-756H11.3	-20.89	1.84e-68	2.12e-64	-0.89	-0.7	Aortic root size;	chr7:65960907	chr7:66654538~66669855:+
PRAD	cis	rs1799949	0.965	rs8176323	ENSG00000198496.9	NBR2	-20.89	1.86e-68	2.14e-64	-0.92	-0.7	Menopause (age at onset);	chr17:43043694	chr17:43125610~43153671:+
PRAD	cis	rs1799949	1	rs12516	ENSG00000198496.9	NBR2	-20.89	1.86e-68	2.14e-64	-0.92	-0.7	Menopause (age at onset);	chr17:43044391	chr17:43125610~43153671:+
PRAD	cis	rs1799949	1	rs4793190	ENSG00000198496.9	NBR2	-20.89	1.86e-68	2.14e-64	-0.92	-0.7	Menopause (age at onset);	chr17:43048092	chr17:43125610~43153671:+
PRAD	cis	rs1799949	1	rs8176297	ENSG00000198496.9	NBR2	-20.89	1.86e-68	2.14e-64	-0.92	-0.7	Menopause (age at onset);	chr17:43051308	chr17:43125610~43153671:+
PRAD	cis	rs1799949	1	rs8176296	ENSG00000198496.9	NBR2	-20.89	1.86e-68	2.14e-64	-0.92	-0.7	Menopause (age at onset);	chr17:43051574	chr17:43125610~43153671:+
PRAD	cis	rs1799949	1	rs4793191	ENSG00000198496.9	NBR2	-20.89	1.86e-68	2.14e-64	-0.92	-0.7	Menopause (age at onset);	chr17:43052360	chr17:43125610~43153671:+
PRAD	cis	rs1799949	1	rs4793192	ENSG00000198496.9	NBR2	-20.89	1.86e-68	2.14e-64	-0.92	-0.7	Menopause (age at onset);	chr17:43052373	chr17:43125610~43153671:+
PRAD	cis	rs1799949	1	rs8176289	ENSG00000198496.9	NBR2	-20.89	1.86e-68	2.14e-64	-0.92	-0.7	Menopause (age at onset);	chr17:43054039	chr17:43125610~43153671:+
PRAD	cis	rs4853012	0.838	rs4429500	ENSG00000217702.2	RP11-287D1.4	20.89	1.99e-68	2.29e-64	1.06	0.7	Gestational age at birth (maternal effect);	chr2:74118209	chr2:74130583~74135395:+
PRAD	cis	rs1799949	1	rs8176202	ENSG00000198496.9	NBR2	-20.88	2.08e-68	2.38e-64	-0.93	-0.7	Menopause (age at onset);	chr17:43078211	chr17:43125610~43153671:+
PRAD	cis	rs875971	0.522	rs2949690	ENSG00000226824.5	RP4-756H11.3	20.88	2.11e-68	2.42e-64	0.88	0.7	Aortic root size;	chr7:66018255	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.522	rs1617484	ENSG00000226824.5	RP4-756H11.3	-20.88	2.15e-68	2.47e-64	-0.88	-0.7	Aortic root size;	chr7:65998108	chr7:66654538~66669855:+
PRAD	cis	rs4423214	0.921	rs11603330	ENSG00000254682.1	RP11-660L16.2	20.86	2.79e-68	3.18e-64	0.9	0.7	Vitamin D levels;	chr11:71442413	chr11:71448674~71452157:+
PRAD	cis	rs2739330	0.627	rs9608219	ENSG00000273295.1	AP000350.5	20.85	3.04e-68	3.46e-64	0.84	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23901432~23907068:-
PRAD	cis	rs1799949	0.965	rs8176322	ENSG00000198496.9	NBR2	-20.84	3.17e-68	3.61e-64	-0.92	-0.7	Menopause (age at onset);	chr17:43043756	chr17:43125610~43153671:+
PRAD	cis	rs1799949	0.93	rs3092987	ENSG00000198496.9	NBR2	-20.84	3.37e-68	3.83e-64	-0.93	-0.7	Menopause (age at onset);	chr17:43070706	chr17:43125610~43153671:+
PRAD	cis	rs2486288	0.656	rs8039153	ENSG00000259520.4	CTD-2651B20.3	20.83	3.5e-68	3.97e-64	0.9	0.7	Glomerular filtration rate;	chr15:45287615	chr15:45251580~45279251:-
PRAD	cis	rs916888	0.773	rs169201	ENSG00000262500.1	RP11-259G18.2	20.83	3.7e-68	4.2e-64	1.11	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46243606~46245044:+
PRAD	cis	rs2739330	0.796	rs1006771	ENSG00000273295.1	AP000350.5	20.81	4.47e-68	5.06e-64	0.83	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23901432~23907068:-
PRAD	cis	rs4423214	0.918	rs11233789	ENSG00000254682.1	RP11-660L16.2	20.81	4.57e-68	5.16e-64	0.9	0.7	Vitamin D levels;	chr11:71470039	chr11:71448674~71452157:+
PRAD	cis	rs2739330	0.796	rs5760097	ENSG00000218537.1	MIF-AS1	20.78	6.39e-68	7.19e-64	0.94	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23894426~23898930:-
PRAD	cis	rs9322193	0.847	rs880246	ENSG00000231760.4	RP11-350J20.5	20.77	6.59e-68	7.41e-64	0.93	0.7	Lung cancer;	chr6:149845972	chr6:149796151~149826294:-
PRAD	cis	rs916888	0.779	rs199528	ENSG00000262500.1	RP11-259G18.2	20.77	6.89e-68	7.74e-64	1.12	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46243606~46245044:+
PRAD	cis	rs916888	0.821	rs199525	ENSG00000262500.1	RP11-259G18.2	20.77	6.89e-68	7.74e-64	1.12	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46243606~46245044:+
PRAD	cis	rs1799949	1	rs35330014	ENSG00000198496.9	NBR2	-20.76	7.49e-68	8.41e-64	-0.93	-0.7	Menopause (age at onset);	chr17:43060530	chr17:43125610~43153671:+
PRAD	cis	rs2486288	0.554	rs1719235	ENSG00000259520.4	CTD-2651B20.3	20.76	7.63e-68	8.56e-64	0.9	0.7	Glomerular filtration rate;	chr15:45283910	chr15:45251580~45279251:-
PRAD	cis	rs801193	0.742	rs9969300	ENSG00000226824.5	RP4-756H11.3	20.76	8.02e-68	9e-64	0.9	0.7	Aortic root size;	chr7:66316659	chr7:66654538~66669855:+
PRAD	cis	rs2882667	0.628	rs13173618	ENSG00000253404.1	AC034243.1	20.74	9.43e-68	1.05e-63	1.06	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138804091	chr5:138744434~138753309:-
PRAD	cis	rs1799949	1	rs8176133	ENSG00000198496.9	NBR2	-20.73	1.03e-67	1.14e-63	-0.92	-0.7	Menopause (age at onset);	chr17:43105441	chr17:43125610~43153671:+
PRAD	cis	rs12439619	0.846	rs62012059	ENSG00000278603.1	RP13-608F4.5	20.73	1.07e-67	1.19e-63	1.1	0.7	Intelligence (multi-trait analysis);	chr15:82251669	chr15:82472203~82472426:+
PRAD	cis	rs12439619	0.768	rs28694364	ENSG00000278603.1	RP13-608F4.5	20.73	1.07e-67	1.19e-63	1.09	0.7	Intelligence (multi-trait analysis);	chr15:82208119	chr15:82472203~82472426:+
PRAD	cis	rs858239	0.669	rs1006709	ENSG00000230658.1	KLHL7-AS1	20.73	1.09e-67	1.21e-63	0.85	0.7	Cerebrospinal fluid biomarker levels;	chr7:23100480	chr7:23101228~23105703:-
PRAD	cis	rs12439619	0.846	rs62012003	ENSG00000278603.1	RP13-608F4.5	20.71	1.31e-67	1.45e-63	1.09	0.7	Intelligence (multi-trait analysis);	chr15:82183236	chr15:82472203~82472426:+
PRAD	cis	rs9326248	0.861	rs4938353	ENSG00000254851.1	RP11-109L13.1	-20.71	1.39e-67	1.54e-63	-1.1	-0.7	Blood protein levels;	chr11:117175481	chr11:117135528~117138582:+
PRAD	cis	rs1799949	1	rs1060915	ENSG00000198496.9	NBR2	-20.7	1.42e-67	1.58e-63	-0.92	-0.7	Menopause (age at onset);	chr17:43082453	chr17:43125610~43153671:+
PRAD	cis	rs1799949	0.93	rs8176194	ENSG00000198496.9	NBR2	-20.7	1.47e-67	1.63e-63	-0.93	-0.7	Menopause (age at onset);	chr17:43079204	chr17:43125610~43153671:+
PRAD	cis	rs875971	0.54	rs1723268	ENSG00000226824.5	RP4-756H11.3	-20.7	1.51e-67	1.68e-63	-0.87	-0.7	Aortic root size;	chr7:66008093	chr7:66654538~66669855:+
PRAD	cis	rs4853012	0.838	rs2177707	ENSG00000217702.2	RP11-287D1.4	20.68	1.88e-67	2.08e-63	1.15	0.7	Gestational age at birth (maternal effect);	chr2:74129723	chr2:74130583~74135395:+
PRAD	cis	rs916888	0.773	rs1378358	ENSG00000262500.1	RP11-259G18.2	20.67	2.13e-67	2.35e-63	1.09	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46243606~46245044:+
PRAD	cis	rs2739330	0.791	rs9612520	ENSG00000273295.1	AP000350.5	20.66	2.17e-67	2.4e-63	0.84	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23901432~23907068:-
PRAD	cis	rs1799949	1	rs4793236	ENSG00000198496.9	NBR2	-20.65	2.39e-67	2.63e-63	-0.93	-0.7	Menopause (age at onset);	chr17:43359072	chr17:43125610~43153671:+
PRAD	cis	rs2739330	0.828	rs5760098	ENSG00000218537.1	MIF-AS1	20.65	2.56e-67	2.82e-63	0.93	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23894426~23898930:-
PRAD	cis	rs2739330	0.828	rs5760102	ENSG00000218537.1	MIF-AS1	20.63	3.25e-67	3.58e-63	0.93	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23894426~23898930:-
PRAD	cis	rs10256972	0.591	rs10229680	ENSG00000229043.2	AC091729.9	-20.62	3.36e-67	3.69e-63	-0.86	-0.7	Endometriosis;Longevity;	chr7:1118929	chr7:1160374~1165267:+
PRAD	cis	rs858239	0.899	rs2268745	ENSG00000230658.1	KLHL7-AS1	20.62	3.58e-67	3.94e-63	0.88	0.69	Cerebrospinal fluid biomarker levels;	chr7:23277981	chr7:23101228~23105703:-
PRAD	cis	rs17711722	0.701	rs781145	ENSG00000226824.5	RP4-756H11.3	-20.61	3.86e-67	4.24e-63	-0.87	-0.69	Calcium levels;	chr7:65975383	chr7:66654538~66669855:+
PRAD	cis	rs17711722	0.727	rs2658585	ENSG00000226824.5	RP4-756H11.3	-20.61	3.86e-67	4.24e-63	-0.87	-0.69	Calcium levels;	chr7:65996954	chr7:66654538~66669855:+
PRAD	cis	rs4853012	0.887	rs2280642	ENSG00000217702.2	RP11-287D1.4	20.61	3.94e-67	4.33e-63	1.15	0.69	Gestational age at birth (maternal effect);	chr2:74131125	chr2:74130583~74135395:+
PRAD	cis	rs17711722	0.701	rs781143	ENSG00000226824.5	RP4-756H11.3	-20.61	3.97e-67	4.36e-63	-0.87	-0.69	Calcium levels;	chr7:65974892	chr7:66654538~66669855:+
PRAD	cis	rs17711722	0.64	rs13237956	ENSG00000226824.5	RP4-756H11.3	-20.6	4.09e-67	4.49e-63	-0.87	-0.69	Calcium levels;	chr7:65853042	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.522	rs4718285	ENSG00000226824.5	RP4-756H11.3	-20.6	4.14e-67	4.54e-63	-0.87	-0.69	Aortic root size;	chr7:65827018	chr7:66654538~66669855:+
PRAD	cis	rs11673344	0.563	rs256744	ENSG00000226686.6	LINC01535	-20.6	4.46e-67	4.88e-63	-0.91	-0.69	Obesity-related traits;	chr19:37364586	chr19:37251912~37265535:+
PRAD	cis	rs875971	0.54	rs4717275	ENSG00000226824.5	RP4-756H11.3	20.59	4.66e-67	5.1e-63	0.87	0.69	Aortic root size;	chr7:65800193	chr7:66654538~66669855:+
PRAD	cis	rs12439619	0.846	rs62012056	ENSG00000278603.1	RP13-608F4.5	20.59	4.93e-67	5.39e-63	1.1	0.69	Intelligence (multi-trait analysis);	chr15:82247278	chr15:82472203~82472426:+
PRAD	cis	rs875971	0.516	rs6945322	ENSG00000226824.5	RP4-756H11.3	-20.58	5.26e-67	5.74e-63	-0.87	-0.69	Aortic root size;	chr7:65871069	chr7:66654538~66669855:+
PRAD	cis	rs17711722	0.701	rs55773927	ENSG00000226824.5	RP4-756H11.3	-20.58	5.26e-67	5.74e-63	-0.87	-0.69	Calcium levels;	chr7:65872915	chr7:66654538~66669855:+
PRAD	cis	rs17711722	0.727	rs35850374	ENSG00000226824.5	RP4-756H11.3	-20.58	5.26e-67	5.74e-63	-0.87	-0.69	Calcium levels;	chr7:65892789	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.522	rs4718286	ENSG00000226824.5	RP4-756H11.3	-20.58	5.32e-67	5.81e-63	-0.87	-0.69	Aortic root size;	chr7:65827777	chr7:66654538~66669855:+
PRAD	cis	rs17711722	0.585	rs6942660	ENSG00000226824.5	RP4-756H11.3	-20.58	5.32e-67	5.81e-63	-0.87	-0.69	Calcium levels;	chr7:65837419	chr7:66654538~66669855:+
PRAD	cis	rs1799949	0.965	rs34633610	ENSG00000198496.9	NBR2	-20.57	5.62e-67	6.12e-63	-0.92	-0.69	Menopause (age at onset);	chr17:43342017	chr17:43125610~43153671:+
PRAD	cis	rs1799949	0.965	rs11654051	ENSG00000198496.9	NBR2	-20.57	5.62e-67	6.12e-63	-0.92	-0.69	Menopause (age at onset);	chr17:43342288	chr17:43125610~43153671:+
PRAD	cis	rs1799949	0.93	rs56729776	ENSG00000198496.9	NBR2	-20.57	5.62e-67	6.12e-63	-0.92	-0.69	Menopause (age at onset);	chr17:43344763	chr17:43125610~43153671:+
PRAD	cis	rs12439619	0.81	rs28876157	ENSG00000278603.1	RP13-608F4.5	20.57	5.75e-67	6.26e-63	1.08	0.69	Intelligence (multi-trait analysis);	chr15:82216708	chr15:82472203~82472426:+
PRAD	cis	rs875971	0.522	rs7784623	ENSG00000226824.5	RP4-756H11.3	-20.57	5.93e-67	6.45e-63	-0.87	-0.69	Aortic root size;	chr7:65930047	chr7:66654538~66669855:+
PRAD	cis	rs801193	0.844	rs2244022	ENSG00000226824.5	RP4-756H11.3	-20.57	6.12e-67	6.65e-63	-0.92	-0.69	Aortic root size;	chr7:66737443	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.505	rs6955582	ENSG00000226824.5	RP4-756H11.3	-20.56	6.68e-67	7.26e-63	-0.87	-0.69	Aortic root size;	chr7:65966699	chr7:66654538~66669855:+
PRAD	cis	rs17711722	1	rs17711722	ENSG00000226824.5	RP4-756H11.3	20.55	6.99e-67	7.58e-63	0.87	0.69	Calcium levels;	chr7:65806210	chr7:66654538~66669855:+
PRAD	cis	rs17711722	0.675	rs6947132	ENSG00000226824.5	RP4-756H11.3	20.55	6.99e-67	7.58e-63	0.87	0.69	Calcium levels;	chr7:65808508	chr7:66654538~66669855:+
PRAD	cis	rs2486288	0.656	rs8041702	ENSG00000259520.4	CTD-2651B20.3	20.54	8.01e-67	8.69e-63	0.88	0.69	Glomerular filtration rate;	chr15:45254895	chr15:45251580~45279251:-
PRAD	cis	rs12439619	0.846	rs62010071	ENSG00000278603.1	RP13-608F4.5	20.53	8.89e-67	9.64e-63	1.09	0.69	Intelligence (multi-trait analysis);	chr15:82289442	chr15:82472203~82472426:+
PRAD	cis	rs1930961	1	rs6004669	ENSG00000100058.11	CRYBB2P1	20.53	9.43e-67	1.02e-62	1.08	0.69	Bipolar disorder with mood-incongruent psychosis;	chr22:25479836	chr22:25448105~25520854:+
PRAD	cis	rs1930961	1	rs997872	ENSG00000100058.11	CRYBB2P1	20.53	9.43e-67	1.02e-62	1.08	0.69	Bipolar disorder with mood-incongruent psychosis;	chr22:25482647	chr22:25448105~25520854:+
PRAD	cis	rs10256972	0.63	rs13235747	ENSG00000229043.2	AC091729.9	-20.51	1.11e-66	1.2e-62	-0.86	-0.69	Endometriosis;Longevity;	chr7:1089487	chr7:1160374~1165267:+
PRAD	cis	rs875971	0.522	rs10807697	ENSG00000226824.5	RP4-756H11.3	-20.5	1.24e-66	1.34e-62	-0.87	-0.69	Aortic root size;	chr7:65951183	chr7:66654538~66669855:+
PRAD	cis	rs17711722	0.727	rs1880555	ENSG00000226824.5	RP4-756H11.3	-20.5	1.26e-66	1.36e-62	-0.87	-0.69	Calcium levels;	chr7:65967580	chr7:66654538~66669855:+
PRAD	cis	rs7195287	0.826	rs9925824	ENSG00000276791.1	CTD-2270P14.5	-20.5	1.28e-66	1.39e-62	-0.74	-0.69	Eosinophil counts;	chr16:2777972	chr16:2777319~2780568:+
PRAD	cis	rs858239	0.73	rs858279	ENSG00000230658.1	KLHL7-AS1	20.5	1.29e-66	1.4e-62	0.89	0.69	Cerebrospinal fluid biomarker levels;	chr7:23211386	chr7:23101228~23105703:-
PRAD	cis	rs2739330	0.796	rs5760106	ENSG00000218537.1	MIF-AS1	-20.49	1.31e-66	1.42e-62	-0.94	-0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23894426~23898930:-
PRAD	cis	rs875971	0.522	rs2008188	ENSG00000226824.5	RP4-756H11.3	-20.49	1.33e-66	1.43e-62	-0.87	-0.69	Aortic root size;	chr7:65964026	chr7:66654538~66669855:+
PRAD	cis	rs916888	0.773	rs538628	ENSG00000262500.1	RP11-259G18.2	20.49	1.35e-66	1.46e-62	1.07	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:46243606~46245044:+
PRAD	cis	rs875971	0.522	rs4502988	ENSG00000226824.5	RP4-756H11.3	-20.49	1.36e-66	1.46e-62	-0.87	-0.69	Aortic root size;	chr7:65832759	chr7:66654538~66669855:+
PRAD	cis	rs1799949	1	rs36036395	ENSG00000198496.9	NBR2	-20.48	1.56e-66	1.68e-62	-0.93	-0.69	Menopause (age at onset);	chr17:43029280	chr17:43125610~43153671:+
PRAD	cis	rs1799949	1	rs72829113	ENSG00000198496.9	NBR2	-20.48	1.56e-66	1.68e-62	-0.93	-0.69	Menopause (age at onset);	chr17:43029818	chr17:43125610~43153671:+
PRAD	cis	rs1799949	1	rs11653253	ENSG00000198496.9	NBR2	-20.48	1.56e-66	1.68e-62	-0.93	-0.69	Menopause (age at onset);	chr17:43030645	chr17:43125610~43153671:+
PRAD	cis	rs1799949	1	rs12951869	ENSG00000198496.9	NBR2	-20.48	1.56e-66	1.68e-62	-0.93	-0.69	Menopause (age at onset);	chr17:43035550	chr17:43125610~43153671:+
PRAD	cis	rs1799949	1	rs11654452	ENSG00000198496.9	NBR2	-20.48	1.56e-66	1.68e-62	-0.93	-0.69	Menopause (age at onset);	chr17:43037366	chr17:43125610~43153671:+
PRAD	cis	rs1799949	1	rs4793189	ENSG00000198496.9	NBR2	-20.48	1.56e-66	1.68e-62	-0.93	-0.69	Menopause (age at onset);	chr17:43038698	chr17:43125610~43153671:+
PRAD	cis	rs1799949	1	rs11657053	ENSG00000198496.9	NBR2	-20.48	1.56e-66	1.68e-62	-0.93	-0.69	Menopause (age at onset);	chr17:43039112	chr17:43125610~43153671:+
PRAD	cis	rs1799949	1	rs8176318	ENSG00000198496.9	NBR2	-20.48	1.59e-66	1.7e-62	-0.92	-0.69	Menopause (age at onset);	chr17:43045257	chr17:43125610~43153671:+
PRAD	cis	rs4853012	0.838	rs4563249	ENSG00000217702.2	RP11-287D1.4	20.47	1.62e-66	1.74e-62	1.05	0.69	Gestational age at birth (maternal effect);	chr2:74126889	chr2:74130583~74135395:+
PRAD	cis	rs1799949	1	rs4793231	ENSG00000198496.9	NBR2	-20.47	1.67e-66	1.79e-62	-0.92	-0.69	Menopause (age at onset);	chr17:43350101	chr17:43125610~43153671:+
PRAD	cis	rs1930961	1	rs7285549	ENSG00000100058.11	CRYBB2P1	20.47	1.75e-66	1.87e-62	1.08	0.69	Bipolar disorder with mood-incongruent psychosis;	chr22:25478613	chr22:25448105~25520854:+
PRAD	cis	rs1930961	1	rs5996946	ENSG00000100058.11	CRYBB2P1	20.47	1.75e-66	1.87e-62	1.08	0.69	Bipolar disorder with mood-incongruent psychosis;	chr22:25480021	chr22:25448105~25520854:+
PRAD	cis	rs1930961	1	rs997873	ENSG00000100058.11	CRYBB2P1	20.47	1.75e-66	1.87e-62	1.08	0.69	Bipolar disorder with mood-incongruent psychosis;	chr22:25482315	chr22:25448105~25520854:+
PRAD	cis	rs17711722	0.74	rs7809991	ENSG00000226824.5	RP4-756H11.3	-20.46	1.85e-66	1.98e-62	-0.87	-0.69	Calcium levels;	chr7:65941231	chr7:66654538~66669855:+
PRAD	cis	rs1799949	1	rs2298862	ENSG00000198496.9	NBR2	-20.46	1.93e-66	2.06e-62	-0.93	-0.69	Menopause (age at onset);	chr17:43024671	chr17:43125610~43153671:+
PRAD	cis	rs1799949	0.93	rs2298861	ENSG00000198496.9	NBR2	-20.46	1.93e-66	2.06e-62	-0.93	-0.69	Menopause (age at onset);	chr17:43024814	chr17:43125610~43153671:+
PRAD	cis	rs858239	0.699	rs1881201	ENSG00000230658.1	KLHL7-AS1	-20.45	2.08e-66	2.23e-62	-0.85	-0.69	Cerebrospinal fluid biomarker levels;	chr7:23154394	chr7:23101228~23105703:-
PRAD	cis	rs11673344	0.562	rs256740	ENSG00000226686.6	LINC01535	-20.44	2.34e-66	2.5e-62	-0.91	-0.69	Obesity-related traits;	chr19:37365451	chr19:37251912~37265535:+
PRAD	cis	rs10256972	0.591	rs6950319	ENSG00000229043.2	AC091729.9	-20.44	2.41e-66	2.58e-62	-0.85	-0.69	Endometriosis;Longevity;	chr7:1121688	chr7:1160374~1165267:+
PRAD	cis	rs1799949	1	rs12944458	ENSG00000198496.9	NBR2	-20.44	2.45e-66	2.62e-62	-0.93	-0.69	Menopause (age at onset);	chr17:43028755	chr17:43125610~43153671:+
PRAD	cis	rs1799949	1	rs8176242	ENSG00000198496.9	NBR2	-20.43	2.55e-66	2.72e-62	-0.92	-0.69	Menopause (age at onset);	chr17:43065857	chr17:43125610~43153671:+
PRAD	cis	rs2739330	0.652	rs2000469	ENSG00000273295.1	AP000350.5	20.42	3.04e-66	3.23e-62	0.85	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23901432~23907068:-
PRAD	cis	rs2882667	0.628	rs13154573	ENSG00000253404.1	AC034243.1	20.4	3.52e-66	3.74e-62	1.04	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138812375	chr5:138744434~138753309:-
PRAD	cis	rs1799949	1	rs11659028	ENSG00000198496.9	NBR2	-20.4	3.67e-66	3.9e-62	-0.93	-0.69	Menopause (age at onset);	chr17:43043008	chr17:43125610~43153671:+
PRAD	cis	rs858239	0.806	rs10268610	ENSG00000230658.1	KLHL7-AS1	20.4	3.75e-66	3.98e-62	0.86	0.69	Cerebrospinal fluid biomarker levels;	chr7:23235145	chr7:23101228~23105703:-
PRAD	cis	rs10256972	0.568	rs1133043	ENSG00000229043.2	AC091729.9	-20.38	4.32e-66	4.58e-62	-0.85	-0.69	Endometriosis;Longevity;	chr7:1093669	chr7:1160374~1165267:+
PRAD	cis	rs12439619	0.846	rs62011975	ENSG00000278603.1	RP13-608F4.5	20.38	4.34e-66	4.59e-62	1.09	0.69	Intelligence (multi-trait analysis);	chr15:82159213	chr15:82472203~82472426:+
PRAD	cis	rs9326248	0.768	rs4936366	ENSG00000254851.1	RP11-109L13.1	-20.38	4.37e-66	4.62e-62	-1.1	-0.69	Blood protein levels;	chr11:117156169	chr11:117135528~117138582:+
PRAD	cis	rs1799949	1	rs9646417	ENSG00000198496.9	NBR2	-20.37	4.78e-66	5.05e-62	-0.92	-0.69	Menopause (age at onset);	chr17:43346885	chr17:43125610~43153671:+
PRAD	cis	rs1799949	1	rs1545764	ENSG00000198496.9	NBR2	-20.37	4.78e-66	5.05e-62	-0.92	-0.69	Menopause (age at onset);	chr17:43347197	chr17:43125610~43153671:+
PRAD	cis	rs1799949	1	rs9646412	ENSG00000198496.9	NBR2	-20.37	4.78e-66	5.05e-62	-0.92	-0.69	Menopause (age at onset);	chr17:43348525	chr17:43125610~43153671:+
PRAD	cis	rs858239	0.896	rs1637193	ENSG00000230658.1	KLHL7-AS1	20.37	4.89e-66	5.17e-62	0.86	0.69	Cerebrospinal fluid biomarker levels;	chr7:23220632	chr7:23101228~23105703:-
PRAD	cis	rs1799949	0.931	rs34410138	ENSG00000198496.9	NBR2	-20.37	5.13e-66	5.41e-62	-0.9	-0.69	Menopause (age at onset);	chr17:43127753	chr17:43125610~43153671:+
PRAD	cis	rs10256972	0.641	rs12702017	ENSG00000229043.2	AC091729.9	-20.36	5.59e-66	5.88e-62	-0.86	-0.69	Endometriosis;Longevity;	chr7:1089777	chr7:1160374~1165267:+
PRAD	cis	rs1799949	1	rs11652332	ENSG00000198496.9	NBR2	-20.35	5.89e-66	6.19e-62	-0.91	-0.69	Menopause (age at onset);	chr17:43143472	chr17:43125610~43153671:+
PRAD	cis	rs17711722	0.701	rs4467826	ENSG00000226824.5	RP4-756H11.3	-20.34	6.67e-66	7e-62	-0.86	-0.69	Calcium levels;	chr7:65903721	chr7:66654538~66669855:+
PRAD	cis	rs11763147	1	rs11763147	ENSG00000226824.5	RP4-756H11.3	20.34	6.75e-66	7.08e-62	0.87	0.69	Corneal structure;	chr7:65861834	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.522	rs1701760	ENSG00000226824.5	RP4-756H11.3	-20.34	6.91e-66	7.25e-62	-0.87	-0.69	Aortic root size;	chr7:66008701	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.522	rs34973832	ENSG00000226824.5	RP4-756H11.3	-20.33	7.49e-66	7.84e-62	-0.86	-0.69	Aortic root size;	chr7:65931217	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.522	rs6960048	ENSG00000226824.5	RP4-756H11.3	-20.32	8.15e-66	8.53e-62	-0.87	-0.69	Aortic root size;	chr7:65943052	chr7:66654538~66669855:+
PRAD	cis	rs12439619	0.705	rs4778665	ENSG00000278603.1	RP13-608F4.5	20.31	9.01e-66	9.41e-62	1.1	0.69	Intelligence (multi-trait analysis);	chr15:82144163	chr15:82472203~82472426:+
PRAD	cis	rs9326248	0.861	rs4938352	ENSG00000254851.1	RP11-109L13.1	-20.31	9.15e-66	9.56e-62	-1.09	-0.69	Blood protein levels;	chr11:117156765	chr11:117135528~117138582:+
PRAD	cis	rs916888	0.773	rs199439	ENSG00000262500.1	RP11-259G18.2	20.3	1.02e-65	1.07e-61	1.07	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:46243606~46245044:+
PRAD	cis	rs1799949	1	rs67060599	ENSG00000198496.9	NBR2	-20.29	1.13e-65	1.18e-61	-0.92	-0.69	Menopause (age at onset);	chr17:43103085	chr17:43125610~43153671:+
PRAD	cis	rs9326248	0.861	rs7931335	ENSG00000254851.1	RP11-109L13.1	-20.28	1.26e-65	1.31e-61	-1.09	-0.69	Blood protein levels;	chr11:117166089	chr11:117135528~117138582:+
PRAD	cis	rs1930961	1	rs6004667	ENSG00000100058.11	CRYBB2P1	-20.28	1.27e-65	1.32e-61	-1.09	-0.69	Bipolar disorder with mood-incongruent psychosis;	chr22:25478497	chr22:25448105~25520854:+
PRAD	cis	rs2882667	0.628	rs13162420	ENSG00000253404.1	AC034243.1	20.28	1.28e-65	1.33e-61	1.04	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138839070	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.628	rs13167462	ENSG00000253404.1	AC034243.1	20.28	1.28e-65	1.33e-61	1.04	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138841572	chr5:138744434~138753309:-
PRAD	cis	rs858239	0.699	rs1881200	ENSG00000230658.1	KLHL7-AS1	-20.27	1.47e-65	1.53e-61	-0.86	-0.69	Cerebrospinal fluid biomarker levels;	chr7:23162018	chr7:23101228~23105703:-
PRAD	cis	rs1799949	0.965	rs1842147	ENSG00000198496.9	NBR2	-20.26	1.56e-65	1.62e-61	-0.92	-0.69	Menopause (age at onset);	chr17:43357824	chr17:43125610~43153671:+
PRAD	cis	rs12439619	0.846	rs62012004	ENSG00000278603.1	RP13-608F4.5	20.26	1.57e-65	1.63e-61	1.08	0.69	Intelligence (multi-trait analysis);	chr15:82183924	chr15:82472203~82472426:+
PRAD	cis	rs12439619	0.739	rs62012046	ENSG00000278603.1	RP13-608F4.5	20.26	1.62e-65	1.68e-61	1.08	0.69	Intelligence (multi-trait analysis);	chr15:82236824	chr15:82472203~82472426:+
PRAD	cis	rs12439619	0.774	rs62012047	ENSG00000278603.1	RP13-608F4.5	20.26	1.62e-65	1.68e-61	1.08	0.69	Intelligence (multi-trait analysis);	chr15:82236852	chr15:82472203~82472426:+
PRAD	cis	rs12439619	0.81	rs62012049	ENSG00000278603.1	RP13-608F4.5	20.26	1.62e-65	1.68e-61	1.08	0.69	Intelligence (multi-trait analysis);	chr15:82237722	chr15:82472203~82472426:+
PRAD	cis	rs2739330	0.828	rs4822451	ENSG00000218537.1	MIF-AS1	20.25	1.75e-65	1.81e-61	0.93	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23894426~23898930:-
PRAD	cis	rs1799949	1	rs8176083	ENSG00000198496.9	NBR2	-20.25	1.77e-65	1.84e-61	-0.91	-0.69	Menopause (age at onset);	chr17:43123134	chr17:43125610~43153671:+
PRAD	cis	rs2739330	0.828	rs5760099	ENSG00000218537.1	MIF-AS1	20.25	1.85e-65	1.92e-61	0.93	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23894426~23898930:-
PRAD	cis	rs1799949	1	rs16941	ENSG00000198496.9	NBR2	-20.23	2.12e-65	2.19e-61	-0.91	-0.69	Menopause (age at onset);	chr17:43092418	chr17:43125610~43153671:+
PRAD	cis	rs1799949	0.965	rs33961729	ENSG00000198496.9	NBR2	-20.23	2.17e-65	2.23e-61	-0.91	-0.69	Menopause (age at onset);	chr17:43135907	chr17:43125610~43153671:+
PRAD	cis	rs1799949	1	rs11657835	ENSG00000198496.9	NBR2	-20.23	2.17e-65	2.23e-61	-0.91	-0.69	Menopause (age at onset);	chr17:43139936	chr17:43125610~43153671:+
PRAD	cis	rs1799949	1	rs1135214	ENSG00000198496.9	NBR2	-20.23	2.17e-65	2.23e-61	-0.91	-0.69	Menopause (age at onset);	chr17:43140306	chr17:43125610~43153671:+
PRAD	cis	rs1799949	1	rs4793212	ENSG00000198496.9	NBR2	-20.23	2.17e-65	2.23e-61	-0.91	-0.69	Menopause (age at onset);	chr17:43150733	chr17:43125610~43153671:+
PRAD	cis	rs1799949	1	rs34534709	ENSG00000198496.9	NBR2	-20.23	2.17e-65	2.23e-61	-0.91	-0.69	Menopause (age at onset);	chr17:43150923	chr17:43125610~43153671:+
PRAD	cis	rs1799949	1	rs34059614	ENSG00000198496.9	NBR2	-20.23	2.17e-65	2.23e-61	-0.91	-0.69	Menopause (age at onset);	chr17:43151054	chr17:43125610~43153671:+
PRAD	cis	rs875971	0.54	rs781152	ENSG00000226824.5	RP4-756H11.3	-20.23	2.3e-65	2.37e-61	-0.87	-0.69	Aortic root size;	chr7:66014585	chr7:66654538~66669855:+
PRAD	cis	rs17711722	0.727	rs781151	ENSG00000226824.5	RP4-756H11.3	-20.23	2.3e-65	2.37e-61	-0.87	-0.69	Calcium levels;	chr7:66014891	chr7:66654538~66669855:+
PRAD	cis	rs4853012	0.838	rs60964317	ENSG00000217702.2	RP11-287D1.4	20.22	2.58e-65	2.65e-61	1.06	0.69	Gestational age at birth (maternal effect);	chr2:74116296	chr2:74130583~74135395:+
PRAD	cis	rs858239	0.738	rs13225593	ENSG00000230658.1	KLHL7-AS1	20.2	3.19e-65	3.28e-61	0.85	0.69	Cerebrospinal fluid biomarker levels;	chr7:23220688	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.72	rs10227559	ENSG00000230658.1	KLHL7-AS1	20.19	3.34e-65	3.43e-61	0.86	0.69	Cerebrospinal fluid biomarker levels;	chr7:23232525	chr7:23101228~23105703:-
PRAD	cis	rs4423214	1	rs12419279	ENSG00000254682.1	RP11-660L16.2	20.17	4.06e-65	4.16e-61	0.89	0.69	Vitamin D levels;	chr11:71428015	chr11:71448674~71452157:+
PRAD	cis	rs11155671	0.53	rs6935829	ENSG00000223701.3	RAET1E-AS1	20.15	5.47e-65	5.58e-61	0.93	0.69	Testicular germ cell tumor;	chr6:149896675	chr6:149884431~149919508:+
PRAD	cis	rs2739330	0.734	rs2000467	ENSG00000273295.1	AP000350.5	-20.14	5.51e-65	5.61e-61	-0.84	-0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23901432~23907068:-
PRAD	cis	rs2739330	0.828	rs5751770	ENSG00000225282.1	AP000350.6	20.13	6.13e-65	6.24e-61	0.9	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23926900~23929574:+
PRAD	cis	rs1799949	1	rs3092988	ENSG00000198496.9	NBR2	-20.13	6.58e-65	6.7e-61	-0.92	-0.69	Menopause (age at onset);	chr17:43049685	chr17:43125610~43153671:+
PRAD	cis	rs916888	0.821	rs199499	ENSG00000214401.4	KANSL1-AS1	20.11	7.63e-65	7.75e-61	1.23	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788132	chr17:46193576~46196723:+
PRAD	cis	rs9326248	0.861	rs1871757	ENSG00000254851.1	RP11-109L13.1	-20.11	8.29e-65	8.42e-61	-1.1	-0.69	Blood protein levels;	chr11:117159865	chr11:117135528~117138582:+
PRAD	cis	rs10256972	0.681	rs12702016	ENSG00000229043.2	AC091729.9	-20.11	8.36e-65	8.48e-61	-0.85	-0.69	Endometriosis;Longevity;	chr7:1089756	chr7:1160374~1165267:+
PRAD	cis	rs1799949	0.55	rs2343818	ENSG00000198496.9	NBR2	-20.1	8.65e-65	8.76e-61	-0.92	-0.69	Menopause (age at onset);	chr17:43332406	chr17:43125610~43153671:+
PRAD	cis	rs1799949	0.526	rs4352088	ENSG00000198496.9	NBR2	-20.1	8.65e-65	8.76e-61	-0.92	-0.69	Menopause (age at onset);	chr17:43337311	chr17:43125610~43153671:+
PRAD	cis	rs858239	0.636	rs7808488	ENSG00000230658.1	KLHL7-AS1	20.1	8.73e-65	8.84e-61	0.86	0.69	Cerebrospinal fluid biomarker levels;	chr7:23182251	chr7:23101228~23105703:-
PRAD	cis	rs1930961	1	rs1930961	ENSG00000100058.11	CRYBB2P1	20.1	8.78e-65	8.89e-61	1.08	0.69	Bipolar disorder with mood-incongruent psychosis;	chr22:25479298	chr22:25448105~25520854:+
PRAD	cis	rs916888	0.61	rs199529	ENSG00000214401.4	KANSL1-AS1	20.1	9.1e-65	9.2e-61	1.08	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:46193576~46196723:+
PRAD	cis	rs858239	0.67	rs3807452	ENSG00000230658.1	KLHL7-AS1	-20.1	9.17e-65	9.27e-61	-0.83	-0.69	Cerebrospinal fluid biomarker levels;	chr7:23122462	chr7:23101228~23105703:-
PRAD	cis	rs1799949	0.93	rs66499067	ENSG00000198496.9	NBR2	-20.1	9.2e-65	9.29e-61	-0.91	-0.69	Menopause (age at onset);	chr17:43096467	chr17:43125610~43153671:+
PRAD	cis	rs875971	0.54	rs736270	ENSG00000226824.5	RP4-756H11.3	-20.09	1.02e-64	1.03e-60	-0.87	-0.69	Aortic root size;	chr7:65963835	chr7:66654538~66669855:+
PRAD	cis	rs1930961	1	rs6004675	ENSG00000100058.11	CRYBB2P1	20.09	1.02e-64	1.03e-60	1.09	0.69	Bipolar disorder with mood-incongruent psychosis;	chr22:25493418	chr22:25448105~25520854:+
PRAD	cis	rs2739330	0.828	rs2877178	ENSG00000225282.1	AP000350.6	20.08	1.13e-64	1.14e-60	0.9	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23926900~23929574:+
PRAD	cis	rs2739330	0.828	rs2154593	ENSG00000225282.1	AP000350.6	20.08	1.13e-64	1.14e-60	0.9	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23926900~23929574:+
PRAD	cis	rs4423214	0.879	rs12803256	ENSG00000254682.1	RP11-660L16.2	20.06	1.33e-64	1.34e-60	0.9	0.69	Vitamin D levels;	chr11:71421822	chr11:71448674~71452157:+
PRAD	cis	rs1799949	1	rs16940	ENSG00000198496.9	NBR2	-20.06	1.36e-64	1.36e-60	-0.91	-0.69	Menopause (age at onset);	chr17:43093220	chr17:43125610~43153671:+
PRAD	cis	rs10793273	1	rs10793273	ENSG00000246174.6	KCTD21-AS1	-20.05	1.5e-64	1.5e-60	-0.84	-0.68	Pelvic organ prolapse;	chr11:78031549	chr11:78139771~78175323:+
PRAD	cis	rs2739330	0.828	rs5760108	ENSG00000225282.1	AP000350.6	20.03	1.82e-64	1.83e-60	0.9	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23926900~23929574:+
PRAD	cis	rs858239	0.67	rs6967526	ENSG00000230658.1	KLHL7-AS1	20.03	1.85e-64	1.85e-60	0.84	0.68	Cerebrospinal fluid biomarker levels;	chr7:23119622	chr7:23101228~23105703:-
PRAD	cis	rs11155671	0.53	rs9371544	ENSG00000223701.3	RAET1E-AS1	20.03	1.87e-64	1.87e-60	0.92	0.68	Testicular germ cell tumor;	chr6:149896224	chr6:149884431~149919508:+
PRAD	cis	rs2739330	0.627	rs9608219	ENSG00000225282.1	AP000350.6	20.03	1.87e-64	1.87e-60	0.89	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23926900~23929574:+
PRAD	cis	rs875971	0.522	rs1917563	ENSG00000226824.5	RP4-756H11.3	20.03	1.89e-64	1.89e-60	0.86	0.68	Aortic root size;	chr7:65950660	chr7:66654538~66669855:+
PRAD	cis	rs858239	0.932	rs858272	ENSG00000230658.1	KLHL7-AS1	20.02	2.1e-64	2.09e-60	0.85	0.68	Cerebrospinal fluid biomarker levels;	chr7:23237166	chr7:23101228~23105703:-
PRAD	cis	rs9322193	0.884	rs880245	ENSG00000231760.4	RP11-350J20.5	-20.01	2.38e-64	2.37e-60	-0.92	-0.68	Lung cancer;	chr6:149846262	chr6:149796151~149826294:-
PRAD	cis	rs1799949	1	rs8176273	ENSG00000198496.9	NBR2	-20.01	2.43e-64	2.41e-60	-0.92	-0.68	Menopause (age at onset);	chr17:43059636	chr17:43125610~43153671:+
PRAD	cis	rs1799949	1	rs8176269	ENSG00000198496.9	NBR2	-20.01	2.43e-64	2.41e-60	-0.92	-0.68	Menopause (age at onset);	chr17:43061609	chr17:43125610~43153671:+
PRAD	cis	rs1799949	1	rs8176265	ENSG00000198496.9	NBR2	-20.01	2.43e-64	2.41e-60	-0.92	-0.68	Menopause (age at onset);	chr17:43061979	chr17:43125610~43153671:+
PRAD	cis	rs1799949	1	rs12942277	ENSG00000198496.9	NBR2	-19.99	2.77e-64	2.75e-60	-0.93	-0.68	Menopause (age at onset);	chr17:43035957	chr17:43125610~43153671:+
PRAD	cis	rs2486288	0.656	rs2413768	ENSG00000259520.4	CTD-2651B20.3	19.97	3.43e-64	3.4e-60	0.87	0.68	Glomerular filtration rate;	chr15:45269786	chr15:45251580~45279251:-
PRAD	cis	rs2486288	0.656	rs7162022	ENSG00000259520.4	CTD-2651B20.3	19.97	3.43e-64	3.4e-60	0.87	0.68	Glomerular filtration rate;	chr15:45273055	chr15:45251580~45279251:-
PRAD	cis	rs9322193	0.884	rs1108889	ENSG00000231760.4	RP11-350J20.5	19.96	3.98e-64	3.94e-60	0.92	0.68	Lung cancer;	chr6:149845433	chr6:149796151~149826294:-
PRAD	cis	rs2283792	0.846	rs240053	ENSG00000224086.5	LL22NC03-86G7.1	-19.96	4.1e-64	4.05e-60	-0.8	-0.68	Multiple sclerosis;	chr22:21911000	chr22:21938293~21977632:+
PRAD	cis	rs858239	1	rs858239	ENSG00000230658.1	KLHL7-AS1	19.95	4.37e-64	4.32e-60	0.84	0.68	Cerebrospinal fluid biomarker levels;	chr7:23246696	chr7:23101228~23105703:-
PRAD	cis	rs1799949	1	rs915945	ENSG00000198496.9	NBR2	-19.94	5.05e-64	4.99e-60	-0.93	-0.68	Menopause (age at onset);	chr17:43027847	chr17:43125610~43153671:+
PRAD	cis	rs1799949	1	rs12944597	ENSG00000198496.9	NBR2	-19.94	5.05e-64	4.99e-60	-0.93	-0.68	Menopause (age at onset);	chr17:43035667	chr17:43125610~43153671:+
PRAD	cis	rs1799949	0.965	rs34616041	ENSG00000198496.9	NBR2	-19.94	5.05e-64	4.99e-60	-0.93	-0.68	Menopause (age at onset);	chr17:43036769	chr17:43125610~43153671:+
PRAD	cis	rs858239	0.738	rs7807879	ENSG00000230658.1	KLHL7-AS1	19.94	5.16e-64	5.09e-60	0.84	0.68	Cerebrospinal fluid biomarker levels;	chr7:23220969	chr7:23101228~23105703:-
PRAD	cis	rs2283792	0.846	rs240051	ENSG00000224086.5	LL22NC03-86G7.1	-19.92	5.94e-64	5.86e-60	-0.8	-0.68	Multiple sclerosis;	chr22:21909763	chr22:21938293~21977632:+
PRAD	cis	rs858239	0.698	rs858295	ENSG00000230658.1	KLHL7-AS1	19.89	8.12e-64	7.98e-60	0.86	0.68	Cerebrospinal fluid biomarker levels;	chr7:23205950	chr7:23101228~23105703:-
PRAD	cis	rs858239	1	rs156407	ENSG00000230658.1	KLHL7-AS1	19.89	8.33e-64	8.18e-60	0.84	0.68	Cerebrospinal fluid biomarker levels;	chr7:23276020	chr7:23101228~23105703:-
PRAD	cis	rs916888	0.821	rs70600	ENSG00000262500.1	RP11-259G18.2	19.89	8.37e-64	8.21e-60	1.09	0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46243606~46245044:+
PRAD	cis	rs4423214	1	rs12419334	ENSG00000254682.1	RP11-660L16.2	19.89	8.4e-64	8.24e-60	0.88	0.68	Vitamin D levels;	chr11:71428426	chr11:71448674~71452157:+
PRAD	cis	rs11673344	0.642	rs55926714	ENSG00000226686.6	LINC01535	19.87	9.89e-64	9.67e-60	0.9	0.68	Obesity-related traits;	chr19:37307974	chr19:37251912~37265535:+
PRAD	cis	rs11673344	0.642	rs12462487	ENSG00000226686.6	LINC01535	19.87	9.89e-64	9.67e-60	0.9	0.68	Obesity-related traits;	chr19:37311211	chr19:37251912~37265535:+
PRAD	cis	rs2486288	0.656	rs11632724	ENSG00000259520.4	CTD-2651B20.3	19.85	1.29e-63	1.26e-59	0.86	0.68	Glomerular filtration rate;	chr15:45258593	chr15:45251580~45279251:-
PRAD	cis	rs2486288	0.656	rs11632651	ENSG00000259520.4	CTD-2651B20.3	19.85	1.29e-63	1.26e-59	0.86	0.68	Glomerular filtration rate;	chr15:45258640	chr15:45251580~45279251:-
PRAD	cis	rs858239	1	rs858240	ENSG00000230658.1	KLHL7-AS1	19.85	1.33e-63	1.3e-59	0.84	0.68	Cerebrospinal fluid biomarker levels;	chr7:23244618	chr7:23101228~23105703:-
PRAD	cis	rs11673344	0.642	rs73025481	ENSG00000226686.6	LINC01535	19.85	1.33e-63	1.3e-59	0.9	0.68	Obesity-related traits;	chr19:37346437	chr19:37251912~37265535:+
PRAD	cis	rs2739330	0.791	rs9612520	ENSG00000225282.1	AP000350.6	19.84	1.44e-63	1.4e-59	0.89	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23926900~23929574:+
PRAD	cis	rs11155671	0.53	rs7742993	ENSG00000223701.3	RAET1E-AS1	19.83	1.52e-63	1.48e-59	0.92	0.68	Testicular germ cell tumor;	chr6:149883959	chr6:149884431~149919508:+
PRAD	cis	rs2486288	0.656	rs11637920	ENSG00000259520.4	CTD-2651B20.3	19.83	1.56e-63	1.51e-59	0.86	0.68	Glomerular filtration rate;	chr15:45258707	chr15:45251580~45279251:-
PRAD	cis	rs2486288	0.656	rs11632777	ENSG00000259520.4	CTD-2651B20.3	19.83	1.56e-63	1.51e-59	0.86	0.68	Glomerular filtration rate;	chr15:45258847	chr15:45251580~45279251:-
PRAD	cis	rs2486288	0.656	rs11632778	ENSG00000259520.4	CTD-2651B20.3	19.83	1.56e-63	1.51e-59	0.86	0.68	Glomerular filtration rate;	chr15:45258858	chr15:45251580~45279251:-
PRAD	cis	rs2486288	0.656	rs11632752	ENSG00000259520.4	CTD-2651B20.3	19.83	1.56e-63	1.51e-59	0.86	0.68	Glomerular filtration rate;	chr15:45258942	chr15:45251580~45279251:-
PRAD	cis	rs1930961	1	rs6004671	ENSG00000100058.11	CRYBB2P1	19.83	1.6e-63	1.56e-59	1.08	0.68	Bipolar disorder with mood-incongruent psychosis;	chr22:25483507	chr22:25448105~25520854:+
PRAD	cis	rs1930961	1	rs6004672	ENSG00000100058.11	CRYBB2P1	19.83	1.6e-63	1.56e-59	1.08	0.68	Bipolar disorder with mood-incongruent psychosis;	chr22:25485046	chr22:25448105~25520854:+
PRAD	cis	rs2486288	0.656	rs12911186	ENSG00000259520.4	CTD-2651B20.3	19.83	1.62e-63	1.57e-59	0.86	0.68	Glomerular filtration rate;	chr15:45259225	chr15:45251580~45279251:-
PRAD	cis	rs2486288	0.656	rs12915314	ENSG00000259520.4	CTD-2651B20.3	19.83	1.62e-63	1.57e-59	0.86	0.68	Glomerular filtration rate;	chr15:45259293	chr15:45251580~45279251:-
PRAD	cis	rs2486288	0.656	rs8039138	ENSG00000259520.4	CTD-2651B20.3	19.83	1.62e-63	1.57e-59	0.86	0.68	Glomerular filtration rate;	chr15:45259394	chr15:45251580~45279251:-
PRAD	cis	rs9326248	0.727	rs4938347	ENSG00000254851.1	RP11-109L13.1	-19.81	1.96e-63	1.9e-59	-1.1	-0.68	Blood protein levels;	chr11:117151043	chr11:117135528~117138582:+
PRAD	cis	rs9326248	0.813	rs4938350	ENSG00000254851.1	RP11-109L13.1	-19.81	1.96e-63	1.9e-59	-1.1	-0.68	Blood protein levels;	chr11:117151560	chr11:117135528~117138582:+
PRAD	cis	rs858239	0.665	rs858306	ENSG00000230658.1	KLHL7-AS1	19.81	2.05e-63	1.99e-59	0.86	0.68	Cerebrospinal fluid biomarker levels;	chr7:23203135	chr7:23101228~23105703:-
PRAD	cis	rs2486288	0.656	rs11639420	ENSG00000259520.4	CTD-2651B20.3	19.8	2.1e-63	2.03e-59	0.87	0.68	Glomerular filtration rate;	chr15:45267070	chr15:45251580~45279251:-
PRAD	cis	rs9326248	0.773	rs1060211	ENSG00000254851.1	RP11-109L13.1	-19.8	2.15e-63	2.08e-59	-1.09	-0.68	Blood protein levels;	chr11:117169081	chr11:117135528~117138582:+
PRAD	cis	rs1799949	1	rs8070085	ENSG00000198496.9	NBR2	19.8	2.27e-63	2.19e-59	0.9	0.68	Menopause (age at onset);	chr17:43189967	chr17:43125610~43153671:+
PRAD	cis	rs2486288	0.656	rs11632419	ENSG00000259520.4	CTD-2651B20.3	19.77	2.91e-63	2.81e-59	0.87	0.68	Glomerular filtration rate;	chr15:45265258	chr15:45251580~45279251:-
PRAD	cis	rs2486288	0.656	rs2271438	ENSG00000259520.4	CTD-2651B20.3	19.77	2.91e-63	2.81e-59	0.87	0.68	Glomerular filtration rate;	chr15:45265270	chr15:45251580~45279251:-
PRAD	cis	rs2486288	0.656	rs11854365	ENSG00000259520.4	CTD-2651B20.3	19.77	2.91e-63	2.81e-59	0.87	0.68	Glomerular filtration rate;	chr15:45265885	chr15:45251580~45279251:-
PRAD	cis	rs9326248	0.813	rs474488	ENSG00000254851.1	RP11-109L13.1	-19.77	2.95e-63	2.84e-59	-1.1	-0.68	Blood protein levels;	chr11:117198261	chr11:117135528~117138582:+
PRAD	cis	rs858239	0.965	rs156429	ENSG00000230658.1	KLHL7-AS1	19.77	3.07e-63	2.96e-59	0.82	0.68	Cerebrospinal fluid biomarker levels;	chr7:23266401	chr7:23101228~23105703:-
PRAD	cis	rs2486288	0.656	rs11637838	ENSG00000259520.4	CTD-2651B20.3	19.76	3.41e-63	3.28e-59	0.86	0.68	Glomerular filtration rate;	chr15:45258459	chr15:45251580~45279251:-
PRAD	cis	rs858239	1	rs199347	ENSG00000230658.1	KLHL7-AS1	19.75	3.64e-63	3.49e-59	0.83	0.68	Cerebrospinal fluid biomarker levels;	chr7:23254127	chr7:23101228~23105703:-
PRAD	cis	rs2486288	0.656	rs8039540	ENSG00000259520.4	CTD-2651B20.3	19.74	3.95e-63	3.79e-59	0.86	0.68	Glomerular filtration rate;	chr15:45259644	chr15:45251580~45279251:-
PRAD	cis	rs2486288	0.656	rs8040185	ENSG00000259520.4	CTD-2651B20.3	19.74	3.95e-63	3.79e-59	0.86	0.68	Glomerular filtration rate;	chr15:45259883	chr15:45251580~45279251:-
PRAD	cis	rs2486288	0.656	rs1060896	ENSG00000259520.4	CTD-2651B20.3	19.74	3.95e-63	3.79e-59	0.86	0.68	Glomerular filtration rate;	chr15:45262069	chr15:45251580~45279251:-
PRAD	cis	rs2486288	0.656	rs9921025	ENSG00000259520.4	CTD-2651B20.3	19.72	4.93e-63	4.71e-59	0.86	0.68	Glomerular filtration rate;	chr15:45254404	chr15:45251580~45279251:-
PRAD	cis	rs2486288	0.656	rs11629807	ENSG00000259520.4	CTD-2651B20.3	19.72	4.93e-63	4.71e-59	0.86	0.68	Glomerular filtration rate;	chr15:45254839	chr15:45251580~45279251:-
PRAD	cis	rs2486288	0.587	rs12899942	ENSG00000259520.4	CTD-2651B20.3	19.72	4.93e-63	4.71e-59	0.86	0.68	Glomerular filtration rate;	chr15:45255082	chr15:45251580~45279251:-
PRAD	cis	rs2486288	0.656	rs12899058	ENSG00000259520.4	CTD-2651B20.3	19.72	4.93e-63	4.71e-59	0.86	0.68	Glomerular filtration rate;	chr15:45255126	chr15:45251580~45279251:-
PRAD	cis	rs2486288	0.656	rs12904150	ENSG00000259520.4	CTD-2651B20.3	19.72	4.93e-63	4.71e-59	0.86	0.68	Glomerular filtration rate;	chr15:45255407	chr15:45251580~45279251:-
PRAD	cis	rs2486288	0.656	rs9920290	ENSG00000259520.4	CTD-2651B20.3	19.72	4.93e-63	4.71e-59	0.86	0.68	Glomerular filtration rate;	chr15:45255837	chr15:45251580~45279251:-
PRAD	cis	rs2486288	0.656	rs11854325	ENSG00000259520.4	CTD-2651B20.3	19.72	4.93e-63	4.71e-59	0.86	0.68	Glomerular filtration rate;	chr15:45256761	chr15:45251580~45279251:-
PRAD	cis	rs916888	0.821	rs199514	ENSG00000262500.1	RP11-259G18.2	-19.72	5.18e-63	4.93e-59	-1.06	-0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:46243606~46245044:+
PRAD	cis	rs2739330	0.731	rs5751792	ENSG00000250470.1	AP000351.3	19.71	5.6e-63	5.33e-59	0.9	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23976904~23977585:-
PRAD	cis	rs2739330	0.761	rs5760176	ENSG00000250470.1	AP000351.3	-19.71	5.6e-63	5.33e-59	-0.9	-0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23976904~23977585:-
PRAD	cis	rs7188445	0.736	rs11642757	ENSG00000261390.4	RP11-345M22.2	-19.71	5.86e-63	5.57e-59	-0.79	-0.68	Urate levels;	chr16:79719570	chr16:79715232~79770563:-
PRAD	cis	rs2486288	0.656	rs8039354	ENSG00000259520.4	CTD-2651B20.3	-19.7	6.13e-63	5.82e-59	-0.85	-0.68	Glomerular filtration rate;	chr15:45259558	chr15:45251580~45279251:-
PRAD	cis	rs11155671	0.53	rs7756850	ENSG00000223701.3	RAET1E-AS1	19.69	7.06e-63	6.68e-59	0.91	0.68	Testicular germ cell tumor;	chr6:149891460	chr6:149884431~149919508:+
PRAD	cis	rs11155671	0.53	rs9371542	ENSG00000223701.3	RAET1E-AS1	19.69	7.06e-63	6.68e-59	0.91	0.68	Testicular germ cell tumor;	chr6:149891949	chr6:149884431~149919508:+
PRAD	cis	rs11155671	0.53	rs9371223	ENSG00000223701.3	RAET1E-AS1	19.69	7.06e-63	6.68e-59	0.91	0.68	Testicular germ cell tumor;	chr6:149893670	chr6:149884431~149919508:+
PRAD	cis	rs2486288	0.656	rs2413774	ENSG00000259520.4	CTD-2651B20.3	19.69	7.15e-63	6.76e-59	0.86	0.68	Glomerular filtration rate;	chr15:45257225	chr15:45251580~45279251:-
PRAD	cis	rs11155671	0.53	rs2342769	ENSG00000223701.3	RAET1E-AS1	19.68	8.23e-63	7.77e-59	0.91	0.68	Testicular germ cell tumor;	chr6:149895371	chr6:149884431~149919508:+
PRAD	cis	rs11155671	0.53	rs2342770	ENSG00000223701.3	RAET1E-AS1	19.68	8.23e-63	7.77e-59	0.91	0.68	Testicular germ cell tumor;	chr6:149895549	chr6:149884431~149919508:+
PRAD	cis	rs916888	0.821	rs415430	ENSG00000262500.1	RP11-259G18.2	-19.67	8.35e-63	7.88e-59	-1.06	-0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:46243606~46245044:+
PRAD	cis	rs916888	0.779	rs430685	ENSG00000262500.1	RP11-259G18.2	-19.67	8.35e-63	7.88e-59	-1.06	-0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:46243606~46245044:+
PRAD	cis	rs7195287	0.779	rs2335454	ENSG00000276791.1	CTD-2270P14.5	19.67	8.6e-63	8.1e-59	0.74	0.68	Eosinophil counts;	chr16:2778156	chr16:2777319~2780568:+
PRAD	cis	rs858239	0.665	rs858305	ENSG00000230658.1	KLHL7-AS1	-19.65	1.05e-62	9.93e-59	-0.86	-0.68	Cerebrospinal fluid biomarker levels;	chr7:23203211	chr7:23101228~23105703:-
PRAD	cis	rs10256972	0.516	rs12702081	ENSG00000229043.2	AC091729.9	-19.65	1.06e-62	1e-58	-0.82	-0.68	Endometriosis;Longevity;	chr7:1101892	chr7:1160374~1165267:+
PRAD	cis	rs858239	0.636	rs28706766	ENSG00000230658.1	KLHL7-AS1	19.64	1.16e-62	1.09e-58	0.83	0.68	Cerebrospinal fluid biomarker levels;	chr7:23130215	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.536	rs6956974	ENSG00000230658.1	KLHL7-AS1	-19.64	1.17e-62	1.1e-58	-0.85	-0.68	Cerebrospinal fluid biomarker levels;	chr7:23212699	chr7:23101228~23105703:-
PRAD	cis	rs2486288	0.656	rs2413772	ENSG00000259520.4	CTD-2651B20.3	19.64	1.22e-62	1.15e-58	0.86	0.68	Glomerular filtration rate;	chr15:45257664	chr15:45251580~45279251:-
PRAD	cis	rs9326248	0.813	rs588534	ENSG00000254851.1	RP11-109L13.1	-19.62	1.44e-62	1.35e-58	-1.1	-0.68	Blood protein levels;	chr11:117197788	chr11:117135528~117138582:+
PRAD	cis	rs875971	0.508	rs10258739	ENSG00000226824.5	RP4-756H11.3	19.62	1.52e-62	1.42e-58	0.88	0.68	Aortic root size;	chr7:66597948	chr7:66654538~66669855:+
PRAD	cis	rs9326248	0.861	rs4938348	ENSG00000254851.1	RP11-109L13.1	-19.59	2.05e-62	1.9e-58	-1.09	-0.68	Blood protein levels;	chr11:117151161	chr11:117135528~117138582:+
PRAD	cis	rs2739330	0.796	rs1006771	ENSG00000218537.1	MIF-AS1	19.59	2.05e-62	1.91e-58	0.89	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23894426~23898930:-
PRAD	cis	rs992157	1	rs10932766	ENSG00000261338.2	RP11-378A13.1	19.59	2.14e-62	1.99e-58	0.77	0.68	Colorectal cancer;	chr2:218257367	chr2:218255319~218257366:+
PRAD	cis	rs11673344	0.642	rs12462708	ENSG00000226686.6	LINC01535	-19.58	2.34e-62	2.17e-58	-0.9	-0.68	Obesity-related traits;	chr19:37306676	chr19:37251912~37265535:+
PRAD	cis	rs2486288	0.656	rs2413773	ENSG00000259520.4	CTD-2651B20.3	19.56	2.7e-62	2.5e-58	0.86	0.68	Glomerular filtration rate;	chr15:45257244	chr15:45251580~45279251:-
PRAD	cis	rs858239	0.899	rs858271	ENSG00000230658.1	KLHL7-AS1	19.56	2.83e-62	2.62e-58	0.84	0.68	Cerebrospinal fluid biomarker levels;	chr7:23238664	chr7:23101228~23105703:-
PRAD	cis	rs801193	0.773	rs801207	ENSG00000226824.5	RP4-756H11.3	19.55	3.02e-62	2.79e-58	0.88	0.68	Aortic root size;	chr7:66555603	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.543	rs801191	ENSG00000226824.5	RP4-756H11.3	19.55	3.02e-62	2.79e-58	0.88	0.68	Aortic root size;	chr7:66567968	chr7:66654538~66669855:+
PRAD	cis	rs992157	1	rs2292553	ENSG00000261338.2	RP11-378A13.1	19.55	3.19e-62	2.94e-58	0.77	0.68	Colorectal cancer;	chr2:218282080	chr2:218255319~218257366:+
PRAD	cis	rs1930961	1	rs6004668	ENSG00000100058.11	CRYBB2P1	-19.55	3.26e-62	3e-58	-1.07	-0.68	Bipolar disorder with mood-incongruent psychosis;	chr22:25478535	chr22:25448105~25520854:+
PRAD	cis	rs875971	0.508	rs6947808	ENSG00000226824.5	RP4-756H11.3	19.54	3.32e-62	3.06e-58	0.88	0.68	Aortic root size;	chr7:66580095	chr7:66654538~66669855:+
PRAD	cis	rs2739330	0.753	rs4822452	ENSG00000225282.1	AP000350.6	19.54	3.59e-62	3.31e-58	0.89	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23926900~23929574:+
PRAD	cis	rs2486288	0.656	rs10519018	ENSG00000259520.4	CTD-2651B20.3	19.54	3.66e-62	3.37e-58	0.86	0.68	Glomerular filtration rate;	chr15:45257067	chr15:45251580~45279251:-
PRAD	cis	rs875971	0.508	rs10242423	ENSG00000226824.5	RP4-756H11.3	19.53	4.04e-62	3.71e-58	0.88	0.68	Aortic root size;	chr7:66594188	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.508	rs10253883	ENSG00000226824.5	RP4-756H11.3	19.53	4.04e-62	3.71e-58	0.88	0.68	Aortic root size;	chr7:66596151	chr7:66654538~66669855:+
PRAD	cis	rs950027	0.549	rs1719250	ENSG00000259520.4	CTD-2651B20.3	-19.52	4.09e-62	3.75e-58	-0.84	-0.68	Response to fenofibrate (adiponectin levels);	chr15:45317575	chr15:45251580~45279251:-
PRAD	cis	rs11673344	0.555	rs502546	ENSG00000226686.6	LINC01535	-19.52	4.09e-62	3.76e-58	-0.9	-0.68	Obesity-related traits;	chr19:37361788	chr19:37251912~37265535:+
PRAD	cis	rs11673344	0.642	rs55755939	ENSG00000226686.6	LINC01535	19.52	4.14e-62	3.8e-58	0.9	0.68	Obesity-related traits;	chr19:37353723	chr19:37251912~37265535:+
PRAD	cis	rs9326248	0.817	rs6589598	ENSG00000254851.1	RP11-109L13.1	-19.52	4.29e-62	3.94e-58	-1.04	-0.68	Blood protein levels;	chr11:117131687	chr11:117135528~117138582:+
PRAD	cis	rs858239	1	rs199351	ENSG00000230658.1	KLHL7-AS1	19.51	4.8e-62	4.4e-58	0.83	0.67	Cerebrospinal fluid biomarker levels;	chr7:23260430	chr7:23101228~23105703:-
PRAD	cis	rs916888	0.697	rs199516	ENSG00000262500.1	RP11-259G18.2	-19.51	4.86e-62	4.45e-58	-1.05	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:46243606~46245044:+
PRAD	cis	rs916888	0.821	rs199512	ENSG00000262500.1	RP11-259G18.2	-19.51	4.86e-62	4.45e-58	-1.05	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:46243606~46245044:+
PRAD	cis	rs916888	0.821	rs199509	ENSG00000262500.1	RP11-259G18.2	-19.51	4.86e-62	4.45e-58	-1.05	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:46243606~46245044:+
PRAD	cis	rs916888	0.821	rs199507	ENSG00000262500.1	RP11-259G18.2	-19.51	4.86e-62	4.45e-58	-1.05	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:46243606~46245044:+
PRAD	cis	rs2283792	0.633	rs240068	ENSG00000224086.5	LL22NC03-86G7.1	-19.47	7.13e-62	6.49e-58	-0.78	-0.67	Multiple sclerosis;	chr22:21936031	chr22:21938293~21977632:+
PRAD	cis	rs9326248	0.861	rs7120309	ENSG00000254851.1	RP11-109L13.1	-19.47	7.74e-62	7.04e-58	-1.09	-0.67	Blood protein levels;	chr11:117172100	chr11:117135528~117138582:+
PRAD	cis	rs9326248	0.861	rs7120449	ENSG00000254851.1	RP11-109L13.1	-19.47	7.74e-62	7.04e-58	-1.09	-0.67	Blood protein levels;	chr11:117172183	chr11:117135528~117138582:+
PRAD	cis	rs2486288	0.656	rs11632920	ENSG00000259520.4	CTD-2651B20.3	19.46	8.38e-62	7.63e-58	0.85	0.67	Glomerular filtration rate;	chr15:45259066	chr15:45251580~45279251:-
PRAD	cis	rs9322193	0.567	rs7747457	ENSG00000223701.3	RAET1E-AS1	19.46	8.39e-62	7.63e-58	0.9	0.67	Lung cancer;	chr6:149892366	chr6:149884431~149919508:+
PRAD	cis	rs2882667	0.964	rs67296915	ENSG00000253404.1	AC034243.1	19.46	8.58e-62	7.8e-58	0.89	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138965910	chr5:138744434~138753309:-
PRAD	cis	rs11155671	0.53	rs9968871	ENSG00000223701.3	RAET1E-AS1	19.45	9.38e-62	8.51e-58	0.9	0.67	Testicular germ cell tumor;	chr6:149888060	chr6:149884431~149919508:+
PRAD	cis	rs11155671	0.53	rs9969044	ENSG00000223701.3	RAET1E-AS1	19.45	9.38e-62	8.51e-58	0.9	0.67	Testicular germ cell tumor;	chr6:149888068	chr6:149884431~149919508:+
PRAD	cis	rs801193	0.844	rs732465	ENSG00000226824.5	RP4-756H11.3	-19.43	1.12e-61	1.01e-57	-0.87	-0.67	Aortic root size;	chr7:66533463	chr7:66654538~66669855:+
PRAD	cis	rs992157	1	rs3731859	ENSG00000261338.2	RP11-378A13.1	19.43	1.13e-61	1.02e-57	0.77	0.67	Colorectal cancer;	chr2:218259499	chr2:218255319~218257366:+
PRAD	cis	rs992157	1	rs11554825	ENSG00000261338.2	RP11-378A13.1	19.43	1.13e-61	1.02e-57	0.77	0.67	Colorectal cancer;	chr2:218261086	chr2:218255319~218257366:+
PRAD	cis	rs4853012	0.887	rs77148265	ENSG00000217702.2	RP11-287D1.4	19.43	1.16e-61	1.05e-57	1.13	0.67	Gestational age at birth (maternal effect);	chr2:74112392	chr2:74130583~74135395:+
PRAD	cis	rs2882667	0.893	rs10044672	ENSG00000253404.1	AC034243.1	19.43	1.18e-61	1.07e-57	0.91	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138954790	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.893	rs13180851	ENSG00000253404.1	AC034243.1	19.43	1.18e-61	1.07e-57	0.91	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138954918	chr5:138744434~138753309:-
PRAD	cis	rs992157	0.932	rs56109829	ENSG00000261338.2	RP11-378A13.1	19.42	1.26e-61	1.14e-57	0.76	0.67	Colorectal cancer;	chr2:218285017	chr2:218255319~218257366:+
PRAD	cis	rs916888	0.821	rs199513	ENSG00000262500.1	RP11-259G18.2	-19.42	1.3e-61	1.18e-57	-1.05	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46243606~46245044:+
PRAD	cis	rs858239	0.536	rs6961109	ENSG00000230658.1	KLHL7-AS1	19.41	1.38e-61	1.25e-57	0.85	0.67	Cerebrospinal fluid biomarker levels;	chr7:23212794	chr7:23101228~23105703:-
PRAD	cis	rs916888	0.773	rs9896243	ENSG00000262500.1	RP11-259G18.2	19.41	1.39e-61	1.26e-57	1.03	0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46243606~46245044:+
PRAD	cis	rs2486288	0.656	rs1719236	ENSG00000259520.4	CTD-2651B20.3	19.39	1.73e-61	1.55e-57	0.89	0.67	Glomerular filtration rate;	chr15:45285585	chr15:45251580~45279251:-
PRAD	cis	rs2739330	0.732	rs5760175	ENSG00000250470.1	AP000351.3	19.38	1.87e-61	1.68e-57	0.9	0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23976904~23977585:-
PRAD	cis	rs12439619	0.693	rs7165536	ENSG00000278603.1	RP13-608F4.5	19.37	2.09e-61	1.88e-57	1.01	0.67	Intelligence (multi-trait analysis);	chr15:82273743	chr15:82472203~82472426:+
PRAD	cis	rs2739330	0.791	rs4822458	ENSG00000273295.1	AP000350.5	19.36	2.44e-61	2.19e-57	0.8	0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23901432~23907068:-
PRAD	cis	rs12439619	0.693	rs4778989	ENSG00000278603.1	RP13-608F4.5	19.34	2.9e-61	2.59e-57	1.01	0.67	Intelligence (multi-trait analysis);	chr15:82276963	chr15:82472203~82472426:+
PRAD	cis	rs916888	0.821	rs199506	ENSG00000262500.1	RP11-259G18.2	-19.33	3.13e-61	2.79e-57	-1.05	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:46243606~46245044:+
PRAD	cis	rs2882667	0.893	rs10054796	ENSG00000253404.1	AC034243.1	19.33	3.3e-61	2.95e-57	0.91	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138958655	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.893	rs10069961	ENSG00000253404.1	AC034243.1	19.33	3.3e-61	2.95e-57	0.91	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138958879	chr5:138744434~138753309:-
PRAD	cis	rs2739330	0.685	rs4822453	ENSG00000273295.1	AP000350.5	19.31	3.92e-61	3.49e-57	0.8	0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23901432~23907068:-
PRAD	cis	rs2486288	0.656	rs9921035	ENSG00000259520.4	CTD-2651B20.3	19.31	3.97e-61	3.54e-57	0.85	0.67	Glomerular filtration rate;	chr15:45254462	chr15:45251580~45279251:-
PRAD	cis	rs916888	0.821	rs199505	ENSG00000262500.1	RP11-259G18.2	-19.31	4.1e-61	3.65e-57	-1.05	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:46243606~46245044:+
PRAD	cis	rs916888	0.821	rs70602	ENSG00000262500.1	RP11-259G18.2	-19.31	4.1e-61	3.65e-57	-1.05	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:46243606~46245044:+
PRAD	cis	rs9326248	0.813	rs7115562	ENSG00000254851.1	RP11-109L13.1	-19.31	4.14e-61	3.69e-57	-1.08	-0.67	Blood protein levels;	chr11:117149754	chr11:117135528~117138582:+
PRAD	cis	rs1930961	1	rs6004673	ENSG00000100058.11	CRYBB2P1	19.3	4.51e-61	4.01e-57	1.06	0.67	Bipolar disorder with mood-incongruent psychosis;	chr22:25489386	chr22:25448105~25520854:+
PRAD	cis	rs916888	0.738	rs199515	ENSG00000262500.1	RP11-259G18.2	-19.3	4.6e-61	4.08e-57	-1.04	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:46243606~46245044:+
PRAD	cis	rs9326248	0.652	rs7128382	ENSG00000254851.1	RP11-109L13.1	-19.29	4.84e-61	4.3e-57	-1.08	-0.67	Blood protein levels;	chr11:117152771	chr11:117135528~117138582:+
PRAD	cis	rs875971	0.508	rs10950045	ENSG00000226824.5	RP4-756H11.3	19.28	5.33e-61	4.72e-57	0.88	0.67	Aortic root size;	chr7:66601386	chr7:66654538~66669855:+
PRAD	cis	rs801193	0.839	rs6968619	ENSG00000226824.5	RP4-756H11.3	19.28	5.33e-61	4.72e-57	0.88	0.67	Aortic root size;	chr7:66603880	chr7:66654538~66669855:+
PRAD	cis	rs801193	0.839	rs12534943	ENSG00000226824.5	RP4-756H11.3	19.28	5.33e-61	4.72e-57	0.88	0.67	Aortic root size;	chr7:66605533	chr7:66654538~66669855:+
PRAD	cis	rs801193	0.805	rs12532355	ENSG00000226824.5	RP4-756H11.3	19.28	5.33e-61	4.72e-57	0.88	0.67	Aortic root size;	chr7:66605597	chr7:66654538~66669855:+
PRAD	cis	rs1930961	1	rs760555	ENSG00000100058.11	CRYBB2P1	19.28	5.39e-61	4.77e-57	1.06	0.67	Bipolar disorder with mood-incongruent psychosis;	chr22:25476870	chr22:25448105~25520854:+
PRAD	cis	rs992157	1	rs736730	ENSG00000261338.2	RP11-378A13.1	19.28	5.64e-61	4.98e-57	0.76	0.67	Colorectal cancer;	chr2:218255532	chr2:218255319~218257366:+
PRAD	cis	rs4423214	1	rs1981412	ENSG00000254682.1	RP11-660L16.2	19.27	6.19e-61	5.47e-57	0.87	0.67	Vitamin D levels;	chr11:71427664	chr11:71448674~71452157:+
PRAD	cis	rs11673344	0.642	rs11083420	ENSG00000226686.6	LINC01535	19.26	6.62e-61	5.84e-57	0.9	0.67	Obesity-related traits;	chr19:37317901	chr19:37251912~37265535:+
PRAD	cis	rs2739330	0.791	rs4822458	ENSG00000225282.1	AP000350.6	19.26	6.95e-61	6.13e-57	0.86	0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23926900~23929574:+
PRAD	cis	rs992157	1	rs736731	ENSG00000261338.2	RP11-378A13.1	19.25	7.64e-61	6.74e-57	0.76	0.67	Colorectal cancer;	chr2:218255865	chr2:218255319~218257366:+
PRAD	cis	rs858239	0.633	rs858300	ENSG00000230658.1	KLHL7-AS1	19.24	8.66e-61	7.63e-57	0.84	0.67	Cerebrospinal fluid biomarker levels;	chr7:23205012	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.73	rs858290	ENSG00000230658.1	KLHL7-AS1	19.24	8.66e-61	7.63e-57	0.84	0.67	Cerebrospinal fluid biomarker levels;	chr7:23208417	chr7:23101228~23105703:-
PRAD	cis	rs992157	0.965	rs13427681	ENSG00000261338.2	RP11-378A13.1	19.24	8.69e-61	7.65e-57	0.76	0.67	Colorectal cancer;	chr2:218302840	chr2:218255319~218257366:+
PRAD	cis	rs992157	1	rs13003334	ENSG00000261338.2	RP11-378A13.1	19.24	8.79e-61	7.73e-57	0.76	0.67	Colorectal cancer;	chr2:218260198	chr2:218255319~218257366:+
PRAD	cis	rs2283792	0.622	rs239917	ENSG00000224086.5	LL22NC03-86G7.1	-19.23	9.22e-61	8.11e-57	-0.78	-0.67	Multiple sclerosis;	chr22:21960091	chr22:21938293~21977632:+
PRAD	cis	rs4853012	0.941	rs2421752	ENSG00000217702.2	RP11-287D1.4	19.23	9.53e-61	8.38e-57	1.11	0.67	Gestational age at birth (maternal effect);	chr2:74114488	chr2:74130583~74135395:+
PRAD	cis	rs7188445	0.932	rs73575095	ENSG00000261390.4	RP11-345M22.2	-19.21	1.13e-60	9.9e-57	-0.81	-0.67	Urate levels;	chr16:79716435	chr16:79715232~79770563:-
PRAD	cis	rs2882667	0.893	rs7717375	ENSG00000253404.1	AC034243.1	19.21	1.17e-60	1.02e-56	0.9	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138955716	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.964	rs2288824	ENSG00000253404.1	AC034243.1	19.21	1.17e-60	1.03e-56	0.9	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138962707	chr5:138744434~138753309:-
PRAD	cis	rs12439619	0.693	rs8034801	ENSG00000278603.1	RP13-608F4.5	19.2	1.26e-60	1.1e-56	1	0.67	Intelligence (multi-trait analysis);	chr15:82183996	chr15:82472203~82472426:+
PRAD	cis	rs7188445	0.932	rs17767904	ENSG00000261390.4	RP11-345M22.2	-19.2	1.26e-60	1.1e-56	-0.81	-0.67	Urate levels;	chr16:79716078	chr16:79715232~79770563:-
PRAD	cis	rs858239	0.73	rs858289	ENSG00000230658.1	KLHL7-AS1	19.2	1.28e-60	1.12e-56	0.84	0.67	Cerebrospinal fluid biomarker levels;	chr7:23208539	chr7:23101228~23105703:-
PRAD	cis	rs11155671	0.53	rs9322228	ENSG00000223701.3	RAET1E-AS1	19.19	1.39e-60	1.21e-56	0.9	0.67	Testicular germ cell tumor;	chr6:149888173	chr6:149884431~149919508:+
PRAD	cis	rs11155671	0.53	rs7774787	ENSG00000223701.3	RAET1E-AS1	19.19	1.39e-60	1.21e-56	0.9	0.67	Testicular germ cell tumor;	chr6:149888296	chr6:149884431~149919508:+
PRAD	cis	rs11155671	0.53	rs2342767	ENSG00000223701.3	RAET1E-AS1	19.19	1.39e-60	1.21e-56	0.9	0.67	Testicular germ cell tumor;	chr6:149888581	chr6:149884431~149919508:+
PRAD	cis	rs11155671	0.53	rs7764376	ENSG00000223701.3	RAET1E-AS1	19.19	1.39e-60	1.21e-56	0.9	0.67	Testicular germ cell tumor;	chr6:149889208	chr6:149884431~149919508:+
PRAD	cis	rs11155671	0.53	rs6933882	ENSG00000223701.3	RAET1E-AS1	19.19	1.39e-60	1.21e-56	0.9	0.67	Testicular germ cell tumor;	chr6:149889666	chr6:149884431~149919508:+
PRAD	cis	rs11155671	0.53	rs6939761	ENSG00000223701.3	RAET1E-AS1	19.19	1.39e-60	1.21e-56	0.9	0.67	Testicular germ cell tumor;	chr6:149889858	chr6:149884431~149919508:+
PRAD	cis	rs11155671	0.53	rs3823021	ENSG00000223701.3	RAET1E-AS1	19.19	1.39e-60	1.21e-56	0.9	0.67	Testicular germ cell tumor;	chr6:149889863	chr6:149884431~149919508:+
PRAD	cis	rs11155671	0.53	rs4869763	ENSG00000223701.3	RAET1E-AS1	19.19	1.39e-60	1.21e-56	0.9	0.67	Testicular germ cell tumor;	chr6:149890548	chr6:149884431~149919508:+
PRAD	cis	rs11155671	0.53	rs4869764	ENSG00000223701.3	RAET1E-AS1	19.19	1.39e-60	1.21e-56	0.9	0.67	Testicular germ cell tumor;	chr6:149890692	chr6:149884431~149919508:+
PRAD	cis	rs992157	1	rs6736362	ENSG00000261338.2	RP11-378A13.1	19.15	2.13e-60	1.85e-56	0.77	0.67	Colorectal cancer;	chr2:218250385	chr2:218255319~218257366:+
PRAD	cis	rs11155671	0.53	rs7757984	ENSG00000223701.3	RAET1E-AS1	19.11	3.47e-60	3e-56	0.9	0.67	Testicular germ cell tumor;	chr6:149887515	chr6:149884431~149919508:+
PRAD	cis	rs7188445	0.836	rs3813580	ENSG00000261390.4	RP11-345M22.2	-19.1	3.78e-60	3.26e-56	-0.81	-0.67	Urate levels;	chr16:79715383	chr16:79715232~79770563:-
PRAD	cis	rs2486288	0.656	rs11629858	ENSG00000259520.4	CTD-2651B20.3	19.09	4.09e-60	3.52e-56	0.86	0.67	Glomerular filtration rate;	chr15:45254916	chr15:45251580~45279251:-
PRAD	cis	rs2486288	0.656	rs11629859	ENSG00000259520.4	CTD-2651B20.3	19.09	4.09e-60	3.52e-56	0.86	0.67	Glomerular filtration rate;	chr15:45254923	chr15:45251580~45279251:-
PRAD	cis	rs2739330	0.731	rs4822450	ENSG00000225282.1	AP000350.6	19.07	5.24e-60	4.5e-56	0.87	0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23926900~23929574:+
PRAD	cis	rs2739330	0.76	rs1007888	ENSG00000273295.1	AP000350.5	19.06	6.07e-60	5.21e-56	0.8	0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23901432~23907068:-
PRAD	cis	rs9322193	0.567	rs7742692	ENSG00000223701.3	RAET1E-AS1	19.05	6.25e-60	5.36e-56	0.9	0.67	Lung cancer;	chr6:149892363	chr6:149884431~149919508:+
PRAD	cis	rs12439619	0.693	rs28689861	ENSG00000278603.1	RP13-608F4.5	19.05	6.66e-60	5.71e-56	0.99	0.67	Intelligence (multi-trait analysis);	chr15:82206369	chr15:82472203~82472426:+
PRAD	cis	rs2882667	0.964	rs12108892	ENSG00000253404.1	AC034243.1	19.04	6.82e-60	5.85e-56	0.88	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138963941	chr5:138744434~138753309:-
PRAD	cis	rs12439619	0.693	rs9944185	ENSG00000278603.1	RP13-608F4.5	19.04	6.91e-60	5.93e-56	0.99	0.67	Intelligence (multi-trait analysis);	chr15:82157927	chr15:82472203~82472426:+
PRAD	cis	rs2739330	0.627	rs9608219	ENSG00000218537.1	MIF-AS1	19.04	6.99e-60	5.99e-56	0.89	0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23894426~23898930:-
PRAD	cis	rs7188445	0.932	rs73575083	ENSG00000261390.4	RP11-345M22.2	-19.04	7.22e-60	6.18e-56	-0.8	-0.67	Urate levels;	chr16:79713958	chr16:79715232~79770563:-
PRAD	cis	rs7188445	0.932	rs73575085	ENSG00000261390.4	RP11-345M22.2	-19.04	7.22e-60	6.18e-56	-0.8	-0.67	Urate levels;	chr16:79714179	chr16:79715232~79770563:-
PRAD	cis	rs7188445	0.932	rs73575086	ENSG00000261390.4	RP11-345M22.2	-19.04	7.22e-60	6.18e-56	-0.8	-0.67	Urate levels;	chr16:79714588	chr16:79715232~79770563:-
PRAD	cis	rs12439619	0.693	rs17269819	ENSG00000278603.1	RP13-608F4.5	19.02	8.65e-60	7.38e-56	0.99	0.67	Intelligence (multi-trait analysis);	chr15:82174660	chr15:82472203~82472426:+
PRAD	cis	rs10256972	0.706	rs4285396	ENSG00000229043.2	AC091729.9	-19.01	9.33e-60	7.97e-56	-0.83	-0.67	Endometriosis;Longevity;	chr7:1084102	chr7:1160374~1165267:+
PRAD	cis	rs11155671	0.53	rs9383577	ENSG00000223701.3	RAET1E-AS1	19.01	9.73e-60	8.29e-56	0.89	0.67	Testicular germ cell tumor;	chr6:149886059	chr6:149884431~149919508:+
PRAD	cis	rs11155671	0.53	rs9383914	ENSG00000223701.3	RAET1E-AS1	19.01	9.73e-60	8.29e-56	0.89	0.67	Testicular germ cell tumor;	chr6:149886098	chr6:149884431~149919508:+
PRAD	cis	rs11155671	0.517	rs9397058	ENSG00000223701.3	RAET1E-AS1	19.01	9.73e-60	8.29e-56	0.89	0.67	Testicular germ cell tumor;	chr6:149886113	chr6:149884431~149919508:+
PRAD	cis	rs11155671	0.53	rs9383912	ENSG00000223701.3	RAET1E-AS1	19.01	1.01e-59	8.59e-56	0.89	0.67	Testicular germ cell tumor;	chr6:149885479	chr6:149884431~149919508:+
PRAD	cis	rs11155671	0.53	rs7768626	ENSG00000223701.3	RAET1E-AS1	19.01	1.01e-59	8.59e-56	0.89	0.67	Testicular germ cell tumor;	chr6:149886826	chr6:149884431~149919508:+
PRAD	cis	rs11155671	0.53	rs7768665	ENSG00000223701.3	RAET1E-AS1	19.01	1.01e-59	8.59e-56	0.89	0.67	Testicular germ cell tumor;	chr6:149886888	chr6:149884431~149919508:+
PRAD	cis	rs11155671	0.53	rs7758020	ENSG00000223701.3	RAET1E-AS1	19.01	1.01e-59	8.59e-56	0.89	0.67	Testicular germ cell tumor;	chr6:149886975	chr6:149884431~149919508:+
PRAD	cis	rs4853012	1	rs2280643	ENSG00000217702.2	RP11-287D1.4	19.01	1.02e-59	8.65e-56	1.06	0.67	Gestational age at birth (maternal effect);	chr2:74131159	chr2:74130583~74135395:+
PRAD	cis	rs4853012	0.887	rs2280644	ENSG00000217702.2	RP11-287D1.4	19.01	1.02e-59	8.65e-56	1.06	0.67	Gestational age at birth (maternal effect);	chr2:74131284	chr2:74130583~74135395:+
PRAD	cis	rs858239	1	rs199348	ENSG00000230658.1	KLHL7-AS1	19	1.12e-59	9.49e-56	0.81	0.67	Cerebrospinal fluid biomarker levels;	chr7:23253479	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.932	rs199355	ENSG00000230658.1	KLHL7-AS1	19	1.12e-59	9.49e-56	0.81	0.67	Cerebrospinal fluid biomarker levels;	chr7:23256914	chr7:23101228~23105703:-
PRAD	cis	rs992157	1	rs4791	ENSG00000261338.2	RP11-378A13.1	18.99	1.19e-59	1.01e-55	0.76	0.66	Colorectal cancer;	chr2:218274217	chr2:218255319~218257366:+
PRAD	cis	rs2739330	0.828	rs5760098	ENSG00000225282.1	AP000350.6	18.97	1.46e-59	1.24e-55	0.87	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23926900~23929574:+
PRAD	cis	rs1799949	0.965	rs9646418	ENSG00000198496.9	NBR2	-18.95	1.77e-59	1.5e-55	-0.87	-0.66	Menopause (age at onset);	chr17:43348533	chr17:43125610~43153671:+
PRAD	cis	rs11155671	0.53	rs9397420	ENSG00000223701.3	RAET1E-AS1	-18.95	1.8e-59	1.52e-55	-0.89	-0.66	Testicular germ cell tumor;	chr6:149885645	chr6:149884431~149919508:+
PRAD	cis	rs2283792	0.622	rs381523	ENSG00000224086.5	LL22NC03-86G7.1	-18.94	2.09e-59	1.77e-55	-0.77	-0.66	Multiple sclerosis;	chr22:21951257	chr22:21938293~21977632:+
PRAD	cis	rs916888	0.821	rs199504	ENSG00000262500.1	RP11-259G18.2	-18.94	2.14e-59	1.81e-55	-1.03	-0.66	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:46243606~46245044:+
PRAD	cis	rs992157	1	rs2168704	ENSG00000261338.2	RP11-378A13.1	18.94	2.17e-59	1.83e-55	0.74	0.66	Colorectal cancer;	chr2:218277769	chr2:218255319~218257366:+
PRAD	cis	rs11673344	0.58	rs320881	ENSG00000226686.6	LINC01535	18.93	2.37e-59	2e-55	0.9	0.66	Obesity-related traits;	chr19:37246948	chr19:37251912~37265535:+
PRAD	cis	rs2739330	0.791	rs9612520	ENSG00000218537.1	MIF-AS1	18.92	2.49e-59	2.1e-55	0.89	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23894426~23898930:-
PRAD	cis	rs2739330	0.828	rs5760102	ENSG00000225282.1	AP000350.6	18.92	2.67e-59	2.25e-55	0.87	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23926900~23929574:+
PRAD	cis	rs2739330	0.796	rs5760097	ENSG00000225282.1	AP000350.6	18.91	2.77e-59	2.34e-55	0.88	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23926900~23929574:+
PRAD	cis	rs858239	0.669	rs1990365	ENSG00000230658.1	KLHL7-AS1	18.91	2.8e-59	2.36e-55	0.83	0.66	Cerebrospinal fluid biomarker levels;	chr7:23076347	chr7:23101228~23105703:-
PRAD	cis	rs2739330	0.828	rs2330635	ENSG00000225282.1	AP000350.6	18.89	3.41e-59	2.87e-55	0.88	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23926900~23929574:+
PRAD	cis	rs858239	0.932	rs1728313	ENSG00000230658.1	KLHL7-AS1	18.86	4.6e-59	3.84e-55	0.82	0.66	Cerebrospinal fluid biomarker levels;	chr7:23231412	chr7:23101228~23105703:-
PRAD	cis	rs2739330	0.731	rs4822450	ENSG00000273295.1	AP000350.5	18.86	4.84e-59	4.04e-55	0.8	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23901432~23907068:-
PRAD	cis	rs992157	0.965	rs62182826	ENSG00000261338.2	RP11-378A13.1	18.85	5.57e-59	4.65e-55	0.74	0.66	Colorectal cancer;	chr2:218284000	chr2:218255319~218257366:+
PRAD	cis	rs2739330	0.828	rs5760107	ENSG00000225282.1	AP000350.6	18.84	5.65e-59	4.71e-55	0.88	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23926900~23929574:+
PRAD	cis	rs2739330	0.789	rs5760109	ENSG00000225282.1	AP000350.6	18.84	5.65e-59	4.71e-55	0.88	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23926900~23929574:+
PRAD	cis	rs2739330	0.796	rs1006771	ENSG00000225282.1	AP000350.6	18.84	5.73e-59	4.78e-55	0.86	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23926900~23929574:+
PRAD	cis	rs2739330	0.828	rs4822454	ENSG00000225282.1	AP000350.6	18.82	7.37e-59	6.13e-55	0.88	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23926900~23929574:+
PRAD	cis	rs2739330	0.703	rs5760112	ENSG00000225282.1	AP000350.6	18.81	7.9e-59	6.54e-55	0.86	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23926900~23929574:+
PRAD	cis	rs7188445	0.932	rs17689455	ENSG00000261390.4	RP11-345M22.2	-18.81	8.08e-59	6.69e-55	-0.8	-0.66	Urate levels;	chr16:79712438	chr16:79715232~79770563:-
PRAD	cis	rs858239	0.932	rs1728320	ENSG00000230658.1	KLHL7-AS1	18.8	8.69e-59	7.19e-55	0.83	0.66	Cerebrospinal fluid biomarker levels;	chr7:23280170	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.932	rs1637190	ENSG00000230658.1	KLHL7-AS1	18.8	8.86e-59	7.32e-55	0.82	0.66	Cerebrospinal fluid biomarker levels;	chr7:23229446	chr7:23101228~23105703:-
PRAD	cis	rs992157	1	rs13429408	ENSG00000261338.2	RP11-378A13.1	18.77	1.22e-58	1e-54	0.73	0.66	Colorectal cancer;	chr2:218278137	chr2:218255319~218257366:+
PRAD	cis	rs1577917	0.654	rs9450284	ENSG00000203875.9	SNHG5	18.77	1.25e-58	1.03e-54	0.7	0.66	Response to antipsychotic treatment;	chr6:85489611	chr6:85660950~85678736:-
PRAD	cis	rs858239	0.932	rs1624451	ENSG00000230658.1	KLHL7-AS1	-18.76	1.38e-58	1.13e-54	-0.81	-0.66	Cerebrospinal fluid biomarker levels;	chr7:23222816	chr7:23101228~23105703:-
PRAD	cis	rs7188445	0.899	rs57652769	ENSG00000261390.4	RP11-345M22.2	-18.75	1.54e-58	1.26e-54	-0.8	-0.66	Urate levels;	chr16:79720079	chr16:79715232~79770563:-
PRAD	cis	rs11155671	0.53	rs7758033	ENSG00000223701.3	RAET1E-AS1	18.74	1.67e-58	1.37e-54	0.89	0.66	Testicular germ cell tumor;	chr6:149886999	chr6:149884431~149919508:+
PRAD	cis	rs11155671	0.53	rs1334510	ENSG00000223701.3	RAET1E-AS1	18.71	2.46e-58	2e-54	0.9	0.66	Testicular germ cell tumor;	chr6:149880043	chr6:149884431~149919508:+
PRAD	cis	rs1799949	0.965	rs6503727	ENSG00000198496.9	NBR2	-18.7	2.74e-58	2.22e-54	-0.87	-0.66	Menopause (age at onset);	chr17:43160842	chr17:43125610~43153671:+
PRAD	cis	rs858239	0.932	rs858275	ENSG00000230658.1	KLHL7-AS1	18.68	3.16e-58	2.56e-54	0.8	0.66	Cerebrospinal fluid biomarker levels;	chr7:23254525	chr7:23101228~23105703:-
PRAD	cis	rs858239	0.896	rs1637192	ENSG00000230658.1	KLHL7-AS1	18.67	3.79e-58	3.06e-54	0.8	0.66	Cerebrospinal fluid biomarker levels;	chr7:23220895	chr7:23101228~23105703:-
PRAD	cis	rs2739330	0.76	rs1007888	ENSG00000225282.1	AP000350.6	18.66	3.93e-58	3.17e-54	0.86	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23926900~23929574:+
PRAD	cis	rs2739330	0.703	rs5760112	ENSG00000273295.1	AP000350.5	18.65	4.45e-58	3.58e-54	0.79	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23901432~23907068:-
PRAD	cis	rs2739330	0.828	rs2186366	ENSG00000225282.1	AP000350.6	-18.65	4.49e-58	3.61e-54	-0.87	-0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23926900~23929574:+
PRAD	cis	rs7188445	0.932	rs17689625	ENSG00000261390.4	RP11-345M22.2	-18.64	4.97e-58	3.99e-54	-0.8	-0.66	Urate levels;	chr16:79715065	chr16:79715232~79770563:-
PRAD	cis	rs858239	0.829	rs2268744	ENSG00000230658.1	KLHL7-AS1	18.63	5.27e-58	4.22e-54	0.83	0.66	Cerebrospinal fluid biomarker levels;	chr7:23292661	chr7:23101228~23105703:-
PRAD	cis	rs7188445	0.932	rs7203756	ENSG00000261390.4	RP11-345M22.2	18.63	5.74e-58	4.59e-54	0.79	0.66	Urate levels;	chr16:79711709	chr16:79715232~79770563:-
PRAD	cis	rs875971	1	rs6956179	ENSG00000226824.5	RP4-756H11.3	18.62	5.84e-58	4.68e-54	0.86	0.66	Aortic root size;	chr7:66341672	chr7:66654538~66669855:+
PRAD	cis	rs9660180	0.62	rs3817856	ENSG00000268575.1	RP1-283E3.8	18.61	7.15e-58	5.71e-54	0.7	0.66	Body mass index;	chr1:1732392	chr1:1702736~1737688:-
PRAD	cis	rs2739330	0.796	rs2154594	ENSG00000225282.1	AP000350.6	-18.57	1.01e-57	8.02e-54	-0.87	-0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23926900~23929574:+
PRAD	cis	rs7188445	0.899	rs58722186	ENSG00000261390.4	RP11-345M22.2	-18.57	1.08e-57	8.57e-54	-0.8	-0.66	Urate levels;	chr16:79717694	chr16:79715232~79770563:-
PRAD	cis	rs11155671	0.53	rs7763849	ENSG00000223701.3	RAET1E-AS1	18.55	1.25e-57	9.89e-54	0.87	0.66	Testicular germ cell tumor;	chr6:149885244	chr6:149884431~149919508:+
PRAD	cis	rs17507216	1	rs17507216	ENSG00000278603.1	RP13-608F4.5	-18.55	1.28e-57	1.01e-53	-1	-0.66	Excessive daytime sleepiness;	chr15:82558175	chr15:82472203~82472426:+
PRAD	cis	rs2739330	0.76	rs1002286	ENSG00000225282.1	AP000350.6	-18.55	1.34e-57	1.06e-53	-0.85	-0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23926900~23929574:+
PRAD	cis	rs1799949	0.965	rs4793230	ENSG00000198496.9	NBR2	-18.54	1.44e-57	1.14e-53	-0.86	-0.66	Menopause (age at onset);	chr17:43350035	chr17:43125610~43153671:+
PRAD	cis	rs2882667	0.964	rs11958050	ENSG00000253404.1	AC034243.1	18.53	1.55e-57	1.23e-53	0.85	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138966139	chr5:138744434~138753309:-
PRAD	cis	rs2739330	0.828	rs4820572	ENSG00000225282.1	AP000350.6	18.52	1.68e-57	1.33e-53	0.87	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23926900~23929574:+
PRAD	cis	rs10716631	1	rs10716631	ENSG00000261338.2	RP11-378A13.1	18.52	1.78e-57	1.41e-53	0.73	0.66	Plateletcrit;High light scatter reticulocyte percentage of red cells;	chr2:218273447	chr2:218255319~218257366:+
PRAD	cis	rs2739330	0.828	rs5760099	ENSG00000225282.1	AP000350.6	18.51	2.04e-57	1.61e-53	0.86	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23926900~23929574:+
PRAD	cis	rs2739330	0.828	rs4822451	ENSG00000225282.1	AP000350.6	18.5	2.13e-57	1.68e-53	0.86	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23926900~23929574:+
PRAD	cis	rs4423214	0.819	rs7938885	ENSG00000254682.1	RP11-660L16.2	18.48	2.73e-57	2.15e-53	0.85	0.65	Vitamin D levels;	chr11:71458997	chr11:71448674~71452157:+
PRAD	cis	rs4423214	0.959	rs12800438	ENSG00000254682.1	RP11-660L16.2	18.48	2.73e-57	2.15e-53	0.85	0.65	Vitamin D levels;	chr11:71459957	chr11:71448674~71452157:+
PRAD	cis	rs4423214	1	rs12807718	ENSG00000254682.1	RP11-660L16.2	18.48	2.73e-57	2.15e-53	0.85	0.65	Vitamin D levels;	chr11:71460124	chr11:71448674~71452157:+
PRAD	cis	rs4423214	1	rs4423214	ENSG00000254682.1	RP11-660L16.2	18.48	2.73e-57	2.15e-53	0.85	0.65	Vitamin D levels;	chr11:71462208	chr11:71448674~71452157:+
PRAD	cis	rs2739330	0.685	rs4822453	ENSG00000225282.1	AP000350.6	18.48	2.78e-57	2.18e-53	0.84	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23926900~23929574:+
PRAD	cis	rs858239	1	rs166663	ENSG00000230658.1	KLHL7-AS1	18.47	2.94e-57	2.31e-53	0.82	0.65	Cerebrospinal fluid biomarker levels;	chr7:23277123	chr7:23101228~23105703:-
PRAD	cis	rs1153858	0.621	rs2413769	ENSG00000259520.4	CTD-2651B20.3	-18.47	3.08e-57	2.42e-53	-0.86	-0.65	Homoarginine levels;	chr15:45269670	chr15:45251580~45279251:-
PRAD	cis	rs4853012	0.941	rs78128123	ENSG00000217702.2	RP11-287D1.4	18.47	3.12e-57	2.45e-53	1.11	0.65	Gestational age at birth (maternal effect);	chr2:74120398	chr2:74130583~74135395:+
PRAD	cis	rs4853012	0.887	rs6737314	ENSG00000217702.2	RP11-287D1.4	18.45	3.62e-57	2.84e-53	1.08	0.65	Gestational age at birth (maternal effect);	chr2:74112459	chr2:74130583~74135395:+
PRAD	cis	rs7188445	0.932	rs17689159	ENSG00000261390.4	RP11-345M22.2	-18.45	3.83e-57	3e-53	-0.78	-0.65	Urate levels;	chr16:79708493	chr16:79715232~79770563:-
PRAD	cis	rs992157	0.965	rs13419763	ENSG00000261338.2	RP11-378A13.1	18.44	4.18e-57	3.27e-53	0.73	0.65	Colorectal cancer;	chr2:218270227	chr2:218255319~218257366:+
PRAD	cis	rs4423214	1	rs2276362	ENSG00000254682.1	RP11-660L16.2	18.43	4.54e-57	3.54e-53	0.85	0.65	Vitamin D levels;	chr11:71463406	chr11:71448674~71452157:+
PRAD	cis	rs10256972	0.706	rs12701970	ENSG00000229043.2	AC091729.9	-18.43	4.62e-57	3.61e-53	-0.82	-0.65	Endometriosis;Longevity;	chr7:1082322	chr7:1160374~1165267:+
PRAD	cis	rs7188445	0.932	rs73575079	ENSG00000261390.4	RP11-345M22.2	-18.43	4.64e-57	3.62e-53	-0.78	-0.65	Urate levels;	chr16:79711344	chr16:79715232~79770563:-
PRAD	cis	rs875971	1	rs3981131	ENSG00000226824.5	RP4-756H11.3	-18.42	5.26e-57	4.1e-53	-0.86	-0.65	Aortic root size;	chr7:66486690	chr7:66654538~66669855:+
PRAD	cis	rs992157	1	rs992157	ENSG00000261338.2	RP11-378A13.1	-18.41	5.97e-57	4.64e-53	-0.73	-0.65	Colorectal cancer;	chr2:218290058	chr2:218255319~218257366:+
PRAD	cis	rs1799949	0.965	rs9646413	ENSG00000198496.9	NBR2	-18.4	6.62e-57	5.14e-53	-0.85	-0.65	Menopause (age at onset);	chr17:43348789	chr17:43125610~43153671:+
PRAD	cis	rs4423214	1	rs4944062	ENSG00000254682.1	RP11-660L16.2	18.39	6.92e-57	5.37e-53	0.85	0.65	Vitamin D levels;	chr11:71476248	chr11:71448674~71452157:+
PRAD	cis	rs2739330	0.76	rs1002286	ENSG00000273295.1	AP000350.5	-18.39	7.1e-57	5.51e-53	-0.79	-0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23901432~23907068:-
PRAD	cis	rs1799949	0.965	rs4793237	ENSG00000198496.9	NBR2	-18.39	7.22e-57	5.6e-53	-0.85	-0.65	Menopause (age at onset);	chr17:43359227	chr17:43125610~43153671:+
PRAD	cis	rs950027	0.62	rs872192	ENSG00000259520.4	CTD-2651B20.3	-18.37	8.45e-57	6.55e-53	-0.82	-0.65	Response to fenofibrate (adiponectin levels);	chr15:45322304	chr15:45251580~45279251:-
PRAD	cis	rs9322193	0.847	rs4870054	ENSG00000231760.4	RP11-350J20.5	18.37	8.88e-57	6.88e-53	0.89	0.65	Lung cancer;	chr6:149848402	chr6:149796151~149826294:-
PRAD	cis	rs1799949	0.931	rs9912203	ENSG00000198496.9	NBR2	18.37	8.95e-57	6.93e-53	0.84	0.65	Menopause (age at onset);	chr17:43367777	chr17:43125610~43153671:+
PRAD	cis	rs6597981	0.604	rs7945912	ENSG00000279672.1	CMB9-55F22.1	18.36	9.31e-57	7.2e-53	0.73	0.65	Breast cancer;	chr11:750849	chr11:779617~780755:+
PRAD	cis	rs507080	0.922	rs654792	ENSG00000255239.1	AP002954.6	-18.36	1.01e-56	7.79e-53	-0.9	-0.65	Serum metabolite levels;	chr11:118682287	chr11:118688039~118690600:-
PRAD	cis	rs1799949	1	rs35070007	ENSG00000198496.9	NBR2	18.35	1.04e-56	8.02e-53	0.85	0.65	Menopause (age at onset);	chr17:43164730	chr17:43125610~43153671:+
PRAD	cis	rs7188445	0.932	rs73575076	ENSG00000261390.4	RP11-345M22.2	-18.33	1.32e-56	1.02e-52	-0.78	-0.65	Urate levels;	chr16:79710251	chr16:79715232~79770563:-
PRAD	cis	rs11155671	0.53	rs4870080	ENSG00000223701.3	RAET1E-AS1	18.31	1.61e-56	1.24e-52	0.88	0.65	Testicular germ cell tumor;	chr6:149881508	chr6:149884431~149919508:+
PRAD	cis	rs7188445	0.932	rs3813582	ENSG00000261390.4	RP11-345M22.2	-18.3	1.73e-56	1.33e-52	-0.78	-0.65	Urate levels;	chr16:79715456	chr16:79715232~79770563:-
PRAD	cis	rs1799949	0.859	rs11657004	ENSG00000198496.9	NBR2	-18.29	2.04e-56	1.56e-52	-0.83	-0.65	Menopause (age at onset);	chr17:43365383	chr17:43125610~43153671:+
PRAD	cis	rs1799949	0.931	rs34474989	ENSG00000198496.9	NBR2	-18.29	2.04e-56	1.56e-52	-0.83	-0.65	Menopause (age at onset);	chr17:43368042	chr17:43125610~43153671:+
PRAD	cis	rs11155671	0.53	rs9397398	ENSG00000223701.3	RAET1E-AS1	18.29	2.06e-56	1.58e-52	0.89	0.65	Testicular germ cell tumor;	chr6:149872467	chr6:149884431~149919508:+
PRAD	cis	rs1799949	0.965	rs4239149	ENSG00000198496.9	NBR2	18.28	2.31e-56	1.77e-52	0.85	0.65	Menopause (age at onset);	chr17:43176078	chr17:43125610~43153671:+
PRAD	cis	rs1799949	0.965	rs11080034	ENSG00000198496.9	NBR2	-18.28	2.36e-56	1.8e-52	-0.85	-0.65	Menopause (age at onset);	chr17:43365646	chr17:43125610~43153671:+
PRAD	cis	rs7174755	0.961	rs58175526	ENSG00000260657.2	RP11-315D16.4	18.26	2.81e-56	2.15e-52	0.8	0.65	Major depressive disorder;	chr15:68300789	chr15:68267792~68277994:-
PRAD	cis	rs858239	0.831	rs7796541	ENSG00000230658.1	KLHL7-AS1	18.25	2.96e-56	2.25e-52	0.81	0.65	Cerebrospinal fluid biomarker levels;	chr7:23349454	chr7:23101228~23105703:-
PRAD	cis	rs2739330	0.731	rs2000468	ENSG00000225282.1	AP000350.6	18.25	3.01e-56	2.29e-52	0.86	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23926900~23929574:+
PRAD	cis	rs2486288	0.656	rs8037583	ENSG00000259520.4	CTD-2651B20.3	18.25	3.11e-56	2.37e-52	0.82	0.65	Glomerular filtration rate;	chr15:45254180	chr15:45251580~45279251:-
PRAD	cis	rs10256972	0.681	rs6979076	ENSG00000229043.2	AC091729.9	18.25	3.24e-56	2.47e-52	0.81	0.65	Endometriosis;Longevity;	chr7:1076611	chr7:1160374~1165267:+
PRAD	cis	rs7188445	0.932	rs56738967	ENSG00000261390.4	RP11-345M22.2	-18.24	3.4e-56	2.58e-52	-0.79	-0.65	Urate levels;	chr16:79706644	chr16:79715232~79770563:-
PRAD	cis	rs17507216	1	rs17356118	ENSG00000278603.1	RP13-608F4.5	18.22	4.39e-56	3.33e-52	0.95	0.65	Excessive daytime sleepiness;	chr15:82569149	chr15:82472203~82472426:+
PRAD	cis	rs1799949	0.965	rs9897425	ENSG00000198496.9	NBR2	-18.18	6.25e-56	4.71e-52	-0.85	-0.65	Menopause (age at onset);	chr17:43352811	chr17:43125610~43153671:+
PRAD	cis	rs4853012	0.941	rs4852329	ENSG00000217702.2	RP11-287D1.4	18.18	6.62e-56	4.98e-52	1.1	0.65	Gestational age at birth (maternal effect);	chr2:74127417	chr2:74130583~74135395:+
PRAD	cis	rs1153858	0.621	rs1706824	ENSG00000259520.4	CTD-2651B20.3	-18.15	8.84e-56	6.63e-52	-0.85	-0.65	Homoarginine levels;	chr15:45287750	chr15:45251580~45279251:-
PRAD	cis	rs1799949	0.773	rs2137990	ENSG00000198496.9	NBR2	18.13	1.15e-55	8.6e-52	0.84	0.65	Menopause (age at onset);	chr17:43165879	chr17:43125610~43153671:+
PRAD	cis	rs1799949	0.683	rs55737636	ENSG00000198496.9	NBR2	-18.12	1.24e-55	9.24e-52	-0.84	-0.65	Menopause (age at onset);	chr17:43112722	chr17:43125610~43153671:+
PRAD	cis	rs2739330	0.791	rs4822458	ENSG00000218537.1	MIF-AS1	18.12	1.25e-55	9.34e-52	0.85	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23894426~23898930:-
PRAD	cis	rs4423214	1	rs12792306	ENSG00000254682.1	RP11-660L16.2	18.11	1.33e-55	9.91e-52	0.84	0.65	Vitamin D levels;	chr11:71455946	chr11:71448674~71452157:+
PRAD	cis	rs4423214	1	rs4944955	ENSG00000254682.1	RP11-660L16.2	18.11	1.33e-55	9.91e-52	0.84	0.65	Vitamin D levels;	chr11:71456631	chr11:71448674~71452157:+
PRAD	cis	rs4423214	1	rs4944956	ENSG00000254682.1	RP11-660L16.2	18.11	1.33e-55	9.91e-52	0.84	0.65	Vitamin D levels;	chr11:71456719	chr11:71448674~71452157:+
PRAD	cis	rs7188445	0.932	rs17767383	ENSG00000261390.4	RP11-345M22.2	-18.11	1.38e-55	1.02e-51	-0.77	-0.65	Urate levels;	chr16:79710504	chr16:79715232~79770563:-
PRAD	cis	rs4853012	0.941	rs7571083	ENSG00000217702.2	RP11-287D1.4	18.1	1.43e-55	1.06e-51	1.04	0.65	Gestational age at birth (maternal effect);	chr2:74115133	chr2:74130583~74135395:+
PRAD	cis	rs7188445	0.899	rs17689024	ENSG00000261390.4	RP11-345M22.2	-18.1	1.5e-55	1.11e-51	-0.79	-0.65	Urate levels;	chr16:79706081	chr16:79715232~79770563:-
PRAD	cis	rs1799949	0.965	rs6503726	ENSG00000198496.9	NBR2	-18.1	1.51e-55	1.12e-51	-0.84	-0.65	Menopause (age at onset);	chr17:43132725	chr17:43125610~43153671:+
PRAD	cis	rs7174755	1	rs7174755	ENSG00000260657.2	RP11-315D16.4	-18.1	1.52e-55	1.13e-51	-0.77	-0.65	Major depressive disorder;	chr15:68304789	chr15:68267792~68277994:-
PRAD	cis	rs4423214	1	rs2040323	ENSG00000254682.1	RP11-660L16.2	18.1	1.54e-55	1.14e-51	0.85	0.65	Vitamin D levels;	chr11:71461737	chr11:71448674~71452157:+
PRAD	cis	rs950027	0.549	rs11070452	ENSG00000259520.4	CTD-2651B20.3	18.1	1.57e-55	1.16e-51	0.84	0.65	Response to fenofibrate (adiponectin levels);	chr15:45302638	chr15:45251580~45279251:-
PRAD	cis	rs2019137	0.56	rs7421852	ENSG00000189223.12	PAX8-AS1	-18.09	1.7e-55	1.26e-51	-0.87	-0.65	Lymphocyte counts;	chr2:113232684	chr2:113211522~113276581:+
PRAD	cis	rs7174755	0.924	rs8035431	ENSG00000260657.2	RP11-315D16.4	18.08	1.89e-55	1.4e-51	0.78	0.65	Major depressive disorder;	chr15:68305012	chr15:68267792~68277994:-
PRAD	cis	rs992157	0.798	rs10932772	ENSG00000261338.2	RP11-378A13.1	18.08	1.89e-55	1.4e-51	0.73	0.65	Colorectal cancer;	chr2:218312425	chr2:218255319~218257366:+
PRAD	cis	rs9660180	0.62	rs34298494	ENSG00000268575.1	RP1-283E3.8	18.07	2.04e-55	1.51e-51	0.7	0.65	Body mass index;	chr1:1731963	chr1:1702736~1737688:-
PRAD	cis	rs858239	0.796	rs433395	ENSG00000230658.1	KLHL7-AS1	18.06	2.2e-55	1.63e-51	0.79	0.65	Cerebrospinal fluid biomarker levels;	chr7:23362336	chr7:23101228~23105703:-
PRAD	cis	rs9660180	0.967	rs10907191	ENSG00000231050.1	RP1-140A9.1	18.06	2.26e-55	1.67e-51	0.73	0.65	Body mass index;	chr1:1843381	chr1:1891471~1892658:+
PRAD	cis	rs9660180	1	rs9660180	ENSG00000231050.1	RP1-140A9.1	18.06	2.4e-55	1.77e-51	0.73	0.65	Body mass index;	chr1:1791592	chr1:1891471~1892658:+
PRAD	cis	rs992157	0.798	rs1017698	ENSG00000261338.2	RP11-378A13.1	-18.05	2.45e-55	1.8e-51	-0.72	-0.65	Colorectal cancer;	chr2:218305802	chr2:218255319~218257366:+
PRAD	cis	rs2739330	0.731	rs2000468	ENSG00000273295.1	AP000350.5	18.05	2.59e-55	1.9e-51	0.79	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23901432~23907068:-
PRAD	cis	rs1577917	0.629	rs7761762	ENSG00000203875.9	SNHG5	18.03	2.98e-55	2.18e-51	0.68	0.65	Response to antipsychotic treatment;	chr6:85496250	chr6:85660950~85678736:-
PRAD	cis	rs858239	0.698	rs4265084	ENSG00000230658.1	KLHL7-AS1	18.03	2.99e-55	2.18e-51	0.8	0.65	Cerebrospinal fluid biomarker levels;	chr7:23367621	chr7:23101228~23105703:-
PRAD	cis	rs7174755	0.961	rs12148843	ENSG00000260657.2	RP11-315D16.4	18.03	3.09e-55	2.26e-51	0.79	0.65	Major depressive disorder;	chr15:68302184	chr15:68267792~68277994:-
PRAD	cis	rs858239	0.799	rs10279941	ENSG00000230658.1	KLHL7-AS1	18.03	3.14e-55	2.29e-51	0.81	0.65	Cerebrospinal fluid biomarker levels;	chr7:23330889	chr7:23101228~23105703:-
PRAD	cis	rs73086581	0.787	rs73084505	ENSG00000229539.1	RP11-119B16.2	18.03	3.14e-55	2.29e-51	1.16	0.65	Response to antidepressants in depression;	chr20:3876227	chr20:3888239~3888868:-
PRAD	cis	rs858239	0.73	rs10255155	ENSG00000230658.1	KLHL7-AS1	-18.03	3.19e-55	2.33e-51	-0.8	-0.65	Cerebrospinal fluid biomarker levels;	chr7:23362528	chr7:23101228~23105703:-
PRAD	cis	rs7188445	0.787	rs7189954	ENSG00000261390.4	RP11-345M22.2	18.02	3.41e-55	2.49e-51	0.76	0.65	Urate levels;	chr16:79701150	chr16:79715232~79770563:-
PRAD	cis	rs875971	0.965	rs10267430	ENSG00000226824.5	RP4-756H11.3	18.02	3.67e-55	2.67e-51	0.85	0.65	Aortic root size;	chr7:66278036	chr7:66654538~66669855:+
PRAD	cis	rs875971	1	rs10257427	ENSG00000226824.5	RP4-756H11.3	18.02	3.67e-55	2.67e-51	0.85	0.65	Aortic root size;	chr7:66278221	chr7:66654538~66669855:+
PRAD	cis	rs875971	1	rs10215948	ENSG00000226824.5	RP4-756H11.3	18.02	3.67e-55	2.67e-51	0.85	0.65	Aortic root size;	chr7:66282799	chr7:66654538~66669855:+
PRAD	cis	rs9660180	0.967	rs11260623	ENSG00000231050.1	RP1-140A9.1	18	4.24e-55	3.08e-51	0.73	0.64	Body mass index;	chr1:1850017	chr1:1891471~1892658:+
PRAD	cis	rs9660180	0.837	rs915292	ENSG00000231050.1	RP1-140A9.1	18	4.24e-55	3.08e-51	0.73	0.64	Body mass index;	chr1:1860718	chr1:1891471~1892658:+
PRAD	cis	rs9660180	0.967	rs9660106	ENSG00000231050.1	RP1-140A9.1	18	4.24e-55	3.08e-51	0.73	0.64	Body mass index;	chr1:1866508	chr1:1891471~1892658:+
PRAD	cis	rs875971	0.964	rs55748098	ENSG00000226824.5	RP4-756H11.3	17.99	4.75e-55	3.44e-51	0.85	0.64	Aortic root size;	chr7:66298631	chr7:66654538~66669855:+
PRAD	cis	rs9660180	0.967	rs2272908	ENSG00000231050.1	RP1-140A9.1	-17.98	5.21e-55	3.77e-51	-0.72	-0.64	Body mass index;	chr1:1790040	chr1:1891471~1892658:+
PRAD	cis	rs9660180	0.935	rs2180311	ENSG00000231050.1	RP1-140A9.1	17.98	5.33e-55	3.85e-51	0.73	0.64	Body mass index;	chr1:1817295	chr1:1891471~1892658:+
PRAD	cis	rs9660180	0.967	rs6664664	ENSG00000231050.1	RP1-140A9.1	17.98	5.33e-55	3.85e-51	0.73	0.64	Body mass index;	chr1:1819825	chr1:1891471~1892658:+
PRAD	cis	rs992157	0.835	rs7559416	ENSG00000261338.2	RP11-378A13.1	-17.98	5.55e-55	4.01e-51	-0.72	-0.64	Colorectal cancer;	chr2:218285488	chr2:218255319~218257366:+
PRAD	cis	rs2283792	0.622	rs5756323	ENSG00000224086.5	LL22NC03-86G7.1	17.97	5.67e-55	4.1e-51	0.75	0.64	Multiple sclerosis;	chr22:21980398	chr22:21938293~21977632:+
PRAD	cis	rs992157	1	rs4674280	ENSG00000261338.2	RP11-378A13.1	-17.97	6.15e-55	4.44e-51	-0.72	-0.64	Colorectal cancer;	chr2:218276735	chr2:218255319~218257366:+
PRAD	cis	rs7174755	0.961	rs1122247	ENSG00000260657.2	RP11-315D16.4	17.97	6.16e-55	4.45e-51	0.79	0.64	Major depressive disorder;	chr15:68302523	chr15:68267792~68277994:-
PRAD	cis	rs9660180	0.967	rs6687065	ENSG00000231050.1	RP1-140A9.1	17.97	6.16e-55	4.45e-51	0.73	0.64	Body mass index;	chr1:1847030	chr1:1891471~1892658:+
PRAD	cis	rs9660180	0.839	rs12040826	ENSG00000231050.1	RP1-140A9.1	17.97	6.2e-55	4.47e-51	0.73	0.64	Body mass index;	chr1:1773848	chr1:1891471~1892658:+
PRAD	cis	rs2019137	0.56	rs10206269	ENSG00000189223.12	PAX8-AS1	-17.96	6.48e-55	4.67e-51	-0.87	-0.64	Lymphocyte counts;	chr2:113232816	chr2:113211522~113276581:+
PRAD	cis	rs875971	1	rs6961717	ENSG00000226824.5	RP4-756H11.3	17.96	6.52e-55	4.7e-51	0.84	0.64	Aortic root size;	chr7:66122550	chr7:66654538~66669855:+
PRAD	cis	rs875971	1	rs2087647	ENSG00000226824.5	RP4-756H11.3	17.96	6.52e-55	4.7e-51	0.84	0.64	Aortic root size;	chr7:66128201	chr7:66654538~66669855:+
PRAD	cis	rs875971	1	rs6958484	ENSG00000226824.5	RP4-756H11.3	17.96	6.52e-55	4.7e-51	0.84	0.64	Aortic root size;	chr7:66134459	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.964	rs778723	ENSG00000226824.5	RP4-756H11.3	-17.96	6.64e-55	4.77e-51	-0.84	-0.64	Aortic root size;	chr7:66364510	chr7:66654538~66669855:+
PRAD	cis	rs9660180	0.967	rs12044597	ENSG00000231050.1	RP1-140A9.1	17.96	6.8e-55	4.88e-51	0.73	0.64	Body mass index;	chr1:1777362	chr1:1891471~1892658:+
PRAD	cis	rs950027	0.549	rs9920634	ENSG00000259520.4	CTD-2651B20.3	17.95	7.03e-55	5.05e-51	0.84	0.64	Response to fenofibrate (adiponectin levels);	chr15:45304348	chr15:45251580~45279251:-
PRAD	cis	rs875971	1	rs7801282	ENSG00000226824.5	RP4-756H11.3	17.95	7.08e-55	5.08e-51	0.84	0.64	Aortic root size;	chr7:66148700	chr7:66654538~66669855:+
PRAD	cis	rs9660180	0.935	rs9786942	ENSG00000231050.1	RP1-140A9.1	17.95	7.27e-55	5.22e-51	0.73	0.64	Body mass index;	chr1:1827774	chr1:1891471~1892658:+
PRAD	cis	rs9660180	0.934	rs34849348	ENSG00000231050.1	RP1-140A9.1	17.95	7.27e-55	5.22e-51	0.73	0.64	Body mass index;	chr1:1831318	chr1:1891471~1892658:+
PRAD	cis	rs875971	1	rs4718307	ENSG00000226824.5	RP4-756H11.3	17.95	7.34e-55	5.27e-51	0.84	0.64	Aortic root size;	chr7:66146001	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.895	rs3857684	ENSG00000226824.5	RP4-756H11.3	-17.95	7.4e-55	5.31e-51	-0.84	-0.64	Aortic root size;	chr7:66473171	chr7:66654538~66669855:+
PRAD	cis	rs875971	1	rs12533997	ENSG00000226824.5	RP4-756H11.3	-17.95	7.4e-55	5.31e-51	-0.84	-0.64	Aortic root size;	chr7:66500390	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.929	rs10950041	ENSG00000226824.5	RP4-756H11.3	-17.94	7.78e-55	5.57e-51	-0.84	-0.64	Aortic root size;	chr7:66508888	chr7:66654538~66669855:+
PRAD	cis	rs875971	1	rs875971	ENSG00000226824.5	RP4-756H11.3	17.94	7.89e-55	5.65e-51	0.84	0.64	Aortic root size;	chr7:66152608	chr7:66654538~66669855:+
PRAD	cis	rs992157	0.731	rs1399132	ENSG00000261338.2	RP11-378A13.1	17.94	8.19e-55	5.86e-51	0.73	0.64	Colorectal cancer;	chr2:218295047	chr2:218255319~218257366:+
PRAD	cis	rs992157	0.796	rs55680399	ENSG00000261338.2	RP11-378A13.1	17.94	8.47e-55	6.06e-51	0.73	0.64	Colorectal cancer;	chr2:218295898	chr2:218255319~218257366:+
PRAD	cis	rs875971	0.965	rs9969301	ENSG00000226824.5	RP4-756H11.3	17.93	8.92e-55	6.37e-51	0.84	0.64	Aortic root size;	chr7:66316668	chr7:66654538~66669855:+
PRAD	cis	rs11155671	0.53	rs9371215	ENSG00000223701.3	RAET1E-AS1	17.92	9.85e-55	7.02e-51	0.87	0.64	Testicular germ cell tumor;	chr6:149873162	chr6:149884431~149919508:+
PRAD	cis	rs992157	0.732	rs10932771	ENSG00000261338.2	RP11-378A13.1	17.92	9.97e-55	7.1e-51	0.72	0.64	Colorectal cancer;	chr2:218305513	chr2:218255319~218257366:+
PRAD	cis	rs4423214	1	rs2276360	ENSG00000254682.1	RP11-660L16.2	17.92	1.03e-54	7.36e-51	0.83	0.64	Vitamin D levels;	chr11:71458501	chr11:71448674~71452157:+
PRAD	cis	rs875971	0.929	rs778712	ENSG00000226824.5	RP4-756H11.3	-17.91	1.06e-54	7.53e-51	-0.84	-0.64	Aortic root size;	chr7:66384991	chr7:66654538~66669855:+
PRAD	cis	rs875971	1	rs778710	ENSG00000226824.5	RP4-756H11.3	-17.91	1.06e-54	7.53e-51	-0.84	-0.64	Aortic root size;	chr7:66389847	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.964	rs778708	ENSG00000226824.5	RP4-756H11.3	-17.91	1.06e-54	7.53e-51	-0.84	-0.64	Aortic root size;	chr7:66391332	chr7:66654538~66669855:+
PRAD	cis	rs875971	1	rs778696	ENSG00000226824.5	RP4-756H11.3	-17.91	1.06e-54	7.53e-51	-0.84	-0.64	Aortic root size;	chr7:66405826	chr7:66654538~66669855:+
PRAD	cis	rs875971	1	rs778694	ENSG00000226824.5	RP4-756H11.3	-17.91	1.06e-54	7.53e-51	-0.84	-0.64	Aortic root size;	chr7:66406571	chr7:66654538~66669855:+
PRAD	cis	rs875971	1	rs4718344	ENSG00000226824.5	RP4-756H11.3	-17.91	1.06e-54	7.53e-51	-0.84	-0.64	Aortic root size;	chr7:66409394	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.737	rs7803424	ENSG00000226824.5	RP4-756H11.3	-17.91	1.06e-54	7.53e-51	-0.84	-0.64	Aortic root size;	chr7:66415618	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.83	rs7799834	ENSG00000226824.5	RP4-756H11.3	-17.91	1.06e-54	7.53e-51	-0.84	-0.64	Aortic root size;	chr7:66415707	chr7:66654538~66669855:+
PRAD	cis	rs875971	1	rs9986696	ENSG00000226824.5	RP4-756H11.3	17.91	1.07e-54	7.62e-51	0.84	0.64	Aortic root size;	chr7:66239589	chr7:66654538~66669855:+
PRAD	cis	rs9660180	0.592	rs2076325	ENSG00000268575.1	RP1-283E3.8	17.91	1.07e-54	7.63e-51	0.7	0.64	Body mass index;	chr1:1735176	chr1:1702736~1737688:-
PRAD	cis	rs875971	1	rs778726	ENSG00000226824.5	RP4-756H11.3	-17.91	1.08e-54	7.68e-51	-0.84	-0.64	Aortic root size;	chr7:66363744	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.767	rs1695815	ENSG00000226824.5	RP4-756H11.3	-17.91	1.08e-54	7.68e-51	-0.84	-0.64	Aortic root size;	chr7:66366357	chr7:66654538~66669855:+
PRAD	cis	rs875971	1	rs778685	ENSG00000226824.5	RP4-756H11.3	-17.91	1.08e-54	7.68e-51	-0.84	-0.64	Aortic root size;	chr7:66371189	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.929	rs778682	ENSG00000226824.5	RP4-756H11.3	-17.91	1.09e-54	7.76e-51	-0.84	-0.64	Aortic root size;	chr7:66372947	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.964	rs11765965	ENSG00000226824.5	RP4-756H11.3	-17.91	1.09e-54	7.76e-51	-0.84	-0.64	Aortic root size;	chr7:66377234	chr7:66654538~66669855:+
PRAD	cis	rs7174755	0.961	rs11631030	ENSG00000260657.2	RP11-315D16.4	17.91	1.12e-54	7.97e-51	0.78	0.64	Major depressive disorder;	chr15:68303463	chr15:68267792~68277994:-
PRAD	cis	rs4423214	1	rs2276361	ENSG00000254682.1	RP11-660L16.2	17.91	1.16e-54	8.23e-51	0.84	0.64	Vitamin D levels;	chr11:71458602	chr11:71448674~71452157:+
PRAD	cis	rs875971	1	rs6963646	ENSG00000226824.5	RP4-756H11.3	17.91	1.17e-54	8.27e-51	0.84	0.64	Aortic root size;	chr7:66220780	chr7:66654538~66669855:+
PRAD	cis	rs875971	1	rs4718357	ENSG00000226824.5	RP4-756H11.3	-17.9	1.18e-54	8.34e-51	-0.84	-0.64	Aortic root size;	chr7:66495891	chr7:66654538~66669855:+
PRAD	cis	rs875971	1	rs12698523	ENSG00000226824.5	RP4-756H11.3	-17.9	1.2e-54	8.44e-51	-0.84	-0.64	Aortic root size;	chr7:66503126	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.964	rs6978429	ENSG00000226824.5	RP4-756H11.3	-17.9	1.21e-54	8.5e-51	-0.84	-0.64	Aortic root size;	chr7:66494889	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.929	rs12535036	ENSG00000226824.5	RP4-756H11.3	-17.9	1.21e-54	8.5e-51	-0.84	-0.64	Aortic root size;	chr7:66499076	chr7:66654538~66669855:+
PRAD	cis	rs875971	1	rs6970030	ENSG00000226824.5	RP4-756H11.3	-17.9	1.21e-54	8.5e-51	-0.84	-0.64	Aortic root size;	chr7:66503692	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.928	rs6970357	ENSG00000226824.5	RP4-756H11.3	-17.9	1.21e-54	8.5e-51	-0.84	-0.64	Aortic root size;	chr7:66503891	chr7:66654538~66669855:+
PRAD	cis	rs2283792	0.622	rs2266979	ENSG00000224086.5	LL22NC03-86G7.1	-17.9	1.21e-54	8.52e-51	-0.74	-0.64	Multiple sclerosis;	chr22:21977447	chr22:21938293~21977632:+
PRAD	cis	rs2739330	0.761	rs5760176	ENSG00000231271.1	AP000350.8	-17.9	1.24e-54	8.75e-51	-0.85	-0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23949918~23954042:+
PRAD	cis	rs2739330	0.731	rs5751792	ENSG00000231271.1	AP000350.8	17.9	1.24e-54	8.75e-51	0.85	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23949918~23954042:+
PRAD	cis	rs2739330	0.76	rs5751760	ENSG00000225282.1	AP000350.6	17.9	1.25e-54	8.8e-51	0.85	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23926900~23929574:+
PRAD	cis	rs2739330	0.796	rs5760106	ENSG00000225282.1	AP000350.6	-17.9	1.26e-54	8.9e-51	-0.85	-0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23926900~23929574:+
PRAD	cis	rs875971	0.929	rs6970860	ENSG00000226824.5	RP4-756H11.3	-17.9	1.27e-54	8.96e-51	-0.84	-0.64	Aortic root size;	chr7:66511647	chr7:66654538~66669855:+
PRAD	cis	rs875971	1	rs55962648	ENSG00000226824.5	RP4-756H11.3	17.9	1.29e-54	9.07e-51	0.84	0.64	Aortic root size;	chr7:66160764	chr7:66654538~66669855:+
PRAD	cis	rs875971	1	rs2420168	ENSG00000226824.5	RP4-756H11.3	17.9	1.29e-54	9.07e-51	0.84	0.64	Aortic root size;	chr7:66165644	chr7:66654538~66669855:+
PRAD	cis	rs7174755	1	rs68069953	ENSG00000260657.2	RP11-315D16.4	17.9	1.3e-54	9.11e-51	0.77	0.64	Major depressive disorder;	chr15:68304235	chr15:68267792~68277994:-
PRAD	cis	rs875971	1	rs709595	ENSG00000226824.5	RP4-756H11.3	-17.89	1.31e-54	9.2e-51	-0.84	-0.64	Aortic root size;	chr7:66352346	chr7:66654538~66669855:+
PRAD	cis	rs875971	1	rs811880	ENSG00000226824.5	RP4-756H11.3	-17.89	1.31e-54	9.2e-51	-0.84	-0.64	Aortic root size;	chr7:66353659	chr7:66654538~66669855:+
PRAD	cis	rs858239	1	rs156425	ENSG00000230658.1	KLHL7-AS1	-17.89	1.38e-54	9.68e-51	-0.77	-0.64	Cerebrospinal fluid biomarker levels;	chr7:23269500	chr7:23101228~23105703:-
PRAD	cis	rs950027	0.549	rs2899375	ENSG00000259520.4	CTD-2651B20.3	17.89	1.39e-54	9.71e-51	0.83	0.64	Response to fenofibrate (adiponectin levels);	chr15:45306137	chr15:45251580~45279251:-
PRAD	cis	rs2739330	0.76	rs5760095	ENSG00000225282.1	AP000350.6	17.88	1.45e-54	1.02e-50	0.84	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23926900~23929574:+
PRAD	cis	rs875971	0.965	rs6971509	ENSG00000226824.5	RP4-756H11.3	17.88	1.59e-54	1.11e-50	0.85	0.64	Aortic root size;	chr7:66249983	chr7:66654538~66669855:+
PRAD	cis	rs2739330	0.76	rs5751760	ENSG00000273295.1	AP000350.5	17.87	1.65e-54	1.15e-50	0.79	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23901432~23907068:-
PRAD	cis	rs2739330	0.732	rs5760175	ENSG00000231271.1	AP000350.8	17.87	1.67e-54	1.16e-50	0.86	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23949918~23954042:+
PRAD	cis	rs2283792	0.73	rs2027790	ENSG00000224086.5	LL22NC03-86G7.1	-17.87	1.72e-54	1.2e-50	-0.76	-0.64	Multiple sclerosis;	chr22:21933592	chr22:21938293~21977632:+
PRAD	cis	rs875971	0.964	rs1643388	ENSG00000226824.5	RP4-756H11.3	-17.87	1.73e-54	1.2e-50	-0.84	-0.64	Aortic root size;	chr7:66379575	chr7:66654538~66669855:+
PRAD	cis	rs875971	1	rs778722	ENSG00000226824.5	RP4-756H11.3	-17.87	1.73e-54	1.2e-50	-0.84	-0.64	Aortic root size;	chr7:66379841	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.964	rs778721	ENSG00000226824.5	RP4-756H11.3	-17.87	1.73e-54	1.2e-50	-0.84	-0.64	Aortic root size;	chr7:66380410	chr7:66654538~66669855:+
PRAD	cis	rs875971	1	rs778706	ENSG00000226824.5	RP4-756H11.3	-17.87	1.73e-54	1.2e-50	-0.84	-0.64	Aortic root size;	chr7:66395437	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.895	rs778700	ENSG00000226824.5	RP4-756H11.3	-17.87	1.73e-54	1.2e-50	-0.84	-0.64	Aortic root size;	chr7:66401463	chr7:66654538~66669855:+
PRAD	cis	rs875971	1	rs778699	ENSG00000226824.5	RP4-756H11.3	-17.87	1.73e-54	1.2e-50	-0.84	-0.64	Aortic root size;	chr7:66403303	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.929	rs778692	ENSG00000226824.5	RP4-756H11.3	-17.87	1.73e-54	1.2e-50	-0.84	-0.64	Aortic root size;	chr7:66407462	chr7:66654538~66669855:+
PRAD	cis	rs875971	1	rs4718343	ENSG00000226824.5	RP4-756H11.3	-17.87	1.73e-54	1.2e-50	-0.84	-0.64	Aortic root size;	chr7:66409301	chr7:66654538~66669855:+
PRAD	cis	rs875971	1	rs1968225	ENSG00000226824.5	RP4-756H11.3	-17.87	1.73e-54	1.2e-50	-0.84	-0.64	Aortic root size;	chr7:66409786	chr7:66654538~66669855:+
PRAD	cis	rs875971	1	rs6460295	ENSG00000226824.5	RP4-756H11.3	-17.87	1.73e-54	1.2e-50	-0.84	-0.64	Aortic root size;	chr7:66417741	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.964	rs6978721	ENSG00000226824.5	RP4-756H11.3	-17.87	1.73e-54	1.2e-50	-0.84	-0.64	Aortic root size;	chr7:66418217	chr7:66654538~66669855:+
PRAD	cis	rs875971	1	rs12532998	ENSG00000226824.5	RP4-756H11.3	-17.87	1.75e-54	1.22e-50	-0.84	-0.64	Aortic root size;	chr7:66502472	chr7:66654538~66669855:+
PRAD	cis	rs875971	1	rs11974219	ENSG00000226824.5	RP4-756H11.3	17.87	1.77e-54	1.23e-50	0.84	0.64	Aortic root size;	chr7:66182423	chr7:66654538~66669855:+
PRAD	cis	rs875971	1	rs1565531	ENSG00000226824.5	RP4-756H11.3	17.87	1.77e-54	1.23e-50	0.84	0.64	Aortic root size;	chr7:66198126	chr7:66654538~66669855:+
PRAD	cis	rs11673344	0.502	rs17304703	ENSG00000226686.6	LINC01535	17.86	1.79e-54	1.24e-50	0.87	0.64	Obesity-related traits;	chr19:37582646	chr19:37251912~37265535:+
PRAD	cis	rs11673344	0.526	rs2306201	ENSG00000226686.6	LINC01535	17.86	1.79e-54	1.24e-50	0.87	0.64	Obesity-related traits;	chr19:37586573	chr19:37251912~37265535:+
PRAD	cis	rs875971	0.838	rs2173570	ENSG00000226824.5	RP4-756H11.3	17.86	1.81e-54	1.26e-50	0.84	0.64	Aortic root size;	chr7:66297976	chr7:66654538~66669855:+
PRAD	cis	rs1799949	0.894	rs36062488	ENSG00000198496.9	NBR2	17.86	1.82e-54	1.26e-50	0.83	0.64	Menopause (age at onset);	chr17:43185455	chr17:43125610~43153671:+
PRAD	cis	rs2739330	0.734	rs2000467	ENSG00000218537.1	MIF-AS1	-17.86	1.91e-54	1.32e-50	-0.86	-0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23894426~23898930:-
PRAD	cis	rs875971	0.965	rs28682868	ENSG00000226824.5	RP4-756H11.3	17.85	2.04e-54	1.41e-50	0.84	0.64	Aortic root size;	chr7:66224822	chr7:66654538~66669855:+
PRAD	cis	rs7188445	1	rs7190187	ENSG00000261390.4	RP11-345M22.2	-17.85	2.16e-54	1.49e-50	-0.78	-0.64	Urate levels;	chr16:79701281	chr16:79715232~79770563:-
PRAD	cis	rs1153858	0.621	rs12913645	ENSG00000259520.4	CTD-2651B20.3	17.85	2.18e-54	1.51e-50	0.85	0.64	Homoarginine levels;	chr15:45262868	chr15:45251580~45279251:-
PRAD	cis	rs12439619	0.921	rs4778672	ENSG00000278603.1	RP13-608F4.5	-17.85	2.2e-54	1.52e-50	-0.92	-0.64	Intelligence (multi-trait analysis);	chr15:82245013	chr15:82472203~82472426:+
PRAD	cis	rs73086581	0.787	rs67633417	ENSG00000229539.1	RP11-119B16.2	17.84	2.26e-54	1.56e-50	1.15	0.64	Response to antidepressants in depression;	chr20:3887610	chr20:3888239~3888868:-
PRAD	cis	rs6597981	0.592	rs10902218	ENSG00000279672.1	CMB9-55F22.1	-17.84	2.27e-54	1.57e-50	-0.68	-0.64	Breast cancer;	chr11:743813	chr11:779617~780755:+
PRAD	cis	rs858239	0.704	rs199657	ENSG00000230658.1	KLHL7-AS1	-17.83	2.5e-54	1.73e-50	-0.8	-0.64	Cerebrospinal fluid biomarker levels;	chr7:23297888	chr7:23101228~23105703:-
PRAD	cis	rs875971	1	rs3735148	ENSG00000226824.5	RP4-756H11.3	-17.83	2.54e-54	1.75e-50	-0.84	-0.64	Aortic root size;	chr7:66506022	chr7:66654538~66669855:+
PRAD	cis	rs875971	1	rs937495	ENSG00000226824.5	RP4-756H11.3	17.83	2.61e-54	1.8e-50	0.84	0.64	Aortic root size;	chr7:66314811	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.898	rs6977501	ENSG00000226824.5	RP4-756H11.3	17.82	2.99e-54	2.06e-50	0.84	0.64	Aortic root size;	chr7:66228355	chr7:66654538~66669855:+
PRAD	cis	rs11673344	0.624	rs862234	ENSG00000226686.6	LINC01535	-17.81	3.06e-54	2.11e-50	-0.88	-0.64	Obesity-related traits;	chr19:37237100	chr19:37251912~37265535:+
PRAD	cis	rs2283792	0.73	rs2083565	ENSG00000224086.5	LL22NC03-86G7.1	-17.81	3.29e-54	2.26e-50	-0.76	-0.64	Multiple sclerosis;	chr22:21929985	chr22:21938293~21977632:+
PRAD	cis	rs9660180	0.967	rs6603803	ENSG00000231050.1	RP1-140A9.1	17.8	3.64e-54	2.5e-50	0.72	0.64	Body mass index;	chr1:1881249	chr1:1891471~1892658:+
PRAD	cis	rs2019137	0.56	rs6707386	ENSG00000189223.12	PAX8-AS1	-17.78	4.34e-54	2.97e-50	-0.86	-0.64	Lymphocyte counts;	chr2:113223445	chr2:113211522~113276581:+
PRAD	cis	rs1799949	0.965	rs799910	ENSG00000198496.9	NBR2	-17.78	4.45e-54	3.04e-50	-0.84	-0.64	Menopause (age at onset);	chr17:43127544	chr17:43125610~43153671:+
PRAD	cis	rs73086581	0.787	rs68127408	ENSG00000229539.1	RP11-119B16.2	17.78	4.51e-54	3.08e-50	1.14	0.64	Response to antidepressants in depression;	chr20:3887800	chr20:3888239~3888868:-
PRAD	cis	rs73086581	0.787	rs67202952	ENSG00000229539.1	RP11-119B16.2	17.78	4.51e-54	3.08e-50	1.14	0.64	Response to antidepressants in depression;	chr20:3888452	chr20:3888239~3888868:-
PRAD	cis	rs11673344	0.526	rs55909413	ENSG00000226686.6	LINC01535	17.78	4.54e-54	3.1e-50	0.86	0.64	Obesity-related traits;	chr19:37578663	chr19:37251912~37265535:+
PRAD	cis	rs11673344	0.526	rs73033122	ENSG00000226686.6	LINC01535	17.78	4.54e-54	3.1e-50	0.86	0.64	Obesity-related traits;	chr19:37586006	chr19:37251912~37265535:+
PRAD	cis	rs875971	1	rs11971949	ENSG00000226824.5	RP4-756H11.3	17.77	4.64e-54	3.16e-50	0.84	0.64	Aortic root size;	chr7:66161027	chr7:66654538~66669855:+
PRAD	cis	rs2283792	0.73	rs2329884	ENSG00000224086.5	LL22NC03-86G7.1	-17.77	4.7e-54	3.2e-50	-0.76	-0.64	Multiple sclerosis;	chr22:21927890	chr22:21938293~21977632:+
PRAD	cis	rs1799949	0.536	rs4793227	ENSG00000198496.9	NBR2	-17.77	4.9e-54	3.33e-50	-0.84	-0.64	Menopause (age at onset);	chr17:43334882	chr17:43125610~43153671:+
PRAD	cis	rs7174755	0.923	rs9672310	ENSG00000260657.2	RP11-315D16.4	17.77	4.91e-54	3.34e-50	0.78	0.64	Major depressive disorder;	chr15:68306578	chr15:68267792~68277994:-
PRAD	cis	rs2019137	0.539	rs11123170	ENSG00000189223.12	PAX8-AS1	-17.77	4.92e-54	3.34e-50	-0.87	-0.64	Lymphocyte counts;	chr2:113221363	chr2:113211522~113276581:+
PRAD	cis	rs17507216	0.958	rs28648832	ENSG00000278603.1	RP13-608F4.5	17.77	4.97e-54	3.38e-50	0.93	0.64	Excessive daytime sleepiness;	chr15:82567642	chr15:82472203~82472426:+
PRAD	cis	rs7188445	0.932	rs17767419	ENSG00000261390.4	RP11-345M22.2	-17.77	4.98e-54	3.39e-50	-0.76	-0.64	Urate levels;	chr16:79710651	chr16:79715232~79770563:-
PRAD	cis	rs73086581	0.787	rs67724338	ENSG00000229539.1	RP11-119B16.2	17.76	5.19e-54	3.53e-50	1.14	0.64	Response to antidepressants in depression;	chr20:3888410	chr20:3888239~3888868:-
PRAD	cis	rs875971	1	rs11974264	ENSG00000226824.5	RP4-756H11.3	17.75	6.32e-54	4.28e-50	0.84	0.64	Aortic root size;	chr7:66182595	chr7:66654538~66669855:+
PRAD	cis	rs875971	1	rs1540651	ENSG00000226824.5	RP4-756H11.3	17.75	6.32e-54	4.28e-50	0.84	0.64	Aortic root size;	chr7:66185134	chr7:66654538~66669855:+
PRAD	cis	rs875971	1	rs2036264	ENSG00000226824.5	RP4-756H11.3	17.74	6.39e-54	4.32e-50	0.84	0.64	Aortic root size;	chr7:66334917	chr7:66654538~66669855:+
PRAD	cis	rs875971	1	rs7783613	ENSG00000226824.5	RP4-756H11.3	17.74	6.39e-54	4.32e-50	0.84	0.64	Aortic root size;	chr7:66340274	chr7:66654538~66669855:+
PRAD	cis	rs2739330	0.652	rs2000469	ENSG00000218537.1	MIF-AS1	17.74	6.93e-54	4.68e-50	0.87	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23894426~23898930:-
PRAD	cis	rs11673344	0.526	rs2291001	ENSG00000226686.6	LINC01535	17.73	7.21e-54	4.87e-50	0.87	0.64	Obesity-related traits;	chr19:37594431	chr19:37251912~37265535:+
PRAD	cis	rs858239	1	rs199357	ENSG00000230658.1	KLHL7-AS1	-17.73	7.25e-54	4.9e-50	-0.77	-0.64	Cerebrospinal fluid biomarker levels;	chr7:23248690	chr7:23101228~23105703:-
PRAD	cis	rs11673344	0.526	rs17244769	ENSG00000226686.6	LINC01535	17.72	8.05e-54	5.43e-50	0.86	0.64	Obesity-related traits;	chr19:37562031	chr19:37251912~37265535:+
PRAD	cis	rs858239	0.704	rs199656	ENSG00000230658.1	KLHL7-AS1	-17.72	8.16e-54	5.5e-50	-0.8	-0.64	Cerebrospinal fluid biomarker levels;	chr7:23297996	chr7:23101228~23105703:-
PRAD	cis	rs11673344	0.526	rs8101610	ENSG00000226686.6	LINC01535	-17.72	8.18e-54	5.51e-50	-0.86	-0.64	Obesity-related traits;	chr19:37566604	chr19:37251912~37265535:+
PRAD	cis	rs4423214	1	rs7928249	ENSG00000254682.1	RP11-660L16.2	17.72	8.65e-54	5.83e-50	0.83	0.64	Vitamin D levels;	chr11:71450017	chr11:71448674~71452157:+
PRAD	cis	rs9660180	0.868	rs72634846	ENSG00000231050.1	RP1-140A9.1	17.71	8.91e-54	6e-50	0.72	0.64	Body mass index;	chr1:1773476	chr1:1891471~1892658:+
PRAD	cis	rs73086581	0.687	rs16989002	ENSG00000229539.1	RP11-119B16.2	17.7	9.79e-54	6.58e-50	1.13	0.64	Response to antidepressants in depression;	chr20:3870056	chr20:3888239~3888868:-
PRAD	cis	rs1799949	0.929	rs799905	ENSG00000198496.9	NBR2	-17.7	9.95e-54	6.69e-50	-0.83	-0.64	Menopause (age at onset);	chr17:43125170	chr17:43125610~43153671:+
PRAD	cis	rs9660180	0.934	rs12729990	ENSG00000231050.1	RP1-140A9.1	17.7	1.02e-53	6.87e-50	0.73	0.64	Body mass index;	chr1:1880596	chr1:1891471~1892658:+
PRAD	cis	rs950027	0.549	rs12909409	ENSG00000259520.4	CTD-2651B20.3	17.69	1.17e-53	7.87e-50	0.81	0.64	Response to fenofibrate (adiponectin levels);	chr15:45316384	chr15:45251580~45279251:-
PRAD	cis	rs1799949	0.965	rs8176198	ENSG00000198496.9	NBR2	-17.69	1.18e-53	7.92e-50	-0.82	-0.64	Menopause (age at onset);	chr17:43078520	chr17:43125610~43153671:+
PRAD	cis	rs11673344	0.526	rs55865869	ENSG00000226686.6	LINC01535	17.68	1.19e-53	7.99e-50	0.86	0.64	Obesity-related traits;	chr19:37578683	chr19:37251912~37265535:+
PRAD	cis	rs875971	1	rs6957199	ENSG00000226824.5	RP4-756H11.3	-17.68	1.19e-53	7.99e-50	-0.83	-0.64	Aortic root size;	chr7:66513532	chr7:66654538~66669855:+
PRAD	cis	rs11673344	0.526	rs73035160	ENSG00000226686.6	LINC01535	17.68	1.27e-53	8.46e-50	0.87	0.64	Obesity-related traits;	chr19:37655135	chr19:37251912~37265535:+
PRAD	cis	rs11673344	0.526	rs1871196	ENSG00000226686.6	LINC01535	17.68	1.27e-53	8.46e-50	0.87	0.64	Obesity-related traits;	chr19:37656022	chr19:37251912~37265535:+
PRAD	cis	rs11673344	0.526	rs35153242	ENSG00000226686.6	LINC01535	-17.68	1.27e-53	8.46e-50	-0.87	-0.64	Obesity-related traits;	chr19:37660841	chr19:37251912~37265535:+
PRAD	cis	rs9660180	1	rs3737628	ENSG00000231050.1	RP1-140A9.1	17.68	1.29e-53	8.62e-50	0.73	0.64	Body mass index;	chr1:1791493	chr1:1891471~1892658:+
PRAD	cis	rs7188445	0.932	rs4575545	ENSG00000261390.4	RP11-345M22.2	-17.67	1.43e-53	9.55e-50	-0.78	-0.64	Urate levels;	chr16:79721549	chr16:79715232~79770563:-
PRAD	cis	rs1799949	0.93	rs34210004	ENSG00000198496.9	NBR2	-17.67	1.46e-53	9.71e-50	-0.84	-0.64	Menopause (age at onset);	chr17:43218318	chr17:43125610~43153671:+
PRAD	cis	rs875971	0.895	rs4718349	ENSG00000226824.5	RP4-756H11.3	-17.66	1.52e-53	1.01e-49	-0.83	-0.64	Aortic root size;	chr7:66444024	chr7:66654538~66669855:+
PRAD	cis	rs875971	1	rs2042133	ENSG00000226824.5	RP4-756H11.3	-17.66	1.52e-53	1.01e-49	-0.83	-0.64	Aortic root size;	chr7:66466935	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.964	rs2161065	ENSG00000226824.5	RP4-756H11.3	-17.66	1.52e-53	1.01e-49	-0.83	-0.64	Aortic root size;	chr7:66467918	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.862	rs12698521	ENSG00000226824.5	RP4-756H11.3	-17.66	1.52e-53	1.01e-49	-0.83	-0.64	Aortic root size;	chr7:66474502	chr7:66654538~66669855:+
PRAD	cis	rs12439619	0.883	rs62012045	ENSG00000278603.1	RP13-608F4.5	17.66	1.55e-53	1.03e-49	0.92	0.64	Intelligence (multi-trait analysis);	chr15:82229366	chr15:82472203~82472426:+
PRAD	cis	rs950027	0.572	rs12910764	ENSG00000259520.4	CTD-2651B20.3	17.65	1.63e-53	1.09e-49	0.81	0.64	Response to fenofibrate (adiponectin levels);	chr15:45317162	chr15:45251580~45279251:-
PRAD	cis	rs11155671	0.53	rs6557133	ENSG00000223701.3	RAET1E-AS1	17.65	1.71e-53	1.14e-49	0.86	0.64	Testicular germ cell tumor;	chr6:149874248	chr6:149884431~149919508:+
PRAD	cis	rs875971	0.964	rs60193905	ENSG00000226824.5	RP4-756H11.3	-17.65	1.72e-53	1.14e-49	-0.83	-0.64	Aortic root size;	chr7:66506273	chr7:66654538~66669855:+
PRAD	cis	rs7174755	0.923	rs4777033	ENSG00000260657.2	RP11-315D16.4	-17.65	1.75e-53	1.16e-49	-0.77	-0.64	Major depressive disorder;	chr15:68308010	chr15:68267792~68277994:-
PRAD	cis	rs11673344	0.518	rs73033134	ENSG00000226686.6	LINC01535	17.64	1.83e-53	1.21e-49	0.86	0.64	Obesity-related traits;	chr19:37596046	chr19:37251912~37265535:+
PRAD	cis	rs11673344	0.526	rs17303902	ENSG00000226686.6	LINC01535	17.64	1.87e-53	1.24e-49	0.85	0.64	Obesity-related traits;	chr19:37551912	chr19:37251912~37265535:+
PRAD	cis	rs11673344	0.526	rs55754546	ENSG00000226686.6	LINC01535	17.64	1.87e-53	1.24e-49	0.85	0.64	Obesity-related traits;	chr19:37552860	chr19:37251912~37265535:+
PRAD	cis	rs1799949	0.965	rs799912	ENSG00000198496.9	NBR2	-17.64	1.92e-53	1.27e-49	-0.83	-0.64	Menopause (age at onset);	chr17:43105117	chr17:43125610~43153671:+
PRAD	cis	rs801193	0.66	rs2659897	ENSG00000226824.5	RP4-756H11.3	17.64	1.92e-53	1.27e-49	0.86	0.64	Aortic root size;	chr7:66722728	chr7:66654538~66669855:+
PRAD	cis	rs17507216	0.958	rs72751643	ENSG00000278603.1	RP13-608F4.5	17.64	1.93e-53	1.28e-49	0.97	0.64	Excessive daytime sleepiness;	chr15:82559444	chr15:82472203~82472426:+
PRAD	cis	rs11673344	0.526	rs17244713	ENSG00000226686.6	LINC01535	17.64	1.93e-53	1.28e-49	0.85	0.64	Obesity-related traits;	chr19:37559938	chr19:37251912~37265535:+
PRAD	cis	rs11673344	0.526	rs8111790	ENSG00000226686.6	LINC01535	17.64	1.93e-53	1.28e-49	0.85	0.64	Obesity-related traits;	chr19:37565861	chr19:37251912~37265535:+
PRAD	cis	rs9660180	0.967	rs12040325	ENSG00000231050.1	RP1-140A9.1	17.64	1.98e-53	1.31e-49	0.73	0.64	Body mass index;	chr1:1770997	chr1:1891471~1892658:+
PRAD	cis	rs7188445	0.899	rs7195321	ENSG00000261390.4	RP11-345M22.2	-17.63	2.07e-53	1.37e-49	-0.78	-0.64	Urate levels;	chr16:79701065	chr16:79715232~79770563:-
PRAD	cis	rs875971	1	rs6460296	ENSG00000226824.5	RP4-756H11.3	-17.63	2.18e-53	1.44e-49	-0.83	-0.64	Aortic root size;	chr7:66430152	chr7:66654538~66669855:+
PRAD	cis	rs2019137	0.56	rs7578633	ENSG00000189223.12	PAX8-AS1	-17.63	2.19e-53	1.45e-49	-0.86	-0.64	Lymphocyte counts;	chr2:113221073	chr2:113211522~113276581:+
PRAD	cis	rs875971	1	rs6945843	ENSG00000226824.5	RP4-756H11.3	17.63	2.23e-53	1.48e-49	0.84	0.64	Aortic root size;	chr7:66269796	chr7:66654538~66669855:+
PRAD	cis	rs9660180	0.967	rs12034740	ENSG00000231050.1	RP1-140A9.1	17.62	2.29e-53	1.51e-49	0.72	0.64	Body mass index;	chr1:1797530	chr1:1891471~1892658:+
PRAD	cis	rs2882667	0.964	rs12055237	ENSG00000253404.1	AC034243.1	17.62	2.38e-53	1.57e-49	0.86	0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138971617	chr5:138744434~138753309:-
PRAD	cis	rs875971	0.83	rs4718358	ENSG00000226824.5	RP4-756H11.3	-17.62	2.42e-53	1.59e-49	-0.84	-0.64	Aortic root size;	chr7:66508681	chr7:66654538~66669855:+
PRAD	cis	rs875971	1	rs2420591	ENSG00000226824.5	RP4-756H11.3	-17.62	2.47e-53	1.62e-49	-0.83	-0.64	Aortic root size;	chr7:66447394	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.895	rs10755833	ENSG00000226824.5	RP4-756H11.3	-17.62	2.47e-53	1.62e-49	-0.83	-0.64	Aortic root size;	chr7:66448930	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.895	rs12698520	ENSG00000226824.5	RP4-756H11.3	-17.62	2.47e-53	1.62e-49	-0.83	-0.64	Aortic root size;	chr7:66453720	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.895	rs1833495	ENSG00000226824.5	RP4-756H11.3	-17.62	2.47e-53	1.62e-49	-0.83	-0.64	Aortic root size;	chr7:66456608	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.964	rs6945032	ENSG00000226824.5	RP4-756H11.3	-17.62	2.47e-53	1.62e-49	-0.83	-0.64	Aortic root size;	chr7:66457499	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.929	rs12673810	ENSG00000226824.5	RP4-756H11.3	-17.62	2.47e-53	1.62e-49	-0.83	-0.64	Aortic root size;	chr7:66458866	chr7:66654538~66669855:+
PRAD	cis	rs875971	1	rs35149210	ENSG00000226824.5	RP4-756H11.3	-17.62	2.47e-53	1.62e-49	-0.83	-0.64	Aortic root size;	chr7:66464938	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.929	rs34406470	ENSG00000226824.5	RP4-756H11.3	-17.62	2.47e-53	1.62e-49	-0.83	-0.64	Aortic root size;	chr7:66464969	chr7:66654538~66669855:+
PRAD	cis	rs875971	1	rs6961155	ENSG00000226824.5	RP4-756H11.3	-17.62	2.47e-53	1.62e-49	-0.83	-0.64	Aortic root size;	chr7:66468308	chr7:66654538~66669855:+
PRAD	cis	rs875971	1	rs7789768	ENSG00000226824.5	RP4-756H11.3	-17.62	2.47e-53	1.62e-49	-0.83	-0.64	Aortic root size;	chr7:66473993	chr7:66654538~66669855:+
PRAD	cis	rs875971	1	rs1363055	ENSG00000226824.5	RP4-756H11.3	-17.62	2.47e-53	1.62e-49	-0.83	-0.64	Aortic root size;	chr7:66478288	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.964	rs9691480	ENSG00000226824.5	RP4-756H11.3	-17.62	2.47e-53	1.62e-49	-0.83	-0.64	Aortic root size;	chr7:66479319	chr7:66654538~66669855:+
PRAD	cis	rs875971	1	rs7789554	ENSG00000226824.5	RP4-756H11.3	-17.62	2.47e-53	1.62e-49	-0.83	-0.64	Aortic root size;	chr7:66481051	chr7:66654538~66669855:+
PRAD	cis	rs875971	1	rs4717300	ENSG00000226824.5	RP4-756H11.3	-17.62	2.47e-53	1.62e-49	-0.83	-0.64	Aortic root size;	chr7:66482393	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.895	rs1974769	ENSG00000226824.5	RP4-756H11.3	-17.62	2.47e-53	1.62e-49	-0.83	-0.64	Aortic root size;	chr7:66485627	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.895	rs6460300	ENSG00000226824.5	RP4-756H11.3	-17.62	2.47e-53	1.62e-49	-0.83	-0.64	Aortic root size;	chr7:66487937	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.862	rs7803416	ENSG00000226824.5	RP4-756H11.3	-17.62	2.47e-53	1.62e-49	-0.83	-0.64	Aortic root size;	chr7:66489212	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.862	rs1981799	ENSG00000226824.5	RP4-756H11.3	-17.62	2.47e-53	1.62e-49	-0.83	-0.64	Aortic root size;	chr7:66490572	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.964	rs2277911	ENSG00000226824.5	RP4-756H11.3	-17.62	2.47e-53	1.62e-49	-0.83	-0.64	Aortic root size;	chr7:66493638	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.965	rs7794930	ENSG00000226824.5	RP4-756H11.3	17.61	2.58e-53	1.69e-49	0.84	0.64	Aortic root size;	chr7:66313559	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.867	rs1002053	ENSG00000226824.5	RP4-756H11.3	17.61	2.59e-53	1.7e-49	0.83	0.64	Aortic root size;	chr7:66333558	chr7:66654538~66669855:+
PRAD	cis	rs875971	1	rs6460292	ENSG00000226824.5	RP4-756H11.3	17.61	2.59e-53	1.7e-49	0.83	0.64	Aortic root size;	chr7:66345088	chr7:66654538~66669855:+
PRAD	cis	rs875971	1	rs6979382	ENSG00000226824.5	RP4-756H11.3	-17.61	2.6e-53	1.71e-49	-0.84	-0.64	Aortic root size;	chr7:66421388	chr7:66654538~66669855:+
PRAD	cis	rs875971	1	rs6961990	ENSG00000226824.5	RP4-756H11.3	-17.61	2.6e-53	1.71e-49	-0.84	-0.64	Aortic root size;	chr7:66423583	chr7:66654538~66669855:+
PRAD	cis	rs9322193	0.504	rs7771014	ENSG00000223701.3	RAET1E-AS1	17.61	2.65e-53	1.74e-49	0.86	0.64	Lung cancer;	chr6:149884310	chr6:149884431~149919508:+
PRAD	cis	rs801193	0.548	rs2659904	ENSG00000226824.5	RP4-756H11.3	-17.6	2.89e-53	1.89e-49	-0.87	-0.64	Aortic root size;	chr7:66713615	chr7:66654538~66669855:+
PRAD	cis	rs992157	0.798	rs2382817	ENSG00000261338.2	RP11-378A13.1	17.6	3.03e-53	1.98e-49	0.71	0.64	Colorectal cancer;	chr2:218286495	chr2:218255319~218257366:+
PRAD	cis	rs62229266	0.804	rs2835241	ENSG00000231106.2	LINC01436	-17.58	3.51e-53	2.29e-49	-0.8	-0.64	Mitral valve prolapse;	chr21:36039082	chr21:36005338~36007838:+
PRAD	cis	rs875971	1	rs2077593	ENSG00000226824.5	RP4-756H11.3	-17.58	3.54e-53	2.31e-49	-0.83	-0.64	Aortic root size;	chr7:66427543	chr7:66654538~66669855:+
PRAD	cis	rs875971	1	rs4717292	ENSG00000226824.5	RP4-756H11.3	-17.58	3.54e-53	2.31e-49	-0.83	-0.64	Aortic root size;	chr7:66430611	chr7:66654538~66669855:+
PRAD	cis	rs875971	1	rs7781698	ENSG00000226824.5	RP4-756H11.3	-17.58	3.66e-53	2.39e-49	-0.83	-0.64	Aortic root size;	chr7:66431325	chr7:66654538~66669855:+
PRAD	cis	rs12439619	0.921	rs56042848	ENSG00000278603.1	RP13-608F4.5	17.58	3.72e-53	2.42e-49	0.91	0.64	Intelligence (multi-trait analysis);	chr15:82235244	chr15:82472203~82472426:+
PRAD	cis	rs2283792	0.73	rs894095	ENSG00000224086.5	LL22NC03-86G7.1	-17.57	3.82e-53	2.49e-49	-0.75	-0.64	Multiple sclerosis;	chr22:21928404	chr22:21938293~21977632:+
PRAD	cis	rs11673344	0.526	rs17305193	ENSG00000226686.6	LINC01535	17.57	3.99e-53	2.6e-49	0.86	0.64	Obesity-related traits;	chr19:37598764	chr19:37251912~37265535:+
PRAD	cis	rs875971	1	rs6958271	ENSG00000226824.5	RP4-756H11.3	-17.57	4.01e-53	2.61e-49	-0.84	-0.64	Aortic root size;	chr7:66514344	chr7:66654538~66669855:+
PRAD	cis	rs875971	1	rs6958277	ENSG00000226824.5	RP4-756H11.3	-17.57	4.01e-53	2.61e-49	-0.84	-0.64	Aortic root size;	chr7:66514362	chr7:66654538~66669855:+
PRAD	cis	rs801193	0.636	rs2659895	ENSG00000226824.5	RP4-756H11.3	-17.56	4.25e-53	2.77e-49	-0.86	-0.64	Aortic root size;	chr7:66731484	chr7:66654538~66669855:+
PRAD	cis	rs9660180	0.836	rs72634845	ENSG00000231050.1	RP1-140A9.1	17.56	4.58e-53	2.98e-49	0.72	0.64	Body mass index;	chr1:1773460	chr1:1891471~1892658:+
PRAD	cis	rs7174755	0.884	rs11634026	ENSG00000260657.2	RP11-315D16.4	17.56	4.62e-53	3e-49	0.79	0.64	Major depressive disorder;	chr15:68305668	chr15:68267792~68277994:-
PRAD	cis	rs801193	0.591	rs2707839	ENSG00000226824.5	RP4-756H11.3	-17.55	4.77e-53	3.1e-49	-0.86	-0.64	Aortic root size;	chr7:66728097	chr7:66654538~66669855:+
PRAD	cis	rs992157	0.835	rs6707559	ENSG00000261338.2	RP11-378A13.1	17.55	5e-53	3.24e-49	0.71	0.64	Colorectal cancer;	chr2:218278050	chr2:218255319~218257366:+
PRAD	cis	rs11155671	0.53	rs6935829	ENSG00000268592.3	RAET1E-AS1	17.54	5.27e-53	3.41e-49	0.88	0.64	Testicular germ cell tumor;	chr6:149896675	chr6:149863494~149919507:+
PRAD	cis	rs875971	0.964	rs12668936	ENSG00000226824.5	RP4-756H11.3	-17.54	5.45e-53	3.53e-49	-0.83	-0.64	Aortic root size;	chr7:66449417	chr7:66654538~66669855:+
PRAD	cis	rs62229266	0.771	rs11701590	ENSG00000231106.2	LINC01436	17.54	5.54e-53	3.59e-49	0.81	0.64	Mitral valve prolapse;	chr21:36012432	chr21:36005338~36007838:+
PRAD	cis	rs200895692	1	rs200895692	ENSG00000227533.4	SLC2A1-AS1	17.54	5.68e-53	3.67e-49	0.91	0.64	Monocyte count;	chr1:42956299	chr1:42959049~42983358:+
PRAD	cis	rs875971	0.964	rs778735	ENSG00000226824.5	RP4-756H11.3	-17.53	6.04e-53	3.9e-49	-0.83	-0.63	Aortic root size;	chr7:66349822	chr7:66654538~66669855:+
PRAD	cis	rs992157	0.798	rs4996257	ENSG00000261338.2	RP11-378A13.1	17.52	6.51e-53	4.2e-49	0.72	0.63	Colorectal cancer;	chr2:218298113	chr2:218255319~218257366:+
PRAD	cis	rs9660180	0.967	rs6603802	ENSG00000231050.1	RP1-140A9.1	17.52	6.65e-53	4.29e-49	0.72	0.63	Body mass index;	chr1:1881082	chr1:1891471~1892658:+
PRAD	cis	rs62229266	0.773	rs878606	ENSG00000231106.2	LINC01436	17.52	6.74e-53	4.35e-49	0.81	0.63	Mitral valve prolapse;	chr21:36034394	chr21:36005338~36007838:+
PRAD	cis	rs7174755	0.923	rs898590	ENSG00000260657.2	RP11-315D16.4	-17.52	6.85e-53	4.42e-49	-0.78	-0.63	Major depressive disorder;	chr15:68311837	chr15:68267792~68277994:-
PRAD	cis	rs7174755	0.923	rs9672383	ENSG00000260657.2	RP11-315D16.4	17.52	6.89e-53	4.44e-49	0.77	0.63	Major depressive disorder;	chr15:68306731	chr15:68267792~68277994:-
PRAD	cis	rs2739330	0.76	rs5760095	ENSG00000273295.1	AP000350.5	17.51	7.09e-53	4.57e-49	0.77	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23901432~23907068:-
PRAD	cis	rs1153858	0.723	rs1719238	ENSG00000259520.4	CTD-2651B20.3	17.5	8.01e-53	5.14e-49	0.87	0.63	Homoarginine levels;	chr15:45302568	chr15:45251580~45279251:-
PRAD	cis	rs1153858	0.723	rs4580098	ENSG00000259520.4	CTD-2651B20.3	-17.5	8.01e-53	5.14e-49	-0.87	-0.63	Homoarginine levels;	chr15:45304711	chr15:45251580~45279251:-
PRAD	cis	rs7174755	0.923	rs11634149	ENSG00000260657.2	RP11-315D16.4	17.5	8.18e-53	5.24e-49	0.77	0.63	Major depressive disorder;	chr15:68306072	chr15:68267792~68277994:-
PRAD	cis	rs801193	0.66	rs10950049	ENSG00000226824.5	RP4-756H11.3	-17.5	8.45e-53	5.42e-49	-0.86	-0.63	Aortic root size;	chr7:66765873	chr7:66654538~66669855:+
PRAD	cis	rs801193	0.66	rs1016265	ENSG00000226824.5	RP4-756H11.3	-17.5	8.67e-53	5.55e-49	-0.86	-0.63	Aortic root size;	chr7:66749580	chr7:66654538~66669855:+
PRAD	cis	rs801193	0.66	rs4610622	ENSG00000226824.5	RP4-756H11.3	-17.49	9.19e-53	5.88e-49	-0.86	-0.63	Aortic root size;	chr7:66759510	chr7:66654538~66669855:+
PRAD	cis	rs62229266	0.654	rs62230787	ENSG00000231106.2	LINC01436	17.48	9.72e-53	6.21e-49	0.82	0.63	Mitral valve prolapse;	chr21:36004182	chr21:36005338~36007838:+
PRAD	cis	rs4423214	0.65	rs2186777	ENSG00000254682.1	RP11-660L16.2	17.48	9.79e-53	6.25e-49	0.86	0.63	Vitamin D levels;	chr11:71508757	chr11:71448674~71452157:+
PRAD	cis	rs801193	0.613	rs2659900	ENSG00000226824.5	RP4-756H11.3	-17.48	1.01e-52	6.42e-49	-0.86	-0.63	Aortic root size;	chr7:66719456	chr7:66654538~66669855:+
PRAD	cis	rs801193	0.66	rs974239	ENSG00000226824.5	RP4-756H11.3	-17.47	1.15e-52	7.34e-49	-0.86	-0.63	Aortic root size;	chr7:66748504	chr7:66654538~66669855:+
PRAD	cis	rs875971	1	rs1981798	ENSG00000226824.5	RP4-756H11.3	-17.46	1.27e-52	8.04e-49	-0.83	-0.63	Aortic root size;	chr7:66489916	chr7:66654538~66669855:+
PRAD	cis	rs992157	0.835	rs2271543	ENSG00000261338.2	RP11-378A13.1	-17.46	1.31e-52	8.3e-49	-0.71	-0.63	Colorectal cancer;	chr2:218277768	chr2:218255319~218257366:+
PRAD	cis	rs9660180	0.967	rs61422524	ENSG00000231050.1	RP1-140A9.1	17.46	1.33e-52	8.43e-49	0.72	0.63	Body mass index;	chr1:1836126	chr1:1891471~1892658:+
PRAD	cis	rs73086581	0.741	rs17212649	ENSG00000229539.1	RP11-119B16.2	17.45	1.38e-52	8.72e-49	1.12	0.63	Response to antidepressants in depression;	chr20:3872446	chr20:3888239~3888868:-
PRAD	cis	rs801193	0.66	rs1962050	ENSG00000226824.5	RP4-756H11.3	17.44	1.56e-52	9.81e-49	0.85	0.63	Aortic root size;	chr7:66775021	chr7:66654538~66669855:+
PRAD	cis	rs2739330	0.76	rs1007888	ENSG00000218537.1	MIF-AS1	17.44	1.58e-52	9.97e-49	0.84	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23894426~23898930:-
PRAD	cis	rs9660180	0.78	rs12038111	ENSG00000231050.1	RP1-140A9.1	17.44	1.63e-52	1.03e-48	0.72	0.63	Body mass index;	chr1:1772410	chr1:1891471~1892658:+
PRAD	cis	rs9660180	0.836	rs12038134	ENSG00000231050.1	RP1-140A9.1	17.44	1.63e-52	1.03e-48	0.72	0.63	Body mass index;	chr1:1772426	chr1:1891471~1892658:+
PRAD	cis	rs992157	0.835	rs2292551	ENSG00000261338.2	RP11-378A13.1	-17.43	1.71e-52	1.07e-48	-0.71	-0.63	Colorectal cancer;	chr2:218278506	chr2:218255319~218257366:+
PRAD	cis	rs992157	0.835	rs12987180	ENSG00000261338.2	RP11-378A13.1	-17.43	1.71e-52	1.07e-48	-0.71	-0.63	Colorectal cancer;	chr2:218279366	chr2:218255319~218257366:+
PRAD	cis	rs992157	0.835	rs4674283	ENSG00000261338.2	RP11-378A13.1	-17.43	1.71e-52	1.07e-48	-0.71	-0.63	Colorectal cancer;	chr2:218279531	chr2:218255319~218257366:+
PRAD	cis	rs992157	0.835	rs2045434	ENSG00000261338.2	RP11-378A13.1	-17.43	1.71e-52	1.07e-48	-0.71	-0.63	Colorectal cancer;	chr2:218279775	chr2:218255319~218257366:+
PRAD	cis	rs2739330	0.703	rs5760112	ENSG00000218537.1	MIF-AS1	17.42	1.83e-52	1.15e-48	0.84	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23894426~23898930:-
PRAD	cis	rs62229266	0.74	rs4817759	ENSG00000231106.2	LINC01436	17.42	1.87e-52	1.17e-48	0.8	0.63	Mitral valve prolapse;	chr21:36017261	chr21:36005338~36007838:+
PRAD	cis	rs62229266	0.771	rs2835232	ENSG00000231106.2	LINC01436	17.42	1.87e-52	1.17e-48	0.8	0.63	Mitral valve prolapse;	chr21:36021129	chr21:36005338~36007838:+
PRAD	cis	rs62229266	0.74	rs2835233	ENSG00000231106.2	LINC01436	17.42	1.87e-52	1.17e-48	0.8	0.63	Mitral valve prolapse;	chr21:36021284	chr21:36005338~36007838:+
PRAD	cis	rs1153858	0.668	rs63603561	ENSG00000259520.4	CTD-2651B20.3	17.42	1.9e-52	1.19e-48	0.87	0.63	Homoarginine levels;	chr15:45301125	chr15:45251580~45279251:-
PRAD	cis	rs992157	0.866	rs2292554	ENSG00000261338.2	RP11-378A13.1	-17.42	1.96e-52	1.23e-48	-0.71	-0.63	Colorectal cancer;	chr2:218282145	chr2:218255319~218257366:+
PRAD	cis	rs992157	0.835	rs7585702	ENSG00000261338.2	RP11-378A13.1	-17.42	2.02e-52	1.27e-48	-0.71	-0.63	Colorectal cancer;	chr2:218281884	chr2:218255319~218257366:+
PRAD	cis	rs992157	0.835	rs10932769	ENSG00000261338.2	RP11-378A13.1	-17.42	2.02e-52	1.27e-48	-0.71	-0.63	Colorectal cancer;	chr2:218282522	chr2:218255319~218257366:+
PRAD	cis	rs875971	1	rs709597	ENSG00000226824.5	RP4-756H11.3	17.41	2.06e-52	1.29e-48	0.83	0.63	Aortic root size;	chr7:66360996	chr7:66654538~66669855:+
PRAD	cis	rs62229266	0.804	rs2835231	ENSG00000231106.2	LINC01436	17.4	2.26e-52	1.42e-48	0.79	0.63	Mitral valve prolapse;	chr21:36018300	chr21:36005338~36007838:+
PRAD	cis	rs62229266	0.771	rs62230790	ENSG00000231106.2	LINC01436	17.4	2.34e-52	1.47e-48	0.8	0.63	Mitral valve prolapse;	chr21:36016613	chr21:36005338~36007838:+
PRAD	cis	rs4423214	1	rs11233746	ENSG00000254682.1	RP11-660L16.2	17.4	2.41e-52	1.51e-48	0.83	0.63	Vitamin D levels;	chr11:71460394	chr11:71448674~71452157:+
PRAD	cis	rs992157	0.835	rs6729058	ENSG00000261338.2	RP11-378A13.1	-17.39	2.57e-52	1.61e-48	-0.71	-0.63	Colorectal cancer;	chr2:218283646	chr2:218255319~218257366:+
PRAD	cis	rs992157	0.804	rs7559525	ENSG00000261338.2	RP11-378A13.1	-17.39	2.57e-52	1.61e-48	-0.71	-0.63	Colorectal cancer;	chr2:218285584	chr2:218255319~218257366:+
PRAD	cis	rs992157	0.835	rs13005100	ENSG00000261338.2	RP11-378A13.1	-17.39	2.57e-52	1.61e-48	-0.71	-0.63	Colorectal cancer;	chr2:218287044	chr2:218255319~218257366:+
PRAD	cis	rs992157	0.835	rs13031757	ENSG00000261338.2	RP11-378A13.1	-17.39	2.57e-52	1.61e-48	-0.71	-0.63	Colorectal cancer;	chr2:218287203	chr2:218255319~218257366:+
PRAD	cis	rs2019137	0.56	rs11123172	ENSG00000189223.12	PAX8-AS1	17.39	2.61e-52	1.63e-48	0.84	0.63	Lymphocyte counts;	chr2:113226726	chr2:113211522~113276581:+
PRAD	cis	rs2882667	0.964	rs11739351	ENSG00000253404.1	AC034243.1	17.38	2.97e-52	1.85e-48	0.85	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138976053	chr5:138744434~138753309:-
PRAD	cis	rs2019137	0.56	rs10175462	ENSG00000189223.12	PAX8-AS1	-17.37	3.23e-52	2.01e-48	-0.84	-0.63	Lymphocyte counts;	chr2:113230915	chr2:113211522~113276581:+
PRAD	cis	rs2283792	0.73	rs738858	ENSG00000224086.5	LL22NC03-86G7.1	-17.37	3.29e-52	2.05e-48	-0.74	-0.63	Multiple sclerosis;	chr22:21926544	chr22:21938293~21977632:+
PRAD	cis	rs992157	0.717	rs3817266	ENSG00000261338.2	RP11-378A13.1	-17.37	3.33e-52	2.07e-48	-0.71	-0.63	Colorectal cancer;	chr2:218277871	chr2:218255319~218257366:+
PRAD	cis	rs992157	0.835	rs4674282	ENSG00000261338.2	RP11-378A13.1	-17.36	3.53e-52	2.19e-48	-0.7	-0.63	Colorectal cancer;	chr2:218279507	chr2:218255319~218257366:+
PRAD	cis	rs9326248	0.861	rs4938343	ENSG00000254851.1	RP11-109L13.1	-17.36	3.68e-52	2.28e-48	-1.03	-0.63	Blood protein levels;	chr11:117132812	chr11:117135528~117138582:+
PRAD	cis	rs11673344	0.615	rs2921561	ENSG00000226686.6	LINC01535	17.36	3.73e-52	2.31e-48	0.81	0.63	Obesity-related traits;	chr19:37348969	chr19:37251912~37265535:+
PRAD	cis	rs875971	0.895	rs7788984	ENSG00000226824.5	RP4-756H11.3	-17.35	3.83e-52	2.38e-48	-0.83	-0.63	Aortic root size;	chr7:66450629	chr7:66654538~66669855:+
PRAD	cis	rs801193	0.66	rs2659914	ENSG00000226824.5	RP4-756H11.3	-17.35	3.86e-52	2.39e-48	-0.85	-0.63	Aortic root size;	chr7:66691927	chr7:66654538~66669855:+
PRAD	cis	rs992157	0.835	rs2292555	ENSG00000261338.2	RP11-378A13.1	-17.35	3.87e-52	2.4e-48	-0.72	-0.63	Colorectal cancer;	chr2:218282159	chr2:218255319~218257366:+
PRAD	cis	rs2739330	0.734	rs2000467	ENSG00000225282.1	AP000350.6	-17.34	4.44e-52	2.75e-48	-0.83	-0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23926900~23929574:+
PRAD	cis	rs992157	0.717	rs11692780	ENSG00000261338.2	RP11-378A13.1	-17.34	4.45e-52	2.75e-48	-0.71	-0.63	Colorectal cancer;	chr2:218284440	chr2:218255319~218257366:+
PRAD	cis	rs875971	0.964	rs6945019	ENSG00000226824.5	RP4-756H11.3	-17.34	4.59e-52	2.83e-48	-0.83	-0.63	Aortic root size;	chr7:66457471	chr7:66654538~66669855:+
PRAD	cis	rs1799949	0.929	rs799906	ENSG00000198496.9	NBR2	-17.33	4.94e-52	3.05e-48	-0.82	-0.63	Menopause (age at onset);	chr17:43126099	chr17:43125610~43153671:+
PRAD	cis	rs1799949	0.965	rs799908	ENSG00000198496.9	NBR2	-17.33	4.94e-52	3.05e-48	-0.82	-0.63	Menopause (age at onset);	chr17:43126899	chr17:43125610~43153671:+
PRAD	cis	rs1799949	0.93	rs1554063	ENSG00000198496.9	NBR2	-17.33	4.94e-52	3.05e-48	-0.82	-0.63	Menopause (age at onset);	chr17:43135128	chr17:43125610~43153671:+
PRAD	cis	rs992157	0.775	rs1877714	ENSG00000261338.2	RP11-378A13.1	-17.33	5.13e-52	3.16e-48	-0.71	-0.63	Colorectal cancer;	chr2:218270205	chr2:218255319~218257366:+
PRAD	cis	rs992157	0.835	rs11677953	ENSG00000261338.2	RP11-378A13.1	-17.33	5.17e-52	3.19e-48	-0.71	-0.63	Colorectal cancer;	chr2:218256940	chr2:218255319~218257366:+
PRAD	cis	rs2739330	0.731	rs4822450	ENSG00000218537.1	MIF-AS1	17.31	6.3e-52	3.87e-48	0.84	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23894426~23898930:-
PRAD	cis	rs992157	0.835	rs12987219	ENSG00000261338.2	RP11-378A13.1	-17.3	6.6e-52	4.05e-48	-0.71	-0.63	Colorectal cancer;	chr2:218279426	chr2:218255319~218257366:+
PRAD	cis	rs7174755	0.962	rs4777034	ENSG00000260657.2	RP11-315D16.4	-17.29	7.4e-52	4.54e-48	-0.76	-0.63	Major depressive disorder;	chr15:68309546	chr15:68267792~68277994:-
PRAD	cis	rs7174755	0.962	rs1020842	ENSG00000260657.2	RP11-315D16.4	-17.29	7.4e-52	4.54e-48	-0.76	-0.63	Major depressive disorder;	chr15:68309840	chr15:68267792~68277994:-
PRAD	cis	rs2455601	0.638	rs2742484	ENSG00000254860.4	TMEM9B-AS1	17.28	8.35e-52	5.1e-48	0.73	0.63	Schizophrenia;	chr11:8966536	chr11:8964675~8977527:+
PRAD	cis	rs2455601	0.638	rs2248245	ENSG00000254860.4	TMEM9B-AS1	17.28	8.35e-52	5.1e-48	0.73	0.63	Schizophrenia;	chr11:8966803	chr11:8964675~8977527:+
PRAD	cis	rs875971	1	rs7792762	ENSG00000226824.5	RP4-756H11.3	-17.28	8.43e-52	5.15e-48	-0.83	-0.63	Aortic root size;	chr7:66539151	chr7:66654538~66669855:+
PRAD	cis	rs1799949	0.965	rs8067269	ENSG00000198496.9	NBR2	-17.27	9.24e-52	5.64e-48	-0.81	-0.63	Menopause (age at onset);	chr17:43083782	chr17:43125610~43153671:+
PRAD	cis	rs2486288	0.656	rs12908581	ENSG00000259520.4	CTD-2651B20.3	17.26	1e-51	6.13e-48	0.82	0.63	Glomerular filtration rate;	chr15:45256437	chr15:45251580~45279251:-
PRAD	cis	rs73086581	0.687	rs73082600	ENSG00000229539.1	RP11-119B16.2	17.25	1.08e-51	6.61e-48	1.12	0.63	Response to antidepressants in depression;	chr20:3863718	chr20:3888239~3888868:-
PRAD	cis	rs12439619	0.705	rs17354185	ENSG00000278603.1	RP13-608F4.5	-17.25	1.12e-51	6.83e-48	-0.99	-0.63	Intelligence (multi-trait analysis);	chr15:82133829	chr15:82472203~82472426:+
PRAD	cis	rs11673344	0.526	rs17305823	ENSG00000226686.6	LINC01535	-17.24	1.27e-51	7.74e-48	-0.85	-0.63	Obesity-related traits;	chr19:37644145	chr19:37251912~37265535:+
PRAD	cis	rs992157	0.775	rs7559428	ENSG00000261338.2	RP11-378A13.1	-17.23	1.37e-51	8.36e-48	-0.71	-0.63	Colorectal cancer;	chr2:218285515	chr2:218255319~218257366:+
PRAD	cis	rs7188445	0.932	rs17767742	ENSG00000261390.4	RP11-345M22.2	-17.23	1.38e-51	8.41e-48	-0.77	-0.63	Urate levels;	chr16:79715108	chr16:79715232~79770563:-
PRAD	cis	rs2019137	0.56	rs4849179	ENSG00000189223.12	PAX8-AS1	-17.23	1.47e-51	8.95e-48	-0.84	-0.63	Lymphocyte counts;	chr2:113227593	chr2:113211522~113276581:+
PRAD	cis	rs11155671	0.53	rs9371215	ENSG00000268592.3	RAET1E-AS1	17.22	1.58e-51	9.58e-48	0.87	0.63	Testicular germ cell tumor;	chr6:149873162	chr6:149863494~149919507:+
PRAD	cis	rs11155671	0.53	rs7756850	ENSG00000268592.3	RAET1E-AS1	17.21	1.76e-51	1.07e-47	0.86	0.63	Testicular germ cell tumor;	chr6:149891460	chr6:149863494~149919507:+
PRAD	cis	rs11155671	0.53	rs9371542	ENSG00000268592.3	RAET1E-AS1	17.21	1.76e-51	1.07e-47	0.86	0.63	Testicular germ cell tumor;	chr6:149891949	chr6:149863494~149919507:+
PRAD	cis	rs11155671	0.53	rs9371223	ENSG00000268592.3	RAET1E-AS1	17.21	1.76e-51	1.07e-47	0.86	0.63	Testicular germ cell tumor;	chr6:149893670	chr6:149863494~149919507:+
PRAD	cis	rs950027	0.549	rs11636114	ENSG00000259520.4	CTD-2651B20.3	-17.21	1.78e-51	1.08e-47	-0.79	-0.63	Response to fenofibrate (adiponectin levels);	chr15:45309214	chr15:45251580~45279251:-
PRAD	cis	rs11155671	0.53	rs9371544	ENSG00000268592.3	RAET1E-AS1	17.21	1.81e-51	1.1e-47	0.86	0.63	Testicular germ cell tumor;	chr6:149896224	chr6:149863494~149919507:+
PRAD	cis	rs1799949	0.894	rs71367985	ENSG00000198496.9	NBR2	-17.19	2.05e-51	1.24e-47	-0.82	-0.63	Menopause (age at onset);	chr17:43222443	chr17:43125610~43153671:+
PRAD	cis	rs11155671	0.53	rs2342769	ENSG00000268592.3	RAET1E-AS1	17.19	2.1e-51	1.27e-47	0.86	0.63	Testicular germ cell tumor;	chr6:149895371	chr6:149863494~149919507:+
PRAD	cis	rs11155671	0.53	rs2342770	ENSG00000268592.3	RAET1E-AS1	17.19	2.1e-51	1.27e-47	0.86	0.63	Testicular germ cell tumor;	chr6:149895549	chr6:149863494~149919507:+
PRAD	cis	rs2739330	0.76	rs5751761	ENSG00000225282.1	AP000350.6	-17.18	2.3e-51	1.39e-47	-0.79	-0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23926900~23929574:+
PRAD	cis	rs858239	1	rs156421	ENSG00000230658.1	KLHL7-AS1	17.18	2.44e-51	1.47e-47	0.76	0.63	Cerebrospinal fluid biomarker levels;	chr7:23272868	chr7:23101228~23105703:-
PRAD	cis	rs1799949	0.965	rs799916	ENSG00000198496.9	NBR2	17.17	2.59e-51	1.56e-47	0.82	0.63	Menopause (age at onset);	chr17:43091173	chr17:43125610~43153671:+
PRAD	cis	rs62229266	0.804	rs2255858	ENSG00000231106.2	LINC01436	17.17	2.67e-51	1.6e-47	0.8	0.63	Mitral valve prolapse;	chr21:36040454	chr21:36005338~36007838:+
PRAD	cis	rs62229266	0.804	rs12483151	ENSG00000231106.2	LINC01436	17.17	2.67e-51	1.6e-47	0.8	0.63	Mitral valve prolapse;	chr21:36047280	chr21:36005338~36007838:+
PRAD	cis	rs62229266	0.804	rs880221	ENSG00000231106.2	LINC01436	17.17	2.67e-51	1.6e-47	0.8	0.63	Mitral valve prolapse;	chr21:36048487	chr21:36005338~36007838:+
PRAD	cis	rs62229266	0.804	rs56279140	ENSG00000231106.2	LINC01436	17.17	2.67e-51	1.6e-47	0.8	0.63	Mitral valve prolapse;	chr21:36052063	chr21:36005338~36007838:+
PRAD	cis	rs62229266	0.804	rs62230821	ENSG00000231106.2	LINC01436	17.17	2.67e-51	1.6e-47	0.8	0.63	Mitral valve prolapse;	chr21:36052818	chr21:36005338~36007838:+
PRAD	cis	rs62229266	0.804	rs2835259	ENSG00000231106.2	LINC01436	17.17	2.67e-51	1.6e-47	0.8	0.63	Mitral valve prolapse;	chr21:36053004	chr21:36005338~36007838:+
PRAD	cis	rs7188445	0.932	rs11150191	ENSG00000261390.4	RP11-345M22.2	-17.17	2.68e-51	1.61e-47	-0.77	-0.63	Urate levels;	chr16:79700390	chr16:79715232~79770563:-
PRAD	cis	rs11673344	0.734	rs320887	ENSG00000226686.6	LINC01535	-17.17	2.72e-51	1.63e-47	-0.87	-0.63	Obesity-related traits;	chr19:37202536	chr19:37251912~37265535:+
PRAD	cis	rs1153858	0.621	rs1719237	ENSG00000259520.4	CTD-2651B20.3	-17.15	3.12e-51	1.87e-47	-0.84	-0.63	Homoarginine levels;	chr15:45287624	chr15:45251580~45279251:-
PRAD	cis	rs992157	0.835	rs34353396	ENSG00000261338.2	RP11-378A13.1	-17.14	3.5e-51	2.09e-47	-0.7	-0.63	Colorectal cancer;	chr2:218289259	chr2:218255319~218257366:+
PRAD	cis	rs875971	1	rs1167612	ENSG00000226824.5	RP4-756H11.3	17.14	3.52e-51	2.1e-47	0.84	0.63	Aortic root size;	chr7:66102989	chr7:66654538~66669855:+
PRAD	cis	rs4423214	0.57	rs7118246	ENSG00000254682.1	RP11-660L16.2	17.14	3.59e-51	2.14e-47	0.85	0.63	Vitamin D levels;	chr11:71520078	chr11:71448674~71452157:+
PRAD	cis	rs2739330	0.732	rs5760175	ENSG00000273295.1	AP000350.5	17.14	3.63e-51	2.17e-47	0.75	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23901432~23907068:-
PRAD	cis	rs992157	0.835	rs10932768	ENSG00000261338.2	RP11-378A13.1	-17.14	3.74e-51	2.23e-47	-0.71	-0.63	Colorectal cancer;	chr2:218281476	chr2:218255319~218257366:+
PRAD	cis	rs62229266	0.804	rs11088331	ENSG00000231106.2	LINC01436	17.13	3.8e-51	2.26e-47	0.8	0.63	Mitral valve prolapse;	chr21:36049574	chr21:36005338~36007838:+
PRAD	cis	rs1799949	0.965	rs2236762	ENSG00000198496.9	NBR2	-17.13	3.88e-51	2.31e-47	-0.81	-0.63	Menopause (age at onset);	chr17:43074658	chr17:43125610~43153671:+
PRAD	cis	rs2739330	0.731	rs5751792	ENSG00000273295.1	AP000350.5	17.12	4.51e-51	2.68e-47	0.74	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23901432~23907068:-
PRAD	cis	rs2739330	0.761	rs5760176	ENSG00000273295.1	AP000350.5	-17.12	4.51e-51	2.68e-47	-0.74	-0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23901432~23907068:-
PRAD	cis	rs875971	0.964	rs697969	ENSG00000226824.5	RP4-756H11.3	17.11	4.88e-51	2.89e-47	0.84	0.63	Aortic root size;	chr7:66093491	chr7:66654538~66669855:+
PRAD	cis	rs875971	1	rs1182882	ENSG00000226824.5	RP4-756H11.3	17.11	4.88e-51	2.89e-47	0.84	0.63	Aortic root size;	chr7:66097076	chr7:66654538~66669855:+
PRAD	cis	rs7174755	0.923	rs4777036	ENSG00000260657.2	RP11-315D16.4	-17.11	4.94e-51	2.93e-47	-0.77	-0.63	Major depressive disorder;	chr15:68313230	chr15:68267792~68277994:-
PRAD	cis	rs1799949	0.965	rs799917	ENSG00000198496.9	NBR2	-17.1	5.32e-51	3.15e-47	-0.82	-0.63	Menopause (age at onset);	chr17:43092919	chr17:43125610~43153671:+
PRAD	cis	rs1930961	0.85	rs5996945	ENSG00000272977.1	CTA-390C10.10	17.1	5.4e-51	3.19e-47	0.96	0.63	Bipolar disorder with mood-incongruent psychosis;	chr22:25479606	chr22:25476218~25479971:+
PRAD	cis	rs7188445	0.932	rs17767491	ENSG00000261390.4	RP11-345M22.2	-17.09	6.13e-51	3.61e-47	-0.77	-0.63	Urate levels;	chr16:79711590	chr16:79715232~79770563:-
PRAD	cis	rs1577917	0.839	rs6454492	ENSG00000203875.9	SNHG5	-17.09	6.22e-51	3.66e-47	-0.69	-0.63	Response to antipsychotic treatment;	chr6:85773496	chr6:85660950~85678736:-
PRAD	cis	rs2019137	0.539	rs6755040	ENSG00000189223.12	PAX8-AS1	-17.08	6.41e-51	3.77e-47	-0.83	-0.63	Lymphocyte counts;	chr2:113223560	chr2:113211522~113276581:+
PRAD	cis	rs2019137	0.539	rs4849177	ENSG00000189223.12	PAX8-AS1	-17.08	6.41e-51	3.77e-47	-0.83	-0.63	Lymphocyte counts;	chr2:113225007	chr2:113211522~113276581:+
PRAD	cis	rs11155671	0.53	rs9968871	ENSG00000268592.3	RAET1E-AS1	17.08	6.79e-51	3.98e-47	0.86	0.63	Testicular germ cell tumor;	chr6:149888060	chr6:149863494~149919507:+
PRAD	cis	rs11155671	0.53	rs9969044	ENSG00000268592.3	RAET1E-AS1	17.08	6.79e-51	3.98e-47	0.86	0.63	Testicular germ cell tumor;	chr6:149888068	chr6:149863494~149919507:+
PRAD	cis	rs875971	1	rs6946143	ENSG00000226824.5	RP4-756H11.3	-17.07	7.26e-51	4.25e-47	-0.82	-0.62	Aortic root size;	chr7:66114735	chr7:66654538~66669855:+
PRAD	cis	rs2739330	0.76	rs1002286	ENSG00000218537.1	MIF-AS1	-17.07	7.44e-51	4.36e-47	-0.83	-0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23894426~23898930:-
PRAD	cis	rs7188445	1	rs11150189	ENSG00000261390.4	RP11-345M22.2	-17.07	7.69e-51	4.5e-47	-0.76	-0.62	Urate levels;	chr16:79700330	chr16:79715232~79770563:-
PRAD	cis	rs1577917	0.74	rs9353327	ENSG00000203875.9	SNHG5	-17.07	7.78e-51	4.56e-47	-0.68	-0.62	Response to antipsychotic treatment;	chr6:85684348	chr6:85660950~85678736:-
PRAD	cis	rs62229266	0.804	rs62230822	ENSG00000231106.2	LINC01436	17.04	9.88e-51	5.77e-47	0.79	0.62	Mitral valve prolapse;	chr21:36057647	chr21:36005338~36007838:+
PRAD	cis	rs992157	0.767	rs2014615	ENSG00000261338.2	RP11-378A13.1	17.03	1.15e-50	6.7e-47	0.69	0.62	Colorectal cancer;	chr2:218306468	chr2:218255319~218257366:+
PRAD	cis	rs4853012	0.775	rs12465641	ENSG00000217702.2	RP11-287D1.4	-17.01	1.35e-50	7.82e-47	-0.99	-0.62	Gestational age at birth (maternal effect);	chr2:74110588	chr2:74130583~74135395:+
PRAD	cis	rs11155671	0.53	rs7742993	ENSG00000268592.3	RAET1E-AS1	17	1.52e-50	8.81e-47	0.86	0.62	Testicular germ cell tumor;	chr6:149883959	chr6:149863494~149919507:+
PRAD	cis	rs992157	0.804	rs6758540	ENSG00000261338.2	RP11-378A13.1	-17	1.54e-50	8.96e-47	-0.7	-0.62	Colorectal cancer;	chr2:218273902	chr2:218255319~218257366:+
PRAD	cis	rs875971	1	rs10244498	ENSG00000226824.5	RP4-756H11.3	-17	1.59e-50	9.2e-47	-0.84	-0.62	Aortic root size;	chr7:66651069	chr7:66654538~66669855:+
PRAD	cis	rs875971	1	rs697970	ENSG00000226824.5	RP4-756H11.3	17	1.63e-50	9.45e-47	0.83	0.62	Aortic root size;	chr7:66095065	chr7:66654538~66669855:+
PRAD	cis	rs7208859	0.673	rs11651802	ENSG00000263531.1	RP13-753N3.1	16.99	1.64e-50	9.49e-47	1.31	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832642	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.673	rs17826219	ENSG00000263531.1	RP13-753N3.1	16.99	1.64e-50	9.49e-47	1.31	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834827	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.673	rs61223749	ENSG00000263531.1	RP13-753N3.1	16.99	1.64e-50	9.49e-47	1.31	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30836729	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.673	rs3764421	ENSG00000263531.1	RP13-753N3.1	16.99	1.64e-50	9.49e-47	1.31	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30840635	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs11651858	ENSG00000263531.1	RP13-753N3.1	16.99	1.64e-50	9.49e-47	1.31	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30843700	chr17:30863921~30864940:-
PRAD	cis	rs9322193	0.567	rs7747457	ENSG00000268592.3	RAET1E-AS1	16.98	1.85e-50	1.07e-46	0.85	0.62	Lung cancer;	chr6:149892366	chr6:149863494~149919507:+
PRAD	cis	rs17826219	0.706	rs9905827	ENSG00000263531.1	RP13-753N3.1	16.98	2.01e-50	1.16e-46	1.31	0.62	Body mass index;	chr17:30865150	chr17:30863921~30864940:-
PRAD	cis	rs992157	0.798	rs7557709	ENSG00000261338.2	RP11-378A13.1	16.97	2.02e-50	1.17e-46	0.7	0.62	Colorectal cancer;	chr2:218302806	chr2:218255319~218257366:+
PRAD	cis	rs2739330	0.685	rs4822453	ENSG00000218537.1	MIF-AS1	16.96	2.42e-50	1.4e-46	0.82	0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23894426~23898930:-
PRAD	cis	rs62229266	0.682	rs11700546	ENSG00000231106.2	LINC01436	16.95	2.52e-50	1.45e-46	0.82	0.62	Mitral valve prolapse;	chr21:35998841	chr21:36005338~36007838:+
PRAD	cis	rs7188445	1	rs7188445	ENSG00000261390.4	RP11-345M22.2	-16.95	2.57e-50	1.48e-46	-0.75	-0.62	Urate levels;	chr16:79701090	chr16:79715232~79770563:-
PRAD	cis	rs1153858	0.621	rs2687512	ENSG00000259520.4	CTD-2651B20.3	16.95	2.64e-50	1.52e-46	0.85	0.62	Homoarginine levels;	chr15:45289297	chr15:45251580~45279251:-
PRAD	cis	rs801193	0.636	rs10233806	ENSG00000226824.5	RP4-756H11.3	16.93	3.28e-50	1.89e-46	0.84	0.62	Aortic root size;	chr7:66653261	chr7:66654538~66669855:+
PRAD	cis	rs11155671	0.53	rs4458704	ENSG00000223701.3	RAET1E-AS1	16.93	3.38e-50	1.95e-46	0.87	0.62	Testicular germ cell tumor;	chr6:149911743	chr6:149884431~149919508:+
PRAD	cis	rs7208859	0.673	rs36056619	ENSG00000263531.1	RP13-753N3.1	16.92	3.41e-50	1.95e-46	1.31	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30845266	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.673	rs9909497	ENSG00000263531.1	RP13-753N3.1	16.92	3.41e-50	1.95e-46	1.31	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30846210	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.673	rs11080135	ENSG00000263531.1	RP13-753N3.1	16.92	3.41e-50	1.95e-46	1.31	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30849463	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.673	rs9894876	ENSG00000263531.1	RP13-753N3.1	16.92	3.41e-50	1.95e-46	1.31	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30855002	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.673	rs60020217	ENSG00000263531.1	RP13-753N3.1	16.92	3.41e-50	1.95e-46	1.31	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30858036	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.573	rs73277974	ENSG00000263531.1	RP13-753N3.1	16.92	3.41e-50	1.95e-46	1.31	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862851	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.673	rs73277978	ENSG00000263531.1	RP13-753N3.1	16.92	3.41e-50	1.95e-46	1.31	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30864431	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs11657391	ENSG00000263531.1	RP13-753N3.1	16.92	3.41e-50	1.95e-46	1.31	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30867269	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs58089675	ENSG00000263531.1	RP13-753N3.1	16.92	3.41e-50	1.95e-46	1.31	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869746	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.673	rs73263755	ENSG00000263531.1	RP13-753N3.1	16.92	3.41e-50	1.95e-46	1.31	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30871954	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.673	rs9899349	ENSG00000263531.1	RP13-753N3.1	16.92	3.41e-50	1.95e-46	1.31	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30873104	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs11652358	ENSG00000263531.1	RP13-753N3.1	16.92	3.41e-50	1.95e-46	1.31	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30878462	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.673	rs9891179	ENSG00000263531.1	RP13-753N3.1	16.92	3.41e-50	1.95e-46	1.31	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881142	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.673	rs9891413	ENSG00000263531.1	RP13-753N3.1	16.92	3.41e-50	1.95e-46	1.31	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881191	chr17:30863921~30864940:-
PRAD	cis	rs858239	0.676	rs199359	ENSG00000230658.1	KLHL7-AS1	-16.92	3.59e-50	2.05e-46	-0.78	-0.62	Cerebrospinal fluid biomarker levels;	chr7:23298895	chr7:23101228~23105703:-
PRAD	cis	rs7188445	0.966	rs8053589	ENSG00000261390.4	RP11-345M22.2	-16.92	3.66e-50	2.09e-46	-0.78	-0.62	Urate levels;	chr16:79693093	chr16:79715232~79770563:-
PRAD	cis	rs858239	0.862	rs1728292	ENSG00000230658.1	KLHL7-AS1	16.92	3.69e-50	2.11e-46	0.76	0.62	Cerebrospinal fluid biomarker levels;	chr7:23223855	chr7:23101228~23105703:-
PRAD	cis	rs2739330	0.652	rs2000469	ENSG00000225282.1	AP000350.6	16.91	3.81e-50	2.18e-46	0.83	0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23926900~23929574:+
PRAD	cis	rs992157	0.767	rs2382822	ENSG00000261338.2	RP11-378A13.1	-16.91	3.83e-50	2.19e-46	-0.7	-0.62	Colorectal cancer;	chr2:218308604	chr2:218255319~218257366:+
PRAD	cis	rs2882667	1	rs10064201	ENSG00000253404.1	AC034243.1	16.91	3.93e-50	2.25e-46	0.85	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138973716	chr5:138744434~138753309:-
PRAD	cis	rs11155671	0.53	rs1334510	ENSG00000268592.3	RAET1E-AS1	16.91	4.1e-50	2.34e-46	0.86	0.62	Testicular germ cell tumor;	chr6:149880043	chr6:149863494~149919507:+
PRAD	cis	rs875971	1	rs2220626	ENSG00000226824.5	RP4-756H11.3	16.9	4.22e-50	2.4e-46	0.83	0.62	Aortic root size;	chr7:66081075	chr7:66654538~66669855:+
PRAD	cis	rs11155671	0.53	rs9383940	ENSG00000223701.3	RAET1E-AS1	16.9	4.26e-50	2.43e-46	0.86	0.62	Testicular germ cell tumor;	chr6:149904923	chr6:149884431~149919508:+
PRAD	cis	rs858239	0.614	rs10229956	ENSG00000230658.1	KLHL7-AS1	-16.9	4.44e-50	2.53e-46	-0.76	-0.62	Cerebrospinal fluid biomarker levels;	chr7:23363317	chr7:23101228~23105703:-
PRAD	cis	rs62229266	0.804	rs2835263	ENSG00000231106.2	LINC01436	-16.89	4.71e-50	2.68e-46	-0.79	-0.62	Mitral valve prolapse;	chr21:36057947	chr21:36005338~36007838:+
PRAD	cis	rs1799949	0.965	rs8070179	ENSG00000198496.9	NBR2	-16.88	5.18e-50	2.94e-46	-0.82	-0.62	Menopause (age at onset);	chr17:43050671	chr17:43125610~43153671:+
PRAD	cis	rs992157	0.835	rs2292550	ENSG00000261338.2	RP11-378A13.1	-16.88	5.24e-50	2.97e-46	-0.7	-0.62	Colorectal cancer;	chr2:218275565	chr2:218255319~218257366:+
PRAD	cis	rs11673344	0.526	rs57654288	ENSG00000226686.6	LINC01535	16.88	5.41e-50	3.07e-46	0.82	0.62	Obesity-related traits;	chr19:37587870	chr19:37251912~37265535:+
PRAD	cis	rs992157	0.698	rs6746089	ENSG00000261338.2	RP11-378A13.1	16.88	5.42e-50	3.08e-46	0.69	0.62	Colorectal cancer;	chr2:218305654	chr2:218255319~218257366:+
PRAD	cis	rs7208859	0.673	rs73263776	ENSG00000263531.1	RP13-753N3.1	16.87	5.75e-50	3.25e-46	1.3	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30884313	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs11650271	ENSG00000263531.1	RP13-753N3.1	16.87	5.75e-50	3.25e-46	1.3	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30886925	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.673	rs73263785	ENSG00000263531.1	RP13-753N3.1	16.87	5.75e-50	3.25e-46	1.3	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887790	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.673	rs55904046	ENSG00000263531.1	RP13-753N3.1	16.87	5.75e-50	3.25e-46	1.3	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30888373	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.673	rs9889968	ENSG00000263531.1	RP13-753N3.1	16.87	5.75e-50	3.25e-46	1.3	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30893110	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.673	rs61348930	ENSG00000263531.1	RP13-753N3.1	16.87	5.75e-50	3.25e-46	1.3	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30894745	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.614	rs28758251	ENSG00000263531.1	RP13-753N3.1	16.87	5.75e-50	3.25e-46	1.3	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896294	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.673	rs9899943	ENSG00000263531.1	RP13-753N3.1	16.87	5.75e-50	3.25e-46	1.3	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896907	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.673	rs11080138	ENSG00000263531.1	RP13-753N3.1	16.87	5.75e-50	3.25e-46	1.3	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30897524	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.673	rs73265612	ENSG00000263531.1	RP13-753N3.1	16.87	5.75e-50	3.25e-46	1.3	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30898965	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.673	rs2433	ENSG00000263531.1	RP13-753N3.1	16.87	5.75e-50	3.25e-46	1.3	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30899210	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.673	rs11658435	ENSG00000263531.1	RP13-753N3.1	16.87	5.75e-50	3.25e-46	1.3	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30901543	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.673	rs73265624	ENSG00000263531.1	RP13-753N3.1	16.87	5.75e-50	3.25e-46	1.3	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30905048	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.673	rs2269915	ENSG00000263531.1	RP13-753N3.1	16.87	5.75e-50	3.25e-46	1.3	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906326	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.673	rs2269916	ENSG00000263531.1	RP13-753N3.1	16.87	5.75e-50	3.25e-46	1.3	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906745	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.673	rs11649765	ENSG00000263531.1	RP13-753N3.1	16.87	5.75e-50	3.25e-46	1.3	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906870	chr17:30863921~30864940:-
PRAD	cis	rs916888	0.61	rs199529	ENSG00000262500.1	RP11-259G18.2	16.86	6.55e-50	3.7e-46	0.92	0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:46243606~46245044:+
PRAD	cis	rs11155671	0.53	rs7757984	ENSG00000268592.3	RAET1E-AS1	16.86	6.79e-50	3.83e-46	0.85	0.62	Testicular germ cell tumor;	chr6:149887515	chr6:149863494~149919507:+
PRAD	cis	rs2882667	1	rs10064130	ENSG00000253404.1	AC034243.1	16.83	9.15e-50	5.13e-46	0.86	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138973618	chr5:138744434~138753309:-
PRAD	cis	rs7208859	0.673	rs12103759	ENSG00000263531.1	RP13-753N3.1	16.82	9.69e-50	5.42e-46	1.31	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30908669	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs59029591	ENSG00000263531.1	RP13-753N3.1	16.82	9.69e-50	5.42e-46	1.31	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30908728	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.673	rs73265633	ENSG00000263531.1	RP13-753N3.1	16.82	9.69e-50	5.42e-46	1.31	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30909288	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.673	rs9913782	ENSG00000263531.1	RP13-753N3.1	16.82	9.69e-50	5.42e-46	1.31	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910366	chr17:30863921~30864940:-
PRAD	cis	rs1799949	0.965	rs8176310	ENSG00000198496.9	NBR2	-16.82	9.95e-50	5.56e-46	-0.82	-0.62	Menopause (age at onset);	chr17:43047896	chr17:43125610~43153671:+
PRAD	cis	rs992157	0.798	rs10193383	ENSG00000261338.2	RP11-378A13.1	16.8	1.28e-49	7.12e-46	0.69	0.62	Colorectal cancer;	chr2:218292969	chr2:218255319~218257366:+
PRAD	cis	rs992157	0.798	rs10206064	ENSG00000261338.2	RP11-378A13.1	16.8	1.28e-49	7.12e-46	0.69	0.62	Colorectal cancer;	chr2:218293236	chr2:218255319~218257366:+
PRAD	cis	rs992157	0.7	rs10165153	ENSG00000261338.2	RP11-378A13.1	16.8	1.28e-49	7.12e-46	0.69	0.62	Colorectal cancer;	chr2:218294906	chr2:218255319~218257366:+
PRAD	cis	rs2739330	0.76	rs5760095	ENSG00000218537.1	MIF-AS1	16.79	1.4e-49	7.77e-46	0.83	0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23894426~23898930:-
PRAD	cis	rs7208859	0.673	rs11657270	ENSG00000263531.1	RP13-753N3.1	16.78	1.54e-49	8.52e-46	1.3	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887369	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.673	rs9895684	ENSG00000263531.1	RP13-753N3.1	16.78	1.54e-49	8.52e-46	1.3	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30915582	chr17:30863921~30864940:-
PRAD	cis	rs950027	0.62	rs1617634	ENSG00000259520.4	CTD-2651B20.3	-16.75	2.02e-49	1.12e-45	-0.78	-0.62	Response to fenofibrate (adiponectin levels);	chr15:45323380	chr15:45251580~45279251:-
PRAD	cis	rs992157	0.798	rs12053514	ENSG00000261338.2	RP11-378A13.1	-16.75	2.21e-49	1.22e-45	-0.7	-0.62	Colorectal cancer;	chr2:218303242	chr2:218255319~218257366:+
PRAD	cis	rs801193	0.613	rs2016325	ENSG00000226824.5	RP4-756H11.3	16.74	2.26e-49	1.25e-45	0.79	0.62	Aortic root size;	chr7:66858513	chr7:66654538~66669855:+
PRAD	cis	rs1577917	0.883	rs9450375	ENSG00000203875.9	SNHG5	16.73	2.59e-49	1.43e-45	0.66	0.62	Response to antipsychotic treatment;	chr6:86046911	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.883	rs1337854	ENSG00000203875.9	SNHG5	16.73	2.69e-49	1.48e-45	0.66	0.62	Response to antipsychotic treatment;	chr6:86014297	chr6:85660950~85678736:-
PRAD	cis	rs7208859	0.623	rs58908911	ENSG00000263531.1	RP13-753N3.1	16.72	2.89e-49	1.59e-45	1.3	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30917540	chr17:30863921~30864940:-
PRAD	cis	rs992157	0.798	rs2382818	ENSG00000261338.2	RP11-378A13.1	-16.7	3.38e-49	1.86e-45	-0.69	-0.62	Colorectal cancer;	chr2:218291184	chr2:218255319~218257366:+
PRAD	cis	rs992157	0.798	rs2382819	ENSG00000261338.2	RP11-378A13.1	-16.7	3.38e-49	1.86e-45	-0.69	-0.62	Colorectal cancer;	chr2:218291186	chr2:218255319~218257366:+
PRAD	cis	rs2882667	1	rs10515505	ENSG00000253404.1	AC034243.1	16.7	3.43e-49	1.89e-45	0.84	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138977457	chr5:138744434~138753309:-
PRAD	cis	rs2882667	1	rs2060222	ENSG00000253404.1	AC034243.1	16.69	3.94e-49	2.16e-45	0.85	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138972777	chr5:138744434~138753309:-
PRAD	cis	rs1799949	0.965	rs9911630	ENSG00000198496.9	NBR2	-16.68	4.27e-49	2.34e-45	-0.8	-0.62	Menopause (age at onset);	chr17:43036325	chr17:43125610~43153671:+
PRAD	cis	rs62229266	0.835	rs998384	ENSG00000231106.2	LINC01436	16.68	4.39e-49	2.41e-45	0.79	0.62	Mitral valve prolapse;	chr21:36073228	chr21:36005338~36007838:+
PRAD	cis	rs17507216	1	rs3850610	ENSG00000278603.1	RP13-608F4.5	-16.67	4.61e-49	2.53e-45	-0.87	-0.62	Excessive daytime sleepiness;	chr15:82552642	chr15:82472203~82472426:+
PRAD	cis	rs875971	1	rs1544549	ENSG00000226824.5	RP4-756H11.3	16.67	4.64e-49	2.54e-45	0.83	0.62	Aortic root size;	chr7:66625676	chr7:66654538~66669855:+
PRAD	cis	rs992157	0.798	rs7587220	ENSG00000261338.2	RP11-378A13.1	-16.67	4.65e-49	2.55e-45	-0.7	-0.62	Colorectal cancer;	chr2:218296141	chr2:218255319~218257366:+
PRAD	cis	rs992157	0.798	rs4674284	ENSG00000261338.2	RP11-378A13.1	-16.67	4.65e-49	2.55e-45	-0.7	-0.62	Colorectal cancer;	chr2:218296518	chr2:218255319~218257366:+
PRAD	cis	rs2283792	0.566	rs1005579	ENSG00000224086.5	LL22NC03-86G7.1	-16.67	4.71e-49	2.58e-45	-0.72	-0.62	Multiple sclerosis;	chr22:21946569	chr22:21938293~21977632:+
PRAD	cis	rs11673344	0.734	rs1234250	ENSG00000226686.6	LINC01535	-16.66	5.28e-49	2.89e-45	-0.85	-0.62	Obesity-related traits;	chr19:37199518	chr19:37251912~37265535:+
PRAD	cis	rs17507216	1	rs17158413	ENSG00000278603.1	RP13-608F4.5	16.63	7.24e-49	3.95e-45	0.92	0.61	Excessive daytime sleepiness;	chr15:82566658	chr15:82472203~82472426:+
PRAD	cis	rs1577917	0.793	rs9362245	ENSG00000203875.9	SNHG5	-16.63	7.37e-49	4.02e-45	-0.67	-0.61	Response to antipsychotic treatment;	chr6:85786602	chr6:85660950~85678736:-
PRAD	cis	rs858239	0.669	rs6461688	ENSG00000230658.1	KLHL7-AS1	16.61	8.63e-49	4.7e-45	0.76	0.61	Cerebrospinal fluid biomarker levels;	chr7:23076996	chr7:23101228~23105703:-
PRAD	cis	rs1577917	0.696	rs2842617	ENSG00000203875.9	SNHG5	-16.6	9.59e-49	5.22e-45	-0.66	-0.61	Response to antipsychotic treatment;	chr6:85599980	chr6:85660950~85678736:-
PRAD	cis	rs11155671	0.53	rs9322228	ENSG00000268592.3	RAET1E-AS1	16.59	1.12e-48	6.06e-45	0.84	0.61	Testicular germ cell tumor;	chr6:149888173	chr6:149863494~149919507:+
PRAD	cis	rs11155671	0.53	rs7774787	ENSG00000268592.3	RAET1E-AS1	16.59	1.12e-48	6.06e-45	0.84	0.61	Testicular germ cell tumor;	chr6:149888296	chr6:149863494~149919507:+
PRAD	cis	rs11155671	0.53	rs2342767	ENSG00000268592.3	RAET1E-AS1	16.59	1.12e-48	6.06e-45	0.84	0.61	Testicular germ cell tumor;	chr6:149888581	chr6:149863494~149919507:+
PRAD	cis	rs11155671	0.53	rs7764376	ENSG00000268592.3	RAET1E-AS1	16.59	1.12e-48	6.06e-45	0.84	0.61	Testicular germ cell tumor;	chr6:149889208	chr6:149863494~149919507:+
PRAD	cis	rs11155671	0.53	rs6933882	ENSG00000268592.3	RAET1E-AS1	16.59	1.12e-48	6.06e-45	0.84	0.61	Testicular germ cell tumor;	chr6:149889666	chr6:149863494~149919507:+
PRAD	cis	rs11155671	0.53	rs6939761	ENSG00000268592.3	RAET1E-AS1	16.59	1.12e-48	6.06e-45	0.84	0.61	Testicular germ cell tumor;	chr6:149889858	chr6:149863494~149919507:+
PRAD	cis	rs11155671	0.53	rs3823021	ENSG00000268592.3	RAET1E-AS1	16.59	1.12e-48	6.06e-45	0.84	0.61	Testicular germ cell tumor;	chr6:149889863	chr6:149863494~149919507:+
PRAD	cis	rs11155671	0.53	rs4869763	ENSG00000268592.3	RAET1E-AS1	16.59	1.12e-48	6.06e-45	0.84	0.61	Testicular germ cell tumor;	chr6:149890548	chr6:149863494~149919507:+
PRAD	cis	rs11155671	0.53	rs4869764	ENSG00000268592.3	RAET1E-AS1	16.59	1.12e-48	6.06e-45	0.84	0.61	Testicular germ cell tumor;	chr6:149890692	chr6:149863494~149919507:+
PRAD	cis	rs875971	1	rs2420820	ENSG00000226824.5	RP4-756H11.3	16.58	1.24e-48	6.71e-45	0.82	0.61	Aortic root size;	chr7:66626920	chr7:66654538~66669855:+
PRAD	cis	rs992157	0.737	rs3731860	ENSG00000261338.2	RP11-378A13.1	-16.57	1.35e-48	7.3e-45	-0.71	-0.61	Colorectal cancer;	chr2:218292256	chr2:218255319~218257366:+
PRAD	cis	rs2455601	0.638	rs2568092	ENSG00000254860.4	TMEM9B-AS1	-16.57	1.41e-48	7.62e-45	-0.69	-0.61	Schizophrenia;	chr11:8965891	chr11:8964675~8977527:+
PRAD	cis	rs1799949	0.965	rs8071278	ENSG00000198496.9	NBR2	-16.56	1.49e-48	8.06e-45	-0.82	-0.61	Menopause (age at onset);	chr17:43041893	chr17:43125610~43153671:+
PRAD	cis	rs492146	1	rs419833	ENSG00000243236.5	GSTA9P	-16.55	1.75e-48	9.46e-45	-0.75	-0.61	Epilepsy (remission after treatment);	chr6:52973187	chr6:52939726~52957521:-
PRAD	cis	rs492146	1	rs449690	ENSG00000243236.5	GSTA9P	-16.55	1.75e-48	9.46e-45	-0.75	-0.61	Epilepsy (remission after treatment);	chr6:52973360	chr6:52939726~52957521:-
PRAD	cis	rs2882667	0.929	rs17207828	ENSG00000253404.1	AC034243.1	16.54	1.92e-48	1.04e-44	0.85	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138964146	chr5:138744434~138753309:-
PRAD	cis	rs62229266	0.804	rs998383	ENSG00000231106.2	LINC01436	16.53	2.01e-48	1.08e-44	0.78	0.61	Mitral valve prolapse;	chr21:36073441	chr21:36005338~36007838:+
PRAD	cis	rs7208859	0.673	rs3764420	ENSG00000263531.1	RP13-753N3.1	16.53	2.15e-48	1.15e-44	1.28	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30837136	chr17:30863921~30864940:-
PRAD	cis	rs2739330	0.76	rs5751760	ENSG00000218537.1	MIF-AS1	16.52	2.35e-48	1.25e-44	0.83	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23894426~23898930:-
PRAD	cis	rs11155671	0.53	rs9397398	ENSG00000268592.3	RAET1E-AS1	16.52	2.4e-48	1.28e-44	0.85	0.61	Testicular germ cell tumor;	chr6:149872467	chr6:149863494~149919507:+
PRAD	cis	rs6597981	0.592	rs28625355	ENSG00000279672.1	CMB9-55F22.1	16.51	2.41e-48	1.29e-44	0.67	0.61	Breast cancer;	chr11:736334	chr11:779617~780755:+
PRAD	cis	rs7208859	0.673	rs9911989	ENSG00000263531.1	RP13-753N3.1	-16.51	2.47e-48	1.31e-44	-1.26	-0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910684	chr17:30863921~30864940:-
PRAD	cis	rs1577917	0.883	rs2660575	ENSG00000203875.9	SNHG5	-16.51	2.59e-48	1.38e-44	-0.66	-0.61	Response to antipsychotic treatment;	chr6:85975277	chr6:85660950~85678736:-
PRAD	cis	rs11155671	0.53	rs4458704	ENSG00000268592.3	RAET1E-AS1	16.5	2.94e-48	1.56e-44	0.87	0.61	Testicular germ cell tumor;	chr6:149911743	chr6:149863494~149919507:+
PRAD	cis	rs2739330	0.731	rs2000468	ENSG00000218537.1	MIF-AS1	16.49	3.22e-48	1.7e-44	0.82	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23894426~23898930:-
PRAD	cis	rs1799949	0.965	rs7212284	ENSG00000198496.9	NBR2	-16.48	3.39e-48	1.79e-44	-0.8	-0.61	Menopause (age at onset);	chr17:43053924	chr17:43125610~43153671:+
PRAD	cis	rs2739330	0.627	rs9608219	ENSG00000250470.1	AP000351.3	16.48	3.64e-48	1.92e-44	0.82	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23976904~23977585:-
PRAD	cis	rs492146	1	rs693733	ENSG00000243236.5	GSTA9P	-16.47	4e-48	2.11e-44	-0.75	-0.61	Epilepsy (remission after treatment);	chr6:52971958	chr6:52939726~52957521:-
PRAD	cis	rs62229266	0.682	rs2835224	ENSG00000231106.2	LINC01436	16.45	4.96e-48	2.61e-44	0.8	0.61	Mitral valve prolapse;	chr21:35997732	chr21:36005338~36007838:+
PRAD	cis	rs7309	0.935	rs10930013	ENSG00000227403.1	AC009299.3	-16.43	6.04e-48	3.17e-44	-0.8	-0.61	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161213814	chr2:161244739~161249050:+
PRAD	cis	rs858239	0.669	rs6461687	ENSG00000230658.1	KLHL7-AS1	16.42	6.48e-48	3.4e-44	0.76	0.61	Cerebrospinal fluid biomarker levels;	chr7:23076961	chr7:23101228~23105703:-
PRAD	cis	rs11155671	0.53	rs9397420	ENSG00000268592.3	RAET1E-AS1	-16.42	6.55e-48	3.43e-44	-0.84	-0.61	Testicular germ cell tumor;	chr6:149885645	chr6:149863494~149919507:+
PRAD	cis	rs11155671	0.53	rs9383912	ENSG00000268592.3	RAET1E-AS1	16.41	7.2e-48	3.77e-44	0.83	0.61	Testicular germ cell tumor;	chr6:149885479	chr6:149863494~149919507:+
PRAD	cis	rs11155671	0.53	rs7768626	ENSG00000268592.3	RAET1E-AS1	16.41	7.2e-48	3.77e-44	0.83	0.61	Testicular germ cell tumor;	chr6:149886826	chr6:149863494~149919507:+
PRAD	cis	rs11155671	0.53	rs7768665	ENSG00000268592.3	RAET1E-AS1	16.41	7.2e-48	3.77e-44	0.83	0.61	Testicular germ cell tumor;	chr6:149886888	chr6:149863494~149919507:+
PRAD	cis	rs11155671	0.53	rs7758020	ENSG00000268592.3	RAET1E-AS1	16.41	7.2e-48	3.77e-44	0.83	0.61	Testicular germ cell tumor;	chr6:149886975	chr6:149863494~149919507:+
PRAD	cis	rs1153858	1	rs28679834	ENSG00000259520.4	CTD-2651B20.3	-16.41	7.28e-48	3.81e-44	-0.8	-0.61	Homoarginine levels;	chr15:45324008	chr15:45251580~45279251:-
PRAD	cis	rs1891275	0.513	rs1539041	ENSG00000228701.1	TNKS2-AS1	-16.41	7.32e-48	3.83e-44	-0.87	-0.61	Intelligence (multi-trait analysis);	chr10:91817384	chr10:91782839~91798291:-
PRAD	cis	rs62229266	0.804	rs62230788	ENSG00000231106.2	LINC01436	16.41	7.4e-48	3.87e-44	0.81	0.61	Mitral valve prolapse;	chr21:36008039	chr21:36005338~36007838:+
PRAD	cis	rs1799949	0.965	rs7223952	ENSG00000198496.9	NBR2	-16.4	8.09e-48	4.23e-44	-0.81	-0.61	Menopause (age at onset);	chr17:43042868	chr17:43125610~43153671:+
PRAD	cis	rs7208859	0.623	rs3752019	ENSG00000263531.1	RP13-753N3.1	16.4	8.1e-48	4.23e-44	1.25	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824687	chr17:30863921~30864940:-
PRAD	cis	rs9322193	0.543	rs9371533	ENSG00000223701.3	RAET1E-AS1	16.4	8.13e-48	4.24e-44	0.84	0.61	Lung cancer;	chr6:149889545	chr6:149884431~149919508:+
PRAD	cis	rs11155671	0.53	rs9383940	ENSG00000268592.3	RAET1E-AS1	16.4	8.15e-48	4.26e-44	0.87	0.61	Testicular germ cell tumor;	chr6:149904923	chr6:149863494~149919507:+
PRAD	cis	rs7309	0.935	rs1921309	ENSG00000227403.1	AC009299.3	-16.39	8.48e-48	4.43e-44	-0.79	-0.61	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161192464	chr2:161244739~161249050:+
PRAD	cis	rs7309	0.935	rs11884495	ENSG00000227403.1	AC009299.3	-16.39	8.48e-48	4.43e-44	-0.79	-0.61	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161203458	chr2:161244739~161249050:+
PRAD	cis	rs492146	1	rs492146	ENSG00000243236.5	GSTA9P	-16.39	8.52e-48	4.45e-44	-0.75	-0.61	Epilepsy (remission after treatment);	chr6:52971097	chr6:52939726~52957521:-
PRAD	cis	rs9322193	0.567	rs7742692	ENSG00000268592.3	RAET1E-AS1	16.38	9.71e-48	5.05e-44	0.84	0.61	Lung cancer;	chr6:149892363	chr6:149863494~149919507:+
PRAD	cis	rs1799949	1	rs8077486	ENSG00000198496.9	NBR2	-16.38	9.95e-48	5.17e-44	-0.8	-0.61	Menopause (age at onset);	chr17:43060788	chr17:43125610~43153671:+
PRAD	cis	rs492146	1	rs426169	ENSG00000243236.5	GSTA9P	-16.37	1.13e-47	5.86e-44	-0.75	-0.61	Epilepsy (remission after treatment);	chr6:52975090	chr6:52939726~52957521:-
PRAD	cis	rs73086581	0.947	rs73084523	ENSG00000229539.1	RP11-119B16.2	16.36	1.2e-47	6.24e-44	1.06	0.61	Response to antidepressants in depression;	chr20:3894979	chr20:3888239~3888868:-
PRAD	cis	rs760794	0.577	rs17483277	ENSG00000228412.5	RP4-625H18.2	16.36	1.2e-47	6.24e-44	0.76	0.61	Endometriosis;	chr6:19790340	chr6:19802164~19804752:-
PRAD	cis	rs916888	0.821	rs199499	ENSG00000262500.1	RP11-259G18.2	16.36	1.21e-47	6.29e-44	1.03	0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788132	chr17:46243606~46245044:+
PRAD	cis	rs1153858	1	rs59889118	ENSG00000259520.4	CTD-2651B20.3	-16.36	1.23e-47	6.36e-44	-0.8	-0.61	Homoarginine levels;	chr15:45326532	chr15:45251580~45279251:-
PRAD	cis	rs1577917	0.883	rs1415749	ENSG00000203875.9	SNHG5	16.36	1.25e-47	6.49e-44	0.66	0.61	Response to antipsychotic treatment;	chr6:86069366	chr6:85660950~85678736:-
PRAD	cis	rs2739330	0.791	rs9612520	ENSG00000250470.1	AP000351.3	16.35	1.28e-47	6.64e-44	0.82	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23976904~23977585:-
PRAD	cis	rs1153858	1	rs12593370	ENSG00000259520.4	CTD-2651B20.3	-16.35	1.31e-47	6.8e-44	-0.79	-0.61	Homoarginine levels;	chr15:45325219	chr15:45251580~45279251:-
PRAD	cis	rs11155671	0.53	rs9383577	ENSG00000268592.3	RAET1E-AS1	16.34	1.43e-47	7.38e-44	0.83	0.61	Testicular germ cell tumor;	chr6:149886059	chr6:149863494~149919507:+
PRAD	cis	rs11155671	0.53	rs9383914	ENSG00000268592.3	RAET1E-AS1	16.34	1.43e-47	7.38e-44	0.83	0.61	Testicular germ cell tumor;	chr6:149886098	chr6:149863494~149919507:+
PRAD	cis	rs11155671	0.517	rs9397058	ENSG00000268592.3	RAET1E-AS1	16.34	1.43e-47	7.38e-44	0.83	0.61	Testicular germ cell tumor;	chr6:149886113	chr6:149863494~149919507:+
PRAD	cis	rs7309	0.81	rs11684253	ENSG00000227403.1	AC009299.3	-16.34	1.53e-47	7.89e-44	-0.79	-0.61	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161178025	chr2:161244739~161249050:+
PRAD	cis	rs7309	0.935	rs6432674	ENSG00000227403.1	AC009299.3	-16.33	1.56e-47	8.06e-44	-0.79	-0.61	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161168811	chr2:161244739~161249050:+
PRAD	cis	rs1153858	0.895	rs12593402	ENSG00000259520.4	CTD-2651B20.3	-16.33	1.57e-47	8.12e-44	-0.79	-0.61	Homoarginine levels;	chr15:45325194	chr15:45251580~45279251:-
PRAD	cis	rs2882667	0.964	rs12719517	ENSG00000253404.1	AC034243.1	16.32	1.84e-47	9.5e-44	0.85	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138969813	chr5:138744434~138753309:-
PRAD	cis	rs7188445	0.933	rs56892402	ENSG00000261390.4	RP11-345M22.2	-16.32	1.86e-47	9.57e-44	-0.74	-0.61	Urate levels;	chr16:79682728	chr16:79715232~79770563:-
PRAD	cis	rs492146	1	rs428957	ENSG00000243236.5	GSTA9P	-16.32	1.89e-47	9.76e-44	-0.74	-0.61	Epilepsy (remission after treatment);	chr6:52974387	chr6:52939726~52957521:-
PRAD	cis	rs1153858	1	rs1980288	ENSG00000259520.4	CTD-2651B20.3	-16.3	2.23e-47	1.14e-43	-0.78	-0.61	Homoarginine levels;	chr15:45328414	chr15:45251580~45279251:-
PRAD	cis	rs1577917	0.959	rs2816822	ENSG00000203875.9	SNHG5	-16.3	2.27e-47	1.16e-43	-0.65	-0.61	Response to antipsychotic treatment;	chr6:85948574	chr6:85660950~85678736:-
PRAD	cis	rs7208859	0.673	rs999797	ENSG00000263531.1	RP13-753N3.1	16.3	2.3e-47	1.18e-43	1.24	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832311	chr17:30863921~30864940:-
PRAD	cis	rs492146	0.967	rs400804	ENSG00000243236.5	GSTA9P	-16.29	2.5e-47	1.28e-43	-0.74	-0.61	Epilepsy (remission after treatment);	chr6:52972292	chr6:52939726~52957521:-
PRAD	cis	rs1577917	0.804	rs2786854	ENSG00000203875.9	SNHG5	-16.28	2.6e-47	1.34e-43	-0.65	-0.61	Response to antipsychotic treatment;	chr6:85959022	chr6:85660950~85678736:-
PRAD	cis	rs492146	1	rs380646	ENSG00000243236.5	GSTA9P	-16.28	2.65e-47	1.36e-43	-0.74	-0.61	Epilepsy (remission after treatment);	chr6:52972842	chr6:52939726~52957521:-
PRAD	cis	rs7208859	0.673	rs73277967	ENSG00000263531.1	RP13-753N3.1	16.28	2.67e-47	1.37e-43	1.29	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30857148	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.673	rs11656845	ENSG00000263531.1	RP13-753N3.1	16.28	2.67e-47	1.37e-43	1.29	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30879146	chr17:30863921~30864940:-
PRAD	cis	rs492146	0.967	rs387853	ENSG00000243236.5	GSTA9P	-16.27	3.09e-47	1.58e-43	-0.74	-0.61	Epilepsy (remission after treatment);	chr6:52975456	chr6:52939726~52957521:-
PRAD	cis	rs1577917	0.92	rs1337842	ENSG00000203875.9	SNHG5	-16.26	3.21e-47	1.64e-43	-0.65	-0.61	Response to antipsychotic treatment;	chr6:85965379	chr6:85660950~85678736:-
PRAD	cis	rs7208859	0.623	rs73271869	ENSG00000263531.1	RP13-753N3.1	16.26	3.51e-47	1.79e-43	1.25	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30825203	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs73271872	ENSG00000263531.1	RP13-753N3.1	16.26	3.51e-47	1.79e-43	1.25	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30825210	chr17:30863921~30864940:-
PRAD	cis	rs17826219	0.568	rs9907834	ENSG00000263531.1	RP13-753N3.1	16.26	3.51e-47	1.79e-43	1.25	0.61	Body mass index;	chr17:30826995	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.673	rs73271887	ENSG00000263531.1	RP13-753N3.1	16.26	3.51e-47	1.79e-43	1.25	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827917	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.673	rs9898858	ENSG00000263531.1	RP13-753N3.1	16.26	3.51e-47	1.79e-43	1.25	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829193	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.673	rs55658077	ENSG00000263531.1	RP13-753N3.1	16.26	3.51e-47	1.79e-43	1.25	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829501	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs9899692	ENSG00000263531.1	RP13-753N3.1	16.26	3.51e-47	1.79e-43	1.25	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829921	chr17:30863921~30864940:-
PRAD	cis	rs1577917	0.883	rs12214536	ENSG00000203875.9	SNHG5	-16.25	3.64e-47	1.86e-43	-0.65	-0.61	Response to antipsychotic treatment;	chr6:86080592	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.883	rs2782263	ENSG00000203875.9	SNHG5	-16.25	3.85e-47	1.96e-43	-0.65	-0.61	Response to antipsychotic treatment;	chr6:86081589	chr6:85660950~85678736:-
PRAD	cis	rs3931020	0.53	rs6668736	ENSG00000272864.1	RP11-17E13.2	-16.23	4.41e-47	2.25e-43	-0.61	-0.61	Resistin levels;	chr1:74768866	chr1:74698769~74699333:-
PRAD	cis	rs1799949	0.86	rs8176279	ENSG00000198496.9	NBR2	-16.21	5.39e-47	2.74e-43	-0.78	-0.61	Menopause (age at onset);	chr17:43058379	chr17:43125610~43153671:+
PRAD	cis	rs62229266	0.618	rs11088334	ENSG00000231106.2	LINC01436	16.21	5.46e-47	2.77e-43	0.78	0.61	Mitral valve prolapse;	chr21:36094531	chr21:36005338~36007838:+
PRAD	cis	rs7104764	1	rs1128322	ENSG00000277290.1	RP11-326C3.16	16.2	6.06e-47	3.07e-43	0.58	0.6	Menarche (age at onset);	chr11:244197	chr11:243099~243483:-
PRAD	cis	rs73086581	0.947	rs56123574	ENSG00000229539.1	RP11-119B16.2	16.2	6.18e-47	3.13e-43	1.06	0.6	Response to antidepressants in depression;	chr20:3897434	chr20:3888239~3888868:-
PRAD	cis	rs7208859	0.623	rs9906957	ENSG00000263531.1	RP13-753N3.1	16.2	6.19e-47	3.13e-43	1.25	0.6	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30830737	chr17:30863921~30864940:-
PRAD	cis	rs7188445	0.933	rs12449109	ENSG00000261390.4	RP11-345M22.2	-16.2	6.57e-47	3.32e-43	-0.73	-0.6	Urate levels;	chr16:79682146	chr16:79715232~79770563:-
PRAD	cis	rs7188445	0.933	rs12449161	ENSG00000261390.4	RP11-345M22.2	-16.2	6.57e-47	3.32e-43	-0.73	-0.6	Urate levels;	chr16:79682409	chr16:79715232~79770563:-
PRAD	cis	rs7208859	0.673	rs79541516	ENSG00000263531.1	RP13-753N3.1	16.18	7.34e-47	3.71e-43	1.29	0.6	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30913565	chr17:30863921~30864940:-
PRAD	cis	rs12439619	1	rs35152457	ENSG00000278603.1	RP13-608F4.5	16.18	7.5e-47	3.78e-43	0.85	0.6	Intelligence (multi-trait analysis);	chr15:82254207	chr15:82472203~82472426:+
PRAD	cis	rs7208859	0.673	rs9915139	ENSG00000263531.1	RP13-753N3.1	16.18	7.61e-47	3.84e-43	1.23	0.6	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30831497	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.673	rs78799101	ENSG00000263531.1	RP13-753N3.1	16.18	7.97e-47	4.02e-43	1.24	0.6	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30888142	chr17:30863921~30864940:-
PRAD	cis	rs11155671	0.53	rs7763849	ENSG00000268592.3	RAET1E-AS1	16.16	9.2e-47	4.63e-43	0.82	0.6	Testicular germ cell tumor;	chr6:149885244	chr6:149863494~149919507:+
PRAD	cis	rs875971	1	rs1167411	ENSG00000226824.5	RP4-756H11.3	16.16	9.5e-47	4.78e-43	0.81	0.6	Aortic root size;	chr7:66074277	chr7:66654538~66669855:+
PRAD	cis	rs875971	1	rs1144895	ENSG00000226824.5	RP4-756H11.3	16.16	9.5e-47	4.78e-43	0.81	0.6	Aortic root size;	chr7:66076320	chr7:66654538~66669855:+
PRAD	cis	rs1577917	0.655	rs7742691	ENSG00000203875.9	SNHG5	16.14	1.18e-46	5.88e-43	0.65	0.6	Response to antipsychotic treatment;	chr6:85568973	chr6:85660950~85678736:-
PRAD	cis	rs875971	0.965	rs697968	ENSG00000226824.5	RP4-756H11.3	16.13	1.3e-46	6.48e-43	0.81	0.6	Aortic root size;	chr7:66070046	chr7:66654538~66669855:+
PRAD	cis	rs875971	1	rs1183245	ENSG00000226824.5	RP4-756H11.3	16.13	1.3e-46	6.48e-43	0.81	0.6	Aortic root size;	chr7:66076198	chr7:66654538~66669855:+
PRAD	cis	rs875971	1	rs1144894	ENSG00000226824.5	RP4-756H11.3	16.13	1.3e-46	6.48e-43	0.81	0.6	Aortic root size;	chr7:66077907	chr7:66654538~66669855:+
PRAD	cis	rs3931020	0.548	rs17618340	ENSG00000272864.1	RP11-17E13.2	-16.12	1.42e-46	7.07e-43	-0.62	-0.6	Resistin levels;	chr1:74781933	chr1:74698769~74699333:-
PRAD	cis	rs2739330	0.732	rs5760175	ENSG00000225282.1	AP000350.6	16.11	1.62e-46	8.05e-43	0.78	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23926900~23929574:+
PRAD	cis	rs9487094	0.666	rs9480958	ENSG00000260273.1	RP11-425D10.10	-16.11	1.63e-46	8.13e-43	-0.79	-0.6	Height;	chr6:109432968	chr6:109382795~109383666:+
PRAD	cis	rs1577917	0.74	rs9344542	ENSG00000203875.9	SNHG5	16.11	1.66e-46	8.25e-43	0.65	0.6	Response to antipsychotic treatment;	chr6:85684187	chr6:85660950~85678736:-
PRAD	cis	rs2739330	0.731	rs5751792	ENSG00000225282.1	AP000350.6	16.1	1.69e-46	8.41e-43	0.77	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23926900~23929574:+
PRAD	cis	rs2739330	0.761	rs5760176	ENSG00000225282.1	AP000350.6	-16.1	1.69e-46	8.41e-43	-0.77	-0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23926900~23929574:+
PRAD	cis	rs11690935	0.959	rs6433314	ENSG00000228389.1	AC068039.4	16.1	1.71e-46	8.49e-43	0.71	0.6	Schizophrenia;	chr2:171804461	chr2:171773482~171775844:+
PRAD	cis	rs492146	1	rs375872	ENSG00000243236.5	GSTA9P	-16.09	1.87e-46	9.26e-43	-0.74	-0.6	Epilepsy (remission after treatment);	chr6:52970119	chr6:52939726~52957521:-
PRAD	cis	rs7208859	0.614	rs73265646	ENSG00000263531.1	RP13-753N3.1	16.08	2.07e-46	1.03e-42	1.28	0.6	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30917005	chr17:30863921~30864940:-
PRAD	cis	rs2455601	0.638	rs2742485	ENSG00000254860.4	TMEM9B-AS1	16.08	2.13e-46	1.06e-42	0.7	0.6	Schizophrenia;	chr11:8965240	chr11:8964675~8977527:+
PRAD	cis	rs1577917	0.71	rs9342041	ENSG00000203875.9	SNHG5	16.08	2.19e-46	1.09e-42	0.65	0.6	Response to antipsychotic treatment;	chr6:85571157	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.682	rs6935918	ENSG00000203875.9	SNHG5	16.08	2.19e-46	1.09e-42	0.65	0.6	Response to antipsychotic treatment;	chr6:85573857	chr6:85660950~85678736:-
PRAD	cis	rs7188445	0.933	rs76390413	ENSG00000261390.4	RP11-345M22.2	-16.07	2.29e-46	1.13e-42	-0.73	-0.6	Urate levels;	chr16:79680019	chr16:79715232~79770563:-
PRAD	cis	rs7188445	0.933	rs74037509	ENSG00000261390.4	RP11-345M22.2	-16.07	2.42e-46	1.2e-42	-0.73	-0.6	Urate levels;	chr16:79679107	chr16:79715232~79770563:-
PRAD	cis	rs1153858	1	rs4775895	ENSG00000259520.4	CTD-2651B20.3	-16.07	2.45e-46	1.21e-42	-0.78	-0.6	Homoarginine levels;	chr15:45325759	chr15:45251580~45279251:-
PRAD	cis	rs11155671	0.53	rs7758033	ENSG00000268592.3	RAET1E-AS1	16.06	2.52e-46	1.24e-42	0.83	0.6	Testicular germ cell tumor;	chr6:149886999	chr6:149863494~149919507:+
PRAD	cis	rs2739330	0.76	rs5751761	ENSG00000273295.1	AP000350.5	-16.06	2.62e-46	1.29e-42	-0.7	-0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23901432~23907068:-
PRAD	cis	rs12022452	0.506	rs6673386	ENSG00000238287.1	RP11-656D10.3	-16.06	2.7e-46	1.33e-42	-0.93	-0.6	Age-related hearing impairment (SNP x SNP interaction);	chr1:40546207	chr1:40493157~40508661:-
PRAD	cis	rs12022452	0.506	rs61779163	ENSG00000238287.1	RP11-656D10.3	-16.06	2.7e-46	1.33e-42	-0.93	-0.6	Age-related hearing impairment (SNP x SNP interaction);	chr1:40549751	chr1:40493157~40508661:-
PRAD	cis	rs2739330	0.791	rs4822458	ENSG00000250470.1	AP000351.3	16.06	2.71e-46	1.33e-42	0.8	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23976904~23977585:-
PRAD	cis	rs1577917	0.74	rs2758842	ENSG00000203875.9	SNHG5	-16.03	3.43e-46	1.69e-42	-0.65	-0.6	Response to antipsychotic treatment;	chr6:85599013	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.572	rs911927	ENSG00000203875.9	SNHG5	-16.03	3.43e-46	1.69e-42	-0.65	-0.6	Response to antipsychotic treatment;	chr6:85618142	chr6:85660950~85678736:-
PRAD	cis	rs950027	0.62	rs1617984	ENSG00000259520.4	CTD-2651B20.3	-16.03	3.46e-46	1.7e-42	-0.75	-0.6	Response to fenofibrate (adiponectin levels);	chr15:45330464	chr15:45251580~45279251:-
PRAD	cis	rs1577917	0.74	rs2758843	ENSG00000203875.9	SNHG5	-16.03	3.55e-46	1.75e-42	-0.65	-0.6	Response to antipsychotic treatment;	chr6:85618713	chr6:85660950~85678736:-
PRAD	cis	rs62229266	0.771	rs7280136	ENSG00000231106.2	LINC01436	-16.03	3.62e-46	1.78e-42	-0.76	-0.6	Mitral valve prolapse;	chr21:36060612	chr21:36005338~36007838:+
PRAD	cis	rs9326248	0.581	rs10892076	ENSG00000254851.1	RP11-109L13.1	-16.03	3.69e-46	1.81e-42	-0.77	-0.6	Blood protein levels;	chr11:117118220	chr11:117135528~117138582:+
PRAD	cis	rs875971	0.929	rs4122249	ENSG00000226824.5	RP4-756H11.3	-16.02	3.87e-46	1.9e-42	-0.79	-0.6	Aortic root size;	chr7:66455949	chr7:66654538~66669855:+
PRAD	cis	rs1577917	0.839	rs6929514	ENSG00000203875.9	SNHG5	-16.02	3.94e-46	1.93e-42	-0.65	-0.6	Response to antipsychotic treatment;	chr6:85816050	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.74	rs7771612	ENSG00000203875.9	SNHG5	16.02	3.98e-46	1.95e-42	0.64	0.6	Response to antipsychotic treatment;	chr6:85554656	chr6:85660950~85678736:-
PRAD	cis	rs11690935	0.959	rs12692974	ENSG00000228389.1	AC068039.4	16.02	4.15e-46	2.03e-42	0.71	0.6	Schizophrenia;	chr2:171806746	chr2:171773482~171775844:+
PRAD	cis	rs9326248	0.689	rs4516002	ENSG00000254851.1	RP11-109L13.1	-16.01	4.22e-46	2.07e-42	-1.07	-0.6	Blood protein levels;	chr11:117128343	chr11:117135528~117138582:+
PRAD	cis	rs1577917	0.74	rs9344533	ENSG00000203875.9	SNHG5	16.01	4.31e-46	2.12e-42	0.64	0.6	Response to antipsychotic treatment;	chr6:85526470	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.883	rs2166664	ENSG00000203875.9	SNHG5	-16	4.78e-46	2.34e-42	-0.65	-0.6	Response to antipsychotic treatment;	chr6:85886904	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.883	rs9450348	ENSG00000203875.9	SNHG5	-16	4.78e-46	2.34e-42	-0.65	-0.6	Response to antipsychotic treatment;	chr6:85888318	chr6:85660950~85678736:-
PRAD	cis	rs2739330	0.587	rs4820571	ENSG00000225282.1	AP000350.6	16	4.91e-46	2.4e-42	0.77	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23926900~23929574:+
PRAD	cis	rs4423214	1	rs4944957	ENSG00000254682.1	RP11-660L16.2	-15.99	5.42e-46	2.65e-42	-0.78	-0.6	Vitamin D levels;	chr11:71456989	chr11:71448674~71452157:+
PRAD	cis	rs2882667	1	rs2882667	ENSG00000253404.1	AC034243.1	15.98	5.87e-46	2.87e-42	0.84	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138978417	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.931	rs10070021	ENSG00000253404.1	AC034243.1	15.97	6.95e-46	3.39e-42	0.8	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138989017	chr5:138744434~138753309:-
PRAD	cis	rs492146	0.902	rs385636	ENSG00000243236.5	GSTA9P	-15.96	7.11e-46	3.46e-42	-0.74	-0.6	Epilepsy (remission after treatment);	chr6:52976139	chr6:52939726~52957521:-
PRAD	cis	rs950027	0.595	rs2486288	ENSG00000259520.4	CTD-2651B20.3	-15.95	8.33e-46	4.05e-42	-0.75	-0.6	Response to fenofibrate (adiponectin levels);	chr15:45420141	chr15:45251580~45279251:-
PRAD	cis	rs4423214	0.65	rs7940244	ENSG00000254682.1	RP11-660L16.2	-15.95	8.47e-46	4.12e-42	-0.8	-0.6	Vitamin D levels;	chr11:71510528	chr11:71448674~71452157:+
PRAD	cis	rs2882667	0.931	rs11955952	ENSG00000253404.1	AC034243.1	15.95	8.51e-46	4.14e-42	0.79	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138993430	chr5:138744434~138753309:-
PRAD	cis	rs12022452	0.591	rs6672398	ENSG00000238287.1	RP11-656D10.3	-15.94	8.7e-46	4.23e-42	-0.9	-0.6	Age-related hearing impairment (SNP x SNP interaction);	chr1:40536505	chr1:40493157~40508661:-
PRAD	cis	rs11155671	0.53	rs4870080	ENSG00000268592.3	RAET1E-AS1	15.94	9.03e-46	4.39e-42	0.83	0.6	Testicular germ cell tumor;	chr6:149881508	chr6:149863494~149919507:+
PRAD	cis	rs2486288	0.539	rs2433601	ENSG00000259520.4	CTD-2651B20.3	-15.94	9.05e-46	4.4e-42	-0.75	-0.6	Glomerular filtration rate;	chr15:45424227	chr15:45251580~45279251:-
PRAD	cis	rs858239	0.712	rs200717	ENSG00000230658.1	KLHL7-AS1	15.92	1.15e-45	5.58e-42	0.72	0.6	Cerebrospinal fluid biomarker levels;	chr7:23352652	chr7:23101228~23105703:-
PRAD	cis	rs7188445	0.933	rs7187128	ENSG00000261390.4	RP11-345M22.2	-15.91	1.27e-45	6.16e-42	-0.72	-0.6	Urate levels;	chr16:79675606	chr16:79715232~79770563:-
PRAD	cis	rs12022452	0.63	rs3795346	ENSG00000238287.1	RP11-656D10.3	-15.91	1.3e-45	6.29e-42	-0.91	-0.6	Age-related hearing impairment (SNP x SNP interaction);	chr1:40508753	chr1:40493157~40508661:-
PRAD	cis	rs977987	0.735	rs11149831	ENSG00000261783.1	RP11-252K23.2	-15.9	1.32e-45	6.41e-42	-0.85	-0.6	Dupuytren's disease;	chr16:75417563	chr16:75379818~75381260:-
PRAD	cis	rs4423214	0.65	rs4245442	ENSG00000254682.1	RP11-660L16.2	15.9	1.4e-45	6.75e-42	0.8	0.6	Vitamin D levels;	chr11:71509863	chr11:71448674~71452157:+
PRAD	cis	rs11690935	0.959	rs1474074	ENSG00000228389.1	AC068039.4	15.89	1.45e-45	7e-42	0.71	0.6	Schizophrenia;	chr2:171803342	chr2:171773482~171775844:+
PRAD	cis	rs11690935	0.851	rs9808259	ENSG00000228389.1	AC068039.4	15.88	1.72e-45	8.27e-42	0.7	0.6	Schizophrenia;	chr2:171792464	chr2:171773482~171775844:+
PRAD	cis	rs1577917	0.74	rs7775864	ENSG00000203875.9	SNHG5	15.88	1.73e-45	8.35e-42	0.64	0.6	Response to antipsychotic treatment;	chr6:85538041	chr6:85660950~85678736:-
PRAD	cis	rs10256972	0.524	rs6945202	ENSG00000229043.2	AC091729.9	-15.88	1.74e-45	8.38e-42	-0.74	-0.6	Endometriosis;Longevity;	chr7:1076922	chr7:1160374~1165267:+
PRAD	cis	rs9326248	0.861	rs494356	ENSG00000254851.1	RP11-109L13.1	-15.87	1.86e-45	8.94e-42	-1.06	-0.6	Blood protein levels;	chr11:117201254	chr11:117135528~117138582:+
PRAD	cis	rs977987	0.735	rs166013	ENSG00000261783.1	RP11-252K23.2	15.86	1.96e-45	9.42e-42	0.84	0.6	Dupuytren's disease;	chr16:75400248	chr16:75379818~75381260:-
PRAD	cis	rs1972460	0.506	rs62012050	ENSG00000278603.1	RP13-608F4.5	15.86	1.99e-45	9.56e-42	0.85	0.6	Intelligence (multi-trait analysis);	chr15:82239933	chr15:82472203~82472426:+
PRAD	cis	rs950027	0.62	rs1719246	ENSG00000259520.4	CTD-2651B20.3	-15.85	2.24e-45	1.08e-41	-0.75	-0.6	Response to fenofibrate (adiponectin levels);	chr15:45333281	chr15:45251580~45279251:-
PRAD	cis	rs7104764	0.957	rs10794301	ENSG00000277290.1	RP11-326C3.16	-15.85	2.38e-45	1.14e-41	-0.58	-0.6	Menarche (age at onset);	chr11:220401	chr11:243099~243483:-
PRAD	cis	rs7188445	0.898	rs74037508	ENSG00000261390.4	RP11-345M22.2	-15.84	2.47e-45	1.18e-41	-0.73	-0.6	Urate levels;	chr16:79677439	chr16:79715232~79770563:-
PRAD	cis	rs950027	0.62	rs1153862	ENSG00000259520.4	CTD-2651B20.3	-15.83	2.8e-45	1.34e-41	-0.75	-0.6	Response to fenofibrate (adiponectin levels);	chr15:45339670	chr15:45251580~45279251:-
PRAD	cis	rs1577917	0.74	rs9353320	ENSG00000203875.9	SNHG5	15.83	2.87e-45	1.37e-41	0.64	0.6	Response to antipsychotic treatment;	chr6:85535130	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.74	rs2758845	ENSG00000203875.9	SNHG5	-15.82	3.1e-45	1.48e-41	-0.65	-0.6	Response to antipsychotic treatment;	chr6:85625130	chr6:85660950~85678736:-
PRAD	cis	rs950027	0.62	rs35861938	ENSG00000259520.4	CTD-2651B20.3	-15.82	3.23e-45	1.54e-41	-0.75	-0.6	Response to fenofibrate (adiponectin levels);	chr15:45345145	chr15:45251580~45279251:-
PRAD	cis	rs1577917	0.883	rs6454505	ENSG00000203875.9	SNHG5	-15.81	3.29e-45	1.57e-41	-0.66	-0.6	Response to antipsychotic treatment;	chr6:85882644	chr6:85660950~85678736:-
PRAD	cis	rs12439619	1	rs12439619	ENSG00000278603.1	RP13-608F4.5	15.81	3.35e-45	1.6e-41	0.84	0.6	Intelligence (multi-trait analysis);	chr15:82254605	chr15:82472203~82472426:+
PRAD	cis	rs7188445	0.933	rs11644082	ENSG00000261390.4	RP11-345M22.2	-15.81	3.38e-45	1.61e-41	-0.72	-0.6	Urate levels;	chr16:79680519	chr16:79715232~79770563:-
PRAD	cis	rs12022452	0.591	rs4660415	ENSG00000238287.1	RP11-656D10.3	-15.81	3.39e-45	1.62e-41	-0.91	-0.6	Age-related hearing impairment (SNP x SNP interaction);	chr1:40512819	chr1:40493157~40508661:-
PRAD	cis	rs12022452	0.556	rs11208298	ENSG00000238287.1	RP11-656D10.3	-15.81	3.39e-45	1.62e-41	-0.91	-0.6	Age-related hearing impairment (SNP x SNP interaction);	chr1:40513206	chr1:40493157~40508661:-
PRAD	cis	rs12022452	0.591	rs61781641	ENSG00000238287.1	RP11-656D10.3	-15.81	3.42e-45	1.63e-41	-0.91	-0.6	Age-related hearing impairment (SNP x SNP interaction);	chr1:40517412	chr1:40493157~40508661:-
PRAD	cis	rs12022452	0.591	rs12049435	ENSG00000238287.1	RP11-656D10.3	-15.81	3.42e-45	1.63e-41	-0.91	-0.6	Age-related hearing impairment (SNP x SNP interaction);	chr1:40524888	chr1:40493157~40508661:-
PRAD	cis	rs950027	0.62	rs1719245	ENSG00000259520.4	CTD-2651B20.3	-15.81	3.46e-45	1.65e-41	-0.75	-0.6	Response to fenofibrate (adiponectin levels);	chr15:45331584	chr15:45251580~45279251:-
PRAD	cis	rs858239	0.676	rs3807459	ENSG00000230658.1	KLHL7-AS1	15.81	3.59e-45	1.71e-41	0.73	0.6	Cerebrospinal fluid biomarker levels;	chr7:23350132	chr7:23101228~23105703:-
PRAD	cis	rs492146	0.935	rs316135	ENSG00000243236.5	GSTA9P	-15.8	3.62e-45	1.73e-41	-0.74	-0.6	Epilepsy (remission after treatment);	chr6:52981979	chr6:52939726~52957521:-
PRAD	cis	rs950027	0.596	rs2467853	ENSG00000259520.4	CTD-2651B20.3	-15.8	3.7e-45	1.76e-41	-0.74	-0.6	Response to fenofibrate (adiponectin levels);	chr15:45406595	chr15:45251580~45279251:-
PRAD	cis	rs17507216	0.718	rs28587782	ENSG00000278603.1	RP13-608F4.5	15.8	3.77e-45	1.8e-41	0.95	0.6	Excessive daytime sleepiness;	chr15:82576881	chr15:82472203~82472426:+
PRAD	cis	rs7309	0.967	rs3754970	ENSG00000227403.1	AC009299.3	-15.8	3.9e-45	1.86e-41	-0.79	-0.6	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161235325	chr2:161244739~161249050:+
PRAD	cis	rs492146	0.935	rs316137	ENSG00000243236.5	GSTA9P	-15.79	4.03e-45	1.92e-41	-0.74	-0.6	Epilepsy (remission after treatment);	chr6:52981882	chr6:52939726~52957521:-
PRAD	cis	rs492146	0.902	rs316136	ENSG00000243236.5	GSTA9P	-15.79	4.03e-45	1.92e-41	-0.74	-0.6	Epilepsy (remission after treatment);	chr6:52981971	chr6:52939726~52957521:-
PRAD	cis	rs7104764	0.879	rs6598072	ENSG00000277290.1	RP11-326C3.16	-15.79	4.04e-45	1.92e-41	-0.58	-0.6	Menarche (age at onset);	chr11:219793	chr11:243099~243483:-
PRAD	cis	rs7104764	0.957	rs6598071	ENSG00000277290.1	RP11-326C3.16	-15.79	4.04e-45	1.92e-41	-0.58	-0.6	Menarche (age at onset);	chr11:219800	chr11:243099~243483:-
PRAD	cis	rs12022452	0.591	rs16827359	ENSG00000238287.1	RP11-656D10.3	15.79	4.04e-45	1.92e-41	0.91	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr1:40535766	chr1:40493157~40508661:-
PRAD	cis	rs1577917	0.74	rs2842614	ENSG00000203875.9	SNHG5	-15.79	4.09e-45	1.95e-41	-0.65	-0.6	Response to antipsychotic treatment;	chr6:85596351	chr6:85660950~85678736:-
PRAD	cis	rs12022452	0.591	rs11208356	ENSG00000238287.1	RP11-656D10.3	-15.79	4.12e-45	1.96e-41	-0.92	-0.6	Age-related hearing impairment (SNP x SNP interaction);	chr1:40541259	chr1:40493157~40508661:-
PRAD	cis	rs7188445	0.933	rs28773265	ENSG00000261390.4	RP11-345M22.2	-15.79	4.2e-45	2e-41	-0.73	-0.59	Urate levels;	chr16:79678864	chr16:79715232~79770563:-
PRAD	cis	rs7617773	0.746	rs11713476	ENSG00000229759.1	MRPS18AP1	15.79	4.38e-45	2.08e-41	0.63	0.59	Coronary artery disease;	chr3:48333944	chr3:48256350~48256938:-
PRAD	cis	rs7188445	0.583	rs80170002	ENSG00000261390.4	RP11-345M22.2	-15.77	5e-45	2.38e-41	-0.73	-0.59	Urate levels;	chr16:79677817	chr16:79715232~79770563:-
PRAD	cis	rs12022452	0.506	rs11208363	ENSG00000238287.1	RP11-656D10.3	-15.77	5.23e-45	2.48e-41	-0.91	-0.59	Age-related hearing impairment (SNP x SNP interaction);	chr1:40544782	chr1:40493157~40508661:-
PRAD	cis	rs11155671	0.53	rs6557133	ENSG00000268592.3	RAET1E-AS1	15.77	5.24e-45	2.49e-41	0.82	0.59	Testicular germ cell tumor;	chr6:149874248	chr6:149863494~149919507:+
PRAD	cis	rs950027	0.596	rs2467865	ENSG00000259520.4	CTD-2651B20.3	-15.77	5.29e-45	2.51e-41	-0.74	-0.59	Response to fenofibrate (adiponectin levels);	chr15:45346109	chr15:45251580~45279251:-
PRAD	cis	rs950027	0.62	rs2461700	ENSG00000259520.4	CTD-2651B20.3	-15.77	5.29e-45	2.51e-41	-0.74	-0.59	Response to fenofibrate (adiponectin levels);	chr15:45348429	chr15:45251580~45279251:-
PRAD	cis	rs950027	0.62	rs2453533	ENSG00000259520.4	CTD-2651B20.3	-15.77	5.29e-45	2.51e-41	-0.74	-0.59	Response to fenofibrate (adiponectin levels);	chr15:45349027	chr15:45251580~45279251:-
PRAD	cis	rs2455601	0.671	rs2568091	ENSG00000254860.4	TMEM9B-AS1	15.77	5.31e-45	2.52e-41	0.69	0.59	Schizophrenia;	chr11:8964501	chr11:8964675~8977527:+
PRAD	cis	rs9487094	0.689	rs1074766	ENSG00000260273.1	RP11-425D10.10	15.76	5.6e-45	2.66e-41	0.78	0.59	Height;	chr6:109360263	chr6:109382795~109383666:+
PRAD	cis	rs2882667	0.931	rs1433009	ENSG00000253404.1	AC034243.1	15.76	5.7e-45	2.7e-41	0.79	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:138998095	chr5:138744434~138753309:-
PRAD	cis	rs12022452	0.591	rs11208315	ENSG00000238287.1	RP11-656D10.3	-15.76	5.89e-45	2.79e-41	-0.9	-0.59	Age-related hearing impairment (SNP x SNP interaction);	chr1:40519730	chr1:40493157~40508661:-
PRAD	cis	rs950027	0.62	rs1145093	ENSG00000259520.4	CTD-2651B20.3	-15.75	6.33e-45	3e-41	-0.74	-0.59	Response to fenofibrate (adiponectin levels);	chr15:45357615	chr15:45251580~45279251:-
PRAD	cis	rs950027	0.62	rs1145089	ENSG00000259520.4	CTD-2651B20.3	-15.75	6.33e-45	3e-41	-0.74	-0.59	Response to fenofibrate (adiponectin levels);	chr15:45359856	chr15:45251580~45279251:-
PRAD	cis	rs950027	0.62	rs1049518	ENSG00000259520.4	CTD-2651B20.3	-15.75	6.33e-45	3e-41	-0.74	-0.59	Response to fenofibrate (adiponectin levels);	chr15:45361169	chr15:45251580~45279251:-
PRAD	cis	rs950027	0.584	rs1145086	ENSG00000259520.4	CTD-2651B20.3	-15.75	6.33e-45	3e-41	-0.74	-0.59	Response to fenofibrate (adiponectin levels);	chr15:45362129	chr15:45251580~45279251:-
PRAD	cis	rs950027	0.62	rs1153857	ENSG00000259520.4	CTD-2651B20.3	-15.75	6.33e-45	3e-41	-0.74	-0.59	Response to fenofibrate (adiponectin levels);	chr15:45366897	chr15:45251580~45279251:-
PRAD	cis	rs950027	0.62	rs1153855	ENSG00000259520.4	CTD-2651B20.3	-15.75	6.33e-45	3e-41	-0.74	-0.59	Response to fenofibrate (adiponectin levels);	chr15:45368560	chr15:45251580~45279251:-
PRAD	cis	rs950027	0.62	rs2486274	ENSG00000259520.4	CTD-2651B20.3	-15.75	6.33e-45	3e-41	-0.74	-0.59	Response to fenofibrate (adiponectin levels);	chr15:45374030	chr15:45251580~45279251:-
PRAD	cis	rs950027	0.62	rs1145084	ENSG00000259520.4	CTD-2651B20.3	-15.75	6.33e-45	3e-41	-0.74	-0.59	Response to fenofibrate (adiponectin levels);	chr15:45383242	chr15:45251580~45279251:-
PRAD	cis	rs950027	0.62	rs1145080	ENSG00000259520.4	CTD-2651B20.3	-15.75	6.33e-45	3e-41	-0.74	-0.59	Response to fenofibrate (adiponectin levels);	chr15:45389140	chr15:45251580~45279251:-
PRAD	cis	rs950027	0.62	rs1426932	ENSG00000259520.4	CTD-2651B20.3	-15.75	6.33e-45	3e-41	-0.74	-0.59	Response to fenofibrate (adiponectin levels);	chr15:45395058	chr15:45251580~45279251:-
PRAD	cis	rs9322193	0.543	rs9371533	ENSG00000268592.3	RAET1E-AS1	15.74	6.96e-45	3.28e-41	0.84	0.59	Lung cancer;	chr6:149889545	chr6:149863494~149919507:+
PRAD	cis	rs1577917	0.74	rs7752502	ENSG00000203875.9	SNHG5	15.74	7.23e-45	3.41e-41	0.64	0.59	Response to antipsychotic treatment;	chr6:85700933	chr6:85660950~85678736:-
PRAD	cis	rs11690935	0.959	rs7608403	ENSG00000228389.1	AC068039.4	15.73	7.51e-45	3.54e-41	0.69	0.59	Schizophrenia;	chr2:171790255	chr2:171773482~171775844:+
PRAD	cis	rs7188445	0.871	rs8047723	ENSG00000261390.4	RP11-345M22.2	15.72	8.29e-45	3.9e-41	0.7	0.59	Urate levels;	chr16:79671018	chr16:79715232~79770563:-
PRAD	cis	rs10256972	0.732	rs12701856	ENSG00000229043.2	AC091729.9	-15.72	8.85e-45	4.16e-41	-0.73	-0.59	Endometriosis;Longevity;	chr7:1068071	chr7:1160374~1165267:+
PRAD	cis	rs7104764	1	rs6598060	ENSG00000277290.1	RP11-326C3.16	-15.72	8.85e-45	4.17e-41	-0.57	-0.59	Menarche (age at onset);	chr11:243987	chr11:243099~243483:-
PRAD	cis	rs9487094	0.689	rs9487069	ENSG00000260273.1	RP11-425D10.10	15.71	9.67e-45	4.54e-41	0.78	0.59	Height;	chr6:109358652	chr6:109382795~109383666:+
PRAD	cis	rs950027	0.62	rs2467862	ENSG00000259520.4	CTD-2651B20.3	-15.71	1.01e-44	4.73e-41	-0.74	-0.59	Response to fenofibrate (adiponectin levels);	chr15:45351645	chr15:45251580~45279251:-
PRAD	cis	rs950027	0.62	rs1145076	ENSG00000259520.4	CTD-2651B20.3	-15.7	1.02e-44	4.77e-41	-0.74	-0.59	Response to fenofibrate (adiponectin levels);	chr15:45392310	chr15:45251580~45279251:-
PRAD	cis	rs73086581	0.947	rs73084531	ENSG00000229539.1	RP11-119B16.2	15.7	1.02e-44	4.81e-41	1.06	0.59	Response to antidepressants in depression;	chr20:3897782	chr20:3888239~3888868:-
PRAD	cis	rs950027	0.62	rs1153860	ENSG00000259520.4	CTD-2651B20.3	15.7	1.06e-44	4.98e-41	0.74	0.59	Response to fenofibrate (adiponectin levels);	chr15:45344386	chr15:45251580~45279251:-
PRAD	cis	rs11690935	0.959	rs10167419	ENSG00000228389.1	AC068039.4	15.7	1.11e-44	5.21e-41	0.69	0.59	Schizophrenia;	chr2:171793316	chr2:171773482~171775844:+
PRAD	cis	rs492146	0.935	rs405729	ENSG00000243236.5	GSTA9P	-15.69	1.12e-44	5.25e-41	-0.74	-0.59	Epilepsy (remission after treatment);	chr6:52977983	chr6:52939726~52957521:-
PRAD	cis	rs1577917	0.696	rs2842603	ENSG00000203875.9	SNHG5	-15.69	1.13e-44	5.3e-41	-0.65	-0.59	Response to antipsychotic treatment;	chr6:85626619	chr6:85660950~85678736:-
PRAD	cis	rs1930961	1	rs6004668	ENSG00000272977.1	CTA-390C10.10	15.69	1.14e-44	5.36e-41	0.94	0.59	Bipolar disorder with mood-incongruent psychosis;	chr22:25478535	chr22:25476218~25479971:+
PRAD	cis	rs2882667	0.931	rs10069528	ENSG00000253404.1	AC034243.1	15.69	1.19e-44	5.56e-41	0.79	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:139018338	chr5:138744434~138753309:-
PRAD	cis	rs7104764	1	rs10902112	ENSG00000277290.1	RP11-326C3.16	-15.69	1.19e-44	5.57e-41	-0.57	-0.59	Menarche (age at onset);	chr11:244106	chr11:243099~243483:-
PRAD	cis	rs7104764	0.917	rs7107362	ENSG00000277290.1	RP11-326C3.16	-15.69	1.19e-44	5.57e-41	-0.57	-0.59	Menarche (age at onset);	chr11:244108	chr11:243099~243483:-
PRAD	cis	rs7104764	1	rs7128044	ENSG00000277290.1	RP11-326C3.16	-15.69	1.19e-44	5.57e-41	-0.57	-0.59	Menarche (age at onset);	chr11:244115	chr11:243099~243483:-
PRAD	cis	rs7104764	0.957	rs7116130	ENSG00000277290.1	RP11-326C3.16	-15.69	1.19e-44	5.57e-41	-0.57	-0.59	Menarche (age at onset);	chr11:244129	chr11:243099~243483:-
PRAD	cis	rs7104764	1	rs7128029	ENSG00000277290.1	RP11-326C3.16	-15.69	1.19e-44	5.57e-41	-0.57	-0.59	Menarche (age at onset);	chr11:244141	chr11:243099~243483:-
PRAD	cis	rs7104764	1	rs1128320	ENSG00000277290.1	RP11-326C3.16	-15.69	1.19e-44	5.57e-41	-0.57	-0.59	Menarche (age at onset);	chr11:244167	chr11:243099~243483:-
PRAD	cis	rs7104764	0.957	rs1128321	ENSG00000277290.1	RP11-326C3.16	-15.69	1.19e-44	5.57e-41	-0.57	-0.59	Menarche (age at onset);	chr11:244171	chr11:243099~243483:-
PRAD	cis	rs7104764	1	rs2272565	ENSG00000277290.1	RP11-326C3.16	-15.69	1.19e-44	5.57e-41	-0.57	-0.59	Menarche (age at onset);	chr11:244414	chr11:243099~243483:-
PRAD	cis	rs7104764	1	rs10902113	ENSG00000277290.1	RP11-326C3.16	-15.69	1.19e-44	5.57e-41	-0.57	-0.59	Menarche (age at onset);	chr11:245523	chr11:243099~243483:-
PRAD	cis	rs7104764	1	rs7482591	ENSG00000277290.1	RP11-326C3.16	-15.69	1.19e-44	5.57e-41	-0.57	-0.59	Menarche (age at onset);	chr11:245861	chr11:243099~243483:-
PRAD	cis	rs17507216	0.718	rs4779033	ENSG00000278603.1	RP13-608F4.5	-15.68	1.24e-44	5.78e-41	-0.98	-0.59	Excessive daytime sleepiness;	chr15:82576634	chr15:82472203~82472426:+
PRAD	cis	rs1577917	0.816	rs12664099	ENSG00000203875.9	SNHG5	-15.68	1.25e-44	5.84e-41	-0.64	-0.59	Response to antipsychotic treatment;	chr6:85938854	chr6:85660950~85678736:-
PRAD	cis	rs492146	0.935	rs375887	ENSG00000243236.5	GSTA9P	-15.68	1.28e-44	5.96e-41	-0.74	-0.59	Epilepsy (remission after treatment);	chr6:52978679	chr6:52939726~52957521:-
PRAD	cis	rs7104764	1	rs6598069	ENSG00000277290.1	RP11-326C3.16	-15.68	1.28e-44	5.96e-41	-0.57	-0.59	Menarche (age at onset);	chr11:240664	chr11:243099~243483:-
PRAD	cis	rs7104764	0.917	rs6598068	ENSG00000277290.1	RP11-326C3.16	-15.68	1.28e-44	5.96e-41	-0.57	-0.59	Menarche (age at onset);	chr11:243092	chr11:243099~243483:-
PRAD	cis	rs7104764	0.917	rs6598067	ENSG00000277290.1	RP11-326C3.16	-15.68	1.28e-44	5.96e-41	-0.57	-0.59	Menarche (age at onset);	chr11:243093	chr11:243099~243483:-
PRAD	cis	rs7104764	1	rs6598065	ENSG00000277290.1	RP11-326C3.16	-15.68	1.28e-44	5.96e-41	-0.57	-0.59	Menarche (age at onset);	chr11:243211	chr11:243099~243483:-
PRAD	cis	rs7104764	0.957	rs6598064	ENSG00000277290.1	RP11-326C3.16	-15.68	1.28e-44	5.96e-41	-0.57	-0.59	Menarche (age at onset);	chr11:243557	chr11:243099~243483:-
PRAD	cis	rs7104764	1	rs6598063	ENSG00000277290.1	RP11-326C3.16	-15.68	1.28e-44	5.96e-41	-0.57	-0.59	Menarche (age at onset);	chr11:243672	chr11:243099~243483:-
PRAD	cis	rs7104764	1	rs6598062	ENSG00000277290.1	RP11-326C3.16	-15.68	1.28e-44	5.96e-41	-0.57	-0.59	Menarche (age at onset);	chr11:243712	chr11:243099~243483:-
PRAD	cis	rs7104764	1	rs6598061	ENSG00000277290.1	RP11-326C3.16	-15.68	1.28e-44	5.96e-41	-0.57	-0.59	Menarche (age at onset);	chr11:243853	chr11:243099~243483:-
PRAD	cis	rs4423214	1	rs3750997	ENSG00000254682.1	RP11-660L16.2	15.68	1.3e-44	6.06e-41	0.75	0.59	Vitamin D levels;	chr11:71447795	chr11:71448674~71452157:+
PRAD	cis	rs950027	0.62	rs1145077	ENSG00000259520.4	CTD-2651B20.3	15.68	1.32e-44	6.12e-41	0.75	0.59	Response to fenofibrate (adiponectin levels);	chr15:45391597	chr15:45251580~45279251:-
PRAD	cis	rs1577917	0.839	rs1596990	ENSG00000203875.9	SNHG5	-15.68	1.33e-44	6.18e-41	-0.64	-0.59	Response to antipsychotic treatment;	chr6:85840974	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.637	rs1838957	ENSG00000203875.9	SNHG5	-15.68	1.33e-44	6.18e-41	-0.64	-0.59	Response to antipsychotic treatment;	chr6:85855338	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.839	rs1838956	ENSG00000203875.9	SNHG5	-15.68	1.33e-44	6.18e-41	-0.64	-0.59	Response to antipsychotic treatment;	chr6:85855545	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.839	rs12216103	ENSG00000203875.9	SNHG5	-15.68	1.33e-44	6.18e-41	-0.64	-0.59	Response to antipsychotic treatment;	chr6:85861410	chr6:85660950~85678736:-
PRAD	cis	rs7104764	1	rs10794302	ENSG00000277290.1	RP11-326C3.16	-15.67	1.41e-44	6.55e-41	-0.57	-0.59	Menarche (age at onset);	chr11:234102	chr11:243099~243483:-
PRAD	cis	rs4423214	0.959	rs11606033	ENSG00000254682.1	RP11-660L16.2	15.67	1.42e-44	6.58e-41	0.75	0.59	Vitamin D levels;	chr11:71443158	chr11:71448674~71452157:+
PRAD	cis	rs4423214	1	rs1044482	ENSG00000254682.1	RP11-660L16.2	15.67	1.42e-44	6.58e-41	0.75	0.59	Vitamin D levels;	chr11:71444125	chr11:71448674~71452157:+
PRAD	cis	rs492146	0.935	rs316139	ENSG00000243236.5	GSTA9P	-15.67	1.49e-44	6.92e-41	-0.74	-0.59	Epilepsy (remission after treatment);	chr6:52981574	chr6:52939726~52957521:-
PRAD	cis	rs7208859	0.623	rs56325146	ENSG00000263531.1	RP13-753N3.1	15.66	1.66e-44	7.7e-41	1.18	0.59	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824006	chr17:30863921~30864940:-
PRAD	cis	rs1577917	0.74	rs2475792	ENSG00000203875.9	SNHG5	15.65	1.68e-44	7.81e-41	0.63	0.59	Response to antipsychotic treatment;	chr6:85682384	chr6:85660950~85678736:-
PRAD	cis	rs10256972	0.732	rs1574108	ENSG00000229043.2	AC091729.9	-15.65	1.84e-44	8.51e-41	-0.73	-0.59	Endometriosis;Longevity;	chr7:1066169	chr7:1160374~1165267:+
PRAD	cis	rs11690935	0.959	rs6705200	ENSG00000228389.1	AC068039.4	15.65	1.84e-44	8.54e-41	0.69	0.59	Schizophrenia;	chr2:171781090	chr2:171773482~171775844:+
PRAD	cis	rs7104764	1	rs7104764	ENSG00000277290.1	RP11-326C3.16	-15.65	1.85e-44	8.56e-41	-0.57	-0.59	Menarche (age at onset);	chr11:229977	chr11:243099~243483:-
PRAD	cis	rs7104764	1	rs7483951	ENSG00000277290.1	RP11-326C3.16	-15.65	1.85e-44	8.56e-41	-0.57	-0.59	Menarche (age at onset);	chr11:231758	chr11:243099~243483:-
PRAD	cis	rs7104764	1	rs9795476	ENSG00000277290.1	RP11-326C3.16	-15.65	1.85e-44	8.56e-41	-0.57	-0.59	Menarche (age at onset);	chr11:235894	chr11:243099~243483:-
PRAD	cis	rs2882667	0.931	rs10075039	ENSG00000253404.1	AC034243.1	15.64	1.94e-44	8.99e-41	0.78	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:139002165	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.931	rs10068237	ENSG00000253404.1	AC034243.1	15.64	1.94e-44	8.99e-41	0.78	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:139002271	chr5:138744434~138753309:-
PRAD	cis	rs3931020	0.53	rs12125889	ENSG00000272864.1	RP11-17E13.2	-15.62	2.32e-44	1.07e-40	-0.6	-0.59	Resistin levels;	chr1:74776287	chr1:74698769~74699333:-
PRAD	cis	rs1577917	0.796	rs12661231	ENSG00000203875.9	SNHG5	-15.62	2.36e-44	1.09e-40	-0.64	-0.59	Response to antipsychotic treatment;	chr6:85834753	chr6:85660950~85678736:-
PRAD	cis	rs7208859	0.673	rs56146117	ENSG00000263531.1	RP13-753N3.1	15.62	2.39e-44	1.1e-40	1.23	0.59	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30826307	chr17:30863921~30864940:-
PRAD	cis	rs2882667	0.931	rs6596457	ENSG00000253404.1	AC034243.1	15.62	2.42e-44	1.11e-40	0.79	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:138987690	chr5:138744434~138753309:-
PRAD	cis	rs17507216	0.609	rs1431716	ENSG00000278603.1	RP13-608F4.5	15.62	2.43e-44	1.12e-40	0.98	0.59	Excessive daytime sleepiness;	chr15:82676180	chr15:82472203~82472426:+
PRAD	cis	rs7208859	0.623	rs55724095	ENSG00000263531.1	RP13-753N3.1	15.62	2.45e-44	1.13e-40	1.19	0.59	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30826040	chr17:30863921~30864940:-
PRAD	cis	rs17826219	0.568	rs9903854	ENSG00000263531.1	RP13-753N3.1	15.62	2.45e-44	1.13e-40	1.19	0.59	Body mass index;	chr17:30826980	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs80355557	ENSG00000263531.1	RP13-753N3.1	15.62	2.45e-44	1.13e-40	1.19	0.59	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827403	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs9911173	ENSG00000263531.1	RP13-753N3.1	15.62	2.45e-44	1.13e-40	1.19	0.59	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827732	chr17:30863921~30864940:-
PRAD	cis	rs1577917	0.839	rs12055653	ENSG00000203875.9	SNHG5	-15.61	2.61e-44	1.2e-40	-0.64	-0.59	Response to antipsychotic treatment;	chr6:85836945	chr6:85660950~85678736:-
PRAD	cis	rs7104764	0.957	rs3817629	ENSG00000277290.1	RP11-326C3.16	-15.61	2.62e-44	1.2e-40	-0.57	-0.59	Menarche (age at onset);	chr11:237312	chr11:243099~243483:-
PRAD	cis	rs1577917	0.916	rs12661611	ENSG00000203875.9	SNHG5	-15.61	2.63e-44	1.21e-40	-0.64	-0.59	Response to antipsychotic treatment;	chr6:85844117	chr6:85660950~85678736:-
PRAD	cis	rs9322193	0.504	rs7771014	ENSG00000268592.3	RAET1E-AS1	15.61	2.72e-44	1.25e-40	0.82	0.59	Lung cancer;	chr6:149884310	chr6:149863494~149919507:+
PRAD	cis	rs2882667	0.931	rs10075951	ENSG00000253404.1	AC034243.1	15.6	2.94e-44	1.35e-40	0.79	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:139020274	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.894	rs10054478	ENSG00000253404.1	AC034243.1	15.6	2.95e-44	1.35e-40	0.78	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:139018386	chr5:138744434~138753309:-
PRAD	cis	rs7208859	0.673	rs28588622	ENSG00000263531.1	RP13-753N3.1	15.6	2.95e-44	1.35e-40	1.23	0.59	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30918681	chr17:30863921~30864940:-
PRAD	cis	rs7188445	0.966	rs79193369	ENSG00000261390.4	RP11-345M22.2	-15.6	2.97e-44	1.36e-40	-0.76	-0.59	Urate levels;	chr16:79691119	chr16:79715232~79770563:-
PRAD	cis	rs1577917	0.655	rs9359658	ENSG00000203875.9	SNHG5	15.6	2.99e-44	1.37e-40	0.64	0.59	Response to antipsychotic treatment;	chr6:85596051	chr6:85660950~85678736:-
PRAD	cis	rs492146	0.935	rs316128	ENSG00000243236.5	GSTA9P	-15.6	3.03e-44	1.39e-40	-0.73	-0.59	Epilepsy (remission after treatment);	chr6:52984348	chr6:52939726~52957521:-
PRAD	cis	rs2739330	0.76	rs5751761	ENSG00000218537.1	MIF-AS1	-15.6	3.07e-44	1.41e-40	-0.76	-0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23894426~23898930:-
PRAD	cis	rs12022452	0.556	rs12037288	ENSG00000238287.1	RP11-656D10.3	-15.6	3.08e-44	1.41e-40	-0.9	-0.59	Age-related hearing impairment (SNP x SNP interaction);	chr1:40530625	chr1:40493157~40508661:-
PRAD	cis	rs12022452	0.591	rs1001400	ENSG00000238287.1	RP11-656D10.3	-15.6	3.08e-44	1.41e-40	-0.9	-0.59	Age-related hearing impairment (SNP x SNP interaction);	chr1:40533230	chr1:40493157~40508661:-
PRAD	cis	rs7104764	1	rs10902114	ENSG00000277290.1	RP11-326C3.16	-15.6	3.08e-44	1.41e-40	-0.57	-0.59	Menarche (age at onset);	chr11:246234	chr11:243099~243483:-
PRAD	cis	rs1577917	0.682	rs1173419	ENSG00000203875.9	SNHG5	-15.6	3.1e-44	1.42e-40	-0.63	-0.59	Response to antipsychotic treatment;	chr6:85692445	chr6:85660950~85678736:-
PRAD	cis	rs12022452	0.544	rs11208423	ENSG00000238287.1	RP11-656D10.3	-15.59	3.16e-44	1.45e-40	-0.92	-0.59	Age-related hearing impairment (SNP x SNP interaction);	chr1:40563942	chr1:40493157~40508661:-
PRAD	cis	rs9487094	0.601	rs4945831	ENSG00000260273.1	RP11-425D10.10	15.59	3.31e-44	1.51e-40	0.78	0.59	Height;	chr6:109440234	chr6:109382795~109383666:+
PRAD	cis	rs9487094	0.689	rs1476387	ENSG00000260273.1	RP11-425D10.10	15.59	3.31e-44	1.51e-40	0.78	0.59	Height;	chr6:109443332	chr6:109382795~109383666:+
PRAD	cis	rs492146	0.935	rs492825	ENSG00000243236.5	GSTA9P	-15.59	3.43e-44	1.57e-40	-0.73	-0.59	Epilepsy (remission after treatment);	chr6:52980595	chr6:52939726~52957521:-
PRAD	cis	rs10256972	0.684	rs4724039	ENSG00000229043.2	AC091729.9	-15.58	3.58e-44	1.63e-40	-0.71	-0.59	Endometriosis;Longevity;	chr7:1071997	chr7:1160374~1165267:+
PRAD	cis	rs9487094	0.666	rs736830	ENSG00000260273.1	RP11-425D10.10	15.58	3.72e-44	1.7e-40	0.78	0.59	Height;	chr6:109392096	chr6:109382795~109383666:+
PRAD	cis	rs7104764	1	rs7395328	ENSG00000277290.1	RP11-326C3.16	-15.57	4.03e-44	1.84e-40	-0.57	-0.59	Menarche (age at onset);	chr11:242624	chr11:243099~243483:-
PRAD	cis	rs760794	0.577	rs7752808	ENSG00000228412.5	RP4-625H18.2	15.56	4.48e-44	2.04e-40	0.74	0.59	Endometriosis;	chr6:19792665	chr6:19802164~19804752:-
PRAD	cis	rs9322193	0.543	rs9371533	ENSG00000231760.4	RP11-350J20.5	15.56	4.56e-44	2.07e-40	0.82	0.59	Lung cancer;	chr6:149889545	chr6:149796151~149826294:-
PRAD	cis	rs7104764	1	rs2272563	ENSG00000277290.1	RP11-326C3.16	-15.55	4.97e-44	2.26e-40	-0.57	-0.59	Menarche (age at onset);	chr11:236871	chr11:243099~243483:-
PRAD	cis	rs7104764	0.917	rs1045288	ENSG00000277290.1	RP11-326C3.16	-15.55	4.97e-44	2.26e-40	-0.57	-0.59	Menarche (age at onset);	chr11:237087	chr11:243099~243483:-
PRAD	cis	rs17507216	0.681	rs28877110	ENSG00000278603.1	RP13-608F4.5	15.55	5.03e-44	2.29e-40	0.97	0.59	Excessive daytime sleepiness;	chr15:82672111	chr15:82472203~82472426:+
PRAD	cis	rs7188445	0.898	rs74247468	ENSG00000261390.4	RP11-345M22.2	-15.54	5.21e-44	2.36e-40	-0.72	-0.59	Urate levels;	chr16:79679188	chr16:79715232~79770563:-
PRAD	cis	rs7104764	1	rs10902110	ENSG00000277290.1	RP11-326C3.16	-15.54	5.22e-44	2.37e-40	-0.56	-0.59	Menarche (age at onset);	chr11:237648	chr11:243099~243483:-
PRAD	cis	rs7104764	1	rs7481993	ENSG00000277290.1	RP11-326C3.16	-15.54	5.22e-44	2.37e-40	-0.56	-0.59	Menarche (age at onset);	chr11:237875	chr11:243099~243483:-
PRAD	cis	rs9487094	0.689	rs699700	ENSG00000260273.1	RP11-425D10.10	15.54	5.59e-44	2.53e-40	0.78	0.59	Height;	chr6:109367528	chr6:109382795~109383666:+
PRAD	cis	rs9487094	0.689	rs11251	ENSG00000260273.1	RP11-425D10.10	15.54	5.59e-44	2.53e-40	0.78	0.59	Height;	chr6:109368704	chr6:109382795~109383666:+
PRAD	cis	rs7617773	0.817	rs11709691	ENSG00000229759.1	MRPS18AP1	15.54	5.67e-44	2.57e-40	0.64	0.59	Coronary artery disease;	chr3:48262179	chr3:48256350~48256938:-
PRAD	cis	rs1577917	0.839	rs12664634	ENSG00000203875.9	SNHG5	-15.54	5.69e-44	2.58e-40	-0.64	-0.59	Response to antipsychotic treatment;	chr6:85869696	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.839	rs6454504	ENSG00000203875.9	SNHG5	-15.54	5.69e-44	2.58e-40	-0.64	-0.59	Response to antipsychotic treatment;	chr6:85870612	chr6:85660950~85678736:-
PRAD	cis	rs35160687	0.64	rs13015186	ENSG00000273080.1	RP11-301O19.1	15.53	5.85e-44	2.65e-40	0.69	0.59	Night sleep phenotypes;	chr2:86258455	chr2:86195590~86196049:+
PRAD	cis	rs1930961	1	rs7285549	ENSG00000272977.1	CTA-390C10.10	-15.53	5.96e-44	2.7e-40	-0.93	-0.59	Bipolar disorder with mood-incongruent psychosis;	chr22:25478613	chr22:25476218~25479971:+
PRAD	cis	rs1930961	1	rs5996946	ENSG00000272977.1	CTA-390C10.10	-15.53	5.96e-44	2.7e-40	-0.93	-0.59	Bipolar disorder with mood-incongruent psychosis;	chr22:25480021	chr22:25476218~25479971:+
PRAD	cis	rs1930961	1	rs997873	ENSG00000272977.1	CTA-390C10.10	-15.53	5.96e-44	2.7e-40	-0.93	-0.59	Bipolar disorder with mood-incongruent psychosis;	chr22:25482315	chr22:25476218~25479971:+
PRAD	cis	rs10256972	0.684	rs2363279	ENSG00000229043.2	AC091729.9	-15.53	6e-44	2.72e-40	-0.73	-0.59	Endometriosis;Longevity;	chr7:1056507	chr7:1160374~1165267:+
PRAD	cis	rs1577917	0.682	rs1173417	ENSG00000203875.9	SNHG5	15.53	6.2e-44	2.8e-40	0.63	0.59	Response to antipsychotic treatment;	chr6:85694223	chr6:85660950~85678736:-
PRAD	cis	rs73086581	0.947	rs67356712	ENSG00000229539.1	RP11-119B16.2	15.53	6.24e-44	2.82e-40	1.01	0.59	Response to antidepressants in depression;	chr20:3912239	chr20:3888239~3888868:-
PRAD	cis	rs7104764	0.957	rs3829998	ENSG00000277290.1	RP11-326C3.16	-15.52	6.51e-44	2.94e-40	-0.56	-0.59	Menarche (age at onset);	chr11:230751	chr11:243099~243483:-
PRAD	cis	rs1577917	0.682	rs6909767	ENSG00000203875.9	SNHG5	15.52	6.62e-44	2.99e-40	0.63	0.59	Response to antipsychotic treatment;	chr6:85518391	chr6:85660950~85678736:-
PRAD	cis	rs9487094	0.666	rs9480956	ENSG00000260273.1	RP11-425D10.10	15.52	6.67e-44	3.01e-40	0.77	0.59	Height;	chr6:109424305	chr6:109382795~109383666:+
PRAD	cis	rs9487094	0.689	rs12214147	ENSG00000260273.1	RP11-425D10.10	15.52	6.67e-44	3.01e-40	0.77	0.59	Height;	chr6:109425054	chr6:109382795~109383666:+
PRAD	cis	rs9487094	0.689	rs17070591	ENSG00000260273.1	RP11-425D10.10	15.52	6.67e-44	3.01e-40	0.77	0.59	Height;	chr6:109426518	chr6:109382795~109383666:+
PRAD	cis	rs9487094	0.666	rs7751582	ENSG00000260273.1	RP11-425D10.10	15.52	6.67e-44	3.01e-40	0.77	0.59	Height;	chr6:109427644	chr6:109382795~109383666:+
PRAD	cis	rs9487094	0.689	rs9487103	ENSG00000260273.1	RP11-425D10.10	15.52	6.67e-44	3.01e-40	0.77	0.59	Height;	chr6:109430292	chr6:109382795~109383666:+
PRAD	cis	rs7617773	0.817	rs13059037	ENSG00000229759.1	MRPS18AP1	15.52	6.76e-44	3.05e-40	0.64	0.59	Coronary artery disease;	chr3:48246389	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.817	rs35414021	ENSG00000229759.1	MRPS18AP1	15.52	6.76e-44	3.05e-40	0.64	0.59	Coronary artery disease;	chr3:48252034	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.817	rs13068265	ENSG00000229759.1	MRPS18AP1	15.52	6.76e-44	3.05e-40	0.64	0.59	Coronary artery disease;	chr3:48260124	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.817	rs17786132	ENSG00000229759.1	MRPS18AP1	15.52	6.8e-44	3.07e-40	0.64	0.59	Coronary artery disease;	chr3:48207930	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.817	rs35456569	ENSG00000229759.1	MRPS18AP1	15.52	6.8e-44	3.07e-40	0.64	0.59	Coronary artery disease;	chr3:48209409	chr3:48256350~48256938:-
PRAD	cis	rs9487094	0.666	rs1074765	ENSG00000260273.1	RP11-425D10.10	-15.52	6.99e-44	3.15e-40	-0.77	-0.59	Height;	chr6:109360458	chr6:109382795~109383666:+
PRAD	cis	rs35160687	0.829	rs13017143	ENSG00000273080.1	RP11-301O19.1	-15.51	7.72e-44	3.47e-40	-0.68	-0.59	Night sleep phenotypes;	chr2:86239426	chr2:86195590~86196049:+
PRAD	cis	rs35160687	0.862	rs17737955	ENSG00000273080.1	RP11-301O19.1	15.5	7.86e-44	3.53e-40	0.69	0.59	Night sleep phenotypes;	chr2:86280891	chr2:86195590~86196049:+
PRAD	cis	rs17507216	0.718	rs7161977	ENSG00000278603.1	RP13-608F4.5	15.49	8.79e-44	3.94e-40	0.97	0.59	Excessive daytime sleepiness;	chr15:82646782	chr15:82472203~82472426:+
PRAD	cis	rs2882667	0.931	rs10044736	ENSG00000253404.1	AC034243.1	-15.49	8.81e-44	3.95e-40	-0.79	-0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:138985120	chr5:138744434~138753309:-
PRAD	cis	rs2739330	0.587	rs4820571	ENSG00000273295.1	AP000350.5	15.48	9.68e-44	4.34e-40	0.7	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23901432~23907068:-
PRAD	cis	rs7617773	0.851	rs7647817	ENSG00000229759.1	MRPS18AP1	15.48	9.71e-44	4.35e-40	0.64	0.59	Coronary artery disease;	chr3:48195017	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.817	rs11707606	ENSG00000229759.1	MRPS18AP1	15.48	9.71e-44	4.35e-40	0.64	0.59	Coronary artery disease;	chr3:48195597	chr3:48256350~48256938:-
PRAD	cis	rs875971	0.83	rs427973	ENSG00000226824.5	RP4-756H11.3	-15.48	1.02e-43	4.56e-40	-0.76	-0.59	Aortic root size;	chr7:66061661	chr7:66654538~66669855:+
PRAD	cis	rs11690935	0.959	rs10184866	ENSG00000228389.1	AC068039.4	15.48	1.04e-43	4.66e-40	0.69	0.59	Schizophrenia;	chr2:171752446	chr2:171773482~171775844:+
PRAD	cis	rs9487094	0.689	rs8465	ENSG00000260273.1	RP11-425D10.10	15.48	1.05e-43	4.7e-40	0.77	0.59	Height;	chr6:109367335	chr6:109382795~109383666:+
PRAD	cis	rs9487094	0.666	rs974034	ENSG00000260273.1	RP11-425D10.10	15.48	1.05e-43	4.7e-40	0.77	0.59	Height;	chr6:109368228	chr6:109382795~109383666:+
PRAD	cis	rs12439619	0.739	rs4778988	ENSG00000278603.1	RP13-608F4.5	15.47	1.1e-43	4.93e-40	0.82	0.59	Intelligence (multi-trait analysis);	chr15:82247996	chr15:82472203~82472426:+
PRAD	cis	rs9487094	0.62	rs7768973	ENSG00000260273.1	RP11-425D10.10	15.47	1.14e-43	5.08e-40	0.77	0.59	Height;	chr6:109424122	chr6:109382795~109383666:+
PRAD	cis	rs9487094	0.689	rs3818933	ENSG00000260273.1	RP11-425D10.10	15.46	1.27e-43	5.65e-40	0.77	0.59	Height;	chr6:109370741	chr6:109382795~109383666:+
PRAD	cis	rs9487094	0.689	rs9487076	ENSG00000260273.1	RP11-425D10.10	15.46	1.27e-43	5.65e-40	0.77	0.59	Height;	chr6:109371524	chr6:109382795~109383666:+
PRAD	cis	rs1930961	1	rs1930961	ENSG00000272977.1	CTA-390C10.10	-15.46	1.28e-43	5.69e-40	-0.93	-0.59	Bipolar disorder with mood-incongruent psychosis;	chr22:25479298	chr22:25476218~25479971:+
PRAD	cis	rs950027	0.62	rs1346267	ENSG00000259520.4	CTD-2651B20.3	-15.45	1.29e-43	5.77e-40	-0.73	-0.59	Response to fenofibrate (adiponectin levels);	chr15:45398791	chr15:45251580~45279251:-
PRAD	cis	rs11690935	0.959	rs35391289	ENSG00000228389.1	AC068039.4	15.45	1.31e-43	5.82e-40	0.7	0.59	Schizophrenia;	chr2:171778473	chr2:171773482~171775844:+
PRAD	cis	rs916888	0.61	rs199454	ENSG00000262539.1	RP11-259G18.3	-15.45	1.31e-43	5.83e-40	-0.83	-0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:46259551~46260606:-
PRAD	cis	rs7208859	0.673	rs11654331	ENSG00000263531.1	RP13-753N3.1	15.45	1.41e-43	6.26e-40	1.16	0.59	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30837999	chr17:30863921~30864940:-
PRAD	cis	rs11690935	0.959	rs4667694	ENSG00000228389.1	AC068039.4	15.45	1.41e-43	6.27e-40	0.7	0.59	Schizophrenia;	chr2:171748889	chr2:171773482~171775844:+
PRAD	cis	rs11690935	0.959	rs10497374	ENSG00000228389.1	AC068039.4	15.45	1.42e-43	6.33e-40	0.69	0.59	Schizophrenia;	chr2:171784113	chr2:171773482~171775844:+
PRAD	cis	rs1577917	0.771	rs7762321	ENSG00000203875.9	SNHG5	15.44	1.47e-43	6.56e-40	0.64	0.59	Response to antipsychotic treatment;	chr6:85702428	chr6:85660950~85678736:-
PRAD	cis	rs9326248	0.689	rs236916	ENSG00000254851.1	RP11-109L13.1	15.43	1.59e-43	7.1e-40	1.08	0.59	Blood protein levels;	chr11:117218912	chr11:117135528~117138582:+
PRAD	cis	rs9487094	0.689	rs9487070	ENSG00000260273.1	RP11-425D10.10	15.43	1.61e-43	7.18e-40	0.77	0.59	Height;	chr6:109361200	chr6:109382795~109383666:+
PRAD	cis	rs9487094	0.696	rs1853330	ENSG00000260273.1	RP11-425D10.10	15.43	1.69e-43	7.53e-40	0.77	0.59	Height;	chr6:109375548	chr6:109382795~109383666:+
PRAD	cis	rs17711722	0.653	rs2460421	ENSG00000226824.5	RP4-756H11.3	15.43	1.7e-43	7.58e-40	0.75	0.59	Calcium levels;	chr7:66026136	chr7:66654538~66669855:+
PRAD	cis	rs9487094	0.517	rs3778474	ENSG00000260273.1	RP11-425D10.10	15.43	1.7e-43	7.58e-40	0.78	0.59	Height;	chr6:109374782	chr6:109382795~109383666:+
PRAD	cis	rs1577917	0.883	rs13212415	ENSG00000203875.9	SNHG5	-15.42	1.76e-43	7.81e-40	-0.64	-0.59	Response to antipsychotic treatment;	chr6:85898365	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.839	rs1447159	ENSG00000203875.9	SNHG5	-15.42	1.76e-43	7.81e-40	-0.64	-0.59	Response to antipsychotic treatment;	chr6:85899531	chr6:85660950~85678736:-
PRAD	cis	rs1153858	1	rs7171577	ENSG00000259520.4	CTD-2651B20.3	-15.42	1.87e-43	8.31e-40	-0.76	-0.59	Homoarginine levels;	chr15:45335781	chr15:45251580~45279251:-
PRAD	cis	rs1153858	1	rs10519021	ENSG00000259520.4	CTD-2651B20.3	-15.42	1.87e-43	8.31e-40	-0.76	-0.59	Homoarginine levels;	chr15:45339597	chr15:45251580~45279251:-
PRAD	cis	rs7208859	0.673	rs73277964	ENSG00000263531.1	RP13-753N3.1	15.41	1.97e-43	8.73e-40	1.16	0.59	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30852183	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.673	rs11652409	ENSG00000263531.1	RP13-753N3.1	15.41	1.97e-43	8.73e-40	1.16	0.59	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30855689	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.673	rs9896095	ENSG00000263531.1	RP13-753N3.1	15.41	1.97e-43	8.73e-40	1.16	0.59	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30860479	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.573	rs58920731	ENSG00000263531.1	RP13-753N3.1	15.41	1.97e-43	8.73e-40	1.16	0.59	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30864728	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.673	rs73277984	ENSG00000263531.1	RP13-753N3.1	15.41	1.97e-43	8.73e-40	1.16	0.59	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869115	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.673	rs73277986	ENSG00000263531.1	RP13-753N3.1	15.41	1.97e-43	8.73e-40	1.16	0.59	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869179	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.673	rs12103588	ENSG00000263531.1	RP13-753N3.1	15.41	1.97e-43	8.73e-40	1.16	0.59	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30870442	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.614	rs9914534	ENSG00000263531.1	RP13-753N3.1	15.41	1.97e-43	8.73e-40	1.16	0.59	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30875646	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.673	rs11658344	ENSG00000263531.1	RP13-753N3.1	15.41	1.97e-43	8.73e-40	1.16	0.59	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30880727	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs9900144	ENSG00000263531.1	RP13-753N3.1	15.41	1.97e-43	8.73e-40	1.16	0.59	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881371	chr17:30863921~30864940:-
PRAD	cis	rs11690935	0.959	rs7355594	ENSG00000228389.1	AC068039.4	15.41	1.99e-43	8.83e-40	0.69	0.59	Schizophrenia;	chr2:171782938	chr2:171773482~171775844:+
PRAD	cis	rs916888	0.61	rs199453	ENSG00000262539.1	RP11-259G18.3	15.41	2.13e-43	9.42e-40	0.83	0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:46259551~46260606:-
PRAD	cis	rs875971	0.564	rs313804	ENSG00000226824.5	RP4-756H11.3	-15.41	2.14e-43	9.45e-40	-0.75	-0.59	Aortic root size;	chr7:66049635	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.662	rs448725	ENSG00000226824.5	RP4-756H11.3	-15.41	2.14e-43	9.45e-40	-0.75	-0.59	Aortic root size;	chr7:66049641	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.658	rs432667	ENSG00000226824.5	RP4-756H11.3	-15.41	2.14e-43	9.45e-40	-0.75	-0.59	Aortic root size;	chr7:66049646	chr7:66654538~66669855:+
PRAD	cis	rs11673344	0.536	rs62108291	ENSG00000226686.6	LINC01535	15.4	2.17e-43	9.61e-40	0.76	0.59	Obesity-related traits;	chr19:37659457	chr19:37251912~37265535:+
PRAD	cis	rs507080	0.501	rs516503	ENSG00000255239.1	AP002954.6	15.39	2.57e-43	1.13e-39	0.76	0.59	Serum metabolite levels;	chr11:118709639	chr11:118688039~118690600:-
PRAD	cis	rs7188445	0.871	rs7202770	ENSG00000261390.4	RP11-345M22.2	-15.39	2.58e-43	1.14e-39	-0.7	-0.59	Urate levels;	chr16:79672643	chr16:79715232~79770563:-
PRAD	cis	rs7188445	0.835	rs1424231	ENSG00000261390.4	RP11-345M22.2	-15.39	2.58e-43	1.14e-39	-0.7	-0.59	Urate levels;	chr16:79672854	chr16:79715232~79770563:-
PRAD	cis	rs11690935	0.959	rs7562356	ENSG00000228389.1	AC068039.4	15.39	2.63e-43	1.16e-39	0.69	0.58	Schizophrenia;	chr2:171770101	chr2:171773482~171775844:+
PRAD	cis	rs11690935	0.959	rs1113389	ENSG00000228389.1	AC068039.4	15.39	2.63e-43	1.16e-39	0.69	0.58	Schizophrenia;	chr2:171778855	chr2:171773482~171775844:+
PRAD	cis	rs7104764	0.879	rs6421986	ENSG00000277290.1	RP11-326C3.16	-15.38	2.74e-43	1.21e-39	-0.56	-0.58	Menarche (age at onset);	chr11:221659	chr11:243099~243483:-
PRAD	cis	rs1577917	0.633	rs7770835	ENSG00000203875.9	SNHG5	-15.38	2.81e-43	1.24e-39	-0.63	-0.58	Response to antipsychotic treatment;	chr6:85899189	chr6:85660950~85678736:-
PRAD	cis	rs35160687	0.862	rs13024964	ENSG00000273080.1	RP11-301O19.1	15.38	2.88e-43	1.27e-39	0.68	0.58	Night sleep phenotypes;	chr2:86284745	chr2:86195590~86196049:+
PRAD	cis	rs9487094	0.689	rs1046943	ENSG00000260273.1	RP11-425D10.10	15.38	2.89e-43	1.27e-39	0.77	0.58	Height;	chr6:109462738	chr6:109382795~109383666:+
PRAD	cis	rs9487094	0.689	rs6939548	ENSG00000260273.1	RP11-425D10.10	15.38	2.89e-43	1.27e-39	0.77	0.58	Height;	chr6:109464011	chr6:109382795~109383666:+
PRAD	cis	rs9487094	0.62	rs6939953	ENSG00000260273.1	RP11-425D10.10	15.37	2.92e-43	1.29e-39	0.77	0.58	Height;	chr6:109390116	chr6:109382795~109383666:+
PRAD	cis	rs9487094	0.666	rs3734652	ENSG00000260273.1	RP11-425D10.10	15.37	2.97e-43	1.31e-39	0.77	0.58	Height;	chr6:109465777	chr6:109382795~109383666:+
PRAD	cis	rs7208859	0.673	rs11650305	ENSG00000263531.1	RP13-753N3.1	15.37	2.99e-43	1.32e-39	1.15	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30902343	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.673	rs11654914	ENSG00000263531.1	RP13-753N3.1	15.37	2.99e-43	1.32e-39	1.15	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30902406	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.673	rs9914271	ENSG00000263531.1	RP13-753N3.1	15.37	2.99e-43	1.32e-39	1.15	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30905607	chr17:30863921~30864940:-
PRAD	cis	rs9487094	0.67	rs1885691	ENSG00000260273.1	RP11-425D10.10	15.37	3e-43	1.32e-39	0.77	0.58	Height;	chr6:109382188	chr6:109382795~109383666:+
PRAD	cis	rs9487094	0.644	rs3757230	ENSG00000260273.1	RP11-425D10.10	15.37	3e-43	1.32e-39	0.77	0.58	Height;	chr6:109383239	chr6:109382795~109383666:+
PRAD	cis	rs9487094	0.644	rs3757231	ENSG00000260273.1	RP11-425D10.10	15.37	3e-43	1.32e-39	0.77	0.58	Height;	chr6:109383248	chr6:109382795~109383666:+
PRAD	cis	rs3931020	0.548	rs2134836	ENSG00000272864.1	RP11-17E13.2	-15.37	3.17e-43	1.4e-39	-0.61	-0.58	Resistin levels;	chr1:74805962	chr1:74698769~74699333:-
PRAD	cis	rs17507216	0.718	rs7165690	ENSG00000278603.1	RP13-608F4.5	15.37	3.19e-43	1.4e-39	0.96	0.58	Excessive daytime sleepiness;	chr15:82654804	chr15:82472203~82472426:+
PRAD	cis	rs1577917	0.74	rs12212560	ENSG00000203875.9	SNHG5	-15.36	3.23e-43	1.42e-39	-0.64	-0.58	Response to antipsychotic treatment;	chr6:85632961	chr6:85660950~85678736:-
PRAD	cis	rs7208859	0.573	rs11656121	ENSG00000263531.1	RP13-753N3.1	15.36	3.23e-43	1.42e-39	1.16	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887025	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs11650973	ENSG00000263531.1	RP13-753N3.1	15.36	3.23e-43	1.42e-39	1.16	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887027	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.673	rs56085216	ENSG00000263531.1	RP13-753N3.1	15.36	3.23e-43	1.42e-39	1.16	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30890216	chr17:30863921~30864940:-
PRAD	cis	rs916888	0.61	rs199436	ENSG00000262539.1	RP11-259G18.3	-15.36	3.49e-43	1.53e-39	-0.83	-0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:46259551~46260606:-
PRAD	cis	rs35160687	0.862	rs12476706	ENSG00000273080.1	RP11-301O19.1	15.35	3.58e-43	1.57e-39	0.68	0.58	Night sleep phenotypes;	chr2:86301247	chr2:86195590~86196049:+
PRAD	cis	rs7208859	0.673	rs4131618	ENSG00000263531.1	RP13-753N3.1	15.35	3.68e-43	1.61e-39	1.16	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30877783	chr17:30863921~30864940:-
PRAD	cis	rs916888	0.647	rs199449	ENSG00000262539.1	RP11-259G18.3	15.35	3.69e-43	1.62e-39	0.84	0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:46259551~46260606:-
PRAD	cis	rs916888	0.61	rs199444	ENSG00000262539.1	RP11-259G18.3	15.35	3.69e-43	1.62e-39	0.84	0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:46259551~46260606:-
PRAD	cis	rs916888	0.61	rs199442	ENSG00000262539.1	RP11-259G18.3	15.35	3.69e-43	1.62e-39	0.84	0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:46259551~46260606:-
PRAD	cis	rs9487094	0.666	rs3778478	ENSG00000260273.1	RP11-425D10.10	15.35	3.87e-43	1.7e-39	0.76	0.58	Height;	chr6:109470427	chr6:109382795~109383666:+
PRAD	cis	rs9487094	0.644	rs9791241	ENSG00000260273.1	RP11-425D10.10	15.35	3.87e-43	1.7e-39	0.76	0.58	Height;	chr6:109470900	chr6:109382795~109383666:+
PRAD	cis	rs916888	0.61	rs199446	ENSG00000262539.1	RP11-259G18.3	-15.35	3.92e-43	1.72e-39	-0.83	-0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:46259551~46260606:-
PRAD	cis	rs916888	0.61	rs199536	ENSG00000262539.1	RP11-259G18.3	-15.35	3.92e-43	1.72e-39	-0.83	-0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:46259551~46260606:-
PRAD	cis	rs11690935	0.959	rs7597387	ENSG00000228389.1	AC068039.4	15.34	4.03e-43	1.76e-39	0.68	0.58	Schizophrenia;	chr2:171720606	chr2:171773482~171775844:+
PRAD	cis	rs11690935	0.959	rs6754817	ENSG00000228389.1	AC068039.4	15.33	4.44e-43	1.94e-39	0.69	0.58	Schizophrenia;	chr2:171806884	chr2:171773482~171775844:+
PRAD	cis	rs2739330	0.732	rs5760175	ENSG00000218537.1	MIF-AS1	15.33	4.59e-43	2.01e-39	0.77	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23894426~23898930:-
PRAD	cis	rs11690935	0.959	rs6745143	ENSG00000228389.1	AC068039.4	15.33	4.71e-43	2.06e-39	0.69	0.58	Schizophrenia;	chr2:171793872	chr2:171773482~171775844:+
PRAD	cis	rs11690935	0.959	rs6758704	ENSG00000228389.1	AC068039.4	15.33	4.71e-43	2.06e-39	0.69	0.58	Schizophrenia;	chr2:171798587	chr2:171773482~171775844:+
PRAD	cis	rs977987	0.868	rs10871313	ENSG00000261783.1	RP11-252K23.2	-15.32	4.86e-43	2.12e-39	-0.83	-0.58	Dupuytren's disease;	chr16:75473196	chr16:75379818~75381260:-
PRAD	cis	rs17507216	0.718	rs72751675	ENSG00000278603.1	RP13-608F4.5	15.32	5.25e-43	2.29e-39	0.96	0.58	Excessive daytime sleepiness;	chr15:82630452	chr15:82472203~82472426:+
PRAD	cis	rs35160687	0.862	rs13023154	ENSG00000273080.1	RP11-301O19.1	-15.32	5.29e-43	2.31e-39	-0.68	-0.58	Night sleep phenotypes;	chr2:86289861	chr2:86195590~86196049:+
PRAD	cis	rs7617773	0.746	rs6796343	ENSG00000229759.1	MRPS18AP1	15.31	5.56e-43	2.42e-39	0.64	0.58	Coronary artery disease;	chr3:48240531	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.817	rs13100815	ENSG00000229759.1	MRPS18AP1	15.31	5.56e-43	2.42e-39	0.64	0.58	Coronary artery disease;	chr3:48245959	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.71	rs36064160	ENSG00000229759.1	MRPS18AP1	15.31	5.59e-43	2.43e-39	0.64	0.58	Coronary artery disease;	chr3:48201611	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.784	rs11715799	ENSG00000229759.1	MRPS18AP1	15.31	5.59e-43	2.43e-39	0.64	0.58	Coronary artery disease;	chr3:48213730	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.817	rs34728236	ENSG00000229759.1	MRPS18AP1	15.31	5.59e-43	2.43e-39	0.64	0.58	Coronary artery disease;	chr3:48217618	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.817	rs79310258	ENSG00000229759.1	MRPS18AP1	15.31	5.59e-43	2.43e-39	0.64	0.58	Coronary artery disease;	chr3:48218177	chr3:48256350~48256938:-
PRAD	cis	rs9487094	0.666	rs7748669	ENSG00000260273.1	RP11-425D10.10	15.3	6.31e-43	2.74e-39	0.78	0.58	Height;	chr6:109424139	chr6:109382795~109383666:+
PRAD	cis	rs11690935	0.921	rs6710698	ENSG00000228389.1	AC068039.4	15.3	6.37e-43	2.77e-39	0.68	0.58	Schizophrenia;	chr2:171739568	chr2:171773482~171775844:+
PRAD	cis	rs2882667	0.931	rs10074461	ENSG00000253404.1	AC034243.1	15.29	6.92e-43	3e-39	0.79	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:138984126	chr5:138744434~138753309:-
PRAD	cis	rs8037818	1	rs4643284	ENSG00000276724.1	RP11-1000B6.7	-15.29	7.03e-43	3.05e-39	-0.8	-0.58	Obesity-related traits;	chr15:32639897	chr15:32583612~32584312:+
PRAD	cis	rs11690935	0.959	rs2292815	ENSG00000228389.1	AC068039.4	15.28	7.42e-43	3.21e-39	0.69	0.58	Schizophrenia;	chr2:171730141	chr2:171773482~171775844:+
PRAD	cis	rs9487094	0.666	rs2236084	ENSG00000260273.1	RP11-425D10.10	15.28	7.47e-43	3.24e-39	0.77	0.58	Height;	chr6:109476101	chr6:109382795~109383666:+
PRAD	cis	rs9326248	0.861	rs11216172	ENSG00000254851.1	RP11-109L13.1	-15.28	7.56e-43	3.27e-39	-0.88	-0.58	Blood protein levels;	chr11:116879162	chr11:117135528~117138582:+
PRAD	cis	rs7188445	0.871	rs16950997	ENSG00000261390.4	RP11-345M22.2	-15.28	7.64e-43	3.31e-39	-0.7	-0.58	Urate levels;	chr16:79673733	chr16:79715232~79770563:-
PRAD	cis	rs2882667	0.894	rs1433008	ENSG00000253404.1	AC034243.1	15.27	8.05e-43	3.48e-39	0.77	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:138997975	chr5:138744434~138753309:-
PRAD	cis	rs9487094	0.666	rs2277113	ENSG00000260273.1	RP11-425D10.10	15.27	8.4e-43	3.63e-39	0.77	0.58	Height;	chr6:109454233	chr6:109382795~109383666:+
PRAD	cis	rs9487094	0.689	rs9480949	ENSG00000260273.1	RP11-425D10.10	15.27	8.47e-43	3.66e-39	0.78	0.58	Height;	chr6:109407238	chr6:109382795~109383666:+
PRAD	cis	rs7208859	0.673	rs75142521	ENSG00000263531.1	RP13-753N3.1	15.26	9.13e-43	3.94e-39	1.15	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30913519	chr17:30863921~30864940:-
PRAD	cis	rs2882667	0.931	rs12719518	ENSG00000253404.1	AC034243.1	15.26	9.5e-43	4.1e-39	0.77	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139005287	chr5:138744434~138753309:-
PRAD	cis	rs2455601	0.638	rs2742478	ENSG00000254860.4	TMEM9B-AS1	15.25	9.96e-43	4.29e-39	0.7	0.58	Schizophrenia;	chr11:8974552	chr11:8964675~8977527:+
PRAD	cis	rs17507216	0.718	rs72751657	ENSG00000278603.1	RP13-608F4.5	15.25	1.01e-42	4.35e-39	0.98	0.58	Excessive daytime sleepiness;	chr15:82581259	chr15:82472203~82472426:+
PRAD	cis	rs2882667	0.931	rs10075893	ENSG00000253404.1	AC034243.1	-15.25	1.04e-42	4.49e-39	-0.77	-0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139020182	chr5:138744434~138753309:-
PRAD	cis	rs1577917	0.816	rs1838952	ENSG00000203875.9	SNHG5	-15.25	1.04e-42	4.49e-39	-0.64	-0.58	Response to antipsychotic treatment;	chr6:85891426	chr6:85660950~85678736:-
PRAD	cis	rs7104764	1	rs2293167	ENSG00000277290.1	RP11-326C3.16	15.25	1.07e-42	4.62e-39	0.56	0.58	Menarche (age at onset);	chr11:211644	chr11:243099~243483:-
PRAD	cis	rs7104764	1	rs76552490	ENSG00000277290.1	RP11-326C3.16	15.25	1.07e-42	4.62e-39	0.56	0.58	Menarche (age at onset);	chr11:212015	chr11:243099~243483:-
PRAD	cis	rs11155671	0.53	rs9371215	ENSG00000216906.2	RP11-350J20.9	15.24	1.12e-42	4.83e-39	0.68	0.58	Testicular germ cell tumor;	chr6:149873162	chr6:149904243~149906418:+
PRAD	cis	rs7617773	0.817	rs936427	ENSG00000229759.1	MRPS18AP1	-15.24	1.13e-42	4.87e-39	-0.63	-0.58	Coronary artery disease;	chr3:48259584	chr3:48256350~48256938:-
PRAD	cis	rs2882667	0.931	rs10077896	ENSG00000253404.1	AC034243.1	15.24	1.18e-42	5.09e-39	0.77	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021067	chr5:138744434~138753309:-
PRAD	cis	rs875971	0.793	rs460678	ENSG00000226824.5	RP4-756H11.3	-15.23	1.27e-42	5.48e-39	-0.75	-0.58	Aortic root size;	chr7:66062213	chr7:66654538~66669855:+
PRAD	cis	rs7104764	1	rs1533825	ENSG00000277290.1	RP11-326C3.16	15.23	1.28e-42	5.48e-39	0.56	0.58	Menarche (age at onset);	chr11:214163	chr11:243099~243483:-
PRAD	cis	rs507080	0.501	rs494459	ENSG00000255239.1	AP002954.6	-15.23	1.28e-42	5.51e-39	-0.75	-0.58	Serum metabolite levels;	chr11:118703966	chr11:118688039~118690600:-
PRAD	cis	rs507080	0.524	rs524409	ENSG00000255239.1	AP002954.6	15.23	1.28e-42	5.51e-39	0.75	0.58	Serum metabolite levels;	chr11:118703602	chr11:118688039~118690600:-
PRAD	cis	rs507080	0.501	rs626645	ENSG00000255239.1	AP002954.6	15.23	1.28e-42	5.51e-39	0.75	0.58	Serum metabolite levels;	chr11:118704471	chr11:118688039~118690600:-
PRAD	cis	rs17507216	0.718	rs4779034	ENSG00000278603.1	RP13-608F4.5	15.23	1.29e-42	5.53e-39	0.91	0.58	Excessive daytime sleepiness;	chr15:82576799	chr15:82472203~82472426:+
PRAD	cis	rs2283792	0.567	rs2027789	ENSG00000224086.5	LL22NC03-86G7.1	-15.23	1.3e-42	5.56e-39	-0.7	-0.58	Multiple sclerosis;	chr22:21933490	chr22:21938293~21977632:+
PRAD	cis	rs2739330	0.703	rs5760112	ENSG00000250470.1	AP000351.3	15.23	1.3e-42	5.56e-39	0.78	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23976904~23977585:-
PRAD	cis	rs507080	0.501	rs637563	ENSG00000255239.1	AP002954.6	15.23	1.32e-42	5.65e-39	0.75	0.58	Serum metabolite levels;	chr11:118704770	chr11:118688039~118690600:-
PRAD	cis	rs12022452	0.506	rs12569328	ENSG00000238287.1	RP11-656D10.3	-15.22	1.34e-42	5.75e-39	-0.89	-0.58	Age-related hearing impairment (SNP x SNP interaction);	chr1:40553549	chr1:40493157~40508661:-
PRAD	cis	rs7617773	0.817	rs34225441	ENSG00000229759.1	MRPS18AP1	15.22	1.34e-42	5.77e-39	0.64	0.58	Coronary artery disease;	chr3:48267401	chr3:48256350~48256938:-
PRAD	cis	rs11690935	0.959	rs3770451	ENSG00000228389.1	AC068039.4	15.22	1.41e-42	6.06e-39	0.69	0.58	Schizophrenia;	chr2:171812205	chr2:171773482~171775844:+
PRAD	cis	rs7617773	0.817	rs6787500	ENSG00000229759.1	MRPS18AP1	15.21	1.51e-42	6.46e-39	0.6	0.58	Coronary artery disease;	chr3:48257949	chr3:48256350~48256938:-
PRAD	cis	rs11690935	1	rs34542126	ENSG00000228389.1	AC068039.4	-15.21	1.53e-42	6.57e-39	-0.69	-0.58	Schizophrenia;	chr2:171686195	chr2:171773482~171775844:+
PRAD	cis	rs494459	0.964	rs576283	ENSG00000255239.1	AP002954.6	15.21	1.55e-42	6.62e-39	0.75	0.58	Height;	chr11:118703185	chr11:118688039~118690600:-
PRAD	cis	rs494459	0.929	rs627391	ENSG00000255239.1	AP002954.6	15.21	1.55e-42	6.62e-39	0.75	0.58	Height;	chr11:118703207	chr11:118688039~118690600:-
PRAD	cis	rs9487094	0.689	rs9480936	ENSG00000260273.1	RP11-425D10.10	15.21	1.55e-42	6.64e-39	0.78	0.58	Height;	chr6:109358227	chr6:109382795~109383666:+
PRAD	cis	rs2739330	0.761	rs5760176	ENSG00000218537.1	MIF-AS1	-15.21	1.57e-42	6.7e-39	-0.76	-0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23894426~23898930:-
PRAD	cis	rs2739330	0.731	rs5751792	ENSG00000218537.1	MIF-AS1	15.21	1.57e-42	6.7e-39	0.76	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23894426~23898930:-
PRAD	cis	rs2455601	0.638	rs11042148	ENSG00000254860.4	TMEM9B-AS1	15.21	1.59e-42	6.79e-39	0.71	0.58	Schizophrenia;	chr11:8987127	chr11:8964675~8977527:+
PRAD	cis	rs3931020	0.548	rs12145183	ENSG00000272864.1	RP11-17E13.2	-15.21	1.61e-42	6.89e-39	-0.61	-0.58	Resistin levels;	chr1:74806796	chr1:74698769~74699333:-
PRAD	cis	rs3931020	0.566	rs1409782	ENSG00000272864.1	RP11-17E13.2	-15.21	1.61e-42	6.89e-39	-0.61	-0.58	Resistin levels;	chr1:74807251	chr1:74698769~74699333:-
PRAD	cis	rs2882667	0.931	rs13153618	ENSG00000253404.1	AC034243.1	15.21	1.62e-42	6.91e-39	0.77	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139017087	chr5:138744434~138753309:-
PRAD	cis	rs9487094	0.666	rs4946967	ENSG00000260273.1	RP11-425D10.10	15.21	1.63e-42	6.96e-39	0.77	0.58	Height;	chr6:109357369	chr6:109382795~109383666:+
PRAD	cis	rs9487094	0.643	rs35146243	ENSG00000260273.1	RP11-425D10.10	15.2	1.64e-42	7.01e-39	0.77	0.58	Height;	chr6:109477209	chr6:109382795~109383666:+
PRAD	cis	rs492146	0.783	rs613764	ENSG00000243236.5	GSTA9P	-15.19	1.88e-42	8.03e-39	-0.72	-0.58	Epilepsy (remission after treatment);	chr6:52975437	chr6:52939726~52957521:-
PRAD	cis	rs7104764	1	rs10400248	ENSG00000277290.1	RP11-326C3.16	-15.19	1.92e-42	8.2e-39	-0.56	-0.58	Menarche (age at onset);	chr11:247029	chr11:243099~243483:-
PRAD	cis	rs8072100	0.84	rs9895746	ENSG00000228782.6	CTD-2026D20.3	15.19	1.97e-42	8.4e-39	0.6	0.58	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47401733	chr17:47450568~47492492:-
PRAD	cis	rs73086581	0.891	rs11907503	ENSG00000229539.1	RP11-119B16.2	15.18	2.01e-42	8.58e-39	0.97	0.58	Response to antidepressants in depression;	chr20:3906943	chr20:3888239~3888868:-
PRAD	cis	rs11673344	0.502	rs62108306	ENSG00000226686.6	LINC01535	15.18	2.17e-42	9.21e-39	0.75	0.58	Obesity-related traits;	chr19:37691789	chr19:37251912~37265535:+
PRAD	cis	rs875971	0.83	rs587360	ENSG00000226824.5	RP4-756H11.3	-15.18	2.18e-42	9.25e-39	-0.75	-0.58	Aortic root size;	chr7:66057711	chr7:66654538~66669855:+
PRAD	cis	rs8072100	0.84	rs9912311	ENSG00000228782.6	CTD-2026D20.3	15.17	2.24e-42	9.51e-39	0.6	0.58	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47469766	chr17:47450568~47492492:-
PRAD	cis	rs2739330	0.791	rs9612520	ENSG00000231271.1	AP000350.8	15.17	2.25e-42	9.58e-39	0.78	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23949918~23954042:+
PRAD	cis	rs11690935	0.959	rs10166005	ENSG00000228389.1	AC068039.4	15.17	2.3e-42	9.76e-39	0.69	0.58	Schizophrenia;	chr2:171750784	chr2:171773482~171775844:+
PRAD	cis	rs11690935	0.959	rs4668412	ENSG00000228389.1	AC068039.4	15.17	2.3e-42	9.76e-39	0.69	0.58	Schizophrenia;	chr2:171763260	chr2:171773482~171775844:+
PRAD	cis	rs11690935	0.959	rs13419987	ENSG00000228389.1	AC068039.4	15.17	2.3e-42	9.76e-39	0.69	0.58	Schizophrenia;	chr2:171767404	chr2:171773482~171775844:+
PRAD	cis	rs11690935	0.959	rs10194102	ENSG00000228389.1	AC068039.4	15.17	2.3e-42	9.76e-39	0.69	0.58	Schizophrenia;	chr2:171769633	chr2:171773482~171775844:+
PRAD	cis	rs11690935	0.959	rs11904009	ENSG00000228389.1	AC068039.4	15.17	2.3e-42	9.76e-39	0.69	0.58	Schizophrenia;	chr2:171770833	chr2:171773482~171775844:+
PRAD	cis	rs11690935	0.959	rs7572215	ENSG00000228389.1	AC068039.4	15.17	2.3e-42	9.76e-39	0.69	0.58	Schizophrenia;	chr2:171777718	chr2:171773482~171775844:+
PRAD	cis	rs11673344	0.548	rs2058852	ENSG00000226686.6	LINC01535	15.17	2.34e-42	9.92e-39	0.73	0.58	Obesity-related traits;	chr19:37673701	chr19:37251912~37265535:+
PRAD	cis	rs11690935	0.959	rs12692973	ENSG00000228389.1	AC068039.4	-15.17	2.41e-42	1.02e-38	-0.68	-0.58	Schizophrenia;	chr2:171785547	chr2:171773482~171775844:+
PRAD	cis	rs875971	0.8	rs427557	ENSG00000226824.5	RP4-756H11.3	-15.17	2.43e-42	1.03e-38	-0.75	-0.58	Aortic root size;	chr7:66054263	chr7:66654538~66669855:+
PRAD	cis	rs8100891	0.537	rs11880569	ENSG00000267213.4	AC007773.2	-15.16	2.47e-42	1.05e-38	-0.74	-0.58	Neuroticism;	chr19:32478348	chr19:32390050~32405560:-
PRAD	cis	rs916888	0.61	rs199452	ENSG00000262539.1	RP11-259G18.3	15.15	2.99e-42	1.27e-38	0.81	0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:46259551~46260606:-
PRAD	cis	rs2739330	0.627	rs9608219	ENSG00000231271.1	AP000350.8	15.14	3e-42	1.27e-38	0.78	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23949918~23954042:+
PRAD	cis	rs11690935	1	rs6433311	ENSG00000228389.1	AC068039.4	-15.13	3.33e-42	1.41e-38	-0.69	-0.58	Schizophrenia;	chr2:171692738	chr2:171773482~171775844:+
PRAD	cis	rs9326248	0.581	rs7106437	ENSG00000254851.1	RP11-109L13.1	-15.13	3.34e-42	1.41e-38	-0.73	-0.58	Blood protein levels;	chr11:117121360	chr11:117135528~117138582:+
PRAD	cis	rs8072100	0.84	rs9900360	ENSG00000228782.6	CTD-2026D20.3	15.13	3.63e-42	1.53e-38	0.6	0.58	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47414613	chr17:47450568~47492492:-
PRAD	cis	rs8072100	0.84	rs56952963	ENSG00000228782.6	CTD-2026D20.3	15.13	3.63e-42	1.53e-38	0.6	0.58	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47416460	chr17:47450568~47492492:-
PRAD	cis	rs2283792	0.935	rs2283794	ENSG00000224086.5	LL22NC03-86G7.1	-15.12	3.72e-42	1.57e-38	-0.67	-0.58	Multiple sclerosis;	chr22:21858180	chr22:21938293~21977632:+
PRAD	cis	rs11690935	0.879	rs908671	ENSG00000228389.1	AC068039.4	15.12	3.73e-42	1.57e-38	0.69	0.58	Schizophrenia;	chr2:171833755	chr2:171773482~171775844:+
PRAD	cis	rs7617773	0.78	rs3197223	ENSG00000229759.1	MRPS18AP1	15.12	3.78e-42	1.6e-38	0.64	0.58	Coronary artery disease;	chr3:48294367	chr3:48256350~48256938:-
PRAD	cis	rs9487094	0.666	rs13219952	ENSG00000260273.1	RP11-425D10.10	15.12	3.86e-42	1.63e-38	0.78	0.58	Height;	chr6:109391084	chr6:109382795~109383666:+
PRAD	cis	rs11690935	0.959	rs6722757	ENSG00000228389.1	AC068039.4	15.12	4e-42	1.69e-38	0.69	0.58	Schizophrenia;	chr2:171735453	chr2:171773482~171775844:+
PRAD	cis	rs2455601	0.574	rs2568094	ENSG00000254860.4	TMEM9B-AS1	15.11	4.25e-42	1.79e-38	0.69	0.58	Schizophrenia;	chr11:8970671	chr11:8964675~8977527:+
PRAD	cis	rs9487094	0.643	rs730089	ENSG00000260273.1	RP11-425D10.10	15.11	4.26e-42	1.79e-38	0.76	0.58	Height;	chr6:109393881	chr6:109382795~109383666:+
PRAD	cis	rs6920372	0.799	rs9480947	ENSG00000260273.1	RP11-425D10.10	15.11	4.26e-42	1.79e-38	0.76	0.58	Height;	chr6:109397362	chr6:109382795~109383666:+
PRAD	cis	rs9487094	0.666	rs6920372	ENSG00000260273.1	RP11-425D10.10	15.11	4.26e-42	1.79e-38	0.76	0.58	Height;	chr6:109402736	chr6:109382795~109383666:+
PRAD	cis	rs9487094	0.644	rs9320286	ENSG00000260273.1	RP11-425D10.10	15.11	4.26e-42	1.79e-38	0.76	0.58	Height;	chr6:109403734	chr6:109382795~109383666:+
PRAD	cis	rs2882667	0.898	rs10058347	ENSG00000253404.1	AC034243.1	15.11	4.31e-42	1.82e-38	0.77	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139025669	chr5:138744434~138753309:-
PRAD	cis	rs7208859	0.573	rs73277960	ENSG00000263531.1	RP13-753N3.1	15.11	4.43e-42	1.86e-38	1.14	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30850423	chr17:30863921~30864940:-
PRAD	cis	rs2882667	0.931	rs7720150	ENSG00000253404.1	AC034243.1	15.11	4.44e-42	1.87e-38	0.78	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:138998380	chr5:138744434~138753309:-
PRAD	cis	rs2283792	0.967	rs5999823	ENSG00000224086.5	LL22NC03-86G7.1	-15.11	4.47e-42	1.88e-38	-0.67	-0.58	Multiple sclerosis;	chr22:21856587	chr22:21938293~21977632:+
PRAD	cis	rs875971	0.964	rs160635	ENSG00000226824.5	RP4-756H11.3	-15.1	4.52e-42	1.9e-38	-0.75	-0.58	Aortic root size;	chr7:66063931	chr7:66654538~66669855:+
PRAD	cis	rs9487094	0.666	rs746794	ENSG00000260273.1	RP11-425D10.10	15.1	4.65e-42	1.95e-38	0.76	0.58	Height;	chr6:109391534	chr6:109382795~109383666:+
PRAD	cis	rs1930961	1	rs6004675	ENSG00000272977.1	CTA-390C10.10	-15.1	4.66e-42	1.96e-38	-0.93	-0.58	Bipolar disorder with mood-incongruent psychosis;	chr22:25493418	chr22:25476218~25479971:+
PRAD	cis	rs7617773	0.817	rs11130163	ENSG00000229759.1	MRPS18AP1	15.1	4.69e-42	1.97e-38	0.6	0.58	Coronary artery disease;	chr3:48271168	chr3:48256350~48256938:-
PRAD	cis	rs11690935	0.918	rs11757	ENSG00000228389.1	AC068039.4	15.1	4.7e-42	1.97e-38	0.68	0.58	Schizophrenia;	chr2:171784535	chr2:171773482~171775844:+
PRAD	cis	rs7104764	1	rs6598074	ENSG00000277290.1	RP11-326C3.16	-15.1	4.88e-42	2.05e-38	-0.57	-0.58	Menarche (age at onset);	chr11:219398	chr11:243099~243483:-
PRAD	cis	rs4423214	0.879	rs1792283	ENSG00000254682.1	RP11-660L16.2	-15.09	4.99e-42	2.09e-38	-0.84	-0.58	Vitamin D levels;	chr11:71424090	chr11:71448674~71452157:+
PRAD	cis	rs4423214	0.879	rs1792282	ENSG00000254682.1	RP11-660L16.2	-15.09	4.99e-42	2.09e-38	-0.84	-0.58	Vitamin D levels;	chr11:71424120	chr11:71448674~71452157:+
PRAD	cis	rs9487094	0.644	rs910730	ENSG00000260273.1	RP11-425D10.10	15.09	5.19e-42	2.17e-38	0.77	0.58	Height;	chr6:109447092	chr6:109382795~109383666:+
PRAD	cis	rs7617773	0.643	rs78159520	ENSG00000229759.1	MRPS18AP1	15.09	5.26e-42	2.2e-38	0.64	0.58	Coronary artery disease;	chr3:48307533	chr3:48256350~48256938:-
PRAD	cis	rs7208859	0.673	rs3816780	ENSG00000263531.1	RP13-753N3.1	15.09	5.3e-42	2.22e-38	1.13	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834340	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs9912440	ENSG00000263531.1	RP13-753N3.1	15.09	5.42e-42	2.27e-38	1.14	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30821754	chr17:30863921~30864940:-
PRAD	cis	rs7188445	0.871	rs8048928	ENSG00000261390.4	RP11-345M22.2	-15.09	5.49e-42	2.3e-38	-0.69	-0.58	Urate levels;	chr16:79671039	chr16:79715232~79770563:-
PRAD	cis	rs7188445	1	rs11644836	ENSG00000261390.4	RP11-345M22.2	-15.08	5.72e-42	2.39e-38	-0.75	-0.58	Urate levels;	chr16:79678758	chr16:79715232~79770563:-
PRAD	cis	rs7617773	0.78	rs11706277	ENSG00000229759.1	MRPS18AP1	15.08	5.86e-42	2.45e-38	0.64	0.58	Coronary artery disease;	chr3:48318943	chr3:48256350~48256938:-
PRAD	cis	rs2739330	0.76	rs1002286	ENSG00000250470.1	AP000351.3	-15.08	5.97e-42	2.5e-38	-0.77	-0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23976904~23977585:-
PRAD	cis	rs2882667	0.931	rs10038799	ENSG00000253404.1	AC034243.1	15.07	6.2e-42	2.59e-38	0.77	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139026594	chr5:138744434~138753309:-
PRAD	cis	rs9487094	0.666	rs2211288	ENSG00000260273.1	RP11-425D10.10	15.07	6.24e-42	2.61e-38	0.76	0.58	Height;	chr6:109383848	chr6:109382795~109383666:+
PRAD	cis	rs9487094	0.666	rs4946970	ENSG00000260273.1	RP11-425D10.10	15.07	6.24e-42	2.61e-38	0.76	0.58	Height;	chr6:109384807	chr6:109382795~109383666:+
PRAD	cis	rs2882667	0.898	rs6862393	ENSG00000253404.1	AC034243.1	15.07	6.26e-42	2.62e-38	0.77	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139029009	chr5:138744434~138753309:-
PRAD	cis	rs9487094	0.666	rs3757235	ENSG00000260273.1	RP11-425D10.10	15.07	6.32e-42	2.64e-38	0.76	0.58	Height;	chr6:109390638	chr6:109382795~109383666:+
PRAD	cis	rs7104764	0.957	rs3782120	ENSG00000277290.1	RP11-326C3.16	15.07	6.34e-42	2.65e-38	0.56	0.58	Menarche (age at onset);	chr11:206089	chr11:243099~243483:-
PRAD	cis	rs2283792	0.935	rs5750113	ENSG00000224086.5	LL22NC03-86G7.1	-15.07	6.61e-42	2.76e-38	-0.67	-0.58	Multiple sclerosis;	chr22:21865784	chr22:21938293~21977632:+
PRAD	cis	rs2882667	0.931	rs10077796	ENSG00000253404.1	AC034243.1	-15.06	6.87e-42	2.86e-38	-0.78	-0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021086	chr5:138744434~138753309:-
PRAD	cis	rs7104764	0.957	rs56357554	ENSG00000277290.1	RP11-326C3.16	15.06	6.92e-42	2.88e-38	0.56	0.58	Menarche (age at onset);	chr11:204715	chr11:243099~243483:-
PRAD	cis	rs7617773	0.78	rs7645425	ENSG00000229759.1	MRPS18AP1	15.06	7.12e-42	2.96e-38	0.63	0.58	Coronary artery disease;	chr3:48320879	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.743	rs11716371	ENSG00000229759.1	MRPS18AP1	15.06	7.12e-42	2.96e-38	0.63	0.58	Coronary artery disease;	chr3:48321260	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.78	rs6793223	ENSG00000229759.1	MRPS18AP1	15.06	7.12e-42	2.96e-38	0.63	0.58	Coronary artery disease;	chr3:48322611	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.78	rs4541431	ENSG00000229759.1	MRPS18AP1	15.06	7.12e-42	2.96e-38	0.63	0.58	Coronary artery disease;	chr3:48323728	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.78	rs11714944	ENSG00000229759.1	MRPS18AP1	15.06	7.12e-42	2.96e-38	0.63	0.58	Coronary artery disease;	chr3:48325481	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.743	rs13071960	ENSG00000229759.1	MRPS18AP1	15.06	7.12e-42	2.96e-38	0.63	0.58	Coronary artery disease;	chr3:48326047	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.743	rs4632568	ENSG00000229759.1	MRPS18AP1	15.06	7.12e-42	2.96e-38	0.63	0.58	Coronary artery disease;	chr3:48326329	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.78	rs11130164	ENSG00000229759.1	MRPS18AP1	15.06	7.12e-42	2.96e-38	0.63	0.58	Coronary artery disease;	chr3:48327544	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.78	rs7653336	ENSG00000229759.1	MRPS18AP1	15.06	7.12e-42	2.96e-38	0.63	0.58	Coronary artery disease;	chr3:48327974	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.747	rs34076262	ENSG00000229759.1	MRPS18AP1	15.06	7.12e-42	2.96e-38	0.63	0.58	Coronary artery disease;	chr3:48328926	chr3:48256350~48256938:-
PRAD	cis	rs2882667	0.861	rs10037106	ENSG00000253404.1	AC034243.1	15.06	7.18e-42	2.98e-38	0.77	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139029801	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.898	rs13163536	ENSG00000253404.1	AC034243.1	15.06	7.18e-42	2.98e-38	0.77	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139041530	chr5:138744434~138753309:-
PRAD	cis	rs17507216	0.718	rs72751662	ENSG00000278603.1	RP13-608F4.5	15.06	7.27e-42	3.02e-38	0.96	0.58	Excessive daytime sleepiness;	chr15:82594705	chr15:82472203~82472426:+
PRAD	cis	rs7617773	0.817	rs13094727	ENSG00000229759.1	MRPS18AP1	15.05	7.5e-42	3.11e-38	0.63	0.58	Coronary artery disease;	chr3:48281999	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.817	rs13072018	ENSG00000229759.1	MRPS18AP1	15.05	7.58e-42	3.15e-38	0.63	0.58	Coronary artery disease;	chr3:48278842	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.78	rs13067450	ENSG00000229759.1	MRPS18AP1	15.05	7.61e-42	3.16e-38	0.64	0.58	Coronary artery disease;	chr3:48295716	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.78	rs4479622	ENSG00000229759.1	MRPS18AP1	15.05	7.61e-42	3.16e-38	0.64	0.58	Coronary artery disease;	chr3:48296683	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.78	rs34946886	ENSG00000229759.1	MRPS18AP1	15.05	7.61e-42	3.16e-38	0.64	0.58	Coronary artery disease;	chr3:48296997	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.78	rs34589064	ENSG00000229759.1	MRPS18AP1	15.05	7.61e-42	3.16e-38	0.64	0.58	Coronary artery disease;	chr3:48298059	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.78	rs2541	ENSG00000229759.1	MRPS18AP1	15.05	7.61e-42	3.16e-38	0.64	0.58	Coronary artery disease;	chr3:48298128	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.78	rs13085251	ENSG00000229759.1	MRPS18AP1	15.05	7.61e-42	3.16e-38	0.64	0.58	Coronary artery disease;	chr3:48298555	chr3:48256350~48256938:-
PRAD	cis	rs8100891	0.537	rs738093	ENSG00000267213.4	AC007773.2	-15.05	7.63e-42	3.17e-38	-0.74	-0.58	Neuroticism;	chr19:32439601	chr19:32390050~32405560:-
PRAD	cis	rs62229266	1	rs62229266	ENSG00000231106.2	LINC01436	15.05	7.78e-42	3.23e-38	0.73	0.58	Mitral valve prolapse;	chr21:36087973	chr21:36005338~36007838:+
PRAD	cis	rs7617773	0.817	rs11720622	ENSG00000229759.1	MRPS18AP1	15.05	7.79e-42	3.23e-38	0.6	0.58	Coronary artery disease;	chr3:48205189	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.779	rs77957078	ENSG00000229759.1	MRPS18AP1	15.05	7.97e-42	3.3e-38	0.64	0.58	Coronary artery disease;	chr3:48289796	chr3:48256350~48256938:-
PRAD	cis	rs8100891	0.537	rs7253039	ENSG00000267213.4	AC007773.2	-15.05	7.99e-42	3.31e-38	-0.73	-0.58	Neuroticism;	chr19:32482171	chr19:32390050~32405560:-
PRAD	cis	rs8100891	0.537	rs1057395	ENSG00000267213.4	AC007773.2	-15.05	7.99e-42	3.31e-38	-0.73	-0.58	Neuroticism;	chr19:32483832	chr19:32390050~32405560:-
PRAD	cis	rs8100891	0.537	rs1057397	ENSG00000267213.4	AC007773.2	-15.05	7.99e-42	3.31e-38	-0.73	-0.58	Neuroticism;	chr19:32484007	chr19:32390050~32405560:-
PRAD	cis	rs8100891	0.537	rs737093	ENSG00000267213.4	AC007773.2	-15.05	7.99e-42	3.31e-38	-0.73	-0.58	Neuroticism;	chr19:32486500	chr19:32390050~32405560:-
PRAD	cis	rs7617773	0.78	rs36121690	ENSG00000229759.1	MRPS18AP1	15.05	8.18e-42	3.39e-38	0.64	0.58	Coronary artery disease;	chr3:48304021	chr3:48256350~48256938:-
PRAD	cis	rs7104764	0.957	rs1045454	ENSG00000277290.1	RP11-326C3.16	15.04	8.84e-42	3.65e-38	0.56	0.58	Menarche (age at onset);	chr11:204228	chr11:243099~243483:-
PRAD	cis	rs8100891	0.506	rs10408437	ENSG00000267213.4	AC007773.2	-15.04	8.97e-42	3.71e-38	-0.73	-0.58	Neuroticism;	chr19:32497094	chr19:32390050~32405560:-
PRAD	cis	rs7208859	0.573	rs79505916	ENSG00000263531.1	RP13-753N3.1	15.04	9.04e-42	3.73e-38	1.17	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30735308	chr17:30863921~30864940:-
PRAD	cis	rs2283792	1	rs2283792	ENSG00000224086.5	LL22NC03-86G7.1	-15.03	9.11e-42	3.76e-38	-0.67	-0.58	Multiple sclerosis;	chr22:21776836	chr22:21938293~21977632:+
PRAD	cis	rs7617773	0.78	rs7653152	ENSG00000229759.1	MRPS18AP1	15.03	9.15e-42	3.78e-38	0.63	0.58	Coronary artery disease;	chr3:48320607	chr3:48256350~48256938:-
PRAD	cis	rs9326248	0.581	rs7120515	ENSG00000254851.1	RP11-109L13.1	-15.03	9.16e-42	3.78e-38	-0.73	-0.58	Blood protein levels;	chr11:117121210	chr11:117135528~117138582:+
PRAD	cis	rs11690935	1	rs6757773	ENSG00000228389.1	AC068039.4	-15.03	9.28e-42	3.83e-38	-0.69	-0.58	Schizophrenia;	chr2:171693120	chr2:171773482~171775844:+
PRAD	cis	rs11690935	1	rs11678984	ENSG00000228389.1	AC068039.4	-15.03	9.48e-42	3.91e-38	-0.69	-0.58	Schizophrenia;	chr2:171679338	chr2:171773482~171775844:+
PRAD	cis	rs492146	0.935	rs419129	ENSG00000243236.5	GSTA9P	-15.03	9.52e-42	3.93e-38	-0.71	-0.58	Epilepsy (remission after treatment);	chr6:52977197	chr6:52939726~52957521:-
PRAD	cis	rs8072100	0.744	rs34537623	ENSG00000228782.6	CTD-2026D20.3	15.03	9.63e-42	3.98e-38	0.6	0.58	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47452837	chr17:47450568~47492492:-
PRAD	cis	rs2882667	0.898	rs6867343	ENSG00000253404.1	AC034243.1	15.03	9.82e-42	4.05e-38	0.77	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139038739	chr5:138744434~138753309:-
PRAD	cis	rs7208859	0.623	rs9914242	ENSG00000263531.1	RP13-753N3.1	15.03	9.83e-42	4.05e-38	1.15	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30889227	chr17:30863921~30864940:-
PRAD	cis	rs492146	0.819	rs584124	ENSG00000243236.5	GSTA9P	-15.02	1.03e-41	4.25e-38	-0.72	-0.58	Epilepsy (remission after treatment);	chr6:52973398	chr6:52939726~52957521:-
PRAD	cis	rs1930961	1	rs760555	ENSG00000272977.1	CTA-390C10.10	-15.02	1.04e-41	4.27e-38	-0.91	-0.58	Bipolar disorder with mood-incongruent psychosis;	chr22:25476870	chr22:25476218~25479971:+
PRAD	cis	rs7617773	0.78	rs35297395	ENSG00000229759.1	MRPS18AP1	15.02	1.06e-41	4.35e-38	0.63	0.58	Coronary artery disease;	chr3:48301392	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.78	rs36075665	ENSG00000229759.1	MRPS18AP1	15.02	1.06e-41	4.35e-38	0.63	0.58	Coronary artery disease;	chr3:48301597	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.78	rs34630841	ENSG00000229759.1	MRPS18AP1	15.02	1.06e-41	4.35e-38	0.63	0.58	Coronary artery disease;	chr3:48301771	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.78	rs35190747	ENSG00000229759.1	MRPS18AP1	15.02	1.06e-41	4.35e-38	0.63	0.58	Coronary artery disease;	chr3:48301800	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.743	rs7621785	ENSG00000229759.1	MRPS18AP1	15.02	1.06e-41	4.35e-38	0.63	0.58	Coronary artery disease;	chr3:48302218	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.78	rs4511915	ENSG00000229759.1	MRPS18AP1	15.02	1.06e-41	4.35e-38	0.63	0.58	Coronary artery disease;	chr3:48302368	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.78	rs13066758	ENSG00000229759.1	MRPS18AP1	15.02	1.06e-41	4.35e-38	0.63	0.58	Coronary artery disease;	chr3:48302387	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.78	rs4392440	ENSG00000229759.1	MRPS18AP1	15.02	1.06e-41	4.35e-38	0.63	0.58	Coronary artery disease;	chr3:48302430	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.78	rs13082859	ENSG00000229759.1	MRPS18AP1	15.02	1.06e-41	4.35e-38	0.63	0.58	Coronary artery disease;	chr3:48303185	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.78	rs35778847	ENSG00000229759.1	MRPS18AP1	15.02	1.06e-41	4.35e-38	0.63	0.58	Coronary artery disease;	chr3:48305495	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.78	rs34749846	ENSG00000229759.1	MRPS18AP1	15.02	1.06e-41	4.35e-38	0.63	0.58	Coronary artery disease;	chr3:48305678	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.78	rs7632297	ENSG00000229759.1	MRPS18AP1	15.02	1.06e-41	4.35e-38	0.63	0.58	Coronary artery disease;	chr3:48306673	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.78	rs79089926	ENSG00000229759.1	MRPS18AP1	15.02	1.06e-41	4.35e-38	0.63	0.58	Coronary artery disease;	chr3:48307074	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.78	rs4511916	ENSG00000229759.1	MRPS18AP1	15.02	1.06e-41	4.35e-38	0.63	0.58	Coronary artery disease;	chr3:48308876	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.815	rs7624450	ENSG00000229759.1	MRPS18AP1	15.02	1.06e-41	4.35e-38	0.63	0.58	Coronary artery disease;	chr3:48308885	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.815	rs6793150	ENSG00000229759.1	MRPS18AP1	15.02	1.06e-41	4.35e-38	0.63	0.58	Coronary artery disease;	chr3:48310070	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.78	rs6793239	ENSG00000229759.1	MRPS18AP1	15.02	1.06e-41	4.35e-38	0.63	0.58	Coronary artery disease;	chr3:48310128	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.78	rs6782166	ENSG00000229759.1	MRPS18AP1	15.02	1.06e-41	4.35e-38	0.63	0.58	Coronary artery disease;	chr3:48310193	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.78	rs4130522	ENSG00000229759.1	MRPS18AP1	15.02	1.06e-41	4.35e-38	0.63	0.58	Coronary artery disease;	chr3:48310823	chr3:48256350~48256938:-
PRAD	cis	rs7208859	0.623	rs9895785	ENSG00000263531.1	RP13-753N3.1	-15.02	1.08e-41	4.44e-38	-1.15	-0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780690	chr17:30863921~30864940:-
PRAD	cis	rs11690935	0.959	rs12185567	ENSG00000228389.1	AC068039.4	-15.02	1.11e-41	4.54e-38	-0.68	-0.58	Schizophrenia;	chr2:171704219	chr2:171773482~171775844:+
PRAD	cis	rs8100891	0.537	rs7258196	ENSG00000267213.4	AC007773.2	-15.01	1.12e-41	4.58e-38	-0.73	-0.58	Neuroticism;	chr19:32453659	chr19:32390050~32405560:-
PRAD	cis	rs8100891	0.537	rs4805762	ENSG00000267213.4	AC007773.2	-15.01	1.12e-41	4.58e-38	-0.73	-0.58	Neuroticism;	chr19:32473048	chr19:32390050~32405560:-
PRAD	cis	rs7208859	0.623	rs9915566	ENSG00000263531.1	RP13-753N3.1	15.01	1.14e-41	4.68e-38	1.16	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805140	chr17:30863921~30864940:-
PRAD	cis	rs11690935	1	rs312918	ENSG00000228389.1	AC068039.4	15.01	1.21e-41	4.94e-38	0.67	0.58	Schizophrenia;	chr2:171713077	chr2:171773482~171775844:+
PRAD	cis	rs4718428	1	rs4718428	ENSG00000226824.5	RP4-756H11.3	-15	1.27e-41	5.2e-38	-0.74	-0.58	Corneal structure;	chr7:66956459	chr7:66654538~66669855:+
PRAD	cis	rs2882667	0.898	rs11950819	ENSG00000253404.1	AC034243.1	15	1.32e-41	5.39e-38	0.76	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061411	chr5:138744434~138753309:-
PRAD	cis	rs9326248	0.52	rs74830	ENSG00000254851.1	RP11-109L13.1	15	1.32e-41	5.39e-38	0.72	0.58	Blood protein levels;	chr11:117219842	chr11:117135528~117138582:+
PRAD	cis	rs10256972	0.521	rs7811577	ENSG00000229043.2	AC091729.9	-15	1.33e-41	5.43e-38	-0.7	-0.58	Endometriosis;Longevity;	chr7:1063193	chr7:1160374~1165267:+
PRAD	cis	rs11690935	0.959	rs7604918	ENSG00000228389.1	AC068039.4	15	1.33e-41	5.45e-38	0.68	0.58	Schizophrenia;	chr2:171731584	chr2:171773482~171775844:+
PRAD	cis	rs10256972	0.616	rs6957733	ENSG00000229043.2	AC091729.9	-15	1.36e-41	5.56e-38	-0.7	-0.58	Endometriosis;Longevity;	chr7:1066691	chr7:1160374~1165267:+
PRAD	cis	rs11690935	0.959	rs76324055	ENSG00000228389.1	AC068039.4	14.99	1.37e-41	5.61e-38	0.7	0.58	Schizophrenia;	chr2:171763640	chr2:171773482~171775844:+
PRAD	cis	rs11690935	0.959	rs77280952	ENSG00000228389.1	AC068039.4	14.99	1.37e-41	5.61e-38	0.7	0.58	Schizophrenia;	chr2:171763641	chr2:171773482~171775844:+
PRAD	cis	rs11690935	0.959	rs75922913	ENSG00000228389.1	AC068039.4	14.99	1.37e-41	5.61e-38	0.7	0.58	Schizophrenia;	chr2:171763642	chr2:171773482~171775844:+
PRAD	cis	rs11690935	0.959	rs2674484	ENSG00000228389.1	AC068039.4	14.99	1.42e-41	5.79e-38	0.68	0.57	Schizophrenia;	chr2:171718102	chr2:171773482~171775844:+
PRAD	cis	rs11690935	0.959	rs10206062	ENSG00000228389.1	AC068039.4	14.99	1.42e-41	5.79e-38	0.68	0.57	Schizophrenia;	chr2:171720766	chr2:171773482~171775844:+
PRAD	cis	rs11690935	0.959	rs973889	ENSG00000228389.1	AC068039.4	14.99	1.42e-41	5.79e-38	0.68	0.57	Schizophrenia;	chr2:171723444	chr2:171773482~171775844:+
PRAD	cis	rs11690935	0.959	rs10207085	ENSG00000228389.1	AC068039.4	14.99	1.42e-41	5.79e-38	0.68	0.57	Schizophrenia;	chr2:171729375	chr2:171773482~171775844:+
PRAD	cis	rs7208859	0.524	rs11653098	ENSG00000263531.1	RP13-753N3.1	14.99	1.44e-41	5.87e-38	1.16	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795483	chr17:30863921~30864940:-
PRAD	cis	rs8072100	0.777	rs9914653	ENSG00000228782.6	CTD-2026D20.3	14.99	1.47e-41	6e-38	0.6	0.57	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47460029	chr17:47450568~47492492:-
PRAD	cis	rs7617773	0.817	rs6806112	ENSG00000229759.1	MRPS18AP1	14.99	1.48e-41	6.04e-38	0.6	0.57	Coronary artery disease;	chr3:48234587	chr3:48256350~48256938:-
PRAD	cis	rs507080	0.501	rs625735	ENSG00000255239.1	AP002954.6	14.99	1.49e-41	6.07e-38	0.74	0.57	Serum metabolite levels;	chr11:118704710	chr11:118688039~118690600:-
PRAD	cis	rs2882667	0.898	rs6882583	ENSG00000253404.1	AC034243.1	14.98	1.51e-41	6.17e-38	0.77	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139050107	chr5:138744434~138753309:-
PRAD	cis	rs7617773	0.78	rs13081169	ENSG00000229759.1	MRPS18AP1	14.98	1.54e-41	6.27e-38	0.63	0.57	Coronary artery disease;	chr3:48315307	chr3:48256350~48256938:-
PRAD	cis	rs1577917	0.839	rs9450333	ENSG00000203875.9	SNHG5	-14.98	1.55e-41	6.3e-38	-0.62	-0.57	Response to antipsychotic treatment;	chr6:85810037	chr6:85660950~85678736:-
PRAD	cis	rs7208859	0.623	rs59447372	ENSG00000263531.1	RP13-753N3.1	14.98	1.57e-41	6.4e-38	1.16	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30730567	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs8079891	ENSG00000263531.1	RP13-753N3.1	14.98	1.57e-41	6.4e-38	1.16	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30731845	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs73267858	ENSG00000263531.1	RP13-753N3.1	14.98	1.57e-41	6.4e-38	1.16	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732719	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs56095789	ENSG00000263531.1	RP13-753N3.1	14.98	1.57e-41	6.4e-38	1.16	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733152	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs11656844	ENSG00000263531.1	RP13-753N3.1	14.98	1.57e-41	6.4e-38	1.16	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733579	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs11652533	ENSG00000263531.1	RP13-753N3.1	14.98	1.57e-41	6.4e-38	1.16	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733583	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs11652631	ENSG00000263531.1	RP13-753N3.1	14.98	1.57e-41	6.4e-38	1.16	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733748	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.524	rs77498725	ENSG00000263531.1	RP13-753N3.1	14.98	1.57e-41	6.4e-38	1.16	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30736968	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.573	rs73267865	ENSG00000263531.1	RP13-753N3.1	14.98	1.57e-41	6.4e-38	1.16	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737186	chr17:30863921~30864940:-
PRAD	cis	rs4718428	1	rs12534637	ENSG00000226824.5	RP4-756H11.3	-14.98	1.58e-41	6.41e-38	-0.74	-0.57	Corneal structure;	chr7:66862667	chr7:66654538~66669855:+
PRAD	cis	rs2882667	0.898	rs6882330	ENSG00000253404.1	AC034243.1	14.98	1.59e-41	6.45e-38	0.76	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139046493	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.898	rs6882526	ENSG00000253404.1	AC034243.1	14.98	1.59e-41	6.45e-38	0.76	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139046679	chr5:138744434~138753309:-
PRAD	cis	rs11690935	0.959	rs3770452	ENSG00000228389.1	AC068039.4	14.98	1.59e-41	6.45e-38	0.69	0.57	Schizophrenia;	chr2:171812172	chr2:171773482~171775844:+
PRAD	cis	rs11155671	0.53	rs9371215	ENSG00000231760.4	RP11-350J20.5	14.98	1.6e-41	6.49e-38	0.79	0.57	Testicular germ cell tumor;	chr6:149873162	chr6:149796151~149826294:-
PRAD	cis	rs2739330	0.76	rs5760095	ENSG00000250470.1	AP000351.3	14.98	1.61e-41	6.55e-38	0.78	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23976904~23977585:-
PRAD	cis	rs9487094	0.689	rs4636056	ENSG00000260273.1	RP11-425D10.10	14.98	1.62e-41	6.59e-38	0.76	0.57	Height;	chr6:109409679	chr6:109382795~109383666:+
PRAD	cis	rs8100891	0.537	rs73034207	ENSG00000267213.4	AC007773.2	-14.98	1.62e-41	6.6e-38	-0.74	-0.57	Neuroticism;	chr19:32384863	chr19:32390050~32405560:-
PRAD	cis	rs7188445	0.871	rs11150187	ENSG00000261390.4	RP11-345M22.2	14.98	1.63e-41	6.63e-38	0.69	0.57	Urate levels;	chr16:79670515	chr16:79715232~79770563:-
PRAD	cis	rs3931020	0.566	rs1327086	ENSG00000272864.1	RP11-17E13.2	-14.98	1.65e-41	6.71e-38	-0.59	-0.57	Resistin levels;	chr1:74805348	chr1:74698769~74699333:-
PRAD	cis	rs11690935	1	rs312925	ENSG00000228389.1	AC068039.4	14.97	1.69e-41	6.87e-38	0.68	0.57	Schizophrenia;	chr2:171707412	chr2:171773482~171775844:+
PRAD	cis	rs11690935	0.959	rs67204065	ENSG00000228389.1	AC068039.4	14.97	1.71e-41	6.95e-38	0.68	0.57	Schizophrenia;	chr2:171816114	chr2:171773482~171775844:+
PRAD	cis	rs11690935	0.798	rs13018768	ENSG00000228389.1	AC068039.4	14.97	1.76e-41	7.1e-38	0.68	0.57	Schizophrenia;	chr2:171742082	chr2:171773482~171775844:+
PRAD	cis	rs7208859	0.623	rs34756112	ENSG00000263531.1	RP13-753N3.1	14.97	1.76e-41	7.1e-38	1.15	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785998	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.573	rs60724269	ENSG00000263531.1	RP13-753N3.1	14.97	1.76e-41	7.1e-38	1.15	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786255	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs76633166	ENSG00000263531.1	RP13-753N3.1	14.97	1.76e-41	7.1e-38	1.15	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786347	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs1061346	ENSG00000263531.1	RP13-753N3.1	14.97	1.76e-41	7.1e-38	1.15	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787211	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs1061343	ENSG00000263531.1	RP13-753N3.1	14.97	1.76e-41	7.1e-38	1.15	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787258	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs73269988	ENSG00000263531.1	RP13-753N3.1	14.97	1.76e-41	7.1e-38	1.15	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30791127	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.673	rs9899525	ENSG00000263531.1	RP13-753N3.1	14.97	1.76e-41	7.1e-38	1.15	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793278	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs9911784	ENSG00000263531.1	RP13-753N3.1	14.97	1.76e-41	7.1e-38	1.15	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797562	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs9911997	ENSG00000263531.1	RP13-753N3.1	14.97	1.76e-41	7.1e-38	1.15	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797630	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs9890862	ENSG00000263531.1	RP13-753N3.1	14.97	1.76e-41	7.1e-38	1.15	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30798432	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs78071511	ENSG00000263531.1	RP13-753N3.1	14.97	1.76e-41	7.1e-38	1.15	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30801136	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs2035494	ENSG00000263531.1	RP13-753N3.1	14.97	1.76e-41	7.1e-38	1.15	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803375	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.573	rs8064686	ENSG00000263531.1	RP13-753N3.1	14.97	1.76e-41	7.1e-38	1.15	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30807821	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs11657369	ENSG00000263531.1	RP13-753N3.1	14.97	1.76e-41	7.1e-38	1.15	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809450	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs8075341	ENSG00000263531.1	RP13-753N3.1	14.97	1.76e-41	7.1e-38	1.15	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809547	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs73271842	ENSG00000263531.1	RP13-753N3.1	14.97	1.76e-41	7.1e-38	1.15	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30810137	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.673	rs8077116	ENSG00000263531.1	RP13-753N3.1	14.97	1.76e-41	7.1e-38	1.15	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813144	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.524	rs28760584	ENSG00000263531.1	RP13-753N3.1	14.97	1.76e-41	7.1e-38	1.15	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813999	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs7212991	ENSG00000263531.1	RP13-753N3.1	14.97	1.76e-41	7.1e-38	1.15	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816731	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs28627615	ENSG00000263531.1	RP13-753N3.1	14.97	1.76e-41	7.1e-38	1.15	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30818799	chr17:30863921~30864940:-
PRAD	cis	rs1930961	1	rs6004669	ENSG00000272977.1	CTA-390C10.10	-14.97	1.76e-41	7.1e-38	-0.91	-0.57	Bipolar disorder with mood-incongruent psychosis;	chr22:25479836	chr22:25476218~25479971:+
PRAD	cis	rs1930961	1	rs997872	ENSG00000272977.1	CTA-390C10.10	-14.97	1.76e-41	7.1e-38	-0.91	-0.57	Bipolar disorder with mood-incongruent psychosis;	chr22:25482647	chr22:25476218~25479971:+
PRAD	cis	rs2882667	0.861	rs10043676	ENSG00000253404.1	AC034243.1	14.96	1.88e-41	7.58e-38	0.76	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139053872	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.898	rs10038121	ENSG00000253404.1	AC034243.1	14.96	1.88e-41	7.58e-38	0.76	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139053913	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.861	rs10075541	ENSG00000253404.1	AC034243.1	14.96	1.88e-41	7.58e-38	0.76	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139054629	chr5:138744434~138753309:-
PRAD	cis	rs11690935	0.921	rs10200608	ENSG00000228389.1	AC068039.4	14.96	1.92e-41	7.71e-38	0.68	0.57	Schizophrenia;	chr2:171741419	chr2:171773482~171775844:+
PRAD	cis	rs11690935	0.959	rs11897196	ENSG00000228389.1	AC068039.4	14.96	1.92e-41	7.71e-38	0.67	0.57	Schizophrenia;	chr2:171729085	chr2:171773482~171775844:+
PRAD	cis	rs17826219	0.5	rs57005940	ENSG00000263531.1	RP13-753N3.1	14.96	1.92e-41	7.71e-38	1.16	0.57	Body mass index;	chr17:30739311	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs56812022	ENSG00000263531.1	RP13-753N3.1	14.96	1.92e-41	7.71e-38	1.16	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741715	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.524	rs57670615	ENSG00000263531.1	RP13-753N3.1	14.96	1.92e-41	7.71e-38	1.16	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30742480	chr17:30863921~30864940:-
PRAD	cis	rs17826219	0.5	rs2874724	ENSG00000263531.1	RP13-753N3.1	14.96	1.92e-41	7.71e-38	1.16	0.57	Body mass index;	chr17:30745415	chr17:30863921~30864940:-
PRAD	cis	rs17826219	0.568	rs9898097	ENSG00000263531.1	RP13-753N3.1	14.96	1.92e-41	7.71e-38	1.16	0.57	Body mass index;	chr17:30745654	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs9911490	ENSG00000263531.1	RP13-753N3.1	14.96	1.92e-41	7.71e-38	1.16	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30745995	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs7503542	ENSG00000263531.1	RP13-753N3.1	14.96	1.92e-41	7.71e-38	1.16	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746812	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.573	rs11656278	ENSG00000263531.1	RP13-753N3.1	14.96	1.92e-41	7.71e-38	1.16	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748170	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs6505207	ENSG00000263531.1	RP13-753N3.1	14.96	1.92e-41	7.71e-38	1.16	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749553	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.573	rs7223803	ENSG00000263531.1	RP13-753N3.1	14.96	1.92e-41	7.71e-38	1.16	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750175	chr17:30863921~30864940:-
PRAD	cis	rs17826219	0.5	rs2449749	ENSG00000263531.1	RP13-753N3.1	14.96	1.92e-41	7.71e-38	1.16	0.57	Body mass index;	chr17:30751280	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs9894709	ENSG00000263531.1	RP13-753N3.1	14.96	1.92e-41	7.71e-38	1.16	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751436	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs9896603	ENSG00000263531.1	RP13-753N3.1	14.96	1.92e-41	7.71e-38	1.16	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751494	chr17:30863921~30864940:-
PRAD	cis	rs17826219	0.636	rs4055314	ENSG00000263531.1	RP13-753N3.1	14.96	1.92e-41	7.71e-38	1.16	0.57	Body mass index;	chr17:30752751	chr17:30863921~30864940:-
PRAD	cis	rs17507216	0.671	rs4779035	ENSG00000278603.1	RP13-608F4.5	14.96	1.96e-41	7.85e-38	0.93	0.57	Excessive daytime sleepiness;	chr15:82591686	chr15:82472203~82472426:+
PRAD	cis	rs11690935	0.694	rs312921	ENSG00000228389.1	AC068039.4	14.96	2.01e-41	8.06e-38	0.68	0.57	Schizophrenia;	chr2:171710715	chr2:171773482~171775844:+
PRAD	cis	rs7208859	0.673	rs11656462	ENSG00000263531.1	RP13-753N3.1	14.96	2.03e-41	8.12e-38	1.13	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30833682	chr17:30863921~30864940:-
PRAD	cis	rs2882667	0.867	rs11749045	ENSG00000253404.1	AC034243.1	14.95	2.04e-41	8.19e-38	0.76	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139085271	chr5:138744434~138753309:-
PRAD	cis	rs8100891	0.537	rs2302773	ENSG00000267213.4	AC007773.2	-14.95	2.09e-41	8.37e-38	-0.74	-0.57	Neuroticism;	chr19:32436405	chr19:32390050~32405560:-
PRAD	cis	rs2882667	0.898	rs2882792	ENSG00000253404.1	AC034243.1	14.95	2.12e-41	8.47e-38	0.77	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139044791	chr5:138744434~138753309:-
PRAD	cis	rs11673344	0.536	rs7259272	ENSG00000226686.6	LINC01535	14.95	2.17e-41	8.69e-38	0.74	0.57	Obesity-related traits;	chr19:37692214	chr19:37251912~37265535:+
PRAD	cis	rs2283792	1	rs5999515	ENSG00000224086.5	LL22NC03-86G7.1	14.95	2.22e-41	8.87e-38	0.67	0.57	Multiple sclerosis;	chr22:21790812	chr22:21938293~21977632:+
PRAD	cis	rs7208859	0.623	rs55814012	ENSG00000263531.1	RP13-753N3.1	14.95	2.24e-41	8.95e-38	1.16	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750679	chr17:30863921~30864940:-
PRAD	cis	rs916888	0.647	rs199523	ENSG00000262539.1	RP11-259G18.3	-14.95	2.25e-41	8.99e-38	-0.84	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:46259551~46260606:-
PRAD	cis	rs62229266	0.839	rs11088335	ENSG00000231106.2	LINC01436	14.95	2.26e-41	9.02e-38	0.72	0.57	Mitral valve prolapse;	chr21:36098037	chr21:36005338~36007838:+
PRAD	cis	rs7617773	0.817	rs11130162	ENSG00000229759.1	MRPS18AP1	14.94	2.28e-41	9.11e-38	0.6	0.57	Coronary artery disease;	chr3:48256121	chr3:48256350~48256938:-
PRAD	cis	rs1577917	0.74	rs9450302	ENSG00000203875.9	SNHG5	14.94	2.29e-41	9.14e-38	0.63	0.57	Response to antipsychotic treatment;	chr6:85579955	chr6:85660950~85678736:-
PRAD	cis	rs2283792	0.967	rs5999550	ENSG00000224086.5	LL22NC03-86G7.1	-14.94	2.33e-41	9.33e-38	-0.66	-0.57	Multiple sclerosis;	chr22:21796997	chr22:21938293~21977632:+
PRAD	cis	rs2882667	0.861	rs11242445	ENSG00000253404.1	AC034243.1	14.94	2.33e-41	9.33e-38	0.76	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139081365	chr5:138744434~138753309:-
PRAD	cis	rs8072100	0.811	rs9889709	ENSG00000228782.6	CTD-2026D20.3	14.94	2.43e-41	9.69e-38	0.6	0.57	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47367863	chr17:47450568~47492492:-
PRAD	cis	rs11690935	0.959	rs66835971	ENSG00000228389.1	AC068039.4	14.94	2.43e-41	9.71e-38	0.68	0.57	Schizophrenia;	chr2:171820949	chr2:171773482~171775844:+
PRAD	cis	rs492146	0.819	rs612483	ENSG00000243236.5	GSTA9P	14.94	2.43e-41	9.71e-38	0.71	0.57	Epilepsy (remission after treatment);	chr6:52975160	chr6:52939726~52957521:-
PRAD	cis	rs1153858	1	rs7167900	ENSG00000259520.4	CTD-2651B20.3	-14.94	2.45e-41	9.77e-38	-0.74	-0.57	Homoarginine levels;	chr15:45347273	chr15:45251580~45279251:-
PRAD	cis	rs2283792	0.967	rs743409	ENSG00000224086.5	LL22NC03-86G7.1	-14.94	2.46e-41	9.81e-38	-0.66	-0.57	Multiple sclerosis;	chr22:21774926	chr22:21938293~21977632:+
PRAD	cis	rs2283792	1	rs5999521	ENSG00000224086.5	LL22NC03-86G7.1	-14.94	2.46e-41	9.82e-38	-0.66	-0.57	Multiple sclerosis;	chr22:21792110	chr22:21938293~21977632:+
PRAD	cis	rs2283792	1	rs2266967	ENSG00000224086.5	LL22NC03-86G7.1	-14.94	2.46e-41	9.82e-38	-0.66	-0.57	Multiple sclerosis;	chr22:21802500	chr22:21938293~21977632:+
PRAD	cis	rs2283792	1	rs5749986	ENSG00000224086.5	LL22NC03-86G7.1	14.94	2.46e-41	9.82e-38	0.66	0.57	Multiple sclerosis;	chr22:21803372	chr22:21938293~21977632:+
PRAD	cis	rs7208859	0.623	rs7208441	ENSG00000263531.1	RP13-753N3.1	14.93	2.5e-41	9.98e-38	1.16	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816845	chr17:30863921~30864940:-
PRAD	cis	rs2283792	0.967	rs11704205	ENSG00000224086.5	LL22NC03-86G7.1	-14.93	2.5e-41	9.99e-38	-0.66	-0.57	Multiple sclerosis;	chr22:21790964	chr22:21938293~21977632:+
PRAD	cis	rs1153858	1	rs11070453	ENSG00000259520.4	CTD-2651B20.3	-14.93	2.56e-41	1.02e-37	-0.74	-0.57	Homoarginine levels;	chr15:45352956	chr15:45251580~45279251:-
PRAD	cis	rs1153858	1	rs12593230	ENSG00000259520.4	CTD-2651B20.3	-14.93	2.56e-41	1.02e-37	-0.74	-0.57	Homoarginine levels;	chr15:45354770	chr15:45251580~45279251:-
PRAD	cis	rs7617773	0.78	rs35411187	ENSG00000229759.1	MRPS18AP1	14.93	2.59e-41	1.03e-37	0.63	0.57	Coronary artery disease;	chr3:48318527	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.78	rs11714176	ENSG00000229759.1	MRPS18AP1	14.93	2.59e-41	1.03e-37	0.63	0.57	Coronary artery disease;	chr3:48319372	chr3:48256350~48256938:-
PRAD	cis	rs7208859	0.623	rs8080882	ENSG00000263531.1	RP13-753N3.1	14.93	2.63e-41	1.04e-37	1.15	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30754128	chr17:30863921~30864940:-
PRAD	cis	rs17826219	0.5	rs28452421	ENSG00000263531.1	RP13-753N3.1	14.93	2.63e-41	1.04e-37	1.15	0.57	Body mass index;	chr17:30756962	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.573	rs28779471	ENSG00000263531.1	RP13-753N3.1	14.93	2.63e-41	1.04e-37	1.15	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757351	chr17:30863921~30864940:-
PRAD	cis	rs17826219	0.5	rs61685770	ENSG00000263531.1	RP13-753N3.1	14.93	2.63e-41	1.04e-37	1.15	0.57	Body mass index;	chr17:30758695	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs57486336	ENSG00000263531.1	RP13-753N3.1	14.93	2.63e-41	1.04e-37	1.15	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758713	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs12103440	ENSG00000263531.1	RP13-753N3.1	14.93	2.63e-41	1.04e-37	1.15	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759639	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs11657777	ENSG00000263531.1	RP13-753N3.1	14.93	2.63e-41	1.04e-37	1.15	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30764767	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs8075163	ENSG00000263531.1	RP13-753N3.1	14.93	2.63e-41	1.04e-37	1.15	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779292	chr17:30863921~30864940:-
PRAD	cis	rs17826219	0.706	rs8075107	ENSG00000263531.1	RP13-753N3.1	14.93	2.63e-41	1.04e-37	1.15	0.57	Body mass index;	chr17:30779631	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs7223209	ENSG00000263531.1	RP13-753N3.1	14.93	2.63e-41	1.04e-37	1.15	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780202	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs7223404	ENSG00000263531.1	RP13-753N3.1	14.93	2.63e-41	1.04e-37	1.15	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780345	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs9916725	ENSG00000263531.1	RP13-753N3.1	14.93	2.63e-41	1.04e-37	1.15	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780453	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs9916727	ENSG00000263531.1	RP13-753N3.1	14.93	2.63e-41	1.04e-37	1.15	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780454	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs73269945	ENSG00000263531.1	RP13-753N3.1	14.93	2.63e-41	1.04e-37	1.15	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781741	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs9897728	ENSG00000263531.1	RP13-753N3.1	14.93	2.63e-41	1.04e-37	1.15	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781786	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs1054400	ENSG00000263531.1	RP13-753N3.1	14.93	2.63e-41	1.04e-37	1.15	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30782936	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs1054397	ENSG00000263531.1	RP13-753N3.1	14.93	2.63e-41	1.04e-37	1.15	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783178	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs9890558	ENSG00000263531.1	RP13-753N3.1	14.93	2.63e-41	1.04e-37	1.15	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783337	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs9912283	ENSG00000263531.1	RP13-753N3.1	14.93	2.63e-41	1.04e-37	1.15	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783355	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs3752020	ENSG00000263531.1	RP13-753N3.1	14.93	2.63e-41	1.04e-37	1.15	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784107	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs9890855	ENSG00000263531.1	RP13-753N3.1	14.93	2.63e-41	1.04e-37	1.15	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784689	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs9893422	ENSG00000263531.1	RP13-753N3.1	14.93	2.63e-41	1.04e-37	1.15	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784697	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs9891166	ENSG00000263531.1	RP13-753N3.1	14.93	2.63e-41	1.04e-37	1.15	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784884	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs73269974	ENSG00000263531.1	RP13-753N3.1	14.93	2.63e-41	1.04e-37	1.15	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785366	chr17:30863921~30864940:-
PRAD	cis	rs2882667	0.931	rs3749665	ENSG00000253404.1	AC034243.1	14.93	2.66e-41	1.05e-37	0.79	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021522	chr5:138744434~138753309:-
PRAD	cis	rs1153858	1	rs2056493	ENSG00000259520.4	CTD-2651B20.3	-14.93	2.67e-41	1.06e-37	-0.74	-0.57	Homoarginine levels;	chr15:45356074	chr15:45251580~45279251:-
PRAD	cis	rs8100891	0.537	rs10417152	ENSG00000267213.4	AC007773.2	-14.93	2.73e-41	1.08e-37	-0.73	-0.57	Neuroticism;	chr19:32397994	chr19:32390050~32405560:-
PRAD	cis	rs8100891	0.537	rs58591218	ENSG00000267213.4	AC007773.2	-14.91	3.1e-41	1.23e-37	-0.75	-0.57	Neuroticism;	chr19:32399876	chr19:32390050~32405560:-
PRAD	cis	rs1153858	1	rs11852800	ENSG00000259520.4	CTD-2651B20.3	14.91	3.15e-41	1.24e-37	0.74	0.57	Homoarginine levels;	chr15:45346933	chr15:45251580~45279251:-
PRAD	cis	rs17507216	0.628	rs4627310	ENSG00000278603.1	RP13-608F4.5	14.91	3.16e-41	1.25e-37	0.94	0.57	Excessive daytime sleepiness;	chr15:82708330	chr15:82472203~82472426:+
PRAD	cis	rs2882667	0.898	rs3925110	ENSG00000253404.1	AC034243.1	14.91	3.16e-41	1.25e-37	0.77	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139035676	chr5:138744434~138753309:-
PRAD	cis	rs6504950	0.79	rs8076984	ENSG00000275710.1	RP11-257O5.4	14.91	3.25e-41	1.28e-37	0.78	0.57	Breast cancer;	chr17:54958067	chr17:54964474~54964679:+
PRAD	cis	rs6504950	0.83	rs17745231	ENSG00000275710.1	RP11-257O5.4	14.91	3.25e-41	1.28e-37	0.78	0.57	Breast cancer;	chr17:54959168	chr17:54964474~54964679:+
PRAD	cis	rs6504950	0.83	rs12938118	ENSG00000275710.1	RP11-257O5.4	14.91	3.25e-41	1.28e-37	0.78	0.57	Breast cancer;	chr17:54959998	chr17:54964474~54964679:+
PRAD	cis	rs6504950	0.83	rs1802212	ENSG00000275710.1	RP11-257O5.4	14.91	3.25e-41	1.28e-37	0.78	0.57	Breast cancer;	chr17:54961293	chr17:54964474~54964679:+
PRAD	cis	rs6504950	0.83	rs17817901	ENSG00000275710.1	RP11-257O5.4	14.91	3.25e-41	1.28e-37	0.78	0.57	Breast cancer;	chr17:54961384	chr17:54964474~54964679:+
PRAD	cis	rs6504950	0.83	rs12150038	ENSG00000275710.1	RP11-257O5.4	14.91	3.25e-41	1.28e-37	0.78	0.57	Breast cancer;	chr17:54964159	chr17:54964474~54964679:+
PRAD	cis	rs6504950	0.83	rs12951542	ENSG00000275710.1	RP11-257O5.4	14.91	3.25e-41	1.28e-37	0.78	0.57	Breast cancer;	chr17:54964604	chr17:54964474~54964679:+
PRAD	cis	rs1153858	1	rs16952714	ENSG00000259520.4	CTD-2651B20.3	-14.9	3.42e-41	1.35e-37	-0.74	-0.57	Homoarginine levels;	chr15:45358160	chr15:45251580~45279251:-
PRAD	cis	rs8072100	0.84	rs11079774	ENSG00000228782.6	CTD-2026D20.3	14.9	3.54e-41	1.4e-37	0.6	0.57	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402340	chr17:47450568~47492492:-
PRAD	cis	rs7208859	0.524	rs59923796	ENSG00000263531.1	RP13-753N3.1	14.9	3.66e-41	1.44e-37	1.16	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737901	chr17:30863921~30864940:-
PRAD	cis	rs8100891	0.537	rs4805755	ENSG00000267213.4	AC007773.2	14.89	3.74e-41	1.47e-37	0.72	0.57	Neuroticism;	chr19:32363564	chr19:32390050~32405560:-
PRAD	cis	rs2882667	0.898	rs13182437	ENSG00000253404.1	AC034243.1	14.89	3.74e-41	1.47e-37	0.77	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139051460	chr5:138744434~138753309:-
PRAD	cis	rs11690935	0.921	rs4668414	ENSG00000228389.1	AC068039.4	14.89	3.91e-41	1.54e-37	0.68	0.57	Schizophrenia;	chr2:171847781	chr2:171773482~171775844:+
PRAD	cis	rs7617773	0.78	rs13090538	ENSG00000229759.1	MRPS18AP1	14.89	3.92e-41	1.54e-37	0.63	0.57	Coronary artery disease;	chr3:48329279	chr3:48256350~48256938:-
PRAD	cis	rs7208859	0.623	rs7220999	ENSG00000263531.1	RP13-753N3.1	14.89	3.98e-41	1.56e-37	1.13	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822280	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs55638872	ENSG00000263531.1	RP13-753N3.1	14.89	3.98e-41	1.56e-37	1.13	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822534	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs9899268	ENSG00000263531.1	RP13-753N3.1	14.89	3.98e-41	1.56e-37	1.13	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30823237	chr17:30863921~30864940:-
PRAD	cis	rs8072100	0.84	rs9893901	ENSG00000228782.6	CTD-2026D20.3	14.89	3.98e-41	1.56e-37	0.6	0.57	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47429316	chr17:47450568~47492492:-
PRAD	cis	rs11690935	0.959	rs6709156	ENSG00000228389.1	AC068039.4	14.88	4.17e-41	1.64e-37	0.68	0.57	Schizophrenia;	chr2:171735434	chr2:171773482~171775844:+
PRAD	cis	rs11690935	0.959	rs12692970	ENSG00000228389.1	AC068039.4	14.88	4.17e-41	1.64e-37	0.68	0.57	Schizophrenia;	chr2:171737687	chr2:171773482~171775844:+
PRAD	cis	rs8100891	0.537	rs16967141	ENSG00000267213.4	AC007773.2	-14.88	4.31e-41	1.69e-37	-0.74	-0.57	Neuroticism;	chr19:32480317	chr19:32390050~32405560:-
PRAD	cis	rs8100891	0.537	rs3746016	ENSG00000267213.4	AC007773.2	-14.88	4.44e-41	1.74e-37	-0.75	-0.57	Neuroticism;	chr19:32386353	chr19:32390050~32405560:-
PRAD	cis	rs7104764	1	rs6598066	ENSG00000277290.1	RP11-326C3.16	-14.88	4.46e-41	1.75e-37	-0.56	-0.57	Menarche (age at onset);	chr11:243185	chr11:243099~243483:-
PRAD	cis	rs916888	0.647	rs199449	ENSG00000214401.4	KANSL1-AS1	14.88	4.53e-41	1.78e-37	0.81	0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:46193576~46196723:+
PRAD	cis	rs916888	0.61	rs199444	ENSG00000214401.4	KANSL1-AS1	14.88	4.53e-41	1.78e-37	0.81	0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:46193576~46196723:+
PRAD	cis	rs916888	0.61	rs199442	ENSG00000214401.4	KANSL1-AS1	14.88	4.53e-41	1.78e-37	0.81	0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:46193576~46196723:+
PRAD	cis	rs977987	0.832	rs37597	ENSG00000261783.1	RP11-252K23.2	14.87	4.58e-41	1.79e-37	0.8	0.57	Dupuytren's disease;	chr16:75466377	chr16:75379818~75381260:-
PRAD	cis	rs524281	0.773	rs7925123	ENSG00000255320.1	RP11-755F10.1	14.87	4.7e-41	1.84e-37	0.96	0.57	Electroencephalogram traits;	chr11:66225742	chr11:66244840~66246239:-
PRAD	cis	rs875971	0.83	rs427575	ENSG00000226824.5	RP4-756H11.3	-14.87	4.78e-41	1.87e-37	-0.74	-0.57	Aortic root size;	chr7:66054232	chr7:66654538~66669855:+
PRAD	cis	rs17507216	0.588	rs28864981	ENSG00000278603.1	RP13-608F4.5	14.87	4.92e-41	1.93e-37	0.94	0.57	Excessive daytime sleepiness;	chr15:82695420	chr15:82472203~82472426:+
PRAD	cis	rs17507216	0.628	rs8032321	ENSG00000278603.1	RP13-608F4.5	14.87	4.92e-41	1.93e-37	0.94	0.57	Excessive daytime sleepiness;	chr15:82698956	chr15:82472203~82472426:+
PRAD	cis	rs17507216	0.628	rs8040488	ENSG00000278603.1	RP13-608F4.5	14.87	4.92e-41	1.93e-37	0.94	0.57	Excessive daytime sleepiness;	chr15:82699081	chr15:82472203~82472426:+
PRAD	cis	rs7208859	0.673	rs11655623	ENSG00000263531.1	RP13-753N3.1	14.87	4.93e-41	1.93e-37	1.12	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30835155	chr17:30863921~30864940:-
PRAD	cis	rs7104764	0.879	rs6598070	ENSG00000277290.1	RP11-326C3.16	-14.87	5e-41	1.96e-37	-0.57	-0.57	Menarche (age at onset);	chr11:225466	chr11:243099~243483:-
PRAD	cis	rs10170846	0.924	rs3768973	ENSG00000261428.2	RP11-16P6.1	14.86	5.05e-41	1.98e-37	0.77	0.57	Schizophrenia (inflammation and infection response interaction);	chr2:222571683	chr2:222566899~222569719:-
PRAD	cis	rs11690935	1	rs2138348	ENSG00000228389.1	AC068039.4	-14.86	5.19e-41	2.03e-37	-0.68	-0.57	Schizophrenia;	chr2:171701662	chr2:171773482~171775844:+
PRAD	cis	rs7208859	0.573	rs73267872	ENSG00000263531.1	RP13-753N3.1	14.86	5.21e-41	2.04e-37	1.15	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30740189	chr17:30863921~30864940:-
PRAD	cis	rs2283792	1	rs5749806	ENSG00000224086.5	LL22NC03-86G7.1	-14.86	5.24e-41	2.05e-37	-0.67	-0.57	Multiple sclerosis;	chr22:21752329	chr22:21938293~21977632:+
PRAD	cis	rs11690935	0.959	rs6759575	ENSG00000228389.1	AC068039.4	14.86	5.26e-41	2.05e-37	0.68	0.57	Schizophrenia;	chr2:171832558	chr2:171773482~171775844:+
PRAD	cis	rs916888	0.647	rs199524	ENSG00000262539.1	RP11-259G18.3	-14.86	5.52e-41	2.16e-37	-0.84	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:46259551~46260606:-
PRAD	cis	rs6504950	0.83	rs72831295	ENSG00000275710.1	RP11-257O5.4	14.86	5.53e-41	2.16e-37	0.79	0.57	Breast cancer;	chr17:54966443	chr17:54964474~54964679:+
PRAD	cis	rs11690935	0.921	rs908670	ENSG00000228389.1	AC068039.4	14.86	5.53e-41	2.16e-37	0.67	0.57	Schizophrenia;	chr2:171833670	chr2:171773482~171775844:+
PRAD	cis	rs492146	0.819	rs5028437	ENSG00000243236.5	GSTA9P	14.85	5.61e-41	2.19e-37	0.71	0.57	Epilepsy (remission after treatment);	chr6:52970876	chr6:52939726~52957521:-
PRAD	cis	rs11690935	0.959	rs10204501	ENSG00000228389.1	AC068039.4	14.85	5.69e-41	2.22e-37	0.67	0.57	Schizophrenia;	chr2:171732355	chr2:171773482~171775844:+
PRAD	cis	rs11690935	0.959	rs10204502	ENSG00000228389.1	AC068039.4	14.85	5.69e-41	2.22e-37	0.67	0.57	Schizophrenia;	chr2:171732356	chr2:171773482~171775844:+
PRAD	cis	rs11690935	0.959	rs10204622	ENSG00000228389.1	AC068039.4	14.85	5.69e-41	2.22e-37	0.67	0.57	Schizophrenia;	chr2:171732472	chr2:171773482~171775844:+
PRAD	cis	rs524281	0.731	rs11227433	ENSG00000255320.1	RP11-755F10.1	14.85	5.77e-41	2.25e-37	0.95	0.57	Electroencephalogram traits;	chr11:66237222	chr11:66244840~66246239:-
PRAD	cis	rs11690935	0.921	rs7355523	ENSG00000228389.1	AC068039.4	14.85	5.82e-41	2.27e-37	0.68	0.57	Schizophrenia;	chr2:171887911	chr2:171773482~171775844:+
PRAD	cis	rs7617773	0.78	rs13079728	ENSG00000229759.1	MRPS18AP1	14.85	5.92e-41	2.31e-37	0.63	0.57	Coronary artery disease;	chr3:48297870	chr3:48256350~48256938:-
PRAD	cis	rs524281	0.773	rs2236651	ENSG00000255320.1	RP11-755F10.1	14.85	5.95e-41	2.32e-37	0.95	0.57	Electroencephalogram traits;	chr11:66233947	chr11:66244840~66246239:-
PRAD	cis	rs524281	0.773	rs4393319	ENSG00000255320.1	RP11-755F10.1	14.85	5.95e-41	2.32e-37	0.95	0.57	Electroencephalogram traits;	chr11:66234407	chr11:66244840~66246239:-
PRAD	cis	rs524281	0.773	rs10896105	ENSG00000255320.1	RP11-755F10.1	14.85	5.95e-41	2.32e-37	0.95	0.57	Electroencephalogram traits;	chr11:66234789	chr11:66244840~66246239:-
PRAD	cis	rs524281	0.773	rs2236652	ENSG00000255320.1	RP11-755F10.1	14.85	5.95e-41	2.32e-37	0.95	0.57	Electroencephalogram traits;	chr11:66235210	chr11:66244840~66246239:-
PRAD	cis	rs524281	0.773	rs10791861	ENSG00000255320.1	RP11-755F10.1	14.85	5.95e-41	2.32e-37	0.95	0.57	Electroencephalogram traits;	chr11:66240999	chr11:66244840~66246239:-
PRAD	cis	rs524281	0.773	rs10791862	ENSG00000255320.1	RP11-755F10.1	14.85	5.95e-41	2.32e-37	0.95	0.57	Electroencephalogram traits;	chr11:66246193	chr11:66244840~66246239:-
PRAD	cis	rs524281	0.773	rs2155198	ENSG00000255320.1	RP11-755F10.1	14.85	5.95e-41	2.32e-37	0.95	0.57	Electroencephalogram traits;	chr11:66246829	chr11:66244840~66246239:-
PRAD	cis	rs875971	0.825	rs1129531	ENSG00000226824.5	RP4-756H11.3	14.85	5.96e-41	2.32e-37	0.77	0.57	Aortic root size;	chr7:66154117	chr7:66654538~66669855:+
PRAD	cis	rs7208859	0.673	rs9895815	ENSG00000263531.1	RP13-753N3.1	14.85	5.99e-41	2.33e-37	1.13	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811015	chr17:30863921~30864940:-
PRAD	cis	rs17826219	0.706	rs73271850	ENSG00000263531.1	RP13-753N3.1	14.85	5.99e-41	2.33e-37	1.13	0.57	Body mass index;	chr17:30815122	chr17:30863921~30864940:-
PRAD	cis	rs17826219	0.636	rs79565452	ENSG00000263531.1	RP13-753N3.1	14.85	5.99e-41	2.33e-37	1.13	0.57	Body mass index;	chr17:30815823	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs7208088	ENSG00000263531.1	RP13-753N3.1	14.85	5.99e-41	2.33e-37	1.13	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816649	chr17:30863921~30864940:-
PRAD	cis	rs7617773	0.709	rs4404473	ENSG00000229759.1	MRPS18AP1	14.85	6.16e-41	2.39e-37	0.66	0.57	Coronary artery disease;	chr3:48312136	chr3:48256350~48256938:-
PRAD	cis	rs492146	0.819	rs677636	ENSG00000243236.5	GSTA9P	-14.84	6.46e-41	2.51e-37	-0.71	-0.57	Epilepsy (remission after treatment);	chr6:52972509	chr6:52939726~52957521:-
PRAD	cis	rs916888	0.61	rs142167	ENSG00000262539.1	RP11-259G18.3	-14.84	6.69e-41	2.6e-37	-0.81	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:46259551~46260606:-
PRAD	cis	rs7104764	0.957	rs519592	ENSG00000277290.1	RP11-326C3.16	-14.84	6.72e-41	2.61e-37	-0.55	-0.57	Menarche (age at onset);	chr11:236811	chr11:243099~243483:-
PRAD	cis	rs7188445	1	rs76819459	ENSG00000261390.4	RP11-345M22.2	-14.84	6.72e-41	2.61e-37	-0.72	-0.57	Urate levels;	chr16:79685020	chr16:79715232~79770563:-
PRAD	cis	rs11155671	0.53	rs7757984	ENSG00000216906.2	RP11-350J20.9	14.84	6.75e-41	2.62e-37	0.66	0.57	Testicular germ cell tumor;	chr6:149887515	chr6:149904243~149906418:+
PRAD	cis	rs524281	0.682	rs4483592	ENSG00000255320.1	RP11-755F10.1	14.83	6.84e-41	2.65e-37	0.95	0.57	Electroencephalogram traits;	chr11:66222968	chr11:66244840~66246239:-
PRAD	cis	rs524281	0.773	rs2155201	ENSG00000255320.1	RP11-755F10.1	14.83	6.84e-41	2.65e-37	0.95	0.57	Electroencephalogram traits;	chr11:66224873	chr11:66244840~66246239:-
PRAD	cis	rs1930961	1	rs6004671	ENSG00000272977.1	CTA-390C10.10	-14.83	6.85e-41	2.66e-37	-0.91	-0.57	Bipolar disorder with mood-incongruent psychosis;	chr22:25483507	chr22:25476218~25479971:+
PRAD	cis	rs1930961	1	rs6004672	ENSG00000272977.1	CTA-390C10.10	-14.83	6.85e-41	2.66e-37	-0.91	-0.57	Bipolar disorder with mood-incongruent psychosis;	chr22:25485046	chr22:25476218~25479971:+
PRAD	cis	rs2739330	0.731	rs4822450	ENSG00000250470.1	AP000351.3	14.83	6.95e-41	2.69e-37	0.77	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23976904~23977585:-
PRAD	cis	rs1153858	1	rs9783731	ENSG00000259520.4	CTD-2651B20.3	14.83	6.98e-41	2.71e-37	0.74	0.57	Homoarginine levels;	chr15:45350686	chr15:45251580~45279251:-
PRAD	cis	rs8072100	0.84	rs12453233	ENSG00000228782.6	CTD-2026D20.3	14.83	6.99e-41	2.71e-37	0.6	0.57	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47377204	chr17:47450568~47492492:-
PRAD	cis	rs2283792	1	rs13943	ENSG00000224086.5	LL22NC03-86G7.1	-14.83	7.08e-41	2.75e-37	-0.66	-0.57	Multiple sclerosis;	chr22:21761913	chr22:21938293~21977632:+
PRAD	cis	rs2882667	0.931	rs7706391	ENSG00000253404.1	AC034243.1	14.83	7.11e-41	2.76e-37	0.77	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139013475	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.898	rs2043272	ENSG00000253404.1	AC034243.1	14.83	7.15e-41	2.77e-37	0.76	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139054942	chr5:138744434~138753309:-
PRAD	cis	rs1153858	1	rs56850226	ENSG00000259520.4	CTD-2651B20.3	-14.83	7.18e-41	2.78e-37	-0.74	-0.57	Homoarginine levels;	chr15:45340920	chr15:45251580~45279251:-
PRAD	cis	rs2283792	1	rs6518986	ENSG00000224086.5	LL22NC03-86G7.1	-14.82	7.56e-41	2.93e-37	-0.66	-0.57	Multiple sclerosis;	chr22:21831058	chr22:21938293~21977632:+
PRAD	cis	rs2929278	0.589	rs2411284	ENSG00000205771.5	CATSPER2P1	14.82	7.57e-41	2.93e-37	0.66	0.57	Schizophrenia;	chr15:43746701	chr15:43726918~43747094:-
PRAD	cis	rs2929278	0.617	rs12908467	ENSG00000205771.5	CATSPER2P1	14.82	7.57e-41	2.93e-37	0.66	0.57	Schizophrenia;	chr15:43755232	chr15:43726918~43747094:-
PRAD	cis	rs8100891	0.537	rs73036023	ENSG00000267213.4	AC007773.2	-14.82	7.65e-41	2.96e-37	-0.74	-0.57	Neuroticism;	chr19:32457414	chr19:32390050~32405560:-
PRAD	cis	rs7617773	0.78	rs13082158	ENSG00000229759.1	MRPS18AP1	14.82	7.71e-41	2.98e-37	0.63	0.57	Coronary artery disease;	chr3:48330980	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.676	rs13060020	ENSG00000229759.1	MRPS18AP1	14.82	7.71e-41	2.98e-37	0.63	0.57	Coronary artery disease;	chr3:48331156	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.78	rs11710257	ENSG00000229759.1	MRPS18AP1	14.82	7.71e-41	2.98e-37	0.63	0.57	Coronary artery disease;	chr3:48331724	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.707	rs13061269	ENSG00000229759.1	MRPS18AP1	14.82	7.71e-41	2.98e-37	0.63	0.57	Coronary artery disease;	chr3:48331853	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.78	rs71323395	ENSG00000229759.1	MRPS18AP1	14.82	7.71e-41	2.98e-37	0.63	0.57	Coronary artery disease;	chr3:48332587	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.743	rs71323397	ENSG00000229759.1	MRPS18AP1	14.82	7.71e-41	2.98e-37	0.63	0.57	Coronary artery disease;	chr3:48333384	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.78	rs13066044	ENSG00000229759.1	MRPS18AP1	14.82	7.71e-41	2.98e-37	0.63	0.57	Coronary artery disease;	chr3:48335786	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.778	rs11715776	ENSG00000229759.1	MRPS18AP1	14.82	7.71e-41	2.98e-37	0.63	0.57	Coronary artery disease;	chr3:48336121	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.778	rs11707997	ENSG00000229759.1	MRPS18AP1	14.82	7.71e-41	2.98e-37	0.63	0.57	Coronary artery disease;	chr3:48336385	chr3:48256350~48256938:-
PRAD	cis	rs1153858	1	rs11858495	ENSG00000259520.4	CTD-2651B20.3	14.82	7.71e-41	2.98e-37	0.74	0.57	Homoarginine levels;	chr15:45345464	chr15:45251580~45279251:-
PRAD	cis	rs2882667	0.898	rs2351465	ENSG00000253404.1	AC034243.1	14.82	7.86e-41	3.04e-37	0.76	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139028162	chr5:138744434~138753309:-
PRAD	cis	rs2283792	0.935	rs8141851	ENSG00000224086.5	LL22NC03-86G7.1	-14.82	8.03e-41	3.1e-37	-0.67	-0.57	Multiple sclerosis;	chr22:21812161	chr22:21938293~21977632:+
PRAD	cis	rs916888	0.779	rs199498	ENSG00000262539.1	RP11-259G18.3	14.82	8.05e-41	3.11e-37	0.88	0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:46259551~46260606:-
PRAD	cis	rs9326248	0.52	rs236919	ENSG00000254851.1	RP11-109L13.1	-14.82	8.16e-41	3.15e-37	-0.72	-0.57	Blood protein levels;	chr11:117224645	chr11:117135528~117138582:+
PRAD	cis	rs7617773	0.78	rs77044321	ENSG00000229759.1	MRPS18AP1	14.82	8.2e-41	3.17e-37	0.63	0.57	Coronary artery disease;	chr3:48307824	chr3:48256350~48256938:-
PRAD	cis	rs11155671	0.53	rs4458704	ENSG00000231760.4	RP11-350J20.5	14.82	8.22e-41	3.17e-37	0.8	0.57	Testicular germ cell tumor;	chr6:149911743	chr6:149796151~149826294:-
PRAD	cis	rs4718428	1	rs1830070	ENSG00000226824.5	RP4-756H11.3	-14.81	8.47e-41	3.27e-37	-0.73	-0.57	Corneal structure;	chr7:66884684	chr7:66654538~66669855:+
PRAD	cis	rs2882667	0.861	rs13176902	ENSG00000253404.1	AC034243.1	14.81	8.73e-41	3.37e-37	0.76	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139057640	chr5:138744434~138753309:-
PRAD	cis	rs2283792	1	rs5999750	ENSG00000224086.5	LL22NC03-86G7.1	-14.81	8.75e-41	3.38e-37	-0.66	-0.57	Multiple sclerosis;	chr22:21833720	chr22:21938293~21977632:+
PRAD	cis	rs916888	0.61	rs199530	ENSG00000262539.1	RP11-259G18.3	-14.81	8.93e-41	3.45e-37	-0.82	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:46259551~46260606:-
PRAD	cis	rs2929278	0.617	rs693919	ENSG00000205771.5	CATSPER2P1	14.8	9.22e-41	3.56e-37	0.65	0.57	Schizophrenia;	chr15:43810130	chr15:43726918~43747094:-
PRAD	cis	rs2882667	0.898	rs6890272	ENSG00000253404.1	AC034243.1	14.8	9.32e-41	3.59e-37	0.76	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139035427	chr5:138744434~138753309:-
PRAD	cis	rs1153858	1	rs10519022	ENSG00000259520.4	CTD-2651B20.3	14.8	9.73e-41	3.75e-37	0.74	0.57	Homoarginine levels;	chr15:45371486	chr15:45251580~45279251:-
PRAD	cis	rs1153858	1	rs56669689	ENSG00000259520.4	CTD-2651B20.3	-14.8	9.9e-41	3.81e-37	-0.74	-0.57	Homoarginine levels;	chr15:45345531	chr15:45251580~45279251:-
PRAD	cis	rs1153858	1	rs56806728	ENSG00000259520.4	CTD-2651B20.3	-14.8	9.9e-41	3.81e-37	-0.74	-0.57	Homoarginine levels;	chr15:45345616	chr15:45251580~45279251:-
PRAD	cis	rs1153858	1	rs4775906	ENSG00000259520.4	CTD-2651B20.3	-14.8	9.9e-41	3.81e-37	-0.74	-0.57	Homoarginine levels;	chr15:45346096	chr15:45251580~45279251:-
PRAD	cis	rs1153858	1	rs7179743	ENSG00000259520.4	CTD-2651B20.3	-14.8	9.9e-41	3.81e-37	-0.74	-0.57	Homoarginine levels;	chr15:45346133	chr15:45251580~45279251:-
PRAD	cis	rs1153858	1	rs4775907	ENSG00000259520.4	CTD-2651B20.3	-14.8	9.9e-41	3.81e-37	-0.74	-0.57	Homoarginine levels;	chr15:45346449	chr15:45251580~45279251:-
PRAD	cis	rs1153858	1	rs7163720	ENSG00000259520.4	CTD-2651B20.3	-14.8	9.9e-41	3.81e-37	-0.74	-0.57	Homoarginine levels;	chr15:45347176	chr15:45251580~45279251:-
PRAD	cis	rs1153858	1	rs12591058	ENSG00000259520.4	CTD-2651B20.3	-14.8	9.9e-41	3.81e-37	-0.74	-0.57	Homoarginine levels;	chr15:45347974	chr15:45251580~45279251:-
PRAD	cis	rs1153858	1	rs7169587	ENSG00000259520.4	CTD-2651B20.3	-14.8	9.9e-41	3.81e-37	-0.74	-0.57	Homoarginine levels;	chr15:45348181	chr15:45251580~45279251:-
PRAD	cis	rs5850	0.55	rs76983703	ENSG00000230658.1	KLHL7-AS1	14.8	9.92e-41	3.82e-37	0.81	0.57	Blood protein levels;	chr7:23337094	chr7:23101228~23105703:-
PRAD	cis	rs492146	0.729	rs426013	ENSG00000243236.5	GSTA9P	-14.8	9.96e-41	3.83e-37	-0.73	-0.57	Epilepsy (remission after treatment);	chr6:52975947	chr6:52939726~52957521:-
PRAD	cis	rs492146	0.756	rs374275	ENSG00000243236.5	GSTA9P	-14.8	9.96e-41	3.83e-37	-0.73	-0.57	Epilepsy (remission after treatment);	chr6:52975999	chr6:52939726~52957521:-
PRAD	cis	rs8072100	0.84	rs4968319	ENSG00000228782.6	CTD-2026D20.3	14.8	1.01e-40	3.87e-37	0.59	0.57	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47387601	chr17:47450568~47492492:-
PRAD	cis	rs7617773	0.817	rs17647717	ENSG00000229759.1	MRPS18AP1	14.8	1.02e-40	3.91e-37	0.64	0.57	Coronary artery disease;	chr3:48263966	chr3:48256350~48256938:-
PRAD	cis	rs1153858	0.943	rs28605551	ENSG00000259520.4	CTD-2651B20.3	-14.79	1.02e-40	3.94e-37	-0.74	-0.57	Homoarginine levels;	chr15:45349522	chr15:45251580~45279251:-
PRAD	cis	rs7617773	0.746	rs4371540	ENSG00000229759.1	MRPS18AP1	14.79	1.05e-40	4.02e-37	0.64	0.57	Coronary artery disease;	chr3:48312053	chr3:48256350~48256938:-
PRAD	cis	rs916888	0.779	rs199498	ENSG00000214401.4	KANSL1-AS1	14.79	1.08e-40	4.15e-37	0.87	0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:46193576~46196723:+
PRAD	cis	rs8072100	0.84	rs12452796	ENSG00000228782.6	CTD-2026D20.3	-14.78	1.16e-40	4.43e-37	-0.59	-0.57	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402367	chr17:47450568~47492492:-
PRAD	cis	rs8037818	1	rs8037102	ENSG00000276724.1	RP11-1000B6.7	-14.78	1.16e-40	4.44e-37	-0.81	-0.57	Obesity-related traits;	chr15:32640449	chr15:32583612~32584312:+
PRAD	cis	rs17507216	0.628	rs28371837	ENSG00000278603.1	RP13-608F4.5	14.78	1.18e-40	4.53e-37	0.94	0.57	Excessive daytime sleepiness;	chr15:82714435	chr15:82472203~82472426:+
PRAD	cis	rs7617773	0.743	rs13081633	ENSG00000229759.1	MRPS18AP1	14.78	1.19e-40	4.56e-37	0.63	0.57	Coronary artery disease;	chr3:48315791	chr3:48256350~48256938:-
PRAD	cis	rs8072100	0.84	rs1912482	ENSG00000228782.6	CTD-2026D20.3	14.78	1.23e-40	4.69e-37	0.59	0.57	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47377517	chr17:47450568~47492492:-
PRAD	cis	rs8072100	0.84	rs2136751	ENSG00000228782.6	CTD-2026D20.3	14.78	1.23e-40	4.69e-37	0.59	0.57	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47378727	chr17:47450568~47492492:-
PRAD	cis	rs11155671	0.53	rs9968871	ENSG00000216906.2	RP11-350J20.9	14.78	1.23e-40	4.69e-37	0.65	0.57	Testicular germ cell tumor;	chr6:149888060	chr6:149904243~149906418:+
PRAD	cis	rs11155671	0.53	rs9969044	ENSG00000216906.2	RP11-350J20.9	14.78	1.23e-40	4.69e-37	0.65	0.57	Testicular germ cell tumor;	chr6:149888068	chr6:149904243~149906418:+
PRAD	cis	rs7617773	0.78	rs11716848	ENSG00000229759.1	MRPS18AP1	14.78	1.24e-40	4.76e-37	0.63	0.57	Coronary artery disease;	chr3:48337010	chr3:48256350~48256938:-
PRAD	cis	rs7208859	0.623	rs73263788	ENSG00000263531.1	RP13-753N3.1	14.77	1.26e-40	4.8e-37	1.12	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30889472	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.673	rs12949860	ENSG00000263531.1	RP13-753N3.1	14.77	1.26e-40	4.8e-37	1.12	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896014	chr17:30863921~30864940:-
PRAD	cis	rs2882667	0.898	rs10045761	ENSG00000253404.1	AC034243.1	14.77	1.28e-40	4.88e-37	0.76	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061600	chr5:138744434~138753309:-
PRAD	cis	rs2929278	0.617	rs663214	ENSG00000205771.5	CATSPER2P1	14.77	1.29e-40	4.93e-37	0.66	0.57	Schizophrenia;	chr15:43821584	chr15:43726918~43747094:-
PRAD	cis	rs2882667	0.898	rs2116789	ENSG00000253404.1	AC034243.1	14.77	1.32e-40	5.03e-37	0.76	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139058573	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.898	rs11956089	ENSG00000253404.1	AC034243.1	-14.77	1.37e-40	5.24e-37	-0.77	-0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139058915	chr5:138744434~138753309:-
PRAD	cis	rs71403859	0.73	rs12931191	ENSG00000260886.1	TAT-AS1	-14.76	1.39e-40	5.3e-37	-0.99	-0.57	Post bronchodilator FEV1;	chr16:71587470	chr16:71565789~71578187:+
PRAD	cis	rs2882667	0.858	rs4643949	ENSG00000253404.1	AC034243.1	14.76	1.41e-40	5.38e-37	0.76	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139036656	chr5:138744434~138753309:-
PRAD	cis	rs10256972	0.758	rs7799391	ENSG00000229043.2	AC091729.9	-14.76	1.44e-40	5.48e-37	-0.69	-0.57	Endometriosis;Longevity;	chr7:1042930	chr7:1160374~1165267:+
PRAD	cis	rs7208859	0.623	rs3794796	ENSG00000263531.1	RP13-753N3.1	14.76	1.46e-40	5.55e-37	1.17	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803862	chr17:30863921~30864940:-
PRAD	cis	rs1153858	1	rs4534782	ENSG00000259520.4	CTD-2651B20.3	-14.76	1.5e-40	5.71e-37	-0.74	-0.57	Homoarginine levels;	chr15:45360735	chr15:45251580~45279251:-
PRAD	cis	rs1153858	1	rs12595087	ENSG00000259520.4	CTD-2651B20.3	-14.76	1.5e-40	5.71e-37	-0.74	-0.57	Homoarginine levels;	chr15:45363034	chr15:45251580~45279251:-
PRAD	cis	rs2283792	1	rs3810610	ENSG00000224086.5	LL22NC03-86G7.1	-14.75	1.53e-40	5.84e-37	-0.66	-0.57	Multiple sclerosis;	chr22:21761209	chr22:21938293~21977632:+
PRAD	cis	rs2882667	0.861	rs11959727	ENSG00000253404.1	AC034243.1	14.75	1.56e-40	5.96e-37	0.75	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061276	chr5:138744434~138753309:-
PRAD	cis	rs17507216	0.718	rs17158403	ENSG00000278603.1	RP13-608F4.5	14.75	1.65e-40	6.27e-37	0.9	0.57	Excessive daytime sleepiness;	chr15:82572478	chr15:82472203~82472426:+
PRAD	cis	rs17507216	0.718	rs72753931	ENSG00000278603.1	RP13-608F4.5	14.75	1.65e-40	6.29e-37	0.96	0.57	Excessive daytime sleepiness;	chr15:82721485	chr15:82472203~82472426:+
PRAD	cis	rs1153858	1	rs16942000	ENSG00000259520.4	CTD-2651B20.3	-14.74	1.7e-40	6.45e-37	-0.74	-0.57	Homoarginine levels;	chr15:45340805	chr15:45251580~45279251:-
PRAD	cis	rs1153858	0.945	rs7182300	ENSG00000259520.4	CTD-2651B20.3	-14.74	1.7e-40	6.45e-37	-0.74	-0.57	Homoarginine levels;	chr15:45342730	chr15:45251580~45279251:-
PRAD	cis	rs1153858	0.887	rs7171163	ENSG00000259520.4	CTD-2651B20.3	-14.74	1.7e-40	6.45e-37	-0.74	-0.57	Homoarginine levels;	chr15:45344197	chr15:45251580~45279251:-
PRAD	cis	rs7617773	0.674	rs13069029	ENSG00000229759.1	MRPS18AP1	14.74	1.74e-40	6.6e-37	0.63	0.57	Coronary artery disease;	chr3:48313534	chr3:48256350~48256938:-
PRAD	cis	rs1153858	1	rs12909158	ENSG00000259520.4	CTD-2651B20.3	-14.74	1.74e-40	6.62e-37	-0.73	-0.57	Homoarginine levels;	chr15:45328976	chr15:45251580~45279251:-
PRAD	cis	rs916888	0.61	rs199438	ENSG00000262539.1	RP11-259G18.3	14.74	1.77e-40	6.71e-37	0.81	0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:46259551~46260606:-
PRAD	cis	rs492146	0.765	rs367836	ENSG00000243236.5	GSTA9P	-14.73	1.9e-40	7.2e-37	-0.73	-0.57	Epilepsy (remission after treatment);	chr6:52978333	chr6:52939726~52957521:-
PRAD	cis	rs2283792	1	rs1892846	ENSG00000224086.5	LL22NC03-86G7.1	-14.73	1.96e-40	7.42e-37	-0.66	-0.57	Multiple sclerosis;	chr22:21832190	chr22:21938293~21977632:+
PRAD	cis	rs2283792	1	rs1892848	ENSG00000224086.5	LL22NC03-86G7.1	-14.73	1.96e-40	7.42e-37	-0.66	-0.57	Multiple sclerosis;	chr22:21832273	chr22:21938293~21977632:+
PRAD	cis	rs7617773	0.78	rs11718350	ENSG00000229759.1	MRPS18AP1	14.73	2e-40	7.59e-37	0.63	0.57	Coronary artery disease;	chr3:48319502	chr3:48256350~48256938:-
PRAD	cis	rs8072100	0.875	rs4794047	ENSG00000228782.6	CTD-2026D20.3	-14.73	2.02e-40	7.65e-37	-0.6	-0.57	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47685639	chr17:47450568~47492492:-
PRAD	cis	rs492146	0.765	rs670960	ENSG00000243236.5	GSTA9P	-14.73	2.04e-40	7.72e-37	-0.73	-0.57	Epilepsy (remission after treatment);	chr6:52978998	chr6:52939726~52957521:-
PRAD	cis	rs916888	0.531	rs183211	ENSG00000262539.1	RP11-259G18.3	14.72	2.13e-40	8.05e-37	0.81	0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:46259551~46260606:-
PRAD	cis	rs73086581	0.947	rs11906612	ENSG00000229539.1	RP11-119B16.2	14.72	2.14e-40	8.09e-37	1.03	0.57	Response to antidepressants in depression;	chr20:3922987	chr20:3888239~3888868:-
PRAD	cis	rs11690935	1	rs6721680	ENSG00000228389.1	AC068039.4	-14.72	2.15e-40	8.15e-37	-0.68	-0.57	Schizophrenia;	chr2:171687403	chr2:171773482~171775844:+
PRAD	cis	rs8100891	0.537	rs28562777	ENSG00000267213.4	AC007773.2	-14.72	2.17e-40	8.22e-37	-0.72	-0.57	Neuroticism;	chr19:32409913	chr19:32390050~32405560:-
PRAD	cis	rs2882667	0.838	rs11958529	ENSG00000253404.1	AC034243.1	14.71	2.28e-40	8.64e-37	0.75	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139059379	chr5:138744434~138753309:-
PRAD	cis	rs10256972	0.721	rs2030959	ENSG00000229043.2	AC091729.9	-14.71	2.37e-40	8.96e-37	-0.7	-0.57	Endometriosis;Longevity;	chr7:1036270	chr7:1160374~1165267:+
PRAD	cis	rs6504950	0.76	rs7214573	ENSG00000275710.1	RP11-257O5.4	14.71	2.37e-40	8.96e-37	0.78	0.57	Breast cancer;	chr17:54929293	chr17:54964474~54964679:+
PRAD	cis	rs2882667	0.898	rs12719519	ENSG00000253404.1	AC034243.1	14.71	2.42e-40	9.12e-37	0.76	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139039998	chr5:138744434~138753309:-
PRAD	cis	rs8100891	0.537	rs73038232	ENSG00000267213.4	AC007773.2	-14.71	2.42e-40	9.14e-37	-0.75	-0.57	Neuroticism;	chr19:32496747	chr19:32390050~32405560:-
PRAD	cis	rs6504950	0.76	rs17745189	ENSG00000275710.1	RP11-257O5.4	14.7	2.52e-40	9.49e-37	0.78	0.57	Breast cancer;	chr17:54936619	chr17:54964474~54964679:+
PRAD	cis	rs1153858	1	rs4775909	ENSG00000259520.4	CTD-2651B20.3	-14.7	2.54e-40	9.56e-37	-0.73	-0.57	Homoarginine levels;	chr15:45350844	chr15:45251580~45279251:-
PRAD	cis	rs2929278	0.562	rs8033846	ENSG00000205771.5	CATSPER2P1	14.7	2.6e-40	9.78e-37	0.65	0.57	Schizophrenia;	chr15:43743165	chr15:43726918~43747094:-
PRAD	cis	rs2929278	0.617	rs11070410	ENSG00000205771.5	CATSPER2P1	14.7	2.64e-40	9.91e-37	0.65	0.57	Schizophrenia;	chr15:43764847	chr15:43726918~43747094:-
PRAD	cis	rs7208859	0.623	rs7214570	ENSG00000263531.1	RP13-753N3.1	14.7	2.72e-40	1.02e-36	1.13	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30820146	chr17:30863921~30864940:-
PRAD	cis	rs8072100	0.745	rs7214410	ENSG00000228782.6	CTD-2026D20.3	14.7	2.76e-40	1.04e-36	0.59	0.57	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47345262	chr17:47450568~47492492:-
PRAD	cis	rs8100891	0.537	rs2302772	ENSG00000267213.4	AC007773.2	-14.69	3e-40	1.13e-36	-0.72	-0.57	Neuroticism;	chr19:32411144	chr19:32390050~32405560:-
PRAD	cis	rs8072100	0.807	rs2175290	ENSG00000228782.6	CTD-2026D20.3	14.68	3.07e-40	1.15e-36	0.6	0.57	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402551	chr17:47450568~47492492:-
PRAD	cis	rs8100891	0.537	rs2111504	ENSG00000267213.4	AC007773.2	-14.68	3.11e-40	1.17e-36	-0.72	-0.57	Neuroticism;	chr19:32426549	chr19:32390050~32405560:-
PRAD	cis	rs11690935	0.959	rs7586207	ENSG00000228389.1	AC068039.4	14.68	3.25e-40	1.22e-36	0.67	0.57	Schizophrenia;	chr2:171814584	chr2:171773482~171775844:+
PRAD	cis	rs17826219	0.568	rs11658027	ENSG00000263531.1	RP13-753N3.1	-14.68	3.25e-40	1.22e-36	-1.11	-0.57	Body mass index;	chr17:30767864	chr17:30863921~30864940:-
PRAD	cis	rs1153858	1	rs11070457	ENSG00000259520.4	CTD-2651B20.3	-14.68	3.36e-40	1.26e-36	-0.73	-0.57	Homoarginine levels;	chr15:45394745	chr15:45251580~45279251:-
PRAD	cis	rs11673344	0.544	rs6508721	ENSG00000226686.6	LINC01535	-14.67	3.48e-40	1.3e-36	-0.71	-0.57	Obesity-related traits;	chr19:37419119	chr19:37251912~37265535:+
PRAD	cis	rs11690935	1	rs1554166	ENSG00000228389.1	AC068039.4	14.67	3.49e-40	1.31e-36	0.68	0.57	Schizophrenia;	chr2:171685099	chr2:171773482~171775844:+
PRAD	cis	rs1153858	1	rs1890565	ENSG00000259520.4	CTD-2651B20.3	-14.67	3.53e-40	1.32e-36	-0.73	-0.57	Homoarginine levels;	chr15:45371101	chr15:45251580~45279251:-
PRAD	cis	rs1153858	1	rs12594857	ENSG00000259520.4	CTD-2651B20.3	-14.67	3.53e-40	1.32e-36	-0.73	-0.57	Homoarginine levels;	chr15:45374980	chr15:45251580~45279251:-
PRAD	cis	rs1153858	1	rs12437840	ENSG00000259520.4	CTD-2651B20.3	-14.67	3.53e-40	1.32e-36	-0.73	-0.57	Homoarginine levels;	chr15:45376857	chr15:45251580~45279251:-
PRAD	cis	rs1153858	1	rs12437887	ENSG00000259520.4	CTD-2651B20.3	-14.67	3.53e-40	1.32e-36	-0.73	-0.57	Homoarginine levels;	chr15:45376896	chr15:45251580~45279251:-
PRAD	cis	rs1153858	1	rs16942568	ENSG00000259520.4	CTD-2651B20.3	-14.67	3.53e-40	1.32e-36	-0.73	-0.57	Homoarginine levels;	chr15:45385192	chr15:45251580~45279251:-
PRAD	cis	rs1153858	1	rs4775937	ENSG00000259520.4	CTD-2651B20.3	-14.67	3.53e-40	1.32e-36	-0.73	-0.57	Homoarginine levels;	chr15:45386416	chr15:45251580~45279251:-
PRAD	cis	rs1153858	0.943	rs11070454	ENSG00000259520.4	CTD-2651B20.3	-14.67	3.53e-40	1.32e-36	-0.73	-0.57	Homoarginine levels;	chr15:45388054	chr15:45251580~45279251:-
PRAD	cis	rs11155671	0.53	rs9397398	ENSG00000216906.2	RP11-350J20.9	14.67	3.69e-40	1.38e-36	0.66	0.57	Testicular germ cell tumor;	chr6:149872467	chr6:149904243~149906418:+
PRAD	cis	rs8100891	0.537	rs73034216	ENSG00000267213.4	AC007773.2	-14.67	3.69e-40	1.38e-36	-0.73	-0.57	Neuroticism;	chr19:32392510	chr19:32390050~32405560:-
PRAD	cis	rs9487094	0.689	rs7754650	ENSG00000260273.1	RP11-425D10.10	14.66	3.75e-40	1.4e-36	0.76	0.57	Height;	chr6:109405536	chr6:109382795~109383666:+
PRAD	cis	rs7208859	0.573	rs11654035	ENSG00000263531.1	RP13-753N3.1	14.66	3.79e-40	1.41e-36	1.17	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809408	chr17:30863921~30864940:-
PRAD	cis	rs1153858	1	rs1365610	ENSG00000259520.4	CTD-2651B20.3	-14.66	3.96e-40	1.48e-36	-0.73	-0.57	Homoarginine levels;	chr15:45402412	chr15:45251580~45279251:-
PRAD	cis	rs8072100	0.811	rs1912483	ENSG00000228782.6	CTD-2026D20.3	14.66	4e-40	1.49e-36	0.59	0.57	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47366128	chr17:47450568~47492492:-
PRAD	cis	rs7617773	0.78	rs13084616	ENSG00000229759.1	MRPS18AP1	-14.66	4.03e-40	1.51e-36	-0.62	-0.57	Coronary artery disease;	chr3:48298209	chr3:48256350~48256938:-
PRAD	cis	rs6504950	0.83	rs12936860	ENSG00000275710.1	RP11-257O5.4	14.65	4.19e-40	1.56e-36	0.77	0.57	Breast cancer;	chr17:54952865	chr17:54964474~54964679:+
PRAD	cis	rs11673344	0.566	rs185368	ENSG00000226686.6	LINC01535	-14.65	4.22e-40	1.57e-36	-0.72	-0.57	Obesity-related traits;	chr19:37381827	chr19:37251912~37265535:+
PRAD	cis	rs2929278	0.589	rs11638972	ENSG00000205771.5	CATSPER2P1	14.65	4.24e-40	1.58e-36	0.65	0.57	Schizophrenia;	chr15:43782493	chr15:43726918~43747094:-
PRAD	cis	rs6504950	0.83	rs56175787	ENSG00000275710.1	RP11-257O5.4	14.65	4.33e-40	1.61e-36	0.78	0.57	Breast cancer;	chr17:54940386	chr17:54964474~54964679:+
PRAD	cis	rs6504950	0.83	rs17817847	ENSG00000275710.1	RP11-257O5.4	14.65	4.33e-40	1.61e-36	0.78	0.57	Breast cancer;	chr17:54940920	chr17:54964474~54964679:+
PRAD	cis	rs6504950	0.83	rs35097996	ENSG00000275710.1	RP11-257O5.4	14.65	4.33e-40	1.61e-36	0.78	0.57	Breast cancer;	chr17:54944562	chr17:54964474~54964679:+
PRAD	cis	rs17507216	0.628	rs4513065	ENSG00000278603.1	RP13-608F4.5	14.65	4.37e-40	1.63e-36	0.93	0.57	Excessive daytime sleepiness;	chr15:82712096	chr15:82472203~82472426:+
PRAD	cis	rs1930961	1	rs6004667	ENSG00000272977.1	CTA-390C10.10	14.65	4.47e-40	1.67e-36	0.9	0.57	Bipolar disorder with mood-incongruent psychosis;	chr22:25478497	chr22:25476218~25479971:+
PRAD	cis	rs1153858	1	rs9788780	ENSG00000259520.4	CTD-2651B20.3	-14.64	4.64e-40	1.73e-36	-0.73	-0.57	Homoarginine levels;	chr15:45393289	chr15:45251580~45279251:-
PRAD	cis	rs9487094	0.644	rs13201430	ENSG00000260273.1	RP11-425D10.10	14.64	4.68e-40	1.74e-36	0.75	0.57	Height;	chr6:109634847	chr6:109382795~109383666:+
PRAD	cis	rs7617773	0.817	rs3731555	ENSG00000229759.1	MRPS18AP1	14.64	4.79e-40	1.79e-36	0.63	0.57	Coronary artery disease;	chr3:48164612	chr3:48256350~48256938:-
PRAD	cis	rs992157	0.71	rs13026485	ENSG00000261338.2	RP11-378A13.1	-14.64	4.8e-40	1.79e-36	-0.63	-0.57	Colorectal cancer;	chr2:218193261	chr2:218255319~218257366:+
PRAD	cis	rs2882667	0.898	rs11749944	ENSG00000253404.1	AC034243.1	14.64	4.83e-40	1.8e-36	0.75	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139077090	chr5:138744434~138753309:-
PRAD	cis	rs11673344	0.566	rs1545755	ENSG00000226686.6	LINC01535	14.64	4.92e-40	1.83e-36	0.72	0.57	Obesity-related traits;	chr19:37490607	chr19:37251912~37265535:+
PRAD	cis	rs10853057	0.541	rs62065481	ENSG00000214174.7	AMZ2P1	14.64	4.98e-40	1.85e-36	1	0.57	White matter microstructure (global fractional anisotropy);	chr17:65008273	chr17:64966550~64975576:-
PRAD	cis	rs492146	0.765	rs672281	ENSG00000243236.5	GSTA9P	-14.64	5.06e-40	1.88e-36	-0.73	-0.57	Epilepsy (remission after treatment);	chr6:52979247	chr6:52939726~52957521:-
PRAD	cis	rs10170846	1	rs10170846	ENSG00000261428.2	RP11-16P6.1	-14.63	5.22e-40	1.94e-36	-0.76	-0.57	Schizophrenia (inflammation and infection response interaction);	chr2:222652986	chr2:222566899~222569719:-
PRAD	cis	rs2929278	0.589	rs7174732	ENSG00000205771.5	CATSPER2P1	14.63	5.26e-40	1.95e-36	0.65	0.57	Schizophrenia;	chr15:43746265	chr15:43726918~43747094:-
PRAD	cis	rs71403859	0.803	rs8063455	ENSG00000260886.1	TAT-AS1	14.63	5.29e-40	1.96e-36	1.02	0.57	Post bronchodilator FEV1;	chr16:71566074	chr16:71565789~71578187:+
PRAD	cis	rs73086581	1	rs73084594	ENSG00000229539.1	RP11-119B16.2	14.63	5.34e-40	1.98e-36	0.97	0.57	Response to antidepressants in depression;	chr20:3935733	chr20:3888239~3888868:-
PRAD	cis	rs492146	0.729	rs644100	ENSG00000243236.5	GSTA9P	-14.63	5.41e-40	2.01e-36	-0.72	-0.57	Epilepsy (remission after treatment);	chr6:52977573	chr6:52939726~52957521:-
PRAD	cis	rs7208859	0.623	rs11658022	ENSG00000263531.1	RP13-753N3.1	14.63	5.54e-40	2.05e-36	1.17	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758341	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs73269923	ENSG00000263531.1	RP13-753N3.1	14.63	5.54e-40	2.05e-36	1.17	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775553	chr17:30863921~30864940:-
PRAD	cis	rs8100891	0.537	rs10410770	ENSG00000267213.4	AC007773.2	-14.62	5.85e-40	2.17e-36	-0.73	-0.57	Neuroticism;	chr19:32411498	chr19:32390050~32405560:-
PRAD	cis	rs11673344	0.566	rs10419281	ENSG00000226686.6	LINC01535	-14.61	6.26e-40	2.32e-36	-0.72	-0.57	Obesity-related traits;	chr19:37459351	chr19:37251912~37265535:+
PRAD	cis	rs1153858	1	rs12439274	ENSG00000259520.4	CTD-2651B20.3	-14.61	6.3e-40	2.33e-36	-0.73	-0.57	Homoarginine levels;	chr15:45344469	chr15:45251580~45279251:-
PRAD	cis	rs11690935	0.921	rs3770445	ENSG00000228389.1	AC068039.4	14.61	6.5e-40	2.4e-36	0.67	0.57	Schizophrenia;	chr2:171852409	chr2:171773482~171775844:+
PRAD	cis	rs1153858	1	rs67831559	ENSG00000259520.4	CTD-2651B20.3	-14.61	6.76e-40	2.5e-36	-0.73	-0.56	Homoarginine levels;	chr15:45357109	chr15:45251580~45279251:-
PRAD	cis	rs1153858	1	rs4774577	ENSG00000259520.4	CTD-2651B20.3	-14.6	6.85e-40	2.53e-36	-0.73	-0.56	Homoarginine levels;	chr15:45352487	chr15:45251580~45279251:-
PRAD	cis	rs1153858	1	rs4774578	ENSG00000259520.4	CTD-2651B20.3	-14.6	6.85e-40	2.53e-36	-0.73	-0.56	Homoarginine levels;	chr15:45353853	chr15:45251580~45279251:-
PRAD	cis	rs61524473	1	rs61524473	ENSG00000259520.4	CTD-2651B20.3	-14.6	6.85e-40	2.53e-36	-0.73	-0.56	Metabolite levels (small molecules and protein measures);	chr15:45354085	chr15:45251580~45279251:-
PRAD	cis	rs1153858	1	rs10444821	ENSG00000259520.4	CTD-2651B20.3	-14.6	6.85e-40	2.53e-36	-0.73	-0.56	Homoarginine levels;	chr15:45355038	chr15:45251580~45279251:-
PRAD	cis	rs1153858	1	rs72623915	ENSG00000259520.4	CTD-2651B20.3	-14.6	6.85e-40	2.53e-36	-0.73	-0.56	Homoarginine levels;	chr15:45355235	chr15:45251580~45279251:-
PRAD	cis	rs1153858	0.725	rs74572151	ENSG00000259520.4	CTD-2651B20.3	-14.6	6.85e-40	2.53e-36	-0.73	-0.56	Homoarginine levels;	chr15:45355328	chr15:45251580~45279251:-
PRAD	cis	rs1153858	1	rs66714503	ENSG00000259520.4	CTD-2651B20.3	-14.6	6.85e-40	2.53e-36	-0.73	-0.56	Homoarginine levels;	chr15:45355840	chr15:45251580~45279251:-
PRAD	cis	rs7188445	1	rs12444166	ENSG00000261390.4	RP11-345M22.2	-14.6	6.88e-40	2.54e-36	-0.72	-0.56	Urate levels;	chr16:79676053	chr16:79715232~79770563:-
PRAD	cis	rs2739330	0.76	rs1007888	ENSG00000250470.1	AP000351.3	14.6	7.06e-40	2.6e-36	0.76	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23976904~23977585:-
PRAD	cis	rs6504950	0.79	rs8066833	ENSG00000275710.1	RP11-257O5.4	14.6	7.32e-40	2.7e-36	0.78	0.56	Breast cancer;	chr17:54948114	chr17:54964474~54964679:+
PRAD	cis	rs6504950	0.821	rs8066588	ENSG00000275710.1	RP11-257O5.4	14.6	7.32e-40	2.7e-36	0.78	0.56	Breast cancer;	chr17:54948328	chr17:54964474~54964679:+
PRAD	cis	rs6504950	0.83	rs3087650	ENSG00000275710.1	RP11-257O5.4	14.6	7.32e-40	2.7e-36	0.78	0.56	Breast cancer;	chr17:54951967	chr17:54964474~54964679:+
PRAD	cis	rs6504950	0.83	rs12937006	ENSG00000275710.1	RP11-257O5.4	14.6	7.32e-40	2.7e-36	0.78	0.56	Breast cancer;	chr17:54953100	chr17:54964474~54964679:+
PRAD	cis	rs8100891	0.537	rs10403370	ENSG00000267213.4	AC007773.2	-14.6	7.34e-40	2.7e-36	-0.74	-0.56	Neuroticism;	chr19:32501949	chr19:32390050~32405560:-
PRAD	cis	rs11690935	0.959	rs6724337	ENSG00000228389.1	AC068039.4	14.6	7.45e-40	2.75e-36	0.67	0.56	Schizophrenia;	chr2:171878819	chr2:171773482~171775844:+
PRAD	cis	rs10256972	0.713	rs10435026	ENSG00000229043.2	AC091729.9	-14.59	7.84e-40	2.88e-36	-0.7	-0.56	Endometriosis;Longevity;	chr7:1026312	chr7:1160374~1165267:+
PRAD	cis	rs1153858	0.943	rs7402632	ENSG00000259520.4	CTD-2651B20.3	-14.59	7.89e-40	2.9e-36	-0.74	-0.56	Homoarginine levels;	chr15:45409715	chr15:45251580~45279251:-
PRAD	cis	rs11690935	1	rs3795999	ENSG00000228389.1	AC068039.4	-14.59	8.13e-40	2.99e-36	-0.67	-0.56	Schizophrenia;	chr2:171687973	chr2:171773482~171775844:+
PRAD	cis	rs324126	0.78	rs11084150	ENSG00000277977.1	CTD-3018O17.5	-14.59	8.29e-40	3.04e-36	-0.62	-0.56	Colonoscopy-negative controls vs population controls;	chr19:52381851	chr19:52392659~52392755:+
PRAD	cis	rs324126	0.78	rs1993531	ENSG00000277977.1	CTD-3018O17.5	14.59	8.29e-40	3.04e-36	0.62	0.56	Colonoscopy-negative controls vs population controls;	chr19:52381633	chr19:52392659~52392755:+
PRAD	cis	rs324126	0.78	rs11084153	ENSG00000277977.1	CTD-3018O17.5	14.59	8.29e-40	3.04e-36	0.62	0.56	Colonoscopy-negative controls vs population controls;	chr19:52382142	chr19:52392659~52392755:+
PRAD	cis	rs324126	0.78	rs11084154	ENSG00000277977.1	CTD-3018O17.5	14.59	8.29e-40	3.04e-36	0.62	0.56	Colonoscopy-negative controls vs population controls;	chr19:52382168	chr19:52392659~52392755:+
PRAD	cis	rs324126	0.78	rs11084155	ENSG00000277977.1	CTD-3018O17.5	14.59	8.29e-40	3.04e-36	0.62	0.56	Colonoscopy-negative controls vs population controls;	chr19:52383613	chr19:52392659~52392755:+
PRAD	cis	rs324126	0.752	rs11084156	ENSG00000277977.1	CTD-3018O17.5	14.59	8.29e-40	3.04e-36	0.62	0.56	Colonoscopy-negative controls vs population controls;	chr19:52383634	chr19:52392659~52392755:+
PRAD	cis	rs324126	0.78	rs11084157	ENSG00000277977.1	CTD-3018O17.5	14.59	8.29e-40	3.04e-36	0.62	0.56	Colonoscopy-negative controls vs population controls;	chr19:52383652	chr19:52392659~52392755:+
PRAD	cis	rs324126	0.78	rs8104808	ENSG00000277977.1	CTD-3018O17.5	14.59	8.29e-40	3.04e-36	0.62	0.56	Colonoscopy-negative controls vs population controls;	chr19:52384174	chr19:52392659~52392755:+
PRAD	cis	rs324126	0.78	rs8104812	ENSG00000277977.1	CTD-3018O17.5	14.59	8.29e-40	3.04e-36	0.62	0.56	Colonoscopy-negative controls vs population controls;	chr19:52384184	chr19:52392659~52392755:+
PRAD	cis	rs6504950	0.751	rs12937760	ENSG00000275710.1	RP11-257O5.4	14.58	8.38e-40	3.08e-36	0.77	0.56	Breast cancer;	chr17:54938769	chr17:54964474~54964679:+
PRAD	cis	rs7208859	0.623	rs11657662	ENSG00000263531.1	RP13-753N3.1	-14.58	8.41e-40	3.09e-36	-1.16	-0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749329	chr17:30863921~30864940:-
PRAD	cis	rs11155671	0.53	rs7742993	ENSG00000216906.2	RP11-350J20.9	14.58	8.48e-40	3.11e-36	0.65	0.56	Testicular germ cell tumor;	chr6:149883959	chr6:149904243~149906418:+
PRAD	cis	rs1153858	1	rs2066090	ENSG00000259520.4	CTD-2651B20.3	-14.58	8.97e-40	3.29e-36	-0.73	-0.56	Homoarginine levels;	chr15:45357820	chr15:45251580~45279251:-
PRAD	cis	rs1153858	1	rs61365925	ENSG00000259520.4	CTD-2651B20.3	-14.58	8.97e-40	3.29e-36	-0.73	-0.56	Homoarginine levels;	chr15:45358113	chr15:45251580~45279251:-
PRAD	cis	rs1153858	1	rs12101539	ENSG00000259520.4	CTD-2651B20.3	-14.58	8.97e-40	3.29e-36	-0.73	-0.56	Homoarginine levels;	chr15:45358468	chr15:45251580~45279251:-
PRAD	cis	rs11690935	0.959	rs10803863	ENSG00000228389.1	AC068039.4	-14.58	9.02e-40	3.31e-36	-0.68	-0.56	Schizophrenia;	chr2:171678827	chr2:171773482~171775844:+
PRAD	cis	rs11690935	1	rs12053003	ENSG00000228389.1	AC068039.4	-14.58	9.02e-40	3.31e-36	-0.68	-0.56	Schizophrenia;	chr2:171680840	chr2:171773482~171775844:+
PRAD	cis	rs7617773	0.78	rs3731489	ENSG00000229759.1	MRPS18AP1	14.58	9.05e-40	3.32e-36	0.62	0.56	Coronary artery disease;	chr3:48187416	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.779	rs3731487	ENSG00000229759.1	MRPS18AP1	14.58	9.05e-40	3.32e-36	0.62	0.56	Coronary artery disease;	chr3:48188134	chr3:48256350~48256938:-
PRAD	cis	rs492146	0.765	rs316133	ENSG00000243236.5	GSTA9P	-14.57	9.53e-40	3.49e-36	-0.73	-0.56	Epilepsy (remission after treatment);	chr6:52982753	chr6:52939726~52957521:-
PRAD	cis	rs11155671	0.53	rs2342769	ENSG00000216906.2	RP11-350J20.9	14.57	9.85e-40	3.6e-36	0.64	0.56	Testicular germ cell tumor;	chr6:149895371	chr6:149904243~149906418:+
PRAD	cis	rs11155671	0.53	rs2342770	ENSG00000216906.2	RP11-350J20.9	14.57	9.85e-40	3.6e-36	0.64	0.56	Testicular germ cell tumor;	chr6:149895549	chr6:149904243~149906418:+
PRAD	cis	rs11155671	0.53	rs6935829	ENSG00000216906.2	RP11-350J20.9	14.57	1.01e-39	3.69e-36	0.65	0.56	Testicular germ cell tumor;	chr6:149896675	chr6:149904243~149906418:+
PRAD	cis	rs7617773	0.746	rs7619865	ENSG00000229759.1	MRPS18AP1	14.56	1.03e-39	3.78e-36	0.58	0.56	Coronary artery disease;	chr3:48329090	chr3:48256350~48256938:-
PRAD	cis	rs2882667	0.898	rs11952020	ENSG00000253404.1	AC034243.1	14.56	1.03e-39	3.78e-36	0.74	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139059467	chr5:138744434~138753309:-
PRAD	cis	rs324126	0.78	rs62108320	ENSG00000277977.1	CTD-3018O17.5	14.56	1.05e-39	3.83e-36	0.63	0.56	Colonoscopy-negative controls vs population controls;	chr19:52380770	chr19:52392659~52392755:+
PRAD	cis	rs324126	0.752	rs62108321	ENSG00000277977.1	CTD-3018O17.5	14.56	1.05e-39	3.83e-36	0.63	0.56	Colonoscopy-negative controls vs population controls;	chr19:52380825	chr19:52392659~52392755:+
PRAD	cis	rs73086581	1	rs14047	ENSG00000229539.1	RP11-119B16.2	14.56	1.05e-39	3.84e-36	0.96	0.56	Response to antidepressants in depression;	chr20:3933568	chr20:3888239~3888868:-
PRAD	cis	rs875971	0.862	rs1983372	ENSG00000226824.5	RP4-756H11.3	14.56	1.08e-39	3.96e-36	0.76	0.56	Aortic root size;	chr7:66146364	chr7:66654538~66669855:+
PRAD	cis	rs11155671	0.53	rs7756850	ENSG00000216906.2	RP11-350J20.9	14.56	1.1e-39	4e-36	0.64	0.56	Testicular germ cell tumor;	chr6:149891460	chr6:149904243~149906418:+
PRAD	cis	rs11155671	0.53	rs9371542	ENSG00000216906.2	RP11-350J20.9	14.56	1.1e-39	4e-36	0.64	0.56	Testicular germ cell tumor;	chr6:149891949	chr6:149904243~149906418:+
PRAD	cis	rs11155671	0.53	rs9371223	ENSG00000216906.2	RP11-350J20.9	14.56	1.1e-39	4e-36	0.64	0.56	Testicular germ cell tumor;	chr6:149893670	chr6:149904243~149906418:+
PRAD	cis	rs1799949	0.628	rs4474733	ENSG00000198496.9	NBR2	-14.55	1.17e-39	4.24e-36	-0.83	-0.56	Menopause (age at onset);	chr17:43356292	chr17:43125610~43153671:+
PRAD	cis	rs1153858	1	rs7402650	ENSG00000259520.4	CTD-2651B20.3	-14.55	1.17e-39	4.25e-36	-0.73	-0.56	Homoarginine levels;	chr15:45409697	chr15:45251580~45279251:-
PRAD	cis	rs1153858	1	rs8042786	ENSG00000259520.4	CTD-2651B20.3	-14.55	1.17e-39	4.25e-36	-0.73	-0.56	Homoarginine levels;	chr15:45411341	chr15:45251580~45279251:-
PRAD	cis	rs1153858	1	rs12440038	ENSG00000259520.4	CTD-2651B20.3	-14.55	1.17e-39	4.25e-36	-0.73	-0.56	Homoarginine levels;	chr15:45414541	chr15:45251580~45279251:-
PRAD	cis	rs17507216	0.671	rs28582623	ENSG00000278603.1	RP13-608F4.5	14.55	1.19e-39	4.32e-36	0.88	0.56	Excessive daytime sleepiness;	chr15:82577381	chr15:82472203~82472426:+
PRAD	cis	rs8100891	0.537	rs10415744	ENSG00000267213.4	AC007773.2	-14.55	1.2e-39	4.36e-36	-0.72	-0.56	Neuroticism;	chr19:32389674	chr19:32390050~32405560:-
PRAD	cis	rs8100891	0.537	rs10409835	ENSG00000267213.4	AC007773.2	-14.55	1.2e-39	4.37e-36	-0.7	-0.56	Neuroticism;	chr19:32397754	chr19:32390050~32405560:-
PRAD	cis	rs11673344	0.566	rs2385181	ENSG00000226686.6	LINC01535	-14.55	1.22e-39	4.42e-36	-0.71	-0.56	Obesity-related traits;	chr19:37395428	chr19:37251912~37265535:+
PRAD	cis	rs492146	0.765	rs316141	ENSG00000243236.5	GSTA9P	-14.54	1.24e-39	4.52e-36	-0.73	-0.56	Epilepsy (remission after treatment);	chr6:52981360	chr6:52939726~52957521:-
PRAD	cis	rs492146	0.765	rs316140	ENSG00000243236.5	GSTA9P	-14.54	1.24e-39	4.52e-36	-0.73	-0.56	Epilepsy (remission after treatment);	chr6:52981390	chr6:52939726~52957521:-
PRAD	cis	rs492146	0.691	rs316138	ENSG00000243236.5	GSTA9P	-14.54	1.24e-39	4.52e-36	-0.73	-0.56	Epilepsy (remission after treatment);	chr6:52981621	chr6:52939726~52957521:-
PRAD	cis	rs492146	0.765	rs622902	ENSG00000243236.5	GSTA9P	-14.54	1.24e-39	4.52e-36	-0.73	-0.56	Epilepsy (remission after treatment);	chr6:52981676	chr6:52939726~52957521:-
PRAD	cis	rs492146	0.765	rs316132	ENSG00000243236.5	GSTA9P	-14.54	1.24e-39	4.52e-36	-0.73	-0.56	Epilepsy (remission after treatment);	chr6:52983168	chr6:52939726~52957521:-
PRAD	cis	rs492146	0.765	rs316131	ENSG00000243236.5	GSTA9P	-14.54	1.24e-39	4.52e-36	-0.73	-0.56	Epilepsy (remission after treatment);	chr6:52983351	chr6:52939726~52957521:-
PRAD	cis	rs492146	0.729	rs316130	ENSG00000243236.5	GSTA9P	-14.54	1.24e-39	4.52e-36	-0.73	-0.56	Epilepsy (remission after treatment);	chr6:52983402	chr6:52939726~52957521:-
PRAD	cis	rs492146	0.765	rs316129	ENSG00000243236.5	GSTA9P	-14.54	1.24e-39	4.52e-36	-0.73	-0.56	Epilepsy (remission after treatment);	chr6:52984107	chr6:52939726~52957521:-
PRAD	cis	rs916888	0.61	rs199446	ENSG00000214401.4	KANSL1-AS1	-14.54	1.25e-39	4.56e-36	-0.79	-0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:46193576~46196723:+
PRAD	cis	rs916888	0.61	rs199536	ENSG00000214401.4	KANSL1-AS1	-14.54	1.25e-39	4.56e-36	-0.79	-0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:46193576~46196723:+
PRAD	cis	rs1153858	1	rs4775911	ENSG00000259520.4	CTD-2651B20.3	14.54	1.26e-39	4.56e-36	0.73	0.56	Homoarginine levels;	chr15:45357589	chr15:45251580~45279251:-
PRAD	cis	rs2283792	0.967	rs3810609	ENSG00000224086.5	LL22NC03-86G7.1	-14.54	1.27e-39	4.6e-36	-0.65	-0.56	Multiple sclerosis;	chr22:21758513	chr22:21938293~21977632:+
PRAD	cis	rs1577917	0.559	rs7763210	ENSG00000203875.9	SNHG5	-14.54	1.29e-39	4.68e-36	-0.61	-0.56	Response to antipsychotic treatment;	chr6:86098900	chr6:85660950~85678736:-
PRAD	cis	rs992157	0.71	rs56364928	ENSG00000261338.2	RP11-378A13.1	14.54	1.3e-39	4.71e-36	0.64	0.56	Colorectal cancer;	chr2:218194335	chr2:218255319~218257366:+
PRAD	cis	rs7208859	0.623	rs60890550	ENSG00000263531.1	RP13-753N3.1	14.54	1.33e-39	4.83e-36	1.16	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30703843	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.573	rs55661352	ENSG00000263531.1	RP13-753N3.1	14.54	1.33e-39	4.83e-36	1.16	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30718610	chr17:30863921~30864940:-
PRAD	cis	rs9487094	0.67	rs11755641	ENSG00000260273.1	RP11-425D10.10	14.54	1.35e-39	4.88e-36	0.76	0.56	Height;	chr6:109586733	chr6:109382795~109383666:+
PRAD	cis	rs10256972	0.758	rs9801444	ENSG00000229043.2	AC091729.9	14.54	1.37e-39	4.97e-36	0.69	0.56	Endometriosis;Longevity;	chr7:1040808	chr7:1160374~1165267:+
PRAD	cis	rs324126	0.78	rs4802926	ENSG00000277977.1	CTD-3018O17.5	-14.53	1.42e-39	5.16e-36	-0.62	-0.56	Colonoscopy-negative controls vs population controls;	chr19:52377012	chr19:52392659~52392755:+
PRAD	cis	rs2739330	0.791	rs4822458	ENSG00000231271.1	AP000350.8	14.53	1.45e-39	5.25e-36	0.75	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23949918~23954042:+
PRAD	cis	rs9487094	0.67	rs729888	ENSG00000260273.1	RP11-425D10.10	-14.53	1.46e-39	5.3e-36	-0.76	-0.56	Height;	chr6:109636120	chr6:109382795~109383666:+
PRAD	cis	rs524281	0.773	rs7951079	ENSG00000255320.1	RP11-755F10.1	14.53	1.47e-39	5.31e-36	0.97	0.56	Electroencephalogram traits;	chr11:66213079	chr11:66244840~66246239:-
PRAD	cis	rs1577917	0.559	rs2223788	ENSG00000203875.9	SNHG5	-14.53	1.48e-39	5.38e-36	-0.62	-0.56	Response to antipsychotic treatment;	chr6:86102202	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.523	rs1413724	ENSG00000203875.9	SNHG5	-14.53	1.48e-39	5.38e-36	-0.62	-0.56	Response to antipsychotic treatment;	chr6:86104831	chr6:85660950~85678736:-
PRAD	cis	rs7617773	0.746	rs4130995	ENSG00000229759.1	MRPS18AP1	14.52	1.53e-39	5.51e-36	0.59	0.56	Coronary artery disease;	chr3:48316765	chr3:48256350~48256938:-
PRAD	cis	rs6504950	0.8	rs35647022	ENSG00000275710.1	RP11-257O5.4	14.52	1.54e-39	5.57e-36	0.78	0.56	Breast cancer;	chr17:54930710	chr17:54964474~54964679:+
PRAD	cis	rs324126	0.78	rs62108319	ENSG00000277977.1	CTD-3018O17.5	14.52	1.55e-39	5.59e-36	0.62	0.56	Colonoscopy-negative controls vs population controls;	chr19:52380577	chr19:52392659~52392755:+
PRAD	cis	rs8100891	0.537	rs28729153	ENSG00000267213.4	AC007773.2	-14.52	1.55e-39	5.62e-36	-0.72	-0.56	Neuroticism;	chr19:32416672	chr19:32390050~32405560:-
PRAD	cis	rs992157	0.71	rs12996912	ENSG00000261338.2	RP11-378A13.1	14.52	1.63e-39	5.88e-36	0.64	0.56	Colorectal cancer;	chr2:218245832	chr2:218255319~218257366:+
PRAD	cis	rs62229266	0.839	rs11702763	ENSG00000231106.2	LINC01436	14.52	1.67e-39	6.04e-36	0.73	0.56	Mitral valve prolapse;	chr21:36098406	chr21:36005338~36007838:+
PRAD	cis	rs7617773	0.78	rs11720026	ENSG00000229759.1	MRPS18AP1	14.51	1.68e-39	6.07e-36	0.63	0.56	Coronary artery disease;	chr3:48336431	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.743	rs11715876	ENSG00000229759.1	MRPS18AP1	14.51	1.68e-39	6.07e-36	0.63	0.56	Coronary artery disease;	chr3:48336432	chr3:48256350~48256938:-
PRAD	cis	rs11673344	0.566	rs7254009	ENSG00000226686.6	LINC01535	-14.51	1.69e-39	6.1e-36	-0.71	-0.56	Obesity-related traits;	chr19:37427707	chr19:37251912~37265535:+
PRAD	cis	rs11673344	0.566	rs2385180	ENSG00000226686.6	LINC01535	-14.51	1.69e-39	6.1e-36	-0.71	-0.56	Obesity-related traits;	chr19:37431454	chr19:37251912~37265535:+
PRAD	cis	rs2882667	0.861	rs7703288	ENSG00000253404.1	AC034243.1	14.51	1.7e-39	6.12e-36	0.77	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139030850	chr5:138744434~138753309:-
PRAD	cis	rs875971	0.862	rs10276077	ENSG00000226824.5	RP4-756H11.3	14.51	1.7e-39	6.13e-36	0.77	0.56	Aortic root size;	chr7:66263424	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.792	rs6971752	ENSG00000226824.5	RP4-756H11.3	14.51	1.7e-39	6.13e-36	0.77	0.56	Aortic root size;	chr7:66272999	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.862	rs10950033	ENSG00000226824.5	RP4-756H11.3	14.51	1.7e-39	6.13e-36	0.77	0.56	Aortic root size;	chr7:66274686	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.862	rs11760844	ENSG00000226824.5	RP4-756H11.3	14.51	1.7e-39	6.13e-36	0.77	0.56	Aortic root size;	chr7:66274896	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.862	rs4149461	ENSG00000226824.5	RP4-756H11.3	14.51	1.7e-39	6.13e-36	0.77	0.56	Aortic root size;	chr7:66279745	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.862	rs10261398	ENSG00000226824.5	RP4-756H11.3	14.51	1.7e-39	6.13e-36	0.77	0.56	Aortic root size;	chr7:66285177	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.862	rs10224872	ENSG00000226824.5	RP4-756H11.3	14.51	1.7e-39	6.13e-36	0.77	0.56	Aortic root size;	chr7:66294786	chr7:66654538~66669855:+
PRAD	cis	rs1153858	1	rs8032904	ENSG00000259520.4	CTD-2651B20.3	-14.51	1.81e-39	6.51e-36	-0.73	-0.56	Homoarginine levels;	chr15:45359111	chr15:45251580~45279251:-
PRAD	cis	rs1153858	1	rs2467863	ENSG00000259520.4	CTD-2651B20.3	-14.5	1.9e-39	6.84e-36	-0.74	-0.56	Homoarginine levels;	chr15:45349682	chr15:45251580~45279251:-
PRAD	cis	rs875971	0.862	rs4718330	ENSG00000226824.5	RP4-756H11.3	14.5	1.95e-39	7.01e-36	0.77	0.56	Aortic root size;	chr7:66250256	chr7:66654538~66669855:+
PRAD	cis	rs992157	0.661	rs17653757	ENSG00000261338.2	RP11-378A13.1	14.5	1.95e-39	7.02e-36	0.64	0.56	Colorectal cancer;	chr2:218244641	chr2:218255319~218257366:+
PRAD	cis	rs7617773	0.817	rs9311421	ENSG00000229759.1	MRPS18AP1	14.5	2.02e-39	7.25e-36	0.6	0.56	Coronary artery disease;	chr3:48251588	chr3:48256350~48256938:-
PRAD	cis	rs875971	0.862	rs4236208	ENSG00000226824.5	RP4-756H11.3	14.5	2.02e-39	7.26e-36	0.77	0.56	Aortic root size;	chr7:66284091	chr7:66654538~66669855:+
PRAD	cis	rs2739330	0.731	rs5751792	ENSG00000235689.1	AP000351.13	14.5	2.02e-39	7.27e-36	0.66	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:24006305~24008258:-
PRAD	cis	rs2739330	0.761	rs5760176	ENSG00000235689.1	AP000351.13	-14.5	2.02e-39	7.27e-36	-0.66	-0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:24006305~24008258:-
PRAD	cis	rs916888	0.61	rs199453	ENSG00000214401.4	KANSL1-AS1	14.5	2.03e-39	7.29e-36	0.78	0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:46193576~46196723:+
PRAD	cis	rs992157	0.687	rs10206984	ENSG00000261338.2	RP11-378A13.1	14.5	2.04e-39	7.33e-36	0.63	0.56	Colorectal cancer;	chr2:218202257	chr2:218255319~218257366:+
PRAD	cis	rs7617773	0.817	rs6796490	ENSG00000229759.1	MRPS18AP1	14.49	2.06e-39	7.4e-36	0.58	0.56	Coronary artery disease;	chr3:48195614	chr3:48256350~48256938:-
PRAD	cis	rs916888	0.61	rs199530	ENSG00000214401.4	KANSL1-AS1	-14.49	2.07e-39	7.45e-36	-0.79	-0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:46193576~46196723:+
PRAD	cis	rs7617773	0.78	rs35297486	ENSG00000229759.1	MRPS18AP1	14.49	2.08e-39	7.49e-36	0.62	0.56	Coronary artery disease;	chr3:48336657	chr3:48256350~48256938:-
PRAD	cis	rs916888	0.61	rs199452	ENSG00000214401.4	KANSL1-AS1	14.49	2.1e-39	7.56e-36	0.78	0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:46193576~46196723:+
PRAD	cis	rs992157	0.697	rs13384682	ENSG00000261338.2	RP11-378A13.1	14.49	2.11e-39	7.57e-36	0.63	0.56	Colorectal cancer;	chr2:218204414	chr2:218255319~218257366:+
PRAD	cis	rs992157	0.71	rs7569907	ENSG00000261338.2	RP11-378A13.1	14.49	2.11e-39	7.57e-36	0.63	0.56	Colorectal cancer;	chr2:218205828	chr2:218255319~218257366:+
PRAD	cis	rs11690935	0.921	rs7594711	ENSG00000228389.1	AC068039.4	14.49	2.13e-39	7.63e-36	0.67	0.56	Schizophrenia;	chr2:172030734	chr2:171773482~171775844:+
PRAD	cis	rs11673344	0.566	rs256735	ENSG00000226686.6	LINC01535	-14.49	2.13e-39	7.63e-36	-0.71	-0.56	Obesity-related traits;	chr19:37375141	chr19:37251912~37265535:+
PRAD	cis	rs11673344	0.566	rs185369	ENSG00000226686.6	LINC01535	-14.49	2.13e-39	7.63e-36	-0.71	-0.56	Obesity-related traits;	chr19:37376137	chr19:37251912~37265535:+
PRAD	cis	rs1930961	1	rs6004673	ENSG00000272977.1	CTA-390C10.10	-14.49	2.16e-39	7.74e-36	-0.9	-0.56	Bipolar disorder with mood-incongruent psychosis;	chr22:25489386	chr22:25476218~25479971:+
PRAD	cis	rs875971	0.862	rs28470208	ENSG00000226824.5	RP4-756H11.3	14.49	2.18e-39	7.81e-36	0.77	0.56	Aortic root size;	chr7:66119713	chr7:66654538~66669855:+
PRAD	cis	rs8100891	0.537	rs113427979	ENSG00000267213.4	AC007773.2	-14.49	2.22e-39	7.97e-36	-0.73	-0.56	Neuroticism;	chr19:32364502	chr19:32390050~32405560:-
PRAD	cis	rs875971	0.893	rs62465470	ENSG00000226824.5	RP4-756H11.3	14.49	2.22e-39	7.98e-36	0.76	0.56	Aortic root size;	chr7:66136231	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.862	rs6460290	ENSG00000226824.5	RP4-756H11.3	14.48	2.32e-39	8.33e-36	0.76	0.56	Aortic root size;	chr7:66344119	chr7:66654538~66669855:+
PRAD	cis	rs7617773	0.817	rs3731534	ENSG00000229759.1	MRPS18AP1	14.48	2.36e-39	8.45e-36	0.62	0.56	Coronary artery disease;	chr3:48170287	chr3:48256350~48256938:-
PRAD	cis	rs2739330	0.703	rs5760112	ENSG00000231271.1	AP000350.8	14.48	2.36e-39	8.47e-36	0.75	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23949918~23954042:+
PRAD	cis	rs875971	0.862	rs12537823	ENSG00000226824.5	RP4-756H11.3	-14.48	2.4e-39	8.61e-36	-0.77	-0.56	Aortic root size;	chr7:66255897	chr7:66654538~66669855:+
PRAD	cis	rs2929278	0.617	rs4617832	ENSG00000205771.5	CATSPER2P1	14.48	2.42e-39	8.68e-36	0.65	0.56	Schizophrenia;	chr15:43738381	chr15:43726918~43747094:-
PRAD	cis	rs9660180	0.967	rs12040325	ENSG00000268575.1	RP1-283E3.8	-14.48	2.48e-39	8.87e-36	-0.59	-0.56	Body mass index;	chr1:1770997	chr1:1702736~1737688:-
PRAD	cis	rs916888	0.61	rs199436	ENSG00000214401.4	KANSL1-AS1	-14.47	2.5e-39	8.95e-36	-0.79	-0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:46193576~46196723:+
PRAD	cis	rs8100891	0.506	rs4804992	ENSG00000267213.4	AC007773.2	-14.47	2.51e-39	9e-36	-0.71	-0.56	Neuroticism;	chr19:32367885	chr19:32390050~32405560:-
PRAD	cis	rs875971	0.862	rs949930	ENSG00000226824.5	RP4-756H11.3	14.47	2.55e-39	9.11e-36	0.77	0.56	Aortic root size;	chr7:66301835	chr7:66654538~66669855:+
PRAD	cis	rs6504950	0.83	rs12949538	ENSG00000275710.1	RP11-257O5.4	-14.47	2.55e-39	9.14e-36	-0.77	-0.56	Breast cancer;	chr17:54933309	chr17:54964474~54964679:+
PRAD	cis	rs2882667	0.898	rs10079634	ENSG00000253404.1	AC034243.1	14.47	2.63e-39	9.4e-36	0.75	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139077364	chr5:138744434~138753309:-
PRAD	cis	rs492146	0.765	rs423475	ENSG00000243236.5	GSTA9P	-14.47	2.69e-39	9.62e-36	-0.73	-0.56	Epilepsy (remission after treatment);	chr6:52979785	chr6:52939726~52957521:-
PRAD	cis	rs492146	0.765	rs419427	ENSG00000243236.5	GSTA9P	-14.47	2.69e-39	9.62e-36	-0.73	-0.56	Epilepsy (remission after treatment);	chr6:52980088	chr6:52939726~52957521:-
PRAD	cis	rs1153858	1	rs1554521	ENSG00000259520.4	CTD-2651B20.3	14.47	2.74e-39	9.8e-36	0.73	0.56	Homoarginine levels;	chr15:45371991	chr15:45251580~45279251:-
PRAD	cis	rs11155671	0.53	rs9383940	ENSG00000231760.4	RP11-350J20.5	14.47	2.75e-39	9.81e-36	0.79	0.56	Testicular germ cell tumor;	chr6:149904923	chr6:149796151~149826294:-
PRAD	cis	rs992157	0.643	rs10191283	ENSG00000261338.2	RP11-378A13.1	14.47	2.75e-39	9.82e-36	0.64	0.56	Colorectal cancer;	chr2:218192032	chr2:218255319~218257366:+
PRAD	cis	rs324126	0.78	rs10445583	ENSG00000277977.1	CTD-3018O17.5	14.46	2.77e-39	9.88e-36	0.62	0.56	Colonoscopy-negative controls vs population controls;	chr19:52379480	chr19:52392659~52392755:+
PRAD	cis	rs324126	0.752	rs10445584	ENSG00000277977.1	CTD-3018O17.5	14.46	2.77e-39	9.88e-36	0.62	0.56	Colonoscopy-negative controls vs population controls;	chr19:52379552	chr19:52392659~52392755:+
PRAD	cis	rs324126	0.78	rs10445585	ENSG00000277977.1	CTD-3018O17.5	14.46	2.77e-39	9.88e-36	0.62	0.56	Colonoscopy-negative controls vs population controls;	chr19:52379571	chr19:52392659~52392755:+
PRAD	cis	rs875971	0.862	rs908915	ENSG00000226824.5	RP4-756H11.3	14.46	2.83e-39	1.01e-35	0.76	0.56	Aortic root size;	chr7:66149664	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.862	rs7809814	ENSG00000226824.5	RP4-756H11.3	14.46	2.83e-39	1.01e-35	0.76	0.56	Aortic root size;	chr7:66150410	chr7:66654538~66669855:+
PRAD	cis	rs1153858	1	rs60476496	ENSG00000259520.4	CTD-2651B20.3	-14.46	2.9e-39	1.03e-35	-0.73	-0.56	Homoarginine levels;	chr15:45421603	chr15:45251580~45279251:-
PRAD	cis	rs875971	0.756	rs4718328	ENSG00000226824.5	RP4-756H11.3	14.46	2.94e-39	1.05e-35	0.76	0.56	Aortic root size;	chr7:66228350	chr7:66654538~66669855:+
PRAD	cis	rs9322193	0.543	rs9371533	ENSG00000216906.2	RP11-350J20.9	14.46	2.96e-39	1.05e-35	0.66	0.56	Lung cancer;	chr6:149889545	chr6:149904243~149906418:+
PRAD	cis	rs2111504	0.945	rs1861780	ENSG00000267213.4	AC007773.2	-14.46	2.99e-39	1.07e-35	-0.71	-0.56	Bipolar disorder;	chr19:32372138	chr19:32390050~32405560:-
PRAD	cis	rs875971	0.862	rs4368860	ENSG00000226824.5	RP4-756H11.3	14.45	3.06e-39	1.09e-35	0.76	0.56	Aortic root size;	chr7:66143495	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.825	rs1000464	ENSG00000226824.5	RP4-756H11.3	14.45	3.14e-39	1.12e-35	0.77	0.56	Aortic root size;	chr7:66312922	chr7:66654538~66669855:+
PRAD	cis	rs492146	0.765	rs673197	ENSG00000243236.5	GSTA9P	-14.45	3.17e-39	1.13e-35	-0.72	-0.56	Epilepsy (remission after treatment);	chr6:52979459	chr6:52939726~52957521:-
PRAD	cis	rs992157	0.71	rs12612347	ENSG00000261338.2	RP11-378A13.1	-14.45	3.18e-39	1.13e-35	-0.63	-0.56	Colorectal cancer;	chr2:218192615	chr2:218255319~218257366:+
PRAD	cis	rs8100891	0.537	rs10405382	ENSG00000267213.4	AC007773.2	-14.45	3.2e-39	1.14e-35	-0.71	-0.56	Neuroticism;	chr19:32405810	chr19:32390050~32405560:-
PRAD	cis	rs11673344	0.566	rs256733	ENSG00000226686.6	LINC01535	14.45	3.23e-39	1.15e-35	0.71	0.56	Obesity-related traits;	chr19:37384729	chr19:37251912~37265535:+
PRAD	cis	rs11155671	0.53	rs1334510	ENSG00000216906.2	RP11-350J20.9	14.45	3.26e-39	1.16e-35	0.65	0.56	Testicular germ cell tumor;	chr6:149880043	chr6:149904243~149906418:+
PRAD	cis	rs324126	0.78	rs10445586	ENSG00000277977.1	CTD-3018O17.5	14.45	3.3e-39	1.17e-35	0.62	0.56	Colonoscopy-negative controls vs population controls;	chr19:52379870	chr19:52392659~52392755:+
PRAD	cis	rs324126	0.78	rs62108317	ENSG00000277977.1	CTD-3018O17.5	14.45	3.3e-39	1.17e-35	0.62	0.56	Colonoscopy-negative controls vs population controls;	chr19:52380230	chr19:52392659~52392755:+
PRAD	cis	rs875971	0.862	rs1167390	ENSG00000226824.5	RP4-756H11.3	14.44	3.38e-39	1.2e-35	0.76	0.56	Aortic root size;	chr7:66110906	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.862	rs35034167	ENSG00000226824.5	RP4-756H11.3	14.44	3.38e-39	1.2e-35	0.76	0.56	Aortic root size;	chr7:66115179	chr7:66654538~66669855:+
PRAD	cis	rs977987	0.705	rs4888377	ENSG00000261783.1	RP11-252K23.2	-14.44	3.4e-39	1.21e-35	-0.8	-0.56	Dupuytren's disease;	chr16:75291788	chr16:75379818~75381260:-
PRAD	cis	rs7208859	0.673	rs11653955	ENSG00000263531.1	RP13-753N3.1	14.44	3.42e-39	1.22e-35	1.16	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30706274	chr17:30863921~30864940:-
PRAD	cis	rs7617773	0.78	rs3731550	ENSG00000229759.1	MRPS18AP1	14.44	3.46e-39	1.23e-35	0.62	0.56	Coronary artery disease;	chr3:48165093	chr3:48256350~48256938:-
PRAD	cis	rs6504950	0.72	rs9914836	ENSG00000275710.1	RP11-257O5.4	14.44	3.53e-39	1.25e-35	0.77	0.56	Breast cancer;	chr17:54920514	chr17:54964474~54964679:+
PRAD	cis	rs7208859	0.623	rs7220289	ENSG00000263531.1	RP13-753N3.1	14.44	3.54e-39	1.26e-35	1.13	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30776744	chr17:30863921~30864940:-
PRAD	cis	rs2455601	0.638	rs3815991	ENSG00000254860.4	TMEM9B-AS1	-14.44	3.57e-39	1.27e-35	-0.7	-0.56	Schizophrenia;	chr11:8986122	chr11:8964675~8977527:+
PRAD	cis	rs7208859	0.573	rs7214313	ENSG00000263531.1	RP13-753N3.1	14.44	3.61e-39	1.28e-35	1.11	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811578	chr17:30863921~30864940:-
PRAD	cis	rs17507216	0.591	rs7163848	ENSG00000278603.1	RP13-608F4.5	14.44	3.62e-39	1.28e-35	0.92	0.56	Excessive daytime sleepiness;	chr15:82729563	chr15:82472203~82472426:+
PRAD	cis	rs7617773	0.817	rs3731497	ENSG00000229759.1	MRPS18AP1	14.44	3.62e-39	1.28e-35	0.62	0.56	Coronary artery disease;	chr3:48185063	chr3:48256350~48256938:-
PRAD	cis	rs6504950	0.83	rs8073158	ENSG00000275710.1	RP11-257O5.4	14.44	3.64e-39	1.29e-35	0.77	0.56	Breast cancer;	chr17:54951254	chr17:54964474~54964679:+
PRAD	cis	rs1153858	0.943	rs8038342	ENSG00000259520.4	CTD-2651B20.3	-14.44	3.68e-39	1.3e-35	-0.73	-0.56	Homoarginine levels;	chr15:45359339	chr15:45251580~45279251:-
PRAD	cis	rs1153858	1	rs4774579	ENSG00000259520.4	CTD-2651B20.3	-14.44	3.68e-39	1.3e-35	-0.73	-0.56	Homoarginine levels;	chr15:45359605	chr15:45251580~45279251:-
PRAD	cis	rs1153858	1	rs4625670	ENSG00000259520.4	CTD-2651B20.3	-14.44	3.68e-39	1.3e-35	-0.73	-0.56	Homoarginine levels;	chr15:45360728	chr15:45251580~45279251:-
PRAD	cis	rs1153858	1	rs1049503	ENSG00000259520.4	CTD-2651B20.3	-14.44	3.68e-39	1.3e-35	-0.73	-0.56	Homoarginine levels;	chr15:45361509	chr15:45251580~45279251:-
PRAD	cis	rs1153858	1	rs3759899	ENSG00000259520.4	CTD-2651B20.3	-14.44	3.68e-39	1.3e-35	-0.73	-0.56	Homoarginine levels;	chr15:45363705	chr15:45251580~45279251:-
PRAD	cis	rs9487094	0.689	rs2884037	ENSG00000260273.1	RP11-425D10.10	14.44	3.72e-39	1.32e-35	0.74	0.56	Height;	chr6:109354092	chr6:109382795~109383666:+
PRAD	cis	rs11155671	0.53	rs9371544	ENSG00000216906.2	RP11-350J20.9	14.43	3.78e-39	1.34e-35	0.65	0.56	Testicular germ cell tumor;	chr6:149896224	chr6:149904243~149906418:+
PRAD	cis	rs992157	0.735	rs13392177	ENSG00000261338.2	RP11-378A13.1	-14.43	3.83e-39	1.36e-35	-0.64	-0.56	Colorectal cancer;	chr2:218248233	chr2:218255319~218257366:+
PRAD	cis	rs12022452	0.591	rs12042242	ENSG00000238287.1	RP11-656D10.3	14.43	4.01e-39	1.42e-35	0.87	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr1:40528201	chr1:40493157~40508661:-
PRAD	cis	rs2882667	0.898	rs4380651	ENSG00000253404.1	AC034243.1	14.43	4.05e-39	1.43e-35	0.76	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139055383	chr5:138744434~138753309:-
PRAD	cis	rs2486288	0.656	rs1706767	ENSG00000259520.4	CTD-2651B20.3	14.43	4.06e-39	1.44e-35	0.77	0.56	Glomerular filtration rate;	chr15:45276901	chr15:45251580~45279251:-
PRAD	cis	rs992157	0.735	rs13393821	ENSG00000261338.2	RP11-378A13.1	14.42	4.12e-39	1.46e-35	0.63	0.56	Colorectal cancer;	chr2:218212019	chr2:218255319~218257366:+
PRAD	cis	rs2739330	0.732	rs5760175	ENSG00000235689.1	AP000351.13	14.42	4.27e-39	1.51e-35	0.67	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:24006305~24008258:-
PRAD	cis	rs875971	0.862	rs880166	ENSG00000226824.5	RP4-756H11.3	14.42	4.35e-39	1.53e-35	0.76	0.56	Aortic root size;	chr7:66205775	chr7:66654538~66669855:+
PRAD	cis	rs9487094	0.6	rs1885690	ENSG00000260273.1	RP11-425D10.10	14.42	4.45e-39	1.57e-35	0.75	0.56	Height;	chr6:109351795	chr6:109382795~109383666:+
PRAD	cis	rs9487094	0.67	rs12199154	ENSG00000260273.1	RP11-425D10.10	-14.41	4.65e-39	1.64e-35	-0.75	-0.56	Height;	chr6:109501793	chr6:109382795~109383666:+
PRAD	cis	rs324126	0.743	rs34221182	ENSG00000277977.1	CTD-3018O17.5	14.41	4.73e-39	1.67e-35	0.62	0.56	Colonoscopy-negative controls vs population controls;	chr19:52378107	chr19:52392659~52392755:+
PRAD	cis	rs8100891	0.537	rs4805758	ENSG00000267213.4	AC007773.2	-14.41	4.79e-39	1.69e-35	-0.72	-0.56	Neuroticism;	chr19:32375518	chr19:32390050~32405560:-
PRAD	cis	rs324126	0.78	rs3170100	ENSG00000277977.1	CTD-3018O17.5	14.41	4.89e-39	1.73e-35	0.62	0.56	Colonoscopy-negative controls vs population controls;	chr19:52385367	chr19:52392659~52392755:+
PRAD	cis	rs7188445	0.966	rs11150188	ENSG00000261390.4	RP11-345M22.2	-14.41	4.9e-39	1.73e-35	-0.7	-0.56	Urate levels;	chr16:79673401	chr16:79715232~79770563:-
PRAD	cis	rs10256972	0.758	rs2280724	ENSG00000229043.2	AC091729.9	-14.41	4.91e-39	1.73e-35	-0.69	-0.56	Endometriosis;Longevity;	chr7:1025084	chr7:1160374~1165267:+
PRAD	cis	rs71403859	0.685	rs12444890	ENSG00000260886.1	TAT-AS1	14.41	4.94e-39	1.74e-35	1.02	0.56	Post bronchodilator FEV1;	chr16:71602123	chr16:71565789~71578187:+
PRAD	cis	rs1799949	0.602	rs8176235	ENSG00000198496.9	NBR2	-14.41	4.99e-39	1.76e-35	-0.82	-0.56	Menopause (age at onset);	chr17:43067543	chr17:43125610~43153671:+
PRAD	cis	rs875971	0.862	rs1612452	ENSG00000226824.5	RP4-756H11.3	14.41	5.01e-39	1.77e-35	0.77	0.56	Aortic root size;	chr7:66108909	chr7:66654538~66669855:+
PRAD	cis	rs8100891	0.537	rs16967057	ENSG00000267213.4	AC007773.2	14.4	5.12e-39	1.8e-35	0.71	0.56	Neuroticism;	chr19:32423172	chr19:32390050~32405560:-
PRAD	cis	rs875971	0.895	rs4145009	ENSG00000226824.5	RP4-756H11.3	14.4	5.4e-39	1.9e-35	0.78	0.56	Aortic root size;	chr7:66261628	chr7:66654538~66669855:+
PRAD	cis	rs9487094	0.696	rs11153188	ENSG00000260273.1	RP11-425D10.10	14.4	5.42e-39	1.91e-35	0.74	0.56	Height;	chr6:109558247	chr6:109382795~109383666:+
PRAD	cis	rs9487094	0.67	rs12528781	ENSG00000260273.1	RP11-425D10.10	14.39	5.57e-39	1.96e-35	0.74	0.56	Height;	chr6:109608105	chr6:109382795~109383666:+
PRAD	cis	rs8037818	1	rs4544214	ENSG00000276724.1	RP11-1000B6.7	14.39	5.58e-39	1.96e-35	0.8	0.56	Obesity-related traits;	chr15:32639703	chr15:32583612~32584312:+
PRAD	cis	rs875971	0.862	rs7786892	ENSG00000226824.5	RP4-756H11.3	14.39	5.62e-39	1.98e-35	0.76	0.56	Aortic root size;	chr7:66163889	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.862	rs2420174	ENSG00000226824.5	RP4-756H11.3	14.39	5.75e-39	2.02e-35	0.76	0.56	Aortic root size;	chr7:66180374	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.862	rs2420173	ENSG00000226824.5	RP4-756H11.3	14.39	5.75e-39	2.02e-35	0.76	0.56	Aortic root size;	chr7:66180412	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.862	rs4718319	ENSG00000226824.5	RP4-756H11.3	14.39	5.75e-39	2.02e-35	0.76	0.56	Aortic root size;	chr7:66187797	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.723	rs28391294	ENSG00000226824.5	RP4-756H11.3	14.39	5.75e-39	2.02e-35	0.76	0.56	Aortic root size;	chr7:66189328	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.83	rs6967708	ENSG00000226824.5	RP4-756H11.3	14.39	5.75e-39	2.02e-35	0.76	0.56	Aortic root size;	chr7:66192326	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.895	rs7782806	ENSG00000226824.5	RP4-756H11.3	14.39	5.75e-39	2.02e-35	0.76	0.56	Aortic root size;	chr7:66192910	chr7:66654538~66669855:+
PRAD	cis	rs1153858	1	rs4271549	ENSG00000259520.4	CTD-2651B20.3	-14.39	5.81e-39	2.04e-35	-0.73	-0.56	Homoarginine levels;	chr15:45360532	chr15:45251580~45279251:-
PRAD	cis	rs1153858	1	rs4627277	ENSG00000259520.4	CTD-2651B20.3	-14.39	5.81e-39	2.04e-35	-0.73	-0.56	Homoarginine levels;	chr15:45360570	chr15:45251580~45279251:-
PRAD	cis	rs6504950	0.83	rs17817877	ENSG00000275710.1	RP11-257O5.4	14.39	5.92e-39	2.08e-35	0.78	0.56	Breast cancer;	chr17:54957267	chr17:54964474~54964679:+
PRAD	cis	rs7617773	0.694	rs13099560	ENSG00000229759.1	MRPS18AP1	-14.39	5.97e-39	2.09e-35	-0.58	-0.56	Coronary artery disease;	chr3:48163278	chr3:48256350~48256938:-
PRAD	cis	rs11673344	0.566	rs8109103	ENSG00000226686.6	LINC01535	14.39	6.07e-39	2.13e-35	0.71	0.56	Obesity-related traits;	chr19:37503209	chr19:37251912~37265535:+
PRAD	cis	rs7208859	0.623	rs55811708	ENSG00000263531.1	RP13-753N3.1	14.38	6.27e-39	2.2e-35	1.12	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777713	chr17:30863921~30864940:-
PRAD	cis	rs1153858	1	rs7181167	ENSG00000259520.4	CTD-2651B20.3	-14.38	6.33e-39	2.22e-35	-0.73	-0.56	Homoarginine levels;	chr15:45394038	chr15:45251580~45279251:-
PRAD	cis	rs73086581	1	rs73084575	ENSG00000229539.1	RP11-119B16.2	14.38	6.33e-39	2.22e-35	0.98	0.56	Response to antidepressants in depression;	chr20:3926121	chr20:3888239~3888868:-
PRAD	cis	rs9487094	0.626	rs1980591	ENSG00000260273.1	RP11-425D10.10	14.38	6.49e-39	2.28e-35	0.74	0.56	Height;	chr6:109618620	chr6:109382795~109383666:+
PRAD	cis	rs9487094	0.696	rs12191353	ENSG00000260273.1	RP11-425D10.10	14.38	6.49e-39	2.28e-35	0.74	0.56	Height;	chr6:109620772	chr6:109382795~109383666:+
PRAD	cis	rs992157	0.687	rs35271699	ENSG00000261338.2	RP11-378A13.1	14.38	6.57e-39	2.3e-35	0.64	0.56	Colorectal cancer;	chr2:218252759	chr2:218255319~218257366:+
PRAD	cis	rs9660180	0.78	rs12038111	ENSG00000268575.1	RP1-283E3.8	-14.38	6.63e-39	2.32e-35	-0.59	-0.56	Body mass index;	chr1:1772410	chr1:1702736~1737688:-
PRAD	cis	rs9660180	0.836	rs12038134	ENSG00000268575.1	RP1-283E3.8	-14.38	6.63e-39	2.32e-35	-0.59	-0.56	Body mass index;	chr1:1772426	chr1:1702736~1737688:-
PRAD	cis	rs875971	0.862	rs709596	ENSG00000226824.5	RP4-756H11.3	-14.38	6.66e-39	2.33e-35	-0.75	-0.56	Aortic root size;	chr7:66360926	chr7:66654538~66669855:+
PRAD	cis	rs7617773	0.817	rs3729577	ENSG00000229759.1	MRPS18AP1	14.37	6.76e-39	2.37e-35	0.62	0.56	Coronary artery disease;	chr3:48187504	chr3:48256350~48256938:-
PRAD	cis	rs528808	1	rs528808	ENSG00000219755.1	RP1-199J3.5	14.37	6.96e-39	2.43e-35	0.8	0.56	Age-related hearing impairment;	chr6:99656413	chr6:99575712~99576456:+
PRAD	cis	rs9322193	0.567	rs7747457	ENSG00000216906.2	RP11-350J20.9	14.37	7.09e-39	2.48e-35	0.64	0.56	Lung cancer;	chr6:149892366	chr6:149904243~149906418:+
PRAD	cis	rs7617773	0.817	rs3731513	ENSG00000229759.1	MRPS18AP1	14.37	7.36e-39	2.57e-35	0.62	0.56	Coronary artery disease;	chr3:48178047	chr3:48256350~48256938:-
PRAD	cis	rs8100891	0.537	rs28672356	ENSG00000267213.4	AC007773.2	-14.37	7.41e-39	2.59e-35	-0.71	-0.56	Neuroticism;	chr19:32416937	chr19:32390050~32405560:-
PRAD	cis	rs1153858	0.943	rs4774580	ENSG00000259520.4	CTD-2651B20.3	-14.36	7.53e-39	2.63e-35	-0.72	-0.56	Homoarginine levels;	chr15:45359888	chr15:45251580~45279251:-
PRAD	cis	rs11155671	0.53	rs6557133	ENSG00000216906.2	RP11-350J20.9	14.36	7.6e-39	2.65e-35	0.64	0.56	Testicular germ cell tumor;	chr6:149874248	chr6:149904243~149906418:+
PRAD	cis	rs7617773	0.779	rs11718329	ENSG00000229759.1	MRPS18AP1	14.36	7.92e-39	2.76e-35	0.59	0.56	Coronary artery disease;	chr3:48268338	chr3:48256350~48256938:-
PRAD	cis	rs8072100	0.817	rs9912101	ENSG00000228782.6	CTD-2026D20.3	14.36	7.95e-39	2.77e-35	0.59	0.56	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47469712	chr17:47450568~47492492:-
PRAD	cis	rs8072100	0.817	rs9905581	ENSG00000228782.6	CTD-2026D20.3	14.36	7.95e-39	2.77e-35	0.59	0.56	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47469819	chr17:47450568~47492492:-
PRAD	cis	rs8072100	0.817	rs12449647	ENSG00000228782.6	CTD-2026D20.3	14.36	7.95e-39	2.77e-35	0.59	0.56	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47471592	chr17:47450568~47492492:-
PRAD	cis	rs8072100	0.748	rs9908016	ENSG00000228782.6	CTD-2026D20.3	14.36	7.95e-39	2.77e-35	0.59	0.56	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47473995	chr17:47450568~47492492:-
PRAD	cis	rs8072100	0.782	rs28507314	ENSG00000228782.6	CTD-2026D20.3	14.36	7.95e-39	2.77e-35	0.59	0.56	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47474036	chr17:47450568~47492492:-
PRAD	cis	rs1153858	1	rs11070456	ENSG00000259520.4	CTD-2651B20.3	-14.36	7.96e-39	2.77e-35	-0.73	-0.56	Homoarginine levels;	chr15:45394637	chr15:45251580~45279251:-
PRAD	cis	rs9487094	0.67	rs2024850	ENSG00000260273.1	RP11-425D10.10	-14.36	7.98e-39	2.78e-35	-0.75	-0.56	Height;	chr6:109497253	chr6:109382795~109383666:+
PRAD	cis	rs7208859	0.573	rs73267829	ENSG00000263531.1	RP13-753N3.1	14.36	7.99e-39	2.78e-35	1.15	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30676921	chr17:30863921~30864940:-
PRAD	cis	rs9487094	0.67	rs11752791	ENSG00000260273.1	RP11-425D10.10	14.36	8.03e-39	2.8e-35	0.74	0.56	Height;	chr6:109564443	chr6:109382795~109383666:+
PRAD	cis	rs9487094	0.67	rs4490694	ENSG00000260273.1	RP11-425D10.10	14.36	8.03e-39	2.8e-35	0.74	0.56	Height;	chr6:109571489	chr6:109382795~109383666:+
PRAD	cis	rs9487094	0.67	rs12214639	ENSG00000260273.1	RP11-425D10.10	14.36	8.03e-39	2.8e-35	0.74	0.56	Height;	chr6:109576414	chr6:109382795~109383666:+
PRAD	cis	rs17507216	0.628	rs28607761	ENSG00000278603.1	RP13-608F4.5	14.36	8.06e-39	2.8e-35	0.91	0.56	Excessive daytime sleepiness;	chr15:82715317	chr15:82472203~82472426:+
PRAD	cis	rs492146	0.765	rs597348	ENSG00000243236.5	GSTA9P	-14.36	8.08e-39	2.81e-35	-0.72	-0.56	Epilepsy (remission after treatment);	chr6:52980599	chr6:52939726~52957521:-
PRAD	cis	rs10256972	0.721	rs4720249	ENSG00000229043.2	AC091729.9	-14.36	8.09e-39	2.81e-35	-0.69	-0.56	Endometriosis;Longevity;	chr7:1032927	chr7:1160374~1165267:+
PRAD	cis	rs9487094	0.644	rs1960325	ENSG00000260273.1	RP11-425D10.10	14.35	8.29e-39	2.88e-35	0.74	0.56	Height;	chr6:109592105	chr6:109382795~109383666:+
PRAD	cis	rs875971	0.928	rs2036263	ENSG00000226824.5	RP4-756H11.3	14.35	8.33e-39	2.9e-35	0.76	0.56	Aortic root size;	chr7:66335210	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.862	rs10240949	ENSG00000226824.5	RP4-756H11.3	14.35	8.33e-39	2.9e-35	0.76	0.56	Aortic root size;	chr7:66339430	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.862	rs7782704	ENSG00000226824.5	RP4-756H11.3	14.35	8.33e-39	2.9e-35	0.76	0.56	Aortic root size;	chr7:66340379	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.862	rs6959268	ENSG00000226824.5	RP4-756H11.3	14.35	8.33e-39	2.9e-35	0.76	0.56	Aortic root size;	chr7:66347979	chr7:66654538~66669855:+
PRAD	cis	rs1153858	1	rs66528868	ENSG00000259520.4	CTD-2651B20.3	-14.35	8.4e-39	2.91e-35	-0.72	-0.56	Homoarginine levels;	chr15:45376349	chr15:45251580~45279251:-
PRAD	cis	rs1153858	1	rs7494956	ENSG00000259520.4	CTD-2651B20.3	-14.35	8.4e-39	2.91e-35	-0.72	-0.56	Homoarginine levels;	chr15:45376367	chr15:45251580~45279251:-
PRAD	cis	rs1153858	0.887	rs7164139	ENSG00000259520.4	CTD-2651B20.3	-14.35	8.4e-39	2.91e-35	-0.72	-0.56	Homoarginine levels;	chr15:45378653	chr15:45251580~45279251:-
PRAD	cis	rs1153858	1	rs7164602	ENSG00000259520.4	CTD-2651B20.3	-14.35	8.4e-39	2.91e-35	-0.72	-0.56	Homoarginine levels;	chr15:45379127	chr15:45251580~45279251:-
PRAD	cis	rs1153858	1	rs12441971	ENSG00000259520.4	CTD-2651B20.3	-14.35	8.4e-39	2.91e-35	-0.72	-0.56	Homoarginine levels;	chr15:45379759	chr15:45251580~45279251:-
PRAD	cis	rs1153858	1	rs1346268	ENSG00000259520.4	CTD-2651B20.3	-14.35	8.4e-39	2.91e-35	-0.72	-0.56	Homoarginine levels;	chr15:45380831	chr15:45251580~45279251:-
PRAD	cis	rs1153858	1	rs67461176	ENSG00000259520.4	CTD-2651B20.3	-14.35	8.4e-39	2.91e-35	-0.72	-0.56	Homoarginine levels;	chr15:45384621	chr15:45251580~45279251:-
PRAD	cis	rs1153858	1	rs66939267	ENSG00000259520.4	CTD-2651B20.3	-14.35	8.4e-39	2.91e-35	-0.72	-0.56	Homoarginine levels;	chr15:45384704	chr15:45251580~45279251:-
PRAD	cis	rs1153858	0.943	rs67045941	ENSG00000259520.4	CTD-2651B20.3	-14.35	8.4e-39	2.91e-35	-0.72	-0.56	Homoarginine levels;	chr15:45384813	chr15:45251580~45279251:-
PRAD	cis	rs1153858	1	rs67744121	ENSG00000259520.4	CTD-2651B20.3	-14.35	8.4e-39	2.91e-35	-0.72	-0.56	Homoarginine levels;	chr15:45385039	chr15:45251580~45279251:-
PRAD	cis	rs11155671	0.53	rs4870080	ENSG00000216906.2	RP11-350J20.9	14.35	8.42e-39	2.92e-35	0.65	0.56	Testicular germ cell tumor;	chr6:149881508	chr6:149904243~149906418:+
PRAD	cis	rs875971	0.862	rs778734	ENSG00000226824.5	RP4-756H11.3	-14.35	8.52e-39	2.96e-35	-0.76	-0.56	Aortic root size;	chr7:66349862	chr7:66654538~66669855:+
PRAD	cis	rs916888	0.61	rs142167	ENSG00000214401.4	KANSL1-AS1	-14.35	8.54e-39	2.96e-35	-0.78	-0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:46193576~46196723:+
PRAD	cis	rs1153858	1	rs3809472	ENSG00000259520.4	CTD-2651B20.3	-14.35	8.78e-39	3.05e-35	-0.73	-0.56	Homoarginine levels;	chr15:45402120	chr15:45251580~45279251:-
PRAD	cis	rs1153858	1	rs1820518	ENSG00000259520.4	CTD-2651B20.3	-14.35	8.78e-39	3.05e-35	-0.73	-0.56	Homoarginine levels;	chr15:45402381	chr15:45251580~45279251:-
PRAD	cis	rs7208859	0.524	rs8065744	ENSG00000263531.1	RP13-753N3.1	14.35	8.94e-39	3.1e-35	1.13	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30772431	chr17:30863921~30864940:-
PRAD	cis	rs17826219	0.706	rs8071236	ENSG00000263531.1	RP13-753N3.1	14.35	8.94e-39	3.1e-35	1.13	0.56	Body mass index;	chr17:30772984	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs56163556	ENSG00000263531.1	RP13-753N3.1	14.35	8.94e-39	3.1e-35	1.13	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774850	chr17:30863921~30864940:-
PRAD	cis	rs1153858	0.943	rs12439575	ENSG00000259520.4	CTD-2651B20.3	-14.34	9.32e-39	3.23e-35	-0.72	-0.56	Homoarginine levels;	chr15:45392618	chr15:45251580~45279251:-
PRAD	cis	rs916888	0.61	rs199454	ENSG00000214401.4	KANSL1-AS1	-14.34	9.59e-39	3.32e-35	-0.77	-0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:46193576~46196723:+
PRAD	cis	rs7617773	0.817	rs11928691	ENSG00000229759.1	MRPS18AP1	14.34	9.72e-39	3.36e-35	0.59	0.56	Coronary artery disease;	chr3:48245275	chr3:48256350~48256938:-
PRAD	cis	rs992157	0.71	rs12694432	ENSG00000261338.2	RP11-378A13.1	14.33	1.07e-38	3.69e-35	0.64	0.56	Colorectal cancer;	chr2:218217607	chr2:218255319~218257366:+
PRAD	cis	rs524281	0.773	rs11227448	ENSG00000255320.1	RP11-755F10.1	14.33	1.07e-38	3.71e-35	0.95	0.56	Electroencephalogram traits;	chr11:66281020	chr11:66244840~66246239:-
PRAD	cis	rs9487094	0.67	rs13199135	ENSG00000260273.1	RP11-425D10.10	14.33	1.08e-38	3.73e-35	0.74	0.56	Height;	chr6:109588639	chr6:109382795~109383666:+
PRAD	cis	rs9487094	0.67	rs12193719	ENSG00000260273.1	RP11-425D10.10	14.33	1.08e-38	3.73e-35	0.74	0.56	Height;	chr6:109589051	chr6:109382795~109383666:+
PRAD	cis	rs6504950	0.615	rs66898273	ENSG00000275710.1	RP11-257O5.4	14.33	1.08e-38	3.73e-35	0.76	0.56	Breast cancer;	chr17:54916595	chr17:54964474~54964679:+
PRAD	cis	rs1799949	0.602	rs8176257	ENSG00000198496.9	NBR2	-14.33	1.09e-38	3.76e-35	-0.83	-0.56	Menopause (age at onset);	chr17:43064188	chr17:43125610~43153671:+
PRAD	cis	rs11690935	0.802	rs34636594	ENSG00000228389.1	AC068039.4	14.32	1.12e-38	3.88e-35	0.67	0.56	Schizophrenia;	chr2:172046366	chr2:171773482~171775844:+
PRAD	cis	rs11155671	0.53	rs9383912	ENSG00000216906.2	RP11-350J20.9	14.32	1.15e-38	3.98e-35	0.64	0.56	Testicular germ cell tumor;	chr6:149885479	chr6:149904243~149906418:+
PRAD	cis	rs11155671	0.53	rs7768626	ENSG00000216906.2	RP11-350J20.9	14.32	1.15e-38	3.98e-35	0.64	0.56	Testicular germ cell tumor;	chr6:149886826	chr6:149904243~149906418:+
PRAD	cis	rs11155671	0.53	rs7768665	ENSG00000216906.2	RP11-350J20.9	14.32	1.15e-38	3.98e-35	0.64	0.56	Testicular germ cell tumor;	chr6:149886888	chr6:149904243~149906418:+
PRAD	cis	rs11155671	0.53	rs7758020	ENSG00000216906.2	RP11-350J20.9	14.32	1.15e-38	3.98e-35	0.64	0.56	Testicular germ cell tumor;	chr6:149886975	chr6:149904243~149906418:+
PRAD	cis	rs9487094	0.67	rs11754340	ENSG00000260273.1	RP11-425D10.10	14.32	1.16e-38	4.01e-35	0.74	0.56	Height;	chr6:109584789	chr6:109382795~109383666:+
PRAD	cis	rs992157	0.71	rs10169718	ENSG00000261338.2	RP11-378A13.1	-14.32	1.17e-38	4.02e-35	-0.63	-0.56	Colorectal cancer;	chr2:218238857	chr2:218255319~218257366:+
PRAD	cis	rs992157	0.735	rs12990082	ENSG00000261338.2	RP11-378A13.1	14.32	1.17e-38	4.02e-35	0.63	0.56	Colorectal cancer;	chr2:218237609	chr2:218255319~218257366:+
PRAD	cis	rs7208859	0.562	rs11650923	ENSG00000263531.1	RP13-753N3.1	14.32	1.18e-38	4.06e-35	1.15	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30681149	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs56378576	ENSG00000263531.1	RP13-753N3.1	14.32	1.18e-38	4.06e-35	1.15	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30683102	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs35916850	ENSG00000263531.1	RP13-753N3.1	14.32	1.18e-38	4.06e-35	1.15	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30684155	chr17:30863921~30864940:-
PRAD	cis	rs73086581	1	rs73088421	ENSG00000229539.1	RP11-119B16.2	14.31	1.26e-38	4.33e-35	0.96	0.56	Response to antidepressants in depression;	chr20:4017224	chr20:3888239~3888868:-
PRAD	cis	rs1153858	1	rs4395020	ENSG00000259520.4	CTD-2651B20.3	-14.31	1.29e-38	4.43e-35	-0.72	-0.56	Homoarginine levels;	chr15:45360691	chr15:45251580~45279251:-
PRAD	cis	rs2929278	0.561	rs62018952	ENSG00000205771.5	CATSPER2P1	14.31	1.29e-38	4.45e-35	0.64	0.56	Schizophrenia;	chr15:43788539	chr15:43726918~43747094:-
PRAD	cis	rs992157	0.735	rs2271541	ENSG00000261338.2	RP11-378A13.1	14.31	1.3e-38	4.48e-35	0.63	0.56	Colorectal cancer;	chr2:218217396	chr2:218255319~218257366:+
PRAD	cis	rs324126	0.78	rs60935857	ENSG00000277977.1	CTD-3018O17.5	14.3	1.39e-38	4.74e-35	0.62	0.56	Colonoscopy-negative controls vs population controls;	chr19:52382606	chr19:52392659~52392755:+
PRAD	cis	rs11155671	0.53	rs9322228	ENSG00000216906.2	RP11-350J20.9	14.3	1.4e-38	4.78e-35	0.64	0.56	Testicular germ cell tumor;	chr6:149888173	chr6:149904243~149906418:+
PRAD	cis	rs11155671	0.53	rs7774787	ENSG00000216906.2	RP11-350J20.9	14.3	1.4e-38	4.78e-35	0.64	0.56	Testicular germ cell tumor;	chr6:149888296	chr6:149904243~149906418:+
PRAD	cis	rs11155671	0.53	rs2342767	ENSG00000216906.2	RP11-350J20.9	14.3	1.4e-38	4.78e-35	0.64	0.56	Testicular germ cell tumor;	chr6:149888581	chr6:149904243~149906418:+
PRAD	cis	rs11155671	0.53	rs7764376	ENSG00000216906.2	RP11-350J20.9	14.3	1.4e-38	4.78e-35	0.64	0.56	Testicular germ cell tumor;	chr6:149889208	chr6:149904243~149906418:+
PRAD	cis	rs11155671	0.53	rs6933882	ENSG00000216906.2	RP11-350J20.9	14.3	1.4e-38	4.78e-35	0.64	0.56	Testicular germ cell tumor;	chr6:149889666	chr6:149904243~149906418:+
PRAD	cis	rs11155671	0.53	rs6939761	ENSG00000216906.2	RP11-350J20.9	14.3	1.4e-38	4.78e-35	0.64	0.56	Testicular germ cell tumor;	chr6:149889858	chr6:149904243~149906418:+
PRAD	cis	rs11155671	0.53	rs3823021	ENSG00000216906.2	RP11-350J20.9	14.3	1.4e-38	4.78e-35	0.64	0.56	Testicular germ cell tumor;	chr6:149889863	chr6:149904243~149906418:+
PRAD	cis	rs11155671	0.53	rs4869763	ENSG00000216906.2	RP11-350J20.9	14.3	1.4e-38	4.78e-35	0.64	0.56	Testicular germ cell tumor;	chr6:149890548	chr6:149904243~149906418:+
PRAD	cis	rs11155671	0.53	rs4869764	ENSG00000216906.2	RP11-350J20.9	14.3	1.4e-38	4.78e-35	0.64	0.56	Testicular germ cell tumor;	chr6:149890692	chr6:149904243~149906418:+
PRAD	cis	rs992157	0.71	rs6752254	ENSG00000261338.2	RP11-378A13.1	14.3	1.43e-38	4.88e-35	0.63	0.56	Colorectal cancer;	chr2:218194020	chr2:218255319~218257366:+
PRAD	cis	rs11155671	0.53	rs9383577	ENSG00000216906.2	RP11-350J20.9	14.3	1.46e-38	4.96e-35	0.64	0.56	Testicular germ cell tumor;	chr6:149886059	chr6:149904243~149906418:+
PRAD	cis	rs11155671	0.53	rs9383914	ENSG00000216906.2	RP11-350J20.9	14.3	1.46e-38	4.96e-35	0.64	0.56	Testicular germ cell tumor;	chr6:149886098	chr6:149904243~149906418:+
PRAD	cis	rs11155671	0.517	rs9397058	ENSG00000216906.2	RP11-350J20.9	14.3	1.46e-38	4.96e-35	0.64	0.56	Testicular germ cell tumor;	chr6:149886113	chr6:149904243~149906418:+
PRAD	cis	rs875971	0.825	rs4587224	ENSG00000226824.5	RP4-756H11.3	14.29	1.5e-38	5.11e-35	0.76	0.56	Aortic root size;	chr7:66271195	chr7:66654538~66669855:+
PRAD	cis	rs9487094	0.6	rs9372213	ENSG00000260273.1	RP11-425D10.10	14.29	1.56e-38	5.32e-35	0.75	0.56	Height;	chr6:109370985	chr6:109382795~109383666:+
PRAD	cis	rs8100891	0.537	rs11883143	ENSG00000267213.4	AC007773.2	-14.29	1.57e-38	5.33e-35	-0.68	-0.56	Neuroticism;	chr19:32478350	chr19:32390050~32405560:-
PRAD	cis	rs11673344	0.583	rs7247090	ENSG00000226686.6	LINC01535	14.29	1.58e-38	5.37e-35	0.71	0.56	Obesity-related traits;	chr19:37522509	chr19:37251912~37265535:+
PRAD	cis	rs6504950	0.745	rs1962045	ENSG00000275710.1	RP11-257O5.4	14.29	1.6e-38	5.44e-35	0.76	0.56	Breast cancer;	chr17:54918789	chr17:54964474~54964679:+
PRAD	cis	rs6504950	0.72	rs9914596	ENSG00000275710.1	RP11-257O5.4	14.29	1.6e-38	5.44e-35	0.76	0.56	Breast cancer;	chr17:54919190	chr17:54964474~54964679:+
PRAD	cis	rs2739330	0.76	rs5751760	ENSG00000250470.1	AP000351.3	14.28	1.71e-38	5.8e-35	0.76	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23976904~23977585:-
PRAD	cis	rs916888	0.779	rs199498	ENSG00000262500.1	RP11-259G18.2	14.28	1.74e-38	5.91e-35	0.79	0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:46243606~46245044:+
PRAD	cis	rs2470135	1	rs2470135	ENSG00000205771.5	CATSPER2P1	-14.27	1.84e-38	6.24e-35	-0.64	-0.56	Diastolic blood pressure;	chr15:43703591	chr15:43726918~43747094:-
PRAD	cis	rs977987	0.654	rs8054194	ENSG00000261783.1	RP11-252K23.2	-14.27	1.84e-38	6.25e-35	-0.77	-0.56	Dupuytren's disease;	chr16:75463262	chr16:75379818~75381260:-
PRAD	cis	rs977987	0.581	rs8056141	ENSG00000261783.1	RP11-252K23.2	-14.27	1.84e-38	6.25e-35	-0.77	-0.56	Dupuytren's disease;	chr16:75463264	chr16:75379818~75381260:-
PRAD	cis	rs2929278	0.617	rs575082	ENSG00000205771.5	CATSPER2P1	14.27	1.86e-38	6.32e-35	0.64	0.56	Schizophrenia;	chr15:43817944	chr15:43726918~43747094:-
PRAD	cis	rs8100891	0.537	rs2012353	ENSG00000267213.4	AC007773.2	-14.27	1.91e-38	6.47e-35	-0.72	-0.56	Neuroticism;	chr19:32408387	chr19:32390050~32405560:-
PRAD	cis	rs73086581	1	rs17286768	ENSG00000229539.1	RP11-119B16.2	14.26	2.12e-38	7.17e-35	0.95	0.56	Response to antidepressants in depression;	chr20:3943922	chr20:3888239~3888868:-
PRAD	cis	rs73086581	1	rs17214621	ENSG00000229539.1	RP11-119B16.2	14.26	2.12e-38	7.17e-35	0.95	0.56	Response to antidepressants in depression;	chr20:3945277	chr20:3888239~3888868:-
PRAD	cis	rs10256972	0.758	rs11979275	ENSG00000229043.2	AC091729.9	-14.26	2.17e-38	7.34e-35	-0.69	-0.56	Endometriosis;Longevity;	chr7:1029699	chr7:1160374~1165267:+
PRAD	cis	rs10256972	0.758	rs11980081	ENSG00000229043.2	AC091729.9	-14.26	2.17e-38	7.34e-35	-0.69	-0.56	Endometriosis;Longevity;	chr7:1029736	chr7:1160374~1165267:+
PRAD	cis	rs524281	0.773	rs10791863	ENSG00000255320.1	RP11-755F10.1	14.25	2.22e-38	7.51e-35	0.95	0.56	Electroencephalogram traits;	chr11:66259887	chr11:66244840~66246239:-
PRAD	cis	rs524281	0.773	rs10750781	ENSG00000255320.1	RP11-755F10.1	14.25	2.22e-38	7.51e-35	0.95	0.56	Electroencephalogram traits;	chr11:66269799	chr11:66244840~66246239:-
PRAD	cis	rs524281	0.773	rs2017969	ENSG00000255320.1	RP11-755F10.1	14.25	2.22e-38	7.51e-35	0.95	0.56	Electroencephalogram traits;	chr11:66271561	chr11:66244840~66246239:-
PRAD	cis	rs3931020	0.548	rs969435	ENSG00000272864.1	RP11-17E13.2	14.25	2.26e-38	7.62e-35	0.58	0.56	Resistin levels;	chr1:74808182	chr1:74698769~74699333:-
PRAD	cis	rs11155671	0.53	rs9397420	ENSG00000216906.2	RP11-350J20.9	-14.25	2.26e-38	7.63e-35	-0.64	-0.56	Testicular germ cell tumor;	chr6:149885645	chr6:149904243~149906418:+
PRAD	cis	rs7208859	0.623	rs7219361	ENSG00000263531.1	RP13-753N3.1	14.25	2.3e-38	7.75e-35	1.11	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753375	chr17:30863921~30864940:-
PRAD	cis	rs9487094	0.6	rs10457193	ENSG00000260273.1	RP11-425D10.10	14.25	2.33e-38	7.87e-35	0.73	0.56	Height;	chr6:109507364	chr6:109382795~109383666:+
PRAD	cis	rs9487094	0.558	rs10457194	ENSG00000260273.1	RP11-425D10.10	14.25	2.33e-38	7.87e-35	0.73	0.56	Height;	chr6:109507366	chr6:109382795~109383666:+
PRAD	cis	rs875971	0.862	rs10282433	ENSG00000226824.5	RP4-756H11.3	14.25	2.41e-38	8.13e-35	0.76	0.56	Aortic root size;	chr7:66256452	chr7:66654538~66669855:+
PRAD	cis	rs2739330	0.76	rs1002286	ENSG00000231271.1	AP000350.8	-14.24	2.48e-38	8.35e-35	-0.74	-0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23949918~23954042:+
PRAD	cis	rs9326248	0.539	rs7120565	ENSG00000254851.1	RP11-109L13.1	-14.24	2.52e-38	8.48e-35	-0.7	-0.56	Blood protein levels;	chr11:117172233	chr11:117135528~117138582:+
PRAD	cis	rs71403859	0.803	rs10500562	ENSG00000260886.1	TAT-AS1	14.24	2.53e-38	8.52e-35	1	0.56	Post bronchodilator FEV1;	chr16:71593828	chr16:71565789~71578187:+
PRAD	cis	rs6907340	0.517	rs9465533	ENSG00000228412.5	RP4-625H18.2	14.24	2.65e-38	8.93e-35	0.74	0.56	Endometriosis;	chr6:19801477	chr6:19802164~19804752:-
PRAD	cis	rs524281	0.731	rs11227439	ENSG00000255320.1	RP11-755F10.1	14.23	2.76e-38	9.26e-35	0.95	0.56	Electroencephalogram traits;	chr11:66258208	chr11:66244840~66246239:-
PRAD	cis	rs2283792	0.871	rs8136867	ENSG00000224086.5	LL22NC03-86G7.1	-14.23	2.8e-38	9.41e-35	-0.65	-0.55	Multiple sclerosis;	chr22:21850504	chr22:21938293~21977632:+
PRAD	cis	rs73086581	1	rs73088416	ENSG00000229539.1	RP11-119B16.2	14.23	2.84e-38	9.53e-35	0.94	0.55	Response to antidepressants in depression;	chr20:4014629	chr20:3888239~3888868:-
PRAD	cis	rs11673344	0.566	rs1968251	ENSG00000226686.6	LINC01535	-14.23	2.9e-38	9.74e-35	-0.7	-0.55	Obesity-related traits;	chr19:37457005	chr19:37251912~37265535:+
PRAD	cis	rs9326248	0.52	rs6589602	ENSG00000254851.1	RP11-109L13.1	-14.23	2.98e-38	1e-34	-0.7	-0.55	Blood protein levels;	chr11:117166349	chr11:117135528~117138582:+
PRAD	cis	rs2929278	0.617	rs2955969	ENSG00000205771.5	CATSPER2P1	14.22	3.09e-38	1.04e-34	0.64	0.55	Schizophrenia;	chr15:43822329	chr15:43726918~43747094:-
PRAD	cis	rs9660180	0.875	rs4648727	ENSG00000231050.1	RP1-140A9.1	-14.22	3.19e-38	1.07e-34	-0.63	-0.55	Body mass index;	chr1:1844830	chr1:1891471~1892658:+
PRAD	cis	rs2929278	0.588	rs1975364	ENSG00000205771.5	CATSPER2P1	-14.22	3.21e-38	1.08e-34	-0.64	-0.55	Schizophrenia;	chr15:43857991	chr15:43726918~43747094:-
PRAD	cis	rs9487094	0.67	rs12194157	ENSG00000260273.1	RP11-425D10.10	14.22	3.3e-38	1.1e-34	0.74	0.55	Height;	chr6:109640141	chr6:109382795~109383666:+
PRAD	cis	rs9487094	0.67	rs12197950	ENSG00000260273.1	RP11-425D10.10	14.22	3.3e-38	1.1e-34	0.74	0.55	Height;	chr6:109642186	chr6:109382795~109383666:+
PRAD	cis	rs9487094	0.67	rs7767525	ENSG00000260273.1	RP11-425D10.10	14.22	3.3e-38	1.1e-34	0.74	0.55	Height;	chr6:109646187	chr6:109382795~109383666:+
PRAD	cis	rs9487094	0.504	rs71541003	ENSG00000260273.1	RP11-425D10.10	14.22	3.3e-38	1.1e-34	0.74	0.55	Height;	chr6:109652694	chr6:109382795~109383666:+
PRAD	cis	rs9487094	0.67	rs3899233	ENSG00000260273.1	RP11-425D10.10	14.22	3.3e-38	1.1e-34	0.74	0.55	Height;	chr6:109655791	chr6:109382795~109383666:+
PRAD	cis	rs2739330	0.731	rs2000468	ENSG00000250470.1	AP000351.3	14.21	3.32e-38	1.11e-34	0.75	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23976904~23977585:-
PRAD	cis	rs8072100	0.748	rs9912592	ENSG00000228782.6	CTD-2026D20.3	14.21	3.38e-38	1.13e-34	0.59	0.55	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47479579	chr17:47450568~47492492:-
PRAD	cis	rs992157	0.764	rs10932774	ENSG00000261338.2	RP11-378A13.1	14.21	3.42e-38	1.14e-34	0.64	0.55	Colorectal cancer;	chr2:218326846	chr2:218255319~218257366:+
PRAD	cis	rs9326248	0.501	rs4938351	ENSG00000254851.1	RP11-109L13.1	-14.21	3.43e-38	1.15e-34	-0.7	-0.55	Blood protein levels;	chr11:117151636	chr11:117135528~117138582:+
PRAD	cis	rs9322193	0.567	rs7742692	ENSG00000216906.2	RP11-350J20.9	14.21	3.54e-38	1.18e-34	0.64	0.55	Lung cancer;	chr6:149892363	chr6:149904243~149906418:+
PRAD	cis	rs7617773	0.817	rs9818937	ENSG00000229759.1	MRPS18AP1	14.21	3.55e-38	1.19e-34	0.6	0.55	Coronary artery disease;	chr3:48283791	chr3:48256350~48256938:-
PRAD	cis	rs71403859	0.803	rs17282500	ENSG00000260886.1	TAT-AS1	14.21	3.57e-38	1.19e-34	1.02	0.55	Post bronchodilator FEV1;	chr16:71599750	chr16:71565789~71578187:+
PRAD	cis	rs10256972	0.521	rs10280960	ENSG00000229043.2	AC091729.9	-14.21	3.62e-38	1.21e-34	-0.67	-0.55	Endometriosis;Longevity;	chr7:1064061	chr7:1160374~1165267:+
PRAD	cis	rs324126	0.78	rs2059817	ENSG00000277977.1	CTD-3018O17.5	14.2	3.65e-38	1.22e-34	0.62	0.55	Colonoscopy-negative controls vs population controls;	chr19:52379032	chr19:52392659~52392755:+
PRAD	cis	rs8037818	1	rs11071856	ENSG00000276724.1	RP11-1000B6.7	-14.2	3.65e-38	1.22e-34	-0.81	-0.55	Obesity-related traits;	chr15:32633591	chr15:32583612~32584312:+
PRAD	cis	rs875971	0.862	rs778686	ENSG00000226824.5	RP4-756H11.3	-14.2	3.77e-38	1.26e-34	-0.75	-0.55	Aortic root size;	chr7:66370923	chr7:66654538~66669855:+
PRAD	cis	rs17507216	0.628	rs28737193	ENSG00000278603.1	RP13-608F4.5	14.2	3.84e-38	1.28e-34	0.9	0.55	Excessive daytime sleepiness;	chr15:82701318	chr15:82472203~82472426:+
PRAD	cis	rs9487094	0.67	rs12194061	ENSG00000260273.1	RP11-425D10.10	14.2	3.9e-38	1.3e-34	0.74	0.55	Height;	chr6:109546439	chr6:109382795~109383666:+
PRAD	cis	rs6920372	0.731	rs2357124	ENSG00000260273.1	RP11-425D10.10	14.2	3.9e-38	1.3e-34	0.74	0.55	Height;	chr6:109551060	chr6:109382795~109383666:+
PRAD	cis	rs9487094	0.67	rs7755941	ENSG00000260273.1	RP11-425D10.10	14.2	3.94e-38	1.31e-34	0.74	0.55	Height;	chr6:109494148	chr6:109382795~109383666:+
PRAD	cis	rs9487094	0.626	rs12195904	ENSG00000260273.1	RP11-425D10.10	14.2	3.94e-38	1.31e-34	0.74	0.55	Height;	chr6:109494760	chr6:109382795~109383666:+
PRAD	cis	rs9326248	0.52	rs2735183	ENSG00000254851.1	RP11-109L13.1	-14.19	4.06e-38	1.35e-34	-0.7	-0.55	Blood protein levels;	chr11:117144479	chr11:117135528~117138582:+
PRAD	cis	rs10256972	0.758	rs4723649	ENSG00000229043.2	AC091729.9	-14.19	4.22e-38	1.4e-34	-0.69	-0.55	Endometriosis;Longevity;	chr7:1032269	chr7:1160374~1165267:+
PRAD	cis	rs7617773	0.779	rs9833309	ENSG00000229759.1	MRPS18AP1	14.19	4.3e-38	1.43e-34	0.6	0.55	Coronary artery disease;	chr3:48285960	chr3:48256350~48256938:-
PRAD	cis	rs2882667	0.898	rs3828600	ENSG00000253404.1	AC034243.1	14.19	4.36e-38	1.45e-34	0.74	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139051170	chr5:138744434~138753309:-
PRAD	cis	rs9487094	0.626	rs12192776	ENSG00000260273.1	RP11-425D10.10	14.19	4.39e-38	1.46e-34	0.74	0.55	Height;	chr6:109634150	chr6:109382795~109383666:+
PRAD	cis	rs11155671	0.53	rs7763849	ENSG00000216906.2	RP11-350J20.9	14.18	4.6e-38	1.52e-34	0.63	0.55	Testicular germ cell tumor;	chr6:149885244	chr6:149904243~149906418:+
PRAD	cis	rs9487094	0.67	rs2024853	ENSG00000260273.1	RP11-425D10.10	14.18	4.89e-38	1.62e-34	0.74	0.55	Height;	chr6:109498751	chr6:109382795~109383666:+
PRAD	cis	rs9487094	0.67	rs12197180	ENSG00000260273.1	RP11-425D10.10	14.18	4.89e-38	1.62e-34	0.74	0.55	Height;	chr6:109500687	chr6:109382795~109383666:+
PRAD	cis	rs6907340	0.517	rs9465531	ENSG00000228412.5	RP4-625H18.2	14.17	5.07e-38	1.68e-34	0.73	0.55	Endometriosis;	chr6:19798418	chr6:19802164~19804752:-
PRAD	cis	rs7617773	0.817	rs6794644	ENSG00000229759.1	MRPS18AP1	14.17	5.08e-38	1.68e-34	0.61	0.55	Coronary artery disease;	chr3:48288547	chr3:48256350~48256938:-
PRAD	cis	rs4722166	0.508	rs1474348	ENSG00000179428.2	AC073072.5	-14.17	5.17e-38	1.71e-34	-0.67	-0.55	Lung cancer;	chr7:22728289	chr7:22725395~22727620:-
PRAD	cis	rs11690935	1	rs35549875	ENSG00000228389.1	AC068039.4	-14.17	5.24e-38	1.73e-34	-0.67	-0.55	Schizophrenia;	chr2:171675882	chr2:171773482~171775844:+
PRAD	cis	rs992157	0.735	rs10932765	ENSG00000261338.2	RP11-378A13.1	14.17	5.33e-38	1.76e-34	0.64	0.55	Colorectal cancer;	chr2:218234761	chr2:218255319~218257366:+
PRAD	cis	rs324126	0.78	rs55748277	ENSG00000277977.1	CTD-3018O17.5	14.17	5.37e-38	1.77e-34	0.61	0.55	Colonoscopy-negative controls vs population controls;	chr19:52384992	chr19:52392659~52392755:+
PRAD	cis	rs2929278	0.617	rs3087657	ENSG00000205771.5	CATSPER2P1	-14.16	5.48e-38	1.81e-34	-0.64	-0.55	Schizophrenia;	chr15:43771661	chr15:43726918~43747094:-
PRAD	cis	rs62229266	0.633	rs743420	ENSG00000231106.2	LINC01436	14.16	5.77e-38	1.9e-34	0.68	0.55	Mitral valve prolapse;	chr21:36015104	chr21:36005338~36007838:+
PRAD	cis	rs8072100	0.817	rs9892497	ENSG00000228782.6	CTD-2026D20.3	14.16	5.84e-38	1.93e-34	0.59	0.55	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47468553	chr17:47450568~47492492:-
PRAD	cis	rs992157	0.735	rs13388024	ENSG00000261338.2	RP11-378A13.1	14.16	5.91e-38	1.95e-34	0.63	0.55	Colorectal cancer;	chr2:218233050	chr2:218255319~218257366:+
PRAD	cis	rs916888	0.647	rs199524	ENSG00000214401.4	KANSL1-AS1	-14.15	5.97e-38	1.97e-34	-0.8	-0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:46193576~46196723:+
PRAD	cis	rs7208859	0.51	rs216402	ENSG00000263531.1	RP13-753N3.1	14.15	6.1e-38	2.01e-34	1.15	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30590108	chr17:30863921~30864940:-
PRAD	cis	rs2111504	0.887	rs68013007	ENSG00000267213.4	AC007773.2	-14.15	6.1e-38	2.01e-34	-0.68	-0.55	Bipolar disorder;	chr19:32447775	chr19:32390050~32405560:-
PRAD	cis	rs9322193	0.504	rs7771014	ENSG00000216906.2	RP11-350J20.9	14.15	6.12e-38	2.02e-34	0.64	0.55	Lung cancer;	chr6:149884310	chr6:149904243~149906418:+
PRAD	cis	rs73086581	1	rs17214949	ENSG00000229539.1	RP11-119B16.2	14.15	6.19e-38	2.04e-34	0.93	0.55	Response to antidepressants in depression;	chr20:3960305	chr20:3888239~3888868:-
PRAD	cis	rs73086581	1	rs17215054	ENSG00000229539.1	RP11-119B16.2	14.15	6.19e-38	2.04e-34	0.93	0.55	Response to antidepressants in depression;	chr20:3964132	chr20:3888239~3888868:-
PRAD	cis	rs73086581	1	rs17287486	ENSG00000229539.1	RP11-119B16.2	14.15	6.19e-38	2.04e-34	0.93	0.55	Response to antidepressants in depression;	chr20:3965620	chr20:3888239~3888868:-
PRAD	cis	rs73086581	1	rs73086540	ENSG00000229539.1	RP11-119B16.2	14.15	6.19e-38	2.04e-34	0.93	0.55	Response to antidepressants in depression;	chr20:3970203	chr20:3888239~3888868:-
PRAD	cis	rs73086581	1	rs73086544	ENSG00000229539.1	RP11-119B16.2	14.15	6.19e-38	2.04e-34	0.93	0.55	Response to antidepressants in depression;	chr20:3970281	chr20:3888239~3888868:-
PRAD	cis	rs73086581	1	rs2326289	ENSG00000229539.1	RP11-119B16.2	14.15	6.19e-38	2.04e-34	0.93	0.55	Response to antidepressants in depression;	chr20:3971653	chr20:3888239~3888868:-
PRAD	cis	rs73086581	1	rs73086549	ENSG00000229539.1	RP11-119B16.2	14.15	6.19e-38	2.04e-34	0.93	0.55	Response to antidepressants in depression;	chr20:3974015	chr20:3888239~3888868:-
PRAD	cis	rs73086581	1	rs113812453	ENSG00000229539.1	RP11-119B16.2	14.15	6.19e-38	2.04e-34	0.93	0.55	Response to antidepressants in depression;	chr20:3982546	chr20:3888239~3888868:-
PRAD	cis	rs73086581	0.947	rs17287577	ENSG00000229539.1	RP11-119B16.2	14.15	6.19e-38	2.04e-34	0.93	0.55	Response to antidepressants in depression;	chr20:3985607	chr20:3888239~3888868:-
PRAD	cis	rs9487094	0.67	rs34928881	ENSG00000260273.1	RP11-425D10.10	14.14	6.9e-38	2.26e-34	0.73	0.55	Height;	chr6:109526846	chr6:109382795~109383666:+
PRAD	cis	rs324126	0.78	rs1993530	ENSG00000277977.1	CTD-3018O17.5	-14.14	6.9e-38	2.26e-34	-0.62	-0.55	Colonoscopy-negative controls vs population controls;	chr19:52381756	chr19:52392659~52392755:+
PRAD	cis	rs6504950	0.745	rs35079296	ENSG00000275710.1	RP11-257O5.4	14.14	6.92e-38	2.27e-34	0.75	0.55	Breast cancer;	chr17:54916849	chr17:54964474~54964679:+
PRAD	cis	rs2111504	0.583	rs1015839	ENSG00000267213.4	AC007773.2	14.14	7.1e-38	2.33e-34	0.58	0.55	Bipolar disorder;	chr19:32390365	chr19:32390050~32405560:-
PRAD	cis	rs67383717	0.777	rs591486	ENSG00000175611.10	LINC00476	-14.14	7.19e-38	2.35e-34	-0.64	-0.55	Parkinson's disease (pesticide exposure interaction);	chr9:95887764	chr9:95759231~95875977:-
PRAD	cis	rs916888	0.647	rs199523	ENSG00000214401.4	KANSL1-AS1	-14.13	7.29e-38	2.39e-34	-0.8	-0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:46193576~46196723:+
PRAD	cis	rs7617773	0.817	rs9853804	ENSG00000229759.1	MRPS18AP1	14.13	7.48e-38	2.45e-34	0.6	0.55	Coronary artery disease;	chr3:48286239	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.817	rs9834095	ENSG00000229759.1	MRPS18AP1	14.13	7.48e-38	2.45e-34	0.6	0.55	Coronary artery disease;	chr3:48286261	chr3:48256350~48256938:-
PRAD	cis	rs4722166	0.541	rs1800795	ENSG00000179428.2	AC073072.5	-14.13	7.69e-38	2.51e-34	-0.67	-0.55	Lung cancer;	chr7:22727026	chr7:22725395~22727620:-
PRAD	cis	rs7208859	0.573	rs216442	ENSG00000263531.1	RP13-753N3.1	14.13	7.92e-38	2.59e-34	1.15	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604179	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs216445	ENSG00000263531.1	RP13-753N3.1	14.13	7.92e-38	2.59e-34	1.15	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606558	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs216446	ENSG00000263531.1	RP13-753N3.1	14.13	7.92e-38	2.59e-34	1.15	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606700	chr17:30863921~30864940:-
PRAD	cis	rs2929278	0.617	rs694461	ENSG00000205771.5	CATSPER2P1	14.12	8.23e-38	2.69e-34	0.64	0.55	Schizophrenia;	chr15:43803865	chr15:43726918~43747094:-
PRAD	cis	rs9487094	0.67	rs10782163	ENSG00000260273.1	RP11-425D10.10	14.12	8.37e-38	2.73e-34	0.73	0.55	Height;	chr6:109533040	chr6:109382795~109383666:+
PRAD	cis	rs9487094	0.67	rs10457195	ENSG00000260273.1	RP11-425D10.10	14.12	8.37e-38	2.73e-34	0.73	0.55	Height;	chr6:109534269	chr6:109382795~109383666:+
PRAD	cis	rs9487094	0.67	rs11754455	ENSG00000260273.1	RP11-425D10.10	14.12	8.63e-38	2.82e-34	0.73	0.55	Height;	chr6:109496680	chr6:109382795~109383666:+
PRAD	cis	rs9487094	0.67	rs2024849	ENSG00000260273.1	RP11-425D10.10	14.12	8.63e-38	2.82e-34	0.73	0.55	Height;	chr6:109497088	chr6:109382795~109383666:+
PRAD	cis	rs7617773	0.817	rs4131361	ENSG00000229759.1	MRPS18AP1	14.12	8.71e-38	2.84e-34	0.6	0.55	Coronary artery disease;	chr3:48287322	chr3:48256350~48256938:-
PRAD	cis	rs8100891	0.537	rs10415145	ENSG00000267213.4	AC007773.2	14.12	8.72e-38	2.85e-34	0.69	0.55	Neuroticism;	chr19:32350147	chr19:32390050~32405560:-
PRAD	cis	rs7617773	0.78	rs9846818	ENSG00000229759.1	MRPS18AP1	14.11	8.9e-38	2.9e-34	0.58	0.55	Coronary artery disease;	chr3:48334195	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.817	rs6800492	ENSG00000229759.1	MRPS18AP1	14.11	8.92e-38	2.91e-34	0.6	0.55	Coronary artery disease;	chr3:48282400	chr3:48256350~48256938:-
PRAD	cis	rs9487094	0.666	rs12529733	ENSG00000260273.1	RP11-425D10.10	14.11	8.98e-38	2.93e-34	0.74	0.55	Height;	chr6:109332929	chr6:109382795~109383666:+
PRAD	cis	rs7617773	0.744	rs2125482	ENSG00000229759.1	MRPS18AP1	14.11	9.07e-38	2.96e-34	0.6	0.55	Coronary artery disease;	chr3:48281643	chr3:48256350~48256938:-
PRAD	cis	rs6907340	0.517	rs6939160	ENSG00000228412.5	RP4-625H18.2	14.11	9.41e-38	3.06e-34	0.73	0.55	Endometriosis;	chr6:19802086	chr6:19802164~19804752:-
PRAD	cis	rs9487094	0.67	rs1406899	ENSG00000260273.1	RP11-425D10.10	14.1	9.84e-38	3.2e-34	0.73	0.55	Height;	chr6:109495102	chr6:109382795~109383666:+
PRAD	cis	rs2882667	0.867	rs6868085	ENSG00000253404.1	AC034243.1	14.1	9.85e-38	3.2e-34	0.74	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139096757	chr5:138744434~138753309:-
PRAD	cis	rs10256972	0.721	rs6975972	ENSG00000229043.2	AC091729.9	-14.1	9.9e-38	3.22e-34	-0.69	-0.55	Endometriosis;Longevity;	chr7:1030832	chr7:1160374~1165267:+
PRAD	cis	rs71403859	1	rs71403859	ENSG00000260886.1	TAT-AS1	14.1	9.9e-38	3.22e-34	1.02	0.55	Post bronchodilator FEV1;	chr16:71606304	chr16:71565789~71578187:+
PRAD	cis	rs71403859	0.803	rs34381861	ENSG00000260886.1	TAT-AS1	14.1	9.9e-38	3.22e-34	1.02	0.55	Post bronchodilator FEV1;	chr16:71606327	chr16:71565789~71578187:+
PRAD	cis	rs11673344	0.566	rs11666708	ENSG00000226686.6	LINC01535	-14.1	1e-37	3.25e-34	-0.7	-0.55	Obesity-related traits;	chr19:37396208	chr19:37251912~37265535:+
PRAD	cis	rs7208859	0.623	rs170051	ENSG00000263531.1	RP13-753N3.1	14.1	1.01e-37	3.28e-34	1.15	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587135	chr17:30863921~30864940:-
PRAD	cis	rs11155671	0.53	rs7758033	ENSG00000231760.4	RP11-350J20.5	14.1	1.02e-37	3.32e-34	0.75	0.55	Testicular germ cell tumor;	chr6:149886999	chr6:149796151~149826294:-
PRAD	cis	rs977987	0.866	rs17696831	ENSG00000261783.1	RP11-252K23.2	-14.1	1.03e-37	3.34e-34	-0.76	-0.55	Dupuytren's disease;	chr16:75459400	chr16:75379818~75381260:-
PRAD	cis	rs1153858	1	rs2114501	ENSG00000259520.4	CTD-2651B20.3	-14.1	1.03e-37	3.34e-34	-0.72	-0.55	Homoarginine levels;	chr15:45378118	chr15:45251580~45279251:-
PRAD	cis	rs11155671	0.53	rs9383577	ENSG00000231760.4	RP11-350J20.5	14.1	1.05e-37	3.41e-34	0.74	0.55	Testicular germ cell tumor;	chr6:149886059	chr6:149796151~149826294:-
PRAD	cis	rs11155671	0.53	rs9383914	ENSG00000231760.4	RP11-350J20.5	14.1	1.05e-37	3.41e-34	0.74	0.55	Testicular germ cell tumor;	chr6:149886098	chr6:149796151~149826294:-
PRAD	cis	rs11155671	0.517	rs9397058	ENSG00000231760.4	RP11-350J20.5	14.1	1.05e-37	3.41e-34	0.74	0.55	Testicular germ cell tumor;	chr6:149886113	chr6:149796151~149826294:-
PRAD	cis	rs7208859	0.623	rs216434	ENSG00000263531.1	RP13-753N3.1	14.09	1.09e-37	3.53e-34	1.15	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595317	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs216436	ENSG00000263531.1	RP13-753N3.1	14.09	1.09e-37	3.53e-34	1.15	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595882	chr17:30863921~30864940:-
PRAD	cis	rs801193	0.569	rs7782587	ENSG00000226824.5	RP4-756H11.3	-14.09	1.1e-37	3.55e-34	-0.76	-0.55	Aortic root size;	chr7:66701485	chr7:66654538~66669855:+
PRAD	cis	rs62229266	0.659	rs2835258	ENSG00000231106.2	LINC01436	14.09	1.15e-37	3.71e-34	0.68	0.55	Mitral valve prolapse;	chr21:36052067	chr21:36005338~36007838:+
PRAD	cis	rs73086581	1	rs56141565	ENSG00000229539.1	RP11-119B16.2	14.09	1.16e-37	3.75e-34	0.96	0.55	Response to antidepressants in depression;	chr20:4017956	chr20:3888239~3888868:-
PRAD	cis	rs9660180	0.868	rs72634846	ENSG00000268575.1	RP1-283E3.8	-14.09	1.18e-37	3.81e-34	-0.58	-0.55	Body mass index;	chr1:1773476	chr1:1702736~1737688:-
PRAD	cis	rs977987	0.931	rs11641430	ENSG00000261783.1	RP11-252K23.2	-14.08	1.22e-37	3.95e-34	-0.75	-0.55	Dupuytren's disease;	chr16:75461378	chr16:75379818~75381260:-
PRAD	cis	rs977987	0.931	rs7195161	ENSG00000261783.1	RP11-252K23.2	-14.08	1.22e-37	3.95e-34	-0.75	-0.55	Dupuytren's disease;	chr16:75461674	chr16:75379818~75381260:-
PRAD	cis	rs524281	0.773	rs7945723	ENSG00000255320.1	RP11-755F10.1	14.08	1.27e-37	4.09e-34	0.93	0.55	Electroencephalogram traits;	chr11:66288986	chr11:66244840~66246239:-
PRAD	cis	rs2153535	0.58	rs9393022	ENSG00000230939.1	RP11-314C16.1	-14.08	1.27e-37	4.09e-34	-0.69	-0.55	Motion sickness;	chr6:8466355	chr6:8784178~8785445:+
PRAD	cis	rs9487094	0.621	rs9398202	ENSG00000260273.1	RP11-425D10.10	14.07	1.33e-37	4.28e-34	0.74	0.55	Height;	chr6:109458989	chr6:109382795~109383666:+
PRAD	cis	rs7208859	0.623	rs216439	ENSG00000263531.1	RP13-753N3.1	14.07	1.41e-37	4.55e-34	1.15	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30600866	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs609063	ENSG00000263531.1	RP13-753N3.1	14.07	1.41e-37	4.55e-34	1.15	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624495	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs383436	ENSG00000263531.1	RP13-753N3.1	14.07	1.41e-37	4.55e-34	1.15	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30632161	chr17:30863921~30864940:-
PRAD	cis	rs2581828	0.656	rs34530577	ENSG00000242142.1	SERBP1P3	14.06	1.47e-37	4.73e-34	0.61	0.55	Crohn's disease;	chr3:53069780	chr3:53064283~53065091:-
PRAD	cis	rs2153535	0.601	rs7738877	ENSG00000230939.1	RP11-314C16.1	-14.06	1.48e-37	4.75e-34	-0.67	-0.55	Motion sickness;	chr6:8541997	chr6:8784178~8785445:+
PRAD	cis	rs7617773	0.817	rs6791930	ENSG00000229759.1	MRPS18AP1	14.06	1.48e-37	4.75e-34	0.6	0.55	Coronary artery disease;	chr3:48288410	chr3:48256350~48256938:-
PRAD	cis	rs3814244	0.569	rs11177008	ENSG00000255733.4	IFNG-AS1	14.06	1.49e-37	4.8e-34	0.61	0.55	Itch intensity from mosquito bite adjusted by bite size;	chr12:68021024	chr12:67989445~68234686:+
PRAD	cis	rs9487094	0.67	rs749517	ENSG00000260273.1	RP11-425D10.10	-14.06	1.54e-37	4.94e-34	-0.74	-0.55	Height;	chr6:109531713	chr6:109382795~109383666:+
PRAD	cis	rs2739330	0.76	rs5760095	ENSG00000231271.1	AP000350.8	14.06	1.55e-37	4.96e-34	0.74	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23949918~23954042:+
PRAD	cis	rs2283792	0.967	rs5755099	ENSG00000224086.5	LL22NC03-86G7.1	-14.06	1.58e-37	5.08e-34	-0.63	-0.55	Multiple sclerosis;	chr22:21770751	chr22:21938293~21977632:+
PRAD	cis	rs11155671	0.53	rs9383912	ENSG00000231760.4	RP11-350J20.5	14.05	1.61e-37	5.15e-34	0.74	0.55	Testicular germ cell tumor;	chr6:149885479	chr6:149796151~149826294:-
PRAD	cis	rs11155671	0.53	rs7768626	ENSG00000231760.4	RP11-350J20.5	14.05	1.61e-37	5.15e-34	0.74	0.55	Testicular germ cell tumor;	chr6:149886826	chr6:149796151~149826294:-
PRAD	cis	rs11155671	0.53	rs7768665	ENSG00000231760.4	RP11-350J20.5	14.05	1.61e-37	5.15e-34	0.74	0.55	Testicular germ cell tumor;	chr6:149886888	chr6:149796151~149826294:-
PRAD	cis	rs11155671	0.53	rs7758020	ENSG00000231760.4	RP11-350J20.5	14.05	1.61e-37	5.15e-34	0.74	0.55	Testicular germ cell tumor;	chr6:149886975	chr6:149796151~149826294:-
PRAD	cis	rs73086581	1	rs73086505	ENSG00000229539.1	RP11-119B16.2	14.05	1.61e-37	5.16e-34	0.94	0.55	Response to antidepressants in depression;	chr20:3940924	chr20:3888239~3888868:-
PRAD	cis	rs73086581	1	rs73086508	ENSG00000229539.1	RP11-119B16.2	14.05	1.61e-37	5.16e-34	0.94	0.55	Response to antidepressants in depression;	chr20:3941068	chr20:3888239~3888868:-
PRAD	cis	rs73086581	1	rs73086510	ENSG00000229539.1	RP11-119B16.2	14.05	1.61e-37	5.16e-34	0.94	0.55	Response to antidepressants in depression;	chr20:3941484	chr20:3888239~3888868:-
PRAD	cis	rs977987	0.966	rs6564261	ENSG00000261783.1	RP11-252K23.2	-14.05	1.64e-37	5.25e-34	-0.75	-0.55	Dupuytren's disease;	chr16:75458344	chr16:75379818~75381260:-
PRAD	cis	rs7847628	0.765	rs10985024	ENSG00000226752.6	PSMD5-AS1	-14.05	1.64e-37	5.26e-34	-0.7	-0.55	Birth weight;	chr9:120754534	chr9:120824828~120854385:+
PRAD	cis	rs7208859	0.623	rs11651857	ENSG00000263531.1	RP13-753N3.1	14.05	1.67e-37	5.35e-34	1.15	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30599344	chr17:30863921~30864940:-
PRAD	cis	rs875971	0.862	rs778724	ENSG00000226824.5	RP4-756H11.3	-14.05	1.69e-37	5.41e-34	-0.75	-0.55	Aortic root size;	chr7:66364304	chr7:66654538~66669855:+
PRAD	cis	rs324126	0.78	rs62108318	ENSG00000277977.1	CTD-3018O17.5	14.04	1.81e-37	5.78e-34	0.61	0.55	Colonoscopy-negative controls vs population controls;	chr19:52380322	chr19:52392659~52392755:+
PRAD	cis	rs12022452	0.822	rs11208390	ENSG00000238287.1	RP11-656D10.3	-14.04	1.82e-37	5.82e-34	-0.89	-0.55	Age-related hearing impairment (SNP x SNP interaction);	chr1:40556342	chr1:40493157~40508661:-
PRAD	cis	rs9660180	0.836	rs72634845	ENSG00000268575.1	RP1-283E3.8	-14.04	1.82e-37	5.83e-34	-0.58	-0.55	Body mass index;	chr1:1773460	chr1:1702736~1737688:-
PRAD	cis	rs73086581	1	rs73086535	ENSG00000229539.1	RP11-119B16.2	14.04	1.83e-37	5.85e-34	0.92	0.55	Response to antidepressants in depression;	chr20:3963503	chr20:3888239~3888868:-
PRAD	cis	rs73086581	0.947	rs55794220	ENSG00000229539.1	RP11-119B16.2	14.04	1.83e-37	5.85e-34	0.92	0.55	Response to antidepressants in depression;	chr20:3975755	chr20:3888239~3888868:-
PRAD	cis	rs73086581	0.891	rs55871214	ENSG00000229539.1	RP11-119B16.2	14.04	1.83e-37	5.85e-34	0.92	0.55	Response to antidepressants in depression;	chr20:3985059	chr20:3888239~3888868:-
PRAD	cis	rs73086581	1	rs56069856	ENSG00000229539.1	RP11-119B16.2	14.04	1.83e-37	5.85e-34	0.92	0.55	Response to antidepressants in depression;	chr20:3985062	chr20:3888239~3888868:-
PRAD	cis	rs916888	0.531	rs183211	ENSG00000214401.4	KANSL1-AS1	14.04	1.86e-37	5.95e-34	0.77	0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:46193576~46196723:+
PRAD	cis	rs524281	0.731	rs2276036	ENSG00000255320.1	RP11-755F10.1	14.04	1.86e-37	5.96e-34	0.93	0.55	Electroencephalogram traits;	chr11:66265959	chr11:66244840~66246239:-
PRAD	cis	rs992157	0.735	rs13430006	ENSG00000261338.2	RP11-378A13.1	-14.04	1.86e-37	5.96e-34	-0.63	-0.55	Colorectal cancer;	chr2:218248366	chr2:218255319~218257366:+
PRAD	cis	rs9322193	0.504	rs7771014	ENSG00000231760.4	RP11-350J20.5	14.04	1.89e-37	6.05e-34	0.75	0.55	Lung cancer;	chr6:149884310	chr6:149796151~149826294:-
PRAD	cis	rs12022452	0.822	rs6600343	ENSG00000238287.1	RP11-656D10.3	-14.04	1.9e-37	6.07e-34	-0.89	-0.55	Age-related hearing impairment (SNP x SNP interaction);	chr1:40562538	chr1:40493157~40508661:-
PRAD	cis	rs494459	0.688	rs1048040	ENSG00000255239.1	AP002954.6	14.03	1.99e-37	6.36e-34	0.71	0.55	Height;	chr11:118747911	chr11:118688039~118690600:-
PRAD	cis	rs7617773	0.817	rs4131362	ENSG00000229759.1	MRPS18AP1	14.02	2.24e-37	7.16e-34	0.6	0.55	Coronary artery disease;	chr3:48287546	chr3:48256350~48256938:-
PRAD	cis	rs7188445	1	rs16950982	ENSG00000261390.4	RP11-345M22.2	-14.02	2.29e-37	7.31e-34	-0.7	-0.55	Urate levels;	chr16:79668474	chr16:79715232~79770563:-
PRAD	cis	rs7208859	0.673	rs9889755	ENSG00000263531.1	RP13-753N3.1	-14.02	2.36e-37	7.53e-34	-0.99	-0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30907487	chr17:30863921~30864940:-
PRAD	cis	rs916888	0.61	rs199438	ENSG00000214401.4	KANSL1-AS1	14.01	2.37e-37	7.57e-34	0.77	0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:46193576~46196723:+
PRAD	cis	rs73086581	1	rs73086581	ENSG00000229539.1	RP11-119B16.2	14.01	2.38e-37	7.58e-34	0.93	0.55	Response to antidepressants in depression;	chr20:3996678	chr20:3888239~3888868:-
PRAD	cis	rs9487094	0.689	rs9487066	ENSG00000260273.1	RP11-425D10.10	14.01	2.38e-37	7.58e-34	0.74	0.55	Height;	chr6:109347707	chr6:109382795~109383666:+
PRAD	cis	rs62229266	0.557	rs4817760	ENSG00000231106.2	LINC01436	14.01	2.47e-37	7.85e-34	0.74	0.55	Mitral valve prolapse;	chr21:36023003	chr21:36005338~36007838:+
PRAD	cis	rs62229266	0.625	rs2051395	ENSG00000231106.2	LINC01436	-14.01	2.6e-37	8.28e-34	-0.67	-0.55	Mitral valve prolapse;	chr21:36058967	chr21:36005338~36007838:+
PRAD	cis	rs494459	0.838	rs1784543	ENSG00000255239.1	AP002954.6	14	2.77e-37	8.8e-34	0.7	0.55	Height;	chr11:118760944	chr11:118688039~118690600:-
PRAD	cis	rs2455601	0.744	rs2163626	ENSG00000254860.4	TMEM9B-AS1	14	2.84e-37	9.01e-34	0.64	0.55	Schizophrenia;	chr11:8962000	chr11:8964675~8977527:+
PRAD	cis	rs7044106	0.791	rs10985004	ENSG00000226752.6	PSMD5-AS1	-14	2.87e-37	9.09e-34	-0.68	-0.55	Hip circumference adjusted for BMI;	chr9:120722659	chr9:120824828~120854385:+
PRAD	cis	rs10256972	0.521	rs871019	ENSG00000229043.2	AC091729.9	-14	2.88e-37	9.14e-34	-0.66	-0.55	Endometriosis;Longevity;	chr7:1065594	chr7:1160374~1165267:+
PRAD	cis	rs11155671	0.53	rs9322228	ENSG00000231760.4	RP11-350J20.5	13.99	2.89e-37	9.16e-34	0.74	0.55	Testicular germ cell tumor;	chr6:149888173	chr6:149796151~149826294:-
PRAD	cis	rs11155671	0.53	rs7774787	ENSG00000231760.4	RP11-350J20.5	13.99	2.89e-37	9.16e-34	0.74	0.55	Testicular germ cell tumor;	chr6:149888296	chr6:149796151~149826294:-
PRAD	cis	rs11155671	0.53	rs2342767	ENSG00000231760.4	RP11-350J20.5	13.99	2.89e-37	9.16e-34	0.74	0.55	Testicular germ cell tumor;	chr6:149888581	chr6:149796151~149826294:-
PRAD	cis	rs11155671	0.53	rs7764376	ENSG00000231760.4	RP11-350J20.5	13.99	2.89e-37	9.16e-34	0.74	0.55	Testicular germ cell tumor;	chr6:149889208	chr6:149796151~149826294:-
PRAD	cis	rs11155671	0.53	rs6933882	ENSG00000231760.4	RP11-350J20.5	13.99	2.89e-37	9.16e-34	0.74	0.55	Testicular germ cell tumor;	chr6:149889666	chr6:149796151~149826294:-
PRAD	cis	rs11155671	0.53	rs6939761	ENSG00000231760.4	RP11-350J20.5	13.99	2.89e-37	9.16e-34	0.74	0.55	Testicular germ cell tumor;	chr6:149889858	chr6:149796151~149826294:-
PRAD	cis	rs11155671	0.53	rs3823021	ENSG00000231760.4	RP11-350J20.5	13.99	2.89e-37	9.16e-34	0.74	0.55	Testicular germ cell tumor;	chr6:149889863	chr6:149796151~149826294:-
PRAD	cis	rs11155671	0.53	rs4869763	ENSG00000231760.4	RP11-350J20.5	13.99	2.89e-37	9.16e-34	0.74	0.55	Testicular germ cell tumor;	chr6:149890548	chr6:149796151~149826294:-
PRAD	cis	rs11155671	0.53	rs4869764	ENSG00000231760.4	RP11-350J20.5	13.99	2.89e-37	9.16e-34	0.74	0.55	Testicular germ cell tumor;	chr6:149890692	chr6:149796151~149826294:-
PRAD	cis	rs9399135	0.967	rs1590975	ENSG00000232876.1	CTA-212D2.2	-13.99	2.9e-37	9.2e-34	-0.67	-0.55	Red blood cell count;	chr6:135030950	chr6:135055033~135060550:+
PRAD	cis	rs10256972	0.616	rs6463001	ENSG00000229043.2	AC091729.9	-13.99	2.94e-37	9.32e-34	-0.66	-0.55	Endometriosis;Longevity;	chr7:1068636	chr7:1160374~1165267:+
PRAD	cis	rs2153535	0.58	rs1932280	ENSG00000230939.1	RP11-314C16.1	-13.99	2.99e-37	9.47e-34	-0.68	-0.55	Motion sickness;	chr6:8473421	chr6:8784178~8785445:+
PRAD	cis	rs524281	0.773	rs11227447	ENSG00000255320.1	RP11-755F10.1	13.99	3.04e-37	9.64e-34	0.93	0.55	Electroencephalogram traits;	chr11:66280809	chr11:66244840~66246239:-
PRAD	cis	rs875971	0.862	rs11773628	ENSG00000226824.5	RP4-756H11.3	13.99	3.07e-37	9.73e-34	0.74	0.55	Aortic root size;	chr7:66517644	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.862	rs6460302	ENSG00000226824.5	RP4-756H11.3	-13.99	3.14e-37	9.92e-34	-0.74	-0.55	Aortic root size;	chr7:66495270	chr7:66654538~66669855:+
PRAD	cis	rs7617773	0.817	rs745116	ENSG00000229759.1	MRPS18AP1	13.98	3.33e-37	1.05e-33	0.59	0.55	Coronary artery disease;	chr3:48231046	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.78	rs71323396	ENSG00000229759.1	MRPS18AP1	13.98	3.37e-37	1.06e-33	0.6	0.55	Coronary artery disease;	chr3:48333244	chr3:48256350~48256938:-
PRAD	cis	rs494459	0.838	rs607125	ENSG00000255239.1	AP002954.6	13.98	3.37e-37	1.07e-33	0.7	0.55	Height;	chr11:118746590	chr11:118688039~118690600:-
PRAD	cis	rs916888	0.61	rs199453	ENSG00000262500.1	RP11-259G18.2	13.98	3.38e-37	1.07e-33	0.72	0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:46243606~46245044:+
PRAD	cis	rs1577917	0.771	rs2484355	ENSG00000203875.9	SNHG5	-13.97	3.7e-37	1.17e-33	-0.61	-0.55	Response to antipsychotic treatment;	chr6:85684685	chr6:85660950~85678736:-
PRAD	cis	rs11155671	0.53	rs1334510	ENSG00000231760.4	RP11-350J20.5	13.97	3.72e-37	1.17e-33	0.75	0.55	Testicular germ cell tumor;	chr6:149880043	chr6:149796151~149826294:-
PRAD	cis	rs73086581	0.68	rs11908158	ENSG00000229539.1	RP11-119B16.2	13.97	3.74e-37	1.18e-33	0.89	0.55	Response to antidepressants in depression;	chr20:3956025	chr20:3888239~3888868:-
PRAD	cis	rs2581828	0.656	rs2581782	ENSG00000242142.1	SERBP1P3	13.97	3.75e-37	1.18e-33	0.61	0.55	Crohn's disease;	chr3:53088241	chr3:53064283~53065091:-
PRAD	cis	rs2581828	0.656	rs2581783	ENSG00000242142.1	SERBP1P3	13.97	3.75e-37	1.18e-33	0.61	0.55	Crohn's disease;	chr3:53088242	chr3:53064283~53065091:-
PRAD	cis	rs2882667	0.898	rs6863347	ENSG00000253404.1	AC034243.1	13.96	3.93e-37	1.24e-33	0.74	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139025446	chr5:138744434~138753309:-
PRAD	cis	rs2153535	0.56	rs9379214	ENSG00000230939.1	RP11-314C16.1	-13.96	3.95e-37	1.24e-33	-0.68	-0.55	Motion sickness;	chr6:8480637	chr6:8784178~8785445:+
PRAD	cis	rs7617773	0.817	rs9847953	ENSG00000229759.1	MRPS18AP1	13.96	3.96e-37	1.25e-33	0.59	0.55	Coronary artery disease;	chr3:48241205	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.817	rs11710861	ENSG00000229759.1	MRPS18AP1	13.96	3.96e-37	1.25e-33	0.59	0.55	Coronary artery disease;	chr3:48256070	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.784	rs9850672	ENSG00000229759.1	MRPS18AP1	13.96	3.96e-37	1.25e-33	0.59	0.55	Coronary artery disease;	chr3:48259682	chr3:48256350~48256938:-
PRAD	cis	rs992157	0.71	rs10167446	ENSG00000261338.2	RP11-378A13.1	13.96	3.97e-37	1.25e-33	0.62	0.55	Colorectal cancer;	chr2:218192143	chr2:218255319~218257366:+
PRAD	cis	rs2283792	1	rs3788332	ENSG00000224086.5	LL22NC03-86G7.1	-13.96	4.17e-37	1.31e-33	-0.64	-0.55	Multiple sclerosis;	chr22:21817278	chr22:21938293~21977632:+
PRAD	cis	rs9660180	0.846	rs10907195	ENSG00000268575.1	RP1-283E3.8	13.96	4.24e-37	1.33e-33	0.58	0.55	Body mass index;	chr1:1781909	chr1:1702736~1737688:-
PRAD	cis	rs2153535	0.58	rs1119688	ENSG00000230939.1	RP11-314C16.1	-13.95	4.29e-37	1.35e-33	-0.68	-0.55	Motion sickness;	chr6:8460617	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.541	rs6923558	ENSG00000230939.1	RP11-314C16.1	-13.95	4.29e-37	1.35e-33	-0.68	-0.55	Motion sickness;	chr6:8461234	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs1577470	ENSG00000230939.1	RP11-314C16.1	-13.95	4.29e-37	1.35e-33	-0.68	-0.55	Motion sickness;	chr6:8462193	chr6:8784178~8785445:+
PRAD	cis	rs875971	0.862	rs11763189	ENSG00000226824.5	RP4-756H11.3	-13.95	4.31e-37	1.35e-33	-0.74	-0.55	Aortic root size;	chr7:66518542	chr7:66654538~66669855:+
PRAD	cis	rs1153858	1	rs2467864	ENSG00000259520.4	CTD-2651B20.3	13.95	4.35e-37	1.37e-33	0.72	0.55	Homoarginine levels;	chr15:45348900	chr15:45251580~45279251:-
PRAD	cis	rs2153535	0.58	rs763376	ENSG00000230939.1	RP11-314C16.1	-13.95	4.36e-37	1.37e-33	-0.68	-0.55	Motion sickness;	chr6:8492543	chr6:8784178~8785445:+
PRAD	cis	rs916888	0.61	rs199452	ENSG00000262500.1	RP11-259G18.2	13.95	4.39e-37	1.38e-33	0.71	0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:46243606~46245044:+
PRAD	cis	rs2153535	0.58	rs6905242	ENSG00000230939.1	RP11-314C16.1	-13.95	4.49e-37	1.41e-33	-0.68	-0.55	Motion sickness;	chr6:8471566	chr6:8784178~8785445:+
PRAD	cis	rs62229266	0.557	rs4817761	ENSG00000231106.2	LINC01436	13.95	4.62e-37	1.45e-33	0.73	0.55	Mitral valve prolapse;	chr21:36023258	chr21:36005338~36007838:+
PRAD	cis	rs2153535	0.58	rs9406158	ENSG00000230939.1	RP11-314C16.1	-13.95	4.64e-37	1.45e-33	-0.68	-0.55	Motion sickness;	chr6:8463919	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs9406159	ENSG00000230939.1	RP11-314C16.1	-13.95	4.64e-37	1.45e-33	-0.68	-0.55	Motion sickness;	chr6:8464626	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs1335637	ENSG00000230939.1	RP11-314C16.1	-13.95	4.64e-37	1.45e-33	-0.68	-0.55	Motion sickness;	chr6:8464868	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs9406162	ENSG00000230939.1	RP11-314C16.1	-13.95	4.64e-37	1.45e-33	-0.68	-0.55	Motion sickness;	chr6:8465963	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.541	rs9392222	ENSG00000230939.1	RP11-314C16.1	-13.95	4.64e-37	1.45e-33	-0.68	-0.55	Motion sickness;	chr6:8467416	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.541	rs6932434	ENSG00000230939.1	RP11-314C16.1	-13.95	4.64e-37	1.45e-33	-0.68	-0.55	Motion sickness;	chr6:8467446	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs1034273	ENSG00000230939.1	RP11-314C16.1	-13.95	4.64e-37	1.45e-33	-0.68	-0.55	Motion sickness;	chr6:8467912	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.541	rs9328471	ENSG00000230939.1	RP11-314C16.1	-13.95	4.64e-37	1.45e-33	-0.68	-0.55	Motion sickness;	chr6:8468609	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.601	rs9505451	ENSG00000230939.1	RP11-314C16.1	-13.95	4.64e-37	1.45e-33	-0.68	-0.55	Motion sickness;	chr6:8469717	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs9393023	ENSG00000230939.1	RP11-314C16.1	-13.95	4.64e-37	1.45e-33	-0.68	-0.55	Motion sickness;	chr6:8469761	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs1414346	ENSG00000230939.1	RP11-314C16.1	-13.95	4.64e-37	1.45e-33	-0.68	-0.55	Motion sickness;	chr6:8471341	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs1932279	ENSG00000230939.1	RP11-314C16.1	-13.95	4.64e-37	1.45e-33	-0.68	-0.55	Motion sickness;	chr6:8473420	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs2152347	ENSG00000230939.1	RP11-314C16.1	-13.95	4.64e-37	1.45e-33	-0.68	-0.55	Motion sickness;	chr6:8474048	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs9379213	ENSG00000230939.1	RP11-314C16.1	-13.95	4.64e-37	1.45e-33	-0.68	-0.55	Motion sickness;	chr6:8474712	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs9505457	ENSG00000230939.1	RP11-314C16.1	-13.95	4.64e-37	1.45e-33	-0.68	-0.55	Motion sickness;	chr6:8478909	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs2225765	ENSG00000230939.1	RP11-314C16.1	-13.95	4.64e-37	1.45e-33	-0.68	-0.55	Motion sickness;	chr6:8481552	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs1577472	ENSG00000230939.1	RP11-314C16.1	-13.95	4.64e-37	1.45e-33	-0.68	-0.55	Motion sickness;	chr6:8485982	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.542	rs1120393	ENSG00000230939.1	RP11-314C16.1	-13.95	4.64e-37	1.45e-33	-0.68	-0.55	Motion sickness;	chr6:8486657	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.563	rs4428546	ENSG00000230939.1	RP11-314C16.1	-13.95	4.64e-37	1.45e-33	-0.68	-0.55	Motion sickness;	chr6:8490143	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.505	rs1335629	ENSG00000230939.1	RP11-314C16.1	-13.95	4.64e-37	1.45e-33	-0.68	-0.55	Motion sickness;	chr6:8491630	chr6:8784178~8785445:+
PRAD	cis	rs9660180	0.967	rs2272908	ENSG00000268575.1	RP1-283E3.8	13.94	5.01e-37	1.57e-33	0.56	0.55	Body mass index;	chr1:1790040	chr1:1702736~1737688:-
PRAD	cis	rs2153535	0.58	rs6421948	ENSG00000230939.1	RP11-314C16.1	-13.94	5.07e-37	1.59e-33	-0.68	-0.55	Motion sickness;	chr6:8530787	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs6421949	ENSG00000230939.1	RP11-314C16.1	-13.94	5.07e-37	1.59e-33	-0.68	-0.55	Motion sickness;	chr6:8531536	chr6:8784178~8785445:+
PRAD	cis	rs9660180	0.783	rs1107910	ENSG00000231050.1	RP1-140A9.1	13.94	5.1e-37	1.6e-33	0.62	0.55	Body mass index;	chr1:1760882	chr1:1891471~1892658:+
PRAD	cis	rs11155671	0.53	rs4870080	ENSG00000231760.4	RP11-350J20.5	13.94	5.19e-37	1.62e-33	0.74	0.55	Testicular germ cell tumor;	chr6:149881508	chr6:149796151~149826294:-
PRAD	cis	rs4722166	0.508	rs2069832	ENSG00000179428.2	AC073072.5	-13.93	5.29e-37	1.65e-33	-0.67	-0.55	Lung cancer;	chr7:22727814	chr7:22725395~22727620:-
PRAD	cis	rs1800795	0.901	rs2069833	ENSG00000179428.2	AC073072.5	-13.93	5.29e-37	1.65e-33	-0.67	-0.55	Cerebrospinal fluid clusterin levels in APOEe4- carriers;	chr7:22728045	chr7:22725395~22727620:-
PRAD	cis	rs2412819	0.599	rs2470120	ENSG00000205771.5	CATSPER2P1	-13.93	5.31e-37	1.66e-33	-0.63	-0.55	Lung cancer;	chr15:43636872	chr15:43726918~43747094:-
PRAD	cis	rs324126	0.78	rs34425941	ENSG00000277977.1	CTD-3018O17.5	13.93	5.4e-37	1.69e-33	0.61	0.55	Colonoscopy-negative controls vs population controls;	chr19:52377359	chr19:52392659~52392755:+
PRAD	cis	rs916888	0.647	rs199449	ENSG00000262500.1	RP11-259G18.2	13.93	5.48e-37	1.71e-33	0.73	0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:46243606~46245044:+
PRAD	cis	rs916888	0.61	rs199444	ENSG00000262500.1	RP11-259G18.2	13.93	5.48e-37	1.71e-33	0.73	0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:46243606~46245044:+
PRAD	cis	rs916888	0.61	rs199442	ENSG00000262500.1	RP11-259G18.2	13.93	5.48e-37	1.71e-33	0.73	0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:46243606~46245044:+
PRAD	cis	rs524281	0.731	rs476551	ENSG00000255320.1	RP11-755F10.1	13.93	5.59e-37	1.74e-33	0.9	0.55	Electroencephalogram traits;	chr11:66238852	chr11:66244840~66246239:-
PRAD	cis	rs62229266	0.609	rs12482541	ENSG00000231106.2	LINC01436	13.93	5.69e-37	1.77e-33	0.67	0.55	Mitral valve prolapse;	chr21:36047445	chr21:36005338~36007838:+
PRAD	cis	rs62229266	0.609	rs2835253	ENSG00000231106.2	LINC01436	13.93	5.69e-37	1.77e-33	0.67	0.55	Mitral valve prolapse;	chr21:36047447	chr21:36005338~36007838:+
PRAD	cis	rs73086581	1	rs3746666	ENSG00000229539.1	RP11-119B16.2	13.92	5.76e-37	1.8e-33	0.93	0.55	Response to antidepressants in depression;	chr20:3930214	chr20:3888239~3888868:-
PRAD	cis	rs73086581	1	rs17286349	ENSG00000229539.1	RP11-119B16.2	13.92	5.76e-37	1.8e-33	0.93	0.55	Response to antidepressants in depression;	chr20:3933655	chr20:3888239~3888868:-
PRAD	cis	rs524281	0.773	rs2155030	ENSG00000255320.1	RP11-755F10.1	13.92	5.88e-37	1.83e-33	0.93	0.55	Electroencephalogram traits;	chr11:66263216	chr11:66244840~66246239:-
PRAD	cis	rs524281	0.773	rs2155031	ENSG00000255320.1	RP11-755F10.1	13.92	5.88e-37	1.83e-33	0.93	0.55	Electroencephalogram traits;	chr11:66263456	chr11:66244840~66246239:-
PRAD	cis	rs524281	0.773	rs2298468	ENSG00000255320.1	RP11-755F10.1	13.92	5.88e-37	1.83e-33	0.93	0.55	Electroencephalogram traits;	chr11:66275491	chr11:66244840~66246239:-
PRAD	cis	rs524281	0.773	rs79770412	ENSG00000255320.1	RP11-755F10.1	13.92	5.88e-37	1.83e-33	0.93	0.55	Electroencephalogram traits;	chr11:66277873	chr11:66244840~66246239:-
PRAD	cis	rs8100891	0.537	rs1030094	ENSG00000267213.4	AC007773.2	-13.92	5.91e-37	1.84e-33	-0.67	-0.55	Neuroticism;	chr19:32419525	chr19:32390050~32405560:-
PRAD	cis	rs9487094	0.689	rs9487064	ENSG00000260273.1	RP11-425D10.10	13.92	5.95e-37	1.85e-33	0.74	0.55	Height;	chr6:109346560	chr6:109382795~109383666:+
PRAD	cis	rs524281	0.773	rs2282568	ENSG00000255320.1	RP11-755F10.1	13.92	6.1e-37	1.9e-33	0.93	0.55	Electroencephalogram traits;	chr11:66285361	chr11:66244840~66246239:-
PRAD	cis	rs11155671	0.53	rs9397420	ENSG00000231760.4	RP11-350J20.5	-13.91	6.37e-37	1.98e-33	-0.74	-0.55	Testicular germ cell tumor;	chr6:149885645	chr6:149796151~149826294:-
PRAD	cis	rs977987	0.902	rs34539062	ENSG00000261783.1	RP11-252K23.2	-13.91	6.5e-37	2.02e-33	-0.75	-0.55	Dupuytren's disease;	chr16:75459381	chr16:75379818~75381260:-
PRAD	cis	rs977987	0.898	rs12918797	ENSG00000261783.1	RP11-252K23.2	-13.91	6.5e-37	2.02e-33	-0.75	-0.55	Dupuytren's disease;	chr16:75459912	chr16:75379818~75381260:-
PRAD	cis	rs977987	0.898	rs12918974	ENSG00000261783.1	RP11-252K23.2	-13.91	6.5e-37	2.02e-33	-0.75	-0.55	Dupuytren's disease;	chr16:75460045	chr16:75379818~75381260:-
PRAD	cis	rs977987	0.866	rs12932606	ENSG00000261783.1	RP11-252K23.2	-13.91	6.5e-37	2.02e-33	-0.75	-0.55	Dupuytren's disease;	chr16:75460046	chr16:75379818~75381260:-
PRAD	cis	rs62229266	0.659	rs62230814	ENSG00000231106.2	LINC01436	13.91	6.6e-37	2.05e-33	0.67	0.55	Mitral valve prolapse;	chr21:36031248	chr21:36005338~36007838:+
PRAD	cis	rs62229266	0.633	rs34259635	ENSG00000231106.2	LINC01436	13.91	6.6e-37	2.05e-33	0.67	0.55	Mitral valve prolapse;	chr21:36031272	chr21:36005338~36007838:+
PRAD	cis	rs62229266	0.659	rs7275820	ENSG00000231106.2	LINC01436	13.91	6.6e-37	2.05e-33	0.67	0.55	Mitral valve prolapse;	chr21:36037116	chr21:36005338~36007838:+
PRAD	cis	rs62229266	0.652	rs7280551	ENSG00000231106.2	LINC01436	13.91	6.6e-37	2.05e-33	0.67	0.55	Mitral valve prolapse;	chr21:36037311	chr21:36005338~36007838:+
PRAD	cis	rs62229266	0.659	rs2255734	ENSG00000231106.2	LINC01436	13.91	6.6e-37	2.05e-33	0.67	0.55	Mitral valve prolapse;	chr21:36039611	chr21:36005338~36007838:+
PRAD	cis	rs62229266	0.659	rs2835242	ENSG00000231106.2	LINC01436	13.91	6.6e-37	2.05e-33	0.67	0.55	Mitral valve prolapse;	chr21:36041234	chr21:36005338~36007838:+
PRAD	cis	rs62229266	0.659	rs2835243	ENSG00000231106.2	LINC01436	13.91	6.6e-37	2.05e-33	0.67	0.55	Mitral valve prolapse;	chr21:36041648	chr21:36005338~36007838:+
PRAD	cis	rs2153535	0.505	rs1737583	ENSG00000230939.1	RP11-314C16.1	-13.91	6.9e-37	2.14e-33	-0.68	-0.55	Motion sickness;	chr6:8536579	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.563	rs3117071	ENSG00000230939.1	RP11-314C16.1	-13.91	6.9e-37	2.14e-33	-0.68	-0.55	Motion sickness;	chr6:8537675	chr6:8784178~8785445:+
PRAD	cis	rs2581828	0.656	rs2564940	ENSG00000242142.1	SERBP1P3	13.91	6.93e-37	2.15e-33	0.61	0.55	Crohn's disease;	chr3:53073553	chr3:53064283~53065091:-
PRAD	cis	rs2153535	0.58	rs1855769	ENSG00000230939.1	RP11-314C16.1	-13.9	7.1e-37	2.21e-33	-0.68	-0.55	Motion sickness;	chr6:8472862	chr6:8784178~8785445:+
PRAD	cis	rs11155671	0.53	rs7758033	ENSG00000216906.2	RP11-350J20.9	13.9	7.24e-37	2.25e-33	0.63	0.55	Testicular germ cell tumor;	chr6:149886999	chr6:149904243~149906418:+
PRAD	cis	rs2404602	0.598	rs11855999	ENSG00000259422.1	RP11-593F23.1	-13.9	7.28e-37	2.26e-33	-0.76	-0.55	Blood metabolite levels;	chr15:76334992	chr15:76174891~76181486:-
PRAD	cis	rs2283792	0.967	rs5749998	ENSG00000224086.5	LL22NC03-86G7.1	-13.9	7.52e-37	2.33e-33	-0.64	-0.55	Multiple sclerosis;	chr22:21808085	chr22:21938293~21977632:+
PRAD	cis	rs2283792	1	rs9607287	ENSG00000224086.5	LL22NC03-86G7.1	-13.9	7.52e-37	2.33e-33	-0.64	-0.55	Multiple sclerosis;	chr22:21809136	chr22:21938293~21977632:+
PRAD	cis	rs977987	0.931	rs1424013	ENSG00000261783.1	RP11-252K23.2	-13.9	7.52e-37	2.33e-33	-0.75	-0.55	Dupuytren's disease;	chr16:75462088	chr16:75379818~75381260:-
PRAD	cis	rs17507216	0.628	rs8028130	ENSG00000278603.1	RP13-608F4.5	13.9	7.52e-37	2.33e-33	0.9	0.55	Excessive daytime sleepiness;	chr15:82734974	chr15:82472203~82472426:+
PRAD	cis	rs7208859	0.524	rs8069400	ENSG00000263531.1	RP13-753N3.1	13.89	7.71e-37	2.39e-33	1.16	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748949	chr17:30863921~30864940:-
PRAD	cis	rs2153535	0.58	rs9328484	ENSG00000230939.1	RP11-314C16.1	-13.89	7.73e-37	2.39e-33	-0.68	-0.55	Motion sickness;	chr6:8524610	chr6:8784178~8785445:+
PRAD	cis	rs9660180	0.839	rs12040826	ENSG00000268575.1	RP1-283E3.8	-13.89	8.07e-37	2.49e-33	-0.57	-0.55	Body mass index;	chr1:1773848	chr1:1702736~1737688:-
PRAD	cis	rs1153858	1	rs1719247	ENSG00000259520.4	CTD-2651B20.3	-13.89	8.22e-37	2.54e-33	-0.71	-0.55	Homoarginine levels;	chr15:45328787	chr15:45251580~45279251:-
PRAD	cis	rs2581828	0.656	rs2564921	ENSG00000242142.1	SERBP1P3	-13.89	8.26e-37	2.55e-33	-0.61	-0.55	Crohn's disease;	chr3:53091569	chr3:53064283~53065091:-
PRAD	cis	rs7617773	0.78	rs6442111	ENSG00000229759.1	MRPS18AP1	13.89	8.29e-37	2.56e-33	0.59	0.55	Coronary artery disease;	chr3:48270570	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.851	rs6775179	ENSG00000229759.1	MRPS18AP1	13.89	8.29e-37	2.56e-33	0.59	0.55	Coronary artery disease;	chr3:48271928	chr3:48256350~48256938:-
PRAD	cis	rs8100891	0.537	rs10424665	ENSG00000267213.4	AC007773.2	-13.89	8.45e-37	2.61e-33	-0.67	-0.55	Neuroticism;	chr19:32404725	chr19:32390050~32405560:-
PRAD	cis	rs62388641	1	rs62388641	ENSG00000272279.1	RP11-157J24.2	13.88	8.74e-37	2.7e-33	0.94	0.55	Daytime sleep phenotypes;	chr6:1539849	chr6:1528364~1528911:-
PRAD	cis	rs2153535	0.58	rs1928184	ENSG00000230939.1	RP11-314C16.1	-13.88	8.94e-37	2.76e-33	-0.67	-0.55	Motion sickness;	chr6:8531875	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs6597335	ENSG00000230939.1	RP11-314C16.1	-13.88	8.97e-37	2.76e-33	-0.68	-0.55	Motion sickness;	chr6:8527481	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs9328486	ENSG00000230939.1	RP11-314C16.1	-13.88	8.97e-37	2.76e-33	-0.68	-0.55	Motion sickness;	chr6:8527775	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs2183112	ENSG00000230939.1	RP11-314C16.1	-13.88	8.97e-37	2.76e-33	-0.68	-0.55	Motion sickness;	chr6:8527979	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.601	rs2143353	ENSG00000230939.1	RP11-314C16.1	-13.88	8.97e-37	2.76e-33	-0.68	-0.55	Motion sickness;	chr6:8529878	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.601	rs2143352	ENSG00000230939.1	RP11-314C16.1	-13.88	8.97e-37	2.76e-33	-0.68	-0.55	Motion sickness;	chr6:8530015	chr6:8784178~8785445:+
PRAD	cis	rs7208859	0.573	rs4055105	ENSG00000263531.1	RP13-753N3.1	13.88	8.99e-37	2.77e-33	1.09	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775532	chr17:30863921~30864940:-
PRAD	cis	rs10256972	0.721	rs10435145	ENSG00000229043.2	AC091729.9	-13.88	9.14e-37	2.82e-33	-0.67	-0.55	Endometriosis;Longevity;	chr7:1026352	chr7:1160374~1165267:+
PRAD	cis	rs3814244	0.569	rs2051993	ENSG00000255733.4	IFNG-AS1	13.88	9.3e-37	2.87e-33	0.6	0.55	Itch intensity from mosquito bite adjusted by bite size;	chr12:68019898	chr12:67989445~68234686:+
PRAD	cis	rs9487094	0.6	rs3799842	ENSG00000260273.1	RP11-425D10.10	13.87	9.38e-37	2.89e-33	0.71	0.55	Height;	chr6:109471826	chr6:109382795~109383666:+
PRAD	cis	rs7847628	0.666	rs2031974	ENSG00000226752.6	PSMD5-AS1	-13.87	9.81e-37	3.02e-33	-0.69	-0.55	Birth weight;	chr9:120765243	chr9:120824828~120854385:+
PRAD	cis	rs2153535	0.58	rs718502	ENSG00000230939.1	RP11-314C16.1	-13.87	9.83e-37	3.02e-33	-0.68	-0.55	Motion sickness;	chr6:8527167	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs718503	ENSG00000230939.1	RP11-314C16.1	-13.87	9.83e-37	3.02e-33	-0.68	-0.55	Motion sickness;	chr6:8527230	chr6:8784178~8785445:+
PRAD	cis	rs7174755	0.743	rs4777035	ENSG00000260657.2	RP11-315D16.4	-13.87	1.02e-36	3.12e-33	-0.63	-0.55	Major depressive disorder;	chr15:68312831	chr15:68267792~68277994:-
PRAD	cis	rs2581828	0.607	rs2581784	ENSG00000242142.1	SERBP1P3	13.86	1.06e-36	3.26e-33	0.6	0.54	Crohn's disease;	chr3:53088354	chr3:53064283~53065091:-
PRAD	cis	rs2581828	0.656	rs891368	ENSG00000242142.1	SERBP1P3	13.86	1.06e-36	3.26e-33	0.6	0.54	Crohn's disease;	chr3:53089257	chr3:53064283~53065091:-
PRAD	cis	rs2581828	0.656	rs1078968	ENSG00000242142.1	SERBP1P3	13.86	1.06e-36	3.26e-33	0.6	0.54	Crohn's disease;	chr3:53089470	chr3:53064283~53065091:-
PRAD	cis	rs2581828	0.656	rs2581786	ENSG00000242142.1	SERBP1P3	13.86	1.06e-36	3.26e-33	0.6	0.54	Crohn's disease;	chr3:53092127	chr3:53064283~53065091:-
PRAD	cis	rs62229266	0.659	rs2026259	ENSG00000231106.2	LINC01436	13.86	1.06e-36	3.26e-33	0.67	0.54	Mitral valve prolapse;	chr21:36058329	chr21:36005338~36007838:+
PRAD	cis	rs2581828	0.656	rs2253209	ENSG00000242142.1	SERBP1P3	13.86	1.06e-36	3.27e-33	0.6	0.54	Crohn's disease;	chr3:53081144	chr3:53064283~53065091:-
PRAD	cis	rs2581828	0.694	rs2336725	ENSG00000242142.1	SERBP1P3	13.86	1.07e-36	3.28e-33	0.6	0.54	Crohn's disease;	chr3:53084723	chr3:53064283~53065091:-
PRAD	cis	rs2581828	0.656	rs2253656	ENSG00000242142.1	SERBP1P3	13.86	1.07e-36	3.28e-33	0.6	0.54	Crohn's disease;	chr3:53085083	chr3:53064283~53065091:-
PRAD	cis	rs2581828	0.656	rs2253685	ENSG00000242142.1	SERBP1P3	13.86	1.07e-36	3.28e-33	0.6	0.54	Crohn's disease;	chr3:53085687	chr3:53064283~53065091:-
PRAD	cis	rs2581828	0.656	rs2253796	ENSG00000242142.1	SERBP1P3	13.86	1.07e-36	3.28e-33	0.6	0.54	Crohn's disease;	chr3:53086082	chr3:53064283~53065091:-
PRAD	cis	rs2581828	0.656	rs11130338	ENSG00000242142.1	SERBP1P3	13.86	1.07e-36	3.28e-33	0.6	0.54	Crohn's disease;	chr3:53086908	chr3:53064283~53065091:-
PRAD	cis	rs2153535	0.58	rs2184586	ENSG00000230939.1	RP11-314C16.1	-13.86	1.07e-36	3.29e-33	-0.67	-0.54	Motion sickness;	chr6:8473949	chr6:8784178~8785445:+
PRAD	cis	rs62229266	0.659	rs2835245	ENSG00000231106.2	LINC01436	13.86	1.07e-36	3.3e-33	0.68	0.54	Mitral valve prolapse;	chr21:36044410	chr21:36005338~36007838:+
PRAD	cis	rs2153535	0.58	rs1335643	ENSG00000230939.1	RP11-314C16.1	-13.86	1.08e-36	3.32e-33	-0.67	-0.54	Motion sickness;	chr6:8487788	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs7743995	ENSG00000230939.1	RP11-314C16.1	-13.86	1.1e-36	3.36e-33	-0.68	-0.54	Motion sickness;	chr6:8495979	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs2327060	ENSG00000230939.1	RP11-314C16.1	-13.86	1.13e-36	3.46e-33	-0.67	-0.54	Motion sickness;	chr6:8446878	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs6929206	ENSG00000230939.1	RP11-314C16.1	-13.86	1.13e-36	3.46e-33	-0.67	-0.54	Motion sickness;	chr6:8447728	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs6921036	ENSG00000230939.1	RP11-314C16.1	-13.86	1.13e-36	3.46e-33	-0.67	-0.54	Motion sickness;	chr6:8455167	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs6926759	ENSG00000230939.1	RP11-314C16.1	-13.86	1.13e-36	3.46e-33	-0.67	-0.54	Motion sickness;	chr6:8455943	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.584	rs9502721	ENSG00000230939.1	RP11-314C16.1	-13.86	1.13e-36	3.46e-33	-0.67	-0.54	Motion sickness;	chr6:8541146	chr6:8784178~8785445:+
PRAD	cis	rs7182621	0.639	rs12906068	ENSG00000259363.4	CTD-2054N24.2	-13.85	1.14e-36	3.49e-33	-0.59	-0.54	Colonoscopy-negative controls vs population controls;	chr15:99873422	chr15:99807023~99877148:+
PRAD	cis	rs12022452	0.822	rs7545012	ENSG00000238287.1	RP11-656D10.3	13.85	1.15e-36	3.52e-33	0.86	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr1:40562178	chr1:40493157~40508661:-
PRAD	cis	rs9322193	0.567	rs7742692	ENSG00000231760.4	RP11-350J20.5	13.85	1.19e-36	3.64e-33	0.74	0.54	Lung cancer;	chr6:149892363	chr6:149796151~149826294:-
PRAD	cis	rs17826219	0.714	rs11650821	ENSG00000263531.1	RP13-753N3.1	13.85	1.22e-36	3.73e-33	1.14	0.54	Body mass index;	chr17:30641132	chr17:30863921~30864940:-
PRAD	cis	rs2929278	0.561	rs2927071	ENSG00000205771.5	CATSPER2P1	-13.85	1.23e-36	3.74e-33	-0.63	-0.54	Schizophrenia;	chr15:43626883	chr15:43726918~43747094:-
PRAD	cis	rs2153535	0.601	rs7741024	ENSG00000230939.1	RP11-314C16.1	-13.85	1.23e-36	3.74e-33	-0.68	-0.54	Motion sickness;	chr6:8530080	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs9505467	ENSG00000230939.1	RP11-314C16.1	-13.84	1.28e-36	3.9e-33	-0.68	-0.54	Motion sickness;	chr6:8519986	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs1360054	ENSG00000230939.1	RP11-314C16.1	-13.84	1.28e-36	3.9e-33	-0.68	-0.54	Motion sickness;	chr6:8520144	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs9328483	ENSG00000230939.1	RP11-314C16.1	-13.84	1.28e-36	3.9e-33	-0.68	-0.54	Motion sickness;	chr6:8521062	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs9393033	ENSG00000230939.1	RP11-314C16.1	-13.84	1.28e-36	3.9e-33	-0.68	-0.54	Motion sickness;	chr6:8521213	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.541	rs6938688	ENSG00000230939.1	RP11-314C16.1	-13.84	1.28e-36	3.9e-33	-0.68	-0.54	Motion sickness;	chr6:8521396	chr6:8784178~8785445:+
PRAD	cis	rs7208859	0.623	rs55938328	ENSG00000263531.1	RP13-753N3.1	13.84	1.33e-36	4.05e-33	1.05	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30789992	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs55961983	ENSG00000263531.1	RP13-753N3.1	13.84	1.33e-36	4.05e-33	1.05	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792268	chr17:30863921~30864940:-
PRAD	cis	rs17826219	0.568	rs7213925	ENSG00000263531.1	RP13-753N3.1	13.84	1.33e-36	4.05e-33	1.05	0.54	Body mass index;	chr17:30794616	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs11658945	ENSG00000263531.1	RP13-753N3.1	13.84	1.33e-36	4.05e-33	1.05	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795491	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs11657990	ENSG00000263531.1	RP13-753N3.1	13.84	1.33e-36	4.05e-33	1.05	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797182	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs11650982	ENSG00000263531.1	RP13-753N3.1	13.84	1.33e-36	4.05e-33	1.05	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30802937	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs9915546	ENSG00000263531.1	RP13-753N3.1	13.84	1.33e-36	4.05e-33	1.05	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805126	chr17:30863921~30864940:-
PRAD	cis	rs875971	0.862	rs778684	ENSG00000226824.5	RP4-756H11.3	-13.84	1.35e-36	4.1e-33	-0.74	-0.54	Aortic root size;	chr7:66371416	chr7:66654538~66669855:+
PRAD	cis	rs2153535	0.58	rs1932283	ENSG00000230939.1	RP11-314C16.1	-13.84	1.36e-36	4.14e-33	-0.67	-0.54	Motion sickness;	chr6:8477428	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.563	rs1737585	ENSG00000230939.1	RP11-314C16.1	13.84	1.37e-36	4.15e-33	0.67	0.54	Motion sickness;	chr6:8536361	chr6:8784178~8785445:+
PRAD	cis	rs2581828	0.646	rs2564923	ENSG00000242142.1	SERBP1P3	13.84	1.37e-36	4.16e-33	0.61	0.54	Crohn's disease;	chr3:53069246	chr3:53064283~53065091:-
PRAD	cis	rs17826219	0.706	rs8075357	ENSG00000263531.1	RP13-753N3.1	13.84	1.38e-36	4.2e-33	1.06	0.54	Body mass index;	chr17:30730179	chr17:30863921~30864940:-
PRAD	cis	rs17826219	0.706	rs61643715	ENSG00000263531.1	RP13-753N3.1	13.84	1.38e-36	4.2e-33	1.06	0.54	Body mass index;	chr17:30730744	chr17:30863921~30864940:-
PRAD	cis	rs17826219	0.636	rs8080829	ENSG00000263531.1	RP13-753N3.1	13.84	1.38e-36	4.2e-33	1.06	0.54	Body mass index;	chr17:30731712	chr17:30863921~30864940:-
PRAD	cis	rs7104764	0.957	rs58692051	ENSG00000277290.1	RP11-326C3.16	13.84	1.38e-36	4.2e-33	0.51	0.54	Menarche (age at onset);	chr11:207410	chr11:243099~243483:-
PRAD	cis	rs875971	0.767	rs1643394	ENSG00000226824.5	RP4-756H11.3	-13.83	1.39e-36	4.23e-33	-0.74	-0.54	Aortic root size;	chr7:66371107	chr7:66654538~66669855:+
PRAD	cis	rs1799949	0.602	rs8176199	ENSG00000198496.9	NBR2	-13.83	1.41e-36	4.28e-33	-0.83	-0.54	Menopause (age at onset);	chr17:43078507	chr17:43125610~43153671:+
PRAD	cis	rs9326248	0.53	rs11216171	ENSG00000254851.1	RP11-109L13.1	-13.83	1.49e-36	4.53e-33	-0.78	-0.54	Blood protein levels;	chr11:116878397	chr11:117135528~117138582:+
PRAD	cis	rs7617773	0.817	rs3937	ENSG00000229759.1	MRPS18AP1	13.83	1.5e-36	4.55e-33	0.58	0.54	Coronary artery disease;	chr3:48270912	chr3:48256350~48256938:-
PRAD	cis	rs1153858	1	rs1145091	ENSG00000259520.4	CTD-2651B20.3	-13.83	1.5e-36	4.55e-33	-0.71	-0.54	Homoarginine levels;	chr15:45357798	chr15:45251580~45279251:-
PRAD	cis	rs1799949	0.587	rs1824890	ENSG00000198496.9	NBR2	-13.83	1.52e-36	4.61e-33	-0.83	-0.54	Menopause (age at onset);	chr17:43344536	chr17:43125610~43153671:+
PRAD	cis	rs11155671	0.53	rs7742993	ENSG00000231760.4	RP11-350J20.5	13.83	1.53e-36	4.63e-33	0.74	0.54	Testicular germ cell tumor;	chr6:149883959	chr6:149796151~149826294:-
PRAD	cis	rs2153535	0.58	rs6914276	ENSG00000230939.1	RP11-314C16.1	13.82	1.58e-36	4.78e-33	0.68	0.54	Motion sickness;	chr6:8450202	chr6:8784178~8785445:+
PRAD	cis	rs7208859	0.623	rs73269913	ENSG00000263531.1	RP13-753N3.1	13.82	1.59e-36	4.82e-33	1.05	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765165	chr17:30863921~30864940:-
PRAD	cis	rs2153535	0.542	rs915354	ENSG00000230939.1	RP11-314C16.1	-13.82	1.6e-36	4.84e-33	-0.68	-0.54	Motion sickness;	chr6:8440124	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs5001130	ENSG00000230939.1	RP11-314C16.1	-13.82	1.6e-36	4.84e-33	-0.68	-0.54	Motion sickness;	chr6:8442065	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs2327057	ENSG00000230939.1	RP11-314C16.1	-13.82	1.6e-36	4.84e-33	-0.68	-0.54	Motion sickness;	chr6:8443086	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs1577466	ENSG00000230939.1	RP11-314C16.1	-13.82	1.6e-36	4.84e-33	-0.68	-0.54	Motion sickness;	chr6:8443959	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs2327067	ENSG00000230939.1	RP11-314C16.1	-13.82	1.61e-36	4.87e-33	-0.68	-0.54	Motion sickness;	chr6:8518249	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.541	rs9328477	ENSG00000230939.1	RP11-314C16.1	-13.82	1.61e-36	4.87e-33	-0.68	-0.54	Motion sickness;	chr6:8518876	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs9328478	ENSG00000230939.1	RP11-314C16.1	-13.82	1.61e-36	4.87e-33	-0.68	-0.54	Motion sickness;	chr6:8518950	chr6:8784178~8785445:+
PRAD	cis	rs17826219	0.706	rs9893922	ENSG00000263531.1	RP13-753N3.1	13.82	1.64e-36	4.95e-33	1.05	0.54	Body mass index;	chr17:30741407	chr17:30863921~30864940:-
PRAD	cis	rs17826219	0.5	rs9891256	ENSG00000263531.1	RP13-753N3.1	13.82	1.64e-36	4.95e-33	1.05	0.54	Body mass index;	chr17:30745674	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs7503335	ENSG00000263531.1	RP13-753N3.1	13.82	1.64e-36	4.95e-33	1.05	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746944	chr17:30863921~30864940:-
PRAD	cis	rs2153535	0.58	rs1932284	ENSG00000230939.1	RP11-314C16.1	-13.82	1.65e-36	5e-33	-0.67	-0.54	Motion sickness;	chr6:8477461	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs1932285	ENSG00000230939.1	RP11-314C16.1	-13.82	1.65e-36	5e-33	-0.67	-0.54	Motion sickness;	chr6:8477486	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs7775909	ENSG00000230939.1	RP11-314C16.1	-13.82	1.65e-36	5e-33	-0.67	-0.54	Motion sickness;	chr6:8477545	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs9505454	ENSG00000230939.1	RP11-314C16.1	-13.82	1.67e-36	5.04e-33	-0.67	-0.54	Motion sickness;	chr6:8478299	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.541	rs9505456	ENSG00000230939.1	RP11-314C16.1	-13.82	1.67e-36	5.04e-33	-0.67	-0.54	Motion sickness;	chr6:8478768	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs9505458	ENSG00000230939.1	RP11-314C16.1	-13.82	1.67e-36	5.04e-33	-0.67	-0.54	Motion sickness;	chr6:8478982	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs9379215	ENSG00000230939.1	RP11-314C16.1	-13.82	1.67e-36	5.04e-33	-0.67	-0.54	Motion sickness;	chr6:8480992	chr6:8784178~8785445:+
PRAD	cis	rs2929278	0.546	rs686666	ENSG00000205771.5	CATSPER2P1	-13.82	1.68e-36	5.07e-33	-0.63	-0.54	Schizophrenia;	chr15:43869352	chr15:43726918~43747094:-
PRAD	cis	rs2153535	0.58	rs7767780	ENSG00000230939.1	RP11-314C16.1	-13.82	1.68e-36	5.08e-33	-0.67	-0.54	Motion sickness;	chr6:8453229	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.601	rs330105	ENSG00000230939.1	RP11-314C16.1	-13.81	1.71e-36	5.15e-33	-0.67	-0.54	Motion sickness;	chr6:8543748	chr6:8784178~8785445:+
PRAD	cis	rs62388641	0.802	rs13202504	ENSG00000272279.1	RP11-157J24.2	13.81	1.71e-36	5.16e-33	0.93	0.54	Daytime sleep phenotypes;	chr6:1537640	chr6:1528364~1528911:-
PRAD	cis	rs2153535	0.601	rs9379224	ENSG00000230939.1	RP11-314C16.1	-13.81	1.73e-36	5.21e-33	-0.67	-0.54	Motion sickness;	chr6:8538180	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.563	rs6942177	ENSG00000230939.1	RP11-314C16.1	13.81	1.73e-36	5.21e-33	0.67	0.54	Motion sickness;	chr6:8534227	chr6:8784178~8785445:+
PRAD	cis	rs62229266	0.625	rs62230813	ENSG00000231106.2	LINC01436	13.81	1.73e-36	5.22e-33	0.67	0.54	Mitral valve prolapse;	chr21:36031134	chr21:36005338~36007838:+
PRAD	cis	rs9545047	0.935	rs4885633	ENSG00000227676.3	LINC01068	-13.81	1.74e-36	5.24e-33	-0.67	-0.54	Schizophrenia;	chr13:79469720	chr13:79566727~79571436:+
PRAD	cis	rs9399135	0.933	rs28384512	ENSG00000232876.1	CTA-212D2.2	-13.81	1.74e-36	5.25e-33	-0.66	-0.54	Red blood cell count;	chr6:135055094	chr6:135055033~135060550:+
PRAD	cis	rs17826219	0.568	rs2626985	ENSG00000263531.1	RP13-753N3.1	13.81	1.76e-36	5.29e-33	1.05	0.54	Body mass index;	chr17:30750419	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.573	rs7222803	ENSG00000263531.1	RP13-753N3.1	13.8	1.87e-36	5.63e-33	1.05	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792879	chr17:30863921~30864940:-
PRAD	cis	rs2153535	0.58	rs7741456	ENSG00000230939.1	RP11-314C16.1	-13.8	1.87e-36	5.63e-33	-0.67	-0.54	Motion sickness;	chr6:8452191	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs7742689	ENSG00000230939.1	RP11-314C16.1	-13.8	1.87e-36	5.63e-33	-0.67	-0.54	Motion sickness;	chr6:8452200	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs7767756	ENSG00000230939.1	RP11-314C16.1	-13.8	1.87e-36	5.63e-33	-0.67	-0.54	Motion sickness;	chr6:8453195	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs7767926	ENSG00000230939.1	RP11-314C16.1	-13.8	1.87e-36	5.63e-33	-0.67	-0.54	Motion sickness;	chr6:8453324	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs2327062	ENSG00000230939.1	RP11-314C16.1	-13.8	1.87e-36	5.63e-33	-0.67	-0.54	Motion sickness;	chr6:8453625	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.623	rs2152346	ENSG00000230939.1	RP11-314C16.1	-13.8	1.87e-36	5.63e-33	-0.67	-0.54	Motion sickness;	chr6:8454419	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs1832101	ENSG00000230939.1	RP11-314C16.1	-13.8	1.87e-36	5.63e-33	-0.67	-0.54	Motion sickness;	chr6:8459944	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs1119690	ENSG00000230939.1	RP11-314C16.1	-13.8	1.87e-36	5.63e-33	-0.67	-0.54	Motion sickness;	chr6:8460427	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs1119689	ENSG00000230939.1	RP11-314C16.1	-13.8	1.87e-36	5.63e-33	-0.67	-0.54	Motion sickness;	chr6:8460521	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs6597325	ENSG00000230939.1	RP11-314C16.1	-13.8	1.87e-36	5.63e-33	-0.67	-0.54	Motion sickness;	chr6:8460820	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs6918391	ENSG00000230939.1	RP11-314C16.1	-13.8	1.87e-36	5.63e-33	-0.67	-0.54	Motion sickness;	chr6:8460945	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs9379210	ENSG00000230939.1	RP11-314C16.1	-13.8	1.87e-36	5.63e-33	-0.67	-0.54	Motion sickness;	chr6:8461695	chr6:8784178~8785445:+
PRAD	cis	rs10256972	0.621	rs2280725	ENSG00000229043.2	AC091729.9	-13.8	1.88e-36	5.65e-33	-0.66	-0.54	Endometriosis;Longevity;	chr7:1047790	chr7:1160374~1165267:+
PRAD	cis	rs9399135	0.967	rs2150681	ENSG00000232876.1	CTA-212D2.2	13.8	1.89e-36	5.69e-33	0.67	0.54	Red blood cell count;	chr6:135054094	chr6:135055033~135060550:+
PRAD	cis	rs7208859	0.623	rs1061342	ENSG00000263531.1	RP13-753N3.1	13.8	1.91e-36	5.73e-33	1.05	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787445	chr17:30863921~30864940:-
PRAD	cis	rs916888	0.61	rs199436	ENSG00000262500.1	RP11-259G18.2	-13.8	1.91e-36	5.75e-33	-0.71	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:46243606~46245044:+
PRAD	cis	rs9487094	0.67	rs1998811	ENSG00000260273.1	RP11-425D10.10	13.8	1.92e-36	5.76e-33	0.72	0.54	Height;	chr6:109490935	chr6:109382795~109383666:+
PRAD	cis	rs62229266	0.693	rs2835264	ENSG00000231106.2	LINC01436	13.8	1.92e-36	5.77e-33	0.69	0.54	Mitral valve prolapse;	chr21:36063667	chr21:36005338~36007838:+
PRAD	cis	rs2153535	0.58	rs6905237	ENSG00000230939.1	RP11-314C16.1	-13.8	1.94e-36	5.82e-33	-0.67	-0.54	Motion sickness;	chr6:8471557	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.542	rs4440510	ENSG00000230939.1	RP11-314C16.1	-13.8	1.94e-36	5.82e-33	-0.67	-0.54	Motion sickness;	chr6:8471585	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.541	rs1414347	ENSG00000230939.1	RP11-314C16.1	-13.8	1.94e-36	5.82e-33	-0.67	-0.54	Motion sickness;	chr6:8471598	chr6:8784178~8785445:+
PRAD	cis	rs7208859	0.573	rs8078656	ENSG00000263531.1	RP13-753N3.1	13.8	1.96e-36	5.86e-33	1.05	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753953	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs9898084	ENSG00000263531.1	RP13-753N3.1	13.8	1.96e-36	5.86e-33	1.05	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30755316	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs28556733	ENSG00000263531.1	RP13-753N3.1	13.8	1.96e-36	5.86e-33	1.05	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30756927	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs28433704	ENSG00000263531.1	RP13-753N3.1	13.8	1.96e-36	5.86e-33	1.05	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757267	chr17:30863921~30864940:-
PRAD	cis	rs17826219	0.706	rs55764512	ENSG00000263531.1	RP13-753N3.1	13.8	1.96e-36	5.86e-33	1.05	0.54	Body mass index;	chr17:30758740	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs12103508	ENSG00000263531.1	RP13-753N3.1	13.8	1.96e-36	5.86e-33	1.05	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759763	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.524	rs11653605	ENSG00000263531.1	RP13-753N3.1	13.8	1.96e-36	5.86e-33	1.05	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30761367	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs7217984	ENSG00000263531.1	RP13-753N3.1	13.8	1.96e-36	5.86e-33	1.05	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765748	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs73269916	ENSG00000263531.1	RP13-753N3.1	13.8	1.96e-36	5.86e-33	1.05	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30769308	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.524	rs60114476	ENSG00000263531.1	RP13-753N3.1	13.8	1.96e-36	5.86e-33	1.05	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770649	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.562	rs8078897	ENSG00000263531.1	RP13-753N3.1	13.8	1.96e-36	5.86e-33	1.05	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779239	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs9914499	ENSG00000263531.1	RP13-753N3.1	13.8	1.96e-36	5.86e-33	1.05	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780570	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs12006	ENSG00000263531.1	RP13-753N3.1	13.8	1.96e-36	5.86e-33	1.05	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783634	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs3752021	ENSG00000263531.1	RP13-753N3.1	13.8	1.96e-36	5.86e-33	1.05	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784025	chr17:30863921~30864940:-
PRAD	cis	rs2153535	0.58	rs7747306	ENSG00000230939.1	RP11-314C16.1	13.8	1.99e-36	5.94e-33	0.67	0.54	Motion sickness;	chr6:8453430	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.562	rs9379211	ENSG00000230939.1	RP11-314C16.1	-13.8	1.99e-36	5.94e-33	-0.67	-0.54	Motion sickness;	chr6:8463694	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs965706	ENSG00000230939.1	RP11-314C16.1	-13.8	1.99e-36	5.94e-33	-0.67	-0.54	Motion sickness;	chr6:8464475	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs6938071	ENSG00000230939.1	RP11-314C16.1	-13.8	1.99e-36	5.94e-33	-0.67	-0.54	Motion sickness;	chr6:8464612	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.601	rs9406160	ENSG00000230939.1	RP11-314C16.1	-13.8	1.99e-36	5.94e-33	-0.67	-0.54	Motion sickness;	chr6:8464674	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs1335636	ENSG00000230939.1	RP11-314C16.1	-13.8	1.99e-36	5.94e-33	-0.67	-0.54	Motion sickness;	chr6:8464814	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs986060	ENSG00000230939.1	RP11-314C16.1	-13.8	1.99e-36	5.94e-33	-0.67	-0.54	Motion sickness;	chr6:8465195	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs9406161	ENSG00000230939.1	RP11-314C16.1	-13.8	1.99e-36	5.94e-33	-0.67	-0.54	Motion sickness;	chr6:8465911	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs9405390	ENSG00000230939.1	RP11-314C16.1	-13.8	1.99e-36	5.94e-33	-0.67	-0.54	Motion sickness;	chr6:8465976	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs9405391	ENSG00000230939.1	RP11-314C16.1	-13.8	1.99e-36	5.94e-33	-0.67	-0.54	Motion sickness;	chr6:8466315	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs9406163	ENSG00000230939.1	RP11-314C16.1	-13.8	1.99e-36	5.94e-33	-0.67	-0.54	Motion sickness;	chr6:8466409	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.504	rs9405393	ENSG00000230939.1	RP11-314C16.1	-13.8	1.99e-36	5.94e-33	-0.67	-0.54	Motion sickness;	chr6:8467199	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs2184584	ENSG00000230939.1	RP11-314C16.1	-13.8	1.99e-36	5.94e-33	-0.67	-0.54	Motion sickness;	chr6:8468174	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.541	rs7774752	ENSG00000230939.1	RP11-314C16.1	-13.8	1.99e-36	5.94e-33	-0.67	-0.54	Motion sickness;	chr6:8468745	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs1034272	ENSG00000230939.1	RP11-314C16.1	-13.8	1.99e-36	5.94e-33	-0.67	-0.54	Motion sickness;	chr6:8469102	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs9505450	ENSG00000230939.1	RP11-314C16.1	-13.8	1.99e-36	5.94e-33	-0.67	-0.54	Motion sickness;	chr6:8469669	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs9406164	ENSG00000230939.1	RP11-314C16.1	-13.8	1.99e-36	5.94e-33	-0.67	-0.54	Motion sickness;	chr6:8469815	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs7341201	ENSG00000230939.1	RP11-314C16.1	-13.8	1.99e-36	5.94e-33	-0.67	-0.54	Motion sickness;	chr6:8470037	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs7341206	ENSG00000230939.1	RP11-314C16.1	-13.8	1.99e-36	5.94e-33	-0.67	-0.54	Motion sickness;	chr6:8470256	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs7341382	ENSG00000230939.1	RP11-314C16.1	-13.8	1.99e-36	5.94e-33	-0.67	-0.54	Motion sickness;	chr6:8470316	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs7341383	ENSG00000230939.1	RP11-314C16.1	-13.8	1.99e-36	5.94e-33	-0.67	-0.54	Motion sickness;	chr6:8470401	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.504	rs9328472	ENSG00000230939.1	RP11-314C16.1	-13.8	1.99e-36	5.94e-33	-0.67	-0.54	Motion sickness;	chr6:8470615	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs1414345	ENSG00000230939.1	RP11-314C16.1	-13.8	1.99e-36	5.94e-33	-0.67	-0.54	Motion sickness;	chr6:8471304	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs1414349	ENSG00000230939.1	RP11-314C16.1	-13.8	1.99e-36	5.94e-33	-0.67	-0.54	Motion sickness;	chr6:8472057	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs1414350	ENSG00000230939.1	RP11-314C16.1	-13.8	1.99e-36	5.94e-33	-0.67	-0.54	Motion sickness;	chr6:8472098	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs9392224	ENSG00000230939.1	RP11-314C16.1	-13.8	1.99e-36	5.94e-33	-0.67	-0.54	Motion sickness;	chr6:8472381	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.542	rs9378553	ENSG00000230939.1	RP11-314C16.1	-13.8	1.99e-36	5.94e-33	-0.67	-0.54	Motion sickness;	chr6:8472399	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.601	rs1855768	ENSG00000230939.1	RP11-314C16.1	-13.8	1.99e-36	5.94e-33	-0.67	-0.54	Motion sickness;	chr6:8472736	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs1932281	ENSG00000230939.1	RP11-314C16.1	-13.8	1.99e-36	5.94e-33	-0.67	-0.54	Motion sickness;	chr6:8473532	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs6900007	ENSG00000230939.1	RP11-314C16.1	-13.8	1.99e-36	5.94e-33	-0.67	-0.54	Motion sickness;	chr6:8473802	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs2184585	ENSG00000230939.1	RP11-314C16.1	-13.8	1.99e-36	5.94e-33	-0.67	-0.54	Motion sickness;	chr6:8473935	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs6902001	ENSG00000230939.1	RP11-314C16.1	-13.8	1.99e-36	5.94e-33	-0.67	-0.54	Motion sickness;	chr6:8476822	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs4960423	ENSG00000230939.1	RP11-314C16.1	-13.8	1.99e-36	5.94e-33	-0.67	-0.54	Motion sickness;	chr6:8476977	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs1932282	ENSG00000230939.1	RP11-314C16.1	-13.8	1.99e-36	5.94e-33	-0.67	-0.54	Motion sickness;	chr6:8477097	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs9505455	ENSG00000230939.1	RP11-314C16.1	-13.8	1.99e-36	5.94e-33	-0.67	-0.54	Motion sickness;	chr6:8478389	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs9379216	ENSG00000230939.1	RP11-314C16.1	-13.8	1.99e-36	5.94e-33	-0.67	-0.54	Motion sickness;	chr6:8481002	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs7450817	ENSG00000230939.1	RP11-314C16.1	-13.8	1.99e-36	5.94e-33	-0.67	-0.54	Motion sickness;	chr6:8481188	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.56	rs2210798	ENSG00000230939.1	RP11-314C16.1	-13.8	1.99e-36	5.94e-33	-0.67	-0.54	Motion sickness;	chr6:8481289	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs6597327	ENSG00000230939.1	RP11-314C16.1	-13.8	1.99e-36	5.94e-33	-0.67	-0.54	Motion sickness;	chr6:8481924	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs7763190	ENSG00000230939.1	RP11-314C16.1	-13.8	1.99e-36	5.94e-33	-0.67	-0.54	Motion sickness;	chr6:8483964	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.546	rs1335640	ENSG00000230939.1	RP11-314C16.1	-13.8	1.99e-36	5.94e-33	-0.67	-0.54	Motion sickness;	chr6:8485092	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.541	rs1414352	ENSG00000230939.1	RP11-314C16.1	-13.8	1.99e-36	5.94e-33	-0.67	-0.54	Motion sickness;	chr6:8485314	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs1577471	ENSG00000230939.1	RP11-314C16.1	-13.8	1.99e-36	5.94e-33	-0.67	-0.54	Motion sickness;	chr6:8485672	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs1120392	ENSG00000230939.1	RP11-314C16.1	-13.8	1.99e-36	5.94e-33	-0.67	-0.54	Motion sickness;	chr6:8486820	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs1335641	ENSG00000230939.1	RP11-314C16.1	-13.8	1.99e-36	5.94e-33	-0.67	-0.54	Motion sickness;	chr6:8487627	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs9378554	ENSG00000230939.1	RP11-314C16.1	-13.8	1.99e-36	5.94e-33	-0.67	-0.54	Motion sickness;	chr6:8488235	chr6:8784178~8785445:+
PRAD	cis	rs7617773	0.743	rs6804986	ENSG00000229759.1	MRPS18AP1	13.8	2.02e-36	6.03e-33	0.58	0.54	Coronary artery disease;	chr3:48322105	chr3:48256350~48256938:-
PRAD	cis	rs2153535	0.58	rs9378551	ENSG00000230939.1	RP11-314C16.1	-13.8	2.04e-36	6.07e-33	-0.67	-0.54	Motion sickness;	chr6:8463511	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs9378552	ENSG00000230939.1	RP11-314C16.1	-13.8	2.04e-36	6.07e-33	-0.67	-0.54	Motion sickness;	chr6:8463515	chr6:8784178~8785445:+
PRAD	cis	rs875971	0.862	rs10256544	ENSG00000226824.5	RP4-756H11.3	-13.79	2.07e-36	6.18e-33	-0.74	-0.54	Aortic root size;	chr7:66210141	chr7:66654538~66669855:+
PRAD	cis	rs10256972	0.621	rs10951594	ENSG00000229043.2	AC091729.9	-13.79	2.09e-36	6.22e-33	-0.66	-0.54	Endometriosis;Longevity;	chr7:1048971	chr7:1160374~1165267:+
PRAD	cis	rs2153535	0.58	rs1319169	ENSG00000230939.1	RP11-314C16.1	-13.79	2.09e-36	6.23e-33	-0.67	-0.54	Motion sickness;	chr6:8464223	chr6:8784178~8785445:+
PRAD	cis	rs1800795	0.652	rs7802307	ENSG00000179428.2	AC073072.5	-13.79	2.09e-36	6.23e-33	-0.65	-0.54	Cerebrospinal fluid clusterin levels in APOEe4- carriers;	chr7:22726814	chr7:22725395~22727620:-
PRAD	cis	rs2153535	0.525	rs1335644	ENSG00000230939.1	RP11-314C16.1	-13.79	2.14e-36	6.38e-33	-0.67	-0.54	Motion sickness;	chr6:8487808	chr6:8784178~8785445:+
PRAD	cis	rs2581828	0.656	rs11242	ENSG00000242142.1	SERBP1P3	-13.79	2.15e-36	6.41e-33	-0.6	-0.54	Crohn's disease;	chr3:53091906	chr3:53064283~53065091:-
PRAD	cis	rs977987	0.671	rs9922008	ENSG00000261783.1	RP11-252K23.2	-13.78	2.28e-36	6.77e-33	-0.78	-0.54	Dupuytren's disease;	chr16:75301508	chr16:75379818~75381260:-
PRAD	cis	rs2153535	0.58	rs2327051	ENSG00000230939.1	RP11-314C16.1	13.78	2.29e-36	6.82e-33	0.67	0.54	Motion sickness;	chr6:8440917	chr6:8784178~8785445:+
PRAD	cis	rs875971	0.862	rs778702	ENSG00000226824.5	RP4-756H11.3	-13.78	2.32e-36	6.89e-33	-0.74	-0.54	Aortic root size;	chr7:66399848	chr7:66654538~66669855:+
PRAD	cis	rs9399135	0.967	rs6569990	ENSG00000232876.1	CTA-212D2.2	-13.78	2.34e-36	6.96e-33	-0.66	-0.54	Red blood cell count;	chr6:135044680	chr6:135055033~135060550:+
PRAD	cis	rs9399135	0.967	rs6908512	ENSG00000232876.1	CTA-212D2.2	-13.78	2.34e-36	6.96e-33	-0.66	-0.54	Red blood cell count;	chr6:135046619	chr6:135055033~135060550:+
PRAD	cis	rs9399135	0.967	rs11755229	ENSG00000232876.1	CTA-212D2.2	-13.78	2.34e-36	6.96e-33	-0.66	-0.54	Red blood cell count;	chr6:135048775	chr6:135055033~135060550:+
PRAD	cis	rs9399135	0.967	rs9389261	ENSG00000232876.1	CTA-212D2.2	-13.78	2.34e-36	6.96e-33	-0.66	-0.54	Red blood cell count;	chr6:135050010	chr6:135055033~135060550:+
PRAD	cis	rs9399135	0.967	rs9376085	ENSG00000232876.1	CTA-212D2.2	-13.78	2.34e-36	6.96e-33	-0.66	-0.54	Red blood cell count;	chr6:135050086	chr6:135055033~135060550:+
PRAD	cis	rs9399135	0.967	rs13191501	ENSG00000232876.1	CTA-212D2.2	-13.78	2.4e-36	7.13e-33	-0.66	-0.54	Red blood cell count;	chr6:135045742	chr6:135055033~135060550:+
PRAD	cis	rs2153535	0.58	rs1414348	ENSG00000230939.1	RP11-314C16.1	-13.78	2.42e-36	7.19e-33	-0.67	-0.54	Motion sickness;	chr6:8471707	chr6:8784178~8785445:+
PRAD	cis	rs494459	0.838	rs555649	ENSG00000255239.1	AP002954.6	13.78	2.43e-36	7.21e-33	0.69	0.54	Height;	chr11:118781100	chr11:118688039~118690600:-
PRAD	cis	rs2153535	0.58	rs7745043	ENSG00000230939.1	RP11-314C16.1	-13.78	2.46e-36	7.31e-33	-0.67	-0.54	Motion sickness;	chr6:8513274	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs9406170	ENSG00000230939.1	RP11-314C16.1	-13.78	2.46e-36	7.31e-33	-0.67	-0.54	Motion sickness;	chr6:8513920	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs9379222	ENSG00000230939.1	RP11-314C16.1	-13.78	2.46e-36	7.31e-33	-0.67	-0.54	Motion sickness;	chr6:8514555	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs9406172	ENSG00000230939.1	RP11-314C16.1	-13.78	2.46e-36	7.31e-33	-0.67	-0.54	Motion sickness;	chr6:8515231	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs9406174	ENSG00000230939.1	RP11-314C16.1	-13.78	2.46e-36	7.31e-33	-0.67	-0.54	Motion sickness;	chr6:8516531	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs2143356	ENSG00000230939.1	RP11-314C16.1	-13.78	2.46e-36	7.31e-33	-0.67	-0.54	Motion sickness;	chr6:8517442	chr6:8784178~8785445:+
PRAD	cis	rs9326248	0.731	rs90192	ENSG00000254851.1	RP11-109L13.1	-13.77	2.53e-36	7.5e-33	-0.94	-0.54	Blood protein levels;	chr11:117188631	chr11:117135528~117138582:+
PRAD	cis	rs916888	0.61	rs199454	ENSG00000262500.1	RP11-259G18.2	-13.77	2.59e-36	7.69e-33	-0.7	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:46243606~46245044:+
PRAD	cis	rs9487094	0.67	rs1476388	ENSG00000260273.1	RP11-425D10.10	13.77	2.64e-36	7.82e-33	0.72	0.54	Height;	chr6:109518783	chr6:109382795~109383666:+
PRAD	cis	rs9399135	1	rs1014021	ENSG00000232876.1	CTA-212D2.2	13.77	2.64e-36	7.82e-33	0.66	0.54	Red blood cell count;	chr6:135013462	chr6:135055033~135060550:+
PRAD	cis	rs2153535	0.542	rs9505465	ENSG00000230939.1	RP11-314C16.1	-13.77	2.66e-36	7.89e-33	-0.67	-0.54	Motion sickness;	chr6:8510613	chr6:8784178~8785445:+
PRAD	cis	rs875971	0.79	rs10257911	ENSG00000226824.5	RP4-756H11.3	13.77	2.68e-36	7.94e-33	0.75	0.54	Aortic root size;	chr7:66278783	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.798	rs6460304	ENSG00000226824.5	RP4-756H11.3	-13.77	2.7e-36	7.99e-33	-0.73	-0.54	Aortic root size;	chr7:66499741	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.862	rs6945775	ENSG00000226824.5	RP4-756H11.3	-13.77	2.7e-36	7.99e-33	-0.73	-0.54	Aortic root size;	chr7:66503987	chr7:66654538~66669855:+
PRAD	cis	rs1153858	1	rs1613559	ENSG00000259520.4	CTD-2651B20.3	-13.77	2.71e-36	8.02e-33	-0.71	-0.54	Homoarginine levels;	chr15:45329918	chr15:45251580~45279251:-
PRAD	cis	rs1153858	1	rs1618874	ENSG00000259520.4	CTD-2651B20.3	-13.77	2.71e-36	8.02e-33	-0.71	-0.54	Homoarginine levels;	chr15:45330588	chr15:45251580~45279251:-
PRAD	cis	rs1075265	0.633	rs7591431	ENSG00000233266.1	HMGB1P31	13.77	2.71e-36	8.03e-33	0.74	0.54	Chronotype;Morning vs. evening chronotype;	chr2:53995028	chr2:54051334~54051760:+
PRAD	cis	rs875971	0.862	rs1875057	ENSG00000226824.5	RP4-756H11.3	13.77	2.72e-36	8.05e-33	0.75	0.54	Aortic root size;	chr7:66266868	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.862	rs6960446	ENSG00000226824.5	RP4-756H11.3	13.77	2.72e-36	8.05e-33	0.75	0.54	Aortic root size;	chr7:66268272	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.789	rs10260426	ENSG00000226824.5	RP4-756H11.3	13.77	2.72e-36	8.05e-33	0.75	0.54	Aortic root size;	chr7:66271055	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.862	rs7796162	ENSG00000226824.5	RP4-756H11.3	13.77	2.72e-36	8.05e-33	0.75	0.54	Aortic root size;	chr7:66280771	chr7:66654538~66669855:+
PRAD	cis	rs2153535	0.563	rs7739249	ENSG00000230939.1	RP11-314C16.1	-13.76	2.77e-36	8.18e-33	-0.67	-0.54	Motion sickness;	chr6:8534357	chr6:8784178~8785445:+
PRAD	cis	rs524281	0.861	rs10791855	ENSG00000255320.1	RP11-755F10.1	13.76	2.83e-36	8.38e-33	0.86	0.54	Electroencephalogram traits;	chr11:66196266	chr11:66244840~66246239:-
PRAD	cis	rs2153535	0.58	rs6941670	ENSG00000230939.1	RP11-314C16.1	-13.76	2.83e-36	8.38e-33	-0.67	-0.54	Motion sickness;	chr6:8446113	chr6:8784178~8785445:+
PRAD	cis	rs2404602	0.622	rs2003344	ENSG00000259422.1	RP11-593F23.1	-13.76	2.87e-36	8.47e-33	-0.74	-0.54	Blood metabolite levels;	chr15:76339960	chr15:76174891~76181486:-
PRAD	cis	rs2739330	0.587	rs4820571	ENSG00000250470.1	AP000351.3	13.76	2.94e-36	8.69e-33	0.72	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23976904~23977585:-
PRAD	cis	rs2153535	0.58	rs9393021	ENSG00000230939.1	RP11-314C16.1	-13.76	2.95e-36	8.72e-33	-0.67	-0.54	Motion sickness;	chr6:8465890	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.607	rs9502722	ENSG00000230939.1	RP11-314C16.1	-13.76	2.96e-36	8.75e-33	-0.67	-0.54	Motion sickness;	chr6:8541250	chr6:8784178~8785445:+
PRAD	cis	rs977987	0.864	rs37592	ENSG00000261783.1	RP11-252K23.2	13.76	3.02e-36	8.9e-33	0.76	0.54	Dupuytren's disease;	chr16:75462893	chr16:75379818~75381260:-
PRAD	cis	rs977987	0.864	rs37595	ENSG00000261783.1	RP11-252K23.2	13.76	3.02e-36	8.9e-33	0.76	0.54	Dupuytren's disease;	chr16:75463065	chr16:75379818~75381260:-
PRAD	cis	rs9660180	0.783	rs1107910	ENSG00000268575.1	RP1-283E3.8	-13.75	3.06e-36	9.03e-33	-0.56	-0.54	Body mass index;	chr1:1760882	chr1:1702736~1737688:-
PRAD	cis	rs11690935	0.885	rs6727017	ENSG00000228389.1	AC068039.4	13.75	3.09e-36	9.12e-33	0.64	0.54	Schizophrenia;	chr2:171910337	chr2:171773482~171775844:+
PRAD	cis	rs977987	0.864	rs40446	ENSG00000261783.1	RP11-252K23.2	13.75	3.15e-36	9.3e-33	0.76	0.54	Dupuytren's disease;	chr16:75462760	chr16:75379818~75381260:-
PRAD	cis	rs977987	0.864	rs37593	ENSG00000261783.1	RP11-252K23.2	13.75	3.15e-36	9.3e-33	0.76	0.54	Dupuytren's disease;	chr16:75463009	chr16:75379818~75381260:-
PRAD	cis	rs977987	0.864	rs37594	ENSG00000261783.1	RP11-252K23.2	13.75	3.15e-36	9.3e-33	0.76	0.54	Dupuytren's disease;	chr16:75463045	chr16:75379818~75381260:-
PRAD	cis	rs17826219	0.706	rs57698184	ENSG00000263531.1	RP13-753N3.1	13.75	3.2e-36	9.44e-33	1.05	0.54	Body mass index;	chr17:30737900	chr17:30863921~30864940:-
PRAD	cis	rs2153535	0.542	rs6912740	ENSG00000230939.1	RP11-314C16.1	-13.75	3.24e-36	9.55e-33	-0.67	-0.54	Motion sickness;	chr6:8439726	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.542	rs6905925	ENSG00000230939.1	RP11-314C16.1	-13.75	3.24e-36	9.55e-33	-0.67	-0.54	Motion sickness;	chr6:8439797	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.541	rs6905934	ENSG00000230939.1	RP11-314C16.1	-13.75	3.24e-36	9.55e-33	-0.67	-0.54	Motion sickness;	chr6:8439810	chr6:8784178~8785445:+
PRAD	cis	rs9487094	0.626	rs1322124	ENSG00000260273.1	RP11-425D10.10	13.74	3.4e-36	1e-32	0.74	0.54	Height;	chr6:109741670	chr6:109382795~109383666:+
PRAD	cis	rs2153535	0.58	rs7743686	ENSG00000230939.1	RP11-314C16.1	-13.74	3.47e-36	1.02e-32	-0.67	-0.54	Motion sickness;	chr6:8525878	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.601	rs718504	ENSG00000230939.1	RP11-314C16.1	-13.74	3.47e-36	1.02e-32	-0.67	-0.54	Motion sickness;	chr6:8527279	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.601	rs9328487	ENSG00000230939.1	RP11-314C16.1	-13.74	3.47e-36	1.02e-32	-0.67	-0.54	Motion sickness;	chr6:8529145	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs9328488	ENSG00000230939.1	RP11-314C16.1	-13.74	3.47e-36	1.02e-32	-0.67	-0.54	Motion sickness;	chr6:8529178	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.601	rs7775274	ENSG00000230939.1	RP11-314C16.1	-13.74	3.47e-36	1.02e-32	-0.67	-0.54	Motion sickness;	chr6:8530070	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.623	rs6597338	ENSG00000230939.1	RP11-314C16.1	-13.74	3.47e-36	1.02e-32	-0.67	-0.54	Motion sickness;	chr6:8533275	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs9406167	ENSG00000230939.1	RP11-314C16.1	-13.74	3.49e-36	1.03e-32	-0.67	-0.54	Motion sickness;	chr6:8502619	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs6597334	ENSG00000230939.1	RP11-314C16.1	-13.74	3.49e-36	1.03e-32	-0.67	-0.54	Motion sickness;	chr6:8504546	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs7748455	ENSG00000230939.1	RP11-314C16.1	-13.74	3.65e-36	1.07e-32	-0.67	-0.54	Motion sickness;	chr6:8453392	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs2327064	ENSG00000230939.1	RP11-314C16.1	-13.74	3.67e-36	1.08e-32	-0.67	-0.54	Motion sickness;	chr6:8453819	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs6937186	ENSG00000230939.1	RP11-314C16.1	-13.73	3.78e-36	1.11e-32	-0.67	-0.54	Motion sickness;	chr6:8494260	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs6921964	ENSG00000230939.1	RP11-314C16.1	-13.73	3.79e-36	1.12e-32	-0.67	-0.54	Motion sickness;	chr6:8446162	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.541	rs4637688	ENSG00000230939.1	RP11-314C16.1	-13.73	3.79e-36	1.12e-32	-0.67	-0.54	Motion sickness;	chr6:8446268	chr6:8784178~8785445:+
PRAD	cis	rs9660180	0.967	rs12034740	ENSG00000268575.1	RP1-283E3.8	-13.73	3.86e-36	1.13e-32	-0.57	-0.54	Body mass index;	chr1:1797530	chr1:1702736~1737688:-
PRAD	cis	rs11690935	0.851	rs7573003	ENSG00000228389.1	AC068039.4	13.73	3.87e-36	1.14e-32	0.64	0.54	Schizophrenia;	chr2:171884905	chr2:171773482~171775844:+
PRAD	cis	rs7617773	0.78	rs34523942	ENSG00000229759.1	MRPS18AP1	13.73	3.9e-36	1.14e-32	0.58	0.54	Coronary artery disease;	chr3:48301179	chr3:48256350~48256938:-
PRAD	cis	rs2153535	0.58	rs2327061	ENSG00000230939.1	RP11-314C16.1	-13.73	3.92e-36	1.15e-32	-0.66	-0.54	Motion sickness;	chr6:8446998	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs7453115	ENSG00000230939.1	RP11-314C16.1	-13.73	3.92e-36	1.15e-32	-0.66	-0.54	Motion sickness;	chr6:8447028	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs6910742	ENSG00000230939.1	RP11-314C16.1	-13.73	3.92e-36	1.15e-32	-0.66	-0.54	Motion sickness;	chr6:8448095	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.521	rs6939827	ENSG00000230939.1	RP11-314C16.1	-13.73	3.92e-36	1.15e-32	-0.66	-0.54	Motion sickness;	chr6:8461127	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs9393019	ENSG00000230939.1	RP11-314C16.1	-13.73	3.92e-36	1.15e-32	-0.66	-0.54	Motion sickness;	chr6:8461858	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs7341381	ENSG00000230939.1	RP11-314C16.1	-13.73	3.92e-36	1.15e-32	-0.66	-0.54	Motion sickness;	chr6:8470304	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs1414344	ENSG00000230939.1	RP11-314C16.1	-13.73	3.92e-36	1.15e-32	-0.66	-0.54	Motion sickness;	chr6:8471132	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs7766852	ENSG00000230939.1	RP11-314C16.1	-13.73	3.92e-36	1.15e-32	-0.66	-0.54	Motion sickness;	chr6:8472184	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs2152348	ENSG00000230939.1	RP11-314C16.1	-13.73	3.92e-36	1.15e-32	-0.66	-0.54	Motion sickness;	chr6:8474068	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs6597326	ENSG00000230939.1	RP11-314C16.1	-13.73	3.92e-36	1.15e-32	-0.66	-0.54	Motion sickness;	chr6:8481786	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.541	rs1414353	ENSG00000230939.1	RP11-314C16.1	-13.73	3.92e-36	1.15e-32	-0.66	-0.54	Motion sickness;	chr6:8485409	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs9393025	ENSG00000230939.1	RP11-314C16.1	-13.73	3.92e-36	1.15e-32	-0.66	-0.54	Motion sickness;	chr6:8490385	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs1414340	ENSG00000230939.1	RP11-314C16.1	-13.73	3.92e-36	1.15e-32	-0.66	-0.54	Motion sickness;	chr6:8490906	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs1335628	ENSG00000230939.1	RP11-314C16.1	-13.73	3.92e-36	1.15e-32	-0.66	-0.54	Motion sickness;	chr6:8491509	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs6597330	ENSG00000230939.1	RP11-314C16.1	-13.73	3.92e-36	1.15e-32	-0.66	-0.54	Motion sickness;	chr6:8491843	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.563	rs1737586	ENSG00000230939.1	RP11-314C16.1	-13.73	3.92e-36	1.15e-32	-0.66	-0.54	Motion sickness;	chr6:8535664	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.563	rs1737584	ENSG00000230939.1	RP11-314C16.1	-13.73	3.92e-36	1.15e-32	-0.66	-0.54	Motion sickness;	chr6:8536509	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.601	rs9505472	ENSG00000230939.1	RP11-314C16.1	-13.73	3.92e-36	1.15e-32	-0.66	-0.54	Motion sickness;	chr6:8538532	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.601	rs9505473	ENSG00000230939.1	RP11-314C16.1	-13.73	3.92e-36	1.15e-32	-0.66	-0.54	Motion sickness;	chr6:8538544	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.601	rs9502719	ENSG00000230939.1	RP11-314C16.1	-13.73	3.92e-36	1.15e-32	-0.66	-0.54	Motion sickness;	chr6:8540799	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.547	rs9502720	ENSG00000230939.1	RP11-314C16.1	-13.73	3.92e-36	1.15e-32	-0.66	-0.54	Motion sickness;	chr6:8541129	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.547	rs9505475	ENSG00000230939.1	RP11-314C16.1	-13.73	3.92e-36	1.15e-32	-0.66	-0.54	Motion sickness;	chr6:8542657	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.601	rs6906170	ENSG00000230939.1	RP11-314C16.1	-13.73	3.92e-36	1.15e-32	-0.66	-0.54	Motion sickness;	chr6:8542895	chr6:8784178~8785445:+
PRAD	cis	rs875971	0.862	rs2901152	ENSG00000226824.5	RP4-756H11.3	13.73	3.94e-36	1.15e-32	0.74	0.54	Aortic root size;	chr7:66300017	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.862	rs10263690	ENSG00000226824.5	RP4-756H11.3	13.73	3.94e-36	1.15e-32	0.74	0.54	Aortic root size;	chr7:66301466	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.862	rs11984115	ENSG00000226824.5	RP4-756H11.3	13.73	3.98e-36	1.17e-32	0.74	0.54	Aortic root size;	chr7:66308872	chr7:66654538~66669855:+
PRAD	cis	rs4660456	0.711	rs12409109	ENSG00000237899.1	RP4-739H11.3	-13.73	4e-36	1.17e-32	-0.78	-0.54	Platelet count;	chr1:40727216	chr1:40669089~40687588:-
PRAD	cis	rs9660180	0.967	rs12044597	ENSG00000268575.1	RP1-283E3.8	-13.72	4.12e-36	1.21e-32	-0.56	-0.54	Body mass index;	chr1:1777362	chr1:1702736~1737688:-
PRAD	cis	rs2153535	0.58	rs4587214	ENSG00000230939.1	RP11-314C16.1	-13.72	4.16e-36	1.22e-32	-0.67	-0.54	Motion sickness;	chr6:8453886	chr6:8784178~8785445:+
PRAD	cis	rs875971	0.862	rs10250544	ENSG00000226824.5	RP4-756H11.3	13.72	4.2e-36	1.23e-32	0.74	0.54	Aortic root size;	chr7:66301574	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.895	rs12531677	ENSG00000226824.5	RP4-756H11.3	13.72	4.2e-36	1.23e-32	0.74	0.54	Aortic root size;	chr7:66304099	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.862	rs7798630	ENSG00000226824.5	RP4-756H11.3	13.72	4.2e-36	1.23e-32	0.74	0.54	Aortic root size;	chr7:66306492	chr7:66654538~66669855:+
PRAD	cis	rs2283792	1	rs6928	ENSG00000224086.5	LL22NC03-86G7.1	-13.72	4.3e-36	1.26e-32	-0.63	-0.54	Multiple sclerosis;	chr22:21760715	chr22:21938293~21977632:+
PRAD	cis	rs9660180	0.967	rs6687065	ENSG00000268575.1	RP1-283E3.8	-13.72	4.39e-36	1.28e-32	-0.57	-0.54	Body mass index;	chr1:1847030	chr1:1702736~1737688:-
PRAD	cis	rs9399135	0.967	rs34546690	ENSG00000232876.1	CTA-212D2.2	-13.71	4.48e-36	1.31e-32	-0.65	-0.54	Red blood cell count;	chr6:135048571	chr6:135055033~135060550:+
PRAD	cis	rs9399135	0.967	rs9373122	ENSG00000232876.1	CTA-212D2.2	-13.71	4.48e-36	1.31e-32	-0.65	-0.54	Red blood cell count;	chr6:135052396	chr6:135055033~135060550:+
PRAD	cis	rs9399135	0.933	rs41294852	ENSG00000232876.1	CTA-212D2.2	-13.71	4.48e-36	1.31e-32	-0.65	-0.54	Red blood cell count;	chr6:135055241	chr6:135055033~135060550:+
PRAD	cis	rs2153535	0.58	rs1832100	ENSG00000230939.1	RP11-314C16.1	-13.71	4.49e-36	1.31e-32	-0.66	-0.54	Motion sickness;	chr6:8446723	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs2327058	ENSG00000230939.1	RP11-314C16.1	-13.71	4.49e-36	1.31e-32	-0.66	-0.54	Motion sickness;	chr6:8446785	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.601	rs2327059	ENSG00000230939.1	RP11-314C16.1	-13.71	4.49e-36	1.31e-32	-0.66	-0.54	Motion sickness;	chr6:8446838	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs2184582	ENSG00000230939.1	RP11-314C16.1	-13.71	4.49e-36	1.31e-32	-0.66	-0.54	Motion sickness;	chr6:8447560	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs2184583	ENSG00000230939.1	RP11-314C16.1	-13.71	4.49e-36	1.31e-32	-0.66	-0.54	Motion sickness;	chr6:8447575	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs9505446	ENSG00000230939.1	RP11-314C16.1	-13.71	4.49e-36	1.31e-32	-0.66	-0.54	Motion sickness;	chr6:8448458	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs1335633	ENSG00000230939.1	RP11-314C16.1	-13.71	4.49e-36	1.31e-32	-0.66	-0.54	Motion sickness;	chr6:8448567	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs1115079	ENSG00000230939.1	RP11-314C16.1	-13.71	4.49e-36	1.31e-32	-0.66	-0.54	Motion sickness;	chr6:8449382	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs1115078	ENSG00000230939.1	RP11-314C16.1	-13.71	4.49e-36	1.31e-32	-0.66	-0.54	Motion sickness;	chr6:8449405	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs6597322	ENSG00000230939.1	RP11-314C16.1	-13.71	4.49e-36	1.31e-32	-0.66	-0.54	Motion sickness;	chr6:8449719	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs962590	ENSG00000230939.1	RP11-314C16.1	-13.71	4.49e-36	1.31e-32	-0.66	-0.54	Motion sickness;	chr6:8450666	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs5001324	ENSG00000230939.1	RP11-314C16.1	-13.71	4.49e-36	1.31e-32	-0.66	-0.54	Motion sickness;	chr6:8451371	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs5001322	ENSG00000230939.1	RP11-314C16.1	-13.71	4.49e-36	1.31e-32	-0.66	-0.54	Motion sickness;	chr6:8451375	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs969422	ENSG00000230939.1	RP11-314C16.1	-13.71	4.49e-36	1.31e-32	-0.66	-0.54	Motion sickness;	chr6:8451547	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs969421	ENSG00000230939.1	RP11-314C16.1	-13.71	4.49e-36	1.31e-32	-0.66	-0.54	Motion sickness;	chr6:8451716	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.601	rs969420	ENSG00000230939.1	RP11-314C16.1	-13.71	4.49e-36	1.31e-32	-0.66	-0.54	Motion sickness;	chr6:8451733	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.562	rs6901765	ENSG00000230939.1	RP11-314C16.1	-13.71	4.49e-36	1.31e-32	-0.66	-0.54	Motion sickness;	chr6:8455203	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.601	rs9502715	ENSG00000230939.1	RP11-314C16.1	-13.71	4.49e-36	1.31e-32	-0.66	-0.54	Motion sickness;	chr6:8455476	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs6912193	ENSG00000230939.1	RP11-314C16.1	-13.71	4.49e-36	1.31e-32	-0.66	-0.54	Motion sickness;	chr6:8456073	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs6912374	ENSG00000230939.1	RP11-314C16.1	-13.71	4.49e-36	1.31e-32	-0.66	-0.54	Motion sickness;	chr6:8456190	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.541	rs6908504	ENSG00000230939.1	RP11-314C16.1	-13.71	4.49e-36	1.31e-32	-0.66	-0.54	Motion sickness;	chr6:8456545	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs6913100	ENSG00000230939.1	RP11-314C16.1	-13.71	4.49e-36	1.31e-32	-0.66	-0.54	Motion sickness;	chr6:8456622	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs7769020	ENSG00000230939.1	RP11-314C16.1	-13.71	4.49e-36	1.31e-32	-0.66	-0.54	Motion sickness;	chr6:8457491	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs9392220	ENSG00000230939.1	RP11-314C16.1	-13.71	4.49e-36	1.31e-32	-0.66	-0.54	Motion sickness;	chr6:8457713	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs9379206	ENSG00000230939.1	RP11-314C16.1	-13.71	4.49e-36	1.31e-32	-0.66	-0.54	Motion sickness;	chr6:8457788	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.541	rs9379207	ENSG00000230939.1	RP11-314C16.1	-13.71	4.49e-36	1.31e-32	-0.66	-0.54	Motion sickness;	chr6:8457953	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs9393016	ENSG00000230939.1	RP11-314C16.1	-13.71	4.49e-36	1.31e-32	-0.66	-0.54	Motion sickness;	chr6:8458340	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs4960421	ENSG00000230939.1	RP11-314C16.1	-13.71	4.49e-36	1.31e-32	-0.66	-0.54	Motion sickness;	chr6:8459059	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs4960422	ENSG00000230939.1	RP11-314C16.1	-13.71	4.49e-36	1.31e-32	-0.66	-0.54	Motion sickness;	chr6:8459076	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs7742794	ENSG00000230939.1	RP11-314C16.1	-13.71	4.49e-36	1.31e-32	-0.66	-0.54	Motion sickness;	chr6:8459490	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs9505448	ENSG00000230939.1	RP11-314C16.1	-13.71	4.49e-36	1.31e-32	-0.66	-0.54	Motion sickness;	chr6:8459571	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.601	rs2015281	ENSG00000230939.1	RP11-314C16.1	-13.71	4.49e-36	1.31e-32	-0.66	-0.54	Motion sickness;	chr6:8539440	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.601	rs9505474	ENSG00000230939.1	RP11-314C16.1	-13.71	4.49e-36	1.31e-32	-0.66	-0.54	Motion sickness;	chr6:8539561	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.601	rs2327091	ENSG00000230939.1	RP11-314C16.1	-13.71	4.49e-36	1.31e-32	-0.66	-0.54	Motion sickness;	chr6:8540136	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.584	rs9502723	ENSG00000230939.1	RP11-314C16.1	-13.71	4.49e-36	1.31e-32	-0.66	-0.54	Motion sickness;	chr6:8541271	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.601	rs4140584	ENSG00000230939.1	RP11-314C16.1	13.71	4.49e-36	1.31e-32	0.66	0.54	Motion sickness;	chr6:8540381	chr6:8784178~8785445:+
PRAD	cis	rs6142102	0.602	rs2268086	ENSG00000276073.1	RP5-1125A11.7	13.71	4.51e-36	1.31e-32	0.53	0.54	Skin pigmentation;	chr20:34060932	chr20:33985617~33988989:-
PRAD	cis	rs3814244	0.528	rs7952790	ENSG00000255733.4	IFNG-AS1	13.71	4.63e-36	1.35e-32	0.59	0.54	Itch intensity from mosquito bite adjusted by bite size;	chr12:68012672	chr12:67989445~68234686:+
PRAD	cis	rs7208859	0.623	rs7219712	ENSG00000263531.1	RP13-753N3.1	13.71	4.76e-36	1.38e-32	1.05	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753552	chr17:30863921~30864940:-
PRAD	cis	rs2581828	0.656	rs1864367	ENSG00000242142.1	SERBP1P3	13.71	4.94e-36	1.44e-32	0.6	0.54	Crohn's disease;	chr3:53077688	chr3:53064283~53065091:-
PRAD	cis	rs2153535	0.541	rs945304	ENSG00000230939.1	RP11-314C16.1	-13.7	4.96e-36	1.44e-32	-0.67	-0.54	Motion sickness;	chr6:8442659	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs1889715	ENSG00000230939.1	RP11-314C16.1	-13.7	4.96e-36	1.44e-32	-0.67	-0.54	Motion sickness;	chr6:8443242	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.526	rs7748404	ENSG00000230939.1	RP11-314C16.1	-13.7	4.96e-36	1.44e-32	-0.67	-0.54	Motion sickness;	chr6:8472267	chr6:8784178~8785445:+
PRAD	cis	rs9545047	0.935	rs7339303	ENSG00000227676.3	LINC01068	-13.7	5.06e-36	1.47e-32	-0.67	-0.54	Schizophrenia;	chr13:79516730	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.905	rs7321953	ENSG00000227676.3	LINC01068	-13.7	5.06e-36	1.47e-32	-0.67	-0.54	Schizophrenia;	chr13:79517404	chr13:79566727~79571436:+
PRAD	cis	rs11155671	0.53	rs7757984	ENSG00000231760.4	RP11-350J20.5	13.7	5.06e-36	1.47e-32	0.73	0.54	Testicular germ cell tumor;	chr6:149887515	chr6:149796151~149826294:-
PRAD	cis	rs2153535	0.58	rs4639392	ENSG00000230939.1	RP11-314C16.1	-13.7	5.13e-36	1.49e-32	-0.67	-0.54	Motion sickness;	chr6:8446314	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.563	rs1796687	ENSG00000230939.1	RP11-314C16.1	-13.7	5.18e-36	1.5e-32	-0.68	-0.54	Motion sickness;	chr6:8535885	chr6:8784178~8785445:+
PRAD	cis	rs4660456	0.913	rs4660449	ENSG00000237899.1	RP4-739H11.3	13.7	5.2e-36	1.51e-32	0.78	0.54	Platelet count;	chr1:40739780	chr1:40669089~40687588:-
PRAD	cis	rs875971	0.862	rs778680	ENSG00000226824.5	RP4-756H11.3	-13.7	5.28e-36	1.53e-32	-0.73	-0.54	Aortic root size;	chr7:66375427	chr7:66654538~66669855:+
PRAD	cis	rs2153535	0.58	rs1577468	ENSG00000230939.1	RP11-314C16.1	-13.7	5.31e-36	1.54e-32	-0.67	-0.54	Motion sickness;	chr6:8444033	chr6:8784178~8785445:+
PRAD	cis	rs2739330	0.731	rs4822450	ENSG00000231271.1	AP000350.8	13.7	5.34e-36	1.55e-32	0.73	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23949918~23954042:+
PRAD	cis	rs4660456	0.913	rs7542019	ENSG00000237899.1	RP4-739H11.3	13.69	5.45e-36	1.58e-32	0.78	0.54	Platelet count;	chr1:40704039	chr1:40669089~40687588:-
PRAD	cis	rs4660456	0.913	rs1494	ENSG00000237899.1	RP4-739H11.3	13.69	5.45e-36	1.58e-32	0.78	0.54	Platelet count;	chr1:40706176	chr1:40669089~40687588:-
PRAD	cis	rs4660456	0.869	rs7518344	ENSG00000237899.1	RP4-739H11.3	13.69	5.45e-36	1.58e-32	0.78	0.54	Platelet count;	chr1:40708327	chr1:40669089~40687588:-
PRAD	cis	rs4660456	0.827	rs10736404	ENSG00000237899.1	RP4-739H11.3	13.69	5.45e-36	1.58e-32	0.78	0.54	Platelet count;	chr1:40710331	chr1:40669089~40687588:-
PRAD	cis	rs9545047	0.935	rs2760102	ENSG00000227676.3	LINC01068	13.69	5.65e-36	1.64e-32	0.68	0.54	Schizophrenia;	chr13:79555193	chr13:79566727~79571436:+
PRAD	cis	rs875971	0.798	rs57739047	ENSG00000226824.5	RP4-756H11.3	-13.69	5.65e-36	1.64e-32	-0.73	-0.54	Aortic root size;	chr7:66507579	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.83	rs6950137	ENSG00000226824.5	RP4-756H11.3	-13.69	5.65e-36	1.64e-32	-0.73	-0.54	Aortic root size;	chr7:66511623	chr7:66654538~66669855:+
PRAD	cis	rs7617773	0.817	rs9837228	ENSG00000229759.1	MRPS18AP1	-13.69	5.75e-36	1.67e-32	-0.58	-0.54	Coronary artery disease;	chr3:48282976	chr3:48256350~48256938:-
PRAD	cis	rs875971	0.755	rs10228885	ENSG00000226824.5	RP4-756H11.3	13.69	5.82e-36	1.69e-32	0.74	0.54	Aortic root size;	chr7:66315542	chr7:66654538~66669855:+
PRAD	cis	rs10256972	0.786	rs3735686	ENSG00000229043.2	AC091729.9	-13.69	5.82e-36	1.69e-32	-0.66	-0.54	Endometriosis;Longevity;	chr7:1022891	chr7:1160374~1165267:+
PRAD	cis	rs494459	0.838	rs567680	ENSG00000255239.1	AP002954.6	13.69	5.83e-36	1.69e-32	0.7	0.54	Height;	chr11:118737823	chr11:118688039~118690600:-
PRAD	cis	rs2153535	0.504	rs5001323	ENSG00000230939.1	RP11-314C16.1	-13.69	5.87e-36	1.7e-32	-0.66	-0.54	Motion sickness;	chr6:8451372	chr6:8784178~8785445:+
PRAD	cis	rs10256972	0.616	rs7806746	ENSG00000229043.2	AC091729.9	-13.69	5.94e-36	1.72e-32	-0.64	-0.54	Endometriosis;Longevity;	chr7:1035937	chr7:1160374~1165267:+
PRAD	cis	rs2153535	0.542	rs915353	ENSG00000230939.1	RP11-314C16.1	-13.69	5.99e-36	1.73e-32	-0.67	-0.54	Motion sickness;	chr6:8440137	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs2327050	ENSG00000230939.1	RP11-314C16.1	-13.69	5.99e-36	1.73e-32	-0.67	-0.54	Motion sickness;	chr6:8440397	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs4404802	ENSG00000230939.1	RP11-314C16.1	-13.69	5.99e-36	1.73e-32	-0.67	-0.54	Motion sickness;	chr6:8441819	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs1932275	ENSG00000230939.1	RP11-314C16.1	-13.69	5.99e-36	1.73e-32	-0.67	-0.54	Motion sickness;	chr6:8442100	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs1932276	ENSG00000230939.1	RP11-314C16.1	-13.69	5.99e-36	1.73e-32	-0.67	-0.54	Motion sickness;	chr6:8442360	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs915352	ENSG00000230939.1	RP11-314C16.1	-13.69	5.99e-36	1.73e-32	-0.67	-0.54	Motion sickness;	chr6:8442533	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs915351	ENSG00000230939.1	RP11-314C16.1	-13.69	5.99e-36	1.73e-32	-0.67	-0.54	Motion sickness;	chr6:8442560	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs2327056	ENSG00000230939.1	RP11-314C16.1	-13.69	5.99e-36	1.73e-32	-0.67	-0.54	Motion sickness;	chr6:8443072	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs3938660	ENSG00000230939.1	RP11-314C16.1	-13.69	5.99e-36	1.73e-32	-0.67	-0.54	Motion sickness;	chr6:8443102	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs1577467	ENSG00000230939.1	RP11-314C16.1	-13.69	5.99e-36	1.73e-32	-0.67	-0.54	Motion sickness;	chr6:8444008	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.601	rs1855765	ENSG00000230939.1	RP11-314C16.1	-13.69	5.99e-36	1.73e-32	-0.67	-0.54	Motion sickness;	chr6:8444092	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs9406143	ENSG00000230939.1	RP11-314C16.1	-13.69	5.99e-36	1.73e-32	-0.67	-0.54	Motion sickness;	chr6:8444350	chr6:8784178~8785445:+
PRAD	cis	rs673078	0.607	rs882927	ENSG00000275759.1	RP11-131L12.3	-13.68	6.04e-36	1.75e-32	-0.8	-0.54	Glucose homeostasis traits;	chr12:118406737	chr12:118428281~118428870:+
PRAD	cis	rs2019137	0.56	rs7421852	ENSG00000274877.1	RP11-65I12.1	-13.68	6.17e-36	1.78e-32	-0.74	-0.54	Lymphocyte counts;	chr2:113232684	chr2:113237595~113240825:+
PRAD	cis	rs3091242	0.804	rs631133	ENSG00000224183.1	SDHDP6	-13.68	6.18e-36	1.79e-32	-0.63	-0.54	Erythrocyte sedimentation rate;	chr1:25397655	chr1:25294164~25294643:-
PRAD	cis	rs8100891	0.537	rs4805754	ENSG00000267213.4	AC007773.2	-13.68	6.23e-36	1.8e-32	-0.71	-0.54	Neuroticism;	chr19:32346260	chr19:32390050~32405560:-
PRAD	cis	rs2153535	0.58	rs2143357	ENSG00000230939.1	RP11-314C16.1	-13.68	6.24e-36	1.8e-32	-0.67	-0.54	Motion sickness;	chr6:8496963	chr6:8784178~8785445:+
PRAD	cis	rs875971	0.862	rs11769079	ENSG00000226824.5	RP4-756H11.3	-13.68	6.24e-36	1.8e-32	-0.73	-0.54	Aortic root size;	chr7:66377141	chr7:66654538~66669855:+
PRAD	cis	rs4660456	0.913	rs12727412	ENSG00000237899.1	RP4-739H11.3	-13.68	6.25e-36	1.8e-32	-0.78	-0.54	Platelet count;	chr1:40723243	chr1:40669089~40687588:-
PRAD	cis	rs4660456	0.913	rs4660448	ENSG00000237899.1	RP4-739H11.3	-13.68	6.25e-36	1.8e-32	-0.78	-0.54	Platelet count;	chr1:40724682	chr1:40669089~40687588:-
PRAD	cis	rs4660456	0.913	rs7532802	ENSG00000237899.1	RP4-739H11.3	-13.68	6.25e-36	1.8e-32	-0.78	-0.54	Platelet count;	chr1:40725528	chr1:40669089~40687588:-
PRAD	cis	rs4660456	0.913	rs2361648	ENSG00000237899.1	RP4-739H11.3	-13.68	6.25e-36	1.8e-32	-0.78	-0.54	Platelet count;	chr1:40726825	chr1:40669089~40687588:-
PRAD	cis	rs4660456	0.913	rs6675886	ENSG00000237899.1	RP4-739H11.3	-13.68	6.25e-36	1.8e-32	-0.78	-0.54	Platelet count;	chr1:40727955	chr1:40669089~40687588:-
PRAD	cis	rs4660456	0.913	rs6668453	ENSG00000237899.1	RP4-739H11.3	-13.68	6.25e-36	1.8e-32	-0.78	-0.54	Platelet count;	chr1:40733299	chr1:40669089~40687588:-
PRAD	cis	rs4660456	0.913	rs35881320	ENSG00000237899.1	RP4-739H11.3	-13.68	6.25e-36	1.8e-32	-0.78	-0.54	Platelet count;	chr1:40733893	chr1:40669089~40687588:-
PRAD	cis	rs4660456	0.871	rs34512220	ENSG00000237899.1	RP4-739H11.3	-13.68	6.25e-36	1.8e-32	-0.78	-0.54	Platelet count;	chr1:40733912	chr1:40669089~40687588:-
PRAD	cis	rs4660456	0.913	rs6664044	ENSG00000237899.1	RP4-739H11.3	-13.68	6.25e-36	1.8e-32	-0.78	-0.54	Platelet count;	chr1:40735089	chr1:40669089~40687588:-
PRAD	cis	rs4660456	0.913	rs6702983	ENSG00000237899.1	RP4-739H11.3	-13.68	6.25e-36	1.8e-32	-0.78	-0.54	Platelet count;	chr1:40735585	chr1:40669089~40687588:-
PRAD	cis	rs4660456	0.913	rs12566733	ENSG00000237899.1	RP4-739H11.3	-13.68	6.25e-36	1.8e-32	-0.78	-0.54	Platelet count;	chr1:40736067	chr1:40669089~40687588:-
PRAD	cis	rs2153535	0.58	rs7755284	ENSG00000230939.1	RP11-314C16.1	-13.68	6.25e-36	1.81e-32	-0.66	-0.54	Motion sickness;	chr6:8457246	chr6:8784178~8785445:+
PRAD	cis	rs9660180	0.935	rs9786942	ENSG00000268575.1	RP1-283E3.8	-13.68	6.34e-36	1.83e-32	-0.56	-0.54	Body mass index;	chr1:1827774	chr1:1702736~1737688:-
PRAD	cis	rs9660180	0.934	rs34849348	ENSG00000268575.1	RP1-283E3.8	-13.68	6.34e-36	1.83e-32	-0.56	-0.54	Body mass index;	chr1:1831318	chr1:1702736~1737688:-
PRAD	cis	rs9487094	0.626	rs10457192	ENSG00000260273.1	RP11-425D10.10	13.68	6.38e-36	1.84e-32	0.72	0.54	Height;	chr6:109507271	chr6:109382795~109383666:+
PRAD	cis	rs55794721	0.509	rs2375313	ENSG00000261349.1	RP3-465N24.5	-13.68	6.51e-36	1.88e-32	-0.6	-0.54	Mean corpuscular volume;Plateletcrit;	chr1:25421744	chr1:25266102~25267136:-
PRAD	cis	rs6504950	0.745	rs9915913	ENSG00000275710.1	RP11-257O5.4	13.68	6.53e-36	1.88e-32	0.73	0.54	Breast cancer;	chr17:54920807	chr17:54964474~54964679:+
PRAD	cis	rs875971	0.862	rs1695820	ENSG00000226824.5	RP4-756H11.3	-13.68	6.57e-36	1.89e-32	-0.73	-0.54	Aortic root size;	chr7:66379576	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.83	rs778715	ENSG00000226824.5	RP4-756H11.3	-13.68	6.57e-36	1.89e-32	-0.73	-0.54	Aortic root size;	chr7:66384222	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.83	rs809025	ENSG00000226824.5	RP4-756H11.3	-13.68	6.57e-36	1.89e-32	-0.73	-0.54	Aortic root size;	chr7:66384832	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.862	rs1643375	ENSG00000226824.5	RP4-756H11.3	-13.68	6.57e-36	1.89e-32	-0.73	-0.54	Aortic root size;	chr7:66407690	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.862	rs6962717	ENSG00000226824.5	RP4-756H11.3	-13.68	6.57e-36	1.89e-32	-0.73	-0.54	Aortic root size;	chr7:66418748	chr7:66654538~66669855:+
PRAD	cis	rs9660180	0.935	rs2180311	ENSG00000268575.1	RP1-283E3.8	-13.67	6.79e-36	1.96e-32	-0.56	-0.54	Body mass index;	chr1:1817295	chr1:1702736~1737688:-
PRAD	cis	rs9660180	0.967	rs6664664	ENSG00000268575.1	RP1-283E3.8	-13.67	6.79e-36	1.96e-32	-0.56	-0.54	Body mass index;	chr1:1819825	chr1:1702736~1737688:-
PRAD	cis	rs7617773	0.817	rs6801801	ENSG00000229759.1	MRPS18AP1	13.67	6.89e-36	1.98e-32	0.58	0.54	Coronary artery disease;	chr3:48284943	chr3:48256350~48256938:-
PRAD	cis	rs2153535	0.58	rs9406169	ENSG00000230939.1	RP11-314C16.1	-13.67	6.93e-36	2e-32	-0.66	-0.54	Motion sickness;	chr6:8509237	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs1328862	ENSG00000230939.1	RP11-314C16.1	-13.67	6.93e-36	2e-32	-0.66	-0.54	Motion sickness;	chr6:8526448	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.601	rs1928183	ENSG00000230939.1	RP11-314C16.1	-13.67	6.93e-36	2e-32	-0.66	-0.54	Motion sickness;	chr6:8529785	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs6597337	ENSG00000230939.1	RP11-314C16.1	-13.67	6.93e-36	2e-32	-0.66	-0.54	Motion sickness;	chr6:8531419	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs9406165	ENSG00000230939.1	RP11-314C16.1	-13.67	6.96e-36	2e-32	-0.67	-0.54	Motion sickness;	chr6:8488604	chr6:8784178~8785445:+
PRAD	cis	rs11155671	0.53	rs9397398	ENSG00000231760.4	RP11-350J20.5	13.67	7.17e-36	2.06e-32	0.74	0.54	Testicular germ cell tumor;	chr6:149872467	chr6:149796151~149826294:-
PRAD	cis	rs6142102	0.625	rs6142068	ENSG00000276073.1	RP5-1125A11.7	13.67	7.26e-36	2.09e-32	0.53	0.54	Skin pigmentation;	chr20:33969366	chr20:33985617~33988989:-
PRAD	cis	rs6142102	0.602	rs2268079	ENSG00000276073.1	RP5-1125A11.7	-13.67	7.26e-36	2.09e-32	-0.52	-0.54	Skin pigmentation;	chr20:34008944	chr20:33985617~33988989:-
PRAD	cis	rs524281	0.861	rs10791854	ENSG00000255320.1	RP11-755F10.1	13.66	7.38e-36	2.12e-32	0.86	0.54	Electroencephalogram traits;	chr11:66196072	chr11:66244840~66246239:-
PRAD	cis	rs524281	0.861	rs2177053	ENSG00000255320.1	RP11-755F10.1	13.66	7.38e-36	2.12e-32	0.86	0.54	Electroencephalogram traits;	chr11:66198674	chr11:66244840~66246239:-
PRAD	cis	rs524281	0.814	rs10896098	ENSG00000255320.1	RP11-755F10.1	13.66	7.38e-36	2.12e-32	0.86	0.54	Electroencephalogram traits;	chr11:66200945	chr11:66244840~66246239:-
PRAD	cis	rs71403859	0.803	rs7203606	ENSG00000260886.1	TAT-AS1	13.66	7.44e-36	2.14e-32	0.96	0.54	Post bronchodilator FEV1;	chr16:71556608	chr16:71565789~71578187:+
PRAD	cis	rs2153535	0.58	rs1410766	ENSG00000230939.1	RP11-314C16.1	-13.66	7.47e-36	2.15e-32	-0.66	-0.54	Motion sickness;	chr6:8525127	chr6:8784178~8785445:+
PRAD	cis	rs875971	0.825	rs6951503	ENSG00000226824.5	RP4-756H11.3	13.66	7.59e-36	2.18e-32	0.74	0.54	Aortic root size;	chr7:66253949	chr7:66654538~66669855:+
PRAD	cis	rs4660456	0.871	rs669072	ENSG00000237899.1	RP4-739H11.3	13.66	7.76e-36	2.23e-32	0.78	0.54	Platelet count;	chr1:40679946	chr1:40669089~40687588:-
PRAD	cis	rs4660456	0.912	rs658806	ENSG00000237899.1	RP4-739H11.3	13.66	7.76e-36	2.23e-32	0.78	0.54	Platelet count;	chr1:40683312	chr1:40669089~40687588:-
PRAD	cis	rs4660456	0.913	rs489222	ENSG00000237899.1	RP4-739H11.3	13.66	7.76e-36	2.23e-32	0.78	0.54	Platelet count;	chr1:40683422	chr1:40669089~40687588:-
PRAD	cis	rs4660456	0.871	rs671704	ENSG00000237899.1	RP4-739H11.3	13.66	7.76e-36	2.23e-32	0.78	0.54	Platelet count;	chr1:40683974	chr1:40669089~40687588:-
PRAD	cis	rs2153535	0.58	rs7753192	ENSG00000230939.1	RP11-314C16.1	-13.66	7.85e-36	2.25e-32	-0.67	-0.54	Motion sickness;	chr6:8482404	chr6:8784178~8785445:+
PRAD	cis	rs4660456	0.826	rs507914	ENSG00000237899.1	RP4-739H11.3	13.66	7.91e-36	2.27e-32	0.78	0.54	Platelet count;	chr1:40686529	chr1:40669089~40687588:-
PRAD	cis	rs4660456	0.913	rs2780950	ENSG00000237899.1	RP4-739H11.3	13.66	7.91e-36	2.27e-32	0.78	0.54	Platelet count;	chr1:40686937	chr1:40669089~40687588:-
PRAD	cis	rs9326248	0.603	rs7396061	ENSG00000254851.1	RP11-109L13.1	-13.66	7.93e-36	2.27e-32	-0.69	-0.54	Blood protein levels;	chr11:116880158	chr11:117135528~117138582:+
PRAD	cis	rs11118620	0.535	rs1389750	ENSG00000238078.1	LINC01352	13.66	7.97e-36	2.28e-32	0.63	0.54	Heart failure;	chr1:220866829	chr1:220829255~220832429:+
PRAD	cis	rs11155671	0.53	rs2342769	ENSG00000231760.4	RP11-350J20.5	13.65	8.11e-36	2.32e-32	0.73	0.54	Testicular germ cell tumor;	chr6:149895371	chr6:149796151~149826294:-
PRAD	cis	rs11155671	0.53	rs2342770	ENSG00000231760.4	RP11-350J20.5	13.65	8.11e-36	2.32e-32	0.73	0.54	Testicular germ cell tumor;	chr6:149895549	chr6:149796151~149826294:-
PRAD	cis	rs2153535	0.542	rs9393012	ENSG00000230939.1	RP11-314C16.1	-13.65	8.14e-36	2.33e-32	-0.67	-0.54	Motion sickness;	chr6:8439576	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs7741403	ENSG00000230939.1	RP11-314C16.1	13.65	8.17e-36	2.34e-32	0.66	0.54	Motion sickness;	chr6:8530345	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.601	rs1737581	ENSG00000230939.1	RP11-314C16.1	-13.65	8.22e-36	2.35e-32	-0.66	-0.54	Motion sickness;	chr6:8538905	chr6:8784178~8785445:+
PRAD	cis	rs524281	0.861	rs10791858	ENSG00000255320.1	RP11-755F10.1	13.65	8.33e-36	2.38e-32	0.87	0.54	Electroencephalogram traits;	chr11:66210925	chr11:66244840~66246239:-
PRAD	cis	rs524281	0.817	rs10791859	ENSG00000255320.1	RP11-755F10.1	13.65	8.33e-36	2.38e-32	0.87	0.54	Electroencephalogram traits;	chr11:66210982	chr11:66244840~66246239:-
PRAD	cis	rs916888	0.61	rs199446	ENSG00000262500.1	RP11-259G18.2	-13.65	8.41e-36	2.41e-32	-0.71	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:46243606~46245044:+
PRAD	cis	rs916888	0.61	rs199536	ENSG00000262500.1	RP11-259G18.2	-13.65	8.41e-36	2.41e-32	-0.71	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:46243606~46245044:+
PRAD	cis	rs673078	0.607	rs7137055	ENSG00000275759.1	RP11-131L12.3	-13.65	8.47e-36	2.42e-32	-0.81	-0.54	Glucose homeostasis traits;	chr12:118395030	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.607	rs7137184	ENSG00000275759.1	RP11-131L12.3	-13.65	8.47e-36	2.42e-32	-0.81	-0.54	Glucose homeostasis traits;	chr12:118395163	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.562	rs4767672	ENSG00000275759.1	RP11-131L12.3	-13.65	8.47e-36	2.42e-32	-0.81	-0.54	Glucose homeostasis traits;	chr12:118397048	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.607	rs73205594	ENSG00000275759.1	RP11-131L12.3	-13.65	8.47e-36	2.42e-32	-0.81	-0.54	Glucose homeostasis traits;	chr12:118397168	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.607	rs61943400	ENSG00000275759.1	RP11-131L12.3	-13.65	8.47e-36	2.42e-32	-0.81	-0.54	Glucose homeostasis traits;	chr12:118398236	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.607	rs61943401	ENSG00000275759.1	RP11-131L12.3	-13.65	8.47e-36	2.42e-32	-0.81	-0.54	Glucose homeostasis traits;	chr12:118398527	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.607	rs61943402	ENSG00000275759.1	RP11-131L12.3	-13.65	8.47e-36	2.42e-32	-0.81	-0.54	Glucose homeostasis traits;	chr12:118398808	chr12:118428281~118428870:+
PRAD	cis	rs875971	0.862	rs7783779	ENSG00000226824.5	RP4-756H11.3	13.65	8.49e-36	2.43e-32	0.74	0.54	Aortic root size;	chr7:66331639	chr7:66654538~66669855:+
PRAD	cis	rs71403859	0.614	rs12447033	ENSG00000260886.1	TAT-AS1	13.65	8.56e-36	2.45e-32	0.91	0.54	Post bronchodilator FEV1;	chr16:71549752	chr16:71565789~71578187:+
PRAD	cis	rs17826219	0.636	rs7221463	ENSG00000263531.1	RP13-753N3.1	13.65	8.57e-36	2.45e-32	1.05	0.54	Body mass index;	chr17:30753533	chr17:30863921~30864940:-
PRAD	cis	rs2153535	0.58	rs9328479	ENSG00000230939.1	RP11-314C16.1	-13.65	8.69e-36	2.48e-32	-0.66	-0.54	Motion sickness;	chr6:8519413	chr6:8784178~8785445:+
PRAD	cis	rs7104764	0.957	rs6598075	ENSG00000277290.1	RP11-326C3.16	13.65	8.8e-36	2.51e-32	0.51	0.54	Menarche (age at onset);	chr11:207275	chr11:243099~243483:-
PRAD	cis	rs2739330	0.929	rs5751775	ENSG00000231271.1	AP000350.8	13.64	8.92e-36	2.55e-32	0.73	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23949918~23954042:+
PRAD	cis	rs4660456	0.83	rs12566786	ENSG00000237899.1	RP4-739H11.3	-13.64	8.94e-36	2.55e-32	-0.78	-0.54	Platelet count;	chr1:40742709	chr1:40669089~40687588:-
PRAD	cis	rs4660456	0.871	rs2274957	ENSG00000237899.1	RP4-739H11.3	-13.64	8.94e-36	2.55e-32	-0.78	-0.54	Platelet count;	chr1:40747290	chr1:40669089~40687588:-
PRAD	cis	rs4660456	0.913	rs4660173	ENSG00000237899.1	RP4-739H11.3	-13.64	8.94e-36	2.55e-32	-0.78	-0.54	Platelet count;	chr1:40747876	chr1:40669089~40687588:-
PRAD	cis	rs4660456	0.913	rs4660452	ENSG00000237899.1	RP4-739H11.3	-13.64	8.94e-36	2.55e-32	-0.78	-0.54	Platelet count;	chr1:40748519	chr1:40669089~40687588:-
PRAD	cis	rs4660456	0.913	rs12567925	ENSG00000237899.1	RP4-739H11.3	-13.64	8.94e-36	2.55e-32	-0.78	-0.54	Platelet count;	chr1:40751428	chr1:40669089~40687588:-
PRAD	cis	rs4660456	0.913	rs12728776	ENSG00000237899.1	RP4-739H11.3	-13.64	8.94e-36	2.55e-32	-0.78	-0.54	Platelet count;	chr1:40751718	chr1:40669089~40687588:-
PRAD	cis	rs4660456	0.913	rs12567755	ENSG00000237899.1	RP4-739H11.3	-13.64	8.94e-36	2.55e-32	-0.78	-0.54	Platelet count;	chr1:40751813	chr1:40669089~40687588:-
PRAD	cis	rs4660456	0.913	rs16827532	ENSG00000237899.1	RP4-739H11.3	-13.64	8.94e-36	2.55e-32	-0.78	-0.54	Platelet count;	chr1:40755064	chr1:40669089~40687588:-
PRAD	cis	rs4660456	0.913	rs12729696	ENSG00000237899.1	RP4-739H11.3	-13.64	8.94e-36	2.55e-32	-0.78	-0.54	Platelet count;	chr1:40755099	chr1:40669089~40687588:-
PRAD	cis	rs11155671	0.53	rs4458704	ENSG00000216906.2	RP11-350J20.9	13.64	8.94e-36	2.55e-32	0.64	0.54	Testicular germ cell tumor;	chr6:149911743	chr6:149904243~149906418:+
PRAD	cis	rs73086581	0.898	rs11906452	ENSG00000229539.1	RP11-119B16.2	13.64	8.97e-36	2.56e-32	0.88	0.54	Response to antidepressants in depression;	chr20:4000912	chr20:3888239~3888868:-
PRAD	cis	rs73086581	1	rs6107386	ENSG00000229539.1	RP11-119B16.2	13.64	9.09e-36	2.59e-32	0.89	0.54	Response to antidepressants in depression;	chr20:3992109	chr20:3888239~3888868:-
PRAD	cis	rs875971	0.862	rs1167408	ENSG00000226824.5	RP4-756H11.3	13.64	9.16e-36	2.61e-32	0.75	0.54	Aortic root size;	chr7:66091121	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.83	rs1167406	ENSG00000226824.5	RP4-756H11.3	13.64	9.16e-36	2.61e-32	0.75	0.54	Aortic root size;	chr7:66091949	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.862	rs1167399	ENSG00000226824.5	RP4-756H11.3	13.64	9.16e-36	2.61e-32	0.75	0.54	Aortic root size;	chr7:66096890	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.862	rs57866200	ENSG00000226824.5	RP4-756H11.3	13.64	9.16e-36	2.61e-32	0.75	0.54	Aortic root size;	chr7:66100405	chr7:66654538~66669855:+
PRAD	cis	rs11155671	0.53	rs7756850	ENSG00000231760.4	RP11-350J20.5	13.64	9.47e-36	2.7e-32	0.72	0.54	Testicular germ cell tumor;	chr6:149891460	chr6:149796151~149826294:-
PRAD	cis	rs11155671	0.53	rs9371542	ENSG00000231760.4	RP11-350J20.5	13.64	9.47e-36	2.7e-32	0.72	0.54	Testicular germ cell tumor;	chr6:149891949	chr6:149796151~149826294:-
PRAD	cis	rs11155671	0.53	rs9371223	ENSG00000231760.4	RP11-350J20.5	13.64	9.47e-36	2.7e-32	0.72	0.54	Testicular germ cell tumor;	chr6:149893670	chr6:149796151~149826294:-
PRAD	cis	rs2019137	0.539	rs11123170	ENSG00000274877.1	RP11-65I12.1	-13.64	9.58e-36	2.73e-32	-0.75	-0.54	Lymphocyte counts;	chr2:113221363	chr2:113237595~113240825:+
PRAD	cis	rs2153535	0.58	rs6597332	ENSG00000230939.1	RP11-314C16.1	-13.64	9.74e-36	2.77e-32	-0.67	-0.54	Motion sickness;	chr6:8504515	chr6:8784178~8785445:+
PRAD	cis	rs9660180	0.967	rs11260623	ENSG00000268575.1	RP1-283E3.8	-13.63	9.93e-36	2.82e-32	-0.56	-0.54	Body mass index;	chr1:1850017	chr1:1702736~1737688:-
PRAD	cis	rs9660180	0.837	rs915292	ENSG00000268575.1	RP1-283E3.8	-13.63	9.93e-36	2.82e-32	-0.56	-0.54	Body mass index;	chr1:1860718	chr1:1702736~1737688:-
PRAD	cis	rs9660180	0.967	rs9660106	ENSG00000268575.1	RP1-283E3.8	-13.63	9.93e-36	2.82e-32	-0.56	-0.54	Body mass index;	chr1:1866508	chr1:1702736~1737688:-
PRAD	cis	rs2153535	0.58	rs2327053	ENSG00000230939.1	RP11-314C16.1	-13.63	9.95e-36	2.83e-32	-0.67	-0.54	Motion sickness;	chr6:8442894	chr6:8784178~8785445:+
PRAD	cis	rs71403859	0.73	rs12922775	ENSG00000260886.1	TAT-AS1	13.63	1e-35	2.84e-32	0.95	0.54	Post bronchodilator FEV1;	chr16:71550451	chr16:71565789~71578187:+
PRAD	cis	rs4660456	0.913	rs6667368	ENSG00000237899.1	RP4-739H11.3	13.63	1e-35	2.85e-32	0.79	0.54	Platelet count;	chr1:40694887	chr1:40669089~40687588:-
PRAD	cis	rs673078	0.607	rs61943403	ENSG00000275759.1	RP11-131L12.3	-13.63	1e-35	2.85e-32	-0.79	-0.54	Glucose homeostasis traits;	chr12:118399887	chr12:118428281~118428870:+
PRAD	cis	rs524281	0.861	rs2293121	ENSG00000255320.1	RP11-755F10.1	13.63	1.03e-35	2.94e-32	0.86	0.54	Electroencephalogram traits;	chr11:66193876	chr11:66244840~66246239:-
PRAD	cis	rs2153535	0.58	rs2225766	ENSG00000230939.1	RP11-314C16.1	-13.63	1.04e-35	2.96e-32	-0.66	-0.54	Motion sickness;	chr6:8481600	chr6:8784178~8785445:+
PRAD	cis	rs6700559	0.804	rs11588318	ENSG00000260088.1	RP11-92G12.3	-13.63	1.05e-35	2.99e-32	-0.66	-0.54	Coronary artery disease;	chr1:200669534	chr1:200669507~200694250:+
PRAD	cis	rs2153535	0.58	rs6927589	ENSG00000230939.1	RP11-314C16.1	13.63	1.06e-35	3e-32	0.66	0.54	Motion sickness;	chr6:8456399	chr6:8784178~8785445:+
PRAD	cis	rs11155671	0.53	rs7763849	ENSG00000231760.4	RP11-350J20.5	13.63	1.07e-35	3.04e-32	0.72	0.54	Testicular germ cell tumor;	chr6:149885244	chr6:149796151~149826294:-
PRAD	cis	rs4660456	0.913	rs2780953	ENSG00000237899.1	RP4-739H11.3	13.62	1.08e-35	3.06e-32	0.78	0.54	Platelet count;	chr1:40694105	chr1:40669089~40687588:-
PRAD	cis	rs7208859	0.623	rs79607958	ENSG00000263531.1	RP13-753N3.1	13.62	1.1e-35	3.11e-32	1.14	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607530	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs75136574	ENSG00000263531.1	RP13-753N3.1	13.62	1.1e-35	3.11e-32	1.14	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607531	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs77544470	ENSG00000263531.1	RP13-753N3.1	13.62	1.1e-35	3.11e-32	1.14	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607532	chr17:30863921~30864940:-
PRAD	cis	rs1075265	0.588	rs1477258	ENSG00000233266.1	HMGB1P31	13.62	1.11e-35	3.15e-32	0.74	0.54	Chronotype;Morning vs. evening chronotype;	chr2:54000031	chr2:54051334~54051760:+
PRAD	cis	rs2739330	0.929	rs5751777	ENSG00000231271.1	AP000350.8	13.62	1.12e-35	3.17e-32	0.73	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23949918~23954042:+
PRAD	cis	rs875971	0.862	rs709609	ENSG00000226824.5	RP4-756H11.3	13.62	1.13e-35	3.19e-32	0.75	0.54	Aortic root size;	chr7:66095574	chr7:66654538~66669855:+
PRAD	cis	rs9487094	0.67	rs13220915	ENSG00000260273.1	RP11-425D10.10	13.62	1.13e-35	3.2e-32	0.72	0.54	Height;	chr6:109503623	chr6:109382795~109383666:+
PRAD	cis	rs875971	0.862	rs13232191	ENSG00000226824.5	RP4-756H11.3	-13.62	1.16e-35	3.27e-32	-0.73	-0.54	Aortic root size;	chr7:66521661	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.862	rs35378740	ENSG00000226824.5	RP4-756H11.3	-13.62	1.16e-35	3.27e-32	-0.73	-0.54	Aortic root size;	chr7:66522725	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.862	rs10950043	ENSG00000226824.5	RP4-756H11.3	-13.62	1.16e-35	3.27e-32	-0.73	-0.54	Aortic root size;	chr7:66523623	chr7:66654538~66669855:+
PRAD	cis	rs9487094	0.67	rs12212476	ENSG00000260273.1	RP11-425D10.10	13.62	1.16e-35	3.27e-32	0.72	0.54	Height;	chr6:109501402	chr6:109382795~109383666:+
PRAD	cis	rs9487094	0.67	rs12198938	ENSG00000260273.1	RP11-425D10.10	13.62	1.16e-35	3.27e-32	0.72	0.54	Height;	chr6:109501429	chr6:109382795~109383666:+
PRAD	cis	rs3096299	0.685	rs12935112	ENSG00000274627.1	RP11-104N10.2	-13.62	1.16e-35	3.28e-32	-0.53	-0.54	Multiple myeloma (IgH translocation);	chr16:89476450	chr16:89516797~89522217:+
PRAD	cis	rs73086581	0.945	rs6052219	ENSG00000229539.1	RP11-119B16.2	13.62	1.16e-35	3.29e-32	0.88	0.54	Response to antidepressants in depression;	chr20:3989660	chr20:3888239~3888868:-
PRAD	cis	rs2111504	0.583	rs2111503	ENSG00000267213.4	AC007773.2	13.62	1.17e-35	3.31e-32	0.57	0.54	Bipolar disorder;	chr19:32383819	chr19:32390050~32405560:-
PRAD	cis	rs2153535	0.58	rs7743418	ENSG00000230939.1	RP11-314C16.1	-13.61	1.19e-35	3.36e-32	-0.68	-0.54	Motion sickness;	chr6:8437895	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.601	rs2327054	ENSG00000230939.1	RP11-314C16.1	-13.61	1.2e-35	3.4e-32	-0.67	-0.54	Motion sickness;	chr6:8442897	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.623	rs2327055	ENSG00000230939.1	RP11-314C16.1	-13.61	1.2e-35	3.4e-32	-0.67	-0.54	Motion sickness;	chr6:8442912	chr6:8784178~8785445:+
PRAD	cis	rs1153858	1	rs2453541	ENSG00000259520.4	CTD-2651B20.3	-13.61	1.21e-35	3.41e-32	-0.7	-0.54	Homoarginine levels;	chr15:45353180	chr15:45251580~45279251:-
PRAD	cis	rs1153858	1	rs2461702	ENSG00000259520.4	CTD-2651B20.3	-13.61	1.21e-35	3.41e-32	-0.7	-0.54	Homoarginine levels;	chr15:45355229	chr15:45251580~45279251:-
PRAD	cis	rs3091242	0.804	rs631133	ENSG00000261349.1	RP3-465N24.5	-13.61	1.22e-35	3.45e-32	-0.6	-0.54	Erythrocyte sedimentation rate;	chr1:25397655	chr1:25266102~25267136:-
PRAD	cis	rs3091242	0.9	rs669063	ENSG00000261349.1	RP3-465N24.5	-13.61	1.22e-35	3.46e-32	-0.59	-0.54	Erythrocyte sedimentation rate;	chr1:25394663	chr1:25266102~25267136:-
PRAD	cis	rs875971	0.862	rs6952182	ENSG00000226824.5	RP4-756H11.3	13.61	1.24e-35	3.49e-32	0.74	0.54	Aortic root size;	chr7:66218330	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.862	rs6964437	ENSG00000226824.5	RP4-756H11.3	13.61	1.24e-35	3.49e-32	0.74	0.54	Aortic root size;	chr7:66221457	chr7:66654538~66669855:+
PRAD	cis	rs2153535	0.541	rs9405386	ENSG00000230939.1	RP11-314C16.1	-13.61	1.24e-35	3.5e-32	-0.66	-0.54	Motion sickness;	chr6:8457834	chr6:8784178~8785445:+
PRAD	cis	rs916888	0.531	rs183211	ENSG00000262500.1	RP11-259G18.2	13.61	1.24e-35	3.51e-32	0.71	0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:46243606~46245044:+
PRAD	cis	rs10853057	0.541	rs77675516	ENSG00000214174.7	AMZ2P1	13.61	1.25e-35	3.53e-32	0.91	0.54	White matter microstructure (global fractional anisotropy);	chr17:65050690	chr17:64966550~64975576:-
PRAD	cis	rs9487094	0.626	rs7773950	ENSG00000260273.1	RP11-425D10.10	13.61	1.26e-35	3.55e-32	0.72	0.54	Height;	chr6:109494237	chr6:109382795~109383666:+
PRAD	cis	rs2153535	0.58	rs9378556	ENSG00000230939.1	RP11-314C16.1	-13.61	1.27e-35	3.58e-32	-0.66	-0.54	Motion sickness;	chr6:8514462	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs9406171	ENSG00000230939.1	RP11-314C16.1	-13.61	1.27e-35	3.58e-32	-0.66	-0.54	Motion sickness;	chr6:8515129	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.54	rs9378557	ENSG00000230939.1	RP11-314C16.1	-13.61	1.27e-35	3.58e-32	-0.66	-0.54	Motion sickness;	chr6:8517148	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs2143355	ENSG00000230939.1	RP11-314C16.1	-13.61	1.27e-35	3.58e-32	-0.66	-0.54	Motion sickness;	chr6:8517623	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs2143354	ENSG00000230939.1	RP11-314C16.1	-13.61	1.27e-35	3.58e-32	-0.66	-0.54	Motion sickness;	chr6:8517674	chr6:8784178~8785445:+
PRAD	cis	rs73086581	0.945	rs6052222	ENSG00000229539.1	RP11-119B16.2	13.61	1.28e-35	3.62e-32	0.88	0.54	Response to antidepressants in depression;	chr20:3992146	chr20:3888239~3888868:-
PRAD	cis	rs6504950	0.72	rs28564882	ENSG00000275710.1	RP11-257O5.4	13.61	1.31e-35	3.68e-32	0.73	0.54	Breast cancer;	chr17:54912237	chr17:54964474~54964679:+
PRAD	cis	rs875971	0.862	rs2088653	ENSG00000226824.5	RP4-756H11.3	13.6	1.31e-35	3.7e-32	0.74	0.54	Aortic root size;	chr7:66343621	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.862	rs6460293	ENSG00000226824.5	RP4-756H11.3	13.6	1.31e-35	3.7e-32	0.74	0.54	Aortic root size;	chr7:66345205	chr7:66654538~66669855:+
PRAD	cis	rs4660456	0.83	rs12742219	ENSG00000237899.1	RP4-739H11.3	-13.6	1.31e-35	3.71e-32	-0.78	-0.54	Platelet count;	chr1:40728665	chr1:40669089~40687588:-
PRAD	cis	rs7182621	0.639	rs35049216	ENSG00000259363.4	CTD-2054N24.2	-13.6	1.33e-35	3.75e-32	-0.58	-0.54	Colonoscopy-negative controls vs population controls;	chr15:99872562	chr15:99807023~99877148:+
PRAD	cis	rs9545047	0.901	rs73235963	ENSG00000227676.3	LINC01068	13.6	1.34e-35	3.78e-32	0.67	0.54	Schizophrenia;	chr13:79562805	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.935	rs2484343	ENSG00000227676.3	LINC01068	13.6	1.34e-35	3.78e-32	0.67	0.54	Schizophrenia;	chr13:79563587	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.868	rs2476173	ENSG00000227676.3	LINC01068	13.6	1.34e-35	3.78e-32	0.67	0.54	Schizophrenia;	chr13:79565740	chr13:79566727~79571436:+
PRAD	cis	rs73086581	1	rs11906274	ENSG00000229539.1	RP11-119B16.2	13.6	1.34e-35	3.79e-32	0.88	0.54	Response to antidepressants in depression;	chr20:3964889	chr20:3888239~3888868:-
PRAD	cis	rs73086581	1	rs6052196	ENSG00000229539.1	RP11-119B16.2	13.6	1.34e-35	3.79e-32	0.88	0.54	Response to antidepressants in depression;	chr20:3965177	chr20:3888239~3888868:-
PRAD	cis	rs73086581	1	rs6116130	ENSG00000229539.1	RP11-119B16.2	13.6	1.34e-35	3.79e-32	0.88	0.54	Response to antidepressants in depression;	chr20:3966379	chr20:3888239~3888868:-
PRAD	cis	rs73086581	1	rs6052209	ENSG00000229539.1	RP11-119B16.2	13.6	1.34e-35	3.79e-32	0.88	0.54	Response to antidepressants in depression;	chr20:3981100	chr20:3888239~3888868:-
PRAD	cis	rs73086581	1	rs6052217	ENSG00000229539.1	RP11-119B16.2	13.6	1.34e-35	3.79e-32	0.88	0.54	Response to antidepressants in depression;	chr20:3989564	chr20:3888239~3888868:-
PRAD	cis	rs73086581	1	rs6052218	ENSG00000229539.1	RP11-119B16.2	13.6	1.34e-35	3.79e-32	0.88	0.54	Response to antidepressants in depression;	chr20:3989565	chr20:3888239~3888868:-
PRAD	cis	rs524281	0.861	rs9645684	ENSG00000255320.1	RP11-755F10.1	13.6	1.35e-35	3.81e-32	0.86	0.54	Electroencephalogram traits;	chr11:66140493	chr11:66244840~66246239:-
PRAD	cis	rs7208859	0.623	rs56018041	ENSG00000263531.1	RP13-753N3.1	13.6	1.38e-35	3.88e-32	1.04	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732967	chr17:30863921~30864940:-
PRAD	cis	rs11673344	0.9	rs11671112	ENSG00000226686.6	LINC01535	13.6	1.41e-35	3.96e-32	0.78	0.54	Obesity-related traits;	chr19:37169384	chr19:37251912~37265535:+
PRAD	cis	rs3091242	0.9	rs1883427	ENSG00000261349.1	RP3-465N24.5	-13.6	1.41e-35	3.98e-32	-0.6	-0.54	Erythrocyte sedimentation rate;	chr1:25417977	chr1:25266102~25267136:-
PRAD	cis	rs9399135	0.967	rs7763836	ENSG00000232876.1	CTA-212D2.2	-13.6	1.42e-35	3.98e-32	-0.65	-0.54	Red blood cell count;	chr6:135041240	chr6:135055033~135060550:+
PRAD	cis	rs9487094	0.67	rs2024852	ENSG00000260273.1	RP11-425D10.10	13.6	1.42e-35	3.99e-32	0.72	0.54	Height;	chr6:109498586	chr6:109382795~109383666:+
PRAD	cis	rs9487094	0.67	rs13203587	ENSG00000260273.1	RP11-425D10.10	13.6	1.42e-35	3.99e-32	0.72	0.54	Height;	chr6:109499759	chr6:109382795~109383666:+
PRAD	cis	rs875971	0.862	rs6460282	ENSG00000226824.5	RP4-756H11.3	13.6	1.42e-35	3.99e-32	0.74	0.54	Aortic root size;	chr7:66226259	chr7:66654538~66669855:+
PRAD	cis	rs62229266	0.563	rs6517325	ENSG00000231106.2	LINC01436	13.6	1.42e-35	4e-32	0.68	0.54	Mitral valve prolapse;	chr21:36062680	chr21:36005338~36007838:+
PRAD	cis	rs801193	0.569	rs2659908	ENSG00000226824.5	RP4-756H11.3	-13.59	1.46e-35	4.1e-32	-0.74	-0.54	Aortic root size;	chr7:66695835	chr7:66654538~66669855:+
PRAD	cis	rs801193	0.569	rs2659907	ENSG00000226824.5	RP4-756H11.3	-13.59	1.46e-35	4.1e-32	-0.74	-0.54	Aortic root size;	chr7:66699045	chr7:66654538~66669855:+
PRAD	cis	rs801193	0.569	rs4717315	ENSG00000226824.5	RP4-756H11.3	-13.59	1.46e-35	4.1e-32	-0.74	-0.54	Aortic root size;	chr7:66713338	chr7:66654538~66669855:+
PRAD	cis	rs801193	0.527	rs2707837	ENSG00000226824.5	RP4-756H11.3	-13.59	1.46e-35	4.1e-32	-0.74	-0.54	Aortic root size;	chr7:66716086	chr7:66654538~66669855:+
PRAD	cis	rs4722166	0.564	rs1800797	ENSG00000179428.2	AC073072.5	-13.59	1.47e-35	4.14e-32	-0.66	-0.54	Lung cancer;	chr7:22726602	chr7:22725395~22727620:-
PRAD	cis	rs2153535	0.601	rs9393030	ENSG00000230939.1	RP11-314C16.1	-13.59	1.48e-35	4.16e-32	-0.66	-0.54	Motion sickness;	chr6:8516256	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.526	rs9406179	ENSG00000230939.1	RP11-314C16.1	-13.59	1.49e-35	4.17e-32	-0.66	-0.54	Motion sickness;	chr6:8537991	chr6:8784178~8785445:+
PRAD	cis	rs9399135	0.967	rs1854865	ENSG00000232876.1	CTA-212D2.2	-13.59	1.51e-35	4.23e-32	-0.66	-0.54	Red blood cell count;	chr6:135039162	chr6:135055033~135060550:+
PRAD	cis	rs9545047	0.901	rs1212082	ENSG00000227676.3	LINC01068	13.59	1.52e-35	4.25e-32	0.68	0.54	Schizophrenia;	chr13:79552633	chr13:79566727~79571436:+
PRAD	cis	rs673078	0.607	rs61943404	ENSG00000275759.1	RP11-131L12.3	-13.59	1.52e-35	4.27e-32	-0.82	-0.54	Glucose homeostasis traits;	chr12:118402062	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.607	rs7136676	ENSG00000275759.1	RP11-131L12.3	-13.59	1.52e-35	4.27e-32	-0.82	-0.54	Glucose homeostasis traits;	chr12:118403605	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.607	rs17441033	ENSG00000275759.1	RP11-131L12.3	-13.59	1.52e-35	4.27e-32	-0.82	-0.54	Glucose homeostasis traits;	chr12:118404101	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.562	rs61943405	ENSG00000275759.1	RP11-131L12.3	-13.59	1.52e-35	4.27e-32	-0.82	-0.54	Glucose homeostasis traits;	chr12:118405030	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.607	rs61943406	ENSG00000275759.1	RP11-131L12.3	-13.59	1.52e-35	4.27e-32	-0.82	-0.54	Glucose homeostasis traits;	chr12:118405767	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.607	rs17441075	ENSG00000275759.1	RP11-131L12.3	-13.59	1.52e-35	4.27e-32	-0.82	-0.54	Glucose homeostasis traits;	chr12:118410542	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.607	rs965524	ENSG00000275759.1	RP11-131L12.3	-13.59	1.52e-35	4.27e-32	-0.82	-0.54	Glucose homeostasis traits;	chr12:118412361	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.607	rs74685643	ENSG00000275759.1	RP11-131L12.3	-13.59	1.52e-35	4.27e-32	-0.82	-0.54	Glucose homeostasis traits;	chr12:118412761	chr12:118428281~118428870:+
PRAD	cis	rs916888	0.61	rs199530	ENSG00000262500.1	RP11-259G18.2	-13.59	1.55e-35	4.34e-32	-0.71	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:46243606~46245044:+
PRAD	cis	rs524281	0.861	rs10896085	ENSG00000255320.1	RP11-755F10.1	13.59	1.57e-35	4.39e-32	0.86	0.54	Electroencephalogram traits;	chr11:66146361	chr11:66244840~66246239:-
PRAD	cis	rs524281	0.861	rs7931544	ENSG00000255320.1	RP11-755F10.1	13.59	1.57e-35	4.39e-32	0.86	0.54	Electroencephalogram traits;	chr11:66149563	chr11:66244840~66246239:-
PRAD	cis	rs9487094	0.67	rs12197838	ENSG00000260273.1	RP11-425D10.10	13.59	1.58e-35	4.43e-32	0.72	0.54	Height;	chr6:109672088	chr6:109382795~109383666:+
PRAD	cis	rs3814244	0.528	rs7306466	ENSG00000255733.4	IFNG-AS1	13.58	1.63e-35	4.57e-32	0.58	0.54	Itch intensity from mosquito bite adjusted by bite size;	chr12:68014942	chr12:67989445~68234686:+
PRAD	cis	rs9487094	0.67	rs2277114	ENSG00000260273.1	RP11-425D10.10	13.58	1.63e-35	4.57e-32	0.72	0.54	Height;	chr6:109506513	chr6:109382795~109383666:+
PRAD	cis	rs2882667	0.858	rs11957633	ENSG00000253404.1	AC034243.1	13.58	1.65e-35	4.63e-32	0.77	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139028705	chr5:138744434~138753309:-
PRAD	cis	rs494459	0.838	rs581045	ENSG00000255239.1	AP002954.6	13.58	1.66e-35	4.65e-32	0.68	0.54	Height;	chr11:118761813	chr11:118688039~118690600:-
PRAD	cis	rs2153535	0.505	rs9405395	ENSG00000230939.1	RP11-314C16.1	-13.58	1.66e-35	4.65e-32	-0.67	-0.54	Motion sickness;	chr6:8468389	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs9392223	ENSG00000230939.1	RP11-314C16.1	-13.58	1.66e-35	4.65e-32	-0.67	-0.54	Motion sickness;	chr6:8468417	chr6:8784178~8785445:+
PRAD	cis	rs9545047	0.935	rs9530922	ENSG00000227676.3	LINC01068	-13.58	1.66e-35	4.65e-32	-0.67	-0.54	Schizophrenia;	chr13:79469002	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.935	rs7988601	ENSG00000227676.3	LINC01068	-13.58	1.67e-35	4.67e-32	-0.66	-0.54	Schizophrenia;	chr13:79475648	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.935	rs6563110	ENSG00000227676.3	LINC01068	-13.58	1.67e-35	4.67e-32	-0.66	-0.54	Schizophrenia;	chr13:79477137	chr13:79566727~79571436:+
PRAD	cis	rs1153858	1	rs1153858	ENSG00000259520.4	CTD-2651B20.3	13.58	1.68e-35	4.69e-32	0.7	0.54	Homoarginine levels;	chr15:45360505	chr15:45251580~45279251:-
PRAD	cis	rs1153858	1	rs1049508	ENSG00000259520.4	CTD-2651B20.3	-13.58	1.68e-35	4.69e-32	-0.7	-0.54	Homoarginine levels;	chr15:45361394	chr15:45251580~45279251:-
PRAD	cis	rs1153858	1	rs1145085	ENSG00000259520.4	CTD-2651B20.3	-13.58	1.68e-35	4.69e-32	-0.7	-0.54	Homoarginine levels;	chr15:45365606	chr15:45251580~45279251:-
PRAD	cis	rs1153858	1	rs1288775	ENSG00000259520.4	CTD-2651B20.3	-13.58	1.68e-35	4.69e-32	-0.7	-0.54	Homoarginine levels;	chr15:45369480	chr15:45251580~45279251:-
PRAD	cis	rs1153858	1	rs1145081	ENSG00000259520.4	CTD-2651B20.3	-13.58	1.68e-35	4.69e-32	-0.7	-0.54	Homoarginine levels;	chr15:45387469	chr15:45251580~45279251:-
PRAD	cis	rs1153858	0.943	rs1145079	ENSG00000259520.4	CTD-2651B20.3	-13.58	1.68e-35	4.69e-32	-0.7	-0.54	Homoarginine levels;	chr15:45389563	chr15:45251580~45279251:-
PRAD	cis	rs1153858	0.832	rs1145078	ENSG00000259520.4	CTD-2651B20.3	-13.58	1.68e-35	4.69e-32	-0.7	-0.54	Homoarginine levels;	chr15:45390079	chr15:45251580~45279251:-
PRAD	cis	rs2153535	0.563	rs1796688	ENSG00000230939.1	RP11-314C16.1	-13.58	1.7e-35	4.76e-32	-0.66	-0.54	Motion sickness;	chr6:8536190	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.526	rs1796689	ENSG00000230939.1	RP11-314C16.1	-13.58	1.7e-35	4.76e-32	-0.66	-0.54	Motion sickness;	chr6:8536200	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs4140586	ENSG00000230939.1	RP11-314C16.1	-13.58	1.74e-35	4.86e-32	-0.66	-0.54	Motion sickness;	chr6:8502959	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.601	rs4140585	ENSG00000230939.1	RP11-314C16.1	-13.58	1.74e-35	4.86e-32	-0.66	-0.54	Motion sickness;	chr6:8503065	chr6:8784178~8785445:+
PRAD	cis	rs7174755	0.772	rs80187654	ENSG00000260657.2	RP11-315D16.4	13.57	1.77e-35	4.95e-32	0.71	0.54	Major depressive disorder;	chr15:68082833	chr15:68267792~68277994:-
PRAD	cis	rs4660456	0.913	rs16827552	ENSG00000237899.1	RP4-739H11.3	-13.57	1.8e-35	5.01e-32	-0.78	-0.54	Platelet count;	chr1:40758336	chr1:40669089~40687588:-
PRAD	cis	rs4660456	0.913	rs16827569	ENSG00000237899.1	RP4-739H11.3	-13.57	1.8e-35	5.01e-32	-0.78	-0.54	Platelet count;	chr1:40761655	chr1:40669089~40687588:-
PRAD	cis	rs2739330	0.587	rs4820571	ENSG00000218537.1	MIF-AS1	13.57	1.8e-35	5.02e-32	0.7	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23894426~23898930:-
PRAD	cis	rs2153535	0.58	rs6597318	ENSG00000230939.1	RP11-314C16.1	-13.57	1.81e-35	5.04e-32	-0.67	-0.54	Motion sickness;	chr6:8437056	chr6:8784178~8785445:+
PRAD	cis	rs524281	0.861	rs10750779	ENSG00000255320.1	RP11-755F10.1	13.57	1.81e-35	5.06e-32	0.86	0.54	Electroencephalogram traits;	chr11:66207120	chr11:66244840~66246239:-
PRAD	cis	rs2153535	0.58	rs1414342	ENSG00000230939.1	RP11-314C16.1	-13.57	1.82e-35	5.07e-32	-0.66	-0.54	Motion sickness;	chr6:8462319	chr6:8784178~8785445:+
PRAD	cis	rs4718428	0.924	rs6971897	ENSG00000226824.5	RP4-756H11.3	-13.57	1.84e-35	5.13e-32	-0.69	-0.54	Corneal structure;	chr7:66947787	chr7:66654538~66669855:+
PRAD	cis	rs1153858	1	rs7169818	ENSG00000259520.4	CTD-2651B20.3	-13.57	1.85e-35	5.16e-32	-0.7	-0.54	Homoarginine levels;	chr15:45347993	chr15:45251580~45279251:-
PRAD	cis	rs1153858	1	rs1346266	ENSG00000259520.4	CTD-2651B20.3	-13.57	1.9e-35	5.3e-32	-0.7	-0.54	Homoarginine levels;	chr15:45402318	chr15:45251580~45279251:-
PRAD	cis	rs7044106	0.791	rs10760116	ENSG00000226752.6	PSMD5-AS1	-13.57	1.91e-35	5.31e-32	-0.66	-0.54	Hip circumference adjusted for BMI;	chr9:120732403	chr9:120824828~120854385:+
PRAD	cis	rs10853057	0.541	rs8076716	ENSG00000214174.7	AMZ2P1	13.57	1.91e-35	5.33e-32	0.91	0.54	White matter microstructure (global fractional anisotropy);	chr17:65051891	chr17:64966550~64975576:-
PRAD	cis	rs7617773	0.815	rs9825637	ENSG00000229759.1	MRPS18AP1	13.56	1.93e-35	5.39e-32	0.58	0.54	Coronary artery disease;	chr3:48330792	chr3:48256350~48256938:-
PRAD	cis	rs9545047	0.868	rs1208049	ENSG00000227676.3	LINC01068	13.56	1.96e-35	5.45e-32	0.67	0.54	Schizophrenia;	chr13:79570220	chr13:79566727~79571436:+
PRAD	cis	rs916888	0.61	rs199438	ENSG00000262500.1	RP11-259G18.2	13.56	2e-35	5.56e-32	0.71	0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:46243606~46245044:+
PRAD	cis	rs2019137	0.56	rs6707386	ENSG00000274877.1	RP11-65I12.1	-13.56	2e-35	5.57e-32	-0.74	-0.54	Lymphocyte counts;	chr2:113223445	chr2:113237595~113240825:+
PRAD	cis	rs524281	0.861	rs10896081	ENSG00000255320.1	RP11-755F10.1	13.56	2.03e-35	5.65e-32	0.85	0.54	Electroencephalogram traits;	chr11:66112883	chr11:66244840~66246239:-
PRAD	cis	rs2581828	0.656	rs2163167	ENSG00000242142.1	SERBP1P3	13.56	2.05e-35	5.71e-32	0.6	0.54	Crohn's disease;	chr3:53097756	chr3:53064283~53065091:-
PRAD	cis	rs2581828	0.541	rs2115781	ENSG00000242142.1	SERBP1P3	13.56	2.05e-35	5.71e-32	0.6	0.54	Crohn's disease;	chr3:53097813	chr3:53064283~53065091:-
PRAD	cis	rs2019137	0.56	rs7578633	ENSG00000274877.1	RP11-65I12.1	-13.56	2.05e-35	5.72e-32	-0.74	-0.54	Lymphocyte counts;	chr2:113221073	chr2:113237595~113240825:+
PRAD	cis	rs3091242	1	rs9689	ENSG00000261349.1	RP3-465N24.5	-13.56	2.08e-35	5.78e-32	-0.59	-0.54	Erythrocyte sedimentation rate;	chr1:25361785	chr1:25266102~25267136:-
PRAD	cis	rs9660180	1	rs9660180	ENSG00000268575.1	RP1-283E3.8	-13.56	2.08e-35	5.79e-32	-0.56	-0.54	Body mass index;	chr1:1791592	chr1:1702736~1737688:-
PRAD	cis	rs2153535	0.58	rs4365970	ENSG00000230939.1	RP11-314C16.1	13.55	2.14e-35	5.94e-32	0.66	0.54	Motion sickness;	chr6:8453580	chr6:8784178~8785445:+
PRAD	cis	rs2882667	0.929	rs34846849	ENSG00000253404.1	AC034243.1	13.55	2.17e-35	6.02e-32	0.76	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139024889	chr5:138744434~138753309:-
PRAD	cis	rs9487094	0.67	rs6911700	ENSG00000260273.1	RP11-425D10.10	13.55	2.19e-35	6.08e-32	0.72	0.54	Height;	chr6:109676091	chr6:109382795~109383666:+
PRAD	cis	rs2283792	1	rs2006893	ENSG00000224086.5	LL22NC03-86G7.1	-13.55	2.2e-35	6.12e-32	-0.62	-0.54	Multiple sclerosis;	chr22:21774389	chr22:21938293~21977632:+
PRAD	cis	rs494459	0.657	rs614554	ENSG00000255239.1	AP002954.6	13.55	2.26e-35	6.27e-32	0.68	0.54	Height;	chr11:118764443	chr11:118688039~118690600:-
PRAD	cis	rs3096299	0.685	rs3803681	ENSG00000274627.1	RP11-104N10.2	13.55	2.28e-35	6.33e-32	0.53	0.54	Multiple myeloma (IgH translocation);	chr16:89478348	chr16:89516797~89522217:+
PRAD	cis	rs3096299	0.685	rs12446145	ENSG00000274627.1	RP11-104N10.2	13.55	2.29e-35	6.37e-32	0.53	0.54	Multiple myeloma (IgH translocation);	chr16:89476287	chr16:89516797~89522217:+
PRAD	cis	rs7208859	0.673	rs1347360	ENSG00000263531.1	RP13-753N3.1	13.55	2.32e-35	6.44e-32	1	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587514	chr17:30863921~30864940:-
PRAD	cis	rs4660456	0.826	rs2744802	ENSG00000237899.1	RP4-739H11.3	13.54	2.35e-35	6.52e-32	0.78	0.54	Platelet count;	chr1:40687577	chr1:40669089~40687588:-
PRAD	cis	rs494459	0.838	rs488219	ENSG00000255239.1	AP002954.6	13.54	2.36e-35	6.54e-32	0.68	0.54	Height;	chr11:118749988	chr11:118688039~118690600:-
PRAD	cis	rs4660456	0.913	rs3754179	ENSG00000237899.1	RP4-739H11.3	-13.54	2.4e-35	6.65e-32	-0.78	-0.54	Platelet count;	chr1:40768464	chr1:40669089~40687588:-
PRAD	cis	rs801193	0.569	rs2707824	ENSG00000226824.5	RP4-756H11.3	-13.54	2.4e-35	6.65e-32	-0.74	-0.54	Aortic root size;	chr7:66724256	chr7:66654538~66669855:+
PRAD	cis	rs4660456	0.913	rs656230	ENSG00000237899.1	RP4-739H11.3	13.54	2.41e-35	6.69e-32	0.77	0.54	Platelet count;	chr1:40692701	chr1:40669089~40687588:-
PRAD	cis	rs524281	0.773	rs11227413	ENSG00000255320.1	RP11-755F10.1	13.54	2.47e-35	6.85e-32	0.86	0.54	Electroencephalogram traits;	chr11:66116225	chr11:66244840~66246239:-
PRAD	cis	rs875971	0.83	rs6976714	ENSG00000226824.5	RP4-756H11.3	-13.54	2.53e-35	7e-32	-0.73	-0.54	Aortic root size;	chr7:66426474	chr7:66654538~66669855:+
PRAD	cis	rs3091242	0.967	rs665372	ENSG00000261349.1	RP3-465N24.5	-13.54	2.54e-35	7.03e-32	-0.59	-0.54	Erythrocyte sedimentation rate;	chr1:25392744	chr1:25266102~25267136:-
PRAD	cis	rs2739330	0.76	rs1007888	ENSG00000231271.1	AP000350.8	13.54	2.54e-35	7.04e-32	0.72	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23949918~23954042:+
PRAD	cis	rs4718428	0.96	rs6460317	ENSG00000226824.5	RP4-756H11.3	-13.54	2.55e-35	7.06e-32	-0.68	-0.54	Corneal structure;	chr7:66925268	chr7:66654538~66669855:+
PRAD	cis	rs73086581	1	rs34640283	ENSG00000229539.1	RP11-119B16.2	13.53	2.6e-35	7.18e-32	0.9	0.54	Response to antidepressants in depression;	chr20:4008929	chr20:3888239~3888868:-
PRAD	cis	rs9322193	0.884	rs880245	ENSG00000223701.3	RAET1E-AS1	-13.53	2.6e-35	7.2e-32	-0.71	-0.54	Lung cancer;	chr6:149846262	chr6:149884431~149919508:+
PRAD	cis	rs17507216	0.667	rs13379724	ENSG00000278603.1	RP13-608F4.5	13.53	2.6e-35	7.2e-32	0.83	0.54	Excessive daytime sleepiness;	chr15:82619892	chr15:82472203~82472426:+
PRAD	cis	rs6700559	1	rs6700559	ENSG00000260088.1	RP11-92G12.3	13.53	2.7e-35	7.45e-32	0.65	0.54	Coronary artery disease;	chr1:200676945	chr1:200669507~200694250:+
PRAD	cis	rs4660456	0.913	rs3767950	ENSG00000237899.1	RP4-739H11.3	-13.53	2.7e-35	7.46e-32	-0.78	-0.54	Platelet count;	chr1:40767541	chr1:40669089~40687588:-
PRAD	cis	rs9487094	0.67	rs11153183	ENSG00000260273.1	RP11-425D10.10	13.53	2.7e-35	7.47e-32	0.72	0.54	Height;	chr6:109496073	chr6:109382795~109383666:+
PRAD	cis	rs2929278	0.561	rs3099045	ENSG00000205771.5	CATSPER2P1	-13.53	2.71e-35	7.49e-32	-0.62	-0.54	Schizophrenia;	chr15:43631757	chr15:43726918~43747094:-
PRAD	cis	rs673078	0.607	rs61943391	ENSG00000275759.1	RP11-131L12.3	-13.53	2.71e-35	7.5e-32	-0.81	-0.54	Glucose homeostasis traits;	chr12:118382603	chr12:118428281~118428870:+
PRAD	cis	rs11673344	0.838	rs112401881	ENSG00000226686.6	LINC01535	13.53	2.72e-35	7.51e-32	0.79	0.54	Obesity-related traits;	chr19:37156092	chr19:37251912~37265535:+
PRAD	cis	rs6142102	0.602	rs4911396	ENSG00000276073.1	RP5-1125A11.7	-13.53	2.74e-35	7.57e-32	-0.52	-0.54	Skin pigmentation;	chr20:33992139	chr20:33985617~33988989:-
PRAD	cis	rs3096299	0.685	rs3803682	ENSG00000274627.1	RP11-104N10.2	13.53	2.74e-35	7.58e-32	0.53	0.54	Multiple myeloma (IgH translocation);	chr16:89478228	chr16:89516797~89522217:+
PRAD	cis	rs6142102	0.602	rs4911395	ENSG00000276073.1	RP5-1125A11.7	-13.53	2.75e-35	7.6e-32	-0.52	-0.54	Skin pigmentation;	chr20:33992095	chr20:33985617~33988989:-
PRAD	cis	rs2658782	1	rs2658781	ENSG00000279684.1	RP11-755E23.2	13.53	2.78e-35	7.67e-32	0.88	0.54	Pulmonary function decline;	chr11:93433202	chr11:93286629~93288903:-
PRAD	cis	rs4660456	0.913	rs2780952	ENSG00000237899.1	RP4-739H11.3	13.53	2.8e-35	7.74e-32	0.77	0.54	Platelet count;	chr1:40689711	chr1:40669089~40687588:-
PRAD	cis	rs9601248	0.529	rs2783125	ENSG00000227676.3	LINC01068	13.52	2.99e-35	8.25e-32	0.68	0.54	Major depressive disorder;	chr13:79583755	chr13:79566727~79571436:+
PRAD	cis	rs673078	0.607	rs61943388	ENSG00000275759.1	RP11-131L12.3	-13.52	2.99e-35	8.25e-32	-0.81	-0.54	Glucose homeostasis traits;	chr12:118374590	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.607	rs61943389	ENSG00000275759.1	RP11-131L12.3	-13.52	2.99e-35	8.25e-32	-0.81	-0.54	Glucose homeostasis traits;	chr12:118377467	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.607	rs7299040	ENSG00000275759.1	RP11-131L12.3	-13.52	2.99e-35	8.25e-32	-0.81	-0.54	Glucose homeostasis traits;	chr12:118380660	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.607	rs7968011	ENSG00000275759.1	RP11-131L12.3	-13.52	2.99e-35	8.25e-32	-0.81	-0.54	Glucose homeostasis traits;	chr12:118382001	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.607	rs61943399	ENSG00000275759.1	RP11-131L12.3	-13.52	2.99e-35	8.25e-32	-0.81	-0.54	Glucose homeostasis traits;	chr12:118393628	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.607	rs17440942	ENSG00000275759.1	RP11-131L12.3	13.52	2.99e-35	8.25e-32	0.81	0.54	Glucose homeostasis traits;	chr12:118394030	chr12:118428281~118428870:+
PRAD	cis	rs875971	0.862	rs2460432	ENSG00000226824.5	RP4-756H11.3	13.52	3.02e-35	8.32e-32	0.75	0.54	Aortic root size;	chr7:66089398	chr7:66654538~66669855:+
PRAD	cis	rs494459	0.838	rs566733	ENSG00000255239.1	AP002954.6	13.52	3.02e-35	8.33e-32	0.69	0.54	Height;	chr11:118737916	chr11:118688039~118690600:-
PRAD	cis	rs2739330	0.685	rs4822453	ENSG00000250470.1	AP000351.3	13.52	3.08e-35	8.47e-32	0.71	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23976904~23977585:-
PRAD	cis	rs2882667	0.858	rs35812969	ENSG00000253404.1	AC034243.1	13.52	3.11e-35	8.56e-32	0.76	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139041861	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.858	rs11242442	ENSG00000253404.1	AC034243.1	13.52	3.11e-35	8.56e-32	0.76	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139044800	chr5:138744434~138753309:-
PRAD	cis	rs3931020	0.745	rs1969111	ENSG00000272864.1	RP11-17E13.2	13.51	3.25e-35	8.95e-32	0.55	0.54	Resistin levels;	chr1:74797801	chr1:74698769~74699333:-
PRAD	cis	rs9660180	0.967	rs10907191	ENSG00000268575.1	RP1-283E3.8	-13.51	3.28e-35	9.02e-32	-0.56	-0.54	Body mass index;	chr1:1843381	chr1:1702736~1737688:-
PRAD	cis	rs11690935	1	rs312924	ENSG00000228389.1	AC068039.4	-13.51	3.32e-35	9.1e-32	-0.63	-0.54	Schizophrenia;	chr2:171707511	chr2:171773482~171775844:+
PRAD	cis	rs977987	0.843	rs59155720	ENSG00000261783.1	RP11-252K23.2	-13.51	3.32e-35	9.1e-32	-0.74	-0.54	Dupuytren's disease;	chr16:75449908	chr16:75379818~75381260:-
PRAD	cis	rs9545047	0.837	rs9601242	ENSG00000227676.3	LINC01068	13.51	3.36e-35	9.22e-32	0.67	0.54	Schizophrenia;	chr13:79561543	chr13:79566727~79571436:+
PRAD	cis	rs324126	0.78	rs2059818	ENSG00000277977.1	CTD-3018O17.5	13.51	3.39e-35	9.29e-32	0.61	0.53	Colonoscopy-negative controls vs population controls;	chr19:52379267	chr19:52392659~52392755:+
PRAD	cis	rs8072100	0.676	rs7221345	ENSG00000228782.6	CTD-2026D20.3	13.51	3.39e-35	9.3e-32	0.57	0.53	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47327778	chr17:47450568~47492492:-
PRAD	cis	rs2153535	0.58	rs6941771	ENSG00000230939.1	RP11-314C16.1	-13.5	3.46e-35	9.48e-32	-0.66	-0.53	Motion sickness;	chr6:8494219	chr6:8784178~8785445:+
PRAD	cis	rs3814244	0.528	rs2870960	ENSG00000255733.4	IFNG-AS1	13.5	3.5e-35	9.58e-32	0.59	0.53	Itch intensity from mosquito bite adjusted by bite size;	chr12:68032848	chr12:67989445~68234686:+
PRAD	cis	rs2153535	0.58	rs4960433	ENSG00000230939.1	RP11-314C16.1	-13.5	3.54e-35	9.72e-32	-0.66	-0.53	Motion sickness;	chr6:8523464	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs4451187	ENSG00000230939.1	RP11-314C16.1	-13.5	3.56e-35	9.75e-32	-0.66	-0.53	Motion sickness;	chr6:8473677	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.504	rs4493781	ENSG00000230939.1	RP11-314C16.1	-13.5	3.56e-35	9.75e-32	-0.66	-0.53	Motion sickness;	chr6:8473708	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.541	rs5026687	ENSG00000230939.1	RP11-314C16.1	-13.5	3.56e-35	9.75e-32	-0.66	-0.53	Motion sickness;	chr6:8473724	chr6:8784178~8785445:+
PRAD	cis	rs6142102	0.602	rs932388	ENSG00000276073.1	RP5-1125A11.7	-13.5	3.64e-35	9.95e-32	-0.52	-0.53	Skin pigmentation;	chr20:34069572	chr20:33985617~33988989:-
PRAD	cis	rs524281	0.861	rs10896094	ENSG00000255320.1	RP11-755F10.1	13.5	3.65e-35	9.98e-32	0.86	0.53	Electroencephalogram traits;	chr11:66191735	chr11:66244840~66246239:-
PRAD	cis	rs9487094	0.626	rs12204548	ENSG00000260273.1	RP11-425D10.10	13.5	3.66e-35	9.99e-32	0.73	0.53	Height;	chr6:109715504	chr6:109382795~109383666:+
PRAD	cis	rs9487094	0.626	rs3799849	ENSG00000260273.1	RP11-425D10.10	13.5	3.66e-35	9.99e-32	0.73	0.53	Height;	chr6:109715560	chr6:109382795~109383666:+
PRAD	cis	rs11155671	0.53	rs9383940	ENSG00000216906.2	RP11-350J20.9	13.5	3.66e-35	1e-31	0.64	0.53	Testicular germ cell tumor;	chr6:149904923	chr6:149904243~149906418:+
PRAD	cis	rs7044106	0.791	rs4836831	ENSG00000226752.6	PSMD5-AS1	-13.5	3.68e-35	1.01e-31	-0.66	-0.53	Hip circumference adjusted for BMI;	chr9:120734292	chr9:120824828~120854385:+
PRAD	cis	rs494459	0.838	rs12796102	ENSG00000255239.1	AP002954.6	13.5	3.7e-35	1.01e-31	0.67	0.53	Height;	chr11:118791319	chr11:118688039~118690600:-
PRAD	cis	rs2581828	0.656	rs2581787	ENSG00000242142.1	SERBP1P3	13.5	3.8e-35	1.04e-31	0.6	0.53	Crohn's disease;	chr3:53093661	chr3:53064283~53065091:-
PRAD	cis	rs2019137	0.56	rs10206269	ENSG00000274877.1	RP11-65I12.1	-13.49	3.81e-35	1.04e-31	-0.74	-0.53	Lymphocyte counts;	chr2:113232816	chr2:113237595~113240825:+
PRAD	cis	rs11673344	0.864	rs1533736	ENSG00000226686.6	LINC01535	13.49	3.82e-35	1.04e-31	0.78	0.53	Obesity-related traits;	chr19:37164074	chr19:37251912~37265535:+
PRAD	cis	rs7104764	0.673	rs3782118	ENSG00000277290.1	RP11-326C3.16	-13.49	3.92e-35	1.07e-31	-0.5	-0.53	Menarche (age at onset);	chr11:222620	chr11:243099~243483:-
PRAD	cis	rs2153535	0.58	rs915350	ENSG00000230939.1	RP11-314C16.1	-13.49	3.94e-35	1.07e-31	-0.66	-0.53	Motion sickness;	chr6:8443253	chr6:8784178~8785445:+
PRAD	cis	rs6452524	0.618	rs4266384	ENSG00000249664.1	CTD-2227C6.2	13.49	3.95e-35	1.08e-31	0.63	0.53	Hypertension (SNP x SNP interaction);	chr5:83080872	chr5:83012285~83013109:-
PRAD	cis	rs673078	0.607	rs2055534	ENSG00000275759.1	RP11-131L12.3	-13.49	3.95e-35	1.08e-31	-0.82	-0.53	Glucose homeostasis traits;	chr12:118386527	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.607	rs56157623	ENSG00000275759.1	RP11-131L12.3	-13.49	3.95e-35	1.08e-31	-0.82	-0.53	Glucose homeostasis traits;	chr12:118388162	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.607	rs4767669	ENSG00000275759.1	RP11-131L12.3	-13.49	3.95e-35	1.08e-31	-0.82	-0.53	Glucose homeostasis traits;	chr12:118390651	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.607	rs4767670	ENSG00000275759.1	RP11-131L12.3	-13.49	3.95e-35	1.08e-31	-0.82	-0.53	Glucose homeostasis traits;	chr12:118390737	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.607	rs950288	ENSG00000275759.1	RP11-131L12.3	-13.49	3.95e-35	1.08e-31	-0.82	-0.53	Glucose homeostasis traits;	chr12:118392201	chr12:118428281~118428870:+
PRAD	cis	rs4660456	0.913	rs556875	ENSG00000237899.1	RP4-739H11.3	-13.49	4.02e-35	1.09e-31	-0.77	-0.53	Platelet count;	chr1:40688571	chr1:40669089~40687588:-
PRAD	cis	rs4660456	0.913	rs2361650	ENSG00000237899.1	RP4-739H11.3	-13.49	4.02e-35	1.09e-31	-0.77	-0.53	Platelet count;	chr1:40764678	chr1:40669089~40687588:-
PRAD	cis	rs4660456	0.913	rs954654	ENSG00000237899.1	RP4-739H11.3	-13.49	4.02e-35	1.09e-31	-0.77	-0.53	Platelet count;	chr1:40764979	chr1:40669089~40687588:-
PRAD	cis	rs4660456	0.913	rs34212676	ENSG00000237899.1	RP4-739H11.3	-13.49	4.02e-35	1.09e-31	-0.77	-0.53	Platelet count;	chr1:40766522	chr1:40669089~40687588:-
PRAD	cis	rs9487094	0.626	rs3799845	ENSG00000260273.1	RP11-425D10.10	13.49	4.02e-35	1.09e-31	0.73	0.53	Height;	chr6:109706514	chr6:109382795~109383666:+
PRAD	cis	rs992157	0.71	rs6719789	ENSG00000261338.2	RP11-378A13.1	-13.49	4.07e-35	1.11e-31	-0.6	-0.53	Colorectal cancer;	chr2:218193087	chr2:218255319~218257366:+
PRAD	cis	rs71403859	0.73	rs17347255	ENSG00000260886.1	TAT-AS1	13.49	4.09e-35	1.11e-31	0.96	0.53	Post bronchodilator FEV1;	chr16:71553322	chr16:71565789~71578187:+
PRAD	cis	rs2929278	0.588	rs688009	ENSG00000205771.5	CATSPER2P1	-13.49	4.1e-35	1.11e-31	-0.62	-0.53	Schizophrenia;	chr15:43864104	chr15:43726918~43747094:-
PRAD	cis	rs6452524	0.618	rs1478487	ENSG00000249664.1	CTD-2227C6.2	13.49	4.1e-35	1.12e-31	0.63	0.53	Hypertension (SNP x SNP interaction);	chr5:83080900	chr5:83012285~83013109:-
PRAD	cis	rs673078	0.607	rs17441061	ENSG00000275759.1	RP11-131L12.3	-13.49	4.13e-35	1.12e-31	-0.81	-0.53	Glucose homeostasis traits;	chr12:118409847	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.607	rs61943443	ENSG00000275759.1	RP11-131L12.3	-13.48	4.22e-35	1.15e-31	-0.81	-0.53	Glucose homeostasis traits;	chr12:118416602	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.607	rs7305647	ENSG00000275759.1	RP11-131L12.3	-13.48	4.22e-35	1.15e-31	-0.81	-0.53	Glucose homeostasis traits;	chr12:118417761	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.607	rs61943444	ENSG00000275759.1	RP11-131L12.3	-13.48	4.22e-35	1.15e-31	-0.81	-0.53	Glucose homeostasis traits;	chr12:118421641	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.607	rs73207504	ENSG00000275759.1	RP11-131L12.3	-13.48	4.22e-35	1.15e-31	-0.81	-0.53	Glucose homeostasis traits;	chr12:118427914	chr12:118428281~118428870:+
PRAD	cis	rs9545047	1	rs9545086	ENSG00000227676.3	LINC01068	13.48	4.23e-35	1.15e-31	0.69	0.53	Schizophrenia;	chr13:79364233	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.967	rs9545087	ENSG00000227676.3	LINC01068	13.48	4.23e-35	1.15e-31	0.69	0.53	Schizophrenia;	chr13:79364440	chr13:79566727~79571436:+
PRAD	cis	rs62388641	0.813	rs62390562	ENSG00000272279.1	RP11-157J24.2	13.48	4.27e-35	1.16e-31	0.82	0.53	Daytime sleep phenotypes;	chr6:1551467	chr6:1528364~1528911:-
PRAD	cis	rs9601248	0.529	rs2783126	ENSG00000227676.3	LINC01068	13.48	4.29e-35	1.16e-31	0.67	0.53	Major depressive disorder;	chr13:79584566	chr13:79566727~79571436:+
PRAD	cis	rs9601248	0.529	rs9545142	ENSG00000227676.3	LINC01068	13.48	4.29e-35	1.16e-31	0.67	0.53	Major depressive disorder;	chr13:79588420	chr13:79566727~79571436:+
PRAD	cis	rs2153535	0.58	rs6920779	ENSG00000230939.1	RP11-314C16.1	-13.48	4.32e-35	1.17e-31	-0.67	-0.53	Motion sickness;	chr6:8437391	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs4960411	ENSG00000230939.1	RP11-314C16.1	-13.48	4.32e-35	1.17e-31	-0.67	-0.53	Motion sickness;	chr6:8437998	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs4960412	ENSG00000230939.1	RP11-314C16.1	-13.48	4.32e-35	1.17e-31	-0.67	-0.53	Motion sickness;	chr6:8438028	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.58	rs4960413	ENSG00000230939.1	RP11-314C16.1	-13.48	4.32e-35	1.17e-31	-0.67	-0.53	Motion sickness;	chr6:8438233	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.601	rs4960414	ENSG00000230939.1	RP11-314C16.1	-13.48	4.32e-35	1.17e-31	-0.67	-0.53	Motion sickness;	chr6:8438308	chr6:8784178~8785445:+
PRAD	cis	rs524281	0.861	rs10896091	ENSG00000255320.1	RP11-755F10.1	13.48	4.39e-35	1.19e-31	0.86	0.53	Electroencephalogram traits;	chr11:66183354	chr11:66244840~66246239:-
PRAD	cis	rs524281	0.861	rs7929909	ENSG00000255320.1	RP11-755F10.1	13.48	4.39e-35	1.19e-31	0.86	0.53	Electroencephalogram traits;	chr11:66184227	chr11:66244840~66246239:-
PRAD	cis	rs11690935	0.885	rs6750058	ENSG00000228389.1	AC068039.4	13.48	4.43e-35	1.2e-31	0.63	0.53	Schizophrenia;	chr2:171930399	chr2:171773482~171775844:+
PRAD	cis	rs7617773	0.817	rs9830016	ENSG00000229759.1	MRPS18AP1	13.48	4.45e-35	1.21e-31	0.57	0.53	Coronary artery disease;	chr3:48241004	chr3:48256350~48256938:-
PRAD	cis	rs524281	0.861	rs7943911	ENSG00000255320.1	RP11-755F10.1	13.48	4.56e-35	1.23e-31	0.86	0.53	Electroencephalogram traits;	chr11:66175583	chr11:66244840~66246239:-
PRAD	cis	rs3091242	0.836	rs34997029	ENSG00000261349.1	RP3-465N24.5	13.48	4.59e-35	1.24e-31	0.59	0.53	Erythrocyte sedimentation rate;	chr1:25457332	chr1:25266102~25267136:-
PRAD	cis	rs6700559	0.967	rs6688581	ENSG00000260088.1	RP11-92G12.3	-13.48	4.59e-35	1.24e-31	-0.65	-0.53	Coronary artery disease;	chr1:200670028	chr1:200669507~200694250:+
PRAD	cis	rs6700559	1	rs3806358	ENSG00000260088.1	RP11-92G12.3	-13.48	4.59e-35	1.24e-31	-0.65	-0.53	Coronary artery disease;	chr1:200670555	chr1:200669507~200694250:+
PRAD	cis	rs7044106	0.791	rs7043969	ENSG00000226752.6	PSMD5-AS1	-13.48	4.6e-35	1.25e-31	-0.65	-0.53	Hip circumference adjusted for BMI;	chr9:120731711	chr9:120824828~120854385:+
PRAD	cis	rs2882667	0.858	rs11744972	ENSG00000253404.1	AC034243.1	13.47	4.65e-35	1.26e-31	0.73	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139093100	chr5:138744434~138753309:-
PRAD	cis	rs524281	0.861	rs10896087	ENSG00000255320.1	RP11-755F10.1	13.47	4.65e-35	1.26e-31	0.85	0.53	Electroencephalogram traits;	chr11:66157078	chr11:66244840~66246239:-
PRAD	cis	rs524281	0.861	rs4013917	ENSG00000255320.1	RP11-755F10.1	13.47	4.65e-35	1.26e-31	0.85	0.53	Electroencephalogram traits;	chr11:66158714	chr11:66244840~66246239:-
PRAD	cis	rs524281	0.861	rs918299	ENSG00000255320.1	RP11-755F10.1	13.47	4.65e-35	1.26e-31	0.85	0.53	Electroencephalogram traits;	chr11:66160136	chr11:66244840~66246239:-
PRAD	cis	rs524281	0.861	rs10750778	ENSG00000255320.1	RP11-755F10.1	13.47	4.65e-35	1.26e-31	0.85	0.53	Electroencephalogram traits;	chr11:66181177	chr11:66244840~66246239:-
PRAD	cis	rs524281	0.861	rs6591208	ENSG00000255320.1	RP11-755F10.1	13.47	4.65e-35	1.26e-31	0.85	0.53	Electroencephalogram traits;	chr11:66182218	chr11:66244840~66246239:-
PRAD	cis	rs524281	0.861	rs11227415	ENSG00000255320.1	RP11-755F10.1	-13.47	4.65e-35	1.26e-31	-0.85	-0.53	Electroencephalogram traits;	chr11:66117988	chr11:66244840~66246239:-
PRAD	cis	rs17826219	0.706	rs28469200	ENSG00000263531.1	RP13-753N3.1	13.47	4.77e-35	1.29e-31	1.03	0.53	Body mass index;	chr17:30806554	chr17:30863921~30864940:-
PRAD	cis	rs6142102	0.602	rs4911399	ENSG00000276073.1	RP5-1125A11.7	-13.47	4.78e-35	1.29e-31	-0.52	-0.53	Skin pigmentation;	chr20:34035612	chr20:33985617~33988989:-
PRAD	cis	rs673078	0.607	rs4766900	ENSG00000275759.1	RP11-131L12.3	-13.47	4.81e-35	1.3e-31	-0.79	-0.53	Glucose homeostasis traits;	chr12:118375139	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.607	rs884844	ENSG00000275759.1	RP11-131L12.3	-13.47	4.81e-35	1.3e-31	-0.79	-0.53	Glucose homeostasis traits;	chr12:118377033	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.607	rs61943398	ENSG00000275759.1	RP11-131L12.3	-13.47	4.81e-35	1.3e-31	-0.79	-0.53	Glucose homeostasis traits;	chr12:118393280	chr12:118428281~118428870:+
PRAD	cis	rs9660180	0.967	rs6603802	ENSG00000268575.1	RP1-283E3.8	-13.47	4.87e-35	1.32e-31	-0.55	-0.53	Body mass index;	chr1:1881082	chr1:1702736~1737688:-
PRAD	cis	rs875971	0.862	rs778736	ENSG00000226824.5	RP4-756H11.3	-13.47	4.89e-35	1.32e-31	-0.73	-0.53	Aortic root size;	chr7:66348861	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.862	rs3893216	ENSG00000226824.5	RP4-756H11.3	13.47	4.89e-35	1.32e-31	0.73	0.53	Aortic root size;	chr7:66325720	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.862	rs6958294	ENSG00000226824.5	RP4-756H11.3	13.47	4.89e-35	1.32e-31	0.73	0.53	Aortic root size;	chr7:66329809	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.862	rs2088655	ENSG00000226824.5	RP4-756H11.3	13.47	4.89e-35	1.32e-31	0.73	0.53	Aortic root size;	chr7:66330724	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.895	rs10447522	ENSG00000226824.5	RP4-756H11.3	13.47	4.89e-35	1.32e-31	0.73	0.53	Aortic root size;	chr7:66331087	chr7:66654538~66669855:+
PRAD	cis	rs9399135	0.935	rs4445070	ENSG00000232876.1	CTA-212D2.2	-13.47	4.91e-35	1.33e-31	-0.66	-0.53	Red blood cell count;	chr6:134988074	chr6:135055033~135060550:+
PRAD	cis	rs11690935	0.885	rs10202823	ENSG00000228389.1	AC068039.4	13.47	5.04e-35	1.36e-31	0.63	0.53	Schizophrenia;	chr2:171923622	chr2:171773482~171775844:+
PRAD	cis	rs3091242	0.933	rs12402120	ENSG00000261349.1	RP3-465N24.5	-13.47	5.06e-35	1.37e-31	-0.59	-0.53	Erythrocyte sedimentation rate;	chr1:25425141	chr1:25266102~25267136:-
PRAD	cis	rs801193	0.569	rs35070132	ENSG00000226824.5	RP4-756H11.3	-13.47	5.06e-35	1.37e-31	-0.74	-0.53	Aortic root size;	chr7:66773096	chr7:66654538~66669855:+
PRAD	cis	rs7208859	0.524	rs73988172	ENSG00000263531.1	RP13-753N3.1	13.46	5.12e-35	1.38e-31	1.03	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759314	chr17:30863921~30864940:-
PRAD	cis	rs494459	0.756	rs570806	ENSG00000255239.1	AP002954.6	13.46	5.29e-35	1.42e-31	0.67	0.53	Height;	chr11:118786602	chr11:118688039~118690600:-
PRAD	cis	rs73086581	1	rs73086588	ENSG00000229539.1	RP11-119B16.2	13.46	5.37e-35	1.45e-31	0.9	0.53	Response to antidepressants in depression;	chr20:4001577	chr20:3888239~3888868:-
PRAD	cis	rs73086581	1	rs73086595	ENSG00000229539.1	RP11-119B16.2	13.46	5.37e-35	1.45e-31	0.9	0.53	Response to antidepressants in depression;	chr20:4002801	chr20:3888239~3888868:-
PRAD	cis	rs3096299	0.658	rs34590044	ENSG00000274627.1	RP11-104N10.2	13.46	5.43e-35	1.46e-31	0.52	0.53	Multiple myeloma (IgH translocation);	chr16:89476749	chr16:89516797~89522217:+
PRAD	cis	rs524281	0.861	rs3825067	ENSG00000255320.1	RP11-755F10.1	-13.46	5.46e-35	1.47e-31	-0.86	-0.53	Electroencephalogram traits;	chr11:66110948	chr11:66244840~66246239:-
PRAD	cis	rs524281	0.861	rs11607393	ENSG00000255320.1	RP11-755F10.1	13.46	5.46e-35	1.47e-31	0.86	0.53	Electroencephalogram traits;	chr11:66107678	chr11:66244840~66246239:-
PRAD	cis	rs524281	0.861	rs10896080	ENSG00000255320.1	RP11-755F10.1	13.46	5.46e-35	1.47e-31	0.86	0.53	Electroencephalogram traits;	chr11:66109325	chr11:66244840~66246239:-
PRAD	cis	rs524281	0.861	rs11227411	ENSG00000255320.1	RP11-755F10.1	13.46	5.46e-35	1.47e-31	0.86	0.53	Electroencephalogram traits;	chr11:66112007	chr11:66244840~66246239:-
PRAD	cis	rs4718428	1	rs4718421	ENSG00000226824.5	RP4-756H11.3	-13.46	5.47e-35	1.47e-31	-0.68	-0.53	Corneal structure;	chr7:66885313	chr7:66654538~66669855:+
PRAD	cis	rs11673344	0.75	rs78241494	ENSG00000226686.6	LINC01535	13.45	5.66e-35	1.52e-31	0.78	0.53	Obesity-related traits;	chr19:37158846	chr19:37251912~37265535:+
PRAD	cis	rs11673344	0.838	rs111827672	ENSG00000226686.6	LINC01535	13.45	5.66e-35	1.52e-31	0.78	0.53	Obesity-related traits;	chr19:37158964	chr19:37251912~37265535:+
PRAD	cis	rs8072100	0.875	rs7208530	ENSG00000228782.6	CTD-2026D20.3	13.45	5.72e-35	1.54e-31	0.57	0.53	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47466741	chr17:47450568~47492492:-
PRAD	cis	rs8072100	0.875	rs12451409	ENSG00000228782.6	CTD-2026D20.3	13.45	5.72e-35	1.54e-31	0.57	0.53	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47467490	chr17:47450568~47492492:-
PRAD	cis	rs7208859	0.573	rs56031503	ENSG00000263531.1	RP13-753N3.1	13.45	5.73e-35	1.54e-31	1.02	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748647	chr17:30863921~30864940:-
PRAD	cis	rs875971	0.862	rs1968126	ENSG00000226824.5	RP4-756H11.3	13.45	5.75e-35	1.54e-31	0.73	0.53	Aortic root size;	chr7:66592017	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.862	rs6460306	ENSG00000226824.5	RP4-756H11.3	13.45	5.75e-35	1.54e-31	0.73	0.53	Aortic root size;	chr7:66595806	chr7:66654538~66669855:+
PRAD	cis	rs3091242	0.967	rs665372	ENSG00000224183.1	SDHDP6	-13.45	5.77e-35	1.55e-31	-0.62	-0.53	Erythrocyte sedimentation rate;	chr1:25392744	chr1:25294164~25294643:-
PRAD	cis	rs2153535	0.546	rs9378559	ENSG00000230939.1	RP11-314C16.1	-13.45	5.88e-35	1.58e-31	-0.65	-0.53	Motion sickness;	chr6:8538825	chr6:8784178~8785445:+
PRAD	cis	rs673078	0.607	rs61943392	ENSG00000275759.1	RP11-131L12.3	-13.45	5.91e-35	1.58e-31	-0.81	-0.53	Glucose homeostasis traits;	chr12:118382618	chr12:118428281~118428870:+
PRAD	cis	rs3931020	0.772	rs11485555	ENSG00000272864.1	RP11-17E13.2	-13.45	5.92e-35	1.59e-31	-0.56	-0.53	Resistin levels;	chr1:74720825	chr1:74698769~74699333:-
PRAD	cis	rs9326248	0.581	rs10892072	ENSG00000254851.1	RP11-109L13.1	-13.45	5.94e-35	1.59e-31	-0.68	-0.53	Blood protein levels;	chr11:117089597	chr11:117135528~117138582:+
PRAD	cis	rs6142102	0.602	rs6142069	ENSG00000276073.1	RP5-1125A11.7	-13.45	5.94e-35	1.59e-31	-0.51	-0.53	Skin pigmentation;	chr20:33972736	chr20:33985617~33988989:-
PRAD	cis	rs2487048	0.725	rs2246293	ENSG00000226334.1	RP11-217B7.2	13.45	5.96e-35	1.6e-31	0.69	0.53	Intraocular pressure;	chr9:104928557	chr9:104927553~104928892:+
PRAD	cis	rs10256972	0.685	rs10263665	ENSG00000229043.2	AC091729.9	-13.45	6e-35	1.61e-31	-0.65	-0.53	Endometriosis;Longevity;	chr7:1070992	chr7:1160374~1165267:+
PRAD	cis	rs6700559	0.903	rs6661240	ENSG00000260088.1	RP11-92G12.3	-13.45	6.02e-35	1.61e-31	-0.65	-0.53	Coronary artery disease;	chr1:200669719	chr1:200669507~200694250:+
PRAD	cis	rs7847628	0.765	rs7026635	ENSG00000226752.6	PSMD5-AS1	13.45	6.09e-35	1.63e-31	0.71	0.53	Birth weight;	chr9:120787749	chr9:120824828~120854385:+
PRAD	cis	rs17507216	0.667	rs72753916	ENSG00000278603.1	RP13-608F4.5	13.45	6.1e-35	1.63e-31	0.82	0.53	Excessive daytime sleepiness;	chr15:82684001	chr15:82472203~82472426:+
PRAD	cis	rs6700559	0.683	rs4915450	ENSG00000260088.1	RP11-92G12.3	-13.45	6.1e-35	1.63e-31	-0.65	-0.53	Coronary artery disease;	chr1:200672461	chr1:200669507~200694250:+
PRAD	cis	rs875971	0.825	rs59466412	ENSG00000226824.5	RP4-756H11.3	13.45	6.16e-35	1.65e-31	0.74	0.53	Aortic root size;	chr7:66100371	chr7:66654538~66669855:+
PRAD	cis	rs3096299	0.632	rs8051537	ENSG00000274627.1	RP11-104N10.2	13.44	6.19e-35	1.66e-31	0.53	0.53	Multiple myeloma (IgH translocation);	chr16:89477976	chr16:89516797~89522217:+
PRAD	cis	rs673078	0.607	rs7304342	ENSG00000275759.1	RP11-131L12.3	-13.44	6.25e-35	1.67e-31	-0.79	-0.53	Glucose homeostasis traits;	chr12:118390166	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.615	rs61943397	ENSG00000275759.1	RP11-131L12.3	-13.44	6.25e-35	1.67e-31	-0.79	-0.53	Glucose homeostasis traits;	chr12:118390996	chr12:118428281~118428870:+
PRAD	cis	rs4660456	0.913	rs7551747	ENSG00000237899.1	RP4-739H11.3	13.44	6.27e-35	1.68e-31	0.77	0.53	Platelet count;	chr1:40699407	chr1:40669089~40687588:-
PRAD	cis	rs1075265	0.61	rs6746965	ENSG00000233266.1	HMGB1P31	13.44	6.3e-35	1.69e-31	0.73	0.53	Chronotype;Morning vs. evening chronotype;	chr2:53996388	chr2:54051334~54051760:+
PRAD	cis	rs1075265	0.527	rs10167891	ENSG00000233266.1	HMGB1P31	13.44	6.3e-35	1.69e-31	0.73	0.53	Chronotype;Morning vs. evening chronotype;	chr2:54003658	chr2:54051334~54051760:+
PRAD	cis	rs2455601	0.786	rs3763914	ENSG00000254860.4	TMEM9B-AS1	13.44	6.52e-35	1.74e-31	0.65	0.53	Schizophrenia;	chr11:8919156	chr11:8964675~8977527:+
PRAD	cis	rs1075265	0.633	rs28653587	ENSG00000233266.1	HMGB1P31	13.44	6.6e-35	1.76e-31	0.73	0.53	Chronotype;Morning vs. evening chronotype;	chr2:53992435	chr2:54051334~54051760:+
PRAD	cis	rs6452524	0.618	rs6452504	ENSG00000249664.1	CTD-2227C6.2	13.44	6.64e-35	1.77e-31	0.62	0.53	Hypertension (SNP x SNP interaction);	chr5:83074625	chr5:83012285~83013109:-
PRAD	cis	rs6504950	0.679	rs9897646	ENSG00000275710.1	RP11-257O5.4	13.44	6.73e-35	1.8e-31	0.73	0.53	Breast cancer;	chr17:54907990	chr17:54964474~54964679:+
PRAD	cis	rs673078	0.607	rs73207564	ENSG00000275759.1	RP11-131L12.3	-13.43	6.8e-35	1.82e-31	-0.81	-0.53	Glucose homeostasis traits;	chr12:118429566	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.607	rs61943447	ENSG00000275759.1	RP11-131L12.3	-13.43	6.8e-35	1.82e-31	-0.81	-0.53	Glucose homeostasis traits;	chr12:118430598	chr12:118428281~118428870:+
PRAD	cis	rs875971	0.798	rs12698522	ENSG00000226824.5	RP4-756H11.3	-13.43	6.9e-35	1.84e-31	-0.73	-0.53	Aortic root size;	chr7:66502354	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.83	rs28714531	ENSG00000226824.5	RP4-756H11.3	-13.43	6.9e-35	1.84e-31	-0.73	-0.53	Aortic root size;	chr7:66503250	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.862	rs12698526	ENSG00000226824.5	RP4-756H11.3	-13.43	6.9e-35	1.84e-31	-0.73	-0.53	Aortic root size;	chr7:66504118	chr7:66654538~66669855:+
PRAD	cis	rs494459	0.726	rs1784300	ENSG00000255239.1	AP002954.6	13.43	6.96e-35	1.86e-31	0.68	0.53	Height;	chr11:118808920	chr11:118688039~118690600:-
PRAD	cis	rs3814244	0.528	rs12228471	ENSG00000255733.4	IFNG-AS1	13.43	6.97e-35	1.86e-31	0.59	0.53	Itch intensity from mosquito bite adjusted by bite size;	chr12:68027842	chr12:67989445~68234686:+
PRAD	cis	rs9322193	0.884	rs1108889	ENSG00000223701.3	RAET1E-AS1	13.43	7e-35	1.87e-31	0.71	0.53	Lung cancer;	chr6:149845433	chr6:149884431~149919508:+
PRAD	cis	rs7208859	0.573	rs8070182	ENSG00000263531.1	RP13-753N3.1	13.43	7.03e-35	1.88e-31	1	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30808576	chr17:30863921~30864940:-
PRAD	cis	rs875971	0.651	rs2420596	ENSG00000226824.5	RP4-756H11.3	-13.43	7.05e-35	1.88e-31	-0.73	-0.53	Aortic root size;	chr7:66450996	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.52	rs2420597	ENSG00000226824.5	RP4-756H11.3	-13.43	7.05e-35	1.88e-31	-0.73	-0.53	Aortic root size;	chr7:66450999	chr7:66654538~66669855:+
PRAD	cis	rs4660456	1	rs4660456	ENSG00000237899.1	RP4-739H11.3	-13.43	7.09e-35	1.89e-31	-0.77	-0.53	Platelet count;	chr1:40773839	chr1:40669089~40687588:-
PRAD	cis	rs9326248	0.954	rs521171	ENSG00000280143.1	AP000892.6	13.43	7.09e-35	1.89e-31	0.45	0.53	Blood protein levels;	chr11:117193977	chr11:117204967~117210292:+
PRAD	cis	rs977987	0.931	rs1834013	ENSG00000261783.1	RP11-252K23.2	-13.43	7.11e-35	1.9e-31	-0.74	-0.53	Dupuytren's disease;	chr16:75462265	chr16:75379818~75381260:-
PRAD	cis	rs62388641	0.813	rs34779492	ENSG00000272279.1	RP11-157J24.2	13.43	7.15e-35	1.91e-31	0.82	0.53	Daytime sleep phenotypes;	chr6:1547737	chr6:1528364~1528911:-
PRAD	cis	rs62388641	0.774	rs13212794	ENSG00000272279.1	RP11-157J24.2	13.43	7.15e-35	1.91e-31	0.82	0.53	Daytime sleep phenotypes;	chr6:1548349	chr6:1528364~1528911:-
PRAD	cis	rs801193	0.569	rs2659893	ENSG00000226824.5	RP4-756H11.3	-13.43	7.17e-35	1.91e-31	-0.74	-0.53	Aortic root size;	chr7:66735006	chr7:66654538~66669855:+
PRAD	cis	rs801193	0.569	rs2659892	ENSG00000226824.5	RP4-756H11.3	-13.43	7.17e-35	1.91e-31	-0.74	-0.53	Aortic root size;	chr7:66735318	chr7:66654538~66669855:+
PRAD	cis	rs801193	0.548	rs2659891	ENSG00000226824.5	RP4-756H11.3	-13.43	7.17e-35	1.91e-31	-0.74	-0.53	Aortic root size;	chr7:66736127	chr7:66654538~66669855:+
PRAD	cis	rs801193	0.569	rs2707847	ENSG00000226824.5	RP4-756H11.3	-13.43	7.17e-35	1.91e-31	-0.74	-0.53	Aortic root size;	chr7:66737884	chr7:66654538~66669855:+
PRAD	cis	rs801193	0.548	rs7805152	ENSG00000226824.5	RP4-756H11.3	-13.43	7.17e-35	1.91e-31	-0.74	-0.53	Aortic root size;	chr7:66744266	chr7:66654538~66669855:+
PRAD	cis	rs801193	0.569	rs13226966	ENSG00000226824.5	RP4-756H11.3	-13.43	7.29e-35	1.94e-31	-0.74	-0.53	Aortic root size;	chr7:66768636	chr7:66654538~66669855:+
PRAD	cis	rs7208859	0.623	rs426434	ENSG00000263531.1	RP13-753N3.1	13.43	7.4e-35	1.97e-31	1	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30598335	chr17:30863921~30864940:-
PRAD	cis	rs2455601	0.573	rs2653573	ENSG00000254860.4	TMEM9B-AS1	13.43	7.4e-35	1.97e-31	0.59	0.53	Schizophrenia;	chr11:8968327	chr11:8964675~8977527:+
PRAD	cis	rs977987	0.931	rs8057084	ENSG00000261783.1	RP11-252K23.2	13.42	7.5e-35	2e-31	0.74	0.53	Dupuytren's disease;	chr16:75458808	chr16:75379818~75381260:-
PRAD	cis	rs9601248	0.508	rs9601240	ENSG00000227676.3	LINC01068	13.42	7.52e-35	2e-31	0.67	0.53	Major depressive disorder;	chr13:79558238	chr13:79566727~79571436:+
PRAD	cis	rs801193	0.569	rs11761542	ENSG00000226824.5	RP4-756H11.3	-13.42	7.58e-35	2.02e-31	-0.74	-0.53	Aortic root size;	chr7:66753209	chr7:66654538~66669855:+
PRAD	cis	rs1075265	0.633	rs7564912	ENSG00000233266.1	HMGB1P31	13.42	7.65e-35	2.04e-31	0.73	0.53	Chronotype;Morning vs. evening chronotype;	chr2:53995048	chr2:54051334~54051760:+
PRAD	cis	rs977987	0.778	rs35415181	ENSG00000261783.1	RP11-252K23.2	-13.42	7.68e-35	2.04e-31	-0.72	-0.53	Dupuytren's disease;	chr16:75369226	chr16:75379818~75381260:-
PRAD	cis	rs6452524	0.618	rs6452503	ENSG00000249664.1	CTD-2227C6.2	13.42	7.69e-35	2.05e-31	0.62	0.53	Hypertension (SNP x SNP interaction);	chr5:83074596	chr5:83012285~83013109:-
PRAD	cis	rs4718428	0.672	rs12530806	ENSG00000226824.5	RP4-756H11.3	-13.42	7.74e-35	2.06e-31	-0.72	-0.53	Corneal structure;	chr7:66925737	chr7:66654538~66669855:+
PRAD	cis	rs2882667	0.858	rs17207870	ENSG00000253404.1	AC034243.1	13.42	7.78e-35	2.07e-31	0.76	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139052048	chr5:138744434~138753309:-
PRAD	cis	rs6920372	0.731	rs9386799	ENSG00000260273.1	RP11-425D10.10	13.42	7.86e-35	2.09e-31	0.72	0.53	Height;	chr6:109333398	chr6:109382795~109383666:+
PRAD	cis	rs3814244	0.528	rs56393928	ENSG00000255733.4	IFNG-AS1	13.42	7.89e-35	2.1e-31	0.59	0.53	Itch intensity from mosquito bite adjusted by bite size;	chr12:68029927	chr12:67989445~68234686:+
PRAD	cis	rs916888	0.61	rs142167	ENSG00000262500.1	RP11-259G18.2	-13.42	7.91e-35	2.1e-31	-0.7	-0.53	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:46243606~46245044:+
PRAD	cis	rs801193	0.569	rs11772819	ENSG00000226824.5	RP4-756H11.3	-13.42	7.98e-35	2.12e-31	-0.74	-0.53	Aortic root size;	chr7:66752983	chr7:66654538~66669855:+
PRAD	cis	rs801193	0.569	rs7800620	ENSG00000226824.5	RP4-756H11.3	-13.42	7.98e-35	2.12e-31	-0.74	-0.53	Aortic root size;	chr7:66758701	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.862	rs28491091	ENSG00000226824.5	RP4-756H11.3	13.42	8.09e-35	2.15e-31	0.73	0.53	Aortic root size;	chr7:66204077	chr7:66654538~66669855:+
PRAD	cis	rs6142102	0.602	rs2300209	ENSG00000276073.1	RP5-1125A11.7	-13.42	8.14e-35	2.16e-31	-0.52	-0.53	Skin pigmentation;	chr20:34055294	chr20:33985617~33988989:-
PRAD	cis	rs12022452	0.818	rs11810978	ENSG00000238287.1	RP11-656D10.3	-13.42	8.2e-35	2.18e-31	-0.93	-0.53	Age-related hearing impairment (SNP x SNP interaction);	chr1:40554175	chr1:40493157~40508661:-
PRAD	cis	rs6504950	0.705	rs17745123	ENSG00000275710.1	RP11-257O5.4	13.41	8.26e-35	2.19e-31	0.74	0.53	Breast cancer;	chr17:54910871	chr17:54964474~54964679:+
PRAD	cis	rs3091242	0.9	rs35345536	ENSG00000261349.1	RP3-465N24.5	-13.41	8.38e-35	2.22e-31	-0.59	-0.53	Erythrocyte sedimentation rate;	chr1:25439997	chr1:25266102~25267136:-
PRAD	cis	rs55794721	0.509	rs12027135	ENSG00000261349.1	RP3-465N24.5	-13.41	8.38e-35	2.22e-31	-0.59	-0.53	Mean corpuscular volume;Plateletcrit;	chr1:25449242	chr1:25266102~25267136:-
PRAD	cis	rs9322193	0.923	rs2880436	ENSG00000223701.3	RAET1E-AS1	13.41	8.39e-35	2.23e-31	0.71	0.53	Lung cancer;	chr6:149859123	chr6:149884431~149919508:+
PRAD	cis	rs6964833	1	rs34324835	ENSG00000123965.13	PMS2P5	13.41	8.41e-35	2.23e-31	0.83	0.53	Menarche (age at onset);	chr7:74717986	chr7:74894116~74897835:+
PRAD	cis	rs7044106	0.791	rs10985008	ENSG00000226752.6	PSMD5-AS1	-13.41	8.47e-35	2.25e-31	-0.65	-0.53	Hip circumference adjusted for BMI;	chr9:120730682	chr9:120824828~120854385:+
PRAD	cis	rs673078	0.607	rs17512644	ENSG00000275759.1	RP11-131L12.3	-13.41	8.59e-35	2.28e-31	-0.81	-0.53	Glucose homeostasis traits;	chr12:118359963	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.607	rs17512652	ENSG00000275759.1	RP11-131L12.3	-13.41	8.59e-35	2.28e-31	-0.81	-0.53	Glucose homeostasis traits;	chr12:118361278	chr12:118428281~118428870:+
PRAD	cis	rs977987	0.843	rs10871312	ENSG00000261783.1	RP11-252K23.2	-13.41	8.66e-35	2.29e-31	-0.73	-0.53	Dupuytren's disease;	chr16:75452304	chr16:75379818~75381260:-
PRAD	cis	rs11723261	0.621	rs6599306	ENSG00000275426.1	CH17-262A2.1	-13.41	8.93e-35	2.37e-31	-0.81	-0.53	Immune response to smallpox vaccine (IL-6);	chr4:149655	chr4:149738~150317:+
PRAD	cis	rs3096299	0.582	rs12935119	ENSG00000274627.1	RP11-104N10.2	13.41	8.95e-35	2.37e-31	0.54	0.53	Multiple myeloma (IgH translocation);	chr16:89476466	chr16:89516797~89522217:+
PRAD	cis	rs1426063	0.614	rs78681370	ENSG00000249717.1	RP11-44F21.3	13.4	9.18e-35	2.43e-31	1.27	0.53	QT interval;	chr4:75081556	chr4:74955974~74970362:-
PRAD	cis	rs1426063	0.614	rs17000212	ENSG00000249717.1	RP11-44F21.3	13.4	9.18e-35	2.43e-31	1.27	0.53	QT interval;	chr4:75081611	chr4:74955974~74970362:-
PRAD	cis	rs1426063	0.614	rs77018380	ENSG00000249717.1	RP11-44F21.3	13.4	9.18e-35	2.43e-31	1.27	0.53	QT interval;	chr4:75081621	chr4:74955974~74970362:-
PRAD	cis	rs1426063	0.614	rs75846524	ENSG00000249717.1	RP11-44F21.3	13.4	9.18e-35	2.43e-31	1.27	0.53	QT interval;	chr4:75083172	chr4:74955974~74970362:-
PRAD	cis	rs1426063	0.614	rs76325897	ENSG00000249717.1	RP11-44F21.3	13.4	9.18e-35	2.43e-31	1.27	0.53	QT interval;	chr4:75084747	chr4:74955974~74970362:-
PRAD	cis	rs1426063	0.614	rs76093954	ENSG00000249717.1	RP11-44F21.3	13.4	9.18e-35	2.43e-31	1.27	0.53	QT interval;	chr4:75087994	chr4:74955974~74970362:-
PRAD	cis	rs1426063	0.614	rs114977200	ENSG00000249717.1	RP11-44F21.3	13.4	9.18e-35	2.43e-31	1.27	0.53	QT interval;	chr4:75088736	chr4:74955974~74970362:-
PRAD	cis	rs1426063	0.614	rs77625282	ENSG00000249717.1	RP11-44F21.3	13.4	9.18e-35	2.43e-31	1.27	0.53	QT interval;	chr4:75089646	chr4:74955974~74970362:-
PRAD	cis	rs1426063	0.614	rs75112697	ENSG00000249717.1	RP11-44F21.3	13.4	9.18e-35	2.43e-31	1.27	0.53	QT interval;	chr4:75089725	chr4:74955974~74970362:-
PRAD	cis	rs1426063	0.614	rs7684790	ENSG00000249717.1	RP11-44F21.3	13.4	9.18e-35	2.43e-31	1.27	0.53	QT interval;	chr4:75090873	chr4:74955974~74970362:-
PRAD	cis	rs1426063	0.614	rs7671634	ENSG00000249717.1	RP11-44F21.3	13.4	9.18e-35	2.43e-31	1.27	0.53	QT interval;	chr4:75090883	chr4:74955974~74970362:-
PRAD	cis	rs1426063	0.614	rs6534447	ENSG00000249717.1	RP11-44F21.3	-13.4	9.18e-35	2.43e-31	-1.27	-0.53	QT interval;	chr4:75080682	chr4:74955974~74970362:-
PRAD	cis	rs4660456	0.913	rs6661855	ENSG00000237899.1	RP4-739H11.3	13.4	9.2e-35	2.43e-31	0.77	0.53	Platelet count;	chr1:40703245	chr1:40669089~40687588:-
PRAD	cis	rs7044106	0.791	rs2900177	ENSG00000226752.6	PSMD5-AS1	-13.4	9.23e-35	2.44e-31	-0.65	-0.53	Hip circumference adjusted for BMI;	chr9:120735367	chr9:120824828~120854385:+
PRAD	cis	rs2581828	0.656	rs4687701	ENSG00000242142.1	SERBP1P3	-13.4	9.32e-35	2.46e-31	-0.6	-0.53	Crohn's disease;	chr3:53087260	chr3:53064283~53065091:-
PRAD	cis	rs11673344	0.583	rs10421436	ENSG00000226686.6	LINC01535	-13.4	9.33e-35	2.47e-31	-0.67	-0.53	Obesity-related traits;	chr19:37394601	chr19:37251912~37265535:+
PRAD	cis	rs7044106	0.5	rs56725168	ENSG00000226752.6	PSMD5-AS1	-13.4	9.36e-35	2.47e-31	-0.65	-0.53	Hip circumference adjusted for BMI;	chr9:120730298	chr9:120824828~120854385:+
PRAD	cis	rs6452524	0.618	rs6452506	ENSG00000249664.1	CTD-2227C6.2	13.4	9.37e-35	2.48e-31	0.62	0.53	Hypertension (SNP x SNP interaction);	chr5:83075844	chr5:83012285~83013109:-
PRAD	cis	rs4718428	0.705	rs4717328	ENSG00000226824.5	RP4-756H11.3	-13.4	9.41e-35	2.48e-31	-0.72	-0.53	Corneal structure;	chr7:66887678	chr7:66654538~66669855:+
PRAD	cis	rs4718428	0.705	rs4718422	ENSG00000226824.5	RP4-756H11.3	-13.4	9.41e-35	2.48e-31	-0.72	-0.53	Corneal structure;	chr7:66894282	chr7:66654538~66669855:+
PRAD	cis	rs4718428	0.705	rs13231140	ENSG00000226824.5	RP4-756H11.3	-13.4	9.41e-35	2.48e-31	-0.72	-0.53	Corneal structure;	chr7:66896631	chr7:66654538~66669855:+
PRAD	cis	rs4718428	0.705	rs4718424	ENSG00000226824.5	RP4-756H11.3	-13.4	9.41e-35	2.48e-31	-0.72	-0.53	Corneal structure;	chr7:66911108	chr7:66654538~66669855:+
PRAD	cis	rs6700559	1	rs6656619	ENSG00000260088.1	RP11-92G12.3	13.4	9.44e-35	2.49e-31	0.65	0.53	Coronary artery disease;	chr1:200671664	chr1:200669507~200694250:+
PRAD	cis	rs9532669	0.926	rs11147823	ENSG00000176268.5	CYCSP34	-13.4	9.48e-35	2.5e-31	-0.55	-0.53	Cervical cancer;	chr13:40878138	chr13:40863599~40863902:-
PRAD	cis	rs7044106	0.791	rs10985009	ENSG00000226752.6	PSMD5-AS1	13.4	9.52e-35	2.51e-31	0.65	0.53	Hip circumference adjusted for BMI;	chr9:120730761	chr9:120824828~120854385:+
PRAD	cis	rs11673344	0.801	rs56343212	ENSG00000226686.6	LINC01535	13.4	9.62e-35	2.54e-31	0.76	0.53	Obesity-related traits;	chr19:37167684	chr19:37251912~37265535:+
PRAD	cis	rs9660180	0.967	rs61422524	ENSG00000268575.1	RP1-283E3.8	-13.4	9.79e-35	2.58e-31	-0.55	-0.53	Body mass index;	chr1:1836126	chr1:1702736~1737688:-
PRAD	cis	rs4722166	0.63	rs10950916	ENSG00000179428.2	AC073072.5	-13.4	9.87e-35	2.6e-31	-0.65	-0.53	Lung cancer;	chr7:22760048	chr7:22725395~22727620:-
PRAD	cis	rs875971	0.895	rs6460278	ENSG00000226824.5	RP4-756H11.3	13.4	9.91e-35	2.61e-31	0.73	0.53	Aortic root size;	chr7:66197749	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.862	rs6460279	ENSG00000226824.5	RP4-756H11.3	13.4	9.91e-35	2.61e-31	0.73	0.53	Aortic root size;	chr7:66197774	chr7:66654538~66669855:+
PRAD	cis	rs4660456	0.826	rs3767952	ENSG00000237899.1	RP4-739H11.3	-13.4	9.94e-35	2.62e-31	-0.77	-0.53	Platelet count;	chr1:40765360	chr1:40669089~40687588:-
PRAD	cis	rs4718428	0.672	rs36038499	ENSG00000226824.5	RP4-756H11.3	-13.39	1.01e-34	2.67e-31	-0.72	-0.53	Corneal structure;	chr7:66824628	chr7:66654538~66669855:+
PRAD	cis	rs4718428	0.705	rs62465692	ENSG00000226824.5	RP4-756H11.3	-13.39	1.01e-34	2.67e-31	-0.72	-0.53	Corneal structure;	chr7:66830758	chr7:66654538~66669855:+
PRAD	cis	rs4718428	0.662	rs34577323	ENSG00000226824.5	RP4-756H11.3	-13.39	1.01e-34	2.67e-31	-0.72	-0.53	Corneal structure;	chr7:66845054	chr7:66654538~66669855:+
PRAD	cis	rs11155671	0.53	rs9371544	ENSG00000231760.4	RP11-350J20.5	13.39	1.01e-34	2.67e-31	0.72	0.53	Testicular germ cell tumor;	chr6:149896224	chr6:149796151~149826294:-
PRAD	cis	rs2283792	0.776	rs9610458	ENSG00000224086.5	LL22NC03-86G7.1	-13.39	1.02e-34	2.68e-31	-0.63	-0.53	Multiple sclerosis;	chr22:21851064	chr22:21938293~21977632:+
PRAD	cis	rs4660456	0.913	rs2744799	ENSG00000237899.1	RP4-739H11.3	13.39	1.05e-34	2.77e-31	0.77	0.53	Platelet count;	chr1:40719862	chr1:40669089~40687588:-
PRAD	cis	rs11690935	0.843	rs9784070	ENSG00000228389.1	AC068039.4	13.39	1.05e-34	2.77e-31	0.63	0.53	Schizophrenia;	chr2:171928497	chr2:171773482~171775844:+
PRAD	cis	rs3091242	0.935	rs3093632	ENSG00000261349.1	RP3-465N24.5	-13.39	1.06e-34	2.8e-31	-0.58	-0.53	Erythrocyte sedimentation rate;	chr1:25357521	chr1:25266102~25267136:-
PRAD	cis	rs524281	0.861	rs7941431	ENSG00000255320.1	RP11-755F10.1	13.39	1.06e-34	2.8e-31	0.85	0.53	Electroencephalogram traits;	chr11:66192686	chr11:66244840~66246239:-
PRAD	cis	rs875971	0.862	rs6955837	ENSG00000226824.5	RP4-756H11.3	13.39	1.07e-34	2.81e-31	0.73	0.53	Aortic root size;	chr7:66578155	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.825	rs10281499	ENSG00000226824.5	RP4-756H11.3	13.39	1.07e-34	2.81e-31	0.73	0.53	Aortic root size;	chr7:66583979	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.862	rs4718377	ENSG00000226824.5	RP4-756H11.3	13.39	1.07e-34	2.81e-31	0.73	0.53	Aortic root size;	chr7:66584691	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.862	rs10278014	ENSG00000226824.5	RP4-756H11.3	13.39	1.07e-34	2.81e-31	0.73	0.53	Aortic root size;	chr7:66586277	chr7:66654538~66669855:+
PRAD	cis	rs6142102	0.602	rs4911402	ENSG00000276073.1	RP5-1125A11.7	-13.39	1.07e-34	2.81e-31	-0.52	-0.53	Skin pigmentation;	chr20:34079839	chr20:33985617~33988989:-
PRAD	cis	rs977987	0.933	rs1834014	ENSG00000261783.1	RP11-252K23.2	-13.39	1.08e-34	2.84e-31	-0.74	-0.53	Dupuytren's disease;	chr16:75467376	chr16:75379818~75381260:-
PRAD	cis	rs6452524	0.618	rs1993948	ENSG00000249664.1	CTD-2227C6.2	13.39	1.09e-34	2.86e-31	0.62	0.53	Hypertension (SNP x SNP interaction);	chr5:83076461	chr5:83012285~83013109:-
PRAD	cis	rs3096299	0.685	rs4238830	ENSG00000274627.1	RP11-104N10.2	13.39	1.09e-34	2.87e-31	0.53	0.53	Multiple myeloma (IgH translocation);	chr16:89473833	chr16:89516797~89522217:+
PRAD	cis	rs524281	0.861	rs10750780	ENSG00000255320.1	RP11-755F10.1	13.38	1.12e-34	2.94e-31	0.85	0.53	Electroencephalogram traits;	chr11:66207121	chr11:66244840~66246239:-
PRAD	cis	rs1426063	0.614	rs78046076	ENSG00000249717.1	RP11-44F21.3	13.38	1.12e-34	2.94e-31	1.27	0.53	QT interval;	chr4:75091818	chr4:74955974~74970362:-
PRAD	cis	rs1426063	0.614	rs74670563	ENSG00000249717.1	RP11-44F21.3	13.38	1.12e-34	2.94e-31	1.27	0.53	QT interval;	chr4:75094656	chr4:74955974~74970362:-
PRAD	cis	rs1426063	0.614	rs115338890	ENSG00000249717.1	RP11-44F21.3	13.38	1.12e-34	2.94e-31	1.27	0.53	QT interval;	chr4:75094719	chr4:74955974~74970362:-
PRAD	cis	rs1426063	0.541	rs116304289	ENSG00000249717.1	RP11-44F21.3	13.38	1.12e-34	2.94e-31	1.27	0.53	QT interval;	chr4:75095072	chr4:74955974~74970362:-
PRAD	cis	rs1426063	0.614	rs76204704	ENSG00000249717.1	RP11-44F21.3	13.38	1.12e-34	2.94e-31	1.27	0.53	QT interval;	chr4:75097804	chr4:74955974~74970362:-
PRAD	cis	rs1426063	0.614	rs80030693	ENSG00000249717.1	RP11-44F21.3	13.38	1.12e-34	2.94e-31	1.27	0.53	QT interval;	chr4:75099929	chr4:74955974~74970362:-
PRAD	cis	rs9322193	0.567	rs7747457	ENSG00000231760.4	RP11-350J20.5	13.38	1.14e-34	2.98e-31	0.72	0.53	Lung cancer;	chr6:149892366	chr6:149796151~149826294:-
PRAD	cis	rs2487048	0.725	rs2422493	ENSG00000226334.1	RP11-217B7.2	-13.38	1.14e-34	3e-31	-0.69	-0.53	Intraocular pressure;	chr9:104928714	chr9:104927553~104928892:+
PRAD	cis	rs2882667	0.858	rs11949916	ENSG00000253404.1	AC034243.1	13.38	1.15e-34	3.03e-31	0.76	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139060588	chr5:138744434~138753309:-
PRAD	cis	rs673078	0.607	rs61943367	ENSG00000275759.1	RP11-131L12.3	-13.38	1.17e-34	3.07e-31	-0.81	-0.53	Glucose homeostasis traits;	chr12:118366316	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.607	rs61943368	ENSG00000275759.1	RP11-131L12.3	-13.38	1.17e-34	3.07e-31	-0.81	-0.53	Glucose homeostasis traits;	chr12:118366568	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.607	rs61943385	ENSG00000275759.1	RP11-131L12.3	-13.38	1.17e-34	3.07e-31	-0.81	-0.53	Glucose homeostasis traits;	chr12:118370339	chr12:118428281~118428870:+
PRAD	cis	rs9545047	0.935	rs1475797	ENSG00000227676.3	LINC01068	-13.38	1.18e-34	3.1e-31	-0.66	-0.53	Schizophrenia;	chr13:79519690	chr13:79566727~79571436:+
PRAD	cis	rs73086581	1	rs73086597	ENSG00000229539.1	RP11-119B16.2	13.38	1.19e-34	3.13e-31	0.89	0.53	Response to antidepressants in depression;	chr20:4002924	chr20:3888239~3888868:-
PRAD	cis	rs916888	0.647	rs199523	ENSG00000262500.1	RP11-259G18.2	-13.38	1.21e-34	3.16e-31	-0.72	-0.53	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:46243606~46245044:+
PRAD	cis	rs673078	0.607	rs7132753	ENSG00000275759.1	RP11-131L12.3	-13.38	1.21e-34	3.18e-31	-0.81	-0.53	Glucose homeostasis traits;	chr12:118420383	chr12:118428281~118428870:+
PRAD	cis	rs11723261	0.621	rs11733385	ENSG00000275426.1	CH17-262A2.1	13.37	1.23e-34	3.22e-31	0.8	0.53	Immune response to smallpox vaccine (IL-6);	chr4:146677	chr4:149738~150317:+
PRAD	cis	rs11723261	0.546	rs4315728	ENSG00000275426.1	CH17-262A2.1	13.37	1.23e-34	3.22e-31	0.8	0.53	Immune response to smallpox vaccine (IL-6);	chr4:147237	chr4:149738~150317:+
PRAD	cis	rs4718428	0.705	rs12698547	ENSG00000226824.5	RP4-756H11.3	-13.37	1.23e-34	3.22e-31	-0.72	-0.53	Corneal structure;	chr7:66813271	chr7:66654538~66669855:+
PRAD	cis	rs977987	0.806	rs12051326	ENSG00000261783.1	RP11-252K23.2	-13.37	1.25e-34	3.28e-31	-0.73	-0.53	Dupuytren's disease;	chr16:75403989	chr16:75379818~75381260:-
PRAD	cis	rs4660456	0.913	rs552147	ENSG00000237899.1	RP4-739H11.3	-13.37	1.25e-34	3.28e-31	-0.77	-0.53	Platelet count;	chr1:40689141	chr1:40669089~40687588:-
PRAD	cis	rs801193	0.548	rs6975044	ENSG00000226824.5	RP4-756H11.3	-13.37	1.26e-34	3.31e-31	-0.74	-0.53	Aortic root size;	chr7:66762495	chr7:66654538~66669855:+
PRAD	cis	rs3096299	0.685	rs4785675	ENSG00000274627.1	RP11-104N10.2	13.37	1.27e-34	3.31e-31	0.53	0.53	Multiple myeloma (IgH translocation);	chr16:89473566	chr16:89516797~89522217:+
PRAD	cis	rs11155671	0.53	rs6557133	ENSG00000231760.4	RP11-350J20.5	13.37	1.28e-34	3.35e-31	0.72	0.53	Testicular germ cell tumor;	chr6:149874248	chr6:149796151~149826294:-
PRAD	cis	rs977987	0.806	rs7202596	ENSG00000261783.1	RP11-252K23.2	-13.37	1.3e-34	3.4e-31	-0.73	-0.53	Dupuytren's disease;	chr16:75457174	chr16:75379818~75381260:-
PRAD	cis	rs6504950	1	rs17818028	ENSG00000275710.1	RP11-257O5.4	-13.37	1.32e-34	3.44e-31	-0.73	-0.53	Breast cancer;	chr17:54985394	chr17:54964474~54964679:+
PRAD	cis	rs875971	0.767	rs61348003	ENSG00000226824.5	RP4-756H11.3	-13.37	1.32e-34	3.44e-31	-0.72	-0.53	Aortic root size;	chr7:66540947	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.861	rs801215	ENSG00000226824.5	RP4-756H11.3	13.37	1.32e-34	3.44e-31	0.72	0.53	Aortic root size;	chr7:66546951	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.756	rs2901210	ENSG00000226824.5	RP4-756H11.3	13.37	1.32e-34	3.44e-31	0.72	0.53	Aortic root size;	chr7:66552518	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.862	rs13536	ENSG00000226824.5	RP4-756H11.3	13.37	1.32e-34	3.44e-31	0.72	0.53	Aortic root size;	chr7:66554203	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.862	rs801209	ENSG00000226824.5	RP4-756H11.3	13.37	1.32e-34	3.44e-31	0.72	0.53	Aortic root size;	chr7:66554403	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.862	rs801206	ENSG00000226824.5	RP4-756H11.3	13.37	1.32e-34	3.44e-31	0.72	0.53	Aortic root size;	chr7:66556979	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.862	rs801204	ENSG00000226824.5	RP4-756H11.3	13.37	1.32e-34	3.44e-31	0.72	0.53	Aortic root size;	chr7:66557934	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.862	rs801203	ENSG00000226824.5	RP4-756H11.3	13.37	1.32e-34	3.44e-31	0.72	0.53	Aortic root size;	chr7:66558025	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.825	rs801202	ENSG00000226824.5	RP4-756H11.3	13.37	1.32e-34	3.44e-31	0.72	0.53	Aortic root size;	chr7:66558942	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.862	rs801194	ENSG00000226824.5	RP4-756H11.3	13.37	1.32e-34	3.44e-31	0.72	0.53	Aortic root size;	chr7:66563508	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.862	rs2024192	ENSG00000226824.5	RP4-756H11.3	13.37	1.32e-34	3.44e-31	0.72	0.53	Aortic root size;	chr7:66576460	chr7:66654538~66669855:+
PRAD	cis	rs11690935	0.885	rs6725388	ENSG00000228389.1	AC068039.4	13.37	1.34e-34	3.49e-31	0.63	0.53	Schizophrenia;	chr2:171873505	chr2:171773482~171775844:+
PRAD	cis	rs875971	0.862	rs2909688	ENSG00000226824.5	RP4-756H11.3	-13.36	1.34e-34	3.49e-31	-0.73	-0.53	Aortic root size;	chr7:66376625	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.862	rs778720	ENSG00000226824.5	RP4-756H11.3	13.36	1.35e-34	3.54e-31	0.72	0.53	Aortic root size;	chr7:66381288	chr7:66654538~66669855:+
PRAD	cis	rs9322193	0.923	rs9371207	ENSG00000223701.3	RAET1E-AS1	13.36	1.38e-34	3.6e-31	0.71	0.53	Lung cancer;	chr6:149858087	chr6:149884431~149919508:+
PRAD	cis	rs3931020	0.745	rs10874274	ENSG00000272864.1	RP11-17E13.2	-13.36	1.38e-34	3.6e-31	-0.55	-0.53	Resistin levels;	chr1:74786450	chr1:74698769~74699333:-
PRAD	cis	rs875971	0.862	rs17747530	ENSG00000226824.5	RP4-756H11.3	-13.36	1.39e-34	3.62e-31	-0.72	-0.53	Aortic root size;	chr7:66529742	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.862	rs13226170	ENSG00000226824.5	RP4-756H11.3	-13.36	1.39e-34	3.62e-31	-0.72	-0.53	Aortic root size;	chr7:66534311	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.862	rs2420611	ENSG00000226824.5	RP4-756H11.3	-13.36	1.39e-34	3.62e-31	-0.72	-0.53	Aortic root size;	chr7:66534333	chr7:66654538~66669855:+
PRAD	cis	rs9487094	0.626	rs12215077	ENSG00000260273.1	RP11-425D10.10	-13.36	1.39e-34	3.62e-31	-0.72	-0.53	Height;	chr6:109731677	chr6:109382795~109383666:+
PRAD	cis	rs73086581	1	rs73086512	ENSG00000229539.1	RP11-119B16.2	13.36	1.41e-34	3.66e-31	0.9	0.53	Response to antidepressants in depression;	chr20:3942125	chr20:3888239~3888868:-
PRAD	cis	rs7174755	0.772	rs75395345	ENSG00000260657.2	RP11-315D16.4	13.36	1.41e-34	3.67e-31	0.7	0.53	Major depressive disorder;	chr15:68081380	chr15:68267792~68277994:-
PRAD	cis	rs9326248	0.954	rs4938349	ENSG00000280143.1	AP000892.6	13.36	1.43e-34	3.72e-31	0.45	0.53	Blood protein levels;	chr11:117151207	chr11:117204967~117210292:+
PRAD	cis	rs9326248	0.954	rs10790177	ENSG00000280143.1	AP000892.6	13.36	1.44e-34	3.75e-31	0.45	0.53	Blood protein levels;	chr11:117177701	chr11:117204967~117210292:+
PRAD	cis	rs1577917	0.538	rs6454483	ENSG00000203875.9	SNHG5	13.36	1.45e-34	3.78e-31	0.56	0.53	Response to antipsychotic treatment;	chr6:85708565	chr6:85660950~85678736:-
PRAD	cis	rs6964833	1	rs17515241	ENSG00000123965.13	PMS2P5	-13.35	1.48e-34	3.84e-31	-0.82	-0.53	Menarche (age at onset);	chr7:74717695	chr7:74894116~74897835:+
PRAD	cis	rs977987	0.806	rs11864102	ENSG00000261783.1	RP11-252K23.2	-13.35	1.49e-34	3.88e-31	-0.72	-0.53	Dupuytren's disease;	chr16:75408462	chr16:75379818~75381260:-
PRAD	cis	rs875971	0.862	rs801195	ENSG00000226824.5	RP4-756H11.3	13.35	1.49e-34	3.88e-31	0.73	0.53	Aortic root size;	chr7:66561128	chr7:66654538~66669855:+
PRAD	cis	rs3091242	0.967	rs1053438	ENSG00000224183.1	SDHDP6	13.35	1.5e-34	3.91e-31	0.62	0.53	Erythrocyte sedimentation rate;	chr1:25361410	chr1:25294164~25294643:-
PRAD	cis	rs524281	0.861	rs7120326	ENSG00000255320.1	RP11-755F10.1	13.35	1.52e-34	3.96e-31	0.85	0.53	Electroencephalogram traits;	chr11:66081785	chr11:66244840~66246239:-
PRAD	cis	rs11673344	0.583	rs10425719	ENSG00000226686.6	LINC01535	-13.35	1.53e-34	3.98e-31	-0.67	-0.53	Obesity-related traits;	chr19:37459896	chr19:37251912~37265535:+
PRAD	cis	rs2882667	0.822	rs13187096	ENSG00000253404.1	AC034243.1	13.35	1.55e-34	4.03e-31	0.76	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139068399	chr5:138744434~138753309:-
PRAD	cis	rs11723261	0.564	rs61792258	ENSG00000275426.1	CH17-262A2.1	13.35	1.57e-34	4.08e-31	0.8	0.53	Immune response to smallpox vaccine (IL-6);	chr4:143482	chr4:149738~150317:+
PRAD	cis	rs494459	0.838	rs632124	ENSG00000255239.1	AP002954.6	13.35	1.58e-34	4.09e-31	0.68	0.53	Height;	chr11:118742526	chr11:118688039~118690600:-
PRAD	cis	rs2153535	0.58	rs7761937	ENSG00000230939.1	RP11-314C16.1	-13.35	1.58e-34	4.1e-31	-0.66	-0.53	Motion sickness;	chr6:8459201	chr6:8784178~8785445:+
PRAD	cis	rs2487048	0.761	rs1800976	ENSG00000226334.1	RP11-217B7.2	-13.35	1.59e-34	4.12e-31	-0.69	-0.53	Intraocular pressure;	chr9:104928428	chr9:104927553~104928892:+
PRAD	cis	rs4718428	0.705	rs12536410	ENSG00000226824.5	RP4-756H11.3	-13.35	1.59e-34	4.12e-31	-0.72	-0.53	Corneal structure;	chr7:66789303	chr7:66654538~66669855:+
PRAD	cis	rs6142102	0.602	rs1054534	ENSG00000276073.1	RP5-1125A11.7	-13.35	1.59e-34	4.12e-31	-0.52	-0.53	Skin pigmentation;	chr20:34017521	chr20:33985617~33988989:-
PRAD	cis	rs7104764	0.879	rs511744	ENSG00000277290.1	RP11-326C3.16	-13.35	1.6e-34	4.14e-31	-0.49	-0.53	Menarche (age at onset);	chr11:219089	chr11:243099~243483:-
PRAD	cis	rs3096299	0.754	rs2965816	ENSG00000274627.1	RP11-104N10.2	-13.35	1.6e-34	4.14e-31	-0.53	-0.53	Multiple myeloma (IgH translocation);	chr16:89447775	chr16:89516797~89522217:+
PRAD	cis	rs2739330	0.892	rs5751776	ENSG00000231271.1	AP000350.8	13.35	1.6e-34	4.15e-31	0.71	0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23949918~23954042:+
PRAD	cis	rs875971	0.83	rs778711	ENSG00000226824.5	RP4-756H11.3	-13.35	1.62e-34	4.2e-31	-0.72	-0.53	Aortic root size;	chr7:66386670	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.862	rs1083554	ENSG00000226824.5	RP4-756H11.3	-13.35	1.62e-34	4.2e-31	-0.72	-0.53	Aortic root size;	chr7:66387354	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.862	rs778707	ENSG00000226824.5	RP4-756H11.3	-13.35	1.62e-34	4.2e-31	-0.72	-0.53	Aortic root size;	chr7:66392040	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.862	rs778705	ENSG00000226824.5	RP4-756H11.3	-13.35	1.62e-34	4.2e-31	-0.72	-0.53	Aortic root size;	chr7:66396128	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.862	rs778697	ENSG00000226824.5	RP4-756H11.3	-13.35	1.62e-34	4.2e-31	-0.72	-0.53	Aortic root size;	chr7:66405439	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.798	rs7789615	ENSG00000226824.5	RP4-756H11.3	-13.35	1.62e-34	4.2e-31	-0.72	-0.53	Aortic root size;	chr7:66413674	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.862	rs6978028	ENSG00000226824.5	RP4-756H11.3	-13.35	1.62e-34	4.2e-31	-0.72	-0.53	Aortic root size;	chr7:66421313	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.862	rs6947339	ENSG00000226824.5	RP4-756H11.3	-13.35	1.62e-34	4.2e-31	-0.72	-0.53	Aortic root size;	chr7:66423483	chr7:66654538~66669855:+
PRAD	cis	rs977987	0.736	rs11865296	ENSG00000261783.1	RP11-252K23.2	-13.34	1.63e-34	4.23e-31	-0.72	-0.53	Dupuytren's disease;	chr16:75439795	chr16:75379818~75381260:-
PRAD	cis	rs494459	0.838	rs2510897	ENSG00000255239.1	AP002954.6	13.34	1.65e-34	4.28e-31	0.67	0.53	Height;	chr11:118773873	chr11:118688039~118690600:-
PRAD	cis	rs9399135	0.816	rs4134030	ENSG00000232876.1	CTA-212D2.2	-13.34	1.65e-34	4.29e-31	-0.64	-0.53	Red blood cell count;	chr6:135032956	chr6:135055033~135060550:+
PRAD	cis	rs62388641	0.813	rs55821127	ENSG00000272279.1	RP11-157J24.2	13.34	1.67e-34	4.33e-31	0.82	0.53	Daytime sleep phenotypes;	chr6:1550635	chr6:1528364~1528911:-
PRAD	cis	rs6504950	0.705	rs9899545	ENSG00000275710.1	RP11-257O5.4	13.34	1.7e-34	4.4e-31	0.72	0.53	Breast cancer;	chr17:54909484	chr17:54964474~54964679:+
PRAD	cis	rs977987	0.843	rs12927562	ENSG00000261783.1	RP11-252K23.2	-13.34	1.73e-34	4.48e-31	-0.73	-0.53	Dupuytren's disease;	chr16:75448962	chr16:75379818~75381260:-
PRAD	cis	rs4660456	0.956	rs4660457	ENSG00000237899.1	RP4-739H11.3	-13.34	1.74e-34	4.51e-31	-0.77	-0.53	Platelet count;	chr1:40774121	chr1:40669089~40687588:-
PRAD	cis	rs4660456	0.564	rs34320811	ENSG00000237899.1	RP4-739H11.3	-13.34	1.75e-34	4.52e-31	-0.77	-0.53	Platelet count;	chr1:40763288	chr1:40669089~40687588:-
PRAD	cis	rs524281	0.861	rs10896077	ENSG00000255320.1	RP11-755F10.1	13.34	1.76e-34	4.54e-31	0.85	0.53	Electroencephalogram traits;	chr11:66084262	chr11:66244840~66246239:-
PRAD	cis	rs524281	0.817	rs7115081	ENSG00000255320.1	RP11-755F10.1	13.34	1.76e-34	4.54e-31	0.85	0.53	Electroencephalogram traits;	chr11:66086070	chr11:66244840~66246239:-
PRAD	cis	rs524281	0.861	rs11227403	ENSG00000255320.1	RP11-755F10.1	13.34	1.76e-34	4.54e-31	0.85	0.53	Electroencephalogram traits;	chr11:66090957	chr11:66244840~66246239:-
PRAD	cis	rs524281	0.861	rs7935336	ENSG00000255320.1	RP11-755F10.1	13.34	1.76e-34	4.54e-31	0.85	0.53	Electroencephalogram traits;	chr11:66097854	chr11:66244840~66246239:-
PRAD	cis	rs524281	0.861	rs11227409	ENSG00000255320.1	RP11-755F10.1	13.34	1.76e-34	4.54e-31	0.85	0.53	Electroencephalogram traits;	chr11:66103467	chr11:66244840~66246239:-
PRAD	cis	rs524281	0.861	rs11227410	ENSG00000255320.1	RP11-755F10.1	13.34	1.76e-34	4.54e-31	0.85	0.53	Electroencephalogram traits;	chr11:66105925	chr11:66244840~66246239:-
PRAD	cis	rs11723261	0.509	rs61792240	ENSG00000275426.1	CH17-262A2.1	13.34	1.76e-34	4.55e-31	0.8	0.53	Immune response to smallpox vaccine (IL-6);	chr4:134876	chr4:149738~150317:+
PRAD	cis	rs9487094	0.626	rs4947016	ENSG00000260273.1	RP11-425D10.10	13.34	1.78e-34	4.6e-31	0.72	0.53	Height;	chr6:109740895	chr6:109382795~109383666:+
PRAD	cis	rs9322193	0.847	rs880246	ENSG00000268592.3	RAET1E-AS1	13.33	1.79e-34	4.63e-31	0.72	0.53	Lung cancer;	chr6:149845972	chr6:149863494~149919507:+
PRAD	cis	rs9545047	0.901	rs7982263	ENSG00000227676.3	LINC01068	-13.33	1.82e-34	4.69e-31	-0.65	-0.53	Schizophrenia;	chr13:79486939	chr13:79566727~79571436:+
PRAD	cis	rs6700559	1	rs10494821	ENSG00000260088.1	RP11-92G12.3	-13.33	1.85e-34	4.77e-31	-0.65	-0.53	Coronary artery disease;	chr1:200673357	chr1:200669507~200694250:+
PRAD	cis	rs9326248	0.953	rs488962	ENSG00000280143.1	AP000892.6	-13.33	1.87e-34	4.83e-31	-0.45	-0.53	Blood protein levels;	chr11:117201809	chr11:117204967~117210292:+
PRAD	cis	rs6964833	1	rs6967152	ENSG00000123965.13	PMS2P5	13.33	1.88e-34	4.86e-31	0.82	0.53	Menarche (age at onset);	chr7:74684983	chr7:74894116~74897835:+
PRAD	cis	rs9326248	0.911	rs474339	ENSG00000280143.1	AP000892.6	13.33	1.89e-34	4.88e-31	0.45	0.53	Blood protein levels;	chr11:117188836	chr11:117204967~117210292:+
PRAD	cis	rs6700559	1	rs6667172	ENSG00000260088.1	RP11-92G12.3	-13.33	1.9e-34	4.89e-31	-0.65	-0.53	Coronary artery disease;	chr1:200674710	chr1:200669507~200694250:+
PRAD	cis	rs6700559	1	rs7527499	ENSG00000260088.1	RP11-92G12.3	-13.33	1.9e-34	4.89e-31	-0.65	-0.53	Coronary artery disease;	chr1:200676217	chr1:200669507~200694250:+
PRAD	cis	rs6700559	1	rs6427838	ENSG00000260088.1	RP11-92G12.3	-13.33	1.9e-34	4.89e-31	-0.65	-0.53	Coronary artery disease;	chr1:200676519	chr1:200669507~200694250:+
PRAD	cis	rs6700559	1	rs12061346	ENSG00000260088.1	RP11-92G12.3	-13.33	1.9e-34	4.89e-31	-0.65	-0.53	Coronary artery disease;	chr1:200677648	chr1:200669507~200694250:+
PRAD	cis	rs6700559	1	rs7533971	ENSG00000260088.1	RP11-92G12.3	-13.33	1.9e-34	4.89e-31	-0.65	-0.53	Coronary artery disease;	chr1:200678243	chr1:200669507~200694250:+
PRAD	cis	rs6700559	1	rs10919998	ENSG00000260088.1	RP11-92G12.3	-13.33	1.9e-34	4.89e-31	-0.65	-0.53	Coronary artery disease;	chr1:200679182	chr1:200669507~200694250:+
PRAD	cis	rs6700559	0.967	rs4072552	ENSG00000260088.1	RP11-92G12.3	-13.33	1.9e-34	4.89e-31	-0.65	-0.53	Coronary artery disease;	chr1:200680003	chr1:200669507~200694250:+
PRAD	cis	rs9326248	0.953	rs634960	ENSG00000280143.1	AP000892.6	-13.33	1.92e-34	4.94e-31	-0.45	-0.53	Blood protein levels;	chr11:117202247	chr11:117204967~117210292:+
PRAD	cis	rs4718428	0.705	rs28648401	ENSG00000226824.5	RP4-756H11.3	-13.33	1.96e-34	5.04e-31	-0.72	-0.53	Corneal structure;	chr7:66902145	chr7:66654538~66669855:+
PRAD	cis	rs4718428	0.607	rs66954441	ENSG00000226824.5	RP4-756H11.3	-13.33	1.96e-34	5.04e-31	-0.72	-0.53	Corneal structure;	chr7:66904222	chr7:66654538~66669855:+
PRAD	cis	rs2455601	0.744	rs11042133	ENSG00000254860.4	TMEM9B-AS1	13.32	1.98e-34	5.08e-31	0.65	0.53	Schizophrenia;	chr11:8944964	chr11:8964675~8977527:+
PRAD	cis	rs6964833	1	rs36044436	ENSG00000123965.13	PMS2P5	13.32	1.99e-34	5.11e-31	0.83	0.53	Menarche (age at onset);	chr7:74675495	chr7:74894116~74897835:+
PRAD	cis	rs997154	0.579	rs12889177	ENSG00000279656.1	RP11-298I3.6	-13.32	2.05e-34	5.25e-31	-0.81	-0.53	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:23022120	chr14:23023083~23024217:-
PRAD	cis	rs2111504	0.806	rs2903738	ENSG00000267213.4	AC007773.2	-13.32	2.05e-34	5.28e-31	-0.59	-0.53	Bipolar disorder;	chr19:32455137	chr19:32390050~32405560:-
PRAD	cis	rs3091242	0.933	rs932372	ENSG00000261349.1	RP3-465N24.5	-13.32	2.08e-34	5.33e-31	-0.59	-0.53	Erythrocyte sedimentation rate;	chr1:25428523	chr1:25266102~25267136:-
PRAD	cis	rs673078	0.66	rs17512609	ENSG00000275759.1	RP11-131L12.3	-13.32	2.12e-34	5.43e-31	-0.81	-0.53	Glucose homeostasis traits;	chr12:118354072	chr12:118428281~118428870:+
PRAD	cis	rs2658782	1	rs2019814	ENSG00000279684.1	RP11-755E23.2	-13.32	2.15e-34	5.52e-31	-0.87	-0.53	Pulmonary function decline;	chr11:93435719	chr11:93286629~93288903:-
PRAD	cis	rs9545047	0.935	rs2783119	ENSG00000227676.3	LINC01068	13.31	2.17e-34	5.56e-31	0.66	0.53	Schizophrenia;	chr13:79524983	chr13:79566727~79571436:+
PRAD	cis	rs4660456	0.871	rs7549789	ENSG00000237899.1	RP4-739H11.3	-13.31	2.18e-34	5.58e-31	-0.77	-0.53	Platelet count;	chr1:40759362	chr1:40669089~40687588:-
PRAD	cis	rs524281	0.861	rs7946917	ENSG00000255320.1	RP11-755F10.1	13.31	2.18e-34	5.59e-31	0.85	0.53	Electroencephalogram traits;	chr11:66189106	chr11:66244840~66246239:-
PRAD	cis	rs1153858	0.945	rs16943246	ENSG00000259520.4	CTD-2651B20.3	-13.31	2.19e-34	5.62e-31	-0.69	-0.53	Homoarginine levels;	chr15:45428399	chr15:45251580~45279251:-
PRAD	cis	rs9399135	0.967	rs13199205	ENSG00000232876.1	CTA-212D2.2	-13.31	2.24e-34	5.75e-31	-0.65	-0.53	Red blood cell count;	chr6:134965367	chr6:135055033~135060550:+
PRAD	cis	rs6452524	0.618	rs3899556	ENSG00000249664.1	CTD-2227C6.2	13.31	2.27e-34	5.8e-31	0.61	0.53	Hypertension (SNP x SNP interaction);	chr5:83067862	chr5:83012285~83013109:-
PRAD	cis	rs6452524	0.56	rs6895174	ENSG00000249664.1	CTD-2227C6.2	13.31	2.27e-34	5.8e-31	0.61	0.53	Hypertension (SNP x SNP interaction);	chr5:83071606	chr5:83012285~83013109:-
PRAD	cis	rs524281	0.861	rs1862005	ENSG00000255320.1	RP11-755F10.1	13.31	2.28e-34	5.84e-31	0.85	0.53	Electroencephalogram traits;	chr11:66095931	chr11:66244840~66246239:-
PRAD	cis	rs9399135	0.967	rs6919862	ENSG00000232876.1	CTA-212D2.2	-13.31	2.29e-34	5.86e-31	-0.64	-0.53	Red blood cell count;	chr6:135031305	chr6:135055033~135060550:+
PRAD	cis	rs9399135	0.967	rs10872427	ENSG00000232876.1	CTA-212D2.2	-13.31	2.29e-34	5.86e-31	-0.64	-0.53	Red blood cell count;	chr6:135032314	chr6:135055033~135060550:+
PRAD	cis	rs9399135	0.967	rs7766189	ENSG00000232876.1	CTA-212D2.2	-13.31	2.29e-34	5.86e-31	-0.64	-0.53	Red blood cell count;	chr6:135032713	chr6:135055033~135060550:+
PRAD	cis	rs9399135	0.967	rs9402676	ENSG00000232876.1	CTA-212D2.2	-13.31	2.29e-34	5.86e-31	-0.64	-0.53	Red blood cell count;	chr6:135034369	chr6:135055033~135060550:+
PRAD	cis	rs6964833	1	rs34324835	ENSG00000277053.3	GTF2IP1	-13.31	2.31e-34	5.9e-31	-0.63	-0.53	Menarche (age at onset);	chr7:74717986	chr7:75185385~75237696:-
PRAD	cis	rs6452524	0.618	rs6452502	ENSG00000249664.1	CTD-2227C6.2	13.31	2.33e-34	5.97e-31	0.61	0.53	Hypertension (SNP x SNP interaction);	chr5:83074578	chr5:83012285~83013109:-
PRAD	cis	rs977987	0.806	rs12933281	ENSG00000261783.1	RP11-252K23.2	-13.31	2.34e-34	5.98e-31	-0.73	-0.53	Dupuytren's disease;	chr16:75449166	chr16:75379818~75381260:-
PRAD	cis	rs916888	0.647	rs199524	ENSG00000262500.1	RP11-259G18.2	-13.31	2.35e-34	6e-31	-0.71	-0.53	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:46243606~46245044:+
PRAD	cis	rs2919917	1	rs1384804	ENSG00000254352.1	RP11-578O24.2	13.31	2.37e-34	6.07e-31	0.64	0.53	Lymphocyte counts;	chr8:78659987	chr8:78723796~78724136:-
PRAD	cis	rs7188445	0.736	rs4243177	ENSG00000261390.4	RP11-345M22.2	13.3	2.42e-34	6.18e-31	0.62	0.53	Urate levels;	chr16:79669932	chr16:79715232~79770563:-
PRAD	cis	rs2739330	0.76	rs5751760	ENSG00000231271.1	AP000350.8	13.3	2.42e-34	6.18e-31	0.72	0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23949918~23954042:+
PRAD	cis	rs977987	0.771	rs4888387	ENSG00000261783.1	RP11-252K23.2	-13.3	2.44e-34	6.23e-31	-0.71	-0.53	Dupuytren's disease;	chr16:75355857	chr16:75379818~75381260:-
PRAD	cis	rs9545047	0.901	rs7338530	ENSG00000227676.3	LINC01068	-13.3	2.45e-34	6.26e-31	-0.65	-0.53	Schizophrenia;	chr13:79477715	chr13:79566727~79571436:+
PRAD	cis	rs2919917	1	rs10093654	ENSG00000254352.1	RP11-578O24.2	13.3	2.48e-34	6.35e-31	0.64	0.53	Lymphocyte counts;	chr8:78660360	chr8:78723796~78724136:-
PRAD	cis	rs673078	0.607	rs61944661	ENSG00000275759.1	RP11-131L12.3	-13.3	2.5e-34	6.38e-31	-0.8	-0.53	Glucose homeostasis traits;	chr12:118445514	chr12:118428281~118428870:+
PRAD	cis	rs6452524	0.618	rs2075685	ENSG00000249664.1	CTD-2227C6.2	13.3	2.51e-34	6.4e-31	0.62	0.53	Hypertension (SNP x SNP interaction);	chr5:83076846	chr5:83012285~83013109:-
PRAD	cis	rs5760092	0.755	rs4585126	ENSG00000273295.1	AP000350.5	-13.3	2.58e-34	6.59e-31	-0.7	-0.53	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23901432~23907068:-
PRAD	cis	rs2882667	0.858	rs13176497	ENSG00000253404.1	AC034243.1	13.3	2.6e-34	6.63e-31	0.75	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139110385	chr5:138744434~138753309:-
PRAD	cis	rs673078	0.607	rs7309484	ENSG00000275759.1	RP11-131L12.3	-13.3	2.63e-34	6.7e-31	-0.8	-0.53	Glucose homeostasis traits;	chr12:118400833	chr12:118428281~118428870:+
PRAD	cis	rs3096299	0.658	rs12443705	ENSG00000274627.1	RP11-104N10.2	13.3	2.63e-34	6.7e-31	0.52	0.53	Multiple myeloma (IgH translocation);	chr16:89480646	chr16:89516797~89522217:+
PRAD	cis	rs11673344	0.838	rs55856280	ENSG00000226686.6	LINC01535	13.29	2.63e-34	6.72e-31	0.77	0.53	Obesity-related traits;	chr19:37150747	chr19:37251912~37265535:+
PRAD	cis	rs9326248	1	rs664922	ENSG00000280143.1	AP000892.6	13.29	2.67e-34	6.8e-31	0.45	0.53	Blood protein levels;	chr11:117200179	chr11:117204967~117210292:+
PRAD	cis	rs9326248	1	rs664082	ENSG00000280143.1	AP000892.6	13.29	2.67e-34	6.8e-31	0.45	0.53	Blood protein levels;	chr11:117200354	chr11:117204967~117210292:+
PRAD	cis	rs73086581	1	rs6052220	ENSG00000229539.1	RP11-119B16.2	13.29	2.7e-34	6.88e-31	0.84	0.53	Response to antidepressants in depression;	chr20:3989947	chr20:3888239~3888868:-
PRAD	cis	rs4845570	1	rs4845356	ENSG00000249602.1	RP11-98D18.3	-13.29	2.74e-34	6.98e-31	-0.79	-0.53	Coronary artery disease;	chr1:151786747	chr1:151763384~151769501:-
PRAD	cis	rs10262624	0.504	rs59865844	ENSG00000234286.1	AC006026.13	13.29	2.75e-34	7e-31	0.59	0.53	Schizophrenia;	chr7:23693421	chr7:23680195~23680786:-
PRAD	cis	rs2658782	1	rs2605585	ENSG00000279684.1	RP11-755E23.2	-13.29	2.75e-34	7.02e-31	-0.89	-0.53	Pulmonary function decline;	chr11:93438696	chr11:93286629~93288903:-
PRAD	cis	rs2739330	0.929	rs5751777	ENSG00000250470.1	AP000351.3	13.29	2.77e-34	7.07e-31	0.71	0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23976904~23977585:-
PRAD	cis	rs6504950	0.705	rs9899602	ENSG00000275710.1	RP11-257O5.4	-13.29	2.85e-34	7.25e-31	-0.72	-0.53	Breast cancer;	chr17:54909547	chr17:54964474~54964679:+
PRAD	cis	rs9487094	0.626	rs11153213	ENSG00000260273.1	RP11-425D10.10	13.29	2.86e-34	7.28e-31	0.72	0.53	Height;	chr6:109693890	chr6:109382795~109383666:+
PRAD	cis	rs9487094	0.67	rs12201356	ENSG00000260273.1	RP11-425D10.10	13.29	2.86e-34	7.28e-31	0.72	0.53	Height;	chr6:109694672	chr6:109382795~109383666:+
PRAD	cis	rs6964833	0.935	rs13238996	ENSG00000123965.13	PMS2P5	13.29	2.87e-34	7.31e-31	0.83	0.53	Menarche (age at onset);	chr7:74655318	chr7:74894116~74897835:+
PRAD	cis	rs9545047	0.967	rs9545097	ENSG00000227676.3	LINC01068	13.28	2.94e-34	7.49e-31	0.69	0.53	Schizophrenia;	chr13:79387352	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.967	rs9593396	ENSG00000227676.3	LINC01068	13.28	2.94e-34	7.49e-31	0.69	0.53	Schizophrenia;	chr13:79396164	chr13:79566727~79571436:+
PRAD	cis	rs9545047	1	rs9545101	ENSG00000227676.3	LINC01068	13.28	2.94e-34	7.49e-31	0.69	0.53	Schizophrenia;	chr13:79399806	chr13:79566727~79571436:+
PRAD	cis	rs12022452	0.908	rs11811487	ENSG00000238287.1	RP11-656D10.3	-13.28	2.97e-34	7.56e-31	-0.92	-0.53	Age-related hearing impairment (SNP x SNP interaction);	chr1:40555398	chr1:40493157~40508661:-
PRAD	cis	rs3931020	0.772	rs1409785	ENSG00000272864.1	RP11-17E13.2	-13.28	2.97e-34	7.56e-31	-0.55	-0.53	Resistin levels;	chr1:74782438	chr1:74698769~74699333:-
PRAD	cis	rs977987	0.806	rs4888391	ENSG00000261783.1	RP11-252K23.2	-13.28	3e-34	7.62e-31	-0.71	-0.53	Dupuytren's disease;	chr16:75366848	chr16:75379818~75381260:-
PRAD	cis	rs1153858	0.945	rs1974981	ENSG00000259520.4	CTD-2651B20.3	13.28	3.05e-34	7.76e-31	0.69	0.53	Homoarginine levels;	chr15:45436925	chr15:45251580~45279251:-
PRAD	cis	rs977987	0.806	rs4888390	ENSG00000261783.1	RP11-252K23.2	-13.28	3.08e-34	7.82e-31	-0.71	-0.53	Dupuytren's disease;	chr16:75366422	chr16:75379818~75381260:-
PRAD	cis	rs977987	0.806	rs8054769	ENSG00000261783.1	RP11-252K23.2	-13.28	3.08e-34	7.82e-31	-0.71	-0.53	Dupuytren's disease;	chr16:75367215	chr16:75379818~75381260:-
PRAD	cis	rs9660180	0.967	rs6603803	ENSG00000268575.1	RP1-283E3.8	-13.28	3.08e-34	7.82e-31	-0.55	-0.53	Body mass index;	chr1:1881249	chr1:1702736~1737688:-
PRAD	cis	rs1577917	0.785	rs1885607	ENSG00000203875.9	SNHG5	13.28	3.09e-34	7.85e-31	0.6	0.53	Response to antipsychotic treatment;	chr6:85685187	chr6:85660950~85678736:-
PRAD	cis	rs55794721	0.543	rs1293260	ENSG00000261349.1	RP3-465N24.5	-13.28	3.11e-34	7.88e-31	-0.58	-0.53	Mean corpuscular volume;Plateletcrit;	chr1:25382613	chr1:25266102~25267136:-
PRAD	cis	rs11723261	0.621	rs11721745	ENSG00000275426.1	CH17-262A2.1	13.28	3.12e-34	7.91e-31	0.8	0.53	Immune response to smallpox vaccine (IL-6);	chr4:115052	chr4:149738~150317:+
PRAD	cis	rs673078	0.562	rs56347775	ENSG00000275759.1	RP11-131L12.3	-13.27	3.23e-34	8.18e-31	-0.8	-0.53	Glucose homeostasis traits;	chr12:118438002	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.607	rs61943451	ENSG00000275759.1	RP11-131L12.3	-13.27	3.23e-34	8.18e-31	-0.8	-0.53	Glucose homeostasis traits;	chr12:118438929	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.518	rs61943452	ENSG00000275759.1	RP11-131L12.3	-13.27	3.23e-34	8.18e-31	-0.8	-0.53	Glucose homeostasis traits;	chr12:118438990	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.607	rs61943454	ENSG00000275759.1	RP11-131L12.3	-13.27	3.23e-34	8.18e-31	-0.8	-0.53	Glucose homeostasis traits;	chr12:118439140	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.517	rs61943455	ENSG00000275759.1	RP11-131L12.3	-13.27	3.23e-34	8.18e-31	-0.8	-0.53	Glucose homeostasis traits;	chr12:118439414	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.607	rs73207566	ENSG00000275759.1	RP11-131L12.3	-13.27	3.23e-34	8.18e-31	-0.8	-0.53	Glucose homeostasis traits;	chr12:118439471	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.607	rs2393416	ENSG00000275759.1	RP11-131L12.3	-13.27	3.23e-34	8.18e-31	-0.8	-0.53	Glucose homeostasis traits;	chr12:118439968	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.56	rs4406856	ENSG00000275759.1	RP11-131L12.3	-13.27	3.23e-34	8.18e-31	-0.8	-0.53	Glucose homeostasis traits;	chr12:118440094	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.607	rs4457791	ENSG00000275759.1	RP11-131L12.3	-13.27	3.23e-34	8.18e-31	-0.8	-0.53	Glucose homeostasis traits;	chr12:118440144	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.607	rs61943456	ENSG00000275759.1	RP11-131L12.3	-13.27	3.23e-34	8.18e-31	-0.8	-0.53	Glucose homeostasis traits;	chr12:118440326	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.607	rs17513006	ENSG00000275759.1	RP11-131L12.3	-13.27	3.23e-34	8.18e-31	-0.8	-0.53	Glucose homeostasis traits;	chr12:118440383	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.56	rs61943457	ENSG00000275759.1	RP11-131L12.3	-13.27	3.23e-34	8.18e-31	-0.8	-0.53	Glucose homeostasis traits;	chr12:118440487	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.562	rs55883417	ENSG00000275759.1	RP11-131L12.3	-13.27	3.23e-34	8.18e-31	-0.8	-0.53	Glucose homeostasis traits;	chr12:118440801	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.607	rs55842338	ENSG00000275759.1	RP11-131L12.3	-13.27	3.23e-34	8.18e-31	-0.8	-0.53	Glucose homeostasis traits;	chr12:118441259	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.518	rs17441251	ENSG00000275759.1	RP11-131L12.3	-13.27	3.23e-34	8.18e-31	-0.8	-0.53	Glucose homeostasis traits;	chr12:118441361	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.607	rs17513013	ENSG00000275759.1	RP11-131L12.3	-13.27	3.23e-34	8.18e-31	-0.8	-0.53	Glucose homeostasis traits;	chr12:118442070	chr12:118428281~118428870:+
PRAD	cis	rs6964833	0.786	rs35633336	ENSG00000123965.13	PMS2P5	13.27	3.23e-34	8.19e-31	0.81	0.53	Menarche (age at onset);	chr7:74643961	chr7:74894116~74897835:+
PRAD	cis	rs2882667	0.858	rs10900856	ENSG00000253404.1	AC034243.1	-13.27	3.23e-34	8.19e-31	-0.75	-0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139082057	chr5:138744434~138753309:-
PRAD	cis	rs1426063	0.614	rs115690958	ENSG00000249717.1	RP11-44F21.3	13.27	3.25e-34	8.23e-31	1.26	0.53	QT interval;	chr4:75078364	chr4:74955974~74970362:-
PRAD	cis	rs4660456	0.913	rs3767951	ENSG00000237899.1	RP4-739H11.3	-13.27	3.27e-34	8.27e-31	-0.76	-0.53	Platelet count;	chr1:40767359	chr1:40669089~40687588:-
PRAD	cis	rs1150668	0.835	rs1233696	ENSG00000216901.1	AL022393.7	13.27	3.31e-34	8.38e-31	0.66	0.53	Pubertal anthropometrics;	chr6:28175232	chr6:28176188~28176674:+
PRAD	cis	rs4722166	0.603	rs7801406	ENSG00000179428.2	AC073072.5	-13.27	3.34e-34	8.46e-31	-0.64	-0.53	Lung cancer;	chr7:22748655	chr7:22725395~22727620:-
PRAD	cis	rs9326248	1	rs7946257	ENSG00000280143.1	AP000892.6	13.27	3.35e-34	8.48e-31	0.45	0.53	Blood protein levels;	chr11:117182449	chr11:117204967~117210292:+
PRAD	cis	rs55794721	0.509	rs873308	ENSG00000261349.1	RP3-465N24.5	13.27	3.37e-34	8.53e-31	0.57	0.53	Mean corpuscular volume;Plateletcrit;	chr1:25432164	chr1:25266102~25267136:-
PRAD	cis	rs977987	0.806	rs2865531	ENSG00000261783.1	RP11-252K23.2	-13.27	3.37e-34	8.54e-31	-0.71	-0.53	Dupuytren's disease;	chr16:75356418	chr16:75379818~75381260:-
PRAD	cis	rs2882667	0.858	rs11959851	ENSG00000253404.1	AC034243.1	13.27	3.38e-34	8.56e-31	0.72	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139085716	chr5:138744434~138753309:-
PRAD	cis	rs6964833	0.935	rs7795282	ENSG00000123965.13	PMS2P5	13.27	3.38e-34	8.56e-31	0.82	0.53	Menarche (age at onset);	chr7:74708526	chr7:74894116~74897835:+
PRAD	cis	rs9322193	0.923	rs7769101	ENSG00000268592.3	RAET1E-AS1	13.27	3.41e-34	8.64e-31	0.73	0.53	Lung cancer;	chr6:149848768	chr6:149863494~149919507:+
PRAD	cis	rs977987	0.806	rs1030262	ENSG00000261783.1	RP11-252K23.2	-13.27	3.44e-34	8.71e-31	-0.73	-0.53	Dupuytren's disease;	chr16:75457429	chr16:75379818~75381260:-
PRAD	cis	rs673078	0.607	rs17441172	ENSG00000275759.1	RP11-131L12.3	13.27	3.45e-34	8.71e-31	0.81	0.53	Glucose homeostasis traits;	chr12:118430456	chr12:118428281~118428870:+
PRAD	cis	rs9660180	1	rs3737628	ENSG00000268575.1	RP1-283E3.8	-13.27	3.46e-34	8.76e-31	-0.55	-0.53	Body mass index;	chr1:1791493	chr1:1702736~1737688:-
PRAD	cis	rs977987	0.902	rs4888430	ENSG00000261783.1	RP11-252K23.2	-13.27	3.47e-34	8.79e-31	-0.73	-0.53	Dupuytren's disease;	chr16:75460526	chr16:75379818~75381260:-
PRAD	cis	rs4722166	0.508	rs1474347	ENSG00000179428.2	AC073072.5	13.27	3.49e-34	8.83e-31	0.63	0.53	Lung cancer;	chr7:22728505	chr7:22725395~22727620:-
PRAD	cis	rs11673344	0.832	rs11540540	ENSG00000226686.6	LINC01535	13.27	3.5e-34	8.85e-31	0.75	0.53	Obesity-related traits;	chr19:37129629	chr19:37251912~37265535:+
PRAD	cis	rs673078	0.571	rs17440823	ENSG00000275759.1	RP11-131L12.3	-13.26	3.51e-34	8.87e-31	-0.79	-0.53	Glucose homeostasis traits;	chr12:118353023	chr12:118428281~118428870:+
PRAD	cis	rs172166	0.516	rs1150670	ENSG00000216901.1	AL022393.7	13.26	3.52e-34	8.9e-31	0.65	0.53	Cardiac Troponin-T levels;	chr6:28162781	chr6:28176188~28176674:+
PRAD	cis	rs172166	0.516	rs2021826	ENSG00000216901.1	AL022393.7	13.26	3.52e-34	8.9e-31	0.65	0.53	Cardiac Troponin-T levels;	chr6:28164978	chr6:28176188~28176674:+
PRAD	cis	rs7208859	0.615	rs216462	ENSG00000263531.1	RP13-753N3.1	-13.26	3.57e-34	9.01e-31	-1.04	-0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30568879	chr17:30863921~30864940:-
PRAD	cis	rs11723261	0.621	rs3829	ENSG00000275426.1	CH17-262A2.1	13.26	3.63e-34	9.16e-31	0.79	0.53	Immune response to smallpox vaccine (IL-6);	chr4:141070	chr4:149738~150317:+
PRAD	cis	rs11723261	0.621	rs57013142	ENSG00000275426.1	CH17-262A2.1	13.26	3.63e-34	9.16e-31	0.79	0.53	Immune response to smallpox vaccine (IL-6);	chr4:141956	chr4:149738~150317:+
PRAD	cis	rs4423214	0.592	rs10898186	ENSG00000254682.1	RP11-660L16.2	-13.26	3.65e-34	9.2e-31	-0.83	-0.53	Vitamin D levels;	chr11:71477754	chr11:71448674~71452157:+
PRAD	cis	rs4722166	0.63	rs6461667	ENSG00000179428.2	AC073072.5	-13.26	3.67e-34	9.26e-31	-0.65	-0.53	Lung cancer;	chr7:22757124	chr7:22725395~22727620:-
PRAD	cis	rs2111504	0.806	rs10403559	ENSG00000267213.4	AC007773.2	-13.26	3.7e-34	9.33e-31	-0.59	-0.53	Bipolar disorder;	chr19:32462195	chr19:32390050~32405560:-
PRAD	cis	rs3091242	0.934	rs666686	ENSG00000261349.1	RP3-465N24.5	-13.26	3.71e-34	9.36e-31	-0.58	-0.53	Erythrocyte sedimentation rate;	chr1:25393020	chr1:25266102~25267136:-
PRAD	cis	rs4660456	0.913	rs569159	ENSG00000237899.1	RP4-739H11.3	-13.26	3.73e-34	9.4e-31	-0.77	-0.53	Platelet count;	chr1:40701862	chr1:40669089~40687588:-
PRAD	cis	rs9532669	0.927	rs9532670	ENSG00000176268.5	CYCSP34	-13.26	3.73e-34	9.41e-31	-0.54	-0.53	Cervical cancer;	chr13:40927691	chr13:40863599~40863902:-
PRAD	cis	rs6964833	1	rs4717906	ENSG00000123965.13	PMS2P5	13.26	3.78e-34	9.52e-31	0.81	0.53	Menarche (age at onset);	chr7:74671923	chr7:74894116~74897835:+
PRAD	cis	rs9660180	0.846	rs10907195	ENSG00000231050.1	RP1-140A9.1	-13.26	3.79e-34	9.56e-31	-0.61	-0.53	Body mass index;	chr1:1781909	chr1:1891471~1892658:+
PRAD	cis	rs3091242	0.933	rs1534954	ENSG00000261349.1	RP3-465N24.5	-13.26	3.79e-34	9.56e-31	-0.58	-0.53	Erythrocyte sedimentation rate;	chr1:25435433	chr1:25266102~25267136:-
PRAD	cis	rs2455601	0.786	rs56680262	ENSG00000254860.4	TMEM9B-AS1	13.25	3.89e-34	9.79e-31	0.64	0.53	Schizophrenia;	chr11:8950008	chr11:8964675~8977527:+
PRAD	cis	rs11690935	0.843	rs9784123	ENSG00000228389.1	AC068039.4	13.25	3.9e-34	9.82e-31	0.63	0.53	Schizophrenia;	chr2:171928495	chr2:171773482~171775844:+
PRAD	cis	rs524281	0.725	rs3132851	ENSG00000255320.1	RP11-755F10.1	-13.25	4e-34	1.01e-30	-0.89	-0.53	Electroencephalogram traits;	chr11:66288671	chr11:66244840~66246239:-
PRAD	cis	rs6142102	0.581	rs4911148	ENSG00000276073.1	RP5-1125A11.7	-13.25	4.01e-34	1.01e-30	-0.52	-0.53	Skin pigmentation;	chr20:34080438	chr20:33985617~33988989:-
PRAD	cis	rs977987	0.736	rs4888392	ENSG00000261783.1	RP11-252K23.2	-13.25	4.08e-34	1.03e-30	-0.71	-0.53	Dupuytren's disease;	chr16:75378364	chr16:75379818~75381260:-
PRAD	cis	rs9399135	0.967	rs1041480	ENSG00000232876.1	CTA-212D2.2	-13.25	4.08e-34	1.03e-30	-0.64	-0.53	Red blood cell count;	chr6:135051938	chr6:135055033~135060550:+
PRAD	cis	rs11155671	0.53	rs6935829	ENSG00000231760.4	RP11-350J20.5	13.25	4.09e-34	1.03e-30	0.72	0.53	Testicular germ cell tumor;	chr6:149896675	chr6:149796151~149826294:-
PRAD	cis	rs2739330	0.929	rs5751775	ENSG00000250470.1	AP000351.3	13.25	4.14e-34	1.04e-30	0.71	0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23976904~23977585:-
PRAD	cis	rs6964833	1	rs6964833	ENSG00000123965.13	PMS2P5	13.25	4.14e-34	1.04e-30	0.82	0.53	Menarche (age at onset);	chr7:74687575	chr7:74894116~74897835:+
PRAD	cis	rs9326248	0.559	rs4938334	ENSG00000254851.1	RP11-109L13.1	-13.25	4.18e-34	1.05e-30	-0.66	-0.53	Blood protein levels;	chr11:117060326	chr11:117135528~117138582:+
PRAD	cis	rs6452524	0.618	rs255561	ENSG00000249664.1	CTD-2227C6.2	13.25	4.24e-34	1.07e-30	0.61	0.53	Hypertension (SNP x SNP interaction);	chr5:83054991	chr5:83012285~83013109:-
PRAD	cis	rs9326248	1	rs585849	ENSG00000280143.1	AP000892.6	13.24	4.27e-34	1.07e-30	0.45	0.53	Blood protein levels;	chr11:117198345	chr11:117204967~117210292:+
PRAD	cis	rs977987	0.806	rs12051136	ENSG00000261783.1	RP11-252K23.2	-13.24	4.3e-34	1.08e-30	-0.72	-0.53	Dupuytren's disease;	chr16:75401833	chr16:75379818~75381260:-
PRAD	cis	rs977987	0.778	rs4888409	ENSG00000261783.1	RP11-252K23.2	-13.24	4.3e-34	1.08e-30	-0.72	-0.53	Dupuytren's disease;	chr16:75402333	chr16:75379818~75381260:-
PRAD	cis	rs977987	0.778	rs7206541	ENSG00000261783.1	RP11-252K23.2	-13.24	4.3e-34	1.08e-30	-0.72	-0.53	Dupuytren's disease;	chr16:75402815	chr16:75379818~75381260:-
PRAD	cis	rs977987	0.788	rs7184525	ENSG00000261783.1	RP11-252K23.2	-13.24	4.3e-34	1.08e-30	-0.72	-0.53	Dupuytren's disease;	chr16:75403288	chr16:75379818~75381260:-
PRAD	cis	rs801193	0.591	rs4506088	ENSG00000226824.5	RP4-756H11.3	13.24	4.37e-34	1.1e-30	0.73	0.53	Aortic root size;	chr7:66670470	chr7:66654538~66669855:+
PRAD	cis	rs6964833	0.935	rs35735900	ENSG00000123965.13	PMS2P5	13.24	4.39e-34	1.1e-30	0.81	0.53	Menarche (age at onset);	chr7:74651887	chr7:74894116~74897835:+
PRAD	cis	rs6964833	0.872	rs4717903	ENSG00000123965.13	PMS2P5	13.24	4.39e-34	1.1e-30	0.81	0.53	Menarche (age at onset);	chr7:74653827	chr7:74894116~74897835:+
PRAD	cis	rs673078	0.607	rs1060964	ENSG00000275759.1	RP11-131L12.3	-13.24	4.4e-34	1.1e-30	-0.77	-0.53	Glucose homeostasis traits;	chr12:118414906	chr12:118428281~118428870:+
PRAD	cis	rs3091242	0.967	rs3093614	ENSG00000224183.1	SDHDP6	13.24	4.4e-34	1.11e-30	0.62	0.53	Erythrocyte sedimentation rate;	chr1:25351353	chr1:25294164~25294643:-
PRAD	cis	rs4718428	0.705	rs11028	ENSG00000226824.5	RP4-756H11.3	-13.24	4.6e-34	1.15e-30	-0.71	-0.53	Corneal structure;	chr7:66811230	chr7:66654538~66669855:+
PRAD	cis	rs2882667	0.858	rs11957527	ENSG00000253404.1	AC034243.1	13.24	4.61e-34	1.16e-30	0.74	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139069206	chr5:138744434~138753309:-
PRAD	cis	rs6964833	1	rs2301907	ENSG00000123965.13	PMS2P5	13.24	4.62e-34	1.16e-30	0.82	0.53	Menarche (age at onset);	chr7:74700517	chr7:74894116~74897835:+
PRAD	cis	rs4845570	1	rs4845570	ENSG00000249602.1	RP11-98D18.3	-13.24	4.64e-34	1.16e-30	-0.79	-0.53	Coronary artery disease;	chr1:151786628	chr1:151763384~151769501:-
PRAD	cis	rs673078	0.607	rs8467	ENSG00000275759.1	RP11-131L12.3	-13.24	4.67e-34	1.17e-30	-0.78	-0.53	Glucose homeostasis traits;	chr12:118417479	chr12:118428281~118428870:+
PRAD	cis	rs7044106	0.791	rs747819	ENSG00000226752.6	PSMD5-AS1	-13.23	4.69e-34	1.18e-30	-0.65	-0.53	Hip circumference adjusted for BMI;	chr9:120726163	chr9:120824828~120854385:+
PRAD	cis	rs7044106	0.791	rs735110	ENSG00000226752.6	PSMD5-AS1	-13.23	4.69e-34	1.18e-30	-0.65	-0.53	Hip circumference adjusted for BMI;	chr9:120726662	chr9:120824828~120854385:+
PRAD	cis	rs4718428	0.705	rs68168107	ENSG00000226824.5	RP4-756H11.3	-13.23	4.7e-34	1.18e-30	-0.72	-0.53	Corneal structure;	chr7:66790251	chr7:66654538~66669855:+
PRAD	cis	rs2455601	0.786	rs3751064	ENSG00000254860.4	TMEM9B-AS1	13.23	5e-34	1.25e-30	0.65	0.53	Schizophrenia;	chr11:8937356	chr11:8964675~8977527:+
PRAD	cis	rs4718428	0.705	rs10267335	ENSG00000226824.5	RP4-756H11.3	-13.23	5.07e-34	1.27e-30	-0.73	-0.53	Corneal structure;	chr7:66938233	chr7:66654538~66669855:+
PRAD	cis	rs7044106	0.791	rs735109	ENSG00000226752.6	PSMD5-AS1	-13.23	5.08e-34	1.27e-30	-0.65	-0.53	Hip circumference adjusted for BMI;	chr9:120726601	chr9:120824828~120854385:+
PRAD	cis	rs2111504	0.583	rs8104714	ENSG00000267213.4	AC007773.2	13.23	5.12e-34	1.28e-30	0.56	0.53	Bipolar disorder;	chr19:32381203	chr19:32390050~32405560:-
PRAD	cis	rs524281	0.861	rs12226649	ENSG00000255320.1	RP11-755F10.1	13.22	5.23e-34	1.31e-30	0.85	0.53	Electroencephalogram traits;	chr11:66074576	chr11:66244840~66246239:-
PRAD	cis	rs2919917	1	rs10093797	ENSG00000254352.1	RP11-578O24.2	13.22	5.24e-34	1.31e-30	0.64	0.53	Lymphocyte counts;	chr8:78660478	chr8:78723796~78724136:-
PRAD	cis	rs2919917	1	rs3808619	ENSG00000254352.1	RP11-578O24.2	13.22	5.24e-34	1.31e-30	0.64	0.53	Lymphocyte counts;	chr8:78665491	chr8:78723796~78724136:-
PRAD	cis	rs17826219	0.636	rs2449770	ENSG00000263531.1	RP13-753N3.1	13.22	5.32e-34	1.33e-30	1.02	0.53	Body mass index;	chr17:30774046	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.524	rs59913838	ENSG00000263531.1	RP13-753N3.1	13.22	5.32e-34	1.33e-30	1.02	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774545	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs8067338	ENSG00000263531.1	RP13-753N3.1	13.22	5.32e-34	1.33e-30	1.02	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775327	chr17:30863921~30864940:-
PRAD	cis	rs6964833	0.935	rs34762099	ENSG00000123965.13	PMS2P5	13.22	5.33e-34	1.33e-30	0.81	0.53	Menarche (age at onset);	chr7:74636378	chr7:74894116~74897835:+
PRAD	cis	rs4718428	0.705	rs4717331	ENSG00000226824.5	RP4-756H11.3	-13.22	5.33e-34	1.33e-30	-0.71	-0.53	Corneal structure;	chr7:66913899	chr7:66654538~66669855:+
PRAD	cis	rs7617773	0.817	rs936426	ENSG00000229759.1	MRPS18AP1	13.22	5.34e-34	1.33e-30	0.57	0.53	Coronary artery disease;	chr3:48173763	chr3:48256350~48256938:-
PRAD	cis	rs172166	0.516	rs1225710	ENSG00000216901.1	AL022393.7	-13.22	5.36e-34	1.34e-30	-0.66	-0.53	Cardiac Troponin-T levels;	chr6:28132862	chr6:28176188~28176674:+
PRAD	cis	rs2111504	0.806	rs10421787	ENSG00000267213.4	AC007773.2	-13.22	5.41e-34	1.35e-30	-0.58	-0.53	Bipolar disorder;	chr19:32460316	chr19:32390050~32405560:-
PRAD	cis	rs977987	0.806	rs11860284	ENSG00000261783.1	RP11-252K23.2	-13.22	5.52e-34	1.38e-30	-0.72	-0.53	Dupuytren's disease;	chr16:75379009	chr16:75379818~75381260:-
PRAD	cis	rs7044106	0.734	rs12553070	ENSG00000226752.6	PSMD5-AS1	-13.22	5.55e-34	1.39e-30	-0.65	-0.53	Hip circumference adjusted for BMI;	chr9:120722988	chr9:120824828~120854385:+
PRAD	cis	rs6142102	0.58	rs761233	ENSG00000276073.1	RP5-1125A11.7	-13.22	5.65e-34	1.41e-30	-0.51	-0.53	Skin pigmentation;	chr20:33981080	chr20:33985617~33988989:-
PRAD	cis	rs2882667	0.858	rs11242444	ENSG00000253404.1	AC034243.1	13.21	5.73e-34	1.43e-30	0.75	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139070690	chr5:138744434~138753309:-
PRAD	cis	rs3931020	0.772	rs1475396	ENSG00000272864.1	RP11-17E13.2	-13.21	5.75e-34	1.43e-30	-0.54	-0.53	Resistin levels;	chr1:74776712	chr1:74698769~74699333:-
PRAD	cis	rs2882667	0.858	rs11242448	ENSG00000253404.1	AC034243.1	13.21	5.88e-34	1.46e-30	0.75	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139107465	chr5:138744434~138753309:-
PRAD	cis	rs977987	0.806	rs766521	ENSG00000261783.1	RP11-252K23.2	13.21	5.89e-34	1.47e-30	0.7	0.53	Dupuytren's disease;	chr16:75390256	chr16:75379818~75381260:-
PRAD	cis	rs9545047	0.869	rs3742119	ENSG00000227676.3	LINC01068	13.21	5.95e-34	1.48e-30	0.67	0.53	Schizophrenia;	chr13:79342859	chr13:79566727~79571436:+
PRAD	cis	rs9545047	1	rs9318626	ENSG00000227676.3	LINC01068	13.21	5.95e-34	1.48e-30	0.67	0.53	Schizophrenia;	chr13:79351820	chr13:79566727~79571436:+
PRAD	cis	rs9545047	1	rs56911077	ENSG00000227676.3	LINC01068	13.21	5.95e-34	1.48e-30	0.67	0.53	Schizophrenia;	chr13:79354126	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.935	rs4885634	ENSG00000227676.3	LINC01068	-13.21	6.21e-34	1.54e-30	-0.65	-0.53	Schizophrenia;	chr13:79482772	chr13:79566727~79571436:+
PRAD	cis	rs6504950	0.8	rs12952253	ENSG00000275710.1	RP11-257O5.4	13.21	6.23e-34	1.55e-30	0.69	0.53	Breast cancer;	chr17:54928355	chr17:54964474~54964679:+
PRAD	cis	rs6504950	0.8	rs7208123	ENSG00000275710.1	RP11-257O5.4	13.21	6.23e-34	1.55e-30	0.69	0.53	Breast cancer;	chr17:54928978	chr17:54964474~54964679:+
PRAD	cis	rs977987	0.806	rs11643410	ENSG00000261783.1	RP11-252K23.2	-13.2	6.33e-34	1.57e-30	-0.71	-0.53	Dupuytren's disease;	chr16:75394408	chr16:75379818~75381260:-
PRAD	cis	rs6452524	0.618	rs10051445	ENSG00000249664.1	CTD-2227C6.2	13.2	6.36e-34	1.58e-30	0.61	0.53	Hypertension (SNP x SNP interaction);	chr5:83060280	chr5:83012285~83013109:-
PRAD	cis	rs12049351	0.774	rs1020353	ENSG00000229367.1	HMGN2P19	13.2	6.37e-34	1.58e-30	0.76	0.53	Circulating myeloperoxidase levels (plasma);	chr1:229561571	chr1:229570532~229570796:+
PRAD	cis	rs9326248	0.581	rs4938331	ENSG00000254851.1	RP11-109L13.1	-13.2	6.46e-34	1.6e-30	-0.66	-0.53	Blood protein levels;	chr11:117059966	chr11:117135528~117138582:+
PRAD	cis	rs9326248	0.51	rs4938332	ENSG00000254851.1	RP11-109L13.1	-13.2	6.46e-34	1.6e-30	-0.66	-0.53	Blood protein levels;	chr11:117060082	chr11:117135528~117138582:+
PRAD	cis	rs9326248	0.581	rs6589590	ENSG00000254851.1	RP11-109L13.1	-13.2	6.46e-34	1.6e-30	-0.66	-0.53	Blood protein levels;	chr11:117065365	chr11:117135528~117138582:+
PRAD	cis	rs673078	0.607	rs17440893	ENSG00000275759.1	RP11-131L12.3	-13.2	6.53e-34	1.62e-30	-0.79	-0.53	Glucose homeostasis traits;	chr12:118362532	chr12:118428281~118428870:+
PRAD	cis	rs9487094	0.67	rs12192268	ENSG00000260273.1	RP11-425D10.10	13.2	6.58e-34	1.63e-30	0.71	0.53	Height;	chr6:109690255	chr6:109382795~109383666:+
PRAD	cis	rs6142102	0.602	rs4911145	ENSG00000276073.1	RP5-1125A11.7	13.2	6.6e-34	1.64e-30	0.52	0.53	Skin pigmentation;	chr20:34027417	chr20:33985617~33988989:-
PRAD	cis	rs9545047	0.901	rs314688	ENSG00000227676.3	LINC01068	13.2	6.65e-34	1.65e-30	0.65	0.53	Schizophrenia;	chr13:79449171	chr13:79566727~79571436:+
PRAD	cis	rs977987	0.843	rs12443834	ENSG00000261783.1	RP11-252K23.2	-13.2	6.66e-34	1.65e-30	-0.72	-0.53	Dupuytren's disease;	chr16:75404571	chr16:75379818~75381260:-
PRAD	cis	rs977987	0.806	rs12924920	ENSG00000261783.1	RP11-252K23.2	-13.2	6.66e-34	1.65e-30	-0.72	-0.53	Dupuytren's disease;	chr16:75406235	chr16:75379818~75381260:-
PRAD	cis	rs2111504	0.806	rs7252443	ENSG00000267213.4	AC007773.2	-13.2	6.72e-34	1.67e-30	-0.59	-0.53	Bipolar disorder;	chr19:32449827	chr19:32390050~32405560:-
PRAD	cis	rs62388641	0.813	rs34114087	ENSG00000272279.1	RP11-157J24.2	13.2	6.75e-34	1.67e-30	0.8	0.53	Daytime sleep phenotypes;	chr6:1553203	chr6:1528364~1528911:-
PRAD	cis	rs673078	0.607	rs7958551	ENSG00000275759.1	RP11-131L12.3	-13.2	6.78e-34	1.68e-30	-0.79	-0.53	Glucose homeostasis traits;	chr12:118442585	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.607	rs7958652	ENSG00000275759.1	RP11-131L12.3	-13.2	6.78e-34	1.68e-30	-0.79	-0.53	Glucose homeostasis traits;	chr12:118442630	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.607	rs111607725	ENSG00000275759.1	RP11-131L12.3	-13.2	6.78e-34	1.68e-30	-0.79	-0.53	Glucose homeostasis traits;	chr12:118442957	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.607	rs76809232	ENSG00000275759.1	RP11-131L12.3	-13.2	6.78e-34	1.68e-30	-0.79	-0.53	Glucose homeostasis traits;	chr12:118444979	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.607	rs61944660	ENSG00000275759.1	RP11-131L12.3	-13.2	6.78e-34	1.68e-30	-0.79	-0.53	Glucose homeostasis traits;	chr12:118445326	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.607	rs61944662	ENSG00000275759.1	RP11-131L12.3	-13.2	6.78e-34	1.68e-30	-0.79	-0.53	Glucose homeostasis traits;	chr12:118445520	chr12:118428281~118428870:+
PRAD	cis	rs9399135	0.967	rs2297338	ENSG00000232876.1	CTA-212D2.2	-13.2	6.78e-34	1.68e-30	-0.64	-0.53	Red blood cell count;	chr6:135054624	chr6:135055033~135060550:+
PRAD	cis	rs9399135	0.933	rs9389262	ENSG00000232876.1	CTA-212D2.2	-13.2	6.78e-34	1.68e-30	-0.64	-0.53	Red blood cell count;	chr6:135055271	chr6:135055033~135060550:+
PRAD	cis	rs524281	0.861	rs3953856	ENSG00000255320.1	RP11-755F10.1	13.2	6.81e-34	1.68e-30	0.86	0.53	Electroencephalogram traits;	chr11:66198437	chr11:66244840~66246239:-
PRAD	cis	rs524281	0.861	rs2889313	ENSG00000255320.1	RP11-755F10.1	13.2	6.81e-34	1.68e-30	0.86	0.53	Electroencephalogram traits;	chr11:66198595	chr11:66244840~66246239:-
PRAD	cis	rs6504950	1	rs7221223	ENSG00000275710.1	RP11-257O5.4	13.2	6.81e-34	1.68e-30	0.73	0.53	Breast cancer;	chr17:54981646	chr17:54964474~54964679:+
PRAD	cis	rs11155671	0.53	rs9968871	ENSG00000231760.4	RP11-350J20.5	13.2	6.86e-34	1.7e-30	0.71	0.53	Testicular germ cell tumor;	chr6:149888060	chr6:149796151~149826294:-
PRAD	cis	rs11155671	0.53	rs9969044	ENSG00000231760.4	RP11-350J20.5	13.2	6.86e-34	1.7e-30	0.71	0.53	Testicular germ cell tumor;	chr6:149888068	chr6:149796151~149826294:-
PRAD	cis	rs10256972	0.521	rs7457418	ENSG00000229043.2	AC091729.9	-13.19	6.87e-34	1.7e-30	-0.64	-0.53	Endometriosis;Longevity;	chr7:1070619	chr7:1160374~1165267:+
PRAD	cis	rs3091242	0.836	rs34997029	ENSG00000224183.1	SDHDP6	13.19	6.91e-34	1.71e-30	0.62	0.53	Erythrocyte sedimentation rate;	chr1:25457332	chr1:25294164~25294643:-
PRAD	cis	rs9545047	0.905	rs9318644	ENSG00000227676.3	LINC01068	-13.19	6.99e-34	1.73e-30	-0.65	-0.53	Schizophrenia;	chr13:79510042	chr13:79566727~79571436:+
PRAD	cis	rs10515750	0.643	rs10063413	ENSG00000251405.2	CTB-109A12.1	-13.19	7.01e-34	1.73e-30	-0.99	-0.53	Lung function (FEV1/FVC);	chr5:157384435	chr5:157362615~157460078:-
PRAD	cis	rs3096299	0.632	rs4399533	ENSG00000274627.1	RP11-104N10.2	13.19	7.07e-34	1.75e-30	0.52	0.53	Multiple myeloma (IgH translocation);	chr16:89472974	chr16:89516797~89522217:+
PRAD	cis	rs7044106	0.791	rs10739572	ENSG00000226752.6	PSMD5-AS1	-13.19	7.09e-34	1.75e-30	-0.65	-0.53	Hip circumference adjusted for BMI;	chr9:120727537	chr9:120824828~120854385:+
PRAD	cis	rs1577917	0.518	rs2475787	ENSG00000203875.9	SNHG5	13.19	7.15e-34	1.77e-30	0.56	0.53	Response to antipsychotic treatment;	chr6:85705518	chr6:85660950~85678736:-
PRAD	cis	rs6452524	0.618	rs1871203	ENSG00000249664.1	CTD-2227C6.2	13.19	7.19e-34	1.77e-30	0.61	0.53	Hypertension (SNP x SNP interaction);	chr5:83059567	chr5:83012285~83013109:-
PRAD	cis	rs4423214	0.592	rs7120029	ENSG00000254682.1	RP11-660L16.2	-13.19	7.2e-34	1.78e-30	-0.82	-0.53	Vitamin D levels;	chr11:71487911	chr11:71448674~71452157:+
PRAD	cis	rs6452524	0.618	rs6867727	ENSG00000249664.1	CTD-2227C6.2	13.19	7.21e-34	1.78e-30	0.61	0.53	Hypertension (SNP x SNP interaction);	chr5:83061333	chr5:83012285~83013109:-
PRAD	cis	rs6452524	0.618	rs7723639	ENSG00000249664.1	CTD-2227C6.2	13.19	7.21e-34	1.78e-30	0.61	0.53	Hypertension (SNP x SNP interaction);	chr5:83062610	chr5:83012285~83013109:-
PRAD	cis	rs6452524	0.618	rs2306336	ENSG00000249664.1	CTD-2227C6.2	13.19	7.21e-34	1.78e-30	0.61	0.53	Hypertension (SNP x SNP interaction);	chr5:83064964	chr5:83012285~83013109:-
PRAD	cis	rs6452524	0.589	rs6882386	ENSG00000249664.1	CTD-2227C6.2	13.19	7.21e-34	1.78e-30	0.61	0.53	Hypertension (SNP x SNP interaction);	chr5:83065555	chr5:83012285~83013109:-
PRAD	cis	rs6452524	0.618	rs6860752	ENSG00000249664.1	CTD-2227C6.2	13.19	7.21e-34	1.78e-30	0.61	0.53	Hypertension (SNP x SNP interaction);	chr5:83065587	chr5:83012285~83013109:-
PRAD	cis	rs6452524	0.648	rs27364	ENSG00000249664.1	CTD-2227C6.2	13.19	7.22e-34	1.78e-30	0.61	0.53	Hypertension (SNP x SNP interaction);	chr5:83052137	chr5:83012285~83013109:-
PRAD	cis	rs2882667	0.822	rs11738376	ENSG00000253404.1	AC034243.1	13.19	7.23e-34	1.78e-30	0.75	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139062483	chr5:138744434~138753309:-
PRAD	cis	rs9399135	0.904	rs4895438	ENSG00000232876.1	CTA-212D2.2	-13.19	7.31e-34	1.8e-30	-0.64	-0.53	Red blood cell count;	chr6:134996527	chr6:135055033~135060550:+
PRAD	cis	rs9399135	0.967	rs12526055	ENSG00000232876.1	CTA-212D2.2	-13.19	7.31e-34	1.8e-30	-0.64	-0.53	Red blood cell count;	chr6:135004780	chr6:135055033~135060550:+
PRAD	cis	rs9399135	0.967	rs9389256	ENSG00000232876.1	CTA-212D2.2	-13.19	7.31e-34	1.8e-30	-0.64	-0.53	Red blood cell count;	chr6:135010116	chr6:135055033~135060550:+
PRAD	cis	rs977987	0.806	rs12599361	ENSG00000261783.1	RP11-252K23.2	-13.19	7.32e-34	1.8e-30	-0.72	-0.53	Dupuytren's disease;	chr16:75401075	chr16:75379818~75381260:-
PRAD	cis	rs7044106	0.791	rs12554440	ENSG00000226752.6	PSMD5-AS1	-13.19	7.33e-34	1.81e-30	-0.65	-0.53	Hip circumference adjusted for BMI;	chr9:120723055	chr9:120824828~120854385:+
PRAD	cis	rs2919917	0.915	rs3899796	ENSG00000254352.1	RP11-578O24.2	13.19	7.35e-34	1.81e-30	0.64	0.53	Lymphocyte counts;	chr8:78655847	chr8:78723796~78724136:-
PRAD	cis	rs801193	0.569	rs2013908	ENSG00000226824.5	RP4-756H11.3	13.19	7.37e-34	1.82e-30	0.73	0.53	Aortic root size;	chr7:66656082	chr7:66654538~66669855:+
PRAD	cis	rs801193	0.569	rs13242290	ENSG00000226824.5	RP4-756H11.3	13.19	7.37e-34	1.82e-30	0.73	0.53	Aortic root size;	chr7:66656898	chr7:66654538~66669855:+
PRAD	cis	rs801193	0.548	rs2109297	ENSG00000226824.5	RP4-756H11.3	13.19	7.37e-34	1.82e-30	0.73	0.53	Aortic root size;	chr7:66657397	chr7:66654538~66669855:+
PRAD	cis	rs801193	0.569	rs6978178	ENSG00000226824.5	RP4-756H11.3	13.19	7.37e-34	1.82e-30	0.73	0.53	Aortic root size;	chr7:66658097	chr7:66654538~66669855:+
PRAD	cis	rs801193	0.591	rs721717	ENSG00000226824.5	RP4-756H11.3	13.19	7.37e-34	1.82e-30	0.73	0.53	Aortic root size;	chr7:66665305	chr7:66654538~66669855:+
PRAD	cis	rs801193	0.569	rs6951302	ENSG00000226824.5	RP4-756H11.3	13.19	7.37e-34	1.82e-30	0.73	0.53	Aortic root size;	chr7:66667525	chr7:66654538~66669855:+
PRAD	cis	rs6700559	1	rs4311922	ENSG00000260088.1	RP11-92G12.3	-13.19	7.48e-34	1.84e-30	-0.65	-0.53	Coronary artery disease;	chr1:200674257	chr1:200669507~200694250:+
PRAD	cis	rs6700559	0.967	rs4447009	ENSG00000260088.1	RP11-92G12.3	-13.19	7.48e-34	1.84e-30	-0.65	-0.53	Coronary artery disease;	chr1:200674278	chr1:200669507~200694250:+
PRAD	cis	rs6700559	1	rs4265457	ENSG00000260088.1	RP11-92G12.3	-13.19	7.48e-34	1.84e-30	-0.65	-0.53	Coronary artery disease;	chr1:200674326	chr1:200669507~200694250:+
PRAD	cis	rs524281	0.814	rs10896093	ENSG00000255320.1	RP11-755F10.1	13.18	7.56e-34	1.86e-30	0.84	0.53	Electroencephalogram traits;	chr11:66190940	chr11:66244840~66246239:-
PRAD	cis	rs3814244	0.528	rs17104682	ENSG00000255733.4	IFNG-AS1	-13.18	7.68e-34	1.89e-30	-0.58	-0.53	Itch intensity from mosquito bite adjusted by bite size;	chr12:68033256	chr12:67989445~68234686:+
PRAD	cis	rs9399135	1	rs11754265	ENSG00000232876.1	CTA-212D2.2	-13.18	7.74e-34	1.9e-30	-0.64	-0.53	Red blood cell count;	chr6:135035078	chr6:135055033~135060550:+
PRAD	cis	rs172166	0.56	rs203878	ENSG00000216901.1	AL022393.7	13.18	7.77e-34	1.91e-30	0.65	0.53	Cardiac Troponin-T levels;	chr6:28081218	chr6:28176188~28176674:+
PRAD	cis	rs9322193	0.847	rs880246	ENSG00000223701.3	RAET1E-AS1	13.18	7.83e-34	1.93e-30	0.7	0.53	Lung cancer;	chr6:149845972	chr6:149884431~149919508:+
PRAD	cis	rs977987	0.645	rs34904236	ENSG00000261783.1	RP11-252K23.2	-13.18	7.95e-34	1.96e-30	-0.73	-0.53	Dupuytren's disease;	chr16:75464355	chr16:75379818~75381260:-
PRAD	cis	rs524281	0.648	rs10896089	ENSG00000255320.1	RP11-755F10.1	13.18	7.95e-34	1.96e-30	0.83	0.53	Electroencephalogram traits;	chr11:66168821	chr11:66244840~66246239:-
PRAD	cis	rs673078	0.607	rs4254101	ENSG00000275759.1	RP11-131L12.3	-13.18	8.01e-34	1.97e-30	-0.79	-0.53	Glucose homeostasis traits;	chr12:118445877	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.607	rs4622305	ENSG00000275759.1	RP11-131L12.3	-13.18	8.01e-34	1.97e-30	-0.79	-0.53	Glucose homeostasis traits;	chr12:118445912	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.607	rs73207575	ENSG00000275759.1	RP11-131L12.3	-13.18	8.01e-34	1.97e-30	-0.79	-0.53	Glucose homeostasis traits;	chr12:118446711	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.607	rs61944663	ENSG00000275759.1	RP11-131L12.3	-13.18	8.01e-34	1.97e-30	-0.79	-0.53	Glucose homeostasis traits;	chr12:118446886	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.607	rs73207577	ENSG00000275759.1	RP11-131L12.3	-13.18	8.01e-34	1.97e-30	-0.79	-0.53	Glucose homeostasis traits;	chr12:118447012	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.607	rs73207579	ENSG00000275759.1	RP11-131L12.3	-13.18	8.01e-34	1.97e-30	-0.79	-0.53	Glucose homeostasis traits;	chr12:118447123	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.607	rs7969871	ENSG00000275759.1	RP11-131L12.3	-13.18	8.01e-34	1.97e-30	-0.79	-0.53	Glucose homeostasis traits;	chr12:118447331	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.56	rs7970361	ENSG00000275759.1	RP11-131L12.3	-13.18	8.01e-34	1.97e-30	-0.79	-0.53	Glucose homeostasis traits;	chr12:118447723	chr12:118428281~118428870:+
PRAD	cis	rs1075265	0.633	rs3731967	ENSG00000233266.1	HMGB1P31	-13.18	8.18e-34	2.01e-30	-0.72	-0.53	Chronotype;Morning vs. evening chronotype;	chr2:53975311	chr2:54051334~54051760:+
PRAD	cis	rs2929278	0.617	rs533143	ENSG00000205771.5	CATSPER2P1	-13.18	8.26e-34	2.03e-30	-0.58	-0.53	Schizophrenia;	chr15:43896656	chr15:43726918~43747094:-
PRAD	cis	rs977987	0.806	rs4888404	ENSG00000261783.1	RP11-252K23.2	-13.18	8.28e-34	2.03e-30	-0.71	-0.53	Dupuytren's disease;	chr16:75394199	chr16:75379818~75381260:-
PRAD	cis	rs3091242	0.9	rs35345536	ENSG00000224183.1	SDHDP6	-13.18	8.3e-34	2.04e-30	-0.61	-0.53	Erythrocyte sedimentation rate;	chr1:25439997	chr1:25294164~25294643:-
PRAD	cis	rs55794721	0.509	rs12027135	ENSG00000224183.1	SDHDP6	-13.18	8.3e-34	2.04e-30	-0.61	-0.53	Mean corpuscular volume;Plateletcrit;	chr1:25449242	chr1:25294164~25294643:-
PRAD	cis	rs2882667	0.858	rs11956159	ENSG00000253404.1	AC034243.1	13.18	8.32e-34	2.04e-30	0.75	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139072879	chr5:138744434~138753309:-
PRAD	cis	rs977987	0.806	rs4888411	ENSG00000261783.1	RP11-252K23.2	-13.17	8.36e-34	2.05e-30	-0.71	-0.53	Dupuytren's disease;	chr16:75409285	chr16:75379818~75381260:-
PRAD	cis	rs8072100	0.676	rs9905308	ENSG00000228782.6	CTD-2026D20.3	13.17	8.39e-34	2.06e-30	0.56	0.53	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47332020	chr17:47450568~47492492:-
PRAD	cis	rs7208859	0.623	rs122898	ENSG00000263531.1	RP13-753N3.1	-13.17	8.57e-34	2.1e-30	-1.07	-0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30578236	chr17:30863921~30864940:-
PRAD	cis	rs1075265	0.554	rs10168293	ENSG00000233266.1	HMGB1P31	13.17	8.6e-34	2.11e-30	0.72	0.53	Chronotype;Morning vs. evening chronotype;	chr2:53973793	chr2:54051334~54051760:+
PRAD	cis	rs1075265	0.567	rs66773232	ENSG00000233266.1	HMGB1P31	13.17	8.6e-34	2.11e-30	0.72	0.53	Chronotype;Morning vs. evening chronotype;	chr2:53973970	chr2:54051334~54051760:+
PRAD	cis	rs2283792	0.905	rs5755694	ENSG00000224086.5	LL22NC03-86G7.1	-13.17	8.64e-34	2.12e-30	-0.62	-0.53	Multiple sclerosis;	chr22:21846241	chr22:21938293~21977632:+
PRAD	cis	rs673078	0.607	rs73207573	ENSG00000275759.1	RP11-131L12.3	-13.17	8.67e-34	2.13e-30	-0.79	-0.53	Glucose homeostasis traits;	chr12:118444664	chr12:118428281~118428870:+
PRAD	cis	rs9660180	0.875	rs4648727	ENSG00000268575.1	RP1-283E3.8	13.17	8.88e-34	2.18e-30	0.55	0.53	Body mass index;	chr1:1844830	chr1:1702736~1737688:-
PRAD	cis	rs673078	0.607	rs61944664	ENSG00000275759.1	RP11-131L12.3	-13.17	8.93e-34	2.19e-30	-0.79	-0.53	Glucose homeostasis traits;	chr12:118447145	chr12:118428281~118428870:+
PRAD	cis	rs172166	0.538	rs1150686	ENSG00000216901.1	AL022393.7	13.16	9.5e-34	2.32e-30	0.65	0.53	Cardiac Troponin-T levels;	chr6:28193493	chr6:28176188~28176674:+
PRAD	cis	rs1150688	1	rs1150688	ENSG00000216901.1	AL022393.7	13.16	9.5e-34	2.32e-30	0.65	0.53	Autism spectrum disorder or schizophrenia;	chr6:28195002	chr6:28176188~28176674:+
PRAD	cis	rs55794721	0.509	rs909834	ENSG00000261349.1	RP3-465N24.5	-13.16	9.56e-34	2.34e-30	-0.58	-0.53	Mean corpuscular volume;Plateletcrit;	chr1:25431505	chr1:25266102~25267136:-
PRAD	cis	rs6504950	0.8	rs72829484	ENSG00000275710.1	RP11-257O5.4	13.16	9.66e-34	2.36e-30	0.69	0.53	Breast cancer;	chr17:54931919	chr17:54964474~54964679:+
PRAD	cis	rs6504950	0.8	rs17745183	ENSG00000275710.1	RP11-257O5.4	13.16	9.66e-34	2.36e-30	0.69	0.53	Breast cancer;	chr17:54936234	chr17:54964474~54964679:+
PRAD	cis	rs172166	0.516	rs1225618	ENSG00000216901.1	AL022393.7	13.16	9.68e-34	2.37e-30	0.65	0.53	Cardiac Troponin-T levels;	chr6:28161935	chr6:28176188~28176674:+
PRAD	cis	rs977987	0.806	rs4887824	ENSG00000261783.1	RP11-252K23.2	-13.16	9.71e-34	2.37e-30	-0.71	-0.53	Dupuytren's disease;	chr16:75407715	chr16:75379818~75381260:-
PRAD	cis	rs977987	0.778	rs4888412	ENSG00000261783.1	RP11-252K23.2	-13.16	9.71e-34	2.37e-30	-0.71	-0.53	Dupuytren's disease;	chr16:75409298	chr16:75379818~75381260:-
PRAD	cis	rs977987	0.778	rs4888413	ENSG00000261783.1	RP11-252K23.2	-13.16	9.71e-34	2.37e-30	-0.71	-0.53	Dupuytren's disease;	chr16:75409325	chr16:75379818~75381260:-
PRAD	cis	rs977987	0.778	rs8057849	ENSG00000261783.1	RP11-252K23.2	-13.16	9.71e-34	2.37e-30	-0.71	-0.53	Dupuytren's disease;	chr16:75409918	chr16:75379818~75381260:-
PRAD	cis	rs2658782	1	rs2658778	ENSG00000279684.1	RP11-755E23.2	-13.16	9.78e-34	2.39e-30	-0.86	-0.53	Pulmonary function decline;	chr11:93415782	chr11:93286629~93288903:-
PRAD	cis	rs2658782	1	rs2605583	ENSG00000279684.1	RP11-755E23.2	-13.16	9.78e-34	2.39e-30	-0.86	-0.53	Pulmonary function decline;	chr11:93431791	chr11:93286629~93288903:-
PRAD	cis	rs9399135	0.967	rs6925424	ENSG00000232876.1	CTA-212D2.2	-13.16	9.84e-34	2.4e-30	-0.63	-0.52	Red blood cell count;	chr6:134992810	chr6:135055033~135060550:+
PRAD	cis	rs9399135	0.967	rs17638970	ENSG00000232876.1	CTA-212D2.2	-13.16	9.84e-34	2.4e-30	-0.63	-0.52	Red blood cell count;	chr6:134998925	chr6:135055033~135060550:+
PRAD	cis	rs9402673	0.558	rs9688342	ENSG00000232876.1	CTA-212D2.2	-13.16	9.84e-34	2.4e-30	-0.63	-0.52	High light scatter reticulocyte count;Reticulocyte count;	chr6:135001888	chr6:135055033~135060550:+
PRAD	cis	rs9399135	0.933	rs4559100	ENSG00000232876.1	CTA-212D2.2	-13.16	9.84e-34	2.4e-30	-0.63	-0.52	Red blood cell count;	chr6:135002947	chr6:135055033~135060550:+
PRAD	cis	rs9399135	0.967	rs12527707	ENSG00000232876.1	CTA-212D2.2	-13.16	9.84e-34	2.4e-30	-0.63	-0.52	Red blood cell count;	chr6:135003373	chr6:135055033~135060550:+
PRAD	cis	rs9399135	0.967	rs9389251	ENSG00000232876.1	CTA-212D2.2	-13.16	9.84e-34	2.4e-30	-0.63	-0.52	Red blood cell count;	chr6:135004579	chr6:135055033~135060550:+
PRAD	cis	rs9399135	0.967	rs6929661	ENSG00000232876.1	CTA-212D2.2	-13.16	9.84e-34	2.4e-30	-0.63	-0.52	Red blood cell count;	chr6:135007654	chr6:135055033~135060550:+
PRAD	cis	rs9399135	0.967	rs2327578	ENSG00000232876.1	CTA-212D2.2	-13.16	9.84e-34	2.4e-30	-0.63	-0.52	Red blood cell count;	chr6:135008831	chr6:135055033~135060550:+
PRAD	cis	rs2882667	0.858	rs11959803	ENSG00000253404.1	AC034243.1	13.16	9.87e-34	2.41e-30	0.74	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139115626	chr5:138744434~138753309:-
PRAD	cis	rs673078	0.607	rs73207578	ENSG00000275759.1	RP11-131L12.3	-13.15	1.02e-33	2.49e-30	-0.79	-0.52	Glucose homeostasis traits;	chr12:118447080	chr12:118428281~118428870:+
PRAD	cis	rs172166	0.516	rs2622322	ENSG00000216901.1	AL022393.7	13.15	1.04e-33	2.53e-30	0.65	0.52	Cardiac Troponin-T levels;	chr6:28149665	chr6:28176188~28176674:+
PRAD	cis	rs1150668	0.835	rs203869	ENSG00000216901.1	AL022393.7	13.15	1.04e-33	2.54e-30	0.65	0.52	Pubertal anthropometrics;	chr6:28073041	chr6:28176188~28176674:+
PRAD	cis	rs55794721	0.509	rs6699113	ENSG00000261349.1	RP3-465N24.5	-13.15	1.05e-33	2.55e-30	-0.58	-0.52	Mean corpuscular volume;Plateletcrit;	chr1:25451252	chr1:25266102~25267136:-
PRAD	cis	rs55794721	0.509	rs7554255	ENSG00000261349.1	RP3-465N24.5	-13.15	1.05e-33	2.55e-30	-0.58	-0.52	Mean corpuscular volume;Plateletcrit;	chr1:25451615	chr1:25266102~25267136:-
PRAD	cis	rs55794721	0.509	rs4649085	ENSG00000261349.1	RP3-465N24.5	-13.15	1.05e-33	2.55e-30	-0.58	-0.52	Mean corpuscular volume;Plateletcrit;	chr1:25452341	chr1:25266102~25267136:-
PRAD	cis	rs9399135	0.967	rs6902954	ENSG00000232876.1	CTA-212D2.2	-13.15	1.05e-33	2.55e-30	-0.63	-0.52	Red blood cell count;	chr6:134992856	chr6:135055033~135060550:+
PRAD	cis	rs4722166	0.573	rs35436671	ENSG00000179428.2	AC073072.5	-13.15	1.05e-33	2.56e-30	-0.64	-0.52	Lung cancer;	chr7:22735889	chr7:22725395~22727620:-
PRAD	cis	rs9399135	0.967	rs7741515	ENSG00000232876.1	CTA-212D2.2	13.15	1.06e-33	2.58e-30	0.63	0.52	Red blood cell count;	chr6:135053230	chr6:135055033~135060550:+
PRAD	cis	rs673078	0.607	rs17512763	ENSG00000275759.1	RP11-131L12.3	-13.15	1.06e-33	2.58e-30	-0.78	-0.52	Glucose homeostasis traits;	chr12:118400974	chr12:118428281~118428870:+
PRAD	cis	rs9545047	0.935	rs9530925	ENSG00000227676.3	LINC01068	-13.15	1.07e-33	2.6e-30	-0.64	-0.52	Schizophrenia;	chr13:79492641	chr13:79566727~79571436:+
PRAD	cis	rs1577917	0.771	rs4441928	ENSG00000203875.9	SNHG5	13.15	1.07e-33	2.61e-30	0.58	0.52	Response to antipsychotic treatment;	chr6:85532176	chr6:85660950~85678736:-
PRAD	cis	rs977987	0.806	rs7204984	ENSG00000261783.1	RP11-252K23.2	-13.15	1.08e-33	2.64e-30	-0.71	-0.52	Dupuytren's disease;	chr16:75441622	chr16:75379818~75381260:-
PRAD	cis	rs977987	0.778	rs35214308	ENSG00000261783.1	RP11-252K23.2	-13.15	1.08e-33	2.64e-30	-0.71	-0.52	Dupuytren's disease;	chr16:75442190	chr16:75379818~75381260:-
PRAD	cis	rs977987	0.806	rs4888425	ENSG00000261783.1	RP11-252K23.2	-13.15	1.08e-33	2.64e-30	-0.71	-0.52	Dupuytren's disease;	chr16:75442465	chr16:75379818~75381260:-
PRAD	cis	rs977987	0.778	rs4888426	ENSG00000261783.1	RP11-252K23.2	-13.15	1.08e-33	2.64e-30	-0.71	-0.52	Dupuytren's disease;	chr16:75442553	chr16:75379818~75381260:-
PRAD	cis	rs9399135	0.967	rs9376082	ENSG00000232876.1	CTA-212D2.2	-13.15	1.09e-33	2.66e-30	-0.64	-0.52	Red blood cell count;	chr6:135025251	chr6:135055033~135060550:+
PRAD	cis	rs673078	0.607	rs61944669	ENSG00000275759.1	RP11-131L12.3	-13.15	1.09e-33	2.66e-30	-0.79	-0.52	Glucose homeostasis traits;	chr12:118448530	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.607	rs61944670	ENSG00000275759.1	RP11-131L12.3	-13.15	1.09e-33	2.66e-30	-0.79	-0.52	Glucose homeostasis traits;	chr12:118448697	chr12:118428281~118428870:+
PRAD	cis	rs9322193	0.923	rs9371207	ENSG00000268592.3	RAET1E-AS1	13.14	1.11e-33	2.71e-30	0.72	0.52	Lung cancer;	chr6:149858087	chr6:149863494~149919507:+
PRAD	cis	rs875971	0.862	rs6944374	ENSG00000226824.5	RP4-756H11.3	13.14	1.12e-33	2.72e-30	0.72	0.52	Aortic root size;	chr7:66221942	chr7:66654538~66669855:+
PRAD	cis	rs6964833	1	rs35203738	ENSG00000123965.13	PMS2P5	13.14	1.14e-33	2.77e-30	0.82	0.52	Menarche (age at onset);	chr7:74690864	chr7:74894116~74897835:+
PRAD	cis	rs9399135	0.967	rs9321481	ENSG00000232876.1	CTA-212D2.2	13.14	1.14e-33	2.77e-30	0.64	0.52	Red blood cell count;	chr6:135031510	chr6:135055033~135060550:+
PRAD	cis	rs9399135	0.967	rs45544135	ENSG00000232876.1	CTA-212D2.2	-13.14	1.14e-33	2.78e-30	-0.63	-0.52	Red blood cell count;	chr6:135002913	chr6:135055033~135060550:+
PRAD	cis	rs8100891	0.537	rs1001446	ENSG00000267213.4	AC007773.2	-13.14	1.15e-33	2.79e-30	-0.64	-0.52	Neuroticism;	chr19:32410051	chr19:32390050~32405560:-
PRAD	cis	rs9399135	0.967	rs2327580	ENSG00000232876.1	CTA-212D2.2	-13.14	1.16e-33	2.83e-30	-0.63	-0.52	Red blood cell count;	chr6:135043279	chr6:135055033~135060550:+
PRAD	cis	rs9399135	0.844	rs13209789	ENSG00000232876.1	CTA-212D2.2	-13.14	1.16e-33	2.83e-30	-0.63	-0.52	Red blood cell count;	chr6:135046778	chr6:135055033~135060550:+
PRAD	cis	rs9399135	0.967	rs6915770	ENSG00000232876.1	CTA-212D2.2	-13.14	1.16e-33	2.83e-30	-0.63	-0.52	Red blood cell count;	chr6:135048076	chr6:135055033~135060550:+
PRAD	cis	rs9399135	0.935	rs11759999	ENSG00000232876.1	CTA-212D2.2	-13.14	1.16e-33	2.83e-30	-0.63	-0.52	Red blood cell count;	chr6:135049357	chr6:135055033~135060550:+
PRAD	cis	rs9399135	0.935	rs11760000	ENSG00000232876.1	CTA-212D2.2	-13.14	1.16e-33	2.83e-30	-0.63	-0.52	Red blood cell count;	chr6:135049358	chr6:135055033~135060550:+
PRAD	cis	rs9399135	0.935	rs9376086	ENSG00000232876.1	CTA-212D2.2	-13.14	1.16e-33	2.83e-30	-0.63	-0.52	Red blood cell count;	chr6:135050191	chr6:135055033~135060550:+
PRAD	cis	rs9399135	0.967	rs2297340	ENSG00000232876.1	CTA-212D2.2	-13.14	1.16e-33	2.83e-30	-0.63	-0.52	Red blood cell count;	chr6:135054920	chr6:135055033~135060550:+
PRAD	cis	rs977987	0.806	rs2903033	ENSG00000261783.1	RP11-252K23.2	-13.14	1.17e-33	2.84e-30	-0.7	-0.52	Dupuytren's disease;	chr16:75355708	chr16:75379818~75381260:-
PRAD	cis	rs6964833	0.935	rs7795281	ENSG00000123965.13	PMS2P5	13.14	1.2e-33	2.92e-30	0.82	0.52	Menarche (age at onset);	chr7:74708523	chr7:74894116~74897835:+
PRAD	cis	rs977987	0.778	rs7203157	ENSG00000261783.1	RP11-252K23.2	-13.14	1.2e-33	2.92e-30	-0.71	-0.52	Dupuytren's disease;	chr16:75384022	chr16:75379818~75381260:-
PRAD	cis	rs494459	0.838	rs555639	ENSG00000255239.1	AP002954.6	-13.14	1.21e-33	2.93e-30	-0.67	-0.52	Height;	chr11:118758322	chr11:118688039~118690600:-
PRAD	cis	rs524281	0.817	rs10791849	ENSG00000255320.1	RP11-755F10.1	13.13	1.24e-33	3.01e-30	0.85	0.52	Electroencephalogram traits;	chr11:66123126	chr11:66244840~66246239:-
PRAD	cis	rs524281	0.861	rs7124165	ENSG00000255320.1	RP11-755F10.1	13.13	1.24e-33	3.01e-30	0.85	0.52	Electroencephalogram traits;	chr11:66133747	chr11:66244840~66246239:-
PRAD	cis	rs9487094	0.626	rs2025148	ENSG00000260273.1	RP11-425D10.10	13.13	1.25e-33	3.02e-30	0.71	0.52	Height;	chr6:109706740	chr6:109382795~109383666:+
PRAD	cis	rs9487094	0.626	rs12201444	ENSG00000260273.1	RP11-425D10.10	13.13	1.25e-33	3.02e-30	0.71	0.52	Height;	chr6:109738751	chr6:109382795~109383666:+
PRAD	cis	rs875971	0.767	rs12668005	ENSG00000226824.5	RP4-756H11.3	-13.13	1.26e-33	3.06e-30	-0.72	-0.52	Aortic root size;	chr7:66444034	chr7:66654538~66669855:+
PRAD	cis	rs977987	0.806	rs34021527	ENSG00000261783.1	RP11-252K23.2	-13.13	1.28e-33	3.11e-30	-0.71	-0.52	Dupuytren's disease;	chr16:75440192	chr16:75379818~75381260:-
PRAD	cis	rs977987	0.751	rs56004344	ENSG00000261783.1	RP11-252K23.2	-13.13	1.28e-33	3.11e-30	-0.71	-0.52	Dupuytren's disease;	chr16:75440291	chr16:75379818~75381260:-
PRAD	cis	rs977987	0.836	rs7200053	ENSG00000261783.1	RP11-252K23.2	-13.13	1.28e-33	3.11e-30	-0.71	-0.52	Dupuytren's disease;	chr16:75440720	chr16:75379818~75381260:-
PRAD	cis	rs12049351	0.719	rs12129135	ENSG00000229367.1	HMGN2P19	13.13	1.31e-33	3.17e-30	0.74	0.52	Circulating myeloperoxidase levels (plasma);	chr1:229559940	chr1:229570532~229570796:+
PRAD	cis	rs875971	0.755	rs76288834	ENSG00000226824.5	RP4-756H11.3	13.13	1.32e-33	3.19e-30	0.73	0.52	Aortic root size;	chr7:66604815	chr7:66654538~66669855:+
PRAD	cis	rs977987	0.586	rs12920883	ENSG00000261783.1	RP11-252K23.2	-13.12	1.38e-33	3.33e-30	-0.71	-0.52	Dupuytren's disease;	chr16:75398783	chr16:75379818~75381260:-
PRAD	cis	rs977987	0.624	rs59867374	ENSG00000261783.1	RP11-252K23.2	-13.12	1.38e-33	3.33e-30	-0.71	-0.52	Dupuytren's disease;	chr16:75398784	chr16:75379818~75381260:-
PRAD	cis	rs2455601	0.786	rs3763913	ENSG00000254860.4	TMEM9B-AS1	13.12	1.41e-33	3.4e-30	0.65	0.52	Schizophrenia;	chr11:8929683	chr11:8964675~8977527:+
PRAD	cis	rs524281	0.861	rs10896086	ENSG00000255320.1	RP11-755F10.1	13.12	1.42e-33	3.44e-30	0.85	0.52	Electroencephalogram traits;	chr11:66147293	chr11:66244840~66246239:-
PRAD	cis	rs2919917	1	rs13269243	ENSG00000254352.1	RP11-578O24.2	13.12	1.44e-33	3.47e-30	0.63	0.52	Lymphocyte counts;	chr8:78669501	chr8:78723796~78724136:-
PRAD	cis	rs9326248	1	rs3736120	ENSG00000280143.1	AP000892.6	13.12	1.45e-33	3.5e-30	0.45	0.52	Blood protein levels;	chr11:117161409	chr11:117204967~117210292:+
PRAD	cis	rs55794721	0.509	rs6699896	ENSG00000261349.1	RP3-465N24.5	-13.12	1.45e-33	3.5e-30	-0.58	-0.52	Mean corpuscular volume;Plateletcrit;	chr1:25436411	chr1:25266102~25267136:-
PRAD	cis	rs3091242	0.904	rs6661533	ENSG00000261349.1	RP3-465N24.5	-13.12	1.45e-33	3.5e-30	-0.58	-0.52	Erythrocyte sedimentation rate;	chr1:25445224	chr1:25266102~25267136:-
PRAD	cis	rs56080343	0.808	rs1045552	ENSG00000275759.1	RP11-131L12.3	-13.12	1.46e-33	3.52e-30	-0.79	-0.52	Neuroticism;	chr12:118417678	chr12:118428281~118428870:+
PRAD	cis	rs2882667	0.858	rs13174479	ENSG00000253404.1	AC034243.1	13.12	1.46e-33	3.53e-30	0.73	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139108481	chr5:138744434~138753309:-
PRAD	cis	rs5760092	0.755	rs4585126	ENSG00000225282.1	AP000350.6	-13.12	1.47e-33	3.54e-30	-0.75	-0.52	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23926900~23929574:+
PRAD	cis	rs9326248	0.581	rs11216267	ENSG00000254851.1	RP11-109L13.1	-13.11	1.48e-33	3.57e-30	-0.66	-0.52	Blood protein levels;	chr11:117081676	chr11:117135528~117138582:+
PRAD	cis	rs9399135	0.967	rs6923765	ENSG00000232876.1	CTA-212D2.2	13.11	1.48e-33	3.58e-30	0.63	0.52	Red blood cell count;	chr6:135014038	chr6:135055033~135060550:+
PRAD	cis	rs2658782	1	rs2658782	ENSG00000279684.1	RP11-755E23.2	-13.11	1.5e-33	3.61e-30	-0.86	-0.52	Pulmonary function decline;	chr11:93433565	chr11:93286629~93288903:-
PRAD	cis	rs9399135	0.967	rs4896125	ENSG00000232876.1	CTA-212D2.2	-13.11	1.51e-33	3.64e-30	-0.63	-0.52	Red blood cell count;	chr6:135021431	chr6:135055033~135060550:+
PRAD	cis	rs9399135	0.935	rs949547	ENSG00000232876.1	CTA-212D2.2	-13.11	1.51e-33	3.64e-30	-0.63	-0.52	Red blood cell count;	chr6:135022361	chr6:135055033~135060550:+
PRAD	cis	rs9399135	0.935	rs2150680	ENSG00000232876.1	CTA-212D2.2	-13.11	1.51e-33	3.64e-30	-0.63	-0.52	Red blood cell count;	chr6:135025993	chr6:135055033~135060550:+
PRAD	cis	rs9399135	0.967	rs11756988	ENSG00000232876.1	CTA-212D2.2	-13.11	1.51e-33	3.64e-30	-0.63	-0.52	Red blood cell count;	chr6:135026457	chr6:135055033~135060550:+
PRAD	cis	rs9399135	0.967	rs11754783	ENSG00000232876.1	CTA-212D2.2	-13.11	1.51e-33	3.64e-30	-0.63	-0.52	Red blood cell count;	chr6:135026523	chr6:135055033~135060550:+
PRAD	cis	rs6964833	1	rs13227433	ENSG00000123965.13	PMS2P5	13.11	1.51e-33	3.64e-30	0.81	0.52	Menarche (age at onset);	chr7:74680386	chr7:74894116~74897835:+
PRAD	cis	rs3091242	1	rs3091242	ENSG00000261349.1	RP3-465N24.5	-13.11	1.51e-33	3.64e-30	-0.57	-0.52	Erythrocyte sedimentation rate;	chr1:25348294	chr1:25266102~25267136:-
PRAD	cis	rs3091242	0.967	rs3091240	ENSG00000261349.1	RP3-465N24.5	-13.11	1.51e-33	3.64e-30	-0.57	-0.52	Erythrocyte sedimentation rate;	chr1:25350444	chr1:25266102~25267136:-
PRAD	cis	rs6964833	0.935	rs34630792	ENSG00000123965.13	PMS2P5	13.11	1.52e-33	3.66e-30	0.81	0.52	Menarche (age at onset);	chr7:74646869	chr7:74894116~74897835:+
PRAD	cis	rs1153858	0.887	rs28569043	ENSG00000259520.4	CTD-2651B20.3	-13.11	1.52e-33	3.67e-30	-0.69	-0.52	Homoarginine levels;	chr15:45438728	chr15:45251580~45279251:-
PRAD	cis	rs977987	0.806	rs4887823	ENSG00000261783.1	RP11-252K23.2	-13.11	1.52e-33	3.67e-30	-0.71	-0.52	Dupuytren's disease;	chr16:75399176	chr16:75379818~75381260:-
PRAD	cis	rs2487048	0.761	rs2980083	ENSG00000226334.1	RP11-217B7.2	-13.11	1.54e-33	3.7e-30	-0.69	-0.52	Intraocular pressure;	chr9:104929081	chr9:104927553~104928892:+
PRAD	cis	rs9389248	0.5	rs116273677	ENSG00000232876.1	CTA-212D2.2	-13.11	1.54e-33	3.7e-30	-0.63	-0.52	High light scatter reticulocyte percentage of red cells;	chr6:135017997	chr6:135055033~135060550:+
PRAD	cis	rs9399135	1	rs4896130	ENSG00000232876.1	CTA-212D2.2	-13.11	1.54e-33	3.71e-30	-0.64	-0.52	Red blood cell count;	chr6:135033980	chr6:135055033~135060550:+
PRAD	cis	rs673078	0.607	rs61943393	ENSG00000275759.1	RP11-131L12.3	-13.11	1.55e-33	3.73e-30	-0.81	-0.52	Glucose homeostasis traits;	chr12:118383650	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.607	rs73205576	ENSG00000275759.1	RP11-131L12.3	-13.11	1.55e-33	3.73e-30	-0.81	-0.52	Glucose homeostasis traits;	chr12:118384268	chr12:118428281~118428870:+
PRAD	cis	rs875971	0.862	rs6971059	ENSG00000226824.5	RP4-756H11.3	13.11	1.56e-33	3.76e-30	0.72	0.52	Aortic root size;	chr7:66602045	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.789	rs7808013	ENSG00000226824.5	RP4-756H11.3	13.11	1.56e-33	3.76e-30	0.72	0.52	Aortic root size;	chr7:66606209	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.825	rs7384021	ENSG00000226824.5	RP4-756H11.3	13.11	1.56e-33	3.76e-30	0.72	0.52	Aortic root size;	chr7:66612917	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.825	rs66981195	ENSG00000226824.5	RP4-756H11.3	13.11	1.56e-33	3.76e-30	0.72	0.52	Aortic root size;	chr7:66614048	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.862	rs3926380	ENSG00000226824.5	RP4-756H11.3	13.11	1.56e-33	3.76e-30	0.72	0.52	Aortic root size;	chr7:66615658	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.825	rs1860472	ENSG00000226824.5	RP4-756H11.3	13.11	1.56e-33	3.76e-30	0.72	0.52	Aortic root size;	chr7:66617736	chr7:66654538~66669855:+
PRAD	cis	rs9399135	1	rs6569988	ENSG00000232876.1	CTA-212D2.2	-13.11	1.57e-33	3.78e-30	-0.63	-0.52	Red blood cell count;	chr6:135031165	chr6:135055033~135060550:+
PRAD	cis	rs2882667	0.858	rs11242447	ENSG00000253404.1	AC034243.1	13.11	1.58e-33	3.79e-30	0.73	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139090484	chr5:138744434~138753309:-
PRAD	cis	rs1075265	0.633	rs10183655	ENSG00000233266.1	HMGB1P31	13.11	1.59e-33	3.81e-30	0.71	0.52	Chronotype;Morning vs. evening chronotype;	chr2:53983644	chr2:54051334~54051760:+
PRAD	cis	rs3091242	1	rs9689	ENSG00000224183.1	SDHDP6	-13.11	1.59e-33	3.82e-30	-0.61	-0.52	Erythrocyte sedimentation rate;	chr1:25361785	chr1:25294164~25294643:-
PRAD	cis	rs2919917	1	rs2953475	ENSG00000254352.1	RP11-578O24.2	-13.11	1.62e-33	3.88e-30	-0.65	-0.52	Lymphocyte counts;	chr8:78725903	chr8:78723796~78724136:-
PRAD	cis	rs2919917	0.915	rs2046339	ENSG00000254352.1	RP11-578O24.2	13.1	1.64e-33	3.94e-30	0.65	0.52	Lymphocyte counts;	chr8:78724283	chr8:78723796~78724136:-
PRAD	cis	rs9399135	0.967	rs59329760	ENSG00000232876.1	CTA-212D2.2	-13.1	1.66e-33	3.98e-30	-0.63	-0.52	Red blood cell count;	chr6:135021299	chr6:135055033~135060550:+
PRAD	cis	rs4660456	0.869	rs616954	ENSG00000237899.1	RP4-739H11.3	13.1	1.67e-33	4.01e-30	0.76	0.52	Platelet count;	chr1:40669947	chr1:40669089~40687588:-
PRAD	cis	rs6504950	1	rs17745344	ENSG00000275710.1	RP11-257O5.4	13.1	1.67e-33	4.01e-30	0.73	0.52	Breast cancer;	chr17:54970958	chr17:54964474~54964679:+
PRAD	cis	rs4718428	0.672	rs13241598	ENSG00000226824.5	RP4-756H11.3	-13.1	1.68e-33	4.04e-30	-0.7	-0.52	Corneal structure;	chr7:66835665	chr7:66654538~66669855:+
PRAD	cis	rs1577917	0.771	rs2842608	ENSG00000203875.9	SNHG5	-13.1	1.69e-33	4.05e-30	-0.59	-0.52	Response to antipsychotic treatment;	chr6:85586140	chr6:85660950~85678736:-
PRAD	cis	rs1075265	0.597	rs11694711	ENSG00000233266.1	HMGB1P31	13.1	1.71e-33	4.09e-30	0.71	0.52	Chronotype;Morning vs. evening chronotype;	chr2:53971924	chr2:54051334~54051760:+
PRAD	cis	rs875971	0.862	rs11765791	ENSG00000226824.5	RP4-756H11.3	-13.1	1.71e-33	4.1e-30	-0.72	-0.52	Aortic root size;	chr7:66471587	chr7:66654538~66669855:+
PRAD	cis	rs2919917	1	rs1441438	ENSG00000254352.1	RP11-578O24.2	-13.1	1.74e-33	4.16e-30	-0.65	-0.52	Lymphocyte counts;	chr8:78729534	chr8:78723796~78724136:-
PRAD	cis	rs2919917	1	rs1545228	ENSG00000254352.1	RP11-578O24.2	-13.1	1.74e-33	4.16e-30	-0.65	-0.52	Lymphocyte counts;	chr8:78732202	chr8:78723796~78724136:-
PRAD	cis	rs2919917	1	rs894221	ENSG00000254352.1	RP11-578O24.2	-13.1	1.74e-33	4.16e-30	-0.65	-0.52	Lymphocyte counts;	chr8:78736822	chr8:78723796~78724136:-
PRAD	cis	rs1577917	0.771	rs2842613	ENSG00000203875.9	SNHG5	13.1	1.74e-33	4.18e-30	0.6	0.52	Response to antipsychotic treatment;	chr6:85595984	chr6:85660950~85678736:-
PRAD	cis	rs977987	0.806	rs7185640	ENSG00000261783.1	RP11-252K23.2	-13.1	1.77e-33	4.23e-30	-0.7	-0.52	Dupuytren's disease;	chr16:75360501	chr16:75379818~75381260:-
PRAD	cis	rs977987	0.806	rs11640674	ENSG00000261783.1	RP11-252K23.2	-13.1	1.77e-33	4.23e-30	-0.7	-0.52	Dupuytren's disease;	chr16:75361046	chr16:75379818~75381260:-
PRAD	cis	rs2111504	0.583	rs1008425	ENSG00000267213.4	AC007773.2	13.09	1.8e-33	4.3e-30	0.56	0.52	Bipolar disorder;	chr19:32361239	chr19:32390050~32405560:-
PRAD	cis	rs9322193	0.923	rs2880436	ENSG00000268592.3	RAET1E-AS1	13.09	1.8e-33	4.31e-30	0.72	0.52	Lung cancer;	chr6:149859123	chr6:149863494~149919507:+
PRAD	cis	rs977987	0.527	rs62059844	ENSG00000261783.1	RP11-252K23.2	-13.09	1.8e-33	4.32e-30	-0.71	-0.52	Dupuytren's disease;	chr16:75395839	chr16:75379818~75381260:-
PRAD	cis	rs977987	0.585	rs62059845	ENSG00000261783.1	RP11-252K23.2	-13.09	1.8e-33	4.32e-30	-0.71	-0.52	Dupuytren's disease;	chr16:75396815	chr16:75379818~75381260:-
PRAD	cis	rs977987	0.778	rs62059846	ENSG00000261783.1	RP11-252K23.2	-13.09	1.8e-33	4.32e-30	-0.71	-0.52	Dupuytren's disease;	chr16:75396911	chr16:75379818~75381260:-
PRAD	cis	rs977987	0.843	rs11149824	ENSG00000261783.1	RP11-252K23.2	-13.09	1.8e-33	4.32e-30	-0.71	-0.52	Dupuytren's disease;	chr16:75397932	chr16:75379818~75381260:-
PRAD	cis	rs977987	0.778	rs11862719	ENSG00000261783.1	RP11-252K23.2	-13.09	1.81e-33	4.33e-30	-0.71	-0.52	Dupuytren's disease;	chr16:75397810	chr16:75379818~75381260:-
PRAD	cis	rs1930961	0.85	rs5996945	ENSG00000100058.11	CRYBB2P1	-13.09	1.81e-33	4.33e-30	-0.8	-0.52	Bipolar disorder with mood-incongruent psychosis;	chr22:25479606	chr22:25448105~25520854:+
PRAD	cis	rs9545047	0.935	rs8002042	ENSG00000227676.3	LINC01068	-13.09	1.84e-33	4.41e-30	-0.64	-0.52	Schizophrenia;	chr13:79486552	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.935	rs6563113	ENSG00000227676.3	LINC01068	-13.09	1.84e-33	4.41e-30	-0.64	-0.52	Schizophrenia;	chr13:79490000	chr13:79566727~79571436:+
PRAD	cis	rs9326248	0.954	rs8521	ENSG00000280143.1	AP000892.6	13.09	1.85e-33	4.43e-30	0.44	0.52	Blood protein levels;	chr11:117196983	chr11:117204967~117210292:+
PRAD	cis	rs6142102	0.602	rs10485503	ENSG00000276073.1	RP5-1125A11.7	-13.09	1.86e-33	4.45e-30	-0.51	-0.52	Skin pigmentation;	chr20:33970036	chr20:33985617~33988989:-
PRAD	cis	rs11673344	0.832	rs56210764	ENSG00000226686.6	LINC01535	13.09	1.88e-33	4.49e-30	0.76	0.52	Obesity-related traits;	chr19:37125970	chr19:37251912~37265535:+
PRAD	cis	rs2019137	0.56	rs11123172	ENSG00000274877.1	RP11-65I12.1	13.09	1.88e-33	4.5e-30	0.71	0.52	Lymphocyte counts;	chr2:113226726	chr2:113237595~113240825:+
PRAD	cis	rs673078	0.607	rs2393418	ENSG00000275759.1	RP11-131L12.3	-13.09	1.88e-33	4.5e-30	-0.79	-0.52	Glucose homeostasis traits;	chr12:118445995	chr12:118428281~118428870:+
PRAD	cis	rs1577917	0.771	rs9353318	ENSG00000203875.9	SNHG5	13.09	1.89e-33	4.52e-30	0.6	0.52	Response to antipsychotic treatment;	chr6:85522003	chr6:85660950~85678736:-
PRAD	cis	rs4660456	0.913	rs2223486	ENSG00000237899.1	RP4-739H11.3	-13.09	1.91e-33	4.57e-30	-0.76	-0.52	Platelet count;	chr1:40693557	chr1:40669089~40687588:-
PRAD	cis	rs977987	0.806	rs35552529	ENSG00000261783.1	RP11-252K23.2	-13.09	1.94e-33	4.63e-30	-0.7	-0.52	Dupuytren's disease;	chr16:75371981	chr16:75379818~75381260:-
PRAD	cis	rs3091242	0.867	rs602052	ENSG00000224183.1	SDHDP6	-13.09	1.96e-33	4.68e-30	-0.61	-0.52	Erythrocyte sedimentation rate;	chr1:25395715	chr1:25294164~25294643:-
PRAD	cis	rs9487094	0.626	rs4141930	ENSG00000260273.1	RP11-425D10.10	13.08	1.99e-33	4.75e-30	0.71	0.52	Height;	chr6:109739615	chr6:109382795~109383666:+
PRAD	cis	rs4722166	0.63	rs13311155	ENSG00000179428.2	AC073072.5	-13.08	2.01e-33	4.79e-30	-0.64	-0.52	Lung cancer;	chr7:22750170	chr7:22725395~22727620:-
PRAD	cis	rs4722166	0.63	rs13311199	ENSG00000179428.2	AC073072.5	-13.08	2.01e-33	4.79e-30	-0.64	-0.52	Lung cancer;	chr7:22750174	chr7:22725395~22727620:-
PRAD	cis	rs9326248	0.906	rs171052	ENSG00000280143.1	AP000892.6	-13.08	2.01e-33	4.8e-30	-0.44	-0.52	Blood protein levels;	chr11:117211047	chr11:117204967~117210292:+
PRAD	cis	rs11673344	0.74	rs113752815	ENSG00000226686.6	LINC01535	13.08	2.04e-33	4.86e-30	0.75	0.52	Obesity-related traits;	chr19:37043829	chr19:37251912~37265535:+
PRAD	cis	rs11723261	0.582	rs61792238	ENSG00000275426.1	CH17-262A2.1	13.08	2.08e-33	4.97e-30	0.8	0.52	Immune response to smallpox vaccine (IL-6);	chr4:112398	chr4:149738~150317:+
PRAD	cis	rs2111504	0.559	rs12460112	ENSG00000267213.4	AC007773.2	13.08	2.09e-33	4.98e-30	0.56	0.52	Bipolar disorder;	chr19:32363928	chr19:32390050~32405560:-
PRAD	cis	rs6964833	1	rs3846966	ENSG00000123965.13	PMS2P5	13.08	2.1e-33	5e-30	0.82	0.52	Menarche (age at onset);	chr7:74698811	chr7:74894116~74897835:+
PRAD	cis	rs7208859	0.623	rs8081299	ENSG00000263531.1	RP13-753N3.1	13.08	2.11e-33	5.02e-30	1	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777278	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs8068645	ENSG00000263531.1	RP13-753N3.1	13.08	2.11e-33	5.02e-30	1	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777324	chr17:30863921~30864940:-
PRAD	cis	rs673078	0.607	rs61944671	ENSG00000275759.1	RP11-131L12.3	-13.08	2.11e-33	5.02e-30	-0.79	-0.52	Glucose homeostasis traits;	chr12:118450046	chr12:118428281~118428870:+
PRAD	cis	rs2658782	1	rs2658779	ENSG00000279684.1	RP11-755E23.2	13.08	2.11e-33	5.04e-30	0.85	0.52	Pulmonary function decline;	chr11:93429971	chr11:93286629~93288903:-
PRAD	cis	rs7617773	0.817	rs9819094	ENSG00000229759.1	MRPS18AP1	13.08	2.12e-33	5.04e-30	0.56	0.52	Coronary artery disease;	chr3:48278068	chr3:48256350~48256938:-
PRAD	cis	rs977987	0.806	rs11862582	ENSG00000261783.1	RP11-252K23.2	-13.08	2.15e-33	5.12e-30	-0.71	-0.52	Dupuytren's disease;	chr16:75397397	chr16:75379818~75381260:-
PRAD	cis	rs9660180	0.934	rs12729990	ENSG00000268575.1	RP1-283E3.8	-13.07	2.2e-33	5.22e-30	-0.55	-0.52	Body mass index;	chr1:1880596	chr1:1702736~1737688:-
PRAD	cis	rs977987	0.778	rs2113232	ENSG00000261783.1	RP11-252K23.2	-13.07	2.22e-33	5.29e-30	-0.7	-0.52	Dupuytren's disease;	chr16:75357287	chr16:75379818~75381260:-
PRAD	cis	rs1577917	0.771	rs4419647	ENSG00000203875.9	SNHG5	13.07	2.26e-33	5.37e-30	0.6	0.52	Response to antipsychotic treatment;	chr6:85516021	chr6:85660950~85678736:-
PRAD	cis	rs9326248	0.559	rs12808524	ENSG00000254851.1	RP11-109L13.1	-13.07	2.26e-33	5.37e-30	-0.66	-0.52	Blood protein levels;	chr11:117020277	chr11:117135528~117138582:+
PRAD	cis	rs2919917	1	rs7010897	ENSG00000254352.1	RP11-578O24.2	13.07	2.26e-33	5.37e-30	0.64	0.52	Lymphocyte counts;	chr8:78708119	chr8:78723796~78724136:-
PRAD	cis	rs2919917	1	rs11986947	ENSG00000254352.1	RP11-578O24.2	13.07	2.26e-33	5.37e-30	0.64	0.52	Lymphocyte counts;	chr8:78708957	chr8:78723796~78724136:-
PRAD	cis	rs172166	0.516	rs2791333	ENSG00000216901.1	AL022393.7	13.07	2.27e-33	5.38e-30	0.65	0.52	Cardiac Troponin-T levels;	chr6:28143336	chr6:28176188~28176674:+
PRAD	cis	rs2919917	1	rs7839152	ENSG00000254352.1	RP11-578O24.2	13.07	2.27e-33	5.38e-30	0.63	0.52	Lymphocyte counts;	chr8:78677777	chr8:78723796~78724136:-
PRAD	cis	rs2919917	1	rs9298316	ENSG00000254352.1	RP11-578O24.2	13.07	2.27e-33	5.38e-30	0.63	0.52	Lymphocyte counts;	chr8:78680191	chr8:78723796~78724136:-
PRAD	cis	rs2919917	1	rs7842142	ENSG00000254352.1	RP11-578O24.2	13.07	2.27e-33	5.38e-30	0.63	0.52	Lymphocyte counts;	chr8:78681501	chr8:78723796~78724136:-
PRAD	cis	rs2919917	1	rs11785966	ENSG00000254352.1	RP11-578O24.2	13.07	2.27e-33	5.38e-30	0.63	0.52	Lymphocyte counts;	chr8:78681851	chr8:78723796~78724136:-
PRAD	cis	rs2919917	1	rs10092335	ENSG00000254352.1	RP11-578O24.2	13.07	2.27e-33	5.38e-30	0.63	0.52	Lymphocyte counts;	chr8:78686218	chr8:78723796~78724136:-
PRAD	cis	rs2111504	0.583	rs2868082	ENSG00000267213.4	AC007773.2	13.07	2.27e-33	5.38e-30	0.56	0.52	Bipolar disorder;	chr19:32368475	chr19:32390050~32405560:-
PRAD	cis	rs3931020	0.679	rs28671241	ENSG00000272864.1	RP11-17E13.2	-13.07	2.28e-33	5.42e-30	-0.55	-0.52	Resistin levels;	chr1:74716197	chr1:74698769~74699333:-
PRAD	cis	rs977987	0.806	rs2285225	ENSG00000261783.1	RP11-252K23.2	-13.07	2.31e-33	5.48e-30	-0.71	-0.52	Dupuytren's disease;	chr16:75395354	chr16:75379818~75381260:-
PRAD	cis	rs977987	0.806	rs1544810	ENSG00000261783.1	RP11-252K23.2	-13.06	2.4e-33	5.68e-30	-0.7	-0.52	Dupuytren's disease;	chr16:75377265	chr16:75379818~75381260:-
PRAD	cis	rs11673344	0.77	rs74770693	ENSG00000226686.6	LINC01535	13.06	2.4e-33	5.68e-30	0.76	0.52	Obesity-related traits;	chr19:37135613	chr19:37251912~37265535:+
PRAD	cis	rs2658782	0.547	rs3020064	ENSG00000279684.1	RP11-755E23.2	-13.06	2.42e-33	5.74e-30	-0.77	-0.52	Pulmonary function decline;	chr11:93327685	chr11:93286629~93288903:-
PRAD	cis	rs55794721	0.509	rs12027110	ENSG00000261349.1	RP3-465N24.5	-13.06	2.42e-33	5.74e-30	-0.58	-0.52	Mean corpuscular volume;Plateletcrit;	chr1:25449191	chr1:25266102~25267136:-
PRAD	cis	rs71403859	0.73	rs12927768	ENSG00000260886.1	TAT-AS1	13.06	2.47e-33	5.84e-30	0.94	0.52	Post bronchodilator FEV1;	chr16:71611360	chr16:71565789~71578187:+
PRAD	cis	rs11673344	0.801	rs76806623	ENSG00000226686.6	LINC01535	13.06	2.48e-33	5.88e-30	0.75	0.52	Obesity-related traits;	chr19:37132525	chr19:37251912~37265535:+
PRAD	cis	rs2919917	1	rs1054283	ENSG00000254352.1	RP11-578O24.2	13.06	2.5e-33	5.92e-30	0.64	0.52	Lymphocyte counts;	chr8:78698475	chr8:78723796~78724136:-
PRAD	cis	rs1577917	0.518	rs6454482	ENSG00000203875.9	SNHG5	13.06	2.53e-33	5.98e-30	0.56	0.52	Response to antipsychotic treatment;	chr6:85708470	chr6:85660950~85678736:-
PRAD	cis	rs2882667	0.858	rs11750382	ENSG00000253404.1	AC034243.1	-13.06	2.55e-33	6.03e-30	-0.74	-0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139121305	chr5:138744434~138753309:-
PRAD	cis	rs977987	0.806	rs56343285	ENSG00000261783.1	RP11-252K23.2	-13.06	2.55e-33	6.03e-30	-0.71	-0.52	Dupuytren's disease;	chr16:75375899	chr16:75379818~75381260:-
PRAD	cis	rs2658782	1	rs2608216	ENSG00000279684.1	RP11-755E23.2	-13.06	2.59e-33	6.13e-30	-0.86	-0.52	Pulmonary function decline;	chr11:93416006	chr11:93286629~93288903:-
PRAD	cis	rs2658782	0.95	rs2446061	ENSG00000279684.1	RP11-755E23.2	-13.06	2.59e-33	6.13e-30	-0.86	-0.52	Pulmonary function decline;	chr11:93416111	chr11:93286629~93288903:-
PRAD	cis	rs9545047	1	rs9574418	ENSG00000227676.3	LINC01068	13.06	2.61e-33	6.16e-30	0.68	0.52	Schizophrenia;	chr13:79393874	chr13:79566727~79571436:+
PRAD	cis	rs6452524	0.618	rs7722924	ENSG00000249664.1	CTD-2227C6.2	13.06	2.61e-33	6.18e-30	0.61	0.52	Hypertension (SNP x SNP interaction);	chr5:83060223	chr5:83012285~83013109:-
PRAD	cis	rs9399135	0.967	rs7741626	ENSG00000232876.1	CTA-212D2.2	-13.06	2.61e-33	6.18e-30	-0.63	-0.52	Red blood cell count;	chr6:134993044	chr6:135055033~135060550:+
PRAD	cis	rs9399135	0.967	rs4895439	ENSG00000232876.1	CTA-212D2.2	-13.06	2.61e-33	6.18e-30	-0.63	-0.52	Red blood cell count;	chr6:134997716	chr6:135055033~135060550:+
PRAD	cis	rs9399135	0.935	rs11754504	ENSG00000232876.1	CTA-212D2.2	-13.06	2.61e-33	6.18e-30	-0.63	-0.52	Red blood cell count;	chr6:135000371	chr6:135055033~135060550:+
PRAD	cis	rs9399135	0.869	rs9402675	ENSG00000232876.1	CTA-212D2.2	-13.06	2.61e-33	6.18e-30	-0.63	-0.52	Red blood cell count;	chr6:135004656	chr6:135055033~135060550:+
PRAD	cis	rs9399135	0.967	rs9389253	ENSG00000232876.1	CTA-212D2.2	-13.06	2.61e-33	6.18e-30	-0.63	-0.52	Red blood cell count;	chr6:135008617	chr6:135055033~135060550:+
PRAD	cis	rs9399135	0.967	rs9389254	ENSG00000232876.1	CTA-212D2.2	-13.06	2.61e-33	6.18e-30	-0.63	-0.52	Red blood cell count;	chr6:135009571	chr6:135055033~135060550:+
PRAD	cis	rs9399135	0.967	rs1014020	ENSG00000232876.1	CTA-212D2.2	-13.06	2.61e-33	6.18e-30	-0.63	-0.52	Red blood cell count;	chr6:135013288	chr6:135055033~135060550:+
PRAD	cis	rs9399135	0.967	rs1041481	ENSG00000232876.1	CTA-212D2.2	-13.06	2.61e-33	6.18e-30	-0.63	-0.52	Red blood cell count;	chr6:135013925	chr6:135055033~135060550:+
PRAD	cis	rs9399135	0.967	rs6902438	ENSG00000232876.1	CTA-212D2.2	-13.06	2.61e-33	6.18e-30	-0.63	-0.52	Red blood cell count;	chr6:135015449	chr6:135055033~135060550:+
PRAD	cis	rs9399135	0.935	rs6908681	ENSG00000232876.1	CTA-212D2.2	-13.06	2.61e-33	6.18e-30	-0.63	-0.52	Red blood cell count;	chr6:135016595	chr6:135055033~135060550:+
PRAD	cis	rs977987	0.806	rs35263058	ENSG00000261783.1	RP11-252K23.2	-13.05	2.7e-33	6.38e-30	-0.7	-0.52	Dupuytren's disease;	chr16:75358039	chr16:75379818~75381260:-
PRAD	cis	rs9545047	0.935	rs1577416	ENSG00000227676.3	LINC01068	-13.05	2.72e-33	6.43e-30	-0.64	-0.52	Schizophrenia;	chr13:79500646	chr13:79566727~79571436:+
PRAD	cis	rs3091242	0.933	rs1534954	ENSG00000224183.1	SDHDP6	-13.05	2.73e-33	6.45e-30	-0.61	-0.52	Erythrocyte sedimentation rate;	chr1:25435433	chr1:25294164~25294643:-
PRAD	cis	rs7182621	0.639	rs12906050	ENSG00000259363.4	CTD-2054N24.2	-13.05	2.73e-33	6.46e-30	-0.56	-0.52	Colonoscopy-negative controls vs population controls;	chr15:99873384	chr15:99807023~99877148:+
PRAD	cis	rs7182621	0.639	rs35248328	ENSG00000259363.4	CTD-2054N24.2	-13.05	2.73e-33	6.46e-30	-0.56	-0.52	Colonoscopy-negative controls vs population controls;	chr15:99873399	chr15:99807023~99877148:+
PRAD	cis	rs3091242	0.809	rs660129	ENSG00000261349.1	RP3-465N24.5	-13.05	2.74e-33	6.47e-30	-0.59	-0.52	Erythrocyte sedimentation rate;	chr1:25400947	chr1:25266102~25267136:-
PRAD	cis	rs3091242	0.728	rs706845	ENSG00000261349.1	RP3-465N24.5	-13.05	2.74e-33	6.47e-30	-0.59	-0.52	Erythrocyte sedimentation rate;	chr1:25404222	chr1:25266102~25267136:-
PRAD	cis	rs9326248	0.581	rs10892053	ENSG00000254851.1	RP11-109L13.1	-13.05	2.8e-33	6.61e-30	-0.65	-0.52	Blood protein levels;	chr11:116986287	chr11:117135528~117138582:+
PRAD	cis	rs977987	0.836	rs7198873	ENSG00000261783.1	RP11-252K23.2	-13.05	2.83e-33	6.67e-30	-0.7	-0.52	Dupuytren's disease;	chr16:75440856	chr16:75379818~75381260:-
PRAD	cis	rs11673344	0.832	rs56080874	ENSG00000226686.6	LINC01535	13.05	2.84e-33	6.69e-30	0.74	0.52	Obesity-related traits;	chr19:37085487	chr19:37251912~37265535:+
PRAD	cis	rs11673344	0.77	rs7257135	ENSG00000226686.6	LINC01535	13.05	2.84e-33	6.69e-30	0.74	0.52	Obesity-related traits;	chr19:37088726	chr19:37251912~37265535:+
PRAD	cis	rs524281	0.861	rs11227426	ENSG00000255320.1	RP11-755F10.1	13.05	2.86e-33	6.74e-30	0.8	0.52	Electroencephalogram traits;	chr11:66204480	chr11:66244840~66246239:-
PRAD	cis	rs524281	0.861	rs7942894	ENSG00000255320.1	RP11-755F10.1	13.05	2.86e-33	6.74e-30	0.8	0.52	Electroencephalogram traits;	chr11:66209054	chr11:66244840~66246239:-
PRAD	cis	rs6142102	0.602	rs11696338	ENSG00000276073.1	RP5-1125A11.7	-13.04	2.89e-33	6.82e-30	-0.51	-0.52	Skin pigmentation;	chr20:34099805	chr20:33985617~33988989:-
PRAD	cis	rs6142102	0.58	rs6142101	ENSG00000276073.1	RP5-1125A11.7	-13.04	2.89e-33	6.82e-30	-0.51	-0.52	Skin pigmentation;	chr20:34110039	chr20:33985617~33988989:-
PRAD	cis	rs977987	0.778	rs11858992	ENSG00000261783.1	RP11-252K23.2	-13.04	2.91e-33	6.85e-30	-0.7	-0.52	Dupuytren's disease;	chr16:75377547	chr16:75379818~75381260:-
PRAD	cis	rs977987	0.806	rs4993970	ENSG00000261783.1	RP11-252K23.2	-13.04	2.91e-33	6.85e-30	-0.7	-0.52	Dupuytren's disease;	chr16:75377721	chr16:75379818~75381260:-
PRAD	cis	rs1577917	0.771	rs2842602	ENSG00000203875.9	SNHG5	-13.04	2.92e-33	6.87e-30	-0.6	-0.52	Response to antipsychotic treatment;	chr6:85622169	chr6:85660950~85678736:-
PRAD	cis	rs950027	0.967	rs2486280	ENSG00000259520.4	CTD-2651B20.3	-13.04	2.94e-33	6.94e-30	-0.67	-0.52	Response to fenofibrate (adiponectin levels);	chr15:45459691	chr15:45251580~45279251:-
PRAD	cis	rs4423214	0.569	rs12806918	ENSG00000254682.1	RP11-660L16.2	13.04	2.98e-33	7.02e-30	0.62	0.52	Vitamin D levels;	chr11:71407972	chr11:71448674~71452157:+
PRAD	cis	rs2404602	0.71	rs2469541	ENSG00000259422.1	RP11-593F23.1	-13.04	3.03e-33	7.12e-30	-0.64	-0.52	Blood metabolite levels;	chr15:76269777	chr15:76174891~76181486:-
PRAD	cis	rs2882667	0.858	rs11741150	ENSG00000253404.1	AC034243.1	13.04	3.07e-33	7.22e-30	0.72	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139095768	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.858	rs13170388	ENSG00000253404.1	AC034243.1	13.04	3.07e-33	7.22e-30	0.72	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139101176	chr5:138744434~138753309:-
PRAD	cis	rs3091242	0.934	rs686631	ENSG00000224183.1	SDHDP6	-13.04	3.09e-33	7.26e-30	-0.61	-0.52	Erythrocyte sedimentation rate;	chr1:25393108	chr1:25294164~25294643:-
PRAD	cis	rs9399135	0.967	rs7750300	ENSG00000232876.1	CTA-212D2.2	-13.04	3.17e-33	7.46e-30	-0.63	-0.52	Red blood cell count;	chr6:135029812	chr6:135055033~135060550:+
PRAD	cis	rs2882667	0.858	rs6882112	ENSG00000253404.1	AC034243.1	-13.03	3.21e-33	7.56e-30	-0.72	-0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139078046	chr5:138744434~138753309:-
PRAD	cis	rs9487094	0.626	rs11153215	ENSG00000260273.1	RP11-425D10.10	13.03	3.29e-33	7.74e-30	0.71	0.52	Height;	chr6:109732518	chr6:109382795~109383666:+
PRAD	cis	rs9487094	0.626	rs2273752	ENSG00000260273.1	RP11-425D10.10	13.03	3.29e-33	7.74e-30	0.71	0.52	Height;	chr6:109738307	chr6:109382795~109383666:+
PRAD	cis	rs977987	0.806	rs17696696	ENSG00000261783.1	RP11-252K23.2	13.03	3.3e-33	7.75e-30	0.7	0.52	Dupuytren's disease;	chr16:75359454	chr16:75379818~75381260:-
PRAD	cis	rs3091242	0.933	rs35148262	ENSG00000261349.1	RP3-465N24.5	-13.03	3.3e-33	7.76e-30	-0.57	-0.52	Erythrocyte sedimentation rate;	chr1:25440132	chr1:25266102~25267136:-
PRAD	cis	rs977987	0.806	rs2161684	ENSG00000261783.1	RP11-252K23.2	-13.03	3.33e-33	7.82e-30	-0.71	-0.52	Dupuytren's disease;	chr16:75445255	chr16:75379818~75381260:-
PRAD	cis	rs977987	0.806	rs34996006	ENSG00000261783.1	RP11-252K23.2	-13.03	3.33e-33	7.82e-30	-0.71	-0.52	Dupuytren's disease;	chr16:75445536	chr16:75379818~75381260:-
PRAD	cis	rs6504950	0.72	rs9910653	ENSG00000275710.1	RP11-257O5.4	13.03	3.36e-33	7.88e-30	0.68	0.52	Breast cancer;	chr17:54914907	chr17:54964474~54964679:+
PRAD	cis	rs2658782	0.547	rs10765602	ENSG00000279684.1	RP11-755E23.2	-13.03	3.42e-33	8.03e-30	-0.78	-0.52	Pulmonary function decline;	chr11:93314999	chr11:93286629~93288903:-
PRAD	cis	rs11673344	0.801	rs17707446	ENSG00000226686.6	LINC01535	-13.03	3.43e-33	8.05e-30	-0.74	-0.52	Obesity-related traits;	chr19:37092140	chr19:37251912~37265535:+
PRAD	cis	rs2882667	0.858	rs11948429	ENSG00000253404.1	AC034243.1	13.03	3.45e-33	8.09e-30	0.73	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139122895	chr5:138744434~138753309:-
PRAD	cis	rs2882667	0.858	rs2043271	ENSG00000253404.1	AC034243.1	13.03	3.45e-33	8.09e-30	0.73	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139123419	chr5:138744434~138753309:-
PRAD	cis	rs977987	1	rs977985	ENSG00000261783.1	RP11-252K23.2	-13.03	3.45e-33	8.09e-30	-0.73	-0.52	Dupuytren's disease;	chr16:75473049	chr16:75379818~75381260:-
PRAD	cis	rs73086581	1	rs3746665	ENSG00000229539.1	RP11-119B16.2	-13.03	3.47e-33	8.13e-30	-0.84	-0.52	Response to antidepressants in depression;	chr20:3929759	chr20:3888239~3888868:-
PRAD	cis	rs992157	0.661	rs10171839	ENSG00000261338.2	RP11-378A13.1	13.03	3.47e-33	8.13e-30	0.59	0.52	Colorectal cancer;	chr2:218186591	chr2:218255319~218257366:+
PRAD	cis	rs9545047	1	rs9545078	ENSG00000227676.3	LINC01068	13.03	3.48e-33	8.16e-30	0.67	0.52	Schizophrenia;	chr13:79339216	chr13:79566727~79571436:+
PRAD	cis	rs673078	0.607	rs7967900	ENSG00000275759.1	RP11-131L12.3	13.03	3.49e-33	8.18e-30	0.79	0.52	Glucose homeostasis traits;	chr12:118381902	chr12:118428281~118428870:+
PRAD	cis	rs7617773	0.638	rs7644414	ENSG00000229759.1	MRPS18AP1	13.02	3.5e-33	8.21e-30	0.58	0.52	Coronary artery disease;	chr3:48257589	chr3:48256350~48256938:-
PRAD	cis	rs2019137	0.56	rs10175462	ENSG00000274877.1	RP11-65I12.1	-13.02	3.52e-33	8.25e-30	-0.71	-0.52	Lymphocyte counts;	chr2:113230915	chr2:113237595~113240825:+
PRAD	cis	rs73086581	1	rs6037708	ENSG00000229539.1	RP11-119B16.2	13.02	3.6e-33	8.42e-30	0.84	0.52	Response to antidepressants in depression;	chr20:3980606	chr20:3888239~3888868:-
PRAD	cis	rs4722166	0.604	rs2390715	ENSG00000179428.2	AC073072.5	-13.02	3.79e-33	8.88e-30	-0.64	-0.52	Lung cancer;	chr7:22744259	chr7:22725395~22727620:-
PRAD	cis	rs4722166	0.63	rs4722169	ENSG00000179428.2	AC073072.5	-13.02	3.79e-33	8.88e-30	-0.64	-0.52	Lung cancer;	chr7:22745800	chr7:22725395~22727620:-
PRAD	cis	rs4722166	0.598	rs4722171	ENSG00000179428.2	AC073072.5	-13.02	3.79e-33	8.88e-30	-0.64	-0.52	Lung cancer;	chr7:22746098	chr7:22725395~22727620:-
PRAD	cis	rs17507216	0.628	rs17158396	ENSG00000278603.1	RP13-608F4.5	13.01	3.85e-33	9e-30	0.8	0.52	Excessive daytime sleepiness;	chr15:82615688	chr15:82472203~82472426:+
PRAD	cis	rs4718428	0.705	rs13227468	ENSG00000226824.5	RP4-756H11.3	-13.01	3.91e-33	9.14e-30	-0.72	-0.52	Corneal structure;	chr7:66968576	chr7:66654538~66669855:+
PRAD	cis	rs7182621	0.639	rs1561048	ENSG00000259363.4	CTD-2054N24.2	-13.01	3.94e-33	9.22e-30	-0.56	-0.52	Colonoscopy-negative controls vs population controls;	chr15:99875369	chr15:99807023~99877148:+
PRAD	cis	rs6452524	0.618	rs10462394	ENSG00000249664.1	CTD-2227C6.2	13.01	3.96e-33	9.25e-30	0.6	0.52	Hypertension (SNP x SNP interaction);	chr5:83058735	chr5:83012285~83013109:-
PRAD	cis	rs524281	0.637	rs7126075	ENSG00000255320.1	RP11-755F10.1	13.01	3.97e-33	9.27e-30	0.85	0.52	Electroencephalogram traits;	chr11:66173092	chr11:66244840~66246239:-
PRAD	cis	rs524281	0.861	rs2177054	ENSG00000255320.1	RP11-755F10.1	13.01	3.97e-33	9.27e-30	0.85	0.52	Electroencephalogram traits;	chr11:66177141	chr11:66244840~66246239:-
PRAD	cis	rs9399135	0.838	rs4896126	ENSG00000232876.1	CTA-212D2.2	-13.01	3.99e-33	9.31e-30	-0.63	-0.52	Red blood cell count;	chr6:135021648	chr6:135055033~135060550:+
PRAD	cis	rs9402673	0.517	rs978036	ENSG00000232876.1	CTA-212D2.2	-13.01	3.99e-33	9.31e-30	-0.63	-0.52	High light scatter reticulocyte count;Reticulocyte count;	chr6:135021765	chr6:135055033~135060550:+
PRAD	cis	rs9399135	0.967	rs1023179	ENSG00000232876.1	CTA-212D2.2	-13.01	3.99e-33	9.31e-30	-0.63	-0.52	Red blood cell count;	chr6:135022691	chr6:135055033~135060550:+
PRAD	cis	rs9399135	0.967	rs952674	ENSG00000232876.1	CTA-212D2.2	-13.01	3.99e-33	9.31e-30	-0.63	-0.52	Red blood cell count;	chr6:135028019	chr6:135055033~135060550:+
PRAD	cis	rs9399135	0.935	rs987690	ENSG00000232876.1	CTA-212D2.2	-13.01	4e-33	9.33e-30	-0.63	-0.52	Red blood cell count;	chr6:135029241	chr6:135055033~135060550:+
PRAD	cis	rs977987	0.806	rs11640473	ENSG00000261783.1	RP11-252K23.2	-13.01	4e-33	9.34e-30	-0.7	-0.52	Dupuytren's disease;	chr16:75369391	chr16:75379818~75381260:-
PRAD	cis	rs3091242	0.933	rs35497030	ENSG00000224183.1	SDHDP6	13.01	4.09e-33	9.55e-30	0.61	0.52	Erythrocyte sedimentation rate;	chr1:25456575	chr1:25294164~25294643:-
PRAD	cis	rs9322193	0.923	rs4870052	ENSG00000223701.3	RAET1E-AS1	13.01	4.12e-33	9.61e-30	0.7	0.52	Lung cancer;	chr6:149839978	chr6:149884431~149919508:+
PRAD	cis	rs2658782	0.547	rs4753453	ENSG00000279684.1	RP11-755E23.2	-13.01	4.14e-33	9.66e-30	-0.78	-0.52	Pulmonary function decline;	chr11:93308008	chr11:93286629~93288903:-
PRAD	cis	rs12049351	0.774	rs4148755	ENSG00000229367.1	HMGN2P19	13.01	4.21e-33	9.83e-30	0.74	0.52	Circulating myeloperoxidase levels (plasma);	chr1:229559119	chr1:229570532~229570796:+
PRAD	cis	rs6504950	0.72	rs12602751	ENSG00000275710.1	RP11-257O5.4	13	4.34e-33	1.01e-29	0.68	0.52	Breast cancer;	chr17:54916813	chr17:54964474~54964679:+
PRAD	cis	rs6504950	0.72	rs7216138	ENSG00000275710.1	RP11-257O5.4	13	4.34e-33	1.01e-29	0.68	0.52	Breast cancer;	chr17:54918303	chr17:54964474~54964679:+
PRAD	cis	rs673078	0.607	rs7295288	ENSG00000275759.1	RP11-131L12.3	-13	4.35e-33	1.01e-29	-0.75	-0.52	Glucose homeostasis traits;	chr12:118418008	chr12:118428281~118428870:+
PRAD	cis	rs3091242	0.867	rs602052	ENSG00000261349.1	RP3-465N24.5	-13	4.43e-33	1.03e-29	-0.58	-0.52	Erythrocyte sedimentation rate;	chr1:25395715	chr1:25266102~25267136:-
PRAD	cis	rs2919917	1	rs1021156	ENSG00000254352.1	RP11-578O24.2	13	4.5e-33	1.05e-29	0.63	0.52	Lymphocyte counts;	chr8:78663569	chr8:78723796~78724136:-
PRAD	cis	rs2882667	0.858	rs7724108	ENSG00000253404.1	AC034243.1	-13	4.5e-33	1.05e-29	-0.73	-0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139075233	chr5:138744434~138753309:-
PRAD	cis	rs6964833	1	rs36044436	ENSG00000277053.3	GTF2IP1	-13	4.57e-33	1.06e-29	-0.63	-0.52	Menarche (age at onset);	chr7:74675495	chr7:75185385~75237696:-
PRAD	cis	rs4423214	0.535	rs1540129	ENSG00000254682.1	RP11-660L16.2	13	4.63e-33	1.08e-29	0.7	0.52	Vitamin D levels;	chr11:71418477	chr11:71448674~71452157:+
PRAD	cis	rs6504950	1	rs12940106	ENSG00000275710.1	RP11-257O5.4	13	4.64e-33	1.08e-29	0.72	0.52	Breast cancer;	chr17:54990322	chr17:54964474~54964679:+
PRAD	cis	rs12049351	0.774	rs36021190	ENSG00000229367.1	HMGN2P19	13	4.64e-33	1.08e-29	0.72	0.52	Circulating myeloperoxidase levels (plasma);	chr1:229562116	chr1:229570532~229570796:+
PRAD	cis	rs2658782	0.507	rs4457713	ENSG00000279684.1	RP11-755E23.2	-12.99	4.65e-33	1.08e-29	-0.78	-0.52	Pulmonary function decline;	chr11:93304264	chr11:93286629~93288903:-
PRAD	cis	rs950027	1	rs950027	ENSG00000259520.4	CTD-2651B20.3	12.99	4.66e-33	1.08e-29	0.67	0.52	Response to fenofibrate (adiponectin levels);	chr15:45508837	chr15:45251580~45279251:-
PRAD	cis	rs9532669	0.926	rs2039119	ENSG00000176268.5	CYCSP34	-12.99	4.66e-33	1.08e-29	-0.54	-0.52	Cervical cancer;	chr13:40872432	chr13:40863599~40863902:-
PRAD	cis	rs3096299	0.719	rs2965817	ENSG00000274627.1	RP11-104N10.2	12.99	4.71e-33	1.09e-29	0.53	0.52	Multiple myeloma (IgH translocation);	chr16:89446826	chr16:89516797~89522217:+
PRAD	cis	rs7182621	0.639	rs1561047	ENSG00000259363.4	CTD-2054N24.2	-12.99	4.72e-33	1.1e-29	-0.56	-0.52	Colonoscopy-negative controls vs population controls;	chr15:99874606	chr15:99807023~99877148:+
PRAD	cis	rs12049351	0.774	rs35464914	ENSG00000229367.1	HMGN2P19	12.99	4.86e-33	1.13e-29	0.74	0.52	Circulating myeloperoxidase levels (plasma);	chr1:229554485	chr1:229570532~229570796:+
PRAD	cis	rs9399135	0.967	rs2183709	ENSG00000232876.1	CTA-212D2.2	-12.99	4.88e-33	1.13e-29	-0.63	-0.52	Red blood cell count;	chr6:135055953	chr6:135055033~135060550:+
PRAD	cis	rs9399135	0.967	rs4142299	ENSG00000232876.1	CTA-212D2.2	-12.99	4.88e-33	1.13e-29	-0.63	-0.52	Red blood cell count;	chr6:135056048	chr6:135055033~135060550:+
PRAD	cis	rs9545047	1	rs2484345	ENSG00000227676.3	LINC01068	-12.99	4.97e-33	1.15e-29	-0.67	-0.52	Schizophrenia;	chr13:79427913	chr13:79566727~79571436:+
PRAD	cis	rs9326248	0.559	rs10892064	ENSG00000254851.1	RP11-109L13.1	-12.99	5.02e-33	1.17e-29	-0.65	-0.52	Blood protein levels;	chr11:117025837	chr11:117135528~117138582:+
PRAD	cis	rs9326248	0.539	rs10892065	ENSG00000254851.1	RP11-109L13.1	-12.99	5.02e-33	1.17e-29	-0.65	-0.52	Blood protein levels;	chr11:117026308	chr11:117135528~117138582:+
PRAD	cis	rs2658782	0.526	rs3020062	ENSG00000279684.1	RP11-755E23.2	-12.99	5.03e-33	1.17e-29	-0.76	-0.52	Pulmonary function decline;	chr11:93327993	chr11:93286629~93288903:-
PRAD	cis	rs875971	0.862	rs10274883	ENSG00000226824.5	RP4-756H11.3	12.99	5.04e-33	1.17e-29	0.72	0.52	Aortic root size;	chr7:66651104	chr7:66654538~66669855:+
PRAD	cis	rs801193	0.569	rs881285	ENSG00000226824.5	RP4-756H11.3	12.99	5.04e-33	1.17e-29	0.72	0.52	Aortic root size;	chr7:66654433	chr7:66654538~66669855:+
PRAD	cis	rs801193	0.569	rs3846973	ENSG00000226824.5	RP4-756H11.3	12.99	5.04e-33	1.17e-29	0.72	0.52	Aortic root size;	chr7:66655048	chr7:66654538~66669855:+
PRAD	cis	rs2658782	0.826	rs1975820	ENSG00000279684.1	RP11-755E23.2	-12.99	5.07e-33	1.18e-29	-0.85	-0.52	Pulmonary function decline;	chr11:93348649	chr11:93286629~93288903:-
PRAD	cis	rs4718428	0.705	rs13220977	ENSG00000226824.5	RP4-756H11.3	12.98	5.17e-33	1.2e-29	0.7	0.52	Corneal structure;	chr7:66872661	chr7:66654538~66669855:+
PRAD	cis	rs2882667	0.858	rs66839813	ENSG00000253404.1	AC034243.1	12.98	5.23e-33	1.21e-29	0.72	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139106633	chr5:138744434~138753309:-
PRAD	cis	rs977987	0.806	rs8057203	ENSG00000261783.1	RP11-252K23.2	-12.98	5.26e-33	1.22e-29	-0.7	-0.52	Dupuytren's disease;	chr16:75371076	chr16:75379818~75381260:-
PRAD	cis	rs9399135	0.967	rs9389258	ENSG00000232876.1	CTA-212D2.2	-12.98	5.32e-33	1.23e-29	-0.63	-0.52	Red blood cell count;	chr6:135040002	chr6:135055033~135060550:+
PRAD	cis	rs2882667	0.754	rs11746434	ENSG00000253404.1	AC034243.1	12.98	5.34e-33	1.24e-29	0.73	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139099614	chr5:138744434~138753309:-
PRAD	cis	rs7104764	0.701	rs3782115	ENSG00000277290.1	RP11-326C3.16	-12.98	5.41e-33	1.25e-29	-0.49	-0.52	Menarche (age at onset);	chr11:223272	chr11:243099~243483:-
PRAD	cis	rs11603023	0.805	rs687190	ENSG00000255239.1	AP002954.6	12.98	5.43e-33	1.26e-29	0.65	0.52	Cholesterol, total;	chr11:118671674	chr11:118688039~118690600:-
PRAD	cis	rs977987	0.806	rs4888389	ENSG00000261783.1	RP11-252K23.2	-12.98	5.49e-33	1.27e-29	-0.7	-0.52	Dupuytren's disease;	chr16:75361330	chr16:75379818~75381260:-
PRAD	cis	rs977987	0.806	rs11865004	ENSG00000261783.1	RP11-252K23.2	-12.98	5.49e-33	1.27e-29	-0.7	-0.52	Dupuytren's disease;	chr16:75361879	chr16:75379818~75381260:-
PRAD	cis	rs9326248	0.581	rs10892063	ENSG00000254851.1	RP11-109L13.1	-12.98	5.53e-33	1.28e-29	-0.65	-0.52	Blood protein levels;	chr11:117025439	chr11:117135528~117138582:+
PRAD	cis	rs2882667	0.858	rs13177503	ENSG00000253404.1	AC034243.1	12.98	5.61e-33	1.3e-29	0.72	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139097070	chr5:138744434~138753309:-
PRAD	cis	rs9326248	0.581	rs10892061	ENSG00000254851.1	RP11-109L13.1	-12.97	5.69e-33	1.32e-29	-0.65	-0.52	Blood protein levels;	chr11:117015398	chr11:117135528~117138582:+
PRAD	cis	rs6964833	1	rs4717907	ENSG00000123965.13	PMS2P5	12.97	5.72e-33	1.32e-29	0.79	0.52	Menarche (age at onset);	chr7:74672169	chr7:74894116~74897835:+
PRAD	cis	rs3091242	1	rs646867	ENSG00000224183.1	SDHDP6	-12.97	5.73e-33	1.33e-29	-0.62	-0.52	Erythrocyte sedimentation rate;	chr1:25382767	chr1:25294164~25294643:-
PRAD	cis	rs2919917	0.956	rs10112388	ENSG00000254352.1	RP11-578O24.2	12.97	5.74e-33	1.33e-29	0.64	0.52	Lymphocyte counts;	chr8:78691512	chr8:78723796~78724136:-
PRAD	cis	rs2919917	1	rs6980663	ENSG00000254352.1	RP11-578O24.2	12.97	5.74e-33	1.33e-29	0.64	0.52	Lymphocyte counts;	chr8:78691589	chr8:78723796~78724136:-
PRAD	cis	rs2919917	1	rs7001074	ENSG00000254352.1	RP11-578O24.2	12.97	5.74e-33	1.33e-29	0.64	0.52	Lymphocyte counts;	chr8:78691689	chr8:78723796~78724136:-
PRAD	cis	rs189798	0.738	rs330908	ENSG00000254340.1	RP11-10A14.3	12.97	5.85e-33	1.35e-29	0.65	0.52	Myopia (pathological);	chr8:9137656	chr8:9141424~9145435:+
PRAD	cis	rs9326248	1	rs4938354	ENSG00000280143.1	AP000892.6	12.97	6.02e-33	1.39e-29	0.45	0.52	Blood protein levels;	chr11:117180449	chr11:117204967~117210292:+
PRAD	cis	rs524281	0.861	rs3862386	ENSG00000255320.1	RP11-755F10.1	12.97	6.03e-33	1.39e-29	0.85	0.52	Electroencephalogram traits;	chr11:66126953	chr11:66244840~66246239:-
PRAD	cis	rs10515750	0.643	rs10054755	ENSG00000251405.2	CTB-109A12.1	12.97	6.04e-33	1.39e-29	0.98	0.52	Lung function (FEV1/FVC);	chr5:157384037	chr5:157362615~157460078:-
PRAD	cis	rs10515750	0.643	rs10063539	ENSG00000251405.2	CTB-109A12.1	12.97	6.04e-33	1.39e-29	0.98	0.52	Lung function (FEV1/FVC);	chr5:157384666	chr5:157362615~157460078:-
PRAD	cis	rs11673344	0.832	rs76470527	ENSG00000226686.6	LINC01535	12.97	6.05e-33	1.4e-29	0.74	0.52	Obesity-related traits;	chr19:37035981	chr19:37251912~37265535:+
PRAD	cis	rs1930961	1	rs59226697	ENSG00000100058.11	CRYBB2P1	12.96	6.27e-33	1.45e-29	1.01	0.52	Bipolar disorder with mood-incongruent psychosis;	chr22:25474070	chr22:25448105~25520854:+
PRAD	cis	rs9326248	1	rs664971	ENSG00000280143.1	AP000892.6	-12.96	6.28e-33	1.45e-29	-0.44	-0.52	Blood protein levels;	chr11:117200141	chr11:117204967~117210292:+
PRAD	cis	rs2919917	0.915	rs2953477	ENSG00000254352.1	RP11-578O24.2	12.96	6.35e-33	1.46e-29	0.64	0.52	Lymphocyte counts;	chr8:78712370	chr8:78723796~78724136:-
PRAD	cis	rs3091242	0.934	rs686631	ENSG00000261349.1	RP3-465N24.5	-12.96	6.39e-33	1.47e-29	-0.57	-0.52	Erythrocyte sedimentation rate;	chr1:25393108	chr1:25266102~25267136:-
PRAD	cis	rs977987	0.806	rs72787160	ENSG00000261783.1	RP11-252K23.2	-12.96	6.43e-33	1.48e-29	-0.71	-0.52	Dupuytren's disease;	chr16:75411264	chr16:75379818~75381260:-
PRAD	cis	rs2919917	1	rs2717539	ENSG00000254352.1	RP11-578O24.2	12.96	6.44e-33	1.48e-29	0.64	0.52	Lymphocyte counts;	chr8:78716804	chr8:78723796~78724136:-
PRAD	cis	rs2919917	0.793	rs2625664	ENSG00000254352.1	RP11-578O24.2	12.96	6.44e-33	1.48e-29	0.64	0.52	Lymphocyte counts;	chr8:78718373	chr8:78723796~78724136:-
PRAD	cis	rs2919917	1	rs2717538	ENSG00000254352.1	RP11-578O24.2	12.96	6.44e-33	1.48e-29	0.64	0.52	Lymphocyte counts;	chr8:78720914	chr8:78723796~78724136:-
PRAD	cis	rs9545047	1	rs9545073	ENSG00000227676.3	LINC01068	12.96	6.61e-33	1.52e-29	0.66	0.52	Schizophrenia;	chr13:79334872	chr13:79566727~79571436:+
PRAD	cis	rs524281	0.861	rs9736673	ENSG00000255320.1	RP11-755F10.1	12.96	6.71e-33	1.54e-29	0.8	0.52	Electroencephalogram traits;	chr11:66156553	chr11:66244840~66246239:-
PRAD	cis	rs73086581	0.786	rs6037705	ENSG00000229539.1	RP11-119B16.2	12.96	6.72e-33	1.55e-29	0.83	0.52	Response to antidepressants in depression;	chr20:3972183	chr20:3888239~3888868:-
PRAD	cis	rs73086581	0.945	rs6037715	ENSG00000229539.1	RP11-119B16.2	12.96	6.72e-33	1.55e-29	0.83	0.52	Response to antidepressants in depression;	chr20:3991519	chr20:3888239~3888868:-
PRAD	cis	rs73086581	1	rs17215529	ENSG00000229539.1	RP11-119B16.2	12.96	6.72e-33	1.55e-29	0.83	0.52	Response to antidepressants in depression;	chr20:3994755	chr20:3888239~3888868:-
PRAD	cis	rs977987	0.843	rs6564259	ENSG00000261783.1	RP11-252K23.2	-12.96	6.78e-33	1.56e-29	-0.7	-0.52	Dupuytren's disease;	chr16:75413495	chr16:75379818~75381260:-
PRAD	cis	rs6964833	0.935	rs13238996	ENSG00000277053.3	GTF2IP1	-12.95	6.84e-33	1.57e-29	-0.63	-0.52	Menarche (age at onset);	chr7:74655318	chr7:75185385~75237696:-
PRAD	cis	rs73086581	1	rs6107393	ENSG00000229539.1	RP11-119B16.2	12.95	6.87e-33	1.58e-29	0.84	0.52	Response to antidepressants in depression;	chr20:4007091	chr20:3888239~3888868:-
PRAD	cis	rs2658782	0.951	rs2608215	ENSG00000279684.1	RP11-755E23.2	-12.95	6.88e-33	1.58e-29	-0.84	-0.52	Pulmonary function decline;	chr11:93415651	chr11:93286629~93288903:-
PRAD	cis	rs977987	0.75	rs4888414	ENSG00000261783.1	RP11-252K23.2	-12.95	6.99e-33	1.61e-29	-0.7	-0.52	Dupuytren's disease;	chr16:75413335	chr16:75379818~75381260:-
PRAD	cis	rs977987	0.806	rs6564258	ENSG00000261783.1	RP11-252K23.2	-12.95	6.99e-33	1.61e-29	-0.7	-0.52	Dupuytren's disease;	chr16:75413465	chr16:75379818~75381260:-
PRAD	cis	rs977987	0.806	rs8056236	ENSG00000261783.1	RP11-252K23.2	-12.95	6.99e-33	1.61e-29	-0.7	-0.52	Dupuytren's disease;	chr16:75414375	chr16:75379818~75381260:-
PRAD	cis	rs2658782	0.547	rs3020054	ENSG00000279684.1	RP11-755E23.2	-12.95	7.03e-33	1.62e-29	-0.75	-0.52	Pulmonary function decline;	chr11:93322390	chr11:93286629~93288903:-
PRAD	cis	rs3091242	0.933	rs28633797	ENSG00000261349.1	RP3-465N24.5	-12.95	7.05e-33	1.62e-29	-0.58	-0.52	Erythrocyte sedimentation rate;	chr1:25415138	chr1:25266102~25267136:-
PRAD	cis	rs9326248	0.581	rs11216242	ENSG00000254851.1	RP11-109L13.1	-12.95	7.07e-33	1.63e-29	-0.65	-0.52	Blood protein levels;	chr11:117030833	chr11:117135528~117138582:+
PRAD	cis	rs9326248	0.581	rs12804122	ENSG00000254851.1	RP11-109L13.1	-12.95	7.07e-33	1.63e-29	-0.65	-0.52	Blood protein levels;	chr11:117031900	chr11:117135528~117138582:+
PRAD	cis	rs950027	0.787	rs1153845	ENSG00000259520.4	CTD-2651B20.3	12.95	7.19e-33	1.65e-29	0.64	0.52	Response to fenofibrate (adiponectin levels);	chr15:45432531	chr15:45251580~45279251:-
PRAD	cis	rs2919917	1	rs1026920	ENSG00000254352.1	RP11-578O24.2	12.95	7.21e-33	1.66e-29	0.64	0.52	Lymphocyte counts;	chr8:78719775	chr8:78723796~78724136:-
PRAD	cis	rs2658782	0.547	rs3133454	ENSG00000279684.1	RP11-755E23.2	-12.95	7.26e-33	1.67e-29	-0.76	-0.52	Pulmonary function decline;	chr11:93325853	chr11:93286629~93288903:-
PRAD	cis	rs2739330	0.731	rs2000468	ENSG00000231271.1	AP000350.8	12.95	7.34e-33	1.69e-29	0.7	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23949918~23954042:+
PRAD	cis	rs524281	0.861	rs6591207	ENSG00000255320.1	RP11-755F10.1	12.95	7.44e-33	1.71e-29	0.8	0.52	Electroencephalogram traits;	chr11:66182203	chr11:66244840~66246239:-
PRAD	cis	rs801193	0.569	rs10950050	ENSG00000226824.5	RP4-756H11.3	-12.94	7.59e-33	1.74e-29	-0.72	-0.52	Aortic root size;	chr7:66774601	chr7:66654538~66669855:+
PRAD	cis	rs2019137	0.56	rs4849179	ENSG00000274877.1	RP11-65I12.1	-12.94	7.8e-33	1.79e-29	-0.71	-0.52	Lymphocyte counts;	chr2:113227593	chr2:113237595~113240825:+
PRAD	cis	rs2019137	0.539	rs6755040	ENSG00000274877.1	RP11-65I12.1	-12.94	7.84e-33	1.8e-29	-0.71	-0.52	Lymphocyte counts;	chr2:113223560	chr2:113237595~113240825:+
PRAD	cis	rs2019137	0.539	rs4849177	ENSG00000274877.1	RP11-65I12.1	-12.94	7.84e-33	1.8e-29	-0.71	-0.52	Lymphocyte counts;	chr2:113225007	chr2:113237595~113240825:+
PRAD	cis	rs1577917	0.727	rs9444361	ENSG00000203875.9	SNHG5	12.94	7.88e-33	1.81e-29	0.59	0.52	Response to antipsychotic treatment;	chr6:85691182	chr6:85660950~85678736:-
PRAD	cis	rs4845570	1	rs6673002	ENSG00000249602.1	RP11-98D18.3	-12.94	8.04e-33	1.84e-29	-0.78	-0.52	Coronary artery disease;	chr1:151770799	chr1:151763384~151769501:-
PRAD	cis	rs4718428	0.705	rs3800817	ENSG00000226824.5	RP4-756H11.3	-12.94	8.11e-33	1.86e-29	-0.7	-0.52	Corneal structure;	chr7:66798563	chr7:66654538~66669855:+
PRAD	cis	rs9322193	0.772	rs7738696	ENSG00000268592.3	RAET1E-AS1	12.93	8.28e-33	1.9e-29	0.7	0.52	Lung cancer;	chr6:149848985	chr6:149863494~149919507:+
PRAD	cis	rs2658782	0.547	rs3020065	ENSG00000279684.1	RP11-755E23.2	-12.93	8.34e-33	1.91e-29	-0.76	-0.52	Pulmonary function decline;	chr11:93326733	chr11:93286629~93288903:-
PRAD	cis	rs9326248	0.581	rs10502222	ENSG00000254851.1	RP11-109L13.1	-12.93	8.48e-33	1.94e-29	-0.65	-0.52	Blood protein levels;	chr11:116963014	chr11:117135528~117138582:+
PRAD	cis	rs9326248	0.559	rs10892052	ENSG00000254851.1	RP11-109L13.1	-12.93	8.48e-33	1.94e-29	-0.65	-0.52	Blood protein levels;	chr11:116963597	chr11:117135528~117138582:+
PRAD	cis	rs2283792	0.765	rs34550586	ENSG00000224086.5	LL22NC03-86G7.1	-12.93	8.58e-33	1.96e-29	-0.6	-0.52	Multiple sclerosis;	chr22:21791345	chr22:21938293~21977632:+
PRAD	cis	rs4423214	0.515	rs4944042	ENSG00000254682.1	RP11-660L16.2	12.93	8.69e-33	1.99e-29	0.63	0.52	Vitamin D levels;	chr11:71407742	chr11:71448674~71452157:+
PRAD	cis	rs524281	0.817	rs10896097	ENSG00000255320.1	RP11-755F10.1	12.93	8.78e-33	2.01e-29	0.78	0.52	Electroencephalogram traits;	chr11:66200482	chr11:66244840~66246239:-
PRAD	cis	rs8072100	0.934	rs6504872	ENSG00000228782.6	CTD-2026D20.3	12.93	8.87e-33	2.03e-29	0.56	0.52	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47361586	chr17:47450568~47492492:-
PRAD	cis	rs977987	0.806	rs1895490	ENSG00000261783.1	RP11-252K23.2	-12.93	9.01e-33	2.06e-29	-0.69	-0.52	Dupuytren's disease;	chr16:75358908	chr16:75379818~75381260:-
PRAD	cis	rs9322193	0.884	rs7743823	ENSG00000223701.3	RAET1E-AS1	12.92	9.07e-33	2.07e-29	0.69	0.52	Lung cancer;	chr6:149849744	chr6:149884431~149919508:+
PRAD	cis	rs977987	0.778	rs1109341	ENSG00000261783.1	RP11-252K23.2	-12.92	9.08e-33	2.08e-29	-0.7	-0.52	Dupuytren's disease;	chr16:75411707	chr16:75379818~75381260:-
PRAD	cis	rs10262624	0.528	rs5029444	ENSG00000234286.1	AC006026.13	12.92	9.68e-33	2.21e-29	0.58	0.52	Schizophrenia;	chr7:23698176	chr7:23680195~23680786:-
PRAD	cis	rs9399135	0.967	rs12527683	ENSG00000232876.1	CTA-212D2.2	-12.92	9.7e-33	2.21e-29	-0.63	-0.52	Red blood cell count;	chr6:135003396	chr6:135055033~135060550:+
PRAD	cis	rs2739330	0.685	rs4822453	ENSG00000231271.1	AP000350.8	12.92	9.86e-33	2.25e-29	0.68	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23949918~23954042:+
PRAD	cis	rs977987	0.966	rs8055490	ENSG00000261783.1	RP11-252K23.2	-12.91	9.98e-33	2.28e-29	-0.72	-0.52	Dupuytren's disease;	chr16:75463237	chr16:75379818~75381260:-
PRAD	cis	rs4845570	0.92	rs10788809	ENSG00000249602.1	RP11-98D18.3	-12.91	1e-32	2.28e-29	-0.8	-0.52	Coronary artery disease;	chr1:151788316	chr1:151763384~151769501:-
PRAD	cis	rs9545047	1	rs9574422	ENSG00000227676.3	LINC01068	12.91	1.04e-32	2.37e-29	0.67	0.52	Schizophrenia;	chr13:79415246	chr13:79566727~79571436:+
PRAD	cis	rs9399135	0.967	rs3756799	ENSG00000232876.1	CTA-212D2.2	-12.91	1.04e-32	2.37e-29	-0.63	-0.52	Red blood cell count;	chr6:135019873	chr6:135055033~135060550:+
PRAD	cis	rs6964833	1	rs17515241	ENSG00000277053.3	GTF2IP1	12.91	1.04e-32	2.38e-29	0.61	0.52	Menarche (age at onset);	chr7:74717695	chr7:75185385~75237696:-
PRAD	cis	rs977987	0.806	rs7188604	ENSG00000261783.1	RP11-252K23.2	-12.91	1.05e-32	2.38e-29	-0.7	-0.52	Dupuytren's disease;	chr16:75417272	chr16:75379818~75381260:-
PRAD	cis	rs9326248	0.581	rs6589582	ENSG00000254851.1	RP11-109L13.1	-12.91	1.05e-32	2.39e-29	-0.65	-0.52	Blood protein levels;	chr11:116958484	chr11:117135528~117138582:+
PRAD	cis	rs2919917	1	rs28429528	ENSG00000254352.1	RP11-578O24.2	12.91	1.05e-32	2.39e-29	0.62	0.52	Lymphocyte counts;	chr8:78678782	chr8:78723796~78724136:-
PRAD	cis	rs8046696	1	rs8046696	ENSG00000261783.1	RP11-252K23.2	-12.91	1.05e-32	2.4e-29	-0.7	-0.52	Coronary artery disease;	chr16:75408245	chr16:75379818~75381260:-
PRAD	cis	rs977987	0.737	rs8046697	ENSG00000261783.1	RP11-252K23.2	-12.91	1.05e-32	2.4e-29	-0.7	-0.52	Dupuytren's disease;	chr16:75408246	chr16:75379818~75381260:-
PRAD	cis	rs17826219	0.636	rs12946563	ENSG00000263531.1	RP13-753N3.1	12.91	1.07e-32	2.43e-29	1	0.52	Body mass index;	chr17:30776148	chr17:30863921~30864940:-
PRAD	cis	rs9322193	0.962	rs2342764	ENSG00000223701.3	RAET1E-AS1	12.91	1.07e-32	2.43e-29	0.69	0.52	Lung cancer;	chr6:149835068	chr6:149884431~149919508:+
PRAD	cis	rs977987	0.806	rs8051407	ENSG00000261783.1	RP11-252K23.2	-12.91	1.09e-32	2.49e-29	-0.7	-0.52	Dupuytren's disease;	chr16:75414761	chr16:75379818~75381260:-
PRAD	cis	rs977987	0.806	rs4888416	ENSG00000261783.1	RP11-252K23.2	-12.91	1.09e-32	2.49e-29	-0.7	-0.52	Dupuytren's disease;	chr16:75415278	chr16:75379818~75381260:-
PRAD	cis	rs977987	0.806	rs7199132	ENSG00000261783.1	RP11-252K23.2	-12.91	1.09e-32	2.49e-29	-0.7	-0.52	Dupuytren's disease;	chr16:75416141	chr16:75379818~75381260:-
PRAD	cis	rs977987	0.843	rs12149063	ENSG00000261783.1	RP11-252K23.2	-12.91	1.09e-32	2.49e-29	-0.7	-0.52	Dupuytren's disease;	chr16:75417860	chr16:75379818~75381260:-
PRAD	cis	rs977987	0.806	rs11642572	ENSG00000261783.1	RP11-252K23.2	-12.91	1.09e-32	2.49e-29	-0.7	-0.52	Dupuytren's disease;	chr16:75418884	chr16:75379818~75381260:-
PRAD	cis	rs11723261	0.621	rs61794960	ENSG00000275426.1	CH17-262A2.1	12.9	1.1e-32	2.49e-29	0.79	0.52	Immune response to smallpox vaccine (IL-6);	chr4:156661	chr4:149738~150317:+
PRAD	cis	rs3931020	0.745	rs1980851	ENSG00000272864.1	RP11-17E13.2	-12.9	1.11e-32	2.53e-29	-0.54	-0.52	Resistin levels;	chr1:74803287	chr1:74698769~74699333:-
PRAD	cis	rs73086581	1	rs6107391	ENSG00000229539.1	RP11-119B16.2	12.9	1.13e-32	2.58e-29	0.85	0.52	Response to antidepressants in depression;	chr20:4002436	chr20:3888239~3888868:-
PRAD	cis	rs977987	0.966	rs62060551	ENSG00000261783.1	RP11-252K23.2	-12.9	1.15e-32	2.61e-29	-0.72	-0.52	Dupuytren's disease;	chr16:75468414	chr16:75379818~75381260:-
PRAD	cis	rs9545047	1	rs9545047	ENSG00000227676.3	LINC01068	12.9	1.15e-32	2.61e-29	0.66	0.52	Schizophrenia;	chr13:79285321	chr13:79566727~79571436:+
PRAD	cis	rs12049351	0.774	rs4148758	ENSG00000229367.1	HMGN2P19	12.9	1.18e-32	2.67e-29	0.74	0.52	Circulating myeloperoxidase levels (plasma);	chr1:229557919	chr1:229570532~229570796:+
PRAD	cis	rs875971	0.825	rs28480509	ENSG00000226824.5	RP4-756H11.3	12.9	1.18e-32	2.69e-29	0.71	0.52	Aortic root size;	chr7:66634237	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.862	rs9791712	ENSG00000226824.5	RP4-756H11.3	12.9	1.18e-32	2.69e-29	0.71	0.52	Aortic root size;	chr7:66640176	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.862	rs9791713	ENSG00000226824.5	RP4-756H11.3	12.9	1.18e-32	2.69e-29	0.71	0.52	Aortic root size;	chr7:66640211	chr7:66654538~66669855:+
PRAD	cis	rs12022452	1	rs2184877	ENSG00000238287.1	RP11-656D10.3	-12.9	1.19e-32	2.7e-29	-0.89	-0.52	Age-related hearing impairment (SNP x SNP interaction);	chr1:40531260	chr1:40493157~40508661:-
PRAD	cis	rs7617773	0.962	rs6797587	ENSG00000229759.1	MRPS18AP1	-12.9	1.2e-32	2.71e-29	-0.56	-0.52	Coronary artery disease;	chr3:48156124	chr3:48256350~48256938:-
PRAD	cis	rs3091242	0.933	rs35530120	ENSG00000224183.1	SDHDP6	12.89	1.22e-32	2.76e-29	0.6	0.52	Erythrocyte sedimentation rate;	chr1:25458960	chr1:25294164~25294643:-
PRAD	cis	rs977987	0.933	rs4888431	ENSG00000261783.1	RP11-252K23.2	-12.89	1.22e-32	2.77e-29	-0.72	-0.52	Dupuytren's disease;	chr16:75466801	chr16:75379818~75381260:-
PRAD	cis	rs977987	1	rs62060550	ENSG00000261783.1	RP11-252K23.2	-12.89	1.22e-32	2.77e-29	-0.72	-0.52	Dupuytren's disease;	chr16:75468354	chr16:75379818~75381260:-
PRAD	cis	rs977987	0.645	rs10871311	ENSG00000261783.1	RP11-252K23.2	-12.89	1.24e-32	2.8e-29	-0.7	-0.52	Dupuytren's disease;	chr16:75417014	chr16:75379818~75381260:-
PRAD	cis	rs67383717	0.689	rs1836404	ENSG00000175611.10	LINC00476	-12.89	1.25e-32	2.82e-29	-0.61	-0.52	Parkinson's disease (pesticide exposure interaction);	chr9:95787982	chr9:95759231~95875977:-
PRAD	cis	rs2919917	1	rs10093127	ENSG00000254352.1	RP11-578O24.2	12.89	1.25e-32	2.83e-29	0.62	0.52	Lymphocyte counts;	chr8:78686869	chr8:78723796~78724136:-
PRAD	cis	rs4845570	0.92	rs6694952	ENSG00000249602.1	RP11-98D18.3	-12.89	1.28e-32	2.91e-29	-0.79	-0.52	Coronary artery disease;	chr1:151787655	chr1:151763384~151769501:-
PRAD	cis	rs3091242	0.866	rs11249249	ENSG00000261349.1	RP3-465N24.5	-12.89	1.29e-32	2.91e-29	-0.57	-0.52	Erythrocyte sedimentation rate;	chr1:25431643	chr1:25266102~25267136:-
PRAD	cis	rs2919917	1	rs3736169	ENSG00000254352.1	RP11-578O24.2	12.89	1.29e-32	2.93e-29	0.62	0.52	Lymphocyte counts;	chr8:78675620	chr8:78723796~78724136:-
PRAD	cis	rs3931020	0.72	rs1327090	ENSG00000272864.1	RP11-17E13.2	-12.89	1.3e-32	2.93e-29	-0.54	-0.52	Resistin levels;	chr1:74800795	chr1:74698769~74699333:-
PRAD	cis	rs2919917	1	rs2046338	ENSG00000254352.1	RP11-578O24.2	12.89	1.3e-32	2.94e-29	0.64	0.52	Lymphocyte counts;	chr8:78723734	chr8:78723796~78724136:-
PRAD	cis	rs524281	0.861	rs10791856	ENSG00000255320.1	RP11-755F10.1	12.89	1.32e-32	2.98e-29	0.78	0.52	Electroencephalogram traits;	chr11:66197179	chr11:66244840~66246239:-
PRAD	cis	rs9326248	0.817	rs1242127	ENSG00000280143.1	AP000892.6	-12.88	1.33e-32	3.01e-29	-0.44	-0.52	Blood protein levels;	chr11:117205848	chr11:117204967~117210292:+
PRAD	cis	rs5760092	0.755	rs4585126	ENSG00000218537.1	MIF-AS1	-12.88	1.34e-32	3.03e-29	-0.76	-0.52	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23894426~23898930:-
PRAD	cis	rs3091242	0.933	rs61775174	ENSG00000224183.1	SDHDP6	12.88	1.35e-32	3.05e-29	0.61	0.52	Erythrocyte sedimentation rate;	chr1:25460822	chr1:25294164~25294643:-
PRAD	cis	rs7044106	0.791	rs4617229	ENSG00000226752.6	PSMD5-AS1	-12.88	1.38e-32	3.12e-29	-0.63	-0.52	Hip circumference adjusted for BMI;	chr9:120718418	chr9:120824828~120854385:+
PRAD	cis	rs524281	0.814	rs1055615	ENSG00000255320.1	RP11-755F10.1	12.88	1.45e-32	3.27e-29	0.81	0.52	Electroencephalogram traits;	chr11:66079451	chr11:66244840~66246239:-
PRAD	cis	rs7208859	0.623	rs8067035	ENSG00000263531.1	RP13-753N3.1	12.88	1.45e-32	3.28e-29	1	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775170	chr17:30863921~30864940:-
PRAD	cis	rs4722166	0.63	rs12537614	ENSG00000179428.2	AC073072.5	-12.87	1.48e-32	3.34e-29	-0.63	-0.52	Lung cancer;	chr7:22749932	chr7:22725395~22727620:-
PRAD	cis	rs3096299	0.685	rs4785571	ENSG00000274627.1	RP11-104N10.2	12.87	1.49e-32	3.37e-29	0.54	0.52	Multiple myeloma (IgH translocation);	chr16:89498761	chr16:89516797~89522217:+
PRAD	cis	rs11690935	0.851	rs7581072	ENSG00000228389.1	AC068039.4	12.87	1.52e-32	3.42e-29	0.61	0.52	Schizophrenia;	chr2:171994938	chr2:171773482~171775844:+
PRAD	cis	rs977987	0.843	rs10431974	ENSG00000261783.1	RP11-252K23.2	-12.87	1.53e-32	3.45e-29	-0.71	-0.52	Dupuytren's disease;	chr16:75401563	chr16:75379818~75381260:-
PRAD	cis	rs977987	0.806	rs4993969	ENSG00000261783.1	RP11-252K23.2	-12.87	1.53e-32	3.45e-29	-0.69	-0.52	Dupuytren's disease;	chr16:75377623	chr16:75379818~75381260:-
PRAD	cis	rs9399135	0.967	rs6909975	ENSG00000232876.1	CTA-212D2.2	-12.87	1.54e-32	3.47e-29	-0.63	-0.52	Red blood cell count;	chr6:134994432	chr6:135055033~135060550:+
PRAD	cis	rs9399135	0.967	rs7773126	ENSG00000232876.1	CTA-212D2.2	-12.87	1.54e-32	3.47e-29	-0.63	-0.52	Red blood cell count;	chr6:134997252	chr6:135055033~135060550:+
PRAD	cis	rs977987	0.806	rs2865530	ENSG00000261783.1	RP11-252K23.2	-12.87	1.55e-32	3.49e-29	-0.7	-0.52	Dupuytren's disease;	chr16:75380478	chr16:75379818~75381260:-
PRAD	cis	rs1577917	0.771	rs12199873	ENSG00000203875.9	SNHG5	-12.87	1.57e-32	3.54e-29	-0.59	-0.52	Response to antipsychotic treatment;	chr6:85585229	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.771	rs2842609	ENSG00000203875.9	SNHG5	-12.87	1.57e-32	3.54e-29	-0.59	-0.52	Response to antipsychotic treatment;	chr6:85587070	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.771	rs2842612	ENSG00000203875.9	SNHG5	-12.87	1.57e-32	3.54e-29	-0.59	-0.52	Response to antipsychotic treatment;	chr6:85593373	chr6:85660950~85678736:-
PRAD	cis	rs3096299	0.685	rs8050512	ENSG00000274627.1	RP11-104N10.2	12.86	1.61e-32	3.64e-29	0.51	0.52	Multiple myeloma (IgH translocation);	chr16:89485912	chr16:89516797~89522217:+
PRAD	cis	rs1577917	0.771	rs4351223	ENSG00000203875.9	SNHG5	12.86	1.63e-32	3.67e-29	0.59	0.52	Response to antipsychotic treatment;	chr6:85528079	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.771	rs7452605	ENSG00000203875.9	SNHG5	12.86	1.63e-32	3.67e-29	0.59	0.52	Response to antipsychotic treatment;	chr6:85531233	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.771	rs9294337	ENSG00000203875.9	SNHG5	12.86	1.63e-32	3.67e-29	0.59	0.52	Response to antipsychotic treatment;	chr6:85538742	chr6:85660950~85678736:-
PRAD	cis	rs9326248	0.569	rs10892082	ENSG00000254851.1	RP11-109L13.1	-12.86	1.72e-32	3.87e-29	-1.02	-0.52	Blood protein levels;	chr11:117168609	chr11:117135528~117138582:+
PRAD	cis	rs3814244	0.528	rs61923060	ENSG00000255733.4	IFNG-AS1	12.86	1.74e-32	3.91e-29	0.55	0.52	Itch intensity from mosquito bite adjusted by bite size;	chr12:67997341	chr12:67989445~68234686:+
PRAD	cis	rs3096299	0.658	rs4785679	ENSG00000274627.1	RP11-104N10.2	12.85	1.79e-32	4.02e-29	0.52	0.52	Multiple myeloma (IgH translocation);	chr16:89499705	chr16:89516797~89522217:+
PRAD	cis	rs11690935	0.851	rs10174055	ENSG00000228389.1	AC068039.4	12.85	1.8e-32	4.04e-29	0.61	0.52	Schizophrenia;	chr2:171993303	chr2:171773482~171775844:+
PRAD	cis	rs2658782	0.951	rs117384439	ENSG00000279684.1	RP11-755E23.2	12.85	1.82e-32	4.09e-29	0.84	0.52	Pulmonary function decline;	chr11:93378312	chr11:93286629~93288903:-
PRAD	cis	rs524281	0.861	rs10896095	ENSG00000255320.1	RP11-755F10.1	12.85	1.82e-32	4.1e-29	0.78	0.52	Electroencephalogram traits;	chr11:66195089	chr11:66244840~66246239:-
PRAD	cis	rs977987	0.815	rs11149821	ENSG00000261783.1	RP11-252K23.2	-12.85	1.86e-32	4.17e-29	-0.69	-0.52	Dupuytren's disease;	chr16:75388919	chr16:75379818~75381260:-
PRAD	cis	rs9322193	0.884	rs9383864	ENSG00000223701.3	RAET1E-AS1	12.85	1.91e-32	4.29e-29	0.68	0.52	Lung cancer;	chr6:149851969	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.884	rs1108889	ENSG00000268592.3	RAET1E-AS1	12.85	1.92e-32	4.3e-29	0.71	0.52	Lung cancer;	chr6:149845433	chr6:149863494~149919507:+
PRAD	cis	rs2658782	0.756	rs3019222	ENSG00000279684.1	RP11-755E23.2	-12.85	1.93e-32	4.34e-29	-0.84	-0.52	Pulmonary function decline;	chr11:93346552	chr11:93286629~93288903:-
PRAD	cis	rs9399135	0.967	rs13218642	ENSG00000232876.1	CTA-212D2.2	-12.84	1.97e-32	4.41e-29	-0.63	-0.52	Red blood cell count;	chr6:134988802	chr6:135055033~135060550:+
PRAD	cis	rs977987	0.778	rs11149825	ENSG00000261783.1	RP11-252K23.2	-12.84	2e-32	4.49e-29	-0.7	-0.52	Dupuytren's disease;	chr16:75400980	chr16:75379818~75381260:-
PRAD	cis	rs4423214	0.84	rs4435028	ENSG00000254682.1	RP11-660L16.2	-12.84	2.01e-32	4.5e-29	-0.75	-0.52	Vitamin D levels;	chr11:71472644	chr11:71448674~71452157:+
PRAD	cis	rs4423214	0.802	rs4616066	ENSG00000254682.1	RP11-660L16.2	-12.84	2.01e-32	4.5e-29	-0.75	-0.52	Vitamin D levels;	chr11:71472800	chr11:71448674~71452157:+
PRAD	cis	rs4423214	0.802	rs4402322	ENSG00000254682.1	RP11-660L16.2	-12.84	2.01e-32	4.5e-29	-0.75	-0.52	Vitamin D levels;	chr11:71472969	chr11:71448674~71452157:+
PRAD	cis	rs4423214	0.84	rs3794057	ENSG00000254682.1	RP11-660L16.2	-12.84	2.01e-32	4.5e-29	-0.75	-0.52	Vitamin D levels;	chr11:71475698	chr11:71448674~71452157:+
PRAD	cis	rs4423214	0.84	rs2017686	ENSG00000254682.1	RP11-660L16.2	-12.84	2.01e-32	4.5e-29	-0.75	-0.52	Vitamin D levels;	chr11:71476015	chr11:71448674~71452157:+
PRAD	cis	rs9326248	0.581	rs7120963	ENSG00000254851.1	RP11-109L13.1	12.84	2.02e-32	4.53e-29	0.64	0.52	Blood protein levels;	chr11:116959545	chr11:117135528~117138582:+
PRAD	cis	rs2283792	0.677	rs13340063	ENSG00000224086.5	LL22NC03-86G7.1	12.84	2.06e-32	4.61e-29	0.62	0.52	Multiple sclerosis;	chr22:21742717	chr22:21938293~21977632:+
PRAD	cis	rs9399135	0.967	rs4451151	ENSG00000232876.1	CTA-212D2.2	-12.84	2.08e-32	4.65e-29	-0.62	-0.52	Red blood cell count;	chr6:134989408	chr6:135055033~135060550:+
PRAD	cis	rs4660456	0.913	rs2361651	ENSG00000237899.1	RP4-739H11.3	12.84	2.09e-32	4.69e-29	0.76	0.52	Platelet count;	chr1:40764542	chr1:40669089~40687588:-
PRAD	cis	rs9326248	0.581	rs7120706	ENSG00000254851.1	RP11-109L13.1	12.84	2.09e-32	4.69e-29	0.64	0.52	Blood protein levels;	chr11:116959371	chr11:117135528~117138582:+
PRAD	cis	rs2658782	0.547	rs3020052	ENSG00000279684.1	RP11-755E23.2	-12.84	2.1e-32	4.71e-29	-0.75	-0.52	Pulmonary function decline;	chr11:93322018	chr11:93286629~93288903:-
PRAD	cis	rs977987	0.843	rs6564260	ENSG00000261783.1	RP11-252K23.2	-12.83	2.14e-32	4.77e-29	-0.7	-0.52	Dupuytren's disease;	chr16:75413528	chr16:75379818~75381260:-
PRAD	cis	rs1062177	1	rs2347596	ENSG00000213433.5	RPLP1P6	-12.83	2.15e-32	4.8e-29	-0.6	-0.52	Preschool internalizing problems;	chr5:151799638	chr5:151765859~151766378:-
PRAD	cis	rs9399135	0.967	rs6910530	ENSG00000232876.1	CTA-212D2.2	-12.83	2.21e-32	4.92e-29	-0.62	-0.52	Red blood cell count;	chr6:135011632	chr6:135055033~135060550:+
PRAD	cis	rs977987	0.806	rs4888388	ENSG00000261783.1	RP11-252K23.2	-12.83	2.22e-32	4.96e-29	-0.69	-0.52	Dupuytren's disease;	chr16:75360250	chr16:75379818~75381260:-
PRAD	cis	rs1577917	0.727	rs2758840	ENSG00000203875.9	SNHG5	-12.83	2.27e-32	5.06e-29	-0.59	-0.52	Response to antipsychotic treatment;	chr6:85594907	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.771	rs9362230	ENSG00000203875.9	SNHG5	-12.83	2.27e-32	5.06e-29	-0.59	-0.52	Response to antipsychotic treatment;	chr6:85595295	chr6:85660950~85678736:-
PRAD	cis	rs977987	0.778	rs4888400	ENSG00000261783.1	RP11-252K23.2	-12.83	2.27e-32	5.07e-29	-0.69	-0.52	Dupuytren's disease;	chr16:75391698	chr16:75379818~75381260:-
PRAD	cis	rs9399135	0.967	rs6923827	ENSG00000232876.1	CTA-212D2.2	-12.83	2.28e-32	5.08e-29	-0.62	-0.52	Red blood cell count;	chr6:135014244	chr6:135055033~135060550:+
PRAD	cis	rs6142102	0.625	rs6142067	ENSG00000276073.1	RP5-1125A11.7	-12.83	2.28e-32	5.09e-29	-0.51	-0.52	Skin pigmentation;	chr20:33968766	chr20:33985617~33988989:-
PRAD	cis	rs4423214	0.61	rs12793607	ENSG00000254682.1	RP11-660L16.2	-12.83	2.29e-32	5.1e-29	-0.61	-0.52	Vitamin D levels;	chr11:71418270	chr11:71448674~71452157:+
PRAD	cis	rs4718428	0.705	rs2901311	ENSG00000226824.5	RP4-756H11.3	-12.83	2.31e-32	5.15e-29	-0.71	-0.52	Corneal structure;	chr7:66950082	chr7:66654538~66669855:+
PRAD	cis	rs2658782	0.789	rs56091149	ENSG00000279684.1	RP11-755E23.2	12.83	2.33e-32	5.19e-29	0.86	0.52	Pulmonary function decline;	chr11:93340474	chr11:93286629~93288903:-
PRAD	cis	rs9399135	0.967	rs12661423	ENSG00000232876.1	CTA-212D2.2	-12.83	2.34e-32	5.22e-29	-0.62	-0.52	Red blood cell count;	chr6:135028432	chr6:135055033~135060550:+
PRAD	cis	rs6504950	1	rs9902718	ENSG00000275710.1	RP11-257O5.4	12.82	2.37e-32	5.29e-29	0.69	0.52	Breast cancer;	chr17:54984261	chr17:54964474~54964679:+
PRAD	cis	rs6142102	0.58	rs4911139	ENSG00000276073.1	RP5-1125A11.7	-12.82	2.39e-32	5.33e-29	-0.5	-0.52	Skin pigmentation;	chr20:33963729	chr20:33985617~33988989:-
PRAD	cis	rs2919917	1	rs13280202	ENSG00000254352.1	RP11-578O24.2	-12.82	2.4e-32	5.34e-29	-0.63	-0.52	Lymphocyte counts;	chr8:78700238	chr8:78723796~78724136:-
PRAD	cis	rs977987	0.806	rs4888418	ENSG00000261783.1	RP11-252K23.2	-12.82	2.44e-32	5.43e-29	-0.7	-0.52	Dupuytren's disease;	chr16:75426408	chr16:75379818~75381260:-
PRAD	cis	rs2455601	0.766	rs1109304	ENSG00000254860.4	TMEM9B-AS1	12.82	2.45e-32	5.46e-29	0.64	0.52	Schizophrenia;	chr11:8933908	chr11:8964675~8977527:+
PRAD	cis	rs6452524	0.618	rs6452501	ENSG00000249664.1	CTD-2227C6.2	12.82	2.48e-32	5.52e-29	0.58	0.52	Hypertension (SNP x SNP interaction);	chr5:83068681	chr5:83012285~83013109:-
PRAD	cis	rs3096299	0.719	rs2353581	ENSG00000274627.1	RP11-104N10.2	12.81	2.59e-32	5.75e-29	0.53	0.51	Multiple myeloma (IgH translocation);	chr16:89452500	chr16:89516797~89522217:+
PRAD	cis	rs9545047	0.967	rs3903388	ENSG00000227676.3	LINC01068	12.81	2.61e-32	5.79e-29	0.66	0.51	Schizophrenia;	chr13:79330686	chr13:79566727~79571436:+
PRAD	cis	rs524281	0.861	rs10896090	ENSG00000255320.1	RP11-755F10.1	12.81	2.63e-32	5.85e-29	0.85	0.51	Electroencephalogram traits;	chr11:66177715	chr11:66244840~66246239:-
PRAD	cis	rs9399135	0.967	rs4896121	ENSG00000232876.1	CTA-212D2.2	-12.81	2.66e-32	5.91e-29	-0.63	-0.51	Red blood cell count;	chr6:134972507	chr6:135055033~135060550:+
PRAD	cis	rs8072100	0.688	rs12602134	ENSG00000228782.6	CTD-2026D20.3	-12.81	2.71e-32	6.03e-29	-0.56	-0.51	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47504770	chr17:47450568~47492492:-
PRAD	cis	rs6504950	0.745	rs12603899	ENSG00000275710.1	RP11-257O5.4	12.81	2.72e-32	6.04e-29	0.66	0.51	Breast cancer;	chr17:54932737	chr17:54964474~54964679:+
PRAD	cis	rs6504950	0.8	rs9891704	ENSG00000275710.1	RP11-257O5.4	12.81	2.72e-32	6.04e-29	0.66	0.51	Breast cancer;	chr17:54933394	chr17:54964474~54964679:+
PRAD	cis	rs6504950	0.8	rs9900816	ENSG00000275710.1	RP11-257O5.4	12.81	2.72e-32	6.04e-29	0.66	0.51	Breast cancer;	chr17:54934696	chr17:54964474~54964679:+
PRAD	cis	rs6504950	0.8	rs9907961	ENSG00000275710.1	RP11-257O5.4	12.81	2.72e-32	6.04e-29	0.66	0.51	Breast cancer;	chr17:54935566	chr17:54964474~54964679:+
PRAD	cis	rs3814244	0.528	rs11177002	ENSG00000255733.4	IFNG-AS1	12.81	2.75e-32	6.1e-29	0.55	0.51	Itch intensity from mosquito bite adjusted by bite size;	chr12:68003377	chr12:67989445~68234686:+
PRAD	cis	rs3814244	0.528	rs10878723	ENSG00000255733.4	IFNG-AS1	12.81	2.75e-32	6.1e-29	0.55	0.51	Itch intensity from mosquito bite adjusted by bite size;	chr12:68005493	chr12:67989445~68234686:+
PRAD	cis	rs3814244	0.528	rs12582272	ENSG00000255733.4	IFNG-AS1	12.81	2.75e-32	6.1e-29	0.55	0.51	Itch intensity from mosquito bite adjusted by bite size;	chr12:68006298	chr12:67989445~68234686:+
PRAD	cis	rs17507216	0.588	rs4778687	ENSG00000278603.1	RP13-608F4.5	12.8	2.83e-32	6.28e-29	0.84	0.51	Excessive daytime sleepiness;	chr15:82649085	chr15:82472203~82472426:+
PRAD	cis	rs977987	0.806	rs4888383	ENSG00000261783.1	RP11-252K23.2	-12.8	2.84e-32	6.3e-29	-0.69	-0.51	Dupuytren's disease;	chr16:75352451	chr16:75379818~75381260:-
PRAD	cis	rs1062177	1	rs72802204	ENSG00000213433.5	RPLP1P6	-12.8	2.87e-32	6.36e-29	-0.6	-0.51	Preschool internalizing problems;	chr5:151803622	chr5:151765859~151766378:-
PRAD	cis	rs494459	0.691	rs607472	ENSG00000255239.1	AP002954.6	12.8	2.94e-32	6.52e-29	0.66	0.51	Height;	chr11:118809363	chr11:118688039~118690600:-
PRAD	cis	rs9545047	0.904	rs2760105	ENSG00000227676.3	LINC01068	12.8	3.01e-32	6.67e-29	0.65	0.51	Schizophrenia;	chr13:79535732	chr13:79566727~79571436:+
PRAD	cis	rs9326248	0.53	rs7112513	ENSG00000254851.1	RP11-109L13.1	-12.8	3.05e-32	6.75e-29	-1.02	-0.51	Blood protein levels;	chr11:117166645	chr11:117135528~117138582:+
PRAD	cis	rs71403859	0.73	rs12923781	ENSG00000260886.1	TAT-AS1	12.8	3.06e-32	6.77e-29	0.93	0.51	Post bronchodilator FEV1;	chr16:71619561	chr16:71565789~71578187:+
PRAD	cis	rs4660456	0.913	rs2744808	ENSG00000237899.1	RP4-739H11.3	-12.79	3.12e-32	6.91e-29	-0.74	-0.51	Platelet count;	chr1:40712271	chr1:40669089~40687588:-
PRAD	cis	rs9326248	0.539	rs10892058	ENSG00000254851.1	RP11-109L13.1	-12.79	3.13e-32	6.92e-29	-0.64	-0.51	Blood protein levels;	chr11:117005905	chr11:117135528~117138582:+
PRAD	cis	rs9326248	0.52	rs7127881	ENSG00000254851.1	RP11-109L13.1	-12.79	3.13e-32	6.92e-29	-0.64	-0.51	Blood protein levels;	chr11:117010082	chr11:117135528~117138582:+
PRAD	cis	rs2919917	1	rs1872072	ENSG00000254352.1	RP11-578O24.2	12.79	3.13e-32	6.93e-29	0.63	0.51	Lymphocyte counts;	chr8:78689185	chr8:78723796~78724136:-
PRAD	cis	rs8072100	0.537	rs9912450	ENSG00000228782.6	CTD-2026D20.3	12.79	3.18e-32	7.02e-29	0.56	0.51	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47324842	chr17:47450568~47492492:-
PRAD	cis	rs1062177	1	rs2964571	ENSG00000213433.5	RPLP1P6	-12.79	3.19e-32	7.06e-29	-0.6	-0.51	Preschool internalizing problems;	chr5:151791695	chr5:151765859~151766378:-
PRAD	cis	rs1062177	1	rs2915869	ENSG00000213433.5	RPLP1P6	-12.79	3.19e-32	7.06e-29	-0.6	-0.51	Preschool internalizing problems;	chr5:151791948	chr5:151765859~151766378:-
PRAD	cis	rs3096299	0.692	rs4785565	ENSG00000274627.1	RP11-104N10.2	12.79	3.2e-32	7.08e-29	0.52	0.51	Multiple myeloma (IgH translocation);	chr16:89449351	chr16:89516797~89522217:+
PRAD	cis	rs9399135	0.967	rs4376365	ENSG00000232876.1	CTA-212D2.2	-12.79	3.21e-32	7.11e-29	-0.63	-0.51	Red blood cell count;	chr6:134986602	chr6:135055033~135060550:+
PRAD	cis	rs977987	0.966	rs11643207	ENSG00000261783.1	RP11-252K23.2	-12.79	3.23e-32	7.13e-29	-0.71	-0.51	Dupuytren's disease;	chr16:75464895	chr16:75379818~75381260:-
PRAD	cis	rs1577917	0.771	rs9450290	ENSG00000203875.9	SNHG5	12.79	3.32e-32	7.33e-29	0.59	0.51	Response to antipsychotic treatment;	chr6:85523679	chr6:85660950~85678736:-
PRAD	cis	rs977987	0.806	rs1364077	ENSG00000261783.1	RP11-252K23.2	-12.79	3.36e-32	7.4e-29	-0.69	-0.51	Dupuytren's disease;	chr16:75363093	chr16:75379818~75381260:-
PRAD	cis	rs977987	0.843	rs4887820	ENSG00000261783.1	RP11-252K23.2	-12.79	3.36e-32	7.4e-29	-0.69	-0.51	Dupuytren's disease;	chr16:75363389	chr16:75379818~75381260:-
PRAD	cis	rs977987	0.778	rs34222958	ENSG00000261783.1	RP11-252K23.2	-12.79	3.36e-32	7.4e-29	-0.69	-0.51	Dupuytren's disease;	chr16:75364354	chr16:75379818~75381260:-
PRAD	cis	rs977987	0.778	rs4887821	ENSG00000261783.1	RP11-252K23.2	-12.79	3.36e-32	7.4e-29	-0.69	-0.51	Dupuytren's disease;	chr16:75364676	chr16:75379818~75381260:-
PRAD	cis	rs7188445	0.736	rs8048539	ENSG00000261390.4	RP11-345M22.2	12.79	3.37e-32	7.43e-29	0.61	0.51	Urate levels;	chr16:79670255	chr16:79715232~79770563:-
PRAD	cis	rs875971	0.862	rs1860469	ENSG00000226824.5	RP4-756H11.3	12.79	3.38e-32	7.45e-29	0.71	0.51	Aortic root size;	chr7:66641888	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.862	rs4718383	ENSG00000226824.5	RP4-756H11.3	12.79	3.38e-32	7.45e-29	0.71	0.51	Aortic root size;	chr7:66643422	chr7:66654538~66669855:+
PRAD	cis	rs4845570	1	rs7416415	ENSG00000249602.1	RP11-98D18.3	-12.79	3.39e-32	7.48e-29	-0.79	-0.51	Coronary artery disease;	chr1:151785322	chr1:151763384~151769501:-
PRAD	cis	rs9322193	0.884	rs9397036	ENSG00000223701.3	RAET1E-AS1	12.78	3.45e-32	7.6e-29	0.68	0.51	Lung cancer;	chr6:149851787	chr6:149884431~149919508:+
PRAD	cis	rs977987	0.815	rs11646677	ENSG00000261783.1	RP11-252K23.2	-12.78	3.46e-32	7.62e-29	-0.7	-0.51	Dupuytren's disease;	chr16:75375083	chr16:75379818~75381260:-
PRAD	cis	rs3091242	0.902	rs36003018	ENSG00000224183.1	SDHDP6	12.78	3.48e-32	7.66e-29	0.6	0.51	Erythrocyte sedimentation rate;	chr1:25457827	chr1:25294164~25294643:-
PRAD	cis	rs3091242	0.933	rs35403885	ENSG00000224183.1	SDHDP6	12.78	3.48e-32	7.66e-29	0.6	0.51	Erythrocyte sedimentation rate;	chr1:25458060	chr1:25294164~25294643:-
PRAD	cis	rs3091242	0.967	rs1053438	ENSG00000261349.1	RP3-465N24.5	12.78	3.48e-32	7.67e-29	0.57	0.51	Erythrocyte sedimentation rate;	chr1:25361410	chr1:25266102~25267136:-
PRAD	cis	rs9545047	0.967	rs9574402	ENSG00000227676.3	LINC01068	12.78	3.55e-32	7.81e-29	0.65	0.51	Schizophrenia;	chr13:79298392	chr13:79566727~79571436:+
PRAD	cis	rs3091242	0.933	rs12402120	ENSG00000224183.1	SDHDP6	-12.78	3.61e-32	7.95e-29	-0.6	-0.51	Erythrocyte sedimentation rate;	chr1:25425141	chr1:25294164~25294643:-
PRAD	cis	rs3091242	0.9	rs4649086	ENSG00000224183.1	SDHDP6	-12.78	3.67e-32	8.07e-29	-0.6	-0.51	Erythrocyte sedimentation rate;	chr1:25452476	chr1:25294164~25294643:-
PRAD	cis	rs4718428	0.672	rs4718412	ENSG00000226824.5	RP4-756H11.3	12.78	3.67e-32	8.08e-29	0.71	0.51	Corneal structure;	chr7:66821880	chr7:66654538~66669855:+
PRAD	cis	rs977987	0.806	rs4888386	ENSG00000261783.1	RP11-252K23.2	-12.78	3.72e-32	8.19e-29	-0.69	-0.51	Dupuytren's disease;	chr16:75355842	chr16:75379818~75381260:-
PRAD	cis	rs4845570	0.85	rs4618976	ENSG00000249602.1	RP11-98D18.3	-12.77	3.78e-32	8.3e-29	-0.8	-0.51	Coronary artery disease;	chr1:151794112	chr1:151763384~151769501:-
PRAD	cis	rs9322193	0.884	rs880245	ENSG00000268592.3	RAET1E-AS1	-12.77	3.78e-32	8.32e-29	-0.7	-0.51	Lung cancer;	chr6:149846262	chr6:149863494~149919507:+
PRAD	cis	rs2919917	1	rs2369440	ENSG00000254352.1	RP11-578O24.2	12.77	3.84e-32	8.44e-29	0.6	0.51	Lymphocyte counts;	chr8:78709474	chr8:78723796~78724136:-
PRAD	cis	rs1062177	1	rs892006	ENSG00000213433.5	RPLP1P6	-12.77	3.85e-32	8.46e-29	-0.59	-0.51	Preschool internalizing problems;	chr5:151801329	chr5:151765859~151766378:-
PRAD	cis	rs6504950	1	rs8078550	ENSG00000275710.1	RP11-257O5.4	12.77	3.86e-32	8.48e-29	0.69	0.51	Breast cancer;	chr17:54976018	chr17:54964474~54964679:+
PRAD	cis	rs9326248	0.53	rs7940310	ENSG00000254851.1	RP11-109L13.1	-12.77	3.88e-32	8.52e-29	-1.01	-0.51	Blood protein levels;	chr11:117153765	chr11:117135528~117138582:+
PRAD	cis	rs7188445	0.736	rs7500666	ENSG00000261390.4	RP11-345M22.2	12.77	3.88e-32	8.53e-29	0.61	0.51	Urate levels;	chr16:79672509	chr16:79715232~79770563:-
PRAD	cis	rs11690935	0.838	rs10432423	ENSG00000228389.1	AC068039.4	12.77	3.89e-32	8.56e-29	0.6	0.51	Schizophrenia;	chr2:171896785	chr2:171773482~171775844:+
PRAD	cis	rs35160687	0.901	rs6713456	ENSG00000273080.1	RP11-301O19.1	12.77	3.95e-32	8.67e-29	0.6	0.51	Night sleep phenotypes;	chr2:86280530	chr2:86195590~86196049:+
PRAD	cis	rs3096299	0.685	rs4785676	ENSG00000274627.1	RP11-104N10.2	12.77	4.04e-32	8.86e-29	0.51	0.51	Multiple myeloma (IgH translocation);	chr16:89487216	chr16:89516797~89522217:+
PRAD	cis	rs9322193	0.884	rs9383865	ENSG00000223701.3	RAET1E-AS1	12.77	4.05e-32	8.89e-29	0.68	0.51	Lung cancer;	chr6:149852043	chr6:149884431~149919508:+
PRAD	cis	rs977987	0.806	rs8050059	ENSG00000261783.1	RP11-252K23.2	-12.77	4.12e-32	9.04e-29	-0.69	-0.51	Dupuytren's disease;	chr16:75354833	chr16:75379818~75381260:-
PRAD	cis	rs3814244	0.528	rs7962511	ENSG00000255733.4	IFNG-AS1	12.76	4.14e-32	9.07e-29	0.55	0.51	Itch intensity from mosquito bite adjusted by bite size;	chr12:68002854	chr12:67989445~68234686:+
PRAD	cis	rs11673344	0.77	rs34729406	ENSG00000226686.6	LINC01535	12.76	4.21e-32	9.24e-29	0.74	0.51	Obesity-related traits;	chr19:37012764	chr19:37251912~37265535:+
PRAD	cis	rs977987	0.806	rs8050769	ENSG00000261783.1	RP11-252K23.2	-12.76	4.24e-32	9.28e-29	-0.68	-0.51	Dupuytren's disease;	chr16:75354536	chr16:75379818~75381260:-
PRAD	cis	rs977987	0.806	rs6564252	ENSG00000261783.1	RP11-252K23.2	-12.76	4.24e-32	9.28e-29	-0.68	-0.51	Dupuytren's disease;	chr16:75355042	chr16:75379818~75381260:-
PRAD	cis	rs55794721	0.509	rs909834	ENSG00000224183.1	SDHDP6	-12.76	4.24e-32	9.29e-29	-0.6	-0.51	Mean corpuscular volume;Plateletcrit;	chr1:25431505	chr1:25294164~25294643:-
PRAD	cis	rs9326248	0.648	rs11216257	ENSG00000254851.1	RP11-109L13.1	-12.76	4.25e-32	9.31e-29	-0.83	-0.51	Blood protein levels;	chr11:117061845	chr11:117135528~117138582:+
PRAD	cis	rs1062177	0.906	rs2964573	ENSG00000213433.5	RPLP1P6	-12.76	4.26e-32	9.34e-29	-0.59	-0.51	Preschool internalizing problems;	chr5:151780561	chr5:151765859~151766378:-
PRAD	cis	rs7182621	0.639	rs34701806	ENSG00000259363.4	CTD-2054N24.2	-12.76	4.28e-32	9.38e-29	-0.56	-0.51	Colonoscopy-negative controls vs population controls;	chr15:99872953	chr15:99807023~99877148:+
PRAD	cis	rs9399135	0.967	rs9376077	ENSG00000232876.1	CTA-212D2.2	-12.76	4.3e-32	9.41e-29	-0.63	-0.51	Red blood cell count;	chr6:134978575	chr6:135055033~135060550:+
PRAD	cis	rs2658782	0.756	rs3019223	ENSG00000279684.1	RP11-755E23.2	-12.76	4.3e-32	9.42e-29	-0.84	-0.51	Pulmonary function decline;	chr11:93351016	chr11:93286629~93288903:-
PRAD	cis	rs977987	0.806	rs4146809	ENSG00000261783.1	RP11-252K23.2	12.76	4.32e-32	9.46e-29	0.69	0.51	Dupuytren's disease;	chr16:75381877	chr16:75379818~75381260:-
PRAD	cis	rs9326248	0.581	rs10790167	ENSG00000254851.1	RP11-109L13.1	-12.76	4.33e-32	9.48e-29	-0.64	-0.51	Blood protein levels;	chr11:116930227	chr11:117135528~117138582:+
PRAD	cis	rs9399135	0.933	rs7755680	ENSG00000232876.1	CTA-212D2.2	-12.76	4.34e-32	9.5e-29	-0.63	-0.51	Red blood cell count;	chr6:134973121	chr6:135055033~135060550:+
PRAD	cis	rs9399135	0.967	rs4895436	ENSG00000232876.1	CTA-212D2.2	-12.76	4.43e-32	9.69e-29	-0.62	-0.51	Red blood cell count;	chr6:134973863	chr6:135055033~135060550:+
PRAD	cis	rs9399135	0.967	rs4896122	ENSG00000232876.1	CTA-212D2.2	-12.76	4.43e-32	9.69e-29	-0.62	-0.51	Red blood cell count;	chr6:134973943	chr6:135055033~135060550:+
PRAD	cis	rs9399135	0.967	rs9376075	ENSG00000232876.1	CTA-212D2.2	-12.76	4.43e-32	9.69e-29	-0.62	-0.51	Red blood cell count;	chr6:134975825	chr6:135055033~135060550:+
PRAD	cis	rs9399135	0.935	rs4273704	ENSG00000232876.1	CTA-212D2.2	-12.76	4.43e-32	9.69e-29	-0.62	-0.51	Red blood cell count;	chr6:134976382	chr6:135055033~135060550:+
PRAD	cis	rs9399135	0.967	rs4637662	ENSG00000232876.1	CTA-212D2.2	-12.76	4.43e-32	9.69e-29	-0.62	-0.51	Red blood cell count;	chr6:134977020	chr6:135055033~135060550:+
PRAD	cis	rs3091242	0.933	rs34006994	ENSG00000224183.1	SDHDP6	12.76	4.44e-32	9.71e-29	0.6	0.51	Erythrocyte sedimentation rate;	chr1:25454177	chr1:25294164~25294643:-
PRAD	cis	rs3091242	0.933	rs61775167	ENSG00000224183.1	SDHDP6	12.76	4.44e-32	9.71e-29	0.6	0.51	Erythrocyte sedimentation rate;	chr1:25454402	chr1:25294164~25294643:-
PRAD	cis	rs673078	0.562	rs61944672	ENSG00000275759.1	RP11-131L12.3	-12.76	4.47e-32	9.78e-29	-0.8	-0.51	Glucose homeostasis traits;	chr12:118450123	chr12:118428281~118428870:+
PRAD	cis	rs9326248	0.559	rs1269329	ENSG00000254851.1	RP11-109L13.1	-12.76	4.48e-32	9.79e-29	-0.65	-0.51	Blood protein levels;	chr11:116884325	chr11:117135528~117138582:+
PRAD	cis	rs3091242	0.933	rs35497030	ENSG00000261349.1	RP3-465N24.5	12.76	4.5e-32	9.84e-29	0.57	0.51	Erythrocyte sedimentation rate;	chr1:25456575	chr1:25266102~25267136:-
PRAD	cis	rs2882667	0.515	rs13161286	ENSG00000253404.1	AC034243.1	12.75	4.55e-32	9.94e-29	0.74	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139148416	chr5:138744434~138753309:-
PRAD	cis	rs9322193	0.607	rs9322229	ENSG00000231760.4	RP11-350J20.5	12.75	4.56e-32	9.97e-29	0.78	0.51	Lung cancer;	chr6:149908949	chr6:149796151~149826294:-
PRAD	cis	rs4722166	0.63	rs6969258	ENSG00000179428.2	AC073072.5	-12.75	4.57e-32	9.99e-29	-0.63	-0.51	Lung cancer;	chr7:22742909	chr7:22725395~22727620:-
PRAD	cis	rs2919917	1	rs2919936	ENSG00000254352.1	RP11-578O24.2	12.75	4.82e-32	1.05e-28	0.63	0.51	Lymphocyte counts;	chr8:78721772	chr8:78723796~78724136:-
PRAD	cis	rs3091242	0.933	rs28633797	ENSG00000224183.1	SDHDP6	-12.75	4.94e-32	1.08e-28	-0.61	-0.51	Erythrocyte sedimentation rate;	chr1:25415138	chr1:25294164~25294643:-
PRAD	cis	rs2581828	0.656	rs2336723	ENSG00000242142.1	SERBP1P3	12.74	5.02e-32	1.09e-28	0.57	0.51	Crohn's disease;	chr3:53072031	chr3:53064283~53065091:-
PRAD	cis	rs2658782	0.951	rs2608214	ENSG00000279684.1	RP11-755E23.2	-12.74	5.03e-32	1.1e-28	-0.81	-0.51	Pulmonary function decline;	chr11:93415499	chr11:93286629~93288903:-
PRAD	cis	rs9326248	0.52	rs1446105	ENSG00000254851.1	RP11-109L13.1	-12.74	5.07e-32	1.11e-28	-0.64	-0.51	Blood protein levels;	chr11:116927828	chr11:117135528~117138582:+
PRAD	cis	rs6504950	0.8	rs9916547	ENSG00000275710.1	RP11-257O5.4	12.74	5.1e-32	1.11e-28	0.66	0.51	Breast cancer;	chr17:54929529	chr17:54964474~54964679:+
PRAD	cis	rs6504950	0.8	rs8065361	ENSG00000275710.1	RP11-257O5.4	12.74	5.1e-32	1.11e-28	0.66	0.51	Breast cancer;	chr17:54931492	chr17:54964474~54964679:+
PRAD	cis	rs6597981	0.675	rs4963120	ENSG00000279672.1	CMB9-55F22.1	-12.74	5.13e-32	1.12e-28	-0.55	-0.51	Breast cancer;	chr11:825777	chr11:779617~780755:+
PRAD	cis	rs6504950	0.72	rs9913784	ENSG00000275710.1	RP11-257O5.4	12.74	5.14e-32	1.12e-28	0.68	0.51	Breast cancer;	chr17:54911710	chr17:54964474~54964679:+
PRAD	cis	rs2658782	1	rs2605582	ENSG00000279684.1	RP11-755E23.2	-12.74	5.22e-32	1.14e-28	-0.82	-0.51	Pulmonary function decline;	chr11:93430633	chr11:93286629~93288903:-
PRAD	cis	rs524281	0.817	rs10896092	ENSG00000255320.1	RP11-755F10.1	12.74	5.26e-32	1.15e-28	0.78	0.51	Electroencephalogram traits;	chr11:66190575	chr11:66244840~66246239:-
PRAD	cis	rs12049351	0.613	rs3738185	ENSG00000229367.1	HMGN2P19	12.74	5.27e-32	1.15e-28	0.76	0.51	Circulating myeloperoxidase levels (plasma);	chr1:229499520	chr1:229570532~229570796:+
PRAD	cis	rs12049351	0.774	rs12033713	ENSG00000229367.1	HMGN2P19	12.74	5.27e-32	1.15e-28	0.76	0.51	Circulating myeloperoxidase levels (plasma);	chr1:229502693	chr1:229570532~229570796:+
PRAD	cis	rs524281	0.684	rs7946447	ENSG00000255320.1	RP11-755F10.1	12.74	5.28e-32	1.15e-28	0.8	0.51	Electroencephalogram traits;	chr11:66096867	chr11:66244840~66246239:-
PRAD	cis	rs2658782	0.547	rs4344448	ENSG00000279684.1	RP11-755E23.2	-12.74	5.31e-32	1.15e-28	-0.76	-0.51	Pulmonary function decline;	chr11:93313881	chr11:93286629~93288903:-
PRAD	cis	rs9326248	0.53	rs236918	ENSG00000254851.1	RP11-109L13.1	12.74	5.36e-32	1.17e-28	1.06	0.51	Blood protein levels;	chr11:117220893	chr11:117135528~117138582:+
PRAD	cis	rs2739330	0.892	rs5751776	ENSG00000250470.1	AP000351.3	12.74	5.39e-32	1.17e-28	0.69	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23976904~23977585:-
PRAD	cis	rs2658782	0.951	rs72972357	ENSG00000279684.1	RP11-755E23.2	12.74	5.47e-32	1.19e-28	0.83	0.51	Pulmonary function decline;	chr11:93385674	chr11:93286629~93288903:-
PRAD	cis	rs6504950	1	rs9896044	ENSG00000275710.1	RP11-257O5.4	12.73	5.51e-32	1.2e-28	0.69	0.51	Breast cancer;	chr17:54971181	chr17:54964474~54964679:+
PRAD	cis	rs6504950	1	rs9894529	ENSG00000275710.1	RP11-257O5.4	12.73	5.51e-32	1.2e-28	0.69	0.51	Breast cancer;	chr17:54977885	chr17:54964474~54964679:+
PRAD	cis	rs3091242	0.933	rs28530483	ENSG00000224183.1	SDHDP6	-12.73	5.55e-32	1.21e-28	-0.61	-0.51	Erythrocyte sedimentation rate;	chr1:25414356	chr1:25294164~25294643:-
PRAD	cis	rs11673344	0.864	rs79407399	ENSG00000226686.6	LINC01535	12.73	5.61e-32	1.22e-28	0.74	0.51	Obesity-related traits;	chr19:37000004	chr19:37251912~37265535:+
PRAD	cis	rs7104764	0.917	rs3825075	ENSG00000277290.1	RP11-326C3.16	12.73	5.66e-32	1.23e-28	0.46	0.51	Menarche (age at onset);	chr11:217140	chr11:243099~243483:-
PRAD	cis	rs7182621	0.512	rs71403471	ENSG00000259363.4	CTD-2054N24.2	-12.73	5.67e-32	1.23e-28	-0.58	-0.51	Colonoscopy-negative controls vs population controls;	chr15:99870656	chr15:99807023~99877148:+
PRAD	cis	rs977987	0.771	rs8048527	ENSG00000261783.1	RP11-252K23.2	-12.73	5.69e-32	1.23e-28	-0.69	-0.51	Dupuytren's disease;	chr16:75388156	chr16:75379818~75381260:-
PRAD	cis	rs3096299	0.719	rs2965945	ENSG00000274627.1	RP11-104N10.2	12.73	5.84e-32	1.27e-28	0.51	0.51	Multiple myeloma (IgH translocation);	chr16:89447609	chr16:89516797~89522217:+
PRAD	cis	rs977987	0.815	rs4887829	ENSG00000261783.1	RP11-252K23.2	-12.73	5.88e-32	1.27e-28	-0.72	-0.51	Dupuytren's disease;	chr16:75455037	chr16:75379818~75381260:-
PRAD	cis	rs9399135	1	rs9399135	ENSG00000232876.1	CTA-212D2.2	-12.73	6.02e-32	1.3e-28	-0.62	-0.51	Red blood cell count;	chr6:135047176	chr6:135055033~135060550:+
PRAD	cis	rs55794721	0.509	rs2982358	ENSG00000224183.1	SDHDP6	-12.72	6.23e-32	1.35e-28	-0.61	-0.51	Mean corpuscular volume;Plateletcrit;	chr1:25418713	chr1:25294164~25294643:-
PRAD	cis	rs12022452	0.73	rs2297755	ENSG00000238287.1	RP11-656D10.3	-12.72	6.24e-32	1.35e-28	-0.92	-0.51	Age-related hearing impairment (SNP x SNP interaction);	chr1:40547343	chr1:40493157~40508661:-
PRAD	cis	rs3091242	0.933	rs4649084	ENSG00000261349.1	RP3-465N24.5	-12.72	6.3e-32	1.36e-28	-0.57	-0.51	Erythrocyte sedimentation rate;	chr1:25426126	chr1:25266102~25267136:-
PRAD	cis	rs9487094	0.922	rs9885646	ENSG00000260273.1	RP11-425D10.10	12.72	6.31e-32	1.37e-28	0.71	0.51	Height;	chr6:109421257	chr6:109382795~109383666:+
PRAD	cis	rs7044106	0.791	rs4837792	ENSG00000226752.6	PSMD5-AS1	-12.72	6.46e-32	1.4e-28	-0.63	-0.51	Hip circumference adjusted for BMI;	chr9:120721281	chr9:120824828~120854385:+
PRAD	cis	rs524281	0.861	rs7937281	ENSG00000255320.1	RP11-755F10.1	12.71	6.63e-32	1.43e-28	0.78	0.51	Electroencephalogram traits;	chr11:66182603	chr11:66244840~66246239:-
PRAD	cis	rs9322193	0.923	rs2184370	ENSG00000268592.3	RAET1E-AS1	12.71	6.67e-32	1.44e-28	0.71	0.51	Lung cancer;	chr6:149843242	chr6:149863494~149919507:+
PRAD	cis	rs1577917	0.771	rs2842601	ENSG00000203875.9	SNHG5	-12.71	6.75e-32	1.46e-28	-0.59	-0.51	Response to antipsychotic treatment;	chr6:85620415	chr6:85660950~85678736:-
PRAD	cis	rs950027	0.967	rs2643718	ENSG00000259520.4	CTD-2651B20.3	-12.71	6.82e-32	1.47e-28	-0.66	-0.51	Response to fenofibrate (adiponectin levels);	chr15:45502464	chr15:45251580~45279251:-
PRAD	cis	rs2455601	0.786	rs11042127	ENSG00000254860.4	TMEM9B-AS1	12.71	6.82e-32	1.48e-28	0.64	0.51	Schizophrenia;	chr11:8926039	chr11:8964675~8977527:+
PRAD	cis	rs9322193	0.923	rs7769101	ENSG00000216906.2	RP11-350J20.9	12.71	6.86e-32	1.48e-28	0.59	0.51	Lung cancer;	chr6:149848768	chr6:149904243~149906418:+
PRAD	cis	rs992157	0.56	rs6738394	ENSG00000261338.2	RP11-378A13.1	-12.71	6.94e-32	1.5e-28	-0.57	-0.51	Colorectal cancer;	chr2:218245902	chr2:218255319~218257366:+
PRAD	cis	rs4660456	0.827	rs617413	ENSG00000237899.1	RP4-739H11.3	12.71	6.96e-32	1.5e-28	0.74	0.51	Platelet count;	chr1:40669846	chr1:40669089~40687588:-
PRAD	cis	rs4423214	0.84	rs1792231	ENSG00000254682.1	RP11-660L16.2	-12.71	7.09e-32	1.53e-28	-0.74	-0.51	Vitamin D levels;	chr11:71471635	chr11:71448674~71452157:+
PRAD	cis	rs4423214	0.84	rs1790339	ENSG00000254682.1	RP11-660L16.2	-12.71	7.09e-32	1.53e-28	-0.74	-0.51	Vitamin D levels;	chr11:71471715	chr11:71448674~71452157:+
PRAD	cis	rs3091242	0.933	rs7541095	ENSG00000224183.1	SDHDP6	-12.71	7.2e-32	1.56e-28	-0.6	-0.51	Erythrocyte sedimentation rate;	chr1:25434800	chr1:25294164~25294643:-
PRAD	cis	rs10853057	0.85	rs62065479	ENSG00000214174.7	AMZ2P1	12.71	7.23e-32	1.56e-28	1.05	0.51	White matter microstructure (global fractional anisotropy);	chr17:65002593	chr17:64966550~64975576:-
PRAD	cis	rs5769707	0.967	rs1018812	ENSG00000188511.11	C22orf34	12.7	7.37e-32	1.59e-28	0.54	0.51	Monocyte percentage of white cells;Monocyte count;	chr22:49616425	chr22:49414524~49657542:-
PRAD	cis	rs8072100	0.875	rs62073966	ENSG00000228782.6	CTD-2026D20.3	-12.7	7.38e-32	1.59e-28	-0.56	-0.51	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47522647	chr17:47450568~47492492:-
PRAD	cis	rs992157	0.764	rs4672886	ENSG00000261338.2	RP11-378A13.1	-12.7	7.43e-32	1.6e-28	-0.58	-0.51	Colorectal cancer;	chr2:218320822	chr2:218255319~218257366:+
PRAD	cis	rs6504950	1	rs9915183	ENSG00000275710.1	RP11-257O5.4	12.7	7.52e-32	1.62e-28	0.69	0.51	Breast cancer;	chr17:54969776	chr17:54964474~54964679:+
PRAD	cis	rs6504950	1	rs9895808	ENSG00000275710.1	RP11-257O5.4	12.7	7.52e-32	1.62e-28	0.69	0.51	Breast cancer;	chr17:54971081	chr17:54964474~54964679:+
PRAD	cis	rs6504950	1	rs9897447	ENSG00000275710.1	RP11-257O5.4	12.7	7.52e-32	1.62e-28	0.69	0.51	Breast cancer;	chr17:54971108	chr17:54964474~54964679:+
PRAD	cis	rs6504950	1	rs9902687	ENSG00000275710.1	RP11-257O5.4	12.7	7.52e-32	1.62e-28	0.69	0.51	Breast cancer;	chr17:54971563	chr17:54964474~54964679:+
PRAD	cis	rs6504950	1	rs8080491	ENSG00000275710.1	RP11-257O5.4	12.7	7.52e-32	1.62e-28	0.69	0.51	Breast cancer;	chr17:54972508	chr17:54964474~54964679:+
PRAD	cis	rs6504950	1	rs6504948	ENSG00000275710.1	RP11-257O5.4	12.7	7.52e-32	1.62e-28	0.69	0.51	Breast cancer;	chr17:54972626	chr17:54964474~54964679:+
PRAD	cis	rs6504950	1	rs6504949	ENSG00000275710.1	RP11-257O5.4	12.7	7.52e-32	1.62e-28	0.69	0.51	Breast cancer;	chr17:54972772	chr17:54964474~54964679:+
PRAD	cis	rs6504950	1	rs9914732	ENSG00000275710.1	RP11-257O5.4	12.7	7.52e-32	1.62e-28	0.69	0.51	Breast cancer;	chr17:54977006	chr17:54964474~54964679:+
PRAD	cis	rs6504950	1	rs9916642	ENSG00000275710.1	RP11-257O5.4	12.7	7.52e-32	1.62e-28	0.69	0.51	Breast cancer;	chr17:54977136	chr17:54964474~54964679:+
PRAD	cis	rs6504950	1	rs9915832	ENSG00000275710.1	RP11-257O5.4	12.7	7.52e-32	1.62e-28	0.69	0.51	Breast cancer;	chr17:54977336	chr17:54964474~54964679:+
PRAD	cis	rs6504950	1	rs9893306	ENSG00000275710.1	RP11-257O5.4	12.7	7.52e-32	1.62e-28	0.69	0.51	Breast cancer;	chr17:54977388	chr17:54964474~54964679:+
PRAD	cis	rs6504950	1	rs6504950	ENSG00000275710.1	RP11-257O5.4	12.7	7.52e-32	1.62e-28	0.69	0.51	Breast cancer;	chr17:54979110	chr17:54964474~54964679:+
PRAD	cis	rs6504950	1	rs6504951	ENSG00000275710.1	RP11-257O5.4	12.7	7.52e-32	1.62e-28	0.69	0.51	Breast cancer;	chr17:54979614	chr17:54964474~54964679:+
PRAD	cis	rs6504950	1	rs9903146	ENSG00000275710.1	RP11-257O5.4	12.7	7.52e-32	1.62e-28	0.69	0.51	Breast cancer;	chr17:54980386	chr17:54964474~54964679:+
PRAD	cis	rs6504950	0.962	rs9902950	ENSG00000275710.1	RP11-257O5.4	12.7	7.52e-32	1.62e-28	0.69	0.51	Breast cancer;	chr17:54980403	chr17:54964474~54964679:+
PRAD	cis	rs6504950	1	rs9903220	ENSG00000275710.1	RP11-257O5.4	12.7	7.52e-32	1.62e-28	0.69	0.51	Breast cancer;	chr17:54980504	chr17:54964474~54964679:+
PRAD	cis	rs6504950	1	rs9903444	ENSG00000275710.1	RP11-257O5.4	12.7	7.52e-32	1.62e-28	0.69	0.51	Breast cancer;	chr17:54980532	chr17:54964474~54964679:+
PRAD	cis	rs6504950	1	rs9903825	ENSG00000275710.1	RP11-257O5.4	12.7	7.52e-32	1.62e-28	0.69	0.51	Breast cancer;	chr17:54980553	chr17:54964474~54964679:+
PRAD	cis	rs6504950	1	rs16955471	ENSG00000275710.1	RP11-257O5.4	12.7	7.52e-32	1.62e-28	0.69	0.51	Breast cancer;	chr17:54981446	chr17:54964474~54964679:+
PRAD	cis	rs6504950	1	rs9891865	ENSG00000275710.1	RP11-257O5.4	12.7	7.52e-32	1.62e-28	0.69	0.51	Breast cancer;	chr17:54982672	chr17:54964474~54964679:+
PRAD	cis	rs6504950	1	rs9892173	ENSG00000275710.1	RP11-257O5.4	12.7	7.52e-32	1.62e-28	0.69	0.51	Breast cancer;	chr17:54982853	chr17:54964474~54964679:+
PRAD	cis	rs6504950	1	rs1990674	ENSG00000275710.1	RP11-257O5.4	12.7	7.52e-32	1.62e-28	0.69	0.51	Breast cancer;	chr17:54983714	chr17:54964474~54964679:+
PRAD	cis	rs16828019	0.852	rs12742379	ENSG00000235358.1	RP11-399E6.1	12.7	7.65e-32	1.65e-28	0.96	0.51	Intelligence (multi-trait analysis);	chr1:41060709	chr1:41242373~41284861:+
PRAD	cis	rs16828019	0.852	rs12759023	ENSG00000235358.1	RP11-399E6.1	12.7	7.65e-32	1.65e-28	0.96	0.51	Intelligence (multi-trait analysis);	chr1:41138306	chr1:41242373~41284861:+
PRAD	cis	rs16828019	0.852	rs34286980	ENSG00000235358.1	RP11-399E6.1	12.7	7.65e-32	1.65e-28	0.96	0.51	Intelligence (multi-trait analysis);	chr1:41142717	chr1:41242373~41284861:+
PRAD	cis	rs16828019	0.852	rs71648534	ENSG00000235358.1	RP11-399E6.1	12.7	7.65e-32	1.65e-28	0.96	0.51	Intelligence (multi-trait analysis);	chr1:41148075	chr1:41242373~41284861:+
PRAD	cis	rs16828019	0.852	rs71648535	ENSG00000235358.1	RP11-399E6.1	12.7	7.65e-32	1.65e-28	0.96	0.51	Intelligence (multi-trait analysis);	chr1:41148078	chr1:41242373~41284861:+
PRAD	cis	rs16828019	0.852	rs12048187	ENSG00000235358.1	RP11-399E6.1	12.7	7.65e-32	1.65e-28	0.96	0.51	Intelligence (multi-trait analysis);	chr1:41150511	chr1:41242373~41284861:+
PRAD	cis	rs16828019	0.852	rs71648536	ENSG00000235358.1	RP11-399E6.1	12.7	7.65e-32	1.65e-28	0.96	0.51	Intelligence (multi-trait analysis);	chr1:41166336	chr1:41242373~41284861:+
PRAD	cis	rs16828019	0.852	rs12742803	ENSG00000235358.1	RP11-399E6.1	12.7	7.65e-32	1.65e-28	0.96	0.51	Intelligence (multi-trait analysis);	chr1:41182459	chr1:41242373~41284861:+
PRAD	cis	rs16828019	0.852	rs12408956	ENSG00000235358.1	RP11-399E6.1	12.7	7.65e-32	1.65e-28	0.96	0.51	Intelligence (multi-trait analysis);	chr1:41186280	chr1:41242373~41284861:+
PRAD	cis	rs16828019	0.852	rs35992757	ENSG00000235358.1	RP11-399E6.1	12.7	7.65e-32	1.65e-28	0.96	0.51	Intelligence (multi-trait analysis);	chr1:41187190	chr1:41242373~41284861:+
PRAD	cis	rs16828019	0.852	rs12759050	ENSG00000235358.1	RP11-399E6.1	12.7	7.65e-32	1.65e-28	0.96	0.51	Intelligence (multi-trait analysis);	chr1:41198532	chr1:41242373~41284861:+
PRAD	cis	rs16828019	0.789	rs34216154	ENSG00000235358.1	RP11-399E6.1	12.7	7.65e-32	1.65e-28	0.96	0.51	Intelligence (multi-trait analysis);	chr1:41205235	chr1:41242373~41284861:+
PRAD	cis	rs16828019	0.929	rs12029321	ENSG00000235358.1	RP11-399E6.1	12.7	7.65e-32	1.65e-28	0.96	0.51	Intelligence (multi-trait analysis);	chr1:41216858	chr1:41242373~41284861:+
PRAD	cis	rs16828019	0.929	rs11209734	ENSG00000235358.1	RP11-399E6.1	12.7	7.65e-32	1.65e-28	0.96	0.51	Intelligence (multi-trait analysis);	chr1:41232402	chr1:41242373~41284861:+
PRAD	cis	rs16828019	0.929	rs12037037	ENSG00000235358.1	RP11-399E6.1	12.7	7.65e-32	1.65e-28	0.96	0.51	Intelligence (multi-trait analysis);	chr1:41232584	chr1:41242373~41284861:+
PRAD	cis	rs875971	0.862	rs6460307	ENSG00000226824.5	RP4-756H11.3	-12.7	7.69e-32	1.65e-28	-0.69	-0.51	Aortic root size;	chr7:66595884	chr7:66654538~66669855:+
PRAD	cis	rs9322193	0.962	rs2275045	ENSG00000268592.3	RAET1E-AS1	12.7	7.74e-32	1.66e-28	0.71	0.51	Lung cancer;	chr6:149842775	chr6:149863494~149919507:+
PRAD	cis	rs9399135	0.967	rs9399129	ENSG00000232876.1	CTA-212D2.2	-12.7	7.75e-32	1.67e-28	-0.63	-0.51	Red blood cell count;	chr6:134964010	chr6:135055033~135060550:+
PRAD	cis	rs1426063	0.541	rs58959724	ENSG00000249717.1	RP11-44F21.3	12.7	7.88e-32	1.69e-28	1.23	0.51	QT interval;	chr4:75073543	chr4:74955974~74970362:-
PRAD	cis	rs3091242	0.933	rs61775174	ENSG00000261349.1	RP3-465N24.5	12.7	7.92e-32	1.7e-28	0.57	0.51	Erythrocyte sedimentation rate;	chr1:25460822	chr1:25266102~25267136:-
PRAD	cis	rs3091242	0.933	rs28530483	ENSG00000261349.1	RP3-465N24.5	-12.7	7.98e-32	1.71e-28	-0.57	-0.51	Erythrocyte sedimentation rate;	chr1:25414356	chr1:25266102~25267136:-
PRAD	cis	rs492146	0.817	rs384505	ENSG00000243236.5	GSTA9P	-12.69	8.03e-32	1.73e-28	-0.65	-0.51	Epilepsy (remission after treatment);	chr6:52970774	chr6:52939726~52957521:-
PRAD	cis	rs55794721	0.509	rs2982358	ENSG00000261349.1	RP3-465N24.5	-12.69	8.07e-32	1.73e-28	-0.57	-0.51	Mean corpuscular volume;Plateletcrit;	chr1:25418713	chr1:25266102~25267136:-
PRAD	cis	rs977987	0.843	rs28655617	ENSG00000261783.1	RP11-252K23.2	-12.69	8.14e-32	1.75e-28	-0.72	-0.51	Dupuytren's disease;	chr16:75455744	chr16:75379818~75381260:-
PRAD	cis	rs9399135	0.967	rs4388304	ENSG00000232876.1	CTA-212D2.2	-12.69	8.16e-32	1.75e-28	-0.62	-0.51	Red blood cell count;	chr6:134988459	chr6:135055033~135060550:+
PRAD	cis	rs12049351	0.774	rs34551512	ENSG00000229367.1	HMGN2P19	12.69	8.18e-32	1.76e-28	0.75	0.51	Circulating myeloperoxidase levels (plasma);	chr1:229483141	chr1:229570532~229570796:+
PRAD	cis	rs9545047	0.613	rs79774056	ENSG00000227676.3	LINC01068	12.69	8.41e-32	1.8e-28	0.67	0.51	Schizophrenia;	chr13:79421486	chr13:79566727~79571436:+
PRAD	cis	rs3091242	0.933	rs932372	ENSG00000224183.1	SDHDP6	-12.69	8.43e-32	1.81e-28	-0.6	-0.51	Erythrocyte sedimentation rate;	chr1:25428523	chr1:25294164~25294643:-
PRAD	cis	rs9326248	0.559	rs482371	ENSG00000254851.1	RP11-109L13.1	-12.69	8.45e-32	1.81e-28	-0.64	-0.51	Blood protein levels;	chr11:116881447	chr11:117135528~117138582:+
PRAD	cis	rs4722166	0.63	rs12700390	ENSG00000179428.2	AC073072.5	-12.69	8.48e-32	1.82e-28	-0.63	-0.51	Lung cancer;	chr7:22737510	chr7:22725395~22727620:-
PRAD	cis	rs4722166	0.63	rs12700391	ENSG00000179428.2	AC073072.5	-12.69	8.48e-32	1.82e-28	-0.63	-0.51	Lung cancer;	chr7:22737708	chr7:22725395~22727620:-
PRAD	cis	rs4722166	0.63	rs7781534	ENSG00000179428.2	AC073072.5	-12.69	8.48e-32	1.82e-28	-0.63	-0.51	Lung cancer;	chr7:22738973	chr7:22725395~22727620:-
PRAD	cis	rs4722166	0.63	rs4722168	ENSG00000179428.2	AC073072.5	-12.69	8.48e-32	1.82e-28	-0.63	-0.51	Lung cancer;	chr7:22739383	chr7:22725395~22727620:-
PRAD	cis	rs4722166	0.63	rs1581497	ENSG00000179428.2	AC073072.5	-12.69	8.48e-32	1.82e-28	-0.63	-0.51	Lung cancer;	chr7:22739884	chr7:22725395~22727620:-
PRAD	cis	rs4722166	0.63	rs1829927	ENSG00000179428.2	AC073072.5	-12.69	8.48e-32	1.82e-28	-0.63	-0.51	Lung cancer;	chr7:22740299	chr7:22725395~22727620:-
PRAD	cis	rs9322193	0.884	rs7769115	ENSG00000223701.3	RAET1E-AS1	12.69	8.6e-32	1.84e-28	0.68	0.51	Lung cancer;	chr6:149848796	chr6:149884431~149919508:+
PRAD	cis	rs12022452	1	rs3738471	ENSG00000238287.1	RP11-656D10.3	-12.69	8.71e-32	1.87e-28	-0.91	-0.51	Age-related hearing impairment (SNP x SNP interaction);	chr1:40540873	chr1:40493157~40508661:-
PRAD	cis	rs2882667	0.755	rs55650316	ENSG00000253404.1	AC034243.1	12.68	8.8e-32	1.89e-28	0.72	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139131603	chr5:138744434~138753309:-
PRAD	cis	rs11673344	0.832	rs112380313	ENSG00000226686.6	LINC01535	12.68	8.94e-32	1.91e-28	0.73	0.51	Obesity-related traits;	chr19:37027979	chr19:37251912~37265535:+
PRAD	cis	rs1577917	0.771	rs12205013	ENSG00000203875.9	SNHG5	-12.68	8.96e-32	1.92e-28	-0.59	-0.51	Response to antipsychotic treatment;	chr6:85623311	chr6:85660950~85678736:-
PRAD	cis	rs16828019	0.64	rs1140227	ENSG00000235358.1	RP11-399E6.1	12.68	9.05e-32	1.94e-28	0.96	0.51	Intelligence (multi-trait analysis);	chr1:41028139	chr1:41242373~41284861:+
PRAD	cis	rs16828019	0.777	rs16911	ENSG00000235358.1	RP11-399E6.1	12.68	9.05e-32	1.94e-28	0.96	0.51	Intelligence (multi-trait analysis);	chr1:41032349	chr1:41242373~41284861:+
PRAD	cis	rs16828019	0.777	rs2300658	ENSG00000235358.1	RP11-399E6.1	12.68	9.05e-32	1.94e-28	0.96	0.51	Intelligence (multi-trait analysis);	chr1:41039350	chr1:41242373~41284861:+
PRAD	cis	rs16828019	0.852	rs12729448	ENSG00000235358.1	RP11-399E6.1	12.68	9.05e-32	1.94e-28	0.96	0.51	Intelligence (multi-trait analysis);	chr1:41044162	chr1:41242373~41284861:+
PRAD	cis	rs16828019	0.852	rs2268678	ENSG00000235358.1	RP11-399E6.1	12.68	9.05e-32	1.94e-28	0.96	0.51	Intelligence (multi-trait analysis);	chr1:41045381	chr1:41242373~41284861:+
PRAD	cis	rs16828019	0.852	rs10489520	ENSG00000235358.1	RP11-399E6.1	12.68	9.05e-32	1.94e-28	0.96	0.51	Intelligence (multi-trait analysis);	chr1:41046083	chr1:41242373~41284861:+
PRAD	cis	rs16828019	0.852	rs12406620	ENSG00000235358.1	RP11-399E6.1	12.68	9.05e-32	1.94e-28	0.96	0.51	Intelligence (multi-trait analysis);	chr1:41046992	chr1:41242373~41284861:+
PRAD	cis	rs16828019	0.852	rs12729586	ENSG00000235358.1	RP11-399E6.1	12.68	9.05e-32	1.94e-28	0.96	0.51	Intelligence (multi-trait analysis);	chr1:41056705	chr1:41242373~41284861:+
PRAD	cis	rs16828019	0.704	rs34486565	ENSG00000235358.1	RP11-399E6.1	12.68	9.05e-32	1.94e-28	0.96	0.51	Intelligence (multi-trait analysis);	chr1:41056838	chr1:41242373~41284861:+
PRAD	cis	rs1062177	1	rs2915878	ENSG00000213433.5	RPLP1P6	-12.68	9.15e-32	1.96e-28	-0.59	-0.51	Preschool internalizing problems;	chr5:151770101	chr5:151765859~151766378:-
PRAD	cis	rs1062177	1	rs6890099	ENSG00000213433.5	RPLP1P6	-12.68	9.15e-32	1.96e-28	-0.59	-0.51	Preschool internalizing problems;	chr5:151772401	chr5:151765859~151766378:-
PRAD	cis	rs3091242	0.9	rs1883427	ENSG00000224183.1	SDHDP6	-12.68	9.19e-32	1.97e-28	-0.61	-0.51	Erythrocyte sedimentation rate;	chr1:25417977	chr1:25294164~25294643:-
PRAD	cis	rs977987	0.843	rs28558946	ENSG00000261783.1	RP11-252K23.2	-12.68	9.44e-32	2.02e-28	-0.7	-0.51	Dupuytren's disease;	chr16:75455424	chr16:75379818~75381260:-
PRAD	cis	rs4423214	0.61	rs3763856	ENSG00000254682.1	RP11-660L16.2	12.68	9.48e-32	2.03e-28	0.61	0.51	Vitamin D levels;	chr11:71414299	chr11:71448674~71452157:+
PRAD	cis	rs2739330	0.76	rs5751761	ENSG00000250470.1	AP000351.3	-12.67	9.79e-32	2.09e-28	-0.66	-0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23976904~23977585:-
PRAD	cis	rs977987	0.836	rs4888376	ENSG00000261783.1	RP11-252K23.2	-12.67	9.98e-32	2.13e-28	-0.69	-0.51	Dupuytren's disease;	chr16:75288675	chr16:75379818~75381260:-
PRAD	cis	rs16828019	0.852	rs34979067	ENSG00000235358.1	RP11-399E6.1	12.67	9.98e-32	2.13e-28	0.95	0.51	Intelligence (multi-trait analysis);	chr1:41077412	chr1:41242373~41284861:+
PRAD	cis	rs16828019	0.852	rs35190461	ENSG00000235358.1	RP11-399E6.1	12.67	9.98e-32	2.13e-28	0.95	0.51	Intelligence (multi-trait analysis);	chr1:41077463	chr1:41242373~41284861:+
PRAD	cis	rs16828019	0.852	rs12022978	ENSG00000235358.1	RP11-399E6.1	12.67	9.98e-32	2.13e-28	0.95	0.51	Intelligence (multi-trait analysis);	chr1:41088416	chr1:41242373~41284861:+
PRAD	cis	rs977987	0.843	rs17696749	ENSG00000261783.1	RP11-252K23.2	-12.67	1e-31	2.14e-28	-0.69	-0.51	Dupuytren's disease;	chr16:75369164	chr16:75379818~75381260:-
PRAD	cis	rs977987	0.843	rs8056080	ENSG00000261783.1	RP11-252K23.2	-12.67	1e-31	2.14e-28	-0.7	-0.51	Dupuytren's disease;	chr16:75376900	chr16:75379818~75381260:-
PRAD	cis	rs8072100	0.934	rs8067286	ENSG00000228782.6	CTD-2026D20.3	-12.67	1.01e-31	2.15e-28	-0.56	-0.51	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47517224	chr17:47450568~47492492:-
PRAD	cis	rs977987	0.843	rs11649638	ENSG00000261783.1	RP11-252K23.2	-12.67	1.01e-31	2.16e-28	-0.72	-0.51	Dupuytren's disease;	chr16:75454387	chr16:75379818~75381260:-
PRAD	cis	rs2882667	0.788	rs11959691	ENSG00000253404.1	AC034243.1	12.66	1.07e-31	2.27e-28	0.72	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139145399	chr5:138744434~138753309:-
PRAD	cis	rs6964833	0.935	rs7795281	ENSG00000277053.3	GTF2IP1	-12.66	1.07e-31	2.29e-28	-0.61	-0.51	Menarche (age at onset);	chr7:74708523	chr7:75185385~75237696:-
PRAD	cis	rs977987	0.843	rs7499872	ENSG00000261783.1	RP11-252K23.2	-12.66	1.1e-31	2.35e-28	-0.7	-0.51	Dupuytren's disease;	chr16:75392631	chr16:75379818~75381260:-
PRAD	cis	rs4660456	0.913	rs12040422	ENSG00000237899.1	RP4-739H11.3	12.66	1.11e-31	2.36e-28	0.74	0.51	Platelet count;	chr1:40669239	chr1:40669089~40687588:-
PRAD	cis	rs10262624	0.504	rs4722255	ENSG00000234286.1	AC006026.13	-12.66	1.11e-31	2.36e-28	-0.57	-0.51	Schizophrenia;	chr7:23706453	chr7:23680195~23680786:-
PRAD	cis	rs5769707	0.967	rs2051626	ENSG00000188511.11	C22orf34	12.66	1.11e-31	2.37e-28	0.54	0.51	Monocyte percentage of white cells;Monocyte count;	chr22:49615325	chr22:49414524~49657542:-
PRAD	cis	rs6504950	1	rs28558726	ENSG00000275710.1	RP11-257O5.4	12.66	1.12e-31	2.39e-28	0.68	0.51	Breast cancer;	chr17:54981315	chr17:54964474~54964679:+
PRAD	cis	rs6504950	1	rs9892976	ENSG00000275710.1	RP11-257O5.4	12.66	1.12e-31	2.39e-28	0.68	0.51	Breast cancer;	chr17:54982968	chr17:54964474~54964679:+
PRAD	cis	rs16828019	0.929	rs2363805	ENSG00000235358.1	RP11-399E6.1	12.66	1.13e-31	2.4e-28	0.95	0.51	Intelligence (multi-trait analysis);	chr1:41253762	chr1:41242373~41284861:+
PRAD	cis	rs16828019	0.852	rs71648540	ENSG00000235358.1	RP11-399E6.1	12.66	1.13e-31	2.4e-28	0.95	0.51	Intelligence (multi-trait analysis);	chr1:41256623	chr1:41242373~41284861:+
PRAD	cis	rs8072100	0.935	rs78551919	ENSG00000228782.6	CTD-2026D20.3	-12.66	1.13e-31	2.42e-28	-0.56	-0.51	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47548636	chr17:47450568~47492492:-
PRAD	cis	rs3091242	0.933	rs926438	ENSG00000224183.1	SDHDP6	-12.66	1.15e-31	2.45e-28	-0.6	-0.51	Erythrocyte sedimentation rate;	chr1:25427147	chr1:25294164~25294643:-
PRAD	cis	rs11673344	0.868	rs1047333	ENSG00000226686.6	LINC01535	12.65	1.18e-31	2.52e-28	0.72	0.51	Obesity-related traits;	chr19:37151263	chr19:37251912~37265535:+
PRAD	cis	rs2935183	1	rs2935183	ENSG00000228782.6	CTD-2026D20.3	-12.65	1.19e-31	2.52e-28	-0.56	-0.51	Multiple sclerosis or amyotrophic lateral sclerosis;	chr17:47530206	chr17:47450568~47492492:-
PRAD	cis	rs12049351	0.774	rs35421764	ENSG00000229367.1	HMGN2P19	12.65	1.24e-31	2.64e-28	0.76	0.51	Circulating myeloperoxidase levels (plasma);	chr1:229565742	chr1:229570532~229570796:+
PRAD	cis	rs324126	0.752	rs1054612	ENSG00000277977.1	CTD-3018O17.5	-12.64	1.29e-31	2.73e-28	-0.57	-0.51	Colonoscopy-negative controls vs population controls;	chr19:52366799	chr19:52392659~52392755:+
PRAD	cis	rs7182621	0.512	rs34151878	ENSG00000259363.4	CTD-2054N24.2	-12.64	1.3e-31	2.77e-28	-0.55	-0.51	Colonoscopy-negative controls vs population controls;	chr15:99869179	chr15:99807023~99877148:+
PRAD	cis	rs3096299	0.642	rs12934829	ENSG00000274627.1	RP11-104N10.2	12.64	1.32e-31	2.8e-28	0.52	0.51	Multiple myeloma (IgH translocation);	chr16:89456941	chr16:89516797~89522217:+
PRAD	cis	rs16828019	0.852	rs12044539	ENSG00000235358.1	RP11-399E6.1	12.64	1.33e-31	2.82e-28	0.95	0.51	Intelligence (multi-trait analysis);	chr1:41196060	chr1:41242373~41284861:+
PRAD	cis	rs9532669	0.926	rs7331435	ENSG00000176268.5	CYCSP34	-12.64	1.33e-31	2.83e-28	-0.53	-0.51	Cervical cancer;	chr13:40862396	chr13:40863599~40863902:-
PRAD	cis	rs6504950	0.8	rs7209926	ENSG00000275710.1	RP11-257O5.4	-12.64	1.34e-31	2.84e-28	-0.66	-0.51	Breast cancer;	chr17:54928963	chr17:54964474~54964679:+
PRAD	cis	rs4718428	0.705	rs4718430	ENSG00000226824.5	RP4-756H11.3	-12.64	1.36e-31	2.89e-28	-0.71	-0.51	Corneal structure;	chr7:66967037	chr7:66654538~66669855:+
PRAD	cis	rs12049351	0.774	rs10916516	ENSG00000229367.1	HMGN2P19	12.64	1.39e-31	2.95e-28	0.76	0.51	Circulating myeloperoxidase levels (plasma);	chr1:229564427	chr1:229570532~229570796:+
PRAD	cis	rs7182621	0.512	rs12903892	ENSG00000259363.4	CTD-2054N24.2	-12.63	1.42e-31	3e-28	-0.55	-0.51	Colonoscopy-negative controls vs population controls;	chr15:99869662	chr15:99807023~99877148:+
PRAD	cis	rs9322193	0.772	rs7738696	ENSG00000223701.3	RAET1E-AS1	12.63	1.43e-31	3.03e-28	0.67	0.51	Lung cancer;	chr6:149848985	chr6:149884431~149919508:+
PRAD	cis	rs2404602	0.598	rs71405204	ENSG00000259422.1	RP11-593F23.1	-12.63	1.45e-31	3.06e-28	-0.69	-0.51	Blood metabolite levels;	chr15:76342964	chr15:76174891~76181486:-
PRAD	cis	rs1577917	0.74	rs2842604	ENSG00000203875.9	SNHG5	-12.63	1.45e-31	3.07e-28	-0.59	-0.51	Response to antipsychotic treatment;	chr6:85626582	chr6:85660950~85678736:-
PRAD	cis	rs7104764	0.833	rs12574034	ENSG00000277290.1	RP11-326C3.16	12.63	1.45e-31	3.08e-28	0.46	0.51	Menarche (age at onset);	chr11:212262	chr11:243099~243483:-
PRAD	cis	rs7044106	0.791	rs10984995	ENSG00000226752.6	PSMD5-AS1	-12.63	1.47e-31	3.11e-28	-0.62	-0.51	Hip circumference adjusted for BMI;	chr9:120716932	chr9:120824828~120854385:+
PRAD	cis	rs9326248	0.53	rs11216316	ENSG00000254851.1	RP11-109L13.1	12.63	1.48e-31	3.14e-28	1.05	0.51	Blood protein levels;	chr11:117210784	chr11:117135528~117138582:+
PRAD	cis	rs9322193	0.847	rs4870054	ENSG00000223701.3	RAET1E-AS1	12.63	1.54e-31	3.26e-28	0.69	0.51	Lung cancer;	chr6:149848402	chr6:149884431~149919508:+
PRAD	cis	rs3091242	1	rs646867	ENSG00000261349.1	RP3-465N24.5	-12.62	1.55e-31	3.28e-28	-0.57	-0.51	Erythrocyte sedimentation rate;	chr1:25382767	chr1:25266102~25267136:-
PRAD	cis	rs9399135	1	rs35123050	ENSG00000232876.1	CTA-212D2.2	-12.62	1.63e-31	3.44e-28	-0.62	-0.51	Red blood cell count;	chr6:134981602	chr6:135055033~135060550:+
PRAD	cis	rs528808	1	rs528808	ENSG00000279170.1	RP1-199J3.6	12.62	1.64e-31	3.47e-28	0.81	0.51	Age-related hearing impairment;	chr6:99656413	chr6:99587611~99589898:+
PRAD	cis	rs6991838	0.584	rs1053088	ENSG00000272010.1	CTD-3025N20.3	12.62	1.69e-31	3.55e-28	0.53	0.51	Intelligence (multi-trait analysis);	chr8:65603548	chr8:65591850~65592472:-
PRAD	cis	rs8062405	1	rs7187776	ENSG00000251417.2	RP11-1348G14.4	-12.62	1.69e-31	3.56e-28	-0.55	-0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28846324	chr16:28802743~28817828:+
PRAD	cis	rs6142102	0.625	rs4012234	ENSG00000276073.1	RP5-1125A11.7	-12.62	1.69e-31	3.56e-28	-0.5	-0.51	Skin pigmentation;	chr20:33965241	chr20:33985617~33988989:-
PRAD	cis	rs6142102	0.649	rs4911382	ENSG00000276073.1	RP5-1125A11.7	-12.62	1.69e-31	3.56e-28	-0.5	-0.51	Skin pigmentation;	chr20:33965289	chr20:33985617~33988989:-
PRAD	cis	rs6142102	0.625	rs6141436	ENSG00000276073.1	RP5-1125A11.7	-12.62	1.69e-31	3.56e-28	-0.5	-0.51	Skin pigmentation;	chr20:33966765	chr20:33985617~33988989:-
PRAD	cis	rs17826219	0.706	rs2322197	ENSG00000263531.1	RP13-753N3.1	12.62	1.69e-31	3.57e-28	0.96	0.51	Body mass index;	chr17:30778787	chr17:30863921~30864940:-
PRAD	cis	rs977987	0.843	rs11641801	ENSG00000261783.1	RP11-252K23.2	-12.61	1.71e-31	3.6e-28	-0.68	-0.51	Dupuytren's disease;	chr16:75421550	chr16:75379818~75381260:-
PRAD	cis	rs977987	0.806	rs11648176	ENSG00000261783.1	RP11-252K23.2	-12.61	1.71e-31	3.6e-28	-0.68	-0.51	Dupuytren's disease;	chr16:75422525	chr16:75379818~75381260:-
PRAD	cis	rs1577917	0.666	rs6454471	ENSG00000203875.9	SNHG5	12.61	1.72e-31	3.62e-28	0.58	0.51	Response to antipsychotic treatment;	chr6:85504738	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.665	rs4304137	ENSG00000203875.9	SNHG5	12.61	1.72e-31	3.62e-28	0.58	0.51	Response to antipsychotic treatment;	chr6:85507730	chr6:85660950~85678736:-
PRAD	cis	rs8072100	0.871	rs7206971	ENSG00000228782.6	CTD-2026D20.3	-12.61	1.74e-31	3.65e-28	-0.55	-0.51	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47347749	chr17:47450568~47492492:-
PRAD	cis	rs1062177	1	rs2915877	ENSG00000213433.5	RPLP1P6	-12.61	1.74e-31	3.66e-28	-0.59	-0.51	Preschool internalizing problems;	chr5:151771040	chr5:151765859~151766378:-
PRAD	cis	rs1062177	1	rs2964576	ENSG00000213433.5	RPLP1P6	-12.61	1.74e-31	3.66e-28	-0.59	-0.51	Preschool internalizing problems;	chr5:151771041	chr5:151765859~151766378:-
PRAD	cis	rs11690935	0.885	rs6752812	ENSG00000228389.1	AC068039.4	12.61	1.76e-31	3.71e-28	0.6	0.51	Schizophrenia;	chr2:171986588	chr2:171773482~171775844:+
PRAD	cis	rs8072100	0.967	rs9894905	ENSG00000228782.6	CTD-2026D20.3	12.61	1.77e-31	3.72e-28	0.56	0.51	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47408616	chr17:47450568~47492492:-
PRAD	cis	rs3096299	0.728	rs1011749	ENSG00000274627.1	RP11-104N10.2	12.61	1.77e-31	3.72e-28	0.51	0.51	Multiple myeloma (IgH translocation);	chr16:89444461	chr16:89516797~89522217:+
PRAD	cis	rs67383717	0.527	rs12004422	ENSG00000175611.10	LINC00476	12.61	1.84e-31	3.86e-28	0.61	0.51	Parkinson's disease (pesticide exposure interaction);	chr9:95873393	chr9:95759231~95875977:-
PRAD	cis	rs9322193	0.886	rs4870055	ENSG00000268592.3	RAET1E-AS1	12.61	1.85e-31	3.89e-28	0.7	0.51	Lung cancer;	chr6:149848433	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.923	rs4870050	ENSG00000268592.3	RAET1E-AS1	12.61	1.86e-31	3.91e-28	0.7	0.51	Lung cancer;	chr6:149838917	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.962	rs7752089	ENSG00000268592.3	RAET1E-AS1	12.61	1.86e-31	3.91e-28	0.7	0.51	Lung cancer;	chr6:149839298	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.923	rs4242279	ENSG00000268592.3	RAET1E-AS1	12.61	1.86e-31	3.91e-28	0.7	0.51	Lung cancer;	chr6:149839815	chr6:149863494~149919507:+
PRAD	cis	rs977987	0.75	rs4888406	ENSG00000261783.1	RP11-252K23.2	-12.6	1.9e-31	3.99e-28	-0.7	-0.51	Dupuytren's disease;	chr16:75398436	chr16:75379818~75381260:-
PRAD	cis	rs977987	0.806	rs7188231	ENSG00000261783.1	RP11-252K23.2	-12.6	1.9e-31	3.99e-28	-0.7	-0.51	Dupuytren's disease;	chr16:75402663	chr16:75379818~75381260:-
PRAD	cis	rs12049351	0.774	rs12750869	ENSG00000229367.1	HMGN2P19	12.6	1.91e-31	4.01e-28	0.76	0.51	Circulating myeloperoxidase levels (plasma);	chr1:229570467	chr1:229570532~229570796:+
PRAD	cis	rs4845570	1	rs3790514	ENSG00000249602.1	RP11-98D18.3	12.6	1.93e-31	4.05e-28	0.78	0.51	Coronary artery disease;	chr1:151771692	chr1:151763384~151769501:-
PRAD	cis	rs12049351	0.774	rs2145395	ENSG00000229367.1	HMGN2P19	12.6	1.93e-31	4.05e-28	0.72	0.51	Circulating myeloperoxidase levels (plasma);	chr1:229535234	chr1:229570532~229570796:+
PRAD	cis	rs6504950	0.695	rs9904377	ENSG00000275710.1	RP11-257O5.4	12.6	1.95e-31	4.09e-28	0.66	0.51	Breast cancer;	chr17:54908621	chr17:54964474~54964679:+
PRAD	cis	rs977987	0.806	rs11644306	ENSG00000261783.1	RP11-252K23.2	-12.6	1.95e-31	4.09e-28	-0.7	-0.51	Dupuytren's disease;	chr16:75456155	chr16:75379818~75381260:-
PRAD	cis	rs3091242	0.967	rs3093614	ENSG00000261349.1	RP3-465N24.5	12.6	1.97e-31	4.13e-28	0.56	0.51	Erythrocyte sedimentation rate;	chr1:25351353	chr1:25266102~25267136:-
PRAD	cis	rs36229146	1	rs36229146	ENSG00000179428.2	AC073072.5	-12.6	2.04e-31	4.28e-28	-0.63	-0.51	Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;	chr7:22744893	chr7:22725395~22727620:-
PRAD	cis	rs6142102	0.625	rs4911384	ENSG00000276073.1	RP5-1125A11.7	-12.59	2.07e-31	4.33e-28	-0.5	-0.51	Skin pigmentation;	chr20:33968001	chr20:33985617~33988989:-
PRAD	cis	rs1577917	0.771	rs2475791	ENSG00000203875.9	SNHG5	-12.59	2.07e-31	4.34e-28	-0.59	-0.51	Response to antipsychotic treatment;	chr6:85658446	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.771	rs2783171	ENSG00000203875.9	SNHG5	12.59	2.07e-31	4.34e-28	0.59	0.51	Response to antipsychotic treatment;	chr6:85673047	chr6:85660950~85678736:-
PRAD	cis	rs4845570	1	rs6659705	ENSG00000249602.1	RP11-98D18.3	12.59	2.07e-31	4.35e-28	0.79	0.51	Coronary artery disease;	chr1:151797274	chr1:151763384~151769501:-
PRAD	cis	rs1062177	1	rs2915882	ENSG00000213433.5	RPLP1P6	-12.59	2.09e-31	4.39e-28	-0.59	-0.51	Preschool internalizing problems;	chr5:151765875	chr5:151765859~151766378:-
PRAD	cis	rs1062177	1	rs2915880	ENSG00000213433.5	RPLP1P6	-12.59	2.09e-31	4.39e-28	-0.59	-0.51	Preschool internalizing problems;	chr5:151767773	chr5:151765859~151766378:-
PRAD	cis	rs2404602	0.598	rs11634019	ENSG00000259422.1	RP11-593F23.1	-12.59	2.1e-31	4.39e-28	-0.68	-0.51	Blood metabolite levels;	chr15:76342339	chr15:76174891~76181486:-
PRAD	cis	rs12049351	0.774	rs1053512	ENSG00000229367.1	HMGN2P19	12.59	2.11e-31	4.42e-28	0.74	0.51	Circulating myeloperoxidase levels (plasma);	chr1:229516951	chr1:229570532~229570796:+
PRAD	cis	rs12049351	0.774	rs12138176	ENSG00000229367.1	HMGN2P19	12.59	2.11e-31	4.42e-28	0.74	0.51	Circulating myeloperoxidase levels (plasma);	chr1:229522155	chr1:229570532~229570796:+
PRAD	cis	rs12049351	0.774	rs12022203	ENSG00000229367.1	HMGN2P19	12.59	2.11e-31	4.42e-28	0.74	0.51	Circulating myeloperoxidase levels (plasma);	chr1:229523050	chr1:229570532~229570796:+
PRAD	cis	rs9399135	0.967	rs4896119	ENSG00000232876.1	CTA-212D2.2	-12.59	2.12e-31	4.44e-28	-0.62	-0.51	Red blood cell count;	chr6:134972253	chr6:135055033~135060550:+
PRAD	cis	rs4889009	0.533	rs12596569	ENSG00000261390.4	RP11-345M22.2	12.59	2.13e-31	4.47e-28	0.59	0.51	Thyroid peroxidase antibody positivity;	chr16:79701354	chr16:79715232~79770563:-
PRAD	cis	rs977987	0.843	rs60730309	ENSG00000261783.1	RP11-252K23.2	-12.59	2.18e-31	4.55e-28	-0.7	-0.51	Dupuytren's disease;	chr16:75397871	chr16:75379818~75381260:-
PRAD	cis	rs3091242	0.933	rs9438905	ENSG00000224183.1	SDHDP6	-12.59	2.18e-31	4.56e-28	-0.59	-0.51	Erythrocyte sedimentation rate;	chr1:25437686	chr1:25294164~25294643:-
PRAD	cis	rs9487094	0.813	rs6920962	ENSG00000260273.1	RP11-425D10.10	12.59	2.21e-31	4.61e-28	0.71	0.51	Height;	chr6:109403287	chr6:109382795~109383666:+
PRAD	cis	rs7188445	0.736	rs4888043	ENSG00000261390.4	RP11-345M22.2	12.59	2.22e-31	4.65e-28	0.59	0.51	Urate levels;	chr16:79668744	chr16:79715232~79770563:-
PRAD	cis	rs9326248	1	rs10790175	ENSG00000280143.1	AP000892.6	12.59	2.23e-31	4.65e-28	0.43	0.51	Blood protein levels;	chr11:117164013	chr11:117204967~117210292:+
PRAD	cis	rs977987	0.843	rs11860231	ENSG00000261783.1	RP11-252K23.2	-12.58	2.26e-31	4.72e-28	-0.68	-0.51	Dupuytren's disease;	chr16:75351261	chr16:75379818~75381260:-
PRAD	cis	rs3096299	0.719	rs2911265	ENSG00000274627.1	RP11-104N10.2	12.58	2.32e-31	4.84e-28	0.51	0.51	Multiple myeloma (IgH translocation);	chr16:89444920	chr16:89516797~89522217:+
PRAD	cis	rs7044106	0.762	rs3904197	ENSG00000226752.6	PSMD5-AS1	-12.58	2.34e-31	4.89e-28	-0.62	-0.51	Hip circumference adjusted for BMI;	chr9:120718100	chr9:120824828~120854385:+
PRAD	cis	rs3091242	0.933	rs35530120	ENSG00000261349.1	RP3-465N24.5	12.58	2.35e-31	4.9e-28	0.56	0.51	Erythrocyte sedimentation rate;	chr1:25458960	chr1:25266102~25267136:-
PRAD	cis	rs3931020	0.508	rs11485298	ENSG00000272864.1	RP11-17E13.2	-12.58	2.35e-31	4.9e-28	-0.56	-0.51	Resistin levels;	chr1:74752068	chr1:74698769~74699333:-
PRAD	cis	rs3931020	0.508	rs4145871	ENSG00000272864.1	RP11-17E13.2	-12.58	2.35e-31	4.9e-28	-0.56	-0.51	Resistin levels;	chr1:74753020	chr1:74698769~74699333:-
PRAD	cis	rs9326248	0.53	rs7122944	ENSG00000254851.1	RP11-109L13.1	-12.58	2.43e-31	5.08e-28	-1.04	-0.51	Blood protein levels;	chr11:117163903	chr11:117135528~117138582:+
PRAD	cis	rs2581828	0.896	rs12637287	ENSG00000242142.1	SERBP1P3	12.58	2.46e-31	5.13e-28	0.58	0.51	Crohn's disease;	chr3:53105425	chr3:53064283~53065091:-
PRAD	cis	rs2882667	0.858	rs6596460	ENSG00000253404.1	AC034243.1	12.57	2.58e-31	5.37e-28	0.69	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139078491	chr5:138744434~138753309:-
PRAD	cis	rs16828019	0.852	rs11209531	ENSG00000235358.1	RP11-399E6.1	12.57	2.58e-31	5.38e-28	0.94	0.51	Intelligence (multi-trait analysis);	chr1:41105349	chr1:41242373~41284861:+
PRAD	cis	rs8072100	0.967	rs12452315	ENSG00000228782.6	CTD-2026D20.3	-12.57	2.59e-31	5.4e-28	-0.56	-0.51	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402080	chr17:47450568~47492492:-
PRAD	cis	rs11690935	0.632	rs17581284	ENSG00000228389.1	AC068039.4	-12.57	2.62e-31	5.46e-28	-0.57	-0.51	Schizophrenia;	chr2:171802866	chr2:171773482~171775844:+
PRAD	cis	rs1062177	1	rs12654573	ENSG00000213433.5	RPLP1P6	-12.57	2.63e-31	5.47e-28	-0.58	-0.51	Preschool internalizing problems;	chr5:151827912	chr5:151765859~151766378:-
PRAD	cis	rs4423214	0.802	rs2276358	ENSG00000254682.1	RP11-660L16.2	-12.57	2.63e-31	5.49e-28	-0.75	-0.51	Vitamin D levels;	chr11:71473452	chr11:71448674~71452157:+
PRAD	cis	rs11676348	0.846	rs7607437	ENSG00000261338.2	RP11-378A13.1	-12.57	2.66e-31	5.54e-28	-0.6	-0.51	Ulcerative colitis;	chr2:218143669	chr2:218255319~218257366:+
PRAD	cis	rs977987	0.75	rs4888407	ENSG00000261783.1	RP11-252K23.2	-12.57	2.67e-31	5.55e-28	-0.69	-0.51	Dupuytren's disease;	chr16:75398492	chr16:75379818~75381260:-
PRAD	cis	rs977987	0.843	rs12443904	ENSG00000261783.1	RP11-252K23.2	-12.57	2.67e-31	5.55e-28	-0.7	-0.51	Dupuytren's disease;	chr16:75404872	chr16:75379818~75381260:-
PRAD	cis	rs977987	0.843	rs35737321	ENSG00000261783.1	RP11-252K23.2	-12.57	2.67e-31	5.55e-28	-0.7	-0.51	Dupuytren's disease;	chr16:75405287	chr16:75379818~75381260:-
PRAD	cis	rs2882667	0.756	rs11957953	ENSG00000253404.1	AC034243.1	12.57	2.67e-31	5.55e-28	0.71	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139143688	chr5:138744434~138753309:-
PRAD	cis	rs16828019	0.789	rs36084778	ENSG00000235358.1	RP11-399E6.1	12.56	2.81e-31	5.83e-28	0.95	0.51	Intelligence (multi-trait analysis);	chr1:41013866	chr1:41242373~41284861:+
PRAD	cis	rs16828019	0.777	rs11209363	ENSG00000235358.1	RP11-399E6.1	12.56	2.81e-31	5.83e-28	0.95	0.51	Intelligence (multi-trait analysis);	chr1:41019405	chr1:41242373~41284861:+
PRAD	cis	rs9322193	0.923	rs9767652	ENSG00000223701.3	RAET1E-AS1	12.56	2.94e-31	6.1e-28	0.68	0.51	Lung cancer;	chr6:149734502	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.923	rs10782314	ENSG00000223701.3	RAET1E-AS1	12.56	2.94e-31	6.1e-28	0.68	0.51	Lung cancer;	chr6:149735527	chr6:149884431~149919508:+
PRAD	cis	rs992157	0.56	rs6436047	ENSG00000261338.2	RP11-378A13.1	12.56	2.94e-31	6.1e-28	0.56	0.51	Colorectal cancer;	chr2:218244190	chr2:218255319~218257366:+
PRAD	cis	rs11723261	0.564	rs60994255	ENSG00000275426.1	CH17-262A2.1	12.56	2.96e-31	6.14e-28	0.76	0.51	Immune response to smallpox vaccine (IL-6);	chr4:77554	chr4:149738~150317:+
PRAD	cis	rs4423214	0.798	rs12224205	ENSG00000254682.1	RP11-660L16.2	-12.56	2.96e-31	6.14e-28	-0.73	-0.51	Vitamin D levels;	chr11:71469946	chr11:71448674~71452157:+
PRAD	cis	rs7617773	0.963	rs6771787	ENSG00000229759.1	MRPS18AP1	-12.55	3.01e-31	6.24e-28	-0.54	-0.51	Coronary artery disease;	chr3:48152752	chr3:48256350~48256938:-
PRAD	cis	rs7617773	1	rs6771889	ENSG00000229759.1	MRPS18AP1	-12.55	3.01e-31	6.24e-28	-0.54	-0.51	Coronary artery disease;	chr3:48152836	chr3:48256350~48256938:-
PRAD	cis	rs9399135	0.967	rs4896123	ENSG00000232876.1	CTA-212D2.2	-12.55	3.04e-31	6.32e-28	-0.62	-0.51	Red blood cell count;	chr6:134974272	chr6:135055033~135060550:+
PRAD	cis	rs2404602	0.735	rs11857015	ENSG00000259422.1	RP11-593F23.1	-12.55	3.08e-31	6.38e-28	-0.65	-0.51	Blood metabolite levels;	chr15:76357049	chr15:76174891~76181486:-
PRAD	cis	rs16828019	0.852	rs34386859	ENSG00000235358.1	RP11-399E6.1	12.55	3.09e-31	6.4e-28	0.94	0.51	Intelligence (multi-trait analysis);	chr1:41098352	chr1:41242373~41284861:+
PRAD	cis	rs977987	0.806	rs1109342	ENSG00000261783.1	RP11-252K23.2	12.55	3.15e-31	6.53e-28	0.68	0.51	Dupuytren's disease;	chr16:75411777	chr16:75379818~75381260:-
PRAD	cis	rs977987	0.806	rs11862684	ENSG00000261783.1	RP11-252K23.2	-12.55	3.16e-31	6.55e-28	-0.69	-0.51	Dupuytren's disease;	chr16:75427848	chr16:75379818~75381260:-
PRAD	cis	rs977987	0.815	rs11861810	ENSG00000261783.1	RP11-252K23.2	-12.55	3.16e-31	6.55e-28	-0.69	-0.51	Dupuytren's disease;	chr16:75427931	chr16:75379818~75381260:-
PRAD	cis	rs977987	0.778	rs12929908	ENSG00000261783.1	RP11-252K23.2	-12.55	3.16e-31	6.55e-28	-0.69	-0.51	Dupuytren's disease;	chr16:75428173	chr16:75379818~75381260:-
PRAD	cis	rs977987	0.742	rs12928898	ENSG00000261783.1	RP11-252K23.2	-12.55	3.16e-31	6.55e-28	-0.69	-0.51	Dupuytren's disease;	chr16:75428183	chr16:75379818~75381260:-
PRAD	cis	rs3091242	0.933	rs4649084	ENSG00000224183.1	SDHDP6	-12.55	3.23e-31	6.69e-28	-0.6	-0.51	Erythrocyte sedimentation rate;	chr1:25426126	chr1:25294164~25294643:-
PRAD	cis	rs9326248	0.798	rs10892079	ENSG00000280143.1	AP000892.6	12.54	3.3e-31	6.84e-28	0.44	0.51	Blood protein levels;	chr11:117146108	chr11:117204967~117210292:+
PRAD	cis	rs9326248	0.574	rs1263173	ENSG00000254851.1	RP11-109L13.1	-12.54	3.36e-31	6.96e-28	-0.71	-0.51	Blood protein levels;	chr11:116810292	chr11:117135528~117138582:+
PRAD	cis	rs6142102	0.625	rs4911381	ENSG00000276073.1	RP5-1125A11.7	12.54	3.36e-31	6.96e-28	0.49	0.51	Skin pigmentation;	chr20:33962539	chr20:33985617~33988989:-
PRAD	cis	rs6142102	0.602	rs6141435	ENSG00000276073.1	RP5-1125A11.7	-12.54	3.36e-31	6.96e-28	-0.49	-0.51	Skin pigmentation;	chr20:33963473	chr20:33985617~33988989:-
PRAD	cis	rs6142102	0.625	rs1883707	ENSG00000276073.1	RP5-1125A11.7	12.54	3.36e-31	6.96e-28	0.49	0.51	Skin pigmentation;	chr20:33964781	chr20:33985617~33988989:-
PRAD	cis	rs6142102	0.625	rs1883706	ENSG00000276073.1	RP5-1125A11.7	-12.54	3.36e-31	6.96e-28	-0.49	-0.51	Skin pigmentation;	chr20:33965071	chr20:33985617~33988989:-
PRAD	cis	rs6142102	0.625	rs1883705	ENSG00000276073.1	RP5-1125A11.7	-12.54	3.36e-31	6.96e-28	-0.49	-0.51	Skin pigmentation;	chr20:33965072	chr20:33985617~33988989:-
PRAD	cis	rs2404602	0.735	rs11072598	ENSG00000259422.1	RP11-593F23.1	-12.54	3.4e-31	7.03e-28	-0.66	-0.51	Blood metabolite levels;	chr15:76472447	chr15:76174891~76181486:-
PRAD	cis	rs977987	0.806	rs11149832	ENSG00000261783.1	RP11-252K23.2	-12.54	3.4e-31	7.04e-28	-0.69	-0.51	Dupuytren's disease;	chr16:75428815	chr16:75379818~75381260:-
PRAD	cis	rs4423214	0.84	rs1792224	ENSG00000254682.1	RP11-660L16.2	-12.54	3.45e-31	7.14e-28	-0.74	-0.51	Vitamin D levels;	chr11:71465095	chr11:71448674~71452157:+
PRAD	cis	rs4423214	0.84	rs1792226	ENSG00000254682.1	RP11-660L16.2	-12.54	3.45e-31	7.14e-28	-0.74	-0.51	Vitamin D levels;	chr11:71465528	chr11:71448674~71452157:+
PRAD	cis	rs4423214	0.84	rs1790344	ENSG00000254682.1	RP11-660L16.2	-12.54	3.45e-31	7.14e-28	-0.74	-0.51	Vitamin D levels;	chr11:71465851	chr11:71448674~71452157:+
PRAD	cis	rs4423214	0.84	rs1790343	ENSG00000254682.1	RP11-660L16.2	-12.54	3.45e-31	7.14e-28	-0.74	-0.51	Vitamin D levels;	chr11:71466161	chr11:71448674~71452157:+
PRAD	cis	rs4423214	0.84	rs1792227	ENSG00000254682.1	RP11-660L16.2	-12.54	3.45e-31	7.14e-28	-0.74	-0.51	Vitamin D levels;	chr11:71466366	chr11:71448674~71452157:+
PRAD	cis	rs4423214	0.84	rs1790341	ENSG00000254682.1	RP11-660L16.2	-12.54	3.45e-31	7.14e-28	-0.74	-0.51	Vitamin D levels;	chr11:71466532	chr11:71448674~71452157:+
PRAD	cis	rs4423214	0.84	rs1540127	ENSG00000254682.1	RP11-660L16.2	-12.54	3.45e-31	7.14e-28	-0.74	-0.51	Vitamin D levels;	chr11:71467992	chr11:71448674~71452157:+
PRAD	cis	rs977987	0.806	rs1549306	ENSG00000261783.1	RP11-252K23.2	-12.54	3.53e-31	7.29e-28	-0.7	-0.51	Dupuytren's disease;	chr16:75381443	chr16:75379818~75381260:-
PRAD	cis	rs9322193	0.884	rs9688699	ENSG00000223701.3	RAET1E-AS1	12.53	3.6e-31	7.44e-28	0.68	0.51	Lung cancer;	chr6:149733680	chr6:149884431~149919508:+
PRAD	cis	rs1577917	0.74	rs6926049	ENSG00000203875.9	SNHG5	12.53	3.65e-31	7.54e-28	0.58	0.51	Response to antipsychotic treatment;	chr6:85556415	chr6:85660950~85678736:-
PRAD	cis	rs3091242	0.933	rs9438904	ENSG00000224183.1	SDHDP6	-12.53	3.7e-31	7.63e-28	-0.6	-0.51	Erythrocyte sedimentation rate;	chr1:25430369	chr1:25294164~25294643:-
PRAD	cis	rs2658782	0.826	rs2925355	ENSG00000279684.1	RP11-755E23.2	-12.53	3.75e-31	7.73e-28	-0.82	-0.51	Pulmonary function decline;	chr11:93357721	chr11:93286629~93288903:-
PRAD	cis	rs3091242	0.933	rs10903129	ENSG00000224183.1	SDHDP6	-12.53	3.77e-31	7.79e-28	-0.58	-0.51	Erythrocyte sedimentation rate;	chr1:25442446	chr1:25294164~25294643:-
PRAD	cis	rs55794721	0.509	rs11249248	ENSG00000224183.1	SDHDP6	-12.53	3.83e-31	7.91e-28	-0.59	-0.51	Mean corpuscular volume;Plateletcrit;	chr1:25426560	chr1:25294164~25294643:-
PRAD	cis	rs977987	0.843	rs62062564	ENSG00000261783.1	RP11-252K23.2	-12.53	3.84e-31	7.93e-28	-0.69	-0.51	Dupuytren's disease;	chr16:75408724	chr16:75379818~75381260:-
PRAD	cis	rs3096299	0.667	rs2965947	ENSG00000274627.1	RP11-104N10.2	12.53	3.86e-31	7.96e-28	0.51	0.51	Multiple myeloma (IgH translocation);	chr16:89452262	chr16:89516797~89522217:+
PRAD	cis	rs3091242	0.933	rs10903130	ENSG00000224183.1	SDHDP6	-12.53	3.89e-31	8.03e-28	-0.58	-0.51	Erythrocyte sedimentation rate;	chr1:25442730	chr1:25294164~25294643:-
PRAD	cis	rs3091242	0.933	rs11249251	ENSG00000224183.1	SDHDP6	-12.53	3.89e-31	8.03e-28	-0.58	-0.51	Erythrocyte sedimentation rate;	chr1:25443697	chr1:25294164~25294643:-
PRAD	cis	rs12022452	0.908	rs4660423	ENSG00000238287.1	RP11-656D10.3	-12.53	3.9e-31	8.04e-28	-0.9	-0.51	Age-related hearing impairment (SNP x SNP interaction);	chr1:40554632	chr1:40493157~40508661:-
PRAD	cis	rs9326248	0.53	rs7123517	ENSG00000254851.1	RP11-109L13.1	-12.53	3.93e-31	8.1e-28	-1.03	-0.51	Blood protein levels;	chr11:117157039	chr11:117135528~117138582:+
PRAD	cis	rs7115242	0.514	rs4936367	ENSG00000254851.1	RP11-109L13.1	-12.53	3.93e-31	8.1e-28	-1.03	-0.51	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117171661	chr11:117135528~117138582:+
PRAD	cis	rs9326248	0.53	rs4604928	ENSG00000254851.1	RP11-109L13.1	-12.53	3.93e-31	8.1e-28	-1.03	-0.51	Blood protein levels;	chr11:117173487	chr11:117135528~117138582:+
PRAD	cis	rs6504950	1	rs7222197	ENSG00000275710.1	RP11-257O5.4	-12.52	3.99e-31	8.23e-28	-0.68	-0.51	Breast cancer;	chr17:54970138	chr17:54964474~54964679:+
PRAD	cis	rs35160687	0.798	rs6547674	ENSG00000273080.1	RP11-301O19.1	-12.52	4.01e-31	8.26e-28	-0.59	-0.51	Night sleep phenotypes;	chr2:86325796	chr2:86195590~86196049:+
PRAD	cis	rs35160687	0.798	rs11127029	ENSG00000273080.1	RP11-301O19.1	-12.52	4.01e-31	8.26e-28	-0.59	-0.51	Night sleep phenotypes;	chr2:86327502	chr2:86195590~86196049:+
PRAD	cis	rs6964833	1	rs35203738	ENSG00000277053.3	GTF2IP1	-12.52	4.02e-31	8.27e-28	-0.6	-0.51	Menarche (age at onset);	chr7:74690864	chr7:75185385~75237696:-
PRAD	cis	rs8062405	1	rs62036617	ENSG00000259982.1	CDC37P1	12.52	4.02e-31	8.28e-28	0.66	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28816177	chr16:28700294~28701540:-
PRAD	cis	rs8062405	1	rs4788095	ENSG00000259982.1	CDC37P1	12.52	4.02e-31	8.28e-28	0.66	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28820038	chr16:28700294~28701540:-
PRAD	cis	rs8062405	0.964	rs72793809	ENSG00000259982.1	CDC37P1	12.52	4.02e-31	8.28e-28	0.66	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821061	chr16:28700294~28701540:-
PRAD	cis	rs8062405	1	rs62036620	ENSG00000259982.1	CDC37P1	12.52	4.02e-31	8.28e-28	0.66	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821776	chr16:28700294~28701540:-
PRAD	cis	rs8062405	1	rs62036621	ENSG00000259982.1	CDC37P1	12.52	4.02e-31	8.28e-28	0.66	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821978	chr16:28700294~28701540:-
PRAD	cis	rs16828019	0.929	rs1032728	ENSG00000235358.1	RP11-399E6.1	12.52	4.08e-31	8.41e-28	0.94	0.51	Intelligence (multi-trait analysis);	chr1:41213894	chr1:41242373~41284861:+
PRAD	cis	rs9545047	0.967	rs9318627	ENSG00000227676.3	LINC01068	12.52	4.12e-31	8.48e-28	0.65	0.51	Schizophrenia;	chr13:79355944	chr13:79566727~79571436:+
PRAD	cis	rs12049351	0.774	rs12024146	ENSG00000229367.1	HMGN2P19	12.52	4.16e-31	8.56e-28	0.72	0.51	Circulating myeloperoxidase levels (plasma);	chr1:229525144	chr1:229570532~229570796:+
PRAD	cis	rs2882667	0.824	rs13189485	ENSG00000253404.1	AC034243.1	12.52	4.26e-31	8.75e-28	0.71	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139139712	chr5:138744434~138753309:-
PRAD	cis	rs12022452	1	rs12034162	ENSG00000238287.1	RP11-656D10.3	-12.52	4.26e-31	8.76e-28	-0.91	-0.51	Age-related hearing impairment (SNP x SNP interaction);	chr1:40498933	chr1:40493157~40508661:-
PRAD	cis	rs8062405	0.965	rs8049439	ENSG00000251417.2	RP11-1348G14.4	-12.51	4.39e-31	9e-28	-0.55	-0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826194	chr16:28802743~28817828:+
PRAD	cis	rs977987	0.843	rs4146810	ENSG00000261783.1	RP11-252K23.2	-12.51	4.48e-31	9.19e-28	-0.69	-0.51	Dupuytren's disease;	chr16:75381933	chr16:75379818~75381260:-
PRAD	cis	rs11690935	0.788	rs10201053	ENSG00000228389.1	AC068039.4	12.51	4.66e-31	9.54e-28	0.59	0.51	Schizophrenia;	chr2:172024653	chr2:171773482~171775844:+
PRAD	cis	rs12022452	1	rs75936657	ENSG00000238287.1	RP11-656D10.3	-12.51	4.73e-31	9.68e-28	-0.9	-0.51	Age-related hearing impairment (SNP x SNP interaction);	chr1:40536017	chr1:40493157~40508661:-
PRAD	cis	rs3096299	0.719	rs2965818	ENSG00000274627.1	RP11-104N10.2	12.5	4.84e-31	9.9e-28	0.5	0.51	Multiple myeloma (IgH translocation);	chr16:89444086	chr16:89516797~89522217:+
PRAD	cis	rs1061377	1	rs7685468	ENSG00000249207.1	RP11-360F5.1	-12.5	4.85e-31	9.93e-28	-0.52	-0.51	Uric acid levels;	chr4:39116649	chr4:39112677~39126818:-
PRAD	cis	rs11690935	0.851	rs10930502	ENSG00000228389.1	AC068039.4	12.5	4.85e-31	9.94e-28	0.59	0.51	Schizophrenia;	chr2:172025679	chr2:171773482~171775844:+
PRAD	cis	rs16828019	0.777	rs35044078	ENSG00000235358.1	RP11-399E6.1	12.5	4.86e-31	9.95e-28	0.95	0.51	Intelligence (multi-trait analysis);	chr1:41008728	chr1:41242373~41284861:+
PRAD	cis	rs4423214	0.84	rs1629220	ENSG00000254682.1	RP11-660L16.2	-12.5	5.1e-31	1.04e-27	-0.73	-0.51	Vitamin D levels;	chr11:71463507	chr11:71448674~71452157:+
PRAD	cis	rs9326248	0.53	rs2127905	ENSG00000254851.1	RP11-109L13.1	-12.5	5.12e-31	1.05e-27	-1.04	-0.51	Blood protein levels;	chr11:117155658	chr11:117135528~117138582:+
PRAD	cis	rs4660456	0.913	rs12743517	ENSG00000237899.1	RP4-739H11.3	12.5	5.23e-31	1.07e-27	0.72	0.51	Platelet count;	chr1:40759682	chr1:40669089~40687588:-
PRAD	cis	rs3091242	0.809	rs660129	ENSG00000224183.1	SDHDP6	-12.49	5.29e-31	1.08e-27	-0.6	-0.51	Erythrocyte sedimentation rate;	chr1:25400947	chr1:25294164~25294643:-
PRAD	cis	rs3091242	0.728	rs706845	ENSG00000224183.1	SDHDP6	-12.49	5.29e-31	1.08e-27	-0.6	-0.51	Erythrocyte sedimentation rate;	chr1:25404222	chr1:25294164~25294643:-
PRAD	cis	rs16828019	0.777	rs34502739	ENSG00000235358.1	RP11-399E6.1	12.49	5.29e-31	1.08e-27	0.95	0.51	Intelligence (multi-trait analysis);	chr1:40993474	chr1:41242373~41284861:+
PRAD	cis	rs6504950	0.745	rs9914088	ENSG00000275710.1	RP11-257O5.4	12.49	5.29e-31	1.08e-27	0.67	0.51	Breast cancer;	chr17:54902624	chr17:54964474~54964679:+
PRAD	cis	rs3091242	0.902	rs36003018	ENSG00000261349.1	RP3-465N24.5	12.49	5.33e-31	1.09e-27	0.56	0.51	Erythrocyte sedimentation rate;	chr1:25457827	chr1:25266102~25267136:-
PRAD	cis	rs3091242	0.933	rs35403885	ENSG00000261349.1	RP3-465N24.5	12.49	5.33e-31	1.09e-27	0.56	0.51	Erythrocyte sedimentation rate;	chr1:25458060	chr1:25266102~25267136:-
PRAD	cis	rs35160687	0.901	rs12999029	ENSG00000273080.1	RP11-301O19.1	12.49	5.34e-31	1.09e-27	0.6	0.51	Night sleep phenotypes;	chr2:86275790	chr2:86195590~86196049:+
PRAD	cis	rs7044106	0.762	rs1470307	ENSG00000226752.6	PSMD5-AS1	-12.49	5.34e-31	1.09e-27	-0.61	-0.51	Hip circumference adjusted for BMI;	chr9:120670761	chr9:120824828~120854385:+
PRAD	cis	rs16828019	0.852	rs16827876	ENSG00000235358.1	RP11-399E6.1	12.49	5.34e-31	1.09e-27	0.94	0.51	Intelligence (multi-trait analysis);	chr1:41073864	chr1:41242373~41284861:+
PRAD	cis	rs7617773	1	rs7617773	ENSG00000229759.1	MRPS18AP1	-12.49	5.39e-31	1.1e-27	-0.53	-0.51	Coronary artery disease;	chr3:48152025	chr3:48256350~48256938:-
PRAD	cis	rs58873874	0.522	rs6875379	ENSG00000251405.2	CTB-109A12.1	12.49	5.48e-31	1.12e-27	0.99	0.51	Bipolar disorder (body mass index interaction);	chr5:157391295	chr5:157362615~157460078:-
PRAD	cis	rs16828019	0.852	rs2300649	ENSG00000235358.1	RP11-399E6.1	12.49	5.51e-31	1.12e-27	0.94	0.51	Intelligence (multi-trait analysis);	chr1:41103531	chr1:41242373~41284861:+
PRAD	cis	rs16828019	0.852	rs3904243	ENSG00000235358.1	RP11-399E6.1	12.49	5.51e-31	1.12e-27	0.94	0.51	Intelligence (multi-trait analysis);	chr1:41109180	chr1:41242373~41284861:+
PRAD	cis	rs16828019	0.852	rs11209545	ENSG00000235358.1	RP11-399E6.1	12.49	5.51e-31	1.12e-27	0.94	0.51	Intelligence (multi-trait analysis);	chr1:41110685	chr1:41242373~41284861:+
PRAD	cis	rs16828019	0.852	rs11209576	ENSG00000235358.1	RP11-399E6.1	12.49	5.51e-31	1.12e-27	0.94	0.51	Intelligence (multi-trait analysis);	chr1:41120357	chr1:41242373~41284861:+
PRAD	cis	rs16828019	0.852	rs3766324	ENSG00000235358.1	RP11-399E6.1	12.49	5.51e-31	1.12e-27	0.94	0.51	Intelligence (multi-trait analysis);	chr1:41122981	chr1:41242373~41284861:+
PRAD	cis	rs16828019	0.929	rs8179465	ENSG00000235358.1	RP11-399E6.1	12.49	5.51e-31	1.12e-27	0.94	0.51	Intelligence (multi-trait analysis);	chr1:41236075	chr1:41242373~41284861:+
PRAD	cis	rs7182621	0.546	rs11632596	ENSG00000259363.4	CTD-2054N24.2	-12.49	5.51e-31	1.12e-27	-0.55	-0.51	Colonoscopy-negative controls vs population controls;	chr15:99834385	chr15:99807023~99877148:+
PRAD	cis	rs4423214	0.84	rs1792229	ENSG00000254682.1	RP11-660L16.2	-12.49	5.51e-31	1.12e-27	-0.73	-0.51	Vitamin D levels;	chr11:71468349	chr11:71448674~71452157:+
PRAD	cis	rs9322193	0.607	rs6925151	ENSG00000231760.4	RP11-350J20.5	12.49	5.67e-31	1.16e-27	0.76	0.51	Lung cancer;	chr6:149889587	chr6:149796151~149826294:-
PRAD	cis	rs4423214	0.84	rs1792233	ENSG00000254682.1	RP11-660L16.2	-12.49	5.68e-31	1.16e-27	-0.73	-0.51	Vitamin D levels;	chr11:71471133	chr11:71448674~71452157:+
PRAD	cis	rs6504950	0.72	rs9895901	ENSG00000275710.1	RP11-257O5.4	12.49	5.73e-31	1.17e-27	0.67	0.51	Breast cancer;	chr17:54907524	chr17:54964474~54964679:+
PRAD	cis	rs7182621	0.546	rs12906587	ENSG00000259363.4	CTD-2054N24.2	12.48	5.79e-31	1.18e-27	0.54	0.51	Colonoscopy-negative controls vs population controls;	chr15:99837114	chr15:99807023~99877148:+
PRAD	cis	rs2882667	0.858	rs11951899	ENSG00000253404.1	AC034243.1	12.48	5.8e-31	1.18e-27	0.74	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139038621	chr5:138744434~138753309:-
PRAD	cis	rs1061377	1	rs7685082	ENSG00000249207.1	RP11-360F5.1	-12.48	5.87e-31	1.2e-27	-0.52	-0.51	Uric acid levels;	chr4:39116472	chr4:39112677~39126818:-
PRAD	cis	rs1061377	1	rs7664078	ENSG00000249207.1	RP11-360F5.1	-12.48	5.87e-31	1.2e-27	-0.52	-0.51	Uric acid levels;	chr4:39116583	chr4:39112677~39126818:-
PRAD	cis	rs1061377	1	rs9998481	ENSG00000249207.1	RP11-360F5.1	-12.48	5.87e-31	1.2e-27	-0.52	-0.51	Uric acid levels;	chr4:39117215	chr4:39112677~39126818:-
PRAD	cis	rs8072100	0.905	rs9895274	ENSG00000228782.6	CTD-2026D20.3	12.48	5.95e-31	1.21e-27	0.56	0.51	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47461751	chr17:47450568~47492492:-
PRAD	cis	rs9322193	0.884	rs9383864	ENSG00000268592.3	RAET1E-AS1	12.48	5.99e-31	1.22e-27	0.68	0.51	Lung cancer;	chr6:149851969	chr6:149863494~149919507:+
PRAD	cis	rs55794721	0.509	rs11249248	ENSG00000261349.1	RP3-465N24.5	-12.48	6.02e-31	1.22e-27	-0.56	-0.5	Mean corpuscular volume;Plateletcrit;	chr1:25426560	chr1:25266102~25267136:-
PRAD	cis	rs16828019	0.777	rs12023079	ENSG00000235358.1	RP11-399E6.1	12.48	6.07e-31	1.24e-27	0.94	0.5	Intelligence (multi-trait analysis);	chr1:41004439	chr1:41242373~41284861:+
PRAD	cis	rs2882667	0.824	rs11748097	ENSG00000253404.1	AC034243.1	12.48	6.08e-31	1.24e-27	0.7	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139144198	chr5:138744434~138753309:-
PRAD	cis	rs2919917	1	rs2717547	ENSG00000254352.1	RP11-578O24.2	-12.48	6.23e-31	1.27e-27	-0.62	-0.5	Lymphocyte counts;	chr8:78744754	chr8:78723796~78724136:-
PRAD	cis	rs16828019	0.929	rs35286837	ENSG00000235358.1	RP11-399E6.1	12.47	6.34e-31	1.29e-27	0.94	0.5	Intelligence (multi-trait analysis);	chr1:41217326	chr1:41242373~41284861:+
PRAD	cis	rs9399135	0.967	rs4896120	ENSG00000232876.1	CTA-212D2.2	-12.47	6.46e-31	1.31e-27	-0.62	-0.5	Red blood cell count;	chr6:134972374	chr6:135055033~135060550:+
PRAD	cis	rs16828019	0.704	rs4996176	ENSG00000235358.1	RP11-399E6.1	12.47	6.54e-31	1.33e-27	0.94	0.5	Intelligence (multi-trait analysis);	chr1:41022496	chr1:41242373~41284861:+
PRAD	cis	rs16828019	0.777	rs35496942	ENSG00000235358.1	RP11-399E6.1	12.47	6.54e-31	1.33e-27	0.94	0.5	Intelligence (multi-trait analysis);	chr1:41023232	chr1:41242373~41284861:+
PRAD	cis	rs16828019	0.704	rs12031277	ENSG00000235358.1	RP11-399E6.1	12.47	6.54e-31	1.33e-27	0.94	0.5	Intelligence (multi-trait analysis);	chr1:41026129	chr1:41242373~41284861:+
PRAD	cis	rs1075265	0.584	rs1559037	ENSG00000233266.1	HMGB1P31	12.47	6.63e-31	1.35e-27	0.67	0.5	Chronotype;Morning vs. evening chronotype;	chr2:54051448	chr2:54051334~54051760:+
PRAD	cis	rs8062405	0.964	rs11860513	ENSG00000259982.1	CDC37P1	12.47	6.73e-31	1.37e-27	0.66	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814099	chr16:28700294~28701540:-
PRAD	cis	rs1061377	0.803	rs6857761	ENSG00000249207.1	RP11-360F5.1	-12.47	6.78e-31	1.38e-27	-0.52	-0.5	Uric acid levels;	chr4:39118353	chr4:39112677~39126818:-
PRAD	cis	rs977987	0.806	rs11149833	ENSG00000261783.1	RP11-252K23.2	-12.47	6.85e-31	1.39e-27	-0.69	-0.5	Dupuytren's disease;	chr16:75430104	chr16:75379818~75381260:-
PRAD	cis	rs977987	0.806	rs11641587	ENSG00000261783.1	RP11-252K23.2	-12.47	6.85e-31	1.39e-27	-0.69	-0.5	Dupuytren's disease;	chr16:75430521	chr16:75379818~75381260:-
PRAD	cis	rs977987	0.806	rs12930768	ENSG00000261783.1	RP11-252K23.2	-12.47	6.85e-31	1.39e-27	-0.69	-0.5	Dupuytren's disease;	chr16:75430602	chr16:75379818~75381260:-
PRAD	cis	rs977987	0.778	rs12445726	ENSG00000261783.1	RP11-252K23.2	-12.47	6.85e-31	1.39e-27	-0.69	-0.5	Dupuytren's disease;	chr16:75431677	chr16:75379818~75381260:-
PRAD	cis	rs2658782	0.756	rs2658777	ENSG00000279684.1	RP11-755E23.2	-12.47	6.93e-31	1.41e-27	-0.8	-0.5	Pulmonary function decline;	chr11:93415257	chr11:93286629~93288903:-
PRAD	cis	rs8062405	1	rs1987472	ENSG00000259982.1	CDC37P1	12.46	6.94e-31	1.41e-27	0.66	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814456	chr16:28700294~28701540:-
PRAD	cis	rs8062405	0.895	rs56186137	ENSG00000259982.1	CDC37P1	12.46	6.94e-31	1.41e-27	0.66	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814632	chr16:28700294~28701540:-
PRAD	cis	rs4423214	0.84	rs1790340	ENSG00000254682.1	RP11-660L16.2	-12.46	6.95e-31	1.41e-27	-0.76	-0.5	Vitamin D levels;	chr11:71471543	chr11:71448674~71452157:+
PRAD	cis	rs2284378	0.515	rs6059579	ENSG00000276073.1	RP5-1125A11.7	-12.46	6.99e-31	1.42e-27	-0.49	-0.5	Breast cancer;	chr20:33940059	chr20:33985617~33988989:-
PRAD	cis	rs977987	0.843	rs11644741	ENSG00000261783.1	RP11-252K23.2	-12.46	6.99e-31	1.42e-27	-0.69	-0.5	Dupuytren's disease;	chr16:75432535	chr16:75379818~75381260:-
PRAD	cis	rs977987	0.806	rs12917651	ENSG00000261783.1	RP11-252K23.2	-12.46	6.99e-31	1.42e-27	-0.69	-0.5	Dupuytren's disease;	chr16:75432798	chr16:75379818~75381260:-
PRAD	cis	rs1061377	1	rs9998867	ENSG00000249207.1	RP11-360F5.1	-12.46	7.08e-31	1.43e-27	-0.52	-0.5	Uric acid levels;	chr4:39117542	chr4:39112677~39126818:-
PRAD	cis	rs1061377	1	rs2381284	ENSG00000249207.1	RP11-360F5.1	-12.46	7.08e-31	1.43e-27	-0.52	-0.5	Uric acid levels;	chr4:39117976	chr4:39112677~39126818:-
PRAD	cis	rs4423214	0.84	rs1123007	ENSG00000254682.1	RP11-660L16.2	-12.46	7.35e-31	1.49e-27	-0.74	-0.5	Vitamin D levels;	chr11:71474311	chr11:71448674~71452157:+
PRAD	cis	rs1075265	0.584	rs7590846	ENSG00000233266.1	HMGB1P31	12.46	7.4e-31	1.5e-27	0.67	0.5	Chronotype;Morning vs. evening chronotype;	chr2:54051530	chr2:54051334~54051760:+
PRAD	cis	rs8072100	0.967	rs4338849	ENSG00000228782.6	CTD-2026D20.3	12.46	7.48e-31	1.52e-27	0.56	0.5	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47435117	chr17:47450568~47492492:-
PRAD	cis	rs16828019	0.777	rs67450703	ENSG00000235358.1	RP11-399E6.1	12.46	7.5e-31	1.52e-27	0.94	0.5	Intelligence (multi-trait analysis);	chr1:40994457	chr1:41242373~41284861:+
PRAD	cis	rs7617773	1	rs11711766	ENSG00000229759.1	MRPS18AP1	-12.46	7.59e-31	1.54e-27	-0.54	-0.5	Coronary artery disease;	chr3:48151680	chr3:48256350~48256938:-
PRAD	cis	rs7044106	0.762	rs10760115	ENSG00000226752.6	PSMD5-AS1	-12.46	7.6e-31	1.54e-27	-0.61	-0.5	Hip circumference adjusted for BMI;	chr9:120714674	chr9:120824828~120854385:+
PRAD	cis	rs10262624	0.528	rs722294	ENSG00000234286.1	AC006026.13	12.45	7.63e-31	1.54e-27	0.56	0.5	Schizophrenia;	chr7:23706966	chr7:23680195~23680786:-
PRAD	cis	rs7186831	1	rs7186831	ENSG00000261783.1	RP11-252K23.2	-12.45	7.64e-31	1.55e-27	-0.68	-0.5	Chronic obstructive pulmonary disease;	chr16:75439257	chr16:75379818~75381260:-
PRAD	cis	rs8072100	0.754	rs8081717	ENSG00000228782.6	CTD-2026D20.3	-12.45	7.65e-31	1.55e-27	-0.55	-0.5	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47576555	chr17:47450568~47492492:-
PRAD	cis	rs1577917	0.771	rs9362233	ENSG00000203875.9	SNHG5	-12.45	7.71e-31	1.56e-27	-0.58	-0.5	Response to antipsychotic treatment;	chr6:85648529	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.727	rs9351065	ENSG00000203875.9	SNHG5	-12.45	7.71e-31	1.56e-27	-0.58	-0.5	Response to antipsychotic treatment;	chr6:85650710	chr6:85660950~85678736:-
PRAD	cis	rs2882667	0.824	rs12173085	ENSG00000253404.1	AC034243.1	12.45	7.72e-31	1.56e-27	0.7	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139144336	chr5:138744434~138753309:-
PRAD	cis	rs9326248	0.559	rs476399	ENSG00000254851.1	RP11-109L13.1	-12.45	7.93e-31	1.6e-27	-0.63	-0.5	Blood protein levels;	chr11:116863012	chr11:117135528~117138582:+
PRAD	cis	rs9322193	0.923	rs4870052	ENSG00000268592.3	RAET1E-AS1	12.45	7.96e-31	1.61e-27	0.7	0.5	Lung cancer;	chr6:149839978	chr6:149863494~149919507:+
PRAD	cis	rs2111504	0.559	rs7250813	ENSG00000267213.4	AC007773.2	12.45	7.98e-31	1.61e-27	0.54	0.5	Bipolar disorder;	chr19:32358815	chr19:32390050~32405560:-
PRAD	cis	rs2581828	0.965	rs2581830	ENSG00000242142.1	SERBP1P3	12.45	8.04e-31	1.62e-27	0.56	0.5	Crohn's disease;	chr3:53100082	chr3:53064283~53065091:-
PRAD	cis	rs2581828	0.965	rs35783750	ENSG00000242142.1	SERBP1P3	12.45	8.04e-31	1.62e-27	0.56	0.5	Crohn's disease;	chr3:53100847	chr3:53064283~53065091:-
PRAD	cis	rs2581828	0.965	rs34454739	ENSG00000242142.1	SERBP1P3	12.45	8.04e-31	1.62e-27	0.56	0.5	Crohn's disease;	chr3:53100955	chr3:53064283~53065091:-
PRAD	cis	rs2581828	0.965	rs2564961	ENSG00000242142.1	SERBP1P3	12.45	8.04e-31	1.62e-27	0.56	0.5	Crohn's disease;	chr3:53102445	chr3:53064283~53065091:-
PRAD	cis	rs4423214	0.61	rs12789253	ENSG00000254682.1	RP11-660L16.2	12.45	8.06e-31	1.63e-27	0.6	0.5	Vitamin D levels;	chr11:71414719	chr11:71448674~71452157:+
PRAD	cis	rs8062405	1	rs4451951	ENSG00000259982.1	CDC37P1	12.45	8.12e-31	1.64e-27	0.66	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28824884	chr16:28700294~28701540:-
PRAD	cis	rs1577917	0.739	rs2758846	ENSG00000203875.9	SNHG5	-12.45	8.17e-31	1.65e-27	-0.58	-0.5	Response to antipsychotic treatment;	chr6:85639852	chr6:85660950~85678736:-
PRAD	cis	rs4423214	0.84	rs1792235	ENSG00000254682.1	RP11-660L16.2	-12.44	8.48e-31	1.71e-27	-0.73	-0.5	Vitamin D levels;	chr11:71470427	chr11:71448674~71452157:+
PRAD	cis	rs4423214	0.84	rs1619577	ENSG00000254682.1	RP11-660L16.2	-12.44	8.48e-31	1.71e-27	-0.73	-0.5	Vitamin D levels;	chr11:71470439	chr11:71448674~71452157:+
PRAD	cis	rs4423214	0.84	rs1792234	ENSG00000254682.1	RP11-660L16.2	-12.44	8.48e-31	1.71e-27	-0.73	-0.5	Vitamin D levels;	chr11:71470972	chr11:71448674~71452157:+
PRAD	cis	rs8072100	0.905	rs8077106	ENSG00000228782.6	CTD-2026D20.3	-12.44	8.53e-31	1.72e-27	-0.55	-0.5	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47575925	chr17:47450568~47492492:-
PRAD	cis	rs2404602	0.735	rs11635463	ENSG00000259422.1	RP11-593F23.1	-12.44	8.55e-31	1.73e-27	-0.65	-0.5	Blood metabolite levels;	chr15:76470645	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.709	rs11072597	ENSG00000259422.1	RP11-593F23.1	-12.44	8.55e-31	1.73e-27	-0.65	-0.5	Blood metabolite levels;	chr15:76471173	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.735	rs11857327	ENSG00000259422.1	RP11-593F23.1	-12.44	8.55e-31	1.73e-27	-0.65	-0.5	Blood metabolite levels;	chr15:76471922	chr15:76174891~76181486:-
PRAD	cis	rs12049351	0.665	rs4148761	ENSG00000229367.1	HMGN2P19	12.44	8.59e-31	1.73e-27	0.73	0.5	Circulating myeloperoxidase levels (plasma);	chr1:229526597	chr1:229570532~229570796:+
PRAD	cis	rs3091242	0.933	rs909833	ENSG00000224183.1	SDHDP6	-12.44	8.65e-31	1.74e-27	-0.59	-0.5	Erythrocyte sedimentation rate;	chr1:25427649	chr1:25294164~25294643:-
PRAD	cis	rs1062177	1	rs17741826	ENSG00000213433.5	RPLP1P6	12.44	8.77e-31	1.77e-27	0.58	0.5	Preschool internalizing problems;	chr5:151769701	chr5:151765859~151766378:-
PRAD	cis	rs2404602	0.735	rs2436996	ENSG00000259422.1	RP11-593F23.1	-12.44	8.78e-31	1.77e-27	-0.66	-0.5	Blood metabolite levels;	chr15:76525079	chr15:76174891~76181486:-
PRAD	cis	rs7044106	0.791	rs10985000	ENSG00000226752.6	PSMD5-AS1	-12.44	8.9e-31	1.79e-27	-0.62	-0.5	Hip circumference adjusted for BMI;	chr9:120721837	chr9:120824828~120854385:+
PRAD	cis	rs7044106	0.791	rs10985001	ENSG00000226752.6	PSMD5-AS1	-12.44	8.9e-31	1.79e-27	-0.62	-0.5	Hip circumference adjusted for BMI;	chr9:120721954	chr9:120824828~120854385:+
PRAD	cis	rs11690935	0.61	rs3770458	ENSG00000228389.1	AC068039.4	-12.44	8.9e-31	1.79e-27	-0.57	-0.5	Schizophrenia;	chr2:171794777	chr2:171773482~171775844:+
PRAD	cis	rs11690935	0.632	rs35854151	ENSG00000228389.1	AC068039.4	-12.44	8.9e-31	1.79e-27	-0.57	-0.5	Schizophrenia;	chr2:171800929	chr2:171773482~171775844:+
PRAD	cis	rs7044106	0.762	rs1411158	ENSG00000226752.6	PSMD5-AS1	-12.44	8.93e-31	1.8e-27	-0.61	-0.5	Hip circumference adjusted for BMI;	chr9:120702526	chr9:120824828~120854385:+
PRAD	cis	rs4853012	0.539	rs9789534	ENSG00000217702.2	RP11-287D1.4	12.44	9e-31	1.81e-27	0.79	0.5	Gestational age at birth (maternal effect);	chr2:74135863	chr2:74130583~74135395:+
PRAD	cis	rs977987	0.806	rs35787595	ENSG00000261783.1	RP11-252K23.2	-12.44	9.04e-31	1.82e-27	-0.69	-0.5	Dupuytren's disease;	chr16:75432949	chr16:75379818~75381260:-
PRAD	cis	rs2919917	1	rs1483573	ENSG00000254352.1	RP11-578O24.2	12.43	9.22e-31	1.86e-27	0.62	0.5	Lymphocyte counts;	chr8:78711382	chr8:78723796~78724136:-
PRAD	cis	rs16828019	0.929	rs10524	ENSG00000235358.1	RP11-399E6.1	12.43	9.27e-31	1.86e-27	0.94	0.5	Intelligence (multi-trait analysis);	chr1:41260801	chr1:41242373~41284861:+
PRAD	cis	rs11105298	0.891	rs11105314	ENSG00000258302.2	RP11-981P6.1	12.43	9.35e-31	1.88e-27	0.56	0.5	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89530782	chr12:89561129~89594878:+
PRAD	cis	rs992157	0.56	rs1514132	ENSG00000261338.2	RP11-378A13.1	-12.43	9.65e-31	1.94e-27	-0.56	-0.5	Colorectal cancer;	chr2:218219359	chr2:218255319~218257366:+
PRAD	cis	rs1185460	0.967	rs1786141	ENSG00000271751.1	RP11-110I1.14	-12.43	9.75e-31	1.96e-27	-0.69	-0.5	Coronary artery disease;	chr11:119067604	chr11:119065263~119065677:-
PRAD	cis	rs2919917	1	rs2919917	ENSG00000254352.1	RP11-578O24.2	-12.43	9.78e-31	1.97e-27	-0.63	-0.5	Lymphocyte counts;	chr8:78745028	chr8:78723796~78724136:-
PRAD	cis	rs12049351	0.774	rs12066463	ENSG00000229367.1	HMGN2P19	12.43	9.9e-31	1.99e-27	0.7	0.5	Circulating myeloperoxidase levels (plasma);	chr1:229533540	chr1:229570532~229570796:+
PRAD	cis	rs16828019	0.929	rs111309254	ENSG00000235358.1	RP11-399E6.1	12.43	9.92e-31	1.99e-27	0.94	0.5	Intelligence (multi-trait analysis);	chr1:41270328	chr1:41242373~41284861:+
PRAD	cis	rs16828019	0.929	rs4131949	ENSG00000235358.1	RP11-399E6.1	12.43	9.92e-31	1.99e-27	0.94	0.5	Intelligence (multi-trait analysis);	chr1:41272965	chr1:41242373~41284861:+
PRAD	cis	rs16828019	0.929	rs35813191	ENSG00000235358.1	RP11-399E6.1	12.43	9.92e-31	1.99e-27	0.94	0.5	Intelligence (multi-trait analysis);	chr1:41277128	chr1:41242373~41284861:+
PRAD	cis	rs9322193	0.923	rs12660304	ENSG00000223701.3	RAET1E-AS1	12.43	9.92e-31	1.99e-27	0.67	0.5	Lung cancer;	chr6:149739647	chr6:149884431~149919508:+
PRAD	cis	rs7044106	0.708	rs10760113	ENSG00000226752.6	PSMD5-AS1	-12.43	1e-30	2.01e-27	-0.62	-0.5	Hip circumference adjusted for BMI;	chr9:120711772	chr9:120824828~120854385:+
PRAD	cis	rs3091242	0.933	rs34006994	ENSG00000261349.1	RP3-465N24.5	12.43	1e-30	2.02e-27	0.55	0.5	Erythrocyte sedimentation rate;	chr1:25454177	chr1:25266102~25267136:-
PRAD	cis	rs3091242	0.933	rs61775167	ENSG00000261349.1	RP3-465N24.5	12.43	1e-30	2.02e-27	0.55	0.5	Erythrocyte sedimentation rate;	chr1:25454402	chr1:25266102~25267136:-
PRAD	cis	rs2117029	0.521	rs1039225	ENSG00000258017.1	RP11-386G11.10	-12.42	1.02e-30	2.05e-27	-0.67	-0.5	Intelligence (multi-trait analysis);	chr12:49188909	chr12:49127782~49147869:+
PRAD	cis	rs3091242	0.933	rs926438	ENSG00000261349.1	RP3-465N24.5	-12.42	1.02e-30	2.05e-27	-0.56	-0.5	Erythrocyte sedimentation rate;	chr1:25427147	chr1:25266102~25267136:-
PRAD	cis	rs7208859	0.623	rs8082537	ENSG00000263531.1	RP13-753N3.1	12.42	1.02e-30	2.05e-27	0.89	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30688914	chr17:30863921~30864940:-
PRAD	cis	rs17826219	0.561	rs11655876	ENSG00000263531.1	RP13-753N3.1	12.42	1.02e-30	2.05e-27	0.89	0.5	Body mass index;	chr17:30690132	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.673	rs9907197	ENSG00000263531.1	RP13-753N3.1	12.42	1.02e-30	2.05e-27	0.89	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30691245	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.673	rs9915963	ENSG00000263531.1	RP13-753N3.1	12.42	1.02e-30	2.05e-27	0.89	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30692625	chr17:30863921~30864940:-
PRAD	cis	rs9326248	0.559	rs484646	ENSG00000254851.1	RP11-109L13.1	-12.42	1.03e-30	2.06e-27	-0.63	-0.5	Blood protein levels;	chr11:116862140	chr11:117135528~117138582:+
PRAD	cis	rs2404602	0.735	rs4886798	ENSG00000259422.1	RP11-593F23.1	12.42	1.04e-30	2.09e-27	0.65	0.5	Blood metabolite levels;	chr15:76380885	chr15:76174891~76181486:-
PRAD	cis	rs1150668	0.699	rs1531681	ENSG00000216901.1	AL022393.7	12.42	1.05e-30	2.11e-27	0.63	0.5	Pubertal anthropometrics;	chr6:28259100	chr6:28176188~28176674:+
PRAD	cis	rs9322193	0.884	rs9397036	ENSG00000268592.3	RAET1E-AS1	12.42	1.06e-30	2.12e-27	0.68	0.5	Lung cancer;	chr6:149851787	chr6:149863494~149919507:+
PRAD	cis	rs8062405	1	rs2008514	ENSG00000259982.1	CDC37P1	-12.42	1.06e-30	2.13e-27	-0.65	-0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814284	chr16:28700294~28701540:-
PRAD	cis	rs977987	0.836	rs34673655	ENSG00000261783.1	RP11-252K23.2	-12.42	1.07e-30	2.14e-27	-0.68	-0.5	Dupuytren's disease;	chr16:75289661	chr16:75379818~75381260:-
PRAD	cis	rs977987	0.836	rs17685540	ENSG00000261783.1	RP11-252K23.2	-12.42	1.07e-30	2.14e-27	-0.68	-0.5	Dupuytren's disease;	chr16:75289942	chr16:75379818~75381260:-
PRAD	cis	rs7617773	0.823	rs9839446	ENSG00000229759.1	MRPS18AP1	-12.42	1.07e-30	2.14e-27	-0.54	-0.5	Coronary artery disease;	chr3:48153176	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.823	rs9839447	ENSG00000229759.1	MRPS18AP1	-12.42	1.07e-30	2.14e-27	-0.54	-0.5	Coronary artery disease;	chr3:48153177	chr3:48256350~48256938:-
PRAD	cis	rs1061377	1	rs35116118	ENSG00000249207.1	RP11-360F5.1	-12.42	1.07e-30	2.14e-27	-0.52	-0.5	Uric acid levels;	chr4:39127293	chr4:39112677~39126818:-
PRAD	cis	rs35160687	0.798	rs2367233	ENSG00000273080.1	RP11-301O19.1	-12.42	1.07e-30	2.15e-27	-0.59	-0.5	Night sleep phenotypes;	chr2:86314543	chr2:86195590~86196049:+
PRAD	cis	rs9399135	1	rs4475342	ENSG00000232876.1	CTA-212D2.2	-12.42	1.1e-30	2.2e-27	-0.62	-0.5	Red blood cell count;	chr6:134962210	chr6:135055033~135060550:+
PRAD	cis	rs977987	0.806	rs12448947	ENSG00000261783.1	RP11-252K23.2	-12.42	1.11e-30	2.22e-27	-0.69	-0.5	Dupuytren's disease;	chr16:75429056	chr16:75379818~75381260:-
PRAD	cis	rs977987	0.843	rs12928036	ENSG00000261783.1	RP11-252K23.2	-12.41	1.11e-30	2.22e-27	-0.7	-0.5	Dupuytren's disease;	chr16:75449234	chr16:75379818~75381260:-
PRAD	cis	rs977987	0.843	rs59465235	ENSG00000261783.1	RP11-252K23.2	-12.41	1.11e-30	2.22e-27	-0.7	-0.5	Dupuytren's disease;	chr16:75449912	chr16:75379818~75381260:-
PRAD	cis	rs9322193	0.847	rs868375	ENSG00000223701.3	RAET1E-AS1	12.41	1.13e-30	2.27e-27	0.67	0.5	Lung cancer;	chr6:149844905	chr6:149884431~149919508:+
PRAD	cis	rs11690935	0.589	rs2271758	ENSG00000228389.1	AC068039.4	-12.41	1.15e-30	2.3e-27	-0.57	-0.5	Schizophrenia;	chr2:171844647	chr2:171773482~171775844:+
PRAD	cis	rs8062405	0.728	rs11642449	ENSG00000259982.1	CDC37P1	12.41	1.15e-30	2.3e-27	0.69	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28884694	chr16:28700294~28701540:-
PRAD	cis	rs8062405	0.728	rs8056890	ENSG00000259982.1	CDC37P1	12.41	1.15e-30	2.3e-27	0.69	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28886131	chr16:28700294~28701540:-
PRAD	cis	rs875971	0.83	rs12673450	ENSG00000226824.5	RP4-756H11.3	-12.41	1.16e-30	2.31e-27	-0.71	-0.5	Aortic root size;	chr7:66544233	chr7:66654538~66669855:+
PRAD	cis	rs992157	0.56	rs4674275	ENSG00000261338.2	RP11-378A13.1	-12.41	1.16e-30	2.31e-27	-0.56	-0.5	Colorectal cancer;	chr2:218233015	chr2:218255319~218257366:+
PRAD	cis	rs992157	0.585	rs62182795	ENSG00000261338.2	RP11-378A13.1	-12.41	1.16e-30	2.31e-27	-0.56	-0.5	Colorectal cancer;	chr2:218235479	chr2:218255319~218257366:+
PRAD	cis	rs992157	0.56	rs12987130	ENSG00000261338.2	RP11-378A13.1	-12.41	1.16e-30	2.31e-27	-0.56	-0.5	Colorectal cancer;	chr2:218240267	chr2:218255319~218257366:+
PRAD	cis	rs11690935	0.885	rs7602037	ENSG00000228389.1	AC068039.4	12.41	1.17e-30	2.34e-27	0.59	0.5	Schizophrenia;	chr2:171961268	chr2:171773482~171775844:+
PRAD	cis	rs1075265	0.548	rs805448	ENSG00000233266.1	HMGB1P31	12.41	1.19e-30	2.38e-27	0.68	0.5	Chronotype;Morning vs. evening chronotype;	chr2:53950055	chr2:54051334~54051760:+
PRAD	cis	rs16828019	0.777	rs12047078	ENSG00000235358.1	RP11-399E6.1	12.41	1.19e-30	2.39e-27	0.94	0.5	Intelligence (multi-trait analysis);	chr1:40997314	chr1:41242373~41284861:+
PRAD	cis	rs992157	0.56	rs10932763	ENSG00000261338.2	RP11-378A13.1	-12.41	1.21e-30	2.41e-27	-0.56	-0.5	Colorectal cancer;	chr2:218221140	chr2:218255319~218257366:+
PRAD	cis	rs992157	0.56	rs12992937	ENSG00000261338.2	RP11-378A13.1	-12.41	1.21e-30	2.41e-27	-0.56	-0.5	Colorectal cancer;	chr2:218222349	chr2:218255319~218257366:+
PRAD	cis	rs992157	0.56	rs4674274	ENSG00000261338.2	RP11-378A13.1	-12.41	1.21e-30	2.41e-27	-0.56	-0.5	Colorectal cancer;	chr2:218224408	chr2:218255319~218257366:+
PRAD	cis	rs1577917	0.771	rs9362237	ENSG00000203875.9	SNHG5	12.41	1.21e-30	2.42e-27	0.59	0.5	Response to antipsychotic treatment;	chr6:85699346	chr6:85660950~85678736:-
PRAD	cis	rs494459	0.733	rs556437	ENSG00000255239.1	AP002954.6	12.41	1.21e-30	2.42e-27	0.65	0.5	Height;	chr11:118835044	chr11:118688039~118690600:-
PRAD	cis	rs11603023	0.772	rs540800	ENSG00000255239.1	AP002954.6	12.4	1.23e-30	2.45e-27	0.62	0.5	Cholesterol, total;	chr11:118694942	chr11:118688039~118690600:-
PRAD	cis	rs9322193	0.884	rs7744105	ENSG00000223701.3	RAET1E-AS1	12.4	1.23e-30	2.46e-27	0.66	0.5	Lung cancer;	chr6:149849308	chr6:149884431~149919508:+
PRAD	cis	rs2382817	0.58	rs6756265	ENSG00000261338.2	RP11-378A13.1	-12.4	1.23e-30	2.46e-27	-0.56	-0.5	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr2:218230831	chr2:218255319~218257366:+
PRAD	cis	rs9322193	0.923	rs9688350	ENSG00000223701.3	RAET1E-AS1	12.4	1.23e-30	2.46e-27	0.67	0.5	Lung cancer;	chr6:149730977	chr6:149884431~149919508:+
PRAD	cis	rs7044106	0.708	rs10984992	ENSG00000226752.6	PSMD5-AS1	-12.4	1.24e-30	2.48e-27	-0.61	-0.5	Hip circumference adjusted for BMI;	chr9:120711138	chr9:120824828~120854385:+
PRAD	cis	rs6504950	1	rs10468513	ENSG00000275710.1	RP11-257O5.4	12.4	1.26e-30	2.52e-27	0.67	0.5	Breast cancer;	chr17:54985542	chr17:54964474~54964679:+
PRAD	cis	rs6504950	1	rs56348638	ENSG00000275710.1	RP11-257O5.4	12.4	1.26e-30	2.52e-27	0.67	0.5	Breast cancer;	chr17:54987189	chr17:54964474~54964679:+
PRAD	cis	rs6142102	0.602	rs68051854	ENSG00000276073.1	RP5-1125A11.7	-12.4	1.26e-30	2.53e-27	-0.49	-0.5	Skin pigmentation;	chr20:34114150	chr20:33985617~33988989:-
PRAD	cis	rs2919917	0.955	rs1441850	ENSG00000254352.1	RP11-578O24.2	-12.4	1.26e-30	2.53e-27	-0.63	-0.5	Lymphocyte counts;	chr8:78745431	chr8:78723796~78724136:-
PRAD	cis	rs3091242	0.935	rs4233043	ENSG00000224183.1	SDHDP6	-12.4	1.27e-30	2.54e-27	-0.58	-0.5	Erythrocyte sedimentation rate;	chr1:25438992	chr1:25294164~25294643:-
PRAD	cis	rs3091242	0.933	rs11249250	ENSG00000224183.1	SDHDP6	-12.4	1.27e-30	2.54e-27	-0.58	-0.5	Erythrocyte sedimentation rate;	chr1:25441118	chr1:25294164~25294643:-
PRAD	cis	rs4423214	0.592	rs10898193	ENSG00000254682.1	RP11-660L16.2	12.4	1.28e-30	2.56e-27	0.8	0.5	Vitamin D levels;	chr11:71486037	chr11:71448674~71452157:+
PRAD	cis	rs2117029	0.521	rs11168910	ENSG00000258017.1	RP11-386G11.10	-12.4	1.28e-30	2.56e-27	-0.67	-0.5	Intelligence (multi-trait analysis);	chr12:49192707	chr12:49127782~49147869:+
PRAD	cis	rs9532669	0.926	rs9532657	ENSG00000176268.5	CYCSP34	-12.4	1.31e-30	2.61e-27	-0.51	-0.5	Cervical cancer;	chr13:40918208	chr13:40863599~40863902:-
PRAD	cis	rs189798	0.807	rs330909	ENSG00000254340.1	RP11-10A14.3	12.4	1.31e-30	2.61e-27	0.66	0.5	Myopia (pathological);	chr8:9137877	chr8:9141424~9145435:+
PRAD	cis	rs1061377	1	rs13182	ENSG00000249207.1	RP11-360F5.1	-12.4	1.32e-30	2.63e-27	-0.52	-0.5	Uric acid levels;	chr4:39121293	chr4:39112677~39126818:-
PRAD	cis	rs11105298	0.891	rs10858851	ENSG00000258302.2	RP11-981P6.1	12.4	1.33e-30	2.65e-27	0.56	0.5	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89437093	chr12:89561129~89594878:+
PRAD	cis	rs12022452	1	rs12031278	ENSG00000238287.1	RP11-656D10.3	-12.39	1.35e-30	2.69e-27	-0.9	-0.5	Age-related hearing impairment (SNP x SNP interaction);	chr1:40511246	chr1:40493157~40508661:-
PRAD	cis	rs9326248	0.515	rs2727793	ENSG00000254851.1	RP11-109L13.1	-12.39	1.36e-30	2.72e-27	-0.72	-0.5	Blood protein levels;	chr11:116812658	chr11:117135528~117138582:+
PRAD	cis	rs5769707	0.967	rs2071904	ENSG00000188511.11	C22orf34	12.39	1.37e-30	2.72e-27	0.53	0.5	Monocyte percentage of white cells;Monocyte count;	chr22:49640829	chr22:49414524~49657542:-
PRAD	cis	rs7044106	0.762	rs1324473	ENSG00000226752.6	PSMD5-AS1	12.39	1.37e-30	2.74e-27	0.61	0.5	Hip circumference adjusted for BMI;	chr9:120642332	chr9:120824828~120854385:+
PRAD	cis	rs5769707	0.846	rs5770610	ENSG00000188511.11	C22orf34	12.39	1.39e-30	2.78e-27	0.53	0.5	Monocyte percentage of white cells;Monocyte count;	chr22:49643249	chr22:49414524~49657542:-
PRAD	cis	rs172166	0.538	rs149956	ENSG00000216901.1	AL022393.7	12.39	1.4e-30	2.78e-27	0.62	0.5	Cardiac Troponin-T levels;	chr6:28068473	chr6:28176188~28176674:+
PRAD	cis	rs73086581	0.838	rs73088426	ENSG00000229539.1	RP11-119B16.2	12.39	1.4e-30	2.79e-27	0.86	0.5	Response to antidepressants in depression;	chr20:4022636	chr20:3888239~3888868:-
PRAD	cis	rs4718428	0.576	rs12698546	ENSG00000226824.5	RP4-756H11.3	-12.39	1.4e-30	2.79e-27	-0.71	-0.5	Corneal structure;	chr7:66801919	chr7:66654538~66669855:+
PRAD	cis	rs16828019	0.777	rs12748235	ENSG00000235358.1	RP11-399E6.1	12.39	1.4e-30	2.79e-27	0.94	0.5	Intelligence (multi-trait analysis);	chr1:41000549	chr1:41242373~41284861:+
PRAD	cis	rs6750795	0.502	rs11685196	ENSG00000181798.2	LINC00471	-12.39	1.41e-30	2.8e-27	-0.62	-0.5	Height;	chr2:231516587	chr2:231508426~231514339:-
PRAD	cis	rs7182621	0.546	rs11635811	ENSG00000259363.4	CTD-2054N24.2	-12.39	1.41e-30	2.81e-27	-0.54	-0.5	Colonoscopy-negative controls vs population controls;	chr15:99839918	chr15:99807023~99877148:+
PRAD	cis	rs5769707	0.967	rs763127	ENSG00000188511.11	C22orf34	12.39	1.42e-30	2.83e-27	0.52	0.5	Monocyte percentage of white cells;Monocyte count;	chr22:49612430	chr22:49414524~49657542:-
PRAD	cis	rs9322193	0.884	rs9383865	ENSG00000268592.3	RAET1E-AS1	12.39	1.43e-30	2.85e-27	0.68	0.5	Lung cancer;	chr6:149852043	chr6:149863494~149919507:+
PRAD	cis	rs16828019	0.632	rs12749196	ENSG00000235358.1	RP11-399E6.1	12.39	1.44e-30	2.86e-27	0.94	0.5	Intelligence (multi-trait analysis);	chr1:40995111	chr1:41242373~41284861:+
PRAD	cis	rs16828019	0.777	rs12047657	ENSG00000235358.1	RP11-399E6.1	12.39	1.44e-30	2.86e-27	0.94	0.5	Intelligence (multi-trait analysis);	chr1:40995841	chr1:41242373~41284861:+
PRAD	cis	rs16828019	0.85	rs12027691	ENSG00000235358.1	RP11-399E6.1	12.39	1.44e-30	2.86e-27	0.94	0.5	Intelligence (multi-trait analysis);	chr1:40996360	chr1:41242373~41284861:+
PRAD	cis	rs16828019	0.777	rs12739052	ENSG00000235358.1	RP11-399E6.1	12.39	1.44e-30	2.86e-27	0.94	0.5	Intelligence (multi-trait analysis);	chr1:40998783	chr1:41242373~41284861:+
PRAD	cis	rs977987	0.778	rs4243112	ENSG00000261783.1	RP11-252K23.2	-12.39	1.44e-30	2.87e-27	-0.67	-0.5	Dupuytren's disease;	chr16:75287133	chr16:75379818~75381260:-
PRAD	cis	rs5769707	0.839	rs73176988	ENSG00000188511.11	C22orf34	12.39	1.45e-30	2.88e-27	0.53	0.5	Monocyte percentage of white cells;Monocyte count;	chr22:49596001	chr22:49414524~49657542:-
PRAD	cis	rs7044106	0.762	rs10984972	ENSG00000226752.6	PSMD5-AS1	-12.38	1.49e-30	2.96e-27	-0.61	-0.5	Hip circumference adjusted for BMI;	chr9:120647586	chr9:120824828~120854385:+
PRAD	cis	rs16828019	0.777	rs3738369	ENSG00000235358.1	RP11-399E6.1	12.38	1.49e-30	2.96e-27	0.94	0.5	Intelligence (multi-trait analysis);	chr1:41020736	chr1:41242373~41284861:+
PRAD	cis	rs67383717	0.689	rs62559007	ENSG00000175611.10	LINC00476	-12.38	1.49e-30	2.97e-27	-0.6	-0.5	Parkinson's disease (pesticide exposure interaction);	chr9:95790981	chr9:95759231~95875977:-
PRAD	cis	rs992157	0.56	rs7578940	ENSG00000261338.2	RP11-378A13.1	-12.38	1.5e-30	2.98e-27	-0.57	-0.5	Colorectal cancer;	chr2:218218595	chr2:218255319~218257366:+
PRAD	cis	rs9326248	0.509	rs533556	ENSG00000254851.1	RP11-109L13.1	-12.38	1.51e-30	2.99e-27	-0.64	-0.5	Blood protein levels;	chr11:116870856	chr11:117135528~117138582:+
PRAD	cis	rs907683	0.559	rs11685408	ENSG00000280323.1	AC053503.12	12.38	1.51e-30	3e-27	0.42	0.5	Resting heart rate;	chr2:219426752	chr2:219427477~219429319:+
PRAD	cis	rs907683	0.583	rs10932803	ENSG00000280323.1	AC053503.12	12.38	1.51e-30	3e-27	0.42	0.5	Resting heart rate;	chr2:219428017	chr2:219427477~219429319:+
PRAD	cis	rs907683	0.533	rs12469789	ENSG00000280323.1	AC053503.12	12.38	1.51e-30	3e-27	0.42	0.5	Resting heart rate;	chr2:219428520	chr2:219427477~219429319:+
PRAD	cis	rs9322193	0.884	rs7743823	ENSG00000268592.3	RAET1E-AS1	12.38	1.52e-30	3.02e-27	0.68	0.5	Lung cancer;	chr6:149849744	chr6:149863494~149919507:+
PRAD	cis	rs977987	0.806	rs4888420	ENSG00000261783.1	RP11-252K23.2	-12.38	1.55e-30	3.07e-27	-0.69	-0.5	Dupuytren's disease;	chr16:75429100	chr16:75379818~75381260:-
PRAD	cis	rs977987	0.806	rs12449170	ENSG00000261783.1	RP11-252K23.2	-12.38	1.55e-30	3.07e-27	-0.69	-0.5	Dupuytren's disease;	chr16:75429114	chr16:75379818~75381260:-
PRAD	cis	rs4423214	0.765	rs2002064	ENSG00000254682.1	RP11-660L16.2	-12.38	1.57e-30	3.11e-27	-0.73	-0.5	Vitamin D levels;	chr11:71452374	chr11:71448674~71452157:+
PRAD	cis	rs4423214	0.84	rs1792315	ENSG00000254682.1	RP11-660L16.2	-12.38	1.57e-30	3.11e-27	-0.73	-0.5	Vitamin D levels;	chr11:71454501	chr11:71448674~71452157:+
PRAD	cis	rs3091242	0.933	rs34933589	ENSG00000261349.1	RP3-465N24.5	12.38	1.58e-30	3.14e-27	0.55	0.5	Erythrocyte sedimentation rate;	chr1:25461707	chr1:25266102~25267136:-
PRAD	cis	rs11168854	0.719	rs11168902	ENSG00000258017.1	RP11-386G11.10	-12.38	1.59e-30	3.15e-27	-0.67	-0.5	Body mass index;	chr12:49174483	chr12:49127782~49147869:+
PRAD	cis	rs2117029	0.553	rs11168903	ENSG00000258017.1	RP11-386G11.10	-12.38	1.59e-30	3.15e-27	-0.67	-0.5	Intelligence (multi-trait analysis);	chr12:49174883	chr12:49127782~49147869:+
PRAD	cis	rs9322193	0.923	rs56397000	ENSG00000223701.3	RAET1E-AS1	12.37	1.61e-30	3.19e-27	0.67	0.5	Lung cancer;	chr6:149739347	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.884	rs9689702	ENSG00000223701.3	RAET1E-AS1	12.37	1.61e-30	3.19e-27	0.67	0.5	Lung cancer;	chr6:149740720	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.923	rs10782315	ENSG00000223701.3	RAET1E-AS1	12.37	1.61e-30	3.19e-27	0.67	0.5	Lung cancer;	chr6:149743093	chr6:149884431~149919508:+
PRAD	cis	rs6142102	0.646	rs2223553	ENSG00000276073.1	RP5-1125A11.7	-12.37	1.65e-30	3.27e-27	-0.49	-0.5	Skin pigmentation;	chr20:34121638	chr20:33985617~33988989:-
PRAD	cis	rs1075265	0.584	rs1862121	ENSG00000233266.1	HMGB1P31	12.37	1.65e-30	3.27e-27	0.67	0.5	Chronotype;Morning vs. evening chronotype;	chr2:54058102	chr2:54051334~54051760:+
PRAD	cis	rs9326248	0.53	rs2471884	ENSG00000254851.1	RP11-109L13.1	-12.37	1.65e-30	3.27e-27	-1.01	-0.5	Blood protein levels;	chr11:117139604	chr11:117135528~117138582:+
PRAD	cis	rs1061377	1	rs6829450	ENSG00000249207.1	RP11-360F5.1	-12.37	1.65e-30	3.27e-27	-0.52	-0.5	Uric acid levels;	chr4:39114721	chr4:39112677~39126818:-
PRAD	cis	rs977987	0.806	rs4888405	ENSG00000261783.1	RP11-252K23.2	-12.37	1.67e-30	3.31e-27	-0.69	-0.5	Dupuytren's disease;	chr16:75394298	chr16:75379818~75381260:-
PRAD	cis	rs4845570	1	rs1054479	ENSG00000249602.1	RP11-98D18.3	12.37	1.68e-30	3.34e-27	0.77	0.5	Coronary artery disease;	chr1:151773603	chr1:151763384~151769501:-
PRAD	cis	rs2581828	0.656	rs2581800	ENSG00000242142.1	SERBP1P3	12.36	1.77e-30	3.51e-27	0.55	0.5	Crohn's disease;	chr3:53075336	chr3:53064283~53065091:-
PRAD	cis	rs9487094	1	rs36035949	ENSG00000260273.1	RP11-425D10.10	12.36	1.77e-30	3.51e-27	0.7	0.5	Height;	chr6:109415411	chr6:109382795~109383666:+
PRAD	cis	rs2581828	0.965	rs4337632	ENSG00000242142.1	SERBP1P3	12.36	1.78e-30	3.53e-27	0.56	0.5	Crohn's disease;	chr3:53103295	chr3:53064283~53065091:-
PRAD	cis	rs3091242	0.933	rs9438904	ENSG00000261349.1	RP3-465N24.5	-12.36	1.79e-30	3.54e-27	-0.56	-0.5	Erythrocyte sedimentation rate;	chr1:25430369	chr1:25266102~25267136:-
PRAD	cis	rs73086581	1	rs56324992	ENSG00000229539.1	RP11-119B16.2	12.36	1.79e-30	3.55e-27	0.8	0.5	Response to antidepressants in depression;	chr20:3997506	chr20:3888239~3888868:-
PRAD	cis	rs992157	0.56	rs7605980	ENSG00000261338.2	RP11-378A13.1	12.36	1.8e-30	3.56e-27	0.56	0.5	Colorectal cancer;	chr2:218236146	chr2:218255319~218257366:+
PRAD	cis	rs9322193	0.884	rs7769115	ENSG00000268592.3	RAET1E-AS1	12.36	1.81e-30	3.57e-27	0.68	0.5	Lung cancer;	chr6:149848796	chr6:149863494~149919507:+
PRAD	cis	rs1577917	0.771	rs2758844	ENSG00000203875.9	SNHG5	-12.36	1.83e-30	3.61e-27	-0.58	-0.5	Response to antipsychotic treatment;	chr6:85620397	chr6:85660950~85678736:-
PRAD	cis	rs3091242	0.933	rs10903129	ENSG00000261349.1	RP3-465N24.5	-12.36	1.83e-30	3.61e-27	-0.55	-0.5	Erythrocyte sedimentation rate;	chr1:25442446	chr1:25266102~25267136:-
PRAD	cis	rs7044106	0.762	rs10491783	ENSG00000226752.6	PSMD5-AS1	-12.36	1.83e-30	3.62e-27	-0.61	-0.5	Hip circumference adjusted for BMI;	chr9:120687877	chr9:120824828~120854385:+
PRAD	cis	rs7044106	0.762	rs966397	ENSG00000226752.6	PSMD5-AS1	-12.36	1.83e-30	3.62e-27	-0.61	-0.5	Hip circumference adjusted for BMI;	chr9:120691034	chr9:120824828~120854385:+
PRAD	cis	rs7044106	0.791	rs4836829	ENSG00000226752.6	PSMD5-AS1	-12.36	1.83e-30	3.62e-27	-0.62	-0.5	Hip circumference adjusted for BMI;	chr9:120720469	chr9:120824828~120854385:+
PRAD	cis	rs4845570	1	rs6683364	ENSG00000249602.1	RP11-98D18.3	12.36	1.84e-30	3.63e-27	0.77	0.5	Coronary artery disease;	chr1:151773726	chr1:151763384~151769501:-
PRAD	cis	rs11105298	0.891	rs11105310	ENSG00000258302.2	RP11-981P6.1	12.36	1.86e-30	3.68e-27	0.56	0.5	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89524900	chr12:89561129~89594878:+
PRAD	cis	rs11105298	0.891	rs10858896	ENSG00000258302.2	RP11-981P6.1	12.36	1.86e-30	3.68e-27	0.56	0.5	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89526407	chr12:89561129~89594878:+
PRAD	cis	rs11105298	0.786	rs10777186	ENSG00000258302.2	RP11-981P6.1	12.36	1.86e-30	3.68e-27	0.56	0.5	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89527500	chr12:89561129~89594878:+
PRAD	cis	rs11723261	0.582	rs11248006	ENSG00000275426.1	CH17-262A2.1	12.36	1.87e-30	3.69e-27	0.77	0.5	Immune response to smallpox vaccine (IL-6);	chr4:172914	chr4:149738~150317:+
PRAD	cis	rs3091242	0.933	rs10903130	ENSG00000261349.1	RP3-465N24.5	-12.36	1.87e-30	3.69e-27	-0.55	-0.5	Erythrocyte sedimentation rate;	chr1:25442730	chr1:25266102~25267136:-
PRAD	cis	rs3091242	0.933	rs11249251	ENSG00000261349.1	RP3-465N24.5	-12.36	1.87e-30	3.69e-27	-0.55	-0.5	Erythrocyte sedimentation rate;	chr1:25443697	chr1:25266102~25267136:-
PRAD	cis	rs9532669	0.89	rs4941999	ENSG00000176268.5	CYCSP34	12.36	1.88e-30	3.72e-27	0.54	0.5	Cervical cancer;	chr13:40859926	chr13:40863599~40863902:-
PRAD	cis	rs875971	0.597	rs11763224	ENSG00000237310.1	GS1-124K5.4	12.36	1.9e-30	3.76e-27	0.5	0.5	Aortic root size;	chr7:66518628	chr7:66493706~66495474:+
PRAD	cis	rs10170846	0.8	rs10194743	ENSG00000261428.2	RP11-16P6.1	12.36	1.91e-30	3.77e-27	0.65	0.5	Schizophrenia (inflammation and infection response interaction);	chr2:222653432	chr2:222566899~222569719:-
PRAD	cis	rs62388641	0.547	rs2745610	ENSG00000272279.1	RP11-157J24.2	-12.35	1.94e-30	3.82e-27	-0.69	-0.5	Daytime sleep phenotypes;	chr6:1553741	chr6:1528364~1528911:-
PRAD	cis	rs4423214	0.879	rs1792277	ENSG00000254682.1	RP11-660L16.2	-12.35	1.94e-30	3.83e-27	-0.72	-0.5	Vitamin D levels;	chr11:71427872	chr11:71448674~71452157:+
PRAD	cis	rs1061377	0.965	rs7677729	ENSG00000249207.1	RP11-360F5.1	-12.35	1.94e-30	3.84e-27	-0.52	-0.5	Uric acid levels;	chr4:39120370	chr4:39112677~39126818:-
PRAD	cis	rs1061377	1	rs3796511	ENSG00000249207.1	RP11-360F5.1	-12.35	1.94e-30	3.84e-27	-0.52	-0.5	Uric acid levels;	chr4:39120586	chr4:39112677~39126818:-
PRAD	cis	rs1061377	1	rs3733274	ENSG00000249207.1	RP11-360F5.1	-12.35	1.94e-30	3.84e-27	-0.52	-0.5	Uric acid levels;	chr4:39120957	chr4:39112677~39126818:-
PRAD	cis	rs1061377	1	rs1982009	ENSG00000249207.1	RP11-360F5.1	-12.35	1.94e-30	3.84e-27	-0.52	-0.5	Uric acid levels;	chr4:39123253	chr4:39112677~39126818:-
PRAD	cis	rs1061377	0.965	rs1138494	ENSG00000249207.1	RP11-360F5.1	-12.35	1.94e-30	3.84e-27	-0.52	-0.5	Uric acid levels;	chr4:39123315	chr4:39112677~39126818:-
PRAD	cis	rs1061377	0.965	rs1046655	ENSG00000249207.1	RP11-360F5.1	-12.35	1.94e-30	3.84e-27	-0.52	-0.5	Uric acid levels;	chr4:39126127	chr4:39112677~39126818:-
PRAD	cis	rs1061377	1	rs7694760	ENSG00000249207.1	RP11-360F5.1	-12.35	1.94e-30	3.84e-27	-0.52	-0.5	Uric acid levels;	chr4:39126481	chr4:39112677~39126818:-
PRAD	cis	rs1061377	1	rs34771104	ENSG00000249207.1	RP11-360F5.1	-12.35	1.94e-30	3.84e-27	-0.52	-0.5	Uric acid levels;	chr4:39127432	chr4:39112677~39126818:-
PRAD	cis	rs1061377	0.965	rs11728058	ENSG00000249207.1	RP11-360F5.1	-12.35	1.94e-30	3.84e-27	-0.52	-0.5	Uric acid levels;	chr4:39128224	chr4:39112677~39126818:-
PRAD	cis	rs1061377	1	rs17508864	ENSG00000249207.1	RP11-360F5.1	-12.35	1.94e-30	3.84e-27	-0.52	-0.5	Uric acid levels;	chr4:39129025	chr4:39112677~39126818:-
PRAD	cis	rs977987	0.872	rs1559339	ENSG00000261783.1	RP11-252K23.2	-12.35	1.98e-30	3.91e-27	-0.66	-0.5	Dupuytren's disease;	chr16:75284748	chr16:75379818~75381260:-
PRAD	cis	rs6964833	1	rs6964833	ENSG00000277053.3	GTF2IP1	-12.35	1.98e-30	3.91e-27	-0.6	-0.5	Menarche (age at onset);	chr7:74687575	chr7:75185385~75237696:-
PRAD	cis	rs1075265	0.584	rs4671178	ENSG00000233266.1	HMGB1P31	-12.35	1.99e-30	3.93e-27	-0.67	-0.5	Chronotype;Morning vs. evening chronotype;	chr2:54056356	chr2:54051334~54051760:+
PRAD	cis	rs875971	0.545	rs10950036	ENSG00000237310.1	GS1-124K5.4	12.35	2e-30	3.94e-27	0.5	0.5	Aortic root size;	chr7:66353241	chr7:66493706~66495474:+
PRAD	cis	rs1577917	0.739	rs9344532	ENSG00000203875.9	SNHG5	12.35	2.02e-30	3.98e-27	0.57	0.5	Response to antipsychotic treatment;	chr6:85524352	chr6:85660950~85678736:-
PRAD	cis	rs9532669	0.926	rs4942014	ENSG00000176268.5	CYCSP34	12.35	2.03e-30	3.99e-27	0.51	0.5	Cervical cancer;	chr13:40966366	chr13:40863599~40863902:-
PRAD	cis	rs3091242	0.933	rs909833	ENSG00000261349.1	RP3-465N24.5	-12.35	2.03e-30	4.01e-27	-0.56	-0.5	Erythrocyte sedimentation rate;	chr1:25427649	chr1:25266102~25267136:-
PRAD	cis	rs3091242	0.933	rs11802413	ENSG00000224183.1	SDHDP6	12.35	2.04e-30	4.02e-27	0.58	0.5	Erythrocyte sedimentation rate;	chr1:25434429	chr1:25294164~25294643:-
PRAD	cis	rs992157	0.56	rs6436048	ENSG00000261338.2	RP11-378A13.1	12.35	2.04e-30	4.03e-27	0.56	0.5	Colorectal cancer;	chr2:218244310	chr2:218255319~218257366:+
PRAD	cis	rs875971	0.545	rs6950988	ENSG00000237310.1	GS1-124K5.4	12.35	2.06e-30	4.05e-27	0.5	0.5	Aortic root size;	chr7:66511428	chr7:66493706~66495474:+
PRAD	cis	rs1577917	0.771	rs2842607	ENSG00000203875.9	SNHG5	-12.35	2.06e-30	4.06e-27	-0.58	-0.5	Response to antipsychotic treatment;	chr6:85635321	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.771	rs2758847	ENSG00000203875.9	SNHG5	-12.35	2.06e-30	4.06e-27	-0.58	-0.5	Response to antipsychotic treatment;	chr6:85639385	chr6:85660950~85678736:-
PRAD	cis	rs2739330	0.627	rs9608219	ENSG00000235689.1	AP000351.13	12.35	2.07e-30	4.08e-27	0.6	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:24006305~24008258:-
PRAD	cis	rs1062177	1	rs2964584	ENSG00000213433.5	RPLP1P6	-12.35	2.07e-30	4.08e-27	-0.57	-0.5	Preschool internalizing problems;	chr5:151763317	chr5:151765859~151766378:-
PRAD	cis	rs4660456	0.913	rs657149	ENSG00000237899.1	RP4-739H11.3	12.35	2.08e-30	4.1e-27	0.75	0.5	Platelet count;	chr1:40692486	chr1:40669089~40687588:-
PRAD	cis	rs2658782	0.789	rs1456238	ENSG00000279684.1	RP11-755E23.2	-12.35	2.1e-30	4.13e-27	-0.79	-0.5	Pulmonary function decline;	chr11:93384204	chr11:93286629~93288903:-
PRAD	cis	rs1061377	1	rs10027813	ENSG00000249207.1	RP11-360F5.1	-12.35	2.11e-30	4.15e-27	-0.52	-0.5	Uric acid levels;	chr4:39119818	chr4:39112677~39126818:-
PRAD	cis	rs8062405	1	rs3888190	ENSG00000259982.1	CDC37P1	12.35	2.11e-30	4.16e-27	0.66	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878165	chr16:28700294~28701540:-
PRAD	cis	rs1150668	0.799	rs9301	ENSG00000216901.1	AL022393.7	12.34	2.15e-30	4.23e-27	0.63	0.5	Pubertal anthropometrics;	chr6:28324929	chr6:28176188~28176674:+
PRAD	cis	rs1150668	0.799	rs853684	ENSG00000216901.1	AL022393.7	12.34	2.15e-30	4.23e-27	0.63	0.5	Pubertal anthropometrics;	chr6:28326773	chr6:28176188~28176674:+
PRAD	cis	rs3091242	0.9	rs4649086	ENSG00000261349.1	RP3-465N24.5	-12.34	2.17e-30	4.26e-27	-0.55	-0.5	Erythrocyte sedimentation rate;	chr1:25452476	chr1:25266102~25267136:-
PRAD	cis	rs7044106	0.791	rs4837793	ENSG00000226752.6	PSMD5-AS1	-12.34	2.17e-30	4.27e-27	-0.61	-0.5	Hip circumference adjusted for BMI;	chr9:120721343	chr9:120824828~120854385:+
PRAD	cis	rs7044106	0.762	rs10760112	ENSG00000226752.6	PSMD5-AS1	-12.34	2.17e-30	4.27e-27	-0.61	-0.5	Hip circumference adjusted for BMI;	chr9:120705292	chr9:120824828~120854385:+
PRAD	cis	rs7044106	0.708	rs920745	ENSG00000226752.6	PSMD5-AS1	-12.34	2.18e-30	4.28e-27	-0.6	-0.5	Hip circumference adjusted for BMI;	chr9:120667665	chr9:120824828~120854385:+
PRAD	cis	rs7044106	0.734	rs10491784	ENSG00000226752.6	PSMD5-AS1	-12.34	2.18e-30	4.28e-27	-0.6	-0.5	Hip circumference adjusted for BMI;	chr9:120670011	chr9:120824828~120854385:+
PRAD	cis	rs875971	0.545	rs801199	ENSG00000237310.1	GS1-124K5.4	-12.34	2.21e-30	4.33e-27	-0.5	-0.5	Aortic root size;	chr7:66560286	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.545	rs73152714	ENSG00000237310.1	GS1-124K5.4	12.34	2.21e-30	4.33e-27	0.5	0.5	Aortic root size;	chr7:66534641	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.545	rs4718364	ENSG00000237310.1	GS1-124K5.4	12.34	2.21e-30	4.33e-27	0.5	0.5	Aortic root size;	chr7:66536353	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.545	rs6961853	ENSG00000237310.1	GS1-124K5.4	12.34	2.21e-30	4.33e-27	0.5	0.5	Aortic root size;	chr7:66537035	chr7:66493706~66495474:+
PRAD	cis	rs4814920	0.818	rs4813376	ENSG00000275142.1	RP5-999L4.2	12.34	2.21e-30	4.33e-27	0.81	0.5	Bipolar disorder (body mass index interaction);	chr20:19870811	chr20:19871891~19872284:+
PRAD	cis	rs6504950	0.679	rs9908752	ENSG00000275710.1	RP11-257O5.4	12.34	2.27e-30	4.45e-27	0.66	0.5	Breast cancer;	chr17:54905855	chr17:54964474~54964679:+
PRAD	cis	rs977987	0.843	rs11149820	ENSG00000261783.1	RP11-252K23.2	-12.34	2.27e-30	4.46e-27	-0.68	-0.5	Dupuytren's disease;	chr16:75388862	chr16:75379818~75381260:-
PRAD	cis	rs977987	0.843	rs10514396	ENSG00000261783.1	RP11-252K23.2	-12.34	2.27e-30	4.46e-27	-0.68	-0.5	Dupuytren's disease;	chr16:75389005	chr16:75379818~75381260:-
PRAD	cis	rs1061377	1	rs1897136	ENSG00000249207.1	RP11-360F5.1	-12.34	2.31e-30	4.54e-27	-0.52	-0.5	Uric acid levels;	chr4:39131242	chr4:39112677~39126818:-
PRAD	cis	rs1061377	1	rs1897137	ENSG00000249207.1	RP11-360F5.1	-12.34	2.31e-30	4.54e-27	-0.52	-0.5	Uric acid levels;	chr4:39131387	chr4:39112677~39126818:-
PRAD	cis	rs1061377	1	rs7681116	ENSG00000249207.1	RP11-360F5.1	-12.34	2.31e-30	4.54e-27	-0.52	-0.5	Uric acid levels;	chr4:39133015	chr4:39112677~39126818:-
PRAD	cis	rs2581828	0.965	rs2581829	ENSG00000242142.1	SERBP1P3	-12.33	2.33e-30	4.58e-27	-0.56	-0.5	Crohn's disease;	chr3:53099510	chr3:53064283~53065091:-
PRAD	cis	rs1061377	1	rs9997089	ENSG00000249207.1	RP11-360F5.1	-12.33	2.34e-30	4.58e-27	-0.52	-0.5	Uric acid levels;	chr4:39119263	chr4:39112677~39126818:-
PRAD	cis	rs1061377	1	rs28465556	ENSG00000249207.1	RP11-360F5.1	-12.33	2.34e-30	4.58e-27	-0.52	-0.5	Uric acid levels;	chr4:39119569	chr4:39112677~39126818:-
PRAD	cis	rs1061377	1	rs9990755	ENSG00000249207.1	RP11-360F5.1	-12.33	2.34e-30	4.58e-27	-0.52	-0.5	Uric acid levels;	chr4:39119819	chr4:39112677~39126818:-
PRAD	cis	rs1061377	1	rs7676008	ENSG00000249207.1	RP11-360F5.1	-12.33	2.34e-30	4.58e-27	-0.52	-0.5	Uric acid levels;	chr4:39120154	chr4:39112677~39126818:-
PRAD	cis	rs1061377	1	rs7655122	ENSG00000249207.1	RP11-360F5.1	-12.33	2.34e-30	4.58e-27	-0.52	-0.5	Uric acid levels;	chr4:39120396	chr4:39112677~39126818:-
PRAD	cis	rs1061377	0.932	rs35464499	ENSG00000249207.1	RP11-360F5.1	-12.33	2.34e-30	4.58e-27	-0.52	-0.5	Uric acid levels;	chr4:39127670	chr4:39112677~39126818:-
PRAD	cis	rs9326248	0.59	rs2542063	ENSG00000254851.1	RP11-109L13.1	-12.33	2.34e-30	4.59e-27	-0.7	-0.5	Blood protein levels;	chr11:116814051	chr11:117135528~117138582:+
PRAD	cis	rs977987	0.778	rs12930452	ENSG00000261783.1	RP11-252K23.2	-12.33	2.35e-30	4.6e-27	-0.69	-0.5	Dupuytren's disease;	chr16:75428157	chr16:75379818~75381260:-
PRAD	cis	rs3931020	0.508	rs2345436	ENSG00000272864.1	RP11-17E13.2	-12.33	2.43e-30	4.76e-27	-0.55	-0.5	Resistin levels;	chr1:74733056	chr1:74698769~74699333:-
PRAD	cis	rs3931020	0.508	rs28568334	ENSG00000272864.1	RP11-17E13.2	-12.33	2.43e-30	4.76e-27	-0.55	-0.5	Resistin levels;	chr1:74733615	chr1:74698769~74699333:-
PRAD	cis	rs9326248	0.559	rs573549	ENSG00000254851.1	RP11-109L13.1	-12.33	2.46e-30	4.82e-27	-0.63	-0.5	Blood protein levels;	chr11:116865963	chr11:117135528~117138582:+
PRAD	cis	rs2658782	0.789	rs2658776	ENSG00000279684.1	RP11-755E23.2	-12.33	2.47e-30	4.84e-27	-0.79	-0.5	Pulmonary function decline;	chr11:93414761	chr11:93286629~93288903:-
PRAD	cis	rs7044106	0.791	rs2416799	ENSG00000226752.6	PSMD5-AS1	-12.33	2.48e-30	4.85e-27	-0.61	-0.5	Hip circumference adjusted for BMI;	chr9:120718588	chr9:120824828~120854385:+
PRAD	cis	rs11168854	0.62	rs11168888	ENSG00000258017.1	RP11-386G11.10	-12.33	2.5e-30	4.9e-27	-0.67	-0.5	Body mass index;	chr12:49149614	chr12:49127782~49147869:+
PRAD	cis	rs6504950	1	rs7219874	ENSG00000275710.1	RP11-257O5.4	12.33	2.5e-30	4.9e-27	0.67	0.5	Breast cancer;	chr17:54988446	chr17:54964474~54964679:+
PRAD	cis	rs6504950	1	rs8082471	ENSG00000275710.1	RP11-257O5.4	12.33	2.5e-30	4.9e-27	0.67	0.5	Breast cancer;	chr17:54990632	chr17:54964474~54964679:+
PRAD	cis	rs35160687	0.901	rs67903513	ENSG00000273080.1	RP11-301O19.1	12.33	2.51e-30	4.91e-27	0.6	0.5	Night sleep phenotypes;	chr2:86284976	chr2:86195590~86196049:+
PRAD	cis	rs172166	0.516	rs1225715	ENSG00000216901.1	AL022393.7	-12.33	2.55e-30	4.99e-27	-0.64	-0.5	Cardiac Troponin-T levels;	chr6:28145595	chr6:28176188~28176674:+
PRAD	cis	rs7044106	0.762	rs1886337	ENSG00000226752.6	PSMD5-AS1	-12.32	2.56e-30	5.01e-27	-0.6	-0.5	Hip circumference adjusted for BMI;	chr9:120681498	chr9:120824828~120854385:+
PRAD	cis	rs3096299	0.658	rs3934737	ENSG00000274627.1	RP11-104N10.2	12.32	2.57e-30	5.03e-27	0.5	0.5	Multiple myeloma (IgH translocation);	chr16:89493801	chr16:89516797~89522217:+
PRAD	cis	rs9322193	0.923	rs7769101	ENSG00000223701.3	RAET1E-AS1	12.32	2.58e-30	5.05e-27	0.68	0.5	Lung cancer;	chr6:149848768	chr6:149884431~149919508:+
PRAD	cis	rs9487094	0.961	rs11153175	ENSG00000260273.1	RP11-425D10.10	12.32	2.65e-30	5.18e-27	0.71	0.5	Height;	chr6:109361318	chr6:109382795~109383666:+
PRAD	cis	rs3814244	0.832	rs11177006	ENSG00000255733.4	IFNG-AS1	12.32	2.66e-30	5.2e-27	0.55	0.5	Itch intensity from mosquito bite adjusted by bite size;	chr12:68019317	chr12:67989445~68234686:+
PRAD	cis	rs7617773	1	rs6442108	ENSG00000229759.1	MRPS18AP1	-12.32	2.67e-30	5.22e-27	-0.54	-0.5	Coronary artery disease;	chr3:48151469	chr3:48256350~48256938:-
PRAD	cis	rs7617773	1	rs6442109	ENSG00000229759.1	MRPS18AP1	-12.32	2.67e-30	5.22e-27	-0.54	-0.5	Coronary artery disease;	chr3:48151491	chr3:48256350~48256938:-
PRAD	cis	rs9322193	0.923	rs4869750	ENSG00000268592.3	RAET1E-AS1	12.32	2.68e-30	5.24e-27	0.68	0.5	Lung cancer;	chr6:149855996	chr6:149863494~149919507:+
PRAD	cis	rs1061377	1	rs2890659	ENSG00000249207.1	RP11-360F5.1	-12.32	2.68e-30	5.24e-27	-0.52	-0.5	Uric acid levels;	chr4:39125401	chr4:39112677~39126818:-
PRAD	cis	rs172166	0.561	rs149971	ENSG00000216901.1	AL022393.7	12.32	2.69e-30	5.26e-27	0.62	0.5	Cardiac Troponin-T levels;	chr6:28014374	chr6:28176188~28176674:+
PRAD	cis	rs17826219	0.568	rs59858012	ENSG00000263531.1	RP13-753N3.1	12.32	2.71e-30	5.28e-27	1.11	0.5	Body mass index;	chr17:30751564	chr17:30863921~30864940:-
PRAD	cis	rs5769707	0.935	rs1109320	ENSG00000188511.11	C22orf34	12.32	2.71e-30	5.3e-27	0.52	0.5	Monocyte percentage of white cells;Monocyte count;	chr22:49595458	chr22:49414524~49657542:-
PRAD	cis	rs2404602	0.735	rs4886805	ENSG00000259422.1	RP11-593F23.1	12.32	2.72e-30	5.31e-27	0.65	0.5	Blood metabolite levels;	chr15:76447043	chr15:76174891~76181486:-
PRAD	cis	rs5769707	0.935	rs5770594	ENSG00000188511.11	C22orf34	12.32	2.74e-30	5.35e-27	0.53	0.5	Monocyte percentage of white cells;Monocyte count;	chr22:49624849	chr22:49414524~49657542:-
PRAD	cis	rs5769707	0.967	rs4524218	ENSG00000188511.11	C22orf34	12.32	2.74e-30	5.35e-27	0.53	0.5	Monocyte percentage of white cells;Monocyte count;	chr22:49624991	chr22:49414524~49657542:-
PRAD	cis	rs9532669	0.926	rs4628824	ENSG00000176268.5	CYCSP34	12.32	2.77e-30	5.4e-27	0.52	0.5	Cervical cancer;	chr13:40876217	chr13:40863599~40863902:-
PRAD	cis	rs12429206	0.52	rs1870839	ENSG00000233672.5	RNASEH2B-AS1	-12.32	2.78e-30	5.42e-27	-0.73	-0.5	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50899732	chr13:50862172~50910764:-
PRAD	cis	rs977987	0.8	rs3784935	ENSG00000261783.1	RP11-252K23.2	-12.32	2.8e-30	5.46e-27	-0.68	-0.5	Dupuytren's disease;	chr16:75302532	chr16:75379818~75381260:-
PRAD	cis	rs3091242	0.933	rs7541095	ENSG00000261349.1	RP3-465N24.5	-12.32	2.8e-30	5.46e-27	-0.55	-0.5	Erythrocyte sedimentation rate;	chr1:25434800	chr1:25266102~25267136:-
PRAD	cis	rs1061377	1	rs35437629	ENSG00000249207.1	RP11-360F5.1	-12.31	2.81e-30	5.49e-27	-0.52	-0.5	Uric acid levels;	chr4:39131712	chr4:39112677~39126818:-
PRAD	cis	rs1061377	1	rs7657926	ENSG00000249207.1	RP11-360F5.1	-12.31	2.81e-30	5.49e-27	-0.52	-0.5	Uric acid levels;	chr4:39132443	chr4:39112677~39126818:-
PRAD	cis	rs1061377	1	rs11096982	ENSG00000249207.1	RP11-360F5.1	-12.31	2.81e-30	5.49e-27	-0.52	-0.5	Uric acid levels;	chr4:39133247	chr4:39112677~39126818:-
PRAD	cis	rs1061377	1	rs11727875	ENSG00000249207.1	RP11-360F5.1	-12.31	2.81e-30	5.49e-27	-0.52	-0.5	Uric acid levels;	chr4:39133699	chr4:39112677~39126818:-
PRAD	cis	rs977987	0.8	rs11645329	ENSG00000261783.1	RP11-252K23.2	-12.31	2.83e-30	5.51e-27	-0.68	-0.5	Dupuytren's disease;	chr16:75302781	chr16:75379818~75381260:-
PRAD	cis	rs977987	0.762	rs1364079	ENSG00000261783.1	RP11-252K23.2	-12.31	2.84e-30	5.54e-27	-0.67	-0.5	Dupuytren's disease;	chr16:75359233	chr16:75379818~75381260:-
PRAD	cis	rs6964833	0.935	rs7795282	ENSG00000277053.3	GTF2IP1	-12.31	2.85e-30	5.55e-27	-0.59	-0.5	Menarche (age at onset);	chr7:74708526	chr7:75185385~75237696:-
PRAD	cis	rs35160687	0.901	rs12472676	ENSG00000273080.1	RP11-301O19.1	12.31	2.86e-30	5.57e-27	0.59	0.5	Night sleep phenotypes;	chr2:86283692	chr2:86195590~86196049:+
PRAD	cis	rs2581828	0.931	rs2564942	ENSG00000242142.1	SERBP1P3	12.31	2.87e-30	5.59e-27	0.57	0.5	Crohn's disease;	chr3:53105490	chr3:53064283~53065091:-
PRAD	cis	rs977987	0.806	rs11862095	ENSG00000261783.1	RP11-252K23.2	-12.31	2.88e-30	5.61e-27	-0.67	-0.5	Dupuytren's disease;	chr16:75351520	chr16:75379818~75381260:-
PRAD	cis	rs8062405	0.698	rs7188071	ENSG00000259982.1	CDC37P1	-12.31	2.9e-30	5.65e-27	-0.68	-0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28906323	chr16:28700294~28701540:-
PRAD	cis	rs9532669	0.89	rs12865032	ENSG00000176268.5	CYCSP34	12.31	2.9e-30	5.65e-27	0.52	0.5	Cervical cancer;	chr13:40873801	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.89	rs34123829	ENSG00000176268.5	CYCSP34	12.31	2.9e-30	5.65e-27	0.52	0.5	Cervical cancer;	chr13:40873808	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.926	rs4488324	ENSG00000176268.5	CYCSP34	12.31	2.9e-30	5.65e-27	0.52	0.5	Cervical cancer;	chr13:40873864	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.926	rs4288867	ENSG00000176268.5	CYCSP34	12.31	2.9e-30	5.65e-27	0.52	0.5	Cervical cancer;	chr13:40873880	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.926	rs4415896	ENSG00000176268.5	CYCSP34	12.31	2.9e-30	5.65e-27	0.52	0.5	Cervical cancer;	chr13:40874001	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.89	rs4415897	ENSG00000176268.5	CYCSP34	12.31	2.9e-30	5.65e-27	0.52	0.5	Cervical cancer;	chr13:40874035	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.926	rs4389021	ENSG00000176268.5	CYCSP34	12.31	2.9e-30	5.65e-27	0.52	0.5	Cervical cancer;	chr13:40874209	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.824	rs4628828	ENSG00000176268.5	CYCSP34	12.31	2.9e-30	5.65e-27	0.52	0.5	Cervical cancer;	chr13:40874369	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.737	rs34354179	ENSG00000176268.5	CYCSP34	12.31	2.9e-30	5.65e-27	0.52	0.5	Cervical cancer;	chr13:40874424	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.926	rs9594445	ENSG00000176268.5	CYCSP34	12.31	2.9e-30	5.65e-27	0.52	0.5	Cervical cancer;	chr13:40874859	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.926	rs9594446	ENSG00000176268.5	CYCSP34	12.31	2.9e-30	5.65e-27	0.52	0.5	Cervical cancer;	chr13:40874863	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.926	rs4402423	ENSG00000176268.5	CYCSP34	12.31	2.9e-30	5.65e-27	0.52	0.5	Cervical cancer;	chr13:40875010	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.963	rs9532628	ENSG00000176268.5	CYCSP34	12.31	2.9e-30	5.65e-27	0.52	0.5	Cervical cancer;	chr13:40875172	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.926	rs9532629	ENSG00000176268.5	CYCSP34	12.31	2.9e-30	5.65e-27	0.52	0.5	Cervical cancer;	chr13:40875193	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.926	rs7491149	ENSG00000176268.5	CYCSP34	12.31	2.9e-30	5.65e-27	0.52	0.5	Cervical cancer;	chr13:40875216	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.926	rs9532630	ENSG00000176268.5	CYCSP34	12.31	2.9e-30	5.65e-27	0.52	0.5	Cervical cancer;	chr13:40875472	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.89	rs4306385	ENSG00000176268.5	CYCSP34	12.31	2.9e-30	5.65e-27	0.52	0.5	Cervical cancer;	chr13:40875641	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.926	rs4406939	ENSG00000176268.5	CYCSP34	12.31	2.9e-30	5.65e-27	0.52	0.5	Cervical cancer;	chr13:40876108	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.926	rs9532632	ENSG00000176268.5	CYCSP34	12.31	2.9e-30	5.65e-27	0.52	0.5	Cervical cancer;	chr13:40876309	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.926	rs9532633	ENSG00000176268.5	CYCSP34	12.31	2.9e-30	5.65e-27	0.52	0.5	Cervical cancer;	chr13:40876332	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.926	rs9532634	ENSG00000176268.5	CYCSP34	12.31	2.9e-30	5.65e-27	0.52	0.5	Cervical cancer;	chr13:40876369	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.926	rs9532635	ENSG00000176268.5	CYCSP34	12.31	2.9e-30	5.65e-27	0.52	0.5	Cervical cancer;	chr13:40876397	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.926	rs12428959	ENSG00000176268.5	CYCSP34	12.31	2.9e-30	5.65e-27	0.52	0.5	Cervical cancer;	chr13:40876638	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.895	rs4942009	ENSG00000176268.5	CYCSP34	12.31	2.9e-30	5.65e-27	0.52	0.5	Cervical cancer;	chr13:40877243	chr13:40863599~40863902:-
PRAD	cis	rs73086581	0.838	rs11907416	ENSG00000229539.1	RP11-119B16.2	12.31	2.91e-30	5.67e-27	0.86	0.5	Response to antidepressants in depression;	chr20:4024972	chr20:3888239~3888868:-
PRAD	cis	rs9399135	0.967	rs4895434	ENSG00000232876.1	CTA-212D2.2	-12.31	2.95e-30	5.74e-27	-0.62	-0.5	Red blood cell count;	chr6:134972227	chr6:135055033~135060550:+
PRAD	cis	rs9399135	1	rs4895435	ENSG00000232876.1	CTA-212D2.2	-12.31	2.95e-30	5.74e-27	-0.62	-0.5	Red blood cell count;	chr6:134972325	chr6:135055033~135060550:+
PRAD	cis	rs11105298	0.891	rs10858869	ENSG00000258302.2	RP11-981P6.1	12.31	2.95e-30	5.74e-27	0.56	0.5	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89463834	chr12:89561129~89594878:+
PRAD	cis	rs11105298	0.891	rs10858871	ENSG00000258302.2	RP11-981P6.1	12.31	2.95e-30	5.74e-27	0.56	0.5	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89477836	chr12:89561129~89594878:+
PRAD	cis	rs11105298	0.891	rs11105299	ENSG00000258302.2	RP11-981P6.1	12.31	2.95e-30	5.74e-27	0.56	0.5	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89484166	chr12:89561129~89594878:+
PRAD	cis	rs11105298	0.891	rs1008764	ENSG00000258302.2	RP11-981P6.1	12.31	2.95e-30	5.74e-27	0.56	0.5	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89493872	chr12:89561129~89594878:+
PRAD	cis	rs9322193	0.923	rs12526675	ENSG00000223701.3	RAET1E-AS1	-12.31	2.96e-30	5.76e-27	-0.66	-0.5	Lung cancer;	chr6:149729540	chr6:149884431~149919508:+
PRAD	cis	rs7044106	0.791	rs7036766	ENSG00000226752.6	PSMD5-AS1	-12.31	2.97e-30	5.78e-27	-0.61	-0.5	Hip circumference adjusted for BMI;	chr9:120717343	chr9:120824828~120854385:+
PRAD	cis	rs7208859	0.725	rs9910051	ENSG00000263531.1	RP13-753N3.1	12.31	2.99e-30	5.81e-27	0.87	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834184	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.725	rs7210904	ENSG00000263531.1	RP13-753N3.1	12.31	2.99e-30	5.81e-27	0.87	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30843187	chr17:30863921~30864940:-
PRAD	cis	rs6142102	0.625	rs4911138	ENSG00000276073.1	RP5-1125A11.7	-12.31	3e-30	5.83e-27	-0.49	-0.5	Skin pigmentation;	chr20:33959893	chr20:33985617~33988989:-
PRAD	cis	rs1150668	0.799	rs1736891	ENSG00000216901.1	AL022393.7	12.31	3e-30	5.84e-27	0.64	0.5	Pubertal anthropometrics;	chr6:28219323	chr6:28176188~28176674:+
PRAD	cis	rs11105298	0.891	rs10777184	ENSG00000258302.2	RP11-981P6.1	12.31	3.02e-30	5.87e-27	0.56	0.5	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89525791	chr12:89561129~89594878:+
PRAD	cis	rs11105298	0.891	rs10858898	ENSG00000258302.2	RP11-981P6.1	12.31	3.02e-30	5.87e-27	0.56	0.5	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89528334	chr12:89561129~89594878:+
PRAD	cis	rs977987	0.806	rs4638613	ENSG00000261783.1	RP11-252K23.2	-12.31	3.02e-30	5.87e-27	-0.67	-0.5	Dupuytren's disease;	chr16:75391655	chr16:75379818~75381260:-
PRAD	cis	rs2739330	0.892	rs4822455	ENSG00000231271.1	AP000350.8	12.31	3.03e-30	5.88e-27	0.68	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23949918~23954042:+
PRAD	cis	rs73086581	1	rs17287822	ENSG00000229539.1	RP11-119B16.2	12.31	3.06e-30	5.94e-27	0.79	0.5	Response to antidepressants in depression;	chr20:3997889	chr20:3888239~3888868:-
PRAD	cis	rs9322193	0.923	rs10747276	ENSG00000223701.3	RAET1E-AS1	12.31	3.08e-30	5.99e-27	0.67	0.5	Lung cancer;	chr6:149758739	chr6:149884431~149919508:+
PRAD	cis	rs977987	0.815	rs1364078	ENSG00000261783.1	RP11-252K23.2	-12.3	3.1e-30	6.03e-27	-0.68	-0.5	Dupuytren's disease;	chr16:75362983	chr16:75379818~75381260:-
PRAD	cis	rs7044106	0.762	rs13291660	ENSG00000226752.6	PSMD5-AS1	-12.3	3.16e-30	6.14e-27	-0.6	-0.5	Hip circumference adjusted for BMI;	chr9:120630470	chr9:120824828~120854385:+
PRAD	cis	rs6142102	0.517	rs6142050	ENSG00000276073.1	RP5-1125A11.7	-12.3	3.19e-30	6.19e-27	-0.49	-0.5	Skin pigmentation;	chr20:33939322	chr20:33985617~33988989:-
PRAD	cis	rs8072100	1	rs8072100	ENSG00000228782.6	CTD-2026D20.3	-12.3	3.19e-30	6.19e-27	-0.55	-0.5	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47597321	chr17:47450568~47492492:-
PRAD	cis	rs1061377	1	rs12499266	ENSG00000249207.1	RP11-360F5.1	12.3	3.2e-30	6.21e-27	0.52	0.5	Uric acid levels;	chr4:39118133	chr4:39112677~39126818:-
PRAD	cis	rs9322193	0.923	rs35830138	ENSG00000223701.3	RAET1E-AS1	12.3	3.24e-30	6.29e-27	0.67	0.5	Lung cancer;	chr6:149668635	chr6:149884431~149919508:+
PRAD	cis	rs7044106	0.762	rs3903886	ENSG00000226752.6	PSMD5-AS1	12.3	3.31e-30	6.41e-27	0.61	0.5	Hip circumference adjusted for BMI;	chr9:120621368	chr9:120824828~120854385:+
PRAD	cis	rs9322193	0.923	rs35961297	ENSG00000223701.3	RAET1E-AS1	12.3	3.31e-30	6.41e-27	0.67	0.5	Lung cancer;	chr6:149667929	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.923	rs35967444	ENSG00000223701.3	RAET1E-AS1	12.3	3.31e-30	6.41e-27	0.67	0.5	Lung cancer;	chr6:149675588	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.923	rs62439842	ENSG00000223701.3	RAET1E-AS1	12.3	3.31e-30	6.41e-27	0.67	0.5	Lung cancer;	chr6:149675847	chr6:149884431~149919508:+
PRAD	cis	rs71403859	0.502	rs12927006	ENSG00000260886.1	TAT-AS1	12.3	3.34e-30	6.47e-27	0.86	0.5	Post bronchodilator FEV1;	chr16:71516008	chr16:71565789~71578187:+
PRAD	cis	rs2117029	0.554	rs35884657	ENSG00000258017.1	RP11-386G11.10	-12.29	3.42e-30	6.61e-27	-0.67	-0.5	Intelligence (multi-trait analysis);	chr12:49137317	chr12:49127782~49147869:+
PRAD	cis	rs977987	0.843	rs62062568	ENSG00000261783.1	RP11-252K23.2	-12.29	3.43e-30	6.64e-27	-0.68	-0.5	Dupuytren's disease;	chr16:75411426	chr16:75379818~75381260:-
PRAD	cis	rs11118620	0.535	rs1389750	ENSG00000272823.1	RP11-295M18.6	12.29	3.45e-30	6.68e-27	0.55	0.5	Heart failure;	chr1:220866829	chr1:220828676~220829211:-
PRAD	cis	rs4423214	0.84	rs1790328	ENSG00000254682.1	RP11-660L16.2	-12.29	3.48e-30	6.72e-27	-0.71	-0.5	Vitamin D levels;	chr11:71436992	chr11:71448674~71452157:+
PRAD	cis	rs2111504	0.583	rs10853921	ENSG00000267213.4	AC007773.2	-12.29	3.48e-30	6.74e-27	-0.54	-0.5	Bipolar disorder;	chr19:32370899	chr19:32390050~32405560:-
PRAD	cis	rs1150668	0.699	rs13408	ENSG00000216901.1	AL022393.7	12.29	3.52e-30	6.81e-27	0.63	0.5	Pubertal anthropometrics;	chr6:28244970	chr6:28176188~28176674:+
PRAD	cis	rs6964833	1	rs2301907	ENSG00000277053.3	GTF2IP1	-12.29	3.55e-30	6.86e-27	-0.59	-0.5	Menarche (age at onset);	chr7:74700517	chr7:75185385~75237696:-
PRAD	cis	rs10256972	0.621	rs2363285	ENSG00000229043.2	AC091729.9	-12.29	3.57e-30	6.89e-27	-0.6	-0.5	Endometriosis;Longevity;	chr7:1052008	chr7:1160374~1165267:+
PRAD	cis	rs8062405	0.964	rs78613234	ENSG00000259982.1	CDC37P1	12.29	3.64e-30	7.03e-27	0.66	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828104	chr16:28700294~28701540:-
PRAD	cis	rs8062405	1	rs62036624	ENSG00000259982.1	CDC37P1	12.29	3.64e-30	7.03e-27	0.66	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828609	chr16:28700294~28701540:-
PRAD	cis	rs2929278	0.736	rs2412823	ENSG00000205771.5	CATSPER2P1	12.28	3.75e-30	7.24e-27	0.56	0.5	Schizophrenia;	chr15:43935072	chr15:43726918~43747094:-
PRAD	cis	rs524281	0.861	rs471484	ENSG00000255320.1	RP11-755F10.1	12.28	3.76e-30	7.26e-27	0.76	0.5	Electroencephalogram traits;	chr11:66187673	chr11:66244840~66246239:-
PRAD	cis	rs6142102	0.517	rs6059580	ENSG00000276073.1	RP5-1125A11.7	-12.28	3.79e-30	7.31e-27	-0.49	-0.5	Skin pigmentation;	chr20:33940067	chr20:33985617~33988989:-
PRAD	cis	rs1061377	1	rs10026775	ENSG00000249207.1	RP11-360F5.1	-12.28	3.79e-30	7.31e-27	-0.52	-0.5	Uric acid levels;	chr4:39115155	chr4:39112677~39126818:-
PRAD	cis	rs1061377	1	rs3733276	ENSG00000249207.1	RP11-360F5.1	-12.28	3.79e-30	7.31e-27	-0.52	-0.5	Uric acid levels;	chr4:39115291	chr4:39112677~39126818:-
PRAD	cis	rs1061377	1	rs3733277	ENSG00000249207.1	RP11-360F5.1	-12.28	3.79e-30	7.31e-27	-0.52	-0.5	Uric acid levels;	chr4:39115483	chr4:39112677~39126818:-
PRAD	cis	rs1061377	1	rs3733278	ENSG00000249207.1	RP11-360F5.1	-12.28	3.79e-30	7.31e-27	-0.52	-0.5	Uric acid levels;	chr4:39115615	chr4:39112677~39126818:-
PRAD	cis	rs1061377	1	rs3733279	ENSG00000249207.1	RP11-360F5.1	-12.28	3.79e-30	7.31e-27	-0.52	-0.5	Uric acid levels;	chr4:39115625	chr4:39112677~39126818:-
PRAD	cis	rs1061377	1	rs10018049	ENSG00000249207.1	RP11-360F5.1	-12.28	3.79e-30	7.31e-27	-0.52	-0.5	Uric acid levels;	chr4:39115781	chr4:39112677~39126818:-
PRAD	cis	rs12049351	0.774	rs12138965	ENSG00000229367.1	HMGN2P19	12.28	3.81e-30	7.35e-27	0.71	0.5	Circulating myeloperoxidase levels (plasma);	chr1:229519973	chr1:229570532~229570796:+
PRAD	cis	rs12049351	0.774	rs10916504	ENSG00000229367.1	HMGN2P19	12.28	3.81e-30	7.35e-27	0.71	0.5	Circulating myeloperoxidase levels (plasma);	chr1:229520145	chr1:229570532~229570796:+
PRAD	cis	rs2581828	1	rs2581828	ENSG00000242142.1	SERBP1P3	12.28	3.82e-30	7.37e-27	0.56	0.5	Crohn's disease;	chr3:53099133	chr3:53064283~53065091:-
PRAD	cis	rs11105298	0.786	rs10858867	ENSG00000258302.2	RP11-981P6.1	12.28	3.82e-30	7.37e-27	0.56	0.5	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89457389	chr12:89561129~89594878:+
PRAD	cis	rs11105298	0.786	rs3803128	ENSG00000258302.2	RP11-981P6.1	12.28	3.82e-30	7.37e-27	0.56	0.5	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89466542	chr12:89561129~89594878:+
PRAD	cis	rs11105298	0.891	rs10506972	ENSG00000258302.2	RP11-981P6.1	12.28	3.82e-30	7.37e-27	0.56	0.5	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89467752	chr12:89561129~89594878:+
PRAD	cis	rs11105298	0.891	rs12228177	ENSG00000258302.2	RP11-981P6.1	12.28	3.82e-30	7.37e-27	0.56	0.5	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89468253	chr12:89561129~89594878:+
PRAD	cis	rs11105298	0.838	rs4842488	ENSG00000258302.2	RP11-981P6.1	12.28	3.82e-30	7.37e-27	0.56	0.5	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89487787	chr12:89561129~89594878:+
PRAD	cis	rs11105298	0.891	rs6538189	ENSG00000258302.2	RP11-981P6.1	12.28	3.82e-30	7.37e-27	0.56	0.5	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89492146	chr12:89561129~89594878:+
PRAD	cis	rs11105298	0.891	rs6538190	ENSG00000258302.2	RP11-981P6.1	12.28	3.82e-30	7.37e-27	0.56	0.5	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89492165	chr12:89561129~89594878:+
PRAD	cis	rs1075265	0.584	rs7558126	ENSG00000233266.1	HMGB1P31	12.28	3.86e-30	7.44e-27	0.66	0.5	Chronotype;Morning vs. evening chronotype;	chr2:54053847	chr2:54051334~54051760:+
PRAD	cis	rs35160687	0.865	rs10189492	ENSG00000273080.1	RP11-301O19.1	12.28	3.92e-30	7.54e-27	0.59	0.5	Night sleep phenotypes;	chr2:86251779	chr2:86195590~86196049:+
PRAD	cis	rs9322193	0.923	rs3924871	ENSG00000223701.3	RAET1E-AS1	12.28	3.95e-30	7.6e-27	0.67	0.5	Lung cancer;	chr6:149662080	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.886	rs4870055	ENSG00000216906.2	RP11-350J20.9	12.28	3.95e-30	7.61e-27	0.57	0.5	Lung cancer;	chr6:149848433	chr6:149904243~149906418:+
PRAD	cis	rs977987	0.872	rs4887816	ENSG00000261783.1	RP11-252K23.2	-12.28	3.96e-30	7.61e-27	-0.67	-0.5	Dupuytren's disease;	chr16:75285818	chr16:75379818~75381260:-
PRAD	cis	rs2404602	0.735	rs1607015	ENSG00000259422.1	RP11-593F23.1	-12.28	3.97e-30	7.64e-27	-0.65	-0.5	Blood metabolite levels;	chr15:76410088	chr15:76174891~76181486:-
PRAD	cis	rs524281	0.861	rs535395	ENSG00000255320.1	RP11-755F10.1	-12.28	3.99e-30	7.67e-27	-0.76	-0.5	Electroencephalogram traits;	chr11:66139063	chr11:66244840~66246239:-
PRAD	cis	rs1577917	0.771	rs4145082	ENSG00000203875.9	SNHG5	-12.28	4.01e-30	7.71e-27	-0.58	-0.5	Response to antipsychotic treatment;	chr6:85642298	chr6:85660950~85678736:-
PRAD	cis	rs9326248	1	rs4938344	ENSG00000280143.1	AP000892.6	12.28	4.05e-30	7.78e-27	0.44	0.5	Blood protein levels;	chr11:117133033	chr11:117204967~117210292:+
PRAD	cis	rs977987	0.771	rs12929673	ENSG00000261783.1	RP11-252K23.2	-12.27	4.11e-30	7.91e-27	-0.68	-0.5	Dupuytren's disease;	chr16:75436397	chr16:75379818~75381260:-
PRAD	cis	rs875971	0.545	rs73148639	ENSG00000237310.1	GS1-124K5.4	12.27	4.13e-30	7.95e-27	0.5	0.5	Aortic root size;	chr7:66390342	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.545	rs35459055	ENSG00000237310.1	GS1-124K5.4	12.27	4.13e-30	7.95e-27	0.5	0.5	Aortic root size;	chr7:66479399	chr7:66493706~66495474:+
PRAD	cis	rs929843	1	rs929843	ENSG00000226232.7	RP11-419C5.2	-12.27	4.19e-30	8.05e-27	-0.52	-0.5	Menarche (age at onset);	chr16:70011845	chr16:69976388~69996188:-
PRAD	cis	rs35160687	0.901	rs12620833	ENSG00000273080.1	RP11-301O19.1	12.27	4.19e-30	8.06e-27	0.59	0.5	Night sleep phenotypes;	chr2:86245747	chr2:86195590~86196049:+
PRAD	cis	rs7208859	0.573	rs216443	ENSG00000263531.1	RP13-753N3.1	12.27	4.22e-30	8.12e-27	1.03	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604853	chr17:30863921~30864940:-
PRAD	cis	rs16828019	0.777	rs67460888	ENSG00000235358.1	RP11-399E6.1	12.27	4.23e-30	8.13e-27	0.94	0.5	Intelligence (multi-trait analysis);	chr1:41003665	chr1:41242373~41284861:+
PRAD	cis	rs977987	0.836	rs35209155	ENSG00000261783.1	RP11-252K23.2	-12.27	4.24e-30	8.15e-27	-0.68	-0.5	Dupuytren's disease;	chr16:75436598	chr16:75379818~75381260:-
PRAD	cis	rs2658782	0.906	rs2658791	ENSG00000279684.1	RP11-755E23.2	-12.27	4.26e-30	8.18e-27	-0.85	-0.5	Pulmonary function decline;	chr11:93465817	chr11:93286629~93288903:-
PRAD	cis	rs2739330	0.791	rs9612520	ENSG00000235689.1	AP000351.13	12.27	4.33e-30	8.31e-27	0.6	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:24006305~24008258:-
PRAD	cis	rs977987	0.806	rs12444589	ENSG00000261783.1	RP11-252K23.2	12.27	4.36e-30	8.36e-27	0.67	0.5	Dupuytren's disease;	chr16:75420506	chr16:75379818~75381260:-
PRAD	cis	rs1577917	0.739	rs6922	ENSG00000203875.9	SNHG5	12.27	4.37e-30	8.38e-27	0.57	0.5	Response to antipsychotic treatment;	chr6:85495605	chr6:85660950~85678736:-
PRAD	cis	rs977987	0.8	rs1011121	ENSG00000261783.1	RP11-252K23.2	-12.27	4.37e-30	8.39e-27	-0.68	-0.5	Dupuytren's disease;	chr16:75292035	chr16:75379818~75381260:-
PRAD	cis	rs4423214	0.879	rs10898144	ENSG00000254682.1	RP11-660L16.2	-12.27	4.38e-30	8.4e-27	-0.71	-0.5	Vitamin D levels;	chr11:71440494	chr11:71448674~71452157:+
PRAD	cis	rs1150668	0.699	rs1736895	ENSG00000216901.1	AL022393.7	12.27	4.4e-30	8.44e-27	0.62	0.5	Pubertal anthropometrics;	chr6:28252048	chr6:28176188~28176674:+
PRAD	cis	rs5769707	0.967	rs5769698	ENSG00000188511.11	C22orf34	12.27	4.42e-30	8.49e-27	0.52	0.5	Monocyte percentage of white cells;Monocyte count;	chr22:49604058	chr22:49414524~49657542:-
PRAD	cis	rs1150668	0.699	rs12214383	ENSG00000216901.1	AL022393.7	-12.27	4.43e-30	8.5e-27	-0.62	-0.5	Pubertal anthropometrics;	chr6:28255953	chr6:28176188~28176674:+
PRAD	cis	rs3096299	0.563	rs4600467	ENSG00000274627.1	RP11-104N10.2	12.27	4.44e-30	8.52e-27	0.5	0.5	Multiple myeloma (IgH translocation);	chr16:89496108	chr16:89516797~89522217:+
PRAD	cis	rs4722166	0.645	rs1404006	ENSG00000179428.2	AC073072.5	-12.26	4.5e-30	8.63e-27	-0.58	-0.5	Lung cancer;	chr7:22755458	chr7:22725395~22727620:-
PRAD	cis	rs1150668	0.799	rs1150705	ENSG00000216901.1	AL022393.7	12.26	4.51e-30	8.64e-27	0.62	0.5	Pubertal anthropometrics;	chr6:28226008	chr6:28176188~28176674:+
PRAD	cis	rs7617773	0.963	rs6766754	ENSG00000229759.1	MRPS18AP1	-12.26	4.51e-30	8.65e-27	-0.51	-0.5	Coronary artery disease;	chr3:48141099	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.832	rs6775114	ENSG00000229759.1	MRPS18AP1	-12.26	4.51e-30	8.65e-27	-0.51	-0.5	Coronary artery disease;	chr3:48141130	chr3:48256350~48256938:-
PRAD	cis	rs2404602	0.735	rs12906143	ENSG00000259422.1	RP11-593F23.1	-12.26	4.54e-30	8.7e-27	-0.65	-0.5	Blood metabolite levels;	chr15:76417182	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.735	rs11632222	ENSG00000259422.1	RP11-593F23.1	-12.26	4.54e-30	8.7e-27	-0.65	-0.5	Blood metabolite levels;	chr15:76420586	chr15:76174891~76181486:-
PRAD	cis	rs9487094	0.885	rs1358997	ENSG00000260273.1	RP11-425D10.10	12.26	4.58e-30	8.78e-27	0.7	0.5	Height;	chr6:109380457	chr6:109382795~109383666:+
PRAD	cis	rs9322193	0.923	rs11155670	ENSG00000223701.3	RAET1E-AS1	12.26	4.65e-30	8.91e-27	0.68	0.5	Lung cancer;	chr6:149644992	chr6:149884431~149919508:+
PRAD	cis	rs3091242	0.933	rs9438905	ENSG00000261349.1	RP3-465N24.5	-12.26	4.66e-30	8.93e-27	-0.55	-0.5	Erythrocyte sedimentation rate;	chr1:25437686	chr1:25266102~25267136:-
PRAD	cis	rs2404602	0.647	rs11072612	ENSG00000259422.1	RP11-593F23.1	-12.26	4.69e-30	8.99e-27	-0.66	-0.5	Blood metabolite levels;	chr15:76668643	chr15:76174891~76181486:-
PRAD	cis	rs977987	0.843	rs2059256	ENSG00000261783.1	RP11-252K23.2	-12.26	4.73e-30	9.05e-27	-0.67	-0.5	Dupuytren's disease;	chr16:75361937	chr16:75379818~75381260:-
PRAD	cis	rs11603023	0.804	rs527619	ENSG00000255239.1	AP002954.6	-12.26	4.73e-30	9.06e-27	-0.63	-0.5	Cholesterol, total;	chr11:118692577	chr11:118688039~118690600:-
PRAD	cis	rs11105298	0.891	rs10858879	ENSG00000258302.2	RP11-981P6.1	-12.26	4.74e-30	9.07e-27	-0.56	-0.5	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89492801	chr12:89561129~89594878:+
PRAD	cis	rs2658782	0.724	rs1869914	ENSG00000279684.1	RP11-755E23.2	-12.26	4.74e-30	9.08e-27	-0.78	-0.5	Pulmonary function decline;	chr11:93379326	chr11:93286629~93288903:-
PRAD	cis	rs9532669	0.926	rs4942005	ENSG00000176268.5	CYCSP34	12.26	4.81e-30	9.22e-27	0.51	0.5	Cervical cancer;	chr13:40871636	chr13:40863599~40863902:-
PRAD	cis	rs8062405	1	rs55991577	ENSG00000259982.1	CDC37P1	12.26	4.84e-30	9.27e-27	0.66	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831704	chr16:28700294~28701540:-
PRAD	cis	rs8062405	1	rs56358680	ENSG00000259982.1	CDC37P1	12.26	4.84e-30	9.27e-27	0.66	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831797	chr16:28700294~28701540:-
PRAD	cis	rs11105298	1	rs11105298	ENSG00000258302.2	RP11-981P6.1	-12.26	4.86e-30	9.31e-27	-0.54	-0.5	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89482366	chr12:89561129~89594878:+
PRAD	cis	rs748404	0.518	rs480108	ENSG00000205771.5	CATSPER2P1	-12.26	4.89e-30	9.36e-27	-0.57	-0.5	Lung cancer;	chr15:43525208	chr15:43726918~43747094:-
PRAD	cis	rs1167827	1	rs1167827	ENSG00000127957.15	PMS2P3	-12.25	4.94e-30	9.46e-27	-0.4	-0.5	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75533848	chr7:75502930~75528148:-
PRAD	cis	rs8062405	0.728	rs9931989	ENSG00000259982.1	CDC37P1	-12.25	4.95e-30	9.47e-27	-0.68	-0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28894763	chr16:28700294~28701540:-
PRAD	cis	rs12049351	0.774	rs6701186	ENSG00000229367.1	HMGN2P19	12.25	4.97e-30	9.5e-27	0.7	0.5	Circulating myeloperoxidase levels (plasma);	chr1:229490739	chr1:229570532~229570796:+
PRAD	cis	rs1185460	0.967	rs4454730	ENSG00000271751.1	RP11-110I1.14	-12.25	5.05e-30	9.65e-27	-0.68	-0.5	Coronary artery disease;	chr11:119066733	chr11:119065263~119065677:-
PRAD	cis	rs7115242	0.8	rs7131536	ENSG00000254851.1	RP11-109L13.1	-12.25	5.06e-30	9.67e-27	-1	-0.5	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117128730	chr11:117135528~117138582:+
PRAD	cis	rs977987	0.815	rs11149818	ENSG00000261783.1	RP11-252K23.2	-12.25	5.08e-30	9.72e-27	-0.67	-0.5	Dupuytren's disease;	chr16:75385475	chr16:75379818~75381260:-
PRAD	cis	rs7044106	0.718	rs1981021	ENSG00000226752.6	PSMD5-AS1	-12.25	5.09e-30	9.72e-27	-0.6	-0.5	Hip circumference adjusted for BMI;	chr9:120626115	chr9:120824828~120854385:+
PRAD	cis	rs7044106	0.734	rs1981020	ENSG00000226752.6	PSMD5-AS1	-12.25	5.09e-30	9.72e-27	-0.6	-0.5	Hip circumference adjusted for BMI;	chr9:120626186	chr9:120824828~120854385:+
PRAD	cis	rs1150668	0.699	rs2394049	ENSG00000216901.1	AL022393.7	12.25	5.13e-30	9.8e-27	0.62	0.5	Pubertal anthropometrics;	chr6:28271903	chr6:28176188~28176674:+
PRAD	cis	rs9322193	0.923	rs10872650	ENSG00000268592.3	RAET1E-AS1	12.25	5.17e-30	9.87e-27	0.69	0.5	Lung cancer;	chr6:149760959	chr6:149863494~149919507:+
PRAD	cis	rs2581828	0.931	rs2581774	ENSG00000242142.1	SERBP1P3	12.25	5.2e-30	9.94e-27	0.57	0.5	Crohn's disease;	chr3:53105491	chr3:53064283~53065091:-
PRAD	cis	rs7044106	0.762	rs10984974	ENSG00000226752.6	PSMD5-AS1	-12.25	5.21e-30	9.96e-27	-0.6	-0.5	Hip circumference adjusted for BMI;	chr9:120659278	chr9:120824828~120854385:+
PRAD	cis	rs1061377	0.965	rs10018622	ENSG00000249207.1	RP11-360F5.1	-12.25	5.24e-30	1e-26	-0.51	-0.5	Uric acid levels;	chr4:39133944	chr4:39112677~39126818:-
PRAD	cis	rs3931020	0.671	rs1327088	ENSG00000272864.1	RP11-17E13.2	-12.25	5.27e-30	1.01e-26	-0.5	-0.5	Resistin levels;	chr1:74789807	chr1:74698769~74699333:-
PRAD	cis	rs9322193	0.923	rs10872649	ENSG00000268592.3	RAET1E-AS1	12.25	5.29e-30	1.01e-26	0.68	0.5	Lung cancer;	chr6:149759454	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.923	rs9478291	ENSG00000223701.3	RAET1E-AS1	12.25	5.29e-30	1.01e-26	0.67	0.5	Lung cancer;	chr6:149729434	chr6:149884431~149919508:+
PRAD	cis	rs9532669	0.926	rs4454835	ENSG00000176268.5	CYCSP34	12.25	5.31e-30	1.01e-26	0.51	0.5	Cervical cancer;	chr13:40928978	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.926	rs4270044	ENSG00000176268.5	CYCSP34	12.25	5.35e-30	1.02e-26	0.52	0.5	Cervical cancer;	chr13:40877923	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.926	rs11147824	ENSG00000176268.5	CYCSP34	12.25	5.35e-30	1.02e-26	0.52	0.5	Cervical cancer;	chr13:40878183	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.926	rs4334153	ENSG00000176268.5	CYCSP34	12.25	5.36e-30	1.02e-26	0.52	0.5	Cervical cancer;	chr13:40877737	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.926	rs4309270	ENSG00000176268.5	CYCSP34	12.25	5.36e-30	1.02e-26	0.52	0.5	Cervical cancer;	chr13:40877827	chr13:40863599~40863902:-
PRAD	cis	rs11105298	0.891	rs10858852	ENSG00000258302.2	RP11-981P6.1	12.25	5.37e-30	1.02e-26	0.56	0.5	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89439561	chr12:89561129~89594878:+
PRAD	cis	rs11105298	0.891	rs4842653	ENSG00000258302.2	RP11-981P6.1	12.25	5.37e-30	1.02e-26	0.56	0.5	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89440336	chr12:89561129~89594878:+
PRAD	cis	rs11105298	0.891	rs4842654	ENSG00000258302.2	RP11-981P6.1	12.25	5.37e-30	1.02e-26	0.56	0.5	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89440651	chr12:89561129~89594878:+
PRAD	cis	rs11105298	0.838	rs10858862	ENSG00000258302.2	RP11-981P6.1	12.25	5.37e-30	1.02e-26	0.56	0.5	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89448276	chr12:89561129~89594878:+
PRAD	cis	rs11105298	0.891	rs10858864	ENSG00000258302.2	RP11-981P6.1	12.25	5.37e-30	1.02e-26	0.56	0.5	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89452453	chr12:89561129~89594878:+
PRAD	cis	rs11105298	0.891	rs10858865	ENSG00000258302.2	RP11-981P6.1	12.25	5.37e-30	1.02e-26	0.56	0.5	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89452699	chr12:89561129~89594878:+
PRAD	cis	rs9322193	0.923	rs2185352	ENSG00000223701.3	RAET1E-AS1	12.24	5.43e-30	1.03e-26	0.66	0.5	Lung cancer;	chr6:149714640	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.923	rs12174349	ENSG00000223701.3	RAET1E-AS1	12.24	5.43e-30	1.03e-26	0.66	0.5	Lung cancer;	chr6:149718012	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.923	rs2297932	ENSG00000223701.3	RAET1E-AS1	12.24	5.43e-30	1.03e-26	0.66	0.5	Lung cancer;	chr6:149718225	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.923	rs2297930	ENSG00000223701.3	RAET1E-AS1	12.24	5.43e-30	1.03e-26	0.66	0.5	Lung cancer;	chr6:149718360	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.923	rs9479094	ENSG00000223701.3	RAET1E-AS1	12.24	5.43e-30	1.03e-26	0.66	0.5	Lung cancer;	chr6:149725083	chr6:149884431~149919508:+
PRAD	cis	rs1577917	0.71	rs1059306	ENSG00000203875.9	SNHG5	12.24	5.45e-30	1.04e-26	0.58	0.5	Response to antipsychotic treatment;	chr6:85678391	chr6:85660950~85678736:-
PRAD	cis	rs16828019	0.852	rs3820090	ENSG00000235358.1	RP11-399E6.1	12.24	5.52e-30	1.05e-26	0.92	0.5	Intelligence (multi-trait analysis);	chr1:41107980	chr1:41242373~41284861:+
PRAD	cis	rs9322193	0.923	rs2297928	ENSG00000223701.3	RAET1E-AS1	12.24	5.53e-30	1.05e-26	0.66	0.5	Lung cancer;	chr6:149718584	chr6:149884431~149919508:+
PRAD	cis	rs7044106	0.762	rs4837790	ENSG00000226752.6	PSMD5-AS1	-12.24	5.55e-30	1.06e-26	-0.6	-0.5	Hip circumference adjusted for BMI;	chr9:120684047	chr9:120824828~120854385:+
PRAD	cis	rs3091242	0.934	rs666686	ENSG00000224183.1	SDHDP6	-12.24	5.57e-30	1.06e-26	-0.58	-0.5	Erythrocyte sedimentation rate;	chr1:25393020	chr1:25294164~25294643:-
PRAD	cis	rs9322193	0.923	rs2184370	ENSG00000223701.3	RAET1E-AS1	12.24	5.67e-30	1.08e-26	0.67	0.5	Lung cancer;	chr6:149843242	chr6:149884431~149919508:+
PRAD	cis	rs9532669	0.89	rs35396630	ENSG00000176268.5	CYCSP34	12.24	5.75e-30	1.09e-26	0.51	0.5	Cervical cancer;	chr13:40863135	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.926	rs4942001	ENSG00000176268.5	CYCSP34	12.24	5.75e-30	1.09e-26	0.51	0.5	Cervical cancer;	chr13:40863176	chr13:40863599~40863902:-
PRAD	cis	rs71403859	0.614	rs12935422	ENSG00000260886.1	TAT-AS1	12.24	5.75e-30	1.09e-26	0.88	0.5	Post bronchodilator FEV1;	chr16:71630322	chr16:71565789~71578187:+
PRAD	cis	rs875971	0.545	rs75577046	ENSG00000237310.1	GS1-124K5.4	12.24	5.8e-30	1.1e-26	0.5	0.5	Aortic root size;	chr7:66493729	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.545	rs3735147	ENSG00000237310.1	GS1-124K5.4	12.24	5.8e-30	1.1e-26	0.5	0.5	Aortic root size;	chr7:66505541	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.545	rs1638724	ENSG00000237310.1	GS1-124K5.4	-12.24	5.8e-30	1.1e-26	-0.5	-0.5	Aortic root size;	chr7:66575494	chr7:66493706~66495474:+
PRAD	cis	rs7044106	0.762	rs1158554	ENSG00000226752.6	PSMD5-AS1	-12.24	5.84e-30	1.11e-26	-0.6	-0.5	Hip circumference adjusted for BMI;	chr9:120638620	chr9:120824828~120854385:+
PRAD	cis	rs977987	0.843	rs4888415	ENSG00000261783.1	RP11-252K23.2	-12.24	5.85e-30	1.11e-26	-0.67	-0.5	Dupuytren's disease;	chr16:75415023	chr16:75379818~75381260:-
PRAD	cis	rs8062405	1	rs62036626	ENSG00000259982.1	CDC37P1	12.24	5.89e-30	1.12e-26	0.66	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28832963	chr16:28700294~28701540:-
PRAD	cis	rs8062405	1	rs62036657	ENSG00000259982.1	CDC37P1	12.24	5.89e-30	1.12e-26	0.66	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833044	chr16:28700294~28701540:-
PRAD	cis	rs8062405	1	rs12444171	ENSG00000259982.1	CDC37P1	12.24	5.89e-30	1.12e-26	0.66	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833930	chr16:28700294~28701540:-
PRAD	cis	rs8062405	1	rs56404918	ENSG00000259982.1	CDC37P1	12.24	5.89e-30	1.12e-26	0.66	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835519	chr16:28700294~28701540:-
PRAD	cis	rs8062405	1	rs55719896	ENSG00000259982.1	CDC37P1	12.24	5.89e-30	1.12e-26	0.66	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835545	chr16:28700294~28701540:-
PRAD	cis	rs8062405	1	rs55830740	ENSG00000259982.1	CDC37P1	12.24	5.89e-30	1.12e-26	0.66	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835828	chr16:28700294~28701540:-
PRAD	cis	rs8062405	1	rs3088215	ENSG00000259982.1	CDC37P1	12.24	5.89e-30	1.12e-26	0.66	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28842675	chr16:28700294~28701540:-
PRAD	cis	rs8062405	1	rs28403629	ENSG00000259982.1	CDC37P1	12.24	5.89e-30	1.12e-26	0.66	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28843448	chr16:28700294~28701540:-
PRAD	cis	rs8062405	1	rs61737565	ENSG00000259982.1	CDC37P1	12.24	5.89e-30	1.12e-26	0.66	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844201	chr16:28700294~28701540:-
PRAD	cis	rs8062405	1	rs4788099	ENSG00000259982.1	CDC37P1	12.24	5.89e-30	1.12e-26	0.66	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844406	chr16:28700294~28701540:-
PRAD	cis	rs8062405	1	rs9972693	ENSG00000259982.1	CDC37P1	12.24	5.89e-30	1.12e-26	0.66	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28848481	chr16:28700294~28701540:-
PRAD	cis	rs8062405	0.964	rs9972768	ENSG00000259982.1	CDC37P1	12.24	5.89e-30	1.12e-26	0.66	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850413	chr16:28700294~28701540:-
PRAD	cis	rs8062405	0.965	rs56040780	ENSG00000259982.1	CDC37P1	12.24	5.89e-30	1.12e-26	0.66	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850560	chr16:28700294~28701540:-
PRAD	cis	rs8062405	0.965	rs62037363	ENSG00000259982.1	CDC37P1	12.24	5.89e-30	1.12e-26	0.66	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28853721	chr16:28700294~28701540:-
PRAD	cis	rs8062405	1	rs7205323	ENSG00000259982.1	CDC37P1	12.24	5.89e-30	1.12e-26	0.66	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854571	chr16:28700294~28701540:-
PRAD	cis	rs8062405	1	rs4788101	ENSG00000259982.1	CDC37P1	12.24	5.89e-30	1.12e-26	0.66	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28856483	chr16:28700294~28701540:-
PRAD	cis	rs8062405	1	rs62037365	ENSG00000259982.1	CDC37P1	12.24	5.89e-30	1.12e-26	0.66	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857641	chr16:28700294~28701540:-
PRAD	cis	rs8062405	0.929	rs11150609	ENSG00000259982.1	CDC37P1	12.24	5.89e-30	1.12e-26	0.66	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859275	chr16:28700294~28701540:-
PRAD	cis	rs8062405	0.737	rs11861132	ENSG00000259982.1	CDC37P1	12.24	5.89e-30	1.12e-26	0.66	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860539	chr16:28700294~28701540:-
PRAD	cis	rs8062405	1	rs11861174	ENSG00000259982.1	CDC37P1	12.24	5.89e-30	1.12e-26	0.66	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860668	chr16:28700294~28701540:-
PRAD	cis	rs8062405	1	rs4788102	ENSG00000259982.1	CDC37P1	12.24	5.89e-30	1.12e-26	0.66	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28862077	chr16:28700294~28701540:-
PRAD	cis	rs8062405	1	rs62037367	ENSG00000259982.1	CDC37P1	12.24	5.89e-30	1.12e-26	0.66	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863226	chr16:28700294~28701540:-
PRAD	cis	rs8062405	1	rs7198606	ENSG00000259982.1	CDC37P1	12.24	5.89e-30	1.12e-26	0.66	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863801	chr16:28700294~28701540:-
PRAD	cis	rs8062405	0.929	rs11864750	ENSG00000259982.1	CDC37P1	12.24	5.89e-30	1.12e-26	0.66	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863883	chr16:28700294~28701540:-
PRAD	cis	rs8062405	0.964	rs7193733	ENSG00000259982.1	CDC37P1	12.24	5.89e-30	1.12e-26	0.66	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28864161	chr16:28700294~28701540:-
PRAD	cis	rs8062405	1	rs8055982	ENSG00000259982.1	CDC37P1	12.24	5.89e-30	1.12e-26	0.66	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28869881	chr16:28700294~28701540:-
PRAD	cis	rs8062405	1	rs7498665	ENSG00000259982.1	CDC37P1	12.24	5.89e-30	1.12e-26	0.66	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28871920	chr16:28700294~28701540:-
PRAD	cis	rs8062405	0.964	rs11864107	ENSG00000259982.1	CDC37P1	12.24	5.89e-30	1.12e-26	0.66	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874610	chr16:28700294~28701540:-
PRAD	cis	rs8062405	1	rs62037371	ENSG00000259982.1	CDC37P1	12.24	5.89e-30	1.12e-26	0.66	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878810	chr16:28700294~28701540:-
PRAD	cis	rs8062405	1	rs8055138	ENSG00000259982.1	CDC37P1	12.24	5.89e-30	1.12e-26	0.66	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28880144	chr16:28700294~28701540:-
PRAD	cis	rs1061377	1	rs9999327	ENSG00000249207.1	RP11-360F5.1	-12.23	5.91e-30	1.12e-26	-0.52	-0.5	Uric acid levels;	chr4:39110111	chr4:39112677~39126818:-
PRAD	cis	rs1061377	0.965	rs6833654	ENSG00000249207.1	RP11-360F5.1	-12.23	5.91e-30	1.12e-26	-0.52	-0.5	Uric acid levels;	chr4:39110701	chr4:39112677~39126818:-
PRAD	cis	rs1061377	1	rs1036037	ENSG00000249207.1	RP11-360F5.1	-12.23	5.91e-30	1.12e-26	-0.52	-0.5	Uric acid levels;	chr4:39111272	chr4:39112677~39126818:-
PRAD	cis	rs1061377	1	rs1036038	ENSG00000249207.1	RP11-360F5.1	-12.23	5.91e-30	1.12e-26	-0.52	-0.5	Uric acid levels;	chr4:39111383	chr4:39112677~39126818:-
PRAD	cis	rs1061377	1	rs1560396	ENSG00000249207.1	RP11-360F5.1	-12.23	5.91e-30	1.12e-26	-0.52	-0.5	Uric acid levels;	chr4:39112092	chr4:39112677~39126818:-
PRAD	cis	rs1061377	1	rs1560397	ENSG00000249207.1	RP11-360F5.1	-12.23	5.91e-30	1.12e-26	-0.52	-0.5	Uric acid levels;	chr4:39112265	chr4:39112677~39126818:-
PRAD	cis	rs1061377	1	rs2381285	ENSG00000249207.1	RP11-360F5.1	-12.23	5.91e-30	1.12e-26	-0.52	-0.5	Uric acid levels;	chr4:39112775	chr4:39112677~39126818:-
PRAD	cis	rs1061377	1	rs2163272	ENSG00000249207.1	RP11-360F5.1	-12.23	5.91e-30	1.12e-26	-0.52	-0.5	Uric acid levels;	chr4:39112790	chr4:39112677~39126818:-
PRAD	cis	rs1061377	1	rs2163273	ENSG00000249207.1	RP11-360F5.1	-12.23	5.91e-30	1.12e-26	-0.52	-0.5	Uric acid levels;	chr4:39112835	chr4:39112677~39126818:-
PRAD	cis	rs1061377	1	rs62310332	ENSG00000249207.1	RP11-360F5.1	-12.23	5.91e-30	1.12e-26	-0.52	-0.5	Uric acid levels;	chr4:39112939	chr4:39112677~39126818:-
PRAD	cis	rs1061377	0.965	rs3796510	ENSG00000249207.1	RP11-360F5.1	-12.23	5.91e-30	1.12e-26	-0.52	-0.5	Uric acid levels;	chr4:39113309	chr4:39112677~39126818:-
PRAD	cis	rs1061377	1	rs10030904	ENSG00000249207.1	RP11-360F5.1	-12.23	5.91e-30	1.12e-26	-0.52	-0.5	Uric acid levels;	chr4:39113603	chr4:39112677~39126818:-
PRAD	cis	rs1061377	0.932	rs6855118	ENSG00000249207.1	RP11-360F5.1	-12.23	5.91e-30	1.12e-26	-0.52	-0.5	Uric acid levels;	chr4:39114322	chr4:39112677~39126818:-
PRAD	cis	rs1061377	1	rs6829234	ENSG00000249207.1	RP11-360F5.1	-12.23	5.91e-30	1.12e-26	-0.52	-0.5	Uric acid levels;	chr4:39114586	chr4:39112677~39126818:-
PRAD	cis	rs1061377	1	rs6812540	ENSG00000249207.1	RP11-360F5.1	-12.23	5.91e-30	1.12e-26	-0.52	-0.5	Uric acid levels;	chr4:39114803	chr4:39112677~39126818:-
PRAD	cis	rs11105298	0.891	rs10858872	ENSG00000258302.2	RP11-981P6.1	12.23	5.99e-30	1.13e-26	0.56	0.5	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89479155	chr12:89561129~89594878:+
PRAD	cis	rs11105298	0.891	rs10858854	ENSG00000258302.2	RP11-981P6.1	12.23	6.02e-30	1.14e-26	0.57	0.5	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89441951	chr12:89561129~89594878:+
PRAD	cis	rs3096299	0.685	rs4785568	ENSG00000274627.1	RP11-104N10.2	12.23	6.06e-30	1.15e-26	0.5	0.5	Multiple myeloma (IgH translocation);	chr16:89487299	chr16:89516797~89522217:+
PRAD	cis	rs1577917	0.771	rs2475790	ENSG00000203875.9	SNHG5	-12.23	6.08e-30	1.15e-26	-0.58	-0.5	Response to antipsychotic treatment;	chr6:85658350	chr6:85660950~85678736:-
PRAD	cis	rs7044106	0.791	rs10984998	ENSG00000226752.6	PSMD5-AS1	-12.23	6.13e-30	1.16e-26	-0.61	-0.5	Hip circumference adjusted for BMI;	chr9:120719238	chr9:120824828~120854385:+
PRAD	cis	rs1061377	0.722	rs34803689	ENSG00000249207.1	RP11-360F5.1	-12.23	6.17e-30	1.17e-26	-0.52	-0.5	Uric acid levels;	chr4:39116665	chr4:39112677~39126818:-
PRAD	cis	rs9487094	0.961	rs12193493	ENSG00000260273.1	RP11-425D10.10	12.23	6.17e-30	1.17e-26	0.7	0.5	Height;	chr6:109371573	chr6:109382795~109383666:+
PRAD	cis	rs9487094	0.961	rs3778475	ENSG00000260273.1	RP11-425D10.10	12.23	6.17e-30	1.17e-26	0.7	0.5	Height;	chr6:109375003	chr6:109382795~109383666:+
PRAD	cis	rs9532669	0.926	rs4942003	ENSG00000176268.5	CYCSP34	12.23	6.19e-30	1.17e-26	0.51	0.5	Cervical cancer;	chr13:40863270	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.89	rs4942004	ENSG00000176268.5	CYCSP34	12.23	6.19e-30	1.17e-26	0.51	0.5	Cervical cancer;	chr13:40863598	chr13:40863599~40863902:-
PRAD	cis	rs875971	0.528	rs801213	ENSG00000237310.1	GS1-124K5.4	-12.23	6.22e-30	1.18e-26	-0.49	-0.5	Aortic root size;	chr7:66549931	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.545	rs801212	ENSG00000237310.1	GS1-124K5.4	-12.23	6.22e-30	1.18e-26	-0.49	-0.5	Aortic root size;	chr7:66550643	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.545	rs1267814	ENSG00000237310.1	GS1-124K5.4	-12.23	6.22e-30	1.18e-26	-0.49	-0.5	Aortic root size;	chr7:66579422	chr7:66493706~66495474:+
PRAD	cis	rs8062405	1	rs62037364	ENSG00000259982.1	CDC37P1	12.23	6.32e-30	1.2e-26	0.66	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857374	chr16:28700294~28701540:-
PRAD	cis	rs12022452	1	rs12048678	ENSG00000238287.1	RP11-656D10.3	-12.23	6.34e-30	1.2e-26	-0.91	-0.5	Age-related hearing impairment (SNP x SNP interaction);	chr1:40482096	chr1:40493157~40508661:-
PRAD	cis	rs977987	0.872	rs4887825	ENSG00000261783.1	RP11-252K23.2	-12.23	6.35e-30	1.2e-26	-0.67	-0.5	Dupuytren's disease;	chr16:75438524	chr16:75379818~75381260:-
PRAD	cis	rs9322193	0.923	rs12660304	ENSG00000268592.3	RAET1E-AS1	12.23	6.38e-30	1.21e-26	0.67	0.5	Lung cancer;	chr6:149739647	chr6:149863494~149919507:+
PRAD	cis	rs1075265	0.584	rs1833497	ENSG00000233266.1	HMGB1P31	12.23	6.4e-30	1.21e-26	0.66	0.5	Chronotype;Morning vs. evening chronotype;	chr2:54052186	chr2:54051334~54051760:+
PRAD	cis	rs9322193	0.923	rs12529698	ENSG00000223701.3	RAET1E-AS1	12.23	6.44e-30	1.22e-26	0.67	0.5	Lung cancer;	chr6:149650951	chr6:149884431~149919508:+
PRAD	cis	rs6142102	0.625	rs6141431	ENSG00000276073.1	RP5-1125A11.7	-12.23	6.44e-30	1.22e-26	-0.48	-0.5	Skin pigmentation;	chr20:33952508	chr20:33985617~33988989:-
PRAD	cis	rs9532669	0.89	rs9315791	ENSG00000176268.5	CYCSP34	12.23	6.47e-30	1.22e-26	0.51	0.5	Cervical cancer;	chr13:40863931	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.824	rs9315792	ENSG00000176268.5	CYCSP34	12.23	6.47e-30	1.22e-26	0.51	0.5	Cervical cancer;	chr13:40863951	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.684	rs7139788	ENSG00000176268.5	CYCSP34	12.23	6.47e-30	1.22e-26	0.51	0.5	Cervical cancer;	chr13:40864264	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.926	rs7338617	ENSG00000176268.5	CYCSP34	12.23	6.47e-30	1.22e-26	0.51	0.5	Cervical cancer;	chr13:40870787	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.857	rs6560961	ENSG00000176268.5	CYCSP34	12.23	6.47e-30	1.22e-26	0.51	0.5	Cervical cancer;	chr13:40870878	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.926	rs6560962	ENSG00000176268.5	CYCSP34	12.23	6.47e-30	1.22e-26	0.51	0.5	Cervical cancer;	chr13:40870948	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.926	rs1055588	ENSG00000176268.5	CYCSP34	12.23	6.47e-30	1.22e-26	0.51	0.5	Cervical cancer;	chr13:40871306	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.926	rs3610	ENSG00000176268.5	CYCSP34	12.23	6.47e-30	1.22e-26	0.51	0.5	Cervical cancer;	chr13:40871334	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.926	rs4942006	ENSG00000176268.5	CYCSP34	12.23	6.47e-30	1.22e-26	0.51	0.5	Cervical cancer;	chr13:40871862	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.926	rs4942008	ENSG00000176268.5	CYCSP34	12.23	6.47e-30	1.22e-26	0.51	0.5	Cervical cancer;	chr13:40871989	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.89	rs2039118	ENSG00000176268.5	CYCSP34	12.23	6.47e-30	1.22e-26	0.51	0.5	Cervical cancer;	chr13:40872260	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.926	rs4356347	ENSG00000176268.5	CYCSP34	12.23	6.47e-30	1.22e-26	0.51	0.5	Cervical cancer;	chr13:40872516	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.926	rs7982346	ENSG00000176268.5	CYCSP34	12.23	6.47e-30	1.22e-26	0.51	0.5	Cervical cancer;	chr13:40873273	chr13:40863599~40863902:-
PRAD	cis	rs2581828	0.931	rs2336722	ENSG00000242142.1	SERBP1P3	12.22	6.55e-30	1.24e-26	0.57	0.5	Crohn's disease;	chr3:53105961	chr3:53064283~53065091:-
PRAD	cis	rs11676348	0.846	rs6723449	ENSG00000261338.2	RP11-378A13.1	12.22	6.58e-30	1.24e-26	0.57	0.5	Ulcerative colitis;	chr2:218132857	chr2:218255319~218257366:+
PRAD	cis	rs12049351	0.665	rs10449251	ENSG00000229367.1	HMGN2P19	-12.22	6.62e-30	1.25e-26	-0.71	-0.5	Circulating myeloperoxidase levels (plasma);	chr1:229505164	chr1:229570532~229570796:+
PRAD	cis	rs1185460	0.967	rs4545564	ENSG00000271751.1	RP11-110I1.14	-12.22	6.67e-30	1.26e-26	-0.68	-0.5	Coronary artery disease;	chr11:119066807	chr11:119065263~119065677:-
PRAD	cis	rs9322193	0.923	rs66516768	ENSG00000223701.3	RAET1E-AS1	12.22	6.72e-30	1.27e-26	0.66	0.5	Lung cancer;	chr6:149671999	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.884	rs7744105	ENSG00000268592.3	RAET1E-AS1	12.22	6.74e-30	1.27e-26	0.67	0.5	Lung cancer;	chr6:149849308	chr6:149863494~149919507:+
PRAD	cis	rs11105298	0.891	rs10858900	ENSG00000258302.2	RP11-981P6.1	12.22	6.98e-30	1.32e-26	0.56	0.5	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89531304	chr12:89561129~89594878:+
PRAD	cis	rs11676348	0.755	rs1008562	ENSG00000261338.2	RP11-378A13.1	12.22	7.02e-30	1.32e-26	0.58	0.5	Ulcerative colitis;	chr2:218162249	chr2:218255319~218257366:+
PRAD	cis	rs4423214	0.879	rs1790353	ENSG00000254682.1	RP11-660L16.2	-12.22	7.07e-30	1.33e-26	-0.72	-0.5	Vitamin D levels;	chr11:71425684	chr11:71448674~71452157:+
PRAD	cis	rs11105298	0.891	rs1054807	ENSG00000258302.2	RP11-981P6.1	12.22	7.08e-30	1.33e-26	0.56	0.5	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89519642	chr12:89561129~89594878:+
PRAD	cis	rs11105298	0.891	rs10858894	ENSG00000258302.2	RP11-981P6.1	12.22	7.08e-30	1.33e-26	0.56	0.5	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89520484	chr12:89561129~89594878:+
PRAD	cis	rs2658782	0.789	rs3020057	ENSG00000279684.1	RP11-755E23.2	-12.22	7.08e-30	1.33e-26	-0.78	-0.5	Pulmonary function decline;	chr11:93385349	chr11:93286629~93288903:-
PRAD	cis	rs7044106	0.791	rs3904196	ENSG00000226752.6	PSMD5-AS1	-12.22	7.09e-30	1.34e-26	-0.61	-0.5	Hip circumference adjusted for BMI;	chr9:120718091	chr9:120824828~120854385:+
PRAD	cis	rs9322193	0.847	rs9505972	ENSG00000223701.3	RAET1E-AS1	12.22	7.1e-30	1.34e-26	0.67	0.5	Lung cancer;	chr6:149775255	chr6:149884431~149919508:+
PRAD	cis	rs7044106	0.762	rs10739570	ENSG00000226752.6	PSMD5-AS1	-12.21	7.13e-30	1.34e-26	-0.61	-0.5	Hip circumference adjusted for BMI;	chr9:120618944	chr9:120824828~120854385:+
PRAD	cis	rs875971	0.545	rs2707851	ENSG00000237310.1	GS1-124K5.4	-12.21	7.2e-30	1.36e-26	-0.5	-0.5	Aortic root size;	chr7:66624178	chr7:66493706~66495474:+
PRAD	cis	rs9322193	0.884	rs62439837	ENSG00000223701.3	RAET1E-AS1	12.21	7.25e-30	1.37e-26	0.67	0.5	Lung cancer;	chr6:149670380	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.923	rs11155674	ENSG00000223701.3	RAET1E-AS1	12.21	7.28e-30	1.37e-26	0.66	0.5	Lung cancer;	chr6:149711111	chr6:149884431~149919508:+
PRAD	cis	rs1150668	0.799	rs1150707	ENSG00000216901.1	AL022393.7	12.21	7.32e-30	1.38e-26	0.63	0.5	Pubertal anthropometrics;	chr6:28229827	chr6:28176188~28176674:+
PRAD	cis	rs1061377	0.965	rs7669376	ENSG00000249207.1	RP11-360F5.1	-12.21	7.34e-30	1.38e-26	-0.52	-0.5	Uric acid levels;	chr4:39116717	chr4:39112677~39126818:-
PRAD	cis	rs977987	0.836	rs8055974	ENSG00000261783.1	RP11-252K23.2	-12.21	7.39e-30	1.39e-26	-0.67	-0.5	Dupuytren's disease;	chr16:75437088	chr16:75379818~75381260:-
PRAD	cis	rs7617773	1	rs9832957	ENSG00000229759.1	MRPS18AP1	-12.21	7.62e-30	1.43e-26	-0.53	-0.5	Coronary artery disease;	chr3:48143776	chr3:48256350~48256938:-
PRAD	cis	rs6142102	0.625	rs2050208	ENSG00000276073.1	RP5-1125A11.7	-12.21	7.7e-30	1.45e-26	-0.48	-0.5	Skin pigmentation;	chr20:33955767	chr20:33985617~33988989:-
PRAD	cis	rs3091242	0.933	rs34933589	ENSG00000224183.1	SDHDP6	12.21	7.76e-30	1.46e-26	0.58	0.5	Erythrocyte sedimentation rate;	chr1:25461707	chr1:25294164~25294643:-
PRAD	cis	rs6991838	0.584	rs7463740	ENSG00000272010.1	CTD-3025N20.3	-12.2	7.84e-30	1.47e-26	-0.52	-0.5	Intelligence (multi-trait analysis);	chr8:65573950	chr8:65591850~65592472:-
PRAD	cis	rs3091242	0.935	rs4233043	ENSG00000261349.1	RP3-465N24.5	-12.2	7.87e-30	1.48e-26	-0.54	-0.5	Erythrocyte sedimentation rate;	chr1:25438992	chr1:25266102~25267136:-
PRAD	cis	rs3091242	0.933	rs11249250	ENSG00000261349.1	RP3-465N24.5	-12.2	7.87e-30	1.48e-26	-0.54	-0.5	Erythrocyte sedimentation rate;	chr1:25441118	chr1:25266102~25267136:-
PRAD	cis	rs6142102	0.602	rs4911380	ENSG00000276073.1	RP5-1125A11.7	-12.2	8.09e-30	1.52e-26	-0.48	-0.5	Skin pigmentation;	chr20:33958418	chr20:33985617~33988989:-
PRAD	cis	rs6142102	0.625	rs4243974	ENSG00000276073.1	RP5-1125A11.7	-12.2	8.09e-30	1.52e-26	-0.48	-0.5	Skin pigmentation;	chr20:33960062	chr20:33985617~33988989:-
PRAD	cis	rs6142102	0.625	rs6142062	ENSG00000276073.1	RP5-1125A11.7	-12.2	8.09e-30	1.52e-26	-0.48	-0.5	Skin pigmentation;	chr20:33960706	chr20:33985617~33988989:-
PRAD	cis	rs6142102	0.625	rs6141432	ENSG00000276073.1	RP5-1125A11.7	-12.2	8.09e-30	1.52e-26	-0.48	-0.5	Skin pigmentation;	chr20:33960791	chr20:33985617~33988989:-
PRAD	cis	rs6142102	0.602	rs6141433	ENSG00000276073.1	RP5-1125A11.7	-12.2	8.09e-30	1.52e-26	-0.48	-0.5	Skin pigmentation;	chr20:33961056	chr20:33985617~33988989:-
PRAD	cis	rs524281	0.861	rs485857	ENSG00000255320.1	RP11-755F10.1	12.2	8.19e-30	1.54e-26	0.75	0.5	Electroencephalogram traits;	chr11:66192048	chr11:66244840~66246239:-
PRAD	cis	rs9532669	0.926	rs7328139	ENSG00000176268.5	CYCSP34	12.2	8.2e-30	1.54e-26	0.51	0.5	Cervical cancer;	chr13:40862295	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.926	rs7328145	ENSG00000176268.5	CYCSP34	12.2	8.2e-30	1.54e-26	0.51	0.5	Cervical cancer;	chr13:40862307	chr13:40863599~40863902:-
PRAD	cis	rs3814244	0.868	rs11177007	ENSG00000255733.4	IFNG-AS1	12.2	8.26e-30	1.55e-26	0.54	0.5	Itch intensity from mosquito bite adjusted by bite size;	chr12:68020964	chr12:67989445~68234686:+
PRAD	cis	rs9322193	0.923	rs4870050	ENSG00000223701.3	RAET1E-AS1	12.2	8.34e-30	1.57e-26	0.67	0.5	Lung cancer;	chr6:149838917	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.962	rs7752089	ENSG00000223701.3	RAET1E-AS1	12.2	8.34e-30	1.57e-26	0.67	0.5	Lung cancer;	chr6:149839298	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.923	rs4242279	ENSG00000223701.3	RAET1E-AS1	12.2	8.34e-30	1.57e-26	0.67	0.5	Lung cancer;	chr6:149839815	chr6:149884431~149919508:+
PRAD	cis	rs3091242	0.9	rs669063	ENSG00000224183.1	SDHDP6	-12.2	8.36e-30	1.57e-26	-0.57	-0.5	Erythrocyte sedimentation rate;	chr1:25394663	chr1:25294164~25294643:-
PRAD	cis	rs9322193	0.923	rs9800736	ENSG00000223701.3	RAET1E-AS1	12.2	8.37e-30	1.57e-26	0.66	0.5	Lung cancer;	chr6:149661281	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.962	rs3805749	ENSG00000223701.3	RAET1E-AS1	12.2	8.41e-30	1.58e-26	0.67	0.5	Lung cancer;	chr6:149772546	chr6:149884431~149919508:+
PRAD	cis	rs9532669	0.926	rs9532671	ENSG00000176268.5	CYCSP34	12.2	8.44e-30	1.58e-26	0.51	0.5	Cervical cancer;	chr13:40927761	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.833	rs9532672	ENSG00000176268.5	CYCSP34	12.2	8.44e-30	1.58e-26	0.51	0.5	Cervical cancer;	chr13:40928285	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.963	rs7324625	ENSG00000176268.5	CYCSP34	12.2	8.44e-30	1.58e-26	0.51	0.5	Cervical cancer;	chr13:40928606	chr13:40863599~40863902:-
PRAD	cis	rs12049351	0.719	rs6587338	ENSG00000229367.1	HMGN2P19	12.2	8.45e-30	1.58e-26	0.71	0.5	Circulating myeloperoxidase levels (plasma);	chr1:229496891	chr1:229570532~229570796:+
PRAD	cis	rs4845570	1	rs11586946	ENSG00000249602.1	RP11-98D18.3	12.2	8.46e-30	1.59e-26	0.8	0.5	Coronary artery disease;	chr1:151797330	chr1:151763384~151769501:-
PRAD	cis	rs12049351	0.774	rs12039754	ENSG00000229367.1	HMGN2P19	12.2	8.53e-30	1.6e-26	0.72	0.5	Circulating myeloperoxidase levels (plasma);	chr1:229509149	chr1:229570532~229570796:+
PRAD	cis	rs9322193	0.923	rs12205092	ENSG00000223701.3	RAET1E-AS1	12.19	8.61e-30	1.61e-26	0.67	0.5	Lung cancer;	chr6:149761375	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.923	rs10872651	ENSG00000223701.3	RAET1E-AS1	12.19	8.61e-30	1.61e-26	0.67	0.5	Lung cancer;	chr6:149768273	chr6:149884431~149919508:+
PRAD	cis	rs2153535	0.562	rs10458225	ENSG00000230939.1	RP11-314C16.1	12.19	8.62e-30	1.62e-26	0.61	0.5	Motion sickness;	chr6:8385771	chr6:8784178~8785445:+
PRAD	cis	rs2404602	0.735	rs1607017	ENSG00000259422.1	RP11-593F23.1	-12.19	8.64e-30	1.62e-26	-0.65	-0.5	Blood metabolite levels;	chr15:76434124	chr15:76174891~76181486:-
PRAD	cis	rs748404	0.56	rs1060939	ENSG00000205771.5	CATSPER2P1	-12.19	8.72e-30	1.63e-26	-0.57	-0.5	Lung cancer;	chr15:43524719	chr15:43726918~43747094:-
PRAD	cis	rs9532669	0.89	rs7333274	ENSG00000176268.5	CYCSP34	12.19	8.73e-30	1.64e-26	0.51	0.5	Cervical cancer;	chr13:40862531	chr13:40863599~40863902:-
PRAD	cis	rs9322193	0.847	rs56103941	ENSG00000223701.3	RAET1E-AS1	12.19	8.86e-30	1.66e-26	0.67	0.5	Lung cancer;	chr6:149816095	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.847	rs12210605	ENSG00000223701.3	RAET1E-AS1	12.19	8.86e-30	1.66e-26	0.67	0.5	Lung cancer;	chr6:149817267	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.923	rs9371199	ENSG00000223701.3	RAET1E-AS1	12.19	8.86e-30	1.66e-26	0.67	0.5	Lung cancer;	chr6:149817526	chr6:149884431~149919508:+
PRAD	cis	rs9487094	0.848	rs7372	ENSG00000260273.1	RP11-425D10.10	12.19	8.89e-30	1.67e-26	0.7	0.5	Height;	chr6:109366911	chr6:109382795~109383666:+
PRAD	cis	rs2929278	0.617	rs524908	ENSG00000205771.5	CATSPER2P1	12.19	8.92e-30	1.67e-26	0.57	0.5	Schizophrenia;	chr15:43895793	chr15:43726918~43747094:-
PRAD	cis	rs9322193	0.923	rs9383812	ENSG00000223701.3	RAET1E-AS1	12.19	9.08e-30	1.7e-26	0.66	0.5	Lung cancer;	chr6:149712355	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.847	rs9383844	ENSG00000223701.3	RAET1E-AS1	12.19	9.08e-30	1.7e-26	0.66	0.5	Lung cancer;	chr6:149716268	chr6:149884431~149919508:+
PRAD	cis	rs189798	0.807	rs12785	ENSG00000254340.1	RP11-10A14.3	12.19	9.12e-30	1.71e-26	0.66	0.5	Myopia (pathological);	chr8:9137426	chr8:9141424~9145435:+
PRAD	cis	rs1185460	0.967	rs1784461	ENSG00000271751.1	RP11-110I1.14	-12.19	9.12e-30	1.71e-26	-0.68	-0.5	Coronary artery disease;	chr11:119067274	chr11:119065263~119065677:-
PRAD	cis	rs3091242	0.9	rs1811832	ENSG00000261349.1	RP3-465N24.5	-12.19	9.16e-30	1.71e-26	-0.54	-0.5	Erythrocyte sedimentation rate;	chr1:25427074	chr1:25266102~25267136:-
PRAD	cis	rs4423214	0.879	rs1630498	ENSG00000254682.1	RP11-660L16.2	-12.19	9.18e-30	1.72e-26	-0.71	-0.5	Vitamin D levels;	chr11:71439739	chr11:71448674~71452157:+
PRAD	cis	rs9532669	0.963	rs1571116	ENSG00000176268.5	CYCSP34	12.19	9.18e-30	1.72e-26	0.51	0.5	Cervical cancer;	chr13:40929765	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.963	rs9532673	ENSG00000176268.5	CYCSP34	12.19	9.18e-30	1.72e-26	0.51	0.5	Cervical cancer;	chr13:40930412	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.89	rs9532676	ENSG00000176268.5	CYCSP34	12.19	9.18e-30	1.72e-26	0.51	0.5	Cervical cancer;	chr13:40935626	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.926	rs2324737	ENSG00000176268.5	CYCSP34	12.19	9.31e-30	1.74e-26	0.51	0.5	Cervical cancer;	chr13:40862808	chr13:40863599~40863902:-
PRAD	cis	rs5769707	0.967	rs9616327	ENSG00000188511.11	C22orf34	12.19	9.36e-30	1.75e-26	0.52	0.5	Monocyte percentage of white cells;Monocyte count;	chr22:49617243	chr22:49414524~49657542:-
PRAD	cis	rs9322193	0.923	rs9479494	ENSG00000223701.3	RAET1E-AS1	12.18	9.39e-30	1.76e-26	0.67	0.5	Lung cancer;	chr6:149739108	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.923	rs9800806	ENSG00000223701.3	RAET1E-AS1	12.18	9.39e-30	1.76e-26	0.67	0.5	Lung cancer;	chr6:149740350	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.923	rs9688517	ENSG00000223701.3	RAET1E-AS1	12.18	9.39e-30	1.76e-26	0.67	0.5	Lung cancer;	chr6:149740655	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.923	rs1572229	ENSG00000223701.3	RAET1E-AS1	12.18	9.39e-30	1.76e-26	0.67	0.5	Lung cancer;	chr6:149743841	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.923	rs9689716	ENSG00000223701.3	RAET1E-AS1	12.18	9.48e-30	1.77e-26	0.67	0.5	Lung cancer;	chr6:149655662	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.923	rs9322207	ENSG00000223701.3	RAET1E-AS1	12.18	9.48e-30	1.77e-26	0.67	0.5	Lung cancer;	chr6:149657185	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.923	rs9322208	ENSG00000223701.3	RAET1E-AS1	12.18	9.48e-30	1.77e-26	0.67	0.5	Lung cancer;	chr6:149658547	chr6:149884431~149919508:+
PRAD	cis	rs7617773	1	rs12496784	ENSG00000229759.1	MRPS18AP1	-12.18	9.52e-30	1.78e-26	-0.52	-0.5	Coronary artery disease;	chr3:48144777	chr3:48256350~48256938:-
PRAD	cis	rs5769707	0.967	rs739248	ENSG00000188511.11	C22orf34	12.18	9.56e-30	1.79e-26	0.52	0.5	Monocyte percentage of white cells;Monocyte count;	chr22:49631557	chr22:49414524~49657542:-
PRAD	cis	rs9322193	0.962	rs3805752	ENSG00000223701.3	RAET1E-AS1	12.18	9.57e-30	1.79e-26	0.67	0.5	Lung cancer;	chr6:149795490	chr6:149884431~149919508:+
PRAD	cis	rs12049351	0.719	rs2145394	ENSG00000229367.1	HMGN2P19	12.18	9.61e-30	1.8e-26	0.69	0.5	Circulating myeloperoxidase levels (plasma);	chr1:229535217	chr1:229570532~229570796:+
PRAD	cis	rs11105298	0.891	rs11105316	ENSG00000258302.2	RP11-981P6.1	12.18	9.64e-30	1.8e-26	0.56	0.5	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89531423	chr12:89561129~89594878:+
PRAD	cis	rs11676348	0.755	rs6436026	ENSG00000261338.2	RP11-378A13.1	-12.18	9.65e-30	1.8e-26	-0.56	-0.5	Ulcerative colitis;	chr2:218087015	chr2:218255319~218257366:+
PRAD	cis	rs12049351	0.774	rs6668018	ENSG00000229367.1	HMGN2P19	12.18	9.68e-30	1.81e-26	0.71	0.5	Circulating myeloperoxidase levels (plasma);	chr1:229493306	chr1:229570532~229570796:+
PRAD	cis	rs12049351	0.719	rs10916492	ENSG00000229367.1	HMGN2P19	12.18	9.68e-30	1.81e-26	0.71	0.5	Circulating myeloperoxidase levels (plasma);	chr1:229498649	chr1:229570532~229570796:+
PRAD	cis	rs12049351	0.719	rs10916493	ENSG00000229367.1	HMGN2P19	12.18	9.68e-30	1.81e-26	0.71	0.5	Circulating myeloperoxidase levels (plasma);	chr1:229498650	chr1:229570532~229570796:+
PRAD	cis	rs12049351	0.774	rs10916495	ENSG00000229367.1	HMGN2P19	12.18	9.68e-30	1.81e-26	0.71	0.5	Circulating myeloperoxidase levels (plasma);	chr1:229499774	chr1:229570532~229570796:+
PRAD	cis	rs12049351	0.774	rs754025	ENSG00000229367.1	HMGN2P19	12.18	9.68e-30	1.81e-26	0.71	0.5	Circulating myeloperoxidase levels (plasma);	chr1:229501550	chr1:229570532~229570796:+
PRAD	cis	rs12049351	0.774	rs2381108	ENSG00000229367.1	HMGN2P19	12.18	9.68e-30	1.81e-26	0.71	0.5	Circulating myeloperoxidase levels (plasma);	chr1:229502134	chr1:229570532~229570796:+
PRAD	cis	rs12049351	0.774	rs6662732	ENSG00000229367.1	HMGN2P19	-12.18	9.68e-30	1.81e-26	-0.71	-0.5	Circulating myeloperoxidase levels (plasma);	chr1:229493498	chr1:229570532~229570796:+
PRAD	cis	rs9532669	0.857	rs9525427	ENSG00000176268.5	CYCSP34	12.18	9.89e-30	1.85e-26	0.51	0.5	Cervical cancer;	chr13:40918029	chr13:40863599~40863902:-
PRAD	cis	rs9322193	0.923	rs7767622	ENSG00000223701.3	RAET1E-AS1	12.18	1e-29	1.87e-26	0.66	0.5	Lung cancer;	chr6:149681766	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.923	rs4421206	ENSG00000223701.3	RAET1E-AS1	12.18	1e-29	1.87e-26	0.66	0.5	Lung cancer;	chr6:149682891	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.923	rs3798761	ENSG00000223701.3	RAET1E-AS1	12.18	1e-29	1.87e-26	0.66	0.5	Lung cancer;	chr6:149683643	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.923	rs9322209	ENSG00000223701.3	RAET1E-AS1	12.18	1e-29	1.87e-26	0.66	0.5	Lung cancer;	chr6:149691226	chr6:149884431~149919508:+
PRAD	cis	rs875971	0.545	rs75840613	ENSG00000237310.1	GS1-124K5.4	12.18	1e-29	1.87e-26	0.5	0.5	Aortic root size;	chr7:66376399	chr7:66493706~66495474:+
PRAD	cis	rs6964833	1	rs4717907	ENSG00000277053.3	GTF2IP1	-12.18	1e-29	1.87e-26	-0.58	-0.5	Menarche (age at onset);	chr7:74672169	chr7:75185385~75237696:-
PRAD	cis	rs1061377	1	rs4974997	ENSG00000249207.1	RP11-360F5.1	-12.18	1.01e-29	1.89e-26	-0.52	-0.5	Uric acid levels;	chr4:39109151	chr4:39112677~39126818:-
PRAD	cis	rs2739330	0.796	rs1006771	ENSG00000099984.9	GSTT2	-12.18	1.01e-29	1.89e-26	-0.65	-0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23980123~23983911:+
PRAD	cis	rs1185460	0.967	rs1784460	ENSG00000271751.1	RP11-110I1.14	12.18	1.02e-29	1.9e-26	0.68	0.5	Coronary artery disease;	chr11:119067660	chr11:119065263~119065677:-
PRAD	cis	rs1062177	1	rs2016409	ENSG00000213433.5	RPLP1P6	12.18	1.02e-29	1.9e-26	0.59	0.5	Preschool internalizing problems;	chr5:151746763	chr5:151765859~151766378:-
PRAD	cis	rs7044106	0.791	rs7036196	ENSG00000226752.6	PSMD5-AS1	-12.18	1.02e-29	1.9e-26	-0.6	-0.5	Hip circumference adjusted for BMI;	chr9:120717179	chr9:120824828~120854385:+
PRAD	cis	rs977987	0.742	rs34624768	ENSG00000261783.1	RP11-252K23.2	-12.17	1.03e-29	1.93e-26	-0.68	-0.5	Dupuytren's disease;	chr16:75297674	chr16:75379818~75381260:-
PRAD	cis	rs977987	0.8	rs4888378	ENSG00000261783.1	RP11-252K23.2	-12.17	1.03e-29	1.93e-26	-0.68	-0.5	Dupuytren's disease;	chr16:75298143	chr16:75379818~75381260:-
PRAD	cis	rs977987	0.8	rs12935787	ENSG00000261783.1	RP11-252K23.2	-12.17	1.03e-29	1.93e-26	-0.68	-0.5	Dupuytren's disease;	chr16:75298437	chr16:75379818~75381260:-
PRAD	cis	rs1061377	1	rs3796509	ENSG00000249207.1	RP11-360F5.1	-12.17	1.03e-29	1.93e-26	-0.52	-0.5	Uric acid levels;	chr4:39108566	chr4:39112677~39126818:-
PRAD	cis	rs1061377	1	rs4974998	ENSG00000249207.1	RP11-360F5.1	-12.17	1.04e-29	1.94e-26	-0.52	-0.5	Uric acid levels;	chr4:39109129	chr4:39112677~39126818:-
PRAD	cis	rs9487094	0.961	rs6911838	ENSG00000260273.1	RP11-425D10.10	12.17	1.04e-29	1.94e-26	0.69	0.5	Height;	chr6:109478720	chr6:109382795~109383666:+
PRAD	cis	rs2658782	0.756	rs3019205	ENSG00000279684.1	RP11-755E23.2	-12.17	1.05e-29	1.95e-26	-0.78	-0.5	Pulmonary function decline;	chr11:93376387	chr11:93286629~93288903:-
PRAD	cis	rs9322193	0.923	rs55993747	ENSG00000223701.3	RAET1E-AS1	12.17	1.06e-29	1.97e-26	0.66	0.5	Lung cancer;	chr6:149622016	chr6:149884431~149919508:+
PRAD	cis	rs5769707	0.967	rs5770585	ENSG00000188511.11	C22orf34	12.17	1.06e-29	1.97e-26	0.52	0.5	Monocyte percentage of white cells;Monocyte count;	chr22:49614226	chr22:49414524~49657542:-
PRAD	cis	rs1150668	0.799	rs7206	ENSG00000216901.1	AL022393.7	12.17	1.06e-29	1.97e-26	0.63	0.5	Pubertal anthropometrics;	chr6:28233360	chr6:28176188~28176674:+
PRAD	cis	rs1062177	0.95	rs892005	ENSG00000213433.5	RPLP1P6	-12.17	1.06e-29	1.98e-26	-0.59	-0.5	Preschool internalizing problems;	chr5:151801060	chr5:151765859~151766378:-
PRAD	cis	rs9322193	0.884	rs9322210	ENSG00000223701.3	RAET1E-AS1	12.17	1.06e-29	1.98e-26	0.66	0.5	Lung cancer;	chr6:149695440	chr6:149884431~149919508:+
PRAD	cis	rs11676348	0.791	rs6726126	ENSG00000261338.2	RP11-378A13.1	-12.17	1.07e-29	1.99e-26	-0.56	-0.5	Ulcerative colitis;	chr2:218087510	chr2:218255319~218257366:+
PRAD	cis	rs9326248	0.911	rs11216284	ENSG00000280143.1	AP000892.6	12.17	1.07e-29	2e-26	0.42	0.5	Blood protein levels;	chr11:117132344	chr11:117204967~117210292:+
PRAD	cis	rs9322193	0.962	rs7740784	ENSG00000223701.3	RAET1E-AS1	12.17	1.09e-29	2.02e-26	0.66	0.5	Lung cancer;	chr6:149833364	chr6:149884431~149919508:+
PRAD	cis	rs875971	0.545	rs6460298	ENSG00000237310.1	GS1-124K5.4	12.17	1.09e-29	2.03e-26	0.5	0.5	Aortic root size;	chr7:66442783	chr7:66493706~66495474:+
PRAD	cis	rs9487094	0.885	rs1590306	ENSG00000260273.1	RP11-425D10.10	12.17	1.1e-29	2.04e-26	0.7	0.5	Height;	chr6:109359747	chr6:109382795~109383666:+
PRAD	cis	rs907683	0.584	rs12621188	ENSG00000280323.1	AC053503.12	12.17	1.1e-29	2.04e-26	0.41	0.5	Resting heart rate;	chr2:219423170	chr2:219427477~219429319:+
PRAD	cis	rs35160687	0.901	rs12472390	ENSG00000273080.1	RP11-301O19.1	12.17	1.1e-29	2.05e-26	0.59	0.5	Night sleep phenotypes;	chr2:86247960	chr2:86195590~86196049:+
PRAD	cis	rs6142102	0.625	rs9753690	ENSG00000276073.1	RP5-1125A11.7	-12.17	1.11e-29	2.07e-26	-0.48	-0.5	Skin pigmentation;	chr20:33952995	chr20:33985617~33988989:-
PRAD	cis	rs6142102	0.625	rs7263727	ENSG00000276073.1	RP5-1125A11.7	-12.17	1.11e-29	2.07e-26	-0.48	-0.5	Skin pigmentation;	chr20:33953133	chr20:33985617~33988989:-
PRAD	cis	rs6142102	0.625	rs6142056	ENSG00000276073.1	RP5-1125A11.7	-12.17	1.11e-29	2.07e-26	-0.48	-0.5	Skin pigmentation;	chr20:33953349	chr20:33985617~33988989:-
PRAD	cis	rs1150668	0.799	rs2142730	ENSG00000216901.1	AL022393.7	12.17	1.12e-29	2.08e-26	0.62	0.5	Pubertal anthropometrics;	chr6:28298372	chr6:28176188~28176674:+
PRAD	cis	rs11690935	0.632	rs6723259	ENSG00000228389.1	AC068039.4	-12.16	1.14e-29	2.12e-26	-0.56	-0.5	Schizophrenia;	chr2:171766017	chr2:171773482~171775844:+
PRAD	cis	rs8062405	1	rs8062405	ENSG00000259982.1	CDC37P1	-12.16	1.14e-29	2.12e-26	-0.64	-0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826585	chr16:28700294~28701540:-
PRAD	cis	rs9487094	0.922	rs10872034	ENSG00000260273.1	RP11-425D10.10	12.16	1.14e-29	2.12e-26	0.71	0.5	Height;	chr6:109486036	chr6:109382795~109383666:+
PRAD	cis	rs11105298	0.891	rs10858899	ENSG00000258302.2	RP11-981P6.1	12.16	1.15e-29	2.13e-26	0.55	0.5	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89530034	chr12:89561129~89594878:+
PRAD	cis	rs977987	0.843	rs10459859	ENSG00000261783.1	RP11-252K23.2	-12.16	1.16e-29	2.15e-26	-0.67	-0.5	Dupuytren's disease;	chr16:75348052	chr16:75379818~75381260:-
PRAD	cis	rs1150668	0.768	rs1233713	ENSG00000216901.1	AL022393.7	12.16	1.16e-29	2.15e-26	0.62	0.5	Pubertal anthropometrics;	chr6:28230503	chr6:28176188~28176674:+
PRAD	cis	rs2658782	0.789	rs2658775	ENSG00000279684.1	RP11-755E23.2	-12.16	1.16e-29	2.16e-26	-0.78	-0.5	Pulmonary function decline;	chr11:93393633	chr11:93286629~93288903:-
PRAD	cis	rs2658782	0.789	rs2658773	ENSG00000279684.1	RP11-755E23.2	-12.16	1.16e-29	2.16e-26	-0.78	-0.5	Pulmonary function decline;	chr11:93393748	chr11:93286629~93288903:-
PRAD	cis	rs1577917	0.771	rs7742201	ENSG00000203875.9	SNHG5	-12.16	1.18e-29	2.19e-26	-0.58	-0.5	Response to antipsychotic treatment;	chr6:85723212	chr6:85660950~85678736:-
PRAD	cis	rs12049351	0.774	rs12125125	ENSG00000229367.1	HMGN2P19	12.16	1.18e-29	2.19e-26	0.71	0.5	Circulating myeloperoxidase levels (plasma);	chr1:229491919	chr1:229570532~229570796:+
PRAD	cis	rs12049351	0.774	rs12125978	ENSG00000229367.1	HMGN2P19	12.16	1.18e-29	2.19e-26	0.71	0.5	Circulating myeloperoxidase levels (plasma);	chr1:229491975	chr1:229570532~229570796:+
PRAD	cis	rs875971	0.545	rs66594357	ENSG00000237310.1	GS1-124K5.4	12.16	1.2e-29	2.22e-26	0.5	0.5	Aortic root size;	chr7:66327797	chr7:66493706~66495474:+
PRAD	cis	rs12049351	0.774	rs6704265	ENSG00000229367.1	HMGN2P19	12.16	1.2e-29	2.23e-26	0.71	0.5	Circulating myeloperoxidase levels (plasma);	chr1:229497309	chr1:229570532~229570796:+
PRAD	cis	rs12049351	0.774	rs4925457	ENSG00000229367.1	HMGN2P19	12.16	1.2e-29	2.23e-26	0.71	0.5	Circulating myeloperoxidase levels (plasma);	chr1:229497824	chr1:229570532~229570796:+
PRAD	cis	rs172166	0.561	rs149973	ENSG00000216901.1	AL022393.7	12.16	1.22e-29	2.26e-26	0.61	0.5	Cardiac Troponin-T levels;	chr6:28015835	chr6:28176188~28176674:+
PRAD	cis	rs172166	0.561	rs149974	ENSG00000216901.1	AL022393.7	12.16	1.22e-29	2.26e-26	0.61	0.5	Cardiac Troponin-T levels;	chr6:28017318	chr6:28176188~28176674:+
PRAD	cis	rs9487094	0.885	rs3799839	ENSG00000260273.1	RP11-425D10.10	12.15	1.25e-29	2.31e-26	0.7	0.5	Height;	chr6:109380990	chr6:109382795~109383666:+
PRAD	cis	rs1061377	1	rs7673299	ENSG00000249207.1	RP11-360F5.1	-12.15	1.25e-29	2.31e-26	-0.52	-0.5	Uric acid levels;	chr4:39109138	chr4:39112677~39126818:-
PRAD	cis	rs6142102	0.538	rs6142058	ENSG00000276073.1	RP5-1125A11.7	-12.15	1.25e-29	2.32e-26	-0.48	-0.5	Skin pigmentation;	chr20:33954995	chr20:33985617~33988989:-
PRAD	cis	rs1062177	1	rs973529	ENSG00000213433.5	RPLP1P6	-12.15	1.26e-29	2.33e-26	-0.59	-0.5	Preschool internalizing problems;	chr5:151808597	chr5:151765859~151766378:-
PRAD	cis	rs9322193	0.847	rs12191643	ENSG00000223701.3	RAET1E-AS1	12.15	1.27e-29	2.35e-26	0.66	0.5	Lung cancer;	chr6:149628912	chr6:149884431~149919508:+
PRAD	cis	rs9487094	0.885	rs13212766	ENSG00000260273.1	RP11-425D10.10	12.15	1.28e-29	2.37e-26	0.71	0.49	Height;	chr6:109384228	chr6:109382795~109383666:+
PRAD	cis	rs9487094	0.961	rs3757234	ENSG00000260273.1	RP11-425D10.10	12.15	1.28e-29	2.37e-26	0.71	0.49	Height;	chr6:109385087	chr6:109382795~109383666:+
PRAD	cis	rs9487094	0.961	rs12524639	ENSG00000260273.1	RP11-425D10.10	12.15	1.28e-29	2.37e-26	0.71	0.49	Height;	chr6:109388256	chr6:109382795~109383666:+
PRAD	cis	rs12049351	0.774	rs6670553	ENSG00000229367.1	HMGN2P19	12.15	1.28e-29	2.38e-26	0.71	0.49	Circulating myeloperoxidase levels (plasma);	chr1:229500120	chr1:229570532~229570796:+
PRAD	cis	rs1062177	1	rs62377945	ENSG00000213433.5	RPLP1P6	-12.15	1.29e-29	2.39e-26	-0.58	-0.49	Preschool internalizing problems;	chr5:151828443	chr5:151765859~151766378:-
PRAD	cis	rs907683	0.584	rs12991025	ENSG00000280323.1	AC053503.12	12.15	1.29e-29	2.39e-26	0.41	0.49	Resting heart rate;	chr2:219420057	chr2:219427477~219429319:+
PRAD	cis	rs9322193	0.886	rs2065663	ENSG00000223701.3	RAET1E-AS1	12.15	1.3e-29	2.41e-26	0.66	0.49	Lung cancer;	chr6:149760331	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.962	rs2275045	ENSG00000223701.3	RAET1E-AS1	12.15	1.31e-29	2.42e-26	0.67	0.49	Lung cancer;	chr6:149842775	chr6:149884431~149919508:+
PRAD	cis	rs71403859	0.73	rs17355804	ENSG00000260886.1	TAT-AS1	12.15	1.31e-29	2.42e-26	0.88	0.49	Post bronchodilator FEV1;	chr16:71683311	chr16:71565789~71578187:+
PRAD	cis	rs6142102	0.502	rs58393429	ENSG00000276073.1	RP5-1125A11.7	-12.15	1.32e-29	2.44e-26	-0.48	-0.49	Skin pigmentation;	chr20:33957996	chr20:33985617~33988989:-
PRAD	cis	rs9326248	0.608	rs1076485	ENSG00000254851.1	RP11-109L13.1	12.15	1.32e-29	2.45e-26	0.88	0.49	Blood protein levels;	chr11:116901725	chr11:117135528~117138582:+
PRAD	cis	rs12049351	0.774	rs34405887	ENSG00000229367.1	HMGN2P19	12.15	1.33e-29	2.46e-26	0.71	0.49	Circulating myeloperoxidase levels (plasma);	chr1:229482887	chr1:229570532~229570796:+
PRAD	cis	rs12049351	0.719	rs34804247	ENSG00000229367.1	HMGN2P19	12.15	1.33e-29	2.46e-26	0.71	0.49	Circulating myeloperoxidase levels (plasma);	chr1:229484938	chr1:229570532~229570796:+
PRAD	cis	rs12049351	0.774	rs12030128	ENSG00000229367.1	HMGN2P19	12.15	1.33e-29	2.46e-26	0.71	0.49	Circulating myeloperoxidase levels (plasma);	chr1:229487116	chr1:229570532~229570796:+
PRAD	cis	rs12049351	0.774	rs6678721	ENSG00000229367.1	HMGN2P19	12.15	1.33e-29	2.46e-26	0.71	0.49	Circulating myeloperoxidase levels (plasma);	chr1:229487384	chr1:229570532~229570796:+
PRAD	cis	rs2882667	0.824	rs1560656	ENSG00000253404.1	AC034243.1	-12.15	1.35e-29	2.49e-26	-0.69	-0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139135100	chr5:138744434~138753309:-
PRAD	cis	rs4423214	0.879	rs1792281	ENSG00000254682.1	RP11-660L16.2	-12.15	1.35e-29	2.5e-26	-0.72	-0.49	Vitamin D levels;	chr11:71424450	chr11:71448674~71452157:+
PRAD	cis	rs8072100	1	rs11870935	ENSG00000228782.6	CTD-2026D20.3	-12.14	1.38e-29	2.54e-26	-0.54	-0.49	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47655239	chr17:47450568~47492492:-
PRAD	cis	rs8072100	1	rs4794016	ENSG00000228782.6	CTD-2026D20.3	-12.14	1.39e-29	2.57e-26	-0.54	-0.49	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47648565	chr17:47450568~47492492:-
PRAD	cis	rs907683	0.584	rs2070927	ENSG00000280323.1	AC053503.12	12.14	1.4e-29	2.58e-26	0.42	0.49	Resting heart rate;	chr2:219418233	chr2:219427477~219429319:+
PRAD	cis	rs1061377	1	rs1061377	ENSG00000249207.1	RP11-360F5.1	-12.14	1.4e-29	2.58e-26	-0.51	-0.49	Uric acid levels;	chr4:39123130	chr4:39112677~39126818:-
PRAD	cis	rs1061377	1	rs13109200	ENSG00000249207.1	RP11-360F5.1	-12.14	1.4e-29	2.58e-26	-0.51	-0.49	Uric acid levels;	chr4:39124396	chr4:39112677~39126818:-
PRAD	cis	rs1061377	1	rs13144374	ENSG00000249207.1	RP11-360F5.1	-12.14	1.4e-29	2.58e-26	-0.51	-0.49	Uric acid levels;	chr4:39128859	chr4:39112677~39126818:-
PRAD	cis	rs7044106	0.791	rs10818473	ENSG00000226752.6	PSMD5-AS1	-12.14	1.4e-29	2.59e-26	-0.61	-0.49	Hip circumference adjusted for BMI;	chr9:120721877	chr9:120824828~120854385:+
PRAD	cis	rs12022452	1	rs12022452	ENSG00000238287.1	RP11-656D10.3	-12.14	1.41e-29	2.6e-26	-0.9	-0.49	Age-related hearing impairment (SNP x SNP interaction);	chr1:40487628	chr1:40493157~40508661:-
PRAD	cis	rs6920372	0.708	rs13198852	ENSG00000260273.1	RP11-425D10.10	12.14	1.42e-29	2.62e-26	0.67	0.49	Height;	chr6:109747119	chr6:109382795~109383666:+
PRAD	cis	rs6920372	0.748	rs12528392	ENSG00000260273.1	RP11-425D10.10	12.14	1.42e-29	2.62e-26	0.67	0.49	Height;	chr6:109747411	chr6:109382795~109383666:+
PRAD	cis	rs6920372	0.692	rs11153216	ENSG00000260273.1	RP11-425D10.10	12.14	1.42e-29	2.62e-26	0.67	0.49	Height;	chr6:109748819	chr6:109382795~109383666:+
PRAD	cis	rs6920372	0.748	rs2025147	ENSG00000260273.1	RP11-425D10.10	12.14	1.42e-29	2.62e-26	0.67	0.49	Height;	chr6:109749564	chr6:109382795~109383666:+
PRAD	cis	rs6920372	0.748	rs12190372	ENSG00000260273.1	RP11-425D10.10	12.14	1.42e-29	2.62e-26	0.67	0.49	Height;	chr6:109763331	chr6:109382795~109383666:+
PRAD	cis	rs5769707	0.967	rs9616713	ENSG00000188511.11	C22orf34	12.14	1.42e-29	2.63e-26	0.52	0.49	Monocyte percentage of white cells;Monocyte count;	chr22:49655461	chr22:49414524~49657542:-
PRAD	cis	rs17826219	0.5	rs117560728	ENSG00000263531.1	RP13-753N3.1	12.14	1.43e-29	2.63e-26	1.16	0.49	Body mass index;	chr17:30743920	chr17:30863921~30864940:-
PRAD	cis	rs9322193	0.607	rs6557165	ENSG00000231760.4	RP11-350J20.5	-12.14	1.44e-29	2.65e-26	-0.74	-0.49	Lung cancer;	chr6:149906883	chr6:149796151~149826294:-
PRAD	cis	rs12049351	0.774	rs12033236	ENSG00000229367.1	HMGN2P19	12.14	1.45e-29	2.67e-26	0.7	0.49	Circulating myeloperoxidase levels (plasma);	chr1:229504724	chr1:229570532~229570796:+
PRAD	cis	rs172166	0.585	rs149963	ENSG00000216901.1	AL022393.7	12.14	1.46e-29	2.69e-26	0.61	0.49	Cardiac Troponin-T levels;	chr6:28049354	chr6:28176188~28176674:+
PRAD	cis	rs9532669	0.926	rs2183144	ENSG00000176268.5	CYCSP34	-12.14	1.46e-29	2.69e-26	-0.51	-0.49	Cervical cancer;	chr13:40862129	chr13:40863599~40863902:-
PRAD	cis	rs9322193	0.607	rs10457852	ENSG00000231760.4	RP11-350J20.5	12.14	1.48e-29	2.72e-26	0.78	0.49	Lung cancer;	chr6:149880584	chr6:149796151~149826294:-
PRAD	cis	rs9326248	1	rs9326248	ENSG00000280143.1	AP000892.6	12.13	1.49e-29	2.75e-26	0.44	0.49	Blood protein levels;	chr11:117128509	chr11:117204967~117210292:+
PRAD	cis	rs9487094	0.961	rs12206928	ENSG00000260273.1	RP11-425D10.10	12.13	1.49e-29	2.76e-26	0.7	0.49	Height;	chr6:109357908	chr6:109382795~109383666:+
PRAD	cis	rs9532669	1	rs9532669	ENSG00000176268.5	CYCSP34	12.13	1.5e-29	2.76e-26	0.51	0.49	Cervical cancer;	chr13:40927414	chr13:40863599~40863902:-
PRAD	cis	rs1062177	0.855	rs919262	ENSG00000213433.5	RPLP1P6	12.13	1.5e-29	2.77e-26	0.57	0.49	Preschool internalizing problems;	chr5:151886523	chr5:151765859~151766378:-
PRAD	cis	rs9322193	0.923	rs9766004	ENSG00000268592.3	RAET1E-AS1	12.13	1.5e-29	2.77e-26	0.68	0.49	Lung cancer;	chr6:149754363	chr6:149863494~149919507:+
PRAD	cis	rs6142102	0.58	rs9753679	ENSG00000276073.1	RP5-1125A11.7	-12.13	1.52e-29	2.8e-26	-0.48	-0.49	Skin pigmentation;	chr20:33953054	chr20:33985617~33988989:-
PRAD	cis	rs150992	0.79	rs325220	ENSG00000248489.1	CTD-2007H13.3	12.13	1.54e-29	2.84e-26	0.56	0.49	Body mass index;	chr5:98968860	chr5:98929171~98995013:+
PRAD	cis	rs9487094	0.961	rs1923725	ENSG00000260273.1	RP11-425D10.10	12.13	1.55e-29	2.86e-26	0.71	0.49	Height;	chr6:109387685	chr6:109382795~109383666:+
PRAD	cis	rs12049351	0.774	rs6657735	ENSG00000229367.1	HMGN2P19	12.13	1.56e-29	2.87e-26	0.7	0.49	Circulating myeloperoxidase levels (plasma);	chr1:229491085	chr1:229570532~229570796:+
PRAD	cis	rs9487094	0.922	rs10782162	ENSG00000260273.1	RP11-425D10.10	-12.13	1.57e-29	2.89e-26	-0.71	-0.49	Height;	chr6:109485060	chr6:109382795~109383666:+
PRAD	cis	rs8062405	1	rs8061590	ENSG00000259982.1	CDC37P1	12.13	1.57e-29	2.89e-26	0.66	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28883809	chr16:28700294~28701540:-
PRAD	cis	rs4423214	0.625	rs78685409	ENSG00000254682.1	RP11-660L16.2	-12.13	1.58e-29	2.9e-26	-0.72	-0.49	Vitamin D levels;	chr11:71426337	chr11:71448674~71452157:+
PRAD	cis	rs11676348	0.846	rs3890158	ENSG00000261338.2	RP11-378A13.1	-12.13	1.58e-29	2.91e-26	-0.56	-0.49	Ulcerative colitis;	chr2:218125569	chr2:218255319~218257366:+
PRAD	cis	rs11105298	0.891	rs3825330	ENSG00000258302.2	RP11-981P6.1	12.13	1.59e-29	2.92e-26	0.56	0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89539933	chr12:89561129~89594878:+
PRAD	cis	rs1061377	1	rs28607301	ENSG00000249207.1	RP11-360F5.1	-12.13	1.6e-29	2.94e-26	-0.51	-0.49	Uric acid levels;	chr4:39136460	chr4:39112677~39126818:-
PRAD	cis	rs9322193	0.923	rs6913486	ENSG00000223701.3	RAET1E-AS1	-12.13	1.62e-29	2.97e-26	-0.66	-0.49	Lung cancer;	chr6:149705060	chr6:149884431~149919508:+
PRAD	cis	rs11676348	0.811	rs4674255	ENSG00000261338.2	RP11-378A13.1	-12.13	1.62e-29	2.98e-26	-0.56	-0.49	Ulcerative colitis;	chr2:218122602	chr2:218255319~218257366:+
PRAD	cis	rs6964833	1	rs6967152	ENSG00000277053.3	GTF2IP1	-12.13	1.62e-29	2.99e-26	-0.59	-0.49	Menarche (age at onset);	chr7:74684983	chr7:75185385~75237696:-
PRAD	cis	rs1062177	1	rs2964585	ENSG00000213433.5	RPLP1P6	-12.13	1.63e-29	2.99e-26	-0.58	-0.49	Preschool internalizing problems;	chr5:151762334	chr5:151765859~151766378:-
PRAD	cis	rs1062177	1	rs2964578	ENSG00000213433.5	RPLP1P6	-12.13	1.63e-29	2.99e-26	-0.58	-0.49	Preschool internalizing problems;	chr5:151767637	chr5:151765859~151766378:-
PRAD	cis	rs2019137	0.868	rs6755639	ENSG00000189223.12	PAX8-AS1	-12.13	1.63e-29	3e-26	-0.61	-0.49	Lymphocyte counts;	chr2:113224233	chr2:113211522~113276581:+
PRAD	cis	rs9322193	0.923	rs62439840	ENSG00000223701.3	RAET1E-AS1	12.12	1.63e-29	3e-26	0.66	0.49	Lung cancer;	chr6:149674639	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.962	rs9393175	ENSG00000223701.3	RAET1E-AS1	12.12	1.63e-29	3e-26	0.66	0.49	Lung cancer;	chr6:149677587	chr6:149884431~149919508:+
PRAD	cis	rs5769707	0.967	rs763126	ENSG00000188511.11	C22orf34	-12.12	1.65e-29	3.02e-26	-0.52	-0.49	Monocyte percentage of white cells;Monocyte count;	chr22:49594926	chr22:49414524~49657542:-
PRAD	cis	rs11105298	0.891	rs10858890	ENSG00000258302.2	RP11-981P6.1	12.12	1.65e-29	3.04e-26	0.55	0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89513389	chr12:89561129~89594878:+
PRAD	cis	rs2739330	0.76	rs5760095	ENSG00000235689.1	AP000351.13	12.12	1.66e-29	3.04e-26	0.6	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:24006305~24008258:-
PRAD	cis	rs2404602	0.647	rs11637096	ENSG00000259422.1	RP11-593F23.1	-12.12	1.67e-29	3.06e-26	-0.65	-0.49	Blood metabolite levels;	chr15:76638761	chr15:76174891~76181486:-
PRAD	cis	rs11105298	0.891	rs12369685	ENSG00000258302.2	RP11-981P6.1	12.12	1.67e-29	3.06e-26	0.56	0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89535128	chr12:89561129~89594878:+
PRAD	cis	rs11105298	0.891	rs11105312	ENSG00000258302.2	RP11-981P6.1	12.12	1.67e-29	3.06e-26	0.55	0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89526956	chr12:89561129~89594878:+
PRAD	cis	rs11105298	0.891	rs10777185	ENSG00000258302.2	RP11-981P6.1	12.12	1.67e-29	3.06e-26	0.55	0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89527498	chr12:89561129~89594878:+
PRAD	cis	rs11105298	0.786	rs10858897	ENSG00000258302.2	RP11-981P6.1	12.12	1.67e-29	3.06e-26	0.55	0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89528255	chr12:89561129~89594878:+
PRAD	cis	rs1061377	1	rs7675782	ENSG00000249207.1	RP11-360F5.1	-12.12	1.67e-29	3.06e-26	-0.51	-0.49	Uric acid levels;	chr4:39120048	chr4:39112677~39126818:-
PRAD	cis	rs11105298	0.891	rs4842664	ENSG00000258302.2	RP11-981P6.1	12.12	1.67e-29	3.07e-26	0.55	0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89544253	chr12:89561129~89594878:+
PRAD	cis	rs11105298	0.891	rs11105325	ENSG00000258302.2	RP11-981P6.1	12.12	1.67e-29	3.07e-26	0.55	0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89544813	chr12:89561129~89594878:+
PRAD	cis	rs9322193	0.923	rs10747276	ENSG00000268592.3	RAET1E-AS1	12.12	1.68e-29	3.08e-26	0.67	0.49	Lung cancer;	chr6:149758739	chr6:149863494~149919507:+
PRAD	cis	rs35160687	0.871	rs2278105	ENSG00000273080.1	RP11-301O19.1	12.12	1.68e-29	3.08e-26	0.58	0.49	Night sleep phenotypes;	chr2:86239393	chr2:86195590~86196049:+
PRAD	cis	rs16828019	0.777	rs13376450	ENSG00000235358.1	RP11-399E6.1	12.12	1.72e-29	3.15e-26	0.91	0.49	Intelligence (multi-trait analysis);	chr1:41003371	chr1:41242373~41284861:+
PRAD	cis	rs1150668	0.768	rs1150716	ENSG00000216901.1	AL022393.7	12.12	1.73e-29	3.17e-26	0.62	0.49	Pubertal anthropometrics;	chr6:28294921	chr6:28176188~28176674:+
PRAD	cis	rs9322193	0.923	rs56397000	ENSG00000268592.3	RAET1E-AS1	12.12	1.74e-29	3.2e-26	0.67	0.49	Lung cancer;	chr6:149739347	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.884	rs9689702	ENSG00000268592.3	RAET1E-AS1	12.12	1.74e-29	3.2e-26	0.67	0.49	Lung cancer;	chr6:149740720	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.923	rs10782315	ENSG00000268592.3	RAET1E-AS1	12.12	1.74e-29	3.2e-26	0.67	0.49	Lung cancer;	chr6:149743093	chr6:149863494~149919507:+
PRAD	cis	rs2404602	0.647	rs12440511	ENSG00000259422.1	RP11-593F23.1	-12.12	1.76e-29	3.23e-26	-0.66	-0.49	Blood metabolite levels;	chr15:76700794	chr15:76174891~76181486:-
PRAD	cis	rs4423214	0.879	rs1790330	ENSG00000254682.1	RP11-660L16.2	-12.12	1.76e-29	3.23e-26	-0.71	-0.49	Vitamin D levels;	chr11:71436779	chr11:71448674~71452157:+
PRAD	cis	rs4423214	0.879	rs1792264	ENSG00000254682.1	RP11-660L16.2	-12.12	1.76e-29	3.23e-26	-0.71	-0.49	Vitamin D levels;	chr11:71439201	chr11:71448674~71452157:+
PRAD	cis	rs2658782	0.789	rs3019206	ENSG00000279684.1	RP11-755E23.2	-12.12	1.76e-29	3.24e-26	-0.77	-0.49	Pulmonary function decline;	chr11:93377907	chr11:93286629~93288903:-
PRAD	cis	rs9487094	1	rs9480955	ENSG00000260273.1	RP11-425D10.10	12.12	1.77e-29	3.24e-26	0.69	0.49	Height;	chr6:109423330	chr6:109382795~109383666:+
PRAD	cis	rs9487094	1	rs9320287	ENSG00000260273.1	RP11-425D10.10	12.12	1.77e-29	3.24e-26	0.69	0.49	Height;	chr6:109423487	chr6:109382795~109383666:+
PRAD	cis	rs6964833	0.935	rs34630792	ENSG00000277053.3	GTF2IP1	-12.12	1.77e-29	3.24e-26	-0.58	-0.49	Menarche (age at onset);	chr7:74646869	chr7:75185385~75237696:-
PRAD	cis	rs9532669	0.926	rs2324742	ENSG00000176268.5	CYCSP34	12.12	1.78e-29	3.26e-26	0.51	0.49	Cervical cancer;	chr13:40919059	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.857	rs9594455	ENSG00000176268.5	CYCSP34	12.12	1.78e-29	3.26e-26	0.51	0.49	Cervical cancer;	chr13:40919452	chr13:40863599~40863902:-
PRAD	cis	rs12049351	0.774	rs1053513	ENSG00000229367.1	HMGN2P19	12.11	1.8e-29	3.3e-26	0.68	0.49	Circulating myeloperoxidase levels (plasma);	chr1:229516840	chr1:229570532~229570796:+
PRAD	cis	rs12049351	0.722	rs4148763	ENSG00000229367.1	HMGN2P19	12.11	1.8e-29	3.3e-26	0.68	0.49	Circulating myeloperoxidase levels (plasma);	chr1:229519213	chr1:229570532~229570796:+
PRAD	cis	rs12049351	0.665	rs10799534	ENSG00000229367.1	HMGN2P19	12.11	1.8e-29	3.3e-26	0.68	0.49	Circulating myeloperoxidase levels (plasma);	chr1:229521466	chr1:229570532~229570796:+
PRAD	cis	rs12049351	0.665	rs3738186	ENSG00000229367.1	HMGN2P19	12.11	1.8e-29	3.3e-26	0.68	0.49	Circulating myeloperoxidase levels (plasma);	chr1:229521483	chr1:229570532~229570796:+
PRAD	cis	rs2739330	0.731	rs4822450	ENSG00000235689.1	AP000351.13	12.11	1.81e-29	3.31e-26	0.59	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:24006305~24008258:-
PRAD	cis	rs1061377	1	rs36090629	ENSG00000249207.1	RP11-360F5.1	-12.11	1.81e-29	3.32e-26	-0.51	-0.49	Uric acid levels;	chr4:39137195	chr4:39112677~39126818:-
PRAD	cis	rs1061377	0.87	rs73238544	ENSG00000249207.1	RP11-360F5.1	-12.11	1.81e-29	3.32e-26	-0.51	-0.49	Uric acid levels;	chr4:39137343	chr4:39112677~39126818:-
PRAD	cis	rs9487094	0.922	rs68042406	ENSG00000260273.1	RP11-425D10.10	12.11	1.83e-29	3.36e-26	0.71	0.49	Height;	chr6:109482392	chr6:109382795~109383666:+
PRAD	cis	rs11105298	0.891	rs10858889	ENSG00000258302.2	RP11-981P6.1	12.11	1.84e-29	3.36e-26	0.55	0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89508827	chr12:89561129~89594878:+
PRAD	cis	rs11105298	0.891	rs11105309	ENSG00000258302.2	RP11-981P6.1	12.11	1.84e-29	3.36e-26	0.55	0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89516073	chr12:89561129~89594878:+
PRAD	cis	rs8072100	0.967	rs4580230	ENSG00000228782.6	CTD-2026D20.3	12.11	1.84e-29	3.37e-26	0.54	0.49	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47661495	chr17:47450568~47492492:-
PRAD	cis	rs7115242	0.8	rs6589597	ENSG00000254851.1	RP11-109L13.1	12.11	1.88e-29	3.44e-26	1	0.49	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117127082	chr11:117135528~117138582:+
PRAD	cis	rs1577917	0.771	rs10944133	ENSG00000203875.9	SNHG5	-12.11	1.88e-29	3.44e-26	-0.58	-0.49	Response to antipsychotic treatment;	chr6:85649266	chr6:85660950~85678736:-
PRAD	cis	rs12049351	0.774	rs10799533	ENSG00000229367.1	HMGN2P19	12.11	1.9e-29	3.48e-26	0.69	0.49	Circulating myeloperoxidase levels (plasma);	chr1:229520815	chr1:229570532~229570796:+
PRAD	cis	rs12049351	0.613	rs10799535	ENSG00000229367.1	HMGN2P19	12.11	1.9e-29	3.48e-26	0.69	0.49	Circulating myeloperoxidase levels (plasma);	chr1:229522047	chr1:229570532~229570796:+
PRAD	cis	rs12049351	0.774	rs3767327	ENSG00000229367.1	HMGN2P19	12.11	1.9e-29	3.48e-26	0.69	0.49	Circulating myeloperoxidase levels (plasma);	chr1:229523563	chr1:229570532~229570796:+
PRAD	cis	rs9532669	0.963	rs9532681	ENSG00000176268.5	CYCSP34	12.11	1.92e-29	3.51e-26	0.51	0.49	Cervical cancer;	chr13:40951633	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.926	rs4516083	ENSG00000176268.5	CYCSP34	12.11	1.92e-29	3.51e-26	0.51	0.49	Cervical cancer;	chr13:40951783	chr13:40863599~40863902:-
PRAD	cis	rs9322193	0.923	rs9800614	ENSG00000223701.3	RAET1E-AS1	12.11	1.93e-29	3.53e-26	0.67	0.49	Lung cancer;	chr6:149644604	chr6:149884431~149919508:+
PRAD	cis	rs2404602	0.647	rs12440965	ENSG00000259422.1	RP11-593F23.1	-12.11	1.96e-29	3.59e-26	-0.66	-0.49	Blood metabolite levels;	chr15:76666250	chr15:76174891~76181486:-
PRAD	cis	rs9322193	0.884	rs10872646	ENSG00000223701.3	RAET1E-AS1	12.1	1.97e-29	3.59e-26	0.66	0.49	Lung cancer;	chr6:149746539	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.884	rs12528279	ENSG00000223701.3	RAET1E-AS1	12.1	1.97e-29	3.59e-26	0.66	0.49	Lung cancer;	chr6:149750892	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.809	rs9479808	ENSG00000223701.3	RAET1E-AS1	12.1	1.97e-29	3.59e-26	0.66	0.49	Lung cancer;	chr6:149751328	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.923	rs10782316	ENSG00000223701.3	RAET1E-AS1	12.1	1.97e-29	3.59e-26	0.66	0.49	Lung cancer;	chr6:149752755	chr6:149884431~149919508:+
PRAD	cis	rs7208859	0.725	rs9897673	ENSG00000263531.1	RP13-753N3.1	12.1	1.97e-29	3.6e-26	0.86	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30916348	chr17:30863921~30864940:-
PRAD	cis	rs12049351	0.774	rs4925456	ENSG00000229367.1	HMGN2P19	12.1	1.97e-29	3.6e-26	0.7	0.49	Circulating myeloperoxidase levels (plasma);	chr1:229488149	chr1:229570532~229570796:+
PRAD	cis	rs9322193	0.923	rs10872644	ENSG00000268592.3	RAET1E-AS1	12.1	2.01e-29	3.66e-26	0.68	0.49	Lung cancer;	chr6:149741819	chr6:149863494~149919507:+
PRAD	cis	rs9487094	0.961	rs9487100	ENSG00000260273.1	RP11-425D10.10	12.1	2.01e-29	3.67e-26	0.71	0.49	Height;	chr6:109429207	chr6:109382795~109383666:+
PRAD	cis	rs7617773	0.851	rs13068288	ENSG00000229759.1	MRPS18AP1	12.1	2.03e-29	3.72e-26	0.58	0.49	Coronary artery disease;	chr3:48290261	chr3:48256350~48256938:-
PRAD	cis	rs17711722	0.523	rs365896	ENSG00000226824.5	RP4-756H11.3	12.1	2.04e-29	3.73e-26	0.63	0.49	Calcium levels;	chr7:66045710	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.545	rs17138149	ENSG00000237310.1	GS1-124K5.4	12.1	2.05e-29	3.74e-26	0.49	0.49	Aortic root size;	chr7:66228193	chr7:66493706~66495474:+
PRAD	cis	rs12049351	0.774	rs4148757	ENSG00000229367.1	HMGN2P19	12.1	2.07e-29	3.79e-26	0.66	0.49	Circulating myeloperoxidase levels (plasma);	chr1:229558099	chr1:229570532~229570796:+
PRAD	cis	rs9322193	0.923	rs11155677	ENSG00000223701.3	RAET1E-AS1	12.1	2.08e-29	3.8e-26	0.66	0.49	Lung cancer;	chr6:149756953	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.884	rs9480009	ENSG00000223701.3	RAET1E-AS1	12.1	2.08e-29	3.8e-26	0.66	0.49	Lung cancer;	chr6:149758502	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.923	rs9480031	ENSG00000223701.3	RAET1E-AS1	12.1	2.08e-29	3.8e-26	0.66	0.49	Lung cancer;	chr6:149758875	chr6:149884431~149919508:+
PRAD	cis	rs11690935	0.632	rs11690807	ENSG00000228389.1	AC068039.4	-12.1	2.08e-29	3.8e-26	-0.55	-0.49	Schizophrenia;	chr2:171771610	chr2:171773482~171775844:+
PRAD	cis	rs1185460	0.967	rs1784459	ENSG00000271751.1	RP11-110I1.14	-12.1	2.08e-29	3.8e-26	-0.67	-0.49	Coronary artery disease;	chr11:119067677	chr11:119065263~119065677:-
PRAD	cis	rs1185460	0.967	rs1786684	ENSG00000271751.1	RP11-110I1.14	-12.1	2.08e-29	3.8e-26	-0.67	-0.49	Coronary artery disease;	chr11:119067724	chr11:119065263~119065677:-
PRAD	cis	rs1185460	0.967	rs1786685	ENSG00000271751.1	RP11-110I1.14	-12.1	2.08e-29	3.8e-26	-0.67	-0.49	Coronary artery disease;	chr11:119068246	chr11:119065263~119065677:-
PRAD	cis	rs1185460	0.967	rs1784302	ENSG00000271751.1	RP11-110I1.14	-12.1	2.08e-29	3.8e-26	-0.67	-0.49	Coronary artery disease;	chr11:119070247	chr11:119065263~119065677:-
PRAD	cis	rs9322193	0.923	rs10872649	ENSG00000223701.3	RAET1E-AS1	12.1	2.1e-29	3.84e-26	0.66	0.49	Lung cancer;	chr6:149759454	chr6:149884431~149919508:+
PRAD	cis	rs11168854	0.656	rs7969963	ENSG00000258017.1	RP11-386G11.10	-12.1	2.11e-29	3.85e-26	-0.64	-0.49	Body mass index;	chr12:49118222	chr12:49127782~49147869:+
PRAD	cis	rs12049351	0.722	rs6703347	ENSG00000229367.1	HMGN2P19	12.1	2.12e-29	3.87e-26	0.7	0.49	Circulating myeloperoxidase levels (plasma);	chr1:229490419	chr1:229570532~229570796:+
PRAD	cis	rs2658782	0.789	rs3020076	ENSG00000279684.1	RP11-755E23.2	-12.1	2.13e-29	3.88e-26	-0.77	-0.49	Pulmonary function decline;	chr11:93407892	chr11:93286629~93288903:-
PRAD	cis	rs2658782	0.789	rs2259633	ENSG00000279684.1	RP11-755E23.2	-12.1	2.14e-29	3.9e-26	-0.78	-0.49	Pulmonary function decline;	chr11:93408414	chr11:93286629~93288903:-
PRAD	cis	rs12049351	0.774	rs12023430	ENSG00000229367.1	HMGN2P19	12.1	2.14e-29	3.9e-26	0.74	0.49	Circulating myeloperoxidase levels (plasma);	chr1:229579208	chr1:229570532~229570796:+
PRAD	cis	rs11105298	0.891	rs10858881	ENSG00000258302.2	RP11-981P6.1	12.09	2.18e-29	3.97e-26	0.55	0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89497697	chr12:89561129~89594878:+
PRAD	cis	rs1062177	0.855	rs919263	ENSG00000213433.5	RPLP1P6	-12.09	2.18e-29	3.97e-26	-0.57	-0.49	Preschool internalizing problems;	chr5:151886292	chr5:151765859~151766378:-
PRAD	cis	rs9322193	0.923	rs9766004	ENSG00000223701.3	RAET1E-AS1	12.09	2.24e-29	4.08e-26	0.66	0.49	Lung cancer;	chr6:149754363	chr6:149884431~149919508:+
PRAD	cis	rs11676348	0.846	rs4674260	ENSG00000261338.2	RP11-378A13.1	-12.09	2.25e-29	4.09e-26	-0.56	-0.49	Ulcerative colitis;	chr2:218137653	chr2:218255319~218257366:+
PRAD	cis	rs5769707	0.967	rs9616701	ENSG00000188511.11	C22orf34	12.09	2.25e-29	4.09e-26	0.52	0.49	Monocyte percentage of white cells;Monocyte count;	chr22:49631898	chr22:49414524~49657542:-
PRAD	cis	rs9487094	0.961	rs7773095	ENSG00000260273.1	RP11-425D10.10	-12.09	2.26e-29	4.11e-26	-0.7	-0.49	Height;	chr6:109405874	chr6:109382795~109383666:+
PRAD	cis	rs9322193	0.923	rs9767554	ENSG00000223701.3	RAET1E-AS1	12.09	2.27e-29	4.12e-26	0.66	0.49	Lung cancer;	chr6:149616860	chr6:149884431~149919508:+
PRAD	cis	rs875971	0.545	rs1909508	ENSG00000237310.1	GS1-124K5.4	12.09	2.28e-29	4.15e-26	0.49	0.49	Aortic root size;	chr7:66301366	chr7:66493706~66495474:+
PRAD	cis	rs2739330	0.892	rs4822455	ENSG00000272787.1	KB-226F1.2	-12.09	2.3e-29	4.18e-26	-0.54	-0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23969211~23969873:+
PRAD	cis	rs875971	0.545	rs73378304	ENSG00000237310.1	GS1-124K5.4	12.09	2.3e-29	4.18e-26	0.49	0.49	Aortic root size;	chr7:66175760	chr7:66493706~66495474:+
PRAD	cis	rs172166	0.561	rs149976	ENSG00000216901.1	AL022393.7	-12.09	2.31e-29	4.2e-26	-0.61	-0.49	Cardiac Troponin-T levels;	chr6:28019998	chr6:28176188~28176674:+
PRAD	cis	rs16828019	0.704	rs12024115	ENSG00000235358.1	RP11-399E6.1	12.09	2.33e-29	4.25e-26	0.91	0.49	Intelligence (multi-trait analysis);	chr1:41068685	chr1:41242373~41284861:+
PRAD	cis	rs3091242	0.9	rs1811832	ENSG00000224183.1	SDHDP6	-12.08	2.38e-29	4.32e-26	-0.57	-0.49	Erythrocyte sedimentation rate;	chr1:25427074	chr1:25294164~25294643:-
PRAD	cis	rs11673344	0.683	rs11668615	ENSG00000226686.6	LINC01535	12.08	2.39e-29	4.35e-26	0.73	0.49	Obesity-related traits;	chr19:37063632	chr19:37251912~37265535:+
PRAD	cis	rs673078	0.607	rs2036314	ENSG00000275759.1	RP11-131L12.3	-12.08	2.4e-29	4.36e-26	-0.69	-0.49	Glucose homeostasis traits;	chr12:118367132	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.607	rs61943369	ENSG00000275759.1	RP11-131L12.3	-12.08	2.4e-29	4.36e-26	-0.69	-0.49	Glucose homeostasis traits;	chr12:118368145	chr12:118428281~118428870:+
PRAD	cis	rs1062177	0.951	rs2915876	ENSG00000213433.5	RPLP1P6	-12.08	2.43e-29	4.41e-26	-0.58	-0.49	Preschool internalizing problems;	chr5:151771184	chr5:151765859~151766378:-
PRAD	cis	rs9487094	0.961	rs11153171	ENSG00000260273.1	RP11-425D10.10	12.08	2.43e-29	4.41e-26	0.7	0.49	Height;	chr6:109332622	chr6:109382795~109383666:+
PRAD	cis	rs9322193	0.923	rs9505982	ENSG00000223701.3	RAET1E-AS1	12.08	2.44e-29	4.42e-26	0.66	0.49	Lung cancer;	chr6:149618465	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.923	rs9322196	ENSG00000223701.3	RAET1E-AS1	12.08	2.44e-29	4.42e-26	0.66	0.49	Lung cancer;	chr6:149619645	chr6:149884431~149919508:+
PRAD	cis	rs11105306	1	rs11105306	ENSG00000258302.2	RP11-981P6.1	12.08	2.54e-29	4.61e-26	0.55	0.49	NT-proBNP levels in acute coronary syndrome;	chr12:89503611	chr12:89561129~89594878:+
PRAD	cis	rs9322193	0.923	rs9479494	ENSG00000268592.3	RAET1E-AS1	12.08	2.54e-29	4.61e-26	0.68	0.49	Lung cancer;	chr6:149739108	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.923	rs9800806	ENSG00000268592.3	RAET1E-AS1	12.08	2.54e-29	4.61e-26	0.68	0.49	Lung cancer;	chr6:149740350	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.923	rs9688517	ENSG00000268592.3	RAET1E-AS1	12.08	2.54e-29	4.61e-26	0.68	0.49	Lung cancer;	chr6:149740655	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.923	rs1572229	ENSG00000268592.3	RAET1E-AS1	12.08	2.54e-29	4.61e-26	0.68	0.49	Lung cancer;	chr6:149743841	chr6:149863494~149919507:+
PRAD	cis	rs1061377	0.965	rs3733275	ENSG00000249207.1	RP11-360F5.1	-12.08	2.56e-29	4.64e-26	-0.51	-0.49	Uric acid levels;	chr4:39121077	chr4:39112677~39126818:-
PRAD	cis	rs3096299	0.559	rs9931073	ENSG00000274627.1	RP11-104N10.2	12.07	2.59e-29	4.7e-26	0.5	0.49	Multiple myeloma (IgH translocation);	chr16:89502105	chr16:89516797~89522217:+
PRAD	cis	rs8062405	0.824	rs28698667	ENSG00000259982.1	CDC37P1	12.07	2.62e-29	4.74e-26	0.64	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28521750	chr16:28700294~28701540:-
PRAD	cis	rs8062405	0.754	rs62034323	ENSG00000259982.1	CDC37P1	12.07	2.62e-29	4.74e-26	0.64	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525152	chr16:28700294~28701540:-
PRAD	cis	rs8062405	0.824	rs62034324	ENSG00000259982.1	CDC37P1	12.07	2.62e-29	4.74e-26	0.64	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525441	chr16:28700294~28701540:-
PRAD	cis	rs8062405	0.824	rs62034326	ENSG00000259982.1	CDC37P1	12.07	2.62e-29	4.74e-26	0.64	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527972	chr16:28700294~28701540:-
PRAD	cis	rs8062405	0.824	rs4788084	ENSG00000259982.1	CDC37P1	12.07	2.62e-29	4.74e-26	0.64	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28528527	chr16:28700294~28701540:-
PRAD	cis	rs9322193	0.923	rs10872650	ENSG00000223701.3	RAET1E-AS1	12.07	2.62e-29	4.76e-26	0.66	0.49	Lung cancer;	chr6:149760959	chr6:149884431~149919508:+
PRAD	cis	rs2739330	0.587	rs4820571	ENSG00000231271.1	AP000350.8	12.07	2.64e-29	4.78e-26	0.65	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23949918~23954042:+
PRAD	cis	rs3091242	0.935	rs3093632	ENSG00000224183.1	SDHDP6	-12.07	2.64e-29	4.78e-26	-0.57	-0.49	Erythrocyte sedimentation rate;	chr1:25357521	chr1:25294164~25294643:-
PRAD	cis	rs9322193	0.884	rs10872646	ENSG00000268592.3	RAET1E-AS1	12.07	2.67e-29	4.83e-26	0.68	0.49	Lung cancer;	chr6:149746539	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.884	rs12528279	ENSG00000268592.3	RAET1E-AS1	12.07	2.67e-29	4.83e-26	0.68	0.49	Lung cancer;	chr6:149750892	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.809	rs9479808	ENSG00000268592.3	RAET1E-AS1	12.07	2.67e-29	4.83e-26	0.68	0.49	Lung cancer;	chr6:149751328	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.923	rs10782316	ENSG00000268592.3	RAET1E-AS1	12.07	2.67e-29	4.83e-26	0.68	0.49	Lung cancer;	chr6:149752755	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.887	rs9767113	ENSG00000223701.3	RAET1E-AS1	12.07	2.68e-29	4.85e-26	0.66	0.49	Lung cancer;	chr6:149718157	chr6:149884431~149919508:+
PRAD	cis	rs1062177	1	rs17804178	ENSG00000213433.5	RPLP1P6	-12.07	2.69e-29	4.88e-26	-0.58	-0.49	Preschool internalizing problems;	chr5:151818168	chr5:151765859~151766378:-
PRAD	cis	rs9322193	0.923	rs10782318	ENSG00000223701.3	RAET1E-AS1	12.07	2.71e-29	4.91e-26	0.66	0.49	Lung cancer;	chr6:149754137	chr6:149884431~149919508:+
PRAD	cis	rs67383717	0.672	rs589458	ENSG00000175611.10	LINC00476	12.07	2.75e-29	4.96e-26	0.58	0.49	Parkinson's disease (pesticide exposure interaction);	chr9:95878389	chr9:95759231~95875977:-
PRAD	cis	rs35160687	1	rs35160687	ENSG00000273080.1	RP11-301O19.1	12.07	2.75e-29	4.97e-26	0.58	0.49	Night sleep phenotypes;	chr2:86244991	chr2:86195590~86196049:+
PRAD	cis	rs875971	0.545	rs11767262	ENSG00000237310.1	GS1-124K5.4	12.07	2.75e-29	4.98e-26	0.49	0.49	Aortic root size;	chr7:66302237	chr7:66493706~66495474:+
PRAD	cis	rs11676348	0.818	rs1126579	ENSG00000261338.2	RP11-378A13.1	-12.07	2.77e-29	5e-26	-0.56	-0.49	Ulcerative colitis;	chr2:218136011	chr2:218255319~218257366:+
PRAD	cis	rs977987	0.806	rs35683383	ENSG00000261783.1	RP11-252K23.2	-12.06	2.84e-29	5.13e-26	-0.67	-0.49	Dupuytren's disease;	chr16:75445379	chr16:75379818~75381260:-
PRAD	cis	rs9326248	1	rs7107152	ENSG00000280143.1	AP000892.6	-12.06	2.85e-29	5.15e-26	-0.42	-0.49	Blood protein levels;	chr11:117185364	chr11:117204967~117210292:+
PRAD	cis	rs6964833	1	rs13227433	ENSG00000277053.3	GTF2IP1	-12.06	2.89e-29	5.22e-26	-0.58	-0.49	Menarche (age at onset);	chr7:74680386	chr7:75185385~75237696:-
PRAD	cis	rs9532669	0.963	rs1056835	ENSG00000176268.5	CYCSP34	12.06	2.91e-29	5.25e-26	0.51	0.49	Cervical cancer;	chr13:40932585	chr13:40863599~40863902:-
PRAD	cis	rs11105298	0.891	rs11105319	ENSG00000258302.2	RP11-981P6.1	12.06	2.93e-29	5.29e-26	0.56	0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89533400	chr12:89561129~89594878:+
PRAD	cis	rs6991838	0.584	rs34494846	ENSG00000272010.1	CTD-3025N20.3	-12.06	2.93e-29	5.29e-26	-0.52	-0.49	Intelligence (multi-trait analysis);	chr8:65602397	chr8:65591850~65592472:-
PRAD	cis	rs6991838	0.584	rs1053087	ENSG00000272010.1	CTD-3025N20.3	-12.06	2.93e-29	5.29e-26	-0.52	-0.49	Intelligence (multi-trait analysis);	chr8:65603630	chr8:65591850~65592472:-
PRAD	cis	rs6991838	0.584	rs1053085	ENSG00000272010.1	CTD-3025N20.3	-12.06	2.93e-29	5.29e-26	-0.52	-0.49	Intelligence (multi-trait analysis);	chr8:65603753	chr8:65591850~65592472:-
PRAD	cis	rs9322193	0.923	rs11155677	ENSG00000268592.3	RAET1E-AS1	12.06	2.94e-29	5.3e-26	0.68	0.49	Lung cancer;	chr6:149756953	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.884	rs9480009	ENSG00000268592.3	RAET1E-AS1	12.06	2.94e-29	5.3e-26	0.68	0.49	Lung cancer;	chr6:149758502	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.923	rs9480031	ENSG00000268592.3	RAET1E-AS1	12.06	2.94e-29	5.3e-26	0.68	0.49	Lung cancer;	chr6:149758875	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.923	rs10872644	ENSG00000223701.3	RAET1E-AS1	12.06	2.97e-29	5.35e-26	0.66	0.49	Lung cancer;	chr6:149741819	chr6:149884431~149919508:+
PRAD	cis	rs2739330	0.76	rs1007888	ENSG00000235689.1	AP000351.13	12.06	2.98e-29	5.38e-26	0.59	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:24006305~24008258:-
PRAD	cis	rs2117029	0.555	rs9788140	ENSG00000258017.1	RP11-386G11.10	-12.06	3.02e-29	5.44e-26	-0.64	-0.49	Intelligence (multi-trait analysis);	chr12:49126738	chr12:49127782~49147869:+
PRAD	cis	rs9322193	0.923	rs62441284	ENSG00000268592.3	RAET1E-AS1	12.06	3.05e-29	5.49e-26	0.68	0.49	Lung cancer;	chr6:149751542	chr6:149863494~149919507:+
PRAD	cis	rs6991838	0.557	rs7012578	ENSG00000272010.1	CTD-3025N20.3	-12.06	3.06e-29	5.52e-26	-0.51	-0.49	Intelligence (multi-trait analysis);	chr8:65592592	chr8:65591850~65592472:-
PRAD	cis	rs6991838	0.584	rs7812446	ENSG00000272010.1	CTD-3025N20.3	-12.06	3.06e-29	5.52e-26	-0.51	-0.49	Intelligence (multi-trait analysis);	chr8:65593753	chr8:65591850~65592472:-
PRAD	cis	rs6991838	0.557	rs7812390	ENSG00000272010.1	CTD-3025N20.3	-12.06	3.06e-29	5.52e-26	-0.51	-0.49	Intelligence (multi-trait analysis);	chr8:65593982	chr8:65591850~65592472:-
PRAD	cis	rs6991838	0.584	rs16932245	ENSG00000272010.1	CTD-3025N20.3	-12.06	3.06e-29	5.52e-26	-0.51	-0.49	Intelligence (multi-trait analysis);	chr8:65597810	chr8:65591850~65592472:-
PRAD	cis	rs6991838	0.557	rs57419568	ENSG00000272010.1	CTD-3025N20.3	-12.06	3.06e-29	5.52e-26	-0.51	-0.49	Intelligence (multi-trait analysis);	chr8:65598633	chr8:65591850~65592472:-
PRAD	cis	rs6991838	0.584	rs16932250	ENSG00000272010.1	CTD-3025N20.3	-12.06	3.06e-29	5.52e-26	-0.51	-0.49	Intelligence (multi-trait analysis);	chr8:65598779	chr8:65591850~65592472:-
PRAD	cis	rs71403859	0.667	rs12920890	ENSG00000260886.1	TAT-AS1	12.06	3.09e-29	5.57e-26	0.86	0.49	Post bronchodilator FEV1;	chr16:71753685	chr16:71565789~71578187:+
PRAD	cis	rs17711722	0.523	rs313812	ENSG00000226824.5	RP4-756H11.3	12.06	3.1e-29	5.58e-26	0.63	0.49	Calcium levels;	chr7:66040056	chr7:66654538~66669855:+
PRAD	cis	rs1061377	1	rs9996285	ENSG00000249207.1	RP11-360F5.1	-12.05	3.12e-29	5.62e-26	-0.51	-0.49	Uric acid levels;	chr4:39130556	chr4:39112677~39126818:-
PRAD	cis	rs7208859	0.573	rs73267873	ENSG00000263531.1	RP13-753N3.1	12.05	3.22e-29	5.79e-26	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741439	chr17:30863921~30864940:-
PRAD	cis	rs17826219	0.561	rs4085382	ENSG00000263531.1	RP13-753N3.1	12.05	3.22e-29	5.79e-26	0.88	0.49	Body mass index;	chr17:30744184	chr17:30863921~30864940:-
PRAD	cis	rs977987	0.8	rs11149815	ENSG00000261783.1	RP11-252K23.2	-12.05	3.24e-29	5.82e-26	-0.67	-0.49	Dupuytren's disease;	chr16:75302275	chr16:75379818~75381260:-
PRAD	cis	rs524281	0.861	rs7941469	ENSG00000255320.1	RP11-755F10.1	-12.05	3.28e-29	5.89e-26	-0.73	-0.49	Electroencephalogram traits;	chr11:66132681	chr11:66244840~66246239:-
PRAD	cis	rs9322193	0.772	rs7738696	ENSG00000216906.2	RP11-350J20.9	12.05	3.3e-29	5.93e-26	0.56	0.49	Lung cancer;	chr6:149848985	chr6:149904243~149906418:+
PRAD	cis	rs9532669	0.857	rs7327018	ENSG00000176268.5	CYCSP34	12.05	3.3e-29	5.94e-26	0.53	0.49	Cervical cancer;	chr13:40856376	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.926	rs7327315	ENSG00000176268.5	CYCSP34	12.05	3.3e-29	5.94e-26	0.53	0.49	Cervical cancer;	chr13:40856383	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.926	rs7327059	ENSG00000176268.5	CYCSP34	12.05	3.3e-29	5.94e-26	0.53	0.49	Cervical cancer;	chr13:40856458	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.926	rs9594433	ENSG00000176268.5	CYCSP34	12.05	3.3e-29	5.94e-26	0.53	0.49	Cervical cancer;	chr13:40856935	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.926	rs9525403	ENSG00000176268.5	CYCSP34	12.05	3.3e-29	5.94e-26	0.53	0.49	Cervical cancer;	chr13:40858292	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.926	rs7318768	ENSG00000176268.5	CYCSP34	12.05	3.3e-29	5.94e-26	0.53	0.49	Cervical cancer;	chr13:40859140	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.926	rs4942000	ENSG00000176268.5	CYCSP34	12.05	3.3e-29	5.94e-26	0.53	0.49	Cervical cancer;	chr13:40859979	chr13:40863599~40863902:-
PRAD	cis	rs12049351	0.665	rs12035203	ENSG00000229367.1	HMGN2P19	12.05	3.31e-29	5.95e-26	0.71	0.49	Circulating myeloperoxidase levels (plasma);	chr1:229506770	chr1:229570532~229570796:+
PRAD	cis	rs875971	0.545	rs7783889	ENSG00000237310.1	GS1-124K5.4	12.05	3.36e-29	6.03e-26	0.49	0.49	Aortic root size;	chr7:66283366	chr7:66493706~66495474:+
PRAD	cis	rs2404602	0.684	rs57682236	ENSG00000259422.1	RP11-593F23.1	-12.05	3.38e-29	6.07e-26	-0.66	-0.49	Blood metabolite levels;	chr15:76576137	chr15:76174891~76181486:-
PRAD	cis	rs875971	0.545	rs2420456	ENSG00000237310.1	GS1-124K5.4	12.05	3.39e-29	6.08e-26	0.49	0.49	Aortic root size;	chr7:66280619	chr7:66493706~66495474:+
PRAD	cis	rs71403859	0.614	rs12149533	ENSG00000260886.1	TAT-AS1	12.04	3.43e-29	6.16e-26	0.9	0.49	Post bronchodilator FEV1;	chr16:71768043	chr16:71565789~71578187:+
PRAD	cis	rs1061377	1	rs4974931	ENSG00000249207.1	RP11-360F5.1	-12.04	3.46e-29	6.2e-26	-0.52	-0.49	Uric acid levels;	chr4:39108896	chr4:39112677~39126818:-
PRAD	cis	rs11676348	0.818	rs6436033	ENSG00000261338.2	RP11-378A13.1	-12.04	3.52e-29	6.32e-26	-0.56	-0.49	Ulcerative colitis;	chr2:218119040	chr2:218255319~218257366:+
PRAD	cis	rs11105298	0.891	rs11105313	ENSG00000258302.2	RP11-981P6.1	-12.04	3.56e-29	6.37e-26	-0.54	-0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89529599	chr12:89561129~89594878:+
PRAD	cis	rs875971	0.545	rs1796226	ENSG00000237310.1	GS1-124K5.4	12.04	3.56e-29	6.39e-26	0.49	0.49	Aortic root size;	chr7:66622723	chr7:66493706~66495474:+
PRAD	cis	rs4423214	0.879	rs736894	ENSG00000254682.1	RP11-660L16.2	12.04	3.57e-29	6.39e-26	0.7	0.49	Vitamin D levels;	chr11:71441212	chr11:71448674~71452157:+
PRAD	cis	rs12049351	0.667	rs34382491	ENSG00000229367.1	HMGN2P19	12.04	3.57e-29	6.39e-26	0.71	0.49	Circulating myeloperoxidase levels (plasma);	chr1:229484883	chr1:229570532~229570796:+
PRAD	cis	rs3096299	0.658	rs4291902	ENSG00000274627.1	RP11-104N10.2	12.04	3.58e-29	6.41e-26	0.49	0.49	Multiple myeloma (IgH translocation);	chr16:89493907	chr16:89516797~89522217:+
PRAD	cis	rs12049351	0.774	rs16849844	ENSG00000229367.1	HMGN2P19	-12.04	3.59e-29	6.43e-26	-0.7	-0.49	Circulating myeloperoxidase levels (plasma);	chr1:229484649	chr1:229570532~229570796:+
PRAD	cis	rs2933343	0.951	rs1055128	ENSG00000231305.3	RP11-723O4.2	12.04	3.59e-29	6.43e-26	0.49	0.49	IgG glycosylation;	chr3:128872205	chr3:128861313~128871540:-
PRAD	cis	rs875971	0.545	rs17138156	ENSG00000237310.1	GS1-124K5.4	12.04	3.61e-29	6.47e-26	0.49	0.49	Aortic root size;	chr7:66249708	chr7:66493706~66495474:+
PRAD	cis	rs5769707	1	rs5769707	ENSG00000188511.11	C22orf34	12.04	3.64e-29	6.52e-26	0.52	0.49	Monocyte percentage of white cells;Monocyte count;	chr22:49619754	chr22:49414524~49657542:-
PRAD	cis	rs11676348	0.818	rs7425447	ENSG00000261338.2	RP11-378A13.1	-12.04	3.65e-29	6.53e-26	-0.56	-0.49	Ulcerative colitis;	chr2:218115460	chr2:218255319~218257366:+
PRAD	cis	rs9487094	0.848	rs1322816	ENSG00000260273.1	RP11-425D10.10	12.04	3.68e-29	6.58e-26	0.7	0.49	Height;	chr6:109382524	chr6:109382795~109383666:+
PRAD	cis	rs35160687	0.901	rs13017338	ENSG00000273080.1	RP11-301O19.1	12.04	3.69e-29	6.6e-26	0.58	0.49	Night sleep phenotypes;	chr2:86274430	chr2:86195590~86196049:+
PRAD	cis	rs9322193	0.923	rs57938011	ENSG00000223701.3	RAET1E-AS1	12.04	3.72e-29	6.65e-26	0.66	0.49	Lung cancer;	chr6:149642969	chr6:149884431~149919508:+
PRAD	cis	rs977987	0.836	rs7199062	ENSG00000261783.1	RP11-252K23.2	-12.03	3.76e-29	6.72e-26	-0.66	-0.49	Dupuytren's disease;	chr16:75440929	chr16:75379818~75381260:-
PRAD	cis	rs2404602	0.647	rs11072610	ENSG00000259422.1	RP11-593F23.1	-12.03	3.76e-29	6.73e-26	-0.65	-0.49	Blood metabolite levels;	chr15:76638464	chr15:76174891~76181486:-
PRAD	cis	rs7617773	0.925	rs6442105	ENSG00000229759.1	MRPS18AP1	-12.03	3.84e-29	6.86e-26	-0.51	-0.49	Coronary artery disease;	chr3:48140836	chr3:48256350~48256938:-
PRAD	cis	rs6964833	1	rs4717906	ENSG00000277053.3	GTF2IP1	-12.03	3.86e-29	6.89e-26	-0.58	-0.49	Menarche (age at onset);	chr7:74671923	chr7:75185385~75237696:-
PRAD	cis	rs3096299	0.719	rs2911262	ENSG00000274627.1	RP11-104N10.2	12.03	3.87e-29	6.91e-26	0.5	0.49	Multiple myeloma (IgH translocation);	chr16:89448633	chr16:89516797~89522217:+
PRAD	cis	rs524281	0.773	rs7127808	ENSG00000255320.1	RP11-755F10.1	12.03	3.88e-29	6.93e-26	0.79	0.49	Electroencephalogram traits;	chr11:66164448	chr11:66244840~66246239:-
PRAD	cis	rs9532669	0.89	rs2324738	ENSG00000176268.5	CYCSP34	12.03	3.88e-29	6.93e-26	0.5	0.49	Cervical cancer;	chr13:40925242	chr13:40863599~40863902:-
PRAD	cis	rs977987	0.843	rs67409275	ENSG00000261783.1	RP11-252K23.2	-12.03	3.9e-29	6.96e-26	-0.66	-0.49	Dupuytren's disease;	chr16:75423314	chr16:75379818~75381260:-
PRAD	cis	rs11123170	0.65	rs2289897	ENSG00000189223.12	PAX8-AS1	-12.03	3.92e-29	7e-26	-0.74	-0.49	Renal function-related traits (BUN);	chr2:113219877	chr2:113211522~113276581:+
PRAD	cis	rs4423214	0.569	rs4944044	ENSG00000254682.1	RP11-660L16.2	12.03	3.93e-29	7.03e-26	0.59	0.49	Vitamin D levels;	chr11:71409167	chr11:71448674~71452157:+
PRAD	cis	rs7044106	0.708	rs2416760	ENSG00000226752.6	PSMD5-AS1	-12.03	3.97e-29	7.1e-26	-0.6	-0.49	Hip circumference adjusted for BMI;	chr9:120612361	chr9:120824828~120854385:+
PRAD	cis	rs2117029	0.555	rs9788139	ENSG00000258017.1	RP11-386G11.10	-12.03	4.09e-29	7.31e-26	-0.64	-0.49	Intelligence (multi-trait analysis);	chr12:49126886	chr12:49127782~49147869:+
PRAD	cis	rs1061377	1	rs1036036	ENSG00000249207.1	RP11-360F5.1	-12.03	4.1e-29	7.31e-26	-0.51	-0.49	Uric acid levels;	chr4:39111104	chr4:39112677~39126818:-
PRAD	cis	rs11676348	0.846	rs13009946	ENSG00000261338.2	RP11-378A13.1	-12.02	4.13e-29	7.37e-26	-0.56	-0.49	Ulcerative colitis;	chr2:218143029	chr2:218255319~218257366:+
PRAD	cis	rs977987	0.843	rs4888427	ENSG00000261783.1	RP11-252K23.2	-12.02	4.14e-29	7.38e-26	-0.67	-0.49	Dupuytren's disease;	chr16:75444549	chr16:75379818~75381260:-
PRAD	cis	rs35160687	0.901	rs12622200	ENSG00000273080.1	RP11-301O19.1	-12.02	4.18e-29	7.46e-26	-0.58	-0.49	Night sleep phenotypes;	chr2:86271472	chr2:86195590~86196049:+
PRAD	cis	rs35160687	0.901	rs10520415	ENSG00000273080.1	RP11-301O19.1	-12.02	4.18e-29	7.46e-26	-0.58	-0.49	Night sleep phenotypes;	chr2:86271615	chr2:86195590~86196049:+
PRAD	cis	rs9532669	0.926	rs6560963	ENSG00000176268.5	CYCSP34	12.02	4.2e-29	7.49e-26	0.51	0.49	Cervical cancer;	chr13:40871126	chr13:40863599~40863902:-
PRAD	cis	rs9322193	0.923	rs62441284	ENSG00000223701.3	RAET1E-AS1	12.02	4.2e-29	7.49e-26	0.66	0.49	Lung cancer;	chr6:149751542	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.607	rs12527391	ENSG00000231760.4	RP11-350J20.5	12.02	4.21e-29	7.5e-26	0.77	0.49	Lung cancer;	chr6:149882156	chr6:149796151~149826294:-
PRAD	cis	rs4423214	0.879	rs1792284	ENSG00000254682.1	RP11-660L16.2	12.02	4.21e-29	7.51e-26	0.7	0.49	Vitamin D levels;	chr11:71423920	chr11:71448674~71452157:+
PRAD	cis	rs9532669	0.926	rs12428966	ENSG00000176268.5	CYCSP34	12.02	4.24e-29	7.56e-26	0.51	0.49	Cervical cancer;	chr13:40876552	chr13:40863599~40863902:-
PRAD	cis	rs2919917	0.915	rs10957897	ENSG00000254352.1	RP11-578O24.2	12.02	4.27e-29	7.61e-26	0.62	0.49	Lymphocyte counts;	chr8:78695658	chr8:78723796~78724136:-
PRAD	cis	rs55794721	0.509	rs2375313	ENSG00000224183.1	SDHDP6	-12.02	4.36e-29	7.77e-26	-0.58	-0.49	Mean corpuscular volume;Plateletcrit;	chr1:25421744	chr1:25294164~25294643:-
PRAD	cis	rs71403859	0.502	rs12919417	ENSG00000260886.1	TAT-AS1	-12.02	4.39e-29	7.81e-26	-0.8	-0.49	Post bronchodilator FEV1;	chr16:71545808	chr16:71565789~71578187:+
PRAD	cis	rs9532669	0.75	rs9532598	ENSG00000176268.5	CYCSP34	12.02	4.4e-29	7.83e-26	0.53	0.49	Cervical cancer;	chr13:40860627	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.611	rs9532599	ENSG00000176268.5	CYCSP34	12.02	4.4e-29	7.83e-26	0.53	0.49	Cervical cancer;	chr13:40860633	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.571	rs9525405	ENSG00000176268.5	CYCSP34	12.02	4.4e-29	7.83e-26	0.53	0.49	Cervical cancer;	chr13:40860638	chr13:40863599~40863902:-
PRAD	cis	rs9322193	0.923	rs9404048	ENSG00000223701.3	RAET1E-AS1	12.02	4.41e-29	7.85e-26	0.66	0.49	Lung cancer;	chr6:149616188	chr6:149884431~149919508:+
PRAD	cis	rs9532669	0.926	rs2875421	ENSG00000176268.5	CYCSP34	12.02	4.47e-29	7.95e-26	0.51	0.49	Cervical cancer;	chr13:40936536	chr13:40863599~40863902:-
PRAD	cis	rs11168854	0.651	rs12227770	ENSG00000258017.1	RP11-386G11.10	-12.02	4.48e-29	7.97e-26	-0.63	-0.49	Body mass index;	chr12:49183065	chr12:49127782~49147869:+
PRAD	cis	rs4423214	0.879	rs1790345	ENSG00000254682.1	RP11-660L16.2	-12.02	4.48e-29	7.98e-26	-0.7	-0.49	Vitamin D levels;	chr11:71434895	chr11:71448674~71452157:+
PRAD	cis	rs524281	0.861	rs580891	ENSG00000255320.1	RP11-755F10.1	12.01	4.54e-29	8.07e-26	0.74	0.49	Electroencephalogram traits;	chr11:66187210	chr11:66244840~66246239:-
PRAD	cis	rs4423214	0.879	rs1790324	ENSG00000254682.1	RP11-660L16.2	-12.01	4.55e-29	8.1e-26	-0.69	-0.49	Vitamin D levels;	chr11:71439474	chr11:71448674~71452157:+
PRAD	cis	rs673078	0.607	rs17440956	ENSG00000275759.1	RP11-131L12.3	12.01	4.58e-29	8.14e-26	0.75	0.49	Glucose homeostasis traits;	chr12:118394639	chr12:118428281~118428870:+
PRAD	cis	rs875971	0.545	rs6460276	ENSG00000237310.1	GS1-124K5.4	12.01	4.59e-29	8.16e-26	0.49	0.49	Aortic root size;	chr7:66182290	chr7:66493706~66495474:+
PRAD	cis	rs1062177	1	rs12515762	ENSG00000213433.5	RPLP1P6	-12.01	4.69e-29	8.34e-26	-0.58	-0.49	Preschool internalizing problems;	chr5:151830361	chr5:151765859~151766378:-
PRAD	cis	rs9487094	0.961	rs9480957	ENSG00000260273.1	RP11-425D10.10	12.01	4.72e-29	8.38e-26	0.72	0.49	Height;	chr6:109430398	chr6:109382795~109383666:+
PRAD	cis	rs2739330	0.731	rs2000468	ENSG00000235689.1	AP000351.13	12.01	4.75e-29	8.44e-26	0.6	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:24006305~24008258:-
PRAD	cis	rs12049351	0.832	rs28798529	ENSG00000229367.1	HMGN2P19	12.01	4.77e-29	8.48e-26	0.65	0.49	Circulating myeloperoxidase levels (plasma);	chr1:229535867	chr1:229570532~229570796:+
PRAD	cis	rs12049351	0.774	rs4148760	ENSG00000229367.1	HMGN2P19	12.01	4.77e-29	8.48e-26	0.65	0.49	Circulating myeloperoxidase levels (plasma);	chr1:229538187	chr1:229570532~229570796:+
PRAD	cis	rs12049351	0.774	rs3738187	ENSG00000229367.1	HMGN2P19	12.01	4.77e-29	8.48e-26	0.65	0.49	Circulating myeloperoxidase levels (plasma);	chr1:229547517	chr1:229570532~229570796:+
PRAD	cis	rs5769707	0.967	rs17182154	ENSG00000188511.11	C22orf34	12.01	4.78e-29	8.49e-26	0.51	0.49	Monocyte percentage of white cells;Monocyte count;	chr22:49596822	chr22:49414524~49657542:-
PRAD	cis	rs977987	0.778	rs2865528	ENSG00000261783.1	RP11-252K23.2	-12.01	4.81e-29	8.54e-26	-0.66	-0.49	Dupuytren's disease;	chr16:75422044	chr16:75379818~75381260:-
PRAD	cis	rs4722166	0.63	rs2091115	ENSG00000179428.2	AC073072.5	-12.01	4.84e-29	8.6e-26	-0.59	-0.49	Lung cancer;	chr7:22770547	chr7:22725395~22727620:-
PRAD	cis	rs9487094	0.885	rs12524273	ENSG00000260273.1	RP11-425D10.10	12.01	4.85e-29	8.61e-26	0.7	0.49	Height;	chr6:109395761	chr6:109382795~109383666:+
PRAD	cis	rs9322193	0.923	rs9800871	ENSG00000223701.3	RAET1E-AS1	12.01	4.85e-29	8.62e-26	0.66	0.49	Lung cancer;	chr6:149644540	chr6:149884431~149919508:+
PRAD	cis	rs11105298	0.891	rs10858909	ENSG00000258302.2	RP11-981P6.1	12.01	4.86e-29	8.63e-26	0.55	0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89541610	chr12:89561129~89594878:+
PRAD	cis	rs9532669	0.926	rs9532654	ENSG00000176268.5	CYCSP34	12.01	4.91e-29	8.71e-26	0.51	0.49	Cervical cancer;	chr13:40909812	chr13:40863599~40863902:-
PRAD	cis	rs6142102	0.517	rs6142046	ENSG00000276073.1	RP5-1125A11.7	-12	4.94e-29	8.78e-26	-0.47	-0.49	Skin pigmentation;	chr20:33926255	chr20:33985617~33988989:-
PRAD	cis	rs9322193	0.923	rs11155671	ENSG00000223701.3	RAET1E-AS1	12	4.97e-29	8.82e-26	0.66	0.49	Lung cancer;	chr6:149650996	chr6:149884431~149919508:+
PRAD	cis	rs875971	0.545	rs6460281	ENSG00000237310.1	GS1-124K5.4	12	4.98e-29	8.84e-26	0.5	0.49	Aortic root size;	chr7:66216128	chr7:66493706~66495474:+
PRAD	cis	rs4845570	1	rs7542898	ENSG00000249602.1	RP11-98D18.3	12	5.07e-29	8.99e-26	0.76	0.49	Coronary artery disease;	chr1:151781146	chr1:151763384~151769501:-
PRAD	cis	rs6964833	1	rs3846966	ENSG00000277053.3	GTF2IP1	-12	5.11e-29	9.07e-26	-0.59	-0.49	Menarche (age at onset);	chr7:74698811	chr7:75185385~75237696:-
PRAD	cis	rs8072100	0.967	rs2317826	ENSG00000228782.6	CTD-2026D20.3	12	5.12e-29	9.08e-26	0.53	0.49	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47653533	chr17:47450568~47492492:-
PRAD	cis	rs8062405	0.679	rs72793818	ENSG00000259982.1	CDC37P1	12	5.12e-29	9.09e-26	0.65	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28881816	chr16:28700294~28701540:-
PRAD	cis	rs2739330	0.76	rs5751761	ENSG00000231271.1	AP000350.8	-12	5.13e-29	9.09e-26	-0.64	-0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23949918~23954042:+
PRAD	cis	rs875971	0.545	rs10950027	ENSG00000237310.1	GS1-124K5.4	12	5.13e-29	9.11e-26	0.49	0.49	Aortic root size;	chr7:66169164	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.545	rs10950029	ENSG00000237310.1	GS1-124K5.4	12	5.13e-29	9.11e-26	0.49	0.49	Aortic root size;	chr7:66169334	chr7:66493706~66495474:+
PRAD	cis	rs9322193	0.923	rs9968911	ENSG00000223701.3	RAET1E-AS1	12	5.14e-29	9.12e-26	0.67	0.49	Lung cancer;	chr6:149657419	chr6:149884431~149919508:+
PRAD	cis	rs8072100	0.935	rs12150231	ENSG00000228782.6	CTD-2026D20.3	-12	5.16e-29	9.15e-26	-0.53	-0.49	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47639725	chr17:47450568~47492492:-
PRAD	cis	rs6964833	0.935	rs35735900	ENSG00000277053.3	GTF2IP1	-12	5.29e-29	9.39e-26	-0.58	-0.49	Menarche (age at onset);	chr7:74651887	chr7:75185385~75237696:-
PRAD	cis	rs6964833	0.872	rs4717903	ENSG00000277053.3	GTF2IP1	-12	5.29e-29	9.39e-26	-0.58	-0.49	Menarche (age at onset);	chr7:74653827	chr7:75185385~75237696:-
PRAD	cis	rs3091242	0.933	rs11802413	ENSG00000261349.1	RP3-465N24.5	12	5.35e-29	9.49e-26	0.54	0.49	Erythrocyte sedimentation rate;	chr1:25434429	chr1:25266102~25267136:-
PRAD	cis	rs2455601	0.882	rs11042115	ENSG00000254860.4	TMEM9B-AS1	12	5.36e-29	9.5e-26	0.62	0.49	Schizophrenia;	chr11:8905132	chr11:8964675~8977527:+
PRAD	cis	rs2455601	0.882	rs11042116	ENSG00000254860.4	TMEM9B-AS1	12	5.36e-29	9.5e-26	0.62	0.49	Schizophrenia;	chr11:8906925	chr11:8964675~8977527:+
PRAD	cis	rs11105298	0.891	rs4842661	ENSG00000258302.2	RP11-981P6.1	12	5.37e-29	9.52e-26	0.56	0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89536622	chr12:89561129~89594878:+
PRAD	cis	rs977987	0.872	rs7206665	ENSG00000261783.1	RP11-252K23.2	-12	5.37e-29	9.52e-26	-0.66	-0.49	Dupuytren's disease;	chr16:75441389	chr16:75379818~75381260:-
PRAD	cis	rs2658782	0.639	rs2100552	ENSG00000279684.1	RP11-755E23.2	-11.99	5.44e-29	9.62e-26	-0.7	-0.49	Pulmonary function decline;	chr11:93449083	chr11:93286629~93288903:-
PRAD	cis	rs9487094	0.961	rs11153180	ENSG00000260273.1	RP11-425D10.10	11.99	5.46e-29	9.66e-26	0.7	0.49	Height;	chr6:109423238	chr6:109382795~109383666:+
PRAD	cis	rs6991838	0.584	rs35790435	ENSG00000272010.1	CTD-3025N20.3	-11.99	5.52e-29	9.77e-26	-0.51	-0.49	Intelligence (multi-trait analysis);	chr8:65590288	chr8:65591850~65592472:-
PRAD	cis	rs1075265	0.589	rs2542571	ENSG00000233266.1	HMGB1P31	11.99	5.52e-29	9.77e-26	0.67	0.49	Chronotype;Morning vs. evening chronotype;	chr2:53814846	chr2:54051334~54051760:+
PRAD	cis	rs11676348	0.755	rs62183956	ENSG00000261338.2	RP11-378A13.1	11.99	5.58e-29	9.87e-26	0.57	0.49	Ulcerative colitis;	chr2:218181399	chr2:218255319~218257366:+
PRAD	cis	rs9322193	0.923	rs9688861	ENSG00000223701.3	RAET1E-AS1	11.99	5.6e-29	9.9e-26	0.66	0.49	Lung cancer;	chr6:149637924	chr6:149884431~149919508:+
PRAD	cis	rs35160687	0.901	rs7571424	ENSG00000273080.1	RP11-301O19.1	11.99	5.6e-29	9.9e-26	0.58	0.49	Night sleep phenotypes;	chr2:86312037	chr2:86195590~86196049:+
PRAD	cis	rs71403859	0.667	rs35538253	ENSG00000260886.1	TAT-AS1	11.99	5.61e-29	9.92e-26	0.85	0.49	Post bronchodilator FEV1;	chr16:71644072	chr16:71565789~71578187:+
PRAD	cis	rs9487094	0.922	rs11153181	ENSG00000260273.1	RP11-425D10.10	11.99	5.67e-29	1e-25	0.7	0.49	Height;	chr6:109428824	chr6:109382795~109383666:+
PRAD	cis	rs9532669	0.963	rs2324739	ENSG00000176268.5	CYCSP34	11.99	5.69e-29	1e-25	0.5	0.49	Cervical cancer;	chr13:40925479	chr13:40863599~40863902:-
PRAD	cis	rs11603023	0.874	rs483598	ENSG00000255239.1	AP002954.6	11.99	5.73e-29	1.01e-25	0.61	0.49	Cholesterol, total;	chr11:118638950	chr11:118688039~118690600:-
PRAD	cis	rs2455601	0.882	rs11042118	ENSG00000254860.4	TMEM9B-AS1	11.99	5.75e-29	1.02e-25	0.64	0.49	Schizophrenia;	chr11:8907244	chr11:8964675~8977527:+
PRAD	cis	rs9487094	0.961	rs12528822	ENSG00000260273.1	RP11-425D10.10	11.99	5.75e-29	1.02e-25	0.68	0.49	Height;	chr6:109340338	chr6:109382795~109383666:+
PRAD	cis	rs2739330	0.892	rs5751776	ENSG00000272787.1	KB-226F1.2	-11.99	5.77e-29	1.02e-25	-0.53	-0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23969211~23969873:+
PRAD	cis	rs6964833	0.786	rs35633336	ENSG00000277053.3	GTF2IP1	-11.99	5.78e-29	1.02e-25	-0.58	-0.49	Menarche (age at onset);	chr7:74643961	chr7:75185385~75237696:-
PRAD	cis	rs9322193	0.923	rs9377230	ENSG00000223701.3	RAET1E-AS1	11.99	5.78e-29	1.02e-25	0.66	0.49	Lung cancer;	chr6:149613607	chr6:149884431~149919508:+
PRAD	cis	rs2404602	0.647	rs11629727	ENSG00000259422.1	RP11-593F23.1	-11.99	5.83e-29	1.03e-25	-0.66	-0.49	Blood metabolite levels;	chr15:76716697	chr15:76174891~76181486:-
PRAD	cis	rs11168854	0.656	rs7969967	ENSG00000258017.1	RP11-386G11.10	11.99	5.86e-29	1.03e-25	0.64	0.49	Body mass index;	chr12:49118234	chr12:49127782~49147869:+
PRAD	cis	rs9532669	0.963	rs4600338	ENSG00000176268.5	CYCSP34	11.99	5.89e-29	1.04e-25	0.5	0.49	Cervical cancer;	chr13:40925175	chr13:40863599~40863902:-
PRAD	cis	rs2404602	0.647	rs12914196	ENSG00000259422.1	RP11-593F23.1	-11.99	5.9e-29	1.04e-25	-0.66	-0.49	Blood metabolite levels;	chr15:76649020	chr15:76174891~76181486:-
PRAD	cis	rs1577917	0.771	rs4383777	ENSG00000203875.9	SNHG5	11.99	5.9e-29	1.04e-25	0.56	0.49	Response to antipsychotic treatment;	chr6:85726242	chr6:85660950~85678736:-
PRAD	cis	rs875971	0.545	rs1547529	ENSG00000237310.1	GS1-124K5.4	11.99	5.9e-29	1.04e-25	0.49	0.49	Aortic root size;	chr7:66258859	chr7:66493706~66495474:+
PRAD	cis	rs9322193	0.923	rs9800686	ENSG00000223701.3	RAET1E-AS1	11.98	5.99e-29	1.06e-25	0.66	0.49	Lung cancer;	chr6:149634464	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.81	rs62439811	ENSG00000223701.3	RAET1E-AS1	11.98	5.99e-29	1.06e-25	0.66	0.49	Lung cancer;	chr6:149640416	chr6:149884431~149919508:+
PRAD	cis	rs6991838	0.584	rs4737747	ENSG00000272010.1	CTD-3025N20.3	-11.98	6e-29	1.06e-25	-0.51	-0.49	Intelligence (multi-trait analysis);	chr8:65607024	chr8:65591850~65592472:-
PRAD	cis	rs67383717	0.713	rs1369156	ENSG00000175611.10	LINC00476	-11.98	6.01e-29	1.06e-25	-0.58	-0.49	Parkinson's disease (pesticide exposure interaction);	chr9:95794612	chr9:95759231~95875977:-
PRAD	cis	rs9322193	0.923	rs10747275	ENSG00000223701.3	RAET1E-AS1	11.98	6.02e-29	1.06e-25	0.66	0.49	Lung cancer;	chr6:149622782	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.884	rs9688794	ENSG00000223701.3	RAET1E-AS1	11.98	6.02e-29	1.06e-25	0.66	0.49	Lung cancer;	chr6:149632121	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.923	rs9689084	ENSG00000223701.3	RAET1E-AS1	11.98	6.02e-29	1.06e-25	0.66	0.49	Lung cancer;	chr6:149639648	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.884	rs7450246	ENSG00000223701.3	RAET1E-AS1	11.98	6.05e-29	1.07e-25	0.65	0.49	Lung cancer;	chr6:149702517	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.923	rs4870509	ENSG00000223701.3	RAET1E-AS1	11.98	6.05e-29	1.07e-25	0.66	0.49	Lung cancer;	chr6:149702212	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.923	rs9322214	ENSG00000223701.3	RAET1E-AS1	11.98	6.05e-29	1.07e-25	0.66	0.49	Lung cancer;	chr6:149703986	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.923	rs9505823	ENSG00000223701.3	RAET1E-AS1	11.98	6.1e-29	1.07e-25	0.66	0.49	Lung cancer;	chr6:149628899	chr6:149884431~149919508:+
PRAD	cis	rs2404602	0.647	rs12898810	ENSG00000259422.1	RP11-593F23.1	-11.98	6.11e-29	1.08e-25	-0.66	-0.49	Blood metabolite levels;	chr15:76612397	chr15:76174891~76181486:-
PRAD	cis	rs71403859	0.73	rs12447672	ENSG00000260886.1	TAT-AS1	11.98	6.22e-29	1.1e-25	0.87	0.49	Post bronchodilator FEV1;	chr16:71681228	chr16:71565789~71578187:+
PRAD	cis	rs9322193	0.923	rs55849538	ENSG00000223701.3	RAET1E-AS1	11.98	6.27e-29	1.1e-25	0.66	0.49	Lung cancer;	chr6:149635330	chr6:149884431~149919508:+
PRAD	cis	rs6991838	0.584	rs7823840	ENSG00000272010.1	CTD-3025N20.3	-11.98	6.27e-29	1.1e-25	-0.51	-0.49	Intelligence (multi-trait analysis);	chr8:65606766	chr8:65591850~65592472:-
PRAD	cis	rs5760092	0.755	rs4585126	ENSG00000250470.1	AP000351.3	-11.98	6.31e-29	1.11e-25	-0.72	-0.49	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23976904~23977585:-
PRAD	cis	rs12653946	0.811	rs10866527	ENSG00000249326.1	CTD-2194D22.4	-11.98	6.32e-29	1.11e-25	-0.63	-0.49	Prostate cancer;	chr5:1891686	chr5:1887332~1900493:+
PRAD	cis	rs8072100	0.934	rs9905583	ENSG00000228782.6	CTD-2026D20.3	11.98	6.45e-29	1.13e-25	0.53	0.49	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47663650	chr17:47450568~47492492:-
PRAD	cis	rs2404602	0.611	rs2404734	ENSG00000259422.1	RP11-593F23.1	-11.98	6.45e-29	1.13e-25	-0.65	-0.49	Blood metabolite levels;	chr15:76643824	chr15:76174891~76181486:-
PRAD	cis	rs71403859	0.73	rs17356206	ENSG00000260886.1	TAT-AS1	11.97	6.5e-29	1.14e-25	0.88	0.49	Post bronchodilator FEV1;	chr16:71702456	chr16:71565789~71578187:+
PRAD	cis	rs9322193	0.566	rs12528243	ENSG00000231760.4	RP11-350J20.5	11.97	6.53e-29	1.15e-25	0.76	0.49	Lung cancer;	chr6:149898491	chr6:149796151~149826294:-
PRAD	cis	rs7617773	0.925	rs34513961	ENSG00000229759.1	MRPS18AP1	11.97	6.56e-29	1.15e-25	0.56	0.49	Coronary artery disease;	chr3:48132163	chr3:48256350~48256938:-
PRAD	cis	rs2455601	1	rs72632952	ENSG00000254860.4	TMEM9B-AS1	11.97	6.57e-29	1.15e-25	0.63	0.49	Schizophrenia;	chr11:8896429	chr11:8964675~8977527:+
PRAD	cis	rs9322193	0.886	rs4870049	ENSG00000223701.3	RAET1E-AS1	11.97	6.58e-29	1.16e-25	0.66	0.49	Lung cancer;	chr6:149837058	chr6:149884431~149919508:+
PRAD	cis	rs3931020	0.745	rs7555459	ENSG00000272864.1	RP11-17E13.2	-11.97	6.66e-29	1.17e-25	-0.52	-0.49	Resistin levels;	chr1:74808022	chr1:74698769~74699333:-
PRAD	cis	rs8072100	1	rs8065437	ENSG00000228782.6	CTD-2026D20.3	11.97	6.66e-29	1.17e-25	0.53	0.49	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47644287	chr17:47450568~47492492:-
PRAD	cis	rs9322193	0.607	rs3798763	ENSG00000231760.4	RP11-350J20.5	11.97	6.72e-29	1.18e-25	0.77	0.49	Lung cancer;	chr6:149889964	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.607	rs12204653	ENSG00000231760.4	RP11-350J20.5	11.97	6.72e-29	1.18e-25	0.77	0.49	Lung cancer;	chr6:149891885	chr6:149796151~149826294:-
PRAD	cis	rs2739330	0.703	rs5760112	ENSG00000235689.1	AP000351.13	11.97	6.77e-29	1.19e-25	0.59	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:24006305~24008258:-
PRAD	cis	rs673078	0.607	rs11068926	ENSG00000275759.1	RP11-131L12.3	-11.97	6.79e-29	1.19e-25	-0.69	-0.49	Glucose homeostasis traits;	chr12:118367320	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.607	rs4442583	ENSG00000275759.1	RP11-131L12.3	-11.97	6.79e-29	1.19e-25	-0.69	-0.49	Glucose homeostasis traits;	chr12:118367914	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.607	rs61943370	ENSG00000275759.1	RP11-131L12.3	-11.97	6.79e-29	1.19e-25	-0.69	-0.49	Glucose homeostasis traits;	chr12:118369469	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.607	rs61943371	ENSG00000275759.1	RP11-131L12.3	-11.97	6.79e-29	1.19e-25	-0.69	-0.49	Glucose homeostasis traits;	chr12:118369600	chr12:118428281~118428870:+
PRAD	cis	rs1577917	0.771	rs9362239	ENSG00000203875.9	SNHG5	11.97	6.82e-29	1.2e-25	0.55	0.49	Response to antipsychotic treatment;	chr6:85719545	chr6:85660950~85678736:-
PRAD	cis	rs6504950	0.889	rs1156287	ENSG00000275710.1	RP11-257O5.4	-11.97	6.83e-29	1.2e-25	-0.67	-0.49	Breast cancer;	chr17:54999438	chr17:54964474~54964679:+
PRAD	cis	rs2933343	0.951	rs789220	ENSG00000231305.3	RP11-723O4.2	-11.97	6.84e-29	1.2e-25	-0.49	-0.49	IgG glycosylation;	chr3:128873292	chr3:128861313~128871540:-
PRAD	cis	rs8062405	0.792	rs12446550	ENSG00000259982.1	CDC37P1	11.97	6.86e-29	1.2e-25	0.63	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28532060	chr16:28700294~28701540:-
PRAD	cis	rs2739330	0.76	rs1002286	ENSG00000235689.1	AP000351.13	-11.97	6.86e-29	1.2e-25	-0.59	-0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:24006305~24008258:-
PRAD	cis	rs875971	0.571	rs160647	ENSG00000237310.1	GS1-124K5.4	-11.97	6.92e-29	1.21e-25	-0.5	-0.49	Aortic root size;	chr7:66089365	chr7:66493706~66495474:+
PRAD	cis	rs9532669	0.963	rs1056824	ENSG00000176268.5	CYCSP34	11.97	6.95e-29	1.22e-25	0.51	0.49	Cervical cancer;	chr13:40932748	chr13:40863599~40863902:-
PRAD	cis	rs1577917	0.771	rs9450319	ENSG00000203875.9	SNHG5	11.97	6.98e-29	1.22e-25	0.56	0.49	Response to antipsychotic treatment;	chr6:85717607	chr6:85660950~85678736:-
PRAD	cis	rs2933343	0.859	rs789247	ENSG00000231305.3	RP11-723O4.2	11.97	7.02e-29	1.23e-25	0.49	0.49	IgG glycosylation;	chr3:128861742	chr3:128861313~128871540:-
PRAD	cis	rs2933343	0.903	rs2638846	ENSG00000231305.3	RP11-723O4.2	11.97	7.02e-29	1.23e-25	0.49	0.49	IgG glycosylation;	chr3:128868320	chr3:128861313~128871540:-
PRAD	cis	rs977987	0.872	rs4243111	ENSG00000261783.1	RP11-252K23.2	-11.97	7.03e-29	1.23e-25	-0.66	-0.49	Dupuytren's disease;	chr16:75286929	chr16:75379818~75381260:-
PRAD	cis	rs2117029	0.586	rs11168874	ENSG00000258017.1	RP11-386G11.10	-11.96	7.17e-29	1.26e-25	-0.64	-0.49	Intelligence (multi-trait analysis);	chr12:49133753	chr12:49127782~49147869:+
PRAD	cis	rs11676348	0.846	rs7594532	ENSG00000261338.2	RP11-378A13.1	-11.96	7.17e-29	1.26e-25	-0.56	-0.49	Ulcerative colitis;	chr2:218143277	chr2:218255319~218257366:+
PRAD	cis	rs1577917	0.958	rs12192033	ENSG00000203875.9	SNHG5	-11.96	7.18e-29	1.26e-25	-0.55	-0.49	Response to antipsychotic treatment;	chr6:85762841	chr6:85660950~85678736:-
PRAD	cis	rs8062405	0.931	rs12928404	ENSG00000251417.2	RP11-1348G14.4	-11.96	7.23e-29	1.27e-25	-0.54	-0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835925	chr16:28802743~28817828:+
PRAD	cis	rs11676348	0.846	rs4674259	ENSG00000261338.2	RP11-378A13.1	-11.96	7.31e-29	1.28e-25	-0.56	-0.49	Ulcerative colitis;	chr2:218126282	chr2:218255319~218257366:+
PRAD	cis	rs2404602	0.647	rs2404604	ENSG00000259422.1	RP11-593F23.1	-11.96	7.32e-29	1.28e-25	-0.65	-0.49	Blood metabolite levels;	chr15:76698764	chr15:76174891~76181486:-
PRAD	cis	rs9322193	0.607	rs10457852	ENSG00000223701.3	RAET1E-AS1	11.96	7.34e-29	1.29e-25	0.77	0.49	Lung cancer;	chr6:149880584	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.884	rs62439836	ENSG00000223701.3	RAET1E-AS1	11.96	7.49e-29	1.31e-25	0.66	0.49	Lung cancer;	chr6:149669173	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.923	rs4869812	ENSG00000223701.3	RAET1E-AS1	11.96	7.49e-29	1.31e-25	0.66	0.49	Lung cancer;	chr6:149669447	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.962	rs4380763	ENSG00000223701.3	RAET1E-AS1	11.96	7.5e-29	1.31e-25	0.66	0.49	Lung cancer;	chr6:149678086	chr6:149884431~149919508:+
PRAD	cis	rs9487094	0.961	rs11153177	ENSG00000260273.1	RP11-425D10.10	11.96	7.53e-29	1.32e-25	0.7	0.49	Height;	chr6:109416225	chr6:109382795~109383666:+
PRAD	cis	rs12049351	0.774	rs12140727	ENSG00000229367.1	HMGN2P19	-11.96	7.53e-29	1.32e-25	-0.69	-0.49	Circulating myeloperoxidase levels (plasma);	chr1:229491144	chr1:229570532~229570796:+
PRAD	cis	rs11603023	0.569	rs573905	ENSG00000255239.1	AP002954.6	11.96	7.58e-29	1.33e-25	0.61	0.49	Cholesterol, total;	chr11:118701558	chr11:118688039~118690600:-
PRAD	cis	rs9532669	0.824	rs4941998	ENSG00000176268.5	CYCSP34	11.96	7.61e-29	1.33e-25	0.53	0.49	Cervical cancer;	chr13:40859901	chr13:40863599~40863902:-
PRAD	cis	rs875971	0.545	rs13311962	ENSG00000237310.1	GS1-124K5.4	-11.96	7.63e-29	1.33e-25	-0.49	-0.49	Aortic root size;	chr7:66603142	chr7:66493706~66495474:+
PRAD	cis	rs9322193	0.886	rs9485408	ENSG00000223701.3	RAET1E-AS1	11.96	7.66e-29	1.34e-25	0.66	0.49	Lung cancer;	chr6:149618888	chr6:149884431~149919508:+
PRAD	cis	rs9532669	0.926	rs4941995	ENSG00000176268.5	CYCSP34	11.96	7.73e-29	1.35e-25	0.52	0.49	Cervical cancer;	chr13:40850117	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.926	rs9315789	ENSG00000176268.5	CYCSP34	11.96	7.73e-29	1.35e-25	0.52	0.49	Cervical cancer;	chr13:40852898	chr13:40863599~40863902:-
PRAD	cis	rs9487094	0.922	rs9487098	ENSG00000260273.1	RP11-425D10.10	11.96	7.73e-29	1.35e-25	0.68	0.49	Height;	chr6:109422189	chr6:109382795~109383666:+
PRAD	cis	rs71403859	0.502	rs35981926	ENSG00000260886.1	TAT-AS1	11.96	7.73e-29	1.35e-25	0.91	0.49	Post bronchodilator FEV1;	chr16:71466852	chr16:71565789~71578187:+
PRAD	cis	rs11676348	0.818	rs6436031	ENSG00000261338.2	RP11-378A13.1	-11.96	7.78e-29	1.36e-25	-0.56	-0.49	Ulcerative colitis;	chr2:218114536	chr2:218255319~218257366:+
PRAD	cis	rs1061377	0.76	rs7678457	ENSG00000249207.1	RP11-360F5.1	-11.95	7.83e-29	1.37e-25	-0.51	-0.49	Uric acid levels;	chr4:39136041	chr4:39112677~39126818:-
PRAD	cis	rs9322193	0.962	rs2342764	ENSG00000268592.3	RAET1E-AS1	11.95	7.96e-29	1.39e-25	0.67	0.49	Lung cancer;	chr6:149835068	chr6:149863494~149919507:+
PRAD	cis	rs6142102	0.517	rs6059577	ENSG00000276073.1	RP5-1125A11.7	-11.95	8.01e-29	1.4e-25	-0.47	-0.49	Skin pigmentation;	chr20:33939880	chr20:33985617~33988989:-
PRAD	cis	rs7617773	0.963	rs6800730	ENSG00000229759.1	MRPS18AP1	11.95	8.05e-29	1.4e-25	0.5	0.49	Coronary artery disease;	chr3:48132720	chr3:48256350~48256938:-
PRAD	cis	rs1577917	0.739	rs9450318	ENSG00000203875.9	SNHG5	11.95	8.09e-29	1.41e-25	0.55	0.49	Response to antipsychotic treatment;	chr6:85717459	chr6:85660950~85678736:-
PRAD	cis	rs2455601	1	rs11042114	ENSG00000254860.4	TMEM9B-AS1	11.95	8.14e-29	1.42e-25	0.63	0.49	Schizophrenia;	chr11:8898342	chr11:8964675~8977527:+
PRAD	cis	rs875971	0.545	rs313828	ENSG00000237310.1	GS1-124K5.4	-11.95	8.24e-29	1.44e-25	-0.5	-0.49	Aortic root size;	chr7:66087627	chr7:66493706~66495474:+
PRAD	cis	rs1062177	1	rs2964612	ENSG00000213433.5	RPLP1P6	-11.95	8.26e-29	1.44e-25	-0.58	-0.49	Preschool internalizing problems;	chr5:151819189	chr5:151765859~151766378:-
PRAD	cis	rs11676348	0.846	rs11677534	ENSG00000261338.2	RP11-378A13.1	-11.95	8.26e-29	1.44e-25	-0.56	-0.49	Ulcerative colitis;	chr2:218142337	chr2:218255319~218257366:+
PRAD	cis	rs875971	0.545	rs4441996	ENSG00000237310.1	GS1-124K5.4	-11.95	8.32e-29	1.45e-25	-0.49	-0.49	Aortic root size;	chr7:66123233	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.545	rs316324	ENSG00000237310.1	GS1-124K5.4	-11.95	8.32e-29	1.45e-25	-0.49	-0.49	Aortic root size;	chr7:66145627	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.545	rs316323	ENSG00000237310.1	GS1-124K5.4	-11.95	8.32e-29	1.45e-25	-0.49	-0.49	Aortic root size;	chr7:66146002	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.545	rs316316	ENSG00000237310.1	GS1-124K5.4	-11.95	8.32e-29	1.45e-25	-0.49	-0.49	Aortic root size;	chr7:66149270	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.545	rs2460427	ENSG00000237310.1	GS1-124K5.4	-11.95	8.32e-29	1.45e-25	-0.49	-0.49	Aortic root size;	chr7:66154218	chr7:66493706~66495474:+
PRAD	cis	rs7569084	0.663	rs11694714	ENSG00000204929.10	AC074391.1	11.95	8.38e-29	1.46e-25	0.66	0.49	Sum eosinophil basophil counts;	chr2:65436802	chr2:65436711~66084639:+
PRAD	cis	rs9532669	0.89	rs9532593	ENSG00000176268.5	CYCSP34	11.95	8.42e-29	1.47e-25	0.52	0.49	Cervical cancer;	chr13:40847717	chr13:40863599~40863902:-
PRAD	cis	rs875971	0.502	rs2946580	ENSG00000237310.1	GS1-124K5.4	-11.95	8.42e-29	1.47e-25	-0.5	-0.49	Aortic root size;	chr7:66066855	chr7:66493706~66495474:+
PRAD	cis	rs9322193	0.923	rs9767123	ENSG00000223701.3	RAET1E-AS1	11.95	8.43e-29	1.47e-25	0.66	0.49	Lung cancer;	chr6:149660323	chr6:149884431~149919508:+
PRAD	cis	rs2117029	0.587	rs1865157	ENSG00000258017.1	RP11-386G11.10	-11.95	8.45e-29	1.47e-25	-0.63	-0.49	Intelligence (multi-trait analysis);	chr12:49129003	chr12:49127782~49147869:+
PRAD	cis	rs6142102	0.517	rs8119076	ENSG00000276073.1	RP5-1125A11.7	-11.95	8.48e-29	1.48e-25	-0.47	-0.49	Skin pigmentation;	chr20:33937909	chr20:33985617~33988989:-
PRAD	cis	rs11676348	0.818	rs7423433	ENSG00000261338.2	RP11-378A13.1	-11.95	8.48e-29	1.48e-25	-0.56	-0.49	Ulcerative colitis;	chr2:218120361	chr2:218255319~218257366:+
PRAD	cis	rs1062177	1	rs1062177	ENSG00000213433.5	RPLP1P6	-11.95	8.49e-29	1.48e-25	-0.58	-0.49	Preschool internalizing problems;	chr5:151805140	chr5:151765859~151766378:-
PRAD	cis	rs9322193	0.886	rs4870055	ENSG00000223701.3	RAET1E-AS1	11.95	8.5e-29	1.48e-25	0.66	0.49	Lung cancer;	chr6:149848433	chr6:149884431~149919508:+
PRAD	cis	rs12653946	0.846	rs4975758	ENSG00000249326.1	CTD-2194D22.4	-11.94	8.54e-29	1.49e-25	-0.63	-0.49	Prostate cancer;	chr5:1891060	chr5:1887332~1900493:+
PRAD	cis	rs6142102	0.625	rs6142051	ENSG00000276073.1	RP5-1125A11.7	-11.94	8.6e-29	1.5e-25	-0.47	-0.49	Skin pigmentation;	chr20:33945212	chr20:33985617~33988989:-
PRAD	cis	rs5760092	0.618	rs4461358	ENSG00000225282.1	AP000350.6	-11.94	8.72e-29	1.52e-25	-0.72	-0.49	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23917919	chr22:23926900~23929574:+
PRAD	cis	rs875971	0.545	rs4718348	ENSG00000237310.1	GS1-124K5.4	11.94	8.74e-29	1.52e-25	0.5	0.49	Aortic root size;	chr7:66441589	chr7:66493706~66495474:+
PRAD	cis	rs11676348	0.783	rs13035513	ENSG00000261338.2	RP11-378A13.1	-11.94	8.74e-29	1.52e-25	-0.56	-0.49	Ulcerative colitis;	chr2:218095957	chr2:218255319~218257366:+
PRAD	cis	rs9322193	0.923	rs4870267	ENSG00000223701.3	RAET1E-AS1	11.94	8.81e-29	1.53e-25	0.66	0.49	Lung cancer;	chr6:149671572	chr6:149884431~149919508:+
PRAD	cis	rs8072100	0.817	rs6505049	ENSG00000228782.6	CTD-2026D20.3	-11.94	8.85e-29	1.54e-25	-0.53	-0.49	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47598415	chr17:47450568~47492492:-
PRAD	cis	rs11105298	0.891	rs10858902	ENSG00000258302.2	RP11-981P6.1	11.94	8.87e-29	1.54e-25	0.55	0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89534012	chr12:89561129~89594878:+
PRAD	cis	rs11105298	0.891	rs10858903	ENSG00000258302.2	RP11-981P6.1	11.94	8.87e-29	1.54e-25	0.55	0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89534195	chr12:89561129~89594878:+
PRAD	cis	rs11676348	0.783	rs4674252	ENSG00000261338.2	RP11-378A13.1	-11.94	8.89e-29	1.55e-25	-0.56	-0.49	Ulcerative colitis;	chr2:218119755	chr2:218255319~218257366:+
PRAD	cis	rs11676348	0.714	rs4674254	ENSG00000261338.2	RP11-378A13.1	-11.94	8.89e-29	1.55e-25	-0.56	-0.49	Ulcerative colitis;	chr2:218121354	chr2:218255319~218257366:+
PRAD	cis	rs11676348	0.818	rs4674256	ENSG00000261338.2	RP11-378A13.1	-11.94	8.89e-29	1.55e-25	-0.56	-0.49	Ulcerative colitis;	chr2:218123170	chr2:218255319~218257366:+
PRAD	cis	rs524281	0.861	rs12049852	ENSG00000255320.1	RP11-755F10.1	11.94	8.9e-29	1.55e-25	0.72	0.49	Electroencephalogram traits;	chr11:66117231	chr11:66244840~66246239:-
PRAD	cis	rs11603023	0.874	rs577396	ENSG00000255239.1	AP002954.6	11.94	9.08e-29	1.58e-25	0.61	0.49	Cholesterol, total;	chr11:118628753	chr11:118688039~118690600:-
PRAD	cis	rs11603023	0.874	rs11216934	ENSG00000255239.1	AP002954.6	11.94	9.08e-29	1.58e-25	0.61	0.49	Cholesterol, total;	chr11:118630742	chr11:118688039~118690600:-
PRAD	cis	rs8062405	1	rs12443881	ENSG00000251417.2	RP11-1348G14.4	-11.94	9.14e-29	1.59e-25	-0.56	-0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28830456	chr16:28802743~28817828:+
PRAD	cis	rs35160687	0.901	rs6714362	ENSG00000273080.1	RP11-301O19.1	-11.94	9.21e-29	1.6e-25	-0.57	-0.49	Night sleep phenotypes;	chr2:86249465	chr2:86195590~86196049:+
PRAD	cis	rs12049351	0.774	rs10449250	ENSG00000229367.1	HMGN2P19	11.94	9.27e-29	1.61e-25	0.66	0.49	Circulating myeloperoxidase levels (plasma);	chr1:229505024	chr1:229570532~229570796:+
PRAD	cis	rs4423214	0.592	rs10898191	ENSG00000254682.1	RP11-660L16.2	-11.94	9.3e-29	1.61e-25	-0.79	-0.49	Vitamin D levels;	chr11:71483555	chr11:71448674~71452157:+
PRAD	cis	rs9322193	0.923	rs1934534	ENSG00000223701.3	RAET1E-AS1	11.94	9.31e-29	1.62e-25	0.65	0.49	Lung cancer;	chr6:149711896	chr6:149884431~149919508:+
PRAD	cis	rs2117029	0.619	rs2241727	ENSG00000258017.1	RP11-386G11.10	-11.94	9.34e-29	1.62e-25	-0.63	-0.49	Intelligence (multi-trait analysis);	chr12:49131225	chr12:49127782~49147869:+
PRAD	cis	rs11690935	0.632	rs9789538	ENSG00000228389.1	AC068039.4	-11.93	9.49e-29	1.65e-25	-0.55	-0.49	Schizophrenia;	chr2:171761964	chr2:171773482~171775844:+
PRAD	cis	rs2404602	0.684	rs12591622	ENSG00000259422.1	RP11-593F23.1	-11.93	9.52e-29	1.65e-25	-0.65	-0.49	Blood metabolite levels;	chr15:76638314	chr15:76174891~76181486:-
PRAD	cis	rs7569084	0.687	rs35839762	ENSG00000204929.10	AC074391.1	11.93	9.6e-29	1.67e-25	0.65	0.49	Sum eosinophil basophil counts;	chr2:65441318	chr2:65436711~66084639:+
PRAD	cis	rs35160687	0.901	rs17738096	ENSG00000273080.1	RP11-301O19.1	11.93	9.64e-29	1.67e-25	0.58	0.49	Night sleep phenotypes;	chr2:86286770	chr2:86195590~86196049:+
PRAD	cis	rs12049351	0.774	rs754023	ENSG00000229367.1	HMGN2P19	11.93	9.68e-29	1.68e-25	0.66	0.49	Circulating myeloperoxidase levels (plasma);	chr1:229501756	chr1:229570532~229570796:+
PRAD	cis	rs748404	0.56	rs2255663	ENSG00000205771.5	CATSPER2P1	11.93	9.71e-29	1.68e-25	0.56	0.49	Lung cancer;	chr15:43536810	chr15:43726918~43747094:-
PRAD	cis	rs11676348	0.846	rs4674257	ENSG00000261338.2	RP11-378A13.1	-11.93	9.77e-29	1.69e-25	-0.56	-0.49	Ulcerative colitis;	chr2:218124051	chr2:218255319~218257366:+
PRAD	cis	rs6991838	0.584	rs7463649	ENSG00000272010.1	CTD-3025N20.3	-11.93	9.77e-29	1.69e-25	-0.51	-0.49	Intelligence (multi-trait analysis);	chr8:65573760	chr8:65591850~65592472:-
PRAD	cis	rs6991838	0.584	rs66467166	ENSG00000272010.1	CTD-3025N20.3	-11.93	9.77e-29	1.69e-25	-0.51	-0.49	Intelligence (multi-trait analysis);	chr8:65574165	chr8:65591850~65592472:-
PRAD	cis	rs6991838	0.557	rs67685675	ENSG00000272010.1	CTD-3025N20.3	-11.93	9.77e-29	1.69e-25	-0.51	-0.49	Intelligence (multi-trait analysis);	chr8:65574371	chr8:65591850~65592472:-
PRAD	cis	rs6991838	0.584	rs66486920	ENSG00000272010.1	CTD-3025N20.3	-11.93	9.77e-29	1.69e-25	-0.51	-0.49	Intelligence (multi-trait analysis);	chr8:65574458	chr8:65591850~65592472:-
PRAD	cis	rs6991838	0.584	rs60023200	ENSG00000272010.1	CTD-3025N20.3	-11.93	9.77e-29	1.69e-25	-0.51	-0.49	Intelligence (multi-trait analysis);	chr8:65574547	chr8:65591850~65592472:-
PRAD	cis	rs6991838	0.584	rs61083799	ENSG00000272010.1	CTD-3025N20.3	-11.93	9.77e-29	1.69e-25	-0.51	-0.49	Intelligence (multi-trait analysis);	chr8:65574868	chr8:65591850~65592472:-
PRAD	cis	rs6991838	0.584	rs4449837	ENSG00000272010.1	CTD-3025N20.3	-11.93	9.77e-29	1.69e-25	-0.51	-0.49	Intelligence (multi-trait analysis);	chr8:65575917	chr8:65591850~65592472:-
PRAD	cis	rs1075265	0.589	rs2253760	ENSG00000233266.1	HMGB1P31	11.92	1.06e-28	1.83e-25	0.66	0.49	Chronotype;Morning vs. evening chronotype;	chr2:53806851	chr2:54051334~54051760:+
PRAD	cis	rs875971	0.545	rs316305	ENSG00000237310.1	GS1-124K5.4	-11.92	1.07e-28	1.86e-25	-0.49	-0.49	Aortic root size;	chr7:66152984	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.545	rs316306	ENSG00000237310.1	GS1-124K5.4	-11.92	1.07e-28	1.86e-25	-0.49	-0.49	Aortic root size;	chr7:66153687	chr7:66493706~66495474:+
PRAD	cis	rs6142102	0.625	rs6142061	ENSG00000276073.1	RP5-1125A11.7	-11.92	1.11e-28	1.92e-25	-0.48	-0.49	Skin pigmentation;	chr20:33960529	chr20:33985617~33988989:-
PRAD	cis	rs875971	0.789	rs28815324	ENSG00000237310.1	GS1-124K5.4	-11.92	1.11e-28	1.92e-25	-0.5	-0.49	Aortic root size;	chr7:66100789	chr7:66493706~66495474:+
PRAD	cis	rs7727544	0.735	rs273913	ENSG00000233006.5	AC034220.3	11.91	1.13e-28	1.96e-25	0.44	0.49	Blood metabolite levels;	chr5:132325463	chr5:132311285~132369916:-
PRAD	cis	rs8072100	1	rs4375701	ENSG00000228782.6	CTD-2026D20.3	11.91	1.14e-28	1.97e-25	0.53	0.49	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47634852	chr17:47450568~47492492:-
PRAD	cis	rs8062405	1	rs80275162	ENSG00000259982.1	CDC37P1	11.91	1.14e-28	1.97e-25	0.65	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28852196	chr16:28700294~28701540:-
PRAD	cis	rs73086581	1	rs17215340	ENSG00000229539.1	RP11-119B16.2	-11.91	1.17e-28	2.02e-25	-0.79	-0.49	Response to antidepressants in depression;	chr20:3989526	chr20:3888239~3888868:-
PRAD	cis	rs875971	0.571	rs160641	ENSG00000237310.1	GS1-124K5.4	-11.91	1.18e-28	2.04e-25	-0.49	-0.49	Aortic root size;	chr7:66112359	chr7:66493706~66495474:+
PRAD	cis	rs2404602	0.647	rs36114653	ENSG00000259422.1	RP11-593F23.1	-11.91	1.19e-28	2.05e-25	-0.66	-0.49	Blood metabolite levels;	chr15:76733052	chr15:76174891~76181486:-
PRAD	cis	rs9322193	0.923	rs4870529	ENSG00000223701.3	RAET1E-AS1	11.91	1.2e-28	2.06e-25	0.65	0.49	Lung cancer;	chr6:149716436	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.923	rs9767309	ENSG00000223701.3	RAET1E-AS1	11.91	1.2e-28	2.06e-25	0.65	0.49	Lung cancer;	chr6:149716807	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.923	rs17745062	ENSG00000223701.3	RAET1E-AS1	11.91	1.2e-28	2.06e-25	0.65	0.49	Lung cancer;	chr6:149721079	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.923	rs62441279	ENSG00000223701.3	RAET1E-AS1	11.91	1.2e-28	2.06e-25	0.65	0.49	Lung cancer;	chr6:149721194	chr6:149884431~149919508:+
PRAD	cis	rs7684253	0.565	rs13130605	ENSG00000269949.1	RP11-738E22.3	-11.91	1.21e-28	2.08e-25	-0.55	-0.49	Migraine;	chr4:56943905	chr4:56960927~56961373:-
PRAD	cis	rs9322193	0.847	rs62439808	ENSG00000223701.3	RAET1E-AS1	11.91	1.21e-28	2.09e-25	0.66	0.49	Lung cancer;	chr6:149629690	chr6:149884431~149919508:+
PRAD	cis	rs67383717	0.643	rs72756397	ENSG00000175611.10	LINC00476	-11.91	1.21e-28	2.09e-25	-0.58	-0.49	Parkinson's disease (pesticide exposure interaction);	chr9:95790861	chr9:95759231~95875977:-
PRAD	cis	rs16828019	0.704	rs12743340	ENSG00000235358.1	RP11-399E6.1	11.91	1.22e-28	2.1e-25	0.9	0.49	Intelligence (multi-trait analysis);	chr1:40990360	chr1:41242373~41284861:+
PRAD	cis	rs2404602	0.647	rs34103231	ENSG00000259422.1	RP11-593F23.1	-11.91	1.22e-28	2.1e-25	-0.65	-0.49	Blood metabolite levels;	chr15:76620349	chr15:76174891~76181486:-
PRAD	cis	rs7617773	0.925	rs35942721	ENSG00000229759.1	MRPS18AP1	11.91	1.23e-28	2.11e-25	0.56	0.49	Coronary artery disease;	chr3:48131579	chr3:48256350~48256938:-
PRAD	cis	rs11690935	0.632	rs2292816	ENSG00000228389.1	AC068039.4	-11.9	1.24e-28	2.14e-25	-0.54	-0.49	Schizophrenia;	chr2:171730204	chr2:171773482~171775844:+
PRAD	cis	rs11123170	0.543	rs2166421	ENSG00000189223.12	PAX8-AS1	-11.9	1.25e-28	2.15e-25	-0.76	-0.49	Renal function-related traits (BUN);	chr2:113232665	chr2:113211522~113276581:+
PRAD	cis	rs7182621	0.774	rs12101368	ENSG00000259363.4	CTD-2054N24.2	-11.9	1.26e-28	2.17e-25	-0.48	-0.49	Colonoscopy-negative controls vs population controls;	chr15:99872475	chr15:99807023~99877148:+
PRAD	cis	rs9326248	0.53	rs1242229	ENSG00000254851.1	RP11-109L13.1	-11.9	1.27e-28	2.18e-25	-1.03	-0.49	Blood protein levels;	chr11:117191654	chr11:117135528~117138582:+
PRAD	cis	rs9487094	0.961	rs9480948	ENSG00000260273.1	RP11-425D10.10	11.9	1.27e-28	2.19e-25	0.69	0.49	Height;	chr6:109407148	chr6:109382795~109383666:+
PRAD	cis	rs11603023	0.874	rs613243	ENSG00000255239.1	AP002954.6	11.9	1.27e-28	2.19e-25	0.6	0.49	Cholesterol, total;	chr11:118643304	chr11:118688039~118690600:-
PRAD	cis	rs3091242	0.933	rs35148262	ENSG00000224183.1	SDHDP6	-11.9	1.28e-28	2.21e-25	-0.57	-0.49	Erythrocyte sedimentation rate;	chr1:25440132	chr1:25294164~25294643:-
PRAD	cis	rs2739330	0.796	rs2154594	ENSG00000231271.1	AP000350.8	-11.9	1.29e-28	2.22e-25	-0.66	-0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23949918~23954042:+
PRAD	cis	rs1061377	1	rs56119980	ENSG00000249207.1	RP11-360F5.1	-11.9	1.31e-28	2.25e-25	-0.51	-0.49	Uric acid levels;	chr4:39139390	chr4:39112677~39126818:-
PRAD	cis	rs4853012	0.838	rs72915068	ENSG00000257800.1	FNBP1P1	11.9	1.31e-28	2.25e-25	0.44	0.49	Gestational age at birth (maternal effect);	chr2:74129058	chr2:74120680~74123218:+
PRAD	cis	rs1061377	0.861	rs35739603	ENSG00000249207.1	RP11-360F5.1	-11.9	1.32e-28	2.26e-25	-0.52	-0.49	Uric acid levels;	chr4:39107938	chr4:39112677~39126818:-
PRAD	cis	rs7684253	0.565	rs7697176	ENSG00000269949.1	RP11-738E22.3	-11.9	1.32e-28	2.26e-25	-0.55	-0.49	Migraine;	chr4:56956882	chr4:56960927~56961373:-
PRAD	cis	rs7684253	0.565	rs7680140	ENSG00000269949.1	RP11-738E22.3	-11.9	1.32e-28	2.26e-25	-0.55	-0.49	Migraine;	chr4:56957291	chr4:56960927~56961373:-
PRAD	cis	rs853679	0.506	rs1150711	ENSG00000216901.1	AL022393.7	11.9	1.32e-28	2.27e-25	0.62	0.49	Depression;	chr6:28240757	chr6:28176188~28176674:+
PRAD	cis	rs16828019	0.704	rs35071528	ENSG00000235358.1	RP11-399E6.1	11.9	1.33e-28	2.29e-25	1.04	0.49	Intelligence (multi-trait analysis);	chr1:41146985	chr1:41242373~41284861:+
PRAD	cis	rs875971	0.545	rs221986	ENSG00000237310.1	GS1-124K5.4	-11.9	1.33e-28	2.29e-25	-0.5	-0.49	Aortic root size;	chr7:66105323	chr7:66493706~66495474:+
PRAD	cis	rs7688540	0.511	rs11731927	ENSG00000275426.1	CH17-262A2.1	11.9	1.34e-28	2.3e-25	0.77	0.49	Facial morphology (factor 6, height of vermillion lower lip);	chr4:180316	chr4:149738~150317:+
PRAD	cis	rs55794721	0.509	rs6699113	ENSG00000224183.1	SDHDP6	-11.9	1.34e-28	2.31e-25	-0.57	-0.49	Mean corpuscular volume;Plateletcrit;	chr1:25451252	chr1:25294164~25294643:-
PRAD	cis	rs55794721	0.509	rs7554255	ENSG00000224183.1	SDHDP6	-11.9	1.34e-28	2.31e-25	-0.57	-0.49	Mean corpuscular volume;Plateletcrit;	chr1:25451615	chr1:25294164~25294643:-
PRAD	cis	rs55794721	0.509	rs4649085	ENSG00000224183.1	SDHDP6	-11.9	1.34e-28	2.31e-25	-0.57	-0.49	Mean corpuscular volume;Plateletcrit;	chr1:25452341	chr1:25294164~25294643:-
PRAD	cis	rs12049351	0.774	rs6673421	ENSG00000229367.1	HMGN2P19	11.89	1.35e-28	2.33e-25	0.66	0.49	Circulating myeloperoxidase levels (plasma);	chr1:229500641	chr1:229570532~229570796:+
PRAD	cis	rs11690935	0.632	rs1607254	ENSG00000228389.1	AC068039.4	-11.89	1.36e-28	2.33e-25	-0.55	-0.49	Schizophrenia;	chr2:171770042	chr2:171773482~171775844:+
PRAD	cis	rs9322193	0.923	rs9767105	ENSG00000223701.3	RAET1E-AS1	11.89	1.36e-28	2.34e-25	0.66	0.49	Lung cancer;	chr6:149659591	chr6:149884431~149919508:+
PRAD	cis	rs2404602	0.647	rs35710279	ENSG00000259422.1	RP11-593F23.1	-11.89	1.36e-28	2.34e-25	-0.65	-0.49	Blood metabolite levels;	chr15:76789893	chr15:76174891~76181486:-
PRAD	cis	rs2455601	0.935	rs12049908	ENSG00000254860.4	TMEM9B-AS1	11.89	1.37e-28	2.35e-25	0.62	0.49	Schizophrenia;	chr11:8897762	chr11:8964675~8977527:+
PRAD	cis	rs11105298	0.891	rs4842662	ENSG00000258302.2	RP11-981P6.1	11.89	1.38e-28	2.37e-25	0.54	0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89539669	chr12:89561129~89594878:+
PRAD	cis	rs12049351	0.774	rs12079612	ENSG00000229367.1	HMGN2P19	11.89	1.38e-28	2.38e-25	0.69	0.49	Circulating myeloperoxidase levels (plasma);	chr1:229513625	chr1:229570532~229570796:+
PRAD	cis	rs875971	0.52	rs160645	ENSG00000237310.1	GS1-124K5.4	-11.89	1.42e-28	2.43e-25	-0.5	-0.49	Aortic root size;	chr7:66091320	chr7:66493706~66495474:+
PRAD	cis	rs2739330	0.753	rs4822452	ENSG00000231271.1	AP000350.8	11.89	1.42e-28	2.44e-25	0.66	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23949918~23954042:+
PRAD	cis	rs1075265	0.73	rs11893270	ENSG00000233266.1	HMGB1P31	11.89	1.43e-28	2.45e-25	0.65	0.49	Chronotype;Morning vs. evening chronotype;	chr2:54019828	chr2:54051334~54051760:+
PRAD	cis	rs12049351	0.774	rs767303	ENSG00000229367.1	HMGN2P19	11.89	1.43e-28	2.45e-25	0.66	0.49	Circulating myeloperoxidase levels (plasma);	chr1:229563184	chr1:229570532~229570796:+
PRAD	cis	rs6504950	0.85	rs2628309	ENSG00000275710.1	RP11-257O5.4	-11.89	1.45e-28	2.49e-25	-0.67	-0.49	Breast cancer;	chr17:55038058	chr17:54964474~54964679:+
PRAD	cis	rs8062405	0.755	rs111693583	ENSG00000259982.1	CDC37P1	11.89	1.46e-28	2.5e-25	0.64	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28572289	chr16:28700294~28701540:-
PRAD	cis	rs2117029	0.587	rs57853986	ENSG00000258017.1	RP11-386G11.10	-11.89	1.46e-28	2.51e-25	-0.64	-0.49	Intelligence (multi-trait analysis);	chr12:49124612	chr12:49127782~49147869:+
PRAD	cis	rs9322193	0.923	rs12174716	ENSG00000223701.3	RAET1E-AS1	11.89	1.47e-28	2.51e-25	0.66	0.49	Lung cancer;	chr6:149644487	chr6:149884431~149919508:+
PRAD	cis	rs875971	0.545	rs1796219	ENSG00000237310.1	GS1-124K5.4	-11.88	1.5e-28	2.57e-25	-0.49	-0.49	Aortic root size;	chr7:66645977	chr7:66493706~66495474:+
PRAD	cis	rs11123170	0.64	rs931472	ENSG00000189223.12	PAX8-AS1	11.88	1.51e-28	2.59e-25	0.7	0.49	Renal function-related traits (BUN);	chr2:113212371	chr2:113211522~113276581:+
PRAD	cis	rs9322193	0.923	rs10782317	ENSG00000223701.3	RAET1E-AS1	-11.88	1.52e-28	2.61e-25	-0.65	-0.49	Lung cancer;	chr6:149753911	chr6:149884431~149919508:+
PRAD	cis	rs2739330	0.828	rs2186366	ENSG00000231271.1	AP000350.8	-11.88	1.52e-28	2.61e-25	-0.66	-0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23949918~23954042:+
PRAD	cis	rs11676348	0.818	rs7426289	ENSG00000261338.2	RP11-378A13.1	-11.88	1.54e-28	2.63e-25	-0.56	-0.49	Ulcerative colitis;	chr2:218101592	chr2:218255319~218257366:+
PRAD	cis	rs9322193	0.607	rs915140	ENSG00000231760.4	RP11-350J20.5	11.88	1.54e-28	2.64e-25	0.76	0.49	Lung cancer;	chr6:149899674	chr6:149796151~149826294:-
PRAD	cis	rs1577917	0.538	rs7755996	ENSG00000203875.9	SNHG5	11.88	1.54e-28	2.64e-25	0.53	0.49	Response to antipsychotic treatment;	chr6:85714002	chr6:85660950~85678736:-
PRAD	cis	rs8062405	1	rs7498555	ENSG00000251417.2	RP11-1348G14.4	-11.88	1.55e-28	2.66e-25	-0.56	-0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28882250	chr16:28802743~28817828:+
PRAD	cis	rs11690935	0.632	rs62184165	ENSG00000228389.1	AC068039.4	-11.88	1.55e-28	2.66e-25	-0.54	-0.49	Schizophrenia;	chr2:171701818	chr2:171773482~171775844:+
PRAD	cis	rs9322193	0.923	rs9800614	ENSG00000268592.3	RAET1E-AS1	11.88	1.56e-28	2.66e-25	0.67	0.49	Lung cancer;	chr6:149644604	chr6:149863494~149919507:+
PRAD	cis	rs1075265	0.584	rs1862122	ENSG00000233266.1	HMGB1P31	-11.88	1.56e-28	2.67e-25	-0.64	-0.49	Chronotype;Morning vs. evening chronotype;	chr2:54052992	chr2:54051334~54051760:+
PRAD	cis	rs6504950	0.72	rs2877634	ENSG00000275710.1	RP11-257O5.4	11.88	1.59e-28	2.71e-25	0.63	0.49	Breast cancer;	chr17:54910184	chr17:54964474~54964679:+
PRAD	cis	rs9487094	1	rs12197114	ENSG00000260273.1	RP11-425D10.10	11.88	1.61e-28	2.76e-25	0.69	0.49	Height;	chr6:109414295	chr6:109382795~109383666:+
PRAD	cis	rs7684253	0.565	rs13108570	ENSG00000269949.1	RP11-738E22.3	-11.87	1.63e-28	2.79e-25	-0.55	-0.49	Migraine;	chr4:56940917	chr4:56960927~56961373:-
PRAD	cis	rs6991838	0.584	rs7459944	ENSG00000272010.1	CTD-3025N20.3	-11.87	1.64e-28	2.8e-25	-0.51	-0.49	Intelligence (multi-trait analysis);	chr8:65566040	chr8:65591850~65592472:-
PRAD	cis	rs8062405	1	rs12325113	ENSG00000251417.2	RP11-1348G14.4	-11.87	1.64e-28	2.8e-25	-0.55	-0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28837347	chr16:28802743~28817828:+
PRAD	cis	rs56163509	1	rs56163509	ENSG00000251417.2	RP11-1348G14.4	-11.87	1.64e-28	2.8e-25	-0.55	-0.49	Tonsillectomy;Mean corpuscular volume;	chr16:28853150	chr16:28802743~28817828:+
PRAD	cis	rs8062405	1	rs62037369	ENSG00000251417.2	RP11-1348G14.4	-11.87	1.64e-28	2.8e-25	-0.55	-0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28872520	chr16:28802743~28817828:+
PRAD	cis	rs8062405	0.965	rs7359397	ENSG00000251417.2	RP11-1348G14.4	-11.87	1.64e-28	2.8e-25	-0.55	-0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874338	chr16:28802743~28817828:+
PRAD	cis	rs55794721	0.509	rs6699896	ENSG00000224183.1	SDHDP6	-11.87	1.66e-28	2.83e-25	-0.57	-0.49	Mean corpuscular volume;Plateletcrit;	chr1:25436411	chr1:25294164~25294643:-
PRAD	cis	rs3091242	0.904	rs6661533	ENSG00000224183.1	SDHDP6	-11.87	1.66e-28	2.83e-25	-0.57	-0.49	Erythrocyte sedimentation rate;	chr1:25445224	chr1:25294164~25294643:-
PRAD	cis	rs875971	0.545	rs73376401	ENSG00000237310.1	GS1-124K5.4	11.87	1.69e-28	2.88e-25	0.49	0.49	Aortic root size;	chr7:66174841	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.545	rs67775320	ENSG00000237310.1	GS1-124K5.4	11.87	1.69e-28	2.88e-25	0.49	0.49	Aortic root size;	chr7:66193792	chr7:66493706~66495474:+
PRAD	cis	rs9487094	0.961	rs12192847	ENSG00000260273.1	RP11-425D10.10	11.87	1.69e-28	2.89e-25	0.7	0.49	Height;	chr6:109480428	chr6:109382795~109383666:+
PRAD	cis	rs71403859	0.73	rs17356316	ENSG00000260886.1	TAT-AS1	11.87	1.71e-28	2.92e-25	0.89	0.49	Post bronchodilator FEV1;	chr16:71713018	chr16:71565789~71578187:+
PRAD	cis	rs2455601	0.529	rs2653569	ENSG00000254860.4	TMEM9B-AS1	11.87	1.72e-28	2.93e-25	0.54	0.49	Schizophrenia;	chr11:8965431	chr11:8964675~8977527:+
PRAD	cis	rs10256972	0.9	rs7812072	ENSG00000229043.2	AC091729.9	-11.87	1.73e-28	2.94e-25	-0.6	-0.49	Endometriosis;Longevity;	chr7:1014226	chr7:1160374~1165267:+
PRAD	cis	rs9322193	0.566	rs5024811	ENSG00000231760.4	RP11-350J20.5	-11.87	1.73e-28	2.96e-25	-0.73	-0.49	Lung cancer;	chr6:149924898	chr6:149796151~149826294:-
PRAD	cis	rs6504950	0.85	rs2541242	ENSG00000275710.1	RP11-257O5.4	-11.87	1.74e-28	2.96e-25	-0.66	-0.49	Breast cancer;	chr17:55012326	chr17:54964474~54964679:+
PRAD	cis	rs6504950	0.889	rs2541245	ENSG00000275710.1	RP11-257O5.4	-11.87	1.74e-28	2.96e-25	-0.66	-0.49	Breast cancer;	chr17:55023839	chr17:54964474~54964679:+
PRAD	cis	rs6504950	0.889	rs2787505	ENSG00000275710.1	RP11-257O5.4	-11.87	1.74e-28	2.96e-25	-0.66	-0.49	Breast cancer;	chr17:55030071	chr17:54964474~54964679:+
PRAD	cis	rs6504950	0.85	rs2787507	ENSG00000275710.1	RP11-257O5.4	-11.87	1.74e-28	2.96e-25	-0.66	-0.49	Breast cancer;	chr17:55050563	chr17:54964474~54964679:+
PRAD	cis	rs6504950	0.813	rs9889687	ENSG00000275710.1	RP11-257O5.4	-11.87	1.74e-28	2.96e-25	-0.66	-0.49	Breast cancer;	chr17:55055050	chr17:54964474~54964679:+
PRAD	cis	rs6504950	0.85	rs17745534	ENSG00000275710.1	RP11-257O5.4	-11.87	1.74e-28	2.96e-25	-0.66	-0.49	Breast cancer;	chr17:55060145	chr17:54964474~54964679:+
PRAD	cis	rs6504950	0.889	rs9303363	ENSG00000275710.1	RP11-257O5.4	-11.87	1.74e-28	2.96e-25	-0.66	-0.49	Breast cancer;	chr17:55060613	chr17:54964474~54964679:+
PRAD	cis	rs6991838	0.584	rs4388482	ENSG00000272010.1	CTD-3025N20.3	-11.86	1.78e-28	3.02e-25	-0.5	-0.49	Intelligence (multi-trait analysis);	chr8:65583968	chr8:65591850~65592472:-
PRAD	cis	rs6991838	0.584	rs4637885	ENSG00000272010.1	CTD-3025N20.3	-11.86	1.78e-28	3.02e-25	-0.5	-0.49	Intelligence (multi-trait analysis);	chr8:65584849	chr8:65591850~65592472:-
PRAD	cis	rs6991838	0.556	rs7846527	ENSG00000272010.1	CTD-3025N20.3	-11.86	1.78e-28	3.02e-25	-0.5	-0.49	Intelligence (multi-trait analysis);	chr8:65586522	chr8:65591850~65592472:-
PRAD	cis	rs6991838	0.584	rs4320587	ENSG00000272010.1	CTD-3025N20.3	-11.86	1.78e-28	3.02e-25	-0.5	-0.49	Intelligence (multi-trait analysis);	chr8:65586991	chr8:65591850~65592472:-
PRAD	cis	rs6991838	0.584	rs35941313	ENSG00000272010.1	CTD-3025N20.3	-11.86	1.78e-28	3.02e-25	-0.5	-0.49	Intelligence (multi-trait analysis);	chr8:65587498	chr8:65591850~65592472:-
PRAD	cis	rs6991838	0.557	rs4737222	ENSG00000272010.1	CTD-3025N20.3	-11.86	1.78e-28	3.02e-25	-0.5	-0.49	Intelligence (multi-trait analysis);	chr8:65587878	chr8:65591850~65592472:-
PRAD	cis	rs12049351	0.774	rs1065674	ENSG00000229367.1	HMGN2P19	-11.86	1.81e-28	3.08e-25	-0.65	-0.49	Circulating myeloperoxidase levels (plasma);	chr1:229487591	chr1:229570532~229570796:+
PRAD	cis	rs9322193	0.884	rs10782312	ENSG00000223701.3	RAET1E-AS1	11.86	1.82e-28	3.09e-25	0.65	0.49	Lung cancer;	chr6:149622669	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.886	rs9322198	ENSG00000223701.3	RAET1E-AS1	11.86	1.82e-28	3.09e-25	0.65	0.49	Lung cancer;	chr6:149623772	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.923	rs9689599	ENSG00000223701.3	RAET1E-AS1	11.86	1.82e-28	3.09e-25	0.65	0.49	Lung cancer;	chr6:149631973	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.923	rs9800580	ENSG00000223701.3	RAET1E-AS1	11.86	1.82e-28	3.09e-25	0.65	0.49	Lung cancer;	chr6:149632845	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.884	rs11155669	ENSG00000223701.3	RAET1E-AS1	11.86	1.82e-28	3.09e-25	0.65	0.49	Lung cancer;	chr6:149633501	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.887	rs9505824	ENSG00000223701.3	RAET1E-AS1	11.86	1.82e-28	3.09e-25	0.65	0.49	Lung cancer;	chr6:149633663	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.923	rs9766886	ENSG00000223701.3	RAET1E-AS1	11.86	1.82e-28	3.09e-25	0.65	0.49	Lung cancer;	chr6:149637048	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.923	rs7740278	ENSG00000223701.3	RAET1E-AS1	11.86	1.82e-28	3.09e-25	0.65	0.49	Lung cancer;	chr6:149640116	chr6:149884431~149919508:+
PRAD	cis	rs11105298	0.891	rs10777162	ENSG00000258302.2	RP11-981P6.1	11.86	1.82e-28	3.1e-25	0.54	0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89436746	chr12:89561129~89594878:+
PRAD	cis	rs71403859	0.502	rs35394108	ENSG00000260886.1	TAT-AS1	11.86	1.83e-28	3.11e-25	0.83	0.49	Post bronchodilator FEV1;	chr16:71506736	chr16:71565789~71578187:+
PRAD	cis	rs2739330	0.791	rs4822458	ENSG00000235689.1	AP000351.13	11.86	1.86e-28	3.16e-25	0.58	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:24006305~24008258:-
PRAD	cis	rs9532669	0.926	rs9532659	ENSG00000176268.5	CYCSP34	11.86	1.87e-28	3.18e-25	0.51	0.49	Cervical cancer;	chr13:40920380	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.89	rs9594457	ENSG00000176268.5	CYCSP34	11.86	1.87e-28	3.18e-25	0.51	0.49	Cervical cancer;	chr13:40920439	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.926	rs9594458	ENSG00000176268.5	CYCSP34	11.86	1.87e-28	3.18e-25	0.51	0.49	Cervical cancer;	chr13:40920448	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.926	rs9590562	ENSG00000176268.5	CYCSP34	11.86	1.87e-28	3.18e-25	0.51	0.49	Cervical cancer;	chr13:40920503	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.963	rs12857052	ENSG00000176268.5	CYCSP34	11.86	1.87e-28	3.18e-25	0.51	0.49	Cervical cancer;	chr13:40920831	chr13:40863599~40863902:-
PRAD	cis	rs780096	0.545	rs2280737	ENSG00000234072.1	AC074117.10	-11.86	1.88e-28	3.2e-25	-0.38	-0.49	Total body bone mineral density;	chr2:27366943	chr2:27356246~27367622:+
PRAD	cis	rs875971	0.545	rs10950025	ENSG00000237310.1	GS1-124K5.4	11.86	1.89e-28	3.21e-25	0.49	0.49	Aortic root size;	chr7:66158946	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.52	rs12666485	ENSG00000237310.1	GS1-124K5.4	11.86	1.89e-28	3.21e-25	0.49	0.49	Aortic root size;	chr7:66160135	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.545	rs67688847	ENSG00000237310.1	GS1-124K5.4	11.86	1.89e-28	3.21e-25	0.49	0.49	Aortic root size;	chr7:66161064	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.545	rs7787063	ENSG00000237310.1	GS1-124K5.4	11.86	1.89e-28	3.21e-25	0.49	0.49	Aortic root size;	chr7:66164012	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.545	rs12673308	ENSG00000237310.1	GS1-124K5.4	11.86	1.89e-28	3.21e-25	0.49	0.49	Aortic root size;	chr7:66166374	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.545	rs67397473	ENSG00000237310.1	GS1-124K5.4	11.86	1.89e-28	3.21e-25	0.49	0.49	Aortic root size;	chr7:66168318	chr7:66493706~66495474:+
PRAD	cis	rs9487094	0.961	rs12209691	ENSG00000260273.1	RP11-425D10.10	11.86	1.9e-28	3.22e-25	0.7	0.49	Height;	chr6:109465229	chr6:109382795~109383666:+
PRAD	cis	rs7684253	0.565	rs6830774	ENSG00000269949.1	RP11-738E22.3	-11.86	1.9e-28	3.23e-25	-0.55	-0.49	Migraine;	chr4:56950140	chr4:56960927~56961373:-
PRAD	cis	rs7240205	0.593	rs113592062	ENSG00000275805.1	RP11-349H17.2	-11.86	1.91e-28	3.25e-25	-0.64	-0.49	Breast cancer;	chr18:26566829	chr18:26565723~26575626:-
PRAD	cis	rs6991838	0.584	rs34226237	ENSG00000272010.1	CTD-3025N20.3	-11.86	1.92e-28	3.26e-25	-0.51	-0.49	Intelligence (multi-trait analysis);	chr8:65600930	chr8:65591850~65592472:-
PRAD	cis	rs6991838	0.584	rs6994213	ENSG00000272010.1	CTD-3025N20.3	-11.86	1.92e-28	3.26e-25	-0.51	-0.49	Intelligence (multi-trait analysis);	chr8:65601497	chr8:65591850~65592472:-
PRAD	cis	rs2933343	0.951	rs796862	ENSG00000231305.3	RP11-723O4.2	11.86	1.92e-28	3.27e-25	0.49	0.49	IgG glycosylation;	chr3:128874197	chr3:128861313~128871540:-
PRAD	cis	rs2019137	0.868	rs3748916	ENSG00000189223.12	PAX8-AS1	11.86	1.94e-28	3.3e-25	0.6	0.49	Lymphocyte counts;	chr2:113226456	chr2:113211522~113276581:+
PRAD	cis	rs2404602	0.684	rs1011084	ENSG00000259422.1	RP11-593F23.1	-11.85	1.95e-28	3.3e-25	-0.65	-0.49	Blood metabolite levels;	chr15:76715139	chr15:76174891~76181486:-
PRAD	cis	rs2153535	0.606	rs11243253	ENSG00000230939.1	RP11-314C16.1	11.85	1.95e-28	3.32e-25	0.6	0.49	Motion sickness;	chr6:8379960	chr6:8784178~8785445:+
PRAD	cis	rs9322193	0.886	rs4870049	ENSG00000268592.3	RAET1E-AS1	11.85	2.01e-28	3.41e-25	0.67	0.49	Lung cancer;	chr6:149837058	chr6:149863494~149919507:+
PRAD	cis	rs6504950	0.925	rs181727	ENSG00000275710.1	RP11-257O5.4	11.85	2.03e-28	3.44e-25	0.68	0.49	Breast cancer;	chr17:55113634	chr17:54964474~54964679:+
PRAD	cis	rs7044106	0.708	rs959558	ENSG00000226752.6	PSMD5-AS1	-11.85	2.03e-28	3.45e-25	-0.6	-0.49	Hip circumference adjusted for BMI;	chr9:120606633	chr9:120824828~120854385:+
PRAD	cis	rs7044106	0.718	rs10616	ENSG00000226752.6	PSMD5-AS1	-11.85	2.03e-28	3.45e-25	-0.6	-0.49	Hip circumference adjusted for BMI;	chr9:120601255	chr9:120824828~120854385:+
PRAD	cis	rs2564921	0.765	rs35333155	ENSG00000242142.1	SERBP1P3	11.85	2.04e-28	3.46e-25	0.54	0.49	Height;	chr3:53073764	chr3:53064283~53065091:-
PRAD	cis	rs9322193	0.923	rs10782310	ENSG00000223701.3	RAET1E-AS1	11.85	2.05e-28	3.47e-25	0.66	0.49	Lung cancer;	chr6:149622458	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.923	rs10782311	ENSG00000223701.3	RAET1E-AS1	11.85	2.05e-28	3.47e-25	0.66	0.49	Lung cancer;	chr6:149622592	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.923	rs9322200	ENSG00000223701.3	RAET1E-AS1	11.85	2.05e-28	3.47e-25	0.66	0.49	Lung cancer;	chr6:149630078	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.923	rs9322204	ENSG00000223701.3	RAET1E-AS1	11.85	2.05e-28	3.47e-25	0.66	0.49	Lung cancer;	chr6:149636047	chr6:149884431~149919508:+
PRAD	cis	rs9532669	0.963	rs3736953	ENSG00000176268.5	CYCSP34	11.85	2.09e-28	3.54e-25	0.5	0.49	Cervical cancer;	chr13:40951450	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.926	rs7322399	ENSG00000176268.5	CYCSP34	11.85	2.11e-28	3.57e-25	0.5	0.49	Cervical cancer;	chr13:40952511	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.926	rs7322097	ENSG00000176268.5	CYCSP34	11.85	2.11e-28	3.57e-25	0.5	0.49	Cervical cancer;	chr13:40952513	chr13:40863599~40863902:-
PRAD	cis	rs9322193	0.923	rs9689723	ENSG00000223701.3	RAET1E-AS1	11.84	2.13e-28	3.61e-25	0.66	0.49	Lung cancer;	chr6:149655935	chr6:149884431~149919508:+
PRAD	cis	rs7569084	0.687	rs1437462	ENSG00000204929.10	AC074391.1	11.84	2.15e-28	3.64e-25	0.65	0.49	Sum eosinophil basophil counts;	chr2:65449559	chr2:65436711~66084639:+
PRAD	cis	rs2404602	0.647	rs11855296	ENSG00000259422.1	RP11-593F23.1	-11.84	2.18e-28	3.69e-25	-0.65	-0.49	Blood metabolite levels;	chr15:76800621	chr15:76174891~76181486:-
PRAD	cis	rs6991838	0.584	rs57042777	ENSG00000272010.1	CTD-3025N20.3	-11.84	2.23e-28	3.78e-25	-0.5	-0.49	Intelligence (multi-trait analysis);	chr8:65576855	chr8:65591850~65592472:-
PRAD	cis	rs6991838	0.557	rs67046768	ENSG00000272010.1	CTD-3025N20.3	-11.84	2.23e-28	3.78e-25	-0.5	-0.49	Intelligence (multi-trait analysis);	chr8:65577486	chr8:65591850~65592472:-
PRAD	cis	rs9322193	0.923	rs4354168	ENSG00000223701.3	RAET1E-AS1	11.84	2.24e-28	3.79e-25	0.65	0.49	Lung cancer;	chr6:149696642	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.923	rs4455682	ENSG00000223701.3	RAET1E-AS1	11.84	2.24e-28	3.79e-25	0.65	0.49	Lung cancer;	chr6:149700161	chr6:149884431~149919508:+
PRAD	cis	rs71403859	0.667	rs12149264	ENSG00000260886.1	TAT-AS1	11.84	2.25e-28	3.8e-25	0.82	0.49	Post bronchodilator FEV1;	chr16:71687018	chr16:71565789~71578187:+
PRAD	cis	rs1061377	1	rs9990742	ENSG00000249207.1	RP11-360F5.1	-11.84	2.26e-28	3.82e-25	-0.5	-0.49	Uric acid levels;	chr4:39119794	chr4:39112677~39126818:-
PRAD	cis	rs8062405	0.656	rs7189927	ENSG00000259982.1	CDC37P1	-11.84	2.27e-28	3.83e-25	-0.67	-0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28902466	chr16:28700294~28701540:-
PRAD	cis	rs5760092	0.755	rs4585126	ENSG00000231271.1	AP000350.8	-11.84	2.27e-28	3.83e-25	-0.72	-0.49	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23949918~23954042:+
PRAD	cis	rs673078	0.607	rs11068919	ENSG00000275759.1	RP11-131L12.3	-11.84	2.3e-28	3.87e-25	-0.68	-0.49	Glucose homeostasis traits;	chr12:118354925	chr12:118428281~118428870:+
PRAD	cis	rs2933343	1	rs789227	ENSG00000231305.3	RP11-723O4.2	11.84	2.32e-28	3.91e-25	0.49	0.49	IgG glycosylation;	chr3:128881742	chr3:128861313~128871540:-
PRAD	cis	rs2933343	1	rs789232	ENSG00000231305.3	RP11-723O4.2	11.84	2.32e-28	3.91e-25	0.49	0.49	IgG glycosylation;	chr3:128884237	chr3:128861313~128871540:-
PRAD	cis	rs2933343	1	rs1683811	ENSG00000231305.3	RP11-723O4.2	11.84	2.32e-28	3.91e-25	0.49	0.49	IgG glycosylation;	chr3:128893270	chr3:128861313~128871540:-
PRAD	cis	rs11123170	0.64	rs2863240	ENSG00000189223.12	PAX8-AS1	11.84	2.32e-28	3.92e-25	0.7	0.49	Renal function-related traits (BUN);	chr2:113212539	chr2:113211522~113276581:+
PRAD	cis	rs977987	0.835	rs3863445	ENSG00000261783.1	RP11-252K23.2	-11.84	2.33e-28	3.93e-25	-0.66	-0.49	Dupuytren's disease;	chr16:75337846	chr16:75379818~75381260:-
PRAD	cis	rs3091242	1	rs3091242	ENSG00000224183.1	SDHDP6	-11.83	2.38e-28	4.01e-25	-0.56	-0.49	Erythrocyte sedimentation rate;	chr1:25348294	chr1:25294164~25294643:-
PRAD	cis	rs3091242	0.967	rs3091240	ENSG00000224183.1	SDHDP6	-11.83	2.38e-28	4.01e-25	-0.56	-0.49	Erythrocyte sedimentation rate;	chr1:25350444	chr1:25294164~25294643:-
PRAD	cis	rs9487094	0.813	rs11753645	ENSG00000260273.1	RP11-425D10.10	11.83	2.4e-28	4.04e-25	0.71	0.49	Height;	chr6:109373851	chr6:109382795~109383666:+
PRAD	cis	rs7569084	0.687	rs12614851	ENSG00000204929.10	AC074391.1	11.83	2.42e-28	4.08e-25	0.64	0.49	Sum eosinophil basophil counts;	chr2:65458050	chr2:65436711~66084639:+
PRAD	cis	rs7569084	0.687	rs1344891	ENSG00000204929.10	AC074391.1	11.83	2.42e-28	4.08e-25	0.64	0.49	Sum eosinophil basophil counts;	chr2:65458890	chr2:65436711~66084639:+
PRAD	cis	rs9322193	0.566	rs3922947	ENSG00000231760.4	RP11-350J20.5	-11.83	2.47e-28	4.16e-25	-0.73	-0.48	Lung cancer;	chr6:149924856	chr6:149796151~149826294:-
PRAD	cis	rs11155671	0.546	rs1999633	ENSG00000231760.4	RP11-350J20.5	11.83	2.47e-28	4.16e-25	0.73	0.48	Testicular germ cell tumor;	chr6:149866576	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs1080670	ENSG00000223701.3	RAET1E-AS1	11.83	2.5e-28	4.21e-25	0.65	0.48	Lung cancer;	chr6:149620161	chr6:149884431~149919508:+
PRAD	cis	rs7684253	0.565	rs12641030	ENSG00000269949.1	RP11-738E22.3	-11.83	2.51e-28	4.23e-25	-0.55	-0.48	Migraine;	chr4:56937339	chr4:56960927~56961373:-
PRAD	cis	rs7044106	0.708	rs991121	ENSG00000226752.6	PSMD5-AS1	-11.83	2.52e-28	4.25e-25	-0.6	-0.48	Hip circumference adjusted for BMI;	chr9:120608067	chr9:120824828~120854385:+
PRAD	cis	rs977987	0.835	rs4888379	ENSG00000261783.1	RP11-252K23.2	-11.83	2.55e-28	4.3e-25	-0.66	-0.48	Dupuytren's disease;	chr16:75306333	chr16:75379818~75381260:-
PRAD	cis	rs2404602	0.647	rs11072628	ENSG00000259422.1	RP11-593F23.1	-11.82	2.56e-28	4.3e-25	-0.65	-0.48	Blood metabolite levels;	chr15:76815420	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.647	rs11072631	ENSG00000259422.1	RP11-593F23.1	-11.82	2.56e-28	4.3e-25	-0.65	-0.48	Blood metabolite levels;	chr15:76840568	chr15:76174891~76181486:-
PRAD	cis	rs7617773	0.963	rs12495221	ENSG00000229759.1	MRPS18AP1	-11.82	2.58e-28	4.35e-25	-0.5	-0.48	Coronary artery disease;	chr3:48137688	chr3:48256350~48256938:-
PRAD	cis	rs4423214	0.798	rs1894100	ENSG00000254682.1	RP11-660L16.2	-11.82	2.59e-28	4.36e-25	-0.71	-0.48	Vitamin D levels;	chr11:71419297	chr11:71448674~71452157:+
PRAD	cis	rs2404602	0.684	rs10851888	ENSG00000259422.1	RP11-593F23.1	-11.82	2.63e-28	4.42e-25	-0.65	-0.48	Blood metabolite levels;	chr15:76610165	chr15:76174891~76181486:-
PRAD	cis	rs2564921	0.791	rs36033494	ENSG00000242142.1	SERBP1P3	11.82	2.65e-28	4.45e-25	0.56	0.48	Height;	chr3:53082835	chr3:53064283~53065091:-
PRAD	cis	rs5769707	0.933	rs2157444	ENSG00000188511.11	C22orf34	11.82	2.68e-28	4.5e-25	0.51	0.48	Monocyte percentage of white cells;Monocyte count;	chr22:49600644	chr22:49414524~49657542:-
PRAD	cis	rs875971	0.545	rs313830	ENSG00000237310.1	GS1-124K5.4	-11.82	2.68e-28	4.51e-25	-0.5	-0.48	Aortic root size;	chr7:66086944	chr7:66493706~66495474:+
PRAD	cis	rs8062405	0.964	rs7187333	ENSG00000251417.2	RP11-1348G14.4	-11.82	2.69e-28	4.52e-25	-0.55	-0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854595	chr16:28802743~28817828:+
PRAD	cis	rs1062177	0.855	rs6884630	ENSG00000213433.5	RPLP1P6	-11.82	2.7e-28	4.53e-25	-0.56	-0.48	Preschool internalizing problems;	chr5:151889436	chr5:151765859~151766378:-
PRAD	cis	rs12049351	0.774	rs12117468	ENSG00000229367.1	HMGN2P19	11.82	2.71e-28	4.55e-25	0.64	0.48	Circulating myeloperoxidase levels (plasma);	chr1:229535614	chr1:229570532~229570796:+
PRAD	cis	rs875971	0.545	rs2420612	ENSG00000237310.1	GS1-124K5.4	11.82	2.73e-28	4.59e-25	0.49	0.48	Aortic root size;	chr7:66536825	chr7:66493706~66495474:+
PRAD	cis	rs9487094	0.961	rs1546980	ENSG00000260273.1	RP11-425D10.10	11.82	2.76e-28	4.63e-25	0.69	0.48	Height;	chr6:109452743	chr6:109382795~109383666:+
PRAD	cis	rs4853012	0.838	rs60705299	ENSG00000257800.1	FNBP1P1	11.82	2.77e-28	4.66e-25	0.42	0.48	Gestational age at birth (maternal effect);	chr2:74118243	chr2:74120680~74123218:+
PRAD	cis	rs71403859	0.73	rs35390364	ENSG00000260886.1	TAT-AS1	11.82	2.79e-28	4.69e-25	0.88	0.48	Post bronchodilator FEV1;	chr16:71706146	chr16:71565789~71578187:+
PRAD	cis	rs6991838	0.584	rs3765205	ENSG00000272010.1	CTD-3025N20.3	-11.81	2.8e-28	4.71e-25	-0.5	-0.48	Intelligence (multi-trait analysis);	chr8:65605251	chr8:65591850~65592472:-
PRAD	cis	rs7688540	0.511	rs61794965	ENSG00000275426.1	CH17-262A2.1	11.81	2.82e-28	4.74e-25	0.77	0.48	Facial morphology (factor 6, height of vermillion lower lip);	chr4:177880	chr4:149738~150317:+
PRAD	cis	rs6991838	0.584	rs14213	ENSG00000272010.1	CTD-3025N20.3	11.81	2.84e-28	4.76e-25	0.5	0.48	Intelligence (multi-trait analysis);	chr8:65602719	chr8:65591850~65592472:-
PRAD	cis	rs2404602	0.647	rs55778276	ENSG00000259422.1	RP11-593F23.1	-11.81	2.84e-28	4.77e-25	-0.65	-0.48	Blood metabolite levels;	chr15:76844249	chr15:76174891~76181486:-
PRAD	cis	rs1577917	0.958	rs1545376	ENSG00000203875.9	SNHG5	11.81	2.84e-28	4.77e-25	0.54	0.48	Response to antipsychotic treatment;	chr6:85794864	chr6:85660950~85678736:-
PRAD	cis	rs11168854	0.595	rs11168857	ENSG00000258017.1	RP11-386G11.10	-11.81	2.86e-28	4.79e-25	-0.64	-0.48	Body mass index;	chr12:49096526	chr12:49127782~49147869:+
PRAD	cis	rs71403859	0.667	rs12924650	ENSG00000260886.1	TAT-AS1	11.81	2.86e-28	4.8e-25	0.83	0.48	Post bronchodilator FEV1;	chr16:71672005	chr16:71565789~71578187:+
PRAD	cis	rs11690935	0.731	rs10930491	ENSG00000228389.1	AC068039.4	-11.81	2.88e-28	4.84e-25	-0.54	-0.48	Schizophrenia;	chr2:171713314	chr2:171773482~171775844:+
PRAD	cis	rs9487094	0.778	rs6914498	ENSG00000260273.1	RP11-425D10.10	11.81	2.92e-28	4.9e-25	0.68	0.48	Height;	chr6:109613205	chr6:109382795~109383666:+
PRAD	cis	rs1577917	0.687	rs1470531	ENSG00000203875.9	SNHG5	-11.81	2.92e-28	4.9e-25	-0.54	-0.48	Response to antipsychotic treatment;	chr6:85797651	chr6:85660950~85678736:-
PRAD	cis	rs9532669	0.963	rs9562238	ENSG00000176268.5	CYCSP34	11.81	2.93e-28	4.91e-25	0.5	0.48	Cervical cancer;	chr13:40924785	chr13:40863599~40863902:-
PRAD	cis	rs9487094	0.961	rs12190920	ENSG00000260273.1	RP11-425D10.10	11.81	2.95e-28	4.95e-25	0.7	0.48	Height;	chr6:109479396	chr6:109382795~109383666:+
PRAD	cis	rs9487094	0.922	rs59056467	ENSG00000260273.1	RP11-425D10.10	11.81	2.97e-28	4.98e-25	0.69	0.48	Height;	chr6:109446728	chr6:109382795~109383666:+
PRAD	cis	rs673078	0.607	rs4767671	ENSG00000275759.1	RP11-131L12.3	-11.81	2.99e-28	5.01e-25	-0.76	-0.48	Glucose homeostasis traits;	chr12:118396038	chr12:118428281~118428870:+
PRAD	cis	rs2739330	0.828	rs4820572	ENSG00000231271.1	AP000350.8	11.81	3.03e-28	5.07e-25	0.66	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23949918~23954042:+
PRAD	cis	rs11105298	0.891	rs3741898	ENSG00000258302.2	RP11-981P6.1	11.81	3.06e-28	5.12e-25	0.54	0.48	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89539986	chr12:89561129~89594878:+
PRAD	cis	rs11105298	0.891	rs3741899	ENSG00000258302.2	RP11-981P6.1	11.81	3.06e-28	5.12e-25	0.54	0.48	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89540154	chr12:89561129~89594878:+
PRAD	cis	rs11105298	0.891	rs10858906	ENSG00000258302.2	RP11-981P6.1	11.81	3.06e-28	5.12e-25	0.54	0.48	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89540697	chr12:89561129~89594878:+
PRAD	cis	rs8072100	1	rs11650372	ENSG00000228782.6	CTD-2026D20.3	11.81	3.06e-28	5.13e-25	0.54	0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47644429	chr17:47450568~47492492:-
PRAD	cis	rs8072100	1	rs8065669	ENSG00000228782.6	CTD-2026D20.3	11.81	3.06e-28	5.13e-25	0.54	0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47647630	chr17:47450568~47492492:-
PRAD	cis	rs4853012	0.838	rs4452177	ENSG00000257800.1	FNBP1P1	11.8	3.07e-28	5.15e-25	0.42	0.48	Gestational age at birth (maternal effect);	chr2:74118079	chr2:74120680~74123218:+
PRAD	cis	rs9532669	0.853	rs9315795	ENSG00000176268.5	CYCSP34	11.8	3.1e-28	5.2e-25	0.5	0.48	Cervical cancer;	chr13:40943382	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.963	rs3764056	ENSG00000176268.5	CYCSP34	11.8	3.1e-28	5.2e-25	0.5	0.48	Cervical cancer;	chr13:40943849	chr13:40863599~40863902:-
PRAD	cis	rs4722166	0.597	rs1554606	ENSG00000179428.2	AC073072.5	-11.8	3.12e-28	5.22e-25	-0.56	-0.48	Lung cancer;	chr7:22729088	chr7:22725395~22727620:-
PRAD	cis	rs9487094	0.922	rs13204102	ENSG00000260273.1	RP11-425D10.10	11.8	3.15e-28	5.27e-25	0.68	0.48	Height;	chr6:109617741	chr6:109382795~109383666:+
PRAD	cis	rs9487094	0.922	rs10499053	ENSG00000260273.1	RP11-425D10.10	11.8	3.15e-28	5.27e-25	0.68	0.48	Height;	chr6:109619295	chr6:109382795~109383666:+
PRAD	cis	rs2658782	0.951	rs72972364	ENSG00000279684.1	RP11-755E23.2	11.8	3.15e-28	5.28e-25	0.82	0.48	Pulmonary function decline;	chr11:93388962	chr11:93286629~93288903:-
PRAD	cis	rs1062177	0.855	rs1346489	ENSG00000213433.5	RPLP1P6	-11.8	3.17e-28	5.3e-25	-0.55	-0.48	Preschool internalizing problems;	chr5:151886973	chr5:151765859~151766378:-
PRAD	cis	rs6504950	0.925	rs2787483	ENSG00000275710.1	RP11-257O5.4	11.8	3.17e-28	5.3e-25	0.68	0.48	Breast cancer;	chr17:55132953	chr17:54964474~54964679:+
PRAD	cis	rs1062177	1	rs2915887	ENSG00000213433.5	RPLP1P6	-11.8	3.18e-28	5.31e-25	-0.57	-0.48	Preschool internalizing problems;	chr5:151825943	chr5:151765859~151766378:-
PRAD	cis	rs11676348	0.703	rs6737563	ENSG00000261338.2	RP11-378A13.1	-11.8	3.18e-28	5.32e-25	-0.56	-0.48	Ulcerative colitis;	chr2:218080951	chr2:218255319~218257366:+
PRAD	cis	rs7617773	0.963	rs9822496	ENSG00000229759.1	MRPS18AP1	11.8	3.18e-28	5.33e-25	0.5	0.48	Coronary artery disease;	chr3:48139843	chr3:48256350~48256938:-
PRAD	cis	rs9322193	0.847	rs12234128	ENSG00000223701.3	RAET1E-AS1	11.8	3.2e-28	5.35e-25	0.65	0.48	Lung cancer;	chr6:149627553	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.923	rs57012784	ENSG00000223701.3	RAET1E-AS1	11.8	3.2e-28	5.35e-25	0.65	0.48	Lung cancer;	chr6:149627691	chr6:149884431~149919508:+
PRAD	cis	rs55794721	0.543	rs1293260	ENSG00000224183.1	SDHDP6	-11.8	3.21e-28	5.36e-25	-0.56	-0.48	Mean corpuscular volume;Plateletcrit;	chr1:25382613	chr1:25294164~25294643:-
PRAD	cis	rs7569084	0.663	rs1437461	ENSG00000204929.10	AC074391.1	11.8	3.22e-28	5.38e-25	0.65	0.48	Sum eosinophil basophil counts;	chr2:65452578	chr2:65436711~66084639:+
PRAD	cis	rs7569084	0.687	rs7562559	ENSG00000204929.10	AC074391.1	11.8	3.22e-28	5.38e-25	0.65	0.48	Sum eosinophil basophil counts;	chr2:65452719	chr2:65436711~66084639:+
PRAD	cis	rs9322193	0.923	rs9800871	ENSG00000268592.3	RAET1E-AS1	11.8	3.24e-28	5.41e-25	0.67	0.48	Lung cancer;	chr6:149644540	chr6:149863494~149919507:+
PRAD	cis	rs2739330	0.828	rs2330635	ENSG00000231271.1	AP000350.8	11.8	3.25e-28	5.43e-25	0.66	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23949918~23954042:+
PRAD	cis	rs11105298	0.891	rs12369195	ENSG00000258302.2	RP11-981P6.1	11.8	3.26e-28	5.45e-25	0.54	0.48	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89541195	chr12:89561129~89594878:+
PRAD	cis	rs9322193	0.884	rs1125	ENSG00000223701.3	RAET1E-AS1	11.8	3.27e-28	5.46e-25	0.67	0.48	Lung cancer;	chr6:149658280	chr6:149884431~149919508:+
PRAD	cis	rs8062405	0.824	rs62034319	ENSG00000259982.1	CDC37P1	11.8	3.27e-28	5.47e-25	0.62	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520867	chr16:28700294~28701540:-
PRAD	cis	rs6504950	0.925	rs244358	ENSG00000275710.1	RP11-257O5.4	11.8	3.27e-28	5.47e-25	0.68	0.48	Breast cancer;	chr17:55114870	chr17:54964474~54964679:+
PRAD	cis	rs8062405	0.755	rs4788073	ENSG00000259982.1	CDC37P1	11.8	3.29e-28	5.5e-25	0.63	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28583228	chr16:28700294~28701540:-
PRAD	cis	rs8062405	0.755	rs55792032	ENSG00000259982.1	CDC37P1	11.8	3.29e-28	5.5e-25	0.63	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28588090	chr16:28700294~28701540:-
PRAD	cis	rs9322193	0.566	rs6912330	ENSG00000231760.4	RP11-350J20.5	-11.8	3.31e-28	5.52e-25	-0.75	-0.48	Lung cancer;	chr6:149908811	chr6:149796151~149826294:-
PRAD	cis	rs2404602	0.735	rs11637490	ENSG00000259422.1	RP11-593F23.1	-11.8	3.32e-28	5.54e-25	-0.61	-0.48	Blood metabolite levels;	chr15:76467224	chr15:76174891~76181486:-
PRAD	cis	rs6504950	0.925	rs2787481	ENSG00000275710.1	RP11-257O5.4	-11.8	3.33e-28	5.55e-25	-0.67	-0.48	Breast cancer;	chr17:55133749	chr17:54964474~54964679:+
PRAD	cis	rs9487094	0.961	rs1358998	ENSG00000260273.1	RP11-425D10.10	-11.8	3.33e-28	5.56e-25	-0.69	-0.48	Height;	chr6:109380015	chr6:109382795~109383666:+
PRAD	cis	rs1976403	0.659	rs10799701	ENSG00000227001.3	NBPF2P	11.8	3.34e-28	5.58e-25	0.57	0.48	Liver enzyme levels (alkaline phosphatase);	chr1:21494497	chr1:21424625~21427967:-
PRAD	cis	rs6991838	0.584	rs7841652	ENSG00000272010.1	CTD-3025N20.3	-11.8	3.36e-28	5.6e-25	-0.5	-0.48	Intelligence (multi-trait analysis);	chr8:65606392	chr8:65591850~65592472:-
PRAD	cis	rs875971	0.545	rs1796222	ENSG00000237310.1	GS1-124K5.4	-11.79	3.36e-28	5.61e-25	-0.49	-0.48	Aortic root size;	chr7:66592167	chr7:66493706~66495474:+
PRAD	cis	rs7727544	0.735	rs272884	ENSG00000233006.5	AC034220.3	11.79	3.4e-28	5.66e-25	0.43	0.48	Blood metabolite levels;	chr5:132332961	chr5:132311285~132369916:-
PRAD	cis	rs7727544	0.735	rs272881	ENSG00000233006.5	AC034220.3	11.79	3.4e-28	5.66e-25	0.43	0.48	Blood metabolite levels;	chr5:132333571	chr5:132311285~132369916:-
PRAD	cis	rs7727544	0.735	rs272879	ENSG00000233006.5	AC034220.3	11.79	3.4e-28	5.66e-25	0.43	0.48	Blood metabolite levels;	chr5:132334853	chr5:132311285~132369916:-
PRAD	cis	rs9322193	0.923	rs11155670	ENSG00000268592.3	RAET1E-AS1	11.79	3.4e-28	5.67e-25	0.67	0.48	Lung cancer;	chr6:149644992	chr6:149863494~149919507:+
PRAD	cis	rs8062405	0.755	rs12447461	ENSG00000259982.1	CDC37P1	11.79	3.41e-28	5.69e-25	0.63	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28571620	chr16:28700294~28701540:-
PRAD	cis	rs673078	0.562	rs61944668	ENSG00000275759.1	RP11-131L12.3	-11.79	3.42e-28	5.71e-25	-0.75	-0.48	Glucose homeostasis traits;	chr12:118448446	chr12:118428281~118428870:+
PRAD	cis	rs9322193	0.566	rs9397070	ENSG00000231760.4	RP11-350J20.5	-11.79	3.43e-28	5.72e-25	-0.75	-0.48	Lung cancer;	chr6:149922073	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.566	rs4869767	ENSG00000231760.4	RP11-350J20.5	-11.79	3.43e-28	5.72e-25	-0.74	-0.48	Lung cancer;	chr6:149923974	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.566	rs4869768	ENSG00000231760.4	RP11-350J20.5	-11.79	3.43e-28	5.72e-25	-0.74	-0.48	Lung cancer;	chr6:149924067	chr6:149796151~149826294:-
PRAD	cis	rs7727544	0.735	rs270605	ENSG00000233006.5	AC034220.3	11.79	3.47e-28	5.78e-25	0.43	0.48	Blood metabolite levels;	chr5:132316118	chr5:132311285~132369916:-
PRAD	cis	rs3096299	0.504	rs4785574	ENSG00000274627.1	RP11-104N10.2	11.79	3.48e-28	5.79e-25	0.5	0.48	Multiple myeloma (IgH translocation);	chr16:89502467	chr16:89516797~89522217:+
PRAD	cis	rs9487094	0.885	rs2208209	ENSG00000260273.1	RP11-425D10.10	11.79	3.48e-28	5.8e-25	0.68	0.48	Height;	chr6:109581800	chr6:109382795~109383666:+
PRAD	cis	rs9487094	0.922	rs12208933	ENSG00000260273.1	RP11-425D10.10	11.79	3.48e-28	5.8e-25	0.68	0.48	Height;	chr6:109582583	chr6:109382795~109383666:+
PRAD	cis	rs6003958	1	rs6003958	ENSG00000250470.1	AP000351.3	-11.79	3.52e-28	5.87e-25	-0.78	-0.48	S-phenylmercapturic acid levels in smokers;	chr22:23921902	chr22:23976904~23977585:-
PRAD	cis	rs5760092	0.755	rs6003959	ENSG00000250470.1	AP000351.3	-11.79	3.52e-28	5.87e-25	-0.78	-0.48	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23922208	chr22:23976904~23977585:-
PRAD	cis	rs780096	0.545	rs6716894	ENSG00000234072.1	AC074117.10	-11.79	3.56e-28	5.93e-25	-0.38	-0.48	Total body bone mineral density;	chr2:27360406	chr2:27356246~27367622:+
PRAD	cis	rs2404602	0.647	rs11072618	ENSG00000259422.1	RP11-593F23.1	-11.79	3.57e-28	5.94e-25	-0.65	-0.48	Blood metabolite levels;	chr15:76727001	chr15:76174891~76181486:-
PRAD	cis	rs9532669	0.963	rs9315794	ENSG00000176268.5	CYCSP34	11.79	3.59e-28	5.97e-25	0.5	0.48	Cervical cancer;	chr13:40939489	chr13:40863599~40863902:-
PRAD	cis	rs71403859	0.73	rs71386933	ENSG00000260886.1	TAT-AS1	11.79	3.59e-28	5.97e-25	0.89	0.48	Post bronchodilator FEV1;	chr16:71787897	chr16:71565789~71578187:+
PRAD	cis	rs2739330	0.828	rs5760107	ENSG00000231271.1	AP000350.8	11.79	3.6e-28	5.99e-25	0.66	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23949918~23954042:+
PRAD	cis	rs2739330	0.789	rs5760109	ENSG00000231271.1	AP000350.8	11.79	3.6e-28	5.99e-25	0.66	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23949918~23954042:+
PRAD	cis	rs1075265	0.68	rs6715488	ENSG00000233266.1	HMGB1P31	11.79	3.61e-28	6.01e-25	0.65	0.48	Chronotype;Morning vs. evening chronotype;	chr2:54004130	chr2:54051334~54051760:+
PRAD	cis	rs1075265	0.73	rs7597188	ENSG00000233266.1	HMGB1P31	11.79	3.61e-28	6.01e-25	0.65	0.48	Chronotype;Morning vs. evening chronotype;	chr2:54014732	chr2:54051334~54051760:+
PRAD	cis	rs9322193	0.923	rs9766037	ENSG00000223701.3	RAET1E-AS1	11.79	3.64e-28	6.05e-25	0.66	0.48	Lung cancer;	chr6:149616921	chr6:149884431~149919508:+
PRAD	cis	rs8062405	0.755	rs4788074	ENSG00000259982.1	CDC37P1	-11.79	3.65e-28	6.08e-25	-0.63	-0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582276	chr16:28700294~28701540:-
PRAD	cis	rs9322193	0.607	rs12209310	ENSG00000231760.4	RP11-350J20.5	11.79	3.66e-28	6.08e-25	0.75	0.48	Lung cancer;	chr6:149904882	chr6:149796151~149826294:-
PRAD	cis	rs748404	0.56	rs689797	ENSG00000205771.5	CATSPER2P1	-11.79	3.67e-28	6.11e-25	-0.56	-0.48	Lung cancer;	chr15:43534359	chr15:43726918~43747094:-
PRAD	cis	rs5760092	0.618	rs4461358	ENSG00000273295.1	AP000350.5	-11.78	3.7e-28	6.15e-25	-0.66	-0.48	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23917919	chr22:23901432~23907068:-
PRAD	cis	rs8062405	0.824	rs4788085	ENSG00000259982.1	CDC37P1	11.78	3.72e-28	6.18e-25	0.62	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523682	chr16:28700294~28701540:-
PRAD	cis	rs8062405	0.824	rs28772958	ENSG00000259982.1	CDC37P1	11.78	3.72e-28	6.18e-25	0.62	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523984	chr16:28700294~28701540:-
PRAD	cis	rs9322193	0.923	rs9968911	ENSG00000268592.3	RAET1E-AS1	11.78	3.73e-28	6.2e-25	0.67	0.48	Lung cancer;	chr6:149657419	chr6:149863494~149919507:+
PRAD	cis	rs875971	0.502	rs6460311	ENSG00000237310.1	GS1-124K5.4	-11.78	3.79e-28	6.29e-25	-0.49	-0.48	Aortic root size;	chr7:66646886	chr7:66493706~66495474:+
PRAD	cis	rs2658782	0.789	rs3020073	ENSG00000279684.1	RP11-755E23.2	-11.78	3.81e-28	6.32e-25	-0.76	-0.48	Pulmonary function decline;	chr11:93370664	chr11:93286629~93288903:-
PRAD	cis	rs9322193	0.923	rs9800736	ENSG00000268592.3	RAET1E-AS1	11.78	3.82e-28	6.34e-25	0.66	0.48	Lung cancer;	chr6:149661281	chr6:149863494~149919507:+
PRAD	cis	rs9532669	0.926	rs8002809	ENSG00000176268.5	CYCSP34	11.78	3.83e-28	6.37e-25	0.5	0.48	Cervical cancer;	chr13:40872769	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.929	rs7982421	ENSG00000176268.5	CYCSP34	11.78	3.83e-28	6.37e-25	0.5	0.48	Cervical cancer;	chr13:40872776	chr13:40863599~40863902:-
PRAD	cis	rs3814244	0.528	rs2906859	ENSG00000255733.4	IFNG-AS1	11.78	3.95e-28	6.55e-25	0.51	0.48	Itch intensity from mosquito bite adjusted by bite size;	chr12:68002355	chr12:67989445~68234686:+
PRAD	cis	rs16828019	0.852	rs12045171	ENSG00000235358.1	RP11-399E6.1	11.78	3.95e-28	6.56e-25	0.85	0.48	Intelligence (multi-trait analysis);	chr1:41063133	chr1:41242373~41284861:+
PRAD	cis	rs875971	0.545	rs73136346	ENSG00000237310.1	GS1-124K5.4	-11.78	3.95e-28	6.56e-25	-0.5	-0.48	Aortic root size;	chr7:66101095	chr7:66493706~66495474:+
PRAD	cis	rs11603023	0.967	rs494560	ENSG00000255239.1	AP002954.6	-11.77	4.04e-28	6.69e-25	-0.6	-0.48	Cholesterol, total;	chr11:118650844	chr11:118688039~118690600:-
PRAD	cis	rs1185460	0.967	rs1184902	ENSG00000271751.1	RP11-110I1.14	-11.77	4.04e-28	6.71e-25	-0.67	-0.48	Coronary artery disease;	chr11:119074627	chr11:119065263~119065677:-
PRAD	cis	rs9487094	0.885	rs59906308	ENSG00000260273.1	RP11-425D10.10	11.77	4.06e-28	6.73e-25	0.69	0.48	Height;	chr6:109438349	chr6:109382795~109383666:+
PRAD	cis	rs9487094	0.922	rs1048203	ENSG00000260273.1	RP11-425D10.10	11.77	4.06e-28	6.73e-25	0.69	0.48	Height;	chr6:109441033	chr6:109382795~109383666:+
PRAD	cis	rs9322193	0.923	rs4870050	ENSG00000216906.2	RP11-350J20.9	11.77	4.07e-28	6.74e-25	0.56	0.48	Lung cancer;	chr6:149838917	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.962	rs7752089	ENSG00000216906.2	RP11-350J20.9	11.77	4.07e-28	6.74e-25	0.56	0.48	Lung cancer;	chr6:149839298	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.923	rs4242279	ENSG00000216906.2	RP11-350J20.9	11.77	4.07e-28	6.74e-25	0.56	0.48	Lung cancer;	chr6:149839815	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.884	rs2064521	ENSG00000223701.3	RAET1E-AS1	-11.77	4.09e-28	6.78e-25	-0.65	-0.48	Lung cancer;	chr6:149625336	chr6:149884431~149919508:+
PRAD	cis	rs12049351	0.774	rs1065675	ENSG00000229367.1	HMGN2P19	11.77	4.1e-28	6.8e-25	0.65	0.48	Circulating myeloperoxidase levels (plasma);	chr1:229486415	chr1:229570532~229570796:+
PRAD	cis	rs1426063	0.614	rs17000262	ENSG00000249717.1	RP11-44F21.3	11.77	4.13e-28	6.84e-25	1.03	0.48	QT interval;	chr4:75108836	chr4:74955974~74970362:-
PRAD	cis	rs11123170	0.543	rs2863242	ENSG00000189223.12	PAX8-AS1	-11.77	4.13e-28	6.84e-25	-0.75	-0.48	Renal function-related traits (BUN);	chr2:113231659	chr2:113211522~113276581:+
PRAD	cis	rs2134046	0.555	rs11854483	ENSG00000278603.1	RP13-608F4.5	11.77	4.13e-28	6.85e-25	0.59	0.48	Cognitive ability;	chr15:82267217	chr15:82472203~82472426:+
PRAD	cis	rs1062177	0.855	rs6892117	ENSG00000213433.5	RPLP1P6	11.77	4.15e-28	6.88e-25	0.54	0.48	Preschool internalizing problems;	chr5:151885424	chr5:151765859~151766378:-
PRAD	cis	rs9322193	0.923	rs9505826	ENSG00000223701.3	RAET1E-AS1	11.77	4.18e-28	6.92e-25	0.65	0.48	Lung cancer;	chr6:149633912	chr6:149884431~149919508:+
PRAD	cis	rs6991838	0.584	rs4275254	ENSG00000272010.1	CTD-3025N20.3	-11.77	4.27e-28	7.08e-25	-0.5	-0.48	Intelligence (multi-trait analysis);	chr8:65589129	chr8:65591850~65592472:-
PRAD	cis	rs35160687	0.901	rs35762338	ENSG00000273080.1	RP11-301O19.1	11.77	4.27e-28	7.08e-25	0.57	0.48	Night sleep phenotypes;	chr2:86286430	chr2:86195590~86196049:+
PRAD	cis	rs35160687	0.901	rs12714179	ENSG00000273080.1	RP11-301O19.1	11.77	4.27e-28	7.08e-25	0.57	0.48	Night sleep phenotypes;	chr2:86287835	chr2:86195590~86196049:+
PRAD	cis	rs9322193	0.884	rs11155675	ENSG00000223701.3	RAET1E-AS1	11.77	4.29e-28	7.1e-25	0.66	0.48	Lung cancer;	chr6:149742883	chr6:149884431~149919508:+
PRAD	cis	rs2739330	0.796	rs5760097	ENSG00000231271.1	AP000350.8	11.77	4.33e-28	7.17e-25	0.66	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23949918~23954042:+
PRAD	cis	rs5760092	0.755	rs11090298	ENSG00000250470.1	AP000351.3	-11.77	4.34e-28	7.18e-25	-0.78	-0.48	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919874	chr22:23976904~23977585:-
PRAD	cis	rs9487094	0.813	rs3799835	ENSG00000260273.1	RP11-425D10.10	11.77	4.36e-28	7.22e-25	0.7	0.48	Height;	chr6:109372084	chr6:109382795~109383666:+
PRAD	cis	rs9487094	0.813	rs34131679	ENSG00000260273.1	RP11-425D10.10	11.77	4.36e-28	7.22e-25	0.7	0.48	Height;	chr6:109375848	chr6:109382795~109383666:+
PRAD	cis	rs9532669	0.926	rs9532691	ENSG00000176268.5	CYCSP34	-11.77	4.36e-28	7.22e-25	-0.49	-0.48	Cervical cancer;	chr13:40969358	chr13:40863599~40863902:-
PRAD	cis	rs9322193	0.847	rs4870054	ENSG00000268592.3	RAET1E-AS1	11.77	4.38e-28	7.24e-25	0.67	0.48	Lung cancer;	chr6:149848402	chr6:149863494~149919507:+
PRAD	cis	rs732716	0.74	rs62129356	ENSG00000267769.1	CTB-50L17.9	-11.77	4.38e-28	7.26e-25	-0.55	-0.48	Mean corpuscular volume;	chr19:4400317	chr19:4454014~4455286:+
PRAD	cis	rs2117029	0.521	rs7953169	ENSG00000258017.1	RP11-386G11.10	-11.76	4.45e-28	7.37e-25	-0.63	-0.48	Intelligence (multi-trait analysis);	chr12:49184389	chr12:49127782~49147869:+
PRAD	cis	rs2933343	1	rs2929859	ENSG00000231305.3	RP11-723O4.2	11.76	4.49e-28	7.42e-25	0.48	0.48	IgG glycosylation;	chr3:128889498	chr3:128861313~128871540:-
PRAD	cis	rs9487094	0.922	rs2275650	ENSG00000260273.1	RP11-425D10.10	11.76	4.49e-28	7.42e-25	0.68	0.48	Height;	chr6:109347085	chr6:109382795~109383666:+
PRAD	cis	rs9487094	0.885	rs3818934	ENSG00000260273.1	RP11-425D10.10	11.76	4.49e-28	7.42e-25	0.68	0.48	Height;	chr6:109347277	chr6:109382795~109383666:+
PRAD	cis	rs2739330	0.828	rs4822454	ENSG00000231271.1	AP000350.8	11.76	4.51e-28	7.45e-25	0.66	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23949918~23954042:+
PRAD	cis	rs73086581	0.838	rs73088424	ENSG00000229539.1	RP11-119B16.2	11.76	4.51e-28	7.45e-25	0.83	0.48	Response to antidepressants in depression;	chr20:4020359	chr20:3888239~3888868:-
PRAD	cis	rs1062177	0.95	rs59580263	ENSG00000213433.5	RPLP1P6	-11.76	4.51e-28	7.45e-25	-0.58	-0.48	Preschool internalizing problems;	chr5:151890016	chr5:151765859~151766378:-
PRAD	cis	rs9487094	0.961	rs3778477	ENSG00000260273.1	RP11-425D10.10	11.76	4.56e-28	7.54e-25	0.69	0.48	Height;	chr6:109454855	chr6:109382795~109383666:+
PRAD	cis	rs9322193	0.566	rs4870118	ENSG00000231760.4	RP11-350J20.5	-11.76	4.59e-28	7.58e-25	-0.74	-0.48	Lung cancer;	chr6:149923877	chr6:149796151~149826294:-
PRAD	cis	rs7569084	0.687	rs1370394	ENSG00000204929.10	AC074391.1	11.76	4.6e-28	7.59e-25	0.64	0.48	Sum eosinophil basophil counts;	chr2:65453176	chr2:65436711~66084639:+
PRAD	cis	rs2117029	0.521	rs58336603	ENSG00000258017.1	RP11-386G11.10	-11.76	4.61e-28	7.62e-25	-0.63	-0.48	Intelligence (multi-trait analysis);	chr12:49163105	chr12:49127782~49147869:+
PRAD	cis	rs2117029	0.553	rs1991427	ENSG00000258017.1	RP11-386G11.10	-11.76	4.61e-28	7.62e-25	-0.63	-0.48	Intelligence (multi-trait analysis);	chr12:49164175	chr12:49127782~49147869:+
PRAD	cis	rs2117029	0.521	rs6580702	ENSG00000258017.1	RP11-386G11.10	-11.76	4.61e-28	7.62e-25	-0.63	-0.48	Intelligence (multi-trait analysis);	chr12:49169483	chr12:49127782~49147869:+
PRAD	cis	rs7044106	0.791	rs4836830	ENSG00000226752.6	PSMD5-AS1	-11.76	4.63e-28	7.65e-25	-0.6	-0.48	Hip circumference adjusted for BMI;	chr9:120721390	chr9:120824828~120854385:+
PRAD	cis	rs9322193	0.923	rs2342765	ENSG00000216906.2	RP11-350J20.9	11.76	4.65e-28	7.68e-25	0.56	0.48	Lung cancer;	chr6:149858873	chr6:149904243~149906418:+
PRAD	cis	rs9532669	0.963	rs4343141	ENSG00000176268.5	CYCSP34	11.76	4.68e-28	7.73e-25	0.5	0.48	Cervical cancer;	chr13:40940497	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.963	rs3887418	ENSG00000176268.5	CYCSP34	11.76	4.68e-28	7.73e-25	0.5	0.48	Cervical cancer;	chr13:40940560	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.926	rs1056820	ENSG00000176268.5	CYCSP34	11.76	4.68e-28	7.73e-25	0.5	0.48	Cervical cancer;	chr13:40941150	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.926	rs9532678	ENSG00000176268.5	CYCSP34	11.76	4.68e-28	7.73e-25	0.5	0.48	Cervical cancer;	chr13:40941862	chr13:40863599~40863902:-
PRAD	cis	rs875971	0.545	rs11766183	ENSG00000237310.1	GS1-124K5.4	11.76	4.69e-28	7.75e-25	0.49	0.48	Aortic root size;	chr7:66374173	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.545	rs1065265	ENSG00000237310.1	GS1-124K5.4	11.76	4.69e-28	7.75e-25	0.49	0.48	Aortic root size;	chr7:66376216	chr7:66493706~66495474:+
PRAD	cis	rs1062177	0.855	rs62395861	ENSG00000213433.5	RPLP1P6	-11.76	4.72e-28	7.79e-25	-0.58	-0.48	Preschool internalizing problems;	chr5:151889709	chr5:151765859~151766378:-
PRAD	cis	rs875971	0.545	rs2279757	ENSG00000237310.1	GS1-124K5.4	11.76	4.74e-28	7.83e-25	0.49	0.48	Aortic root size;	chr7:66363676	chr7:66493706~66495474:+
PRAD	cis	rs7569084	0.687	rs7577452	ENSG00000204929.10	AC074391.1	11.76	4.79e-28	7.9e-25	0.64	0.48	Sum eosinophil basophil counts;	chr2:65456694	chr2:65436711~66084639:+
PRAD	cis	rs9487094	0.778	rs11757877	ENSG00000260273.1	RP11-425D10.10	11.75	4.84e-28	7.99e-25	0.7	0.48	Height;	chr6:109360679	chr6:109382795~109383666:+
PRAD	cis	rs8062405	1	rs12446589	ENSG00000251417.2	RP11-1348G14.4	-11.75	4.85e-28	8e-25	-0.55	-0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859641	chr16:28802743~28817828:+
PRAD	cis	rs9322193	0.607	rs12210822	ENSG00000231760.4	RP11-350J20.5	11.75	4.86e-28	8.01e-25	0.74	0.48	Lung cancer;	chr6:149905356	chr6:149796151~149826294:-
PRAD	cis	rs2117029	0.619	rs9325145	ENSG00000258017.1	RP11-386G11.10	-11.75	4.88e-28	8.05e-25	-0.63	-0.48	Intelligence (multi-trait analysis);	chr12:49132101	chr12:49127782~49147869:+
PRAD	cis	rs9322193	0.923	rs2880436	ENSG00000216906.2	RP11-350J20.9	11.75	4.92e-28	8.11e-25	0.55	0.48	Lung cancer;	chr6:149859123	chr6:149904243~149906418:+
PRAD	cis	rs10256972	1	rs10256972	ENSG00000229043.2	AC091729.9	11.75	4.93e-28	8.13e-25	0.57	0.48	Endometriosis;Longevity;	chr7:999367	chr7:1160374~1165267:+
PRAD	cis	rs2117029	0.521	rs12229524	ENSG00000258017.1	RP11-386G11.10	-11.75	4.94e-28	8.15e-25	-0.65	-0.48	Intelligence (multi-trait analysis);	chr12:49191570	chr12:49127782~49147869:+
PRAD	cis	rs1577917	0.917	rs4098044	ENSG00000203875.9	SNHG5	-11.75	4.95e-28	8.15e-25	-0.54	-0.48	Response to antipsychotic treatment;	chr6:85752348	chr6:85660950~85678736:-
PRAD	cis	rs748404	0.56	rs529611	ENSG00000205771.5	CATSPER2P1	-11.75	4.95e-28	8.16e-25	-0.54	-0.48	Lung cancer;	chr15:43513790	chr15:43726918~43747094:-
PRAD	cis	rs7569084	0.687	rs4671663	ENSG00000204929.10	AC074391.1	11.75	4.95e-28	8.16e-25	0.65	0.48	Sum eosinophil basophil counts;	chr2:65434400	chr2:65436711~66084639:+
PRAD	cis	rs7569084	0.687	rs11692813	ENSG00000204929.10	AC074391.1	11.75	4.95e-28	8.16e-25	0.65	0.48	Sum eosinophil basophil counts;	chr2:65435172	chr2:65436711~66084639:+
PRAD	cis	rs1075265	0.704	rs9631059	ENSG00000233266.1	HMGB1P31	11.75	4.96e-28	8.17e-25	0.65	0.48	Chronotype;Morning vs. evening chronotype;	chr2:54015160	chr2:54051334~54051760:+
PRAD	cis	rs1075265	0.73	rs6711105	ENSG00000233266.1	HMGB1P31	11.75	4.96e-28	8.17e-25	0.65	0.48	Chronotype;Morning vs. evening chronotype;	chr2:54017775	chr2:54051334~54051760:+
PRAD	cis	rs1075265	0.704	rs6711217	ENSG00000233266.1	HMGB1P31	11.75	4.96e-28	8.17e-25	0.65	0.48	Chronotype;Morning vs. evening chronotype;	chr2:54017892	chr2:54051334~54051760:+
PRAD	cis	rs875971	0.545	rs7811204	ENSG00000237310.1	GS1-124K5.4	11.75	5.08e-28	8.36e-25	0.49	0.48	Aortic root size;	chr7:66387213	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.571	rs78668714	ENSG00000237310.1	GS1-124K5.4	11.75	5.08e-28	8.36e-25	0.49	0.48	Aortic root size;	chr7:66474464	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.545	rs73150604	ENSG00000237310.1	GS1-124K5.4	11.75	5.08e-28	8.36e-25	0.49	0.48	Aortic root size;	chr7:66480545	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.545	rs7810213	ENSG00000237310.1	GS1-124K5.4	11.75	5.08e-28	8.36e-25	0.49	0.48	Aortic root size;	chr7:66481592	chr7:66493706~66495474:+
PRAD	cis	rs732716	0.785	rs62130979	ENSG00000267769.1	CTB-50L17.9	-11.75	5.11e-28	8.41e-25	-0.56	-0.48	Mean corpuscular volume;	chr19:4432447	chr19:4454014~4455286:+
PRAD	cis	rs9322193	0.516	rs1999632	ENSG00000223701.3	RAET1E-AS1	11.75	5.13e-28	8.45e-25	0.77	0.48	Lung cancer;	chr6:149866737	chr6:149884431~149919508:+
PRAD	cis	rs875971	0.502	rs1796227	ENSG00000237310.1	GS1-124K5.4	-11.75	5.14e-28	8.47e-25	-0.48	-0.48	Aortic root size;	chr7:66622032	chr7:66493706~66495474:+
PRAD	cis	rs12049351	0.719	rs10799537	ENSG00000229367.1	HMGN2P19	11.75	5.17e-28	8.51e-25	0.64	0.48	Circulating myeloperoxidase levels (plasma);	chr1:229528797	chr1:229570532~229570796:+
PRAD	cis	rs12049351	0.774	rs767301	ENSG00000229367.1	HMGN2P19	11.75	5.21e-28	8.58e-25	0.66	0.48	Circulating myeloperoxidase levels (plasma);	chr1:229563268	chr1:229570532~229570796:+
PRAD	cis	rs2658782	0.694	rs3019221	ENSG00000279684.1	RP11-755E23.2	-11.75	5.23e-28	8.61e-25	-0.75	-0.48	Pulmonary function decline;	chr11:93346534	chr11:93286629~93288903:-
PRAD	cis	rs7569084	0.663	rs11126037	ENSG00000204929.10	AC074391.1	11.75	5.23e-28	8.61e-25	0.65	0.48	Sum eosinophil basophil counts;	chr2:65436024	chr2:65436711~66084639:+
PRAD	cis	rs7569084	0.687	rs11126038	ENSG00000204929.10	AC074391.1	11.75	5.23e-28	8.61e-25	0.65	0.48	Sum eosinophil basophil counts;	chr2:65436100	chr2:65436711~66084639:+
PRAD	cis	rs9322193	0.607	rs12527391	ENSG00000223701.3	RAET1E-AS1	11.75	5.25e-28	8.64e-25	0.75	0.48	Lung cancer;	chr6:149882156	chr6:149884431~149919508:+
PRAD	cis	rs7569084	0.64	rs11126039	ENSG00000204929.10	AC074391.1	11.75	5.26e-28	8.65e-25	0.64	0.48	Sum eosinophil basophil counts;	chr2:65457953	chr2:65436711~66084639:+
PRAD	cis	rs7569084	0.687	rs11675538	ENSG00000204929.10	AC074391.1	11.75	5.26e-28	8.65e-25	0.64	0.48	Sum eosinophil basophil counts;	chr2:65459327	chr2:65436711~66084639:+
PRAD	cis	rs2117029	0.653	rs1476137	ENSG00000258017.1	RP11-386G11.10	-11.75	5.26e-28	8.65e-25	-0.63	-0.48	Intelligence (multi-trait analysis);	chr12:49129930	chr12:49127782~49147869:+
PRAD	cis	rs2117029	0.553	rs731350	ENSG00000258017.1	RP11-386G11.10	-11.75	5.26e-28	8.65e-25	-0.63	-0.48	Intelligence (multi-trait analysis);	chr12:49130804	chr12:49127782~49147869:+
PRAD	cis	rs9322193	0.961	rs9767713	ENSG00000223701.3	RAET1E-AS1	11.75	5.27e-28	8.67e-25	0.66	0.48	Lung cancer;	chr6:149588241	chr6:149884431~149919508:+
PRAD	cis	rs10853057	0.717	rs62062479	ENSG00000214174.7	AMZ2P1	11.74	5.3e-28	8.71e-25	0.99	0.48	White matter microstructure (global fractional anisotropy);	chr17:65060017	chr17:64966550~64975576:-
PRAD	cis	rs9322193	0.923	rs9383812	ENSG00000268592.3	RAET1E-AS1	11.74	5.33e-28	8.76e-25	0.65	0.48	Lung cancer;	chr6:149712355	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.847	rs9383844	ENSG00000268592.3	RAET1E-AS1	11.74	5.33e-28	8.76e-25	0.65	0.48	Lung cancer;	chr6:149716268	chr6:149863494~149919507:+
PRAD	cis	rs35160687	0.901	rs13020869	ENSG00000273080.1	RP11-301O19.1	11.74	5.33e-28	8.76e-25	0.57	0.48	Night sleep phenotypes;	chr2:86296237	chr2:86195590~86196049:+
PRAD	cis	rs35160687	0.901	rs12714180	ENSG00000273080.1	RP11-301O19.1	11.74	5.33e-28	8.76e-25	0.57	0.48	Night sleep phenotypes;	chr2:86298200	chr2:86195590~86196049:+
PRAD	cis	rs35160687	0.901	rs35281683	ENSG00000273080.1	RP11-301O19.1	11.74	5.33e-28	8.76e-25	0.57	0.48	Night sleep phenotypes;	chr2:86299249	chr2:86195590~86196049:+
PRAD	cis	rs7688540	0.511	rs61794969	ENSG00000275426.1	CH17-262A2.1	11.74	5.34e-28	8.78e-25	0.75	0.48	Facial morphology (factor 6, height of vermillion lower lip);	chr4:194242	chr4:149738~150317:+
PRAD	cis	rs7688540	0.511	rs77815676	ENSG00000275426.1	CH17-262A2.1	11.74	5.34e-28	8.78e-25	0.75	0.48	Facial morphology (factor 6, height of vermillion lower lip);	chr4:196080	chr4:149738~150317:+
PRAD	cis	rs7688540	0.547	rs11728864	ENSG00000275426.1	CH17-262A2.1	11.74	5.34e-28	8.78e-25	0.75	0.48	Facial morphology (factor 6, height of vermillion lower lip);	chr4:197518	chr4:149738~150317:+
PRAD	cis	rs7688540	0.511	rs76125013	ENSG00000275426.1	CH17-262A2.1	11.74	5.34e-28	8.78e-25	0.75	0.48	Facial morphology (factor 6, height of vermillion lower lip);	chr4:201493	chr4:149738~150317:+
PRAD	cis	rs55794721	0.509	rs12027110	ENSG00000224183.1	SDHDP6	-11.74	5.41e-28	8.88e-25	-0.56	-0.48	Mean corpuscular volume;Plateletcrit;	chr1:25449191	chr1:25294164~25294643:-
PRAD	cis	rs4814920	0.756	rs6075586	ENSG00000275142.1	RP5-999L4.2	-11.74	5.41e-28	8.89e-25	-0.82	-0.48	Bipolar disorder (body mass index interaction);	chr20:19874650	chr20:19871891~19872284:+
PRAD	cis	rs1577917	0.916	rs12206726	ENSG00000203875.9	SNHG5	-11.74	5.42e-28	8.9e-25	-0.55	-0.48	Response to antipsychotic treatment;	chr6:85789998	chr6:85660950~85678736:-
PRAD	cis	rs8062405	1	rs62036622	ENSG00000251417.2	RP11-1348G14.4	-11.74	5.46e-28	8.96e-25	-0.55	-0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28825882	chr16:28802743~28817828:+
PRAD	cis	rs875971	0.545	rs1796217	ENSG00000237310.1	GS1-124K5.4	-11.74	5.48e-28	9e-25	-0.48	-0.48	Aortic root size;	chr7:66620931	chr7:66493706~66495474:+
PRAD	cis	rs9322193	0.923	rs3924871	ENSG00000268592.3	RAET1E-AS1	11.74	5.52e-28	9.07e-25	0.66	0.48	Lung cancer;	chr6:149662080	chr6:149863494~149919507:+
PRAD	cis	rs2739330	0.76	rs5751760	ENSG00000235689.1	AP000351.13	11.74	5.52e-28	9.07e-25	0.59	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:24006305~24008258:-
PRAD	cis	rs977987	0.835	rs3851734	ENSG00000261783.1	RP11-252K23.2	-11.74	5.53e-28	9.08e-25	-0.65	-0.48	Dupuytren's disease;	chr16:75338022	chr16:75379818~75381260:-
PRAD	cis	rs7208859	0.528	rs3764416	ENSG00000263531.1	RP13-753N3.1	-11.74	5.53e-28	9.08e-25	-0.89	-0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30573690	chr17:30863921~30864940:-
PRAD	cis	rs9532669	0.889	rs6560964	ENSG00000176268.5	CYCSP34	11.74	5.54e-28	9.09e-25	0.5	0.48	Cervical cancer;	chr13:40871132	chr13:40863599~40863902:-
PRAD	cis	rs2117029	0.555	rs10783304	ENSG00000258017.1	RP11-386G11.10	-11.74	5.59e-28	9.17e-25	-0.63	-0.48	Intelligence (multi-trait analysis);	chr12:49106615	chr12:49127782~49147869:+
PRAD	cis	rs5760092	0.755	rs11090298	ENSG00000231271.1	AP000350.8	-11.74	5.6e-28	9.2e-25	-0.78	-0.48	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919874	chr22:23949918~23954042:+
PRAD	cis	rs9322193	0.923	rs9689716	ENSG00000268592.3	RAET1E-AS1	11.74	5.66e-28	9.28e-25	0.67	0.48	Lung cancer;	chr6:149655662	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.923	rs9322207	ENSG00000268592.3	RAET1E-AS1	11.74	5.66e-28	9.28e-25	0.67	0.48	Lung cancer;	chr6:149657185	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.923	rs9322208	ENSG00000268592.3	RAET1E-AS1	11.74	5.66e-28	9.28e-25	0.67	0.48	Lung cancer;	chr6:149658547	chr6:149863494~149919507:+
PRAD	cis	rs4423214	0.592	rs10898234	ENSG00000254682.1	RP11-660L16.2	-11.74	5.71e-28	9.36e-25	-0.76	-0.48	Vitamin D levels;	chr11:71525638	chr11:71448674~71452157:+
PRAD	cis	rs4423214	0.547	rs11234030	ENSG00000254682.1	RP11-660L16.2	-11.74	5.71e-28	9.36e-25	-0.76	-0.48	Vitamin D levels;	chr11:71525921	chr11:71448674~71452157:+
PRAD	cis	rs4423214	0.592	rs7130829	ENSG00000254682.1	RP11-660L16.2	-11.74	5.71e-28	9.36e-25	-0.76	-0.48	Vitamin D levels;	chr11:71526656	chr11:71448674~71452157:+
PRAD	cis	rs9487094	0.961	rs752262	ENSG00000260273.1	RP11-425D10.10	11.74	5.76e-28	9.44e-25	0.69	0.48	Height;	chr6:109449796	chr6:109382795~109383666:+
PRAD	cis	rs9487094	0.813	rs3799840	ENSG00000260273.1	RP11-425D10.10	11.74	5.76e-28	9.44e-25	0.71	0.48	Height;	chr6:109381443	chr6:109382795~109383666:+
PRAD	cis	rs7727544	0.709	rs272852	ENSG00000233006.5	AC034220.3	11.74	5.77e-28	9.46e-25	0.43	0.48	Blood metabolite levels;	chr5:132353074	chr5:132311285~132369916:-
PRAD	cis	rs9487094	0.813	rs61233650	ENSG00000260273.1	RP11-425D10.10	11.73	5.8e-28	9.5e-25	0.7	0.48	Height;	chr6:109365409	chr6:109382795~109383666:+
PRAD	cis	rs12429206	0.512	rs9535530	ENSG00000233672.5	RNASEH2B-AS1	-11.73	5.84e-28	9.56e-25	-0.66	-0.48	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50925136	chr13:50862172~50910764:-
PRAD	cis	rs6504950	0.889	rs2628301	ENSG00000275710.1	RP11-257O5.4	-11.73	5.84e-28	9.57e-25	-0.66	-0.48	Breast cancer;	chr17:55081912	chr17:54964474~54964679:+
PRAD	cis	rs673078	1	rs673078	ENSG00000275759.1	RP11-131L12.3	11.73	5.94e-28	9.72e-25	0.65	0.48	Glucose homeostasis traits;	chr12:118353636	chr12:118428281~118428870:+
PRAD	cis	rs9322193	0.923	rs9371486	ENSG00000223701.3	RAET1E-AS1	11.73	5.98e-28	9.78e-25	0.65	0.48	Lung cancer;	chr6:149832090	chr6:149884431~149919508:+
PRAD	cis	rs1062177	0.855	rs6896664	ENSG00000213433.5	RPLP1P6	-11.73	5.99e-28	9.8e-25	-0.54	-0.48	Preschool internalizing problems;	chr5:151885713	chr5:151765859~151766378:-
PRAD	cis	rs8072100	0.846	rs4264433	ENSG00000228782.6	CTD-2026D20.3	-11.73	6.03e-28	9.87e-25	-0.53	-0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47659909	chr17:47450568~47492492:-
PRAD	cis	rs9322193	0.923	rs2184370	ENSG00000216906.2	RP11-350J20.9	11.73	6.06e-28	9.91e-25	0.56	0.48	Lung cancer;	chr6:149843242	chr6:149904243~149906418:+
PRAD	cis	rs2117029	0.521	rs2114845	ENSG00000258017.1	RP11-386G11.10	-11.73	6.1e-28	9.98e-25	-0.63	-0.48	Intelligence (multi-trait analysis);	chr12:49164750	chr12:49127782~49147869:+
PRAD	cis	rs4845570	1	rs11585294	ENSG00000249602.1	RP11-98D18.3	11.73	6.13e-28	1e-24	0.79	0.48	Coronary artery disease;	chr1:151797411	chr1:151763384~151769501:-
PRAD	cis	rs673078	0.607	rs16948230	ENSG00000275759.1	RP11-131L12.3	-11.73	6.18e-28	1.01e-24	-0.74	-0.48	Glucose homeostasis traits;	chr12:118277086	chr12:118428281~118428870:+
PRAD	cis	rs7208859	0.673	rs1347359	ENSG00000263531.1	RP13-753N3.1	11.73	6.19e-28	1.01e-24	0.81	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587511	chr17:30863921~30864940:-
PRAD	cis	rs9487094	0.922	rs1321328	ENSG00000260273.1	RP11-425D10.10	11.73	6.27e-28	1.02e-24	0.68	0.48	Height;	chr6:109655182	chr6:109382795~109383666:+
PRAD	cis	rs673078	0.607	rs7312555	ENSG00000275759.1	RP11-131L12.3	-11.73	6.27e-28	1.03e-24	-0.76	-0.48	Glucose homeostasis traits;	chr12:118414120	chr12:118428281~118428870:+
PRAD	cis	rs2117029	0.619	rs2753	ENSG00000258017.1	RP11-386G11.10	-11.73	6.28e-28	1.03e-24	-0.63	-0.48	Intelligence (multi-trait analysis);	chr12:49127889	chr12:49127782~49147869:+
PRAD	cis	rs673078	0.571	rs61945220	ENSG00000275759.1	RP11-131L12.3	-11.73	6.31e-28	1.03e-24	-0.77	-0.48	Glucose homeostasis traits;	chr12:118272924	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.571	rs61945221	ENSG00000275759.1	RP11-131L12.3	-11.73	6.31e-28	1.03e-24	-0.77	-0.48	Glucose homeostasis traits;	chr12:118272926	chr12:118428281~118428870:+
PRAD	cis	rs8072100	0.539	rs36043200	ENSG00000228782.6	CTD-2026D20.3	-11.73	6.33e-28	1.03e-24	-0.55	-0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47552040	chr17:47450568~47492492:-
PRAD	cis	rs9487094	0.922	rs13204500	ENSG00000260273.1	RP11-425D10.10	11.72	6.36e-28	1.04e-24	0.68	0.48	Height;	chr6:109640682	chr6:109382795~109383666:+
PRAD	cis	rs9487094	0.922	rs971434	ENSG00000260273.1	RP11-425D10.10	11.72	6.36e-28	1.04e-24	0.68	0.48	Height;	chr6:109656105	chr6:109382795~109383666:+
PRAD	cis	rs9487094	0.744	rs13192476	ENSG00000260273.1	RP11-425D10.10	11.72	6.4e-28	1.05e-24	0.72	0.48	Height;	chr6:109403951	chr6:109382795~109383666:+
PRAD	cis	rs748404	0.56	rs572837	ENSG00000205771.5	CATSPER2P1	-11.72	6.45e-28	1.05e-24	-0.56	-0.48	Lung cancer;	chr15:43531615	chr15:43726918~43747094:-
PRAD	cis	rs35160687	0.901	rs10200186	ENSG00000273080.1	RP11-301O19.1	11.72	6.46e-28	1.05e-24	0.57	0.48	Night sleep phenotypes;	chr2:86300300	chr2:86195590~86196049:+
PRAD	cis	rs35160687	0.842	rs10200526	ENSG00000273080.1	RP11-301O19.1	11.72	6.46e-28	1.05e-24	0.57	0.48	Night sleep phenotypes;	chr2:86300476	chr2:86195590~86196049:+
PRAD	cis	rs35160687	0.901	rs34048420	ENSG00000273080.1	RP11-301O19.1	11.72	6.46e-28	1.05e-24	0.57	0.48	Night sleep phenotypes;	chr2:86302625	chr2:86195590~86196049:+
PRAD	cis	rs35160687	0.901	rs34069316	ENSG00000273080.1	RP11-301O19.1	11.72	6.46e-28	1.05e-24	0.57	0.48	Night sleep phenotypes;	chr2:86302669	chr2:86195590~86196049:+
PRAD	cis	rs35160687	0.901	rs11127026	ENSG00000273080.1	RP11-301O19.1	11.72	6.46e-28	1.05e-24	0.57	0.48	Night sleep phenotypes;	chr2:86304625	chr2:86195590~86196049:+
PRAD	cis	rs35160687	0.901	rs12478575	ENSG00000273080.1	RP11-301O19.1	11.72	6.46e-28	1.05e-24	0.57	0.48	Night sleep phenotypes;	chr2:86308191	chr2:86195590~86196049:+
PRAD	cis	rs35160687	0.871	rs11127028	ENSG00000273080.1	RP11-301O19.1	11.72	6.46e-28	1.05e-24	0.57	0.48	Night sleep phenotypes;	chr2:86310386	chr2:86195590~86196049:+
PRAD	cis	rs7727544	0.66	rs272886	ENSG00000233006.5	AC034220.3	11.72	6.57e-28	1.07e-24	0.43	0.48	Blood metabolite levels;	chr5:132330147	chr5:132311285~132369916:-
PRAD	cis	rs9322193	0.607	rs3798763	ENSG00000223701.3	RAET1E-AS1	11.72	6.6e-28	1.08e-24	0.75	0.48	Lung cancer;	chr6:149889964	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.607	rs12204653	ENSG00000223701.3	RAET1E-AS1	11.72	6.6e-28	1.08e-24	0.75	0.48	Lung cancer;	chr6:149891885	chr6:149884431~149919508:+
PRAD	cis	rs8062405	0.755	rs7186573	ENSG00000259982.1	CDC37P1	11.72	6.74e-28	1.1e-24	0.63	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576068	chr16:28700294~28701540:-
PRAD	cis	rs8062405	1	rs72793811	ENSG00000251417.2	RP11-1348G14.4	-11.72	6.83e-28	1.11e-24	-0.55	-0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828071	chr16:28802743~28817828:+
PRAD	cis	rs8062405	1	rs72793812	ENSG00000251417.2	RP11-1348G14.4	-11.71	7.18e-28	1.17e-24	-0.54	-0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28829060	chr16:28802743~28817828:+
PRAD	cis	rs12594515	1	rs6493172	ENSG00000273972.1	CTD-2306A12.1	-11.71	7.2e-28	1.17e-24	-0.54	-0.48	Weight;Waist circumference;	chr15:45695015	chr15:45702640~45703183:+
PRAD	cis	rs11123170	0.543	rs4849178	ENSG00000189223.12	PAX8-AS1	-11.71	7.21e-28	1.17e-24	-0.74	-0.48	Renal function-related traits (BUN);	chr2:113225031	chr2:113211522~113276581:+
PRAD	cis	rs748404	0.588	rs2255410	ENSG00000205771.5	CATSPER2P1	-11.71	7.21e-28	1.17e-24	-0.55	-0.48	Lung cancer;	chr15:43538899	chr15:43726918~43747094:-
PRAD	cis	rs7044106	0.615	rs10818470	ENSG00000226752.6	PSMD5-AS1	-11.71	7.24e-28	1.18e-24	-0.57	-0.48	Hip circumference adjusted for BMI;	chr9:120596926	chr9:120824828~120854385:+
PRAD	cis	rs11673344	0.668	rs7248693	ENSG00000226686.6	LINC01535	11.71	7.26e-28	1.18e-24	0.68	0.48	Obesity-related traits;	chr19:36991864	chr19:37251912~37265535:+
PRAD	cis	rs9322193	0.607	rs4869755	ENSG00000231760.4	RP11-350J20.5	11.71	7.3e-28	1.19e-24	0.75	0.48	Lung cancer;	chr6:149886347	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.639	rs4869756	ENSG00000231760.4	RP11-350J20.5	11.71	7.3e-28	1.19e-24	0.75	0.48	Lung cancer;	chr6:149886360	chr6:149796151~149826294:-
PRAD	cis	rs11123170	0.543	rs4849180	ENSG00000189223.12	PAX8-AS1	-11.71	7.37e-28	1.2e-24	-0.74	-0.48	Renal function-related traits (BUN);	chr2:113227609	chr2:113211522~113276581:+
PRAD	cis	rs11123170	0.543	rs35222158	ENSG00000189223.12	PAX8-AS1	-11.71	7.37e-28	1.2e-24	-0.74	-0.48	Renal function-related traits (BUN);	chr2:113229052	chr2:113211522~113276581:+
PRAD	cis	rs2117029	0.556	rs1057725	ENSG00000258017.1	RP11-386G11.10	-11.71	7.41e-28	1.21e-24	-0.63	-0.48	Intelligence (multi-trait analysis);	chr12:49128795	chr12:49127782~49147869:+
PRAD	cis	rs977987	0.872	rs3743609	ENSG00000261783.1	RP11-252K23.2	-11.71	7.48e-28	1.22e-24	-0.66	-0.48	Dupuytren's disease;	chr16:75433123	chr16:75379818~75381260:-
PRAD	cis	rs2404602	0.647	rs1443115	ENSG00000259422.1	RP11-593F23.1	-11.71	7.54e-28	1.23e-24	-0.65	-0.48	Blood metabolite levels;	chr15:76749488	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.647	rs12898416	ENSG00000259422.1	RP11-593F23.1	-11.71	7.54e-28	1.23e-24	-0.65	-0.48	Blood metabolite levels;	chr15:76749951	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.647	rs12904149	ENSG00000259422.1	RP11-593F23.1	-11.71	7.54e-28	1.23e-24	-0.65	-0.48	Blood metabolite levels;	chr15:76751311	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.672	rs35374222	ENSG00000259422.1	RP11-593F23.1	-11.71	7.54e-28	1.23e-24	-0.65	-0.48	Blood metabolite levels;	chr15:76779053	chr15:76174891~76181486:-
PRAD	cis	rs12594515	1	rs6493169	ENSG00000273972.1	CTD-2306A12.1	11.71	7.55e-28	1.23e-24	0.53	0.48	Weight;Waist circumference;	chr15:45694796	chr15:45702640~45703183:+
PRAD	cis	rs1577917	1	rs6923148	ENSG00000203875.9	SNHG5	11.71	7.59e-28	1.23e-24	0.53	0.48	Response to antipsychotic treatment;	chr6:86058068	chr6:85660950~85678736:-
PRAD	cis	rs9322193	0.607	rs4869755	ENSG00000223701.3	RAET1E-AS1	11.7	7.65e-28	1.24e-24	0.75	0.48	Lung cancer;	chr6:149886347	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.639	rs4869756	ENSG00000223701.3	RAET1E-AS1	11.7	7.65e-28	1.24e-24	0.75	0.48	Lung cancer;	chr6:149886360	chr6:149884431~149919508:+
PRAD	cis	rs12594515	1	rs12906442	ENSG00000273972.1	CTD-2306A12.1	-11.7	7.66e-28	1.25e-24	-0.53	-0.48	Weight;Waist circumference;	chr15:45693056	chr15:45702640~45703183:+
PRAD	cis	rs9322193	0.923	rs9478291	ENSG00000268592.3	RAET1E-AS1	11.7	7.69e-28	1.25e-24	0.66	0.48	Lung cancer;	chr6:149729434	chr6:149863494~149919507:+
PRAD	cis	rs9487094	0.922	rs6916579	ENSG00000260273.1	RP11-425D10.10	11.7	7.75e-28	1.26e-24	0.68	0.48	Height;	chr6:109530435	chr6:109382795~109383666:+
PRAD	cis	rs2117029	0.586	rs1874908	ENSG00000258017.1	RP11-386G11.10	-11.7	7.76e-28	1.26e-24	-0.63	-0.48	Intelligence (multi-trait analysis);	chr12:49190247	chr12:49127782~49147869:+
PRAD	cis	rs9487094	0.961	rs3807005	ENSG00000260273.1	RP11-425D10.10	11.7	7.77e-28	1.26e-24	0.69	0.48	Height;	chr6:109469907	chr6:109382795~109383666:+
PRAD	cis	rs1062177	0.826	rs2053063	ENSG00000213433.5	RPLP1P6	-11.7	7.83e-28	1.27e-24	-0.55	-0.48	Preschool internalizing problems;	chr5:151787203	chr5:151765859~151766378:-
PRAD	cis	rs1062177	1	rs12518722	ENSG00000213433.5	RPLP1P6	-11.7	7.84e-28	1.27e-24	-0.57	-0.48	Preschool internalizing problems;	chr5:151851899	chr5:151765859~151766378:-
PRAD	cis	rs1426063	0.614	rs77982391	ENSG00000249717.1	RP11-44F21.3	11.7	7.85e-28	1.27e-24	1.03	0.48	QT interval;	chr4:75125224	chr4:74955974~74970362:-
PRAD	cis	rs9322193	0.924	rs9322189	ENSG00000223701.3	RAET1E-AS1	11.7	7.9e-28	1.28e-24	0.66	0.48	Lung cancer;	chr6:149588797	chr6:149884431~149919508:+
PRAD	cis	rs9487094	0.813	rs67857472	ENSG00000260273.1	RP11-425D10.10	11.7	7.91e-28	1.28e-24	0.7	0.48	Height;	chr6:109359125	chr6:109382795~109383666:+
PRAD	cis	rs11676348	0.791	rs4133195	ENSG00000261338.2	RP11-378A13.1	11.7	7.92e-28	1.29e-24	0.54	0.48	Ulcerative colitis;	chr2:218086522	chr2:218255319~218257366:+
PRAD	cis	rs55794721	0.509	rs873308	ENSG00000224183.1	SDHDP6	11.7	7.92e-28	1.29e-24	0.55	0.48	Mean corpuscular volume;Plateletcrit;	chr1:25432164	chr1:25294164~25294643:-
PRAD	cis	rs7240205	0.853	rs4555225	ENSG00000275805.1	RP11-349H17.2	-11.7	7.96e-28	1.29e-24	-0.59	-0.48	Breast cancer;	chr18:26561892	chr18:26565723~26575626:-
PRAD	cis	rs977987	0.835	rs4888380	ENSG00000261783.1	RP11-252K23.2	-11.7	8e-28	1.3e-24	-0.66	-0.48	Dupuytren's disease;	chr16:75313792	chr16:75379818~75381260:-
PRAD	cis	rs977987	0.835	rs8057535	ENSG00000261783.1	RP11-252K23.2	-11.7	8e-28	1.3e-24	-0.66	-0.48	Dupuytren's disease;	chr16:75314043	chr16:75379818~75381260:-
PRAD	cis	rs2404602	0.735	rs11629888	ENSG00000259422.1	RP11-593F23.1	-11.7	8.06e-28	1.31e-24	-0.64	-0.48	Blood metabolite levels;	chr15:76427539	chr15:76174891~76181486:-
PRAD	cis	rs977987	0.806	rs35937717	ENSG00000261783.1	RP11-252K23.2	-11.7	8.11e-28	1.32e-24	-0.65	-0.48	Dupuytren's disease;	chr16:75297669	chr16:75379818~75381260:-
PRAD	cis	rs2134046	0.587	rs11854289	ENSG00000278603.1	RP13-608F4.5	-11.7	8.16e-28	1.32e-24	-0.59	-0.48	Cognitive ability;	chr15:82266461	chr15:82472203~82472426:+
PRAD	cis	rs12594515	1	rs12911309	ENSG00000273972.1	CTD-2306A12.1	-11.7	8.17e-28	1.33e-24	-0.54	-0.48	Weight;Waist circumference;	chr15:45693521	chr15:45702640~45703183:+
PRAD	cis	rs12594515	1	rs12595137	ENSG00000273972.1	CTD-2306A12.1	-11.7	8.17e-28	1.33e-24	-0.54	-0.48	Weight;Waist circumference;	chr15:45693907	chr15:45702640~45703183:+
PRAD	cis	rs12594515	0.967	rs12595138	ENSG00000273972.1	CTD-2306A12.1	-11.7	8.17e-28	1.33e-24	-0.54	-0.48	Weight;Waist circumference;	chr15:45693910	chr15:45702640~45703183:+
PRAD	cis	rs73086581	0.838	rs41398349	ENSG00000229539.1	RP11-119B16.2	-11.7	8.2e-28	1.33e-24	-0.81	-0.48	Response to antidepressants in depression;	chr20:4043792	chr20:3888239~3888868:-
PRAD	cis	rs9322193	0.924	rs9322189	ENSG00000268592.3	RAET1E-AS1	11.7	8.21e-28	1.33e-24	0.67	0.48	Lung cancer;	chr6:149588797	chr6:149863494~149919507:+
PRAD	cis	rs6504950	0.889	rs2541237	ENSG00000275710.1	RP11-257O5.4	-11.7	8.23e-28	1.34e-24	-0.65	-0.48	Breast cancer;	chr17:55086676	chr17:54964474~54964679:+
PRAD	cis	rs2404602	0.647	rs12913024	ENSG00000259422.1	RP11-593F23.1	-11.7	8.24e-28	1.34e-24	-0.65	-0.48	Blood metabolite levels;	chr15:76852875	chr15:76174891~76181486:-
PRAD	cis	rs6991838	0.584	rs4737221	ENSG00000272010.1	CTD-3025N20.3	-11.7	8.3e-28	1.35e-24	-0.5	-0.48	Intelligence (multi-trait analysis);	chr8:65569075	chr8:65591850~65592472:-
PRAD	cis	rs2117029	0.586	rs6580701	ENSG00000258017.1	RP11-386G11.10	-11.69	8.33e-28	1.35e-24	-0.63	-0.48	Intelligence (multi-trait analysis);	chr12:49163482	chr12:49127782~49147869:+
PRAD	cis	rs2117029	0.554	rs2334931	ENSG00000258017.1	RP11-386G11.10	-11.69	8.33e-28	1.35e-24	-0.63	-0.48	Intelligence (multi-trait analysis);	chr12:49174130	chr12:49127782~49147869:+
PRAD	cis	rs2117029	0.586	rs10875929	ENSG00000258017.1	RP11-386G11.10	-11.69	8.33e-28	1.35e-24	-0.63	-0.48	Intelligence (multi-trait analysis);	chr12:49174605	chr12:49127782~49147869:+
PRAD	cis	rs2117029	0.554	rs2334930	ENSG00000258017.1	RP11-386G11.10	-11.69	8.33e-28	1.35e-24	-0.63	-0.48	Intelligence (multi-trait analysis);	chr12:49175528	chr12:49127782~49147869:+
PRAD	cis	rs2117029	0.586	rs11168904	ENSG00000258017.1	RP11-386G11.10	-11.69	8.33e-28	1.35e-24	-0.63	-0.48	Intelligence (multi-trait analysis);	chr12:49177234	chr12:49127782~49147869:+
PRAD	cis	rs2117029	0.586	rs10875931	ENSG00000258017.1	RP11-386G11.10	-11.69	8.33e-28	1.35e-24	-0.63	-0.48	Intelligence (multi-trait analysis);	chr12:49179513	chr12:49127782~49147869:+
PRAD	cis	rs2117029	0.554	rs7954530	ENSG00000258017.1	RP11-386G11.10	-11.69	8.33e-28	1.35e-24	-0.63	-0.48	Intelligence (multi-trait analysis);	chr12:49179742	chr12:49127782~49147869:+
PRAD	cis	rs2117029	0.586	rs7957998	ENSG00000258017.1	RP11-386G11.10	-11.69	8.33e-28	1.35e-24	-0.63	-0.48	Intelligence (multi-trait analysis);	chr12:49180240	chr12:49127782~49147869:+
PRAD	cis	rs2117029	0.553	rs11168909	ENSG00000258017.1	RP11-386G11.10	-11.69	8.33e-28	1.35e-24	-0.63	-0.48	Intelligence (multi-trait analysis);	chr12:49183092	chr12:49127782~49147869:+
PRAD	cis	rs2117029	0.554	rs12579015	ENSG00000258017.1	RP11-386G11.10	-11.69	8.35e-28	1.35e-24	-0.63	-0.48	Intelligence (multi-trait analysis);	chr12:49162648	chr12:49127782~49147869:+
PRAD	cis	rs2404602	0.735	rs62028423	ENSG00000259422.1	RP11-593F23.1	-11.69	8.45e-28	1.37e-24	-0.61	-0.48	Blood metabolite levels;	chr15:76462173	chr15:76174891~76181486:-
PRAD	cis	rs7208859	0.673	rs216420	ENSG00000263531.1	RP13-753N3.1	11.69	8.47e-28	1.37e-24	0.81	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30611490	chr17:30863921~30864940:-
PRAD	cis	rs6504950	0.925	rs2787497	ENSG00000275710.1	RP11-257O5.4	-11.69	8.52e-28	1.38e-24	-0.67	-0.48	Breast cancer;	chr17:55098850	chr17:54964474~54964679:+
PRAD	cis	rs9532669	0.926	rs9532690	ENSG00000176268.5	CYCSP34	11.69	8.56e-28	1.39e-24	0.49	0.48	Cervical cancer;	chr13:40968654	chr13:40863599~40863902:-
PRAD	cis	rs2455601	0.882	rs10840139	ENSG00000254860.4	TMEM9B-AS1	11.69	8.61e-28	1.4e-24	0.62	0.48	Schizophrenia;	chr11:8873291	chr11:8964675~8977527:+
PRAD	cis	rs9322193	0.923	rs9688350	ENSG00000268592.3	RAET1E-AS1	11.69	8.66e-28	1.4e-24	0.66	0.48	Lung cancer;	chr6:149730977	chr6:149863494~149919507:+
PRAD	cis	rs1062177	1	rs62394155	ENSG00000213433.5	RPLP1P6	-11.69	8.69e-28	1.41e-24	-0.57	-0.48	Preschool internalizing problems;	chr5:151868508	chr5:151765859~151766378:-
PRAD	cis	rs1062177	1	rs12653926	ENSG00000213433.5	RPLP1P6	-11.69	8.69e-28	1.41e-24	-0.57	-0.48	Preschool internalizing problems;	chr5:151870687	chr5:151765859~151766378:-
PRAD	cis	rs2117029	0.523	rs12227296	ENSG00000258017.1	RP11-386G11.10	-11.69	8.69e-28	1.41e-24	-0.63	-0.48	Intelligence (multi-trait analysis);	chr12:49136712	chr12:49127782~49147869:+
PRAD	cis	rs2117029	0.521	rs10875925	ENSG00000258017.1	RP11-386G11.10	-11.69	8.69e-28	1.41e-24	-0.63	-0.48	Intelligence (multi-trait analysis);	chr12:49142575	chr12:49127782~49147869:+
PRAD	cis	rs2117029	0.586	rs11168882	ENSG00000258017.1	RP11-386G11.10	-11.69	8.69e-28	1.41e-24	-0.63	-0.48	Intelligence (multi-trait analysis);	chr12:49143560	chr12:49127782~49147869:+
PRAD	cis	rs9322193	0.923	rs2297928	ENSG00000268592.3	RAET1E-AS1	11.69	8.72e-28	1.41e-24	0.66	0.48	Lung cancer;	chr6:149718584	chr6:149863494~149919507:+
PRAD	cis	rs9487094	0.961	rs11153174	ENSG00000260273.1	RP11-425D10.10	11.69	8.75e-28	1.42e-24	0.68	0.48	Height;	chr6:109352852	chr6:109382795~109383666:+
PRAD	cis	rs4853012	0.941	rs60291089	ENSG00000257800.1	FNBP1P1	11.69	8.75e-28	1.42e-24	0.42	0.48	Gestational age at birth (maternal effect);	chr2:74117763	chr2:74120680~74123218:+
PRAD	cis	rs4853012	0.838	rs58759652	ENSG00000257800.1	FNBP1P1	11.69	8.75e-28	1.42e-24	0.42	0.48	Gestational age at birth (maternal effect);	chr2:74117775	chr2:74120680~74123218:+
PRAD	cis	rs9322193	0.884	rs10872647	ENSG00000223701.3	RAET1E-AS1	11.69	8.77e-28	1.42e-24	0.65	0.48	Lung cancer;	chr6:149758687	chr6:149884431~149919508:+
PRAD	cis	rs4722166	0.695	rs56061963	ENSG00000179428.2	AC073072.5	-11.69	8.79e-28	1.42e-24	-0.56	-0.48	Lung cancer;	chr7:22760778	chr7:22725395~22727620:-
PRAD	cis	rs7044106	0.537	rs10818474	ENSG00000226752.6	PSMD5-AS1	-11.69	8.79e-28	1.42e-24	-0.64	-0.48	Hip circumference adjusted for BMI;	chr9:120727686	chr9:120824828~120854385:+
PRAD	cis	rs1075265	0.704	rs10084374	ENSG00000233266.1	HMGB1P31	11.69	8.8e-28	1.42e-24	0.64	0.48	Chronotype;Morning vs. evening chronotype;	chr2:54022175	chr2:54051334~54051760:+
PRAD	cis	rs7688540	0.511	rs4522818	ENSG00000275426.1	CH17-262A2.1	11.69	8.83e-28	1.43e-24	0.76	0.48	Facial morphology (factor 6, height of vermillion lower lip);	chr4:187973	chr4:149738~150317:+
PRAD	cis	rs8072100	1	rs3809868	ENSG00000228782.6	CTD-2026D20.3	-11.69	8.9e-28	1.44e-24	-0.52	-0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47673230	chr17:47450568~47492492:-
PRAD	cis	rs8072100	1	rs7210738	ENSG00000228782.6	CTD-2026D20.3	-11.69	8.9e-28	1.44e-24	-0.52	-0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47680232	chr17:47450568~47492492:-
PRAD	cis	rs9322193	0.607	rs9371228	ENSG00000231760.4	RP11-350J20.5	-11.69	8.94e-28	1.45e-24	-0.73	-0.48	Lung cancer;	chr6:149921977	chr6:149796151~149826294:-
PRAD	cis	rs9322193	0.923	rs11155674	ENSG00000268592.3	RAET1E-AS1	11.69	8.98e-28	1.45e-24	0.66	0.48	Lung cancer;	chr6:149711111	chr6:149863494~149919507:+
PRAD	cis	rs5760092	0.755	rs11090298	ENSG00000273295.1	AP000350.5	-11.69	8.99e-28	1.45e-24	-0.7	-0.48	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919874	chr22:23901432~23907068:-
PRAD	cis	rs9399135	0.66	rs9376072	ENSG00000232876.1	CTA-212D2.2	-11.69	9.03e-28	1.46e-24	-0.6	-0.48	Red blood cell count;	chr6:134959381	chr6:135055033~135060550:+
PRAD	cis	rs9322193	0.923	rs12176034	ENSG00000223701.3	RAET1E-AS1	11.68	9.11e-28	1.47e-24	0.65	0.48	Lung cancer;	chr6:149800557	chr6:149884431~149919508:+
PRAD	cis	rs7688540	0.511	rs11735723	ENSG00000275426.1	CH17-262A2.1	11.68	9.16e-28	1.48e-24	0.76	0.48	Facial morphology (factor 6, height of vermillion lower lip);	chr4:205848	chr4:149738~150317:+
PRAD	cis	rs9322193	0.923	rs2185352	ENSG00000268592.3	RAET1E-AS1	11.68	9.25e-28	1.49e-24	0.66	0.48	Lung cancer;	chr6:149714640	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.923	rs12174349	ENSG00000268592.3	RAET1E-AS1	11.68	9.25e-28	1.49e-24	0.66	0.48	Lung cancer;	chr6:149718012	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.923	rs2297932	ENSG00000268592.3	RAET1E-AS1	11.68	9.25e-28	1.49e-24	0.66	0.48	Lung cancer;	chr6:149718225	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.923	rs2297930	ENSG00000268592.3	RAET1E-AS1	11.68	9.25e-28	1.49e-24	0.66	0.48	Lung cancer;	chr6:149718360	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.923	rs9479094	ENSG00000268592.3	RAET1E-AS1	11.68	9.25e-28	1.49e-24	0.66	0.48	Lung cancer;	chr6:149725083	chr6:149863494~149919507:+
PRAD	cis	rs9322193	1	rs9399693	ENSG00000223701.3	RAET1E-AS1	11.68	9.35e-28	1.51e-24	0.65	0.48	Lung cancer;	chr6:149612718	chr6:149884431~149919508:+
PRAD	cis	rs5760092	0.618	rs5996631	ENSG00000225282.1	AP000350.6	-11.68	9.46e-28	1.53e-24	-0.71	-0.48	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23926900~23929574:+
PRAD	cis	rs8072100	0.79	rs7222225	ENSG00000228782.6	CTD-2026D20.3	-11.68	9.47e-28	1.53e-24	-0.52	-0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47616131	chr17:47450568~47492492:-
PRAD	cis	rs2739330	0.828	rs2877178	ENSG00000231271.1	AP000350.8	11.68	9.55e-28	1.54e-24	0.65	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23949918~23954042:+
PRAD	cis	rs2739330	0.828	rs2154593	ENSG00000231271.1	AP000350.8	11.68	9.55e-28	1.54e-24	0.65	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23949918~23954042:+
PRAD	cis	rs4660456	0.913	rs545218	ENSG00000237899.1	RP4-739H11.3	11.68	9.57e-28	1.55e-24	0.71	0.48	Platelet count;	chr1:40675313	chr1:40669089~40687588:-
PRAD	cis	rs9322193	0.884	rs10872648	ENSG00000223701.3	RAET1E-AS1	11.68	9.62e-28	1.55e-24	0.65	0.48	Lung cancer;	chr6:149758699	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.884	rs11155679	ENSG00000223701.3	RAET1E-AS1	11.68	9.62e-28	1.55e-24	0.65	0.48	Lung cancer;	chr6:149758881	chr6:149884431~149919508:+
PRAD	cis	rs12049351	0.524	rs4925495	ENSG00000229367.1	HMGN2P19	11.68	9.62e-28	1.55e-24	0.66	0.48	Circulating myeloperoxidase levels (plasma);	chr1:229488677	chr1:229570532~229570796:+
PRAD	cis	rs12049351	0.719	rs4925493	ENSG00000229367.1	HMGN2P19	11.68	9.68e-28	1.56e-24	0.64	0.48	Circulating myeloperoxidase levels (plasma);	chr1:229487390	chr1:229570532~229570796:+
PRAD	cis	rs2739330	0.731	rs5751792	ENSG00000206090.4	AP000350.7	11.68	9.76e-28	1.58e-24	0.6	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23939998~23942798:+
PRAD	cis	rs2739330	0.761	rs5760176	ENSG00000206090.4	AP000350.7	-11.68	9.76e-28	1.58e-24	-0.6	-0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23939998~23942798:+
PRAD	cis	rs2933343	1	rs789213	ENSG00000231305.3	RP11-723O4.2	-11.68	9.92e-28	1.6e-24	-0.48	-0.48	IgG glycosylation;	chr3:128897516	chr3:128861313~128871540:-
PRAD	cis	rs2117029	0.555	rs2047101	ENSG00000258017.1	RP11-386G11.10	-11.68	9.94e-28	1.6e-24	-0.63	-0.48	Intelligence (multi-trait analysis);	chr12:49103860	chr12:49127782~49147869:+
PRAD	cis	rs12049351	0.774	rs1444727	ENSG00000229367.1	HMGN2P19	11.67	1e-27	1.62e-24	0.64	0.48	Circulating myeloperoxidase levels (plasma);	chr1:229481011	chr1:229570532~229570796:+
PRAD	cis	rs9399135	0.66	rs4472368	ENSG00000232876.1	CTA-212D2.2	-11.67	1.01e-27	1.62e-24	-0.6	-0.48	Red blood cell count;	chr6:134953094	chr6:135055033~135060550:+
PRAD	cis	rs12594515	0.967	rs11070465	ENSG00000273972.1	CTD-2306A12.1	-11.67	1.01e-27	1.63e-24	-0.53	-0.48	Weight;Waist circumference;	chr15:45692701	chr15:45702640~45703183:+
PRAD	cis	rs2019137	0.901	rs4849176	ENSG00000189223.12	PAX8-AS1	11.67	1.01e-27	1.63e-24	0.59	0.48	Lymphocyte counts;	chr2:113220359	chr2:113211522~113276581:+
PRAD	cis	rs8062405	0.755	rs62034325	ENSG00000259982.1	CDC37P1	11.67	1.02e-27	1.64e-24	0.64	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527319	chr16:28700294~28701540:-
PRAD	cis	rs673078	0.66	rs61945190	ENSG00000275759.1	RP11-131L12.3	-11.67	1.02e-27	1.65e-24	-0.75	-0.48	Glucose homeostasis traits;	chr12:118231345	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.66	rs7977403	ENSG00000275759.1	RP11-131L12.3	-11.67	1.02e-27	1.65e-24	-0.75	-0.48	Glucose homeostasis traits;	chr12:118233446	chr12:118428281~118428870:+
PRAD	cis	rs2404602	0.647	rs11852395	ENSG00000259422.1	RP11-593F23.1	-11.67	1.04e-27	1.67e-24	-0.64	-0.48	Blood metabolite levels;	chr15:76795444	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.647	rs12439141	ENSG00000259422.1	RP11-593F23.1	-11.67	1.04e-27	1.67e-24	-0.64	-0.48	Blood metabolite levels;	chr15:76803082	chr15:76174891~76181486:-
PRAD	cis	rs12594515	1	rs6493167	ENSG00000273972.1	CTD-2306A12.1	-11.67	1.04e-27	1.67e-24	-0.53	-0.48	Weight;Waist circumference;	chr15:45694611	chr15:45702640~45703183:+
PRAD	cis	rs12594515	1	rs6493168	ENSG00000273972.1	CTD-2306A12.1	-11.67	1.04e-27	1.67e-24	-0.53	-0.48	Weight;Waist circumference;	chr15:45694613	chr15:45702640~45703183:+
PRAD	cis	rs2739330	0.828	rs5760108	ENSG00000231271.1	AP000350.8	11.67	1.04e-27	1.68e-24	0.65	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23949918~23954042:+
PRAD	cis	rs1075265	0.73	rs7597189	ENSG00000233266.1	HMGB1P31	11.67	1.04e-27	1.68e-24	0.64	0.48	Chronotype;Morning vs. evening chronotype;	chr2:54014733	chr2:54051334~54051760:+
PRAD	cis	rs12429206	0.547	rs75419800	ENSG00000233672.5	RNASEH2B-AS1	-11.67	1.05e-27	1.69e-24	-0.7	-0.48	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50898897	chr13:50862172~50910764:-
PRAD	cis	rs1061377	0.862	rs12508577	ENSG00000249207.1	RP11-360F5.1	-11.67	1.05e-27	1.69e-24	-0.52	-0.48	Uric acid levels;	chr4:39107779	chr4:39112677~39126818:-
PRAD	cis	rs1062177	0.774	rs2964574	ENSG00000213433.5	RPLP1P6	-11.67	1.05e-27	1.69e-24	-0.55	-0.48	Preschool internalizing problems;	chr5:151776150	chr5:151765859~151766378:-
PRAD	cis	rs4814920	0.818	rs4813377	ENSG00000275142.1	RP5-999L4.2	-11.67	1.05e-27	1.69e-24	-0.74	-0.48	Bipolar disorder (body mass index interaction);	chr20:19870822	chr20:19871891~19872284:+
PRAD	cis	rs12594515	1	rs8039974	ENSG00000273972.1	CTD-2306A12.1	-11.67	1.06e-27	1.7e-24	-0.53	-0.48	Weight;Waist circumference;	chr15:45694467	chr15:45702640~45703183:+
PRAD	cis	rs9322193	0.923	rs9688452	ENSG00000223701.3	RAET1E-AS1	11.67	1.06e-27	1.71e-24	0.65	0.48	Lung cancer;	chr6:149658764	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.884	rs9383864	ENSG00000216906.2	RP11-350J20.9	11.67	1.06e-27	1.71e-24	0.54	0.48	Lung cancer;	chr6:149851969	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.923	rs9767652	ENSG00000268592.3	RAET1E-AS1	11.67	1.07e-27	1.72e-24	0.66	0.48	Lung cancer;	chr6:149734502	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.923	rs10782314	ENSG00000268592.3	RAET1E-AS1	11.67	1.07e-27	1.72e-24	0.66	0.48	Lung cancer;	chr6:149735527	chr6:149863494~149919507:+
PRAD	cis	rs7772486	0.641	rs2253757	ENSG00000235652.6	RP11-545I5.3	11.67	1.07e-27	1.72e-24	0.53	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145878550	chr6:145799409~145886585:+
PRAD	cis	rs2117029	0.555	rs3741621	ENSG00000258017.1	RP11-386G11.10	-11.67	1.07e-27	1.73e-24	-0.63	-0.48	Intelligence (multi-trait analysis);	chr12:49100242	chr12:49127782~49147869:+
PRAD	cis	rs673078	0.607	rs55929628	ENSG00000275759.1	RP11-131L12.3	-11.67	1.08e-27	1.74e-24	-0.76	-0.48	Glucose homeostasis traits;	chr12:118371332	chr12:118428281~118428870:+
PRAD	cis	rs9487094	0.744	rs2275652	ENSG00000260273.1	RP11-425D10.10	11.67	1.08e-27	1.74e-24	0.71	0.48	Height;	chr6:109382480	chr6:109382795~109383666:+
PRAD	cis	rs12594515	1	rs8025258	ENSG00000273972.1	CTD-2306A12.1	-11.67	1.08e-27	1.74e-24	-0.53	-0.48	Weight;Waist circumference;	chr15:45695356	chr15:45702640~45703183:+
PRAD	cis	rs12594515	1	rs8027000	ENSG00000273972.1	CTD-2306A12.1	-11.67	1.08e-27	1.74e-24	-0.53	-0.48	Weight;Waist circumference;	chr15:45695597	chr15:45702640~45703183:+
PRAD	cis	rs9322193	0.923	rs55993747	ENSG00000268592.3	RAET1E-AS1	11.67	1.08e-27	1.74e-24	0.66	0.48	Lung cancer;	chr6:149622016	chr6:149863494~149919507:+
PRAD	cis	rs17711722	0.522	rs4642526	ENSG00000226824.5	RP4-756H11.3	-11.67	1.09e-27	1.75e-24	-0.61	-0.48	Calcium levels;	chr7:65751755	chr7:66654538~66669855:+
PRAD	cis	rs9322193	0.923	rs66516768	ENSG00000268592.3	RAET1E-AS1	11.67	1.09e-27	1.75e-24	0.65	0.48	Lung cancer;	chr6:149671999	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.923	rs10782317	ENSG00000268592.3	RAET1E-AS1	-11.67	1.09e-27	1.75e-24	-0.66	-0.48	Lung cancer;	chr6:149753911	chr6:149863494~149919507:+
PRAD	cis	rs12429206	0.52	rs75594262	ENSG00000233672.5	RNASEH2B-AS1	-11.66	1.09e-27	1.75e-24	-0.7	-0.48	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50900249	chr13:50862172~50910764:-
PRAD	cis	rs9322193	0.923	rs2342765	ENSG00000268592.3	RAET1E-AS1	11.66	1.1e-27	1.77e-24	0.66	0.48	Lung cancer;	chr6:149858873	chr6:149863494~149919507:+
PRAD	cis	rs2455601	0.786	rs2568068	ENSG00000254860.4	TMEM9B-AS1	11.66	1.12e-27	1.8e-24	0.54	0.48	Schizophrenia;	chr11:8956283	chr11:8964675~8977527:+
PRAD	cis	rs1150668	0.83	rs213240	ENSG00000216901.1	AL022393.7	11.66	1.12e-27	1.8e-24	0.61	0.48	Pubertal anthropometrics;	chr6:28348098	chr6:28176188~28176674:+
PRAD	cis	rs8062405	0.755	rs17640009	ENSG00000259982.1	CDC37P1	11.66	1.13e-27	1.81e-24	0.63	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28584379	chr16:28700294~28701540:-
PRAD	cis	rs8072100	0.79	rs3760371	ENSG00000228782.6	CTD-2026D20.3	-11.66	1.13e-27	1.81e-24	-0.52	-0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47618548	chr17:47450568~47492492:-
PRAD	cis	rs7688540	0.511	rs75433628	ENSG00000275426.1	CH17-262A2.1	11.66	1.14e-27	1.83e-24	0.75	0.48	Facial morphology (factor 6, height of vermillion lower lip);	chr4:184563	chr4:149738~150317:+
PRAD	cis	rs11676348	0.811	rs13027120	ENSG00000261338.2	RP11-378A13.1	11.66	1.15e-27	1.84e-24	0.54	0.48	Ulcerative colitis;	chr2:218156191	chr2:218255319~218257366:+
PRAD	cis	rs7569084	0.687	rs6755006	ENSG00000204929.10	AC074391.1	-11.66	1.15e-27	1.84e-24	-0.65	-0.48	Sum eosinophil basophil counts;	chr2:65426008	chr2:65436711~66084639:+
PRAD	cis	rs7569084	0.687	rs6755128	ENSG00000204929.10	AC074391.1	-11.66	1.15e-27	1.84e-24	-0.65	-0.48	Sum eosinophil basophil counts;	chr2:65426065	chr2:65436711~66084639:+
PRAD	cis	rs6504950	0.925	rs2628317	ENSG00000275710.1	RP11-257O5.4	11.66	1.15e-27	1.85e-24	0.67	0.48	Breast cancer;	chr17:55135212	chr17:54964474~54964679:+
PRAD	cis	rs7743045	0.652	rs72970476	ENSG00000253194.1	RP11-351A11.1	11.66	1.15e-27	1.85e-24	0.63	0.48	Mean platelet volume;	chr6:118997887	chr6:118934785~119031541:+
PRAD	cis	rs9487094	0.961	rs1040284	ENSG00000260273.1	RP11-425D10.10	11.66	1.15e-27	1.85e-24	0.68	0.48	Height;	chr6:109352730	chr6:109382795~109383666:+
PRAD	cis	rs9487094	0.961	rs34202013	ENSG00000260273.1	RP11-425D10.10	11.66	1.15e-27	1.85e-24	0.68	0.48	Height;	chr6:109353355	chr6:109382795~109383666:+
PRAD	cis	rs6003958	1	rs6003958	ENSG00000231271.1	AP000350.8	-11.66	1.16e-27	1.85e-24	-0.77	-0.48	S-phenylmercapturic acid levels in smokers;	chr22:23921902	chr22:23949918~23954042:+
PRAD	cis	rs5760092	0.755	rs6003959	ENSG00000231271.1	AP000350.8	-11.66	1.16e-27	1.85e-24	-0.77	-0.48	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23922208	chr22:23949918~23954042:+
PRAD	cis	rs732716	0.785	rs56272533	ENSG00000267769.1	CTB-50L17.9	-11.66	1.17e-27	1.87e-24	-0.54	-0.48	Mean corpuscular volume;	chr19:4420045	chr19:4454014~4455286:+
PRAD	cis	rs3096299	0.685	rs4329923	ENSG00000274627.1	RP11-104N10.2	11.66	1.18e-27	1.9e-24	0.48	0.48	Multiple myeloma (IgH translocation);	chr16:89493770	chr16:89516797~89522217:+
PRAD	cis	rs4853012	0.838	rs6707729	ENSG00000257800.1	FNBP1P1	11.65	1.2e-27	1.92e-24	0.42	0.48	Gestational age at birth (maternal effect);	chr2:74117558	chr2:74120680~74123218:+
PRAD	cis	rs8062405	0.691	rs11646653	ENSG00000259982.1	CDC37P1	-11.65	1.22e-27	1.95e-24	-0.64	-0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910828	chr16:28700294~28701540:-
PRAD	cis	rs867371	0.502	rs3759800	ENSG00000278603.1	RP13-608F4.5	-11.65	1.22e-27	1.96e-24	-0.59	-0.48	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82240622	chr15:82472203~82472426:+
PRAD	cis	rs5769707	0.967	rs2187891	ENSG00000188511.11	C22orf34	11.65	1.23e-27	1.98e-24	0.51	0.48	Monocyte percentage of white cells;Monocyte count;	chr22:49600446	chr22:49414524~49657542:-
PRAD	cis	rs1061377	0.965	rs12511857	ENSG00000249207.1	RP11-360F5.1	-11.65	1.26e-27	2.02e-24	-0.52	-0.48	Uric acid levels;	chr4:39143252	chr4:39112677~39126818:-
PRAD	cis	rs9322193	0.884	rs7743823	ENSG00000216906.2	RP11-350J20.9	11.65	1.27e-27	2.04e-24	0.54	0.48	Lung cancer;	chr6:149849744	chr6:149904243~149906418:+
PRAD	cis	rs11123170	0.64	rs1015754	ENSG00000189223.12	PAX8-AS1	11.65	1.27e-27	2.04e-24	0.69	0.48	Renal function-related traits (BUN);	chr2:113210413	chr2:113211522~113276581:+
PRAD	cis	rs875971	0.545	rs6969224	ENSG00000237310.1	GS1-124K5.4	11.65	1.29e-27	2.06e-24	0.48	0.48	Aortic root size;	chr7:66370011	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.502	rs2465121	ENSG00000237310.1	GS1-124K5.4	-11.65	1.29e-27	2.06e-24	-0.49	-0.48	Aortic root size;	chr7:66156017	chr7:66493706~66495474:+
PRAD	cis	rs673078	0.607	rs61946067	ENSG00000275759.1	RP11-131L12.3	-11.65	1.29e-27	2.07e-24	-0.77	-0.48	Glucose homeostasis traits;	chr12:118303152	chr12:118428281~118428870:+
PRAD	cis	rs2455601	0.882	rs11042106	ENSG00000254860.4	TMEM9B-AS1	-11.65	1.3e-27	2.08e-24	-0.61	-0.48	Schizophrenia;	chr11:8874536	chr11:8964675~8977527:+
PRAD	cis	rs2882667	0.66	rs6894907	ENSG00000253404.1	AC034243.1	11.64	1.31e-27	2.1e-24	0.6	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139106815	chr5:138744434~138753309:-
PRAD	cis	rs673078	0.607	rs6490177	ENSG00000275759.1	RP11-131L12.3	-11.64	1.32e-27	2.12e-24	-0.65	-0.48	Glucose homeostasis traits;	chr12:118358280	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.607	rs56080343	ENSG00000275759.1	RP11-131L12.3	-11.64	1.33e-27	2.12e-24	-0.65	-0.48	Glucose homeostasis traits;	chr12:118439113	chr12:118428281~118428870:+
PRAD	cis	rs9322193	0.923	rs7767622	ENSG00000268592.3	RAET1E-AS1	11.64	1.35e-27	2.16e-24	0.66	0.48	Lung cancer;	chr6:149681766	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.923	rs4421206	ENSG00000268592.3	RAET1E-AS1	11.64	1.35e-27	2.16e-24	0.66	0.48	Lung cancer;	chr6:149682891	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.923	rs3798761	ENSG00000268592.3	RAET1E-AS1	11.64	1.35e-27	2.16e-24	0.66	0.48	Lung cancer;	chr6:149683643	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.923	rs9322209	ENSG00000268592.3	RAET1E-AS1	11.64	1.35e-27	2.16e-24	0.66	0.48	Lung cancer;	chr6:149691226	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.962	rs2275045	ENSG00000216906.2	RP11-350J20.9	11.64	1.35e-27	2.16e-24	0.55	0.48	Lung cancer;	chr6:149842775	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.847	rs868375	ENSG00000268592.3	RAET1E-AS1	11.64	1.36e-27	2.17e-24	0.65	0.48	Lung cancer;	chr6:149844905	chr6:149863494~149919507:+
PRAD	cis	rs3814244	0.528	rs2906854	ENSG00000255733.4	IFNG-AS1	-11.64	1.37e-27	2.19e-24	-0.51	-0.48	Itch intensity from mosquito bite adjusted by bite size;	chr12:67993566	chr12:67989445~68234686:+
PRAD	cis	rs875971	0.545	rs1638735	ENSG00000237310.1	GS1-124K5.4	11.64	1.37e-27	2.19e-24	0.48	0.48	Aortic root size;	chr7:66630751	chr7:66493706~66495474:+
PRAD	cis	rs11123170	0.543	rs12472361	ENSG00000189223.12	PAX8-AS1	-11.64	1.37e-27	2.19e-24	-0.74	-0.48	Renal function-related traits (BUN);	chr2:113223068	chr2:113211522~113276581:+
PRAD	cis	rs2739330	0.732	rs5760175	ENSG00000206090.4	AP000350.7	11.64	1.37e-27	2.19e-24	0.6	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23939998~23942798:+
PRAD	cis	rs9322193	0.923	rs11155671	ENSG00000268592.3	RAET1E-AS1	11.64	1.38e-27	2.2e-24	0.66	0.48	Lung cancer;	chr6:149650996	chr6:149863494~149919507:+
PRAD	cis	rs7569084	0.687	rs934731	ENSG00000204929.10	AC074391.1	11.64	1.38e-27	2.2e-24	0.63	0.48	Sum eosinophil basophil counts;	chr2:65456353	chr2:65436711~66084639:+
PRAD	cis	rs875971	0.545	rs11770063	ENSG00000237310.1	GS1-124K5.4	11.64	1.38e-27	2.2e-24	0.48	0.48	Aortic root size;	chr7:66318029	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.545	rs3936065	ENSG00000237310.1	GS1-124K5.4	11.64	1.38e-27	2.2e-24	0.48	0.48	Aortic root size;	chr7:66325577	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.545	rs4718335	ENSG00000237310.1	GS1-124K5.4	11.64	1.38e-27	2.2e-24	0.48	0.48	Aortic root size;	chr7:66339619	chr7:66493706~66495474:+
PRAD	cis	rs2117029	0.521	rs11168885	ENSG00000258017.1	RP11-386G11.10	-11.64	1.39e-27	2.22e-24	-0.63	-0.48	Intelligence (multi-trait analysis);	chr12:49146204	chr12:49127782~49147869:+
PRAD	cis	rs143626010	1	rs143626010	ENSG00000259982.1	CDC37P1	11.64	1.39e-27	2.23e-24	0.64	0.48	Mosquito bite size;	chr16:28528081	chr16:28700294~28701540:-
PRAD	cis	rs673078	0.517	rs73205578	ENSG00000275759.1	RP11-131L12.3	-11.64	1.4e-27	2.23e-24	-0.76	-0.48	Glucose homeostasis traits;	chr12:118385113	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.66	rs73205579	ENSG00000275759.1	RP11-131L12.3	-11.64	1.4e-27	2.23e-24	-0.76	-0.48	Glucose homeostasis traits;	chr12:118385125	chr12:118428281~118428870:+
PRAD	cis	rs9322193	0.884	rs9371201	ENSG00000223701.3	RAET1E-AS1	11.64	1.4e-27	2.24e-24	0.65	0.48	Lung cancer;	chr6:149823865	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.884	rs9322210	ENSG00000268592.3	RAET1E-AS1	11.64	1.4e-27	2.24e-24	0.66	0.48	Lung cancer;	chr6:149695440	chr6:149863494~149919507:+
PRAD	cis	rs6003958	1	rs6003958	ENSG00000273295.1	AP000350.5	-11.64	1.4e-27	2.24e-24	-0.69	-0.48	S-phenylmercapturic acid levels in smokers;	chr22:23921902	chr22:23901432~23907068:-
PRAD	cis	rs5760092	0.755	rs6003959	ENSG00000273295.1	AP000350.5	-11.64	1.4e-27	2.24e-24	-0.69	-0.48	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23922208	chr22:23901432~23907068:-
PRAD	cis	rs12049351	0.774	rs11805194	ENSG00000229367.1	HMGN2P19	11.64	1.42e-27	2.26e-24	0.67	0.48	Circulating myeloperoxidase levels (plasma);	chr1:229495987	chr1:229570532~229570796:+
PRAD	cis	rs9487094	0.744	rs13199519	ENSG00000260273.1	RP11-425D10.10	11.64	1.42e-27	2.27e-24	0.71	0.48	Height;	chr6:109387972	chr6:109382795~109383666:+
PRAD	cis	rs8062405	0.895	rs62036658	ENSG00000251417.2	RP11-1348G14.4	-11.64	1.42e-27	2.27e-24	-0.54	-0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28839050	chr16:28802743~28817828:+
PRAD	cis	rs6142102	0.625	rs4911137	ENSG00000276073.1	RP5-1125A11.7	-11.63	1.44e-27	2.3e-24	-0.46	-0.48	Skin pigmentation;	chr20:33947657	chr20:33985617~33988989:-
PRAD	cis	rs673078	0.66	rs17440433	ENSG00000275759.1	RP11-131L12.3	-11.63	1.45e-27	2.31e-24	-0.76	-0.48	Glucose homeostasis traits;	chr12:118201507	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.66	rs17512219	ENSG00000275759.1	RP11-131L12.3	-11.63	1.45e-27	2.31e-24	-0.76	-0.48	Glucose homeostasis traits;	chr12:118211468	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.66	rs61945212	ENSG00000275759.1	RP11-131L12.3	-11.63	1.45e-27	2.31e-24	-0.76	-0.48	Glucose homeostasis traits;	chr12:118252351	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.66	rs73205531	ENSG00000275759.1	RP11-131L12.3	-11.63	1.45e-27	2.31e-24	-0.76	-0.48	Glucose homeostasis traits;	chr12:118282063	chr12:118428281~118428870:+
PRAD	cis	rs9322193	0.923	rs10872649	ENSG00000216906.2	RP11-350J20.9	11.63	1.45e-27	2.32e-24	0.55	0.48	Lung cancer;	chr6:149759454	chr6:149904243~149906418:+
PRAD	cis	rs17826219	0.706	rs609472	ENSG00000263531.1	RP13-753N3.1	11.63	1.45e-27	2.32e-24	0.8	0.48	Body mass index;	chr17:30624409	chr17:30863921~30864940:-
PRAD	cis	rs7044106	0.762	rs7044226	ENSG00000226752.6	PSMD5-AS1	-11.63	1.46e-27	2.34e-24	-0.58	-0.48	Hip circumference adjusted for BMI;	chr9:120704050	chr9:120824828~120854385:+
PRAD	cis	rs7688540	0.511	rs61794991	ENSG00000275426.1	CH17-262A2.1	11.63	1.48e-27	2.36e-24	0.74	0.48	Facial morphology (factor 6, height of vermillion lower lip);	chr4:204418	chr4:149738~150317:+
PRAD	cis	rs6504950	0.889	rs1484769	ENSG00000275710.1	RP11-257O5.4	-11.63	1.48e-27	2.36e-24	-0.65	-0.48	Breast cancer;	chr17:55089290	chr17:54964474~54964679:+
PRAD	cis	rs9532669	0.926	rs9566582	ENSG00000176268.5	CYCSP34	11.63	1.48e-27	2.36e-24	0.52	0.48	Cervical cancer;	chr13:40852121	chr13:40863599~40863902:-
PRAD	cis	rs977987	0.8	rs12922951	ENSG00000261783.1	RP11-252K23.2	-11.63	1.48e-27	2.37e-24	-0.65	-0.48	Dupuytren's disease;	chr16:75321198	chr16:75379818~75381260:-
PRAD	cis	rs2404602	0.647	rs11632765	ENSG00000259422.1	RP11-593F23.1	11.63	1.49e-27	2.37e-24	0.63	0.48	Blood metabolite levels;	chr15:76681920	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.735	rs4886800	ENSG00000259422.1	RP11-593F23.1	-11.63	1.49e-27	2.38e-24	-0.64	-0.48	Blood metabolite levels;	chr15:76386351	chr15:76174891~76181486:-
PRAD	cis	rs9322193	0.884	rs9397036	ENSG00000216906.2	RP11-350J20.9	11.63	1.49e-27	2.38e-24	0.54	0.48	Lung cancer;	chr6:149851787	chr6:149904243~149906418:+
PRAD	cis	rs5760092	0.618	rs5996631	ENSG00000273295.1	AP000350.5	-11.63	1.5e-27	2.39e-24	-0.65	-0.48	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23901432~23907068:-
PRAD	cis	rs7044106	0.791	rs10984997	ENSG00000226752.6	PSMD5-AS1	-11.63	1.5e-27	2.4e-24	-0.6	-0.48	Hip circumference adjusted for BMI;	chr9:120718928	chr9:120824828~120854385:+
PRAD	cis	rs3096299	0.746	rs9931120	ENSG00000274627.1	RP11-104N10.2	11.63	1.51e-27	2.4e-24	0.48	0.48	Multiple myeloma (IgH translocation);	chr16:89434949	chr16:89516797~89522217:+
PRAD	cis	rs9322193	0.923	rs9371207	ENSG00000216906.2	RP11-350J20.9	11.63	1.51e-27	2.41e-24	0.55	0.48	Lung cancer;	chr6:149858087	chr6:149904243~149906418:+
PRAD	cis	rs9487094	0.961	rs11967108	ENSG00000260273.1	RP11-425D10.10	11.63	1.53e-27	2.44e-24	0.68	0.48	Height;	chr6:109354040	chr6:109382795~109383666:+
PRAD	cis	rs748404	0.56	rs570933	ENSG00000205771.5	CATSPER2P1	-11.63	1.54e-27	2.45e-24	-0.55	-0.48	Lung cancer;	chr15:43531832	chr15:43726918~43747094:-
PRAD	cis	rs9322193	0.923	rs4869750	ENSG00000216906.2	RP11-350J20.9	11.63	1.56e-27	2.48e-24	0.55	0.48	Lung cancer;	chr6:149855996	chr6:149904243~149906418:+
PRAD	cis	rs2658782	0.901	rs11604909	ENSG00000279684.1	RP11-755E23.2	-11.62	1.57e-27	2.49e-24	-0.8	-0.48	Pulmonary function decline;	chr11:93485189	chr11:93286629~93288903:-
PRAD	cis	rs7772486	0.597	rs1970306	ENSG00000235652.6	RP11-545I5.3	11.62	1.57e-27	2.5e-24	0.53	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145833407	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.597	rs9386136	ENSG00000235652.6	RP11-545I5.3	11.62	1.57e-27	2.5e-24	0.53	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145837164	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.597	rs2246132	ENSG00000235652.6	RP11-545I5.3	11.62	1.57e-27	2.5e-24	0.53	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145861379	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.597	rs2485631	ENSG00000235652.6	RP11-545I5.3	11.62	1.57e-27	2.5e-24	0.53	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145868941	chr6:145799409~145886585:+
PRAD	cis	rs2117029	0.521	rs1056875	ENSG00000258017.1	RP11-386G11.10	-11.62	1.57e-27	2.5e-24	-0.62	-0.48	Intelligence (multi-trait analysis);	chr12:49186397	chr12:49127782~49147869:+
PRAD	cis	rs2739330	0.828	rs5760102	ENSG00000231271.1	AP000350.8	11.62	1.57e-27	2.5e-24	0.65	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23949918~23954042:+
PRAD	cis	rs9322193	0.923	rs10872644	ENSG00000216906.2	RP11-350J20.9	11.62	1.6e-27	2.54e-24	0.55	0.48	Lung cancer;	chr6:149741819	chr6:149904243~149906418:+
PRAD	cis	rs3814244	0.528	rs1468487	ENSG00000255733.4	IFNG-AS1	-11.62	1.63e-27	2.59e-24	-0.5	-0.48	Itch intensity from mosquito bite adjusted by bite size;	chr12:67996602	chr12:67989445~68234686:+
PRAD	cis	rs4423214	0.592	rs11233977	ENSG00000254682.1	RP11-660L16.2	-11.62	1.63e-27	2.59e-24	-0.76	-0.48	Vitamin D levels;	chr11:71510559	chr11:71448674~71452157:+
PRAD	cis	rs12594515	1	rs6493170	ENSG00000273972.1	CTD-2306A12.1	-11.62	1.66e-27	2.64e-24	-0.53	-0.48	Weight;Waist circumference;	chr15:45694821	chr15:45702640~45703183:+
PRAD	cis	rs9532669	0.963	rs4942012	ENSG00000176268.5	CYCSP34	11.62	1.68e-27	2.67e-24	0.49	0.48	Cervical cancer;	chr13:40939112	chr13:40863599~40863902:-
PRAD	cis	rs2658782	0.789	rs2605574	ENSG00000279684.1	RP11-755E23.2	-11.62	1.7e-27	2.7e-24	-0.72	-0.48	Pulmonary function decline;	chr11:93403278	chr11:93286629~93288903:-
PRAD	cis	rs9487094	1	rs35056702	ENSG00000260273.1	RP11-425D10.10	11.62	1.7e-27	2.7e-24	0.66	0.48	Height;	chr6:109415123	chr6:109382795~109383666:+
PRAD	cis	rs8062405	0.755	rs4788080	ENSG00000259982.1	CDC37P1	11.62	1.71e-27	2.72e-24	0.63	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546760	chr16:28700294~28701540:-
PRAD	cis	rs8062405	0.723	rs4788079	ENSG00000259982.1	CDC37P1	11.62	1.71e-27	2.72e-24	0.63	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548042	chr16:28700294~28701540:-
PRAD	cis	rs8062405	0.755	rs4787456	ENSG00000259982.1	CDC37P1	11.62	1.71e-27	2.72e-24	0.63	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548252	chr16:28700294~28701540:-
PRAD	cis	rs8062405	0.755	rs4788078	ENSG00000259982.1	CDC37P1	11.62	1.71e-27	2.72e-24	0.63	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548660	chr16:28700294~28701540:-
PRAD	cis	rs8062405	0.755	rs62034350	ENSG00000259982.1	CDC37P1	11.62	1.71e-27	2.72e-24	0.63	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28550935	chr16:28700294~28701540:-
PRAD	cis	rs7240205	0.535	rs72887347	ENSG00000275805.1	RP11-349H17.2	-11.61	1.72e-27	2.74e-24	-0.63	-0.48	Breast cancer;	chr18:26570275	chr18:26565723~26575626:-
PRAD	cis	rs9487094	0.922	rs2236582	ENSG00000260273.1	RP11-425D10.10	-11.61	1.72e-27	2.74e-24	-0.68	-0.48	Height;	chr6:109444615	chr6:109382795~109383666:+
PRAD	cis	rs1577917	0.958	rs34795473	ENSG00000203875.9	SNHG5	-11.61	1.76e-27	2.8e-24	-0.54	-0.48	Response to antipsychotic treatment;	chr6:85752081	chr6:85660950~85678736:-
PRAD	cis	rs9322193	0.923	rs10872650	ENSG00000216906.2	RP11-350J20.9	11.61	1.76e-27	2.8e-24	0.55	0.48	Lung cancer;	chr6:149760959	chr6:149904243~149906418:+
PRAD	cis	rs12049351	0.665	rs6663689	ENSG00000229367.1	HMGN2P19	11.61	1.77e-27	2.81e-24	0.67	0.48	Circulating myeloperoxidase levels (plasma);	chr1:229494416	chr1:229570532~229570796:+
PRAD	cis	rs9322193	0.847	rs12191643	ENSG00000268592.3	RAET1E-AS1	11.61	1.77e-27	2.81e-24	0.65	0.48	Lung cancer;	chr6:149628912	chr6:149863494~149919507:+
PRAD	cis	rs2117029	0.586	rs10875928	ENSG00000258017.1	RP11-386G11.10	-11.61	1.78e-27	2.82e-24	-0.63	-0.48	Intelligence (multi-trait analysis);	chr12:49162520	chr12:49127782~49147869:+
PRAD	cis	rs673078	0.66	rs61946068	ENSG00000275759.1	RP11-131L12.3	-11.61	1.78e-27	2.83e-24	-0.77	-0.48	Glucose homeostasis traits;	chr12:118305861	chr12:118428281~118428870:+
PRAD	cis	rs780096	0.587	rs4665969	ENSG00000234072.1	AC074117.10	11.61	1.79e-27	2.83e-24	0.37	0.48	Total body bone mineral density;	chr2:27352086	chr2:27356246~27367622:+
PRAD	cis	rs2404602	0.647	rs10851892	ENSG00000259422.1	RP11-593F23.1	-11.61	1.79e-27	2.83e-24	-0.65	-0.48	Blood metabolite levels;	chr15:76884150	chr15:76174891~76181486:-
PRAD	cis	rs11123170	0.529	rs1015755	ENSG00000189223.12	PAX8-AS1	-11.61	1.8e-27	2.86e-24	-0.73	-0.48	Renal function-related traits (BUN);	chr2:113210730	chr2:113211522~113276581:+
PRAD	cis	rs9322193	0.923	rs12529698	ENSG00000268592.3	RAET1E-AS1	11.61	1.8e-27	2.86e-24	0.66	0.48	Lung cancer;	chr6:149650951	chr6:149863494~149919507:+
PRAD	cis	rs8072100	0.79	rs6505048	ENSG00000228782.6	CTD-2026D20.3	-11.61	1.82e-27	2.88e-24	-0.52	-0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47597632	chr17:47450568~47492492:-
PRAD	cis	rs1426063	0.614	rs78784058	ENSG00000249717.1	RP11-44F21.3	11.61	1.83e-27	2.91e-24	1.02	0.48	QT interval;	chr4:75108738	chr4:74955974~74970362:-
PRAD	cis	rs2739330	0.828	rs5760098	ENSG00000231271.1	AP000350.8	11.61	1.86e-27	2.95e-24	0.65	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23949918~23954042:+
PRAD	cis	rs2739330	0.753	rs4822452	ENSG00000250470.1	AP000351.3	11.61	1.86e-27	2.95e-24	0.65	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23976904~23977585:-
PRAD	cis	rs17711722	0.522	rs62469933	ENSG00000226824.5	RP4-756H11.3	-11.6	1.88e-27	2.98e-24	-0.61	-0.48	Calcium levels;	chr7:65800652	chr7:66654538~66669855:+
PRAD	cis	rs1577917	0.837	rs806529	ENSG00000203875.9	SNHG5	-11.6	1.88e-27	2.98e-24	-0.53	-0.48	Response to antipsychotic treatment;	chr6:85757403	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.958	rs6921315	ENSG00000203875.9	SNHG5	-11.6	1.88e-27	2.98e-24	-0.53	-0.48	Response to antipsychotic treatment;	chr6:85761950	chr6:85660950~85678736:-
PRAD	cis	rs6991838	0.584	rs6993876	ENSG00000272010.1	CTD-3025N20.3	11.6	1.89e-27	2.99e-24	0.5	0.48	Intelligence (multi-trait analysis);	chr8:65601240	chr8:65591850~65592472:-
PRAD	cis	rs9322193	0.847	rs880246	ENSG00000216906.2	RP11-350J20.9	11.6	1.9e-27	3.01e-24	0.54	0.48	Lung cancer;	chr6:149845972	chr6:149904243~149906418:+
PRAD	cis	rs7396835	0.537	rs10892035	ENSG00000254851.1	RP11-109L13.1	-11.6	1.95e-27	3.08e-24	-0.8	-0.48	Quantitative traits;	chr11:116824222	chr11:117135528~117138582:+
PRAD	cis	rs1577917	0.958	rs6900436	ENSG00000203875.9	SNHG5	-11.6	1.96e-27	3.1e-24	-0.53	-0.48	Response to antipsychotic treatment;	chr6:85796570	chr6:85660950~85678736:-
PRAD	cis	rs9322193	0.923	rs1934534	ENSG00000268592.3	RAET1E-AS1	11.6	1.96e-27	3.11e-24	0.65	0.48	Lung cancer;	chr6:149711896	chr6:149863494~149919507:+
PRAD	cis	rs8062405	0.755	rs12445823	ENSG00000259982.1	CDC37P1	11.6	1.98e-27	3.13e-24	0.63	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576728	chr16:28700294~28701540:-
PRAD	cis	rs8062405	0.723	rs12445744	ENSG00000259982.1	CDC37P1	11.6	1.98e-27	3.13e-24	0.63	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28577074	chr16:28700294~28701540:-
PRAD	cis	rs8062405	0.755	rs4787455	ENSG00000259982.1	CDC37P1	11.6	1.98e-27	3.13e-24	0.63	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28578134	chr16:28700294~28701540:-
PRAD	cis	rs875971	0.545	rs12671152	ENSG00000237310.1	GS1-124K5.4	11.6	1.98e-27	3.13e-24	0.5	0.48	Aortic root size;	chr7:66311140	chr7:66493706~66495474:+
PRAD	cis	rs11690935	0.632	rs34531723	ENSG00000228389.1	AC068039.4	-11.6	1.99e-27	3.15e-24	-0.53	-0.48	Schizophrenia;	chr2:171707584	chr2:171773482~171775844:+
PRAD	cis	rs673078	0.66	rs75752792	ENSG00000275759.1	RP11-131L12.3	-11.6	2.02e-27	3.19e-24	-0.75	-0.48	Glucose homeostasis traits;	chr12:118187005	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.66	rs75571641	ENSG00000275759.1	RP11-131L12.3	-11.6	2.02e-27	3.19e-24	-0.75	-0.48	Glucose homeostasis traits;	chr12:118187012	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.66	rs17512177	ENSG00000275759.1	RP11-131L12.3	-11.6	2.02e-27	3.19e-24	-0.75	-0.48	Glucose homeostasis traits;	chr12:118192335	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.66	rs17512198	ENSG00000275759.1	RP11-131L12.3	-11.6	2.02e-27	3.19e-24	-0.75	-0.48	Glucose homeostasis traits;	chr12:118194217	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.66	rs10507286	ENSG00000275759.1	RP11-131L12.3	-11.6	2.02e-27	3.19e-24	-0.75	-0.48	Glucose homeostasis traits;	chr12:118197101	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.66	rs61945183	ENSG00000275759.1	RP11-131L12.3	-11.6	2.02e-27	3.19e-24	-0.75	-0.48	Glucose homeostasis traits;	chr12:118221966	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.66	rs16948193	ENSG00000275759.1	RP11-131L12.3	-11.6	2.02e-27	3.19e-24	-0.75	-0.48	Glucose homeostasis traits;	chr12:118227115	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.66	rs61945187	ENSG00000275759.1	RP11-131L12.3	-11.6	2.02e-27	3.19e-24	-0.75	-0.48	Glucose homeostasis traits;	chr12:118228989	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.66	rs73205512	ENSG00000275759.1	RP11-131L12.3	-11.6	2.02e-27	3.19e-24	-0.75	-0.48	Glucose homeostasis traits;	chr12:118235770	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.66	rs61945206	ENSG00000275759.1	RP11-131L12.3	-11.6	2.02e-27	3.19e-24	-0.75	-0.48	Glucose homeostasis traits;	chr12:118238295	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.66	rs7970481	ENSG00000275759.1	RP11-131L12.3	-11.6	2.02e-27	3.19e-24	-0.75	-0.48	Glucose homeostasis traits;	chr12:118242112	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.66	rs7973455	ENSG00000275759.1	RP11-131L12.3	-11.6	2.02e-27	3.19e-24	-0.75	-0.48	Glucose homeostasis traits;	chr12:118247490	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.66	rs58113338	ENSG00000275759.1	RP11-131L12.3	-11.6	2.02e-27	3.19e-24	-0.75	-0.48	Glucose homeostasis traits;	chr12:118251335	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.615	rs16948204	ENSG00000275759.1	RP11-131L12.3	-11.6	2.02e-27	3.19e-24	-0.75	-0.48	Glucose homeostasis traits;	chr12:118258252	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.66	rs7303417	ENSG00000275759.1	RP11-131L12.3	-11.6	2.02e-27	3.19e-24	-0.75	-0.48	Glucose homeostasis traits;	chr12:118258859	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.66	rs7965350	ENSG00000275759.1	RP11-131L12.3	-11.6	2.02e-27	3.19e-24	-0.75	-0.48	Glucose homeostasis traits;	chr12:118266710	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.66	rs17433217	ENSG00000275759.1	RP11-131L12.3	-11.6	2.02e-27	3.19e-24	-0.75	-0.48	Glucose homeostasis traits;	chr12:118269076	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.66	rs73205526	ENSG00000275759.1	RP11-131L12.3	-11.6	2.02e-27	3.19e-24	-0.75	-0.48	Glucose homeostasis traits;	chr12:118273172	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.66	rs56708462	ENSG00000275759.1	RP11-131L12.3	-11.6	2.02e-27	3.19e-24	-0.75	-0.48	Glucose homeostasis traits;	chr12:118284135	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.66	rs7962185	ENSG00000275759.1	RP11-131L12.3	-11.6	2.02e-27	3.19e-24	-0.75	-0.48	Glucose homeostasis traits;	chr12:118287842	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.66	rs76621503	ENSG00000275759.1	RP11-131L12.3	-11.6	2.03e-27	3.2e-24	-0.76	-0.48	Glucose homeostasis traits;	chr12:118179370	chr12:118428281~118428870:+
PRAD	cis	rs4722166	0.597	rs2069845	ENSG00000179428.2	AC073072.5	-11.6	2.04e-27	3.21e-24	-0.55	-0.48	Lung cancer;	chr7:22730530	chr7:22725395~22727620:-
PRAD	cis	rs71403859	0.73	rs12446333	ENSG00000260886.1	TAT-AS1	11.59	2.07e-27	3.26e-24	0.87	0.48	Post bronchodilator FEV1;	chr16:71718254	chr16:71565789~71578187:+
PRAD	cis	rs524281	0.692	rs10896076	ENSG00000255320.1	RP11-755F10.1	11.59	2.07e-27	3.26e-24	0.74	0.48	Electroencephalogram traits;	chr11:66073197	chr11:66244840~66246239:-
PRAD	cis	rs9532669	0.963	rs7989303	ENSG00000176268.5	CYCSP34	11.59	2.07e-27	3.27e-24	0.5	0.48	Cervical cancer;	chr13:40950087	chr13:40863599~40863902:-
PRAD	cis	rs2117029	0.521	rs12227610	ENSG00000258017.1	RP11-386G11.10	-11.59	2.08e-27	3.28e-24	-0.62	-0.48	Intelligence (multi-trait analysis);	chr12:49146153	chr12:49127782~49147869:+
PRAD	cis	rs3814244	0.528	rs2860609	ENSG00000255733.4	IFNG-AS1	-11.59	2.09e-27	3.29e-24	-0.5	-0.48	Itch intensity from mosquito bite adjusted by bite size;	chr12:67997215	chr12:67989445~68234686:+
PRAD	cis	rs7240205	0.853	rs34288695	ENSG00000275805.1	RP11-349H17.2	11.59	2.1e-27	3.3e-24	0.58	0.48	Breast cancer;	chr18:26563122	chr18:26565723~26575626:-
PRAD	cis	rs9487094	1	rs10080429	ENSG00000260273.1	RP11-425D10.10	11.59	2.1e-27	3.31e-24	0.66	0.48	Height;	chr6:109416903	chr6:109382795~109383666:+
PRAD	cis	rs1577917	0.958	rs12190603	ENSG00000203875.9	SNHG5	-11.59	2.11e-27	3.32e-24	-0.54	-0.48	Response to antipsychotic treatment;	chr6:85766000	chr6:85660950~85678736:-
PRAD	cis	rs2929278	0.589	rs11638972	ENSG00000249839.1	AC011330.5	11.59	2.12e-27	3.33e-24	0.61	0.48	Schizophrenia;	chr15:43782493	chr15:43663654~43684339:-
PRAD	cis	rs11673344	0.67	rs73039188	ENSG00000226686.6	LINC01535	11.59	2.12e-27	3.35e-24	0.67	0.48	Obesity-related traits;	chr19:36922449	chr19:37251912~37265535:+
PRAD	cis	rs12049351	0.774	rs4925455	ENSG00000229367.1	HMGN2P19	11.59	2.15e-27	3.38e-24	0.66	0.48	Circulating myeloperoxidase levels (plasma);	chr1:229487918	chr1:229570532~229570796:+
PRAD	cis	rs673078	0.66	rs61945180	ENSG00000275759.1	RP11-131L12.3	-11.59	2.15e-27	3.38e-24	-0.75	-0.48	Glucose homeostasis traits;	chr12:118216335	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.66	rs61945181	ENSG00000275759.1	RP11-131L12.3	-11.59	2.15e-27	3.38e-24	-0.75	-0.48	Glucose homeostasis traits;	chr12:118216651	chr12:118428281~118428870:+
PRAD	cis	rs8062405	0.69	rs7187604	ENSG00000259982.1	CDC37P1	11.59	2.16e-27	3.41e-24	0.63	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554632	chr16:28700294~28701540:-
PRAD	cis	rs9322193	0.961	rs4870144	ENSG00000268592.3	RAET1E-AS1	11.59	2.17e-27	3.42e-24	0.67	0.48	Lung cancer;	chr6:149575540	chr6:149863494~149919507:+
PRAD	cis	rs7617773	0.963	rs12493256	ENSG00000229759.1	MRPS18AP1	-11.59	2.2e-27	3.46e-24	-0.49	-0.48	Coronary artery disease;	chr3:48135257	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.963	rs12494304	ENSG00000229759.1	MRPS18AP1	-11.59	2.2e-27	3.46e-24	-0.49	-0.48	Coronary artery disease;	chr3:48136539	chr3:48256350~48256938:-
PRAD	cis	rs2404602	0.574	rs4886795	ENSG00000259422.1	RP11-593F23.1	-11.59	2.2e-27	3.47e-24	-0.64	-0.48	Blood metabolite levels;	chr15:76349877	chr15:76174891~76181486:-
PRAD	cis	rs6907340	0.513	rs6938418	ENSG00000228412.5	RP4-625H18.2	-11.59	2.21e-27	3.47e-24	-0.65	-0.48	Endometriosis;	chr6:19808802	chr6:19802164~19804752:-
PRAD	cis	rs34375054	0.672	rs10400509	ENSG00000279233.1	RP11-158L12.4	11.59	2.21e-27	3.48e-24	0.44	0.48	Post bronchodilator FEV1/FVC ratio;	chr12:125107627	chr12:125138245~125141711:+
PRAD	cis	rs11723261	0.545	rs6812799	ENSG00000275426.1	CH17-262A2.1	11.59	2.22e-27	3.5e-24	0.74	0.48	Immune response to smallpox vaccine (IL-6);	chr4:203545	chr4:149738~150317:+
PRAD	cis	rs7688540	0.511	rs6845131	ENSG00000275426.1	CH17-262A2.1	11.59	2.22e-27	3.5e-24	0.74	0.48	Facial morphology (factor 6, height of vermillion lower lip);	chr4:206358	chr4:149738~150317:+
PRAD	cis	rs7688540	0.511	rs11731623	ENSG00000275426.1	CH17-262A2.1	11.59	2.22e-27	3.5e-24	0.74	0.48	Facial morphology (factor 6, height of vermillion lower lip);	chr4:207221	chr4:149738~150317:+
PRAD	cis	rs9532669	0.963	rs4941391	ENSG00000176268.5	CYCSP34	11.59	2.23e-27	3.5e-24	0.5	0.48	Cervical cancer;	chr13:40939787	chr13:40863599~40863902:-
PRAD	cis	rs9322193	0.923	rs9479494	ENSG00000216906.2	RP11-350J20.9	11.59	2.24e-27	3.52e-24	0.55	0.48	Lung cancer;	chr6:149739108	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.923	rs9800806	ENSG00000216906.2	RP11-350J20.9	11.59	2.24e-27	3.52e-24	0.55	0.48	Lung cancer;	chr6:149740350	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.923	rs9688517	ENSG00000216906.2	RP11-350J20.9	11.59	2.24e-27	3.52e-24	0.55	0.48	Lung cancer;	chr6:149740655	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.923	rs1572229	ENSG00000216906.2	RP11-350J20.9	11.59	2.24e-27	3.52e-24	0.55	0.48	Lung cancer;	chr6:149743841	chr6:149904243~149906418:+
PRAD	cis	rs34375054	0.525	rs12316499	ENSG00000279233.1	RP11-158L12.4	11.58	2.26e-27	3.55e-24	0.45	0.48	Post bronchodilator FEV1/FVC ratio;	chr12:125108772	chr12:125138245~125141711:+
PRAD	cis	rs8062405	0.789	rs2106480	ENSG00000259982.1	CDC37P1	11.58	2.26e-27	3.55e-24	0.61	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28526650	chr16:28700294~28701540:-
PRAD	cis	rs11723261	0.546	rs57839456	ENSG00000275426.1	CH17-262A2.1	11.58	2.28e-27	3.58e-24	0.67	0.48	Immune response to smallpox vaccine (IL-6);	chr4:154494	chr4:149738~150317:+
PRAD	cis	rs7569084	0.663	rs4671128	ENSG00000204929.10	AC074391.1	11.58	2.31e-27	3.62e-24	0.63	0.48	Sum eosinophil basophil counts;	chr2:65438130	chr2:65436711~66084639:+
PRAD	cis	rs1577917	0.771	rs6454486	ENSG00000203875.9	SNHG5	11.58	2.31e-27	3.63e-24	0.55	0.48	Response to antipsychotic treatment;	chr6:85723869	chr6:85660950~85678736:-
PRAD	cis	rs6964833	0.935	rs34762099	ENSG00000277053.3	GTF2IP1	-11.58	2.35e-27	3.69e-24	-0.57	-0.48	Menarche (age at onset);	chr7:74636378	chr7:75185385~75237696:-
PRAD	cis	rs1426063	0.614	rs17000260	ENSG00000249717.1	RP11-44F21.3	11.58	2.35e-27	3.69e-24	1.01	0.48	QT interval;	chr4:75108576	chr4:74955974~74970362:-
PRAD	cis	rs1577917	0.958	rs2324817	ENSG00000203875.9	SNHG5	-11.58	2.37e-27	3.72e-24	-0.53	-0.48	Response to antipsychotic treatment;	chr6:85752936	chr6:85660950~85678736:-
PRAD	cis	rs9322193	0.884	rs7450246	ENSG00000268592.3	RAET1E-AS1	11.58	2.39e-27	3.76e-24	0.65	0.48	Lung cancer;	chr6:149702517	chr6:149863494~149919507:+
PRAD	cis	rs2404602	0.552	rs11630185	ENSG00000259422.1	RP11-593F23.1	-11.58	2.4e-27	3.77e-24	-0.66	-0.48	Blood metabolite levels;	chr15:76667442	chr15:76174891~76181486:-
PRAD	cis	rs977987	0.741	rs10514393	ENSG00000261783.1	RP11-252K23.2	-11.58	2.41e-27	3.77e-24	-0.65	-0.48	Dupuytren's disease;	chr16:75310578	chr16:75379818~75381260:-
PRAD	cis	rs12049351	0.719	rs3818237	ENSG00000229367.1	HMGN2P19	11.58	2.43e-27	3.81e-24	0.66	0.48	Circulating myeloperoxidase levels (plasma);	chr1:229495446	chr1:229570532~229570796:+
PRAD	cis	rs4853012	0.838	rs72911122	ENSG00000257800.1	FNBP1P1	11.58	2.45e-27	3.83e-24	0.42	0.48	Gestational age at birth (maternal effect);	chr2:74116992	chr2:74120680~74123218:+
PRAD	cis	rs977987	0.835	rs1010630	ENSG00000261783.1	RP11-252K23.2	-11.58	2.45e-27	3.84e-24	-0.65	-0.48	Dupuytren's disease;	chr16:75294693	chr16:75379818~75381260:-
PRAD	cis	rs3096299	0.503	rs4785677	ENSG00000274627.1	RP11-104N10.2	11.58	2.45e-27	3.85e-24	0.48	0.48	Multiple myeloma (IgH translocation);	chr16:89488693	chr16:89516797~89522217:+
PRAD	cis	rs9322193	0.884	rs7744105	ENSG00000216906.2	RP11-350J20.9	11.57	2.49e-27	3.9e-24	0.54	0.48	Lung cancer;	chr6:149849308	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.884	rs9383865	ENSG00000216906.2	RP11-350J20.9	11.57	2.49e-27	3.91e-24	0.54	0.48	Lung cancer;	chr6:149852043	chr6:149904243~149906418:+
PRAD	cis	rs7208859	0.673	rs56846352	ENSG00000263531.1	RP13-753N3.1	11.57	2.5e-27	3.92e-24	0.81	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792170	chr17:30863921~30864940:-
PRAD	cis	rs875971	0.545	rs6970498	ENSG00000237310.1	GS1-124K5.4	11.57	2.52e-27	3.94e-24	0.48	0.48	Aortic root size;	chr7:66275908	chr7:66493706~66495474:+
PRAD	cis	rs2906856	0.848	rs3015001	ENSG00000255733.4	IFNG-AS1	-11.57	2.53e-27	3.96e-24	-0.51	-0.48	Mosquito bite size;	chr12:68003593	chr12:67989445~68234686:+
PRAD	cis	rs9322193	0.887	rs4870139	ENSG00000223701.3	RAET1E-AS1	11.57	2.53e-27	3.97e-24	0.66	0.48	Lung cancer;	chr6:149575182	chr6:149884431~149919508:+
PRAD	cis	rs780096	0.587	rs6760828	ENSG00000234072.1	AC074117.10	-11.57	2.54e-27	3.98e-24	-0.38	-0.48	Total body bone mineral density;	chr2:27356364	chr2:27356246~27367622:+
PRAD	cis	rs9322193	0.516	rs1999632	ENSG00000231760.4	RP11-350J20.5	11.57	2.55e-27	3.99e-24	0.76	0.48	Lung cancer;	chr6:149866737	chr6:149796151~149826294:-
PRAD	cis	rs7772486	0.79	rs2253768	ENSG00000235652.6	RP11-545I5.3	11.57	2.55e-27	4e-24	0.49	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145878786	chr6:145799409~145886585:+
PRAD	cis	rs8062405	1	rs62036616	ENSG00000251417.2	RP11-1348G14.4	-11.57	2.56e-27	4e-24	-0.54	-0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814986	chr16:28802743~28817828:+
PRAD	cis	rs7569084	0.687	rs12993075	ENSG00000204929.10	AC074391.1	11.57	2.56e-27	4.01e-24	0.64	0.48	Sum eosinophil basophil counts;	chr2:65431010	chr2:65436711~66084639:+
PRAD	cis	rs7772486	0.754	rs13214277	ENSG00000235652.6	RP11-545I5.3	11.57	2.57e-27	4.02e-24	0.49	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145814989	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.754	rs9386132	ENSG00000235652.6	RP11-545I5.3	11.57	2.57e-27	4.02e-24	0.49	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145819615	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.754	rs9386134	ENSG00000235652.6	RP11-545I5.3	11.57	2.57e-27	4.02e-24	0.49	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145824372	chr6:145799409~145886585:+
PRAD	cis	rs6452524	0.534	rs10061690	ENSG00000249664.1	CTD-2227C6.2	11.57	2.58e-27	4.04e-24	0.57	0.48	Hypertension (SNP x SNP interaction);	chr5:83063226	chr5:83012285~83013109:-
PRAD	cis	rs8062405	0.722	rs3785354	ENSG00000259982.1	CDC37P1	11.57	2.68e-27	4.2e-24	0.63	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28539346	chr16:28700294~28701540:-
PRAD	cis	rs8062405	0.755	rs4787457	ENSG00000259982.1	CDC37P1	11.57	2.68e-27	4.2e-24	0.63	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544079	chr16:28700294~28701540:-
PRAD	cis	rs9322193	0.607	rs10457852	ENSG00000268592.3	RAET1E-AS1	11.56	2.7e-27	4.23e-24	0.76	0.48	Lung cancer;	chr6:149880584	chr6:149863494~149919507:+
PRAD	cis	rs765787	0.53	rs4775819	ENSG00000259520.4	CTD-2651B20.3	11.56	2.7e-27	4.23e-24	0.58	0.48	Uric acid levels;	chr15:45233768	chr15:45251580~45279251:-
PRAD	cis	rs2348418	0.733	rs2019011	ENSG00000247934.4	RP11-967K21.1	11.56	2.72e-27	4.25e-24	0.44	0.48	Lung function (FEV1);Lung function (FVC);	chr12:28228144	chr12:28163298~28190738:-
PRAD	cis	rs4423214	0.592	rs10898211	ENSG00000254682.1	RP11-660L16.2	-11.56	2.72e-27	4.26e-24	-0.76	-0.48	Vitamin D levels;	chr11:71499631	chr11:71448674~71452157:+
PRAD	cis	rs2404602	0.647	rs11072625	ENSG00000259422.1	RP11-593F23.1	11.56	2.75e-27	4.29e-24	0.64	0.48	Blood metabolite levels;	chr15:76792643	chr15:76174891~76181486:-
PRAD	cis	rs8062405	0.824	rs4788083	ENSG00000259982.1	CDC37P1	11.56	2.75e-27	4.29e-24	0.61	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534128	chr16:28700294~28701540:-
PRAD	cis	rs1185460	0.967	rs1177563	ENSG00000271751.1	RP11-110I1.14	-11.56	2.75e-27	4.31e-24	-0.67	-0.48	Coronary artery disease;	chr11:119078373	chr11:119065263~119065677:-
PRAD	cis	rs673078	0.607	rs59594854	ENSG00000275759.1	RP11-131L12.3	-11.56	2.76e-27	4.31e-24	-0.63	-0.48	Glucose homeostasis traits;	chr12:118374000	chr12:118428281~118428870:+
PRAD	cis	rs4423214	0.559	rs10898228	ENSG00000254682.1	RP11-660L16.2	-11.56	2.76e-27	4.31e-24	-0.75	-0.48	Vitamin D levels;	chr11:71517312	chr11:71448674~71452157:+
PRAD	cis	rs9487094	0.813	rs13203252	ENSG00000260273.1	RP11-425D10.10	11.56	2.78e-27	4.34e-24	0.69	0.48	Height;	chr6:109351533	chr6:109382795~109383666:+
PRAD	cis	rs9322193	0.923	rs9767554	ENSG00000268592.3	RAET1E-AS1	11.56	2.8e-27	4.37e-24	0.66	0.48	Lung cancer;	chr6:149616860	chr6:149863494~149919507:+
PRAD	cis	rs1930961	0.702	rs1930966	ENSG00000100058.11	CRYBB2P1	11.56	2.8e-27	4.37e-24	0.9	0.48	Bipolar disorder with mood-incongruent psychosis;	chr22:25489737	chr22:25448105~25520854:+
PRAD	cis	rs1577917	0.917	rs1414201	ENSG00000203875.9	SNHG5	-11.56	2.81e-27	4.38e-24	-0.54	-0.48	Response to antipsychotic treatment;	chr6:85790598	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.958	rs12209259	ENSG00000203875.9	SNHG5	-11.56	2.81e-27	4.38e-24	-0.54	-0.48	Response to antipsychotic treatment;	chr6:85792630	chr6:85660950~85678736:-
PRAD	cis	rs732716	0.785	rs11667543	ENSG00000267769.1	CTB-50L17.9	-11.56	2.82e-27	4.4e-24	-0.55	-0.48	Mean corpuscular volume;	chr19:4374853	chr19:4454014~4455286:+
PRAD	cis	rs9322193	0.923	rs9767123	ENSG00000268592.3	RAET1E-AS1	11.56	2.82e-27	4.41e-24	0.66	0.48	Lung cancer;	chr6:149660323	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.923	rs9505982	ENSG00000268592.3	RAET1E-AS1	11.56	2.83e-27	4.42e-24	0.66	0.48	Lung cancer;	chr6:149618465	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.923	rs9322196	ENSG00000268592.3	RAET1E-AS1	11.56	2.83e-27	4.42e-24	0.66	0.48	Lung cancer;	chr6:149619645	chr6:149863494~149919507:+
PRAD	cis	rs875971	0.545	rs6979636	ENSG00000237310.1	GS1-124K5.4	11.56	2.85e-27	4.44e-24	0.48	0.48	Aortic root size;	chr7:66276638	chr7:66493706~66495474:+
PRAD	cis	rs2455601	0.882	rs11042105	ENSG00000254860.4	TMEM9B-AS1	11.56	2.85e-27	4.45e-24	0.6	0.48	Schizophrenia;	chr11:8872963	chr11:8964675~8977527:+
PRAD	cis	rs3829251	0.786	rs7103591	ENSG00000254682.1	RP11-660L16.2	-11.56	2.86e-27	4.47e-24	-0.75	-0.48	Vitamin D levels;	chr11:71526573	chr11:71448674~71452157:+
PRAD	cis	rs7617773	0.925	rs7374376	ENSG00000229759.1	MRPS18AP1	-11.56	2.87e-27	4.47e-24	-0.49	-0.48	Coronary artery disease;	chr3:48131197	chr3:48256350~48256938:-
PRAD	cis	rs4853012	0.793	rs6707619	ENSG00000257800.1	FNBP1P1	11.56	2.87e-27	4.47e-24	0.42	0.48	Gestational age at birth (maternal effect);	chr2:74117529	chr2:74120680~74123218:+
PRAD	cis	rs7104764	0.778	rs7930823	ENSG00000277290.1	RP11-326C3.16	11.56	2.87e-27	4.48e-24	0.42	0.48	Menarche (age at onset);	chr11:206767	chr11:243099~243483:-
PRAD	cis	rs4845570	1	rs3811415	ENSG00000249602.1	RP11-98D18.3	11.56	2.88e-27	4.49e-24	0.78	0.48	Coronary artery disease;	chr1:151791291	chr1:151763384~151769501:-
PRAD	cis	rs8062405	0.789	rs240704	ENSG00000259982.1	CDC37P1	11.56	2.9e-27	4.53e-24	0.62	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28518628	chr16:28700294~28701540:-
PRAD	cis	rs9487094	1	rs9487094	ENSG00000260273.1	RP11-425D10.10	11.56	2.91e-27	4.54e-24	0.66	0.48	Height;	chr6:109420812	chr6:109382795~109383666:+
PRAD	cis	rs150992	0.632	rs34489	ENSG00000248489.1	CTD-2007H13.3	-11.55	2.94e-27	4.59e-24	-0.54	-0.48	Body mass index;	chr5:98977180	chr5:98929171~98995013:+
PRAD	cis	rs780096	0.505	rs12475426	ENSG00000234072.1	AC074117.10	-11.55	2.96e-27	4.61e-24	-0.38	-0.48	Total body bone mineral density;	chr2:27376265	chr2:27356246~27367622:+
PRAD	cis	rs7208859	0.673	rs450585	ENSG00000263531.1	RP13-753N3.1	11.55	2.96e-27	4.62e-24	0.8	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624021	chr17:30863921~30864940:-
PRAD	cis	rs2404602	0.647	rs7181506	ENSG00000259422.1	RP11-593F23.1	11.55	2.99e-27	4.66e-24	0.63	0.48	Blood metabolite levels;	chr15:76643336	chr15:76174891~76181486:-
PRAD	cis	rs2658782	0.547	rs2085334	ENSG00000279684.1	RP11-755E23.2	-11.55	3e-27	4.68e-24	-0.66	-0.48	Pulmonary function decline;	chr11:93447884	chr11:93286629~93288903:-
PRAD	cis	rs9487094	1	rs9480953	ENSG00000260273.1	RP11-425D10.10	11.55	3e-27	4.68e-24	0.66	0.48	Height;	chr6:109417941	chr6:109382795~109383666:+
PRAD	cis	rs9322193	0.923	rs35830138	ENSG00000268592.3	RAET1E-AS1	11.55	3.02e-27	4.71e-24	0.66	0.48	Lung cancer;	chr6:149668635	chr6:149863494~149919507:+
PRAD	cis	rs875971	0.545	rs73146609	ENSG00000237310.1	GS1-124K5.4	11.55	3.03e-27	4.72e-24	0.48	0.48	Aortic root size;	chr7:66302477	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.545	rs2173571	ENSG00000237310.1	GS1-124K5.4	11.55	3.03e-27	4.72e-24	0.48	0.48	Aortic root size;	chr7:66305392	chr7:66493706~66495474:+
PRAD	cis	rs673078	0.607	rs7307393	ENSG00000275759.1	RP11-131L12.3	-11.55	3.09e-27	4.81e-24	-0.75	-0.48	Glucose homeostasis traits;	chr12:118308537	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.607	rs17440669	ENSG00000275759.1	RP11-131L12.3	-11.55	3.09e-27	4.81e-24	-0.75	-0.48	Glucose homeostasis traits;	chr12:118310397	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.607	rs7309671	ENSG00000275759.1	RP11-131L12.3	-11.55	3.09e-27	4.81e-24	-0.75	-0.48	Glucose homeostasis traits;	chr12:118313188	chr12:118428281~118428870:+
PRAD	cis	rs9322193	0.923	rs4870267	ENSG00000268592.3	RAET1E-AS1	11.55	3.13e-27	4.87e-24	0.66	0.48	Lung cancer;	chr6:149671572	chr6:149863494~149919507:+
PRAD	cis	rs1075265	0.704	rs10181999	ENSG00000233266.1	HMGB1P31	11.55	3.14e-27	4.89e-24	0.64	0.48	Chronotype;Morning vs. evening chronotype;	chr2:54025360	chr2:54051334~54051760:+
PRAD	cis	rs732716	0.785	rs56033249	ENSG00000267769.1	CTB-50L17.9	-11.55	3.15e-27	4.91e-24	-0.56	-0.48	Mean corpuscular volume;	chr19:4369450	chr19:4454014~4455286:+
PRAD	cis	rs4722166	0.695	rs7787893	ENSG00000179428.2	AC073072.5	-11.55	3.15e-27	4.91e-24	-0.55	-0.48	Lung cancer;	chr7:22734818	chr7:22725395~22727620:-
PRAD	cis	rs12049351	0.631	rs2166160	ENSG00000229367.1	HMGN2P19	11.55	3.17e-27	4.94e-24	0.63	0.48	Circulating myeloperoxidase levels (plasma);	chr1:229534344	chr1:229570532~229570796:+
PRAD	cis	rs9487094	0.778	rs61318425	ENSG00000260273.1	RP11-425D10.10	11.55	3.19e-27	4.97e-24	0.71	0.48	Height;	chr6:109427303	chr6:109382795~109383666:+
PRAD	cis	rs9322193	0.924	rs9498382	ENSG00000223701.3	RAET1E-AS1	11.55	3.22e-27	5.01e-24	0.64	0.48	Lung cancer;	chr6:149610982	chr6:149884431~149919508:+
PRAD	cis	rs4853012	0.838	rs59570457	ENSG00000257800.1	FNBP1P1	11.54	3.22e-27	5.02e-24	0.42	0.48	Gestational age at birth (maternal effect);	chr2:74117155	chr2:74120680~74123218:+
PRAD	cis	rs9322193	0.923	rs35961297	ENSG00000268592.3	RAET1E-AS1	11.54	3.23e-27	5.03e-24	0.66	0.48	Lung cancer;	chr6:149667929	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.923	rs35967444	ENSG00000268592.3	RAET1E-AS1	11.54	3.23e-27	5.03e-24	0.66	0.48	Lung cancer;	chr6:149675588	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.923	rs62439842	ENSG00000268592.3	RAET1E-AS1	11.54	3.23e-27	5.03e-24	0.66	0.48	Lung cancer;	chr6:149675847	chr6:149863494~149919507:+
PRAD	cis	rs875971	0.545	rs316328	ENSG00000237310.1	GS1-124K5.4	-11.54	3.26e-27	5.07e-24	-0.46	-0.48	Aortic root size;	chr7:66143851	chr7:66493706~66495474:+
PRAD	cis	rs9322193	0.923	rs10747275	ENSG00000268592.3	RAET1E-AS1	11.54	3.34e-27	5.19e-24	0.66	0.48	Lung cancer;	chr6:149622782	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.884	rs9688794	ENSG00000268592.3	RAET1E-AS1	11.54	3.34e-27	5.19e-24	0.66	0.48	Lung cancer;	chr6:149632121	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.923	rs9689084	ENSG00000268592.3	RAET1E-AS1	11.54	3.34e-27	5.19e-24	0.66	0.48	Lung cancer;	chr6:149639648	chr6:149863494~149919507:+
PRAD	cis	rs2404602	0.647	rs11072620	ENSG00000259422.1	RP11-593F23.1	-11.54	3.34e-27	5.19e-24	-0.63	-0.48	Blood metabolite levels;	chr15:76756429	chr15:76174891~76181486:-
PRAD	cis	rs9322193	0.923	rs9689723	ENSG00000268592.3	RAET1E-AS1	11.54	3.41e-27	5.29e-24	0.66	0.48	Lung cancer;	chr6:149655935	chr6:149863494~149919507:+
PRAD	cis	rs8072100	0.79	rs11079783	ENSG00000228782.6	CTD-2026D20.3	-11.54	3.41e-27	5.3e-24	-0.52	-0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47608650	chr17:47450568~47492492:-
PRAD	cis	rs673078	0.607	rs2036489	ENSG00000275759.1	RP11-131L12.3	-11.54	3.44e-27	5.35e-24	-0.62	-0.48	Glucose homeostasis traits;	chr12:118364643	chr12:118428281~118428870:+
PRAD	cis	rs56080343	0.688	rs10083190	ENSG00000275759.1	RP11-131L12.3	-11.54	3.44e-27	5.35e-24	-0.62	-0.48	Neuroticism;	chr12:118365385	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.607	rs10082823	ENSG00000275759.1	RP11-131L12.3	-11.54	3.44e-27	5.35e-24	-0.62	-0.48	Glucose homeostasis traits;	chr12:118365386	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.607	rs2062519	ENSG00000275759.1	RP11-131L12.3	-11.54	3.44e-27	5.35e-24	-0.62	-0.48	Glucose homeostasis traits;	chr12:118367577	chr12:118428281~118428870:+
PRAD	cis	rs8062405	0.964	rs62036614	ENSG00000251417.2	RP11-1348G14.4	-11.54	3.46e-27	5.37e-24	-0.54	-0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28813364	chr16:28802743~28817828:+
PRAD	cis	rs35160687	0.901	rs12478653	ENSG00000273080.1	RP11-301O19.1	-11.54	3.49e-27	5.42e-24	-0.56	-0.48	Night sleep phenotypes;	chr2:86308271	chr2:86195590~86196049:+
PRAD	cis	rs9322193	0.923	rs9377230	ENSG00000268592.3	RAET1E-AS1	11.54	3.5e-27	5.44e-24	0.65	0.48	Lung cancer;	chr6:149613607	chr6:149863494~149919507:+
PRAD	cis	rs9532669	0.89	rs9525417	ENSG00000176268.5	CYCSP34	11.53	3.54e-27	5.49e-24	0.5	0.48	Cervical cancer;	chr13:40878431	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.89	rs9532638	ENSG00000176268.5	CYCSP34	11.53	3.54e-27	5.49e-24	0.5	0.48	Cervical cancer;	chr13:40878471	chr13:40863599~40863902:-
PRAD	cis	rs673078	0.66	rs16948234	ENSG00000275759.1	RP11-131L12.3	11.53	3.57e-27	5.54e-24	0.74	0.48	Glucose homeostasis traits;	chr12:118282464	chr12:118428281~118428870:+
PRAD	cis	rs12594515	1	rs8026221	ENSG00000273972.1	CTD-2306A12.1	-11.53	3.6e-27	5.59e-24	-0.53	-0.48	Weight;Waist circumference;	chr15:45695712	chr15:45702640~45703183:+
PRAD	cis	rs12594515	1	rs8031128	ENSG00000273972.1	CTD-2306A12.1	-11.53	3.6e-27	5.59e-24	-0.53	-0.48	Weight;Waist circumference;	chr15:45696330	chr15:45702640~45703183:+
PRAD	cis	rs12594515	1	rs8032361	ENSG00000273972.1	CTD-2306A12.1	-11.53	3.6e-27	5.59e-24	-0.53	-0.48	Weight;Waist circumference;	chr15:45696355	chr15:45702640~45703183:+
PRAD	cis	rs12594515	0.967	rs71405295	ENSG00000273972.1	CTD-2306A12.1	-11.53	3.6e-27	5.59e-24	-0.53	-0.48	Weight;Waist circumference;	chr15:45696723	chr15:45702640~45703183:+
PRAD	cis	rs12594515	1	rs6493175	ENSG00000273972.1	CTD-2306A12.1	-11.53	3.6e-27	5.59e-24	-0.53	-0.48	Weight;Waist circumference;	chr15:45697700	chr15:45702640~45703183:+
PRAD	cis	rs12594515	1	rs6493176	ENSG00000273972.1	CTD-2306A12.1	-11.53	3.6e-27	5.59e-24	-0.53	-0.48	Weight;Waist circumference;	chr15:45697828	chr15:45702640~45703183:+
PRAD	cis	rs12594515	0.967	rs8039088	ENSG00000273972.1	CTD-2306A12.1	-11.53	3.6e-27	5.59e-24	-0.53	-0.48	Weight;Waist circumference;	chr15:45697980	chr15:45702640~45703183:+
PRAD	cis	rs12594515	1	rs8038320	ENSG00000273972.1	CTD-2306A12.1	-11.53	3.6e-27	5.59e-24	-0.53	-0.48	Weight;Waist circumference;	chr15:45698069	chr15:45702640~45703183:+
PRAD	cis	rs12594515	0.967	rs67854274	ENSG00000273972.1	CTD-2306A12.1	-11.53	3.6e-27	5.59e-24	-0.53	-0.48	Weight;Waist circumference;	chr15:45698320	chr15:45702640~45703183:+
PRAD	cis	rs12594515	1	rs58368732	ENSG00000273972.1	CTD-2306A12.1	-11.53	3.6e-27	5.59e-24	-0.53	-0.48	Weight;Waist circumference;	chr15:45698333	chr15:45702640~45703183:+
PRAD	cis	rs12594515	1	rs7172161	ENSG00000273972.1	CTD-2306A12.1	-11.53	3.6e-27	5.59e-24	-0.53	-0.48	Weight;Waist circumference;	chr15:45698582	chr15:45702640~45703183:+
PRAD	cis	rs12594515	1	rs7173144	ENSG00000273972.1	CTD-2306A12.1	-11.53	3.6e-27	5.59e-24	-0.53	-0.48	Weight;Waist circumference;	chr15:45698998	chr15:45702640~45703183:+
PRAD	cis	rs9322193	0.923	rs11155677	ENSG00000216906.2	RP11-350J20.9	11.53	3.61e-27	5.59e-24	0.55	0.48	Lung cancer;	chr6:149756953	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.884	rs9480009	ENSG00000216906.2	RP11-350J20.9	11.53	3.61e-27	5.59e-24	0.55	0.48	Lung cancer;	chr6:149758502	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.923	rs9480031	ENSG00000216906.2	RP11-350J20.9	11.53	3.61e-27	5.59e-24	0.55	0.48	Lung cancer;	chr6:149758875	chr6:149904243~149906418:+
PRAD	cis	rs7208859	0.673	rs73263981	ENSG00000263531.1	RP13-753N3.1	11.53	3.62e-27	5.61e-24	0.8	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30593484	chr17:30863921~30864940:-
PRAD	cis	rs1185460	0.967	rs1168568	ENSG00000271751.1	RP11-110I1.14	-11.53	3.65e-27	5.65e-24	-0.66	-0.48	Coronary artery disease;	chr11:119079089	chr11:119065263~119065677:-
PRAD	cis	rs1185460	0.967	rs1307145	ENSG00000271751.1	RP11-110I1.14	-11.53	3.65e-27	5.65e-24	-0.66	-0.48	Coronary artery disease;	chr11:119079507	chr11:119065263~119065677:-
PRAD	cis	rs12594515	1	rs8038058	ENSG00000273972.1	CTD-2306A12.1	-11.53	3.69e-27	5.71e-24	-0.53	-0.48	Weight;Waist circumference;	chr15:45698074	chr15:45702640~45703183:+
PRAD	cis	rs9322193	0.884	rs10872646	ENSG00000216906.2	RP11-350J20.9	11.53	3.71e-27	5.75e-24	0.55	0.48	Lung cancer;	chr6:149746539	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.884	rs12528279	ENSG00000216906.2	RP11-350J20.9	11.53	3.71e-27	5.75e-24	0.55	0.48	Lung cancer;	chr6:149750892	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.809	rs9479808	ENSG00000216906.2	RP11-350J20.9	11.53	3.71e-27	5.75e-24	0.55	0.48	Lung cancer;	chr6:149751328	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.923	rs10782316	ENSG00000216906.2	RP11-350J20.9	11.53	3.71e-27	5.75e-24	0.55	0.48	Lung cancer;	chr6:149752755	chr6:149904243~149906418:+
PRAD	cis	rs6504950	0.745	rs12949718	ENSG00000275710.1	RP11-257O5.4	-11.53	3.72e-27	5.75e-24	-0.62	-0.48	Breast cancer;	chr17:54904492	chr17:54964474~54964679:+
PRAD	cis	rs2404602	0.647	rs2404600	ENSG00000259422.1	RP11-593F23.1	-11.53	3.73e-27	5.78e-24	-0.64	-0.48	Blood metabolite levels;	chr15:76881216	chr15:76174891~76181486:-
PRAD	cis	rs1426063	0.614	rs74949513	ENSG00000249717.1	RP11-44F21.3	11.53	3.76e-27	5.81e-24	1.03	0.48	QT interval;	chr4:75124631	chr4:74955974~74970362:-
PRAD	cis	rs1426063	0.541	rs116664844	ENSG00000249717.1	RP11-44F21.3	11.53	3.76e-27	5.81e-24	1.03	0.48	QT interval;	chr4:75125677	chr4:74955974~74970362:-
PRAD	cis	rs1426063	0.541	rs114162294	ENSG00000249717.1	RP11-44F21.3	11.53	3.76e-27	5.81e-24	1.03	0.48	QT interval;	chr4:75125682	chr4:74955974~74970362:-
PRAD	cis	rs1426063	0.614	rs76087197	ENSG00000249717.1	RP11-44F21.3	11.53	3.76e-27	5.81e-24	1.03	0.48	QT interval;	chr4:75134108	chr4:74955974~74970362:-
PRAD	cis	rs1426063	0.614	rs115279737	ENSG00000249717.1	RP11-44F21.3	11.53	3.76e-27	5.82e-24	1.03	0.48	QT interval;	chr4:75107557	chr4:74955974~74970362:-
PRAD	cis	rs3091242	0.866	rs11249249	ENSG00000224183.1	SDHDP6	-11.53	3.77e-27	5.83e-24	-0.55	-0.48	Erythrocyte sedimentation rate;	chr1:25431643	chr1:25294164~25294643:-
PRAD	cis	rs732716	0.785	rs11666453	ENSG00000267769.1	CTB-50L17.9	-11.53	3.81e-27	5.89e-24	-0.55	-0.48	Mean corpuscular volume;	chr19:4368800	chr19:4454014~4455286:+
PRAD	cis	rs2404602	0.735	rs4886495	ENSG00000259422.1	RP11-593F23.1	11.53	3.83e-27	5.92e-24	0.61	0.48	Blood metabolite levels;	chr15:76446618	chr15:76174891~76181486:-
PRAD	cis	rs4722166	0.63	rs7808457	ENSG00000179428.2	AC073072.5	11.53	3.83e-27	5.92e-24	0.6	0.48	Lung cancer;	chr7:22758646	chr7:22725395~22727620:-
PRAD	cis	rs11690935	0.632	rs34242651	ENSG00000228389.1	AC068039.4	-11.53	3.84e-27	5.93e-24	-0.54	-0.48	Schizophrenia;	chr2:171697489	chr2:171773482~171775844:+
PRAD	cis	rs1075265	0.568	rs10865278	ENSG00000233266.1	HMGB1P31	11.53	3.85e-27	5.95e-24	0.62	0.48	Chronotype;Morning vs. evening chronotype;	chr2:54074902	chr2:54051334~54051760:+
PRAD	cis	rs12594515	0.506	rs74199860	ENSG00000273972.1	CTD-2306A12.1	-11.52	3.87e-27	5.98e-24	-0.53	-0.48	Weight;Waist circumference;	chr15:45696992	chr15:45702640~45703183:+
PRAD	cis	rs748404	0.66	rs542898	ENSG00000205771.5	CATSPER2P1	-11.52	3.87e-27	5.99e-24	-0.52	-0.48	Lung cancer;	chr15:43427194	chr15:43726918~43747094:-
PRAD	cis	rs748404	0.66	rs689767	ENSG00000205771.5	CATSPER2P1	-11.52	3.87e-27	5.99e-24	-0.52	-0.48	Lung cancer;	chr15:43429879	chr15:43726918~43747094:-
PRAD	cis	rs12594515	1	rs12594515	ENSG00000273972.1	CTD-2306A12.1	11.52	3.88e-27	6e-24	0.53	0.48	Weight;Waist circumference;	chr15:45692873	chr15:45702640~45703183:+
PRAD	cis	rs3814244	0.868	rs10878726	ENSG00000255733.4	IFNG-AS1	11.52	3.91e-27	6.04e-24	0.53	0.48	Itch intensity from mosquito bite adjusted by bite size;	chr12:68022865	chr12:67989445~68234686:+
PRAD	cis	rs9322193	0.923	rs12174716	ENSG00000268592.3	RAET1E-AS1	11.52	3.94e-27	6.08e-24	0.66	0.48	Lung cancer;	chr6:149644487	chr6:149863494~149919507:+
PRAD	cis	rs492146	0.74	rs1032418	ENSG00000243236.5	GSTA9P	11.52	3.95e-27	6.1e-24	0.58	0.48	Epilepsy (remission after treatment);	chr6:52970159	chr6:52939726~52957521:-
PRAD	cis	rs875971	0.545	rs4718325	ENSG00000237310.1	GS1-124K5.4	11.52	3.96e-27	6.12e-24	0.48	0.48	Aortic root size;	chr7:66215323	chr7:66493706~66495474:+
PRAD	cis	rs9487094	0.813	rs13195517	ENSG00000260273.1	RP11-425D10.10	11.52	3.97e-27	6.13e-24	0.7	0.48	Height;	chr6:109415050	chr6:109382795~109383666:+
PRAD	cis	rs4423214	0.592	rs11234027	ENSG00000254682.1	RP11-660L16.2	-11.52	3.98e-27	6.14e-24	-0.75	-0.48	Vitamin D levels;	chr11:71523061	chr11:71448674~71452157:+
PRAD	cis	rs4423214	0.592	rs7114252	ENSG00000254682.1	RP11-660L16.2	-11.52	3.98e-27	6.14e-24	-0.75	-0.48	Vitamin D levels;	chr11:71526560	chr11:71448674~71452157:+
PRAD	cis	rs9322193	0.923	rs4869750	ENSG00000223701.3	RAET1E-AS1	11.52	4.02e-27	6.2e-24	0.63	0.48	Lung cancer;	chr6:149855996	chr6:149884431~149919508:+
PRAD	cis	rs8062405	0.755	rs7193402	ENSG00000259982.1	CDC37P1	11.52	4.03e-27	6.23e-24	0.62	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574806	chr16:28700294~28701540:-
PRAD	cis	rs8062405	0.755	rs62034358	ENSG00000259982.1	CDC37P1	11.52	4.03e-27	6.23e-24	0.62	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576276	chr16:28700294~28701540:-
PRAD	cis	rs9322193	0.607	rs9383941	ENSG00000231760.4	RP11-350J20.5	-11.52	4.05e-27	6.24e-24	-0.74	-0.48	Lung cancer;	chr6:149912100	chr6:149796151~149826294:-
PRAD	cis	rs2117029	0.586	rs10783307	ENSG00000258017.1	RP11-386G11.10	-11.52	4.05e-27	6.24e-24	-0.62	-0.48	Intelligence (multi-trait analysis);	chr12:49135822	chr12:49127782~49147869:+
PRAD	cis	rs2117029	0.554	rs12306494	ENSG00000258017.1	RP11-386G11.10	-11.52	4.05e-27	6.24e-24	-0.62	-0.48	Intelligence (multi-trait analysis);	chr12:49136998	chr12:49127782~49147869:+
PRAD	cis	rs2117029	0.586	rs11168884	ENSG00000258017.1	RP11-386G11.10	-11.52	4.05e-27	6.24e-24	-0.62	-0.48	Intelligence (multi-trait analysis);	chr12:49146109	chr12:49127782~49147869:+
PRAD	cis	rs9322193	0.847	rs62439808	ENSG00000268592.3	RAET1E-AS1	11.52	4.06e-27	6.27e-24	0.65	0.48	Lung cancer;	chr6:149629690	chr6:149863494~149919507:+
PRAD	cis	rs2882667	0.66	rs3088052	ENSG00000253404.1	AC034243.1	11.52	4.08e-27	6.29e-24	0.6	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139121126	chr5:138744434~138753309:-
PRAD	cis	rs6504950	1	rs9892848	ENSG00000275710.1	RP11-257O5.4	11.52	4.08e-27	6.3e-24	0.67	0.48	Breast cancer;	chr17:54982414	chr17:54964474~54964679:+
PRAD	cis	rs748404	0.66	rs690012	ENSG00000205771.5	CATSPER2P1	-11.52	4.11e-27	6.34e-24	-0.52	-0.48	Lung cancer;	chr15:43427557	chr15:43726918~43747094:-
PRAD	cis	rs8062405	0.824	rs240702	ENSG00000259982.1	CDC37P1	11.52	4.13e-27	6.37e-24	0.61	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520032	chr16:28700294~28701540:-
PRAD	cis	rs1062177	1	rs41494545	ENSG00000213433.5	RPLP1P6	11.52	4.17e-27	6.43e-24	0.56	0.48	Preschool internalizing problems;	chr5:151855533	chr5:151765859~151766378:-
PRAD	cis	rs8062405	0.965	rs8049439	ENSG00000259982.1	CDC37P1	11.52	4.19e-27	6.46e-24	0.61	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826194	chr16:28700294~28701540:-
PRAD	cis	rs977987	0.835	rs3851733	ENSG00000261783.1	RP11-252K23.2	-11.51	4.24e-27	6.52e-24	-0.65	-0.48	Dupuytren's disease;	chr16:75336365	chr16:75379818~75381260:-
PRAD	cis	rs780096	0.526	rs3845687	ENSG00000234072.1	AC074117.10	-11.51	4.24e-27	6.53e-24	-0.37	-0.48	Total body bone mineral density;	chr2:27467032	chr2:27356246~27367622:+
PRAD	cis	rs780096	0.506	rs8395	ENSG00000234072.1	AC074117.10	-11.51	4.24e-27	6.53e-24	-0.37	-0.48	Total body bone mineral density;	chr2:27492340	chr2:27356246~27367622:+
PRAD	cis	rs9487094	1	rs10872032	ENSG00000260273.1	RP11-425D10.10	11.51	4.27e-27	6.58e-24	0.65	0.47	Height;	chr6:109355573	chr6:109382795~109383666:+
PRAD	cis	rs7688540	0.511	rs6841415	ENSG00000275426.1	CH17-262A2.1	11.51	4.29e-27	6.61e-24	0.74	0.47	Facial morphology (factor 6, height of vermillion lower lip);	chr4:203594	chr4:149738~150317:+
PRAD	cis	rs2882667	0.66	rs11951084	ENSG00000253404.1	AC034243.1	11.51	4.32e-27	6.65e-24	0.61	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139125858	chr5:138744434~138753309:-
PRAD	cis	rs9322193	0.923	rs9404048	ENSG00000268592.3	RAET1E-AS1	11.51	4.34e-27	6.67e-24	0.66	0.47	Lung cancer;	chr6:149616188	chr6:149863494~149919507:+
PRAD	cis	rs673078	0.66	rs76842574	ENSG00000275759.1	RP11-131L12.3	-11.51	4.35e-27	6.69e-24	-0.62	-0.47	Glucose homeostasis traits;	chr12:118371789	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.615	rs56324376	ENSG00000275759.1	RP11-131L12.3	-11.51	4.35e-27	6.69e-24	-0.62	-0.47	Glucose homeostasis traits;	chr12:118372134	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.607	rs4766899	ENSG00000275759.1	RP11-131L12.3	-11.51	4.35e-27	6.69e-24	-0.62	-0.47	Glucose homeostasis traits;	chr12:118374888	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.607	rs10850967	ENSG00000275759.1	RP11-131L12.3	-11.51	4.35e-27	6.69e-24	-0.62	-0.47	Glucose homeostasis traits;	chr12:118380072	chr12:118428281~118428870:+
PRAD	cis	rs9322193	0.884	rs7769115	ENSG00000216906.2	RP11-350J20.9	11.51	4.38e-27	6.73e-24	0.54	0.47	Lung cancer;	chr6:149848796	chr6:149904243~149906418:+
PRAD	cis	rs2739330	0.828	rs4820572	ENSG00000250470.1	AP000351.3	11.51	4.4e-27	6.78e-24	0.65	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23976904~23977585:-
PRAD	cis	rs9322193	0.923	rs9688861	ENSG00000268592.3	RAET1E-AS1	11.51	4.41e-27	6.79e-24	0.65	0.47	Lung cancer;	chr6:149637924	chr6:149863494~149919507:+
PRAD	cis	rs2404602	0.735	rs2454450	ENSG00000259422.1	RP11-593F23.1	-11.51	4.45e-27	6.84e-24	-0.6	-0.47	Blood metabolite levels;	chr15:76538895	chr15:76174891~76181486:-
PRAD	cis	rs4423214	0.55	rs4944885	ENSG00000254682.1	RP11-660L16.2	11.51	4.46e-27	6.85e-24	0.57	0.47	Vitamin D levels;	chr11:71403029	chr11:71448674~71452157:+
PRAD	cis	rs2404602	0.735	rs283789	ENSG00000259422.1	RP11-593F23.1	11.51	4.49e-27	6.91e-24	0.59	0.47	Blood metabolite levels;	chr15:76485236	chr15:76174891~76181486:-
PRAD	cis	rs2929278	0.617	rs3087657	ENSG00000249839.1	AC011330.5	-11.51	4.5e-27	6.93e-24	-0.61	-0.47	Schizophrenia;	chr15:43771661	chr15:43663654~43684339:-
PRAD	cis	rs2739330	0.828	rs5751770	ENSG00000231271.1	AP000350.8	11.51	4.53e-27	6.97e-24	0.64	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23949918~23954042:+
PRAD	cis	rs4423214	0.559	rs11234042	ENSG00000254682.1	RP11-660L16.2	-11.51	4.54e-27	6.98e-24	-0.75	-0.47	Vitamin D levels;	chr11:71528040	chr11:71448674~71452157:+
PRAD	cis	rs780096	0.546	rs7563162	ENSG00000234072.1	AC074117.10	-11.51	4.55e-27	6.99e-24	-0.38	-0.47	Total body bone mineral density;	chr2:27408324	chr2:27356246~27367622:+
PRAD	cis	rs765787	0.53	rs2554454	ENSG00000259520.4	CTD-2651B20.3	11.51	4.58e-27	7.04e-24	0.59	0.47	Uric acid levels;	chr15:45229338	chr15:45251580~45279251:-
PRAD	cis	rs2117029	0.586	rs10783308	ENSG00000258017.1	RP11-386G11.10	-11.51	4.59e-27	7.05e-24	-0.62	-0.47	Intelligence (multi-trait analysis);	chr12:49137675	chr12:49127782~49147869:+
PRAD	cis	rs9322193	0.884	rs9688699	ENSG00000268592.3	RAET1E-AS1	11.51	4.59e-27	7.05e-24	0.65	0.47	Lung cancer;	chr6:149733680	chr6:149863494~149919507:+
PRAD	cis	rs7727544	0.735	rs273914	ENSG00000233006.5	AC034220.3	11.51	4.61e-27	7.08e-24	0.42	0.47	Blood metabolite levels;	chr5:132324738	chr5:132311285~132369916:-
PRAD	cis	rs7727544	0.735	rs272894	ENSG00000233006.5	AC034220.3	11.51	4.61e-27	7.08e-24	0.42	0.47	Blood metabolite levels;	chr5:132326767	chr5:132311285~132369916:-
PRAD	cis	rs2933343	0.951	rs789251	ENSG00000231305.3	RP11-723O4.2	11.51	4.61e-27	7.08e-24	0.48	0.47	IgG glycosylation;	chr3:128857927	chr3:128861313~128871540:-
PRAD	cis	rs9322193	0.923	rs9767105	ENSG00000268592.3	RAET1E-AS1	11.5	4.62e-27	7.09e-24	0.66	0.47	Lung cancer;	chr6:149659591	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.884	rs2064521	ENSG00000268592.3	RAET1E-AS1	-11.5	4.62e-27	7.1e-24	-0.66	-0.47	Lung cancer;	chr6:149625336	chr6:149863494~149919507:+
PRAD	cis	rs12594515	1	rs11070464	ENSG00000273972.1	CTD-2306A12.1	-11.5	4.65e-27	7.14e-24	-0.53	-0.47	Weight;Waist circumference;	chr15:45692578	chr15:45702640~45703183:+
PRAD	cis	rs780096	0.546	rs1647284	ENSG00000234072.1	AC074117.10	-11.5	4.66e-27	7.15e-24	-0.38	-0.47	Total body bone mineral density;	chr2:27385248	chr2:27356246~27367622:+
PRAD	cis	rs780096	0.526	rs7594812	ENSG00000234072.1	AC074117.10	-11.5	4.66e-27	7.15e-24	-0.38	-0.47	Total body bone mineral density;	chr2:27388602	chr2:27356246~27367622:+
PRAD	cis	rs780096	0.526	rs809058	ENSG00000234072.1	AC074117.10	-11.5	4.66e-27	7.15e-24	-0.38	-0.47	Total body bone mineral density;	chr2:27393923	chr2:27356246~27367622:+
PRAD	cis	rs704795	0.836	rs1083865	ENSG00000234072.1	AC074117.10	-11.5	4.66e-27	7.15e-24	-0.38	-0.47	Menopause (age at onset);	chr2:27397960	chr2:27356246~27367622:+
PRAD	cis	rs977987	0.835	rs7200616	ENSG00000261783.1	RP11-252K23.2	-11.5	4.68e-27	7.19e-24	-0.65	-0.47	Dupuytren's disease;	chr16:75332191	chr16:75379818~75381260:-
PRAD	cis	rs6570726	0.599	rs9376951	ENSG00000235652.6	RP11-545I5.3	11.5	4.72e-27	7.25e-24	0.54	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145577775	chr6:145799409~145886585:+
PRAD	cis	rs1075265	0.568	rs805416	ENSG00000233266.1	HMGB1P31	-11.5	4.75e-27	7.28e-24	-0.66	-0.47	Chronotype;Morning vs. evening chronotype;	chr2:53898121	chr2:54051334~54051760:+
PRAD	cis	rs1577917	0.816	rs9353349	ENSG00000203875.9	SNHG5	11.5	4.77e-27	7.32e-24	0.53	0.47	Response to antipsychotic treatment;	chr6:85998007	chr6:85660950~85678736:-
PRAD	cis	rs1577917	1	rs12215037	ENSG00000203875.9	SNHG5	-11.5	4.82e-27	7.39e-24	-0.55	-0.47	Response to antipsychotic treatment;	chr6:86017913	chr6:85660950~85678736:-
PRAD	cis	rs11168854	0.719	rs11168890	ENSG00000258017.1	RP11-386G11.10	-11.5	4.82e-27	7.39e-24	-0.62	-0.47	Body mass index;	chr12:49150130	chr12:49127782~49147869:+
PRAD	cis	rs2117029	0.586	rs7954521	ENSG00000258017.1	RP11-386G11.10	-11.5	4.82e-27	7.39e-24	-0.62	-0.47	Intelligence (multi-trait analysis);	chr12:49151857	chr12:49127782~49147869:+
PRAD	cis	rs2117029	0.553	rs2162644	ENSG00000258017.1	RP11-386G11.10	-11.5	4.82e-27	7.39e-24	-0.62	-0.47	Intelligence (multi-trait analysis);	chr12:49154407	chr12:49127782~49147869:+
PRAD	cis	rs11676348	0.729	rs13013361	ENSG00000261338.2	RP11-378A13.1	-11.5	4.82e-27	7.4e-24	-0.54	-0.47	Ulcerative colitis;	chr2:218082792	chr2:218255319~218257366:+
PRAD	cis	rs9532669	0.926	rs9532689	ENSG00000176268.5	CYCSP34	11.5	4.83e-27	7.4e-24	0.49	0.47	Cervical cancer;	chr13:40957990	chr13:40863599~40863902:-
PRAD	cis	rs8072100	0.846	rs6503796	ENSG00000228782.6	CTD-2026D20.3	11.5	4.84e-27	7.42e-24	0.52	0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47687883	chr17:47450568~47492492:-
PRAD	cis	rs9532669	0.89	rs35073784	ENSG00000176268.5	CYCSP34	11.5	4.91e-27	7.52e-24	0.49	0.47	Cervical cancer;	chr13:40993428	chr13:40863599~40863902:-
PRAD	cis	rs2739330	0.892	rs4822455	ENSG00000250470.1	AP000351.3	11.5	4.93e-27	7.55e-24	0.64	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23976904~23977585:-
PRAD	cis	rs1426063	0.614	rs76512224	ENSG00000249717.1	RP11-44F21.3	11.5	4.96e-27	7.59e-24	1.03	0.47	QT interval;	chr4:75144808	chr4:74955974~74970362:-
PRAD	cis	rs12049351	0.665	rs1838464	ENSG00000229367.1	HMGN2P19	11.5	4.97e-27	7.6e-24	0.66	0.47	Circulating myeloperoxidase levels (plasma);	chr1:229480946	chr1:229570532~229570796:+
PRAD	cis	rs2739330	0.796	rs5760106	ENSG00000231271.1	AP000350.8	-11.5	4.97e-27	7.61e-24	-0.65	-0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23949918~23954042:+
PRAD	cis	rs7240205	0.853	rs58806199	ENSG00000275805.1	RP11-349H17.2	-11.5	4.98e-27	7.63e-24	-0.58	-0.47	Breast cancer;	chr18:26562683	chr18:26565723~26575626:-
PRAD	cis	rs6504950	0.85	rs11658717	ENSG00000275710.1	RP11-257O5.4	-11.5	5e-27	7.65e-24	-0.62	-0.47	Breast cancer;	chr17:54999625	chr17:54964474~54964679:+
PRAD	cis	rs7208859	0.673	rs423151	ENSG00000263531.1	RP13-753N3.1	11.5	5.01e-27	7.67e-24	0.79	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30625268	chr17:30863921~30864940:-
PRAD	cis	rs2348418	0.733	rs7137557	ENSG00000247934.4	RP11-967K21.1	11.5	5.02e-27	7.68e-24	0.44	0.47	Lung function (FEV1);Lung function (FVC);	chr12:28221259	chr12:28163298~28190738:-
PRAD	cis	rs2348418	0.733	rs12425200	ENSG00000247934.4	RP11-967K21.1	11.5	5.02e-27	7.68e-24	0.44	0.47	Lung function (FEV1);Lung function (FVC);	chr12:28237896	chr12:28163298~28190738:-
PRAD	cis	rs9322193	0.923	rs62441284	ENSG00000216906.2	RP11-350J20.9	11.5	5.03e-27	7.69e-24	0.55	0.47	Lung cancer;	chr6:149751542	chr6:149904243~149906418:+
PRAD	cis	rs8062405	1	rs7187776	ENSG00000259982.1	CDC37P1	11.49	5.08e-27	7.77e-24	0.61	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28846324	chr16:28700294~28701540:-
PRAD	cis	rs1426063	0.614	rs79750906	ENSG00000249717.1	RP11-44F21.3	11.49	5.1e-27	7.81e-24	1.03	0.47	QT interval;	chr4:75139193	chr4:74955974~74970362:-
PRAD	cis	rs2404602	0.647	rs10152247	ENSG00000259422.1	RP11-593F23.1	-11.49	5.19e-27	7.95e-24	-0.63	-0.47	Blood metabolite levels;	chr15:76649911	chr15:76174891~76181486:-
PRAD	cis	rs12594515	1	rs11070467	ENSG00000273972.1	CTD-2306A12.1	11.49	5.22e-27	7.98e-24	0.52	0.47	Weight;Waist circumference;	chr15:45692803	chr15:45702640~45703183:+
PRAD	cis	rs9322193	0.886	rs9767555	ENSG00000223701.3	RAET1E-AS1	11.49	5.24e-27	8.02e-24	0.64	0.47	Lung cancer;	chr6:149647022	chr6:149884431~149919508:+
PRAD	cis	rs6504950	1	rs9890971	ENSG00000275710.1	RP11-257O5.4	11.49	5.25e-27	8.03e-24	0.67	0.47	Breast cancer;	chr17:54982415	chr17:54964474~54964679:+
PRAD	cis	rs11105298	0.891	rs11105318	ENSG00000258302.2	RP11-981P6.1	11.49	5.26e-27	8.05e-24	0.54	0.47	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89532881	chr12:89561129~89594878:+
PRAD	cis	rs780096	0.526	rs4582	ENSG00000234072.1	AC074117.10	-11.49	5.27e-27	8.06e-24	-0.38	-0.47	Total body bone mineral density;	chr2:27381412	chr2:27356246~27367622:+
PRAD	cis	rs8072100	0.656	rs2610367	ENSG00000228782.6	CTD-2026D20.3	11.49	5.3e-27	8.1e-24	0.51	0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47492449	chr17:47450568~47492492:-
PRAD	cis	rs9322193	0.923	rs4870529	ENSG00000268592.3	RAET1E-AS1	11.49	5.32e-27	8.13e-24	0.65	0.47	Lung cancer;	chr6:149716436	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.923	rs9767309	ENSG00000268592.3	RAET1E-AS1	11.49	5.32e-27	8.13e-24	0.65	0.47	Lung cancer;	chr6:149716807	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.923	rs17745062	ENSG00000268592.3	RAET1E-AS1	11.49	5.32e-27	8.13e-24	0.65	0.47	Lung cancer;	chr6:149721079	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.923	rs62441279	ENSG00000268592.3	RAET1E-AS1	11.49	5.32e-27	8.13e-24	0.65	0.47	Lung cancer;	chr6:149721194	chr6:149863494~149919507:+
PRAD	cis	rs12594515	0.967	rs11070466	ENSG00000273972.1	CTD-2306A12.1	-11.49	5.34e-27	8.16e-24	-0.52	-0.47	Weight;Waist circumference;	chr15:45692757	chr15:45702640~45703183:+
PRAD	cis	rs1577917	0.958	rs4707223	ENSG00000203875.9	SNHG5	-11.49	5.38e-27	8.21e-24	-0.53	-0.47	Response to antipsychotic treatment;	chr6:85800084	chr6:85660950~85678736:-
PRAD	cis	rs2117029	0.586	rs2114846	ENSG00000258017.1	RP11-386G11.10	-11.49	5.45e-27	8.32e-24	-0.62	-0.47	Intelligence (multi-trait analysis);	chr12:49154493	chr12:49127782~49147869:+
PRAD	cis	rs9322193	0.961	rs2064520	ENSG00000223701.3	RAET1E-AS1	11.49	5.48e-27	8.36e-24	0.64	0.47	Lung cancer;	chr6:149603650	chr6:149884431~149919508:+
PRAD	cis	rs2404602	0.647	rs11072616	ENSG00000259422.1	RP11-593F23.1	-11.48	5.53e-27	8.43e-24	-0.62	-0.47	Blood metabolite levels;	chr15:76692928	chr15:76174891~76181486:-
PRAD	cis	rs8062405	0.723	rs113208333	ENSG00000259982.1	CDC37P1	11.48	5.54e-27	8.46e-24	0.63	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28594839	chr16:28700294~28701540:-
PRAD	cis	rs12594515	1	rs8039622	ENSG00000273972.1	CTD-2306A12.1	-11.48	5.62e-27	8.58e-24	-0.53	-0.47	Weight;Waist circumference;	chr15:45694233	chr15:45702640~45703183:+
PRAD	cis	rs9322193	0.923	rs66516768	ENSG00000216906.2	RP11-350J20.9	11.48	5.67e-27	8.65e-24	0.54	0.47	Lung cancer;	chr6:149671999	chr6:149904243~149906418:+
PRAD	cis	rs11676348	0.776	rs11690316	ENSG00000261338.2	RP11-378A13.1	-11.48	5.75e-27	8.77e-24	-0.54	-0.47	Ulcerative colitis;	chr2:218152739	chr2:218255319~218257366:+
PRAD	cis	rs7598759	0.548	rs1584462	ENSG00000181798.2	LINC00471	-11.48	5.78e-27	8.8e-24	-0.56	-0.47	Noise-induced hearing loss;	chr2:231505087	chr2:231508426~231514339:-
PRAD	cis	rs2739330	0.929	rs5751777	ENSG00000272787.1	KB-226F1.2	-11.48	5.78e-27	8.81e-24	-0.51	-0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23969211~23969873:+
PRAD	cis	rs11105298	0.891	rs10777163	ENSG00000258302.2	RP11-981P6.1	11.48	5.83e-27	8.88e-24	0.52	0.47	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89436943	chr12:89561129~89594878:+
PRAD	cis	rs2729354	0.953	rs2649650	ENSG00000265566.2	RN7SL605P	-11.48	5.87e-27	8.95e-24	-0.72	-0.47	Blood protein levels;	chr11:57560094	chr11:57528085~57528365:-
PRAD	cis	rs7727544	0.735	rs4705933	ENSG00000233006.5	AC034220.3	11.48	5.88e-27	8.96e-24	0.43	0.47	Blood metabolite levels;	chr5:132342719	chr5:132311285~132369916:-
PRAD	cis	rs7727544	0.735	rs272867	ENSG00000233006.5	AC034220.3	11.48	5.88e-27	8.96e-24	0.43	0.47	Blood metabolite levels;	chr5:132345364	chr5:132311285~132369916:-
PRAD	cis	rs1577917	0.958	rs13207173	ENSG00000203875.9	SNHG5	-11.48	5.89e-27	8.97e-24	-0.54	-0.47	Response to antipsychotic treatment;	chr6:85747804	chr6:85660950~85678736:-
PRAD	cis	rs1426063	0.614	rs75345649	ENSG00000249717.1	RP11-44F21.3	11.48	5.93e-27	9.03e-24	1.02	0.47	QT interval;	chr4:75100963	chr4:74955974~74970362:-
PRAD	cis	rs1426063	0.614	rs77333523	ENSG00000249717.1	RP11-44F21.3	11.48	5.93e-27	9.03e-24	1.02	0.47	QT interval;	chr4:75101024	chr4:74955974~74970362:-
PRAD	cis	rs1426063	0.614	rs17199632	ENSG00000249717.1	RP11-44F21.3	11.48	5.93e-27	9.03e-24	1.02	0.47	QT interval;	chr4:75103663	chr4:74955974~74970362:-
PRAD	cis	rs2739330	0.828	rs2330635	ENSG00000250470.1	AP000351.3	11.48	6e-27	9.13e-24	0.65	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23976904~23977585:-
PRAD	cis	rs12594515	0.967	rs11856523	ENSG00000273972.1	CTD-2306A12.1	-11.48	6.01e-27	9.15e-24	-0.53	-0.47	Weight;Waist circumference;	chr15:45697297	chr15:45702640~45703183:+
PRAD	cis	rs147858478	1	rs147858478	ENSG00000233006.5	AC034220.3	11.47	6.1e-27	9.28e-24	0.43	0.47	High light scatter reticulocyte percentage of red cells;	chr5:132347099	chr5:132311285~132369916:-
PRAD	cis	rs17711722	0.522	rs6957759	ENSG00000226824.5	RP4-756H11.3	-11.47	6.11e-27	9.31e-24	-0.6	-0.47	Calcium levels;	chr7:65806798	chr7:66654538~66669855:+
PRAD	cis	rs7727544	0.735	rs274559	ENSG00000233006.5	AC034220.3	-11.47	6.13e-27	9.33e-24	-0.42	-0.47	Blood metabolite levels;	chr5:132384378	chr5:132311285~132369916:-
PRAD	cis	rs7598759	0.527	rs12987949	ENSG00000181798.2	LINC00471	-11.47	6.19e-27	9.42e-24	-0.56	-0.47	Noise-induced hearing loss;	chr2:231502800	chr2:231508426~231514339:-
PRAD	cis	rs875971	0.545	rs73142233	ENSG00000237310.1	GS1-124K5.4	11.47	6.28e-27	9.55e-24	0.48	0.47	Aortic root size;	chr7:66221293	chr7:66493706~66495474:+
PRAD	cis	rs9322193	0.961	rs9285521	ENSG00000268592.3	RAET1E-AS1	11.47	6.3e-27	9.58e-24	0.66	0.47	Lung cancer;	chr6:149585576	chr6:149863494~149919507:+
PRAD	cis	rs875971	0.545	rs73142245	ENSG00000237310.1	GS1-124K5.4	11.47	6.32e-27	9.61e-24	0.48	0.47	Aortic root size;	chr7:66226662	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.502	rs11769702	ENSG00000237310.1	GS1-124K5.4	11.47	6.32e-27	9.61e-24	0.48	0.47	Aortic root size;	chr7:66255529	chr7:66493706~66495474:+
PRAD	cis	rs5760092	0.627	rs6519489	ENSG00000231271.1	AP000350.8	-11.47	6.33e-27	9.62e-24	-0.77	-0.47	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919659	chr22:23949918~23954042:+
PRAD	cis	rs2404602	0.684	rs965818	ENSG00000259422.1	RP11-593F23.1	-11.47	6.38e-27	9.71e-24	-0.62	-0.47	Blood metabolite levels;	chr15:76574444	chr15:76174891~76181486:-
PRAD	cis	rs977987	0.872	rs4888422	ENSG00000261783.1	RP11-252K23.2	-11.47	6.39e-27	9.72e-24	-0.64	-0.47	Dupuytren's disease;	chr16:75436678	chr16:75379818~75381260:-
PRAD	cis	rs9322193	1	rs9377228	ENSG00000223701.3	RAET1E-AS1	11.47	6.54e-27	9.93e-24	0.64	0.47	Lung cancer;	chr6:149600862	chr6:149884431~149919508:+
PRAD	cis	rs7240205	0.853	rs10853666	ENSG00000275805.1	RP11-349H17.2	11.47	6.54e-27	9.94e-24	0.58	0.47	Breast cancer;	chr18:26564147	chr18:26565723~26575626:-
PRAD	cis	rs2665103	0.632	rs3902959	ENSG00000278603.1	RP13-608F4.5	11.47	6.6e-27	1e-23	0.58	0.47	Intelligence (multi-trait analysis);	chr15:82252586	chr15:82472203~82472426:+
PRAD	cis	rs2739330	0.828	rs5760107	ENSG00000250470.1	AP000351.3	11.46	6.63e-27	1.01e-23	0.65	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23976904~23977585:-
PRAD	cis	rs2739330	0.789	rs5760109	ENSG00000250470.1	AP000351.3	11.46	6.63e-27	1.01e-23	0.65	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23976904~23977585:-
PRAD	cis	rs12049351	0.774	rs12042841	ENSG00000229367.1	HMGN2P19	-11.46	6.65e-27	1.01e-23	-0.65	-0.47	Circulating myeloperoxidase levels (plasma);	chr1:229504870	chr1:229570532~229570796:+
PRAD	cis	rs673078	0.607	rs17512525	ENSG00000275759.1	RP11-131L12.3	-11.46	6.66e-27	1.01e-23	-0.75	-0.47	Glucose homeostasis traits;	chr12:118315467	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.607	rs17440774	ENSG00000275759.1	RP11-131L12.3	-11.46	6.66e-27	1.01e-23	-0.75	-0.47	Glucose homeostasis traits;	chr12:118316155	chr12:118428281~118428870:+
PRAD	cis	rs1577917	1	rs955196	ENSG00000203875.9	SNHG5	11.46	6.68e-27	1.01e-23	0.54	0.47	Response to antipsychotic treatment;	chr6:86020233	chr6:85660950~85678736:-
PRAD	cis	rs9322193	0.923	rs9505823	ENSG00000268592.3	RAET1E-AS1	11.46	6.69e-27	1.02e-23	0.65	0.47	Lung cancer;	chr6:149628899	chr6:149863494~149919507:+
PRAD	cis	rs977987	0.806	rs4887818	ENSG00000261783.1	RP11-252K23.2	-11.46	6.71e-27	1.02e-23	-0.64	-0.47	Dupuytren's disease;	chr16:75328097	chr16:75379818~75381260:-
PRAD	cis	rs9595066	1	rs66786230	ENSG00000227258.4	SMIM2-AS1	11.46	6.76e-27	1.03e-23	0.88	0.47	Schizophrenia;	chr13:44137489	chr13:44110451~44240517:+
PRAD	cis	rs732716	0.785	rs9973266	ENSG00000267769.1	CTB-50L17.9	-11.46	6.85e-27	1.04e-23	-0.54	-0.47	Mean corpuscular volume;	chr19:4392718	chr19:4454014~4455286:+
PRAD	cis	rs9487094	0.813	rs35969918	ENSG00000260273.1	RP11-425D10.10	11.46	6.86e-27	1.04e-23	0.7	0.47	Height;	chr6:109441837	chr6:109382795~109383666:+
PRAD	cis	rs9481169	0.85	rs60962769	ENSG00000255389.1	C6orf3	-11.46	6.9e-27	1.05e-23	-0.91	-0.47	Inflammatory skin disease;	chr6:111598221	chr6:111599875~111602295:+
PRAD	cis	rs6991838	0.584	rs73236948	ENSG00000272010.1	CTD-3025N20.3	-11.46	6.91e-27	1.05e-23	-0.5	-0.47	Intelligence (multi-trait analysis);	chr8:65609176	chr8:65591850~65592472:-
PRAD	cis	rs2739330	0.796	rs5760097	ENSG00000250470.1	AP000351.3	11.46	6.92e-27	1.05e-23	0.65	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23976904~23977585:-
PRAD	cis	rs9487094	0.813	rs12528566	ENSG00000260273.1	RP11-425D10.10	11.46	7e-27	1.06e-23	0.69	0.47	Height;	chr6:109416945	chr6:109382795~109383666:+
PRAD	cis	rs7772486	0.597	rs6570732	ENSG00000235652.6	RP11-545I5.3	-11.46	7.04e-27	1.07e-23	-0.54	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145924015	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.597	rs6912351	ENSG00000235652.6	RP11-545I5.3	-11.46	7.04e-27	1.07e-23	-0.54	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145942935	chr6:145799409~145886585:+
PRAD	cis	rs11673344	0.698	rs56161518	ENSG00000226686.6	LINC01535	11.46	7.04e-27	1.07e-23	0.69	0.47	Obesity-related traits;	chr19:36978555	chr19:37251912~37265535:+
PRAD	cis	rs2404602	0.684	rs62026898	ENSG00000259422.1	RP11-593F23.1	-11.46	7.06e-27	1.07e-23	-0.62	-0.47	Blood metabolite levels;	chr15:76652030	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.622	rs11632670	ENSG00000259422.1	RP11-593F23.1	-11.46	7.12e-27	1.08e-23	-0.63	-0.47	Blood metabolite levels;	chr15:76681714	chr15:76174891~76181486:-
PRAD	cis	rs9322193	0.923	rs9688452	ENSG00000268592.3	RAET1E-AS1	11.46	7.12e-27	1.08e-23	0.66	0.47	Lung cancer;	chr6:149658764	chr6:149863494~149919507:+
PRAD	cis	rs2658782	0.666	rs2925361	ENSG00000279684.1	RP11-755E23.2	-11.46	7.17e-27	1.09e-23	-0.75	-0.47	Pulmonary function decline;	chr11:93365657	chr11:93286629~93288903:-
PRAD	cis	rs2404602	0.647	rs11631394	ENSG00000259422.1	RP11-593F23.1	-11.46	7.19e-27	1.09e-23	-0.62	-0.47	Blood metabolite levels;	chr15:76680868	chr15:76174891~76181486:-
PRAD	cis	rs2882667	0.683	rs13188935	ENSG00000253404.1	AC034243.1	11.45	7.28e-27	1.1e-23	0.59	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139116536	chr5:138744434~138753309:-
PRAD	cis	rs2117029	0.555	rs7978448	ENSG00000258017.1	RP11-386G11.10	-11.45	7.36e-27	1.11e-23	-0.63	-0.47	Intelligence (multi-trait analysis);	chr12:49113157	chr12:49127782~49147869:+
PRAD	cis	rs673078	0.607	rs17441214	ENSG00000275759.1	RP11-131L12.3	-11.45	7.37e-27	1.12e-23	-0.74	-0.47	Glucose homeostasis traits;	chr12:118436721	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.66	rs17440364	ENSG00000275759.1	RP11-131L12.3	-11.45	7.39e-27	1.12e-23	-0.74	-0.47	Glucose homeostasis traits;	chr12:118186613	chr12:118428281~118428870:+
PRAD	cis	rs7044106	0.537	rs10739573	ENSG00000226752.6	PSMD5-AS1	-11.45	7.4e-27	1.12e-23	-0.64	-0.47	Hip circumference adjusted for BMI;	chr9:120727540	chr9:120824828~120854385:+
PRAD	cis	rs7208859	0.524	rs73263982	ENSG00000263531.1	RP13-753N3.1	11.45	7.47e-27	1.13e-23	0.8	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30593606	chr17:30863921~30864940:-
PRAD	cis	rs7208859	0.623	rs216433	ENSG00000263531.1	RP13-753N3.1	11.45	7.47e-27	1.13e-23	0.8	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30594842	chr17:30863921~30864940:-
PRAD	cis	rs780096	0.546	rs4665976	ENSG00000234072.1	AC074117.10	-11.45	7.52e-27	1.14e-23	-0.38	-0.47	Total body bone mineral density;	chr2:27417458	chr2:27356246~27367622:+
PRAD	cis	rs780096	0.526	rs2911713	ENSG00000234072.1	AC074117.10	-11.45	7.52e-27	1.14e-23	-0.38	-0.47	Total body bone mineral density;	chr2:27418113	chr2:27356246~27367622:+
PRAD	cis	rs7743045	0.777	rs6916491	ENSG00000253194.1	RP11-351A11.1	11.45	7.6e-27	1.15e-23	0.65	0.47	Mean platelet volume;	chr6:118926569	chr6:118934785~119031541:+
PRAD	cis	rs673078	0.615	rs61943528	ENSG00000275759.1	RP11-131L12.3	-11.45	7.63e-27	1.15e-23	-0.75	-0.47	Glucose homeostasis traits;	chr12:118163134	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.66	rs61943535	ENSG00000275759.1	RP11-131L12.3	-11.45	7.63e-27	1.15e-23	-0.75	-0.47	Glucose homeostasis traits;	chr12:118168307	chr12:118428281~118428870:+
PRAD	cis	rs9322193	0.923	rs4354168	ENSG00000268592.3	RAET1E-AS1	11.45	7.71e-27	1.17e-23	0.65	0.47	Lung cancer;	chr6:149696642	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.923	rs4455682	ENSG00000268592.3	RAET1E-AS1	11.45	7.71e-27	1.17e-23	0.65	0.47	Lung cancer;	chr6:149700161	chr6:149863494~149919507:+
PRAD	cis	rs10853057	0.85	rs8076385	ENSG00000214174.7	AMZ2P1	11.45	7.74e-27	1.17e-23	0.85	0.47	White matter microstructure (global fractional anisotropy);	chr17:65002369	chr17:64966550~64975576:-
PRAD	cis	rs12594515	1	rs7162201	ENSG00000273972.1	CTD-2306A12.1	-11.45	7.79e-27	1.18e-23	-0.53	-0.47	Weight;Waist circumference;	chr15:45700460	chr15:45702640~45703183:+
PRAD	cis	rs12594515	1	rs8029209	ENSG00000273972.1	CTD-2306A12.1	-11.45	7.79e-27	1.18e-23	-0.53	-0.47	Weight;Waist circumference;	chr15:45701291	chr15:45702640~45703183:+
PRAD	cis	rs7208859	0.673	rs216435	ENSG00000263531.1	RP13-753N3.1	11.45	7.8e-27	1.18e-23	0.8	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595719	chr17:30863921~30864940:-
PRAD	cis	rs780096	0.546	rs2911712	ENSG00000234072.1	AC074117.10	-11.44	7.91e-27	1.19e-23	-0.38	-0.47	Total body bone mineral density;	chr2:27404078	chr2:27356246~27367622:+
PRAD	cis	rs704795	0.867	rs7566052	ENSG00000234072.1	AC074117.10	-11.44	7.91e-27	1.19e-23	-0.38	-0.47	Menopause (age at onset);	chr2:27405768	chr2:27356246~27367622:+
PRAD	cis	rs732716	0.785	rs11085073	ENSG00000267769.1	CTB-50L17.9	11.44	7.99e-27	1.21e-23	0.54	0.47	Mean corpuscular volume;	chr19:4375165	chr19:4454014~4455286:+
PRAD	cis	rs9532669	0.926	rs2324747	ENSG00000176268.5	CYCSP34	11.44	8.04e-27	1.21e-23	0.49	0.47	Cervical cancer;	chr13:40988883	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.926	rs9525439	ENSG00000176268.5	CYCSP34	11.44	8.04e-27	1.21e-23	0.49	0.47	Cervical cancer;	chr13:40992645	chr13:40863599~40863902:-
PRAD	cis	rs1167827	0.805	rs809439	ENSG00000127957.15	PMS2P3	11.44	8.04e-27	1.21e-23	0.4	0.47	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75531992	chr7:75502930~75528148:-
PRAD	cis	rs9532669	0.89	rs11619117	ENSG00000176268.5	CYCSP34	11.44	8.09e-27	1.22e-23	0.49	0.47	Cervical cancer;	chr13:40880020	chr13:40863599~40863902:-
PRAD	cis	rs12594515	1	rs8043291	ENSG00000273972.1	CTD-2306A12.1	-11.44	8.09e-27	1.22e-23	-0.53	-0.47	Weight;Waist circumference;	chr15:45704049	chr15:45702640~45703183:+
PRAD	cis	rs12594515	0.935	rs8042519	ENSG00000273972.1	CTD-2306A12.1	-11.44	8.09e-27	1.22e-23	-0.53	-0.47	Weight;Waist circumference;	chr15:45704143	chr15:45702640~45703183:+
PRAD	cis	rs12594515	1	rs56412446	ENSG00000273972.1	CTD-2306A12.1	-11.44	8.09e-27	1.22e-23	-0.53	-0.47	Weight;Waist circumference;	chr15:45704226	chr15:45702640~45703183:+
PRAD	cis	rs12594515	1	rs57299255	ENSG00000273972.1	CTD-2306A12.1	-11.44	8.09e-27	1.22e-23	-0.53	-0.47	Weight;Waist circumference;	chr15:45704334	chr15:45702640~45703183:+
PRAD	cis	rs12594515	1	rs56220882	ENSG00000273972.1	CTD-2306A12.1	-11.44	8.09e-27	1.22e-23	-0.53	-0.47	Weight;Waist circumference;	chr15:45704877	chr15:45702640~45703183:+
PRAD	cis	rs12049351	0.719	rs10916499	ENSG00000229367.1	HMGN2P19	11.44	8.12e-27	1.22e-23	0.65	0.47	Circulating myeloperoxidase levels (plasma);	chr1:229505331	chr1:229570532~229570796:+
PRAD	cis	rs704795	0.805	rs1728926	ENSG00000234072.1	AC074117.10	-11.44	8.12e-27	1.22e-23	-0.38	-0.47	Menopause (age at onset);	chr2:27390070	chr2:27356246~27367622:+
PRAD	cis	rs704795	0.836	rs1647281	ENSG00000234072.1	AC074117.10	-11.44	8.12e-27	1.22e-23	-0.38	-0.47	Menopause (age at onset);	chr2:27390071	chr2:27356246~27367622:+
PRAD	cis	rs9322193	1	rs9399693	ENSG00000268592.3	RAET1E-AS1	11.44	8.17e-27	1.23e-23	0.66	0.47	Lung cancer;	chr6:149612718	chr6:149863494~149919507:+
PRAD	cis	rs12594515	0.904	rs8032875	ENSG00000273972.1	CTD-2306A12.1	-11.44	8.18e-27	1.23e-23	-0.53	-0.47	Weight;Waist circumference;	chr15:45705812	chr15:45702640~45703183:+
PRAD	cis	rs12594515	0.874	rs8032878	ENSG00000273972.1	CTD-2306A12.1	-11.44	8.18e-27	1.23e-23	-0.53	-0.47	Weight;Waist circumference;	chr15:45705817	chr15:45702640~45703183:+
PRAD	cis	rs2404602	0.647	rs10851889	ENSG00000259422.1	RP11-593F23.1	-11.44	8.22e-27	1.24e-23	-0.62	-0.47	Blood metabolite levels;	chr15:76730995	chr15:76174891~76181486:-
PRAD	cis	rs867371	0.502	rs7176926	ENSG00000278603.1	RP13-608F4.5	11.44	8.23e-27	1.24e-23	0.58	0.47	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82245753	chr15:82472203~82472426:+
PRAD	cis	rs9322193	0.923	rs12526675	ENSG00000268592.3	RAET1E-AS1	-11.44	8.27e-27	1.25e-23	-0.64	-0.47	Lung cancer;	chr6:149729540	chr6:149863494~149919507:+
PRAD	cis	rs9545047	0.704	rs9530904	ENSG00000227676.3	LINC01068	11.44	8.33e-27	1.26e-23	0.58	0.47	Schizophrenia;	chr13:79370157	chr13:79566727~79571436:+
PRAD	cis	rs7684253	0.55	rs4566710	ENSG00000269949.1	RP11-738E22.3	-11.44	8.35e-27	1.26e-23	-0.53	-0.47	Migraine;	chr4:56879297	chr4:56960927~56961373:-
PRAD	cis	rs7727544	0.735	rs2569266	ENSG00000233006.5	AC034220.3	-11.44	8.36e-27	1.26e-23	-0.42	-0.47	Blood metabolite levels;	chr5:132371099	chr5:132311285~132369916:-
PRAD	cis	rs8062405	0.691	rs743590	ENSG00000259982.1	CDC37P1	11.44	8.38e-27	1.26e-23	0.63	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28596909	chr16:28700294~28701540:-
PRAD	cis	rs2404602	0.735	rs2957614	ENSG00000259422.1	RP11-593F23.1	11.44	8.45e-27	1.27e-23	0.59	0.47	Blood metabolite levels;	chr15:76404294	chr15:76174891~76181486:-
PRAD	cis	rs12594515	1	rs35182335	ENSG00000273972.1	CTD-2306A12.1	-11.44	8.46e-27	1.27e-23	-0.53	-0.47	Weight;Waist circumference;	chr15:45702986	chr15:45702640~45703183:+
PRAD	cis	rs12594515	1	rs11855509	ENSG00000273972.1	CTD-2306A12.1	-11.44	8.46e-27	1.27e-23	-0.53	-0.47	Weight;Waist circumference;	chr15:45703276	chr15:45702640~45703183:+
PRAD	cis	rs12594515	1	rs11855562	ENSG00000273972.1	CTD-2306A12.1	-11.44	8.46e-27	1.27e-23	-0.53	-0.47	Weight;Waist circumference;	chr15:45703461	chr15:45702640~45703183:+
PRAD	cis	rs12594515	1	rs12592190	ENSG00000273972.1	CTD-2306A12.1	-11.44	8.46e-27	1.27e-23	-0.53	-0.47	Weight;Waist circumference;	chr15:45701830	chr15:45702640~45703183:+
PRAD	cis	rs12594515	1	rs11854554	ENSG00000273972.1	CTD-2306A12.1	-11.44	8.46e-27	1.27e-23	-0.53	-0.47	Weight;Waist circumference;	chr15:45702348	chr15:45702640~45703183:+
PRAD	cis	rs9322193	0.886	rs9485408	ENSG00000268592.3	RAET1E-AS1	11.44	8.47e-27	1.28e-23	0.65	0.47	Lung cancer;	chr6:149618888	chr6:149863494~149919507:+
PRAD	cis	rs4964805	0.594	rs954920	ENSG00000257681.1	RP11-341G23.4	11.44	8.51e-27	1.28e-23	0.44	0.47	Attention deficit hyperactivity disorder;	chr12:103779532	chr12:103746315~103768858:-
PRAD	cis	rs732716	0.719	rs56088814	ENSG00000267769.1	CTB-50L17.9	-11.44	8.54e-27	1.29e-23	-0.54	-0.47	Mean corpuscular volume;	chr19:4422181	chr19:4454014~4455286:+
PRAD	cis	rs9322193	0.961	rs9285521	ENSG00000223701.3	RAET1E-AS1	11.44	8.58e-27	1.29e-23	0.64	0.47	Lung cancer;	chr6:149585576	chr6:149884431~149919508:+
PRAD	cis	rs1577917	1	rs2816815	ENSG00000203875.9	SNHG5	-11.43	8.72e-27	1.31e-23	-0.52	-0.47	Response to antipsychotic treatment;	chr6:85981938	chr6:85660950~85678736:-
PRAD	cis	rs4964805	0.505	rs15918	ENSG00000257681.1	RP11-341G23.4	11.43	8.87e-27	1.33e-23	0.44	0.47	Attention deficit hyperactivity disorder;	chr12:103773246	chr12:103746315~103768858:-
PRAD	cis	rs5760092	0.618	rs5996631	ENSG00000218537.1	MIF-AS1	-11.43	8.93e-27	1.34e-23	-0.71	-0.47	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23894426~23898930:-
PRAD	cis	rs9322193	0.923	rs10782310	ENSG00000268592.3	RAET1E-AS1	11.43	8.95e-27	1.35e-23	0.65	0.47	Lung cancer;	chr6:149622458	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.923	rs10782311	ENSG00000268592.3	RAET1E-AS1	11.43	8.95e-27	1.35e-23	0.65	0.47	Lung cancer;	chr6:149622592	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.923	rs9322200	ENSG00000268592.3	RAET1E-AS1	11.43	8.95e-27	1.35e-23	0.65	0.47	Lung cancer;	chr6:149630078	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.923	rs9322204	ENSG00000268592.3	RAET1E-AS1	11.43	8.95e-27	1.35e-23	0.65	0.47	Lung cancer;	chr6:149636047	chr6:149863494~149919507:+
PRAD	cis	rs9326248	0.813	rs588534	ENSG00000280143.1	AP000892.6	11.43	8.99e-27	1.35e-23	0.46	0.47	Blood protein levels;	chr11:117197788	chr11:117204967~117210292:+
PRAD	cis	rs765787	0.53	rs4774550	ENSG00000259520.4	CTD-2651B20.3	11.43	9.06e-27	1.36e-23	0.58	0.47	Uric acid levels;	chr15:45250114	chr15:45251580~45279251:-
PRAD	cis	rs732716	0.785	rs62130978	ENSG00000267769.1	CTB-50L17.9	-11.43	9.2e-27	1.38e-23	-0.53	-0.47	Mean corpuscular volume;	chr19:4429010	chr19:4454014~4455286:+
PRAD	cis	rs867371	0.502	rs1846908	ENSG00000278603.1	RP13-608F4.5	11.43	9.28e-27	1.39e-23	0.58	0.47	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82230185	chr15:82472203~82472426:+
PRAD	cis	rs2665103	0.655	rs1501367	ENSG00000278603.1	RP13-608F4.5	11.43	9.28e-27	1.39e-23	0.58	0.47	Intelligence (multi-trait analysis);	chr15:82230475	chr15:82472203~82472426:+
PRAD	cis	rs867371	0.502	rs28610286	ENSG00000278603.1	RP13-608F4.5	11.43	9.28e-27	1.39e-23	0.58	0.47	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82233314	chr15:82472203~82472426:+
PRAD	cis	rs867371	0.502	rs2047679	ENSG00000278603.1	RP13-608F4.5	11.43	9.28e-27	1.39e-23	0.58	0.47	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82239540	chr15:82472203~82472426:+
PRAD	cis	rs748404	0.66	rs509306	ENSG00000205771.5	CATSPER2P1	-11.43	9.29e-27	1.4e-23	-0.52	-0.47	Lung cancer;	chr15:43422973	chr15:43726918~43747094:-
PRAD	cis	rs1577917	0.958	rs11755864	ENSG00000203875.9	SNHG5	-11.43	9.33e-27	1.4e-23	-0.53	-0.47	Response to antipsychotic treatment;	chr6:85982073	chr6:85660950~85678736:-
PRAD	cis	rs2348418	0.669	rs7959641	ENSG00000247934.4	RP11-967K21.1	11.43	9.37e-27	1.41e-23	0.44	0.47	Lung function (FEV1);Lung function (FVC);	chr12:28237267	chr12:28163298~28190738:-
PRAD	cis	rs2739330	0.828	rs5760099	ENSG00000231271.1	AP000350.8	11.43	9.41e-27	1.41e-23	0.64	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23949918~23954042:+
PRAD	cis	rs7598759	0.548	rs6750795	ENSG00000181798.2	LINC00471	-11.42	9.45e-27	1.42e-23	-0.56	-0.47	Noise-induced hearing loss;	chr2:231513520	chr2:231508426~231514339:-
PRAD	cis	rs1577917	0.958	rs9647601	ENSG00000203875.9	SNHG5	-11.42	9.52e-27	1.43e-23	-0.53	-0.47	Response to antipsychotic treatment;	chr6:85740109	chr6:85660950~85678736:-
PRAD	cis	rs853679	0.527	rs707907	ENSG00000216901.1	AL022393.7	11.42	9.55e-27	1.43e-23	0.61	0.47	Depression;	chr6:28323463	chr6:28176188~28176674:+
PRAD	cis	rs6504950	0.85	rs2628308	ENSG00000275710.1	RP11-257O5.4	-11.42	9.58e-27	1.44e-23	-0.62	-0.47	Breast cancer;	chr17:55046212	chr17:54964474~54964679:+
PRAD	cis	rs4964805	0.594	rs3812805	ENSG00000257681.1	RP11-341G23.4	11.42	9.67e-27	1.45e-23	0.44	0.47	Attention deficit hyperactivity disorder;	chr12:103777094	chr12:103746315~103768858:-
PRAD	cis	rs9322193	0.607	rs7764677	ENSG00000231760.4	RP11-350J20.5	11.42	9.67e-27	1.45e-23	0.72	0.47	Lung cancer;	chr6:149906197	chr6:149796151~149826294:-
PRAD	cis	rs1577917	0.958	rs11758508	ENSG00000203875.9	SNHG5	11.42	9.75e-27	1.46e-23	0.54	0.47	Response to antipsychotic treatment;	chr6:85797160	chr6:85660950~85678736:-
PRAD	cis	rs9322193	0.884	rs10782312	ENSG00000268592.3	RAET1E-AS1	11.42	9.79e-27	1.47e-23	0.65	0.47	Lung cancer;	chr6:149622669	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.886	rs9322198	ENSG00000268592.3	RAET1E-AS1	11.42	9.79e-27	1.47e-23	0.65	0.47	Lung cancer;	chr6:149623772	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.923	rs9689599	ENSG00000268592.3	RAET1E-AS1	11.42	9.79e-27	1.47e-23	0.65	0.47	Lung cancer;	chr6:149631973	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.923	rs9800580	ENSG00000268592.3	RAET1E-AS1	11.42	9.79e-27	1.47e-23	0.65	0.47	Lung cancer;	chr6:149632845	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.884	rs11155669	ENSG00000268592.3	RAET1E-AS1	11.42	9.79e-27	1.47e-23	0.65	0.47	Lung cancer;	chr6:149633501	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.887	rs9505824	ENSG00000268592.3	RAET1E-AS1	11.42	9.79e-27	1.47e-23	0.65	0.47	Lung cancer;	chr6:149633663	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.923	rs9766886	ENSG00000268592.3	RAET1E-AS1	11.42	9.79e-27	1.47e-23	0.65	0.47	Lung cancer;	chr6:149637048	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.923	rs7740278	ENSG00000268592.3	RAET1E-AS1	11.42	9.79e-27	1.47e-23	0.65	0.47	Lung cancer;	chr6:149640116	chr6:149863494~149919507:+
PRAD	cis	rs2564921	0.765	rs2581799	ENSG00000242142.1	SERBP1P3	-11.42	9.8e-27	1.47e-23	-0.52	-0.47	Height;	chr3:53074760	chr3:53064283~53065091:-
PRAD	cis	rs9487094	0.813	rs34320275	ENSG00000260273.1	RP11-425D10.10	11.42	9.95e-27	1.49e-23	0.7	0.47	Height;	chr6:109436760	chr6:109382795~109383666:+
PRAD	cis	rs2404602	0.583	rs11072580	ENSG00000259422.1	RP11-593F23.1	11.42	9.96e-27	1.49e-23	0.56	0.47	Blood metabolite levels;	chr15:76247890	chr15:76174891~76181486:-
PRAD	cis	rs9322193	0.923	rs2342765	ENSG00000223701.3	RAET1E-AS1	11.42	1.01e-26	1.51e-23	0.64	0.47	Lung cancer;	chr6:149858873	chr6:149884431~149919508:+
PRAD	cis	rs9487094	1	rs9480933	ENSG00000260273.1	RP11-425D10.10	11.42	1.01e-26	1.51e-23	0.66	0.47	Height;	chr6:109350188	chr6:109382795~109383666:+
PRAD	cis	rs7772486	0.754	rs9373476	ENSG00000235652.6	RP11-545I5.3	11.42	1.02e-26	1.52e-23	0.48	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145818605	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.727	rs11155442	ENSG00000235652.6	RP11-545I5.3	11.42	1.02e-26	1.52e-23	0.48	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145819589	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.754	rs9390358	ENSG00000235652.6	RP11-545I5.3	11.42	1.02e-26	1.52e-23	0.48	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145824542	chr6:145799409~145886585:+
PRAD	cis	rs17711722	0.565	rs73372653	ENSG00000226824.5	RP4-756H11.3	-11.42	1.02e-26	1.52e-23	-0.6	-0.47	Calcium levels;	chr7:65977808	chr7:66654538~66669855:+
PRAD	cis	rs7743045	0.652	rs9387621	ENSG00000253194.1	RP11-351A11.1	11.42	1.02e-26	1.53e-23	0.63	0.47	Mean platelet volume;	chr6:118973412	chr6:118934785~119031541:+
PRAD	cis	rs2404602	0.662	rs908817	ENSG00000259422.1	RP11-593F23.1	-11.42	1.03e-26	1.54e-23	-0.6	-0.47	Blood metabolite levels;	chr15:76346850	chr15:76174891~76181486:-
PRAD	cis	rs12049351	0.774	rs34232465	ENSG00000229367.1	HMGN2P19	11.41	1.04e-26	1.55e-23	0.65	0.47	Circulating myeloperoxidase levels (plasma);	chr1:229495365	chr1:229570532~229570796:+
PRAD	cis	rs5760092	0.618	rs4461358	ENSG00000218537.1	MIF-AS1	-11.41	1.06e-26	1.58e-23	-0.71	-0.47	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23917919	chr22:23894426~23898930:-
PRAD	cis	rs2404602	0.709	rs11072591	ENSG00000259422.1	RP11-593F23.1	11.41	1.08e-26	1.61e-23	0.59	0.47	Blood metabolite levels;	chr15:76357221	chr15:76174891~76181486:-
PRAD	cis	rs2739330	0.828	rs4822451	ENSG00000231271.1	AP000350.8	11.41	1.09e-26	1.63e-23	0.64	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23949918~23954042:+
PRAD	cis	rs9322193	0.923	rs12529698	ENSG00000216906.2	RP11-350J20.9	11.41	1.1e-26	1.63e-23	0.54	0.47	Lung cancer;	chr6:149650951	chr6:149904243~149906418:+
PRAD	cis	rs12049351	0.774	rs2295624	ENSG00000229367.1	HMGN2P19	11.41	1.1e-26	1.64e-23	0.65	0.47	Circulating myeloperoxidase levels (plasma);	chr1:229508410	chr1:229570532~229570796:+
PRAD	cis	rs11603023	0.967	rs654423	ENSG00000255239.1	AP002954.6	-11.41	1.1e-26	1.64e-23	-0.59	-0.47	Cholesterol, total;	chr11:118641039	chr11:118688039~118690600:-
PRAD	cis	rs9532669	0.926	rs9532693	ENSG00000176268.5	CYCSP34	11.41	1.1e-26	1.64e-23	0.49	0.47	Cervical cancer;	chr13:40980557	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.926	rs2324748	ENSG00000176268.5	CYCSP34	11.41	1.1e-26	1.64e-23	0.49	0.47	Cervical cancer;	chr13:40989452	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.926	rs4245311	ENSG00000176268.5	CYCSP34	11.41	1.1e-26	1.64e-23	0.49	0.47	Cervical cancer;	chr13:40990003	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.89	rs9594473	ENSG00000176268.5	CYCSP34	11.41	1.1e-26	1.64e-23	0.49	0.47	Cervical cancer;	chr13:40997997	chr13:40863599~40863902:-
PRAD	cis	rs732716	0.785	rs62129354	ENSG00000267769.1	CTB-50L17.9	-11.41	1.12e-26	1.67e-23	-0.55	-0.47	Mean corpuscular volume;	chr19:4396508	chr19:4454014~4455286:+
PRAD	cis	rs780096	0.546	rs12473776	ENSG00000234072.1	AC074117.10	-11.41	1.13e-26	1.68e-23	-0.38	-0.47	Total body bone mineral density;	chr2:27413607	chr2:27356246~27367622:+
PRAD	cis	rs780096	0.506	rs1728922	ENSG00000234072.1	AC074117.10	-11.41	1.13e-26	1.68e-23	-0.38	-0.47	Total body bone mineral density;	chr2:27421597	chr2:27356246~27367622:+
PRAD	cis	rs189798	0.807	rs9949	ENSG00000254340.1	RP11-10A14.3	11.41	1.13e-26	1.68e-23	0.65	0.47	Myopia (pathological);	chr8:9137002	chr8:9141424~9145435:+
PRAD	cis	rs2404602	0.735	rs4886493	ENSG00000259422.1	RP11-593F23.1	-11.41	1.13e-26	1.68e-23	-0.6	-0.47	Blood metabolite levels;	chr15:76386685	chr15:76174891~76181486:-
PRAD	cis	rs4845570	0.834	rs1196467	ENSG00000249602.1	RP11-98D18.3	-11.4	1.13e-26	1.69e-23	-0.76	-0.47	Coronary artery disease;	chr1:151737562	chr1:151763384~151769501:-
PRAD	cis	rs2404602	0.684	rs12437981	ENSG00000259422.1	RP11-593F23.1	-11.4	1.14e-26	1.7e-23	-0.62	-0.47	Blood metabolite levels;	chr15:76550060	chr15:76174891~76181486:-
PRAD	cis	rs17711722	0.565	rs4275112	ENSG00000226824.5	RP4-756H11.3	11.4	1.14e-26	1.7e-23	0.6	0.47	Calcium levels;	chr7:65733651	chr7:66654538~66669855:+
PRAD	cis	rs780096	0.587	rs6743819	ENSG00000234072.1	AC074117.10	-11.4	1.15e-26	1.71e-23	-0.38	-0.47	Total body bone mineral density;	chr2:27344540	chr2:27356246~27367622:+
PRAD	cis	rs6504950	0.85	rs11079143	ENSG00000275710.1	RP11-257O5.4	-11.4	1.16e-26	1.73e-23	-0.62	-0.47	Breast cancer;	chr17:55005761	chr17:54964474~54964679:+
PRAD	cis	rs4814920	0.818	rs6046387	ENSG00000275142.1	RP5-999L4.2	-11.4	1.16e-26	1.73e-23	-0.78	-0.47	Bipolar disorder (body mass index interaction);	chr20:19869186	chr20:19871891~19872284:+
PRAD	cis	rs2882667	0.652	rs6596463	ENSG00000253404.1	AC034243.1	11.4	1.16e-26	1.74e-23	0.62	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139109237	chr5:138744434~138753309:-
PRAD	cis	rs2404602	0.684	rs1011083	ENSG00000259422.1	RP11-593F23.1	-11.4	1.17e-26	1.74e-23	-0.62	-0.47	Blood metabolite levels;	chr15:76715186	chr15:76174891~76181486:-
PRAD	cis	rs11603023	0.967	rs4245184	ENSG00000255239.1	AP002954.6	-11.4	1.18e-26	1.75e-23	-0.59	-0.47	Cholesterol, total;	chr11:118639844	chr11:118688039~118690600:-
PRAD	cis	rs11603023	0.967	rs644273	ENSG00000255239.1	AP002954.6	-11.4	1.18e-26	1.75e-23	-0.59	-0.47	Cholesterol, total;	chr11:118640634	chr11:118688039~118690600:-
PRAD	cis	rs2404602	0.647	rs4312276	ENSG00000259422.1	RP11-593F23.1	-11.4	1.18e-26	1.76e-23	-0.64	-0.47	Blood metabolite levels;	chr15:76872020	chr15:76174891~76181486:-
PRAD	cis	rs1577917	1	rs6454513	ENSG00000203875.9	SNHG5	11.4	1.18e-26	1.76e-23	0.52	0.47	Response to antipsychotic treatment;	chr6:86010331	chr6:85660950~85678736:-
PRAD	cis	rs6452524	0.561	rs4331874	ENSG00000249664.1	CTD-2227C6.2	11.4	1.2e-26	1.78e-23	0.56	0.47	Hypertension (SNP x SNP interaction);	chr5:83068253	chr5:83012285~83013109:-
PRAD	cis	rs732716	0.819	rs12459919	ENSG00000267769.1	CTB-50L17.9	-11.4	1.2e-26	1.79e-23	-0.53	-0.47	Mean corpuscular volume;	chr19:4434506	chr19:4454014~4455286:+
PRAD	cis	rs673078	0.66	rs11068917	ENSG00000275759.1	RP11-131L12.3	-11.4	1.2e-26	1.79e-23	-0.65	-0.47	Glucose homeostasis traits;	chr12:118353315	chr12:118428281~118428870:+
PRAD	cis	rs71403859	0.502	rs34766979	ENSG00000260886.1	TAT-AS1	11.4	1.22e-26	1.81e-23	0.81	0.47	Post bronchodilator FEV1;	chr16:71441608	chr16:71565789~71578187:+
PRAD	cis	rs9322193	0.923	rs56397000	ENSG00000216906.2	RP11-350J20.9	11.4	1.22e-26	1.82e-23	0.54	0.47	Lung cancer;	chr6:149739347	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.884	rs9689702	ENSG00000216906.2	RP11-350J20.9	11.4	1.22e-26	1.82e-23	0.54	0.47	Lung cancer;	chr6:149740720	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.923	rs10782315	ENSG00000216906.2	RP11-350J20.9	11.4	1.22e-26	1.82e-23	0.54	0.47	Lung cancer;	chr6:149743093	chr6:149904243~149906418:+
PRAD	cis	rs780096	0.546	rs6547626	ENSG00000234072.1	AC074117.10	-11.4	1.22e-26	1.82e-23	-0.38	-0.47	Total body bone mineral density;	chr2:27423903	chr2:27356246~27367622:+
PRAD	cis	rs9326248	0.817	rs6589598	ENSG00000280143.1	AP000892.6	11.4	1.22e-26	1.82e-23	0.44	0.47	Blood protein levels;	chr11:117131687	chr11:117204967~117210292:+
PRAD	cis	rs5760092	0.627	rs6519489	ENSG00000250470.1	AP000351.3	-11.39	1.24e-26	1.84e-23	-0.77	-0.47	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919659	chr22:23976904~23977585:-
PRAD	cis	rs7727544	0.735	rs274568	ENSG00000233006.5	AC034220.3	-11.39	1.24e-26	1.84e-23	-0.42	-0.47	Blood metabolite levels;	chr5:132377886	chr5:132311285~132369916:-
PRAD	cis	rs9322193	0.847	rs12234128	ENSG00000268592.3	RAET1E-AS1	11.39	1.24e-26	1.84e-23	0.65	0.47	Lung cancer;	chr6:149627553	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.923	rs57012784	ENSG00000268592.3	RAET1E-AS1	11.39	1.24e-26	1.84e-23	0.65	0.47	Lung cancer;	chr6:149627691	chr6:149863494~149919507:+
PRAD	cis	rs673078	0.66	rs73220119	ENSG00000275759.1	RP11-131L12.3	-11.39	1.25e-26	1.85e-23	-0.75	-0.47	Glucose homeostasis traits;	chr12:118159864	chr12:118428281~118428870:+
PRAD	cis	rs8062405	0.72	rs9926245	ENSG00000259982.1	CDC37P1	11.39	1.26e-26	1.87e-23	0.61	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544385	chr16:28700294~28701540:-
PRAD	cis	rs9326248	0.813	rs474488	ENSG00000280143.1	AP000892.6	11.39	1.28e-26	1.91e-23	0.46	0.47	Blood protein levels;	chr11:117198261	chr11:117204967~117210292:+
PRAD	cis	rs5760092	0.755	rs915589	ENSG00000231271.1	AP000350.8	-11.39	1.3e-26	1.93e-23	-0.77	-0.47	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23949918~23954042:+
PRAD	cis	rs7598759	0.527	rs4973417	ENSG00000181798.2	LINC00471	-11.39	1.31e-26	1.94e-23	-0.56	-0.47	Noise-induced hearing loss;	chr2:231484925	chr2:231508426~231514339:-
PRAD	cis	rs2404602	0.591	rs11635162	ENSG00000259422.1	RP11-593F23.1	-11.39	1.32e-26	1.96e-23	-0.65	-0.47	Blood metabolite levels;	chr15:76658764	chr15:76174891~76181486:-
PRAD	cis	rs2919917	0.688	rs6993386	ENSG00000254352.1	RP11-578O24.2	-11.39	1.32e-26	1.96e-23	-0.56	-0.47	Lymphocyte counts;	chr8:78741910	chr8:78723796~78724136:-
PRAD	cis	rs73086581	0.617	rs2300213	ENSG00000229539.1	RP11-119B16.2	-11.39	1.33e-26	1.97e-23	-0.66	-0.47	Response to antidepressants in depression;	chr20:4006076	chr20:3888239~3888868:-
PRAD	cis	rs1577917	1	rs955197	ENSG00000203875.9	SNHG5	-11.39	1.33e-26	1.98e-23	-0.54	-0.47	Response to antipsychotic treatment;	chr6:86019957	chr6:85660950~85678736:-
PRAD	cis	rs7727544	0.735	rs274566	ENSG00000233006.5	AC034220.3	-11.39	1.34e-26	1.99e-23	-0.42	-0.47	Blood metabolite levels;	chr5:132379319	chr5:132311285~132369916:-
PRAD	cis	rs1577917	0.958	rs6454488	ENSG00000203875.9	SNHG5	-11.38	1.35e-26	2.01e-23	-0.53	-0.47	Response to antipsychotic treatment;	chr6:85741124	chr6:85660950~85678736:-
PRAD	cis	rs875971	0.545	rs73142265	ENSG00000237310.1	GS1-124K5.4	11.38	1.35e-26	2.01e-23	0.48	0.47	Aortic root size;	chr7:66234510	chr7:66493706~66495474:+
PRAD	cis	rs765787	0.53	rs4331289	ENSG00000259520.4	CTD-2651B20.3	11.38	1.36e-26	2.02e-23	0.58	0.47	Uric acid levels;	chr15:45223140	chr15:45251580~45279251:-
PRAD	cis	rs7772486	0.558	rs62435775	ENSG00000235652.6	RP11-545I5.3	11.38	1.37e-26	2.03e-23	0.52	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145815279	chr6:145799409~145886585:+
PRAD	cis	rs6504950	0.925	rs244315	ENSG00000275710.1	RP11-257O5.4	11.38	1.37e-26	2.03e-23	0.65	0.47	Breast cancer;	chr17:55137293	chr17:54964474~54964679:+
PRAD	cis	rs9322193	0.923	rs11155670	ENSG00000216906.2	RP11-350J20.9	11.38	1.37e-26	2.04e-23	0.55	0.47	Lung cancer;	chr6:149644992	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.923	rs11155671	ENSG00000216906.2	RP11-350J20.9	11.38	1.38e-26	2.05e-23	0.55	0.47	Lung cancer;	chr6:149650996	chr6:149904243~149906418:+
PRAD	cis	rs8062405	0.824	rs153106	ENSG00000259982.1	CDC37P1	11.38	1.39e-26	2.05e-23	0.61	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28515576	chr16:28700294~28701540:-
PRAD	cis	rs7397814	0.558	rs4764447	ENSG00000256673.1	RP11-599J14.2	11.38	1.39e-26	2.06e-23	0.56	0.47	IgG glycosylation;	chr12:9426513	chr12:9398355~9414851:-
PRAD	cis	rs1061377	1	rs12646251	ENSG00000249207.1	RP11-360F5.1	-11.38	1.4e-26	2.07e-23	-0.5	-0.47	Uric acid levels;	chr4:39132751	chr4:39112677~39126818:-
PRAD	cis	rs11676348	0.755	rs13410318	ENSG00000261338.2	RP11-378A13.1	11.38	1.41e-26	2.08e-23	0.53	0.47	Ulcerative colitis;	chr2:218158187	chr2:218255319~218257366:+
PRAD	cis	rs780096	0.587	rs10205219	ENSG00000234072.1	AC074117.10	-11.38	1.41e-26	2.08e-23	-0.38	-0.47	Total body bone mineral density;	chr2:27345698	chr2:27356246~27367622:+
PRAD	cis	rs1577917	0.958	rs1414199	ENSG00000203875.9	SNHG5	-11.38	1.41e-26	2.09e-23	-0.53	-0.47	Response to antipsychotic treatment;	chr6:85812652	chr6:85660950~85678736:-
PRAD	cis	rs2404602	0.575	rs11633309	ENSG00000259422.1	RP11-593F23.1	-11.38	1.42e-26	2.11e-23	-0.65	-0.47	Blood metabolite levels;	chr15:76670008	chr15:76174891~76181486:-
PRAD	cis	rs3096299	0.503	rs9925045	ENSG00000274627.1	RP11-104N10.2	11.38	1.44e-26	2.13e-23	0.47	0.47	Multiple myeloma (IgH translocation);	chr16:89490068	chr16:89516797~89522217:+
PRAD	cis	rs9322193	0.923	rs9478291	ENSG00000216906.2	RP11-350J20.9	11.38	1.47e-26	2.17e-23	0.54	0.47	Lung cancer;	chr6:149729434	chr6:149904243~149906418:+
PRAD	cis	rs12049351	0.675	rs754024	ENSG00000229367.1	HMGN2P19	11.38	1.47e-26	2.18e-23	0.65	0.47	Circulating myeloperoxidase levels (plasma);	chr1:229501667	chr1:229570532~229570796:+
PRAD	cis	rs12049351	0.774	rs754022	ENSG00000229367.1	HMGN2P19	11.38	1.47e-26	2.18e-23	0.65	0.47	Circulating myeloperoxidase levels (plasma);	chr1:229501898	chr1:229570532~229570796:+
PRAD	cis	rs12049351	0.774	rs6671385	ENSG00000229367.1	HMGN2P19	11.37	1.48e-26	2.19e-23	0.65	0.47	Circulating myeloperoxidase levels (plasma);	chr1:229506905	chr1:229570532~229570796:+
PRAD	cis	rs9322193	0.886	rs4870049	ENSG00000216906.2	RP11-350J20.9	11.37	1.52e-26	2.24e-23	0.54	0.47	Lung cancer;	chr6:149837058	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.923	rs9800614	ENSG00000216906.2	RP11-350J20.9	11.37	1.53e-26	2.26e-23	0.55	0.47	Lung cancer;	chr6:149644604	chr6:149904243~149906418:+
PRAD	cis	rs2729354	0.909	rs2729374	ENSG00000265566.2	RN7SL605P	-11.37	1.53e-26	2.26e-23	-0.72	-0.47	Blood protein levels;	chr11:57559454	chr11:57528085~57528365:-
PRAD	cis	rs9322193	0.607	rs12527391	ENSG00000268592.3	RAET1E-AS1	11.37	1.55e-26	2.29e-23	0.75	0.47	Lung cancer;	chr6:149882156	chr6:149863494~149919507:+
PRAD	cis	rs7684253	0.587	rs2002154	ENSG00000269949.1	RP11-738E22.3	-11.37	1.56e-26	2.31e-23	-0.53	-0.47	Migraine;	chr4:56879851	chr4:56960927~56961373:-
PRAD	cis	rs7684253	0.587	rs7670313	ENSG00000269949.1	RP11-738E22.3	-11.37	1.56e-26	2.31e-23	-0.53	-0.47	Migraine;	chr4:56880007	chr4:56960927~56961373:-
PRAD	cis	rs7684253	0.587	rs2170074	ENSG00000269949.1	RP11-738E22.3	-11.37	1.56e-26	2.31e-23	-0.53	-0.47	Migraine;	chr4:56880190	chr4:56960927~56961373:-
PRAD	cis	rs7684253	0.587	rs2170073	ENSG00000269949.1	RP11-738E22.3	-11.37	1.56e-26	2.31e-23	-0.53	-0.47	Migraine;	chr4:56880659	chr4:56960927~56961373:-
PRAD	cis	rs9322193	0.607	rs3798763	ENSG00000268592.3	RAET1E-AS1	11.37	1.58e-26	2.34e-23	0.75	0.47	Lung cancer;	chr6:149889964	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.607	rs12204653	ENSG00000268592.3	RAET1E-AS1	11.37	1.58e-26	2.34e-23	0.75	0.47	Lung cancer;	chr6:149891885	chr6:149863494~149919507:+
PRAD	cis	rs6750795	0.765	rs6742387	ENSG00000181798.2	LINC00471	-11.37	1.58e-26	2.34e-23	-0.56	-0.47	Height;	chr2:231490121	chr2:231508426~231514339:-
PRAD	cis	rs907683	0.584	rs12920	ENSG00000280323.1	AC053503.12	11.37	1.59e-26	2.35e-23	0.39	0.47	Resting heart rate;	chr2:219420944	chr2:219427477~219429319:+
PRAD	cis	rs7772486	0.603	rs2223411	ENSG00000235652.6	RP11-545I5.3	-11.37	1.59e-26	2.35e-23	-0.52	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145707631	chr6:145799409~145886585:+
PRAD	cis	rs7598759	0.548	rs11693738	ENSG00000181798.2	LINC00471	-11.37	1.61e-26	2.38e-23	-0.56	-0.47	Noise-induced hearing loss;	chr2:231495773	chr2:231508426~231514339:-
PRAD	cis	rs7598759	0.548	rs11686485	ENSG00000181798.2	LINC00471	-11.37	1.61e-26	2.38e-23	-0.56	-0.47	Noise-induced hearing loss;	chr2:231495986	chr2:231508426~231514339:-
PRAD	cis	rs1426063	0.614	rs114761716	ENSG00000249717.1	RP11-44F21.3	11.37	1.61e-26	2.38e-23	1.01	0.47	QT interval;	chr4:75107209	chr4:74955974~74970362:-
PRAD	cis	rs10256972	0.967	rs1881122	ENSG00000229043.2	AC091729.9	-11.36	1.62e-26	2.39e-23	-0.56	-0.47	Endometriosis;Longevity;	chr7:1001310	chr7:1160374~1165267:+
PRAD	cis	rs2739330	0.587	rs4820571	ENSG00000235689.1	AP000351.13	11.36	1.62e-26	2.4e-23	0.55	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:24006305~24008258:-
PRAD	cis	rs9322193	0.923	rs9505826	ENSG00000268592.3	RAET1E-AS1	11.36	1.64e-26	2.41e-23	0.65	0.47	Lung cancer;	chr6:149633912	chr6:149863494~149919507:+
PRAD	cis	rs7743045	0.643	rs114000233	ENSG00000253194.1	RP11-351A11.1	11.36	1.64e-26	2.42e-23	0.63	0.47	Mean platelet volume;	chr6:118935167	chr6:118934785~119031541:+
PRAD	cis	rs748404	0.66	rs693510	ENSG00000205771.5	CATSPER2P1	-11.36	1.64e-26	2.43e-23	-0.52	-0.47	Lung cancer;	chr15:43422427	chr15:43726918~43747094:-
PRAD	cis	rs748404	0.66	rs690512	ENSG00000205771.5	CATSPER2P1	-11.36	1.64e-26	2.43e-23	-0.52	-0.47	Lung cancer;	chr15:43425480	chr15:43726918~43747094:-
PRAD	cis	rs748404	0.66	rs2249952	ENSG00000205771.5	CATSPER2P1	-11.36	1.64e-26	2.43e-23	-0.52	-0.47	Lung cancer;	chr15:43428335	chr15:43726918~43747094:-
PRAD	cis	rs748404	0.66	rs2439845	ENSG00000205771.5	CATSPER2P1	-11.36	1.64e-26	2.43e-23	-0.52	-0.47	Lung cancer;	chr15:43430412	chr15:43726918~43747094:-
PRAD	cis	rs748404	0.631	rs2467745	ENSG00000205771.5	CATSPER2P1	-11.36	1.64e-26	2.43e-23	-0.52	-0.47	Lung cancer;	chr15:43430544	chr15:43726918~43747094:-
PRAD	cis	rs2404602	0.735	rs56246286	ENSG00000259422.1	RP11-593F23.1	-11.36	1.67e-26	2.46e-23	-0.6	-0.47	Blood metabolite levels;	chr15:76398390	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.735	rs12903874	ENSG00000259422.1	RP11-593F23.1	-11.36	1.67e-26	2.46e-23	-0.6	-0.47	Blood metabolite levels;	chr15:76400977	chr15:76174891~76181486:-
PRAD	cis	rs7240205	0.853	rs4404156	ENSG00000275805.1	RP11-349H17.2	11.36	1.67e-26	2.46e-23	0.57	0.47	Breast cancer;	chr18:26563490	chr18:26565723~26575626:-
PRAD	cis	rs9322193	0.884	rs62439836	ENSG00000268592.3	RAET1E-AS1	11.36	1.67e-26	2.47e-23	0.65	0.47	Lung cancer;	chr6:149669173	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.923	rs4869812	ENSG00000268592.3	RAET1E-AS1	11.36	1.67e-26	2.47e-23	0.65	0.47	Lung cancer;	chr6:149669447	chr6:149863494~149919507:+
PRAD	cis	rs2919917	0.662	rs1483572	ENSG00000254352.1	RP11-578O24.2	11.36	1.69e-26	2.49e-23	0.56	0.47	Lymphocyte counts;	chr8:78723008	chr8:78723796~78724136:-
PRAD	cis	rs9322193	0.923	rs9766037	ENSG00000268592.3	RAET1E-AS1	11.36	1.7e-26	2.51e-23	0.65	0.47	Lung cancer;	chr6:149616921	chr6:149863494~149919507:+
PRAD	cis	rs7727544	0.66	rs2631361	ENSG00000233006.5	AC034220.3	-11.36	1.7e-26	2.51e-23	-0.42	-0.47	Blood metabolite levels;	chr5:132371688	chr5:132311285~132369916:-
PRAD	cis	rs11690935	0.788	rs6715929	ENSG00000228389.1	AC068039.4	11.36	1.71e-26	2.52e-23	0.54	0.47	Schizophrenia;	chr2:172012600	chr2:171773482~171775844:+
PRAD	cis	rs7598759	0.527	rs7571691	ENSG00000181798.2	LINC00471	-11.36	1.71e-26	2.52e-23	-0.55	-0.47	Noise-induced hearing loss;	chr2:231504690	chr2:231508426~231514339:-
PRAD	cis	rs977987	0.872	rs1542864	ENSG00000261783.1	RP11-252K23.2	-11.36	1.71e-26	2.53e-23	-0.64	-0.47	Dupuytren's disease;	chr16:75437480	chr16:75379818~75381260:-
PRAD	cis	rs7727544	0.684	rs272889	ENSG00000233006.5	AC034220.3	11.36	1.72e-26	2.53e-23	0.42	0.47	Blood metabolite levels;	chr5:132329685	chr5:132311285~132369916:-
PRAD	cis	rs7772486	0.597	rs7746618	ENSG00000235652.6	RP11-545I5.3	-11.36	1.74e-26	2.57e-23	-0.53	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145960231	chr6:145799409~145886585:+
PRAD	cis	rs9322193	0.962	rs4380763	ENSG00000268592.3	RAET1E-AS1	11.36	1.75e-26	2.58e-23	0.65	0.47	Lung cancer;	chr6:149678086	chr6:149863494~149919507:+
PRAD	cis	rs4845570	0.834	rs7007	ENSG00000249602.1	RP11-98D18.3	11.36	1.77e-26	2.6e-23	0.8	0.47	Coronary artery disease;	chr1:151763100	chr1:151763384~151769501:-
PRAD	cis	rs780096	0.506	rs2950834	ENSG00000234072.1	AC074117.10	-11.35	1.77e-26	2.6e-23	-0.37	-0.47	Total body bone mineral density;	chr2:27404499	chr2:27356246~27367622:+
PRAD	cis	rs2019137	0.936	rs902696	ENSG00000189223.12	PAX8-AS1	-11.35	1.77e-26	2.6e-23	-0.57	-0.47	Lymphocyte counts;	chr2:113197302	chr2:113211522~113276581:+
PRAD	cis	rs7772486	0.79	rs9403749	ENSG00000235652.6	RP11-545I5.3	11.35	1.78e-26	2.62e-23	0.48	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145841103	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.79	rs2265474	ENSG00000235652.6	RP11-545I5.3	11.35	1.78e-26	2.62e-23	0.48	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145860956	chr6:145799409~145886585:+
PRAD	cis	rs7208859	0.623	rs216423	ENSG00000263531.1	RP13-753N3.1	11.35	1.79e-26	2.64e-23	0.79	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30615091	chr17:30863921~30864940:-
PRAD	cis	rs11690935	0.632	rs12991740	ENSG00000228389.1	AC068039.4	-11.35	1.8e-26	2.65e-23	-0.52	-0.47	Schizophrenia;	chr2:172021092	chr2:171773482~171775844:+
PRAD	cis	rs6570726	0.577	rs867056	ENSG00000235652.6	RP11-545I5.3	-11.35	1.82e-26	2.68e-23	-0.53	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145463669	chr6:145799409~145886585:+
PRAD	cis	rs732716	0.785	rs7769	ENSG00000267769.1	CTB-50L17.9	-11.35	1.83e-26	2.7e-23	-0.55	-0.47	Mean corpuscular volume;	chr19:4360546	chr19:4454014~4455286:+
PRAD	cis	rs977987	0.835	rs11641532	ENSG00000261783.1	RP11-252K23.2	-11.35	1.83e-26	2.7e-23	-0.63	-0.47	Dupuytren's disease;	chr16:75295582	chr16:75379818~75381260:-
PRAD	cis	rs11690935	0.632	rs6433323	ENSG00000228389.1	AC068039.4	11.35	1.84e-26	2.71e-23	0.52	0.47	Schizophrenia;	chr2:172008155	chr2:171773482~171775844:+
PRAD	cis	rs853679	0.527	rs853690	ENSG00000216901.1	AL022393.7	11.35	1.85e-26	2.72e-23	0.6	0.47	Depression;	chr6:28317705	chr6:28176188~28176674:+
PRAD	cis	rs2658782	0.526	rs7131487	ENSG00000279684.1	RP11-755E23.2	-11.35	1.85e-26	2.72e-23	-0.66	-0.47	Pulmonary function decline;	chr11:93452786	chr11:93286629~93288903:-
PRAD	cis	rs71403859	0.502	rs17345863	ENSG00000260886.1	TAT-AS1	11.35	1.86e-26	2.74e-23	0.82	0.47	Post bronchodilator FEV1;	chr16:71489358	chr16:71565789~71578187:+
PRAD	cis	rs867371	0.502	rs8025964	ENSG00000278603.1	RP13-608F4.5	11.35	1.87e-26	2.75e-23	0.58	0.47	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82229429	chr15:82472203~82472426:+
PRAD	cis	rs6903823	0.527	rs4713158	ENSG00000216901.1	AL022393.7	11.35	1.87e-26	2.76e-23	0.6	0.47	Pulmonary function;	chr6:28309994	chr6:28176188~28176674:+
PRAD	cis	rs2404602	0.735	rs2280306	ENSG00000259422.1	RP11-593F23.1	-11.35	1.87e-26	2.76e-23	-0.59	-0.47	Blood metabolite levels;	chr15:76359917	chr15:76174891~76181486:-
PRAD	cis	rs11603023	0.967	rs7936556	ENSG00000255239.1	AP002954.6	-11.35	1.88e-26	2.77e-23	-0.59	-0.47	Cholesterol, total;	chr11:118630582	chr11:118688039~118690600:-
PRAD	cis	rs1075265	0.568	rs10865277	ENSG00000233266.1	HMGB1P31	11.35	1.89e-26	2.78e-23	0.62	0.47	Chronotype;Morning vs. evening chronotype;	chr2:54074865	chr2:54051334~54051760:+
PRAD	cis	rs9322193	0.923	rs1080670	ENSG00000268592.3	RAET1E-AS1	11.35	1.89e-26	2.78e-23	0.65	0.47	Lung cancer;	chr6:149620161	chr6:149863494~149919507:+
PRAD	cis	rs1426063	0.614	rs76931926	ENSG00000249717.1	RP11-44F21.3	11.35	1.89e-26	2.78e-23	1.01	0.47	QT interval;	chr4:75106902	chr4:74955974~74970362:-
PRAD	cis	rs780096	0.565	rs813592	ENSG00000234072.1	AC074117.10	-11.35	1.9e-26	2.8e-23	-0.37	-0.47	Total body bone mineral density;	chr2:27499104	chr2:27356246~27367622:+
PRAD	cis	rs9322193	0.607	rs4869755	ENSG00000268592.3	RAET1E-AS1	11.35	1.91e-26	2.8e-23	0.75	0.47	Lung cancer;	chr6:149886347	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.639	rs4869756	ENSG00000268592.3	RAET1E-AS1	11.35	1.91e-26	2.8e-23	0.75	0.47	Lung cancer;	chr6:149886360	chr6:149863494~149919507:+
PRAD	cis	rs765787	0.53	rs2433229	ENSG00000259520.4	CTD-2651B20.3	11.35	1.91e-26	2.8e-23	0.58	0.47	Uric acid levels;	chr15:45223037	chr15:45251580~45279251:-
PRAD	cis	rs2404602	0.698	rs12909656	ENSG00000259422.1	RP11-593F23.1	-11.35	1.91e-26	2.8e-23	-0.59	-0.47	Blood metabolite levels;	chr15:76372037	chr15:76174891~76181486:-
PRAD	cis	rs2739330	0.828	rs2186366	ENSG00000250470.1	AP000351.3	-11.35	1.91e-26	2.81e-23	-0.64	-0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23976904~23977585:-
PRAD	cis	rs7727544	0.735	rs272842	ENSG00000233006.5	AC034220.3	11.35	1.91e-26	2.81e-23	0.42	0.47	Blood metabolite levels;	chr5:132320824	chr5:132311285~132369916:-
PRAD	cis	rs1577917	1	rs1962716	ENSG00000203875.9	SNHG5	-11.35	1.91e-26	2.81e-23	-0.54	-0.47	Response to antipsychotic treatment;	chr6:85938718	chr6:85660950~85678736:-
PRAD	cis	rs7772486	0.558	rs702322	ENSG00000235652.6	RP11-545I5.3	-11.35	1.92e-26	2.82e-23	-0.52	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145686030	chr6:145799409~145886585:+
PRAD	cis	rs12049351	0.613	rs12037690	ENSG00000229367.1	HMGN2P19	11.35	1.92e-26	2.82e-23	0.65	0.47	Circulating myeloperoxidase levels (plasma);	chr1:229506638	chr1:229570532~229570796:+
PRAD	cis	rs12049351	0.774	rs6661924	ENSG00000229367.1	HMGN2P19	11.35	1.92e-26	2.82e-23	0.65	0.47	Circulating myeloperoxidase levels (plasma);	chr1:229506993	chr1:229570532~229570796:+
PRAD	cis	rs7772486	0.754	rs9399567	ENSG00000235652.6	RP11-545I5.3	11.35	1.93e-26	2.83e-23	0.48	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145826159	chr6:145799409~145886585:+
PRAD	cis	rs7044106	0.537	rs4434680	ENSG00000226752.6	PSMD5-AS1	-11.34	1.94e-26	2.85e-23	-0.64	-0.47	Hip circumference adjusted for BMI;	chr9:120727410	chr9:120824828~120854385:+
PRAD	cis	rs2739330	0.828	rs4822454	ENSG00000250470.1	AP000351.3	11.34	1.96e-26	2.89e-23	0.64	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23976904~23977585:-
PRAD	cis	rs8062405	0.755	rs2077031	ENSG00000259982.1	CDC37P1	11.34	1.97e-26	2.9e-23	0.62	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28591847	chr16:28700294~28701540:-
PRAD	cis	rs11690935	0.655	rs12997093	ENSG00000228389.1	AC068039.4	-11.34	1.97e-26	2.9e-23	-0.52	-0.47	Schizophrenia;	chr2:171707928	chr2:171773482~171775844:+
PRAD	cis	rs7044106	0.648	rs2031369	ENSG00000226752.6	PSMD5-AS1	-11.34	1.99e-26	2.92e-23	-0.56	-0.47	Hip circumference adjusted for BMI;	chr9:120598016	chr9:120824828~120854385:+
PRAD	cis	rs1577917	0.958	rs10944136	ENSG00000203875.9	SNHG5	-11.34	1.99e-26	2.92e-23	-0.53	-0.47	Response to antipsychotic treatment;	chr6:85738781	chr6:85660950~85678736:-
PRAD	cis	rs780096	0.546	rs1060525	ENSG00000234072.1	AC074117.10	-11.34	1.99e-26	2.92e-23	-0.37	-0.47	Total body bone mineral density;	chr2:27412715	chr2:27356246~27367622:+
PRAD	cis	rs2404602	0.684	rs11072602	ENSG00000259422.1	RP11-593F23.1	-11.34	2e-26	2.94e-23	-0.62	-0.47	Blood metabolite levels;	chr15:76581126	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.684	rs11854850	ENSG00000259422.1	RP11-593F23.1	-11.34	2.02e-26	2.96e-23	-0.61	-0.47	Blood metabolite levels;	chr15:76552230	chr15:76174891~76181486:-
PRAD	cis	rs2019137	1	rs2019137	ENSG00000189223.12	PAX8-AS1	11.34	2.04e-26	2.99e-23	0.58	0.47	Lymphocyte counts;	chr2:113216055	chr2:113211522~113276581:+
PRAD	cis	rs732716	0.785	rs55660045	ENSG00000267769.1	CTB-50L17.9	-11.34	2.04e-26	3e-23	-0.53	-0.47	Mean corpuscular volume;	chr19:4425308	chr19:4454014~4455286:+
PRAD	cis	rs1075265	0.548	rs2542575	ENSG00000233266.1	HMGB1P31	11.34	2.05e-26	3.01e-23	0.64	0.47	Chronotype;Morning vs. evening chronotype;	chr2:53821221	chr2:54051334~54051760:+
PRAD	cis	rs1075265	0.568	rs2542577	ENSG00000233266.1	HMGB1P31	11.34	2.05e-26	3.01e-23	0.64	0.47	Chronotype;Morning vs. evening chronotype;	chr2:53822111	chr2:54051334~54051760:+
PRAD	cis	rs1075265	0.568	rs3095756	ENSG00000233266.1	HMGB1P31	11.34	2.05e-26	3.01e-23	0.64	0.47	Chronotype;Morning vs. evening chronotype;	chr2:53822332	chr2:54051334~54051760:+
PRAD	cis	rs780096	0.565	rs10169261	ENSG00000234072.1	AC074117.10	-11.34	2.06e-26	3.01e-23	-0.37	-0.47	Total body bone mineral density;	chr2:27504447	chr2:27356246~27367622:+
PRAD	cis	rs11690935	0.655	rs12052995	ENSG00000228389.1	AC068039.4	-11.34	2.06e-26	3.02e-23	-0.53	-0.47	Schizophrenia;	chr2:171680702	chr2:171773482~171775844:+
PRAD	cis	rs9322193	0.923	rs10747276	ENSG00000216906.2	RP11-350J20.9	11.34	2.06e-26	3.02e-23	0.54	0.47	Lung cancer;	chr6:149758739	chr6:149904243~149906418:+
PRAD	cis	rs7727544	0.735	rs2631370	ENSG00000233006.5	AC034220.3	-11.34	2.06e-26	3.03e-23	-0.42	-0.47	Blood metabolite levels;	chr5:132368084	chr5:132311285~132369916:-
PRAD	cis	rs2019137	0.967	rs895412	ENSG00000189223.12	PAX8-AS1	11.34	2.07e-26	3.03e-23	0.58	0.47	Lymphocyte counts;	chr2:113216387	chr2:113211522~113276581:+
PRAD	cis	rs765787	0.53	rs1706832	ENSG00000259520.4	CTD-2651B20.3	11.34	2.07e-26	3.03e-23	0.58	0.47	Uric acid levels;	chr15:45224975	chr15:45251580~45279251:-
PRAD	cis	rs12594515	1	rs12185095	ENSG00000273972.1	CTD-2306A12.1	-11.34	2.07e-26	3.04e-23	-0.53	-0.47	Weight;Waist circumference;	chr15:45702437	chr15:45702640~45703183:+
PRAD	cis	rs7727544	0.661	rs273900	ENSG00000233006.5	AC034220.3	11.34	2.09e-26	3.06e-23	0.42	0.47	Blood metabolite levels;	chr5:132358913	chr5:132311285~132369916:-
PRAD	cis	rs7727544	0.684	rs611084	ENSG00000233006.5	AC034220.3	-11.34	2.09e-26	3.06e-23	-0.42	-0.47	Blood metabolite levels;	chr5:132374047	chr5:132311285~132369916:-
PRAD	cis	rs9322193	0.923	rs9968911	ENSG00000216906.2	RP11-350J20.9	11.34	2.11e-26	3.08e-23	0.55	0.47	Lung cancer;	chr6:149657419	chr6:149904243~149906418:+
PRAD	cis	rs2404602	0.552	rs11636612	ENSG00000259422.1	RP11-593F23.1	-11.33	2.13e-26	3.12e-23	-0.66	-0.47	Blood metabolite levels;	chr15:76667189	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.647	rs11072619	ENSG00000259422.1	RP11-593F23.1	-11.33	2.15e-26	3.14e-23	-0.62	-0.47	Blood metabolite levels;	chr15:76750901	chr15:76174891~76181486:-
PRAD	cis	rs2019137	0.936	rs3811059	ENSG00000189223.12	PAX8-AS1	11.33	2.15e-26	3.15e-23	0.58	0.47	Lymphocyte counts;	chr2:113204494	chr2:113211522~113276581:+
PRAD	cis	rs2019137	0.936	rs12620738	ENSG00000189223.12	PAX8-AS1	11.33	2.15e-26	3.15e-23	0.58	0.47	Lymphocyte counts;	chr2:113206162	chr2:113211522~113276581:+
PRAD	cis	rs907683	0.546	rs1058261	ENSG00000280323.1	AC053503.12	-11.33	2.18e-26	3.19e-23	-0.39	-0.47	Resting heart rate;	chr2:219420587	chr2:219427477~219429319:+
PRAD	cis	rs907683	0.584	rs1058284	ENSG00000280323.1	AC053503.12	-11.33	2.19e-26	3.2e-23	-0.39	-0.47	Resting heart rate;	chr2:219421420	chr2:219427477~219429319:+
PRAD	cis	rs1150668	0.745	rs213238	ENSG00000216901.1	AL022393.7	11.33	2.19e-26	3.21e-23	0.6	0.47	Pubertal anthropometrics;	chr6:28354216	chr6:28176188~28176674:+
PRAD	cis	rs2729354	0.953	rs2848625	ENSG00000265566.2	RN7SL605P	-11.33	2.21e-26	3.23e-23	-0.71	-0.47	Blood protein levels;	chr11:57563177	chr11:57528085~57528365:-
PRAD	cis	rs7772486	0.558	rs2142978	ENSG00000235652.6	RP11-545I5.3	-11.33	2.21e-26	3.23e-23	-0.52	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145690925	chr6:145799409~145886585:+
PRAD	cis	rs2404602	0.684	rs8029283	ENSG00000259422.1	RP11-593F23.1	-11.33	2.25e-26	3.3e-23	-0.62	-0.47	Blood metabolite levels;	chr15:76544799	chr15:76174891~76181486:-
PRAD	cis	rs780096	0.546	rs715325	ENSG00000234072.1	AC074117.10	-11.33	2.25e-26	3.3e-23	-0.37	-0.47	Total body bone mineral density;	chr2:27502705	chr2:27356246~27367622:+
PRAD	cis	rs673078	0.66	rs61943524	ENSG00000275759.1	RP11-131L12.3	-11.33	2.26e-26	3.31e-23	-0.75	-0.47	Glucose homeostasis traits;	chr12:118151530	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.66	rs17440315	ENSG00000275759.1	RP11-131L12.3	-11.33	2.26e-26	3.31e-23	-0.75	-0.47	Glucose homeostasis traits;	chr12:118158819	chr12:118428281~118428870:+
PRAD	cis	rs4423214	0.559	rs7949129	ENSG00000254682.1	RP11-660L16.2	-11.33	2.28e-26	3.32e-23	-0.76	-0.47	Vitamin D levels;	chr11:71482089	chr11:71448674~71452157:+
PRAD	cis	rs34779708	0.966	rs7070427	ENSG00000230534.5	RP11-297A16.2	11.33	2.28e-26	3.33e-23	0.62	0.47	Inflammatory bowel disease;Crohn's disease;	chr10:35196761	chr10:35098006~35127020:-
PRAD	cis	rs4713118	0.505	rs156740	ENSG00000216901.1	AL022393.7	11.33	2.29e-26	3.34e-23	0.59	0.47	Parkinson's disease;	chr6:27992657	chr6:28176188~28176674:+
PRAD	cis	rs7772486	0.79	rs2249386	ENSG00000235652.6	RP11-545I5.3	11.32	2.32e-26	3.39e-23	0.48	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145865475	chr6:145799409~145886585:+
PRAD	cis	rs2404602	0.53	rs12915184	ENSG00000259422.1	RP11-593F23.1	-11.32	2.33e-26	3.4e-23	-0.65	-0.47	Blood metabolite levels;	chr15:76673581	chr15:76174891~76181486:-
PRAD	cis	rs12594515	0.967	rs11857628	ENSG00000273972.1	CTD-2306A12.1	-11.32	2.34e-26	3.41e-23	-0.52	-0.47	Weight;Waist circumference;	chr15:45706008	chr15:45702640~45703183:+
PRAD	cis	rs4722166	0.695	rs4722177	ENSG00000179428.2	AC073072.5	-11.32	2.34e-26	3.42e-23	-0.54	-0.47	Lung cancer;	chr7:22758912	chr7:22725395~22727620:-
PRAD	cis	rs2929278	0.617	rs4617832	ENSG00000249839.1	AC011330.5	11.32	2.37e-26	3.45e-23	0.59	0.47	Schizophrenia;	chr15:43738381	chr15:43663654~43684339:-
PRAD	cis	rs9532669	0.963	rs9532662	ENSG00000176268.5	CYCSP34	11.32	2.37e-26	3.46e-23	0.48	0.47	Cervical cancer;	chr13:40926215	chr13:40863599~40863902:-
PRAD	cis	rs8072100	0.79	rs1962307	ENSG00000228782.6	CTD-2026D20.3	11.32	2.38e-26	3.47e-23	0.51	0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47630505	chr17:47450568~47492492:-
PRAD	cis	rs6504950	0.889	rs1484776	ENSG00000275710.1	RP11-257O5.4	-11.32	2.38e-26	3.47e-23	-0.61	-0.47	Breast cancer;	chr17:55034022	chr17:54964474~54964679:+
PRAD	cis	rs1062177	0.901	rs1549622	ENSG00000213433.5	RPLP1P6	-11.32	2.41e-26	3.51e-23	-0.56	-0.47	Preschool internalizing problems;	chr5:151886488	chr5:151765859~151766378:-
PRAD	cis	rs5760092	0.618	rs5996631	ENSG00000231271.1	AP000350.8	-11.32	2.42e-26	3.54e-23	-0.71	-0.47	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23949918~23954042:+
PRAD	cis	rs2929278	0.562	rs8033846	ENSG00000249839.1	AC011330.5	11.32	2.45e-26	3.57e-23	0.59	0.47	Schizophrenia;	chr15:43743165	chr15:43663654~43684339:-
PRAD	cis	rs5760092	0.755	rs915589	ENSG00000250470.1	AP000351.3	-11.32	2.45e-26	3.58e-23	-0.76	-0.47	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23976904~23977585:-
PRAD	cis	rs2658782	0.526	rs7127240	ENSG00000279684.1	RP11-755E23.2	-11.32	2.46e-26	3.58e-23	-0.65	-0.47	Pulmonary function decline;	chr11:93451726	chr11:93286629~93288903:-
PRAD	cis	rs71403859	0.502	rs17280181	ENSG00000260886.1	TAT-AS1	11.32	2.46e-26	3.59e-23	0.82	0.47	Post bronchodilator FEV1;	chr16:71489611	chr16:71565789~71578187:+
PRAD	cis	rs11690935	0.688	rs7600835	ENSG00000228389.1	AC068039.4	11.32	2.49e-26	3.63e-23	0.56	0.47	Schizophrenia;	chr2:171665317	chr2:171773482~171775844:+
PRAD	cis	rs7208859	0.673	rs216409	ENSG00000263531.1	RP13-753N3.1	-11.32	2.49e-26	3.63e-23	-0.79	-0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30579251	chr17:30863921~30864940:-
PRAD	cis	rs748404	0.631	rs2412781	ENSG00000205771.5	CATSPER2P1	11.32	2.5e-26	3.64e-23	0.52	0.47	Lung cancer;	chr15:43375702	chr15:43726918~43747094:-
PRAD	cis	rs9545047	0.704	rs3742120	ENSG00000227676.3	LINC01068	11.32	2.52e-26	3.67e-23	0.58	0.47	Schizophrenia;	chr13:79386700	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.716	rs3742122	ENSG00000227676.3	LINC01068	11.32	2.52e-26	3.67e-23	0.58	0.47	Schizophrenia;	chr13:79387061	chr13:79566727~79571436:+
PRAD	cis	rs4660456	0.504	rs587064	ENSG00000237899.1	RP4-739H11.3	11.31	2.53e-26	3.69e-23	0.66	0.47	Platelet count;	chr1:40640238	chr1:40669089~40687588:-
PRAD	cis	rs4964805	0.594	rs10861096	ENSG00000257681.1	RP11-341G23.4	11.31	2.54e-26	3.7e-23	0.44	0.47	Attention deficit hyperactivity disorder;	chr12:103775578	chr12:103746315~103768858:-
PRAD	cis	rs7727544	0.636	rs2631365	ENSG00000233006.5	AC034220.3	-11.31	2.55e-26	3.72e-23	-0.41	-0.47	Blood metabolite levels;	chr5:132370257	chr5:132311285~132369916:-
PRAD	cis	rs9322193	0.923	rs9766004	ENSG00000216906.2	RP11-350J20.9	11.31	2.58e-26	3.76e-23	0.54	0.47	Lung cancer;	chr6:149754363	chr6:149904243~149906418:+
PRAD	cis	rs4722166	0.695	rs35779989	ENSG00000179428.2	AC073072.5	-11.31	2.61e-26	3.8e-23	-0.54	-0.47	Lung cancer;	chr7:22760695	chr7:22725395~22727620:-
PRAD	cis	rs9322193	0.923	rs9800736	ENSG00000216906.2	RP11-350J20.9	11.31	2.62e-26	3.81e-23	0.54	0.47	Lung cancer;	chr6:149661281	chr6:149904243~149906418:+
PRAD	cis	rs7240205	0.818	rs4264473	ENSG00000275805.1	RP11-349H17.2	11.31	2.62e-26	3.81e-23	0.56	0.47	Breast cancer;	chr18:26565915	chr18:26565723~26575626:-
PRAD	cis	rs7240205	0.818	rs12964926	ENSG00000275805.1	RP11-349H17.2	11.31	2.62e-26	3.81e-23	0.56	0.47	Breast cancer;	chr18:26567363	chr18:26565723~26575626:-
PRAD	cis	rs780096	0.506	rs1262430	ENSG00000234072.1	AC074117.10	-11.31	2.63e-26	3.82e-23	-0.37	-0.47	Total body bone mineral density;	chr2:27450931	chr2:27356246~27367622:+
PRAD	cis	rs8062405	0.755	rs4788076	ENSG00000259982.1	CDC37P1	11.31	2.66e-26	3.87e-23	0.61	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558684	chr16:28700294~28701540:-
PRAD	cis	rs71403859	0.502	rs12927456	ENSG00000260886.1	TAT-AS1	11.31	2.67e-26	3.88e-23	0.81	0.47	Post bronchodilator FEV1;	chr16:71471803	chr16:71565789~71578187:+
PRAD	cis	rs9322193	0.884	rs7450246	ENSG00000216906.2	RP11-350J20.9	11.31	2.68e-26	3.89e-23	0.53	0.47	Lung cancer;	chr6:149702517	chr6:149904243~149906418:+
PRAD	cis	rs17711722	0.565	rs4717276	ENSG00000226824.5	RP4-756H11.3	-11.31	2.69e-26	3.91e-23	-0.59	-0.47	Calcium levels;	chr7:65829754	chr7:66654538~66669855:+
PRAD	cis	rs9322193	0.651	rs9322188	ENSG00000268592.3	RAET1E-AS1	-11.31	2.7e-26	3.93e-23	-0.65	-0.47	Lung cancer;	chr6:149588355	chr6:149863494~149919507:+
PRAD	cis	rs780096	0.546	rs1104	ENSG00000234072.1	AC074117.10	-11.31	2.71e-26	3.94e-23	-0.37	-0.47	Total body bone mineral density;	chr2:27377008	chr2:27356246~27367622:+
PRAD	cis	rs7598759	0.548	rs1823328	ENSG00000181798.2	LINC00471	-11.31	2.71e-26	3.94e-23	-0.56	-0.47	Noise-induced hearing loss;	chr2:231490473	chr2:231508426~231514339:-
PRAD	cis	rs2117029	0.561	rs7957983	ENSG00000258017.1	RP11-386G11.10	-11.31	2.71e-26	3.94e-23	-0.61	-0.47	Intelligence (multi-trait analysis);	chr12:49115204	chr12:49127782~49147869:+
PRAD	cis	rs2117029	0.587	rs7958572	ENSG00000258017.1	RP11-386G11.10	-11.31	2.71e-26	3.94e-23	-0.61	-0.47	Intelligence (multi-trait analysis);	chr12:49115658	chr12:49127782~49147869:+
PRAD	cis	rs9487094	0.813	rs12528712	ENSG00000260273.1	RP11-425D10.10	11.31	2.72e-26	3.96e-23	0.67	0.47	Height;	chr6:109339681	chr6:109382795~109383666:+
PRAD	cis	rs10875746	0.951	rs2228500	ENSG00000240399.1	RP1-228P16.1	11.31	2.75e-26	3.99e-23	0.48	0.47	Longevity (90 years and older);	chr12:48132929	chr12:48054813~48055591:-
PRAD	cis	rs2929278	0.617	rs11070410	ENSG00000249839.1	AC011330.5	11.31	2.75e-26	4e-23	0.59	0.47	Schizophrenia;	chr15:43764847	chr15:43663654~43684339:-
PRAD	cis	rs7684253	0.587	rs4339274	ENSG00000269949.1	RP11-738E22.3	11.3	2.76e-26	4.01e-23	0.53	0.47	Migraine;	chr4:56881468	chr4:56960927~56961373:-
PRAD	cis	rs780096	0.526	rs704795	ENSG00000234072.1	AC074117.10	-11.3	2.76e-26	4.01e-23	-0.37	-0.47	Total body bone mineral density;	chr2:27493627	chr2:27356246~27367622:+
PRAD	cis	rs673078	0.66	rs17512574	ENSG00000275759.1	RP11-131L12.3	-11.3	2.8e-26	4.07e-23	-0.68	-0.47	Glucose homeostasis traits;	chr12:118350198	chr12:118428281~118428870:+
PRAD	cis	rs9322193	0.924	rs9498382	ENSG00000268592.3	RAET1E-AS1	11.3	2.8e-26	4.07e-23	0.65	0.47	Lung cancer;	chr6:149610982	chr6:149863494~149919507:+
PRAD	cis	rs2404602	0.647	rs12910081	ENSG00000259422.1	RP11-593F23.1	-11.3	2.81e-26	4.07e-23	-0.62	-0.47	Blood metabolite levels;	chr15:76730618	chr15:76174891~76181486:-
PRAD	cis	rs5760092	0.627	rs6519489	ENSG00000273295.1	AP000350.5	-11.3	2.84e-26	4.12e-23	-0.68	-0.47	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919659	chr22:23901432~23907068:-
PRAD	cis	rs9532669	0.926	rs9525438	ENSG00000176268.5	CYCSP34	11.3	2.86e-26	4.15e-23	0.47	0.47	Cervical cancer;	chr13:40964123	chr13:40863599~40863902:-
PRAD	cis	rs2282300	0.956	rs654710	ENSG00000242353.1	RP4-710M3.1	11.3	2.87e-26	4.17e-23	0.54	0.47	Morning vs. evening chronotype;	chr11:30372756	chr11:30368148~30368646:+
PRAD	cis	rs3096299	0.781	rs2965819	ENSG00000274627.1	RP11-104N10.2	-11.3	2.88e-26	4.18e-23	-0.46	-0.47	Multiple myeloma (IgH translocation);	chr16:89434622	chr16:89516797~89522217:+
PRAD	cis	rs8062405	1	rs80275162	ENSG00000251417.2	RP11-1348G14.4	-11.3	2.92e-26	4.23e-23	-0.53	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28852196	chr16:28802743~28817828:+
PRAD	cis	rs6504950	0.886	rs2541236	ENSG00000275710.1	RP11-257O5.4	-11.3	2.92e-26	4.23e-23	-0.61	-0.47	Breast cancer;	chr17:55082471	chr17:54964474~54964679:+
PRAD	cis	rs7208859	0.673	rs216418	ENSG00000263531.1	RP13-753N3.1	11.3	2.94e-26	4.27e-23	0.79	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30609519	chr17:30863921~30864940:-
PRAD	cis	rs2404602	0.735	rs3765115	ENSG00000259422.1	RP11-593F23.1	-11.3	2.96e-26	4.3e-23	-0.59	-0.47	Blood metabolite levels;	chr15:76381375	chr15:76174891~76181486:-
PRAD	cis	rs75422866	0.867	rs73111258	ENSG00000257433.4	RP1-197B17.3	11.3	2.96e-26	4.3e-23	1.04	0.47	Pneumonia;	chr12:47597313	chr12:47706085~47742294:+
PRAD	cis	rs75422866	0.867	rs117388682	ENSG00000257433.4	RP1-197B17.3	11.3	2.96e-26	4.3e-23	1.04	0.47	Pneumonia;	chr12:47599713	chr12:47706085~47742294:+
PRAD	cis	rs75422866	0.867	rs79113930	ENSG00000257433.4	RP1-197B17.3	11.3	2.96e-26	4.3e-23	1.04	0.47	Pneumonia;	chr12:47600628	chr12:47706085~47742294:+
PRAD	cis	rs4423214	0.592	rs3829251	ENSG00000254682.1	RP11-660L16.2	-11.3	2.98e-26	4.32e-23	-0.76	-0.47	Vitamin D levels;	chr11:71483513	chr11:71448674~71452157:+
PRAD	cis	rs780096	0.526	rs4803	ENSG00000234072.1	AC074117.10	-11.3	3e-26	4.35e-23	-0.37	-0.47	Total body bone mineral density;	chr2:27444430	chr2:27356246~27367622:+
PRAD	cis	rs977987	0.835	rs8046109	ENSG00000261783.1	RP11-252K23.2	-11.29	3.02e-26	4.38e-23	-0.64	-0.47	Dupuytren's disease;	chr16:75326198	chr16:75379818~75381260:-
PRAD	cis	rs780096	0.526	rs1406295	ENSG00000234072.1	AC074117.10	-11.29	3.07e-26	4.45e-23	-0.37	-0.47	Total body bone mineral density;	chr2:27466833	chr2:27356246~27367622:+
PRAD	cis	rs7743045	0.711	rs4946371	ENSG00000253194.1	RP11-351A11.1	11.29	3.08e-26	4.46e-23	0.63	0.47	Mean platelet volume;	chr6:118935483	chr6:118934785~119031541:+
PRAD	cis	rs1075265	0.568	rs7604357	ENSG00000233266.1	HMGB1P31	11.29	3.08e-26	4.46e-23	0.62	0.47	Chronotype;Morning vs. evening chronotype;	chr2:54074026	chr2:54051334~54051760:+
PRAD	cis	rs34375054	0.672	rs2291247	ENSG00000279233.1	RP11-158L12.4	11.29	3.09e-26	4.48e-23	0.43	0.47	Post bronchodilator FEV1/FVC ratio;	chr12:125134407	chr12:125138245~125141711:+
PRAD	cis	rs4660456	0.504	rs491619	ENSG00000237899.1	RP4-739H11.3	11.29	3.09e-26	4.48e-23	0.66	0.47	Platelet count;	chr1:40641688	chr1:40669089~40687588:-
PRAD	cis	rs10256972	0.933	rs35696159	ENSG00000229043.2	AC091729.9	-11.29	3.13e-26	4.53e-23	-0.56	-0.47	Endometriosis;Longevity;	chr7:1007558	chr7:1160374~1165267:+
PRAD	cis	rs8062405	0.723	rs762633	ENSG00000259982.1	CDC37P1	11.29	3.13e-26	4.53e-23	0.62	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597020	chr16:28700294~28701540:-
PRAD	cis	rs11690935	0.549	rs796839	ENSG00000228389.1	AC068039.4	-11.29	3.14e-26	4.54e-23	-0.53	-0.47	Schizophrenia;	chr2:172051486	chr2:171773482~171775844:+
PRAD	cis	rs11690935	0.549	rs2129475	ENSG00000228389.1	AC068039.4	-11.29	3.14e-26	4.54e-23	-0.53	-0.47	Schizophrenia;	chr2:172052044	chr2:171773482~171775844:+
PRAD	cis	rs780096	0.526	rs2010087	ENSG00000234072.1	AC074117.10	-11.29	3.16e-26	4.57e-23	-0.37	-0.47	Total body bone mineral density;	chr2:27414368	chr2:27356246~27367622:+
PRAD	cis	rs1062177	0.756	rs2964592	ENSG00000213433.5	RPLP1P6	11.29	3.16e-26	4.58e-23	0.54	0.47	Preschool internalizing problems;	chr5:151736127	chr5:151765859~151766378:-
PRAD	cis	rs780094	0.606	rs6729709	ENSG00000234072.1	AC074117.10	-11.29	3.17e-26	4.59e-23	-0.36	-0.47	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27360289	chr2:27356246~27367622:+
PRAD	cis	rs780094	0.585	rs7586601	ENSG00000234072.1	AC074117.10	-11.29	3.17e-26	4.59e-23	-0.36	-0.47	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27361799	chr2:27356246~27367622:+
PRAD	cis	rs9322193	0.923	rs9383812	ENSG00000216906.2	RP11-350J20.9	11.29	3.2e-26	4.64e-23	0.53	0.47	Lung cancer;	chr6:149712355	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.847	rs9383844	ENSG00000216906.2	RP11-350J20.9	11.29	3.2e-26	4.64e-23	0.53	0.47	Lung cancer;	chr6:149716268	chr6:149904243~149906418:+
PRAD	cis	rs780096	0.525	rs13388159	ENSG00000234072.1	AC074117.10	-11.29	3.22e-26	4.65e-23	-0.37	-0.47	Total body bone mineral density;	chr2:27425417	chr2:27356246~27367622:+
PRAD	cis	rs5760092	0.755	rs11090298	ENSG00000225282.1	AP000350.6	-11.29	3.22e-26	4.65e-23	-0.73	-0.47	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919874	chr22:23926900~23929574:+
PRAD	cis	rs7044106	0.791	rs2416797	ENSG00000226752.6	PSMD5-AS1	-11.29	3.27e-26	4.73e-23	-0.59	-0.47	Hip circumference adjusted for BMI;	chr9:120718322	chr9:120824828~120854385:+
PRAD	cis	rs7044106	0.791	rs2416798	ENSG00000226752.6	PSMD5-AS1	-11.29	3.27e-26	4.73e-23	-0.59	-0.47	Hip circumference adjusted for BMI;	chr9:120718325	chr9:120824828~120854385:+
PRAD	cis	rs1062177	0.826	rs2915879	ENSG00000213433.5	RPLP1P6	-11.29	3.27e-26	4.73e-23	-0.53	-0.47	Preschool internalizing problems;	chr5:151767881	chr5:151765859~151766378:-
PRAD	cis	rs7727544	0.735	rs274558	ENSG00000233006.5	AC034220.3	-11.29	3.28e-26	4.74e-23	-0.41	-0.47	Blood metabolite levels;	chr5:132385482	chr5:132311285~132369916:-
PRAD	cis	rs7727544	0.735	rs274557	ENSG00000233006.5	AC034220.3	-11.29	3.28e-26	4.74e-23	-0.41	-0.47	Blood metabolite levels;	chr5:132385512	chr5:132311285~132369916:-
PRAD	cis	rs2739330	0.796	rs2154594	ENSG00000250470.1	AP000351.3	-11.28	3.3e-26	4.78e-23	-0.64	-0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23976904~23977585:-
PRAD	cis	rs75422866	0.867	rs35044089	ENSG00000257433.4	RP1-197B17.3	11.28	3.31e-26	4.78e-23	1.02	0.47	Pneumonia;	chr12:47610881	chr12:47706085~47742294:+
PRAD	cis	rs75422866	0.867	rs78912815	ENSG00000257433.4	RP1-197B17.3	11.28	3.31e-26	4.78e-23	1.02	0.47	Pneumonia;	chr12:47612065	chr12:47706085~47742294:+
PRAD	cis	rs2929278	0.589	rs2411284	ENSG00000249839.1	AC011330.5	11.28	3.34e-26	4.82e-23	0.59	0.47	Schizophrenia;	chr15:43746701	chr15:43663654~43684339:-
PRAD	cis	rs2929278	0.617	rs12908467	ENSG00000249839.1	AC011330.5	11.28	3.34e-26	4.82e-23	0.59	0.47	Schizophrenia;	chr15:43755232	chr15:43663654~43684339:-
PRAD	cis	rs6991838	0.53	rs35038843	ENSG00000272010.1	CTD-3025N20.3	-11.28	3.34e-26	4.82e-23	-0.49	-0.47	Intelligence (multi-trait analysis);	chr8:65610263	chr8:65591850~65592472:-
PRAD	cis	rs6991838	0.584	rs4737748	ENSG00000272010.1	CTD-3025N20.3	11.28	3.34e-26	4.82e-23	0.49	0.47	Intelligence (multi-trait analysis);	chr8:65613630	chr8:65591850~65592472:-
PRAD	cis	rs6991838	0.55	rs12335006	ENSG00000272010.1	CTD-3025N20.3	11.28	3.34e-26	4.82e-23	0.49	0.47	Intelligence (multi-trait analysis);	chr8:65619394	chr8:65591850~65592472:-
PRAD	cis	rs6991838	0.584	rs10957361	ENSG00000272010.1	CTD-3025N20.3	11.28	3.34e-26	4.82e-23	0.49	0.47	Intelligence (multi-trait analysis);	chr8:65619626	chr8:65591850~65592472:-
PRAD	cis	rs6991838	0.612	rs12335276	ENSG00000272010.1	CTD-3025N20.3	11.28	3.34e-26	4.82e-23	0.49	0.47	Intelligence (multi-trait analysis);	chr8:65619668	chr8:65591850~65592472:-
PRAD	cis	rs6991838	0.612	rs7832407	ENSG00000272010.1	CTD-3025N20.3	11.28	3.34e-26	4.82e-23	0.49	0.47	Intelligence (multi-trait analysis);	chr8:65621071	chr8:65591850~65592472:-
PRAD	cis	rs6991838	0.551	rs7007505	ENSG00000272010.1	CTD-3025N20.3	11.28	3.34e-26	4.82e-23	0.49	0.47	Intelligence (multi-trait analysis);	chr8:65621719	chr8:65591850~65592472:-
PRAD	cis	rs6991838	0.584	rs7012856	ENSG00000272010.1	CTD-3025N20.3	11.28	3.34e-26	4.82e-23	0.49	0.47	Intelligence (multi-trait analysis);	chr8:65622740	chr8:65591850~65592472:-
PRAD	cis	rs6991838	0.55	rs7817112	ENSG00000272010.1	CTD-3025N20.3	11.28	3.34e-26	4.82e-23	0.49	0.47	Intelligence (multi-trait analysis);	chr8:65624885	chr8:65591850~65592472:-
PRAD	cis	rs6991838	0.584	rs2048650	ENSG00000272010.1	CTD-3025N20.3	11.28	3.34e-26	4.82e-23	0.49	0.47	Intelligence (multi-trait analysis);	chr8:65625664	chr8:65591850~65592472:-
PRAD	cis	rs6991838	0.584	rs4737749	ENSG00000272010.1	CTD-3025N20.3	11.28	3.34e-26	4.82e-23	0.49	0.47	Intelligence (multi-trait analysis);	chr8:65627672	chr8:65591850~65592472:-
PRAD	cis	rs6991838	0.584	rs10092109	ENSG00000272010.1	CTD-3025N20.3	11.28	3.34e-26	4.82e-23	0.49	0.47	Intelligence (multi-trait analysis);	chr8:65627683	chr8:65591850~65592472:-
PRAD	cis	rs6991838	0.584	rs6997959	ENSG00000272010.1	CTD-3025N20.3	11.28	3.34e-26	4.82e-23	0.49	0.47	Intelligence (multi-trait analysis);	chr8:65628247	chr8:65591850~65592472:-
PRAD	cis	rs6991838	0.584	rs7814841	ENSG00000272010.1	CTD-3025N20.3	11.28	3.34e-26	4.82e-23	0.49	0.47	Intelligence (multi-trait analysis);	chr8:65629328	chr8:65591850~65592472:-
PRAD	cis	rs6991838	0.584	rs11985628	ENSG00000272010.1	CTD-3025N20.3	11.28	3.34e-26	4.82e-23	0.49	0.47	Intelligence (multi-trait analysis);	chr8:65630504	chr8:65591850~65592472:-
PRAD	cis	rs6991838	0.557	rs13266834	ENSG00000272010.1	CTD-3025N20.3	11.28	3.34e-26	4.82e-23	0.49	0.47	Intelligence (multi-trait analysis);	chr8:65631303	chr8:65591850~65592472:-
PRAD	cis	rs6991838	0.584	rs13268343	ENSG00000272010.1	CTD-3025N20.3	11.28	3.34e-26	4.82e-23	0.49	0.47	Intelligence (multi-trait analysis);	chr8:65631742	chr8:65591850~65592472:-
PRAD	cis	rs6991838	0.584	rs7835313	ENSG00000272010.1	CTD-3025N20.3	11.28	3.34e-26	4.82e-23	0.49	0.47	Intelligence (multi-trait analysis);	chr8:65633891	chr8:65591850~65592472:-
PRAD	cis	rs6991838	0.53	rs6472217	ENSG00000272010.1	CTD-3025N20.3	11.28	3.34e-26	4.82e-23	0.49	0.47	Intelligence (multi-trait analysis);	chr8:65635496	chr8:65591850~65592472:-
PRAD	cis	rs6991838	0.584	rs6472218	ENSG00000272010.1	CTD-3025N20.3	11.28	3.34e-26	4.82e-23	0.49	0.47	Intelligence (multi-trait analysis);	chr8:65635502	chr8:65591850~65592472:-
PRAD	cis	rs6991838	0.584	rs1533285	ENSG00000272010.1	CTD-3025N20.3	11.28	3.34e-26	4.82e-23	0.49	0.47	Intelligence (multi-trait analysis);	chr8:65637129	chr8:65591850~65592472:-
PRAD	cis	rs4845570	1	rs6681093	ENSG00000249602.1	RP11-98D18.3	11.28	3.35e-26	4.83e-23	0.76	0.47	Coronary artery disease;	chr1:151782808	chr1:151763384~151769501:-
PRAD	cis	rs875971	0.545	rs12670811	ENSG00000237310.1	GS1-124K5.4	11.28	3.35e-26	4.83e-23	0.47	0.47	Aortic root size;	chr7:66358032	chr7:66493706~66495474:+
PRAD	cis	rs9399135	0.684	rs1135205	ENSG00000232876.1	CTA-212D2.2	-11.28	3.38e-26	4.88e-23	-0.58	-0.47	Red blood cell count;	chr6:134960657	chr6:135055033~135060550:+
PRAD	cis	rs2404602	0.61	rs28823285	ENSG00000259422.1	RP11-593F23.1	-11.28	3.44e-26	4.96e-23	-0.62	-0.47	Blood metabolite levels;	chr15:76758054	chr15:76174891~76181486:-
PRAD	cis	rs8062405	0.823	rs7202948	ENSG00000259982.1	CDC37P1	11.28	3.46e-26	4.98e-23	0.6	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546968	chr16:28700294~28701540:-
PRAD	cis	rs1577917	1	rs12199516	ENSG00000203875.9	SNHG5	-11.28	3.46e-26	4.99e-23	-0.54	-0.47	Response to antipsychotic treatment;	chr6:86016503	chr6:85660950~85678736:-
PRAD	cis	rs780096	0.526	rs1647267	ENSG00000234072.1	AC074117.10	-11.28	3.46e-26	4.99e-23	-0.37	-0.47	Total body bone mineral density;	chr2:27428187	chr2:27356246~27367622:+
PRAD	cis	rs780096	0.526	rs10182937	ENSG00000234072.1	AC074117.10	-11.28	3.46e-26	4.99e-23	-0.37	-0.47	Total body bone mineral density;	chr2:27428826	chr2:27356246~27367622:+
PRAD	cis	rs780096	0.506	rs780100	ENSG00000234072.1	AC074117.10	-11.28	3.46e-26	4.99e-23	-0.37	-0.47	Total body bone mineral density;	chr2:27429286	chr2:27356246~27367622:+
PRAD	cis	rs780096	0.526	rs704791	ENSG00000234072.1	AC074117.10	-11.28	3.46e-26	4.99e-23	-0.37	-0.47	Total body bone mineral density;	chr2:27434300	chr2:27356246~27367622:+
PRAD	cis	rs780096	0.526	rs780102	ENSG00000234072.1	AC074117.10	-11.28	3.46e-26	4.99e-23	-0.37	-0.47	Total body bone mineral density;	chr2:27436624	chr2:27356246~27367622:+
PRAD	cis	rs780096	0.526	rs1260341	ENSG00000234072.1	AC074117.10	-11.28	3.46e-26	4.99e-23	-0.37	-0.47	Total body bone mineral density;	chr2:27440348	chr2:27356246~27367622:+
PRAD	cis	rs780096	0.526	rs1260342	ENSG00000234072.1	AC074117.10	-11.28	3.46e-26	4.99e-23	-0.37	-0.47	Total body bone mineral density;	chr2:27440549	chr2:27356246~27367622:+
PRAD	cis	rs780096	0.526	rs780112	ENSG00000234072.1	AC074117.10	-11.28	3.46e-26	4.99e-23	-0.37	-0.47	Total body bone mineral density;	chr2:27442494	chr2:27356246~27367622:+
PRAD	cis	rs780096	0.565	rs780104	ENSG00000234072.1	AC074117.10	-11.28	3.46e-26	4.99e-23	-0.37	-0.47	Total body bone mineral density;	chr2:27454824	chr2:27356246~27367622:+
PRAD	cis	rs780096	0.526	rs780106	ENSG00000234072.1	AC074117.10	-11.28	3.46e-26	4.99e-23	-0.37	-0.47	Total body bone mineral density;	chr2:27458731	chr2:27356246~27367622:+
PRAD	cis	rs780096	0.526	rs780107	ENSG00000234072.1	AC074117.10	-11.28	3.46e-26	4.99e-23	-0.37	-0.47	Total body bone mineral density;	chr2:27461867	chr2:27356246~27367622:+
PRAD	cis	rs780096	0.526	rs1647276	ENSG00000234072.1	AC074117.10	-11.28	3.46e-26	4.99e-23	-0.37	-0.47	Total body bone mineral density;	chr2:27465734	chr2:27356246~27367622:+
PRAD	cis	rs780096	0.506	rs1647265	ENSG00000234072.1	AC074117.10	-11.28	3.46e-26	4.99e-23	-0.37	-0.47	Total body bone mineral density;	chr2:27469394	chr2:27356246~27367622:+
PRAD	cis	rs780096	0.526	rs1647266	ENSG00000234072.1	AC074117.10	-11.28	3.46e-26	4.99e-23	-0.37	-0.47	Total body bone mineral density;	chr2:27470618	chr2:27356246~27367622:+
PRAD	cis	rs7743045	0.652	rs3756940	ENSG00000253194.1	RP11-351A11.1	11.28	3.47e-26	5e-23	0.62	0.47	Mean platelet volume;	chr6:119002822	chr6:118934785~119031541:+
PRAD	cis	rs4845570	1	rs17568246	ENSG00000249602.1	RP11-98D18.3	11.28	3.51e-26	5.05e-23	0.79	0.47	Coronary artery disease;	chr1:151763980	chr1:151763384~151769501:-
PRAD	cis	rs7727544	0.684	rs2631363	ENSG00000233006.5	AC034220.3	-11.28	3.53e-26	5.08e-23	-0.42	-0.47	Blood metabolite levels;	chr5:132371403	chr5:132311285~132369916:-
PRAD	cis	rs1061377	0.965	rs12504238	ENSG00000249207.1	RP11-360F5.1	-11.27	3.62e-26	5.21e-23	-0.5	-0.47	Uric acid levels;	chr4:39142824	chr4:39112677~39126818:-
PRAD	cis	rs2404602	0.735	rs11638767	ENSG00000259422.1	RP11-593F23.1	-11.27	3.64e-26	5.23e-23	-0.59	-0.47	Blood metabolite levels;	chr15:76363597	chr15:76174891~76181486:-
PRAD	cis	rs748404	0.516	rs523156	ENSG00000205771.5	CATSPER2P1	11.27	3.65e-26	5.25e-23	0.55	0.47	Lung cancer;	chr15:43519645	chr15:43726918~43747094:-
PRAD	cis	rs2929278	0.617	rs663214	ENSG00000249839.1	AC011330.5	11.27	3.66e-26	5.26e-23	0.6	0.47	Schizophrenia;	chr15:43821584	chr15:43663654~43684339:-
PRAD	cis	rs765787	0.53	rs1706835	ENSG00000259520.4	CTD-2651B20.3	11.27	3.69e-26	5.29e-23	0.58	0.47	Uric acid levels;	chr15:45225686	chr15:45251580~45279251:-
PRAD	cis	rs765787	0.53	rs1631533	ENSG00000259520.4	CTD-2651B20.3	11.27	3.69e-26	5.29e-23	0.58	0.47	Uric acid levels;	chr15:45226430	chr15:45251580~45279251:-
PRAD	cis	rs765787	0.53	rs1706837	ENSG00000259520.4	CTD-2651B20.3	11.27	3.69e-26	5.29e-23	0.58	0.47	Uric acid levels;	chr15:45226838	chr15:45251580~45279251:-
PRAD	cis	rs765787	0.53	rs11636440	ENSG00000259520.4	CTD-2651B20.3	11.27	3.69e-26	5.29e-23	0.58	0.47	Uric acid levels;	chr15:45243784	chr15:45251580~45279251:-
PRAD	cis	rs765787	0.53	rs28396110	ENSG00000259520.4	CTD-2651B20.3	11.27	3.69e-26	5.29e-23	0.58	0.47	Uric acid levels;	chr15:45244711	chr15:45251580~45279251:-
PRAD	cis	rs765787	0.53	rs4775834	ENSG00000259520.4	CTD-2651B20.3	11.27	3.69e-26	5.29e-23	0.58	0.47	Uric acid levels;	chr15:45245313	chr15:45251580~45279251:-
PRAD	cis	rs765787	0.53	rs4775835	ENSG00000259520.4	CTD-2651B20.3	11.27	3.69e-26	5.29e-23	0.58	0.47	Uric acid levels;	chr15:45245355	chr15:45251580~45279251:-
PRAD	cis	rs765787	0.53	rs4775836	ENSG00000259520.4	CTD-2651B20.3	11.27	3.69e-26	5.29e-23	0.58	0.47	Uric acid levels;	chr15:45245466	chr15:45251580~45279251:-
PRAD	cis	rs765787	0.53	rs4775837	ENSG00000259520.4	CTD-2651B20.3	11.27	3.69e-26	5.29e-23	0.58	0.47	Uric acid levels;	chr15:45245486	chr15:45251580~45279251:-
PRAD	cis	rs765787	0.53	rs12917187	ENSG00000259520.4	CTD-2651B20.3	11.27	3.69e-26	5.29e-23	0.58	0.47	Uric acid levels;	chr15:45246099	chr15:45251580~45279251:-
PRAD	cis	rs765787	0.53	rs11639403	ENSG00000259520.4	CTD-2651B20.3	11.27	3.69e-26	5.29e-23	0.58	0.47	Uric acid levels;	chr15:45246152	chr15:45251580~45279251:-
PRAD	cis	rs765787	0.53	rs2413782	ENSG00000259520.4	CTD-2651B20.3	11.27	3.69e-26	5.29e-23	0.58	0.47	Uric acid levels;	chr15:45246292	chr15:45251580~45279251:-
PRAD	cis	rs765787	0.53	rs2413780	ENSG00000259520.4	CTD-2651B20.3	11.27	3.69e-26	5.29e-23	0.58	0.47	Uric acid levels;	chr15:45246668	chr15:45251580~45279251:-
PRAD	cis	rs765787	0.53	rs11636018	ENSG00000259520.4	CTD-2651B20.3	11.27	3.69e-26	5.29e-23	0.58	0.47	Uric acid levels;	chr15:45246939	chr15:45251580~45279251:-
PRAD	cis	rs765787	0.556	rs2413778	ENSG00000259520.4	CTD-2651B20.3	11.27	3.69e-26	5.29e-23	0.58	0.47	Uric acid levels;	chr15:45247199	chr15:45251580~45279251:-
PRAD	cis	rs765787	0.53	rs28756676	ENSG00000259520.4	CTD-2651B20.3	11.27	3.69e-26	5.29e-23	0.58	0.47	Uric acid levels;	chr15:45248162	chr15:45251580~45279251:-
PRAD	cis	rs765787	0.53	rs55771002	ENSG00000259520.4	CTD-2651B20.3	11.27	3.69e-26	5.29e-23	0.58	0.47	Uric acid levels;	chr15:45249368	chr15:45251580~45279251:-
PRAD	cis	rs765787	0.53	rs55920042	ENSG00000259520.4	CTD-2651B20.3	11.27	3.69e-26	5.29e-23	0.58	0.47	Uric acid levels;	chr15:45249379	chr15:45251580~45279251:-
PRAD	cis	rs765787	0.53	rs4238376	ENSG00000259520.4	CTD-2651B20.3	11.27	3.69e-26	5.29e-23	0.58	0.47	Uric acid levels;	chr15:45249689	chr15:45251580~45279251:-
PRAD	cis	rs765787	0.53	rs4238377	ENSG00000259520.4	CTD-2651B20.3	11.27	3.69e-26	5.29e-23	0.58	0.47	Uric acid levels;	chr15:45249783	chr15:45251580~45279251:-
PRAD	cis	rs765787	0.53	rs4775844	ENSG00000259520.4	CTD-2651B20.3	11.27	3.69e-26	5.29e-23	0.58	0.47	Uric acid levels;	chr15:45249850	chr15:45251580~45279251:-
PRAD	cis	rs765787	0.53	rs3759893	ENSG00000259520.4	CTD-2651B20.3	11.27	3.69e-26	5.29e-23	0.58	0.47	Uric acid levels;	chr15:45250752	chr15:45251580~45279251:-
PRAD	cis	rs9481169	0.85	rs13210247	ENSG00000255389.1	C6orf3	-11.27	3.71e-26	5.32e-23	-0.84	-0.47	Inflammatory skin disease;	chr6:111601517	chr6:111599875~111602295:+
PRAD	cis	rs34779708	0.931	rs7920095	ENSG00000230534.5	RP11-297A16.2	11.27	3.72e-26	5.34e-23	0.64	0.47	Inflammatory bowel disease;Crohn's disease;	chr10:35014406	chr10:35098006~35127020:-
PRAD	cis	rs172166	0.61	rs276369	ENSG00000216901.1	AL022393.7	11.27	3.75e-26	5.38e-23	0.59	0.47	Cardiac Troponin-T levels;	chr6:27951465	chr6:28176188~28176674:+
PRAD	cis	rs1577917	1	rs12205336	ENSG00000203875.9	SNHG5	-11.27	3.75e-26	5.38e-23	-0.54	-0.47	Response to antipsychotic treatment;	chr6:86012649	chr6:85660950~85678736:-
PRAD	cis	rs1577917	1	rs1337850	ENSG00000203875.9	SNHG5	-11.27	3.75e-26	5.38e-23	-0.54	-0.47	Response to antipsychotic treatment;	chr6:86019385	chr6:85660950~85678736:-
PRAD	cis	rs75422866	0.717	rs73113159	ENSG00000257433.4	RP1-197B17.3	11.27	3.77e-26	5.41e-23	1.02	0.47	Pneumonia;	chr12:47631318	chr12:47706085~47742294:+
PRAD	cis	rs75422866	0.717	rs73113161	ENSG00000257433.4	RP1-197B17.3	11.27	3.77e-26	5.41e-23	1.02	0.47	Pneumonia;	chr12:47632361	chr12:47706085~47742294:+
PRAD	cis	rs75422866	0.867	rs117022227	ENSG00000257433.4	RP1-197B17.3	11.27	3.77e-26	5.41e-23	1.02	0.47	Pneumonia;	chr12:47633282	chr12:47706085~47742294:+
PRAD	cis	rs75422866	1	rs73102120	ENSG00000257433.4	RP1-197B17.3	11.27	3.77e-26	5.41e-23	1.02	0.47	Pneumonia;	chr12:47637280	chr12:47706085~47742294:+
PRAD	cis	rs75422866	0.867	rs12422974	ENSG00000257433.4	RP1-197B17.3	11.27	3.77e-26	5.41e-23	1.02	0.47	Pneumonia;	chr12:47644559	chr12:47706085~47742294:+
PRAD	cis	rs75422866	0.867	rs73102127	ENSG00000257433.4	RP1-197B17.3	11.27	3.77e-26	5.41e-23	1.02	0.47	Pneumonia;	chr12:47645341	chr12:47706085~47742294:+
PRAD	cis	rs75422866	0.867	rs73102140	ENSG00000257433.4	RP1-197B17.3	11.27	3.77e-26	5.41e-23	1.02	0.47	Pneumonia;	chr12:47647497	chr12:47706085~47742294:+
PRAD	cis	rs75422866	0.867	rs73102148	ENSG00000257433.4	RP1-197B17.3	11.27	3.77e-26	5.41e-23	1.02	0.47	Pneumonia;	chr12:47648013	chr12:47706085~47742294:+
PRAD	cis	rs75422866	0.867	rs73102151	ENSG00000257433.4	RP1-197B17.3	11.27	3.77e-26	5.41e-23	1.02	0.47	Pneumonia;	chr12:47648023	chr12:47706085~47742294:+
PRAD	cis	rs75422866	0.867	rs73102166	ENSG00000257433.4	RP1-197B17.3	11.27	3.77e-26	5.41e-23	1.02	0.47	Pneumonia;	chr12:47653769	chr12:47706085~47742294:+
PRAD	cis	rs75422866	0.867	rs73102168	ENSG00000257433.4	RP1-197B17.3	11.27	3.77e-26	5.41e-23	1.02	0.47	Pneumonia;	chr12:47654010	chr12:47706085~47742294:+
PRAD	cis	rs75422866	0.867	rs73102171	ENSG00000257433.4	RP1-197B17.3	11.27	3.77e-26	5.41e-23	1.02	0.47	Pneumonia;	chr12:47656077	chr12:47706085~47742294:+
PRAD	cis	rs75422866	0.867	rs76100981	ENSG00000257433.4	RP1-197B17.3	11.27	3.77e-26	5.41e-23	1.02	0.47	Pneumonia;	chr12:47660092	chr12:47706085~47742294:+
PRAD	cis	rs75422866	0.867	rs73102188	ENSG00000257433.4	RP1-197B17.3	11.27	3.77e-26	5.41e-23	1.02	0.47	Pneumonia;	chr12:47662993	chr12:47706085~47742294:+
PRAD	cis	rs75422866	0.867	rs73102195	ENSG00000257433.4	RP1-197B17.3	11.27	3.77e-26	5.41e-23	1.02	0.47	Pneumonia;	chr12:47666309	chr12:47706085~47742294:+
PRAD	cis	rs75422866	0.867	rs73102201	ENSG00000257433.4	RP1-197B17.3	11.27	3.77e-26	5.41e-23	1.02	0.47	Pneumonia;	chr12:47669269	chr12:47706085~47742294:+
PRAD	cis	rs75422866	0.867	rs73104103	ENSG00000257433.4	RP1-197B17.3	11.27	3.77e-26	5.41e-23	1.02	0.47	Pneumonia;	chr12:47669604	chr12:47706085~47742294:+
PRAD	cis	rs75422866	0.867	rs73104104	ENSG00000257433.4	RP1-197B17.3	11.27	3.77e-26	5.41e-23	1.02	0.47	Pneumonia;	chr12:47671986	chr12:47706085~47742294:+
PRAD	cis	rs75422866	0.867	rs73104111	ENSG00000257433.4	RP1-197B17.3	11.27	3.77e-26	5.41e-23	1.02	0.47	Pneumonia;	chr12:47673994	chr12:47706085~47742294:+
PRAD	cis	rs75422866	0.867	rs73104115	ENSG00000257433.4	RP1-197B17.3	11.27	3.77e-26	5.41e-23	1.02	0.47	Pneumonia;	chr12:47684843	chr12:47706085~47742294:+
PRAD	cis	rs75422866	0.867	rs73104116	ENSG00000257433.4	RP1-197B17.3	11.27	3.77e-26	5.41e-23	1.02	0.47	Pneumonia;	chr12:47685023	chr12:47706085~47742294:+
PRAD	cis	rs75422866	0.867	rs73104138	ENSG00000257433.4	RP1-197B17.3	11.27	3.77e-26	5.41e-23	1.02	0.47	Pneumonia;	chr12:47692302	chr12:47706085~47742294:+
PRAD	cis	rs75422866	0.717	rs73104143	ENSG00000257433.4	RP1-197B17.3	11.27	3.77e-26	5.41e-23	1.02	0.47	Pneumonia;	chr12:47693449	chr12:47706085~47742294:+
PRAD	cis	rs75422866	0.867	rs73104144	ENSG00000257433.4	RP1-197B17.3	11.27	3.77e-26	5.41e-23	1.02	0.47	Pneumonia;	chr12:47694390	chr12:47706085~47742294:+
PRAD	cis	rs75422866	0.867	rs73104148	ENSG00000257433.4	RP1-197B17.3	11.27	3.77e-26	5.41e-23	1.02	0.47	Pneumonia;	chr12:47696732	chr12:47706085~47742294:+
PRAD	cis	rs75422866	0.867	rs73104152	ENSG00000257433.4	RP1-197B17.3	11.27	3.77e-26	5.41e-23	1.02	0.47	Pneumonia;	chr12:47699091	chr12:47706085~47742294:+
PRAD	cis	rs75422866	0.867	rs73104155	ENSG00000257433.4	RP1-197B17.3	11.27	3.77e-26	5.41e-23	1.02	0.47	Pneumonia;	chr12:47700790	chr12:47706085~47742294:+
PRAD	cis	rs2919917	0.614	rs10102877	ENSG00000254352.1	RP11-578O24.2	11.27	3.79e-26	5.43e-23	0.55	0.47	Lymphocyte counts;	chr8:78686127	chr8:78723796~78724136:-
PRAD	cis	rs7743045	0.652	rs12527291	ENSG00000253194.1	RP11-351A11.1	11.27	3.83e-26	5.49e-23	0.62	0.47	Mean platelet volume;	chr6:118977672	chr6:118934785~119031541:+
PRAD	cis	rs1577917	0.916	rs4142546	ENSG00000203875.9	SNHG5	-11.27	3.84e-26	5.5e-23	-0.53	-0.47	Response to antipsychotic treatment;	chr6:85795593	chr6:85660950~85678736:-
PRAD	cis	rs7714584	1	rs58717741	ENSG00000197083.10	ZNF300P1	11.27	3.86e-26	5.53e-23	0.78	0.47	Crohn's disease;	chr5:150905374	chr5:150930645~150946289:-
PRAD	cis	rs9532669	0.89	rs1543589	ENSG00000176268.5	CYCSP34	11.27	3.9e-26	5.59e-23	0.49	0.47	Cervical cancer;	chr13:40999064	chr13:40863599~40863902:-
PRAD	cis	rs2919917	0.688	rs3780003	ENSG00000254352.1	RP11-578O24.2	11.27	3.93e-26	5.62e-23	0.55	0.47	Lymphocyte counts;	chr8:78696019	chr8:78723796~78724136:-
PRAD	cis	rs1426063	0.614	rs17000261	ENSG00000249717.1	RP11-44F21.3	11.26	3.94e-26	5.64e-23	1	0.47	QT interval;	chr4:75108766	chr4:74955974~74970362:-
PRAD	cis	rs11105298	0.891	rs11105287	ENSG00000258302.2	RP11-981P6.1	11.26	4e-26	5.72e-23	0.51	0.47	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89435693	chr12:89561129~89594878:+
PRAD	cis	rs34779708	0.931	rs4934700	ENSG00000230534.5	RP11-297A16.2	11.26	4.03e-26	5.77e-23	0.63	0.47	Inflammatory bowel disease;Crohn's disease;	chr10:35021914	chr10:35098006~35127020:-
PRAD	cis	rs6991838	0.584	rs7836349	ENSG00000272010.1	CTD-3025N20.3	-11.26	4.05e-26	5.8e-23	-0.49	-0.47	Intelligence (multi-trait analysis);	chr8:65591328	chr8:65591850~65592472:-
PRAD	cis	rs8062405	0.723	rs35175818	ENSG00000259982.1	CDC37P1	11.26	4.14e-26	5.92e-23	0.62	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597425	chr16:28700294~28701540:-
PRAD	cis	rs8062405	0.723	rs62031562	ENSG00000259982.1	CDC37P1	11.26	4.14e-26	5.92e-23	0.62	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28598008	chr16:28700294~28701540:-
PRAD	cis	rs71403859	0.502	rs36122765	ENSG00000260886.1	TAT-AS1	11.26	4.14e-26	5.92e-23	0.81	0.47	Post bronchodilator FEV1;	chr16:71470280	chr16:71565789~71578187:+
PRAD	cis	rs1577917	1	rs16876529	ENSG00000203875.9	SNHG5	-11.26	4.18e-26	5.98e-23	-0.52	-0.47	Response to antipsychotic treatment;	chr6:85881484	chr6:85660950~85678736:-
PRAD	cis	rs7727544	0.709	rs441969	ENSG00000233006.5	AC034220.3	11.26	4.21e-26	6.01e-23	0.42	0.47	Blood metabolite levels;	chr5:132366428	chr5:132311285~132369916:-
PRAD	cis	rs9322193	1	rs9377228	ENSG00000268592.3	RAET1E-AS1	11.26	4.23e-26	6.05e-23	0.64	0.47	Lung cancer;	chr6:149600862	chr6:149863494~149919507:+
PRAD	cis	rs8062405	0.679	rs72793818	ENSG00000251417.2	RP11-1348G14.4	-11.26	4.25e-26	6.07e-23	-0.53	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28881816	chr16:28802743~28817828:+
PRAD	cis	rs1577917	0.958	rs66807489	ENSG00000203875.9	SNHG5	-11.25	4.34e-26	6.2e-23	-0.53	-0.47	Response to antipsychotic treatment;	chr6:85730984	chr6:85660950~85678736:-
PRAD	cis	rs7772486	0.79	rs2253307	ENSG00000235652.6	RP11-545I5.3	11.25	4.38e-26	6.25e-23	0.48	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145875045	chr6:145799409~145886585:+
PRAD	cis	rs1577917	1	rs12204015	ENSG00000203875.9	SNHG5	-11.25	4.39e-26	6.26e-23	-0.52	-0.47	Response to antipsychotic treatment;	chr6:85888616	chr6:85660950~85678736:-
PRAD	cis	rs7772486	0.79	rs2253654	ENSG00000235652.6	RP11-545I5.3	11.25	4.4e-26	6.28e-23	0.48	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145878309	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.692	rs2265915	ENSG00000235652.6	RP11-545I5.3	11.25	4.41e-26	6.3e-23	0.48	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145873196	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.713	rs1986729	ENSG00000235652.6	RP11-545I5.3	11.25	4.41e-26	6.3e-23	0.48	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145873695	chr6:145799409~145886585:+
PRAD	cis	rs7727544	0.684	rs272849	ENSG00000233006.5	AC034220.3	11.25	4.41e-26	6.3e-23	0.42	0.47	Blood metabolite levels;	chr5:132354548	chr5:132311285~132369916:-
PRAD	cis	rs2665103	0.61	rs56398167	ENSG00000278603.1	RP13-608F4.5	11.25	4.47e-26	6.38e-23	0.57	0.47	Intelligence (multi-trait analysis);	chr15:82237482	chr15:82472203~82472426:+
PRAD	cis	rs9322193	0.923	rs9689723	ENSG00000216906.2	RP11-350J20.9	11.25	4.48e-26	6.39e-23	0.54	0.47	Lung cancer;	chr6:149655935	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.961	rs4870144	ENSG00000223701.3	RAET1E-AS1	11.25	4.48e-26	6.4e-23	0.64	0.47	Lung cancer;	chr6:149575540	chr6:149884431~149919508:+
PRAD	cis	rs7714584	1	rs11741861	ENSG00000197083.10	ZNF300P1	-11.25	4.55e-26	6.49e-23	-0.83	-0.47	Crohn's disease;	chr5:150898347	chr5:150930645~150946289:-
PRAD	cis	rs9322193	0.923	rs10747275	ENSG00000216906.2	RP11-350J20.9	11.25	4.56e-26	6.51e-23	0.54	0.47	Lung cancer;	chr6:149622782	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.884	rs9688794	ENSG00000216906.2	RP11-350J20.9	11.25	4.56e-26	6.51e-23	0.54	0.47	Lung cancer;	chr6:149632121	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.923	rs9689084	ENSG00000216906.2	RP11-350J20.9	11.25	4.56e-26	6.51e-23	0.54	0.47	Lung cancer;	chr6:149639648	chr6:149904243~149906418:+
PRAD	cis	rs2404602	0.647	rs11634266	ENSG00000259422.1	RP11-593F23.1	-11.25	4.59e-26	6.54e-23	-0.62	-0.47	Blood metabolite levels;	chr15:76801120	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.647	rs12905181	ENSG00000259422.1	RP11-593F23.1	-11.25	4.59e-26	6.54e-23	-0.62	-0.47	Blood metabolite levels;	chr15:76806090	chr15:76174891~76181486:-
PRAD	cis	rs324126	1	rs324126	ENSG00000277977.1	CTD-3018O17.5	-11.25	4.61e-26	6.57e-23	-0.51	-0.47	Colonoscopy-negative controls vs population controls;	chr19:52382884	chr19:52392659~52392755:+
PRAD	cis	rs765787	0.53	rs2433228	ENSG00000259520.4	CTD-2651B20.3	11.25	4.63e-26	6.6e-23	0.57	0.47	Uric acid levels;	chr15:45223173	chr15:45251580~45279251:-
PRAD	cis	rs765787	0.53	rs11854690	ENSG00000259520.4	CTD-2651B20.3	11.25	4.63e-26	6.6e-23	0.57	0.47	Uric acid levels;	chr15:45223818	chr15:45251580~45279251:-
PRAD	cis	rs765787	0.53	rs28733848	ENSG00000259520.4	CTD-2651B20.3	11.25	4.63e-26	6.6e-23	0.57	0.47	Uric acid levels;	chr15:45223849	chr15:45251580~45279251:-
PRAD	cis	rs765787	0.53	rs11854689	ENSG00000259520.4	CTD-2651B20.3	11.25	4.63e-26	6.6e-23	0.57	0.47	Uric acid levels;	chr15:45223854	chr15:45251580~45279251:-
PRAD	cis	rs765787	0.53	rs1706830	ENSG00000259520.4	CTD-2651B20.3	11.25	4.63e-26	6.6e-23	0.57	0.47	Uric acid levels;	chr15:45224031	chr15:45251580~45279251:-
PRAD	cis	rs765787	0.53	rs1706831	ENSG00000259520.4	CTD-2651B20.3	11.25	4.63e-26	6.6e-23	0.57	0.47	Uric acid levels;	chr15:45224032	chr15:45251580~45279251:-
PRAD	cis	rs765787	0.53	rs2433227	ENSG00000259520.4	CTD-2651B20.3	11.25	4.63e-26	6.6e-23	0.57	0.47	Uric acid levels;	chr15:45224921	chr15:45251580~45279251:-
PRAD	cis	rs765787	0.53	rs2668751	ENSG00000259520.4	CTD-2651B20.3	11.25	4.63e-26	6.6e-23	0.57	0.47	Uric acid levels;	chr15:45225095	chr15:45251580~45279251:-
PRAD	cis	rs765787	0.53	rs1648286	ENSG00000259520.4	CTD-2651B20.3	11.25	4.63e-26	6.6e-23	0.57	0.47	Uric acid levels;	chr15:45225188	chr15:45251580~45279251:-
PRAD	cis	rs34779708	0.931	rs2384283	ENSG00000230534.5	RP11-297A16.2	11.25	4.66e-26	6.63e-23	0.63	0.47	Inflammatory bowel disease;Crohn's disease;	chr10:35037861	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.931	rs66887762	ENSG00000230534.5	RP11-297A16.2	11.25	4.66e-26	6.63e-23	0.63	0.47	Inflammatory bowel disease;Crohn's disease;	chr10:35041649	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.931	rs59418206	ENSG00000230534.5	RP11-297A16.2	11.25	4.66e-26	6.63e-23	0.63	0.47	Inflammatory bowel disease;Crohn's disease;	chr10:35042696	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.897	rs4934529	ENSG00000230534.5	RP11-297A16.2	11.25	4.66e-26	6.63e-23	0.63	0.47	Inflammatory bowel disease;Crohn's disease;	chr10:35013448	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.897	rs12830	ENSG00000230534.5	RP11-297A16.2	11.25	4.66e-26	6.63e-23	0.63	0.47	Inflammatory bowel disease;Crohn's disease;	chr10:35013777	chr10:35098006~35127020:-
PRAD	cis	rs2404602	0.647	rs7178250	ENSG00000259422.1	RP11-593F23.1	-11.25	4.68e-26	6.66e-23	-0.62	-0.47	Blood metabolite levels;	chr15:76806766	chr15:76174891~76181486:-
PRAD	cis	rs1577917	1	rs12209127	ENSG00000203875.9	SNHG5	-11.25	4.69e-26	6.67e-23	-0.54	-0.47	Response to antipsychotic treatment;	chr6:86014709	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.958	rs7453105	ENSG00000203875.9	SNHG5	-11.25	4.69e-26	6.68e-23	-0.53	-0.47	Response to antipsychotic treatment;	chr6:85791043	chr6:85660950~85678736:-
PRAD	cis	rs7727544	0.735	rs272875	ENSG00000233006.5	AC034220.3	11.24	4.73e-26	6.73e-23	0.42	0.47	Blood metabolite levels;	chr5:132339195	chr5:132311285~132369916:-
PRAD	cis	rs4654748	0.507	rs10799702	ENSG00000227001.3	NBPF2P	-11.24	4.74e-26	6.75e-23	-0.56	-0.47	Folate pathway vitamin levels;	chr1:21495387	chr1:21424625~21427967:-
PRAD	cis	rs34779708	0.966	rs1057108	ENSG00000230534.5	RP11-297A16.2	11.24	4.8e-26	6.83e-23	0.62	0.47	Inflammatory bowel disease;Crohn's disease;	chr10:35196021	chr10:35098006~35127020:-
PRAD	cis	rs73086581	0.592	rs2300217	ENSG00000229539.1	RP11-119B16.2	11.24	4.81e-26	6.85e-23	0.63	0.47	Response to antidepressants in depression;	chr20:3957928	chr20:3888239~3888868:-
PRAD	cis	rs11673344	0.931	rs73622783	ENSG00000226686.6	LINC01535	11.24	4.82e-26	6.85e-23	0.65	0.47	Obesity-related traits;	chr19:37165155	chr19:37251912~37265535:+
PRAD	cis	rs853679	0.527	rs1997660	ENSG00000216901.1	AL022393.7	11.24	4.82e-26	6.85e-23	0.6	0.47	Depression;	chr6:28301886	chr6:28176188~28176674:+
PRAD	cis	rs73086581	0.838	rs56401022	ENSG00000229539.1	RP11-119B16.2	11.24	4.83e-26	6.87e-23	0.77	0.47	Response to antidepressants in depression;	chr20:4043634	chr20:3888239~3888868:-
PRAD	cis	rs7772486	0.558	rs9376965	ENSG00000235652.6	RP11-545I5.3	11.24	4.86e-26	6.92e-23	0.52	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145808919	chr6:145799409~145886585:+
PRAD	cis	rs7727544	0.684	rs272893	ENSG00000233006.5	AC034220.3	11.24	4.88e-26	6.94e-23	0.42	0.47	Blood metabolite levels;	chr5:132327369	chr5:132311285~132369916:-
PRAD	cis	rs2404602	0.622	rs9635380	ENSG00000259422.1	RP11-593F23.1	-11.24	4.9e-26	6.96e-23	-0.63	-0.47	Blood metabolite levels;	chr15:76811138	chr15:76174891~76181486:-
PRAD	cis	rs6570726	0.599	rs426371	ENSG00000235652.6	RP11-545I5.3	-11.24	4.92e-26	6.99e-23	-0.52	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145565333	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.791	rs6912079	ENSG00000235652.6	RP11-545I5.3	11.24	4.95e-26	7.04e-23	0.49	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145573813	chr6:145799409~145886585:+
PRAD	cis	rs6664467	1	rs6664467	ENSG00000249602.1	RP11-98D18.3	11.24	4.97e-26	7.06e-23	0.77	0.47	Carotid plaque burden;	chr1:151765927	chr1:151763384~151769501:-
PRAD	cis	rs34779708	0.897	rs9787566	ENSG00000230534.5	RP11-297A16.2	11.24	5e-26	7.11e-23	0.63	0.47	Inflammatory bowel disease;Crohn's disease;	chr10:34990527	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.931	rs4351760	ENSG00000230534.5	RP11-297A16.2	11.24	5e-26	7.11e-23	0.63	0.47	Inflammatory bowel disease;Crohn's disease;	chr10:34991326	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.898	rs4934695	ENSG00000230534.5	RP11-297A16.2	11.24	5e-26	7.11e-23	0.63	0.47	Inflammatory bowel disease;Crohn's disease;	chr10:34991677	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.931	rs11597483	ENSG00000230534.5	RP11-297A16.2	11.24	5e-26	7.11e-23	0.63	0.47	Inflammatory bowel disease;Crohn's disease;	chr10:34996189	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.931	rs35317849	ENSG00000230534.5	RP11-297A16.2	11.24	5e-26	7.11e-23	0.63	0.47	Inflammatory bowel disease;Crohn's disease;	chr10:34996793	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.931	rs4934697	ENSG00000230534.5	RP11-297A16.2	11.24	5e-26	7.11e-23	0.63	0.47	Inflammatory bowel disease;Crohn's disease;	chr10:34998264	chr10:35098006~35127020:-
PRAD	cis	rs853679	0.527	rs853683	ENSG00000216901.1	AL022393.7	11.24	5.01e-26	7.11e-23	0.6	0.47	Depression;	chr6:28327262	chr6:28176188~28176674:+
PRAD	cis	rs673078	0.66	rs16948197	ENSG00000275759.1	RP11-131L12.3	11.24	5.09e-26	7.24e-23	0.72	0.47	Glucose homeostasis traits;	chr12:118239135	chr12:118428281~118428870:+
PRAD	cis	rs9322193	0.923	rs12205092	ENSG00000268592.3	RAET1E-AS1	11.24	5.11e-26	7.26e-23	0.64	0.47	Lung cancer;	chr6:149761375	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.923	rs10872651	ENSG00000268592.3	RAET1E-AS1	11.24	5.11e-26	7.26e-23	0.64	0.47	Lung cancer;	chr6:149768273	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.923	rs4870052	ENSG00000216906.2	RP11-350J20.9	11.23	5.15e-26	7.32e-23	0.54	0.47	Lung cancer;	chr6:149839978	chr6:149904243~149906418:+
PRAD	cis	rs2404602	0.735	rs2468130	ENSG00000259422.1	RP11-593F23.1	-11.23	5.15e-26	7.32e-23	-0.6	-0.47	Blood metabolite levels;	chr15:76504155	chr15:76174891~76181486:-
PRAD	cis	rs1976403	0.659	rs10799699	ENSG00000227001.3	NBPF2P	11.23	5.17e-26	7.34e-23	0.55	0.47	Liver enzyme levels (alkaline phosphatase);	chr1:21494468	chr1:21424625~21427967:-
PRAD	cis	rs6504950	0.785	rs2628304	ENSG00000275710.1	RP11-257O5.4	-11.23	5.2e-26	7.38e-23	-0.6	-0.47	Breast cancer;	chr17:55079828	chr17:54964474~54964679:+
PRAD	cis	rs75422866	0.867	rs73113139	ENSG00000257433.4	RP1-197B17.3	11.23	5.22e-26	7.41e-23	1.02	0.47	Pneumonia;	chr12:47622826	chr12:47706085~47742294:+
PRAD	cis	rs7772486	0.79	rs2485632	ENSG00000235652.6	RP11-545I5.3	11.23	5.24e-26	7.43e-23	0.48	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145872092	chr6:145799409~145886585:+
PRAD	cis	rs9322193	0.884	rs1108889	ENSG00000216906.2	RP11-350J20.9	11.23	5.27e-26	7.48e-23	0.53	0.47	Lung cancer;	chr6:149845433	chr6:149904243~149906418:+
PRAD	cis	rs2729354	1	rs2511983	ENSG00000265566.2	RN7SL605P	-11.23	5.27e-26	7.48e-23	-0.71	-0.47	Blood protein levels;	chr11:57579401	chr11:57528085~57528365:-
PRAD	cis	rs8062405	0.755	rs4149398	ENSG00000259982.1	CDC37P1	11.23	5.41e-26	7.67e-23	0.62	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597617	chr16:28700294~28701540:-
PRAD	cis	rs4964805	0.505	rs4981032	ENSG00000257681.1	RP11-341G23.4	11.23	5.46e-26	7.74e-23	0.43	0.47	Attention deficit hyperactivity disorder;	chr12:103772086	chr12:103746315~103768858:-
PRAD	cis	rs4964805	0.594	rs9132	ENSG00000257681.1	RP11-341G23.4	11.23	5.46e-26	7.74e-23	0.43	0.47	Attention deficit hyperactivity disorder;	chr12:103772465	chr12:103746315~103768858:-
PRAD	cis	rs6570726	0.577	rs399502	ENSG00000235652.6	RP11-545I5.3	11.23	5.48e-26	7.77e-23	0.52	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145484738	chr6:145799409~145886585:+
PRAD	cis	rs7727544	0.684	rs270602	ENSG00000233006.5	AC034220.3	11.23	5.5e-26	7.79e-23	0.42	0.47	Blood metabolite levels;	chr5:132321007	chr5:132311285~132369916:-
PRAD	cis	rs9595066	1	rs4942281	ENSG00000227258.4	SMIM2-AS1	11.23	5.54e-26	7.86e-23	0.86	0.47	Schizophrenia;	chr13:44133990	chr13:44110451~44240517:+
PRAD	cis	rs9595066	1	rs4942282	ENSG00000227258.4	SMIM2-AS1	11.23	5.54e-26	7.86e-23	0.86	0.47	Schizophrenia;	chr13:44134280	chr13:44110451~44240517:+
PRAD	cis	rs2658782	0.901	rs7116173	ENSG00000279684.1	RP11-755E23.2	11.23	5.56e-26	7.89e-23	0.76	0.47	Pulmonary function decline;	chr11:93489145	chr11:93286629~93288903:-
PRAD	cis	rs4423214	0.592	rs78300366	ENSG00000254682.1	RP11-660L16.2	-11.22	5.65e-26	8e-23	-0.75	-0.47	Vitamin D levels;	chr11:71494468	chr11:71448674~71452157:+
PRAD	cis	rs9322193	0.923	rs12174716	ENSG00000216906.2	RP11-350J20.9	11.22	5.68e-26	8.04e-23	0.54	0.47	Lung cancer;	chr6:149644487	chr6:149904243~149906418:+
PRAD	cis	rs1153858	0.848	rs9806699	ENSG00000259520.4	CTD-2651B20.3	-11.22	5.68e-26	8.05e-23	-0.62	-0.47	Homoarginine levels;	chr15:45448194	chr15:45251580~45279251:-
PRAD	cis	rs34779708	0.931	rs79749947	ENSG00000230534.5	RP11-297A16.2	11.22	5.7e-26	8.07e-23	0.63	0.47	Inflammatory bowel disease;Crohn's disease;	chr10:34988153	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.931	rs9663401	ENSG00000230534.5	RP11-297A16.2	11.22	5.7e-26	8.07e-23	0.63	0.47	Inflammatory bowel disease;Crohn's disease;	chr10:34989921	chr10:35098006~35127020:-
PRAD	cis	rs7772486	0.558	rs9497403	ENSG00000235652.6	RP11-545I5.3	-11.22	5.71e-26	8.08e-23	-0.51	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145733559	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.727	rs2235481	ENSG00000235652.6	RP11-545I5.3	-11.22	5.71e-26	8.08e-23	-0.51	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145735712	chr6:145799409~145886585:+
PRAD	cis	rs853679	0.517	rs9393893	ENSG00000280107.1	AL022393.9	-11.22	5.73e-26	8.1e-23	-0.6	-0.47	Depression;	chr6:28141484	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs4713146	ENSG00000280107.1	AL022393.9	-11.22	5.73e-26	8.1e-23	-0.6	-0.47	Depression;	chr6:28143758	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs9393894	ENSG00000280107.1	AL022393.9	-11.22	5.73e-26	8.1e-23	-0.6	-0.47	Depression;	chr6:28144784	chr6:28170845~28172521:+
PRAD	cis	rs6570726	0.62	rs367693	ENSG00000235652.6	RP11-545I5.3	11.22	5.75e-26	8.13e-23	0.52	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145494813	chr6:145799409~145886585:+
PRAD	cis	rs9322193	0.847	rs56103941	ENSG00000268592.3	RAET1E-AS1	11.22	5.76e-26	8.15e-23	0.64	0.47	Lung cancer;	chr6:149816095	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.847	rs12210605	ENSG00000268592.3	RAET1E-AS1	11.22	5.76e-26	8.15e-23	0.64	0.47	Lung cancer;	chr6:149817267	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.923	rs9371199	ENSG00000268592.3	RAET1E-AS1	11.22	5.76e-26	8.15e-23	0.64	0.47	Lung cancer;	chr6:149817526	chr6:149863494~149919507:+
PRAD	cis	rs12594515	1	rs8032835	ENSG00000273972.1	CTD-2306A12.1	-11.22	5.77e-26	8.16e-23	-0.52	-0.47	Weight;Waist circumference;	chr15:45705699	chr15:45702640~45703183:+
PRAD	cis	rs12594515	1	rs8033148	ENSG00000273972.1	CTD-2306A12.1	-11.22	5.77e-26	8.16e-23	-0.52	-0.47	Weight;Waist circumference;	chr15:45705731	chr15:45702640~45703183:+
PRAD	cis	rs4660456	0.504	rs587963	ENSG00000237899.1	RP4-739H11.3	11.22	5.79e-26	8.18e-23	0.66	0.47	Platelet count;	chr1:40640045	chr1:40669089~40687588:-
PRAD	cis	rs765787	0.53	rs16941017	ENSG00000259520.4	CTD-2651B20.3	11.22	5.8e-26	8.2e-23	0.57	0.47	Uric acid levels;	chr15:45251083	chr15:45251580~45279251:-
PRAD	cis	rs6903823	0.508	rs1150726	ENSG00000216901.1	AL022393.7	11.22	5.81e-26	8.21e-23	0.59	0.47	Pulmonary function;	chr6:28275265	chr6:28176188~28176674:+
PRAD	cis	rs9399135	0.66	rs9389248	ENSG00000232876.1	CTA-212D2.2	-11.22	5.83e-26	8.24e-23	-0.57	-0.47	Red blood cell count;	chr6:134961518	chr6:135055033~135060550:+
PRAD	cis	rs6570726	0.62	rs12201226	ENSG00000235652.6	RP11-545I5.3	11.22	5.87e-26	8.29e-23	0.53	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145592283	chr6:145799409~145886585:+
PRAD	cis	rs2404602	0.735	rs2461871	ENSG00000259422.1	RP11-593F23.1	-11.22	5.87e-26	8.29e-23	-0.6	-0.47	Blood metabolite levels;	chr15:76530077	chr15:76174891~76181486:-
PRAD	cis	rs8072100	0.544	rs9284377	ENSG00000228782.6	CTD-2026D20.3	11.22	5.9e-26	8.34e-23	0.51	0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47309046	chr17:47450568~47492492:-
PRAD	cis	rs4774565	0.762	rs34565064	ENSG00000244879.4	GABPB1-AS1	-11.22	5.91e-26	8.35e-23	-0.41	-0.47	Breast cancer;	chr15:50371706	chr15:50354959~50372202:+
PRAD	cis	rs11105298	0.891	rs8181784	ENSG00000258302.2	RP11-981P6.1	11.22	5.92e-26	8.36e-23	0.5	0.47	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89434814	chr12:89561129~89594878:+
PRAD	cis	rs6504950	0.889	rs2628296	ENSG00000275710.1	RP11-257O5.4	-11.22	5.92e-26	8.36e-23	-0.6	-0.47	Breast cancer;	chr17:55089134	chr17:54964474~54964679:+
PRAD	cis	rs172166	0.61	rs156737	ENSG00000216901.1	AL022393.7	11.22	5.93e-26	8.38e-23	0.58	0.47	Cardiac Troponin-T levels;	chr6:27927435	chr6:28176188~28176674:+
PRAD	cis	rs7727544	0.684	rs272869	ENSG00000233006.5	AC034220.3	11.22	5.94e-26	8.39e-23	0.42	0.47	Blood metabolite levels;	chr5:132342304	chr5:132311285~132369916:-
PRAD	cis	rs2019137	0.936	rs4849169	ENSG00000189223.12	PAX8-AS1	11.22	6e-26	8.47e-23	0.57	0.47	Lymphocyte counts;	chr2:113196080	chr2:113211522~113276581:+
PRAD	cis	rs9322193	0.923	rs9404048	ENSG00000216906.2	RP11-350J20.9	11.22	6.05e-26	8.53e-23	0.54	0.47	Lung cancer;	chr6:149616188	chr6:149904243~149906418:+
PRAD	cis	rs2455601	0.507	rs2568044	ENSG00000254860.4	TMEM9B-AS1	-11.22	6.06e-26	8.56e-23	-0.51	-0.47	Schizophrenia;	chr11:8980930	chr11:8964675~8977527:+
PRAD	cis	rs2404602	0.647	rs907593	ENSG00000259422.1	RP11-593F23.1	-11.22	6.1e-26	8.6e-23	-0.63	-0.47	Blood metabolite levels;	chr15:76904612	chr15:76174891~76181486:-
PRAD	cis	rs2739330	0.828	rs5760098	ENSG00000250470.1	AP000351.3	11.22	6.1e-26	8.61e-23	0.63	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23976904~23977585:-
PRAD	cis	rs34375054	0.66	rs12578446	ENSG00000279233.1	RP11-158L12.4	11.21	6.14e-26	8.65e-23	0.46	0.47	Post bronchodilator FEV1/FVC ratio;	chr12:125121341	chr12:125138245~125141711:+
PRAD	cis	rs9322193	0.886	rs9718079	ENSG00000223701.3	RAET1E-AS1	11.21	6.14e-26	8.66e-23	0.63	0.47	Lung cancer;	chr6:149645947	chr6:149884431~149919508:+
PRAD	cis	rs2739330	0.828	rs5760102	ENSG00000250470.1	AP000351.3	11.21	6.15e-26	8.67e-23	0.63	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23976904~23977585:-
PRAD	cis	rs9322193	0.923	rs9800871	ENSG00000216906.2	RP11-350J20.9	11.21	6.24e-26	8.79e-23	0.54	0.47	Lung cancer;	chr6:149644540	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.847	rs9505972	ENSG00000268592.3	RAET1E-AS1	11.21	6.25e-26	8.81e-23	0.64	0.47	Lung cancer;	chr6:149775255	chr6:149863494~149919507:+
PRAD	cis	rs1577917	1	rs791856	ENSG00000203875.9	SNHG5	11.21	6.32e-26	8.91e-23	0.51	0.47	Response to antipsychotic treatment;	chr6:85972123	chr6:85660950~85678736:-
PRAD	cis	rs6903823	0.508	rs1778484	ENSG00000216901.1	AL022393.7	11.21	6.36e-26	8.96e-23	0.59	0.47	Pulmonary function;	chr6:28273021	chr6:28176188~28176674:+
PRAD	cis	rs7182621	0.793	rs12904168	ENSG00000259363.4	CTD-2054N24.2	-11.21	6.38e-26	8.99e-23	-0.46	-0.47	Colonoscopy-negative controls vs population controls;	chr15:99869495	chr15:99807023~99877148:+
PRAD	cis	rs4774565	0.762	rs11634585	ENSG00000244879.4	GABPB1-AS1	11.21	6.39e-26	9e-23	0.41	0.47	Breast cancer;	chr15:50364252	chr15:50354959~50372202:+
PRAD	cis	rs34779708	0.966	rs4934539	ENSG00000230534.5	RP11-297A16.2	11.21	6.41e-26	9.03e-23	0.61	0.47	Inflammatory bowel disease;Crohn's disease;	chr10:35183271	chr10:35098006~35127020:-
PRAD	cis	rs2404602	0.684	rs4886816	ENSG00000259422.1	RP11-593F23.1	-11.21	6.41e-26	9.03e-23	-0.62	-0.47	Blood metabolite levels;	chr15:76582366	chr15:76174891~76181486:-
PRAD	cis	rs1577917	1	rs12212733	ENSG00000203875.9	SNHG5	-11.21	6.42e-26	9.04e-23	-0.53	-0.47	Response to antipsychotic treatment;	chr6:86016295	chr6:85660950~85678736:-
PRAD	cis	rs7240205	0.853	rs10432165	ENSG00000275805.1	RP11-349H17.2	-11.21	6.45e-26	9.09e-23	-0.58	-0.47	Breast cancer;	chr18:26555361	chr18:26565723~26575626:-
PRAD	cis	rs3931020	0.72	rs927904	ENSG00000272864.1	RP11-17E13.2	-11.21	6.46e-26	9.11e-23	-0.5	-0.47	Resistin levels;	chr1:74794644	chr1:74698769~74699333:-
PRAD	cis	rs10256972	0.967	rs4723338	ENSG00000229043.2	AC091729.9	-11.21	6.47e-26	9.12e-23	-0.55	-0.47	Endometriosis;Longevity;	chr7:996605	chr7:1160374~1165267:+
PRAD	cis	rs9322193	0.962	rs3805752	ENSG00000268592.3	RAET1E-AS1	11.21	6.47e-26	9.12e-23	0.64	0.47	Lung cancer;	chr6:149795490	chr6:149863494~149919507:+
PRAD	cis	rs8072100	0.817	rs7213086	ENSG00000228782.6	CTD-2026D20.3	11.21	6.5e-26	9.15e-23	0.51	0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47674944	chr17:47450568~47492492:-
PRAD	cis	rs853679	0.517	rs868987	ENSG00000280107.1	AL022393.9	11.21	6.55e-26	9.22e-23	0.6	0.47	Depression;	chr6:28142370	chr6:28170845~28172521:+
PRAD	cis	rs2404602	0.552	rs11634428	ENSG00000259422.1	RP11-593F23.1	-11.21	6.61e-26	9.31e-23	-0.65	-0.47	Blood metabolite levels;	chr15:76792241	chr15:76174891~76181486:-
PRAD	cis	rs9322193	0.884	rs62439836	ENSG00000216906.2	RP11-350J20.9	11.21	6.68e-26	9.4e-23	0.54	0.47	Lung cancer;	chr6:149669173	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.923	rs4869812	ENSG00000216906.2	RP11-350J20.9	11.21	6.68e-26	9.4e-23	0.54	0.47	Lung cancer;	chr6:149669447	chr6:149904243~149906418:+
PRAD	cis	rs1930961	0.702	rs1930966	ENSG00000272977.1	CTA-390C10.10	-11.2	6.73e-26	9.47e-23	-0.89	-0.47	Bipolar disorder with mood-incongruent psychosis;	chr22:25489737	chr22:25476218~25479971:+
PRAD	cis	rs6003958	1	rs6003958	ENSG00000225282.1	AP000350.6	-11.2	6.75e-26	9.5e-23	-0.73	-0.47	S-phenylmercapturic acid levels in smokers;	chr22:23921902	chr22:23926900~23929574:+
PRAD	cis	rs5760092	0.755	rs6003959	ENSG00000225282.1	AP000350.6	-11.2	6.75e-26	9.5e-23	-0.73	-0.47	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23922208	chr22:23926900~23929574:+
PRAD	cis	rs2564921	0.73	rs60579898	ENSG00000242142.1	SERBP1P3	-11.2	6.77e-26	9.53e-23	-0.54	-0.46	Height;	chr3:53069965	chr3:53064283~53065091:-
PRAD	cis	rs9545047	0.74	rs9574409	ENSG00000227676.3	LINC01068	11.2	6.8e-26	9.57e-23	0.56	0.46	Schizophrenia;	chr13:79341844	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.68	rs7987769	ENSG00000227676.3	LINC01068	11.2	6.8e-26	9.57e-23	0.56	0.46	Schizophrenia;	chr13:79343965	chr13:79566727~79571436:+
PRAD	cis	rs1577917	0.958	rs12191340	ENSG00000203875.9	SNHG5	-11.2	6.85e-26	9.63e-23	-0.52	-0.46	Response to antipsychotic treatment;	chr6:85811682	chr6:85660950~85678736:-
PRAD	cis	rs2404602	0.647	rs12910820	ENSG00000259422.1	RP11-593F23.1	-11.2	6.92e-26	9.74e-23	-0.61	-0.46	Blood metabolite levels;	chr15:76730484	chr15:76174891~76181486:-
PRAD	cis	rs9322193	0.607	rs915140	ENSG00000223701.3	RAET1E-AS1	11.2	7.03e-26	9.89e-23	0.72	0.46	Lung cancer;	chr6:149899674	chr6:149884431~149919508:+
PRAD	cis	rs780096	0.526	rs13391837	ENSG00000234072.1	AC074117.10	-11.2	7.04e-26	9.9e-23	-0.37	-0.46	Total body bone mineral density;	chr2:27426508	chr2:27356246~27367622:+
PRAD	cis	rs12594515	0.967	rs11854477	ENSG00000273972.1	CTD-2306A12.1	-11.2	7.07e-26	9.94e-23	-0.52	-0.46	Weight;Waist circumference;	chr15:45706147	chr15:45702640~45703183:+
PRAD	cis	rs9322193	0.962	rs4380763	ENSG00000216906.2	RP11-350J20.9	11.2	7.1e-26	9.98e-23	0.54	0.46	Lung cancer;	chr6:149678086	chr6:149904243~149906418:+
PRAD	cis	rs7727544	0.645	rs272857	ENSG00000233006.5	AC034220.3	11.2	7.15e-26	1e-22	0.42	0.46	Blood metabolite levels;	chr5:132349604	chr5:132311285~132369916:-
PRAD	cis	rs9322193	0.962	rs3805749	ENSG00000268592.3	RAET1E-AS1	11.2	7.15e-26	1.01e-22	0.64	0.46	Lung cancer;	chr6:149772546	chr6:149863494~149919507:+
PRAD	cis	rs6570726	0.577	rs406868	ENSG00000235652.6	RP11-545I5.3	11.2	7.17e-26	1.01e-22	0.52	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145488847	chr6:145799409~145886585:+
PRAD	cis	rs4713118	0.505	rs276371	ENSG00000216901.1	AL022393.7	11.2	7.18e-26	1.01e-22	0.58	0.46	Parkinson's disease;	chr6:27942930	chr6:28176188~28176674:+
PRAD	cis	rs4853012	0.838	rs6715351	ENSG00000257800.1	FNBP1P1	11.2	7.2e-26	1.01e-22	0.41	0.46	Gestational age at birth (maternal effect);	chr2:74118992	chr2:74120680~74123218:+
PRAD	cis	rs4853012	0.838	rs61521879	ENSG00000257800.1	FNBP1P1	11.2	7.2e-26	1.01e-22	0.41	0.46	Gestational age at birth (maternal effect);	chr2:74119081	chr2:74120680~74123218:+
PRAD	cis	rs7044106	0.762	rs7849566	ENSG00000226752.6	PSMD5-AS1	-11.2	7.24e-26	1.02e-22	-0.58	-0.46	Hip circumference adjusted for BMI;	chr9:120698491	chr9:120824828~120854385:+
PRAD	cis	rs2282300	0.956	rs2685286	ENSG00000242353.1	RP4-710M3.1	-11.2	7.27e-26	1.02e-22	-0.54	-0.46	Morning vs. evening chronotype;	chr11:30360041	chr11:30368148~30368646:+
PRAD	cis	rs2282300	0.956	rs1717773	ENSG00000242353.1	RP4-710M3.1	-11.2	7.27e-26	1.02e-22	-0.54	-0.46	Morning vs. evening chronotype;	chr11:30361607	chr11:30368148~30368646:+
PRAD	cis	rs34779708	0.966	rs12775799	ENSG00000230534.5	RP11-297A16.2	11.2	7.28e-26	1.02e-22	0.61	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35199336	chr10:35098006~35127020:-
PRAD	cis	rs2282300	0.91	rs528292	ENSG00000242353.1	RP4-710M3.1	11.19	7.34e-26	1.03e-22	0.54	0.46	Morning vs. evening chronotype;	chr11:30368163	chr11:30368148~30368646:+
PRAD	cis	rs2282300	0.956	rs594937	ENSG00000242353.1	RP4-710M3.1	11.19	7.34e-26	1.03e-22	0.54	0.46	Morning vs. evening chronotype;	chr11:30368585	chr11:30368148~30368646:+
PRAD	cis	rs7714584	1	rs11743488	ENSG00000197083.10	ZNF300P1	11.19	7.39e-26	1.04e-22	0.81	0.46	Crohn's disease;	chr5:150899656	chr5:150930645~150946289:-
PRAD	cis	rs4845570	0.764	rs12141652	ENSG00000249602.1	RP11-98D18.3	11.19	7.4e-26	1.04e-22	0.78	0.46	Coronary artery disease;	chr1:151744235	chr1:151763384~151769501:-
PRAD	cis	rs4845570	0.764	rs12122917	ENSG00000249602.1	RP11-98D18.3	11.19	7.4e-26	1.04e-22	0.78	0.46	Coronary artery disease;	chr1:151744236	chr1:151763384~151769501:-
PRAD	cis	rs4845570	0.834	rs13376155	ENSG00000249602.1	RP11-98D18.3	11.19	7.4e-26	1.04e-22	0.78	0.46	Coronary artery disease;	chr1:151748794	chr1:151763384~151769501:-
PRAD	cis	rs6504950	0.925	rs8082622	ENSG00000275710.1	RP11-257O5.4	-11.19	7.41e-26	1.04e-22	-0.62	-0.46	Breast cancer;	chr17:55100206	chr17:54964474~54964679:+
PRAD	cis	rs6504950	0.925	rs244377	ENSG00000275710.1	RP11-257O5.4	-11.19	7.41e-26	1.04e-22	-0.62	-0.46	Breast cancer;	chr17:55105718	chr17:54964474~54964679:+
PRAD	cis	rs6570726	0.557	rs403956	ENSG00000235652.6	RP11-545I5.3	11.19	7.42e-26	1.04e-22	0.52	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145508820	chr6:145799409~145886585:+
PRAD	cis	rs1185460	0.967	rs11217137	ENSG00000271751.1	RP11-110I1.14	-11.19	7.43e-26	1.04e-22	-0.66	-0.46	Coronary artery disease;	chr11:119060319	chr11:119065263~119065677:-
PRAD	cis	rs867371	0.519	rs1566560	ENSG00000278603.1	RP13-608F4.5	11.19	7.44e-26	1.04e-22	0.57	0.46	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82232116	chr15:82472203~82472426:+
PRAD	cis	rs867371	0.519	rs1566559	ENSG00000278603.1	RP13-608F4.5	11.19	7.44e-26	1.04e-22	0.57	0.46	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82232120	chr15:82472203~82472426:+
PRAD	cis	rs1577917	1	rs12207305	ENSG00000203875.9	SNHG5	-11.19	7.44e-26	1.04e-22	-0.53	-0.46	Response to antipsychotic treatment;	chr6:86013784	chr6:85660950~85678736:-
PRAD	cis	rs1577917	1	rs12199784	ENSG00000203875.9	SNHG5	-11.19	7.44e-26	1.04e-22	-0.53	-0.46	Response to antipsychotic treatment;	chr6:86017090	chr6:85660950~85678736:-
PRAD	cis	rs9322193	0.923	rs9505982	ENSG00000216906.2	RP11-350J20.9	11.19	7.47e-26	1.05e-22	0.54	0.46	Lung cancer;	chr6:149618465	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.923	rs9322196	ENSG00000216906.2	RP11-350J20.9	11.19	7.47e-26	1.05e-22	0.54	0.46	Lung cancer;	chr6:149619645	chr6:149904243~149906418:+
PRAD	cis	rs853679	0.517	rs1904841	ENSG00000280107.1	AL022393.9	-11.19	7.52e-26	1.05e-22	-0.6	-0.46	Depression;	chr6:28140307	chr6:28170845~28172521:+
PRAD	cis	rs4964805	0.594	rs4964830	ENSG00000257681.1	RP11-341G23.4	-11.19	7.52e-26	1.05e-22	-0.44	-0.46	Attention deficit hyperactivity disorder;	chr12:103775130	chr12:103746315~103768858:-
PRAD	cis	rs2404602	0.647	rs11631959	ENSG00000259422.1	RP11-593F23.1	-11.19	7.64e-26	1.07e-22	-0.62	-0.46	Blood metabolite levels;	chr15:76747707	chr15:76174891~76181486:-
PRAD	cis	rs67311347	1	rs6801859	ENSG00000223797.4	ENTPD3-AS1	-11.19	7.71e-26	1.08e-22	-0.41	-0.46	Renal cell carcinoma;	chr3:40451727	chr3:40313802~40453329:-
PRAD	cis	rs1577917	0.917	rs35038582	ENSG00000203875.9	SNHG5	-11.19	7.71e-26	1.08e-22	-0.53	-0.46	Response to antipsychotic treatment;	chr6:86011587	chr6:85660950~85678736:-
PRAD	cis	rs1577917	1	rs7760207	ENSG00000203875.9	SNHG5	-11.19	7.71e-26	1.08e-22	-0.53	-0.46	Response to antipsychotic treatment;	chr6:86011982	chr6:85660950~85678736:-
PRAD	cis	rs2929278	0.561	rs62018952	ENSG00000249839.1	AC011330.5	11.19	7.71e-26	1.08e-22	0.59	0.46	Schizophrenia;	chr15:43788539	chr15:43663654~43684339:-
PRAD	cis	rs9322193	0.847	rs12234128	ENSG00000216906.2	RP11-350J20.9	11.19	7.75e-26	1.09e-22	0.54	0.46	Lung cancer;	chr6:149627553	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.923	rs57012784	ENSG00000216906.2	RP11-350J20.9	11.19	7.75e-26	1.09e-22	0.54	0.46	Lung cancer;	chr6:149627691	chr6:149904243~149906418:+
PRAD	cis	rs4660456	0.542	rs850009	ENSG00000237899.1	RP4-739H11.3	11.19	7.76e-26	1.09e-22	0.66	0.46	Platelet count;	chr1:40643593	chr1:40669089~40687588:-
PRAD	cis	rs9487094	0.71	rs71558370	ENSG00000260273.1	RP11-425D10.10	11.19	7.77e-26	1.09e-22	0.73	0.46	Height;	chr6:109455700	chr6:109382795~109383666:+
PRAD	cis	rs4853012	0.838	rs12619982	ENSG00000257800.1	FNBP1P1	11.19	7.8e-26	1.09e-22	0.43	0.46	Gestational age at birth (maternal effect);	chr2:74128895	chr2:74120680~74123218:+
PRAD	cis	rs6903823	0.508	rs1150724	ENSG00000216901.1	AL022393.7	11.19	7.8e-26	1.09e-22	0.59	0.46	Pulmonary function;	chr6:28282459	chr6:28176188~28176674:+
PRAD	cis	rs875971	0.545	rs10261710	ENSG00000237310.1	GS1-124K5.4	11.19	7.82e-26	1.09e-22	0.48	0.46	Aortic root size;	chr7:66249202	chr7:66493706~66495474:+
PRAD	cis	rs11603023	1	rs11603023	ENSG00000255239.1	AP002954.6	11.19	7.84e-26	1.1e-22	0.59	0.46	Cholesterol, total;	chr11:118615352	chr11:118688039~118690600:-
PRAD	cis	rs2929278	0.589	rs7174732	ENSG00000249839.1	AC011330.5	11.19	7.85e-26	1.1e-22	0.59	0.46	Schizophrenia;	chr15:43746265	chr15:43663654~43684339:-
PRAD	cis	rs7727544	0.684	rs274560	ENSG00000233006.5	AC034220.3	-11.19	7.89e-26	1.1e-22	-0.41	-0.46	Blood metabolite levels;	chr5:132383758	chr5:132311285~132369916:-
PRAD	cis	rs11723261	0.582	rs11732336	ENSG00000275426.1	CH17-262A2.1	11.19	7.92e-26	1.11e-22	0.65	0.46	Immune response to smallpox vaccine (IL-6);	chr4:146728	chr4:149738~150317:+
PRAD	cis	rs853679	0.517	rs9283884	ENSG00000280107.1	AL022393.9	11.19	7.95e-26	1.11e-22	0.61	0.46	Depression;	chr6:28167882	chr6:28170845~28172521:+
PRAD	cis	rs9532669	0.926	rs7997560	ENSG00000176268.5	CYCSP34	11.18	8.03e-26	1.12e-22	0.49	0.46	Cervical cancer;	chr13:40878723	chr13:40863599~40863902:-
PRAD	cis	rs7714584	1	rs17727568	ENSG00000197083.10	ZNF300P1	11.18	8.08e-26	1.13e-22	0.83	0.46	Crohn's disease;	chr5:150865126	chr5:150930645~150946289:-
PRAD	cis	rs2404602	0.684	rs2454451	ENSG00000259422.1	RP11-593F23.1	11.18	8.09e-26	1.13e-22	0.6	0.46	Blood metabolite levels;	chr15:76569120	chr15:76174891~76181486:-
PRAD	cis	rs9322193	0.923	rs55993747	ENSG00000216906.2	RP11-350J20.9	11.18	8.12e-26	1.13e-22	0.53	0.46	Lung cancer;	chr6:149622016	chr6:149904243~149906418:+
PRAD	cis	rs6570726	0.599	rs4398765	ENSG00000235652.6	RP11-545I5.3	11.18	8.14e-26	1.14e-22	0.53	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145613870	chr6:145799409~145886585:+
PRAD	cis	rs9322193	0.923	rs9766037	ENSG00000216906.2	RP11-350J20.9	11.18	8.15e-26	1.14e-22	0.54	0.46	Lung cancer;	chr6:149616921	chr6:149904243~149906418:+
PRAD	cis	rs853679	0.517	rs1904840	ENSG00000280107.1	AL022393.9	-11.18	8.16e-26	1.14e-22	-0.6	-0.46	Depression;	chr6:28140454	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs9368555	ENSG00000280107.1	AL022393.9	-11.18	8.16e-26	1.14e-22	-0.6	-0.46	Depression;	chr6:28141189	chr6:28170845~28172521:+
PRAD	cis	rs12049351	0.774	rs6681212	ENSG00000229367.1	HMGN2P19	11.18	8.24e-26	1.15e-22	0.64	0.46	Circulating myeloperoxidase levels (plasma);	chr1:229503337	chr1:229570532~229570796:+
PRAD	cis	rs4853012	0.838	rs2177707	ENSG00000257800.1	FNBP1P1	11.18	8.3e-26	1.16e-22	0.44	0.46	Gestational age at birth (maternal effect);	chr2:74129723	chr2:74120680~74123218:+
PRAD	cis	rs780096	0.506	rs1647285	ENSG00000234072.1	AC074117.10	-11.18	8.31e-26	1.16e-22	-0.37	-0.46	Total body bone mineral density;	chr2:27491644	chr2:27356246~27367622:+
PRAD	cis	rs780096	0.506	rs1647286	ENSG00000234072.1	AC074117.10	-11.18	8.31e-26	1.16e-22	-0.37	-0.46	Total body bone mineral density;	chr2:27491650	chr2:27356246~27367622:+
PRAD	cis	rs7044106	0.762	rs966396	ENSG00000226752.6	PSMD5-AS1	-11.18	8.33e-26	1.16e-22	-0.58	-0.46	Hip circumference adjusted for BMI;	chr9:120691003	chr9:120824828~120854385:+
PRAD	cis	rs2739330	0.731	rs4822450	ENSG00000224205.1	AP000351.4	11.18	8.34e-26	1.16e-22	0.57	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23987320~23991421:-
PRAD	cis	rs8062405	1	rs62037364	ENSG00000251417.2	RP11-1348G14.4	-11.18	8.36e-26	1.17e-22	-0.52	-0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857374	chr16:28802743~28817828:+
PRAD	cis	rs8062405	1	rs2008514	ENSG00000251417.2	RP11-1348G14.4	11.18	8.41e-26	1.18e-22	0.51	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814284	chr16:28802743~28817828:+
PRAD	cis	rs2929278	0.617	rs694461	ENSG00000249839.1	AC011330.5	11.18	8.52e-26	1.19e-22	0.6	0.46	Schizophrenia;	chr15:43803865	chr15:43663654~43684339:-
PRAD	cis	rs4853012	0.887	rs2280642	ENSG00000257800.1	FNBP1P1	11.18	8.67e-26	1.21e-22	0.44	0.46	Gestational age at birth (maternal effect);	chr2:74131125	chr2:74120680~74123218:+
PRAD	cis	rs9322193	0.884	rs880245	ENSG00000216906.2	RP11-350J20.9	-11.18	8.67e-26	1.21e-22	-0.53	-0.46	Lung cancer;	chr6:149846262	chr6:149904243~149906418:+
PRAD	cis	rs9532669	0.926	rs7997536	ENSG00000176268.5	CYCSP34	11.18	8.69e-26	1.21e-22	0.49	0.46	Cervical cancer;	chr13:40878685	chr13:40863599~40863902:-
PRAD	cis	rs11673344	0.665	rs74435359	ENSG00000226686.6	LINC01535	11.18	8.72e-26	1.22e-22	0.66	0.46	Obesity-related traits;	chr19:36955252	chr19:37251912~37265535:+
PRAD	cis	rs34779708	0.966	rs4934735	ENSG00000230534.5	RP11-297A16.2	-11.17	8.76e-26	1.22e-22	-0.61	-0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35207802	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.931	rs4934721	ENSG00000230534.5	RP11-297A16.2	11.17	8.8e-26	1.23e-22	0.63	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35088787	chr10:35098006~35127020:-
PRAD	cis	rs4774565	0.762	rs8041193	ENSG00000244879.4	GABPB1-AS1	-11.17	8.84e-26	1.23e-22	-0.41	-0.46	Breast cancer;	chr15:50369960	chr15:50354959~50372202:+
PRAD	cis	rs2658782	0.789	rs2605580	ENSG00000279684.1	RP11-755E23.2	-11.17	8.93e-26	1.25e-22	-0.69	-0.46	Pulmonary function decline;	chr11:93413888	chr11:93286629~93288903:-
PRAD	cis	rs2882667	0.638	rs6895690	ENSG00000253404.1	AC034243.1	11.17	8.94e-26	1.25e-22	0.59	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139130162	chr5:138744434~138753309:-
PRAD	cis	rs6991838	0.584	rs3812412	ENSG00000272010.1	CTD-3025N20.3	11.17	9.13e-26	1.27e-22	0.49	0.46	Intelligence (multi-trait analysis);	chr8:65634857	chr8:65591850~65592472:-
PRAD	cis	rs2739330	0.828	rs2877178	ENSG00000250470.1	AP000351.3	11.17	9.14e-26	1.27e-22	0.63	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23976904~23977585:-
PRAD	cis	rs2739330	0.828	rs2154593	ENSG00000250470.1	AP000351.3	11.17	9.14e-26	1.27e-22	0.63	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23976904~23977585:-
PRAD	cis	rs6903823	0.508	rs1150721	ENSG00000216901.1	AL022393.7	11.17	9.32e-26	1.3e-22	0.59	0.46	Pulmonary function;	chr6:28287263	chr6:28176188~28176674:+
PRAD	cis	rs6903823	0.508	rs1150718	ENSG00000216901.1	AL022393.7	11.17	9.32e-26	1.3e-22	0.59	0.46	Pulmonary function;	chr6:28289170	chr6:28176188~28176674:+
PRAD	cis	rs6903823	0.508	rs1233660	ENSG00000216901.1	AL022393.7	11.17	9.32e-26	1.3e-22	0.59	0.46	Pulmonary function;	chr6:28292472	chr6:28176188~28176674:+
PRAD	cis	rs6504950	0.925	rs244336	ENSG00000275710.1	RP11-257O5.4	11.17	9.34e-26	1.3e-22	0.62	0.46	Breast cancer;	chr17:55124141	chr17:54964474~54964679:+
PRAD	cis	rs1075265	0.568	rs959286	ENSG00000233266.1	HMGB1P31	11.17	9.39e-26	1.31e-22	0.61	0.46	Chronotype;Morning vs. evening chronotype;	chr2:54078941	chr2:54051334~54051760:+
PRAD	cis	rs1075265	0.527	rs959285	ENSG00000233266.1	HMGB1P31	11.17	9.39e-26	1.31e-22	0.61	0.46	Chronotype;Morning vs. evening chronotype;	chr2:54078964	chr2:54051334~54051760:+
PRAD	cis	rs12130219	0.5	rs4845743	ENSG00000237975.5	FLG-AS1	-11.17	9.45e-26	1.32e-22	-0.65	-0.46	Inflammatory skin disease;	chr1:152211673	chr1:152168125~152445456:+
PRAD	cis	rs765787	0.53	rs1648285	ENSG00000259520.4	CTD-2651B20.3	11.17	9.46e-26	1.32e-22	0.57	0.46	Uric acid levels;	chr15:45225307	chr15:45251580~45279251:-
PRAD	cis	rs7772486	0.534	rs34541797	ENSG00000235652.6	RP11-545I5.3	11.17	9.53e-26	1.33e-22	0.52	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145884168	chr6:145799409~145886585:+
PRAD	cis	rs6504950	0.925	rs244348	ENSG00000275710.1	RP11-257O5.4	11.17	9.53e-26	1.33e-22	0.61	0.46	Breast cancer;	chr17:55118930	chr17:54964474~54964679:+
PRAD	cis	rs4964805	0.594	rs10861095	ENSG00000257681.1	RP11-341G23.4	11.16	9.65e-26	1.34e-22	0.43	0.46	Attention deficit hyperactivity disorder;	chr12:103771609	chr12:103746315~103768858:-
PRAD	cis	rs780096	0.546	rs1528533	ENSG00000234072.1	AC074117.10	-11.16	9.71e-26	1.35e-22	-0.37	-0.46	Total body bone mineral density;	chr2:27372889	chr2:27356246~27367622:+
PRAD	cis	rs4853012	0.838	rs4563249	ENSG00000257800.1	FNBP1P1	11.16	9.77e-26	1.36e-22	0.4	0.46	Gestational age at birth (maternal effect);	chr2:74126889	chr2:74120680~74123218:+
PRAD	cis	rs34779708	0.931	rs2148482	ENSG00000230534.5	RP11-297A16.2	11.16	9.91e-26	1.38e-22	0.61	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35059982	chr10:35098006~35127020:-
PRAD	cis	rs2739330	0.828	rs5760108	ENSG00000250470.1	AP000351.3	11.16	9.94e-26	1.38e-22	0.63	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23976904~23977585:-
PRAD	cis	rs7044106	0.791	rs10984994	ENSG00000226752.6	PSMD5-AS1	11.16	9.95e-26	1.38e-22	0.57	0.46	Hip circumference adjusted for BMI;	chr9:120716491	chr9:120824828~120854385:+
PRAD	cis	rs7772486	0.754	rs697054	ENSG00000235652.6	RP11-545I5.3	11.16	1e-25	1.39e-22	0.48	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145682634	chr6:145799409~145886585:+
PRAD	cis	rs907683	0.545	rs3755054	ENSG00000280323.1	AC053503.12	11.16	1.01e-25	1.4e-22	0.38	0.46	Resting heart rate;	chr2:219416252	chr2:219427477~219429319:+
PRAD	cis	rs9545047	0.692	rs314694	ENSG00000227676.3	LINC01068	-11.16	1.01e-25	1.4e-22	-0.57	-0.46	Schizophrenia;	chr13:79432467	chr13:79566727~79571436:+
PRAD	cis	rs9322193	0.886	rs9718079	ENSG00000268592.3	RAET1E-AS1	11.16	1.02e-25	1.41e-22	0.65	0.46	Lung cancer;	chr6:149645947	chr6:149863494~149919507:+
PRAD	cis	rs8062405	1	rs62036626	ENSG00000251417.2	RP11-1348G14.4	-11.16	1.02e-25	1.41e-22	-0.52	-0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28832963	chr16:28802743~28817828:+
PRAD	cis	rs8062405	1	rs62036657	ENSG00000251417.2	RP11-1348G14.4	-11.16	1.02e-25	1.41e-22	-0.52	-0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833044	chr16:28802743~28817828:+
PRAD	cis	rs8062405	1	rs12444171	ENSG00000251417.2	RP11-1348G14.4	-11.16	1.02e-25	1.41e-22	-0.52	-0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833930	chr16:28802743~28817828:+
PRAD	cis	rs8062405	1	rs56404918	ENSG00000251417.2	RP11-1348G14.4	-11.16	1.02e-25	1.41e-22	-0.52	-0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835519	chr16:28802743~28817828:+
PRAD	cis	rs8062405	1	rs55719896	ENSG00000251417.2	RP11-1348G14.4	-11.16	1.02e-25	1.41e-22	-0.52	-0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835545	chr16:28802743~28817828:+
PRAD	cis	rs8062405	1	rs55830740	ENSG00000251417.2	RP11-1348G14.4	-11.16	1.02e-25	1.41e-22	-0.52	-0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835828	chr16:28802743~28817828:+
PRAD	cis	rs8062405	1	rs3088215	ENSG00000251417.2	RP11-1348G14.4	-11.16	1.02e-25	1.41e-22	-0.52	-0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28842675	chr16:28802743~28817828:+
PRAD	cis	rs8062405	1	rs28403629	ENSG00000251417.2	RP11-1348G14.4	-11.16	1.02e-25	1.41e-22	-0.52	-0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28843448	chr16:28802743~28817828:+
PRAD	cis	rs8062405	1	rs61737565	ENSG00000251417.2	RP11-1348G14.4	-11.16	1.02e-25	1.41e-22	-0.52	-0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844201	chr16:28802743~28817828:+
PRAD	cis	rs8062405	1	rs4788099	ENSG00000251417.2	RP11-1348G14.4	-11.16	1.02e-25	1.41e-22	-0.52	-0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844406	chr16:28802743~28817828:+
PRAD	cis	rs8062405	1	rs9972693	ENSG00000251417.2	RP11-1348G14.4	-11.16	1.02e-25	1.41e-22	-0.52	-0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28848481	chr16:28802743~28817828:+
PRAD	cis	rs8062405	0.964	rs9972768	ENSG00000251417.2	RP11-1348G14.4	-11.16	1.02e-25	1.41e-22	-0.52	-0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850413	chr16:28802743~28817828:+
PRAD	cis	rs8062405	0.965	rs56040780	ENSG00000251417.2	RP11-1348G14.4	-11.16	1.02e-25	1.41e-22	-0.52	-0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850560	chr16:28802743~28817828:+
PRAD	cis	rs8062405	0.965	rs62037363	ENSG00000251417.2	RP11-1348G14.4	-11.16	1.02e-25	1.41e-22	-0.52	-0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28853721	chr16:28802743~28817828:+
PRAD	cis	rs8062405	1	rs7205323	ENSG00000251417.2	RP11-1348G14.4	-11.16	1.02e-25	1.41e-22	-0.52	-0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854571	chr16:28802743~28817828:+
PRAD	cis	rs8062405	1	rs4788101	ENSG00000251417.2	RP11-1348G14.4	-11.16	1.02e-25	1.41e-22	-0.52	-0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28856483	chr16:28802743~28817828:+
PRAD	cis	rs8062405	1	rs62037365	ENSG00000251417.2	RP11-1348G14.4	-11.16	1.02e-25	1.41e-22	-0.52	-0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857641	chr16:28802743~28817828:+
PRAD	cis	rs8062405	0.929	rs11150609	ENSG00000251417.2	RP11-1348G14.4	-11.16	1.02e-25	1.41e-22	-0.52	-0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859275	chr16:28802743~28817828:+
PRAD	cis	rs8062405	0.737	rs11861132	ENSG00000251417.2	RP11-1348G14.4	-11.16	1.02e-25	1.41e-22	-0.52	-0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860539	chr16:28802743~28817828:+
PRAD	cis	rs8062405	1	rs11861174	ENSG00000251417.2	RP11-1348G14.4	-11.16	1.02e-25	1.41e-22	-0.52	-0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860668	chr16:28802743~28817828:+
PRAD	cis	rs8062405	1	rs4788102	ENSG00000251417.2	RP11-1348G14.4	-11.16	1.02e-25	1.41e-22	-0.52	-0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28862077	chr16:28802743~28817828:+
PRAD	cis	rs8062405	1	rs62037367	ENSG00000251417.2	RP11-1348G14.4	-11.16	1.02e-25	1.41e-22	-0.52	-0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863226	chr16:28802743~28817828:+
PRAD	cis	rs8062405	1	rs7198606	ENSG00000251417.2	RP11-1348G14.4	-11.16	1.02e-25	1.41e-22	-0.52	-0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863801	chr16:28802743~28817828:+
PRAD	cis	rs8062405	0.929	rs11864750	ENSG00000251417.2	RP11-1348G14.4	-11.16	1.02e-25	1.41e-22	-0.52	-0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863883	chr16:28802743~28817828:+
PRAD	cis	rs8062405	0.964	rs7193733	ENSG00000251417.2	RP11-1348G14.4	-11.16	1.02e-25	1.41e-22	-0.52	-0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28864161	chr16:28802743~28817828:+
PRAD	cis	rs8062405	1	rs8055982	ENSG00000251417.2	RP11-1348G14.4	-11.16	1.02e-25	1.41e-22	-0.52	-0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28869881	chr16:28802743~28817828:+
PRAD	cis	rs8062405	1	rs7498665	ENSG00000251417.2	RP11-1348G14.4	-11.16	1.02e-25	1.41e-22	-0.52	-0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28871920	chr16:28802743~28817828:+
PRAD	cis	rs8062405	0.964	rs11864107	ENSG00000251417.2	RP11-1348G14.4	-11.16	1.02e-25	1.41e-22	-0.52	-0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874610	chr16:28802743~28817828:+
PRAD	cis	rs8062405	1	rs62037371	ENSG00000251417.2	RP11-1348G14.4	-11.16	1.02e-25	1.41e-22	-0.52	-0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878810	chr16:28802743~28817828:+
PRAD	cis	rs8062405	1	rs8055138	ENSG00000251417.2	RP11-1348G14.4	-11.16	1.02e-25	1.41e-22	-0.52	-0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28880144	chr16:28802743~28817828:+
PRAD	cis	rs1577917	1	rs2812972	ENSG00000203875.9	SNHG5	-11.16	1.03e-25	1.43e-22	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85960162	chr6:85660950~85678736:-
PRAD	cis	rs9322193	0.923	rs12660304	ENSG00000216906.2	RP11-350J20.9	11.16	1.04e-25	1.44e-22	0.53	0.46	Lung cancer;	chr6:149739647	chr6:149904243~149906418:+
PRAD	cis	rs6570726	0.791	rs1280276	ENSG00000235652.6	RP11-545I5.3	11.16	1.04e-25	1.44e-22	0.48	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145571214	chr6:145799409~145886585:+
PRAD	cis	rs2117029	0.555	rs7958241	ENSG00000258017.1	RP11-386G11.10	11.15	1.04e-25	1.44e-22	0.6	0.46	Intelligence (multi-trait analysis);	chr12:49115479	chr12:49127782~49147869:+
PRAD	cis	rs875971	0.862	rs6460302	ENSG00000237310.1	GS1-124K5.4	11.15	1.04e-25	1.45e-22	0.42	0.46	Aortic root size;	chr7:66495270	chr7:66493706~66495474:+
PRAD	cis	rs2282300	0.739	rs1616223	ENSG00000254532.1	RP11-624D11.2	11.15	1.05e-25	1.45e-22	0.66	0.46	Morning vs. evening chronotype;	chr11:30317236	chr11:30044058~30084343:-
PRAD	cis	rs7044106	0.762	rs1867254	ENSG00000226752.6	PSMD5-AS1	-11.15	1.05e-25	1.46e-22	-0.58	-0.46	Hip circumference adjusted for BMI;	chr9:120666800	chr9:120824828~120854385:+
PRAD	cis	rs1577917	0.876	rs4618490	ENSG00000203875.9	SNHG5	-11.15	1.06e-25	1.46e-22	-0.52	-0.46	Response to antipsychotic treatment;	chr6:85808685	chr6:85660950~85678736:-
PRAD	cis	rs765787	0.53	rs2554457	ENSG00000259520.4	CTD-2651B20.3	11.15	1.06e-25	1.47e-22	0.57	0.46	Uric acid levels;	chr15:45228728	chr15:45251580~45279251:-
PRAD	cis	rs765787	0.53	rs2554456	ENSG00000259520.4	CTD-2651B20.3	11.15	1.06e-25	1.47e-22	0.57	0.46	Uric acid levels;	chr15:45228940	chr15:45251580~45279251:-
PRAD	cis	rs765787	0.53	rs10467979	ENSG00000259520.4	CTD-2651B20.3	11.15	1.06e-25	1.47e-22	0.57	0.46	Uric acid levels;	chr15:45229072	chr15:45251580~45279251:-
PRAD	cis	rs765787	0.53	rs2554455	ENSG00000259520.4	CTD-2651B20.3	11.15	1.06e-25	1.47e-22	0.57	0.46	Uric acid levels;	chr15:45229106	chr15:45251580~45279251:-
PRAD	cis	rs765787	0.53	rs4774542	ENSG00000259520.4	CTD-2651B20.3	-11.15	1.07e-25	1.47e-22	-0.57	-0.46	Uric acid levels;	chr15:45233828	chr15:45251580~45279251:-
PRAD	cis	rs6504950	0.925	rs244317	ENSG00000275710.1	RP11-257O5.4	-11.15	1.07e-25	1.48e-22	-0.67	-0.46	Breast cancer;	chr17:55139624	chr17:54964474~54964679:+
PRAD	cis	rs4814920	0.818	rs6035467	ENSG00000275142.1	RP5-999L4.2	-11.15	1.07e-25	1.48e-22	-0.78	-0.46	Bipolar disorder (body mass index interaction);	chr20:19879602	chr20:19871891~19872284:+
PRAD	cis	rs1976403	0.659	rs10799700	ENSG00000227001.3	NBPF2P	11.15	1.08e-25	1.49e-22	0.55	0.46	Liver enzyme levels (alkaline phosphatase);	chr1:21494475	chr1:21424625~21427967:-
PRAD	cis	rs12653946	0.846	rs10866528	ENSG00000249326.1	CTD-2194D22.4	-11.15	1.08e-25	1.49e-22	-0.58	-0.46	Prostate cancer;	chr5:1891707	chr5:1887332~1900493:+
PRAD	cis	rs853679	0.527	rs9468333	ENSG00000216901.1	AL022393.7	11.15	1.09e-25	1.51e-22	0.6	0.46	Depression;	chr6:28303421	chr6:28176188~28176674:+
PRAD	cis	rs11673344	0.932	rs76350084	ENSG00000226686.6	LINC01535	11.15	1.1e-25	1.52e-22	0.65	0.46	Obesity-related traits;	chr19:37187917	chr19:37251912~37265535:+
PRAD	cis	rs1577917	0.958	rs12195776	ENSG00000203875.9	SNHG5	-11.15	1.1e-25	1.52e-22	-0.53	-0.46	Response to antipsychotic treatment;	chr6:85778881	chr6:85660950~85678736:-
PRAD	cis	rs765787	0.53	rs11636367	ENSG00000259520.4	CTD-2651B20.3	11.15	1.11e-25	1.53e-22	0.57	0.46	Uric acid levels;	chr15:45243664	chr15:45251580~45279251:-
PRAD	cis	rs9322193	0.923	rs9689716	ENSG00000216906.2	RP11-350J20.9	11.15	1.11e-25	1.53e-22	0.53	0.46	Lung cancer;	chr6:149655662	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.923	rs9322207	ENSG00000216906.2	RP11-350J20.9	11.15	1.11e-25	1.53e-22	0.53	0.46	Lung cancer;	chr6:149657185	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.923	rs9322208	ENSG00000216906.2	RP11-350J20.9	11.15	1.11e-25	1.53e-22	0.53	0.46	Lung cancer;	chr6:149658547	chr6:149904243~149906418:+
PRAD	cis	rs1075265	0.584	rs34769118	ENSG00000233266.1	HMGB1P31	11.15	1.11e-25	1.54e-22	0.62	0.46	Chronotype;Morning vs. evening chronotype;	chr2:54102173	chr2:54051334~54051760:+
PRAD	cis	rs853679	0.513	rs9468296	ENSG00000280107.1	AL022393.9	-11.15	1.11e-25	1.54e-22	-0.6	-0.46	Depression;	chr6:28145952	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs4711164	ENSG00000280107.1	AL022393.9	-11.15	1.11e-25	1.54e-22	-0.6	-0.46	Depression;	chr6:28147378	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs4711165	ENSG00000280107.1	AL022393.9	-11.15	1.11e-25	1.54e-22	-0.6	-0.46	Depression;	chr6:28147406	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs4713148	ENSG00000280107.1	AL022393.9	-11.15	1.11e-25	1.54e-22	-0.6	-0.46	Depression;	chr6:28148143	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs9348794	ENSG00000280107.1	AL022393.9	-11.15	1.11e-25	1.54e-22	-0.6	-0.46	Depression;	chr6:28149979	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs9295758	ENSG00000280107.1	AL022393.9	-11.15	1.11e-25	1.54e-22	-0.6	-0.46	Depression;	chr6:28152885	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs17774663	ENSG00000280107.1	AL022393.9	-11.15	1.11e-25	1.54e-22	-0.6	-0.46	Depression;	chr6:28153120	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs9468298	ENSG00000280107.1	AL022393.9	-11.15	1.11e-25	1.54e-22	-0.6	-0.46	Depression;	chr6:28154567	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs9295759	ENSG00000280107.1	AL022393.9	-11.15	1.11e-25	1.54e-22	-0.6	-0.46	Depression;	chr6:28156691	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs9348796	ENSG00000280107.1	AL022393.9	-11.15	1.11e-25	1.54e-22	-0.6	-0.46	Depression;	chr6:28158424	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs11552219	ENSG00000280107.1	AL022393.9	-11.15	1.11e-25	1.54e-22	-0.6	-0.46	Depression;	chr6:28159056	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs9380058	ENSG00000280107.1	AL022393.9	-11.15	1.11e-25	1.54e-22	-0.6	-0.46	Depression;	chr6:28159666	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs9393895	ENSG00000280107.1	AL022393.9	-11.15	1.11e-25	1.54e-22	-0.6	-0.46	Depression;	chr6:28159843	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs9393896	ENSG00000280107.1	AL022393.9	-11.15	1.11e-25	1.54e-22	-0.6	-0.46	Depression;	chr6:28159925	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs9393897	ENSG00000280107.1	AL022393.9	-11.15	1.11e-25	1.54e-22	-0.6	-0.46	Depression;	chr6:28159932	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs9357066	ENSG00000280107.1	AL022393.9	-11.15	1.11e-25	1.54e-22	-0.6	-0.46	Depression;	chr6:28162053	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs9393898	ENSG00000280107.1	AL022393.9	-11.15	1.11e-25	1.54e-22	-0.6	-0.46	Depression;	chr6:28162598	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs9368556	ENSG00000280107.1	AL022393.9	-11.15	1.11e-25	1.54e-22	-0.6	-0.46	Depression;	chr6:28163375	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs9368557	ENSG00000280107.1	AL022393.9	-11.15	1.11e-25	1.54e-22	-0.6	-0.46	Depression;	chr6:28163759	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs9380059	ENSG00000280107.1	AL022393.9	-11.15	1.11e-25	1.54e-22	-0.6	-0.46	Depression;	chr6:28164580	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs9380060	ENSG00000280107.1	AL022393.9	-11.15	1.11e-25	1.54e-22	-0.6	-0.46	Depression;	chr6:28164825	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs35227624	ENSG00000280107.1	AL022393.9	-11.15	1.11e-25	1.54e-22	-0.6	-0.46	Depression;	chr6:28164948	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs9380061	ENSG00000280107.1	AL022393.9	-11.15	1.11e-25	1.54e-22	-0.6	-0.46	Depression;	chr6:28165025	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs9368558	ENSG00000280107.1	AL022393.9	-11.15	1.11e-25	1.54e-22	-0.6	-0.46	Depression;	chr6:28165528	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.587	rs9393899	ENSG00000280107.1	AL022393.9	-11.15	1.11e-25	1.54e-22	-0.6	-0.46	Parkinson's disease;	chr6:28165750	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs4713150	ENSG00000280107.1	AL022393.9	-11.15	1.11e-25	1.54e-22	-0.6	-0.46	Depression;	chr6:28168434	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.527	rs4713151	ENSG00000280107.1	AL022393.9	-11.15	1.11e-25	1.54e-22	-0.6	-0.46	Parkinson's disease;	chr6:28168578	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs9393901	ENSG00000280107.1	AL022393.9	-11.15	1.11e-25	1.54e-22	-0.6	-0.46	Depression;	chr6:28169019	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs3173443	ENSG00000280107.1	AL022393.9	-11.15	1.11e-25	1.54e-22	-0.6	-0.46	Depression;	chr6:28169249	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs4713152	ENSG00000280107.1	AL022393.9	-11.15	1.11e-25	1.54e-22	-0.6	-0.46	Depression;	chr6:28169676	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs9348797	ENSG00000280107.1	AL022393.9	-11.15	1.11e-25	1.54e-22	-0.6	-0.46	Depression;	chr6:28169755	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs9380062	ENSG00000280107.1	AL022393.9	-11.15	1.11e-25	1.54e-22	-0.6	-0.46	Depression;	chr6:28169791	chr6:28170845~28172521:+
PRAD	cis	rs2019137	0.936	rs2305133	ENSG00000189223.12	PAX8-AS1	11.15	1.11e-25	1.54e-22	0.57	0.46	Lymphocyte counts;	chr2:113199244	chr2:113211522~113276581:+
PRAD	cis	rs2019137	0.936	rs12612729	ENSG00000189223.12	PAX8-AS1	11.15	1.11e-25	1.54e-22	0.57	0.46	Lymphocyte counts;	chr2:113199471	chr2:113211522~113276581:+
PRAD	cis	rs2019137	0.936	rs731834	ENSG00000189223.12	PAX8-AS1	11.15	1.11e-25	1.54e-22	0.57	0.46	Lymphocyte counts;	chr2:113199621	chr2:113211522~113276581:+
PRAD	cis	rs7772486	0.764	rs7762562	ENSG00000235652.6	RP11-545I5.3	11.15	1.11e-25	1.54e-22	0.47	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145837858	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.754	rs9386133	ENSG00000235652.6	RP11-545I5.3	11.15	1.12e-25	1.55e-22	0.47	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145820077	chr6:145799409~145886585:+
PRAD	cis	rs1062177	0.756	rs2964588	ENSG00000213433.5	RPLP1P6	11.15	1.12e-25	1.55e-22	0.53	0.46	Preschool internalizing problems;	chr5:151738825	chr5:151765859~151766378:-
PRAD	cis	rs765787	0.53	rs2668737	ENSG00000259520.4	CTD-2651B20.3	11.15	1.13e-25	1.55e-22	0.57	0.46	Uric acid levels;	chr15:45230601	chr15:45251580~45279251:-
PRAD	cis	rs765787	0.53	rs1706764	ENSG00000259520.4	CTD-2651B20.3	11.15	1.13e-25	1.55e-22	0.57	0.46	Uric acid levels;	chr15:45232058	chr15:45251580~45279251:-
PRAD	cis	rs765787	0.53	rs2413786	ENSG00000259520.4	CTD-2651B20.3	11.15	1.13e-25	1.55e-22	0.57	0.46	Uric acid levels;	chr15:45233196	chr15:45251580~45279251:-
PRAD	cis	rs765787	0.53	rs28815867	ENSG00000259520.4	CTD-2651B20.3	11.15	1.13e-25	1.55e-22	0.57	0.46	Uric acid levels;	chr15:45234607	chr15:45251580~45279251:-
PRAD	cis	rs765787	0.53	rs4775822	ENSG00000259520.4	CTD-2651B20.3	11.15	1.13e-25	1.55e-22	0.57	0.46	Uric acid levels;	chr15:45234929	chr15:45251580~45279251:-
PRAD	cis	rs765787	0.53	rs11854294	ENSG00000259520.4	CTD-2651B20.3	11.15	1.13e-25	1.55e-22	0.57	0.46	Uric acid levels;	chr15:45235798	chr15:45251580~45279251:-
PRAD	cis	rs765787	0.53	rs2899381	ENSG00000259520.4	CTD-2651B20.3	11.15	1.13e-25	1.55e-22	0.57	0.46	Uric acid levels;	chr15:45237432	chr15:45251580~45279251:-
PRAD	cis	rs765787	0.53	rs2413785	ENSG00000259520.4	CTD-2651B20.3	11.15	1.13e-25	1.55e-22	0.57	0.46	Uric acid levels;	chr15:45238183	chr15:45251580~45279251:-
PRAD	cis	rs765787	0.53	rs2413784	ENSG00000259520.4	CTD-2651B20.3	11.15	1.13e-25	1.55e-22	0.57	0.46	Uric acid levels;	chr15:45238318	chr15:45251580~45279251:-
PRAD	cis	rs765787	0.53	rs7165889	ENSG00000259520.4	CTD-2651B20.3	11.15	1.13e-25	1.55e-22	0.57	0.46	Uric acid levels;	chr15:45239442	chr15:45251580~45279251:-
PRAD	cis	rs765787	0.53	rs11070451	ENSG00000259520.4	CTD-2651B20.3	11.15	1.13e-25	1.55e-22	0.57	0.46	Uric acid levels;	chr15:45241343	chr15:45251580~45279251:-
PRAD	cis	rs765787	0.53	rs28897155	ENSG00000259520.4	CTD-2651B20.3	11.15	1.13e-25	1.55e-22	0.57	0.46	Uric acid levels;	chr15:45241776	chr15:45251580~45279251:-
PRAD	cis	rs765787	0.53	rs4775831	ENSG00000259520.4	CTD-2651B20.3	11.15	1.13e-25	1.55e-22	0.57	0.46	Uric acid levels;	chr15:45242524	chr15:45251580~45279251:-
PRAD	cis	rs765787	0.53	rs4775832	ENSG00000259520.4	CTD-2651B20.3	11.15	1.13e-25	1.55e-22	0.57	0.46	Uric acid levels;	chr15:45242630	chr15:45251580~45279251:-
PRAD	cis	rs765787	0.53	rs4442750	ENSG00000259520.4	CTD-2651B20.3	11.15	1.13e-25	1.55e-22	0.57	0.46	Uric acid levels;	chr15:45243130	chr15:45251580~45279251:-
PRAD	cis	rs765787	0.53	rs4270107	ENSG00000259520.4	CTD-2651B20.3	11.15	1.13e-25	1.55e-22	0.57	0.46	Uric acid levels;	chr15:45243152	chr15:45251580~45279251:-
PRAD	cis	rs765787	0.53	rs4544188	ENSG00000259520.4	CTD-2651B20.3	11.15	1.13e-25	1.55e-22	0.57	0.46	Uric acid levels;	chr15:45243195	chr15:45251580~45279251:-
PRAD	cis	rs853679	0.542	rs9380063	ENSG00000280107.1	AL022393.9	-11.15	1.13e-25	1.56e-22	-0.6	-0.46	Depression;	chr6:28170075	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs9357065	ENSG00000280107.1	AL022393.9	-11.15	1.13e-25	1.56e-22	-0.6	-0.46	Depression;	chr6:28161802	chr6:28170845~28172521:+
PRAD	cis	rs2348418	0.733	rs9651832	ENSG00000247934.4	RP11-967K21.1	-11.14	1.14e-25	1.57e-22	-0.43	-0.46	Lung function (FEV1);Lung function (FVC);	chr12:28242489	chr12:28163298~28190738:-
PRAD	cis	rs4722166	0.695	rs7808122	ENSG00000179428.2	AC073072.5	-11.14	1.15e-25	1.59e-22	-0.53	-0.46	Lung cancer;	chr7:22758461	chr7:22725395~22727620:-
PRAD	cis	rs732716	0.785	rs34080966	ENSG00000267769.1	CTB-50L17.9	11.14	1.16e-25	1.59e-22	0.52	0.46	Mean corpuscular volume;	chr19:4417848	chr19:4454014~4455286:+
PRAD	cis	rs34779708	0.868	rs2384352	ENSG00000230534.5	RP11-297A16.2	11.14	1.16e-25	1.59e-22	0.62	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35203904	chr10:35098006~35127020:-
PRAD	cis	rs2019137	0.905	rs2276561	ENSG00000189223.12	PAX8-AS1	11.14	1.16e-25	1.59e-22	0.57	0.46	Lymphocyte counts;	chr2:113198794	chr2:113211522~113276581:+
PRAD	cis	rs907683	0.584	rs2854903	ENSG00000280323.1	AC053503.12	-11.14	1.16e-25	1.6e-22	-0.38	-0.46	Resting heart rate;	chr2:219424257	chr2:219427477~219429319:+
PRAD	cis	rs2739330	0.796	rs5760106	ENSG00000250470.1	AP000351.3	-11.14	1.16e-25	1.6e-22	-0.63	-0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23976904~23977585:-
PRAD	cis	rs9545047	0.735	rs314690	ENSG00000227676.3	LINC01068	11.14	1.18e-25	1.62e-22	0.59	0.46	Schizophrenia;	chr13:79434822	chr13:79566727~79571436:+
PRAD	cis	rs34779708	0.931	rs58159560	ENSG00000230534.5	RP11-297A16.2	11.14	1.18e-25	1.62e-22	0.63	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35062321	chr10:35098006~35127020:-
PRAD	cis	rs73086581	0.592	rs6037702	ENSG00000229539.1	RP11-119B16.2	-11.14	1.18e-25	1.62e-22	-0.63	-0.46	Response to antidepressants in depression;	chr20:3955745	chr20:3888239~3888868:-
PRAD	cis	rs11676348	0.935	rs2230054	ENSG00000261338.2	RP11-378A13.1	-11.14	1.18e-25	1.63e-22	-0.52	-0.46	Ulcerative colitis;	chr2:218135587	chr2:218255319~218257366:+
PRAD	cis	rs12130219	0.5	rs4845737	ENSG00000237975.5	FLG-AS1	-11.14	1.19e-25	1.63e-22	-0.66	-0.46	Inflammatory skin disease;	chr1:152205063	chr1:152168125~152445456:+
PRAD	cis	rs8062405	0.755	rs56209193	ENSG00000259982.1	CDC37P1	11.14	1.19e-25	1.64e-22	0.61	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574315	chr16:28700294~28701540:-
PRAD	cis	rs2019137	0.936	rs3828189	ENSG00000189223.12	PAX8-AS1	11.14	1.21e-25	1.66e-22	0.57	0.46	Lymphocyte counts;	chr2:113196919	chr2:113211522~113276581:+
PRAD	cis	rs9545047	0.716	rs7327386	ENSG00000227676.3	LINC01068	11.14	1.21e-25	1.66e-22	0.56	0.46	Schizophrenia;	chr13:79347901	chr13:79566727~79571436:+
PRAD	cis	rs6991838	0.55	rs4737750	ENSG00000272010.1	CTD-3025N20.3	11.14	1.21e-25	1.67e-22	0.48	0.46	Intelligence (multi-trait analysis);	chr8:65638724	chr8:65591850~65592472:-
PRAD	cis	rs2282300	0.739	rs7926465	ENSG00000254532.1	RP11-624D11.2	-11.14	1.22e-25	1.67e-22	-0.67	-0.46	Morning vs. evening chronotype;	chr11:30311469	chr11:30044058~30084343:-
PRAD	cis	rs7208859	0.562	rs216408	ENSG00000263531.1	RP13-753N3.1	-11.14	1.22e-25	1.68e-22	-0.78	-0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30580739	chr17:30863921~30864940:-
PRAD	cis	rs2658782	0.901	rs10466368	ENSG00000279684.1	RP11-755E23.2	-11.14	1.23e-25	1.69e-22	-0.79	-0.46	Pulmonary function decline;	chr11:93496590	chr11:93286629~93288903:-
PRAD	cis	rs2019137	0.967	rs902695	ENSG00000189223.12	PAX8-AS1	11.14	1.24e-25	1.7e-22	0.57	0.46	Lymphocyte counts;	chr2:113197497	chr2:113211522~113276581:+
PRAD	cis	rs765787	0.53	rs7167389	ENSG00000259520.4	CTD-2651B20.3	11.13	1.24e-25	1.71e-22	0.57	0.46	Uric acid levels;	chr15:45243485	chr15:45251580~45279251:-
PRAD	cis	rs748404	0.69	rs2244981	ENSG00000205771.5	CATSPER2P1	-11.13	1.25e-25	1.72e-22	-0.51	-0.46	Lung cancer;	chr15:43460553	chr15:43726918~43747094:-
PRAD	cis	rs34779708	0.931	rs4934524	ENSG00000230534.5	RP11-297A16.2	11.13	1.26e-25	1.73e-22	0.62	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:34981993	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.931	rs4934693	ENSG00000230534.5	RP11-297A16.2	11.13	1.26e-25	1.73e-22	0.62	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:34982916	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.931	rs11592404	ENSG00000230534.5	RP11-297A16.2	11.13	1.26e-25	1.73e-22	0.62	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:34984548	chr10:35098006~35127020:-
PRAD	cis	rs7772486	0.79	rs9485024	ENSG00000235652.6	RP11-545I5.3	-11.13	1.26e-25	1.73e-22	-0.47	-0.46	Lobe attachment (rater-scored or self-reported);	chr6:145821351	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.738	rs2246334	ENSG00000235652.6	RP11-545I5.3	11.13	1.27e-25	1.74e-22	0.47	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145862499	chr6:145799409~145886585:+
PRAD	cis	rs11690935	0.595	rs788170	ENSG00000228389.1	AC068039.4	-11.13	1.28e-25	1.75e-22	-0.52	-0.46	Schizophrenia;	chr2:172055230	chr2:171773482~171775844:+
PRAD	cis	rs780096	0.526	rs7602534	ENSG00000234072.1	AC074117.10	-11.13	1.28e-25	1.75e-22	-0.37	-0.46	Total body bone mineral density;	chr2:27369556	chr2:27356246~27367622:+
PRAD	cis	rs2933343	0.951	rs789217	ENSG00000231305.3	RP11-723O4.2	11.13	1.28e-25	1.76e-22	0.47	0.46	IgG glycosylation;	chr3:128874358	chr3:128861313~128871540:-
PRAD	cis	rs12049351	0.943	rs6687883	ENSG00000229367.1	HMGN2P19	-11.13	1.29e-25	1.77e-22	-0.67	-0.46	Circulating myeloperoxidase levels (plasma);	chr1:229582109	chr1:229570532~229570796:+
PRAD	cis	rs3096299	0.503	rs9940093	ENSG00000274627.1	RP11-104N10.2	11.13	1.31e-25	1.79e-22	0.46	0.46	Multiple myeloma (IgH translocation);	chr16:89492297	chr16:89516797~89522217:+
PRAD	cis	rs11123170	0.569	rs1049137	ENSG00000189223.12	PAX8-AS1	-11.13	1.31e-25	1.79e-22	-0.71	-0.46	Renal function-related traits (BUN);	chr2:113217533	chr2:113211522~113276581:+
PRAD	cis	rs7044106	0.762	rs10818471	ENSG00000226752.6	PSMD5-AS1	-11.13	1.31e-25	1.8e-22	-0.58	-0.46	Hip circumference adjusted for BMI;	chr9:120631767	chr9:120824828~120854385:+
PRAD	cis	rs9326248	0.861	rs7931335	ENSG00000280143.1	AP000892.6	11.13	1.32e-25	1.8e-22	0.44	0.46	Blood protein levels;	chr11:117166089	chr11:117204967~117210292:+
PRAD	cis	rs11690935	0.61	rs59844139	ENSG00000228389.1	AC068039.4	-11.13	1.32e-25	1.81e-22	-0.52	-0.46	Schizophrenia;	chr2:171875473	chr2:171773482~171775844:+
PRAD	cis	rs11690935	0.595	rs788171	ENSG00000228389.1	AC068039.4	-11.13	1.32e-25	1.81e-22	-0.51	-0.46	Schizophrenia;	chr2:172057104	chr2:171773482~171775844:+
PRAD	cis	rs8062405	1	rs55991577	ENSG00000251417.2	RP11-1348G14.4	-11.13	1.33e-25	1.82e-22	-0.52	-0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831704	chr16:28802743~28817828:+
PRAD	cis	rs8062405	1	rs56358680	ENSG00000251417.2	RP11-1348G14.4	-11.13	1.33e-25	1.82e-22	-0.52	-0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831797	chr16:28802743~28817828:+
PRAD	cis	rs9545047	0.644	rs9318624	ENSG00000227676.3	LINC01068	11.13	1.33e-25	1.83e-22	0.56	0.46	Schizophrenia;	chr13:79350915	chr13:79566727~79571436:+
PRAD	cis	rs7615952	0.932	rs13065725	ENSG00000171084.14	FAM86JP	11.13	1.33e-25	1.83e-22	0.82	0.46	Blood pressure (smoking interaction);	chr3:125913446	chr3:125916620~125930024:+
PRAD	cis	rs853679	0.517	rs9380056	ENSG00000280107.1	AL022393.9	-11.13	1.33e-25	1.83e-22	-0.6	-0.46	Depression;	chr6:28136698	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs9380057	ENSG00000280107.1	AL022393.9	-11.13	1.33e-25	1.83e-22	-0.6	-0.46	Depression;	chr6:28136856	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs1947862	ENSG00000280107.1	AL022393.9	-11.13	1.33e-25	1.83e-22	-0.6	-0.46	Depression;	chr6:28137418	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs6941992	ENSG00000280107.1	AL022393.9	-11.13	1.33e-25	1.83e-22	-0.6	-0.46	Depression;	chr6:28138363	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.516	rs4713142	ENSG00000280107.1	AL022393.9	-11.13	1.33e-25	1.83e-22	-0.6	-0.46	Parkinson's disease;	chr6:28138569	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs4713143	ENSG00000280107.1	AL022393.9	-11.13	1.33e-25	1.83e-22	-0.6	-0.46	Depression;	chr6:28138981	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs4713144	ENSG00000280107.1	AL022393.9	-11.13	1.33e-25	1.83e-22	-0.6	-0.46	Depression;	chr6:28139012	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs3757187	ENSG00000280107.1	AL022393.9	-11.13	1.33e-25	1.83e-22	-0.6	-0.46	Depression;	chr6:28139876	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs3757185	ENSG00000280107.1	AL022393.9	-11.13	1.33e-25	1.83e-22	-0.6	-0.46	Depression;	chr6:28139998	chr6:28170845~28172521:+
PRAD	cis	rs2564921	0.73	rs2253675	ENSG00000242142.1	SERBP1P3	-11.13	1.35e-25	1.84e-22	-0.52	-0.46	Height;	chr3:53085518	chr3:53064283~53065091:-
PRAD	cis	rs2739330	0.828	rs5760099	ENSG00000250470.1	AP000351.3	11.13	1.35e-25	1.84e-22	0.63	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23976904~23977585:-
PRAD	cis	rs34779708	0.658	rs4934715	ENSG00000230534.5	RP11-297A16.2	11.13	1.35e-25	1.85e-22	0.61	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35076064	chr10:35098006~35127020:-
PRAD	cis	rs7044106	0.762	rs1547268	ENSG00000226752.6	PSMD5-AS1	-11.13	1.35e-25	1.85e-22	-0.58	-0.46	Hip circumference adjusted for BMI;	chr9:120646410	chr9:120824828~120854385:+
PRAD	cis	rs7044106	0.762	rs1547267	ENSG00000226752.6	PSMD5-AS1	-11.13	1.35e-25	1.85e-22	-0.58	-0.46	Hip circumference adjusted for BMI;	chr9:120646458	chr9:120824828~120854385:+
PRAD	cis	rs7044106	0.762	rs4142158	ENSG00000226752.6	PSMD5-AS1	-11.13	1.35e-25	1.85e-22	-0.58	-0.46	Hip circumference adjusted for BMI;	chr9:120648541	chr9:120824828~120854385:+
PRAD	cis	rs2282300	0.739	rs1222216	ENSG00000254532.1	RP11-624D11.2	11.12	1.36e-25	1.86e-22	0.67	0.46	Morning vs. evening chronotype;	chr11:30324505	chr11:30044058~30084343:-
PRAD	cis	rs1577917	0.958	rs12213343	ENSG00000203875.9	SNHG5	-11.12	1.36e-25	1.86e-22	-0.53	-0.46	Response to antipsychotic treatment;	chr6:85733301	chr6:85660950~85678736:-
PRAD	cis	rs9326248	0.861	rs7120309	ENSG00000280143.1	AP000892.6	11.12	1.37e-25	1.87e-22	0.45	0.46	Blood protein levels;	chr11:117172100	chr11:117204967~117210292:+
PRAD	cis	rs9326248	0.861	rs7120449	ENSG00000280143.1	AP000892.6	11.12	1.37e-25	1.87e-22	0.45	0.46	Blood protein levels;	chr11:117172183	chr11:117204967~117210292:+
PRAD	cis	rs2019137	0.836	rs4848318	ENSG00000189223.12	PAX8-AS1	11.12	1.38e-25	1.88e-22	0.57	0.46	Lymphocyte counts;	chr2:113196375	chr2:113211522~113276581:+
PRAD	cis	rs2019137	0.936	rs2241978	ENSG00000189223.12	PAX8-AS1	11.12	1.38e-25	1.88e-22	0.57	0.46	Lymphocyte counts;	chr2:113196429	chr2:113211522~113276581:+
PRAD	cis	rs2019137	0.936	rs3828188	ENSG00000189223.12	PAX8-AS1	11.12	1.38e-25	1.88e-22	0.57	0.46	Lymphocyte counts;	chr2:113196670	chr2:113211522~113276581:+
PRAD	cis	rs8062405	1	rs4451951	ENSG00000251417.2	RP11-1348G14.4	-11.12	1.39e-25	1.9e-22	-0.51	-0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28824884	chr16:28802743~28817828:+
PRAD	cis	rs9326248	0.861	rs4938348	ENSG00000280143.1	AP000892.6	11.12	1.4e-25	1.91e-22	0.45	0.46	Blood protein levels;	chr11:117151161	chr11:117204967~117210292:+
PRAD	cis	rs9326248	0.861	rs4938353	ENSG00000280143.1	AP000892.6	11.12	1.4e-25	1.91e-22	0.44	0.46	Blood protein levels;	chr11:117175481	chr11:117204967~117210292:+
PRAD	cis	rs1976403	0.633	rs1697422	ENSG00000227001.3	NBPF2P	11.12	1.4e-25	1.92e-22	0.55	0.46	Liver enzyme levels (alkaline phosphatase);	chr1:21495404	chr1:21424625~21427967:-
PRAD	cis	rs9322193	0.923	rs9377230	ENSG00000216906.2	RP11-350J20.9	11.12	1.41e-25	1.92e-22	0.53	0.46	Lung cancer;	chr6:149613607	chr6:149904243~149906418:+
PRAD	cis	rs10853057	0.541	rs11656396	ENSG00000214174.7	AMZ2P1	11.12	1.42e-25	1.94e-22	0.69	0.46	White matter microstructure (global fractional anisotropy);	chr17:65049958	chr17:64966550~64975576:-
PRAD	cis	rs1075265	0.528	rs2018747	ENSG00000233266.1	HMGB1P31	11.12	1.43e-25	1.95e-22	0.61	0.46	Chronotype;Morning vs. evening chronotype;	chr2:54082487	chr2:54051334~54051760:+
PRAD	cis	rs2404602	0.647	rs62026889	ENSG00000259422.1	RP11-593F23.1	-11.12	1.44e-25	1.96e-22	-0.61	-0.46	Blood metabolite levels;	chr15:76625544	chr15:76174891~76181486:-
PRAD	cis	rs1577917	0.958	rs1337843	ENSG00000203875.9	SNHG5	-11.12	1.44e-25	1.96e-22	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85965827	chr6:85660950~85678736:-
PRAD	cis	rs9322193	0.607	rs12209310	ENSG00000223701.3	RAET1E-AS1	11.12	1.44e-25	1.96e-22	0.71	0.46	Lung cancer;	chr6:149904882	chr6:149884431~149919508:+
PRAD	cis	rs7727544	0.684	rs274567	ENSG00000233006.5	AC034220.3	-11.12	1.45e-25	1.97e-22	-0.41	-0.46	Blood metabolite levels;	chr5:132378717	chr5:132311285~132369916:-
PRAD	cis	rs853679	0.517	rs9468297	ENSG00000280107.1	AL022393.9	-11.12	1.45e-25	1.97e-22	-0.6	-0.46	Depression;	chr6:28151096	chr6:28170845~28172521:+
PRAD	cis	rs1062177	0.826	rs2915822	ENSG00000213433.5	RPLP1P6	11.12	1.46e-25	1.99e-22	0.54	0.46	Preschool internalizing problems;	chr5:151751340	chr5:151765859~151766378:-
PRAD	cis	rs6570726	0.577	rs9497315	ENSG00000235652.6	RP11-545I5.3	-11.12	1.48e-25	2.01e-22	-0.52	-0.46	Lobe attachment (rater-scored or self-reported);	chr6:145470831	chr6:145799409~145886585:+
PRAD	cis	rs780094	0.544	rs780110	ENSG00000234072.1	AC074117.10	-11.11	1.49e-25	2.03e-22	-0.36	-0.46	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27462521	chr2:27356246~27367622:+
PRAD	cis	rs8062405	1	rs62036617	ENSG00000251417.2	RP11-1348G14.4	-11.11	1.49e-25	2.03e-22	-0.51	-0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28816177	chr16:28802743~28817828:+
PRAD	cis	rs8062405	1	rs4788095	ENSG00000251417.2	RP11-1348G14.4	-11.11	1.49e-25	2.03e-22	-0.51	-0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28820038	chr16:28802743~28817828:+
PRAD	cis	rs8062405	0.964	rs72793809	ENSG00000251417.2	RP11-1348G14.4	-11.11	1.49e-25	2.03e-22	-0.51	-0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821061	chr16:28802743~28817828:+
PRAD	cis	rs8062405	1	rs62036620	ENSG00000251417.2	RP11-1348G14.4	-11.11	1.49e-25	2.03e-22	-0.51	-0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821776	chr16:28802743~28817828:+
PRAD	cis	rs8062405	1	rs62036621	ENSG00000251417.2	RP11-1348G14.4	-11.11	1.49e-25	2.03e-22	-0.51	-0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821978	chr16:28802743~28817828:+
PRAD	cis	rs2404602	0.569	rs2469249	ENSG00000259422.1	RP11-593F23.1	-11.11	1.51e-25	2.05e-22	-0.6	-0.46	Blood metabolite levels;	chr15:76479721	chr15:76174891~76181486:-
PRAD	cis	rs6504950	0.889	rs2628305	ENSG00000275710.1	RP11-257O5.4	11.11	1.52e-25	2.07e-22	0.6	0.46	Breast cancer;	chr17:55063066	chr17:54964474~54964679:+
PRAD	cis	rs7714584	1	rs17800987	ENSG00000197083.10	ZNF300P1	11.11	1.52e-25	2.07e-22	0.77	0.46	Crohn's disease;	chr5:150943866	chr5:150930645~150946289:-
PRAD	cis	rs9545047	0.716	rs9545108	ENSG00000227676.3	LINC01068	11.11	1.52e-25	2.07e-22	0.57	0.46	Schizophrenia;	chr13:79411175	chr13:79566727~79571436:+
PRAD	cis	rs9322193	0.923	rs9688861	ENSG00000216906.2	RP11-350J20.9	11.11	1.52e-25	2.07e-22	0.53	0.46	Lung cancer;	chr6:149637924	chr6:149904243~149906418:+
PRAD	cis	rs780096	0.527	rs59644396	ENSG00000234072.1	AC074117.10	-11.11	1.53e-25	2.08e-22	-0.36	-0.46	Total body bone mineral density;	chr2:27423216	chr2:27356246~27367622:+
PRAD	cis	rs1577917	1	rs13196930	ENSG00000203875.9	SNHG5	-11.11	1.53e-25	2.08e-22	-0.54	-0.46	Response to antipsychotic treatment;	chr6:85942527	chr6:85660950~85678736:-
PRAD	cis	rs2404602	0.622	rs1567671	ENSG00000259422.1	RP11-593F23.1	-11.11	1.54e-25	2.1e-22	-0.63	-0.46	Blood metabolite levels;	chr15:76916859	chr15:76174891~76181486:-
PRAD	cis	rs9595066	1	rs7981575	ENSG00000227258.4	SMIM2-AS1	11.11	1.55e-25	2.11e-22	0.84	0.46	Schizophrenia;	chr13:44136811	chr13:44110451~44240517:+
PRAD	cis	rs34779708	0.931	rs67976880	ENSG00000230534.5	RP11-297A16.2	11.11	1.55e-25	2.11e-22	0.63	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35083333	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.931	rs72789687	ENSG00000230534.5	RP11-297A16.2	11.11	1.55e-25	2.11e-22	0.63	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35083561	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.931	rs35997236	ENSG00000230534.5	RP11-297A16.2	11.11	1.55e-25	2.11e-22	0.63	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35087762	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.931	rs4934719	ENSG00000230534.5	RP11-297A16.2	11.11	1.55e-25	2.11e-22	0.63	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35087841	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.931	rs4934720	ENSG00000230534.5	RP11-297A16.2	11.11	1.55e-25	2.11e-22	0.63	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35087872	chr10:35098006~35127020:-
PRAD	cis	rs1577917	1	rs10498958	ENSG00000203875.9	SNHG5	11.11	1.56e-25	2.12e-22	0.53	0.46	Response to antipsychotic treatment;	chr6:85939987	chr6:85660950~85678736:-
PRAD	cis	rs9322193	0.886	rs2065663	ENSG00000268592.3	RAET1E-AS1	11.11	1.56e-25	2.12e-22	0.63	0.46	Lung cancer;	chr6:149760331	chr6:149863494~149919507:+
PRAD	cis	rs34779708	0.966	rs35079558	ENSG00000230534.5	RP11-297A16.2	11.11	1.56e-25	2.12e-22	0.62	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35190958	chr10:35098006~35127020:-
PRAD	cis	rs9326248	0.53	rs10750101	ENSG00000254851.1	RP11-109L13.1	-11.11	1.57e-25	2.14e-22	-0.98	-0.46	Blood protein levels;	chr11:117108973	chr11:117135528~117138582:+
PRAD	cis	rs1150668	0.83	rs2023493	ENSG00000216901.1	AL022393.7	11.11	1.58e-25	2.14e-22	0.59	0.46	Pubertal anthropometrics;	chr6:28432385	chr6:28176188~28176674:+
PRAD	cis	rs4964805	0.641	rs11111755	ENSG00000257681.1	RP11-341G23.4	11.11	1.58e-25	2.15e-22	0.43	0.46	Attention deficit hyperactivity disorder;	chr12:103765889	chr12:103746315~103768858:-
PRAD	cis	rs4964805	0.641	rs10861094	ENSG00000257681.1	RP11-341G23.4	11.11	1.58e-25	2.15e-22	0.43	0.46	Attention deficit hyperactivity disorder;	chr12:103765938	chr12:103746315~103768858:-
PRAD	cis	rs9322193	0.923	rs4870529	ENSG00000216906.2	RP11-350J20.9	11.11	1.6e-25	2.18e-22	0.53	0.46	Lung cancer;	chr6:149716436	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.923	rs9767309	ENSG00000216906.2	RP11-350J20.9	11.11	1.6e-25	2.18e-22	0.53	0.46	Lung cancer;	chr6:149716807	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.923	rs17745062	ENSG00000216906.2	RP11-350J20.9	11.11	1.6e-25	2.18e-22	0.53	0.46	Lung cancer;	chr6:149721079	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.923	rs62441279	ENSG00000216906.2	RP11-350J20.9	11.11	1.6e-25	2.18e-22	0.53	0.46	Lung cancer;	chr6:149721194	chr6:149904243~149906418:+
PRAD	cis	rs780096	0.587	rs1049817	ENSG00000234072.1	AC074117.10	-11.11	1.6e-25	2.18e-22	-0.37	-0.46	Total body bone mineral density;	chr2:27328100	chr2:27356246~27367622:+
PRAD	cis	rs2658782	0.901	rs2605611	ENSG00000279684.1	RP11-755E23.2	-11.11	1.61e-25	2.18e-22	-0.78	-0.46	Pulmonary function decline;	chr11:93496153	chr11:93286629~93288903:-
PRAD	cis	rs9322193	0.923	rs35830138	ENSG00000216906.2	RP11-350J20.9	11.11	1.61e-25	2.19e-22	0.53	0.46	Lung cancer;	chr6:149668635	chr6:149904243~149906418:+
PRAD	cis	rs11673344	0.966	rs56330606	ENSG00000226686.6	LINC01535	11.1	1.63e-25	2.21e-22	0.64	0.46	Obesity-related traits;	chr19:37183051	chr19:37251912~37265535:+
PRAD	cis	rs2455601	0.786	rs2568070	ENSG00000254860.4	TMEM9B-AS1	11.1	1.63e-25	2.21e-22	0.53	0.46	Schizophrenia;	chr11:8955346	chr11:8964675~8977527:+
PRAD	cis	rs10875746	0.951	rs8804	ENSG00000240399.1	RP1-228P16.1	-11.1	1.63e-25	2.21e-22	-0.46	-0.46	Longevity (90 years and older);	chr12:48147974	chr12:48054813~48055591:-
PRAD	cis	rs2282300	0.739	rs1222215	ENSG00000254532.1	RP11-624D11.2	11.1	1.63e-25	2.22e-22	0.67	0.46	Morning vs. evening chronotype;	chr11:30326049	chr11:30044058~30084343:-
PRAD	cis	rs2282300	0.696	rs1222214	ENSG00000254532.1	RP11-624D11.2	11.1	1.63e-25	2.22e-22	0.67	0.46	Morning vs. evening chronotype;	chr11:30326148	chr11:30044058~30084343:-
PRAD	cis	rs1976403	0.633	rs1780324	ENSG00000227001.3	NBPF2P	11.1	1.64e-25	2.23e-22	0.55	0.46	Liver enzyme levels (alkaline phosphatase);	chr1:21495264	chr1:21424625~21427967:-
PRAD	cis	rs34779708	0.931	rs11593858	ENSG00000230534.5	RP11-297A16.2	11.1	1.65e-25	2.23e-22	0.63	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35092445	chr10:35098006~35127020:-
PRAD	cis	rs11673344	0.864	rs7260386	ENSG00000226686.6	LINC01535	11.1	1.65e-25	2.24e-22	0.63	0.46	Obesity-related traits;	chr19:37158656	chr19:37251912~37265535:+
PRAD	cis	rs7044106	0.762	rs7357638	ENSG00000226752.6	PSMD5-AS1	-11.1	1.66e-25	2.25e-22	-0.58	-0.46	Hip circumference adjusted for BMI;	chr9:120626926	chr9:120824828~120854385:+
PRAD	cis	rs7044106	0.718	rs1960421	ENSG00000226752.6	PSMD5-AS1	-11.1	1.66e-25	2.25e-22	-0.58	-0.46	Hip circumference adjusted for BMI;	chr9:120632616	chr9:120824828~120854385:+
PRAD	cis	rs13392177	0.672	rs1877715	ENSG00000261338.2	RP11-378A13.1	11.1	1.67e-25	2.26e-22	0.51	0.46	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218187823	chr2:218255319~218257366:+
PRAD	cis	rs1577917	1	rs2324843	ENSG00000203875.9	SNHG5	-11.1	1.67e-25	2.27e-22	-0.54	-0.46	Response to antipsychotic treatment;	chr6:85907783	chr6:85660950~85678736:-
PRAD	cis	rs2933343	0.951	rs7648327	ENSG00000231305.3	RP11-723O4.2	11.1	1.69e-25	2.28e-22	0.46	0.46	IgG glycosylation;	chr3:128851865	chr3:128861313~128871540:-
PRAD	cis	rs9545047	0.716	rs8002838	ENSG00000227676.3	LINC01068	11.1	1.69e-25	2.29e-22	0.57	0.46	Schizophrenia;	chr13:79421681	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.669	rs9545113	ENSG00000227676.3	LINC01068	11.1	1.69e-25	2.29e-22	0.57	0.46	Schizophrenia;	chr13:79422017	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.68	rs9545114	ENSG00000227676.3	LINC01068	11.1	1.69e-25	2.29e-22	0.57	0.46	Schizophrenia;	chr13:79423744	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.716	rs586219	ENSG00000227676.3	LINC01068	-11.1	1.69e-25	2.29e-22	-0.57	-0.46	Schizophrenia;	chr13:79425177	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.716	rs2265377	ENSG00000227676.3	LINC01068	-11.1	1.69e-25	2.29e-22	-0.57	-0.46	Schizophrenia;	chr13:79425485	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.716	rs2265378	ENSG00000227676.3	LINC01068	-11.1	1.69e-25	2.29e-22	-0.57	-0.46	Schizophrenia;	chr13:79425581	chr13:79566727~79571436:+
PRAD	cis	rs11690935	0.595	rs788166	ENSG00000228389.1	AC068039.4	-11.1	1.7e-25	2.3e-22	-0.52	-0.46	Schizophrenia;	chr2:172050761	chr2:171773482~171775844:+
PRAD	cis	rs1577917	0.958	rs2324840	ENSG00000203875.9	SNHG5	-11.1	1.7e-25	2.31e-22	-0.52	-0.46	Response to antipsychotic treatment;	chr6:85847902	chr6:85660950~85678736:-
PRAD	cis	rs7044106	0.762	rs10760107	ENSG00000226752.6	PSMD5-AS1	-11.1	1.7e-25	2.31e-22	-0.58	-0.46	Hip circumference adjusted for BMI;	chr9:120621352	chr9:120824828~120854385:+
PRAD	cis	rs9545047	0.669	rs2095477	ENSG00000227676.3	LINC01068	-11.1	1.71e-25	2.32e-22	-0.57	-0.46	Schizophrenia;	chr13:79427869	chr13:79566727~79571436:+
PRAD	cis	rs1150668	0.796	rs1124132	ENSG00000216901.1	AL022393.7	11.1	1.71e-25	2.32e-22	0.58	0.46	Pubertal anthropometrics;	chr6:28412544	chr6:28176188~28176674:+
PRAD	cis	rs1150668	0.796	rs2531832	ENSG00000216901.1	AL022393.7	11.1	1.71e-25	2.32e-22	0.58	0.46	Pubertal anthropometrics;	chr6:28421445	chr6:28176188~28176674:+
PRAD	cis	rs7772486	0.754	rs4896839	ENSG00000235652.6	RP11-545I5.3	-11.1	1.72e-25	2.32e-22	-0.47	-0.46	Lobe attachment (rater-scored or self-reported);	chr6:145698553	chr6:145799409~145886585:+
PRAD	cis	rs11690935	0.655	rs1028127	ENSG00000228389.1	AC068039.4	-11.1	1.72e-25	2.33e-22	-0.53	-0.46	Schizophrenia;	chr2:171673526	chr2:171773482~171775844:+
PRAD	cis	rs11690935	0.632	rs12998411	ENSG00000228389.1	AC068039.4	-11.1	1.72e-25	2.33e-22	-0.53	-0.46	Schizophrenia;	chr2:171674197	chr2:171773482~171775844:+
PRAD	cis	rs9322193	0.962	rs7740784	ENSG00000268592.3	RAET1E-AS1	11.1	1.72e-25	2.33e-22	0.63	0.46	Lung cancer;	chr6:149833364	chr6:149863494~149919507:+
PRAD	cis	rs1577917	0.958	rs13213899	ENSG00000203875.9	SNHG5	-11.1	1.73e-25	2.34e-22	-0.56	-0.46	Response to antipsychotic treatment;	chr6:85763422	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.958	rs10806337	ENSG00000203875.9	SNHG5	-11.1	1.73e-25	2.34e-22	-0.56	-0.46	Response to antipsychotic treatment;	chr6:85764531	chr6:85660950~85678736:-
PRAD	cis	rs9322193	0.847	rs62439808	ENSG00000216906.2	RP11-350J20.9	11.1	1.73e-25	2.34e-22	0.53	0.46	Lung cancer;	chr6:149629690	chr6:149904243~149906418:+
PRAD	cis	rs2739330	0.828	rs4822451	ENSG00000250470.1	AP000351.3	11.1	1.75e-25	2.37e-22	0.63	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23976904~23977585:-
PRAD	cis	rs9322193	0.923	rs35961297	ENSG00000216906.2	RP11-350J20.9	11.1	1.75e-25	2.37e-22	0.53	0.46	Lung cancer;	chr6:149667929	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.923	rs35967444	ENSG00000216906.2	RP11-350J20.9	11.1	1.75e-25	2.37e-22	0.53	0.46	Lung cancer;	chr6:149675588	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.923	rs62439842	ENSG00000216906.2	RP11-350J20.9	11.1	1.75e-25	2.37e-22	0.53	0.46	Lung cancer;	chr6:149675847	chr6:149904243~149906418:+
PRAD	cis	rs2282300	0.739	rs1717772	ENSG00000254532.1	RP11-624D11.2	11.1	1.75e-25	2.37e-22	0.66	0.46	Morning vs. evening chronotype;	chr11:30318586	chr11:30044058~30084343:-
PRAD	cis	rs2404602	0.735	rs2048856	ENSG00000259422.1	RP11-593F23.1	-11.09	1.77e-25	2.39e-22	-0.6	-0.46	Blood metabolite levels;	chr15:76507742	chr15:76174891~76181486:-
PRAD	cis	rs875971	0.798	rs57739047	ENSG00000237310.1	GS1-124K5.4	11.09	1.77e-25	2.4e-22	0.42	0.46	Aortic root size;	chr7:66507579	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.83	rs6950137	ENSG00000237310.1	GS1-124K5.4	11.09	1.77e-25	2.4e-22	0.42	0.46	Aortic root size;	chr7:66511623	chr7:66493706~66495474:+
PRAD	cis	rs4964805	0.594	rs11111759	ENSG00000257681.1	RP11-341G23.4	11.09	1.78e-25	2.41e-22	0.43	0.46	Attention deficit hyperactivity disorder;	chr12:103769405	chr12:103746315~103768858:-
PRAD	cis	rs1577917	0.958	rs11752180	ENSG00000203875.9	SNHG5	-11.09	1.8e-25	2.44e-22	-0.52	-0.46	Response to antipsychotic treatment;	chr6:85863447	chr6:85660950~85678736:-
PRAD	cis	rs34779708	0.897	rs7897827	ENSG00000230534.5	RP11-297A16.2	11.09	1.82e-25	2.45e-22	0.61	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35097309	chr10:35098006~35127020:-
PRAD	cis	rs9322193	0.923	rs4870267	ENSG00000216906.2	RP11-350J20.9	11.09	1.82e-25	2.46e-22	0.53	0.46	Lung cancer;	chr6:149671572	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.923	rs9767123	ENSG00000216906.2	RP11-350J20.9	11.09	1.82e-25	2.47e-22	0.53	0.46	Lung cancer;	chr6:149660323	chr6:149904243~149906418:+
PRAD	cis	rs34779708	0.931	rs34087268	ENSG00000230534.5	RP11-297A16.2	11.09	1.85e-25	2.5e-22	0.62	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35057796	chr10:35098006~35127020:-
PRAD	cis	rs748404	0.66	rs2602141	ENSG00000205771.5	CATSPER2P1	-11.09	1.87e-25	2.52e-22	-0.51	-0.46	Lung cancer;	chr15:43432448	chr15:43726918~43747094:-
PRAD	cis	rs2665103	0.589	rs3858953	ENSG00000278603.1	RP13-608F4.5	11.09	1.9e-25	2.56e-22	0.57	0.46	Intelligence (multi-trait analysis);	chr15:82238049	chr15:82472203~82472426:+
PRAD	cis	rs4964805	0.594	rs3751204	ENSG00000257681.1	RP11-341G23.4	11.09	1.91e-25	2.58e-22	0.43	0.46	Attention deficit hyperactivity disorder;	chr12:103777677	chr12:103746315~103768858:-
PRAD	cis	rs748404	0.66	rs690472	ENSG00000205771.5	CATSPER2P1	-11.09	1.92e-25	2.59e-22	-0.51	-0.46	Lung cancer;	chr15:43472170	chr15:43726918~43747094:-
PRAD	cis	rs9322193	0.961	rs2064520	ENSG00000268592.3	RAET1E-AS1	11.09	1.92e-25	2.6e-22	0.63	0.46	Lung cancer;	chr6:149603650	chr6:149863494~149919507:+
PRAD	cis	rs7688540	0.511	rs10003260	ENSG00000275426.1	CH17-262A2.1	11.09	1.93e-25	2.6e-22	0.73	0.46	Facial morphology (factor 6, height of vermillion lower lip);	chr4:191053	chr4:149738~150317:+
PRAD	cis	rs875971	0.862	rs6460307	ENSG00000237310.1	GS1-124K5.4	11.08	1.93e-25	2.6e-22	0.42	0.46	Aortic root size;	chr7:66595884	chr7:66493706~66495474:+
PRAD	cis	rs780096	0.526	rs780117	ENSG00000234072.1	AC074117.10	-11.08	1.94e-25	2.61e-22	-0.37	-0.46	Total body bone mineral density;	chr2:27475476	chr2:27356246~27367622:+
PRAD	cis	rs6061231	0.837	rs6121558	ENSG00000273619.1	RP5-908M14.9	-11.08	1.95e-25	2.62e-22	-0.33	-0.46	Colorectal cancer;	chr20:62386309	chr20:62386303~62386970:-
PRAD	cis	rs1577917	1	rs10455455	ENSG00000203875.9	SNHG5	-11.08	1.95e-25	2.62e-22	-0.53	-0.46	Response to antipsychotic treatment;	chr6:85960496	chr6:85660950~85678736:-
PRAD	cis	rs780096	0.526	rs12476704	ENSG00000234072.1	AC074117.10	-11.08	1.95e-25	2.62e-22	-0.36	-0.46	Total body bone mineral density;	chr2:27390164	chr2:27356246~27367622:+
PRAD	cis	rs6570726	0.577	rs441982	ENSG00000235652.6	RP11-545I5.3	11.08	1.95e-25	2.62e-22	0.52	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145521712	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.577	rs403345	ENSG00000235652.6	RP11-545I5.3	11.08	1.95e-25	2.62e-22	0.52	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145524035	chr6:145799409~145886585:+
PRAD	cis	rs150992	0.886	rs161948	ENSG00000248489.1	CTD-2007H13.3	11.08	1.96e-25	2.64e-22	0.52	0.46	Body mass index;	chr5:98932333	chr5:98929171~98995013:+
PRAD	cis	rs4964805	0.58	rs10861097	ENSG00000257681.1	RP11-341G23.4	11.08	1.97e-25	2.65e-22	0.43	0.46	Attention deficit hyperactivity disorder;	chr12:103776696	chr12:103746315~103768858:-
PRAD	cis	rs11123170	0.529	rs35606997	ENSG00000189223.12	PAX8-AS1	-11.08	1.97e-25	2.66e-22	-0.69	-0.46	Renal function-related traits (BUN);	chr2:113215773	chr2:113211522~113276581:+
PRAD	cis	rs4814920	0.756	rs6046400	ENSG00000275142.1	RP5-999L4.2	-11.08	1.97e-25	2.66e-22	-0.78	-0.46	Bipolar disorder (body mass index interaction);	chr20:19878482	chr20:19871891~19872284:+
PRAD	cis	rs34779708	0.966	rs10827493	ENSG00000230534.5	RP11-297A16.2	11.08	2e-25	2.69e-22	0.61	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35166048	chr10:35098006~35127020:-
PRAD	cis	rs2282300	0.739	rs1222219	ENSG00000254532.1	RP11-624D11.2	11.08	2e-25	2.69e-22	0.67	0.46	Morning vs. evening chronotype;	chr11:30322798	chr11:30044058~30084343:-
PRAD	cis	rs7727544	0.735	rs272860	ENSG00000233006.5	AC034220.3	11.08	2e-25	2.69e-22	0.42	0.46	Blood metabolite levels;	chr5:132348482	chr5:132311285~132369916:-
PRAD	cis	rs9322193	0.884	rs10782312	ENSG00000216906.2	RP11-350J20.9	11.08	2.01e-25	2.7e-22	0.53	0.46	Lung cancer;	chr6:149622669	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.886	rs9322198	ENSG00000216906.2	RP11-350J20.9	11.08	2.01e-25	2.7e-22	0.53	0.46	Lung cancer;	chr6:149623772	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.923	rs9689599	ENSG00000216906.2	RP11-350J20.9	11.08	2.01e-25	2.7e-22	0.53	0.46	Lung cancer;	chr6:149631973	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.923	rs9800580	ENSG00000216906.2	RP11-350J20.9	11.08	2.01e-25	2.7e-22	0.53	0.46	Lung cancer;	chr6:149632845	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.884	rs11155669	ENSG00000216906.2	RP11-350J20.9	11.08	2.01e-25	2.7e-22	0.53	0.46	Lung cancer;	chr6:149633501	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.887	rs9505824	ENSG00000216906.2	RP11-350J20.9	11.08	2.01e-25	2.7e-22	0.53	0.46	Lung cancer;	chr6:149633663	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.923	rs9766886	ENSG00000216906.2	RP11-350J20.9	11.08	2.01e-25	2.7e-22	0.53	0.46	Lung cancer;	chr6:149637048	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.923	rs7740278	ENSG00000216906.2	RP11-350J20.9	11.08	2.01e-25	2.7e-22	0.53	0.46	Lung cancer;	chr6:149640116	chr6:149904243~149906418:+
PRAD	cis	rs34779708	0.966	rs34630580	ENSG00000230534.5	RP11-297A16.2	11.08	2.03e-25	2.73e-22	0.62	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35160300	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.931	rs35126129	ENSG00000230534.5	RP11-297A16.2	11.08	2.03e-25	2.73e-22	0.62	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35163213	chr10:35098006~35127020:-
PRAD	cis	rs1062177	0.756	rs2915826	ENSG00000213433.5	RPLP1P6	11.08	2.03e-25	2.74e-22	0.53	0.46	Preschool internalizing problems;	chr5:151740402	chr5:151765859~151766378:-
PRAD	cis	rs1062177	0.756	rs2964587	ENSG00000213433.5	RPLP1P6	11.08	2.03e-25	2.74e-22	0.53	0.46	Preschool internalizing problems;	chr5:151740411	chr5:151765859~151766378:-
PRAD	cis	rs6570726	0.599	rs455001	ENSG00000235652.6	RP11-545I5.3	11.08	2.05e-25	2.76e-22	0.52	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145533314	chr6:145799409~145886585:+
PRAD	cis	rs34779708	0.833	rs12777517	ENSG00000230534.5	RP11-297A16.2	11.08	2.05e-25	2.76e-22	0.62	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35184999	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.897	rs34481177	ENSG00000230534.5	RP11-297A16.2	11.08	2.06e-25	2.77e-22	0.63	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35091985	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.931	rs4934723	ENSG00000230534.5	RP11-297A16.2	11.08	2.06e-25	2.77e-22	0.63	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35092835	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.931	rs72789690	ENSG00000230534.5	RP11-297A16.2	11.08	2.06e-25	2.77e-22	0.63	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35093889	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.931	rs68039650	ENSG00000230534.5	RP11-297A16.2	11.08	2.06e-25	2.77e-22	0.63	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35096571	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.931	rs35136660	ENSG00000230534.5	RP11-297A16.2	11.08	2.06e-25	2.77e-22	0.63	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35097045	chr10:35098006~35127020:-
PRAD	cis	rs853679	0.517	rs4713141	ENSG00000280107.1	AL022393.9	-11.08	2.08e-25	2.79e-22	-0.6	-0.46	Depression;	chr6:28133900	chr6:28170845~28172521:+
PRAD	cis	rs7617773	0.539	rs2017858	ENSG00000229759.1	MRPS18AP1	11.08	2.08e-25	2.8e-22	0.49	0.46	Coronary artery disease;	chr3:48340792	chr3:48256350~48256938:-
PRAD	cis	rs2739330	0.929	rs5751775	ENSG00000272787.1	KB-226F1.2	-11.08	2.1e-25	2.83e-22	-0.5	-0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23969211~23969873:+
PRAD	cis	rs9322193	0.923	rs9767554	ENSG00000216906.2	RP11-350J20.9	11.07	2.13e-25	2.86e-22	0.53	0.46	Lung cancer;	chr6:149616860	chr6:149904243~149906418:+
PRAD	cis	rs853679	0.517	rs9393884	ENSG00000280107.1	AL022393.9	-11.07	2.14e-25	2.87e-22	-0.6	-0.46	Depression;	chr6:28079011	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs9393887	ENSG00000280107.1	AL022393.9	-11.07	2.14e-25	2.87e-22	-0.6	-0.46	Depression;	chr6:28091242	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.542	rs9393892	ENSG00000280107.1	AL022393.9	-11.07	2.14e-25	2.87e-22	-0.6	-0.46	Depression;	chr6:28113616	chr6:28170845~28172521:+
PRAD	cis	rs2283792	0.715	rs55891647	ENSG00000224086.5	LL22NC03-86G7.1	-11.07	2.15e-25	2.89e-22	-0.55	-0.46	Multiple sclerosis;	chr22:21824198	chr22:21938293~21977632:+
PRAD	cis	rs8072100	1	rs4794048	ENSG00000228782.6	CTD-2026D20.3	11.07	2.17e-25	2.92e-22	0.51	0.46	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47685707	chr17:47450568~47492492:-
PRAD	cis	rs1577917	1	rs12200330	ENSG00000203875.9	SNHG5	-11.07	2.18e-25	2.93e-22	-0.53	-0.46	Response to antipsychotic treatment;	chr6:85946935	chr6:85660950~85678736:-
PRAD	cis	rs3096299	0.586	rs4572400	ENSG00000274627.1	RP11-104N10.2	11.07	2.21e-25	2.96e-22	0.46	0.46	Multiple myeloma (IgH translocation);	chr16:89467108	chr16:89516797~89522217:+
PRAD	cis	rs2739330	0.828	rs5751770	ENSG00000250470.1	AP000351.3	11.07	2.22e-25	2.98e-22	0.62	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23976904~23977585:-
PRAD	cis	rs2286503	0.65	rs1990279	ENSG00000228649.7	AC005682.5	11.07	2.22e-25	2.98e-22	0.53	0.46	Fibrinogen;	chr7:22851123	chr7:22854178~22861579:+
PRAD	cis	rs1577917	0.958	rs1335442	ENSG00000203875.9	SNHG5	-11.07	2.24e-25	3e-22	-0.55	-0.46	Response to antipsychotic treatment;	chr6:85756974	chr6:85660950~85678736:-
PRAD	cis	rs2658782	0.901	rs11601056	ENSG00000279684.1	RP11-755E23.2	11.07	2.24e-25	3.01e-22	0.8	0.46	Pulmonary function decline;	chr11:93495995	chr11:93286629~93288903:-
PRAD	cis	rs6570726	0.818	rs437147	ENSG00000235652.6	RP11-545I5.3	11.07	2.25e-25	3.02e-22	0.48	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145554287	chr6:145799409~145886585:+
PRAD	cis	rs5760092	0.618	rs4461358	ENSG00000231271.1	AP000350.8	-11.07	2.26e-25	3.03e-22	-0.7	-0.46	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23917919	chr22:23949918~23954042:+
PRAD	cis	rs4964805	0.594	rs4981036	ENSG00000257681.1	RP11-341G23.4	11.07	2.27e-25	3.04e-22	0.43	0.46	Attention deficit hyperactivity disorder;	chr12:103770566	chr12:103746315~103768858:-
PRAD	cis	rs12130219	0.5	rs1552991	ENSG00000237975.5	FLG-AS1	-11.07	2.27e-25	3.05e-22	-0.66	-0.46	Inflammatory skin disease;	chr1:152193402	chr1:152168125~152445456:+
PRAD	cis	rs2282300	0.739	rs34951229	ENSG00000254532.1	RP11-624D11.2	11.07	2.28e-25	3.05e-22	0.66	0.46	Morning vs. evening chronotype;	chr11:30243619	chr11:30044058~30084343:-
PRAD	cis	rs2282300	0.739	rs6484478	ENSG00000254532.1	RP11-624D11.2	-11.07	2.28e-25	3.05e-22	-0.67	-0.46	Morning vs. evening chronotype;	chr11:30284893	chr11:30044058~30084343:-
PRAD	cis	rs2282300	0.739	rs10742237	ENSG00000254532.1	RP11-624D11.2	-11.07	2.28e-25	3.05e-22	-0.67	-0.46	Morning vs. evening chronotype;	chr11:30289112	chr11:30044058~30084343:-
PRAD	cis	rs2282300	0.739	rs1933342	ENSG00000254532.1	RP11-624D11.2	-11.07	2.28e-25	3.05e-22	-0.67	-0.46	Morning vs. evening chronotype;	chr11:30291278	chr11:30044058~30084343:-
PRAD	cis	rs2282300	0.739	rs2225909	ENSG00000254532.1	RP11-624D11.2	-11.07	2.28e-25	3.05e-22	-0.67	-0.46	Morning vs. evening chronotype;	chr11:30308197	chr11:30044058~30084343:-
PRAD	cis	rs2282300	0.702	rs2211018	ENSG00000254532.1	RP11-624D11.2	-11.07	2.28e-25	3.05e-22	-0.67	-0.46	Morning vs. evening chronotype;	chr11:30308532	chr11:30044058~30084343:-
PRAD	cis	rs875971	0.545	rs73376394	ENSG00000237310.1	GS1-124K5.4	11.07	2.28e-25	3.06e-22	0.46	0.46	Aortic root size;	chr7:66172694	chr7:66493706~66495474:+
PRAD	cis	rs2929278	0.617	rs693919	ENSG00000249839.1	AC011330.5	11.07	2.3e-25	3.08e-22	0.58	0.46	Schizophrenia;	chr15:43810130	chr15:43663654~43684339:-
PRAD	cis	rs853679	0.517	rs12174753	ENSG00000280107.1	AL022393.9	-11.06	2.31e-25	3.09e-22	-0.6	-0.46	Depression;	chr6:28074687	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs55747925	ENSG00000280107.1	AL022393.9	-11.06	2.31e-25	3.09e-22	-0.6	-0.46	Depression;	chr6:28076559	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs56310871	ENSG00000280107.1	AL022393.9	-11.06	2.31e-25	3.09e-22	-0.6	-0.46	Depression;	chr6:28076704	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs34716816	ENSG00000280107.1	AL022393.9	-11.06	2.31e-25	3.09e-22	-0.6	-0.46	Depression;	chr6:28078391	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs9380049	ENSG00000280107.1	AL022393.9	-11.06	2.31e-25	3.09e-22	-0.6	-0.46	Depression;	chr6:28080757	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs9380050	ENSG00000280107.1	AL022393.9	-11.06	2.31e-25	3.09e-22	-0.6	-0.46	Depression;	chr6:28080760	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs9393885	ENSG00000280107.1	AL022393.9	-11.06	2.31e-25	3.09e-22	-0.6	-0.46	Depression;	chr6:28082231	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs9393886	ENSG00000280107.1	AL022393.9	-11.06	2.31e-25	3.09e-22	-0.6	-0.46	Depression;	chr6:28082261	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.515	rs9368549	ENSG00000280107.1	AL022393.9	-11.06	2.31e-25	3.09e-22	-0.6	-0.46	Parkinson's disease;	chr6:28082269	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs56364346	ENSG00000280107.1	AL022393.9	-11.06	2.31e-25	3.09e-22	-0.6	-0.46	Depression;	chr6:28082984	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs9357061	ENSG00000280107.1	AL022393.9	-11.06	2.31e-25	3.09e-22	-0.6	-0.46	Depression;	chr6:28083994	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs9368550	ENSG00000280107.1	AL022393.9	-11.06	2.31e-25	3.09e-22	-0.6	-0.46	Depression;	chr6:28084025	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.542	rs2295594	ENSG00000280107.1	AL022393.9	-11.06	2.31e-25	3.09e-22	-0.6	-0.46	Depression;	chr6:28085319	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs2273564	ENSG00000280107.1	AL022393.9	-11.06	2.31e-25	3.09e-22	-0.6	-0.46	Depression;	chr6:28089816	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs1853097	ENSG00000280107.1	AL022393.9	-11.06	2.31e-25	3.09e-22	-0.6	-0.46	Depression;	chr6:28090857	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs9393888	ENSG00000280107.1	AL022393.9	-11.06	2.31e-25	3.09e-22	-0.6	-0.46	Depression;	chr6:28091439	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs3734573	ENSG00000280107.1	AL022393.9	-11.06	2.31e-25	3.09e-22	-0.6	-0.46	Depression;	chr6:28091659	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs9357063	ENSG00000280107.1	AL022393.9	-11.06	2.31e-25	3.09e-22	-0.6	-0.46	Depression;	chr6:28092227	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs3823180	ENSG00000280107.1	AL022393.9	-11.06	2.31e-25	3.09e-22	-0.6	-0.46	Depression;	chr6:28093966	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs9368551	ENSG00000280107.1	AL022393.9	-11.06	2.31e-25	3.09e-22	-0.6	-0.46	Depression;	chr6:28094014	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs9393890	ENSG00000280107.1	AL022393.9	-11.06	2.31e-25	3.09e-22	-0.6	-0.46	Depression;	chr6:28096077	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs9366715	ENSG00000280107.1	AL022393.9	-11.06	2.31e-25	3.09e-22	-0.6	-0.46	Depression;	chr6:28096855	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.598	rs9380054	ENSG00000280107.1	AL022393.9	-11.06	2.31e-25	3.09e-22	-0.6	-0.46	Depression;	chr6:28099759	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.547	rs2116981	ENSG00000280107.1	AL022393.9	-11.06	2.31e-25	3.09e-22	-0.6	-0.46	Parkinson's disease;	chr6:28100173	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs9368552	ENSG00000280107.1	AL022393.9	-11.06	2.31e-25	3.09e-22	-0.6	-0.46	Depression;	chr6:28100648	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs2281588	ENSG00000280107.1	AL022393.9	-11.06	2.31e-25	3.09e-22	-0.6	-0.46	Depression;	chr6:28104824	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.542	rs34131763	ENSG00000280107.1	AL022393.9	-11.06	2.31e-25	3.09e-22	-0.6	-0.46	Depression;	chr6:28107222	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs35193936	ENSG00000280107.1	AL022393.9	-11.06	2.31e-25	3.09e-22	-0.6	-0.46	Depression;	chr6:28108492	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs36078605	ENSG00000280107.1	AL022393.9	-11.06	2.31e-25	3.09e-22	-0.6	-0.46	Depression;	chr6:28110254	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs9393891	ENSG00000280107.1	AL022393.9	-11.06	2.31e-25	3.09e-22	-0.6	-0.46	Depression;	chr6:28111382	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs9468286	ENSG00000280107.1	AL022393.9	-11.06	2.31e-25	3.09e-22	-0.6	-0.46	Depression;	chr6:28111650	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.516	rs7739216	ENSG00000280107.1	AL022393.9	-11.06	2.31e-25	3.09e-22	-0.6	-0.46	Parkinson's disease;	chr6:28112168	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs35512245	ENSG00000280107.1	AL022393.9	-11.06	2.31e-25	3.09e-22	-0.6	-0.46	Depression;	chr6:28112175	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs9380055	ENSG00000280107.1	AL022393.9	-11.06	2.31e-25	3.09e-22	-0.6	-0.46	Depression;	chr6:28113851	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs9368553	ENSG00000280107.1	AL022393.9	-11.06	2.31e-25	3.09e-22	-0.6	-0.46	Depression;	chr6:28114487	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs9368554	ENSG00000280107.1	AL022393.9	-11.06	2.31e-25	3.09e-22	-0.6	-0.46	Depression;	chr6:28114933	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs4713137	ENSG00000280107.1	AL022393.9	-11.06	2.31e-25	3.09e-22	-0.6	-0.46	Depression;	chr6:28115743	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs9348793	ENSG00000280107.1	AL022393.9	-11.06	2.31e-25	3.09e-22	-0.6	-0.46	Depression;	chr6:28116411	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.586	rs6905516	ENSG00000280107.1	AL022393.9	-11.06	2.31e-25	3.09e-22	-0.6	-0.46	Parkinson's disease;	chr6:28118700	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.586	rs6905522	ENSG00000280107.1	AL022393.9	-11.06	2.31e-25	3.09e-22	-0.6	-0.46	Parkinson's disease;	chr6:28118701	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.586	rs9468290	ENSG00000280107.1	AL022393.9	-11.06	2.31e-25	3.09e-22	-0.6	-0.46	Parkinson's disease;	chr6:28119896	chr6:28170845~28172521:+
PRAD	cis	rs673078	0.66	rs17619932	ENSG00000275759.1	RP11-131L12.3	-11.06	2.32e-25	3.1e-22	-0.63	-0.46	Glucose homeostasis traits;	chr12:118352228	chr12:118428281~118428870:+
PRAD	cis	rs853679	0.517	rs4713145	ENSG00000280107.1	AL022393.9	-11.06	2.32e-25	3.11e-22	-0.59	-0.46	Depression;	chr6:28139049	chr6:28170845~28172521:+
PRAD	cis	rs7772486	0.754	rs10872580	ENSG00000235652.6	RP11-545I5.3	-11.06	2.33e-25	3.11e-22	-0.47	-0.46	Lobe attachment (rater-scored or self-reported);	chr6:145819145	chr6:145799409~145886585:+
PRAD	cis	rs2404602	0.647	rs11072626	ENSG00000259422.1	RP11-593F23.1	-11.06	2.33e-25	3.11e-22	-0.61	-0.46	Blood metabolite levels;	chr15:76798485	chr15:76174891~76181486:-
PRAD	cis	rs34779708	0.9	rs73262807	ENSG00000230534.5	RP11-297A16.2	11.06	2.33e-25	3.12e-22	0.61	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35207458	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.966	rs17591781	ENSG00000230534.5	RP11-297A16.2	11.06	2.33e-25	3.12e-22	0.61	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35209610	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.966	rs17591857	ENSG00000230534.5	RP11-297A16.2	-11.06	2.33e-25	3.12e-22	-0.61	-0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35210115	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.931	rs11010125	ENSG00000230534.5	RP11-297A16.2	11.06	2.33e-25	3.12e-22	0.61	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35214025	chr10:35098006~35127020:-
PRAD	cis	rs2404602	0.583	rs2469542	ENSG00000259422.1	RP11-593F23.1	-11.06	2.35e-25	3.13e-22	-0.55	-0.46	Blood metabolite levels;	chr15:76265135	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.583	rs2456076	ENSG00000259422.1	RP11-593F23.1	-11.06	2.35e-25	3.13e-22	-0.55	-0.46	Blood metabolite levels;	chr15:76265212	chr15:76174891~76181486:-
PRAD	cis	rs4845570	0.749	rs11576810	ENSG00000249602.1	RP11-98D18.3	11.06	2.35e-25	3.14e-22	0.77	0.46	Coronary artery disease;	chr1:151739725	chr1:151763384~151769501:-
PRAD	cis	rs2282300	0.653	rs12800124	ENSG00000254532.1	RP11-624D11.2	11.06	2.39e-25	3.19e-22	0.67	0.46	Morning vs. evening chronotype;	chr11:30218318	chr11:30044058~30084343:-
PRAD	cis	rs2282300	0.739	rs34224414	ENSG00000254532.1	RP11-624D11.2	11.06	2.39e-25	3.19e-22	0.67	0.46	Morning vs. evening chronotype;	chr11:30229494	chr11:30044058~30084343:-
PRAD	cis	rs2282300	0.739	rs12577729	ENSG00000254532.1	RP11-624D11.2	11.06	2.39e-25	3.19e-22	0.67	0.46	Morning vs. evening chronotype;	chr11:30235830	chr11:30044058~30084343:-
PRAD	cis	rs2282300	0.739	rs34044331	ENSG00000254532.1	RP11-624D11.2	11.06	2.39e-25	3.19e-22	0.67	0.46	Morning vs. evening chronotype;	chr11:30242939	chr11:30044058~30084343:-
PRAD	cis	rs2282300	0.667	rs10734405	ENSG00000254532.1	RP11-624D11.2	-11.06	2.39e-25	3.19e-22	-0.67	-0.46	Morning vs. evening chronotype;	chr11:30252203	chr11:30044058~30084343:-
PRAD	cis	rs780094	0.564	rs4665978	ENSG00000234072.1	AC074117.10	-11.06	2.43e-25	3.24e-22	-0.36	-0.46	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27425859	chr2:27356246~27367622:+
PRAD	cis	rs4964805	0.594	rs751448	ENSG00000257681.1	RP11-341G23.4	11.06	2.43e-25	3.24e-22	0.43	0.46	Attention deficit hyperactivity disorder;	chr12:103773407	chr12:103746315~103768858:-
PRAD	cis	rs9322193	0.923	rs10782310	ENSG00000216906.2	RP11-350J20.9	11.06	2.44e-25	3.26e-22	0.53	0.46	Lung cancer;	chr6:149622458	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.923	rs10782311	ENSG00000216906.2	RP11-350J20.9	11.06	2.44e-25	3.26e-22	0.53	0.46	Lung cancer;	chr6:149622592	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.923	rs9322200	ENSG00000216906.2	RP11-350J20.9	11.06	2.44e-25	3.26e-22	0.53	0.46	Lung cancer;	chr6:149630078	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.923	rs9322204	ENSG00000216906.2	RP11-350J20.9	11.06	2.44e-25	3.26e-22	0.53	0.46	Lung cancer;	chr6:149636047	chr6:149904243~149906418:+
PRAD	cis	rs1150668	0.799	rs7206	ENSG00000204709.4	LINC01556	11.06	2.45e-25	3.27e-22	0.59	0.46	Pubertal anthropometrics;	chr6:28233360	chr6:28943877~28944537:+
PRAD	cis	rs55879323	1	rs55879323	ENSG00000237975.5	FLG-AS1	-11.06	2.45e-25	3.27e-22	-0.66	-0.46	Inflammatory skin disease;	chr1:152196264	chr1:152168125~152445456:+
PRAD	cis	rs1577917	0.958	rs12205492	ENSG00000203875.9	SNHG5	-11.06	2.46e-25	3.28e-22	-0.56	-0.46	Response to antipsychotic treatment;	chr6:85766258	chr6:85660950~85678736:-
PRAD	cis	rs9545047	0.645	rs9635027	ENSG00000227676.3	LINC01068	11.06	2.49e-25	3.33e-22	0.56	0.46	Schizophrenia;	chr13:79295538	chr13:79566727~79571436:+
PRAD	cis	rs2282300	0.653	rs67745574	ENSG00000254532.1	RP11-624D11.2	11.06	2.51e-25	3.34e-22	0.67	0.46	Morning vs. evening chronotype;	chr11:30213292	chr11:30044058~30084343:-
PRAD	cis	rs11123170	0.529	rs112692022	ENSG00000189223.12	PAX8-AS1	-11.05	2.52e-25	3.35e-22	-0.69	-0.46	Renal function-related traits (BUN);	chr2:113212605	chr2:113211522~113276581:+
PRAD	cis	rs673078	0.571	rs7954330	ENSG00000275759.1	RP11-131L12.3	-11.05	2.52e-25	3.35e-22	-0.74	-0.46	Glucose homeostasis traits;	chr12:118275284	chr12:118428281~118428870:+
PRAD	cis	rs780094	0.544	rs2303370	ENSG00000234072.1	AC074117.10	-11.05	2.52e-25	3.36e-22	-0.36	-0.46	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27428508	chr2:27356246~27367622:+
PRAD	cis	rs34779708	0.966	rs4934540	ENSG00000230534.5	RP11-297A16.2	11.05	2.53e-25	3.37e-22	0.61	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35185771	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.966	rs1478463	ENSG00000230534.5	RP11-297A16.2	11.05	2.54e-25	3.39e-22	0.6	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35184107	chr10:35098006~35127020:-
PRAD	cis	rs1075265	0.547	rs6741891	ENSG00000233266.1	HMGB1P31	11.05	2.55e-25	3.4e-22	0.61	0.46	Chronotype;Morning vs. evening chronotype;	chr2:54088529	chr2:54051334~54051760:+
PRAD	cis	rs7044106	0.762	rs7024046	ENSG00000226752.6	PSMD5-AS1	-11.05	2.57e-25	3.42e-22	-0.57	-0.46	Hip circumference adjusted for BMI;	chr9:120656900	chr9:120824828~120854385:+
PRAD	cis	rs34375054	0.738	rs3751181	ENSG00000279233.1	RP11-158L12.4	11.05	2.57e-25	3.42e-22	0.41	0.46	Post bronchodilator FEV1/FVC ratio;	chr12:125141989	chr12:125138245~125141711:+
PRAD	cis	rs11673344	0.801	rs112263309	ENSG00000226686.6	LINC01535	11.05	2.58e-25	3.43e-22	0.63	0.46	Obesity-related traits;	chr19:37160333	chr19:37251912~37265535:+
PRAD	cis	rs12049351	0.665	rs10916491	ENSG00000229367.1	HMGN2P19	11.05	2.59e-25	3.45e-22	0.68	0.46	Circulating myeloperoxidase levels (plasma);	chr1:229492923	chr1:229570532~229570796:+
PRAD	cis	rs1577917	1	rs35385043	ENSG00000203875.9	SNHG5	-11.05	2.61e-25	3.48e-22	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85938828	chr6:85660950~85678736:-
PRAD	cis	rs1577917	1	rs35760725	ENSG00000203875.9	SNHG5	-11.05	2.61e-25	3.48e-22	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85939267	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.958	rs2660576	ENSG00000203875.9	SNHG5	-11.05	2.61e-25	3.48e-22	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85941885	chr6:85660950~85678736:-
PRAD	cis	rs1577917	1	rs6914463	ENSG00000203875.9	SNHG5	-11.05	2.61e-25	3.48e-22	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85943697	chr6:85660950~85678736:-
PRAD	cis	rs75422866	0.867	rs75568526	ENSG00000257433.4	RP1-197B17.3	11.05	2.62e-25	3.49e-22	1	0.46	Pneumonia;	chr12:47649718	chr12:47706085~47742294:+
PRAD	cis	rs75422866	0.867	rs116302411	ENSG00000257433.4	RP1-197B17.3	11.05	2.62e-25	3.49e-22	1	0.46	Pneumonia;	chr12:47649788	chr12:47706085~47742294:+
PRAD	cis	rs1062177	0.826	rs1549920	ENSG00000213433.5	RPLP1P6	-11.05	2.62e-25	3.49e-22	-0.54	-0.46	Preschool internalizing problems;	chr5:151761283	chr5:151765859~151766378:-
PRAD	cis	rs34779708	0.966	rs17500582	ENSG00000230534.5	RP11-297A16.2	11.05	2.63e-25	3.5e-22	0.61	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35209860	chr10:35098006~35127020:-
PRAD	cis	rs11673344	0.931	rs1234251	ENSG00000226686.6	LINC01535	11.05	2.64e-25	3.51e-22	0.64	0.46	Obesity-related traits;	chr19:37180354	chr19:37251912~37265535:+
PRAD	cis	rs7727544	0.684	rs2516788	ENSG00000233006.5	AC034220.3	-11.05	2.64e-25	3.52e-22	-0.41	-0.46	Blood metabolite levels;	chr5:132379873	chr5:132311285~132369916:-
PRAD	cis	rs7727544	0.66	rs274563	ENSG00000233006.5	AC034220.3	-11.05	2.64e-25	3.52e-22	-0.41	-0.46	Blood metabolite levels;	chr5:132382167	chr5:132311285~132369916:-
PRAD	cis	rs9326248	0.652	rs7128382	ENSG00000280143.1	AP000892.6	11.05	2.65e-25	3.53e-22	0.45	0.46	Blood protein levels;	chr11:117152771	chr11:117204967~117210292:+
PRAD	cis	rs6570726	0.791	rs383841	ENSG00000235652.6	RP11-545I5.3	-11.05	2.7e-25	3.58e-22	-0.48	-0.46	Lobe attachment (rater-scored or self-reported);	chr6:145567193	chr6:145799409~145886585:+
PRAD	cis	rs780096	0.526	rs13472	ENSG00000234072.1	AC074117.10	-11.04	2.75e-25	3.65e-22	-0.36	-0.46	Total body bone mineral density;	chr2:27377372	chr2:27356246~27367622:+
PRAD	cis	rs34375054	0.66	rs58624919	ENSG00000279233.1	RP11-158L12.4	11.04	2.76e-25	3.66e-22	0.46	0.46	Post bronchodilator FEV1/FVC ratio;	chr12:125111912	chr12:125138245~125141711:+
PRAD	cis	rs34779708	0.897	rs12764820	ENSG00000230534.5	RP11-297A16.2	11.04	2.77e-25	3.68e-22	0.62	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35097393	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.931	rs67261877	ENSG00000230534.5	RP11-297A16.2	11.04	2.77e-25	3.68e-22	0.62	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35097412	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.931	rs12768019	ENSG00000230534.5	RP11-297A16.2	11.04	2.77e-25	3.68e-22	0.62	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35100915	chr10:35098006~35127020:-
PRAD	cis	rs9322193	0.651	rs9322188	ENSG00000223701.3	RAET1E-AS1	-11.04	2.77e-25	3.68e-22	-0.62	-0.46	Lung cancer;	chr6:149588355	chr6:149884431~149919508:+
PRAD	cis	rs8072100	0.79	rs34200664	ENSG00000228782.6	CTD-2026D20.3	-11.04	2.78e-25	3.69e-22	-0.5	-0.46	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47667286	chr17:47450568~47492492:-
PRAD	cis	rs7772486	0.754	rs697053	ENSG00000235652.6	RP11-545I5.3	-11.04	2.79e-25	3.7e-22	-0.47	-0.46	Lobe attachment (rater-scored or self-reported);	chr6:145668671	chr6:145799409~145886585:+
PRAD	cis	rs9545047	0.716	rs9545053	ENSG00000227676.3	LINC01068	11.04	2.8e-25	3.72e-22	0.56	0.46	Schizophrenia;	chr13:79296079	chr13:79566727~79571436:+
PRAD	cis	rs9322193	0.923	rs9505826	ENSG00000216906.2	RP11-350J20.9	11.04	2.81e-25	3.73e-22	0.53	0.46	Lung cancer;	chr6:149633912	chr6:149904243~149906418:+
PRAD	cis	rs7240205	0.816	rs2019480	ENSG00000275805.1	RP11-349H17.2	11.04	2.82e-25	3.74e-22	0.57	0.46	Breast cancer;	chr18:26545720	chr18:26565723~26575626:-
PRAD	cis	rs765787	0.53	rs2554453	ENSG00000259520.4	CTD-2651B20.3	11.04	2.83e-25	3.75e-22	0.57	0.46	Uric acid levels;	chr15:45229909	chr15:45251580~45279251:-
PRAD	cis	rs765787	0.53	rs11858988	ENSG00000259520.4	CTD-2651B20.3	11.04	2.83e-25	3.75e-22	0.57	0.46	Uric acid levels;	chr15:45229916	chr15:45251580~45279251:-
PRAD	cis	rs765787	0.53	rs11855435	ENSG00000259520.4	CTD-2651B20.3	11.04	2.83e-25	3.75e-22	0.57	0.46	Uric acid levels;	chr15:45229919	chr15:45251580~45279251:-
PRAD	cis	rs765787	0.53	rs2458224	ENSG00000259520.4	CTD-2651B20.3	11.04	2.83e-25	3.75e-22	0.57	0.46	Uric acid levels;	chr15:45229932	chr15:45251580~45279251:-
PRAD	cis	rs2404602	0.647	rs11072607	ENSG00000259422.1	RP11-593F23.1	-11.04	2.83e-25	3.76e-22	-0.6	-0.46	Blood metabolite levels;	chr15:76616188	chr15:76174891~76181486:-
PRAD	cis	rs1150668	0.799	rs1150707	ENSG00000204709.4	LINC01556	11.04	2.86e-25	3.79e-22	0.58	0.46	Pubertal anthropometrics;	chr6:28229827	chr6:28943877~28944537:+
PRAD	cis	rs875971	0.651	rs2420596	ENSG00000237310.1	GS1-124K5.4	11.04	2.87e-25	3.8e-22	0.42	0.46	Aortic root size;	chr7:66450996	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.52	rs2420597	ENSG00000237310.1	GS1-124K5.4	11.04	2.87e-25	3.8e-22	0.42	0.46	Aortic root size;	chr7:66450999	chr7:66493706~66495474:+
PRAD	cis	rs6570726	0.738	rs7746330	ENSG00000235652.6	RP11-545I5.3	11.04	2.87e-25	3.81e-22	0.48	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145578121	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.791	rs12208812	ENSG00000235652.6	RP11-545I5.3	11.04	2.87e-25	3.81e-22	0.48	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145579788	chr6:145799409~145886585:+
PRAD	cis	rs7044106	0.762	rs1158553	ENSG00000226752.6	PSMD5-AS1	-11.04	2.88e-25	3.81e-22	-0.57	-0.46	Hip circumference adjusted for BMI;	chr9:120638696	chr9:120824828~120854385:+
PRAD	cis	rs1577917	0.958	rs36042496	ENSG00000203875.9	SNHG5	-11.04	2.88e-25	3.82e-22	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85814496	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.917	rs1584273	ENSG00000203875.9	SNHG5	-11.04	2.88e-25	3.82e-22	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85814859	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.958	rs12198971	ENSG00000203875.9	SNHG5	-11.04	2.88e-25	3.82e-22	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85815727	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.958	rs34230196	ENSG00000203875.9	SNHG5	-11.04	2.88e-25	3.82e-22	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85816304	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.917	rs4707226	ENSG00000203875.9	SNHG5	-11.04	2.88e-25	3.82e-22	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85818110	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.876	rs12212808	ENSG00000203875.9	SNHG5	-11.04	2.88e-25	3.82e-22	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85824254	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.917	rs13213603	ENSG00000203875.9	SNHG5	-11.04	2.88e-25	3.82e-22	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85825040	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.958	rs2324839	ENSG00000203875.9	SNHG5	-11.04	2.88e-25	3.82e-22	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85827224	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.958	rs3900313	ENSG00000203875.9	SNHG5	-11.04	2.88e-25	3.82e-22	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85827436	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.652	rs75593931	ENSG00000203875.9	SNHG5	-11.04	2.9e-25	3.84e-22	-0.53	-0.46	Response to antipsychotic treatment;	chr6:86009821	chr6:85660950~85678736:-
PRAD	cis	rs765787	0.53	rs2413776	ENSG00000259520.4	CTD-2651B20.3	11.04	2.9e-25	3.85e-22	0.57	0.46	Uric acid levels;	chr15:45251972	chr15:45251580~45279251:-
PRAD	cis	rs34779708	0.966	rs12260130	ENSG00000230534.5	RP11-297A16.2	11.04	2.91e-25	3.85e-22	0.61	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35178743	chr10:35098006~35127020:-
PRAD	cis	rs7208859	0.673	rs216424	ENSG00000263531.1	RP13-753N3.1	11.04	2.91e-25	3.85e-22	0.8	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30616046	chr17:30863921~30864940:-
PRAD	cis	rs7044106	0.762	rs4837789	ENSG00000226752.6	PSMD5-AS1	-11.04	2.91e-25	3.85e-22	-0.57	-0.46	Hip circumference adjusted for BMI;	chr9:120663978	chr9:120824828~120854385:+
PRAD	cis	rs9322193	0.962	rs2342764	ENSG00000216906.2	RP11-350J20.9	11.04	2.92e-25	3.86e-22	0.52	0.46	Lung cancer;	chr6:149835068	chr6:149904243~149906418:+
PRAD	cis	rs2404602	0.647	rs7165053	ENSG00000259422.1	RP11-593F23.1	-11.04	2.93e-25	3.88e-22	-0.6	-0.46	Blood metabolite levels;	chr15:76686577	chr15:76174891~76181486:-
PRAD	cis	rs150992	0.742	rs34495	ENSG00000248489.1	CTD-2007H13.3	11.04	2.93e-25	3.88e-22	0.52	0.46	Body mass index;	chr5:98930103	chr5:98929171~98995013:+
PRAD	cis	rs2929278	0.617	rs575082	ENSG00000249839.1	AC011330.5	11.04	2.94e-25	3.89e-22	0.58	0.46	Schizophrenia;	chr15:43817944	chr15:43663654~43684339:-
PRAD	cis	rs853679	0.55	rs1150692	ENSG00000280107.1	AL022393.9	-11.04	2.97e-25	3.93e-22	-0.59	-0.46	Depression;	chr6:28206179	chr6:28170845~28172521:+
PRAD	cis	rs1577917	1	rs12192992	ENSG00000203875.9	SNHG5	-11.04	2.98e-25	3.94e-22	-0.53	-0.46	Response to antipsychotic treatment;	chr6:85900197	chr6:85660950~85678736:-
PRAD	cis	rs7772486	0.79	rs7742333	ENSG00000235652.6	RP11-545I5.3	-11.03	3e-25	3.97e-22	-0.46	-0.46	Lobe attachment (rater-scored or self-reported);	chr6:145837893	chr6:145799409~145886585:+
PRAD	cis	rs748404	0.66	rs690446	ENSG00000205771.5	CATSPER2P1	-11.03	3.01e-25	3.99e-22	-0.51	-0.46	Lung cancer;	chr15:43469066	chr15:43726918~43747094:-
PRAD	cis	rs748404	0.631	rs560191	ENSG00000205771.5	CATSPER2P1	-11.03	3.01e-25	3.99e-22	-0.51	-0.46	Lung cancer;	chr15:43475576	chr15:43726918~43747094:-
PRAD	cis	rs34779708	0.966	rs11010122	ENSG00000230534.5	RP11-297A16.2	11.03	3.05e-25	4.03e-22	0.6	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35204590	chr10:35098006~35127020:-
PRAD	cis	rs2455601	0.744	rs2568085	ENSG00000254860.4	TMEM9B-AS1	-11.03	3.06e-25	4.04e-22	-0.51	-0.46	Schizophrenia;	chr11:8954201	chr11:8964675~8977527:+
PRAD	cis	rs1577917	1	rs13199006	ENSG00000203875.9	SNHG5	-11.03	3.06e-25	4.05e-22	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85898990	chr6:85660950~85678736:-
PRAD	cis	rs1577917	1	rs7766645	ENSG00000203875.9	SNHG5	-11.03	3.06e-25	4.05e-22	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85912520	chr6:85660950~85678736:-
PRAD	cis	rs1577917	1	rs9647603	ENSG00000203875.9	SNHG5	-11.03	3.06e-25	4.05e-22	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85929623	chr6:85660950~85678736:-
PRAD	cis	rs9532669	0.926	rs11147831	ENSG00000176268.5	CYCSP34	11.03	3.07e-25	4.05e-22	0.48	0.46	Cervical cancer;	chr13:40978593	chr13:40863599~40863902:-
PRAD	cis	rs2404602	0.622	rs11632365	ENSG00000259422.1	RP11-593F23.1	-11.03	3.07e-25	4.05e-22	-0.65	-0.46	Blood metabolite levels;	chr15:76846739	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.608	rs12439484	ENSG00000259422.1	RP11-593F23.1	11.03	3.1e-25	4.1e-22	0.56	0.46	Blood metabolite levels;	chr15:76310596	chr15:76174891~76181486:-
PRAD	cis	rs6700559	0.873	rs7526031	ENSG00000260088.1	RP11-92G12.3	-11.03	3.12e-25	4.13e-22	-0.59	-0.46	Coronary artery disease;	chr1:200695174	chr1:200669507~200694250:+
PRAD	cis	rs9322193	0.923	rs10782317	ENSG00000216906.2	RP11-350J20.9	-11.03	3.13e-25	4.14e-22	-0.53	-0.46	Lung cancer;	chr6:149753911	chr6:149904243~149906418:+
PRAD	cis	rs780096	0.526	rs75855890	ENSG00000234072.1	AC074117.10	-11.03	3.14e-25	4.15e-22	-0.36	-0.46	Total body bone mineral density;	chr2:27402138	chr2:27356246~27367622:+
PRAD	cis	rs2442825	0.693	rs2728928	ENSG00000206573.7	THUMPD3-AS1	-11.03	3.16e-25	4.18e-22	-0.33	-0.46	Cerebrospinal fluid clusterin levels;	chr3:9388275	chr3:9349689~9398579:-
PRAD	cis	rs1075265	0.584	rs2357954	ENSG00000233266.1	HMGB1P31	11.03	3.17e-25	4.19e-22	0.62	0.46	Chronotype;Morning vs. evening chronotype;	chr2:54135300	chr2:54051334~54051760:+
PRAD	cis	rs10875746	0.903	rs11168414	ENSG00000240399.1	RP1-228P16.1	-11.03	3.17e-25	4.19e-22	-0.47	-0.46	Longevity (90 years and older);	chr12:48118548	chr12:48054813~48055591:-
PRAD	cis	rs34779708	0.931	rs12771399	ENSG00000230534.5	RP11-297A16.2	11.03	3.17e-25	4.19e-22	0.62	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35163449	chr10:35098006~35127020:-
PRAD	cis	rs7714584	1	rs11747065	ENSG00000197083.10	ZNF300P1	11.03	3.18e-25	4.19e-22	0.78	0.46	Crohn's disease;	chr5:150915924	chr5:150930645~150946289:-
PRAD	cis	rs7714584	1	rs11740172	ENSG00000197083.10	ZNF300P1	11.03	3.18e-25	4.19e-22	0.78	0.46	Crohn's disease;	chr5:150920716	chr5:150930645~150946289:-
PRAD	cis	rs7714584	1	rs12656600	ENSG00000197083.10	ZNF300P1	11.03	3.18e-25	4.19e-22	0.78	0.46	Crohn's disease;	chr5:150932310	chr5:150930645~150946289:-
PRAD	cis	rs34375054	0.66	rs57491100	ENSG00000279233.1	RP11-158L12.4	11.03	3.18e-25	4.2e-22	0.46	0.46	Post bronchodilator FEV1/FVC ratio;	chr12:125108464	chr12:125138245~125141711:+
PRAD	cis	rs34375054	0.66	rs57031290	ENSG00000279233.1	RP11-158L12.4	11.03	3.18e-25	4.2e-22	0.46	0.46	Post bronchodilator FEV1/FVC ratio;	chr12:125108507	chr12:125138245~125141711:+
PRAD	cis	rs9322193	0.923	rs9767652	ENSG00000216906.2	RP11-350J20.9	11.03	3.2e-25	4.22e-22	0.53	0.46	Lung cancer;	chr6:149734502	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.923	rs10782314	ENSG00000216906.2	RP11-350J20.9	11.03	3.2e-25	4.22e-22	0.53	0.46	Lung cancer;	chr6:149735527	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.962	rs3805752	ENSG00000216906.2	RP11-350J20.9	11.03	3.2e-25	4.22e-22	0.53	0.46	Lung cancer;	chr6:149795490	chr6:149904243~149906418:+
PRAD	cis	rs4423214	0.592	rs79634040	ENSG00000254682.1	RP11-660L16.2	-11.03	3.2e-25	4.23e-22	-0.74	-0.46	Vitamin D levels;	chr11:71519123	chr11:71448674~71452157:+
PRAD	cis	rs9322193	0.924	rs9322189	ENSG00000216906.2	RP11-350J20.9	11.03	3.26e-25	4.3e-22	0.54	0.46	Lung cancer;	chr6:149588797	chr6:149904243~149906418:+
PRAD	cis	rs1577917	0.958	rs12215265	ENSG00000203875.9	SNHG5	-11.02	3.27e-25	4.32e-22	-0.52	-0.46	Response to antipsychotic treatment;	chr6:85734251	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.958	rs12197463	ENSG00000203875.9	SNHG5	-11.02	3.27e-25	4.32e-22	-0.52	-0.46	Response to antipsychotic treatment;	chr6:85735524	chr6:85660950~85678736:-
PRAD	cis	rs2404602	0.622	rs11637296	ENSG00000259422.1	RP11-593F23.1	-11.02	3.3e-25	4.35e-22	-0.62	-0.46	Blood metabolite levels;	chr15:76915544	chr15:76174891~76181486:-
PRAD	cis	rs853679	0.517	rs9380047	ENSG00000280107.1	AL022393.9	-11.02	3.31e-25	4.37e-22	-0.59	-0.46	Depression;	chr6:28070115	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs7755442	ENSG00000280107.1	AL022393.9	-11.02	3.31e-25	4.37e-22	-0.59	-0.46	Depression;	chr6:28071237	chr6:28170845~28172521:+
PRAD	cis	rs7772486	0.754	rs9390356	ENSG00000235652.6	RP11-545I5.3	-11.02	3.32e-25	4.38e-22	-0.47	-0.46	Lobe attachment (rater-scored or self-reported);	chr6:145797847	chr6:145799409~145886585:+
PRAD	cis	rs853679	0.517	rs6922063	ENSG00000280107.1	AL022393.9	-11.02	3.32e-25	4.38e-22	-0.6	-0.46	Depression;	chr6:28126588	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs2275508	ENSG00000280107.1	AL022393.9	-11.02	3.32e-25	4.38e-22	-0.6	-0.46	Depression;	chr6:28126953	chr6:28170845~28172521:+
PRAD	cis	rs875971	0.798	rs6460304	ENSG00000237310.1	GS1-124K5.4	11.02	3.33e-25	4.39e-22	0.42	0.46	Aortic root size;	chr7:66499741	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.862	rs6945775	ENSG00000237310.1	GS1-124K5.4	11.02	3.33e-25	4.39e-22	0.42	0.46	Aortic root size;	chr7:66503987	chr7:66493706~66495474:+
PRAD	cis	rs7772486	0.754	rs6570718	ENSG00000235652.6	RP11-545I5.3	-11.02	3.35e-25	4.41e-22	-0.47	-0.46	Lobe attachment (rater-scored or self-reported);	chr6:145767307	chr6:145799409~145886585:+
PRAD	cis	rs9322193	0.923	rs4354168	ENSG00000216906.2	RP11-350J20.9	11.02	3.35e-25	4.42e-22	0.53	0.46	Lung cancer;	chr6:149696642	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.923	rs4455682	ENSG00000216906.2	RP11-350J20.9	11.02	3.35e-25	4.42e-22	0.53	0.46	Lung cancer;	chr6:149700161	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.886	rs9485408	ENSG00000216906.2	RP11-350J20.9	11.02	3.37e-25	4.44e-22	0.53	0.46	Lung cancer;	chr6:149618888	chr6:149904243~149906418:+
PRAD	cis	rs853679	0.517	rs12332979	ENSG00000280107.1	AL022393.9	-11.02	3.4e-25	4.47e-22	-0.6	-0.46	Depression;	chr6:28173770	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs67878650	ENSG00000280107.1	AL022393.9	-11.02	3.4e-25	4.47e-22	-0.6	-0.46	Depression;	chr6:28174809	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.569	rs9348798	ENSG00000280107.1	AL022393.9	-11.02	3.4e-25	4.47e-22	-0.6	-0.46	Depression;	chr6:28175233	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs9380065	ENSG00000280107.1	AL022393.9	-11.02	3.4e-25	4.47e-22	-0.6	-0.46	Depression;	chr6:28176973	chr6:28170845~28172521:+
PRAD	cis	rs1577917	0.917	rs35738006	ENSG00000203875.9	SNHG5	-11.02	3.47e-25	4.56e-22	-0.53	-0.46	Response to antipsychotic treatment;	chr6:85936591	chr6:85660950~85678736:-
PRAD	cis	rs8062405	0.824	rs7191618	ENSG00000259982.1	CDC37P1	11.02	3.49e-25	4.59e-22	0.59	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554346	chr16:28700294~28701540:-
PRAD	cis	rs8062405	0.754	rs3859172	ENSG00000259982.1	CDC37P1	11.02	3.49e-25	4.59e-22	0.59	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554837	chr16:28700294~28701540:-
PRAD	cis	rs10875746	0.855	rs10875730	ENSG00000240399.1	RP1-228P16.1	-11.02	3.49e-25	4.59e-22	-0.46	-0.46	Longevity (90 years and older);	chr12:48034092	chr12:48054813~48055591:-
PRAD	cis	rs35160687	0.814	rs7563887	ENSG00000273080.1	RP11-301O19.1	11.02	3.5e-25	4.6e-22	0.53	0.46	Night sleep phenotypes;	chr2:86288998	chr2:86195590~86196049:+
PRAD	cis	rs11690935	0.851	rs6433319	ENSG00000228389.1	AC068039.4	11.02	3.52e-25	4.63e-22	0.53	0.46	Schizophrenia;	chr2:171974442	chr2:171773482~171775844:+
PRAD	cis	rs7044106	0.762	rs12003646	ENSG00000226752.6	PSMD5-AS1	-11.02	3.54e-25	4.66e-22	-0.58	-0.46	Hip circumference adjusted for BMI;	chr9:120708343	chr9:120824828~120854385:+
PRAD	cis	rs7772486	0.558	rs7753273	ENSG00000235652.6	RP11-545I5.3	-11.02	3.55e-25	4.66e-22	-0.51	-0.46	Lobe attachment (rater-scored or self-reported);	chr6:145744903	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.59	rs1890170	ENSG00000235652.6	RP11-545I5.3	-11.02	3.55e-25	4.66e-22	-0.51	-0.46	Lobe attachment (rater-scored or self-reported);	chr6:145750703	chr6:145799409~145886585:+
PRAD	cis	rs780096	0.545	rs11695549	ENSG00000234072.1	AC074117.10	-11.02	3.55e-25	4.67e-22	-0.37	-0.46	Total body bone mineral density;	chr2:27363288	chr2:27356246~27367622:+
PRAD	cis	rs8062405	0.964	rs78613234	ENSG00000251417.2	RP11-1348G14.4	-11.01	3.58e-25	4.7e-22	-0.51	-0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828104	chr16:28802743~28817828:+
PRAD	cis	rs8062405	1	rs62036624	ENSG00000251417.2	RP11-1348G14.4	-11.01	3.58e-25	4.7e-22	-0.51	-0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828609	chr16:28802743~28817828:+
PRAD	cis	rs853679	0.542	rs6934769	ENSG00000280107.1	AL022393.9	-11.01	3.59e-25	4.71e-22	-0.59	-0.46	Depression;	chr6:28123153	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs17711801	ENSG00000280107.1	AL022393.9	-11.01	3.59e-25	4.71e-22	-0.59	-0.46	Depression;	chr6:28124529	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.527	rs9461433	ENSG00000280107.1	AL022393.9	-11.01	3.59e-25	4.71e-22	-0.59	-0.46	Parkinson's disease;	chr6:28127394	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs9468292	ENSG00000280107.1	AL022393.9	-11.01	3.59e-25	4.71e-22	-0.59	-0.46	Depression;	chr6:28127577	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs1947863	ENSG00000280107.1	AL022393.9	-11.01	3.59e-25	4.71e-22	-0.59	-0.46	Depression;	chr6:28131566	chr6:28170845~28172521:+
PRAD	cis	rs1577917	0.958	rs12216074	ENSG00000203875.9	SNHG5	-11.01	3.59e-25	4.72e-22	-0.52	-0.46	Response to antipsychotic treatment;	chr6:85810284	chr6:85660950~85678736:-
PRAD	cis	rs75422866	0.867	rs73113117	ENSG00000257433.4	RP1-197B17.3	11.01	3.6e-25	4.72e-22	1	0.46	Pneumonia;	chr12:47617299	chr12:47706085~47742294:+
PRAD	cis	rs75422866	0.867	rs73113143	ENSG00000257433.4	RP1-197B17.3	11.01	3.6e-25	4.72e-22	1	0.46	Pneumonia;	chr12:47623060	chr12:47706085~47742294:+
PRAD	cis	rs7772486	0.754	rs857881	ENSG00000235652.6	RP11-545I5.3	-11.01	3.6e-25	4.72e-22	-0.47	-0.46	Lobe attachment (rater-scored or self-reported);	chr6:145649657	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.727	rs6941429	ENSG00000235652.6	RP11-545I5.3	11.01	3.6e-25	4.72e-22	0.47	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145631147	chr6:145799409~145886585:+
PRAD	cis	rs200367988	1	rs200367988	ENSG00000271670.1	RP11-95I16.4	-11.01	3.6e-25	4.73e-22	-0.49	-0.46	Prostate-specific antigen levels (conditioned on lead SNPs);Prostate-specific antigen levels;	chr10:120915337	chr10:120879256~120880667:-
PRAD	cis	rs853679	0.517	rs17711344	ENSG00000280107.1	AL022393.9	11.01	3.61e-25	4.74e-22	0.6	0.46	Depression;	chr6:28109824	chr6:28170845~28172521:+
PRAD	cis	rs1075265	0.547	rs11125520	ENSG00000233266.1	HMGB1P31	11.01	3.63e-25	4.76e-22	0.6	0.46	Chronotype;Morning vs. evening chronotype;	chr2:54076696	chr2:54051334~54051760:+
PRAD	cis	rs748404	0.66	rs2467741	ENSG00000205771.5	CATSPER2P1	-11.01	3.65e-25	4.79e-22	-0.51	-0.46	Lung cancer;	chr15:43450428	chr15:43726918~43747094:-
PRAD	cis	rs9326248	0.813	rs7115562	ENSG00000280143.1	AP000892.6	11.01	3.65e-25	4.79e-22	0.45	0.46	Blood protein levels;	chr11:117149754	chr11:117204967~117210292:+
PRAD	cis	rs34779708	0.966	rs1545757	ENSG00000230534.5	RP11-297A16.2	11.01	3.66e-25	4.8e-22	0.62	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35156660	chr10:35098006~35127020:-
PRAD	cis	rs7617773	0.539	rs13087050	ENSG00000229759.1	MRPS18AP1	11.01	3.66e-25	4.81e-22	0.48	0.46	Coronary artery disease;	chr3:48351310	chr3:48256350~48256938:-
PRAD	cis	rs7772486	0.719	rs2206141	ENSG00000235652.6	RP11-545I5.3	-11.01	3.68e-25	4.82e-22	-0.47	-0.46	Lobe attachment (rater-scored or self-reported);	chr6:145765056	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.654	rs6906402	ENSG00000235652.6	RP11-545I5.3	-11.01	3.68e-25	4.82e-22	-0.47	-0.46	Lobe attachment (rater-scored or self-reported);	chr6:145768171	chr6:145799409~145886585:+
PRAD	cis	rs12439619	0.508	rs17354842	ENSG00000278603.1	RP13-608F4.5	-11.01	3.69e-25	4.84e-22	-0.6	-0.46	Intelligence (multi-trait analysis);	chr15:82177259	chr15:82472203~82472426:+
PRAD	cis	rs1577917	0.959	rs12201739	ENSG00000203875.9	SNHG5	-11.01	3.71e-25	4.86e-22	-0.53	-0.46	Response to antipsychotic treatment;	chr6:86011021	chr6:85660950~85678736:-
PRAD	cis	rs2086824	0.538	rs4785673	ENSG00000274627.1	RP11-104N10.2	11.01	3.72e-25	4.87e-22	0.45	0.46	Multiple myeloma (IgH translocation);	chr16:89470137	chr16:89516797~89522217:+
PRAD	cis	rs7044106	0.762	rs10760110	ENSG00000226752.6	PSMD5-AS1	11.01	3.74e-25	4.91e-22	0.57	0.46	Hip circumference adjusted for BMI;	chr9:120650285	chr9:120824828~120854385:+
PRAD	cis	rs9322193	0.923	rs9767105	ENSG00000216906.2	RP11-350J20.9	11.01	3.75e-25	4.91e-22	0.53	0.46	Lung cancer;	chr6:149659591	chr6:149904243~149906418:+
PRAD	cis	rs11105298	0.891	rs11105302	ENSG00000258302.2	RP11-981P6.1	-11.01	3.75e-25	4.91e-22	-0.49	-0.46	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89497589	chr12:89561129~89594878:+
PRAD	cis	rs2282300	0.739	rs35229181	ENSG00000254532.1	RP11-624D11.2	11.01	3.78e-25	4.95e-22	0.67	0.46	Morning vs. evening chronotype;	chr11:30220151	chr11:30044058~30084343:-
PRAD	cis	rs2282300	0.739	rs34234618	ENSG00000254532.1	RP11-624D11.2	11.01	3.78e-25	4.95e-22	0.67	0.46	Morning vs. evening chronotype;	chr11:30220154	chr11:30044058~30084343:-
PRAD	cis	rs9322193	0.887	rs4870139	ENSG00000268592.3	RAET1E-AS1	11.01	3.78e-25	4.95e-22	0.65	0.46	Lung cancer;	chr6:149575182	chr6:149863494~149919507:+
PRAD	cis	rs1577917	1	rs12190604	ENSG00000203875.9	SNHG5	-11.01	3.79e-25	4.97e-22	-0.53	-0.46	Response to antipsychotic treatment;	chr6:86006497	chr6:85660950~85678736:-
PRAD	cis	rs34779708	0.733	rs11597184	ENSG00000230534.5	RP11-297A16.2	11.01	3.8e-25	4.99e-22	0.62	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35108468	chr10:35098006~35127020:-
PRAD	cis	rs7714584	1	rs4579248	ENSG00000197083.10	ZNF300P1	11.01	3.82e-25	5e-22	0.81	0.46	Crohn's disease;	chr5:150888589	chr5:150930645~150946289:-
PRAD	cis	rs9322193	0.923	rs2185352	ENSG00000216906.2	RP11-350J20.9	11.01	3.86e-25	5.05e-22	0.52	0.46	Lung cancer;	chr6:149714640	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.923	rs12174349	ENSG00000216906.2	RP11-350J20.9	11.01	3.86e-25	5.05e-22	0.52	0.46	Lung cancer;	chr6:149718012	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.923	rs2297932	ENSG00000216906.2	RP11-350J20.9	11.01	3.86e-25	5.05e-22	0.52	0.46	Lung cancer;	chr6:149718225	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.923	rs2297930	ENSG00000216906.2	RP11-350J20.9	11.01	3.86e-25	5.05e-22	0.52	0.46	Lung cancer;	chr6:149718360	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.923	rs9479094	ENSG00000216906.2	RP11-350J20.9	11.01	3.86e-25	5.05e-22	0.52	0.46	Lung cancer;	chr6:149725083	chr6:149904243~149906418:+
PRAD	cis	rs9487094	0.744	rs13204787	ENSG00000260273.1	RP11-425D10.10	11.01	3.87e-25	5.06e-22	0.68	0.46	Height;	chr6:109618283	chr6:109382795~109383666:+
PRAD	cis	rs9322193	0.566	rs12528243	ENSG00000268592.3	RAET1E-AS1	11.01	3.87e-25	5.07e-22	0.72	0.46	Lung cancer;	chr6:149898491	chr6:149863494~149919507:+
PRAD	cis	rs1577917	1	rs12205548	ENSG00000203875.9	SNHG5	-11.01	3.88e-25	5.08e-22	-0.54	-0.46	Response to antipsychotic treatment;	chr6:86050052	chr6:85660950~85678736:-
PRAD	cis	rs1577917	1	rs12665321	ENSG00000203875.9	SNHG5	-11.01	3.88e-25	5.08e-22	-0.54	-0.46	Response to antipsychotic treatment;	chr6:86059571	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.958	rs12196175	ENSG00000203875.9	SNHG5	-11.01	3.88e-25	5.08e-22	-0.54	-0.46	Response to antipsychotic treatment;	chr6:86069652	chr6:85660950~85678736:-
PRAD	cis	rs1577917	1	rs2816821	ENSG00000203875.9	SNHG5	-11.01	3.89e-25	5.09e-22	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85947366	chr6:85660950~85678736:-
PRAD	cis	rs9322193	0.884	rs9688699	ENSG00000216906.2	RP11-350J20.9	11	3.91e-25	5.11e-22	0.53	0.46	Lung cancer;	chr6:149733680	chr6:149904243~149906418:+
PRAD	cis	rs34779708	0.931	rs4934535	ENSG00000230534.5	RP11-297A16.2	11	3.91e-25	5.12e-22	0.62	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35143793	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.966	rs4934734	ENSG00000230534.5	RP11-297A16.2	11	3.91e-25	5.12e-22	0.62	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35145445	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.966	rs12769575	ENSG00000230534.5	RP11-297A16.2	11	3.91e-25	5.12e-22	0.62	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35146999	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.966	rs4934536	ENSG00000230534.5	RP11-297A16.2	11	3.91e-25	5.12e-22	0.62	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35152241	chr10:35098006~35127020:-
PRAD	cis	rs1577917	1	rs955227	ENSG00000203875.9	SNHG5	-11	3.92e-25	5.13e-22	-0.54	-0.46	Response to antipsychotic treatment;	chr6:85941314	chr6:85660950~85678736:-
PRAD	cis	rs9545047	0.716	rs8001795	ENSG00000227676.3	LINC01068	11	3.92e-25	5.13e-22	0.57	0.46	Schizophrenia;	chr13:79421402	chr13:79566727~79571436:+
PRAD	cis	rs9322193	0.923	rs2297928	ENSG00000216906.2	RP11-350J20.9	11	3.92e-25	5.13e-22	0.52	0.46	Lung cancer;	chr6:149718584	chr6:149904243~149906418:+
PRAD	cis	rs853679	0.517	rs16893666	ENSG00000280107.1	AL022393.9	11	3.93e-25	5.14e-22	0.59	0.46	Depression;	chr6:28086929	chr6:28170845~28172521:+
PRAD	cis	rs9487094	0.778	rs13214717	ENSG00000260273.1	RP11-425D10.10	11	3.94e-25	5.15e-22	0.67	0.46	Height;	chr6:109573151	chr6:109382795~109383666:+
PRAD	cis	rs2919917	0.617	rs4641056	ENSG00000254352.1	RP11-578O24.2	11	3.98e-25	5.21e-22	0.58	0.46	Lymphocyte counts;	chr8:78670261	chr8:78723796~78724136:-
PRAD	cis	rs9326248	0.727	rs4938347	ENSG00000280143.1	AP000892.6	11	4e-25	5.23e-22	0.45	0.46	Blood protein levels;	chr11:117151043	chr11:117204967~117210292:+
PRAD	cis	rs9326248	0.813	rs4938350	ENSG00000280143.1	AP000892.6	11	4e-25	5.23e-22	0.45	0.46	Blood protein levels;	chr11:117151560	chr11:117204967~117210292:+
PRAD	cis	rs4964805	0.612	rs11111758	ENSG00000257681.1	RP11-341G23.4	11	4e-25	5.23e-22	0.43	0.46	Attention deficit hyperactivity disorder;	chr12:103767306	chr12:103746315~103768858:-
PRAD	cis	rs8062405	0.964	rs11860513	ENSG00000251417.2	RP11-1348G14.4	-11	4.03e-25	5.27e-22	-0.51	-0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814099	chr16:28802743~28817828:+
PRAD	cis	rs71403859	0.502	rs71403847	ENSG00000260886.1	TAT-AS1	11	4.04e-25	5.29e-22	0.79	0.46	Post bronchodilator FEV1;	chr16:71434323	chr16:71565789~71578187:+
PRAD	cis	rs8062405	1	rs1987472	ENSG00000251417.2	RP11-1348G14.4	-11	4.08e-25	5.33e-22	-0.51	-0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814456	chr16:28802743~28817828:+
PRAD	cis	rs8062405	0.895	rs56186137	ENSG00000251417.2	RP11-1348G14.4	-11	4.08e-25	5.33e-22	-0.51	-0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814632	chr16:28802743~28817828:+
PRAD	cis	rs6570726	0.791	rs370112	ENSG00000235652.6	RP11-545I5.3	11	4.1e-25	5.36e-22	0.47	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145538717	chr6:145799409~145886585:+
PRAD	cis	rs71403859	0.502	rs71403849	ENSG00000260886.1	TAT-AS1	11	4.12e-25	5.38e-22	0.76	0.46	Post bronchodilator FEV1;	chr16:71450462	chr16:71565789~71578187:+
PRAD	cis	rs2117029	0.619	rs10747562	ENSG00000258017.1	RP11-386G11.10	-11	4.15e-25	5.42e-22	-0.6	-0.46	Intelligence (multi-trait analysis);	chr12:49111401	chr12:49127782~49147869:+
PRAD	cis	rs2117029	0.619	rs11168862	ENSG00000258017.1	RP11-386G11.10	-11	4.15e-25	5.42e-22	-0.6	-0.46	Intelligence (multi-trait analysis);	chr12:49112175	chr12:49127782~49147869:+
PRAD	cis	rs2282300	0.739	rs1631451	ENSG00000254532.1	RP11-624D11.2	11	4.18e-25	5.45e-22	0.66	0.46	Morning vs. evening chronotype;	chr11:30327586	chr11:30044058~30084343:-
PRAD	cis	rs2933343	0.818	rs6764681	ENSG00000231305.3	RP11-723O4.2	-11	4.21e-25	5.5e-22	-0.48	-0.46	IgG glycosylation;	chr3:128849537	chr3:128861313~128871540:-
PRAD	cis	rs11690935	0.851	rs6731562	ENSG00000228389.1	AC068039.4	11	4.23e-25	5.52e-22	0.53	0.46	Schizophrenia;	chr2:171941742	chr2:171773482~171775844:+
PRAD	cis	rs7617773	0.501	rs12185901	ENSG00000229759.1	MRPS18AP1	11	4.24e-25	5.53e-22	0.48	0.46	Coronary artery disease;	chr3:48341429	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.539	rs13082217	ENSG00000229759.1	MRPS18AP1	11	4.24e-25	5.53e-22	0.48	0.46	Coronary artery disease;	chr3:48341774	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.539	rs11706939	ENSG00000229759.1	MRPS18AP1	11	4.24e-25	5.53e-22	0.48	0.46	Coronary artery disease;	chr3:48342502	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.539	rs11130165	ENSG00000229759.1	MRPS18AP1	11	4.24e-25	5.53e-22	0.48	0.46	Coronary artery disease;	chr3:48343231	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.539	rs1471217	ENSG00000229759.1	MRPS18AP1	11	4.24e-25	5.53e-22	0.48	0.46	Coronary artery disease;	chr3:48343405	chr3:48256350~48256938:-
PRAD	cis	rs1577917	0.959	rs16876540	ENSG00000203875.9	SNHG5	-11	4.25e-25	5.55e-22	-0.54	-0.46	Response to antipsychotic treatment;	chr6:85902801	chr6:85660950~85678736:-
PRAD	cis	rs1577917	1	rs35761942	ENSG00000203875.9	SNHG5	-11	4.25e-25	5.55e-22	-0.54	-0.46	Response to antipsychotic treatment;	chr6:85919786	chr6:85660950~85678736:-
PRAD	cis	rs73086581	0.735	rs6037730	ENSG00000229539.1	RP11-119B16.2	11	4.25e-25	5.55e-22	0.77	0.46	Response to antidepressants in depression;	chr20:4046171	chr20:3888239~3888868:-
PRAD	cis	rs73086581	0.838	rs6052265	ENSG00000229539.1	RP11-119B16.2	11	4.25e-25	5.55e-22	0.77	0.46	Response to antidepressants in depression;	chr20:4046188	chr20:3888239~3888868:-
PRAD	cis	rs1577917	0.958	rs12213431	ENSG00000203875.9	SNHG5	-11	4.25e-25	5.55e-22	-0.52	-0.46	Response to antipsychotic treatment;	chr6:85791238	chr6:85660950~85678736:-
PRAD	cis	rs1577917	1	rs2166663	ENSG00000203875.9	SNHG5	-10.99	4.26e-25	5.56e-22	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85884178	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.958	rs16876530	ENSG00000203875.9	SNHG5	-10.99	4.26e-25	5.56e-22	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85885923	chr6:85660950~85678736:-
PRAD	cis	rs907683	0.635	rs11691617	ENSG00000280323.1	AC053503.12	10.99	4.28e-25	5.58e-22	0.38	0.46	Resting heart rate;	chr2:219430445	chr2:219427477~219429319:+
PRAD	cis	rs2404602	0.684	rs157759	ENSG00000259422.1	RP11-593F23.1	10.99	4.29e-25	5.59e-22	0.59	0.46	Blood metabolite levels;	chr15:76554649	chr15:76174891~76181486:-
PRAD	cis	rs34779708	0.931	rs11596502	ENSG00000230534.5	RP11-297A16.2	10.99	4.3e-25	5.61e-22	0.62	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35098259	chr10:35098006~35127020:-
PRAD	cis	rs5760092	0.755	rs915589	ENSG00000273295.1	AP000350.5	-10.99	4.32e-25	5.64e-22	-0.67	-0.46	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23901432~23907068:-
PRAD	cis	rs765787	0.53	rs4444275	ENSG00000259520.4	CTD-2651B20.3	10.99	4.32e-25	5.64e-22	0.57	0.46	Uric acid levels;	chr15:45243149	chr15:45251580~45279251:-
PRAD	cis	rs2404602	0.66	rs11852777	ENSG00000259422.1	RP11-593F23.1	-10.99	4.35e-25	5.67e-22	-0.6	-0.46	Blood metabolite levels;	chr15:76637451	chr15:76174891~76181486:-
PRAD	cis	rs1062177	0.756	rs2915815	ENSG00000213433.5	RPLP1P6	10.99	4.37e-25	5.69e-22	0.54	0.46	Preschool internalizing problems;	chr5:151736322	chr5:151765859~151766378:-
PRAD	cis	rs6991838	0.584	rs7842085	ENSG00000272010.1	CTD-3025N20.3	10.99	4.37e-25	5.7e-22	0.48	0.46	Intelligence (multi-trait analysis);	chr8:65636787	chr8:65591850~65592472:-
PRAD	cis	rs11723261	0.582	rs6814287	ENSG00000275426.1	CH17-262A2.1	10.99	4.37e-25	5.7e-22	0.64	0.46	Immune response to smallpox vaccine (IL-6);	chr4:122443	chr4:149738~150317:+
PRAD	cis	rs9322193	0.847	rs9505972	ENSG00000216906.2	RP11-350J20.9	10.99	4.39e-25	5.72e-22	0.53	0.46	Lung cancer;	chr6:149775255	chr6:149904243~149906418:+
PRAD	cis	rs7727544	0.684	rs274546	ENSG00000233006.5	AC034220.3	10.99	4.39e-25	5.72e-22	0.41	0.46	Blood metabolite levels;	chr5:132364175	chr5:132311285~132369916:-
PRAD	cis	rs2933343	1	rs1683782	ENSG00000231305.3	RP11-723O4.2	10.99	4.39e-25	5.72e-22	0.46	0.46	IgG glycosylation;	chr3:128921434	chr3:128861313~128871540:-
PRAD	cis	rs853679	0.517	rs6932109	ENSG00000280107.1	AL022393.9	10.99	4.39e-25	5.73e-22	0.59	0.46	Depression;	chr6:28110525	chr6:28170845~28172521:+
PRAD	cis	rs9322193	0.923	rs3924871	ENSG00000216906.2	RP11-350J20.9	10.99	4.42e-25	5.77e-22	0.53	0.46	Lung cancer;	chr6:149662080	chr6:149904243~149906418:+
PRAD	cis	rs748404	0.66	rs690367	ENSG00000205771.5	CATSPER2P1	10.99	4.43e-25	5.77e-22	0.51	0.46	Lung cancer;	chr15:43456106	chr15:43726918~43747094:-
PRAD	cis	rs2929278	0.617	rs2955969	ENSG00000249839.1	AC011330.5	10.99	4.43e-25	5.78e-22	0.58	0.46	Schizophrenia;	chr15:43822329	chr15:43663654~43684339:-
PRAD	cis	rs2282300	0.739	rs1222208	ENSG00000254532.1	RP11-624D11.2	10.99	4.45e-25	5.8e-22	0.66	0.46	Morning vs. evening chronotype;	chr11:30339830	chr11:30044058~30084343:-
PRAD	cis	rs9545047	0.716	rs418150	ENSG00000227676.3	LINC01068	-10.99	4.49e-25	5.84e-22	-0.56	-0.46	Schizophrenia;	chr13:79432675	chr13:79566727~79571436:+
PRAD	cis	rs11723261	0.582	rs3747693	ENSG00000275426.1	CH17-262A2.1	10.99	4.49e-25	5.84e-22	0.64	0.46	Immune response to smallpox vaccine (IL-6);	chr4:124493	chr4:149738~150317:+
PRAD	cis	rs9532669	0.926	rs4555012	ENSG00000176268.5	CYCSP34	10.99	4.49e-25	5.85e-22	0.49	0.46	Cervical cancer;	chr13:40879997	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.926	rs12871420	ENSG00000176268.5	CYCSP34	10.99	4.49e-25	5.85e-22	0.49	0.46	Cervical cancer;	chr13:40880034	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.926	rs12871735	ENSG00000176268.5	CYCSP34	10.99	4.49e-25	5.85e-22	0.49	0.46	Cervical cancer;	chr13:40880169	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.926	rs12871895	ENSG00000176268.5	CYCSP34	10.99	4.49e-25	5.85e-22	0.49	0.46	Cervical cancer;	chr13:40880189	chr13:40863599~40863902:-
PRAD	cis	rs9322193	0.923	rs1080670	ENSG00000216906.2	RP11-350J20.9	10.99	4.5e-25	5.86e-22	0.53	0.46	Lung cancer;	chr6:149620161	chr6:149904243~149906418:+
PRAD	cis	rs34779708	0.966	rs34605125	ENSG00000230534.5	RP11-297A16.2	10.99	4.53e-25	5.89e-22	0.62	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35122318	chr10:35098006~35127020:-
PRAD	cis	rs1150668	0.764	rs9368565	ENSG00000216901.1	AL022393.7	-10.99	4.54e-25	5.91e-22	-0.58	-0.46	Pubertal anthropometrics;	chr6:28377433	chr6:28176188~28176674:+
PRAD	cis	rs1150668	0.796	rs1052215	ENSG00000216901.1	AL022393.7	-10.99	4.54e-25	5.91e-22	-0.58	-0.46	Pubertal anthropometrics;	chr6:28380381	chr6:28176188~28176674:+
PRAD	cis	rs1577917	1	rs4707239	ENSG00000203875.9	SNHG5	-10.99	4.55e-25	5.92e-22	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85900999	chr6:85660950~85678736:-
PRAD	cis	rs1577917	1	rs1911552	ENSG00000203875.9	SNHG5	-10.99	4.55e-25	5.92e-22	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85928306	chr6:85660950~85678736:-
PRAD	cis	rs2282300	0.739	rs10835647	ENSG00000254532.1	RP11-624D11.2	10.99	4.55e-25	5.92e-22	0.66	0.46	Morning vs. evening chronotype;	chr11:30291721	chr11:30044058~30084343:-
PRAD	cis	rs2282300	0.702	rs4379811	ENSG00000254532.1	RP11-624D11.2	-10.99	4.55e-25	5.92e-22	-0.66	-0.46	Morning vs. evening chronotype;	chr11:30273213	chr11:30044058~30084343:-
PRAD	cis	rs2282300	0.739	rs3858428	ENSG00000254532.1	RP11-624D11.2	-10.99	4.55e-25	5.92e-22	-0.66	-0.46	Morning vs. evening chronotype;	chr11:30275003	chr11:30044058~30084343:-
PRAD	cis	rs2282300	0.739	rs1933343	ENSG00000254532.1	RP11-624D11.2	-10.99	4.55e-25	5.92e-22	-0.66	-0.46	Morning vs. evening chronotype;	chr11:30289445	chr11:30044058~30084343:-
PRAD	cis	rs9322193	0.847	rs12191643	ENSG00000216906.2	RP11-350J20.9	10.99	4.56e-25	5.93e-22	0.52	0.46	Lung cancer;	chr6:149628912	chr6:149904243~149906418:+
PRAD	cis	rs6570726	0.791	rs436498	ENSG00000235652.6	RP11-545I5.3	10.99	4.62e-25	6.01e-22	0.47	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145555211	chr6:145799409~145886585:+
PRAD	cis	rs765787	0.53	rs28414644	ENSG00000259520.4	CTD-2651B20.3	10.99	4.62e-25	6.01e-22	0.57	0.46	Uric acid levels;	chr15:45244523	chr15:45251580~45279251:-
PRAD	cis	rs780094	0.544	rs780108	ENSG00000234072.1	AC074117.10	-10.99	4.62e-25	6.01e-22	-0.36	-0.46	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27462090	chr2:27356246~27367622:+
PRAD	cis	rs2665103	0.61	rs1972460	ENSG00000278603.1	RP13-608F4.5	10.99	4.62e-25	6.01e-22	0.56	0.46	Intelligence (multi-trait analysis);	chr15:82238289	chr15:82472203~82472426:+
PRAD	cis	rs34779708	0.931	rs11010101	ENSG00000230534.5	RP11-297A16.2	10.98	4.64e-25	6.04e-22	0.61	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35122117	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.966	rs11010102	ENSG00000230534.5	RP11-297A16.2	10.98	4.64e-25	6.04e-22	0.61	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35122138	chr10:35098006~35127020:-
PRAD	cis	rs9322193	0.884	rs62439837	ENSG00000216906.2	RP11-350J20.9	10.98	4.65e-25	6.05e-22	0.53	0.46	Lung cancer;	chr6:149670380	chr6:149904243~149906418:+
PRAD	cis	rs1577917	0.958	rs10944137	ENSG00000203875.9	SNHG5	-10.98	4.66e-25	6.06e-22	-0.55	-0.46	Response to antipsychotic treatment;	chr6:85744596	chr6:85660950~85678736:-
PRAD	cis	rs2919917	0.628	rs7010299	ENSG00000254352.1	RP11-578O24.2	10.98	4.67e-25	6.07e-22	0.6	0.46	Lymphocyte counts;	chr8:78707786	chr8:78723796~78724136:-
PRAD	cis	rs2282300	0.739	rs35883696	ENSG00000254532.1	RP11-624D11.2	10.98	4.71e-25	6.12e-22	0.66	0.46	Morning vs. evening chronotype;	chr11:30224860	chr11:30044058~30084343:-
PRAD	cis	rs6570726	0.764	rs9399553	ENSG00000235652.6	RP11-545I5.3	10.98	4.74e-25	6.16e-22	0.47	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145552528	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.791	rs408443	ENSG00000235652.6	RP11-545I5.3	10.98	4.74e-25	6.16e-22	0.47	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145553507	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.791	rs436156	ENSG00000235652.6	RP11-545I5.3	10.98	4.74e-25	6.16e-22	0.47	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145553737	chr6:145799409~145886585:+
PRAD	cis	rs1577917	0.958	rs12193904	ENSG00000203875.9	SNHG5	-10.98	4.76e-25	6.18e-22	-0.55	-0.46	Response to antipsychotic treatment;	chr6:85742985	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.958	rs11754330	ENSG00000203875.9	SNHG5	-10.98	4.76e-25	6.18e-22	-0.55	-0.46	Response to antipsychotic treatment;	chr6:85745352	chr6:85660950~85678736:-
PRAD	cis	rs2282300	0.739	rs7942129	ENSG00000254532.1	RP11-624D11.2	10.98	4.82e-25	6.26e-22	0.66	0.46	Morning vs. evening chronotype;	chr11:30203145	chr11:30044058~30084343:-
PRAD	cis	rs2282300	0.739	rs34855782	ENSG00000254532.1	RP11-624D11.2	10.98	4.82e-25	6.26e-22	0.66	0.46	Morning vs. evening chronotype;	chr11:30203923	chr11:30044058~30084343:-
PRAD	cis	rs34779708	0.966	rs4934537	ENSG00000230534.5	RP11-297A16.2	10.98	4.84e-25	6.28e-22	0.62	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35152584	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.966	rs12784482	ENSG00000230534.5	RP11-297A16.2	10.98	4.84e-25	6.28e-22	0.62	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35157937	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.966	rs113170867	ENSG00000230534.5	RP11-297A16.2	10.98	4.84e-25	6.28e-22	0.62	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35161219	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.966	rs17499811	ENSG00000230534.5	RP11-297A16.2	10.98	4.84e-25	6.28e-22	0.62	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35167287	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.966	rs35146199	ENSG00000230534.5	RP11-297A16.2	10.98	4.84e-25	6.28e-22	0.62	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35172011	chr10:35098006~35127020:-
PRAD	cis	rs875971	0.862	rs778680	ENSG00000237310.1	GS1-124K5.4	10.98	4.84e-25	6.28e-22	0.42	0.46	Aortic root size;	chr7:66375427	chr7:66493706~66495474:+
PRAD	cis	rs9532669	0.926	rs4600337	ENSG00000176268.5	CYCSP34	10.98	4.87e-25	6.33e-22	0.49	0.46	Cervical cancer;	chr13:40879564	chr13:40863599~40863902:-
PRAD	cis	rs34779708	0.966	rs4934538	ENSG00000230534.5	RP11-297A16.2	10.98	4.89e-25	6.34e-22	0.62	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35183222	chr10:35098006~35127020:-
PRAD	cis	rs3814244	1	rs3814244	ENSG00000255733.4	IFNG-AS1	-10.98	4.9e-25	6.35e-22	-0.49	-0.46	Itch intensity from mosquito bite adjusted by bite size;	chr12:68019691	chr12:67989445~68234686:+
PRAD	cis	rs1075265	0.584	rs11896781	ENSG00000233266.1	HMGB1P31	10.98	4.91e-25	6.37e-22	0.61	0.46	Chronotype;Morning vs. evening chronotype;	chr2:54096987	chr2:54051334~54051760:+
PRAD	cis	rs1075265	0.547	rs10865279	ENSG00000233266.1	HMGB1P31	10.98	4.91e-25	6.37e-22	0.61	0.46	Chronotype;Morning vs. evening chronotype;	chr2:54097564	chr2:54051334~54051760:+
PRAD	cis	rs9532669	0.926	rs12872288	ENSG00000176268.5	CYCSP34	10.98	4.91e-25	6.37e-22	0.49	0.46	Cervical cancer;	chr13:40880268	chr13:40863599~40863902:-
PRAD	cis	rs1577917	1	rs10944163	ENSG00000203875.9	SNHG5	-10.98	4.92e-25	6.39e-22	-0.53	-0.46	Response to antipsychotic treatment;	chr6:85948975	chr6:85660950~85678736:-
PRAD	cis	rs1577917	1	rs12661204	ENSG00000203875.9	SNHG5	-10.98	4.92e-25	6.39e-22	-0.53	-0.46	Response to antipsychotic treatment;	chr6:85968868	chr6:85660950~85678736:-
PRAD	cis	rs1062177	0.826	rs2915873	ENSG00000213433.5	RPLP1P6	-10.98	4.94e-25	6.4e-22	-0.53	-0.46	Preschool internalizing problems;	chr5:151777097	chr5:151765859~151766378:-
PRAD	cis	rs9322193	0.923	rs9688350	ENSG00000216906.2	RP11-350J20.9	10.98	4.97e-25	6.44e-22	0.52	0.46	Lung cancer;	chr6:149730977	chr6:149904243~149906418:+
PRAD	cis	rs1577917	1	rs12201571	ENSG00000203875.9	SNHG5	-10.98	4.99e-25	6.47e-22	-0.53	-0.46	Response to antipsychotic treatment;	chr6:85900032	chr6:85660950~85678736:-
PRAD	cis	rs1577917	1	rs11759855	ENSG00000203875.9	SNHG5	-10.98	4.99e-25	6.47e-22	-0.53	-0.46	Response to antipsychotic treatment;	chr6:85901123	chr6:85660950~85678736:-
PRAD	cis	rs1577917	1	rs1857964	ENSG00000203875.9	SNHG5	-10.98	4.99e-25	6.47e-22	-0.53	-0.46	Response to antipsychotic treatment;	chr6:85926276	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.798	rs7772384	ENSG00000203875.9	SNHG5	-10.98	4.99e-25	6.47e-22	-0.53	-0.46	Response to antipsychotic treatment;	chr6:85929962	chr6:85660950~85678736:-
PRAD	cis	rs10875746	0.855	rs11168369	ENSG00000240399.1	RP1-228P16.1	-10.98	5.03e-25	6.52e-22	-0.46	-0.46	Longevity (90 years and older);	chr12:48037385	chr12:48054813~48055591:-
PRAD	cis	rs10875746	0.855	rs10875731	ENSG00000240399.1	RP1-228P16.1	-10.98	5.03e-25	6.52e-22	-0.46	-0.46	Longevity (90 years and older);	chr12:48038960	chr12:48054813~48055591:-
PRAD	cis	rs748404	0.66	rs2467742	ENSG00000205771.5	CATSPER2P1	-10.98	5.05e-25	6.55e-22	-0.51	-0.46	Lung cancer;	chr15:43458039	chr15:43726918~43747094:-
PRAD	cis	rs34779708	0.966	rs7077242	ENSG00000230534.5	RP11-297A16.2	-10.98	5.06e-25	6.55e-22	-0.6	-0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35193037	chr10:35098006~35127020:-
PRAD	cis	rs1577917	1	rs68171315	ENSG00000203875.9	SNHG5	-10.97	5.11e-25	6.62e-22	-0.52	-0.46	Response to antipsychotic treatment;	chr6:85997682	chr6:85660950~85678736:-
PRAD	cis	rs2282300	0.739	rs7925340	ENSG00000254532.1	RP11-624D11.2	-10.97	5.13e-25	6.64e-22	-0.66	-0.46	Morning vs. evening chronotype;	chr11:30258861	chr11:30044058~30084343:-
PRAD	cis	rs1075265	0.547	rs41385746	ENSG00000233266.1	HMGB1P31	-10.97	5.15e-25	6.67e-22	-0.6	-0.46	Chronotype;Morning vs. evening chronotype;	chr2:54077893	chr2:54051334~54051760:+
PRAD	cis	rs34779708	0.931	rs7079498	ENSG00000230534.5	RP11-297A16.2	10.97	5.16e-25	6.69e-22	0.61	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35086416	chr10:35098006~35127020:-
PRAD	cis	rs7772486	0.754	rs6570708	ENSG00000235652.6	RP11-545I5.3	-10.97	5.18e-25	6.71e-22	-0.46	-0.46	Lobe attachment (rater-scored or self-reported);	chr6:145668292	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.754	rs702304	ENSG00000235652.6	RP11-545I5.3	-10.97	5.18e-25	6.71e-22	-0.46	-0.46	Lobe attachment (rater-scored or self-reported);	chr6:145669661	chr6:145799409~145886585:+
PRAD	cis	rs9545047	0.716	rs416660	ENSG00000227676.3	LINC01068	-10.97	5.21e-25	6.75e-22	-0.56	-0.46	Schizophrenia;	chr13:79432726	chr13:79566727~79571436:+
PRAD	cis	rs34779708	0.966	rs12782948	ENSG00000230534.5	RP11-297A16.2	10.97	5.22e-25	6.76e-22	0.6	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35161679	chr10:35098006~35127020:-
PRAD	cis	rs780096	0.546	rs1260320	ENSG00000234072.1	AC074117.10	10.97	5.34e-25	6.9e-22	0.36	0.46	Total body bone mineral density;	chr2:27499549	chr2:27356246~27367622:+
PRAD	cis	rs2919917	0.628	rs6997255	ENSG00000254352.1	RP11-578O24.2	10.97	5.41e-25	7e-22	0.6	0.46	Lymphocyte counts;	chr8:78694850	chr8:78723796~78724136:-
PRAD	cis	rs2919917	0.628	rs7017898	ENSG00000254352.1	RP11-578O24.2	10.97	5.41e-25	7e-22	0.6	0.46	Lymphocyte counts;	chr8:78697147	chr8:78723796~78724136:-
PRAD	cis	rs9322193	0.566	rs12528243	ENSG00000223701.3	RAET1E-AS1	10.97	5.42e-25	7.01e-22	0.71	0.46	Lung cancer;	chr6:149898491	chr6:149884431~149919508:+
PRAD	cis	rs7772486	0.754	rs4895682	ENSG00000235652.6	RP11-545I5.3	-10.97	5.42e-25	7.01e-22	-0.47	-0.46	Lobe attachment (rater-scored or self-reported);	chr6:145741725	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.791	rs446362	ENSG00000235652.6	RP11-545I5.3	10.97	5.47e-25	7.07e-22	0.47	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145557580	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.791	rs414600	ENSG00000235652.6	RP11-545I5.3	10.97	5.47e-25	7.07e-22	0.47	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145558470	chr6:145799409~145886585:+
PRAD	cis	rs9322193	0.607	rs12210822	ENSG00000223701.3	RAET1E-AS1	10.97	5.49e-25	7.09e-22	0.7	0.46	Lung cancer;	chr6:149905356	chr6:149884431~149919508:+
PRAD	cis	rs875971	0.83	rs6976714	ENSG00000237310.1	GS1-124K5.4	10.97	5.5e-25	7.11e-22	0.42	0.46	Aortic root size;	chr7:66426474	chr7:66493706~66495474:+
PRAD	cis	rs2404602	0.583	rs12592501	ENSG00000259422.1	RP11-593F23.1	10.97	5.52e-25	7.13e-22	0.56	0.46	Blood metabolite levels;	chr15:76262449	chr15:76174891~76181486:-
PRAD	cis	rs6570726	0.791	rs10457788	ENSG00000235652.6	RP11-545I5.3	10.97	5.52e-25	7.14e-22	0.48	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145600000	chr6:145799409~145886585:+
PRAD	cis	rs9322193	0.962	rs3805749	ENSG00000216906.2	RP11-350J20.9	10.97	5.53e-25	7.14e-22	0.53	0.46	Lung cancer;	chr6:149772546	chr6:149904243~149906418:+
PRAD	cis	rs1577917	0.958	rs6454487	ENSG00000203875.9	SNHG5	10.96	5.56e-25	7.19e-22	0.52	0.46	Response to antipsychotic treatment;	chr6:85737150	chr6:85660950~85678736:-
PRAD	cis	rs34779708	0.897	rs16935880	ENSG00000230534.5	RP11-297A16.2	10.96	5.59e-25	7.22e-22	0.62	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35126540	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.966	rs4934730	ENSG00000230534.5	RP11-297A16.2	10.96	5.59e-25	7.22e-22	0.62	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35126627	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.966	rs2045918	ENSG00000230534.5	RP11-297A16.2	10.96	5.59e-25	7.22e-22	0.62	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35129589	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.966	rs4294520	ENSG00000230534.5	RP11-297A16.2	10.96	5.59e-25	7.22e-22	0.62	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35133578	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.931	rs34876468	ENSG00000230534.5	RP11-297A16.2	10.96	5.59e-25	7.22e-22	0.62	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35135522	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.966	rs35814343	ENSG00000230534.5	RP11-297A16.2	10.96	5.59e-25	7.22e-22	0.62	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35138786	chr10:35098006~35127020:-
PRAD	cis	rs71403859	0.502	rs7195767	ENSG00000260886.1	TAT-AS1	10.96	5.62e-25	7.26e-22	0.75	0.46	Post bronchodilator FEV1;	chr16:71431040	chr16:71565789~71578187:+
PRAD	cis	rs6570726	0.791	rs9403729	ENSG00000235652.6	RP11-545I5.3	10.96	5.63e-25	7.28e-22	0.48	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145585871	chr6:145799409~145886585:+
PRAD	cis	rs2933343	1	rs1680784	ENSG00000231305.3	RP11-723O4.2	10.96	5.65e-25	7.3e-22	0.46	0.46	IgG glycosylation;	chr3:128925615	chr3:128861313~128871540:-
PRAD	cis	rs507080	0.663	rs523793	ENSG00000255422.1	AP002954.4	-10.96	5.67e-25	7.31e-22	-0.56	-0.46	Serum metabolite levels;	chr11:118699988	chr11:118704607~118750263:+
PRAD	cis	rs507080	0.736	rs659564	ENSG00000255422.1	AP002954.4	-10.96	5.67e-25	7.31e-22	-0.56	-0.46	Serum metabolite levels;	chr11:118700205	chr11:118704607~118750263:+
PRAD	cis	rs507080	0.736	rs642224	ENSG00000255422.1	AP002954.4	-10.96	5.67e-25	7.31e-22	-0.56	-0.46	Serum metabolite levels;	chr11:118700210	chr11:118704607~118750263:+
PRAD	cis	rs507080	0.733	rs541631	ENSG00000255422.1	AP002954.4	-10.96	5.67e-25	7.31e-22	-0.56	-0.46	Serum metabolite levels;	chr11:118700314	chr11:118704607~118750263:+
PRAD	cis	rs507080	0.736	rs658676	ENSG00000255422.1	AP002954.4	-10.96	5.67e-25	7.31e-22	-0.56	-0.46	Serum metabolite levels;	chr11:118700414	chr11:118704607~118750263:+
PRAD	cis	rs507080	0.733	rs488141	ENSG00000255422.1	AP002954.4	-10.96	5.67e-25	7.31e-22	-0.56	-0.46	Serum metabolite levels;	chr11:118700459	chr11:118704607~118750263:+
PRAD	cis	rs507080	0.733	rs657769	ENSG00000255422.1	AP002954.4	-10.96	5.67e-25	7.31e-22	-0.56	-0.46	Serum metabolite levels;	chr11:118700607	chr11:118704607~118750263:+
PRAD	cis	rs507080	0.733	rs544452	ENSG00000255422.1	AP002954.4	-10.96	5.67e-25	7.31e-22	-0.56	-0.46	Serum metabolite levels;	chr11:118700648	chr11:118704607~118750263:+
PRAD	cis	rs507080	0.697	rs656287	ENSG00000255422.1	AP002954.4	-10.96	5.67e-25	7.31e-22	-0.56	-0.46	Serum metabolite levels;	chr11:118701081	chr11:118704607~118750263:+
PRAD	cis	rs507080	0.733	rs570949	ENSG00000255422.1	AP002954.4	-10.96	5.67e-25	7.31e-22	-0.56	-0.46	Serum metabolite levels;	chr11:118701202	chr11:118704607~118750263:+
PRAD	cis	rs507080	0.733	rs611733	ENSG00000255422.1	AP002954.4	-10.96	5.67e-25	7.31e-22	-0.56	-0.46	Serum metabolite levels;	chr11:118702051	chr11:118704607~118750263:+
PRAD	cis	rs34779708	0.966	rs12765038	ENSG00000230534.5	RP11-297A16.2	10.96	5.69e-25	7.34e-22	0.61	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35127585	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.966	rs2045917	ENSG00000230534.5	RP11-297A16.2	10.96	5.69e-25	7.34e-22	0.61	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35129598	chr10:35098006~35127020:-
PRAD	cis	rs9322193	0.923	rs11155674	ENSG00000216906.2	RP11-350J20.9	10.96	5.73e-25	7.4e-22	0.52	0.46	Lung cancer;	chr6:149711111	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.887	rs9767113	ENSG00000268592.3	RAET1E-AS1	10.96	5.75e-25	7.42e-22	0.63	0.46	Lung cancer;	chr6:149718157	chr6:149863494~149919507:+
PRAD	cis	rs1577917	1	rs13194429	ENSG00000203875.9	SNHG5	-10.96	5.75e-25	7.42e-22	-0.53	-0.46	Response to antipsychotic treatment;	chr6:85936987	chr6:85660950~85678736:-
PRAD	cis	rs35160687	0.814	rs6547673	ENSG00000273080.1	RP11-301O19.1	10.96	5.77e-25	7.44e-22	0.52	0.46	Night sleep phenotypes;	chr2:86301815	chr2:86195590~86196049:+
PRAD	cis	rs1577917	0.958	rs11755642	ENSG00000203875.9	SNHG5	-10.96	5.78e-25	7.45e-22	-0.55	-0.46	Response to antipsychotic treatment;	chr6:85740348	chr6:85660950~85678736:-
PRAD	cis	rs9322193	0.923	rs12205092	ENSG00000216906.2	RP11-350J20.9	10.96	5.84e-25	7.53e-22	0.53	0.46	Lung cancer;	chr6:149761375	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.923	rs10872651	ENSG00000216906.2	RP11-350J20.9	10.96	5.84e-25	7.53e-22	0.53	0.46	Lung cancer;	chr6:149768273	chr6:149904243~149906418:+
PRAD	cis	rs875971	0.862	rs11769079	ENSG00000237310.1	GS1-124K5.4	10.96	5.85e-25	7.55e-22	0.42	0.46	Aortic root size;	chr7:66377141	chr7:66493706~66495474:+
PRAD	cis	rs9545047	0.716	rs7333904	ENSG00000227676.3	LINC01068	10.96	5.85e-25	7.55e-22	0.55	0.46	Schizophrenia;	chr13:79281413	chr13:79566727~79571436:+
PRAD	cis	rs9532669	0.926	rs9532640	ENSG00000176268.5	CYCSP34	10.96	5.86e-25	7.56e-22	0.49	0.46	Cervical cancer;	chr13:40880628	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.89	rs9532641	ENSG00000176268.5	CYCSP34	10.96	5.86e-25	7.56e-22	0.49	0.46	Cervical cancer;	chr13:40880648	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.926	rs9532643	ENSG00000176268.5	CYCSP34	10.96	5.86e-25	7.56e-22	0.49	0.46	Cervical cancer;	chr13:40880800	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.963	rs9532644	ENSG00000176268.5	CYCSP34	10.96	5.86e-25	7.56e-22	0.49	0.46	Cervical cancer;	chr13:40880860	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.926	rs9532645	ENSG00000176268.5	CYCSP34	10.96	5.86e-25	7.56e-22	0.49	0.46	Cervical cancer;	chr13:40880898	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.926	rs9532646	ENSG00000176268.5	CYCSP34	10.96	5.86e-25	7.56e-22	0.49	0.46	Cervical cancer;	chr13:40880989	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.926	rs9525419	ENSG00000176268.5	CYCSP34	10.96	5.86e-25	7.56e-22	0.49	0.46	Cervical cancer;	chr13:40881047	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.926	rs9532647	ENSG00000176268.5	CYCSP34	10.96	5.86e-25	7.56e-22	0.49	0.46	Cervical cancer;	chr13:40881799	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.89	rs9525420	ENSG00000176268.5	CYCSP34	10.96	5.86e-25	7.56e-22	0.49	0.46	Cervical cancer;	chr13:40882628	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.926	rs7324383	ENSG00000176268.5	CYCSP34	10.96	5.86e-25	7.56e-22	0.49	0.46	Cervical cancer;	chr13:40882754	chr13:40863599~40863902:-
PRAD	cis	rs9532669	0.926	rs9532648	ENSG00000176268.5	CYCSP34	10.96	5.86e-25	7.56e-22	0.49	0.46	Cervical cancer;	chr13:40882795	chr13:40863599~40863902:-
PRAD	cis	rs34779708	0.966	rs4934736	ENSG00000230534.5	RP11-297A16.2	10.96	5.87e-25	7.56e-22	0.6	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35207940	chr10:35098006~35127020:-
PRAD	cis	rs1577917	0.958	rs12212480	ENSG00000203875.9	SNHG5	-10.96	5.89e-25	7.59e-22	-0.55	-0.46	Response to antipsychotic treatment;	chr6:85749059	chr6:85660950~85678736:-
PRAD	cis	rs2404602	0.647	rs3812908	ENSG00000259422.1	RP11-593F23.1	10.96	5.91e-25	7.62e-22	0.6	0.46	Blood metabolite levels;	chr15:76883817	chr15:76174891~76181486:-
PRAD	cis	rs7617773	0.539	rs13069884	ENSG00000229759.1	MRPS18AP1	10.96	5.93e-25	7.64e-22	0.48	0.46	Coronary artery disease;	chr3:48339658	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.539	rs2017859	ENSG00000229759.1	MRPS18AP1	10.96	5.93e-25	7.64e-22	0.48	0.46	Coronary artery disease;	chr3:48340771	chr3:48256350~48256938:-
PRAD	cis	rs2404602	0.583	rs2139190	ENSG00000259422.1	RP11-593F23.1	10.96	5.94e-25	7.65e-22	0.56	0.46	Blood metabolite levels;	chr15:76263198	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.583	rs12438741	ENSG00000259422.1	RP11-593F23.1	10.96	5.95e-25	7.66e-22	0.56	0.46	Blood metabolite levels;	chr15:76249773	chr15:76174891~76181486:-
PRAD	cis	rs853679	0.517	rs9295761	ENSG00000280107.1	AL022393.9	-10.96	5.95e-25	7.67e-22	-0.6	-0.46	Depression;	chr6:28180209	chr6:28170845~28172521:+
PRAD	cis	rs1062177	0.756	rs2915817	ENSG00000213433.5	RPLP1P6	10.96	5.97e-25	7.69e-22	0.53	0.46	Preschool internalizing problems;	chr5:151735956	chr5:151765859~151766378:-
PRAD	cis	rs9326248	0.768	rs4936366	ENSG00000280143.1	AP000892.6	10.96	5.99e-25	7.71e-22	0.44	0.46	Blood protein levels;	chr11:117156169	chr11:117204967~117210292:+
PRAD	cis	rs1577917	0.958	rs34622605	ENSG00000203875.9	SNHG5	-10.96	6.03e-25	7.76e-22	-0.55	-0.46	Response to antipsychotic treatment;	chr6:85746801	chr6:85660950~85678736:-
PRAD	cis	rs2404602	0.735	rs437131	ENSG00000259422.1	RP11-593F23.1	10.95	6.04e-25	7.78e-22	0.58	0.46	Blood metabolite levels;	chr15:76488710	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.684	rs1603860	ENSG00000259422.1	RP11-593F23.1	-10.95	6.15e-25	7.89e-22	-0.59	-0.46	Blood metabolite levels;	chr15:76557250	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.684	rs8037847	ENSG00000259422.1	RP11-593F23.1	-10.95	6.15e-25	7.89e-22	-0.59	-0.46	Blood metabolite levels;	chr15:76564210	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.684	rs28895952	ENSG00000259422.1	RP11-593F23.1	-10.95	6.15e-25	7.89e-22	-0.59	-0.46	Blood metabolite levels;	chr15:76564435	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.684	rs11072600	ENSG00000259422.1	RP11-593F23.1	-10.95	6.15e-25	7.89e-22	-0.59	-0.46	Blood metabolite levels;	chr15:76575574	chr15:76174891~76181486:-
PRAD	cis	rs6538678	0.746	rs4762630	ENSG00000258343.1	RP11-536G4.2	-10.95	6.18e-25	7.94e-22	-0.7	-0.46	Lupus nephritis in systemic lupus erythematosus;	chr12:95850631	chr12:95795345~95858839:-
PRAD	cis	rs638893	0.636	rs493720	ENSG00000278376.1	RP11-158I9.8	-10.95	6.19e-25	7.95e-22	-0.54	-0.46	Vitiligo;	chr11:118733969	chr11:118791254~118793137:+
PRAD	cis	rs7714584	1	rs11746807	ENSG00000197083.10	ZNF300P1	10.95	6.21e-25	7.98e-22	0.78	0.46	Crohn's disease;	chr5:150920857	chr5:150930645~150946289:-
PRAD	cis	rs638893	0.636	rs526850	ENSG00000278376.1	RP11-158I9.8	-10.95	6.22e-25	7.99e-22	-0.54	-0.46	Vitiligo;	chr11:118734418	chr11:118791254~118793137:+
PRAD	cis	rs9399135	0.66	rs4440481	ENSG00000232876.1	CTA-212D2.2	-10.95	6.23e-25	8e-22	-0.56	-0.46	Red blood cell count;	chr6:134955558	chr6:135055033~135060550:+
PRAD	cis	rs780096	0.546	rs8179225	ENSG00000234072.1	AC074117.10	-10.95	6.25e-25	8.02e-22	-0.36	-0.46	Total body bone mineral density;	chr2:27514314	chr2:27356246~27367622:+
PRAD	cis	rs10875746	0.951	rs61918826	ENSG00000240399.1	RP1-228P16.1	-10.95	6.25e-25	8.03e-22	-0.47	-0.46	Longevity (90 years and older);	chr12:48150195	chr12:48054813~48055591:-
PRAD	cis	rs875971	0.862	rs1695820	ENSG00000237310.1	GS1-124K5.4	10.95	6.25e-25	8.03e-22	0.42	0.46	Aortic root size;	chr7:66379576	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.83	rs778715	ENSG00000237310.1	GS1-124K5.4	10.95	6.25e-25	8.03e-22	0.42	0.46	Aortic root size;	chr7:66384222	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.83	rs809025	ENSG00000237310.1	GS1-124K5.4	10.95	6.25e-25	8.03e-22	0.42	0.46	Aortic root size;	chr7:66384832	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.862	rs1643375	ENSG00000237310.1	GS1-124K5.4	10.95	6.25e-25	8.03e-22	0.42	0.46	Aortic root size;	chr7:66407690	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.862	rs6962717	ENSG00000237310.1	GS1-124K5.4	10.95	6.25e-25	8.03e-22	0.42	0.46	Aortic root size;	chr7:66418748	chr7:66493706~66495474:+
PRAD	cis	rs4845570	0.831	rs11588634	ENSG00000249602.1	RP11-98D18.3	10.95	6.32e-25	8.1e-22	0.76	0.46	Coronary artery disease;	chr1:151808210	chr1:151763384~151769501:-
PRAD	cis	rs10875746	0.903	rs11168420	ENSG00000240399.1	RP1-228P16.1	-10.95	6.33e-25	8.1e-22	-0.46	-0.46	Longevity (90 years and older);	chr12:48122113	chr12:48054813~48055591:-
PRAD	cis	rs9322193	0.847	rs56103941	ENSG00000216906.2	RP11-350J20.9	10.95	6.35e-25	8.12e-22	0.53	0.46	Lung cancer;	chr6:149816095	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.847	rs12210605	ENSG00000216906.2	RP11-350J20.9	10.95	6.35e-25	8.12e-22	0.53	0.46	Lung cancer;	chr6:149817267	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.923	rs9371199	ENSG00000216906.2	RP11-350J20.9	10.95	6.35e-25	8.12e-22	0.53	0.46	Lung cancer;	chr6:149817526	chr6:149904243~149906418:+
PRAD	cis	rs5760092	0.627	rs6519489	ENSG00000225282.1	AP000350.6	-10.95	6.37e-25	8.15e-22	-0.72	-0.46	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919659	chr22:23926900~23929574:+
PRAD	cis	rs12429206	0.587	rs17589481	ENSG00000233672.5	RNASEH2B-AS1	-10.95	6.37e-25	8.15e-22	-0.69	-0.46	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50892028	chr13:50862172~50910764:-
PRAD	cis	rs7772486	0.536	rs9373467	ENSG00000235652.6	RP11-545I5.3	10.95	6.38e-25	8.16e-22	0.51	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145634469	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.791	rs12208019	ENSG00000235652.6	RP11-545I5.3	10.95	6.38e-25	8.17e-22	0.48	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145614436	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.791	rs11155435	ENSG00000235652.6	RP11-545I5.3	10.95	6.38e-25	8.17e-22	0.48	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145617409	chr6:145799409~145886585:+
PRAD	cis	rs4814920	0.818	rs6081790	ENSG00000275142.1	RP5-999L4.2	-10.95	6.42e-25	8.21e-22	-0.79	-0.46	Bipolar disorder (body mass index interaction);	chr20:19882273	chr20:19871891~19872284:+
PRAD	cis	rs6570726	0.791	rs6915094	ENSG00000235652.6	RP11-545I5.3	10.95	6.43e-25	8.23e-22	0.47	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145562404	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.791	rs365869	ENSG00000235652.6	RP11-545I5.3	10.95	6.43e-25	8.23e-22	0.47	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145563615	chr6:145799409~145886585:+
PRAD	cis	rs2564921	0.73	rs2564922	ENSG00000242142.1	SERBP1P3	10.95	6.44e-25	8.24e-22	0.52	0.46	Height;	chr3:53091453	chr3:53064283~53065091:-
PRAD	cis	rs9322193	0.962	rs17673294	ENSG00000216906.2	RP11-350J20.9	10.95	6.44e-25	8.24e-22	0.53	0.46	Lung cancer;	chr6:149813857	chr6:149904243~149906418:+
PRAD	cis	rs34779708	0.966	rs34296409	ENSG00000230534.5	RP11-297A16.2	10.95	6.47e-25	8.27e-22	0.62	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35115685	chr10:35098006~35127020:-
PRAD	cis	rs1577917	0.57	rs114854865	ENSG00000203875.9	SNHG5	-10.95	6.52e-25	8.33e-22	-0.52	-0.46	Response to antipsychotic treatment;	chr6:85844518	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.916	rs4706252	ENSG00000203875.9	SNHG5	-10.95	6.52e-25	8.33e-22	-0.52	-0.46	Response to antipsychotic treatment;	chr6:85845462	chr6:85660950~85678736:-
PRAD	cis	rs1577917	1	rs1999852	ENSG00000203875.9	SNHG5	-10.95	6.58e-25	8.41e-22	-0.52	-0.46	Response to antipsychotic treatment;	chr6:85996020	chr6:85660950~85678736:-
PRAD	cis	rs4845570	0.831	rs11588258	ENSG00000249602.1	RP11-98D18.3	10.94	6.63e-25	8.48e-22	0.76	0.46	Coronary artery disease;	chr1:151808252	chr1:151763384~151769501:-
PRAD	cis	rs7714584	1	rs4958842	ENSG00000197083.10	ZNF300P1	10.94	6.64e-25	8.49e-22	0.8	0.46	Crohn's disease;	chr5:150845315	chr5:150930645~150946289:-
PRAD	cis	rs2404602	0.647	rs12904417	ENSG00000259422.1	RP11-593F23.1	10.94	6.67e-25	8.53e-22	0.6	0.46	Blood metabolite levels;	chr15:76671811	chr15:76174891~76181486:-
PRAD	cis	rs9487094	0.961	rs9487068	ENSG00000260273.1	RP11-425D10.10	10.94	6.68e-25	8.54e-22	0.62	0.46	Height;	chr6:109350642	chr6:109382795~109383666:+
PRAD	cis	rs9322193	0.607	rs9383941	ENSG00000223701.3	RAET1E-AS1	-10.94	6.82e-25	8.72e-22	-0.7	-0.46	Lung cancer;	chr6:149912100	chr6:149884431~149919508:+
PRAD	cis	rs1062177	0.756	rs2964589	ENSG00000213433.5	RPLP1P6	10.94	6.94e-25	8.86e-22	0.53	0.46	Preschool internalizing problems;	chr5:151738628	chr5:151765859~151766378:-
PRAD	cis	rs9322193	0.962	rs4870048	ENSG00000223701.3	RAET1E-AS1	10.94	6.97e-25	8.9e-22	0.61	0.46	Lung cancer;	chr6:149834324	chr6:149884431~149919508:+
PRAD	cis	rs10875746	0.904	rs10875750	ENSG00000240399.1	RP1-228P16.1	-10.94	6.98e-25	8.92e-22	-0.47	-0.46	Longevity (90 years and older);	chr12:48151847	chr12:48054813~48055591:-
PRAD	cis	rs10875746	0.951	rs7485355	ENSG00000240399.1	RP1-228P16.1	-10.94	6.98e-25	8.92e-22	-0.47	-0.46	Longevity (90 years and older);	chr12:48154559	chr12:48054813~48055591:-
PRAD	cis	rs748404	0.631	rs7163288	ENSG00000205771.5	CATSPER2P1	-10.94	7.03e-25	8.97e-22	-0.51	-0.46	Lung cancer;	chr15:43379157	chr15:43726918~43747094:-
PRAD	cis	rs1891275	0.515	rs1361552	ENSG00000228701.1	TNKS2-AS1	-10.94	7.08e-25	9.03e-22	-0.57	-0.46	Intelligence (multi-trait analysis);	chr10:91774867	chr10:91782839~91798291:-
PRAD	cis	rs875971	0.862	rs778720	ENSG00000237310.1	GS1-124K5.4	-10.94	7.14e-25	9.11e-22	-0.42	-0.46	Aortic root size;	chr7:66381288	chr7:66493706~66495474:+
PRAD	cis	rs7174755	0.558	rs11071975	ENSG00000260657.2	RP11-315D16.4	-10.94	7.14e-25	9.11e-22	-0.61	-0.46	Major depressive disorder;	chr15:68037106	chr15:68267792~68277994:-
PRAD	cis	rs507080	0.733	rs7108144	ENSG00000255422.1	AP002954.4	-10.94	7.18e-25	9.16e-22	-0.56	-0.46	Serum metabolite levels;	chr11:118698985	chr11:118704607~118750263:+
PRAD	cis	rs2404602	0.608	rs17361504	ENSG00000259422.1	RP11-593F23.1	10.93	7.22e-25	9.2e-22	0.55	0.46	Blood metabolite levels;	chr15:76309530	chr15:76174891~76181486:-
PRAD	cis	rs1577917	0.958	rs12196230	ENSG00000203875.9	SNHG5	-10.93	7.27e-25	9.28e-22	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85810242	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.958	rs34994386	ENSG00000203875.9	SNHG5	-10.93	7.27e-25	9.28e-22	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85814417	chr6:85660950~85678736:-
PRAD	cis	rs7849270	1	rs3739843	ENSG00000268707.1	RP11-247A12.7	-10.93	7.28e-25	9.29e-22	-0.51	-0.46	Blood metabolite ratios;	chr9:129120682	chr9:129170434~129170940:+
PRAD	cis	rs7849270	1	rs10988214	ENSG00000268707.1	RP11-247A12.7	-10.93	7.28e-25	9.29e-22	-0.51	-0.46	Blood metabolite ratios;	chr9:129121473	chr9:129170434~129170940:+
PRAD	cis	rs7849270	1	rs932833	ENSG00000268707.1	RP11-247A12.7	-10.93	7.28e-25	9.29e-22	-0.51	-0.46	Blood metabolite ratios;	chr9:129121762	chr9:129170434~129170940:+
PRAD	cis	rs7849270	1	rs7020708	ENSG00000268707.1	RP11-247A12.7	-10.93	7.28e-25	9.29e-22	-0.51	-0.46	Blood metabolite ratios;	chr9:129122852	chr9:129170434~129170940:+
PRAD	cis	rs1577917	1	rs12196037	ENSG00000203875.9	SNHG5	-10.93	7.32e-25	9.33e-22	-0.53	-0.46	Response to antipsychotic treatment;	chr6:85984913	chr6:85660950~85678736:-
PRAD	cis	rs7772486	0.701	rs7772717	ENSG00000235652.6	RP11-545I5.3	10.93	7.35e-25	9.36e-22	0.47	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145633718	chr6:145799409~145886585:+
PRAD	cis	rs8523	0.586	rs1225744	ENSG00000230314.5	ELOVL2-AS1	10.93	7.38e-25	9.4e-22	0.51	0.46	Red blood cell fatty acid levels;	chr6:10954307	chr6:11043524~11078226:+
PRAD	cis	rs6700559	0.873	rs7542210	ENSG00000260088.1	RP11-92G12.3	-10.93	7.39e-25	9.42e-22	-0.58	-0.46	Coronary artery disease;	chr1:200693087	chr1:200669507~200694250:+
PRAD	cis	rs2933343	1	rs6785869	ENSG00000231305.3	RP11-723O4.2	10.93	7.42e-25	9.46e-22	0.46	0.46	IgG glycosylation;	chr3:128924301	chr3:128861313~128871540:-
PRAD	cis	rs2933343	1	rs1683778	ENSG00000231305.3	RP11-723O4.2	10.93	7.42e-25	9.46e-22	0.46	0.46	IgG glycosylation;	chr3:128925752	chr3:128861313~128871540:-
PRAD	cis	rs1150668	0.83	rs2531831	ENSG00000204709.4	LINC01556	10.93	7.43e-25	9.47e-22	0.56	0.46	Pubertal anthropometrics;	chr6:28420988	chr6:28943877~28944537:+
PRAD	cis	rs1577917	1	rs34581302	ENSG00000203875.9	SNHG5	-10.93	7.5e-25	9.55e-22	-0.52	-0.46	Response to antipsychotic treatment;	chr6:85996230	chr6:85660950~85678736:-
PRAD	cis	rs7772486	0.754	rs12199362	ENSG00000235652.6	RP11-545I5.3	10.93	7.56e-25	9.62e-22	0.47	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145797089	chr6:145799409~145886585:+
PRAD	cis	rs9322193	1	rs9399693	ENSG00000216906.2	RP11-350J20.9	10.93	7.57e-25	9.64e-22	0.53	0.46	Lung cancer;	chr6:149612718	chr6:149904243~149906418:+
PRAD	cis	rs11690935	0.851	rs10201430	ENSG00000228389.1	AC068039.4	10.93	7.58e-25	9.65e-22	0.52	0.46	Schizophrenia;	chr2:171956715	chr2:171773482~171775844:+
PRAD	cis	rs6142102	0.961	rs2377957	ENSG00000276073.1	RP5-1125A11.7	-10.93	7.59e-25	9.66e-22	-0.46	-0.46	Skin pigmentation;	chr20:33966667	chr20:33985617~33988989:-
PRAD	cis	rs7727544	0.684	rs274561	ENSG00000233006.5	AC034220.3	10.93	7.59e-25	9.67e-22	0.41	0.46	Blood metabolite levels;	chr5:132383536	chr5:132311285~132369916:-
PRAD	cis	rs1062177	0.724	rs2915828	ENSG00000213433.5	RPLP1P6	10.93	7.62e-25	9.7e-22	0.53	0.46	Preschool internalizing problems;	chr5:151738560	chr5:151765859~151766378:-
PRAD	cis	rs1062177	0.724	rs2964590	ENSG00000213433.5	RPLP1P6	10.93	7.62e-25	9.7e-22	0.53	0.46	Preschool internalizing problems;	chr5:151738585	chr5:151765859~151766378:-
PRAD	cis	rs2283792	0.935	rs9610375	ENSG00000224086.5	LL22NC03-86G7.1	-10.93	7.64e-25	9.73e-22	-0.54	-0.46	Multiple sclerosis;	chr22:21832804	chr22:21938293~21977632:+
PRAD	cis	rs1577917	1	rs35797755	ENSG00000203875.9	SNHG5	-10.93	7.66e-25	9.75e-22	-0.52	-0.46	Response to antipsychotic treatment;	chr6:85996836	chr6:85660950~85678736:-
PRAD	cis	rs875971	0.862	rs6955837	ENSG00000237310.1	GS1-124K5.4	-10.93	7.67e-25	9.76e-22	-0.42	-0.46	Aortic root size;	chr7:66578155	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.825	rs10281499	ENSG00000237310.1	GS1-124K5.4	-10.93	7.67e-25	9.76e-22	-0.42	-0.46	Aortic root size;	chr7:66583979	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.862	rs4718377	ENSG00000237310.1	GS1-124K5.4	-10.93	7.67e-25	9.76e-22	-0.42	-0.46	Aortic root size;	chr7:66584691	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.862	rs10278014	ENSG00000237310.1	GS1-124K5.4	-10.93	7.67e-25	9.76e-22	-0.42	-0.46	Aortic root size;	chr7:66586277	chr7:66493706~66495474:+
PRAD	cis	rs150992	0.593	rs326491	ENSG00000248489.1	CTD-2007H13.3	10.93	7.75e-25	9.86e-22	0.51	0.46	Body mass index;	chr5:98972225	chr5:98929171~98995013:+
PRAD	cis	rs9399135	0.636	rs4646871	ENSG00000232876.1	CTA-212D2.2	10.93	7.76e-25	9.88e-22	0.57	0.46	Red blood cell count;	chr6:134944479	chr6:135055033~135060550:+
PRAD	cis	rs2919917	0.628	rs1384803	ENSG00000254352.1	RP11-578O24.2	-10.93	7.77e-25	9.88e-22	-0.59	-0.46	Lymphocyte counts;	chr8:78669393	chr8:78723796~78724136:-
PRAD	cis	rs9322193	0.923	rs7767622	ENSG00000216906.2	RP11-350J20.9	10.93	7.83e-25	9.96e-22	0.52	0.46	Lung cancer;	chr6:149681766	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.923	rs4421206	ENSG00000216906.2	RP11-350J20.9	10.93	7.83e-25	9.96e-22	0.52	0.46	Lung cancer;	chr6:149682891	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.923	rs3798761	ENSG00000216906.2	RP11-350J20.9	10.93	7.83e-25	9.96e-22	0.52	0.46	Lung cancer;	chr6:149683643	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.923	rs9322209	ENSG00000216906.2	RP11-350J20.9	10.93	7.83e-25	9.96e-22	0.52	0.46	Lung cancer;	chr6:149691226	chr6:149904243~149906418:+
PRAD	cis	rs7849270	1	rs7849160	ENSG00000268707.1	RP11-247A12.7	-10.93	7.84e-25	9.96e-22	-0.51	-0.46	Blood metabolite ratios;	chr9:129112273	chr9:129170434~129170940:+
PRAD	cis	rs1150668	0.768	rs1150716	ENSG00000204709.4	LINC01556	10.92	7.86e-25	9.99e-22	0.58	0.46	Pubertal anthropometrics;	chr6:28294921	chr6:28943877~28944537:+
PRAD	cis	rs34779708	0.966	rs10827487	ENSG00000230534.5	RP11-297A16.2	10.92	7.89e-25	1e-21	0.61	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35117950	chr10:35098006~35127020:-
PRAD	cis	rs1823874	0.581	rs12905599	ENSG00000182397.13	DNM1P46	-10.92	7.96e-25	1.01e-21	-0.48	-0.46	IgG glycosylation;	chr15:99799733	chr15:99790156~99806927:-
PRAD	cis	rs34779708	0.931	rs4934724	ENSG00000230534.5	RP11-297A16.2	10.92	8.03e-25	1.02e-21	0.62	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35104741	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.966	rs4934725	ENSG00000230534.5	RP11-297A16.2	10.92	8.03e-25	1.02e-21	0.62	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35109308	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.966	rs12774834	ENSG00000230534.5	RP11-297A16.2	10.92	8.03e-25	1.02e-21	0.62	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35111142	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.966	rs12775759	ENSG00000230534.5	RP11-297A16.2	10.92	8.03e-25	1.02e-21	0.62	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35111255	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.966	rs35777088	ENSG00000230534.5	RP11-297A16.2	10.92	8.03e-25	1.02e-21	0.62	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35120120	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.966	rs11592567	ENSG00000230534.5	RP11-297A16.2	10.92	8.03e-25	1.02e-21	0.62	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35120441	chr10:35098006~35127020:-
PRAD	cis	rs907683	0.559	rs4674394	ENSG00000280323.1	AC053503.12	-10.92	8.1e-25	1.03e-21	-0.38	-0.46	Resting heart rate;	chr2:219425148	chr2:219427477~219429319:+
PRAD	cis	rs8062405	1	rs8061590	ENSG00000251417.2	RP11-1348G14.4	-10.92	8.15e-25	1.03e-21	-0.51	-0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28883809	chr16:28802743~28817828:+
PRAD	cis	rs9322193	0.884	rs9322210	ENSG00000216906.2	RP11-350J20.9	10.92	8.2e-25	1.04e-21	0.52	0.46	Lung cancer;	chr6:149695440	chr6:149904243~149906418:+
PRAD	cis	rs189798	0.807	rs330912	ENSG00000254340.1	RP11-10A14.3	10.92	8.23e-25	1.04e-21	0.62	0.46	Myopia (pathological);	chr8:9138784	chr8:9141424~9145435:+
PRAD	cis	rs9322193	0.576	rs7452592	ENSG00000223701.3	RAET1E-AS1	10.92	8.25e-25	1.05e-21	0.71	0.46	Lung cancer;	chr6:149875445	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.566	rs9397070	ENSG00000223701.3	RAET1E-AS1	-10.92	8.27e-25	1.05e-21	-0.7	-0.46	Lung cancer;	chr6:149922073	chr6:149884431~149919508:+
PRAD	cis	rs1185460	0.967	rs3825061	ENSG00000271751.1	RP11-110I1.14	-10.92	8.27e-25	1.05e-21	-0.65	-0.46	Coronary artery disease;	chr11:119073965	chr11:119065263~119065677:-
PRAD	cis	rs6538678	0.824	rs7299632	ENSG00000258343.1	RP11-536G4.2	-10.92	8.4e-25	1.07e-21	-0.69	-0.46	Lupus nephritis in systemic lupus erythematosus;	chr12:95838376	chr12:95795345~95858839:-
PRAD	cis	rs7240205	0.853	rs10454719	ENSG00000275805.1	RP11-349H17.2	-10.92	8.41e-25	1.07e-21	-0.56	-0.46	Breast cancer;	chr18:26559666	chr18:26565723~26575626:-
PRAD	cis	rs907683	0.57	rs3755056	ENSG00000280323.1	AC053503.12	10.92	8.43e-25	1.07e-21	0.38	0.46	Resting heart rate;	chr2:219416294	chr2:219427477~219429319:+
PRAD	cis	rs2933343	1	rs1680790	ENSG00000231305.3	RP11-723O4.2	10.92	8.47e-25	1.07e-21	0.46	0.46	IgG glycosylation;	chr3:128907010	chr3:128861313~128871540:-
PRAD	cis	rs2933343	1	rs876755	ENSG00000231305.3	RP11-723O4.2	10.92	8.47e-25	1.07e-21	0.46	0.46	IgG glycosylation;	chr3:128909090	chr3:128861313~128871540:-
PRAD	cis	rs10875746	0.903	rs11168427	ENSG00000240399.1	RP1-228P16.1	-10.92	8.53e-25	1.08e-21	-0.46	-0.46	Longevity (90 years and older);	chr12:48145196	chr12:48054813~48055591:-
PRAD	cis	rs12049351	0.631	rs11810108	ENSG00000229367.1	HMGN2P19	-10.92	8.54e-25	1.08e-21	-0.57	-0.46	Circulating myeloperoxidase levels (plasma);	chr1:229532924	chr1:229570532~229570796:+
PRAD	cis	rs2282300	0.739	rs1717775	ENSG00000254532.1	RP11-624D11.2	10.91	8.56e-25	1.08e-21	0.65	0.46	Morning vs. evening chronotype;	chr11:30328707	chr11:30044058~30084343:-
PRAD	cis	rs6570726	0.791	rs440477	ENSG00000235652.6	RP11-545I5.3	10.91	8.59e-25	1.09e-21	0.47	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145533052	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.791	rs385729	ENSG00000235652.6	RP11-545I5.3	10.91	8.59e-25	1.09e-21	0.47	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145534329	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.791	rs7755253	ENSG00000235652.6	RP11-545I5.3	10.91	8.59e-25	1.09e-21	0.47	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145537757	chr6:145799409~145886585:+
PRAD	cis	rs1062177	0.756	rs2964591	ENSG00000213433.5	RPLP1P6	10.91	8.6e-25	1.09e-21	0.52	0.46	Preschool internalizing problems;	chr5:151737836	chr5:151765859~151766378:-
PRAD	cis	rs11123170	0.529	rs1015753	ENSG00000189223.12	PAX8-AS1	-10.91	8.6e-25	1.09e-21	-0.68	-0.46	Renal function-related traits (BUN);	chr2:113211226	chr2:113211522~113276581:+
PRAD	cis	rs9322193	0.923	rs9505823	ENSG00000216906.2	RP11-350J20.9	10.91	8.62e-25	1.09e-21	0.52	0.46	Lung cancer;	chr6:149628899	chr6:149904243~149906418:+
PRAD	cis	rs748404	0.631	rs6493083	ENSG00000205771.5	CATSPER2P1	-10.91	8.63e-25	1.09e-21	-0.51	-0.46	Lung cancer;	chr15:43345787	chr15:43726918~43747094:-
PRAD	cis	rs2739330	0.76	rs5760095	ENSG00000224205.1	AP000351.4	10.91	8.67e-25	1.1e-21	0.57	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23987320~23991421:-
PRAD	cis	rs4814920	0.818	rs6046403	ENSG00000275142.1	RP5-999L4.2	-10.91	8.74e-25	1.11e-21	-0.78	-0.46	Bipolar disorder (body mass index interaction);	chr20:19882329	chr20:19871891~19872284:+
PRAD	cis	rs10875746	0.903	rs17122666	ENSG00000240399.1	RP1-228P16.1	-10.91	8.78e-25	1.11e-21	-0.46	-0.46	Longevity (90 years and older);	chr12:48108791	chr12:48054813~48055591:-
PRAD	cis	rs10875746	0.951	rs2286021	ENSG00000240399.1	RP1-228P16.1	-10.91	8.78e-25	1.11e-21	-0.46	-0.46	Longevity (90 years and older);	chr12:48134437	chr12:48054813~48055591:-
PRAD	cis	rs875971	0.862	rs11763189	ENSG00000237310.1	GS1-124K5.4	10.91	8.81e-25	1.11e-21	0.42	0.46	Aortic root size;	chr7:66518542	chr7:66493706~66495474:+
PRAD	cis	rs7240205	0.853	rs6508448	ENSG00000275805.1	RP11-349H17.2	10.91	8.83e-25	1.12e-21	0.56	0.46	Breast cancer;	chr18:26556863	chr18:26565723~26575626:-
PRAD	cis	rs7849270	0.921	rs6478864	ENSG00000268707.1	RP11-247A12.7	-10.91	8.87e-25	1.12e-21	-0.51	-0.46	Blood metabolite ratios;	chr9:129118351	chr9:129170434~129170940:+
PRAD	cis	rs7849270	0.851	rs7861663	ENSG00000268707.1	RP11-247A12.7	-10.91	8.87e-25	1.12e-21	-0.51	-0.46	Blood metabolite ratios;	chr9:129118667	chr9:129170434~129170940:+
PRAD	cis	rs7849270	1	rs10819466	ENSG00000268707.1	RP11-247A12.7	-10.91	8.87e-25	1.12e-21	-0.51	-0.46	Blood metabolite ratios;	chr9:129119213	chr9:129170434~129170940:+
PRAD	cis	rs9322193	0.923	rs10782318	ENSG00000268592.3	RAET1E-AS1	10.91	8.95e-25	1.13e-21	0.62	0.46	Lung cancer;	chr6:149754137	chr6:149863494~149919507:+
PRAD	cis	rs2348418	0.733	rs1904386	ENSG00000247934.4	RP11-967K21.1	-10.91	8.97e-25	1.13e-21	-0.42	-0.46	Lung function (FEV1);Lung function (FVC);	chr12:28202321	chr12:28163298~28190738:-
PRAD	cis	rs7772486	0.754	rs2328709	ENSG00000235652.6	RP11-545I5.3	-10.91	8.99e-25	1.14e-21	-0.47	-0.46	Lobe attachment (rater-scored or self-reported);	chr6:145785683	chr6:145799409~145886585:+
PRAD	cis	rs1150668	0.796	rs1005125	ENSG00000204709.4	LINC01556	10.91	8.99e-25	1.14e-21	0.58	0.46	Pubertal anthropometrics;	chr6:28399578	chr6:28943877~28944537:+
PRAD	cis	rs6538678	0.784	rs7297403	ENSG00000258343.1	RP11-536G4.2	-10.91	9.01e-25	1.14e-21	-0.69	-0.46	Lupus nephritis in systemic lupus erythematosus;	chr12:95846683	chr12:95795345~95858839:-
PRAD	cis	rs2933343	1	rs876756	ENSG00000231305.3	RP11-723O4.2	10.91	9.03e-25	1.14e-21	0.46	0.46	IgG glycosylation;	chr3:128908780	chr3:128861313~128871540:-
PRAD	cis	rs34779708	0.931	rs17591135	ENSG00000230534.5	RP11-297A16.2	10.91	9.04e-25	1.14e-21	0.61	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35176262	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.931	rs55724039	ENSG00000230534.5	RP11-297A16.2	10.91	9.04e-25	1.14e-21	0.61	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35176469	chr10:35098006~35127020:-
PRAD	cis	rs9322193	0.962	rs4552	ENSG00000216906.2	RP11-350J20.9	10.91	9.1e-25	1.15e-21	0.53	0.46	Lung cancer;	chr6:149811183	chr6:149904243~149906418:+
PRAD	cis	rs8062405	1	rs3888190	ENSG00000251417.2	RP11-1348G14.4	-10.91	9.13e-25	1.15e-21	-0.51	-0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878165	chr16:28802743~28817828:+
PRAD	cis	rs9545047	0.716	rs643778	ENSG00000227676.3	LINC01068	-10.91	9.15e-25	1.16e-21	-0.56	-0.46	Schizophrenia;	chr13:79423937	chr13:79566727~79571436:+
PRAD	cis	rs9322193	0.884	rs1125	ENSG00000268592.3	RAET1E-AS1	10.91	9.18e-25	1.16e-21	0.64	0.46	Lung cancer;	chr6:149658280	chr6:149863494~149919507:+
PRAD	cis	rs875971	0.862	rs778684	ENSG00000237310.1	GS1-124K5.4	10.91	9.23e-25	1.17e-21	0.42	0.46	Aortic root size;	chr7:66371416	chr7:66493706~66495474:+
PRAD	cis	rs11673344	0.931	rs7256746	ENSG00000226686.6	LINC01535	10.91	9.29e-25	1.17e-21	0.64	0.46	Obesity-related traits;	chr19:37175073	chr19:37251912~37265535:+
PRAD	cis	rs11723261	0.621	rs7692530	ENSG00000275426.1	CH17-262A2.1	10.91	9.3e-25	1.17e-21	0.64	0.46	Immune response to smallpox vaccine (IL-6);	chr4:123563	chr4:149738~150317:+
PRAD	cis	rs2470135	1	rs2470135	ENSG00000249839.1	AC011330.5	-10.91	9.31e-25	1.18e-21	-0.58	-0.46	Diastolic blood pressure;	chr15:43703591	chr15:43663654~43684339:-
PRAD	cis	rs9322193	0.923	rs12176034	ENSG00000268592.3	RAET1E-AS1	10.9	9.36e-25	1.18e-21	0.63	0.46	Lung cancer;	chr6:149800557	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.847	rs868375	ENSG00000216906.2	RP11-350J20.9	10.9	9.41e-25	1.19e-21	0.52	0.46	Lung cancer;	chr6:149844905	chr6:149904243~149906418:+
PRAD	cis	rs2404602	0.583	rs12908334	ENSG00000259422.1	RP11-593F23.1	10.9	9.58e-25	1.21e-21	0.56	0.46	Blood metabolite levels;	chr15:76289251	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.618	rs12442266	ENSG00000259422.1	RP11-593F23.1	10.9	9.64e-25	1.22e-21	0.56	0.46	Blood metabolite levels;	chr15:76274801	chr15:76174891~76181486:-
PRAD	cis	rs7772486	0.754	rs9373475	ENSG00000235652.6	RP11-545I5.3	10.9	9.65e-25	1.22e-21	0.47	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145805283	chr6:145799409~145886585:+
PRAD	cis	rs4853012	0.838	rs4429500	ENSG00000257800.1	FNBP1P1	10.9	9.7e-25	1.22e-21	0.39	0.46	Gestational age at birth (maternal effect);	chr2:74118209	chr2:74120680~74123218:+
PRAD	cis	rs2117029	0.555	rs10747561	ENSG00000258017.1	RP11-386G11.10	-10.9	1e-24	1.26e-21	-0.59	-0.45	Intelligence (multi-trait analysis);	chr12:49106726	chr12:49127782~49147869:+
PRAD	cis	rs11123170	0.503	rs28679654	ENSG00000189223.12	PAX8-AS1	-10.9	1e-24	1.26e-21	-0.68	-0.45	Renal function-related traits (BUN);	chr2:113210040	chr2:113211522~113276581:+
PRAD	cis	rs10875746	0.951	rs11168433	ENSG00000240399.1	RP1-228P16.1	-10.9	1.01e-24	1.27e-21	-0.47	-0.45	Longevity (90 years and older);	chr12:48164281	chr12:48054813~48055591:-
PRAD	cis	rs1150668	0.768	rs1233713	ENSG00000204709.4	LINC01556	10.9	1.01e-24	1.28e-21	0.57	0.45	Pubertal anthropometrics;	chr6:28230503	chr6:28943877~28944537:+
PRAD	cis	rs2455601	0.744	rs7938995	ENSG00000254860.4	TMEM9B-AS1	10.9	1.02e-24	1.28e-21	0.53	0.45	Schizophrenia;	chr11:8954128	chr11:8964675~8977527:+
PRAD	cis	rs1577917	0.876	rs66986937	ENSG00000203875.9	SNHG5	-10.89	1.02e-24	1.28e-21	-0.54	-0.45	Response to antipsychotic treatment;	chr6:85822473	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.958	rs10944144	ENSG00000203875.9	SNHG5	-10.89	1.02e-24	1.28e-21	-0.54	-0.45	Response to antipsychotic treatment;	chr6:85828037	chr6:85660950~85678736:-
PRAD	cis	rs8062405	1	rs8062405	ENSG00000251417.2	RP11-1348G14.4	10.89	1.03e-24	1.3e-21	0.5	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826585	chr16:28802743~28817828:+
PRAD	cis	rs11690935	0.632	rs12052246	ENSG00000228389.1	AC068039.4	-10.89	1.03e-24	1.3e-21	-0.51	-0.45	Schizophrenia;	chr2:172030703	chr2:171773482~171775844:+
PRAD	cis	rs9322193	0.923	rs4870509	ENSG00000268592.3	RAET1E-AS1	10.89	1.03e-24	1.3e-21	0.62	0.45	Lung cancer;	chr6:149702212	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.923	rs9322214	ENSG00000268592.3	RAET1E-AS1	10.89	1.03e-24	1.3e-21	0.62	0.45	Lung cancer;	chr6:149703986	chr6:149863494~149919507:+
PRAD	cis	rs6570726	0.818	rs412350	ENSG00000235652.6	RP11-545I5.3	10.89	1.04e-24	1.31e-21	0.47	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145531273	chr6:145799409~145886585:+
PRAD	cis	rs1577917	1	rs4706254	ENSG00000203875.9	SNHG5	-10.89	1.05e-24	1.32e-21	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85893095	chr6:85660950~85678736:-
PRAD	cis	rs9545047	0.716	rs314693	ENSG00000227676.3	LINC01068	-10.89	1.05e-24	1.32e-21	-0.56	-0.45	Schizophrenia;	chr13:79432792	chr13:79566727~79571436:+
PRAD	cis	rs2404602	0.684	rs4886819	ENSG00000259422.1	RP11-593F23.1	-10.89	1.07e-24	1.35e-21	-0.6	-0.45	Blood metabolite levels;	chr15:76609357	chr15:76174891~76181486:-
PRAD	cis	rs2919917	0.628	rs1351742	ENSG00000254352.1	RP11-578O24.2	10.89	1.07e-24	1.35e-21	0.59	0.45	Lymphocyte counts;	chr8:78655823	chr8:78723796~78724136:-
PRAD	cis	rs2919917	0.666	rs982032	ENSG00000254352.1	RP11-578O24.2	10.89	1.07e-24	1.35e-21	0.59	0.45	Lymphocyte counts;	chr8:78655825	chr8:78723796~78724136:-
PRAD	cis	rs10853057	0.541	rs8082708	ENSG00000214174.7	AMZ2P1	-10.89	1.08e-24	1.35e-21	-0.68	-0.45	White matter microstructure (global fractional anisotropy);	chr17:65046182	chr17:64966550~64975576:-
PRAD	cis	rs10875746	0.951	rs10875747	ENSG00000240399.1	RP1-228P16.1	-10.89	1.08e-24	1.36e-21	-0.46	-0.45	Longevity (90 years and older);	chr12:48132078	chr12:48054813~48055591:-
PRAD	cis	rs10875746	0.951	rs10875748	ENSG00000240399.1	RP1-228P16.1	-10.89	1.08e-24	1.36e-21	-0.46	-0.45	Longevity (90 years and older);	chr12:48132577	chr12:48054813~48055591:-
PRAD	cis	rs73086581	0.838	rs11906481	ENSG00000229539.1	RP11-119B16.2	10.89	1.08e-24	1.36e-21	0.76	0.45	Response to antidepressants in depression;	chr20:4048059	chr20:3888239~3888868:-
PRAD	cis	rs780096	0.526	rs11126999	ENSG00000234072.1	AC074117.10	-10.89	1.09e-24	1.37e-21	-0.35	-0.45	Total body bone mineral density;	chr2:27447440	chr2:27356246~27367622:+
PRAD	cis	rs2933343	0.953	rs2933344	ENSG00000231305.3	RP11-723O4.2	10.89	1.09e-24	1.37e-21	0.44	0.45	IgG glycosylation;	chr3:128939872	chr3:128861313~128871540:-
PRAD	cis	rs9322193	0.962	rs7745915	ENSG00000216906.2	RP11-350J20.9	10.89	1.1e-24	1.38e-21	0.53	0.45	Lung cancer;	chr6:149834111	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.884	rs11155675	ENSG00000268592.3	RAET1E-AS1	10.89	1.1e-24	1.39e-21	0.63	0.45	Lung cancer;	chr6:149742883	chr6:149863494~149919507:+
PRAD	cis	rs2739330	0.734	rs2000467	ENSG00000231271.1	AP000350.8	-10.89	1.1e-24	1.39e-21	-0.62	-0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23949918~23954042:+
PRAD	cis	rs875971	0.862	rs1968126	ENSG00000237310.1	GS1-124K5.4	-10.89	1.1e-24	1.39e-21	-0.42	-0.45	Aortic root size;	chr7:66592017	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.862	rs6460306	ENSG00000237310.1	GS1-124K5.4	-10.89	1.1e-24	1.39e-21	-0.42	-0.45	Aortic root size;	chr7:66595806	chr7:66493706~66495474:+
PRAD	cis	rs780096	0.527	rs12471703	ENSG00000234072.1	AC074117.10	-10.88	1.11e-24	1.4e-21	-0.36	-0.45	Total body bone mineral density;	chr2:27515987	chr2:27356246~27367622:+
PRAD	cis	rs2282300	0.739	rs16920406	ENSG00000254532.1	RP11-624D11.2	10.88	1.11e-24	1.4e-21	0.66	0.45	Morning vs. evening chronotype;	chr11:30194611	chr11:30044058~30084343:-
PRAD	cis	rs1577917	0.916	rs7759727	ENSG00000203875.9	SNHG5	-10.88	1.12e-24	1.41e-21	-0.5	-0.45	Response to antipsychotic treatment;	chr6:85809160	chr6:85660950~85678736:-
PRAD	cis	rs9322193	0.961	rs9767713	ENSG00000268592.3	RAET1E-AS1	10.88	1.12e-24	1.41e-21	0.63	0.45	Lung cancer;	chr6:149588241	chr6:149863494~149919507:+
PRAD	cis	rs10875746	0.904	rs11168422	ENSG00000240399.1	RP1-228P16.1	-10.88	1.13e-24	1.42e-21	-0.46	-0.45	Longevity (90 years and older);	chr12:48125722	chr12:48054813~48055591:-
PRAD	cis	rs6570726	0.764	rs9403733	ENSG00000235652.6	RP11-545I5.3	10.88	1.14e-24	1.43e-21	0.47	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145591175	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.738	rs6917199	ENSG00000235652.6	RP11-545I5.3	10.88	1.14e-24	1.43e-21	0.47	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145597184	chr6:145799409~145886585:+
PRAD	cis	rs9322193	0.884	rs10872647	ENSG00000268592.3	RAET1E-AS1	10.88	1.14e-24	1.43e-21	0.63	0.45	Lung cancer;	chr6:149758687	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.884	rs2064521	ENSG00000216906.2	RP11-350J20.9	-10.88	1.14e-24	1.43e-21	-0.53	-0.45	Lung cancer;	chr6:149625336	chr6:149904243~149906418:+
PRAD	cis	rs6570726	0.689	rs411785	ENSG00000235652.6	RP11-545I5.3	10.88	1.15e-24	1.45e-21	0.47	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145567262	chr6:145799409~145886585:+
PRAD	cis	rs780096	0.506	rs56076827	ENSG00000234072.1	AC074117.10	-10.88	1.16e-24	1.45e-21	-0.35	-0.45	Total body bone mineral density;	chr2:27453420	chr2:27356246~27367622:+
PRAD	cis	rs704795	0.902	rs11887784	ENSG00000234072.1	AC074117.10	-10.88	1.16e-24	1.45e-21	-0.35	-0.45	Menopause (age at onset);	chr2:27457052	chr2:27356246~27367622:+
PRAD	cis	rs780096	0.526	rs72819536	ENSG00000234072.1	AC074117.10	-10.88	1.16e-24	1.45e-21	-0.35	-0.45	Total body bone mineral density;	chr2:27459983	chr2:27356246~27367622:+
PRAD	cis	rs780096	0.526	rs11127013	ENSG00000234072.1	AC074117.10	-10.88	1.16e-24	1.45e-21	-0.35	-0.45	Total body bone mineral density;	chr2:27470106	chr2:27356246~27367622:+
PRAD	cis	rs780096	0.506	rs2303369	ENSG00000234072.1	AC074117.10	-10.88	1.16e-24	1.45e-21	-0.35	-0.45	Total body bone mineral density;	chr2:27492549	chr2:27356246~27367622:+
PRAD	cis	rs748404	0.66	rs518288	ENSG00000205771.5	CATSPER2P1	-10.88	1.17e-24	1.47e-21	-0.5	-0.45	Lung cancer;	chr15:43471801	chr15:43726918~43747094:-
PRAD	cis	rs6570726	0.791	rs427128	ENSG00000235652.6	RP11-545I5.3	10.88	1.18e-24	1.48e-21	0.47	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145544781	chr6:145799409~145886585:+
PRAD	cis	rs875971	0.767	rs1643394	ENSG00000237310.1	GS1-124K5.4	10.88	1.19e-24	1.49e-21	0.42	0.45	Aortic root size;	chr7:66371107	chr7:66493706~66495474:+
PRAD	cis	rs1577917	0.876	rs1582126	ENSG00000203875.9	SNHG5	-10.88	1.19e-24	1.49e-21	-0.53	-0.45	Response to antipsychotic treatment;	chr6:85987487	chr6:85660950~85678736:-
PRAD	cis	rs2919917	0.628	rs2625663	ENSG00000254352.1	RP11-578O24.2	10.88	1.19e-24	1.49e-21	0.6	0.45	Lymphocyte counts;	chr8:78718106	chr8:78723796~78724136:-
PRAD	cis	rs875971	0.862	rs778702	ENSG00000237310.1	GS1-124K5.4	10.88	1.19e-24	1.49e-21	0.42	0.45	Aortic root size;	chr7:66399848	chr7:66493706~66495474:+
PRAD	cis	rs780096	0.546	rs4425043	ENSG00000234072.1	AC074117.10	-10.88	1.19e-24	1.5e-21	-0.36	-0.45	Total body bone mineral density;	chr2:27510585	chr2:27356246~27367622:+
PRAD	cis	rs9322193	0.887	rs9767113	ENSG00000216906.2	RP11-350J20.9	10.87	1.21e-24	1.52e-21	0.52	0.45	Lung cancer;	chr6:149718157	chr6:149904243~149906418:+
PRAD	cis	rs34779708	0.966	rs11599606	ENSG00000230534.5	RP11-297A16.2	10.87	1.22e-24	1.52e-21	0.62	0.45	Inflammatory bowel disease;Crohn's disease;	chr10:35117698	chr10:35098006~35127020:-
PRAD	cis	rs1062177	0.756	rs2915827	ENSG00000213433.5	RPLP1P6	10.87	1.22e-24	1.53e-21	0.53	0.45	Preschool internalizing problems;	chr5:151740144	chr5:151765859~151766378:-
PRAD	cis	rs2919917	0.628	rs7823970	ENSG00000254352.1	RP11-578O24.2	10.87	1.23e-24	1.54e-21	0.58	0.45	Lymphocyte counts;	chr8:78681364	chr8:78723796~78724136:-
PRAD	cis	rs2919917	0.616	rs7823723	ENSG00000254352.1	RP11-578O24.2	10.87	1.23e-24	1.54e-21	0.58	0.45	Lymphocyte counts;	chr8:78681390	chr8:78723796~78724136:-
PRAD	cis	rs34779708	1	rs12769189	ENSG00000230534.5	RP11-297A16.2	10.87	1.24e-24	1.55e-21	0.62	0.45	Inflammatory bowel disease;Crohn's disease;	chr10:35110740	chr10:35098006~35127020:-
PRAD	cis	rs6061231	0.724	rs1570027	ENSG00000273619.1	RP5-908M14.9	-10.87	1.24e-24	1.56e-21	-0.33	-0.45	Colorectal cancer;	chr20:62393540	chr20:62386303~62386970:-
PRAD	cis	rs2282300	0.739	rs67670125	ENSG00000254532.1	RP11-624D11.2	10.87	1.24e-24	1.56e-21	0.66	0.45	Morning vs. evening chronotype;	chr11:30193367	chr11:30044058~30084343:-
PRAD	cis	rs10875746	0.903	rs11168401	ENSG00000240399.1	RP1-228P16.1	-10.87	1.25e-24	1.56e-21	-0.46	-0.45	Longevity (90 years and older);	chr12:48087736	chr12:48054813~48055591:-
PRAD	cis	rs10875746	0.903	rs12304476	ENSG00000240399.1	RP1-228P16.1	-10.87	1.25e-24	1.56e-21	-0.46	-0.45	Longevity (90 years and older);	chr12:48088370	chr12:48054813~48055591:-
PRAD	cis	rs10875746	0.903	rs12306451	ENSG00000240399.1	RP1-228P16.1	-10.87	1.25e-24	1.56e-21	-0.46	-0.45	Longevity (90 years and older);	chr12:48089458	chr12:48054813~48055591:-
PRAD	cis	rs10875746	0.903	rs3782911	ENSG00000240399.1	RP1-228P16.1	-10.87	1.25e-24	1.56e-21	-0.46	-0.45	Longevity (90 years and older);	chr12:48089709	chr12:48054813~48055591:-
PRAD	cis	rs10875746	0.859	rs3782910	ENSG00000240399.1	RP1-228P16.1	-10.87	1.25e-24	1.56e-21	-0.46	-0.45	Longevity (90 years and older);	chr12:48089724	chr12:48054813~48055591:-
PRAD	cis	rs10875746	0.903	rs61918806	ENSG00000240399.1	RP1-228P16.1	-10.87	1.25e-24	1.56e-21	-0.46	-0.45	Longevity (90 years and older);	chr12:48090650	chr12:48054813~48055591:-
PRAD	cis	rs10875746	0.903	rs11168403	ENSG00000240399.1	RP1-228P16.1	-10.87	1.25e-24	1.56e-21	-0.46	-0.45	Longevity (90 years and older);	chr12:48091175	chr12:48054813~48055591:-
PRAD	cis	rs10875746	0.903	rs10875740	ENSG00000240399.1	RP1-228P16.1	-10.87	1.25e-24	1.56e-21	-0.46	-0.45	Longevity (90 years and older);	chr12:48095334	chr12:48054813~48055591:-
PRAD	cis	rs7772486	0.754	rs6932863	ENSG00000235652.6	RP11-545I5.3	-10.87	1.25e-24	1.57e-21	-0.47	-0.45	Lobe attachment (rater-scored or self-reported);	chr6:145700119	chr6:145799409~145886585:+
PRAD	cis	rs34375054	0.641	rs34624329	ENSG00000279233.1	RP11-158L12.4	10.87	1.28e-24	1.6e-21	0.41	0.45	Post bronchodilator FEV1/FVC ratio;	chr12:125123482	chr12:125138245~125141711:+
PRAD	cis	rs2739330	0.828	rs5751770	ENSG00000272787.1	KB-226F1.2	-10.87	1.28e-24	1.61e-21	-0.49	-0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23969211~23969873:+
PRAD	cis	rs748404	0.69	rs2467737	ENSG00000205771.5	CATSPER2P1	-10.87	1.29e-24	1.61e-21	-0.5	-0.45	Lung cancer;	chr15:43444990	chr15:43726918~43747094:-
PRAD	cis	rs748404	0.66	rs2439846	ENSG00000205771.5	CATSPER2P1	-10.87	1.29e-24	1.61e-21	-0.5	-0.45	Lung cancer;	chr15:43448772	chr15:43726918~43747094:-
PRAD	cis	rs6700559	0.873	rs7542840	ENSG00000260088.1	RP11-92G12.3	-10.87	1.29e-24	1.62e-21	-0.58	-0.45	Coronary artery disease;	chr1:200686558	chr1:200669507~200694250:+
PRAD	cis	rs7772486	0.72	rs991507	ENSG00000235652.6	RP11-545I5.3	-10.87	1.3e-24	1.63e-21	-0.46	-0.45	Lobe attachment (rater-scored or self-reported);	chr6:145702473	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.791	rs2096201	ENSG00000235652.6	RP11-545I5.3	10.87	1.31e-24	1.64e-21	0.47	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145613137	chr6:145799409~145886585:+
PRAD	cis	rs7714584	0.826	rs12655654	ENSG00000197083.10	ZNF300P1	10.87	1.31e-24	1.64e-21	0.84	0.45	Crohn's disease;	chr5:150794733	chr5:150930645~150946289:-
PRAD	cis	rs7714584	1	rs74955473	ENSG00000197083.10	ZNF300P1	10.87	1.31e-24	1.64e-21	0.84	0.45	Crohn's disease;	chr5:150794996	chr5:150930645~150946289:-
PRAD	cis	rs7714584	1	rs79780973	ENSG00000197083.10	ZNF300P1	10.87	1.31e-24	1.64e-21	0.84	0.45	Crohn's disease;	chr5:150795248	chr5:150930645~150946289:-
PRAD	cis	rs34779708	0.966	rs12769484	ENSG00000230534.5	RP11-297A16.2	10.87	1.32e-24	1.65e-21	0.61	0.45	Inflammatory bowel disease;Crohn's disease;	chr10:35176818	chr10:35098006~35127020:-
PRAD	cis	rs9322193	0.962	rs4869730	ENSG00000216906.2	RP11-350J20.9	10.87	1.32e-24	1.65e-21	0.52	0.45	Lung cancer;	chr6:149808187	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.923	rs2151913	ENSG00000216906.2	RP11-350J20.9	10.87	1.32e-24	1.65e-21	0.52	0.45	Lung cancer;	chr6:149809506	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.884	rs10872648	ENSG00000268592.3	RAET1E-AS1	10.87	1.32e-24	1.65e-21	0.63	0.45	Lung cancer;	chr6:149758699	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.884	rs11155679	ENSG00000268592.3	RAET1E-AS1	10.87	1.32e-24	1.65e-21	0.63	0.45	Lung cancer;	chr6:149758881	chr6:149863494~149919507:+
PRAD	cis	rs748404	0.631	rs7167882	ENSG00000205771.5	CATSPER2P1	-10.86	1.32e-24	1.65e-21	-0.5	-0.45	Lung cancer;	chr15:43386465	chr15:43726918~43747094:-
PRAD	cis	rs1062177	0.694	rs2915816	ENSG00000213433.5	RPLP1P6	10.86	1.32e-24	1.65e-21	0.52	0.45	Preschool internalizing problems;	chr5:151736296	chr5:151765859~151766378:-
PRAD	cis	rs7615952	0.551	rs6438945	ENSG00000171084.14	FAM86JP	10.86	1.35e-24	1.68e-21	0.81	0.45	Blood pressure (smoking interaction);	chr3:125915630	chr3:125916620~125930024:+
PRAD	cis	rs7615952	0.673	rs7632557	ENSG00000171084.14	FAM86JP	10.86	1.35e-24	1.68e-21	0.81	0.45	Blood pressure (smoking interaction);	chr3:125916038	chr3:125916620~125930024:+
PRAD	cis	rs7615952	0.932	rs9841157	ENSG00000171084.14	FAM86JP	10.86	1.35e-24	1.68e-21	0.81	0.45	Blood pressure (smoking interaction);	chr3:125916812	chr3:125916620~125930024:+
PRAD	cis	rs7615952	0.551	rs12695470	ENSG00000171084.14	FAM86JP	10.86	1.35e-24	1.68e-21	0.81	0.45	Blood pressure (smoking interaction);	chr3:125916875	chr3:125916620~125930024:+
PRAD	cis	rs7044106	0.664	rs7861679	ENSG00000226752.6	PSMD5-AS1	10.86	1.36e-24	1.69e-21	0.55	0.45	Hip circumference adjusted for BMI;	chr9:120613311	chr9:120824828~120854385:+
PRAD	cis	rs2404602	0.647	rs3812909	ENSG00000259422.1	RP11-593F23.1	-10.86	1.36e-24	1.7e-21	-0.6	-0.45	Blood metabolite levels;	chr15:76883859	chr15:76174891~76181486:-
PRAD	cis	rs1185460	0.934	rs10892328	ENSG00000271751.1	RP11-110I1.14	-10.86	1.36e-24	1.7e-21	-0.64	-0.45	Coronary artery disease;	chr11:119071944	chr11:119065263~119065677:-
PRAD	cis	rs507080	0.733	rs489126	ENSG00000255422.1	AP002954.4	-10.86	1.38e-24	1.72e-21	-0.55	-0.45	Serum metabolite levels;	chr11:118702038	chr11:118704607~118750263:+
PRAD	cis	rs2282300	0.739	rs1222211	ENSG00000254532.1	RP11-624D11.2	10.86	1.38e-24	1.72e-21	0.65	0.45	Morning vs. evening chronotype;	chr11:30340692	chr11:30044058~30084343:-
PRAD	cis	rs9487094	0.71	rs10499052	ENSG00000260273.1	RP11-425D10.10	10.86	1.38e-24	1.73e-21	0.68	0.45	Height;	chr6:109564272	chr6:109382795~109383666:+
PRAD	cis	rs9545047	0.68	rs9574405	ENSG00000227676.3	LINC01068	10.86	1.39e-24	1.74e-21	0.55	0.45	Schizophrenia;	chr13:79328943	chr13:79566727~79571436:+
PRAD	cis	rs1150668	0.83	rs2859365	ENSG00000204709.4	LINC01556	-10.86	1.39e-24	1.74e-21	-0.56	-0.45	Pubertal anthropometrics;	chr6:28423688	chr6:28943877~28944537:+
PRAD	cis	rs507080	0.733	rs4486664	ENSG00000255422.1	AP002954.4	-10.86	1.4e-24	1.74e-21	-0.55	-0.45	Serum metabolite levels;	chr11:118698358	chr11:118704607~118750263:+
PRAD	cis	rs748404	0.69	rs1079309	ENSG00000205771.5	CATSPER2P1	-10.86	1.4e-24	1.74e-21	-0.5	-0.45	Lung cancer;	chr15:43490966	chr15:43726918~43747094:-
PRAD	cis	rs4713118	0.587	rs61471148	ENSG00000280107.1	AL022393.9	-10.86	1.4e-24	1.75e-21	-0.58	-0.45	Parkinson's disease;	chr6:28069254	chr6:28170845~28172521:+
PRAD	cis	rs9322193	0.576	rs7452592	ENSG00000231760.4	RP11-350J20.5	10.86	1.41e-24	1.76e-21	0.72	0.45	Lung cancer;	chr6:149875445	chr6:149796151~149826294:-
PRAD	cis	rs875971	0.755	rs76288834	ENSG00000237310.1	GS1-124K5.4	-10.86	1.42e-24	1.76e-21	-0.43	-0.45	Aortic root size;	chr7:66604815	chr7:66493706~66495474:+
PRAD	cis	rs34375054	0.525	rs1080910	ENSG00000279233.1	RP11-158L12.4	10.86	1.42e-24	1.77e-21	0.43	0.45	Post bronchodilator FEV1/FVC ratio;	chr12:125123946	chr12:125138245~125141711:+
PRAD	cis	rs1577917	0.917	rs2197651	ENSG00000203875.9	SNHG5	-10.86	1.43e-24	1.78e-21	-0.55	-0.45	Response to antipsychotic treatment;	chr6:85785724	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.958	rs10455448	ENSG00000203875.9	SNHG5	-10.86	1.43e-24	1.78e-21	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85823893	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.917	rs13196576	ENSG00000203875.9	SNHG5	-10.86	1.43e-24	1.78e-21	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85824348	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.958	rs3857480	ENSG00000203875.9	SNHG5	-10.86	1.43e-24	1.78e-21	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85825431	chr6:85660950~85678736:-
PRAD	cis	rs9322193	0.962	rs9322220	ENSG00000216906.2	RP11-350J20.9	10.85	1.44e-24	1.8e-21	0.53	0.45	Lung cancer;	chr6:149782897	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.962	rs10214845	ENSG00000216906.2	RP11-350J20.9	10.85	1.44e-24	1.8e-21	0.53	0.45	Lung cancer;	chr6:149783124	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.962	rs9767122	ENSG00000216906.2	RP11-350J20.9	10.85	1.44e-24	1.8e-21	0.53	0.45	Lung cancer;	chr6:149783553	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.923	rs1413654	ENSG00000216906.2	RP11-350J20.9	10.85	1.44e-24	1.8e-21	0.53	0.45	Lung cancer;	chr6:149783956	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.683	rs113281309	ENSG00000216906.2	RP11-350J20.9	10.85	1.44e-24	1.8e-21	0.53	0.45	Lung cancer;	chr6:149787289	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.962	rs9688809	ENSG00000216906.2	RP11-350J20.9	10.85	1.44e-24	1.8e-21	0.53	0.45	Lung cancer;	chr6:149787920	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.962	rs9689242	ENSG00000216906.2	RP11-350J20.9	10.85	1.44e-24	1.8e-21	0.53	0.45	Lung cancer;	chr6:149787970	chr6:149904243~149906418:+
PRAD	cis	rs9322193	1	rs9767077	ENSG00000216906.2	RP11-350J20.9	10.85	1.44e-24	1.8e-21	0.53	0.45	Lung cancer;	chr6:149788479	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.923	rs9688938	ENSG00000216906.2	RP11-350J20.9	10.85	1.44e-24	1.8e-21	0.53	0.45	Lung cancer;	chr6:149788941	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.962	rs9688940	ENSG00000216906.2	RP11-350J20.9	10.85	1.44e-24	1.8e-21	0.53	0.45	Lung cancer;	chr6:149788977	chr6:149904243~149906418:+
PRAD	cis	rs2919917	0.628	rs13265305	ENSG00000254352.1	RP11-578O24.2	10.85	1.45e-24	1.8e-21	0.58	0.45	Lymphocyte counts;	chr8:78656575	chr8:78723796~78724136:-
PRAD	cis	rs1577917	1	rs1415753	ENSG00000203875.9	SNHG5	-10.85	1.45e-24	1.81e-21	-0.53	-0.45	Response to antipsychotic treatment;	chr6:86043356	chr6:85660950~85678736:-
PRAD	cis	rs1577917	1	rs1577919	ENSG00000203875.9	SNHG5	-10.85	1.45e-24	1.81e-21	-0.53	-0.45	Response to antipsychotic treatment;	chr6:86047578	chr6:85660950~85678736:-
PRAD	cis	rs1577917	1	rs12203493	ENSG00000203875.9	SNHG5	-10.85	1.45e-24	1.81e-21	-0.53	-0.45	Response to antipsychotic treatment;	chr6:86048924	chr6:85660950~85678736:-
PRAD	cis	rs1577917	1	rs12203924	ENSG00000203875.9	SNHG5	-10.85	1.45e-24	1.81e-21	-0.53	-0.45	Response to antipsychotic treatment;	chr6:86066694	chr6:85660950~85678736:-
PRAD	cis	rs853679	0.517	rs1340004	ENSG00000280107.1	AL022393.9	-10.85	1.46e-24	1.81e-21	-0.59	-0.45	Depression;	chr6:28135913	chr6:28170845~28172521:+
PRAD	cis	rs9322193	0.962	rs2065664	ENSG00000216906.2	RP11-350J20.9	10.85	1.47e-24	1.83e-21	0.52	0.45	Lung cancer;	chr6:149762485	chr6:149904243~149906418:+
PRAD	cis	rs1577917	0.917	rs12665464	ENSG00000203875.9	SNHG5	-10.85	1.47e-24	1.83e-21	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85864415	chr6:85660950~85678736:-
PRAD	cis	rs6700559	0.683	rs7548530	ENSG00000260088.1	RP11-92G12.3	-10.85	1.47e-24	1.83e-21	-0.59	-0.45	Coronary artery disease;	chr1:200687904	chr1:200669507~200694250:+
PRAD	cis	rs6700559	0.683	rs7526136	ENSG00000260088.1	RP11-92G12.3	-10.85	1.47e-24	1.83e-21	-0.59	-0.45	Coronary artery disease;	chr1:200687911	chr1:200669507~200694250:+
PRAD	cis	rs6700559	0.733	rs7526265	ENSG00000260088.1	RP11-92G12.3	-10.85	1.47e-24	1.83e-21	-0.59	-0.45	Coronary artery disease;	chr1:200687916	chr1:200669507~200694250:+
PRAD	cis	rs2739330	0.76	rs1007888	ENSG00000224205.1	AP000351.4	10.85	1.47e-24	1.83e-21	0.56	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23987320~23991421:-
PRAD	cis	rs2919917	0.628	rs10111658	ENSG00000254352.1	RP11-578O24.2	10.85	1.48e-24	1.84e-21	0.59	0.45	Lymphocyte counts;	chr8:78652834	chr8:78723796~78724136:-
PRAD	cis	rs2919917	0.59	rs10098472	ENSG00000254352.1	RP11-578O24.2	10.85	1.48e-24	1.84e-21	0.59	0.45	Lymphocyte counts;	chr8:78652955	chr8:78723796~78724136:-
PRAD	cis	rs2919917	0.628	rs13251931	ENSG00000254352.1	RP11-578O24.2	10.85	1.48e-24	1.84e-21	0.59	0.45	Lymphocyte counts;	chr8:78653990	chr8:78723796~78724136:-
PRAD	cis	rs1577917	0.874	rs11756621	ENSG00000203875.9	SNHG5	-10.85	1.48e-24	1.84e-21	-0.54	-0.45	Response to antipsychotic treatment;	chr6:86030345	chr6:85660950~85678736:-
PRAD	cis	rs1577917	1	rs12196411	ENSG00000203875.9	SNHG5	-10.85	1.48e-24	1.84e-21	-0.54	-0.45	Response to antipsychotic treatment;	chr6:86070044	chr6:85660950~85678736:-
PRAD	cis	rs7617773	0.539	rs13094496	ENSG00000229759.1	MRPS18AP1	10.85	1.49e-24	1.85e-21	0.48	0.45	Coronary artery disease;	chr3:48345560	chr3:48256350~48256938:-
PRAD	cis	rs2729354	0.903	rs2729371	ENSG00000265566.2	RN7SL605P	-10.85	1.49e-24	1.85e-21	-0.69	-0.45	Blood protein levels;	chr11:57553849	chr11:57528085~57528365:-
PRAD	cis	rs2919917	0.628	rs2887482	ENSG00000254352.1	RP11-578O24.2	10.85	1.49e-24	1.86e-21	0.59	0.45	Lymphocyte counts;	chr8:78659633	chr8:78723796~78724136:-
PRAD	cis	rs2919917	0.628	rs1905364	ENSG00000254352.1	RP11-578O24.2	10.85	1.49e-24	1.86e-21	0.59	0.45	Lymphocyte counts;	chr8:78660244	chr8:78723796~78724136:-
PRAD	cis	rs9322193	0.962	rs9478848	ENSG00000223701.3	RAET1E-AS1	10.85	1.51e-24	1.88e-21	0.6	0.45	Lung cancer;	chr6:149825080	chr6:149884431~149919508:+
PRAD	cis	rs274567	0.602	rs272853	ENSG00000233006.5	AC034220.3	10.85	1.52e-24	1.89e-21	0.41	0.45	Blood metabolite levels;	chr5:132352868	chr5:132311285~132369916:-
PRAD	cis	rs4964805	0.672	rs11111757	ENSG00000257681.1	RP11-341G23.4	10.85	1.52e-24	1.89e-21	0.43	0.45	Attention deficit hyperactivity disorder;	chr12:103766984	chr12:103746315~103768858:-
PRAD	cis	rs1577917	0.958	rs12202188	ENSG00000203875.9	SNHG5	-10.85	1.52e-24	1.89e-21	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85852982	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.958	rs36035797	ENSG00000203875.9	SNHG5	-10.85	1.52e-24	1.89e-21	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85853162	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.917	rs2084293	ENSG00000203875.9	SNHG5	-10.85	1.52e-24	1.89e-21	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85856284	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.958	rs12209668	ENSG00000203875.9	SNHG5	-10.85	1.52e-24	1.89e-21	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85856799	chr6:85660950~85678736:-
PRAD	cis	rs1150668	0.796	rs2247002	ENSG00000204709.4	LINC01556	10.85	1.53e-24	1.9e-21	0.56	0.45	Pubertal anthropometrics;	chr6:28430174	chr6:28943877~28944537:+
PRAD	cis	rs10875746	0.903	rs2158516	ENSG00000240399.1	RP1-228P16.1	-10.85	1.53e-24	1.9e-21	-0.46	-0.45	Longevity (90 years and older);	chr12:48097051	chr12:48054813~48055591:-
PRAD	cis	rs10875746	0.903	rs12313404	ENSG00000240399.1	RP1-228P16.1	-10.85	1.53e-24	1.9e-21	-0.46	-0.45	Longevity (90 years and older);	chr12:48098265	chr12:48054813~48055591:-
PRAD	cis	rs10875746	0.855	rs73102067	ENSG00000240399.1	RP1-228P16.1	-10.85	1.53e-24	1.9e-21	-0.46	-0.45	Longevity (90 years and older);	chr12:48100643	chr12:48054813~48055591:-
PRAD	cis	rs1577917	1	rs12208493	ENSG00000203875.9	SNHG5	-10.85	1.54e-24	1.91e-21	-0.52	-0.45	Response to antipsychotic treatment;	chr6:85952549	chr6:85660950~85678736:-
PRAD	cis	rs1577917	1	rs12213149	ENSG00000203875.9	SNHG5	-10.85	1.54e-24	1.91e-21	-0.52	-0.45	Response to antipsychotic treatment;	chr6:85958926	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.958	rs11756615	ENSG00000203875.9	SNHG5	-10.85	1.54e-24	1.91e-21	-0.52	-0.45	Response to antipsychotic treatment;	chr6:85970117	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.958	rs10944168	ENSG00000203875.9	SNHG5	-10.85	1.54e-24	1.91e-21	-0.52	-0.45	Response to antipsychotic treatment;	chr6:85970438	chr6:85660950~85678736:-
PRAD	cis	rs765787	0.53	rs11636410	ENSG00000259520.4	CTD-2651B20.3	-10.85	1.55e-24	1.92e-21	-0.56	-0.45	Uric acid levels;	chr15:45243715	chr15:45251580~45279251:-
PRAD	cis	rs9322193	0.607	rs915140	ENSG00000268592.3	RAET1E-AS1	10.85	1.55e-24	1.92e-21	0.72	0.45	Lung cancer;	chr6:149899674	chr6:149863494~149919507:+
PRAD	cis	rs7772486	0.719	rs702307	ENSG00000235652.6	RP11-545I5.3	-10.85	1.55e-24	1.93e-21	-0.46	-0.45	Lobe attachment (rater-scored or self-reported);	chr6:145672318	chr6:145799409~145886585:+
PRAD	cis	rs11723261	0.582	rs6599293	ENSG00000275426.1	CH17-262A2.1	10.85	1.55e-24	1.93e-21	0.62	0.45	Immune response to smallpox vaccine (IL-6);	chr4:139246	chr4:149738~150317:+
PRAD	cis	rs11723261	0.582	rs4634177	ENSG00000275426.1	CH17-262A2.1	10.85	1.55e-24	1.93e-21	0.62	0.45	Immune response to smallpox vaccine (IL-6);	chr4:143055	chr4:149738~150317:+
PRAD	cis	rs6570726	0.643	rs9403735	ENSG00000235652.6	RP11-545I5.3	10.85	1.56e-24	1.93e-21	0.47	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145615455	chr6:145799409~145886585:+
PRAD	cis	rs6700559	0.873	rs7524025	ENSG00000260088.1	RP11-92G12.3	-10.85	1.56e-24	1.94e-21	-0.58	-0.45	Coronary artery disease;	chr1:200687859	chr1:200669507~200694250:+
PRAD	cis	rs6700559	0.815	rs7526365	ENSG00000260088.1	RP11-92G12.3	-10.85	1.56e-24	1.94e-21	-0.58	-0.45	Coronary artery disease;	chr1:200688020	chr1:200669507~200694250:+
PRAD	cis	rs1150668	0.799	rs9301	ENSG00000204709.4	LINC01556	10.85	1.57e-24	1.95e-21	0.57	0.45	Pubertal anthropometrics;	chr6:28324929	chr6:28943877~28944537:+
PRAD	cis	rs1150668	0.799	rs853684	ENSG00000204709.4	LINC01556	10.85	1.57e-24	1.95e-21	0.57	0.45	Pubertal anthropometrics;	chr6:28326773	chr6:28943877~28944537:+
PRAD	cis	rs9487094	0.885	rs11153214	ENSG00000260273.1	RP11-425D10.10	10.84	1.58e-24	1.96e-21	0.65	0.45	Height;	chr6:109694120	chr6:109382795~109383666:+
PRAD	cis	rs507080	0.733	rs517445	ENSG00000255422.1	AP002954.4	-10.84	1.58e-24	1.96e-21	-0.55	-0.45	Serum metabolite levels;	chr11:118702826	chr11:118704607~118750263:+
PRAD	cis	rs507080	0.771	rs687664	ENSG00000255422.1	AP002954.4	-10.84	1.58e-24	1.96e-21	-0.55	-0.45	Serum metabolite levels;	chr11:118703476	chr11:118704607~118750263:+
PRAD	cis	rs507080	0.771	rs523715	ENSG00000255422.1	AP002954.4	-10.84	1.58e-24	1.96e-21	-0.55	-0.45	Serum metabolite levels;	chr11:118703479	chr11:118704607~118750263:+
PRAD	cis	rs2455601	0.786	rs10279	ENSG00000254860.4	TMEM9B-AS1	10.84	1.61e-24	2e-21	0.53	0.45	Schizophrenia;	chr11:8947762	chr11:8964675~8977527:+
PRAD	cis	rs7849270	1	rs7036236	ENSG00000268707.1	RP11-247A12.7	-10.84	1.62e-24	2.01e-21	-0.51	-0.45	Blood metabolite ratios;	chr9:129137020	chr9:129170434~129170940:+
PRAD	cis	rs7849270	0.959	rs7039031	ENSG00000268707.1	RP11-247A12.7	-10.84	1.62e-24	2.01e-21	-0.51	-0.45	Blood metabolite ratios;	chr9:129137116	chr9:129170434~129170940:+
PRAD	cis	rs9545047	0.716	rs9545061	ENSG00000227676.3	LINC01068	10.84	1.63e-24	2.02e-21	0.55	0.45	Schizophrenia;	chr13:79310695	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.716	rs9545067	ENSG00000227676.3	LINC01068	10.84	1.63e-24	2.02e-21	0.55	0.45	Schizophrenia;	chr13:79323429	chr13:79566727~79571436:+
PRAD	cis	rs34779708	0.931	rs12776390	ENSG00000230534.5	RP11-297A16.2	10.84	1.64e-24	2.03e-21	0.61	0.45	Inflammatory bowel disease;Crohn's disease;	chr10:35102607	chr10:35098006~35127020:-
PRAD	cis	rs1577917	1	rs10944169	ENSG00000203875.9	SNHG5	-10.84	1.64e-24	2.03e-21	-0.52	-0.45	Response to antipsychotic treatment;	chr6:85973318	chr6:85660950~85678736:-
PRAD	cis	rs9322193	0.923	rs9688452	ENSG00000216906.2	RP11-350J20.9	10.84	1.65e-24	2.04e-21	0.53	0.45	Lung cancer;	chr6:149658764	chr6:149904243~149906418:+
PRAD	cis	rs2404602	0.647	rs11633869	ENSG00000259422.1	RP11-593F23.1	10.84	1.66e-24	2.05e-21	0.6	0.45	Blood metabolite levels;	chr15:76840981	chr15:76174891~76181486:-
PRAD	cis	rs6142102	0.961	rs2235596	ENSG00000276073.1	RP5-1125A11.7	10.84	1.66e-24	2.06e-21	0.46	0.45	Skin pigmentation;	chr20:34096503	chr20:33985617~33988989:-
PRAD	cis	rs13392177	0.637	rs61041183	ENSG00000261338.2	RP11-378A13.1	10.84	1.67e-24	2.07e-21	0.51	0.45	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218191657	chr2:218255319~218257366:+
PRAD	cis	rs11723261	0.582	rs11735742	ENSG00000275426.1	CH17-262A2.1	-10.84	1.68e-24	2.08e-21	-0.61	-0.45	Immune response to smallpox vaccine (IL-6);	chr4:148766	chr4:149738~150317:+
PRAD	cis	rs6570726	0.791	rs443628	ENSG00000235652.6	RP11-545I5.3	10.84	1.69e-24	2.09e-21	0.47	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145562348	chr6:145799409~145886585:+
PRAD	cis	rs6538678	0.857	rs4762626	ENSG00000258343.1	RP11-536G4.2	-10.84	1.69e-24	2.09e-21	-0.69	-0.45	Lupus nephritis in systemic lupus erythematosus;	chr12:95811383	chr12:95795345~95858839:-
PRAD	cis	rs7849270	1	rs10819464	ENSG00000268707.1	RP11-247A12.7	-10.84	1.69e-24	2.09e-21	-0.51	-0.45	Blood metabolite ratios;	chr9:129113998	chr9:129170434~129170940:+
PRAD	cis	rs7714584	1	rs11739677	ENSG00000197083.10	ZNF300P1	10.83	1.72e-24	2.13e-21	0.79	0.45	Crohn's disease;	chr5:150915321	chr5:150930645~150946289:-
PRAD	cis	rs7714584	1	rs76433514	ENSG00000197083.10	ZNF300P1	10.83	1.72e-24	2.13e-21	0.79	0.45	Crohn's disease;	chr5:150926970	chr5:150930645~150946289:-
PRAD	cis	rs2739330	0.734	rs2000467	ENSG00000250470.1	AP000351.3	-10.83	1.75e-24	2.17e-21	-0.61	-0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23976904~23977585:-
PRAD	cis	rs507080	0.733	rs552079	ENSG00000255422.1	AP002954.4	-10.83	1.8e-24	2.22e-21	-0.55	-0.45	Serum metabolite levels;	chr11:118702313	chr11:118704607~118750263:+
PRAD	cis	rs507080	0.733	rs673547	ENSG00000255422.1	AP002954.4	-10.83	1.8e-24	2.22e-21	-0.55	-0.45	Serum metabolite levels;	chr11:118702630	chr11:118704607~118750263:+
PRAD	cis	rs9322193	0.962	rs9397022	ENSG00000223701.3	RAET1E-AS1	10.83	1.8e-24	2.23e-21	0.6	0.45	Lung cancer;	chr6:149812052	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.962	rs9397357	ENSG00000223701.3	RAET1E-AS1	10.83	1.8e-24	2.23e-21	0.6	0.45	Lung cancer;	chr6:149812465	chr6:149884431~149919508:+
PRAD	cis	rs4964805	0.802	rs11111778	ENSG00000257681.1	RP11-341G23.4	10.83	1.82e-24	2.24e-21	0.43	0.45	Attention deficit hyperactivity disorder;	chr12:103791653	chr12:103746315~103768858:-
PRAD	cis	rs9322193	0.923	rs14314	ENSG00000216906.2	RP11-350J20.9	10.83	1.82e-24	2.25e-21	0.52	0.45	Lung cancer;	chr6:149820395	chr6:149904243~149906418:+
PRAD	cis	rs7849270	1	rs2297112	ENSG00000268707.1	RP11-247A12.7	-10.83	1.85e-24	2.28e-21	-0.51	-0.45	Blood metabolite ratios;	chr9:129137901	chr9:129170434~129170940:+
PRAD	cis	rs3931020	1	rs12410060	ENSG00000272864.1	RP11-17E13.2	-10.83	1.85e-24	2.28e-21	-0.49	-0.45	Resistin levels;	chr1:74780164	chr1:74698769~74699333:-
PRAD	cis	rs7849270	0.921	rs7019373	ENSG00000268707.1	RP11-247A12.7	-10.82	1.87e-24	2.31e-21	-0.51	-0.45	Blood metabolite ratios;	chr9:129134942	chr9:129170434~129170940:+
PRAD	cis	rs748404	0.66	rs548704	ENSG00000205771.5	CATSPER2P1	-10.82	1.88e-24	2.32e-21	-0.5	-0.45	Lung cancer;	chr15:43499508	chr15:43726918~43747094:-
PRAD	cis	rs2348418	0.733	rs7294486	ENSG00000247934.4	RP11-967K21.1	-10.82	1.9e-24	2.34e-21	-0.41	-0.45	Lung function (FEV1);Lung function (FVC);	chr12:28181989	chr12:28163298~28190738:-
PRAD	cis	rs9487094	0.744	rs13220304	ENSG00000260273.1	RP11-425D10.10	10.82	1.9e-24	2.35e-21	0.66	0.45	Height;	chr6:109331033	chr6:109382795~109383666:+
PRAD	cis	rs2739330	0.828	rs5760108	ENSG00000272787.1	KB-226F1.2	-10.82	1.92e-24	2.36e-21	-0.49	-0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23969211~23969873:+
PRAD	cis	rs2282300	0.956	rs1222212	ENSG00000242353.1	RP4-710M3.1	-10.82	1.92e-24	2.37e-21	-0.52	-0.45	Morning vs. evening chronotype;	chr11:30353096	chr11:30368148~30368646:+
PRAD	cis	rs71403859	0.502	rs8051974	ENSG00000260886.1	TAT-AS1	10.82	1.93e-24	2.38e-21	0.73	0.45	Post bronchodilator FEV1;	chr16:71454868	chr16:71565789~71578187:+
PRAD	cis	rs9322193	0.566	rs4869767	ENSG00000223701.3	RAET1E-AS1	-10.82	1.93e-24	2.38e-21	-0.69	-0.45	Lung cancer;	chr6:149923974	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.566	rs4869768	ENSG00000223701.3	RAET1E-AS1	-10.82	1.93e-24	2.38e-21	-0.69	-0.45	Lung cancer;	chr6:149924067	chr6:149884431~149919508:+
PRAD	cis	rs11673344	0.808	rs57916401	ENSG00000226686.6	LINC01535	10.82	1.94e-24	2.38e-21	0.62	0.45	Obesity-related traits;	chr19:37153149	chr19:37251912~37265535:+
PRAD	cis	rs1577917	0.917	rs12202170	ENSG00000203875.9	SNHG5	-10.82	1.94e-24	2.38e-21	-0.54	-0.45	Response to antipsychotic treatment;	chr6:85880668	chr6:85660950~85678736:-
PRAD	cis	rs1577917	1	rs10455449	ENSG00000203875.9	SNHG5	-10.82	1.94e-24	2.38e-21	-0.54	-0.45	Response to antipsychotic treatment;	chr6:85882508	chr6:85660950~85678736:-
PRAD	cis	rs7772486	0.701	rs11155438	ENSG00000235652.6	RP11-545I5.3	10.82	1.94e-24	2.39e-21	0.46	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145628976	chr6:145799409~145886585:+
PRAD	cis	rs9545047	0.716	rs6563096	ENSG00000227676.3	LINC01068	-10.82	1.94e-24	2.39e-21	-0.54	-0.45	Schizophrenia;	chr13:79284100	chr13:79566727~79571436:+
PRAD	cis	rs1577917	0.958	rs11756510	ENSG00000203875.9	SNHG5	-10.82	1.94e-24	2.39e-21	-0.52	-0.45	Response to antipsychotic treatment;	chr6:85990076	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.958	rs34765423	ENSG00000203875.9	SNHG5	-10.82	1.94e-24	2.39e-21	-0.55	-0.45	Response to antipsychotic treatment;	chr6:85774730	chr6:85660950~85678736:-
PRAD	cis	rs7849270	0.959	rs713218	ENSG00000268707.1	RP11-247A12.7	-10.82	1.95e-24	2.4e-21	-0.51	-0.45	Blood metabolite ratios;	chr9:129138491	chr9:129170434~129170940:+
PRAD	cis	rs11673344	0.864	rs7259513	ENSG00000226686.6	LINC01535	10.82	1.96e-24	2.41e-21	0.62	0.45	Obesity-related traits;	chr19:37085802	chr19:37251912~37265535:+
PRAD	cis	rs11673344	0.864	rs7256876	ENSG00000226686.6	LINC01535	10.82	1.96e-24	2.41e-21	0.62	0.45	Obesity-related traits;	chr19:37088570	chr19:37251912~37265535:+
PRAD	cis	rs9487094	1	rs17070580	ENSG00000260273.1	RP11-425D10.10	-10.82	1.98e-24	2.44e-21	-0.62	-0.45	Height;	chr6:109417511	chr6:109382795~109383666:+
PRAD	cis	rs150992	0.632	rs162341	ENSG00000248489.1	CTD-2007H13.3	10.82	2e-24	2.46e-21	0.51	0.45	Body mass index;	chr5:98967230	chr5:98929171~98995013:+
PRAD	cis	rs7772486	0.754	rs9399561	ENSG00000235652.6	RP11-545I5.3	10.82	2.01e-24	2.47e-21	0.46	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145634551	chr6:145799409~145886585:+
PRAD	cis	rs11723261	0.582	rs7679573	ENSG00000275426.1	CH17-262A2.1	10.82	2.01e-24	2.47e-21	0.63	0.45	Immune response to smallpox vaccine (IL-6);	chr4:157810	chr4:149738~150317:+
PRAD	cis	rs9322193	0.923	rs1934534	ENSG00000216906.2	RP11-350J20.9	10.82	2.02e-24	2.48e-21	0.52	0.45	Lung cancer;	chr6:149711896	chr6:149904243~149906418:+
PRAD	cis	rs2739330	0.828	rs2877178	ENSG00000272787.1	KB-226F1.2	-10.82	2.02e-24	2.48e-21	-0.49	-0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23969211~23969873:+
PRAD	cis	rs2739330	0.828	rs2154593	ENSG00000272787.1	KB-226F1.2	-10.82	2.02e-24	2.48e-21	-0.49	-0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23969211~23969873:+
PRAD	cis	rs1426063	0.614	rs77982391	ENSG00000260265.1	RP11-44F21.5	10.81	2.04e-24	2.51e-21	0.95	0.45	QT interval;	chr4:75125224	chr4:75081702~75084717:-
PRAD	cis	rs1577917	0.917	rs35283633	ENSG00000203875.9	SNHG5	-10.81	2.06e-24	2.53e-21	-0.52	-0.45	Response to antipsychotic treatment;	chr6:85981069	chr6:85660950~85678736:-
PRAD	cis	rs638893	0.636	rs583213	ENSG00000278376.1	RP11-158I9.8	-10.81	2.06e-24	2.53e-21	-0.54	-0.45	Vitiligo;	chr11:118798469	chr11:118791254~118793137:+
PRAD	cis	rs9322193	0.884	rs11155689	ENSG00000216906.2	RP11-350J20.9	10.81	2.06e-24	2.53e-21	0.52	0.45	Lung cancer;	chr6:149808470	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.923	rs2342857	ENSG00000216906.2	RP11-350J20.9	10.81	2.06e-24	2.53e-21	0.52	0.45	Lung cancer;	chr6:149809537	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.884	rs933055	ENSG00000216906.2	RP11-350J20.9	10.81	2.06e-24	2.53e-21	0.52	0.45	Lung cancer;	chr6:149809701	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.962	rs4869731	ENSG00000216906.2	RP11-350J20.9	10.81	2.06e-24	2.53e-21	0.52	0.45	Lung cancer;	chr6:149810072	chr6:149904243~149906418:+
PRAD	cis	rs9326248	0.861	rs1871757	ENSG00000280143.1	AP000892.6	10.81	2.06e-24	2.54e-21	0.44	0.45	Blood protein levels;	chr11:117159865	chr11:117204967~117210292:+
PRAD	cis	rs875971	0.767	rs61348003	ENSG00000237310.1	GS1-124K5.4	10.81	2.12e-24	2.61e-21	0.42	0.45	Aortic root size;	chr7:66540947	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.861	rs801215	ENSG00000237310.1	GS1-124K5.4	-10.81	2.12e-24	2.61e-21	-0.42	-0.45	Aortic root size;	chr7:66546951	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.756	rs2901210	ENSG00000237310.1	GS1-124K5.4	-10.81	2.12e-24	2.61e-21	-0.42	-0.45	Aortic root size;	chr7:66552518	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.862	rs13536	ENSG00000237310.1	GS1-124K5.4	-10.81	2.12e-24	2.61e-21	-0.42	-0.45	Aortic root size;	chr7:66554203	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.862	rs801209	ENSG00000237310.1	GS1-124K5.4	-10.81	2.12e-24	2.61e-21	-0.42	-0.45	Aortic root size;	chr7:66554403	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.862	rs801206	ENSG00000237310.1	GS1-124K5.4	-10.81	2.12e-24	2.61e-21	-0.42	-0.45	Aortic root size;	chr7:66556979	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.862	rs801204	ENSG00000237310.1	GS1-124K5.4	-10.81	2.12e-24	2.61e-21	-0.42	-0.45	Aortic root size;	chr7:66557934	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.862	rs801203	ENSG00000237310.1	GS1-124K5.4	-10.81	2.12e-24	2.61e-21	-0.42	-0.45	Aortic root size;	chr7:66558025	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.825	rs801202	ENSG00000237310.1	GS1-124K5.4	-10.81	2.12e-24	2.61e-21	-0.42	-0.45	Aortic root size;	chr7:66558942	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.862	rs801194	ENSG00000237310.1	GS1-124K5.4	-10.81	2.12e-24	2.61e-21	-0.42	-0.45	Aortic root size;	chr7:66563508	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.862	rs2024192	ENSG00000237310.1	GS1-124K5.4	-10.81	2.12e-24	2.61e-21	-0.42	-0.45	Aortic root size;	chr7:66576460	chr7:66493706~66495474:+
PRAD	cis	rs9322193	0.607	rs4870078	ENSG00000231760.4	RP11-350J20.5	-10.81	2.14e-24	2.63e-21	-0.7	-0.45	Lung cancer;	chr6:149880676	chr6:149796151~149826294:-
PRAD	cis	rs6538678	0.824	rs2887026	ENSG00000258343.1	RP11-536G4.2	-10.81	2.14e-24	2.63e-21	-0.69	-0.45	Lupus nephritis in systemic lupus erythematosus;	chr12:95854713	chr12:95795345~95858839:-
PRAD	cis	rs7044106	0.762	rs1530370	ENSG00000226752.6	PSMD5-AS1	-10.81	2.19e-24	2.68e-21	-0.56	-0.45	Hip circumference adjusted for BMI;	chr9:120662274	chr9:120824828~120854385:+
PRAD	cis	rs2282300	0.739	rs1765133	ENSG00000254532.1	RP11-624D11.2	10.81	2.19e-24	2.69e-21	0.66	0.45	Morning vs. evening chronotype;	chr11:30317853	chr11:30044058~30084343:-
PRAD	cis	rs34375054	0.672	rs58416336	ENSG00000279233.1	RP11-158L12.4	10.81	2.2e-24	2.69e-21	0.41	0.45	Post bronchodilator FEV1/FVC ratio;	chr12:125121882	chr12:125138245~125141711:+
PRAD	cis	rs7617773	0.539	rs35460860	ENSG00000229759.1	MRPS18AP1	10.81	2.2e-24	2.69e-21	0.47	0.45	Coronary artery disease;	chr3:48350595	chr3:48256350~48256938:-
PRAD	cis	rs748404	0.69	rs2924369	ENSG00000205771.5	CATSPER2P1	10.81	2.2e-24	2.7e-21	0.5	0.45	Lung cancer;	chr15:43485787	chr15:43726918~43747094:-
PRAD	cis	rs875971	0.767	rs12668005	ENSG00000237310.1	GS1-124K5.4	10.81	2.21e-24	2.71e-21	0.42	0.45	Aortic root size;	chr7:66444034	chr7:66493706~66495474:+
PRAD	cis	rs2404602	0.583	rs35707798	ENSG00000259422.1	RP11-593F23.1	10.8	2.23e-24	2.74e-21	0.56	0.45	Blood metabolite levels;	chr15:76272685	chr15:76174891~76181486:-
PRAD	cis	rs12049351	0.591	rs10916508	ENSG00000229367.1	HMGN2P19	10.8	2.24e-24	2.75e-21	0.59	0.45	Circulating myeloperoxidase levels (plasma);	chr1:229524044	chr1:229570532~229570796:+
PRAD	cis	rs9322193	0.923	rs57938011	ENSG00000268592.3	RAET1E-AS1	10.8	2.25e-24	2.76e-21	0.62	0.45	Lung cancer;	chr6:149642969	chr6:149863494~149919507:+
PRAD	cis	rs9322193	1	rs9377228	ENSG00000216906.2	RP11-350J20.9	10.8	2.25e-24	2.76e-21	0.52	0.45	Lung cancer;	chr6:149600862	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.923	rs62439840	ENSG00000216906.2	RP11-350J20.9	10.8	2.25e-24	2.76e-21	0.52	0.45	Lung cancer;	chr6:149674639	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.962	rs9393175	ENSG00000216906.2	RP11-350J20.9	10.8	2.25e-24	2.76e-21	0.52	0.45	Lung cancer;	chr6:149677587	chr6:149904243~149906418:+
PRAD	cis	rs780096	0.526	rs3845686	ENSG00000234072.1	AC074117.10	-10.8	2.26e-24	2.77e-21	-0.35	-0.45	Total body bone mineral density;	chr2:27432580	chr2:27356246~27367622:+
PRAD	cis	rs9322193	0.962	rs7740784	ENSG00000216906.2	RP11-350J20.9	10.8	2.27e-24	2.79e-21	0.52	0.45	Lung cancer;	chr6:149833364	chr6:149904243~149906418:+
PRAD	cis	rs875971	0.862	rs17747530	ENSG00000237310.1	GS1-124K5.4	10.8	2.28e-24	2.79e-21	0.42	0.45	Aortic root size;	chr7:66529742	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.862	rs13226170	ENSG00000237310.1	GS1-124K5.4	10.8	2.28e-24	2.79e-21	0.42	0.45	Aortic root size;	chr7:66534311	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.862	rs2420611	ENSG00000237310.1	GS1-124K5.4	10.8	2.28e-24	2.79e-21	0.42	0.45	Aortic root size;	chr7:66534333	chr7:66493706~66495474:+
PRAD	cis	rs10875746	0.81	rs10875732	ENSG00000240399.1	RP1-228P16.1	-10.8	2.3e-24	2.82e-21	-0.46	-0.45	Longevity (90 years and older);	chr12:48048322	chr12:48054813~48055591:-
PRAD	cis	rs1577917	0.958	rs72907388	ENSG00000203875.9	SNHG5	-10.8	2.31e-24	2.82e-21	-0.55	-0.45	Response to antipsychotic treatment;	chr6:85730489	chr6:85660950~85678736:-
PRAD	cis	rs10875746	0.855	rs73102065	ENSG00000240399.1	RP1-228P16.1	-10.8	2.31e-24	2.83e-21	-0.46	-0.45	Longevity (90 years and older);	chr12:48098824	chr12:48054813~48055591:-
PRAD	cis	rs2882667	0.627	rs1549203	ENSG00000253404.1	AC034243.1	-10.8	2.32e-24	2.84e-21	-0.59	-0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139132655	chr5:138744434~138753309:-
PRAD	cis	rs2919917	0.628	rs1021157	ENSG00000254352.1	RP11-578O24.2	10.8	2.32e-24	2.84e-21	0.58	0.45	Lymphocyte counts;	chr8:78662938	chr8:78723796~78724136:-
PRAD	cis	rs4820294	0.669	rs732857	ENSG00000233360.4	Z83844.1	10.8	2.33e-24	2.85e-21	0.55	0.45	Fat distribution (HIV);	chr22:37664843	chr22:37641832~37658377:-
PRAD	cis	rs875971	0.862	rs11765791	ENSG00000237310.1	GS1-124K5.4	10.8	2.33e-24	2.86e-21	0.42	0.45	Aortic root size;	chr7:66471587	chr7:66493706~66495474:+
PRAD	cis	rs7714584	1	rs12656538	ENSG00000197083.10	ZNF300P1	10.8	2.35e-24	2.87e-21	0.79	0.45	Crohn's disease;	chr5:150871818	chr5:150930645~150946289:-
PRAD	cis	rs11673344	0.864	rs1879497	ENSG00000226686.6	LINC01535	10.8	2.35e-24	2.88e-21	0.62	0.45	Obesity-related traits;	chr19:37141975	chr19:37251912~37265535:+
PRAD	cis	rs2337406	0.929	rs12050233	ENSG00000274576.2	IGHV2-70	-10.8	2.37e-24	2.9e-21	-0.47	-0.45	Alzheimer's disease (late onset);	chr14:106781123	chr14:106770577~106771020:-
PRAD	cis	rs2337406	0.852	rs12050466	ENSG00000274576.2	IGHV2-70	-10.8	2.37e-24	2.9e-21	-0.47	-0.45	Alzheimer's disease (late onset);	chr14:106781131	chr14:106770577~106771020:-
PRAD	cis	rs1426063	0.614	rs17199779	ENSG00000249717.1	RP11-44F21.3	-10.8	2.38e-24	2.92e-21	-0.94	-0.45	QT interval;	chr4:75105647	chr4:74955974~74970362:-
PRAD	cis	rs11676348	0.805	rs13007219	ENSG00000261338.2	RP11-378A13.1	-10.8	2.39e-24	2.92e-21	-0.51	-0.45	Ulcerative colitis;	chr2:218099136	chr2:218255319~218257366:+
PRAD	cis	rs9322193	0.923	rs6913486	ENSG00000268592.3	RAET1E-AS1	-10.8	2.39e-24	2.93e-21	-0.62	-0.45	Lung cancer;	chr6:149705060	chr6:149863494~149919507:+
PRAD	cis	rs6570726	0.791	rs11759979	ENSG00000235652.6	RP11-545I5.3	10.8	2.42e-24	2.97e-21	0.47	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145597745	chr6:145799409~145886585:+
PRAD	cis	rs2282300	0.696	rs12578061	ENSG00000254532.1	RP11-624D11.2	10.79	2.43e-24	2.97e-21	0.66	0.45	Morning vs. evening chronotype;	chr11:30227818	chr11:30044058~30084343:-
PRAD	cis	rs780094	0.585	rs3739095	ENSG00000234072.1	AC074117.10	-10.79	2.45e-24	2.99e-21	-0.35	-0.45	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27333854	chr2:27356246~27367622:+
PRAD	cis	rs4713118	0.516	rs6931858	ENSG00000280107.1	AL022393.9	-10.79	2.46e-24	3e-21	-0.59	-0.45	Parkinson's disease;	chr6:28110633	chr6:28170845~28172521:+
PRAD	cis	rs6570726	0.693	rs450921	ENSG00000235652.6	RP11-545I5.3	10.79	2.46e-24	3.01e-21	0.47	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145543124	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.791	rs365747	ENSG00000235652.6	RP11-545I5.3	10.79	2.46e-24	3.01e-21	0.47	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145545648	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.764	rs448258	ENSG00000235652.6	RP11-545I5.3	10.79	2.46e-24	3.01e-21	0.47	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145548009	chr6:145799409~145886585:+
PRAD	cis	rs7044106	0.708	rs1324472	ENSG00000226752.6	PSMD5-AS1	-10.79	2.47e-24	3.02e-21	-0.57	-0.45	Hip circumference adjusted for BMI;	chr9:120612832	chr9:120824828~120854385:+
PRAD	cis	rs2117029	0.555	rs2279596	ENSG00000258017.1	RP11-386G11.10	-10.79	2.48e-24	3.03e-21	-0.58	-0.45	Intelligence (multi-trait analysis);	chr12:49104968	chr12:49127782~49147869:+
PRAD	cis	rs9322193	0.884	rs62439837	ENSG00000268592.3	RAET1E-AS1	10.79	2.48e-24	3.03e-21	0.62	0.45	Lung cancer;	chr6:149670380	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.607	rs12209310	ENSG00000268592.3	RAET1E-AS1	10.79	2.48e-24	3.04e-21	0.71	0.45	Lung cancer;	chr6:149904882	chr6:149863494~149919507:+
PRAD	cis	rs875971	0.862	rs6971059	ENSG00000237310.1	GS1-124K5.4	-10.79	2.5e-24	3.06e-21	-0.42	-0.45	Aortic root size;	chr7:66602045	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.789	rs7808013	ENSG00000237310.1	GS1-124K5.4	-10.79	2.5e-24	3.06e-21	-0.42	-0.45	Aortic root size;	chr7:66606209	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.825	rs7384021	ENSG00000237310.1	GS1-124K5.4	-10.79	2.5e-24	3.06e-21	-0.42	-0.45	Aortic root size;	chr7:66612917	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.825	rs66981195	ENSG00000237310.1	GS1-124K5.4	-10.79	2.5e-24	3.06e-21	-0.42	-0.45	Aortic root size;	chr7:66614048	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.862	rs3926380	ENSG00000237310.1	GS1-124K5.4	-10.79	2.5e-24	3.06e-21	-0.42	-0.45	Aortic root size;	chr7:66615658	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.825	rs1860472	ENSG00000237310.1	GS1-124K5.4	-10.79	2.5e-24	3.06e-21	-0.42	-0.45	Aortic root size;	chr7:66617736	chr7:66493706~66495474:+
PRAD	cis	rs10875746	0.951	rs10875756	ENSG00000240399.1	RP1-228P16.1	-10.79	2.5e-24	3.06e-21	-0.46	-0.45	Longevity (90 years and older);	chr12:48168521	chr12:48054813~48055591:-
PRAD	cis	rs6700559	0.873	rs7526482	ENSG00000260088.1	RP11-92G12.3	-10.79	2.51e-24	3.06e-21	-0.58	-0.45	Coronary artery disease;	chr1:200688310	chr1:200669507~200694250:+
PRAD	cis	rs6700559	0.873	rs7526853	ENSG00000260088.1	RP11-92G12.3	-10.79	2.51e-24	3.06e-21	-0.58	-0.45	Coronary artery disease;	chr1:200688529	chr1:200669507~200694250:+
PRAD	cis	rs6700559	0.844	rs61825137	ENSG00000260088.1	RP11-92G12.3	-10.79	2.51e-24	3.06e-21	-0.58	-0.45	Coronary artery disease;	chr1:200689267	chr1:200669507~200694250:+
PRAD	cis	rs6700559	0.873	rs7545177	ENSG00000260088.1	RP11-92G12.3	-10.79	2.51e-24	3.06e-21	-0.58	-0.45	Coronary artery disease;	chr1:200690727	chr1:200669507~200694250:+
PRAD	cis	rs6700559	0.873	rs7539646	ENSG00000260088.1	RP11-92G12.3	-10.79	2.51e-24	3.06e-21	-0.58	-0.45	Coronary artery disease;	chr1:200692534	chr1:200669507~200694250:+
PRAD	cis	rs6700559	0.873	rs7519383	ENSG00000260088.1	RP11-92G12.3	-10.79	2.51e-24	3.06e-21	-0.58	-0.45	Coronary artery disease;	chr1:200692968	chr1:200669507~200694250:+
PRAD	cis	rs6700559	0.815	rs12141497	ENSG00000260088.1	RP11-92G12.3	-10.79	2.51e-24	3.06e-21	-0.58	-0.45	Coronary artery disease;	chr1:200693389	chr1:200669507~200694250:+
PRAD	cis	rs6700559	0.873	rs12126708	ENSG00000260088.1	RP11-92G12.3	-10.79	2.51e-24	3.06e-21	-0.58	-0.45	Coronary artery disease;	chr1:200693397	chr1:200669507~200694250:+
PRAD	cis	rs6700559	0.873	rs10920008	ENSG00000260088.1	RP11-92G12.3	-10.79	2.51e-24	3.06e-21	-0.58	-0.45	Coronary artery disease;	chr1:200694546	chr1:200669507~200694250:+
PRAD	cis	rs748404	0.66	rs2444251	ENSG00000205771.5	CATSPER2P1	-10.79	2.52e-24	3.08e-21	-0.5	-0.45	Lung cancer;	chr15:43496397	chr15:43726918~43747094:-
PRAD	cis	rs2404602	0.583	rs12913096	ENSG00000259422.1	RP11-593F23.1	10.79	2.55e-24	3.11e-21	0.55	0.45	Blood metabolite levels;	chr15:76259511	chr15:76174891~76181486:-
PRAD	cis	rs7772486	0.701	rs697056	ENSG00000235652.6	RP11-545I5.3	-10.79	2.56e-24	3.12e-21	-0.46	-0.45	Lobe attachment (rater-scored or self-reported);	chr6:145682761	chr6:145799409~145886585:+
PRAD	cis	rs1577917	1	rs12216203	ENSG00000203875.9	SNHG5	-10.79	2.59e-24	3.16e-21	-0.52	-0.45	Response to antipsychotic treatment;	chr6:85965583	chr6:85660950~85678736:-
PRAD	cis	rs2348418	0.701	rs6487670	ENSG00000247934.4	RP11-967K21.1	-10.79	2.6e-24	3.17e-21	-0.41	-0.45	Lung function (FEV1);Lung function (FVC);	chr12:28210856	chr12:28163298~28190738:-
PRAD	cis	rs2348418	0.733	rs4931078	ENSG00000247934.4	RP11-967K21.1	-10.79	2.6e-24	3.17e-21	-0.41	-0.45	Lung function (FEV1);Lung function (FVC);	chr12:28215067	chr12:28163298~28190738:-
PRAD	cis	rs1577917	0.958	rs12198876	ENSG00000203875.9	SNHG5	-10.79	2.63e-24	3.21e-21	-0.54	-0.45	Response to antipsychotic treatment;	chr6:85815758	chr6:85660950~85678736:-
PRAD	cis	rs12049351	1	rs12049351	ENSG00000229367.1	HMGN2P19	10.78	2.65e-24	3.23e-21	0.61	0.45	Circulating myeloperoxidase levels (plasma);	chr1:229582254	chr1:229570532~229570796:+
PRAD	cis	rs710216	0.536	rs710222	ENSG00000227533.4	SLC2A1-AS1	10.78	2.71e-24	3.3e-21	0.5	0.45	Red cell distribution width;	chr1:42947982	chr1:42959049~42983358:+
PRAD	cis	rs875971	0.798	rs12698522	ENSG00000237310.1	GS1-124K5.4	10.78	2.72e-24	3.31e-21	0.42	0.45	Aortic root size;	chr7:66502354	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.83	rs28714531	ENSG00000237310.1	GS1-124K5.4	10.78	2.72e-24	3.31e-21	0.42	0.45	Aortic root size;	chr7:66503250	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.862	rs12698526	ENSG00000237310.1	GS1-124K5.4	10.78	2.72e-24	3.31e-21	0.42	0.45	Aortic root size;	chr7:66504118	chr7:66493706~66495474:+
PRAD	cis	rs34779708	0.966	rs17591163	ENSG00000230534.5	RP11-297A16.2	10.78	2.72e-24	3.31e-21	0.61	0.45	Inflammatory bowel disease;Crohn's disease;	chr10:35176351	chr10:35098006~35127020:-
PRAD	cis	rs1577917	1	rs7747824	ENSG00000203875.9	SNHG5	-10.78	2.74e-24	3.33e-21	-0.5	-0.45	Response to antipsychotic treatment;	chr6:85937388	chr6:85660950~85678736:-
PRAD	cis	rs9322193	0.886	rs2065663	ENSG00000216906.2	RP11-350J20.9	10.78	2.76e-24	3.36e-21	0.52	0.45	Lung cancer;	chr6:149760331	chr6:149904243~149906418:+
PRAD	cis	rs9532669	0.926	rs4942007	ENSG00000176268.5	CYCSP34	10.78	2.78e-24	3.38e-21	0.46	0.45	Cervical cancer;	chr13:40871887	chr13:40863599~40863902:-
PRAD	cis	rs11676348	0.967	rs4674258	ENSG00000261338.2	RP11-378A13.1	-10.78	2.78e-24	3.38e-21	-0.51	-0.45	Ulcerative colitis;	chr2:218125863	chr2:218255319~218257366:+
PRAD	cis	rs9322193	0.962	rs3763162	ENSG00000216906.2	RP11-350J20.9	-10.78	2.79e-24	3.39e-21	-0.52	-0.45	Lung cancer;	chr6:149819674	chr6:149904243~149906418:+
PRAD	cis	rs9545047	0.716	rs314692	ENSG00000227676.3	LINC01068	-10.78	2.79e-24	3.4e-21	-0.55	-0.45	Schizophrenia;	chr13:79433091	chr13:79566727~79571436:+
PRAD	cis	rs7617773	0.563	rs13082269	ENSG00000229759.1	MRPS18AP1	10.78	2.8e-24	3.4e-21	0.47	0.45	Coronary artery disease;	chr3:48350784	chr3:48256350~48256938:-
PRAD	cis	rs6570726	0.764	rs376257	ENSG00000235652.6	RP11-545I5.3	10.78	2.84e-24	3.45e-21	0.47	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145541813	chr6:145799409~145886585:+
PRAD	cis	rs3931020	1	rs10874122	ENSG00000272864.1	RP11-17E13.2	-10.78	2.84e-24	3.46e-21	-0.49	-0.45	Resistin levels;	chr1:74770182	chr1:74698769~74699333:-
PRAD	cis	rs9898641	1	rs9898641	ENSG00000266992.1	DHX40P1	10.78	2.86e-24	3.48e-21	0.52	0.45	Interleukin-1-beta levels;	chr17:59493672	chr17:59976009~60002384:-
PRAD	cis	rs7714584	1	rs59531858	ENSG00000197083.10	ZNF300P1	10.77	2.9e-24	3.53e-21	0.79	0.45	Crohn's disease;	chr5:150867501	chr5:150930645~150946289:-
PRAD	cis	rs9322193	0.923	rs4870509	ENSG00000216906.2	RP11-350J20.9	10.77	2.92e-24	3.55e-21	0.52	0.45	Lung cancer;	chr6:149702212	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.923	rs9322214	ENSG00000216906.2	RP11-350J20.9	10.77	2.92e-24	3.55e-21	0.52	0.45	Lung cancer;	chr6:149703986	chr6:149904243~149906418:+
PRAD	cis	rs2455601	1	rs12418190	ENSG00000254860.4	TMEM9B-AS1	10.77	2.93e-24	3.57e-21	0.63	0.45	Schizophrenia;	chr11:8878271	chr11:8964675~8977527:+
PRAD	cis	rs17826219	0.562	rs719600	ENSG00000263531.1	RP13-753N3.1	-10.77	2.96e-24	3.59e-21	-0.89	-0.45	Body mass index;	chr17:30404244	chr17:30863921~30864940:-
PRAD	cis	rs6570726	0.791	rs4335004	ENSG00000235652.6	RP11-545I5.3	10.77	2.97e-24	3.61e-21	0.47	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145583628	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.791	rs9399558	ENSG00000235652.6	RP11-545I5.3	10.77	2.98e-24	3.62e-21	0.47	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145590594	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.791	rs9376953	ENSG00000235652.6	RP11-545I5.3	10.77	2.98e-24	3.62e-21	0.47	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145591090	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.791	rs13202312	ENSG00000235652.6	RP11-545I5.3	10.77	2.98e-24	3.62e-21	0.47	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145591957	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.791	rs7765675	ENSG00000235652.6	RP11-545I5.3	10.77	2.98e-24	3.62e-21	0.47	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145593941	chr6:145799409~145886585:+
PRAD	cis	rs9322193	1	rs58189451	ENSG00000223701.3	RAET1E-AS1	10.77	2.98e-24	3.62e-21	0.61	0.45	Lung cancer;	chr6:149600252	chr6:149884431~149919508:+
PRAD	cis	rs7615952	0.8	rs11915699	ENSG00000171084.14	FAM86JP	10.77	3.01e-24	3.66e-21	0.76	0.45	Blood pressure (smoking interaction);	chr3:125913841	chr3:125916620~125930024:+
PRAD	cis	rs9322193	0.962	rs7818	ENSG00000216906.2	RP11-350J20.9	10.77	3.01e-24	3.66e-21	0.52	0.45	Lung cancer;	chr6:149810956	chr6:149904243~149906418:+
PRAD	cis	rs2442825	0.693	rs2600194	ENSG00000206573.7	THUMPD3-AS1	10.77	3.02e-24	3.66e-21	0.33	0.45	Cerebrospinal fluid clusterin levels;	chr3:9382941	chr3:9349689~9398579:-
PRAD	cis	rs2348418	0.832	rs7294553	ENSG00000247934.4	RP11-967K21.1	10.77	3.02e-24	3.67e-21	0.41	0.45	Lung function (FEV1);Lung function (FVC);	chr12:28334832	chr12:28163298~28190738:-
PRAD	cis	rs8072100	0.79	rs11656856	ENSG00000228782.6	CTD-2026D20.3	-10.77	3.04e-24	3.7e-21	-0.5	-0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47637305	chr17:47450568~47492492:-
PRAD	cis	rs7617773	0.539	rs12486935	ENSG00000229759.1	MRPS18AP1	10.77	3.08e-24	3.74e-21	0.47	0.45	Coronary artery disease;	chr3:48348674	chr3:48256350~48256938:-
PRAD	cis	rs7772486	0.754	rs2064185	ENSG00000235652.6	RP11-545I5.3	-10.76	3.18e-24	3.85e-21	-0.46	-0.45	Lobe attachment (rater-scored or self-reported);	chr6:145745678	chr6:145799409~145886585:+
PRAD	cis	rs2404602	0.647	rs920712	ENSG00000259422.1	RP11-593F23.1	-10.76	3.18e-24	3.86e-21	-0.59	-0.45	Blood metabolite levels;	chr15:76741593	chr15:76174891~76181486:-
PRAD	cis	rs875971	0.825	rs28480509	ENSG00000237310.1	GS1-124K5.4	-10.76	3.2e-24	3.89e-21	-0.42	-0.45	Aortic root size;	chr7:66634237	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.862	rs9791712	ENSG00000237310.1	GS1-124K5.4	-10.76	3.2e-24	3.89e-21	-0.42	-0.45	Aortic root size;	chr7:66640176	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.862	rs9791713	ENSG00000237310.1	GS1-124K5.4	-10.76	3.2e-24	3.89e-21	-0.42	-0.45	Aortic root size;	chr7:66640211	chr7:66493706~66495474:+
PRAD	cis	rs1577917	1	rs34281561	ENSG00000203875.9	SNHG5	-10.76	3.21e-24	3.9e-21	-0.52	-0.45	Response to antipsychotic treatment;	chr6:85992154	chr6:85660950~85678736:-
PRAD	cis	rs1577917	1	rs35419329	ENSG00000203875.9	SNHG5	-10.76	3.21e-24	3.9e-21	-0.52	-0.45	Response to antipsychotic treatment;	chr6:85992573	chr6:85660950~85678736:-
PRAD	cis	rs1577917	1	rs12216328	ENSG00000203875.9	SNHG5	-10.76	3.21e-24	3.9e-21	-0.52	-0.45	Response to antipsychotic treatment;	chr6:85993700	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.917	rs1838959	ENSG00000203875.9	SNHG5	-10.76	3.23e-24	3.91e-21	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85847086	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.917	rs1579886	ENSG00000203875.9	SNHG5	-10.76	3.23e-24	3.91e-21	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85847473	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.958	rs1816937	ENSG00000203875.9	SNHG5	-10.76	3.23e-24	3.91e-21	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85847533	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.958	rs7382798	ENSG00000203875.9	SNHG5	-10.76	3.23e-24	3.91e-21	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85850116	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.958	rs1838958	ENSG00000203875.9	SNHG5	-10.76	3.23e-24	3.91e-21	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85854250	chr6:85660950~85678736:-
PRAD	cis	rs9545047	0.716	rs943710	ENSG00000227676.3	LINC01068	10.76	3.23e-24	3.92e-21	0.55	0.45	Schizophrenia;	chr13:79282987	chr13:79566727~79571436:+
PRAD	cis	rs7044106	0.69	rs10739569	ENSG00000226752.6	PSMD5-AS1	-10.76	3.26e-24	3.95e-21	-0.54	-0.45	Hip circumference adjusted for BMI;	chr9:120598749	chr9:120824828~120854385:+
PRAD	cis	rs274567	0.711	rs404771	ENSG00000233006.5	AC034220.3	10.76	3.29e-24	3.98e-21	0.43	0.45	Blood metabolite levels;	chr5:132299399	chr5:132311285~132369916:-
PRAD	cis	rs1823874	0.581	rs12910401	ENSG00000182397.13	DNM1P46	-10.76	3.32e-24	4.02e-21	-0.48	-0.45	IgG glycosylation;	chr15:99799692	chr15:99790156~99806927:-
PRAD	cis	rs853679	0.55	rs1237875	ENSG00000280107.1	AL022393.9	10.76	3.33e-24	4.03e-21	0.57	0.45	Depression;	chr6:28205232	chr6:28170845~28172521:+
PRAD	cis	rs35160687	0.814	rs1863063	ENSG00000273080.1	RP11-301O19.1	10.76	3.36e-24	4.07e-21	0.52	0.45	Night sleep phenotypes;	chr2:86291126	chr2:86195590~86196049:+
PRAD	cis	rs9487094	0.645	rs34292461	ENSG00000260273.1	RP11-425D10.10	10.76	3.37e-24	4.09e-21	0.7	0.45	Height;	chr6:109352277	chr6:109382795~109383666:+
PRAD	cis	rs4845570	0.749	rs11586446	ENSG00000249602.1	RP11-98D18.3	10.76	3.4e-24	4.11e-21	0.78	0.45	Coronary artery disease;	chr1:151740012	chr1:151763384~151769501:-
PRAD	cis	rs6570726	0.791	rs9403734	ENSG00000235652.6	RP11-545I5.3	10.76	3.42e-24	4.14e-21	0.47	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145610323	chr6:145799409~145886585:+
PRAD	cis	rs748404	0.587	rs9920879	ENSG00000205771.5	CATSPER2P1	-10.76	3.43e-24	4.15e-21	-0.5	-0.45	Lung cancer;	chr15:43347572	chr15:43726918~43747094:-
PRAD	cis	rs748404	0.631	rs7166812	ENSG00000205771.5	CATSPER2P1	-10.76	3.43e-24	4.15e-21	-0.5	-0.45	Lung cancer;	chr15:43352562	chr15:43726918~43747094:-
PRAD	cis	rs748404	0.631	rs1133395	ENSG00000205771.5	CATSPER2P1	-10.76	3.43e-24	4.15e-21	-0.5	-0.45	Lung cancer;	chr15:43358186	chr15:43726918~43747094:-
PRAD	cis	rs2404602	0.684	rs2047504	ENSG00000259422.1	RP11-593F23.1	-10.75	3.44e-24	4.16e-21	-0.59	-0.45	Blood metabolite levels;	chr15:76591175	chr15:76174891~76181486:-
PRAD	cis	rs7772486	0.72	rs6901888	ENSG00000235652.6	RP11-545I5.3	-10.75	3.45e-24	4.17e-21	-0.46	-0.45	Lobe attachment (rater-scored or self-reported);	chr6:145702008	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.754	rs4896841	ENSG00000235652.6	RP11-545I5.3	-10.75	3.45e-24	4.17e-21	-0.46	-0.45	Lobe attachment (rater-scored or self-reported);	chr6:145720386	chr6:145799409~145886585:+
PRAD	cis	rs2882667	0.522	rs7731574	ENSG00000253404.1	AC034243.1	-10.75	3.46e-24	4.18e-21	-0.57	-0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139118503	chr5:138744434~138753309:-
PRAD	cis	rs7849270	0.885	rs10760588	ENSG00000268707.1	RP11-247A12.7	-10.75	3.46e-24	4.19e-21	-0.51	-0.45	Blood metabolite ratios;	chr9:129115195	chr9:129170434~129170940:+
PRAD	cis	rs2564921	0.73	rs930122	ENSG00000242142.1	SERBP1P3	10.75	3.48e-24	4.21e-21	0.51	0.45	Height;	chr3:53085313	chr3:53064283~53065091:-
PRAD	cis	rs6538678	0.824	rs1436120	ENSG00000258343.1	RP11-536G4.2	10.75	3.49e-24	4.23e-21	0.68	0.45	Lupus nephritis in systemic lupus erythematosus;	chr12:95826872	chr12:95795345~95858839:-
PRAD	cis	rs2404602	0.583	rs12907668	ENSG00000259422.1	RP11-593F23.1	10.75	3.51e-24	4.24e-21	0.55	0.45	Blood metabolite levels;	chr15:76297426	chr15:76174891~76181486:-
PRAD	cis	rs7617773	0.563	rs62263035	ENSG00000229759.1	MRPS18AP1	10.75	3.51e-24	4.25e-21	0.47	0.45	Coronary artery disease;	chr3:48350079	chr3:48256350~48256938:-
PRAD	cis	rs7772486	0.754	rs9497401	ENSG00000235652.6	RP11-545I5.3	-10.75	3.51e-24	4.25e-21	-0.46	-0.45	Lobe attachment (rater-scored or self-reported);	chr6:145730135	chr6:145799409~145886585:+
PRAD	cis	rs2933343	1	rs2933343	ENSG00000231305.3	RP11-723O4.2	10.75	3.52e-24	4.26e-21	0.46	0.45	IgG glycosylation;	chr3:128939649	chr3:128861313~128871540:-
PRAD	cis	rs2404602	0.647	rs35940181	ENSG00000259422.1	RP11-593F23.1	-10.75	3.54e-24	4.29e-21	-0.6	-0.45	Blood metabolite levels;	chr15:76887678	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.583	rs12898415	ENSG00000259422.1	RP11-593F23.1	10.75	3.55e-24	4.29e-21	0.55	0.45	Blood metabolite levels;	chr15:76281891	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.583	rs3759853	ENSG00000259422.1	RP11-593F23.1	10.75	3.55e-24	4.29e-21	0.55	0.45	Blood metabolite levels;	chr15:76295436	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.583	rs4381566	ENSG00000259422.1	RP11-593F23.1	10.75	3.55e-24	4.29e-21	0.55	0.45	Blood metabolite levels;	chr15:76296921	chr15:76174891~76181486:-
PRAD	cis	rs9322193	0.962	rs3763163	ENSG00000223701.3	RAET1E-AS1	10.75	3.6e-24	4.35e-21	0.59	0.45	Lung cancer;	chr6:149819770	chr6:149884431~149919508:+
PRAD	cis	rs1577917	0.958	rs2225754	ENSG00000203875.9	SNHG5	-10.75	3.61e-24	4.37e-21	-0.55	-0.45	Response to antipsychotic treatment;	chr6:85739980	chr6:85660950~85678736:-
PRAD	cis	rs9322193	0.924	rs9498382	ENSG00000216906.2	RP11-350J20.9	10.75	3.62e-24	4.37e-21	0.52	0.45	Lung cancer;	chr6:149610982	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.566	rs4870118	ENSG00000223701.3	RAET1E-AS1	-10.75	3.64e-24	4.4e-21	-0.69	-0.45	Lung cancer;	chr6:149923877	chr6:149884431~149919508:+
PRAD	cis	rs7772486	0.72	rs6931553	ENSG00000235652.6	RP11-545I5.3	-10.75	3.64e-24	4.4e-21	-0.46	-0.45	Lobe attachment (rater-scored or self-reported);	chr6:145791212	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.754	rs6937661	ENSG00000235652.6	RP11-545I5.3	-10.75	3.64e-24	4.4e-21	-0.46	-0.45	Lobe attachment (rater-scored or self-reported);	chr6:145792163	chr6:145799409~145886585:+
PRAD	cis	rs783540	0.592	rs2567632	ENSG00000276710.3	CSPG4P8	10.75	3.67e-24	4.43e-21	0.5	0.45	Schizophrenia;	chr15:82616053	chr15:82459472~82477258:+
PRAD	cis	rs2929278	0.561	rs2927071	ENSG00000249839.1	AC011330.5	-10.75	3.69e-24	4.46e-21	-0.57	-0.45	Schizophrenia;	chr15:43626883	chr15:43663654~43684339:-
PRAD	cis	rs150992	0.751	rs172874	ENSG00000248489.1	CTD-2007H13.3	10.75	3.69e-24	4.46e-21	0.51	0.45	Body mass index;	chr5:98969402	chr5:98929171~98995013:+
PRAD	cis	rs9322193	0.962	rs12175575	ENSG00000216906.2	RP11-350J20.9	10.75	3.69e-24	4.46e-21	0.52	0.45	Lung cancer;	chr6:149763351	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.962	rs4869966	ENSG00000216906.2	RP11-350J20.9	10.75	3.69e-24	4.46e-21	0.52	0.45	Lung cancer;	chr6:149763714	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.962	rs1112730	ENSG00000216906.2	RP11-350J20.9	10.75	3.69e-24	4.46e-21	0.52	0.45	Lung cancer;	chr6:149766383	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.923	rs1112729	ENSG00000216906.2	RP11-350J20.9	10.75	3.69e-24	4.46e-21	0.52	0.45	Lung cancer;	chr6:149766491	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.962	rs10452626	ENSG00000216906.2	RP11-350J20.9	10.75	3.69e-24	4.46e-21	0.52	0.45	Lung cancer;	chr6:149767481	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.923	rs62441303	ENSG00000216906.2	RP11-350J20.9	10.75	3.69e-24	4.46e-21	0.52	0.45	Lung cancer;	chr6:149767547	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.962	rs9765929	ENSG00000216906.2	RP11-350J20.9	10.75	3.69e-24	4.46e-21	0.52	0.45	Lung cancer;	chr6:149769680	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.962	rs3805748	ENSG00000216906.2	RP11-350J20.9	10.75	3.69e-24	4.46e-21	0.52	0.45	Lung cancer;	chr6:149772542	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.736	rs10457851	ENSG00000216906.2	RP11-350J20.9	10.75	3.69e-24	4.46e-21	0.52	0.45	Lung cancer;	chr6:149775216	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.886	rs10872652	ENSG00000216906.2	RP11-350J20.9	10.75	3.69e-24	4.46e-21	0.52	0.45	Lung cancer;	chr6:149775303	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.886	rs12525871	ENSG00000216906.2	RP11-350J20.9	10.75	3.69e-24	4.46e-21	0.52	0.45	Lung cancer;	chr6:149775882	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.886	rs17672976	ENSG00000216906.2	RP11-350J20.9	10.75	3.69e-24	4.46e-21	0.52	0.45	Lung cancer;	chr6:149776207	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.923	rs2184369	ENSG00000216906.2	RP11-350J20.9	10.75	3.69e-24	4.46e-21	0.52	0.45	Lung cancer;	chr6:149776681	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.962	rs2342861	ENSG00000216906.2	RP11-350J20.9	10.75	3.69e-24	4.46e-21	0.52	0.45	Lung cancer;	chr6:149777561	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.926	rs2342860	ENSG00000216906.2	RP11-350J20.9	10.75	3.69e-24	4.46e-21	0.52	0.45	Lung cancer;	chr6:149777641	chr6:149904243~149906418:+
PRAD	cis	rs1150668	0.799	rs2142730	ENSG00000204709.4	LINC01556	10.75	3.71e-24	4.47e-21	0.56	0.45	Pubertal anthropometrics;	chr6:28298372	chr6:28943877~28944537:+
PRAD	cis	rs10853057	0.717	rs58524282	ENSG00000214174.7	AMZ2P1	10.74	3.75e-24	4.52e-21	0.87	0.45	White matter microstructure (global fractional anisotropy);	chr17:65060479	chr17:64966550~64975576:-
PRAD	cis	rs73086581	0.568	rs6084541	ENSG00000229539.1	RP11-119B16.2	-10.74	3.76e-24	4.54e-21	-0.59	-0.45	Response to antidepressants in depression;	chr20:3982084	chr20:3888239~3888868:-
PRAD	cis	rs9322193	0.923	rs10782318	ENSG00000216906.2	RP11-350J20.9	10.74	3.77e-24	4.54e-21	0.52	0.45	Lung cancer;	chr6:149754137	chr6:149904243~149906418:+
PRAD	cis	rs7772486	0.79	rs7753833	ENSG00000235652.6	RP11-545I5.3	10.74	3.78e-24	4.57e-21	0.46	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145840296	chr6:145799409~145886585:+
PRAD	cis	rs1577917	0.958	rs12215232	ENSG00000203875.9	SNHG5	-10.74	3.83e-24	4.62e-21	-0.53	-0.45	Response to antipsychotic treatment;	chr6:86075712	chr6:85660950~85678736:-
PRAD	cis	rs780096	0.546	rs2293571	ENSG00000234072.1	AC074117.10	-10.74	3.86e-24	4.66e-21	-0.35	-0.45	Total body bone mineral density;	chr2:27506613	chr2:27356246~27367622:+
PRAD	cis	rs2919917	0.628	rs2717540	ENSG00000254352.1	RP11-578O24.2	10.74	3.88e-24	4.68e-21	0.61	0.45	Lymphocyte counts;	chr8:78710128	chr8:78723796~78724136:-
PRAD	cis	rs7617773	0.539	rs17593974	ENSG00000229759.1	MRPS18AP1	10.74	3.89e-24	4.69e-21	0.47	0.45	Coronary artery disease;	chr3:48345844	chr3:48256350~48256938:-
PRAD	cis	rs7617773	0.514	rs11130166	ENSG00000229759.1	MRPS18AP1	10.74	3.89e-24	4.69e-21	0.47	0.45	Coronary artery disease;	chr3:48346566	chr3:48256350~48256938:-
PRAD	cis	rs9399135	0.66	rs4267967	ENSG00000232876.1	CTA-212D2.2	-10.74	3.91e-24	4.71e-21	-0.56	-0.45	Red blood cell count;	chr6:134951339	chr6:135055033~135060550:+
PRAD	cis	rs9322193	0.923	rs55849538	ENSG00000268592.3	RAET1E-AS1	10.74	3.91e-24	4.71e-21	0.62	0.45	Lung cancer;	chr6:149635330	chr6:149863494~149919507:+
PRAD	cis	rs853679	0.55	rs1233704	ENSG00000280107.1	AL022393.9	10.74	3.93e-24	4.74e-21	0.57	0.45	Depression;	chr6:28199145	chr6:28170845~28172521:+
PRAD	cis	rs875971	0.862	rs2909688	ENSG00000237310.1	GS1-124K5.4	10.74	3.94e-24	4.75e-21	0.42	0.45	Aortic root size;	chr7:66376625	chr7:66493706~66495474:+
PRAD	cis	rs7849270	0.959	rs7032712	ENSG00000268707.1	RP11-247A12.7	-10.74	3.95e-24	4.76e-21	-0.5	-0.45	Blood metabolite ratios;	chr9:129130808	chr9:129170434~129170940:+
PRAD	cis	rs507080	0.733	rs4393358	ENSG00000255422.1	AP002954.4	-10.74	3.99e-24	4.81e-21	-0.55	-0.45	Serum metabolite levels;	chr11:118698388	chr11:118704607~118750263:+
PRAD	cis	rs853679	0.55	rs1233699	ENSG00000280107.1	AL022393.9	-10.74	3.99e-24	4.81e-21	-0.57	-0.45	Depression;	chr6:28201380	chr6:28170845~28172521:+
PRAD	cis	rs11673344	0.864	rs8108727	ENSG00000226686.6	LINC01535	10.74	4.07e-24	4.91e-21	0.62	0.45	Obesity-related traits;	chr19:37090622	chr19:37251912~37265535:+
PRAD	cis	rs7772486	0.754	rs2328707	ENSG00000235652.6	RP11-545I5.3	-10.74	4.08e-24	4.91e-21	-0.46	-0.45	Lobe attachment (rater-scored or self-reported);	chr6:145732362	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.727	rs10447449	ENSG00000235652.6	RP11-545I5.3	10.73	4.1e-24	4.93e-21	0.46	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145817571	chr6:145799409~145886585:+
PRAD	cis	rs10875746	0.903	rs989144	ENSG00000240399.1	RP1-228P16.1	-10.73	4.12e-24	4.96e-21	-0.45	-0.45	Longevity (90 years and older);	chr12:48090190	chr12:48054813~48055591:-
PRAD	cis	rs11676348	1	rs11676348	ENSG00000261338.2	RP11-378A13.1	-10.73	4.12e-24	4.97e-21	-0.5	-0.45	Ulcerative colitis;	chr2:218145423	chr2:218255319~218257366:+
PRAD	cis	rs1185460	0.967	rs11217133	ENSG00000271751.1	RP11-110I1.14	-10.73	4.13e-24	4.97e-21	-0.64	-0.45	Coronary artery disease;	chr11:119057538	chr11:119065263~119065677:-
PRAD	cis	rs783540	0.656	rs783524	ENSG00000276710.3	CSPG4P8	10.73	4.19e-24	5.04e-21	0.5	0.45	Schizophrenia;	chr15:82615393	chr15:82459472~82477258:+
PRAD	cis	rs1155848	0.892	rs9574424	ENSG00000227354.5	RBM26-AS1	-10.73	4.2e-24	5.06e-21	-0.87	-0.45	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79448541	chr13:79406309~79424328:+
PRAD	cis	rs9322193	0.926	rs9766562	ENSG00000216906.2	RP11-350J20.9	10.73	4.21e-24	5.07e-21	0.52	0.45	Lung cancer;	chr6:149788709	chr6:149904243~149906418:+
PRAD	cis	rs1150668	0.796	rs9468372	ENSG00000204709.4	LINC01556	10.73	4.21e-24	5.07e-21	0.55	0.45	Pubertal anthropometrics;	chr6:28411584	chr6:28943877~28944537:+
PRAD	cis	rs2404602	0.647	rs4886837	ENSG00000259422.1	RP11-593F23.1	-10.73	4.21e-24	5.07e-21	-0.59	-0.45	Blood metabolite levels;	chr15:76864076	chr15:76174891~76181486:-
PRAD	cis	rs11690935	0.632	rs6737308	ENSG00000228389.1	AC068039.4	-10.73	4.24e-24	5.1e-21	-0.5	-0.45	Schizophrenia;	chr2:172007137	chr2:171773482~171775844:+
PRAD	cis	rs9326248	0.773	rs1060211	ENSG00000280143.1	AP000892.6	10.73	4.27e-24	5.14e-21	0.44	0.45	Blood protein levels;	chr11:117169081	chr11:117204967~117210292:+
PRAD	cis	rs704795	0.775	rs4665975	ENSG00000234072.1	AC074117.10	-10.73	4.28e-24	5.15e-21	-0.36	-0.45	Menopause (age at onset);	chr2:27403150	chr2:27356246~27367622:+
PRAD	cis	rs11951515	0.738	rs12189016	ENSG00000188850.9	RP11-159F24.2	10.73	4.3e-24	5.17e-21	0.53	0.45	Metabolite levels  (X-11787);	chr5:43334686	chr5:43336164~43348716:+
PRAD	cis	rs9322193	0.962	rs9322206	ENSG00000216906.2	RP11-350J20.9	10.73	4.33e-24	5.2e-21	0.52	0.45	Lung cancer;	chr6:149641481	chr6:149904243~149906418:+
PRAD	cis	rs6142102	0.923	rs4911383	ENSG00000276073.1	RP5-1125A11.7	-10.73	4.35e-24	5.23e-21	-0.47	-0.45	Skin pigmentation;	chr20:33967973	chr20:33985617~33988989:-
PRAD	cis	rs34375054	0.525	rs10846829	ENSG00000279233.1	RP11-158L12.4	10.73	4.37e-24	5.25e-21	0.43	0.45	Post bronchodilator FEV1/FVC ratio;	chr12:125110512	chr12:125138245~125141711:+
PRAD	cis	rs6860806	0.531	rs270612	ENSG00000233006.5	AC034220.3	10.73	4.38e-24	5.26e-21	0.43	0.45	Breast cancer;	chr5:132301645	chr5:132311285~132369916:-
PRAD	cis	rs2348418	0.765	rs12368743	ENSG00000247934.4	RP11-967K21.1	-10.73	4.38e-24	5.26e-21	-0.41	-0.45	Lung function (FEV1);Lung function (FVC);	chr12:28192409	chr12:28163298~28190738:-
PRAD	cis	rs1150668	0.796	rs2531825	ENSG00000204709.4	LINC01556	10.73	4.42e-24	5.31e-21	0.55	0.45	Pubertal anthropometrics;	chr6:28381487	chr6:28943877~28944537:+
PRAD	cis	rs9322193	0.962	rs1889473	ENSG00000223701.3	RAET1E-AS1	10.72	4.5e-24	5.41e-21	0.59	0.45	Lung cancer;	chr6:149825485	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.923	rs12176034	ENSG00000216906.2	RP11-350J20.9	10.72	4.54e-24	5.45e-21	0.52	0.45	Lung cancer;	chr6:149800557	chr6:149904243~149906418:+
PRAD	cis	rs1577917	0.917	rs2218594	ENSG00000203875.9	SNHG5	-10.72	4.55e-24	5.46e-21	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85834048	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.958	rs2197648	ENSG00000203875.9	SNHG5	-10.72	4.55e-24	5.46e-21	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85834169	chr6:85660950~85678736:-
PRAD	cis	rs10875746	0.855	rs2269936	ENSG00000240399.1	RP1-228P16.1	-10.72	4.55e-24	5.46e-21	-0.46	-0.45	Longevity (90 years and older);	chr12:48031452	chr12:48054813~48055591:-
PRAD	cis	rs1426063	0.614	rs17000264	ENSG00000249717.1	RP11-44F21.3	10.72	4.55e-24	5.47e-21	0.92	0.45	QT interval;	chr4:75108962	chr4:74955974~74970362:-
PRAD	cis	rs2404602	0.647	rs4886840	ENSG00000259422.1	RP11-593F23.1	-10.72	4.58e-24	5.5e-21	-0.59	-0.45	Blood metabolite levels;	chr15:76886661	chr15:76174891~76181486:-
PRAD	cis	rs4713118	0.621	rs10484403	ENSG00000280107.1	AL022393.9	-10.72	4.6e-24	5.52e-21	-0.58	-0.45	Parkinson's disease;	chr6:28065745	chr6:28170845~28172521:+
PRAD	cis	rs780096	0.527	rs11127044	ENSG00000234072.1	AC074117.10	-10.72	4.6e-24	5.52e-21	-0.36	-0.45	Total body bone mineral density;	chr2:27517537	chr2:27356246~27367622:+
PRAD	cis	rs2729354	1	rs2729355	ENSG00000265566.2	RN7SL605P	-10.72	4.62e-24	5.54e-21	-0.67	-0.45	Blood protein levels;	chr11:57586510	chr11:57528085~57528365:-
PRAD	cis	rs34375054	0.525	rs7133614	ENSG00000279233.1	RP11-158L12.4	10.72	4.63e-24	5.55e-21	0.42	0.45	Post bronchodilator FEV1/FVC ratio;	chr12:125121411	chr12:125138245~125141711:+
PRAD	cis	rs748404	0.66	rs493377	ENSG00000205771.5	CATSPER2P1	-10.72	4.65e-24	5.57e-21	-0.5	-0.45	Lung cancer;	chr15:43481269	chr15:43726918~43747094:-
PRAD	cis	rs9487094	0.645	rs1322818	ENSG00000260273.1	RP11-425D10.10	10.72	4.65e-24	5.58e-21	0.7	0.45	Height;	chr6:109369898	chr6:109382795~109383666:+
PRAD	cis	rs9481169	0.85	rs35815577	ENSG00000255389.1	C6orf3	-10.72	4.65e-24	5.58e-21	-0.98	-0.45	Inflammatory skin disease;	chr6:111603527	chr6:111599875~111602295:+
PRAD	cis	rs875971	0.862	rs778686	ENSG00000237310.1	GS1-124K5.4	10.72	4.66e-24	5.59e-21	0.41	0.45	Aortic root size;	chr7:66370923	chr7:66493706~66495474:+
PRAD	cis	rs62388641	0.539	rs56016631	ENSG00000272279.1	RP11-157J24.2	10.72	4.66e-24	5.6e-21	0.59	0.45	Daytime sleep phenotypes;	chr6:1542340	chr6:1528364~1528911:-
PRAD	cis	rs9322193	0.962	rs9689447	ENSG00000216906.2	RP11-350J20.9	10.72	4.68e-24	5.62e-21	0.52	0.45	Lung cancer;	chr6:149789350	chr6:149904243~149906418:+
PRAD	cis	rs10853057	0.717	rs62062478	ENSG00000214174.7	AMZ2P1	10.72	4.72e-24	5.67e-21	0.87	0.45	White matter microstructure (global fractional anisotropy);	chr17:65059458	chr17:64966550~64975576:-
PRAD	cis	rs1823874	0.581	rs9920347	ENSG00000182397.13	DNM1P46	10.72	4.73e-24	5.67e-21	0.46	0.45	IgG glycosylation;	chr15:99799126	chr15:99790156~99806927:-
PRAD	cis	rs7772486	0.641	rs2748489	ENSG00000235652.6	RP11-545I5.3	10.72	4.73e-24	5.68e-21	0.5	0.45	Lobe attachment (rater-scored or self-reported);	chr6:146010151	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.641	rs2777485	ENSG00000235652.6	RP11-545I5.3	10.72	4.73e-24	5.68e-21	0.5	0.45	Lobe attachment (rater-scored or self-reported);	chr6:146013241	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.72	rs702320	ENSG00000235652.6	RP11-545I5.3	-10.72	4.74e-24	5.69e-21	-0.46	-0.45	Lobe attachment (rater-scored or self-reported);	chr6:145685518	chr6:145799409~145886585:+
PRAD	cis	rs9322193	0.923	rs1984111	ENSG00000223701.3	RAET1E-AS1	10.72	4.75e-24	5.69e-21	0.59	0.45	Lung cancer;	chr6:149831720	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.962	rs6899661	ENSG00000216906.2	RP11-350J20.9	10.72	4.76e-24	5.71e-21	0.52	0.45	Lung cancer;	chr6:149818093	chr6:149904243~149906418:+
PRAD	cis	rs150992	0.609	rs161935	ENSG00000248489.1	CTD-2007H13.3	10.72	4.77e-24	5.71e-21	0.5	0.45	Body mass index;	chr5:98982733	chr5:98929171~98995013:+
PRAD	cis	rs150992	0.632	rs161936	ENSG00000248489.1	CTD-2007H13.3	10.72	4.77e-24	5.71e-21	0.5	0.45	Body mass index;	chr5:98982953	chr5:98929171~98995013:+
PRAD	cis	rs6142102	0.961	rs6057957	ENSG00000276073.1	RP5-1125A11.7	-10.72	4.77e-24	5.71e-21	-0.46	-0.45	Skin pigmentation;	chr20:33962052	chr20:33985617~33988989:-
PRAD	cis	rs9322193	0.923	rs9800686	ENSG00000268592.3	RAET1E-AS1	10.72	4.8e-24	5.75e-21	0.62	0.45	Lung cancer;	chr6:149634464	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.81	rs62439811	ENSG00000268592.3	RAET1E-AS1	10.72	4.8e-24	5.75e-21	0.62	0.45	Lung cancer;	chr6:149640416	chr6:149863494~149919507:+
PRAD	cis	rs875971	0.862	rs1860469	ENSG00000237310.1	GS1-124K5.4	-10.72	4.83e-24	5.79e-21	-0.42	-0.45	Aortic root size;	chr7:66641888	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.862	rs4718383	ENSG00000237310.1	GS1-124K5.4	-10.72	4.83e-24	5.79e-21	-0.42	-0.45	Aortic root size;	chr7:66643422	chr7:66493706~66495474:+
PRAD	cis	rs9322193	0.962	rs9505974	ENSG00000223701.3	RAET1E-AS1	10.71	4.91e-24	5.88e-21	0.59	0.45	Lung cancer;	chr6:149779294	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.926	rs9689036	ENSG00000223701.3	RAET1E-AS1	10.71	4.91e-24	5.88e-21	0.59	0.45	Lung cancer;	chr6:149780563	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.962	rs9322218	ENSG00000223701.3	RAET1E-AS1	10.71	4.91e-24	5.88e-21	0.59	0.45	Lung cancer;	chr6:149782183	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.962	rs9322219	ENSG00000223701.3	RAET1E-AS1	10.71	4.91e-24	5.88e-21	0.59	0.45	Lung cancer;	chr6:149782263	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.962	rs9322223	ENSG00000223701.3	RAET1E-AS1	10.71	4.91e-24	5.88e-21	0.59	0.45	Lung cancer;	chr6:149801509	chr6:149884431~149919508:+
PRAD	cis	rs3931020	0.962	rs2185695	ENSG00000272864.1	RP11-17E13.2	-10.71	4.93e-24	5.9e-21	-0.48	-0.45	Resistin levels;	chr1:74792197	chr1:74698769~74699333:-
PRAD	cis	rs6860806	0.507	rs270614	ENSG00000233006.5	AC034220.3	10.71	4.94e-24	5.91e-21	0.43	0.45	Breast cancer;	chr5:132305120	chr5:132311285~132369916:-
PRAD	cis	rs34779708	0.966	rs12775548	ENSG00000230534.5	RP11-297A16.2	10.71	4.97e-24	5.95e-21	0.6	0.45	Inflammatory bowel disease;Crohn's disease;	chr10:35190576	chr10:35098006~35127020:-
PRAD	cis	rs10875746	0.807	rs12297004	ENSG00000240399.1	RP1-228P16.1	-10.71	4.99e-24	5.97e-21	-0.46	-0.45	Longevity (90 years and older);	chr12:48060037	chr12:48054813~48055591:-
PRAD	cis	rs10875746	0.903	rs58952582	ENSG00000240399.1	RP1-228P16.1	-10.71	4.99e-24	5.97e-21	-0.46	-0.45	Longevity (90 years and older);	chr12:48064665	chr12:48054813~48055591:-
PRAD	cis	rs10875746	0.903	rs10875735	ENSG00000240399.1	RP1-228P16.1	-10.71	4.99e-24	5.97e-21	-0.46	-0.45	Longevity (90 years and older);	chr12:48070023	chr12:48054813~48055591:-
PRAD	cis	rs10875746	0.855	rs17122620	ENSG00000240399.1	RP1-228P16.1	-10.71	4.99e-24	5.97e-21	-0.46	-0.45	Longevity (90 years and older);	chr12:48070692	chr12:48054813~48055591:-
PRAD	cis	rs10875746	0.859	rs4760680	ENSG00000240399.1	RP1-228P16.1	-10.71	4.99e-24	5.97e-21	-0.46	-0.45	Longevity (90 years and older);	chr12:48072914	chr12:48054813~48055591:-
PRAD	cis	rs10875746	0.903	rs11168386	ENSG00000240399.1	RP1-228P16.1	-10.71	4.99e-24	5.97e-21	-0.46	-0.45	Longevity (90 years and older);	chr12:48074194	chr12:48054813~48055591:-
PRAD	cis	rs10875746	0.807	rs12313300	ENSG00000240399.1	RP1-228P16.1	-10.71	4.99e-24	5.97e-21	-0.46	-0.45	Longevity (90 years and older);	chr12:48076934	chr12:48054813~48055591:-
PRAD	cis	rs10875746	0.903	rs12315625	ENSG00000240399.1	RP1-228P16.1	-10.71	4.99e-24	5.97e-21	-0.46	-0.45	Longevity (90 years and older);	chr12:48078670	chr12:48054813~48055591:-
PRAD	cis	rs10875746	0.903	rs10875738	ENSG00000240399.1	RP1-228P16.1	-10.71	4.99e-24	5.97e-21	-0.46	-0.45	Longevity (90 years and older);	chr12:48079956	chr12:48054813~48055591:-
PRAD	cis	rs10875746	0.903	rs12301339	ENSG00000240399.1	RP1-228P16.1	-10.71	4.99e-24	5.97e-21	-0.46	-0.45	Longevity (90 years and older);	chr12:48081450	chr12:48054813~48055591:-
PRAD	cis	rs10875746	0.903	rs886588	ENSG00000240399.1	RP1-228P16.1	-10.71	4.99e-24	5.97e-21	-0.46	-0.45	Longevity (90 years and older);	chr12:48083639	chr12:48054813~48055591:-
PRAD	cis	rs875971	0.83	rs778711	ENSG00000237310.1	GS1-124K5.4	10.71	4.99e-24	5.97e-21	0.41	0.45	Aortic root size;	chr7:66386670	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.862	rs1083554	ENSG00000237310.1	GS1-124K5.4	10.71	4.99e-24	5.97e-21	0.41	0.45	Aortic root size;	chr7:66387354	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.862	rs778707	ENSG00000237310.1	GS1-124K5.4	10.71	4.99e-24	5.97e-21	0.41	0.45	Aortic root size;	chr7:66392040	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.862	rs778705	ENSG00000237310.1	GS1-124K5.4	10.71	4.99e-24	5.97e-21	0.41	0.45	Aortic root size;	chr7:66396128	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.862	rs778697	ENSG00000237310.1	GS1-124K5.4	10.71	4.99e-24	5.97e-21	0.41	0.45	Aortic root size;	chr7:66405439	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.798	rs7789615	ENSG00000237310.1	GS1-124K5.4	10.71	4.99e-24	5.97e-21	0.41	0.45	Aortic root size;	chr7:66413674	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.862	rs6978028	ENSG00000237310.1	GS1-124K5.4	10.71	4.99e-24	5.97e-21	0.41	0.45	Aortic root size;	chr7:66421313	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.862	rs6947339	ENSG00000237310.1	GS1-124K5.4	10.71	4.99e-24	5.97e-21	0.41	0.45	Aortic root size;	chr7:66423483	chr7:66493706~66495474:+
PRAD	cis	rs9322193	0.926	rs9383546	ENSG00000223701.3	RAET1E-AS1	10.71	5.02e-24	6.01e-21	0.6	0.45	Lung cancer;	chr6:149822743	chr6:149884431~149919508:+
PRAD	cis	rs2729354	1	rs2729354	ENSG00000265566.2	RN7SL605P	-10.71	5.03e-24	6.01e-21	-0.67	-0.45	Blood protein levels;	chr11:57588497	chr11:57528085~57528365:-
PRAD	cis	rs748404	0.587	rs690276	ENSG00000205771.5	CATSPER2P1	-10.71	5.04e-24	6.02e-21	-0.5	-0.45	Lung cancer;	chr15:43412360	chr15:43726918~43747094:-
PRAD	cis	rs7208859	0.614	rs4794874	ENSG00000263531.1	RP13-753N3.1	-10.71	5.05e-24	6.04e-21	-0.85	-0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30514300	chr17:30863921~30864940:-
PRAD	cis	rs9322193	0.886	rs4039600	ENSG00000268592.3	RAET1E-AS1	10.71	5.08e-24	6.07e-21	0.63	0.45	Lung cancer;	chr6:149576319	chr6:149863494~149919507:+
PRAD	cis	rs1150668	0.796	rs213236	ENSG00000204709.4	LINC01556	10.71	5.09e-24	6.08e-21	0.55	0.45	Pubertal anthropometrics;	chr6:28356620	chr6:28943877~28944537:+
PRAD	cis	rs11951515	0.637	rs4866813	ENSG00000188850.9	RP11-159F24.2	10.71	5.13e-24	6.13e-21	0.53	0.45	Metabolite levels  (X-11787);	chr5:43300642	chr5:43336164~43348716:+
PRAD	cis	rs9322193	0.923	rs10872645	ENSG00000216906.2	RP11-350J20.9	10.71	5.15e-24	6.15e-21	0.52	0.45	Lung cancer;	chr6:149742840	chr6:149904243~149906418:+
PRAD	cis	rs11603023	0.625	rs633683	ENSG00000255239.1	AP002954.6	10.71	5.15e-24	6.15e-21	0.55	0.45	Cholesterol, total;	chr11:118634025	chr11:118688039~118690600:-
PRAD	cis	rs62388641	0.539	rs56304710	ENSG00000272279.1	RP11-157J24.2	10.71	5.17e-24	6.18e-21	0.59	0.45	Daytime sleep phenotypes;	chr6:1542341	chr6:1528364~1528911:-
PRAD	cis	rs10170846	0.861	rs6740452	ENSG00000261428.2	RP11-16P6.1	10.71	5.19e-24	6.2e-21	0.57	0.45	Schizophrenia (inflammation and infection response interaction);	chr2:222653733	chr2:222566899~222569719:-
PRAD	cis	rs10170846	0.789	rs972650	ENSG00000261428.2	RP11-16P6.1	10.71	5.19e-24	6.2e-21	0.57	0.45	Schizophrenia (inflammation and infection response interaction);	chr2:222655568	chr2:222566899~222569719:-
PRAD	cis	rs10170846	0.861	rs12694582	ENSG00000261428.2	RP11-16P6.1	10.71	5.19e-24	6.2e-21	0.57	0.45	Schizophrenia (inflammation and infection response interaction);	chr2:222657236	chr2:222566899~222569719:-
PRAD	cis	rs10170846	0.731	rs10180632	ENSG00000261428.2	RP11-16P6.1	10.71	5.19e-24	6.2e-21	0.57	0.45	Schizophrenia (inflammation and infection response interaction);	chr2:222661665	chr2:222566899~222569719:-
PRAD	cis	rs10170846	0.8	rs10180462	ENSG00000261428.2	RP11-16P6.1	10.71	5.19e-24	6.2e-21	0.57	0.45	Schizophrenia (inflammation and infection response interaction);	chr2:222661666	chr2:222566899~222569719:-
PRAD	cis	rs853679	0.517	rs9380052	ENSG00000280107.1	AL022393.9	-10.71	5.24e-24	6.26e-21	-0.58	-0.45	Depression;	chr6:28096845	chr6:28170845~28172521:+
PRAD	cis	rs7714584	1	rs1000113	ENSG00000197083.10	ZNF300P1	10.71	5.26e-24	6.27e-21	0.75	0.45	Crohn's disease;	chr5:150860514	chr5:150930645~150946289:-
PRAD	cis	rs9322193	0.566	rs6912330	ENSG00000268592.3	RAET1E-AS1	-10.71	5.26e-24	6.28e-21	-0.7	-0.45	Lung cancer;	chr6:149908811	chr6:149863494~149919507:+
PRAD	cis	rs2348418	0.733	rs2169752	ENSG00000247934.4	RP11-967K21.1	-10.7	5.29e-24	6.32e-21	-0.41	-0.45	Lung function (FEV1);Lung function (FVC);	chr12:28239279	chr12:28163298~28190738:-
PRAD	cis	rs9322193	0.607	rs6557165	ENSG00000268592.3	RAET1E-AS1	-10.7	5.29e-24	6.32e-21	-0.68	-0.45	Lung cancer;	chr6:149906883	chr6:149863494~149919507:+
PRAD	cis	rs6570726	0.764	rs367065	ENSG00000235652.6	RP11-545I5.3	10.7	5.33e-24	6.36e-21	0.47	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145561173	chr6:145799409~145886585:+
PRAD	cis	rs9322193	0.923	rs6913486	ENSG00000216906.2	RP11-350J20.9	-10.7	5.35e-24	6.38e-21	-0.51	-0.45	Lung cancer;	chr6:149705060	chr6:149904243~149906418:+
PRAD	cis	rs2919917	0.628	rs10113703	ENSG00000254352.1	RP11-578O24.2	10.7	5.35e-24	6.39e-21	0.59	0.45	Lymphocyte counts;	chr8:78688404	chr8:78723796~78724136:-
PRAD	cis	rs34375054	0.735	rs34961756	ENSG00000279233.1	RP11-158L12.4	10.7	5.36e-24	6.39e-21	0.41	0.45	Post bronchodilator FEV1/FVC ratio;	chr12:125144052	chr12:125138245~125141711:+
PRAD	cis	rs11951515	0.738	rs4866737	ENSG00000188850.9	RP11-159F24.2	10.7	5.37e-24	6.4e-21	0.53	0.45	Metabolite levels  (X-11787);	chr5:43317279	chr5:43336164~43348716:+
PRAD	cis	rs11951515	0.691	rs56206275	ENSG00000188850.9	RP11-159F24.2	10.7	5.37e-24	6.4e-21	0.53	0.45	Metabolite levels  (X-11787);	chr5:43335468	chr5:43336164~43348716:+
PRAD	cis	rs11951515	0.738	rs4866818	ENSG00000188850.9	RP11-159F24.2	10.7	5.37e-24	6.4e-21	0.53	0.45	Metabolite levels  (X-11787);	chr5:43337432	chr5:43336164~43348716:+
PRAD	cis	rs9322193	0.566	rs6912330	ENSG00000223701.3	RAET1E-AS1	-10.7	5.37e-24	6.41e-21	-0.69	-0.45	Lung cancer;	chr6:149908811	chr6:149884431~149919508:+
PRAD	cis	rs1577917	0.876	rs11752223	ENSG00000203875.9	SNHG5	-10.7	5.39e-24	6.42e-21	-0.5	-0.45	Response to antipsychotic treatment;	chr6:85863676	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.958	rs12660846	ENSG00000203875.9	SNHG5	-10.7	5.39e-24	6.42e-21	-0.5	-0.45	Response to antipsychotic treatment;	chr6:85864091	chr6:85660950~85678736:-
PRAD	cis	rs11951515	0.714	rs56071328	ENSG00000188850.9	RP11-159F24.2	10.7	5.39e-24	6.43e-21	0.53	0.45	Metabolite levels  (X-11787);	chr5:43341225	chr5:43336164~43348716:+
PRAD	cis	rs7208859	0.614	rs7216394	ENSG00000263531.1	RP13-753N3.1	-10.7	5.39e-24	6.43e-21	-0.85	-0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30498738	chr17:30863921~30864940:-
PRAD	cis	rs9322193	0.923	rs57938011	ENSG00000216906.2	RP11-350J20.9	10.7	5.43e-24	6.48e-21	0.52	0.45	Lung cancer;	chr6:149642969	chr6:149904243~149906418:+
PRAD	cis	rs7772486	0.754	rs6906258	ENSG00000235652.6	RP11-545I5.3	-10.7	5.45e-24	6.5e-21	-0.46	-0.45	Lobe attachment (rater-scored or self-reported);	chr6:145768220	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.754	rs6915718	ENSG00000235652.6	RP11-545I5.3	-10.7	5.45e-24	6.5e-21	-0.46	-0.45	Lobe attachment (rater-scored or self-reported);	chr6:145779540	chr6:145799409~145886585:+
PRAD	cis	rs2919917	0.628	rs9298314	ENSG00000254352.1	RP11-578O24.2	10.7	5.48e-24	6.53e-21	0.58	0.45	Lymphocyte counts;	chr8:78660874	chr8:78723796~78724136:-
PRAD	cis	rs7772486	0.754	rs864148	ENSG00000235652.6	RP11-545I5.3	-10.7	5.5e-24	6.56e-21	-0.46	-0.45	Lobe attachment (rater-scored or self-reported);	chr6:145655539	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.754	rs702306	ENSG00000235652.6	RP11-545I5.3	-10.7	5.5e-24	6.56e-21	-0.46	-0.45	Lobe attachment (rater-scored or self-reported);	chr6:145669893	chr6:145799409~145886585:+
PRAD	cis	rs7714584	1	rs4958426	ENSG00000197083.10	ZNF300P1	10.7	5.54e-24	6.6e-21	0.81	0.45	Crohn's disease;	chr5:150898784	chr5:150930645~150946289:-
PRAD	cis	rs7615952	0.932	rs13325495	ENSG00000171084.14	FAM86JP	10.7	5.56e-24	6.62e-21	0.81	0.45	Blood pressure (smoking interaction);	chr3:125918573	chr3:125916620~125930024:+
PRAD	cis	rs4713118	0.629	rs203889	ENSG00000280107.1	AL022393.9	-10.7	5.56e-24	6.63e-21	-0.57	-0.45	Parkinson's disease;	chr6:28053997	chr6:28170845~28172521:+
PRAD	cis	rs2404602	0.647	rs8025991	ENSG00000259422.1	RP11-593F23.1	-10.7	5.57e-24	6.64e-21	-0.59	-0.45	Blood metabolite levels;	chr15:76862927	chr15:76174891~76181486:-
PRAD	cis	rs9322193	0.632	rs3828700	ENSG00000216906.2	RP11-350J20.9	10.7	5.6e-24	6.67e-21	0.52	0.45	Lung cancer;	chr6:149791033	chr6:149904243~149906418:+
PRAD	cis	rs8062405	0.755	rs17707300	ENSG00000259982.1	CDC37P1	10.7	5.6e-24	6.68e-21	0.58	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582026	chr16:28700294~28701540:-
PRAD	cis	rs2404602	0.583	rs2176623	ENSG00000259422.1	RP11-593F23.1	10.7	5.61e-24	6.69e-21	0.55	0.45	Blood metabolite levels;	chr15:76276238	chr15:76174891~76181486:-
PRAD	cis	rs9322193	0.962	rs2065664	ENSG00000268592.3	RAET1E-AS1	10.7	5.64e-24	6.72e-21	0.61	0.45	Lung cancer;	chr6:149762485	chr6:149863494~149919507:+
PRAD	cis	rs780096	0.506	rs2288155	ENSG00000234072.1	AC074117.10	-10.7	5.69e-24	6.77e-21	-0.35	-0.45	Total body bone mineral density;	chr2:27491659	chr2:27356246~27367622:+
PRAD	cis	rs6700559	0.873	rs6427840	ENSG00000260088.1	RP11-92G12.3	-10.7	5.71e-24	6.8e-21	-0.58	-0.45	Coronary artery disease;	chr1:200685659	chr1:200669507~200694250:+
PRAD	cis	rs11676348	0.901	rs7562334	ENSG00000261338.2	RP11-378A13.1	-10.7	5.73e-24	6.82e-21	-0.5	-0.45	Ulcerative colitis;	chr2:218138637	chr2:218255319~218257366:+
PRAD	cis	rs11676348	0.967	rs4672873	ENSG00000261338.2	RP11-378A13.1	-10.7	5.73e-24	6.82e-21	-0.5	-0.45	Ulcerative colitis;	chr2:218140487	chr2:218255319~218257366:+
PRAD	cis	rs8072100	0.544	rs7214993	ENSG00000228782.6	CTD-2026D20.3	10.7	5.74e-24	6.83e-21	0.49	0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47309431	chr17:47450568~47492492:-
PRAD	cis	rs34375054	0.66	rs12303416	ENSG00000279233.1	RP11-158L12.4	10.7	5.75e-24	6.85e-21	0.43	0.45	Post bronchodilator FEV1/FVC ratio;	chr12:125108812	chr12:125138245~125141711:+
PRAD	cis	rs7714584	1	rs12652003	ENSG00000197083.10	ZNF300P1	10.69	5.84e-24	6.95e-21	0.76	0.45	Crohn's disease;	chr5:150852383	chr5:150930645~150946289:-
PRAD	cis	rs34779708	0.966	rs11010129	ENSG00000230534.5	RP11-297A16.2	10.69	5.86e-24	6.97e-21	0.59	0.45	Inflammatory bowel disease;Crohn's disease;	chr10:35221894	chr10:35098006~35127020:-
PRAD	cis	rs11951515	0.714	rs12519001	ENSG00000188850.9	RP11-159F24.2	10.69	5.97e-24	7.11e-21	0.53	0.45	Metabolite levels  (X-11787);	chr5:43329953	chr5:43336164~43348716:+
PRAD	cis	rs2348418	0.966	rs7136139	ENSG00000247934.4	RP11-967K21.1	10.69	6.03e-24	7.17e-21	0.41	0.45	Lung function (FEV1);Lung function (FVC);	chr12:28531087	chr12:28163298~28190738:-
PRAD	cis	rs1075265	0.749	rs10203095	ENSG00000233266.1	HMGB1P31	10.69	6.04e-24	7.19e-21	0.61	0.45	Chronotype;Morning vs. evening chronotype;	chr2:53737150	chr2:54051334~54051760:+
PRAD	cis	rs10875746	0.855	rs12296244	ENSG00000240399.1	RP1-228P16.1	-10.69	6.05e-24	7.19e-21	-0.46	-0.45	Longevity (90 years and older);	chr12:48047696	chr12:48054813~48055591:-
PRAD	cis	rs10875746	0.855	rs12310999	ENSG00000240399.1	RP1-228P16.1	-10.69	6.05e-24	7.19e-21	-0.46	-0.45	Longevity (90 years and older);	chr12:48053875	chr12:48054813~48055591:-
PRAD	cis	rs10875746	0.903	rs61918774	ENSG00000240399.1	RP1-228P16.1	-10.69	6.05e-24	7.19e-21	-0.46	-0.45	Longevity (90 years and older);	chr12:48054351	chr12:48054813~48055591:-
PRAD	cis	rs4853012	0.838	rs60964317	ENSG00000257800.1	FNBP1P1	10.69	6.07e-24	7.22e-21	0.39	0.45	Gestational age at birth (maternal effect);	chr2:74116296	chr2:74120680~74123218:+
PRAD	cis	rs11951515	0.738	rs12514399	ENSG00000188850.9	RP11-159F24.2	10.69	6.1e-24	7.24e-21	0.53	0.45	Metabolite levels  (X-11787);	chr5:43313468	chr5:43336164~43348716:+
PRAD	cis	rs11951515	0.738	rs12515072	ENSG00000188850.9	RP11-159F24.2	10.69	6.1e-24	7.24e-21	0.53	0.45	Metabolite levels  (X-11787);	chr5:43313974	chr5:43336164~43348716:+
PRAD	cis	rs11951515	0.738	rs67817333	ENSG00000188850.9	RP11-159F24.2	10.69	6.1e-24	7.24e-21	0.53	0.45	Metabolite levels  (X-11787);	chr5:43314947	chr5:43336164~43348716:+
PRAD	cis	rs11951515	0.738	rs2126949	ENSG00000188850.9	RP11-159F24.2	10.69	6.1e-24	7.24e-21	0.53	0.45	Metabolite levels  (X-11787);	chr5:43316288	chr5:43336164~43348716:+
PRAD	cis	rs11951515	0.646	rs2126948	ENSG00000188850.9	RP11-159F24.2	10.69	6.1e-24	7.24e-21	0.53	0.45	Metabolite levels  (X-11787);	chr5:43316367	chr5:43336164~43348716:+
PRAD	cis	rs11951515	0.738	rs4866738	ENSG00000188850.9	RP11-159F24.2	10.69	6.1e-24	7.24e-21	0.53	0.45	Metabolite levels  (X-11787);	chr5:43317354	chr5:43336164~43348716:+
PRAD	cis	rs11951515	0.738	rs11739009	ENSG00000188850.9	RP11-159F24.2	10.69	6.1e-24	7.24e-21	0.53	0.45	Metabolite levels  (X-11787);	chr5:43318536	chr5:43336164~43348716:+
PRAD	cis	rs11951515	0.738	rs58679159	ENSG00000188850.9	RP11-159F24.2	10.69	6.1e-24	7.24e-21	0.53	0.45	Metabolite levels  (X-11787);	chr5:43319720	chr5:43336164~43348716:+
PRAD	cis	rs11951515	0.738	rs57401732	ENSG00000188850.9	RP11-159F24.2	10.69	6.1e-24	7.24e-21	0.53	0.45	Metabolite levels  (X-11787);	chr5:43320567	chr5:43336164~43348716:+
PRAD	cis	rs11951515	0.714	rs67497876	ENSG00000188850.9	RP11-159F24.2	10.69	6.1e-24	7.24e-21	0.53	0.45	Metabolite levels  (X-11787);	chr5:43320746	chr5:43336164~43348716:+
PRAD	cis	rs11951515	0.714	rs66914803	ENSG00000188850.9	RP11-159F24.2	10.69	6.1e-24	7.24e-21	0.53	0.45	Metabolite levels  (X-11787);	chr5:43320754	chr5:43336164~43348716:+
PRAD	cis	rs11951515	0.714	rs60445501	ENSG00000188850.9	RP11-159F24.2	10.69	6.1e-24	7.24e-21	0.53	0.45	Metabolite levels  (X-11787);	chr5:43321234	chr5:43336164~43348716:+
PRAD	cis	rs11951515	0.738	rs55634155	ENSG00000188850.9	RP11-159F24.2	10.69	6.1e-24	7.24e-21	0.53	0.45	Metabolite levels  (X-11787);	chr5:43321417	chr5:43336164~43348716:+
PRAD	cis	rs11951515	0.738	rs67651757	ENSG00000188850.9	RP11-159F24.2	10.69	6.1e-24	7.24e-21	0.53	0.45	Metabolite levels  (X-11787);	chr5:43322815	chr5:43336164~43348716:+
PRAD	cis	rs11951515	0.738	rs4866739	ENSG00000188850.9	RP11-159F24.2	10.69	6.1e-24	7.24e-21	0.53	0.45	Metabolite levels  (X-11787);	chr5:43324272	chr5:43336164~43348716:+
PRAD	cis	rs11951515	0.738	rs4866740	ENSG00000188850.9	RP11-159F24.2	10.69	6.1e-24	7.24e-21	0.53	0.45	Metabolite levels  (X-11787);	chr5:43328588	chr5:43336164~43348716:+
PRAD	cis	rs11951515	0.738	rs4866817	ENSG00000188850.9	RP11-159F24.2	10.69	6.1e-24	7.24e-21	0.53	0.45	Metabolite levels  (X-11787);	chr5:43328956	chr5:43336164~43348716:+
PRAD	cis	rs11951515	0.668	rs56055740	ENSG00000188850.9	RP11-159F24.2	10.69	6.1e-24	7.24e-21	0.53	0.45	Metabolite levels  (X-11787);	chr5:43330672	chr5:43336164~43348716:+
PRAD	cis	rs11951515	0.668	rs55722964	ENSG00000188850.9	RP11-159F24.2	10.69	6.1e-24	7.24e-21	0.53	0.45	Metabolite levels  (X-11787);	chr5:43330684	chr5:43336164~43348716:+
PRAD	cis	rs11951515	0.738	rs56690587	ENSG00000188850.9	RP11-159F24.2	10.69	6.1e-24	7.24e-21	0.53	0.45	Metabolite levels  (X-11787);	chr5:43331789	chr5:43336164~43348716:+
PRAD	cis	rs11951515	0.714	rs56063506	ENSG00000188850.9	RP11-159F24.2	10.69	6.1e-24	7.24e-21	0.53	0.45	Metabolite levels  (X-11787);	chr5:43332496	chr5:43336164~43348716:+
PRAD	cis	rs11951515	0.738	rs59078439	ENSG00000188850.9	RP11-159F24.2	10.69	6.1e-24	7.24e-21	0.53	0.45	Metabolite levels  (X-11787);	chr5:43332847	chr5:43336164~43348716:+
PRAD	cis	rs11951515	0.607	rs11747834	ENSG00000188850.9	RP11-159F24.2	10.69	6.1e-24	7.24e-21	0.53	0.45	Metabolite levels  (X-11787);	chr5:43332919	chr5:43336164~43348716:+
PRAD	cis	rs11951515	0.738	rs11741246	ENSG00000188850.9	RP11-159F24.2	10.69	6.1e-24	7.24e-21	0.53	0.45	Metabolite levels  (X-11787);	chr5:43333091	chr5:43336164~43348716:+
PRAD	cis	rs11951515	0.738	rs10941628	ENSG00000188850.9	RP11-159F24.2	10.69	6.1e-24	7.24e-21	0.53	0.45	Metabolite levels  (X-11787);	chr5:43333635	chr5:43336164~43348716:+
PRAD	cis	rs11951515	0.714	rs4591755	ENSG00000188850.9	RP11-159F24.2	10.69	6.1e-24	7.24e-21	0.53	0.45	Metabolite levels  (X-11787);	chr5:43333931	chr5:43336164~43348716:+
PRAD	cis	rs11951515	0.738	rs12189447	ENSG00000188850.9	RP11-159F24.2	10.69	6.1e-24	7.24e-21	0.53	0.45	Metabolite levels  (X-11787);	chr5:43335882	chr5:43336164~43348716:+
PRAD	cis	rs11951515	0.738	rs4574553	ENSG00000188850.9	RP11-159F24.2	10.69	6.1e-24	7.24e-21	0.53	0.45	Metabolite levels  (X-11787);	chr5:43336316	chr5:43336164~43348716:+
PRAD	cis	rs11951515	0.675	rs72754530	ENSG00000188850.9	RP11-159F24.2	10.69	6.1e-24	7.24e-21	0.53	0.45	Metabolite levels  (X-11787);	chr5:43339370	chr5:43336164~43348716:+
PRAD	cis	rs11951515	0.738	rs55673816	ENSG00000188850.9	RP11-159F24.2	10.69	6.1e-24	7.24e-21	0.53	0.45	Metabolite levels  (X-11787);	chr5:43339682	chr5:43336164~43348716:+
PRAD	cis	rs11951515	0.738	rs1564196	ENSG00000188850.9	RP11-159F24.2	-10.69	6.1e-24	7.24e-21	-0.53	-0.45	Metabolite levels  (X-11787);	chr5:43338774	chr5:43336164~43348716:+
PRAD	cis	rs10256972	0.967	rs7799110	ENSG00000229043.2	AC091729.9	-10.69	6.13e-24	7.28e-21	-0.54	-0.45	Endometriosis;Longevity;	chr7:999429	chr7:1160374~1165267:+
PRAD	cis	rs6538678	0.824	rs2367583	ENSG00000258343.1	RP11-536G4.2	-10.69	6.14e-24	7.29e-21	-0.69	-0.45	Lupus nephritis in systemic lupus erythematosus;	chr12:95856582	chr12:95795345~95858839:-
PRAD	cis	rs2153535	1	rs11243251	ENSG00000230939.1	RP11-314C16.1	10.69	6.24e-24	7.4e-21	0.55	0.45	Motion sickness;	chr6:8367974	chr6:8784178~8785445:+
PRAD	cis	rs6860806	0.507	rs156322	ENSG00000233006.5	AC034220.3	10.69	6.26e-24	7.43e-21	0.42	0.45	Breast cancer;	chr5:132318232	chr5:132311285~132369916:-
PRAD	cis	rs9322193	0.962	rs2275046	ENSG00000216906.2	RP11-350J20.9	10.68	6.31e-24	7.49e-21	0.52	0.45	Lung cancer;	chr6:149835865	chr6:149904243~149906418:+
PRAD	cis	rs10170846	0.861	rs4674677	ENSG00000261428.2	RP11-16P6.1	10.68	6.33e-24	7.5e-21	0.57	0.45	Schizophrenia (inflammation and infection response interaction);	chr2:222664939	chr2:222566899~222569719:-
PRAD	cis	rs2919917	0.628	rs1036751	ENSG00000254352.1	RP11-578O24.2	-10.68	6.34e-24	7.52e-21	-0.6	-0.45	Lymphocyte counts;	chr8:78729671	chr8:78723796~78724136:-
PRAD	cis	rs2919917	0.628	rs894222	ENSG00000254352.1	RP11-578O24.2	-10.68	6.34e-24	7.52e-21	-0.6	-0.45	Lymphocyte counts;	chr8:78737034	chr8:78723796~78724136:-
PRAD	cis	rs274567	0.55	rs272885	ENSG00000233006.5	AC034220.3	10.68	6.37e-24	7.56e-21	0.42	0.45	Blood metabolite levels;	chr5:132332043	chr5:132311285~132369916:-
PRAD	cis	rs6860806	0.507	rs272883	ENSG00000233006.5	AC034220.3	10.68	6.37e-24	7.56e-21	0.42	0.45	Breast cancer;	chr5:132333005	chr5:132311285~132369916:-
PRAD	cis	rs6860806	0.507	rs272882	ENSG00000233006.5	AC034220.3	10.68	6.37e-24	7.56e-21	0.42	0.45	Breast cancer;	chr5:132333468	chr5:132311285~132369916:-
PRAD	cis	rs270601	0.866	rs460271	ENSG00000233006.5	AC034220.3	10.68	6.43e-24	7.62e-21	0.43	0.45	Acylcarnitine levels;	chr5:132294369	chr5:132311285~132369916:-
PRAD	cis	rs7615952	0.673	rs35955861	ENSG00000171084.14	FAM86JP	10.68	6.43e-24	7.62e-21	0.85	0.45	Blood pressure (smoking interaction);	chr3:125907358	chr3:125916620~125930024:+
PRAD	cis	rs638893	0.636	rs7119702	ENSG00000278376.1	RP11-158I9.8	-10.68	6.46e-24	7.65e-21	-0.54	-0.45	Vitiligo;	chr11:118736985	chr11:118791254~118793137:+
PRAD	cis	rs748404	0.66	rs694725	ENSG00000205771.5	CATSPER2P1	-10.68	6.51e-24	7.71e-21	-0.49	-0.45	Lung cancer;	chr15:43464012	chr15:43726918~43747094:-
PRAD	cis	rs10875746	0.951	rs4760689	ENSG00000240399.1	RP1-228P16.1	-10.68	6.52e-24	7.72e-21	-0.46	-0.45	Longevity (90 years and older);	chr12:48169861	chr12:48054813~48055591:-
PRAD	cis	rs10875746	0.951	rs58865997	ENSG00000240399.1	RP1-228P16.1	-10.68	6.52e-24	7.72e-21	-0.46	-0.45	Longevity (90 years and older);	chr12:48173090	chr12:48054813~48055591:-
PRAD	cis	rs2348418	0.8	rs6487667	ENSG00000247934.4	RP11-967K21.1	-10.68	6.52e-24	7.72e-21	-0.41	-0.45	Lung function (FEV1);Lung function (FVC);	chr12:28195643	chr12:28163298~28190738:-
PRAD	cis	rs4713118	0.662	rs9380046	ENSG00000280107.1	AL022393.9	-10.68	6.54e-24	7.74e-21	-0.57	-0.45	Parkinson's disease;	chr6:28062721	chr6:28170845~28172521:+
PRAD	cis	rs9322193	0.923	rs12526675	ENSG00000216906.2	RP11-350J20.9	-10.68	6.54e-24	7.75e-21	-0.51	-0.45	Lung cancer;	chr6:149729540	chr6:149904243~149906418:+
PRAD	cis	rs150992	0.632	rs326493	ENSG00000248489.1	CTD-2007H13.3	10.68	6.58e-24	7.79e-21	0.5	0.45	Body mass index;	chr5:98966251	chr5:98929171~98995013:+
PRAD	cis	rs270601	0.817	rs460089	ENSG00000233006.5	AC034220.3	10.68	6.61e-24	7.82e-21	0.43	0.45	Acylcarnitine levels;	chr5:132294079	chr5:132311285~132369916:-
PRAD	cis	rs2729354	0.953	rs2649663	ENSG00000265566.2	RN7SL605P	-10.68	6.65e-24	7.86e-21	-0.67	-0.45	Blood protein levels;	chr11:57589832	chr11:57528085~57528365:-
PRAD	cis	rs9322193	0.607	rs6925151	ENSG00000223701.3	RAET1E-AS1	10.68	6.65e-24	7.87e-21	0.67	0.45	Lung cancer;	chr6:149889587	chr6:149884431~149919508:+
PRAD	cis	rs189798	0.807	rs330905	ENSG00000254340.1	RP11-10A14.3	10.68	6.7e-24	7.93e-21	0.58	0.45	Myopia (pathological);	chr8:9136041	chr8:9141424~9145435:+
PRAD	cis	rs2442825	0.693	rs2596913	ENSG00000206573.7	THUMPD3-AS1	10.68	6.72e-24	7.96e-21	0.32	0.45	Cerebrospinal fluid clusterin levels;	chr3:9394788	chr3:9349689~9398579:-
PRAD	cis	rs2348418	0.765	rs6487665	ENSG00000247934.4	RP11-967K21.1	10.68	6.73e-24	7.96e-21	0.41	0.45	Lung function (FEV1);Lung function (FVC);	chr12:28177726	chr12:28163298~28190738:-
PRAD	cis	rs9322193	0.607	rs7764677	ENSG00000268592.3	RAET1E-AS1	10.68	6.81e-24	8.05e-21	0.7	0.45	Lung cancer;	chr6:149906197	chr6:149863494~149919507:+
PRAD	cis	rs2348418	0.832	rs2126894	ENSG00000247934.4	RP11-967K21.1	10.67	6.87e-24	8.13e-21	0.41	0.45	Lung function (FEV1);Lung function (FVC);	chr12:28323914	chr12:28163298~28190738:-
PRAD	cis	rs9322193	0.962	rs3805753	ENSG00000216906.2	RP11-350J20.9	10.67	6.89e-24	8.15e-21	0.51	0.45	Lung cancer;	chr6:149795662	chr6:149904243~149906418:+
PRAD	cis	rs2348418	0.966	rs11049699	ENSG00000247934.4	RP11-967K21.1	10.67	6.92e-24	8.18e-21	0.41	0.45	Lung function (FEV1);Lung function (FVC);	chr12:28535487	chr12:28163298~28190738:-
PRAD	cis	rs9322193	0.923	rs62439840	ENSG00000268592.3	RAET1E-AS1	10.67	6.93e-24	8.19e-21	0.62	0.45	Lung cancer;	chr6:149674639	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.962	rs9393175	ENSG00000268592.3	RAET1E-AS1	10.67	6.93e-24	8.19e-21	0.62	0.45	Lung cancer;	chr6:149677587	chr6:149863494~149919507:+
PRAD	cis	rs6061231	0.798	rs2427308	ENSG00000273619.1	RP5-908M14.9	-10.67	6.93e-24	8.2e-21	-0.33	-0.45	Colorectal cancer;	chr20:62394395	chr20:62386303~62386970:-
PRAD	cis	rs875971	0.893	rs62465470	ENSG00000237310.1	GS1-124K5.4	-10.67	6.94e-24	8.2e-21	-0.41	-0.45	Aortic root size;	chr7:66136231	chr7:66493706~66495474:+
PRAD	cis	rs9532669	0.889	rs7333447	ENSG00000176268.5	CYCSP34	10.67	6.98e-24	8.25e-21	0.45	0.45	Cervical cancer;	chr13:40917586	chr13:40863599~40863902:-
PRAD	cis	rs9322193	0.962	rs13215691	ENSG00000223701.3	RAET1E-AS1	10.67	6.99e-24	8.27e-21	0.59	0.45	Lung cancer;	chr6:149792666	chr6:149884431~149919508:+
PRAD	cis	rs9326248	0.861	rs4938352	ENSG00000280143.1	AP000892.6	10.67	7.06e-24	8.34e-21	0.43	0.45	Blood protein levels;	chr11:117156765	chr11:117204967~117210292:+
PRAD	cis	rs875971	0.862	rs13232191	ENSG00000237310.1	GS1-124K5.4	10.67	7.06e-24	8.35e-21	0.41	0.45	Aortic root size;	chr7:66521661	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.862	rs35378740	ENSG00000237310.1	GS1-124K5.4	10.67	7.06e-24	8.35e-21	0.41	0.45	Aortic root size;	chr7:66522725	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.862	rs10950043	ENSG00000237310.1	GS1-124K5.4	10.67	7.06e-24	8.35e-21	0.41	0.45	Aortic root size;	chr7:66523623	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.862	rs908915	ENSG00000237310.1	GS1-124K5.4	-10.67	7.07e-24	8.36e-21	-0.41	-0.45	Aortic root size;	chr7:66149664	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.862	rs7809814	ENSG00000237310.1	GS1-124K5.4	-10.67	7.07e-24	8.36e-21	-0.41	-0.45	Aortic root size;	chr7:66150410	chr7:66493706~66495474:+
PRAD	cis	rs7772486	0.754	rs1415747	ENSG00000235652.6	RP11-545I5.3	10.67	7.1e-24	8.39e-21	0.46	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145756113	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.791	rs400329	ENSG00000235652.6	RP11-545I5.3	10.67	7.1e-24	8.39e-21	0.46	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145558306	chr6:145799409~145886585:+
PRAD	cis	rs1891275	0.515	rs1592051	ENSG00000228701.1	TNKS2-AS1	10.67	7.12e-24	8.41e-21	0.56	0.45	Intelligence (multi-trait analysis);	chr10:91782429	chr10:91782839~91798291:-
PRAD	cis	rs2348418	0.966	rs11049698	ENSG00000247934.4	RP11-967K21.1	10.67	7.12e-24	8.41e-21	0.41	0.45	Lung function (FEV1);Lung function (FVC);	chr12:28535354	chr12:28163298~28190738:-
PRAD	cis	rs9487094	0.645	rs34533653	ENSG00000260273.1	RP11-425D10.10	10.67	7.13e-24	8.42e-21	0.69	0.45	Height;	chr6:109479488	chr6:109382795~109383666:+
PRAD	cis	rs875971	0.862	rs4368860	ENSG00000237310.1	GS1-124K5.4	-10.67	7.15e-24	8.45e-21	-0.41	-0.45	Aortic root size;	chr7:66143495	chr7:66493706~66495474:+
PRAD	cis	rs1577917	0.958	rs12213331	ENSG00000203875.9	SNHG5	-10.67	7.23e-24	8.54e-21	-0.53	-0.45	Response to antipsychotic treatment;	chr6:85795079	chr6:85660950~85678736:-
PRAD	cis	rs638893	0.578	rs500254	ENSG00000278376.1	RP11-158I9.8	10.67	7.26e-24	8.57e-21	0.52	0.45	Vitiligo;	chr11:118808071	chr11:118791254~118793137:+
PRAD	cis	rs6570726	0.791	rs435671	ENSG00000235652.6	RP11-545I5.3	10.67	7.33e-24	8.64e-21	0.46	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145560079	chr6:145799409~145886585:+
PRAD	cis	rs5760092	0.755	rs915589	ENSG00000225282.1	AP000350.6	-10.67	7.33e-24	8.65e-21	-0.71	-0.45	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23926900~23929574:+
PRAD	cis	rs7772486	0.754	rs4896838	ENSG00000235652.6	RP11-545I5.3	-10.67	7.35e-24	8.67e-21	-0.46	-0.45	Lobe attachment (rater-scored or self-reported);	chr6:145694315	chr6:145799409~145886585:+
PRAD	cis	rs7208859	0.614	rs216474	ENSG00000263531.1	RP13-753N3.1	-10.67	7.35e-24	8.67e-21	-0.9	-0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30538073	chr17:30863921~30864940:-
PRAD	cis	rs9322193	0.962	rs9397022	ENSG00000216906.2	RP11-350J20.9	10.67	7.37e-24	8.69e-21	0.51	0.45	Lung cancer;	chr6:149812052	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.962	rs9397357	ENSG00000216906.2	RP11-350J20.9	10.67	7.37e-24	8.69e-21	0.51	0.45	Lung cancer;	chr6:149812465	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.607	rs9383941	ENSG00000268592.3	RAET1E-AS1	-10.67	7.42e-24	8.75e-21	-0.7	-0.45	Lung cancer;	chr6:149912100	chr6:149863494~149919507:+
PRAD	cis	rs7240205	0.816	rs7233016	ENSG00000275805.1	RP11-349H17.2	-10.66	7.5e-24	8.85e-21	-0.53	-0.45	Breast cancer;	chr18:26541387	chr18:26565723~26575626:-
PRAD	cis	rs1150668	0.796	rs1005125	ENSG00000216901.1	AL022393.7	10.66	7.52e-24	8.87e-21	0.56	0.45	Pubertal anthropometrics;	chr6:28399578	chr6:28176188~28176674:+
PRAD	cis	rs2919917	0.628	rs2583759	ENSG00000254352.1	RP11-578O24.2	-10.66	7.55e-24	8.9e-21	-0.6	-0.45	Lymphocyte counts;	chr8:78732729	chr8:78723796~78724136:-
PRAD	cis	rs2919917	0.628	rs2583778	ENSG00000254352.1	RP11-578O24.2	-10.66	7.55e-24	8.9e-21	-0.6	-0.45	Lymphocyte counts;	chr8:78738906	chr8:78723796~78724136:-
PRAD	cis	rs4845570	1	rs4845579	ENSG00000249602.1	RP11-98D18.3	10.66	7.57e-24	8.92e-21	0.65	0.45	Coronary artery disease;	chr1:151797662	chr1:151763384~151769501:-
PRAD	cis	rs1150668	0.799	rs1736891	ENSG00000204709.4	LINC01556	10.66	7.57e-24	8.93e-21	0.57	0.45	Pubertal anthropometrics;	chr6:28219323	chr6:28943877~28944537:+
PRAD	cis	rs1577917	0.876	rs12201992	ENSG00000203875.9	SNHG5	-10.66	7.59e-24	8.95e-21	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85908501	chr6:85660950~85678736:-
PRAD	cis	rs1577917	1	rs12201880	ENSG00000203875.9	SNHG5	-10.66	7.59e-24	8.95e-21	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85917289	chr6:85660950~85678736:-
PRAD	cis	rs1577917	1	rs7756203	ENSG00000203875.9	SNHG5	-10.66	7.59e-24	8.95e-21	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85917989	chr6:85660950~85678736:-
PRAD	cis	rs1577917	1	rs10944161	ENSG00000203875.9	SNHG5	-10.66	7.59e-24	8.95e-21	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85920658	chr6:85660950~85678736:-
PRAD	cis	rs1577917	1	rs1857965	ENSG00000203875.9	SNHG5	-10.66	7.59e-24	8.95e-21	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85921058	chr6:85660950~85678736:-
PRAD	cis	rs1577917	1	rs7771342	ENSG00000203875.9	SNHG5	-10.66	7.59e-24	8.95e-21	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85922218	chr6:85660950~85678736:-
PRAD	cis	rs1577917	1	rs12154056	ENSG00000203875.9	SNHG5	-10.66	7.59e-24	8.95e-21	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85924376	chr6:85660950~85678736:-
PRAD	cis	rs6570726	0.791	rs370654	ENSG00000235652.6	RP11-545I5.3	10.66	7.64e-24	9e-21	0.46	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145557869	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.754	rs697055	ENSG00000235652.6	RP11-545I5.3	10.66	7.65e-24	9.01e-21	0.45	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145682654	chr6:145799409~145886585:+
PRAD	cis	rs9322193	0.962	rs1413655	ENSG00000223701.3	RAET1E-AS1	10.66	7.66e-24	9.02e-21	0.6	0.45	Lung cancer;	chr6:149821815	chr6:149884431~149919508:+
PRAD	cis	rs4853012	0.887	rs77148265	ENSG00000257800.1	FNBP1P1	10.66	7.67e-24	9.03e-21	0.43	0.45	Gestational age at birth (maternal effect);	chr2:74112392	chr2:74120680~74123218:+
PRAD	cis	rs9322193	0.923	rs12175504	ENSG00000216906.2	RP11-350J20.9	10.66	7.73e-24	9.1e-21	0.52	0.45	Lung cancer;	chr6:149664079	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.962	rs62439843	ENSG00000216906.2	RP11-350J20.9	10.66	7.73e-24	9.1e-21	0.52	0.45	Lung cancer;	chr6:149676521	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.962	rs1413655	ENSG00000216906.2	RP11-350J20.9	10.66	7.74e-24	9.11e-21	0.51	0.45	Lung cancer;	chr6:149821815	chr6:149904243~149906418:+
PRAD	cis	rs853679	0.506	rs1150693	ENSG00000280107.1	AL022393.9	-10.66	7.77e-24	9.14e-21	-0.58	-0.45	Depression;	chr6:28206812	chr6:28170845~28172521:+
PRAD	cis	rs9322193	0.962	rs10872653	ENSG00000216906.2	RP11-350J20.9	10.66	7.77e-24	9.14e-21	0.51	0.45	Lung cancer;	chr6:149778907	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.923	rs11155683	ENSG00000216906.2	RP11-350J20.9	10.66	7.77e-24	9.14e-21	0.51	0.45	Lung cancer;	chr6:149779341	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.923	rs9372044	ENSG00000216906.2	RP11-350J20.9	10.66	7.77e-24	9.14e-21	0.51	0.45	Lung cancer;	chr6:149780867	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.962	rs11155685	ENSG00000216906.2	RP11-350J20.9	10.66	7.77e-24	9.14e-21	0.51	0.45	Lung cancer;	chr6:149781649	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.962	rs9689269	ENSG00000216906.2	RP11-350J20.9	10.66	7.77e-24	9.14e-21	0.51	0.45	Lung cancer;	chr6:149791861	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.962	rs62441335	ENSG00000216906.2	RP11-350J20.9	10.66	7.77e-24	9.14e-21	0.51	0.45	Lung cancer;	chr6:149792658	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.962	rs4816	ENSG00000216906.2	RP11-350J20.9	10.66	7.77e-24	9.14e-21	0.51	0.45	Lung cancer;	chr6:149793609	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.926	rs952166	ENSG00000216906.2	RP11-350J20.9	10.66	7.77e-24	9.14e-21	0.51	0.45	Lung cancer;	chr6:149798774	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.962	rs952165	ENSG00000216906.2	RP11-350J20.9	10.66	7.77e-24	9.14e-21	0.51	0.45	Lung cancer;	chr6:149798900	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.926	rs9285525	ENSG00000216906.2	RP11-350J20.9	10.66	7.77e-24	9.14e-21	0.51	0.45	Lung cancer;	chr6:149801253	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.962	rs6914319	ENSG00000216906.2	RP11-350J20.9	10.66	7.77e-24	9.14e-21	0.51	0.45	Lung cancer;	chr6:149806304	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.884	rs2095375	ENSG00000216906.2	RP11-350J20.9	10.66	7.77e-24	9.14e-21	0.51	0.45	Lung cancer;	chr6:149807037	chr6:149904243~149906418:+
PRAD	cis	rs150992	0.593	rs34497	ENSG00000248489.1	CTD-2007H13.3	10.66	7.8e-24	9.18e-21	0.5	0.45	Body mass index;	chr5:98962885	chr5:98929171~98995013:+
PRAD	cis	rs150992	0.593	rs34496	ENSG00000248489.1	CTD-2007H13.3	10.66	7.8e-24	9.18e-21	0.5	0.45	Body mass index;	chr5:98963812	chr5:98929171~98995013:+
PRAD	cis	rs673078	0.66	rs61945217	ENSG00000275759.1	RP11-131L12.3	-10.66	7.8e-24	9.18e-21	-0.73	-0.45	Glucose homeostasis traits;	chr12:118261194	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.66	rs117091919	ENSG00000275759.1	RP11-131L12.3	-10.66	7.8e-24	9.18e-21	-0.73	-0.45	Glucose homeostasis traits;	chr12:118273228	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.66	rs7314987	ENSG00000275759.1	RP11-131L12.3	-10.66	7.8e-24	9.18e-21	-0.73	-0.45	Glucose homeostasis traits;	chr12:118274072	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.66	rs61945224	ENSG00000275759.1	RP11-131L12.3	-10.66	7.8e-24	9.18e-21	-0.73	-0.45	Glucose homeostasis traits;	chr12:118288623	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.66	rs61945225	ENSG00000275759.1	RP11-131L12.3	-10.66	7.8e-24	9.18e-21	-0.73	-0.45	Glucose homeostasis traits;	chr12:118288960	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.66	rs17512407	ENSG00000275759.1	RP11-131L12.3	-10.66	7.8e-24	9.18e-21	-0.73	-0.45	Glucose homeostasis traits;	chr12:118292705	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.66	rs61946064	ENSG00000275759.1	RP11-131L12.3	-10.66	7.8e-24	9.18e-21	-0.73	-0.45	Glucose homeostasis traits;	chr12:118294495	chr12:118428281~118428870:+
PRAD	cis	rs2348418	0.966	rs4144964	ENSG00000247934.4	RP11-967K21.1	10.66	7.84e-24	9.23e-21	0.41	0.45	Lung function (FEV1);Lung function (FVC);	chr12:28531249	chr12:28163298~28190738:-
PRAD	cis	rs875971	0.862	rs1612452	ENSG00000237310.1	GS1-124K5.4	-10.66	7.9e-24	9.29e-21	-0.41	-0.45	Aortic root size;	chr7:66108909	chr7:66493706~66495474:+
PRAD	cis	rs274567	0.501	rs272856	ENSG00000233006.5	AC034220.3	10.66	7.91e-24	9.3e-21	0.42	0.45	Blood metabolite levels;	chr5:132351388	chr5:132311285~132369916:-
PRAD	cis	rs2564921	0.693	rs2581798	ENSG00000242142.1	SERBP1P3	10.66	7.93e-24	9.33e-21	0.52	0.45	Height;	chr3:53073584	chr3:53064283~53065091:-
PRAD	cis	rs6700559	0.873	rs7526367	ENSG00000260088.1	RP11-92G12.3	-10.66	7.99e-24	9.4e-21	-0.57	-0.45	Coronary artery disease;	chr1:200688025	chr1:200669507~200694250:+
PRAD	cis	rs11690935	0.571	rs1008151	ENSG00000228389.1	AC068039.4	-10.66	8.05e-24	9.46e-21	-0.5	-0.45	Schizophrenia;	chr2:172047370	chr2:171773482~171775844:+
PRAD	cis	rs2739330	0.703	rs5760112	ENSG00000224205.1	AP000351.4	10.66	8.09e-24	9.51e-21	0.55	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23987320~23991421:-
PRAD	cis	rs638893	0.636	rs2186781	ENSG00000278376.1	RP11-158I9.8	-10.65	8.14e-24	9.57e-21	-0.54	-0.45	Vitiligo;	chr11:118734738	chr11:118791254~118793137:+
PRAD	cis	rs9322193	0.962	rs17673294	ENSG00000268592.3	RAET1E-AS1	10.65	8.16e-24	9.59e-21	0.62	0.45	Lung cancer;	chr6:149813857	chr6:149863494~149919507:+
PRAD	cis	rs4964805	0.549	rs1976256	ENSG00000257681.1	RP11-341G23.4	10.65	8.16e-24	9.59e-21	0.42	0.45	Attention deficit hyperactivity disorder;	chr12:103763121	chr12:103746315~103768858:-
PRAD	cis	rs11690935	0.549	rs62183819	ENSG00000228389.1	AC068039.4	-10.65	8.19e-24	9.63e-21	-0.5	-0.45	Schizophrenia;	chr2:172039610	chr2:171773482~171775844:+
PRAD	cis	rs10875746	0.951	rs4760690	ENSG00000240399.1	RP1-228P16.1	-10.65	8.22e-24	9.66e-21	-0.46	-0.45	Longevity (90 years and older);	chr12:48169870	chr12:48054813~48055591:-
PRAD	cis	rs2729354	1	rs2848630	ENSG00000265566.2	RN7SL605P	-10.65	8.24e-24	9.68e-21	-0.68	-0.45	Blood protein levels;	chr11:57589434	chr11:57528085~57528365:-
PRAD	cis	rs11676348	0.904	rs10804264	ENSG00000261338.2	RP11-378A13.1	-10.65	8.26e-24	9.7e-21	-0.51	-0.45	Ulcerative colitis;	chr2:218091086	chr2:218255319~218257366:+
PRAD	cis	rs875971	0.928	rs2036263	ENSG00000237310.1	GS1-124K5.4	-10.65	8.29e-24	9.74e-21	-0.41	-0.45	Aortic root size;	chr7:66335210	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.862	rs10240949	ENSG00000237310.1	GS1-124K5.4	-10.65	8.29e-24	9.74e-21	-0.41	-0.45	Aortic root size;	chr7:66339430	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.862	rs7782704	ENSG00000237310.1	GS1-124K5.4	-10.65	8.29e-24	9.74e-21	-0.41	-0.45	Aortic root size;	chr7:66340379	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.862	rs6959268	ENSG00000237310.1	GS1-124K5.4	-10.65	8.29e-24	9.74e-21	-0.41	-0.45	Aortic root size;	chr7:66347979	chr7:66493706~66495474:+
PRAD	cis	rs1555322	0.53	rs2297789	ENSG00000126005.14	MMP24-AS1	-10.65	8.33e-24	9.78e-21	-0.54	-0.45	Attention deficit hyperactivity disorder;	chr20:35279445	chr20:35216462~35278131:-
PRAD	cis	rs780096	0.546	rs2293572	ENSG00000234072.1	AC074117.10	10.65	8.33e-24	9.78e-21	0.35	0.45	Total body bone mineral density;	chr2:27505910	chr2:27356246~27367622:+
PRAD	cis	rs783540	0.609	rs803686	ENSG00000276710.3	CSPG4P8	10.65	8.39e-24	9.85e-21	0.52	0.45	Schizophrenia;	chr15:82550590	chr15:82459472~82477258:+
PRAD	cis	rs9322193	0.923	rs9479810	ENSG00000216906.2	RP11-350J20.9	10.65	8.51e-24	9.98e-21	0.51	0.45	Lung cancer;	chr6:149751359	chr6:149904243~149906418:+
PRAD	cis	rs2337406	0.789	rs60000589	ENSG00000274576.2	IGHV2-70	-10.65	8.51e-24	9.99e-21	-0.46	-0.45	Alzheimer's disease (late onset);	chr14:106782459	chr14:106770577~106771020:-
PRAD	cis	rs2337406	0.866	rs111881598	ENSG00000274576.2	IGHV2-70	-10.65	8.51e-24	9.99e-21	-0.46	-0.45	Alzheimer's disease (late onset);	chr14:106783113	chr14:106770577~106771020:-
PRAD	cis	rs2337406	0.866	rs61164979	ENSG00000274576.2	IGHV2-70	-10.65	8.51e-24	9.99e-21	-0.46	-0.45	Alzheimer's disease (late onset);	chr14:106783133	chr14:106770577~106771020:-
PRAD	cis	rs2337406	0.866	rs61419485	ENSG00000274576.2	IGHV2-70	-10.65	8.51e-24	9.99e-21	-0.46	-0.45	Alzheimer's disease (late onset);	chr14:106783374	chr14:106770577~106771020:-
PRAD	cis	rs2337406	0.866	rs8015361	ENSG00000274576.2	IGHV2-70	-10.65	8.51e-24	9.99e-21	-0.46	-0.45	Alzheimer's disease (late onset);	chr14:106783991	chr14:106770577~106771020:-
PRAD	cis	rs1150668	0.796	rs728122	ENSG00000204709.4	LINC01556	10.65	8.55e-24	1e-20	0.55	0.45	Pubertal anthropometrics;	chr6:28431347	chr6:28943877~28944537:+
PRAD	cis	rs1577917	0.958	rs7747897	ENSG00000203875.9	SNHG5	-10.65	8.57e-24	1e-20	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85937631	chr6:85660950~85678736:-
PRAD	cis	rs6570726	0.791	rs392612	ENSG00000235652.6	RP11-545I5.3	-10.65	8.58e-24	1.01e-20	-0.46	-0.45	Lobe attachment (rater-scored or self-reported);	chr6:145560450	chr6:145799409~145886585:+
PRAD	cis	rs7396835	0.5	rs5092	ENSG00000254851.1	RP11-109L13.1	-10.65	8.61e-24	1.01e-20	-0.79	-0.45	Quantitative traits;	chr11:116822748	chr11:117135528~117138582:+
PRAD	cis	rs858239	0.698	rs858295	ENSG00000226816.2	AC005082.12	10.65	8.64e-24	1.01e-20	0.52	0.45	Cerebrospinal fluid biomarker levels;	chr7:23205950	chr7:23206013~23208045:+
PRAD	cis	rs9322193	0.884	rs9371201	ENSG00000268592.3	RAET1E-AS1	10.65	8.69e-24	1.02e-20	0.62	0.45	Lung cancer;	chr6:149823865	chr6:149863494~149919507:+
PRAD	cis	rs875971	0.862	rs6944374	ENSG00000237310.1	GS1-124K5.4	-10.65	8.7e-24	1.02e-20	-0.42	-0.45	Aortic root size;	chr7:66221942	chr7:66493706~66495474:+
PRAD	cis	rs2348418	0.765	rs4931734	ENSG00000247934.4	RP11-967K21.1	-10.65	8.73e-24	1.02e-20	-0.41	-0.45	Lung function (FEV1);Lung function (FVC);	chr12:28196661	chr12:28163298~28190738:-
PRAD	cis	rs2348418	0.733	rs1824769	ENSG00000247934.4	RP11-967K21.1	-10.65	8.73e-24	1.02e-20	-0.41	-0.45	Lung function (FEV1);Lung function (FVC);	chr12:28202322	chr12:28163298~28190738:-
PRAD	cis	rs2348418	0.671	rs2169753	ENSG00000247934.4	RP11-967K21.1	-10.65	8.73e-24	1.02e-20	-0.41	-0.45	Lung function (FEV1);Lung function (FVC);	chr12:28203481	chr12:28163298~28190738:-
PRAD	cis	rs10875746	0.903	rs725454	ENSG00000240399.1	RP1-228P16.1	-10.65	8.77e-24	1.03e-20	-0.45	-0.45	Longevity (90 years and older);	chr12:48108317	chr12:48054813~48055591:-
PRAD	cis	rs10875746	0.903	rs4760681	ENSG00000240399.1	RP1-228P16.1	-10.65	8.77e-24	1.03e-20	-0.45	-0.45	Longevity (90 years and older);	chr12:48111447	chr12:48054813~48055591:-
PRAD	cis	rs10875746	0.903	rs11168418	ENSG00000240399.1	RP1-228P16.1	-10.65	8.77e-24	1.03e-20	-0.45	-0.45	Longevity (90 years and older);	chr12:48121971	chr12:48054813~48055591:-
PRAD	cis	rs2919917	0.578	rs11783804	ENSG00000254352.1	RP11-578O24.2	10.65	8.8e-24	1.03e-20	0.58	0.45	Lymphocyte counts;	chr8:78652776	chr8:78723796~78724136:-
PRAD	cis	rs6504950	0.886	rs12449538	ENSG00000275710.1	RP11-257O5.4	-10.65	8.85e-24	1.04e-20	-0.56	-0.45	Breast cancer;	chr17:55033760	chr17:54964474~54964679:+
PRAD	cis	rs1577917	0.958	rs2100109	ENSG00000203875.9	SNHG5	-10.64	9.02e-24	1.06e-20	-0.5	-0.45	Response to antipsychotic treatment;	chr6:85835208	chr6:85660950~85678736:-
PRAD	cis	rs11951515	0.738	rs11738086	ENSG00000188850.9	RP11-159F24.2	10.64	9.05e-24	1.06e-20	0.53	0.45	Metabolite levels  (X-11787);	chr5:43352399	chr5:43336164~43348716:+
PRAD	cis	rs11676348	0.935	rs13007992	ENSG00000261338.2	RP11-378A13.1	-10.64	9.16e-24	1.07e-20	-0.51	-0.45	Ulcerative colitis;	chr2:218099328	chr2:218255319~218257366:+
PRAD	cis	rs150992	0.962	rs327811	ENSG00000248489.1	CTD-2007H13.3	10.64	9.28e-24	1.09e-20	0.5	0.45	Body mass index;	chr5:98935471	chr5:98929171~98995013:+
PRAD	cis	rs748404	0.676	rs4401024	ENSG00000205771.5	CATSPER2P1	-10.64	9.31e-24	1.09e-20	-0.49	-0.45	Lung cancer;	chr15:43358137	chr15:43726918~43747094:-
PRAD	cis	rs748404	0.631	rs6493086	ENSG00000205771.5	CATSPER2P1	-10.64	9.31e-24	1.09e-20	-0.49	-0.45	Lung cancer;	chr15:43363196	chr15:43726918~43747094:-
PRAD	cis	rs34375054	0.66	rs12305181	ENSG00000279233.1	RP11-158L12.4	10.64	9.32e-24	1.09e-20	0.43	0.45	Post bronchodilator FEV1/FVC ratio;	chr12:125109610	chr12:125138245~125141711:+
PRAD	cis	rs780096	0.506	rs72819512	ENSG00000234072.1	AC074117.10	-10.64	9.37e-24	1.1e-20	-0.36	-0.45	Total body bone mineral density;	chr2:27391582	chr2:27356246~27367622:+
PRAD	cis	rs4713118	0.621	rs4713132	ENSG00000280107.1	AL022393.9	-10.64	9.37e-24	1.1e-20	-0.58	-0.45	Parkinson's disease;	chr6:28066257	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.621	rs4713133	ENSG00000280107.1	AL022393.9	-10.64	9.37e-24	1.1e-20	-0.58	-0.45	Parkinson's disease;	chr6:28066263	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.621	rs4713134	ENSG00000280107.1	AL022393.9	-10.64	9.37e-24	1.1e-20	-0.58	-0.45	Parkinson's disease;	chr6:28066343	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.621	rs9368548	ENSG00000280107.1	AL022393.9	-10.64	9.37e-24	1.1e-20	-0.58	-0.45	Parkinson's disease;	chr6:28066959	chr6:28170845~28172521:+
PRAD	cis	rs4964805	0.549	rs11111752	ENSG00000257681.1	RP11-341G23.4	10.64	9.41e-24	1.1e-20	0.42	0.45	Attention deficit hyperactivity disorder;	chr12:103762774	chr12:103746315~103768858:-
PRAD	cis	rs17023223	0.537	rs12097967	ENSG00000231365.4	RP11-418J17.1	-10.64	9.43e-24	1.1e-20	-0.46	-0.45	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119160290	chr1:119140396~119275973:+
PRAD	cis	rs853679	0.55	rs1233707	ENSG00000280107.1	AL022393.9	-10.64	9.44e-24	1.1e-20	-0.57	-0.45	Depression;	chr6:28205175	chr6:28170845~28172521:+
PRAD	cis	rs2282300	1	rs12796693	ENSG00000242353.1	RP4-710M3.1	-10.64	9.45e-24	1.1e-20	-0.51	-0.45	Morning vs. evening chronotype;	chr11:30408036	chr11:30368148~30368646:+
PRAD	cis	rs853679	0.55	rs9295762	ENSG00000280107.1	AL022393.9	10.64	9.46e-24	1.11e-20	0.57	0.45	Depression;	chr6:28187640	chr6:28170845~28172521:+
PRAD	cis	rs11673344	0.636	rs7255595	ENSG00000226686.6	LINC01535	10.64	9.47e-24	1.11e-20	0.64	0.45	Obesity-related traits;	chr19:36896260	chr19:37251912~37265535:+
PRAD	cis	rs2337406	0.866	rs4583128	ENSG00000274576.2	IGHV2-70	-10.64	9.5e-24	1.11e-20	-0.46	-0.45	Alzheimer's disease (late onset);	chr14:106780669	chr14:106770577~106771020:-
PRAD	cis	rs2337406	0.929	rs12050200	ENSG00000274576.2	IGHV2-70	-10.64	9.5e-24	1.11e-20	-0.46	-0.45	Alzheimer's disease (late onset);	chr14:106780983	chr14:106770577~106771020:-
PRAD	cis	rs2337406	0.852	rs12050239	ENSG00000274576.2	IGHV2-70	-10.64	9.5e-24	1.11e-20	-0.46	-0.45	Alzheimer's disease (late onset);	chr14:106781132	chr14:106770577~106771020:-
PRAD	cis	rs2337406	0.929	rs59263250	ENSG00000274576.2	IGHV2-70	-10.64	9.5e-24	1.11e-20	-0.46	-0.45	Alzheimer's disease (late onset);	chr14:106781183	chr14:106770577~106771020:-
PRAD	cis	rs2337406	0.866	rs58083017	ENSG00000274576.2	IGHV2-70	-10.64	9.5e-24	1.11e-20	-0.46	-0.45	Alzheimer's disease (late onset);	chr14:106781256	chr14:106770577~106771020:-
PRAD	cis	rs2337406	0.789	rs60390024	ENSG00000274576.2	IGHV2-70	-10.64	9.5e-24	1.11e-20	-0.46	-0.45	Alzheimer's disease (late onset);	chr14:106781327	chr14:106770577~106771020:-
PRAD	cis	rs2337406	0.866	rs74092532	ENSG00000274576.2	IGHV2-70	-10.64	9.5e-24	1.11e-20	-0.46	-0.45	Alzheimer's disease (late onset);	chr14:106781363	chr14:106770577~106771020:-
PRAD	cis	rs2337406	0.866	rs74092534	ENSG00000274576.2	IGHV2-70	-10.64	9.5e-24	1.11e-20	-0.46	-0.45	Alzheimer's disease (late onset);	chr14:106781364	chr14:106770577~106771020:-
PRAD	cis	rs2337406	0.866	rs74092535	ENSG00000274576.2	IGHV2-70	-10.64	9.5e-24	1.11e-20	-0.46	-0.45	Alzheimer's disease (late onset);	chr14:106781722	chr14:106770577~106771020:-
PRAD	cis	rs2337406	0.866	rs74092537	ENSG00000274576.2	IGHV2-70	-10.64	9.5e-24	1.11e-20	-0.46	-0.45	Alzheimer's disease (late onset);	chr14:106781883	chr14:106770577~106771020:-
PRAD	cis	rs2337406	0.81	rs74092538	ENSG00000274576.2	IGHV2-70	-10.64	9.5e-24	1.11e-20	-0.46	-0.45	Alzheimer's disease (late onset);	chr14:106781942	chr14:106770577~106771020:-
PRAD	cis	rs34375054	0.525	rs7398636	ENSG00000279233.1	RP11-158L12.4	10.64	9.57e-24	1.12e-20	0.42	0.45	Post bronchodilator FEV1/FVC ratio;	chr12:125114058	chr12:125138245~125141711:+
PRAD	cis	rs2404602	0.552	rs4886823	ENSG00000259422.1	RP11-593F23.1	-10.64	9.57e-24	1.12e-20	-0.6	-0.45	Blood metabolite levels;	chr15:76673061	chr15:76174891~76181486:-
PRAD	cis	rs4964805	0.672	rs4964823	ENSG00000257681.1	RP11-341G23.4	10.64	9.6e-24	1.12e-20	0.42	0.45	Attention deficit hyperactivity disorder;	chr12:103787642	chr12:103746315~103768858:-
PRAD	cis	rs748404	0.631	rs3809482	ENSG00000205771.5	CATSPER2P1	-10.64	9.62e-24	1.12e-20	-0.49	-0.45	Lung cancer;	chr15:43369604	chr15:43726918~43747094:-
PRAD	cis	rs875971	0.862	rs7786892	ENSG00000237310.1	GS1-124K5.4	-10.64	9.64e-24	1.13e-20	-0.41	-0.45	Aortic root size;	chr7:66163889	chr7:66493706~66495474:+
PRAD	cis	rs9322193	0.923	rs12211511	ENSG00000216906.2	RP11-350J20.9	10.63	9.66e-24	1.13e-20	0.51	0.45	Lung cancer;	chr6:149745206	chr6:149904243~149906418:+
PRAD	cis	rs1577917	0.958	rs2875456	ENSG00000203875.9	SNHG5	-10.63	9.67e-24	1.13e-20	-0.52	-0.45	Response to antipsychotic treatment;	chr6:85892566	chr6:85660950~85678736:-
PRAD	cis	rs2348418	0.733	rs11049508	ENSG00000247934.4	RP11-967K21.1	10.63	9.67e-24	1.13e-20	0.41	0.45	Lung function (FEV1);Lung function (FVC);	chr12:28289633	chr12:28163298~28190738:-
PRAD	cis	rs2404602	1	rs2404741	ENSG00000259422.1	RP11-593F23.1	10.63	9.71e-24	1.13e-20	0.56	0.45	Blood metabolite levels;	chr15:76559394	chr15:76174891~76181486:-
PRAD	cis	rs2404602	1	rs2404740	ENSG00000259422.1	RP11-593F23.1	10.63	9.71e-24	1.13e-20	0.56	0.45	Blood metabolite levels;	chr15:76559802	chr15:76174891~76181486:-
PRAD	cis	rs2919917	0.554	rs2086755	ENSG00000254352.1	RP11-578O24.2	10.63	9.82e-24	1.15e-20	0.59	0.45	Lymphocyte counts;	chr8:78701809	chr8:78723796~78724136:-
PRAD	cis	rs2412819	0.599	rs2470120	ENSG00000249839.1	AC011330.5	-10.63	9.89e-24	1.15e-20	-0.56	-0.45	Lung cancer;	chr15:43636872	chr15:43663654~43684339:-
PRAD	cis	rs2919917	0.628	rs12544041	ENSG00000254352.1	RP11-578O24.2	-10.63	9.91e-24	1.16e-20	-0.6	-0.45	Lymphocyte counts;	chr8:78731404	chr8:78723796~78724136:-
PRAD	cis	rs1185460	0.967	rs2509121	ENSG00000271751.1	RP11-110I1.14	-10.63	9.98e-24	1.16e-20	-0.63	-0.45	Coronary artery disease;	chr11:119057542	chr11:119065263~119065677:-
PRAD	cis	rs875971	0.825	rs1000464	ENSG00000237310.1	GS1-124K5.4	-10.63	1.01e-23	1.18e-20	-0.41	-0.45	Aortic root size;	chr7:66312922	chr7:66493706~66495474:+
PRAD	cis	rs9322193	0.962	rs2065664	ENSG00000223701.3	RAET1E-AS1	10.63	1.01e-23	1.18e-20	0.59	0.45	Lung cancer;	chr6:149762485	chr6:149884431~149919508:+
PRAD	cis	rs11690935	0.632	rs62183783	ENSG00000228389.1	AC068039.4	-10.63	1.02e-23	1.19e-20	-0.5	-0.45	Schizophrenia;	chr2:172000868	chr2:171773482~171775844:+
PRAD	cis	rs17826219	0.585	rs8064302	ENSG00000263531.1	RP13-753N3.1	-10.63	1.02e-23	1.19e-20	-0.88	-0.45	Body mass index;	chr17:30397920	chr17:30863921~30864940:-
PRAD	cis	rs9487094	0.813	rs12524502	ENSG00000260273.1	RP11-425D10.10	10.63	1.02e-23	1.19e-20	0.64	0.45	Height;	chr6:109333018	chr6:109382795~109383666:+
PRAD	cis	rs9322193	0.962	rs9322220	ENSG00000268592.3	RAET1E-AS1	10.63	1.02e-23	1.19e-20	0.62	0.45	Lung cancer;	chr6:149782897	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.962	rs10214845	ENSG00000268592.3	RAET1E-AS1	10.63	1.02e-23	1.19e-20	0.62	0.45	Lung cancer;	chr6:149783124	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.962	rs9767122	ENSG00000268592.3	RAET1E-AS1	10.63	1.02e-23	1.19e-20	0.62	0.45	Lung cancer;	chr6:149783553	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.923	rs1413654	ENSG00000268592.3	RAET1E-AS1	10.63	1.02e-23	1.19e-20	0.62	0.45	Lung cancer;	chr6:149783956	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.683	rs113281309	ENSG00000268592.3	RAET1E-AS1	10.63	1.02e-23	1.19e-20	0.62	0.45	Lung cancer;	chr6:149787289	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.962	rs9688809	ENSG00000268592.3	RAET1E-AS1	10.63	1.02e-23	1.19e-20	0.62	0.45	Lung cancer;	chr6:149787920	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.962	rs9689242	ENSG00000268592.3	RAET1E-AS1	10.63	1.02e-23	1.19e-20	0.62	0.45	Lung cancer;	chr6:149787970	chr6:149863494~149919507:+
PRAD	cis	rs9322193	1	rs9767077	ENSG00000268592.3	RAET1E-AS1	10.63	1.02e-23	1.19e-20	0.62	0.45	Lung cancer;	chr6:149788479	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.923	rs9688938	ENSG00000268592.3	RAET1E-AS1	10.63	1.02e-23	1.19e-20	0.62	0.45	Lung cancer;	chr6:149788941	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.962	rs9688940	ENSG00000268592.3	RAET1E-AS1	10.63	1.02e-23	1.19e-20	0.62	0.45	Lung cancer;	chr6:149788977	chr6:149863494~149919507:+
PRAD	cis	rs9487094	0.677	rs4428538	ENSG00000260273.1	RP11-425D10.10	10.63	1.02e-23	1.19e-20	0.69	0.45	Height;	chr6:109409645	chr6:109382795~109383666:+
PRAD	cis	rs10875746	0.855	rs10875729	ENSG00000240399.1	RP1-228P16.1	-10.63	1.02e-23	1.19e-20	-0.45	-0.45	Longevity (90 years and older);	chr12:48032943	chr12:48054813~48055591:-
PRAD	cis	rs10256972	0.869	rs4720158	ENSG00000229043.2	AC091729.9	-10.63	1.02e-23	1.19e-20	-0.54	-0.45	Endometriosis;Longevity;	chr7:1000689	chr7:1160374~1165267:+
PRAD	cis	rs34375054	0.66	rs900411	ENSG00000279233.1	RP11-158L12.4	10.63	1.03e-23	1.2e-20	0.43	0.45	Post bronchodilator FEV1/FVC ratio;	chr12:125128293	chr12:125138245~125141711:+
PRAD	cis	rs11951515	0.738	rs11951584	ENSG00000188850.9	RP11-159F24.2	10.63	1.03e-23	1.2e-20	0.53	0.45	Metabolite levels  (X-11787);	chr5:43348904	chr5:43336164~43348716:+
PRAD	cis	rs11951515	0.738	rs6863246	ENSG00000188850.9	RP11-159F24.2	10.63	1.03e-23	1.2e-20	0.53	0.45	Metabolite levels  (X-11787);	chr5:43349398	chr5:43336164~43348716:+
PRAD	cis	rs11951515	0.738	rs10941630	ENSG00000188850.9	RP11-159F24.2	10.63	1.03e-23	1.2e-20	0.53	0.45	Metabolite levels  (X-11787);	chr5:43350116	chr5:43336164~43348716:+
PRAD	cis	rs11951515	0.738	rs6887351	ENSG00000188850.9	RP11-159F24.2	10.63	1.03e-23	1.2e-20	0.53	0.45	Metabolite levels  (X-11787);	chr5:43350203	chr5:43336164~43348716:+
PRAD	cis	rs9322193	0.923	rs12174035	ENSG00000223701.3	RAET1E-AS1	10.63	1.03e-23	1.21e-20	0.6	0.45	Lung cancer;	chr6:149763311	chr6:149884431~149919508:+
PRAD	cis	rs2929278	0.561	rs3099045	ENSG00000249839.1	AC011330.5	-10.63	1.04e-23	1.21e-20	-0.57	-0.45	Schizophrenia;	chr15:43631757	chr15:43663654~43684339:-
PRAD	cis	rs2929278	0.588	rs1975364	ENSG00000249839.1	AC011330.5	-10.63	1.04e-23	1.21e-20	-0.57	-0.45	Schizophrenia;	chr15:43857991	chr15:43663654~43684339:-
PRAD	cis	rs2404602	0.647	rs12903331	ENSG00000259422.1	RP11-593F23.1	-10.63	1.04e-23	1.21e-20	-0.59	-0.45	Blood metabolite levels;	chr15:76875927	chr15:76174891~76181486:-
PRAD	cis	rs9322193	0.607	rs12210822	ENSG00000268592.3	RAET1E-AS1	10.63	1.04e-23	1.21e-20	0.7	0.45	Lung cancer;	chr6:149905356	chr6:149863494~149919507:+
PRAD	cis	rs673078	0.66	rs78690826	ENSG00000275759.1	RP11-131L12.3	-10.63	1.04e-23	1.21e-20	-0.73	-0.45	Glucose homeostasis traits;	chr12:118176693	chr12:118428281~118428870:+
PRAD	cis	rs150992	0.632	rs34491	ENSG00000248489.1	CTD-2007H13.3	10.63	1.04e-23	1.22e-20	0.5	0.45	Body mass index;	chr5:98974118	chr5:98929171~98995013:+
PRAD	cis	rs783540	0.656	rs783538	ENSG00000276710.3	CSPG4P8	10.63	1.05e-23	1.22e-20	0.5	0.45	Schizophrenia;	chr15:82584394	chr15:82459472~82477258:+
PRAD	cis	rs2919917	0.628	rs979564	ENSG00000254352.1	RP11-578O24.2	10.63	1.05e-23	1.23e-20	0.58	0.45	Lymphocyte counts;	chr8:78663924	chr8:78723796~78724136:-
PRAD	cis	rs1577917	0.958	rs7739241	ENSG00000203875.9	SNHG5	-10.62	1.06e-23	1.23e-20	-0.5	-0.45	Response to antipsychotic treatment;	chr6:85866078	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.958	rs12202712	ENSG00000203875.9	SNHG5	-10.62	1.06e-23	1.23e-20	-0.5	-0.45	Response to antipsychotic treatment;	chr6:85868823	chr6:85660950~85678736:-
PRAD	cis	rs875971	0.862	rs880166	ENSG00000237310.1	GS1-124K5.4	-10.62	1.06e-23	1.23e-20	-0.41	-0.45	Aortic root size;	chr7:66205775	chr7:66493706~66495474:+
PRAD	cis	rs9322193	0.926	rs9383546	ENSG00000216906.2	RP11-350J20.9	10.62	1.06e-23	1.23e-20	0.51	0.45	Lung cancer;	chr6:149822743	chr6:149904243~149906418:+
PRAD	cis	rs2348418	0.733	rs2169754	ENSG00000247934.4	RP11-967K21.1	-10.62	1.06e-23	1.23e-20	-0.41	-0.45	Lung function (FEV1);Lung function (FVC);	chr12:28187712	chr12:28163298~28190738:-
PRAD	cis	rs1577917	0.958	rs1447160	ENSG00000203875.9	SNHG5	-10.62	1.07e-23	1.24e-20	-0.5	-0.45	Response to antipsychotic treatment;	chr6:85836405	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.958	rs12198061	ENSG00000203875.9	SNHG5	-10.62	1.07e-23	1.24e-20	-0.5	-0.45	Response to antipsychotic treatment;	chr6:85841267	chr6:85660950~85678736:-
PRAD	cis	rs7772486	0.754	rs1055212	ENSG00000235652.6	RP11-545I5.3	-10.62	1.07e-23	1.25e-20	-0.45	-0.45	Lobe attachment (rater-scored or self-reported);	chr6:145737179	chr6:145799409~145886585:+
PRAD	cis	rs2337406	0.866	rs74090151	ENSG00000274576.2	IGHV2-70	-10.62	1.07e-23	1.25e-20	-0.46	-0.45	Alzheimer's disease (late onset);	chr14:106785377	chr14:106770577~106771020:-
PRAD	cis	rs9322193	0.962	rs6903998	ENSG00000223701.3	RAET1E-AS1	10.62	1.08e-23	1.25e-20	0.59	0.45	Lung cancer;	chr6:149831357	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.961	rs9285521	ENSG00000216906.2	RP11-350J20.9	10.62	1.08e-23	1.25e-20	0.52	0.45	Lung cancer;	chr6:149585576	chr6:149904243~149906418:+
PRAD	cis	rs6504950	0.886	rs2787501	ENSG00000275710.1	RP11-257O5.4	10.62	1.08e-23	1.26e-20	0.56	0.45	Breast cancer;	chr17:55016604	chr17:54964474~54964679:+
PRAD	cis	rs2739330	0.731	rs5751792	ENSG00000224205.1	AP000351.4	10.62	1.09e-23	1.27e-20	0.54	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23987320~23991421:-
PRAD	cis	rs2739330	0.761	rs5760176	ENSG00000224205.1	AP000351.4	-10.62	1.09e-23	1.27e-20	-0.54	-0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23987320~23991421:-
PRAD	cis	rs34779708	0.931	rs13377158	ENSG00000230534.5	RP11-297A16.2	-10.62	1.09e-23	1.27e-20	-0.59	-0.45	Inflammatory bowel disease;Crohn's disease;	chr10:35081537	chr10:35098006~35127020:-
PRAD	cis	rs9322193	0.962	rs9688750	ENSG00000216906.2	RP11-350J20.9	10.62	1.1e-23	1.28e-20	0.52	0.45	Lung cancer;	chr6:149657633	chr6:149904243~149906418:+
PRAD	cis	rs2282300	0.956	rs1717779	ENSG00000242353.1	RP4-710M3.1	-10.62	1.11e-23	1.29e-20	-0.51	-0.45	Morning vs. evening chronotype;	chr11:30355151	chr11:30368148~30368646:+
PRAD	cis	rs4964805	0.549	rs2292682	ENSG00000257681.1	RP11-341G23.4	10.62	1.13e-23	1.32e-20	0.43	0.45	Attention deficit hyperactivity disorder;	chr12:103762742	chr12:103746315~103768858:-
PRAD	cis	rs9532669	0.926	rs7329302	ENSG00000176268.5	CYCSP34	-10.62	1.14e-23	1.32e-20	-0.47	-0.45	Cervical cancer;	chr13:40962396	chr13:40863599~40863902:-
PRAD	cis	rs875971	0.862	rs2420174	ENSG00000237310.1	GS1-124K5.4	-10.62	1.14e-23	1.32e-20	-0.41	-0.45	Aortic root size;	chr7:66180374	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.862	rs2420173	ENSG00000237310.1	GS1-124K5.4	-10.62	1.14e-23	1.32e-20	-0.41	-0.45	Aortic root size;	chr7:66180412	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.862	rs4718319	ENSG00000237310.1	GS1-124K5.4	-10.62	1.14e-23	1.32e-20	-0.41	-0.45	Aortic root size;	chr7:66187797	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.723	rs28391294	ENSG00000237310.1	GS1-124K5.4	-10.62	1.14e-23	1.32e-20	-0.41	-0.45	Aortic root size;	chr7:66189328	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.83	rs6967708	ENSG00000237310.1	GS1-124K5.4	-10.62	1.14e-23	1.32e-20	-0.41	-0.45	Aortic root size;	chr7:66192326	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.895	rs7782806	ENSG00000237310.1	GS1-124K5.4	-10.62	1.14e-23	1.32e-20	-0.41	-0.45	Aortic root size;	chr7:66192910	chr7:66493706~66495474:+
PRAD	cis	rs7772486	0.719	rs702317	ENSG00000235652.6	RP11-545I5.3	-10.62	1.14e-23	1.33e-20	-0.45	-0.45	Lobe attachment (rater-scored or self-reported);	chr6:145683874	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.72	rs4896837	ENSG00000235652.6	RP11-545I5.3	-10.62	1.14e-23	1.33e-20	-0.45	-0.45	Lobe attachment (rater-scored or self-reported);	chr6:145693032	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.727	rs4896843	ENSG00000235652.6	RP11-545I5.3	-10.62	1.14e-23	1.33e-20	-0.45	-0.45	Lobe attachment (rater-scored or self-reported);	chr6:145742315	chr6:145799409~145886585:+
PRAD	cis	rs7115242	0.66	rs236911	ENSG00000254851.1	RP11-109L13.1	10.61	1.15e-23	1.33e-20	0.89	0.45	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117214554	chr11:117135528~117138582:+
PRAD	cis	rs9322193	0.736	rs3828701	ENSG00000216906.2	RP11-350J20.9	10.61	1.15e-23	1.34e-20	0.52	0.45	Lung cancer;	chr6:149791063	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.736	rs3805750	ENSG00000216906.2	RP11-350J20.9	10.61	1.15e-23	1.34e-20	0.52	0.45	Lung cancer;	chr6:149791065	chr6:149904243~149906418:+
PRAD	cis	rs1577917	0.958	rs12199832	ENSG00000203875.9	SNHG5	-10.61	1.15e-23	1.34e-20	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85943030	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.958	rs12207374	ENSG00000203875.9	SNHG5	-10.61	1.15e-23	1.34e-20	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85946927	chr6:85660950~85678736:-
PRAD	cis	rs9532669	0.926	rs9562254	ENSG00000176268.5	CYCSP34	-10.61	1.15e-23	1.34e-20	-0.47	-0.45	Cervical cancer;	chr13:40960902	chr13:40863599~40863902:-
PRAD	cis	rs673078	0.66	rs61943362	ENSG00000275759.1	RP11-131L12.3	-10.61	1.16e-23	1.35e-20	-0.73	-0.45	Glucose homeostasis traits;	chr12:118322042	chr12:118428281~118428870:+
PRAD	cis	rs853679	0.55	rs1225598	ENSG00000280107.1	AL022393.9	-10.61	1.17e-23	1.35e-20	-0.57	-0.45	Depression;	chr6:28193021	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.55	rs1150689	ENSG00000280107.1	AL022393.9	-10.61	1.17e-23	1.35e-20	-0.57	-0.45	Depression;	chr6:28197321	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.55	rs1225599	ENSG00000280107.1	AL022393.9	-10.61	1.17e-23	1.35e-20	-0.57	-0.45	Depression;	chr6:28197412	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.574	rs1233705	ENSG00000280107.1	AL022393.9	-10.61	1.17e-23	1.35e-20	-0.57	-0.45	Depression;	chr6:28198669	chr6:28170845~28172521:+
PRAD	cis	rs4820294	0.669	rs9622678	ENSG00000233360.4	Z83844.1	10.61	1.17e-23	1.35e-20	0.54	0.45	Fat distribution (HIV);	chr22:37661331	chr22:37641832~37658377:-
PRAD	cis	rs6003958	1	rs6003958	ENSG00000218537.1	MIF-AS1	-10.61	1.18e-23	1.37e-20	-0.71	-0.45	S-phenylmercapturic acid levels in smokers;	chr22:23921902	chr22:23894426~23898930:-
PRAD	cis	rs5760092	0.755	rs6003959	ENSG00000218537.1	MIF-AS1	-10.61	1.18e-23	1.37e-20	-0.71	-0.45	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23922208	chr22:23894426~23898930:-
PRAD	cis	rs2337406	0.866	rs11488879	ENSG00000274576.2	IGHV2-70	-10.61	1.2e-23	1.39e-20	-0.46	-0.45	Alzheimer's disease (late onset);	chr14:106786097	chr14:106770577~106771020:-
PRAD	cis	rs2337406	0.866	rs8012619	ENSG00000274576.2	IGHV2-70	-10.61	1.2e-23	1.39e-20	-0.46	-0.45	Alzheimer's disease (late onset);	chr14:106793907	chr14:106770577~106771020:-
PRAD	cis	rs73086581	0.645	rs2103659	ENSG00000229539.1	RP11-119B16.2	-10.61	1.2e-23	1.39e-20	-0.59	-0.45	Response to antidepressants in depression;	chr20:4001925	chr20:3888239~3888868:-
PRAD	cis	rs10170846	0.861	rs7571732	ENSG00000261428.2	RP11-16P6.1	-10.61	1.21e-23	1.41e-20	-0.57	-0.45	Schizophrenia (inflammation and infection response interaction);	chr2:222673597	chr2:222566899~222569719:-
PRAD	cis	rs9322193	0.962	rs17673294	ENSG00000223701.3	RAET1E-AS1	10.61	1.22e-23	1.41e-20	0.6	0.45	Lung cancer;	chr6:149813857	chr6:149884431~149919508:+
PRAD	cis	rs875971	0.862	rs1167390	ENSG00000237310.1	GS1-124K5.4	-10.61	1.22e-23	1.41e-20	-0.41	-0.45	Aortic root size;	chr7:66110906	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.862	rs35034167	ENSG00000237310.1	GS1-124K5.4	-10.61	1.22e-23	1.41e-20	-0.41	-0.45	Aortic root size;	chr7:66115179	chr7:66493706~66495474:+
PRAD	cis	rs6142102	0.961	rs1883524	ENSG00000276073.1	RP5-1125A11.7	-10.61	1.22e-23	1.41e-20	-0.45	-0.45	Skin pigmentation;	chr20:34038301	chr20:33985617~33988989:-
PRAD	cis	rs6504950	0.783	rs7211787	ENSG00000275710.1	RP11-257O5.4	10.61	1.22e-23	1.41e-20	0.64	0.45	Breast cancer;	chr17:55157551	chr17:54964474~54964679:+
PRAD	cis	rs6504950	0.783	rs12936639	ENSG00000275710.1	RP11-257O5.4	10.61	1.22e-23	1.41e-20	0.64	0.45	Breast cancer;	chr17:55158621	chr17:54964474~54964679:+
PRAD	cis	rs9322193	0.926	rs3805751	ENSG00000216906.2	RP11-350J20.9	10.61	1.22e-23	1.41e-20	0.51	0.45	Lung cancer;	chr6:149791193	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.962	rs10872656	ENSG00000216906.2	RP11-350J20.9	10.61	1.22e-23	1.41e-20	0.51	0.45	Lung cancer;	chr6:149799444	chr6:149904243~149906418:+
PRAD	cis	rs11951515	0.7	rs3733769	ENSG00000188850.9	RP11-159F24.2	10.61	1.22e-23	1.41e-20	0.53	0.45	Metabolite levels  (X-11787);	chr5:43297042	chr5:43336164~43348716:+
PRAD	cis	rs12049351	0.612	rs34926904	ENSG00000229367.1	HMGN2P19	10.61	1.22e-23	1.41e-20	0.71	0.45	Circulating myeloperoxidase levels (plasma);	chr1:229471759	chr1:229570532~229570796:+
PRAD	cis	rs2282300	1	rs2282300	ENSG00000242353.1	RP4-710M3.1	-10.61	1.22e-23	1.42e-20	-0.52	-0.45	Morning vs. evening chronotype;	chr11:30414038	chr11:30368148~30368646:+
PRAD	cis	rs4853012	0.941	rs2421752	ENSG00000257800.1	FNBP1P1	10.61	1.24e-23	1.43e-20	0.42	0.45	Gestational age at birth (maternal effect);	chr2:74114488	chr2:74120680~74123218:+
PRAD	cis	rs11123170	0.542	rs28522253	ENSG00000189223.12	PAX8-AS1	-10.61	1.25e-23	1.44e-20	-0.66	-0.45	Renal function-related traits (BUN);	chr2:113209810	chr2:113211522~113276581:+
PRAD	cis	rs673078	0.607	rs2784	ENSG00000275759.1	RP11-131L12.3	-10.6	1.25e-23	1.45e-20	-0.72	-0.45	Glucose homeostasis traits;	chr12:118311745	chr12:118428281~118428870:+
PRAD	cis	rs6860806	0.531	rs2631359	ENSG00000233006.5	AC034220.3	-10.6	1.25e-23	1.45e-20	-0.42	-0.45	Breast cancer;	chr5:132372200	chr5:132311285~132369916:-
PRAD	cis	rs2348418	0.966	rs11049695	ENSG00000247934.4	RP11-967K21.1	10.6	1.26e-23	1.46e-20	0.41	0.45	Lung function (FEV1);Lung function (FVC);	chr12:28527934	chr12:28163298~28190738:-
PRAD	cis	rs4964805	0.626	rs11111767	ENSG00000257681.1	RP11-341G23.4	-10.6	1.27e-23	1.47e-20	-0.43	-0.45	Attention deficit hyperactivity disorder;	chr12:103782468	chr12:103746315~103768858:-
PRAD	cis	rs7044106	0.512	rs7873848	ENSG00000226752.6	PSMD5-AS1	-10.6	1.27e-23	1.47e-20	-0.53	-0.45	Hip circumference adjusted for BMI;	chr9:120591944	chr9:120824828~120854385:+
PRAD	cis	rs2404602	0.735	rs2436994	ENSG00000259422.1	RP11-593F23.1	-10.6	1.27e-23	1.47e-20	-0.56	-0.45	Blood metabolite levels;	chr15:76508722	chr15:76174891~76181486:-
PRAD	cis	rs11155671	0.546	rs1999633	ENSG00000223701.3	RAET1E-AS1	10.6	1.27e-23	1.47e-20	0.67	0.45	Testicular germ cell tumor;	chr6:149866576	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.516	rs1999632	ENSG00000268592.3	RAET1E-AS1	10.6	1.28e-23	1.48e-20	0.72	0.45	Lung cancer;	chr6:149866737	chr6:149863494~149919507:+
PRAD	cis	rs4964805	0.77	rs11111779	ENSG00000257681.1	RP11-341G23.4	10.6	1.28e-23	1.48e-20	0.41	0.45	Attention deficit hyperactivity disorder;	chr12:103791718	chr12:103746315~103768858:-
PRAD	cis	rs8072100	0.688	rs7221224	ENSG00000228782.6	CTD-2026D20.3	-10.6	1.28e-23	1.48e-20	-0.51	-0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47341695	chr17:47450568~47492492:-
PRAD	cis	rs7714584	1	rs61530785	ENSG00000197083.10	ZNF300P1	10.6	1.28e-23	1.48e-20	0.78	0.45	Crohn's disease;	chr5:150881802	chr5:150930645~150946289:-
PRAD	cis	rs1555322	0.505	rs591590	ENSG00000126005.14	MMP24-AS1	10.6	1.29e-23	1.5e-20	0.55	0.45	Attention deficit hyperactivity disorder;	chr20:35278225	chr20:35216462~35278131:-
PRAD	cis	rs9322193	0.961	rs4870144	ENSG00000216906.2	RP11-350J20.9	10.6	1.3e-23	1.5e-20	0.52	0.45	Lung cancer;	chr6:149575540	chr6:149904243~149906418:+
PRAD	cis	rs6504950	0.886	rs4794551	ENSG00000275710.1	RP11-257O5.4	-10.6	1.3e-23	1.51e-20	-0.56	-0.45	Breast cancer;	chr17:54998066	chr17:54964474~54964679:+
PRAD	cis	rs9322193	0.884	rs2342858	ENSG00000216906.2	RP11-350J20.9	10.6	1.32e-23	1.52e-20	0.51	0.44	Lung cancer;	chr6:149805967	chr6:149904243~149906418:+
PRAD	cis	rs2933343	0.951	rs1055128	ENSG00000261159.1	RP11-723O4.9	10.6	1.34e-23	1.55e-20	0.42	0.44	IgG glycosylation;	chr3:128872205	chr3:128859716~128860526:-
PRAD	cis	rs9399135	0.636	rs7749106	ENSG00000232876.1	CTA-212D2.2	-10.6	1.36e-23	1.57e-20	-0.56	-0.44	Red blood cell count;	chr6:134947004	chr6:135055033~135060550:+
PRAD	cis	rs2729354	1	rs2649662	ENSG00000265566.2	RN7SL605P	10.59	1.37e-23	1.58e-20	0.65	0.44	Blood protein levels;	chr11:57585089	chr11:57528085~57528365:-
PRAD	cis	rs2337406	0.866	rs7152832	ENSG00000274576.2	IGHV2-70	-10.59	1.37e-23	1.58e-20	-0.46	-0.44	Alzheimer's disease (late onset);	chr14:106778427	chr14:106770577~106771020:-
PRAD	cis	rs2337406	0.5	rs7152934	ENSG00000274576.2	IGHV2-70	-10.59	1.37e-23	1.58e-20	-0.46	-0.44	Alzheimer's disease (late onset);	chr14:106778702	chr14:106770577~106771020:-
PRAD	cis	rs2337406	0.789	rs12050392	ENSG00000274576.2	IGHV2-70	-10.59	1.37e-23	1.58e-20	-0.46	-0.44	Alzheimer's disease (late onset);	chr14:106779073	chr14:106770577~106771020:-
PRAD	cis	rs2337406	0.866	rs74092505	ENSG00000274576.2	IGHV2-70	-10.59	1.37e-23	1.58e-20	-0.46	-0.44	Alzheimer's disease (late onset);	chr14:106779163	chr14:106770577~106771020:-
PRAD	cis	rs2337406	0.789	rs74092507	ENSG00000274576.2	IGHV2-70	-10.59	1.37e-23	1.58e-20	-0.46	-0.44	Alzheimer's disease (late onset);	chr14:106779174	chr14:106770577~106771020:-
PRAD	cis	rs2337406	0.866	rs74092511	ENSG00000274576.2	IGHV2-70	-10.59	1.37e-23	1.58e-20	-0.46	-0.44	Alzheimer's disease (late onset);	chr14:106779234	chr14:106770577~106771020:-
PRAD	cis	rs2337406	0.866	rs74092512	ENSG00000274576.2	IGHV2-70	-10.59	1.37e-23	1.58e-20	-0.46	-0.44	Alzheimer's disease (late onset);	chr14:106779306	chr14:106770577~106771020:-
PRAD	cis	rs2337406	0.789	rs74092514	ENSG00000274576.2	IGHV2-70	-10.59	1.37e-23	1.58e-20	-0.46	-0.44	Alzheimer's disease (late onset);	chr14:106779385	chr14:106770577~106771020:-
PRAD	cis	rs2337406	0.866	rs74092520	ENSG00000274576.2	IGHV2-70	-10.59	1.37e-23	1.58e-20	-0.46	-0.44	Alzheimer's disease (late onset);	chr14:106779632	chr14:106770577~106771020:-
PRAD	cis	rs1577917	0.958	rs1591438	ENSG00000203875.9	SNHG5	-10.59	1.38e-23	1.59e-20	-0.52	-0.44	Response to antipsychotic treatment;	chr6:85815496	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.958	rs1591437	ENSG00000203875.9	SNHG5	-10.59	1.38e-23	1.59e-20	-0.52	-0.44	Response to antipsychotic treatment;	chr6:85815587	chr6:85660950~85678736:-
PRAD	cis	rs34779708	0.931	rs11010130	ENSG00000230534.5	RP11-297A16.2	10.59	1.38e-23	1.59e-20	0.6	0.44	Inflammatory bowel disease;Crohn's disease;	chr10:35224379	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.897	rs11010131	ENSG00000230534.5	RP11-297A16.2	10.59	1.38e-23	1.59e-20	0.6	0.44	Inflammatory bowel disease;Crohn's disease;	chr10:35224388	chr10:35098006~35127020:-
PRAD	cis	rs1823874	0.581	rs11855419	ENSG00000182397.13	DNM1P46	10.59	1.38e-23	1.59e-20	0.46	0.44	IgG glycosylation;	chr15:99787275	chr15:99790156~99806927:-
PRAD	cis	rs2283792	0.819	rs2266965	ENSG00000224086.5	LL22NC03-86G7.1	-10.59	1.38e-23	1.6e-20	-0.52	-0.44	Multiple sclerosis;	chr22:21766866	chr22:21938293~21977632:+
PRAD	cis	rs35160687	0.787	rs10186289	ENSG00000273080.1	RP11-301O19.1	10.59	1.39e-23	1.6e-20	0.52	0.44	Night sleep phenotypes;	chr2:86285865	chr2:86195590~86196049:+
PRAD	cis	rs11951515	0.7	rs13659	ENSG00000188850.9	RP11-159F24.2	10.59	1.39e-23	1.61e-20	0.53	0.44	Metabolite levels  (X-11787);	chr5:43290598	chr5:43336164~43348716:+
PRAD	cis	rs11951515	0.7	rs55794239	ENSG00000188850.9	RP11-159F24.2	10.59	1.39e-23	1.61e-20	0.53	0.44	Metabolite levels  (X-11787);	chr5:43292806	chr5:43336164~43348716:+
PRAD	cis	rs11951515	0.7	rs35239179	ENSG00000188850.9	RP11-159F24.2	10.59	1.39e-23	1.61e-20	0.53	0.44	Metabolite levels  (X-11787);	chr5:43298455	chr5:43336164~43348716:+
PRAD	cis	rs11951515	0.7	rs7720165	ENSG00000188850.9	RP11-159F24.2	-10.59	1.39e-23	1.61e-20	-0.53	-0.44	Metabolite levels  (X-11787);	chr5:43301442	chr5:43336164~43348716:+
PRAD	cis	rs3762637	1	rs16845530	ENSG00000272758.4	RP11-299J3.8	-10.59	1.4e-23	1.61e-20	-0.64	-0.44	LDL cholesterol levels;	chr3:122423600	chr3:122416207~122443180:+
PRAD	cis	rs3762637	0.882	rs72958418	ENSG00000272758.4	RP11-299J3.8	-10.59	1.4e-23	1.61e-20	-0.64	-0.44	LDL cholesterol levels;	chr3:122441526	chr3:122416207~122443180:+
PRAD	cis	rs3762637	1	rs7609972	ENSG00000272758.4	RP11-299J3.8	-10.59	1.4e-23	1.61e-20	-0.64	-0.44	LDL cholesterol levels;	chr3:122480579	chr3:122416207~122443180:+
PRAD	cis	rs3762637	0.941	rs7653592	ENSG00000272758.4	RP11-299J3.8	-10.59	1.4e-23	1.61e-20	-0.64	-0.44	LDL cholesterol levels;	chr3:122499524	chr3:122416207~122443180:+
PRAD	cis	rs1577917	0.958	rs28442244	ENSG00000203875.9	SNHG5	10.59	1.4e-23	1.62e-20	0.52	0.44	Response to antipsychotic treatment;	chr6:85991518	chr6:85660950~85678736:-
PRAD	cis	rs2919917	0.628	rs10109359	ENSG00000254352.1	RP11-578O24.2	10.59	1.41e-23	1.62e-20	0.59	0.44	Lymphocyte counts;	chr8:78694369	chr8:78723796~78724136:-
PRAD	cis	rs783540	0.632	rs17356528	ENSG00000276710.3	CSPG4P8	10.59	1.41e-23	1.63e-20	0.49	0.44	Schizophrenia;	chr15:82636799	chr15:82459472~82477258:+
PRAD	cis	rs6570726	0.791	rs378937	ENSG00000235652.6	RP11-545I5.3	10.59	1.42e-23	1.63e-20	0.46	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145513609	chr6:145799409~145886585:+
PRAD	cis	rs9322193	0.962	rs2275046	ENSG00000223701.3	RAET1E-AS1	10.59	1.42e-23	1.64e-20	0.6	0.44	Lung cancer;	chr6:149835865	chr6:149884431~149919508:+
PRAD	cis	rs2739330	0.76	rs5751761	ENSG00000235689.1	AP000351.13	-10.59	1.42e-23	1.64e-20	-0.52	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:24006305~24008258:-
PRAD	cis	rs12049351	0.559	rs6587337	ENSG00000229367.1	HMGN2P19	10.59	1.43e-23	1.65e-20	0.69	0.44	Circulating myeloperoxidase levels (plasma);	chr1:229475173	chr1:229570532~229570796:+
PRAD	cis	rs2404602	0.647	rs12903586	ENSG00000259422.1	RP11-593F23.1	-10.59	1.43e-23	1.65e-20	-0.59	-0.44	Blood metabolite levels;	chr15:76875899	chr15:76174891~76181486:-
PRAD	cis	rs1155848	0.892	rs1023293	ENSG00000227354.5	RBM26-AS1	10.59	1.44e-23	1.66e-20	0.88	0.44	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79480285	chr13:79406309~79424328:+
PRAD	cis	rs1426063	0.614	rs115279737	ENSG00000260265.1	RP11-44F21.5	10.59	1.44e-23	1.66e-20	0.94	0.44	QT interval;	chr4:75107557	chr4:75081702~75084717:-
PRAD	cis	rs7201929	1	rs12920514	ENSG00000259982.1	CDC37P1	-10.59	1.47e-23	1.69e-20	-0.62	-0.44	QT interval;	chr16:28824579	chr16:28700294~28701540:-
PRAD	cis	rs9322193	0.962	rs7745915	ENSG00000223701.3	RAET1E-AS1	10.59	1.47e-23	1.69e-20	0.6	0.44	Lung cancer;	chr6:149834111	chr6:149884431~149919508:+
PRAD	cis	rs1426063	0.614	rs114761716	ENSG00000260265.1	RP11-44F21.5	10.59	1.48e-23	1.7e-20	0.93	0.44	QT interval;	chr4:75107209	chr4:75081702~75084717:-
PRAD	cis	rs875971	0.862	rs778734	ENSG00000237310.1	GS1-124K5.4	10.59	1.48e-23	1.7e-20	0.41	0.44	Aortic root size;	chr7:66349862	chr7:66493706~66495474:+
PRAD	cis	rs9322193	0.884	rs9371201	ENSG00000216906.2	RP11-350J20.9	10.59	1.48e-23	1.7e-20	0.52	0.44	Lung cancer;	chr6:149823865	chr6:149904243~149906418:+
PRAD	cis	rs7182621	0.846	rs12915935	ENSG00000259363.4	CTD-2054N24.2	-10.59	1.48e-23	1.71e-20	-0.44	-0.44	Colonoscopy-negative controls vs population controls;	chr15:99871875	chr15:99807023~99877148:+
PRAD	cis	rs1075265	0.749	rs2357693	ENSG00000233266.1	HMGB1P31	10.59	1.48e-23	1.71e-20	0.6	0.44	Chronotype;Morning vs. evening chronotype;	chr2:53735699	chr2:54051334~54051760:+
PRAD	cis	rs71403859	0.502	rs34380814	ENSG00000260886.1	TAT-AS1	10.58	1.48e-23	1.71e-20	0.7	0.44	Post bronchodilator FEV1;	chr16:71454272	chr16:71565789~71578187:+
PRAD	cis	rs6142102	0.812	rs761238	ENSG00000276073.1	RP5-1125A11.7	10.58	1.49e-23	1.72e-20	0.46	0.44	Skin pigmentation;	chr20:33932182	chr20:33985617~33988989:-
PRAD	cis	rs1577917	1	rs1577917	ENSG00000203875.9	SNHG5	-10.58	1.5e-23	1.72e-20	-0.52	-0.44	Response to antipsychotic treatment;	chr6:85982222	chr6:85660950~85678736:-
PRAD	cis	rs875971	0.862	rs3893216	ENSG00000237310.1	GS1-124K5.4	-10.58	1.5e-23	1.73e-20	-0.41	-0.44	Aortic root size;	chr7:66325720	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.862	rs6958294	ENSG00000237310.1	GS1-124K5.4	-10.58	1.5e-23	1.73e-20	-0.41	-0.44	Aortic root size;	chr7:66329809	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.862	rs2088655	ENSG00000237310.1	GS1-124K5.4	-10.58	1.5e-23	1.73e-20	-0.41	-0.44	Aortic root size;	chr7:66330724	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.895	rs10447522	ENSG00000237310.1	GS1-124K5.4	-10.58	1.5e-23	1.73e-20	-0.41	-0.44	Aortic root size;	chr7:66331087	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.862	rs778736	ENSG00000237310.1	GS1-124K5.4	10.58	1.5e-23	1.73e-20	0.41	0.44	Aortic root size;	chr7:66348861	chr7:66493706~66495474:+
PRAD	cis	rs858239	0.636	rs7808488	ENSG00000226816.2	AC005082.12	10.58	1.5e-23	1.73e-20	0.51	0.44	Cerebrospinal fluid biomarker levels;	chr7:23182251	chr7:23206013~23208045:+
PRAD	cis	rs6860806	0.507	rs270606	ENSG00000233006.5	AC034220.3	10.58	1.5e-23	1.73e-20	0.41	0.44	Breast cancer;	chr5:132315174	chr5:132311285~132369916:-
PRAD	cis	rs4713118	0.621	rs9295756	ENSG00000280107.1	AL022393.9	-10.58	1.5e-23	1.73e-20	-0.57	-0.44	Parkinson's disease;	chr6:28065618	chr6:28170845~28172521:+
PRAD	cis	rs4820294	0.669	rs1894532	ENSG00000233360.4	Z83844.1	10.58	1.51e-23	1.73e-20	0.54	0.44	Fat distribution (HIV);	chr22:37663743	chr22:37641832~37658377:-
PRAD	cis	rs801193	0.591	rs9986881	ENSG00000226824.5	RP4-756H11.3	-10.58	1.53e-23	1.76e-20	-0.58	-0.44	Aortic root size;	chr7:66708053	chr7:66654538~66669855:+
PRAD	cis	rs2933343	0.716	rs9872706	ENSG00000231305.3	RP11-723O4.2	-10.58	1.53e-23	1.76e-20	-0.47	-0.44	IgG glycosylation;	chr3:128848262	chr3:128861313~128871540:-
PRAD	cis	rs6991838	0.584	rs10089708	ENSG00000272010.1	CTD-3025N20.3	10.58	1.53e-23	1.77e-20	0.47	0.44	Intelligence (multi-trait analysis);	chr8:65642927	chr8:65591850~65592472:-
PRAD	cis	rs6860806	0.507	rs2631362	ENSG00000233006.5	AC034220.3	-10.58	1.53e-23	1.77e-20	-0.41	-0.44	Breast cancer;	chr5:132371601	chr5:132311285~132369916:-
PRAD	cis	rs853679	0.55	rs1233701	ENSG00000280107.1	AL022393.9	10.58	1.54e-23	1.77e-20	0.57	0.44	Depression;	chr6:28200948	chr6:28170845~28172521:+
PRAD	cis	rs4964805	0.802	rs934847	ENSG00000257681.1	RP11-341G23.4	10.58	1.55e-23	1.78e-20	0.42	0.44	Attention deficit hyperactivity disorder;	chr12:103791915	chr12:103746315~103768858:-
PRAD	cis	rs2348418	0.801	rs7298379	ENSG00000247934.4	RP11-967K21.1	10.58	1.55e-23	1.79e-20	0.41	0.44	Lung function (FEV1);Lung function (FVC);	chr12:28270541	chr12:28163298~28190738:-
PRAD	cis	rs11723261	0.582	rs6830247	ENSG00000275426.1	CH17-262A2.1	10.58	1.56e-23	1.79e-20	0.61	0.44	Immune response to smallpox vaccine (IL-6);	chr4:156885	chr4:149738~150317:+
PRAD	cis	rs1577917	1	rs12201735	ENSG00000203875.9	SNHG5	-10.58	1.58e-23	1.81e-20	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85947221	chr6:85660950~85678736:-
PRAD	cis	rs4845570	0.85	rs4504897	ENSG00000249602.1	RP11-98D18.3	-10.58	1.58e-23	1.82e-20	-0.65	-0.44	Coronary artery disease;	chr1:151794375	chr1:151763384~151769501:-
PRAD	cis	rs6860806	0.507	rs272878	ENSG00000233006.5	AC034220.3	-10.58	1.59e-23	1.82e-20	-0.42	-0.44	Breast cancer;	chr5:132336076	chr5:132311285~132369916:-
PRAD	cis	rs1577917	0.958	rs4707236	ENSG00000203875.9	SNHG5	-10.58	1.59e-23	1.83e-20	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85874249	chr6:85660950~85678736:-
PRAD	cis	rs638893	0.636	rs6421569	ENSG00000278376.1	RP11-158I9.8	-10.58	1.6e-23	1.84e-20	-0.53	-0.44	Vitiligo;	chr11:118785066	chr11:118791254~118793137:+
PRAD	cis	rs638893	0.578	rs1790188	ENSG00000278376.1	RP11-158I9.8	-10.58	1.6e-23	1.84e-20	-0.53	-0.44	Vitiligo;	chr11:118790346	chr11:118791254~118793137:+
PRAD	cis	rs11676348	0.935	rs4674248	ENSG00000261338.2	RP11-378A13.1	-10.58	1.61e-23	1.85e-20	-0.5	-0.44	Ulcerative colitis;	chr2:218095408	chr2:218255319~218257366:+
PRAD	cis	rs7772486	0.641	rs9390370	ENSG00000235652.6	RP11-545I5.3	10.57	1.62e-23	1.86e-20	0.49	0.44	Lobe attachment (rater-scored or self-reported);	chr6:146036433	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.641	rs960385	ENSG00000235652.6	RP11-545I5.3	10.57	1.62e-23	1.86e-20	0.49	0.44	Lobe attachment (rater-scored or self-reported);	chr6:146049938	chr6:145799409~145886585:+
PRAD	cis	rs2933343	0.859	rs789247	ENSG00000261159.1	RP11-723O4.9	10.57	1.62e-23	1.86e-20	0.41	0.44	IgG glycosylation;	chr3:128861742	chr3:128859716~128860526:-
PRAD	cis	rs2933343	0.903	rs2638846	ENSG00000261159.1	RP11-723O4.9	10.57	1.62e-23	1.86e-20	0.41	0.44	IgG glycosylation;	chr3:128868320	chr3:128859716~128860526:-
PRAD	cis	rs3931020	1	rs3931020	ENSG00000272864.1	RP11-17E13.2	-10.57	1.62e-23	1.86e-20	-0.48	-0.44	Resistin levels;	chr1:74769633	chr1:74698769~74699333:-
PRAD	cis	rs12439619	0.508	rs8042665	ENSG00000278603.1	RP13-608F4.5	10.57	1.62e-23	1.86e-20	0.58	0.44	Intelligence (multi-trait analysis);	chr15:82189008	chr15:82472203~82472426:+
PRAD	cis	rs9322193	0.923	rs9322197	ENSG00000216906.2	RP11-350J20.9	10.57	1.62e-23	1.86e-20	0.52	0.44	Lung cancer;	chr6:149622577	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.884	rs9688858	ENSG00000216906.2	RP11-350J20.9	10.57	1.62e-23	1.86e-20	0.52	0.44	Lung cancer;	chr6:149637911	chr6:149904243~149906418:+
PRAD	cis	rs1555322	0.53	rs2425043	ENSG00000126005.14	MMP24-AS1	-10.57	1.64e-23	1.88e-20	-0.54	-0.44	Attention deficit hyperactivity disorder;	chr20:35280899	chr20:35216462~35278131:-
PRAD	cis	rs2404602	0.647	rs11072636	ENSG00000259422.1	RP11-593F23.1	-10.57	1.64e-23	1.89e-20	-0.59	-0.44	Blood metabolite levels;	chr15:76893445	chr15:76174891~76181486:-
PRAD	cis	rs1426063	0.614	rs76931926	ENSG00000260265.1	RP11-44F21.5	10.57	1.65e-23	1.89e-20	0.93	0.44	QT interval;	chr4:75106902	chr4:75081702~75084717:-
PRAD	cis	rs34375054	0.623	rs2297478	ENSG00000279233.1	RP11-158L12.4	10.57	1.65e-23	1.9e-20	0.43	0.44	Post bronchodilator FEV1/FVC ratio;	chr12:125107298	chr12:125138245~125141711:+
PRAD	cis	rs780096	0.546	rs35073769	ENSG00000234072.1	AC074117.10	-10.57	1.65e-23	1.9e-20	-0.35	-0.44	Total body bone mineral density;	chr2:27508509	chr2:27356246~27367622:+
PRAD	cis	rs9545047	0.716	rs9545063	ENSG00000227676.3	LINC01068	10.57	1.66e-23	1.91e-20	0.54	0.44	Schizophrenia;	chr13:79316989	chr13:79566727~79571436:+
PRAD	cis	rs2348418	0.703	rs12368149	ENSG00000247934.4	RP11-967K21.1	-10.57	1.66e-23	1.91e-20	-0.41	-0.44	Lung function (FEV1);Lung function (FVC);	chr12:28168625	chr12:28163298~28190738:-
PRAD	cis	rs7772486	0.641	rs9390374	ENSG00000235652.6	RP11-545I5.3	10.57	1.69e-23	1.94e-20	0.49	0.44	Lobe attachment (rater-scored or self-reported);	chr6:146047039	chr6:145799409~145886585:+
PRAD	cis	rs2337406	0.866	rs7152038	ENSG00000274576.2	IGHV2-70	-10.57	1.69e-23	1.94e-20	-0.46	-0.44	Alzheimer's disease (late onset);	chr14:106778230	chr14:106770577~106771020:-
PRAD	cis	rs875971	0.862	rs801195	ENSG00000237310.1	GS1-124K5.4	-10.57	1.7e-23	1.95e-20	-0.41	-0.44	Aortic root size;	chr7:66561128	chr7:66493706~66495474:+
PRAD	cis	rs9322193	0.923	rs9371486	ENSG00000268592.3	RAET1E-AS1	10.57	1.7e-23	1.95e-20	0.62	0.44	Lung cancer;	chr6:149832090	chr6:149863494~149919507:+
PRAD	cis	rs2404602	0.608	rs12911035	ENSG00000259422.1	RP11-593F23.1	10.57	1.71e-23	1.96e-20	0.54	0.44	Blood metabolite levels;	chr15:76314250	chr15:76174891~76181486:-
PRAD	cis	rs34375054	0.66	rs35941060	ENSG00000279233.1	RP11-158L12.4	10.57	1.72e-23	1.98e-20	0.43	0.44	Post bronchodilator FEV1/FVC ratio;	chr12:125109699	chr12:125138245~125141711:+
PRAD	cis	rs34375054	0.738	rs10773145	ENSG00000279233.1	RP11-158L12.4	-10.57	1.73e-23	1.98e-20	-0.4	-0.44	Post bronchodilator FEV1/FVC ratio;	chr12:125141057	chr12:125138245~125141711:+
PRAD	cis	rs34779708	0.966	rs4934737	ENSG00000230534.5	RP11-297A16.2	10.57	1.73e-23	1.99e-20	0.59	0.44	Inflammatory bowel disease;Crohn's disease;	chr10:35223871	chr10:35098006~35127020:-
PRAD	cis	rs2348418	0.832	rs11049560	ENSG00000247934.4	RP11-967K21.1	10.57	1.74e-23	1.99e-20	0.4	0.44	Lung function (FEV1);Lung function (FVC);	chr12:28372504	chr12:28163298~28190738:-
PRAD	cis	rs7772486	0.79	rs4280983	ENSG00000235652.6	RP11-545I5.3	-10.57	1.74e-23	1.99e-20	-0.46	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145959654	chr6:145799409~145886585:+
PRAD	cis	rs7208859	0.614	rs216477	ENSG00000263531.1	RP13-753N3.1	-10.57	1.75e-23	2e-20	-0.85	-0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30539726	chr17:30863921~30864940:-
PRAD	cis	rs9322193	0.962	rs9322220	ENSG00000223701.3	RAET1E-AS1	10.57	1.75e-23	2e-20	0.6	0.44	Lung cancer;	chr6:149782897	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.962	rs10214845	ENSG00000223701.3	RAET1E-AS1	10.57	1.75e-23	2e-20	0.6	0.44	Lung cancer;	chr6:149783124	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.962	rs9767122	ENSG00000223701.3	RAET1E-AS1	10.57	1.75e-23	2e-20	0.6	0.44	Lung cancer;	chr6:149783553	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.923	rs1413654	ENSG00000223701.3	RAET1E-AS1	10.57	1.75e-23	2e-20	0.6	0.44	Lung cancer;	chr6:149783956	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.683	rs113281309	ENSG00000223701.3	RAET1E-AS1	10.57	1.75e-23	2e-20	0.6	0.44	Lung cancer;	chr6:149787289	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.962	rs9688809	ENSG00000223701.3	RAET1E-AS1	10.57	1.75e-23	2e-20	0.6	0.44	Lung cancer;	chr6:149787920	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.962	rs9689242	ENSG00000223701.3	RAET1E-AS1	10.57	1.75e-23	2e-20	0.6	0.44	Lung cancer;	chr6:149787970	chr6:149884431~149919508:+
PRAD	cis	rs9322193	1	rs9767077	ENSG00000223701.3	RAET1E-AS1	10.57	1.75e-23	2e-20	0.6	0.44	Lung cancer;	chr6:149788479	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.923	rs9688938	ENSG00000223701.3	RAET1E-AS1	10.57	1.75e-23	2e-20	0.6	0.44	Lung cancer;	chr6:149788941	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.962	rs9688940	ENSG00000223701.3	RAET1E-AS1	10.57	1.75e-23	2e-20	0.6	0.44	Lung cancer;	chr6:149788977	chr6:149884431~149919508:+
PRAD	cis	rs2282300	1	rs12799529	ENSG00000242353.1	RP4-710M3.1	-10.57	1.76e-23	2.01e-20	-0.51	-0.44	Morning vs. evening chronotype;	chr11:30387005	chr11:30368148~30368646:+
PRAD	cis	rs7772486	0.764	rs7745696	ENSG00000235652.6	RP11-545I5.3	10.57	1.76e-23	2.01e-20	0.45	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145841693	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.79	rs9403750	ENSG00000235652.6	RP11-545I5.3	10.57	1.76e-23	2.01e-20	0.45	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145846626	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.79	rs1832362	ENSG00000235652.6	RP11-545I5.3	10.57	1.76e-23	2.01e-20	0.45	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145858819	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.79	rs9376968	ENSG00000235652.6	RP11-545I5.3	10.57	1.76e-23	2.01e-20	0.45	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145859228	chr6:145799409~145886585:+
PRAD	cis	rs2929278	0.546	rs686666	ENSG00000249839.1	AC011330.5	-10.57	1.76e-23	2.01e-20	-0.57	-0.44	Schizophrenia;	chr15:43869352	chr15:43663654~43684339:-
PRAD	cis	rs150992	1	rs150992	ENSG00000248489.1	CTD-2007H13.3	10.57	1.76e-23	2.01e-20	0.49	0.44	Body mass index;	chr5:98939493	chr5:98929171~98995013:+
PRAD	cis	rs9322193	0.923	rs55849538	ENSG00000216906.2	RP11-350J20.9	10.56	1.76e-23	2.02e-20	0.51	0.44	Lung cancer;	chr6:149635330	chr6:149904243~149906418:+
PRAD	cis	rs1150668	0.796	rs1124132	ENSG00000204709.4	LINC01556	10.56	1.77e-23	2.03e-20	0.56	0.44	Pubertal anthropometrics;	chr6:28412544	chr6:28943877~28944537:+
PRAD	cis	rs1150668	0.796	rs2531832	ENSG00000204709.4	LINC01556	10.56	1.77e-23	2.03e-20	0.56	0.44	Pubertal anthropometrics;	chr6:28421445	chr6:28943877~28944537:+
PRAD	cis	rs9322193	0.962	rs35031906	ENSG00000216906.2	RP11-350J20.9	10.56	1.77e-23	2.03e-20	0.51	0.44	Lung cancer;	chr6:149677438	chr6:149904243~149906418:+
PRAD	cis	rs1426063	0.614	rs79750906	ENSG00000260265.1	RP11-44F21.5	10.56	1.8e-23	2.06e-20	0.94	0.44	QT interval;	chr4:75139193	chr4:75081702~75084717:-
PRAD	cis	rs1426063	0.614	rs76512224	ENSG00000260265.1	RP11-44F21.5	10.56	1.8e-23	2.06e-20	0.93	0.44	QT interval;	chr4:75144808	chr4:75081702~75084717:-
PRAD	cis	rs11723261	0.582	rs11248005	ENSG00000275426.1	CH17-262A2.1	10.56	1.81e-23	2.07e-20	0.63	0.44	Immune response to smallpox vaccine (IL-6);	chr4:172826	chr4:149738~150317:+
PRAD	cis	rs11723261	0.582	rs11733927	ENSG00000275426.1	CH17-262A2.1	10.56	1.81e-23	2.07e-20	0.63	0.44	Immune response to smallpox vaccine (IL-6);	chr4:173039	chr4:149738~150317:+
PRAD	cis	rs2919917	0.628	rs9643739	ENSG00000254352.1	RP11-578O24.2	10.56	1.82e-23	2.08e-20	0.58	0.44	Lymphocyte counts;	chr8:78679535	chr8:78723796~78724136:-
PRAD	cis	rs2919917	0.628	rs2170732	ENSG00000254352.1	RP11-578O24.2	10.56	1.82e-23	2.08e-20	0.58	0.44	Lymphocyte counts;	chr8:78684261	chr8:78723796~78724136:-
PRAD	cis	rs2348418	0.765	rs2078016	ENSG00000247934.4	RP11-967K21.1	-10.56	1.82e-23	2.08e-20	-0.4	-0.44	Lung function (FEV1);Lung function (FVC);	chr12:28180174	chr12:28163298~28190738:-
PRAD	cis	rs2282300	0.739	rs1222210	ENSG00000254532.1	RP11-624D11.2	-10.56	1.83e-23	2.1e-20	-0.65	-0.44	Morning vs. evening chronotype;	chr11:30340578	chr11:30044058~30084343:-
PRAD	cis	rs1426063	0.614	rs74949513	ENSG00000260265.1	RP11-44F21.5	10.56	1.84e-23	2.1e-20	0.93	0.44	QT interval;	chr4:75124631	chr4:75081702~75084717:-
PRAD	cis	rs1426063	0.541	rs116664844	ENSG00000260265.1	RP11-44F21.5	10.56	1.84e-23	2.1e-20	0.93	0.44	QT interval;	chr4:75125677	chr4:75081702~75084717:-
PRAD	cis	rs1426063	0.541	rs114162294	ENSG00000260265.1	RP11-44F21.5	10.56	1.84e-23	2.1e-20	0.93	0.44	QT interval;	chr4:75125682	chr4:75081702~75084717:-
PRAD	cis	rs1426063	0.614	rs76087197	ENSG00000260265.1	RP11-44F21.5	10.56	1.84e-23	2.1e-20	0.93	0.44	QT interval;	chr4:75134108	chr4:75081702~75084717:-
PRAD	cis	rs17023223	0.537	rs6677107	ENSG00000231365.4	RP11-418J17.1	-10.56	1.85e-23	2.11e-20	-0.46	-0.44	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119166142	chr1:119140396~119275973:+
PRAD	cis	rs17023223	0.537	rs12064033	ENSG00000231365.4	RP11-418J17.1	-10.56	1.85e-23	2.11e-20	-0.46	-0.44	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119166935	chr1:119140396~119275973:+
PRAD	cis	rs17023223	0.537	rs12064137	ENSG00000231365.4	RP11-418J17.1	-10.56	1.85e-23	2.11e-20	-0.46	-0.44	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119167126	chr1:119140396~119275973:+
PRAD	cis	rs17023223	0.509	rs56195272	ENSG00000231365.4	RP11-418J17.1	-10.56	1.85e-23	2.11e-20	-0.46	-0.44	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119171374	chr1:119140396~119275973:+
PRAD	cis	rs17023223	0.537	rs12065809	ENSG00000231365.4	RP11-418J17.1	-10.56	1.85e-23	2.11e-20	-0.46	-0.44	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119181912	chr1:119140396~119275973:+
PRAD	cis	rs17023223	0.553	rs11484962	ENSG00000231365.4	RP11-418J17.1	-10.56	1.85e-23	2.11e-20	-0.46	-0.44	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119182563	chr1:119140396~119275973:+
PRAD	cis	rs17023223	0.537	rs55836852	ENSG00000231365.4	RP11-418J17.1	-10.56	1.85e-23	2.11e-20	-0.46	-0.44	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119182778	chr1:119140396~119275973:+
PRAD	cis	rs17023223	0.537	rs66715579	ENSG00000231365.4	RP11-418J17.1	-10.56	1.85e-23	2.11e-20	-0.46	-0.44	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119182809	chr1:119140396~119275973:+
PRAD	cis	rs17023223	0.537	rs11487668	ENSG00000231365.4	RP11-418J17.1	-10.56	1.85e-23	2.11e-20	-0.46	-0.44	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119184173	chr1:119140396~119275973:+
PRAD	cis	rs17023223	0.537	rs10923766	ENSG00000231365.4	RP11-418J17.1	-10.56	1.85e-23	2.11e-20	-0.46	-0.44	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119184309	chr1:119140396~119275973:+
PRAD	cis	rs17023223	0.537	rs10923767	ENSG00000231365.4	RP11-418J17.1	-10.56	1.86e-23	2.12e-20	-0.46	-0.44	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119189724	chr1:119140396~119275973:+
PRAD	cis	rs2348418	0.832	rs1552761	ENSG00000247934.4	RP11-967K21.1	10.56	1.86e-23	2.12e-20	0.4	0.44	Lung function (FEV1);Lung function (FVC);	chr12:28383406	chr12:28163298~28190738:-
PRAD	cis	rs2739330	0.76	rs5751760	ENSG00000224205.1	AP000351.4	10.56	1.87e-23	2.14e-20	0.56	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23987320~23991421:-
PRAD	cis	rs7182621	0.622	rs12904160	ENSG00000259363.4	CTD-2054N24.2	-10.56	1.9e-23	2.16e-20	-0.44	-0.44	Colonoscopy-negative controls vs population controls;	chr15:99869471	chr15:99807023~99877148:+
PRAD	cis	rs875971	0.862	rs28470208	ENSG00000237310.1	GS1-124K5.4	-10.56	1.9e-23	2.17e-20	-0.41	-0.44	Aortic root size;	chr7:66119713	chr7:66493706~66495474:+
PRAD	cis	rs7201929	1	rs7499878	ENSG00000259982.1	CDC37P1	-10.56	1.9e-23	2.17e-20	-0.62	-0.44	QT interval;	chr16:28857143	chr16:28700294~28701540:-
PRAD	cis	rs17826219	0.733	rs7221691	ENSG00000263531.1	RP13-753N3.1	-10.56	1.91e-23	2.18e-20	-0.88	-0.44	Body mass index;	chr17:30396601	chr17:30863921~30864940:-
PRAD	cis	rs7240205	0.853	rs2000649	ENSG00000275805.1	RP11-349H17.2	10.55	1.92e-23	2.19e-20	0.55	0.44	Breast cancer;	chr18:26552897	chr18:26565723~26575626:-
PRAD	cis	rs7240205	0.853	rs1941160	ENSG00000275805.1	RP11-349H17.2	10.55	1.92e-23	2.19e-20	0.55	0.44	Breast cancer;	chr18:26553529	chr18:26565723~26575626:-
PRAD	cis	rs6860806	0.531	rs272887	ENSG00000233006.5	AC034220.3	10.55	1.92e-23	2.2e-20	0.41	0.44	Breast cancer;	chr5:132330020	chr5:132311285~132369916:-
PRAD	cis	rs6538678	0.824	rs4762631	ENSG00000258343.1	RP11-536G4.2	-10.55	1.93e-23	2.2e-20	-0.68	-0.44	Lupus nephritis in systemic lupus erythematosus;	chr12:95855698	chr12:95795345~95858839:-
PRAD	cis	rs75422866	0.867	rs73102125	ENSG00000257433.4	RP1-197B17.3	10.55	1.93e-23	2.2e-20	0.93	0.44	Pneumonia;	chr12:47637869	chr12:47706085~47742294:+
PRAD	cis	rs75422866	0.867	rs12426849	ENSG00000257433.4	RP1-197B17.3	10.55	1.93e-23	2.2e-20	0.93	0.44	Pneumonia;	chr12:47638975	chr12:47706085~47742294:+
PRAD	cis	rs75422866	0.867	rs117950951	ENSG00000257433.4	RP1-197B17.3	10.55	1.93e-23	2.2e-20	0.93	0.44	Pneumonia;	chr12:47639794	chr12:47706085~47742294:+
PRAD	cis	rs75422866	0.867	rs7954764	ENSG00000257433.4	RP1-197B17.3	10.55	1.93e-23	2.2e-20	0.93	0.44	Pneumonia;	chr12:47641136	chr12:47706085~47742294:+
PRAD	cis	rs2404602	0.735	rs2461870	ENSG00000259422.1	RP11-593F23.1	-10.55	1.94e-23	2.21e-20	-0.56	-0.44	Blood metabolite levels;	chr15:76521579	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.735	rs2454454	ENSG00000259422.1	RP11-593F23.1	-10.55	1.94e-23	2.21e-20	-0.56	-0.44	Blood metabolite levels;	chr15:76531306	chr15:76174891~76181486:-
PRAD	cis	rs875971	0.862	rs12537823	ENSG00000237310.1	GS1-124K5.4	10.55	1.94e-23	2.21e-20	0.41	0.44	Aortic root size;	chr7:66255897	chr7:66493706~66495474:+
PRAD	cis	rs1185460	0.967	rs1177562	ENSG00000271751.1	RP11-110I1.14	-10.55	1.98e-23	2.25e-20	-0.63	-0.44	Coronary artery disease;	chr11:119078621	chr11:119065263~119065677:-
PRAD	cis	rs875971	0.862	rs11773628	ENSG00000237310.1	GS1-124K5.4	-10.55	1.98e-23	2.26e-20	-0.41	-0.44	Aortic root size;	chr7:66517644	chr7:66493706~66495474:+
PRAD	cis	rs9322193	0.851	rs9322194	ENSG00000223701.3	RAET1E-AS1	10.55	1.98e-23	2.26e-20	0.61	0.44	Lung cancer;	chr6:149599113	chr6:149884431~149919508:+
PRAD	cis	rs875971	0.862	rs4718330	ENSG00000237310.1	GS1-124K5.4	-10.55	2.01e-23	2.29e-20	-0.41	-0.44	Aortic root size;	chr7:66250256	chr7:66493706~66495474:+
PRAD	cis	rs7714584	1	rs11957134	ENSG00000197083.10	ZNF300P1	-10.55	2.02e-23	2.3e-20	-0.76	-0.44	Crohn's disease;	chr5:150851388	chr5:150930645~150946289:-
PRAD	cis	rs2658782	0.688	rs2658768	ENSG00000279684.1	RP11-755E23.2	-10.55	2.02e-23	2.3e-20	-0.71	-0.44	Pulmonary function decline;	chr11:93517661	chr11:93286629~93288903:-
PRAD	cis	rs7772486	0.79	rs2249147	ENSG00000235652.6	RP11-545I5.3	10.55	2.03e-23	2.31e-20	0.45	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145863863	chr6:145799409~145886585:+
PRAD	cis	rs71403859	0.502	rs34015581	ENSG00000260886.1	TAT-AS1	10.55	2.06e-23	2.35e-20	0.75	0.44	Post bronchodilator FEV1;	chr16:71474326	chr16:71565789~71578187:+
PRAD	cis	rs9322193	0.961	rs2064520	ENSG00000216906.2	RP11-350J20.9	10.55	2.07e-23	2.35e-20	0.51	0.44	Lung cancer;	chr6:149603650	chr6:149904243~149906418:+
PRAD	cis	rs875971	0.862	rs10282433	ENSG00000237310.1	GS1-124K5.4	-10.55	2.08e-23	2.36e-20	-0.41	-0.44	Aortic root size;	chr7:66256452	chr7:66493706~66495474:+
PRAD	cis	rs6570726	0.791	rs11155433	ENSG00000235652.6	RP11-545I5.3	-10.54	2.09e-23	2.38e-20	-0.46	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145586695	chr6:145799409~145886585:+
PRAD	cis	rs10853057	0.85	rs35151435	ENSG00000214174.7	AMZ2P1	10.54	2.1e-23	2.4e-20	0.86	0.44	White matter microstructure (global fractional anisotropy);	chr17:65000600	chr17:64966550~64975576:-
PRAD	cis	rs783540	0.5	rs783541	ENSG00000276710.3	CSPG4P8	10.54	2.11e-23	2.4e-20	0.52	0.44	Schizophrenia;	chr15:82586310	chr15:82459472~82477258:+
PRAD	cis	rs748404	0.578	rs2278856	ENSG00000205771.5	CATSPER2P1	-10.54	2.11e-23	2.41e-20	-0.49	-0.44	Lung cancer;	chr15:43339158	chr15:43726918~43747094:-
PRAD	cis	rs7772486	0.764	rs2265468	ENSG00000235652.6	RP11-545I5.3	10.54	2.13e-23	2.43e-20	0.46	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145897210	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.79	rs9497431	ENSG00000235652.6	RP11-545I5.3	-10.54	2.13e-23	2.43e-20	-0.46	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145927041	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.79	rs7753092	ENSG00000235652.6	RP11-545I5.3	-10.54	2.13e-23	2.43e-20	-0.46	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145927727	chr6:145799409~145886585:+
PRAD	cis	rs189798	1	rs189798	ENSG00000254340.1	RP11-10A14.3	-10.54	2.15e-23	2.44e-20	-0.55	-0.44	Myopia (pathological);	chr8:9133067	chr8:9141424~9145435:+
PRAD	cis	rs875971	0.862	rs949930	ENSG00000237310.1	GS1-124K5.4	-10.54	2.15e-23	2.44e-20	-0.41	-0.44	Aortic root size;	chr7:66301835	chr7:66493706~66495474:+
PRAD	cis	rs2348418	0.703	rs10843122	ENSG00000247934.4	RP11-967K21.1	-10.54	2.16e-23	2.45e-20	-0.4	-0.44	Lung function (FEV1);Lung function (FVC);	chr12:28174153	chr12:28163298~28190738:-
PRAD	cis	rs977987	0.843	rs4888372	ENSG00000261783.1	RP11-252K23.2	-10.54	2.16e-23	2.46e-20	-0.6	-0.44	Dupuytren's disease;	chr16:75279587	chr16:75379818~75381260:-
PRAD	cis	rs7772486	0.72	rs1890171	ENSG00000235652.6	RP11-545I5.3	-10.54	2.16e-23	2.46e-20	-0.45	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145750978	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.72	rs4896844	ENSG00000235652.6	RP11-545I5.3	-10.54	2.16e-23	2.46e-20	-0.45	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145754088	chr6:145799409~145886585:+
PRAD	cis	rs9322193	0.576	rs7452592	ENSG00000268592.3	RAET1E-AS1	10.54	2.16e-23	2.46e-20	0.71	0.44	Lung cancer;	chr6:149875445	chr6:149863494~149919507:+
PRAD	cis	rs2933343	0.951	rs796862	ENSG00000261159.1	RP11-723O4.9	10.54	2.18e-23	2.47e-20	0.41	0.44	IgG glycosylation;	chr3:128874197	chr3:128859716~128860526:-
PRAD	cis	rs12049351	0.559	rs7515662	ENSG00000229367.1	HMGN2P19	10.54	2.18e-23	2.48e-20	0.7	0.44	Circulating myeloperoxidase levels (plasma);	chr1:229467070	chr1:229570532~229570796:+
PRAD	cis	rs4845570	0.92	rs11810571	ENSG00000249602.1	RP11-98D18.3	-10.54	2.18e-23	2.48e-20	-0.65	-0.44	Coronary artery disease;	chr1:151789832	chr1:151763384~151769501:-
PRAD	cis	rs1075265	0.633	rs4671190	ENSG00000233266.1	HMGB1P31	10.54	2.19e-23	2.48e-20	0.59	0.44	Chronotype;Morning vs. evening chronotype;	chr2:54085604	chr2:54051334~54051760:+
PRAD	cis	rs3762637	1	rs72960431	ENSG00000272758.4	RP11-299J3.8	-10.54	2.21e-23	2.51e-20	-0.64	-0.44	LDL cholesterol levels;	chr3:122509814	chr3:122416207~122443180:+
PRAD	cis	rs3762637	1	rs28434553	ENSG00000272758.4	RP11-299J3.8	-10.54	2.21e-23	2.51e-20	-0.64	-0.44	LDL cholesterol levels;	chr3:122510668	chr3:122416207~122443180:+
PRAD	cis	rs3762637	0.941	rs9837149	ENSG00000272758.4	RP11-299J3.8	-10.54	2.21e-23	2.51e-20	-0.64	-0.44	LDL cholesterol levels;	chr3:122511998	chr3:122416207~122443180:+
PRAD	cis	rs3762637	0.943	rs72960447	ENSG00000272758.4	RP11-299J3.8	-10.54	2.21e-23	2.51e-20	-0.64	-0.44	LDL cholesterol levels;	chr3:122516258	chr3:122416207~122443180:+
PRAD	cis	rs3762637	0.943	rs6762156	ENSG00000272758.4	RP11-299J3.8	-10.54	2.21e-23	2.51e-20	-0.64	-0.44	LDL cholesterol levels;	chr3:122517178	chr3:122416207~122443180:+
PRAD	cis	rs3762637	0.943	rs9872708	ENSG00000272758.4	RP11-299J3.8	-10.54	2.21e-23	2.51e-20	-0.64	-0.44	LDL cholesterol levels;	chr3:122523960	chr3:122416207~122443180:+
PRAD	cis	rs9545047	0.716	rs9530920	ENSG00000227676.3	LINC01068	10.54	2.24e-23	2.54e-20	0.55	0.44	Schizophrenia;	chr13:79423254	chr13:79566727~79571436:+
PRAD	cis	rs11951515	0.676	rs10941623	ENSG00000188850.9	RP11-159F24.2	10.54	2.26e-23	2.57e-20	0.52	0.44	Metabolite levels  (X-11787);	chr5:43308739	chr5:43336164~43348716:+
PRAD	cis	rs7743045	0.614	rs4946386	ENSG00000253194.1	RP11-351A11.1	10.54	2.27e-23	2.57e-20	0.6	0.44	Mean platelet volume;	chr6:119001827	chr6:118934785~119031541:+
PRAD	cis	rs7772486	0.641	rs67882056	ENSG00000235652.6	RP11-545I5.3	10.53	2.28e-23	2.58e-20	0.49	0.44	Lobe attachment (rater-scored or self-reported);	chr6:146095165	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.79	rs9376970	ENSG00000235652.6	RP11-545I5.3	-10.53	2.29e-23	2.6e-20	-0.46	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145920336	chr6:145799409~145886585:+
PRAD	cis	rs6860806	0.507	rs272880	ENSG00000233006.5	AC034220.3	10.53	2.3e-23	2.61e-20	0.41	0.44	Breast cancer;	chr5:132334485	chr5:132311285~132369916:-
PRAD	cis	rs7615952	0.604	rs9837847	ENSG00000171084.14	FAM86JP	10.53	2.3e-23	2.61e-20	0.85	0.44	Blood pressure (smoking interaction);	chr3:125905076	chr3:125916620~125930024:+
PRAD	cis	rs9322193	0.962	rs3763163	ENSG00000216906.2	RP11-350J20.9	10.53	2.32e-23	2.63e-20	0.5	0.44	Lung cancer;	chr6:149819770	chr6:149904243~149906418:+
PRAD	cis	rs638893	0.527	rs7933859	ENSG00000278376.1	RP11-158I9.8	-10.53	2.33e-23	2.64e-20	-0.54	-0.44	Vitiligo;	chr11:118791336	chr11:118791254~118793137:+
PRAD	cis	rs638893	0.578	rs4508234	ENSG00000278376.1	RP11-158I9.8	-10.53	2.33e-23	2.64e-20	-0.54	-0.44	Vitiligo;	chr11:118791494	chr11:118791254~118793137:+
PRAD	cis	rs638893	0.578	rs5006102	ENSG00000278376.1	RP11-158I9.8	-10.53	2.33e-23	2.64e-20	-0.54	-0.44	Vitiligo;	chr11:118791631	chr11:118791254~118793137:+
PRAD	cis	rs2348418	0.832	rs12301674	ENSG00000247934.4	RP11-967K21.1	10.53	2.35e-23	2.67e-20	0.4	0.44	Lung function (FEV1);Lung function (FVC);	chr12:28357543	chr12:28163298~28190738:-
PRAD	cis	rs2282300	0.739	rs1765139	ENSG00000254532.1	RP11-624D11.2	10.53	2.36e-23	2.68e-20	0.63	0.44	Morning vs. evening chronotype;	chr11:30332178	chr11:30044058~30084343:-
PRAD	cis	rs9322193	0.962	rs4869730	ENSG00000223701.3	RAET1E-AS1	10.53	2.37e-23	2.68e-20	0.6	0.44	Lung cancer;	chr6:149808187	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.923	rs2151913	ENSG00000223701.3	RAET1E-AS1	10.53	2.37e-23	2.68e-20	0.6	0.44	Lung cancer;	chr6:149809506	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.851	rs9322194	ENSG00000216906.2	RP11-350J20.9	10.53	2.37e-23	2.69e-20	0.52	0.44	Lung cancer;	chr6:149599113	chr6:149904243~149906418:+
PRAD	cis	rs2153535	1	rs2153535	ENSG00000230939.1	RP11-314C16.1	10.53	2.38e-23	2.7e-20	0.54	0.44	Motion sickness;	chr6:8369446	chr6:8784178~8785445:+
PRAD	cis	rs75422866	0.867	rs73104163	ENSG00000257433.4	RP1-197B17.3	10.53	2.38e-23	2.7e-20	1	0.44	Pneumonia;	chr12:47706187	chr12:47706085~47742294:+
PRAD	cis	rs75422866	1	rs12423045	ENSG00000257433.4	RP1-197B17.3	10.53	2.38e-23	2.7e-20	1	0.44	Pneumonia;	chr12:47706275	chr12:47706085~47742294:+
PRAD	cis	rs7727544	0.836	rs10463892	ENSG00000233006.5	AC034220.3	10.53	2.39e-23	2.71e-20	0.38	0.44	Blood metabolite levels;	chr5:132263012	chr5:132311285~132369916:-
PRAD	cis	rs7727544	0.901	rs55633655	ENSG00000233006.5	AC034220.3	10.53	2.39e-23	2.71e-20	0.38	0.44	Blood metabolite levels;	chr5:132263063	chr5:132311285~132369916:-
PRAD	cis	rs6452524	0.935	rs7718284	ENSG00000249664.1	CTD-2227C6.2	-10.53	2.39e-23	2.71e-20	-0.52	-0.44	Hypertension (SNP x SNP interaction);	chr5:83082488	chr5:83012285~83013109:-
PRAD	cis	rs1577917	0.958	rs13219504	ENSG00000203875.9	SNHG5	-10.53	2.42e-23	2.74e-20	-0.53	-0.44	Response to antipsychotic treatment;	chr6:85847199	chr6:85660950~85678736:-
PRAD	cis	rs9322193	0.923	rs9800686	ENSG00000216906.2	RP11-350J20.9	10.53	2.43e-23	2.75e-20	0.51	0.44	Lung cancer;	chr6:149634464	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.81	rs62439811	ENSG00000216906.2	RP11-350J20.9	10.53	2.43e-23	2.75e-20	0.51	0.44	Lung cancer;	chr6:149640416	chr6:149904243~149906418:+
PRAD	cis	rs2348418	0.864	rs11049578	ENSG00000247934.4	RP11-967K21.1	10.53	2.44e-23	2.76e-20	0.4	0.44	Lung function (FEV1);Lung function (FVC);	chr12:28414520	chr12:28163298~28190738:-
PRAD	cis	rs875971	0.862	rs10276077	ENSG00000237310.1	GS1-124K5.4	-10.53	2.45e-23	2.77e-20	-0.41	-0.44	Aortic root size;	chr7:66263424	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.792	rs6971752	ENSG00000237310.1	GS1-124K5.4	-10.53	2.45e-23	2.77e-20	-0.41	-0.44	Aortic root size;	chr7:66272999	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.862	rs10950033	ENSG00000237310.1	GS1-124K5.4	-10.53	2.45e-23	2.77e-20	-0.41	-0.44	Aortic root size;	chr7:66274686	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.862	rs11760844	ENSG00000237310.1	GS1-124K5.4	-10.53	2.45e-23	2.77e-20	-0.41	-0.44	Aortic root size;	chr7:66274896	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.862	rs4149461	ENSG00000237310.1	GS1-124K5.4	-10.53	2.45e-23	2.77e-20	-0.41	-0.44	Aortic root size;	chr7:66279745	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.862	rs10261398	ENSG00000237310.1	GS1-124K5.4	-10.53	2.45e-23	2.77e-20	-0.41	-0.44	Aortic root size;	chr7:66285177	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.862	rs10224872	ENSG00000237310.1	GS1-124K5.4	-10.53	2.45e-23	2.77e-20	-0.41	-0.44	Aortic root size;	chr7:66294786	chr7:66493706~66495474:+
PRAD	cis	rs4713118	0.629	rs203888	ENSG00000280107.1	AL022393.9	-10.53	2.45e-23	2.78e-20	-0.56	-0.44	Parkinson's disease;	chr6:28053811	chr6:28170845~28172521:+
PRAD	cis	rs6142102	0.812	rs4911375	ENSG00000276073.1	RP5-1125A11.7	-10.53	2.47e-23	2.79e-20	-0.45	-0.44	Skin pigmentation;	chr20:33928216	chr20:33985617~33988989:-
PRAD	cis	rs4713118	0.662	rs9357060	ENSG00000280107.1	AL022393.9	-10.53	2.48e-23	2.8e-20	-0.57	-0.44	Parkinson's disease;	chr6:28056708	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.662	rs9468271	ENSG00000280107.1	AL022393.9	-10.53	2.48e-23	2.8e-20	-0.57	-0.44	Parkinson's disease;	chr6:28056792	chr6:28170845~28172521:+
PRAD	cis	rs732716	0.74	rs62129356	ENSG00000267980.1	AC007292.6	-10.52	2.49e-23	2.82e-20	-0.46	-0.44	Mean corpuscular volume;	chr19:4400317	chr19:4363789~4364640:+
PRAD	cis	rs7772486	0.754	rs9497419	ENSG00000235652.6	RP11-545I5.3	10.52	2.49e-23	2.82e-20	0.45	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145821473	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.754	rs6921073	ENSG00000235652.6	RP11-545I5.3	10.52	2.49e-23	2.82e-20	0.45	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145823241	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.727	rs12190966	ENSG00000235652.6	RP11-545I5.3	10.52	2.49e-23	2.82e-20	0.45	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145825684	chr6:145799409~145886585:+
PRAD	cis	rs1577917	0.958	rs1838955	ENSG00000203875.9	SNHG5	-10.52	2.49e-23	2.82e-20	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85855731	chr6:85660950~85678736:-
PRAD	cis	rs2348418	0.966	rs7315631	ENSG00000247934.4	RP11-967K21.1	10.52	2.52e-23	2.84e-20	0.41	0.44	Lung function (FEV1);Lung function (FVC);	chr12:28545311	chr12:28163298~28190738:-
PRAD	cis	rs2348418	0.966	rs7316351	ENSG00000247934.4	RP11-967K21.1	10.52	2.52e-23	2.84e-20	0.41	0.44	Lung function (FEV1);Lung function (FVC);	chr12:28545595	chr12:28163298~28190738:-
PRAD	cis	rs1577917	0.958	rs13213551	ENSG00000203875.9	SNHG5	-10.52	2.52e-23	2.85e-20	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85898983	chr6:85660950~85678736:-
PRAD	cis	rs1577917	1	rs34622557	ENSG00000203875.9	SNHG5	-10.52	2.52e-23	2.85e-20	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85921134	chr6:85660950~85678736:-
PRAD	cis	rs1577917	1	rs1911553	ENSG00000203875.9	SNHG5	-10.52	2.52e-23	2.85e-20	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85921174	chr6:85660950~85678736:-
PRAD	cis	rs1577917	1	rs1995688	ENSG00000203875.9	SNHG5	-10.52	2.52e-23	2.85e-20	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85922601	chr6:85660950~85678736:-
PRAD	cis	rs875971	0.756	rs4718328	ENSG00000237310.1	GS1-124K5.4	-10.52	2.53e-23	2.86e-20	-0.41	-0.44	Aortic root size;	chr7:66228350	chr7:66493706~66495474:+
PRAD	cis	rs6142102	0.886	rs4911147	ENSG00000276073.1	RP5-1125A11.7	-10.52	2.54e-23	2.87e-20	-0.47	-0.44	Skin pigmentation;	chr20:34079801	chr20:33985617~33988989:-
PRAD	cis	rs1577917	1	rs12663690	ENSG00000203875.9	SNHG5	10.52	2.55e-23	2.88e-20	0.51	0.44	Response to antipsychotic treatment;	chr6:85930444	chr6:85660950~85678736:-
PRAD	cis	rs4713118	0.629	rs203890	ENSG00000280107.1	AL022393.9	-10.52	2.55e-23	2.88e-20	-0.57	-0.44	Parkinson's disease;	chr6:28054470	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.662	rs9380045	ENSG00000280107.1	AL022393.9	-10.52	2.56e-23	2.89e-20	-0.57	-0.44	Parkinson's disease;	chr6:28057501	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.616	rs9348789	ENSG00000280107.1	AL022393.9	-10.52	2.56e-23	2.89e-20	-0.57	-0.44	Parkinson's disease;	chr6:28057708	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.662	rs9468274	ENSG00000280107.1	AL022393.9	-10.52	2.56e-23	2.89e-20	-0.57	-0.44	Parkinson's disease;	chr6:28058299	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.662	rs9468275	ENSG00000280107.1	AL022393.9	-10.52	2.56e-23	2.89e-20	-0.57	-0.44	Parkinson's disease;	chr6:28058358	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.662	rs9468276	ENSG00000280107.1	AL022393.9	-10.52	2.56e-23	2.89e-20	-0.57	-0.44	Parkinson's disease;	chr6:28059910	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.662	rs9468277	ENSG00000280107.1	AL022393.9	-10.52	2.56e-23	2.89e-20	-0.57	-0.44	Parkinson's disease;	chr6:28060612	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.662	rs9468278	ENSG00000280107.1	AL022393.9	-10.52	2.56e-23	2.89e-20	-0.57	-0.44	Parkinson's disease;	chr6:28060704	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.662	rs13218430	ENSG00000280107.1	AL022393.9	-10.52	2.56e-23	2.89e-20	-0.57	-0.44	Parkinson's disease;	chr6:28062059	chr6:28170845~28172521:+
PRAD	cis	rs10256972	0.869	rs1007766	ENSG00000229043.2	AC091729.9	-10.52	2.56e-23	2.89e-20	-0.53	-0.44	Endometriosis;Longevity;	chr7:995267	chr7:1160374~1165267:+
PRAD	cis	rs7772486	0.754	rs1415746	ENSG00000235652.6	RP11-545I5.3	-10.52	2.57e-23	2.9e-20	-0.45	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145755971	chr6:145799409~145886585:+
PRAD	cis	rs11951515	0.7	rs10805672	ENSG00000188850.9	RP11-159F24.2	10.52	2.57e-23	2.9e-20	0.52	0.44	Metabolite levels  (X-11787);	chr5:43303646	chr5:43336164~43348716:+
PRAD	cis	rs11951515	0.675	rs9790987	ENSG00000188850.9	RP11-159F24.2	10.52	2.57e-23	2.9e-20	0.52	0.44	Metabolite levels  (X-11787);	chr5:43306131	chr5:43336164~43348716:+
PRAD	cis	rs11951515	0.663	rs66691321	ENSG00000188850.9	RP11-159F24.2	10.52	2.57e-23	2.9e-20	0.52	0.44	Metabolite levels  (X-11787);	chr5:43308353	chr5:43336164~43348716:+
PRAD	cis	rs11951515	0.638	rs10941621	ENSG00000188850.9	RP11-159F24.2	10.52	2.57e-23	2.9e-20	0.52	0.44	Metabolite levels  (X-11787);	chr5:43308533	chr5:43336164~43348716:+
PRAD	cis	rs11951515	0.676	rs10941622	ENSG00000188850.9	RP11-159F24.2	10.52	2.57e-23	2.9e-20	0.52	0.44	Metabolite levels  (X-11787);	chr5:43308588	chr5:43336164~43348716:+
PRAD	cis	rs11951515	0.7	rs10512825	ENSG00000188850.9	RP11-159F24.2	10.52	2.57e-23	2.9e-20	0.52	0.44	Metabolite levels  (X-11787);	chr5:43309088	chr5:43336164~43348716:+
PRAD	cis	rs9399135	0.66	rs4646868	ENSG00000232876.1	CTA-212D2.2	-10.52	2.57e-23	2.9e-20	-0.55	-0.44	Red blood cell count;	chr6:134950808	chr6:135055033~135060550:+
PRAD	cis	rs11951515	0.7	rs12520012	ENSG00000188850.9	RP11-159F24.2	10.52	2.59e-23	2.92e-20	0.52	0.44	Metabolite levels  (X-11787);	chr5:43296063	chr5:43336164~43348716:+
PRAD	cis	rs11951515	0.7	rs11739665	ENSG00000188850.9	RP11-159F24.2	10.52	2.59e-23	2.92e-20	0.52	0.44	Metabolite levels  (X-11787);	chr5:43301791	chr5:43336164~43348716:+
PRAD	cis	rs11951515	0.7	rs12518032	ENSG00000188850.9	RP11-159F24.2	10.52	2.59e-23	2.92e-20	0.52	0.44	Metabolite levels  (X-11787);	chr5:43311252	chr5:43336164~43348716:+
PRAD	cis	rs2348418	0.798	rs10843161	ENSG00000247934.4	RP11-967K21.1	10.52	2.6e-23	2.94e-20	0.4	0.44	Lung function (FEV1);Lung function (FVC);	chr12:28367688	chr12:28163298~28190738:-
PRAD	cis	rs2348418	0.798	rs7309905	ENSG00000247934.4	RP11-967K21.1	10.52	2.6e-23	2.94e-20	0.4	0.44	Lung function (FEV1);Lung function (FVC);	chr12:28373473	chr12:28163298~28190738:-
PRAD	cis	rs2348418	0.832	rs10506031	ENSG00000247934.4	RP11-967K21.1	-10.52	2.6e-23	2.94e-20	-0.4	-0.44	Lung function (FEV1);Lung function (FVC);	chr12:28379061	chr12:28163298~28190738:-
PRAD	cis	rs17023223	0.537	rs12083510	ENSG00000231365.4	RP11-418J17.1	-10.52	2.61e-23	2.95e-20	-0.46	-0.44	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119203997	chr1:119140396~119275973:+
PRAD	cis	rs17023223	0.537	rs4590715	ENSG00000231365.4	RP11-418J17.1	-10.52	2.61e-23	2.95e-20	-0.46	-0.44	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119207578	chr1:119140396~119275973:+
PRAD	cis	rs9322193	0.651	rs9322188	ENSG00000216906.2	RP11-350J20.9	-10.52	2.61e-23	2.95e-20	-0.51	-0.44	Lung cancer;	chr6:149588355	chr6:149904243~149906418:+
PRAD	cis	rs11951515	0.7	rs1548097	ENSG00000188850.9	RP11-159F24.2	10.52	2.61e-23	2.95e-20	0.52	0.44	Metabolite levels  (X-11787);	chr5:43310713	chr5:43336164~43348716:+
PRAD	cis	rs6570726	0.738	rs4495284	ENSG00000235652.6	RP11-545I5.3	10.52	2.63e-23	2.97e-20	0.46	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145595481	chr6:145799409~145886585:+
PRAD	cis	rs9322193	0.926	rs9766562	ENSG00000268592.3	RAET1E-AS1	10.52	2.66e-23	3e-20	0.62	0.44	Lung cancer;	chr6:149788709	chr6:149863494~149919507:+
PRAD	cis	rs2739330	0.796	rs5760106	ENSG00000272787.1	KB-226F1.2	10.52	2.67e-23	3.01e-20	0.48	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23969211~23969873:+
PRAD	cis	rs10170846	0.893	rs1447108	ENSG00000261428.2	RP11-16P6.1	10.52	2.67e-23	3.01e-20	0.58	0.44	Schizophrenia (inflammation and infection response interaction);	chr2:222677512	chr2:222566899~222569719:-
PRAD	cis	rs10170846	0.893	rs12614976	ENSG00000261428.2	RP11-16P6.1	10.52	2.67e-23	3.01e-20	0.58	0.44	Schizophrenia (inflammation and infection response interaction);	chr2:222678177	chr2:222566899~222569719:-
PRAD	cis	rs7714584	1	rs17800886	ENSG00000197083.10	ZNF300P1	10.52	2.68e-23	3.02e-20	0.74	0.44	Crohn's disease;	chr5:150929977	chr5:150930645~150946289:-
PRAD	cis	rs6142102	0.961	rs4911401	ENSG00000276073.1	RP5-1125A11.7	-10.51	2.7e-23	3.04e-20	-0.46	-0.44	Skin pigmentation;	chr20:34066756	chr20:33985617~33988989:-
PRAD	cis	rs11676348	0.935	rs4674250	ENSG00000261338.2	RP11-378A13.1	-10.51	2.7e-23	3.05e-20	-0.5	-0.44	Ulcerative colitis;	chr2:218112808	chr2:218255319~218257366:+
PRAD	cis	rs2348418	0.798	rs10771423	ENSG00000247934.4	RP11-967K21.1	10.51	2.71e-23	3.06e-20	0.41	0.44	Lung function (FEV1);Lung function (FVC);	chr12:28396205	chr12:28163298~28190738:-
PRAD	cis	rs1577917	1	rs12213740	ENSG00000203875.9	SNHG5	-10.51	2.72e-23	3.06e-20	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85947015	chr6:85660950~85678736:-
PRAD	cis	rs3762637	1	rs9843165	ENSG00000272758.4	RP11-299J3.8	-10.51	2.72e-23	3.06e-20	-0.64	-0.44	LDL cholesterol levels;	chr3:122412264	chr3:122416207~122443180:+
PRAD	cis	rs3762637	1	rs12630576	ENSG00000272758.4	RP11-299J3.8	-10.51	2.72e-23	3.06e-20	-0.64	-0.44	LDL cholesterol levels;	chr3:122420670	chr3:122416207~122443180:+
PRAD	cis	rs3762637	1	rs55853677	ENSG00000272758.4	RP11-299J3.8	-10.51	2.72e-23	3.06e-20	-0.64	-0.44	LDL cholesterol levels;	chr3:122421769	chr3:122416207~122443180:+
PRAD	cis	rs3762637	1	rs3762637	ENSG00000272758.4	RP11-299J3.8	-10.51	2.72e-23	3.06e-20	-0.64	-0.44	LDL cholesterol levels;	chr3:122426477	chr3:122416207~122443180:+
PRAD	cis	rs3762637	1	rs9833415	ENSG00000272758.4	RP11-299J3.8	-10.51	2.72e-23	3.06e-20	-0.64	-0.44	LDL cholesterol levels;	chr3:122440993	chr3:122416207~122443180:+
PRAD	cis	rs3762637	1	rs9882100	ENSG00000272758.4	RP11-299J3.8	-10.51	2.72e-23	3.06e-20	-0.64	-0.44	LDL cholesterol levels;	chr3:122451061	chr3:122416207~122443180:+
PRAD	cis	rs3762637	1	rs9968189	ENSG00000272758.4	RP11-299J3.8	-10.51	2.72e-23	3.06e-20	-0.64	-0.44	LDL cholesterol levels;	chr3:122456289	chr3:122416207~122443180:+
PRAD	cis	rs3762637	0.941	rs60222267	ENSG00000272758.4	RP11-299J3.8	-10.51	2.72e-23	3.06e-20	-0.64	-0.44	LDL cholesterol levels;	chr3:122460785	chr3:122416207~122443180:+
PRAD	cis	rs3762637	0.882	rs56074178	ENSG00000272758.4	RP11-299J3.8	-10.51	2.72e-23	3.06e-20	-0.64	-0.44	LDL cholesterol levels;	chr3:122461164	chr3:122416207~122443180:+
PRAD	cis	rs3762637	1	rs72958458	ENSG00000272758.4	RP11-299J3.8	-10.51	2.72e-23	3.06e-20	-0.64	-0.44	LDL cholesterol levels;	chr3:122466702	chr3:122416207~122443180:+
PRAD	cis	rs3762637	1	rs7642869	ENSG00000272758.4	RP11-299J3.8	-10.51	2.72e-23	3.06e-20	-0.64	-0.44	LDL cholesterol levels;	chr3:122471939	chr3:122416207~122443180:+
PRAD	cis	rs3762637	1	rs7617042	ENSG00000272758.4	RP11-299J3.8	-10.51	2.72e-23	3.06e-20	-0.64	-0.44	LDL cholesterol levels;	chr3:122472138	chr3:122416207~122443180:+
PRAD	cis	rs3762637	1	rs6790051	ENSG00000272758.4	RP11-299J3.8	-10.51	2.72e-23	3.06e-20	-0.64	-0.44	LDL cholesterol levels;	chr3:122473999	chr3:122416207~122443180:+
PRAD	cis	rs3762637	1	rs9878699	ENSG00000272758.4	RP11-299J3.8	-10.51	2.72e-23	3.06e-20	-0.64	-0.44	LDL cholesterol levels;	chr3:122475384	chr3:122416207~122443180:+
PRAD	cis	rs3762637	1	rs12638866	ENSG00000272758.4	RP11-299J3.8	-10.51	2.72e-23	3.06e-20	-0.64	-0.44	LDL cholesterol levels;	chr3:122475535	chr3:122416207~122443180:+
PRAD	cis	rs3762637	1	rs10049131	ENSG00000272758.4	RP11-299J3.8	-10.51	2.72e-23	3.06e-20	-0.64	-0.44	LDL cholesterol levels;	chr3:122483255	chr3:122416207~122443180:+
PRAD	cis	rs1577917	1	rs12664335	ENSG00000203875.9	SNHG5	10.51	2.72e-23	3.07e-20	0.51	0.44	Response to antipsychotic treatment;	chr6:85888056	chr6:85660950~85678736:-
PRAD	cis	rs2348418	0.767	rs7972954	ENSG00000247934.4	RP11-967K21.1	10.51	2.75e-23	3.1e-20	0.4	0.44	Lung function (FEV1);Lung function (FVC);	chr12:28260273	chr12:28163298~28190738:-
PRAD	cis	rs4853012	1	rs2280643	ENSG00000257800.1	FNBP1P1	10.51	2.76e-23	3.11e-20	0.4	0.44	Gestational age at birth (maternal effect);	chr2:74131159	chr2:74120680~74123218:+
PRAD	cis	rs4853012	0.887	rs2280644	ENSG00000257800.1	FNBP1P1	10.51	2.76e-23	3.11e-20	0.4	0.44	Gestational age at birth (maternal effect);	chr2:74131284	chr2:74120680~74123218:+
PRAD	cis	rs673078	0.66	rs7961312	ENSG00000275759.1	RP11-131L12.3	-10.51	2.76e-23	3.11e-20	-0.73	-0.44	Glucose homeostasis traits;	chr12:118324431	chr12:118428281~118428870:+
PRAD	cis	rs875971	0.862	rs2088653	ENSG00000237310.1	GS1-124K5.4	-10.51	2.77e-23	3.12e-20	-0.41	-0.44	Aortic root size;	chr7:66343621	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.862	rs6460293	ENSG00000237310.1	GS1-124K5.4	-10.51	2.77e-23	3.12e-20	-0.41	-0.44	Aortic root size;	chr7:66345205	chr7:66493706~66495474:+
PRAD	cis	rs673078	0.66	rs17440336	ENSG00000275759.1	RP11-131L12.3	10.51	2.77e-23	3.12e-20	0.66	0.44	Glucose homeostasis traits;	chr12:118163305	chr12:118428281~118428870:+
PRAD	cis	rs5760092	0.755	rs11090298	ENSG00000218537.1	MIF-AS1	-10.51	2.8e-23	3.15e-20	-0.71	-0.44	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919874	chr22:23894426~23898930:-
PRAD	cis	rs9322193	0.962	rs2151912	ENSG00000216906.2	RP11-350J20.9	10.51	2.81e-23	3.16e-20	0.51	0.44	Lung cancer;	chr6:149831772	chr6:149904243~149906418:+
PRAD	cis	rs274567	0.501	rs272855	ENSG00000233006.5	AC034220.3	10.51	2.83e-23	3.18e-20	0.42	0.44	Blood metabolite levels;	chr5:132351482	chr5:132311285~132369916:-
PRAD	cis	rs2348418	0.864	rs6487688	ENSG00000247934.4	RP11-967K21.1	-10.51	2.84e-23	3.19e-20	-0.41	-0.44	Lung function (FEV1);Lung function (FVC);	chr12:28558278	chr12:28163298~28190738:-
PRAD	cis	rs7849270	1	rs10819471	ENSG00000268707.1	RP11-247A12.7	-10.51	2.84e-23	3.19e-20	-0.5	-0.44	Blood metabolite ratios;	chr9:129134046	chr9:129170434~129170940:+
PRAD	cis	rs1577917	1	rs6940458	ENSG00000203875.9	SNHG5	-10.51	2.84e-23	3.2e-20	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85935274	chr6:85660950~85678736:-
PRAD	cis	rs4964805	0.626	rs4964827	ENSG00000257681.1	RP11-341G23.4	10.51	2.85e-23	3.2e-20	0.42	0.44	Attention deficit hyperactivity disorder;	chr12:103783303	chr12:103746315~103768858:-
PRAD	cis	rs2337406	0.866	rs112089985	ENSG00000274576.2	IGHV2-70	-10.51	2.85e-23	3.2e-20	-0.45	-0.44	Alzheimer's disease (late onset);	chr14:106780074	chr14:106770577~106771020:-
PRAD	cis	rs1577917	1	rs36096931	ENSG00000203875.9	SNHG5	-10.51	2.85e-23	3.2e-20	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85983416	chr6:85660950~85678736:-
PRAD	cis	rs11951515	0.738	rs10805674	ENSG00000188850.9	RP11-159F24.2	10.51	2.87e-23	3.22e-20	0.52	0.44	Metabolite levels  (X-11787);	chr5:43349758	chr5:43336164~43348716:+
PRAD	cis	rs6570726	0.791	rs11155426	ENSG00000235652.6	RP11-545I5.3	10.51	2.91e-23	3.27e-20	0.46	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145495994	chr6:145799409~145886585:+
PRAD	cis	rs1577917	1	rs12215903	ENSG00000203875.9	SNHG5	-10.51	2.91e-23	3.27e-20	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85965310	chr6:85660950~85678736:-
PRAD	cis	rs638893	0.636	rs6589687	ENSG00000278376.1	RP11-158I9.8	-10.51	2.91e-23	3.27e-20	-0.53	-0.44	Vitiligo;	chr11:118744951	chr11:118791254~118793137:+
PRAD	cis	rs638893	0.53	rs1961138	ENSG00000278376.1	RP11-158I9.8	-10.51	2.91e-23	3.27e-20	-0.53	-0.44	Vitiligo;	chr11:118748714	chr11:118791254~118793137:+
PRAD	cis	rs638893	0.578	rs485901	ENSG00000278376.1	RP11-158I9.8	-10.51	2.91e-23	3.27e-20	-0.53	-0.44	Vitiligo;	chr11:118751536	chr11:118791254~118793137:+
PRAD	cis	rs638893	0.578	rs580079	ENSG00000278376.1	RP11-158I9.8	-10.51	2.91e-23	3.27e-20	-0.53	-0.44	Vitiligo;	chr11:118754900	chr11:118791254~118793137:+
PRAD	cis	rs638893	0.588	rs2508929	ENSG00000278376.1	RP11-158I9.8	-10.51	2.91e-23	3.27e-20	-0.53	-0.44	Vitiligo;	chr11:118770742	chr11:118791254~118793137:+
PRAD	cis	rs638893	0.636	rs548167	ENSG00000278376.1	RP11-158I9.8	-10.51	2.91e-23	3.27e-20	-0.53	-0.44	Vitiligo;	chr11:118777687	chr11:118791254~118793137:+
PRAD	cis	rs638893	0.685	rs486651	ENSG00000278376.1	RP11-158I9.8	-10.51	2.91e-23	3.27e-20	-0.53	-0.44	Vitiligo;	chr11:118779150	chr11:118791254~118793137:+
PRAD	cis	rs673078	0.66	rs17512142	ENSG00000275759.1	RP11-131L12.3	-10.51	2.93e-23	3.29e-20	-0.71	-0.44	Glucose homeostasis traits;	chr12:118186186	chr12:118428281~118428870:+
PRAD	cis	rs9545047	0.716	rs9565500	ENSG00000227676.3	LINC01068	-10.5	2.94e-23	3.3e-20	-0.54	-0.44	Schizophrenia;	chr13:79433416	chr13:79566727~79571436:+
PRAD	cis	rs7772486	0.782	rs7747576	ENSG00000235652.6	RP11-545I5.3	-10.5	2.97e-23	3.34e-20	-0.46	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145956691	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.79	rs9399571	ENSG00000235652.6	RP11-545I5.3	-10.5	2.97e-23	3.34e-20	-0.46	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145960925	chr6:145799409~145886585:+
PRAD	cis	rs6142102	0.961	rs1055857	ENSG00000276073.1	RP5-1125A11.7	-10.5	2.98e-23	3.34e-20	-0.44	-0.44	Skin pigmentation;	chr20:34026067	chr20:33985617~33988989:-
PRAD	cis	rs2348418	0.832	rs11611382	ENSG00000247934.4	RP11-967K21.1	10.5	3.01e-23	3.38e-20	0.4	0.44	Lung function (FEV1);Lung function (FVC);	chr12:28310959	chr12:28163298~28190738:-
PRAD	cis	rs2348418	0.798	rs7310297	ENSG00000247934.4	RP11-967K21.1	10.5	3.01e-23	3.38e-20	0.4	0.44	Lung function (FEV1);Lung function (FVC);	chr12:28313638	chr12:28163298~28190738:-
PRAD	cis	rs9906595	1	rs9906595	ENSG00000263874.1	LINC00672	10.5	3.01e-23	3.38e-20	0.76	0.44	Obesity-related traits;	chr17:38945127	chr17:38925168~38928057:+
PRAD	cis	rs8072100	0.666	rs9913014	ENSG00000228782.6	CTD-2026D20.3	10.5	3.02e-23	3.39e-20	0.5	0.44	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47382823	chr17:47450568~47492492:-
PRAD	cis	rs12439619	0.508	rs8023960	ENSG00000278603.1	RP13-608F4.5	10.5	3.02e-23	3.39e-20	0.57	0.44	Intelligence (multi-trait analysis);	chr15:82206704	chr15:82472203~82472426:+
PRAD	cis	rs875971	0.862	rs1167408	ENSG00000237310.1	GS1-124K5.4	-10.5	3.04e-23	3.41e-20	-0.42	-0.44	Aortic root size;	chr7:66091121	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.83	rs1167406	ENSG00000237310.1	GS1-124K5.4	-10.5	3.04e-23	3.41e-20	-0.42	-0.44	Aortic root size;	chr7:66091949	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.862	rs1167399	ENSG00000237310.1	GS1-124K5.4	-10.5	3.04e-23	3.41e-20	-0.42	-0.44	Aortic root size;	chr7:66096890	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.862	rs57866200	ENSG00000237310.1	GS1-124K5.4	-10.5	3.04e-23	3.41e-20	-0.42	-0.44	Aortic root size;	chr7:66100405	chr7:66493706~66495474:+
PRAD	cis	rs1577917	0.958	rs2084294	ENSG00000203875.9	SNHG5	-10.5	3.04e-23	3.41e-20	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85856225	chr6:85660950~85678736:-
PRAD	cis	rs4845570	0.92	rs1521185	ENSG00000249602.1	RP11-98D18.3	-10.5	3.08e-23	3.45e-20	-0.65	-0.44	Coronary artery disease;	chr1:151791573	chr1:151763384~151769501:-
PRAD	cis	rs1577917	1	rs10944170	ENSG00000203875.9	SNHG5	-10.5	3.09e-23	3.47e-20	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85975751	chr6:85660950~85678736:-
PRAD	cis	rs6860806	0.507	rs272868	ENSG00000233006.5	AC034220.3	10.5	3.11e-23	3.48e-20	0.42	0.44	Breast cancer;	chr5:132345058	chr5:132311285~132369916:-
PRAD	cis	rs875971	0.862	rs778724	ENSG00000237310.1	GS1-124K5.4	10.5	3.12e-23	3.5e-20	0.41	0.44	Aortic root size;	chr7:66364304	chr7:66493706~66495474:+
PRAD	cis	rs6142102	0.923	rs3787230	ENSG00000276073.1	RP5-1125A11.7	-10.5	3.12e-23	3.5e-20	-0.45	-0.44	Skin pigmentation;	chr20:34052466	chr20:33985617~33988989:-
PRAD	cis	rs6142102	0.961	rs2284389	ENSG00000276073.1	RP5-1125A11.7	-10.5	3.12e-23	3.5e-20	-0.45	-0.44	Skin pigmentation;	chr20:34069035	chr20:33985617~33988989:-
PRAD	cis	rs11673344	0.864	rs56208574	ENSG00000226686.6	LINC01535	10.5	3.13e-23	3.5e-20	0.61	0.44	Obesity-related traits;	chr19:37007843	chr19:37251912~37265535:+
PRAD	cis	rs6750795	0.87	rs6754952	ENSG00000181798.2	LINC00471	10.5	3.14e-23	3.52e-20	0.51	0.44	Height;	chr2:231516534	chr2:231508426~231514339:-
PRAD	cis	rs748404	0.631	rs8042688	ENSG00000205771.5	CATSPER2P1	-10.49	3.21e-23	3.59e-20	-0.49	-0.44	Lung cancer;	chr15:43346327	chr15:43726918~43747094:-
PRAD	cis	rs748404	0.631	rs4296223	ENSG00000205771.5	CATSPER2P1	-10.49	3.21e-23	3.59e-20	-0.49	-0.44	Lung cancer;	chr15:43353048	chr15:43726918~43747094:-
PRAD	cis	rs748404	0.631	rs6493084	ENSG00000205771.5	CATSPER2P1	-10.49	3.21e-23	3.59e-20	-0.49	-0.44	Lung cancer;	chr15:43355429	chr15:43726918~43747094:-
PRAD	cis	rs748404	0.631	rs12905772	ENSG00000205771.5	CATSPER2P1	-10.49	3.21e-23	3.59e-20	-0.49	-0.44	Lung cancer;	chr15:43356246	chr15:43726918~43747094:-
PRAD	cis	rs2348418	0.832	rs7136426	ENSG00000247934.4	RP11-967K21.1	10.49	3.21e-23	3.6e-20	0.41	0.44	Lung function (FEV1);Lung function (FVC);	chr12:28400129	chr12:28163298~28190738:-
PRAD	cis	rs1075265	0.87	rs6749817	ENSG00000233266.1	HMGB1P31	10.49	3.21e-23	3.6e-20	0.59	0.44	Chronotype;Morning vs. evening chronotype;	chr2:54032396	chr2:54051334~54051760:+
PRAD	cis	rs748404	0.631	rs11070399	ENSG00000205771.5	CATSPER2P1	-10.49	3.23e-23	3.62e-20	-0.49	-0.44	Lung cancer;	chr15:43354149	chr15:43726918~43747094:-
PRAD	cis	rs17023223	0.509	rs61806978	ENSG00000231365.4	RP11-418J17.1	-10.49	3.24e-23	3.62e-20	-0.45	-0.44	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119170592	chr1:119140396~119275973:+
PRAD	cis	rs4845570	0.85	rs11204892	ENSG00000249602.1	RP11-98D18.3	-10.49	3.25e-23	3.63e-20	-0.65	-0.44	Coronary artery disease;	chr1:151795572	chr1:151763384~151769501:-
PRAD	cis	rs11951515	0.663	rs11742171	ENSG00000188850.9	RP11-159F24.2	10.49	3.25e-23	3.64e-20	0.53	0.44	Metabolite levels  (X-11787);	chr5:43358607	chr5:43336164~43348716:+
PRAD	cis	rs11951515	0.738	rs7708779	ENSG00000188850.9	RP11-159F24.2	10.49	3.25e-23	3.64e-20	0.53	0.44	Metabolite levels  (X-11787);	chr5:43359181	chr5:43336164~43348716:+
PRAD	cis	rs11951515	0.738	rs4866824	ENSG00000188850.9	RP11-159F24.2	10.49	3.25e-23	3.64e-20	0.53	0.44	Metabolite levels  (X-11787);	chr5:43359343	chr5:43336164~43348716:+
PRAD	cis	rs11951515	0.738	rs4866825	ENSG00000188850.9	RP11-159F24.2	10.49	3.25e-23	3.64e-20	0.53	0.44	Metabolite levels  (X-11787);	chr5:43359517	chr5:43336164~43348716:+
PRAD	cis	rs12049351	0.83	rs12042088	ENSG00000229367.1	HMGN2P19	10.49	3.27e-23	3.66e-20	0.69	0.44	Circulating myeloperoxidase levels (plasma);	chr1:229582388	chr1:229570532~229570796:+
PRAD	cis	rs1155848	0.892	rs953005	ENSG00000227354.5	RBM26-AS1	10.49	3.29e-23	3.68e-20	0.86	0.44	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79480544	chr13:79406309~79424328:+
PRAD	cis	rs673078	0.607	rs7302387	ENSG00000275759.1	RP11-131L12.3	-10.49	3.3e-23	3.69e-20	-0.72	-0.44	Glucose homeostasis traits;	chr12:118316546	chr12:118428281~118428870:+
PRAD	cis	rs2933343	1	rs2929859	ENSG00000261159.1	RP11-723O4.9	10.49	3.3e-23	3.69e-20	0.41	0.44	IgG glycosylation;	chr3:128889498	chr3:128859716~128860526:-
PRAD	cis	rs2933343	1	rs789227	ENSG00000261159.1	RP11-723O4.9	10.49	3.32e-23	3.71e-20	0.41	0.44	IgG glycosylation;	chr3:128881742	chr3:128859716~128860526:-
PRAD	cis	rs2933343	1	rs789232	ENSG00000261159.1	RP11-723O4.9	10.49	3.32e-23	3.71e-20	0.41	0.44	IgG glycosylation;	chr3:128884237	chr3:128859716~128860526:-
PRAD	cis	rs2933343	1	rs1683811	ENSG00000261159.1	RP11-723O4.9	10.49	3.32e-23	3.71e-20	0.41	0.44	IgG glycosylation;	chr3:128893270	chr3:128859716~128860526:-
PRAD	cis	rs507080	0.922	rs4936433	ENSG00000255422.1	AP002954.4	10.49	3.33e-23	3.72e-20	0.55	0.44	Serum metabolite levels;	chr11:118681711	chr11:118704607~118750263:+
PRAD	cis	rs9322193	0.962	rs7818	ENSG00000223701.3	RAET1E-AS1	10.49	3.34e-23	3.74e-20	0.59	0.44	Lung cancer;	chr6:149810956	chr6:149884431~149919508:+
PRAD	cis	rs150992	0.609	rs363929	ENSG00000248489.1	CTD-2007H13.3	10.49	3.34e-23	3.74e-20	0.5	0.44	Body mass index;	chr5:98985933	chr5:98929171~98995013:+
PRAD	cis	rs9322193	0.962	rs2151912	ENSG00000223701.3	RAET1E-AS1	10.49	3.36e-23	3.76e-20	0.59	0.44	Lung cancer;	chr6:149831772	chr6:149884431~149919508:+
PRAD	cis	rs4820294	0.669	rs12628135	ENSG00000233360.4	Z83844.1	10.49	3.37e-23	3.77e-20	0.54	0.44	Fat distribution (HIV);	chr22:37669648	chr22:37641832~37658377:-
PRAD	cis	rs2739330	0.828	rs5760107	ENSG00000272787.1	KB-226F1.2	-10.49	3.38e-23	3.77e-20	-0.48	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23969211~23969873:+
PRAD	cis	rs2739330	0.789	rs5760109	ENSG00000272787.1	KB-226F1.2	-10.49	3.38e-23	3.77e-20	-0.48	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23969211~23969873:+
PRAD	cis	rs7772486	0.79	rs3924499	ENSG00000235652.6	RP11-545I5.3	-10.49	3.38e-23	3.78e-20	-0.46	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145911842	chr6:145799409~145886585:+
PRAD	cis	rs9487094	0.744	rs13212535	ENSG00000260273.1	RP11-425D10.10	10.49	3.39e-23	3.78e-20	0.65	0.44	Height;	chr6:109713188	chr6:109382795~109383666:+
PRAD	cis	rs9322193	1	rs58189451	ENSG00000216906.2	RP11-350J20.9	10.49	3.39e-23	3.79e-20	0.51	0.44	Lung cancer;	chr6:149600252	chr6:149904243~149906418:+
PRAD	cis	rs1577917	0.958	rs36053156	ENSG00000203875.9	SNHG5	-10.49	3.39e-23	3.79e-20	-0.53	-0.44	Response to antipsychotic treatment;	chr6:85865791	chr6:85660950~85678736:-
PRAD	cis	rs2283792	0.691	rs11913721	ENSG00000224086.5	LL22NC03-86G7.1	-10.49	3.4e-23	3.8e-20	-0.53	-0.44	Multiple sclerosis;	chr22:21855846	chr22:21938293~21977632:+
PRAD	cis	rs11673344	0.832	rs11084871	ENSG00000226686.6	LINC01535	10.49	3.42e-23	3.82e-20	0.6	0.44	Obesity-related traits;	chr19:37042023	chr19:37251912~37265535:+
PRAD	cis	rs11673344	0.832	rs77772684	ENSG00000226686.6	LINC01535	10.49	3.42e-23	3.82e-20	0.6	0.44	Obesity-related traits;	chr19:37055838	chr19:37251912~37265535:+
PRAD	cis	rs11951515	0.663	rs11746629	ENSG00000188850.9	RP11-159F24.2	10.49	3.43e-23	3.83e-20	0.52	0.44	Metabolite levels  (X-11787);	chr5:43284109	chr5:43336164~43348716:+
PRAD	cis	rs11951515	0.7	rs57392430	ENSG00000188850.9	RP11-159F24.2	10.49	3.43e-23	3.83e-20	0.52	0.44	Metabolite levels  (X-11787);	chr5:43284329	chr5:43336164~43348716:+
PRAD	cis	rs11951515	0.7	rs56029402	ENSG00000188850.9	RP11-159F24.2	10.49	3.43e-23	3.83e-20	0.52	0.44	Metabolite levels  (X-11787);	chr5:43284353	chr5:43336164~43348716:+
PRAD	cis	rs11951515	0.7	rs56023994	ENSG00000188850.9	RP11-159F24.2	10.49	3.43e-23	3.83e-20	0.52	0.44	Metabolite levels  (X-11787);	chr5:43285291	chr5:43336164~43348716:+
PRAD	cis	rs11951515	0.676	rs55647314	ENSG00000188850.9	RP11-159F24.2	10.49	3.43e-23	3.83e-20	0.52	0.44	Metabolite levels  (X-11787);	chr5:43285294	chr5:43336164~43348716:+
PRAD	cis	rs2739330	0.732	rs5760175	ENSG00000224205.1	AP000351.4	10.49	3.44e-23	3.84e-20	0.54	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23987320~23991421:-
PRAD	cis	rs11951515	0.663	rs4395639	ENSG00000188850.9	RP11-159F24.2	10.49	3.48e-23	3.89e-20	0.52	0.44	Metabolite levels  (X-11787);	chr5:43286361	chr5:43336164~43348716:+
PRAD	cis	rs7772486	0.79	rs6926657	ENSG00000235652.6	RP11-545I5.3	-10.48	3.53e-23	3.94e-20	-0.46	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145934658	chr6:145799409~145886585:+
PRAD	cis	rs1577917	0.874	rs1838954	ENSG00000203875.9	SNHG5	-10.48	3.55e-23	3.96e-20	-0.49	-0.44	Response to antipsychotic treatment;	chr6:85855760	chr6:85660950~85678736:-
PRAD	cis	rs7714584	1	rs11167515	ENSG00000197083.10	ZNF300P1	10.48	3.55e-23	3.96e-20	0.75	0.44	Crohn's disease;	chr5:150859909	chr5:150930645~150946289:-
PRAD	cis	rs34779708	0.931	rs4007289	ENSG00000230534.5	RP11-297A16.2	10.48	3.55e-23	3.97e-20	0.58	0.44	Inflammatory bowel disease;Crohn's disease;	chr10:34980862	chr10:35098006~35127020:-
PRAD	cis	rs2337406	0.866	rs7152809	ENSG00000274576.2	IGHV2-70	-10.48	3.56e-23	3.97e-20	-0.45	-0.44	Alzheimer's disease (late onset);	chr14:106778385	chr14:106770577~106771020:-
PRAD	cis	rs858239	0.633	rs858300	ENSG00000226816.2	AC005082.12	10.48	3.56e-23	3.97e-20	0.51	0.44	Cerebrospinal fluid biomarker levels;	chr7:23205012	chr7:23206013~23208045:+
PRAD	cis	rs858239	0.73	rs858290	ENSG00000226816.2	AC005082.12	10.48	3.56e-23	3.97e-20	0.51	0.44	Cerebrospinal fluid biomarker levels;	chr7:23208417	chr7:23206013~23208045:+
PRAD	cis	rs2933343	1	rs1683776	ENSG00000231305.3	RP11-723O4.2	10.48	3.56e-23	3.97e-20	0.45	0.44	IgG glycosylation;	chr3:128903917	chr3:128861313~128871540:-
PRAD	cis	rs2933343	1	rs2630252	ENSG00000231305.3	RP11-723O4.2	10.48	3.56e-23	3.97e-20	0.45	0.44	IgG glycosylation;	chr3:128905929	chr3:128861313~128871540:-
PRAD	cis	rs7714584	1	rs12659118	ENSG00000197083.10	ZNF300P1	10.48	3.56e-23	3.97e-20	0.79	0.44	Crohn's disease;	chr5:150945060	chr5:150930645~150946289:-
PRAD	cis	rs7772486	0.79	rs7753696	ENSG00000235652.6	RP11-545I5.3	-10.48	3.57e-23	3.99e-20	-0.46	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145957962	chr6:145799409~145886585:+
PRAD	cis	rs2739330	0.828	rs2330635	ENSG00000272787.1	KB-226F1.2	-10.48	3.58e-23	4e-20	-0.48	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23969211~23969873:+
PRAD	cis	rs34779708	0.931	rs72789609	ENSG00000230534.5	RP11-297A16.2	10.48	3.6e-23	4.01e-20	0.59	0.44	Inflammatory bowel disease;Crohn's disease;	chr10:35017278	chr10:35098006~35127020:-
PRAD	cis	rs11951515	0.7	rs6814	ENSG00000188850.9	RP11-159F24.2	10.48	3.64e-23	4.06e-20	0.52	0.44	Metabolite levels  (X-11787);	chr5:43289606	chr5:43336164~43348716:+
PRAD	cis	rs2348418	0.832	rs12303069	ENSG00000247934.4	RP11-967K21.1	10.48	3.7e-23	4.13e-20	0.4	0.44	Lung function (FEV1);Lung function (FVC);	chr12:28294319	chr12:28163298~28190738:-
PRAD	cis	rs9322193	0.962	rs4552	ENSG00000268592.3	RAET1E-AS1	10.48	3.71e-23	4.13e-20	0.61	0.44	Lung cancer;	chr6:149811183	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.632	rs3828700	ENSG00000268592.3	RAET1E-AS1	10.48	3.72e-23	4.14e-20	0.61	0.44	Lung cancer;	chr6:149791033	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.887	rs11155662	ENSG00000223701.3	RAET1E-AS1	10.48	3.73e-23	4.15e-20	0.61	0.44	Lung cancer;	chr6:149592731	chr6:149884431~149919508:+
PRAD	cis	rs2348418	0.83	rs4930821	ENSG00000247934.4	RP11-967K21.1	10.48	3.73e-23	4.15e-20	0.4	0.44	Lung function (FEV1);Lung function (FVC);	chr12:28410948	chr12:28163298~28190738:-
PRAD	cis	rs2153535	0.869	rs11962457	ENSG00000230939.1	RP11-314C16.1	10.48	3.73e-23	4.16e-20	0.54	0.44	Motion sickness;	chr6:8375622	chr6:8784178~8785445:+
PRAD	cis	rs1075265	0.669	rs805317	ENSG00000233266.1	HMGB1P31	10.48	3.75e-23	4.17e-20	0.58	0.44	Chronotype;Morning vs. evening chronotype;	chr2:53907867	chr2:54051334~54051760:+
PRAD	cis	rs1075265	0.692	rs805318	ENSG00000233266.1	HMGB1P31	10.48	3.75e-23	4.17e-20	0.58	0.44	Chronotype;Morning vs. evening chronotype;	chr2:53907915	chr2:54051334~54051760:+
PRAD	cis	rs17023223	0.537	rs61806983	ENSG00000231365.4	RP11-418J17.1	-10.48	3.75e-23	4.17e-20	-0.45	-0.44	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119188901	chr1:119140396~119275973:+
PRAD	cis	rs17023223	0.537	rs12087987	ENSG00000231365.4	RP11-418J17.1	-10.48	3.75e-23	4.17e-20	-0.45	-0.44	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119192198	chr1:119140396~119275973:+
PRAD	cis	rs1577917	1	rs10455456	ENSG00000203875.9	SNHG5	-10.48	3.75e-23	4.17e-20	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85960604	chr6:85660950~85678736:-
PRAD	cis	rs1577917	1	rs10455158	ENSG00000203875.9	SNHG5	-10.48	3.75e-23	4.17e-20	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85963107	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.959	rs34258068	ENSG00000203875.9	SNHG5	-10.48	3.75e-23	4.17e-20	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85969731	chr6:85660950~85678736:-
PRAD	cis	rs9322193	0.923	rs7753812	ENSG00000216906.2	RP11-350J20.9	10.48	3.75e-23	4.18e-20	0.51	0.44	Lung cancer;	chr6:149690150	chr6:149904243~149906418:+
PRAD	cis	rs6142102	0.961	rs8123521	ENSG00000276073.1	RP5-1125A11.7	-10.48	3.76e-23	4.19e-20	-0.47	-0.44	Skin pigmentation;	chr20:34081079	chr20:33985617~33988989:-
PRAD	cis	rs6142102	0.961	rs2284386	ENSG00000276073.1	RP5-1125A11.7	-10.48	3.79e-23	4.22e-20	-0.44	-0.44	Skin pigmentation;	chr20:34056590	chr20:33985617~33988989:-
PRAD	cis	rs4660456	0.504	rs2744805	ENSG00000237899.1	RP4-739H11.3	10.47	3.8e-23	4.23e-20	0.65	0.44	Platelet count;	chr1:40654827	chr1:40669089~40687588:-
PRAD	cis	rs4713118	0.662	rs464312	ENSG00000280107.1	AL022393.9	-10.47	3.8e-23	4.23e-20	-0.56	-0.44	Parkinson's disease;	chr6:27999813	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.662	rs469228	ENSG00000280107.1	AL022393.9	-10.47	3.8e-23	4.23e-20	-0.56	-0.44	Parkinson's disease;	chr6:28002926	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.54	rs469227	ENSG00000280107.1	AL022393.9	-10.47	3.8e-23	4.23e-20	-0.56	-0.44	Parkinson's disease;	chr6:28002927	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.662	rs149948	ENSG00000280107.1	AL022393.9	-10.47	3.8e-23	4.23e-20	-0.56	-0.44	Parkinson's disease;	chr6:28007039	chr6:28170845~28172521:+
PRAD	cis	rs1075265	0.811	rs805322	ENSG00000233266.1	HMGB1P31	-10.47	3.81e-23	4.24e-20	-0.59	-0.44	Chronotype;Morning vs. evening chronotype;	chr2:53912758	chr2:54051334~54051760:+
PRAD	cis	rs853679	0.55	rs6901017	ENSG00000280107.1	AL022393.9	-10.47	3.81e-23	4.24e-20	-0.57	-0.44	Depression;	chr6:28184805	chr6:28170845~28172521:+
PRAD	cis	rs9487094	0.645	rs12529505	ENSG00000260273.1	RP11-425D10.10	-10.47	3.81e-23	4.24e-20	-0.65	-0.44	Height;	chr6:109625358	chr6:109382795~109383666:+
PRAD	cis	rs6142102	0.961	rs4911146	ENSG00000276073.1	RP5-1125A11.7	-10.47	3.84e-23	4.27e-20	-0.47	-0.44	Skin pigmentation;	chr20:34052241	chr20:33985617~33988989:-
PRAD	cis	rs9322193	0.923	rs12195866	ENSG00000216906.2	RP11-350J20.9	10.47	3.85e-23	4.28e-20	0.51	0.44	Lung cancer;	chr6:149693334	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.923	rs9285524	ENSG00000216906.2	RP11-350J20.9	10.47	3.85e-23	4.28e-20	0.51	0.44	Lung cancer;	chr6:149694122	chr6:149904243~149906418:+
PRAD	cis	rs2348418	0.832	rs1552760	ENSG00000247934.4	RP11-967K21.1	10.47	3.85e-23	4.28e-20	0.4	0.44	Lung function (FEV1);Lung function (FVC);	chr12:28383884	chr12:28163298~28190738:-
PRAD	cis	rs1891275	0.515	rs6583784	ENSG00000228701.1	TNKS2-AS1	10.47	3.88e-23	4.31e-20	0.56	0.44	Intelligence (multi-trait analysis);	chr10:91731819	chr10:91782839~91798291:-
PRAD	cis	rs732716	0.785	rs11666453	ENSG00000267980.1	AC007292.6	-10.47	3.89e-23	4.32e-20	-0.47	-0.44	Mean corpuscular volume;	chr19:4368800	chr19:4363789~4364640:+
PRAD	cis	rs875971	0.862	rs7783779	ENSG00000237310.1	GS1-124K5.4	-10.47	3.9e-23	4.33e-20	-0.41	-0.44	Aortic root size;	chr7:66331639	chr7:66493706~66495474:+
PRAD	cis	rs9322193	0.962	rs9505974	ENSG00000216906.2	RP11-350J20.9	10.47	3.92e-23	4.35e-20	0.5	0.44	Lung cancer;	chr6:149779294	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.926	rs9689036	ENSG00000216906.2	RP11-350J20.9	10.47	3.92e-23	4.35e-20	0.5	0.44	Lung cancer;	chr6:149780563	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.962	rs9322218	ENSG00000216906.2	RP11-350J20.9	10.47	3.92e-23	4.35e-20	0.5	0.44	Lung cancer;	chr6:149782183	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.962	rs9322219	ENSG00000216906.2	RP11-350J20.9	10.47	3.92e-23	4.35e-20	0.5	0.44	Lung cancer;	chr6:149782263	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.962	rs9322223	ENSG00000216906.2	RP11-350J20.9	10.47	3.92e-23	4.35e-20	0.5	0.44	Lung cancer;	chr6:149801509	chr6:149904243~149906418:+
PRAD	cis	rs9532669	0.89	rs9532627	ENSG00000176268.5	CYCSP34	10.47	3.92e-23	4.36e-20	0.45	0.44	Cervical cancer;	chr13:40874811	chr13:40863599~40863902:-
PRAD	cis	rs7727544	0.904	rs58835386	ENSG00000233006.5	AC034220.3	10.47	3.93e-23	4.37e-20	0.38	0.44	Blood metabolite levels;	chr5:132264866	chr5:132311285~132369916:-
PRAD	cis	rs7727544	0.904	rs7736102	ENSG00000233006.5	AC034220.3	10.47	3.93e-23	4.37e-20	0.38	0.44	Blood metabolite levels;	chr5:132268564	chr5:132311285~132369916:-
PRAD	cis	rs7727544	0.904	rs6897575	ENSG00000233006.5	AC034220.3	10.47	3.93e-23	4.37e-20	0.38	0.44	Blood metabolite levels;	chr5:132268842	chr5:132311285~132369916:-
PRAD	cis	rs1075265	0.783	rs805424	ENSG00000233266.1	HMGB1P31	10.47	3.96e-23	4.4e-20	0.59	0.44	Chronotype;Morning vs. evening chronotype;	chr2:53901098	chr2:54051334~54051760:+
PRAD	cis	rs858239	0.665	rs858306	ENSG00000226816.2	AC005082.12	10.47	3.99e-23	4.43e-20	0.51	0.44	Cerebrospinal fluid biomarker levels;	chr7:23203135	chr7:23206013~23208045:+
PRAD	cis	rs9322193	0.923	rs12174035	ENSG00000216906.2	RP11-350J20.9	10.47	3.99e-23	4.43e-20	0.51	0.44	Lung cancer;	chr6:149763311	chr6:149904243~149906418:+
PRAD	cis	rs7772486	0.79	rs4896852	ENSG00000235652.6	RP11-545I5.3	-10.47	4e-23	4.44e-20	-0.46	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145963485	chr6:145799409~145886585:+
PRAD	cis	rs2739330	0.627	rs9608219	ENSG00000206090.4	AP000350.7	10.47	4.02e-23	4.46e-20	0.56	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23939998~23942798:+
PRAD	cis	rs1150668	0.83	rs2023493	ENSG00000204709.4	LINC01556	10.47	4.04e-23	4.49e-20	0.56	0.44	Pubertal anthropometrics;	chr6:28432385	chr6:28943877~28944537:+
PRAD	cis	rs2348418	0.832	rs1907692	ENSG00000247934.4	RP11-967K21.1	10.47	4.04e-23	4.49e-20	0.4	0.44	Lung function (FEV1);Lung function (FVC);	chr12:28385178	chr12:28163298~28190738:-
PRAD	cis	rs5769707	0.837	rs1573726	ENSG00000188511.11	C22orf34	10.47	4.04e-23	4.49e-20	0.46	0.44	Monocyte percentage of white cells;Monocyte count;	chr22:49639224	chr22:49414524~49657542:-
PRAD	cis	rs6142102	0.961	rs6088355	ENSG00000276073.1	RP5-1125A11.7	-10.47	4.05e-23	4.5e-20	-0.45	-0.44	Skin pigmentation;	chr20:33958081	chr20:33985617~33988989:-
PRAD	cis	rs4380275	0.782	rs4854276	ENSG00000223751.1	AC116609.2	10.47	4.08e-23	4.53e-20	0.56	0.44	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:764357	chr2:742488~747767:+
PRAD	cis	rs1577917	1	rs34106666	ENSG00000203875.9	SNHG5	-10.47	4.09e-23	4.53e-20	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85966540	chr6:85660950~85678736:-
PRAD	cis	rs1577917	1	rs1337844	ENSG00000203875.9	SNHG5	-10.47	4.09e-23	4.53e-20	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85967555	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.958	rs884842	ENSG00000203875.9	SNHG5	-10.47	4.09e-23	4.53e-20	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85970679	chr6:85660950~85678736:-
PRAD	cis	rs853679	0.517	rs16893666	ENSG00000219392.1	RP1-265C24.5	10.47	4.12e-23	4.57e-20	0.57	0.44	Depression;	chr6:28086929	chr6:28115628~28116551:+
PRAD	cis	rs6452524	0.711	rs1478486	ENSG00000249664.1	CTD-2227C6.2	10.46	4.14e-23	4.59e-20	0.53	0.44	Hypertension (SNP x SNP interaction);	chr5:83081185	chr5:83012285~83013109:-
PRAD	cis	rs6570726	0.791	rs422099	ENSG00000235652.6	RP11-545I5.3	10.46	4.16e-23	4.61e-20	0.46	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145485800	chr6:145799409~145886585:+
PRAD	cis	rs875971	0.825	rs4587224	ENSG00000237310.1	GS1-124K5.4	-10.46	4.17e-23	4.62e-20	-0.41	-0.44	Aortic root size;	chr7:66271195	chr7:66493706~66495474:+
PRAD	cis	rs4713118	0.621	rs9295755	ENSG00000280107.1	AL022393.9	10.46	4.18e-23	4.64e-20	0.57	0.44	Parkinson's disease;	chr6:28065396	chr6:28170845~28172521:+
PRAD	cis	rs17023223	0.537	rs4508058	ENSG00000231365.4	RP11-418J17.1	-10.46	4.22e-23	4.68e-20	-0.45	-0.44	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119141627	chr1:119140396~119275973:+
PRAD	cis	rs9322193	0.607	rs9322229	ENSG00000268592.3	RAET1E-AS1	10.46	4.25e-23	4.7e-20	0.68	0.44	Lung cancer;	chr6:149908949	chr6:149863494~149919507:+
PRAD	cis	rs3762637	0.943	rs28403550	ENSG00000272758.4	RP11-299J3.8	-10.46	4.25e-23	4.7e-20	-0.64	-0.44	LDL cholesterol levels;	chr3:122532991	chr3:122416207~122443180:+
PRAD	cis	rs34779708	0.931	rs7908573	ENSG00000230534.5	RP11-297A16.2	10.46	4.26e-23	4.72e-20	0.59	0.44	Inflammatory bowel disease;Crohn's disease;	chr10:35020585	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.931	rs17583009	ENSG00000230534.5	RP11-297A16.2	10.46	4.26e-23	4.72e-20	0.59	0.44	Inflammatory bowel disease;Crohn's disease;	chr10:35031987	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.898	rs11595898	ENSG00000230534.5	RP11-297A16.2	10.46	4.26e-23	4.72e-20	0.59	0.44	Inflammatory bowel disease;Crohn's disease;	chr10:35037335	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.931	rs35886556	ENSG00000230534.5	RP11-297A16.2	10.46	4.26e-23	4.72e-20	0.59	0.44	Inflammatory bowel disease;Crohn's disease;	chr10:35046057	chr10:35098006~35127020:-
PRAD	cis	rs3762637	1	rs9867429	ENSG00000272758.4	RP11-299J3.8	-10.46	4.27e-23	4.72e-20	-0.64	-0.44	LDL cholesterol levels;	chr3:122513821	chr3:122416207~122443180:+
PRAD	cis	rs3762637	0.823	rs59569049	ENSG00000272758.4	RP11-299J3.8	-10.46	4.27e-23	4.72e-20	-0.64	-0.44	LDL cholesterol levels;	chr3:122519941	chr3:122416207~122443180:+
PRAD	cis	rs2348418	0.864	rs11049580	ENSG00000247934.4	RP11-967K21.1	10.46	4.29e-23	4.74e-20	0.4	0.44	Lung function (FEV1);Lung function (FVC);	chr12:28414696	chr12:28163298~28190738:-
PRAD	cis	rs1577917	0.958	rs13207354	ENSG00000203875.9	SNHG5	-10.46	4.29e-23	4.75e-20	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85990545	chr6:85660950~85678736:-
PRAD	cis	rs1577917	1	rs12204365	ENSG00000203875.9	SNHG5	-10.46	4.29e-23	4.75e-20	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85990814	chr6:85660950~85678736:-
PRAD	cis	rs1577917	1	rs12663651	ENSG00000203875.9	SNHG5	-10.46	4.29e-23	4.75e-20	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85991937	chr6:85660950~85678736:-
PRAD	cis	rs2658782	0.724	rs1563445	ENSG00000279684.1	RP11-755E23.2	-10.46	4.37e-23	4.83e-20	-0.71	-0.44	Pulmonary function decline;	chr11:93512876	chr11:93286629~93288903:-
PRAD	cis	rs7569084	0.687	rs963539	ENSG00000204929.10	AC074391.1	-10.46	4.37e-23	4.84e-20	-0.6	-0.44	Sum eosinophil basophil counts;	chr2:65421413	chr2:65436711~66084639:+
PRAD	cis	rs2283792	0.715	rs56036797	ENSG00000224086.5	LL22NC03-86G7.1	-10.46	4.37e-23	4.84e-20	-0.53	-0.44	Multiple sclerosis;	chr22:21860875	chr22:21938293~21977632:+
PRAD	cis	rs6142102	0.961	rs6120519	ENSG00000276073.1	RP5-1125A11.7	-10.46	4.39e-23	4.85e-20	-0.44	-0.44	Skin pigmentation;	chr20:34100307	chr20:33985617~33988989:-
PRAD	cis	rs4722166	0.695	rs6946509	ENSG00000179428.2	AC073072.5	-10.46	4.41e-23	4.88e-20	-0.51	-0.44	Lung cancer;	chr7:22769871	chr7:22725395~22727620:-
PRAD	cis	rs34779708	0.966	rs11010135	ENSG00000230534.5	RP11-297A16.2	10.46	4.46e-23	4.93e-20	0.6	0.44	Inflammatory bowel disease;Crohn's disease;	chr10:35229135	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.897	rs4934527	ENSG00000230534.5	RP11-297A16.2	10.46	4.46e-23	4.93e-20	0.58	0.44	Inflammatory bowel disease;Crohn's disease;	chr10:34992190	chr10:35098006~35127020:-
PRAD	cis	rs732716	0.785	rs56033249	ENSG00000267980.1	AC007292.6	-10.46	4.49e-23	4.96e-20	-0.47	-0.44	Mean corpuscular volume;	chr19:4369450	chr19:4363789~4364640:+
PRAD	cis	rs2348418	0.798	rs11049546	ENSG00000247934.4	RP11-967K21.1	10.46	4.49e-23	4.96e-20	0.4	0.44	Lung function (FEV1);Lung function (FVC);	chr12:28346942	chr12:28163298~28190738:-
PRAD	cis	rs2658782	0.724	rs2658769	ENSG00000279684.1	RP11-755E23.2	-10.45	4.5e-23	4.98e-20	-0.7	-0.44	Pulmonary function decline;	chr11:93518864	chr11:93286629~93288903:-
PRAD	cis	rs2882667	0.638	rs2351905	ENSG00000253404.1	AC034243.1	10.45	4.51e-23	4.98e-20	0.58	0.44	Age-related hearing impairment (SNP x SNP interaction);	chr5:139135641	chr5:138744434~138753309:-
PRAD	cis	rs34375054	0.525	rs7136220	ENSG00000279233.1	RP11-158L12.4	10.45	4.52e-23	4.99e-20	0.41	0.44	Post bronchodilator FEV1/FVC ratio;	chr12:125118138	chr12:125138245~125141711:+
PRAD	cis	rs7772486	0.692	rs1577916	ENSG00000235652.6	RP11-545I5.3	-10.45	4.52e-23	5e-20	-0.45	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145748653	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.72	rs7752286	ENSG00000235652.6	RP11-545I5.3	-10.45	4.52e-23	5e-20	-0.45	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145751526	chr6:145799409~145886585:+
PRAD	cis	rs34779708	0.931	rs35848945	ENSG00000230534.5	RP11-297A16.2	10.45	4.55e-23	5.03e-20	0.59	0.44	Inflammatory bowel disease;Crohn's disease;	chr10:34998633	chr10:35098006~35127020:-
PRAD	cis	rs8062405	0.964	rs12448902	ENSG00000251417.2	RP11-1348G14.4	-10.45	4.56e-23	5.04e-20	-0.52	-0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859870	chr16:28802743~28817828:+
PRAD	cis	rs7772486	0.79	rs2254283	ENSG00000235652.6	RP11-545I5.3	10.45	4.57e-23	5.04e-20	0.46	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145883153	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.79	rs1062067	ENSG00000235652.6	RP11-545I5.3	10.45	4.57e-23	5.04e-20	0.46	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145886427	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.79	rs2256998	ENSG00000235652.6	RP11-545I5.3	10.45	4.57e-23	5.04e-20	0.46	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145886521	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.79	rs2814880	ENSG00000235652.6	RP11-545I5.3	10.45	4.57e-23	5.04e-20	0.46	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145887801	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.79	rs2265917	ENSG00000235652.6	RP11-545I5.3	10.45	4.57e-23	5.04e-20	0.46	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145891149	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.79	rs2265469	ENSG00000235652.6	RP11-545I5.3	10.45	4.57e-23	5.04e-20	0.46	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145897913	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.79	rs2265918	ENSG00000235652.6	RP11-545I5.3	10.45	4.57e-23	5.04e-20	0.46	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145898028	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.79	rs2265472	ENSG00000235652.6	RP11-545I5.3	10.45	4.57e-23	5.04e-20	0.46	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145899622	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.79	rs2265919	ENSG00000235652.6	RP11-545I5.3	10.45	4.57e-23	5.04e-20	0.46	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145900617	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.79	rs9403755	ENSG00000235652.6	RP11-545I5.3	-10.45	4.57e-23	5.04e-20	-0.46	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145910334	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.79	rs4435956	ENSG00000235652.6	RP11-545I5.3	-10.45	4.57e-23	5.04e-20	-0.46	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145911267	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.79	rs6926076	ENSG00000235652.6	RP11-545I5.3	-10.45	4.57e-23	5.04e-20	-0.46	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145911668	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.79	rs6917482	ENSG00000235652.6	RP11-545I5.3	-10.45	4.57e-23	5.04e-20	-0.46	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145922445	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.754	rs4566902	ENSG00000235652.6	RP11-545I5.3	-10.45	4.57e-23	5.04e-20	-0.46	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145922992	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.79	rs9376971	ENSG00000235652.6	RP11-545I5.3	-10.45	4.57e-23	5.04e-20	-0.46	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145938369	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.79	rs4314514	ENSG00000235652.6	RP11-545I5.3	-10.45	4.57e-23	5.04e-20	-0.46	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145938874	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.72	rs9403757	ENSG00000235652.6	RP11-545I5.3	-10.45	4.57e-23	5.04e-20	-0.46	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145940135	chr6:145799409~145886585:+
PRAD	cis	rs9322193	0.962	rs12175575	ENSG00000268592.3	RAET1E-AS1	10.45	4.58e-23	5.05e-20	0.61	0.44	Lung cancer;	chr6:149763351	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.962	rs4869966	ENSG00000268592.3	RAET1E-AS1	10.45	4.58e-23	5.05e-20	0.61	0.44	Lung cancer;	chr6:149763714	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.962	rs1112730	ENSG00000268592.3	RAET1E-AS1	10.45	4.58e-23	5.05e-20	0.61	0.44	Lung cancer;	chr6:149766383	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.923	rs1112729	ENSG00000268592.3	RAET1E-AS1	10.45	4.58e-23	5.05e-20	0.61	0.44	Lung cancer;	chr6:149766491	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.962	rs10452626	ENSG00000268592.3	RAET1E-AS1	10.45	4.58e-23	5.05e-20	0.61	0.44	Lung cancer;	chr6:149767481	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.923	rs62441303	ENSG00000268592.3	RAET1E-AS1	10.45	4.58e-23	5.05e-20	0.61	0.44	Lung cancer;	chr6:149767547	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.962	rs9765929	ENSG00000268592.3	RAET1E-AS1	10.45	4.58e-23	5.05e-20	0.61	0.44	Lung cancer;	chr6:149769680	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.962	rs3805748	ENSG00000268592.3	RAET1E-AS1	10.45	4.58e-23	5.05e-20	0.61	0.44	Lung cancer;	chr6:149772542	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.736	rs10457851	ENSG00000268592.3	RAET1E-AS1	10.45	4.58e-23	5.05e-20	0.61	0.44	Lung cancer;	chr6:149775216	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.886	rs10872652	ENSG00000268592.3	RAET1E-AS1	10.45	4.58e-23	5.05e-20	0.61	0.44	Lung cancer;	chr6:149775303	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.886	rs12525871	ENSG00000268592.3	RAET1E-AS1	10.45	4.58e-23	5.05e-20	0.61	0.44	Lung cancer;	chr6:149775882	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.886	rs17672976	ENSG00000268592.3	RAET1E-AS1	10.45	4.58e-23	5.05e-20	0.61	0.44	Lung cancer;	chr6:149776207	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.923	rs2184369	ENSG00000268592.3	RAET1E-AS1	10.45	4.58e-23	5.05e-20	0.61	0.44	Lung cancer;	chr6:149776681	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.962	rs2342861	ENSG00000268592.3	RAET1E-AS1	10.45	4.58e-23	5.05e-20	0.61	0.44	Lung cancer;	chr6:149777561	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.926	rs2342860	ENSG00000268592.3	RAET1E-AS1	10.45	4.58e-23	5.05e-20	0.61	0.44	Lung cancer;	chr6:149777641	chr6:149863494~149919507:+
PRAD	cis	rs6860806	0.507	rs272872	ENSG00000233006.5	AC034220.3	-10.45	4.58e-23	5.05e-20	-0.41	-0.44	Breast cancer;	chr5:132340171	chr5:132311285~132369916:-
PRAD	cis	rs2919917	0.628	rs4739135	ENSG00000254352.1	RP11-578O24.2	10.45	4.66e-23	5.14e-20	0.57	0.44	Lymphocyte counts;	chr8:78656057	chr8:78723796~78724136:-
PRAD	cis	rs4722166	0.695	rs7793125	ENSG00000179428.2	AC073072.5	-10.45	4.67e-23	5.15e-20	-0.51	-0.44	Lung cancer;	chr7:22769541	chr7:22725395~22727620:-
PRAD	cis	rs2348418	0.966	rs11049694	ENSG00000247934.4	RP11-967K21.1	10.45	4.7e-23	5.18e-20	0.41	0.44	Lung function (FEV1);Lung function (FVC);	chr12:28527925	chr12:28163298~28190738:-
PRAD	cis	rs2739330	0.828	rs4822454	ENSG00000272787.1	KB-226F1.2	-10.45	4.75e-23	5.23e-20	-0.48	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23969211~23969873:+
PRAD	cis	rs9322193	0.607	rs9371228	ENSG00000223701.3	RAET1E-AS1	-10.45	4.75e-23	5.24e-20	-0.67	-0.44	Lung cancer;	chr6:149921977	chr6:149884431~149919508:+
PRAD	cis	rs1577917	1	rs884841	ENSG00000203875.9	SNHG5	-10.45	4.76e-23	5.24e-20	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85970582	chr6:85660950~85678736:-
PRAD	cis	rs853679	0.517	rs4713135	ENSG00000280107.1	AL022393.9	-10.45	4.84e-23	5.33e-20	-0.58	-0.44	Depression;	chr6:28071808	chr6:28170845~28172521:+
PRAD	cis	rs875971	0.862	rs4236208	ENSG00000237310.1	GS1-124K5.4	-10.45	4.84e-23	5.33e-20	-0.41	-0.44	Aortic root size;	chr7:66284091	chr7:66493706~66495474:+
PRAD	cis	rs11951515	0.738	rs12514393	ENSG00000188850.9	RP11-159F24.2	10.45	4.85e-23	5.34e-20	0.52	0.44	Metabolite levels  (X-11787);	chr5:43313429	chr5:43336164~43348716:+
PRAD	cis	rs17023223	0.581	rs11811859	ENSG00000231365.4	RP11-418J17.1	-10.44	4.92e-23	5.41e-20	-0.45	-0.44	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119165057	chr1:119140396~119275973:+
PRAD	cis	rs2282300	1	rs12575085	ENSG00000242353.1	RP4-710M3.1	-10.44	4.93e-23	5.43e-20	-0.5	-0.44	Morning vs. evening chronotype;	chr11:30406715	chr11:30368148~30368646:+
PRAD	cis	rs6570726	0.791	rs621382	ENSG00000235652.6	RP11-545I5.3	10.44	4.94e-23	5.43e-20	0.46	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145478008	chr6:145799409~145886585:+
PRAD	cis	rs2283792	0.74	rs11912377	ENSG00000224086.5	LL22NC03-86G7.1	-10.44	4.94e-23	5.44e-20	-0.53	-0.44	Multiple sclerosis;	chr22:21864332	chr22:21938293~21977632:+
PRAD	cis	rs6142102	0.961	rs6119447	ENSG00000276073.1	RP5-1125A11.7	-10.44	4.95e-23	5.44e-20	-0.44	-0.44	Skin pigmentation;	chr20:34080770	chr20:33985617~33988989:-
PRAD	cis	rs9322193	0.851	rs9322194	ENSG00000268592.3	RAET1E-AS1	10.44	4.96e-23	5.46e-20	0.62	0.44	Lung cancer;	chr6:149599113	chr6:149863494~149919507:+
PRAD	cis	rs853679	0.517	rs9468297	ENSG00000219392.1	RP1-265C24.5	-10.44	4.98e-23	5.48e-20	-0.57	-0.44	Depression;	chr6:28151096	chr6:28115628~28116551:+
PRAD	cis	rs7772486	0.79	rs3923579	ENSG00000235652.6	RP11-545I5.3	-10.44	4.98e-23	5.48e-20	-0.46	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145909096	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.79	rs3924498	ENSG00000235652.6	RP11-545I5.3	-10.44	4.98e-23	5.48e-20	-0.46	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145912202	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.79	rs9390365	ENSG00000235652.6	RP11-545I5.3	-10.44	4.98e-23	5.48e-20	-0.46	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145914490	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.79	rs6923545	ENSG00000235652.6	RP11-545I5.3	-10.44	4.98e-23	5.48e-20	-0.46	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145923607	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.754	rs6922507	ENSG00000235652.6	RP11-545I5.3	-10.44	4.98e-23	5.48e-20	-0.46	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145929019	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.79	rs4075694	ENSG00000235652.6	RP11-545I5.3	-10.44	4.98e-23	5.48e-20	-0.46	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145929972	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.754	rs9497434	ENSG00000235652.6	RP11-545I5.3	-10.44	4.98e-23	5.48e-20	-0.46	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145939617	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.79	rs6924159	ENSG00000235652.6	RP11-545I5.3	-10.44	4.98e-23	5.48e-20	-0.46	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145946737	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.79	rs2254257	ENSG00000235652.6	RP11-545I5.3	10.44	4.98e-23	5.48e-20	0.46	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145882588	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.79	rs1062068	ENSG00000235652.6	RP11-545I5.3	10.44	4.98e-23	5.48e-20	0.46	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145886329	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.79	rs2247429	ENSG00000235652.6	RP11-545I5.3	10.44	4.98e-23	5.48e-20	0.46	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145896633	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.79	rs2247666	ENSG00000235652.6	RP11-545I5.3	10.44	4.98e-23	5.48e-20	0.46	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145899273	chr6:145799409~145886585:+
PRAD	cis	rs1577917	1	rs12207610	ENSG00000203875.9	SNHG5	-10.44	5.03e-23	5.53e-20	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85978298	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.958	rs12203457	ENSG00000203875.9	SNHG5	-10.44	5.03e-23	5.53e-20	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85979559	chr6:85660950~85678736:-
PRAD	cis	rs4713118	0.662	rs156744	ENSG00000280107.1	AL022393.9	-10.44	5.06e-23	5.57e-20	-0.57	-0.44	Parkinson's disease;	chr6:27999496	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.662	rs149947	ENSG00000280107.1	AL022393.9	-10.44	5.08e-23	5.58e-20	-0.57	-0.44	Parkinson's disease;	chr6:28004655	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.662	rs149969	ENSG00000280107.1	AL022393.9	-10.44	5.08e-23	5.58e-20	-0.57	-0.44	Parkinson's disease;	chr6:28009959	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.662	rs149946	ENSG00000280107.1	AL022393.9	10.44	5.08e-23	5.58e-20	0.57	0.44	Parkinson's disease;	chr6:28002253	chr6:28170845~28172521:+
PRAD	cis	rs7772486	0.754	rs702318	ENSG00000235652.6	RP11-545I5.3	-10.44	5.08e-23	5.58e-20	-0.46	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145684737	chr6:145799409~145886585:+
PRAD	cis	rs3762637	1	rs7615673	ENSG00000272758.4	RP11-299J3.8	-10.44	5.1e-23	5.61e-20	-0.66	-0.44	LDL cholesterol levels;	chr3:122406697	chr3:122416207~122443180:+
PRAD	cis	rs9322193	0.884	rs11155675	ENSG00000216906.2	RP11-350J20.9	10.44	5.15e-23	5.66e-20	0.51	0.44	Lung cancer;	chr6:149742883	chr6:149904243~149906418:+
PRAD	cis	rs1577917	1	rs6936048	ENSG00000203875.9	SNHG5	-10.44	5.17e-23	5.68e-20	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85992890	chr6:85660950~85678736:-
PRAD	cis	rs1150668	0.764	rs9368565	ENSG00000204709.4	LINC01556	-10.44	5.21e-23	5.71e-20	-0.56	-0.44	Pubertal anthropometrics;	chr6:28377433	chr6:28943877~28944537:+
PRAD	cis	rs1150668	0.796	rs1052215	ENSG00000204709.4	LINC01556	-10.44	5.21e-23	5.71e-20	-0.56	-0.44	Pubertal anthropometrics;	chr6:28380381	chr6:28943877~28944537:+
PRAD	cis	rs6142102	0.961	rs6120487	ENSG00000276073.1	RP5-1125A11.7	-10.44	5.22e-23	5.73e-20	-0.44	-0.44	Skin pigmentation;	chr20:34034802	chr20:33985617~33988989:-
PRAD	cis	rs6142102	0.812	rs6059558	ENSG00000276073.1	RP5-1125A11.7	-10.44	5.28e-23	5.8e-20	-0.45	-0.44	Skin pigmentation;	chr20:33929024	chr20:33985617~33988989:-
PRAD	cis	rs9322193	0.886	rs9767555	ENSG00000268592.3	RAET1E-AS1	10.44	5.29e-23	5.8e-20	0.61	0.44	Lung cancer;	chr6:149647022	chr6:149863494~149919507:+
PRAD	cis	rs1891275	0.515	rs7911755	ENSG00000228701.1	TNKS2-AS1	-10.44	5.29e-23	5.8e-20	-0.55	-0.44	Intelligence (multi-trait analysis);	chr10:91730060	chr10:91782839~91798291:-
PRAD	cis	rs2919917	0.628	rs6990105	ENSG00000254352.1	RP11-578O24.2	10.44	5.29e-23	5.81e-20	0.59	0.44	Lymphocyte counts;	chr8:78689652	chr8:78723796~78724136:-
PRAD	cis	rs4964805	0.58	rs1866292	ENSG00000257681.1	RP11-341G23.4	10.43	5.35e-23	5.87e-20	0.42	0.44	Attention deficit hyperactivity disorder;	chr12:103780414	chr12:103746315~103768858:-
PRAD	cis	rs34779708	0.931	rs13376871	ENSG00000230534.5	RP11-297A16.2	10.43	5.35e-23	5.87e-20	0.57	0.44	Inflammatory bowel disease;Crohn's disease;	chr10:35080128	chr10:35098006~35127020:-
PRAD	cis	rs8072100	0.713	rs2292346	ENSG00000228782.6	CTD-2026D20.3	10.43	5.37e-23	5.89e-20	0.5	0.44	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47378107	chr17:47450568~47492492:-
PRAD	cis	rs9322193	0.886	rs9718079	ENSG00000216906.2	RP11-350J20.9	10.43	5.38e-23	5.9e-20	0.51	0.44	Lung cancer;	chr6:149645947	chr6:149904243~149906418:+
PRAD	cis	rs11951515	0.7	rs1545753	ENSG00000188850.9	RP11-159F24.2	10.43	5.39e-23	5.92e-20	0.52	0.44	Metabolite levels  (X-11787);	chr5:43288264	chr5:43336164~43348716:+
PRAD	cis	rs1577917	0.958	rs4707229	ENSG00000203875.9	SNHG5	-10.43	5.4e-23	5.92e-20	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85836519	chr6:85660950~85678736:-
PRAD	cis	rs9322193	0.962	rs9689447	ENSG00000268592.3	RAET1E-AS1	10.43	5.4e-23	5.92e-20	0.61	0.44	Lung cancer;	chr6:149789350	chr6:149863494~149919507:+
PRAD	cis	rs6860806	0.507	rs270608	ENSG00000233006.5	AC034220.3	10.43	5.4e-23	5.92e-20	0.41	0.44	Breast cancer;	chr5:132312713	chr5:132311285~132369916:-
PRAD	cis	rs17023223	0.537	rs12085308	ENSG00000231365.4	RP11-418J17.1	-10.43	5.44e-23	5.97e-20	-0.45	-0.44	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119134930	chr1:119140396~119275973:+
PRAD	cis	rs7772486	0.719	rs7753770	ENSG00000235652.6	RP11-545I5.3	-10.43	5.45e-23	5.98e-20	-0.45	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145745025	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.655	rs2142981	ENSG00000235652.6	RP11-545I5.3	-10.43	5.45e-23	5.98e-20	-0.45	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145750559	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.72	rs6570713	ENSG00000235652.6	RP11-545I5.3	-10.43	5.45e-23	5.98e-20	-0.45	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145753949	chr6:145799409~145886585:+
PRAD	cis	rs1150668	0.796	rs213237	ENSG00000204709.4	LINC01556	10.43	5.47e-23	6e-20	0.54	0.44	Pubertal anthropometrics;	chr6:28356161	chr6:28943877~28944537:+
PRAD	cis	rs6860806	0.507	rs272854	ENSG00000233006.5	AC034220.3	10.43	5.48e-23	6.01e-20	0.41	0.44	Breast cancer;	chr5:132352324	chr5:132311285~132369916:-
PRAD	cis	rs7615952	0.673	rs35001498	ENSG00000171084.14	FAM86JP	10.43	5.49e-23	6.02e-20	0.84	0.44	Blood pressure (smoking interaction);	chr3:125909801	chr3:125916620~125930024:+
PRAD	cis	rs6860806	0.507	rs272892	ENSG00000233006.5	AC034220.3	10.43	5.55e-23	6.08e-20	0.41	0.44	Breast cancer;	chr5:132328656	chr5:132311285~132369916:-
PRAD	cis	rs6860806	0.531	rs272888	ENSG00000233006.5	AC034220.3	10.43	5.55e-23	6.08e-20	0.41	0.44	Breast cancer;	chr5:132329730	chr5:132311285~132369916:-
PRAD	cis	rs9322193	0.962	rs9397022	ENSG00000268592.3	RAET1E-AS1	10.43	5.55e-23	6.08e-20	0.6	0.44	Lung cancer;	chr6:149812052	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.962	rs9397357	ENSG00000268592.3	RAET1E-AS1	10.43	5.55e-23	6.08e-20	0.6	0.44	Lung cancer;	chr6:149812465	chr6:149863494~149919507:+
PRAD	cis	rs732716	0.785	rs11085073	ENSG00000267980.1	AC007292.6	10.43	5.56e-23	6.09e-20	0.46	0.44	Mean corpuscular volume;	chr19:4375165	chr19:4363789~4364640:+
PRAD	cis	rs3762637	1	rs10934602	ENSG00000272758.4	RP11-299J3.8	10.43	5.56e-23	6.1e-20	0.64	0.44	LDL cholesterol levels;	chr3:122504335	chr3:122416207~122443180:+
PRAD	cis	rs2348418	0.966	rs7316797	ENSG00000247934.4	RP11-967K21.1	10.43	5.57e-23	6.11e-20	0.4	0.44	Lung function (FEV1);Lung function (FVC);	chr12:28529776	chr12:28163298~28190738:-
PRAD	cis	rs9322193	0.566	rs3922947	ENSG00000223701.3	RAET1E-AS1	-10.43	5.58e-23	6.11e-20	-0.66	-0.44	Lung cancer;	chr6:149924856	chr6:149884431~149919508:+
PRAD	cis	rs4380275	0.809	rs6753699	ENSG00000272342.1	RP13-539J13.1	10.43	5.6e-23	6.13e-20	0.56	0.44	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:766081	chr2:739588~740164:-
PRAD	cis	rs748404	0.604	rs2278857	ENSG00000205771.5	CATSPER2P1	-10.43	5.62e-23	6.16e-20	-0.49	-0.44	Lung cancer;	chr15:43340351	chr15:43726918~43747094:-
PRAD	cis	rs1891275	0.508	rs2096079	ENSG00000228701.1	TNKS2-AS1	-10.43	5.64e-23	6.18e-20	-0.55	-0.44	Intelligence (multi-trait analysis);	chr10:91736910	chr10:91782839~91798291:-
PRAD	cis	rs5769707	0.872	rs5770604	ENSG00000188511.11	C22orf34	10.43	5.64e-23	6.18e-20	0.46	0.44	Monocyte percentage of white cells;Monocyte count;	chr22:49637024	chr22:49414524~49657542:-
PRAD	cis	rs2348418	0.831	rs2348416	ENSG00000247934.4	RP11-967K21.1	10.43	5.67e-23	6.21e-20	0.41	0.44	Lung function (FEV1);Lung function (FVC);	chr12:28556283	chr12:28163298~28190738:-
PRAD	cis	rs6860806	0.507	rs270601	ENSG00000233006.5	AC034220.3	10.43	5.69e-23	6.23e-20	0.41	0.44	Breast cancer;	chr5:132321304	chr5:132311285~132369916:-
PRAD	cis	rs270601	0.913	rs273916	ENSG00000233006.5	AC034220.3	10.43	5.69e-23	6.23e-20	0.41	0.44	Acylcarnitine levels;	chr5:132324137	chr5:132311285~132369916:-
PRAD	cis	rs6860806	0.507	rs273915	ENSG00000233006.5	AC034220.3	10.43	5.69e-23	6.23e-20	0.41	0.44	Breast cancer;	chr5:132324426	chr5:132311285~132369916:-
PRAD	cis	rs6700559	1	rs10800720	ENSG00000260088.1	RP11-92G12.3	-10.43	5.69e-23	6.23e-20	-0.56	-0.44	Coronary artery disease;	chr1:200679441	chr1:200669507~200694250:+
PRAD	cis	rs6700559	0.935	rs4072553	ENSG00000260088.1	RP11-92G12.3	-10.43	5.69e-23	6.23e-20	-0.56	-0.44	Coronary artery disease;	chr1:200680036	chr1:200669507~200694250:+
PRAD	cis	rs6142102	0.961	rs2300204	ENSG00000276073.1	RP5-1125A11.7	-10.43	5.7e-23	6.23e-20	-0.44	-0.44	Skin pigmentation;	chr20:34000967	chr20:33985617~33988989:-
PRAD	cis	rs875971	0.862	rs28491091	ENSG00000237310.1	GS1-124K5.4	-10.43	5.77e-23	6.32e-20	-0.41	-0.44	Aortic root size;	chr7:66204077	chr7:66493706~66495474:+
PRAD	cis	rs9322193	0.962	rs4552	ENSG00000223701.3	RAET1E-AS1	10.43	5.8e-23	6.34e-20	0.59	0.44	Lung cancer;	chr6:149811183	chr6:149884431~149919508:+
PRAD	cis	rs6142102	0.961	rs2268089	ENSG00000276073.1	RP5-1125A11.7	-10.42	5.85e-23	6.39e-20	-0.44	-0.44	Skin pigmentation;	chr20:34079492	chr20:33985617~33988989:-
PRAD	cis	rs2665103	0.589	rs2134046	ENSG00000278603.1	RP13-608F4.5	10.42	5.85e-23	6.39e-20	0.55	0.44	Intelligence (multi-trait analysis);	chr15:82232203	chr15:82472203~82472426:+
PRAD	cis	rs6860806	0.507	rs273901	ENSG00000233006.5	AC034220.3	10.42	5.85e-23	6.4e-20	0.41	0.44	Breast cancer;	chr5:132358667	chr5:132311285~132369916:-
PRAD	cis	rs6570726	0.764	rs366673	ENSG00000235652.6	RP11-545I5.3	10.42	5.86e-23	6.41e-20	0.46	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145493492	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.791	rs447992	ENSG00000235652.6	RP11-545I5.3	10.42	5.86e-23	6.41e-20	0.46	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145496048	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.791	rs425999	ENSG00000235652.6	RP11-545I5.3	10.42	5.86e-23	6.41e-20	0.46	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145498234	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.791	rs387376	ENSG00000235652.6	RP11-545I5.3	10.42	5.86e-23	6.41e-20	0.46	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145501429	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.764	rs1912023	ENSG00000235652.6	RP11-545I5.3	10.42	5.86e-23	6.41e-20	0.46	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145503142	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.791	rs9376945	ENSG00000235652.6	RP11-545I5.3	10.42	5.86e-23	6.41e-20	0.46	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145506944	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.755	rs451699	ENSG00000235652.6	RP11-545I5.3	10.42	5.86e-23	6.41e-20	0.46	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145509458	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.791	rs401561	ENSG00000235652.6	RP11-545I5.3	10.42	5.86e-23	6.41e-20	0.46	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145514781	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.791	rs405206	ENSG00000235652.6	RP11-545I5.3	10.42	5.86e-23	6.41e-20	0.46	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145515737	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.791	rs374478	ENSG00000235652.6	RP11-545I5.3	10.42	5.86e-23	6.41e-20	0.46	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145518886	chr6:145799409~145886585:+
PRAD	cis	rs34375054	0.525	rs7133006	ENSG00000279233.1	RP11-158L12.4	10.42	5.87e-23	6.41e-20	0.41	0.44	Post bronchodilator FEV1/FVC ratio;	chr12:125121577	chr12:125138245~125141711:+
PRAD	cis	rs34375054	0.525	rs7133864	ENSG00000279233.1	RP11-158L12.4	10.42	5.87e-23	6.41e-20	0.41	0.44	Post bronchodilator FEV1/FVC ratio;	chr12:125121634	chr12:125138245~125141711:+
PRAD	cis	rs2739330	0.76	rs1002286	ENSG00000224205.1	AP000351.4	-10.42	5.88e-23	6.42e-20	-0.54	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23987320~23991421:-
PRAD	cis	rs875971	0.755	rs10228885	ENSG00000237310.1	GS1-124K5.4	-10.42	5.99e-23	6.54e-20	-0.41	-0.44	Aortic root size;	chr7:66315542	chr7:66493706~66495474:+
PRAD	cis	rs7714584	0.793	rs12653039	ENSG00000197083.10	ZNF300P1	10.42	6e-23	6.55e-20	0.75	0.44	Crohn's disease;	chr5:150873069	chr5:150930645~150946289:-
PRAD	cis	rs6570726	0.791	rs407887	ENSG00000235652.6	RP11-545I5.3	10.42	6.02e-23	6.57e-20	0.46	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145522623	chr6:145799409~145886585:+
PRAD	cis	rs875971	0.895	rs6460278	ENSG00000237310.1	GS1-124K5.4	-10.42	6.03e-23	6.59e-20	-0.41	-0.44	Aortic root size;	chr7:66197749	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.862	rs6460279	ENSG00000237310.1	GS1-124K5.4	-10.42	6.03e-23	6.59e-20	-0.41	-0.44	Aortic root size;	chr7:66197774	chr7:66493706~66495474:+
PRAD	cis	rs2739330	0.828	rs2186366	ENSG00000272787.1	KB-226F1.2	10.42	6.07e-23	6.62e-20	0.48	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23969211~23969873:+
PRAD	cis	rs9322193	0.566	rs9397070	ENSG00000268592.3	RAET1E-AS1	-10.42	6.1e-23	6.65e-20	-0.69	-0.44	Lung cancer;	chr6:149922073	chr6:149863494~149919507:+
PRAD	cis	rs1577917	1	rs1018184	ENSG00000203875.9	SNHG5	10.42	6.11e-23	6.66e-20	0.49	0.44	Response to antipsychotic treatment;	chr6:85938757	chr6:85660950~85678736:-
PRAD	cis	rs2739330	0.791	rs4822458	ENSG00000206090.4	AP000350.7	10.42	6.17e-23	6.72e-20	0.55	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23939998~23942798:+
PRAD	cis	rs11951515	0.738	rs59814709	ENSG00000188850.9	RP11-159F24.2	10.42	6.18e-23	6.73e-20	0.52	0.44	Metabolite levels  (X-11787);	chr5:43359992	chr5:43336164~43348716:+
PRAD	cis	rs2348418	0.832	rs11049587	ENSG00000247934.4	RP11-967K21.1	10.42	6.19e-23	6.74e-20	0.4	0.44	Lung function (FEV1);Lung function (FVC);	chr12:28418090	chr12:28163298~28190738:-
PRAD	cis	rs17023223	0.537	rs12081198	ENSG00000231365.4	RP11-418J17.1	-10.42	6.2e-23	6.76e-20	-0.45	-0.44	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119143481	chr1:119140396~119275973:+
PRAD	cis	rs17023223	0.537	rs12081327	ENSG00000231365.4	RP11-418J17.1	-10.42	6.2e-23	6.76e-20	-0.45	-0.44	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119143735	chr1:119140396~119275973:+
PRAD	cis	rs17023223	0.537	rs12086686	ENSG00000231365.4	RP11-418J17.1	-10.42	6.2e-23	6.76e-20	-0.45	-0.44	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119146461	chr1:119140396~119275973:+
PRAD	cis	rs17023223	0.537	rs12085616	ENSG00000231365.4	RP11-418J17.1	-10.42	6.2e-23	6.76e-20	-0.45	-0.44	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119146525	chr1:119140396~119275973:+
PRAD	cis	rs2442825	0.693	rs2258768	ENSG00000206573.7	THUMPD3-AS1	10.42	6.2e-23	6.76e-20	0.32	0.44	Cerebrospinal fluid clusterin levels;	chr3:9363193	chr3:9349689~9398579:-
PRAD	cis	rs6991838	0.584	rs6991731	ENSG00000272010.1	CTD-3025N20.3	10.42	6.23e-23	6.79e-20	0.46	0.44	Intelligence (multi-trait analysis);	chr8:65643232	chr8:65591850~65592472:-
PRAD	cis	rs9322193	0.962	rs7818	ENSG00000268592.3	RAET1E-AS1	10.42	6.25e-23	6.81e-20	0.6	0.44	Lung cancer;	chr6:149810956	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.884	rs11155689	ENSG00000268592.3	RAET1E-AS1	10.42	6.26e-23	6.82e-20	0.61	0.44	Lung cancer;	chr6:149808470	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.923	rs2342857	ENSG00000268592.3	RAET1E-AS1	10.42	6.26e-23	6.82e-20	0.61	0.44	Lung cancer;	chr6:149809537	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.884	rs933055	ENSG00000268592.3	RAET1E-AS1	10.42	6.26e-23	6.82e-20	0.61	0.44	Lung cancer;	chr6:149809701	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.962	rs4869731	ENSG00000268592.3	RAET1E-AS1	10.42	6.26e-23	6.82e-20	0.61	0.44	Lung cancer;	chr6:149810072	chr6:149863494~149919507:+
PRAD	cis	rs13392177	0.684	rs11695527	ENSG00000261338.2	RP11-378A13.1	10.42	6.27e-23	6.83e-20	0.49	0.44	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218203380	chr2:218255319~218257366:+
PRAD	cis	rs494459	0.536	rs10790267	ENSG00000255239.1	AP002954.6	10.42	6.27e-23	6.83e-20	0.57	0.44	Height;	chr11:118856460	chr11:118688039~118690600:-
PRAD	cis	rs494459	0.536	rs11217067	ENSG00000255239.1	AP002954.6	10.42	6.27e-23	6.83e-20	0.57	0.44	Height;	chr11:118856623	chr11:118688039~118690600:-
PRAD	cis	rs2510897	0.675	rs4936442	ENSG00000255239.1	AP002954.6	10.42	6.27e-23	6.83e-20	0.57	0.44	Height;	chr11:118857611	chr11:118688039~118690600:-
PRAD	cis	rs11951515	0.646	rs58102827	ENSG00000188850.9	RP11-159F24.2	10.41	6.32e-23	6.88e-20	0.52	0.44	Metabolite levels  (X-11787);	chr5:43331514	chr5:43336164~43348716:+
PRAD	cis	rs1577917	0.958	rs67024565	ENSG00000203875.9	SNHG5	-10.41	6.33e-23	6.89e-20	-0.53	-0.44	Response to antipsychotic treatment;	chr6:85844279	chr6:85660950~85678736:-
PRAD	cis	rs4718428	0.672	rs36038499	ENSG00000273142.1	RP11-458F8.4	-10.41	6.35e-23	6.92e-20	-0.34	-0.44	Corneal structure;	chr7:66824628	chr7:66902857~66906297:+
PRAD	cis	rs4718428	0.705	rs62465692	ENSG00000273142.1	RP11-458F8.4	-10.41	6.35e-23	6.92e-20	-0.34	-0.44	Corneal structure;	chr7:66830758	chr7:66902857~66906297:+
PRAD	cis	rs4718428	0.662	rs34577323	ENSG00000273142.1	RP11-458F8.4	-10.41	6.35e-23	6.92e-20	-0.34	-0.44	Corneal structure;	chr7:66845054	chr7:66902857~66906297:+
PRAD	cis	rs9487094	0.665	rs13207864	ENSG00000260273.1	RP11-425D10.10	10.41	6.36e-23	6.92e-20	0.65	0.44	Height;	chr6:109708527	chr6:109382795~109383666:+
PRAD	cis	rs9487094	0.553	rs11968891	ENSG00000260273.1	RP11-425D10.10	10.41	6.4e-23	6.96e-20	0.67	0.44	Height;	chr6:109548647	chr6:109382795~109383666:+
PRAD	cis	rs11951515	0.7	rs10941620	ENSG00000188850.9	RP11-159F24.2	10.41	6.44e-23	7.01e-20	0.52	0.44	Metabolite levels  (X-11787);	chr5:43283594	chr5:43336164~43348716:+
PRAD	cis	rs9322193	0.884	rs11155689	ENSG00000223701.3	RAET1E-AS1	10.41	6.45e-23	7.02e-20	0.59	0.44	Lung cancer;	chr6:149808470	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.923	rs2342857	ENSG00000223701.3	RAET1E-AS1	10.41	6.45e-23	7.02e-20	0.59	0.44	Lung cancer;	chr6:149809537	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.884	rs933055	ENSG00000223701.3	RAET1E-AS1	10.41	6.45e-23	7.02e-20	0.59	0.44	Lung cancer;	chr6:149809701	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.962	rs4869731	ENSG00000223701.3	RAET1E-AS1	10.41	6.45e-23	7.02e-20	0.59	0.44	Lung cancer;	chr6:149810072	chr6:149884431~149919508:+
PRAD	cis	rs4718428	0.705	rs2901311	ENSG00000232546.1	RP11-458F8.1	-10.41	6.46e-23	7.02e-20	-0.36	-0.44	Corneal structure;	chr7:66950082	chr7:66848496~66858136:+
PRAD	cis	rs11118620	0.622	rs11118618	ENSG00000238078.1	LINC01352	10.41	6.46e-23	7.03e-20	0.66	0.44	Heart failure;	chr1:220838204	chr1:220829255~220832429:+
PRAD	cis	rs17023223	0.537	rs3934789	ENSG00000231365.4	RP11-418J17.1	-10.41	6.47e-23	7.04e-20	-0.45	-0.44	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119140440	chr1:119140396~119275973:+
PRAD	cis	rs9322193	0.962	rs13215691	ENSG00000216906.2	RP11-350J20.9	10.41	6.48e-23	7.05e-20	0.5	0.44	Lung cancer;	chr6:149792666	chr6:149904243~149906418:+
PRAD	cis	rs875971	0.862	rs709609	ENSG00000237310.1	GS1-124K5.4	-10.41	6.48e-23	7.05e-20	-0.41	-0.44	Aortic root size;	chr7:66095574	chr7:66493706~66495474:+
PRAD	cis	rs6142102	0.961	rs2056990	ENSG00000276073.1	RP5-1125A11.7	-10.41	6.5e-23	7.07e-20	-0.46	-0.44	Skin pigmentation;	chr20:34035658	chr20:33985617~33988989:-
PRAD	cis	rs875971	0.862	rs2901152	ENSG00000237310.1	GS1-124K5.4	-10.41	6.51e-23	7.09e-20	-0.41	-0.44	Aortic root size;	chr7:66300017	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.862	rs10263690	ENSG00000237310.1	GS1-124K5.4	-10.41	6.51e-23	7.09e-20	-0.41	-0.44	Aortic root size;	chr7:66301466	chr7:66493706~66495474:+
PRAD	cis	rs11951515	0.738	rs10805673	ENSG00000188850.9	RP11-159F24.2	10.41	6.54e-23	7.11e-20	0.52	0.44	Metabolite levels  (X-11787);	chr5:43347921	chr5:43336164~43348716:+
PRAD	cis	rs9322193	0.887	rs3734295	ENSG00000216906.2	RP11-350J20.9	10.41	6.54e-23	7.12e-20	0.52	0.44	Lung cancer;	chr6:149593917	chr6:149904243~149906418:+
PRAD	cis	rs858239	0.73	rs858289	ENSG00000226816.2	AC005082.12	10.41	6.55e-23	7.13e-20	0.51	0.44	Cerebrospinal fluid biomarker levels;	chr7:23208539	chr7:23206013~23208045:+
PRAD	cis	rs2348418	0.832	rs11611406	ENSG00000247934.4	RP11-967K21.1	10.41	6.56e-23	7.14e-20	0.4	0.44	Lung function (FEV1);Lung function (FVC);	chr12:28310910	chr12:28163298~28190738:-
PRAD	cis	rs11951515	0.738	rs4866822	ENSG00000188850.9	RP11-159F24.2	10.41	6.57e-23	7.14e-20	0.52	0.44	Metabolite levels  (X-11787);	chr5:43357992	chr5:43336164~43348716:+
PRAD	cis	rs8062405	0.688	rs3924376	ENSG00000251417.2	RP11-1348G14.4	10.41	6.58e-23	7.15e-20	0.51	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28914657	chr16:28802743~28817828:+
PRAD	cis	rs2933343	0.951	rs789220	ENSG00000261159.1	RP11-723O4.9	-10.41	6.62e-23	7.19e-20	-0.41	-0.44	IgG glycosylation;	chr3:128873292	chr3:128859716~128860526:-
PRAD	cis	rs853679	0.517	rs6932109	ENSG00000219392.1	RP1-265C24.5	10.41	6.64e-23	7.21e-20	0.57	0.44	Depression;	chr6:28110525	chr6:28115628~28116551:+
PRAD	cis	rs6570726	0.764	rs451108	ENSG00000235652.6	RP11-545I5.3	10.41	6.64e-23	7.22e-20	0.46	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145523173	chr6:145799409~145886585:+
PRAD	cis	rs11673344	0.864	rs8106386	ENSG00000226686.6	LINC01535	-10.41	6.68e-23	7.25e-20	-0.6	-0.44	Obesity-related traits;	chr19:37012997	chr19:37251912~37265535:+
PRAD	cis	rs780096	0.565	rs8179252	ENSG00000234072.1	AC074117.10	-10.41	6.68e-23	7.26e-20	-0.35	-0.44	Total body bone mineral density;	chr2:27523965	chr2:27356246~27367622:+
PRAD	cis	rs3762637	1	rs76599189	ENSG00000272758.4	RP11-299J3.8	-10.41	6.7e-23	7.27e-20	-0.66	-0.44	LDL cholesterol levels;	chr3:122405229	chr3:122416207~122443180:+
PRAD	cis	rs1891275	0.515	rs1418161	ENSG00000228701.1	TNKS2-AS1	-10.41	6.72e-23	7.3e-20	-0.55	-0.44	Intelligence (multi-trait analysis);	chr10:91724898	chr10:91782839~91798291:-
PRAD	cis	rs9322193	0.887	rs3734295	ENSG00000268592.3	RAET1E-AS1	10.41	6.76e-23	7.34e-20	0.62	0.44	Lung cancer;	chr6:149593917	chr6:149863494~149919507:+
PRAD	cis	rs9487094	0.744	rs13211604	ENSG00000260273.1	RP11-425D10.10	10.41	6.78e-23	7.36e-20	0.64	0.44	Height;	chr6:109712525	chr6:109382795~109383666:+
PRAD	cis	rs2739330	0.791	rs9612520	ENSG00000206090.4	AP000350.7	10.41	6.79e-23	7.38e-20	0.56	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23939998~23942798:+
PRAD	cis	rs9399135	0.622	rs3817776	ENSG00000232876.1	CTA-212D2.2	10.41	6.8e-23	7.38e-20	0.54	0.44	Red blood cell count;	chr6:134935618	chr6:135055033~135060550:+
PRAD	cis	rs9322193	0.884	rs1125	ENSG00000216906.2	RP11-350J20.9	10.41	6.82e-23	7.4e-20	0.52	0.44	Lung cancer;	chr6:149658280	chr6:149904243~149906418:+
PRAD	cis	rs6504950	0.888	rs2628315	ENSG00000275710.1	RP11-257O5.4	10.41	6.83e-23	7.41e-20	0.55	0.44	Breast cancer;	chr17:55149261	chr17:54964474~54964679:+
PRAD	cis	rs17023223	0.537	rs10923759	ENSG00000231365.4	RP11-418J17.1	10.41	6.83e-23	7.41e-20	0.45	0.44	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119149571	chr1:119140396~119275973:+
PRAD	cis	rs17023223	0.537	rs10923756	ENSG00000231365.4	RP11-418J17.1	-10.41	6.83e-23	7.42e-20	-0.45	-0.44	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119132025	chr1:119140396~119275973:+
PRAD	cis	rs2404602	0.53	rs11072614	ENSG00000259422.1	RP11-593F23.1	-10.41	6.87e-23	7.45e-20	-0.59	-0.44	Blood metabolite levels;	chr15:76674864	chr15:76174891~76181486:-
PRAD	cis	rs1577917	0.837	rs10944157	ENSG00000203875.9	SNHG5	-10.4	6.94e-23	7.53e-20	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85867481	chr6:85660950~85678736:-
PRAD	cis	rs2919917	0.628	rs6981103	ENSG00000254352.1	RP11-578O24.2	10.4	6.96e-23	7.55e-20	0.58	0.44	Lymphocyte counts;	chr8:78691702	chr8:78723796~78724136:-
PRAD	cis	rs2348418	0.864	rs7295120	ENSG00000247934.4	RP11-967K21.1	10.4	7e-23	7.59e-20	0.41	0.44	Lung function (FEV1);Lung function (FVC);	chr12:28565175	chr12:28163298~28190738:-
PRAD	cis	rs11951515	0.663	rs67415672	ENSG00000188850.9	RP11-159F24.2	10.4	7.02e-23	7.61e-20	0.52	0.44	Metabolite levels  (X-11787);	chr5:43287059	chr5:43336164~43348716:+
PRAD	cis	rs11673344	0.864	rs79927931	ENSG00000226686.6	LINC01535	10.4	7.02e-23	7.61e-20	0.6	0.44	Obesity-related traits;	chr19:37012241	chr19:37251912~37265535:+
PRAD	cis	rs2442825	0.693	rs2596916	ENSG00000206573.7	THUMPD3-AS1	10.4	7.03e-23	7.62e-20	0.31	0.44	Cerebrospinal fluid clusterin levels;	chr3:9380526	chr3:9349689~9398579:-
PRAD	cis	rs1891275	0.515	rs2153653	ENSG00000228701.1	TNKS2-AS1	-10.4	7.04e-23	7.63e-20	-0.55	-0.44	Intelligence (multi-trait analysis);	chr10:91736169	chr10:91782839~91798291:-
PRAD	cis	rs7174755	0.608	rs10162905	ENSG00000260657.2	RP11-315D16.4	10.4	7.06e-23	7.65e-20	0.56	0.44	Major depressive disorder;	chr15:68103709	chr15:68267792~68277994:-
PRAD	cis	rs1891275	0.515	rs7475294	ENSG00000228701.1	TNKS2-AS1	-10.4	7.11e-23	7.7e-20	-0.55	-0.44	Intelligence (multi-trait analysis);	chr10:91748442	chr10:91782839~91798291:-
PRAD	cis	rs2348418	0.832	rs11049559	ENSG00000247934.4	RP11-967K21.1	10.4	7.13e-23	7.72e-20	0.39	0.44	Lung function (FEV1);Lung function (FVC);	chr12:28372264	chr12:28163298~28190738:-
PRAD	cis	rs783540	0.542	rs62009945	ENSG00000276710.3	CSPG4P8	10.4	7.17e-23	7.76e-20	0.52	0.44	Schizophrenia;	chr15:82631205	chr15:82459472~82477258:+
PRAD	cis	rs2739330	0.892	rs5751776	ENSG00000099984.9	GSTT2	-10.4	7.25e-23	7.84e-20	-0.58	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23980123~23983911:+
PRAD	cis	rs875971	0.862	rs10250544	ENSG00000237310.1	GS1-124K5.4	-10.4	7.28e-23	7.88e-20	-0.41	-0.44	Aortic root size;	chr7:66301574	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.895	rs12531677	ENSG00000237310.1	GS1-124K5.4	-10.4	7.28e-23	7.88e-20	-0.41	-0.44	Aortic root size;	chr7:66304099	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.862	rs7798630	ENSG00000237310.1	GS1-124K5.4	-10.4	7.28e-23	7.88e-20	-0.41	-0.44	Aortic root size;	chr7:66306492	chr7:66493706~66495474:+
PRAD	cis	rs6142102	0.961	rs6059587	ENSG00000276073.1	RP5-1125A11.7	-10.4	7.33e-23	7.92e-20	-0.45	-0.44	Skin pigmentation;	chr20:33955120	chr20:33985617~33988989:-
PRAD	cis	rs2933343	1	rs789237	ENSG00000231305.3	RP11-723O4.2	10.4	7.34e-23	7.93e-20	0.44	0.44	IgG glycosylation;	chr3:128918118	chr3:128861313~128871540:-
PRAD	cis	rs2337406	0.714	rs117798641	ENSG00000274576.2	IGHV2-70	-10.4	7.34e-23	7.94e-20	-0.45	-0.44	Alzheimer's disease (late onset);	chr14:106777984	chr14:106770577~106771020:-
PRAD	cis	rs783540	0.681	rs1259178	ENSG00000276710.3	CSPG4P8	10.4	7.35e-23	7.95e-20	0.49	0.44	Schizophrenia;	chr15:82603127	chr15:82459472~82477258:+
PRAD	cis	rs6142102	0.961	rs6059596	ENSG00000276073.1	RP5-1125A11.7	-10.4	7.37e-23	7.97e-20	-0.46	-0.44	Skin pigmentation;	chr20:33969313	chr20:33985617~33988989:-
PRAD	cis	rs6142102	0.961	rs6088360	ENSG00000276073.1	RP5-1125A11.7	-10.4	7.37e-23	7.97e-20	-0.46	-0.44	Skin pigmentation;	chr20:33969383	chr20:33985617~33988989:-
PRAD	cis	rs6142102	0.961	rs1007090	ENSG00000276073.1	RP5-1125A11.7	-10.4	7.37e-23	7.97e-20	-0.46	-0.44	Skin pigmentation;	chr20:33995065	chr20:33985617~33988989:-
PRAD	cis	rs6142102	0.923	rs2284377	ENSG00000276073.1	RP5-1125A11.7	-10.4	7.37e-23	7.97e-20	-0.46	-0.44	Skin pigmentation;	chr20:33998876	chr20:33985617~33988989:-
PRAD	cis	rs6142102	0.961	rs2284378	ENSG00000276073.1	RP5-1125A11.7	-10.4	7.37e-23	7.97e-20	-0.46	-0.44	Skin pigmentation;	chr20:34000289	chr20:33985617~33988989:-
PRAD	cis	rs2300206	1	rs2300206	ENSG00000276073.1	RP5-1125A11.7	-10.4	7.37e-23	7.97e-20	-0.46	-0.44	Cancer (pleiotropy);Cancer;	chr20:34002002	chr20:33985617~33988989:-
PRAD	cis	rs6142102	0.961	rs2268080	ENSG00000276073.1	RP5-1125A11.7	-10.4	7.37e-23	7.97e-20	-0.46	-0.44	Skin pigmentation;	chr20:34009910	chr20:33985617~33988989:-
PRAD	cis	rs12439619	0.508	rs8032033	ENSG00000278603.1	RP13-608F4.5	10.4	7.38e-23	7.98e-20	0.57	0.44	Intelligence (multi-trait analysis);	chr15:82165555	chr15:82472203~82472426:+
PRAD	cis	rs853679	0.517	rs9357065	ENSG00000219392.1	RP1-265C24.5	-10.4	7.39e-23	7.98e-20	-0.57	-0.44	Depression;	chr6:28161802	chr6:28115628~28116551:+
PRAD	cis	rs10256972	0.626	rs62433138	ENSG00000229043.2	AC091729.9	-10.4	7.4e-23	8e-20	-0.54	-0.44	Endometriosis;Longevity;	chr7:1011241	chr7:1160374~1165267:+
PRAD	cis	rs6860806	0.507	rs582490	ENSG00000233006.5	AC034220.3	-10.4	7.45e-23	8.05e-20	-0.41	-0.44	Breast cancer;	chr5:132374403	chr5:132311285~132369916:-
PRAD	cis	rs274567	0.501	rs581968	ENSG00000233006.5	AC034220.3	-10.4	7.45e-23	8.05e-20	-0.41	-0.44	Blood metabolite levels;	chr5:132374510	chr5:132311285~132369916:-
PRAD	cis	rs6860806	0.507	rs274572	ENSG00000233006.5	AC034220.3	-10.4	7.45e-23	8.05e-20	-0.41	-0.44	Breast cancer;	chr5:132375225	chr5:132311285~132369916:-
PRAD	cis	rs274567	0.501	rs274571	ENSG00000233006.5	AC034220.3	-10.4	7.45e-23	8.05e-20	-0.41	-0.44	Blood metabolite levels;	chr5:132376433	chr5:132311285~132369916:-
PRAD	cis	rs2337406	0.866	rs8003852	ENSG00000274576.2	IGHV2-70	-10.39	7.49e-23	8.09e-20	-0.45	-0.44	Alzheimer's disease (late onset);	chr14:106776648	chr14:106770577~106771020:-
PRAD	cis	rs2337406	0.866	rs988131	ENSG00000274576.2	IGHV2-70	-10.39	7.49e-23	8.09e-20	-0.45	-0.44	Alzheimer's disease (late onset);	chr14:106776833	chr14:106770577~106771020:-
PRAD	cis	rs2337406	0.866	rs8005518	ENSG00000274576.2	IGHV2-70	-10.39	7.49e-23	8.09e-20	-0.45	-0.44	Alzheimer's disease (late onset);	chr14:106777009	chr14:106770577~106771020:-
PRAD	cis	rs2337406	0.866	rs988130	ENSG00000274576.2	IGHV2-70	-10.39	7.49e-23	8.09e-20	-0.45	-0.44	Alzheimer's disease (late onset);	chr14:106777154	chr14:106770577~106771020:-
PRAD	cis	rs2337406	0.866	rs57684263	ENSG00000274576.2	IGHV2-70	-10.39	7.49e-23	8.09e-20	-0.45	-0.44	Alzheimer's disease (late onset);	chr14:106777263	chr14:106770577~106771020:-
PRAD	cis	rs1577917	1	rs34852683	ENSG00000203875.9	SNHG5	-10.39	7.49e-23	8.1e-20	-0.49	-0.44	Response to antipsychotic treatment;	chr6:85992612	chr6:85660950~85678736:-
PRAD	cis	rs7772486	0.79	rs2250387	ENSG00000235652.6	RP11-545I5.3	10.39	7.51e-23	8.11e-20	0.46	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145884097	chr6:145799409~145886585:+
PRAD	cis	rs10875746	0.903	rs11168370	ENSG00000240399.1	RP1-228P16.1	-10.39	7.51e-23	8.11e-20	-0.42	-0.44	Longevity (90 years and older);	chr12:48041497	chr12:48054813~48055591:-
PRAD	cis	rs2729354	0.953	rs1846567	ENSG00000265566.2	RN7SL605P	-10.39	7.55e-23	8.15e-20	-0.66	-0.44	Blood protein levels;	chr11:57590120	chr11:57528085~57528365:-
PRAD	cis	rs2404602	0.647	rs907594	ENSG00000259422.1	RP11-593F23.1	-10.39	7.68e-23	8.29e-20	-0.59	-0.44	Blood metabolite levels;	chr15:76905404	chr15:76174891~76181486:-
PRAD	cis	rs11673344	0.8	rs8108214	ENSG00000226686.6	LINC01535	-10.39	7.68e-23	8.29e-20	-0.6	-0.44	Obesity-related traits;	chr19:37025184	chr19:37251912~37265535:+
PRAD	cis	rs2739330	0.731	rs5751792	ENSG00000228039.3	KB-1125A3.10	10.39	7.69e-23	8.3e-20	0.56	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23963780~23964374:+
PRAD	cis	rs2739330	0.761	rs5760176	ENSG00000228039.3	KB-1125A3.10	-10.39	7.69e-23	8.3e-20	-0.56	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23963780~23964374:+
PRAD	cis	rs7615952	0.688	rs7624806	ENSG00000171084.14	FAM86JP	10.39	7.7e-23	8.31e-20	0.75	0.44	Blood pressure (smoking interaction);	chr3:125880231	chr3:125916620~125930024:+
PRAD	cis	rs9322193	0.884	rs10872648	ENSG00000216906.2	RP11-350J20.9	10.39	7.76e-23	8.37e-20	0.51	0.44	Lung cancer;	chr6:149758699	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.884	rs11155679	ENSG00000216906.2	RP11-350J20.9	10.39	7.76e-23	8.37e-20	0.51	0.44	Lung cancer;	chr6:149758881	chr6:149904243~149906418:+
PRAD	cis	rs1075265	0.749	rs6738369	ENSG00000233266.1	HMGB1P31	10.39	7.76e-23	8.37e-20	0.6	0.44	Chronotype;Morning vs. evening chronotype;	chr2:53756547	chr2:54051334~54051760:+
PRAD	cis	rs4380275	0.782	rs60367761	ENSG00000272342.1	RP13-539J13.1	10.39	7.76e-23	8.38e-20	0.56	0.44	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:766414	chr2:739588~740164:-
PRAD	cis	rs9322193	0.847	rs4870054	ENSG00000216906.2	RP11-350J20.9	10.39	7.77e-23	8.38e-20	0.51	0.44	Lung cancer;	chr6:149848402	chr6:149904243~149906418:+
PRAD	cis	rs1075265	0.729	rs7571086	ENSG00000233266.1	HMGB1P31	10.39	7.81e-23	8.42e-20	0.58	0.44	Chronotype;Morning vs. evening chronotype;	chr2:54007899	chr2:54051334~54051760:+
PRAD	cis	rs6452524	0.534	rs17284134	ENSG00000249664.1	CTD-2227C6.2	-10.39	7.84e-23	8.46e-20	-0.53	-0.44	Hypertension (SNP x SNP interaction);	chr5:83068325	chr5:83012285~83013109:-
PRAD	cis	rs10129255	0.509	rs756583	ENSG00000211972.2	IGHV3-66	10.39	7.91e-23	8.53e-20	0.39	0.44	Kawasaki disease;	chr14:106680002	chr14:106675017~106675544:-
PRAD	cis	rs10129255	0.536	rs3944157	ENSG00000211972.2	IGHV3-66	10.39	7.91e-23	8.53e-20	0.39	0.44	Kawasaki disease;	chr14:106682286	chr14:106675017~106675544:-
PRAD	cis	rs9322193	0.632	rs3828700	ENSG00000223701.3	RAET1E-AS1	10.39	7.96e-23	8.58e-20	0.59	0.44	Lung cancer;	chr6:149791033	chr6:149884431~149919508:+
PRAD	cis	rs748404	0.631	rs28702649	ENSG00000205771.5	CATSPER2P1	-10.39	8.04e-23	8.67e-20	-0.5	-0.44	Lung cancer;	chr15:43356431	chr15:43726918~43747094:-
PRAD	cis	rs9322193	0.884	rs10872647	ENSG00000216906.2	RP11-350J20.9	10.39	8.05e-23	8.68e-20	0.51	0.44	Lung cancer;	chr6:149758687	chr6:149904243~149906418:+
PRAD	cis	rs13392177	0.66	rs62185964	ENSG00000261338.2	RP11-378A13.1	-10.39	8.12e-23	8.75e-20	-0.49	-0.44	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218209022	chr2:218255319~218257366:+
PRAD	cis	rs13392177	0.684	rs62185965	ENSG00000261338.2	RP11-378A13.1	-10.39	8.12e-23	8.75e-20	-0.49	-0.44	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218209056	chr2:218255319~218257366:+
PRAD	cis	rs10129255	0.556	rs9324093	ENSG00000211972.2	IGHV3-66	10.38	8.15e-23	8.78e-20	0.39	0.44	Kawasaki disease;	chr14:106683893	chr14:106675017~106675544:-
PRAD	cis	rs2739330	0.828	rs4820572	ENSG00000272787.1	KB-226F1.2	-10.38	8.16e-23	8.79e-20	-0.48	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23969211~23969873:+
PRAD	cis	rs853679	0.517	rs1904841	ENSG00000219392.1	RP1-265C24.5	-10.38	8.23e-23	8.86e-20	-0.57	-0.44	Depression;	chr6:28140307	chr6:28115628~28116551:+
PRAD	cis	rs875971	0.862	rs1875057	ENSG00000237310.1	GS1-124K5.4	-10.38	8.26e-23	8.89e-20	-0.41	-0.44	Aortic root size;	chr7:66266868	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.862	rs6960446	ENSG00000237310.1	GS1-124K5.4	-10.38	8.26e-23	8.89e-20	-0.41	-0.44	Aortic root size;	chr7:66268272	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.789	rs10260426	ENSG00000237310.1	GS1-124K5.4	-10.38	8.26e-23	8.89e-20	-0.41	-0.44	Aortic root size;	chr7:66271055	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.862	rs7796162	ENSG00000237310.1	GS1-124K5.4	-10.38	8.26e-23	8.89e-20	-0.41	-0.44	Aortic root size;	chr7:66280771	chr7:66493706~66495474:+
PRAD	cis	rs9906595	0.702	rs1262618	ENSG00000263874.1	LINC00672	10.38	8.32e-23	8.96e-20	0.77	0.44	Obesity-related traits;	chr17:38950918	chr17:38925168~38928057:+
PRAD	cis	rs34779708	0.966	rs12761675	ENSG00000230534.5	RP11-297A16.2	-10.38	8.33e-23	8.97e-20	-0.59	-0.44	Inflammatory bowel disease;Crohn's disease;	chr10:35149409	chr10:35098006~35127020:-
PRAD	cis	rs3762637	0.823	rs9849013	ENSG00000272758.4	RP11-299J3.8	-10.38	8.4e-23	9.04e-20	-0.64	-0.44	LDL cholesterol levels;	chr3:122531758	chr3:122416207~122443180:+
PRAD	cis	rs8062405	0.655	rs7184597	ENSG00000251417.2	RP11-1348G14.4	10.38	8.41e-23	9.05e-20	0.51	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910488	chr16:28802743~28817828:+
PRAD	cis	rs12439619	0.53	rs28883606	ENSG00000278603.1	RP13-608F4.5	10.38	8.46e-23	9.1e-20	0.57	0.44	Intelligence (multi-trait analysis);	chr15:82216713	chr15:82472203~82472426:+
PRAD	cis	rs7714584	1	rs73282209	ENSG00000197083.10	ZNF300P1	10.38	8.47e-23	9.12e-20	0.79	0.44	Crohn's disease;	chr5:150795397	chr5:150930645~150946289:-
PRAD	cis	rs1075265	0.692	rs805358	ENSG00000233266.1	HMGB1P31	10.38	8.53e-23	9.18e-20	0.58	0.44	Chronotype;Morning vs. evening chronotype;	chr2:53934885	chr2:54051334~54051760:+
PRAD	cis	rs1555322	0.53	rs932562	ENSG00000126005.14	MMP24-AS1	-10.38	8.53e-23	9.18e-20	-0.53	-0.44	Attention deficit hyperactivity disorder;	chr20:35283507	chr20:35216462~35278131:-
PRAD	cis	rs853679	0.517	rs1904840	ENSG00000219392.1	RP1-265C24.5	-10.38	8.53e-23	9.18e-20	-0.57	-0.44	Depression;	chr6:28140454	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs9368555	ENSG00000219392.1	RP1-265C24.5	-10.38	8.53e-23	9.18e-20	-0.57	-0.44	Depression;	chr6:28141189	chr6:28115628~28116551:+
PRAD	cis	rs13392177	0.684	rs11682371	ENSG00000261338.2	RP11-378A13.1	-10.38	8.57e-23	9.22e-20	-0.49	-0.44	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218214790	chr2:218255319~218257366:+
PRAD	cis	rs6570726	0.791	rs401331	ENSG00000235652.6	RP11-545I5.3	10.38	8.67e-23	9.33e-20	0.46	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145510272	chr6:145799409~145886585:+
PRAD	cis	rs6991838	0.612	rs7842162	ENSG00000272010.1	CTD-3025N20.3	10.38	8.68e-23	9.34e-20	0.46	0.44	Intelligence (multi-trait analysis);	chr8:65644057	chr8:65591850~65592472:-
PRAD	cis	rs9322193	0.962	rs9688412	ENSG00000216906.2	RP11-350J20.9	-10.38	8.7e-23	9.35e-20	-0.5	-0.44	Lung cancer;	chr6:149803147	chr6:149904243~149906418:+
PRAD	cis	rs1075265	0.722	rs13414216	ENSG00000233266.1	HMGB1P31	10.38	8.7e-23	9.35e-20	0.6	0.44	Chronotype;Morning vs. evening chronotype;	chr2:53699166	chr2:54051334~54051760:+
PRAD	cis	rs875971	0.79	rs10257911	ENSG00000237310.1	GS1-124K5.4	-10.38	8.72e-23	9.38e-20	-0.41	-0.44	Aortic root size;	chr7:66278783	chr7:66493706~66495474:+
PRAD	cis	rs11690935	0.632	rs12987931	ENSG00000228389.1	AC068039.4	-10.38	8.82e-23	9.49e-20	-0.5	-0.44	Schizophrenia;	chr2:172036045	chr2:171773482~171775844:+
PRAD	cis	rs1555322	0.53	rs6060347	ENSG00000126005.14	MMP24-AS1	-10.38	8.84e-23	9.5e-20	-0.53	-0.44	Attention deficit hyperactivity disorder;	chr20:35286348	chr20:35216462~35278131:-
PRAD	cis	rs10129255	0.536	rs6576201	ENSG00000211972.2	IGHV3-66	-10.37	8.89e-23	9.55e-20	-0.38	-0.44	Kawasaki disease;	chr14:106683696	chr14:106675017~106675544:-
PRAD	cis	rs12049351	0.665	rs3753884	ENSG00000229367.1	HMGN2P19	10.37	8.99e-23	9.66e-20	0.68	0.44	Circulating myeloperoxidase levels (plasma);	chr1:229436507	chr1:229570532~229570796:+
PRAD	cis	rs6565180	0.507	rs4471699	ENSG00000183604.13	SMG1P5	-10.37	9.01e-23	9.68e-20	-0.4	-0.44	Tonsillectomy;	chr16:30308986	chr16:30267553~30335374:-
PRAD	cis	rs2729354	0.903	rs1846568	ENSG00000265566.2	RN7SL605P	-10.37	9.02e-23	9.69e-20	-0.65	-0.44	Blood protein levels;	chr11:57590241	chr11:57528085~57528365:-
PRAD	cis	rs9322193	0.962	rs9689447	ENSG00000223701.3	RAET1E-AS1	10.37	9.07e-23	9.74e-20	0.59	0.44	Lung cancer;	chr6:149789350	chr6:149884431~149919508:+
PRAD	cis	rs6142102	0.961	rs4911407	ENSG00000276073.1	RP5-1125A11.7	-10.37	9.09e-23	9.76e-20	-0.46	-0.44	Skin pigmentation;	chr20:34095759	chr20:33985617~33988989:-
PRAD	cis	rs9322193	0.926	rs9766562	ENSG00000223701.3	RAET1E-AS1	10.37	9.14e-23	9.81e-20	0.6	0.44	Lung cancer;	chr6:149788709	chr6:149884431~149919508:+
PRAD	cis	rs9309473	0.615	rs62151562	ENSG00000163016.8	ALMS1P	10.37	9.16e-23	9.84e-20	0.63	0.44	Metabolite levels;	chr2:73376412	chr2:73644919~73685576:+
PRAD	cis	rs638893	0.588	rs529717	ENSG00000278376.1	RP11-158I9.8	-10.37	9.21e-23	9.89e-20	-0.52	-0.44	Vitiligo;	chr11:118769372	chr11:118791254~118793137:+
PRAD	cis	rs9322193	0.923	rs10872645	ENSG00000223701.3	RAET1E-AS1	10.37	9.26e-23	9.94e-20	0.59	0.44	Lung cancer;	chr6:149742840	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.962	rs4869730	ENSG00000268592.3	RAET1E-AS1	10.37	9.3e-23	9.97e-20	0.6	0.44	Lung cancer;	chr6:149808187	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.923	rs2151913	ENSG00000268592.3	RAET1E-AS1	10.37	9.3e-23	9.97e-20	0.6	0.44	Lung cancer;	chr6:149809506	chr6:149863494~149919507:+
PRAD	cis	rs673078	0.66	rs61943525	ENSG00000275759.1	RP11-131L12.3	-10.37	9.34e-23	1e-19	-0.71	-0.44	Glucose homeostasis traits;	chr12:118152927	chr12:118428281~118428870:+
PRAD	cis	rs13392177	0.684	rs6720105	ENSG00000261338.2	RP11-378A13.1	-10.37	9.36e-23	1e-19	-0.49	-0.44	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218215995	chr2:218255319~218257366:+
PRAD	cis	rs13392177	0.684	rs6720449	ENSG00000261338.2	RP11-378A13.1	-10.37	9.36e-23	1e-19	-0.49	-0.44	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218216255	chr2:218255319~218257366:+
PRAD	cis	rs2882667	0.505	rs6596465	ENSG00000253404.1	AC034243.1	-10.37	9.36e-23	1e-19	-0.55	-0.44	Age-related hearing impairment (SNP x SNP interaction);	chr5:139147337	chr5:138744434~138753309:-
PRAD	cis	rs6142102	0.961	rs2284379	ENSG00000276073.1	RP5-1125A11.7	-10.37	9.48e-23	1.02e-19	-0.46	-0.44	Skin pigmentation;	chr20:34006836	chr20:33985617~33988989:-
PRAD	cis	rs6142102	0.961	rs8119937	ENSG00000276073.1	RP5-1125A11.7	-10.37	9.49e-23	1.02e-19	-0.44	-0.44	Skin pigmentation;	chr20:34057745	chr20:33985617~33988989:-
PRAD	cis	rs6142102	0.961	rs4911144	ENSG00000276073.1	RP5-1125A11.7	-10.37	9.54e-23	1.02e-19	-0.46	-0.44	Skin pigmentation;	chr20:34026565	chr20:33985617~33988989:-
PRAD	cis	rs2933343	1	rs789213	ENSG00000261159.1	RP11-723O4.9	-10.37	9.55e-23	1.02e-19	-0.4	-0.44	IgG glycosylation;	chr3:128897516	chr3:128859716~128860526:-
PRAD	cis	rs6142102	0.961	rs2268088	ENSG00000276073.1	RP5-1125A11.7	-10.37	9.55e-23	1.02e-19	-0.46	-0.44	Skin pigmentation;	chr20:34061258	chr20:33985617~33988989:-
PRAD	cis	rs6142102	0.961	rs2284388	ENSG00000276073.1	RP5-1125A11.7	-10.37	9.55e-23	1.02e-19	-0.46	-0.44	Skin pigmentation;	chr20:34067935	chr20:33985617~33988989:-
PRAD	cis	rs34779708	0.931	rs4934711	ENSG00000230534.5	RP11-297A16.2	10.37	9.58e-23	1.03e-19	0.57	0.44	Inflammatory bowel disease;Crohn's disease;	chr10:35071382	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.931	rs1926556	ENSG00000230534.5	RP11-297A16.2	10.37	9.59e-23	1.03e-19	0.59	0.44	Inflammatory bowel disease;Crohn's disease;	chr10:35055979	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.931	rs1926554	ENSG00000230534.5	RP11-297A16.2	10.37	9.59e-23	1.03e-19	0.59	0.44	Inflammatory bowel disease;Crohn's disease;	chr10:35056041	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.931	rs4934710	ENSG00000230534.5	RP11-297A16.2	10.37	9.59e-23	1.03e-19	0.59	0.44	Inflammatory bowel disease;Crohn's disease;	chr10:35061488	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.897	rs35784065	ENSG00000230534.5	RP11-297A16.2	10.37	9.59e-23	1.03e-19	0.59	0.44	Inflammatory bowel disease;Crohn's disease;	chr10:35064646	chr10:35098006~35127020:-
PRAD	cis	rs13392177	0.66	rs10932762	ENSG00000261338.2	RP11-378A13.1	-10.37	9.64e-23	1.03e-19	-0.49	-0.44	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218211490	chr2:218255319~218257366:+
PRAD	cis	rs6964833	0.554	rs2527380	ENSG00000277053.3	GTF2IP1	10.37	9.64e-23	1.03e-19	0.47	0.44	Menarche (age at onset);	chr7:74690372	chr7:75185385~75237696:-
PRAD	cis	rs524281	0.64	rs61895584	ENSG00000255320.1	RP11-755F10.1	-10.36	9.68e-23	1.04e-19	-0.79	-0.44	Electroencephalogram traits;	chr11:66042738	chr11:66244840~66246239:-
PRAD	cis	rs11690935	0.527	rs7586556	ENSG00000228389.1	AC068039.4	-10.36	9.72e-23	1.04e-19	-0.49	-0.44	Schizophrenia;	chr2:172036983	chr2:171773482~171775844:+
PRAD	cis	rs9322193	0.923	rs12211511	ENSG00000223701.3	RAET1E-AS1	10.36	9.72e-23	1.04e-19	0.59	0.44	Lung cancer;	chr6:149745206	chr6:149884431~149919508:+
PRAD	cis	rs2929278	0.638	rs2016840	ENSG00000205771.5	CATSPER2P1	10.36	9.74e-23	1.04e-19	0.51	0.44	Schizophrenia;	chr15:43919670	chr15:43726918~43747094:-
PRAD	cis	rs6142102	0.961	rs4911392	ENSG00000276073.1	RP5-1125A11.7	-10.36	9.78e-23	1.05e-19	-0.44	-0.44	Skin pigmentation;	chr20:33982712	chr20:33985617~33988989:-
PRAD	cis	rs6142102	0.961	rs4911393	ENSG00000276073.1	RP5-1125A11.7	-10.36	9.78e-23	1.05e-19	-0.44	-0.44	Skin pigmentation;	chr20:33983120	chr20:33985617~33988989:-
PRAD	cis	rs1075265	0.84	rs10084355	ENSG00000233266.1	HMGB1P31	10.36	9.79e-23	1.05e-19	0.58	0.44	Chronotype;Morning vs. evening chronotype;	chr2:54021711	chr2:54051334~54051760:+
PRAD	cis	rs783540	0.5	rs7178459	ENSG00000276710.3	CSPG4P8	-10.36	9.83e-23	1.05e-19	-0.52	-0.44	Schizophrenia;	chr15:82729632	chr15:82459472~82477258:+
PRAD	cis	rs34779708	0.931	rs12268745	ENSG00000230534.5	RP11-297A16.2	10.36	9.89e-23	1.06e-19	0.58	0.44	Inflammatory bowel disease;Crohn's disease;	chr10:35017061	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.931	rs7923172	ENSG00000230534.5	RP11-297A16.2	10.36	9.89e-23	1.06e-19	0.58	0.44	Inflammatory bowel disease;Crohn's disease;	chr10:35020439	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.931	rs7099036	ENSG00000230534.5	RP11-297A16.2	10.36	9.89e-23	1.06e-19	0.58	0.44	Inflammatory bowel disease;Crohn's disease;	chr10:35060646	chr10:35098006~35127020:-
PRAD	cis	rs1426063	0.614	rs75345649	ENSG00000260265.1	RP11-44F21.5	10.36	9.92e-23	1.06e-19	0.92	0.44	QT interval;	chr4:75100963	chr4:75081702~75084717:-
PRAD	cis	rs1426063	0.614	rs77333523	ENSG00000260265.1	RP11-44F21.5	10.36	9.92e-23	1.06e-19	0.92	0.44	QT interval;	chr4:75101024	chr4:75081702~75084717:-
PRAD	cis	rs1426063	0.614	rs17199632	ENSG00000260265.1	RP11-44F21.5	10.36	9.92e-23	1.06e-19	0.92	0.44	QT interval;	chr4:75103663	chr4:75081702~75084717:-
PRAD	cis	rs875971	0.862	rs11984115	ENSG00000237310.1	GS1-124K5.4	-10.36	9.93e-23	1.06e-19	-0.41	-0.44	Aortic root size;	chr7:66308872	chr7:66493706~66495474:+
PRAD	cis	rs6142102	0.961	rs6059649	ENSG00000276073.1	RP5-1125A11.7	-10.36	9.94e-23	1.06e-19	-0.46	-0.44	Skin pigmentation;	chr20:34056071	chr20:33985617~33988989:-
PRAD	cis	rs6142102	0.961	rs6059651	ENSG00000276073.1	RP5-1125A11.7	-10.36	9.94e-23	1.06e-19	-0.46	-0.44	Skin pigmentation;	chr20:34057246	chr20:33985617~33988989:-
PRAD	cis	rs11676348	0.935	rs6716276	ENSG00000261338.2	RP11-378A13.1	-10.36	9.95e-23	1.06e-19	-0.5	-0.44	Ulcerative colitis;	chr2:218097482	chr2:218255319~218257366:+
PRAD	cis	rs9322193	0.884	rs2342858	ENSG00000223701.3	RAET1E-AS1	10.36	9.96e-23	1.07e-19	0.59	0.44	Lung cancer;	chr6:149805967	chr6:149884431~149919508:+
PRAD	cis	rs7772486	0.79	rs2253764	ENSG00000235652.6	RP11-545I5.3	10.36	1e-22	1.07e-19	0.45	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145878745	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.79	rs2253880	ENSG00000235652.6	RP11-545I5.3	10.36	1e-22	1.07e-19	0.45	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145879638	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.79	rs2814879	ENSG00000235652.6	RP11-545I5.3	10.36	1e-22	1.07e-19	0.45	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145880607	chr6:145799409~145886585:+
PRAD	cis	rs2404602	0.622	rs4886506	ENSG00000259422.1	RP11-593F23.1	10.36	1.01e-22	1.08e-19	0.58	0.44	Blood metabolite levels;	chr15:76914936	chr15:76174891~76181486:-
PRAD	cis	rs73086581	0.524	rs2253977	ENSG00000229539.1	RP11-119B16.2	-10.36	1.01e-22	1.08e-19	-0.57	-0.44	Response to antidepressants in depression;	chr20:3958493	chr20:3888239~3888868:-
PRAD	cis	rs9322193	0.962	rs9688412	ENSG00000268592.3	RAET1E-AS1	-10.36	1.01e-22	1.08e-19	-0.6	-0.44	Lung cancer;	chr6:149803147	chr6:149863494~149919507:+
PRAD	cis	rs6142102	0.923	rs4911379	ENSG00000276073.1	RP5-1125A11.7	-10.36	1.02e-22	1.09e-19	-0.45	-0.44	Skin pigmentation;	chr20:33947499	chr20:33985617~33988989:-
PRAD	cis	rs853679	0.513	rs9468296	ENSG00000219392.1	RP1-265C24.5	-10.36	1.03e-22	1.1e-19	-0.57	-0.44	Depression;	chr6:28145952	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs4711164	ENSG00000219392.1	RP1-265C24.5	-10.36	1.03e-22	1.1e-19	-0.57	-0.44	Depression;	chr6:28147378	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs4711165	ENSG00000219392.1	RP1-265C24.5	-10.36	1.03e-22	1.1e-19	-0.57	-0.44	Depression;	chr6:28147406	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs4713148	ENSG00000219392.1	RP1-265C24.5	-10.36	1.03e-22	1.1e-19	-0.57	-0.44	Depression;	chr6:28148143	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs9348794	ENSG00000219392.1	RP1-265C24.5	-10.36	1.03e-22	1.1e-19	-0.57	-0.44	Depression;	chr6:28149979	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs9295758	ENSG00000219392.1	RP1-265C24.5	-10.36	1.03e-22	1.1e-19	-0.57	-0.44	Depression;	chr6:28152885	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs17774663	ENSG00000219392.1	RP1-265C24.5	-10.36	1.03e-22	1.1e-19	-0.57	-0.44	Depression;	chr6:28153120	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs9468298	ENSG00000219392.1	RP1-265C24.5	-10.36	1.03e-22	1.1e-19	-0.57	-0.44	Depression;	chr6:28154567	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs9295759	ENSG00000219392.1	RP1-265C24.5	-10.36	1.03e-22	1.1e-19	-0.57	-0.44	Depression;	chr6:28156691	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs9348796	ENSG00000219392.1	RP1-265C24.5	-10.36	1.03e-22	1.1e-19	-0.57	-0.44	Depression;	chr6:28158424	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs11552219	ENSG00000219392.1	RP1-265C24.5	-10.36	1.03e-22	1.1e-19	-0.57	-0.44	Depression;	chr6:28159056	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs9380058	ENSG00000219392.1	RP1-265C24.5	-10.36	1.03e-22	1.1e-19	-0.57	-0.44	Depression;	chr6:28159666	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs9393895	ENSG00000219392.1	RP1-265C24.5	-10.36	1.03e-22	1.1e-19	-0.57	-0.44	Depression;	chr6:28159843	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs9393896	ENSG00000219392.1	RP1-265C24.5	-10.36	1.03e-22	1.1e-19	-0.57	-0.44	Depression;	chr6:28159925	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs9393897	ENSG00000219392.1	RP1-265C24.5	-10.36	1.03e-22	1.1e-19	-0.57	-0.44	Depression;	chr6:28159932	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs9357066	ENSG00000219392.1	RP1-265C24.5	-10.36	1.03e-22	1.1e-19	-0.57	-0.44	Depression;	chr6:28162053	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs9393898	ENSG00000219392.1	RP1-265C24.5	-10.36	1.03e-22	1.1e-19	-0.57	-0.44	Depression;	chr6:28162598	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs9368556	ENSG00000219392.1	RP1-265C24.5	-10.36	1.03e-22	1.1e-19	-0.57	-0.44	Depression;	chr6:28163375	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs9368557	ENSG00000219392.1	RP1-265C24.5	-10.36	1.03e-22	1.1e-19	-0.57	-0.44	Depression;	chr6:28163759	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs9380059	ENSG00000219392.1	RP1-265C24.5	-10.36	1.03e-22	1.1e-19	-0.57	-0.44	Depression;	chr6:28164580	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs9380060	ENSG00000219392.1	RP1-265C24.5	-10.36	1.03e-22	1.1e-19	-0.57	-0.44	Depression;	chr6:28164825	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs35227624	ENSG00000219392.1	RP1-265C24.5	-10.36	1.03e-22	1.1e-19	-0.57	-0.44	Depression;	chr6:28164948	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs9380061	ENSG00000219392.1	RP1-265C24.5	-10.36	1.03e-22	1.1e-19	-0.57	-0.44	Depression;	chr6:28165025	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs9368558	ENSG00000219392.1	RP1-265C24.5	-10.36	1.03e-22	1.1e-19	-0.57	-0.44	Depression;	chr6:28165528	chr6:28115628~28116551:+
PRAD	cis	rs4713118	0.587	rs9393899	ENSG00000219392.1	RP1-265C24.5	-10.36	1.03e-22	1.1e-19	-0.57	-0.44	Parkinson's disease;	chr6:28165750	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs4713150	ENSG00000219392.1	RP1-265C24.5	-10.36	1.03e-22	1.1e-19	-0.57	-0.44	Depression;	chr6:28168434	chr6:28115628~28116551:+
PRAD	cis	rs4713118	0.527	rs4713151	ENSG00000219392.1	RP1-265C24.5	-10.36	1.03e-22	1.1e-19	-0.57	-0.44	Parkinson's disease;	chr6:28168578	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs9393901	ENSG00000219392.1	RP1-265C24.5	-10.36	1.03e-22	1.1e-19	-0.57	-0.44	Depression;	chr6:28169019	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs3173443	ENSG00000219392.1	RP1-265C24.5	-10.36	1.03e-22	1.1e-19	-0.57	-0.44	Depression;	chr6:28169249	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs4713152	ENSG00000219392.1	RP1-265C24.5	-10.36	1.03e-22	1.1e-19	-0.57	-0.44	Depression;	chr6:28169676	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs9348797	ENSG00000219392.1	RP1-265C24.5	-10.36	1.03e-22	1.1e-19	-0.57	-0.44	Depression;	chr6:28169755	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs9380062	ENSG00000219392.1	RP1-265C24.5	-10.36	1.03e-22	1.1e-19	-0.57	-0.44	Depression;	chr6:28169791	chr6:28115628~28116551:+
PRAD	cis	rs2442825	0.693	rs2648536	ENSG00000206573.7	THUMPD3-AS1	10.36	1.03e-22	1.1e-19	0.31	0.44	Cerebrospinal fluid clusterin levels;	chr3:9365338	chr3:9349689~9398579:-
PRAD	cis	rs11673344	0.704	rs1667384	ENSG00000226686.6	LINC01535	10.36	1.03e-22	1.1e-19	0.59	0.44	Obesity-related traits;	chr19:36925852	chr19:37251912~37265535:+
PRAD	cis	rs11673344	0.832	rs76781063	ENSG00000226686.6	LINC01535	10.36	1.03e-22	1.1e-19	0.6	0.44	Obesity-related traits;	chr19:37036040	chr19:37251912~37265535:+
PRAD	cis	rs11673344	0.618	rs4420645	ENSG00000226686.6	LINC01535	10.36	1.03e-22	1.1e-19	0.6	0.44	Obesity-related traits;	chr19:37054086	chr19:37251912~37265535:+
PRAD	cis	rs11673344	0.832	rs2011475	ENSG00000226686.6	LINC01535	10.36	1.03e-22	1.1e-19	0.6	0.44	Obesity-related traits;	chr19:37054712	chr19:37251912~37265535:+
PRAD	cis	rs6142102	0.812	rs6059578	ENSG00000276073.1	RP5-1125A11.7	-10.36	1.04e-22	1.11e-19	-0.45	-0.44	Skin pigmentation;	chr20:33939900	chr20:33985617~33988989:-
PRAD	cis	rs6142102	0.886	rs6059583	ENSG00000276073.1	RP5-1125A11.7	-10.36	1.04e-22	1.11e-19	-0.45	-0.44	Skin pigmentation;	chr20:33944308	chr20:33985617~33988989:-
PRAD	cis	rs4718428	0.672	rs12530806	ENSG00000232546.1	RP11-458F8.1	-10.36	1.04e-22	1.11e-19	-0.35	-0.44	Corneal structure;	chr7:66925737	chr7:66848496~66858136:+
PRAD	cis	rs7772486	0.79	rs6570723	ENSG00000235652.6	RP11-545I5.3	10.36	1.04e-22	1.11e-19	0.44	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145830094	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.79	rs6570724	ENSG00000235652.6	RP11-545I5.3	10.36	1.04e-22	1.11e-19	0.44	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145830147	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.79	rs6917135	ENSG00000235652.6	RP11-545I5.3	10.36	1.04e-22	1.11e-19	0.44	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145831290	chr6:145799409~145886585:+
PRAD	cis	rs13392177	0.647	rs6718220	ENSG00000261338.2	RP11-378A13.1	-10.36	1.05e-22	1.12e-19	-0.49	-0.44	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218201795	chr2:218255319~218257366:+
PRAD	cis	rs780096	0.565	rs11681351	ENSG00000234072.1	AC074117.10	-10.35	1.06e-22	1.13e-19	-0.35	-0.44	Total body bone mineral density;	chr2:27520556	chr2:27356246~27367622:+
PRAD	cis	rs11951515	0.789	rs55759722	ENSG00000188850.9	RP11-159F24.2	10.35	1.06e-22	1.13e-19	0.52	0.44	Metabolite levels  (X-11787);	chr5:43356812	chr5:43336164~43348716:+
PRAD	cis	rs2442825	0.693	rs2728924	ENSG00000206573.7	THUMPD3-AS1	10.35	1.06e-22	1.13e-19	0.32	0.44	Cerebrospinal fluid clusterin levels;	chr3:9381294	chr3:9349689~9398579:-
PRAD	cis	rs783540	0.521	rs28719490	ENSG00000276710.3	CSPG4P8	-10.35	1.07e-22	1.14e-19	-0.52	-0.44	Schizophrenia;	chr15:82720688	chr15:82459472~82477258:+
PRAD	cis	rs9322193	0.566	rs4869767	ENSG00000268592.3	RAET1E-AS1	-10.35	1.07e-22	1.14e-19	-0.68	-0.44	Lung cancer;	chr6:149923974	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.566	rs4869768	ENSG00000268592.3	RAET1E-AS1	-10.35	1.07e-22	1.14e-19	-0.68	-0.44	Lung cancer;	chr6:149924067	chr6:149863494~149919507:+
PRAD	cis	rs10246939	0.529	rs60165685	ENSG00000228775.6	WEE2-AS1	10.35	1.08e-22	1.15e-19	0.55	0.44	Bitter taste perception;	chr7:141861190	chr7:141704338~141738346:-
PRAD	cis	rs875971	0.862	rs6952182	ENSG00000237310.1	GS1-124K5.4	-10.35	1.08e-22	1.15e-19	-0.41	-0.44	Aortic root size;	chr7:66218330	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.862	rs6964437	ENSG00000237310.1	GS1-124K5.4	-10.35	1.08e-22	1.15e-19	-0.41	-0.44	Aortic root size;	chr7:66221457	chr7:66493706~66495474:+
PRAD	cis	rs2658782	0.704	rs2605614	ENSG00000279684.1	RP11-755E23.2	-10.35	1.08e-22	1.15e-19	-0.68	-0.44	Pulmonary function decline;	chr11:93499579	chr11:93286629~93288903:-
PRAD	cis	rs2658782	0.615	rs2605615	ENSG00000279684.1	RP11-755E23.2	-10.35	1.08e-22	1.15e-19	-0.68	-0.44	Pulmonary function decline;	chr11:93499902	chr11:93286629~93288903:-
PRAD	cis	rs1577917	0.958	rs12665542	ENSG00000203875.9	SNHG5	-10.35	1.08e-22	1.15e-19	-0.52	-0.44	Response to antipsychotic treatment;	chr6:85834725	chr6:85660950~85678736:-
PRAD	cis	rs11673344	0.864	rs7247589	ENSG00000226686.6	LINC01535	10.35	1.09e-22	1.16e-19	0.6	0.44	Obesity-related traits;	chr19:37019879	chr19:37251912~37265535:+
PRAD	cis	rs9322193	0.962	rs1889473	ENSG00000216906.2	RP11-350J20.9	10.35	1.09e-22	1.16e-19	0.49	0.44	Lung cancer;	chr6:149825485	chr6:149904243~149906418:+
PRAD	cis	rs6860806	0.507	rs272891	ENSG00000233006.5	AC034220.3	10.35	1.09e-22	1.16e-19	0.41	0.44	Breast cancer;	chr5:132328701	chr5:132311285~132369916:-
PRAD	cis	rs7772486	0.686	rs1292334	ENSG00000235652.6	RP11-545I5.3	10.35	1.1e-22	1.17e-19	0.45	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145647152	chr6:145799409~145886585:+
PRAD	cis	rs858239	0.932	rs1624451	ENSG00000226816.2	AC005082.12	-10.35	1.1e-22	1.17e-19	-0.49	-0.44	Cerebrospinal fluid biomarker levels;	chr7:23222816	chr7:23206013~23208045:+
PRAD	cis	rs34779708	0.931	rs34375045	ENSG00000230534.5	RP11-297A16.2	10.35	1.1e-22	1.17e-19	0.59	0.44	Inflammatory bowel disease;Crohn's disease;	chr10:35073428	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.931	rs34304999	ENSG00000230534.5	RP11-297A16.2	10.35	1.1e-22	1.17e-19	0.59	0.44	Inflammatory bowel disease;Crohn's disease;	chr10:35076777	chr10:35098006~35127020:-
PRAD	cis	rs3762637	1	rs9836309	ENSG00000272758.4	RP11-299J3.8	-10.35	1.11e-22	1.18e-19	-0.65	-0.44	LDL cholesterol levels;	chr3:122416348	chr3:122416207~122443180:+
PRAD	cis	rs3762637	0.941	rs9873842	ENSG00000272758.4	RP11-299J3.8	-10.35	1.11e-22	1.18e-19	-0.65	-0.44	LDL cholesterol levels;	chr3:122416484	chr3:122416207~122443180:+
PRAD	cis	rs3762637	1	rs12633461	ENSG00000272758.4	RP11-299J3.8	-10.35	1.11e-22	1.18e-19	-0.65	-0.44	LDL cholesterol levels;	chr3:122417050	chr3:122416207~122443180:+
PRAD	cis	rs3762637	1	rs9879508	ENSG00000272758.4	RP11-299J3.8	-10.35	1.11e-22	1.18e-19	-0.65	-0.44	LDL cholesterol levels;	chr3:122417633	chr3:122416207~122443180:+
PRAD	cis	rs3762637	1	rs9858558	ENSG00000272758.4	RP11-299J3.8	-10.35	1.11e-22	1.18e-19	-0.65	-0.44	LDL cholesterol levels;	chr3:122420895	chr3:122416207~122443180:+
PRAD	cis	rs3762637	1	rs7626861	ENSG00000272758.4	RP11-299J3.8	-10.35	1.11e-22	1.18e-19	-0.65	-0.44	LDL cholesterol levels;	chr3:122436349	chr3:122416207~122443180:+
PRAD	cis	rs3762637	1	rs9842736	ENSG00000272758.4	RP11-299J3.8	-10.35	1.11e-22	1.18e-19	-0.65	-0.44	LDL cholesterol levels;	chr3:122442254	chr3:122416207~122443180:+
PRAD	cis	rs3762637	1	rs13321097	ENSG00000272758.4	RP11-299J3.8	-10.35	1.11e-22	1.18e-19	-0.65	-0.44	LDL cholesterol levels;	chr3:122443160	chr3:122416207~122443180:+
PRAD	cis	rs3762637	0.941	rs112768052	ENSG00000272758.4	RP11-299J3.8	-10.35	1.11e-22	1.18e-19	-0.65	-0.44	LDL cholesterol levels;	chr3:122450537	chr3:122416207~122443180:+
PRAD	cis	rs3762637	0.941	rs77599736	ENSG00000272758.4	RP11-299J3.8	-10.35	1.11e-22	1.18e-19	-0.65	-0.44	LDL cholesterol levels;	chr3:122460662	chr3:122416207~122443180:+
PRAD	cis	rs3762637	0.943	rs10439995	ENSG00000272758.4	RP11-299J3.8	-10.35	1.11e-22	1.18e-19	-0.65	-0.44	LDL cholesterol levels;	chr3:122470313	chr3:122416207~122443180:+
PRAD	cis	rs3762637	0.882	rs7630833	ENSG00000272758.4	RP11-299J3.8	-10.35	1.11e-22	1.18e-19	-0.65	-0.44	LDL cholesterol levels;	chr3:122471577	chr3:122416207~122443180:+
PRAD	cis	rs3762637	1	rs7644540	ENSG00000272758.4	RP11-299J3.8	-10.35	1.11e-22	1.18e-19	-0.65	-0.44	LDL cholesterol levels;	chr3:122491205	chr3:122416207~122443180:+
PRAD	cis	rs3762637	1	rs7645862	ENSG00000272758.4	RP11-299J3.8	-10.35	1.11e-22	1.18e-19	-0.65	-0.44	LDL cholesterol levels;	chr3:122502292	chr3:122416207~122443180:+
PRAD	cis	rs3762637	1	rs78381804	ENSG00000272758.4	RP11-299J3.8	-10.35	1.11e-22	1.18e-19	-0.65	-0.44	LDL cholesterol levels;	chr3:122503415	chr3:122416207~122443180:+
PRAD	cis	rs3762637	1	rs28497203	ENSG00000272758.4	RP11-299J3.8	-10.35	1.11e-22	1.18e-19	-0.65	-0.44	LDL cholesterol levels;	chr3:122512972	chr3:122416207~122443180:+
PRAD	cis	rs3762637	0.943	rs9822345	ENSG00000272758.4	RP11-299J3.8	-10.35	1.11e-22	1.18e-19	-0.65	-0.44	LDL cholesterol levels;	chr3:122526751	chr3:122416207~122443180:+
PRAD	cis	rs6142102	0.659	rs6057945	ENSG00000276073.1	RP5-1125A11.7	-10.35	1.11e-22	1.18e-19	-0.45	-0.44	Skin pigmentation;	chr20:33929374	chr20:33985617~33988989:-
PRAD	cis	rs2348418	0.832	rs1032391	ENSG00000247934.4	RP11-967K21.1	10.35	1.11e-22	1.18e-19	0.4	0.44	Lung function (FEV1);Lung function (FVC);	chr12:28383775	chr12:28163298~28190738:-
PRAD	cis	rs732716	0.785	rs7769	ENSG00000267980.1	AC007292.6	-10.35	1.11e-22	1.18e-19	-0.47	-0.44	Mean corpuscular volume;	chr19:4360546	chr19:4363789~4364640:+
PRAD	cis	rs7849270	0.879	rs6478866	ENSG00000268707.1	RP11-247A12.7	-10.35	1.12e-22	1.19e-19	-0.5	-0.44	Blood metabolite ratios;	chr9:129133585	chr9:129170434~129170940:+
PRAD	cis	rs5769707	0.837	rs5769709	ENSG00000188511.11	C22orf34	10.35	1.12e-22	1.19e-19	0.46	0.44	Monocyte percentage of white cells;Monocyte count;	chr22:49628109	chr22:49414524~49657542:-
PRAD	cis	rs7849270	0.959	rs10739742	ENSG00000268707.1	RP11-247A12.7	-10.35	1.12e-22	1.19e-19	-0.5	-0.44	Blood metabolite ratios;	chr9:129159389	chr9:129170434~129170940:+
PRAD	cis	rs11690935	0.655	rs17614941	ENSG00000228389.1	AC068039.4	-10.35	1.13e-22	1.2e-19	-0.5	-0.44	Schizophrenia;	chr2:171684868	chr2:171773482~171775844:+
PRAD	cis	rs34779708	0.931	rs7084196	ENSG00000230534.5	RP11-297A16.2	10.35	1.13e-22	1.2e-19	0.58	0.44	Inflammatory bowel disease;Crohn's disease;	chr10:35078233	chr10:35098006~35127020:-
PRAD	cis	rs875971	0.825	rs1129531	ENSG00000237310.1	GS1-124K5.4	-10.35	1.13e-22	1.2e-19	-0.4	-0.44	Aortic root size;	chr7:66154117	chr7:66493706~66495474:+
PRAD	cis	rs3096299	0.685	rs4785571	ENSG00000261118.1	RP11-104N10.1	10.35	1.13e-22	1.2e-19	0.44	0.44	Multiple myeloma (IgH translocation);	chr16:89498761	chr16:89492017~89504460:-
PRAD	cis	rs2348418	0.832	rs4930822	ENSG00000247934.4	RP11-967K21.1	10.35	1.13e-22	1.2e-19	0.4	0.44	Lung function (FEV1);Lung function (FVC);	chr12:28421789	chr12:28163298~28190738:-
PRAD	cis	rs2348418	0.832	rs4930823	ENSG00000247934.4	RP11-967K21.1	10.35	1.13e-22	1.2e-19	0.4	0.44	Lung function (FEV1);Lung function (FVC);	chr12:28421892	chr12:28163298~28190738:-
PRAD	cis	rs1075265	0.729	rs10201364	ENSG00000233266.1	HMGB1P31	10.35	1.13e-22	1.21e-19	0.58	0.44	Chronotype;Morning vs. evening chronotype;	chr2:53990220	chr2:54051334~54051760:+
PRAD	cis	rs1891275	0.515	rs7092745	ENSG00000228701.1	TNKS2-AS1	-10.35	1.13e-22	1.21e-19	-0.55	-0.44	Intelligence (multi-trait analysis);	chr10:91724063	chr10:91782839~91798291:-
PRAD	cis	rs7569084	0.663	rs6546150	ENSG00000204929.10	AC074391.1	-10.35	1.14e-22	1.21e-19	-0.6	-0.44	Sum eosinophil basophil counts;	chr2:65415066	chr2:65436711~66084639:+
PRAD	cis	rs9322193	0.923	rs14314	ENSG00000223701.3	RAET1E-AS1	10.35	1.14e-22	1.21e-19	0.59	0.44	Lung cancer;	chr6:149820395	chr6:149884431~149919508:+
PRAD	cis	rs7201929	0.801	rs9933198	ENSG00000259982.1	CDC37P1	-10.34	1.15e-22	1.22e-19	-0.61	-0.44	QT interval;	chr16:28877088	chr16:28700294~28701540:-
PRAD	cis	rs2348418	0.832	rs11049512	ENSG00000247934.4	RP11-967K21.1	10.34	1.15e-22	1.22e-19	0.4	0.44	Lung function (FEV1);Lung function (FVC);	chr12:28295880	chr12:28163298~28190738:-
PRAD	cis	rs1555322	0.53	rs2275275	ENSG00000126005.14	MMP24-AS1	-10.34	1.15e-22	1.22e-19	-0.53	-0.44	Attention deficit hyperactivity disorder;	chr20:35284508	chr20:35216462~35278131:-
PRAD	cis	rs4718428	0.705	rs4717331	ENSG00000232546.1	RP11-458F8.1	-10.34	1.16e-22	1.23e-19	-0.35	-0.44	Corneal structure;	chr7:66913899	chr7:66848496~66858136:+
PRAD	cis	rs34779708	0.966	rs4934732	ENSG00000230534.5	RP11-297A16.2	10.34	1.16e-22	1.23e-19	0.57	0.44	Inflammatory bowel disease;Crohn's disease;	chr10:35142756	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.966	rs878264	ENSG00000230534.5	RP11-297A16.2	10.34	1.16e-22	1.23e-19	0.57	0.44	Inflammatory bowel disease;Crohn's disease;	chr10:35151653	chr10:35098006~35127020:-
PRAD	cis	rs12439619	0.693	rs28665836	ENSG00000278603.1	RP13-608F4.5	10.34	1.17e-22	1.25e-19	0.57	0.44	Intelligence (multi-trait analysis);	chr15:82218955	chr15:82472203~82472426:+
PRAD	cis	rs2739330	0.627	rs9608219	ENSG00000224205.1	AP000351.4	10.34	1.18e-22	1.26e-19	0.54	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23987320~23991421:-
PRAD	cis	rs9487094	0.553	rs13191995	ENSG00000260273.1	RP11-425D10.10	10.34	1.18e-22	1.26e-19	0.65	0.44	Height;	chr6:109645257	chr6:109382795~109383666:+
PRAD	cis	rs2739330	0.791	rs4822458	ENSG00000224205.1	AP000351.4	10.34	1.19e-22	1.26e-19	0.53	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23987320~23991421:-
PRAD	cis	rs34779708	0.897	rs4934716	ENSG00000230534.5	RP11-297A16.2	10.34	1.19e-22	1.26e-19	0.57	0.44	Inflammatory bowel disease;Crohn's disease;	chr10:35080371	chr10:35098006~35127020:-
PRAD	cis	rs9322193	0.961	rs9767713	ENSG00000216906.2	RP11-350J20.9	10.34	1.19e-22	1.26e-19	0.51	0.44	Lung cancer;	chr6:149588241	chr6:149904243~149906418:+
PRAD	cis	rs11673344	0.864	rs7256213	ENSG00000226686.6	LINC01535	10.34	1.19e-22	1.26e-19	0.59	0.44	Obesity-related traits;	chr19:37020589	chr19:37251912~37265535:+
PRAD	cis	rs11673344	0.832	rs8104296	ENSG00000226686.6	LINC01535	10.34	1.19e-22	1.26e-19	0.59	0.44	Obesity-related traits;	chr19:37025634	chr19:37251912~37265535:+
PRAD	cis	rs5760092	0.618	rs5996631	ENSG00000250470.1	AP000351.3	-10.34	1.19e-22	1.27e-19	-0.66	-0.44	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23976904~23977585:-
PRAD	cis	rs1426063	0.614	rs78784058	ENSG00000260265.1	RP11-44F21.5	10.34	1.2e-22	1.27e-19	0.9	0.44	QT interval;	chr4:75108738	chr4:75081702~75084717:-
PRAD	cis	rs6142102	0.961	rs909884	ENSG00000276073.1	RP5-1125A11.7	-10.34	1.2e-22	1.27e-19	-0.46	-0.44	Skin pigmentation;	chr20:34058257	chr20:33985617~33988989:-
PRAD	cis	rs34779708	0.931	rs7897457	ENSG00000230534.5	RP11-297A16.2	10.34	1.2e-22	1.27e-19	0.58	0.44	Inflammatory bowel disease;Crohn's disease;	chr10:35097112	chr10:35098006~35127020:-
PRAD	cis	rs765787	0.53	rs3759895	ENSG00000259520.4	CTD-2651B20.3	10.34	1.2e-22	1.27e-19	0.54	0.44	Uric acid levels;	chr15:45251672	chr15:45251580~45279251:-
PRAD	cis	rs875971	0.862	rs10274883	ENSG00000237310.1	GS1-124K5.4	-10.34	1.21e-22	1.28e-19	-0.41	-0.44	Aortic root size;	chr7:66651104	chr7:66493706~66495474:+
PRAD	cis	rs801193	0.569	rs881285	ENSG00000237310.1	GS1-124K5.4	-10.34	1.21e-22	1.28e-19	-0.41	-0.44	Aortic root size;	chr7:66654433	chr7:66493706~66495474:+
PRAD	cis	rs801193	0.569	rs3846973	ENSG00000237310.1	GS1-124K5.4	-10.34	1.21e-22	1.28e-19	-0.41	-0.44	Aortic root size;	chr7:66655048	chr7:66493706~66495474:+
PRAD	cis	rs9322193	0.923	rs12174035	ENSG00000268592.3	RAET1E-AS1	10.34	1.21e-22	1.28e-19	0.6	0.44	Lung cancer;	chr6:149763311	chr6:149863494~149919507:+
PRAD	cis	rs11951515	0.738	rs56185290	ENSG00000188850.9	RP11-159F24.2	10.34	1.21e-22	1.28e-19	0.52	0.44	Metabolite levels  (X-11787);	chr5:43356604	chr5:43336164~43348716:+
PRAD	cis	rs875971	0.825	rs59466412	ENSG00000237310.1	GS1-124K5.4	-10.34	1.22e-22	1.29e-19	-0.41	-0.44	Aortic root size;	chr7:66100371	chr7:66493706~66495474:+
PRAD	cis	rs2404602	1	rs2896954	ENSG00000259422.1	RP11-593F23.1	10.34	1.22e-22	1.3e-19	0.54	0.44	Blood metabolite levels;	chr15:76559351	chr15:76174891~76181486:-
PRAD	cis	rs1075265	0.722	rs805374	ENSG00000233266.1	HMGB1P31	10.34	1.22e-22	1.3e-19	0.59	0.44	Chronotype;Morning vs. evening chronotype;	chr2:53862720	chr2:54051334~54051760:+
PRAD	cis	rs10129255	0.536	rs10139058	ENSG00000211972.2	IGHV3-66	10.34	1.23e-22	1.3e-19	0.38	0.44	Kawasaki disease;	chr14:106685899	chr14:106675017~106675544:-
PRAD	cis	rs10129255	0.536	rs8004835	ENSG00000211972.2	IGHV3-66	10.34	1.23e-22	1.3e-19	0.38	0.44	Kawasaki disease;	chr14:106686361	chr14:106675017~106675544:-
PRAD	cis	rs9322193	0.962	rs6899661	ENSG00000223701.3	RAET1E-AS1	10.34	1.23e-22	1.3e-19	0.59	0.44	Lung cancer;	chr6:149818093	chr6:149884431~149919508:+
PRAD	cis	rs17023223	0.537	rs10923754	ENSG00000231365.4	RP11-418J17.1	-10.33	1.25e-22	1.32e-19	-0.45	-0.44	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119126017	chr1:119140396~119275973:+
PRAD	cis	rs2739330	0.796	rs1006771	ENSG00000231271.1	AP000350.8	10.33	1.25e-22	1.32e-19	0.58	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23949918~23954042:+
PRAD	cis	rs11951515	0.603	rs59625262	ENSG00000188850.9	RP11-159F24.2	10.33	1.25e-22	1.33e-19	0.52	0.44	Metabolite levels  (X-11787);	chr5:43355270	chr5:43336164~43348716:+
PRAD	cis	rs6964833	0.554	rs112506907	ENSG00000277053.3	GTF2IP1	-10.33	1.26e-22	1.33e-19	-0.47	-0.44	Menarche (age at onset);	chr7:74654407	chr7:75185385~75237696:-
PRAD	cis	rs7849270	1	rs7849270	ENSG00000268707.1	RP11-247A12.7	-10.33	1.27e-22	1.34e-19	-0.49	-0.44	Blood metabolite ratios;	chr9:129112362	chr9:129170434~129170940:+
PRAD	cis	rs4713118	0.662	rs149901	ENSG00000280107.1	AL022393.9	-10.33	1.27e-22	1.35e-19	-0.56	-0.44	Parkinson's disease;	chr6:27997725	chr6:28170845~28172521:+
PRAD	cis	rs11951515	0.738	rs4866821	ENSG00000188850.9	RP11-159F24.2	10.33	1.27e-22	1.35e-19	0.52	0.44	Metabolite levels  (X-11787);	chr5:43353719	chr5:43336164~43348716:+
PRAD	cis	rs11951515	0.603	rs58358642	ENSG00000188850.9	RP11-159F24.2	10.33	1.27e-22	1.35e-19	0.52	0.44	Metabolite levels  (X-11787);	chr5:43355066	chr5:43336164~43348716:+
PRAD	cis	rs11951515	0.628	rs57066570	ENSG00000188850.9	RP11-159F24.2	10.33	1.27e-22	1.35e-19	0.52	0.44	Metabolite levels  (X-11787);	chr5:43355217	chr5:43336164~43348716:+
PRAD	cis	rs9322193	0.962	rs6903998	ENSG00000216906.2	RP11-350J20.9	10.33	1.28e-22	1.35e-19	0.49	0.44	Lung cancer;	chr6:149831357	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.962	rs9688412	ENSG00000223701.3	RAET1E-AS1	-10.33	1.28e-22	1.35e-19	-0.58	-0.44	Lung cancer;	chr6:149803147	chr6:149884431~149919508:+
PRAD	cis	rs4718428	0.705	rs12698547	ENSG00000273142.1	RP11-458F8.4	-10.33	1.28e-22	1.36e-19	-0.34	-0.44	Corneal structure;	chr7:66813271	chr7:66902857~66906297:+
PRAD	cis	rs4713118	0.662	rs175954	ENSG00000280107.1	AL022393.9	-10.33	1.28e-22	1.36e-19	-0.56	-0.44	Parkinson's disease;	chr6:28043807	chr6:28170845~28172521:+
PRAD	cis	rs9322193	0.886	rs4039600	ENSG00000216906.2	RP11-350J20.9	10.33	1.29e-22	1.36e-19	0.51	0.44	Lung cancer;	chr6:149576319	chr6:149904243~149906418:+
PRAD	cis	rs7849270	1	rs10760589	ENSG00000268707.1	RP11-247A12.7	-10.33	1.29e-22	1.36e-19	-0.49	-0.44	Blood metabolite ratios;	chr9:129144014	chr9:129170434~129170940:+
PRAD	cis	rs7849270	0.851	rs1819381	ENSG00000268707.1	RP11-247A12.7	-10.33	1.29e-22	1.36e-19	-0.49	-0.44	Blood metabolite ratios;	chr9:129145728	chr9:129170434~129170940:+
PRAD	cis	rs7849270	1	rs746489	ENSG00000268707.1	RP11-247A12.7	-10.33	1.29e-22	1.36e-19	-0.49	-0.44	Blood metabolite ratios;	chr9:129147814	chr9:129170434~129170940:+
PRAD	cis	rs7849270	0.959	rs913275	ENSG00000268707.1	RP11-247A12.7	-10.33	1.29e-22	1.36e-19	-0.49	-0.44	Blood metabolite ratios;	chr9:129148365	chr9:129170434~129170940:+
PRAD	cis	rs7849270	1	rs7869804	ENSG00000268707.1	RP11-247A12.7	-10.33	1.29e-22	1.36e-19	-0.49	-0.44	Blood metabolite ratios;	chr9:129150865	chr9:129170434~129170940:+
PRAD	cis	rs7849270	1	rs1571229	ENSG00000268707.1	RP11-247A12.7	-10.33	1.29e-22	1.36e-19	-0.49	-0.44	Blood metabolite ratios;	chr9:129151432	chr9:129170434~129170940:+
PRAD	cis	rs2929278	0.588	rs688009	ENSG00000249839.1	AC011330.5	-10.33	1.29e-22	1.36e-19	-0.55	-0.44	Schizophrenia;	chr15:43864104	chr15:43663654~43684339:-
PRAD	cis	rs9322193	0.926	rs9383546	ENSG00000268592.3	RAET1E-AS1	10.33	1.3e-22	1.37e-19	0.6	0.44	Lung cancer;	chr6:149822743	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.923	rs1984111	ENSG00000216906.2	RP11-350J20.9	10.33	1.31e-22	1.38e-19	0.49	0.44	Lung cancer;	chr6:149831720	chr6:149904243~149906418:+
PRAD	cis	rs5769707	0.732	rs135865	ENSG00000188511.11	C22orf34	10.33	1.31e-22	1.39e-19	0.48	0.44	Monocyte percentage of white cells;Monocyte count;	chr22:49611181	chr22:49414524~49657542:-
PRAD	cis	rs6142102	0.961	rs761235	ENSG00000276073.1	RP5-1125A11.7	-10.33	1.31e-22	1.39e-19	-0.45	-0.44	Skin pigmentation;	chr20:33946602	chr20:33985617~33988989:-
PRAD	cis	rs12049351	0.613	rs10458374	ENSG00000229367.1	HMGN2P19	10.33	1.32e-22	1.39e-19	0.68	0.44	Circulating myeloperoxidase levels (plasma);	chr1:229440389	chr1:229570532~229570796:+
PRAD	cis	rs2348418	0.864	rs1949978	ENSG00000247934.4	RP11-967K21.1	10.33	1.32e-22	1.4e-19	0.4	0.44	Lung function (FEV1);Lung function (FVC);	chr12:28443951	chr12:28163298~28190738:-
PRAD	cis	rs9322193	0.886	rs4039600	ENSG00000223701.3	RAET1E-AS1	10.33	1.32e-22	1.4e-19	0.6	0.44	Lung cancer;	chr6:149576319	chr6:149884431~149919508:+
PRAD	cis	rs7174755	0.608	rs62004789	ENSG00000260657.2	RP11-315D16.4	10.33	1.33e-22	1.4e-19	0.55	0.44	Major depressive disorder;	chr15:68148268	chr15:68267792~68277994:-
PRAD	cis	rs1577917	0.958	rs10944147	ENSG00000203875.9	SNHG5	-10.33	1.33e-22	1.4e-19	-0.52	-0.44	Response to antipsychotic treatment;	chr6:85841068	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.958	rs13201730	ENSG00000203875.9	SNHG5	-10.33	1.33e-22	1.4e-19	-0.52	-0.44	Response to antipsychotic treatment;	chr6:85846929	chr6:85660950~85678736:-
PRAD	cis	rs1577917	0.958	rs12196377	ENSG00000203875.9	SNHG5	-10.33	1.33e-22	1.4e-19	-0.52	-0.44	Response to antipsychotic treatment;	chr6:85857057	chr6:85660950~85678736:-
PRAD	cis	rs6964833	0.554	rs112506907	ENSG00000123965.13	PMS2P5	10.33	1.33e-22	1.4e-19	0.61	0.44	Menarche (age at onset);	chr7:74654407	chr7:74894116~74897835:+
PRAD	cis	rs34779708	0.931	rs7099593	ENSG00000230534.5	RP11-297A16.2	10.33	1.33e-22	1.4e-19	0.57	0.44	Inflammatory bowel disease;Crohn's disease;	chr10:35077950	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.931	rs13376801	ENSG00000230534.5	RP11-297A16.2	10.33	1.33e-22	1.4e-19	0.57	0.44	Inflammatory bowel disease;Crohn's disease;	chr10:35081515	chr10:35098006~35127020:-
PRAD	cis	rs1075265	0.716	rs7573991	ENSG00000233266.1	HMGB1P31	10.33	1.33e-22	1.41e-19	0.59	0.44	Chronotype;Morning vs. evening chronotype;	chr2:53726830	chr2:54051334~54051760:+
PRAD	cis	rs9322193	0.607	rs10457852	ENSG00000216906.2	RP11-350J20.9	10.33	1.34e-22	1.41e-19	0.58	0.44	Lung cancer;	chr6:149880584	chr6:149904243~149906418:+
PRAD	cis	rs2739330	0.652	rs2000469	ENSG00000231271.1	AP000350.8	10.32	1.36e-22	1.43e-19	0.6	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23949918~23954042:+
PRAD	cis	rs9322193	0.961	rs9027	ENSG00000216906.2	RP11-350J20.9	10.32	1.36e-22	1.44e-19	0.51	0.44	Lung cancer;	chr6:149594921	chr6:149904243~149906418:+
PRAD	cis	rs2739330	0.791	rs9612520	ENSG00000224205.1	AP000351.4	10.32	1.36e-22	1.44e-19	0.54	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23987320~23991421:-
PRAD	cis	rs6061231	0.793	rs2427320	ENSG00000273619.1	RP5-908M14.9	-10.32	1.36e-22	1.44e-19	-0.32	-0.44	Colorectal cancer;	chr20:62401667	chr20:62386303~62386970:-
PRAD	cis	rs6061231	0.793	rs6061512	ENSG00000273619.1	RP5-908M14.9	-10.32	1.36e-22	1.44e-19	-0.32	-0.44	Colorectal cancer;	chr20:62401873	chr20:62386303~62386970:-
PRAD	cis	rs732716	0.785	rs9973266	ENSG00000267980.1	AC007292.6	-10.32	1.37e-22	1.44e-19	-0.45	-0.44	Mean corpuscular volume;	chr19:4392718	chr19:4363789~4364640:+
PRAD	cis	rs12049351	0.665	rs12140368	ENSG00000229367.1	HMGN2P19	10.32	1.37e-22	1.45e-19	0.63	0.44	Circulating myeloperoxidase levels (plasma);	chr1:229435823	chr1:229570532~229570796:+
PRAD	cis	rs9322193	0.887	rs3734295	ENSG00000223701.3	RAET1E-AS1	10.32	1.38e-22	1.45e-19	0.6	0.44	Lung cancer;	chr6:149593917	chr6:149884431~149919508:+
PRAD	cis	rs853679	0.517	rs9380056	ENSG00000219392.1	RP1-265C24.5	-10.32	1.38e-22	1.45e-19	-0.56	-0.44	Depression;	chr6:28136698	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs9380057	ENSG00000219392.1	RP1-265C24.5	-10.32	1.38e-22	1.45e-19	-0.56	-0.44	Depression;	chr6:28136856	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs1947862	ENSG00000219392.1	RP1-265C24.5	-10.32	1.38e-22	1.45e-19	-0.56	-0.44	Depression;	chr6:28137418	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs6941992	ENSG00000219392.1	RP1-265C24.5	-10.32	1.38e-22	1.45e-19	-0.56	-0.44	Depression;	chr6:28138363	chr6:28115628~28116551:+
PRAD	cis	rs4713118	0.516	rs4713142	ENSG00000219392.1	RP1-265C24.5	-10.32	1.38e-22	1.45e-19	-0.56	-0.44	Parkinson's disease;	chr6:28138569	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs4713143	ENSG00000219392.1	RP1-265C24.5	-10.32	1.38e-22	1.45e-19	-0.56	-0.44	Depression;	chr6:28138981	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs4713144	ENSG00000219392.1	RP1-265C24.5	-10.32	1.38e-22	1.45e-19	-0.56	-0.44	Depression;	chr6:28139012	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs3757187	ENSG00000219392.1	RP1-265C24.5	-10.32	1.38e-22	1.45e-19	-0.56	-0.44	Depression;	chr6:28139876	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs3757185	ENSG00000219392.1	RP1-265C24.5	-10.32	1.38e-22	1.45e-19	-0.56	-0.44	Depression;	chr6:28139998	chr6:28115628~28116551:+
PRAD	cis	rs9532669	0.926	rs9525418	ENSG00000176268.5	CYCSP34	-10.32	1.38e-22	1.46e-19	-0.49	-0.44	Cervical cancer;	chr13:40879081	chr13:40863599~40863902:-
PRAD	cis	rs853679	0.527	rs853693	ENSG00000216901.1	AL022393.7	10.32	1.39e-22	1.46e-19	0.56	0.44	Depression;	chr6:28314871	chr6:28176188~28176674:+
PRAD	cis	rs11118620	0.853	rs12037861	ENSG00000238078.1	LINC01352	10.32	1.39e-22	1.47e-19	0.59	0.44	Heart failure;	chr1:220864835	chr1:220829255~220832429:+
PRAD	cis	rs9322193	0.607	rs7764677	ENSG00000223701.3	RAET1E-AS1	10.32	1.39e-22	1.47e-19	0.66	0.44	Lung cancer;	chr6:149906197	chr6:149884431~149919508:+
PRAD	cis	rs10170846	0.893	rs11692810	ENSG00000261428.2	RP11-16P6.1	-10.32	1.39e-22	1.47e-19	-0.57	-0.44	Schizophrenia (inflammation and infection response interaction);	chr2:222679377	chr2:222566899~222569719:-
PRAD	cis	rs10170846	0.893	rs10932967	ENSG00000261428.2	RP11-16P6.1	10.32	1.39e-22	1.47e-19	0.57	0.44	Schizophrenia (inflammation and infection response interaction);	chr2:222679392	chr2:222566899~222569719:-
PRAD	cis	rs6504950	0.566	rs12937360	ENSG00000275710.1	RP11-257O5.4	10.32	1.4e-22	1.47e-19	0.52	0.44	Breast cancer;	chr17:54968937	chr17:54964474~54964679:+
PRAD	cis	rs7772486	0.658	rs9403737	ENSG00000235652.6	RP11-545I5.3	10.32	1.41e-22	1.49e-19	0.45	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145641057	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.754	rs4896832	ENSG00000235652.6	RP11-545I5.3	10.32	1.41e-22	1.49e-19	0.45	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145643015	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.686	rs857883	ENSG00000235652.6	RP11-545I5.3	-10.32	1.41e-22	1.49e-19	-0.45	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145648078	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.686	rs857882	ENSG00000235652.6	RP11-545I5.3	-10.32	1.41e-22	1.49e-19	-0.45	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145648580	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.686	rs857877	ENSG00000235652.6	RP11-545I5.3	-10.32	1.41e-22	1.49e-19	-0.45	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145655094	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.791	rs9497357	ENSG00000235652.6	RP11-545I5.3	10.32	1.41e-22	1.49e-19	0.45	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145591752	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.764	rs4263604	ENSG00000235652.6	RP11-545I5.3	10.32	1.41e-22	1.49e-19	0.45	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145595561	chr6:145799409~145886585:+
PRAD	cis	rs34779708	0.966	rs34776628	ENSG00000230534.5	RP11-297A16.2	10.32	1.41e-22	1.49e-19	0.57	0.44	Inflammatory bowel disease;Crohn's disease;	chr10:35137396	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.966	rs17499247	ENSG00000230534.5	RP11-297A16.2	10.32	1.41e-22	1.49e-19	0.57	0.44	Inflammatory bowel disease;Crohn's disease;	chr10:35137827	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.966	rs10827491	ENSG00000230534.5	RP11-297A16.2	10.32	1.41e-22	1.49e-19	0.57	0.44	Inflammatory bowel disease;Crohn's disease;	chr10:35138467	chr10:35098006~35127020:-
PRAD	cis	rs11673344	0.864	rs11670216	ENSG00000226686.6	LINC01535	10.32	1.42e-22	1.5e-19	0.6	0.44	Obesity-related traits;	chr19:37012526	chr19:37251912~37265535:+
PRAD	cis	rs11673344	0.864	rs8104919	ENSG00000226686.6	LINC01535	10.32	1.42e-22	1.5e-19	0.6	0.44	Obesity-related traits;	chr19:37012881	chr19:37251912~37265535:+
PRAD	cis	rs9545047	0.604	rs9530906	ENSG00000227676.3	LINC01068	10.32	1.43e-22	1.51e-19	0.52	0.44	Schizophrenia;	chr13:79372401	chr13:79566727~79571436:+
PRAD	cis	rs1075265	0.692	rs805361	ENSG00000233266.1	HMGB1P31	10.32	1.44e-22	1.52e-19	0.57	0.44	Chronotype;Morning vs. evening chronotype;	chr2:53938709	chr2:54051334~54051760:+
PRAD	cis	rs2282300	0.739	rs1222210	ENSG00000242353.1	RP4-710M3.1	10.32	1.44e-22	1.52e-19	0.53	0.44	Morning vs. evening chronotype;	chr11:30340578	chr11:30368148~30368646:+
PRAD	cis	rs9322193	0.923	rs12211511	ENSG00000268592.3	RAET1E-AS1	10.32	1.44e-22	1.52e-19	0.6	0.44	Lung cancer;	chr6:149745206	chr6:149863494~149919507:+
PRAD	cis	rs2739330	0.828	rs5760102	ENSG00000272787.1	KB-226F1.2	-10.32	1.45e-22	1.52e-19	-0.47	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23969211~23969873:+
PRAD	cis	rs2442825	0.693	rs2728949	ENSG00000206573.7	THUMPD3-AS1	10.32	1.45e-22	1.53e-19	0.31	0.44	Cerebrospinal fluid clusterin levels;	chr3:9364977	chr3:9349689~9398579:-
PRAD	cis	rs853679	0.517	rs9393893	ENSG00000219392.1	RP1-265C24.5	-10.32	1.45e-22	1.53e-19	-0.57	-0.44	Depression;	chr6:28141484	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs4713146	ENSG00000219392.1	RP1-265C24.5	-10.32	1.45e-22	1.53e-19	-0.57	-0.44	Depression;	chr6:28143758	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs9393894	ENSG00000219392.1	RP1-265C24.5	-10.32	1.45e-22	1.53e-19	-0.57	-0.44	Depression;	chr6:28144784	chr6:28115628~28116551:+
PRAD	cis	rs2348418	0.832	rs1405811	ENSG00000247934.4	RP11-967K21.1	10.32	1.45e-22	1.53e-19	0.4	0.44	Lung function (FEV1);Lung function (FVC);	chr12:28428169	chr12:28163298~28190738:-
PRAD	cis	rs853679	0.628	rs9368560	ENSG00000280107.1	AL022393.9	-10.32	1.46e-22	1.53e-19	-0.57	-0.44	Depression;	chr6:28192182	chr6:28170845~28172521:+
PRAD	cis	rs1891275	0.55	rs4933694	ENSG00000228701.1	TNKS2-AS1	-10.32	1.46e-22	1.53e-19	-0.55	-0.44	Intelligence (multi-trait analysis);	chr10:91739456	chr10:91782839~91798291:-
PRAD	cis	rs6964833	0.554	rs2527367	ENSG00000123965.13	PMS2P5	-10.32	1.46e-22	1.54e-19	-0.61	-0.44	Menarche (age at onset);	chr7:74684804	chr7:74894116~74897835:+
PRAD	cis	rs1075265	0.818	rs12713253	ENSG00000233266.1	HMGB1P31	10.32	1.47e-22	1.54e-19	0.59	0.44	Chronotype;Morning vs. evening chronotype;	chr2:54037323	chr2:54051334~54051760:+
PRAD	cis	rs2348418	0.83	rs7977418	ENSG00000247934.4	RP11-967K21.1	10.32	1.47e-22	1.55e-19	0.4	0.44	Lung function (FEV1);Lung function (FVC);	chr12:28435309	chr12:28163298~28190738:-
PRAD	cis	rs1075265	0.87	rs17268179	ENSG00000233266.1	HMGB1P31	10.31	1.47e-22	1.55e-19	0.59	0.44	Chronotype;Morning vs. evening chronotype;	chr2:54036876	chr2:54051334~54051760:+
PRAD	cis	rs9322193	0.923	rs10872645	ENSG00000268592.3	RAET1E-AS1	10.31	1.49e-22	1.56e-19	0.6	0.44	Lung cancer;	chr6:149742840	chr6:149863494~149919507:+
PRAD	cis	rs6142102	0.961	rs1555075	ENSG00000276073.1	RP5-1125A11.7	-10.31	1.49e-22	1.57e-19	-0.46	-0.44	Skin pigmentation;	chr20:34022595	chr20:33985617~33988989:-
PRAD	cis	rs34779708	0.771	rs12098283	ENSG00000230534.5	RP11-297A16.2	10.31	1.49e-22	1.57e-19	0.58	0.44	Inflammatory bowel disease;Crohn's disease;	chr10:35189187	chr10:35098006~35127020:-
PRAD	cis	rs9322193	0.962	rs10872653	ENSG00000268592.3	RAET1E-AS1	10.31	1.5e-22	1.58e-19	0.6	0.44	Lung cancer;	chr6:149778907	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.923	rs11155683	ENSG00000268592.3	RAET1E-AS1	10.31	1.5e-22	1.58e-19	0.6	0.44	Lung cancer;	chr6:149779341	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.923	rs9372044	ENSG00000268592.3	RAET1E-AS1	10.31	1.5e-22	1.58e-19	0.6	0.44	Lung cancer;	chr6:149780867	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.962	rs11155685	ENSG00000268592.3	RAET1E-AS1	10.31	1.5e-22	1.58e-19	0.6	0.44	Lung cancer;	chr6:149781649	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.962	rs9689269	ENSG00000268592.3	RAET1E-AS1	10.31	1.5e-22	1.58e-19	0.6	0.44	Lung cancer;	chr6:149791861	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.962	rs62441335	ENSG00000268592.3	RAET1E-AS1	10.31	1.5e-22	1.58e-19	0.6	0.44	Lung cancer;	chr6:149792658	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.962	rs4816	ENSG00000268592.3	RAET1E-AS1	10.31	1.5e-22	1.58e-19	0.6	0.44	Lung cancer;	chr6:149793609	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.926	rs952166	ENSG00000268592.3	RAET1E-AS1	10.31	1.5e-22	1.58e-19	0.6	0.44	Lung cancer;	chr6:149798774	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.962	rs952165	ENSG00000268592.3	RAET1E-AS1	10.31	1.5e-22	1.58e-19	0.6	0.44	Lung cancer;	chr6:149798900	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.926	rs9285525	ENSG00000268592.3	RAET1E-AS1	10.31	1.5e-22	1.58e-19	0.6	0.44	Lung cancer;	chr6:149801253	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.962	rs6914319	ENSG00000268592.3	RAET1E-AS1	10.31	1.5e-22	1.58e-19	0.6	0.44	Lung cancer;	chr6:149806304	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.884	rs2095375	ENSG00000268592.3	RAET1E-AS1	10.31	1.5e-22	1.58e-19	0.6	0.44	Lung cancer;	chr6:149807037	chr6:149863494~149919507:+
PRAD	cis	rs2658782	0.654	rs2605617	ENSG00000279684.1	RP11-755E23.2	-10.31	1.51e-22	1.59e-19	-0.68	-0.44	Pulmonary function decline;	chr11:93510167	chr11:93286629~93288903:-
PRAD	cis	rs1075265	0.749	rs805434	ENSG00000233266.1	HMGB1P31	10.31	1.52e-22	1.59e-19	0.6	0.44	Chronotype;Morning vs. evening chronotype;	chr2:53836196	chr2:54051334~54051760:+
PRAD	cis	rs150992	0.673	rs330419	ENSG00000248489.1	CTD-2007H13.3	-10.31	1.52e-22	1.59e-19	-0.49	-0.44	Body mass index;	chr5:98857460	chr5:98929171~98995013:+
PRAD	cis	rs270601	0.955	rs273911	ENSG00000233006.5	AC034220.3	10.31	1.53e-22	1.6e-19	0.4	0.44	Acylcarnitine levels;	chr5:132325833	chr5:132311285~132369916:-
PRAD	cis	rs801193	0.569	rs2013908	ENSG00000237310.1	GS1-124K5.4	-10.31	1.53e-22	1.6e-19	-0.41	-0.44	Aortic root size;	chr7:66656082	chr7:66493706~66495474:+
PRAD	cis	rs801193	0.569	rs13242290	ENSG00000237310.1	GS1-124K5.4	-10.31	1.53e-22	1.6e-19	-0.41	-0.44	Aortic root size;	chr7:66656898	chr7:66493706~66495474:+
PRAD	cis	rs801193	0.548	rs2109297	ENSG00000237310.1	GS1-124K5.4	-10.31	1.53e-22	1.6e-19	-0.41	-0.44	Aortic root size;	chr7:66657397	chr7:66493706~66495474:+
PRAD	cis	rs801193	0.569	rs6978178	ENSG00000237310.1	GS1-124K5.4	-10.31	1.53e-22	1.6e-19	-0.41	-0.44	Aortic root size;	chr7:66658097	chr7:66493706~66495474:+
PRAD	cis	rs801193	0.591	rs721717	ENSG00000237310.1	GS1-124K5.4	-10.31	1.53e-22	1.6e-19	-0.41	-0.44	Aortic root size;	chr7:66665305	chr7:66493706~66495474:+
PRAD	cis	rs801193	0.569	rs6951302	ENSG00000237310.1	GS1-124K5.4	-10.31	1.53e-22	1.6e-19	-0.41	-0.44	Aortic root size;	chr7:66667525	chr7:66493706~66495474:+
PRAD	cis	rs1891275	0.515	rs2421694	ENSG00000228701.1	TNKS2-AS1	-10.31	1.53e-22	1.6e-19	-0.55	-0.44	Intelligence (multi-trait analysis);	chr10:91756347	chr10:91782839~91798291:-
PRAD	cis	rs9322193	0.962	rs3805753	ENSG00000268592.3	RAET1E-AS1	10.31	1.53e-22	1.61e-19	0.6	0.44	Lung cancer;	chr6:149795662	chr6:149863494~149919507:+
PRAD	cis	rs34779708	0.897	rs9665538	ENSG00000230534.5	RP11-297A16.2	10.31	1.54e-22	1.61e-19	0.57	0.44	Inflammatory bowel disease;Crohn's disease;	chr10:35172110	chr10:35098006~35127020:-
PRAD	cis	rs4713118	0.699	rs573179	ENSG00000280107.1	AL022393.9	-10.31	1.54e-22	1.61e-19	-0.57	-0.44	Parkinson's disease;	chr6:27881898	chr6:28170845~28172521:+
PRAD	cis	rs1426063	0.614	rs17000260	ENSG00000260265.1	RP11-44F21.5	10.31	1.54e-22	1.62e-19	0.9	0.44	QT interval;	chr4:75108576	chr4:75081702~75084717:-
PRAD	cis	rs853679	0.517	rs9283884	ENSG00000219392.1	RP1-265C24.5	10.31	1.56e-22	1.63e-19	0.57	0.44	Depression;	chr6:28167882	chr6:28115628~28116551:+
PRAD	cis	rs10246939	0.544	rs6955562	ENSG00000228775.6	WEE2-AS1	10.31	1.56e-22	1.63e-19	0.57	0.44	Bitter taste perception;	chr7:141886641	chr7:141704338~141738346:-
PRAD	cis	rs6860806	0.507	rs273917	ENSG00000233006.5	AC034220.3	10.31	1.57e-22	1.64e-19	0.4	0.44	Breast cancer;	chr5:132323925	chr5:132311285~132369916:-
PRAD	cis	rs6860806	0.507	rs2631364	ENSG00000233006.5	AC034220.3	-10.31	1.59e-22	1.66e-19	-0.41	-0.44	Breast cancer;	chr5:132371222	chr5:132311285~132369916:-
PRAD	cis	rs9322193	0.923	rs9479810	ENSG00000268592.3	RAET1E-AS1	10.31	1.59e-22	1.67e-19	0.6	0.44	Lung cancer;	chr6:149751359	chr6:149863494~149919507:+
PRAD	cis	rs1075265	0.749	rs805436	ENSG00000233266.1	HMGB1P31	10.31	1.6e-22	1.67e-19	0.59	0.44	Chronotype;Morning vs. evening chronotype;	chr2:53837843	chr2:54051334~54051760:+
PRAD	cis	rs9322193	0.962	rs2275046	ENSG00000268592.3	RAET1E-AS1	10.3	1.6e-22	1.68e-19	0.6	0.43	Lung cancer;	chr6:149835865	chr6:149863494~149919507:+
PRAD	cis	rs853679	0.517	rs9380047	ENSG00000219392.1	RP1-265C24.5	-10.3	1.61e-22	1.69e-19	-0.57	-0.43	Depression;	chr6:28070115	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs7755442	ENSG00000219392.1	RP1-265C24.5	-10.3	1.61e-22	1.69e-19	-0.57	-0.43	Depression;	chr6:28071237	chr6:28115628~28116551:+
PRAD	cis	rs11723261	0.621	rs7440274	ENSG00000275426.1	CH17-262A2.1	-10.3	1.63e-22	1.71e-19	-0.61	-0.43	Immune response to smallpox vaccine (IL-6);	chr4:161923	chr4:149738~150317:+
PRAD	cis	rs7743045	0.625	rs12664251	ENSG00000253194.1	RP11-351A11.1	10.3	1.64e-22	1.72e-19	0.57	0.43	Mean platelet volume;	chr6:119023381	chr6:118934785~119031541:+
PRAD	cis	rs7684253	0.548	rs13106200	ENSG00000269949.1	RP11-738E22.3	-10.3	1.64e-22	1.72e-19	-0.51	-0.43	Migraine;	chr4:56852029	chr4:56960927~56961373:-
PRAD	cis	rs11951515	0.7	rs11740128	ENSG00000188850.9	RP11-159F24.2	-10.3	1.64e-22	1.72e-19	-0.52	-0.43	Metabolite levels  (X-11787);	chr5:43283918	chr5:43336164~43348716:+
PRAD	cis	rs9322193	0.962	rs10872653	ENSG00000223701.3	RAET1E-AS1	10.3	1.65e-22	1.72e-19	0.58	0.43	Lung cancer;	chr6:149778907	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.923	rs11155683	ENSG00000223701.3	RAET1E-AS1	10.3	1.65e-22	1.72e-19	0.58	0.43	Lung cancer;	chr6:149779341	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.923	rs9372044	ENSG00000223701.3	RAET1E-AS1	10.3	1.65e-22	1.72e-19	0.58	0.43	Lung cancer;	chr6:149780867	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.962	rs11155685	ENSG00000223701.3	RAET1E-AS1	10.3	1.65e-22	1.72e-19	0.58	0.43	Lung cancer;	chr6:149781649	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.962	rs9689269	ENSG00000223701.3	RAET1E-AS1	10.3	1.65e-22	1.72e-19	0.58	0.43	Lung cancer;	chr6:149791861	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.962	rs62441335	ENSG00000223701.3	RAET1E-AS1	10.3	1.65e-22	1.72e-19	0.58	0.43	Lung cancer;	chr6:149792658	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.962	rs4816	ENSG00000223701.3	RAET1E-AS1	10.3	1.65e-22	1.72e-19	0.58	0.43	Lung cancer;	chr6:149793609	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.926	rs952166	ENSG00000223701.3	RAET1E-AS1	10.3	1.65e-22	1.72e-19	0.58	0.43	Lung cancer;	chr6:149798774	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.962	rs952165	ENSG00000223701.3	RAET1E-AS1	10.3	1.65e-22	1.72e-19	0.58	0.43	Lung cancer;	chr6:149798900	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.926	rs9285525	ENSG00000223701.3	RAET1E-AS1	10.3	1.65e-22	1.72e-19	0.58	0.43	Lung cancer;	chr6:149801253	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.962	rs6914319	ENSG00000223701.3	RAET1E-AS1	10.3	1.65e-22	1.72e-19	0.58	0.43	Lung cancer;	chr6:149806304	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.884	rs2095375	ENSG00000223701.3	RAET1E-AS1	10.3	1.65e-22	1.72e-19	0.58	0.43	Lung cancer;	chr6:149807037	chr6:149884431~149919508:+
PRAD	cis	rs6452524	0.534	rs11746747	ENSG00000249664.1	CTD-2227C6.2	10.3	1.65e-22	1.72e-19	0.53	0.43	Hypertension (SNP x SNP interaction);	chr5:83067666	chr5:83012285~83013109:-
PRAD	cis	rs9322193	0.962	rs1413655	ENSG00000268592.3	RAET1E-AS1	10.3	1.65e-22	1.73e-19	0.59	0.43	Lung cancer;	chr6:149821815	chr6:149863494~149919507:+
PRAD	cis	rs6570726	0.791	rs1509213	ENSG00000235652.6	RP11-545I5.3	-10.3	1.67e-22	1.74e-19	-0.45	-0.43	Lobe attachment (rater-scored or self-reported);	chr6:145462224	chr6:145799409~145886585:+
PRAD	cis	rs1075265	0.783	rs805450	ENSG00000233266.1	HMGB1P31	10.3	1.68e-22	1.75e-19	0.58	0.43	Chronotype;Morning vs. evening chronotype;	chr2:53951772	chr2:54051334~54051760:+
PRAD	cis	rs9322193	0.923	rs12175504	ENSG00000223701.3	RAET1E-AS1	10.3	1.68e-22	1.76e-19	0.59	0.43	Lung cancer;	chr6:149664079	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.962	rs62439843	ENSG00000223701.3	RAET1E-AS1	10.3	1.68e-22	1.76e-19	0.59	0.43	Lung cancer;	chr6:149676521	chr6:149884431~149919508:+
PRAD	cis	rs1426063	0.614	rs17000262	ENSG00000260265.1	RP11-44F21.5	10.3	1.69e-22	1.76e-19	0.9	0.43	QT interval;	chr4:75108836	chr4:75081702~75084717:-
PRAD	cis	rs853679	0.542	rs9380063	ENSG00000219392.1	RP1-265C24.5	-10.3	1.69e-22	1.76e-19	-0.57	-0.43	Depression;	chr6:28170075	chr6:28115628~28116551:+
PRAD	cis	rs2404602	0.684	rs3910756	ENSG00000259422.1	RP11-593F23.1	-10.3	1.69e-22	1.77e-19	-0.58	-0.43	Blood metabolite levels;	chr15:76653028	chr15:76174891~76181486:-
PRAD	cis	rs8100891	0.665	rs7259259	ENSG00000267213.4	AC007773.2	-10.3	1.71e-22	1.78e-19	-0.45	-0.43	Neuroticism;	chr19:32328935	chr19:32390050~32405560:-
PRAD	cis	rs12439619	0.53	rs7162177	ENSG00000278603.1	RP13-608F4.5	10.3	1.71e-22	1.78e-19	0.56	0.43	Intelligence (multi-trait analysis);	chr15:82181728	chr15:82472203~82472426:+
PRAD	cis	rs9322193	0.887	rs4870139	ENSG00000216906.2	RP11-350J20.9	10.3	1.71e-22	1.78e-19	0.51	0.43	Lung cancer;	chr6:149575182	chr6:149904243~149906418:+
PRAD	cis	rs732716	0.785	rs11667543	ENSG00000267980.1	AC007292.6	-10.3	1.73e-22	1.81e-19	-0.46	-0.43	Mean corpuscular volume;	chr19:4374853	chr19:4363789~4364640:+
PRAD	cis	rs6570726	0.599	rs9403725	ENSG00000235652.6	RP11-545I5.3	-10.3	1.73e-22	1.81e-19	-0.5	-0.43	Lobe attachment (rater-scored or self-reported);	chr6:145576486	chr6:145799409~145886585:+
PRAD	cis	rs7849270	1	rs10988224	ENSG00000268707.1	RP11-247A12.7	-10.3	1.74e-22	1.82e-19	-0.49	-0.43	Blood metabolite ratios;	chr9:129141055	chr9:129170434~129170940:+
PRAD	cis	rs9322193	0.923	rs9479810	ENSG00000223701.3	RAET1E-AS1	10.29	1.75e-22	1.83e-19	0.58	0.43	Lung cancer;	chr6:149751359	chr6:149884431~149919508:+
PRAD	cis	rs2348418	0.831	rs1581074	ENSG00000247934.4	RP11-967K21.1	10.29	1.78e-22	1.86e-19	0.4	0.43	Lung function (FEV1);Lung function (FVC);	chr12:28571031	chr12:28163298~28190738:-
PRAD	cis	rs2153535	0.935	rs11243254	ENSG00000230939.1	RP11-314C16.1	10.29	1.78e-22	1.86e-19	0.53	0.43	Motion sickness;	chr6:8381009	chr6:8784178~8785445:+
PRAD	cis	rs9322193	0.566	rs4870118	ENSG00000268592.3	RAET1E-AS1	-10.29	1.79e-22	1.87e-19	-0.68	-0.43	Lung cancer;	chr6:149923877	chr6:149863494~149919507:+
PRAD	cis	rs2348418	0.831	rs10843173	ENSG00000247934.4	RP11-967K21.1	10.29	1.79e-22	1.87e-19	0.4	0.43	Lung function (FEV1);Lung function (FVC);	chr12:28453092	chr12:28163298~28190738:-
PRAD	cis	rs2348418	0.864	rs10843174	ENSG00000247934.4	RP11-967K21.1	10.29	1.79e-22	1.87e-19	0.4	0.43	Lung function (FEV1);Lung function (FVC);	chr12:28453135	chr12:28163298~28190738:-
PRAD	cis	rs2348418	0.864	rs7299039	ENSG00000247934.4	RP11-967K21.1	10.29	1.79e-22	1.87e-19	0.4	0.43	Lung function (FEV1);Lung function (FVC);	chr12:28454083	chr12:28163298~28190738:-
PRAD	cis	rs11673344	0.864	rs12151313	ENSG00000226686.6	LINC01535	10.29	1.8e-22	1.87e-19	0.6	0.43	Obesity-related traits;	chr19:37072309	chr19:37251912~37265535:+
PRAD	cis	rs10246939	0.505	rs12703409	ENSG00000228775.6	WEE2-AS1	10.29	1.8e-22	1.87e-19	0.58	0.43	Bitter taste perception;	chr7:141812058	chr7:141704338~141738346:-
PRAD	cis	rs7684253	0.548	rs62308071	ENSG00000269949.1	RP11-738E22.3	-10.29	1.8e-22	1.88e-19	-0.51	-0.43	Migraine;	chr4:56850720	chr4:56960927~56961373:-
PRAD	cis	rs853679	0.517	rs9393884	ENSG00000219392.1	RP1-265C24.5	-10.29	1.82e-22	1.89e-19	-0.57	-0.43	Depression;	chr6:28079011	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs9393887	ENSG00000219392.1	RP1-265C24.5	-10.29	1.82e-22	1.89e-19	-0.57	-0.43	Depression;	chr6:28091242	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.542	rs9393892	ENSG00000219392.1	RP1-265C24.5	-10.29	1.82e-22	1.89e-19	-0.57	-0.43	Depression;	chr6:28113616	chr6:28115628~28116551:+
PRAD	cis	rs4718428	0.705	rs4717328	ENSG00000273142.1	RP11-458F8.4	-10.29	1.83e-22	1.91e-19	-0.34	-0.43	Corneal structure;	chr7:66887678	chr7:66902857~66906297:+
PRAD	cis	rs4718428	0.705	rs4718422	ENSG00000273142.1	RP11-458F8.4	-10.29	1.83e-22	1.91e-19	-0.34	-0.43	Corneal structure;	chr7:66894282	chr7:66902857~66906297:+
PRAD	cis	rs4718428	0.705	rs13231140	ENSG00000273142.1	RP11-458F8.4	-10.29	1.83e-22	1.91e-19	-0.34	-0.43	Corneal structure;	chr7:66896631	chr7:66902857~66906297:+
PRAD	cis	rs4718428	0.705	rs4718424	ENSG00000273142.1	RP11-458F8.4	-10.29	1.83e-22	1.91e-19	-0.34	-0.43	Corneal structure;	chr7:66911108	chr7:66902857~66906297:+
PRAD	cis	rs9322193	0.962	rs3805753	ENSG00000223701.3	RAET1E-AS1	10.29	1.84e-22	1.91e-19	0.58	0.43	Lung cancer;	chr6:149795662	chr6:149884431~149919508:+
PRAD	cis	rs34779708	0.966	rs12773647	ENSG00000230534.5	RP11-297A16.2	10.29	1.84e-22	1.92e-19	0.58	0.43	Inflammatory bowel disease;Crohn's disease;	chr10:35151399	chr10:35098006~35127020:-
PRAD	cis	rs9326248	0.53	rs900012	ENSG00000254851.1	RP11-109L13.1	-10.29	1.85e-22	1.92e-19	-0.89	-0.43	Blood protein levels;	chr11:117095719	chr11:117135528~117138582:+
PRAD	cis	rs34779708	0.931	rs3740083	ENSG00000230534.5	RP11-297A16.2	10.29	1.85e-22	1.92e-19	0.58	0.43	Inflammatory bowel disease;Crohn's disease;	chr10:35031455	chr10:35098006~35127020:-
PRAD	cis	rs9322193	0.962	rs12175575	ENSG00000223701.3	RAET1E-AS1	10.29	1.85e-22	1.93e-19	0.58	0.43	Lung cancer;	chr6:149763351	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.962	rs4869966	ENSG00000223701.3	RAET1E-AS1	10.29	1.85e-22	1.93e-19	0.58	0.43	Lung cancer;	chr6:149763714	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.962	rs1112730	ENSG00000223701.3	RAET1E-AS1	10.29	1.85e-22	1.93e-19	0.58	0.43	Lung cancer;	chr6:149766383	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.923	rs1112729	ENSG00000223701.3	RAET1E-AS1	10.29	1.85e-22	1.93e-19	0.58	0.43	Lung cancer;	chr6:149766491	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.962	rs10452626	ENSG00000223701.3	RAET1E-AS1	10.29	1.85e-22	1.93e-19	0.58	0.43	Lung cancer;	chr6:149767481	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.923	rs62441303	ENSG00000223701.3	RAET1E-AS1	10.29	1.85e-22	1.93e-19	0.58	0.43	Lung cancer;	chr6:149767547	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.962	rs9765929	ENSG00000223701.3	RAET1E-AS1	10.29	1.85e-22	1.93e-19	0.58	0.43	Lung cancer;	chr6:149769680	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.962	rs3805748	ENSG00000223701.3	RAET1E-AS1	10.29	1.85e-22	1.93e-19	0.58	0.43	Lung cancer;	chr6:149772542	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.736	rs10457851	ENSG00000223701.3	RAET1E-AS1	10.29	1.85e-22	1.93e-19	0.58	0.43	Lung cancer;	chr6:149775216	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.886	rs10872652	ENSG00000223701.3	RAET1E-AS1	10.29	1.85e-22	1.93e-19	0.58	0.43	Lung cancer;	chr6:149775303	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.886	rs12525871	ENSG00000223701.3	RAET1E-AS1	10.29	1.85e-22	1.93e-19	0.58	0.43	Lung cancer;	chr6:149775882	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.886	rs17672976	ENSG00000223701.3	RAET1E-AS1	10.29	1.85e-22	1.93e-19	0.58	0.43	Lung cancer;	chr6:149776207	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.923	rs2184369	ENSG00000223701.3	RAET1E-AS1	10.29	1.85e-22	1.93e-19	0.58	0.43	Lung cancer;	chr6:149776681	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.962	rs2342861	ENSG00000223701.3	RAET1E-AS1	10.29	1.85e-22	1.93e-19	0.58	0.43	Lung cancer;	chr6:149777561	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.926	rs2342860	ENSG00000223701.3	RAET1E-AS1	10.29	1.85e-22	1.93e-19	0.58	0.43	Lung cancer;	chr6:149777641	chr6:149884431~149919508:+
PRAD	cis	rs4814920	0.756	rs1543472	ENSG00000275142.1	RP5-999L4.2	10.29	1.88e-22	1.96e-19	0.67	0.43	Bipolar disorder (body mass index interaction);	chr20:19867383	chr20:19871891~19872284:+
PRAD	cis	rs7684253	0.548	rs922570	ENSG00000269949.1	RP11-738E22.3	-10.29	1.88e-22	1.96e-19	-0.51	-0.43	Migraine;	chr4:56851192	chr4:56960927~56961373:-
PRAD	cis	rs2348418	0.832	rs4244844	ENSG00000247934.4	RP11-967K21.1	10.29	1.88e-22	1.96e-19	0.4	0.43	Lung function (FEV1);Lung function (FVC);	chr12:28434062	chr12:28163298~28190738:-
PRAD	cis	rs34779708	1	rs34779708	ENSG00000230534.5	RP11-297A16.2	10.29	1.88e-22	1.96e-19	0.58	0.43	Inflammatory bowel disease;Crohn's disease;	chr10:35177257	chr10:35098006~35127020:-
PRAD	cis	rs853679	0.517	rs12174753	ENSG00000219392.1	RP1-265C24.5	-10.29	1.89e-22	1.96e-19	-0.56	-0.43	Depression;	chr6:28074687	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs55747925	ENSG00000219392.1	RP1-265C24.5	-10.29	1.89e-22	1.96e-19	-0.56	-0.43	Depression;	chr6:28076559	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs56310871	ENSG00000219392.1	RP1-265C24.5	-10.29	1.89e-22	1.96e-19	-0.56	-0.43	Depression;	chr6:28076704	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs34716816	ENSG00000219392.1	RP1-265C24.5	-10.29	1.89e-22	1.96e-19	-0.56	-0.43	Depression;	chr6:28078391	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs9380049	ENSG00000219392.1	RP1-265C24.5	-10.29	1.89e-22	1.96e-19	-0.56	-0.43	Depression;	chr6:28080757	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs9380050	ENSG00000219392.1	RP1-265C24.5	-10.29	1.89e-22	1.96e-19	-0.56	-0.43	Depression;	chr6:28080760	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs9393885	ENSG00000219392.1	RP1-265C24.5	-10.29	1.89e-22	1.96e-19	-0.56	-0.43	Depression;	chr6:28082231	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs9393886	ENSG00000219392.1	RP1-265C24.5	-10.29	1.89e-22	1.96e-19	-0.56	-0.43	Depression;	chr6:28082261	chr6:28115628~28116551:+
PRAD	cis	rs4713118	0.515	rs9368549	ENSG00000219392.1	RP1-265C24.5	-10.29	1.89e-22	1.96e-19	-0.56	-0.43	Parkinson's disease;	chr6:28082269	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs56364346	ENSG00000219392.1	RP1-265C24.5	-10.29	1.89e-22	1.96e-19	-0.56	-0.43	Depression;	chr6:28082984	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs9357061	ENSG00000219392.1	RP1-265C24.5	-10.29	1.89e-22	1.96e-19	-0.56	-0.43	Depression;	chr6:28083994	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs9368550	ENSG00000219392.1	RP1-265C24.5	-10.29	1.89e-22	1.96e-19	-0.56	-0.43	Depression;	chr6:28084025	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.542	rs2295594	ENSG00000219392.1	RP1-265C24.5	-10.29	1.89e-22	1.96e-19	-0.56	-0.43	Depression;	chr6:28085319	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs2273564	ENSG00000219392.1	RP1-265C24.5	-10.29	1.89e-22	1.96e-19	-0.56	-0.43	Depression;	chr6:28089816	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs1853097	ENSG00000219392.1	RP1-265C24.5	-10.29	1.89e-22	1.96e-19	-0.56	-0.43	Depression;	chr6:28090857	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs9393888	ENSG00000219392.1	RP1-265C24.5	-10.29	1.89e-22	1.96e-19	-0.56	-0.43	Depression;	chr6:28091439	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs3734573	ENSG00000219392.1	RP1-265C24.5	-10.29	1.89e-22	1.96e-19	-0.56	-0.43	Depression;	chr6:28091659	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs9357063	ENSG00000219392.1	RP1-265C24.5	-10.29	1.89e-22	1.96e-19	-0.56	-0.43	Depression;	chr6:28092227	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs3823180	ENSG00000219392.1	RP1-265C24.5	-10.29	1.89e-22	1.96e-19	-0.56	-0.43	Depression;	chr6:28093966	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs9368551	ENSG00000219392.1	RP1-265C24.5	-10.29	1.89e-22	1.96e-19	-0.56	-0.43	Depression;	chr6:28094014	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs9393890	ENSG00000219392.1	RP1-265C24.5	-10.29	1.89e-22	1.96e-19	-0.56	-0.43	Depression;	chr6:28096077	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs9366715	ENSG00000219392.1	RP1-265C24.5	-10.29	1.89e-22	1.96e-19	-0.56	-0.43	Depression;	chr6:28096855	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.598	rs9380054	ENSG00000219392.1	RP1-265C24.5	-10.29	1.89e-22	1.96e-19	-0.56	-0.43	Depression;	chr6:28099759	chr6:28115628~28116551:+
PRAD	cis	rs4713118	0.547	rs2116981	ENSG00000219392.1	RP1-265C24.5	-10.29	1.89e-22	1.96e-19	-0.56	-0.43	Parkinson's disease;	chr6:28100173	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs9368552	ENSG00000219392.1	RP1-265C24.5	-10.29	1.89e-22	1.96e-19	-0.56	-0.43	Depression;	chr6:28100648	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs2281588	ENSG00000219392.1	RP1-265C24.5	-10.29	1.89e-22	1.96e-19	-0.56	-0.43	Depression;	chr6:28104824	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.542	rs34131763	ENSG00000219392.1	RP1-265C24.5	-10.29	1.89e-22	1.96e-19	-0.56	-0.43	Depression;	chr6:28107222	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs35193936	ENSG00000219392.1	RP1-265C24.5	-10.29	1.89e-22	1.96e-19	-0.56	-0.43	Depression;	chr6:28108492	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs36078605	ENSG00000219392.1	RP1-265C24.5	-10.29	1.89e-22	1.96e-19	-0.56	-0.43	Depression;	chr6:28110254	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs9393891	ENSG00000219392.1	RP1-265C24.5	-10.29	1.89e-22	1.96e-19	-0.56	-0.43	Depression;	chr6:28111382	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs9468286	ENSG00000219392.1	RP1-265C24.5	-10.29	1.89e-22	1.96e-19	-0.56	-0.43	Depression;	chr6:28111650	chr6:28115628~28116551:+
PRAD	cis	rs4713118	0.516	rs7739216	ENSG00000219392.1	RP1-265C24.5	-10.29	1.89e-22	1.96e-19	-0.56	-0.43	Parkinson's disease;	chr6:28112168	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs35512245	ENSG00000219392.1	RP1-265C24.5	-10.29	1.89e-22	1.96e-19	-0.56	-0.43	Depression;	chr6:28112175	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs9380055	ENSG00000219392.1	RP1-265C24.5	-10.29	1.89e-22	1.96e-19	-0.56	-0.43	Depression;	chr6:28113851	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs9368553	ENSG00000219392.1	RP1-265C24.5	-10.29	1.89e-22	1.96e-19	-0.56	-0.43	Depression;	chr6:28114487	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs9368554	ENSG00000219392.1	RP1-265C24.5	-10.29	1.89e-22	1.96e-19	-0.56	-0.43	Depression;	chr6:28114933	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs4713137	ENSG00000219392.1	RP1-265C24.5	-10.29	1.89e-22	1.96e-19	-0.56	-0.43	Depression;	chr6:28115743	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs9348793	ENSG00000219392.1	RP1-265C24.5	-10.29	1.89e-22	1.96e-19	-0.56	-0.43	Depression;	chr6:28116411	chr6:28115628~28116551:+
PRAD	cis	rs4713118	0.586	rs6905516	ENSG00000219392.1	RP1-265C24.5	-10.29	1.89e-22	1.96e-19	-0.56	-0.43	Parkinson's disease;	chr6:28118700	chr6:28115628~28116551:+
PRAD	cis	rs4713118	0.586	rs6905522	ENSG00000219392.1	RP1-265C24.5	-10.29	1.89e-22	1.96e-19	-0.56	-0.43	Parkinson's disease;	chr6:28118701	chr6:28115628~28116551:+
PRAD	cis	rs4713118	0.586	rs9468290	ENSG00000219392.1	RP1-265C24.5	-10.29	1.89e-22	1.96e-19	-0.56	-0.43	Parkinson's disease;	chr6:28119896	chr6:28115628~28116551:+
PRAD	cis	rs2348418	0.579	rs2126896	ENSG00000247934.4	RP11-967K21.1	-10.28	1.9e-22	1.97e-19	-0.39	-0.43	Lung function (FEV1);Lung function (FVC);	chr12:28239701	chr12:28163298~28190738:-
PRAD	cis	rs2283792	0.765	rs2283793	ENSG00000224086.5	LL22NC03-86G7.1	-10.28	1.9e-22	1.97e-19	-0.52	-0.43	Multiple sclerosis;	chr22:21827189	chr22:21938293~21977632:+
PRAD	cis	rs10885396	1	rs10885396	ENSG00000233547.1	RP11-57H14.2	-10.28	1.9e-22	1.98e-19	-0.36	-0.43	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr10:112951996	chr10:112950646~112951875:-
PRAD	cis	rs75422866	0.85	rs73111210	ENSG00000257433.4	RP1-197B17.3	10.28	1.91e-22	1.98e-19	1.03	0.43	Pneumonia;	chr12:47576949	chr12:47706085~47742294:+
PRAD	cis	rs6142102	0.812	rs725478	ENSG00000276073.1	RP5-1125A11.7	10.28	1.92e-22	1.99e-19	0.45	0.43	Skin pigmentation;	chr20:33930548	chr20:33985617~33988989:-
PRAD	cis	rs6142102	0.886	rs6142098	ENSG00000276073.1	RP5-1125A11.7	-10.28	1.93e-22	2e-19	-0.44	-0.43	Skin pigmentation;	chr20:34100488	chr20:33985617~33988989:-
PRAD	cis	rs6142102	0.961	rs6087557	ENSG00000276073.1	RP5-1125A11.7	-10.28	1.93e-22	2e-19	-0.44	-0.43	Skin pigmentation;	chr20:34110469	chr20:33985617~33988989:-
PRAD	cis	rs6504950	0.924	rs2628316	ENSG00000275710.1	RP11-257O5.4	-10.28	1.93e-22	2e-19	-0.55	-0.43	Breast cancer;	chr17:55142476	chr17:54964474~54964679:+
PRAD	cis	rs4718428	0.705	rs4718430	ENSG00000232546.1	RP11-458F8.1	-10.28	1.93e-22	2e-19	-0.36	-0.43	Corneal structure;	chr7:66967037	chr7:66848496~66858136:+
PRAD	cis	rs9322193	0.926	rs3805751	ENSG00000223701.3	RAET1E-AS1	10.28	1.93e-22	2e-19	0.58	0.43	Lung cancer;	chr6:149791193	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.962	rs10872656	ENSG00000223701.3	RAET1E-AS1	10.28	1.93e-22	2e-19	0.58	0.43	Lung cancer;	chr6:149799444	chr6:149884431~149919508:+
PRAD	cis	rs4718428	0.672	rs12530806	ENSG00000273142.1	RP11-458F8.4	-10.28	1.93e-22	2e-19	-0.34	-0.43	Corneal structure;	chr7:66925737	chr7:66902857~66906297:+
PRAD	cis	rs34779708	0.931	rs11597392	ENSG00000230534.5	RP11-297A16.2	10.28	1.94e-22	2.01e-19	0.59	0.43	Inflammatory bowel disease;Crohn's disease;	chr10:34999647	chr10:35098006~35127020:-
PRAD	cis	rs2442825	0.72	rs2648561	ENSG00000206573.7	THUMPD3-AS1	10.28	1.94e-22	2.01e-19	0.31	0.43	Cerebrospinal fluid clusterin levels;	chr3:9376399	chr3:9349689~9398579:-
PRAD	cis	rs71403859	0.568	rs12149489	ENSG00000260886.1	TAT-AS1	10.28	1.95e-22	2.02e-19	0.75	0.43	Post bronchodilator FEV1;	chr16:71779877	chr16:71565789~71578187:+
PRAD	cis	rs1555322	0.53	rs6060341	ENSG00000126005.14	MMP24-AS1	10.28	1.96e-22	2.03e-19	0.53	0.43	Attention deficit hyperactivity disorder;	chr20:35275830	chr20:35216462~35278131:-
PRAD	cis	rs9322193	0.962	rs9322206	ENSG00000223701.3	RAET1E-AS1	10.28	1.98e-22	2.05e-19	0.59	0.43	Lung cancer;	chr6:149641481	chr6:149884431~149919508:+
PRAD	cis	rs34375054	0.738	rs10846834	ENSG00000279233.1	RP11-158L12.4	10.28	1.98e-22	2.05e-19	0.4	0.43	Post bronchodilator FEV1/FVC ratio;	chr12:125141024	chr12:125138245~125141711:+
PRAD	cis	rs13392177	0.66	rs12988046	ENSG00000261338.2	RP11-378A13.1	-10.28	1.98e-22	2.05e-19	-0.5	-0.43	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218209081	chr2:218255319~218257366:+
PRAD	cis	rs2348418	0.966	rs1527578	ENSG00000247934.4	RP11-967K21.1	10.28	1.99e-22	2.06e-19	0.4	0.43	Lung function (FEV1);Lung function (FVC);	chr12:28536903	chr12:28163298~28190738:-
PRAD	cis	rs2348418	0.966	rs16932891	ENSG00000247934.4	RP11-967K21.1	10.28	1.99e-22	2.06e-19	0.4	0.43	Lung function (FEV1);Lung function (FVC);	chr12:28537055	chr12:28163298~28190738:-
PRAD	cis	rs2348418	0.932	rs7968515	ENSG00000247934.4	RP11-967K21.1	10.28	1.99e-22	2.06e-19	0.4	0.43	Lung function (FEV1);Lung function (FVC);	chr12:28542914	chr12:28163298~28190738:-
PRAD	cis	rs2348418	0.966	rs2881910	ENSG00000247934.4	RP11-967K21.1	10.28	1.99e-22	2.06e-19	0.4	0.43	Lung function (FEV1);Lung function (FVC);	chr12:28544459	chr12:28163298~28190738:-
PRAD	cis	rs7849270	0.959	rs1410017	ENSG00000268707.1	RP11-247A12.7	-10.28	1.99e-22	2.06e-19	-0.49	-0.43	Blood metabolite ratios;	chr9:129151151	chr9:129170434~129170940:+
PRAD	cis	rs801193	0.569	rs13226966	ENSG00000237310.1	GS1-124K5.4	10.28	2.01e-22	2.08e-19	0.41	0.43	Aortic root size;	chr7:66768636	chr7:66493706~66495474:+
PRAD	cis	rs6142102	0.812	rs761236	ENSG00000276073.1	RP5-1125A11.7	-10.28	2.01e-22	2.09e-19	-0.45	-0.43	Skin pigmentation;	chr20:33932245	chr20:33985617~33988989:-
PRAD	cis	rs9545047	0.604	rs1616547	ENSG00000227676.3	LINC01068	10.28	2.03e-22	2.1e-19	0.52	0.43	Schizophrenia;	chr13:79411901	chr13:79566727~79571436:+
PRAD	cis	rs1075265	0.722	rs7596349	ENSG00000233266.1	HMGB1P31	10.28	2.03e-22	2.1e-19	0.59	0.43	Chronotype;Morning vs. evening chronotype;	chr2:53709123	chr2:54051334~54051760:+
PRAD	cis	rs7772486	0.688	rs1884364	ENSG00000235652.6	RP11-545I5.3	10.28	2.04e-22	2.11e-19	0.47	0.43	Lobe attachment (rater-scored or self-reported);	chr6:146016681	chr6:145799409~145886585:+
PRAD	cis	rs7615952	0.932	rs11922218	ENSG00000171084.14	FAM86JP	10.28	2.04e-22	2.11e-19	0.76	0.43	Blood pressure (smoking interaction);	chr3:125912446	chr3:125916620~125930024:+
PRAD	cis	rs7615952	0.866	rs11922276	ENSG00000171084.14	FAM86JP	10.28	2.04e-22	2.11e-19	0.76	0.43	Blood pressure (smoking interaction);	chr3:125912483	chr3:125916620~125930024:+
PRAD	cis	rs7684253	0.548	rs13108002	ENSG00000269949.1	RP11-738E22.3	-10.28	2.04e-22	2.11e-19	-0.51	-0.43	Migraine;	chr4:56852087	chr4:56960927~56961373:-
PRAD	cis	rs34779708	0.931	rs12261654	ENSG00000230534.5	RP11-297A16.2	10.28	2.05e-22	2.12e-19	0.57	0.43	Inflammatory bowel disease;Crohn's disease;	chr10:35033096	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.931	rs11010083	ENSG00000230534.5	RP11-297A16.2	10.28	2.05e-22	2.12e-19	0.57	0.43	Inflammatory bowel disease;Crohn's disease;	chr10:35062603	chr10:35098006~35127020:-
PRAD	cis	rs17023223	0.508	rs12096448	ENSG00000231365.4	RP11-418J17.1	-10.28	2.05e-22	2.13e-19	-0.45	-0.43	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119140767	chr1:119140396~119275973:+
PRAD	cis	rs6142102	0.961	rs4911385	ENSG00000276073.1	RP5-1125A11.7	-10.27	2.07e-22	2.15e-19	-0.45	-0.43	Skin pigmentation;	chr20:33970787	chr20:33985617~33988989:-
PRAD	cis	rs2337406	0.866	rs79901786	ENSG00000274576.2	IGHV2-70	-10.27	2.08e-22	2.15e-19	-0.45	-0.43	Alzheimer's disease (late onset);	chr14:106777623	chr14:106770577~106771020:-
PRAD	cis	rs9322193	0.607	rs4870078	ENSG00000223701.3	RAET1E-AS1	-10.27	2.08e-22	2.15e-19	-0.67	-0.43	Lung cancer;	chr6:149880676	chr6:149884431~149919508:+
PRAD	cis	rs4853012	0.887	rs6737314	ENSG00000257800.1	FNBP1P1	10.27	2.09e-22	2.16e-19	0.41	0.43	Gestational age at birth (maternal effect);	chr2:74112459	chr2:74120680~74123218:+
PRAD	cis	rs2283792	0.765	rs9607298	ENSG00000224086.5	LL22NC03-86G7.1	-10.27	2.09e-22	2.16e-19	-0.51	-0.43	Multiple sclerosis;	chr22:21829844	chr22:21938293~21977632:+
PRAD	cis	rs8072100	0.713	rs4968318	ENSG00000228782.6	CTD-2026D20.3	10.27	2.1e-22	2.18e-19	0.48	0.43	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47374528	chr17:47450568~47492492:-
PRAD	cis	rs3762637	0.943	rs3817040	ENSG00000272758.4	RP11-299J3.8	-10.27	2.12e-22	2.19e-19	-0.64	-0.43	LDL cholesterol levels;	chr3:122535922	chr3:122416207~122443180:+
PRAD	cis	rs12134133	1	rs28371597	ENSG00000274245.1	RP11-357P18.2	10.27	2.13e-22	2.2e-19	0.63	0.43	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207323551	chr1:207372559~207373252:+
PRAD	cis	rs9322193	0.962	rs9505974	ENSG00000268592.3	RAET1E-AS1	10.27	2.14e-22	2.21e-19	0.59	0.43	Lung cancer;	chr6:149779294	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.926	rs9689036	ENSG00000268592.3	RAET1E-AS1	10.27	2.14e-22	2.21e-19	0.59	0.43	Lung cancer;	chr6:149780563	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.962	rs9322218	ENSG00000268592.3	RAET1E-AS1	10.27	2.14e-22	2.21e-19	0.59	0.43	Lung cancer;	chr6:149782183	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.962	rs9322219	ENSG00000268592.3	RAET1E-AS1	10.27	2.14e-22	2.21e-19	0.59	0.43	Lung cancer;	chr6:149782263	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.962	rs9322223	ENSG00000268592.3	RAET1E-AS1	10.27	2.14e-22	2.21e-19	0.59	0.43	Lung cancer;	chr6:149801509	chr6:149863494~149919507:+
PRAD	cis	rs6142102	0.812	rs6059554	ENSG00000276073.1	RP5-1125A11.7	-10.27	2.15e-22	2.22e-19	-0.45	-0.43	Skin pigmentation;	chr20:33926286	chr20:33985617~33988989:-
PRAD	cis	rs6142102	0.778	rs6059555	ENSG00000276073.1	RP5-1125A11.7	-10.27	2.15e-22	2.22e-19	-0.45	-0.43	Skin pigmentation;	chr20:33926518	chr20:33985617~33988989:-
PRAD	cis	rs2442825	0.693	rs1054975	ENSG00000206573.7	THUMPD3-AS1	10.27	2.15e-22	2.22e-19	0.31	0.43	Cerebrospinal fluid clusterin levels;	chr3:9365152	chr3:9349689~9398579:-
PRAD	cis	rs11690935	0.571	rs13020884	ENSG00000228389.1	AC068039.4	-10.27	2.16e-22	2.23e-19	-0.48	-0.43	Schizophrenia;	chr2:172036795	chr2:171773482~171775844:+
PRAD	cis	rs11951515	0.7	rs66585077	ENSG00000188850.9	RP11-159F24.2	10.27	2.16e-22	2.23e-19	0.51	0.43	Metabolite levels  (X-11787);	chr5:43281754	chr5:43336164~43348716:+
PRAD	cis	rs9322193	0.887	rs3777949	ENSG00000223701.3	RAET1E-AS1	10.27	2.18e-22	2.25e-19	0.59	0.43	Lung cancer;	chr6:149596021	chr6:149884431~149919508:+
PRAD	cis	rs2933343	0.951	rs789251	ENSG00000261159.1	RP11-723O4.9	10.27	2.18e-22	2.25e-19	0.41	0.43	IgG glycosylation;	chr3:128857927	chr3:128859716~128860526:-
PRAD	cis	rs7688540	0.771	rs61795001	ENSG00000275426.1	CH17-262A2.1	10.27	2.19e-22	2.26e-19	0.67	0.43	Facial morphology (factor 6, height of vermillion lower lip);	chr4:248268	chr4:149738~150317:+
PRAD	cis	rs7684253	0.526	rs34112167	ENSG00000269949.1	RP11-738E22.3	-10.27	2.2e-22	2.27e-19	-0.51	-0.43	Migraine;	chr4:56853383	chr4:56960927~56961373:-
PRAD	cis	rs7615952	0.673	rs9821905	ENSG00000171084.14	FAM86JP	-10.27	2.2e-22	2.27e-19	-0.82	-0.43	Blood pressure (smoking interaction);	chr3:125902007	chr3:125916620~125930024:+
PRAD	cis	rs748404	0.578	rs4547312	ENSG00000205771.5	CATSPER2P1	-10.27	2.2e-22	2.27e-19	-0.48	-0.43	Lung cancer;	chr15:43339940	chr15:43726918~43747094:-
PRAD	cis	rs2442825	0.693	rs2648535	ENSG00000206573.7	THUMPD3-AS1	10.27	2.24e-22	2.31e-19	0.31	0.43	Cerebrospinal fluid clusterin levels;	chr3:9366759	chr3:9349689~9398579:-
PRAD	cis	rs12049351	0.613	rs10799530	ENSG00000229367.1	HMGN2P19	10.27	2.24e-22	2.31e-19	0.67	0.43	Circulating myeloperoxidase levels (plasma);	chr1:229439986	chr1:229570532~229570796:+
PRAD	cis	rs3762637	0.943	rs78429050	ENSG00000272758.4	RP11-299J3.8	-10.26	2.25e-22	2.32e-19	-0.65	-0.43	LDL cholesterol levels;	chr3:122533581	chr3:122416207~122443180:+
PRAD	cis	rs1075265	0.749	rs805380	ENSG00000233266.1	HMGB1P31	10.26	2.27e-22	2.34e-19	0.58	0.43	Chronotype;Morning vs. evening chronotype;	chr2:53867284	chr2:54051334~54051760:+
PRAD	cis	rs34779708	0.931	rs34954932	ENSG00000230534.5	RP11-297A16.2	10.26	2.27e-22	2.34e-19	0.57	0.43	Inflammatory bowel disease;Crohn's disease;	chr10:35121879	chr10:35098006~35127020:-
PRAD	cis	rs1891275	0.515	rs11186666	ENSG00000228701.1	TNKS2-AS1	-10.26	2.28e-22	2.35e-19	-0.54	-0.43	Intelligence (multi-trait analysis);	chr10:91718162	chr10:91782839~91798291:-
PRAD	cis	rs8062405	0.755	rs62031607	ENSG00000259982.1	CDC37P1	10.26	2.28e-22	2.35e-19	0.58	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620209	chr16:28700294~28701540:-
PRAD	cis	rs9322193	0.962	rs3763162	ENSG00000223701.3	RAET1E-AS1	-10.26	2.29e-22	2.36e-19	-0.58	-0.43	Lung cancer;	chr6:149819674	chr6:149884431~149919508:+
PRAD	cis	rs150992	0.79	rs45931	ENSG00000248489.1	CTD-2007H13.3	10.26	2.29e-22	2.36e-19	0.49	0.43	Body mass index;	chr5:98978344	chr5:98929171~98995013:+
PRAD	cis	rs8062405	1	rs62036622	ENSG00000259982.1	CDC37P1	10.26	2.3e-22	2.37e-19	0.58	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28825882	chr16:28700294~28701540:-
PRAD	cis	rs801193	0.591	rs4506088	ENSG00000237310.1	GS1-124K5.4	-10.26	2.31e-22	2.38e-19	-0.4	-0.43	Aortic root size;	chr7:66670470	chr7:66493706~66495474:+
PRAD	cis	rs1930961	1	rs6004668	ENSG00000272942.1	CTA-246H3.12	10.26	2.31e-22	2.38e-19	0.69	0.43	Bipolar disorder with mood-incongruent psychosis;	chr22:25478535	chr22:25434324~25435070:-
PRAD	cis	rs801193	0.569	rs11772819	ENSG00000237310.1	GS1-124K5.4	10.26	2.31e-22	2.38e-19	0.41	0.43	Aortic root size;	chr7:66752983	chr7:66493706~66495474:+
PRAD	cis	rs801193	0.569	rs7800620	ENSG00000237310.1	GS1-124K5.4	10.26	2.31e-22	2.38e-19	0.41	0.43	Aortic root size;	chr7:66758701	chr7:66493706~66495474:+
PRAD	cis	rs3814244	0.54	rs2159064	ENSG00000255733.4	IFNG-AS1	-10.26	2.32e-22	2.39e-19	-0.44	-0.43	Itch intensity from mosquito bite adjusted by bite size;	chr12:68017126	chr12:67989445~68234686:+
PRAD	cis	rs1891275	0.515	rs4244930	ENSG00000228701.1	TNKS2-AS1	-10.26	2.32e-22	2.39e-19	-0.54	-0.43	Intelligence (multi-trait analysis);	chr10:91707092	chr10:91782839~91798291:-
PRAD	cis	rs1075265	0.722	rs2111623	ENSG00000233266.1	HMGB1P31	-10.26	2.34e-22	2.4e-19	-0.6	-0.43	Chronotype;Morning vs. evening chronotype;	chr2:53757820	chr2:54051334~54051760:+
PRAD	cis	rs9918079	0.56	rs7662032	ENSG00000273133.1	RP11-799M12.2	-10.26	2.34e-22	2.41e-19	-0.55	-0.43	Obesity-related traits;	chr4:15633791	chr4:15563698~15564253:-
PRAD	cis	rs9322193	0.962	rs6899661	ENSG00000268592.3	RAET1E-AS1	10.26	2.35e-22	2.42e-19	0.6	0.43	Lung cancer;	chr6:149818093	chr6:149863494~149919507:+
PRAD	cis	rs2729354	0.779	rs2454663	ENSG00000265566.2	RN7SL605P	-10.26	2.35e-22	2.42e-19	-0.65	-0.43	Blood protein levels;	chr11:57590610	chr11:57528085~57528365:-
PRAD	cis	rs6142102	0.961	rs973409	ENSG00000276073.1	RP5-1125A11.7	-10.26	2.36e-22	2.43e-19	-0.45	-0.43	Skin pigmentation;	chr20:33948558	chr20:33985617~33988989:-
PRAD	cis	rs150992	0.632	rs34490	ENSG00000248489.1	CTD-2007H13.3	10.26	2.37e-22	2.44e-19	0.48	0.43	Body mass index;	chr5:98974967	chr5:98929171~98995013:+
PRAD	cis	rs1075265	0.756	rs2542576	ENSG00000233266.1	HMGB1P31	10.26	2.37e-22	2.44e-19	0.59	0.43	Chronotype;Morning vs. evening chronotype;	chr2:53821659	chr2:54051334~54051760:+
PRAD	cis	rs2739330	0.929	rs5751777	ENSG00000099984.9	GSTT2	-10.26	2.38e-22	2.45e-19	-0.58	-0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23980123~23983911:+
PRAD	cis	rs10246939	0.511	rs62475469	ENSG00000228775.6	WEE2-AS1	10.26	2.39e-22	2.46e-19	0.55	0.43	Bitter taste perception;	chr7:141864846	chr7:141704338~141738346:-
PRAD	cis	rs2665103	0.715	rs7403041	ENSG00000278603.1	RP13-608F4.5	-10.26	2.4e-22	2.47e-19	-0.54	-0.43	Intelligence (multi-trait analysis);	chr15:82287841	chr15:82472203~82472426:+
PRAD	cis	rs7115242	0.8	rs7931770	ENSG00000254851.1	RP11-109L13.1	-10.26	2.42e-22	2.49e-19	-0.83	-0.43	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116995574	chr11:117135528~117138582:+
PRAD	cis	rs6964833	0.554	rs2527366	ENSG00000123965.13	PMS2P5	-10.26	2.42e-22	2.49e-19	-0.6	-0.43	Menarche (age at onset);	chr7:74684615	chr7:74894116~74897835:+
PRAD	cis	rs6964833	0.554	rs2527367	ENSG00000277053.3	GTF2IP1	10.26	2.43e-22	2.5e-19	0.46	0.43	Menarche (age at onset);	chr7:74684804	chr7:75185385~75237696:-
PRAD	cis	rs2739330	0.828	rs5760098	ENSG00000272787.1	KB-226F1.2	-10.26	2.44e-22	2.51e-19	-0.47	-0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23969211~23969873:+
PRAD	cis	rs1075265	0.783	rs6545376	ENSG00000233266.1	HMGB1P31	10.25	2.45e-22	2.52e-19	0.58	0.43	Chronotype;Morning vs. evening chronotype;	chr2:53987685	chr2:54051334~54051760:+
PRAD	cis	rs1075265	0.704	rs805402	ENSG00000233266.1	HMGB1P31	10.25	2.46e-22	2.53e-19	0.58	0.43	Chronotype;Morning vs. evening chronotype;	chr2:53889212	chr2:54051334~54051760:+
PRAD	cis	rs2919917	0.59	rs2919919	ENSG00000254352.1	RP11-578O24.2	-10.25	2.47e-22	2.53e-19	-0.59	-0.43	Lymphocyte counts;	chr8:78745274	chr8:78723796~78724136:-
PRAD	cis	rs4660456	0.504	rs2253835	ENSG00000237899.1	RP4-739H11.3	10.25	2.47e-22	2.54e-19	0.64	0.43	Platelet count;	chr1:40635900	chr1:40669089~40687588:-
PRAD	cis	rs9322193	1	rs9322193	ENSG00000216906.2	RP11-350J20.9	10.25	2.48e-22	2.55e-19	0.5	0.43	Lung cancer;	chr6:149598007	chr6:149904243~149906418:+
PRAD	cis	rs2739330	0.652	rs2000469	ENSG00000250470.1	AP000351.3	10.25	2.49e-22	2.56e-19	0.59	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23976904~23977585:-
PRAD	cis	rs5760092	0.618	rs4461358	ENSG00000250470.1	AP000351.3	-10.25	2.49e-22	2.56e-19	-0.66	-0.43	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23917919	chr22:23976904~23977585:-
PRAD	cis	rs780096	0.565	rs13022659	ENSG00000234072.1	AC074117.10	-10.25	2.5e-22	2.57e-19	-0.35	-0.43	Total body bone mineral density;	chr2:27520763	chr2:27356246~27367622:+
PRAD	cis	rs1075265	0.73	rs2111868	ENSG00000233266.1	HMGB1P31	10.25	2.5e-22	2.57e-19	0.58	0.43	Chronotype;Morning vs. evening chronotype;	chr2:53958916	chr2:54051334~54051760:+
PRAD	cis	rs11118620	0.853	rs11118622	ENSG00000238078.1	LINC01352	10.25	2.52e-22	2.59e-19	0.58	0.43	Heart failure;	chr1:220868833	chr1:220829255~220832429:+
PRAD	cis	rs1075265	0.87	rs7569214	ENSG00000233266.1	HMGB1P31	10.25	2.53e-22	2.59e-19	0.58	0.43	Chronotype;Morning vs. evening chronotype;	chr2:53989049	chr2:54051334~54051760:+
PRAD	cis	rs1075265	0.749	rs805430	ENSG00000233266.1	HMGB1P31	10.25	2.53e-22	2.6e-19	0.59	0.43	Chronotype;Morning vs. evening chronotype;	chr2:53848279	chr2:54051334~54051760:+
PRAD	cis	rs12049351	0.507	rs10916484	ENSG00000229367.1	HMGN2P19	10.25	2.54e-22	2.6e-19	0.63	0.43	Circulating myeloperoxidase levels (plasma);	chr1:229465926	chr1:229570532~229570796:+
PRAD	cis	rs853679	0.517	rs6922063	ENSG00000219392.1	RP1-265C24.5	-10.25	2.55e-22	2.61e-19	-0.56	-0.43	Depression;	chr6:28126588	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs2275508	ENSG00000219392.1	RP1-265C24.5	-10.25	2.55e-22	2.61e-19	-0.56	-0.43	Depression;	chr6:28126953	chr6:28115628~28116551:+
PRAD	cis	rs7615952	0.611	rs9681518	ENSG00000171084.14	FAM86JP	10.25	2.55e-22	2.61e-19	0.83	0.43	Blood pressure (smoking interaction);	chr3:125896287	chr3:125916620~125930024:+
PRAD	cis	rs1075265	0.783	rs805359	ENSG00000233266.1	HMGB1P31	10.25	2.56e-22	2.62e-19	0.58	0.43	Chronotype;Morning vs. evening chronotype;	chr2:53935317	chr2:54051334~54051760:+
PRAD	cis	rs7714584	1	rs7724036	ENSG00000197083.10	ZNF300P1	-10.25	2.56e-22	2.62e-19	-0.66	-0.43	Crohn's disease;	chr5:150905246	chr5:150930645~150946289:-
PRAD	cis	rs11951515	0.663	rs35231094	ENSG00000188850.9	RP11-159F24.2	10.25	2.57e-22	2.64e-19	0.51	0.43	Metabolite levels  (X-11787);	chr5:43281983	chr5:43336164~43348716:+
PRAD	cis	rs2919917	0.628	rs2717544	ENSG00000254352.1	RP11-578O24.2	-10.25	2.57e-22	2.64e-19	-0.57	-0.43	Lymphocyte counts;	chr8:78724307	chr8:78723796~78724136:-
PRAD	cis	rs732716	0.785	rs62130979	ENSG00000267980.1	AC007292.6	-10.25	2.57e-22	2.64e-19	-0.46	-0.43	Mean corpuscular volume;	chr19:4432447	chr19:4363789~4364640:+
PRAD	cis	rs7201929	1	rs11644151	ENSG00000259982.1	CDC37P1	-10.25	2.57e-22	2.64e-19	-0.62	-0.43	QT interval;	chr16:28884339	chr16:28700294~28701540:-
PRAD	cis	rs1577917	1	rs11758849	ENSG00000203875.9	SNHG5	-10.25	2.59e-22	2.65e-19	-0.51	-0.43	Response to antipsychotic treatment;	chr6:85998544	chr6:85660950~85678736:-
PRAD	cis	rs1577917	1	rs13217384	ENSG00000203875.9	SNHG5	-10.25	2.6e-22	2.66e-19	-0.51	-0.43	Response to antipsychotic treatment;	chr6:86010282	chr6:85660950~85678736:-
PRAD	cis	rs4380275	0.809	rs6753699	ENSG00000223751.1	AC116609.2	10.25	2.62e-22	2.68e-19	0.55	0.43	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:766081	chr2:742488~747767:+
PRAD	cis	rs4713118	0.699	rs200978	ENSG00000280107.1	AL022393.9	-10.25	2.62e-22	2.69e-19	-0.57	-0.43	Parkinson's disease;	chr6:27885390	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.542	rs6934769	ENSG00000219392.1	RP1-265C24.5	-10.25	2.64e-22	2.7e-19	-0.56	-0.43	Depression;	chr6:28123153	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs17711801	ENSG00000219392.1	RP1-265C24.5	-10.25	2.64e-22	2.7e-19	-0.56	-0.43	Depression;	chr6:28124529	chr6:28115628~28116551:+
PRAD	cis	rs4713118	0.527	rs9461433	ENSG00000219392.1	RP1-265C24.5	-10.25	2.64e-22	2.7e-19	-0.56	-0.43	Parkinson's disease;	chr6:28127394	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs9468292	ENSG00000219392.1	RP1-265C24.5	-10.25	2.64e-22	2.7e-19	-0.56	-0.43	Depression;	chr6:28127577	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs1947863	ENSG00000219392.1	RP1-265C24.5	-10.25	2.64e-22	2.7e-19	-0.56	-0.43	Depression;	chr6:28131566	chr6:28115628~28116551:+
PRAD	cis	rs6142102	0.778	rs4911374	ENSG00000276073.1	RP5-1125A11.7	-10.25	2.65e-22	2.71e-19	-0.45	-0.43	Skin pigmentation;	chr20:33928195	chr20:33985617~33988989:-
PRAD	cis	rs9322193	0.736	rs3828701	ENSG00000268592.3	RAET1E-AS1	10.25	2.65e-22	2.72e-19	0.6	0.43	Lung cancer;	chr6:149791063	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.736	rs3805750	ENSG00000268592.3	RAET1E-AS1	10.25	2.65e-22	2.72e-19	0.6	0.43	Lung cancer;	chr6:149791065	chr6:149863494~149919507:+
PRAD	cis	rs7849270	1	rs1360172	ENSG00000268707.1	RP11-247A12.7	-10.25	2.65e-22	2.72e-19	-0.49	-0.43	Blood metabolite ratios;	chr9:129145701	chr9:129170434~129170940:+
PRAD	cis	rs801193	0.569	rs11761542	ENSG00000237310.1	GS1-124K5.4	10.24	2.67e-22	2.73e-19	0.41	0.43	Aortic root size;	chr7:66753209	chr7:66493706~66495474:+
PRAD	cis	rs9322193	0.962	rs4870048	ENSG00000216906.2	RP11-350J20.9	10.24	2.68e-22	2.74e-19	0.49	0.43	Lung cancer;	chr6:149834324	chr6:149904243~149906418:+
PRAD	cis	rs10129255	0.5	rs4774008	ENSG00000223648.3	IGHV3-64	10.24	2.68e-22	2.74e-19	0.39	0.43	Kawasaki disease;	chr14:106681273	chr14:106643132~106658258:-
PRAD	cis	rs10129255	0.5	rs9324092	ENSG00000223648.3	IGHV3-64	-10.24	2.68e-22	2.74e-19	-0.39	-0.43	Kawasaki disease;	chr14:106683806	chr14:106643132~106658258:-
PRAD	cis	rs9322193	0.884	rs2342858	ENSG00000268592.3	RAET1E-AS1	10.24	2.69e-22	2.75e-19	0.59	0.43	Lung cancer;	chr6:149805967	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.923	rs9322197	ENSG00000223701.3	RAET1E-AS1	10.24	2.7e-22	2.76e-19	0.59	0.43	Lung cancer;	chr6:149622577	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.884	rs9688858	ENSG00000223701.3	RAET1E-AS1	10.24	2.7e-22	2.76e-19	0.59	0.43	Lung cancer;	chr6:149637911	chr6:149884431~149919508:+
PRAD	cis	rs638893	0.636	rs1784295	ENSG00000278376.1	RP11-158I9.8	-10.24	2.7e-22	2.76e-19	-0.53	-0.43	Vitiligo;	chr11:118790223	chr11:118791254~118793137:+
PRAD	cis	rs7849270	0.879	rs7042928	ENSG00000268707.1	RP11-247A12.7	10.24	2.72e-22	2.78e-19	0.5	0.43	Blood metabolite ratios;	chr9:129092996	chr9:129170434~129170940:+
PRAD	cis	rs11673344	0.864	rs2562606	ENSG00000226686.6	LINC01535	10.24	2.73e-22	2.79e-19	0.59	0.43	Obesity-related traits;	chr19:37029628	chr19:37251912~37265535:+
PRAD	cis	rs11673344	0.864	rs2263167	ENSG00000226686.6	LINC01535	10.24	2.73e-22	2.79e-19	0.59	0.43	Obesity-related traits;	chr19:37030025	chr19:37251912~37265535:+
PRAD	cis	rs2739330	0.685	rs4822453	ENSG00000235689.1	AP000351.13	10.24	2.74e-22	2.8e-19	0.51	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:24006305~24008258:-
PRAD	cis	rs3762637	1	rs7615930	ENSG00000272758.4	RP11-299J3.8	-10.24	2.75e-22	2.81e-19	-0.63	-0.43	LDL cholesterol levels;	chr3:122406903	chr3:122416207~122443180:+
PRAD	cis	rs11673344	0.573	rs73039109	ENSG00000226686.6	LINC01535	10.24	2.76e-22	2.82e-19	0.62	0.43	Obesity-related traits;	chr19:36891073	chr19:37251912~37265535:+
PRAD	cis	rs9322193	0.923	rs9371486	ENSG00000216906.2	RP11-350J20.9	10.24	2.77e-22	2.83e-19	0.5	0.43	Lung cancer;	chr6:149832090	chr6:149904243~149906418:+
PRAD	cis	rs12134133	1	rs4844590	ENSG00000274245.1	RP11-357P18.2	10.24	2.77e-22	2.83e-19	0.62	0.43	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207322784	chr1:207372559~207373252:+
PRAD	cis	rs1577917	0.916	rs12203358	ENSG00000203875.9	SNHG5	-10.24	2.77e-22	2.83e-19	-0.5	-0.43	Response to antipsychotic treatment;	chr6:85893506	chr6:85660950~85678736:-
PRAD	cis	rs10246939	0.579	rs12703413	ENSG00000228775.6	WEE2-AS1	-10.24	2.78e-22	2.84e-19	-0.54	-0.43	Bitter taste perception;	chr7:141847047	chr7:141704338~141738346:-
PRAD	cis	rs6142102	0.961	rs4911390	ENSG00000276073.1	RP5-1125A11.7	-10.24	2.8e-22	2.86e-19	-0.45	-0.43	Skin pigmentation;	chr20:33977401	chr20:33985617~33988989:-
PRAD	cis	rs2348418	1	rs2348418	ENSG00000247934.4	RP11-967K21.1	10.24	2.81e-22	2.87e-19	0.4	0.43	Lung function (FEV1);Lung function (FVC);	chr12:28536581	chr12:28163298~28190738:-
PRAD	cis	rs7115242	0.925	rs7925256	ENSG00000254851.1	RP11-109L13.1	-10.24	2.81e-22	2.87e-19	-1.06	-0.43	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117174619	chr11:117135528~117138582:+
PRAD	cis	rs150992	0.609	rs78721487	ENSG00000248489.1	CTD-2007H13.3	10.24	2.82e-22	2.88e-19	0.48	0.43	Body mass index;	chr5:98992926	chr5:98929171~98995013:+
PRAD	cis	rs34779708	0.966	rs10827492	ENSG00000230534.5	RP11-297A16.2	-10.24	2.83e-22	2.89e-19	-0.57	-0.43	Inflammatory bowel disease;Crohn's disease;	chr10:35140897	chr10:35098006~35127020:-
PRAD	cis	rs6860806	0.507	rs183898	ENSG00000233006.5	AC034220.3	-10.24	2.83e-22	2.89e-19	-0.41	-0.43	Breast cancer;	chr5:132381210	chr5:132311285~132369916:-
PRAD	cis	rs10256972	0.647	rs10233430	ENSG00000229043.2	AC091729.9	-10.24	2.83e-22	2.89e-19	-0.54	-0.43	Endometriosis;Longevity;	chr7:1012028	chr7:1160374~1165267:+
PRAD	cis	rs4718428	0.705	rs13220977	ENSG00000232546.1	RP11-458F8.1	10.24	2.84e-22	2.9e-19	0.34	0.43	Corneal structure;	chr7:66872661	chr7:66848496~66858136:+
PRAD	cis	rs1891275	0.551	rs4933687	ENSG00000228701.1	TNKS2-AS1	-10.24	2.86e-22	2.92e-19	-0.58	-0.43	Intelligence (multi-trait analysis);	chr10:91650642	chr10:91782839~91798291:-
PRAD	cis	rs6570726	0.791	rs398408	ENSG00000235652.6	RP11-545I5.3	10.24	2.86e-22	2.92e-19	0.45	0.43	Lobe attachment (rater-scored or self-reported);	chr6:145479884	chr6:145799409~145886585:+
PRAD	cis	rs801193	0.569	rs2659893	ENSG00000237310.1	GS1-124K5.4	10.24	2.87e-22	2.93e-19	0.41	0.43	Aortic root size;	chr7:66735006	chr7:66493706~66495474:+
PRAD	cis	rs801193	0.569	rs2659892	ENSG00000237310.1	GS1-124K5.4	10.24	2.87e-22	2.93e-19	0.41	0.43	Aortic root size;	chr7:66735318	chr7:66493706~66495474:+
PRAD	cis	rs801193	0.548	rs2659891	ENSG00000237310.1	GS1-124K5.4	10.24	2.87e-22	2.93e-19	0.41	0.43	Aortic root size;	chr7:66736127	chr7:66493706~66495474:+
PRAD	cis	rs801193	0.569	rs2707847	ENSG00000237310.1	GS1-124K5.4	10.24	2.87e-22	2.93e-19	0.41	0.43	Aortic root size;	chr7:66737884	chr7:66493706~66495474:+
PRAD	cis	rs801193	0.548	rs7805152	ENSG00000237310.1	GS1-124K5.4	10.24	2.87e-22	2.93e-19	0.41	0.43	Aortic root size;	chr7:66744266	chr7:66493706~66495474:+
PRAD	cis	rs7688540	0.723	rs1986386	ENSG00000275426.1	CH17-262A2.1	10.24	2.88e-22	2.94e-19	0.66	0.43	Facial morphology (factor 6, height of vermillion lower lip);	chr4:235020	chr4:149738~150317:+
PRAD	cis	rs6142102	0.812	rs2377955	ENSG00000276073.1	RP5-1125A11.7	-10.23	2.89e-22	2.95e-19	-0.45	-0.43	Skin pigmentation;	chr20:33937564	chr20:33985617~33988989:-
PRAD	cis	rs34779708	0.966	rs7913615	ENSG00000230534.5	RP11-297A16.2	10.23	2.9e-22	2.96e-19	0.58	0.43	Inflammatory bowel disease;Crohn's disease;	chr10:35134029	chr10:35098006~35127020:-
PRAD	cis	rs1075265	0.749	rs805375	ENSG00000233266.1	HMGB1P31	10.23	2.91e-22	2.96e-19	0.58	0.43	Chronotype;Morning vs. evening chronotype;	chr2:53863268	chr2:54051334~54051760:+
PRAD	cis	rs875971	0.895	rs4145009	ENSG00000237310.1	GS1-124K5.4	-10.23	2.91e-22	2.97e-19	-0.41	-0.43	Aortic root size;	chr7:66261628	chr7:66493706~66495474:+
PRAD	cis	rs9309711	0.621	rs12993215	ENSG00000225234.1	TRAPPC12-AS1	-10.23	2.92e-22	2.98e-19	-0.44	-0.43	Neurofibrillary tangles;	chr2:3469956	chr2:3481242~3482409:-
PRAD	cis	rs4718428	0.705	rs4717328	ENSG00000232546.1	RP11-458F8.1	-10.23	2.93e-22	2.99e-19	-0.35	-0.43	Corneal structure;	chr7:66887678	chr7:66848496~66858136:+
PRAD	cis	rs4718428	0.705	rs4718422	ENSG00000232546.1	RP11-458F8.1	-10.23	2.93e-22	2.99e-19	-0.35	-0.43	Corneal structure;	chr7:66894282	chr7:66848496~66858136:+
PRAD	cis	rs4718428	0.705	rs13231140	ENSG00000232546.1	RP11-458F8.1	-10.23	2.93e-22	2.99e-19	-0.35	-0.43	Corneal structure;	chr7:66896631	chr7:66848496~66858136:+
PRAD	cis	rs4718428	0.705	rs4718424	ENSG00000232546.1	RP11-458F8.1	-10.23	2.93e-22	2.99e-19	-0.35	-0.43	Corneal structure;	chr7:66911108	chr7:66848496~66858136:+
PRAD	cis	rs783540	0.521	rs1259176	ENSG00000276710.3	CSPG4P8	10.23	2.94e-22	2.99e-19	0.52	0.43	Schizophrenia;	chr15:82602149	chr15:82459472~82477258:+
PRAD	cis	rs34779708	0.966	rs12257770	ENSG00000230534.5	RP11-297A16.2	10.23	2.97e-22	3.02e-19	0.57	0.43	Inflammatory bowel disease;Crohn's disease;	chr10:35228306	chr10:35098006~35127020:-
PRAD	cis	rs10875746	0.729	rs11168355	ENSG00000240399.1	RP1-228P16.1	10.23	2.98e-22	3.04e-19	0.41	0.43	Longevity (90 years and older);	chr12:48017195	chr12:48054813~48055591:-
PRAD	cis	rs10875746	0.855	rs10875728	ENSG00000240399.1	RP1-228P16.1	-10.23	2.98e-22	3.04e-19	-0.42	-0.43	Longevity (90 years and older);	chr12:48032609	chr12:48054813~48055591:-
PRAD	cis	rs2283792	0.765	rs9607241	ENSG00000224086.5	LL22NC03-86G7.1	-10.23	3e-22	3.05e-19	-0.51	-0.43	Multiple sclerosis;	chr22:21750584	chr22:21938293~21977632:+
PRAD	cis	rs6860806	0.507	rs270615	ENSG00000233006.5	AC034220.3	10.23	3e-22	3.06e-19	0.41	0.43	Breast cancer;	chr5:132305880	chr5:132311285~132369916:-
PRAD	cis	rs9322193	0.962	rs13215691	ENSG00000268592.3	RAET1E-AS1	10.23	3.06e-22	3.12e-19	0.59	0.43	Lung cancer;	chr6:149792666	chr6:149863494~149919507:+
PRAD	cis	rs8062405	0.698	rs10499	ENSG00000251417.2	RP11-1348G14.4	10.23	3.1e-22	3.15e-19	0.51	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28904206	chr16:28802743~28817828:+
PRAD	cis	rs9322193	1	rs9377229	ENSG00000216906.2	RP11-350J20.9	10.23	3.1e-22	3.15e-19	0.5	0.43	Lung cancer;	chr6:149607655	chr6:149904243~149906418:+
PRAD	cis	rs3814244	0.515	rs2906856	ENSG00000255733.4	IFNG-AS1	-10.23	3.11e-22	3.16e-19	-0.44	-0.43	Itch intensity from mosquito bite adjusted by bite size;	chr12:67996421	chr12:67989445~68234686:+
PRAD	cis	rs7772486	0.754	rs702319	ENSG00000235652.6	RP11-545I5.3	-10.23	3.12e-22	3.18e-19	-0.44	-0.43	Lobe attachment (rater-scored or self-reported);	chr6:145684981	chr6:145799409~145886585:+
PRAD	cis	rs13392177	0.543	rs12623716	ENSG00000261338.2	RP11-378A13.1	-10.23	3.14e-22	3.19e-19	-0.49	-0.43	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218208295	chr2:218255319~218257366:+
PRAD	cis	rs270601	0.913	rs273899	ENSG00000233006.5	AC034220.3	10.23	3.14e-22	3.19e-19	0.41	0.43	Acylcarnitine levels;	chr5:132359485	chr5:132311285~132369916:-
PRAD	cis	rs11673344	0.864	rs2562595	ENSG00000226686.6	LINC01535	10.22	3.16e-22	3.21e-19	0.59	0.43	Obesity-related traits;	chr19:37023964	chr19:37251912~37265535:+
PRAD	cis	rs11673344	0.832	rs8101407	ENSG00000226686.6	LINC01535	10.22	3.16e-22	3.21e-19	0.59	0.43	Obesity-related traits;	chr19:37024444	chr19:37251912~37265535:+
PRAD	cis	rs1075265	0.87	rs1421617	ENSG00000233266.1	HMGB1P31	10.22	3.16e-22	3.22e-19	0.58	0.43	Chronotype;Morning vs. evening chronotype;	chr2:54032995	chr2:54051334~54051760:+
PRAD	cis	rs875971	0.862	rs1983372	ENSG00000237310.1	GS1-124K5.4	-10.22	3.19e-22	3.24e-19	-0.4	-0.43	Aortic root size;	chr7:66146364	chr7:66493706~66495474:+
PRAD	cis	rs4774565	0.724	rs606118	ENSG00000244879.4	GABPB1-AS1	-10.22	3.2e-22	3.25e-19	-0.4	-0.43	Breast cancer;	chr15:50362974	chr15:50354959~50372202:+
PRAD	cis	rs10885396	0.967	rs7094871	ENSG00000233547.1	RP11-57H14.2	-10.22	3.21e-22	3.26e-19	-0.35	-0.43	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr10:112952395	chr10:112950646~112951875:-
PRAD	cis	rs12049351	0.612	rs7555749	ENSG00000229367.1	HMGN2P19	10.22	3.23e-22	3.28e-19	0.65	0.43	Circulating myeloperoxidase levels (plasma);	chr1:229466537	chr1:229570532~229570796:+
PRAD	cis	rs4380275	0.782	rs60367761	ENSG00000223751.1	AC116609.2	10.22	3.25e-22	3.3e-19	0.55	0.43	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:766414	chr2:742488~747767:+
PRAD	cis	rs8100891	0.922	rs7255223	ENSG00000267213.4	AC007773.2	10.22	3.26e-22	3.31e-19	0.46	0.43	Neuroticism;	chr19:32333404	chr19:32390050~32405560:-
PRAD	cis	rs1577917	0.876	rs1582127	ENSG00000203875.9	SNHG5	-10.22	3.27e-22	3.32e-19	-0.49	-0.43	Response to antipsychotic treatment;	chr6:85987486	chr6:85660950~85678736:-
PRAD	cis	rs1891275	0.551	rs7071844	ENSG00000228701.1	TNKS2-AS1	-10.22	3.28e-22	3.33e-19	-0.58	-0.43	Intelligence (multi-trait analysis);	chr10:91644092	chr10:91782839~91798291:-
PRAD	cis	rs8062405	0.931	rs12928404	ENSG00000259982.1	CDC37P1	10.22	3.29e-22	3.34e-19	0.56	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835925	chr16:28700294~28701540:-
PRAD	cis	rs6504950	0.566	rs7208403	ENSG00000275710.1	RP11-257O5.4	10.22	3.31e-22	3.36e-19	0.51	0.43	Breast cancer;	chr17:54969306	chr17:54964474~54964679:+
PRAD	cis	rs34779708	0.931	rs12773169	ENSG00000230534.5	RP11-297A16.2	10.22	3.32e-22	3.37e-19	0.57	0.43	Inflammatory bowel disease;Crohn's disease;	chr10:35077534	chr10:35098006~35127020:-
PRAD	cis	rs9545047	0.716	rs7140027	ENSG00000227676.3	LINC01068	10.22	3.33e-22	3.37e-19	0.51	0.43	Schizophrenia;	chr13:79281162	chr13:79566727~79571436:+
PRAD	cis	rs17608059	0.504	rs11656981	ENSG00000141028.6	CDRT15P1	-10.22	3.33e-22	3.38e-19	-0.56	-0.43	Temperament;	chr17:14075460	chr17:14024514~14025488:+
PRAD	cis	rs7849270	0.959	rs10760591	ENSG00000268707.1	RP11-247A12.7	-10.22	3.34e-22	3.39e-19	-0.49	-0.43	Blood metabolite ratios;	chr9:129152749	chr9:129170434~129170940:+
PRAD	cis	rs7849270	1	rs10988232	ENSG00000268707.1	RP11-247A12.7	-10.22	3.34e-22	3.39e-19	-0.49	-0.43	Blood metabolite ratios;	chr9:129153069	chr9:129170434~129170940:+
PRAD	cis	rs7849270	0.959	rs10988233	ENSG00000268707.1	RP11-247A12.7	-10.22	3.34e-22	3.39e-19	-0.49	-0.43	Blood metabolite ratios;	chr9:129153647	chr9:129170434~129170940:+
PRAD	cis	rs7849270	1	rs1009242	ENSG00000268707.1	RP11-247A12.7	-10.22	3.34e-22	3.39e-19	-0.49	-0.43	Blood metabolite ratios;	chr9:129154553	chr9:129170434~129170940:+
PRAD	cis	rs7849270	0.959	rs913276	ENSG00000268707.1	RP11-247A12.7	-10.22	3.34e-22	3.39e-19	-0.49	-0.43	Blood metabolite ratios;	chr9:129154885	chr9:129170434~129170940:+
PRAD	cis	rs7849270	1	rs7868408	ENSG00000268707.1	RP11-247A12.7	-10.22	3.34e-22	3.39e-19	-0.49	-0.43	Blood metabolite ratios;	chr9:129155585	chr9:129170434~129170940:+
PRAD	cis	rs1891275	0.551	rs4933684	ENSG00000228701.1	TNKS2-AS1	-10.22	3.34e-22	3.39e-19	-0.58	-0.43	Intelligence (multi-trait analysis);	chr10:91647805	chr10:91782839~91798291:-
PRAD	cis	rs1891275	0.551	rs7088831	ENSG00000228701.1	TNKS2-AS1	-10.22	3.34e-22	3.39e-19	-0.58	-0.43	Intelligence (multi-trait analysis);	chr10:91652695	chr10:91782839~91798291:-
PRAD	cis	rs1891275	0.576	rs2000178	ENSG00000228701.1	TNKS2-AS1	-10.22	3.34e-22	3.39e-19	-0.58	-0.43	Intelligence (multi-trait analysis);	chr10:91653287	chr10:91782839~91798291:-
PRAD	cis	rs1891275	0.551	rs2027486	ENSG00000228701.1	TNKS2-AS1	-10.22	3.34e-22	3.39e-19	-0.58	-0.43	Intelligence (multi-trait analysis);	chr10:91654229	chr10:91782839~91798291:-
PRAD	cis	rs1891275	0.551	rs2421623	ENSG00000228701.1	TNKS2-AS1	-10.22	3.34e-22	3.39e-19	-0.58	-0.43	Intelligence (multi-trait analysis);	chr10:91654700	chr10:91782839~91798291:-
PRAD	cis	rs1891275	0.551	rs10881941	ENSG00000228701.1	TNKS2-AS1	-10.22	3.34e-22	3.39e-19	-0.58	-0.43	Intelligence (multi-trait analysis);	chr10:91655154	chr10:91782839~91798291:-
PRAD	cis	rs1891275	0.576	rs10881942	ENSG00000228701.1	TNKS2-AS1	-10.22	3.34e-22	3.39e-19	-0.58	-0.43	Intelligence (multi-trait analysis);	chr10:91655263	chr10:91782839~91798291:-
PRAD	cis	rs1891275	0.516	rs10881943	ENSG00000228701.1	TNKS2-AS1	-10.22	3.34e-22	3.39e-19	-0.58	-0.43	Intelligence (multi-trait analysis);	chr10:91655373	chr10:91782839~91798291:-
PRAD	cis	rs801193	0.569	rs10950050	ENSG00000237310.1	GS1-124K5.4	10.22	3.35e-22	3.4e-19	0.4	0.43	Aortic root size;	chr7:66774601	chr7:66493706~66495474:+
PRAD	cis	rs6452524	0.507	rs28592576	ENSG00000249664.1	CTD-2227C6.2	10.22	3.35e-22	3.4e-19	0.53	0.43	Hypertension (SNP x SNP interaction);	chr5:83074772	chr5:83012285~83013109:-
PRAD	cis	rs1075265	0.749	rs2692518	ENSG00000233266.1	HMGB1P31	10.21	3.44e-22	3.48e-19	0.58	0.43	Chronotype;Morning vs. evening chronotype;	chr2:53804746	chr2:54051334~54051760:+
PRAD	cis	rs8072100	0.688	rs8079142	ENSG00000228782.6	CTD-2026D20.3	10.21	3.46e-22	3.5e-19	0.48	0.43	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47364683	chr17:47450568~47492492:-
PRAD	cis	rs8072100	0.688	rs8075843	ENSG00000228782.6	CTD-2026D20.3	10.21	3.46e-22	3.5e-19	0.48	0.43	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47364997	chr17:47450568~47492492:-
PRAD	cis	rs9322193	0.962	rs9478848	ENSG00000216906.2	RP11-350J20.9	10.21	3.46e-22	3.51e-19	0.49	0.43	Lung cancer;	chr6:149825080	chr6:149904243~149906418:+
PRAD	cis	rs7714584	1	rs57406211	ENSG00000197083.10	ZNF300P1	10.21	3.47e-22	3.51e-19	0.8	0.43	Crohn's disease;	chr5:150791404	chr5:150930645~150946289:-
PRAD	cis	rs7714584	1	rs79442859	ENSG00000197083.10	ZNF300P1	10.21	3.47e-22	3.51e-19	0.8	0.43	Crohn's disease;	chr5:150791648	chr5:150930645~150946289:-
PRAD	cis	rs7714584	1	rs76872831	ENSG00000197083.10	ZNF300P1	10.21	3.47e-22	3.51e-19	0.8	0.43	Crohn's disease;	chr5:150791997	chr5:150930645~150946289:-
PRAD	cis	rs673078	0.571	rs7963464	ENSG00000275759.1	RP11-131L12.3	-10.21	3.47e-22	3.51e-19	-0.62	-0.43	Glucose homeostasis traits;	chr12:118264924	chr12:118428281~118428870:+
PRAD	cis	rs7849270	0.959	rs2297111	ENSG00000268707.1	RP11-247A12.7	-10.21	3.48e-22	3.52e-19	-0.49	-0.43	Blood metabolite ratios;	chr9:129142015	chr9:129170434~129170940:+
PRAD	cis	rs34779708	0.931	rs10437420	ENSG00000230534.5	RP11-297A16.2	-10.21	3.5e-22	3.54e-19	-0.56	-0.43	Inflammatory bowel disease;Crohn's disease;	chr10:35046116	chr10:35098006~35127020:-
PRAD	cis	rs6142102	0.961	rs2235597	ENSG00000276073.1	RP5-1125A11.7	-10.21	3.5e-22	3.55e-19	-0.45	-0.43	Skin pigmentation;	chr20:34077808	chr20:33985617~33988989:-
PRAD	cis	rs6142102	0.923	rs6057961	ENSG00000276073.1	RP5-1125A11.7	-10.21	3.5e-22	3.55e-19	-0.45	-0.43	Skin pigmentation;	chr20:33986005	chr20:33985617~33988989:-
PRAD	cis	rs2153535	0.553	rs2984099	ENSG00000230939.1	RP11-314C16.1	10.21	3.51e-22	3.56e-19	0.61	0.43	Motion sickness;	chr6:8637041	chr6:8784178~8785445:+
PRAD	cis	rs6452524	0.562	rs10474080	ENSG00000249664.1	CTD-2227C6.2	10.21	3.52e-22	3.56e-19	0.53	0.43	Hypertension (SNP x SNP interaction);	chr5:83078300	chr5:83012285~83013109:-
PRAD	cis	rs2455601	1	rs56336128	ENSG00000254860.4	TMEM9B-AS1	10.21	3.53e-22	3.57e-19	0.59	0.43	Schizophrenia;	chr11:8886752	chr11:8964675~8977527:+
PRAD	cis	rs9322193	0.923	rs7753812	ENSG00000223701.3	RAET1E-AS1	10.21	3.55e-22	3.59e-19	0.58	0.43	Lung cancer;	chr6:149690150	chr6:149884431~149919508:+
PRAD	cis	rs9918079	0.506	rs7696127	ENSG00000273133.1	RP11-799M12.2	-10.21	3.59e-22	3.63e-19	-0.54	-0.43	Obesity-related traits;	chr4:15641330	chr4:15563698~15564253:-
PRAD	cis	rs7727544	1	rs10076701	ENSG00000233006.5	AC034220.3	10.21	3.6e-22	3.64e-19	0.37	0.43	Blood metabolite levels;	chr5:132260726	chr5:132311285~132369916:-
PRAD	cis	rs2739330	0.76	rs5751761	ENSG00000224205.1	AP000351.4	-10.21	3.6e-22	3.64e-19	-0.52	-0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23987320~23991421:-
PRAD	cis	rs7772486	0.79	rs11760	ENSG00000235652.6	RP11-545I5.3	10.21	3.6e-22	3.64e-19	0.45	0.43	Lobe attachment (rater-scored or self-reported);	chr6:145884837	chr6:145799409~145886585:+
PRAD	cis	rs9322193	0.607	rs6925151	ENSG00000268592.3	RAET1E-AS1	10.21	3.64e-22	3.68e-19	0.66	0.43	Lung cancer;	chr6:149889587	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.923	rs12195866	ENSG00000223701.3	RAET1E-AS1	10.21	3.64e-22	3.68e-19	0.58	0.43	Lung cancer;	chr6:149693334	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.923	rs9285524	ENSG00000223701.3	RAET1E-AS1	10.21	3.64e-22	3.68e-19	0.58	0.43	Lung cancer;	chr6:149694122	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.886	rs9767555	ENSG00000216906.2	RP11-350J20.9	10.21	3.66e-22	3.7e-19	0.5	0.43	Lung cancer;	chr6:149647022	chr6:149904243~149906418:+
PRAD	cis	rs7772486	0.686	rs857880	ENSG00000235652.6	RP11-545I5.3	-10.21	3.68e-22	3.72e-19	-0.44	-0.43	Lobe attachment (rater-scored or self-reported);	chr6:145649979	chr6:145799409~145886585:+
PRAD	cis	rs9487094	0.677	rs13203636	ENSG00000260273.1	RP11-425D10.10	10.21	3.68e-22	3.72e-19	0.65	0.43	Height;	chr6:109741085	chr6:109382795~109383666:+
PRAD	cis	rs7688540	0.771	rs11724417	ENSG00000275426.1	CH17-262A2.1	10.21	3.7e-22	3.73e-19	0.65	0.43	Facial morphology (factor 6, height of vermillion lower lip);	chr4:229563	chr4:149738~150317:+
PRAD	cis	rs7688540	0.771	rs11724176	ENSG00000275426.1	CH17-262A2.1	10.21	3.7e-22	3.73e-19	0.65	0.43	Facial morphology (factor 6, height of vermillion lower lip);	chr4:231112	chr4:149738~150317:+
PRAD	cis	rs9326248	0.53	rs2000614	ENSG00000254851.1	RP11-109L13.1	-10.2	3.73e-22	3.77e-19	-0.82	-0.43	Blood protein levels;	chr11:117045026	chr11:117135528~117138582:+
PRAD	cis	rs9326248	0.53	rs2000616	ENSG00000254851.1	RP11-109L13.1	-10.2	3.73e-22	3.77e-19	-0.82	-0.43	Blood protein levels;	chr11:117045813	chr11:117135528~117138582:+
PRAD	cis	rs9326248	0.53	rs10750100	ENSG00000254851.1	RP11-109L13.1	-10.2	3.73e-22	3.77e-19	-0.82	-0.43	Blood protein levels;	chr11:117046528	chr11:117135528~117138582:+
PRAD	cis	rs11951515	0.579	rs58966636	ENSG00000188850.9	RP11-159F24.2	10.2	3.79e-22	3.82e-19	0.51	0.43	Metabolite levels  (X-11787);	chr5:43355264	chr5:43336164~43348716:+
PRAD	cis	rs9322193	0.962	rs35443312	ENSG00000216906.2	RP11-350J20.9	10.2	3.81e-22	3.84e-19	0.5	0.43	Lung cancer;	chr6:149670625	chr6:149904243~149906418:+
PRAD	cis	rs9545047	0.604	rs7327603	ENSG00000227676.3	LINC01068	10.2	3.83e-22	3.86e-19	0.51	0.43	Schizophrenia;	chr13:79366676	chr13:79566727~79571436:+
PRAD	cis	rs2739330	0.796	rs2154594	ENSG00000099984.9	GSTT2	10.2	3.85e-22	3.88e-19	0.58	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23980123~23983911:+
PRAD	cis	rs9322193	0.962	rs9688750	ENSG00000223701.3	RAET1E-AS1	10.2	3.85e-22	3.88e-19	0.59	0.43	Lung cancer;	chr6:149657633	chr6:149884431~149919508:+
PRAD	cis	rs2442825	0.693	rs2648523	ENSG00000206573.7	THUMPD3-AS1	10.2	3.85e-22	3.88e-19	0.31	0.43	Cerebrospinal fluid clusterin levels;	chr3:9370654	chr3:9349689~9398579:-
PRAD	cis	rs6142102	0.961	rs4911389	ENSG00000276073.1	RP5-1125A11.7	-10.2	3.87e-22	3.9e-19	-0.45	-0.43	Skin pigmentation;	chr20:33977235	chr20:33985617~33988989:-
PRAD	cis	rs6452524	0.563	rs10473863	ENSG00000249664.1	CTD-2227C6.2	10.2	3.9e-22	3.93e-19	0.52	0.43	Hypertension (SNP x SNP interaction);	chr5:83057500	chr5:83012285~83013109:-
PRAD	cis	rs9545047	0.589	rs9545090	ENSG00000227676.3	LINC01068	10.2	3.91e-22	3.94e-19	0.51	0.43	Schizophrenia;	chr13:79367276	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs9530902	ENSG00000227676.3	LINC01068	10.2	3.91e-22	3.94e-19	0.51	0.43	Schizophrenia;	chr13:79367748	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs9545092	ENSG00000227676.3	LINC01068	10.2	3.91e-22	3.94e-19	0.51	0.43	Schizophrenia;	chr13:79369809	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.611	rs9545093	ENSG00000227676.3	LINC01068	10.2	3.91e-22	3.94e-19	0.51	0.43	Schizophrenia;	chr13:79371969	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs8001392	ENSG00000227676.3	LINC01068	10.2	3.91e-22	3.94e-19	0.51	0.43	Schizophrenia;	chr13:79374211	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs4146473	ENSG00000227676.3	LINC01068	10.2	3.91e-22	3.94e-19	0.51	0.43	Schizophrenia;	chr13:79374548	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.584	rs1619669	ENSG00000227676.3	LINC01068	10.2	3.91e-22	3.94e-19	0.51	0.43	Schizophrenia;	chr13:79378363	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs6563100	ENSG00000227676.3	LINC01068	10.2	3.91e-22	3.94e-19	0.51	0.43	Schizophrenia;	chr13:79382978	chr13:79566727~79571436:+
PRAD	cis	rs1075265	0.783	rs805453	ENSG00000233266.1	HMGB1P31	10.2	3.92e-22	3.94e-19	0.58	0.43	Chronotype;Morning vs. evening chronotype;	chr2:53955761	chr2:54051334~54051760:+
PRAD	cis	rs9322193	0.962	rs35031906	ENSG00000223701.3	RAET1E-AS1	10.2	3.92e-22	3.95e-19	0.58	0.43	Lung cancer;	chr6:149677438	chr6:149884431~149919508:+
PRAD	cis	rs4718428	0.705	rs4717331	ENSG00000273142.1	RP11-458F8.4	-10.2	3.94e-22	3.97e-19	-0.33	-0.43	Corneal structure;	chr7:66913899	chr7:66902857~66906297:+
PRAD	cis	rs875971	0.862	rs6460290	ENSG00000237310.1	GS1-124K5.4	-10.2	3.95e-22	3.98e-19	-0.39	-0.43	Aortic root size;	chr7:66344119	chr7:66493706~66495474:+
PRAD	cis	rs11673344	0.864	rs55792845	ENSG00000226686.6	LINC01535	10.2	3.99e-22	4.01e-19	0.59	0.43	Obesity-related traits;	chr19:37007783	chr19:37251912~37265535:+
PRAD	cis	rs853679	0.517	rs4713141	ENSG00000219392.1	RP1-265C24.5	-10.2	4e-22	4.03e-19	-0.56	-0.43	Depression;	chr6:28133900	chr6:28115628~28116551:+
PRAD	cis	rs9309473	0.615	rs62149774	ENSG00000163016.8	ALMS1P	10.2	4.02e-22	4.05e-19	0.65	0.43	Metabolite levels;	chr2:73560525	chr2:73644919~73685576:+
PRAD	cis	rs9309473	0.606	rs62149777	ENSG00000163016.8	ALMS1P	10.2	4.02e-22	4.05e-19	0.65	0.43	Metabolite levels;	chr2:73568237	chr2:73644919~73685576:+
PRAD	cis	rs853679	0.517	rs4713145	ENSG00000219392.1	RP1-265C24.5	-10.2	4.02e-22	4.05e-19	-0.56	-0.43	Depression;	chr6:28139049	chr6:28115628~28116551:+
PRAD	cis	rs11673344	0.864	rs8107192	ENSG00000226686.6	LINC01535	10.2	4.03e-22	4.05e-19	0.59	0.43	Obesity-related traits;	chr19:37008725	chr19:37251912~37265535:+
PRAD	cis	rs1577917	0.958	rs2121594	ENSG00000203875.9	SNHG5	-10.2	4.04e-22	4.06e-19	-0.51	-0.43	Response to antipsychotic treatment;	chr6:85867136	chr6:85660950~85678736:-
PRAD	cis	rs11118620	0.81	rs4587570	ENSG00000238078.1	LINC01352	10.19	4.04e-22	4.07e-19	0.58	0.43	Heart failure;	chr1:220860693	chr1:220829255~220832429:+
PRAD	cis	rs9322193	0.926	rs3805751	ENSG00000268592.3	RAET1E-AS1	10.19	4.06e-22	4.09e-19	0.59	0.43	Lung cancer;	chr6:149791193	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.962	rs10872656	ENSG00000268592.3	RAET1E-AS1	10.19	4.06e-22	4.09e-19	0.59	0.43	Lung cancer;	chr6:149799444	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.962	rs35443312	ENSG00000223701.3	RAET1E-AS1	10.19	4.11e-22	4.14e-19	0.58	0.43	Lung cancer;	chr6:149670625	chr6:149884431~149919508:+
PRAD	cis	rs6452524	0.534	rs10037377	ENSG00000249664.1	CTD-2227C6.2	10.19	4.12e-22	4.14e-19	0.52	0.43	Hypertension (SNP x SNP interaction);	chr5:83071150	chr5:83012285~83013109:-
PRAD	cis	rs11673344	0.864	rs826322	ENSG00000226686.6	LINC01535	10.19	4.13e-22	4.15e-19	0.59	0.43	Obesity-related traits;	chr19:37013694	chr19:37251912~37265535:+
PRAD	cis	rs783540	0.5	rs783541	ENSG00000255769.6	GOLGA2P10	10.19	4.15e-22	4.17e-19	0.56	0.43	Schizophrenia;	chr15:82586310	chr15:82472993~82513950:-
PRAD	cis	rs5760092	0.755	rs4585126	ENSG00000235689.1	AP000351.13	-10.19	4.16e-22	4.19e-19	-0.57	-0.43	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:24006305~24008258:-
PRAD	cis	rs1858037	0.867	rs1553675	ENSG00000204929.10	AC074391.1	-10.19	4.17e-22	4.19e-19	-0.59	-0.43	Rheumatoid arthritis;	chr2:65343173	chr2:65436711~66084639:+
PRAD	cis	rs9322193	0.566	rs5024811	ENSG00000223701.3	RAET1E-AS1	-10.19	4.17e-22	4.19e-19	-0.64	-0.43	Lung cancer;	chr6:149924898	chr6:149884431~149919508:+
PRAD	cis	rs6860806	0.507	rs2631369	ENSG00000233006.5	AC034220.3	-10.19	4.17e-22	4.19e-19	-0.4	-0.43	Breast cancer;	chr5:132369574	chr5:132311285~132369916:-
PRAD	cis	rs274567	0.501	rs2631368	ENSG00000233006.5	AC034220.3	-10.19	4.17e-22	4.19e-19	-0.4	-0.43	Blood metabolite levels;	chr5:132369605	chr5:132311285~132369916:-
PRAD	cis	rs6452524	0.534	rs7727691	ENSG00000249664.1	CTD-2227C6.2	10.19	4.19e-22	4.21e-19	0.53	0.43	Hypertension (SNP x SNP interaction);	chr5:83075876	chr5:83012285~83013109:-
PRAD	cis	rs507080	0.845	rs481903	ENSG00000255422.1	AP002954.4	-10.19	4.21e-22	4.23e-19	-0.54	-0.43	Serum metabolite levels;	chr11:118697024	chr11:118704607~118750263:+
PRAD	cis	rs853679	0.517	rs4713135	ENSG00000219392.1	RP1-265C24.5	-10.19	4.24e-22	4.26e-19	-0.57	-0.43	Depression;	chr6:28071808	chr6:28115628~28116551:+
PRAD	cis	rs150992	0.673	rs692832	ENSG00000248489.1	CTD-2007H13.3	10.19	4.25e-22	4.27e-19	0.48	0.43	Body mass index;	chr5:98856761	chr5:98929171~98995013:+
PRAD	cis	rs150992	0.79	rs40075	ENSG00000248489.1	CTD-2007H13.3	10.19	4.26e-22	4.28e-19	0.49	0.43	Body mass index;	chr5:98976743	chr5:98929171~98995013:+
PRAD	cis	rs673078	0.607	rs17512483	ENSG00000275759.1	RP11-131L12.3	10.19	4.27e-22	4.29e-19	0.68	0.43	Glucose homeostasis traits;	chr12:118312380	chr12:118428281~118428870:+
PRAD	cis	rs875971	0.825	rs6951503	ENSG00000237310.1	GS1-124K5.4	-10.19	4.27e-22	4.29e-19	-0.4	-0.43	Aortic root size;	chr7:66253949	chr7:66493706~66495474:+
PRAD	cis	rs2283792	0.715	rs56227348	ENSG00000224086.5	LL22NC03-86G7.1	-10.19	4.27e-22	4.29e-19	-0.51	-0.43	Multiple sclerosis;	chr22:21791443	chr22:21938293~21977632:+
PRAD	cis	rs6860806	0.507	rs635620	ENSG00000233006.5	AC034220.3	-10.19	4.3e-22	4.32e-19	-0.4	-0.43	Breast cancer;	chr5:132384571	chr5:132311285~132369916:-
PRAD	cis	rs6860806	0.507	rs635619	ENSG00000233006.5	AC034220.3	-10.19	4.3e-22	4.32e-19	-0.4	-0.43	Breast cancer;	chr5:132384573	chr5:132311285~132369916:-
PRAD	cis	rs17826219	0.789	rs4794873	ENSG00000263531.1	RP13-753N3.1	10.19	4.3e-22	4.32e-19	0.83	0.43	Body mass index;	chr17:30421334	chr17:30863921~30864940:-
PRAD	cis	rs6860806	0.531	rs270607	ENSG00000233006.5	AC034220.3	10.19	4.31e-22	4.33e-19	0.4	0.43	Breast cancer;	chr5:132313493	chr5:132311285~132369916:-
PRAD	cis	rs2348418	0.832	rs4931080	ENSG00000247934.4	RP11-967K21.1	10.19	4.32e-22	4.34e-19	0.39	0.43	Lung function (FEV1);Lung function (FVC);	chr12:28433843	chr12:28163298~28190738:-
PRAD	cis	rs8100891	1	rs8100891	ENSG00000267213.4	AC007773.2	-10.19	4.33e-22	4.34e-19	-0.46	-0.43	Neuroticism;	chr19:32338607	chr19:32390050~32405560:-
PRAD	cis	rs7688540	0.723	rs61794999	ENSG00000275426.1	CH17-262A2.1	10.19	4.33e-22	4.35e-19	0.66	0.43	Facial morphology (factor 6, height of vermillion lower lip);	chr4:238578	chr4:149738~150317:+
PRAD	cis	rs7688540	0.609	rs77700883	ENSG00000275426.1	CH17-262A2.1	10.19	4.33e-22	4.35e-19	0.66	0.43	Facial morphology (factor 6, height of vermillion lower lip);	chr4:238743	chr4:149738~150317:+
PRAD	cis	rs7688540	0.609	rs78896226	ENSG00000275426.1	CH17-262A2.1	10.19	4.33e-22	4.35e-19	0.66	0.43	Facial morphology (factor 6, height of vermillion lower lip);	chr4:238744	chr4:149738~150317:+
PRAD	cis	rs7688540	0.771	rs7686546	ENSG00000275426.1	CH17-262A2.1	10.19	4.33e-22	4.35e-19	0.66	0.43	Facial morphology (factor 6, height of vermillion lower lip);	chr4:246825	chr4:149738~150317:+
PRAD	cis	rs7688540	0.771	rs61795002	ENSG00000275426.1	CH17-262A2.1	10.19	4.33e-22	4.35e-19	0.66	0.43	Facial morphology (factor 6, height of vermillion lower lip);	chr4:249008	chr4:149738~150317:+
PRAD	cis	rs4713118	0.629	rs149899	ENSG00000280107.1	AL022393.9	-10.19	4.33e-22	4.35e-19	-0.56	-0.43	Parkinson's disease;	chr6:28052201	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.629	rs172165	ENSG00000280107.1	AL022393.9	-10.19	4.33e-22	4.35e-19	-0.56	-0.43	Parkinson's disease;	chr6:28053036	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.597	rs172166	ENSG00000280107.1	AL022393.9	-10.19	4.33e-22	4.35e-19	-0.56	-0.43	Parkinson's disease;	chr6:28053042	chr6:28170845~28172521:+
PRAD	cis	rs2882667	0.505	rs7721110	ENSG00000253404.1	AC034243.1	10.19	4.36e-22	4.37e-19	0.55	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:139146817	chr5:138744434~138753309:-
PRAD	cis	rs6921919	0.697	rs12180820	ENSG00000216901.1	AL022393.7	-10.18	4.4e-22	4.41e-19	-0.57	-0.43	Autism spectrum disorder or schizophrenia;	chr6:28348701	chr6:28176188~28176674:+
PRAD	cis	rs7115242	0.8	rs4245168	ENSG00000254851.1	RP11-109L13.1	-10.18	4.42e-22	4.43e-19	-0.82	-0.43	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117011922	chr11:117135528~117138582:+
PRAD	cis	rs6003958	1	rs6003958	ENSG00000235689.1	AP000351.13	-10.18	4.44e-22	4.45e-19	-0.62	-0.43	S-phenylmercapturic acid levels in smokers;	chr22:23921902	chr22:24006305~24008258:-
PRAD	cis	rs5760092	0.755	rs6003959	ENSG00000235689.1	AP000351.13	-10.18	4.44e-22	4.45e-19	-0.62	-0.43	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23922208	chr22:24006305~24008258:-
PRAD	cis	rs7849270	1	rs932835	ENSG00000268707.1	RP11-247A12.7	-10.18	4.45e-22	4.46e-19	-0.48	-0.43	Blood metabolite ratios;	chr9:129124792	chr9:129170434~129170940:+
PRAD	cis	rs8062405	0.964	rs62036614	ENSG00000259982.1	CDC37P1	10.18	4.47e-22	4.48e-19	0.58	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28813364	chr16:28700294~28701540:-
PRAD	cis	rs858239	0.665	rs858305	ENSG00000226816.2	AC005082.12	-10.18	4.47e-22	4.48e-19	-0.5	-0.43	Cerebrospinal fluid biomarker levels;	chr7:23203211	chr7:23206013~23208045:+
PRAD	cis	rs9918079	0.56	rs12651550	ENSG00000273133.1	RP11-799M12.2	-10.18	4.52e-22	4.53e-19	-0.54	-0.43	Obesity-related traits;	chr4:15639395	chr4:15563698~15564253:-
PRAD	cis	rs6061231	0.837	rs6061235	ENSG00000273619.1	RP5-908M14.9	-10.18	4.56e-22	4.57e-19	-0.32	-0.43	Colorectal cancer;	chr20:62403468	chr20:62386303~62386970:-
PRAD	cis	rs6504950	0.566	rs7226272	ENSG00000275710.1	RP11-257O5.4	10.18	4.57e-22	4.57e-19	0.51	0.43	Breast cancer;	chr17:54969086	chr17:54964474~54964679:+
PRAD	cis	rs6504950	0.888	rs244294	ENSG00000275710.1	RP11-257O5.4	10.18	4.58e-22	4.59e-19	0.55	0.43	Breast cancer;	chr17:55151182	chr17:54964474~54964679:+
PRAD	cis	rs9322193	0.887	rs3777949	ENSG00000268592.3	RAET1E-AS1	10.18	4.58e-22	4.59e-19	0.6	0.43	Lung cancer;	chr6:149596021	chr6:149863494~149919507:+
PRAD	cis	rs1891275	0.551	rs2421624	ENSG00000228701.1	TNKS2-AS1	-10.18	4.6e-22	4.6e-19	-0.58	-0.43	Intelligence (multi-trait analysis);	chr10:91656659	chr10:91782839~91798291:-
PRAD	cis	rs1891275	0.551	rs2421625	ENSG00000228701.1	TNKS2-AS1	-10.18	4.6e-22	4.6e-19	-0.58	-0.43	Intelligence (multi-trait analysis);	chr10:91656744	chr10:91782839~91798291:-
PRAD	cis	rs1891275	0.576	rs7900117	ENSG00000228701.1	TNKS2-AS1	-10.18	4.6e-22	4.6e-19	-0.58	-0.43	Intelligence (multi-trait analysis);	chr10:91657530	chr10:91782839~91798291:-
PRAD	cis	rs1891275	0.551	rs4933213	ENSG00000228701.1	TNKS2-AS1	-10.18	4.6e-22	4.6e-19	-0.58	-0.43	Intelligence (multi-trait analysis);	chr10:91657947	chr10:91782839~91798291:-
PRAD	cis	rs1891275	0.506	rs4933214	ENSG00000228701.1	TNKS2-AS1	-10.18	4.6e-22	4.6e-19	-0.58	-0.43	Intelligence (multi-trait analysis);	chr10:91658004	chr10:91782839~91798291:-
PRAD	cis	rs1891275	0.515	rs7358148	ENSG00000228701.1	TNKS2-AS1	-10.18	4.6e-22	4.6e-19	-0.58	-0.43	Intelligence (multi-trait analysis);	chr10:91658775	chr10:91782839~91798291:-
PRAD	cis	rs1891275	0.601	rs7358034	ENSG00000228701.1	TNKS2-AS1	-10.18	4.6e-22	4.6e-19	-0.58	-0.43	Intelligence (multi-trait analysis);	chr10:91659007	chr10:91782839~91798291:-
PRAD	cis	rs1891275	0.551	rs7908547	ENSG00000228701.1	TNKS2-AS1	-10.18	4.6e-22	4.6e-19	-0.58	-0.43	Intelligence (multi-trait analysis);	chr10:91659230	chr10:91782839~91798291:-
PRAD	cis	rs1891275	0.515	rs7908980	ENSG00000228701.1	TNKS2-AS1	-10.18	4.6e-22	4.6e-19	-0.58	-0.43	Intelligence (multi-trait analysis);	chr10:91659545	chr10:91782839~91798291:-
PRAD	cis	rs1891275	0.551	rs4933690	ENSG00000228701.1	TNKS2-AS1	-10.18	4.6e-22	4.6e-19	-0.58	-0.43	Intelligence (multi-trait analysis);	chr10:91659810	chr10:91782839~91798291:-
PRAD	cis	rs1891275	0.576	rs4933216	ENSG00000228701.1	TNKS2-AS1	-10.18	4.6e-22	4.6e-19	-0.58	-0.43	Intelligence (multi-trait analysis);	chr10:91659825	chr10:91782839~91798291:-
PRAD	cis	rs1891275	0.551	rs4933691	ENSG00000228701.1	TNKS2-AS1	-10.18	4.6e-22	4.6e-19	-0.58	-0.43	Intelligence (multi-trait analysis);	chr10:91660200	chr10:91782839~91798291:-
PRAD	cis	rs1891275	0.551	rs2421626	ENSG00000228701.1	TNKS2-AS1	-10.18	4.6e-22	4.6e-19	-0.58	-0.43	Intelligence (multi-trait analysis);	chr10:91661177	chr10:91782839~91798291:-
PRAD	cis	rs1891275	0.551	rs2421627	ENSG00000228701.1	TNKS2-AS1	-10.18	4.6e-22	4.6e-19	-0.58	-0.43	Intelligence (multi-trait analysis);	chr10:91662226	chr10:91782839~91798291:-
PRAD	cis	rs1891275	0.551	rs2421628	ENSG00000228701.1	TNKS2-AS1	-10.18	4.6e-22	4.6e-19	-0.58	-0.43	Intelligence (multi-trait analysis);	chr10:91662412	chr10:91782839~91798291:-
PRAD	cis	rs1891275	0.515	rs10881945	ENSG00000228701.1	TNKS2-AS1	-10.18	4.6e-22	4.6e-19	-0.58	-0.43	Intelligence (multi-trait analysis);	chr10:91663826	chr10:91782839~91798291:-
PRAD	cis	rs1891275	0.551	rs2421629	ENSG00000228701.1	TNKS2-AS1	-10.18	4.6e-22	4.6e-19	-0.58	-0.43	Intelligence (multi-trait analysis);	chr10:91664018	chr10:91782839~91798291:-
PRAD	cis	rs7688540	0.623	rs11735968	ENSG00000275426.1	CH17-262A2.1	10.18	4.61e-22	4.61e-19	0.66	0.43	Facial morphology (factor 6, height of vermillion lower lip);	chr4:245031	chr4:149738~150317:+
PRAD	cis	rs6452524	0.506	rs7891	ENSG00000249664.1	CTD-2227C6.2	10.18	4.61e-22	4.61e-19	0.52	0.43	Hypertension (SNP x SNP interaction);	chr5:83053558	chr5:83012285~83013109:-
PRAD	cis	rs4718428	0.705	rs12536410	ENSG00000232546.1	RP11-458F8.1	-10.18	4.63e-22	4.63e-19	-0.35	-0.43	Corneal structure;	chr7:66789303	chr7:66848496~66858136:+
PRAD	cis	rs7727544	1	rs7727038	ENSG00000233006.5	AC034220.3	10.18	4.64e-22	4.64e-19	0.37	0.43	Blood metabolite levels;	chr5:132254564	chr5:132311285~132369916:-
PRAD	cis	rs7727544	1	rs7727544	ENSG00000233006.5	AC034220.3	10.18	4.64e-22	4.64e-19	0.37	0.43	Blood metabolite levels;	chr5:132254841	chr5:132311285~132369916:-
PRAD	cis	rs10246939	0.579	rs58093678	ENSG00000228775.6	WEE2-AS1	10.18	4.67e-22	4.67e-19	0.54	0.43	Bitter taste perception;	chr7:141856719	chr7:141704338~141738346:-
PRAD	cis	rs11951515	0.663	rs7734293	ENSG00000188850.9	RP11-159F24.2	10.18	4.67e-22	4.67e-19	0.51	0.43	Metabolite levels  (X-11787);	chr5:43283100	chr5:43336164~43348716:+
PRAD	cis	rs11118620	0.535	rs1389750	ENSG00000257551.1	HLX-AS1	10.18	4.68e-22	4.68e-19	0.48	0.43	Heart failure;	chr1:220866829	chr1:220832763~220880140:-
PRAD	cis	rs4718428	0.672	rs4718412	ENSG00000273142.1	RP11-458F8.4	10.18	4.71e-22	4.7e-19	0.34	0.43	Corneal structure;	chr7:66821880	chr7:66902857~66906297:+
PRAD	cis	rs2658782	0.654	rs2605623	ENSG00000279684.1	RP11-755E23.2	-10.18	4.72e-22	4.72e-19	-0.67	-0.43	Pulmonary function decline;	chr11:93516193	chr11:93286629~93288903:-
PRAD	cis	rs2283792	0.765	rs6518968	ENSG00000224086.5	LL22NC03-86G7.1	-10.18	4.74e-22	4.74e-19	-0.51	-0.43	Multiple sclerosis;	chr22:21793327	chr22:21938293~21977632:+
PRAD	cis	rs858239	0.896	rs1637192	ENSG00000226816.2	AC005082.12	10.18	4.74e-22	4.74e-19	0.48	0.43	Cerebrospinal fluid biomarker levels;	chr7:23220895	chr7:23206013~23208045:+
PRAD	cis	rs2739330	0.796	rs1006771	ENSG00000250470.1	AP000351.3	10.18	4.76e-22	4.76e-19	0.57	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23976904~23977585:-
PRAD	cis	rs853679	0.517	rs12332979	ENSG00000219392.1	RP1-265C24.5	-10.18	4.77e-22	4.76e-19	-0.57	-0.43	Depression;	chr6:28173770	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs67878650	ENSG00000219392.1	RP1-265C24.5	-10.18	4.77e-22	4.76e-19	-0.57	-0.43	Depression;	chr6:28174809	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.569	rs9348798	ENSG00000219392.1	RP1-265C24.5	-10.18	4.77e-22	4.76e-19	-0.57	-0.43	Depression;	chr6:28175233	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs9380065	ENSG00000219392.1	RP1-265C24.5	-10.18	4.77e-22	4.76e-19	-0.57	-0.43	Depression;	chr6:28176973	chr6:28115628~28116551:+
PRAD	cis	rs10246939	0.543	rs12538701	ENSG00000228775.6	WEE2-AS1	10.17	4.84e-22	4.83e-19	0.58	0.43	Bitter taste perception;	chr7:141893634	chr7:141704338~141738346:-
PRAD	cis	rs11673344	0.864	rs703535	ENSG00000226686.6	LINC01535	10.17	4.86e-22	4.85e-19	0.59	0.43	Obesity-related traits;	chr19:37014838	chr19:37251912~37265535:+
PRAD	cis	rs6452524	0.534	rs72765386	ENSG00000249664.1	CTD-2227C6.2	10.17	4.88e-22	4.87e-19	0.52	0.43	Hypertension (SNP x SNP interaction);	chr5:83061502	chr5:83012285~83013109:-
PRAD	cis	rs6452524	0.534	rs9293328	ENSG00000249664.1	CTD-2227C6.2	10.17	4.88e-22	4.87e-19	0.52	0.43	Hypertension (SNP x SNP interaction);	chr5:83066855	chr5:83012285~83013109:-
PRAD	cis	rs34779708	0.931	rs4934704	ENSG00000230534.5	RP11-297A16.2	10.17	4.89e-22	4.88e-19	0.57	0.43	Inflammatory bowel disease;Crohn's disease;	chr10:35043236	chr10:35098006~35127020:-
PRAD	cis	rs4718428	0.672	rs13241598	ENSG00000273142.1	RP11-458F8.4	-10.17	4.93e-22	4.92e-19	-0.33	-0.43	Corneal structure;	chr7:66835665	chr7:66902857~66906297:+
PRAD	cis	rs2283792	0.765	rs2266969	ENSG00000224086.5	LL22NC03-86G7.1	-10.17	4.94e-22	4.92e-19	-0.51	-0.43	Multiple sclerosis;	chr22:21819618	chr22:21938293~21977632:+
PRAD	cis	rs4774565	0.762	rs7164848	ENSG00000244879.4	GABPB1-AS1	10.17	4.96e-22	4.95e-19	0.38	0.43	Breast cancer;	chr15:50370833	chr15:50354959~50372202:+
PRAD	cis	rs8062405	0.698	rs8046545	ENSG00000251417.2	RP11-1348G14.4	10.17	4.97e-22	4.96e-19	0.51	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28903896	chr16:28802743~28817828:+
PRAD	cis	rs12049351	0.665	rs12142272	ENSG00000229367.1	HMGN2P19	10.17	4.98e-22	4.97e-19	0.68	0.43	Circulating myeloperoxidase levels (plasma);	chr1:229443068	chr1:229570532~229570796:+
PRAD	cis	rs4964805	0.626	rs11111771	ENSG00000257681.1	RP11-341G23.4	-10.17	5.02e-22	5e-19	-0.41	-0.43	Attention deficit hyperactivity disorder;	chr12:103785493	chr12:103746315~103768858:-
PRAD	cis	rs2153535	0.967	rs10484750	ENSG00000230939.1	RP11-314C16.1	10.17	5.03e-22	5.02e-19	0.52	0.43	Motion sickness;	chr6:8378376	chr6:8784178~8785445:+
PRAD	cis	rs6142102	0.923	rs4911394	ENSG00000276073.1	RP5-1125A11.7	-10.17	5.05e-22	5.03e-19	-0.45	-0.43	Skin pigmentation;	chr20:33989521	chr20:33985617~33988989:-
PRAD	cis	rs9322193	0.962	rs3763162	ENSG00000268592.3	RAET1E-AS1	-10.17	5.08e-22	5.06e-19	-0.59	-0.43	Lung cancer;	chr6:149819674	chr6:149863494~149919507:+
PRAD	cis	rs875971	0.862	rs709596	ENSG00000237310.1	GS1-124K5.4	10.17	5.08e-22	5.06e-19	0.39	0.43	Aortic root size;	chr7:66360926	chr7:66493706~66495474:+
PRAD	cis	rs2283792	0.74	rs2283791	ENSG00000224086.5	LL22NC03-86G7.1	-10.17	5.11e-22	5.09e-19	-0.51	-0.43	Multiple sclerosis;	chr22:21776656	chr22:21938293~21977632:+
PRAD	cis	rs3762637	0.943	rs10222564	ENSG00000272758.4	RP11-299J3.8	-10.17	5.14e-22	5.12e-19	-0.65	-0.43	LDL cholesterol levels;	chr3:122547489	chr3:122416207~122443180:+
PRAD	cis	rs3762637	0.943	rs9289198	ENSG00000272758.4	RP11-299J3.8	-10.17	5.14e-22	5.12e-19	-0.65	-0.43	LDL cholesterol levels;	chr3:122558313	chr3:122416207~122443180:+
PRAD	cis	rs3762637	0.943	rs9289199	ENSG00000272758.4	RP11-299J3.8	-10.17	5.14e-22	5.12e-19	-0.65	-0.43	LDL cholesterol levels;	chr3:122558325	chr3:122416207~122443180:+
PRAD	cis	rs17023223	0.581	rs10923750	ENSG00000231365.4	RP11-418J17.1	-10.17	5.15e-22	5.12e-19	-0.44	-0.43	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119108172	chr1:119140396~119275973:+
PRAD	cis	rs4718428	0.705	rs68168107	ENSG00000273142.1	RP11-458F8.4	-10.17	5.16e-22	5.13e-19	-0.33	-0.43	Corneal structure;	chr7:66790251	chr7:66902857~66906297:+
PRAD	cis	rs34375054	0.752	rs12582808	ENSG00000279233.1	RP11-158L12.4	10.17	5.17e-22	5.15e-19	0.45	0.43	Post bronchodilator FEV1/FVC ratio;	chr12:125176913	chr12:125138245~125141711:+
PRAD	cis	rs875971	0.862	rs2460432	ENSG00000237310.1	GS1-124K5.4	-10.17	5.18e-22	5.15e-19	-0.41	-0.43	Aortic root size;	chr7:66089398	chr7:66493706~66495474:+
PRAD	cis	rs9309473	0.66	rs10496192	ENSG00000163016.8	ALMS1P	10.17	5.18e-22	5.16e-19	0.63	0.43	Metabolite levels;	chr2:73452739	chr2:73644919~73685576:+
PRAD	cis	rs4774565	0.762	rs1056682	ENSG00000244879.4	GABPB1-AS1	-10.16	5.21e-22	5.18e-19	-0.4	-0.43	Breast cancer;	chr15:50368004	chr15:50354959~50372202:+
PRAD	cis	rs4774565	0.762	rs17431150	ENSG00000244879.4	GABPB1-AS1	-10.16	5.21e-22	5.18e-19	-0.4	-0.43	Breast cancer;	chr15:50371385	chr15:50354959~50372202:+
PRAD	cis	rs4774565	0.762	rs17431171	ENSG00000244879.4	GABPB1-AS1	-10.16	5.21e-22	5.18e-19	-0.4	-0.43	Breast cancer;	chr15:50371424	chr15:50354959~50372202:+
PRAD	cis	rs4718428	0.705	rs68168107	ENSG00000232546.1	RP11-458F8.1	-10.16	5.23e-22	5.21e-19	-0.35	-0.43	Corneal structure;	chr7:66790251	chr7:66848496~66858136:+
PRAD	cis	rs2442825	0.693	rs2255558	ENSG00000206573.7	THUMPD3-AS1	10.16	5.25e-22	5.22e-19	0.31	0.43	Cerebrospinal fluid clusterin levels;	chr3:9375148	chr3:9349689~9398579:-
PRAD	cis	rs4845570	0.92	rs1196456	ENSG00000249602.1	RP11-98D18.3	-10.16	5.25e-22	5.23e-19	-0.63	-0.43	Coronary artery disease;	chr1:151764873	chr1:151763384~151769501:-
PRAD	cis	rs9918079	0.56	rs10008975	ENSG00000273133.1	RP11-799M12.2	-10.16	5.29e-22	5.26e-19	-0.54	-0.43	Obesity-related traits;	chr4:15622948	chr4:15563698~15564253:-
PRAD	cis	rs9918079	0.56	rs7438356	ENSG00000273133.1	RP11-799M12.2	-10.16	5.29e-22	5.26e-19	-0.54	-0.43	Obesity-related traits;	chr4:15623147	chr4:15563698~15564253:-
PRAD	cis	rs4713118	0.587	rs61471148	ENSG00000219392.1	RP1-265C24.5	-10.16	5.31e-22	5.28e-19	-0.56	-0.43	Parkinson's disease;	chr6:28069254	chr6:28115628~28116551:+
PRAD	cis	rs1577917	0.916	rs12198730	ENSG00000203875.9	SNHG5	-10.16	5.32e-22	5.29e-19	-0.51	-0.43	Response to antipsychotic treatment;	chr6:85845420	chr6:85660950~85678736:-
PRAD	cis	rs748404	0.578	rs512628	ENSG00000205771.5	CATSPER2P1	-10.16	5.34e-22	5.31e-19	-0.48	-0.43	Lung cancer;	chr15:43326536	chr15:43726918~43747094:-
PRAD	cis	rs2019137	0.589	rs7560701	ENSG00000189223.12	PAX8-AS1	-10.16	5.37e-22	5.34e-19	-0.54	-0.43	Lymphocyte counts;	chr2:113269305	chr2:113211522~113276581:+
PRAD	cis	rs2337406	0.789	rs9324095	ENSG00000274576.2	IGHV2-70	-10.16	5.38e-22	5.35e-19	-0.43	-0.43	Alzheimer's disease (late onset);	chr14:106795885	chr14:106770577~106771020:-
PRAD	cis	rs2337406	0.866	rs58154560	ENSG00000274576.2	IGHV2-70	-10.16	5.38e-22	5.35e-19	-0.43	-0.43	Alzheimer's disease (late onset);	chr14:106799601	chr14:106770577~106771020:-
PRAD	cis	rs1075265	0.84	rs805309	ENSG00000233266.1	HMGB1P31	10.16	5.47e-22	5.44e-19	0.57	0.43	Chronotype;Morning vs. evening chronotype;	chr2:53968877	chr2:54051334~54051760:+
PRAD	cis	rs9322193	0.923	rs14314	ENSG00000268592.3	RAET1E-AS1	10.16	5.57e-22	5.53e-19	0.59	0.43	Lung cancer;	chr6:149820395	chr6:149863494~149919507:+
PRAD	cis	rs9918079	0.542	rs6414765	ENSG00000273133.1	RP11-799M12.2	-10.16	5.6e-22	5.55e-19	-0.54	-0.43	Obesity-related traits;	chr4:15624870	chr4:15563698~15564253:-
PRAD	cis	rs8062405	1	rs62036616	ENSG00000259982.1	CDC37P1	10.16	5.61e-22	5.56e-19	0.57	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814986	chr16:28700294~28701540:-
PRAD	cis	rs4718428	0.672	rs36038499	ENSG00000232546.1	RP11-458F8.1	-10.16	5.63e-22	5.58e-19	-0.35	-0.43	Corneal structure;	chr7:66824628	chr7:66848496~66858136:+
PRAD	cis	rs4718428	0.705	rs62465692	ENSG00000232546.1	RP11-458F8.1	-10.16	5.63e-22	5.58e-19	-0.35	-0.43	Corneal structure;	chr7:66830758	chr7:66848496~66858136:+
PRAD	cis	rs4718428	0.662	rs34577323	ENSG00000232546.1	RP11-458F8.1	-10.16	5.63e-22	5.58e-19	-0.35	-0.43	Corneal structure;	chr7:66845054	chr7:66848496~66858136:+
PRAD	cis	rs4718428	0.705	rs28648401	ENSG00000273142.1	RP11-458F8.4	-10.15	5.65e-22	5.6e-19	-0.33	-0.43	Corneal structure;	chr7:66902145	chr7:66902857~66906297:+
PRAD	cis	rs4718428	0.607	rs66954441	ENSG00000273142.1	RP11-458F8.4	-10.15	5.65e-22	5.6e-19	-0.33	-0.43	Corneal structure;	chr7:66904222	chr7:66902857~66906297:+
PRAD	cis	rs4964805	1	rs12228207	ENSG00000257681.1	RP11-341G23.4	10.15	5.65e-22	5.6e-19	0.43	0.43	Attention deficit hyperactivity disorder;	chr12:103802956	chr12:103746315~103768858:-
PRAD	cis	rs6964833	0.554	rs2527380	ENSG00000123965.13	PMS2P5	-10.15	5.65e-22	5.6e-19	-0.6	-0.43	Menarche (age at onset);	chr7:74690372	chr7:74894116~74897835:+
PRAD	cis	rs4774565	0.762	rs7182201	ENSG00000244879.4	GABPB1-AS1	-10.15	5.67e-22	5.63e-19	-0.4	-0.43	Breast cancer;	chr15:50364377	chr15:50354959~50372202:+
PRAD	cis	rs4774565	0.724	rs2555486	ENSG00000244879.4	GABPB1-AS1	10.15	5.67e-22	5.63e-19	0.4	0.43	Breast cancer;	chr15:50363924	chr15:50354959~50372202:+
PRAD	cis	rs1891275	0.54	rs10732773	ENSG00000228701.1	TNKS2-AS1	-10.15	5.68e-22	5.64e-19	-0.58	-0.43	Intelligence (multi-trait analysis);	chr10:91656468	chr10:91782839~91798291:-
PRAD	cis	rs7617773	0.539	rs12486944	ENSG00000229759.1	MRPS18AP1	10.15	5.7e-22	5.65e-19	0.45	0.43	Coronary artery disease;	chr3:48348526	chr3:48256350~48256938:-
PRAD	cis	rs2658782	0.654	rs2605622	ENSG00000279684.1	RP11-755E23.2	-10.15	5.73e-22	5.68e-19	-0.67	-0.43	Pulmonary function decline;	chr11:93515076	chr11:93286629~93288903:-
PRAD	cis	rs4845570	0.92	rs3811414	ENSG00000249602.1	RP11-98D18.3	10.15	5.8e-22	5.75e-19	0.63	0.43	Coronary artery disease;	chr1:151790770	chr1:151763384~151769501:-
PRAD	cis	rs7201929	1	rs7201929	ENSG00000259982.1	CDC37P1	10.15	5.81e-22	5.76e-19	0.59	0.43	QT interval;	chr16:28860645	chr16:28700294~28701540:-
PRAD	cis	rs9532669	0.926	rs7799	ENSG00000176268.5	CYCSP34	10.15	5.81e-22	5.76e-19	0.45	0.43	Cervical cancer;	chr13:40958916	chr13:40863599~40863902:-
PRAD	cis	rs2929278	0.617	rs524908	ENSG00000249839.1	AC011330.5	10.15	5.87e-22	5.82e-19	0.54	0.43	Schizophrenia;	chr15:43895793	chr15:43663654~43684339:-
PRAD	cis	rs1815787	1	rs1815787	ENSG00000254851.1	RP11-109L13.1	-10.15	5.89e-22	5.83e-19	-0.82	-0.43	Subjective well-being;	chr11:117050681	chr11:117135528~117138582:+
PRAD	cis	rs2283792	0.765	rs9610338	ENSG00000224086.5	LL22NC03-86G7.1	10.15	5.91e-22	5.85e-19	0.51	0.43	Multiple sclerosis;	chr22:21797532	chr22:21938293~21977632:+
PRAD	cis	rs9322193	0.607	rs4869755	ENSG00000216906.2	RP11-350J20.9	10.15	5.91e-22	5.85e-19	0.57	0.43	Lung cancer;	chr6:149886347	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.639	rs4869756	ENSG00000216906.2	RP11-350J20.9	10.15	5.91e-22	5.85e-19	0.57	0.43	Lung cancer;	chr6:149886360	chr6:149904243~149906418:+
PRAD	cis	rs4718428	0.705	rs12536410	ENSG00000273142.1	RP11-458F8.4	-10.15	5.95e-22	5.89e-19	-0.33	-0.43	Corneal structure;	chr7:66789303	chr7:66902857~66906297:+
PRAD	cis	rs2933343	0.951	rs789218	ENSG00000231305.3	RP11-723O4.2	10.15	5.96e-22	5.9e-19	0.45	0.43	IgG glycosylation;	chr3:128873827	chr3:128861313~128871540:-
PRAD	cis	rs9322193	0.607	rs9371228	ENSG00000268592.3	RAET1E-AS1	-10.15	6e-22	5.94e-19	-0.67	-0.43	Lung cancer;	chr6:149921977	chr6:149863494~149919507:+
PRAD	cis	rs7615952	0.611	rs7632305	ENSG00000171084.14	FAM86JP	10.15	6.03e-22	5.96e-19	0.82	0.43	Blood pressure (smoking interaction);	chr3:125915924	chr3:125916620~125930024:+
PRAD	cis	rs7615952	0.673	rs9841194	ENSG00000171084.14	FAM86JP	10.15	6.03e-22	5.96e-19	0.82	0.43	Blood pressure (smoking interaction);	chr3:125916896	chr3:125916620~125930024:+
PRAD	cis	rs7615952	0.673	rs9289270	ENSG00000171084.14	FAM86JP	10.15	6.03e-22	5.96e-19	0.82	0.43	Blood pressure (smoking interaction);	chr3:125918136	chr3:125916620~125930024:+
PRAD	cis	rs12049351	0.665	rs12036589	ENSG00000229367.1	HMGN2P19	10.15	6.03e-22	5.97e-19	0.62	0.43	Circulating myeloperoxidase levels (plasma);	chr1:229437829	chr1:229570532~229570796:+
PRAD	cis	rs12049351	0.613	rs1887634	ENSG00000229367.1	HMGN2P19	10.15	6.03e-22	5.97e-19	0.62	0.43	Circulating myeloperoxidase levels (plasma);	chr1:229439032	chr1:229570532~229570796:+
PRAD	cis	rs710216	0.536	rs710221	ENSG00000227533.4	SLC2A1-AS1	10.15	6.04e-22	5.98e-19	0.48	0.43	Red cell distribution width;	chr1:42948529	chr1:42959049~42983358:+
PRAD	cis	rs7688540	0.771	rs11248009	ENSG00000275426.1	CH17-262A2.1	10.15	6.07e-22	6e-19	0.66	0.43	Facial morphology (factor 6, height of vermillion lower lip);	chr4:226360	chr4:149738~150317:+
PRAD	cis	rs875971	0.862	rs6460282	ENSG00000237310.1	GS1-124K5.4	-10.15	6.07e-22	6.01e-19	-0.4	-0.43	Aortic root size;	chr7:66226259	chr7:66493706~66495474:+
PRAD	cis	rs6142102	0.961	rs2284387	ENSG00000276073.1	RP5-1125A11.7	-10.15	6.07e-22	6.01e-19	-0.45	-0.43	Skin pigmentation;	chr20:34056782	chr20:33985617~33988989:-
PRAD	cis	rs6504950	0.924	rs187242	ENSG00000275710.1	RP11-257O5.4	10.15	6.08e-22	6.02e-19	0.55	0.43	Breast cancer;	chr17:55115585	chr17:54964474~54964679:+
PRAD	cis	rs7714584	1	rs1428554	ENSG00000197083.10	ZNF300P1	10.15	6.09e-22	6.02e-19	0.69	0.43	Crohn's disease;	chr5:150878054	chr5:150930645~150946289:-
PRAD	cis	rs7849270	1	rs10819469	ENSG00000268707.1	RP11-247A12.7	-10.15	6.11e-22	6.04e-19	-0.49	-0.43	Blood metabolite ratios;	chr9:129119788	chr9:129170434~129170940:+
PRAD	cis	rs7714584	1	rs1428551	ENSG00000197083.10	ZNF300P1	10.15	6.13e-22	6.06e-19	0.7	0.43	Crohn's disease;	chr5:150880270	chr5:150930645~150946289:-
PRAD	cis	rs10875746	0.729	rs11168357	ENSG00000240399.1	RP1-228P16.1	-10.15	6.13e-22	6.06e-19	-0.41	-0.43	Longevity (90 years and older);	chr12:48018355	chr12:48054813~48055591:-
PRAD	cis	rs801193	0.569	rs2707824	ENSG00000237310.1	GS1-124K5.4	10.14	6.14e-22	6.07e-19	0.4	0.43	Aortic root size;	chr7:66724256	chr7:66493706~66495474:+
PRAD	cis	rs732716	0.719	rs56088814	ENSG00000267980.1	AC007292.6	-10.14	6.18e-22	6.11e-19	-0.45	-0.43	Mean corpuscular volume;	chr19:4422181	chr19:4363789~4364640:+
PRAD	cis	rs7617773	0.539	rs6779517	ENSG00000229759.1	MRPS18AP1	10.14	6.23e-22	6.15e-19	0.45	0.43	Coronary artery disease;	chr3:48342898	chr3:48256350~48256938:-
PRAD	cis	rs6504950	0.85	rs2628321	ENSG00000275710.1	RP11-257O5.4	10.14	6.25e-22	6.17e-19	0.54	0.43	Breast cancer;	chr17:55128556	chr17:54964474~54964679:+
PRAD	cis	rs732716	0.785	rs62129354	ENSG00000267980.1	AC007292.6	-10.14	6.33e-22	6.25e-19	-0.46	-0.43	Mean corpuscular volume;	chr19:4396508	chr19:4363789~4364640:+
PRAD	cis	rs1075265	0.73	rs7601692	ENSG00000233266.1	HMGB1P31	10.14	6.33e-22	6.26e-19	0.58	0.43	Chronotype;Morning vs. evening chronotype;	chr2:53705532	chr2:54051334~54051760:+
PRAD	cis	rs7849270	0.692	rs4397510	ENSG00000268707.1	RP11-247A12.7	-10.14	6.38e-22	6.3e-19	-0.49	-0.43	Blood metabolite ratios;	chr9:129092671	chr9:129170434~129170940:+
PRAD	cis	rs7849270	0.879	rs10739741	ENSG00000268707.1	RP11-247A12.7	-10.14	6.38e-22	6.3e-19	-0.49	-0.43	Blood metabolite ratios;	chr9:129092881	chr9:129170434~129170940:+
PRAD	cis	rs7847628	0.566	rs10739575	ENSG00000226752.6	PSMD5-AS1	10.14	6.39e-22	6.31e-19	0.63	0.43	Birth weight;	chr9:120843823	chr9:120824828~120854385:+
PRAD	cis	rs3096299	0.658	rs4785679	ENSG00000261118.1	RP11-104N10.1	10.14	6.45e-22	6.36e-19	0.42	0.43	Multiple myeloma (IgH translocation);	chr16:89499705	chr16:89492017~89504460:-
PRAD	cis	rs4964805	1	rs11111791	ENSG00000257681.1	RP11-341G23.4	10.14	6.5e-22	6.41e-19	0.43	0.43	Attention deficit hyperactivity disorder;	chr12:103799493	chr12:103746315~103768858:-
PRAD	cis	rs6539288	0.63	rs1055332	ENSG00000260329.1	RP11-412D9.4	-10.14	6.57e-22	6.48e-19	-0.37	-0.43	Total body bone mineral density;	chr12:106954847	chr12:106954029~106955497:-
PRAD	cis	rs8062405	0.756	rs151182	ENSG00000259982.1	CDC37P1	10.14	6.6e-22	6.5e-19	0.57	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28484431	chr16:28700294~28701540:-
PRAD	cis	rs4380275	0.782	rs11691064	ENSG00000223751.1	AC116609.2	10.14	6.62e-22	6.53e-19	0.55	0.43	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:755718	chr2:742488~747767:+
PRAD	cis	rs6452524	0.905	rs7736289	ENSG00000249664.1	CTD-2227C6.2	10.14	6.64e-22	6.54e-19	0.5	0.43	Hypertension (SNP x SNP interaction);	chr5:83082401	chr5:83012285~83013109:-
PRAD	cis	rs7688540	0.771	rs61794997	ENSG00000275426.1	CH17-262A2.1	10.14	6.66e-22	6.56e-19	0.65	0.43	Facial morphology (factor 6, height of vermillion lower lip);	chr4:228314	chr4:149738~150317:+
PRAD	cis	rs4380275	0.782	rs4854276	ENSG00000272342.1	RP13-539J13.1	10.13	6.69e-22	6.59e-19	0.55	0.43	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:764357	chr2:739588~740164:-
PRAD	cis	rs6452524	0.534	rs7724935	ENSG00000249664.1	CTD-2227C6.2	10.13	6.7e-22	6.61e-19	0.52	0.43	Hypertension (SNP x SNP interaction);	chr5:83057264	chr5:83012285~83013109:-
PRAD	cis	rs6452524	0.506	rs7707143	ENSG00000249664.1	CTD-2227C6.2	10.13	6.7e-22	6.61e-19	0.52	0.43	Hypertension (SNP x SNP interaction);	chr5:83057268	chr5:83012285~83013109:-
PRAD	cis	rs6539288	0.677	rs2287163	ENSG00000260329.1	RP11-412D9.4	-10.13	6.76e-22	6.66e-19	-0.37	-0.43	Total body bone mineral density;	chr12:106955516	chr12:106954029~106955497:-
PRAD	cis	rs10256972	0.669	rs10229964	ENSG00000229043.2	AC091729.9	-10.13	6.76e-22	6.66e-19	-0.53	-0.43	Endometriosis;Longevity;	chr7:1012140	chr7:1160374~1165267:+
PRAD	cis	rs7849270	1	rs6478867	ENSG00000268707.1	RP11-247A12.7	10.13	6.77e-22	6.67e-19	0.48	0.43	Blood metabolite ratios;	chr9:129141644	chr9:129170434~129170940:+
PRAD	cis	rs1891275	0.551	rs7087959	ENSG00000228701.1	TNKS2-AS1	-10.13	6.8e-22	6.7e-19	-0.58	-0.43	Intelligence (multi-trait analysis);	chr10:91656160	chr10:91782839~91798291:-
PRAD	cis	rs2348418	0.733	rs10771414	ENSG00000247934.4	RP11-967K21.1	10.13	6.81e-22	6.7e-19	0.39	0.43	Lung function (FEV1);Lung function (FVC);	chr12:28241369	chr12:28163298~28190738:-
PRAD	cis	rs8062405	0.756	rs151301	ENSG00000259982.1	CDC37P1	10.13	6.81e-22	6.71e-19	0.57	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28485738	chr16:28700294~28701540:-
PRAD	cis	rs2933343	0.951	rs789217	ENSG00000261159.1	RP11-723O4.9	10.13	6.81e-22	6.71e-19	0.41	0.43	IgG glycosylation;	chr3:128874358	chr3:128859716~128860526:-
PRAD	cis	rs7688540	0.723	rs17521834	ENSG00000275426.1	CH17-262A2.1	-10.13	6.84e-22	6.73e-19	-0.65	-0.43	Facial morphology (factor 6, height of vermillion lower lip);	chr4:231660	chr4:149738~150317:+
PRAD	cis	rs4774565	0.762	rs720599	ENSG00000244879.4	GABPB1-AS1	-10.13	6.87e-22	6.76e-19	-0.39	-0.43	Breast cancer;	chr15:50372318	chr15:50354959~50372202:+
PRAD	cis	rs1150668	0.83	rs213240	ENSG00000204709.4	LINC01556	10.13	6.9e-22	6.79e-19	0.55	0.43	Pubertal anthropometrics;	chr6:28348098	chr6:28943877~28944537:+
PRAD	cis	rs1075265	0.783	rs6708095	ENSG00000233266.1	HMGB1P31	10.13	6.93e-22	6.82e-19	0.59	0.43	Chronotype;Morning vs. evening chronotype;	chr2:53710365	chr2:54051334~54051760:+
PRAD	cis	rs9309473	0.615	rs62153183	ENSG00000163016.8	ALMS1P	10.13	6.93e-22	6.82e-19	0.65	0.43	Metabolite levels;	chr2:73536239	chr2:73644919~73685576:+
PRAD	cis	rs9309473	0.615	rs74523560	ENSG00000163016.8	ALMS1P	10.13	6.93e-22	6.82e-19	0.65	0.43	Metabolite levels;	chr2:73537058	chr2:73644919~73685576:+
PRAD	cis	rs9322193	0.962	rs9322206	ENSG00000268592.3	RAET1E-AS1	10.13	6.94e-22	6.82e-19	0.6	0.43	Lung cancer;	chr6:149641481	chr6:149863494~149919507:+
PRAD	cis	rs2933343	0.859	rs789245	ENSG00000231305.3	RP11-723O4.2	10.13	6.99e-22	6.87e-19	0.45	0.43	IgG glycosylation;	chr3:128864737	chr3:128861313~128871540:-
PRAD	cis	rs2739330	0.731	rs2000468	ENSG00000224205.1	AP000351.4	10.13	7.02e-22	6.9e-19	0.54	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23987320~23991421:-
PRAD	cis	rs3762637	0.943	rs9841897	ENSG00000272758.4	RP11-299J3.8	-10.13	7.02e-22	6.9e-19	-0.65	-0.43	LDL cholesterol levels;	chr3:122563722	chr3:122416207~122443180:+
PRAD	cis	rs3762637	0.943	rs28372690	ENSG00000272758.4	RP11-299J3.8	-10.13	7.02e-22	6.9e-19	-0.65	-0.43	LDL cholesterol levels;	chr3:122564248	chr3:122416207~122443180:+
PRAD	cis	rs12049351	0.612	rs4925491	ENSG00000229367.1	HMGN2P19	10.13	7.04e-22	6.91e-19	0.62	0.43	Circulating myeloperoxidase levels (plasma);	chr1:229472542	chr1:229570532~229570796:+
PRAD	cis	rs7772486	0.79	rs9403756	ENSG00000235652.6	RP11-545I5.3	-10.13	7.1e-22	6.97e-19	-0.44	-0.43	Lobe attachment (rater-scored or self-reported);	chr6:145936625	chr6:145799409~145886585:+
PRAD	cis	rs11951515	0.7	rs12519554	ENSG00000188850.9	RP11-159F24.2	-10.13	7.1e-22	6.98e-19	-0.5	-0.43	Metabolite levels  (X-11787);	chr5:43283241	chr5:43336164~43348716:+
PRAD	cis	rs1891275	0.527	rs35812291	ENSG00000228701.1	TNKS2-AS1	-10.13	7.15e-22	7.02e-19	-0.58	-0.43	Intelligence (multi-trait analysis);	chr10:91642584	chr10:91782839~91798291:-
PRAD	cis	rs1891275	0.551	rs4933681	ENSG00000228701.1	TNKS2-AS1	-10.13	7.15e-22	7.02e-19	-0.58	-0.43	Intelligence (multi-trait analysis);	chr10:91643365	chr10:91782839~91798291:-
PRAD	cis	rs9326248	0.53	rs2155583	ENSG00000254851.1	RP11-109L13.1	-10.13	7.18e-22	7.05e-19	-0.83	-0.43	Blood protein levels;	chr11:117044501	chr11:117135528~117138582:+
PRAD	cis	rs2739330	0.828	rs5760099	ENSG00000272787.1	KB-226F1.2	-10.13	7.22e-22	7.09e-19	-0.47	-0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23969211~23969873:+
PRAD	cis	rs5769707	0.749	rs8137251	ENSG00000188511.11	C22orf34	10.13	7.24e-22	7.11e-19	0.48	0.43	Monocyte percentage of white cells;Monocyte count;	chr22:49643021	chr22:49414524~49657542:-
PRAD	cis	rs34779708	0.931	rs11010132	ENSG00000230534.5	RP11-297A16.2	10.12	7.26e-22	7.13e-19	0.56	0.43	Inflammatory bowel disease;Crohn's disease;	chr10:35228337	chr10:35098006~35127020:-
PRAD	cis	rs1075265	0.783	rs805438	ENSG00000233266.1	HMGB1P31	10.12	7.28e-22	7.15e-19	0.58	0.43	Chronotype;Morning vs. evening chronotype;	chr2:53829051	chr2:54051334~54051760:+
PRAD	cis	rs2348418	0.831	rs7299042	ENSG00000247934.4	RP11-967K21.1	10.12	7.29e-22	7.16e-19	0.4	0.43	Lung function (FEV1);Lung function (FVC);	chr12:28571750	chr12:28163298~28190738:-
PRAD	cis	rs1577917	1	rs12201741	ENSG00000203875.9	SNHG5	-10.12	7.4e-22	7.26e-19	-0.49	-0.43	Response to antipsychotic treatment;	chr6:85892901	chr6:85660950~85678736:-
PRAD	cis	rs2739330	0.796	rs2154594	ENSG00000272787.1	KB-226F1.2	10.12	7.4e-22	7.26e-19	0.47	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23969211~23969873:+
PRAD	cis	rs34779708	0.931	rs7079205	ENSG00000230534.5	RP11-297A16.2	10.12	7.41e-22	7.27e-19	0.57	0.43	Inflammatory bowel disease;Crohn's disease;	chr10:35035691	chr10:35098006~35127020:-
PRAD	cis	rs2404602	0.569	rs283793	ENSG00000259422.1	RP11-593F23.1	10.12	7.46e-22	7.31e-19	0.55	0.43	Blood metabolite levels;	chr15:76482411	chr15:76174891~76181486:-
PRAD	cis	rs7811142	0.83	rs6955367	ENSG00000242294.5	STAG3L5P	10.12	7.54e-22	7.39e-19	0.28	0.43	Platelet count;	chr7:100363571	chr7:100336079~100351900:+
PRAD	cis	rs783540	0.656	rs783524	ENSG00000255769.6	GOLGA2P10	10.12	7.56e-22	7.41e-19	0.53	0.43	Schizophrenia;	chr15:82615393	chr15:82472993~82513950:-
PRAD	cis	rs10800713	0.607	rs6682828	ENSG00000260088.1	RP11-92G12.3	-10.12	7.57e-22	7.42e-19	-0.56	-0.43	Tandem gait;	chr1:200537968	chr1:200669507~200694250:+
PRAD	cis	rs1930961	0.702	rs8141065	ENSG00000272977.1	CTA-390C10.10	10.12	7.58e-22	7.43e-19	0.81	0.43	Bipolar disorder with mood-incongruent psychosis;	chr22:25489221	chr22:25476218~25479971:+
PRAD	cis	rs12049351	0.665	rs35085232	ENSG00000229367.1	HMGN2P19	10.12	7.58e-22	7.43e-19	0.63	0.43	Circulating myeloperoxidase levels (plasma);	chr1:229466333	chr1:229570532~229570796:+
PRAD	cis	rs7772486	0.764	rs2265471	ENSG00000235652.6	RP11-545I5.3	10.12	7.6e-22	7.44e-19	0.44	0.43	Lobe attachment (rater-scored or self-reported);	chr6:145899114	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.594	rs6901864	ENSG00000235652.6	RP11-545I5.3	-10.12	7.61e-22	7.46e-19	-0.45	-0.43	Lobe attachment (rater-scored or self-reported);	chr6:145701914	chr6:145799409~145886585:+
PRAD	cis	rs71327718	1	rs71327718	ENSG00000171084.14	FAM86JP	10.12	7.64e-22	7.48e-19	0.85	0.43	Metabolite levels (HVA/5-HIAA ratio);	chr3:125874014	chr3:125916620~125930024:+
PRAD	cis	rs3813579	0.654	rs4480821	ENSG00000261390.4	RP11-345M22.2	-10.12	7.67e-22	7.52e-19	-0.52	-0.43	Thyroid volume;	chr16:79711416	chr16:79715232~79770563:-
PRAD	cis	rs60065504	1	rs60065504	ENSG00000251022.5	THAP9-AS1	-10.12	7.7e-22	7.54e-19	-0.42	-0.43	Lymphocyte percentage of white cells;	chr4:82964057	chr4:82893009~82900960:-
PRAD	cis	rs7714584	1	rs1816256	ENSG00000197083.10	ZNF300P1	10.12	7.71e-22	7.56e-19	0.7	0.43	Crohn's disease;	chr5:150893291	chr5:150930645~150946289:-
PRAD	cis	rs7714584	1	rs59321715	ENSG00000197083.10	ZNF300P1	10.12	7.75e-22	7.59e-19	0.81	0.43	Crohn's disease;	chr5:150933918	chr5:150930645~150946289:-
PRAD	cis	rs10246939	0.543	rs10952509	ENSG00000228775.6	WEE2-AS1	10.12	7.82e-22	7.66e-19	0.58	0.43	Bitter taste perception;	chr7:141890884	chr7:141704338~141738346:-
PRAD	cis	rs2658782	0.724	rs2605627	ENSG00000279684.1	RP11-755E23.2	-10.12	7.87e-22	7.71e-19	-0.68	-0.43	Pulmonary function decline;	chr11:93526349	chr11:93286629~93288903:-
PRAD	cis	rs1891275	0.551	rs4933692	ENSG00000228701.1	TNKS2-AS1	-10.11	7.88e-22	7.72e-19	-0.58	-0.43	Intelligence (multi-trait analysis);	chr10:91664876	chr10:91782839~91798291:-
PRAD	cis	rs9326248	0.53	rs1351452	ENSG00000254851.1	RP11-109L13.1	10.11	7.92e-22	7.75e-19	0.81	0.43	Blood protein levels;	chr11:117072638	chr11:117135528~117138582:+
PRAD	cis	rs2739330	0.732	rs5760175	ENSG00000228039.3	KB-1125A3.10	10.11	7.96e-22	7.79e-19	0.55	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23963780~23964374:+
PRAD	cis	rs6504950	0.924	rs244338	ENSG00000275710.1	RP11-257O5.4	10.11	8.02e-22	7.85e-19	0.54	0.43	Breast cancer;	chr17:55123057	chr17:54964474~54964679:+
PRAD	cis	rs7849270	1	rs3814492	ENSG00000268707.1	RP11-247A12.7	-10.11	8.03e-22	7.85e-19	-0.49	-0.43	Blood metabolite ratios;	chr9:129110943	chr9:129170434~129170940:+
PRAD	cis	rs2739330	0.828	rs4822451	ENSG00000272787.1	KB-226F1.2	-10.11	8.06e-22	7.89e-19	-0.47	-0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23969211~23969873:+
PRAD	cis	rs783540	0.592	rs2567632	ENSG00000255769.6	GOLGA2P10	10.11	8.08e-22	7.9e-19	0.53	0.43	Schizophrenia;	chr15:82616053	chr15:82472993~82513950:-
PRAD	cis	rs12439619	0.508	rs11856561	ENSG00000278603.1	RP13-608F4.5	10.11	8.08e-22	7.91e-19	0.56	0.43	Intelligence (multi-trait analysis);	chr15:82161415	chr15:82472203~82472426:+
PRAD	cis	rs9322193	0.607	rs3798763	ENSG00000216906.2	RP11-350J20.9	10.11	8.11e-22	7.94e-19	0.57	0.43	Lung cancer;	chr6:149889964	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.607	rs12204653	ENSG00000216906.2	RP11-350J20.9	10.11	8.11e-22	7.94e-19	0.57	0.43	Lung cancer;	chr6:149891885	chr6:149904243~149906418:+
PRAD	cis	rs6860806	0.507	rs200837	ENSG00000233006.5	AC034220.3	10.11	8.12e-22	7.95e-19	0.4	0.43	Breast cancer;	chr5:132364266	chr5:132311285~132369916:-
PRAD	cis	rs8062405	0.964	rs7187333	ENSG00000259982.1	CDC37P1	10.11	8.14e-22	7.96e-19	0.58	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854595	chr16:28700294~28701540:-
PRAD	cis	rs1555322	0.53	rs2425047	ENSG00000126005.14	MMP24-AS1	10.11	8.16e-22	7.98e-19	0.52	0.43	Attention deficit hyperactivity disorder;	chr20:35283872	chr20:35216462~35278131:-
PRAD	cis	rs2283792	0.765	rs7290469	ENSG00000224086.5	LL22NC03-86G7.1	-10.11	8.17e-22	7.99e-19	-0.51	-0.43	Multiple sclerosis;	chr22:21796693	chr22:21938293~21977632:+
PRAD	cis	rs7115242	0.8	rs10736487	ENSG00000254851.1	RP11-109L13.1	-10.11	8.19e-22	8e-19	-0.83	-0.43	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117079516	chr11:117135528~117138582:+
PRAD	cis	rs67311347	1	rs9865348	ENSG00000223797.4	ENTPD3-AS1	10.11	8.22e-22	8.04e-19	0.39	0.43	Renal cell carcinoma;	chr3:40356167	chr3:40313802~40453329:-
PRAD	cis	rs67311347	1	rs9849992	ENSG00000223797.4	ENTPD3-AS1	10.11	8.22e-22	8.04e-19	0.39	0.43	Renal cell carcinoma;	chr3:40360649	chr3:40313802~40453329:-
PRAD	cis	rs853679	0.517	rs868987	ENSG00000219392.1	RP1-265C24.5	10.11	8.27e-22	8.08e-19	0.56	0.43	Depression;	chr6:28142370	chr6:28115628~28116551:+
PRAD	cis	rs4423214	0.524	rs4944046	ENSG00000254682.1	RP11-660L16.2	10.11	8.32e-22	8.13e-19	0.53	0.43	Vitamin D levels;	chr11:71412748	chr11:71448674~71452157:+
PRAD	cis	rs8062405	0.721	rs151303	ENSG00000259982.1	CDC37P1	10.11	8.36e-22	8.17e-19	0.57	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28481189	chr16:28700294~28701540:-
PRAD	cis	rs9309473	0.948	rs7603647	ENSG00000163016.8	ALMS1P	10.11	8.37e-22	8.18e-19	0.52	0.43	Metabolite levels;	chr2:73590111	chr2:73644919~73685576:+
PRAD	cis	rs9309473	0.948	rs13391552	ENSG00000163016.8	ALMS1P	10.11	8.37e-22	8.18e-19	0.52	0.43	Metabolite levels;	chr2:73591809	chr2:73644919~73685576:+
PRAD	cis	rs1891275	0.576	rs1891272	ENSG00000228701.1	TNKS2-AS1	-10.11	8.4e-22	8.21e-19	-0.58	-0.43	Intelligence (multi-trait analysis);	chr10:91666306	chr10:91782839~91798291:-
PRAD	cis	rs7849270	0.837	rs4642748	ENSG00000268707.1	RP11-247A12.7	-10.11	8.43e-22	8.24e-19	-0.49	-0.43	Blood metabolite ratios;	chr9:129092668	chr9:129170434~129170940:+
PRAD	cis	rs4718428	0.705	rs13220977	ENSG00000273142.1	RP11-458F8.4	10.11	8.47e-22	8.27e-19	0.33	0.43	Corneal structure;	chr7:66872661	chr7:66902857~66906297:+
PRAD	cis	rs801193	0.569	rs2659908	ENSG00000237310.1	GS1-124K5.4	10.11	8.55e-22	8.35e-19	0.4	0.43	Aortic root size;	chr7:66695835	chr7:66493706~66495474:+
PRAD	cis	rs801193	0.569	rs2659907	ENSG00000237310.1	GS1-124K5.4	10.11	8.55e-22	8.35e-19	0.4	0.43	Aortic root size;	chr7:66699045	chr7:66493706~66495474:+
PRAD	cis	rs801193	0.569	rs4717315	ENSG00000237310.1	GS1-124K5.4	10.11	8.55e-22	8.35e-19	0.4	0.43	Aortic root size;	chr7:66713338	chr7:66493706~66495474:+
PRAD	cis	rs801193	0.527	rs2707837	ENSG00000237310.1	GS1-124K5.4	10.11	8.55e-22	8.35e-19	0.4	0.43	Aortic root size;	chr7:66716086	chr7:66493706~66495474:+
PRAD	cis	rs7714584	1	rs7724558	ENSG00000197083.10	ZNF300P1	10.1	8.63e-22	8.43e-19	0.79	0.43	Crohn's disease;	chr5:150949304	chr5:150930645~150946289:-
PRAD	cis	rs3762637	1	rs6777596	ENSG00000272758.4	RP11-299J3.8	-10.1	8.64e-22	8.43e-19	-0.65	-0.43	LDL cholesterol levels;	chr3:122414474	chr3:122416207~122443180:+
PRAD	cis	rs9326248	0.53	rs588918	ENSG00000254851.1	RP11-109L13.1	-10.1	8.68e-22	8.47e-19	-0.82	-0.43	Blood protein levels;	chr11:116985926	chr11:117135528~117138582:+
PRAD	cis	rs507080	0.961	rs642530	ENSG00000255422.1	AP002954.4	-10.1	8.7e-22	8.49e-19	-0.52	-0.43	Serum metabolite levels;	chr11:118680047	chr11:118704607~118750263:+
PRAD	cis	rs7586673	0.893	rs889925	ENSG00000227403.1	AC009299.3	-10.1	8.78e-22	8.56e-19	-0.57	-0.43	Intelligence (multi-trait analysis);	chr2:161115086	chr2:161244739~161249050:+
PRAD	cis	rs7586673	0.93	rs2884364	ENSG00000227403.1	AC009299.3	-10.1	8.78e-22	8.56e-19	-0.57	-0.43	Intelligence (multi-trait analysis);	chr2:161121136	chr2:161244739~161249050:+
PRAD	cis	rs10129255	0.5	rs2105989	ENSG00000223648.3	IGHV3-64	10.1	8.87e-22	8.65e-19	0.38	0.43	Kawasaki disease;	chr14:106682199	chr14:106643132~106658258:-
PRAD	cis	rs4380275	0.782	rs11127506	ENSG00000223751.1	AC116609.2	-10.1	8.94e-22	8.72e-19	-0.55	-0.43	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:751300	chr2:742488~747767:+
PRAD	cis	rs9322193	0.607	rs4870078	ENSG00000268592.3	RAET1E-AS1	-10.1	8.99e-22	8.76e-19	-0.67	-0.43	Lung cancer;	chr6:149880676	chr6:149863494~149919507:+
PRAD	cis	rs4964805	0.626	rs869993	ENSG00000257681.1	RP11-341G23.4	10.1	9.01e-22	8.79e-19	0.4	0.43	Attention deficit hyperactivity disorder;	chr12:103781360	chr12:103746315~103768858:-
PRAD	cis	rs67311347	0.955	rs4974068	ENSG00000223797.4	ENTPD3-AS1	10.1	9.02e-22	8.79e-19	0.39	0.43	Renal cell carcinoma;	chr3:40335438	chr3:40313802~40453329:-
PRAD	cis	rs4718428	0.705	rs10267335	ENSG00000232546.1	RP11-458F8.1	-10.1	9.14e-22	8.9e-19	-0.35	-0.43	Corneal structure;	chr7:66938233	chr7:66848496~66858136:+
PRAD	cis	rs7174755	0.637	rs113002386	ENSG00000260657.2	RP11-315D16.4	10.1	9.15e-22	8.92e-19	0.54	0.43	Major depressive disorder;	chr15:68172375	chr15:68267792~68277994:-
PRAD	cis	rs6570726	0.791	rs1509214	ENSG00000235652.6	RP11-545I5.3	-10.1	9.16e-22	8.93e-19	-0.44	-0.43	Lobe attachment (rater-scored or self-reported);	chr6:145463470	chr6:145799409~145886585:+
PRAD	cis	rs875971	0.651	rs313829	ENSG00000237310.1	GS1-124K5.4	-10.1	9.17e-22	8.93e-19	-0.41	-0.43	Aortic root size;	chr7:66087510	chr7:66493706~66495474:+
PRAD	cis	rs3931020	0.688	rs1051122	ENSG00000272864.1	RP11-17E13.2	-10.1	9.23e-22	8.99e-19	-0.49	-0.43	Resistin levels;	chr1:74724768	chr1:74698769~74699333:-
PRAD	cis	rs3931020	0.688	rs968358	ENSG00000272864.1	RP11-17E13.2	-10.1	9.23e-22	8.99e-19	-0.49	-0.43	Resistin levels;	chr1:74728305	chr1:74698769~74699333:-
PRAD	cis	rs34779708	0.966	rs12762493	ENSG00000230534.5	RP11-297A16.2	10.1	9.27e-22	9.03e-19	0.56	0.43	Inflammatory bowel disease;Crohn's disease;	chr10:35182945	chr10:35098006~35127020:-
PRAD	cis	rs6452524	0.534	rs10514246	ENSG00000249664.1	CTD-2227C6.2	10.09	9.31e-22	9.07e-19	0.52	0.43	Hypertension (SNP x SNP interaction);	chr5:83069979	chr5:83012285~83013109:-
PRAD	cis	rs5760092	0.755	rs11090298	ENSG00000235689.1	AP000351.13	-10.09	9.31e-22	9.07e-19	-0.62	-0.43	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919874	chr22:24006305~24008258:-
PRAD	cis	rs9309473	0.848	rs9750915	ENSG00000163016.8	ALMS1P	10.09	9.37e-22	9.12e-19	0.52	0.43	Metabolite levels;	chr2:73584753	chr2:73644919~73685576:+
PRAD	cis	rs9322193	0.962	rs9478848	ENSG00000268592.3	RAET1E-AS1	10.09	9.38e-22	9.14e-19	0.58	0.43	Lung cancer;	chr6:149825080	chr6:149863494~149919507:+
PRAD	cis	rs6570726	0.755	rs2092297	ENSG00000235652.6	RP11-545I5.3	10.09	9.4e-22	9.15e-19	0.44	0.43	Lobe attachment (rater-scored or self-reported);	chr6:145572629	chr6:145799409~145886585:+
PRAD	cis	rs9545047	0.588	rs9530913	ENSG00000227676.3	LINC01068	10.09	9.4e-22	9.15e-19	0.51	0.43	Schizophrenia;	chr13:79384539	chr13:79566727~79571436:+
PRAD	cis	rs9322193	0.961	rs9027	ENSG00000268592.3	RAET1E-AS1	10.09	9.43e-22	9.18e-19	0.59	0.43	Lung cancer;	chr6:149594921	chr6:149863494~149919507:+
PRAD	cis	rs7115242	0.8	rs493134	ENSG00000254851.1	RP11-109L13.1	-10.09	9.51e-22	9.25e-19	-0.83	-0.43	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116962963	chr11:117135528~117138582:+
PRAD	cis	rs7849270	1	rs2541161	ENSG00000268707.1	RP11-247A12.7	10.09	9.51e-22	9.26e-19	0.48	0.43	Blood metabolite ratios;	chr9:129122523	chr9:129170434~129170940:+
PRAD	cis	rs9545047	0.604	rs9530915	ENSG00000227676.3	LINC01068	10.09	9.52e-22	9.26e-19	0.51	0.43	Schizophrenia;	chr13:79396512	chr13:79566727~79571436:+
PRAD	cis	rs4713118	0.699	rs200969	ENSG00000280107.1	AL022393.9	-10.09	9.55e-22	9.29e-19	-0.56	-0.43	Parkinson's disease;	chr6:27891675	chr6:28170845~28172521:+
PRAD	cis	rs783540	0.521	rs28719490	ENSG00000255769.6	GOLGA2P10	-10.09	9.56e-22	9.31e-19	-0.57	-0.43	Schizophrenia;	chr15:82720688	chr15:82472993~82513950:-
PRAD	cis	rs9545047	0.604	rs7329331	ENSG00000227676.3	LINC01068	10.09	9.63e-22	9.36e-19	0.51	0.43	Schizophrenia;	chr13:79384986	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs7330479	ENSG00000227676.3	LINC01068	10.09	9.63e-22	9.36e-19	0.51	0.43	Schizophrenia;	chr13:79385058	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs6563104	ENSG00000227676.3	LINC01068	10.09	9.63e-22	9.36e-19	0.51	0.43	Schizophrenia;	chr13:79389718	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs7981500	ENSG00000227676.3	LINC01068	10.09	9.63e-22	9.36e-19	0.51	0.43	Schizophrenia;	chr13:79391461	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs57821487	ENSG00000227676.3	LINC01068	10.09	9.63e-22	9.36e-19	0.51	0.43	Schizophrenia;	chr13:79392810	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs7323246	ENSG00000227676.3	LINC01068	10.09	9.63e-22	9.36e-19	0.51	0.43	Schizophrenia;	chr13:79392903	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs7331766	ENSG00000227676.3	LINC01068	10.09	9.63e-22	9.36e-19	0.51	0.43	Schizophrenia;	chr13:79394076	chr13:79566727~79571436:+
PRAD	cis	rs1891275	0.551	rs7908678	ENSG00000228701.1	TNKS2-AS1	10.09	9.76e-22	9.48e-19	0.57	0.43	Intelligence (multi-trait analysis);	chr10:91659253	chr10:91782839~91798291:-
PRAD	cis	rs67311347	1	rs7617989	ENSG00000223797.4	ENTPD3-AS1	-10.09	9.79e-22	9.52e-19	-0.38	-0.43	Renal cell carcinoma;	chr3:40470972	chr3:40313802~40453329:-
PRAD	cis	rs9918079	0.56	rs6414767	ENSG00000273133.1	RP11-799M12.2	-10.09	9.85e-22	9.57e-19	-0.54	-0.43	Obesity-related traits;	chr4:15654098	chr4:15563698~15564253:-
PRAD	cis	rs9322193	0.962	rs2151912	ENSG00000268592.3	RAET1E-AS1	10.09	9.86e-22	9.58e-19	0.58	0.43	Lung cancer;	chr6:149831772	chr6:149863494~149919507:+
PRAD	cis	rs7811142	0.83	rs11768967	ENSG00000242294.5	STAG3L5P	10.09	9.93e-22	9.65e-19	0.28	0.43	Platelet count;	chr7:100370021	chr7:100336079~100351900:+
PRAD	cis	rs997154	0.655	rs2008345	ENSG00000279656.1	RP11-298I3.6	10.09	1.01e-21	9.78e-19	0.61	0.43	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22932233	chr14:23023083~23024217:-
PRAD	cis	rs875971	0.862	rs10256544	ENSG00000237310.1	GS1-124K5.4	10.09	1.01e-21	9.81e-19	0.4	0.43	Aortic root size;	chr7:66210141	chr7:66493706~66495474:+
PRAD	cis	rs6570726	0.791	rs9390336	ENSG00000235652.6	RP11-545I5.3	10.08	1.01e-21	9.83e-19	0.44	0.43	Lobe attachment (rater-scored or self-reported);	chr6:145575687	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.738	rs6925594	ENSG00000235652.6	RP11-545I5.3	10.08	1.01e-21	9.83e-19	0.44	0.43	Lobe attachment (rater-scored or self-reported);	chr6:145577318	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.791	rs11155432	ENSG00000235652.6	RP11-545I5.3	10.08	1.01e-21	9.83e-19	0.44	0.43	Lobe attachment (rater-scored or self-reported);	chr6:145577625	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.791	rs6913727	ENSG00000235652.6	RP11-545I5.3	10.08	1.01e-21	9.83e-19	0.44	0.43	Lobe attachment (rater-scored or self-reported);	chr6:145578690	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.791	rs10872577	ENSG00000235652.6	RP11-545I5.3	10.08	1.01e-21	9.83e-19	0.44	0.43	Lobe attachment (rater-scored or self-reported);	chr6:145579424	chr6:145799409~145886585:+
PRAD	cis	rs9918079	0.56	rs4698402	ENSG00000273133.1	RP11-799M12.2	-10.08	1.01e-21	9.83e-19	-0.54	-0.43	Obesity-related traits;	chr4:15628180	chr4:15563698~15564253:-
PRAD	cis	rs6570726	0.791	rs418701	ENSG00000235652.6	RP11-545I5.3	10.08	1.02e-21	9.85e-19	0.44	0.43	Lobe attachment (rater-scored or self-reported);	chr6:145568856	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.791	rs1280275	ENSG00000235652.6	RP11-545I5.3	10.08	1.02e-21	9.85e-19	0.44	0.43	Lobe attachment (rater-scored or self-reported);	chr6:145571266	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.791	rs6900040	ENSG00000235652.6	RP11-545I5.3	10.08	1.02e-21	9.85e-19	0.44	0.43	Lobe attachment (rater-scored or self-reported);	chr6:145571998	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.791	rs6923074	ENSG00000235652.6	RP11-545I5.3	10.08	1.02e-21	9.85e-19	0.44	0.43	Lobe attachment (rater-scored or self-reported);	chr6:145572196	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.755	rs2092296	ENSG00000235652.6	RP11-545I5.3	10.08	1.02e-21	9.85e-19	0.44	0.43	Lobe attachment (rater-scored or self-reported);	chr6:145572548	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.755	rs2103633	ENSG00000235652.6	RP11-545I5.3	10.08	1.02e-21	9.85e-19	0.44	0.43	Lobe attachment (rater-scored or self-reported);	chr6:145572885	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.791	rs9373463	ENSG00000235652.6	RP11-545I5.3	10.08	1.02e-21	9.85e-19	0.44	0.43	Lobe attachment (rater-scored or self-reported);	chr6:145573626	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.764	rs9322028	ENSG00000235652.6	RP11-545I5.3	10.08	1.02e-21	9.85e-19	0.44	0.43	Lobe attachment (rater-scored or self-reported);	chr6:145574661	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.791	rs12205752	ENSG00000235652.6	RP11-545I5.3	10.08	1.02e-21	9.85e-19	0.44	0.43	Lobe attachment (rater-scored or self-reported);	chr6:145574982	chr6:145799409~145886585:+
PRAD	cis	rs2455601	1	rs12223690	ENSG00000254860.4	TMEM9B-AS1	10.08	1.02e-21	9.87e-19	0.58	0.43	Schizophrenia;	chr11:8880277	chr11:8964675~8977527:+
PRAD	cis	rs2455601	1	rs7104661	ENSG00000254860.4	TMEM9B-AS1	10.08	1.02e-21	9.87e-19	0.58	0.43	Schizophrenia;	chr11:8880954	chr11:8964675~8977527:+
PRAD	cis	rs2739330	0.929	rs5751775	ENSG00000099984.9	GSTT2	-10.08	1.02e-21	9.91e-19	-0.57	-0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23980123~23983911:+
PRAD	cis	rs1891275	0.551	rs2000177	ENSG00000228701.1	TNKS2-AS1	-10.08	1.02e-21	9.91e-19	-0.58	-0.43	Intelligence (multi-trait analysis);	chr10:91653237	chr10:91782839~91798291:-
PRAD	cis	rs2739330	0.828	rs4822454	ENSG00000099984.9	GSTT2	-10.08	1.03e-21	9.94e-19	-0.58	-0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23980123~23983911:+
PRAD	cis	rs11673344	0.711	rs112857724	ENSG00000226686.6	LINC01535	10.08	1.03e-21	9.96e-19	0.57	0.43	Obesity-related traits;	chr19:37030176	chr19:37251912~37265535:+
PRAD	cis	rs67311347	1	rs11129876	ENSG00000223797.4	ENTPD3-AS1	-10.08	1.03e-21	9.97e-19	-0.39	-0.43	Renal cell carcinoma;	chr3:40360145	chr3:40313802~40453329:-
PRAD	cis	rs67311347	1	rs11539046	ENSG00000223797.4	ENTPD3-AS1	-10.08	1.03e-21	9.98e-19	-0.39	-0.43	Renal cell carcinoma;	chr3:40462318	chr3:40313802~40453329:-
PRAD	cis	rs67311347	1	rs12633431	ENSG00000223797.4	ENTPD3-AS1	-10.08	1.03e-21	9.98e-19	-0.39	-0.43	Renal cell carcinoma;	chr3:40464249	chr3:40313802~40453329:-
PRAD	cis	rs67311347	0.956	rs6771527	ENSG00000223797.4	ENTPD3-AS1	-10.08	1.03e-21	9.98e-19	-0.39	-0.43	Renal cell carcinoma;	chr3:40465057	chr3:40313802~40453329:-
PRAD	cis	rs67311347	0.955	rs6782746	ENSG00000223797.4	ENTPD3-AS1	-10.08	1.03e-21	9.98e-19	-0.39	-0.43	Renal cell carcinoma;	chr3:40469101	chr3:40313802~40453329:-
PRAD	cis	rs67311347	1	rs7628247	ENSG00000223797.4	ENTPD3-AS1	-10.08	1.03e-21	9.98e-19	-0.39	-0.43	Renal cell carcinoma;	chr3:40471191	chr3:40313802~40453329:-
PRAD	cis	rs8072100	0.57	rs9905073	ENSG00000228782.6	CTD-2026D20.3	10.08	1.03e-21	1e-18	0.48	0.43	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47390930	chr17:47450568~47492492:-
PRAD	cis	rs2404602	0.532	rs744336	ENSG00000259422.1	RP11-593F23.1	10.08	1.03e-21	1e-18	0.54	0.43	Blood metabolite levels;	chr15:76382283	chr15:76174891~76181486:-
PRAD	cis	rs2739330	0.796	rs5760097	ENSG00000272787.1	KB-226F1.2	-10.08	1.03e-21	1e-18	-0.47	-0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23969211~23969873:+
PRAD	cis	rs7115242	0.8	rs519794	ENSG00000254851.1	RP11-109L13.1	-10.08	1.04e-21	1e-18	-0.81	-0.43	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116988737	chr11:117135528~117138582:+
PRAD	cis	rs11673344	0.864	rs703530	ENSG00000226686.6	LINC01535	10.08	1.04e-21	1e-18	0.59	0.43	Obesity-related traits;	chr19:37010016	chr19:37251912~37265535:+
PRAD	cis	rs7811142	0.83	rs6975660	ENSG00000242294.5	STAG3L5P	10.08	1.04e-21	1.01e-18	0.28	0.43	Platelet count;	chr7:100377643	chr7:100336079~100351900:+
PRAD	cis	rs7811142	0.83	rs73401443	ENSG00000242294.5	STAG3L5P	10.08	1.04e-21	1.01e-18	0.28	0.43	Platelet count;	chr7:100379959	chr7:100336079~100351900:+
PRAD	cis	rs67311347	1	rs2276871	ENSG00000223797.4	ENTPD3-AS1	10.08	1.04e-21	1.01e-18	0.39	0.43	Renal cell carcinoma;	chr3:40457782	chr3:40313802~40453329:-
PRAD	cis	rs858239	0.699	rs1881200	ENSG00000226816.2	AC005082.12	-10.08	1.05e-21	1.01e-18	-0.49	-0.43	Cerebrospinal fluid biomarker levels;	chr7:23162018	chr7:23206013~23208045:+
PRAD	cis	rs7849270	0.837	rs10819463	ENSG00000268707.1	RP11-247A12.7	-10.08	1.05e-21	1.02e-18	-0.49	-0.43	Blood metabolite ratios;	chr9:129100958	chr9:129170434~129170940:+
PRAD	cis	rs6504950	0.888	rs244319	ENSG00000275710.1	RP11-257O5.4	10.08	1.05e-21	1.02e-18	0.54	0.43	Breast cancer;	chr17:55145513	chr17:54964474~54964679:+
PRAD	cis	rs9322193	0.607	rs12527391	ENSG00000216906.2	RP11-350J20.9	10.08	1.05e-21	1.02e-18	0.57	0.43	Lung cancer;	chr6:149882156	chr6:149904243~149906418:+
PRAD	cis	rs8072100	0.713	rs2136750	ENSG00000228782.6	CTD-2026D20.3	10.08	1.05e-21	1.02e-18	0.48	0.43	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47378734	chr17:47450568~47492492:-
PRAD	cis	rs8072100	0.713	rs9807106	ENSG00000228782.6	CTD-2026D20.3	10.08	1.05e-21	1.02e-18	0.48	0.43	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47379736	chr17:47450568~47492492:-
PRAD	cis	rs8072100	0.607	rs9894594	ENSG00000228782.6	CTD-2026D20.3	10.08	1.05e-21	1.02e-18	0.48	0.43	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47384017	chr17:47450568~47492492:-
PRAD	cis	rs7309	0.87	rs2358016	ENSG00000227403.1	AC009299.3	10.08	1.07e-21	1.03e-18	0.53	0.43	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161150919	chr2:161244739~161249050:+
PRAD	cis	rs7714584	1	rs7734928	ENSG00000197083.10	ZNF300P1	10.08	1.07e-21	1.03e-18	0.69	0.43	Crohn's disease;	chr5:150877051	chr5:150930645~150946289:-
PRAD	cis	rs7714584	1	rs10463240	ENSG00000197083.10	ZNF300P1	10.08	1.07e-21	1.03e-18	0.69	0.43	Crohn's disease;	chr5:150877291	chr5:150930645~150946289:-
PRAD	cis	rs7811142	0.83	rs7792959	ENSG00000242294.5	STAG3L5P	10.08	1.07e-21	1.04e-18	0.28	0.43	Platelet count;	chr7:100374780	chr7:100336079~100351900:+
PRAD	cis	rs67311347	0.956	rs12633446	ENSG00000223797.4	ENTPD3-AS1	-10.08	1.07e-21	1.04e-18	-0.38	-0.43	Renal cell carcinoma;	chr3:40464170	chr3:40313802~40453329:-
PRAD	cis	rs10129255	0.5	rs1974468	ENSG00000223648.3	IGHV3-64	10.08	1.07e-21	1.04e-18	0.38	0.43	Kawasaki disease;	chr14:106686149	chr14:106643132~106658258:-
PRAD	cis	rs673078	0.66	rs7974718	ENSG00000275759.1	RP11-131L12.3	-10.08	1.08e-21	1.04e-18	-0.61	-0.43	Glucose homeostasis traits;	chr12:118243258	chr12:118428281~118428870:+
PRAD	cis	rs4853012	0.941	rs7571083	ENSG00000257800.1	FNBP1P1	10.08	1.08e-21	1.05e-18	0.39	0.43	Gestational age at birth (maternal effect);	chr2:74115133	chr2:74120680~74123218:+
PRAD	cis	rs9322193	0.923	rs9322197	ENSG00000268592.3	RAET1E-AS1	10.08	1.09e-21	1.05e-18	0.59	0.43	Lung cancer;	chr6:149622577	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.884	rs9688858	ENSG00000268592.3	RAET1E-AS1	10.08	1.09e-21	1.05e-18	0.59	0.43	Lung cancer;	chr6:149637911	chr6:149863494~149919507:+
PRAD	cis	rs9309473	0.898	rs28879089	ENSG00000163016.8	ALMS1P	10.08	1.09e-21	1.06e-18	0.52	0.43	Metabolite levels;	chr2:73585759	chr2:73644919~73685576:+
PRAD	cis	rs889312	0.532	rs16886181	ENSG00000271828.1	CTD-2310F14.1	10.08	1.1e-21	1.06e-18	0.76	0.43	Breast cancer (early onset);Breast cancer;	chr5:56733416	chr5:56927874~56929573:+
PRAD	cis	rs4718428	0.705	rs12698547	ENSG00000232546.1	RP11-458F8.1	-10.07	1.11e-21	1.07e-18	-0.34	-0.43	Corneal structure;	chr7:66813271	chr7:66848496~66858136:+
PRAD	cis	rs9545047	0.604	rs9545048	ENSG00000227676.3	LINC01068	10.07	1.12e-21	1.08e-18	0.5	0.43	Schizophrenia;	chr13:79285593	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs1626333	ENSG00000227676.3	LINC01068	10.07	1.12e-21	1.08e-18	0.5	0.43	Schizophrenia;	chr13:79286932	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.567	rs1856996	ENSG00000227676.3	LINC01068	10.07	1.12e-21	1.08e-18	0.5	0.43	Schizophrenia;	chr13:79287453	chr13:79566727~79571436:+
PRAD	cis	rs1891275	0.508	rs7099557	ENSG00000228701.1	TNKS2-AS1	-10.07	1.12e-21	1.08e-18	-0.53	-0.43	Intelligence (multi-trait analysis);	chr10:91685607	chr10:91782839~91798291:-
PRAD	cis	rs2348418	0.932	rs12305750	ENSG00000247934.4	RP11-967K21.1	-10.07	1.12e-21	1.08e-18	-0.4	-0.43	Lung function (FEV1);Lung function (FVC);	chr12:28535758	chr12:28163298~28190738:-
PRAD	cis	rs2283792	0.765	rs9610374	ENSG00000224086.5	LL22NC03-86G7.1	-10.07	1.12e-21	1.09e-18	-0.51	-0.43	Multiple sclerosis;	chr22:21832514	chr22:21938293~21977632:+
PRAD	cis	rs2283792	0.765	rs5999752	ENSG00000224086.5	LL22NC03-86G7.1	-10.07	1.12e-21	1.09e-18	-0.51	-0.43	Multiple sclerosis;	chr22:21833894	chr22:21938293~21977632:+
PRAD	cis	rs8062405	0.698	rs8046545	ENSG00000259982.1	CDC37P1	-10.07	1.12e-21	1.09e-18	-0.6	-0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28903896	chr16:28700294~28701540:-
PRAD	cis	rs75422866	0.85	rs73111212	ENSG00000257433.4	RP1-197B17.3	10.07	1.13e-21	1.09e-18	1.06	0.43	Pneumonia;	chr12:47577638	chr12:47706085~47742294:+
PRAD	cis	rs75422866	0.85	rs73111216	ENSG00000257433.4	RP1-197B17.3	10.07	1.13e-21	1.09e-18	1.06	0.43	Pneumonia;	chr12:47577671	chr12:47706085~47742294:+
PRAD	cis	rs75422866	0.85	rs73111217	ENSG00000257433.4	RP1-197B17.3	10.07	1.13e-21	1.09e-18	1.06	0.43	Pneumonia;	chr12:47577693	chr12:47706085~47742294:+
PRAD	cis	rs6700559	0.967	rs12041320	ENSG00000260088.1	RP11-92G12.3	-10.07	1.13e-21	1.1e-18	-0.55	-0.43	Coronary artery disease;	chr1:200652107	chr1:200669507~200694250:+
PRAD	cis	rs8062405	1	rs72793812	ENSG00000259982.1	CDC37P1	10.07	1.14e-21	1.1e-18	0.57	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28829060	chr16:28700294~28701540:-
PRAD	cis	rs9545047	0.604	rs7322901	ENSG00000227676.3	LINC01068	10.07	1.14e-21	1.1e-18	0.51	0.43	Schizophrenia;	chr13:79383505	chr13:79566727~79571436:+
PRAD	cis	rs6452524	0.901	rs10079680	ENSG00000249664.1	CTD-2227C6.2	10.07	1.15e-21	1.11e-18	0.5	0.43	Hypertension (SNP x SNP interaction);	chr5:83082746	chr5:83012285~83013109:-
PRAD	cis	rs2739330	0.929	rs5751775	ENSG00000235689.1	AP000351.13	10.07	1.15e-21	1.11e-18	0.52	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:24006305~24008258:-
PRAD	cis	rs3762637	0.941	rs79493664	ENSG00000272758.4	RP11-299J3.8	-10.07	1.16e-21	1.12e-18	-0.64	-0.43	LDL cholesterol levels;	chr3:122390699	chr3:122416207~122443180:+
PRAD	cis	rs4713118	0.662	rs149970	ENSG00000280107.1	AL022393.9	-10.07	1.17e-21	1.12e-18	-0.55	-0.43	Parkinson's disease;	chr6:28012442	chr6:28170845~28172521:+
PRAD	cis	rs6964833	0.554	rs2527366	ENSG00000277053.3	GTF2IP1	10.07	1.17e-21	1.13e-18	0.45	0.43	Menarche (age at onset);	chr7:74684615	chr7:75185385~75237696:-
PRAD	cis	rs7849270	0.879	rs2229419	ENSG00000268707.1	RP11-247A12.7	10.07	1.17e-21	1.13e-18	0.49	0.43	Blood metabolite ratios;	chr9:129095351	chr9:129170434~129170940:+
PRAD	cis	rs2283792	0.765	rs8139376	ENSG00000224086.5	LL22NC03-86G7.1	-10.07	1.17e-21	1.13e-18	-0.5	-0.43	Multiple sclerosis;	chr22:21755307	chr22:21938293~21977632:+
PRAD	cis	rs2787486	1	rs2787486	ENSG00000275710.1	RP11-257O5.4	10.07	1.17e-21	1.13e-18	0.54	0.43	Breast cancer;	chr17:55132413	chr17:54964474~54964679:+
PRAD	cis	rs6921919	0.638	rs2108926	ENSG00000216901.1	AL022393.7	10.07	1.17e-21	1.13e-18	0.56	0.43	Autism spectrum disorder or schizophrenia;	chr6:28340970	chr6:28176188~28176674:+
PRAD	cis	rs2404602	0.552	rs11072613	ENSG00000259422.1	RP11-593F23.1	-10.07	1.18e-21	1.14e-18	-0.58	-0.43	Blood metabolite levels;	chr15:76669185	chr15:76174891~76181486:-
PRAD	cis	rs1789	0.839	rs9997068	ENSG00000273133.1	RP11-799M12.2	-10.07	1.18e-21	1.14e-18	-0.54	-0.43	Blood protein levels;	chr4:15649367	chr4:15563698~15564253:-
PRAD	cis	rs4718428	0.705	rs28648401	ENSG00000232546.1	RP11-458F8.1	-10.07	1.19e-21	1.15e-18	-0.34	-0.43	Corneal structure;	chr7:66902145	chr7:66848496~66858136:+
PRAD	cis	rs4718428	0.607	rs66954441	ENSG00000232546.1	RP11-458F8.1	-10.07	1.19e-21	1.15e-18	-0.34	-0.43	Corneal structure;	chr7:66904222	chr7:66848496~66858136:+
PRAD	cis	rs10246939	0.579	rs35647444	ENSG00000228775.6	WEE2-AS1	10.06	1.2e-21	1.16e-18	0.53	0.43	Bitter taste perception;	chr7:141833957	chr7:141704338~141738346:-
PRAD	cis	rs150992	0.861	rs151102	ENSG00000248489.1	CTD-2007H13.3	-10.06	1.21e-21	1.16e-18	-0.47	-0.43	Body mass index;	chr5:98947626	chr5:98929171~98995013:+
PRAD	cis	rs17023223	0.553	rs56234947	ENSG00000231365.4	RP11-418J17.1	-10.06	1.21e-21	1.16e-18	-0.44	-0.43	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119165121	chr1:119140396~119275973:+
PRAD	cis	rs6452524	0.935	rs7718472	ENSG00000249664.1	CTD-2227C6.2	10.06	1.21e-21	1.17e-18	0.49	0.43	Hypertension (SNP x SNP interaction);	chr5:83082603	chr5:83012285~83013109:-
PRAD	cis	rs6142102	0.961	rs4911408	ENSG00000276073.1	RP5-1125A11.7	-10.06	1.22e-21	1.18e-18	-0.45	-0.43	Skin pigmentation;	chr20:34112760	chr20:33985617~33988989:-
PRAD	cis	rs4820294	0.669	rs9622677	ENSG00000233360.4	Z83844.1	10.06	1.23e-21	1.18e-18	0.52	0.43	Fat distribution (HIV);	chr22:37658255	chr22:37641832~37658377:-
PRAD	cis	rs4820294	0.669	rs7287340	ENSG00000233360.4	Z83844.1	10.06	1.23e-21	1.18e-18	0.52	0.43	Fat distribution (HIV);	chr22:37658318	chr22:37641832~37658377:-
PRAD	cis	rs4820294	0.669	rs7287358	ENSG00000233360.4	Z83844.1	10.06	1.23e-21	1.18e-18	0.52	0.43	Fat distribution (HIV);	chr22:37658396	chr22:37641832~37658377:-
PRAD	cis	rs67311347	1	rs11715214	ENSG00000223797.4	ENTPD3-AS1	10.06	1.23e-21	1.19e-18	0.38	0.43	Renal cell carcinoma;	chr3:40361513	chr3:40313802~40453329:-
PRAD	cis	rs67311347	1	rs9860162	ENSG00000223797.4	ENTPD3-AS1	10.06	1.23e-21	1.19e-18	0.38	0.43	Renal cell carcinoma;	chr3:40362384	chr3:40313802~40453329:-
PRAD	cis	rs67311347	1	rs11914297	ENSG00000223797.4	ENTPD3-AS1	10.06	1.23e-21	1.19e-18	0.38	0.43	Renal cell carcinoma;	chr3:40368579	chr3:40313802~40453329:-
PRAD	cis	rs9309473	0.95	rs6756885	ENSG00000163016.8	ALMS1P	10.06	1.23e-21	1.19e-18	0.52	0.43	Metabolite levels;	chr2:73578045	chr2:73644919~73685576:+
PRAD	cis	rs6452524	0.537	rs1583	ENSG00000249664.1	CTD-2227C6.2	10.06	1.24e-21	1.19e-18	0.52	0.43	Hypertension (SNP x SNP interaction);	chr5:83052403	chr5:83012285~83013109:-
PRAD	cis	rs4713118	0.662	rs149900	ENSG00000280107.1	AL022393.9	-10.06	1.24e-21	1.2e-18	-0.57	-0.43	Parkinson's disease;	chr6:28046819	chr6:28170845~28172521:+
PRAD	cis	rs67311347	1	rs9968170	ENSG00000223797.4	ENTPD3-AS1	-10.06	1.24e-21	1.2e-18	-0.38	-0.43	Renal cell carcinoma;	chr3:40452783	chr3:40313802~40453329:-
PRAD	cis	rs7684446	1	rs7684446	ENSG00000273133.1	RP11-799M12.2	10.06	1.25e-21	1.2e-18	0.52	0.43	Red blood cell count;	chr4:15591241	chr4:15563698~15564253:-
PRAD	cis	rs1789	0.653	rs13142069	ENSG00000273133.1	RP11-799M12.2	10.06	1.25e-21	1.2e-18	0.52	0.43	Blood protein levels;	chr4:15592069	chr4:15563698~15564253:-
PRAD	cis	rs11098499	0.954	rs13145352	ENSG00000245958.5	RP11-33B1.1	10.06	1.25e-21	1.21e-18	0.43	0.43	Corneal astigmatism;	chr4:119488808	chr4:119454791~119552025:+
PRAD	cis	rs9918079	0.56	rs10008376	ENSG00000273133.1	RP11-799M12.2	10.06	1.25e-21	1.21e-18	0.54	0.43	Obesity-related traits;	chr4:15622332	chr4:15563698~15564253:-
PRAD	cis	rs6538678	0.824	rs4762633	ENSG00000258343.1	RP11-536G4.2	-10.06	1.25e-21	1.21e-18	-0.62	-0.43	Lupus nephritis in systemic lupus erythematosus;	chr12:95860295	chr12:95795345~95858839:-
PRAD	cis	rs6504950	0.813	rs244321	ENSG00000275710.1	RP11-257O5.4	10.06	1.26e-21	1.21e-18	0.54	0.43	Breast cancer;	chr17:55146637	chr17:54964474~54964679:+
PRAD	cis	rs524281	0.814	rs2270448	ENSG00000255320.1	RP11-755F10.1	10.06	1.26e-21	1.22e-18	0.68	0.43	Electroencephalogram traits;	chr11:66068460	chr11:66244840~66246239:-
PRAD	cis	rs12134133	1	rs28371614	ENSG00000274245.1	RP11-357P18.2	10.06	1.27e-21	1.22e-18	0.6	0.43	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207331929	chr1:207372559~207373252:+
PRAD	cis	rs783540	0.5	rs7178459	ENSG00000255769.6	GOLGA2P10	-10.06	1.29e-21	1.24e-18	-0.57	-0.43	Schizophrenia;	chr15:82729632	chr15:82472993~82513950:-
PRAD	cis	rs507080	0.885	rs4938530	ENSG00000255422.1	AP002954.4	-10.06	1.29e-21	1.24e-18	-0.53	-0.43	Serum metabolite levels;	chr11:118689861	chr11:118704607~118750263:+
PRAD	cis	rs9322193	0.923	rs7753812	ENSG00000268592.3	RAET1E-AS1	10.06	1.3e-21	1.25e-18	0.58	0.43	Lung cancer;	chr6:149690150	chr6:149863494~149919507:+
PRAD	cis	rs4820294	0.646	rs9622675	ENSG00000233360.4	Z83844.1	10.05	1.3e-21	1.25e-18	0.52	0.43	Fat distribution (HIV);	chr22:37657658	chr22:37641832~37658377:-
PRAD	cis	rs34779708	0.966	rs1148245	ENSG00000230534.5	RP11-297A16.2	10.05	1.31e-21	1.26e-18	0.56	0.43	Inflammatory bowel disease;Crohn's disease;	chr10:35222966	chr10:35098006~35127020:-
PRAD	cis	rs6921919	0.638	rs1416920	ENSG00000216901.1	AL022393.7	10.05	1.31e-21	1.26e-18	0.56	0.43	Autism spectrum disorder or schizophrenia;	chr6:28335007	chr6:28176188~28176674:+
PRAD	cis	rs6921919	0.525	rs1361386	ENSG00000216901.1	AL022393.7	10.05	1.31e-21	1.26e-18	0.56	0.43	Autism spectrum disorder or schizophrenia;	chr6:28337827	chr6:28176188~28176674:+
PRAD	cis	rs6921919	0.638	rs6456815	ENSG00000216901.1	AL022393.7	10.05	1.31e-21	1.26e-18	0.56	0.43	Autism spectrum disorder or schizophrenia;	chr6:28338360	chr6:28176188~28176674:+
PRAD	cis	rs9322193	0.736	rs3828701	ENSG00000223701.3	RAET1E-AS1	10.05	1.31e-21	1.26e-18	0.58	0.43	Lung cancer;	chr6:149791063	chr6:149884431~149919508:+
PRAD	cis	rs9322193	0.736	rs3805750	ENSG00000223701.3	RAET1E-AS1	10.05	1.31e-21	1.26e-18	0.58	0.43	Lung cancer;	chr6:149791065	chr6:149884431~149919508:+
PRAD	cis	rs7714584	1	rs11746560	ENSG00000197083.10	ZNF300P1	10.05	1.31e-21	1.26e-18	0.82	0.43	Crohn's disease;	chr5:150806363	chr5:150930645~150946289:-
PRAD	cis	rs7714584	1	rs4958422	ENSG00000197083.10	ZNF300P1	10.05	1.31e-21	1.26e-18	0.82	0.43	Crohn's disease;	chr5:150807172	chr5:150930645~150946289:-
PRAD	cis	rs7714584	1	rs59715748	ENSG00000197083.10	ZNF300P1	10.05	1.31e-21	1.26e-18	0.82	0.43	Crohn's disease;	chr5:150809725	chr5:150930645~150946289:-
PRAD	cis	rs673078	0.66	rs2280711	ENSG00000275759.1	RP11-131L12.3	-10.05	1.32e-21	1.27e-18	-0.61	-0.43	Glucose homeostasis traits;	chr12:118212149	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.615	rs73222058	ENSG00000275759.1	RP11-131L12.3	-10.05	1.32e-21	1.27e-18	-0.61	-0.43	Glucose homeostasis traits;	chr12:118221066	chr12:118428281~118428870:+
PRAD	cis	rs780096	0.526	rs11682621	ENSG00000234072.1	AC074117.10	-10.05	1.32e-21	1.27e-18	-0.35	-0.43	Total body bone mineral density;	chr2:27526802	chr2:27356246~27367622:+
PRAD	cis	rs10246939	0.505	rs10952508	ENSG00000228775.6	WEE2-AS1	10.05	1.32e-21	1.27e-18	0.57	0.43	Bitter taste perception;	chr7:141879415	chr7:141704338~141738346:-
PRAD	cis	rs9322193	0.923	rs12195866	ENSG00000268592.3	RAET1E-AS1	10.05	1.32e-21	1.27e-18	0.58	0.43	Lung cancer;	chr6:149693334	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.923	rs9285524	ENSG00000268592.3	RAET1E-AS1	10.05	1.32e-21	1.27e-18	0.58	0.43	Lung cancer;	chr6:149694122	chr6:149863494~149919507:+
PRAD	cis	rs673078	0.66	rs17586342	ENSG00000275759.1	RP11-131L12.3	-10.05	1.32e-21	1.27e-18	-0.61	-0.43	Glucose homeostasis traits;	chr12:118162399	chr12:118428281~118428870:+
PRAD	cis	rs10246939	0.579	rs10464444	ENSG00000228775.6	WEE2-AS1	-10.05	1.33e-21	1.28e-18	-0.53	-0.43	Bitter taste perception;	chr7:141832387	chr7:141704338~141738346:-
PRAD	cis	rs9322193	0.962	rs9688750	ENSG00000268592.3	RAET1E-AS1	10.05	1.34e-21	1.29e-18	0.59	0.43	Lung cancer;	chr6:149657633	chr6:149863494~149919507:+
PRAD	cis	rs9322193	1	rs58189451	ENSG00000268592.3	RAET1E-AS1	10.05	1.35e-21	1.3e-18	0.59	0.43	Lung cancer;	chr6:149600252	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.566	rs3922947	ENSG00000268592.3	RAET1E-AS1	-10.05	1.37e-21	1.32e-18	-0.65	-0.43	Lung cancer;	chr6:149924856	chr6:149863494~149919507:+
PRAD	cis	rs67311347	1	rs2276870	ENSG00000223797.4	ENTPD3-AS1	-10.05	1.38e-21	1.32e-18	-0.38	-0.43	Renal cell carcinoma;	chr3:40457691	chr3:40313802~40453329:-
PRAD	cis	rs9918079	0.56	rs4557256	ENSG00000273133.1	RP11-799M12.2	-10.05	1.38e-21	1.33e-18	-0.54	-0.43	Obesity-related traits;	chr4:15625024	chr4:15563698~15564253:-
PRAD	cis	rs1263173	0.696	rs1263172	ENSG00000254851.1	RP11-109L13.1	-10.05	1.39e-21	1.33e-18	-0.61	-0.43	HDL cholesterol;	chr11:116810202	chr11:117135528~117138582:+
PRAD	cis	rs34375054	0.687	rs12303572	ENSG00000279233.1	RP11-158L12.4	10.05	1.39e-21	1.33e-18	0.41	0.43	Post bronchodilator FEV1/FVC ratio;	chr12:125126725	chr12:125138245~125141711:+
PRAD	cis	rs2153535	0.585	rs9378565	ENSG00000230939.1	RP11-314C16.1	-10.05	1.39e-21	1.34e-18	-0.53	-0.43	Motion sickness;	chr6:8664580	chr6:8784178~8785445:+
PRAD	cis	rs673078	0.66	rs12229607	ENSG00000275759.1	RP11-131L12.3	-10.05	1.41e-21	1.35e-18	-0.61	-0.43	Glucose homeostasis traits;	chr12:118338333	chr12:118428281~118428870:+
PRAD	cis	rs8072100	0.738	rs9915222	ENSG00000228782.6	CTD-2026D20.3	10.05	1.41e-21	1.35e-18	0.47	0.43	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47371249	chr17:47450568~47492492:-
PRAD	cis	rs7714584	1	rs75774363	ENSG00000197083.10	ZNF300P1	10.05	1.41e-21	1.35e-18	0.71	0.43	Crohn's disease;	chr5:150844160	chr5:150930645~150946289:-
PRAD	cis	rs1891275	0.515	rs7093728	ENSG00000228701.1	TNKS2-AS1	-10.04	1.42e-21	1.37e-18	-0.53	-0.43	Intelligence (multi-trait analysis);	chr10:91683860	chr10:91782839~91798291:-
PRAD	cis	rs1891275	0.515	rs10786010	ENSG00000228701.1	TNKS2-AS1	-10.04	1.42e-21	1.37e-18	-0.53	-0.43	Intelligence (multi-trait analysis);	chr10:91684016	chr10:91782839~91798291:-
PRAD	cis	rs1891275	0.515	rs1986941	ENSG00000228701.1	TNKS2-AS1	-10.04	1.42e-21	1.37e-18	-0.53	-0.43	Intelligence (multi-trait analysis);	chr10:91684586	chr10:91782839~91798291:-
PRAD	cis	rs1891275	0.515	rs7098763	ENSG00000228701.1	TNKS2-AS1	-10.04	1.42e-21	1.37e-18	-0.53	-0.43	Intelligence (multi-trait analysis);	chr10:91685070	chr10:91782839~91798291:-
PRAD	cis	rs10875746	0.729	rs1990028	ENSG00000240399.1	RP1-228P16.1	-10.04	1.43e-21	1.37e-18	-0.4	-0.43	Longevity (90 years and older);	chr12:48014230	chr12:48054813~48055591:-
PRAD	cis	rs7811142	0.83	rs10085549	ENSG00000242294.5	STAG3L5P	10.04	1.43e-21	1.38e-18	0.28	0.43	Platelet count;	chr7:100385512	chr7:100336079~100351900:+
PRAD	cis	rs150992	0.72	rs469018	ENSG00000248489.1	CTD-2007H13.3	10.04	1.44e-21	1.38e-18	0.48	0.43	Body mass index;	chr5:98953530	chr5:98929171~98995013:+
PRAD	cis	rs9326248	0.53	rs10732856	ENSG00000254851.1	RP11-109L13.1	-10.04	1.44e-21	1.38e-18	-0.81	-0.43	Blood protein levels;	chr11:117036397	chr11:117135528~117138582:+
PRAD	cis	rs9309473	0.904	rs79145598	ENSG00000163016.8	ALMS1P	10.04	1.45e-21	1.39e-18	0.53	0.43	Metabolite levels;	chr2:73594255	chr2:73644919~73685576:+
PRAD	cis	rs9309473	0.904	rs62149783	ENSG00000163016.8	ALMS1P	10.04	1.45e-21	1.39e-18	0.53	0.43	Metabolite levels;	chr2:73594257	chr2:73644919~73685576:+
PRAD	cis	rs2348418	0.932	rs16932850	ENSG00000247934.4	RP11-967K21.1	10.04	1.45e-21	1.39e-18	0.39	0.43	Lung function (FEV1);Lung function (FVC);	chr12:28457941	chr12:28163298~28190738:-
PRAD	cis	rs6860806	0.507	rs2631371	ENSG00000233006.5	AC034220.3	-10.04	1.45e-21	1.39e-18	-0.4	-0.43	Breast cancer;	chr5:132367999	chr5:132311285~132369916:-
PRAD	cis	rs2153535	0.585	rs9406188	ENSG00000230939.1	RP11-314C16.1	-10.04	1.45e-21	1.39e-18	-0.53	-0.43	Motion sickness;	chr6:8667604	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.56	rs9379239	ENSG00000230939.1	RP11-314C16.1	-10.04	1.45e-21	1.39e-18	-0.53	-0.43	Motion sickness;	chr6:8670263	chr6:8784178~8785445:+
PRAD	cis	rs1891275	0.551	rs7900863	ENSG00000228701.1	TNKS2-AS1	-10.04	1.45e-21	1.39e-18	-0.58	-0.43	Intelligence (multi-trait analysis);	chr10:91665737	chr10:91782839~91798291:-
PRAD	cis	rs2153535	0.585	rs9328501	ENSG00000230939.1	RP11-314C16.1	-10.04	1.45e-21	1.39e-18	-0.53	-0.43	Motion sickness;	chr6:8669287	chr6:8784178~8785445:+
PRAD	cis	rs2929278	0.617	rs533143	ENSG00000249839.1	AC011330.5	-10.04	1.46e-21	1.4e-18	-0.52	-0.43	Schizophrenia;	chr15:43896656	chr15:43663654~43684339:-
PRAD	cis	rs2153535	0.585	rs1033803	ENSG00000230939.1	RP11-314C16.1	-10.04	1.46e-21	1.4e-18	-0.53	-0.43	Motion sickness;	chr6:8674779	chr6:8784178~8785445:+
PRAD	cis	rs507080	0.922	rs514143	ENSG00000255422.1	AP002954.4	-10.04	1.47e-21	1.41e-18	-0.53	-0.43	Serum metabolite levels;	chr11:118687740	chr11:118704607~118750263:+
PRAD	cis	rs9309473	1	rs2421555	ENSG00000163016.8	ALMS1P	10.04	1.47e-21	1.41e-18	0.52	0.43	Metabolite levels;	chr2:73589828	chr2:73644919~73685576:+
PRAD	cis	rs2455601	1	rs11042108	ENSG00000254860.4	TMEM9B-AS1	10.04	1.47e-21	1.41e-18	0.58	0.43	Schizophrenia;	chr11:8884474	chr11:8964675~8977527:+
PRAD	cis	rs4964805	0.954	rs10861104	ENSG00000257681.1	RP11-341G23.4	10.04	1.47e-21	1.41e-18	0.42	0.43	Attention deficit hyperactivity disorder;	chr12:103796145	chr12:103746315~103768858:-
PRAD	cis	rs10246939	0.505	rs6967189	ENSG00000228775.6	WEE2-AS1	10.04	1.47e-21	1.41e-18	0.56	0.43	Bitter taste perception;	chr7:141826220	chr7:141704338~141738346:-
PRAD	cis	rs1858037	0.806	rs12612780	ENSG00000204929.10	AC074391.1	10.04	1.48e-21	1.42e-18	0.58	0.43	Rheumatoid arthritis;	chr2:65355967	chr2:65436711~66084639:+
PRAD	cis	rs1858037	0.867	rs871974	ENSG00000204929.10	AC074391.1	-10.04	1.48e-21	1.42e-18	-0.58	-0.43	Rheumatoid arthritis;	chr2:65330153	chr2:65436711~66084639:+
PRAD	cis	rs1891275	0.551	rs2421621	ENSG00000228701.1	TNKS2-AS1	-10.04	1.49e-21	1.42e-18	-0.58	-0.43	Intelligence (multi-trait analysis);	chr10:91640344	chr10:91782839~91798291:-
PRAD	cis	rs7115242	0.8	rs1320668	ENSG00000254851.1	RP11-109L13.1	-10.04	1.49e-21	1.43e-18	-0.88	-0.43	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117096950	chr11:117135528~117138582:+
PRAD	cis	rs11690935	0.589	rs62182403	ENSG00000228389.1	AC068039.4	-10.04	1.51e-21	1.45e-18	-0.48	-0.43	Schizophrenia;	chr2:171890672	chr2:171773482~171775844:+
PRAD	cis	rs12049351	0.665	rs66521073	ENSG00000229367.1	HMGN2P19	10.04	1.52e-21	1.45e-18	0.62	0.43	Circulating myeloperoxidase levels (plasma);	chr1:229434771	chr1:229570532~229570796:+
PRAD	cis	rs2153535	0.561	rs9405407	ENSG00000230939.1	RP11-314C16.1	-10.04	1.52e-21	1.46e-18	-0.53	-0.43	Motion sickness;	chr6:8665199	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.585	rs9378566	ENSG00000230939.1	RP11-314C16.1	-10.04	1.52e-21	1.46e-18	-0.53	-0.43	Motion sickness;	chr6:8665203	chr6:8784178~8785445:+
PRAD	cis	rs67311347	1	rs2276868	ENSG00000223797.4	ENTPD3-AS1	-10.04	1.52e-21	1.46e-18	-0.38	-0.43	Renal cell carcinoma;	chr3:40457354	chr3:40313802~40453329:-
PRAD	cis	rs673078	0.66	rs61945219	ENSG00000275759.1	RP11-131L12.3	-10.03	1.54e-21	1.47e-18	-0.61	-0.43	Glucose homeostasis traits;	chr12:118272916	chr12:118428281~118428870:+
PRAD	cis	rs10875746	0.68	rs4760610	ENSG00000240399.1	RP1-228P16.1	-10.03	1.54e-21	1.47e-18	-0.41	-0.43	Longevity (90 years and older);	chr12:48024442	chr12:48054813~48055591:-
PRAD	cis	rs2665103	0.715	rs11639440	ENSG00000278603.1	RP13-608F4.5	10.03	1.54e-21	1.47e-18	0.54	0.43	Intelligence (multi-trait analysis);	chr15:82278705	chr15:82472203~82472426:+
PRAD	cis	rs9545047	0.604	rs1028770	ENSG00000227676.3	LINC01068	-10.03	1.54e-21	1.47e-18	-0.49	-0.43	Schizophrenia;	chr13:79297346	chr13:79566727~79571436:+
PRAD	cis	rs780096	0.647	rs11682083	ENSG00000234072.1	AC074117.10	-10.03	1.55e-21	1.48e-18	-0.35	-0.43	Total body bone mineral density;	chr2:27529429	chr2:27356246~27367622:+
PRAD	cis	rs7688540	0.771	rs61794996	ENSG00000275426.1	CH17-262A2.1	10.03	1.55e-21	1.48e-18	0.65	0.43	Facial morphology (factor 6, height of vermillion lower lip);	chr4:215539	chr4:149738~150317:+
PRAD	cis	rs67311347	0.955	rs12487955	ENSG00000223797.4	ENTPD3-AS1	10.03	1.55e-21	1.48e-18	0.38	0.43	Renal cell carcinoma;	chr3:40371362	chr3:40313802~40453329:-
PRAD	cis	rs67311347	0.911	rs58282210	ENSG00000223797.4	ENTPD3-AS1	10.03	1.55e-21	1.48e-18	0.38	0.43	Renal cell carcinoma;	chr3:40376452	chr3:40313802~40453329:-
PRAD	cis	rs7617773	0.502	rs6804828	ENSG00000229759.1	MRPS18AP1	10.03	1.55e-21	1.49e-18	0.44	0.43	Coronary artery disease;	chr3:48352066	chr3:48256350~48256938:-
PRAD	cis	rs6504950	0.732	rs244373	ENSG00000275710.1	RP11-257O5.4	-10.03	1.55e-21	1.49e-18	-0.54	-0.43	Breast cancer;	chr17:55107588	chr17:54964474~54964679:+
PRAD	cis	rs8072100	0.713	rs8074451	ENSG00000228782.6	CTD-2026D20.3	10.03	1.56e-21	1.49e-18	0.47	0.43	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47400207	chr17:47450568~47492492:-
PRAD	cis	rs638893	0.528	rs521910	ENSG00000278376.1	RP11-158I9.8	10.03	1.57e-21	1.5e-18	0.49	0.43	Vitiligo;	chr11:118739920	chr11:118791254~118793137:+
PRAD	cis	rs9545047	0.604	rs7981067	ENSG00000227676.3	LINC01068	10.03	1.57e-21	1.5e-18	0.49	0.43	Schizophrenia;	chr13:79341254	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs7996652	ENSG00000227676.3	LINC01068	10.03	1.57e-21	1.5e-18	0.49	0.43	Schizophrenia;	chr13:79341474	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs9565488	ENSG00000227676.3	LINC01068	10.03	1.57e-21	1.5e-18	0.49	0.43	Schizophrenia;	chr13:79341604	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.625	rs9565489	ENSG00000227676.3	LINC01068	10.03	1.57e-21	1.5e-18	0.49	0.43	Schizophrenia;	chr13:79342106	chr13:79566727~79571436:+
PRAD	cis	rs6890270	1	rs6890270	ENSG00000271828.1	CTD-2310F14.1	10.03	1.57e-21	1.5e-18	0.73	0.43	Breast cancer;	chr5:56964779	chr5:56927874~56929573:+
PRAD	cis	rs6504950	0.888	rs244320	ENSG00000275710.1	RP11-257O5.4	10.03	1.58e-21	1.51e-18	0.54	0.43	Breast cancer;	chr17:55145559	chr17:54964474~54964679:+
PRAD	cis	rs7714584	1	rs6874560	ENSG00000197083.10	ZNF300P1	10.03	1.58e-21	1.51e-18	0.81	0.43	Crohn's disease;	chr5:150803151	chr5:150930645~150946289:-
PRAD	cis	rs7714584	1	rs11748553	ENSG00000197083.10	ZNF300P1	10.03	1.58e-21	1.51e-18	0.81	0.43	Crohn's disease;	chr5:150804991	chr5:150930645~150946289:-
PRAD	cis	rs2739330	0.753	rs4822452	ENSG00000272787.1	KB-226F1.2	-10.03	1.58e-21	1.51e-18	-0.46	-0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23969211~23969873:+
PRAD	cis	rs853679	0.527	rs9461443	ENSG00000280107.1	AL022393.9	-10.03	1.6e-21	1.53e-18	-0.56	-0.43	Depression;	chr6:28226851	chr6:28170845~28172521:+
PRAD	cis	rs5760092	0.627	rs6519489	ENSG00000218537.1	MIF-AS1	-10.03	1.61e-21	1.53e-18	-0.69	-0.43	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919659	chr22:23894426~23898930:-
PRAD	cis	rs12049351	0.507	rs41271481	ENSG00000229367.1	HMGN2P19	10.03	1.63e-21	1.55e-18	0.62	0.43	Circulating myeloperoxidase levels (plasma);	chr1:229432890	chr1:229570532~229570796:+
PRAD	cis	rs7615952	0.609	rs13088451	ENSG00000171084.14	FAM86JP	10.03	1.63e-21	1.56e-18	0.67	0.43	Blood pressure (smoking interaction);	chr3:125834656	chr3:125916620~125930024:+
PRAD	cis	rs783540	0.542	rs62009945	ENSG00000255769.6	GOLGA2P10	10.03	1.66e-21	1.58e-18	0.56	0.43	Schizophrenia;	chr15:82631205	chr15:82472993~82513950:-
PRAD	cis	rs7714584	1	rs9324660	ENSG00000197083.10	ZNF300P1	10.03	1.66e-21	1.58e-18	0.68	0.43	Crohn's disease;	chr5:150877492	chr5:150930645~150946289:-
PRAD	cis	rs1858037	0.867	rs953312	ENSG00000204929.10	AC074391.1	10.03	1.66e-21	1.59e-18	0.59	0.43	Rheumatoid arthritis;	chr2:65340556	chr2:65436711~66084639:+
PRAD	cis	rs1858037	0.867	rs9789444	ENSG00000204929.10	AC074391.1	10.03	1.66e-21	1.59e-18	0.59	0.43	Rheumatoid arthritis;	chr2:65342093	chr2:65436711~66084639:+
PRAD	cis	rs10129255	0.536	rs6576201	ENSG00000223648.3	IGHV3-64	-10.02	1.67e-21	1.6e-18	-0.38	-0.43	Kawasaki disease;	chr14:106683696	chr14:106643132~106658258:-
PRAD	cis	rs10129255	0.5	rs8021941	ENSG00000223648.3	IGHV3-64	10.02	1.68e-21	1.6e-18	0.38	0.43	Kawasaki disease;	chr14:106781490	chr14:106643132~106658258:-
PRAD	cis	rs10129255	0.5	rs10142931	ENSG00000223648.3	IGHV3-64	10.02	1.68e-21	1.6e-18	0.38	0.43	Kawasaki disease;	chr14:106782288	chr14:106643132~106658258:-
PRAD	cis	rs7849270	1	rs7023900	ENSG00000268707.1	RP11-247A12.7	-10.02	1.68e-21	1.6e-18	-0.48	-0.43	Blood metabolite ratios;	chr9:129128873	chr9:129170434~129170940:+
PRAD	cis	rs3096299	0.754	rs2965816	ENSG00000261118.1	RP11-104N10.1	-10.02	1.68e-21	1.6e-18	-0.41	-0.43	Multiple myeloma (IgH translocation);	chr16:89447775	chr16:89492017~89504460:-
PRAD	cis	rs6504950	0.924	rs244342	ENSG00000275710.1	RP11-257O5.4	10.02	1.69e-21	1.62e-18	0.54	0.43	Breast cancer;	chr17:55121046	chr17:54964474~54964679:+
PRAD	cis	rs638893	0.947	rs515707	ENSG00000278376.1	RP11-158I9.8	-10.02	1.7e-21	1.62e-18	-0.46	-0.43	Vitiligo;	chr11:118814772	chr11:118791254~118793137:+
PRAD	cis	rs8072100	0.64	rs3851808	ENSG00000228782.6	CTD-2026D20.3	10.02	1.7e-21	1.62e-18	0.47	0.43	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47347778	chr17:47450568~47492492:-
PRAD	cis	rs2658782	0.724	rs2605626	ENSG00000279684.1	RP11-755E23.2	-10.02	1.7e-21	1.62e-18	-0.67	-0.43	Pulmonary function decline;	chr11:93520737	chr11:93286629~93288903:-
PRAD	cis	rs1858037	0.867	rs4671658	ENSG00000204929.10	AC074391.1	-10.02	1.71e-21	1.63e-18	-0.58	-0.43	Rheumatoid arthritis;	chr2:65334258	chr2:65436711~66084639:+
PRAD	cis	rs4380275	0.782	rs11691064	ENSG00000272342.1	RP13-539J13.1	10.02	1.71e-21	1.63e-18	0.55	0.43	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:755718	chr2:739588~740164:-
PRAD	cis	rs9532669	0.889	rs7339089	ENSG00000176268.5	CYCSP34	10.02	1.72e-21	1.64e-18	0.43	0.43	Cervical cancer;	chr13:40863790	chr13:40863599~40863902:-
PRAD	cis	rs12134133	1	rs7526831	ENSG00000274245.1	RP11-357P18.2	10.02	1.72e-21	1.64e-18	0.62	0.43	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207265261	chr1:207372559~207373252:+
PRAD	cis	rs2658782	0.704	rs2658766	ENSG00000279684.1	RP11-755E23.2	-10.02	1.72e-21	1.64e-18	-0.66	-0.43	Pulmonary function decline;	chr11:93499063	chr11:93286629~93288903:-
PRAD	cis	rs34375054	0.558	rs67041765	ENSG00000279233.1	RP11-158L12.4	10.02	1.74e-21	1.66e-18	0.43	0.43	Post bronchodilator FEV1/FVC ratio;	chr12:125188367	chr12:125138245~125141711:+
PRAD	cis	rs12049351	0.613	rs7525324	ENSG00000229367.1	HMGN2P19	10.02	1.74e-21	1.66e-18	0.69	0.43	Circulating myeloperoxidase levels (plasma);	chr1:229463478	chr1:229570532~229570796:+
PRAD	cis	rs67311347	1	rs7628796	ENSG00000223797.4	ENTPD3-AS1	-10.02	1.74e-21	1.66e-18	-0.38	-0.43	Renal cell carcinoma;	chr3:40465841	chr3:40313802~40453329:-
PRAD	cis	rs67311347	0.91	rs7651204	ENSG00000223797.4	ENTPD3-AS1	-10.02	1.74e-21	1.66e-18	-0.38	-0.43	Renal cell carcinoma;	chr3:40471344	chr3:40313802~40453329:-
PRAD	cis	rs1891275	0.515	rs7092884	ENSG00000228701.1	TNKS2-AS1	10.02	1.75e-21	1.67e-18	0.53	0.43	Intelligence (multi-trait analysis);	chr10:91724115	chr10:91782839~91798291:-
PRAD	cis	rs507080	0.922	rs558907	ENSG00000255422.1	AP002954.4	-10.02	1.75e-21	1.67e-18	-0.53	-0.43	Serum metabolite levels;	chr11:118687746	chr11:118704607~118750263:+
PRAD	cis	rs11673344	0.864	rs11667146	ENSG00000226686.6	LINC01535	10.02	1.76e-21	1.67e-18	0.59	0.43	Obesity-related traits;	chr19:37004493	chr19:37251912~37265535:+
PRAD	cis	rs11118620	0.853	rs12037861	ENSG00000272823.1	RP11-295M18.6	10.02	1.77e-21	1.68e-18	0.54	0.43	Heart failure;	chr1:220864835	chr1:220828676~220829211:-
PRAD	cis	rs2348418	0.798	rs11049486	ENSG00000247934.4	RP11-967K21.1	-10.02	1.78e-21	1.69e-18	-0.39	-0.43	Lung function (FEV1);Lung function (FVC);	chr12:28253224	chr12:28163298~28190738:-
PRAD	cis	rs150992	0.79	rs161731	ENSG00000248489.1	CTD-2007H13.3	10.02	1.78e-21	1.7e-18	0.48	0.43	Body mass index;	chr5:98984339	chr5:98929171~98995013:+
PRAD	cis	rs4718428	0.705	rs10267335	ENSG00000273142.1	RP11-458F8.4	-10.02	1.79e-21	1.7e-18	-0.33	-0.43	Corneal structure;	chr7:66938233	chr7:66902857~66906297:+
PRAD	cis	rs10129255	0.518	rs2006284	ENSG00000223648.3	IGHV3-64	10.02	1.8e-21	1.71e-18	0.38	0.43	Kawasaki disease;	chr14:106676185	chr14:106643132~106658258:-
PRAD	cis	rs3096299	0.559	rs9931073	ENSG00000261118.1	RP11-104N10.1	10.02	1.8e-21	1.71e-18	0.42	0.43	Multiple myeloma (IgH translocation);	chr16:89502105	chr16:89492017~89504460:-
PRAD	cis	rs1891275	0.551	rs1891271	ENSG00000228701.1	TNKS2-AS1	-10.02	1.81e-21	1.72e-18	-0.58	-0.43	Intelligence (multi-trait analysis);	chr10:91666566	chr10:91782839~91798291:-
PRAD	cis	rs9309473	1	rs10169714	ENSG00000163016.8	ALMS1P	10.02	1.81e-21	1.72e-18	0.52	0.42	Metabolite levels;	chr2:73581646	chr2:73644919~73685576:+
PRAD	cis	rs9545047	0.604	rs9530891	ENSG00000227676.3	LINC01068	10.01	1.82e-21	1.73e-18	0.5	0.42	Schizophrenia;	chr13:79284750	chr13:79566727~79571436:+
PRAD	cis	rs801193	0.569	rs35070132	ENSG00000237310.1	GS1-124K5.4	10.01	1.82e-21	1.73e-18	0.4	0.42	Aortic root size;	chr7:66773096	chr7:66493706~66495474:+
PRAD	cis	rs71403859	0.502	rs12708914	ENSG00000260886.1	TAT-AS1	10.01	1.83e-21	1.74e-18	0.65	0.42	Post bronchodilator FEV1;	chr16:71436733	chr16:71565789~71578187:+
PRAD	cis	rs67311347	1	rs11714912	ENSG00000223797.4	ENTPD3-AS1	-10.01	1.84e-21	1.75e-18	-0.37	-0.42	Renal cell carcinoma;	chr3:40452574	chr3:40313802~40453329:-
PRAD	cis	rs11673344	0.704	rs1644710	ENSG00000226686.6	LINC01535	10.01	1.85e-21	1.76e-18	0.58	0.42	Obesity-related traits;	chr19:36926160	chr19:37251912~37265535:+
PRAD	cis	rs801193	0.548	rs6975044	ENSG00000237310.1	GS1-124K5.4	10.01	1.85e-21	1.76e-18	0.4	0.42	Aortic root size;	chr7:66762495	chr7:66493706~66495474:+
PRAD	cis	rs9918079	0.542	rs12499412	ENSG00000273133.1	RP11-799M12.2	10.01	1.85e-21	1.76e-18	0.54	0.42	Obesity-related traits;	chr4:15600629	chr4:15563698~15564253:-
PRAD	cis	rs4713118	0.662	rs149961	ENSG00000280107.1	AL022393.9	-10.01	1.86e-21	1.77e-18	-0.55	-0.42	Parkinson's disease;	chr6:28047791	chr6:28170845~28172521:+
PRAD	cis	rs270601	0.909	rs2569265	ENSG00000233006.5	AC034220.3	-10.01	1.87e-21	1.77e-18	-0.4	-0.42	Acylcarnitine levels;	chr5:132368827	chr5:132311285~132369916:-
PRAD	cis	rs1185460	0.967	rs1786690	ENSG00000271751.1	RP11-110I1.14	-10.01	1.87e-21	1.78e-18	-0.59	-0.42	Coronary artery disease;	chr11:119071357	chr11:119065263~119065677:-
PRAD	cis	rs1799810	0.739	rs13030284	ENSG00000236682.1	AC068282.3	10.01	1.9e-21	1.81e-18	0.53	0.42	Self-rated health;	chr2:127401143	chr2:127389130~127400580:+
PRAD	cis	rs6142102	0.961	rs1319363	ENSG00000276073.1	RP5-1125A11.7	-10.01	1.92e-21	1.82e-18	-0.44	-0.42	Skin pigmentation;	chr20:33954070	chr20:33985617~33988989:-
PRAD	cis	rs6700559	1	rs12076877	ENSG00000260088.1	RP11-92G12.3	-10.01	1.92e-21	1.82e-18	-0.55	-0.42	Coronary artery disease;	chr1:200674277	chr1:200669507~200694250:+
PRAD	cis	rs4718428	0.705	rs13227468	ENSG00000232546.1	RP11-458F8.1	-10.01	1.92e-21	1.82e-18	-0.35	-0.42	Corneal structure;	chr7:66968576	chr7:66848496~66858136:+
PRAD	cis	rs2933343	0.818	rs6764681	ENSG00000261159.1	RP11-723O4.9	-10.01	1.93e-21	1.83e-18	-0.41	-0.42	IgG glycosylation;	chr3:128849537	chr3:128859716~128860526:-
PRAD	cis	rs11118620	0.622	rs11118618	ENSG00000272823.1	RP11-295M18.6	10.01	1.94e-21	1.84e-18	0.6	0.42	Heart failure;	chr1:220838204	chr1:220828676~220829211:-
PRAD	cis	rs1555322	0.53	rs7004	ENSG00000126005.14	MMP24-AS1	-10.01	1.94e-21	1.84e-18	-0.53	-0.42	Attention deficit hyperactivity disorder;	chr20:35278950	chr20:35216462~35278131:-
PRAD	cis	rs10246939	0.579	rs9640205	ENSG00000228775.6	WEE2-AS1	10.01	1.95e-21	1.85e-18	0.53	0.42	Bitter taste perception;	chr7:141844400	chr7:141704338~141738346:-
PRAD	cis	rs6921919	0.697	rs6942030	ENSG00000216901.1	AL022393.7	10.01	1.95e-21	1.85e-18	0.56	0.42	Autism spectrum disorder or schizophrenia;	chr6:28348181	chr6:28176188~28176674:+
PRAD	cis	rs3931020	0.688	rs455032	ENSG00000272864.1	RP11-17E13.2	10.01	1.96e-21	1.86e-18	0.49	0.42	Resistin levels;	chr1:74730804	chr1:74698769~74699333:-
PRAD	cis	rs150992	0.609	rs366000	ENSG00000248489.1	CTD-2007H13.3	-10	1.97e-21	1.87e-18	-0.47	-0.42	Body mass index;	chr5:98991705	chr5:98929171~98995013:+
PRAD	cis	rs2348418	0.932	rs11049623	ENSG00000247934.4	RP11-967K21.1	10	1.98e-21	1.88e-18	0.39	0.42	Lung function (FEV1);Lung function (FVC);	chr12:28458374	chr12:28163298~28190738:-
PRAD	cis	rs9918079	0.506	rs10214	ENSG00000273133.1	RP11-799M12.2	10	1.98e-21	1.88e-18	0.54	0.42	Obesity-related traits;	chr4:15604808	chr4:15563698~15564253:-
PRAD	cis	rs1185460	0.934	rs1006195	ENSG00000271751.1	RP11-110I1.14	10	2e-21	1.9e-18	0.6	0.42	Coronary artery disease;	chr11:119088159	chr11:119065263~119065677:-
PRAD	cis	rs12049351	0.665	rs970103	ENSG00000229367.1	HMGN2P19	10	2e-21	1.9e-18	0.62	0.42	Circulating myeloperoxidase levels (plasma);	chr1:229434388	chr1:229570532~229570796:+
PRAD	cis	rs3931020	0.626	rs277402	ENSG00000272864.1	RP11-17E13.2	10	2.01e-21	1.9e-18	0.5	0.42	Resistin levels;	chr1:74722637	chr1:74698769~74699333:-
PRAD	cis	rs1150668	0.699	rs1736895	ENSG00000204709.4	LINC01556	10	2.01e-21	1.91e-18	0.53	0.42	Pubertal anthropometrics;	chr6:28252048	chr6:28943877~28944537:+
PRAD	cis	rs1150668	0.699	rs12214383	ENSG00000204709.4	LINC01556	-10	2.01e-21	1.91e-18	-0.53	-0.42	Pubertal anthropometrics;	chr6:28255953	chr6:28943877~28944537:+
PRAD	cis	rs270601	0.837	rs367805	ENSG00000233006.5	AC034220.3	10	2.01e-21	1.91e-18	0.4	0.42	Acylcarnitine levels;	chr5:132365587	chr5:132311285~132369916:-
PRAD	cis	rs1858037	0.867	rs67817304	ENSG00000204929.10	AC074391.1	10	2.02e-21	1.91e-18	0.58	0.42	Rheumatoid arthritis;	chr2:65346982	chr2:65436711~66084639:+
PRAD	cis	rs1150668	0.796	rs213237	ENSG00000216901.1	AL022393.7	10	2.02e-21	1.91e-18	0.52	0.42	Pubertal anthropometrics;	chr6:28356161	chr6:28176188~28176674:+
PRAD	cis	rs4964805	1	rs73192052	ENSG00000257681.1	RP11-341G23.4	10	2.03e-21	1.92e-18	0.42	0.42	Attention deficit hyperactivity disorder;	chr12:103797076	chr12:103746315~103768858:-
PRAD	cis	rs1075265	0.744	rs2909460	ENSG00000233266.1	HMGB1P31	10	2.03e-21	1.93e-18	0.57	0.42	Chronotype;Morning vs. evening chronotype;	chr2:53967611	chr2:54051334~54051760:+
PRAD	cis	rs1075265	0.811	rs805308	ENSG00000233266.1	HMGB1P31	10	2.03e-21	1.93e-18	0.57	0.42	Chronotype;Morning vs. evening chronotype;	chr2:53967797	chr2:54051334~54051760:+
PRAD	cis	rs507080	0.883	rs558593	ENSG00000255422.1	AP002954.4	-10	2.03e-21	1.93e-18	-0.52	-0.42	Serum metabolite levels;	chr11:118691811	chr11:118704607~118750263:+
PRAD	cis	rs732716	0.785	rs55660045	ENSG00000267980.1	AC007292.6	-10	2.04e-21	1.93e-18	-0.44	-0.42	Mean corpuscular volume;	chr19:4425308	chr19:4363789~4364640:+
PRAD	cis	rs2283792	0.765	rs5999749	ENSG00000224086.5	LL22NC03-86G7.1	10	2.06e-21	1.95e-18	0.51	0.42	Multiple sclerosis;	chr22:21833371	chr22:21938293~21977632:+
PRAD	cis	rs2283792	0.765	rs9610328	ENSG00000224086.5	LL22NC03-86G7.1	-10	2.07e-21	1.96e-18	-0.5	-0.42	Multiple sclerosis;	chr22:21793085	chr22:21938293~21977632:+
PRAD	cis	rs1891275	0.515	rs10881957	ENSG00000228701.1	TNKS2-AS1	-10	2.07e-21	1.96e-18	-0.53	-0.42	Intelligence (multi-trait analysis);	chr10:91742119	chr10:91782839~91798291:-
PRAD	cis	rs9322193	0.887	rs3777949	ENSG00000216906.2	RP11-350J20.9	10	2.09e-21	1.97e-18	0.5	0.42	Lung cancer;	chr6:149596021	chr6:149904243~149906418:+
PRAD	cis	rs6750795	0.569	rs1667308	ENSG00000181798.2	LINC00471	-10	2.09e-21	1.98e-18	-0.49	-0.42	Height;	chr2:231541633	chr2:231508426~231514339:-
PRAD	cis	rs1858037	0.867	rs6727013	ENSG00000204929.10	AC074391.1	10	2.12e-21	2.01e-18	0.58	0.42	Rheumatoid arthritis;	chr2:65331241	chr2:65436711~66084639:+
PRAD	cis	rs6991838	0.584	rs2175810	ENSG00000272010.1	CTD-3025N20.3	-9.99	2.14e-21	2.02e-18	-0.43	-0.42	Intelligence (multi-trait analysis);	chr8:65643583	chr8:65591850~65592472:-
PRAD	cis	rs507080	0.922	rs478371	ENSG00000255422.1	AP002954.4	-9.99	2.14e-21	2.02e-18	-0.52	-0.42	Serum metabolite levels;	chr11:118694627	chr11:118704607~118750263:+
PRAD	cis	rs7688540	0.771	rs4582105	ENSG00000275426.1	CH17-262A2.1	9.99	2.15e-21	2.03e-18	0.65	0.42	Facial morphology (factor 6, height of vermillion lower lip);	chr4:252553	chr4:149738~150317:+
PRAD	cis	rs673078	0.607	rs11068906	ENSG00000275759.1	RP11-131L12.3	-9.99	2.21e-21	2.09e-18	-0.6	-0.42	Glucose homeostasis traits;	chr12:118315098	chr12:118428281~118428870:+
PRAD	cis	rs7714584	1	rs7734778	ENSG00000197083.10	ZNF300P1	9.99	2.22e-21	2.1e-18	0.68	0.42	Crohn's disease;	chr5:150876994	chr5:150930645~150946289:-
PRAD	cis	rs853679	0.517	rs17711344	ENSG00000219392.1	RP1-265C24.5	9.99	2.23e-21	2.1e-18	0.56	0.42	Depression;	chr6:28109824	chr6:28115628~28116551:+
PRAD	cis	rs10885396	0.967	rs7094463	ENSG00000233547.1	RP11-57H14.2	9.99	2.24e-21	2.11e-18	0.34	0.42	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr10:112952224	chr10:112950646~112951875:-
PRAD	cis	rs9326248	0.53	rs473188	ENSG00000254851.1	RP11-109L13.1	-9.99	2.24e-21	2.11e-18	-0.82	-0.42	Blood protein levels;	chr11:116941313	chr11:117135528~117138582:+
PRAD	cis	rs8072100	0.713	rs4968257	ENSG00000228782.6	CTD-2026D20.3	9.99	2.24e-21	2.12e-18	0.47	0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47353168	chr17:47450568~47492492:-
PRAD	cis	rs1075265	0.669	rs805330	ENSG00000233266.1	HMGB1P31	9.99	2.24e-21	2.12e-18	0.56	0.42	Chronotype;Morning vs. evening chronotype;	chr2:53921194	chr2:54051334~54051760:+
PRAD	cis	rs4774565	0.762	rs17431095	ENSG00000244879.4	GABPB1-AS1	-9.99	2.24e-21	2.12e-18	-0.39	-0.42	Breast cancer;	chr15:50369252	chr15:50354959~50372202:+
PRAD	cis	rs9545047	0.604	rs4885625	ENSG00000227676.3	LINC01068	9.99	2.24e-21	2.12e-18	0.5	0.42	Schizophrenia;	chr13:79290355	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs1324873	ENSG00000227676.3	LINC01068	9.99	2.24e-21	2.12e-18	0.5	0.42	Schizophrenia;	chr13:79292246	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs4573813	ENSG00000227676.3	LINC01068	9.99	2.24e-21	2.12e-18	0.5	0.42	Schizophrenia;	chr13:79293357	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs2147566	ENSG00000227676.3	LINC01068	9.99	2.24e-21	2.12e-18	0.5	0.42	Schizophrenia;	chr13:79296580	chr13:79566727~79571436:+
PRAD	cis	rs6504950	0.924	rs244353	ENSG00000275710.1	RP11-257O5.4	-9.99	2.25e-21	2.12e-18	-0.54	-0.42	Breast cancer;	chr17:55117408	chr17:54964474~54964679:+
PRAD	cis	rs9309473	1	rs7558944	ENSG00000163016.8	ALMS1P	9.99	2.25e-21	2.13e-18	0.52	0.42	Metabolite levels;	chr2:73583782	chr2:73644919~73685576:+
PRAD	cis	rs9309473	1	rs13432605	ENSG00000163016.8	ALMS1P	9.99	2.25e-21	2.13e-18	0.52	0.42	Metabolite levels;	chr2:73583854	chr2:73644919~73685576:+
PRAD	cis	rs9309473	1	rs7582606	ENSG00000163016.8	ALMS1P	9.99	2.25e-21	2.13e-18	0.52	0.42	Metabolite levels;	chr2:73586818	chr2:73644919~73685576:+
PRAD	cis	rs9918079	0.56	rs7685083	ENSG00000273133.1	RP11-799M12.2	9.99	2.25e-21	2.13e-18	0.54	0.42	Obesity-related traits;	chr4:15609148	chr4:15563698~15564253:-
PRAD	cis	rs1858037	0.867	rs67453645	ENSG00000204929.10	AC074391.1	9.99	2.26e-21	2.14e-18	0.58	0.42	Rheumatoid arthritis;	chr2:65358908	chr2:65436711~66084639:+
PRAD	cis	rs1858037	0.867	rs57913336	ENSG00000204929.10	AC074391.1	9.99	2.26e-21	2.14e-18	0.58	0.42	Rheumatoid arthritis;	chr2:65360485	chr2:65436711~66084639:+
PRAD	cis	rs10246939	0.505	rs9640203	ENSG00000228775.6	WEE2-AS1	9.99	2.28e-21	2.16e-18	0.54	0.42	Bitter taste perception;	chr7:141844295	chr7:141704338~141738346:-
PRAD	cis	rs10246939	0.505	rs892354	ENSG00000228775.6	WEE2-AS1	9.99	2.28e-21	2.16e-18	0.54	0.42	Bitter taste perception;	chr7:141844934	chr7:141704338~141738346:-
PRAD	cis	rs9545047	0.604	rs9545052	ENSG00000227676.3	LINC01068	9.99	2.29e-21	2.16e-18	0.5	0.42	Schizophrenia;	chr13:79294875	chr13:79566727~79571436:+
PRAD	cis	rs3096299	0.658	rs3934737	ENSG00000261118.1	RP11-104N10.1	9.99	2.3e-21	2.17e-18	0.41	0.42	Multiple myeloma (IgH translocation);	chr16:89493801	chr16:89492017~89504460:-
PRAD	cis	rs34375054	0.526	rs883315	ENSG00000279233.1	RP11-158L12.4	9.99	2.31e-21	2.18e-18	0.42	0.42	Post bronchodilator FEV1/FVC ratio;	chr12:125192343	chr12:125138245~125141711:+
PRAD	cis	rs34375054	0.526	rs2343638	ENSG00000279233.1	RP11-158L12.4	9.99	2.31e-21	2.18e-18	0.42	0.42	Post bronchodilator FEV1/FVC ratio;	chr12:125192576	chr12:125138245~125141711:+
PRAD	cis	rs34375054	0.526	rs7302475	ENSG00000279233.1	RP11-158L12.4	9.99	2.31e-21	2.18e-18	0.42	0.42	Post bronchodilator FEV1/FVC ratio;	chr12:125193340	chr12:125138245~125141711:+
PRAD	cis	rs1891275	0.588	rs6583782	ENSG00000228701.1	TNKS2-AS1	-9.99	2.32e-21	2.19e-18	-0.58	-0.42	Intelligence (multi-trait analysis);	chr10:91666022	chr10:91782839~91798291:-
PRAD	cis	rs3762637	1	rs11932	ENSG00000272758.4	RP11-299J3.8	9.98	2.33e-21	2.2e-18	0.59	0.42	LDL cholesterol levels;	chr3:122422288	chr3:122416207~122443180:+
PRAD	cis	rs1858037	0.836	rs17475335	ENSG00000204929.10	AC074391.1	9.98	2.36e-21	2.22e-18	0.58	0.42	Rheumatoid arthritis;	chr2:65378646	chr2:65436711~66084639:+
PRAD	cis	rs853679	0.517	rs9295761	ENSG00000219392.1	RP1-265C24.5	-9.98	2.39e-21	2.25e-18	-0.56	-0.42	Depression;	chr6:28180209	chr6:28115628~28116551:+
PRAD	cis	rs507080	0.961	rs642497	ENSG00000255422.1	AP002954.4	-9.98	2.4e-21	2.26e-18	-0.51	-0.42	Serum metabolite levels;	chr11:118680075	chr11:118704607~118750263:+
PRAD	cis	rs11673344	0.8	rs826323	ENSG00000226686.6	LINC01535	9.98	2.42e-21	2.28e-18	0.57	0.42	Obesity-related traits;	chr19:37014051	chr19:37251912~37265535:+
PRAD	cis	rs9322193	0.962	rs3763163	ENSG00000268592.3	RAET1E-AS1	9.98	2.43e-21	2.29e-18	0.57	0.42	Lung cancer;	chr6:149819770	chr6:149863494~149919507:+
PRAD	cis	rs10129255	0.509	rs756583	ENSG00000223648.3	IGHV3-64	9.98	2.44e-21	2.3e-18	0.38	0.42	Kawasaki disease;	chr14:106680002	chr14:106643132~106658258:-
PRAD	cis	rs10129255	0.536	rs3944157	ENSG00000223648.3	IGHV3-64	9.98	2.44e-21	2.3e-18	0.38	0.42	Kawasaki disease;	chr14:106682286	chr14:106643132~106658258:-
PRAD	cis	rs6860806	0.531	rs274556	ENSG00000233006.5	AC034220.3	-9.98	2.45e-21	2.31e-18	-0.4	-0.42	Breast cancer;	chr5:132386383	chr5:132311285~132369916:-
PRAD	cis	rs6452524	0.508	rs40214	ENSG00000249664.1	CTD-2227C6.2	-9.98	2.45e-21	2.31e-18	-0.51	-0.42	Hypertension (SNP x SNP interaction);	chr5:83000359	chr5:83012285~83013109:-
PRAD	cis	rs2283792	0.765	rs9340	ENSG00000224086.5	LL22NC03-86G7.1	-9.98	2.46e-21	2.32e-18	-0.5	-0.42	Multiple sclerosis;	chr22:21761064	chr22:21938293~21977632:+
PRAD	cis	rs2283792	0.765	rs1063311	ENSG00000224086.5	LL22NC03-86G7.1	-9.98	2.46e-21	2.32e-18	-0.5	-0.42	Multiple sclerosis;	chr22:21762178	chr22:21938293~21977632:+
PRAD	cis	rs1930961	1	rs6004675	ENSG00000272942.1	CTA-246H3.12	-9.98	2.47e-21	2.32e-18	-0.68	-0.42	Bipolar disorder with mood-incongruent psychosis;	chr22:25493418	chr22:25434324~25435070:-
PRAD	cis	rs507080	0.961	rs600969	ENSG00000255422.1	AP002954.4	-9.98	2.48e-21	2.33e-18	-0.52	-0.42	Serum metabolite levels;	chr11:118675087	chr11:118704607~118750263:+
PRAD	cis	rs7688540	0.771	rs77234191	ENSG00000275426.1	CH17-262A2.1	9.98	2.49e-21	2.34e-18	0.65	0.42	Facial morphology (factor 6, height of vermillion lower lip);	chr4:264505	chr4:149738~150317:+
PRAD	cis	rs1075265	0.73	rs6713088	ENSG00000233266.1	HMGB1P31	9.98	2.5e-21	2.35e-18	0.57	0.42	Chronotype;Morning vs. evening chronotype;	chr2:54118332	chr2:54051334~54051760:+
PRAD	cis	rs1555322	0.53	rs2425044	ENSG00000126005.14	MMP24-AS1	-9.98	2.5e-21	2.35e-18	-0.52	-0.42	Attention deficit hyperactivity disorder;	chr20:35281932	chr20:35216462~35278131:-
PRAD	cis	rs9309473	0.898	rs10170786	ENSG00000163016.8	ALMS1P	9.98	2.51e-21	2.36e-18	0.52	0.42	Metabolite levels;	chr2:73585861	chr2:73644919~73685576:+
PRAD	cis	rs1555322	0.53	rs2425042	ENSG00000126005.14	MMP24-AS1	-9.97	2.52e-21	2.37e-18	-0.53	-0.42	Attention deficit hyperactivity disorder;	chr20:35278092	chr20:35216462~35278131:-
PRAD	cis	rs3813579	0.679	rs4329928	ENSG00000261390.4	RP11-345M22.2	9.97	2.52e-21	2.37e-18	0.49	0.42	Thyroid volume;	chr16:79713988	chr16:79715232~79770563:-
PRAD	cis	rs1729407	0.647	rs2727791	ENSG00000254851.1	RP11-109L13.1	-9.97	2.52e-21	2.37e-18	-0.55	-0.42	Apolipoprotein A-IV levels;	chr11:116813846	chr11:117135528~117138582:+
PRAD	cis	rs6142102	0.923	rs6059586	ENSG00000276073.1	RP5-1125A11.7	-9.97	2.53e-21	2.38e-18	-0.42	-0.42	Skin pigmentation;	chr20:33952695	chr20:33985617~33988989:-
PRAD	cis	rs7250849	1	rs7250849	ENSG00000273837.1	LLNLR-470E3.1	9.97	2.54e-21	2.38e-18	0.75	0.42	Blood protein levels;	chr19:51655063	chr19:51639478~51639931:-
PRAD	cis	rs12049351	0.612	rs10916487	ENSG00000229367.1	HMGN2P19	9.97	2.6e-21	2.44e-18	0.6	0.42	Circulating myeloperoxidase levels (plasma);	chr1:229476995	chr1:229570532~229570796:+
PRAD	cis	rs8072100	0.651	rs1912484	ENSG00000228782.6	CTD-2026D20.3	9.97	2.61e-21	2.45e-18	0.47	0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47366298	chr17:47450568~47492492:-
PRAD	cis	rs9326248	0.53	rs7121347	ENSG00000254851.1	RP11-109L13.1	-9.97	2.63e-21	2.47e-18	-0.83	-0.42	Blood protein levels;	chr11:116996493	chr11:117135528~117138582:+
PRAD	cis	rs9326248	0.53	rs7114963	ENSG00000254851.1	RP11-109L13.1	-9.97	2.63e-21	2.47e-18	-0.83	-0.42	Blood protein levels;	chr11:117005267	chr11:117135528~117138582:+
PRAD	cis	rs7115242	0.72	rs10790169	ENSG00000254851.1	RP11-109L13.1	-9.97	2.63e-21	2.47e-18	-0.83	-0.42	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117006443	chr11:117135528~117138582:+
PRAD	cis	rs2282300	0.739	rs1765133	ENSG00000242353.1	RP4-710M3.1	-9.97	2.64e-21	2.48e-18	-0.52	-0.42	Morning vs. evening chronotype;	chr11:30317853	chr11:30368148~30368646:+
PRAD	cis	rs9532669	0.927	rs9532670	ENSG00000168852.11	TPTE2P5	-9.97	2.64e-21	2.48e-18	-0.4	-0.42	Cervical cancer;	chr13:40927691	chr13:40822296~40921749:-
PRAD	cis	rs10875746	0.951	rs2269935	ENSG00000240399.1	RP1-228P16.1	-9.97	2.64e-21	2.48e-18	-0.45	-0.42	Longevity (90 years and older);	chr12:48122681	chr12:48054813~48055591:-
PRAD	cis	rs34779708	0.931	rs11010067	ENSG00000230534.5	RP11-297A16.2	-9.97	2.65e-21	2.49e-18	-0.56	-0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35006503	chr10:35098006~35127020:-
PRAD	cis	rs9322193	0.961	rs9027	ENSG00000223701.3	RAET1E-AS1	9.97	2.67e-21	2.51e-18	0.57	0.42	Lung cancer;	chr6:149594921	chr6:149884431~149919508:+
PRAD	cis	rs6750795	0.569	rs1667305	ENSG00000181798.2	LINC00471	-9.97	2.68e-21	2.52e-18	-0.49	-0.42	Height;	chr2:231539118	chr2:231508426~231514339:-
PRAD	cis	rs1891275	0.509	rs34190234	ENSG00000228701.1	TNKS2-AS1	-9.97	2.69e-21	2.52e-18	-0.53	-0.42	Intelligence (multi-trait analysis);	chr10:91683317	chr10:91782839~91798291:-
PRAD	cis	rs1891275	0.509	rs76313529	ENSG00000228701.1	TNKS2-AS1	-9.97	2.69e-21	2.52e-18	-0.53	-0.42	Intelligence (multi-trait analysis);	chr10:91683319	chr10:91782839~91798291:-
PRAD	cis	rs853679	0.55	rs34477097	ENSG00000280107.1	AL022393.9	-9.97	2.7e-21	2.53e-18	-0.55	-0.42	Depression;	chr6:28229408	chr6:28170845~28172521:+
PRAD	cis	rs9309473	1	rs1534471	ENSG00000163016.8	ALMS1P	9.97	2.7e-21	2.53e-18	0.52	0.42	Metabolite levels;	chr2:73420380	chr2:73644919~73685576:+
PRAD	cis	rs9322193	0.962	rs7745915	ENSG00000268592.3	RAET1E-AS1	9.97	2.71e-21	2.54e-18	0.59	0.42	Lung cancer;	chr6:149834111	chr6:149863494~149919507:+
PRAD	cis	rs8062405	0.754	rs151179	ENSG00000259982.1	CDC37P1	9.97	2.72e-21	2.55e-18	0.56	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28475735	chr16:28700294~28701540:-
PRAD	cis	rs9322193	0.923	rs12175504	ENSG00000268592.3	RAET1E-AS1	9.96	2.74e-21	2.57e-18	0.58	0.42	Lung cancer;	chr6:149664079	chr6:149863494~149919507:+
PRAD	cis	rs9322193	0.962	rs62439843	ENSG00000268592.3	RAET1E-AS1	9.96	2.74e-21	2.57e-18	0.58	0.42	Lung cancer;	chr6:149676521	chr6:149863494~149919507:+
PRAD	cis	rs1150668	0.699	rs2394049	ENSG00000204709.4	LINC01556	9.96	2.77e-21	2.59e-18	0.53	0.42	Pubertal anthropometrics;	chr6:28271903	chr6:28943877~28944537:+
PRAD	cis	rs783540	0.656	rs783538	ENSG00000255769.6	GOLGA2P10	9.96	2.78e-21	2.61e-18	0.52	0.42	Schizophrenia;	chr15:82584394	chr15:82472993~82513950:-
PRAD	cis	rs9545047	0.604	rs3742117	ENSG00000227676.3	LINC01068	9.96	2.79e-21	2.61e-18	0.49	0.42	Schizophrenia;	chr13:79342498	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.647	rs3742118	ENSG00000227676.3	LINC01068	9.96	2.79e-21	2.61e-18	0.49	0.42	Schizophrenia;	chr13:79342838	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.625	rs7319320	ENSG00000227676.3	LINC01068	9.96	2.79e-21	2.61e-18	0.49	0.42	Schizophrenia;	chr13:79343072	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs3752994	ENSG00000227676.3	LINC01068	9.96	2.79e-21	2.61e-18	0.49	0.42	Schizophrenia;	chr13:79345076	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.567	rs4884129	ENSG00000227676.3	LINC01068	9.96	2.79e-21	2.61e-18	0.49	0.42	Schizophrenia;	chr13:79346448	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.567	rs1410336	ENSG00000227676.3	LINC01068	9.96	2.79e-21	2.61e-18	0.49	0.42	Schizophrenia;	chr13:79347598	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs9565492	ENSG00000227676.3	LINC01068	9.96	2.79e-21	2.61e-18	0.49	0.42	Schizophrenia;	chr13:79348554	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs9318625	ENSG00000227676.3	LINC01068	9.96	2.79e-21	2.61e-18	0.49	0.42	Schizophrenia;	chr13:79351429	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs9530899	ENSG00000227676.3	LINC01068	9.96	2.79e-21	2.61e-18	0.49	0.42	Schizophrenia;	chr13:79352461	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs7338677	ENSG00000227676.3	LINC01068	9.96	2.79e-21	2.61e-18	0.49	0.42	Schizophrenia;	chr13:79352580	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs7322744	ENSG00000227676.3	LINC01068	9.96	2.79e-21	2.61e-18	0.49	0.42	Schizophrenia;	chr13:79354070	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs9530900	ENSG00000227676.3	LINC01068	9.96	2.79e-21	2.61e-18	0.49	0.42	Schizophrenia;	chr13:79355048	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs9530901	ENSG00000227676.3	LINC01068	9.96	2.79e-21	2.61e-18	0.49	0.42	Schizophrenia;	chr13:79355191	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs4328330	ENSG00000227676.3	LINC01068	9.96	2.79e-21	2.61e-18	0.49	0.42	Schizophrenia;	chr13:79355503	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.567	rs4497554	ENSG00000227676.3	LINC01068	9.96	2.79e-21	2.61e-18	0.49	0.42	Schizophrenia;	chr13:79355651	chr13:79566727~79571436:+
PRAD	cis	rs507080	0.922	rs555356	ENSG00000255422.1	AP002954.4	-9.96	2.8e-21	2.62e-18	-0.52	-0.42	Serum metabolite levels;	chr11:118687369	chr11:118704607~118750263:+
PRAD	cis	rs507080	0.883	rs692750	ENSG00000255422.1	AP002954.4	-9.96	2.8e-21	2.63e-18	-0.52	-0.42	Serum metabolite levels;	chr11:118667599	chr11:118704607~118750263:+
PRAD	cis	rs9545047	0.604	rs2182873	ENSG00000227676.3	LINC01068	9.96	2.82e-21	2.64e-18	0.49	0.42	Schizophrenia;	chr13:79356846	chr13:79566727~79571436:+
PRAD	cis	rs9309473	1	rs6710438	ENSG00000163016.8	ALMS1P	-9.96	2.82e-21	2.64e-18	-0.51	-0.42	Metabolite levels;	chr2:73592981	chr2:73644919~73685576:+
PRAD	cis	rs507080	0.961	rs673770	ENSG00000255422.1	AP002954.4	-9.96	2.84e-21	2.66e-18	-0.51	-0.42	Serum metabolite levels;	chr11:118679892	chr11:118704607~118750263:+
PRAD	cis	rs12049351	0.665	rs10753458	ENSG00000229367.1	HMGN2P19	9.96	2.84e-21	2.66e-18	0.61	0.42	Circulating myeloperoxidase levels (plasma);	chr1:229439962	chr1:229570532~229570796:+
PRAD	cis	rs8062405	1	rs72793811	ENSG00000259982.1	CDC37P1	9.96	2.85e-21	2.66e-18	0.57	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828071	chr16:28700294~28701540:-
PRAD	cis	rs10129255	0.556	rs9324093	ENSG00000223648.3	IGHV3-64	9.96	2.85e-21	2.67e-18	0.38	0.42	Kawasaki disease;	chr14:106683893	chr14:106643132~106658258:-
PRAD	cis	rs9545047	0.604	rs2025913	ENSG00000227676.3	LINC01068	9.96	2.85e-21	2.67e-18	0.49	0.42	Schizophrenia;	chr13:79357315	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs9545082	ENSG00000227676.3	LINC01068	9.96	2.85e-21	2.67e-18	0.49	0.42	Schizophrenia;	chr13:79358994	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs7332913	ENSG00000227676.3	LINC01068	9.96	2.85e-21	2.67e-18	0.49	0.42	Schizophrenia;	chr13:79359149	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs9545083	ENSG00000227676.3	LINC01068	9.96	2.85e-21	2.67e-18	0.49	0.42	Schizophrenia;	chr13:79360695	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs7322756	ENSG00000227676.3	LINC01068	9.96	2.85e-21	2.67e-18	0.49	0.42	Schizophrenia;	chr13:79361120	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs7324006	ENSG00000227676.3	LINC01068	9.96	2.85e-21	2.67e-18	0.49	0.42	Schizophrenia;	chr13:79361225	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs7322673	ENSG00000227676.3	LINC01068	9.96	2.85e-21	2.67e-18	0.49	0.42	Schizophrenia;	chr13:79361266	chr13:79566727~79571436:+
PRAD	cis	rs12049351	0.665	rs10916477	ENSG00000229367.1	HMGN2P19	9.96	2.86e-21	2.67e-18	0.61	0.42	Circulating myeloperoxidase levels (plasma);	chr1:229441218	chr1:229570532~229570796:+
PRAD	cis	rs9918079	0.58	rs13120905	ENSG00000273133.1	RP11-799M12.2	9.96	2.86e-21	2.68e-18	0.54	0.42	Obesity-related traits;	chr4:15610665	chr4:15563698~15564253:-
PRAD	cis	rs6504950	0.854	rs244322	ENSG00000275710.1	RP11-257O5.4	9.96	2.88e-21	2.7e-18	0.53	0.42	Breast cancer;	chr17:55147398	chr17:54964474~54964679:+
PRAD	cis	rs7714584	1	rs11747270	ENSG00000197083.10	ZNF300P1	-9.96	2.9e-21	2.72e-18	-0.67	-0.42	Crohn's disease;	chr5:150879305	chr5:150930645~150946289:-
PRAD	cis	rs3762637	0.943	rs7629285	ENSG00000272758.4	RP11-299J3.8	9.96	2.91e-21	2.72e-18	0.63	0.42	LDL cholesterol levels;	chr3:122546892	chr3:122416207~122443180:+
PRAD	cis	rs1577917	0.958	rs12192546	ENSG00000203875.9	SNHG5	9.96	2.91e-21	2.72e-18	0.53	0.42	Response to antipsychotic treatment;	chr6:85766766	chr6:85660950~85678736:-
PRAD	cis	rs3762637	0.941	rs6788746	ENSG00000272758.4	RP11-299J3.8	-9.96	2.91e-21	2.73e-18	-0.63	-0.42	LDL cholesterol levels;	chr3:122387896	chr3:122416207~122443180:+
PRAD	cis	rs9322193	1	rs9322193	ENSG00000268592.3	RAET1E-AS1	9.96	2.94e-21	2.75e-18	0.59	0.42	Lung cancer;	chr6:149598007	chr6:149863494~149919507:+
PRAD	cis	rs67311347	1	rs7631893	ENSG00000223797.4	ENTPD3-AS1	9.96	2.94e-21	2.75e-18	0.37	0.42	Renal cell carcinoma;	chr3:40399378	chr3:40313802~40453329:-
PRAD	cis	rs10246939	0.505	rs13236432	ENSG00000228775.6	WEE2-AS1	9.96	2.96e-21	2.76e-18	0.54	0.42	Bitter taste perception;	chr7:141850980	chr7:141704338~141738346:-
PRAD	cis	rs8072100	0.512	rs9674670	ENSG00000228782.6	CTD-2026D20.3	9.96	2.96e-21	2.77e-18	0.47	0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47308791	chr17:47450568~47492492:-
PRAD	cis	rs2283792	0.765	rs9607285	ENSG00000224086.5	LL22NC03-86G7.1	-9.96	2.96e-21	2.77e-18	-0.5	-0.42	Multiple sclerosis;	chr22:21808704	chr22:21938293~21977632:+
PRAD	cis	rs12049351	0.665	rs10799531	ENSG00000229367.1	HMGN2P19	-9.96	2.97e-21	2.78e-18	-0.61	-0.42	Circulating myeloperoxidase levels (plasma);	chr1:229448670	chr1:229570532~229570796:+
PRAD	cis	rs3096299	0.809	rs2911264	ENSG00000274627.1	RP11-104N10.2	9.95	2.98e-21	2.79e-18	0.44	0.42	Multiple myeloma (IgH translocation);	chr16:89432864	chr16:89516797~89522217:+
PRAD	cis	rs7688540	0.771	rs12505835	ENSG00000275426.1	CH17-262A2.1	9.95	3e-21	2.8e-18	0.66	0.42	Facial morphology (factor 6, height of vermillion lower lip);	chr4:303736	chr4:149738~150317:+
PRAD	cis	rs907683	0.57	rs2666104	ENSG00000280323.1	AC053503.12	-9.95	3.03e-21	2.83e-18	-0.36	-0.42	Resting heart rate;	chr2:219416288	chr2:219427477~219429319:+
PRAD	cis	rs2282300	0.637	rs2065418	ENSG00000242353.1	RP4-710M3.1	-9.95	3.04e-21	2.84e-18	-0.44	-0.42	Morning vs. evening chronotype;	chr11:30400521	chr11:30368148~30368646:+
PRAD	cis	rs2665103	0.715	rs16973457	ENSG00000278603.1	RP13-608F4.5	9.95	3.05e-21	2.85e-18	0.53	0.42	Intelligence (multi-trait analysis);	chr15:82271650	chr15:82472203~82472426:+
PRAD	cis	rs853679	0.517	rs9380052	ENSG00000219392.1	RP1-265C24.5	-9.95	3.06e-21	2.86e-18	-0.55	-0.42	Depression;	chr6:28096845	chr6:28115628~28116551:+
PRAD	cis	rs4380275	0.782	rs4335978	ENSG00000223751.1	AC116609.2	9.95	3.07e-21	2.87e-18	0.55	0.42	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:750078	chr2:742488~747767:+
PRAD	cis	rs7849270	1	rs7036114	ENSG00000268707.1	RP11-247A12.7	-9.95	3.09e-21	2.88e-18	-0.47	-0.42	Blood metabolite ratios;	chr9:129131127	chr9:129170434~129170940:+
PRAD	cis	rs7849270	1	rs34055941	ENSG00000268707.1	RP11-247A12.7	-9.95	3.09e-21	2.88e-18	-0.47	-0.42	Blood metabolite ratios;	chr9:129132797	chr9:129170434~129170940:+
PRAD	cis	rs732716	0.819	rs12459919	ENSG00000267980.1	AC007292.6	-9.95	3.09e-21	2.88e-18	-0.43	-0.42	Mean corpuscular volume;	chr19:4434506	chr19:4363789~4364640:+
PRAD	cis	rs6142102	0.923	rs2268078	ENSG00000276073.1	RP5-1125A11.7	-9.95	3.1e-21	2.89e-18	-0.45	-0.42	Skin pigmentation;	chr20:34008898	chr20:33985617~33988989:-
PRAD	cis	rs7772486	0.875	rs2180192	ENSG00000235652.6	RP11-545I5.3	9.95	3.11e-21	2.9e-18	0.43	0.42	Lobe attachment (rater-scored or self-reported);	chr6:146001148	chr6:145799409~145886585:+
PRAD	cis	rs6061231	1	rs13043313	ENSG00000273619.1	RP5-908M14.9	-9.95	3.12e-21	2.92e-18	-0.29	-0.42	Colorectal cancer;	chr20:62383213	chr20:62386303~62386970:-
PRAD	cis	rs6452524	0.935	rs10942321	ENSG00000249664.1	CTD-2227C6.2	9.95	3.18e-21	2.96e-18	0.49	0.42	Hypertension (SNP x SNP interaction);	chr5:83083200	chr5:83012285~83013109:-
PRAD	cis	rs3096299	0.685	rs4785675	ENSG00000261118.1	RP11-104N10.1	9.95	3.18e-21	2.97e-18	0.4	0.42	Multiple myeloma (IgH translocation);	chr16:89473566	chr16:89492017~89504460:-
PRAD	cis	rs34779708	0.966	rs10508816	ENSG00000230534.5	RP11-297A16.2	9.95	3.18e-21	2.97e-18	0.55	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35171048	chr10:35098006~35127020:-
PRAD	cis	rs12049351	0.665	rs4338396	ENSG00000229367.1	HMGN2P19	9.95	3.19e-21	2.97e-18	0.63	0.42	Circulating myeloperoxidase levels (plasma);	chr1:229444474	chr1:229570532~229570796:+
PRAD	cis	rs12049351	0.612	rs10753459	ENSG00000229367.1	HMGN2P19	9.95	3.2e-21	2.99e-18	0.61	0.42	Circulating myeloperoxidase levels (plasma);	chr1:229440017	chr1:229570532~229570796:+
PRAD	cis	rs11951515	0.738	rs11950448	ENSG00000188850.9	RP11-159F24.2	-9.95	3.21e-21	3e-18	-0.49	-0.42	Metabolite levels  (X-11787);	chr5:43360163	chr5:43336164~43348716:+
PRAD	cis	rs12049351	0.612	rs16849836	ENSG00000229367.1	HMGN2P19	9.95	3.23e-21	3.01e-18	0.59	0.42	Circulating myeloperoxidase levels (plasma);	chr1:229478715	chr1:229570532~229570796:+
PRAD	cis	rs9309473	0.898	rs6546851	ENSG00000163016.8	ALMS1P	9.94	3.23e-21	3.02e-18	0.52	0.42	Metabolite levels;	chr2:73606156	chr2:73644919~73685576:+
PRAD	cis	rs9545047	0.604	rs943711	ENSG00000227676.3	LINC01068	9.94	3.26e-21	3.04e-18	0.5	0.42	Schizophrenia;	chr13:79282886	chr13:79566727~79571436:+
PRAD	cis	rs150992	0.861	rs467728	ENSG00000248489.1	CTD-2007H13.3	9.94	3.27e-21	3.05e-18	0.47	0.42	Body mass index;	chr5:98953863	chr5:98929171~98995013:+
PRAD	cis	rs3931020	0.688	rs277396	ENSG00000272864.1	RP11-17E13.2	9.94	3.3e-21	3.07e-18	0.49	0.42	Resistin levels;	chr1:74747964	chr1:74698769~74699333:-
PRAD	cis	rs8072100	0.967	rs8074149	ENSG00000228782.6	CTD-2026D20.3	-9.94	3.3e-21	3.08e-18	-0.46	-0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47506009	chr17:47450568~47492492:-
PRAD	cis	rs6142102	0.778	rs6059581	ENSG00000276073.1	RP5-1125A11.7	-9.94	3.3e-21	3.08e-18	-0.43	-0.42	Skin pigmentation;	chr20:33940582	chr20:33985617~33988989:-
PRAD	cis	rs4718428	0.705	rs13227468	ENSG00000273142.1	RP11-458F8.4	-9.94	3.3e-21	3.08e-18	-0.33	-0.42	Corneal structure;	chr7:66968576	chr7:66902857~66906297:+
PRAD	cis	rs4718428	0.576	rs12698546	ENSG00000232546.1	RP11-458F8.1	-9.94	3.31e-21	3.08e-18	-0.35	-0.42	Corneal structure;	chr7:66801919	chr7:66848496~66858136:+
PRAD	cis	rs9326248	0.861	rs4938343	ENSG00000280143.1	AP000892.6	9.94	3.35e-21	3.12e-18	0.42	0.42	Blood protein levels;	chr11:117132812	chr11:117204967~117210292:+
PRAD	cis	rs1577917	1	rs12190598	ENSG00000203875.9	SNHG5	-9.94	3.35e-21	3.12e-18	-0.5	-0.42	Response to antipsychotic treatment;	chr6:85976356	chr6:85660950~85678736:-
PRAD	cis	rs673078	0.66	rs61945176	ENSG00000275759.1	RP11-131L12.3	-9.94	3.35e-21	3.12e-18	-0.6	-0.42	Glucose homeostasis traits;	chr12:118204735	chr12:118428281~118428870:+
PRAD	cis	rs2946504	0.501	rs2977092	ENSG00000251468.2	RP11-369K16.1	-9.94	3.36e-21	3.13e-18	-0.49	-0.42	Type 2 diabetes;	chr8:12949867	chr8:12958387~12962200:+
PRAD	cis	rs12049351	0.612	rs10916486	ENSG00000229367.1	HMGN2P19	9.94	3.38e-21	3.15e-18	0.6	0.42	Circulating myeloperoxidase levels (plasma);	chr1:229473714	chr1:229570532~229570796:+
PRAD	cis	rs9545047	0.604	rs943712	ENSG00000227676.3	LINC01068	9.94	3.39e-21	3.15e-18	0.5	0.42	Schizophrenia;	chr13:79282671	chr13:79566727~79571436:+
PRAD	cis	rs507080	0.922	rs4589335	ENSG00000255422.1	AP002954.4	-9.94	3.39e-21	3.16e-18	-0.52	-0.42	Serum metabolite levels;	chr11:118668431	chr11:118704607~118750263:+
PRAD	cis	rs9322193	1	rs9377229	ENSG00000268592.3	RAET1E-AS1	9.94	3.4e-21	3.17e-18	0.58	0.42	Lung cancer;	chr6:149607655	chr6:149863494~149919507:+
PRAD	cis	rs34375054	0.526	rs4412800	ENSG00000279233.1	RP11-158L12.4	-9.94	3.41e-21	3.17e-18	-0.42	-0.42	Post bronchodilator FEV1/FVC ratio;	chr12:125190196	chr12:125138245~125141711:+
PRAD	cis	rs9309473	0.66	rs62151564	ENSG00000163016.8	ALMS1P	9.94	3.41e-21	3.17e-18	0.61	0.42	Metabolite levels;	chr2:73388321	chr2:73644919~73685576:+
PRAD	cis	rs1426063	0.614	rs17000261	ENSG00000260265.1	RP11-44F21.5	9.94	3.42e-21	3.18e-18	0.88	0.42	QT interval;	chr4:75108766	chr4:75081702~75084717:-
PRAD	cis	rs67311347	1	rs17078511	ENSG00000223797.4	ENTPD3-AS1	9.94	3.42e-21	3.18e-18	0.38	0.42	Renal cell carcinoma;	chr3:40354763	chr3:40313802~40453329:-
PRAD	cis	rs673078	0.66	rs11068908	ENSG00000275759.1	RP11-131L12.3	-9.94	3.43e-21	3.19e-18	-0.6	-0.42	Glucose homeostasis traits;	chr12:118327265	chr12:118428281~118428870:+
PRAD	cis	rs1150668	0.799	rs1150705	ENSG00000204709.4	LINC01556	9.94	3.45e-21	3.21e-18	0.53	0.42	Pubertal anthropometrics;	chr6:28226008	chr6:28943877~28944537:+
PRAD	cis	rs9545047	0.532	rs9545079	ENSG00000227676.3	LINC01068	9.94	3.46e-21	3.22e-18	0.49	0.42	Schizophrenia;	chr13:79346044	chr13:79566727~79571436:+
PRAD	cis	rs62103177	0.564	rs7228971	ENSG00000261126.6	RP11-795F19.1	-9.94	3.47e-21	3.23e-18	-0.59	-0.42	Opioid sensitivity;	chr18:79978025	chr18:80046900~80095482:+
PRAD	cis	rs2665103	0.687	rs11633000	ENSG00000278603.1	RP13-608F4.5	9.94	3.49e-21	3.25e-18	0.53	0.42	Intelligence (multi-trait analysis);	chr15:82269320	chr15:82472203~82472426:+
PRAD	cis	rs1891275	0.516	rs10881935	ENSG00000228701.1	TNKS2-AS1	-9.94	3.5e-21	3.25e-18	-0.58	-0.42	Intelligence (multi-trait analysis);	chr10:91637944	chr10:91782839~91798291:-
PRAD	cis	rs783540	0.632	rs17356528	ENSG00000255769.6	GOLGA2P10	9.94	3.5e-21	3.26e-18	0.52	0.42	Schizophrenia;	chr15:82636799	chr15:82472993~82513950:-
PRAD	cis	rs9322193	1	rs9322193	ENSG00000223701.3	RAET1E-AS1	9.93	3.51e-21	3.27e-18	0.57	0.42	Lung cancer;	chr6:149598007	chr6:149884431~149919508:+
PRAD	cis	rs9545047	0.604	rs2763810	ENSG00000227676.3	LINC01068	9.93	3.52e-21	3.27e-18	0.5	0.42	Schizophrenia;	chr13:79405544	chr13:79566727~79571436:+
PRAD	cis	rs9532669	0.889	rs1989252	ENSG00000176268.5	CYCSP34	-9.93	3.52e-21	3.27e-18	-0.44	-0.42	Cervical cancer;	chr13:40911532	chr13:40863599~40863902:-
PRAD	cis	rs9545047	0.553	rs7332004	ENSG00000227676.3	LINC01068	-9.93	3.54e-21	3.29e-18	-0.5	-0.42	Schizophrenia;	chr13:79364128	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs9545104	ENSG00000227676.3	LINC01068	9.93	3.55e-21	3.3e-18	0.5	0.42	Schizophrenia;	chr13:79404000	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs9545106	ENSG00000227676.3	LINC01068	9.93	3.55e-21	3.3e-18	0.5	0.42	Schizophrenia;	chr13:79404130	chr13:79566727~79571436:+
PRAD	cis	rs2282300	0.637	rs10767841	ENSG00000242353.1	RP4-710M3.1	-9.93	3.55e-21	3.3e-18	-0.44	-0.42	Morning vs. evening chronotype;	chr11:30406728	chr11:30368148~30368646:+
PRAD	cis	rs2282300	0.637	rs7942037	ENSG00000242353.1	RP4-710M3.1	-9.93	3.55e-21	3.3e-18	-0.44	-0.42	Morning vs. evening chronotype;	chr11:30408785	chr11:30368148~30368646:+
PRAD	cis	rs9545047	0.567	rs7321186	ENSG00000227676.3	LINC01068	9.93	3.56e-21	3.3e-18	0.51	0.42	Schizophrenia;	chr13:79383403	chr13:79566727~79571436:+
PRAD	cis	rs2282300	0.637	rs13642	ENSG00000242353.1	RP4-710M3.1	-9.93	3.57e-21	3.32e-18	-0.44	-0.42	Morning vs. evening chronotype;	chr11:30410673	chr11:30368148~30368646:+
PRAD	cis	rs7688540	0.771	rs6599318	ENSG00000275426.1	CH17-262A2.1	9.93	3.58e-21	3.32e-18	0.64	0.42	Facial morphology (factor 6, height of vermillion lower lip);	chr4:250179	chr4:149738~150317:+
PRAD	cis	rs7688540	0.771	rs74984113	ENSG00000275426.1	CH17-262A2.1	9.93	3.58e-21	3.32e-18	0.64	0.42	Facial morphology (factor 6, height of vermillion lower lip);	chr4:256733	chr4:149738~150317:+
PRAD	cis	rs2283792	0.765	rs2266966	ENSG00000224086.5	LL22NC03-86G7.1	-9.93	3.59e-21	3.34e-18	-0.5	-0.42	Multiple sclerosis;	chr22:21767265	chr22:21938293~21977632:+
PRAD	cis	rs1150668	0.699	rs13408	ENSG00000204709.4	LINC01556	9.93	3.6e-21	3.34e-18	0.53	0.42	Pubertal anthropometrics;	chr6:28244970	chr6:28943877~28944537:+
PRAD	cis	rs6822297	0.542	rs35499018	ENSG00000240005.4	RP11-293A21.1	-9.93	3.64e-21	3.38e-18	-0.46	-0.42	Obesity-related traits;	chr4:27004489	chr4:26859806~26860599:-
PRAD	cis	rs12049351	0.943	rs6678454	ENSG00000229367.1	HMGN2P19	-9.93	3.64e-21	3.38e-18	-0.56	-0.42	Circulating myeloperoxidase levels (plasma);	chr1:229582232	chr1:229570532~229570796:+
PRAD	cis	rs6539288	0.63	rs10778520	ENSG00000260329.1	RP11-412D9.4	9.93	3.69e-21	3.43e-18	0.36	0.42	Total body bone mineral density;	chr12:106971095	chr12:106954029~106955497:-
PRAD	cis	rs1555322	0.53	rs2250205	ENSG00000126005.14	MMP24-AS1	-9.93	3.71e-21	3.44e-18	-0.53	-0.42	Attention deficit hyperactivity disorder;	chr20:35280121	chr20:35216462~35278131:-
PRAD	cis	rs9487094	0.744	rs11964533	ENSG00000260273.1	RP11-425D10.10	9.93	3.72e-21	3.45e-18	0.62	0.42	Height;	chr6:109737797	chr6:109382795~109383666:+
PRAD	cis	rs10875746	0.859	rs12305511	ENSG00000240399.1	RP1-228P16.1	9.93	3.73e-21	3.46e-18	0.41	0.42	Longevity (90 years and older);	chr12:48188933	chr12:48054813~48055591:-
PRAD	cis	rs4964805	1	rs34307072	ENSG00000257681.1	RP11-341G23.4	9.93	3.73e-21	3.46e-18	0.41	0.42	Attention deficit hyperactivity disorder;	chr12:103802526	chr12:103746315~103768858:-
PRAD	cis	rs9322193	0.962	rs4870048	ENSG00000268592.3	RAET1E-AS1	9.93	3.76e-21	3.48e-18	0.58	0.42	Lung cancer;	chr6:149834324	chr6:149863494~149919507:+
PRAD	cis	rs7714584	1	rs11950957	ENSG00000197083.10	ZNF300P1	9.93	3.78e-21	3.5e-18	0.67	0.42	Crohn's disease;	chr5:150874352	chr5:150930645~150946289:-
PRAD	cis	rs7714584	0.793	rs11958146	ENSG00000197083.10	ZNF300P1	9.93	3.78e-21	3.5e-18	0.67	0.42	Crohn's disease;	chr5:150874596	chr5:150930645~150946289:-
PRAD	cis	rs7714584	1	rs10061105	ENSG00000197083.10	ZNF300P1	9.93	3.78e-21	3.5e-18	0.67	0.42	Crohn's disease;	chr5:150875623	chr5:150930645~150946289:-
PRAD	cis	rs7714584	1	rs6579803	ENSG00000197083.10	ZNF300P1	9.93	3.78e-21	3.5e-18	0.67	0.42	Crohn's disease;	chr5:150875997	chr5:150930645~150946289:-
PRAD	cis	rs7714584	1	rs6579804	ENSG00000197083.10	ZNF300P1	9.93	3.78e-21	3.5e-18	0.67	0.42	Crohn's disease;	chr5:150876369	chr5:150930645~150946289:-
PRAD	cis	rs9322193	1	rs9377229	ENSG00000223701.3	RAET1E-AS1	9.93	3.79e-21	3.51e-18	0.57	0.42	Lung cancer;	chr6:149607655	chr6:149884431~149919508:+
PRAD	cis	rs2882667	0.537	rs10057545	ENSG00000253404.1	AC034243.1	9.92	3.81e-21	3.53e-18	0.53	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139095319	chr5:138744434~138753309:-
PRAD	cis	rs1185460	1	rs1784305	ENSG00000271751.1	RP11-110I1.14	-9.92	3.84e-21	3.56e-18	-0.58	-0.42	Coronary artery disease;	chr11:119071338	chr11:119065263~119065677:-
PRAD	cis	rs67311347	1	rs9874499	ENSG00000223797.4	ENTPD3-AS1	9.92	3.87e-21	3.58e-18	0.38	0.42	Renal cell carcinoma;	chr3:40400417	chr3:40313802~40453329:-
PRAD	cis	rs2108622	0.527	rs67617968	ENSG00000267453.5	AC004791.2	-9.92	3.89e-21	3.6e-18	-0.54	-0.42	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866755	chr19:15851993~15864904:-
PRAD	cis	rs67311347	0.911	rs6775936	ENSG00000223797.4	ENTPD3-AS1	9.92	3.91e-21	3.61e-18	0.38	0.42	Renal cell carcinoma;	chr3:40335908	chr3:40313802~40453329:-
PRAD	cis	rs34779708	0.966	rs57081218	ENSG00000230534.5	RP11-297A16.2	9.92	3.93e-21	3.64e-18	0.54	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35145680	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.966	rs6481941	ENSG00000230534.5	RP11-297A16.2	9.92	3.93e-21	3.64e-18	0.54	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35151213	chr10:35098006~35127020:-
PRAD	cis	rs1075265	0.626	rs805320	ENSG00000233266.1	HMGB1P31	9.92	3.95e-21	3.65e-18	0.56	0.42	Chronotype;Morning vs. evening chronotype;	chr2:53911305	chr2:54051334~54051760:+
PRAD	cis	rs9918079	0.56	rs13147590	ENSG00000273133.1	RP11-799M12.2	9.92	3.95e-21	3.66e-18	0.53	0.42	Obesity-related traits;	chr4:15619565	chr4:15563698~15564253:-
PRAD	cis	rs2283792	0.74	rs8138075	ENSG00000224086.5	LL22NC03-86G7.1	-9.92	3.95e-21	3.66e-18	-0.5	-0.42	Multiple sclerosis;	chr22:21755092	chr22:21938293~21977632:+
PRAD	cis	rs5760092	0.627	rs6519489	ENSG00000235689.1	AP000351.13	-9.92	3.96e-21	3.66e-18	-0.61	-0.42	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919659	chr22:24006305~24008258:-
PRAD	cis	rs4820294	0.77	rs7285699	ENSG00000233360.4	Z83844.1	9.92	3.96e-21	3.67e-18	0.52	0.42	Fat distribution (HIV);	chr22:37670549	chr22:37641832~37658377:-
PRAD	cis	rs4423214	0.559	rs10898203	ENSG00000254682.1	RP11-660L16.2	-9.92	3.96e-21	3.67e-18	-0.7	-0.42	Vitamin D levels;	chr11:71492390	chr11:71448674~71452157:+
PRAD	cis	rs1075265	0.783	rs698858	ENSG00000233266.1	HMGB1P31	9.92	3.99e-21	3.69e-18	0.57	0.42	Chronotype;Morning vs. evening chronotype;	chr2:53943333	chr2:54051334~54051760:+
PRAD	cis	rs4964805	1	rs11111792	ENSG00000257681.1	RP11-341G23.4	9.92	4e-21	3.7e-18	0.41	0.42	Attention deficit hyperactivity disorder;	chr12:103801079	chr12:103746315~103768858:-
PRAD	cis	rs7688540	0.771	rs11248013	ENSG00000275426.1	CH17-262A2.1	9.92	4.01e-21	3.71e-18	0.67	0.42	Facial morphology (factor 6, height of vermillion lower lip);	chr4:317636	chr4:149738~150317:+
PRAD	cis	rs62103177	0.608	rs613847	ENSG00000261126.6	RP11-795F19.1	-9.92	4.01e-21	3.71e-18	-0.55	-0.42	Opioid sensitivity;	chr18:80087736	chr18:80046900~80095482:+
PRAD	cis	rs62103177	0.525	rs612913	ENSG00000261126.6	RP11-795F19.1	-9.92	4.01e-21	3.71e-18	-0.55	-0.42	Opioid sensitivity;	chr18:80087974	chr18:80046900~80095482:+
PRAD	cis	rs34779708	0.931	rs7923217	ENSG00000230534.5	RP11-297A16.2	9.92	4.01e-21	3.71e-18	0.54	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35020661	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.931	rs2384289	ENSG00000230534.5	RP11-297A16.2	9.92	4.01e-21	3.71e-18	0.54	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35054597	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.931	rs11010082	ENSG00000230534.5	RP11-297A16.2	9.92	4.01e-21	3.71e-18	0.54	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35062227	chr10:35098006~35127020:-
PRAD	cis	rs783540	0.521	rs1259176	ENSG00000255769.6	GOLGA2P10	9.92	4.04e-21	3.73e-18	0.56	0.42	Schizophrenia;	chr15:82602149	chr15:82472993~82513950:-
PRAD	cis	rs1075265	0.622	rs4671529	ENSG00000233266.1	HMGB1P31	9.92	4.05e-21	3.74e-18	0.58	0.42	Chronotype;Morning vs. evening chronotype;	chr2:53697167	chr2:54051334~54051760:+
PRAD	cis	rs2658782	0.724	rs2248655	ENSG00000279684.1	RP11-755E23.2	-9.92	4.06e-21	3.75e-18	-0.67	-0.42	Pulmonary function decline;	chr11:93521446	chr11:93286629~93288903:-
PRAD	cis	rs11690935	0.686	rs10165126	ENSG00000228389.1	AC068039.4	9.92	4.06e-21	3.75e-18	0.49	0.42	Schizophrenia;	chr2:171963793	chr2:171773482~171775844:+
PRAD	cis	rs10875746	0.859	rs11168371	ENSG00000240399.1	RP1-228P16.1	-9.92	4.06e-21	3.75e-18	-0.43	-0.42	Longevity (90 years and older);	chr12:48043903	chr12:48054813~48055591:-
PRAD	cis	rs853679	0.517	rs6932109	ENSG00000272009.1	RP1-313I6.12	9.92	4.07e-21	3.76e-18	0.43	0.42	Depression;	chr6:28110525	chr6:28078792~28081130:-
PRAD	cis	rs6504950	0.886	rs2787500	ENSG00000275710.1	RP11-257O5.4	-9.92	4.07e-21	3.76e-18	-0.53	-0.42	Breast cancer;	chr17:55092445	chr17:54964474~54964679:+
PRAD	cis	rs4500972	1	rs4500972	ENSG00000163016.8	ALMS1P	9.92	4.09e-21	3.77e-18	0.53	0.42	Glomerular filtration rate (creatinine);	chr2:73540770	chr2:73644919~73685576:+
PRAD	cis	rs4380275	0.782	rs4854369	ENSG00000223751.1	AC116609.2	9.92	4.12e-21	3.8e-18	0.55	0.42	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:752530	chr2:742488~747767:+
PRAD	cis	rs1858037	0.867	rs4671660	ENSG00000204929.10	AC074391.1	9.92	4.13e-21	3.8e-18	0.58	0.42	Rheumatoid arthritis;	chr2:65349302	chr2:65436711~66084639:+
PRAD	cis	rs507080	0.807	rs7926944	ENSG00000255422.1	AP002954.4	-9.91	4.15e-21	3.82e-18	-0.53	-0.42	Serum metabolite levels;	chr11:118689119	chr11:118704607~118750263:+
PRAD	cis	rs11951515	0.738	rs17244818	ENSG00000188850.9	RP11-159F24.2	-9.91	4.16e-21	3.83e-18	-0.5	-0.42	Metabolite levels  (X-11787);	chr5:43339433	chr5:43336164~43348716:+
PRAD	cis	rs3931020	0.688	rs525487	ENSG00000272864.1	RP11-17E13.2	9.91	4.16e-21	3.83e-18	0.5	0.42	Resistin levels;	chr1:74751736	chr1:74698769~74699333:-
PRAD	cis	rs9326248	0.53	rs7950364	ENSG00000254851.1	RP11-109L13.1	-9.91	4.18e-21	3.85e-18	-0.82	-0.42	Blood protein levels;	chr11:117028170	chr11:117135528~117138582:+
PRAD	cis	rs3096299	0.685	rs12935112	ENSG00000261118.1	RP11-104N10.1	-9.91	4.2e-21	3.87e-18	-0.4	-0.42	Multiple myeloma (IgH translocation);	chr16:89476450	chr16:89492017~89504460:-
PRAD	cis	rs4380275	0.782	rs11127506	ENSG00000272342.1	RP13-539J13.1	-9.91	4.21e-21	3.87e-18	-0.55	-0.42	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:751300	chr2:739588~740164:-
PRAD	cis	rs2282300	0.637	rs7941828	ENSG00000242353.1	RP4-710M3.1	-9.91	4.22e-21	3.88e-18	-0.44	-0.42	Morning vs. evening chronotype;	chr11:30408784	chr11:30368148~30368646:+
PRAD	cis	rs8062405	1	rs12325113	ENSG00000259982.1	CDC37P1	9.91	4.22e-21	3.89e-18	0.57	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28837347	chr16:28700294~28701540:-
PRAD	cis	rs56163509	1	rs56163509	ENSG00000259982.1	CDC37P1	9.91	4.22e-21	3.89e-18	0.57	0.42	Tonsillectomy;Mean corpuscular volume;	chr16:28853150	chr16:28700294~28701540:-
PRAD	cis	rs8062405	1	rs62037369	ENSG00000259982.1	CDC37P1	9.91	4.22e-21	3.89e-18	0.57	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28872520	chr16:28700294~28701540:-
PRAD	cis	rs8062405	0.965	rs7359397	ENSG00000259982.1	CDC37P1	9.91	4.22e-21	3.89e-18	0.57	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874338	chr16:28700294~28701540:-
PRAD	cis	rs11673344	0.864	rs55921822	ENSG00000226686.6	LINC01535	9.91	4.24e-21	3.9e-18	0.58	0.42	Obesity-related traits;	chr19:37005910	chr19:37251912~37265535:+
PRAD	cis	rs9481169	0.85	rs4947128	ENSG00000255389.1	C6orf3	-9.91	4.26e-21	3.92e-18	-0.78	-0.42	Inflammatory skin disease;	chr6:111597665	chr6:111599875~111602295:+
PRAD	cis	rs9309473	1	rs1114380	ENSG00000163016.8	ALMS1P	9.91	4.29e-21	3.95e-18	0.51	0.42	Metabolite levels;	chr2:73577581	chr2:73644919~73685576:+
PRAD	cis	rs2282300	0.739	rs1222208	ENSG00000242353.1	RP4-710M3.1	-9.91	4.3e-21	3.96e-18	-0.51	-0.42	Morning vs. evening chronotype;	chr11:30339830	chr11:30368148~30368646:+
PRAD	cis	rs8523	0.548	rs7773173	ENSG00000230314.5	ELOVL2-AS1	9.91	4.32e-21	3.98e-18	0.46	0.42	Red blood cell fatty acid levels;	chr6:10956470	chr6:11043524~11078226:+
PRAD	cis	rs507080	0.961	rs34413584	ENSG00000255422.1	AP002954.4	-9.91	4.33e-21	3.98e-18	-0.52	-0.42	Serum metabolite levels;	chr11:118675072	chr11:118704607~118750263:+
PRAD	cis	rs4718428	0.705	rs3800817	ENSG00000232546.1	RP11-458F8.1	-9.91	4.33e-21	3.98e-18	-0.34	-0.42	Corneal structure;	chr7:66798563	chr7:66848496~66858136:+
PRAD	cis	rs9545047	0.604	rs9530897	ENSG00000227676.3	LINC01068	9.91	4.39e-21	4.03e-18	0.49	0.42	Schizophrenia;	chr13:79336420	chr13:79566727~79571436:+
PRAD	cis	rs3096299	0.685	rs4785568	ENSG00000261118.1	RP11-104N10.1	9.9	4.5e-21	4.13e-18	0.4	0.42	Multiple myeloma (IgH translocation);	chr16:89487299	chr16:89492017~89504460:-
PRAD	cis	rs67311347	0.956	rs4974029	ENSG00000223797.4	ENTPD3-AS1	9.9	4.5e-21	4.13e-18	0.38	0.42	Renal cell carcinoma;	chr3:40479827	chr3:40313802~40453329:-
PRAD	cis	rs67311347	0.911	rs6776044	ENSG00000223797.4	ENTPD3-AS1	9.9	4.5e-21	4.13e-18	0.38	0.42	Renal cell carcinoma;	chr3:40336012	chr3:40313802~40453329:-
PRAD	cis	rs67311347	0.955	rs6764102	ENSG00000223797.4	ENTPD3-AS1	9.9	4.5e-21	4.13e-18	0.38	0.42	Renal cell carcinoma;	chr3:40336662	chr3:40313802~40453329:-
PRAD	cis	rs2348418	0.765	rs10843119	ENSG00000247934.4	RP11-967K21.1	-9.9	4.52e-21	4.15e-18	-0.39	-0.42	Lung function (FEV1);Lung function (FVC);	chr12:28164675	chr12:28163298~28190738:-
PRAD	cis	rs10246939	0.579	rs17133534	ENSG00000228775.6	WEE2-AS1	9.9	4.54e-21	4.17e-18	0.53	0.42	Bitter taste perception;	chr7:141860855	chr7:141704338~141738346:-
PRAD	cis	rs1075265	0.783	rs805439	ENSG00000233266.1	HMGB1P31	9.9	4.55e-21	4.18e-18	0.57	0.42	Chronotype;Morning vs. evening chronotype;	chr2:53829437	chr2:54051334~54051760:+
PRAD	cis	rs1061377	0.748	rs12642261	ENSG00000249207.1	RP11-360F5.1	-9.9	4.58e-21	4.2e-18	-0.44	-0.42	Uric acid levels;	chr4:39096278	chr4:39112677~39126818:-
PRAD	cis	rs7688540	0.771	rs17164747	ENSG00000275426.1	CH17-262A2.1	9.9	4.58e-21	4.2e-18	0.64	0.42	Facial morphology (factor 6, height of vermillion lower lip);	chr4:266798	chr4:149738~150317:+
PRAD	cis	rs7714584	1	rs7715981	ENSG00000197083.10	ZNF300P1	9.9	4.58e-21	4.2e-18	0.67	0.42	Crohn's disease;	chr5:150878545	chr5:150930645~150946289:-
PRAD	cis	rs7714584	1	rs7736554	ENSG00000197083.10	ZNF300P1	9.9	4.58e-21	4.2e-18	0.67	0.42	Crohn's disease;	chr5:150878746	chr5:150930645~150946289:-
PRAD	cis	rs7714584	1	rs7736873	ENSG00000197083.10	ZNF300P1	9.9	4.58e-21	4.2e-18	0.67	0.42	Crohn's disease;	chr5:150878920	chr5:150930645~150946289:-
PRAD	cis	rs7714584	1	rs7716903	ENSG00000197083.10	ZNF300P1	9.9	4.58e-21	4.2e-18	0.67	0.42	Crohn's disease;	chr5:150879012	chr5:150930645~150946289:-
PRAD	cis	rs7714584	1	rs11167518	ENSG00000197083.10	ZNF300P1	9.9	4.58e-21	4.2e-18	0.67	0.42	Crohn's disease;	chr5:150879358	chr5:150930645~150946289:-
PRAD	cis	rs7714584	1	rs10041072	ENSG00000197083.10	ZNF300P1	9.9	4.58e-21	4.2e-18	0.67	0.42	Crohn's disease;	chr5:150880080	chr5:150930645~150946289:-
PRAD	cis	rs7714584	1	rs1428552	ENSG00000197083.10	ZNF300P1	9.9	4.58e-21	4.2e-18	0.67	0.42	Crohn's disease;	chr5:150880269	chr5:150930645~150946289:-
PRAD	cis	rs7714584	1	rs10463310	ENSG00000197083.10	ZNF300P1	9.9	4.58e-21	4.2e-18	0.67	0.42	Crohn's disease;	chr5:150881343	chr5:150930645~150946289:-
PRAD	cis	rs7714584	1	rs73284126	ENSG00000197083.10	ZNF300P1	9.9	4.58e-21	4.2e-18	0.67	0.42	Crohn's disease;	chr5:150881745	chr5:150930645~150946289:-
PRAD	cis	rs7714584	1	rs7732945	ENSG00000197083.10	ZNF300P1	9.9	4.58e-21	4.2e-18	0.67	0.42	Crohn's disease;	chr5:150882039	chr5:150930645~150946289:-
PRAD	cis	rs7714584	1	rs1820682	ENSG00000197083.10	ZNF300P1	9.9	4.58e-21	4.2e-18	0.67	0.42	Crohn's disease;	chr5:150882580	chr5:150930645~150946289:-
PRAD	cis	rs7714584	1	rs4560537	ENSG00000197083.10	ZNF300P1	9.9	4.58e-21	4.2e-18	0.67	0.42	Crohn's disease;	chr5:150883024	chr5:150930645~150946289:-
PRAD	cis	rs7714584	1	rs11746108	ENSG00000197083.10	ZNF300P1	9.9	4.58e-21	4.2e-18	0.67	0.42	Crohn's disease;	chr5:150885060	chr5:150930645~150946289:-
PRAD	cis	rs7714584	1	rs11739619	ENSG00000197083.10	ZNF300P1	9.9	4.58e-21	4.2e-18	0.67	0.42	Crohn's disease;	chr5:150885100	chr5:150930645~150946289:-
PRAD	cis	rs7714584	1	rs11167519	ENSG00000197083.10	ZNF300P1	9.9	4.58e-21	4.2e-18	0.67	0.42	Crohn's disease;	chr5:150885845	chr5:150930645~150946289:-
PRAD	cis	rs7714584	1	rs11167520	ENSG00000197083.10	ZNF300P1	9.9	4.58e-21	4.2e-18	0.67	0.42	Crohn's disease;	chr5:150886077	chr5:150930645~150946289:-
PRAD	cis	rs7714584	1	rs73284141	ENSG00000197083.10	ZNF300P1	9.9	4.58e-21	4.2e-18	0.67	0.42	Crohn's disease;	chr5:150886524	chr5:150930645~150946289:-
PRAD	cis	rs7714584	1	rs3906527	ENSG00000197083.10	ZNF300P1	9.9	4.58e-21	4.2e-18	0.67	0.42	Crohn's disease;	chr5:150886830	chr5:150930645~150946289:-
PRAD	cis	rs7714584	1	rs2345001	ENSG00000197083.10	ZNF300P1	9.9	4.58e-21	4.2e-18	0.67	0.42	Crohn's disease;	chr5:150886956	chr5:150930645~150946289:-
PRAD	cis	rs7714584	1	rs3906528	ENSG00000197083.10	ZNF300P1	9.9	4.58e-21	4.2e-18	0.67	0.42	Crohn's disease;	chr5:150887156	chr5:150930645~150946289:-
PRAD	cis	rs7714584	1	rs2880791	ENSG00000197083.10	ZNF300P1	9.9	4.58e-21	4.2e-18	0.67	0.42	Crohn's disease;	chr5:150887814	chr5:150930645~150946289:-
PRAD	cis	rs7714584	1	rs3857422	ENSG00000197083.10	ZNF300P1	9.9	4.58e-21	4.2e-18	0.67	0.42	Crohn's disease;	chr5:150889047	chr5:150930645~150946289:-
PRAD	cis	rs7714584	0.59	rs4352593	ENSG00000197083.10	ZNF300P1	9.9	4.58e-21	4.2e-18	0.67	0.42	Crohn's disease;	chr5:150889770	chr5:150930645~150946289:-
PRAD	cis	rs7714584	1	rs7709464	ENSG00000197083.10	ZNF300P1	9.9	4.58e-21	4.2e-18	0.67	0.42	Crohn's disease;	chr5:150889879	chr5:150930645~150946289:-
PRAD	cis	rs7714584	1	rs10053750	ENSG00000197083.10	ZNF300P1	9.9	4.58e-21	4.2e-18	0.67	0.42	Crohn's disease;	chr5:150890489	chr5:150930645~150946289:-
PRAD	cis	rs7714584	1	rs7714584	ENSG00000197083.10	ZNF300P1	9.9	4.58e-21	4.2e-18	0.67	0.42	Crohn's disease;	chr5:150890858	chr5:150930645~150946289:-
PRAD	cis	rs7714584	1	rs6579806	ENSG00000197083.10	ZNF300P1	9.9	4.58e-21	4.2e-18	0.67	0.42	Crohn's disease;	chr5:150891522	chr5:150930645~150946289:-
PRAD	cis	rs7714584	1	rs4958848	ENSG00000197083.10	ZNF300P1	9.9	4.58e-21	4.2e-18	0.67	0.42	Crohn's disease;	chr5:150891560	chr5:150930645~150946289:-
PRAD	cis	rs7714584	1	rs11167521	ENSG00000197083.10	ZNF300P1	9.9	4.58e-21	4.2e-18	0.67	0.42	Crohn's disease;	chr5:150892223	chr5:150930645~150946289:-
PRAD	cis	rs7714584	1	rs10057988	ENSG00000197083.10	ZNF300P1	9.9	4.58e-21	4.2e-18	0.67	0.42	Crohn's disease;	chr5:150892500	chr5:150930645~150946289:-
PRAD	cis	rs7714584	1	rs10052606	ENSG00000197083.10	ZNF300P1	9.9	4.58e-21	4.2e-18	0.67	0.42	Crohn's disease;	chr5:150892655	chr5:150930645~150946289:-
PRAD	cis	rs7714584	1	rs57001853	ENSG00000197083.10	ZNF300P1	9.9	4.58e-21	4.2e-18	0.67	0.42	Crohn's disease;	chr5:150892890	chr5:150930645~150946289:-
PRAD	cis	rs7714584	1	rs2217266	ENSG00000197083.10	ZNF300P1	9.9	4.58e-21	4.2e-18	0.67	0.42	Crohn's disease;	chr5:150893059	chr5:150930645~150946289:-
PRAD	cis	rs8072100	0.738	rs9900123	ENSG00000228782.6	CTD-2026D20.3	9.9	4.6e-21	4.22e-18	0.47	0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47471689	chr17:47450568~47492492:-
PRAD	cis	rs507080	0.845	rs667982	ENSG00000255422.1	AP002954.4	-9.9	4.61e-21	4.23e-18	-0.51	-0.42	Serum metabolite levels;	chr11:118692058	chr11:118704607~118750263:+
PRAD	cis	rs8072100	0.738	rs9895509	ENSG00000228782.6	CTD-2026D20.3	-9.9	4.63e-21	4.25e-18	-0.47	-0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47472252	chr17:47450568~47492492:-
PRAD	cis	rs1930961	0.702	rs8141065	ENSG00000100058.11	CRYBB2P1	-9.9	4.64e-21	4.25e-18	-0.79	-0.42	Bipolar disorder with mood-incongruent psychosis;	chr22:25489221	chr22:25448105~25520854:+
PRAD	cis	rs67311347	1	rs7642906	ENSG00000223797.4	ENTPD3-AS1	-9.9	4.65e-21	4.26e-18	-0.37	-0.42	Renal cell carcinoma;	chr3:40451142	chr3:40313802~40453329:-
PRAD	cis	rs8072100	0.807	rs4561509	ENSG00000228782.6	CTD-2026D20.3	9.9	4.7e-21	4.3e-18	0.47	0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47704433	chr17:47450568~47492492:-
PRAD	cis	rs67311347	1	rs4973898	ENSG00000223797.4	ENTPD3-AS1	-9.9	4.73e-21	4.34e-18	-0.37	-0.42	Renal cell carcinoma;	chr3:40418041	chr3:40313802~40453329:-
PRAD	cis	rs12049351	0.665	rs12044993	ENSG00000229367.1	HMGN2P19	9.9	4.73e-21	4.34e-18	0.68	0.42	Circulating myeloperoxidase levels (plasma);	chr1:229457578	chr1:229570532~229570796:+
PRAD	cis	rs7849270	0.879	rs7046990	ENSG00000268707.1	RP11-247A12.7	-9.9	4.77e-21	4.37e-18	-0.48	-0.42	Blood metabolite ratios;	chr9:129093859	chr9:129170434~129170940:+
PRAD	cis	rs62355901	0.609	rs66893416	ENSG00000271828.1	CTD-2310F14.1	9.9	4.77e-21	4.37e-18	0.75	0.42	Breast cancer;	chr5:56755769	chr5:56927874~56929573:+
PRAD	cis	rs507080	0.922	rs12788848	ENSG00000255422.1	AP002954.4	-9.9	4.77e-21	4.37e-18	-0.51	-0.42	Serum metabolite levels;	chr11:118683079	chr11:118704607~118750263:+
PRAD	cis	rs507080	0.922	rs4474473	ENSG00000255422.1	AP002954.4	-9.9	4.77e-21	4.37e-18	-0.51	-0.42	Serum metabolite levels;	chr11:118683180	chr11:118704607~118750263:+
PRAD	cis	rs507080	0.922	rs12796373	ENSG00000255422.1	AP002954.4	-9.9	4.77e-21	4.37e-18	-0.51	-0.42	Serum metabolite levels;	chr11:118684230	chr11:118704607~118750263:+
PRAD	cis	rs1075265	0.84	rs2884254	ENSG00000233266.1	HMGB1P31	9.9	4.8e-21	4.39e-18	0.56	0.42	Chronotype;Morning vs. evening chronotype;	chr2:53979326	chr2:54051334~54051760:+
PRAD	cis	rs67311347	0.868	rs10865895	ENSG00000223797.4	ENTPD3-AS1	9.9	4.81e-21	4.4e-18	0.38	0.42	Renal cell carcinoma;	chr3:40337186	chr3:40313802~40453329:-
PRAD	cis	rs9309473	0.95	rs6745480	ENSG00000163016.8	ALMS1P	9.9	4.82e-21	4.42e-18	0.52	0.42	Metabolite levels;	chr2:73612928	chr2:73644919~73685576:+
PRAD	cis	rs9309473	1	rs10496193	ENSG00000163016.8	ALMS1P	9.9	4.83e-21	4.42e-18	0.52	0.42	Metabolite levels;	chr2:73546376	chr2:73644919~73685576:+
PRAD	cis	rs1075265	0.756	rs809280	ENSG00000233266.1	HMGB1P31	9.9	4.84e-21	4.43e-18	0.56	0.42	Chronotype;Morning vs. evening chronotype;	chr2:53921270	chr2:54051334~54051760:+
PRAD	cis	rs7714584	1	rs12054923	ENSG00000197083.10	ZNF300P1	9.9	4.86e-21	4.44e-18	0.68	0.42	Crohn's disease;	chr5:150869497	chr5:150930645~150946289:-
PRAD	cis	rs7714584	1	rs77698001	ENSG00000197083.10	ZNF300P1	9.9	4.86e-21	4.44e-18	0.68	0.42	Crohn's disease;	chr5:150870805	chr5:150930645~150946289:-
PRAD	cis	rs507080	0.885	rs533144	ENSG00000255422.1	AP002954.4	-9.9	4.86e-21	4.45e-18	-0.52	-0.42	Serum metabolite levels;	chr11:118688538	chr11:118704607~118750263:+
PRAD	cis	rs507080	0.883	rs12798453	ENSG00000255422.1	AP002954.4	-9.9	4.86e-21	4.45e-18	-0.52	-0.42	Serum metabolite levels;	chr11:118690701	chr11:118704607~118750263:+
PRAD	cis	rs9309473	1	rs13383871	ENSG00000163016.8	ALMS1P	9.9	4.87e-21	4.45e-18	0.52	0.42	Metabolite levels;	chr2:73404651	chr2:73644919~73685576:+
PRAD	cis	rs1891275	0.515	rs1080496	ENSG00000228701.1	TNKS2-AS1	9.89	4.88e-21	4.46e-18	0.52	0.42	Intelligence (multi-trait analysis);	chr10:91684505	chr10:91782839~91798291:-
PRAD	cis	rs7849270	1	rs1107328	ENSG00000268707.1	RP11-247A12.7	9.89	4.88e-21	4.46e-18	0.49	0.42	Blood metabolite ratios;	chr9:129155255	chr9:129170434~129170940:+
PRAD	cis	rs67311347	0.955	rs4974067	ENSG00000223797.4	ENTPD3-AS1	9.89	4.91e-21	4.49e-18	0.38	0.42	Renal cell carcinoma;	chr3:40333060	chr3:40313802~40453329:-
PRAD	cis	rs9322193	0.923	rs1984111	ENSG00000268592.3	RAET1E-AS1	9.89	4.91e-21	4.49e-18	0.57	0.42	Lung cancer;	chr6:149831720	chr6:149863494~149919507:+
PRAD	cis	rs858239	0.932	rs1637190	ENSG00000226816.2	AC005082.12	9.89	4.93e-21	4.51e-18	0.48	0.42	Cerebrospinal fluid biomarker levels;	chr7:23229446	chr7:23206013~23208045:+
PRAD	cis	rs507080	0.922	rs471227	ENSG00000255422.1	AP002954.4	-9.89	4.98e-21	4.55e-18	-0.52	-0.42	Serum metabolite levels;	chr11:118693892	chr11:118704607~118750263:+
PRAD	cis	rs507080	0.922	rs516153	ENSG00000255422.1	AP002954.4	-9.89	4.98e-21	4.55e-18	-0.52	-0.42	Serum metabolite levels;	chr11:118694053	chr11:118704607~118750263:+
PRAD	cis	rs507080	0.922	rs518028	ENSG00000255422.1	AP002954.4	-9.89	4.98e-21	4.55e-18	-0.52	-0.42	Serum metabolite levels;	chr11:118694273	chr11:118704607~118750263:+
PRAD	cis	rs507080	0.922	rs519982	ENSG00000255422.1	AP002954.4	-9.89	4.98e-21	4.55e-18	-0.52	-0.42	Serum metabolite levels;	chr11:118694522	chr11:118704607~118750263:+
PRAD	cis	rs507080	0.922	rs502601	ENSG00000255422.1	AP002954.4	-9.89	4.98e-21	4.55e-18	-0.52	-0.42	Serum metabolite levels;	chr11:118694970	chr11:118704607~118750263:+
PRAD	cis	rs11118620	0.853	rs11118622	ENSG00000272823.1	RP11-295M18.6	9.89	4.99e-21	4.56e-18	0.53	0.42	Heart failure;	chr1:220868833	chr1:220828676~220829211:-
PRAD	cis	rs507080	0.922	rs558781	ENSG00000255422.1	AP002954.4	-9.89	4.99e-21	4.56e-18	-0.52	-0.42	Serum metabolite levels;	chr11:118693688	chr11:118704607~118750263:+
PRAD	cis	rs7849270	0.879	rs10760587	ENSG00000268707.1	RP11-247A12.7	9.89	5e-21	4.57e-18	0.47	0.42	Blood metabolite ratios;	chr9:129083737	chr9:129170434~129170940:+
PRAD	cis	rs9322193	0.962	rs1889473	ENSG00000268592.3	RAET1E-AS1	9.89	5.06e-21	4.63e-18	0.57	0.42	Lung cancer;	chr6:149825485	chr6:149863494~149919507:+
PRAD	cis	rs67311347	0.955	rs9821036	ENSG00000223797.4	ENTPD3-AS1	9.89	5.09e-21	4.65e-18	0.38	0.42	Renal cell carcinoma;	chr3:40337516	chr3:40313802~40453329:-
PRAD	cis	rs8062405	0.755	rs1074631	ENSG00000259982.1	CDC37P1	-9.89	5.15e-21	4.7e-18	-0.56	-0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28542787	chr16:28700294~28701540:-
PRAD	cis	rs9326248	0.53	rs2000615	ENSG00000254851.1	RP11-109L13.1	-9.89	5.17e-21	4.72e-18	-0.81	-0.42	Blood protein levels;	chr11:117045103	chr11:117135528~117138582:+
PRAD	cis	rs9326248	0.53	rs6589589	ENSG00000254851.1	RP11-109L13.1	-9.89	5.17e-21	4.72e-18	-0.81	-0.42	Blood protein levels;	chr11:117061712	chr11:117135528~117138582:+
PRAD	cis	rs9326248	0.53	rs2513093	ENSG00000254851.1	RP11-109L13.1	-9.89	5.2e-21	4.75e-18	-0.82	-0.42	Blood protein levels;	chr11:116935971	chr11:117135528~117138582:+
PRAD	cis	rs6539288	0.677	rs10735418	ENSG00000260329.1	RP11-412D9.4	-9.89	5.24e-21	4.78e-18	-0.37	-0.42	Total body bone mineral density;	chr12:106949598	chr12:106954029~106955497:-
PRAD	cis	rs12049351	0.507	rs11803533	ENSG00000229367.1	HMGN2P19	9.89	5.25e-21	4.79e-18	0.61	0.42	Circulating myeloperoxidase levels (plasma);	chr1:229432885	chr1:229570532~229570796:+
PRAD	cis	rs12049351	0.665	rs7534252	ENSG00000229367.1	HMGN2P19	9.89	5.25e-21	4.79e-18	0.61	0.42	Circulating myeloperoxidase levels (plasma);	chr1:229433845	chr1:229570532~229570796:+
PRAD	cis	rs4380275	0.782	rs4335978	ENSG00000272342.1	RP13-539J13.1	9.88	5.31e-21	4.84e-18	0.55	0.42	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:750078	chr2:739588~740164:-
PRAD	cis	rs9309473	0.851	rs6546850	ENSG00000163016.8	ALMS1P	9.88	5.32e-21	4.85e-18	0.52	0.42	Metabolite levels;	chr2:73604020	chr2:73644919~73685576:+
PRAD	cis	rs9309473	0.898	rs6546852	ENSG00000163016.8	ALMS1P	9.88	5.32e-21	4.85e-18	0.52	0.42	Metabolite levels;	chr2:73606304	chr2:73644919~73685576:+
PRAD	cis	rs9309473	0.95	rs6546853	ENSG00000163016.8	ALMS1P	9.88	5.32e-21	4.85e-18	0.52	0.42	Metabolite levels;	chr2:73606612	chr2:73644919~73685576:+
PRAD	cis	rs11673344	0.864	rs703537	ENSG00000226686.6	LINC01535	9.88	5.34e-21	4.86e-18	0.57	0.42	Obesity-related traits;	chr19:37016827	chr19:37251912~37265535:+
PRAD	cis	rs9545047	0.604	rs9545085	ENSG00000227676.3	LINC01068	9.88	5.35e-21	4.88e-18	0.5	0.42	Schizophrenia;	chr13:79363969	chr13:79566727~79571436:+
PRAD	cis	rs4964805	0.537	rs11111750	ENSG00000257681.1	RP11-341G23.4	9.88	5.36e-21	4.89e-18	0.39	0.42	Attention deficit hyperactivity disorder;	chr12:103761762	chr12:103746315~103768858:-
PRAD	cis	rs7849270	1	rs2541164	ENSG00000268707.1	RP11-247A12.7	-9.88	5.36e-21	4.89e-18	-0.49	-0.42	Blood metabolite ratios;	chr9:129114629	chr9:129170434~129170940:+
PRAD	cis	rs7615952	0.932	rs13321217	ENSG00000171084.14	FAM86JP	9.88	5.39e-21	4.91e-18	0.7	0.42	Blood pressure (smoking interaction);	chr3:125912928	chr3:125916620~125930024:+
PRAD	cis	rs8100891	0.734	rs8104048	ENSG00000267213.4	AC007773.2	-9.88	5.39e-21	4.91e-18	-0.44	-0.42	Neuroticism;	chr19:32338400	chr19:32390050~32405560:-
PRAD	cis	rs67311347	0.956	rs13066971	ENSG00000223797.4	ENTPD3-AS1	-9.88	5.45e-21	4.96e-18	-0.37	-0.42	Renal cell carcinoma;	chr3:40421019	chr3:40313802~40453329:-
PRAD	cis	rs62103177	0.608	rs551643	ENSG00000261126.6	RP11-795F19.1	-9.88	5.45e-21	4.96e-18	-0.55	-0.42	Opioid sensitivity;	chr18:80081068	chr18:80046900~80095482:+
PRAD	cis	rs9309473	0.95	rs6546854	ENSG00000163016.8	ALMS1P	9.88	5.45e-21	4.97e-18	0.51	0.42	Metabolite levels;	chr2:73606907	chr2:73644919~73685576:+
PRAD	cis	rs507080	0.922	rs7114458	ENSG00000255422.1	AP002954.4	-9.88	5.51e-21	5.02e-18	-0.52	-0.42	Serum metabolite levels;	chr11:118695466	chr11:118704607~118750263:+
PRAD	cis	rs507080	0.922	rs7114216	ENSG00000255422.1	AP002954.4	-9.88	5.51e-21	5.02e-18	-0.52	-0.42	Serum metabolite levels;	chr11:118695525	chr11:118704607~118750263:+
PRAD	cis	rs507080	0.922	rs533646	ENSG00000255422.1	AP002954.4	-9.88	5.51e-21	5.02e-18	-0.52	-0.42	Serum metabolite levels;	chr11:118696037	chr11:118704607~118750263:+
PRAD	cis	rs507080	0.922	rs519848	ENSG00000255422.1	AP002954.4	-9.88	5.52e-21	5.02e-18	-0.51	-0.42	Serum metabolite levels;	chr11:118682006	chr11:118704607~118750263:+
PRAD	cis	rs7849270	1	rs7021449	ENSG00000268707.1	RP11-247A12.7	-9.88	5.52e-21	5.02e-18	-0.47	-0.42	Blood metabolite ratios;	chr9:129137033	chr9:129170434~129170940:+
PRAD	cis	rs7849270	1	rs713219	ENSG00000268707.1	RP11-247A12.7	-9.88	5.52e-21	5.02e-18	-0.47	-0.42	Blood metabolite ratios;	chr9:129138641	chr9:129170434~129170940:+
PRAD	cis	rs507080	0.922	rs625513	ENSG00000255422.1	AP002954.4	-9.88	5.52e-21	5.03e-18	-0.52	-0.42	Serum metabolite levels;	chr11:118685010	chr11:118704607~118750263:+
PRAD	cis	rs2739330	0.929	rs5751777	ENSG00000235689.1	AP000351.13	9.88	5.53e-21	5.03e-18	0.51	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:24006305~24008258:-
PRAD	cis	rs3096299	0.563	rs4600467	ENSG00000261118.1	RP11-104N10.1	9.88	5.57e-21	5.07e-18	0.4	0.42	Multiple myeloma (IgH translocation);	chr16:89496108	chr16:89492017~89504460:-
PRAD	cis	rs9545047	0.541	rs36152718	ENSG00000227676.3	LINC01068	9.88	5.6e-21	5.09e-18	0.51	0.42	Schizophrenia;	chr13:79306069	chr13:79566727~79571436:+
PRAD	cis	rs853679	0.517	rs1340004	ENSG00000219392.1	RP1-265C24.5	-9.88	5.62e-21	5.11e-18	-0.55	-0.42	Depression;	chr6:28135913	chr6:28115628~28116551:+
PRAD	cis	rs507080	0.922	rs525485	ENSG00000255422.1	AP002954.4	-9.88	5.62e-21	5.11e-18	-0.52	-0.42	Serum metabolite levels;	chr11:118685045	chr11:118704607~118750263:+
PRAD	cis	rs10246939	0.579	rs6969430	ENSG00000228775.6	WEE2-AS1	9.88	5.62e-21	5.11e-18	0.52	0.42	Bitter taste perception;	chr7:141831340	chr7:141704338~141738346:-
PRAD	cis	rs6061231	1	rs11908473	ENSG00000273619.1	RP5-908M14.9	-9.88	5.63e-21	5.12e-18	-0.28	-0.42	Colorectal cancer;	chr20:62382714	chr20:62386303~62386970:-
PRAD	cis	rs2153535	0.585	rs9505512	ENSG00000230939.1	RP11-314C16.1	-9.88	5.64e-21	5.13e-18	-0.52	-0.42	Motion sickness;	chr6:8667337	chr6:8784178~8785445:+
PRAD	cis	rs8062405	0.691	rs11646653	ENSG00000251417.2	RP11-1348G14.4	9.88	5.67e-21	5.16e-18	0.48	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910828	chr16:28802743~28817828:+
PRAD	cis	rs34779708	0.931	rs10508815	ENSG00000230534.5	RP11-297A16.2	9.88	5.68e-21	5.16e-18	0.55	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35043693	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.931	rs6481935	ENSG00000230534.5	RP11-297A16.2	9.88	5.68e-21	5.16e-18	0.55	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35054031	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.931	rs12242882	ENSG00000230534.5	RP11-297A16.2	9.88	5.68e-21	5.16e-18	0.55	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35058932	chr10:35098006~35127020:-
PRAD	cis	rs673078	0.66	rs11068891	ENSG00000275759.1	RP11-131L12.3	9.88	5.7e-21	5.18e-18	0.59	0.42	Glucose homeostasis traits;	chr12:118259814	chr12:118428281~118428870:+
PRAD	cis	rs507080	0.922	rs582630	ENSG00000255422.1	AP002954.4	-9.88	5.7e-21	5.18e-18	-0.52	-0.42	Serum metabolite levels;	chr11:118692090	chr11:118704607~118750263:+
PRAD	cis	rs507080	0.883	rs527475	ENSG00000255422.1	AP002954.4	-9.88	5.7e-21	5.18e-18	-0.52	-0.42	Serum metabolite levels;	chr11:118692530	chr11:118704607~118750263:+
PRAD	cis	rs2337406	0.636	rs74090069	ENSG00000274576.2	IGHV2-70	-9.88	5.7e-21	5.18e-18	-0.45	-0.42	Alzheimer's disease (late onset);	chr14:106777532	chr14:106770577~106771020:-
PRAD	cis	rs2337406	0.866	rs74090071	ENSG00000274576.2	IGHV2-70	-9.88	5.7e-21	5.18e-18	-0.45	-0.42	Alzheimer's disease (late onset);	chr14:106777533	chr14:106770577~106771020:-
PRAD	cis	rs7714584	1	rs11951694	ENSG00000197083.10	ZNF300P1	9.88	5.74e-21	5.22e-18	0.67	0.42	Crohn's disease;	chr5:150874776	chr5:150930645~150946289:-
PRAD	cis	rs7714584	1	rs11955172	ENSG00000197083.10	ZNF300P1	9.88	5.74e-21	5.22e-18	0.67	0.42	Crohn's disease;	chr5:150874816	chr5:150930645~150946289:-
PRAD	cis	rs7714584	0.793	rs11955174	ENSG00000197083.10	ZNF300P1	9.88	5.74e-21	5.22e-18	0.67	0.42	Crohn's disease;	chr5:150874829	chr5:150930645~150946289:-
PRAD	cis	rs507080	0.922	rs585039	ENSG00000255422.1	AP002954.4	-9.87	5.75e-21	5.23e-18	-0.52	-0.42	Serum metabolite levels;	chr11:118692672	chr11:118704607~118750263:+
PRAD	cis	rs858239	0.669	rs1618339	ENSG00000226816.2	AC005082.12	9.87	5.76e-21	5.23e-18	0.49	0.42	Cerebrospinal fluid biomarker levels;	chr7:23190155	chr7:23206013~23208045:+
PRAD	cis	rs9309473	0.95	rs6546858	ENSG00000163016.8	ALMS1P	9.87	5.77e-21	5.24e-18	0.52	0.42	Metabolite levels;	chr2:73611486	chr2:73644919~73685576:+
PRAD	cis	rs9309473	0.948	rs2421577	ENSG00000163016.8	ALMS1P	9.87	5.77e-21	5.24e-18	0.52	0.42	Metabolite levels;	chr2:73613871	chr2:73644919~73685576:+
PRAD	cis	rs9545047	0.604	rs7986306	ENSG00000227676.3	LINC01068	9.87	5.77e-21	5.24e-18	0.5	0.42	Schizophrenia;	chr13:79392530	chr13:79566727~79571436:+
PRAD	cis	rs172166	0.538	rs1150686	ENSG00000204709.4	LINC01556	9.87	5.78e-21	5.25e-18	0.52	0.42	Cardiac Troponin-T levels;	chr6:28193493	chr6:28943877~28944537:+
PRAD	cis	rs1150688	1	rs1150688	ENSG00000204709.4	LINC01556	9.87	5.78e-21	5.25e-18	0.52	0.42	Autism spectrum disorder or schizophrenia;	chr6:28195002	chr6:28943877~28944537:+
PRAD	cis	rs2404602	1	rs12594212	ENSG00000259422.1	RP11-593F23.1	9.87	5.84e-21	5.3e-18	0.52	0.42	Blood metabolite levels;	chr15:76509673	chr15:76174891~76181486:-
PRAD	cis	rs3931020	0.657	rs277369	ENSG00000272864.1	RP11-17E13.2	9.87	5.86e-21	5.32e-18	0.49	0.42	Resistin levels;	chr1:74768977	chr1:74698769~74699333:-
PRAD	cis	rs6538678	0.824	rs7307510	ENSG00000258343.1	RP11-536G4.2	-9.87	5.9e-21	5.35e-18	-0.61	-0.42	Lupus nephritis in systemic lupus erythematosus;	chr12:95843792	chr12:95795345~95858839:-
PRAD	cis	rs71403859	0.502	rs8053720	ENSG00000260886.1	TAT-AS1	9.87	6e-21	5.44e-18	0.69	0.42	Post bronchodilator FEV1;	chr16:71422239	chr16:71565789~71578187:+
PRAD	cis	rs10800713	0.954	rs6427835	ENSG00000260088.1	RP11-92G12.3	-9.87	6e-21	5.45e-18	-0.61	-0.42	Tandem gait;	chr1:200591725	chr1:200669507~200694250:+
PRAD	cis	rs62103177	0.608	rs34383580	ENSG00000261126.6	RP11-795F19.1	-9.87	6.02e-21	5.46e-18	-0.55	-0.42	Opioid sensitivity;	chr18:80074960	chr18:80046900~80095482:+
PRAD	cis	rs7811142	0.83	rs6979910	ENSG00000242294.5	STAG3L5P	9.87	6.03e-21	5.47e-18	0.27	0.42	Platelet count;	chr7:100343007	chr7:100336079~100351900:+
PRAD	cis	rs8062405	0.698	rs10499	ENSG00000259982.1	CDC37P1	-9.87	6.06e-21	5.49e-18	-0.59	-0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28904206	chr16:28700294~28701540:-
PRAD	cis	rs4879677	1	rs10968050	ENSG00000260390.1	RP11-575I8.1	-9.87	6.08e-21	5.51e-18	-0.56	-0.42	Gut microbiome composition (summer and winter);	chr9:27677633	chr9:27829276~27844481:+
PRAD	cis	rs9309473	0.95	rs7566364	ENSG00000163016.8	ALMS1P	9.87	6.08e-21	5.51e-18	0.52	0.42	Metabolite levels;	chr2:73615762	chr2:73644919~73685576:+
PRAD	cis	rs7849270	1	rs7855278	ENSG00000268707.1	RP11-247A12.7	9.87	6.1e-21	5.53e-18	0.48	0.42	Blood metabolite ratios;	chr9:129159086	chr9:129170434~129170940:+
PRAD	cis	rs2348418	0.765	rs10843120	ENSG00000247934.4	RP11-967K21.1	-9.87	6.15e-21	5.56e-18	-0.39	-0.42	Lung function (FEV1);Lung function (FVC);	chr12:28165881	chr12:28163298~28190738:-
PRAD	cis	rs3002131	0.604	rs3008644	ENSG00000225265.1	TAF1A-AS1	-9.87	6.16e-21	5.58e-18	-0.74	-0.42	Interleukin-10 levels;	chr1:222577402	chr1:222589825~222593032:+
PRAD	cis	rs507080	0.922	rs508640	ENSG00000255422.1	AP002954.4	-9.87	6.16e-21	5.58e-18	-0.52	-0.42	Serum metabolite levels;	chr11:118693704	chr11:118704607~118750263:+
PRAD	cis	rs9322193	0.962	rs6903998	ENSG00000268592.3	RAET1E-AS1	9.87	6.17e-21	5.58e-18	0.57	0.42	Lung cancer;	chr6:149831357	chr6:149863494~149919507:+
PRAD	cis	rs4964805	1	rs4964806	ENSG00000257681.1	RP11-341G23.4	9.87	6.18e-21	5.59e-18	0.41	0.42	Attention deficit hyperactivity disorder;	chr12:103798982	chr12:103746315~103768858:-
PRAD	cis	rs4964805	1	rs4964794	ENSG00000257681.1	RP11-341G23.4	9.87	6.18e-21	5.59e-18	0.41	0.42	Attention deficit hyperactivity disorder;	chr12:103800640	chr12:103746315~103768858:-
PRAD	cis	rs1075265	0.756	rs805423	ENSG00000233266.1	HMGB1P31	9.87	6.21e-21	5.62e-18	0.56	0.42	Chronotype;Morning vs. evening chronotype;	chr2:53899904	chr2:54051334~54051760:+
PRAD	cis	rs6452524	0.935	rs6868416	ENSG00000249664.1	CTD-2227C6.2	9.87	6.22e-21	5.62e-18	0.49	0.42	Hypertension (SNP x SNP interaction);	chr5:83084320	chr5:83012285~83013109:-
PRAD	cis	rs6452524	0.935	rs1478485	ENSG00000249664.1	CTD-2227C6.2	9.87	6.22e-21	5.62e-18	0.49	0.42	Hypertension (SNP x SNP interaction);	chr5:83084708	chr5:83012285~83013109:-
PRAD	cis	rs9309473	0.948	rs7566385	ENSG00000163016.8	ALMS1P	9.87	6.23e-21	5.63e-18	0.52	0.42	Metabolite levels;	chr2:73529690	chr2:73644919~73685576:+
PRAD	cis	rs9309473	1	rs6755217	ENSG00000163016.8	ALMS1P	9.87	6.23e-21	5.63e-18	0.54	0.42	Metabolite levels;	chr2:73414157	chr2:73644919~73685576:+
PRAD	cis	rs1858037	0.867	rs876933	ENSG00000204929.10	AC074391.1	9.86	6.25e-21	5.66e-18	0.57	0.42	Rheumatoid arthritis;	chr2:65382303	chr2:65436711~66084639:+
PRAD	cis	rs732716	0.785	rs56272533	ENSG00000267980.1	AC007292.6	-9.86	6.27e-21	5.67e-18	-0.44	-0.42	Mean corpuscular volume;	chr19:4420045	chr19:4363789~4364640:+
PRAD	cis	rs2739330	0.703	rs5760112	ENSG00000206090.4	AP000350.7	9.86	6.29e-21	5.69e-18	0.53	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23939998~23942798:+
PRAD	cis	rs2153535	0.609	rs2146159	ENSG00000230939.1	RP11-314C16.1	-9.86	6.29e-21	5.69e-18	-0.52	-0.42	Motion sickness;	chr6:8667222	chr6:8784178~8785445:+
PRAD	cis	rs17023223	0.537	rs61319010	ENSG00000231365.4	RP11-418J17.1	-9.86	6.4e-21	5.79e-18	-0.44	-0.42	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119200388	chr1:119140396~119275973:+
PRAD	cis	rs62103177	0.608	rs8088089	ENSG00000261126.6	RP11-795F19.1	-9.86	6.42e-21	5.8e-18	-0.55	-0.42	Opioid sensitivity;	chr18:80073851	chr18:80046900~80095482:+
PRAD	cis	rs11118620	0.81	rs1603047	ENSG00000238078.1	LINC01352	9.86	6.45e-21	5.82e-18	0.57	0.42	Heart failure;	chr1:220849953	chr1:220829255~220832429:+
PRAD	cis	rs11118620	1	rs11118620	ENSG00000238078.1	LINC01352	9.86	6.45e-21	5.82e-18	0.57	0.42	Heart failure;	chr1:220855166	chr1:220829255~220832429:+
PRAD	cis	rs8072100	0.713	rs8075058	ENSG00000228782.6	CTD-2026D20.3	9.86	6.46e-21	5.83e-18	0.46	0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47405491	chr17:47450568~47492492:-
PRAD	cis	rs8072100	0.713	rs11651643	ENSG00000228782.6	CTD-2026D20.3	9.86	6.46e-21	5.83e-18	0.46	0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47405863	chr17:47450568~47492492:-
PRAD	cis	rs6539288	0.677	rs7315989	ENSG00000260329.1	RP11-412D9.4	-9.86	6.54e-21	5.9e-18	-0.37	-0.42	Total body bone mineral density;	chr12:106946010	chr12:106954029~106955497:-
PRAD	cis	rs6539288	0.641	rs12318060	ENSG00000260329.1	RP11-412D9.4	-9.86	6.54e-21	5.9e-18	-0.37	-0.42	Total body bone mineral density;	chr12:106946834	chr12:106954029~106955497:-
PRAD	cis	rs2153535	0.585	rs9379238	ENSG00000230939.1	RP11-314C16.1	-9.86	6.55e-21	5.91e-18	-0.52	-0.42	Motion sickness;	chr6:8667806	chr6:8784178~8785445:+
PRAD	cis	rs853679	0.517	rs9393884	ENSG00000272009.1	RP1-313I6.12	-9.86	6.57e-21	5.93e-18	-0.43	-0.42	Depression;	chr6:28079011	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs9393887	ENSG00000272009.1	RP1-313I6.12	-9.86	6.57e-21	5.93e-18	-0.43	-0.42	Depression;	chr6:28091242	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.542	rs9393892	ENSG00000272009.1	RP1-313I6.12	-9.86	6.57e-21	5.93e-18	-0.43	-0.42	Depression;	chr6:28113616	chr6:28078792~28081130:-
PRAD	cis	rs507080	0.885	rs693037	ENSG00000255422.1	AP002954.4	-9.86	6.6e-21	5.95e-18	-0.52	-0.42	Serum metabolite levels;	chr11:118682617	chr11:118704607~118750263:+
PRAD	cis	rs507080	0.922	rs546890	ENSG00000255422.1	AP002954.4	-9.86	6.6e-21	5.95e-18	-0.52	-0.42	Serum metabolite levels;	chr11:118686489	chr11:118704607~118750263:+
PRAD	cis	rs507080	0.883	rs693306	ENSG00000255422.1	AP002954.4	-9.86	6.6e-21	5.95e-18	-0.52	-0.42	Serum metabolite levels;	chr11:118687624	chr11:118704607~118750263:+
PRAD	cis	rs507080	0.922	rs561845	ENSG00000255422.1	AP002954.4	-9.86	6.6e-21	5.95e-18	-0.52	-0.42	Serum metabolite levels;	chr11:118688118	chr11:118704607~118750263:+
PRAD	cis	rs507080	0.922	rs638805	ENSG00000255422.1	AP002954.4	-9.86	6.6e-21	5.95e-18	-0.52	-0.42	Serum metabolite levels;	chr11:118688180	chr11:118704607~118750263:+
PRAD	cis	rs507080	0.845	rs510408	ENSG00000255422.1	AP002954.4	-9.86	6.6e-21	5.95e-18	-0.52	-0.42	Serum metabolite levels;	chr11:118688192	chr11:118704607~118750263:+
PRAD	cis	rs507080	0.845	rs509641	ENSG00000255422.1	AP002954.4	-9.86	6.6e-21	5.95e-18	-0.52	-0.42	Serum metabolite levels;	chr11:118688243	chr11:118704607~118750263:+
PRAD	cis	rs507080	0.883	rs563549	ENSG00000255422.1	AP002954.4	-9.86	6.6e-21	5.95e-18	-0.52	-0.42	Serum metabolite levels;	chr11:118688244	chr11:118704607~118750263:+
PRAD	cis	rs507080	0.885	rs7926959	ENSG00000255422.1	AP002954.4	-9.86	6.6e-21	5.95e-18	-0.52	-0.42	Serum metabolite levels;	chr11:118689157	chr11:118704607~118750263:+
PRAD	cis	rs507080	0.663	rs7926970	ENSG00000255422.1	AP002954.4	-9.86	6.6e-21	5.95e-18	-0.52	-0.42	Serum metabolite levels;	chr11:118689172	chr11:118704607~118750263:+
PRAD	cis	rs7743045	0.504	rs10499090	ENSG00000253194.1	RP11-351A11.1	9.86	6.61e-21	5.96e-18	0.54	0.42	Mean platelet volume;	chr6:119000386	chr6:118934785~119031541:+
PRAD	cis	rs2739330	0.828	rs2877178	ENSG00000099984.9	GSTT2	-9.86	6.64e-21	5.99e-18	-0.56	-0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23980123~23983911:+
PRAD	cis	rs2739330	0.828	rs2154593	ENSG00000099984.9	GSTT2	-9.86	6.64e-21	5.99e-18	-0.56	-0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23980123~23983911:+
PRAD	cis	rs12049351	0.665	rs11809370	ENSG00000229367.1	HMGN2P19	9.86	6.66e-21	6e-18	0.6	0.42	Circulating myeloperoxidase levels (plasma);	chr1:229451386	chr1:229570532~229570796:+
PRAD	cis	rs4964805	1	rs4964805	ENSG00000257681.1	RP11-341G23.4	9.86	6.72e-21	6.05e-18	0.41	0.42	Attention deficit hyperactivity disorder;	chr12:103799046	chr12:103746315~103768858:-
PRAD	cis	rs2337406	0.866	rs4280141	ENSG00000274576.2	IGHV2-70	9.86	6.75e-21	6.08e-18	0.42	0.42	Alzheimer's disease (late onset);	chr14:106780476	chr14:106770577~106771020:-
PRAD	cis	rs1075265	0.605	rs805418	ENSG00000233266.1	HMGB1P31	9.85	6.77e-21	6.1e-18	0.55	0.42	Chronotype;Morning vs. evening chronotype;	chr2:53898634	chr2:54051334~54051760:+
PRAD	cis	rs2404602	1	rs12443137	ENSG00000259422.1	RP11-593F23.1	9.85	6.79e-21	6.11e-18	0.52	0.42	Blood metabolite levels;	chr15:76548491	chr15:76174891~76181486:-
PRAD	cis	rs2404602	1	rs12594541	ENSG00000259422.1	RP11-593F23.1	9.85	6.82e-21	6.14e-18	0.52	0.42	Blood metabolite levels;	chr15:76542027	chr15:76174891~76181486:-
PRAD	cis	rs7772486	0.875	rs854146	ENSG00000235652.6	RP11-545I5.3	9.85	6.84e-21	6.16e-18	0.43	0.42	Lobe attachment (rater-scored or self-reported);	chr6:146019897	chr6:145799409~145886585:+
PRAD	cis	rs4879677	1	rs10125353	ENSG00000260390.1	RP11-575I8.1	9.85	6.85e-21	6.16e-18	0.55	0.42	Gut microbiome composition (summer and winter);	chr9:27677546	chr9:27829276~27844481:+
PRAD	cis	rs10129255	0.536	rs10139058	ENSG00000223648.3	IGHV3-64	9.85	6.87e-21	6.18e-18	0.38	0.42	Kawasaki disease;	chr14:106685899	chr14:106643132~106658258:-
PRAD	cis	rs10129255	0.536	rs8004835	ENSG00000223648.3	IGHV3-64	9.85	6.87e-21	6.18e-18	0.38	0.42	Kawasaki disease;	chr14:106686361	chr14:106643132~106658258:-
PRAD	cis	rs2933343	0.951	rs7648327	ENSG00000261159.1	RP11-723O4.9	9.85	6.88e-21	6.19e-18	0.39	0.42	IgG glycosylation;	chr3:128851865	chr3:128859716~128860526:-
PRAD	cis	rs1062177	0.855	rs919263	ENSG00000253921.1	CTB-113P19.3	-9.85	6.92e-21	6.23e-18	-0.55	-0.42	Preschool internalizing problems;	chr5:151886292	chr5:151753992~151767247:+
PRAD	cis	rs4718428	0.705	rs3800817	ENSG00000273142.1	RP11-458F8.4	-9.85	6.95e-21	6.25e-18	-0.32	-0.42	Corneal structure;	chr7:66798563	chr7:66902857~66906297:+
PRAD	cis	rs7714584	1	rs7732643	ENSG00000197083.10	ZNF300P1	9.85	6.96e-21	6.26e-18	0.66	0.42	Crohn's disease;	chr5:150881874	chr5:150930645~150946289:-
PRAD	cis	rs7714584	1	rs2344181	ENSG00000197083.10	ZNF300P1	9.85	6.96e-21	6.26e-18	0.66	0.42	Crohn's disease;	chr5:150883012	chr5:150930645~150946289:-
PRAD	cis	rs7714584	1	rs2344180	ENSG00000197083.10	ZNF300P1	9.85	6.96e-21	6.26e-18	0.66	0.42	Crohn's disease;	chr5:150887795	chr5:150930645~150946289:-
PRAD	cis	rs7714584	1	rs1863998	ENSG00000197083.10	ZNF300P1	9.85	6.96e-21	6.26e-18	0.66	0.42	Crohn's disease;	chr5:150892191	chr5:150930645~150946289:-
PRAD	cis	rs9545047	0.604	rs1856997	ENSG00000227676.3	LINC01068	9.85	6.97e-21	6.27e-18	0.51	0.42	Schizophrenia;	chr13:79287487	chr13:79566727~79571436:+
PRAD	cis	rs5760092	0.755	rs915589	ENSG00000218537.1	MIF-AS1	-9.85	7e-21	6.29e-18	-0.68	-0.42	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23894426~23898930:-
PRAD	cis	rs3931020	0.688	rs277375	ENSG00000272864.1	RP11-17E13.2	-9.85	7.05e-21	6.34e-18	-0.49	-0.42	Resistin levels;	chr1:74738459	chr1:74698769~74699333:-
PRAD	cis	rs3762637	0.941	rs28679619	ENSG00000272758.4	RP11-299J3.8	-9.85	7.05e-21	6.34e-18	-0.63	-0.42	LDL cholesterol levels;	chr3:122381502	chr3:122416207~122443180:+
PRAD	cis	rs3931020	0.688	rs452242	ENSG00000272864.1	RP11-17E13.2	9.85	7.05e-21	6.34e-18	0.5	0.42	Resistin levels;	chr1:74759941	chr1:74698769~74699333:-
PRAD	cis	rs1075265	0.756	rs805367	ENSG00000233266.1	HMGB1P31	9.85	7.08e-21	6.37e-18	0.57	0.42	Chronotype;Morning vs. evening chronotype;	chr2:53943956	chr2:54051334~54051760:+
PRAD	cis	rs2564921	0.73	rs58492539	ENSG00000242142.1	SERBP1P3	-9.85	7.1e-21	6.38e-18	-0.49	-0.42	Height;	chr3:53052712	chr3:53064283~53065091:-
PRAD	cis	rs638893	0.717	rs622690	ENSG00000278376.1	RP11-158I9.8	-9.85	7.1e-21	6.38e-18	-0.49	-0.42	Vitiligo;	chr11:118833556	chr11:118791254~118793137:+
PRAD	cis	rs4423214	0.592	rs10898223	ENSG00000254682.1	RP11-660L16.2	-9.85	7.13e-21	6.41e-18	-0.68	-0.42	Vitamin D levels;	chr11:71508218	chr11:71448674~71452157:+
PRAD	cis	rs1075265	0.575	rs2692531	ENSG00000233266.1	HMGB1P31	9.85	7.13e-21	6.41e-18	0.57	0.42	Chronotype;Morning vs. evening chronotype;	chr2:53776640	chr2:54051334~54051760:+
PRAD	cis	rs34779708	0.931	rs11010077	ENSG00000230534.5	RP11-297A16.2	-9.85	7.15e-21	6.43e-18	-0.54	-0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35039160	chr10:35098006~35127020:-
PRAD	cis	rs801193	0.569	rs7782587	ENSG00000237310.1	GS1-124K5.4	9.85	7.15e-21	6.43e-18	0.39	0.42	Aortic root size;	chr7:66701485	chr7:66493706~66495474:+
PRAD	cis	rs2906856	0.921	rs1019076	ENSG00000255733.4	IFNG-AS1	-9.85	7.23e-21	6.5e-18	-0.43	-0.42	Mosquito bite size;	chr12:68004338	chr12:67989445~68234686:+
PRAD	cis	rs34779708	0.931	rs35388511	ENSG00000230534.5	RP11-297A16.2	9.85	7.26e-21	6.52e-18	0.56	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35007688	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.931	rs34815241	ENSG00000230534.5	RP11-297A16.2	9.85	7.26e-21	6.52e-18	0.56	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35007748	chr10:35098006~35127020:-
PRAD	cis	rs62229266	0.647	rs59397717	ENSG00000231106.2	LINC01436	9.85	7.28e-21	6.54e-18	0.55	0.42	Mitral valve prolapse;	chr21:36079427	chr21:36005338~36007838:+
PRAD	cis	rs2564921	0.73	rs1811351	ENSG00000242142.1	SERBP1P3	-9.85	7.3e-21	6.56e-18	-0.49	-0.42	Height;	chr3:53064759	chr3:53064283~53065091:-
PRAD	cis	rs12049351	0.612	rs10916485	ENSG00000229367.1	HMGN2P19	9.85	7.33e-21	6.59e-18	0.62	0.42	Circulating myeloperoxidase levels (plasma);	chr1:229468942	chr1:229570532~229570796:+
PRAD	cis	rs10246939	0.579	rs13232651	ENSG00000228775.6	WEE2-AS1	9.84	7.36e-21	6.61e-18	0.53	0.42	Bitter taste perception;	chr7:141862624	chr7:141704338~141738346:-
PRAD	cis	rs3096299	0.685	rs4238830	ENSG00000261118.1	RP11-104N10.1	9.84	7.38e-21	6.63e-18	0.4	0.42	Multiple myeloma (IgH translocation);	chr16:89473833	chr16:89492017~89504460:-
PRAD	cis	rs8072100	0.713	rs4968228	ENSG00000228782.6	CTD-2026D20.3	9.84	7.38e-21	6.63e-18	0.47	0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47420182	chr17:47450568~47492492:-
PRAD	cis	rs62355902	1	rs62355902	ENSG00000271828.1	CTD-2310F14.1	9.84	7.38e-21	6.63e-18	0.75	0.42	Breast cancer;Breast cancer (estrogen-receptor negative);	chr5:56757896	chr5:56927874~56929573:+
PRAD	cis	rs4964805	0.865	rs11111796	ENSG00000257681.1	RP11-341G23.4	9.84	7.41e-21	6.65e-18	0.42	0.42	Attention deficit hyperactivity disorder;	chr12:103812150	chr12:103746315~103768858:-
PRAD	cis	rs67311347	0.956	rs7640228	ENSG00000223797.4	ENTPD3-AS1	-9.84	7.43e-21	6.67e-18	-0.38	-0.42	Renal cell carcinoma;	chr3:40474699	chr3:40313802~40453329:-
PRAD	cis	rs783540	0.5	rs7163840	ENSG00000276710.3	CSPG4P8	9.84	7.44e-21	6.67e-18	0.5	0.42	Schizophrenia;	chr15:82729551	chr15:82459472~82477258:+
PRAD	cis	rs6142102	0.961	rs4911405	ENSG00000276073.1	RP5-1125A11.7	-9.84	7.44e-21	6.68e-18	-0.44	-0.42	Skin pigmentation;	chr20:34087161	chr20:33985617~33988989:-
PRAD	cis	rs9309473	1	rs11899740	ENSG00000163016.8	ALMS1P	9.84	7.45e-21	6.69e-18	0.53	0.42	Metabolite levels;	chr2:73404084	chr2:73644919~73685576:+
PRAD	cis	rs10129255	0.5	rs2027903	ENSG00000223648.3	IGHV3-64	9.84	7.47e-21	6.7e-18	0.37	0.42	Kawasaki disease;	chr14:106807047	chr14:106643132~106658258:-
PRAD	cis	rs8072100	0.512	rs3809863	ENSG00000228782.6	CTD-2026D20.3	9.84	7.47e-21	6.7e-18	0.47	0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47307646	chr17:47450568~47492492:-
PRAD	cis	rs10875746	0.768	rs4760676	ENSG00000240399.1	RP1-228P16.1	-9.84	7.51e-21	6.74e-18	-0.4	-0.42	Longevity (90 years and older);	chr12:48027880	chr12:48054813~48055591:-
PRAD	cis	rs3931020	0.688	rs277374	ENSG00000272864.1	RP11-17E13.2	9.84	7.53e-21	6.76e-18	0.5	0.42	Resistin levels;	chr1:74734802	chr1:74698769~74699333:-
PRAD	cis	rs7772486	0.597	rs9285508	ENSG00000235652.6	RP11-545I5.3	-9.84	7.54e-21	6.76e-18	-0.51	-0.42	Lobe attachment (rater-scored or self-reported);	chr6:145941561	chr6:145799409~145886585:+
PRAD	cis	rs1858037	0.836	rs2576923	ENSG00000204929.10	AC074391.1	-9.84	7.55e-21	6.77e-18	-0.57	-0.42	Rheumatoid arthritis;	chr2:65406750	chr2:65436711~66084639:+
PRAD	cis	rs34779708	0.931	rs12767414	ENSG00000230534.5	RP11-297A16.2	9.84	7.58e-21	6.8e-18	0.54	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35101265	chr10:35098006~35127020:-
PRAD	cis	rs507080	0.961	rs1784298	ENSG00000255422.1	AP002954.4	-9.84	7.61e-21	6.82e-18	-0.51	-0.42	Serum metabolite levels;	chr11:118677956	chr11:118704607~118750263:+
PRAD	cis	rs507080	0.961	rs4938522	ENSG00000255422.1	AP002954.4	-9.84	7.61e-21	6.82e-18	-0.51	-0.42	Serum metabolite levels;	chr11:118677962	chr11:118704607~118750263:+
PRAD	cis	rs507080	1	rs659969	ENSG00000255422.1	AP002954.4	-9.84	7.61e-21	6.82e-18	-0.51	-0.42	Serum metabolite levels;	chr11:118679094	chr11:118704607~118750263:+
PRAD	cis	rs34375054	0.526	rs34764657	ENSG00000279233.1	RP11-158L12.4	9.84	7.61e-21	6.83e-18	0.42	0.42	Post bronchodilator FEV1/FVC ratio;	chr12:125195093	chr12:125138245~125141711:+
PRAD	cis	rs3002131	0.688	rs2936040	ENSG00000225265.1	TAF1A-AS1	-9.84	7.68e-21	6.89e-18	-0.71	-0.42	Interleukin-10 levels;	chr1:222590319	chr1:222589825~222593032:+
PRAD	cis	rs1858037	0.765	rs67404371	ENSG00000204929.10	AC074391.1	9.84	7.69e-21	6.89e-18	0.58	0.42	Rheumatoid arthritis;	chr2:65370137	chr2:65436711~66084639:+
PRAD	cis	rs7811142	0.775	rs1059129	ENSG00000242294.5	STAG3L5P	9.84	7.71e-21	6.91e-18	0.27	0.42	Platelet count;	chr7:100328899	chr7:100336079~100351900:+
PRAD	cis	rs7811142	0.562	rs7786844	ENSG00000242294.5	STAG3L5P	9.84	7.71e-21	6.91e-18	0.27	0.42	Platelet count;	chr7:100336385	chr7:100336079~100351900:+
PRAD	cis	rs7811142	0.667	rs3873746	ENSG00000242294.5	STAG3L5P	9.84	7.71e-21	6.91e-18	0.27	0.42	Platelet count;	chr7:100337474	chr7:100336079~100351900:+
PRAD	cis	rs1062177	0.855	rs919262	ENSG00000253921.1	CTB-113P19.3	9.84	7.71e-21	6.91e-18	0.55	0.42	Preschool internalizing problems;	chr5:151886523	chr5:151753992~151767247:+
PRAD	cis	rs9545047	0.604	rs9318634	ENSG00000227676.3	LINC01068	-9.84	7.71e-21	6.92e-18	-0.5	-0.42	Schizophrenia;	chr13:79369303	chr13:79566727~79571436:+
PRAD	cis	rs6452524	0.935	rs11750799	ENSG00000249664.1	CTD-2227C6.2	9.84	7.72e-21	6.92e-18	0.49	0.42	Hypertension (SNP x SNP interaction);	chr5:83082983	chr5:83012285~83013109:-
PRAD	cis	rs9322193	0.566	rs5024811	ENSG00000268592.3	RAET1E-AS1	-9.84	7.73e-21	6.92e-18	-0.63	-0.42	Lung cancer;	chr6:149924898	chr6:149863494~149919507:+
PRAD	cis	rs9545047	0.604	rs7319212	ENSG00000227676.3	LINC01068	-9.84	7.74e-21	6.93e-18	-0.5	-0.42	Schizophrenia;	chr13:79365404	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs7319252	ENSG00000227676.3	LINC01068	-9.84	7.74e-21	6.93e-18	-0.5	-0.42	Schizophrenia;	chr13:79365471	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs9318633	ENSG00000227676.3	LINC01068	-9.84	7.74e-21	6.93e-18	-0.5	-0.42	Schizophrenia;	chr13:79369113	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs12872328	ENSG00000227676.3	LINC01068	-9.84	7.74e-21	6.93e-18	-0.5	-0.42	Schizophrenia;	chr13:79370489	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs2182010	ENSG00000227676.3	LINC01068	-9.84	7.74e-21	6.93e-18	-0.5	-0.42	Schizophrenia;	chr13:79370618	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs35476664	ENSG00000227676.3	LINC01068	-9.84	7.74e-21	6.93e-18	-0.5	-0.42	Schizophrenia;	chr13:79375462	chr13:79566727~79571436:+
PRAD	cis	rs2282300	0.589	rs1717776	ENSG00000242353.1	RP4-710M3.1	-9.84	7.74e-21	6.94e-18	-0.44	-0.42	Morning vs. evening chronotype;	chr11:30394229	chr11:30368148~30368646:+
PRAD	cis	rs9545047	0.604	rs9574416	ENSG00000227676.3	LINC01068	-9.84	7.75e-21	6.95e-18	-0.49	-0.42	Schizophrenia;	chr13:79388577	chr13:79566727~79571436:+
PRAD	cis	rs34779708	0.75	rs35032841	ENSG00000230534.5	RP11-297A16.2	9.84	7.77e-21	6.96e-18	0.56	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35023759	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.742	rs35912711	ENSG00000230534.5	RP11-297A16.2	9.84	7.77e-21	6.96e-18	0.56	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35024068	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.931	rs4934702	ENSG00000230534.5	RP11-297A16.2	9.84	7.77e-21	6.96e-18	0.56	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35034146	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.931	rs4934731	ENSG00000230534.5	RP11-297A16.2	9.84	7.78e-21	6.97e-18	0.54	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35142708	chr10:35098006~35127020:-
PRAD	cis	rs8072100	0.676	rs9908049	ENSG00000228782.6	CTD-2026D20.3	9.84	7.79e-21	6.98e-18	0.47	0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47424730	chr17:47450568~47492492:-
PRAD	cis	rs8070463	0.515	rs11655943	ENSG00000228782.6	CTD-2026D20.3	9.84	7.81e-21	7e-18	0.46	0.42	Multiple sclerosis;Ankylosing spondylitis;	chr17:47308274	chr17:47450568~47492492:-
PRAD	cis	rs10800713	0.954	rs6667081	ENSG00000260088.1	RP11-92G12.3	-9.84	7.82e-21	7.01e-18	-0.61	-0.42	Tandem gait;	chr1:200593366	chr1:200669507~200694250:+
PRAD	cis	rs10800713	0.954	rs6673474	ENSG00000260088.1	RP11-92G12.3	-9.84	7.82e-21	7.01e-18	-0.61	-0.42	Tandem gait;	chr1:200594991	chr1:200669507~200694250:+
PRAD	cis	rs172166	0.516	rs2791333	ENSG00000204709.4	LINC01556	9.84	7.83e-21	7.01e-18	0.52	0.42	Cardiac Troponin-T levels;	chr6:28143336	chr6:28943877~28944537:+
PRAD	cis	rs4423214	0.559	rs10898201	ENSG00000254682.1	RP11-660L16.2	-9.84	7.83e-21	7.01e-18	-0.69	-0.42	Vitamin D levels;	chr11:71490481	chr11:71448674~71452157:+
PRAD	cis	rs17023223	0.537	rs12092807	ENSG00000231365.4	RP11-418J17.1	9.84	7.83e-21	7.01e-18	0.47	0.42	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119208021	chr1:119140396~119275973:+
PRAD	cis	rs507080	0.961	rs4938523	ENSG00000255422.1	AP002954.4	-9.84	7.83e-21	7.01e-18	-0.51	-0.42	Serum metabolite levels;	chr11:118678129	chr11:118704607~118750263:+
PRAD	cis	rs4380275	0.782	rs4854369	ENSG00000272342.1	RP13-539J13.1	9.84	7.87e-21	7.05e-18	0.55	0.42	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:752530	chr2:739588~740164:-
PRAD	cis	rs2564921	0.73	rs2564939	ENSG00000242142.1	SERBP1P3	9.84	7.89e-21	7.06e-18	0.49	0.42	Height;	chr3:53072864	chr3:53064283~53065091:-
PRAD	cis	rs17459044	1	rs17459044	ENSG00000268707.1	RP11-247A12.7	-9.84	7.9e-21	7.07e-18	-0.48	-0.42	Pelvic organ prolapse (moderate/severe);	chr9:129091345	chr9:129170434~129170940:+
PRAD	cis	rs2739330	0.828	rs2186366	ENSG00000099984.9	GSTT2	9.84	7.94e-21	7.1e-18	0.56	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23980123~23983911:+
PRAD	cis	rs7772486	0.875	rs1331644	ENSG00000235652.6	RP11-545I5.3	9.84	7.97e-21	7.13e-18	0.43	0.42	Lobe attachment (rater-scored or self-reported);	chr6:146077524	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.875	rs11755334	ENSG00000235652.6	RP11-545I5.3	9.84	7.97e-21	7.13e-18	0.43	0.42	Lobe attachment (rater-scored or self-reported);	chr6:146078161	chr6:145799409~145886585:+
PRAD	cis	rs1075265	0.584	rs10164409	ENSG00000233266.1	HMGB1P31	9.83	8e-21	7.16e-18	0.56	0.42	Chronotype;Morning vs. evening chronotype;	chr2:53940867	chr2:54051334~54051760:+
PRAD	cis	rs6921919	0.638	rs9468344	ENSG00000216901.1	AL022393.7	9.83	8.01e-21	7.16e-18	0.56	0.42	Autism spectrum disorder or schizophrenia;	chr6:28341792	chr6:28176188~28176674:+
PRAD	cis	rs2348418	0.733	rs4931728	ENSG00000247934.4	RP11-967K21.1	-9.83	8.01e-21	7.16e-18	-0.4	-0.42	Lung function (FEV1);Lung function (FVC);	chr12:28146215	chr12:28163298~28190738:-
PRAD	cis	rs11951515	0.7	rs4443426	ENSG00000188850.9	RP11-159F24.2	9.83	8.06e-21	7.2e-18	0.5	0.42	Metabolite levels  (X-11787);	chr5:43279470	chr5:43336164~43348716:+
PRAD	cis	rs9545047	0.519	rs8001281	ENSG00000227676.3	LINC01068	9.83	8.1e-21	7.24e-18	0.49	0.42	Schizophrenia;	chr13:79410707	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.511	rs1624537	ENSG00000227676.3	LINC01068	9.83	8.1e-21	7.24e-18	0.49	0.42	Schizophrenia;	chr13:79411686	chr13:79566727~79571436:+
PRAD	cis	rs67311347	0.869	rs9832311	ENSG00000223797.4	ENTPD3-AS1	9.83	8.11e-21	7.24e-18	0.37	0.42	Renal cell carcinoma;	chr3:40339831	chr3:40313802~40453329:-
PRAD	cis	rs4380275	0.782	rs4468850	ENSG00000223751.1	AC116609.2	9.83	8.12e-21	7.25e-18	0.54	0.42	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:749467	chr2:742488~747767:+
PRAD	cis	rs6570726	0.791	rs6570692	ENSG00000235652.6	RP11-545I5.3	9.83	8.12e-21	7.26e-18	0.44	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145583265	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.791	rs6902410	ENSG00000235652.6	RP11-545I5.3	9.83	8.12e-21	7.26e-18	0.44	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145584125	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.791	rs9322029	ENSG00000235652.6	RP11-545I5.3	9.83	8.12e-21	7.26e-18	0.44	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145585547	chr6:145799409~145886585:+
PRAD	cis	rs10800713	0.954	rs6660637	ENSG00000260088.1	RP11-92G12.3	-9.83	8.13e-21	7.26e-18	-0.61	-0.42	Tandem gait;	chr1:200550893	chr1:200669507~200694250:+
PRAD	cis	rs10800713	0.954	rs10737572	ENSG00000260088.1	RP11-92G12.3	-9.83	8.13e-21	7.26e-18	-0.61	-0.42	Tandem gait;	chr1:200552003	chr1:200669507~200694250:+
PRAD	cis	rs10800713	0.862	rs7533417	ENSG00000260088.1	RP11-92G12.3	-9.83	8.13e-21	7.26e-18	-0.61	-0.42	Tandem gait;	chr1:200558177	chr1:200669507~200694250:+
PRAD	cis	rs6570726	0.818	rs9390338	ENSG00000235652.6	RP11-545I5.3	9.83	8.15e-21	7.28e-18	0.44	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145587129	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.791	rs6570693	ENSG00000235652.6	RP11-545I5.3	9.83	8.15e-21	7.28e-18	0.44	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145589705	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.791	rs6570694	ENSG00000235652.6	RP11-545I5.3	9.83	8.15e-21	7.28e-18	0.44	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145590068	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.791	rs6570695	ENSG00000235652.6	RP11-545I5.3	9.83	8.15e-21	7.28e-18	0.44	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145590150	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.764	rs9386125	ENSG00000235652.6	RP11-545I5.3	9.83	8.15e-21	7.28e-18	0.44	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145590541	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.791	rs9373466	ENSG00000235652.6	RP11-545I5.3	9.83	8.15e-21	7.28e-18	0.44	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145590880	chr6:145799409~145886585:+
PRAD	cis	rs7569084	0.663	rs10190233	ENSG00000204929.10	AC074391.1	-9.83	8.16e-21	7.29e-18	-0.56	-0.42	Sum eosinophil basophil counts;	chr2:65413095	chr2:65436711~66084639:+
PRAD	cis	rs6570726	0.791	rs9403730	ENSG00000235652.6	RP11-545I5.3	9.83	8.19e-21	7.32e-18	0.44	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145586097	chr6:145799409~145886585:+
PRAD	cis	rs2658782	0.724	rs2658770	ENSG00000279684.1	RP11-755E23.2	-9.83	8.2e-21	7.32e-18	-0.67	-0.42	Pulmonary function decline;	chr11:93528720	chr11:93286629~93288903:-
PRAD	cis	rs2404602	1	rs2056544	ENSG00000259422.1	RP11-593F23.1	9.83	8.25e-21	7.36e-18	0.52	0.42	Blood metabolite levels;	chr15:76533662	chr15:76174891~76181486:-
PRAD	cis	rs5760092	0.755	rs915589	ENSG00000235689.1	AP000351.13	-9.83	8.27e-21	7.38e-18	-0.61	-0.42	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:24006305~24008258:-
PRAD	cis	rs9545047	0.567	rs2296287	ENSG00000227676.3	LINC01068	9.83	8.28e-21	7.39e-18	0.49	0.42	Schizophrenia;	chr13:79407045	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs1748761	ENSG00000227676.3	LINC01068	9.83	8.28e-21	7.39e-18	0.49	0.42	Schizophrenia;	chr13:79407491	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs2763809	ENSG00000227676.3	LINC01068	9.83	8.28e-21	7.39e-18	0.49	0.42	Schizophrenia;	chr13:79407544	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs1748762	ENSG00000227676.3	LINC01068	9.83	8.28e-21	7.39e-18	0.49	0.42	Schizophrenia;	chr13:79407914	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs1748763	ENSG00000227676.3	LINC01068	9.83	8.28e-21	7.39e-18	0.49	0.42	Schizophrenia;	chr13:79407965	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs912639	ENSG00000227676.3	LINC01068	-9.83	8.28e-21	7.39e-18	-0.49	-0.42	Schizophrenia;	chr13:79409788	chr13:79566727~79571436:+
PRAD	cis	rs853679	0.517	rs9380047	ENSG00000272009.1	RP1-313I6.12	-9.83	8.29e-21	7.4e-18	-0.43	-0.42	Depression;	chr6:28070115	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs7755442	ENSG00000272009.1	RP1-313I6.12	-9.83	8.29e-21	7.4e-18	-0.43	-0.42	Depression;	chr6:28071237	chr6:28078792~28081130:-
PRAD	cis	rs3002131	0.562	rs2173401	ENSG00000225265.1	TAF1A-AS1	-9.83	8.31e-21	7.42e-18	-0.74	-0.42	Interleukin-10 levels;	chr1:222575992	chr1:222589825~222593032:+
PRAD	cis	rs1061377	0.748	rs11096977	ENSG00000249207.1	RP11-360F5.1	-9.83	8.31e-21	7.42e-18	-0.44	-0.42	Uric acid levels;	chr4:39106186	chr4:39112677~39126818:-
PRAD	cis	rs1061377	0.748	rs6810770	ENSG00000249207.1	RP11-360F5.1	-9.83	8.31e-21	7.42e-18	-0.44	-0.42	Uric acid levels;	chr4:39106545	chr4:39112677~39126818:-
PRAD	cis	rs507080	0.845	rs613377	ENSG00000255422.1	AP002954.4	-9.83	8.31e-21	7.42e-18	-0.52	-0.42	Serum metabolite levels;	chr11:118685375	chr11:118704607~118750263:+
PRAD	cis	rs1075265	0.59	rs810909	ENSG00000233266.1	HMGB1P31	9.83	8.36e-21	7.46e-18	0.55	0.42	Chronotype;Morning vs. evening chronotype;	chr2:53846034	chr2:54051334~54051760:+
PRAD	cis	rs889312	0.504	rs62355900	ENSG00000271828.1	CTD-2310F14.1	9.83	8.37e-21	7.47e-18	0.75	0.42	Breast cancer (early onset);Breast cancer;	chr5:56756868	chr5:56927874~56929573:+
PRAD	cis	rs853679	0.517	rs4713135	ENSG00000272009.1	RP1-313I6.12	-9.83	8.45e-21	7.53e-18	-0.43	-0.42	Depression;	chr6:28071808	chr6:28078792~28081130:-
PRAD	cis	rs1150668	0.835	rs1233696	ENSG00000204709.4	LINC01556	9.83	8.45e-21	7.53e-18	0.52	0.42	Pubertal anthropometrics;	chr6:28175232	chr6:28943877~28944537:+
PRAD	cis	rs6539288	0.677	rs11113144	ENSG00000260329.1	RP11-412D9.4	-9.83	8.48e-21	7.55e-18	-0.37	-0.42	Total body bone mineral density;	chr12:106929644	chr12:106954029~106955497:-
PRAD	cis	rs6539288	0.677	rs2216221	ENSG00000260329.1	RP11-412D9.4	-9.83	8.48e-21	7.55e-18	-0.37	-0.42	Total body bone mineral density;	chr12:106933453	chr12:106954029~106955497:-
PRAD	cis	rs6539288	0.677	rs1348565	ENSG00000260329.1	RP11-412D9.4	-9.83	8.48e-21	7.55e-18	-0.37	-0.42	Total body bone mineral density;	chr12:106935326	chr12:106954029~106955497:-
PRAD	cis	rs10129255	0.5	rs4774189	ENSG00000223648.3	IGHV3-64	9.83	8.49e-21	7.57e-18	0.37	0.42	Kawasaki disease;	chr14:106768275	chr14:106643132~106658258:-
PRAD	cis	rs2739330	0.828	rs5760108	ENSG00000099984.9	GSTT2	-9.83	8.5e-21	7.57e-18	-0.56	-0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23980123~23983911:+
PRAD	cis	rs853679	0.666	rs200956	ENSG00000280107.1	AL022393.9	-9.83	8.57e-21	7.63e-18	-0.59	-0.42	Depression;	chr6:27871968	chr6:28170845~28172521:+
PRAD	cis	rs638893	0.947	rs1170396	ENSG00000278376.1	RP11-158I9.8	-9.83	8.6e-21	7.65e-18	-0.48	-0.42	Vitiligo;	chr11:118833108	chr11:118791254~118793137:+
PRAD	cis	rs1858037	0.867	rs72621551	ENSG00000204929.10	AC074391.1	9.82	8.72e-21	7.76e-18	0.57	0.42	Rheumatoid arthritis;	chr2:65388087	chr2:65436711~66084639:+
PRAD	cis	rs1858037	0.867	rs55945621	ENSG00000204929.10	AC074391.1	9.82	8.72e-21	7.76e-18	0.57	0.42	Rheumatoid arthritis;	chr2:65388220	chr2:65436711~66084639:+
PRAD	cis	rs1858037	0.867	rs964505	ENSG00000204929.10	AC074391.1	9.82	8.72e-21	7.76e-18	0.57	0.42	Rheumatoid arthritis;	chr2:65396055	chr2:65436711~66084639:+
PRAD	cis	rs1061377	0.748	rs6812316	ENSG00000249207.1	RP11-360F5.1	-9.82	8.72e-21	7.76e-18	-0.44	-0.42	Uric acid levels;	chr4:39106617	chr4:39112677~39126818:-
PRAD	cis	rs6538678	0.818	rs7976294	ENSG00000258343.1	RP11-536G4.2	-9.82	8.75e-21	7.78e-18	-0.59	-0.42	Lupus nephritis in systemic lupus erythematosus;	chr12:95876868	chr12:95795345~95858839:-
PRAD	cis	rs6538678	0.818	rs1036429	ENSG00000258343.1	RP11-536G4.2	-9.82	8.75e-21	7.78e-18	-0.59	-0.42	Lupus nephritis in systemic lupus erythematosus;	chr12:95877650	chr12:95795345~95858839:-
PRAD	cis	rs9545047	0.604	rs2265381	ENSG00000227676.3	LINC01068	-9.82	8.75e-21	7.78e-18	-0.49	-0.42	Schizophrenia;	chr13:79425903	chr13:79566727~79571436:+
PRAD	cis	rs7743045	0.504	rs4946385	ENSG00000253194.1	RP11-351A11.1	9.82	8.76e-21	7.8e-18	0.54	0.42	Mean platelet volume;	chr6:118985247	chr6:118934785~119031541:+
PRAD	cis	rs10256972	0.63	rs10282584	ENSG00000229043.2	AC091729.9	-9.82	8.79e-21	7.82e-18	-0.53	-0.42	Endometriosis;Longevity;	chr7:1041806	chr7:1160374~1165267:+
PRAD	cis	rs7772486	0.875	rs2814872	ENSG00000235652.6	RP11-545I5.3	9.82	8.79e-21	7.82e-18	0.43	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145989098	chr6:145799409~145886585:+
PRAD	cis	rs507080	1	rs507080	ENSG00000255422.1	AP002954.4	-9.82	8.79e-21	7.82e-18	-0.51	-0.42	Serum metabolite levels;	chr11:118678873	chr11:118704607~118750263:+
PRAD	cis	rs4964805	0.526	rs934845	ENSG00000257681.1	RP11-341G23.4	9.82	8.8e-21	7.83e-18	0.37	0.42	Attention deficit hyperactivity disorder;	chr12:103791479	chr12:103746315~103768858:-
PRAD	cis	rs62355901	0.8	rs10461612	ENSG00000271828.1	CTD-2310F14.1	9.82	8.82e-21	7.84e-18	0.7	0.42	Breast cancer;	chr5:56708004	chr5:56927874~56929573:+
PRAD	cis	rs62355901	0.8	rs7709971	ENSG00000271828.1	CTD-2310F14.1	9.82	8.82e-21	7.84e-18	0.7	0.42	Breast cancer;	chr5:56711512	chr5:56927874~56929573:+
PRAD	cis	rs10875746	0.768	rs10875724	ENSG00000240399.1	RP1-228P16.1	-9.82	8.84e-21	7.86e-18	-0.4	-0.42	Longevity (90 years and older);	chr12:48026470	chr12:48054813~48055591:-
PRAD	cis	rs6539288	0.677	rs1348566	ENSG00000260329.1	RP11-412D9.4	-9.82	8.84e-21	7.87e-18	-0.37	-0.42	Total body bone mineral density;	chr12:106931870	chr12:106954029~106955497:-
PRAD	cis	rs7772486	0.686	rs9390357	ENSG00000235652.6	RP11-545I5.3	9.82	8.87e-21	7.89e-18	0.43	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145808211	chr6:145799409~145886585:+
PRAD	cis	rs9309473	0.95	rs7596773	ENSG00000163016.8	ALMS1P	9.82	8.88e-21	7.9e-18	0.52	0.42	Metabolite levels;	chr2:73618873	chr2:73644919~73685576:+
PRAD	cis	rs9545047	0.604	rs2265382	ENSG00000227676.3	LINC01068	-9.82	8.89e-21	7.91e-18	-0.49	-0.42	Schizophrenia;	chr13:79426196	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs2477395	ENSG00000227676.3	LINC01068	-9.82	8.89e-21	7.91e-18	-0.49	-0.42	Schizophrenia;	chr13:79427679	chr13:79566727~79571436:+
PRAD	cis	rs67311347	1	rs7625736	ENSG00000223797.4	ENTPD3-AS1	-9.82	8.93e-21	7.94e-18	-0.36	-0.42	Renal cell carcinoma;	chr3:40399854	chr3:40313802~40453329:-
PRAD	cis	rs2348418	0.932	rs10843190	ENSG00000247934.4	RP11-967K21.1	9.82	8.96e-21	7.97e-18	0.39	0.42	Lung function (FEV1);Lung function (FVC);	chr12:28507412	chr12:28163298~28190738:-
PRAD	cis	rs9309473	1	rs6755241	ENSG00000163016.8	ALMS1P	9.82	8.98e-21	7.99e-18	0.52	0.42	Metabolite levels;	chr2:73414236	chr2:73644919~73685576:+
PRAD	cis	rs67311347	1	rs73080137	ENSG00000223797.4	ENTPD3-AS1	9.82	9e-21	8e-18	0.38	0.42	Renal cell carcinoma;	chr3:40474921	chr3:40313802~40453329:-
PRAD	cis	rs9309473	1	rs3738848	ENSG00000163016.8	ALMS1P	9.82	9.02e-21	8.02e-18	0.52	0.42	Metabolite levels;	chr2:73534754	chr2:73644919~73685576:+
PRAD	cis	rs853679	0.517	rs6922063	ENSG00000272009.1	RP1-313I6.12	-9.82	9.03e-21	8.03e-18	-0.43	-0.42	Depression;	chr6:28126588	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs2275508	ENSG00000272009.1	RP1-313I6.12	-9.82	9.03e-21	8.03e-18	-0.43	-0.42	Depression;	chr6:28126953	chr6:28078792~28081130:-
PRAD	cis	rs1075265	0.704	rs805405	ENSG00000233266.1	HMGB1P31	9.82	9.05e-21	8.05e-18	0.56	0.42	Chronotype;Morning vs. evening chronotype;	chr2:53891014	chr2:54051334~54051760:+
PRAD	cis	rs507080	0.961	rs4457789	ENSG00000255422.1	AP002954.4	-9.82	9.05e-21	8.05e-18	-0.52	-0.42	Serum metabolite levels;	chr11:118668461	chr11:118704607~118750263:+
PRAD	cis	rs8523	0.586	rs1225753	ENSG00000230314.5	ELOVL2-AS1	9.82	9.06e-21	8.06e-18	0.47	0.42	Red blood cell fatty acid levels;	chr6:10956456	chr6:11043524~11078226:+
PRAD	cis	rs7743045	0.504	rs4946382	ENSG00000253194.1	RP11-351A11.1	9.82	9.11e-21	8.09e-18	0.54	0.42	Mean platelet volume;	chr6:118979312	chr6:118934785~119031541:+
PRAD	cis	rs853679	0.517	rs12174753	ENSG00000272009.1	RP1-313I6.12	-9.82	9.12e-21	8.1e-18	-0.43	-0.42	Depression;	chr6:28074687	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs55747925	ENSG00000272009.1	RP1-313I6.12	-9.82	9.12e-21	8.1e-18	-0.43	-0.42	Depression;	chr6:28076559	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs56310871	ENSG00000272009.1	RP1-313I6.12	-9.82	9.12e-21	8.1e-18	-0.43	-0.42	Depression;	chr6:28076704	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs34716816	ENSG00000272009.1	RP1-313I6.12	-9.82	9.12e-21	8.1e-18	-0.43	-0.42	Depression;	chr6:28078391	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs9380049	ENSG00000272009.1	RP1-313I6.12	-9.82	9.12e-21	8.1e-18	-0.43	-0.42	Depression;	chr6:28080757	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs9380050	ENSG00000272009.1	RP1-313I6.12	-9.82	9.12e-21	8.1e-18	-0.43	-0.42	Depression;	chr6:28080760	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs9393885	ENSG00000272009.1	RP1-313I6.12	-9.82	9.12e-21	8.1e-18	-0.43	-0.42	Depression;	chr6:28082231	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs9393886	ENSG00000272009.1	RP1-313I6.12	-9.82	9.12e-21	8.1e-18	-0.43	-0.42	Depression;	chr6:28082261	chr6:28078792~28081130:-
PRAD	cis	rs4713118	0.515	rs9368549	ENSG00000272009.1	RP1-313I6.12	-9.82	9.12e-21	8.1e-18	-0.43	-0.42	Parkinson's disease;	chr6:28082269	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs56364346	ENSG00000272009.1	RP1-313I6.12	-9.82	9.12e-21	8.1e-18	-0.43	-0.42	Depression;	chr6:28082984	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs9357061	ENSG00000272009.1	RP1-313I6.12	-9.82	9.12e-21	8.1e-18	-0.43	-0.42	Depression;	chr6:28083994	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs9368550	ENSG00000272009.1	RP1-313I6.12	-9.82	9.12e-21	8.1e-18	-0.43	-0.42	Depression;	chr6:28084025	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.542	rs2295594	ENSG00000272009.1	RP1-313I6.12	-9.82	9.12e-21	8.1e-18	-0.43	-0.42	Depression;	chr6:28085319	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs2273564	ENSG00000272009.1	RP1-313I6.12	-9.82	9.12e-21	8.1e-18	-0.43	-0.42	Depression;	chr6:28089816	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs1853097	ENSG00000272009.1	RP1-313I6.12	-9.82	9.12e-21	8.1e-18	-0.43	-0.42	Depression;	chr6:28090857	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs9393888	ENSG00000272009.1	RP1-313I6.12	-9.82	9.12e-21	8.1e-18	-0.43	-0.42	Depression;	chr6:28091439	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs3734573	ENSG00000272009.1	RP1-313I6.12	-9.82	9.12e-21	8.1e-18	-0.43	-0.42	Depression;	chr6:28091659	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs9357063	ENSG00000272009.1	RP1-313I6.12	-9.82	9.12e-21	8.1e-18	-0.43	-0.42	Depression;	chr6:28092227	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs3823180	ENSG00000272009.1	RP1-313I6.12	-9.82	9.12e-21	8.1e-18	-0.43	-0.42	Depression;	chr6:28093966	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs9368551	ENSG00000272009.1	RP1-313I6.12	-9.82	9.12e-21	8.1e-18	-0.43	-0.42	Depression;	chr6:28094014	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs9393890	ENSG00000272009.1	RP1-313I6.12	-9.82	9.12e-21	8.1e-18	-0.43	-0.42	Depression;	chr6:28096077	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs9366715	ENSG00000272009.1	RP1-313I6.12	-9.82	9.12e-21	8.1e-18	-0.43	-0.42	Depression;	chr6:28096855	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.598	rs9380054	ENSG00000272009.1	RP1-313I6.12	-9.82	9.12e-21	8.1e-18	-0.43	-0.42	Depression;	chr6:28099759	chr6:28078792~28081130:-
PRAD	cis	rs4713118	0.547	rs2116981	ENSG00000272009.1	RP1-313I6.12	-9.82	9.12e-21	8.1e-18	-0.43	-0.42	Parkinson's disease;	chr6:28100173	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs9368552	ENSG00000272009.1	RP1-313I6.12	-9.82	9.12e-21	8.1e-18	-0.43	-0.42	Depression;	chr6:28100648	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs2281588	ENSG00000272009.1	RP1-313I6.12	-9.82	9.12e-21	8.1e-18	-0.43	-0.42	Depression;	chr6:28104824	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.542	rs34131763	ENSG00000272009.1	RP1-313I6.12	-9.82	9.12e-21	8.1e-18	-0.43	-0.42	Depression;	chr6:28107222	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs35193936	ENSG00000272009.1	RP1-313I6.12	-9.82	9.12e-21	8.1e-18	-0.43	-0.42	Depression;	chr6:28108492	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs36078605	ENSG00000272009.1	RP1-313I6.12	-9.82	9.12e-21	8.1e-18	-0.43	-0.42	Depression;	chr6:28110254	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs9393891	ENSG00000272009.1	RP1-313I6.12	-9.82	9.12e-21	8.1e-18	-0.43	-0.42	Depression;	chr6:28111382	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs9468286	ENSG00000272009.1	RP1-313I6.12	-9.82	9.12e-21	8.1e-18	-0.43	-0.42	Depression;	chr6:28111650	chr6:28078792~28081130:-
PRAD	cis	rs4713118	0.516	rs7739216	ENSG00000272009.1	RP1-313I6.12	-9.82	9.12e-21	8.1e-18	-0.43	-0.42	Parkinson's disease;	chr6:28112168	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs35512245	ENSG00000272009.1	RP1-313I6.12	-9.82	9.12e-21	8.1e-18	-0.43	-0.42	Depression;	chr6:28112175	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs9380055	ENSG00000272009.1	RP1-313I6.12	-9.82	9.12e-21	8.1e-18	-0.43	-0.42	Depression;	chr6:28113851	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs9368553	ENSG00000272009.1	RP1-313I6.12	-9.82	9.12e-21	8.1e-18	-0.43	-0.42	Depression;	chr6:28114487	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs9368554	ENSG00000272009.1	RP1-313I6.12	-9.82	9.12e-21	8.1e-18	-0.43	-0.42	Depression;	chr6:28114933	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs4713137	ENSG00000272009.1	RP1-313I6.12	-9.82	9.12e-21	8.1e-18	-0.43	-0.42	Depression;	chr6:28115743	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs9348793	ENSG00000272009.1	RP1-313I6.12	-9.82	9.12e-21	8.1e-18	-0.43	-0.42	Depression;	chr6:28116411	chr6:28078792~28081130:-
PRAD	cis	rs4713118	0.586	rs6905516	ENSG00000272009.1	RP1-313I6.12	-9.82	9.12e-21	8.1e-18	-0.43	-0.42	Parkinson's disease;	chr6:28118700	chr6:28078792~28081130:-
PRAD	cis	rs4713118	0.586	rs6905522	ENSG00000272009.1	RP1-313I6.12	-9.82	9.12e-21	8.1e-18	-0.43	-0.42	Parkinson's disease;	chr6:28118701	chr6:28078792~28081130:-
PRAD	cis	rs4713118	0.586	rs9468290	ENSG00000272009.1	RP1-313I6.12	-9.82	9.12e-21	8.1e-18	-0.43	-0.42	Parkinson's disease;	chr6:28119896	chr6:28078792~28081130:-
PRAD	cis	rs507080	0.922	rs644867	ENSG00000255422.1	AP002954.4	-9.82	9.13e-21	8.1e-18	-0.52	-0.42	Serum metabolite levels;	chr11:118696836	chr11:118704607~118750263:+
PRAD	cis	rs6539288	0.677	rs10778518	ENSG00000260329.1	RP11-412D9.4	9.82	9.17e-21	8.14e-18	0.36	0.42	Total body bone mineral density;	chr12:106950172	chr12:106954029~106955497:-
PRAD	cis	rs9322193	0.962	rs35031906	ENSG00000268592.3	RAET1E-AS1	9.82	9.2e-21	8.16e-18	0.58	0.42	Lung cancer;	chr6:149677438	chr6:149863494~149919507:+
PRAD	cis	rs12049351	0.613	rs7552561	ENSG00000229367.1	HMGN2P19	9.82	9.27e-21	8.23e-18	0.61	0.42	Circulating myeloperoxidase levels (plasma);	chr1:229445239	chr1:229570532~229570796:+
PRAD	cis	rs8062405	1	rs12443881	ENSG00000259982.1	CDC37P1	9.82	9.32e-21	8.27e-18	0.56	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28830456	chr16:28700294~28701540:-
PRAD	cis	rs8062405	1	rs12446589	ENSG00000259982.1	CDC37P1	9.82	9.33e-21	8.27e-18	0.56	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859641	chr16:28700294~28701540:-
PRAD	cis	rs7586673	0.93	rs7591506	ENSG00000227403.1	AC009299.3	-9.82	9.33e-21	8.28e-18	-0.55	-0.42	Intelligence (multi-trait analysis);	chr2:161104414	chr2:161244739~161249050:+
PRAD	cis	rs2933343	1	rs1680795	ENSG00000231305.3	RP11-723O4.2	9.82	9.34e-21	8.29e-18	0.43	0.42	IgG glycosylation;	chr3:128901545	chr3:128861313~128871540:-
PRAD	cis	rs1930961	1	rs6004669	ENSG00000272942.1	CTA-246H3.12	-9.81	9.47e-21	8.4e-18	-0.66	-0.42	Bipolar disorder with mood-incongruent psychosis;	chr22:25479836	chr22:25434324~25435070:-
PRAD	cis	rs1930961	1	rs997872	ENSG00000272942.1	CTA-246H3.12	-9.81	9.47e-21	8.4e-18	-0.66	-0.42	Bipolar disorder with mood-incongruent psychosis;	chr22:25482647	chr22:25434324~25435070:-
PRAD	cis	rs4964805	0.586	rs934846	ENSG00000257681.1	RP11-341G23.4	9.81	9.5e-21	8.43e-18	0.37	0.42	Attention deficit hyperactivity disorder;	chr12:103791519	chr12:103746315~103768858:-
PRAD	cis	rs172166	0.516	rs2622322	ENSG00000204709.4	LINC01556	9.81	9.55e-21	8.47e-18	0.52	0.42	Cardiac Troponin-T levels;	chr6:28149665	chr6:28943877~28944537:+
PRAD	cis	rs270601	0.77	rs10463891	ENSG00000233006.5	AC034220.3	-9.81	9.58e-21	8.5e-18	-0.36	-0.42	Acylcarnitine levels;	chr5:132261699	chr5:132311285~132369916:-
PRAD	cis	rs8072100	0.713	rs11079776	ENSG00000228782.6	CTD-2026D20.3	9.81	9.63e-21	8.54e-18	0.46	0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47469527	chr17:47450568~47492492:-
PRAD	cis	rs1891275	0.601	rs1970506	ENSG00000228701.1	TNKS2-AS1	-9.81	9.64e-21	8.55e-18	-0.57	-0.42	Intelligence (multi-trait analysis);	chr10:91668529	chr10:91782839~91798291:-
PRAD	cis	rs867371	0.656	rs2665103	ENSG00000278603.1	RP13-608F4.5	-9.81	9.64e-21	8.55e-18	-0.53	-0.42	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82140374	chr15:82472203~82472426:+
PRAD	cis	rs507080	0.922	rs12577485	ENSG00000255422.1	AP002954.4	-9.81	9.64e-21	8.55e-18	-0.51	-0.42	Serum metabolite levels;	chr11:118676793	chr11:118704607~118750263:+
PRAD	cis	rs1075265	0.704	rs13417926	ENSG00000233266.1	HMGB1P31	9.81	9.75e-21	8.64e-18	0.57	0.42	Chronotype;Morning vs. evening chronotype;	chr2:53825520	chr2:54051334~54051760:+
PRAD	cis	rs62355901	1	rs62355901	ENSG00000271828.1	CTD-2310F14.1	9.81	9.76e-21	8.65e-18	0.75	0.42	Breast cancer;	chr5:56757708	chr5:56927874~56929573:+
PRAD	cis	rs4853012	0.941	rs78128123	ENSG00000257800.1	FNBP1P1	9.81	9.77e-21	8.66e-18	0.4	0.42	Gestational age at birth (maternal effect);	chr2:74120398	chr2:74120680~74123218:+
PRAD	cis	rs7688540	0.771	rs4129956	ENSG00000275426.1	CH17-262A2.1	9.81	9.9e-21	8.77e-18	0.64	0.42	Facial morphology (factor 6, height of vermillion lower lip);	chr4:308219	chr4:149738~150317:+
PRAD	cis	rs10800713	0.954	rs10800710	ENSG00000260088.1	RP11-92G12.3	-9.81	9.9e-21	8.77e-18	-0.61	-0.42	Tandem gait;	chr1:200569240	chr1:200669507~200694250:+
PRAD	cis	rs10800713	0.954	rs10800711	ENSG00000260088.1	RP11-92G12.3	-9.81	9.9e-21	8.77e-18	-0.61	-0.42	Tandem gait;	chr1:200569757	chr1:200669507~200694250:+
PRAD	cis	rs10800713	0.954	rs12092148	ENSG00000260088.1	RP11-92G12.3	-9.81	9.9e-21	8.77e-18	-0.61	-0.42	Tandem gait;	chr1:200570655	chr1:200669507~200694250:+
PRAD	cis	rs10800713	0.826	rs11586257	ENSG00000260088.1	RP11-92G12.3	-9.81	9.9e-21	8.77e-18	-0.61	-0.42	Tandem gait;	chr1:200572236	chr1:200669507~200694250:+
PRAD	cis	rs10800713	0.954	rs10800712	ENSG00000260088.1	RP11-92G12.3	-9.81	9.9e-21	8.77e-18	-0.61	-0.42	Tandem gait;	chr1:200576059	chr1:200669507~200694250:+
PRAD	cis	rs10800713	0.908	rs10919978	ENSG00000260088.1	RP11-92G12.3	-9.81	9.9e-21	8.77e-18	-0.61	-0.42	Tandem gait;	chr1:200576923	chr1:200669507~200694250:+
PRAD	cis	rs10800713	0.954	rs4353125	ENSG00000260088.1	RP11-92G12.3	-9.81	9.9e-21	8.77e-18	-0.61	-0.42	Tandem gait;	chr1:200582178	chr1:200669507~200694250:+
PRAD	cis	rs10800713	0.908	rs6670625	ENSG00000260088.1	RP11-92G12.3	-9.81	9.9e-21	8.77e-18	-0.61	-0.42	Tandem gait;	chr1:200587514	chr1:200669507~200694250:+
PRAD	cis	rs9309473	0.95	rs6546859	ENSG00000163016.8	ALMS1P	9.81	9.98e-21	8.84e-18	0.52	0.42	Metabolite levels;	chr2:73614928	chr2:73644919~73685576:+
PRAD	cis	rs62229266	0.626	rs2835268	ENSG00000231106.2	LINC01436	9.81	9.98e-21	8.84e-18	0.54	0.42	Mitral valve prolapse;	chr21:36076838	chr21:36005338~36007838:+
PRAD	cis	rs9545047	0.567	rs9530896	ENSG00000227676.3	LINC01068	9.81	1e-20	8.85e-18	0.49	0.42	Schizophrenia;	chr13:79335507	chr13:79566727~79571436:+
PRAD	cis	rs2153535	0.585	rs7770688	ENSG00000230939.1	RP11-314C16.1	-9.81	1e-20	8.86e-18	-0.52	-0.42	Motion sickness;	chr6:8648663	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.585	rs1041279	ENSG00000230939.1	RP11-314C16.1	-9.81	1e-20	8.86e-18	-0.52	-0.42	Motion sickness;	chr6:8650293	chr6:8784178~8785445:+
PRAD	cis	rs3096299	0.658	rs4291902	ENSG00000261118.1	RP11-104N10.1	9.81	1.01e-20	8.92e-18	0.4	0.42	Multiple myeloma (IgH translocation);	chr16:89493907	chr16:89492017~89504460:-
PRAD	cis	rs7586673	0.964	rs34444368	ENSG00000227403.1	AC009299.3	-9.81	1.01e-20	8.93e-18	-0.56	-0.42	Intelligence (multi-trait analysis);	chr2:161097706	chr2:161244739~161249050:+
PRAD	cis	rs9309473	0.95	rs1918863	ENSG00000163016.8	ALMS1P	9.81	1.01e-20	8.95e-18	0.51	0.42	Metabolite levels;	chr2:73417353	chr2:73644919~73685576:+
PRAD	cis	rs13392177	0.672	rs4674270	ENSG00000261338.2	RP11-378A13.1	-9.81	1.01e-20	8.97e-18	-0.47	-0.42	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218188418	chr2:218255319~218257366:+
PRAD	cis	rs853679	0.517	rs9380056	ENSG00000272009.1	RP1-313I6.12	-9.8	1.02e-20	9.04e-18	-0.42	-0.42	Depression;	chr6:28136698	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs9380057	ENSG00000272009.1	RP1-313I6.12	-9.8	1.02e-20	9.04e-18	-0.42	-0.42	Depression;	chr6:28136856	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs1947862	ENSG00000272009.1	RP1-313I6.12	-9.8	1.02e-20	9.04e-18	-0.42	-0.42	Depression;	chr6:28137418	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs6941992	ENSG00000272009.1	RP1-313I6.12	-9.8	1.02e-20	9.04e-18	-0.42	-0.42	Depression;	chr6:28138363	chr6:28078792~28081130:-
PRAD	cis	rs4713118	0.516	rs4713142	ENSG00000272009.1	RP1-313I6.12	-9.8	1.02e-20	9.04e-18	-0.42	-0.42	Parkinson's disease;	chr6:28138569	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs4713143	ENSG00000272009.1	RP1-313I6.12	-9.8	1.02e-20	9.04e-18	-0.42	-0.42	Depression;	chr6:28138981	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs4713144	ENSG00000272009.1	RP1-313I6.12	-9.8	1.02e-20	9.04e-18	-0.42	-0.42	Depression;	chr6:28139012	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs3757187	ENSG00000272009.1	RP1-313I6.12	-9.8	1.02e-20	9.04e-18	-0.42	-0.42	Depression;	chr6:28139876	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs3757185	ENSG00000272009.1	RP1-313I6.12	-9.8	1.02e-20	9.04e-18	-0.42	-0.42	Depression;	chr6:28139998	chr6:28078792~28081130:-
PRAD	cis	rs6570726	0.846	rs7773939	ENSG00000235652.6	RP11-545I5.3	-9.8	1.02e-20	9.05e-18	-0.43	-0.42	Lobe attachment (rater-scored or self-reported);	chr6:145606248	chr6:145799409~145886585:+
PRAD	cis	rs3931020	0.657	rs10890142	ENSG00000272864.1	RP11-17E13.2	-9.8	1.02e-20	9.06e-18	-0.49	-0.42	Resistin levels;	chr1:74713445	chr1:74698769~74699333:-
PRAD	cis	rs4718428	0.576	rs12698546	ENSG00000273142.1	RP11-458F8.4	-9.8	1.02e-20	9.06e-18	-0.34	-0.42	Corneal structure;	chr7:66801919	chr7:66902857~66906297:+
PRAD	cis	rs2658782	0.738	rs2605628	ENSG00000279684.1	RP11-755E23.2	-9.8	1.03e-20	9.07e-18	-0.67	-0.42	Pulmonary function decline;	chr11:93528394	chr11:93286629~93288903:-
PRAD	cis	rs150992	0.821	rs326480	ENSG00000248489.1	CTD-2007H13.3	9.8	1.03e-20	9.1e-18	0.47	0.42	Body mass index;	chr5:98949263	chr5:98929171~98995013:+
PRAD	cis	rs11155671	0.546	rs1999633	ENSG00000268592.3	RAET1E-AS1	9.8	1.03e-20	9.13e-18	0.64	0.42	Testicular germ cell tumor;	chr6:149866576	chr6:149863494~149919507:+
PRAD	cis	rs673078	0.66	rs7136216	ENSG00000275759.1	RP11-131L12.3	-9.8	1.03e-20	9.15e-18	-0.59	-0.42	Glucose homeostasis traits;	chr12:118170475	chr12:118428281~118428870:+
PRAD	cis	rs12701220	0.655	rs7778968	ENSG00000229043.2	AC091729.9	-9.8	1.04e-20	9.18e-18	-0.58	-0.42	Bronchopulmonary dysplasia;	chr7:1104986	chr7:1160374~1165267:+
PRAD	cis	rs2153535	0.585	rs1885203	ENSG00000230939.1	RP11-314C16.1	-9.8	1.04e-20	9.19e-18	-0.51	-0.42	Motion sickness;	chr6:8633646	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.537	rs9379232	ENSG00000230939.1	RP11-314C16.1	-9.8	1.04e-20	9.19e-18	-0.51	-0.42	Motion sickness;	chr6:8634176	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.585	rs9393050	ENSG00000230939.1	RP11-314C16.1	-9.8	1.04e-20	9.19e-18	-0.51	-0.42	Motion sickness;	chr6:8635219	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.585	rs9405403	ENSG00000230939.1	RP11-314C16.1	-9.8	1.04e-20	9.19e-18	-0.51	-0.42	Motion sickness;	chr6:8636061	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.56	rs7748421	ENSG00000230939.1	RP11-314C16.1	-9.8	1.04e-20	9.19e-18	-0.51	-0.42	Motion sickness;	chr6:8636271	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.585	rs2224480	ENSG00000230939.1	RP11-314C16.1	-9.8	1.04e-20	9.19e-18	-0.51	-0.42	Motion sickness;	chr6:8647646	chr6:8784178~8785445:+
PRAD	cis	rs10800713	0.908	rs6686605	ENSG00000260088.1	RP11-92G12.3	-9.8	1.05e-20	9.24e-18	-0.61	-0.42	Tandem gait;	chr1:200539440	chr1:200669507~200694250:+
PRAD	cis	rs7772486	0.817	rs9322047	ENSG00000235652.6	RP11-545I5.3	9.8	1.05e-20	9.25e-18	0.42	0.42	Lobe attachment (rater-scored or self-reported);	chr6:146079258	chr6:145799409~145886585:+
PRAD	cis	rs9309473	0.904	rs78450880	ENSG00000163016.8	ALMS1P	9.8	1.05e-20	9.25e-18	0.52	0.42	Metabolite levels;	chr2:73594254	chr2:73644919~73685576:+
PRAD	cis	rs507080	0.961	rs520543	ENSG00000255422.1	AP002954.4	-9.8	1.05e-20	9.29e-18	-0.52	-0.42	Serum metabolite levels;	chr11:118667448	chr11:118704607~118750263:+
PRAD	cis	rs2153535	0.553	rs2984099	ENSG00000230939.1	RP11-314C16.1	-9.8	1.06e-20	9.35e-18	-0.51	-0.42	Motion sickness;	chr6:8637041	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.585	rs9378564	ENSG00000230939.1	RP11-314C16.1	-9.8	1.06e-20	9.35e-18	-0.51	-0.42	Motion sickness;	chr6:8639694	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.585	rs9379233	ENSG00000230939.1	RP11-314C16.1	-9.8	1.06e-20	9.35e-18	-0.51	-0.42	Motion sickness;	chr6:8639729	chr6:8784178~8785445:+
PRAD	cis	rs9309473	0.95	rs6546849	ENSG00000163016.8	ALMS1P	9.8	1.06e-20	9.38e-18	0.52	0.42	Metabolite levels;	chr2:73603910	chr2:73644919~73685576:+
PRAD	cis	rs2282300	0.696	rs12578061	ENSG00000242353.1	RP4-710M3.1	-9.8	1.06e-20	9.41e-18	-0.51	-0.42	Morning vs. evening chronotype;	chr11:30227818	chr11:30368148~30368646:+
PRAD	cis	rs1075265	0.783	rs718872	ENSG00000233266.1	HMGB1P31	9.8	1.07e-20	9.47e-18	0.57	0.42	Chronotype;Morning vs. evening chronotype;	chr2:53946569	chr2:54051334~54051760:+
PRAD	cis	rs858239	0.932	rs1728313	ENSG00000226816.2	AC005082.12	9.8	1.07e-20	9.48e-18	0.48	0.42	Cerebrospinal fluid biomarker levels;	chr7:23231412	chr7:23206013~23208045:+
PRAD	cis	rs12134133	1	rs61822669	ENSG00000274245.1	RP11-357P18.2	9.8	1.07e-20	9.49e-18	0.6	0.42	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207247869	chr1:207372559~207373252:+
PRAD	cis	rs2739330	0.828	rs5751770	ENSG00000099984.9	GSTT2	-9.8	1.08e-20	9.5e-18	-0.55	-0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23980123~23983911:+
PRAD	cis	rs853679	0.517	rs16893666	ENSG00000272009.1	RP1-313I6.12	9.8	1.08e-20	9.55e-18	0.43	0.42	Depression;	chr6:28086929	chr6:28078792~28081130:-
PRAD	cis	rs2882667	0.518	rs10041986	ENSG00000253404.1	AC034243.1	9.8	1.09e-20	9.58e-18	0.52	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139088748	chr5:138744434~138753309:-
PRAD	cis	rs2243480	0.706	rs34466769	ENSG00000226824.5	RP4-756H11.3	-9.8	1.09e-20	9.61e-18	-0.69	-0.42	Diabetic kidney disease;	chr7:65988305	chr7:66654538~66669855:+
PRAD	cis	rs2153535	0.585	rs9505505	ENSG00000230939.1	RP11-314C16.1	-9.8	1.1e-20	9.67e-18	-0.51	-0.42	Motion sickness;	chr6:8640246	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.561	rs9406184	ENSG00000230939.1	RP11-314C16.1	-9.8	1.1e-20	9.67e-18	-0.51	-0.42	Motion sickness;	chr6:8642681	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.585	rs11243263	ENSG00000230939.1	RP11-314C16.1	-9.8	1.1e-20	9.67e-18	-0.51	-0.42	Motion sickness;	chr6:8642880	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.585	rs9392233	ENSG00000230939.1	RP11-314C16.1	-9.8	1.1e-20	9.67e-18	-0.51	-0.42	Motion sickness;	chr6:8645042	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.561	rs9405404	ENSG00000230939.1	RP11-314C16.1	-9.8	1.1e-20	9.67e-18	-0.51	-0.42	Motion sickness;	chr6:8646583	chr6:8784178~8785445:+
PRAD	cis	rs1426063	0.614	rs17199779	ENSG00000260265.1	RP11-44F21.5	-9.8	1.1e-20	9.71e-18	-0.85	-0.42	QT interval;	chr4:75105647	chr4:75081702~75084717:-
PRAD	cis	rs12049351	0.613	rs7514990	ENSG00000229367.1	HMGN2P19	9.79	1.11e-20	9.77e-18	0.6	0.42	Circulating myeloperoxidase levels (plasma);	chr1:229445419	chr1:229570532~229570796:+
PRAD	cis	rs17507216	0.56	rs2871011	ENSG00000278603.1	RP13-608F4.5	9.79	1.11e-20	9.77e-18	0.54	0.42	Excessive daytime sleepiness;	chr15:82560792	chr15:82472203~82472426:+
PRAD	cis	rs2282300	0.739	rs1631451	ENSG00000242353.1	RP4-710M3.1	-9.79	1.13e-20	9.92e-18	-0.51	-0.42	Morning vs. evening chronotype;	chr11:30327586	chr11:30368148~30368646:+
PRAD	cis	rs3931020	0.688	rs405445	ENSG00000272864.1	RP11-17E13.2	9.79	1.13e-20	9.93e-18	0.49	0.42	Resistin levels;	chr1:74755466	chr1:74698769~74699333:-
PRAD	cis	rs783540	0.681	rs1259178	ENSG00000255769.6	GOLGA2P10	9.79	1.14e-20	1e-17	0.52	0.42	Schizophrenia;	chr15:82603127	chr15:82472993~82513950:-
PRAD	cis	rs34779708	0.931	rs2384275	ENSG00000230534.5	RP11-297A16.2	9.79	1.14e-20	1e-17	0.55	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35008214	chr10:35098006~35127020:-
PRAD	cis	rs2882667	0.537	rs6887866	ENSG00000253404.1	AC034243.1	9.79	1.14e-20	1.01e-17	0.52	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139102007	chr5:138744434~138753309:-
PRAD	cis	rs1075265	0.87	rs7569370	ENSG00000233266.1	HMGB1P31	9.79	1.14e-20	1.01e-17	0.56	0.42	Chronotype;Morning vs. evening chronotype;	chr2:53989212	chr2:54051334~54051760:+
PRAD	cis	rs11673344	0.864	rs2562587	ENSG00000226686.6	LINC01535	9.79	1.14e-20	1.01e-17	0.56	0.42	Obesity-related traits;	chr19:37019357	chr19:37251912~37265535:+
PRAD	cis	rs2564921	0.73	rs2564929	ENSG00000242142.1	SERBP1P3	-9.79	1.14e-20	1.01e-17	-0.49	-0.42	Height;	chr3:53084188	chr3:53064283~53065091:-
PRAD	cis	rs1150668	0.796	rs213236	ENSG00000216901.1	AL022393.7	9.79	1.15e-20	1.01e-17	0.51	0.42	Pubertal anthropometrics;	chr6:28356620	chr6:28176188~28176674:+
PRAD	cis	rs2933343	0.909	rs1683817	ENSG00000231305.3	RP11-723O4.2	9.79	1.15e-20	1.01e-17	0.43	0.42	IgG glycosylation;	chr3:128932693	chr3:128861313~128871540:-
PRAD	cis	rs67311347	0.91	rs13089215	ENSG00000223797.4	ENTPD3-AS1	-9.79	1.15e-20	1.01e-17	-0.37	-0.42	Renal cell carcinoma;	chr3:40454403	chr3:40313802~40453329:-
PRAD	cis	rs12134133	1	rs11584921	ENSG00000274245.1	RP11-357P18.2	9.79	1.16e-20	1.02e-17	0.6	0.42	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207268630	chr1:207372559~207373252:+
PRAD	cis	rs67311347	1	rs7633809	ENSG00000223797.4	ENTPD3-AS1	-9.79	1.16e-20	1.02e-17	-0.37	-0.42	Renal cell carcinoma;	chr3:40476246	chr3:40313802~40453329:-
PRAD	cis	rs8062405	0.721	rs151181	ENSG00000259982.1	CDC37P1	9.79	1.16e-20	1.02e-17	0.55	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28479196	chr16:28700294~28701540:-
PRAD	cis	rs2933343	1	rs1680784	ENSG00000261159.1	RP11-723O4.9	9.79	1.16e-20	1.02e-17	0.39	0.42	IgG glycosylation;	chr3:128925615	chr3:128859716~128860526:-
PRAD	cis	rs2404602	0.503	rs284909	ENSG00000259422.1	RP11-593F23.1	9.79	1.16e-20	1.02e-17	0.52	0.42	Blood metabolite levels;	chr15:76444287	chr15:76174891~76181486:-
PRAD	cis	rs1150668	0.796	rs2247002	ENSG00000216901.1	AL022393.7	9.79	1.16e-20	1.02e-17	0.51	0.42	Pubertal anthropometrics;	chr6:28430174	chr6:28176188~28176674:+
PRAD	cis	rs7772486	0.875	rs6570736	ENSG00000235652.6	RP11-545I5.3	9.79	1.17e-20	1.03e-17	0.42	0.42	Lobe attachment (rater-scored or self-reported);	chr6:146067184	chr6:145799409~145886585:+
PRAD	cis	rs507080	0.961	rs543413	ENSG00000255422.1	AP002954.4	-9.79	1.17e-20	1.03e-17	-0.51	-0.42	Serum metabolite levels;	chr11:118679308	chr11:118704607~118750263:+
PRAD	cis	rs1150668	0.796	rs728122	ENSG00000216901.1	AL022393.7	9.79	1.17e-20	1.03e-17	0.52	0.42	Pubertal anthropometrics;	chr6:28431347	chr6:28176188~28176674:+
PRAD	cis	rs4964805	0.913	rs11111793	ENSG00000257681.1	RP11-341G23.4	9.79	1.18e-20	1.04e-17	0.42	0.42	Attention deficit hyperactivity disorder;	chr12:103804340	chr12:103746315~103768858:-
PRAD	cis	rs9309473	0.66	rs79370894	ENSG00000163016.8	ALMS1P	9.79	1.18e-20	1.04e-17	0.61	0.42	Metabolite levels;	chr2:73456388	chr2:73644919~73685576:+
PRAD	cis	rs4713118	0.587	rs61471148	ENSG00000272009.1	RP1-313I6.12	-9.79	1.19e-20	1.04e-17	-0.42	-0.42	Parkinson's disease;	chr6:28069254	chr6:28078792~28081130:-
PRAD	cis	rs1150668	0.796	rs2531825	ENSG00000216901.1	AL022393.7	9.79	1.19e-20	1.04e-17	0.51	0.42	Pubertal anthropometrics;	chr6:28381487	chr6:28176188~28176674:+
PRAD	cis	rs7772486	0.875	rs9322045	ENSG00000235652.6	RP11-545I5.3	9.79	1.19e-20	1.05e-17	0.42	0.42	Lobe attachment (rater-scored or self-reported);	chr6:146063814	chr6:145799409~145886585:+
PRAD	cis	rs7714584	1	rs3900064	ENSG00000197083.10	ZNF300P1	-9.78	1.2e-20	1.06e-17	-0.67	-0.42	Crohn's disease;	chr5:150884852	chr5:150930645~150946289:-
PRAD	cis	rs8072100	0.713	rs57427906	ENSG00000228782.6	CTD-2026D20.3	9.78	1.2e-20	1.06e-17	0.46	0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47416648	chr17:47450568~47492492:-
PRAD	cis	rs9309473	1	rs7604682	ENSG00000163016.8	ALMS1P	9.78	1.2e-20	1.06e-17	0.51	0.42	Metabolite levels;	chr2:73560899	chr2:73644919~73685576:+
PRAD	cis	rs9309473	0.898	rs7580750	ENSG00000163016.8	ALMS1P	9.78	1.2e-20	1.06e-17	0.51	0.42	Metabolite levels;	chr2:73560999	chr2:73644919~73685576:+
PRAD	cis	rs2739330	0.76	rs1002286	ENSG00000206090.4	AP000350.7	-9.78	1.21e-20	1.06e-17	-0.53	-0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23939998~23942798:+
PRAD	cis	rs10875746	0.859	rs11558768	ENSG00000240399.1	RP1-228P16.1	-9.78	1.22e-20	1.07e-17	-0.4	-0.42	Longevity (90 years and older);	chr12:48184006	chr12:48054813~48055591:-
PRAD	cis	rs2282300	0.637	rs10742240	ENSG00000242353.1	RP4-710M3.1	-9.78	1.22e-20	1.07e-17	-0.44	-0.42	Morning vs. evening chronotype;	chr11:30407891	chr11:30368148~30368646:+
PRAD	cis	rs4774565	0.84	rs55948407	ENSG00000244879.4	GABPB1-AS1	-9.78	1.22e-20	1.07e-17	-0.39	-0.42	Breast cancer;	chr15:50376704	chr15:50354959~50372202:+
PRAD	cis	rs853679	0.517	rs17711344	ENSG00000272009.1	RP1-313I6.12	9.78	1.22e-20	1.08e-17	0.43	0.42	Depression;	chr6:28109824	chr6:28078792~28081130:-
PRAD	cis	rs12594515	0.694	rs2068294	ENSG00000273972.1	CTD-2306A12.1	-9.78	1.23e-20	1.08e-17	-0.47	-0.42	Weight;Waist circumference;	chr15:45693350	chr15:45702640~45703183:+
PRAD	cis	rs9309711	0.666	rs6723126	ENSG00000225234.1	TRAPPC12-AS1	-9.78	1.23e-20	1.08e-17	-0.42	-0.42	Neurofibrillary tangles;	chr2:3480729	chr2:3481242~3482409:-
PRAD	cis	rs6991838	0.584	rs1053088	ENSG00000200714.1	Y_RNA	9.78	1.24e-20	1.08e-17	0.46	0.42	Intelligence (multi-trait analysis);	chr8:65603548	chr8:65592731~65592820:+
PRAD	cis	rs17711722	0.522	rs62469933	ENSG00000228409.4	CCT6P1	-9.78	1.24e-20	1.09e-17	-0.3	-0.42	Calcium levels;	chr7:65800652	chr7:65751142~65763354:+
PRAD	cis	rs10800713	0.826	rs6427834	ENSG00000260088.1	RP11-92G12.3	-9.78	1.24e-20	1.09e-17	-0.61	-0.42	Tandem gait;	chr1:200561936	chr1:200669507~200694250:+
PRAD	cis	rs7174755	0.637	rs10152713	ENSG00000260657.2	RP11-315D16.4	-9.78	1.25e-20	1.09e-17	-0.53	-0.42	Major depressive disorder;	chr15:68179553	chr15:68267792~68277994:-
PRAD	cis	rs9309473	0.95	rs13431529	ENSG00000163016.8	ALMS1P	9.78	1.25e-20	1.1e-17	0.53	0.42	Metabolite levels;	chr2:73648914	chr2:73644919~73685576:+
PRAD	cis	rs34779708	0.931	rs12248333	ENSG00000230534.5	RP11-297A16.2	9.78	1.25e-20	1.1e-17	0.55	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35074049	chr10:35098006~35127020:-
PRAD	cis	rs853679	0.542	rs6934769	ENSG00000272009.1	RP1-313I6.12	-9.78	1.25e-20	1.1e-17	-0.42	-0.42	Depression;	chr6:28123153	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs17711801	ENSG00000272009.1	RP1-313I6.12	-9.78	1.25e-20	1.1e-17	-0.42	-0.42	Depression;	chr6:28124529	chr6:28078792~28081130:-
PRAD	cis	rs4713118	0.527	rs9461433	ENSG00000272009.1	RP1-313I6.12	-9.78	1.25e-20	1.1e-17	-0.42	-0.42	Parkinson's disease;	chr6:28127394	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs9468292	ENSG00000272009.1	RP1-313I6.12	-9.78	1.25e-20	1.1e-17	-0.42	-0.42	Depression;	chr6:28127577	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs1947863	ENSG00000272009.1	RP1-313I6.12	-9.78	1.25e-20	1.1e-17	-0.42	-0.42	Depression;	chr6:28131566	chr6:28078792~28081130:-
PRAD	cis	rs34779708	0.966	rs2045915	ENSG00000230534.5	RP11-297A16.2	9.78	1.26e-20	1.1e-17	0.54	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35129688	chr10:35098006~35127020:-
PRAD	cis	rs4964805	0.865	rs67825151	ENSG00000257681.1	RP11-341G23.4	9.78	1.26e-20	1.11e-17	0.43	0.42	Attention deficit hyperactivity disorder;	chr12:103811666	chr12:103746315~103768858:-
PRAD	cis	rs2404602	0.575	rs11072611	ENSG00000259422.1	RP11-593F23.1	9.78	1.26e-20	1.11e-17	0.56	0.42	Blood metabolite levels;	chr15:76655642	chr15:76174891~76181486:-
PRAD	cis	rs3814244	0.515	rs2906862	ENSG00000255733.4	IFNG-AS1	-9.78	1.27e-20	1.11e-17	-0.43	-0.42	Itch intensity from mosquito bite adjusted by bite size;	chr12:68005371	chr12:67989445~68234686:+
PRAD	cis	rs34779708	0.931	rs12240347	ENSG00000230534.5	RP11-297A16.2	9.78	1.27e-20	1.12e-17	0.55	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35070547	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.931	rs4934533	ENSG00000230534.5	RP11-297A16.2	9.78	1.27e-20	1.12e-17	0.55	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35070691	chr10:35098006~35127020:-
PRAD	cis	rs783540	0.609	rs803686	ENSG00000255769.6	GOLGA2P10	9.78	1.28e-20	1.12e-17	0.54	0.42	Schizophrenia;	chr15:82550590	chr15:82472993~82513950:-
PRAD	cis	rs8072100	0.582	rs3826536	ENSG00000228782.6	CTD-2026D20.3	9.78	1.29e-20	1.13e-17	0.46	0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47424601	chr17:47450568~47492492:-
PRAD	cis	rs9309473	1	rs10184268	ENSG00000163016.8	ALMS1P	9.78	1.3e-20	1.14e-17	0.52	0.42	Metabolite levels;	chr2:73399916	chr2:73644919~73685576:+
PRAD	cis	rs9545047	0.604	rs2765078	ENSG00000227676.3	LINC01068	9.78	1.3e-20	1.14e-17	0.49	0.42	Schizophrenia;	chr13:79420604	chr13:79566727~79571436:+
PRAD	cis	rs34779708	0.931	rs2384287	ENSG00000230534.5	RP11-297A16.2	9.77	1.3e-20	1.14e-17	0.55	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35051631	chr10:35098006~35127020:-
PRAD	cis	rs3002131	0.736	rs2936027	ENSG00000225265.1	TAF1A-AS1	-9.77	1.31e-20	1.15e-17	-0.71	-0.42	Interleukin-10 levels;	chr1:222588974	chr1:222589825~222593032:+
PRAD	cis	rs4879677	1	rs72712238	ENSG00000260390.1	RP11-575I8.1	-9.77	1.33e-20	1.16e-17	-0.55	-0.42	Gut microbiome composition (summer and winter);	chr9:27675371	chr9:27829276~27844481:+
PRAD	cis	rs2282300	0.739	rs1222215	ENSG00000242353.1	RP4-710M3.1	-9.77	1.33e-20	1.16e-17	-0.51	-0.42	Morning vs. evening chronotype;	chr11:30326049	chr11:30368148~30368646:+
PRAD	cis	rs2282300	0.696	rs1222214	ENSG00000242353.1	RP4-710M3.1	-9.77	1.33e-20	1.16e-17	-0.51	-0.42	Morning vs. evening chronotype;	chr11:30326148	chr11:30368148~30368646:+
PRAD	cis	rs2348418	0.932	rs7136886	ENSG00000247934.4	RP11-967K21.1	9.77	1.33e-20	1.16e-17	0.38	0.42	Lung function (FEV1);Lung function (FVC);	chr12:28460684	chr12:28163298~28190738:-
PRAD	cis	rs732716	0.785	rs62130978	ENSG00000267980.1	AC007292.6	-9.77	1.33e-20	1.17e-17	-0.43	-0.42	Mean corpuscular volume;	chr19:4429010	chr19:4363789~4364640:+
PRAD	cis	rs4713118	0.621	rs10484403	ENSG00000272009.1	RP1-313I6.12	-9.77	1.34e-20	1.17e-17	-0.42	-0.42	Parkinson's disease;	chr6:28065745	chr6:28078792~28081130:-
PRAD	cis	rs7849270	0.921	rs7868476	ENSG00000268707.1	RP11-247A12.7	-9.77	1.34e-20	1.17e-17	-0.47	-0.42	Blood metabolite ratios;	chr9:129155854	chr9:129170434~129170940:+
PRAD	cis	rs7849270	0.959	rs2094704	ENSG00000268707.1	RP11-247A12.7	-9.77	1.34e-20	1.17e-17	-0.47	-0.42	Blood metabolite ratios;	chr9:129156015	chr9:129170434~129170940:+
PRAD	cis	rs7849270	1	rs9697030	ENSG00000268707.1	RP11-247A12.7	-9.77	1.34e-20	1.17e-17	-0.47	-0.42	Blood metabolite ratios;	chr9:129157902	chr9:129170434~129170940:+
PRAD	cis	rs2282300	0.739	rs7952339	ENSG00000254532.1	RP11-624D11.2	-9.77	1.34e-20	1.17e-17	-0.58	-0.42	Morning vs. evening chronotype;	chr11:30305797	chr11:30044058~30084343:-
PRAD	cis	rs9326248	0.53	rs10790172	ENSG00000254851.1	RP11-109L13.1	-9.77	1.34e-20	1.18e-17	-0.82	-0.42	Blood protein levels;	chr11:117057024	chr11:117135528~117138582:+
PRAD	cis	rs1061377	0.748	rs1964347	ENSG00000249207.1	RP11-360F5.1	-9.77	1.35e-20	1.18e-17	-0.44	-0.42	Uric acid levels;	chr4:39104956	chr4:39112677~39126818:-
PRAD	cis	rs4879677	1	rs10968051	ENSG00000260390.1	RP11-575I8.1	-9.77	1.35e-20	1.18e-17	-0.56	-0.42	Gut microbiome composition (summer and winter);	chr9:27677646	chr9:27829276~27844481:+
PRAD	cis	rs4964805	0.954	rs4964812	ENSG00000257681.1	RP11-341G23.4	9.77	1.35e-20	1.18e-17	0.4	0.42	Attention deficit hyperactivity disorder;	chr12:103795837	chr12:103746315~103768858:-
PRAD	cis	rs638893	1	rs636736	ENSG00000278376.1	RP11-158I9.8	-9.77	1.36e-20	1.19e-17	-0.48	-0.42	Vitiligo;	chr11:118834436	chr11:118791254~118793137:+
PRAD	cis	rs1061377	0.748	rs4974933	ENSG00000249207.1	RP11-360F5.1	-9.77	1.36e-20	1.19e-17	-0.44	-0.42	Uric acid levels;	chr4:39105636	chr4:39112677~39126818:-
PRAD	cis	rs507080	0.883	rs656575	ENSG00000255422.1	AP002954.4	-9.77	1.36e-20	1.19e-17	-0.51	-0.42	Serum metabolite levels;	chr11:118679199	chr11:118704607~118750263:+
PRAD	cis	rs507080	0.961	rs656505	ENSG00000255422.1	AP002954.4	-9.77	1.36e-20	1.19e-17	-0.51	-0.42	Serum metabolite levels;	chr11:118679245	chr11:118704607~118750263:+
PRAD	cis	rs507080	0.961	rs660489	ENSG00000255422.1	AP002954.4	-9.77	1.36e-20	1.19e-17	-0.51	-0.42	Serum metabolite levels;	chr11:118679255	chr11:118704607~118750263:+
PRAD	cis	rs507080	0.961	rs543327	ENSG00000255422.1	AP002954.4	-9.77	1.36e-20	1.19e-17	-0.51	-0.42	Serum metabolite levels;	chr11:118679276	chr11:118704607~118750263:+
PRAD	cis	rs638893	1	rs649338	ENSG00000278376.1	RP11-158I9.8	-9.77	1.36e-20	1.19e-17	-0.49	-0.42	Vitiligo;	chr11:118834945	chr11:118791254~118793137:+
PRAD	cis	rs34779708	0.931	rs2001893	ENSG00000230534.5	RP11-297A16.2	9.77	1.37e-20	1.2e-17	0.54	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35011695	chr10:35098006~35127020:-
PRAD	cis	rs7772486	0.846	rs9403767	ENSG00000235652.6	RP11-545I5.3	9.77	1.37e-20	1.2e-17	0.43	0.42	Lobe attachment (rater-scored or self-reported);	chr6:146081250	chr6:145799409~145886585:+
PRAD	cis	rs638893	0.947	rs12808822	ENSG00000278376.1	RP11-158I9.8	-9.77	1.37e-20	1.2e-17	-0.48	-0.42	Vitiligo;	chr11:118831560	chr11:118791254~118793137:+
PRAD	cis	rs6539288	0.677	rs10778515	ENSG00000260329.1	RP11-412D9.4	-9.77	1.38e-20	1.2e-17	-0.37	-0.42	Total body bone mineral density;	chr12:106938703	chr12:106954029~106955497:-
PRAD	cis	rs2564921	0.73	rs56386026	ENSG00000242142.1	SERBP1P3	-9.77	1.38e-20	1.21e-17	-0.48	-0.42	Height;	chr3:53080524	chr3:53064283~53065091:-
PRAD	cis	rs783540	0.5	rs1313494	ENSG00000276710.3	CSPG4P8	9.77	1.4e-20	1.22e-17	0.5	0.42	Schizophrenia;	chr15:82605530	chr15:82459472~82477258:+
PRAD	cis	rs9545047	0.625	rs9545109	ENSG00000227676.3	LINC01068	9.77	1.4e-20	1.22e-17	0.49	0.42	Schizophrenia;	chr13:79413480	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.518	rs7328494	ENSG00000227676.3	LINC01068	9.77	1.4e-20	1.22e-17	0.49	0.42	Schizophrenia;	chr13:79414673	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs2147568	ENSG00000227676.3	LINC01068	9.77	1.4e-20	1.22e-17	0.49	0.42	Schizophrenia;	chr13:79417091	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs9530917	ENSG00000227676.3	LINC01068	9.77	1.4e-20	1.22e-17	0.49	0.42	Schizophrenia;	chr13:79417719	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs7990321	ENSG00000227676.3	LINC01068	9.77	1.4e-20	1.22e-17	0.49	0.42	Schizophrenia;	chr13:79418066	chr13:79566727~79571436:+
PRAD	cis	rs1061377	0.748	rs1964345	ENSG00000249207.1	RP11-360F5.1	-9.77	1.4e-20	1.22e-17	-0.44	-0.42	Uric acid levels;	chr4:39104793	chr4:39112677~39126818:-
PRAD	cis	rs8072100	0.713	rs9895776	ENSG00000228782.6	CTD-2026D20.3	9.77	1.41e-20	1.23e-17	0.46	0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47408637	chr17:47450568~47492492:-
PRAD	cis	rs3096299	0.582	rs12935119	ENSG00000261118.1	RP11-104N10.1	9.76	1.41e-20	1.23e-17	0.41	0.42	Multiple myeloma (IgH translocation);	chr16:89476466	chr16:89492017~89504460:-
PRAD	cis	rs9309473	0.95	rs13427832	ENSG00000163016.8	ALMS1P	9.76	1.42e-20	1.24e-17	0.52	0.42	Metabolite levels;	chr2:73617691	chr2:73644919~73685576:+
PRAD	cis	rs507080	0.922	rs4938524	ENSG00000255422.1	AP002954.4	-9.76	1.42e-20	1.24e-17	-0.51	-0.42	Serum metabolite levels;	chr11:118681365	chr11:118704607~118750263:+
PRAD	cis	rs6921919	0.697	rs758398	ENSG00000216901.1	AL022393.7	9.76	1.42e-20	1.24e-17	0.56	0.42	Autism spectrum disorder or schizophrenia;	chr6:28352897	chr6:28176188~28176674:+
PRAD	cis	rs3762637	0.941	rs74467988	ENSG00000272758.4	RP11-299J3.8	-9.76	1.43e-20	1.25e-17	-0.62	-0.42	LDL cholesterol levels;	chr3:122364293	chr3:122416207~122443180:+
PRAD	cis	rs3762637	0.882	rs9818537	ENSG00000272758.4	RP11-299J3.8	-9.76	1.43e-20	1.25e-17	-0.62	-0.42	LDL cholesterol levels;	chr3:122367610	chr3:122416207~122443180:+
PRAD	cis	rs3762637	0.941	rs9863712	ENSG00000272758.4	RP11-299J3.8	-9.76	1.43e-20	1.25e-17	-0.62	-0.42	LDL cholesterol levels;	chr3:122381059	chr3:122416207~122443180:+
PRAD	cis	rs7772486	0.817	rs12198065	ENSG00000235652.6	RP11-545I5.3	9.76	1.43e-20	1.25e-17	0.42	0.42	Lobe attachment (rater-scored or self-reported);	chr6:146064150	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.875	rs9390377	ENSG00000235652.6	RP11-545I5.3	9.76	1.43e-20	1.25e-17	0.42	0.42	Lobe attachment (rater-scored or self-reported);	chr6:146065796	chr6:145799409~145886585:+
PRAD	cis	rs7849270	1	rs3124510	ENSG00000268707.1	RP11-247A12.7	9.76	1.43e-20	1.25e-17	0.47	0.42	Blood metabolite ratios;	chr9:129137411	chr9:129170434~129170940:+
PRAD	cis	rs9309473	0.514	rs62149630	ENSG00000163016.8	ALMS1P	9.76	1.43e-20	1.25e-17	0.6	0.42	Metabolite levels;	chr2:73354627	chr2:73644919~73685576:+
PRAD	cis	rs9309473	0.514	rs62149659	ENSG00000163016.8	ALMS1P	9.76	1.43e-20	1.25e-17	0.6	0.42	Metabolite levels;	chr2:73358068	chr2:73644919~73685576:+
PRAD	cis	rs9545047	0.604	rs943709	ENSG00000227676.3	LINC01068	9.76	1.44e-20	1.25e-17	0.5	0.42	Schizophrenia;	chr13:79282990	chr13:79566727~79571436:+
PRAD	cis	rs2658782	0.654	rs2605620	ENSG00000279684.1	RP11-755E23.2	-9.76	1.44e-20	1.26e-17	-0.63	-0.42	Pulmonary function decline;	chr11:93514480	chr11:93286629~93288903:-
PRAD	cis	rs9545047	0.604	rs2876740	ENSG00000227676.3	LINC01068	-9.76	1.44e-20	1.26e-17	-0.49	-0.42	Schizophrenia;	chr13:79409829	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs314695	ENSG00000227676.3	LINC01068	-9.76	1.44e-20	1.26e-17	-0.49	-0.42	Schizophrenia;	chr13:79432206	chr13:79566727~79571436:+
PRAD	cis	rs1150668	0.83	rs2859365	ENSG00000216901.1	AL022393.7	-9.76	1.45e-20	1.26e-17	-0.51	-0.42	Pubertal anthropometrics;	chr6:28423688	chr6:28176188~28176674:+
PRAD	cis	rs7849270	0.959	rs3124509	ENSG00000268707.1	RP11-247A12.7	9.76	1.45e-20	1.27e-17	0.47	0.42	Blood metabolite ratios;	chr9:129134720	chr9:129170434~129170940:+
PRAD	cis	rs7772486	0.558	rs702316	ENSG00000235652.6	RP11-545I5.3	-9.76	1.45e-20	1.27e-17	-0.49	-0.42	Lobe attachment (rater-scored or self-reported);	chr6:145683541	chr6:145799409~145886585:+
PRAD	cis	rs7849270	1	rs3118632	ENSG00000268707.1	RP11-247A12.7	9.76	1.46e-20	1.27e-17	0.47	0.42	Blood metabolite ratios;	chr9:129139005	chr9:129170434~129170940:+
PRAD	cis	rs6142102	0.961	rs6088361	ENSG00000276073.1	RP5-1125A11.7	-9.76	1.47e-20	1.28e-17	-0.43	-0.42	Skin pigmentation;	chr20:33969520	chr20:33985617~33988989:-
PRAD	cis	rs1930961	1	rs6004667	ENSG00000272942.1	CTA-246H3.12	9.76	1.48e-20	1.29e-17	0.66	0.42	Bipolar disorder with mood-incongruent psychosis;	chr22:25478497	chr22:25434324~25435070:-
PRAD	cis	rs673078	0.66	rs61943365	ENSG00000275759.1	RP11-131L12.3	-9.76	1.48e-20	1.29e-17	-0.58	-0.42	Glucose homeostasis traits;	chr12:118339166	chr12:118428281~118428870:+
PRAD	cis	rs2739330	0.892	rs4822455	ENSG00000099984.9	GSTT2	-9.76	1.48e-20	1.29e-17	-0.56	-0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23980123~23983911:+
PRAD	cis	rs7849270	1	rs4713	ENSG00000268707.1	RP11-247A12.7	9.76	1.49e-20	1.29e-17	0.47	0.42	Blood metabolite ratios;	chr9:129148526	chr9:129170434~129170940:+
PRAD	cis	rs7586673	1	rs7586673	ENSG00000227403.1	AC009299.3	-9.76	1.49e-20	1.29e-17	-0.56	-0.42	Intelligence (multi-trait analysis);	chr2:161067009	chr2:161244739~161249050:+
PRAD	cis	rs3762637	0.882	rs9856011	ENSG00000272758.4	RP11-299J3.8	-9.76	1.49e-20	1.3e-17	-0.63	-0.42	LDL cholesterol levels;	chr3:122374723	chr3:122416207~122443180:+
PRAD	cis	rs10875746	0.859	rs12305647	ENSG00000240399.1	RP1-228P16.1	-9.76	1.5e-20	1.3e-17	-0.4	-0.42	Longevity (90 years and older);	chr12:48189178	chr12:48054813~48055591:-
PRAD	cis	rs9309473	0.948	rs13392691	ENSG00000163016.8	ALMS1P	9.76	1.5e-20	1.3e-17	0.53	0.42	Metabolite levels;	chr2:73521853	chr2:73644919~73685576:+
PRAD	cis	rs9309473	0.95	rs11689588	ENSG00000163016.8	ALMS1P	9.76	1.5e-20	1.3e-17	0.53	0.42	Metabolite levels;	chr2:73546564	chr2:73644919~73685576:+
PRAD	cis	rs9309473	1	rs7598419	ENSG00000163016.8	ALMS1P	9.76	1.5e-20	1.3e-17	0.53	0.42	Metabolite levels;	chr2:73571096	chr2:73644919~73685576:+
PRAD	cis	rs2153535	0.585	rs6934905	ENSG00000230939.1	RP11-314C16.1	-9.76	1.5e-20	1.31e-17	-0.51	-0.42	Motion sickness;	chr6:8661326	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.618	rs11243267	ENSG00000230939.1	RP11-314C16.1	-9.76	1.5e-20	1.31e-17	-0.51	-0.42	Motion sickness;	chr6:8662287	chr6:8784178~8785445:+
PRAD	cis	rs7772486	0.875	rs2814877	ENSG00000235652.6	RP11-545I5.3	9.76	1.5e-20	1.31e-17	0.42	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145978627	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.846	rs372904	ENSG00000235652.6	RP11-545I5.3	9.76	1.51e-20	1.31e-17	0.43	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145566289	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.791	rs414297	ENSG00000235652.6	RP11-545I5.3	9.76	1.51e-20	1.31e-17	0.43	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145566420	chr6:145799409~145886585:+
PRAD	cis	rs12049351	0.665	rs10799532	ENSG00000229367.1	HMGN2P19	9.76	1.53e-20	1.33e-17	0.6	0.42	Circulating myeloperoxidase levels (plasma);	chr1:229448873	chr1:229570532~229570796:+
PRAD	cis	rs8072100	0.738	rs3736438	ENSG00000228782.6	CTD-2026D20.3	9.76	1.53e-20	1.33e-17	0.46	0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47409285	chr17:47450568~47492492:-
PRAD	cis	rs2153535	0.585	rs9328500	ENSG00000230939.1	RP11-314C16.1	9.75	1.53e-20	1.33e-17	0.51	0.42	Motion sickness;	chr6:8658838	chr6:8784178~8785445:+
PRAD	cis	rs748404	0.518	rs480108	ENSG00000249839.1	AC011330.5	-9.75	1.54e-20	1.34e-17	-0.53	-0.42	Lung cancer;	chr15:43525208	chr15:43663654~43684339:-
PRAD	cis	rs7772486	0.846	rs7755440	ENSG00000235652.6	RP11-545I5.3	9.75	1.54e-20	1.34e-17	0.42	0.42	Lobe attachment (rater-scored or self-reported);	chr6:146054770	chr6:145799409~145886585:+
PRAD	cis	rs7182621	0.515	rs3803416	ENSG00000182397.13	DNM1P46	9.75	1.54e-20	1.34e-17	0.51	0.42	Colonoscopy-negative controls vs population controls;	chr15:99788855	chr15:99790156~99806927:-
PRAD	cis	rs9309473	1	rs1881245	ENSG00000163016.8	ALMS1P	9.75	1.54e-20	1.34e-17	0.51	0.42	Metabolite levels;	chr2:73422800	chr2:73644919~73685576:+
PRAD	cis	rs9309473	1	rs10179134	ENSG00000163016.8	ALMS1P	9.75	1.55e-20	1.35e-17	0.51	0.42	Metabolite levels;	chr2:73410391	chr2:73644919~73685576:+
PRAD	cis	rs7772486	0.875	rs2474356	ENSG00000235652.6	RP11-545I5.3	9.75	1.55e-20	1.35e-17	0.42	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145975662	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.875	rs2814875	ENSG00000235652.6	RP11-545I5.3	9.75	1.55e-20	1.35e-17	0.42	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145984674	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.875	rs2814874	ENSG00000235652.6	RP11-545I5.3	9.75	1.55e-20	1.35e-17	0.42	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145984759	chr6:145799409~145886585:+
PRAD	cis	rs9309473	0.898	rs11126403	ENSG00000163016.8	ALMS1P	9.75	1.55e-20	1.35e-17	0.52	0.42	Metabolite levels;	chr2:73569796	chr2:73644919~73685576:+
PRAD	cis	rs9309473	0.898	rs11126404	ENSG00000163016.8	ALMS1P	9.75	1.55e-20	1.35e-17	0.52	0.42	Metabolite levels;	chr2:73569797	chr2:73644919~73685576:+
PRAD	cis	rs4713118	0.662	rs9393881	ENSG00000280107.1	AL022393.9	-9.75	1.55e-20	1.35e-17	-0.55	-0.42	Parkinson's disease;	chr6:28055973	chr6:28170845~28172521:+
PRAD	cis	rs2348418	0.702	rs10843116	ENSG00000247934.4	RP11-967K21.1	-9.75	1.56e-20	1.36e-17	-0.39	-0.42	Lung function (FEV1);Lung function (FVC);	chr12:28162248	chr12:28163298~28190738:-
PRAD	cis	rs7586673	1	rs16845584	ENSG00000227403.1	AC009299.3	9.75	1.56e-20	1.36e-17	0.56	0.42	Intelligence (multi-trait analysis);	chr2:161067319	chr2:161244739~161249050:+
PRAD	cis	rs34779708	0.966	rs2126984	ENSG00000230534.5	RP11-297A16.2	9.75	1.57e-20	1.36e-17	0.54	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35121363	chr10:35098006~35127020:-
PRAD	cis	rs12134133	1	rs2490261	ENSG00000274245.1	RP11-357P18.2	9.75	1.57e-20	1.37e-17	0.57	0.42	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207304124	chr1:207372559~207373252:+
PRAD	cis	rs4964805	0.954	rs11111785	ENSG00000257681.1	RP11-341G23.4	9.75	1.57e-20	1.37e-17	0.4	0.42	Attention deficit hyperactivity disorder;	chr12:103795278	chr12:103746315~103768858:-
PRAD	cis	rs4964805	0.954	rs11111786	ENSG00000257681.1	RP11-341G23.4	9.75	1.57e-20	1.37e-17	0.4	0.42	Attention deficit hyperactivity disorder;	chr12:103795279	chr12:103746315~103768858:-
PRAD	cis	rs7714584	1	rs59980321	ENSG00000197083.10	ZNF300P1	9.75	1.57e-20	1.37e-17	0.67	0.42	Crohn's disease;	chr5:150862251	chr5:150930645~150946289:-
PRAD	cis	rs7714584	1	rs7709650	ENSG00000197083.10	ZNF300P1	9.75	1.57e-20	1.37e-17	0.67	0.42	Crohn's disease;	chr5:150867123	chr5:150930645~150946289:-
PRAD	cis	rs7849270	1	rs3739847	ENSG00000268707.1	RP11-247A12.7	9.75	1.59e-20	1.38e-17	0.47	0.42	Blood metabolite ratios;	chr9:129149295	chr9:129170434~129170940:+
PRAD	cis	rs2282300	0.637	rs1765131	ENSG00000242353.1	RP4-710M3.1	-9.75	1.6e-20	1.39e-17	-0.44	-0.42	Morning vs. evening chronotype;	chr11:30382991	chr11:30368148~30368646:+
PRAD	cis	rs12220777	1	rs11201312	ENSG00000230091.5	TMEM254-AS1	9.75	1.61e-20	1.4e-17	0.83	0.42	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80036022	chr10:80046860~80078912:-
PRAD	cis	rs4964805	0.954	rs10861105	ENSG00000257681.1	RP11-341G23.4	9.75	1.61e-20	1.4e-17	0.4	0.42	Attention deficit hyperactivity disorder;	chr12:103796221	chr12:103746315~103768858:-
PRAD	cis	rs4964805	1	rs11111789	ENSG00000257681.1	RP11-341G23.4	9.75	1.61e-20	1.4e-17	0.4	0.42	Attention deficit hyperactivity disorder;	chr12:103797762	chr12:103746315~103768858:-
PRAD	cis	rs9309473	1	rs11893881	ENSG00000163016.8	ALMS1P	9.75	1.62e-20	1.41e-17	0.51	0.42	Metabolite levels;	chr2:73597246	chr2:73644919~73685576:+
PRAD	cis	rs6876835	0.553	rs7734641	ENSG00000250056.4	LINC01018	9.75	1.63e-20	1.41e-17	0.49	0.42	Visceral fat;	chr5:6598669	chr5:6582136~6588499:+
PRAD	cis	rs997154	0.655	rs8015121	ENSG00000279656.1	RP11-298I3.6	9.75	1.63e-20	1.41e-17	0.6	0.42	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22906042	chr14:23023083~23024217:-
PRAD	cis	rs9309711	0.666	rs6723101	ENSG00000225234.1	TRAPPC12-AS1	-9.75	1.64e-20	1.42e-17	-0.42	-0.42	Neurofibrillary tangles;	chr2:3480672	chr2:3481242~3482409:-
PRAD	cis	rs7849270	1	rs3124513	ENSG00000268707.1	RP11-247A12.7	9.75	1.64e-20	1.43e-17	0.47	0.42	Blood metabolite ratios;	chr9:129142314	chr9:129170434~129170940:+
PRAD	cis	rs7849270	1	rs3124514	ENSG00000268707.1	RP11-247A12.7	9.75	1.64e-20	1.43e-17	0.47	0.42	Blood metabolite ratios;	chr9:129142329	chr9:129170434~129170940:+
PRAD	cis	rs507080	0.922	rs592280	ENSG00000255422.1	AP002954.4	-9.75	1.65e-20	1.43e-17	-0.51	-0.42	Serum metabolite levels;	chr11:118682509	chr11:118704607~118750263:+
PRAD	cis	rs12134133	1	rs61822697	ENSG00000274245.1	RP11-357P18.2	9.75	1.65e-20	1.43e-17	0.6	0.42	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207311819	chr1:207372559~207373252:+
PRAD	cis	rs6570726	0.791	rs6914203	ENSG00000235652.6	RP11-545I5.3	9.75	1.65e-20	1.44e-17	0.43	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145578839	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.791	rs379040	ENSG00000235652.6	RP11-545I5.3	9.75	1.65e-20	1.44e-17	0.43	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145567899	chr6:145799409~145886585:+
PRAD	cis	rs9309473	0.948	rs10170849	ENSG00000163016.8	ALMS1P	9.75	1.66e-20	1.44e-17	0.51	0.42	Metabolite levels;	chr2:73520805	chr2:73644919~73685576:+
PRAD	cis	rs1061377	0.748	rs12506723	ENSG00000249207.1	RP11-360F5.1	-9.75	1.66e-20	1.44e-17	-0.44	-0.42	Uric acid levels;	chr4:39103152	chr4:39112677~39126818:-
PRAD	cis	rs3931020	0.657	rs277368	ENSG00000272864.1	RP11-17E13.2	9.75	1.66e-20	1.44e-17	0.48	0.42	Resistin levels;	chr1:74764922	chr1:74698769~74699333:-
PRAD	cis	rs10246939	0.553	rs34894166	ENSG00000228775.6	WEE2-AS1	9.74	1.67e-20	1.45e-17	0.52	0.42	Bitter taste perception;	chr7:141852158	chr7:141704338~141738346:-
PRAD	cis	rs7714584	1	rs75294883	ENSG00000197083.10	ZNF300P1	9.74	1.67e-20	1.45e-17	0.82	0.42	Crohn's disease;	chr5:150816941	chr5:150930645~150946289:-
PRAD	cis	rs9918079	0.542	rs1789	ENSG00000273133.1	RP11-799M12.2	-9.74	1.68e-20	1.46e-17	-0.52	-0.42	Obesity-related traits;	chr4:15662912	chr4:15563698~15564253:-
PRAD	cis	rs1075265	0.626	rs805412	ENSG00000233266.1	HMGB1P31	9.74	1.69e-20	1.46e-17	0.55	0.42	Chronotype;Morning vs. evening chronotype;	chr2:53893683	chr2:54051334~54051760:+
PRAD	cis	rs9322193	0.887	rs11155662	ENSG00000268592.3	RAET1E-AS1	9.74	1.69e-20	1.47e-17	0.59	0.42	Lung cancer;	chr6:149592731	chr6:149863494~149919507:+
PRAD	cis	rs875971	0.651	rs313829	ENSG00000226824.5	RP4-756H11.3	9.74	1.7e-20	1.47e-17	0.59	0.42	Aortic root size;	chr7:66087510	chr7:66654538~66669855:+
PRAD	cis	rs1075265	0.62	rs10192626	ENSG00000233266.1	HMGB1P31	9.74	1.7e-20	1.48e-17	0.57	0.42	Chronotype;Morning vs. evening chronotype;	chr2:53760885	chr2:54051334~54051760:+
PRAD	cis	rs4639966	0.589	rs480958	ENSG00000255239.1	AP002954.6	9.74	1.71e-20	1.48e-17	0.54	0.42	Systemic lupus erythematosus;	chr11:118707281	chr11:118688039~118690600:-
PRAD	cis	rs6700559	0.967	rs10919992	ENSG00000260088.1	RP11-92G12.3	-9.74	1.71e-20	1.48e-17	-0.53	-0.42	Coronary artery disease;	chr1:200638338	chr1:200669507~200694250:+
PRAD	cis	rs9389248	0.708	rs7750574	ENSG00000232876.1	CTA-212D2.2	-9.74	1.71e-20	1.48e-17	-0.52	-0.42	High light scatter reticulocyte percentage of red cells;	chr6:135029794	chr6:135055033~135060550:+
PRAD	cis	rs748404	0.56	rs529611	ENSG00000249839.1	AC011330.5	-9.74	1.72e-20	1.49e-17	-0.52	-0.42	Lung cancer;	chr15:43513790	chr15:43663654~43684339:-
PRAD	cis	rs1075265	0.68	rs805396	ENSG00000233266.1	HMGB1P31	9.74	1.72e-20	1.49e-17	0.55	0.42	Chronotype;Morning vs. evening chronotype;	chr2:53882314	chr2:54051334~54051760:+
PRAD	cis	rs4927850	1	rs4927704	ENSG00000242086.7	LINC00969	9.74	1.72e-20	1.49e-17	0.37	0.42	Pancreatic cancer;	chr3:196011357	chr3:195658062~195739964:+
PRAD	cis	rs4927850	1	rs4927848	ENSG00000242086.7	LINC00969	9.74	1.72e-20	1.49e-17	0.37	0.42	Pancreatic cancer;	chr3:196011535	chr3:195658062~195739964:+
PRAD	cis	rs6565180	0.525	rs1132812	ENSG00000183604.13	SMG1P5	9.74	1.73e-20	1.5e-17	0.38	0.42	Tonsillectomy;	chr16:30186830	chr16:30267553~30335374:-
PRAD	cis	rs9309473	0.66	rs11686541	ENSG00000163016.8	ALMS1P	9.74	1.73e-20	1.5e-17	0.62	0.42	Metabolite levels;	chr2:73477348	chr2:73644919~73685576:+
PRAD	cis	rs2739330	0.76	rs5760095	ENSG00000206090.4	AP000350.7	9.74	1.74e-20	1.51e-17	0.53	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23939998~23942798:+
PRAD	cis	rs7688540	0.656	rs79657896	ENSG00000275426.1	CH17-262A2.1	9.74	1.76e-20	1.52e-17	0.64	0.42	Facial morphology (factor 6, height of vermillion lower lip);	chr4:305472	chr4:149738~150317:+
PRAD	cis	rs2564921	0.704	rs56058643	ENSG00000242142.1	SERBP1P3	-9.74	1.77e-20	1.54e-17	-0.48	-0.42	Height;	chr3:53093751	chr3:53064283~53065091:-
PRAD	cis	rs2487048	0.905	rs2437812	ENSG00000226334.1	RP11-217B7.2	-9.74	1.78e-20	1.54e-17	-0.57	-0.42	Intraocular pressure;	chr9:104930920	chr9:104927553~104928892:+
PRAD	cis	rs9487605	1	rs9487605	ENSG00000230177.1	RP5-1112D6.4	-9.74	1.79e-20	1.55e-17	-0.48	-0.42	Inflammatory skin disease;	chr6:111261682	chr6:111277932~111278742:+
PRAD	cis	rs8062405	1	rs7498555	ENSG00000259982.1	CDC37P1	9.74	1.79e-20	1.55e-17	0.56	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28882250	chr16:28700294~28701540:-
PRAD	cis	rs17711722	0.522	rs6957759	ENSG00000228409.4	CCT6P1	-9.73	1.81e-20	1.56e-17	-0.3	-0.42	Calcium levels;	chr7:65806798	chr7:65751142~65763354:+
PRAD	cis	rs1075265	0.704	rs805410	ENSG00000233266.1	HMGB1P31	9.73	1.81e-20	1.57e-17	0.56	0.42	Chronotype;Morning vs. evening chronotype;	chr2:53893360	chr2:54051334~54051760:+
PRAD	cis	rs2348418	0.798	rs4930826	ENSG00000247934.4	RP11-967K21.1	9.73	1.81e-20	1.57e-17	0.38	0.42	Lung function (FEV1);Lung function (FVC);	chr12:28574385	chr12:28163298~28190738:-
PRAD	cis	rs1061377	0.748	rs1036034	ENSG00000249207.1	RP11-360F5.1	-9.73	1.83e-20	1.58e-17	-0.44	-0.42	Uric acid levels;	chr4:39105299	chr4:39112677~39126818:-
PRAD	cis	rs9309473	1	rs6705489	ENSG00000163016.8	ALMS1P	9.73	1.84e-20	1.59e-17	0.51	0.42	Metabolite levels;	chr2:73421683	chr2:73644919~73685576:+
PRAD	cis	rs6142102	1	rs6059681	ENSG00000276073.1	RP5-1125A11.7	-9.73	1.84e-20	1.59e-17	-0.43	-0.42	Skin pigmentation;	chr20:34135535	chr20:33985617~33988989:-
PRAD	cis	rs9545047	0.564	rs7336186	ENSG00000227676.3	LINC01068	-9.73	1.85e-20	1.6e-17	-0.49	-0.42	Schizophrenia;	chr13:79385497	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs2182009	ENSG00000227676.3	LINC01068	-9.73	1.85e-20	1.6e-17	-0.49	-0.42	Schizophrenia;	chr13:79397781	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs4605023	ENSG00000227676.3	LINC01068	-9.73	1.85e-20	1.6e-17	-0.49	-0.42	Schizophrenia;	chr13:79398700	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs9565496	ENSG00000227676.3	LINC01068	-9.73	1.85e-20	1.6e-17	-0.49	-0.42	Schizophrenia;	chr13:79398751	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs12877507	ENSG00000227676.3	LINC01068	-9.73	1.85e-20	1.6e-17	-0.49	-0.42	Schizophrenia;	chr13:79401822	chr13:79566727~79571436:+
PRAD	cis	rs7772486	0.875	rs2748501	ENSG00000235652.6	RP11-545I5.3	9.73	1.85e-20	1.6e-17	0.42	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145991122	chr6:145799409~145886585:+
PRAD	cis	rs2286503	1	rs2286499	ENSG00000228649.7	AC005682.5	9.73	1.86e-20	1.61e-17	0.47	0.42	Fibrinogen;	chr7:22817858	chr7:22854178~22861579:+
PRAD	cis	rs4718428	0.672	rs4718412	ENSG00000232546.1	RP11-458F8.1	9.73	1.86e-20	1.61e-17	0.34	0.42	Corneal structure;	chr7:66821880	chr7:66848496~66858136:+
PRAD	cis	rs7772486	0.875	rs9322043	ENSG00000235652.6	RP11-545I5.3	9.73	1.87e-20	1.61e-17	0.42	0.42	Lobe attachment (rater-scored or self-reported);	chr6:146031554	chr6:145799409~145886585:+
PRAD	cis	rs3931020	0.657	rs277376	ENSG00000272864.1	RP11-17E13.2	9.73	1.87e-20	1.61e-17	0.5	0.42	Resistin levels;	chr1:74776562	chr1:74698769~74699333:-
PRAD	cis	rs7772486	0.875	rs865913	ENSG00000235652.6	RP11-545I5.3	9.73	1.87e-20	1.62e-17	0.42	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145987738	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.875	rs2814873	ENSG00000235652.6	RP11-545I5.3	9.73	1.87e-20	1.62e-17	0.42	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145987796	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.84	rs2777478	ENSG00000235652.6	RP11-545I5.3	9.73	1.87e-20	1.62e-17	0.42	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145987981	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.875	rs854148	ENSG00000235652.6	RP11-545I5.3	9.73	1.87e-20	1.62e-17	0.42	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145989843	chr6:145799409~145886585:+
PRAD	cis	rs1729407	0.774	rs2849167	ENSG00000254851.1	RP11-109L13.1	9.73	1.88e-20	1.62e-17	0.53	0.42	Apolipoprotein A-IV levels;	chr11:116814028	chr11:117135528~117138582:+
PRAD	cis	rs12049351	0.665	rs10916479	ENSG00000229367.1	HMGN2P19	9.73	1.89e-20	1.63e-17	0.6	0.41	Circulating myeloperoxidase levels (plasma);	chr1:229447800	chr1:229570532~229570796:+
PRAD	cis	rs3096299	0.933	rs2965938	ENSG00000274627.1	RP11-104N10.2	9.73	1.89e-20	1.63e-17	0.43	0.41	Multiple myeloma (IgH translocation);	chr16:89424928	chr16:89516797~89522217:+
PRAD	cis	rs11118620	0.81	rs4587570	ENSG00000272823.1	RP11-295M18.6	9.73	1.92e-20	1.66e-17	0.52	0.41	Heart failure;	chr1:220860693	chr1:220828676~220829211:-
PRAD	cis	rs7688540	0.771	rs61792116	ENSG00000275426.1	CH17-262A2.1	9.73	1.93e-20	1.67e-17	0.64	0.41	Facial morphology (factor 6, height of vermillion lower lip);	chr4:307288	chr4:149738~150317:+
PRAD	cis	rs7115242	0.669	rs1241658	ENSG00000254851.1	RP11-109L13.1	-9.73	1.95e-20	1.68e-17	-0.81	-0.41	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116948901	chr11:117135528~117138582:+
PRAD	cis	rs4380275	0.782	rs4468850	ENSG00000272342.1	RP13-539J13.1	9.72	1.97e-20	1.7e-17	0.54	0.41	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:749467	chr2:739588~740164:-
PRAD	cis	rs853679	0.517	rs4713141	ENSG00000272009.1	RP1-313I6.12	-9.72	1.97e-20	1.7e-17	-0.42	-0.41	Depression;	chr6:28133900	chr6:28078792~28081130:-
PRAD	cis	rs9309473	1	rs10190219	ENSG00000163016.8	ALMS1P	9.72	1.98e-20	1.7e-17	0.52	0.41	Metabolite levels;	chr2:73431203	chr2:73644919~73685576:+
PRAD	cis	rs7688540	0.771	rs10021364	ENSG00000275426.1	CH17-262A2.1	-9.72	1.98e-20	1.71e-17	-0.64	-0.41	Facial morphology (factor 6, height of vermillion lower lip);	chr4:316902	chr4:149738~150317:+
PRAD	cis	rs1150668	0.796	rs9468372	ENSG00000216901.1	AL022393.7	9.72	1.98e-20	1.71e-17	0.51	0.41	Pubertal anthropometrics;	chr6:28411584	chr6:28176188~28176674:+
PRAD	cis	rs9309473	0.95	rs6546847	ENSG00000163016.8	ALMS1P	9.72	2e-20	1.72e-17	0.51	0.41	Metabolite levels;	chr2:73558231	chr2:73644919~73685576:+
PRAD	cis	rs875971	0.83	rs12673450	ENSG00000237310.1	GS1-124K5.4	9.72	2e-20	1.72e-17	0.4	0.41	Aortic root size;	chr7:66544233	chr7:66493706~66495474:+
PRAD	cis	rs2282300	0.739	rs16920406	ENSG00000242353.1	RP4-710M3.1	-9.72	2e-20	1.72e-17	-0.5	-0.41	Morning vs. evening chronotype;	chr11:30194611	chr11:30368148~30368646:+
PRAD	cis	rs4927850	0.958	rs2044599	ENSG00000242086.7	LINC00969	9.72	2.01e-20	1.73e-17	0.37	0.41	Pancreatic cancer;	chr3:196009869	chr3:195658062~195739964:+
PRAD	cis	rs732716	0.785	rs34080966	ENSG00000267980.1	AC007292.6	9.72	2.03e-20	1.74e-17	0.42	0.41	Mean corpuscular volume;	chr19:4417848	chr19:4363789~4364640:+
PRAD	cis	rs507080	0.922	rs642662	ENSG00000255422.1	AP002954.4	-9.72	2.03e-20	1.75e-17	-0.51	-0.41	Serum metabolite levels;	chr11:118696311	chr11:118704607~118750263:+
PRAD	cis	rs9309473	1	rs7564890	ENSG00000163016.8	ALMS1P	9.72	2.04e-20	1.76e-17	0.51	0.41	Metabolite levels;	chr2:73414725	chr2:73644919~73685576:+
PRAD	cis	rs4718428	0.705	rs11028	ENSG00000273142.1	RP11-458F8.4	-9.72	2.05e-20	1.76e-17	-0.32	-0.41	Corneal structure;	chr7:66811230	chr7:66902857~66906297:+
PRAD	cis	rs1858037	0.867	rs2118305	ENSG00000204929.10	AC074391.1	9.72	2.05e-20	1.76e-17	0.57	0.41	Rheumatoid arthritis;	chr2:65378086	chr2:65436711~66084639:+
PRAD	cis	rs6700559	0.742	rs10399790	ENSG00000260088.1	RP11-92G12.3	-9.72	2.05e-20	1.77e-17	-0.52	-0.41	Coronary artery disease;	chr1:200626241	chr1:200669507~200694250:+
PRAD	cis	rs6700559	0.81	rs10919991	ENSG00000260088.1	RP11-92G12.3	-9.72	2.05e-20	1.77e-17	-0.52	-0.41	Coronary artery disease;	chr1:200627217	chr1:200669507~200694250:+
PRAD	cis	rs2282300	0.739	rs10835648	ENSG00000254532.1	RP11-624D11.2	-9.72	2.07e-20	1.78e-17	-0.58	-0.41	Morning vs. evening chronotype;	chr11:30298959	chr11:30044058~30084343:-
PRAD	cis	rs3002131	0.522	rs2936031	ENSG00000225265.1	TAF1A-AS1	-9.72	2.08e-20	1.79e-17	-0.73	-0.41	Interleukin-10 levels;	chr1:222582910	chr1:222589825~222593032:+
PRAD	cis	rs1075265	0.756	rs3821081	ENSG00000233266.1	HMGB1P31	-9.72	2.08e-20	1.79e-17	-0.56	-0.41	Chronotype;Morning vs. evening chronotype;	chr2:53738252	chr2:54051334~54051760:+
PRAD	cis	rs9309473	0.615	rs11680965	ENSG00000163016.8	ALMS1P	9.72	2.08e-20	1.79e-17	0.62	0.41	Metabolite levels;	chr2:73498789	chr2:73644919~73685576:+
PRAD	cis	rs6822297	0.504	rs10010180	ENSG00000240005.4	RP11-293A21.1	9.72	2.08e-20	1.79e-17	0.46	0.41	Obesity-related traits;	chr4:26984359	chr4:26859806~26860599:-
PRAD	cis	rs4879677	1	rs10968061	ENSG00000260390.1	RP11-575I8.1	9.72	2.1e-20	1.8e-17	0.55	0.41	Gut microbiome composition (summer and winter);	chr9:27688780	chr9:27829276~27844481:+
PRAD	cis	rs3096299	0.9	rs3114867	ENSG00000274627.1	RP11-104N10.2	9.72	2.12e-20	1.82e-17	0.43	0.41	Multiple myeloma (IgH translocation);	chr16:89362559	chr16:89516797~89522217:+
PRAD	cis	rs9399137	0.507	rs4896128	ENSG00000232876.1	CTA-212D2.2	9.71	2.14e-20	1.84e-17	0.52	0.41	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135028618	chr6:135055033~135060550:+
PRAD	cis	rs1061377	0.748	rs6842561	ENSG00000249207.1	RP11-360F5.1	-9.71	2.14e-20	1.84e-17	-0.44	-0.41	Uric acid levels;	chr4:39106873	chr4:39112677~39126818:-
PRAD	cis	rs7714584	1	rs60134818	ENSG00000197083.10	ZNF300P1	9.71	2.15e-20	1.85e-17	0.66	0.41	Crohn's disease;	chr5:150881481	chr5:150930645~150946289:-
PRAD	cis	rs7714584	1	rs7714415	ENSG00000197083.10	ZNF300P1	9.71	2.15e-20	1.85e-17	0.66	0.41	Crohn's disease;	chr5:150890730	chr5:150930645~150946289:-
PRAD	cis	rs10129255	0.518	rs12590732	ENSG00000223648.3	IGHV3-64	-9.71	2.16e-20	1.85e-17	-0.36	-0.41	Kawasaki disease;	chr14:106779612	chr14:106643132~106658258:-
PRAD	cis	rs4964805	1	rs73192053	ENSG00000257681.1	RP11-341G23.4	9.71	2.16e-20	1.86e-17	0.4	0.41	Attention deficit hyperactivity disorder;	chr12:103797077	chr12:103746315~103768858:-
PRAD	cis	rs7201929	1	rs8061877	ENSG00000259982.1	CDC37P1	-9.71	2.18e-20	1.87e-17	-0.59	-0.41	QT interval;	chr16:28845498	chr16:28700294~28701540:-
PRAD	cis	rs2404602	1	rs12148786	ENSG00000259422.1	RP11-593F23.1	9.71	2.19e-20	1.88e-17	0.51	0.41	Blood metabolite levels;	chr15:76508021	chr15:76174891~76181486:-
PRAD	cis	rs12134133	1	rs28371583	ENSG00000274245.1	RP11-357P18.2	9.71	2.2e-20	1.89e-17	0.58	0.41	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207321334	chr1:207372559~207373252:+
PRAD	cis	rs10246939	0.505	rs34726057	ENSG00000228775.6	WEE2-AS1	9.71	2.21e-20	1.9e-17	0.53	0.41	Bitter taste perception;	chr7:141832117	chr7:141704338~141738346:-
PRAD	cis	rs2404602	0.967	rs12148805	ENSG00000259422.1	RP11-593F23.1	9.71	2.21e-20	1.9e-17	0.51	0.41	Blood metabolite levels;	chr15:76508318	chr15:76174891~76181486:-
PRAD	cis	rs7615952	0.673	rs115942855	ENSG00000171084.14	FAM86JP	9.71	2.22e-20	1.9e-17	0.83	0.41	Blood pressure (smoking interaction);	chr3:125883117	chr3:125916620~125930024:+
PRAD	cis	rs7772486	0.806	rs2253648	ENSG00000235652.6	RP11-545I5.3	9.71	2.22e-20	1.91e-17	0.42	0.41	Lobe attachment (rater-scored or self-reported);	chr6:145878160	chr6:145799409~145886585:+
PRAD	cis	rs172166	0.516	rs1150670	ENSG00000204709.4	LINC01556	9.71	2.22e-20	1.91e-17	0.52	0.41	Cardiac Troponin-T levels;	chr6:28162781	chr6:28943877~28944537:+
PRAD	cis	rs172166	0.516	rs2021826	ENSG00000204709.4	LINC01556	9.71	2.22e-20	1.91e-17	0.52	0.41	Cardiac Troponin-T levels;	chr6:28164978	chr6:28943877~28944537:+
PRAD	cis	rs9399137	0.507	rs4594969	ENSG00000232876.1	CTA-212D2.2	-9.71	2.22e-20	1.91e-17	-0.53	-0.41	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134964448	chr6:135055033~135060550:+
PRAD	cis	rs6452524	0.836	rs1478484	ENSG00000249664.1	CTD-2227C6.2	9.71	2.24e-20	1.92e-17	0.48	0.41	Hypertension (SNP x SNP interaction);	chr5:83085055	chr5:83012285~83013109:-
PRAD	cis	rs6452524	0.935	rs7714710	ENSG00000249664.1	CTD-2227C6.2	9.71	2.24e-20	1.92e-17	0.48	0.41	Hypertension (SNP x SNP interaction);	chr5:83085750	chr5:83012285~83013109:-
PRAD	cis	rs1061377	0.748	rs6816202	ENSG00000249207.1	RP11-360F5.1	-9.71	2.24e-20	1.92e-17	-0.44	-0.41	Uric acid levels;	chr4:39106868	chr4:39112677~39126818:-
PRAD	cis	rs9309473	0.95	rs7567585	ENSG00000163016.8	ALMS1P	9.71	2.25e-20	1.92e-17	0.51	0.41	Metabolite levels;	chr2:73524839	chr2:73644919~73685576:+
PRAD	cis	rs6750795	0.569	rs1667313	ENSG00000181798.2	LINC00471	-9.71	2.25e-20	1.93e-17	-0.47	-0.41	Height;	chr2:231543307	chr2:231508426~231514339:-
PRAD	cis	rs12134133	1	rs1583090	ENSG00000274245.1	RP11-357P18.2	9.71	2.26e-20	1.94e-17	0.6	0.41	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207262438	chr1:207372559~207373252:+
PRAD	cis	rs9309473	0.95	rs6546860	ENSG00000163016.8	ALMS1P	9.71	2.29e-20	1.96e-17	0.52	0.41	Metabolite levels;	chr2:73617122	chr2:73644919~73685576:+
PRAD	cis	rs9309473	0.898	rs10209517	ENSG00000163016.8	ALMS1P	9.71	2.29e-20	1.96e-17	0.52	0.41	Metabolite levels;	chr2:73618265	chr2:73644919~73685576:+
PRAD	cis	rs9309473	0.797	rs6723247	ENSG00000163016.8	ALMS1P	9.71	2.29e-20	1.96e-17	0.52	0.41	Metabolite levels;	chr2:73619622	chr2:73644919~73685576:+
PRAD	cis	rs2739330	0.652	rs2000469	ENSG00000099984.9	GSTT2	-9.71	2.29e-20	1.96e-17	-0.56	-0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23980123~23983911:+
PRAD	cis	rs2348418	0.733	rs7955080	ENSG00000247934.4	RP11-967K21.1	-9.71	2.3e-20	1.97e-17	-0.39	-0.41	Lung function (FEV1);Lung function (FVC);	chr12:28153972	chr12:28163298~28190738:-
PRAD	cis	rs2348418	0.701	rs1463570	ENSG00000247934.4	RP11-967K21.1	-9.71	2.3e-20	1.97e-17	-0.39	-0.41	Lung function (FEV1);Lung function (FVC);	chr12:28156095	chr12:28163298~28190738:-
PRAD	cis	rs2348418	0.733	rs12229219	ENSG00000247934.4	RP11-967K21.1	-9.71	2.3e-20	1.97e-17	-0.39	-0.41	Lung function (FEV1);Lung function (FVC);	chr12:28158414	chr12:28163298~28190738:-
PRAD	cis	rs2282300	0.739	rs1222221	ENSG00000254532.1	RP11-624D11.2	9.7	2.31e-20	1.98e-17	0.58	0.41	Morning vs. evening chronotype;	chr11:30321191	chr11:30044058~30084343:-
PRAD	cis	rs2348418	0.868	rs12302861	ENSG00000247934.4	RP11-967K21.1	9.7	2.31e-20	1.98e-17	0.39	0.41	Lung function (FEV1);Lung function (FVC);	chr12:28516269	chr12:28163298~28190738:-
PRAD	cis	rs7772486	0.875	rs1412081	ENSG00000235652.6	RP11-545I5.3	9.7	2.32e-20	1.99e-17	0.42	0.41	Lobe attachment (rater-scored or self-reported);	chr6:146088597	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.875	rs10457792	ENSG00000235652.6	RP11-545I5.3	9.7	2.32e-20	1.99e-17	0.42	0.41	Lobe attachment (rater-scored or self-reported);	chr6:146091279	chr6:145799409~145886585:+
PRAD	cis	rs4718428	0.672	rs13241598	ENSG00000232546.1	RP11-458F8.1	-9.7	2.32e-20	1.99e-17	-0.33	-0.41	Corneal structure;	chr7:66835665	chr7:66848496~66858136:+
PRAD	cis	rs7714584	1	rs10078968	ENSG00000197083.10	ZNF300P1	9.7	2.32e-20	1.99e-17	0.64	0.41	Crohn's disease;	chr5:150864711	chr5:150930645~150946289:-
PRAD	cis	rs7714584	1	rs1896709	ENSG00000197083.10	ZNF300P1	9.7	2.32e-20	1.99e-17	0.64	0.41	Crohn's disease;	chr5:150865470	chr5:150930645~150946289:-
PRAD	cis	rs7714584	1	rs1896707	ENSG00000197083.10	ZNF300P1	9.7	2.32e-20	1.99e-17	0.64	0.41	Crohn's disease;	chr5:150865567	chr5:150930645~150946289:-
PRAD	cis	rs7714584	1	rs6862814	ENSG00000197083.10	ZNF300P1	9.7	2.32e-20	1.99e-17	0.64	0.41	Crohn's disease;	chr5:150865697	chr5:150930645~150946289:-
PRAD	cis	rs7714584	1	rs7709388	ENSG00000197083.10	ZNF300P1	9.7	2.32e-20	1.99e-17	0.64	0.41	Crohn's disease;	chr5:150866977	chr5:150930645~150946289:-
PRAD	cis	rs7714584	0.793	rs7709721	ENSG00000197083.10	ZNF300P1	9.7	2.32e-20	1.99e-17	0.64	0.41	Crohn's disease;	chr5:150867296	chr5:150930645~150946289:-
PRAD	cis	rs7714584	1	rs4958852	ENSG00000197083.10	ZNF300P1	9.7	2.33e-20	1.99e-17	0.78	0.41	Crohn's disease;	chr5:150951069	chr5:150930645~150946289:-
PRAD	cis	rs9309473	1	rs11689392	ENSG00000163016.8	ALMS1P	9.7	2.33e-20	1.99e-17	0.51	0.41	Metabolite levels;	chr2:73394898	chr2:73644919~73685576:+
PRAD	cis	rs7569084	0.687	rs35839762	ENSG00000281920.1	RP11-418H16.1	9.7	2.33e-20	1.99e-17	0.5	0.41	Sum eosinophil basophil counts;	chr2:65441318	chr2:65623272~65628424:+
PRAD	cis	rs7772486	0.806	rs7740785	ENSG00000235652.6	RP11-545I5.3	9.7	2.35e-20	2.01e-17	0.42	0.41	Lobe attachment (rater-scored or self-reported);	chr6:145850163	chr6:145799409~145886585:+
PRAD	cis	rs2739330	0.828	rs2330635	ENSG00000099984.9	GSTT2	-9.7	2.36e-20	2.02e-17	-0.56	-0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23980123~23983911:+
PRAD	cis	rs17711722	0.522	rs4642526	ENSG00000228409.4	CCT6P1	-9.7	2.37e-20	2.02e-17	-0.3	-0.41	Calcium levels;	chr7:65751755	chr7:65751142~65763354:+
PRAD	cis	rs9545047	0.604	rs2477397	ENSG00000227676.3	LINC01068	-9.7	2.37e-20	2.03e-17	-0.49	-0.41	Schizophrenia;	chr13:79428211	chr13:79566727~79571436:+
PRAD	cis	rs2919917	0.628	rs13267679	ENSG00000254352.1	RP11-578O24.2	-9.7	2.39e-20	2.04e-17	-0.57	-0.41	Lymphocyte counts;	chr8:78711603	chr8:78723796~78724136:-
PRAD	cis	rs9309711	0.689	rs4535075	ENSG00000225234.1	TRAPPC12-AS1	-9.7	2.39e-20	2.04e-17	-0.42	-0.41	Neurofibrillary tangles;	chr2:3477945	chr2:3481242~3482409:-
PRAD	cis	rs3814244	0.515	rs3015002	ENSG00000255733.4	IFNG-AS1	-9.7	2.4e-20	2.05e-17	-0.43	-0.41	Itch intensity from mosquito bite adjusted by bite size;	chr12:68010853	chr12:67989445~68234686:+
PRAD	cis	rs6452524	0.935	rs1017794	ENSG00000249664.1	CTD-2227C6.2	9.7	2.4e-20	2.05e-17	0.48	0.41	Hypertension (SNP x SNP interaction);	chr5:83086236	chr5:83012285~83013109:-
PRAD	cis	rs7772486	0.875	rs9403768	ENSG00000235652.6	RP11-545I5.3	9.7	2.41e-20	2.06e-17	0.42	0.41	Lobe attachment (rater-scored or self-reported);	chr6:146085322	chr6:145799409~145886585:+
PRAD	cis	rs1075265	0.756	rs2160931	ENSG00000233266.1	HMGB1P31	9.7	2.42e-20	2.07e-17	0.56	0.41	Chronotype;Morning vs. evening chronotype;	chr2:53712411	chr2:54051334~54051760:+
PRAD	cis	rs6539288	0.63	rs3759316	ENSG00000260329.1	RP11-412D9.4	-9.7	2.44e-20	2.09e-17	-0.36	-0.41	Total body bone mineral density;	chr12:106976432	chr12:106954029~106955497:-
PRAD	cis	rs9545047	0.588	rs9530894	ENSG00000227676.3	LINC01068	9.7	2.45e-20	2.09e-17	0.48	0.41	Schizophrenia;	chr13:79334020	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs9530895	ENSG00000227676.3	LINC01068	9.7	2.45e-20	2.09e-17	0.48	0.41	Schizophrenia;	chr13:79334877	chr13:79566727~79571436:+
PRAD	cis	rs10129255	0.5	rs10143242	ENSG00000223648.3	IGHV3-64	9.7	2.45e-20	2.09e-17	0.37	0.41	Kawasaki disease;	chr14:106681814	chr14:106643132~106658258:-
PRAD	cis	rs9309473	0.528	rs79799178	ENSG00000163016.8	ALMS1P	9.7	2.46e-20	2.1e-17	0.61	0.41	Metabolite levels;	chr2:73564108	chr2:73644919~73685576:+
PRAD	cis	rs17023223	0.537	rs2645295	ENSG00000231365.4	RP11-418J17.1	-9.7	2.47e-20	2.1e-17	-0.42	-0.41	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119039825	chr1:119140396~119275973:+
PRAD	cis	rs1930961	0.85	rs5996945	ENSG00000272942.1	CTA-246H3.12	9.7	2.49e-20	2.12e-17	0.63	0.41	Bipolar disorder with mood-incongruent psychosis;	chr22:25479606	chr22:25434324~25435070:-
PRAD	cis	rs1150668	0.699	rs1531681	ENSG00000204709.4	LINC01556	9.7	2.5e-20	2.13e-17	0.52	0.41	Pubertal anthropometrics;	chr6:28259100	chr6:28943877~28944537:+
PRAD	cis	rs7714584	1	rs11748158	ENSG00000197083.10	ZNF300P1	9.69	2.51e-20	2.14e-17	0.67	0.41	Crohn's disease;	chr5:150846783	chr5:150930645~150946289:-
PRAD	cis	rs2739330	0.685	rs4822453	ENSG00000224205.1	AP000351.4	9.69	2.52e-20	2.15e-17	0.5	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23987320~23991421:-
PRAD	cis	rs9309473	0.948	rs6719753	ENSG00000163016.8	ALMS1P	9.69	2.52e-20	2.15e-17	0.51	0.41	Metabolite levels;	chr2:73521927	chr2:73644919~73685576:+
PRAD	cis	rs1075265	0.655	rs13432632	ENSG00000233266.1	HMGB1P31	9.69	2.54e-20	2.17e-17	0.56	0.41	Chronotype;Morning vs. evening chronotype;	chr2:53713586	chr2:54051334~54051760:+
PRAD	cis	rs9326248	0.53	rs510988	ENSG00000254851.1	RP11-109L13.1	-9.69	2.56e-20	2.18e-17	-0.82	-0.41	Blood protein levels;	chr11:116943088	chr11:117135528~117138582:+
PRAD	cis	rs270601	0.77	rs932019	ENSG00000233006.5	AC034220.3	9.69	2.57e-20	2.19e-17	0.36	0.41	Acylcarnitine levels;	chr5:132263677	chr5:132311285~132369916:-
PRAD	cis	rs1150668	0.745	rs213238	ENSG00000204709.4	LINC01556	9.69	2.58e-20	2.2e-17	0.53	0.41	Pubertal anthropometrics;	chr6:28354216	chr6:28943877~28944537:+
PRAD	cis	rs2153535	0.585	rs4960449	ENSG00000230939.1	RP11-314C16.1	-9.69	2.58e-20	2.2e-17	-0.51	-0.41	Motion sickness;	chr6:8625762	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.585	rs9393048	ENSG00000230939.1	RP11-314C16.1	-9.69	2.58e-20	2.2e-17	-0.51	-0.41	Motion sickness;	chr6:8626321	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.585	rs7766729	ENSG00000230939.1	RP11-314C16.1	-9.69	2.58e-20	2.2e-17	-0.51	-0.41	Motion sickness;	chr6:8627408	chr6:8784178~8785445:+
PRAD	cis	rs9399137	0.507	rs6569986	ENSG00000232876.1	CTA-212D2.2	-9.69	2.59e-20	2.21e-17	-0.52	-0.41	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134990503	chr6:135055033~135060550:+
PRAD	cis	rs9399137	0.507	rs13197750	ENSG00000232876.1	CTA-212D2.2	-9.69	2.59e-20	2.21e-17	-0.52	-0.41	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134991242	chr6:135055033~135060550:+
PRAD	cis	rs9399137	0.507	rs7761964	ENSG00000232876.1	CTA-212D2.2	-9.69	2.59e-20	2.21e-17	-0.52	-0.41	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134993127	chr6:135055033~135060550:+
PRAD	cis	rs9399137	0.507	rs11753673	ENSG00000232876.1	CTA-212D2.2	-9.69	2.59e-20	2.21e-17	-0.52	-0.41	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134995338	chr6:135055033~135060550:+
PRAD	cis	rs9399137	0.507	rs12663447	ENSG00000232876.1	CTA-212D2.2	-9.69	2.59e-20	2.21e-17	-0.52	-0.41	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134995888	chr6:135055033~135060550:+
PRAD	cis	rs9399137	0.507	rs4895437	ENSG00000232876.1	CTA-212D2.2	-9.69	2.59e-20	2.21e-17	-0.52	-0.41	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134996216	chr6:135055033~135060550:+
PRAD	cis	rs6876835	0.511	rs56874700	ENSG00000250056.4	LINC01018	9.69	2.59e-20	2.21e-17	0.48	0.41	Visceral fat;	chr5:6597785	chr5:6582136~6588499:+
PRAD	cis	rs7772486	0.686	rs9376961	ENSG00000235652.6	RP11-545I5.3	9.69	2.6e-20	2.22e-17	0.42	0.41	Lobe attachment (rater-scored or self-reported);	chr6:145727601	chr6:145799409~145886585:+
PRAD	cis	rs9309473	1	rs6736866	ENSG00000163016.8	ALMS1P	9.69	2.61e-20	2.22e-17	0.53	0.41	Metabolite levels;	chr2:73434858	chr2:73644919~73685576:+
PRAD	cis	rs150992	0.609	rs449204	ENSG00000248489.1	CTD-2007H13.3	9.69	2.62e-20	2.23e-17	0.46	0.41	Body mass index;	chr5:98991775	chr5:98929171~98995013:+
PRAD	cis	rs150992	0.609	rs378089	ENSG00000248489.1	CTD-2007H13.3	9.69	2.62e-20	2.23e-17	0.46	0.41	Body mass index;	chr5:98991818	chr5:98929171~98995013:+
PRAD	cis	rs150992	0.587	rs422127	ENSG00000248489.1	CTD-2007H13.3	9.69	2.62e-20	2.23e-17	0.46	0.41	Body mass index;	chr5:98991984	chr5:98929171~98995013:+
PRAD	cis	rs150992	0.609	rs113423144	ENSG00000248489.1	CTD-2007H13.3	9.69	2.62e-20	2.23e-17	0.46	0.41	Body mass index;	chr5:98992055	chr5:98929171~98995013:+
PRAD	cis	rs150992	0.609	rs380156	ENSG00000248489.1	CTD-2007H13.3	9.69	2.62e-20	2.23e-17	0.46	0.41	Body mass index;	chr5:98992386	chr5:98929171~98995013:+
PRAD	cis	rs10256972	0.804	rs10275585	ENSG00000229043.2	AC091729.9	-9.69	2.65e-20	2.26e-17	-0.51	-0.41	Endometriosis;Longevity;	chr7:977703	chr7:1160374~1165267:+
PRAD	cis	rs6570726	0.537	rs1280279	ENSG00000235652.6	RP11-545I5.3	9.69	2.66e-20	2.26e-17	0.5	0.41	Lobe attachment (rater-scored or self-reported);	chr6:145562912	chr6:145799409~145886585:+
PRAD	cis	rs9309711	0.666	rs6767	ENSG00000225234.1	TRAPPC12-AS1	-9.69	2.68e-20	2.28e-17	-0.41	-0.41	Neurofibrillary tangles;	chr2:3479434	chr2:3481242~3482409:-
PRAD	cis	rs9309711	0.623	rs7569694	ENSG00000225234.1	TRAPPC12-AS1	-9.69	2.68e-20	2.28e-17	-0.41	-0.41	Neurofibrillary tangles;	chr2:3479619	chr2:3481242~3482409:-
PRAD	cis	rs34779708	0.966	rs2505639	ENSG00000230534.5	RP11-297A16.2	-9.68	2.72e-20	2.31e-17	-0.53	-0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35185493	chr10:35098006~35127020:-
PRAD	cis	rs3931020	0.657	rs7522428	ENSG00000272864.1	RP11-17E13.2	-9.68	2.72e-20	2.32e-17	-0.48	-0.41	Resistin levels;	chr1:74712676	chr1:74698769~74699333:-
PRAD	cis	rs9309473	0.95	rs17009149	ENSG00000163016.8	ALMS1P	9.68	2.73e-20	2.32e-17	0.51	0.41	Metabolite levels;	chr2:73563241	chr2:73644919~73685576:+
PRAD	cis	rs12049351	0.665	rs3767326	ENSG00000229367.1	HMGN2P19	9.68	2.74e-20	2.33e-17	0.6	0.41	Circulating myeloperoxidase levels (plasma);	chr1:229454303	chr1:229570532~229570796:+
PRAD	cis	rs12049351	0.665	rs7545114	ENSG00000229367.1	HMGN2P19	9.68	2.74e-20	2.33e-17	0.6	0.41	Circulating myeloperoxidase levels (plasma);	chr1:229455851	chr1:229570532~229570796:+
PRAD	cis	rs9309473	1	rs6546835	ENSG00000163016.8	ALMS1P	9.68	2.75e-20	2.34e-17	0.51	0.41	Metabolite levels;	chr2:73437587	chr2:73644919~73685576:+
PRAD	cis	rs2739330	0.892	rs5751776	ENSG00000235689.1	AP000351.13	9.68	2.76e-20	2.35e-17	0.49	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:24006305~24008258:-
PRAD	cis	rs7772486	0.521	rs9485017	ENSG00000235652.6	RP11-545I5.3	9.68	2.77e-20	2.36e-17	0.44	0.41	Lobe attachment (rater-scored or self-reported);	chr6:145702190	chr6:145799409~145886585:+
PRAD	cis	rs2933343	1	rs1683782	ENSG00000261159.1	RP11-723O4.9	9.68	2.78e-20	2.37e-17	0.39	0.41	IgG glycosylation;	chr3:128921434	chr3:128859716~128860526:-
PRAD	cis	rs9309473	0.66	rs56131703	ENSG00000163016.8	ALMS1P	9.68	2.8e-20	2.38e-17	0.62	0.41	Metabolite levels;	chr2:73620133	chr2:73644919~73685576:+
PRAD	cis	rs9309473	1	rs7580825	ENSG00000163016.8	ALMS1P	9.68	2.84e-20	2.41e-17	0.51	0.41	Metabolite levels;	chr2:73408020	chr2:73644919~73685576:+
PRAD	cis	rs10129255	0.518	rs8009594	ENSG00000223648.3	IGHV3-64	9.68	2.85e-20	2.42e-17	0.36	0.41	Kawasaki disease;	chr14:106777494	chr14:106643132~106658258:-
PRAD	cis	rs7772486	0.875	rs10457795	ENSG00000235652.6	RP11-545I5.3	9.68	2.85e-20	2.42e-17	0.42	0.41	Lobe attachment (rater-scored or self-reported);	chr6:146094529	chr6:145799409~145886585:+
PRAD	cis	rs6061231	0.624	rs8668	ENSG00000273619.1	RP5-908M14.9	9.68	2.86e-20	2.43e-17	0.27	0.41	Colorectal cancer;	chr20:62389008	chr20:62386303~62386970:-
PRAD	cis	rs748404	0.56	rs2255663	ENSG00000249839.1	AC011330.5	9.68	2.86e-20	2.43e-17	0.53	0.41	Lung cancer;	chr15:43536810	chr15:43663654~43684339:-
PRAD	cis	rs9545047	0.547	rs1590465	ENSG00000227676.3	LINC01068	-9.68	2.86e-20	2.43e-17	-0.49	-0.41	Schizophrenia;	chr13:79393998	chr13:79566727~79571436:+
PRAD	cis	rs8072100	0.713	rs9899859	ENSG00000228782.6	CTD-2026D20.3	9.68	2.87e-20	2.43e-17	0.46	0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47435683	chr17:47450568~47492492:-
PRAD	cis	rs8072100	0.713	rs1912486	ENSG00000228782.6	CTD-2026D20.3	9.68	2.87e-20	2.43e-17	0.46	0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47437801	chr17:47450568~47492492:-
PRAD	cis	rs8072100	0.667	rs1912485	ENSG00000228782.6	CTD-2026D20.3	9.68	2.87e-20	2.43e-17	0.46	0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47438312	chr17:47450568~47492492:-
PRAD	cis	rs10129255	0.536	rs17113249	ENSG00000223648.3	IGHV3-64	9.68	2.87e-20	2.43e-17	0.37	0.41	Kawasaki disease;	chr14:106678273	chr14:106643132~106658258:-
PRAD	cis	rs10129255	0.5	rs2105991	ENSG00000223648.3	IGHV3-64	9.68	2.87e-20	2.43e-17	0.37	0.41	Kawasaki disease;	chr14:106682022	chr14:106643132~106658258:-
PRAD	cis	rs673078	0.66	rs11068910	ENSG00000275759.1	RP11-131L12.3	-9.68	2.87e-20	2.44e-17	-0.57	-0.41	Glucose homeostasis traits;	chr12:118336076	chr12:118428281~118428870:+
PRAD	cis	rs1062177	0.855	rs6892117	ENSG00000253921.1	CTB-113P19.3	9.68	2.88e-20	2.44e-17	0.53	0.41	Preschool internalizing problems;	chr5:151885424	chr5:151753992~151767247:+
PRAD	cis	rs7772486	0.875	rs9373485	ENSG00000235652.6	RP11-545I5.3	9.68	2.91e-20	2.47e-17	0.42	0.41	Lobe attachment (rater-scored or self-reported);	chr6:146080293	chr6:145799409~145886585:+
PRAD	cis	rs7714584	1	rs4958843	ENSG00000197083.10	ZNF300P1	9.68	2.92e-20	2.48e-17	0.67	0.41	Crohn's disease;	chr5:150845362	chr5:150930645~150946289:-
PRAD	cis	rs7714584	1	rs4958424	ENSG00000197083.10	ZNF300P1	9.68	2.92e-20	2.48e-17	0.67	0.41	Crohn's disease;	chr5:150845474	chr5:150930645~150946289:-
PRAD	cis	rs7714584	0.793	rs35707106	ENSG00000197083.10	ZNF300P1	9.68	2.92e-20	2.48e-17	0.67	0.41	Crohn's disease;	chr5:150845815	chr5:150930645~150946289:-
PRAD	cis	rs7714584	1	rs11748151	ENSG00000197083.10	ZNF300P1	9.68	2.92e-20	2.48e-17	0.67	0.41	Crohn's disease;	chr5:150846730	chr5:150930645~150946289:-
PRAD	cis	rs7714584	1	rs10058821	ENSG00000197083.10	ZNF300P1	9.68	2.92e-20	2.48e-17	0.67	0.41	Crohn's disease;	chr5:150846823	chr5:150930645~150946289:-
PRAD	cis	rs7714584	1	rs10051804	ENSG00000197083.10	ZNF300P1	9.68	2.92e-20	2.48e-17	0.67	0.41	Crohn's disease;	chr5:150846862	chr5:150930645~150946289:-
PRAD	cis	rs7714584	1	rs10058943	ENSG00000197083.10	ZNF300P1	9.68	2.92e-20	2.48e-17	0.67	0.41	Crohn's disease;	chr5:150847024	chr5:150930645~150946289:-
PRAD	cis	rs7714584	1	rs10051924	ENSG00000197083.10	ZNF300P1	9.68	2.92e-20	2.48e-17	0.67	0.41	Crohn's disease;	chr5:150847077	chr5:150930645~150946289:-
PRAD	cis	rs7714584	1	rs17111376	ENSG00000197083.10	ZNF300P1	9.68	2.92e-20	2.48e-17	0.67	0.41	Crohn's disease;	chr5:150847337	chr5:150930645~150946289:-
PRAD	cis	rs7714584	1	rs10065172	ENSG00000197083.10	ZNF300P1	9.68	2.92e-20	2.48e-17	0.67	0.41	Crohn's disease;	chr5:150848436	chr5:150930645~150946289:-
PRAD	cis	rs638893	0.898	rs587816	ENSG00000278376.1	RP11-158I9.8	-9.68	2.93e-20	2.49e-17	-0.45	-0.41	Vitiligo;	chr11:118819162	chr11:118791254~118793137:+
PRAD	cis	rs6700559	0.81	rs7521550	ENSG00000260088.1	RP11-92G12.3	-9.67	2.94e-20	2.49e-17	-0.52	-0.41	Coronary artery disease;	chr1:200623235	chr1:200669507~200694250:+
PRAD	cis	rs7772486	0.701	rs2244308	ENSG00000235652.6	RP11-545I5.3	9.67	2.94e-20	2.5e-17	0.43	0.41	Lobe attachment (rater-scored or self-reported);	chr6:145892570	chr6:145799409~145886585:+
PRAD	cis	rs2919917	0.666	rs10957898	ENSG00000254352.1	RP11-578O24.2	-9.67	2.94e-20	2.5e-17	-0.56	-0.41	Lymphocyte counts;	chr8:78705078	chr8:78723796~78724136:-
PRAD	cis	rs638893	1	rs638893	ENSG00000278376.1	RP11-158I9.8	-9.67	2.95e-20	2.5e-17	-0.48	-0.41	Vitiligo;	chr11:118827828	chr11:118791254~118793137:+
PRAD	cis	rs9309473	1	rs2140195	ENSG00000163016.8	ALMS1P	9.67	2.96e-20	2.51e-17	0.51	0.41	Metabolite levels;	chr2:73475217	chr2:73644919~73685576:+
PRAD	cis	rs1062177	0.855	rs6884630	ENSG00000253921.1	CTB-113P19.3	-9.67	2.96e-20	2.51e-17	-0.54	-0.41	Preschool internalizing problems;	chr5:151889436	chr5:151753992~151767247:+
PRAD	cis	rs1062177	0.547	rs2915818	ENSG00000213433.5	RPLP1P6	9.67	2.97e-20	2.51e-17	0.47	0.41	Preschool internalizing problems;	chr5:151735729	chr5:151765859~151766378:-
PRAD	cis	rs4879677	1	rs10757677	ENSG00000260390.1	RP11-575I8.1	-9.67	2.99e-20	2.53e-17	-0.55	-0.41	Gut microbiome composition (summer and winter);	chr9:27684534	chr9:27829276~27844481:+
PRAD	cis	rs2153535	0.585	rs7763881	ENSG00000230939.1	RP11-314C16.1	9.67	3e-20	2.54e-17	0.51	0.41	Motion sickness;	chr6:8653014	chr6:8784178~8785445:+
PRAD	cis	rs8062405	0.688	rs3924376	ENSG00000259982.1	CDC37P1	-9.67	3e-20	2.54e-17	-0.57	-0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28914657	chr16:28700294~28701540:-
PRAD	cis	rs3096299	0.685	rs12446145	ENSG00000261118.1	RP11-104N10.1	9.67	3e-20	2.54e-17	0.39	0.41	Multiple myeloma (IgH translocation);	chr16:89476287	chr16:89492017~89504460:-
PRAD	cis	rs10875746	0.859	rs4760695	ENSG00000240399.1	RP1-228P16.1	-9.67	3e-20	2.55e-17	-0.41	-0.41	Longevity (90 years and older);	chr12:48198065	chr12:48054813~48055591:-
PRAD	cis	rs9309473	0.861	rs6546856	ENSG00000163016.8	ALMS1P	9.67	3.01e-20	2.55e-17	0.51	0.41	Metabolite levels;	chr2:73610624	chr2:73644919~73685576:+
PRAD	cis	rs7772486	0.686	rs9403746	ENSG00000235652.6	RP11-545I5.3	-9.67	3.01e-20	2.55e-17	-0.42	-0.41	Lobe attachment (rater-scored or self-reported);	chr6:145782632	chr6:145799409~145886585:+
PRAD	cis	rs9309473	1	rs2901438	ENSG00000163016.8	ALMS1P	9.67	3.03e-20	2.57e-17	0.51	0.41	Metabolite levels;	chr2:73438528	chr2:73644919~73685576:+
PRAD	cis	rs9399137	0.507	rs56164974	ENSG00000232876.1	CTA-212D2.2	-9.67	3.04e-20	2.57e-17	-0.53	-0.41	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134967578	chr6:135055033~135060550:+
PRAD	cis	rs9918079	0.56	rs4270584	ENSG00000273133.1	RP11-799M12.2	9.67	3.06e-20	2.59e-17	0.52	0.41	Obesity-related traits;	chr4:15599176	chr4:15563698~15564253:-
PRAD	cis	rs6700559	0.81	rs10919990	ENSG00000260088.1	RP11-92G12.3	-9.67	3.07e-20	2.6e-17	-0.52	-0.41	Coronary artery disease;	chr1:200627076	chr1:200669507~200694250:+
PRAD	cis	rs1075265	0.749	rs805379	ENSG00000233266.1	HMGB1P31	9.67	3.08e-20	2.6e-17	0.55	0.41	Chronotype;Morning vs. evening chronotype;	chr2:53865847	chr2:54051334~54051760:+
PRAD	cis	rs1930961	1	rs7285549	ENSG00000272942.1	CTA-246H3.12	-9.67	3.09e-20	2.61e-17	-0.65	-0.41	Bipolar disorder with mood-incongruent psychosis;	chr22:25478613	chr22:25434324~25435070:-
PRAD	cis	rs1930961	1	rs5996946	ENSG00000272942.1	CTA-246H3.12	-9.67	3.09e-20	2.61e-17	-0.65	-0.41	Bipolar disorder with mood-incongruent psychosis;	chr22:25480021	chr22:25434324~25435070:-
PRAD	cis	rs1930961	1	rs997873	ENSG00000272942.1	CTA-246H3.12	-9.67	3.09e-20	2.61e-17	-0.65	-0.41	Bipolar disorder with mood-incongruent psychosis;	chr22:25482315	chr22:25434324~25435070:-
PRAD	cis	rs2348418	0.932	rs7136429	ENSG00000247934.4	RP11-967K21.1	9.67	3.11e-20	2.63e-17	0.38	0.41	Lung function (FEV1);Lung function (FVC);	chr12:28460306	chr12:28163298~28190738:-
PRAD	cis	rs7714584	1	rs7705542	ENSG00000197083.10	ZNF300P1	9.67	3.13e-20	2.64e-17	0.66	0.41	Crohn's disease;	chr5:150848756	chr5:150930645~150946289:-
PRAD	cis	rs6700559	0.81	rs10399615	ENSG00000260088.1	RP11-92G12.3	9.67	3.13e-20	2.65e-17	0.52	0.41	Coronary artery disease;	chr1:200626145	chr1:200669507~200694250:+
PRAD	cis	rs2739330	0.828	rs5760107	ENSG00000099984.9	GSTT2	-9.67	3.13e-20	2.65e-17	-0.56	-0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23980123~23983911:+
PRAD	cis	rs2739330	0.789	rs5760109	ENSG00000099984.9	GSTT2	-9.67	3.13e-20	2.65e-17	-0.56	-0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23980123~23983911:+
PRAD	cis	rs673078	0.66	rs6490175	ENSG00000275759.1	RP11-131L12.3	-9.67	3.15e-20	2.67e-17	-0.57	-0.41	Glucose homeostasis traits;	chr12:118293559	chr12:118428281~118428870:+
PRAD	cis	rs1858037	0.867	rs61226353	ENSG00000204929.10	AC074391.1	9.67	3.16e-20	2.67e-17	0.56	0.41	Rheumatoid arthritis;	chr2:65363637	chr2:65436711~66084639:+
PRAD	cis	rs10129255	0.518	rs10150460	ENSG00000223648.3	IGHV3-64	-9.67	3.17e-20	2.68e-17	-0.37	-0.41	Kawasaki disease;	chr14:106677179	chr14:106643132~106658258:-
PRAD	cis	rs2282300	0.739	rs1222211	ENSG00000242353.1	RP4-710M3.1	-9.67	3.18e-20	2.69e-17	-0.5	-0.41	Morning vs. evening chronotype;	chr11:30340692	chr11:30368148~30368646:+
PRAD	cis	rs1062177	0.855	rs1346489	ENSG00000253921.1	CTB-113P19.3	-9.66	3.2e-20	2.7e-17	-0.53	-0.41	Preschool internalizing problems;	chr5:151886973	chr5:151753992~151767247:+
PRAD	cis	rs7772486	0.875	rs10457796	ENSG00000235652.6	RP11-545I5.3	9.66	3.22e-20	2.72e-17	0.42	0.41	Lobe attachment (rater-scored or self-reported);	chr6:146094951	chr6:145799409~145886585:+
PRAD	cis	rs9309473	0.948	rs2421550	ENSG00000163016.8	ALMS1P	9.66	3.22e-20	2.72e-17	0.5	0.41	Metabolite levels;	chr2:73431558	chr2:73644919~73685576:+
PRAD	cis	rs2153535	0.585	rs9393056	ENSG00000230939.1	RP11-314C16.1	-9.66	3.23e-20	2.73e-17	-0.52	-0.41	Motion sickness;	chr6:8667641	chr6:8784178~8785445:+
PRAD	cis	rs1577917	0.958	rs12208227	ENSG00000203875.9	SNHG5	-9.66	3.23e-20	2.73e-17	-0.48	-0.41	Response to antipsychotic treatment;	chr6:85961226	chr6:85660950~85678736:-
PRAD	cis	rs150992	0.861	rs428836	ENSG00000248489.1	CTD-2007H13.3	9.66	3.24e-20	2.74e-17	0.46	0.41	Body mass index;	chr5:98951673	chr5:98929171~98995013:+
PRAD	cis	rs1061377	0.748	rs13117988	ENSG00000249207.1	RP11-360F5.1	-9.66	3.25e-20	2.74e-17	-0.44	-0.41	Uric acid levels;	chr4:39092219	chr4:39112677~39126818:-
PRAD	cis	rs9309473	1	rs10496191	ENSG00000163016.8	ALMS1P	9.66	3.25e-20	2.74e-17	0.51	0.41	Metabolite levels;	chr2:73446670	chr2:73644919~73685576:+
PRAD	cis	rs9309473	1	rs6546838	ENSG00000163016.8	ALMS1P	9.66	3.25e-20	2.74e-17	0.51	0.41	Metabolite levels;	chr2:73452153	chr2:73644919~73685576:+
PRAD	cis	rs9309473	1	rs56672945	ENSG00000163016.8	ALMS1P	9.66	3.26e-20	2.75e-17	0.51	0.41	Metabolite levels;	chr2:73395535	chr2:73644919~73685576:+
PRAD	cis	rs9309473	1	rs60844734	ENSG00000163016.8	ALMS1P	9.66	3.26e-20	2.75e-17	0.51	0.41	Metabolite levels;	chr2:73396077	chr2:73644919~73685576:+
PRAD	cis	rs9309473	1	rs11899902	ENSG00000163016.8	ALMS1P	9.66	3.26e-20	2.75e-17	0.51	0.41	Metabolite levels;	chr2:73404436	chr2:73644919~73685576:+
PRAD	cis	rs4964805	0.865	rs35371470	ENSG00000257681.1	RP11-341G23.4	9.66	3.29e-20	2.78e-17	0.42	0.41	Attention deficit hyperactivity disorder;	chr12:103809942	chr12:103746315~103768858:-
PRAD	cis	rs4964805	0.865	rs4964289	ENSG00000257681.1	RP11-341G23.4	9.66	3.29e-20	2.78e-17	0.42	0.41	Attention deficit hyperactivity disorder;	chr12:103810413	chr12:103746315~103768858:-
PRAD	cis	rs6061231	1	rs67941642	ENSG00000273619.1	RP5-908M14.9	-9.66	3.29e-20	2.78e-17	-0.28	-0.41	Colorectal cancer;	chr20:62383052	chr20:62386303~62386970:-
PRAD	cis	rs732716	0.889	rs55637375	ENSG00000267769.1	CTB-50L17.9	-9.66	3.33e-20	2.81e-17	-0.45	-0.41	Mean corpuscular volume;	chr19:4386848	chr19:4454014~4455286:+
PRAD	cis	rs853679	0.517	rs4713145	ENSG00000272009.1	RP1-313I6.12	-9.66	3.35e-20	2.83e-17	-0.42	-0.41	Depression;	chr6:28139049	chr6:28078792~28081130:-
PRAD	cis	rs1061377	0.748	rs35904472	ENSG00000249207.1	RP11-360F5.1	-9.66	3.36e-20	2.84e-17	-0.44	-0.41	Uric acid levels;	chr4:39094901	chr4:39112677~39126818:-
PRAD	cis	rs1061377	0.748	rs10856841	ENSG00000249207.1	RP11-360F5.1	-9.66	3.36e-20	2.84e-17	-0.44	-0.41	Uric acid levels;	chr4:39095240	chr4:39112677~39126818:-
PRAD	cis	rs8072100	0.713	rs3871595	ENSG00000228782.6	CTD-2026D20.3	9.66	3.36e-20	2.84e-17	0.46	0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47434022	chr17:47450568~47492492:-
PRAD	cis	rs1061377	0.748	rs1036033	ENSG00000249207.1	RP11-360F5.1	-9.66	3.37e-20	2.84e-17	-0.44	-0.41	Uric acid levels;	chr4:39105295	chr4:39112677~39126818:-
PRAD	cis	rs9326248	0.53	rs2513095	ENSG00000254851.1	RP11-109L13.1	-9.66	3.38e-20	2.85e-17	-0.81	-0.41	Blood protein levels;	chr11:116935553	chr11:117135528~117138582:+
PRAD	cis	rs1075265	0.73	rs7559380	ENSG00000233266.1	HMGB1P31	9.66	3.39e-20	2.86e-17	0.54	0.41	Chronotype;Morning vs. evening chronotype;	chr2:54129660	chr2:54051334~54051760:+
PRAD	cis	rs7772486	0.875	rs6914813	ENSG00000235652.6	RP11-545I5.3	9.66	3.39e-20	2.86e-17	0.42	0.41	Lobe attachment (rater-scored or self-reported);	chr6:146076662	chr6:145799409~145886585:+
PRAD	cis	rs2933343	1	rs6785869	ENSG00000261159.1	RP11-723O4.9	9.66	3.4e-20	2.86e-17	0.38	0.41	IgG glycosylation;	chr3:128924301	chr3:128859716~128860526:-
PRAD	cis	rs2933343	1	rs1683778	ENSG00000261159.1	RP11-723O4.9	9.66	3.4e-20	2.86e-17	0.38	0.41	IgG glycosylation;	chr3:128925752	chr3:128859716~128860526:-
PRAD	cis	rs7714584	1	rs76548544	ENSG00000197083.10	ZNF300P1	9.66	3.4e-20	2.87e-17	0.67	0.41	Crohn's disease;	chr5:150843953	chr5:150930645~150946289:-
PRAD	cis	rs7714584	1	rs73282255	ENSG00000197083.10	ZNF300P1	9.66	3.4e-20	2.87e-17	0.67	0.41	Crohn's disease;	chr5:150844085	chr5:150930645~150946289:-
PRAD	cis	rs12049351	0.665	rs3767325	ENSG00000229367.1	HMGN2P19	9.66	3.42e-20	2.89e-17	0.58	0.41	Circulating myeloperoxidase levels (plasma);	chr1:229454299	chr1:229570532~229570796:+
PRAD	cis	rs7714584	0.826	rs34005003	ENSG00000197083.10	ZNF300P1	9.66	3.45e-20	2.91e-17	0.67	0.41	Crohn's disease;	chr5:150845637	chr5:150930645~150946289:-
PRAD	cis	rs638893	0.578	rs582200	ENSG00000278376.1	RP11-158I9.8	9.65	3.47e-20	2.93e-17	0.51	0.41	Vitiligo;	chr11:118798199	chr11:118791254~118793137:+
PRAD	cis	rs8062405	0.655	rs7184597	ENSG00000259982.1	CDC37P1	-9.65	3.48e-20	2.94e-17	-0.57	-0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910488	chr16:28700294~28701540:-
PRAD	cis	rs7044106	0.655	rs1359329	ENSG00000226752.6	PSMD5-AS1	-9.65	3.49e-20	2.94e-17	-0.64	-0.41	Hip circumference adjusted for BMI;	chr9:120608707	chr9:120824828~120854385:+
PRAD	cis	rs9918079	0.56	rs4698409	ENSG00000273133.1	RP11-799M12.2	-9.65	3.49e-20	2.94e-17	-0.52	-0.41	Obesity-related traits;	chr4:15658143	chr4:15563698~15564253:-
PRAD	cis	rs9532669	0.926	rs4254182	ENSG00000176268.5	CYCSP34	9.65	3.51e-20	2.95e-17	0.43	0.41	Cervical cancer;	chr13:40879120	chr13:40863599~40863902:-
PRAD	cis	rs673078	0.66	rs6490173	ENSG00000275759.1	RP11-131L12.3	-9.65	3.52e-20	2.96e-17	-0.57	-0.41	Glucose homeostasis traits;	chr12:118278637	chr12:118428281~118428870:+
PRAD	cis	rs9309473	0.66	rs11679594	ENSG00000163016.8	ALMS1P	9.65	3.54e-20	2.98e-17	0.61	0.41	Metabolite levels;	chr2:73552380	chr2:73644919~73685576:+
PRAD	cis	rs2348418	0.932	rs11049662	ENSG00000247934.4	RP11-967K21.1	9.65	3.55e-20	2.99e-17	0.38	0.41	Lung function (FEV1);Lung function (FVC);	chr12:28487344	chr12:28163298~28190738:-
PRAD	cis	rs2348418	0.932	rs7306581	ENSG00000247934.4	RP11-967K21.1	9.65	3.55e-20	2.99e-17	0.38	0.41	Lung function (FEV1);Lung function (FVC);	chr12:28488641	chr12:28163298~28190738:-
PRAD	cis	rs34779708	0.931	rs4934709	ENSG00000230534.5	RP11-297A16.2	-9.65	3.56e-20	3e-17	-0.54	-0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35050396	chr10:35098006~35127020:-
PRAD	cis	rs172166	0.694	rs2791332	ENSG00000280107.1	AL022393.9	-9.65	3.57e-20	3e-17	-0.51	-0.41	Cardiac Troponin-T levels;	chr6:28141010	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs1340004	ENSG00000272009.1	RP1-313I6.12	-9.65	3.58e-20	3.01e-17	-0.42	-0.41	Depression;	chr6:28135913	chr6:28078792~28081130:-
PRAD	cis	rs10246939	0.544	rs6957037	ENSG00000228775.6	WEE2-AS1	9.65	3.59e-20	3.02e-17	0.52	0.41	Bitter taste perception;	chr7:141865557	chr7:141704338~141738346:-
PRAD	cis	rs9309473	1	rs13428235	ENSG00000163016.8	ALMS1P	9.65	3.59e-20	3.02e-17	0.51	0.41	Metabolite levels;	chr2:73406302	chr2:73644919~73685576:+
PRAD	cis	rs4964805	0.865	rs4964780	ENSG00000257681.1	RP11-341G23.4	9.65	3.59e-20	3.02e-17	0.42	0.41	Attention deficit hyperactivity disorder;	chr12:103813081	chr12:103746315~103768858:-
PRAD	cis	rs10129255	0.53	rs11624912	ENSG00000223648.3	IGHV3-64	9.65	3.59e-20	3.03e-17	0.37	0.41	Kawasaki disease;	chr14:106673891	chr14:106643132~106658258:-
PRAD	cis	rs4964805	0.773	rs35746861	ENSG00000257681.1	RP11-341G23.4	9.65	3.6e-20	3.03e-17	0.43	0.41	Attention deficit hyperactivity disorder;	chr12:103831506	chr12:103746315~103768858:-
PRAD	cis	rs4964805	1	rs1866295	ENSG00000257681.1	RP11-341G23.4	9.65	3.6e-20	3.03e-17	0.4	0.41	Attention deficit hyperactivity disorder;	chr12:103793168	chr12:103746315~103768858:-
PRAD	cis	rs6570726	0.764	rs9403731	ENSG00000235652.6	RP11-545I5.3	9.65	3.64e-20	3.06e-17	0.43	0.41	Lobe attachment (rater-scored or self-reported);	chr6:145586801	chr6:145799409~145886585:+
PRAD	cis	rs62103177	0.608	rs4799115	ENSG00000261126.6	RP11-795F19.1	-9.65	3.65e-20	3.07e-17	-0.56	-0.41	Opioid sensitivity;	chr18:79976365	chr18:80046900~80095482:+
PRAD	cis	rs6570726	0.791	rs9373464	ENSG00000235652.6	RP11-545I5.3	9.65	3.66e-20	3.08e-17	0.43	0.41	Lobe attachment (rater-scored or self-reported);	chr6:145586031	chr6:145799409~145886585:+
PRAD	cis	rs7811142	0.666	rs28401739	ENSG00000242294.5	STAG3L5P	9.65	3.67e-20	3.09e-17	0.27	0.41	Platelet count;	chr7:100308061	chr7:100336079~100351900:+
PRAD	cis	rs638893	0.853	rs4938549	ENSG00000278376.1	RP11-158I9.8	-9.65	3.7e-20	3.11e-17	-0.48	-0.41	Vitiligo;	chr11:118830888	chr11:118791254~118793137:+
PRAD	cis	rs638893	0.898	rs530646	ENSG00000278376.1	RP11-158I9.8	-9.65	3.7e-20	3.11e-17	-0.48	-0.41	Vitiligo;	chr11:118830959	chr11:118791254~118793137:+
PRAD	cis	rs7772486	0.625	rs2050027	ENSG00000235652.6	RP11-545I5.3	-9.65	3.71e-20	3.12e-17	-0.42	-0.41	Lobe attachment (rater-scored or self-reported);	chr6:145794977	chr6:145799409~145886585:+
PRAD	cis	rs2564921	0.73	rs73082047	ENSG00000242142.1	SERBP1P3	-9.65	3.73e-20	3.13e-17	-0.48	-0.41	Height;	chr3:53070344	chr3:53064283~53065091:-
PRAD	cis	rs6876835	0.553	rs56822425	ENSG00000250056.4	LINC01018	9.65	3.73e-20	3.14e-17	0.48	0.41	Visceral fat;	chr5:6597387	chr5:6582136~6588499:+
PRAD	cis	rs9309473	0.95	rs13408433	ENSG00000163016.8	ALMS1P	9.65	3.73e-20	3.14e-17	0.51	0.41	Metabolite levels;	chr2:73655945	chr2:73644919~73685576:+
PRAD	cis	rs17507216	0.56	rs28493687	ENSG00000278603.1	RP13-608F4.5	9.65	3.74e-20	3.14e-17	0.53	0.41	Excessive daytime sleepiness;	chr15:82560062	chr15:82472203~82472426:+
PRAD	cis	rs1185460	1	rs1614264	ENSG00000271751.1	RP11-110I1.14	-9.64	3.76e-20	3.16e-17	-0.58	-0.41	Coronary artery disease;	chr11:119071928	chr11:119065263~119065677:-
PRAD	cis	rs4718428	0.705	rs2901311	ENSG00000273142.1	RP11-458F8.4	-9.64	3.76e-20	3.16e-17	-0.32	-0.41	Corneal structure;	chr7:66950082	chr7:66902857~66906297:+
PRAD	cis	rs34375054	0.687	rs35540170	ENSG00000279233.1	RP11-158L12.4	9.64	3.77e-20	3.17e-17	0.42	0.41	Post bronchodilator FEV1/FVC ratio;	chr12:125184576	chr12:125138245~125141711:+
PRAD	cis	rs3762637	0.941	rs9810996	ENSG00000272758.4	RP11-299J3.8	-9.64	3.8e-20	3.2e-17	-0.62	-0.41	LDL cholesterol levels;	chr3:122355540	chr3:122416207~122443180:+
PRAD	cis	rs3762637	0.941	rs9810999	ENSG00000272758.4	RP11-299J3.8	-9.64	3.8e-20	3.2e-17	-0.62	-0.41	LDL cholesterol levels;	chr3:122355544	chr3:122416207~122443180:+
PRAD	cis	rs9906595	0.618	rs62075221	ENSG00000263874.1	LINC00672	9.64	3.81e-20	3.2e-17	0.75	0.41	Obesity-related traits;	chr17:38977399	chr17:38925168~38928057:+
PRAD	cis	rs7714584	1	rs1896708	ENSG00000197083.10	ZNF300P1	9.64	3.81e-20	3.2e-17	0.66	0.41	Crohn's disease;	chr5:150865514	chr5:150930645~150946289:-
PRAD	cis	rs9309711	0.643	rs4264589	ENSG00000225234.1	TRAPPC12-AS1	-9.64	3.84e-20	3.22e-17	-0.41	-0.41	Neurofibrillary tangles;	chr2:3477327	chr2:3481242~3482409:-
PRAD	cis	rs1150668	0.83	rs2531831	ENSG00000216901.1	AL022393.7	9.64	3.85e-20	3.23e-17	0.51	0.41	Pubertal anthropometrics;	chr6:28420988	chr6:28176188~28176674:+
PRAD	cis	rs7772486	0.875	rs6934467	ENSG00000235652.6	RP11-545I5.3	9.64	3.85e-20	3.24e-17	0.42	0.41	Lobe attachment (rater-scored or self-reported);	chr6:146089393	chr6:145799409~145886585:+
PRAD	cis	rs150992	0.673	rs331545	ENSG00000248489.1	CTD-2007H13.3	-9.64	3.87e-20	3.25e-17	-0.46	-0.41	Body mass index;	chr5:98810402	chr5:98929171~98995013:+
PRAD	cis	rs34779708	0.966	rs11010095	ENSG00000230534.5	RP11-297A16.2	9.64	3.89e-20	3.26e-17	0.54	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35107020	chr10:35098006~35127020:-
PRAD	cis	rs150992	0.655	rs327807	ENSG00000248489.1	CTD-2007H13.3	-9.64	3.91e-20	3.28e-17	-0.46	-0.41	Body mass index;	chr5:98942448	chr5:98929171~98995013:+
PRAD	cis	rs9545047	0.584	rs7995243	ENSG00000227676.3	LINC01068	-9.64	3.91e-20	3.28e-17	-0.48	-0.41	Schizophrenia;	chr13:79358645	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs9574410	ENSG00000227676.3	LINC01068	-9.64	3.92e-20	3.29e-17	-0.48	-0.41	Schizophrenia;	chr13:79343091	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs2274555	ENSG00000227676.3	LINC01068	-9.64	3.92e-20	3.29e-17	-0.48	-0.41	Schizophrenia;	chr13:79344188	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs9565491	ENSG00000227676.3	LINC01068	-9.64	3.92e-20	3.29e-17	-0.48	-0.41	Schizophrenia;	chr13:79346037	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs9318623	ENSG00000227676.3	LINC01068	-9.64	3.92e-20	3.29e-17	-0.48	-0.41	Schizophrenia;	chr13:79346913	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.564	rs7998837	ENSG00000227676.3	LINC01068	-9.64	3.92e-20	3.29e-17	-0.48	-0.41	Schizophrenia;	chr13:79349190	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs9574411	ENSG00000227676.3	LINC01068	-9.64	3.92e-20	3.29e-17	-0.48	-0.41	Schizophrenia;	chr13:79354342	chr13:79566727~79571436:+
PRAD	cis	rs9309473	0.606	rs62149804	ENSG00000163016.8	ALMS1P	9.64	3.93e-20	3.29e-17	0.61	0.41	Metabolite levels;	chr2:73609879	chr2:73644919~73685576:+
PRAD	cis	rs2153535	0.56	rs9405406	ENSG00000230939.1	RP11-314C16.1	-9.64	3.94e-20	3.31e-17	-0.5	-0.41	Motion sickness;	chr6:8654625	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.585	rs1998364	ENSG00000230939.1	RP11-314C16.1	-9.64	3.94e-20	3.31e-17	-0.5	-0.41	Motion sickness;	chr6:8657091	chr6:8784178~8785445:+
PRAD	cis	rs9309473	1	rs10187192	ENSG00000163016.8	ALMS1P	9.64	3.94e-20	3.31e-17	0.52	0.41	Metabolite levels;	chr2:73486373	chr2:73644919~73685576:+
PRAD	cis	rs9309473	0.948	rs10183818	ENSG00000163016.8	ALMS1P	9.64	3.94e-20	3.31e-17	0.52	0.41	Metabolite levels;	chr2:73487429	chr2:73644919~73685576:+
PRAD	cis	rs8072100	0.87	rs10432035	ENSG00000228782.6	CTD-2026D20.3	-9.64	3.97e-20	3.33e-17	-0.46	-0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47547547	chr17:47450568~47492492:-
PRAD	cis	rs12134133	1	rs2802235	ENSG00000274245.1	RP11-357P18.2	9.64	3.99e-20	3.34e-17	0.57	0.41	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207298454	chr1:207372559~207373252:+
PRAD	cis	rs9326248	0.53	rs562179	ENSG00000254851.1	RP11-109L13.1	-9.64	3.99e-20	3.35e-17	-0.81	-0.41	Blood protein levels;	chr11:116934488	chr11:117135528~117138582:+
PRAD	cis	rs17361889	0.766	rs1918260	ENSG00000224683.1	RPL36AP29	9.64	3.99e-20	3.35e-17	0.51	0.41	Pediatric bone mineral content (hip);	chr7:16205510	chr7:16208945~16209265:+
PRAD	cis	rs9309473	1	rs7584575	ENSG00000163016.8	ALMS1P	9.64	3.99e-20	3.35e-17	0.5	0.41	Metabolite levels;	chr2:73439274	chr2:73644919~73685576:+
PRAD	cis	rs3762637	0.941	rs75344200	ENSG00000272758.4	RP11-299J3.8	-9.64	4e-20	3.35e-17	-0.62	-0.41	LDL cholesterol levels;	chr3:122354574	chr3:122416207~122443180:+
PRAD	cis	rs9309473	0.606	rs78941213	ENSG00000163016.8	ALMS1P	9.64	4.05e-20	3.39e-17	0.63	0.41	Metabolite levels;	chr2:73658010	chr2:73644919~73685576:+
PRAD	cis	rs9309473	1	rs3813227	ENSG00000163016.8	ALMS1P	-9.64	4.06e-20	3.4e-17	-0.51	-0.41	Metabolite levels;	chr2:73424839	chr2:73644919~73685576:+
PRAD	cis	rs12049351	0.613	rs10916483	ENSG00000229367.1	HMGN2P19	9.64	4.06e-20	3.4e-17	0.61	0.41	Circulating myeloperoxidase levels (plasma);	chr1:229465267	chr1:229570532~229570796:+
PRAD	cis	rs8062405	0.656	rs7189927	ENSG00000251417.2	RP11-1348G14.4	9.64	4.06e-20	3.4e-17	0.48	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28902466	chr16:28802743~28817828:+
PRAD	cis	rs2153535	0.585	rs1328867	ENSG00000230939.1	RP11-314C16.1	-9.63	4.1e-20	3.43e-17	-0.5	-0.41	Motion sickness;	chr6:8652454	chr6:8784178~8785445:+
PRAD	cis	rs9309473	0.861	rs6546857	ENSG00000163016.8	ALMS1P	9.63	4.11e-20	3.44e-17	0.51	0.41	Metabolite levels;	chr2:73610828	chr2:73644919~73685576:+
PRAD	cis	rs6142102	0.962	rs2206448	ENSG00000276073.1	RP5-1125A11.7	-9.63	4.11e-20	3.44e-17	-0.41	-0.41	Skin pigmentation;	chr20:34121719	chr20:33985617~33988989:-
PRAD	cis	rs2153535	0.585	rs9393053	ENSG00000230939.1	RP11-314C16.1	-9.63	4.13e-20	3.46e-17	-0.51	-0.41	Motion sickness;	chr6:8644947	chr6:8784178~8785445:+
PRAD	cis	rs9399137	0.507	rs13196486	ENSG00000232876.1	CTA-212D2.2	-9.63	4.15e-20	3.48e-17	-0.53	-0.41	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134962736	chr6:135055033~135060550:+
PRAD	cis	rs9399137	0.507	rs6918512	ENSG00000232876.1	CTA-212D2.2	-9.63	4.15e-20	3.48e-17	-0.53	-0.41	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134963701	chr6:135055033~135060550:+
PRAD	cis	rs9399137	0.507	rs13064	ENSG00000232876.1	CTA-212D2.2	-9.63	4.15e-20	3.48e-17	-0.53	-0.41	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134966395	chr6:135055033~135060550:+
PRAD	cis	rs9399137	0.507	rs35571217	ENSG00000232876.1	CTA-212D2.2	-9.63	4.15e-20	3.48e-17	-0.53	-0.41	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134969217	chr6:135055033~135060550:+
PRAD	cis	rs9309473	1	rs6546837	ENSG00000163016.8	ALMS1P	9.63	4.16e-20	3.48e-17	0.51	0.41	Metabolite levels;	chr2:73450771	chr2:73644919~73685576:+
PRAD	cis	rs9309473	1	rs6724782	ENSG00000163016.8	ALMS1P	9.63	4.16e-20	3.48e-17	0.51	0.41	Metabolite levels;	chr2:73452863	chr2:73644919~73685576:+
PRAD	cis	rs9309473	1	rs6546839	ENSG00000163016.8	ALMS1P	9.63	4.16e-20	3.48e-17	0.51	0.41	Metabolite levels;	chr2:73453381	chr2:73644919~73685576:+
PRAD	cis	rs9309473	1	rs6756987	ENSG00000163016.8	ALMS1P	9.63	4.16e-20	3.48e-17	0.51	0.41	Metabolite levels;	chr2:73459950	chr2:73644919~73685576:+
PRAD	cis	rs6876835	0.511	rs58514300	ENSG00000250056.4	LINC01018	9.63	4.17e-20	3.49e-17	0.48	0.41	Visceral fat;	chr5:6597909	chr5:6582136~6588499:+
PRAD	cis	rs270601	0.77	rs4361510	ENSG00000233006.5	AC034220.3	9.63	4.17e-20	3.5e-17	0.36	0.41	Acylcarnitine levels;	chr5:132263954	chr5:132311285~132369916:-
PRAD	cis	rs270601	0.77	rs61352298	ENSG00000233006.5	AC034220.3	9.63	4.17e-20	3.5e-17	0.36	0.41	Acylcarnitine levels;	chr5:132264896	chr5:132311285~132369916:-
PRAD	cis	rs270601	0.739	rs1979981	ENSG00000233006.5	AC034220.3	9.63	4.17e-20	3.5e-17	0.36	0.41	Acylcarnitine levels;	chr5:132266027	chr5:132311285~132369916:-
PRAD	cis	rs270601	0.77	rs1007602	ENSG00000233006.5	AC034220.3	9.63	4.17e-20	3.5e-17	0.36	0.41	Acylcarnitine levels;	chr5:132266473	chr5:132311285~132369916:-
PRAD	cis	rs270601	0.71	rs4705852	ENSG00000233006.5	AC034220.3	9.63	4.17e-20	3.5e-17	0.36	0.41	Acylcarnitine levels;	chr5:132267114	chr5:132311285~132369916:-
PRAD	cis	rs9309473	1	rs7585004	ENSG00000163016.8	ALMS1P	9.63	4.2e-20	3.51e-17	0.51	0.41	Metabolite levels;	chr2:73439517	chr2:73644919~73685576:+
PRAD	cis	rs1061377	0.608	rs35168672	ENSG00000249207.1	RP11-360F5.1	-9.63	4.21e-20	3.53e-17	-0.43	-0.41	Uric acid levels;	chr4:39078902	chr4:39112677~39126818:-
PRAD	cis	rs7772486	0.817	rs2144477	ENSG00000235652.6	RP11-545I5.3	9.63	4.21e-20	3.53e-17	0.42	0.41	Lobe attachment (rater-scored or self-reported);	chr6:146085112	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.875	rs6938972	ENSG00000235652.6	RP11-545I5.3	9.63	4.21e-20	3.53e-17	0.42	0.41	Lobe attachment (rater-scored or self-reported);	chr6:146089472	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.875	rs12194437	ENSG00000235652.6	RP11-545I5.3	9.63	4.21e-20	3.53e-17	0.42	0.41	Lobe attachment (rater-scored or self-reported);	chr6:146090304	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.875	rs10457793	ENSG00000235652.6	RP11-545I5.3	9.63	4.21e-20	3.53e-17	0.42	0.41	Lobe attachment (rater-scored or self-reported);	chr6:146094267	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.875	rs10457794	ENSG00000235652.6	RP11-545I5.3	9.63	4.21e-20	3.53e-17	0.42	0.41	Lobe attachment (rater-scored or self-reported);	chr6:146094472	chr6:145799409~145886585:+
PRAD	cis	rs2729354	0.768	rs1001956	ENSG00000265566.2	RN7SL605P	-9.63	4.25e-20	3.56e-17	-0.61	-0.41	Blood protein levels;	chr11:57499476	chr11:57528085~57528365:-
PRAD	cis	rs7772486	0.875	rs9399573	ENSG00000235652.6	RP11-545I5.3	9.63	4.26e-20	3.56e-17	0.42	0.41	Lobe attachment (rater-scored or self-reported);	chr6:146082119	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.846	rs6908063	ENSG00000235652.6	RP11-545I5.3	9.63	4.26e-20	3.56e-17	0.42	0.41	Lobe attachment (rater-scored or self-reported);	chr6:146082482	chr6:145799409~145886585:+
PRAD	cis	rs12134133	1	rs6673333	ENSG00000274245.1	RP11-357P18.2	9.63	4.26e-20	3.56e-17	0.6	0.41	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207285802	chr1:207372559~207373252:+
PRAD	cis	rs4879677	1	rs12235880	ENSG00000260390.1	RP11-575I8.1	-9.63	4.27e-20	3.57e-17	-0.55	-0.41	Gut microbiome composition (summer and winter);	chr9:27674779	chr9:27829276~27844481:+
PRAD	cis	rs638893	0.898	rs577121	ENSG00000278376.1	RP11-158I9.8	-9.63	4.27e-20	3.57e-17	-0.45	-0.41	Vitiligo;	chr11:118819841	chr11:118791254~118793137:+
PRAD	cis	rs7772486	0.875	rs13204280	ENSG00000235652.6	RP11-545I5.3	9.63	4.28e-20	3.58e-17	0.42	0.41	Lobe attachment (rater-scored or self-reported);	chr6:146094232	chr6:145799409~145886585:+
PRAD	cis	rs673078	0.66	rs61946063	ENSG00000275759.1	RP11-131L12.3	-9.63	4.29e-20	3.58e-17	-0.57	-0.41	Glucose homeostasis traits;	chr12:118294448	chr12:118428281~118428870:+
PRAD	cis	rs9309473	1	rs10175180	ENSG00000163016.8	ALMS1P	9.63	4.3e-20	3.59e-17	0.51	0.41	Metabolite levels;	chr2:73445995	chr2:73644919~73685576:+
PRAD	cis	rs2274273	0.901	rs17674563	ENSG00000258413.1	RP11-665C16.6	-9.63	4.31e-20	3.6e-17	-0.53	-0.41	Protein biomarker;	chr14:55364407	chr14:55262767~55272075:-
PRAD	cis	rs9399137	0.507	rs11757723	ENSG00000232876.1	CTA-212D2.2	-9.63	4.32e-20	3.61e-17	-0.53	-0.41	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134970155	chr6:135055033~135060550:+
PRAD	cis	rs7714584	1	rs10463307	ENSG00000197083.10	ZNF300P1	9.63	4.36e-20	3.65e-17	0.67	0.41	Crohn's disease;	chr5:150875058	chr5:150930645~150946289:-
PRAD	cis	rs858239	0.699	rs1881201	ENSG00000226816.2	AC005082.12	-9.63	4.38e-20	3.66e-17	-0.47	-0.41	Cerebrospinal fluid biomarker levels;	chr7:23154394	chr7:23206013~23208045:+
PRAD	cis	rs9545047	0.716	rs9318638	ENSG00000227676.3	LINC01068	-9.62	4.4e-20	3.68e-17	-0.5	-0.41	Schizophrenia;	chr13:79412018	chr13:79566727~79571436:+
PRAD	cis	rs1075265	0.875	rs12616212	ENSG00000233266.1	HMGB1P31	9.62	4.41e-20	3.68e-17	0.56	0.41	Chronotype;Morning vs. evening chronotype;	chr2:54039109	chr2:54051334~54051760:+
PRAD	cis	rs6142102	0.923	rs6059635	ENSG00000276073.1	RP5-1125A11.7	-9.62	4.44e-20	3.71e-17	-0.42	-0.41	Skin pigmentation;	chr20:34025687	chr20:33985617~33988989:-
PRAD	cis	rs150992	0.592	rs10038192	ENSG00000248489.1	CTD-2007H13.3	9.62	4.46e-20	3.73e-17	0.46	0.41	Body mass index;	chr5:98989755	chr5:98929171~98995013:+
PRAD	cis	rs150992	0.571	rs10045959	ENSG00000248489.1	CTD-2007H13.3	9.62	4.46e-20	3.73e-17	0.46	0.41	Body mass index;	chr5:98989767	chr5:98929171~98995013:+
PRAD	cis	rs150992	0.571	rs10037147	ENSG00000248489.1	CTD-2007H13.3	9.62	4.46e-20	3.73e-17	0.46	0.41	Body mass index;	chr5:98989768	chr5:98929171~98995013:+
PRAD	cis	rs6142102	1	rs6059673	ENSG00000276073.1	RP5-1125A11.7	-9.62	4.47e-20	3.73e-17	-0.42	-0.41	Skin pigmentation;	chr20:34117755	chr20:33985617~33988989:-
PRAD	cis	rs9322193	0.566	rs12528243	ENSG00000216906.2	RP11-350J20.9	9.62	4.5e-20	3.75e-17	0.54	0.41	Lung cancer;	chr6:149898491	chr6:149904243~149906418:+
PRAD	cis	rs9309473	0.948	rs7607892	ENSG00000163016.8	ALMS1P	9.62	4.51e-20	3.76e-17	0.51	0.41	Metabolite levels;	chr2:73591580	chr2:73644919~73685576:+
PRAD	cis	rs7923609	0.578	rs3858121	ENSG00000232075.1	MRPL35P2	-9.62	4.52e-20	3.77e-17	-0.44	-0.41	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63640237	chr10:63634317~63634827:-
PRAD	cis	rs2274273	0.837	rs7146748	ENSG00000258413.1	RP11-665C16.6	-9.62	4.53e-20	3.78e-17	-0.53	-0.41	Protein biomarker;	chr14:55280368	chr14:55262767~55272075:-
PRAD	cis	rs4820294	0.669	rs35662099	ENSG00000233360.4	Z83844.1	9.62	4.55e-20	3.8e-17	0.5	0.41	Fat distribution (HIV);	chr22:37657902	chr22:37641832~37658377:-
PRAD	cis	rs6452524	0.935	rs6896953	ENSG00000249664.1	CTD-2227C6.2	-9.62	4.56e-20	3.8e-17	-0.48	-0.41	Hypertension (SNP x SNP interaction);	chr5:83089284	chr5:83012285~83013109:-
PRAD	cis	rs6452524	0.935	rs7736296	ENSG00000249664.1	CTD-2227C6.2	-9.62	4.58e-20	3.82e-17	-0.48	-0.41	Hypertension (SNP x SNP interaction);	chr5:83082421	chr5:83012285~83013109:-
PRAD	cis	rs732716	0.889	rs11085074	ENSG00000267769.1	CTB-50L17.9	-9.62	4.58e-20	3.82e-17	-0.45	-0.41	Mean corpuscular volume;	chr19:4386355	chr19:4454014~4455286:+
PRAD	cis	rs34375054	0.624	rs4073534	ENSG00000279233.1	RP11-158L12.4	9.62	4.6e-20	3.84e-17	0.42	0.41	Post bronchodilator FEV1/FVC ratio;	chr12:125187254	chr12:125138245~125141711:+
PRAD	cis	rs13392177	0.647	rs10932761	ENSG00000261338.2	RP11-378A13.1	-9.62	4.61e-20	3.84e-17	-0.47	-0.41	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218199668	chr2:218255319~218257366:+
PRAD	cis	rs7714584	1	rs11749391	ENSG00000197083.10	ZNF300P1	9.62	4.62e-20	3.85e-17	0.65	0.41	Crohn's disease;	chr5:150849504	chr5:150930645~150946289:-
PRAD	cis	rs6570726	0.846	rs6919684	ENSG00000235652.6	RP11-545I5.3	9.62	4.62e-20	3.85e-17	0.42	0.41	Lobe attachment (rater-scored or self-reported);	chr6:145562665	chr6:145799409~145886585:+
PRAD	cis	rs4879677	1	rs10116400	ENSG00000260390.1	RP11-575I8.1	-9.62	4.62e-20	3.85e-17	-0.54	-0.41	Gut microbiome composition (summer and winter);	chr9:27686882	chr9:27829276~27844481:+
PRAD	cis	rs9322193	0.962	rs35443312	ENSG00000268592.3	RAET1E-AS1	9.62	4.63e-20	3.86e-17	0.57	0.41	Lung cancer;	chr6:149670625	chr6:149863494~149919507:+
PRAD	cis	rs12049351	0.665	rs4925453	ENSG00000229367.1	HMGN2P19	-9.62	4.64e-20	3.87e-17	-0.61	-0.41	Circulating myeloperoxidase levels (plasma);	chr1:229461880	chr1:229570532~229570796:+
PRAD	cis	rs2282300	0.956	rs1717779	ENSG00000254532.1	RP11-624D11.2	9.62	4.64e-20	3.87e-17	0.56	0.41	Morning vs. evening chronotype;	chr11:30355151	chr11:30044058~30084343:-
PRAD	cis	rs7772486	0.79	rs1133832	ENSG00000235652.6	RP11-545I5.3	-9.62	4.67e-20	3.9e-17	-0.42	-0.41	Lobe attachment (rater-scored or self-reported);	chr6:145884468	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.79	rs9497425	ENSG00000235652.6	RP11-545I5.3	-9.62	4.67e-20	3.9e-17	-0.42	-0.41	Lobe attachment (rater-scored or self-reported);	chr6:145913061	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.79	rs9497427	ENSG00000235652.6	RP11-545I5.3	-9.62	4.67e-20	3.9e-17	-0.42	-0.41	Lobe attachment (rater-scored or self-reported);	chr6:145917166	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.764	rs9399569	ENSG00000235652.6	RP11-545I5.3	-9.62	4.67e-20	3.9e-17	-0.42	-0.41	Lobe attachment (rater-scored or self-reported);	chr6:145921806	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.754	rs4360151	ENSG00000235652.6	RP11-545I5.3	-9.62	4.67e-20	3.9e-17	-0.42	-0.41	Lobe attachment (rater-scored or self-reported);	chr6:145933943	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.79	rs9497435	ENSG00000235652.6	RP11-545I5.3	-9.62	4.67e-20	3.9e-17	-0.42	-0.41	Lobe attachment (rater-scored or self-reported);	chr6:145944204	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.79	rs9791313	ENSG00000235652.6	RP11-545I5.3	-9.62	4.67e-20	3.9e-17	-0.42	-0.41	Lobe attachment (rater-scored or self-reported);	chr6:145945036	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.79	rs9386141	ENSG00000235652.6	RP11-545I5.3	-9.62	4.67e-20	3.9e-17	-0.42	-0.41	Lobe attachment (rater-scored or self-reported);	chr6:145947487	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.79	rs2254288	ENSG00000235652.6	RP11-545I5.3	9.62	4.67e-20	3.9e-17	0.42	0.41	Lobe attachment (rater-scored or self-reported);	chr6:145883334	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.79	rs2247206	ENSG00000235652.6	RP11-545I5.3	9.62	4.67e-20	3.9e-17	0.42	0.41	Lobe attachment (rater-scored or self-reported);	chr6:145895048	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.764	rs2247211	ENSG00000235652.6	RP11-545I5.3	9.62	4.67e-20	3.9e-17	0.42	0.41	Lobe attachment (rater-scored or self-reported);	chr6:145895243	chr6:145799409~145886585:+
PRAD	cis	rs5760092	0.618	rs5996631	ENSG00000235689.1	AP000351.13	-9.62	4.69e-20	3.91e-17	-0.56	-0.41	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:24006305~24008258:-
PRAD	cis	rs2282300	0.739	rs7942129	ENSG00000242353.1	RP4-710M3.1	-9.62	4.72e-20	3.93e-17	-0.5	-0.41	Morning vs. evening chronotype;	chr11:30203145	chr11:30368148~30368646:+
PRAD	cis	rs2282300	0.739	rs34855782	ENSG00000242353.1	RP4-710M3.1	-9.62	4.72e-20	3.93e-17	-0.5	-0.41	Morning vs. evening chronotype;	chr11:30203923	chr11:30368148~30368646:+
PRAD	cis	rs9399137	0.507	rs12664898	ENSG00000232876.1	CTA-212D2.2	-9.62	4.73e-20	3.94e-17	-0.53	-0.41	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134967525	chr6:135055033~135060550:+
PRAD	cis	rs9545047	0.604	rs9601217	ENSG00000227676.3	LINC01068	-9.62	4.76e-20	3.97e-17	-0.48	-0.41	Schizophrenia;	chr13:79359797	chr13:79566727~79571436:+
PRAD	cis	rs7772486	0.84	rs11155451	ENSG00000235652.6	RP11-545I5.3	9.62	4.77e-20	3.97e-17	0.42	0.41	Lobe attachment (rater-scored or self-reported);	chr6:146101388	chr6:145799409~145886585:+
PRAD	cis	rs858239	0.932	rs858275	ENSG00000226816.2	AC005082.12	9.61	4.78e-20	3.98e-17	0.46	0.41	Cerebrospinal fluid biomarker levels;	chr7:23254525	chr7:23206013~23208045:+
PRAD	cis	rs6452524	0.935	rs9293330	ENSG00000249664.1	CTD-2227C6.2	9.61	4.78e-20	3.99e-17	0.48	0.41	Hypertension (SNP x SNP interaction);	chr5:83102299	chr5:83012285~83013109:-
PRAD	cis	rs4713118	0.516	rs6931858	ENSG00000219392.1	RP1-265C24.5	-9.61	4.79e-20	3.99e-17	-0.54	-0.41	Parkinson's disease;	chr6:28110633	chr6:28115628~28116551:+
PRAD	cis	rs7714584	1	rs2115069	ENSG00000197083.10	ZNF300P1	9.61	4.79e-20	3.99e-17	0.67	0.41	Crohn's disease;	chr5:150872803	chr5:150930645~150946289:-
PRAD	cis	rs7772486	0.875	rs2748498	ENSG00000235652.6	RP11-545I5.3	9.61	4.8e-20	4e-17	0.42	0.41	Lobe attachment (rater-scored or self-reported);	chr6:145998030	chr6:145799409~145886585:+
PRAD	cis	rs7189233	0.531	rs9929873	ENSG00000279344.1	RP11-44F14.7	9.61	4.81e-20	4.01e-17	0.37	0.41	Intelligence (multi-trait analysis);	chr16:53456764	chr16:53478957~53481550:-
PRAD	cis	rs4927850	1	rs6799572	ENSG00000242086.7	LINC00969	9.61	4.82e-20	4.02e-17	0.36	0.41	Pancreatic cancer;	chr3:196013537	chr3:195658062~195739964:+
PRAD	cis	rs62103177	0.565	rs473119	ENSG00000261126.6	RP11-795F19.1	-9.61	4.83e-20	4.02e-17	-0.54	-0.41	Opioid sensitivity;	chr18:80091557	chr18:80046900~80095482:+
PRAD	cis	rs9309473	0.847	rs13538	ENSG00000163016.8	ALMS1P	9.61	4.84e-20	4.03e-17	0.51	0.41	Metabolite levels;	chr2:73641201	chr2:73644919~73685576:+
PRAD	cis	rs9309473	1	rs6745368	ENSG00000163016.8	ALMS1P	9.61	4.84e-20	4.03e-17	0.51	0.41	Metabolite levels;	chr2:73582847	chr2:73644919~73685576:+
PRAD	cis	rs9309473	0.948	rs10173534	ENSG00000163016.8	ALMS1P	9.61	4.84e-20	4.03e-17	0.51	0.41	Metabolite levels;	chr2:73586305	chr2:73644919~73685576:+
PRAD	cis	rs10129255	0.536	rs10142951	ENSG00000223648.3	IGHV3-64	9.61	4.86e-20	4.05e-17	0.36	0.41	Kawasaki disease;	chr14:106782337	chr14:106643132~106658258:-
PRAD	cis	rs34779708	0.966	rs998658	ENSG00000230534.5	RP11-297A16.2	9.61	4.87e-20	4.05e-17	0.54	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35119726	chr10:35098006~35127020:-
PRAD	cis	rs150992	0.609	rs2937709	ENSG00000248489.1	CTD-2007H13.3	9.61	4.88e-20	4.06e-17	0.46	0.41	Body mass index;	chr5:98993120	chr5:98929171~98995013:+
PRAD	cis	rs150992	0.632	rs1104262	ENSG00000248489.1	CTD-2007H13.3	9.61	4.88e-20	4.06e-17	0.46	0.41	Body mass index;	chr5:98993145	chr5:98929171~98995013:+
PRAD	cis	rs150992	0.609	rs2927654	ENSG00000248489.1	CTD-2007H13.3	9.61	4.88e-20	4.06e-17	0.46	0.41	Body mass index;	chr5:98993195	chr5:98929171~98995013:+
PRAD	cis	rs2658782	0.593	rs2243410	ENSG00000279684.1	RP11-755E23.2	-9.61	4.89e-20	4.07e-17	-0.63	-0.41	Pulmonary function decline;	chr11:93522353	chr11:93286629~93288903:-
PRAD	cis	rs7849270	1	rs2254230	ENSG00000268707.1	RP11-247A12.7	9.61	4.96e-20	4.12e-17	0.48	0.41	Blood metabolite ratios;	chr9:129142898	chr9:129170434~129170940:+
PRAD	cis	rs4879677	1	rs12237023	ENSG00000260390.1	RP11-575I8.1	-9.61	4.97e-20	4.14e-17	-0.55	-0.41	Gut microbiome composition (summer and winter);	chr9:27674972	chr9:27829276~27844481:+
PRAD	cis	rs4879677	0.959	rs10968049	ENSG00000260390.1	RP11-575I8.1	-9.61	4.97e-20	4.14e-17	-0.55	-0.41	Gut microbiome composition (summer and winter);	chr9:27676933	chr9:27829276~27844481:+
PRAD	cis	rs4879677	1	rs10757676	ENSG00000260390.1	RP11-575I8.1	-9.61	4.97e-20	4.14e-17	-0.55	-0.41	Gut microbiome composition (summer and winter);	chr9:27680309	chr9:27829276~27844481:+
PRAD	cis	rs2282300	0.956	rs1222212	ENSG00000254532.1	RP11-624D11.2	9.61	4.98e-20	4.14e-17	0.57	0.41	Morning vs. evening chronotype;	chr11:30353096	chr11:30044058~30084343:-
PRAD	cis	rs7849270	1	rs3124512	ENSG00000268707.1	RP11-247A12.7	9.61	4.98e-20	4.14e-17	0.48	0.41	Blood metabolite ratios;	chr9:129141602	chr9:129170434~129170940:+
PRAD	cis	rs732716	0.853	rs62129349	ENSG00000267769.1	CTB-50L17.9	-9.61	4.98e-20	4.14e-17	-0.45	-0.41	Mean corpuscular volume;	chr19:4385662	chr19:4454014~4455286:+
PRAD	cis	rs7772486	0.79	rs10223507	ENSG00000235652.6	RP11-545I5.3	-9.61	5.02e-20	4.17e-17	-0.42	-0.41	Lobe attachment (rater-scored or self-reported);	chr6:145964068	chr6:145799409~145886585:+
PRAD	cis	rs2404602	0.532	rs12591100	ENSG00000259422.1	RP11-593F23.1	-9.61	5.02e-20	4.17e-17	-0.51	-0.41	Blood metabolite levels;	chr15:76408460	chr15:76174891~76181486:-
PRAD	cis	rs150992	0.609	rs4703049	ENSG00000248489.1	CTD-2007H13.3	9.61	5.05e-20	4.2e-17	0.44	0.41	Body mass index;	chr5:99004679	chr5:98929171~98995013:+
PRAD	cis	rs6142102	0.847	rs4911413	ENSG00000276073.1	RP5-1125A11.7	-9.61	5.05e-20	4.2e-17	-0.41	-0.41	Skin pigmentation;	chr20:34133969	chr20:33985617~33988989:-
PRAD	cis	rs6142102	1	rs2143230	ENSG00000276073.1	RP5-1125A11.7	-9.61	5.05e-20	4.2e-17	-0.41	-0.41	Skin pigmentation;	chr20:34136539	chr20:33985617~33988989:-
PRAD	cis	rs2933343	1	rs876756	ENSG00000261159.1	RP11-723O4.9	9.61	5.05e-20	4.2e-17	0.38	0.41	IgG glycosylation;	chr3:128908780	chr3:128859716~128860526:-
PRAD	cis	rs4964805	0.773	rs4964623	ENSG00000257681.1	RP11-341G23.4	9.61	5.07e-20	4.21e-17	0.43	0.41	Attention deficit hyperactivity disorder;	chr12:103828964	chr12:103746315~103768858:-
PRAD	cis	rs9309473	0.748	rs2421552	ENSG00000163016.8	ALMS1P	9.61	5.12e-20	4.26e-17	0.51	0.41	Metabolite levels;	chr2:73531676	chr2:73644919~73685576:+
PRAD	cis	rs2153535	0.585	rs4960448	ENSG00000230939.1	RP11-314C16.1	-9.61	5.13e-20	4.26e-17	-0.51	-0.41	Motion sickness;	chr6:8624438	chr6:8784178~8785445:+
PRAD	cis	rs10129255	0.5	rs34326748	ENSG00000223648.3	IGHV3-64	9.61	5.14e-20	4.27e-17	0.36	0.41	Kawasaki disease;	chr14:106782523	chr14:106643132~106658258:-
PRAD	cis	rs10129255	0.5	rs10143385	ENSG00000223648.3	IGHV3-64	9.61	5.14e-20	4.27e-17	0.36	0.41	Kawasaki disease;	chr14:106782559	chr14:106643132~106658258:-
PRAD	cis	rs7772486	0.875	rs9403770	ENSG00000235652.6	RP11-545I5.3	9.61	5.17e-20	4.29e-17	0.42	0.41	Lobe attachment (rater-scored or self-reported);	chr6:146102198	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.875	rs11155452	ENSG00000235652.6	RP11-545I5.3	9.61	5.17e-20	4.29e-17	0.42	0.41	Lobe attachment (rater-scored or self-reported);	chr6:146103495	chr6:145799409~145886585:+
PRAD	cis	rs9545047	0.604	rs1752649	ENSG00000227676.3	LINC01068	9.61	5.18e-20	4.3e-17	0.48	0.41	Schizophrenia;	chr13:79331980	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs1749983	ENSG00000227676.3	LINC01068	9.61	5.18e-20	4.3e-17	0.48	0.41	Schizophrenia;	chr13:79332077	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.567	rs1752648	ENSG00000227676.3	LINC01068	9.61	5.18e-20	4.3e-17	0.48	0.41	Schizophrenia;	chr13:79332124	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs1752647	ENSG00000227676.3	LINC01068	9.61	5.18e-20	4.3e-17	0.48	0.41	Schizophrenia;	chr13:79332741	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.532	rs1752646	ENSG00000227676.3	LINC01068	9.61	5.18e-20	4.3e-17	0.48	0.41	Schizophrenia;	chr13:79332752	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs1749988	ENSG00000227676.3	LINC01068	9.61	5.18e-20	4.3e-17	0.48	0.41	Schizophrenia;	chr13:79333103	chr13:79566727~79571436:+
PRAD	cis	rs9399137	0.507	rs4896129	ENSG00000232876.1	CTA-212D2.2	-9.6	5.19e-20	4.31e-17	-0.52	-0.41	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135028707	chr6:135055033~135060550:+
PRAD	cis	rs9545047	0.604	rs9285309	ENSG00000227676.3	LINC01068	9.6	5.21e-20	4.33e-17	0.48	0.41	Schizophrenia;	chr13:79326707	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.584	rs9545069	ENSG00000227676.3	LINC01068	9.6	5.21e-20	4.33e-17	0.48	0.41	Schizophrenia;	chr13:79328065	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.647	rs7317416	ENSG00000227676.3	LINC01068	9.6	5.21e-20	4.33e-17	0.48	0.41	Schizophrenia;	chr13:79328400	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.588	rs1408658	ENSG00000227676.3	LINC01068	9.6	5.21e-20	4.33e-17	0.48	0.41	Schizophrenia;	chr13:79329294	chr13:79566727~79571436:+
PRAD	cis	rs765787	0.53	rs2899378	ENSG00000259520.4	CTD-2651B20.3	-9.6	5.22e-20	4.34e-17	-0.53	-0.41	Uric acid levels;	chr15:45245386	chr15:45251580~45279251:-
PRAD	cis	rs1729407	0.933	rs1729405	ENSG00000254851.1	RP11-109L13.1	-9.6	5.23e-20	4.34e-17	-0.53	-0.41	Apolipoprotein A-IV levels;	chr11:116808044	chr11:117135528~117138582:+
PRAD	cis	rs7772486	0.875	rs7739371	ENSG00000235652.6	RP11-545I5.3	9.6	5.23e-20	4.34e-17	0.42	0.41	Lobe attachment (rater-scored or self-reported);	chr6:146103217	chr6:145799409~145886585:+
PRAD	cis	rs9309473	1	rs9309473	ENSG00000163016.8	ALMS1P	9.6	5.24e-20	4.35e-17	0.51	0.41	Metabolite levels;	chr2:73516855	chr2:73644919~73685576:+
PRAD	cis	rs8062405	0.895	rs62036658	ENSG00000259982.1	CDC37P1	9.6	5.27e-20	4.38e-17	0.55	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28839050	chr16:28700294~28701540:-
PRAD	cis	rs2933343	1	rs1680790	ENSG00000261159.1	RP11-723O4.9	9.6	5.28e-20	4.38e-17	0.38	0.41	IgG glycosylation;	chr3:128907010	chr3:128859716~128860526:-
PRAD	cis	rs2933343	1	rs876755	ENSG00000261159.1	RP11-723O4.9	9.6	5.28e-20	4.38e-17	0.38	0.41	IgG glycosylation;	chr3:128909090	chr3:128859716~128860526:-
PRAD	cis	rs9545047	0.604	rs1007569	ENSG00000227676.3	LINC01068	9.6	5.28e-20	4.38e-17	0.48	0.41	Schizophrenia;	chr13:79306752	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.584	rs4885626	ENSG00000227676.3	LINC01068	9.6	5.28e-20	4.38e-17	0.48	0.41	Schizophrenia;	chr13:79309765	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs4885627	ENSG00000227676.3	LINC01068	9.6	5.28e-20	4.38e-17	0.48	0.41	Schizophrenia;	chr13:79309786	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs4885628	ENSG00000227676.3	LINC01068	9.6	5.28e-20	4.38e-17	0.48	0.41	Schizophrenia;	chr13:79309830	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.554	rs4885629	ENSG00000227676.3	LINC01068	9.6	5.28e-20	4.38e-17	0.48	0.41	Schizophrenia;	chr13:79309855	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs1927506	ENSG00000227676.3	LINC01068	9.6	5.28e-20	4.38e-17	0.48	0.41	Schizophrenia;	chr13:79311350	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs1409019	ENSG00000227676.3	LINC01068	9.6	5.28e-20	4.38e-17	0.48	0.41	Schizophrenia;	chr13:79312431	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs7317343	ENSG00000227676.3	LINC01068	9.6	5.28e-20	4.38e-17	0.48	0.41	Schizophrenia;	chr13:79312542	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs6563098	ENSG00000227676.3	LINC01068	9.6	5.28e-20	4.38e-17	0.48	0.41	Schizophrenia;	chr13:79313102	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.532	rs1748768	ENSG00000227676.3	LINC01068	9.6	5.28e-20	4.38e-17	0.48	0.41	Schizophrenia;	chr13:79313276	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs1748767	ENSG00000227676.3	LINC01068	9.6	5.28e-20	4.38e-17	0.48	0.41	Schizophrenia;	chr13:79313381	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.567	rs1409018	ENSG00000227676.3	LINC01068	9.6	5.28e-20	4.38e-17	0.48	0.41	Schizophrenia;	chr13:79313403	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs1410332	ENSG00000227676.3	LINC01068	9.6	5.28e-20	4.38e-17	0.48	0.41	Schizophrenia;	chr13:79315171	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs9545065	ENSG00000227676.3	LINC01068	9.6	5.28e-20	4.38e-17	0.48	0.41	Schizophrenia;	chr13:79317034	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs3818563	ENSG00000227676.3	LINC01068	9.6	5.28e-20	4.38e-17	0.48	0.41	Schizophrenia;	chr13:79318587	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs3187338	ENSG00000227676.3	LINC01068	9.6	5.28e-20	4.38e-17	0.48	0.41	Schizophrenia;	chr13:79320601	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs9545068	ENSG00000227676.3	LINC01068	9.6	5.28e-20	4.38e-17	0.48	0.41	Schizophrenia;	chr13:79324101	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.625	rs9318621	ENSG00000227676.3	LINC01068	9.6	5.28e-20	4.38e-17	0.48	0.41	Schizophrenia;	chr13:79325662	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs7322167	ENSG00000227676.3	LINC01068	9.6	5.28e-20	4.38e-17	0.48	0.41	Schizophrenia;	chr13:79325931	chr13:79566727~79571436:+
PRAD	cis	rs10129255	0.5	rs8022547	ENSG00000223648.3	IGHV3-64	9.6	5.29e-20	4.39e-17	0.36	0.41	Kawasaki disease;	chr14:106781985	chr14:106643132~106658258:-
PRAD	cis	rs7923609	0.578	rs3858122	ENSG00000232075.1	MRPL35P2	-9.6	5.29e-20	4.39e-17	-0.45	-0.41	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63640320	chr10:63634317~63634827:-
PRAD	cis	rs3096299	0.967	rs2911255	ENSG00000274627.1	RP11-104N10.2	9.6	5.3e-20	4.39e-17	0.42	0.41	Multiple myeloma (IgH translocation);	chr16:89420729	chr16:89516797~89522217:+
PRAD	cis	rs6142102	0.924	rs6059662	ENSG00000276073.1	RP5-1125A11.7	9.6	5.3e-20	4.4e-17	0.44	0.41	Skin pigmentation;	chr20:34087921	chr20:33985617~33988989:-
PRAD	cis	rs7849270	1	rs10988223	ENSG00000268707.1	RP11-247A12.7	-9.6	5.32e-20	4.41e-17	-0.46	-0.41	Blood metabolite ratios;	chr9:129140742	chr9:129170434~129170940:+
PRAD	cis	rs748404	0.56	rs1060939	ENSG00000249839.1	AC011330.5	-9.6	5.34e-20	4.43e-17	-0.52	-0.41	Lung cancer;	chr15:43524719	chr15:43663654~43684339:-
PRAD	cis	rs10129255	0.518	rs8004895	ENSG00000223648.3	IGHV3-64	9.6	5.36e-20	4.44e-17	0.36	0.41	Kawasaki disease;	chr14:106785139	chr14:106643132~106658258:-
PRAD	cis	rs10129255	0.5	rs6576230	ENSG00000223648.3	IGHV3-64	9.6	5.39e-20	4.47e-17	0.36	0.41	Kawasaki disease;	chr14:106778539	chr14:106643132~106658258:-
PRAD	cis	rs10129255	0.518	rs11847766	ENSG00000223648.3	IGHV3-64	9.6	5.39e-20	4.47e-17	0.36	0.41	Kawasaki disease;	chr14:106779186	chr14:106643132~106658258:-
PRAD	cis	rs10129255	0.5	rs59939897	ENSG00000223648.3	IGHV3-64	9.6	5.4e-20	4.48e-17	0.36	0.41	Kawasaki disease;	chr14:106783414	chr14:106643132~106658258:-
PRAD	cis	rs10129255	0.5	rs12101190	ENSG00000223648.3	IGHV3-64	9.6	5.4e-20	4.48e-17	0.36	0.41	Kawasaki disease;	chr14:106784149	chr14:106643132~106658258:-
PRAD	cis	rs4879677	1	rs7859172	ENSG00000260390.1	RP11-575I8.1	-9.6	5.45e-20	4.51e-17	-0.55	-0.41	Gut microbiome composition (summer and winter);	chr9:27659388	chr9:27829276~27844481:+
PRAD	cis	rs2282300	0.653	rs67745574	ENSG00000242353.1	RP4-710M3.1	-9.6	5.46e-20	4.53e-17	-0.5	-0.41	Morning vs. evening chronotype;	chr11:30213292	chr11:30368148~30368646:+
PRAD	cis	rs7688540	0.771	rs7665727	ENSG00000275426.1	CH17-262A2.1	9.6	5.51e-20	4.56e-17	0.62	0.41	Facial morphology (factor 6, height of vermillion lower lip);	chr4:283268	chr4:149738~150317:+
PRAD	cis	rs10129255	0.518	rs28378320	ENSG00000223648.3	IGHV3-64	9.6	5.51e-20	4.56e-17	0.37	0.41	Kawasaki disease;	chr14:106808609	chr14:106643132~106658258:-
PRAD	cis	rs7569084	0.663	rs11694714	ENSG00000281920.1	RP11-418H16.1	9.6	5.51e-20	4.57e-17	0.5	0.41	Sum eosinophil basophil counts;	chr2:65436802	chr2:65623272~65628424:+
PRAD	cis	rs9309473	0.95	rs10207264	ENSG00000163016.8	ALMS1P	9.6	5.51e-20	4.57e-17	0.5	0.41	Metabolite levels;	chr2:73486970	chr2:73644919~73685576:+
PRAD	cis	rs9309473	0.948	rs11884776	ENSG00000163016.8	ALMS1P	9.6	5.53e-20	4.58e-17	0.51	0.41	Metabolite levels;	chr2:73519796	chr2:73644919~73685576:+
PRAD	cis	rs2348418	0.767	rs1478332	ENSG00000247934.4	RP11-967K21.1	-9.6	5.55e-20	4.59e-17	-0.37	-0.41	Lung function (FEV1);Lung function (FVC);	chr12:28255432	chr12:28163298~28190738:-
PRAD	cis	rs7772486	0.875	rs1125461	ENSG00000235652.6	RP11-545I5.3	9.6	5.55e-20	4.6e-17	0.42	0.41	Lobe attachment (rater-scored or self-reported);	chr6:146096517	chr6:145799409~145886585:+
PRAD	cis	rs1075265	0.756	rs1075264	ENSG00000233266.1	HMGB1P31	9.6	5.57e-20	4.61e-17	0.54	0.41	Chronotype;Morning vs. evening chronotype;	chr2:54127916	chr2:54051334~54051760:+
PRAD	cis	rs2282300	0.956	rs2685286	ENSG00000254532.1	RP11-624D11.2	9.6	5.6e-20	4.64e-17	0.57	0.41	Morning vs. evening chronotype;	chr11:30360041	chr11:30044058~30084343:-
PRAD	cis	rs2282300	0.956	rs1717773	ENSG00000254532.1	RP11-624D11.2	9.6	5.6e-20	4.64e-17	0.57	0.41	Morning vs. evening chronotype;	chr11:30361607	chr11:30044058~30084343:-
PRAD	cis	rs748404	0.56	rs689797	ENSG00000249839.1	AC011330.5	-9.59	5.63e-20	4.66e-17	-0.52	-0.41	Lung cancer;	chr15:43534359	chr15:43663654~43684339:-
PRAD	cis	rs67311347	0.955	rs2123999	ENSG00000223797.4	ENTPD3-AS1	9.59	5.65e-20	4.68e-17	0.36	0.41	Renal cell carcinoma;	chr3:40337247	chr3:40313802~40453329:-
PRAD	cis	rs673078	0.66	rs9943819	ENSG00000275759.1	RP11-131L12.3	-9.59	5.7e-20	4.72e-17	-0.56	-0.41	Glucose homeostasis traits;	chr12:118298917	chr12:118428281~118428870:+
PRAD	cis	rs4879677	1	rs10812642	ENSG00000260390.1	RP11-575I8.1	-9.59	5.72e-20	4.73e-17	-0.55	-0.41	Gut microbiome composition (summer and winter);	chr9:27684906	chr9:27829276~27844481:+
PRAD	cis	rs4879677	0.881	rs10968058	ENSG00000260390.1	RP11-575I8.1	-9.59	5.72e-20	4.73e-17	-0.55	-0.41	Gut microbiome composition (summer and winter);	chr9:27685336	chr9:27829276~27844481:+
PRAD	cis	rs4879677	1	rs4879706	ENSG00000260390.1	RP11-575I8.1	-9.59	5.72e-20	4.73e-17	-0.55	-0.41	Gut microbiome composition (summer and winter);	chr9:27685777	chr9:27829276~27844481:+
PRAD	cis	rs8100891	0.734	rs741445	ENSG00000267213.4	AC007773.2	-9.59	5.73e-20	4.74e-17	-0.43	-0.41	Neuroticism;	chr19:32345686	chr19:32390050~32405560:-
PRAD	cis	rs1061377	0.621	rs11096974	ENSG00000249207.1	RP11-360F5.1	-9.59	5.73e-20	4.74e-17	-0.43	-0.41	Uric acid levels;	chr4:39062039	chr4:39112677~39126818:-
PRAD	cis	rs3813579	0.606	rs3813583	ENSG00000261390.4	RP11-345M22.2	-9.59	5.74e-20	4.75e-17	-0.48	-0.41	Thyroid volume;	chr16:79721183	chr16:79715232~79770563:-
PRAD	cis	rs2153535	0.585	rs9405400	ENSG00000230939.1	RP11-314C16.1	-9.59	5.75e-20	4.75e-17	-0.5	-0.41	Motion sickness;	chr6:8606895	chr6:8784178~8785445:+
PRAD	cis	rs9309473	1	rs7576245	ENSG00000163016.8	ALMS1P	9.59	5.8e-20	4.79e-17	0.51	0.41	Metabolite levels;	chr2:73602551	chr2:73644919~73685576:+
PRAD	cis	rs765787	0.53	rs12592055	ENSG00000259520.4	CTD-2651B20.3	-9.59	5.8e-20	4.8e-17	-0.53	-0.41	Uric acid levels;	chr15:45222279	chr15:45251580~45279251:-
PRAD	cis	rs3762637	0.941	rs9289192	ENSG00000272758.4	RP11-299J3.8	-9.59	5.82e-20	4.81e-17	-0.62	-0.41	LDL cholesterol levels;	chr3:122357268	chr3:122416207~122443180:+
PRAD	cis	rs10129255	0.518	rs8010020	ENSG00000223648.3	IGHV3-64	9.59	5.82e-20	4.81e-17	0.36	0.41	Kawasaki disease;	chr14:106778016	chr14:106643132~106658258:-
PRAD	cis	rs10129255	0.5	rs6576225	ENSG00000223648.3	IGHV3-64	9.59	5.82e-20	4.81e-17	0.36	0.41	Kawasaki disease;	chr14:106778120	chr14:106643132~106658258:-
PRAD	cis	rs10129255	0.5	rs6576226	ENSG00000223648.3	IGHV3-64	9.59	5.82e-20	4.81e-17	0.36	0.41	Kawasaki disease;	chr14:106778135	chr14:106643132~106658258:-
PRAD	cis	rs732716	0.889	rs11666856	ENSG00000267769.1	CTB-50L17.9	-9.59	5.85e-20	4.84e-17	-0.45	-0.41	Mean corpuscular volume;	chr19:4437453	chr19:4454014~4455286:+
PRAD	cis	rs9309473	1	rs6546836	ENSG00000163016.8	ALMS1P	9.59	5.88e-20	4.86e-17	0.5	0.41	Metabolite levels;	chr2:73450706	chr2:73644919~73685576:+
PRAD	cis	rs9545047	0.604	rs9574406	ENSG00000227676.3	LINC01068	-9.59	5.94e-20	4.91e-17	-0.48	-0.41	Schizophrenia;	chr13:79338982	chr13:79566727~79571436:+
PRAD	cis	rs9309473	0.95	rs1052162	ENSG00000163016.8	ALMS1P	-9.59	5.95e-20	4.92e-17	-0.51	-0.41	Metabolite levels;	chr2:73602245	chr2:73644919~73685576:+
PRAD	cis	rs6452524	0.935	rs6880566	ENSG00000249664.1	CTD-2227C6.2	9.59	5.96e-20	4.92e-17	0.48	0.41	Hypertension (SNP x SNP interaction);	chr5:83086909	chr5:83012285~83013109:-
PRAD	cis	rs6452524	0.905	rs6884981	ENSG00000249664.1	CTD-2227C6.2	9.59	5.96e-20	4.92e-17	0.48	0.41	Hypertension (SNP x SNP interaction);	chr5:83087339	chr5:83012285~83013109:-
PRAD	cis	rs6452524	0.905	rs6896548	ENSG00000249664.1	CTD-2227C6.2	9.59	5.96e-20	4.92e-17	0.48	0.41	Hypertension (SNP x SNP interaction);	chr5:83089247	chr5:83012285~83013109:-
PRAD	cis	rs9309711	0.621	rs11127428	ENSG00000225234.1	TRAPPC12-AS1	-9.59	5.96e-20	4.93e-17	-0.41	-0.41	Neurofibrillary tangles;	chr2:3467375	chr2:3481242~3482409:-
PRAD	cis	rs10800713	0.954	rs6665951	ENSG00000260088.1	RP11-92G12.3	-9.59	6e-20	4.95e-17	-0.6	-0.41	Tandem gait;	chr1:200589235	chr1:200669507~200694250:+
PRAD	cis	rs7923609	0.578	rs10761789	ENSG00000232075.1	MRPL35P2	-9.59	6.01e-20	4.97e-17	-0.44	-0.41	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63636804	chr10:63634317~63634827:-
PRAD	cis	rs9309473	0.95	rs10169213	ENSG00000163016.8	ALMS1P	9.59	6.06e-20	5.01e-17	0.51	0.41	Metabolite levels;	chr2:73560107	chr2:73644919~73685576:+
PRAD	cis	rs9399137	0.507	rs13209780	ENSG00000232876.1	CTA-212D2.2	-9.58	6.09e-20	5.03e-17	-0.52	-0.41	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135023657	chr6:135055033~135060550:+
PRAD	cis	rs6876835	0.553	rs7720397	ENSG00000250056.4	LINC01018	9.58	6.09e-20	5.03e-17	0.48	0.41	Visceral fat;	chr5:6598780	chr5:6582136~6588499:+
PRAD	cis	rs2564921	0.73	rs62255898	ENSG00000242142.1	SERBP1P3	-9.58	6.12e-20	5.05e-17	-0.48	-0.41	Height;	chr3:53029908	chr3:53064283~53065091:-
PRAD	cis	rs2153535	0.585	rs11243268	ENSG00000230939.1	RP11-314C16.1	-9.58	6.14e-20	5.07e-17	-0.5	-0.41	Motion sickness;	chr6:8662375	chr6:8784178~8785445:+
PRAD	cis	rs10129255	0.5	rs8014529	ENSG00000223648.3	IGHV3-64	9.58	6.19e-20	5.1e-17	0.36	0.41	Kawasaki disease;	chr14:106784065	chr14:106643132~106658258:-
PRAD	cis	rs71403859	0.57	rs78972826	ENSG00000260886.1	TAT-AS1	9.58	6.2e-20	5.11e-17	0.69	0.41	Post bronchodilator FEV1;	chr16:71420361	chr16:71565789~71578187:+
PRAD	cis	rs2933343	0.953	rs2933344	ENSG00000261159.1	RP11-723O4.9	9.58	6.22e-20	5.13e-17	0.37	0.41	IgG glycosylation;	chr3:128939872	chr3:128859716~128860526:-
PRAD	cis	rs6061231	1	rs6061231	ENSG00000273619.1	RP5-908M14.9	-9.58	6.23e-20	5.14e-17	-0.28	-0.41	Colorectal cancer;	chr20:62381861	chr20:62386303~62386970:-
PRAD	cis	rs3931020	0.616	rs277380	ENSG00000272864.1	RP11-17E13.2	9.58	6.23e-20	5.14e-17	0.49	0.41	Resistin levels;	chr1:74797404	chr1:74698769~74699333:-
PRAD	cis	rs2286503	0.966	rs2286507	ENSG00000228649.7	AC005682.5	9.58	6.25e-20	5.15e-17	0.46	0.41	Fibrinogen;	chr7:22815141	chr7:22854178~22861579:+
PRAD	cis	rs7772486	0.686	rs1045820	ENSG00000235652.6	RP11-545I5.3	9.58	6.25e-20	5.15e-17	0.42	0.41	Lobe attachment (rater-scored or self-reported);	chr6:145625944	chr6:145799409~145886585:+
PRAD	cis	rs2739330	0.753	rs4822452	ENSG00000099984.9	GSTT2	-9.58	6.27e-20	5.17e-17	-0.55	-0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23980123~23983911:+
PRAD	cis	rs10129255	0.5	rs7161740	ENSG00000223648.3	IGHV3-64	9.58	6.31e-20	5.2e-17	0.36	0.41	Kawasaki disease;	chr14:106776119	chr14:106643132~106658258:-
PRAD	cis	rs10129255	0.556	rs6576222	ENSG00000223648.3	IGHV3-64	9.58	6.31e-20	5.2e-17	0.36	0.41	Kawasaki disease;	chr14:106776442	chr14:106643132~106658258:-
PRAD	cis	rs10129255	0.536	rs6576223	ENSG00000223648.3	IGHV3-64	9.58	6.31e-20	5.2e-17	0.36	0.41	Kawasaki disease;	chr14:106776448	chr14:106643132~106658258:-
PRAD	cis	rs10129255	0.5	rs988134	ENSG00000223648.3	IGHV3-64	9.58	6.31e-20	5.2e-17	0.36	0.41	Kawasaki disease;	chr14:106776698	chr14:106643132~106658258:-
PRAD	cis	rs10129255	0.5	rs988133	ENSG00000223648.3	IGHV3-64	9.58	6.31e-20	5.2e-17	0.36	0.41	Kawasaki disease;	chr14:106776724	chr14:106643132~106658258:-
PRAD	cis	rs6700559	0.81	rs7529962	ENSG00000260088.1	RP11-92G12.3	-9.58	6.33e-20	5.21e-17	-0.5	-0.41	Coronary artery disease;	chr1:200627849	chr1:200669507~200694250:+
PRAD	cis	rs1930961	0.85	rs5996945	ENSG00000272798.1	CTA-390C10.9	9.58	6.33e-20	5.21e-17	0.64	0.41	Bipolar disorder with mood-incongruent psychosis;	chr22:25479606	chr22:25436312~25436915:+
PRAD	cis	rs7772486	0.79	rs2243665	ENSG00000235652.6	RP11-545I5.3	9.58	6.33e-20	5.22e-17	0.46	0.41	Lobe attachment (rater-scored or self-reported);	chr6:145886984	chr6:145799409~145886585:+
PRAD	cis	rs9545047	0.604	rs9574419	ENSG00000227676.3	LINC01068	-9.58	6.39e-20	5.27e-17	-0.49	-0.41	Schizophrenia;	chr13:79402337	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs9601226	ENSG00000227676.3	LINC01068	-9.58	6.39e-20	5.27e-17	-0.49	-0.41	Schizophrenia;	chr13:79403400	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.567	rs9574420	ENSG00000227676.3	LINC01068	-9.58	6.39e-20	5.27e-17	-0.49	-0.41	Schizophrenia;	chr13:79404342	chr13:79566727~79571436:+
PRAD	cis	rs783540	0.5	rs7163840	ENSG00000255769.6	GOLGA2P10	9.58	6.45e-20	5.31e-17	0.54	0.41	Schizophrenia;	chr15:82729551	chr15:82472993~82513950:-
PRAD	cis	rs6539288	0.691	rs10746071	ENSG00000260329.1	RP11-412D9.4	9.58	6.49e-20	5.35e-17	0.36	0.41	Total body bone mineral density;	chr12:106959817	chr12:106954029~106955497:-
PRAD	cis	rs9326248	0.689	rs4516002	ENSG00000280143.1	AP000892.6	9.58	6.52e-20	5.37e-17	0.44	0.41	Blood protein levels;	chr11:117128343	chr11:117204967~117210292:+
PRAD	cis	rs12594515	0.694	rs2068295	ENSG00000273972.1	CTD-2306A12.1	-9.58	6.53e-20	5.38e-17	-0.47	-0.41	Weight;Waist circumference;	chr15:45693348	chr15:45702640~45703183:+
PRAD	cis	rs9309473	1	rs2056486	ENSG00000163016.8	ALMS1P	9.58	6.59e-20	5.42e-17	0.5	0.41	Metabolite levels;	chr2:73490440	chr2:73644919~73685576:+
PRAD	cis	rs9309473	1	rs10193972	ENSG00000163016.8	ALMS1P	9.58	6.59e-20	5.42e-17	0.5	0.41	Metabolite levels;	chr2:73490529	chr2:73644919~73685576:+
PRAD	cis	rs2564921	0.73	rs6781896	ENSG00000242142.1	SERBP1P3	-9.58	6.59e-20	5.42e-17	-0.48	-0.41	Height;	chr3:53047596	chr3:53064283~53065091:-
PRAD	cis	rs7688540	0.771	rs79366248	ENSG00000275426.1	CH17-262A2.1	9.57	6.62e-20	5.45e-17	0.62	0.41	Facial morphology (factor 6, height of vermillion lower lip);	chr4:272870	chr4:149738~150317:+
PRAD	cis	rs4879677	1	rs10757673	ENSG00000260390.1	RP11-575I8.1	-9.57	6.63e-20	5.46e-17	-0.55	-0.41	Gut microbiome composition (summer and winter);	chr9:27670815	chr9:27829276~27844481:+
PRAD	cis	rs4713118	0.588	rs200994	ENSG00000280107.1	AL022393.9	9.57	6.64e-20	5.46e-17	0.53	0.41	Parkinson's disease;	chr6:27846035	chr6:28170845~28172521:+
PRAD	cis	rs11123170	0.542	rs11123169	ENSG00000189223.12	PAX8-AS1	9.57	6.64e-20	5.46e-17	0.56	0.41	Renal function-related traits (BUN);	chr2:113209498	chr2:113211522~113276581:+
PRAD	cis	rs1858037	0.836	rs1396209	ENSG00000204929.10	AC074391.1	9.57	6.67e-20	5.49e-17	0.56	0.41	Rheumatoid arthritis;	chr2:65374100	chr2:65436711~66084639:+
PRAD	cis	rs9309473	1	rs6740223	ENSG00000163016.8	ALMS1P	9.57	6.7e-20	5.51e-17	0.5	0.41	Metabolite levels;	chr2:73426204	chr2:73644919~73685576:+
PRAD	cis	rs9309473	1	rs6707722	ENSG00000163016.8	ALMS1P	9.57	6.7e-20	5.51e-17	0.5	0.41	Metabolite levels;	chr2:73427235	chr2:73644919~73685576:+
PRAD	cis	rs9309473	1	rs10186501	ENSG00000163016.8	ALMS1P	9.57	6.73e-20	5.54e-17	0.51	0.41	Metabolite levels;	chr2:73470717	chr2:73644919~73685576:+
PRAD	cis	rs8072100	0.764	rs4794371	ENSG00000228782.6	CTD-2026D20.3	-9.57	6.76e-20	5.56e-17	-0.46	-0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47550327	chr17:47450568~47492492:-
PRAD	cis	rs4853012	0.941	rs4852329	ENSG00000257800.1	FNBP1P1	9.57	6.76e-20	5.56e-17	0.4	0.41	Gestational age at birth (maternal effect);	chr2:74127417	chr2:74120680~74123218:+
PRAD	cis	rs2274273	0.84	rs943590	ENSG00000258413.1	RP11-665C16.6	-9.57	6.81e-20	5.6e-17	-0.52	-0.41	Protein biomarker;	chr14:55271878	chr14:55262767~55272075:-
PRAD	cis	rs12134133	1	rs6660254	ENSG00000274245.1	RP11-357P18.2	9.57	6.82e-20	5.61e-17	0.59	0.41	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207272746	chr1:207372559~207373252:+
PRAD	cis	rs6750795	0.542	rs1797388	ENSG00000181798.2	LINC00471	-9.57	6.83e-20	5.62e-17	-0.47	-0.41	Height;	chr2:231551270	chr2:231508426~231514339:-
PRAD	cis	rs2282300	0.739	rs1765139	ENSG00000242353.1	RP4-710M3.1	-9.57	6.86e-20	5.64e-17	-0.49	-0.41	Morning vs. evening chronotype;	chr11:30332178	chr11:30368148~30368646:+
PRAD	cis	rs1061377	0.585	rs3733271	ENSG00000249207.1	RP11-360F5.1	-9.57	6.86e-20	5.64e-17	-0.43	-0.41	Uric acid levels;	chr4:39047948	chr4:39112677~39126818:-
PRAD	cis	rs1061377	0.585	rs12648581	ENSG00000249207.1	RP11-360F5.1	-9.57	6.86e-20	5.64e-17	-0.43	-0.41	Uric acid levels;	chr4:39054024	chr4:39112677~39126818:-
PRAD	cis	rs3813579	0.568	rs4506909	ENSG00000261390.4	RP11-345M22.2	-9.57	6.87e-20	5.65e-17	-0.48	-0.41	Thyroid volume;	chr16:79719622	chr16:79715232~79770563:-
PRAD	cis	rs2282300	0.739	rs1717775	ENSG00000242353.1	RP4-710M3.1	-9.57	6.88e-20	5.65e-17	-0.49	-0.41	Morning vs. evening chronotype;	chr11:30328707	chr11:30368148~30368646:+
PRAD	cis	rs7772486	0.84	rs2474355	ENSG00000235652.6	RP11-545I5.3	9.57	6.89e-20	5.66e-17	0.42	0.41	Lobe attachment (rater-scored or self-reported);	chr6:145991404	chr6:145799409~145886585:+
PRAD	cis	rs2906856	0.524	rs56236103	ENSG00000255733.4	IFNG-AS1	9.57	6.92e-20	5.68e-17	0.47	0.41	Mosquito bite size;	chr12:67937437	chr12:67989445~68234686:+
PRAD	cis	rs2286503	1	rs2286501	ENSG00000228649.7	AC005682.5	9.57	6.93e-20	5.69e-17	0.46	0.41	Fibrinogen;	chr7:22817166	chr7:22854178~22861579:+
PRAD	cis	rs4879677	1	rs10812638	ENSG00000260390.1	RP11-575I8.1	-9.57	6.99e-20	5.74e-17	-0.55	-0.41	Gut microbiome composition (summer and winter);	chr9:27668808	chr9:27829276~27844481:+
PRAD	cis	rs2282300	0.739	rs7926465	ENSG00000242353.1	RP4-710M3.1	9.57	7e-20	5.75e-17	0.5	0.41	Morning vs. evening chronotype;	chr11:30311469	chr11:30368148~30368646:+
PRAD	cis	rs4713118	0.621	rs4713132	ENSG00000272009.1	RP1-313I6.12	-9.57	7.03e-20	5.77e-17	-0.42	-0.41	Parkinson's disease;	chr6:28066257	chr6:28078792~28081130:-
PRAD	cis	rs4713118	0.621	rs4713133	ENSG00000272009.1	RP1-313I6.12	-9.57	7.03e-20	5.77e-17	-0.42	-0.41	Parkinson's disease;	chr6:28066263	chr6:28078792~28081130:-
PRAD	cis	rs4713118	0.621	rs4713134	ENSG00000272009.1	RP1-313I6.12	-9.57	7.03e-20	5.77e-17	-0.42	-0.41	Parkinson's disease;	chr6:28066343	chr6:28078792~28081130:-
PRAD	cis	rs4713118	0.621	rs9368548	ENSG00000272009.1	RP1-313I6.12	-9.57	7.03e-20	5.77e-17	-0.42	-0.41	Parkinson's disease;	chr6:28066959	chr6:28078792~28081130:-
PRAD	cis	rs2282300	0.739	rs6484478	ENSG00000242353.1	RP4-710M3.1	9.57	7.03e-20	5.77e-17	0.5	0.41	Morning vs. evening chronotype;	chr11:30284893	chr11:30368148~30368646:+
PRAD	cis	rs2282300	0.739	rs10742237	ENSG00000242353.1	RP4-710M3.1	9.57	7.03e-20	5.77e-17	0.5	0.41	Morning vs. evening chronotype;	chr11:30289112	chr11:30368148~30368646:+
PRAD	cis	rs2282300	0.739	rs1933342	ENSG00000242353.1	RP4-710M3.1	9.57	7.03e-20	5.77e-17	0.5	0.41	Morning vs. evening chronotype;	chr11:30291278	chr11:30368148~30368646:+
PRAD	cis	rs2282300	0.739	rs2225909	ENSG00000242353.1	RP4-710M3.1	9.57	7.03e-20	5.77e-17	0.5	0.41	Morning vs. evening chronotype;	chr11:30308197	chr11:30368148~30368646:+
PRAD	cis	rs2282300	0.702	rs2211018	ENSG00000242353.1	RP4-710M3.1	9.57	7.03e-20	5.77e-17	0.5	0.41	Morning vs. evening chronotype;	chr11:30308532	chr11:30368148~30368646:+
PRAD	cis	rs2286503	1	rs2286503	ENSG00000228649.7	AC005682.5	9.57	7.04e-20	5.78e-17	0.46	0.41	Fibrinogen;	chr7:22816987	chr7:22854178~22861579:+
PRAD	cis	rs7849270	1	rs3124511	ENSG00000268707.1	RP11-247A12.7	9.57	7.05e-20	5.79e-17	0.48	0.41	Blood metabolite ratios;	chr9:129139179	chr9:129170434~129170940:+
PRAD	cis	rs9595066	0.667	rs6561164	ENSG00000227258.4	SMIM2-AS1	-9.57	7.06e-20	5.79e-17	-0.69	-0.41	Schizophrenia;	chr13:44152317	chr13:44110451~44240517:+
PRAD	cis	rs2404602	0.967	rs2083762	ENSG00000259422.1	RP11-593F23.1	9.57	7.07e-20	5.8e-17	0.51	0.41	Blood metabolite levels;	chr15:76615035	chr15:76174891~76181486:-
PRAD	cis	rs10129255	0.556	rs8010005	ENSG00000223648.3	IGHV3-64	9.57	7.07e-20	5.8e-17	0.36	0.41	Kawasaki disease;	chr14:106777987	chr14:106643132~106658258:-
PRAD	cis	rs10129255	0.556	rs6576224	ENSG00000223648.3	IGHV3-64	9.57	7.07e-20	5.8e-17	0.36	0.41	Kawasaki disease;	chr14:106777997	chr14:106643132~106658258:-
PRAD	cis	rs150992	0.609	rs113868271	ENSG00000248489.1	CTD-2007H13.3	9.57	7.09e-20	5.82e-17	0.46	0.41	Body mass index;	chr5:98992741	chr5:98929171~98995013:+
PRAD	cis	rs150992	0.631	rs112393710	ENSG00000248489.1	CTD-2007H13.3	9.57	7.09e-20	5.82e-17	0.46	0.41	Body mass index;	chr5:98992761	chr5:98929171~98995013:+
PRAD	cis	rs150992	0.631	rs111871078	ENSG00000248489.1	CTD-2007H13.3	9.57	7.09e-20	5.82e-17	0.46	0.41	Body mass index;	chr5:98992766	chr5:98929171~98995013:+
PRAD	cis	rs7772486	0.727	rs10223508	ENSG00000235652.6	RP11-545I5.3	-9.57	7.11e-20	5.84e-17	-0.43	-0.41	Lobe attachment (rater-scored or self-reported);	chr6:145964069	chr6:145799409~145886585:+
PRAD	cis	rs1062177	1	rs892006	ENSG00000253921.1	CTB-113P19.3	-9.57	7.12e-20	5.84e-17	-0.54	-0.41	Preschool internalizing problems;	chr5:151801329	chr5:151753992~151767247:+
PRAD	cis	rs9399137	0.507	rs4580893	ENSG00000232876.1	CTA-212D2.2	-9.57	7.12e-20	5.84e-17	-0.52	-0.41	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134976524	chr6:135055033~135060550:+
PRAD	cis	rs7772486	0.875	rs2814876	ENSG00000235652.6	RP11-545I5.3	9.57	7.12e-20	5.84e-17	0.42	0.41	Lobe attachment (rater-scored or self-reported);	chr6:145982894	chr6:145799409~145886585:+
PRAD	cis	rs4713118	0.621	rs9295755	ENSG00000272009.1	RP1-313I6.12	9.57	7.14e-20	5.86e-17	0.41	0.41	Parkinson's disease;	chr6:28065396	chr6:28078792~28081130:-
PRAD	cis	rs4879677	1	rs10757674	ENSG00000260390.1	RP11-575I8.1	9.56	7.17e-20	5.88e-17	0.55	0.41	Gut microbiome composition (summer and winter);	chr9:27671312	chr9:27829276~27844481:+
PRAD	cis	rs150992	0.711	rs326489	ENSG00000248489.1	CTD-2007H13.3	9.56	7.19e-20	5.89e-17	0.46	0.41	Body mass index;	chr5:98841105	chr5:98929171~98995013:+
PRAD	cis	rs8062405	0.728	rs11642449	ENSG00000251417.2	RP11-1348G14.4	-9.56	7.2e-20	5.91e-17	-0.48	-0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28884694	chr16:28802743~28817828:+
PRAD	cis	rs8062405	0.728	rs8056890	ENSG00000251417.2	RP11-1348G14.4	-9.56	7.2e-20	5.91e-17	-0.48	-0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28886131	chr16:28802743~28817828:+
PRAD	cis	rs10129255	0.518	rs7143784	ENSG00000223648.3	IGHV3-64	9.56	7.24e-20	5.93e-17	0.36	0.41	Kawasaki disease;	chr14:106687277	chr14:106643132~106658258:-
PRAD	cis	rs4713118	0.621	rs9295756	ENSG00000272009.1	RP1-313I6.12	-9.56	7.24e-20	5.94e-17	-0.41	-0.41	Parkinson's disease;	chr6:28065618	chr6:28078792~28081130:-
PRAD	cis	rs8062405	0.698	rs7188071	ENSG00000251417.2	RP11-1348G14.4	9.56	7.26e-20	5.95e-17	0.47	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28906323	chr16:28802743~28817828:+
PRAD	cis	rs6876835	0.511	rs7729233	ENSG00000250056.4	LINC01018	9.56	7.28e-20	5.97e-17	0.48	0.41	Visceral fat;	chr5:6597697	chr5:6582136~6588499:+
PRAD	cis	rs2739330	0.892	rs4822455	ENSG00000235689.1	AP000351.13	9.56	7.29e-20	5.98e-17	0.5	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:24006305~24008258:-
PRAD	cis	rs1075265	0.656	rs2542574	ENSG00000233266.1	HMGB1P31	9.56	7.31e-20	5.99e-17	0.56	0.41	Chronotype;Morning vs. evening chronotype;	chr2:53820295	chr2:54051334~54051760:+
PRAD	cis	rs6860806	0.507	rs273912	ENSG00000233006.5	AC034220.3	-9.56	7.32e-20	6e-17	-0.39	-0.41	Breast cancer;	chr5:132325656	chr5:132311285~132369916:-
PRAD	cis	rs9389248	0.737	rs56358308	ENSG00000232876.1	CTA-212D2.2	-9.56	7.33e-20	6.01e-17	-0.52	-0.41	High light scatter reticulocyte percentage of red cells;	chr6:134985842	chr6:135055033~135060550:+
PRAD	cis	rs9399137	0.507	rs11754021	ENSG00000232876.1	CTA-212D2.2	-9.56	7.33e-20	6.01e-17	-0.52	-0.41	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134987237	chr6:135055033~135060550:+
PRAD	cis	rs17507216	0.518	rs1877240	ENSG00000278603.1	RP13-608F4.5	9.56	7.34e-20	6.01e-17	0.75	0.41	Excessive daytime sleepiness;	chr15:82770126	chr15:82472203~82472426:+
PRAD	cis	rs7849270	1	rs7037163	ENSG00000268707.1	RP11-247A12.7	-9.56	7.38e-20	6.05e-17	-0.47	-0.41	Blood metabolite ratios;	chr9:129132061	chr9:129170434~129170940:+
PRAD	cis	rs2274273	0.868	rs1572611	ENSG00000258413.1	RP11-665C16.6	-9.56	7.42e-20	6.08e-17	-0.53	-0.41	Protein biomarker;	chr14:55367156	chr14:55262767~55272075:-
PRAD	cis	rs7688540	0.771	rs11722197	ENSG00000275426.1	CH17-262A2.1	9.56	7.42e-20	6.08e-17	0.62	0.41	Facial morphology (factor 6, height of vermillion lower lip);	chr4:287918	chr4:149738~150317:+
PRAD	cis	rs7688540	0.771	rs11723261	ENSG00000275426.1	CH17-262A2.1	9.56	7.42e-20	6.08e-17	0.62	0.41	Facial morphology (factor 6, height of vermillion lower lip);	chr4:288710	chr4:149738~150317:+
PRAD	cis	rs1062177	0.855	rs6896664	ENSG00000253921.1	CTB-113P19.3	-9.56	7.44e-20	6.09e-17	-0.52	-0.41	Preschool internalizing problems;	chr5:151885713	chr5:151753992~151767247:+
PRAD	cis	rs1061377	0.56	rs6531690	ENSG00000249207.1	RP11-360F5.1	-9.56	7.44e-20	6.1e-17	-0.43	-0.41	Uric acid levels;	chr4:39072583	chr4:39112677~39126818:-
PRAD	cis	rs7772486	0.558	rs2142980	ENSG00000235652.6	RP11-545I5.3	-9.56	7.47e-20	6.12e-17	-0.49	-0.41	Lobe attachment (rater-scored or self-reported);	chr6:145759543	chr6:145799409~145886585:+
PRAD	cis	rs56080343	0.748	rs56190986	ENSG00000275759.1	RP11-131L12.3	-9.56	7.54e-20	6.17e-17	-0.72	-0.41	Neuroticism;	chr12:118408458	chr12:118428281~118428870:+
PRAD	cis	rs6452524	0.905	rs1478482	ENSG00000249664.1	CTD-2227C6.2	9.56	7.55e-20	6.18e-17	0.48	0.41	Hypertension (SNP x SNP interaction);	chr5:83111279	chr5:83012285~83013109:-
PRAD	cis	rs7849270	0.959	rs2900271	ENSG00000268707.1	RP11-247A12.7	9.56	7.57e-20	6.19e-17	0.48	0.41	Blood metabolite ratios;	chr9:129132655	chr9:129170434~129170940:+
PRAD	cis	rs10129255	0.5	rs1024350	ENSG00000223648.3	IGHV3-64	9.56	7.57e-20	6.2e-17	0.36	0.41	Kawasaki disease;	chr14:106685105	chr14:106643132~106658258:-
PRAD	cis	rs6142102	1	rs4911412	ENSG00000276073.1	RP5-1125A11.7	-9.56	7.6e-20	6.22e-17	-0.42	-0.41	Skin pigmentation;	chr20:34128629	chr20:33985617~33988989:-
PRAD	cis	rs1075265	0.87	rs6724389	ENSG00000233266.1	HMGB1P31	9.56	7.61e-20	6.23e-17	0.55	0.41	Chronotype;Morning vs. evening chronotype;	chr2:53985698	chr2:54051334~54051760:+
PRAD	cis	rs4380275	0.965	rs12621177	ENSG00000272342.1	RP13-539J13.1	9.56	7.62e-20	6.23e-17	0.52	0.41	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:757786	chr2:739588~740164:-
PRAD	cis	rs4380275	1	rs4854376	ENSG00000272342.1	RP13-539J13.1	9.56	7.62e-20	6.23e-17	0.52	0.41	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:763683	chr2:739588~740164:-
PRAD	cis	rs7181230	0.813	rs4924417	ENSG00000275636.1	RP11-521C20.5	9.56	7.64e-20	6.25e-17	0.58	0.41	Dehydroepiandrosterone sulphate levels;	chr15:40074738	chr15:40078892~40079347:+
PRAD	cis	rs12049351	0.665	rs12143267	ENSG00000229367.1	HMGN2P19	9.56	7.68e-20	6.28e-17	0.61	0.41	Circulating myeloperoxidase levels (plasma);	chr1:229459059	chr1:229570532~229570796:+
PRAD	cis	rs4865169	0.791	rs11731868	ENSG00000269949.1	RP11-738E22.3	-9.56	7.7e-20	6.29e-17	-0.48	-0.41	Breast cancer;	chr4:57029048	chr4:56960927~56961373:-
PRAD	cis	rs7044106	1	rs7044106	ENSG00000226752.6	PSMD5-AS1	-9.56	7.7e-20	6.3e-17	-0.56	-0.41	Hip circumference adjusted for BMI;	chr9:120731784	chr9:120824828~120854385:+
PRAD	cis	rs1075265	0.54	rs2542587	ENSG00000233266.1	HMGB1P31	9.56	7.7e-20	6.3e-17	0.56	0.41	Chronotype;Morning vs. evening chronotype;	chr2:53788839	chr2:54051334~54051760:+
PRAD	cis	rs1075265	0.563	rs2692537	ENSG00000233266.1	HMGB1P31	9.56	7.7e-20	6.3e-17	0.56	0.41	Chronotype;Morning vs. evening chronotype;	chr2:53788840	chr2:54051334~54051760:+
PRAD	cis	rs1061377	0.674	rs34506243	ENSG00000249207.1	RP11-360F5.1	-9.56	7.71e-20	6.31e-17	-0.43	-0.41	Uric acid levels;	chr4:39082702	chr4:39112677~39126818:-
PRAD	cis	rs12049351	0.665	rs6665874	ENSG00000229367.1	HMGN2P19	9.55	7.78e-20	6.37e-17	0.59	0.41	Circulating myeloperoxidase levels (plasma);	chr1:229453264	chr1:229570532~229570796:+
PRAD	cis	rs2239557	0.608	rs2041186	ENSG00000259065.1	RP5-1021I20.1	-9.55	7.8e-20	6.38e-17	-0.51	-0.41	Common traits (Other);	chr14:73815334	chr14:73787360~73803270:+
PRAD	cis	rs4879677	0.959	rs10812643	ENSG00000260390.1	RP11-575I8.1	-9.55	7.86e-20	6.42e-17	-0.55	-0.41	Gut microbiome composition (summer and winter);	chr9:27690092	chr9:27829276~27844481:+
PRAD	cis	rs3096299	0.685	rs3803682	ENSG00000261118.1	RP11-104N10.1	9.55	7.86e-20	6.42e-17	0.39	0.41	Multiple myeloma (IgH translocation);	chr16:89478228	chr16:89492017~89504460:-
PRAD	cis	rs7772486	0.846	rs2748499	ENSG00000235652.6	RP11-545I5.3	9.55	7.87e-20	6.43e-17	0.42	0.41	Lobe attachment (rater-scored or self-reported);	chr6:145993866	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.875	rs2814869	ENSG00000235652.6	RP11-545I5.3	9.55	7.87e-20	6.43e-17	0.42	0.41	Lobe attachment (rater-scored or self-reported);	chr6:145994373	chr6:145799409~145886585:+
PRAD	cis	rs9309473	1	rs13421462	ENSG00000163016.8	ALMS1P	9.55	7.88e-20	6.44e-17	0.51	0.41	Metabolite levels;	chr2:73492748	chr2:73644919~73685576:+
PRAD	cis	rs2282300	0.667	rs10734405	ENSG00000242353.1	RP4-710M3.1	9.55	7.89e-20	6.45e-17	0.5	0.41	Morning vs. evening chronotype;	chr11:30252203	chr11:30368148~30368646:+
PRAD	cis	rs2282300	0.653	rs12800124	ENSG00000242353.1	RP4-710M3.1	-9.55	7.89e-20	6.45e-17	-0.5	-0.41	Morning vs. evening chronotype;	chr11:30218318	chr11:30368148~30368646:+
PRAD	cis	rs2282300	0.739	rs34224414	ENSG00000242353.1	RP4-710M3.1	-9.55	7.89e-20	6.45e-17	-0.5	-0.41	Morning vs. evening chronotype;	chr11:30229494	chr11:30368148~30368646:+
PRAD	cis	rs2282300	0.739	rs12577729	ENSG00000242353.1	RP4-710M3.1	-9.55	7.89e-20	6.45e-17	-0.5	-0.41	Morning vs. evening chronotype;	chr11:30235830	chr11:30368148~30368646:+
PRAD	cis	rs2282300	0.739	rs34044331	ENSG00000242353.1	RP4-710M3.1	-9.55	7.89e-20	6.45e-17	-0.5	-0.41	Morning vs. evening chronotype;	chr11:30242939	chr11:30368148~30368646:+
PRAD	cis	rs7772486	0.79	rs9497424	ENSG00000235652.6	RP11-545I5.3	-9.55	7.92e-20	6.47e-17	-0.42	-0.41	Lobe attachment (rater-scored or self-reported);	chr6:145904135	chr6:145799409~145886585:+
PRAD	cis	rs6452524	0.532	rs27363	ENSG00000249664.1	CTD-2227C6.2	9.55	7.92e-20	6.47e-17	0.49	0.41	Hypertension (SNP x SNP interaction);	chr5:83040943	chr5:83012285~83013109:-
PRAD	cis	rs9309473	1	rs10207220	ENSG00000163016.8	ALMS1P	9.55	7.97e-20	6.51e-17	0.5	0.41	Metabolite levels;	chr2:73557919	chr2:73644919~73685576:+
PRAD	cis	rs8062405	0.964	rs12448902	ENSG00000259982.1	CDC37P1	9.55	8e-20	6.53e-17	0.57	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859870	chr16:28700294~28701540:-
PRAD	cis	rs2404602	1	rs12441433	ENSG00000259422.1	RP11-593F23.1	9.55	8e-20	6.54e-17	0.5	0.41	Blood metabolite levels;	chr15:76523674	chr15:76174891~76181486:-
PRAD	cis	rs8072100	0.967	rs62076549	ENSG00000228782.6	CTD-2026D20.3	-9.55	8.02e-20	6.55e-17	-0.45	-0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47502189	chr17:47450568~47492492:-
PRAD	cis	rs67383717	0.527	rs10760718	ENSG00000175611.10	LINC00476	9.55	8.05e-20	6.58e-17	0.48	0.41	Parkinson's disease (pesticide exposure interaction);	chr9:96032397	chr9:95759231~95875977:-
PRAD	cis	rs9322193	0.576	rs7452592	ENSG00000216906.2	RP11-350J20.9	9.55	8.06e-20	6.58e-17	0.55	0.41	Lung cancer;	chr6:149875445	chr6:149904243~149906418:+
PRAD	cis	rs7772486	0.686	rs1011596	ENSG00000235652.6	RP11-545I5.3	9.55	8.1e-20	6.61e-17	0.42	0.41	Lobe attachment (rater-scored or self-reported);	chr6:145755297	chr6:145799409~145886585:+
PRAD	cis	rs12134133	1	rs2782840	ENSG00000274245.1	RP11-357P18.2	9.55	8.11e-20	6.62e-17	0.57	0.41	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207310838	chr1:207372559~207373252:+
PRAD	cis	rs11907546	1	rs11907546	ENSG00000276073.1	RP5-1125A11.7	-9.55	8.12e-20	6.63e-17	-0.41	-0.41	Cancer (pleiotropy);Cancer;	chr20:34131991	chr20:33985617~33988989:-
PRAD	cis	rs2153535	0.585	rs1983603	ENSG00000230939.1	RP11-314C16.1	-9.55	8.14e-20	6.65e-17	-0.51	-0.41	Motion sickness;	chr6:8580747	chr6:8784178~8785445:+
PRAD	cis	rs7714584	0.793	rs2161363	ENSG00000197083.10	ZNF300P1	9.55	8.15e-20	6.65e-17	0.76	0.41	Crohn's disease;	chr5:150802517	chr5:150930645~150946289:-
PRAD	cis	rs7714584	1	rs6875011	ENSG00000197083.10	ZNF300P1	9.55	8.15e-20	6.65e-17	0.76	0.41	Crohn's disease;	chr5:150803148	chr5:150930645~150946289:-
PRAD	cis	rs4774565	0.8	rs34174311	ENSG00000244879.4	GABPB1-AS1	-9.55	8.17e-20	6.67e-17	-0.38	-0.41	Breast cancer;	chr15:50381084	chr15:50354959~50372202:+
PRAD	cis	rs2348418	0.932	rs6487685	ENSG00000247934.4	RP11-967K21.1	9.55	8.25e-20	6.73e-17	0.38	0.41	Lung function (FEV1);Lung function (FVC);	chr12:28505417	chr12:28163298~28190738:-
PRAD	cis	rs2564921	0.704	rs55950520	ENSG00000242142.1	SERBP1P3	-9.55	8.3e-20	6.77e-17	-0.48	-0.41	Height;	chr3:53094335	chr3:53064283~53065091:-
PRAD	cis	rs4713118	0.516	rs6931858	ENSG00000272009.1	RP1-313I6.12	-9.55	8.33e-20	6.79e-17	-0.42	-0.41	Parkinson's disease;	chr6:28110633	chr6:28078792~28081130:-
PRAD	cis	rs7714584	1	rs11167526	ENSG00000197083.10	ZNF300P1	9.55	8.33e-20	6.8e-17	0.77	0.41	Crohn's disease;	chr5:150952919	chr5:150930645~150946289:-
PRAD	cis	rs2282300	0.739	rs35229181	ENSG00000242353.1	RP4-710M3.1	-9.55	8.35e-20	6.81e-17	-0.5	-0.41	Morning vs. evening chronotype;	chr11:30220151	chr11:30368148~30368646:+
PRAD	cis	rs2282300	0.739	rs34234618	ENSG00000242353.1	RP4-710M3.1	-9.55	8.35e-20	6.81e-17	-0.5	-0.41	Morning vs. evening chronotype;	chr11:30220154	chr11:30368148~30368646:+
PRAD	cis	rs9545047	0.604	rs9545076	ENSG00000227676.3	LINC01068	-9.55	8.37e-20	6.82e-17	-0.48	-0.41	Schizophrenia;	chr13:79335983	chr13:79566727~79571436:+
PRAD	cis	rs2564921	0.73	rs62255895	ENSG00000242142.1	SERBP1P3	-9.55	8.37e-20	6.82e-17	-0.48	-0.41	Height;	chr3:53027969	chr3:53064283~53065091:-
PRAD	cis	rs9309473	1	rs58603761	ENSG00000163016.8	ALMS1P	9.55	8.37e-20	6.83e-17	0.51	0.41	Metabolite levels;	chr2:73499478	chr2:73644919~73685576:+
PRAD	cis	rs6570726	0.764	rs9403726	ENSG00000235652.6	RP11-545I5.3	9.55	8.38e-20	6.83e-17	0.43	0.41	Lobe attachment (rater-scored or self-reported);	chr6:145580550	chr6:145799409~145886585:+
PRAD	cis	rs1075265	0.756	rs6751105	ENSG00000233266.1	HMGB1P31	9.54	8.39e-20	6.84e-17	0.54	0.41	Chronotype;Morning vs. evening chronotype;	chr2:54129214	chr2:54051334~54051760:+
PRAD	cis	rs9309473	1	rs62151652	ENSG00000163016.8	ALMS1P	9.54	8.42e-20	6.87e-17	0.5	0.41	Metabolite levels;	chr2:73473004	chr2:73644919~73685576:+
PRAD	cis	rs2153535	0.585	rs9379226	ENSG00000230939.1	RP11-314C16.1	-9.54	8.45e-20	6.89e-17	-0.51	-0.41	Motion sickness;	chr6:8584232	chr6:8784178~8785445:+
PRAD	cis	rs150992	0.673	rs992775	ENSG00000248489.1	CTD-2007H13.3	-9.54	8.46e-20	6.9e-17	-0.46	-0.41	Body mass index;	chr5:98807754	chr5:98929171~98995013:+
PRAD	cis	rs9309473	1	rs11901272	ENSG00000163016.8	ALMS1P	9.54	8.47e-20	6.9e-17	0.51	0.41	Metabolite levels;	chr2:73493317	chr2:73644919~73685576:+
PRAD	cis	rs4879677	1	rs2150022	ENSG00000260390.1	RP11-575I8.1	-9.54	8.5e-20	6.92e-17	-0.54	-0.41	Gut microbiome composition (summer and winter);	chr9:27688031	chr9:27829276~27844481:+
PRAD	cis	rs9309473	1	rs10187416	ENSG00000163016.8	ALMS1P	9.54	8.55e-20	6.97e-17	0.5	0.41	Metabolite levels;	chr2:73486614	chr2:73644919~73685576:+
PRAD	cis	rs2115630	0.645	rs6496284	ENSG00000275120.1	RP11-182J1.17	-9.54	8.55e-20	6.97e-17	-0.48	-0.41	P wave terminal force;	chr15:84635039	chr15:84599434~84606463:-
PRAD	cis	rs7688540	0.771	rs11722521	ENSG00000275426.1	CH17-262A2.1	9.54	8.56e-20	6.98e-17	0.61	0.41	Facial morphology (factor 6, height of vermillion lower lip);	chr4:282976	chr4:149738~150317:+
PRAD	cis	rs7688540	0.771	rs11723615	ENSG00000275426.1	CH17-262A2.1	9.54	8.56e-20	6.98e-17	0.61	0.41	Facial morphology (factor 6, height of vermillion lower lip);	chr4:283194	chr4:149738~150317:+
PRAD	cis	rs2348418	0.681	rs10771435	ENSG00000247934.4	RP11-967K21.1	9.54	8.58e-20	6.99e-17	0.38	0.41	Lung function (FEV1);Lung function (FVC);	chr12:28582769	chr12:28163298~28190738:-
PRAD	cis	rs10129255	0.518	rs8009612	ENSG00000223648.3	IGHV3-64	9.54	8.6e-20	7.01e-17	0.36	0.41	Kawasaki disease;	chr14:106777510	chr14:106643132~106658258:-
PRAD	cis	rs8100891	0.734	rs4804990	ENSG00000267213.4	AC007773.2	-9.54	8.61e-20	7.01e-17	-0.43	-0.41	Neuroticism;	chr19:32346523	chr19:32390050~32405560:-
PRAD	cis	rs4964805	0.913	rs7134701	ENSG00000257681.1	RP11-341G23.4	9.54	8.62e-20	7.02e-17	0.41	0.41	Attention deficit hyperactivity disorder;	chr12:103808913	chr12:103746315~103768858:-
PRAD	cis	rs748404	0.56	rs572837	ENSG00000249839.1	AC011330.5	-9.54	8.63e-20	7.03e-17	-0.52	-0.41	Lung cancer;	chr15:43531615	chr15:43663654~43684339:-
PRAD	cis	rs7772486	0.719	rs4391282	ENSG00000235652.6	RP11-545I5.3	-9.54	8.64e-20	7.04e-17	-0.42	-0.41	Lobe attachment (rater-scored or self-reported);	chr6:145955644	chr6:145799409~145886585:+
PRAD	cis	rs8040855	0.559	rs6496801	ENSG00000259295.5	CSPG4P12	-9.54	8.69e-20	7.08e-17	-0.53	-0.41	Bulimia nervosa;	chr15:85185168	chr15:85191438~85213905:+
PRAD	cis	rs2337406	0.866	rs4773949	ENSG00000274576.2	IGHV2-70	9.54	8.72e-20	7.1e-17	0.4	0.41	Alzheimer's disease (late onset);	chr14:106808070	chr14:106770577~106771020:-
PRAD	cis	rs12134133	1	rs2564973	ENSG00000274245.1	RP11-357P18.2	9.54	8.72e-20	7.1e-17	0.56	0.41	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207306759	chr1:207372559~207373252:+
PRAD	cis	rs2282300	0.91	rs528292	ENSG00000254532.1	RP11-624D11.2	-9.54	8.79e-20	7.15e-17	-0.57	-0.41	Morning vs. evening chronotype;	chr11:30368163	chr11:30044058~30084343:-
PRAD	cis	rs2282300	0.956	rs594937	ENSG00000254532.1	RP11-624D11.2	-9.54	8.79e-20	7.15e-17	-0.57	-0.41	Morning vs. evening chronotype;	chr11:30368585	chr11:30044058~30084343:-
PRAD	cis	rs10129255	0.518	rs10136903	ENSG00000223648.3	IGHV3-64	9.54	8.84e-20	7.2e-17	0.36	0.41	Kawasaki disease;	chr14:106778866	chr14:106643132~106658258:-
PRAD	cis	rs9532669	0.926	rs2039119	ENSG00000168852.11	TPTE2P5	-9.54	8.91e-20	7.25e-17	-0.39	-0.41	Cervical cancer;	chr13:40872432	chr13:40822296~40921749:-
PRAD	cis	rs12134133	1	rs7518565	ENSG00000274245.1	RP11-357P18.2	9.54	8.92e-20	7.26e-17	0.58	0.41	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207246998	chr1:207372559~207373252:+
PRAD	cis	rs2282300	0.739	rs1222216	ENSG00000242353.1	RP4-710M3.1	-9.54	8.92e-20	7.26e-17	-0.49	-0.41	Morning vs. evening chronotype;	chr11:30324505	chr11:30368148~30368646:+
PRAD	cis	rs7772486	0.875	rs2748483	ENSG00000235652.6	RP11-545I5.3	-9.54	8.93e-20	7.27e-17	-0.42	-0.41	Lobe attachment (rater-scored or self-reported);	chr6:146014424	chr6:145799409~145886585:+
PRAD	cis	rs9399137	0.507	rs12663810	ENSG00000232876.1	CTA-212D2.2	-9.54	8.95e-20	7.28e-17	-0.52	-0.41	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134968644	chr6:135055033~135060550:+
PRAD	cis	rs853679	0.517	rs9380052	ENSG00000272009.1	RP1-313I6.12	-9.54	9.06e-20	7.35e-17	-0.42	-0.41	Depression;	chr6:28096845	chr6:28078792~28081130:-
PRAD	cis	rs8072100	0.817	rs11869940	ENSG00000228782.6	CTD-2026D20.3	-9.54	9.08e-20	7.37e-17	-0.45	-0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47501069	chr17:47450568~47492492:-
PRAD	cis	rs8072100	0.967	rs7221548	ENSG00000228782.6	CTD-2026D20.3	-9.54	9.08e-20	7.37e-17	-0.45	-0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47505586	chr17:47450568~47492492:-
PRAD	cis	rs1062177	1	rs2964571	ENSG00000253921.1	CTB-113P19.3	-9.54	9.08e-20	7.37e-17	-0.54	-0.41	Preschool internalizing problems;	chr5:151791695	chr5:151753992~151767247:+
PRAD	cis	rs1062177	1	rs2915869	ENSG00000253921.1	CTB-113P19.3	-9.54	9.08e-20	7.37e-17	-0.54	-0.41	Preschool internalizing problems;	chr5:151791948	chr5:151753992~151767247:+
PRAD	cis	rs7772486	0.875	rs2224121	ENSG00000235652.6	RP11-545I5.3	9.53	9.14e-20	7.41e-17	0.42	0.41	Lobe attachment (rater-scored or self-reported);	chr6:146022078	chr6:145799409~145886585:+
PRAD	cis	rs9399137	0.507	rs6940258	ENSG00000232876.1	CTA-212D2.2	-9.53	9.15e-20	7.42e-17	-0.51	-0.41	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135044994	chr6:135055033~135060550:+
PRAD	cis	rs12134133	1	rs2782846	ENSG00000274245.1	RP11-357P18.2	9.53	9.2e-20	7.46e-17	0.56	0.41	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207300495	chr1:207372559~207373252:+
PRAD	cis	rs7772486	0.875	rs6913797	ENSG00000235652.6	RP11-545I5.3	9.53	9.21e-20	7.47e-17	0.41	0.41	Lobe attachment (rater-scored or self-reported);	chr6:146092622	chr6:145799409~145886585:+
PRAD	cis	rs9309473	1	rs11903916	ENSG00000163016.8	ALMS1P	9.53	9.21e-20	7.47e-17	0.51	0.41	Metabolite levels;	chr2:73588201	chr2:73644919~73685576:+
PRAD	cis	rs8072100	0.935	rs8070759	ENSG00000228782.6	CTD-2026D20.3	-9.53	9.24e-20	7.49e-17	-0.45	-0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47561394	chr17:47450568~47492492:-
PRAD	cis	rs765787	0.53	rs12439643	ENSG00000259520.4	CTD-2651B20.3	-9.53	9.28e-20	7.53e-17	-0.52	-0.41	Uric acid levels;	chr15:45237569	chr15:45251580~45279251:-
PRAD	cis	rs11690935	0.55	rs62183785	ENSG00000228389.1	AC068039.4	-9.53	9.29e-20	7.53e-17	-0.46	-0.41	Schizophrenia;	chr2:172002068	chr2:171773482~171775844:+
PRAD	cis	rs11690935	0.531	rs62183800	ENSG00000228389.1	AC068039.4	-9.53	9.29e-20	7.53e-17	-0.46	-0.41	Schizophrenia;	chr2:172002365	chr2:171773482~171775844:+
PRAD	cis	rs11690935	0.55	rs62183801	ENSG00000228389.1	AC068039.4	-9.53	9.29e-20	7.53e-17	-0.46	-0.41	Schizophrenia;	chr2:172002567	chr2:171773482~171775844:+
PRAD	cis	rs11690935	0.55	rs6718013	ENSG00000228389.1	AC068039.4	-9.53	9.29e-20	7.53e-17	-0.46	-0.41	Schizophrenia;	chr2:172004277	chr2:171773482~171775844:+
PRAD	cis	rs9326248	0.53	rs17120139	ENSG00000254851.1	RP11-109L13.1	9.53	9.29e-20	7.53e-17	0.84	0.41	Blood protein levels;	chr11:116903485	chr11:117135528~117138582:+
PRAD	cis	rs1555322	0.53	rs2425049	ENSG00000126005.14	MMP24-AS1	-9.53	9.35e-20	7.58e-17	-0.48	-0.41	Attention deficit hyperactivity disorder;	chr20:35286917	chr20:35216462~35278131:-
PRAD	cis	rs8072100	0.764	rs2644349	ENSG00000228782.6	CTD-2026D20.3	-9.53	9.36e-20	7.58e-17	-0.45	-0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47564377	chr17:47450568~47492492:-
PRAD	cis	rs1061377	0.585	rs1367296	ENSG00000249207.1	RP11-360F5.1	-9.53	9.37e-20	7.59e-17	-0.43	-0.41	Uric acid levels;	chr4:39066895	chr4:39112677~39126818:-
PRAD	cis	rs11951515	0.527	rs10462047	ENSG00000188850.9	RP11-159F24.2	-9.53	9.52e-20	7.72e-17	-0.49	-0.41	Metabolite levels  (X-11787);	chr5:43258358	chr5:43336164~43348716:+
PRAD	cis	rs9545047	0.604	rs9565497	ENSG00000227676.3	LINC01068	-9.53	9.63e-20	7.8e-17	-0.48	-0.41	Schizophrenia;	chr13:79406330	chr13:79566727~79571436:+
PRAD	cis	rs12049351	0.665	rs2904	ENSG00000229367.1	HMGN2P19	9.53	9.63e-20	7.8e-17	0.62	0.41	Circulating myeloperoxidase levels (plasma);	chr1:229464589	chr1:229570532~229570796:+
PRAD	cis	rs7615952	0.673	rs34209763	ENSG00000171084.14	FAM86JP	9.53	9.66e-20	7.82e-17	0.75	0.41	Blood pressure (smoking interaction);	chr3:125880752	chr3:125916620~125930024:+
PRAD	cis	rs7615952	0.8	rs35390120	ENSG00000171084.14	FAM86JP	9.53	9.66e-20	7.82e-17	0.75	0.41	Blood pressure (smoking interaction);	chr3:125880966	chr3:125916620~125930024:+
PRAD	cis	rs7615952	0.611	rs35321002	ENSG00000171084.14	FAM86JP	9.53	9.66e-20	7.82e-17	0.75	0.41	Blood pressure (smoking interaction);	chr3:125893222	chr3:125916620~125930024:+
PRAD	cis	rs7688540	0.771	rs11730202	ENSG00000275426.1	CH17-262A2.1	9.53	9.66e-20	7.82e-17	0.61	0.41	Facial morphology (factor 6, height of vermillion lower lip);	chr4:216307	chr4:149738~150317:+
PRAD	cis	rs6142102	0.961	rs4911411	ENSG00000276073.1	RP5-1125A11.7	-9.53	9.68e-20	7.84e-17	-0.4	-0.41	Skin pigmentation;	chr20:34128036	chr20:33985617~33988989:-
PRAD	cis	rs9322193	0.607	rs915140	ENSG00000216906.2	RP11-350J20.9	9.53	9.68e-20	7.84e-17	0.54	0.41	Lung cancer;	chr6:149899674	chr6:149904243~149906418:+
PRAD	cis	rs7811142	1	rs11766752	ENSG00000242294.5	STAG3L5P	9.53	9.72e-20	7.86e-17	0.27	0.41	Platelet count;	chr7:100475669	chr7:100336079~100351900:+
PRAD	cis	rs13217239	0.574	rs9366680	ENSG00000241549.7	GUSBP2	9.53	9.72e-20	7.87e-17	0.46	0.41	Schizophrenia;	chr6:27038344	chr6:26871484~26956554:-
PRAD	cis	rs889312	0.532	rs16886165	ENSG00000271828.1	CTD-2310F14.1	9.53	9.75e-20	7.89e-17	0.7	0.41	Breast cancer (early onset);Breast cancer;	chr5:56727256	chr5:56927874~56929573:+
PRAD	cis	rs7772486	0.875	rs2777484	ENSG00000235652.6	RP11-545I5.3	9.53	9.75e-20	7.89e-17	0.41	0.41	Lobe attachment (rater-scored or self-reported);	chr6:146013026	chr6:145799409~145886585:+
PRAD	cis	rs150992	0.609	rs709390	ENSG00000248489.1	CTD-2007H13.3	9.53	9.75e-20	7.89e-17	0.45	0.41	Body mass index;	chr5:98993771	chr5:98929171~98995013:+
PRAD	cis	rs7772486	0.686	rs1415744	ENSG00000235652.6	RP11-545I5.3	9.53	9.76e-20	7.89e-17	0.42	0.41	Lobe attachment (rater-scored or self-reported);	chr6:145701395	chr6:145799409~145886585:+
PRAD	cis	rs765787	0.53	rs12904331	ENSG00000259520.4	CTD-2651B20.3	-9.53	9.76e-20	7.9e-17	-0.53	-0.41	Uric acid levels;	chr15:45226095	chr15:45251580~45279251:-
PRAD	cis	rs12134133	1	rs11580382	ENSG00000274245.1	RP11-357P18.2	9.53	9.78e-20	7.92e-17	0.58	0.41	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207245047	chr1:207372559~207373252:+
PRAD	cis	rs2564921	0.704	rs2336720	ENSG00000242142.1	SERBP1P3	-9.53	9.82e-20	7.95e-17	-0.44	-0.41	Height;	chr3:52994045	chr3:53064283~53065091:-
PRAD	cis	rs2564921	0.73	rs56384586	ENSG00000242142.1	SERBP1P3	-9.53	9.82e-20	7.95e-17	-0.44	-0.41	Height;	chr3:52994990	chr3:53064283~53065091:-
PRAD	cis	rs2255336	1	rs2255336	ENSG00000245648.1	RP11-277P12.20	9.53	9.83e-20	7.95e-17	0.56	0.41	Blood protein levels;	chr12:10379727	chr12:10363769~10398506:+
PRAD	cis	rs2286503	1	rs1029740	ENSG00000228649.7	AC005682.5	9.53	9.84e-20	7.96e-17	0.46	0.41	Fibrinogen;	chr7:22833967	chr7:22854178~22861579:+
PRAD	cis	rs977987	0.872	rs10781976	ENSG00000261783.1	RP11-252K23.2	-9.52	9.92e-20	8.02e-17	-0.55	-0.41	Dupuytren's disease;	chr16:75280940	chr16:75379818~75381260:-
PRAD	cis	rs7201929	0.959	rs35725751	ENSG00000259982.1	CDC37P1	-9.52	9.92e-20	8.02e-17	-0.59	-0.41	QT interval;	chr16:28834263	chr16:28700294~28701540:-
PRAD	cis	rs3096299	0.685	rs4785676	ENSG00000261118.1	RP11-104N10.1	9.52	9.93e-20	8.03e-17	0.39	0.41	Multiple myeloma (IgH translocation);	chr16:89487216	chr16:89492017~89504460:-
PRAD	cis	rs4879677	1	rs620232	ENSG00000260390.1	RP11-575I8.1	9.52	1e-19	8.1e-17	0.54	0.41	Gut microbiome composition (summer and winter);	chr9:27656448	chr9:27829276~27844481:+
PRAD	cis	rs765787	0.53	rs3759892	ENSG00000259520.4	CTD-2651B20.3	-9.52	1e-19	8.11e-17	-0.53	-0.41	Uric acid levels;	chr15:45250511	chr15:45251580~45279251:-
PRAD	cis	rs12049351	0.665	rs1853808	ENSG00000229367.1	HMGN2P19	9.52	1.01e-19	8.16e-17	0.6	0.41	Circulating myeloperoxidase levels (plasma);	chr1:229456585	chr1:229570532~229570796:+
PRAD	cis	rs12134133	1	rs11580387	ENSG00000274245.1	RP11-357P18.2	9.52	1.02e-19	8.22e-17	0.58	0.41	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207245063	chr1:207372559~207373252:+
PRAD	cis	rs8062405	0.69	rs762634	ENSG00000259982.1	CDC37P1	9.52	1.02e-19	8.22e-17	0.55	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28592014	chr16:28700294~28701540:-
PRAD	cis	rs11123170	0.65	rs2289897	ENSG00000274877.1	RP11-65I12.1	-9.52	1.03e-19	8.34e-17	-0.63	-0.41	Renal function-related traits (BUN);	chr2:113219877	chr2:113237595~113240825:+
PRAD	cis	rs1062177	1	rs2347596	ENSG00000253921.1	CTB-113P19.3	-9.52	1.04e-19	8.38e-17	-0.53	-0.41	Preschool internalizing problems;	chr5:151799638	chr5:151753992~151767247:+
PRAD	cis	rs524281	0.731	rs12576969	ENSG00000255320.1	RP11-755F10.1	-9.52	1.04e-19	8.39e-17	-0.68	-0.41	Electroencephalogram traits;	chr11:66035007	chr11:66244840~66246239:-
PRAD	cis	rs8062405	0.728	rs9931989	ENSG00000251417.2	RP11-1348G14.4	9.52	1.04e-19	8.4e-17	0.47	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28894763	chr16:28802743~28817828:+
PRAD	cis	rs1577917	0.958	rs11755048	ENSG00000203875.9	SNHG5	-9.52	1.05e-19	8.46e-17	-0.5	-0.41	Response to antipsychotic treatment;	chr6:85804616	chr6:85660950~85678736:-
PRAD	cis	rs6860806	0.507	rs274570	ENSG00000233006.5	AC034220.3	-9.52	1.05e-19	8.47e-17	-0.39	-0.41	Breast cancer;	chr5:132377534	chr5:132311285~132369916:-
PRAD	cis	rs172166	0.516	rs1225618	ENSG00000204709.4	LINC01556	9.52	1.05e-19	8.5e-17	0.51	0.41	Cardiac Troponin-T levels;	chr6:28161935	chr6:28943877~28944537:+
PRAD	cis	rs7811142	1	rs67239991	ENSG00000242294.5	STAG3L5P	9.52	1.05e-19	8.51e-17	0.27	0.41	Platelet count;	chr7:100448881	chr7:100336079~100351900:+
PRAD	cis	rs7811142	1	rs4472444	ENSG00000242294.5	STAG3L5P	9.52	1.06e-19	8.56e-17	0.27	0.41	Platelet count;	chr7:100473135	chr7:100336079~100351900:+
PRAD	cis	rs7811142	1	rs7809801	ENSG00000242294.5	STAG3L5P	9.52	1.06e-19	8.56e-17	0.27	0.41	Platelet count;	chr7:100474408	chr7:100336079~100351900:+
PRAD	cis	rs34375054	0.724	rs4517581	ENSG00000279233.1	RP11-158L12.4	9.52	1.06e-19	8.56e-17	0.42	0.41	Post bronchodilator FEV1/FVC ratio;	chr12:125182848	chr12:125138245~125141711:+
PRAD	cis	rs67311347	0.869	rs6790495	ENSG00000223797.4	ENTPD3-AS1	9.52	1.06e-19	8.56e-17	0.37	0.41	Renal cell carcinoma;	chr3:40325279	chr3:40313802~40453329:-
PRAD	cis	rs67311347	0.869	rs7646899	ENSG00000223797.4	ENTPD3-AS1	9.52	1.06e-19	8.56e-17	0.37	0.41	Renal cell carcinoma;	chr3:40325491	chr3:40313802~40453329:-
PRAD	cis	rs9309473	0.898	rs9807961	ENSG00000163016.8	ALMS1P	9.52	1.07e-19	8.61e-17	0.5	0.41	Metabolite levels;	chr2:73466916	chr2:73644919~73685576:+
PRAD	cis	rs6570726	0.818	rs9399555	ENSG00000235652.6	RP11-545I5.3	9.51	1.07e-19	8.62e-17	0.42	0.41	Lobe attachment (rater-scored or self-reported);	chr6:145556418	chr6:145799409~145886585:+
PRAD	cis	rs9545047	0.604	rs7332367	ENSG00000227676.3	LINC01068	-9.51	1.07e-19	8.63e-17	-0.47	-0.41	Schizophrenia;	chr13:79339816	chr13:79566727~79571436:+
PRAD	cis	rs172166	0.694	rs536704	ENSG00000280107.1	AL022393.9	-9.51	1.08e-19	8.67e-17	-0.5	-0.41	Cardiac Troponin-T levels;	chr6:28124825	chr6:28170845~28172521:+
PRAD	cis	rs7772486	0.754	rs6570703	ENSG00000235652.6	RP11-545I5.3	9.51	1.08e-19	8.68e-17	0.42	0.41	Lobe attachment (rater-scored or self-reported);	chr6:145635916	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.686	rs6570705	ENSG00000235652.6	RP11-545I5.3	9.51	1.08e-19	8.68e-17	0.42	0.41	Lobe attachment (rater-scored or self-reported);	chr6:145640065	chr6:145799409~145886585:+
PRAD	cis	rs7044106	0.578	rs4837788	ENSG00000226752.6	PSMD5-AS1	-9.51	1.08e-19	8.69e-17	-0.63	-0.41	Hip circumference adjusted for BMI;	chr9:120634523	chr9:120824828~120854385:+
PRAD	cis	rs9399137	0.507	rs13214669	ENSG00000232876.1	CTA-212D2.2	-9.51	1.08e-19	8.69e-17	-0.52	-0.41	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134978821	chr6:135055033~135060550:+
PRAD	cis	rs3002131	0.688	rs3008650	ENSG00000225265.1	TAF1A-AS1	9.51	1.08e-19	8.7e-17	0.63	0.41	Interleukin-10 levels;	chr1:222589873	chr1:222589825~222593032:+
PRAD	cis	rs9309473	1	rs7607014	ENSG00000163016.8	ALMS1P	-9.51	1.08e-19	8.7e-17	-0.5	-0.41	Metabolite levels;	chr2:73503047	chr2:73644919~73685576:+
PRAD	cis	rs3096299	0.719	rs2965945	ENSG00000261118.1	RP11-104N10.1	9.51	1.08e-19	8.72e-17	0.39	0.41	Multiple myeloma (IgH translocation);	chr16:89447609	chr16:89492017~89504460:-
PRAD	cis	rs2282300	0.956	rs654710	ENSG00000254532.1	RP11-624D11.2	-9.51	1.08e-19	8.72e-17	-0.56	-0.41	Morning vs. evening chronotype;	chr11:30372756	chr11:30044058~30084343:-
PRAD	cis	rs62355901	0.83	rs12653202	ENSG00000271828.1	CTD-2310F14.1	9.51	1.08e-19	8.72e-17	0.7	0.41	Breast cancer;	chr5:56721091	chr5:56927874~56929573:+
PRAD	cis	rs9309473	1	rs7594511	ENSG00000163016.8	ALMS1P	9.51	1.09e-19	8.75e-17	0.5	0.41	Metabolite levels;	chr2:73454512	chr2:73644919~73685576:+
PRAD	cis	rs7772486	0.875	rs854145	ENSG00000235652.6	RP11-545I5.3	9.51	1.09e-19	8.76e-17	0.42	0.41	Lobe attachment (rater-scored or self-reported);	chr6:146028514	chr6:145799409~145886585:+
PRAD	cis	rs7849270	0.879	rs10988197	ENSG00000268707.1	RP11-247A12.7	-9.51	1.09e-19	8.77e-17	-0.47	-0.41	Blood metabolite ratios;	chr9:129078980	chr9:129170434~129170940:+
PRAD	cis	rs853679	0.517	rs1904841	ENSG00000272009.1	RP1-313I6.12	-9.51	1.09e-19	8.8e-17	-0.42	-0.41	Depression;	chr6:28140307	chr6:28078792~28081130:-
PRAD	cis	rs6570726	0.791	rs441290	ENSG00000235652.6	RP11-545I5.3	9.51	1.1e-19	8.85e-17	0.42	0.41	Lobe attachment (rater-scored or self-reported);	chr6:145562047	chr6:145799409~145886585:+
PRAD	cis	rs7309	0.935	rs10930013	ENSG00000235724.7	AC009299.2	-9.51	1.1e-19	8.88e-17	-0.49	-0.41	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161213814	chr2:161222785~161308303:-
PRAD	cis	rs4964805	0.913	rs12830701	ENSG00000257681.1	RP11-341G23.4	9.51	1.1e-19	8.89e-17	0.41	0.41	Attention deficit hyperactivity disorder;	chr12:103807904	chr12:103746315~103768858:-
PRAD	cis	rs4964805	0.913	rs35945096	ENSG00000257681.1	RP11-341G23.4	9.51	1.1e-19	8.89e-17	0.41	0.41	Attention deficit hyperactivity disorder;	chr12:103808151	chr12:103746315~103768858:-
PRAD	cis	rs34779708	0.931	rs10466072	ENSG00000230534.5	RP11-297A16.2	9.51	1.11e-19	8.98e-17	0.53	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35113828	chr10:35098006~35127020:-
PRAD	cis	rs7849270	0.959	rs9408986	ENSG00000268707.1	RP11-247A12.7	9.51	1.11e-19	8.98e-17	0.49	0.41	Blood metabolite ratios;	chr9:129126156	chr9:129170434~129170940:+
PRAD	cis	rs6570726	0.846	rs6899900	ENSG00000235652.6	RP11-545I5.3	9.51	1.12e-19	9.03e-17	0.42	0.41	Lobe attachment (rater-scored or self-reported);	chr6:145562737	chr6:145799409~145886585:+
PRAD	cis	rs9326248	0.53	rs511676	ENSG00000254851.1	RP11-109L13.1	-9.51	1.13e-19	9.07e-17	-0.8	-0.41	Blood protein levels;	chr11:116954168	chr11:117135528~117138582:+
PRAD	cis	rs7811142	0.943	rs111493473	ENSG00000242294.5	STAG3L5P	9.51	1.13e-19	9.09e-17	0.26	0.41	Platelet count;	chr7:100452119	chr7:100336079~100351900:+
PRAD	cis	rs12134133	0.962	rs17258843	ENSG00000274245.1	RP11-357P18.2	9.51	1.13e-19	9.12e-17	0.59	0.41	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207241387	chr1:207372559~207373252:+
PRAD	cis	rs11118620	0.81	rs1603047	ENSG00000272823.1	RP11-295M18.6	9.51	1.14e-19	9.15e-17	0.52	0.41	Heart failure;	chr1:220849953	chr1:220828676~220829211:-
PRAD	cis	rs11118620	1	rs11118620	ENSG00000272823.1	RP11-295M18.6	9.51	1.14e-19	9.15e-17	0.52	0.41	Heart failure;	chr1:220855166	chr1:220828676~220829211:-
PRAD	cis	rs9918079	0.56	rs4698406	ENSG00000273133.1	RP11-799M12.2	-9.51	1.14e-19	9.17e-17	-0.53	-0.41	Obesity-related traits;	chr4:15638994	chr4:15563698~15564253:-
PRAD	cis	rs7714584	1	rs73282234	ENSG00000197083.10	ZNF300P1	9.51	1.14e-19	9.18e-17	0.76	0.41	Crohn's disease;	chr5:150816362	chr5:150930645~150946289:-
PRAD	cis	rs11690935	0.55	rs4280427	ENSG00000228389.1	AC068039.4	-9.51	1.14e-19	9.19e-17	-0.46	-0.41	Schizophrenia;	chr2:171956692	chr2:171773482~171775844:+
PRAD	cis	rs11690935	0.531	rs4280428	ENSG00000228389.1	AC068039.4	-9.51	1.14e-19	9.19e-17	-0.46	-0.41	Schizophrenia;	chr2:171956693	chr2:171773482~171775844:+
PRAD	cis	rs9309473	0.847	rs4547554	ENSG00000163016.8	ALMS1P	9.51	1.15e-19	9.22e-17	0.51	0.41	Metabolite levels;	chr2:73640735	chr2:73644919~73685576:+
PRAD	cis	rs4964805	0.913	rs3812803	ENSG00000257681.1	RP11-341G23.4	9.51	1.15e-19	9.22e-17	0.41	0.41	Attention deficit hyperactivity disorder;	chr12:103806682	chr12:103746315~103768858:-
PRAD	cis	rs1577917	0.876	rs12190735	ENSG00000203875.9	SNHG5	-9.51	1.15e-19	9.23e-17	-0.45	-0.41	Response to antipsychotic treatment;	chr6:85976749	chr6:85660950~85678736:-
PRAD	cis	rs2153535	0.585	rs1328873	ENSG00000230939.1	RP11-314C16.1	-9.51	1.15e-19	9.25e-17	-0.5	-0.41	Motion sickness;	chr6:8621171	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.585	rs9393047	ENSG00000230939.1	RP11-314C16.1	-9.51	1.15e-19	9.25e-17	-0.5	-0.41	Motion sickness;	chr6:8622373	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.585	rs9505495	ENSG00000230939.1	RP11-314C16.1	-9.51	1.15e-19	9.25e-17	-0.5	-0.41	Motion sickness;	chr6:8622963	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.585	rs9328499	ENSG00000230939.1	RP11-314C16.1	-9.51	1.15e-19	9.25e-17	-0.5	-0.41	Motion sickness;	chr6:8623546	chr6:8784178~8785445:+
PRAD	cis	rs2882667	0.537	rs7704790	ENSG00000253404.1	AC034243.1	9.51	1.15e-19	9.25e-17	0.51	0.41	Age-related hearing impairment (SNP x SNP interaction);	chr5:139074407	chr5:138744434~138753309:-
PRAD	cis	rs1930961	1	rs6004671	ENSG00000272942.1	CTA-246H3.12	-9.51	1.15e-19	9.26e-17	-0.65	-0.41	Bipolar disorder with mood-incongruent psychosis;	chr22:25483507	chr22:25434324~25435070:-
PRAD	cis	rs1930961	1	rs6004672	ENSG00000272942.1	CTA-246H3.12	-9.51	1.15e-19	9.26e-17	-0.65	-0.41	Bipolar disorder with mood-incongruent psychosis;	chr22:25485046	chr22:25434324~25435070:-
PRAD	cis	rs17361889	0.806	rs7778438	ENSG00000224683.1	RPL36AP29	9.51	1.15e-19	9.27e-17	0.5	0.41	Pediatric bone mineral content (hip);	chr7:16207624	chr7:16208945~16209265:+
PRAD	cis	rs71403859	0.57	rs76231867	ENSG00000260886.1	TAT-AS1	9.51	1.15e-19	9.29e-17	0.68	0.41	Post bronchodilator FEV1;	chr16:71416023	chr16:71565789~71578187:+
PRAD	cis	rs2564921	0.73	rs73079924	ENSG00000242142.1	SERBP1P3	-9.5	1.16e-19	9.31e-17	-0.47	-0.41	Height;	chr3:53034139	chr3:53064283~53065091:-
PRAD	cis	rs638893	0.636	rs61901410	ENSG00000278376.1	RP11-158I9.8	9.5	1.16e-19	9.31e-17	0.53	0.41	Vitiligo;	chr11:118790488	chr11:118791254~118793137:+
PRAD	cis	rs7811142	0.943	rs111757992	ENSG00000242294.5	STAG3L5P	9.5	1.16e-19	9.32e-17	0.27	0.41	Platelet count;	chr7:100418731	chr7:100336079~100351900:+
PRAD	cis	rs7772486	0.686	rs702305	ENSG00000235652.6	RP11-545I5.3	-9.5	1.16e-19	9.36e-17	-0.42	-0.41	Lobe attachment (rater-scored or self-reported);	chr6:145652704	chr6:145799409~145886585:+
PRAD	cis	rs150992	0.64	rs326485	ENSG00000248489.1	CTD-2007H13.3	9.5	1.17e-19	9.43e-17	0.45	0.41	Body mass index;	chr5:98845717	chr5:98929171~98995013:+
PRAD	cis	rs3096299	0.967	rs2911253	ENSG00000274627.1	RP11-104N10.2	9.5	1.18e-19	9.44e-17	0.42	0.41	Multiple myeloma (IgH translocation);	chr16:89422179	chr16:89516797~89522217:+
PRAD	cis	rs12134133	1	rs2802237	ENSG00000274245.1	RP11-357P18.2	9.5	1.18e-19	9.45e-17	0.56	0.41	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207300825	chr1:207372559~207373252:+
PRAD	cis	rs7772486	0.622	rs1292333	ENSG00000235652.6	RP11-545I5.3	-9.5	1.18e-19	9.45e-17	-0.42	-0.41	Lobe attachment (rater-scored or self-reported);	chr6:145661208	chr6:145799409~145886585:+
PRAD	cis	rs2153535	0.536	rs1328876	ENSG00000230939.1	RP11-314C16.1	-9.5	1.18e-19	9.47e-17	-0.5	-0.41	Motion sickness;	chr6:8620940	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.585	rs1328875	ENSG00000230939.1	RP11-314C16.1	-9.5	1.18e-19	9.47e-17	-0.5	-0.41	Motion sickness;	chr6:8620946	chr6:8784178~8785445:+
PRAD	cis	rs6452524	0.935	rs1580311	ENSG00000249664.1	CTD-2227C6.2	9.5	1.18e-19	9.51e-17	0.47	0.41	Hypertension (SNP x SNP interaction);	chr5:83091667	chr5:83012285~83013109:-
PRAD	cis	rs6452524	0.935	rs1382376	ENSG00000249664.1	CTD-2227C6.2	9.5	1.18e-19	9.51e-17	0.47	0.41	Hypertension (SNP x SNP interaction);	chr5:83095418	chr5:83012285~83013109:-
PRAD	cis	rs6452524	0.935	rs12109517	ENSG00000249664.1	CTD-2227C6.2	9.5	1.18e-19	9.51e-17	0.47	0.41	Hypertension (SNP x SNP interaction);	chr5:83095947	chr5:83012285~83013109:-
PRAD	cis	rs6452524	0.935	rs12109514	ENSG00000249664.1	CTD-2227C6.2	9.5	1.18e-19	9.51e-17	0.47	0.41	Hypertension (SNP x SNP interaction);	chr5:83095965	chr5:83012285~83013109:-
PRAD	cis	rs6452524	0.901	rs17284211	ENSG00000249664.1	CTD-2227C6.2	9.5	1.18e-19	9.51e-17	0.47	0.41	Hypertension (SNP x SNP interaction);	chr5:83098706	chr5:83012285~83013109:-
PRAD	cis	rs6452524	0.935	rs1382374	ENSG00000249664.1	CTD-2227C6.2	9.5	1.18e-19	9.51e-17	0.47	0.41	Hypertension (SNP x SNP interaction);	chr5:83101010	chr5:83012285~83013109:-
PRAD	cis	rs9322193	0.566	rs9397070	ENSG00000216906.2	RP11-350J20.9	-9.5	1.19e-19	9.58e-17	-0.53	-0.41	Lung cancer;	chr6:149922073	chr6:149904243~149906418:+
PRAD	cis	rs9309473	1	rs7598396	ENSG00000163016.8	ALMS1P	9.5	1.19e-19	9.58e-17	0.5	0.41	Metabolite levels;	chr2:73425500	chr2:73644919~73685576:+
PRAD	cis	rs9309473	0.95	rs6740766	ENSG00000163016.8	ALMS1P	9.5	1.19e-19	9.58e-17	0.5	0.41	Metabolite levels;	chr2:73553786	chr2:73644919~73685576:+
PRAD	cis	rs9309473	1	rs13431267	ENSG00000163016.8	ALMS1P	9.5	1.19e-19	9.58e-17	0.5	0.41	Metabolite levels;	chr2:73555073	chr2:73644919~73685576:+
PRAD	cis	rs9309473	0.95	rs6735946	ENSG00000163016.8	ALMS1P	9.5	1.19e-19	9.58e-17	0.5	0.41	Metabolite levels;	chr2:73562931	chr2:73644919~73685576:+
PRAD	cis	rs9309473	0.95	rs10198549	ENSG00000163016.8	ALMS1P	9.5	1.19e-19	9.58e-17	0.5	0.41	Metabolite levels;	chr2:73567277	chr2:73644919~73685576:+
PRAD	cis	rs9309473	0.898	rs10185080	ENSG00000163016.8	ALMS1P	9.5	1.19e-19	9.58e-17	0.5	0.41	Metabolite levels;	chr2:73570380	chr2:73644919~73685576:+
PRAD	cis	rs9309473	0.898	rs10197755	ENSG00000163016.8	ALMS1P	9.5	1.19e-19	9.58e-17	0.5	0.41	Metabolite levels;	chr2:73570496	chr2:73644919~73685576:+
PRAD	cis	rs9309473	0.848	rs17009159	ENSG00000163016.8	ALMS1P	9.5	1.19e-19	9.58e-17	0.5	0.41	Metabolite levels;	chr2:73570635	chr2:73644919~73685576:+
PRAD	cis	rs9309473	1	rs7583255	ENSG00000163016.8	ALMS1P	9.5	1.19e-19	9.58e-17	0.5	0.41	Metabolite levels;	chr2:73570869	chr2:73644919~73685576:+
PRAD	cis	rs9309473	1	rs7586463	ENSG00000163016.8	ALMS1P	9.5	1.19e-19	9.58e-17	0.5	0.41	Metabolite levels;	chr2:73571349	chr2:73644919~73685576:+
PRAD	cis	rs7772486	0.686	rs4896828	ENSG00000235652.6	RP11-545I5.3	9.5	1.19e-19	9.58e-17	0.42	0.41	Lobe attachment (rater-scored or self-reported);	chr6:145632203	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.686	rs6570701	ENSG00000235652.6	RP11-545I5.3	9.5	1.19e-19	9.58e-17	0.42	0.41	Lobe attachment (rater-scored or self-reported);	chr6:145632954	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.686	rs857875	ENSG00000235652.6	RP11-545I5.3	-9.5	1.19e-19	9.58e-17	-0.42	-0.41	Lobe attachment (rater-scored or self-reported);	chr6:145658897	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.791	rs1935612	ENSG00000235652.6	RP11-545I5.3	9.5	1.19e-19	9.58e-17	0.42	0.41	Lobe attachment (rater-scored or self-reported);	chr6:145584954	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.791	rs7765687	ENSG00000235652.6	RP11-545I5.3	9.5	1.19e-19	9.59e-17	0.42	0.41	Lobe attachment (rater-scored or self-reported);	chr6:145593964	chr6:145799409~145886585:+
PRAD	cis	rs7189233	0.55	rs3803657	ENSG00000279344.1	RP11-44F14.7	9.5	1.19e-19	9.59e-17	0.37	0.41	Intelligence (multi-trait analysis);	chr16:53482047	chr16:53478957~53481550:-
PRAD	cis	rs9309473	1	rs9653557	ENSG00000163016.8	ALMS1P	9.5	1.2e-19	9.62e-17	0.5	0.41	Metabolite levels;	chr2:73568835	chr2:73644919~73685576:+
PRAD	cis	rs9309711	0.621	rs7586472	ENSG00000225234.1	TRAPPC12-AS1	-9.5	1.2e-19	9.63e-17	-0.41	-0.41	Neurofibrillary tangles;	chr2:3469899	chr2:3481242~3482409:-
PRAD	cis	rs7309	0.935	rs1921309	ENSG00000235724.7	AC009299.2	-9.5	1.2e-19	9.64e-17	-0.49	-0.41	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161192464	chr2:161222785~161308303:-
PRAD	cis	rs7309	0.935	rs11884495	ENSG00000235724.7	AC009299.2	-9.5	1.2e-19	9.64e-17	-0.49	-0.41	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161203458	chr2:161222785~161308303:-
PRAD	cis	rs748404	0.588	rs2255410	ENSG00000249839.1	AC011330.5	-9.5	1.21e-19	9.68e-17	-0.52	-0.41	Lung cancer;	chr15:43538899	chr15:43663654~43684339:-
PRAD	cis	rs75422866	0.867	rs7304743	ENSG00000257433.4	RP1-197B17.3	-9.5	1.21e-19	9.69e-17	-0.8	-0.41	Pneumonia;	chr12:47683658	chr12:47706085~47742294:+
PRAD	cis	rs62229266	0.605	rs2835275	ENSG00000231106.2	LINC01436	9.5	1.21e-19	9.74e-17	0.53	0.41	Mitral valve prolapse;	chr21:36087703	chr21:36005338~36007838:+
PRAD	cis	rs1930961	1	rs1930961	ENSG00000272942.1	CTA-246H3.12	-9.5	1.21e-19	9.74e-17	-0.64	-0.41	Bipolar disorder with mood-incongruent psychosis;	chr22:25479298	chr22:25434324~25435070:-
PRAD	cis	rs2282300	0.739	rs67670125	ENSG00000242353.1	RP4-710M3.1	-9.5	1.22e-19	9.76e-17	-0.49	-0.41	Morning vs. evening chronotype;	chr11:30193367	chr11:30368148~30368646:+
PRAD	cis	rs2153535	0.585	rs58117210	ENSG00000230939.1	RP11-314C16.1	-9.5	1.22e-19	9.79e-17	-0.5	-0.41	Motion sickness;	chr6:8603881	chr6:8784178~8785445:+
PRAD	cis	rs9322193	0.607	rs7764677	ENSG00000216906.2	RP11-350J20.9	9.5	1.23e-19	9.85e-17	0.53	0.41	Lung cancer;	chr6:149906197	chr6:149904243~149906418:+
PRAD	cis	rs12468226	1	rs74766638	ENSG00000273456.1	RP11-686O6.2	9.5	1.23e-19	9.88e-17	0.54	0.41	Urate levels;	chr2:202445168	chr2:202374932~202375604:-
PRAD	cis	rs11123170	0.64	rs931472	ENSG00000274877.1	RP11-65I12.1	9.5	1.23e-19	9.9e-17	0.6	0.41	Renal function-related traits (BUN);	chr2:113212371	chr2:113237595~113240825:+
PRAD	cis	rs765787	0.53	rs12903149	ENSG00000259520.4	CTD-2651B20.3	-9.5	1.24e-19	9.92e-17	-0.53	-0.41	Uric acid levels;	chr15:45246878	chr15:45251580~45279251:-
PRAD	cis	rs507080	0.961	rs607527	ENSG00000255422.1	AP002954.4	9.5	1.25e-19	1e-16	0.49	0.41	Serum metabolite levels;	chr11:118667478	chr11:118704607~118750263:+
PRAD	cis	rs12049351	0.665	rs6690907	ENSG00000229367.1	HMGN2P19	9.49	1.26e-19	1.01e-16	0.59	0.41	Circulating myeloperoxidase levels (plasma);	chr1:229457643	chr1:229570532~229570796:+
PRAD	cis	rs172166	0.516	rs1225710	ENSG00000204709.4	LINC01556	-9.49	1.26e-19	1.01e-16	-0.51	-0.41	Cardiac Troponin-T levels;	chr6:28132862	chr6:28943877~28944537:+
PRAD	cis	rs853679	0.513	rs13437444	ENSG00000280107.1	AL022393.9	-9.49	1.26e-19	1.01e-16	-0.6	-0.41	Depression;	chr6:28103220	chr6:28170845~28172521:+
PRAD	cis	rs7772486	0.686	rs1337841	ENSG00000235652.6	RP11-545I5.3	-9.49	1.27e-19	1.02e-16	-0.41	-0.41	Lobe attachment (rater-scored or self-reported);	chr6:145738351	chr6:145799409~145886585:+
PRAD	cis	rs7182621	0.639	rs36069387	ENSG00000259363.4	CTD-2054N24.2	-9.49	1.27e-19	1.02e-16	-0.37	-0.41	Colonoscopy-negative controls vs population controls;	chr15:99884540	chr15:99807023~99877148:+
PRAD	cis	rs9918079	0.524	rs4235379	ENSG00000273133.1	RP11-799M12.2	-9.49	1.27e-19	1.02e-16	-0.53	-0.41	Obesity-related traits;	chr4:15657655	chr4:15563698~15564253:-
PRAD	cis	rs71403859	0.502	rs75986475	ENSG00000260886.1	TAT-AS1	9.49	1.27e-19	1.02e-16	0.72	0.41	Post bronchodilator FEV1;	chr16:71430155	chr16:71565789~71578187:+
PRAD	cis	rs3096299	0.632	rs4399533	ENSG00000261118.1	RP11-104N10.1	9.49	1.27e-19	1.02e-16	0.39	0.41	Multiple myeloma (IgH translocation);	chr16:89472974	chr16:89492017~89504460:-
PRAD	cis	rs150992	0.673	rs331934	ENSG00000248489.1	CTD-2007H13.3	-9.49	1.28e-19	1.02e-16	-0.46	-0.41	Body mass index;	chr5:98804016	chr5:98929171~98995013:+
PRAD	cis	rs150992	0.673	rs331549	ENSG00000248489.1	CTD-2007H13.3	-9.49	1.28e-19	1.02e-16	-0.46	-0.41	Body mass index;	chr5:98805731	chr5:98929171~98995013:+
PRAD	cis	rs765787	0.53	rs10851423	ENSG00000259520.4	CTD-2651B20.3	-9.49	1.28e-19	1.02e-16	-0.53	-0.41	Uric acid levels;	chr15:45223752	chr15:45251580~45279251:-
PRAD	cis	rs765787	0.53	rs12913123	ENSG00000259520.4	CTD-2651B20.3	-9.49	1.28e-19	1.02e-16	-0.53	-0.41	Uric acid levels;	chr15:45224227	chr15:45251580~45279251:-
PRAD	cis	rs3096299	0.685	rs3803681	ENSG00000261118.1	RP11-104N10.1	9.49	1.28e-19	1.03e-16	0.39	0.41	Multiple myeloma (IgH translocation);	chr16:89478348	chr16:89492017~89504460:-
PRAD	cis	rs1075265	0.73	rs4413193	ENSG00000233266.1	HMGB1P31	9.49	1.28e-19	1.03e-16	0.56	0.41	Chronotype;Morning vs. evening chronotype;	chr2:53710901	chr2:54051334~54051760:+
PRAD	cis	rs10875746	0.768	rs4760609	ENSG00000240399.1	RP1-228P16.1	9.49	1.28e-19	1.03e-16	0.37	0.41	Longevity (90 years and older);	chr12:48021974	chr12:48054813~48055591:-
PRAD	cis	rs6750795	0.569	rs1797387	ENSG00000181798.2	LINC00471	-9.49	1.29e-19	1.03e-16	-0.47	-0.41	Height;	chr2:231549981	chr2:231508426~231514339:-
PRAD	cis	rs62034325	0.697	rs710410	ENSG00000259982.1	CDC37P1	9.49	1.3e-19	1.04e-16	0.55	0.41	Body mass index;	chr16:28592021	chr16:28700294~28701540:-
PRAD	cis	rs858239	0.73	rs858279	ENSG00000226816.2	AC005082.12	9.49	1.3e-19	1.04e-16	0.48	0.41	Cerebrospinal fluid biomarker levels;	chr7:23211386	chr7:23206013~23208045:+
PRAD	cis	rs9322193	0.516	rs1999632	ENSG00000216906.2	RP11-350J20.9	9.49	1.3e-19	1.04e-16	0.55	0.41	Lung cancer;	chr6:149866737	chr6:149904243~149906418:+
PRAD	cis	rs7712401	0.642	rs17388251	ENSG00000263432.2	RN7SL689P	9.49	1.3e-19	1.04e-16	0.41	0.41	Mean platelet volume;	chr5:123024708	chr5:123022487~123022783:-
PRAD	cis	rs9545047	0.625	rs1408657	ENSG00000227676.3	LINC01068	9.49	1.3e-19	1.04e-16	0.47	0.41	Schizophrenia;	chr13:79329315	chr13:79566727~79571436:+
PRAD	cis	rs75422866	0.867	rs7303895	ENSG00000257433.4	RP1-197B17.3	9.49	1.3e-19	1.04e-16	0.78	0.41	Pneumonia;	chr12:47683290	chr12:47706085~47742294:+
PRAD	cis	rs7772486	0.686	rs9386131	ENSG00000235652.6	RP11-545I5.3	9.49	1.3e-19	1.04e-16	0.42	0.41	Lobe attachment (rater-scored or self-reported);	chr6:145800472	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.686	rs7739735	ENSG00000235652.6	RP11-545I5.3	9.49	1.3e-19	1.04e-16	0.42	0.41	Lobe attachment (rater-scored or self-reported);	chr6:145802400	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.686	rs7744014	ENSG00000235652.6	RP11-545I5.3	9.49	1.3e-19	1.04e-16	0.42	0.41	Lobe attachment (rater-scored or self-reported);	chr6:145802682	chr6:145799409~145886585:+
PRAD	cis	rs7714584	1	rs2004711	ENSG00000197083.10	ZNF300P1	9.49	1.31e-19	1.05e-16	0.66	0.41	Crohn's disease;	chr5:150845506	chr5:150930645~150946289:-
PRAD	cis	rs732716	0.74	rs78869060	ENSG00000267769.1	CTB-50L17.9	-9.49	1.31e-19	1.05e-16	-0.44	-0.41	Mean corpuscular volume;	chr19:4444745	chr19:4454014~4455286:+
PRAD	cis	rs4718428	0.705	rs4718430	ENSG00000273142.1	RP11-458F8.4	-9.49	1.32e-19	1.06e-16	-0.32	-0.41	Corneal structure;	chr7:66967037	chr7:66902857~66906297:+
PRAD	cis	rs1930961	1	rs760555	ENSG00000272942.1	CTA-246H3.12	-9.49	1.33e-19	1.06e-16	-0.64	-0.41	Bipolar disorder with mood-incongruent psychosis;	chr22:25476870	chr22:25434324~25435070:-
PRAD	cis	rs748404	0.516	rs523156	ENSG00000249839.1	AC011330.5	9.49	1.33e-19	1.07e-16	0.52	0.41	Lung cancer;	chr15:43519645	chr15:43663654~43684339:-
PRAD	cis	rs9326248	0.581	rs10892076	ENSG00000280143.1	AP000892.6	9.49	1.34e-19	1.07e-16	0.32	0.41	Blood protein levels;	chr11:117118220	chr11:117204967~117210292:+
PRAD	cis	rs62103177	0.525	rs62101233	ENSG00000261126.6	RP11-795F19.1	9.49	1.34e-19	1.07e-16	0.56	0.41	Opioid sensitivity;	chr18:79964288	chr18:80046900~80095482:+
PRAD	cis	rs765787	0.53	rs7167731	ENSG00000259520.4	CTD-2651B20.3	-9.49	1.34e-19	1.07e-16	-0.52	-0.41	Uric acid levels;	chr15:45218702	chr15:45251580~45279251:-
PRAD	cis	rs7569084	0.687	rs12614851	ENSG00000281920.1	RP11-418H16.1	9.49	1.34e-19	1.07e-16	0.48	0.41	Sum eosinophil basophil counts;	chr2:65458050	chr2:65623272~65628424:+
PRAD	cis	rs7569084	0.687	rs1344891	ENSG00000281920.1	RP11-418H16.1	9.49	1.34e-19	1.07e-16	0.48	0.41	Sum eosinophil basophil counts;	chr2:65458890	chr2:65623272~65628424:+
PRAD	cis	rs9309711	0.643	rs4535074	ENSG00000225234.1	TRAPPC12-AS1	-9.49	1.34e-19	1.07e-16	-0.41	-0.41	Neurofibrillary tangles;	chr2:3477866	chr2:3481242~3482409:-
PRAD	cis	rs3096299	0.719	rs2965817	ENSG00000261118.1	RP11-104N10.1	9.49	1.35e-19	1.08e-16	0.39	0.41	Multiple myeloma (IgH translocation);	chr16:89446826	chr16:89492017~89504460:-
PRAD	cis	rs7811142	1	rs112317829	ENSG00000242294.5	STAG3L5P	9.49	1.35e-19	1.08e-16	0.26	0.41	Platelet count;	chr7:100445550	chr7:100336079~100351900:+
PRAD	cis	rs2404602	0.532	rs284892	ENSG00000259422.1	RP11-593F23.1	9.48	1.36e-19	1.08e-16	0.51	0.41	Blood metabolite levels;	chr15:76428696	chr15:76174891~76181486:-
PRAD	cis	rs10246939	0.543	rs9640204	ENSG00000228775.6	WEE2-AS1	9.48	1.36e-19	1.09e-16	0.5	0.41	Bitter taste perception;	chr7:141844300	chr7:141704338~141738346:-
PRAD	cis	rs10246939	0.543	rs9640359	ENSG00000228775.6	WEE2-AS1	9.48	1.36e-19	1.09e-16	0.5	0.41	Bitter taste perception;	chr7:141844399	chr7:141704338~141738346:-
PRAD	cis	rs2286503	0.901	rs10950922	ENSG00000228649.7	AC005682.5	9.48	1.36e-19	1.09e-16	0.46	0.41	Fibrinogen;	chr7:22814387	chr7:22854178~22861579:+
PRAD	cis	rs9545047	0.604	rs7988784	ENSG00000227676.3	LINC01068	-9.48	1.37e-19	1.09e-16	-0.47	-0.41	Schizophrenia;	chr13:79335337	chr13:79566727~79571436:+
PRAD	cis	rs9660180	0.592	rs2076325	ENSG00000231050.1	RP1-140A9.1	-9.48	1.37e-19	1.09e-16	-0.48	-0.41	Body mass index;	chr1:1735176	chr1:1891471~1892658:+
PRAD	cis	rs11123170	0.64	rs2863240	ENSG00000274877.1	RP11-65I12.1	9.48	1.38e-19	1.1e-16	0.6	0.41	Renal function-related traits (BUN);	chr2:113212539	chr2:113237595~113240825:+
PRAD	cis	rs2286503	0.901	rs2286505	ENSG00000228649.7	AC005682.5	9.48	1.38e-19	1.1e-16	0.46	0.41	Fibrinogen;	chr7:22815221	chr7:22854178~22861579:+
PRAD	cis	rs9545047	0.604	rs2057573	ENSG00000227676.3	LINC01068	-9.48	1.38e-19	1.1e-16	-0.48	-0.41	Schizophrenia;	chr13:79357736	chr13:79566727~79571436:+
PRAD	cis	rs2153535	0.585	rs980083	ENSG00000230939.1	RP11-314C16.1	9.48	1.39e-19	1.11e-16	0.5	0.41	Motion sickness;	chr6:8589683	chr6:8784178~8785445:+
PRAD	cis	rs7772486	0.875	rs2748482	ENSG00000235652.6	RP11-545I5.3	9.48	1.41e-19	1.12e-16	0.41	0.41	Lobe attachment (rater-scored or self-reported);	chr6:146015396	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.875	rs1331637	ENSG00000235652.6	RP11-545I5.3	9.48	1.41e-19	1.12e-16	0.41	0.41	Lobe attachment (rater-scored or self-reported);	chr6:146015951	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.846	rs1331636	ENSG00000235652.6	RP11-545I5.3	9.48	1.41e-19	1.12e-16	0.41	0.41	Lobe attachment (rater-scored or self-reported);	chr6:146017690	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.875	rs1929523	ENSG00000235652.6	RP11-545I5.3	9.48	1.41e-19	1.12e-16	0.41	0.41	Lobe attachment (rater-scored or self-reported);	chr6:146018853	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.875	rs2224120	ENSG00000235652.6	RP11-545I5.3	9.48	1.41e-19	1.12e-16	0.41	0.41	Lobe attachment (rater-scored or self-reported);	chr6:146022144	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.875	rs2777476	ENSG00000235652.6	RP11-545I5.3	9.48	1.41e-19	1.12e-16	0.41	0.41	Lobe attachment (rater-scored or self-reported);	chr6:146023888	chr6:145799409~145886585:+
PRAD	cis	rs7712401	0.715	rs15577	ENSG00000263432.2	RN7SL689P	-9.48	1.41e-19	1.13e-16	-0.42	-0.41	Mean platelet volume;	chr5:123023495	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.715	rs451195	ENSG00000263432.2	RN7SL689P	-9.48	1.41e-19	1.13e-16	-0.42	-0.41	Mean platelet volume;	chr5:123023945	chr5:123022487~123022783:-
PRAD	cis	rs2404602	0.646	rs3764245	ENSG00000259422.1	RP11-593F23.1	9.48	1.41e-19	1.13e-16	0.54	0.41	Blood metabolite levels;	chr15:76930835	chr15:76174891~76181486:-
PRAD	cis	rs6142102	1	rs6142102	ENSG00000276073.1	RP5-1125A11.7	-9.48	1.42e-19	1.13e-16	-0.4	-0.41	Skin pigmentation;	chr20:34116821	chr20:33985617~33988989:-
PRAD	cis	rs783540	0.5	rs1313494	ENSG00000255769.6	GOLGA2P10	9.48	1.42e-19	1.13e-16	0.54	0.41	Schizophrenia;	chr15:82605530	chr15:82472993~82513950:-
PRAD	cis	rs3096299	0.658	rs12443705	ENSG00000261118.1	RP11-104N10.1	9.48	1.43e-19	1.14e-16	0.39	0.41	Multiple myeloma (IgH translocation);	chr16:89480646	chr16:89492017~89504460:-
PRAD	cis	rs3931020	0.616	rs277381	ENSG00000272864.1	RP11-17E13.2	9.48	1.44e-19	1.15e-16	0.48	0.41	Resistin levels;	chr1:74801131	chr1:74698769~74699333:-
PRAD	cis	rs17608059	0.518	rs4792436	ENSG00000141028.6	CDRT15P1	9.48	1.44e-19	1.15e-16	0.53	0.41	Temperament;	chr17:14068990	chr17:14024514~14025488:+
PRAD	cis	rs7772486	0.875	rs1331639	ENSG00000235652.6	RP11-545I5.3	-9.48	1.45e-19	1.15e-16	-0.41	-0.41	Lobe attachment (rater-scored or self-reported);	chr6:146110733	chr6:145799409~145886585:+
PRAD	cis	rs9545047	0.604	rs9318640	ENSG00000227676.3	LINC01068	-9.48	1.45e-19	1.16e-16	-0.48	-0.41	Schizophrenia;	chr13:79426527	chr13:79566727~79571436:+
PRAD	cis	rs7811142	0.943	rs28660238	ENSG00000242294.5	STAG3L5P	9.48	1.46e-19	1.16e-16	0.27	0.41	Platelet count;	chr7:100425685	chr7:100336079~100351900:+
PRAD	cis	rs9322193	0.607	rs6557165	ENSG00000223701.3	RAET1E-AS1	-9.48	1.47e-19	1.17e-16	-0.6	-0.41	Lung cancer;	chr6:149906883	chr6:149884431~149919508:+
PRAD	cis	rs6452524	0.935	rs1580310	ENSG00000249664.1	CTD-2227C6.2	9.48	1.47e-19	1.17e-16	0.47	0.41	Hypertension (SNP x SNP interaction);	chr5:83091792	chr5:83012285~83013109:-
PRAD	cis	rs2115630	0.645	rs3825877	ENSG00000275120.1	RP11-182J1.17	-9.48	1.47e-19	1.17e-16	-0.47	-0.41	P wave terminal force;	chr15:84631400	chr15:84599434~84606463:-
PRAD	cis	rs2115630	0.645	rs3825878	ENSG00000275120.1	RP11-182J1.17	-9.48	1.47e-19	1.17e-16	-0.47	-0.41	P wave terminal force;	chr15:84631524	chr15:84599434~84606463:-
PRAD	cis	rs997154	0.655	rs4981454	ENSG00000279656.1	RP11-298I3.6	9.47	1.47e-19	1.17e-16	0.58	0.41	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22952977	chr14:23023083~23024217:-
PRAD	cis	rs853679	0.517	rs1904840	ENSG00000272009.1	RP1-313I6.12	-9.47	1.48e-19	1.18e-16	-0.41	-0.41	Depression;	chr6:28140454	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs9368555	ENSG00000272009.1	RP1-313I6.12	-9.47	1.48e-19	1.18e-16	-0.41	-0.41	Depression;	chr6:28141189	chr6:28078792~28081130:-
PRAD	cis	rs7714584	1	rs80075680	ENSG00000197083.10	ZNF300P1	9.47	1.49e-19	1.18e-16	0.66	0.41	Crohn's disease;	chr5:150844175	chr5:150930645~150946289:-
PRAD	cis	rs765787	0.505	rs4439707	ENSG00000259520.4	CTD-2651B20.3	-9.47	1.49e-19	1.18e-16	-0.53	-0.41	Uric acid levels;	chr15:45232018	chr15:45251580~45279251:-
PRAD	cis	rs765787	0.53	rs12442533	ENSG00000259520.4	CTD-2651B20.3	-9.47	1.49e-19	1.18e-16	-0.53	-0.41	Uric acid levels;	chr15:45237433	chr15:45251580~45279251:-
PRAD	cis	rs1061377	0.585	rs2163271	ENSG00000249207.1	RP11-360F5.1	-9.47	1.49e-19	1.19e-16	-0.43	-0.41	Uric acid levels;	chr4:39076525	chr4:39112677~39126818:-
PRAD	cis	rs1062177	0.906	rs2964573	ENSG00000253921.1	CTB-113P19.3	-9.47	1.5e-19	1.19e-16	-0.53	-0.41	Preschool internalizing problems;	chr5:151780561	chr5:151753992~151767247:+
PRAD	cis	rs2108622	0.727	rs12609900	ENSG00000267453.5	AC004791.2	-9.47	1.5e-19	1.19e-16	-0.53	-0.41	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871604	chr19:15851993~15864904:-
PRAD	cis	rs2108622	0.727	rs62107763	ENSG00000267453.5	AC004791.2	-9.47	1.5e-19	1.19e-16	-0.53	-0.41	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871788	chr19:15851993~15864904:-
PRAD	cis	rs2108622	0.727	rs62107764	ENSG00000267453.5	AC004791.2	-9.47	1.5e-19	1.19e-16	-0.53	-0.41	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871848	chr19:15851993~15864904:-
PRAD	cis	rs2108622	0.727	rs76984410	ENSG00000267453.5	AC004791.2	-9.47	1.5e-19	1.19e-16	-0.53	-0.41	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871890	chr19:15851993~15864904:-
PRAD	cis	rs2108622	0.727	rs77780918	ENSG00000267453.5	AC004791.2	-9.47	1.5e-19	1.19e-16	-0.53	-0.41	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871897	chr19:15851993~15864904:-
PRAD	cis	rs2108622	0.727	rs8101038	ENSG00000267453.5	AC004791.2	-9.47	1.5e-19	1.19e-16	-0.53	-0.41	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15872054	chr19:15851993~15864904:-
PRAD	cis	rs9326248	0.53	rs72645460	ENSG00000254851.1	RP11-109L13.1	9.47	1.5e-19	1.2e-16	0.84	0.41	Blood protein levels;	chr11:116900659	chr11:117135528~117138582:+
PRAD	cis	rs67311347	1	rs1454497	ENSG00000223797.4	ENTPD3-AS1	-9.47	1.5e-19	1.2e-16	-0.36	-0.41	Renal cell carcinoma;	chr3:40454835	chr3:40313802~40453329:-
PRAD	cis	rs4835473	0.932	rs10016223	ENSG00000251600.4	RP11-673E1.1	9.47	1.5e-19	1.2e-16	0.51	0.41	Immature fraction of reticulocytes;	chr4:143777429	chr4:143912331~143982454:+
PRAD	cis	rs7811142	1	rs28490152	ENSG00000242294.5	STAG3L5P	9.47	1.51e-19	1.2e-16	0.27	0.41	Platelet count;	chr7:100423359	chr7:100336079~100351900:+
PRAD	cis	rs6452524	0.901	rs1600362	ENSG00000249664.1	CTD-2227C6.2	9.47	1.51e-19	1.2e-16	0.47	0.41	Hypertension (SNP x SNP interaction);	chr5:83091354	chr5:83012285~83013109:-
PRAD	cis	rs6452524	0.935	rs1011979	ENSG00000249664.1	CTD-2227C6.2	9.47	1.51e-19	1.2e-16	0.47	0.41	Hypertension (SNP x SNP interaction);	chr5:83097431	chr5:83012285~83013109:-
PRAD	cis	rs7712401	0.715	rs434789	ENSG00000263432.2	RN7SL689P	-9.47	1.51e-19	1.2e-16	-0.42	-0.41	Mean platelet volume;	chr5:123021615	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.715	rs1139334	ENSG00000263432.2	RN7SL689P	-9.47	1.51e-19	1.2e-16	-0.42	-0.41	Mean platelet volume;	chr5:123022724	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.715	rs1062350	ENSG00000263432.2	RN7SL689P	-9.47	1.51e-19	1.2e-16	-0.42	-0.41	Mean platelet volume;	chr5:123022811	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.678	rs401535	ENSG00000263432.2	RN7SL689P	-9.47	1.51e-19	1.2e-16	-0.42	-0.41	Mean platelet volume;	chr5:123022990	chr5:123022487~123022783:-
PRAD	cis	rs7772486	0.875	rs2474353	ENSG00000235652.6	RP11-545I5.3	9.47	1.52e-19	1.21e-16	0.41	0.41	Lobe attachment (rater-scored or self-reported);	chr6:146002747	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.79	rs1854900	ENSG00000235652.6	RP11-545I5.3	9.47	1.52e-19	1.21e-16	0.41	0.41	Lobe attachment (rater-scored or self-reported);	chr6:146010246	chr6:145799409~145886585:+
PRAD	cis	rs9309711	0.666	rs11127429	ENSG00000225234.1	TRAPPC12-AS1	-9.47	1.54e-19	1.22e-16	-0.41	-0.41	Neurofibrillary tangles;	chr2:3481453	chr2:3481242~3482409:-
PRAD	cis	rs9309711	0.666	rs11127430	ENSG00000225234.1	TRAPPC12-AS1	-9.47	1.54e-19	1.22e-16	-0.41	-0.41	Neurofibrillary tangles;	chr2:3481471	chr2:3481242~3482409:-
PRAD	cis	rs6452524	0.508	rs256795	ENSG00000249664.1	CTD-2227C6.2	-9.47	1.54e-19	1.22e-16	-0.48	-0.41	Hypertension (SNP x SNP interaction);	chr5:83001543	chr5:83012285~83013109:-
PRAD	cis	rs7712401	0.715	rs6862366	ENSG00000263432.2	RN7SL689P	-9.47	1.54e-19	1.23e-16	-0.42	-0.41	Mean platelet volume;	chr5:123024463	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.715	rs407392	ENSG00000263432.2	RN7SL689P	-9.47	1.54e-19	1.23e-16	-0.42	-0.41	Mean platelet volume;	chr5:123025299	chr5:123022487~123022783:-
PRAD	cis	rs7688540	0.771	rs78343340	ENSG00000275426.1	CH17-262A2.1	9.47	1.54e-19	1.23e-16	0.61	0.41	Facial morphology (factor 6, height of vermillion lower lip);	chr4:273648	chr4:149738~150317:+
PRAD	cis	rs7772486	0.625	rs9390355	ENSG00000235652.6	RP11-545I5.3	-9.47	1.54e-19	1.23e-16	-0.41	-0.41	Lobe attachment (rater-scored or self-reported);	chr6:145791806	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.658	rs4895683	ENSG00000235652.6	RP11-545I5.3	-9.47	1.54e-19	1.23e-16	-0.41	-0.41	Lobe attachment (rater-scored or self-reported);	chr6:145792518	chr6:145799409~145886585:+
PRAD	cis	rs12220777	0.786	rs2342607	ENSG00000230091.5	TMEM254-AS1	9.47	1.55e-19	1.23e-16	0.83	0.41	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80061733	chr10:80046860~80078912:-
PRAD	cis	rs748404	0.56	rs570933	ENSG00000249839.1	AC011330.5	-9.47	1.55e-19	1.23e-16	-0.52	-0.41	Lung cancer;	chr15:43531832	chr15:43663654~43684339:-
PRAD	cis	rs1075265	0.836	rs1363063	ENSG00000233266.1	HMGB1P31	9.47	1.55e-19	1.23e-16	0.55	0.41	Chronotype;Morning vs. evening chronotype;	chr2:54047433	chr2:54051334~54051760:+
PRAD	cis	rs9545047	0.604	rs1853830	ENSG00000227676.3	LINC01068	-9.47	1.55e-19	1.23e-16	-0.48	-0.41	Schizophrenia;	chr13:79406877	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs7987193	ENSG00000227676.3	LINC01068	-9.47	1.55e-19	1.23e-16	-0.48	-0.41	Schizophrenia;	chr13:79408449	chr13:79566727~79571436:+
PRAD	cis	rs67311347	1	rs7641495	ENSG00000223797.4	ENTPD3-AS1	-9.47	1.55e-19	1.23e-16	-0.36	-0.41	Renal cell carcinoma;	chr3:40453199	chr3:40313802~40453329:-
PRAD	cis	rs2286503	0.966	rs6949233	ENSG00000228649.7	AC005682.5	9.47	1.56e-19	1.24e-16	0.45	0.41	Fibrinogen;	chr7:22818572	chr7:22854178~22861579:+
PRAD	cis	rs11690935	0.55	rs11676438	ENSG00000228389.1	AC068039.4	-9.47	1.56e-19	1.24e-16	-0.46	-0.41	Schizophrenia;	chr2:171970147	chr2:171773482~171775844:+
PRAD	cis	rs673078	0.607	rs7294498	ENSG00000275759.1	RP11-131L12.3	-9.47	1.56e-19	1.24e-16	-0.56	-0.41	Glucose homeostasis traits;	chr12:118321680	chr12:118428281~118428870:+
PRAD	cis	rs10800713	0.866	rs6703783	ENSG00000260088.1	RP11-92G12.3	-9.47	1.56e-19	1.24e-16	-0.6	-0.41	Tandem gait;	chr1:200544290	chr1:200669507~200694250:+
PRAD	cis	rs4927850	0.958	rs1975582	ENSG00000242086.7	LINC00969	9.47	1.57e-19	1.25e-16	0.35	0.41	Pancreatic cancer;	chr3:196024568	chr3:195658062~195739964:+
PRAD	cis	rs7712401	0.715	rs436160	ENSG00000263432.2	RN7SL689P	-9.47	1.57e-19	1.25e-16	-0.42	-0.41	Mean platelet volume;	chr5:123020258	chr5:123022487~123022783:-
PRAD	cis	rs8072100	0.902	rs12051716	ENSG00000228782.6	CTD-2026D20.3	-9.47	1.58e-19	1.25e-16	-0.44	-0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47505029	chr17:47450568~47492492:-
PRAD	cis	rs9399137	0.507	rs10484496	ENSG00000232876.1	CTA-212D2.2	-9.47	1.58e-19	1.25e-16	-0.51	-0.41	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134978544	chr6:135055033~135060550:+
PRAD	cis	rs7189233	0.531	rs8046307	ENSG00000279344.1	RP11-44F14.7	9.46	1.6e-19	1.27e-16	0.37	0.41	Intelligence (multi-trait analysis);	chr16:53484774	chr16:53478957~53481550:-
PRAD	cis	rs732716	0.889	rs62129355	ENSG00000267769.1	CTB-50L17.9	-9.46	1.6e-19	1.27e-16	-0.45	-0.41	Mean corpuscular volume;	chr19:4397037	chr19:4454014~4455286:+
PRAD	cis	rs9309473	0.95	rs10206899	ENSG00000163016.8	ALMS1P	9.46	1.6e-19	1.27e-16	0.52	0.41	Metabolite levels;	chr2:73673773	chr2:73644919~73685576:+
PRAD	cis	rs6142102	1	rs6059672	ENSG00000276073.1	RP5-1125A11.7	-9.46	1.61e-19	1.28e-16	-0.42	-0.41	Skin pigmentation;	chr20:34117662	chr20:33985617~33988989:-
PRAD	cis	rs8072100	0.967	rs4794058	ENSG00000228782.6	CTD-2026D20.3	-9.46	1.61e-19	1.28e-16	-0.45	-0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47519732	chr17:47450568~47492492:-
PRAD	cis	rs3096299	0.967	rs2911257	ENSG00000274627.1	RP11-104N10.2	9.46	1.63e-19	1.29e-16	0.41	0.41	Multiple myeloma (IgH translocation);	chr16:89417726	chr16:89516797~89522217:+
PRAD	cis	rs9399135	0.773	rs1331308	ENSG00000232876.1	CTA-212D2.2	9.46	1.63e-19	1.29e-16	0.51	0.41	Red blood cell count;	chr6:135083984	chr6:135055033~135060550:+
PRAD	cis	rs58873874	0.737	rs10061544	ENSG00000251405.2	CTB-109A12.1	9.46	1.64e-19	1.3e-16	0.94	0.41	Bipolar disorder (body mass index interaction);	chr5:157383871	chr5:157362615~157460078:-
PRAD	cis	rs58873874	0.737	rs10078836	ENSG00000251405.2	CTB-109A12.1	9.46	1.64e-19	1.3e-16	0.94	0.41	Bipolar disorder (body mass index interaction);	chr5:157384604	chr5:157362615~157460078:-
PRAD	cis	rs8072100	0.869	rs4439799	ENSG00000228782.6	CTD-2026D20.3	9.46	1.66e-19	1.31e-16	0.45	0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47704233	chr17:47450568~47492492:-
PRAD	cis	rs2404602	0.967	rs7174096	ENSG00000259422.1	RP11-593F23.1	9.46	1.66e-19	1.32e-16	0.5	0.41	Blood metabolite levels;	chr15:76780059	chr15:76174891~76181486:-
PRAD	cis	rs11673344	0.796	rs16971886	ENSG00000226686.6	LINC01535	9.46	1.67e-19	1.32e-16	0.55	0.41	Obesity-related traits;	chr19:36997073	chr19:37251912~37265535:+
PRAD	cis	rs11673344	0.83	rs3745770	ENSG00000226686.6	LINC01535	9.46	1.67e-19	1.32e-16	0.55	0.41	Obesity-related traits;	chr19:36997663	chr19:37251912~37265535:+
PRAD	cis	rs62103177	0.683	rs62101232	ENSG00000261126.6	RP11-795F19.1	9.46	1.67e-19	1.32e-16	0.6	0.41	Opioid sensitivity;	chr18:79962454	chr18:80046900~80095482:+
PRAD	cis	rs2404602	0.967	rs7167613	ENSG00000259422.1	RP11-593F23.1	9.46	1.67e-19	1.32e-16	0.5	0.41	Blood metabolite levels;	chr15:76748851	chr15:76174891~76181486:-
PRAD	cis	rs7712401	0.715	rs6859163	ENSG00000263432.2	RN7SL689P	-9.46	1.67e-19	1.32e-16	-0.42	-0.41	Mean platelet volume;	chr5:123019225	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.715	rs385996	ENSG00000263432.2	RN7SL689P	-9.46	1.67e-19	1.32e-16	-0.42	-0.41	Mean platelet volume;	chr5:123019533	chr5:123022487~123022783:-
PRAD	cis	rs2108622	0.683	rs6512067	ENSG00000267453.5	AC004791.2	-9.46	1.68e-19	1.33e-16	-0.53	-0.41	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15872141	chr19:15851993~15864904:-
PRAD	cis	rs7772486	0.875	rs1331640	ENSG00000235652.6	RP11-545I5.3	9.46	1.68e-19	1.33e-16	0.42	0.41	Lobe attachment (rater-scored or self-reported);	chr6:146106114	chr6:145799409~145886585:+
PRAD	cis	rs17023223	0.537	rs2645292	ENSG00000231365.4	RP11-418J17.1	-9.46	1.68e-19	1.33e-16	-0.41	-0.41	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119030571	chr1:119140396~119275973:+
PRAD	cis	rs17023223	0.537	rs1057991	ENSG00000231365.4	RP11-418J17.1	-9.46	1.68e-19	1.33e-16	-0.41	-0.41	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119032547	chr1:119140396~119275973:+
PRAD	cis	rs17023223	0.537	rs1057990	ENSG00000231365.4	RP11-418J17.1	-9.46	1.68e-19	1.33e-16	-0.41	-0.41	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119032609	chr1:119140396~119275973:+
PRAD	cis	rs2729354	0.768	rs2848640	ENSG00000265566.2	RN7SL605P	-9.46	1.69e-19	1.33e-16	-0.6	-0.41	Blood protein levels;	chr11:57495207	chr11:57528085~57528365:-
PRAD	cis	rs10262624	1	rs13244265	ENSG00000234286.1	AC006026.13	-9.46	1.69e-19	1.34e-16	-0.46	-0.41	Schizophrenia;	chr7:23878284	chr7:23680195~23680786:-
PRAD	cis	rs7569084	0.64	rs11126039	ENSG00000281920.1	RP11-418H16.1	9.46	1.7e-19	1.35e-16	0.48	0.41	Sum eosinophil basophil counts;	chr2:65457953	chr2:65623272~65628424:+
PRAD	cis	rs7569084	0.687	rs11675538	ENSG00000281920.1	RP11-418H16.1	9.46	1.7e-19	1.35e-16	0.48	0.41	Sum eosinophil basophil counts;	chr2:65459327	chr2:65623272~65628424:+
PRAD	cis	rs3096299	0.632	rs8051537	ENSG00000261118.1	RP11-104N10.1	9.46	1.71e-19	1.35e-16	0.39	0.41	Multiple myeloma (IgH translocation);	chr16:89477976	chr16:89492017~89504460:-
PRAD	cis	rs1062177	1	rs72802204	ENSG00000253921.1	CTB-113P19.3	-9.46	1.71e-19	1.35e-16	-0.53	-0.41	Preschool internalizing problems;	chr5:151803622	chr5:151753992~151767247:+
PRAD	cis	rs7772486	0.738	rs75288066	ENSG00000235652.6	RP11-545I5.3	9.46	1.71e-19	1.36e-16	0.42	0.41	Lobe attachment (rater-scored or self-reported);	chr6:145998250	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.713	rs79248977	ENSG00000235652.6	RP11-545I5.3	9.46	1.71e-19	1.36e-16	0.42	0.41	Lobe attachment (rater-scored or self-reported);	chr6:145998252	chr6:145799409~145886585:+
PRAD	cis	rs8072100	0.701	rs10163469	ENSG00000228782.6	CTD-2026D20.3	-9.46	1.72e-19	1.36e-16	-0.45	-0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47610401	chr17:47450568~47492492:-
PRAD	cis	rs8072100	0.967	rs3760370	ENSG00000228782.6	CTD-2026D20.3	-9.46	1.72e-19	1.36e-16	-0.45	-0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47618466	chr17:47450568~47492492:-
PRAD	cis	rs4423214	0.592	rs11233933	ENSG00000254682.1	RP11-660L16.2	-9.46	1.72e-19	1.36e-16	-0.67	-0.41	Vitamin D levels;	chr11:71499024	chr11:71448674~71452157:+
PRAD	cis	rs3096299	0.658	rs34590044	ENSG00000261118.1	RP11-104N10.1	9.45	1.73e-19	1.37e-16	0.38	0.41	Multiple myeloma (IgH translocation);	chr16:89476749	chr16:89492017~89504460:-
PRAD	cis	rs7712401	0.623	rs30043	ENSG00000263432.2	RN7SL689P	9.45	1.74e-19	1.37e-16	0.42	0.41	Mean platelet volume;	chr5:122936598	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.601	rs185009	ENSG00000263432.2	RN7SL689P	9.45	1.74e-19	1.37e-16	0.42	0.41	Mean platelet volume;	chr5:122938072	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.541	rs42537	ENSG00000263432.2	RN7SL689P	9.45	1.74e-19	1.37e-16	0.42	0.41	Mean platelet volume;	chr5:122938993	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.58	rs185008	ENSG00000263432.2	RN7SL689P	9.45	1.74e-19	1.37e-16	0.42	0.41	Mean platelet volume;	chr5:122939039	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.58	rs30041	ENSG00000263432.2	RN7SL689P	9.45	1.74e-19	1.37e-16	0.42	0.41	Mean platelet volume;	chr5:122939658	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.58	rs42536	ENSG00000263432.2	RN7SL689P	9.45	1.74e-19	1.37e-16	0.42	0.41	Mean platelet volume;	chr5:122940728	chr5:123022487~123022783:-
PRAD	cis	rs7772486	0.875	rs10872583	ENSG00000235652.6	RP11-545I5.3	-9.45	1.74e-19	1.37e-16	-0.41	-0.41	Lobe attachment (rater-scored or self-reported);	chr6:146075563	chr6:145799409~145886585:+
PRAD	cis	rs7569084	0.687	rs1437462	ENSG00000281920.1	RP11-418H16.1	9.45	1.74e-19	1.38e-16	0.49	0.41	Sum eosinophil basophil counts;	chr2:65449559	chr2:65623272~65628424:+
PRAD	cis	rs7688540	0.771	rs11729365	ENSG00000275426.1	CH17-262A2.1	9.45	1.74e-19	1.38e-16	0.61	0.41	Facial morphology (factor 6, height of vermillion lower lip);	chr4:278735	chr4:149738~150317:+
PRAD	cis	rs9545047	0.604	rs9545054	ENSG00000227676.3	LINC01068	9.45	1.75e-19	1.39e-16	0.47	0.41	Schizophrenia;	chr13:79298833	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.547	rs2876739	ENSG00000227676.3	LINC01068	9.45	1.75e-19	1.39e-16	0.47	0.41	Schizophrenia;	chr13:79299057	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.567	rs7988331	ENSG00000227676.3	LINC01068	9.45	1.75e-19	1.39e-16	0.47	0.41	Schizophrenia;	chr13:79299745	chr13:79566727~79571436:+
PRAD	cis	rs9309473	0.95	rs2947860	ENSG00000163016.8	ALMS1P	9.45	1.77e-19	1.4e-16	0.5	0.41	Metabolite levels;	chr2:73628259	chr2:73644919~73685576:+
PRAD	cis	rs4774565	0.801	rs12911017	ENSG00000244879.4	GABPB1-AS1	-9.45	1.77e-19	1.4e-16	-0.38	-0.41	Breast cancer;	chr15:50375802	chr15:50354959~50372202:+
PRAD	cis	rs638893	1	rs28827279	ENSG00000278376.1	RP11-158I9.8	-9.45	1.77e-19	1.4e-16	-0.47	-0.41	Vitiligo;	chr11:118830054	chr11:118791254~118793137:+
PRAD	cis	rs7115242	0.858	rs6589592	ENSG00000254851.1	RP11-109L13.1	-9.45	1.78e-19	1.41e-16	-1.01	-0.41	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117087191	chr11:117135528~117138582:+
PRAD	cis	rs7772486	0.686	rs4896833	ENSG00000235652.6	RP11-545I5.3	9.45	1.79e-19	1.41e-16	0.42	0.41	Lobe attachment (rater-scored or self-reported);	chr6:145644537	chr6:145799409~145886585:+
PRAD	cis	rs7811142	0.943	rs67196635	ENSG00000242294.5	STAG3L5P	9.45	1.79e-19	1.42e-16	0.26	0.41	Platelet count;	chr7:100427941	chr7:100336079~100351900:+
PRAD	cis	rs7811142	1	rs6962151	ENSG00000242294.5	STAG3L5P	9.45	1.79e-19	1.42e-16	0.26	0.41	Platelet count;	chr7:100430861	chr7:100336079~100351900:+
PRAD	cis	rs7712401	0.645	rs246316	ENSG00000263432.2	RN7SL689P	9.45	1.8e-19	1.42e-16	0.42	0.41	Mean platelet volume;	chr5:122930502	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.601	rs246315	ENSG00000263432.2	RN7SL689P	9.45	1.8e-19	1.42e-16	0.42	0.41	Mean platelet volume;	chr5:122930743	chr5:123022487~123022783:-
PRAD	cis	rs7849270	0.959	rs3118628	ENSG00000268707.1	RP11-247A12.7	9.45	1.8e-19	1.42e-16	0.49	0.41	Blood metabolite ratios;	chr9:129123000	chr9:129170434~129170940:+
PRAD	cis	rs150992	0.632	rs1472622	ENSG00000248489.1	CTD-2007H13.3	-9.45	1.81e-19	1.43e-16	-0.44	-0.41	Body mass index;	chr5:99000749	chr5:98929171~98995013:+
PRAD	cis	rs7569084	0.663	rs1437461	ENSG00000281920.1	RP11-418H16.1	9.45	1.81e-19	1.43e-16	0.49	0.41	Sum eosinophil basophil counts;	chr2:65452578	chr2:65623272~65628424:+
PRAD	cis	rs7569084	0.687	rs7562559	ENSG00000281920.1	RP11-418H16.1	9.45	1.81e-19	1.43e-16	0.49	0.41	Sum eosinophil basophil counts;	chr2:65452719	chr2:65623272~65628424:+
PRAD	cis	rs6921919	0.638	rs7772827	ENSG00000216901.1	AL022393.7	9.45	1.81e-19	1.43e-16	0.53	0.41	Autism spectrum disorder or schizophrenia;	chr6:28333366	chr6:28176188~28176674:+
PRAD	cis	rs7615952	0.673	rs16834637	ENSG00000171084.14	FAM86JP	9.45	1.82e-19	1.43e-16	0.75	0.41	Blood pressure (smoking interaction);	chr3:125886628	chr3:125916620~125930024:+
PRAD	cis	rs765787	0.53	rs12905246	ENSG00000259520.4	CTD-2651B20.3	-9.45	1.82e-19	1.44e-16	-0.52	-0.4	Uric acid levels;	chr15:45208643	chr15:45251580~45279251:-
PRAD	cis	rs9322193	0.887	rs11155662	ENSG00000216906.2	RP11-350J20.9	9.45	1.83e-19	1.45e-16	0.48	0.4	Lung cancer;	chr6:149592731	chr6:149904243~149906418:+
PRAD	cis	rs6822297	0.504	rs7681802	ENSG00000240005.4	RP11-293A21.1	9.45	1.84e-19	1.46e-16	0.45	0.4	Obesity-related traits;	chr4:26989777	chr4:26859806~26860599:-
PRAD	cis	rs6822297	0.522	rs9998971	ENSG00000240005.4	RP11-293A21.1	9.45	1.84e-19	1.46e-16	0.45	0.4	Obesity-related traits;	chr4:27000082	chr4:26859806~26860599:-
PRAD	cis	rs6822297	0.504	rs12152700	ENSG00000240005.4	RP11-293A21.1	9.45	1.84e-19	1.46e-16	0.45	0.4	Obesity-related traits;	chr4:27005029	chr4:26859806~26860599:-
PRAD	cis	rs2882667	0.537	rs11743534	ENSG00000253404.1	AC034243.1	9.44	1.88e-19	1.48e-16	0.51	0.4	Age-related hearing impairment (SNP x SNP interaction);	chr5:139073318	chr5:138744434~138753309:-
PRAD	cis	rs1858037	0.867	rs1039765	ENSG00000204929.10	AC074391.1	-9.44	1.89e-19	1.49e-16	-0.55	-0.4	Rheumatoid arthritis;	chr2:65387228	chr2:65436711~66084639:+
PRAD	cis	rs4835473	0.897	rs6537170	ENSG00000251600.4	RP11-673E1.1	9.44	1.9e-19	1.5e-16	0.5	0.4	Immature fraction of reticulocytes;	chr4:143691747	chr4:143912331~143982454:+
PRAD	cis	rs6142102	1	rs4911409	ENSG00000276073.1	RP5-1125A11.7	-9.44	1.91e-19	1.51e-16	-0.4	-0.4	Skin pigmentation;	chr20:34122904	chr20:33985617~33988989:-
PRAD	cis	rs6142102	1	rs4911410	ENSG00000276073.1	RP5-1125A11.7	-9.44	1.91e-19	1.51e-16	-0.4	-0.4	Skin pigmentation;	chr20:34123168	chr20:33985617~33988989:-
PRAD	cis	rs10129255	0.5	rs6576231	ENSG00000223648.3	IGHV3-64	9.44	1.92e-19	1.51e-16	0.36	0.4	Kawasaki disease;	chr14:106783693	chr14:106643132~106658258:-
PRAD	cis	rs9399137	0.507	rs28384513	ENSG00000232876.1	CTA-212D2.2	-9.44	1.92e-19	1.51e-16	-0.51	-0.4	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135055071	chr6:135055033~135060550:+
PRAD	cis	rs11690935	0.55	rs6730085	ENSG00000228389.1	AC068039.4	-9.44	1.92e-19	1.52e-16	-0.45	-0.4	Schizophrenia;	chr2:171999938	chr2:171773482~171775844:+
PRAD	cis	rs7772486	0.738	rs9485039	ENSG00000235652.6	RP11-545I5.3	9.44	1.92e-19	1.52e-16	0.42	0.4	Lobe attachment (rater-scored or self-reported);	chr6:145998251	chr6:145799409~145886585:+
PRAD	cis	rs732716	0.813	rs760369	ENSG00000267769.1	CTB-50L17.9	9.44	1.93e-19	1.52e-16	0.44	0.4	Mean corpuscular volume;	chr19:4449290	chr19:4454014~4455286:+
PRAD	cis	rs765787	0.53	rs12906537	ENSG00000259520.4	CTD-2651B20.3	-9.44	1.93e-19	1.52e-16	-0.53	-0.4	Uric acid levels;	chr15:45227863	chr15:45251580~45279251:-
PRAD	cis	rs7309	0.935	rs6432674	ENSG00000235724.7	AC009299.2	-9.44	1.94e-19	1.53e-16	-0.48	-0.4	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161168811	chr2:161222785~161308303:-
PRAD	cis	rs2153535	0.526	rs9505487	ENSG00000230939.1	RP11-314C16.1	-9.44	1.94e-19	1.53e-16	-0.5	-0.4	Motion sickness;	chr6:8593521	chr6:8784178~8785445:+
PRAD	cis	rs765787	0.53	rs12915027	ENSG00000259520.4	CTD-2651B20.3	-9.44	1.95e-19	1.53e-16	-0.52	-0.4	Uric acid levels;	chr15:45220428	chr15:45251580~45279251:-
PRAD	cis	rs4927850	0.881	rs7624638	ENSG00000242086.7	LINC00969	9.44	1.95e-19	1.53e-16	0.35	0.4	Pancreatic cancer;	chr3:196021858	chr3:195658062~195739964:+
PRAD	cis	rs4927850	1	rs10881564	ENSG00000242086.7	LINC00969	9.44	1.95e-19	1.53e-16	0.35	0.4	Pancreatic cancer;	chr3:196023455	chr3:195658062~195739964:+
PRAD	cis	rs494459	0.504	rs7929520	ENSG00000255239.1	AP002954.6	9.44	1.96e-19	1.54e-16	0.52	0.4	Height;	chr11:118859432	chr11:118688039~118690600:-
PRAD	cis	rs4718428	0.705	rs11028	ENSG00000232546.1	RP11-458F8.1	-9.44	1.96e-19	1.54e-16	-0.32	-0.4	Corneal structure;	chr7:66811230	chr7:66848496~66858136:+
PRAD	cis	rs17608059	1	rs17608059	ENSG00000141028.6	CDRT15P1	-9.44	1.96e-19	1.55e-16	-0.51	-0.4	Temperament;	chr17:14007232	chr17:14024514~14025488:+
PRAD	cis	rs9309473	0.95	rs6726694	ENSG00000163016.8	ALMS1P	9.44	2e-19	1.57e-16	0.5	0.4	Metabolite levels;	chr2:73620103	chr2:73644919~73685576:+
PRAD	cis	rs7309	0.81	rs11684253	ENSG00000235724.7	AC009299.2	-9.44	2e-19	1.57e-16	-0.49	-0.4	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161178025	chr2:161222785~161308303:-
PRAD	cis	rs7712401	0.584	rs30037	ENSG00000263432.2	RN7SL689P	9.44	2e-19	1.58e-16	0.42	0.4	Mean platelet volume;	chr5:122942295	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.601	rs30035	ENSG00000263432.2	RN7SL689P	9.44	2e-19	1.58e-16	0.42	0.4	Mean platelet volume;	chr5:122942850	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.601	rs246306	ENSG00000263432.2	RN7SL689P	9.44	2e-19	1.58e-16	0.42	0.4	Mean platelet volume;	chr5:122943523	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.562	rs2927639	ENSG00000263432.2	RN7SL689P	9.44	2e-19	1.58e-16	0.42	0.4	Mean platelet volume;	chr5:122943971	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.601	rs246273	ENSG00000263432.2	RN7SL689P	9.44	2e-19	1.58e-16	0.42	0.4	Mean platelet volume;	chr5:122945280	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.601	rs30026	ENSG00000263432.2	RN7SL689P	9.44	2e-19	1.58e-16	0.42	0.4	Mean platelet volume;	chr5:122948873	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.601	rs30022	ENSG00000263432.2	RN7SL689P	9.44	2e-19	1.58e-16	0.42	0.4	Mean platelet volume;	chr5:122950021	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.546	rs30021	ENSG00000263432.2	RN7SL689P	9.44	2e-19	1.58e-16	0.42	0.4	Mean platelet volume;	chr5:122950199	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.601	rs246328	ENSG00000263432.2	RN7SL689P	9.44	2e-19	1.58e-16	0.42	0.4	Mean platelet volume;	chr5:122951933	chr5:123022487~123022783:-
PRAD	cis	rs2282300	0.739	rs1717772	ENSG00000242353.1	RP4-710M3.1	-9.44	2.01e-19	1.58e-16	-0.49	-0.4	Morning vs. evening chronotype;	chr11:30318586	chr11:30368148~30368646:+
PRAD	cis	rs150992	0.631	rs112047336	ENSG00000248489.1	CTD-2007H13.3	9.44	2.01e-19	1.58e-16	0.45	0.4	Body mass index;	chr5:98990041	chr5:98929171~98995013:+
PRAD	cis	rs6539288	0.63	rs10778519	ENSG00000260329.1	RP11-412D9.4	-9.44	2.01e-19	1.58e-16	-0.35	-0.4	Total body bone mineral density;	chr12:106963551	chr12:106954029~106955497:-
PRAD	cis	rs494459	0.536	rs7103067	ENSG00000255239.1	AP002954.6	9.44	2.01e-19	1.58e-16	0.52	0.4	Height;	chr11:118852670	chr11:118688039~118690600:-
PRAD	cis	rs10262624	1	rs10257777	ENSG00000234286.1	AC006026.13	-9.44	2.02e-19	1.59e-16	-0.46	-0.4	Schizophrenia;	chr7:23871362	chr7:23680195~23680786:-
PRAD	cis	rs4879677	1	rs10812637	ENSG00000260390.1	RP11-575I8.1	-9.44	2.02e-19	1.59e-16	-0.54	-0.4	Gut microbiome composition (summer and winter);	chr9:27664832	chr9:27829276~27844481:+
PRAD	cis	rs4835473	0.932	rs35164917	ENSG00000251600.4	RP11-673E1.1	9.44	2.02e-19	1.59e-16	0.51	0.4	Immature fraction of reticulocytes;	chr4:143748891	chr4:143912331~143982454:+
PRAD	cis	rs7189233	0.531	rs8055279	ENSG00000279344.1	RP11-44F14.7	9.43	2.04e-19	1.61e-16	0.37	0.4	Intelligence (multi-trait analysis);	chr16:53488837	chr16:53478957~53481550:-
PRAD	cis	rs638893	0.636	rs61901411	ENSG00000278376.1	RP11-158I9.8	9.43	2.04e-19	1.61e-16	0.54	0.4	Vitiligo;	chr11:118794615	chr11:118791254~118793137:+
PRAD	cis	rs2739330	0.828	rs4820572	ENSG00000099984.9	GSTT2	-9.43	2.05e-19	1.61e-16	-0.54	-0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23980123~23983911:+
PRAD	cis	rs7772486	0.686	rs9485019	ENSG00000235652.6	RP11-545I5.3	-9.43	2.06e-19	1.62e-16	-0.42	-0.4	Lobe attachment (rater-scored or self-reported);	chr6:145725245	chr6:145799409~145886585:+
PRAD	cis	rs2282300	0.739	rs1222219	ENSG00000242353.1	RP4-710M3.1	-9.43	2.07e-19	1.63e-16	-0.49	-0.4	Morning vs. evening chronotype;	chr11:30322798	chr11:30368148~30368646:+
PRAD	cis	rs9399137	0.507	rs61738647	ENSG00000232876.1	CTA-212D2.2	-9.43	2.07e-19	1.63e-16	-0.52	-0.4	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134961597	chr6:135055033~135060550:+
PRAD	cis	rs7772486	0.875	rs7767660	ENSG00000235652.6	RP11-545I5.3	9.43	2.08e-19	1.63e-16	0.41	0.4	Lobe attachment (rater-scored or self-reported);	chr6:146115414	chr6:145799409~145886585:+
PRAD	cis	rs12134133	0.962	rs7526658	ENSG00000274245.1	RP11-357P18.2	9.43	2.08e-19	1.63e-16	0.58	0.4	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207240098	chr1:207372559~207373252:+
PRAD	cis	rs1577917	0.687	rs34618171	ENSG00000203875.9	SNHG5	-9.43	2.09e-19	1.65e-16	-0.51	-0.4	Response to antipsychotic treatment;	chr6:86101447	chr6:85660950~85678736:-
PRAD	cis	rs2153535	0.585	rs6900539	ENSG00000230939.1	RP11-314C16.1	-9.43	2.1e-19	1.65e-16	-0.5	-0.4	Motion sickness;	chr6:8592054	chr6:8784178~8785445:+
PRAD	cis	rs62103177	0.525	rs4799116	ENSG00000261126.6	RP11-795F19.1	-9.43	2.1e-19	1.65e-16	-0.51	-0.4	Opioid sensitivity;	chr18:79976735	chr18:80046900~80095482:+
PRAD	cis	rs7772486	0.686	rs1569540	ENSG00000235652.6	RP11-545I5.3	-9.43	2.11e-19	1.66e-16	-0.41	-0.4	Lobe attachment (rater-scored or self-reported);	chr6:145747976	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.686	rs2142983	ENSG00000235652.6	RP11-545I5.3	-9.43	2.11e-19	1.66e-16	-0.41	-0.4	Lobe attachment (rater-scored or self-reported);	chr6:145748565	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.714	rs1883365	ENSG00000235652.6	RP11-545I5.3	-9.43	2.11e-19	1.66e-16	-0.41	-0.4	Lobe attachment (rater-scored or self-reported);	chr6:145755613	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.686	rs6933161	ENSG00000235652.6	RP11-545I5.3	-9.43	2.11e-19	1.66e-16	-0.41	-0.4	Lobe attachment (rater-scored or self-reported);	chr6:145760233	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.686	rs9399565	ENSG00000235652.6	RP11-545I5.3	-9.43	2.11e-19	1.66e-16	-0.41	-0.4	Lobe attachment (rater-scored or self-reported);	chr6:145760770	chr6:145799409~145886585:+
PRAD	cis	rs2274273	0.87	rs17741542	ENSG00000258413.1	RP11-665C16.6	9.43	2.11e-19	1.66e-16	0.53	0.4	Protein biomarker;	chr14:55339143	chr14:55262767~55272075:-
PRAD	cis	rs7189233	0.531	rs7199401	ENSG00000279344.1	RP11-44F14.7	9.43	2.11e-19	1.66e-16	0.36	0.4	Intelligence (multi-trait analysis);	chr16:53483038	chr16:53478957~53481550:-
PRAD	cis	rs2108622	0.727	rs62107770	ENSG00000267453.5	AC004791.2	-9.43	2.11e-19	1.66e-16	-0.53	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15874615	chr19:15851993~15864904:-
PRAD	cis	rs11673344	0.864	rs8110696	ENSG00000226686.6	LINC01535	9.43	2.12e-19	1.66e-16	0.57	0.4	Obesity-related traits;	chr19:37009449	chr19:37251912~37265535:+
PRAD	cis	rs9545047	0.604	rs7331867	ENSG00000227676.3	LINC01068	-9.43	2.12e-19	1.66e-16	-0.48	-0.4	Schizophrenia;	chr13:79418791	chr13:79566727~79571436:+
PRAD	cis	rs7712401	0.601	rs28892	ENSG00000263432.2	RN7SL689P	-9.43	2.12e-19	1.67e-16	-0.42	-0.4	Mean platelet volume;	chr5:122948131	chr5:123022487~123022783:-
PRAD	cis	rs1577917	1	rs6933377	ENSG00000203875.9	SNHG5	9.43	2.13e-19	1.67e-16	0.42	0.4	Response to antipsychotic treatment;	chr6:85995537	chr6:85660950~85678736:-
PRAD	cis	rs8177376	1	rs692955	ENSG00000254905.1	RP11-712L6.7	9.43	2.14e-19	1.68e-16	0.51	0.4	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126214601	chr11:126292922~126294254:-
PRAD	cis	rs1075265	0.572	rs3770405	ENSG00000233266.1	HMGB1P31	9.43	2.14e-19	1.68e-16	0.55	0.4	Chronotype;Morning vs. evening chronotype;	chr2:53694884	chr2:54051334~54051760:+
PRAD	cis	rs67311347	1	rs12494022	ENSG00000223797.4	ENTPD3-AS1	9.43	2.14e-19	1.68e-16	0.38	0.4	Renal cell carcinoma;	chr3:40385161	chr3:40313802~40453329:-
PRAD	cis	rs67311347	1	rs11714032	ENSG00000223797.4	ENTPD3-AS1	9.43	2.14e-19	1.68e-16	0.38	0.4	Renal cell carcinoma;	chr3:40390114	chr3:40313802~40453329:-
PRAD	cis	rs4927850	1	rs7625570	ENSG00000242086.7	LINC00969	9.43	2.15e-19	1.69e-16	0.35	0.4	Pancreatic cancer;	chr3:196020527	chr3:195658062~195739964:+
PRAD	cis	rs12134133	0.888	rs11580394	ENSG00000274245.1	RP11-357P18.2	9.43	2.16e-19	1.69e-16	0.58	0.4	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207238567	chr1:207372559~207373252:+
PRAD	cis	rs12134133	0.962	rs7516416	ENSG00000274245.1	RP11-357P18.2	9.43	2.16e-19	1.69e-16	0.58	0.4	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207241050	chr1:207372559~207373252:+
PRAD	cis	rs12134133	0.962	rs6673890	ENSG00000274245.1	RP11-357P18.2	9.43	2.16e-19	1.69e-16	0.58	0.4	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207241788	chr1:207372559~207373252:+
PRAD	cis	rs12134133	0.962	rs11120512	ENSG00000274245.1	RP11-357P18.2	-9.43	2.16e-19	1.69e-16	-0.58	-0.4	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207240370	chr1:207372559~207373252:+
PRAD	cis	rs8072100	0.666	rs9913503	ENSG00000228782.6	CTD-2026D20.3	9.43	2.16e-19	1.69e-16	0.45	0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47698964	chr17:47450568~47492492:-
PRAD	cis	rs9309473	0.948	rs10199224	ENSG00000163016.8	ALMS1P	9.43	2.17e-19	1.7e-16	0.5	0.4	Metabolite levels;	chr2:73534319	chr2:73644919~73685576:+
PRAD	cis	rs9309473	0.95	rs10178678	ENSG00000163016.8	ALMS1P	9.43	2.17e-19	1.7e-16	0.5	0.4	Metabolite levels;	chr2:73535109	chr2:73644919~73685576:+
PRAD	cis	rs853679	0.517	rs9468297	ENSG00000272009.1	RP1-313I6.12	-9.43	2.17e-19	1.7e-16	-0.41	-0.4	Depression;	chr6:28151096	chr6:28078792~28081130:-
PRAD	cis	rs4713118	0.869	rs4713121	ENSG00000280107.1	AL022393.9	-9.43	2.18e-19	1.71e-16	-0.51	-0.4	Parkinson's disease;	chr6:27754285	chr6:28170845~28172521:+
PRAD	cis	rs5760092	0.618	rs4461358	ENSG00000235689.1	AP000351.13	-9.43	2.18e-19	1.71e-16	-0.55	-0.4	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23917919	chr22:24006305~24008258:-
PRAD	cis	rs9326248	0.53	rs579890	ENSG00000254851.1	RP11-109L13.1	-9.42	2.21e-19	1.73e-16	-0.81	-0.4	Blood protein levels;	chr11:116928247	chr11:117135528~117138582:+
PRAD	cis	rs9389248	0.728	rs1022491	ENSG00000232876.1	CTA-212D2.2	9.42	2.22e-19	1.74e-16	0.52	0.4	High light scatter reticulocyte percentage of red cells;	chr6:134938228	chr6:135055033~135060550:+
PRAD	cis	rs7569084	0.687	rs7577452	ENSG00000281920.1	RP11-418H16.1	9.42	2.22e-19	1.74e-16	0.48	0.4	Sum eosinophil basophil counts;	chr2:65456694	chr2:65623272~65628424:+
PRAD	cis	rs321358	0.895	rs7110930	ENSG00000271584.1	RP11-89C3.4	-9.42	2.22e-19	1.74e-16	-0.61	-0.4	Body mass index;	chr11:111088556	chr11:111091932~111097357:-
PRAD	cis	rs7772486	0.686	rs9403741	ENSG00000235652.6	RP11-545I5.3	-9.42	2.23e-19	1.74e-16	-0.42	-0.4	Lobe attachment (rater-scored or self-reported);	chr6:145709412	chr6:145799409~145886585:+
PRAD	cis	rs2153535	0.585	rs9393057	ENSG00000230939.1	RP11-314C16.1	9.42	2.24e-19	1.75e-16	0.49	0.4	Motion sickness;	chr6:8668067	chr6:8784178~8785445:+
PRAD	cis	rs7189233	0.531	rs13337544	ENSG00000279344.1	RP11-44F14.7	9.42	2.24e-19	1.76e-16	0.37	0.4	Intelligence (multi-trait analysis);	chr16:53485123	chr16:53478957~53481550:-
PRAD	cis	rs9532669	0.926	rs4356344	ENSG00000176268.5	CYCSP34	9.42	2.24e-19	1.76e-16	0.44	0.4	Cervical cancer;	chr13:40874086	chr13:40863599~40863902:-
PRAD	cis	rs2282300	0.739	rs1616223	ENSG00000242353.1	RP4-710M3.1	-9.42	2.24e-19	1.76e-16	-0.49	-0.4	Morning vs. evening chronotype;	chr11:30317236	chr11:30368148~30368646:+
PRAD	cis	rs2564921	0.73	rs62255897	ENSG00000242142.1	SERBP1P3	-9.42	2.26e-19	1.77e-16	-0.48	-0.4	Height;	chr3:53029854	chr3:53064283~53065091:-
PRAD	cis	rs2348418	0.932	rs61922464	ENSG00000247934.4	RP11-967K21.1	9.42	2.28e-19	1.78e-16	0.38	0.4	Lung function (FEV1);Lung function (FVC);	chr12:28485665	chr12:28163298~28190738:-
PRAD	cis	rs2348418	0.932	rs11049661	ENSG00000247934.4	RP11-967K21.1	9.42	2.28e-19	1.78e-16	0.38	0.4	Lung function (FEV1);Lung function (FVC);	chr12:28486215	chr12:28163298~28190738:-
PRAD	cis	rs7182621	1	rs7182621	ENSG00000259363.4	CTD-2054N24.2	9.42	2.28e-19	1.78e-16	0.37	0.4	Colonoscopy-negative controls vs population controls;	chr15:99884400	chr15:99807023~99877148:+
PRAD	cis	rs7714584	1	rs1428555	ENSG00000197083.10	ZNF300P1	-9.42	2.29e-19	1.79e-16	-0.64	-0.4	Crohn's disease;	chr5:150877829	chr5:150930645~150946289:-
PRAD	cis	rs7772486	0.875	rs9399572	ENSG00000235652.6	RP11-545I5.3	9.42	2.29e-19	1.79e-16	0.41	0.4	Lobe attachment (rater-scored or self-reported);	chr6:146041809	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.817	rs9386145	ENSG00000235652.6	RP11-545I5.3	9.42	2.29e-19	1.79e-16	0.41	0.4	Lobe attachment (rater-scored or self-reported);	chr6:146042383	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.875	rs9390372	ENSG00000235652.6	RP11-545I5.3	9.42	2.29e-19	1.79e-16	0.41	0.4	Lobe attachment (rater-scored or self-reported);	chr6:146042502	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.875	rs9373483	ENSG00000235652.6	RP11-545I5.3	9.42	2.29e-19	1.79e-16	0.41	0.4	Lobe attachment (rater-scored or self-reported);	chr6:146043058	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.875	rs7766595	ENSG00000235652.6	RP11-545I5.3	9.42	2.29e-19	1.79e-16	0.41	0.4	Lobe attachment (rater-scored or self-reported);	chr6:146043371	chr6:145799409~145886585:+
PRAD	cis	rs7189233	0.531	rs8049033	ENSG00000279344.1	RP11-44F14.7	9.42	2.29e-19	1.8e-16	0.36	0.4	Intelligence (multi-trait analysis);	chr16:53479143	chr16:53478957~53481550:-
PRAD	cis	rs7772486	0.654	rs702321	ENSG00000235652.6	RP11-545I5.3	-9.42	2.3e-19	1.8e-16	-0.42	-0.4	Lobe attachment (rater-scored or self-reported);	chr6:145685559	chr6:145799409~145886585:+
PRAD	cis	rs6822297	0.504	rs9291487	ENSG00000240005.4	RP11-293A21.1	9.42	2.3e-19	1.8e-16	0.45	0.4	Obesity-related traits;	chr4:26965862	chr4:26859806~26860599:-
PRAD	cis	rs172166	0.694	rs1150666	ENSG00000280107.1	AL022393.9	-9.42	2.3e-19	1.8e-16	-0.5	-0.4	Cardiac Troponin-T levels;	chr6:28156150	chr6:28170845~28172521:+
PRAD	cis	rs1799810	0.64	rs55998444	ENSG00000236682.1	AC068282.3	-9.42	2.31e-19	1.81e-16	-0.5	-0.4	Self-rated health;	chr2:127362270	chr2:127389130~127400580:+
PRAD	cis	rs4718428	0.672	rs12530806	ENSG00000230295.1	RP11-458F8.2	-9.42	2.31e-19	1.81e-16	-0.31	-0.4	Corneal structure;	chr7:66925737	chr7:66880708~66882981:+
PRAD	cis	rs9309473	0.898	rs10201159	ENSG00000163016.8	ALMS1P	9.42	2.32e-19	1.81e-16	0.51	0.4	Metabolite levels;	chr2:73631838	chr2:73644919~73685576:+
PRAD	cis	rs1426063	0.668	rs6534595	ENSG00000249717.1	RP11-44F21.3	9.42	2.32e-19	1.81e-16	0.6	0.4	QT interval;	chr4:75104432	chr4:74955974~74970362:-
PRAD	cis	rs62103177	0.525	rs4799117	ENSG00000261126.6	RP11-795F19.1	-9.42	2.32e-19	1.82e-16	-0.52	-0.4	Opioid sensitivity;	chr18:79996604	chr18:80046900~80095482:+
PRAD	cis	rs62103177	0.525	rs4283293	ENSG00000261126.6	RP11-795F19.1	-9.42	2.32e-19	1.82e-16	-0.52	-0.4	Opioid sensitivity;	chr18:79999582	chr18:80046900~80095482:+
PRAD	cis	rs7772486	0.624	rs6930154	ENSG00000235652.6	RP11-545I5.3	-9.42	2.32e-19	1.82e-16	-0.41	-0.4	Lobe attachment (rater-scored or self-reported);	chr6:145704526	chr6:145799409~145886585:+
PRAD	cis	rs7712401	0.601	rs246285	ENSG00000263432.2	RN7SL689P	-9.42	2.33e-19	1.83e-16	-0.4	-0.4	Mean platelet volume;	chr5:122909273	chr5:123022487~123022783:-
PRAD	cis	rs732716	0.853	rs72990643	ENSG00000267769.1	CTB-50L17.9	-9.42	2.34e-19	1.83e-16	-0.44	-0.4	Mean corpuscular volume;	chr19:4454739	chr19:4454014~4455286:+
PRAD	cis	rs2337406	0.866	rs78462736	ENSG00000274576.2	IGHV2-70	-9.42	2.35e-19	1.84e-16	-0.43	-0.4	Alzheimer's disease (late onset);	chr14:106779942	chr14:106770577~106771020:-
PRAD	cis	rs2337406	0.866	rs8016203	ENSG00000274576.2	IGHV2-70	-9.42	2.35e-19	1.84e-16	-0.43	-0.4	Alzheimer's disease (late onset);	chr14:106780575	chr14:106770577~106771020:-
PRAD	cis	rs12134133	1	rs6660557	ENSG00000274245.1	RP11-357P18.2	9.42	2.36e-19	1.84e-16	0.56	0.4	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207281251	chr1:207372559~207373252:+
PRAD	cis	rs12134133	1	rs7521457	ENSG00000274245.1	RP11-357P18.2	9.42	2.36e-19	1.84e-16	0.56	0.4	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207283802	chr1:207372559~207373252:+
PRAD	cis	rs12134133	1	rs7553157	ENSG00000274245.1	RP11-357P18.2	9.42	2.36e-19	1.84e-16	0.56	0.4	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207283922	chr1:207372559~207373252:+
PRAD	cis	rs12134133	1	rs7553339	ENSG00000274245.1	RP11-357P18.2	9.42	2.36e-19	1.84e-16	0.56	0.4	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207284075	chr1:207372559~207373252:+
PRAD	cis	rs12134133	1	rs12134133	ENSG00000274245.1	RP11-357P18.2	9.42	2.36e-19	1.84e-16	0.56	0.4	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207284500	chr1:207372559~207373252:+
PRAD	cis	rs12134133	1	rs6668683	ENSG00000274245.1	RP11-357P18.2	9.42	2.36e-19	1.84e-16	0.56	0.4	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207285846	chr1:207372559~207373252:+
PRAD	cis	rs12134133	1	rs10494889	ENSG00000274245.1	RP11-357P18.2	9.42	2.36e-19	1.84e-16	0.56	0.4	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207286963	chr1:207372559~207373252:+
PRAD	cis	rs150992	0.609	rs447044	ENSG00000248489.1	CTD-2007H13.3	9.42	2.36e-19	1.84e-16	0.44	0.4	Body mass index;	chr5:98995572	chr5:98929171~98995013:+
PRAD	cis	rs200972	1	rs200972	ENSG00000216901.1	AL022393.7	9.42	2.36e-19	1.85e-16	0.52	0.4	Urinary tract infection frequency;	chr6:27891059	chr6:28176188~28176674:+
PRAD	cis	rs34375054	0.624	rs12832525	ENSG00000279233.1	RP11-158L12.4	9.41	2.39e-19	1.87e-16	0.41	0.4	Post bronchodilator FEV1/FVC ratio;	chr12:125195820	chr12:125138245~125141711:+
PRAD	cis	rs34375054	0.624	rs7295689	ENSG00000279233.1	RP11-158L12.4	9.41	2.39e-19	1.87e-16	0.41	0.4	Post bronchodilator FEV1/FVC ratio;	chr12:125196376	chr12:125138245~125141711:+
PRAD	cis	rs7811142	0.943	rs67483801	ENSG00000242294.5	STAG3L5P	9.41	2.4e-19	1.88e-16	0.26	0.4	Platelet count;	chr7:100434135	chr7:100336079~100351900:+
PRAD	cis	rs7811142	1	rs11761784	ENSG00000242294.5	STAG3L5P	9.41	2.4e-19	1.88e-16	0.26	0.4	Platelet count;	chr7:100442347	chr7:100336079~100351900:+
PRAD	cis	rs7712401	0.601	rs30027	ENSG00000263432.2	RN7SL689P	9.41	2.41e-19	1.88e-16	0.42	0.4	Mean platelet volume;	chr5:122947695	chr5:123022487~123022783:-
PRAD	cis	rs2933343	0.716	rs9872706	ENSG00000261159.1	RP11-723O4.9	-9.41	2.41e-19	1.88e-16	-0.4	-0.4	IgG glycosylation;	chr3:128848262	chr3:128859716~128860526:-
PRAD	cis	rs9309473	1	rs10189574	ENSG00000163016.8	ALMS1P	9.41	2.43e-19	1.9e-16	0.5	0.4	Metabolite levels;	chr2:73471391	chr2:73644919~73685576:+
PRAD	cis	rs9309473	1	rs7572722	ENSG00000163016.8	ALMS1P	9.41	2.45e-19	1.91e-16	0.5	0.4	Metabolite levels;	chr2:73497548	chr2:73644919~73685576:+
PRAD	cis	rs9309473	1	rs6753344	ENSG00000163016.8	ALMS1P	-9.41	2.46e-19	1.92e-16	-0.49	-0.4	Metabolite levels;	chr2:73426010	chr2:73644919~73685576:+
PRAD	cis	rs8062405	0.69	rs62034351	ENSG00000259982.1	CDC37P1	9.41	2.47e-19	1.93e-16	0.54	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554168	chr16:28700294~28701540:-
PRAD	cis	rs507080	0.922	rs478296	ENSG00000255422.1	AP002954.4	-9.41	2.47e-19	1.93e-16	-0.5	-0.4	Serum metabolite levels;	chr11:118696666	chr11:118704607~118750263:+
PRAD	cis	rs507080	0.922	rs493834	ENSG00000255422.1	AP002954.4	-9.41	2.47e-19	1.93e-16	-0.5	-0.4	Serum metabolite levels;	chr11:118696735	chr11:118704607~118750263:+
PRAD	cis	rs507080	0.922	rs644498	ENSG00000255422.1	AP002954.4	-9.41	2.47e-19	1.93e-16	-0.5	-0.4	Serum metabolite levels;	chr11:118696777	chr11:118704607~118750263:+
PRAD	cis	rs7772486	0.875	rs7766463	ENSG00000235652.6	RP11-545I5.3	9.41	2.48e-19	1.94e-16	0.41	0.4	Lobe attachment (rater-scored or self-reported);	chr6:146043317	chr6:145799409~145886585:+
PRAD	cis	rs732716	0.853	rs1127888	ENSG00000267769.1	CTB-50L17.9	-9.41	2.49e-19	1.94e-16	-0.44	-0.4	Mean corpuscular volume;	chr19:4454086	chr19:4454014~4455286:+
PRAD	cis	rs172166	0.694	rs1225716	ENSG00000280107.1	AL022393.9	-9.41	2.49e-19	1.95e-16	-0.5	-0.4	Cardiac Troponin-T levels;	chr6:28145968	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.512	rs2622319	ENSG00000280107.1	AL022393.9	-9.41	2.49e-19	1.95e-16	-0.5	-0.4	Parkinson's disease;	chr6:28152623	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.517	rs9393893	ENSG00000272009.1	RP1-313I6.12	-9.41	2.5e-19	1.95e-16	-0.41	-0.4	Depression;	chr6:28141484	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs4713146	ENSG00000272009.1	RP1-313I6.12	-9.41	2.5e-19	1.95e-16	-0.41	-0.4	Depression;	chr6:28143758	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs9393894	ENSG00000272009.1	RP1-313I6.12	-9.41	2.5e-19	1.95e-16	-0.41	-0.4	Depression;	chr6:28144784	chr6:28078792~28081130:-
PRAD	cis	rs4927850	1	rs10881563	ENSG00000242086.7	LINC00969	9.41	2.5e-19	1.95e-16	0.36	0.4	Pancreatic cancer;	chr3:196023354	chr3:195658062~195739964:+
PRAD	cis	rs34375054	0.624	rs12826658	ENSG00000279233.1	RP11-158L12.4	9.41	2.52e-19	1.96e-16	0.41	0.4	Post bronchodilator FEV1/FVC ratio;	chr12:125195691	chr12:125138245~125141711:+
PRAD	cis	rs7712401	0.562	rs246267	ENSG00000263432.2	RN7SL689P	9.41	2.52e-19	1.96e-16	0.41	0.4	Mean platelet volume;	chr5:122920409	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.601	rs246269	ENSG00000263432.2	RN7SL689P	9.41	2.52e-19	1.96e-16	0.41	0.4	Mean platelet volume;	chr5:122921046	chr5:123022487~123022783:-
PRAD	cis	rs6452524	0.532	rs26263	ENSG00000249664.1	CTD-2227C6.2	9.41	2.53e-19	1.98e-16	0.49	0.4	Hypertension (SNP x SNP interaction);	chr5:83044465	chr5:83012285~83013109:-
PRAD	cis	rs1134634	1	rs1134634	ENSG00000273133.1	RP11-799M12.2	9.41	2.53e-19	1.98e-16	0.5	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15601446	chr4:15563698~15564253:-
PRAD	cis	rs7569084	0.687	rs934731	ENSG00000281920.1	RP11-418H16.1	9.41	2.54e-19	1.98e-16	0.48	0.4	Sum eosinophil basophil counts;	chr2:65456353	chr2:65623272~65628424:+
PRAD	cis	rs4713118	0.786	rs200503	ENSG00000280107.1	AL022393.9	-9.41	2.54e-19	1.98e-16	-0.51	-0.4	Parkinson's disease;	chr6:27818104	chr6:28170845~28172521:+
PRAD	cis	rs11168854	0.93	rs10783302	ENSG00000258017.1	RP11-386G11.10	9.41	2.55e-19	1.99e-16	0.52	0.4	Body mass index;	chr12:49104347	chr12:49127782~49147869:+
PRAD	cis	rs10129255	0.5	rs8006888	ENSG00000223648.3	IGHV3-64	9.41	2.55e-19	1.99e-16	0.35	0.4	Kawasaki disease;	chr14:106782219	chr14:106643132~106658258:-
PRAD	cis	rs12134133	0.962	rs6682586	ENSG00000274245.1	RP11-357P18.2	9.4	2.59e-19	2.02e-16	0.58	0.4	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207243122	chr1:207372559~207373252:+
PRAD	cis	rs12134133	0.962	rs6668560	ENSG00000274245.1	RP11-357P18.2	9.4	2.59e-19	2.02e-16	0.58	0.4	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207243462	chr1:207372559~207373252:+
PRAD	cis	rs7772486	0.846	rs866473	ENSG00000235652.6	RP11-545I5.3	9.4	2.59e-19	2.02e-16	0.41	0.4	Lobe attachment (rater-scored or self-reported);	chr6:146032278	chr6:145799409~145886585:+
PRAD	cis	rs7189233	0.531	rs7202621	ENSG00000279344.1	RP11-44F14.7	9.4	2.6e-19	2.03e-16	0.36	0.4	Intelligence (multi-trait analysis);	chr16:53452125	chr16:53478957~53481550:-
PRAD	cis	rs7772486	0.84	rs2814867	ENSG00000235652.6	RP11-545I5.3	9.4	2.62e-19	2.04e-16	0.41	0.4	Lobe attachment (rater-scored or self-reported);	chr6:146012894	chr6:145799409~145886585:+
PRAD	cis	rs2274273	0.84	rs11626751	ENSG00000258413.1	RP11-665C16.6	-9.4	2.65e-19	2.06e-16	-0.52	-0.4	Protein biomarker;	chr14:55368509	chr14:55262767~55272075:-
PRAD	cis	rs9326248	0.569	rs4938315	ENSG00000254851.1	RP11-109L13.1	-9.4	2.65e-19	2.06e-16	-0.8	-0.4	Blood protein levels;	chr11:116860489	chr11:117135528~117138582:+
PRAD	cis	rs853679	0.513	rs9468296	ENSG00000272009.1	RP1-313I6.12	-9.4	2.65e-19	2.06e-16	-0.41	-0.4	Depression;	chr6:28145952	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs4711164	ENSG00000272009.1	RP1-313I6.12	-9.4	2.65e-19	2.06e-16	-0.41	-0.4	Depression;	chr6:28147378	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs4711165	ENSG00000272009.1	RP1-313I6.12	-9.4	2.65e-19	2.06e-16	-0.41	-0.4	Depression;	chr6:28147406	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs4713148	ENSG00000272009.1	RP1-313I6.12	-9.4	2.65e-19	2.06e-16	-0.41	-0.4	Depression;	chr6:28148143	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs9348794	ENSG00000272009.1	RP1-313I6.12	-9.4	2.65e-19	2.06e-16	-0.41	-0.4	Depression;	chr6:28149979	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs9295758	ENSG00000272009.1	RP1-313I6.12	-9.4	2.65e-19	2.06e-16	-0.41	-0.4	Depression;	chr6:28152885	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs17774663	ENSG00000272009.1	RP1-313I6.12	-9.4	2.65e-19	2.06e-16	-0.41	-0.4	Depression;	chr6:28153120	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs9468298	ENSG00000272009.1	RP1-313I6.12	-9.4	2.65e-19	2.06e-16	-0.41	-0.4	Depression;	chr6:28154567	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs9295759	ENSG00000272009.1	RP1-313I6.12	-9.4	2.65e-19	2.06e-16	-0.41	-0.4	Depression;	chr6:28156691	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs9348796	ENSG00000272009.1	RP1-313I6.12	-9.4	2.65e-19	2.06e-16	-0.41	-0.4	Depression;	chr6:28158424	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs11552219	ENSG00000272009.1	RP1-313I6.12	-9.4	2.65e-19	2.06e-16	-0.41	-0.4	Depression;	chr6:28159056	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs9380058	ENSG00000272009.1	RP1-313I6.12	-9.4	2.65e-19	2.06e-16	-0.41	-0.4	Depression;	chr6:28159666	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs9393895	ENSG00000272009.1	RP1-313I6.12	-9.4	2.65e-19	2.06e-16	-0.41	-0.4	Depression;	chr6:28159843	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs9393896	ENSG00000272009.1	RP1-313I6.12	-9.4	2.65e-19	2.06e-16	-0.41	-0.4	Depression;	chr6:28159925	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs9393897	ENSG00000272009.1	RP1-313I6.12	-9.4	2.65e-19	2.06e-16	-0.41	-0.4	Depression;	chr6:28159932	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs9357066	ENSG00000272009.1	RP1-313I6.12	-9.4	2.65e-19	2.06e-16	-0.41	-0.4	Depression;	chr6:28162053	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs9393898	ENSG00000272009.1	RP1-313I6.12	-9.4	2.65e-19	2.06e-16	-0.41	-0.4	Depression;	chr6:28162598	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs9368556	ENSG00000272009.1	RP1-313I6.12	-9.4	2.65e-19	2.06e-16	-0.41	-0.4	Depression;	chr6:28163375	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs9368557	ENSG00000272009.1	RP1-313I6.12	-9.4	2.65e-19	2.06e-16	-0.41	-0.4	Depression;	chr6:28163759	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs9380059	ENSG00000272009.1	RP1-313I6.12	-9.4	2.65e-19	2.06e-16	-0.41	-0.4	Depression;	chr6:28164580	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs9380060	ENSG00000272009.1	RP1-313I6.12	-9.4	2.65e-19	2.06e-16	-0.41	-0.4	Depression;	chr6:28164825	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs35227624	ENSG00000272009.1	RP1-313I6.12	-9.4	2.65e-19	2.06e-16	-0.41	-0.4	Depression;	chr6:28164948	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs9380061	ENSG00000272009.1	RP1-313I6.12	-9.4	2.65e-19	2.06e-16	-0.41	-0.4	Depression;	chr6:28165025	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs9368558	ENSG00000272009.1	RP1-313I6.12	-9.4	2.65e-19	2.06e-16	-0.41	-0.4	Depression;	chr6:28165528	chr6:28078792~28081130:-
PRAD	cis	rs4713118	0.587	rs9393899	ENSG00000272009.1	RP1-313I6.12	-9.4	2.65e-19	2.06e-16	-0.41	-0.4	Parkinson's disease;	chr6:28165750	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs4713150	ENSG00000272009.1	RP1-313I6.12	-9.4	2.65e-19	2.06e-16	-0.41	-0.4	Depression;	chr6:28168434	chr6:28078792~28081130:-
PRAD	cis	rs4713118	0.527	rs4713151	ENSG00000272009.1	RP1-313I6.12	-9.4	2.65e-19	2.06e-16	-0.41	-0.4	Parkinson's disease;	chr6:28168578	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs9393901	ENSG00000272009.1	RP1-313I6.12	-9.4	2.65e-19	2.06e-16	-0.41	-0.4	Depression;	chr6:28169019	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs3173443	ENSG00000272009.1	RP1-313I6.12	-9.4	2.65e-19	2.06e-16	-0.41	-0.4	Depression;	chr6:28169249	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs4713152	ENSG00000272009.1	RP1-313I6.12	-9.4	2.65e-19	2.06e-16	-0.41	-0.4	Depression;	chr6:28169676	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs9348797	ENSG00000272009.1	RP1-313I6.12	-9.4	2.65e-19	2.06e-16	-0.41	-0.4	Depression;	chr6:28169755	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs9380062	ENSG00000272009.1	RP1-313I6.12	-9.4	2.65e-19	2.06e-16	-0.41	-0.4	Depression;	chr6:28169791	chr6:28078792~28081130:-
PRAD	cis	rs1075265	0.73	rs805392	ENSG00000233266.1	HMGB1P31	9.4	2.66e-19	2.07e-16	0.54	0.4	Chronotype;Morning vs. evening chronotype;	chr2:53877594	chr2:54051334~54051760:+
PRAD	cis	rs2933343	1	rs2933343	ENSG00000261159.1	RP11-723O4.9	9.4	2.68e-19	2.09e-16	0.38	0.4	IgG glycosylation;	chr3:128939649	chr3:128859716~128860526:-
PRAD	cis	rs494459	0.536	rs11217063	ENSG00000255239.1	AP002954.6	9.4	2.68e-19	2.09e-16	0.52	0.4	Height;	chr11:118855233	chr11:118688039~118690600:-
PRAD	cis	rs494459	0.536	rs11217065	ENSG00000255239.1	AP002954.6	9.4	2.68e-19	2.09e-16	0.52	0.4	Height;	chr11:118855938	chr11:118688039~118690600:-
PRAD	cis	rs11676348	0.772	rs7422358	ENSG00000261338.2	RP11-378A13.1	-9.4	2.69e-19	2.09e-16	-0.43	-0.4	Ulcerative colitis;	chr2:218088055	chr2:218255319~218257366:+
PRAD	cis	rs9309473	0.66	rs17349321	ENSG00000163016.8	ALMS1P	9.4	2.69e-19	2.09e-16	0.59	0.4	Metabolite levels;	chr2:73416625	chr2:73644919~73685576:+
PRAD	cis	rs2564921	0.704	rs62255931	ENSG00000242142.1	SERBP1P3	-9.4	2.7e-19	2.1e-16	-0.47	-0.4	Height;	chr3:53097932	chr3:53064283~53065091:-
PRAD	cis	rs150992	0.587	rs4703052	ENSG00000248489.1	CTD-2007H13.3	-9.4	2.71e-19	2.11e-16	-0.44	-0.4	Body mass index;	chr5:99008818	chr5:98929171~98995013:+
PRAD	cis	rs6142102	0.812	rs6059574	ENSG00000276073.1	RP5-1125A11.7	9.4	2.72e-19	2.11e-16	0.4	0.4	Skin pigmentation;	chr20:33935366	chr20:33985617~33988989:-
PRAD	cis	rs9660180	0.62	rs3817856	ENSG00000231050.1	RP1-140A9.1	-9.4	2.72e-19	2.12e-16	-0.46	-0.4	Body mass index;	chr1:1732392	chr1:1891471~1892658:+
PRAD	cis	rs2153535	0.585	rs7739573	ENSG00000230939.1	RP11-314C16.1	9.4	2.73e-19	2.13e-16	0.5	0.4	Motion sickness;	chr6:8659671	chr6:8784178~8785445:+
PRAD	cis	rs765787	0.53	rs12904265	ENSG00000259520.4	CTD-2651B20.3	-9.4	2.74e-19	2.13e-16	-0.52	-0.4	Uric acid levels;	chr15:45234515	chr15:45251580~45279251:-
PRAD	cis	rs765787	0.53	rs2899379	ENSG00000259520.4	CTD-2651B20.3	-9.4	2.74e-19	2.13e-16	-0.52	-0.4	Uric acid levels;	chr15:45242601	chr15:45251580~45279251:-
PRAD	cis	rs1426063	0.614	rs17266308	ENSG00000249717.1	RP11-44F21.3	-9.4	2.74e-19	2.13e-16	-0.81	-0.4	QT interval;	chr4:75137695	chr4:74955974~74970362:-
PRAD	cis	rs10129255	0.576	rs2157616	ENSG00000223648.3	IGHV3-64	9.4	2.74e-19	2.13e-16	0.36	0.4	Kawasaki disease;	chr14:106767802	chr14:106643132~106658258:-
PRAD	cis	rs9322193	0.607	rs9322229	ENSG00000216906.2	RP11-350J20.9	9.4	2.75e-19	2.14e-16	0.52	0.4	Lung cancer;	chr6:149908949	chr6:149904243~149906418:+
PRAD	cis	rs67311347	1	rs977652	ENSG00000223797.4	ENTPD3-AS1	9.4	2.75e-19	2.14e-16	0.36	0.4	Renal cell carcinoma;	chr3:40437678	chr3:40313802~40453329:-
PRAD	cis	rs1426063	0.748	rs7654088	ENSG00000249717.1	RP11-44F21.3	-9.4	2.77e-19	2.15e-16	-0.59	-0.4	QT interval;	chr4:75107103	chr4:74955974~74970362:-
PRAD	cis	rs4879677	1	rs10968045	ENSG00000260390.1	RP11-575I8.1	-9.4	2.77e-19	2.16e-16	-0.54	-0.4	Gut microbiome composition (summer and winter);	chr9:27674262	chr9:27829276~27844481:+
PRAD	cis	rs4879677	1	rs10968046	ENSG00000260390.1	RP11-575I8.1	-9.4	2.77e-19	2.16e-16	-0.54	-0.4	Gut microbiome composition (summer and winter);	chr9:27674369	chr9:27829276~27844481:+
PRAD	cis	rs2282300	0.739	rs7925340	ENSG00000242353.1	RP4-710M3.1	9.39	2.79e-19	2.17e-16	0.49	0.4	Morning vs. evening chronotype;	chr11:30258861	chr11:30368148~30368646:+
PRAD	cis	rs4380275	0.965	rs12621177	ENSG00000223751.1	AC116609.2	9.39	2.8e-19	2.18e-16	0.51	0.4	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:757786	chr2:742488~747767:+
PRAD	cis	rs4380275	1	rs4854376	ENSG00000223751.1	AC116609.2	9.39	2.8e-19	2.18e-16	0.51	0.4	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:763683	chr2:742488~747767:+
PRAD	cis	rs2108622	0.727	rs2158511	ENSG00000267453.5	AC004791.2	-9.39	2.8e-19	2.18e-16	-0.53	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15875837	chr19:15851993~15864904:-
PRAD	cis	rs2108622	0.727	rs3093216	ENSG00000267453.5	AC004791.2	-9.39	2.8e-19	2.18e-16	-0.53	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15876927	chr19:15851993~15864904:-
PRAD	cis	rs2108622	0.701	rs3093209	ENSG00000267453.5	AC004791.2	-9.39	2.8e-19	2.18e-16	-0.53	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15877610	chr19:15851993~15864904:-
PRAD	cis	rs2108622	0.727	rs3093207	ENSG00000267453.5	AC004791.2	-9.39	2.8e-19	2.18e-16	-0.53	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15877848	chr19:15851993~15864904:-
PRAD	cis	rs765787	0.53	rs12440321	ENSG00000259520.4	CTD-2651B20.3	-9.39	2.83e-19	2.2e-16	-0.52	-0.4	Uric acid levels;	chr15:45237187	chr15:45251580~45279251:-
PRAD	cis	rs2108622	0.785	rs3093199	ENSG00000267453.5	AC004791.2	-9.39	2.83e-19	2.2e-16	-0.53	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15879061	chr19:15851993~15864904:-
PRAD	cis	rs12134133	1	rs10494890	ENSG00000274245.1	RP11-357P18.2	-9.39	2.83e-19	2.2e-16	-0.57	-0.4	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207251041	chr1:207372559~207373252:+
PRAD	cis	rs2108622	0.727	rs55954696	ENSG00000267453.5	AC004791.2	-9.39	2.86e-19	2.22e-16	-0.52	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15870995	chr19:15851993~15864904:-
PRAD	cis	rs9309473	1	rs56154726	ENSG00000163016.8	ALMS1P	9.39	2.86e-19	2.22e-16	0.5	0.4	Metabolite levels;	chr2:73494640	chr2:73644919~73685576:+
PRAD	cis	rs17023223	0.581	rs2765529	ENSG00000231365.4	RP11-418J17.1	-9.39	2.88e-19	2.24e-16	-0.41	-0.4	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119039277	chr1:119140396~119275973:+
PRAD	cis	rs7189233	0.531	rs4783813	ENSG00000279344.1	RP11-44F14.7	9.39	2.95e-19	2.29e-16	0.37	0.4	Intelligence (multi-trait analysis);	chr16:53484458	chr16:53478957~53481550:-
PRAD	cis	rs12134133	1	rs7522618	ENSG00000274245.1	RP11-357P18.2	9.39	2.96e-19	2.3e-16	0.58	0.4	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207244081	chr1:207372559~207373252:+
PRAD	cis	rs524281	1	rs527897	ENSG00000255320.1	RP11-755F10.1	9.39	2.97e-19	2.3e-16	0.57	0.4	Electroencephalogram traits;	chr11:66133306	chr11:66244840~66246239:-
PRAD	cis	rs6570726	0.846	rs397311	ENSG00000235652.6	RP11-545I5.3	-9.39	2.97e-19	2.31e-16	-0.42	-0.4	Lobe attachment (rater-scored or self-reported);	chr6:145485565	chr6:145799409~145886585:+
PRAD	cis	rs11673344	0.797	rs3745768	ENSG00000226686.6	LINC01535	9.39	2.97e-19	2.31e-16	0.55	0.4	Obesity-related traits;	chr19:36997907	chr19:37251912~37265535:+
PRAD	cis	rs9595066	0.627	rs9562536	ENSG00000227258.4	SMIM2-AS1	9.39	2.98e-19	2.31e-16	0.67	0.4	Schizophrenia;	chr13:44157452	chr13:44110451~44240517:+
PRAD	cis	rs7772486	0.686	rs2328708	ENSG00000235652.6	RP11-545I5.3	-9.39	2.98e-19	2.31e-16	-0.42	-0.4	Lobe attachment (rater-scored or self-reported);	chr6:145774603	chr6:145799409~145886585:+
PRAD	cis	rs1426063	0.614	rs17000264	ENSG00000260265.1	RP11-44F21.5	9.39	2.99e-19	2.32e-16	0.81	0.4	QT interval;	chr4:75108962	chr4:75081702~75084717:-
PRAD	cis	rs12134133	1	rs7532664	ENSG00000274245.1	RP11-357P18.2	9.39	2.99e-19	2.32e-16	0.57	0.4	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207253598	chr1:207372559~207373252:+
PRAD	cis	rs3096299	0.728	rs1011749	ENSG00000261118.1	RP11-104N10.1	9.39	3.01e-19	2.34e-16	0.39	0.4	Multiple myeloma (IgH translocation);	chr16:89444461	chr16:89492017~89504460:-
PRAD	cis	rs11951515	0.738	rs7720681	ENSG00000188850.9	RP11-159F24.2	-9.38	3.02e-19	2.34e-16	-0.49	-0.4	Metabolite levels  (X-11787);	chr5:43373205	chr5:43336164~43348716:+
PRAD	cis	rs494459	0.536	rs57719838	ENSG00000255239.1	AP002954.6	9.38	3.02e-19	2.34e-16	0.52	0.4	Height;	chr11:118854014	chr11:118688039~118690600:-
PRAD	cis	rs4879677	1	rs10435785	ENSG00000260390.1	RP11-575I8.1	-9.38	3.02e-19	2.34e-16	-0.55	-0.4	Gut microbiome composition (summer and winter);	chr9:27683815	chr9:27829276~27844481:+
PRAD	cis	rs2337406	0.866	rs2301536	ENSG00000274576.2	IGHV2-70	-9.38	3.02e-19	2.34e-16	-0.43	-0.4	Alzheimer's disease (late onset);	chr14:106790636	chr14:106770577~106771020:-
PRAD	cis	rs2337406	0.866	rs7144369	ENSG00000274576.2	IGHV2-70	-9.38	3.02e-19	2.34e-16	-0.43	-0.4	Alzheimer's disease (late onset);	chr14:106793065	chr14:106770577~106771020:-
PRAD	cis	rs2337406	0.866	rs78525520	ENSG00000274576.2	IGHV2-70	-9.38	3.02e-19	2.34e-16	-0.43	-0.4	Alzheimer's disease (late onset);	chr14:106795643	chr14:106770577~106771020:-
PRAD	cis	rs2337406	0.866	rs7140974	ENSG00000274576.2	IGHV2-70	-9.38	3.02e-19	2.34e-16	-0.43	-0.4	Alzheimer's disease (late onset);	chr14:106795976	chr14:106770577~106771020:-
PRAD	cis	rs10129255	0.646	rs55995061	ENSG00000274576.2	IGHV2-70	-9.38	3.02e-19	2.34e-16	-0.43	-0.4	Kawasaki disease;	chr14:106799309	chr14:106770577~106771020:-
PRAD	cis	rs2337406	0.866	rs76871148	ENSG00000274576.2	IGHV2-70	-9.38	3.02e-19	2.34e-16	-0.43	-0.4	Alzheimer's disease (late onset);	chr14:106799722	chr14:106770577~106771020:-
PRAD	cis	rs2337406	0.866	rs61521632	ENSG00000274576.2	IGHV2-70	-9.38	3.02e-19	2.34e-16	-0.43	-0.4	Alzheimer's disease (late onset);	chr14:106801091	chr14:106770577~106771020:-
PRAD	cis	rs2153535	0.585	rs9379236	ENSG00000230939.1	RP11-314C16.1	-9.38	3.04e-19	2.35e-16	-0.49	-0.4	Motion sickness;	chr6:8651792	chr6:8784178~8785445:+
PRAD	cis	rs6142102	1	rs4911414	ENSG00000276073.1	RP5-1125A11.7	-9.38	3.04e-19	2.36e-16	-0.42	-0.4	Skin pigmentation;	chr20:34141638	chr20:33985617~33988989:-
PRAD	cis	rs62103177	0.525	rs10438902	ENSG00000261126.6	RP11-795F19.1	-9.38	3.04e-19	2.36e-16	-0.52	-0.4	Opioid sensitivity;	chr18:79985640	chr18:80046900~80095482:+
PRAD	cis	rs67311347	1	rs962847	ENSG00000223797.4	ENTPD3-AS1	-9.38	3.04e-19	2.36e-16	-0.36	-0.4	Renal cell carcinoma;	chr3:40453665	chr3:40313802~40453329:-
PRAD	cis	rs2108622	0.683	rs56228205	ENSG00000267453.5	AC004791.2	-9.38	3.06e-19	2.37e-16	-0.52	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871163	chr19:15851993~15864904:-
PRAD	cis	rs10875746	0.859	rs4760622	ENSG00000240399.1	RP1-228P16.1	-9.38	3.07e-19	2.38e-16	-0.39	-0.4	Longevity (90 years and older);	chr12:48198177	chr12:48054813~48055591:-
PRAD	cis	rs7189233	0.531	rs9941254	ENSG00000279344.1	RP11-44F14.7	9.38	3.07e-19	2.38e-16	0.36	0.4	Intelligence (multi-trait analysis);	chr16:53453306	chr16:53478957~53481550:-
PRAD	cis	rs7189233	0.531	rs7194730	ENSG00000279344.1	RP11-44F14.7	9.38	3.07e-19	2.38e-16	0.36	0.4	Intelligence (multi-trait analysis);	chr16:53455278	chr16:53478957~53481550:-
PRAD	cis	rs7189233	0.531	rs13332406	ENSG00000279344.1	RP11-44F14.7	9.38	3.07e-19	2.38e-16	0.36	0.4	Intelligence (multi-trait analysis);	chr16:53455793	chr16:53478957~53481550:-
PRAD	cis	rs2739330	0.796	rs5760106	ENSG00000099984.9	GSTT2	9.38	3.07e-19	2.38e-16	0.54	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23980123~23983911:+
PRAD	cis	rs9399137	0.507	rs6923512	ENSG00000232876.1	CTA-212D2.2	9.38	3.09e-19	2.4e-16	0.51	0.4	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135014130	chr6:135055033~135060550:+
PRAD	cis	rs9399137	0.507	rs6940878	ENSG00000232876.1	CTA-212D2.2	-9.38	3.1e-19	2.4e-16	-0.51	-0.4	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135045171	chr6:135055033~135060550:+
PRAD	cis	rs2882667	0.537	rs13181793	ENSG00000253404.1	AC034243.1	9.38	3.1e-19	2.4e-16	0.51	0.4	Age-related hearing impairment (SNP x SNP interaction);	chr5:139073267	chr5:138744434~138753309:-
PRAD	cis	rs2274273	0.901	rs8011288	ENSG00000258413.1	RP11-665C16.6	-9.38	3.11e-19	2.41e-16	-0.51	-0.4	Protein biomarker;	chr14:55268394	chr14:55262767~55272075:-
PRAD	cis	rs17023223	0.537	rs1325938	ENSG00000231365.4	RP11-418J17.1	-9.38	3.15e-19	2.44e-16	-0.41	-0.4	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119040019	chr1:119140396~119275973:+
PRAD	cis	rs7569084	0.687	rs1370394	ENSG00000281920.1	RP11-418H16.1	9.38	3.16e-19	2.44e-16	0.48	0.4	Sum eosinophil basophil counts;	chr2:65453176	chr2:65623272~65628424:+
PRAD	cis	rs6538678	0.895	rs7137751	ENSG00000258343.1	RP11-536G4.2	-9.38	3.16e-19	2.44e-16	-0.56	-0.4	Lupus nephritis in systemic lupus erythematosus;	chr12:95861806	chr12:95795345~95858839:-
PRAD	cis	rs62355901	0.739	rs61055995	ENSG00000271828.1	CTD-2310F14.1	9.38	3.16e-19	2.45e-16	0.68	0.4	Breast cancer;	chr5:56723237	chr5:56927874~56929573:+
PRAD	cis	rs6991838	0.584	rs14213	ENSG00000200714.1	Y_RNA	9.38	3.16e-19	2.45e-16	0.44	0.4	Intelligence (multi-trait analysis);	chr8:65602719	chr8:65592731~65592820:+
PRAD	cis	rs7712401	0.601	rs246274	ENSG00000263432.2	RN7SL689P	9.38	3.2e-19	2.48e-16	0.42	0.4	Mean platelet volume;	chr5:122945108	chr5:123022487~123022783:-
PRAD	cis	rs858239	0.699	rs955187	ENSG00000226816.2	AC005082.12	-9.38	3.21e-19	2.48e-16	-0.45	-0.4	Cerebrospinal fluid biomarker levels;	chr7:23154986	chr7:23206013~23208045:+
PRAD	cis	rs6570726	0.846	rs1935616	ENSG00000235652.6	RP11-545I5.3	9.38	3.23e-19	2.5e-16	0.42	0.4	Lobe attachment (rater-scored or self-reported);	chr6:145622376	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.846	rs9376954	ENSG00000235652.6	RP11-545I5.3	9.38	3.23e-19	2.5e-16	0.42	0.4	Lobe attachment (rater-scored or self-reported);	chr6:145622601	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.846	rs9399559	ENSG00000235652.6	RP11-545I5.3	9.38	3.23e-19	2.5e-16	0.42	0.4	Lobe attachment (rater-scored or self-reported);	chr6:145624642	chr6:145799409~145886585:+
PRAD	cis	rs7189233	0.55	rs1861350	ENSG00000279344.1	RP11-44F14.7	9.38	3.23e-19	2.5e-16	0.37	0.4	Intelligence (multi-trait analysis);	chr16:53499430	chr16:53478957~53481550:-
PRAD	cis	rs4879677	1	rs12237360	ENSG00000260390.1	RP11-575I8.1	-9.38	3.24e-19	2.51e-16	-0.55	-0.4	Gut microbiome composition (summer and winter);	chr9:27660200	chr9:27829276~27844481:+
PRAD	cis	rs6822297	0.522	rs7700108	ENSG00000240005.4	RP11-293A21.1	9.38	3.25e-19	2.51e-16	0.45	0.4	Obesity-related traits;	chr4:26967785	chr4:26859806~26860599:-
PRAD	cis	rs11951515	0.714	rs10512828	ENSG00000188850.9	RP11-159F24.2	9.38	3.25e-19	2.51e-16	0.48	0.4	Metabolite levels  (X-11787);	chr5:43368188	chr5:43336164~43348716:+
PRAD	cis	rs150992	0.609	rs112042355	ENSG00000248489.1	CTD-2007H13.3	9.38	3.26e-19	2.52e-16	0.45	0.4	Body mass index;	chr5:98990046	chr5:98929171~98995013:+
PRAD	cis	rs150992	0.587	rs75001231	ENSG00000248489.1	CTD-2007H13.3	9.38	3.26e-19	2.52e-16	0.45	0.4	Body mass index;	chr5:98990085	chr5:98929171~98995013:+
PRAD	cis	rs67311347	1	rs13073003	ENSG00000223797.4	ENTPD3-AS1	-9.37	3.27e-19	2.53e-16	-0.36	-0.4	Renal cell carcinoma;	chr3:40462835	chr3:40313802~40453329:-
PRAD	cis	rs67311347	1	rs6801185	ENSG00000223797.4	ENTPD3-AS1	-9.37	3.27e-19	2.53e-16	-0.36	-0.4	Renal cell carcinoma;	chr3:40463569	chr3:40313802~40453329:-
PRAD	cis	rs67311347	1	rs13095055	ENSG00000223797.4	ENTPD3-AS1	-9.37	3.27e-19	2.53e-16	-0.36	-0.4	Renal cell carcinoma;	chr3:40464175	chr3:40313802~40453329:-
PRAD	cis	rs7772486	0.875	rs9322044	ENSG00000235652.6	RP11-545I5.3	9.37	3.29e-19	2.54e-16	0.41	0.4	Lobe attachment (rater-scored or self-reported);	chr6:146048472	chr6:145799409~145886585:+
PRAD	cis	rs4835473	0.932	rs10857413	ENSG00000251600.4	RP11-673E1.1	9.37	3.29e-19	2.54e-16	0.51	0.4	Immature fraction of reticulocytes;	chr4:143827752	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs6828935	ENSG00000251600.4	RP11-673E1.1	9.37	3.29e-19	2.54e-16	0.51	0.4	Immature fraction of reticulocytes;	chr4:143829113	chr4:143912331~143982454:+
PRAD	cis	rs9322193	0.607	rs12209310	ENSG00000216906.2	RP11-350J20.9	9.37	3.29e-19	2.55e-16	0.53	0.4	Lung cancer;	chr6:149904882	chr6:149904243~149906418:+
PRAD	cis	rs12134133	1	rs55638602	ENSG00000274245.1	RP11-357P18.2	9.37	3.31e-19	2.56e-16	0.57	0.4	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207255597	chr1:207372559~207373252:+
PRAD	cis	rs12134133	1	rs4844588	ENSG00000274245.1	RP11-357P18.2	9.37	3.31e-19	2.56e-16	0.57	0.4	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207256323	chr1:207372559~207373252:+
PRAD	cis	rs12134133	0.927	rs4844589	ENSG00000274245.1	RP11-357P18.2	9.37	3.31e-19	2.56e-16	0.57	0.4	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207259285	chr1:207372559~207373252:+
PRAD	cis	rs12134133	1	rs6540893	ENSG00000274245.1	RP11-357P18.2	9.37	3.31e-19	2.56e-16	0.57	0.4	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207262382	chr1:207372559~207373252:+
PRAD	cis	rs12134133	1	rs61822674	ENSG00000274245.1	RP11-357P18.2	9.37	3.31e-19	2.56e-16	0.57	0.4	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207263378	chr1:207372559~207373252:+
PRAD	cis	rs12134133	1	rs10442696	ENSG00000274245.1	RP11-357P18.2	9.37	3.31e-19	2.56e-16	0.57	0.4	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207264783	chr1:207372559~207373252:+
PRAD	cis	rs12134133	1	rs7535532	ENSG00000274245.1	RP11-357P18.2	9.37	3.31e-19	2.56e-16	0.57	0.4	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207264991	chr1:207372559~207373252:+
PRAD	cis	rs12134133	1	rs7543117	ENSG00000274245.1	RP11-357P18.2	9.37	3.31e-19	2.56e-16	0.57	0.4	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207265351	chr1:207372559~207373252:+
PRAD	cis	rs12134133	1	rs6684804	ENSG00000274245.1	RP11-357P18.2	9.37	3.31e-19	2.56e-16	0.57	0.4	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207265670	chr1:207372559~207373252:+
PRAD	cis	rs12134133	1	rs11582249	ENSG00000274245.1	RP11-357P18.2	9.37	3.31e-19	2.56e-16	0.57	0.4	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207268263	chr1:207372559~207373252:+
PRAD	cis	rs2255336	0.938	rs2255364	ENSG00000245648.1	RP11-277P12.20	9.37	3.31e-19	2.56e-16	0.56	0.4	Blood protein levels;	chr12:10379297	chr12:10363769~10398506:+
PRAD	cis	rs2255336	0.938	rs2255353	ENSG00000245648.1	RP11-277P12.20	9.37	3.31e-19	2.56e-16	0.56	0.4	Blood protein levels;	chr12:10379512	chr12:10363769~10398506:+
PRAD	cis	rs2255336	0.938	rs2617152	ENSG00000245648.1	RP11-277P12.20	9.37	3.31e-19	2.56e-16	0.56	0.4	Blood protein levels;	chr12:10380507	chr12:10363769~10398506:+
PRAD	cis	rs2255336	0.882	rs2733847	ENSG00000245648.1	RP11-277P12.20	9.37	3.31e-19	2.56e-16	0.56	0.4	Blood protein levels;	chr12:10380608	chr12:10363769~10398506:+
PRAD	cis	rs2255336	0.938	rs2417734	ENSG00000245648.1	RP11-277P12.20	9.37	3.31e-19	2.56e-16	0.56	0.4	Blood protein levels;	chr12:10380807	chr12:10363769~10398506:+
PRAD	cis	rs6452524	0.935	rs1543847	ENSG00000249664.1	CTD-2227C6.2	9.37	3.32e-19	2.57e-16	0.47	0.4	Hypertension (SNP x SNP interaction);	chr5:83116044	chr5:83012285~83013109:-
PRAD	cis	rs3809863	0.602	rs11650072	ENSG00000228782.6	CTD-2026D20.3	9.37	3.33e-19	2.57e-16	0.45	0.4	Glaucoma (primary open-angle);	chr17:47316299	chr17:47450568~47492492:-
PRAD	cis	rs9309473	1	rs6711033	ENSG00000163016.8	ALMS1P	9.37	3.34e-19	2.58e-16	0.49	0.4	Metabolite levels;	chr2:73519516	chr2:73644919~73685576:+
PRAD	cis	rs7772486	0.875	rs863820	ENSG00000235652.6	RP11-545I5.3	-9.37	3.34e-19	2.58e-16	-0.41	-0.4	Lobe attachment (rater-scored or self-reported);	chr6:146026266	chr6:145799409~145886585:+
PRAD	cis	rs10178409	1	rs10178409	ENSG00000163016.8	ALMS1P	9.37	3.35e-19	2.59e-16	0.5	0.4	Urinary metabolites;	chr2:73628380	chr2:73644919~73685576:+
PRAD	cis	rs7189233	0.531	rs56126229	ENSG00000279344.1	RP11-44F14.7	9.37	3.36e-19	2.59e-16	0.36	0.4	Intelligence (multi-trait analysis);	chr16:53476775	chr16:53478957~53481550:-
PRAD	cis	rs9309473	1	rs13398956	ENSG00000163016.8	ALMS1P	9.37	3.38e-19	2.61e-16	0.49	0.4	Metabolite levels;	chr2:73493131	chr2:73644919~73685576:+
PRAD	cis	rs17711722	0.565	rs4717276	ENSG00000228409.4	CCT6P1	-9.37	3.38e-19	2.61e-16	-0.29	-0.4	Calcium levels;	chr7:65829754	chr7:65751142~65763354:+
PRAD	cis	rs2933343	1	rs1683776	ENSG00000261159.1	RP11-723O4.9	9.37	3.39e-19	2.61e-16	0.38	0.4	IgG glycosylation;	chr3:128903917	chr3:128859716~128860526:-
PRAD	cis	rs2933343	1	rs2630252	ENSG00000261159.1	RP11-723O4.9	9.37	3.39e-19	2.61e-16	0.38	0.4	IgG glycosylation;	chr3:128905929	chr3:128859716~128860526:-
PRAD	cis	rs10262624	1	rs2023786	ENSG00000234286.1	AC006026.13	-9.37	3.39e-19	2.61e-16	-0.46	-0.4	Schizophrenia;	chr7:23875534	chr7:23680195~23680786:-
PRAD	cis	rs10262624	0.967	rs13244145	ENSG00000234286.1	AC006026.13	-9.37	3.39e-19	2.61e-16	-0.46	-0.4	Schizophrenia;	chr7:23878123	chr7:23680195~23680786:-
PRAD	cis	rs8072100	0.512	rs9303533	ENSG00000228782.6	CTD-2026D20.3	9.37	3.39e-19	2.62e-16	0.46	0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47309174	chr17:47450568~47492492:-
PRAD	cis	rs732716	0.853	rs12459922	ENSG00000267769.1	CTB-50L17.9	-9.37	3.4e-19	2.62e-16	-0.44	-0.4	Mean corpuscular volume;	chr19:4455865	chr19:4454014~4455286:+
PRAD	cis	rs2882667	0.537	rs7701116	ENSG00000253404.1	AC034243.1	9.37	3.43e-19	2.65e-16	0.51	0.4	Age-related hearing impairment (SNP x SNP interaction);	chr5:139070389	chr5:138744434~138753309:-
PRAD	cis	rs7849270	0.959	rs4836641	ENSG00000268707.1	RP11-247A12.7	9.37	3.43e-19	2.65e-16	0.48	0.4	Blood metabolite ratios;	chr9:129149953	chr9:129170434~129170940:+
PRAD	cis	rs7849270	0.879	rs7859344	ENSG00000268707.1	RP11-247A12.7	-9.37	3.45e-19	2.66e-16	-0.47	-0.4	Blood metabolite ratios;	chr9:129086103	chr9:129170434~129170940:+
PRAD	cis	rs8072100	0.701	rs8075566	ENSG00000228782.6	CTD-2026D20.3	9.37	3.47e-19	2.67e-16	0.44	0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47693671	chr17:47450568~47492492:-
PRAD	cis	rs8072100	0.875	rs9635762	ENSG00000228782.6	CTD-2026D20.3	-9.37	3.47e-19	2.68e-16	-0.44	-0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47571080	chr17:47450568~47492492:-
PRAD	cis	rs8072100	0.967	rs4793842	ENSG00000228782.6	CTD-2026D20.3	-9.37	3.47e-19	2.68e-16	-0.44	-0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47594140	chr17:47450568~47492492:-
PRAD	cis	rs8072100	0.967	rs8075411	ENSG00000228782.6	CTD-2026D20.3	-9.37	3.47e-19	2.68e-16	-0.44	-0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47599394	chr17:47450568~47492492:-
PRAD	cis	rs7772486	0.686	rs4895684	ENSG00000235652.6	RP11-545I5.3	-9.37	3.48e-19	2.69e-16	-0.42	-0.4	Lobe attachment (rater-scored or self-reported);	chr6:145792887	chr6:145799409~145886585:+
PRAD	cis	rs2404602	1	rs12898430	ENSG00000259422.1	RP11-593F23.1	9.37	3.49e-19	2.69e-16	0.5	0.4	Blood metabolite levels;	chr15:76582582	chr15:76174891~76181486:-
PRAD	cis	rs7772486	0.875	rs9376975	ENSG00000235652.6	RP11-545I5.3	9.37	3.49e-19	2.69e-16	0.41	0.4	Lobe attachment (rater-scored or self-reported);	chr6:146034445	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.846	rs9376976	ENSG00000235652.6	RP11-545I5.3	9.37	3.49e-19	2.69e-16	0.41	0.4	Lobe attachment (rater-scored or self-reported);	chr6:146034469	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.875	rs7761033	ENSG00000235652.6	RP11-545I5.3	9.37	3.49e-19	2.69e-16	0.41	0.4	Lobe attachment (rater-scored or self-reported);	chr6:146034970	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.875	rs9403763	ENSG00000235652.6	RP11-545I5.3	9.37	3.49e-19	2.69e-16	0.41	0.4	Lobe attachment (rater-scored or self-reported);	chr6:146036519	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.875	rs9403764	ENSG00000235652.6	RP11-545I5.3	9.37	3.49e-19	2.69e-16	0.41	0.4	Lobe attachment (rater-scored or self-reported);	chr6:146039446	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.846	rs9373482	ENSG00000235652.6	RP11-545I5.3	9.37	3.49e-19	2.69e-16	0.41	0.4	Lobe attachment (rater-scored or self-reported);	chr6:146041987	chr6:145799409~145886585:+
PRAD	cis	rs9918079	0.542	rs7688984	ENSG00000273133.1	RP11-799M12.2	-9.37	3.49e-19	2.69e-16	-0.52	-0.4	Obesity-related traits;	chr4:15655630	chr4:15563698~15564253:-
PRAD	cis	rs7189233	0.55	rs4784312	ENSG00000279344.1	RP11-44F14.7	9.37	3.5e-19	2.69e-16	0.36	0.4	Intelligence (multi-trait analysis);	chr16:53464490	chr16:53478957~53481550:-
PRAD	cis	rs4713118	0.868	rs35069907	ENSG00000280107.1	AL022393.9	-9.37	3.5e-19	2.7e-16	-0.52	-0.4	Parkinson's disease;	chr6:27778913	chr6:28170845~28172521:+
PRAD	cis	rs67311347	1	rs9882171	ENSG00000223797.4	ENTPD3-AS1	9.37	3.5e-19	2.7e-16	0.36	0.4	Renal cell carcinoma;	chr3:40477330	chr3:40313802~40453329:-
PRAD	cis	rs6452524	0.935	rs7736783	ENSG00000249664.1	CTD-2227C6.2	9.37	3.52e-19	2.71e-16	0.47	0.4	Hypertension (SNP x SNP interaction);	chr5:83107050	chr5:83012285~83013109:-
PRAD	cis	rs4879677	1	rs642259	ENSG00000260390.1	RP11-575I8.1	-9.37	3.52e-19	2.71e-16	-0.52	-0.4	Gut microbiome composition (summer and winter);	chr9:27661755	chr9:27829276~27844481:+
PRAD	cis	rs9545047	0.604	rs7983344	ENSG00000227676.3	LINC01068	-9.37	3.53e-19	2.72e-16	-0.46	-0.4	Schizophrenia;	chr13:79299295	chr13:79566727~79571436:+
PRAD	cis	rs8072100	0.967	rs11079784	ENSG00000228782.6	CTD-2026D20.3	-9.36	3.56e-19	2.74e-16	-0.45	-0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47624914	chr17:47450568~47492492:-
PRAD	cis	rs6991838	0.798	rs6994889	ENSG00000272010.1	CTD-3025N20.3	9.36	3.56e-19	2.74e-16	0.39	0.4	Intelligence (multi-trait analysis);	chr8:65562547	chr8:65591850~65592472:-
PRAD	cis	rs7189233	0.531	rs4281707	ENSG00000279344.1	RP11-44F14.7	9.36	3.57e-19	2.75e-16	0.36	0.4	Intelligence (multi-trait analysis);	chr16:53468034	chr16:53478957~53481550:-
PRAD	cis	rs3814244	0.933	rs10748093	ENSG00000255733.4	IFNG-AS1	-9.36	3.58e-19	2.76e-16	-0.42	-0.4	Itch intensity from mosquito bite adjusted by bite size;	chr12:68024469	chr12:67989445~68234686:+
PRAD	cis	rs7714584	1	rs34156253	ENSG00000197083.10	ZNF300P1	9.36	3.59e-19	2.76e-16	0.66	0.4	Crohn's disease;	chr5:150846668	chr5:150930645~150946289:-
PRAD	cis	rs2274273	0.87	rs61210954	ENSG00000258413.1	RP11-665C16.6	-9.36	3.59e-19	2.77e-16	-0.53	-0.4	Protein biomarker;	chr14:55298684	chr14:55262767~55272075:-
PRAD	cis	rs7712401	0.601	rs30067	ENSG00000263432.2	RN7SL689P	9.36	3.6e-19	2.77e-16	0.41	0.4	Mean platelet volume;	chr5:122957973	chr5:123022487~123022783:-
PRAD	cis	rs494459	0.536	rs34561290	ENSG00000255239.1	AP002954.6	9.36	3.61e-19	2.78e-16	0.52	0.4	Height;	chr11:118860890	chr11:118688039~118690600:-
PRAD	cis	rs494459	0.536	rs11217072	ENSG00000255239.1	AP002954.6	9.36	3.61e-19	2.78e-16	0.52	0.4	Height;	chr11:118861053	chr11:118688039~118690600:-
PRAD	cis	rs7811142	1	rs11559117	ENSG00000242294.5	STAG3L5P	9.36	3.61e-19	2.78e-16	0.27	0.4	Platelet count;	chr7:100478991	chr7:100336079~100351900:+
PRAD	cis	rs7811142	1	rs4463351	ENSG00000242294.5	STAG3L5P	9.36	3.61e-19	2.78e-16	0.27	0.4	Platelet count;	chr7:100480603	chr7:100336079~100351900:+
PRAD	cis	rs10875746	0.768	rs12305182	ENSG00000240399.1	RP1-228P16.1	-9.36	3.61e-19	2.78e-16	-0.37	-0.4	Longevity (90 years and older);	chr12:48027624	chr12:48054813~48055591:-
PRAD	cis	rs7181230	0.885	rs17723133	ENSG00000275636.1	RP11-521C20.5	-9.36	3.61e-19	2.78e-16	-0.56	-0.4	Dehydroepiandrosterone sulphate levels;	chr15:40073217	chr15:40078892~40079347:+
PRAD	cis	rs2115630	0.645	rs2292463	ENSG00000275120.1	RP11-182J1.17	-9.36	3.61e-19	2.78e-16	-0.47	-0.4	P wave terminal force;	chr15:84632519	chr15:84599434~84606463:-
PRAD	cis	rs2108622	0.727	rs62106155	ENSG00000267453.5	AC004791.2	-9.36	3.64e-19	2.8e-16	-0.53	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869550	chr19:15851993~15864904:-
PRAD	cis	rs2108622	0.727	rs62106157	ENSG00000267453.5	AC004791.2	-9.36	3.64e-19	2.8e-16	-0.53	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869638	chr19:15851993~15864904:-
PRAD	cis	rs2108622	0.727	rs62106158	ENSG00000267453.5	AC004791.2	-9.36	3.64e-19	2.8e-16	-0.53	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869682	chr19:15851993~15864904:-
PRAD	cis	rs2108622	0.727	rs7256877	ENSG00000267453.5	AC004791.2	-9.36	3.64e-19	2.8e-16	-0.53	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869873	chr19:15851993~15864904:-
PRAD	cis	rs2108622	0.727	rs7253873	ENSG00000267453.5	AC004791.2	-9.36	3.64e-19	2.8e-16	-0.53	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15870090	chr19:15851993~15864904:-
PRAD	cis	rs2108622	0.559	rs7252638	ENSG00000267453.5	AC004791.2	-9.36	3.64e-19	2.8e-16	-0.53	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15870215	chr19:15851993~15864904:-
PRAD	cis	rs2108622	0.727	rs7253684	ENSG00000267453.5	AC004791.2	-9.36	3.64e-19	2.8e-16	-0.53	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15870316	chr19:15851993~15864904:-
PRAD	cis	rs62229266	0.626	rs7280896	ENSG00000231106.2	LINC01436	9.36	3.64e-19	2.8e-16	0.52	0.4	Mitral valve prolapse;	chr21:36088608	chr21:36005338~36007838:+
PRAD	cis	rs4879677	0.959	rs10968039	ENSG00000260390.1	RP11-575I8.1	-9.36	3.66e-19	2.81e-16	-0.54	-0.4	Gut microbiome composition (summer and winter);	chr9:27670118	chr9:27829276~27844481:+
PRAD	cis	rs4879677	1	rs10968041	ENSG00000260390.1	RP11-575I8.1	-9.36	3.66e-19	2.81e-16	-0.54	-0.4	Gut microbiome composition (summer and winter);	chr9:27670205	chr9:27829276~27844481:+
PRAD	cis	rs2108622	0.727	rs7254940	ENSG00000267453.5	AC004791.2	-9.36	3.66e-19	2.81e-16	-0.52	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15873698	chr19:15851993~15864904:-
PRAD	cis	rs2564921	0.704	rs12053904	ENSG00000242142.1	SERBP1P3	-9.36	3.67e-19	2.82e-16	-0.46	-0.4	Height;	chr3:52991821	chr3:53064283~53065091:-
PRAD	cis	rs2564921	0.679	rs2115779	ENSG00000242142.1	SERBP1P3	-9.36	3.67e-19	2.82e-16	-0.46	-0.4	Height;	chr3:52992698	chr3:53064283~53065091:-
PRAD	cis	rs172166	0.694	rs188105	ENSG00000280107.1	AL022393.9	-9.36	3.68e-19	2.83e-16	-0.5	-0.4	Cardiac Troponin-T levels;	chr6:28103615	chr6:28170845~28172521:+
PRAD	cis	rs172166	0.611	rs203882	ENSG00000280107.1	AL022393.9	-9.36	3.69e-19	2.83e-16	-0.49	-0.4	Cardiac Troponin-T levels;	chr6:28110724	chr6:28170845~28172521:+
PRAD	cis	rs172166	0.694	rs1770131	ENSG00000280107.1	AL022393.9	-9.36	3.69e-19	2.83e-16	-0.49	-0.4	Cardiac Troponin-T levels;	chr6:28118635	chr6:28170845~28172521:+
PRAD	cis	rs58873874	0.737	rs10515750	ENSG00000251405.2	CTB-109A12.1	9.36	3.7e-19	2.84e-16	0.91	0.4	Bipolar disorder (body mass index interaction);	chr5:157383064	chr5:157362615~157460078:-
PRAD	cis	rs9399137	0.529	rs7739722	ENSG00000232876.1	CTA-212D2.2	-9.36	3.72e-19	2.86e-16	-0.51	-0.4	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134961087	chr6:135055033~135060550:+
PRAD	cis	rs17023223	0.537	rs12086549	ENSG00000231365.4	RP11-418J17.1	9.36	3.72e-19	2.86e-16	0.42	0.4	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119071714	chr1:119140396~119275973:+
PRAD	cis	rs17023223	0.537	rs7525871	ENSG00000231365.4	RP11-418J17.1	-9.36	3.72e-19	2.86e-16	-0.42	-0.4	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119079271	chr1:119140396~119275973:+
PRAD	cis	rs7772486	0.686	rs702314	ENSG00000235652.6	RP11-545I5.3	-9.36	3.77e-19	2.9e-16	-0.42	-0.4	Lobe attachment (rater-scored or self-reported);	chr6:145682374	chr6:145799409~145886585:+
PRAD	cis	rs10262624	1	rs4722286	ENSG00000234286.1	AC006026.13	9.36	3.77e-19	2.9e-16	0.46	0.4	Schizophrenia;	chr7:23874005	chr7:23680195~23680786:-
PRAD	cis	rs10262624	1	rs2106748	ENSG00000234286.1	AC006026.13	-9.35	3.84e-19	2.95e-16	-0.46	-0.4	Schizophrenia;	chr7:23871694	chr7:23680195~23680786:-
PRAD	cis	rs10262624	1	rs2390847	ENSG00000234286.1	AC006026.13	-9.35	3.84e-19	2.95e-16	-0.46	-0.4	Schizophrenia;	chr7:23872082	chr7:23680195~23680786:-
PRAD	cis	rs2564921	0.73	rs12633064	ENSG00000242142.1	SERBP1P3	-9.35	3.84e-19	2.95e-16	-0.47	-0.4	Height;	chr3:53027361	chr3:53064283~53065091:-
PRAD	cis	rs1185460	1	rs1185460	ENSG00000271751.1	RP11-110I1.14	9.35	3.87e-19	2.97e-16	0.57	0.4	Coronary artery disease;	chr11:119072723	chr11:119065263~119065677:-
PRAD	cis	rs11951515	0.663	rs10462048	ENSG00000188850.9	RP11-159F24.2	9.35	3.88e-19	2.98e-16	0.49	0.4	Metabolite levels  (X-11787);	chr5:43258426	chr5:43336164~43348716:+
PRAD	cis	rs2282300	0.739	rs10835647	ENSG00000242353.1	RP4-710M3.1	-9.35	3.88e-19	2.98e-16	-0.48	-0.4	Morning vs. evening chronotype;	chr11:30291721	chr11:30368148~30368646:+
PRAD	cis	rs2282300	0.702	rs4379811	ENSG00000242353.1	RP4-710M3.1	9.35	3.88e-19	2.98e-16	0.48	0.4	Morning vs. evening chronotype;	chr11:30273213	chr11:30368148~30368646:+
PRAD	cis	rs2282300	0.739	rs3858428	ENSG00000242353.1	RP4-710M3.1	9.35	3.88e-19	2.98e-16	0.48	0.4	Morning vs. evening chronotype;	chr11:30275003	chr11:30368148~30368646:+
PRAD	cis	rs2282300	0.739	rs1933343	ENSG00000242353.1	RP4-710M3.1	9.35	3.88e-19	2.98e-16	0.48	0.4	Morning vs. evening chronotype;	chr11:30289445	chr11:30368148~30368646:+
PRAD	cis	rs9545047	0.604	rs11620233	ENSG00000227676.3	LINC01068	-9.35	3.9e-19	2.99e-16	-0.48	-0.4	Schizophrenia;	chr13:79373871	chr13:79566727~79571436:+
PRAD	cis	rs7811142	1	rs60844404	ENSG00000242294.5	STAG3L5P	9.35	3.9e-19	3e-16	0.26	0.4	Platelet count;	chr7:100482851	chr7:100336079~100351900:+
PRAD	cis	rs7811142	1	rs113738841	ENSG00000242294.5	STAG3L5P	9.35	3.9e-19	3e-16	0.26	0.4	Platelet count;	chr7:100483683	chr7:100336079~100351900:+
PRAD	cis	rs10875746	1	rs10875746	ENSG00000240399.1	RP1-228P16.1	-9.35	3.93e-19	3.01e-16	-0.38	-0.4	Longevity (90 years and older);	chr12:48124481	chr12:48054813~48055591:-
PRAD	cis	rs9532669	0.819	rs9532652	ENSG00000176268.5	CYCSP34	9.35	3.94e-19	3.02e-16	0.44	0.4	Cervical cancer;	chr13:40903300	chr13:40863599~40863902:-
PRAD	cis	rs853679	0.517	rs9357065	ENSG00000272009.1	RP1-313I6.12	-9.35	3.94e-19	3.03e-16	-0.41	-0.4	Depression;	chr6:28161802	chr6:28078792~28081130:-
PRAD	cis	rs997154	0.608	rs8007089	ENSG00000279656.1	RP11-298I3.6	9.35	3.96e-19	3.04e-16	0.58	0.4	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22922704	chr14:23023083~23024217:-
PRAD	cis	rs17023223	0.537	rs2361272	ENSG00000231365.4	RP11-418J17.1	-9.35	3.97e-19	3.05e-16	-0.4	-0.4	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119060794	chr1:119140396~119275973:+
PRAD	cis	rs7849270	0.959	rs1107329	ENSG00000268707.1	RP11-247A12.7	9.35	3.98e-19	3.05e-16	0.49	0.4	Blood metabolite ratios;	chr9:129155435	chr9:129170434~129170940:+
PRAD	cis	rs4713118	0.786	rs200502	ENSG00000280107.1	AL022393.9	-9.35	3.98e-19	3.06e-16	-0.51	-0.4	Parkinson's disease;	chr6:27820284	chr6:28170845~28172521:+
PRAD	cis	rs7772486	0.686	rs4896827	ENSG00000235652.6	RP11-545I5.3	9.35	4e-19	3.07e-16	0.41	0.4	Lobe attachment (rater-scored or self-reported);	chr6:145632202	chr6:145799409~145886585:+
PRAD	cis	rs321358	0.895	rs73015151	ENSG00000271584.1	RP11-89C3.4	9.35	4.02e-19	3.09e-16	0.61	0.4	Body mass index;	chr11:111084669	chr11:111091932~111097357:-
PRAD	cis	rs321358	0.895	rs17535886	ENSG00000271584.1	RP11-89C3.4	9.35	4.02e-19	3.09e-16	0.61	0.4	Body mass index;	chr11:111084852	chr11:111091932~111097357:-
PRAD	cis	rs9309473	0.95	rs10189885	ENSG00000163016.8	ALMS1P	9.35	4.02e-19	3.09e-16	0.51	0.4	Metabolite levels;	chr2:73649928	chr2:73644919~73685576:+
PRAD	cis	rs7772486	0.905	rs9373486	ENSG00000235652.6	RP11-545I5.3	-9.35	4.04e-19	3.09e-16	-0.41	-0.4	Lobe attachment (rater-scored or self-reported);	chr6:146124888	chr6:145799409~145886585:+
PRAD	cis	rs6452524	0.935	rs10045744	ENSG00000249664.1	CTD-2227C6.2	9.35	4.04e-19	3.1e-16	0.47	0.4	Hypertension (SNP x SNP interaction);	chr5:83113688	chr5:83012285~83013109:-
PRAD	cis	rs3814244	0.902	rs2870961	ENSG00000255733.4	IFNG-AS1	-9.35	4.04e-19	3.1e-16	-0.42	-0.4	Itch intensity from mosquito bite adjusted by bite size;	chr12:68024262	chr12:67989445~68234686:+
PRAD	cis	rs3814244	0.933	rs11610126	ENSG00000255733.4	IFNG-AS1	-9.35	4.04e-19	3.1e-16	-0.42	-0.4	Itch intensity from mosquito bite adjusted by bite size;	chr12:68026493	chr12:67989445~68234686:+
PRAD	cis	rs2108622	0.649	rs113055956	ENSG00000267453.5	AC004791.2	-9.35	4.05e-19	3.1e-16	-0.53	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866502	chr19:15851993~15864904:-
PRAD	cis	rs67311347	1	rs1047855	ENSG00000223797.4	ENTPD3-AS1	-9.35	4.05e-19	3.1e-16	-0.38	-0.4	Renal cell carcinoma;	chr3:40427405	chr3:40313802~40453329:-
PRAD	cis	rs12134133	1	rs1429904	ENSG00000274245.1	RP11-357P18.2	9.35	4.06e-19	3.11e-16	0.56	0.4	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207288539	chr1:207372559~207373252:+
PRAD	cis	rs12134133	1	rs2782854	ENSG00000274245.1	RP11-357P18.2	9.35	4.06e-19	3.11e-16	0.56	0.4	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207289369	chr1:207372559~207373252:+
PRAD	cis	rs12134133	0.962	rs2564970	ENSG00000274245.1	RP11-357P18.2	9.35	4.06e-19	3.11e-16	0.56	0.4	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207290696	chr1:207372559~207373252:+
PRAD	cis	rs12134133	1	rs2782851	ENSG00000274245.1	RP11-357P18.2	9.35	4.06e-19	3.11e-16	0.56	0.4	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207291717	chr1:207372559~207373252:+
PRAD	cis	rs12134133	1	rs2782850	ENSG00000274245.1	RP11-357P18.2	9.35	4.06e-19	3.11e-16	0.56	0.4	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207292092	chr1:207372559~207373252:+
PRAD	cis	rs2108622	0.727	rs7251296	ENSG00000267453.5	AC004791.2	-9.35	4.08e-19	3.13e-16	-0.52	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15872926	chr19:15851993~15864904:-
PRAD	cis	rs659580	1	rs659580	ENSG00000271811.1	RP1-79C4.4	-9.35	4.09e-19	3.13e-16	-0.49	-0.4	Response to angiotensin II receptor blocker therapy;Lobe attachment (rater-scored or self-reported);	chr1:170664755	chr1:170667381~170669425:+
PRAD	cis	rs7772486	0.654	rs1011597	ENSG00000235652.6	RP11-545I5.3	-9.35	4.09e-19	3.13e-16	-0.41	-0.4	Lobe attachment (rater-scored or self-reported);	chr6:145754536	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.686	rs9399564	ENSG00000235652.6	RP11-545I5.3	-9.35	4.09e-19	3.13e-16	-0.41	-0.4	Lobe attachment (rater-scored or self-reported);	chr6:145757771	chr6:145799409~145886585:+
PRAD	cis	rs7811142	0.943	rs28578163	ENSG00000242294.5	STAG3L5P	9.35	4.09e-19	3.14e-16	0.26	0.4	Platelet count;	chr7:100447131	chr7:100336079~100351900:+
PRAD	cis	rs7684253	0.587	rs9685436	ENSG00000269949.1	RP11-738E22.3	-9.35	4.12e-19	3.16e-16	-0.47	-0.4	Migraine;	chr4:56881195	chr4:56960927~56961373:-
PRAD	cis	rs11673344	0.796	rs9676450	ENSG00000226686.6	LINC01535	9.35	4.13e-19	3.16e-16	0.55	0.4	Obesity-related traits;	chr19:36998505	chr19:37251912~37265535:+
PRAD	cis	rs7714584	1	rs931058	ENSG00000197083.10	ZNF300P1	9.35	4.14e-19	3.17e-16	0.76	0.4	Crohn's disease;	chr5:150954136	chr5:150930645~150946289:-
PRAD	cis	rs11673344	0.704	rs1726724	ENSG00000226686.6	LINC01535	9.35	4.14e-19	3.17e-16	0.54	0.4	Obesity-related traits;	chr19:36925890	chr19:37251912~37265535:+
PRAD	cis	rs67311347	1	rs9822644	ENSG00000223797.4	ENTPD3-AS1	9.34	4.17e-19	3.2e-16	0.37	0.4	Renal cell carcinoma;	chr3:40385118	chr3:40313802~40453329:-
PRAD	cis	rs11673344	0.764	rs10403679	ENSG00000226686.6	LINC01535	9.34	4.18e-19	3.2e-16	0.54	0.4	Obesity-related traits;	chr19:36980810	chr19:37251912~37265535:+
PRAD	cis	rs11673344	0.764	rs13345491	ENSG00000226686.6	LINC01535	9.34	4.18e-19	3.2e-16	0.54	0.4	Obesity-related traits;	chr19:36982197	chr19:37251912~37265535:+
PRAD	cis	rs524281	1	rs565198	ENSG00000255320.1	RP11-755F10.1	-9.34	4.22e-19	3.23e-16	-0.56	-0.4	Electroencephalogram traits;	chr11:66146037	chr11:66244840~66246239:-
PRAD	cis	rs150992	0.609	rs116183885	ENSG00000248489.1	CTD-2007H13.3	9.34	4.23e-19	3.24e-16	0.44	0.4	Body mass index;	chr5:98990735	chr5:98929171~98995013:+
PRAD	cis	rs150992	0.534	rs115121903	ENSG00000248489.1	CTD-2007H13.3	9.34	4.23e-19	3.24e-16	0.44	0.4	Body mass index;	chr5:98990736	chr5:98929171~98995013:+
PRAD	cis	rs150992	0.592	rs2455423	ENSG00000248489.1	CTD-2007H13.3	9.34	4.23e-19	3.24e-16	0.44	0.4	Body mass index;	chr5:98990844	chr5:98929171~98995013:+
PRAD	cis	rs150992	0.609	rs559574	ENSG00000248489.1	CTD-2007H13.3	9.34	4.23e-19	3.24e-16	0.44	0.4	Body mass index;	chr5:98991122	chr5:98929171~98995013:+
PRAD	cis	rs150992	0.609	rs443726	ENSG00000248489.1	CTD-2007H13.3	9.34	4.23e-19	3.24e-16	0.44	0.4	Body mass index;	chr5:98991163	chr5:98929171~98995013:+
PRAD	cis	rs150992	0.592	rs407562	ENSG00000248489.1	CTD-2007H13.3	9.34	4.23e-19	3.24e-16	0.44	0.4	Body mass index;	chr5:98991512	chr5:98929171~98995013:+
PRAD	cis	rs150992	0.632	rs395668	ENSG00000248489.1	CTD-2007H13.3	9.34	4.23e-19	3.24e-16	0.44	0.4	Body mass index;	chr5:98991611	chr5:98929171~98995013:+
PRAD	cis	rs10262624	1	rs10238070	ENSG00000234286.1	AC006026.13	-9.34	4.25e-19	3.26e-16	-0.45	-0.4	Schizophrenia;	chr7:23870172	chr7:23680195~23680786:-
PRAD	cis	rs6452524	0.868	rs10071617	ENSG00000249664.1	CTD-2227C6.2	9.34	4.26e-19	3.26e-16	0.47	0.4	Hypertension (SNP x SNP interaction);	chr5:83103207	chr5:83012285~83013109:-
PRAD	cis	rs150992	0.609	rs77892628	ENSG00000248489.1	CTD-2007H13.3	9.34	4.29e-19	3.28e-16	0.44	0.4	Body mass index;	chr5:98990624	chr5:98929171~98995013:+
PRAD	cis	rs150992	0.609	rs77231989	ENSG00000248489.1	CTD-2007H13.3	9.34	4.29e-19	3.28e-16	0.44	0.4	Body mass index;	chr5:98990650	chr5:98929171~98995013:+
PRAD	cis	rs150992	0.631	rs79191251	ENSG00000248489.1	CTD-2007H13.3	9.34	4.29e-19	3.28e-16	0.44	0.4	Body mass index;	chr5:98990680	chr5:98929171~98995013:+
PRAD	cis	rs853679	0.542	rs9380063	ENSG00000272009.1	RP1-313I6.12	-9.34	4.3e-19	3.29e-16	-0.41	-0.4	Depression;	chr6:28170075	chr6:28078792~28081130:-
PRAD	cis	rs2282300	0.739	rs35883696	ENSG00000242353.1	RP4-710M3.1	-9.34	4.31e-19	3.3e-16	-0.48	-0.4	Morning vs. evening chronotype;	chr11:30224860	chr11:30368148~30368646:+
PRAD	cis	rs8072100	0.701	rs2013383	ENSG00000228782.6	CTD-2026D20.3	9.34	4.31e-19	3.3e-16	0.45	0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47713757	chr17:47450568~47492492:-
PRAD	cis	rs6452524	0.935	rs10076059	ENSG00000249664.1	CTD-2227C6.2	9.34	4.31e-19	3.3e-16	0.47	0.4	Hypertension (SNP x SNP interaction);	chr5:83105698	chr5:83012285~83013109:-
PRAD	cis	rs6452524	0.935	rs11951257	ENSG00000249664.1	CTD-2227C6.2	9.34	4.31e-19	3.3e-16	0.47	0.4	Hypertension (SNP x SNP interaction);	chr5:83107492	chr5:83012285~83013109:-
PRAD	cis	rs6452524	0.935	rs767771	ENSG00000249664.1	CTD-2227C6.2	9.34	4.31e-19	3.3e-16	0.47	0.4	Hypertension (SNP x SNP interaction);	chr5:83108117	chr5:83012285~83013109:-
PRAD	cis	rs6452524	0.935	rs1542539	ENSG00000249664.1	CTD-2227C6.2	9.34	4.31e-19	3.3e-16	0.47	0.4	Hypertension (SNP x SNP interaction);	chr5:83116033	chr5:83012285~83013109:-
PRAD	cis	rs6452524	0.967	rs1564211	ENSG00000249664.1	CTD-2227C6.2	9.34	4.31e-19	3.3e-16	0.47	0.4	Hypertension (SNP x SNP interaction);	chr5:83117014	chr5:83012285~83013109:-
PRAD	cis	rs8072100	0.935	rs12943464	ENSG00000228782.6	CTD-2026D20.3	-9.34	4.35e-19	3.33e-16	-0.44	-0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47612985	chr17:47450568~47492492:-
PRAD	cis	rs8072100	0.935	rs4793978	ENSG00000228782.6	CTD-2026D20.3	-9.34	4.35e-19	3.33e-16	-0.44	-0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47620809	chr17:47450568~47492492:-
PRAD	cis	rs1185460	0.804	rs13929	ENSG00000271751.1	RP11-110I1.14	-9.34	4.35e-19	3.33e-16	-0.55	-0.4	Coronary artery disease;	chr11:119045044	chr11:119065263~119065677:-
PRAD	cis	rs853679	0.55	rs6901017	ENSG00000219392.1	RP1-265C24.5	-9.34	4.36e-19	3.34e-16	-0.52	-0.4	Depression;	chr6:28184805	chr6:28115628~28116551:+
PRAD	cis	rs6570726	0.791	rs448939	ENSG00000235652.6	RP11-545I5.3	9.34	4.36e-19	3.34e-16	0.43	0.4	Lobe attachment (rater-scored or self-reported);	chr6:145487184	chr6:145799409~145886585:+
PRAD	cis	rs2108622	0.727	rs62106156	ENSG00000267453.5	AC004791.2	-9.34	4.36e-19	3.34e-16	-0.52	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869614	chr19:15851993~15864904:-
PRAD	cis	rs7772486	0.686	rs2179323	ENSG00000235652.6	RP11-545I5.3	-9.34	4.37e-19	3.34e-16	-0.42	-0.4	Lobe attachment (rater-scored or self-reported);	chr6:145661650	chr6:145799409~145886585:+
PRAD	cis	rs8062405	0.723	rs4788077	ENSG00000259982.1	CDC37P1	9.34	4.38e-19	3.35e-16	0.54	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558443	chr16:28700294~28701540:-
PRAD	cis	rs7811142	0.775	rs6946768	ENSG00000242294.5	STAG3L5P	9.34	4.4e-19	3.37e-16	0.27	0.4	Platelet count;	chr7:100356770	chr7:100336079~100351900:+
PRAD	cis	rs7811142	0.83	rs11765869	ENSG00000242294.5	STAG3L5P	9.34	4.4e-19	3.37e-16	0.27	0.4	Platelet count;	chr7:100367166	chr7:100336079~100351900:+
PRAD	cis	rs2115630	0.645	rs4842978	ENSG00000275120.1	RP11-182J1.17	-9.34	4.4e-19	3.37e-16	-0.46	-0.4	P wave terminal force;	chr15:84654022	chr15:84599434~84606463:-
PRAD	cis	rs2115630	0.645	rs1107179	ENSG00000275120.1	RP11-182J1.17	9.34	4.4e-19	3.37e-16	0.46	0.4	P wave terminal force;	chr15:84655131	chr15:84599434~84606463:-
PRAD	cis	rs2274273	0.673	rs2209808	ENSG00000258413.1	RP11-665C16.6	-9.34	4.41e-19	3.37e-16	-0.52	-0.4	Protein biomarker;	chr14:55340977	chr14:55262767~55272075:-
PRAD	cis	rs4835473	0.932	rs10030428	ENSG00000251600.4	RP11-673E1.1	9.34	4.41e-19	3.37e-16	0.5	0.4	Immature fraction of reticulocytes;	chr4:143762699	chr4:143912331~143982454:+
PRAD	cis	rs6570726	0.846	rs409553	ENSG00000235652.6	RP11-545I5.3	9.34	4.42e-19	3.38e-16	0.41	0.4	Lobe attachment (rater-scored or self-reported);	chr6:145565827	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.846	rs371186	ENSG00000235652.6	RP11-545I5.3	9.34	4.42e-19	3.38e-16	0.41	0.4	Lobe attachment (rater-scored or self-reported);	chr6:145565835	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.846	rs439035	ENSG00000235652.6	RP11-545I5.3	9.34	4.42e-19	3.38e-16	0.41	0.4	Lobe attachment (rater-scored or self-reported);	chr6:145566854	chr6:145799409~145886585:+
PRAD	cis	rs2404602	0.716	rs17362383	ENSG00000259422.1	RP11-593F23.1	9.34	4.44e-19	3.4e-16	0.5	0.4	Blood metabolite levels;	chr15:76358361	chr15:76174891~76181486:-
PRAD	cis	rs2442825	0.691	rs2596912	ENSG00000206573.7	THUMPD3-AS1	9.34	4.45e-19	3.4e-16	0.31	0.4	Cerebrospinal fluid clusterin levels;	chr3:9397062	chr3:9349689~9398579:-
PRAD	cis	rs12701220	0.553	rs7782024	ENSG00000229043.2	AC091729.9	-9.34	4.48e-19	3.42e-16	-0.56	-0.4	Bronchopulmonary dysplasia;	chr7:1117866	chr7:1160374~1165267:+
PRAD	cis	rs7772486	0.686	rs9376956	ENSG00000235652.6	RP11-545I5.3	9.34	4.48e-19	3.42e-16	0.42	0.4	Lobe attachment (rater-scored or self-reported);	chr6:145628708	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.658	rs6570706	ENSG00000235652.6	RP11-545I5.3	9.34	4.48e-19	3.42e-16	0.42	0.4	Lobe attachment (rater-scored or self-reported);	chr6:145641786	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.651	rs1292338	ENSG00000235652.6	RP11-545I5.3	-9.34	4.48e-19	3.42e-16	-0.42	-0.4	Lobe attachment (rater-scored or self-reported);	chr6:145646335	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.686	rs1292337	ENSG00000235652.6	RP11-545I5.3	-9.34	4.48e-19	3.42e-16	-0.42	-0.4	Lobe attachment (rater-scored or self-reported);	chr6:145646671	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.686	rs857879	ENSG00000235652.6	RP11-545I5.3	-9.34	4.48e-19	3.42e-16	-0.42	-0.4	Lobe attachment (rater-scored or self-reported);	chr6:145652907	chr6:145799409~145886585:+
PRAD	cis	rs9309473	0.95	rs6705977	ENSG00000163016.8	ALMS1P	9.33	4.51e-19	3.45e-16	0.5	0.4	Metabolite levels;	chr2:73622043	chr2:73644919~73685576:+
PRAD	cis	rs9309473	0.95	rs6711001	ENSG00000163016.8	ALMS1P	9.33	4.51e-19	3.45e-16	0.5	0.4	Metabolite levels;	chr2:73623693	chr2:73644919~73685576:+
PRAD	cis	rs10262624	1	rs2106747	ENSG00000234286.1	AC006026.13	-9.33	4.52e-19	3.45e-16	-0.45	-0.4	Schizophrenia;	chr7:23871880	chr7:23680195~23680786:-
PRAD	cis	rs11976180	0.569	rs12703565	ENSG00000273234.1	OR2A13P	-9.33	4.53e-19	3.46e-16	-0.6	-0.4	Obesity-related traits;	chr7:144057308	chr7:144142009~144142938:+
PRAD	cis	rs6570726	0.846	rs426874	ENSG00000235652.6	RP11-545I5.3	9.33	4.54e-19	3.47e-16	0.41	0.4	Lobe attachment (rater-scored or self-reported);	chr6:145559494	chr6:145799409~145886585:+
PRAD	cis	rs9918079	0.56	rs6449153	ENSG00000273133.1	RP11-799M12.2	-9.33	4.57e-19	3.49e-16	-0.52	-0.4	Obesity-related traits;	chr4:15629593	chr4:15563698~15564253:-
PRAD	cis	rs2108622	0.727	rs8102532	ENSG00000267453.5	AC004791.2	-9.33	4.57e-19	3.49e-16	-0.52	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869250	chr19:15851993~15864904:-
PRAD	cis	rs2348418	0.715	rs1581076	ENSG00000247934.4	RP11-967K21.1	9.33	4.58e-19	3.5e-16	0.36	0.4	Lung function (FEV1);Lung function (FVC);	chr12:28570724	chr12:28163298~28190738:-
PRAD	cis	rs7849270	0.725	rs59012667	ENSG00000268707.1	RP11-247A12.7	-9.33	4.61e-19	3.52e-16	-0.47	-0.4	Blood metabolite ratios;	chr9:129088202	chr9:129170434~129170940:+
PRAD	cis	rs2274273	0.934	rs10144418	ENSG00000258413.1	RP11-665C16.6	-9.33	4.61e-19	3.52e-16	-0.52	-0.4	Protein biomarker;	chr14:55350990	chr14:55262767~55272075:-
PRAD	cis	rs4879677	1	rs10812633	ENSG00000260390.1	RP11-575I8.1	-9.33	4.62e-19	3.52e-16	-0.54	-0.4	Gut microbiome composition (summer and winter);	chr9:27656975	chr9:27829276~27844481:+
PRAD	cis	rs6570726	0.791	rs4896820	ENSG00000235652.6	RP11-545I5.3	9.33	4.62e-19	3.53e-16	0.41	0.4	Lobe attachment (rater-scored or self-reported);	chr6:145573821	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.764	rs4896821	ENSG00000235652.6	RP11-545I5.3	9.33	4.62e-19	3.53e-16	0.41	0.4	Lobe attachment (rater-scored or self-reported);	chr6:145575045	chr6:145799409~145886585:+
PRAD	cis	rs7811142	0.83	rs705866	ENSG00000242294.5	STAG3L5P	9.33	4.62e-19	3.53e-16	0.27	0.4	Platelet count;	chr7:100367662	chr7:100336079~100351900:+
PRAD	cis	rs7772486	0.632	rs9386128	ENSG00000235652.6	RP11-545I5.3	-9.33	4.62e-19	3.53e-16	-0.41	-0.4	Lobe attachment (rater-scored or self-reported);	chr6:145727917	chr6:145799409~145886585:+
PRAD	cis	rs11690935	0.55	rs62183784	ENSG00000228389.1	AC068039.4	-9.33	4.66e-19	3.56e-16	-0.45	-0.4	Schizophrenia;	chr2:172001789	chr2:171773482~171775844:+
PRAD	cis	rs638893	1	rs583905	ENSG00000278376.1	RP11-158I9.8	-9.33	4.66e-19	3.56e-16	-0.44	-0.4	Vitiligo;	chr11:118825199	chr11:118791254~118793137:+
PRAD	cis	rs853679	0.713	rs200991	ENSG00000280107.1	AL022393.9	9.33	4.69e-19	3.58e-16	0.58	0.4	Depression;	chr6:27847716	chr6:28170845~28172521:+
PRAD	cis	rs3096299	0.967	rs2965937	ENSG00000274627.1	RP11-104N10.2	9.33	4.72e-19	3.6e-16	0.42	0.4	Multiple myeloma (IgH translocation);	chr16:89422371	chr16:89516797~89522217:+
PRAD	cis	rs7712401	0.601	rs40818	ENSG00000263432.2	RN7SL689P	9.33	4.72e-19	3.6e-16	0.42	0.4	Mean platelet volume;	chr5:122959378	chr5:123022487~123022783:-
PRAD	cis	rs17023223	0.537	rs2765534	ENSG00000231365.4	RP11-418J17.1	-9.33	4.73e-19	3.61e-16	-0.4	-0.4	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119055169	chr1:119140396~119275973:+
PRAD	cis	rs4713118	0.911	rs9461406	ENSG00000280107.1	AL022393.9	9.33	4.75e-19	3.62e-16	0.52	0.4	Parkinson's disease;	chr6:27751985	chr6:28170845~28172521:+
PRAD	cis	rs172166	0.694	rs1631552	ENSG00000280107.1	AL022393.9	-9.33	4.78e-19	3.64e-16	-0.49	-0.4	Cardiac Troponin-T levels;	chr6:28121921	chr6:28170845~28172521:+
PRAD	cis	rs6570726	0.72	rs412623	ENSG00000235652.6	RP11-545I5.3	9.33	4.78e-19	3.65e-16	0.41	0.4	Lobe attachment (rater-scored or self-reported);	chr6:145562121	chr6:145799409~145886585:+
PRAD	cis	rs7181230	0.885	rs2412478	ENSG00000275636.1	RP11-521C20.5	9.33	4.8e-19	3.66e-16	0.57	0.4	Dehydroepiandrosterone sulphate levels;	chr15:40068971	chr15:40078892~40079347:+
PRAD	cis	rs17023223	0.537	rs1343723	ENSG00000231365.4	RP11-418J17.1	-9.33	4.82e-19	3.68e-16	-0.4	-0.4	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119062431	chr1:119140396~119275973:+
PRAD	cis	rs4927850	0.957	rs4927851	ENSG00000242086.7	LINC00969	9.33	4.85e-19	3.69e-16	0.35	0.4	Pancreatic cancer;	chr3:196024982	chr3:195658062~195739964:+
PRAD	cis	rs4927850	0.918	rs4361313	ENSG00000242086.7	LINC00969	9.33	4.85e-19	3.69e-16	0.35	0.4	Pancreatic cancer;	chr3:196025389	chr3:195658062~195739964:+
PRAD	cis	rs6570726	0.846	rs7762536	ENSG00000235652.6	RP11-545I5.3	9.33	4.85e-19	3.7e-16	0.41	0.4	Lobe attachment (rater-scored or self-reported);	chr6:145602009	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.791	rs952406	ENSG00000235652.6	RP11-545I5.3	9.33	4.85e-19	3.7e-16	0.41	0.4	Lobe attachment (rater-scored or self-reported);	chr6:145604480	chr6:145799409~145886585:+
PRAD	cis	rs7189233	0.531	rs62048526	ENSG00000279344.1	RP11-44F14.7	9.32	4.86e-19	3.7e-16	0.36	0.4	Intelligence (multi-trait analysis);	chr16:53478014	chr16:53478957~53481550:-
PRAD	cis	rs13631	0.728	rs10118245	ENSG00000268996.3	MAN1B1-AS1	9.32	4.88e-19	3.71e-16	0.42	0.4	Cerebrospinal fluid biomarker levels;	chr9:137085140	chr9:137084946~137086817:-
PRAD	cis	rs7811142	0.83	rs6965458	ENSG00000242294.5	STAG3L5P	9.32	4.9e-19	3.73e-16	0.27	0.4	Platelet count;	chr7:100375779	chr7:100336079~100351900:+
PRAD	cis	rs7826238	0.564	rs2921053	ENSG00000253893.2	FAM85B	-9.32	4.9e-19	3.74e-16	-0.49	-0.4	Systolic blood pressure;	chr8:8462453	chr8:8167819~8226614:-
PRAD	cis	rs7569084	0.687	rs4671663	ENSG00000281920.1	RP11-418H16.1	9.32	4.91e-19	3.74e-16	0.49	0.4	Sum eosinophil basophil counts;	chr2:65434400	chr2:65623272~65628424:+
PRAD	cis	rs7569084	0.687	rs11692813	ENSG00000281920.1	RP11-418H16.1	9.32	4.91e-19	3.74e-16	0.49	0.4	Sum eosinophil basophil counts;	chr2:65435172	chr2:65623272~65628424:+
PRAD	cis	rs7811142	1	rs2406253	ENSG00000242294.5	STAG3L5P	9.32	4.91e-19	3.74e-16	0.26	0.4	Platelet count;	chr7:100479650	chr7:100336079~100351900:+
PRAD	cis	rs7189233	0.531	rs7204758	ENSG00000279344.1	RP11-44F14.7	9.32	4.92e-19	3.75e-16	0.36	0.4	Intelligence (multi-trait analysis);	chr16:53448453	chr16:53478957~53481550:-
PRAD	cis	rs7189233	0.531	rs9921627	ENSG00000279344.1	RP11-44F14.7	9.32	4.92e-19	3.75e-16	0.36	0.4	Intelligence (multi-trait analysis);	chr16:53448780	chr16:53478957~53481550:-
PRAD	cis	rs9545047	0.604	rs9318641	ENSG00000227676.3	LINC01068	-9.32	4.92e-19	3.75e-16	-0.47	-0.4	Schizophrenia;	chr13:79426545	chr13:79566727~79571436:+
PRAD	cis	rs10262624	1	rs2023787	ENSG00000234286.1	AC006026.13	-9.32	4.94e-19	3.76e-16	-0.45	-0.4	Schizophrenia;	chr7:23875521	chr7:23680195~23680786:-
PRAD	cis	rs10262624	1	rs12671624	ENSG00000234286.1	AC006026.13	-9.32	4.94e-19	3.76e-16	-0.45	-0.4	Schizophrenia;	chr7:23875794	chr7:23680195~23680786:-
PRAD	cis	rs10262624	1	rs10262624	ENSG00000234286.1	AC006026.13	-9.32	4.94e-19	3.76e-16	-0.45	-0.4	Schizophrenia;	chr7:23876057	chr7:23680195~23680786:-
PRAD	cis	rs2337406	0.866	rs4774019	ENSG00000274576.2	IGHV2-70	-9.32	4.94e-19	3.76e-16	-0.42	-0.4	Alzheimer's disease (late onset);	chr14:106805386	chr14:106770577~106771020:-
PRAD	cis	rs7772486	0.686	rs9390349	ENSG00000235652.6	RP11-545I5.3	-9.32	4.96e-19	3.77e-16	-0.41	-0.4	Lobe attachment (rater-scored or self-reported);	chr6:145733294	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.686	rs2072911	ENSG00000235652.6	RP11-545I5.3	-9.32	4.96e-19	3.77e-16	-0.41	-0.4	Lobe attachment (rater-scored or self-reported);	chr6:145735665	chr6:145799409~145886585:+
PRAD	cis	rs7712401	0.562	rs30073	ENSG00000263432.2	RN7SL689P	9.32	4.97e-19	3.78e-16	0.41	0.4	Mean platelet volume;	chr5:122954814	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.601	rs30072	ENSG00000263432.2	RN7SL689P	9.32	4.97e-19	3.78e-16	0.41	0.4	Mean platelet volume;	chr5:122956525	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.601	rs30069	ENSG00000263432.2	RN7SL689P	9.32	4.97e-19	3.78e-16	0.41	0.4	Mean platelet volume;	chr5:122957331	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.601	rs187405	ENSG00000263432.2	RN7SL689P	9.32	4.97e-19	3.78e-16	0.41	0.4	Mean platelet volume;	chr5:122959300	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.562	rs30062	ENSG00000263432.2	RN7SL689P	9.32	4.97e-19	3.78e-16	0.41	0.4	Mean platelet volume;	chr5:122960681	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.601	rs30060	ENSG00000263432.2	RN7SL689P	9.32	4.97e-19	3.78e-16	0.41	0.4	Mean platelet volume;	chr5:122961005	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.525	rs2910150	ENSG00000263432.2	RN7SL689P	9.32	4.97e-19	3.78e-16	0.41	0.4	Mean platelet volume;	chr5:122961050	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.601	rs30059	ENSG00000263432.2	RN7SL689P	9.32	4.97e-19	3.78e-16	0.41	0.4	Mean platelet volume;	chr5:122961814	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.601	rs30058	ENSG00000263432.2	RN7SL689P	9.32	4.97e-19	3.78e-16	0.41	0.4	Mean platelet volume;	chr5:122962008	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.623	rs30057	ENSG00000263432.2	RN7SL689P	9.32	4.97e-19	3.78e-16	0.41	0.4	Mean platelet volume;	chr5:122962423	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.584	rs39820	ENSG00000263432.2	RN7SL689P	9.32	4.97e-19	3.78e-16	0.41	0.4	Mean platelet volume;	chr5:122964226	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.601	rs30055	ENSG00000263432.2	RN7SL689P	9.32	4.97e-19	3.78e-16	0.41	0.4	Mean platelet volume;	chr5:122965384	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.601	rs39819	ENSG00000263432.2	RN7SL689P	9.32	4.97e-19	3.78e-16	0.41	0.4	Mean platelet volume;	chr5:122965981	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.601	rs30054	ENSG00000263432.2	RN7SL689P	9.32	4.97e-19	3.78e-16	0.41	0.4	Mean platelet volume;	chr5:122966304	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.562	rs30053	ENSG00000263432.2	RN7SL689P	9.32	4.97e-19	3.78e-16	0.41	0.4	Mean platelet volume;	chr5:122967948	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.562	rs30052	ENSG00000263432.2	RN7SL689P	9.32	4.97e-19	3.78e-16	0.41	0.4	Mean platelet volume;	chr5:122969314	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.601	rs246321	ENSG00000263432.2	RN7SL689P	9.32	4.97e-19	3.78e-16	0.41	0.4	Mean platelet volume;	chr5:122972604	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.601	rs246320	ENSG00000263432.2	RN7SL689P	9.32	4.97e-19	3.78e-16	0.41	0.4	Mean platelet volume;	chr5:122972886	chr5:123022487~123022783:-
PRAD	cis	rs2564921	0.666	rs62253656	ENSG00000242142.1	SERBP1P3	-9.32	4.98e-19	3.79e-16	-0.46	-0.4	Height;	chr3:52989412	chr3:53064283~53065091:-
PRAD	cis	rs150992	0.609	rs2927648	ENSG00000248489.1	CTD-2007H13.3	9.32	4.99e-19	3.79e-16	0.44	0.4	Body mass index;	chr5:98990273	chr5:98929171~98995013:+
PRAD	cis	rs150992	0.609	rs2927647	ENSG00000248489.1	CTD-2007H13.3	9.32	5e-19	3.8e-16	0.44	0.4	Body mass index;	chr5:98990161	chr5:98929171~98995013:+
PRAD	cis	rs321358	0.895	rs17535942	ENSG00000271584.1	RP11-89C3.4	9.32	5e-19	3.81e-16	0.61	0.4	Body mass index;	chr11:111085233	chr11:111091932~111097357:-
PRAD	cis	rs321358	0.895	rs17457430	ENSG00000271584.1	RP11-89C3.4	9.32	5e-19	3.81e-16	0.61	0.4	Body mass index;	chr11:111085279	chr11:111091932~111097357:-
PRAD	cis	rs321358	0.895	rs7101466	ENSG00000271584.1	RP11-89C3.4	9.32	5e-19	3.81e-16	0.61	0.4	Body mass index;	chr11:111085729	chr11:111091932~111097357:-
PRAD	cis	rs321358	0.895	rs7101576	ENSG00000271584.1	RP11-89C3.4	9.32	5e-19	3.81e-16	0.61	0.4	Body mass index;	chr11:111085795	chr11:111091932~111097357:-
PRAD	cis	rs7712401	0.601	rs30049	ENSG00000263432.2	RN7SL689P	9.32	5.02e-19	3.82e-16	0.41	0.4	Mean platelet volume;	chr5:122970402	chr5:123022487~123022783:-
PRAD	cis	rs10262624	1	rs11767124	ENSG00000234286.1	AC006026.13	-9.32	5.05e-19	3.84e-16	-0.46	-0.4	Schizophrenia;	chr7:23879461	chr7:23680195~23680786:-
PRAD	cis	rs4927850	1	rs4927850	ENSG00000242086.7	LINC00969	-9.32	5.07e-19	3.86e-16	-0.35	-0.4	Pancreatic cancer;	chr3:196024759	chr3:195658062~195739964:+
PRAD	cis	rs9399137	0.507	rs11154791	ENSG00000232876.1	CTA-212D2.2	-9.32	5.09e-19	3.87e-16	-0.51	-0.4	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135058010	chr6:135055033~135060550:+
PRAD	cis	rs2882667	0.537	rs7701338	ENSG00000253404.1	AC034243.1	9.32	5.11e-19	3.89e-16	0.5	0.4	Age-related hearing impairment (SNP x SNP interaction);	chr5:139070305	chr5:138744434~138753309:-
PRAD	cis	rs11951515	0.7	rs11956988	ENSG00000188850.9	RP11-159F24.2	9.32	5.14e-19	3.9e-16	0.48	0.4	Metabolite levels  (X-11787);	chr5:43367267	chr5:43336164~43348716:+
PRAD	cis	rs11951515	0.738	rs12517362	ENSG00000188850.9	RP11-159F24.2	9.32	5.14e-19	3.9e-16	0.48	0.4	Metabolite levels  (X-11787);	chr5:43368060	chr5:43336164~43348716:+
PRAD	cis	rs7189233	0.55	rs9938788	ENSG00000279344.1	RP11-44F14.7	9.32	5.15e-19	3.92e-16	0.36	0.4	Intelligence (multi-trait analysis);	chr16:53447510	chr16:53478957~53481550:-
PRAD	cis	rs1563304	1	rs1563304	ENSG00000262539.1	RP11-259G18.3	9.32	5.16e-19	3.92e-16	0.73	0.4	Neuroticism;	chr17:46797087	chr17:46259551~46260606:-
PRAD	cis	rs67311347	1	rs12488805	ENSG00000223797.4	ENTPD3-AS1	9.32	5.19e-19	3.94e-16	0.37	0.4	Renal cell carcinoma;	chr3:40381378	chr3:40313802~40453329:-
PRAD	cis	rs321358	0.895	rs17457375	ENSG00000271584.1	RP11-89C3.4	9.32	5.19e-19	3.95e-16	0.61	0.4	Body mass index;	chr11:111085100	chr11:111091932~111097357:-
PRAD	cis	rs6570726	0.846	rs973856	ENSG00000235652.6	RP11-545I5.3	-9.32	5.22e-19	3.97e-16	-0.42	-0.4	Lobe attachment (rater-scored or self-reported);	chr6:145460780	chr6:145799409~145886585:+
PRAD	cis	rs2274273	0.934	rs10137307	ENSG00000258413.1	RP11-665C16.6	-9.32	5.22e-19	3.97e-16	-0.52	-0.4	Protein biomarker;	chr14:55378467	chr14:55262767~55272075:-
PRAD	cis	rs17361889	0.738	rs17288304	ENSG00000224683.1	RPL36AP29	9.32	5.24e-19	3.98e-16	0.49	0.4	Pediatric bone mineral content (hip);	chr7:16153112	chr7:16208945~16209265:+
PRAD	cis	rs67311347	0.956	rs9822870	ENSG00000223797.4	ENTPD3-AS1	-9.32	5.25e-19	3.99e-16	-0.36	-0.4	Renal cell carcinoma;	chr3:40473399	chr3:40313802~40453329:-
PRAD	cis	rs2274273	0.901	rs7147136	ENSG00000258413.1	RP11-665C16.6	-9.32	5.25e-19	3.99e-16	-0.52	-0.4	Protein biomarker;	chr14:55359970	chr14:55262767~55272075:-
PRAD	cis	rs150992	0.547	rs325217	ENSG00000248489.1	CTD-2007H13.3	9.32	5.25e-19	3.99e-16	0.45	0.4	Body mass index;	chr5:98844109	chr5:98929171~98995013:+
PRAD	cis	rs6452524	0.901	rs1580309	ENSG00000249664.1	CTD-2227C6.2	9.31	5.26e-19	3.99e-16	0.47	0.4	Hypertension (SNP x SNP interaction);	chr5:83091948	chr5:83012285~83013109:-
PRAD	cis	rs2274273	0.934	rs10140869	ENSG00000258413.1	RP11-665C16.6	-9.31	5.29e-19	4.02e-16	-0.52	-0.4	Protein biomarker;	chr14:55328565	chr14:55262767~55272075:-
PRAD	cis	rs6991838	0.584	rs34494846	ENSG00000200714.1	Y_RNA	-9.31	5.3e-19	4.02e-16	-0.44	-0.4	Intelligence (multi-trait analysis);	chr8:65602397	chr8:65592731~65592820:+
PRAD	cis	rs6991838	0.584	rs1053087	ENSG00000200714.1	Y_RNA	-9.31	5.3e-19	4.02e-16	-0.44	-0.4	Intelligence (multi-trait analysis);	chr8:65603630	chr8:65592731~65592820:+
PRAD	cis	rs6991838	0.584	rs1053085	ENSG00000200714.1	Y_RNA	-9.31	5.3e-19	4.02e-16	-0.44	-0.4	Intelligence (multi-trait analysis);	chr8:65603753	chr8:65592731~65592820:+
PRAD	cis	rs12134133	1	rs2782848	ENSG00000274245.1	RP11-357P18.2	9.31	5.3e-19	4.02e-16	0.56	0.4	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207293407	chr1:207372559~207373252:+
PRAD	cis	rs12134133	0.962	rs2039543	ENSG00000274245.1	RP11-357P18.2	9.31	5.3e-19	4.02e-16	0.56	0.4	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207294228	chr1:207372559~207373252:+
PRAD	cis	rs12134133	1	rs2802232	ENSG00000274245.1	RP11-357P18.2	9.31	5.3e-19	4.02e-16	0.56	0.4	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207294806	chr1:207372559~207373252:+
PRAD	cis	rs12134133	0.962	rs2782847	ENSG00000274245.1	RP11-357P18.2	9.31	5.3e-19	4.02e-16	0.56	0.4	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207295766	chr1:207372559~207373252:+
PRAD	cis	rs7811142	1	rs11763511	ENSG00000242294.5	STAG3L5P	9.31	5.31e-19	4.03e-16	0.26	0.4	Platelet count;	chr7:100484321	chr7:100336079~100351900:+
PRAD	cis	rs9309473	1	rs11674602	ENSG00000163016.8	ALMS1P	9.31	5.33e-19	4.05e-16	0.5	0.4	Metabolite levels;	chr2:73496058	chr2:73644919~73685576:+
PRAD	cis	rs7569084	0.663	rs11126037	ENSG00000281920.1	RP11-418H16.1	9.31	5.34e-19	4.05e-16	0.49	0.4	Sum eosinophil basophil counts;	chr2:65436024	chr2:65623272~65628424:+
PRAD	cis	rs7569084	0.687	rs11126038	ENSG00000281920.1	RP11-418H16.1	9.31	5.34e-19	4.05e-16	0.49	0.4	Sum eosinophil basophil counts;	chr2:65436100	chr2:65623272~65628424:+
PRAD	cis	rs8100891	0.614	rs6510243	ENSG00000267213.4	AC007773.2	-9.31	5.34e-19	4.05e-16	-0.4	-0.4	Neuroticism;	chr19:32342765	chr19:32390050~32405560:-
PRAD	cis	rs4835473	0.808	rs1984810	ENSG00000251600.4	RP11-673E1.1	9.31	5.34e-19	4.05e-16	0.5	0.4	Immature fraction of reticulocytes;	chr4:143824970	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.831	rs1984809	ENSG00000251600.4	RP11-673E1.1	9.31	5.34e-19	4.05e-16	0.5	0.4	Immature fraction of reticulocytes;	chr4:143825018	chr4:143912331~143982454:+
PRAD	cis	rs858239	0.896	rs1637193	ENSG00000226816.2	AC005082.12	9.31	5.35e-19	4.06e-16	0.46	0.4	Cerebrospinal fluid biomarker levels;	chr7:23220632	chr7:23206013~23208045:+
PRAD	cis	rs1075265	0.87	rs1363062	ENSG00000233266.1	HMGB1P31	9.31	5.35e-19	4.06e-16	0.54	0.4	Chronotype;Morning vs. evening chronotype;	chr2:54054625	chr2:54051334~54051760:+
PRAD	cis	rs9545047	0.604	rs7331872	ENSG00000227676.3	LINC01068	-9.31	5.36e-19	4.07e-16	-0.48	-0.4	Schizophrenia;	chr13:79388717	chr13:79566727~79571436:+
PRAD	cis	rs2337406	0.866	rs7153964	ENSG00000274576.2	IGHV2-70	-9.31	5.39e-19	4.09e-16	-0.42	-0.4	Alzheimer's disease (late onset);	chr14:106790480	chr14:106770577~106771020:-
PRAD	cis	rs4713118	0.621	rs10484403	ENSG00000219392.1	RP1-265C24.5	-9.31	5.4e-19	4.1e-16	-0.52	-0.4	Parkinson's disease;	chr6:28065745	chr6:28115628~28116551:+
PRAD	cis	rs6142102	1	rs12480839	ENSG00000276073.1	RP5-1125A11.7	-9.31	5.41e-19	4.11e-16	-0.4	-0.4	Skin pigmentation;	chr20:34139624	chr20:33985617~33988989:-
PRAD	cis	rs2274273	0.868	rs9919926	ENSG00000258413.1	RP11-665C16.6	-9.31	5.42e-19	4.11e-16	-0.52	-0.4	Protein biomarker;	chr14:55347172	chr14:55262767~55272075:-
PRAD	cis	rs150992	0.585	rs331931	ENSG00000248489.1	CTD-2007H13.3	9.31	5.45e-19	4.14e-16	0.45	0.4	Body mass index;	chr5:98834012	chr5:98929171~98995013:+
PRAD	cis	rs4639966	0.569	rs603486	ENSG00000255239.1	AP002954.6	9.31	5.48e-19	4.15e-16	0.5	0.4	Systemic lupus erythematosus;	chr11:118716638	chr11:118688039~118690600:-
PRAD	cis	rs1501911	0.53	rs161941	ENSG00000248489.1	CTD-2007H13.3	-9.31	5.49e-19	4.16e-16	-0.45	-0.4	Lung function (FEV1/FVC);	chr5:98863500	chr5:98929171~98995013:+
PRAD	cis	rs10262624	1	rs17347505	ENSG00000234286.1	AC006026.13	-9.31	5.53e-19	4.19e-16	-0.45	-0.4	Schizophrenia;	chr7:23875664	chr7:23680195~23680786:-
PRAD	cis	rs10262624	1	rs12671584	ENSG00000234286.1	AC006026.13	-9.31	5.53e-19	4.19e-16	-0.45	-0.4	Schizophrenia;	chr7:23875803	chr7:23680195~23680786:-
PRAD	cis	rs638893	0.842	rs480791	ENSG00000278376.1	RP11-158I9.8	-9.31	5.55e-19	4.21e-16	-0.5	-0.4	Vitiligo;	chr11:118833546	chr11:118791254~118793137:+
PRAD	cis	rs17023223	0.537	rs2765530	ENSG00000231365.4	RP11-418J17.1	-9.31	5.56e-19	4.22e-16	-0.4	-0.4	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119041773	chr1:119140396~119275973:+
PRAD	cis	rs17023223	0.537	rs2765531	ENSG00000231365.4	RP11-418J17.1	-9.31	5.56e-19	4.22e-16	-0.4	-0.4	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119042874	chr1:119140396~119275973:+
PRAD	cis	rs17023223	0.537	rs2794313	ENSG00000231365.4	RP11-418J17.1	-9.31	5.56e-19	4.22e-16	-0.4	-0.4	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119044817	chr1:119140396~119275973:+
PRAD	cis	rs17023223	0.537	rs2794312	ENSG00000231365.4	RP11-418J17.1	-9.31	5.56e-19	4.22e-16	-0.4	-0.4	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119048423	chr1:119140396~119275973:+
PRAD	cis	rs4927850	1	rs7627706	ENSG00000242086.7	LINC00969	9.31	5.58e-19	4.23e-16	0.35	0.4	Pancreatic cancer;	chr3:196026482	chr3:195658062~195739964:+
PRAD	cis	rs4927850	0.881	rs7630489	ENSG00000242086.7	LINC00969	9.31	5.58e-19	4.23e-16	0.35	0.4	Pancreatic cancer;	chr3:196026530	chr3:195658062~195739964:+
PRAD	cis	rs4927850	1	rs7627868	ENSG00000242086.7	LINC00969	9.31	5.58e-19	4.23e-16	0.35	0.4	Pancreatic cancer;	chr3:196026602	chr3:195658062~195739964:+
PRAD	cis	rs6061231	1	rs11696991	ENSG00000273619.1	RP5-908M14.9	-9.31	5.59e-19	4.24e-16	-0.26	-0.4	Colorectal cancer;	chr20:62384638	chr20:62386303~62386970:-
PRAD	cis	rs6430553	0.964	rs62168869	ENSG00000224043.6	CCNT2-AS1	-9.31	5.59e-19	4.24e-16	-0.54	-0.4	Blood metabolite levels;	chr2:134889209	chr2:134735464~134918710:-
PRAD	cis	rs673078	0.66	rs73205551	ENSG00000275759.1	RP11-131L12.3	-9.31	5.6e-19	4.24e-16	-0.55	-0.4	Glucose homeostasis traits;	chr12:118330808	chr12:118428281~118428870:+
PRAD	cis	rs4879677	0.959	rs2150021	ENSG00000260390.1	RP11-575I8.1	9.31	5.6e-19	4.24e-16	0.53	0.4	Gut microbiome composition (summer and winter);	chr9:27688292	chr9:27829276~27844481:+
PRAD	cis	rs4879677	0.959	rs4878536	ENSG00000260390.1	RP11-575I8.1	-9.31	5.6e-19	4.25e-16	-0.54	-0.4	Gut microbiome composition (summer and winter);	chr9:27682259	chr9:27829276~27844481:+
PRAD	cis	rs11951515	0.738	rs2330242	ENSG00000188850.9	RP11-159F24.2	9.31	5.61e-19	4.25e-16	0.48	0.4	Metabolite levels  (X-11787);	chr5:43361566	chr5:43336164~43348716:+
PRAD	cis	rs10262624	0.967	rs2390848	ENSG00000234286.1	AC006026.13	-9.31	5.61e-19	4.26e-16	-0.45	-0.4	Schizophrenia;	chr7:23872755	chr7:23680195~23680786:-
PRAD	cis	rs7772486	0.875	rs13198450	ENSG00000235652.6	RP11-545I5.3	9.31	5.63e-19	4.26e-16	0.41	0.4	Lobe attachment (rater-scored or self-reported);	chr6:146049388	chr6:145799409~145886585:+
PRAD	cis	rs7712401	0.601	rs30028	ENSG00000263432.2	RN7SL689P	9.31	5.64e-19	4.27e-16	0.41	0.4	Mean platelet volume;	chr5:122947574	chr5:123022487~123022783:-
PRAD	cis	rs11123170	0.64	rs1015754	ENSG00000274877.1	RP11-65I12.1	9.31	5.66e-19	4.29e-16	0.59	0.4	Renal function-related traits (BUN);	chr2:113210413	chr2:113237595~113240825:+
PRAD	cis	rs12049351	0.665	rs7545592	ENSG00000229367.1	HMGN2P19	9.31	5.67e-19	4.3e-16	0.57	0.4	Circulating myeloperoxidase levels (plasma);	chr1:229456913	chr1:229570532~229570796:+
PRAD	cis	rs9322193	0.566	rs6912330	ENSG00000216906.2	RP11-350J20.9	-9.31	5.68e-19	4.3e-16	-0.52	-0.4	Lung cancer;	chr6:149908811	chr6:149904243~149906418:+
PRAD	cis	rs7189233	0.531	rs16952246	ENSG00000279344.1	RP11-44F14.7	9.3	5.74e-19	4.35e-16	0.36	0.4	Intelligence (multi-trait analysis);	chr16:53446797	chr16:53478957~53481550:-
PRAD	cis	rs9309711	0.643	rs10188449	ENSG00000225234.1	TRAPPC12-AS1	-9.3	5.74e-19	4.35e-16	-0.4	-0.4	Neurofibrillary tangles;	chr2:3476595	chr2:3481242~3482409:-
PRAD	cis	rs6723108	0.517	rs6711390	ENSG00000224043.6	CCNT2-AS1	-9.3	5.75e-19	4.36e-16	-0.54	-0.4	Type 2 diabetes;	chr2:134871869	chr2:134735464~134918710:-
PRAD	cis	rs6538678	0.746	rs1865736	ENSG00000258343.1	RP11-536G4.2	-9.3	5.76e-19	4.37e-16	-0.63	-0.4	Lupus nephritis in systemic lupus erythematosus;	chr12:95854051	chr12:95795345~95858839:-
PRAD	cis	rs2282300	0.739	rs34951229	ENSG00000242353.1	RP4-710M3.1	-9.3	5.78e-19	4.37e-16	-0.48	-0.4	Morning vs. evening chronotype;	chr11:30243619	chr11:30368148~30368646:+
PRAD	cis	rs9322193	0.607	rs6925151	ENSG00000216906.2	RP11-350J20.9	9.3	5.81e-19	4.4e-16	0.51	0.4	Lung cancer;	chr6:149889587	chr6:149904243~149906418:+
PRAD	cis	rs11673344	0.764	rs10424584	ENSG00000226686.6	LINC01535	9.3	5.82e-19	4.4e-16	0.54	0.4	Obesity-related traits;	chr19:36975986	chr19:37251912~37265535:+
PRAD	cis	rs321358	0.895	rs73015171	ENSG00000271584.1	RP11-89C3.4	9.3	5.82e-19	4.4e-16	0.6	0.4	Body mass index;	chr11:111087535	chr11:111091932~111097357:-
PRAD	cis	rs321358	0.895	rs17457658	ENSG00000271584.1	RP11-89C3.4	9.3	5.82e-19	4.4e-16	0.6	0.4	Body mass index;	chr11:111089448	chr11:111091932~111097357:-
PRAD	cis	rs56080343	0.748	rs2893771	ENSG00000275759.1	RP11-131L12.3	-9.3	5.83e-19	4.42e-16	-0.7	-0.4	Neuroticism;	chr12:118440051	chr12:118428281~118428870:+
PRAD	cis	rs10262624	0.967	rs2188845	ENSG00000234286.1	AC006026.13	-9.3	5.86e-19	4.43e-16	-0.46	-0.4	Schizophrenia;	chr7:23882391	chr7:23680195~23680786:-
PRAD	cis	rs4835473	0.897	rs11727223	ENSG00000251600.4	RP11-673E1.1	9.3	5.92e-19	4.48e-16	0.51	0.4	Immature fraction of reticulocytes;	chr4:143707090	chr4:143912331~143982454:+
PRAD	cis	rs67311347	1	rs56992941	ENSG00000223797.4	ENTPD3-AS1	9.3	5.93e-19	4.49e-16	0.35	0.4	Renal cell carcinoma;	chr3:40430943	chr3:40313802~40453329:-
PRAD	cis	rs67311347	1	rs4974017	ENSG00000223797.4	ENTPD3-AS1	9.3	5.93e-19	4.49e-16	0.35	0.4	Renal cell carcinoma;	chr3:40432028	chr3:40313802~40453329:-
PRAD	cis	rs67311347	1	rs6762997	ENSG00000223797.4	ENTPD3-AS1	9.3	5.93e-19	4.49e-16	0.35	0.4	Renal cell carcinoma;	chr3:40436660	chr3:40313802~40453329:-
PRAD	cis	rs12468226	1	rs2350809	ENSG00000273456.1	RP11-686O6.2	9.3	5.93e-19	4.49e-16	0.54	0.4	Urate levels;	chr2:202464210	chr2:202374932~202375604:-
PRAD	cis	rs7811142	0.83	rs75636500	ENSG00000242294.5	STAG3L5P	9.3	5.93e-19	4.49e-16	0.27	0.4	Platelet count;	chr7:100350034	chr7:100336079~100351900:+
PRAD	cis	rs6723108	0.517	rs7580655	ENSG00000224043.6	CCNT2-AS1	-9.3	5.97e-19	4.52e-16	-0.54	-0.4	Type 2 diabetes;	chr2:134869605	chr2:134735464~134918710:-
PRAD	cis	rs7712401	0.601	rs30039	ENSG00000263432.2	RN7SL689P	-9.3	6.02e-19	4.55e-16	-0.41	-0.4	Mean platelet volume;	chr5:122941484	chr5:123022487~123022783:-
PRAD	cis	rs2108622	0.727	rs3093193	ENSG00000267453.5	AC004791.2	-9.3	6.02e-19	4.55e-16	-0.53	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15881104	chr19:15851993~15864904:-
PRAD	cis	rs2919917	0.628	rs12680932	ENSG00000254352.1	RP11-578O24.2	-9.3	6.04e-19	4.57e-16	-0.54	-0.4	Lymphocyte counts;	chr8:78685516	chr8:78723796~78724136:-
PRAD	cis	rs3745672	0.744	rs10403392	ENSG00000219665.7	CTD-2006C1.2	-9.3	6.1e-19	4.62e-16	-0.9	-0.4	Multiple sclerosis;	chr19:12042774	chr19:11987617~12046275:+
PRAD	cis	rs10262624	0.967	rs10229233	ENSG00000234286.1	AC006026.13	-9.3	6.11e-19	4.62e-16	-0.45	-0.4	Schizophrenia;	chr7:23867900	chr7:23680195~23680786:-
PRAD	cis	rs10262624	1	rs10245161	ENSG00000234286.1	AC006026.13	-9.3	6.11e-19	4.62e-16	-0.45	-0.4	Schizophrenia;	chr7:23868073	chr7:23680195~23680786:-
PRAD	cis	rs7189233	0.531	rs1072910	ENSG00000279344.1	RP11-44F14.7	9.3	6.13e-19	4.63e-16	0.36	0.4	Intelligence (multi-trait analysis);	chr16:53465687	chr16:53478957~53481550:-
PRAD	cis	rs67311347	1	rs4973989	ENSG00000223797.4	ENTPD3-AS1	9.3	6.13e-19	4.64e-16	0.37	0.4	Renal cell carcinoma;	chr3:40410052	chr3:40313802~40453329:-
PRAD	cis	rs67311347	1	rs12634013	ENSG00000223797.4	ENTPD3-AS1	9.3	6.13e-19	4.64e-16	0.37	0.4	Renal cell carcinoma;	chr3:40410897	chr3:40313802~40453329:-
PRAD	cis	rs67311347	1	rs6793596	ENSG00000223797.4	ENTPD3-AS1	9.3	6.13e-19	4.64e-16	0.37	0.4	Renal cell carcinoma;	chr3:40416304	chr3:40313802~40453329:-
PRAD	cis	rs67311347	1	rs73078123	ENSG00000223797.4	ENTPD3-AS1	9.3	6.13e-19	4.64e-16	0.37	0.4	Renal cell carcinoma;	chr3:40417472	chr3:40313802~40453329:-
PRAD	cis	rs67311347	1	rs4973998	ENSG00000223797.4	ENTPD3-AS1	9.3	6.13e-19	4.64e-16	0.37	0.4	Renal cell carcinoma;	chr3:40418861	chr3:40313802~40453329:-
PRAD	cis	rs67311347	1	rs73078162	ENSG00000223797.4	ENTPD3-AS1	9.3	6.13e-19	4.64e-16	0.37	0.4	Renal cell carcinoma;	chr3:40435618	chr3:40313802~40453329:-
PRAD	cis	rs67311347	1	rs73078163	ENSG00000223797.4	ENTPD3-AS1	9.3	6.13e-19	4.64e-16	0.37	0.4	Renal cell carcinoma;	chr3:40438467	chr3:40313802~40453329:-
PRAD	cis	rs4964805	0.913	rs36034617	ENSG00000257681.1	RP11-341G23.4	9.3	6.15e-19	4.65e-16	0.4	0.4	Attention deficit hyperactivity disorder;	chr12:103809837	chr12:103746315~103768858:-
PRAD	cis	rs9545047	0.604	rs28579970	ENSG00000227676.3	LINC01068	-9.29	6.2e-19	4.69e-16	-0.46	-0.4	Schizophrenia;	chr13:79308726	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs1980883	ENSG00000227676.3	LINC01068	-9.29	6.2e-19	4.69e-16	-0.46	-0.4	Schizophrenia;	chr13:79310629	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs9565486	ENSG00000227676.3	LINC01068	-9.29	6.2e-19	4.69e-16	-0.46	-0.4	Schizophrenia;	chr13:79317469	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs12875039	ENSG00000227676.3	LINC01068	-9.29	6.2e-19	4.69e-16	-0.46	-0.4	Schizophrenia;	chr13:79327449	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.604	rs9285310	ENSG00000227676.3	LINC01068	-9.29	6.2e-19	4.69e-16	-0.46	-0.4	Schizophrenia;	chr13:79328340	chr13:79566727~79571436:+
PRAD	cis	rs9545047	0.625	rs9593391	ENSG00000227676.3	LINC01068	-9.29	6.2e-19	4.69e-16	-0.46	-0.4	Schizophrenia;	chr13:79329168	chr13:79566727~79571436:+
PRAD	cis	rs3814244	0.788	rs11177014	ENSG00000255733.4	IFNG-AS1	-9.29	6.21e-19	4.69e-16	-0.41	-0.4	Itch intensity from mosquito bite adjusted by bite size;	chr12:68031871	chr12:67989445~68234686:+
PRAD	cis	rs2108622	0.727	rs8104311	ENSG00000267453.5	AC004791.2	-9.29	6.21e-19	4.69e-16	-0.52	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871950	chr19:15851993~15864904:-
PRAD	cis	rs12134133	1	rs2661357	ENSG00000274245.1	RP11-357P18.2	9.29	6.23e-19	4.7e-16	0.55	0.4	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207310593	chr1:207372559~207373252:+
PRAD	cis	rs67311347	0.956	rs9817233	ENSG00000223797.4	ENTPD3-AS1	9.29	6.26e-19	4.73e-16	0.37	0.4	Renal cell carcinoma;	chr3:40384127	chr3:40313802~40453329:-
PRAD	cis	rs67311347	1	rs9817142	ENSG00000223797.4	ENTPD3-AS1	9.29	6.26e-19	4.73e-16	0.37	0.4	Renal cell carcinoma;	chr3:40384283	chr3:40313802~40453329:-
PRAD	cis	rs10800713	0.954	rs4623737	ENSG00000260088.1	RP11-92G12.3	-9.29	6.27e-19	4.73e-16	-0.48	-0.4	Tandem gait;	chr1:200594578	chr1:200669507~200694250:+
PRAD	cis	rs2337406	0.866	rs58850145	ENSG00000274576.2	IGHV2-70	-9.29	6.27e-19	4.74e-16	-0.42	-0.4	Alzheimer's disease (late onset);	chr14:106806185	chr14:106770577~106771020:-
PRAD	cis	rs10262624	0.967	rs35988560	ENSG00000234286.1	AC006026.13	-9.29	6.3e-19	4.75e-16	-0.46	-0.4	Schizophrenia;	chr7:23878561	chr7:23680195~23680786:-
PRAD	cis	rs2404602	1	rs6495206	ENSG00000259422.1	RP11-593F23.1	9.29	6.3e-19	4.75e-16	0.49	0.4	Blood metabolite levels;	chr15:76578622	chr15:76174891~76181486:-
PRAD	cis	rs2404602	1	rs1117367	ENSG00000259422.1	RP11-593F23.1	9.29	6.3e-19	4.75e-16	0.49	0.4	Blood metabolite levels;	chr15:76579989	chr15:76174891~76181486:-
PRAD	cis	rs11951515	0.7	rs7714027	ENSG00000188850.9	RP11-159F24.2	9.29	6.32e-19	4.77e-16	0.48	0.4	Metabolite levels  (X-11787);	chr5:43373116	chr5:43336164~43348716:+
PRAD	cis	rs67311347	1	rs9854493	ENSG00000223797.4	ENTPD3-AS1	9.29	6.33e-19	4.78e-16	0.37	0.4	Renal cell carcinoma;	chr3:40382131	chr3:40313802~40453329:-
PRAD	cis	rs2286503	1	rs2286498	ENSG00000228649.7	AC005682.5	-9.29	6.36e-19	4.8e-16	-0.45	-0.4	Fibrinogen;	chr7:22817885	chr7:22854178~22861579:+
PRAD	cis	rs3002131	0.522	rs2378583	ENSG00000225265.1	TAF1A-AS1	-9.29	6.38e-19	4.81e-16	-0.73	-0.4	Interleukin-10 levels;	chr1:222565958	chr1:222589825~222593032:+
PRAD	cis	rs17023223	0.537	rs2645305	ENSG00000231365.4	RP11-418J17.1	-9.29	6.39e-19	4.82e-16	-0.41	-0.4	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119018742	chr1:119140396~119275973:+
PRAD	cis	rs9322193	0.607	rs12210822	ENSG00000216906.2	RP11-350J20.9	9.29	6.4e-19	4.83e-16	0.52	0.4	Lung cancer;	chr6:149905356	chr6:149904243~149906418:+
PRAD	cis	rs11673344	0.704	rs510757	ENSG00000226686.6	LINC01535	-9.29	6.41e-19	4.84e-16	-0.53	-0.4	Obesity-related traits;	chr19:36931900	chr19:37251912~37265535:+
PRAD	cis	rs11951515	0.714	rs11956635	ENSG00000188850.9	RP11-159F24.2	9.29	6.42e-19	4.85e-16	0.48	0.4	Metabolite levels  (X-11787);	chr5:43371926	chr5:43336164~43348716:+
PRAD	cis	rs4835473	0.897	rs11100812	ENSG00000251600.4	RP11-673E1.1	9.29	6.43e-19	4.85e-16	0.5	0.4	Immature fraction of reticulocytes;	chr4:143790400	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.545	rs10022856	ENSG00000251600.4	RP11-673E1.1	9.29	6.43e-19	4.85e-16	0.5	0.4	Immature fraction of reticulocytes;	chr4:143793157	chr4:143912331~143982454:+
PRAD	cis	rs7772486	0.846	rs2144478	ENSG00000235652.6	RP11-545I5.3	9.29	6.43e-19	4.85e-16	0.41	0.4	Lobe attachment (rater-scored or self-reported);	chr6:146060309	chr6:145799409~145886585:+
PRAD	cis	rs4713118	0.868	rs760587	ENSG00000280107.1	AL022393.9	-9.29	6.52e-19	4.91e-16	-0.52	-0.4	Parkinson's disease;	chr6:27772521	chr6:28170845~28172521:+
PRAD	cis	rs1075265	0.621	rs2542593	ENSG00000233266.1	HMGB1P31	9.29	6.54e-19	4.93e-16	0.54	0.4	Chronotype;Morning vs. evening chronotype;	chr2:53804299	chr2:54051334~54051760:+
PRAD	cis	rs1501911	0.53	rs331926	ENSG00000248489.1	CTD-2007H13.3	9.29	6.56e-19	4.95e-16	0.44	0.4	Lung function (FEV1/FVC);	chr5:98828697	chr5:98929171~98995013:+
PRAD	cis	rs7772486	0.875	rs6930975	ENSG00000235652.6	RP11-545I5.3	9.29	6.61e-19	4.98e-16	0.41	0.4	Lobe attachment (rater-scored or self-reported);	chr6:146065975	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.875	rs9322046	ENSG00000235652.6	RP11-545I5.3	9.29	6.61e-19	4.98e-16	0.41	0.4	Lobe attachment (rater-scored or self-reported);	chr6:146072489	chr6:145799409~145886585:+
PRAD	cis	rs4879677	1	rs4879677	ENSG00000260390.1	RP11-575I8.1	9.29	6.64e-19	5.01e-16	0.54	0.4	Gut microbiome composition (summer and winter);	chr9:27664434	chr9:27829276~27844481:+
PRAD	cis	rs2153535	0.56	rs1328866	ENSG00000230939.1	RP11-314C16.1	-9.29	6.65e-19	5.01e-16	-0.48	-0.4	Motion sickness;	chr6:8653283	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.585	rs1328865	ENSG00000230939.1	RP11-314C16.1	-9.29	6.65e-19	5.01e-16	-0.48	-0.4	Motion sickness;	chr6:8653454	chr6:8784178~8785445:+
PRAD	cis	rs10262624	1	rs17347692	ENSG00000234286.1	AC006026.13	-9.28	6.68e-19	5.03e-16	-0.46	-0.4	Schizophrenia;	chr7:23878748	chr7:23680195~23680786:-
PRAD	cis	rs2404602	0.532	rs206205	ENSG00000259422.1	RP11-593F23.1	9.28	6.7e-19	5.05e-16	0.5	0.4	Blood metabolite levels;	chr15:76443750	chr15:76174891~76181486:-
PRAD	cis	rs4713118	0.866	rs9468217	ENSG00000280107.1	AL022393.9	-9.28	6.74e-19	5.07e-16	-0.51	-0.4	Parkinson's disease;	chr6:27758688	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.911	rs9295746	ENSG00000280107.1	AL022393.9	-9.28	6.74e-19	5.07e-16	-0.51	-0.4	Parkinson's disease;	chr6:27762285	chr6:28170845~28172521:+
PRAD	cis	rs2348418	0.864	rs1343859	ENSG00000247934.4	RP11-967K21.1	9.28	6.76e-19	5.09e-16	0.36	0.4	Lung function (FEV1);Lung function (FVC);	chr12:28559537	chr12:28163298~28190738:-
PRAD	cis	rs2337406	0.866	rs2027901	ENSG00000274576.2	IGHV2-70	-9.28	6.77e-19	5.1e-16	-0.42	-0.4	Alzheimer's disease (late onset);	chr14:106807164	chr14:106770577~106771020:-
PRAD	cis	rs1075265	0.587	rs2949812	ENSG00000233266.1	HMGB1P31	9.28	6.8e-19	5.12e-16	0.54	0.4	Chronotype;Morning vs. evening chronotype;	chr2:53797190	chr2:54051334~54051760:+
PRAD	cis	rs11673344	0.704	rs1726719	ENSG00000226686.6	LINC01535	9.28	6.85e-19	5.15e-16	0.54	0.4	Obesity-related traits;	chr19:36927130	chr19:37251912~37265535:+
PRAD	cis	rs35160687	0.842	rs10200619	ENSG00000273080.1	RP11-301O19.1	-9.28	6.9e-19	5.19e-16	-0.47	-0.4	Night sleep phenotypes;	chr2:86321725	chr2:86195590~86196049:+
PRAD	cis	rs10262624	1	rs17347733	ENSG00000234286.1	AC006026.13	-9.28	6.91e-19	5.2e-16	-0.46	-0.4	Schizophrenia;	chr7:23878891	chr7:23680195~23680786:-
PRAD	cis	rs12468226	1	rs11899836	ENSG00000273456.1	RP11-686O6.2	9.28	6.93e-19	5.22e-16	0.53	0.4	Urate levels;	chr2:202371316	chr2:202374932~202375604:-
PRAD	cis	rs732716	0.889	rs55637375	ENSG00000267980.1	AC007292.6	-9.28	7e-19	5.27e-16	-0.4	-0.4	Mean corpuscular volume;	chr19:4386848	chr19:4363789~4364640:+
PRAD	cis	rs1891275	0.551	rs11186640	ENSG00000228701.1	TNKS2-AS1	-9.28	7e-19	5.27e-16	-0.53	-0.4	Intelligence (multi-trait analysis);	chr10:91640674	chr10:91782839~91798291:-
PRAD	cis	rs17023223	0.537	rs2645301	ENSG00000231365.4	RP11-418J17.1	-9.28	7.02e-19	5.28e-16	-0.4	-0.4	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119047797	chr1:119140396~119275973:+
PRAD	cis	rs75422866	0.764	rs73104177	ENSG00000257433.4	RP1-197B17.3	9.28	7.03e-19	5.29e-16	0.94	0.4	Pneumonia;	chr12:47713550	chr12:47706085~47742294:+
PRAD	cis	rs9399135	0.527	rs61738492	ENSG00000232876.1	CTA-212D2.2	-9.28	7.06e-19	5.31e-16	-0.51	-0.4	Red blood cell count;	chr6:134961633	chr6:135055033~135060550:+
PRAD	cis	rs9309473	1	rs1403284	ENSG00000163016.8	ALMS1P	-9.28	7.12e-19	5.35e-16	-0.51	-0.4	Metabolite levels;	chr2:73499535	chr2:73644919~73685576:+
PRAD	cis	rs2404602	1	rs4886818	ENSG00000259422.1	RP11-593F23.1	9.28	7.13e-19	5.36e-16	0.49	0.4	Blood metabolite levels;	chr15:76588598	chr15:76174891~76181486:-
PRAD	cis	rs2404602	1	rs11072603	ENSG00000259422.1	RP11-593F23.1	9.28	7.13e-19	5.36e-16	0.49	0.4	Blood metabolite levels;	chr15:76588797	chr15:76174891~76181486:-
PRAD	cis	rs9309473	0.95	rs13391258	ENSG00000163016.8	ALMS1P	9.28	7.14e-19	5.37e-16	0.5	0.4	Metabolite levels;	chr2:73621806	chr2:73644919~73685576:+
PRAD	cis	rs9309473	0.898	rs6546861	ENSG00000163016.8	ALMS1P	9.28	7.14e-19	5.37e-16	0.5	0.4	Metabolite levels;	chr2:73622734	chr2:73644919~73685576:+
PRAD	cis	rs17711722	0.565	rs4275112	ENSG00000228409.4	CCT6P1	9.28	7.17e-19	5.39e-16	0.29	0.4	Calcium levels;	chr7:65733651	chr7:65751142~65763354:+
PRAD	cis	rs2274273	0.773	rs10147765	ENSG00000258413.1	RP11-665C16.6	-9.28	7.17e-19	5.39e-16	-0.52	-0.4	Protein biomarker;	chr14:55361108	chr14:55262767~55272075:-
PRAD	cis	rs7712401	0.715	rs13163098	ENSG00000263432.2	RN7SL689P	-9.28	7.19e-19	5.4e-16	-0.41	-0.4	Mean platelet volume;	chr5:123010841	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.715	rs13164161	ENSG00000263432.2	RN7SL689P	-9.28	7.19e-19	5.4e-16	-0.41	-0.4	Mean platelet volume;	chr5:123011202	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.715	rs401226	ENSG00000263432.2	RN7SL689P	-9.28	7.19e-19	5.4e-16	-0.41	-0.4	Mean platelet volume;	chr5:123012031	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.715	rs395981	ENSG00000263432.2	RN7SL689P	-9.28	7.19e-19	5.4e-16	-0.41	-0.4	Mean platelet volume;	chr5:123012216	chr5:123022487~123022783:-
PRAD	cis	rs2348418	0.864	rs7312339	ENSG00000247934.4	RP11-967K21.1	9.27	7.23e-19	5.43e-16	0.36	0.4	Lung function (FEV1);Lung function (FVC);	chr12:28558751	chr12:28163298~28190738:-
PRAD	cis	rs2274273	0.84	rs10136596	ENSG00000258413.1	RP11-665C16.6	-9.27	7.32e-19	5.5e-16	-0.51	-0.4	Protein biomarker;	chr14:55370055	chr14:55262767~55272075:-
PRAD	cis	rs7044106	0.887	rs1359328	ENSG00000226752.6	PSMD5-AS1	-9.27	7.33e-19	5.51e-16	-0.55	-0.4	Hip circumference adjusted for BMI;	chr9:120608544	chr9:120824828~120854385:+
PRAD	cis	rs2404602	0.716	rs12594577	ENSG00000259422.1	RP11-593F23.1	9.27	7.36e-19	5.53e-16	0.5	0.4	Blood metabolite levels;	chr15:76536452	chr15:76174891~76181486:-
PRAD	cis	rs2739330	0.892	rs4822455	ENSG00000224205.1	AP000351.4	9.27	7.37e-19	5.54e-16	0.5	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23987320~23991421:-
PRAD	cis	rs1861353	0.863	rs16952252	ENSG00000279344.1	RP11-44F14.7	9.27	7.4e-19	5.55e-16	0.36	0.4	Intelligence (multi-trait analysis);	chr16:53450068	chr16:53478957~53481550:-
PRAD	cis	rs4266144	0.821	rs4325879	ENSG00000244515.1	KRT18P34	-9.27	7.4e-19	5.55e-16	-0.53	-0.4	Coronary artery disease;	chr3:157134195	chr3:157162663~157163932:-
PRAD	cis	rs2442825	0.526	rs6443237	ENSG00000206573.7	THUMPD3-AS1	-9.27	7.44e-19	5.58e-16	-0.3	-0.4	Cerebrospinal fluid clusterin levels;	chr3:9395777	chr3:9349689~9398579:-
PRAD	cis	rs7811142	1	rs68116612	ENSG00000242294.5	STAG3L5P	9.27	7.52e-19	5.65e-16	0.26	0.4	Platelet count;	chr7:100408870	chr7:100336079~100351900:+
PRAD	cis	rs10262624	0.967	rs13235406	ENSG00000234286.1	AC006026.13	-9.27	7.56e-19	5.67e-16	-0.46	-0.4	Schizophrenia;	chr7:23879212	chr7:23680195~23680786:-
PRAD	cis	rs524281	0.682	rs34274349	ENSG00000255320.1	RP11-755F10.1	-9.27	7.57e-19	5.68e-16	-0.67	-0.4	Electroencephalogram traits;	chr11:66030595	chr11:66244840~66246239:-
PRAD	cis	rs524281	0.731	rs730787	ENSG00000255320.1	RP11-755F10.1	-9.27	7.57e-19	5.68e-16	-0.67	-0.4	Electroencephalogram traits;	chr11:66031488	chr11:66244840~66246239:-
PRAD	cis	rs2658782	0.654	rs2248531	ENSG00000279684.1	RP11-755E23.2	-9.27	7.58e-19	5.69e-16	-0.59	-0.4	Pulmonary function decline;	chr11:93522197	chr11:93286629~93288903:-
PRAD	cis	rs4835473	0.932	rs13152209	ENSG00000251600.4	RP11-673E1.1	9.27	7.58e-19	5.69e-16	0.5	0.4	Immature fraction of reticulocytes;	chr4:143776088	chr4:143912331~143982454:+
PRAD	cis	rs11096990	0.551	rs11724855	ENSG00000249207.1	RP11-360F5.1	-9.27	7.62e-19	5.72e-16	-0.41	-0.4	Cognitive function;	chr4:39163379	chr4:39112677~39126818:-
PRAD	cis	rs67311347	0.955	rs4973999	ENSG00000223797.4	ENTPD3-AS1	9.27	7.73e-19	5.8e-16	0.35	0.4	Renal cell carcinoma;	chr3:40418892	chr3:40313802~40453329:-
PRAD	cis	rs67311347	1	rs1466236	ENSG00000223797.4	ENTPD3-AS1	9.27	7.73e-19	5.8e-16	0.35	0.4	Renal cell carcinoma;	chr3:40420671	chr3:40313802~40453329:-
PRAD	cis	rs6570726	0.846	rs4896824	ENSG00000235652.6	RP11-545I5.3	9.27	7.75e-19	5.81e-16	0.41	0.4	Lobe attachment (rater-scored or self-reported);	chr6:145605912	chr6:145799409~145886585:+
PRAD	cis	rs12220777	0.892	rs72644219	ENSG00000230091.5	TMEM254-AS1	9.27	7.77e-19	5.82e-16	0.76	0.4	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80036457	chr10:80046860~80078912:-
PRAD	cis	rs7849270	0.798	rs7865337	ENSG00000268707.1	RP11-247A12.7	-9.27	7.79e-19	5.84e-16	-0.47	-0.4	Blood metabolite ratios;	chr9:129091799	chr9:129170434~129170940:+
PRAD	cis	rs4713118	0.868	rs7756968	ENSG00000280107.1	AL022393.9	-9.26	7.8e-19	5.85e-16	-0.52	-0.4	Parkinson's disease;	chr6:27767175	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.826	rs2893929	ENSG00000280107.1	AL022393.9	-9.26	7.8e-19	5.85e-16	-0.52	-0.4	Parkinson's disease;	chr6:27770953	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.666	rs4140646	ENSG00000280107.1	AL022393.9	-9.26	7.8e-19	5.85e-16	-0.52	-0.4	Parkinson's disease;	chr6:27771022	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.666	rs2893930	ENSG00000280107.1	AL022393.9	-9.26	7.8e-19	5.85e-16	-0.52	-0.4	Parkinson's disease;	chr6:27771027	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.868	rs742047	ENSG00000280107.1	AL022393.9	-9.26	7.8e-19	5.85e-16	-0.52	-0.4	Parkinson's disease;	chr6:27771601	chr6:28170845~28172521:+
PRAD	cis	rs11676348	0.838	rs17844697	ENSG00000261338.2	RP11-378A13.1	-9.26	7.81e-19	5.85e-16	-0.43	-0.4	Ulcerative colitis;	chr2:218134532	chr2:218255319~218257366:+
PRAD	cis	rs9399137	0.507	rs7772031	ENSG00000232876.1	CTA-212D2.2	9.26	7.81e-19	5.85e-16	0.51	0.4	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134938596	chr6:135055033~135060550:+
PRAD	cis	rs11690935	0.589	rs6729945	ENSG00000228389.1	AC068039.4	-9.26	7.86e-19	5.89e-16	-0.45	-0.4	Schizophrenia;	chr2:171999788	chr2:171773482~171775844:+
PRAD	cis	rs11690935	0.589	rs62183782	ENSG00000228389.1	AC068039.4	-9.26	7.86e-19	5.89e-16	-0.45	-0.4	Schizophrenia;	chr2:172000102	chr2:171773482~171775844:+
PRAD	cis	rs67311347	1	rs1004655	ENSG00000223797.4	ENTPD3-AS1	9.26	7.86e-19	5.89e-16	0.37	0.4	Renal cell carcinoma;	chr3:40448518	chr3:40313802~40453329:-
PRAD	cis	rs7712401	0.601	rs246287	ENSG00000263432.2	RN7SL689P	9.26	7.88e-19	5.91e-16	0.41	0.4	Mean platelet volume;	chr5:122909731	chr5:123022487~123022783:-
PRAD	cis	rs10740039	0.583	rs2127351	ENSG00000254271.1	RP11-131N11.4	-9.26	7.91e-19	5.93e-16	-0.55	-0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60741425	chr10:60734342~60741828:+
PRAD	cis	rs7772486	0.686	rs9497380	ENSG00000235652.6	RP11-545I5.3	9.26	7.93e-19	5.94e-16	0.41	0.4	Lobe attachment (rater-scored or self-reported);	chr6:145634169	chr6:145799409~145886585:+
PRAD	cis	rs11951515	0.738	rs12518127	ENSG00000188850.9	RP11-159F24.2	-9.26	7.95e-19	5.95e-16	-0.48	-0.4	Metabolite levels  (X-11787);	chr5:43369286	chr5:43336164~43348716:+
PRAD	cis	rs11951515	0.738	rs10941631	ENSG00000188850.9	RP11-159F24.2	9.26	7.95e-19	5.95e-16	0.48	0.4	Metabolite levels  (X-11787);	chr5:43363907	chr5:43336164~43348716:+
PRAD	cis	rs11951515	0.714	rs10805675	ENSG00000188850.9	RP11-159F24.2	9.26	7.95e-19	5.95e-16	0.48	0.4	Metabolite levels  (X-11787);	chr5:43363942	chr5:43336164~43348716:+
PRAD	cis	rs11951515	0.7	rs11956936	ENSG00000188850.9	RP11-159F24.2	9.26	7.95e-19	5.95e-16	0.48	0.4	Metabolite levels  (X-11787);	chr5:43367247	chr5:43336164~43348716:+
PRAD	cis	rs11951515	0.738	rs11960415	ENSG00000188850.9	RP11-159F24.2	9.26	7.95e-19	5.95e-16	0.48	0.4	Metabolite levels  (X-11787);	chr5:43367407	chr5:43336164~43348716:+
PRAD	cis	rs11951515	0.738	rs10512827	ENSG00000188850.9	RP11-159F24.2	9.26	7.95e-19	5.95e-16	0.48	0.4	Metabolite levels  (X-11787);	chr5:43367964	chr5:43336164~43348716:+
PRAD	cis	rs2739330	0.828	rs4820572	ENSG00000235689.1	AP000351.13	9.26	7.95e-19	5.96e-16	0.49	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:24006305~24008258:-
PRAD	cis	rs7189233	0.531	rs7204496	ENSG00000279344.1	RP11-44F14.7	-9.26	7.96e-19	5.96e-16	-0.35	-0.4	Intelligence (multi-trait analysis);	chr16:53462686	chr16:53478957~53481550:-
PRAD	cis	rs7811142	1	rs6979335	ENSG00000242294.5	STAG3L5P	9.26	8.01e-19	6e-16	0.27	0.4	Platelet count;	chr7:100492237	chr7:100336079~100351900:+
PRAD	cis	rs9326248	0.52	rs74830	ENSG00000280143.1	AP000892.6	-9.26	8.01e-19	6e-16	-0.3	-0.4	Blood protein levels;	chr11:117219842	chr11:117204967~117210292:+
PRAD	cis	rs4835473	0.9	rs10032963	ENSG00000251600.4	RP11-673E1.1	9.26	8.02e-19	6.01e-16	0.5	0.4	Immature fraction of reticulocytes;	chr4:143733068	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs28796049	ENSG00000251600.4	RP11-673E1.1	9.26	8.02e-19	6.01e-16	0.5	0.4	Immature fraction of reticulocytes;	chr4:143733990	chr4:143912331~143982454:+
PRAD	cis	rs34779708	0.966	rs1213392	ENSG00000230534.5	RP11-297A16.2	9.26	8.04e-19	6.02e-16	0.51	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35141357	chr10:35098006~35127020:-
PRAD	cis	rs6570726	0.846	rs6570700	ENSG00000235652.6	RP11-545I5.3	9.26	8.11e-19	6.07e-16	0.41	0.4	Lobe attachment (rater-scored or self-reported);	chr6:145610416	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.846	rs870491	ENSG00000235652.6	RP11-545I5.3	9.26	8.11e-19	6.07e-16	0.41	0.4	Lobe attachment (rater-scored or self-reported);	chr6:145612254	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.791	rs4332001	ENSG00000235652.6	RP11-545I5.3	9.26	8.11e-19	6.07e-16	0.41	0.4	Lobe attachment (rater-scored or self-reported);	chr6:145613705	chr6:145799409~145886585:+
PRAD	cis	rs11951515	0.714	rs12520895	ENSG00000188850.9	RP11-159F24.2	9.26	8.13e-19	6.09e-16	0.48	0.4	Metabolite levels  (X-11787);	chr5:43369447	chr5:43336164~43348716:+
PRAD	cis	rs35160687	0.842	rs7593440	ENSG00000273080.1	RP11-301O19.1	-9.26	8.2e-19	6.14e-16	-0.47	-0.4	Night sleep phenotypes;	chr2:86323534	chr2:86195590~86196049:+
PRAD	cis	rs35160687	0.814	rs4392258	ENSG00000273080.1	RP11-301O19.1	-9.26	8.2e-19	6.14e-16	-0.47	-0.4	Night sleep phenotypes;	chr2:86325454	chr2:86195590~86196049:+
PRAD	cis	rs35160687	0.842	rs11685863	ENSG00000273080.1	RP11-301O19.1	-9.26	8.2e-19	6.14e-16	-0.47	-0.4	Night sleep phenotypes;	chr2:86327361	chr2:86195590~86196049:+
PRAD	cis	rs2255336	0.882	rs2733853	ENSG00000245648.1	RP11-277P12.20	9.26	8.22e-19	6.15e-16	0.56	0.4	Blood protein levels;	chr12:10381483	chr12:10363769~10398506:+
PRAD	cis	rs2255336	0.938	rs1478310	ENSG00000245648.1	RP11-277P12.20	9.26	8.22e-19	6.15e-16	0.56	0.4	Blood protein levels;	chr12:10382279	chr12:10363769~10398506:+
PRAD	cis	rs35160687	0.842	rs1863052	ENSG00000273080.1	RP11-301O19.1	9.26	8.23e-19	6.16e-16	0.47	0.4	Night sleep phenotypes;	chr2:86332235	chr2:86195590~86196049:+
PRAD	cis	rs7712401	0.623	rs30032	ENSG00000263432.2	RN7SL689P	9.26	8.23e-19	6.16e-16	0.41	0.4	Mean platelet volume;	chr5:122902692	chr5:123022487~123022783:-
PRAD	cis	rs1555322	0.505	rs639763	ENSG00000126005.14	MMP24-AS1	-9.26	8.24e-19	6.17e-16	-0.5	-0.4	Attention deficit hyperactivity disorder;	chr20:35274101	chr20:35216462~35278131:-
PRAD	cis	rs6991838	0.584	rs4737747	ENSG00000200714.1	Y_RNA	-9.26	8.26e-19	6.18e-16	-0.44	-0.4	Intelligence (multi-trait analysis);	chr8:65607024	chr8:65592731~65592820:+
PRAD	cis	rs11690935	0.55	rs55653103	ENSG00000228389.1	AC068039.4	-9.26	8.26e-19	6.18e-16	-0.45	-0.4	Schizophrenia;	chr2:171996909	chr2:171773482~171775844:+
PRAD	cis	rs150992	0.678	rs327793	ENSG00000248489.1	CTD-2007H13.3	9.26	8.27e-19	6.19e-16	0.45	0.4	Body mass index;	chr5:98913717	chr5:98929171~98995013:+
PRAD	cis	rs11951515	0.738	rs6886499	ENSG00000188850.9	RP11-159F24.2	9.26	8.29e-19	6.2e-16	0.48	0.4	Metabolite levels  (X-11787);	chr5:43362976	chr5:43336164~43348716:+
PRAD	cis	rs2739330	0.796	rs5760097	ENSG00000224205.1	AP000351.4	9.26	8.29e-19	6.2e-16	0.5	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23987320~23991421:-
PRAD	cis	rs7712401	0.715	rs424247	ENSG00000263432.2	RN7SL689P	-9.26	8.3e-19	6.21e-16	-0.41	-0.4	Mean platelet volume;	chr5:123012298	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.715	rs424262	ENSG00000263432.2	RN7SL689P	-9.26	8.3e-19	6.21e-16	-0.41	-0.4	Mean platelet volume;	chr5:123012317	chr5:123022487~123022783:-
PRAD	cis	rs4713118	0.868	rs10484401	ENSG00000280107.1	AL022393.9	9.26	8.32e-19	6.22e-16	0.52	0.4	Parkinson's disease;	chr6:27778811	chr6:28170845~28172521:+
PRAD	cis	rs7811142	0.83	rs7341507	ENSG00000242294.5	STAG3L5P	9.26	8.34e-19	6.24e-16	0.26	0.4	Platelet count;	chr7:100353692	chr7:100336079~100351900:+
PRAD	cis	rs4835473	0.868	rs62337303	ENSG00000251600.4	RP11-673E1.1	-9.26	8.37e-19	6.26e-16	-0.51	-0.4	Immature fraction of reticulocytes;	chr4:143824967	chr4:143912331~143982454:+
PRAD	cis	rs3809863	0.602	rs6504833	ENSG00000228782.6	CTD-2026D20.3	9.26	8.39e-19	6.28e-16	0.44	0.4	Glaucoma (primary open-angle);	chr17:47318721	chr17:47450568~47492492:-
PRAD	cis	rs172166	0.516	rs1225715	ENSG00000204709.4	LINC01556	-9.25	8.44e-19	6.31e-16	-0.51	-0.4	Cardiac Troponin-T levels;	chr6:28145595	chr6:28943877~28944537:+
PRAD	cis	rs12701220	0.655	rs6955290	ENSG00000229043.2	AC091729.9	9.25	8.44e-19	6.31e-16	0.55	0.4	Bronchopulmonary dysplasia;	chr7:1111430	chr7:1160374~1165267:+
PRAD	cis	rs3814244	0.751	rs12832728	ENSG00000255733.4	IFNG-AS1	-9.25	8.47e-19	6.33e-16	-0.41	-0.4	Itch intensity from mosquito bite adjusted by bite size;	chr12:68026623	chr12:67989445~68234686:+
PRAD	cis	rs7772486	0.686	rs1004752	ENSG00000235652.6	RP11-545I5.3	-9.25	8.47e-19	6.33e-16	-0.41	-0.4	Lobe attachment (rater-scored or self-reported);	chr6:145716686	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.686	rs9390347	ENSG00000235652.6	RP11-545I5.3	-9.25	8.47e-19	6.33e-16	-0.41	-0.4	Lobe attachment (rater-scored or self-reported);	chr6:145723611	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.686	rs9390348	ENSG00000235652.6	RP11-545I5.3	-9.25	8.47e-19	6.33e-16	-0.41	-0.4	Lobe attachment (rater-scored or self-reported);	chr6:145723612	chr6:145799409~145886585:+
PRAD	cis	rs4835473	0.864	rs61427459	ENSG00000251600.4	RP11-673E1.1	-9.25	8.49e-19	6.35e-16	-0.5	-0.4	Immature fraction of reticulocytes;	chr4:143699605	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.897	rs11100802	ENSG00000251600.4	RP11-673E1.1	-9.25	8.49e-19	6.35e-16	-0.5	-0.4	Immature fraction of reticulocytes;	chr4:143700046	chr4:143912331~143982454:+
PRAD	cis	rs77505915	0.512	rs12921808	ENSG00000261783.1	RP11-252K23.2	9.25	8.55e-19	6.39e-16	0.62	0.4	Migraine;	chr16:75350086	chr16:75379818~75381260:-
PRAD	cis	rs11098499	0.909	rs28884220	ENSG00000245958.5	RP11-33B1.1	-9.25	8.57e-19	6.41e-16	-0.39	-0.4	Corneal astigmatism;	chr4:119386056	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.909	rs28793658	ENSG00000245958.5	RP11-33B1.1	-9.25	8.57e-19	6.41e-16	-0.39	-0.4	Corneal astigmatism;	chr4:119386059	chr4:119454791~119552025:+
PRAD	cis	rs8072100	0.967	rs8078880	ENSG00000228782.6	CTD-2026D20.3	-9.25	8.62e-19	6.45e-16	-0.44	-0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47599160	chr17:47450568~47492492:-
PRAD	cis	rs7811142	1	rs73405353	ENSG00000242294.5	STAG3L5P	9.25	8.63e-19	6.45e-16	0.27	0.4	Platelet count;	chr7:100493592	chr7:100336079~100351900:+
PRAD	cis	rs1075232	0.826	rs16956738	ENSG00000270055.1	CTD-3092A11.2	9.25	8.68e-19	6.48e-16	0.79	0.4	Survival in colorectal cancer (non-distant metastatic);	chr15:31444028	chr15:30487963~30490313:+
PRAD	cis	rs34381861	0.52	rs74382390	ENSG00000260886.1	TAT-AS1	9.25	8.71e-19	6.5e-16	0.66	0.4	Post bronchodilator FEV1;	chr16:71424623	chr16:71565789~71578187:+
PRAD	cis	rs2274273	0.934	rs10139337	ENSG00000258413.1	RP11-665C16.6	-9.25	8.71e-19	6.51e-16	-0.52	-0.4	Protein biomarker;	chr14:55275395	chr14:55262767~55272075:-
PRAD	cis	rs7772486	0.623	rs9485021	ENSG00000235652.6	RP11-545I5.3	-9.25	8.73e-19	6.52e-16	-0.41	-0.4	Lobe attachment (rater-scored or self-reported);	chr6:145747661	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.654	rs6928007	ENSG00000235652.6	RP11-545I5.3	-9.25	8.73e-19	6.52e-16	-0.41	-0.4	Lobe attachment (rater-scored or self-reported);	chr6:145753805	chr6:145799409~145886585:+
PRAD	cis	rs9545047	0.604	rs9601227	ENSG00000227676.3	LINC01068	-9.25	8.75e-19	6.53e-16	-0.47	-0.4	Schizophrenia;	chr13:79420805	chr13:79566727~79571436:+
PRAD	cis	rs6517329	0.513	rs61232790	ENSG00000236830.5	CBR3-AS1	9.25	8.75e-19	6.53e-16	0.41	0.4	Schizophrenia;	chr21:36156559	chr21:36131767~36175815:-
PRAD	cis	rs17023223	0.581	rs12064109	ENSG00000231365.4	RP11-418J17.1	-9.25	8.79e-19	6.56e-16	-0.42	-0.4	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119099673	chr1:119140396~119275973:+
PRAD	cis	rs2283792	0.542	rs9610500	ENSG00000224086.5	LL22NC03-86G7.1	-9.25	8.79e-19	6.57e-16	-0.46	-0.4	Multiple sclerosis;	chr22:21866877	chr22:21938293~21977632:+
PRAD	cis	rs8072100	0.576	rs7216112	ENSG00000228782.6	CTD-2026D20.3	-9.25	8.8e-19	6.57e-16	-0.47	-0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47328979	chr17:47450568~47492492:-
PRAD	cis	rs9545047	0.625	rs7338170	ENSG00000227676.3	LINC01068	-9.25	8.88e-19	6.63e-16	-0.47	-0.4	Schizophrenia;	chr13:79286030	chr13:79566727~79571436:+
PRAD	cis	rs1061377	0.71	rs12503506	ENSG00000249207.1	RP11-360F5.1	-9.25	8.89e-19	6.63e-16	-0.42	-0.4	Uric acid levels;	chr4:39082553	chr4:39112677~39126818:-
PRAD	cis	rs2739330	0.828	rs2186366	ENSG00000235689.1	AP000351.13	-9.25	8.92e-19	6.66e-16	-0.48	-0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:24006305~24008258:-
PRAD	cis	rs7923609	0.578	rs10740138	ENSG00000232075.1	MRPL35P2	-9.25	8.97e-19	6.7e-16	-0.42	-0.4	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63635373	chr10:63634317~63634827:-
PRAD	cis	rs2739330	0.796	rs5760097	ENSG00000235689.1	AP000351.13	9.25	8.98e-19	6.7e-16	0.49	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:24006305~24008258:-
PRAD	cis	rs7772486	0.624	rs9485018	ENSG00000235652.6	RP11-545I5.3	-9.25	9.04e-19	6.74e-16	-0.41	-0.4	Lobe attachment (rater-scored or self-reported);	chr6:145704595	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.686	rs2092263	ENSG00000235652.6	RP11-545I5.3	-9.25	9.04e-19	6.74e-16	-0.41	-0.4	Lobe attachment (rater-scored or self-reported);	chr6:145708551	chr6:145799409~145886585:+
PRAD	cis	rs2404602	0.716	rs117129193	ENSG00000259422.1	RP11-593F23.1	9.25	9.05e-19	6.75e-16	0.49	0.4	Blood metabolite levels;	chr15:76364462	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.716	rs12917430	ENSG00000259422.1	RP11-593F23.1	9.25	9.05e-19	6.75e-16	0.49	0.4	Blood metabolite levels;	chr15:76382019	chr15:76174891~76181486:-
PRAD	cis	rs9660180	0.62	rs34298494	ENSG00000231050.1	RP1-140A9.1	-9.25	9.07e-19	6.77e-16	-0.47	-0.4	Body mass index;	chr1:1731963	chr1:1891471~1892658:+
PRAD	cis	rs3096299	0.933	rs2965939	ENSG00000274627.1	RP11-104N10.2	9.25	9.09e-19	6.78e-16	0.41	0.4	Multiple myeloma (IgH translocation);	chr16:89426635	chr16:89516797~89522217:+
PRAD	cis	rs7712401	0.715	rs6880480	ENSG00000263432.2	RN7SL689P	-9.24	9.13e-19	6.81e-16	-0.41	-0.4	Mean platelet volume;	chr5:123019031	chr5:123022487~123022783:-
PRAD	cis	rs150992	0.587	rs11960896	ENSG00000248489.1	CTD-2007H13.3	-9.24	9.14e-19	6.81e-16	-0.44	-0.4	Body mass index;	chr5:99014294	chr5:98929171~98995013:+
PRAD	cis	rs150992	0.714	rs76798907	ENSG00000248489.1	CTD-2007H13.3	9.24	9.14e-19	6.82e-16	0.44	0.4	Body mass index;	chr5:98990780	chr5:98929171~98995013:+
PRAD	cis	rs9322193	0.566	rs4869767	ENSG00000216906.2	RP11-350J20.9	-9.24	9.19e-19	6.85e-16	-0.52	-0.4	Lung cancer;	chr6:149923974	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.566	rs4869768	ENSG00000216906.2	RP11-350J20.9	-9.24	9.19e-19	6.85e-16	-0.52	-0.4	Lung cancer;	chr6:149924067	chr6:149904243~149906418:+
PRAD	cis	rs9322193	0.607	rs9322229	ENSG00000223701.3	RAET1E-AS1	9.24	9.24e-19	6.89e-16	0.6	0.4	Lung cancer;	chr6:149908949	chr6:149884431~149919508:+
PRAD	cis	rs741668	0.641	rs1022951	ENSG00000235903.6	CPB2-AS1	9.24	9.25e-19	6.89e-16	0.47	0.4	Cerebrospinal fluid clusterin levels;	chr13:46075319	chr13:46052806~46113332:+
PRAD	cis	rs6570726	0.818	rs437978	ENSG00000235652.6	RP11-545I5.3	9.24	9.27e-19	6.91e-16	0.42	0.4	Lobe attachment (rater-scored or self-reported);	chr6:145487998	chr6:145799409~145886585:+
PRAD	cis	rs6723108	0.517	rs12473839	ENSG00000224043.6	CCNT2-AS1	-9.24	9.32e-19	6.94e-16	-0.54	-0.4	Type 2 diabetes;	chr2:134880474	chr2:134735464~134918710:-
PRAD	cis	rs435066	0.525	rs1924527	ENSG00000234264.1	DEPDC1-AS1	-9.24	9.35e-19	6.97e-16	-0.56	-0.4	IgG glycosylation;	chr1:68557909	chr1:68496676~68538627:+
PRAD	cis	rs732716	0.889	rs62129355	ENSG00000267980.1	AC007292.6	-9.24	9.36e-19	6.97e-16	-0.4	-0.4	Mean corpuscular volume;	chr19:4397037	chr19:4363789~4364640:+
PRAD	cis	rs853679	0.55	rs1233707	ENSG00000219392.1	RP1-265C24.5	-9.24	9.37e-19	6.98e-16	-0.51	-0.4	Depression;	chr6:28205175	chr6:28115628~28116551:+
PRAD	cis	rs75422866	0.764	rs73104184	ENSG00000257433.4	RP1-197B17.3	9.24	9.38e-19	6.99e-16	0.94	0.4	Pneumonia;	chr12:47715623	chr12:47706085~47742294:+
PRAD	cis	rs75422866	0.764	rs73104188	ENSG00000257433.4	RP1-197B17.3	9.24	9.38e-19	6.99e-16	0.94	0.4	Pneumonia;	chr12:47715885	chr12:47706085~47742294:+
PRAD	cis	rs9545047	0.584	rs9565485	ENSG00000227676.3	LINC01068	-9.24	9.39e-19	6.99e-16	-0.46	-0.4	Schizophrenia;	chr13:79307428	chr13:79566727~79571436:+
PRAD	cis	rs7772486	0.659	rs9376957	ENSG00000235652.6	RP11-545I5.3	-9.24	9.39e-19	6.99e-16	-0.41	-0.4	Lobe attachment (rater-scored or self-reported);	chr6:145689928	chr6:145799409~145886585:+
PRAD	cis	rs67311347	0.955	rs73078170	ENSG00000223797.4	ENTPD3-AS1	9.24	9.46e-19	7.04e-16	0.38	0.4	Renal cell carcinoma;	chr3:40442456	chr3:40313802~40453329:-
PRAD	cis	rs4713118	0.868	rs2893928	ENSG00000280107.1	AL022393.9	-9.24	9.46e-19	7.05e-16	-0.53	-0.4	Parkinson's disease;	chr6:27770651	chr6:28170845~28172521:+
PRAD	cis	rs7712401	0.54	rs27617	ENSG00000263432.2	RN7SL689P	9.24	9.47e-19	7.06e-16	0.42	0.4	Mean platelet volume;	chr5:122900839	chr5:123022487~123022783:-
PRAD	cis	rs9532669	0.889	rs7320344	ENSG00000176268.5	CYCSP34	9.24	9.51e-19	7.08e-16	0.44	0.4	Cervical cancer;	chr13:40885502	chr13:40863599~40863902:-
PRAD	cis	rs11148252	0.74	rs3803264	ENSG00000278238.1	RP11-245D16.4	9.24	9.53e-19	7.1e-16	0.44	0.4	Lewy body disease;	chr13:52397758	chr13:52454775~52455331:-
PRAD	cis	rs8062405	0.754	rs149299	ENSG00000259982.1	CDC37P1	9.24	9.54e-19	7.1e-16	0.53	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28473820	chr16:28700294~28701540:-
PRAD	cis	rs732716	0.853	rs12459922	ENSG00000267980.1	AC007292.6	-9.24	9.61e-19	7.15e-16	-0.4	-0.4	Mean corpuscular volume;	chr19:4455865	chr19:4363789~4364640:+
PRAD	cis	rs3096299	0.967	rs2911256	ENSG00000274627.1	RP11-104N10.2	9.24	9.62e-19	7.16e-16	0.41	0.4	Multiple myeloma (IgH translocation);	chr16:89418688	chr16:89516797~89522217:+
PRAD	cis	rs3096299	0.692	rs4785565	ENSG00000261118.1	RP11-104N10.1	9.24	9.62e-19	7.17e-16	0.38	0.4	Multiple myeloma (IgH translocation);	chr16:89449351	chr16:89492017~89504460:-
PRAD	cis	rs35160687	0.736	rs6746198	ENSG00000273080.1	RP11-301O19.1	-9.24	9.65e-19	7.18e-16	-0.47	-0.4	Night sleep phenotypes;	chr2:86314990	chr2:86195590~86196049:+
PRAD	cis	rs732716	0.813	rs760369	ENSG00000267980.1	AC007292.6	9.24	9.65e-19	7.18e-16	0.4	0.4	Mean corpuscular volume;	chr19:4449290	chr19:4363789~4364640:+
PRAD	cis	rs2933343	0.951	rs9871612	ENSG00000231305.3	RP11-723O4.2	9.24	9.68e-19	7.2e-16	0.42	0.4	IgG glycosylation;	chr3:128851559	chr3:128861313~128871540:-
PRAD	cis	rs6570726	0.818	rs399516	ENSG00000235652.6	RP11-545I5.3	9.24	9.68e-19	7.21e-16	0.42	0.4	Lobe attachment (rater-scored or self-reported);	chr6:145489713	chr6:145799409~145886585:+
PRAD	cis	rs4835473	0.863	rs7696828	ENSG00000251600.4	RP11-673E1.1	9.24	9.69e-19	7.21e-16	0.5	0.4	Immature fraction of reticulocytes;	chr4:143700846	chr4:143912331~143982454:+
PRAD	cis	rs2108622	0.727	rs9305069	ENSG00000267453.5	AC004791.2	-9.24	9.69e-19	7.21e-16	-0.52	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15872576	chr19:15851993~15864904:-
PRAD	cis	rs240993	0.909	rs11153279	ENSG00000230177.1	RP5-1112D6.4	9.24	9.71e-19	7.23e-16	0.45	0.4	Inflammatory skin disease;Psoriasis;	chr6:111266063	chr6:111277932~111278742:+
PRAD	cis	rs67311347	1	rs7634375	ENSG00000223797.4	ENTPD3-AS1	9.24	9.74e-19	7.24e-16	0.37	0.4	Renal cell carcinoma;	chr3:40390455	chr3:40313802~40453329:-
PRAD	cis	rs2274273	0.934	rs17740741	ENSG00000258413.1	RP11-665C16.6	-9.24	9.76e-19	7.26e-16	-0.52	-0.4	Protein biomarker;	chr14:55295994	chr14:55262767~55272075:-
PRAD	cis	rs2274273	0.901	rs68046603	ENSG00000258413.1	RP11-665C16.6	-9.24	9.76e-19	7.26e-16	-0.52	-0.4	Protein biomarker;	chr14:55296085	chr14:55262767~55272075:-
PRAD	cis	rs2274273	0.901	rs12050099	ENSG00000258413.1	RP11-665C16.6	-9.24	9.76e-19	7.26e-16	-0.52	-0.4	Protein biomarker;	chr14:55297613	chr14:55262767~55272075:-
PRAD	cis	rs17023223	0.537	rs7532510	ENSG00000231365.4	RP11-418J17.1	-9.24	9.76e-19	7.26e-16	-0.41	-0.4	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119051613	chr1:119140396~119275973:+
PRAD	cis	rs4713118	0.868	rs9468220	ENSG00000280107.1	AL022393.9	9.24	9.77e-19	7.27e-16	0.52	0.4	Parkinson's disease;	chr6:27765197	chr6:28170845~28172521:+
PRAD	cis	rs9309473	0.653	rs6718843	ENSG00000163016.8	ALMS1P	9.24	9.86e-19	7.33e-16	0.49	0.4	Metabolite levels;	chr2:73625378	chr2:73644919~73685576:+
PRAD	cis	rs12468226	1	rs16839149	ENSG00000273456.1	RP11-686O6.2	9.23	9.89e-19	7.36e-16	0.53	0.4	Urate levels;	chr2:202427621	chr2:202374932~202375604:-
PRAD	cis	rs3096299	0.667	rs2965947	ENSG00000261118.1	RP11-104N10.1	9.23	9.91e-19	7.37e-16	0.38	0.4	Multiple myeloma (IgH translocation);	chr16:89452262	chr16:89492017~89504460:-
PRAD	cis	rs4713118	0.621	rs9295755	ENSG00000219392.1	RP1-265C24.5	9.23	9.92e-19	7.38e-16	0.51	0.4	Parkinson's disease;	chr6:28065396	chr6:28115628~28116551:+
PRAD	cis	rs12468226	1	rs79919139	ENSG00000273456.1	RP11-686O6.2	9.23	9.92e-19	7.38e-16	0.53	0.4	Urate levels;	chr2:202382786	chr2:202374932~202375604:-
PRAD	cis	rs6991838	0.557	rs7012578	ENSG00000200714.1	Y_RNA	-9.23	9.98e-19	7.42e-16	-0.44	-0.4	Intelligence (multi-trait analysis);	chr8:65592592	chr8:65592731~65592820:+
PRAD	cis	rs6991838	0.584	rs7812446	ENSG00000200714.1	Y_RNA	-9.23	9.98e-19	7.42e-16	-0.44	-0.4	Intelligence (multi-trait analysis);	chr8:65593753	chr8:65592731~65592820:+
PRAD	cis	rs6991838	0.557	rs7812390	ENSG00000200714.1	Y_RNA	-9.23	9.98e-19	7.42e-16	-0.44	-0.4	Intelligence (multi-trait analysis);	chr8:65593982	chr8:65592731~65592820:+
PRAD	cis	rs6991838	0.584	rs16932245	ENSG00000200714.1	Y_RNA	-9.23	9.98e-19	7.42e-16	-0.44	-0.4	Intelligence (multi-trait analysis);	chr8:65597810	chr8:65592731~65592820:+
PRAD	cis	rs6991838	0.557	rs57419568	ENSG00000200714.1	Y_RNA	-9.23	9.98e-19	7.42e-16	-0.44	-0.4	Intelligence (multi-trait analysis);	chr8:65598633	chr8:65592731~65592820:+
PRAD	cis	rs6991838	0.584	rs16932250	ENSG00000200714.1	Y_RNA	-9.23	9.98e-19	7.42e-16	-0.44	-0.4	Intelligence (multi-trait analysis);	chr8:65598779	chr8:65592731~65592820:+
PRAD	cis	rs7772486	0.686	rs9497396	ENSG00000235652.6	RP11-545I5.3	-9.23	9.99e-19	7.42e-16	-0.41	-0.4	Lobe attachment (rater-scored or self-reported);	chr6:145693827	chr6:145799409~145886585:+
PRAD	cis	rs62103177	0.564	rs1715230	ENSG00000261126.6	RP11-795F19.1	9.23	9.99e-19	7.43e-16	0.52	0.4	Opioid sensitivity;	chr18:80090098	chr18:80046900~80095482:+
PRAD	cis	rs2255336	0.938	rs1382265	ENSG00000245648.1	RP11-277P12.20	9.23	1.01e-18	7.47e-16	0.56	0.4	Blood protein levels;	chr12:10381206	chr12:10363769~10398506:+
PRAD	cis	rs2729354	0.768	rs2729384	ENSG00000265566.2	RN7SL605P	-9.23	1.01e-18	7.48e-16	-0.58	-0.4	Blood protein levels;	chr11:57491144	chr11:57528085~57528365:-
PRAD	cis	rs11951515	0.738	rs55759097	ENSG00000188850.9	RP11-159F24.2	9.23	1.01e-18	7.49e-16	0.48	0.4	Metabolite levels  (X-11787);	chr5:43371762	chr5:43336164~43348716:+
PRAD	cis	rs11951515	0.738	rs11950040	ENSG00000188850.9	RP11-159F24.2	9.23	1.01e-18	7.49e-16	0.48	0.4	Metabolite levels  (X-11787);	chr5:43372087	chr5:43336164~43348716:+
PRAD	cis	rs4879677	1	rs9695197	ENSG00000260390.1	RP11-575I8.1	-9.23	1.01e-18	7.49e-16	-0.51	-0.4	Gut microbiome composition (summer and winter);	chr9:27672340	chr9:27829276~27844481:+
PRAD	cis	rs8072100	0.701	rs8078309	ENSG00000228782.6	CTD-2026D20.3	9.23	1.01e-18	7.51e-16	0.44	0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47696706	chr17:47450568~47492492:-
PRAD	cis	rs4718428	0.705	rs4717331	ENSG00000230295.1	RP11-458F8.2	-9.23	1.02e-18	7.54e-16	-0.3	-0.4	Corneal structure;	chr7:66913899	chr7:66880708~66882981:+
PRAD	cis	rs3096299	0.719	rs2965818	ENSG00000261118.1	RP11-104N10.1	9.23	1.02e-18	7.55e-16	0.38	0.4	Multiple myeloma (IgH translocation);	chr16:89444086	chr16:89492017~89504460:-
PRAD	cis	rs1789	0.903	rs4453929	ENSG00000273133.1	RP11-799M12.2	-9.23	1.02e-18	7.58e-16	-0.51	-0.4	Blood protein levels;	chr4:15670550	chr4:15563698~15564253:-
PRAD	cis	rs1789	0.903	rs4616746	ENSG00000273133.1	RP11-799M12.2	-9.23	1.02e-18	7.58e-16	-0.51	-0.4	Blood protein levels;	chr4:15671475	chr4:15563698~15564253:-
PRAD	cis	rs1789	0.868	rs4631041	ENSG00000273133.1	RP11-799M12.2	-9.23	1.02e-18	7.58e-16	-0.51	-0.4	Blood protein levels;	chr4:15671772	chr4:15563698~15564253:-
PRAD	cis	rs10262624	0.564	rs58051142	ENSG00000234286.1	AC006026.13	-9.23	1.02e-18	7.58e-16	-0.45	-0.4	Schizophrenia;	chr7:23866047	chr7:23680195~23680786:-
PRAD	cis	rs6517329	0.513	rs62229302	ENSG00000236830.5	CBR3-AS1	9.23	1.03e-18	7.62e-16	0.41	0.4	Schizophrenia;	chr21:36156202	chr21:36131767~36175815:-
PRAD	cis	rs13631	0.728	rs7466635	ENSG00000268996.3	MAN1B1-AS1	-9.23	1.03e-18	7.62e-16	-0.4	-0.4	Cerebrospinal fluid biomarker levels;	chr9:137085965	chr9:137084946~137086817:-
PRAD	cis	rs10800713	0.954	rs4504918	ENSG00000260088.1	RP11-92G12.3	9.23	1.03e-18	7.63e-16	0.59	0.4	Tandem gait;	chr1:200588639	chr1:200669507~200694250:+
PRAD	cis	rs172166	0.56	rs203878	ENSG00000204709.4	LINC01556	9.23	1.03e-18	7.65e-16	0.49	0.4	Cardiac Troponin-T levels;	chr6:28081218	chr6:28943877~28944537:+
PRAD	cis	rs4835473	0.932	rs6851999	ENSG00000251600.4	RP11-673E1.1	9.23	1.03e-18	7.68e-16	0.5	0.4	Immature fraction of reticulocytes;	chr4:143742567	chr4:143912331~143982454:+
PRAD	cis	rs11690935	0.55	rs6746701	ENSG00000228389.1	AC068039.4	-9.23	1.04e-18	7.69e-16	-0.45	-0.4	Schizophrenia;	chr2:172004347	chr2:171773482~171775844:+
PRAD	cis	rs11673344	0.73	rs1644641	ENSG00000226686.6	LINC01535	9.23	1.04e-18	7.69e-16	0.54	0.4	Obesity-related traits;	chr19:36971237	chr19:37251912~37265535:+
PRAD	cis	rs11673344	0.704	rs826262	ENSG00000226686.6	LINC01535	9.23	1.04e-18	7.72e-16	0.54	0.4	Obesity-related traits;	chr19:36928540	chr19:37251912~37265535:+
PRAD	cis	rs9399137	0.507	rs7745289	ENSG00000232876.1	CTA-212D2.2	-9.23	1.04e-18	7.74e-16	-0.5	-0.4	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135059189	chr6:135055033~135060550:+
PRAD	cis	rs9399137	0.507	rs11759062	ENSG00000232876.1	CTA-212D2.2	-9.23	1.04e-18	7.74e-16	-0.5	-0.4	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135060110	chr6:135055033~135060550:+
PRAD	cis	rs9399137	0.507	rs11759077	ENSG00000232876.1	CTA-212D2.2	-9.23	1.04e-18	7.74e-16	-0.5	-0.4	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135060213	chr6:135055033~135060550:+
PRAD	cis	rs1075265	0.756	rs698854	ENSG00000233266.1	HMGB1P31	9.23	1.04e-18	7.76e-16	0.54	0.4	Chronotype;Morning vs. evening chronotype;	chr2:53826784	chr2:54051334~54051760:+
PRAD	cis	rs9532669	0.926	rs7331435	ENSG00000168852.11	TPTE2P5	-9.23	1.05e-18	7.78e-16	-0.38	-0.4	Cervical cancer;	chr13:40862396	chr13:40822296~40921749:-
PRAD	cis	rs4718428	0.705	rs13227468	ENSG00000230295.1	RP11-458F8.2	-9.23	1.05e-18	7.79e-16	-0.31	-0.4	Corneal structure;	chr7:66968576	chr7:66880708~66882981:+
PRAD	cis	rs7727544	0.606	rs200838	ENSG00000233006.5	AC034220.3	-9.23	1.05e-18	7.8e-16	-0.35	-0.4	Blood metabolite levels;	chr5:132374707	chr5:132311285~132369916:-
PRAD	cis	rs9309473	0.95	rs11126412	ENSG00000163016.8	ALMS1P	9.23	1.05e-18	7.82e-16	0.52	0.4	Metabolite levels;	chr2:73660507	chr2:73644919~73685576:+
PRAD	cis	rs2108622	0.711	rs113059233	ENSG00000267453.5	AC004791.2	-9.23	1.07e-18	7.9e-16	-0.52	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866558	chr19:15851993~15864904:-
PRAD	cis	rs7714584	1	rs61270113	ENSG00000197083.10	ZNF300P1	9.23	1.07e-18	7.91e-16	0.65	0.4	Crohn's disease;	chr5:150846701	chr5:150930645~150946289:-
PRAD	cis	rs4835473	0.932	rs1813908	ENSG00000251600.4	RP11-673E1.1	9.22	1.08e-18	8.02e-16	0.51	0.4	Immature fraction of reticulocytes;	chr4:143728174	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.897	rs4835454	ENSG00000251600.4	RP11-673E1.1	9.22	1.08e-18	8.02e-16	0.51	0.4	Immature fraction of reticulocytes;	chr4:143730081	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs1839449	ENSG00000251600.4	RP11-673E1.1	9.22	1.08e-18	8.02e-16	0.51	0.4	Immature fraction of reticulocytes;	chr4:143730222	chr4:143912331~143982454:+
PRAD	cis	rs4718428	0.705	rs4717328	ENSG00000230295.1	RP11-458F8.2	-9.22	1.08e-18	8.03e-16	-0.3	-0.4	Corneal structure;	chr7:66887678	chr7:66880708~66882981:+
PRAD	cis	rs4718428	0.705	rs4718422	ENSG00000230295.1	RP11-458F8.2	-9.22	1.08e-18	8.03e-16	-0.3	-0.4	Corneal structure;	chr7:66894282	chr7:66880708~66882981:+
PRAD	cis	rs4718428	0.705	rs13231140	ENSG00000230295.1	RP11-458F8.2	-9.22	1.08e-18	8.03e-16	-0.3	-0.4	Corneal structure;	chr7:66896631	chr7:66880708~66882981:+
PRAD	cis	rs4718428	0.705	rs4718424	ENSG00000230295.1	RP11-458F8.2	-9.22	1.08e-18	8.03e-16	-0.3	-0.4	Corneal structure;	chr7:66911108	chr7:66880708~66882981:+
PRAD	cis	rs7181230	0.885	rs3923235	ENSG00000275636.1	RP11-521C20.5	9.22	1.09e-18	8.06e-16	0.58	0.4	Dehydroepiandrosterone sulphate levels;	chr15:40078920	chr15:40078892~40079347:+
PRAD	cis	rs2255336	0.938	rs2733845	ENSG00000245648.1	RP11-277P12.20	-9.22	1.09e-18	8.08e-16	-0.58	-0.4	Blood protein levels;	chr12:10387216	chr12:10363769~10398506:+
PRAD	cis	rs7182621	0.883	rs10468181	ENSG00000259363.4	CTD-2054N24.2	-9.22	1.09e-18	8.11e-16	-0.37	-0.4	Colonoscopy-negative controls vs population controls;	chr15:99885244	chr15:99807023~99877148:+
PRAD	cis	rs8523	0.901	rs4711146	ENSG00000230314.5	ELOVL2-AS1	9.22	1.1e-18	8.13e-16	0.44	0.4	Red blood cell fatty acid levels;	chr6:10961172	chr6:11043524~11078226:+
PRAD	cis	rs9545047	0.604	rs1324870	ENSG00000227676.3	LINC01068	-9.22	1.1e-18	8.14e-16	-0.46	-0.4	Schizophrenia;	chr13:79297911	chr13:79566727~79571436:+
PRAD	cis	rs1789	0.903	rs4470622	ENSG00000273133.1	RP11-799M12.2	-9.22	1.1e-18	8.15e-16	-0.5	-0.4	Blood protein levels;	chr4:15672552	chr4:15563698~15564253:-
PRAD	cis	rs11676348	0.772	rs12471105	ENSG00000261338.2	RP11-378A13.1	-9.22	1.1e-18	8.17e-16	-0.43	-0.4	Ulcerative colitis;	chr2:218085486	chr2:218255319~218257366:+
PRAD	cis	rs853679	0.517	rs12332979	ENSG00000272009.1	RP1-313I6.12	-9.22	1.1e-18	8.18e-16	-0.41	-0.4	Depression;	chr6:28173770	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs67878650	ENSG00000272009.1	RP1-313I6.12	-9.22	1.1e-18	8.18e-16	-0.41	-0.4	Depression;	chr6:28174809	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.569	rs9348798	ENSG00000272009.1	RP1-313I6.12	-9.22	1.1e-18	8.18e-16	-0.41	-0.4	Depression;	chr6:28175233	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.517	rs9380065	ENSG00000272009.1	RP1-313I6.12	-9.22	1.1e-18	8.18e-16	-0.41	-0.4	Depression;	chr6:28176973	chr6:28078792~28081130:-
PRAD	cis	rs6517329	0.538	rs4510305	ENSG00000236830.5	CBR3-AS1	9.22	1.11e-18	8.19e-16	0.42	0.4	Schizophrenia;	chr21:36148374	chr21:36131767~36175815:-
PRAD	cis	rs7772486	0.875	rs2777479	ENSG00000235652.6	RP11-545I5.3	9.22	1.11e-18	8.21e-16	0.4	0.4	Lobe attachment (rater-scored or self-reported);	chr6:145988042	chr6:145799409~145886585:+
PRAD	cis	rs853679	0.517	rs9295761	ENSG00000272009.1	RP1-313I6.12	-9.22	1.11e-18	8.26e-16	-0.41	-0.4	Depression;	chr6:28180209	chr6:28078792~28081130:-
PRAD	cis	rs17023223	0.537	rs17023171	ENSG00000231365.4	RP11-418J17.1	-9.22	1.12e-18	8.27e-16	-0.41	-0.4	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119050645	chr1:119140396~119275973:+
PRAD	cis	rs8062405	0.755	rs56272201	ENSG00000259982.1	CDC37P1	9.22	1.12e-18	8.27e-16	0.53	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569364	chr16:28700294~28701540:-
PRAD	cis	rs8062405	0.755	rs62034355	ENSG00000259982.1	CDC37P1	9.22	1.12e-18	8.27e-16	0.53	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569717	chr16:28700294~28701540:-
PRAD	cis	rs17023223	0.537	rs2765542	ENSG00000231365.4	RP11-418J17.1	-9.22	1.12e-18	8.3e-16	-0.41	-0.4	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119017703	chr1:119140396~119275973:+
PRAD	cis	rs3002131	0.604	rs2936038	ENSG00000225265.1	TAF1A-AS1	-9.22	1.12e-18	8.31e-16	-0.68	-0.4	Interleukin-10 levels;	chr1:222572449	chr1:222589825~222593032:+
PRAD	cis	rs524281	0.731	rs7931167	ENSG00000255320.1	RP11-755F10.1	-9.22	1.12e-18	8.32e-16	-0.67	-0.4	Electroencephalogram traits;	chr11:66036279	chr11:66244840~66246239:-
PRAD	cis	rs732716	0.853	rs72990643	ENSG00000267980.1	AC007292.6	-9.22	1.13e-18	8.33e-16	-0.4	-0.4	Mean corpuscular volume;	chr19:4454739	chr19:4363789~4364640:+
PRAD	cis	rs4835473	0.932	rs2323200	ENSG00000251600.4	RP11-673E1.1	9.22	1.13e-18	8.34e-16	0.5	0.4	Immature fraction of reticulocytes;	chr4:143765448	chr4:143912331~143982454:+
PRAD	cis	rs7569084	0.687	rs12993075	ENSG00000281920.1	RP11-418H16.1	9.22	1.13e-18	8.35e-16	0.48	0.4	Sum eosinophil basophil counts;	chr2:65431010	chr2:65623272~65628424:+
PRAD	cis	rs732716	0.889	rs11085074	ENSG00000267980.1	AC007292.6	-9.22	1.14e-18	8.43e-16	-0.4	-0.4	Mean corpuscular volume;	chr19:4386355	chr19:4363789~4364640:+
PRAD	cis	rs4835473	0.897	rs1391189	ENSG00000251600.4	RP11-673E1.1	-9.22	1.14e-18	8.44e-16	-0.49	-0.4	Immature fraction of reticulocytes;	chr4:143690951	chr4:143912331~143982454:+
PRAD	cis	rs11098499	0.954	rs59866101	ENSG00000245958.5	RP11-33B1.1	-9.22	1.14e-18	8.44e-16	-0.39	-0.4	Corneal astigmatism;	chr4:119375436	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.618	rs6858383	ENSG00000245958.5	RP11-33B1.1	-9.22	1.14e-18	8.44e-16	-0.39	-0.4	Corneal astigmatism;	chr4:119375617	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.697	rs6832410	ENSG00000245958.5	RP11-33B1.1	-9.22	1.14e-18	8.44e-16	-0.39	-0.4	Corneal astigmatism;	chr4:119375645	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.865	rs1112817	ENSG00000245958.5	RP11-33B1.1	-9.22	1.14e-18	8.44e-16	-0.39	-0.4	Corneal astigmatism;	chr4:119376645	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.779	rs10016060	ENSG00000245958.5	RP11-33B1.1	-9.22	1.14e-18	8.44e-16	-0.39	-0.4	Corneal astigmatism;	chr4:119377257	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.954	rs10005644	ENSG00000245958.5	RP11-33B1.1	-9.22	1.14e-18	8.44e-16	-0.39	-0.4	Corneal astigmatism;	chr4:119377322	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.697	rs10016448	ENSG00000245958.5	RP11-33B1.1	-9.22	1.14e-18	8.44e-16	-0.39	-0.4	Corneal astigmatism;	chr4:119377690	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.657	rs9996569	ENSG00000245958.5	RP11-33B1.1	-9.22	1.14e-18	8.44e-16	-0.39	-0.4	Corneal astigmatism;	chr4:119377849	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.908	rs11729050	ENSG00000245958.5	RP11-33B1.1	-9.22	1.14e-18	8.44e-16	-0.39	-0.4	Corneal astigmatism;	chr4:119378911	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.954	rs28429722	ENSG00000245958.5	RP11-33B1.1	-9.22	1.14e-18	8.44e-16	-0.39	-0.4	Corneal astigmatism;	chr4:119378938	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.954	rs10014845	ENSG00000245958.5	RP11-33B1.1	-9.22	1.14e-18	8.44e-16	-0.39	-0.4	Corneal astigmatism;	chr4:119379922	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.779	rs7674500	ENSG00000245958.5	RP11-33B1.1	-9.22	1.14e-18	8.44e-16	-0.39	-0.4	Corneal astigmatism;	chr4:119382438	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.697	rs4373140	ENSG00000245958.5	RP11-33B1.1	-9.22	1.14e-18	8.44e-16	-0.39	-0.4	Corneal astigmatism;	chr4:119386543	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.954	rs13113483	ENSG00000245958.5	RP11-33B1.1	-9.22	1.14e-18	8.44e-16	-0.39	-0.4	Corneal astigmatism;	chr4:119387884	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.542	rs10440343	ENSG00000245958.5	RP11-33B1.1	-9.22	1.14e-18	8.44e-16	-0.39	-0.4	Corneal astigmatism;	chr4:119388632	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.909	rs28668716	ENSG00000245958.5	RP11-33B1.1	-9.22	1.14e-18	8.44e-16	-0.39	-0.4	Corneal astigmatism;	chr4:119388720	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.542	rs7677836	ENSG00000245958.5	RP11-33B1.1	-9.22	1.14e-18	8.44e-16	-0.39	-0.4	Corneal astigmatism;	chr4:119389483	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.909	rs10002083	ENSG00000245958.5	RP11-33B1.1	-9.22	1.14e-18	8.44e-16	-0.39	-0.4	Corneal astigmatism;	chr4:119389997	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.954	rs10024844	ENSG00000245958.5	RP11-33B1.1	-9.22	1.14e-18	8.44e-16	-0.39	-0.4	Corneal astigmatism;	chr4:119390373	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.954	rs4345162	ENSG00000245958.5	RP11-33B1.1	-9.22	1.14e-18	8.44e-16	-0.39	-0.4	Corneal astigmatism;	chr4:119391804	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.657	rs4463052	ENSG00000245958.5	RP11-33B1.1	-9.22	1.14e-18	8.44e-16	-0.39	-0.4	Corneal astigmatism;	chr4:119392103	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.954	rs13151285	ENSG00000245958.5	RP11-33B1.1	-9.22	1.14e-18	8.44e-16	-0.39	-0.4	Corneal astigmatism;	chr4:119393586	chr4:119454791~119552025:+
PRAD	cis	rs3096299	0.719	rs2911265	ENSG00000261118.1	RP11-104N10.1	9.22	1.14e-18	8.45e-16	0.38	0.4	Multiple myeloma (IgH translocation);	chr16:89444920	chr16:89492017~89504460:-
PRAD	cis	rs2255336	0.938	rs1600127	ENSG00000245648.1	RP11-277P12.20	9.22	1.15e-18	8.49e-16	0.56	0.4	Blood protein levels;	chr12:10383648	chr12:10363769~10398506:+
PRAD	cis	rs2255336	0.882	rs2617156	ENSG00000245648.1	RP11-277P12.20	9.22	1.15e-18	8.49e-16	0.56	0.4	Blood protein levels;	chr12:10384280	chr12:10363769~10398506:+
PRAD	cis	rs2255336	0.938	rs2617157	ENSG00000245648.1	RP11-277P12.20	9.22	1.15e-18	8.49e-16	0.56	0.4	Blood protein levels;	chr12:10384299	chr12:10363769~10398506:+
PRAD	cis	rs2255336	0.938	rs2927561	ENSG00000245648.1	RP11-277P12.20	9.22	1.15e-18	8.49e-16	0.56	0.4	Blood protein levels;	chr12:10384974	chr12:10363769~10398506:+
PRAD	cis	rs2255336	0.882	rs2126889	ENSG00000245648.1	RP11-277P12.20	9.22	1.15e-18	8.49e-16	0.56	0.4	Blood protein levels;	chr12:10385280	chr12:10363769~10398506:+
PRAD	cis	rs67311347	1	rs9848083	ENSG00000223797.4	ENTPD3-AS1	-9.22	1.15e-18	8.5e-16	-0.35	-0.4	Renal cell carcinoma;	chr3:40425488	chr3:40313802~40453329:-
PRAD	cis	rs4835473	0.9	rs71612420	ENSG00000251600.4	RP11-673E1.1	-9.22	1.15e-18	8.51e-16	-0.51	-0.4	Immature fraction of reticulocytes;	chr4:143779107	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.9	rs13134869	ENSG00000251600.4	RP11-673E1.1	-9.22	1.15e-18	8.51e-16	-0.51	-0.4	Immature fraction of reticulocytes;	chr4:143782301	chr4:143912331~143982454:+
PRAD	cis	rs9399137	0.507	rs6904897	ENSG00000232876.1	CTA-212D2.2	-9.22	1.15e-18	8.51e-16	-0.51	-0.4	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135061842	chr6:135055033~135060550:+
PRAD	cis	rs2283792	0.73	rs56398890	ENSG00000224086.5	LL22NC03-86G7.1	-9.22	1.15e-18	8.53e-16	-0.46	-0.4	Multiple sclerosis;	chr22:21836496	chr22:21938293~21977632:+
PRAD	cis	rs7772486	0.875	rs2814863	ENSG00000235652.6	RP11-545I5.3	-9.22	1.15e-18	8.54e-16	-0.4	-0.4	Lobe attachment (rater-scored or self-reported);	chr6:146026163	chr6:145799409~145886585:+
PRAD	cis	rs732716	0.853	rs62129349	ENSG00000267980.1	AC007292.6	-9.21	1.16e-18	8.54e-16	-0.4	-0.4	Mean corpuscular volume;	chr19:4385662	chr19:4363789~4364640:+
PRAD	cis	rs3096299	0.719	rs2353581	ENSG00000261118.1	RP11-104N10.1	9.21	1.17e-18	8.64e-16	0.39	0.4	Multiple myeloma (IgH translocation);	chr16:89452500	chr16:89492017~89504460:-
PRAD	cis	rs2739330	0.753	rs4822452	ENSG00000235689.1	AP000351.13	9.21	1.18e-18	8.69e-16	0.48	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:24006305~24008258:-
PRAD	cis	rs4835473	0.932	rs4092718	ENSG00000251600.4	RP11-673E1.1	-9.21	1.18e-18	8.69e-16	-0.51	-0.4	Immature fraction of reticulocytes;	chr4:143799637	chr4:143912331~143982454:+
PRAD	cis	rs6570726	0.846	rs453834	ENSG00000235652.6	RP11-545I5.3	9.21	1.18e-18	8.7e-16	0.41	0.4	Lobe attachment (rater-scored or self-reported);	chr6:145565125	chr6:145799409~145886585:+
PRAD	cis	rs4835473	0.897	rs36083752	ENSG00000251600.4	RP11-673E1.1	-9.21	1.18e-18	8.71e-16	-0.5	-0.4	Immature fraction of reticulocytes;	chr4:143693377	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.897	rs35162238	ENSG00000251600.4	RP11-673E1.1	-9.21	1.18e-18	8.71e-16	-0.5	-0.4	Immature fraction of reticulocytes;	chr4:143693518	chr4:143912331~143982454:+
PRAD	cis	rs2108622	0.683	rs111388185	ENSG00000267453.5	AC004791.2	-9.21	1.18e-18	8.74e-16	-0.52	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866604	chr19:15851993~15864904:-
PRAD	cis	rs2108622	0.683	rs112571591	ENSG00000267453.5	AC004791.2	-9.21	1.18e-18	8.74e-16	-0.52	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866635	chr19:15851993~15864904:-
PRAD	cis	rs2108622	0.647	rs111427692	ENSG00000267453.5	AC004791.2	-9.21	1.18e-18	8.74e-16	-0.52	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866669	chr19:15851993~15864904:-
PRAD	cis	rs2108622	0.727	rs12609468	ENSG00000267453.5	AC004791.2	-9.21	1.18e-18	8.74e-16	-0.52	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867004	chr19:15851993~15864904:-
PRAD	cis	rs2108622	0.727	rs12610967	ENSG00000267453.5	AC004791.2	-9.21	1.18e-18	8.74e-16	-0.52	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867119	chr19:15851993~15864904:-
PRAD	cis	rs2108622	0.711	rs12609820	ENSG00000267453.5	AC004791.2	-9.21	1.18e-18	8.74e-16	-0.52	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867247	chr19:15851993~15864904:-
PRAD	cis	rs2108622	0.668	rs62106153	ENSG00000267453.5	AC004791.2	-9.21	1.18e-18	8.74e-16	-0.52	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867697	chr19:15851993~15864904:-
PRAD	cis	rs2108622	0.727	rs12611242	ENSG00000267453.5	AC004791.2	-9.21	1.18e-18	8.74e-16	-0.52	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867754	chr19:15851993~15864904:-
PRAD	cis	rs2108622	0.727	rs12611308	ENSG00000267453.5	AC004791.2	-9.21	1.18e-18	8.74e-16	-0.52	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867776	chr19:15851993~15864904:-
PRAD	cis	rs2108622	0.727	rs12610189	ENSG00000267453.5	AC004791.2	-9.21	1.18e-18	8.74e-16	-0.52	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867831	chr19:15851993~15864904:-
PRAD	cis	rs2108622	0.711	rs113343664	ENSG00000267453.5	AC004791.2	-9.21	1.18e-18	8.74e-16	-0.52	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15868183	chr19:15851993~15864904:-
PRAD	cis	rs150992	0.587	rs10076291	ENSG00000248489.1	CTD-2007H13.3	-9.21	1.19e-18	8.77e-16	-0.44	-0.4	Body mass index;	chr5:99012954	chr5:98929171~98995013:+
PRAD	cis	rs7688540	0.68	rs77762064	ENSG00000275426.1	CH17-262A2.1	9.21	1.19e-18	8.78e-16	0.61	0.4	Facial morphology (factor 6, height of vermillion lower lip);	chr4:281154	chr4:149738~150317:+
PRAD	cis	rs9399137	0.507	rs4451150	ENSG00000232876.1	CTA-212D2.2	-9.21	1.19e-18	8.82e-16	-0.51	-0.4	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134957925	chr6:135055033~135060550:+
PRAD	cis	rs2739330	0.929	rs5751777	ENSG00000224205.1	AP000351.4	9.21	1.2e-18	8.84e-16	0.49	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23987320~23991421:-
PRAD	cis	rs732716	0.853	rs1127888	ENSG00000267980.1	AC007292.6	-9.21	1.2e-18	8.84e-16	-0.4	-0.4	Mean corpuscular volume;	chr19:4454086	chr19:4363789~4364640:+
PRAD	cis	rs62229266	0.605	rs11701331	ENSG00000231106.2	LINC01436	9.21	1.2e-18	8.85e-16	0.52	0.4	Mitral valve prolapse;	chr21:36086094	chr21:36005338~36007838:+
PRAD	cis	rs172166	0.694	rs9295760	ENSG00000280107.1	AL022393.9	-9.21	1.21e-18	8.89e-16	-0.49	-0.4	Cardiac Troponin-T levels;	chr6:28179607	chr6:28170845~28172521:+
PRAD	cis	rs7189233	0.531	rs9302648	ENSG00000279344.1	RP11-44F14.7	9.21	1.22e-18	9.01e-16	0.37	0.4	Intelligence (multi-trait analysis);	chr16:53493869	chr16:53478957~53481550:-
PRAD	cis	rs4835473	0.9	rs6834494	ENSG00000251600.4	RP11-673E1.1	-9.21	1.23e-18	9.06e-16	-0.51	-0.4	Immature fraction of reticulocytes;	chr4:143822257	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs11734290	ENSG00000251600.4	RP11-673E1.1	-9.21	1.23e-18	9.06e-16	-0.51	-0.4	Immature fraction of reticulocytes;	chr4:143823636	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs11734383	ENSG00000251600.4	RP11-673E1.1	-9.21	1.23e-18	9.06e-16	-0.51	-0.4	Immature fraction of reticulocytes;	chr4:143824093	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.868	rs11735295	ENSG00000251600.4	RP11-673E1.1	-9.21	1.23e-18	9.06e-16	-0.51	-0.4	Immature fraction of reticulocytes;	chr4:143824150	chr4:143912331~143982454:+
PRAD	cis	rs9322193	0.607	rs9383941	ENSG00000216906.2	RP11-350J20.9	-9.21	1.23e-18	9.1e-16	-0.52	-0.4	Lung cancer;	chr6:149912100	chr6:149904243~149906418:+
PRAD	cis	rs2564921	0.693	rs2336721	ENSG00000242142.1	SERBP1P3	-9.21	1.23e-18	9.1e-16	-0.43	-0.4	Height;	chr3:52994359	chr3:53064283~53065091:-
PRAD	cis	rs10262624	1	rs9769098	ENSG00000234286.1	AC006026.13	-9.21	1.24e-18	9.12e-16	-0.45	-0.4	Schizophrenia;	chr7:23877113	chr7:23680195~23680786:-
PRAD	cis	rs10262624	0.967	rs12333669	ENSG00000234286.1	AC006026.13	-9.21	1.24e-18	9.12e-16	-0.45	-0.4	Schizophrenia;	chr7:23877267	chr7:23680195~23680786:-
PRAD	cis	rs10262624	0.935	rs10487596	ENSG00000234286.1	AC006026.13	-9.21	1.24e-18	9.12e-16	-0.45	-0.4	Schizophrenia;	chr7:23877458	chr7:23680195~23680786:-
PRAD	cis	rs10262624	1	rs10950975	ENSG00000234286.1	AC006026.13	-9.21	1.24e-18	9.12e-16	-0.45	-0.4	Schizophrenia;	chr7:23877861	chr7:23680195~23680786:-
PRAD	cis	rs7772486	0.686	rs10872579	ENSG00000235652.6	RP11-545I5.3	9.21	1.24e-18	9.15e-16	0.41	0.4	Lobe attachment (rater-scored or self-reported);	chr6:145644876	chr6:145799409~145886585:+
PRAD	cis	rs4835473	0.932	rs7356305	ENSG00000251600.4	RP11-673E1.1	9.21	1.24e-18	9.17e-16	0.5	0.4	Immature fraction of reticulocytes;	chr4:143737850	chr4:143912331~143982454:+
PRAD	cis	rs3096299	0.685	rs4329923	ENSG00000261118.1	RP11-104N10.1	9.21	1.25e-18	9.19e-16	0.38	0.4	Multiple myeloma (IgH translocation);	chr16:89493770	chr16:89492017~89504460:-
PRAD	cis	rs11317778	1	rs11317778	ENSG00000248489.1	CTD-2007H13.3	9.21	1.25e-18	9.2e-16	0.45	0.4	Eosinophil percentage of white cells;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr5:98905525	chr5:98929171~98995013:+
PRAD	cis	rs150992	0.711	rs2617507	ENSG00000248489.1	CTD-2007H13.3	9.21	1.25e-18	9.2e-16	0.45	0.4	Body mass index;	chr5:98912548	chr5:98929171~98995013:+
PRAD	cis	rs3096299	0.967	rs16965692	ENSG00000274627.1	RP11-104N10.2	9.21	1.25e-18	9.2e-16	0.41	0.4	Multiple myeloma (IgH translocation);	chr16:89405074	chr16:89516797~89522217:+
PRAD	cis	rs4927850	1	rs7630875	ENSG00000242086.7	LINC00969	9.2	1.25e-18	9.22e-16	0.34	0.4	Pancreatic cancer;	chr3:196026895	chr3:195658062~195739964:+
PRAD	cis	rs2442825	0.54	rs35728233	ENSG00000206573.7	THUMPD3-AS1	-9.2	1.25e-18	9.23e-16	-0.31	-0.4	Cerebrospinal fluid clusterin levels;	chr3:9387510	chr3:9349689~9398579:-
PRAD	cis	rs11951515	0.966	rs7706402	ENSG00000188850.9	RP11-159F24.2	9.2	1.26e-18	9.3e-16	0.49	0.4	Metabolite levels  (X-11787);	chr5:43381478	chr5:43336164~43348716:+
PRAD	cis	rs67311347	1	rs11720360	ENSG00000223797.4	ENTPD3-AS1	9.2	1.27e-18	9.36e-16	0.37	0.4	Renal cell carcinoma;	chr3:40406906	chr3:40313802~40453329:-
PRAD	cis	rs7811142	1	rs1000215	ENSG00000242294.5	STAG3L5P	9.2	1.27e-18	9.36e-16	0.26	0.4	Platelet count;	chr7:100406920	chr7:100336079~100351900:+
PRAD	cis	rs67311347	1	rs2085115	ENSG00000223797.4	ENTPD3-AS1	9.2	1.27e-18	9.36e-16	0.37	0.4	Renal cell carcinoma;	chr3:40456049	chr3:40313802~40453329:-
PRAD	cis	rs853679	0.55	rs1233699	ENSG00000219392.1	RP1-265C24.5	-9.2	1.27e-18	9.38e-16	-0.5	-0.4	Depression;	chr6:28201380	chr6:28115628~28116551:+
PRAD	cis	rs4820294	0.961	rs62236664	ENSG00000233360.4	Z83844.1	9.2	1.28e-18	9.42e-16	0.51	0.4	Fat distribution (HIV);	chr22:37663420	chr22:37641832~37658377:-
PRAD	cis	rs4820294	1	rs62236665	ENSG00000233360.4	Z83844.1	9.2	1.28e-18	9.42e-16	0.51	0.4	Fat distribution (HIV);	chr22:37663840	chr22:37641832~37658377:-
PRAD	cis	rs11676348	0.808	rs1008563	ENSG00000261338.2	RP11-378A13.1	-9.2	1.28e-18	9.42e-16	-0.44	-0.4	Ulcerative colitis;	chr2:218162165	chr2:218255319~218257366:+
PRAD	cis	rs524281	0.638	rs4261293	ENSG00000255320.1	RP11-755F10.1	-9.2	1.28e-18	9.42e-16	-0.67	-0.4	Electroencephalogram traits;	chr11:66037664	chr11:66244840~66246239:-
PRAD	cis	rs524281	0.682	rs6591202	ENSG00000255320.1	RP11-755F10.1	-9.2	1.28e-18	9.42e-16	-0.67	-0.4	Electroencephalogram traits;	chr11:66038622	chr11:66244840~66246239:-
PRAD	cis	rs524281	0.731	rs6591203	ENSG00000255320.1	RP11-755F10.1	-9.2	1.28e-18	9.42e-16	-0.67	-0.4	Electroencephalogram traits;	chr11:66038758	chr11:66244840~66246239:-
PRAD	cis	rs524281	0.731	rs9326365	ENSG00000255320.1	RP11-755F10.1	-9.2	1.28e-18	9.42e-16	-0.67	-0.4	Electroencephalogram traits;	chr11:66040414	chr11:66244840~66246239:-
PRAD	cis	rs4835473	0.864	rs57137521	ENSG00000251600.4	RP11-673E1.1	-9.2	1.28e-18	9.44e-16	-0.49	-0.4	Immature fraction of reticulocytes;	chr4:143704045	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.897	rs55945293	ENSG00000251600.4	RP11-673E1.1	-9.2	1.28e-18	9.44e-16	-0.49	-0.4	Immature fraction of reticulocytes;	chr4:143704766	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.897	rs1450246	ENSG00000251600.4	RP11-673E1.1	9.2	1.28e-18	9.44e-16	0.49	0.4	Immature fraction of reticulocytes;	chr4:143702954	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.897	rs7695328	ENSG00000251600.4	RP11-673E1.1	9.2	1.28e-18	9.44e-16	0.49	0.4	Immature fraction of reticulocytes;	chr4:143703768	chr4:143912331~143982454:+
PRAD	cis	rs7712401	0.601	rs246275	ENSG00000263432.2	RN7SL689P	9.2	1.3e-18	9.55e-16	0.41	0.4	Mean platelet volume;	chr5:122895718	chr5:123022487~123022783:-
PRAD	cis	rs9309473	0.606	rs1589576	ENSG00000163016.8	ALMS1P	9.2	1.3e-18	9.57e-16	0.53	0.4	Metabolite levels;	chr2:73511677	chr2:73644919~73685576:+
PRAD	cis	rs11673344	0.734	rs2551047	ENSG00000226686.6	LINC01535	9.2	1.3e-18	9.59e-16	0.54	0.4	Obesity-related traits;	chr19:36935174	chr19:37251912~37265535:+
PRAD	cis	rs11673344	0.704	rs551717	ENSG00000226686.6	LINC01535	9.2	1.3e-18	9.59e-16	0.54	0.4	Obesity-related traits;	chr19:36936977	chr19:37251912~37265535:+
PRAD	cis	rs11673344	0.704	rs826290	ENSG00000226686.6	LINC01535	9.2	1.3e-18	9.59e-16	0.54	0.4	Obesity-related traits;	chr19:36937543	chr19:37251912~37265535:+
PRAD	cis	rs11673344	0.67	rs505717	ENSG00000226686.6	LINC01535	9.2	1.3e-18	9.59e-16	0.54	0.4	Obesity-related traits;	chr19:36939414	chr19:37251912~37265535:+
PRAD	cis	rs11673344	0.704	rs544543	ENSG00000226686.6	LINC01535	9.2	1.3e-18	9.59e-16	0.54	0.4	Obesity-related traits;	chr19:36939921	chr19:37251912~37265535:+
PRAD	cis	rs11673344	0.67	rs568654	ENSG00000226686.6	LINC01535	9.2	1.3e-18	9.59e-16	0.54	0.4	Obesity-related traits;	chr19:36940285	chr19:37251912~37265535:+
PRAD	cis	rs8072100	0.727	rs4794052	ENSG00000228782.6	CTD-2026D20.3	9.2	1.31e-18	9.6e-16	0.44	0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47691870	chr17:47450568~47492492:-
PRAD	cis	rs8072100	0.701	rs4794053	ENSG00000228782.6	CTD-2026D20.3	9.2	1.31e-18	9.6e-16	0.44	0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47692185	chr17:47450568~47492492:-
PRAD	cis	rs853679	0.55	rs1233701	ENSG00000219392.1	RP1-265C24.5	9.2	1.31e-18	9.6e-16	0.51	0.4	Depression;	chr6:28200948	chr6:28115628~28116551:+
PRAD	cis	rs2274273	0.84	rs1045002	ENSG00000258413.1	RP11-665C16.6	-9.2	1.31e-18	9.61e-16	-0.51	-0.4	Protein biomarker;	chr14:55351799	chr14:55262767~55272075:-
PRAD	cis	rs10262624	0.935	rs8180700	ENSG00000234286.1	AC006026.13	-9.2	1.31e-18	9.62e-16	-0.45	-0.4	Schizophrenia;	chr7:23870323	chr7:23680195~23680786:-
PRAD	cis	rs4888378	0.535	rs9319483	ENSG00000261783.1	RP11-252K23.2	9.2	1.31e-18	9.64e-16	0.63	0.4	Coronary artery disease;	chr16:75311893	chr16:75379818~75381260:-
PRAD	cis	rs9545047	0.604	rs7336581	ENSG00000227676.3	LINC01068	9.2	1.31e-18	9.67e-16	0.47	0.4	Schizophrenia;	chr13:79385739	chr13:79566727~79571436:+
PRAD	cis	rs13631	0.697	rs1018330	ENSG00000268996.3	MAN1B1-AS1	9.2	1.32e-18	9.73e-16	0.4	0.4	Cerebrospinal fluid biomarker levels;	chr9:137085933	chr9:137084946~137086817:-
PRAD	cis	rs4820294	1	rs78974622	ENSG00000233360.4	Z83844.1	9.2	1.33e-18	9.79e-16	0.5	0.4	Fat distribution (HIV);	chr22:37663918	chr22:37641832~37658377:-
PRAD	cis	rs7727544	0.606	rs2631360	ENSG00000233006.5	AC034220.3	9.2	1.34e-18	9.82e-16	0.34	0.4	Blood metabolite levels;	chr5:132371737	chr5:132311285~132369916:-
PRAD	cis	rs1075265	0.587	rs2542585	ENSG00000233266.1	HMGB1P31	9.19	1.35e-18	9.94e-16	0.55	0.4	Chronotype;Morning vs. evening chronotype;	chr2:53786407	chr2:54051334~54051760:+
PRAD	cis	rs6061231	0.834	rs2427307	ENSG00000273619.1	RP5-908M14.9	-9.19	1.36e-18	9.98e-16	-0.26	-0.4	Colorectal cancer;	chr20:62391630	chr20:62386303~62386970:-
PRAD	cis	rs12468226	1	rs116635509	ENSG00000273456.1	RP11-686O6.2	9.19	1.36e-18	9.98e-16	0.53	0.4	Urate levels;	chr2:202460027	chr2:202374932~202375604:-
PRAD	cis	rs2799081	1	rs2799081	ENSG00000216901.1	AL022393.7	9.19	1.36e-18	9.98e-16	0.53	0.4	Myopia;	chr6:28302807	chr6:28176188~28176674:+
PRAD	cis	rs2739330	0.828	rs5760098	ENSG00000224205.1	AP000351.4	9.19	1.36e-18	1e-15	0.49	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23987320~23991421:-
PRAD	cis	rs2337406	0.866	rs2301535	ENSG00000274576.2	IGHV2-70	-9.19	1.37e-18	1.01e-15	-0.42	-0.4	Alzheimer's disease (late onset);	chr14:106790663	chr14:106770577~106771020:-
PRAD	cis	rs853679	0.517	rs868987	ENSG00000272009.1	RP1-313I6.12	9.19	1.37e-18	1.01e-15	0.4	0.4	Depression;	chr6:28142370	chr6:28078792~28081130:-
PRAD	cis	rs4835473	0.778	rs2622380	ENSG00000251600.4	RP11-673E1.1	-9.19	1.38e-18	1.01e-15	-0.51	-0.4	Immature fraction of reticulocytes;	chr4:143814571	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs35792820	ENSG00000251600.4	RP11-673E1.1	-9.19	1.38e-18	1.01e-15	-0.51	-0.4	Immature fraction of reticulocytes;	chr4:143814806	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.864	rs62337300	ENSG00000251600.4	RP11-673E1.1	-9.19	1.38e-18	1.01e-15	-0.51	-0.4	Immature fraction of reticulocytes;	chr4:143815897	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs7697498	ENSG00000251600.4	RP11-673E1.1	-9.19	1.38e-18	1.01e-15	-0.51	-0.4	Immature fraction of reticulocytes;	chr4:143816854	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs7656455	ENSG00000251600.4	RP11-673E1.1	-9.19	1.38e-18	1.01e-15	-0.51	-0.4	Immature fraction of reticulocytes;	chr4:143817005	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.9	rs13133239	ENSG00000251600.4	RP11-673E1.1	-9.19	1.38e-18	1.01e-15	-0.51	-0.4	Immature fraction of reticulocytes;	chr4:143818894	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.9	rs13106488	ENSG00000251600.4	RP11-673E1.1	-9.19	1.38e-18	1.01e-15	-0.51	-0.4	Immature fraction of reticulocytes;	chr4:143818969	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs13105102	ENSG00000251600.4	RP11-673E1.1	-9.19	1.38e-18	1.01e-15	-0.51	-0.4	Immature fraction of reticulocytes;	chr4:143819046	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.868	rs13105118	ENSG00000251600.4	RP11-673E1.1	-9.19	1.38e-18	1.01e-15	-0.51	-0.4	Immature fraction of reticulocytes;	chr4:143819077	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs35271123	ENSG00000251600.4	RP11-673E1.1	-9.19	1.38e-18	1.01e-15	-0.51	-0.4	Immature fraction of reticulocytes;	chr4:143819629	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs1383443	ENSG00000251600.4	RP11-673E1.1	-9.19	1.38e-18	1.01e-15	-0.51	-0.4	Immature fraction of reticulocytes;	chr4:143819940	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs7669198	ENSG00000251600.4	RP11-673E1.1	-9.19	1.38e-18	1.01e-15	-0.51	-0.4	Immature fraction of reticulocytes;	chr4:143821229	chr4:143912331~143982454:+
PRAD	cis	rs1789	0.903	rs6850422	ENSG00000273133.1	RP11-799M12.2	-9.19	1.38e-18	1.01e-15	-0.5	-0.4	Blood protein levels;	chr4:15680814	chr4:15563698~15564253:-
PRAD	cis	rs11673344	0.764	rs519551	ENSG00000226686.6	LINC01535	9.19	1.38e-18	1.02e-15	0.53	0.4	Obesity-related traits;	chr19:36965046	chr19:37251912~37265535:+
PRAD	cis	rs2739330	0.731	rs4822450	ENSG00000206090.4	AP000350.7	9.19	1.39e-18	1.02e-15	0.5	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23939998~23942798:+
PRAD	cis	rs7772486	0.875	rs2777481	ENSG00000235652.6	RP11-545I5.3	9.19	1.39e-18	1.02e-15	0.4	0.4	Lobe attachment (rater-scored or self-reported);	chr6:145988900	chr6:145799409~145886585:+
PRAD	cis	rs2404602	1	rs2404602	ENSG00000259422.1	RP11-593F23.1	9.19	1.39e-18	1.02e-15	0.49	0.4	Blood metabolite levels;	chr15:76738451	chr15:76174891~76181486:-
PRAD	cis	rs4835473	0.838	rs6838981	ENSG00000251600.4	RP11-673E1.1	-9.19	1.4e-18	1.03e-15	-0.51	-0.4	Immature fraction of reticulocytes;	chr4:143826484	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs7670010	ENSG00000251600.4	RP11-673E1.1	9.19	1.4e-18	1.03e-15	0.51	0.4	Immature fraction of reticulocytes;	chr4:143821679	chr4:143912331~143982454:+
PRAD	cis	rs34375054	0.624	rs73233307	ENSG00000279233.1	RP11-158L12.4	9.19	1.41e-18	1.03e-15	0.4	0.4	Post bronchodilator FEV1/FVC ratio;	chr12:125191327	chr12:125138245~125141711:+
PRAD	cis	rs34375054	0.624	rs12580033	ENSG00000279233.1	RP11-158L12.4	9.19	1.41e-18	1.03e-15	0.4	0.4	Post bronchodilator FEV1/FVC ratio;	chr12:125191537	chr12:125138245~125141711:+
PRAD	cis	rs11098499	0.738	rs28408407	ENSG00000245958.5	RP11-33B1.1	-9.19	1.41e-18	1.03e-15	-0.39	-0.4	Corneal astigmatism;	chr4:119454875	chr4:119454791~119552025:+
PRAD	cis	rs150992	0.638	rs466340	ENSG00000248489.1	CTD-2007H13.3	9.19	1.42e-18	1.04e-15	0.45	0.4	Body mass index;	chr5:98904318	chr5:98929171~98995013:+
PRAD	cis	rs150992	0.673	rs326463	ENSG00000248489.1	CTD-2007H13.3	9.19	1.42e-18	1.04e-15	0.45	0.4	Body mass index;	chr5:98905785	chr5:98929171~98995013:+
PRAD	cis	rs150992	0.673	rs327792	ENSG00000248489.1	CTD-2007H13.3	9.19	1.42e-18	1.04e-15	0.45	0.4	Body mass index;	chr5:98909802	chr5:98929171~98995013:+
PRAD	cis	rs4879677	0.92	rs3861018	ENSG00000260390.1	RP11-575I8.1	-9.19	1.42e-18	1.05e-15	-0.54	-0.4	Gut microbiome composition (summer and winter);	chr9:27654018	chr9:27829276~27844481:+
PRAD	cis	rs7811142	0.83	rs76798830	ENSG00000242294.5	STAG3L5P	9.19	1.43e-18	1.05e-15	0.27	0.4	Platelet count;	chr7:100355205	chr7:100336079~100351900:+
PRAD	cis	rs11098499	0.863	rs2127823	ENSG00000245958.5	RP11-33B1.1	-9.19	1.43e-18	1.05e-15	-0.39	-0.4	Corneal astigmatism;	chr4:119564515	chr4:119454791~119552025:+
PRAD	cis	rs3814244	0.788	rs3741647	ENSG00000255733.4	IFNG-AS1	-9.19	1.45e-18	1.06e-15	-0.41	-0.4	Itch intensity from mosquito bite adjusted by bite size;	chr12:68028249	chr12:67989445~68234686:+
PRAD	cis	rs12134133	1	rs1782468	ENSG00000274245.1	RP11-357P18.2	9.19	1.46e-18	1.07e-15	0.55	0.4	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207297070	chr1:207372559~207373252:+
PRAD	cis	rs858239	1	rs858240	ENSG00000226816.2	AC005082.12	9.19	1.46e-18	1.07e-15	0.45	0.4	Cerebrospinal fluid biomarker levels;	chr7:23244618	chr7:23206013~23208045:+
PRAD	cis	rs17023223	0.537	rs2765532	ENSG00000231365.4	RP11-418J17.1	-9.18	1.47e-18	1.07e-15	-0.4	-0.4	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119048923	chr1:119140396~119275973:+
PRAD	cis	rs12468226	1	rs76528043	ENSG00000273456.1	RP11-686O6.2	9.18	1.47e-18	1.08e-15	0.53	0.4	Urate levels;	chr2:202466116	chr2:202374932~202375604:-
PRAD	cis	rs12468226	1	rs12468226	ENSG00000273456.1	RP11-686O6.2	9.18	1.47e-18	1.08e-15	0.53	0.4	Urate levels;	chr2:202472278	chr2:202374932~202375604:-
PRAD	cis	rs12468226	1	rs75040639	ENSG00000273456.1	RP11-686O6.2	9.18	1.47e-18	1.08e-15	0.53	0.4	Urate levels;	chr2:202486973	chr2:202374932~202375604:-
PRAD	cis	rs12468226	0.872	rs115187557	ENSG00000273456.1	RP11-686O6.2	9.18	1.47e-18	1.08e-15	0.53	0.4	Urate levels;	chr2:202495351	chr2:202374932~202375604:-
PRAD	cis	rs12468226	1	rs76021735	ENSG00000273456.1	RP11-686O6.2	9.18	1.47e-18	1.08e-15	0.53	0.4	Urate levels;	chr2:202511476	chr2:202374932~202375604:-
PRAD	cis	rs12468226	1	rs57080353	ENSG00000273456.1	RP11-686O6.2	9.18	1.47e-18	1.08e-15	0.53	0.4	Urate levels;	chr2:202511824	chr2:202374932~202375604:-
PRAD	cis	rs12468226	1	rs74508472	ENSG00000273456.1	RP11-686O6.2	9.18	1.47e-18	1.08e-15	0.53	0.4	Urate levels;	chr2:202517290	chr2:202374932~202375604:-
PRAD	cis	rs12468226	0.81	rs3736578	ENSG00000273456.1	RP11-686O6.2	9.18	1.47e-18	1.08e-15	0.53	0.4	Urate levels;	chr2:202519989	chr2:202374932~202375604:-
PRAD	cis	rs12468226	1	rs116439150	ENSG00000273456.1	RP11-686O6.2	9.18	1.47e-18	1.08e-15	0.53	0.4	Urate levels;	chr2:202523814	chr2:202374932~202375604:-
PRAD	cis	rs12468226	1	rs12467409	ENSG00000273456.1	RP11-686O6.2	9.18	1.47e-18	1.08e-15	0.53	0.4	Urate levels;	chr2:202529625	chr2:202374932~202375604:-
PRAD	cis	rs12468226	0.81	rs77090459	ENSG00000273456.1	RP11-686O6.2	9.18	1.47e-18	1.08e-15	0.53	0.4	Urate levels;	chr2:202542132	chr2:202374932~202375604:-
PRAD	cis	rs12468226	0.872	rs1061157	ENSG00000273456.1	RP11-686O6.2	9.18	1.47e-18	1.08e-15	0.53	0.4	Urate levels;	chr2:202556476	chr2:202374932~202375604:-
PRAD	cis	rs2739330	0.828	rs5760102	ENSG00000224205.1	AP000351.4	9.18	1.47e-18	1.08e-15	0.49	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23987320~23991421:-
PRAD	cis	rs12817211	0.502	rs12369049	ENSG00000272368.2	RP4-605O3.4	-9.18	1.48e-18	1.08e-15	-0.39	-0.4	Colorectal or endometrial cancer;	chr12:50116679	chr12:50112197~50165618:+
PRAD	cis	rs4835473	0.897	rs4835333	ENSG00000251600.4	RP11-673E1.1	-9.18	1.48e-18	1.09e-15	-0.49	-0.4	Immature fraction of reticulocytes;	chr4:143703174	chr4:143912331~143982454:+
PRAD	cis	rs2108622	0.701	rs118144071	ENSG00000267453.5	AC004791.2	-9.18	1.49e-18	1.09e-15	-0.52	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15868384	chr19:15851993~15864904:-
PRAD	cis	rs4835473	0.864	rs1597446	ENSG00000251600.4	RP11-673E1.1	9.18	1.49e-18	1.09e-15	0.5	0.4	Immature fraction of reticulocytes;	chr4:143708338	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.835	rs1450247	ENSG00000251600.4	RP11-673E1.1	9.18	1.49e-18	1.09e-15	0.5	0.4	Immature fraction of reticulocytes;	chr4:143708529	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.897	rs7681914	ENSG00000251600.4	RP11-673E1.1	9.18	1.49e-18	1.09e-15	0.5	0.4	Immature fraction of reticulocytes;	chr4:143708838	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.864	rs7682096	ENSG00000251600.4	RP11-673E1.1	9.18	1.49e-18	1.09e-15	0.5	0.4	Immature fraction of reticulocytes;	chr4:143708892	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.897	rs7682128	ENSG00000251600.4	RP11-673E1.1	9.18	1.49e-18	1.09e-15	0.5	0.4	Immature fraction of reticulocytes;	chr4:143708950	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.897	rs7687317	ENSG00000251600.4	RP11-673E1.1	9.18	1.49e-18	1.09e-15	0.5	0.4	Immature fraction of reticulocytes;	chr4:143709010	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.897	rs6537171	ENSG00000251600.4	RP11-673E1.1	9.18	1.49e-18	1.09e-15	0.5	0.4	Immature fraction of reticulocytes;	chr4:143709222	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.897	rs6832722	ENSG00000251600.4	RP11-673E1.1	9.18	1.49e-18	1.09e-15	0.5	0.4	Immature fraction of reticulocytes;	chr4:143709430	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.897	rs6832749	ENSG00000251600.4	RP11-673E1.1	9.18	1.49e-18	1.09e-15	0.5	0.4	Immature fraction of reticulocytes;	chr4:143709473	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.897	rs6831477	ENSG00000251600.4	RP11-673E1.1	9.18	1.49e-18	1.09e-15	0.5	0.4	Immature fraction of reticulocytes;	chr4:143709487	chr4:143912331~143982454:+
PRAD	cis	rs2337406	0.81	rs7161739	ENSG00000274576.2	IGHV2-70	-9.18	1.5e-18	1.1e-15	-0.42	-0.4	Alzheimer's disease (late onset);	chr14:106776118	chr14:106770577~106771020:-
PRAD	cis	rs4718428	0.705	rs4718430	ENSG00000230295.1	RP11-458F8.2	-9.18	1.5e-18	1.1e-15	-0.31	-0.4	Corneal structure;	chr7:66967037	chr7:66880708~66882981:+
PRAD	cis	rs2282300	0.739	rs7952339	ENSG00000242353.1	RP4-710M3.1	9.18	1.5e-18	1.1e-15	0.46	0.4	Morning vs. evening chronotype;	chr11:30305797	chr11:30368148~30368646:+
PRAD	cis	rs2015599	0.623	rs2288128	ENSG00000257176.2	RP11-996F15.2	9.18	1.5e-18	1.1e-15	0.44	0.4	Platelet count;Mean platelet volume;	chr12:29316054	chr12:29280418~29317848:-
PRAD	cis	rs2015599	0.584	rs2288129	ENSG00000257176.2	RP11-996F15.2	9.18	1.5e-18	1.1e-15	0.44	0.4	Platelet count;Mean platelet volume;	chr12:29316355	chr12:29280418~29317848:-
PRAD	cis	rs7923609	0.729	rs7902616	ENSG00000232075.1	MRPL35P2	9.18	1.5e-18	1.1e-15	0.41	0.4	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63576613	chr10:63634317~63634827:-
PRAD	cis	rs7923609	0.756	rs10822183	ENSG00000232075.1	MRPL35P2	9.18	1.5e-18	1.1e-15	0.41	0.4	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63577381	chr10:63634317~63634827:-
PRAD	cis	rs524281	0.954	rs549187	ENSG00000255320.1	RP11-755F10.1	9.18	1.5e-18	1.1e-15	0.55	0.4	Electroencephalogram traits;	chr11:66131160	chr11:66244840~66246239:-
PRAD	cis	rs150992	0.711	rs161735	ENSG00000248489.1	CTD-2007H13.3	9.18	1.51e-18	1.1e-15	0.45	0.4	Body mass index;	chr5:98862026	chr5:98929171~98995013:+
PRAD	cis	rs7923609	0.756	rs7077256	ENSG00000232075.1	MRPL35P2	9.18	1.51e-18	1.11e-15	0.41	0.4	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63576425	chr10:63634317~63634827:-
PRAD	cis	rs4835473	0.932	rs1839448	ENSG00000251600.4	RP11-673E1.1	9.18	1.52e-18	1.11e-15	0.5	0.4	Immature fraction of reticulocytes;	chr4:143752113	chr4:143912331~143982454:+
PRAD	cis	rs524281	1	rs475805	ENSG00000255320.1	RP11-755F10.1	-9.18	1.52e-18	1.11e-15	-0.57	-0.4	Electroencephalogram traits;	chr11:66081267	chr11:66244840~66246239:-
PRAD	cis	rs67311347	0.876	rs13068097	ENSG00000223797.4	ENTPD3-AS1	-9.18	1.52e-18	1.11e-15	-0.35	-0.4	Renal cell carcinoma;	chr3:40462933	chr3:40313802~40453329:-
PRAD	cis	rs67311347	1	rs73080126	ENSG00000223797.4	ENTPD3-AS1	9.18	1.52e-18	1.12e-15	0.37	0.4	Renal cell carcinoma;	chr3:40467662	chr3:40313802~40453329:-
PRAD	cis	rs67311347	1	rs28871903	ENSG00000223797.4	ENTPD3-AS1	9.18	1.52e-18	1.12e-15	0.37	0.4	Renal cell carcinoma;	chr3:40469603	chr3:40313802~40453329:-
PRAD	cis	rs67311347	1	rs56291770	ENSG00000223797.4	ENTPD3-AS1	9.18	1.52e-18	1.12e-15	0.37	0.4	Renal cell carcinoma;	chr3:40473879	chr3:40313802~40453329:-
PRAD	cis	rs67311347	0.955	rs11711994	ENSG00000223797.4	ENTPD3-AS1	9.18	1.52e-18	1.12e-15	0.37	0.4	Renal cell carcinoma;	chr3:40349595	chr3:40313802~40453329:-
PRAD	cis	rs3096299	0.933	rs2930219	ENSG00000274627.1	RP11-104N10.2	9.18	1.53e-18	1.12e-15	0.41	0.4	Multiple myeloma (IgH translocation);	chr16:89425641	chr16:89516797~89522217:+
PRAD	cis	rs7189233	0.55	rs13330182	ENSG00000279344.1	RP11-44F14.7	9.18	1.53e-18	1.12e-15	0.36	0.4	Intelligence (multi-trait analysis);	chr16:53438473	chr16:53478957~53481550:-
PRAD	cis	rs2153535	0.585	rs7762631	ENSG00000230939.1	RP11-314C16.1	9.18	1.53e-18	1.12e-15	0.49	0.4	Motion sickness;	chr6:8635339	chr6:8784178~8785445:+
PRAD	cis	rs2404602	0.716	rs8025134	ENSG00000259422.1	RP11-593F23.1	9.18	1.54e-18	1.12e-15	0.49	0.4	Blood metabolite levels;	chr15:76489388	chr15:76174891~76181486:-
PRAD	cis	rs2739330	0.734	rs2000467	ENSG00000099984.9	GSTT2	9.18	1.54e-18	1.13e-15	0.53	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23980123~23983911:+
PRAD	cis	rs2739330	0.828	rs5760102	ENSG00000099984.9	GSTT2	-9.18	1.54e-18	1.13e-15	-0.53	-0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23980123~23983911:+
PRAD	cis	rs4835473	0.932	rs7664248	ENSG00000251600.4	RP11-673E1.1	9.18	1.54e-18	1.13e-15	0.5	0.4	Immature fraction of reticulocytes;	chr4:143732554	chr4:143912331~143982454:+
PRAD	cis	rs2729354	0.768	rs2584856	ENSG00000265566.2	RN7SL605P	-9.18	1.54e-18	1.13e-15	-0.58	-0.4	Blood protein levels;	chr11:57499839	chr11:57528085~57528365:-
PRAD	cis	rs67311347	1	rs17078916	ENSG00000223797.4	ENTPD3-AS1	9.18	1.54e-18	1.13e-15	0.37	0.4	Renal cell carcinoma;	chr3:40403947	chr3:40313802~40453329:-
PRAD	cis	rs6991838	0.584	rs7823840	ENSG00000200714.1	Y_RNA	-9.18	1.55e-18	1.14e-15	-0.44	-0.4	Intelligence (multi-trait analysis);	chr8:65606766	chr8:65592731~65592820:+
PRAD	cis	rs7567389	0.505	rs1518760	ENSG00000236682.1	AC068282.3	-9.18	1.55e-18	1.14e-15	-0.49	-0.4	Self-rated health;	chr2:127382924	chr2:127389130~127400580:+
PRAD	cis	rs875971	1	rs2036264	ENSG00000237310.1	GS1-124K5.4	-9.18	1.56e-18	1.14e-15	-0.35	-0.4	Aortic root size;	chr7:66334917	chr7:66493706~66495474:+
PRAD	cis	rs875971	1	rs7783613	ENSG00000237310.1	GS1-124K5.4	-9.18	1.56e-18	1.14e-15	-0.35	-0.4	Aortic root size;	chr7:66340274	chr7:66493706~66495474:+
PRAD	cis	rs5769707	0.605	rs9616702	ENSG00000188511.11	C22orf34	9.18	1.56e-18	1.14e-15	0.48	0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49632290	chr22:49414524~49657542:-
PRAD	cis	rs11673344	0.704	rs1644711	ENSG00000226686.6	LINC01535	9.18	1.56e-18	1.14e-15	0.54	0.4	Obesity-related traits;	chr19:36926420	chr19:37251912~37265535:+
PRAD	cis	rs11673344	0.704	rs485034	ENSG00000226686.6	LINC01535	9.18	1.56e-18	1.14e-15	0.54	0.4	Obesity-related traits;	chr19:36931455	chr19:37251912~37265535:+
PRAD	cis	rs11673344	0.704	rs517110	ENSG00000226686.6	LINC01535	9.18	1.56e-18	1.14e-15	0.54	0.4	Obesity-related traits;	chr19:36931492	chr19:37251912~37265535:+
PRAD	cis	rs12931792	0.687	rs8057425	ENSG00000183604.13	SMG1P5	9.18	1.57e-18	1.14e-15	0.36	0.4	Tonsillectomy;	chr16:30171220	chr16:30267553~30335374:-
PRAD	cis	rs11673344	0.764	rs565721	ENSG00000226686.6	LINC01535	9.18	1.57e-18	1.14e-15	0.54	0.4	Obesity-related traits;	chr19:36964929	chr19:37251912~37265535:+
PRAD	cis	rs6723108	0.517	rs6430543	ENSG00000224043.6	CCNT2-AS1	9.18	1.57e-18	1.15e-15	0.54	0.4	Type 2 diabetes;	chr2:134844839	chr2:134735464~134918710:-
PRAD	cis	rs858239	0.932	rs858272	ENSG00000226816.2	AC005082.12	9.18	1.57e-18	1.15e-15	0.45	0.4	Cerebrospinal fluid biomarker levels;	chr7:23237166	chr7:23206013~23208045:+
PRAD	cis	rs6570726	0.818	rs952405	ENSG00000235652.6	RP11-545I5.3	9.18	1.58e-18	1.15e-15	0.4	0.4	Lobe attachment (rater-scored or self-reported);	chr6:145604816	chr6:145799409~145886585:+
PRAD	cis	rs853679	0.55	rs1233704	ENSG00000219392.1	RP1-265C24.5	9.18	1.58e-18	1.15e-15	0.5	0.4	Depression;	chr6:28199145	chr6:28115628~28116551:+
PRAD	cis	rs4835473	0.669	rs75704080	ENSG00000251600.4	RP11-673E1.1	-9.18	1.58e-18	1.15e-15	-0.5	-0.4	Immature fraction of reticulocytes;	chr4:143779066	chr4:143912331~143982454:+
PRAD	cis	rs2739330	0.828	rs5760107	ENSG00000235689.1	AP000351.13	9.18	1.58e-18	1.15e-15	0.48	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:24006305~24008258:-
PRAD	cis	rs2739330	0.789	rs5760109	ENSG00000235689.1	AP000351.13	9.18	1.58e-18	1.15e-15	0.48	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:24006305~24008258:-
PRAD	cis	rs6517329	0.513	rs2835289	ENSG00000236830.5	CBR3-AS1	9.18	1.58e-18	1.16e-15	0.41	0.4	Schizophrenia;	chr21:36163599	chr21:36131767~36175815:-
PRAD	cis	rs11098499	0.954	rs13107475	ENSG00000245958.5	RP11-33B1.1	-9.18	1.58e-18	1.16e-15	-0.39	-0.4	Corneal astigmatism;	chr4:119471856	chr4:119454791~119552025:+
PRAD	cis	rs67311347	1	rs73076046	ENSG00000223797.4	ENTPD3-AS1	9.17	1.58e-18	1.16e-15	0.37	0.4	Renal cell carcinoma;	chr3:40406233	chr3:40313802~40453329:-
PRAD	cis	rs4879677	0.92	rs1826742	ENSG00000260390.1	RP11-575I8.1	-9.17	1.58e-18	1.16e-15	-0.54	-0.4	Gut microbiome composition (summer and winter);	chr9:27654052	chr9:27829276~27844481:+
PRAD	cis	rs17711722	0.523	rs313812	ENSG00000228409.4	CCT6P1	9.17	1.59e-18	1.16e-15	0.29	0.4	Calcium levels;	chr7:66040056	chr7:65751142~65763354:+
PRAD	cis	rs150992	0.57	rs398436	ENSG00000248489.1	CTD-2007H13.3	9.17	1.59e-18	1.16e-15	0.43	0.4	Body mass index;	chr5:98991352	chr5:98929171~98995013:+
PRAD	cis	rs12931792	0.748	rs11150585	ENSG00000183604.13	SMG1P5	9.17	1.59e-18	1.16e-15	0.36	0.4	Tonsillectomy;	chr16:30172965	chr16:30267553~30335374:-
PRAD	cis	rs1426063	0.614	rs17266308	ENSG00000260265.1	RP11-44F21.5	-9.17	1.59e-18	1.16e-15	-0.78	-0.4	QT interval;	chr4:75137695	chr4:75081702~75084717:-
PRAD	cis	rs1930961	1	rs6004668	ENSG00000272798.1	CTA-390C10.9	9.17	1.59e-18	1.16e-15	0.63	0.4	Bipolar disorder with mood-incongruent psychosis;	chr22:25478535	chr22:25436312~25436915:+
PRAD	cis	rs7811142	1	rs67040465	ENSG00000242294.5	STAG3L5P	9.17	1.6e-18	1.17e-15	0.27	0.4	Platelet count;	chr7:100485455	chr7:100336079~100351900:+
PRAD	cis	rs2739330	0.828	rs2330635	ENSG00000235689.1	AP000351.13	9.17	1.6e-18	1.17e-15	0.48	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:24006305~24008258:-
PRAD	cis	rs8072100	0.967	rs4289035	ENSG00000228782.6	CTD-2026D20.3	9.17	1.6e-18	1.17e-15	0.43	0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47629845	chr17:47450568~47492492:-
PRAD	cis	rs875971	1	rs6946143	ENSG00000237310.1	GS1-124K5.4	9.17	1.6e-18	1.17e-15	0.35	0.4	Aortic root size;	chr7:66114735	chr7:66493706~66495474:+
PRAD	cis	rs9326248	0.861	rs494356	ENSG00000280143.1	AP000892.6	9.17	1.6e-18	1.17e-15	0.42	0.4	Blood protein levels;	chr11:117201254	chr11:117204967~117210292:+
PRAD	cis	rs6991838	0.584	rs35790435	ENSG00000200714.1	Y_RNA	-9.17	1.61e-18	1.18e-15	-0.44	-0.4	Intelligence (multi-trait analysis);	chr8:65590288	chr8:65592731~65592820:+
PRAD	cis	rs12134133	1	rs6658718	ENSG00000274245.1	RP11-357P18.2	9.17	1.61e-18	1.18e-15	0.54	0.4	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207285561	chr1:207372559~207373252:+
PRAD	cis	rs524281	1	rs472518	ENSG00000255320.1	RP11-755F10.1	-9.17	1.61e-18	1.18e-15	-0.56	-0.4	Electroencephalogram traits;	chr11:66084431	chr11:66244840~66246239:-
PRAD	cis	rs9309473	0.95	rs73947808	ENSG00000163016.8	ALMS1P	9.17	1.62e-18	1.18e-15	0.51	0.4	Metabolite levels;	chr2:73494123	chr2:73644919~73685576:+
PRAD	cis	rs11673344	0.704	rs484001	ENSG00000226686.6	LINC01535	9.17	1.62e-18	1.18e-15	0.54	0.4	Obesity-related traits;	chr19:36931320	chr19:37251912~37265535:+
PRAD	cis	rs4718428	0.705	rs12698547	ENSG00000230295.1	RP11-458F8.2	-9.17	1.62e-18	1.19e-15	-0.3	-0.4	Corneal structure;	chr7:66813271	chr7:66880708~66882981:+
PRAD	cis	rs3779195	0.697	rs1688606	ENSG00000272950.1	RP11-307C18.1	9.17	1.63e-18	1.19e-15	0.61	0.4	Sex hormone-binding globulin levels;	chr7:98345539	chr7:98322853~98323430:+
PRAD	cis	rs150992	0.587	rs4703340	ENSG00000248489.1	CTD-2007H13.3	-9.17	1.63e-18	1.19e-15	-0.43	-0.39	Body mass index;	chr5:99009083	chr5:98929171~98995013:+
PRAD	cis	rs67311347	0.955	rs11717036	ENSG00000223797.4	ENTPD3-AS1	-9.17	1.64e-18	1.2e-15	-0.35	-0.39	Renal cell carcinoma;	chr3:40338087	chr3:40313802~40453329:-
PRAD	cis	rs875971	1	rs11971949	ENSG00000237310.1	GS1-124K5.4	-9.17	1.64e-18	1.2e-15	-0.35	-0.39	Aortic root size;	chr7:66161027	chr7:66493706~66495474:+
PRAD	cis	rs7923609	0.756	rs7910951	ENSG00000232075.1	MRPL35P2	9.17	1.64e-18	1.2e-15	0.42	0.39	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63578544	chr10:63634317~63634827:-
PRAD	cis	rs7923609	0.756	rs7911761	ENSG00000232075.1	MRPL35P2	9.17	1.64e-18	1.2e-15	0.42	0.39	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63578993	chr10:63634317~63634827:-
PRAD	cis	rs2564921	0.73	rs56026870	ENSG00000242142.1	SERBP1P3	-9.17	1.65e-18	1.2e-15	-0.43	-0.39	Height;	chr3:52998472	chr3:53064283~53065091:-
PRAD	cis	rs9326248	0.53	rs9919599	ENSG00000254851.1	RP11-109L13.1	-9.17	1.65e-18	1.2e-15	-0.8	-0.39	Blood protein levels;	chr11:116874768	chr11:117135528~117138582:+
PRAD	cis	rs6991838	0.584	rs7459944	ENSG00000200714.1	Y_RNA	-9.17	1.65e-18	1.2e-15	-0.44	-0.39	Intelligence (multi-trait analysis);	chr8:65566040	chr8:65592731~65592820:+
PRAD	cis	rs2274273	0.87	rs7153645	ENSG00000258413.1	RP11-665C16.6	-9.17	1.65e-18	1.21e-15	-0.51	-0.39	Protein biomarker;	chr14:55304800	chr14:55262767~55272075:-
PRAD	cis	rs2274273	0.87	rs10139083	ENSG00000258413.1	RP11-665C16.6	-9.17	1.65e-18	1.21e-15	-0.51	-0.39	Protein biomarker;	chr14:55316017	chr14:55262767~55272075:-
PRAD	cis	rs2274273	0.87	rs10145203	ENSG00000258413.1	RP11-665C16.6	-9.17	1.65e-18	1.21e-15	-0.51	-0.39	Protein biomarker;	chr14:55317740	chr14:55262767~55272075:-
PRAD	cis	rs2729354	0.768	rs2581922	ENSG00000265566.2	RN7SL605P	-9.17	1.65e-18	1.21e-15	-0.58	-0.39	Blood protein levels;	chr11:57497927	chr11:57528085~57528365:-
PRAD	cis	rs10740039	0.583	rs2127348	ENSG00000254271.1	RP11-131N11.4	-9.17	1.66e-18	1.21e-15	-0.54	-0.39	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740945	chr10:60734342~60741828:+
PRAD	cis	rs10740039	0.583	rs2127349	ENSG00000254271.1	RP11-131N11.4	-9.17	1.66e-18	1.21e-15	-0.54	-0.39	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740947	chr10:60734342~60741828:+
PRAD	cis	rs7829975	0.514	rs2976926	ENSG00000253893.2	FAM85B	-9.17	1.66e-18	1.21e-15	-0.49	-0.39	Mood instability;	chr8:8404114	chr8:8167819~8226614:-
PRAD	cis	rs2404602	0.716	rs56351018	ENSG00000259422.1	RP11-593F23.1	9.17	1.66e-18	1.21e-15	0.49	0.39	Blood metabolite levels;	chr15:76532250	chr15:76174891~76181486:-
PRAD	cis	rs11673344	0.764	rs16971873	ENSG00000226686.6	LINC01535	9.17	1.66e-18	1.21e-15	0.54	0.39	Obesity-related traits;	chr19:36978521	chr19:37251912~37265535:+
PRAD	cis	rs2404602	0.716	rs12441247	ENSG00000259422.1	RP11-593F23.1	9.17	1.67e-18	1.22e-15	0.49	0.39	Blood metabolite levels;	chr15:76519975	chr15:76174891~76181486:-
PRAD	cis	rs67311347	1	rs73080138	ENSG00000223797.4	ENTPD3-AS1	9.17	1.68e-18	1.23e-15	0.35	0.39	Renal cell carcinoma;	chr3:40474926	chr3:40313802~40453329:-
PRAD	cis	rs67311347	1	rs56303661	ENSG00000223797.4	ENTPD3-AS1	9.17	1.68e-18	1.23e-15	0.37	0.39	Renal cell carcinoma;	chr3:40479287	chr3:40313802~40453329:-
PRAD	cis	rs172166	0.694	rs203884	ENSG00000280107.1	AL022393.9	-9.17	1.69e-18	1.23e-15	-0.49	-0.39	Cardiac Troponin-T levels;	chr6:28109596	chr6:28170845~28172521:+
PRAD	cis	rs8072100	0.782	rs62074054	ENSG00000228782.6	CTD-2026D20.3	9.17	1.69e-18	1.24e-15	0.44	0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47694450	chr17:47450568~47492492:-
PRAD	cis	rs8072100	0.666	rs6503804	ENSG00000228782.6	CTD-2026D20.3	9.17	1.69e-18	1.24e-15	0.44	0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47695081	chr17:47450568~47492492:-
PRAD	cis	rs8072100	0.701	rs6503807	ENSG00000228782.6	CTD-2026D20.3	9.17	1.69e-18	1.24e-15	0.44	0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47695566	chr17:47450568~47492492:-
PRAD	cis	rs150992	0.673	rs331929	ENSG00000248489.1	CTD-2007H13.3	9.17	1.7e-18	1.24e-15	0.44	0.39	Body mass index;	chr5:98830528	chr5:98929171~98995013:+
PRAD	cis	rs4835473	0.9	rs12503074	ENSG00000251600.4	RP11-673E1.1	-9.17	1.7e-18	1.24e-15	-0.51	-0.39	Immature fraction of reticulocytes;	chr4:143812560	chr4:143912331~143982454:+
PRAD	cis	rs34375054	0.624	rs7132026	ENSG00000279233.1	RP11-158L12.4	-9.17	1.71e-18	1.24e-15	-0.39	-0.39	Post bronchodilator FEV1/FVC ratio;	chr12:125193550	chr12:125138245~125141711:+
PRAD	cis	rs11673344	0.73	rs475026	ENSG00000226686.6	LINC01535	9.17	1.71e-18	1.24e-15	0.53	0.39	Obesity-related traits;	chr19:36968115	chr19:37251912~37265535:+
PRAD	cis	rs11673344	0.734	rs1644638	ENSG00000226686.6	LINC01535	9.17	1.71e-18	1.24e-15	0.53	0.39	Obesity-related traits;	chr19:36970513	chr19:37251912~37265535:+
PRAD	cis	rs11673344	0.764	rs1644643	ENSG00000226686.6	LINC01535	9.17	1.71e-18	1.24e-15	0.53	0.39	Obesity-related traits;	chr19:36972269	chr19:37251912~37265535:+
PRAD	cis	rs11673344	0.764	rs1644645	ENSG00000226686.6	LINC01535	9.17	1.71e-18	1.24e-15	0.53	0.39	Obesity-related traits;	chr19:36972528	chr19:37251912~37265535:+
PRAD	cis	rs11951515	0.691	rs36050992	ENSG00000188850.9	RP11-159F24.2	9.17	1.71e-18	1.25e-15	0.48	0.39	Metabolite levels  (X-11787);	chr5:43364305	chr5:43336164~43348716:+
PRAD	cis	rs3858145	0.588	rs61854833	ENSG00000233590.1	RP11-153K11.3	-9.17	1.71e-18	1.25e-15	-0.57	-0.39	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68277570	chr10:68233251~68242379:-
PRAD	cis	rs8072100	0.575	rs1221385	ENSG00000228782.6	CTD-2026D20.3	9.16	1.72e-18	1.25e-15	0.46	0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47450208	chr17:47450568~47492492:-
PRAD	cis	rs11098499	0.863	rs10018280	ENSG00000245958.5	RP11-33B1.1	-9.16	1.72e-18	1.26e-15	-0.39	-0.39	Corneal astigmatism;	chr4:119556984	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.863	rs6534141	ENSG00000245958.5	RP11-33B1.1	-9.16	1.72e-18	1.26e-15	-0.39	-0.39	Corneal astigmatism;	chr4:119564068	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.863	rs3775858	ENSG00000245958.5	RP11-33B1.1	-9.16	1.72e-18	1.26e-15	-0.39	-0.39	Corneal astigmatism;	chr4:119564873	chr4:119454791~119552025:+
PRAD	cis	rs10262624	0.901	rs6966655	ENSG00000234286.1	AC006026.13	-9.16	1.73e-18	1.26e-15	-0.45	-0.39	Schizophrenia;	chr7:23867010	chr7:23680195~23680786:-
PRAD	cis	rs11148252	0.74	rs9536046	ENSG00000278238.1	RP11-245D16.4	-9.16	1.73e-18	1.26e-15	-0.44	-0.39	Lewy body disease;	chr13:52381764	chr13:52454775~52455331:-
PRAD	cis	rs13217239	0.646	rs10946888	ENSG00000241549.7	GUSBP2	9.16	1.73e-18	1.26e-15	0.44	0.39	Schizophrenia;	chr6:26983899	chr6:26871484~26956554:-
PRAD	cis	rs4835473	0.897	rs7657088	ENSG00000251600.4	RP11-673E1.1	-9.16	1.73e-18	1.26e-15	-0.49	-0.39	Immature fraction of reticulocytes;	chr4:143701877	chr4:143912331~143982454:+
PRAD	cis	rs67311347	1	rs11706148	ENSG00000223797.4	ENTPD3-AS1	9.16	1.74e-18	1.27e-15	0.37	0.39	Renal cell carcinoma;	chr3:40365752	chr3:40313802~40453329:-
PRAD	cis	rs2739330	0.828	rs5760098	ENSG00000099984.9	GSTT2	-9.16	1.75e-18	1.27e-15	-0.53	-0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23980123~23983911:+
PRAD	cis	rs12931792	0.72	rs12102320	ENSG00000183604.13	SMG1P5	9.16	1.75e-18	1.28e-15	0.36	0.39	Tonsillectomy;	chr16:30167195	chr16:30267553~30335374:-
PRAD	cis	rs9545047	0.604	rs9565483	ENSG00000227676.3	LINC01068	-9.16	1.75e-18	1.28e-15	-0.46	-0.39	Schizophrenia;	chr13:79294001	chr13:79566727~79571436:+
PRAD	cis	rs7567389	0.505	rs56273408	ENSG00000236682.1	AC068282.3	-9.16	1.76e-18	1.28e-15	-0.49	-0.39	Self-rated health;	chr2:127338012	chr2:127389130~127400580:+
PRAD	cis	rs2581828	0.618	rs6777975	ENSG00000242142.1	SERBP1P3	-9.16	1.76e-18	1.28e-15	-0.46	-0.39	Crohn's disease;	chr3:53132119	chr3:53064283~53065091:-
PRAD	cis	rs11976180	0.517	rs6949375	ENSG00000273234.1	OR2A13P	-9.16	1.76e-18	1.28e-15	-0.59	-0.39	Obesity-related traits;	chr7:144076758	chr7:144142009~144142938:+
PRAD	cis	rs11673344	0.633	rs519606	ENSG00000226686.6	LINC01535	9.16	1.77e-18	1.29e-15	0.54	0.39	Obesity-related traits;	chr19:36942327	chr19:37251912~37265535:+
PRAD	cis	rs11673344	0.67	rs35011739	ENSG00000226686.6	LINC01535	9.16	1.77e-18	1.29e-15	0.54	0.39	Obesity-related traits;	chr19:36943328	chr19:37251912~37265535:+
PRAD	cis	rs11673344	0.704	rs540451	ENSG00000226686.6	LINC01535	9.16	1.77e-18	1.29e-15	0.54	0.39	Obesity-related traits;	chr19:36944619	chr19:37251912~37265535:+
PRAD	cis	rs17023223	0.537	rs1325940	ENSG00000231365.4	RP11-418J17.1	-9.16	1.77e-18	1.29e-15	-0.4	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119044064	chr1:119140396~119275973:+
PRAD	cis	rs8177376	1	rs598169	ENSG00000254905.1	RP11-712L6.7	9.16	1.77e-18	1.29e-15	0.5	0.39	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126219158	chr11:126292922~126294254:-
PRAD	cis	rs8177376	1	rs657361	ENSG00000254905.1	RP11-712L6.7	9.16	1.77e-18	1.29e-15	0.5	0.39	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126241196	chr11:126292922~126294254:-
PRAD	cis	rs9309711	0.623	rs4641971	ENSG00000225234.1	TRAPPC12-AS1	9.16	1.78e-18	1.3e-15	0.4	0.39	Neurofibrillary tangles;	chr2:3478086	chr2:3481242~3482409:-
PRAD	cis	rs10262624	1	rs7792262	ENSG00000234286.1	AC006026.13	9.16	1.79e-18	1.3e-15	0.44	0.39	Schizophrenia;	chr7:23876124	chr7:23680195~23680786:-
PRAD	cis	rs10262624	0.967	rs7792734	ENSG00000234286.1	AC006026.13	-9.16	1.79e-18	1.3e-15	-0.44	-0.39	Schizophrenia;	chr7:23876429	chr7:23680195~23680786:-
PRAD	cis	rs1062177	1	rs2915878	ENSG00000253921.1	CTB-113P19.3	-9.16	1.79e-18	1.31e-15	-0.52	-0.39	Preschool internalizing problems;	chr5:151770101	chr5:151753992~151767247:+
PRAD	cis	rs1062177	1	rs6890099	ENSG00000253921.1	CTB-113P19.3	-9.16	1.79e-18	1.31e-15	-0.52	-0.39	Preschool internalizing problems;	chr5:151772401	chr5:151753992~151767247:+
PRAD	cis	rs8072100	0.837	rs62074055	ENSG00000228782.6	CTD-2026D20.3	9.16	1.79e-18	1.31e-15	0.44	0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47694567	chr17:47450568~47492492:-
PRAD	cis	rs1075265	0.597	rs10490471	ENSG00000233266.1	HMGB1P31	9.16	1.8e-18	1.31e-15	0.54	0.39	Chronotype;Morning vs. evening chronotype;	chr2:53769446	chr2:54051334~54051760:+
PRAD	cis	rs67311347	1	rs28707772	ENSG00000223797.4	ENTPD3-AS1	9.16	1.8e-18	1.31e-15	0.37	0.39	Renal cell carcinoma;	chr3:40463175	chr3:40313802~40453329:-
PRAD	cis	rs2274273	0.84	rs2009291	ENSG00000258413.1	RP11-665C16.6	9.16	1.81e-18	1.32e-15	0.52	0.39	Protein biomarker;	chr14:55371512	chr14:55262767~55272075:-
PRAD	cis	rs2282300	0.739	rs10835648	ENSG00000242353.1	RP4-710M3.1	9.16	1.81e-18	1.32e-15	0.46	0.39	Morning vs. evening chronotype;	chr11:30298959	chr11:30368148~30368646:+
PRAD	cis	rs6723108	0.517	rs6430553	ENSG00000224043.6	CCNT2-AS1	-9.16	1.83e-18	1.33e-15	-0.54	-0.39	Type 2 diabetes;	chr2:134873830	chr2:134735464~134918710:-
PRAD	cis	rs13217239	0.646	rs11756275	ENSG00000241549.7	GUSBP2	-9.16	1.83e-18	1.33e-15	-0.44	-0.39	Schizophrenia;	chr6:27039334	chr6:26871484~26956554:-
PRAD	cis	rs704795	0.702	rs11689803	ENSG00000234072.1	AC074117.10	-9.16	1.83e-18	1.33e-15	-0.35	-0.39	Menopause (age at onset);	chr2:27343653	chr2:27356246~27367622:+
PRAD	cis	rs13217239	0.646	rs4269366	ENSG00000241549.7	GUSBP2	9.16	1.84e-18	1.34e-15	0.44	0.39	Schizophrenia;	chr6:27048634	chr6:26871484~26956554:-
PRAD	cis	rs2153535	0.585	rs6597343	ENSG00000230939.1	RP11-314C16.1	-9.16	1.85e-18	1.34e-15	-0.49	-0.39	Motion sickness;	chr6:8620270	chr6:8784178~8785445:+
PRAD	cis	rs3814244	0.933	rs10878725	ENSG00000255733.4	IFNG-AS1	-9.15	1.85e-18	1.34e-15	-0.4	-0.39	Itch intensity from mosquito bite adjusted by bite size;	chr12:68020930	chr12:67989445~68234686:+
PRAD	cis	rs4835473	0.9	rs4054634	ENSG00000251600.4	RP11-673E1.1	-9.15	1.85e-18	1.35e-15	-0.51	-0.39	Immature fraction of reticulocytes;	chr4:143787045	chr4:143912331~143982454:+
PRAD	cis	rs12701220	0.655	rs10241018	ENSG00000229043.2	AC091729.9	-9.15	1.86e-18	1.35e-15	-0.56	-0.39	Bronchopulmonary dysplasia;	chr7:1105138	chr7:1160374~1165267:+
PRAD	cis	rs4718428	0.672	rs36038499	ENSG00000230295.1	RP11-458F8.2	-9.15	1.86e-18	1.35e-15	-0.3	-0.39	Corneal structure;	chr7:66824628	chr7:66880708~66882981:+
PRAD	cis	rs4718428	0.705	rs62465692	ENSG00000230295.1	RP11-458F8.2	-9.15	1.86e-18	1.35e-15	-0.3	-0.39	Corneal structure;	chr7:66830758	chr7:66880708~66882981:+
PRAD	cis	rs4718428	0.662	rs34577323	ENSG00000230295.1	RP11-458F8.2	-9.15	1.86e-18	1.35e-15	-0.3	-0.39	Corneal structure;	chr7:66845054	chr7:66880708~66882981:+
PRAD	cis	rs4835473	0.932	rs10021860	ENSG00000251600.4	RP11-673E1.1	9.15	1.86e-18	1.35e-15	0.49	0.39	Immature fraction of reticulocytes;	chr4:143754593	chr4:143912331~143982454:+
PRAD	cis	rs853679	0.55	rs1237875	ENSG00000219392.1	RP1-265C24.5	9.15	1.86e-18	1.35e-15	0.5	0.39	Depression;	chr6:28205232	chr6:28115628~28116551:+
PRAD	cis	rs4835473	0.9	rs35670120	ENSG00000251600.4	RP11-673E1.1	-9.15	1.87e-18	1.36e-15	-0.51	-0.39	Immature fraction of reticulocytes;	chr4:143787041	chr4:143912331~143982454:+
PRAD	cis	rs4713118	0.621	rs10484403	ENSG00000226314.6	ZNF192P1	-9.15	1.87e-18	1.36e-15	-0.53	-0.39	Parkinson's disease;	chr6:28065745	chr6:28161781~28169594:+
PRAD	cis	rs2015599	0.623	rs7313552	ENSG00000257176.2	RP11-996F15.2	9.15	1.89e-18	1.37e-15	0.45	0.39	Platelet count;Mean platelet volume;	chr12:29277302	chr12:29280418~29317848:-
PRAD	cis	rs2015599	0.584	rs7299283	ENSG00000257176.2	RP11-996F15.2	9.15	1.89e-18	1.37e-15	0.45	0.39	Platelet count;Mean platelet volume;	chr12:29277442	chr12:29280418~29317848:-
PRAD	cis	rs35160687	0.842	rs1863051	ENSG00000273080.1	RP11-301O19.1	9.15	1.89e-18	1.37e-15	0.46	0.39	Night sleep phenotypes;	chr2:86332025	chr2:86195590~86196049:+
PRAD	cis	rs10129255	0.5	rs8004923	ENSG00000223648.3	IGHV3-64	9.15	1.89e-18	1.37e-15	0.34	0.39	Kawasaki disease;	chr14:106785926	chr14:106643132~106658258:-
PRAD	cis	rs10129255	0.5	rs6576232	ENSG00000223648.3	IGHV3-64	9.15	1.89e-18	1.37e-15	0.34	0.39	Kawasaki disease;	chr14:106787090	chr14:106643132~106658258:-
PRAD	cis	rs12134133	1	rs2782842	ENSG00000274245.1	RP11-357P18.2	9.15	1.91e-18	1.38e-15	0.55	0.39	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207310231	chr1:207372559~207373252:+
PRAD	cis	rs7712401	0.601	rs246303	ENSG00000263432.2	RN7SL689P	9.15	1.91e-18	1.39e-15	0.41	0.39	Mean platelet volume;	chr5:122916022	chr5:123022487~123022783:-
PRAD	cis	rs67311347	0.911	rs9863737	ENSG00000223797.4	ENTPD3-AS1	9.15	1.92e-18	1.39e-15	0.37	0.39	Renal cell carcinoma;	chr3:40398345	chr3:40313802~40453329:-
PRAD	cis	rs17023223	0.537	rs10802075	ENSG00000231365.4	RP11-418J17.1	-9.15	1.93e-18	1.4e-15	-0.42	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119084604	chr1:119140396~119275973:+
PRAD	cis	rs7811142	0.83	rs6948685	ENSG00000242294.5	STAG3L5P	9.15	1.94e-18	1.41e-15	0.26	0.39	Platelet count;	chr7:100372565	chr7:100336079~100351900:+
PRAD	cis	rs4835473	0.897	rs28825455	ENSG00000251600.4	RP11-673E1.1	9.15	1.94e-18	1.41e-15	0.5	0.39	Immature fraction of reticulocytes;	chr4:143707593	chr4:143912331~143982454:+
PRAD	cis	rs7189233	0.592	rs2024449	ENSG00000279344.1	RP11-44F14.7	9.15	1.94e-18	1.41e-15	0.36	0.39	Intelligence (multi-trait analysis);	chr16:53460705	chr16:53478957~53481550:-
PRAD	cis	rs11951515	0.844	rs7727047	ENSG00000188850.9	RP11-159F24.2	9.15	1.95e-18	1.41e-15	0.49	0.39	Metabolite levels  (X-11787);	chr5:43374831	chr5:43336164~43348716:+
PRAD	cis	rs17023223	0.509	rs10923740	ENSG00000231365.4	RP11-418J17.1	-9.15	1.95e-18	1.42e-15	-0.41	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119057664	chr1:119140396~119275973:+
PRAD	cis	rs7772486	0.654	rs9376958	ENSG00000235652.6	RP11-545I5.3	-9.15	1.96e-18	1.42e-15	-0.41	-0.39	Lobe attachment (rater-scored or self-reported);	chr6:145701904	chr6:145799409~145886585:+
PRAD	cis	rs7811142	1	rs11769700	ENSG00000242294.5	STAG3L5P	9.15	1.97e-18	1.43e-15	0.26	0.39	Platelet count;	chr7:100492426	chr7:100336079~100351900:+
PRAD	cis	rs11098499	0.865	rs4001305	ENSG00000245958.5	RP11-33B1.1	-9.15	1.97e-18	1.43e-15	-0.39	-0.39	Corneal astigmatism;	chr4:119438081	chr4:119454791~119552025:+
PRAD	cis	rs875971	1	rs11974264	ENSG00000237310.1	GS1-124K5.4	-9.15	1.97e-18	1.43e-15	-0.35	-0.39	Aortic root size;	chr7:66182595	chr7:66493706~66495474:+
PRAD	cis	rs875971	1	rs1540651	ENSG00000237310.1	GS1-124K5.4	-9.15	1.97e-18	1.43e-15	-0.35	-0.39	Aortic root size;	chr7:66185134	chr7:66493706~66495474:+
PRAD	cis	rs853679	0.517	rs9283884	ENSG00000272009.1	RP1-313I6.12	9.15	1.98e-18	1.43e-15	0.41	0.39	Depression;	chr6:28167882	chr6:28078792~28081130:-
PRAD	cis	rs6517329	0.538	rs1028997	ENSG00000236830.5	CBR3-AS1	9.15	1.98e-18	1.44e-15	0.41	0.39	Schizophrenia;	chr21:36159924	chr21:36131767~36175815:-
PRAD	cis	rs150992	0.609	rs393697	ENSG00000248489.1	CTD-2007H13.3	9.15	1.99e-18	1.44e-15	0.43	0.39	Body mass index;	chr5:98991357	chr5:98929171~98995013:+
PRAD	cis	rs8062405	0.757	rs2411453	ENSG00000259982.1	CDC37P1	-9.15	1.99e-18	1.44e-15	-0.52	-0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620700	chr16:28700294~28701540:-
PRAD	cis	rs7923609	0.756	rs6479908	ENSG00000232075.1	MRPL35P2	9.15	1.99e-18	1.44e-15	0.41	0.39	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63573888	chr10:63634317~63634827:-
PRAD	cis	rs2348418	0.864	rs7957495	ENSG00000247934.4	RP11-967K21.1	-9.15	1.99e-18	1.44e-15	-0.36	-0.39	Lung function (FEV1);Lung function (FVC);	chr12:28564522	chr12:28163298~28190738:-
PRAD	cis	rs321358	0.79	rs4635115	ENSG00000271584.1	RP11-89C3.4	9.15	1.99e-18	1.44e-15	0.59	0.39	Body mass index;	chr11:111076352	chr11:111091932~111097357:-
PRAD	cis	rs11676348	0.808	rs4674261	ENSG00000261338.2	RP11-378A13.1	-9.14	2e-18	1.45e-15	-0.43	-0.39	Ulcerative colitis;	chr2:218140286	chr2:218255319~218257366:+
PRAD	cis	rs4835473	0.897	rs1450249	ENSG00000251600.4	RP11-673E1.1	9.14	2e-18	1.45e-15	0.5	0.39	Immature fraction of reticulocytes;	chr4:143724425	chr4:143912331~143982454:+
PRAD	cis	rs2274273	0.84	rs11547116	ENSG00000258413.1	RP11-665C16.6	-9.14	2.01e-18	1.45e-15	-0.51	-0.39	Protein biomarker;	chr14:55271447	chr14:55262767~55272075:-
PRAD	cis	rs7811142	0.83	rs41280971	ENSG00000242294.5	STAG3L5P	9.14	2.01e-18	1.45e-15	0.26	0.39	Platelet count;	chr7:100356834	chr7:100336079~100351900:+
PRAD	cis	rs7811142	0.83	rs11761426	ENSG00000242294.5	STAG3L5P	9.14	2.01e-18	1.45e-15	0.26	0.39	Platelet count;	chr7:100359270	chr7:100336079~100351900:+
PRAD	cis	rs7811142	0.83	rs77861211	ENSG00000242294.5	STAG3L5P	9.14	2.01e-18	1.45e-15	0.26	0.39	Platelet count;	chr7:100364473	chr7:100336079~100351900:+
PRAD	cis	rs4713118	0.621	rs9295756	ENSG00000219392.1	RP1-265C24.5	-9.14	2.01e-18	1.46e-15	-0.51	-0.39	Parkinson's disease;	chr6:28065618	chr6:28115628~28116551:+
PRAD	cis	rs673078	0.615	rs61945189	ENSG00000275759.1	RP11-131L12.3	-9.14	2.01e-18	1.46e-15	-0.73	-0.39	Glucose homeostasis traits;	chr12:118231056	chr12:118428281~118428870:+
PRAD	cis	rs673078	0.66	rs3852531	ENSG00000275759.1	RP11-131L12.3	-9.14	2.01e-18	1.46e-15	-0.73	-0.39	Glucose homeostasis traits;	chr12:118247808	chr12:118428281~118428870:+
PRAD	cis	rs56080343	0.688	rs7960802	ENSG00000275759.1	RP11-131L12.3	-9.14	2.01e-18	1.46e-15	-0.73	-0.39	Neuroticism;	chr12:118292014	chr12:118428281~118428870:+
PRAD	cis	rs7849270	1	rs3118625	ENSG00000268707.1	RP11-247A12.7	9.14	2.01e-18	1.46e-15	0.47	0.39	Blood metabolite ratios;	chr9:129110977	chr9:129170434~129170940:+
PRAD	cis	rs435066	0.525	rs7540234	ENSG00000234264.1	DEPDC1-AS1	-9.14	2.01e-18	1.46e-15	-0.56	-0.39	IgG glycosylation;	chr1:68545039	chr1:68496676~68538627:+
PRAD	cis	rs11098499	0.954	rs28572238	ENSG00000245958.5	RP11-33B1.1	-9.14	2.01e-18	1.46e-15	-0.39	-0.39	Corneal astigmatism;	chr4:119395531	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.909	rs28714195	ENSG00000245958.5	RP11-33B1.1	-9.14	2.01e-18	1.46e-15	-0.39	-0.39	Corneal astigmatism;	chr4:119395795	chr4:119454791~119552025:+
PRAD	cis	rs9309473	0.606	rs77962988	ENSG00000163016.8	ALMS1P	9.14	2.01e-18	1.46e-15	0.59	0.39	Metabolite levels;	chr2:73658963	chr2:73644919~73685576:+
PRAD	cis	rs9326248	0.53	rs7124741	ENSG00000254851.1	RP11-109L13.1	-9.14	2.02e-18	1.46e-15	-0.8	-0.39	Blood protein levels;	chr11:116881503	chr11:117135528~117138582:+
PRAD	cis	rs2739330	0.828	rs5760099	ENSG00000224205.1	AP000351.4	9.14	2.04e-18	1.47e-15	0.49	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23987320~23991421:-
PRAD	cis	rs875971	0.83	rs4718358	ENSG00000237310.1	GS1-124K5.4	9.14	2.04e-18	1.47e-15	0.35	0.39	Aortic root size;	chr7:66508681	chr7:66493706~66495474:+
PRAD	cis	rs4713118	0.621	rs4713132	ENSG00000219392.1	RP1-265C24.5	-9.14	2.04e-18	1.48e-15	-0.51	-0.39	Parkinson's disease;	chr6:28066257	chr6:28115628~28116551:+
PRAD	cis	rs4713118	0.621	rs4713133	ENSG00000219392.1	RP1-265C24.5	-9.14	2.04e-18	1.48e-15	-0.51	-0.39	Parkinson's disease;	chr6:28066263	chr6:28115628~28116551:+
PRAD	cis	rs4713118	0.621	rs4713134	ENSG00000219392.1	RP1-265C24.5	-9.14	2.04e-18	1.48e-15	-0.51	-0.39	Parkinson's disease;	chr6:28066343	chr6:28115628~28116551:+
PRAD	cis	rs4713118	0.621	rs9368548	ENSG00000219392.1	RP1-265C24.5	-9.14	2.04e-18	1.48e-15	-0.51	-0.39	Parkinson's disease;	chr6:28066959	chr6:28115628~28116551:+
PRAD	cis	rs2153535	0.585	rs6932720	ENSG00000230939.1	RP11-314C16.1	-9.14	2.05e-18	1.48e-15	-0.49	-0.39	Motion sickness;	chr6:8644999	chr6:8784178~8785445:+
PRAD	cis	rs11673344	0.734	rs1667343	ENSG00000226686.6	LINC01535	9.14	2.05e-18	1.49e-15	0.53	0.39	Obesity-related traits;	chr19:36978196	chr19:37251912~37265535:+
PRAD	cis	rs7811142	0.83	rs3087502	ENSG00000242294.5	STAG3L5P	9.14	2.06e-18	1.49e-15	0.26	0.39	Platelet count;	chr7:100357741	chr7:100336079~100351900:+
PRAD	cis	rs7811142	0.83	rs61735533	ENSG00000242294.5	STAG3L5P	9.14	2.06e-18	1.49e-15	0.26	0.39	Platelet count;	chr7:100358243	chr7:100336079~100351900:+
PRAD	cis	rs2348418	0.864	rs2203088	ENSG00000247934.4	RP11-967K21.1	9.14	2.07e-18	1.5e-15	0.36	0.39	Lung function (FEV1);Lung function (FVC);	chr12:28556767	chr12:28163298~28190738:-
PRAD	cis	rs2282300	0.739	rs1222221	ENSG00000242353.1	RP4-710M3.1	-9.14	2.08e-18	1.5e-15	-0.46	-0.39	Morning vs. evening chronotype;	chr11:30321191	chr11:30368148~30368646:+
PRAD	cis	rs7772486	0.875	rs932522	ENSG00000235652.6	RP11-545I5.3	-9.14	2.08e-18	1.51e-15	-0.4	-0.39	Lobe attachment (rater-scored or self-reported);	chr6:146052890	chr6:145799409~145886585:+
PRAD	cis	rs67311347	1	rs9875245	ENSG00000223797.4	ENTPD3-AS1	9.14	2.08e-18	1.51e-15	0.36	0.39	Renal cell carcinoma;	chr3:40400789	chr3:40313802~40453329:-
PRAD	cis	rs67311347	1	rs954589	ENSG00000223797.4	ENTPD3-AS1	9.14	2.08e-18	1.51e-15	0.36	0.39	Renal cell carcinoma;	chr3:40403054	chr3:40313802~40453329:-
PRAD	cis	rs2729354	0.817	rs2250673	ENSG00000265566.2	RN7SL605P	-9.14	2.08e-18	1.51e-15	-0.58	-0.39	Blood protein levels;	chr11:57500697	chr11:57528085~57528365:-
PRAD	cis	rs11098499	0.863	rs3736115	ENSG00000245958.5	RP11-33B1.1	9.14	2.09e-18	1.51e-15	0.39	0.39	Corneal astigmatism;	chr4:119567548	chr4:119454791~119552025:+
PRAD	cis	rs4835473	0.932	rs7356157	ENSG00000251600.4	RP11-673E1.1	9.14	2.09e-18	1.52e-15	0.5	0.39	Immature fraction of reticulocytes;	chr4:143739233	chr4:143912331~143982454:+
PRAD	cis	rs7811142	0.83	rs11769057	ENSG00000242294.5	STAG3L5P	9.14	2.1e-18	1.52e-15	0.26	0.39	Platelet count;	chr7:100367038	chr7:100336079~100351900:+
PRAD	cis	rs2729354	0.729	rs2581923	ENSG00000265566.2	RN7SL605P	-9.14	2.11e-18	1.52e-15	-0.57	-0.39	Blood protein levels;	chr11:57482518	chr11:57528085~57528365:-
PRAD	cis	rs12817211	0.502	rs17124432	ENSG00000272368.2	RP4-605O3.4	9.14	2.11e-18	1.53e-15	0.39	0.39	Colorectal or endometrial cancer;	chr12:50116994	chr12:50112197~50165618:+
PRAD	cis	rs2739330	0.76	rs5751760	ENSG00000206090.4	AP000350.7	9.14	2.11e-18	1.53e-15	0.51	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23939998~23942798:+
PRAD	cis	rs2980439	0.783	rs2955587	ENSG00000253893.2	FAM85B	-9.14	2.11e-18	1.53e-15	-0.51	-0.39	Neuroticism;	chr8:8240557	chr8:8167819~8226614:-
PRAD	cis	rs11723261	0.582	rs4582104	ENSG00000275426.1	CH17-262A2.1	9.14	2.12e-18	1.53e-15	0.51	0.39	Immune response to smallpox vaccine (IL-6);	chr4:143160	chr4:149738~150317:+
PRAD	cis	rs1930961	0.702	rs6004684	ENSG00000272977.1	CTA-390C10.10	9.14	2.12e-18	1.53e-15	0.84	0.39	Bipolar disorder with mood-incongruent psychosis;	chr22:25503972	chr22:25476218~25479971:+
PRAD	cis	rs12701220	0.655	rs12702117	ENSG00000229043.2	AC091729.9	-9.14	2.12e-18	1.53e-15	-0.55	-0.39	Bronchopulmonary dysplasia;	chr7:1109066	chr7:1160374~1165267:+
PRAD	cis	rs12701220	0.604	rs12702122	ENSG00000229043.2	AC091729.9	-9.14	2.12e-18	1.53e-15	-0.55	-0.39	Bronchopulmonary dysplasia;	chr7:1109858	chr7:1160374~1165267:+
PRAD	cis	rs3096299	0.967	rs2965935	ENSG00000274627.1	RP11-104N10.2	-9.14	2.13e-18	1.54e-15	-0.4	-0.39	Multiple myeloma (IgH translocation);	chr16:89414866	chr16:89516797~89522217:+
PRAD	cis	rs4835473	0.778	rs6856553	ENSG00000251600.4	RP11-673E1.1	-9.14	2.13e-18	1.54e-15	-0.5	-0.39	Immature fraction of reticulocytes;	chr4:143825973	chr4:143912331~143982454:+
PRAD	cis	rs150992	0.721	rs2937706	ENSG00000248489.1	CTD-2007H13.3	9.14	2.13e-18	1.54e-15	0.44	0.39	Body mass index;	chr5:98990434	chr5:98929171~98995013:+
PRAD	cis	rs7811142	0.72	rs7795656	ENSG00000242294.5	STAG3L5P	9.14	2.14e-18	1.55e-15	0.26	0.39	Platelet count;	chr7:100352674	chr7:100336079~100351900:+
PRAD	cis	rs150992	0.609	rs78254063	ENSG00000248489.1	CTD-2007H13.3	9.14	2.14e-18	1.55e-15	0.44	0.39	Body mass index;	chr5:98990803	chr5:98929171~98995013:+
PRAD	cis	rs6782228	0.675	rs6806687	ENSG00000242551.2	POU5F1P6	9.14	2.14e-18	1.55e-15	0.49	0.39	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128672946	chr3:128674735~128677005:-
PRAD	cis	rs2739330	0.892	rs5751776	ENSG00000224205.1	AP000351.4	9.14	2.14e-18	1.55e-15	0.48	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23987320~23991421:-
PRAD	cis	rs7712401	0.601	rs30048	ENSG00000263432.2	RN7SL689P	9.14	2.14e-18	1.55e-15	0.4	0.39	Mean platelet volume;	chr5:122934698	chr5:123022487~123022783:-
PRAD	cis	rs4835473	0.868	rs11737787	ENSG00000251600.4	RP11-673E1.1	-9.14	2.15e-18	1.55e-15	-0.5	-0.39	Immature fraction of reticulocytes;	chr4:143826498	chr4:143912331~143982454:+
PRAD	cis	rs7712401	0.601	rs152039	ENSG00000263432.2	RN7SL689P	9.13	2.17e-18	1.57e-15	0.41	0.39	Mean platelet volume;	chr5:122884970	chr5:123022487~123022783:-
PRAD	cis	rs7849270	0.879	rs3124495	ENSG00000268707.1	RP11-247A12.7	9.13	2.17e-18	1.57e-15	0.47	0.39	Blood metabolite ratios;	chr9:129093731	chr9:129170434~129170940:+
PRAD	cis	rs7189233	0.531	rs8062535	ENSG00000279344.1	RP11-44F14.7	9.13	2.19e-18	1.58e-15	0.35	0.39	Intelligence (multi-trait analysis);	chr16:53478576	chr16:53478957~53481550:-
PRAD	cis	rs9326248	0.539	rs7120565	ENSG00000280143.1	AP000892.6	9.13	2.19e-18	1.58e-15	0.3	0.39	Blood protein levels;	chr11:117172233	chr11:117204967~117210292:+
PRAD	cis	rs11690935	0.55	rs7584187	ENSG00000228389.1	AC068039.4	9.13	2.19e-18	1.59e-15	0.44	0.39	Schizophrenia;	chr2:172001198	chr2:171773482~171775844:+
PRAD	cis	rs7189233	0.531	rs9931702	ENSG00000279344.1	RP11-44F14.7	9.13	2.21e-18	1.59e-15	0.36	0.39	Intelligence (multi-trait analysis);	chr16:53492639	chr16:53478957~53481550:-
PRAD	cis	rs6517329	0.538	rs879894	ENSG00000236830.5	CBR3-AS1	9.13	2.21e-18	1.59e-15	0.41	0.39	Schizophrenia;	chr21:36136345	chr21:36131767~36175815:-
PRAD	cis	rs2739330	0.796	rs2154594	ENSG00000235689.1	AP000351.13	-9.13	2.21e-18	1.6e-15	-0.48	-0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:24006305~24008258:-
PRAD	cis	rs1075265	0.611	rs3770403	ENSG00000233266.1	HMGB1P31	9.13	2.21e-18	1.6e-15	0.54	0.39	Chronotype;Morning vs. evening chronotype;	chr2:53695688	chr2:54051334~54051760:+
PRAD	cis	rs9326248	0.52	rs6589602	ENSG00000280143.1	AP000892.6	9.13	2.21e-18	1.6e-15	0.3	0.39	Blood protein levels;	chr11:117166349	chr11:117204967~117210292:+
PRAD	cis	rs7615952	0.611	rs2947646	ENSG00000171084.14	FAM86JP	-9.13	2.22e-18	1.6e-15	-0.74	-0.39	Blood pressure (smoking interaction);	chr3:125874759	chr3:125916620~125930024:+
PRAD	cis	rs997154	0.655	rs7147394	ENSG00000279656.1	RP11-298I3.6	9.13	2.23e-18	1.61e-15	0.56	0.39	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22941845	chr14:23023083~23024217:-
PRAD	cis	rs9322193	0.566	rs4870118	ENSG00000216906.2	RP11-350J20.9	-9.13	2.24e-18	1.62e-15	-0.51	-0.39	Lung cancer;	chr6:149923877	chr6:149904243~149906418:+
PRAD	cis	rs7712401	0.601	rs431878	ENSG00000263432.2	RN7SL689P	-9.13	2.24e-18	1.62e-15	-0.4	-0.39	Mean platelet volume;	chr5:122926096	chr5:123022487~123022783:-
PRAD	cis	rs9326248	0.501	rs4938351	ENSG00000280143.1	AP000892.6	9.13	2.25e-18	1.62e-15	0.3	0.39	Blood protein levels;	chr11:117151636	chr11:117204967~117210292:+
PRAD	cis	rs34779708	0.931	rs2244100	ENSG00000230534.5	RP11-297A16.2	-9.13	2.25e-18	1.63e-15	-0.51	-0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35034708	chr10:35098006~35127020:-
PRAD	cis	rs12594515	0.6	rs12903858	ENSG00000273972.1	CTD-2306A12.1	-9.13	2.26e-18	1.63e-15	-0.44	-0.39	Weight;Waist circumference;	chr15:45679968	chr15:45702640~45703183:+
PRAD	cis	rs2153535	0.585	rs9406183	ENSG00000230939.1	RP11-314C16.1	9.13	2.26e-18	1.63e-15	0.48	0.39	Motion sickness;	chr6:8639538	chr6:8784178~8785445:+
PRAD	cis	rs2404602	0.669	rs1875885	ENSG00000259422.1	RP11-593F23.1	9.13	2.27e-18	1.64e-15	0.49	0.39	Blood metabolite levels;	chr15:76345740	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.669	rs1875884	ENSG00000259422.1	RP11-593F23.1	9.13	2.27e-18	1.64e-15	0.49	0.39	Blood metabolite levels;	chr15:76345820	chr15:76174891~76181486:-
PRAD	cis	rs12468226	1	rs76284304	ENSG00000273456.1	RP11-686O6.2	9.13	2.27e-18	1.64e-15	0.53	0.39	Urate levels;	chr2:202427116	chr2:202374932~202375604:-
PRAD	cis	rs12817211	0.502	rs7961065	ENSG00000272368.2	RP4-605O3.4	-9.13	2.28e-18	1.64e-15	-0.39	-0.39	Colorectal or endometrial cancer;	chr12:50119904	chr12:50112197~50165618:+
PRAD	cis	rs12817211	0.502	rs1554844	ENSG00000272368.2	RP4-605O3.4	-9.13	2.28e-18	1.64e-15	-0.39	-0.39	Colorectal or endometrial cancer;	chr12:50120582	chr12:50112197~50165618:+
PRAD	cis	rs12468226	0.935	rs75597391	ENSG00000273456.1	RP11-686O6.2	9.13	2.28e-18	1.64e-15	0.52	0.39	Urate levels;	chr2:202398850	chr2:202374932~202375604:-
PRAD	cis	rs12468226	1	rs12472408	ENSG00000273456.1	RP11-686O6.2	9.13	2.28e-18	1.64e-15	0.52	0.39	Urate levels;	chr2:202413973	chr2:202374932~202375604:-
PRAD	cis	rs12468226	1	rs115170232	ENSG00000273456.1	RP11-686O6.2	9.13	2.28e-18	1.64e-15	0.52	0.39	Urate levels;	chr2:202416790	chr2:202374932~202375604:-
PRAD	cis	rs2274273	0.805	rs11628437	ENSG00000258413.1	RP11-665C16.6	-9.13	2.28e-18	1.65e-15	-0.51	-0.39	Protein biomarker;	chr14:55308750	chr14:55262767~55272075:-
PRAD	cis	rs2274273	0.837	rs59871474	ENSG00000258413.1	RP11-665C16.6	-9.13	2.28e-18	1.65e-15	-0.51	-0.39	Protein biomarker;	chr14:55312645	chr14:55262767~55272075:-
PRAD	cis	rs2274273	0.87	rs7153612	ENSG00000258413.1	RP11-665C16.6	-9.13	2.28e-18	1.65e-15	-0.51	-0.39	Protein biomarker;	chr14:55322044	chr14:55262767~55272075:-
PRAD	cis	rs2274273	0.837	rs56949365	ENSG00000258413.1	RP11-665C16.6	-9.13	2.28e-18	1.65e-15	-0.51	-0.39	Protein biomarker;	chr14:55323360	chr14:55262767~55272075:-
PRAD	cis	rs2274273	0.87	rs4496026	ENSG00000258413.1	RP11-665C16.6	-9.13	2.28e-18	1.65e-15	-0.51	-0.39	Protein biomarker;	chr14:55323794	chr14:55262767~55272075:-
PRAD	cis	rs2274273	0.87	rs4366639	ENSG00000258413.1	RP11-665C16.6	-9.13	2.28e-18	1.65e-15	-0.51	-0.39	Protein biomarker;	chr14:55323798	chr14:55262767~55272075:-
PRAD	cis	rs2274273	0.87	rs11625423	ENSG00000258413.1	RP11-665C16.6	-9.13	2.28e-18	1.65e-15	-0.51	-0.39	Protein biomarker;	chr14:55329195	chr14:55262767~55272075:-
PRAD	cis	rs6700559	0.81	rs2808250	ENSG00000260088.1	RP11-92G12.3	-9.13	2.29e-18	1.65e-15	-0.49	-0.39	Coronary artery disease;	chr1:200623419	chr1:200669507~200694250:+
PRAD	cis	rs2153535	0.585	rs4959494	ENSG00000230939.1	RP11-314C16.1	-9.13	2.3e-18	1.66e-15	-0.48	-0.39	Motion sickness;	chr6:8640935	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.585	rs4959495	ENSG00000230939.1	RP11-314C16.1	-9.13	2.3e-18	1.66e-15	-0.48	-0.39	Motion sickness;	chr6:8641186	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.585	rs11243264	ENSG00000230939.1	RP11-314C16.1	-9.13	2.3e-18	1.66e-15	-0.48	-0.39	Motion sickness;	chr6:8642912	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.585	rs11243265	ENSG00000230939.1	RP11-314C16.1	-9.13	2.3e-18	1.66e-15	-0.48	-0.39	Motion sickness;	chr6:8642925	chr6:8784178~8785445:+
PRAD	cis	rs4835473	0.897	rs1553070	ENSG00000251600.4	RP11-673E1.1	9.13	2.3e-18	1.66e-15	0.49	0.39	Immature fraction of reticulocytes;	chr4:143715981	chr4:143912331~143982454:+
PRAD	cis	rs4718428	0.705	rs12536410	ENSG00000230295.1	RP11-458F8.2	-9.13	2.31e-18	1.66e-15	-0.3	-0.39	Corneal structure;	chr7:66789303	chr7:66880708~66882981:+
PRAD	cis	rs2739330	0.828	rs4822451	ENSG00000224205.1	AP000351.4	9.13	2.32e-18	1.67e-15	0.49	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23987320~23991421:-
PRAD	cis	rs10740039	0.583	rs2127352	ENSG00000254271.1	RP11-131N11.4	-9.13	2.33e-18	1.68e-15	-0.54	-0.39	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60742129	chr10:60734342~60741828:+
PRAD	cis	rs704795	0.651	rs11693959	ENSG00000234072.1	AC074117.10	-9.13	2.33e-18	1.68e-15	-0.35	-0.39	Menopause (age at onset);	chr2:27351292	chr2:27356246~27367622:+
PRAD	cis	rs2348418	0.832	rs2100924	ENSG00000247934.4	RP11-967K21.1	-9.13	2.33e-18	1.68e-15	-0.37	-0.39	Lung function (FEV1);Lung function (FVC);	chr12:28340798	chr12:28163298~28190738:-
PRAD	cis	rs2348418	0.765	rs11049381	ENSG00000247934.4	RP11-967K21.1	-9.13	2.34e-18	1.68e-15	-0.37	-0.39	Lung function (FEV1);Lung function (FVC);	chr12:28162107	chr12:28163298~28190738:-
PRAD	cis	rs2348418	0.765	rs10843117	ENSG00000247934.4	RP11-967K21.1	-9.13	2.34e-18	1.68e-15	-0.37	-0.39	Lung function (FEV1);Lung function (FVC);	chr12:28162457	chr12:28163298~28190738:-
PRAD	cis	rs2348418	0.765	rs7954851	ENSG00000247934.4	RP11-967K21.1	-9.13	2.34e-18	1.68e-15	-0.37	-0.39	Lung function (FEV1);Lung function (FVC);	chr12:28162909	chr12:28163298~28190738:-
PRAD	cis	rs2348418	0.765	rs7954877	ENSG00000247934.4	RP11-967K21.1	-9.13	2.34e-18	1.68e-15	-0.37	-0.39	Lung function (FEV1);Lung function (FVC);	chr12:28163008	chr12:28163298~28190738:-
PRAD	cis	rs2348418	0.765	rs10843118	ENSG00000247934.4	RP11-967K21.1	-9.12	2.35e-18	1.69e-15	-0.37	-0.39	Lung function (FEV1);Lung function (FVC);	chr12:28164396	chr12:28163298~28190738:-
PRAD	cis	rs2274273	0.804	rs28428911	ENSG00000258413.1	RP11-665C16.6	-9.12	2.35e-18	1.69e-15	-0.51	-0.39	Protein biomarker;	chr14:55376878	chr14:55262767~55272075:-
PRAD	cis	rs465969	0.744	rs71562296	ENSG00000255389.1	C6orf3	-9.12	2.35e-18	1.7e-15	-0.74	-0.39	Psoriasis;	chr6:111521444	chr6:111599875~111602295:+
PRAD	cis	rs465969	0.744	rs6939657	ENSG00000255389.1	C6orf3	-9.12	2.35e-18	1.7e-15	-0.74	-0.39	Psoriasis;	chr6:111521822	chr6:111599875~111602295:+
PRAD	cis	rs150992	0.609	rs1093794	ENSG00000248489.1	CTD-2007H13.3	-9.12	2.35e-18	1.7e-15	-0.42	-0.39	Body mass index;	chr5:98993334	chr5:98929171~98995013:+
PRAD	cis	rs6991838	0.673	rs7462352	ENSG00000272010.1	CTD-3025N20.3	9.12	2.36e-18	1.7e-15	0.38	0.39	Intelligence (multi-trait analysis);	chr8:65584378	chr8:65591850~65592472:-
PRAD	cis	rs17711722	0.523	rs365896	ENSG00000228409.4	CCT6P1	9.12	2.36e-18	1.7e-15	0.29	0.39	Calcium levels;	chr7:66045710	chr7:65751142~65763354:+
PRAD	cis	rs10262624	0.967	rs7804966	ENSG00000234286.1	AC006026.13	-9.12	2.36e-18	1.7e-15	-0.46	-0.39	Schizophrenia;	chr7:23865141	chr7:23680195~23680786:-
PRAD	cis	rs7189233	0.531	rs9932007	ENSG00000279344.1	RP11-44F14.7	9.12	2.37e-18	1.71e-15	0.36	0.39	Intelligence (multi-trait analysis);	chr16:53422749	chr16:53478957~53481550:-
PRAD	cis	rs321358	0.895	rs6589210	ENSG00000271584.1	RP11-89C3.4	9.12	2.38e-18	1.71e-15	0.59	0.39	Body mass index;	chr11:111088408	chr11:111091932~111097357:-
PRAD	cis	rs4835473	0.897	rs924234	ENSG00000251600.4	RP11-673E1.1	9.12	2.39e-18	1.72e-15	0.49	0.39	Immature fraction of reticulocytes;	chr4:143706799	chr4:143912331~143982454:+
PRAD	cis	rs7306456	0.623	rs10902513	ENSG00000256576.2	RP13-977J11.2	9.12	2.39e-18	1.72e-15	0.47	0.39	Anti-saccade response;	chr12:132208942	chr12:132186735~132189695:-
PRAD	cis	rs11951515	0.966	rs11741797	ENSG00000188850.9	RP11-159F24.2	9.12	2.39e-18	1.72e-15	0.49	0.39	Metabolite levels  (X-11787);	chr5:43379690	chr5:43336164~43348716:+
PRAD	cis	rs67311347	1	rs28491638	ENSG00000223797.4	ENTPD3-AS1	9.12	2.39e-18	1.72e-15	0.37	0.39	Renal cell carcinoma;	chr3:40454772	chr3:40313802~40453329:-
PRAD	cis	rs67311347	1	rs28536038	ENSG00000223797.4	ENTPD3-AS1	9.12	2.39e-18	1.72e-15	0.37	0.39	Renal cell carcinoma;	chr3:40454891	chr3:40313802~40453329:-
PRAD	cis	rs67311347	0.955	rs2085114	ENSG00000223797.4	ENTPD3-AS1	9.12	2.39e-18	1.72e-15	0.37	0.39	Renal cell carcinoma;	chr3:40455946	chr3:40313802~40453329:-
PRAD	cis	rs8062405	0.69	rs4787458	ENSG00000259982.1	CDC37P1	9.12	2.4e-18	1.73e-15	0.54	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28519966	chr16:28700294~28701540:-
PRAD	cis	rs17361889	0.711	rs73056339	ENSG00000224683.1	RPL36AP29	9.12	2.41e-18	1.73e-15	0.49	0.39	Pediatric bone mineral content (hip);	chr7:16131751	chr7:16208945~16209265:+
PRAD	cis	rs2153535	0.585	rs9393052	ENSG00000230939.1	RP11-314C16.1	-9.12	2.41e-18	1.74e-15	-0.48	-0.39	Motion sickness;	chr6:8644832	chr6:8784178~8785445:+
PRAD	cis	rs10740039	0.583	rs2170005	ENSG00000254271.1	RP11-131N11.4	9.12	2.42e-18	1.74e-15	0.54	0.39	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740842	chr10:60734342~60741828:+
PRAD	cis	rs10740039	0.583	rs1904399	ENSG00000254271.1	RP11-131N11.4	-9.12	2.42e-18	1.74e-15	-0.54	-0.39	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60739240	chr10:60734342~60741828:+
PRAD	cis	rs10740039	0.583	rs1904400	ENSG00000254271.1	RP11-131N11.4	-9.12	2.42e-18	1.74e-15	-0.54	-0.39	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60739361	chr10:60734342~60741828:+
PRAD	cis	rs10740039	0.515	rs9414742	ENSG00000254271.1	RP11-131N11.4	-9.12	2.42e-18	1.74e-15	-0.54	-0.39	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60739769	chr10:60734342~60741828:+
PRAD	cis	rs10740039	0.583	rs9415609	ENSG00000254271.1	RP11-131N11.4	-9.12	2.42e-18	1.74e-15	-0.54	-0.39	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60739832	chr10:60734342~60741828:+
PRAD	cis	rs10740039	0.583	rs4948263	ENSG00000254271.1	RP11-131N11.4	-9.12	2.42e-18	1.74e-15	-0.54	-0.39	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740132	chr10:60734342~60741828:+
PRAD	cis	rs10740039	0.583	rs4948264	ENSG00000254271.1	RP11-131N11.4	-9.12	2.42e-18	1.74e-15	-0.54	-0.39	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740484	chr10:60734342~60741828:+
PRAD	cis	rs10740039	0.583	rs4948265	ENSG00000254271.1	RP11-131N11.4	-9.12	2.42e-18	1.74e-15	-0.54	-0.39	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740495	chr10:60734342~60741828:+
PRAD	cis	rs10740039	0.583	rs7917700	ENSG00000254271.1	RP11-131N11.4	-9.12	2.42e-18	1.74e-15	-0.54	-0.39	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740596	chr10:60734342~60741828:+
PRAD	cis	rs2274273	0.87	rs11851169	ENSG00000258413.1	RP11-665C16.6	-9.12	2.42e-18	1.74e-15	-0.51	-0.39	Protein biomarker;	chr14:55349214	chr14:55262767~55272075:-
PRAD	cis	rs11098499	0.954	rs6849171	ENSG00000245958.5	RP11-33B1.1	-9.12	2.42e-18	1.74e-15	-0.39	-0.39	Corneal astigmatism;	chr4:119488394	chr4:119454791~119552025:+
PRAD	cis	rs3814244	0.788	rs3741649	ENSG00000255733.4	IFNG-AS1	-9.12	2.42e-18	1.74e-15	-0.4	-0.39	Itch intensity from mosquito bite adjusted by bite size;	chr12:68028351	chr12:67989445~68234686:+
PRAD	cis	rs8072100	0.576	rs12948299	ENSG00000228782.6	CTD-2026D20.3	9.12	2.43e-18	1.75e-15	0.46	0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47325691	chr17:47450568~47492492:-
PRAD	cis	rs2739330	0.796	rs5760106	ENSG00000235689.1	AP000351.13	-9.12	2.44e-18	1.75e-15	-0.48	-0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:24006305~24008258:-
PRAD	cis	rs8177376	1	rs534804	ENSG00000254905.1	RP11-712L6.7	9.12	2.44e-18	1.76e-15	0.49	0.39	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126205873	chr11:126292922~126294254:-
PRAD	cis	rs67311347	1	rs73076035	ENSG00000223797.4	ENTPD3-AS1	9.12	2.45e-18	1.76e-15	0.37	0.39	Renal cell carcinoma;	chr3:40398390	chr3:40313802~40453329:-
PRAD	cis	rs2404602	0.716	rs17364076	ENSG00000259422.1	RP11-593F23.1	9.12	2.45e-18	1.76e-15	0.48	0.39	Blood metabolite levels;	chr15:76468550	chr15:76174891~76181486:-
PRAD	cis	rs853679	0.55	rs9295762	ENSG00000219392.1	RP1-265C24.5	9.12	2.46e-18	1.77e-15	0.51	0.39	Depression;	chr6:28187640	chr6:28115628~28116551:+
PRAD	cis	rs3733309	0.648	rs10016631	ENSG00000269949.1	RP11-738E22.3	9.12	2.46e-18	1.77e-15	0.52	0.39	Height;	chr4:57019797	chr4:56960927~56961373:-
PRAD	cis	rs2729354	0.817	rs2649667	ENSG00000265566.2	RN7SL605P	-9.12	2.46e-18	1.77e-15	-0.57	-0.39	Blood protein levels;	chr11:57503036	chr11:57528085~57528365:-
PRAD	cis	rs17023223	0.537	rs2765533	ENSG00000231365.4	RP11-418J17.1	-9.12	2.46e-18	1.77e-15	-0.4	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119054772	chr1:119140396~119275973:+
PRAD	cis	rs2929278	0.638	rs2016840	ENSG00000249839.1	AC011330.5	9.12	2.47e-18	1.77e-15	0.5	0.39	Schizophrenia;	chr15:43919670	chr15:43663654~43684339:-
PRAD	cis	rs10262624	0.935	rs6966641	ENSG00000234286.1	AC006026.13	-9.12	2.47e-18	1.78e-15	-0.44	-0.39	Schizophrenia;	chr7:23866979	chr7:23680195~23680786:-
PRAD	cis	rs2015599	0.623	rs1006410	ENSG00000257176.2	RP11-996F15.2	9.12	2.48e-18	1.78e-15	0.44	0.39	Platelet count;Mean platelet volume;	chr12:29282682	chr12:29280418~29317848:-
PRAD	cis	rs172166	0.585	rs149963	ENSG00000204709.4	LINC01556	9.12	2.48e-18	1.79e-15	0.49	0.39	Cardiac Troponin-T levels;	chr6:28049354	chr6:28943877~28944537:+
PRAD	cis	rs7189233	0.531	rs3929	ENSG00000279344.1	RP11-44F14.7	-9.12	2.49e-18	1.79e-15	-0.36	-0.39	Intelligence (multi-trait analysis);	chr16:53490396	chr16:53478957~53481550:-
PRAD	cis	rs17023223	0.537	rs2361271	ENSG00000231365.4	RP11-418J17.1	-9.12	2.49e-18	1.79e-15	-0.4	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119060782	chr1:119140396~119275973:+
PRAD	cis	rs1426063	0.748	rs6534607	ENSG00000249717.1	RP11-44F21.3	9.12	2.49e-18	1.79e-15	0.58	0.39	QT interval;	chr4:75106366	chr4:74955974~74970362:-
PRAD	cis	rs11673344	0.764	rs472226	ENSG00000226686.6	LINC01535	9.12	2.5e-18	1.8e-15	0.53	0.39	Obesity-related traits;	chr19:36967811	chr19:37251912~37265535:+
PRAD	cis	rs7811142	0.83	rs6945952	ENSG00000242294.5	STAG3L5P	9.12	2.51e-18	1.81e-15	0.26	0.39	Platelet count;	chr7:100384152	chr7:100336079~100351900:+
PRAD	cis	rs7811142	0.83	rs73401451	ENSG00000242294.5	STAG3L5P	9.12	2.51e-18	1.81e-15	0.26	0.39	Platelet count;	chr7:100384272	chr7:100336079~100351900:+
PRAD	cis	rs1062177	1	rs2915877	ENSG00000253921.1	CTB-113P19.3	-9.12	2.52e-18	1.81e-15	-0.51	-0.39	Preschool internalizing problems;	chr5:151771040	chr5:151753992~151767247:+
PRAD	cis	rs1062177	1	rs2964576	ENSG00000253921.1	CTB-113P19.3	-9.12	2.52e-18	1.81e-15	-0.51	-0.39	Preschool internalizing problems;	chr5:151771041	chr5:151753992~151767247:+
PRAD	cis	rs1062177	0.95	rs892005	ENSG00000253921.1	CTB-113P19.3	-9.12	2.52e-18	1.81e-15	-0.53	-0.39	Preschool internalizing problems;	chr5:151801060	chr5:151753992~151767247:+
PRAD	cis	rs10740039	0.583	rs1904401	ENSG00000254271.1	RP11-131N11.4	-9.12	2.52e-18	1.81e-15	-0.54	-0.39	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60741809	chr10:60734342~60741828:+
PRAD	cis	rs875971	0.964	rs778735	ENSG00000237310.1	GS1-124K5.4	9.12	2.52e-18	1.81e-15	0.35	0.39	Aortic root size;	chr7:66349822	chr7:66493706~66495474:+
PRAD	cis	rs4879677	1	rs7858681	ENSG00000260390.1	RP11-575I8.1	-9.11	2.53e-18	1.82e-15	-0.52	-0.39	Gut microbiome composition (summer and winter);	chr9:27659161	chr9:27829276~27844481:+
PRAD	cis	rs34779708	0.897	rs7900480	ENSG00000230534.5	RP11-297A16.2	-9.11	2.53e-18	1.82e-15	-0.52	-0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35049771	chr10:35098006~35127020:-
PRAD	cis	rs17023223	0.537	rs3936018	ENSG00000231365.4	RP11-418J17.1	-9.11	2.54e-18	1.82e-15	-0.43	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119139747	chr1:119140396~119275973:+
PRAD	cis	rs7811142	0.775	rs1636980	ENSG00000242294.5	STAG3L5P	-9.11	2.54e-18	1.82e-15	-0.26	-0.39	Platelet count;	chr7:100341241	chr7:100336079~100351900:+
PRAD	cis	rs11951515	1	rs3756416	ENSG00000188850.9	RP11-159F24.2	9.11	2.55e-18	1.83e-15	0.48	0.39	Metabolite levels  (X-11787);	chr5:43383400	chr5:43336164~43348716:+
PRAD	cis	rs7849270	0.879	rs3124496	ENSG00000268707.1	RP11-247A12.7	9.11	2.56e-18	1.84e-15	0.47	0.39	Blood metabolite ratios;	chr9:129094583	chr9:129170434~129170940:+
PRAD	cis	rs67311347	1	rs4128740	ENSG00000223797.4	ENTPD3-AS1	9.11	2.58e-18	1.85e-15	0.37	0.39	Renal cell carcinoma;	chr3:40478041	chr3:40313802~40453329:-
PRAD	cis	rs1075265	0.836	rs11687324	ENSG00000233266.1	HMGB1P31	9.11	2.58e-18	1.86e-15	0.53	0.39	Chronotype;Morning vs. evening chronotype;	chr2:54046589	chr2:54051334~54051760:+
PRAD	cis	rs17023223	0.537	rs6662165	ENSG00000231365.4	RP11-418J17.1	-9.11	2.59e-18	1.86e-15	-0.42	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119071448	chr1:119140396~119275973:+
PRAD	cis	rs10740039	0.583	rs2127350	ENSG00000254271.1	RP11-131N11.4	-9.11	2.59e-18	1.86e-15	-0.54	-0.39	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60741079	chr10:60734342~60741828:+
PRAD	cis	rs853679	0.55	rs1225598	ENSG00000219392.1	RP1-265C24.5	-9.11	2.59e-18	1.86e-15	-0.5	-0.39	Depression;	chr6:28193021	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.55	rs1150689	ENSG00000219392.1	RP1-265C24.5	-9.11	2.59e-18	1.86e-15	-0.5	-0.39	Depression;	chr6:28197321	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.55	rs1225599	ENSG00000219392.1	RP1-265C24.5	-9.11	2.59e-18	1.86e-15	-0.5	-0.39	Depression;	chr6:28197412	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.574	rs1233705	ENSG00000219392.1	RP1-265C24.5	-9.11	2.59e-18	1.86e-15	-0.5	-0.39	Depression;	chr6:28198669	chr6:28115628~28116551:+
PRAD	cis	rs4835473	0.932	rs13134808	ENSG00000251600.4	RP11-673E1.1	-9.11	2.6e-18	1.86e-15	-0.51	-0.39	Immature fraction of reticulocytes;	chr4:143798339	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.808	rs6831401	ENSG00000251600.4	RP11-673E1.1	-9.11	2.6e-18	1.86e-15	-0.51	-0.39	Immature fraction of reticulocytes;	chr4:143801038	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.778	rs6853798	ENSG00000251600.4	RP11-673E1.1	-9.11	2.6e-18	1.86e-15	-0.51	-0.39	Immature fraction of reticulocytes;	chr4:143801153	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.9	rs12502940	ENSG00000251600.4	RP11-673E1.1	-9.11	2.6e-18	1.86e-15	-0.51	-0.39	Immature fraction of reticulocytes;	chr4:143812117	chr4:143912331~143982454:+
PRAD	cis	rs13217239	0.646	rs12527111	ENSG00000241549.7	GUSBP2	9.11	2.61e-18	1.87e-15	0.43	0.39	Schizophrenia;	chr6:27038696	chr6:26871484~26956554:-
PRAD	cis	rs11098499	0.865	rs4507344	ENSG00000245958.5	RP11-33B1.1	-9.11	2.63e-18	1.88e-15	-0.39	-0.39	Corneal astigmatism;	chr4:119386330	chr4:119454791~119552025:+
PRAD	cis	rs7772486	0.875	rs2492855	ENSG00000235652.6	RP11-545I5.3	9.11	2.63e-18	1.89e-15	0.4	0.39	Lobe attachment (rater-scored or self-reported);	chr6:145975790	chr6:145799409~145886585:+
PRAD	cis	rs11098499	0.863	rs9997631	ENSG00000245958.5	RP11-33B1.1	-9.11	2.63e-18	1.89e-15	-0.38	-0.39	Corneal astigmatism;	chr4:119548840	chr4:119454791~119552025:+
PRAD	cis	rs3096299	0.685	rs8050512	ENSG00000261118.1	RP11-104N10.1	9.11	2.65e-18	1.9e-15	0.37	0.39	Multiple myeloma (IgH translocation);	chr16:89485912	chr16:89492017~89504460:-
PRAD	cis	rs10875746	0.517	rs12721420	ENSG00000240399.1	RP1-228P16.1	-9.11	2.67e-18	1.91e-15	-0.4	-0.39	Longevity (90 years and older);	chr12:47965011	chr12:48054813~48055591:-
PRAD	cis	rs748404	0.66	rs690012	ENSG00000249839.1	AC011330.5	-9.11	2.67e-18	1.91e-15	-0.48	-0.39	Lung cancer;	chr15:43427557	chr15:43663654~43684339:-
PRAD	cis	rs11098499	0.865	rs11098513	ENSG00000245958.5	RP11-33B1.1	-9.11	2.68e-18	1.92e-15	-0.39	-0.39	Corneal astigmatism;	chr4:119394920	chr4:119454791~119552025:+
PRAD	cis	rs7811142	0.83	rs73401450	ENSG00000242294.5	STAG3L5P	9.11	2.68e-18	1.92e-15	0.26	0.39	Platelet count;	chr7:100384236	chr7:100336079~100351900:+
PRAD	cis	rs17023223	0.581	rs61808932	ENSG00000231365.4	RP11-418J17.1	-9.11	2.68e-18	1.92e-15	-0.41	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119101197	chr1:119140396~119275973:+
PRAD	cis	rs12220777	0.681	rs117394476	ENSG00000230091.5	TMEM254-AS1	9.11	2.69e-18	1.93e-15	0.75	0.39	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80103000	chr10:80046860~80078912:-
PRAD	cis	rs7743045	0.573	rs6929403	ENSG00000253194.1	RP11-351A11.1	9.11	2.7e-18	1.93e-15	0.5	0.39	Mean platelet volume;	chr6:119025747	chr6:118934785~119031541:+
PRAD	cis	rs17023223	0.537	rs2794311	ENSG00000231365.4	RP11-418J17.1	9.11	2.71e-18	1.94e-15	0.39	0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119053326	chr1:119140396~119275973:+
PRAD	cis	rs6061231	0.583	rs2427313	ENSG00000273619.1	RP5-908M14.9	-9.11	2.71e-18	1.94e-15	-0.26	-0.39	Colorectal cancer;	chr20:62395619	chr20:62386303~62386970:-
PRAD	cis	rs7712401	0.601	rs246268	ENSG00000263432.2	RN7SL689P	9.11	2.72e-18	1.95e-15	0.4	0.39	Mean platelet volume;	chr5:122920647	chr5:123022487~123022783:-
PRAD	cis	rs7772486	0.875	rs864390	ENSG00000235652.6	RP11-545I5.3	9.11	2.72e-18	1.95e-15	0.4	0.39	Lobe attachment (rater-scored or self-reported);	chr6:145993899	chr6:145799409~145886585:+
PRAD	cis	rs1075265	0.605	rs805373	ENSG00000233266.1	HMGB1P31	9.11	2.73e-18	1.95e-15	0.52	0.39	Chronotype;Morning vs. evening chronotype;	chr2:53859458	chr2:54051334~54051760:+
PRAD	cis	rs7714584	0.793	rs11949375	ENSG00000197083.10	ZNF300P1	9.1	2.73e-18	1.96e-15	0.65	0.39	Crohn's disease;	chr5:150823418	chr5:150930645~150946289:-
PRAD	cis	rs2283792	0.74	rs8140258	ENSG00000224086.5	LL22NC03-86G7.1	-9.1	2.73e-18	1.96e-15	-0.47	-0.39	Multiple sclerosis;	chr22:21755545	chr22:21938293~21977632:+
PRAD	cis	rs9399135	0.773	rs949895	ENSG00000232876.1	CTA-212D2.2	-9.1	2.75e-18	1.97e-15	-0.49	-0.39	Red blood cell count;	chr6:135084221	chr6:135055033~135060550:+
PRAD	cis	rs7712401	0.562	rs30046	ENSG00000263432.2	RN7SL689P	9.1	2.76e-18	1.97e-15	0.4	0.39	Mean platelet volume;	chr5:122935538	chr5:123022487~123022783:-
PRAD	cis	rs1185460	1	rs1799993	ENSG00000271751.1	RP11-110I1.14	9.1	2.76e-18	1.98e-15	0.54	0.39	Coronary artery disease;	chr11:119087417	chr11:119065263~119065677:-
PRAD	cis	rs9918079	0.643	rs35414597	ENSG00000273133.1	RP11-799M12.2	9.1	2.76e-18	1.98e-15	0.52	0.39	Obesity-related traits;	chr4:15564113	chr4:15563698~15564253:-
PRAD	cis	rs6570726	0.791	rs6902404	ENSG00000235652.6	RP11-545I5.3	9.1	2.77e-18	1.99e-15	0.4	0.39	Lobe attachment (rater-scored or self-reported);	chr6:145584118	chr6:145799409~145886585:+
PRAD	cis	rs7615952	0.611	rs2971298	ENSG00000171084.14	FAM86JP	9.1	2.78e-18	1.99e-15	0.7	0.39	Blood pressure (smoking interaction);	chr3:125883870	chr3:125916620~125930024:+
PRAD	cis	rs7923609	0.756	rs12768534	ENSG00000232075.1	MRPL35P2	-9.1	2.78e-18	1.99e-15	-0.41	-0.39	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63581137	chr10:63634317~63634827:-
PRAD	cis	rs62103177	0.564	rs3930042	ENSG00000261126.6	RP11-795F19.1	9.1	2.79e-18	2e-15	0.55	0.39	Opioid sensitivity;	chr18:79963843	chr18:80046900~80095482:+
PRAD	cis	rs2581828	0.646	rs2564944	ENSG00000242142.1	SERBP1P3	9.1	2.81e-18	2.01e-15	0.46	0.39	Crohn's disease;	chr3:53114439	chr3:53064283~53065091:-
PRAD	cis	rs7772486	0.875	rs2814871	ENSG00000235652.6	RP11-545I5.3	9.1	2.81e-18	2.01e-15	0.4	0.39	Lobe attachment (rater-scored or self-reported);	chr6:145991138	chr6:145799409~145886585:+
PRAD	cis	rs3745672	1	rs111259072	ENSG00000219665.7	CTD-2006C1.2	-9.1	2.81e-18	2.01e-15	-0.82	-0.39	Multiple sclerosis;	chr19:12045754	chr19:11987617~12046275:+
PRAD	cis	rs3745672	0.661	rs112152876	ENSG00000219665.7	CTD-2006C1.2	-9.1	2.81e-18	2.01e-15	-0.82	-0.39	Multiple sclerosis;	chr19:12045864	chr19:11987617~12046275:+
PRAD	cis	rs3745672	1	rs10417006	ENSG00000219665.7	CTD-2006C1.2	-9.1	2.81e-18	2.01e-15	-0.82	-0.39	Multiple sclerosis;	chr19:12046438	chr19:11987617~12046275:+
PRAD	cis	rs3745672	1	rs7255420	ENSG00000219665.7	CTD-2006C1.2	-9.1	2.81e-18	2.01e-15	-0.82	-0.39	Multiple sclerosis;	chr19:12047024	chr19:11987617~12046275:+
PRAD	cis	rs7712401	0.601	rs154506	ENSG00000263432.2	RN7SL689P	9.1	2.82e-18	2.02e-15	0.41	0.39	Mean platelet volume;	chr5:122867086	chr5:123022487~123022783:-
PRAD	cis	rs2564921	0.704	rs56155510	ENSG00000242142.1	SERBP1P3	-9.1	2.83e-18	2.02e-15	-0.45	-0.39	Height;	chr3:53009621	chr3:53064283~53065091:-
PRAD	cis	rs6991838	0.584	rs73236948	ENSG00000200714.1	Y_RNA	-9.1	2.83e-18	2.02e-15	-0.44	-0.39	Intelligence (multi-trait analysis);	chr8:65609176	chr8:65592731~65592820:+
PRAD	cis	rs4835473	0.932	rs17018238	ENSG00000251600.4	RP11-673E1.1	-9.1	2.83e-18	2.03e-15	-0.49	-0.39	Immature fraction of reticulocytes;	chr4:143782737	chr4:143912331~143982454:+
PRAD	cis	rs2638953	0.924	rs1841962	ENSG00000278733.1	RP11-425D17.1	9.1	2.83e-18	2.03e-15	0.46	0.39	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28220919	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs7969582	ENSG00000278733.1	RP11-425D17.1	9.1	2.83e-18	2.03e-15	0.46	0.39	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28236725	chr12:28185625~28186190:-
PRAD	cis	rs67311347	1	rs11707673	ENSG00000223797.4	ENTPD3-AS1	9.1	2.84e-18	2.03e-15	0.37	0.39	Renal cell carcinoma;	chr3:40409113	chr3:40313802~40453329:-
PRAD	cis	rs858239	1	rs858239	ENSG00000226816.2	AC005082.12	9.1	2.84e-18	2.03e-15	0.44	0.39	Cerebrospinal fluid biomarker levels;	chr7:23246696	chr7:23206013~23208045:+
PRAD	cis	rs67311347	1	rs12630072	ENSG00000223797.4	ENTPD3-AS1	9.1	2.85e-18	2.04e-15	0.37	0.39	Renal cell carcinoma;	chr3:40475699	chr3:40313802~40453329:-
PRAD	cis	rs7712401	0.525	rs246312	ENSG00000263432.2	RN7SL689P	9.1	2.85e-18	2.04e-15	0.4	0.39	Mean platelet volume;	chr5:122933760	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.601	rs246308	ENSG00000263432.2	RN7SL689P	9.1	2.85e-18	2.04e-15	0.4	0.39	Mean platelet volume;	chr5:122934395	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.601	rs30047	ENSG00000263432.2	RN7SL689P	9.1	2.85e-18	2.04e-15	0.4	0.39	Mean platelet volume;	chr5:122934829	chr5:123022487~123022783:-
PRAD	cis	rs4835473	0.714	rs10013005	ENSG00000251600.4	RP11-673E1.1	9.1	2.85e-18	2.04e-15	0.49	0.39	Immature fraction of reticulocytes;	chr4:143711351	chr4:143912331~143982454:+
PRAD	cis	rs2274273	0.87	rs3783652	ENSG00000258413.1	RP11-665C16.6	-9.1	2.85e-18	2.04e-15	-0.51	-0.39	Protein biomarker;	chr14:55387490	chr14:55262767~55272075:-
PRAD	cis	rs12049351	0.725	rs1328219	ENSG00000229367.1	HMGN2P19	9.1	2.85e-18	2.04e-15	0.58	0.39	Circulating myeloperoxidase levels (plasma);	chr1:229460513	chr1:229570532~229570796:+
PRAD	cis	rs6517329	0.513	rs9680108	ENSG00000236830.5	CBR3-AS1	9.1	2.86e-18	2.05e-15	0.41	0.39	Schizophrenia;	chr21:36172604	chr21:36131767~36175815:-
PRAD	cis	rs6517329	0.513	rs8131593	ENSG00000236830.5	CBR3-AS1	9.1	2.86e-18	2.05e-15	0.41	0.39	Schizophrenia;	chr21:36173290	chr21:36131767~36175815:-
PRAD	cis	rs7712401	0.623	rs30044	ENSG00000263432.2	RN7SL689P	9.1	2.86e-18	2.05e-15	0.4	0.39	Mean platelet volume;	chr5:122936385	chr5:123022487~123022783:-
PRAD	cis	rs9399137	0.507	rs4520025	ENSG00000232876.1	CTA-212D2.2	-9.1	2.87e-18	2.05e-15	-0.5	-0.39	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134957481	chr6:135055033~135060550:+
PRAD	cis	rs4835473	0.897	rs1545437	ENSG00000251600.4	RP11-673E1.1	-9.1	2.87e-18	2.05e-15	-0.49	-0.39	Immature fraction of reticulocytes;	chr4:143696689	chr4:143912331~143982454:+
PRAD	cis	rs11676348	0.805	rs12694428	ENSG00000261338.2	RP11-378A13.1	-9.1	2.88e-18	2.06e-15	-0.43	-0.39	Ulcerative colitis;	chr2:218094097	chr2:218255319~218257366:+
PRAD	cis	rs150992	0.525	rs331930	ENSG00000248489.1	CTD-2007H13.3	9.1	2.89e-18	2.07e-15	0.43	0.39	Body mass index;	chr5:98833559	chr5:98929171~98995013:+
PRAD	cis	rs4718428	0.705	rs68168107	ENSG00000230295.1	RP11-458F8.2	-9.1	2.9e-18	2.07e-15	-0.3	-0.39	Corneal structure;	chr7:66790251	chr7:66880708~66882981:+
PRAD	cis	rs2658782	0.654	rs2248524	ENSG00000279684.1	RP11-755E23.2	-9.1	2.9e-18	2.08e-15	-0.58	-0.39	Pulmonary function decline;	chr11:93522549	chr11:93286629~93288903:-
PRAD	cis	rs1062177	1	rs17741826	ENSG00000253921.1	CTB-113P19.3	9.1	2.92e-18	2.09e-15	0.52	0.39	Preschool internalizing problems;	chr5:151769701	chr5:151753992~151767247:+
PRAD	cis	rs11098499	0.909	rs1809406	ENSG00000245958.5	RP11-33B1.1	-9.1	2.92e-18	2.09e-15	-0.39	-0.39	Corneal astigmatism;	chr4:119455967	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.865	rs2389809	ENSG00000245958.5	RP11-33B1.1	-9.1	2.92e-18	2.09e-15	-0.39	-0.39	Corneal astigmatism;	chr4:119456244	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.909	rs9994810	ENSG00000245958.5	RP11-33B1.1	-9.1	2.92e-18	2.09e-15	-0.39	-0.39	Corneal astigmatism;	chr4:119460435	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.697	rs10020027	ENSG00000245958.5	RP11-33B1.1	-9.1	2.92e-18	2.09e-15	-0.39	-0.39	Corneal astigmatism;	chr4:119460724	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.779	rs7356491	ENSG00000245958.5	RP11-33B1.1	-9.1	2.92e-18	2.09e-15	-0.39	-0.39	Corneal astigmatism;	chr4:119460819	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.908	rs28499576	ENSG00000245958.5	RP11-33B1.1	-9.1	2.92e-18	2.09e-15	-0.39	-0.39	Corneal astigmatism;	chr4:119465522	chr4:119454791~119552025:+
PRAD	cis	rs1062177	1	rs973529	ENSG00000253921.1	CTB-113P19.3	-9.1	2.94e-18	2.1e-15	-0.53	-0.39	Preschool internalizing problems;	chr5:151808597	chr5:151753992~151767247:+
PRAD	cis	rs17023223	0.537	rs2645302	ENSG00000231365.4	RP11-418J17.1	-9.1	2.94e-18	2.1e-15	-0.4	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119047775	chr1:119140396~119275973:+
PRAD	cis	rs7811142	0.779	rs77370288	ENSG00000242294.5	STAG3L5P	9.1	2.94e-18	2.1e-15	0.26	0.39	Platelet count;	chr7:100350274	chr7:100336079~100351900:+
PRAD	cis	rs12220777	1	rs11201298	ENSG00000230091.5	TMEM254-AS1	9.1	2.95e-18	2.11e-15	0.72	0.39	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80033995	chr10:80046860~80078912:-
PRAD	cis	rs11148252	0.74	rs9536052	ENSG00000278238.1	RP11-245D16.4	9.1	2.95e-18	2.11e-15	0.43	0.39	Lewy body disease;	chr13:52386574	chr13:52454775~52455331:-
PRAD	cis	rs7712401	0.601	rs438196	ENSG00000263432.2	RN7SL689P	9.09	2.96e-18	2.12e-15	0.4	0.39	Mean platelet volume;	chr5:122927368	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.562	rs401729	ENSG00000263432.2	RN7SL689P	9.09	2.96e-18	2.12e-15	0.4	0.39	Mean platelet volume;	chr5:122928590	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.601	rs2910140	ENSG00000263432.2	RN7SL689P	9.09	2.96e-18	2.12e-15	0.4	0.39	Mean platelet volume;	chr5:122928700	chr5:123022487~123022783:-
PRAD	cis	rs853679	0.517	rs9283884	ENSG00000226314.6	ZNF192P1	9.09	2.98e-18	2.13e-15	0.54	0.39	Depression;	chr6:28167882	chr6:28161781~28169594:+
PRAD	cis	rs4835473	0.932	rs1450250	ENSG00000251600.4	RP11-673E1.1	9.09	2.98e-18	2.13e-15	0.5	0.39	Immature fraction of reticulocytes;	chr4:143731873	chr4:143912331~143982454:+
PRAD	cis	rs17023223	0.537	rs61808892	ENSG00000231365.4	RP11-418J17.1	-9.09	2.99e-18	2.13e-15	-0.4	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119056584	chr1:119140396~119275973:+
PRAD	cis	rs2729354	0.729	rs2848634	ENSG00000265566.2	RN7SL605P	-9.09	2.99e-18	2.14e-15	-0.57	-0.39	Blood protein levels;	chr11:57484855	chr11:57528085~57528365:-
PRAD	cis	rs13217239	0.646	rs10946898	ENSG00000241549.7	GUSBP2	9.09	2.99e-18	2.14e-15	0.43	0.39	Schizophrenia;	chr6:27036105	chr6:26871484~26956554:-
PRAD	cis	rs6750795	0.507	rs1667320	ENSG00000181798.2	LINC00471	-9.09	2.99e-18	2.14e-15	-0.45	-0.39	Height;	chr2:231553603	chr2:231508426~231514339:-
PRAD	cis	rs875971	1	rs1981798	ENSG00000237310.1	GS1-124K5.4	9.09	3e-18	2.14e-15	0.35	0.39	Aortic root size;	chr7:66489916	chr7:66493706~66495474:+
PRAD	cis	rs62388641	0.547	rs9391923	ENSG00000272279.1	RP11-157J24.2	-9.09	3.01e-18	2.15e-15	-0.52	-0.39	Daytime sleep phenotypes;	chr6:1554089	chr6:1528364~1528911:-
PRAD	cis	rs7811142	0.83	rs7792525	ENSG00000242294.5	STAG3L5P	9.09	3.01e-18	2.15e-15	0.26	0.39	Platelet count;	chr7:100374499	chr7:100336079~100351900:+
PRAD	cis	rs2274273	0.87	rs66696758	ENSG00000258413.1	RP11-665C16.6	-9.09	3.02e-18	2.15e-15	-0.51	-0.39	Protein biomarker;	chr14:55299791	chr14:55262767~55272075:-
PRAD	cis	rs17023223	0.537	rs2361269	ENSG00000231365.4	RP11-418J17.1	-9.09	3.02e-18	2.16e-15	-0.4	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119059592	chr1:119140396~119275973:+
PRAD	cis	rs17023223	0.537	rs2645300	ENSG00000231365.4	RP11-418J17.1	-9.09	3.02e-18	2.16e-15	-0.4	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119060444	chr1:119140396~119275973:+
PRAD	cis	rs17023223	0.537	rs2361270	ENSG00000231365.4	RP11-418J17.1	-9.09	3.02e-18	2.16e-15	-0.4	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119060699	chr1:119140396~119275973:+
PRAD	cis	rs17023223	0.537	rs2361273	ENSG00000231365.4	RP11-418J17.1	-9.09	3.02e-18	2.16e-15	-0.4	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119061077	chr1:119140396~119275973:+
PRAD	cis	rs17023223	0.537	rs10923741	ENSG00000231365.4	RP11-418J17.1	-9.09	3.02e-18	2.16e-15	-0.4	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119061850	chr1:119140396~119275973:+
PRAD	cis	rs17023223	0.537	rs10802073	ENSG00000231365.4	RP11-418J17.1	-9.09	3.02e-18	2.16e-15	-0.4	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119062032	chr1:119140396~119275973:+
PRAD	cis	rs2274273	0.87	rs67514154	ENSG00000258413.1	RP11-665C16.6	-9.09	3.03e-18	2.16e-15	-0.51	-0.39	Protein biomarker;	chr14:55300664	chr14:55262767~55272075:-
PRAD	cis	rs2404602	0.716	rs17363713	ENSG00000259422.1	RP11-593F23.1	9.09	3.03e-18	2.16e-15	0.49	0.39	Blood metabolite levels;	chr15:76453787	chr15:76174891~76181486:-
PRAD	cis	rs2274273	0.805	rs28660594	ENSG00000258413.1	RP11-665C16.6	-9.09	3.05e-18	2.18e-15	-0.51	-0.39	Protein biomarker;	chr14:55379456	chr14:55262767~55272075:-
PRAD	cis	rs1426063	0.748	rs10005117	ENSG00000249717.1	RP11-44F21.3	9.09	3.06e-18	2.18e-15	0.58	0.39	QT interval;	chr4:75108281	chr4:74955974~74970362:-
PRAD	cis	rs9326248	0.52	rs2735183	ENSG00000280143.1	AP000892.6	9.09	3.06e-18	2.18e-15	0.3	0.39	Blood protein levels;	chr11:117144479	chr11:117204967~117210292:+
PRAD	cis	rs2564921	0.615	rs56129941	ENSG00000242142.1	SERBP1P3	-9.09	3.07e-18	2.19e-15	-0.45	-0.39	Height;	chr3:53007328	chr3:53064283~53065091:-
PRAD	cis	rs2564921	0.679	rs12635933	ENSG00000242142.1	SERBP1P3	-9.09	3.07e-18	2.19e-15	-0.45	-0.39	Height;	chr3:53015087	chr3:53064283~53065091:-
PRAD	cis	rs13217239	0.646	rs62401067	ENSG00000241549.7	GUSBP2	9.09	3.07e-18	2.19e-15	0.43	0.39	Schizophrenia;	chr6:27050322	chr6:26871484~26956554:-
PRAD	cis	rs465969	1	rs4509157	ENSG00000255389.1	C6orf3	-9.09	3.09e-18	2.2e-15	-0.73	-0.39	Psoriasis;	chr6:111513875	chr6:111599875~111602295:+
PRAD	cis	rs732716	0.74	rs78869060	ENSG00000267980.1	AC007292.6	-9.09	3.09e-18	2.21e-15	-0.39	-0.39	Mean corpuscular volume;	chr19:4444745	chr19:4363789~4364640:+
PRAD	cis	rs748404	0.66	rs542898	ENSG00000249839.1	AC011330.5	-9.09	3.1e-18	2.21e-15	-0.48	-0.39	Lung cancer;	chr15:43427194	chr15:43663654~43684339:-
PRAD	cis	rs748404	0.66	rs689767	ENSG00000249839.1	AC011330.5	-9.09	3.1e-18	2.21e-15	-0.48	-0.39	Lung cancer;	chr15:43429879	chr15:43663654~43684339:-
PRAD	cis	rs1075232	1	rs9672214	ENSG00000270055.1	CTD-3092A11.2	-9.09	3.11e-18	2.22e-15	-0.83	-0.39	Survival in colorectal cancer (non-distant metastatic);	chr15:31385572	chr15:30487963~30490313:+
PRAD	cis	rs875971	1	rs937495	ENSG00000237310.1	GS1-124K5.4	-9.09	3.11e-18	2.22e-15	-0.35	-0.39	Aortic root size;	chr7:66314811	chr7:66493706~66495474:+
PRAD	cis	rs7923609	0.756	rs7090758	ENSG00000232075.1	MRPL35P2	9.09	3.11e-18	2.22e-15	0.41	0.39	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63575555	chr10:63634317~63634827:-
PRAD	cis	rs11123170	0.543	rs2166421	ENSG00000274877.1	RP11-65I12.1	-9.09	3.13e-18	2.23e-15	-0.62	-0.39	Renal function-related traits (BUN);	chr2:113232665	chr2:113237595~113240825:+
PRAD	cis	rs17023223	0.537	rs56708249	ENSG00000231365.4	RP11-418J17.1	-9.09	3.13e-18	2.23e-15	-0.39	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119050582	chr1:119140396~119275973:+
PRAD	cis	rs17023223	0.537	rs17023174	ENSG00000231365.4	RP11-418J17.1	-9.09	3.13e-18	2.23e-15	-0.39	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119050678	chr1:119140396~119275973:+
PRAD	cis	rs172166	0.694	rs203893	ENSG00000280107.1	AL022393.9	-9.09	3.14e-18	2.24e-15	-0.48	-0.39	Cardiac Troponin-T levels;	chr6:28094288	chr6:28170845~28172521:+
PRAD	cis	rs172166	0.652	rs476167	ENSG00000280107.1	AL022393.9	-9.09	3.14e-18	2.24e-15	-0.48	-0.39	Cardiac Troponin-T levels;	chr6:28098110	chr6:28170845~28172521:+
PRAD	cis	rs172166	0.694	rs203892	ENSG00000280107.1	AL022393.9	-9.09	3.14e-18	2.24e-15	-0.48	-0.39	Cardiac Troponin-T levels;	chr6:28099418	chr6:28170845~28172521:+
PRAD	cis	rs172166	0.611	rs203883	ENSG00000280107.1	AL022393.9	-9.09	3.14e-18	2.24e-15	-0.48	-0.39	Cardiac Troponin-T levels;	chr6:28110578	chr6:28170845~28172521:+
PRAD	cis	rs6700559	0.81	rs2808248	ENSG00000260088.1	RP11-92G12.3	9.09	3.15e-18	2.24e-15	0.49	0.39	Coronary artery disease;	chr1:200623147	chr1:200669507~200694250:+
PRAD	cis	rs6723108	0.627	rs2166480	ENSG00000224043.6	CCNT2-AS1	9.09	3.15e-18	2.25e-15	0.55	0.39	Type 2 diabetes;	chr2:134879768	chr2:134735464~134918710:-
PRAD	cis	rs2638953	0.924	rs17801442	ENSG00000278733.1	RP11-425D17.1	-9.09	3.15e-18	2.25e-15	-0.47	-0.39	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28165627	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs11049384	ENSG00000278733.1	RP11-425D17.1	-9.09	3.15e-18	2.25e-15	-0.47	-0.39	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28166089	chr12:28185625~28186190:-
PRAD	cis	rs17361889	0.685	rs111795100	ENSG00000224683.1	RPL36AP29	9.09	3.16e-18	2.26e-15	0.48	0.39	Pediatric bone mineral content (hip);	chr7:16112093	chr7:16208945~16209265:+
PRAD	cis	rs2564921	0.704	rs11130333	ENSG00000242142.1	SERBP1P3	-9.09	3.18e-18	2.26e-15	-0.46	-0.39	Height;	chr3:52977358	chr3:53064283~53065091:-
PRAD	cis	rs2153535	0.585	rs6915130	ENSG00000230939.1	RP11-314C16.1	-9.09	3.18e-18	2.26e-15	-0.48	-0.39	Motion sickness;	chr6:8661262	chr6:8784178~8785445:+
PRAD	cis	rs2739330	0.734	rs2000467	ENSG00000235689.1	AP000351.13	-9.09	3.18e-18	2.27e-15	-0.48	-0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:24006305~24008258:-
PRAD	cis	rs6991838	0.765	rs6472219	ENSG00000272010.1	CTD-3025N20.3	9.08	3.21e-18	2.29e-15	0.38	0.39	Intelligence (multi-trait analysis);	chr8:65644487	chr8:65591850~65592472:-
PRAD	cis	rs13217239	0.608	rs6930508	ENSG00000241549.7	GUSBP2	-9.08	3.21e-18	2.29e-15	-0.43	-0.39	Schizophrenia;	chr6:27085363	chr6:26871484~26956554:-
PRAD	cis	rs13217239	0.646	rs2142685	ENSG00000241549.7	GUSBP2	-9.08	3.21e-18	2.29e-15	-0.43	-0.39	Schizophrenia;	chr6:27086718	chr6:26871484~26956554:-
PRAD	cis	rs4835473	0.932	rs1842484	ENSG00000251600.4	RP11-673E1.1	9.08	3.21e-18	2.29e-15	0.49	0.39	Immature fraction of reticulocytes;	chr4:143793829	chr4:143912331~143982454:+
PRAD	cis	rs2739330	0.796	rs5760097	ENSG00000099984.9	GSTT2	-9.08	3.21e-18	2.29e-15	-0.53	-0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23980123~23983911:+
PRAD	cis	rs2404602	0.716	rs67888330	ENSG00000259422.1	RP11-593F23.1	9.08	3.22e-18	2.29e-15	0.49	0.39	Blood metabolite levels;	chr15:76460142	chr15:76174891~76181486:-
PRAD	cis	rs465969	0.546	rs77990243	ENSG00000255389.1	C6orf3	-9.08	3.23e-18	2.3e-15	-0.73	-0.39	Psoriasis;	chr6:111513183	chr6:111599875~111602295:+
PRAD	cis	rs2274273	0.905	rs8007614	ENSG00000258413.1	RP11-665C16.6	-9.08	3.23e-18	2.3e-15	-0.5	-0.39	Protein biomarker;	chr14:55119857	chr14:55262767~55272075:-
PRAD	cis	rs4713118	0.869	rs9283883	ENSG00000280107.1	AL022393.9	-9.08	3.23e-18	2.3e-15	-0.49	-0.39	Parkinson's disease;	chr6:27747691	chr6:28170845~28172521:+
PRAD	cis	rs4718428	0.672	rs4718412	ENSG00000230295.1	RP11-458F8.2	9.08	3.24e-18	2.31e-15	0.3	0.39	Corneal structure;	chr7:66821880	chr7:66880708~66882981:+
PRAD	cis	rs875971	0.838	rs2173570	ENSG00000237310.1	GS1-124K5.4	-9.08	3.25e-18	2.31e-15	-0.35	-0.39	Aortic root size;	chr7:66297976	chr7:66493706~66495474:+
PRAD	cis	rs4713118	0.869	rs10214440	ENSG00000280107.1	AL022393.9	-9.08	3.26e-18	2.32e-15	-0.49	-0.39	Parkinson's disease;	chr6:27734661	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.869	rs6902689	ENSG00000280107.1	AL022393.9	-9.08	3.26e-18	2.32e-15	-0.49	-0.39	Parkinson's disease;	chr6:27741662	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.869	rs9468214	ENSG00000280107.1	AL022393.9	-9.08	3.26e-18	2.32e-15	-0.49	-0.39	Parkinson's disease;	chr6:27745520	chr6:28170845~28172521:+
PRAD	cis	rs2404602	0.692	rs2117369	ENSG00000259422.1	RP11-593F23.1	9.08	3.27e-18	2.33e-15	0.49	0.39	Blood metabolite levels;	chr15:76456520	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.716	rs2164101	ENSG00000259422.1	RP11-593F23.1	9.08	3.27e-18	2.33e-15	0.49	0.39	Blood metabolite levels;	chr15:76456776	chr15:76174891~76181486:-
PRAD	cis	rs2739330	0.587	rs4820571	ENSG00000206090.4	AP000350.7	9.08	3.27e-18	2.33e-15	0.49	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23939998~23942798:+
PRAD	cis	rs4820294	1	rs62236667	ENSG00000233360.4	Z83844.1	9.08	3.29e-18	2.34e-15	0.5	0.39	Fat distribution (HIV);	chr22:37665513	chr22:37641832~37658377:-
PRAD	cis	rs4820294	1	rs62236668	ENSG00000233360.4	Z83844.1	9.08	3.29e-18	2.34e-15	0.5	0.39	Fat distribution (HIV);	chr22:37667863	chr22:37641832~37658377:-
PRAD	cis	rs4820294	1	rs713835	ENSG00000233360.4	Z83844.1	9.08	3.29e-18	2.34e-15	0.5	0.39	Fat distribution (HIV);	chr22:37668643	chr22:37641832~37658377:-
PRAD	cis	rs4820294	1	rs739139	ENSG00000233360.4	Z83844.1	9.08	3.29e-18	2.34e-15	0.5	0.39	Fat distribution (HIV);	chr22:37671004	chr22:37641832~37658377:-
PRAD	cis	rs4835473	0.897	rs6537172	ENSG00000251600.4	RP11-673E1.1	9.08	3.29e-18	2.34e-15	0.49	0.39	Immature fraction of reticulocytes;	chr4:143710612	chr4:143912331~143982454:+
PRAD	cis	rs7115242	1	rs7115242	ENSG00000254851.1	RP11-109L13.1	9.08	3.3e-18	2.35e-15	0.85	0.39	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117037567	chr11:117135528~117138582:+
PRAD	cis	rs17023223	0.537	rs12072768	ENSG00000231365.4	RP11-418J17.1	-9.08	3.31e-18	2.36e-15	-0.4	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119051295	chr1:119140396~119275973:+
PRAD	cis	rs2282300	1	rs12799529	ENSG00000254532.1	RP11-624D11.2	9.08	3.32e-18	2.36e-15	0.54	0.39	Morning vs. evening chronotype;	chr11:30387005	chr11:30044058~30084343:-
PRAD	cis	rs4835473	0.932	rs17694797	ENSG00000251600.4	RP11-673E1.1	-9.08	3.32e-18	2.36e-15	-0.49	-0.39	Immature fraction of reticulocytes;	chr4:143778812	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs35947975	ENSG00000251600.4	RP11-673E1.1	-9.08	3.32e-18	2.36e-15	-0.49	-0.39	Immature fraction of reticulocytes;	chr4:143778969	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.778	rs75562808	ENSG00000251600.4	RP11-673E1.1	-9.08	3.32e-18	2.36e-15	-0.49	-0.39	Immature fraction of reticulocytes;	chr4:143779065	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs1375987	ENSG00000251600.4	RP11-673E1.1	-9.08	3.32e-18	2.36e-15	-0.49	-0.39	Immature fraction of reticulocytes;	chr4:143779622	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs7687151	ENSG00000251600.4	RP11-673E1.1	-9.08	3.32e-18	2.36e-15	-0.49	-0.39	Immature fraction of reticulocytes;	chr4:143781681	chr4:143912331~143982454:+
PRAD	cis	rs8072100	0.967	rs11871606	ENSG00000228782.6	CTD-2026D20.3	-9.08	3.33e-18	2.37e-15	-0.43	-0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47655408	chr17:47450568~47492492:-
PRAD	cis	rs2739330	0.828	rs5760102	ENSG00000235689.1	AP000351.13	9.08	3.34e-18	2.37e-15	0.47	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:24006305~24008258:-
PRAD	cis	rs5769707	0.605	rs2071900	ENSG00000188511.11	C22orf34	9.08	3.35e-18	2.38e-15	0.47	0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49658527	chr22:49414524~49657542:-
PRAD	cis	rs2404602	0.716	rs1588961	ENSG00000259422.1	RP11-593F23.1	9.08	3.35e-18	2.38e-15	0.49	0.39	Blood metabolite levels;	chr15:76460357	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.716	rs12592171	ENSG00000259422.1	RP11-593F23.1	9.08	3.35e-18	2.38e-15	0.49	0.39	Blood metabolite levels;	chr15:76462792	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.679	rs12899871	ENSG00000259422.1	RP11-593F23.1	9.08	3.35e-18	2.38e-15	0.49	0.39	Blood metabolite levels;	chr15:76465006	chr15:76174891~76181486:-
PRAD	cis	rs10515750	0.643	rs10054755	ENSG00000248544.2	CTB-47B11.3	9.08	3.36e-18	2.39e-15	0.73	0.39	Lung function (FEV1/FVC);	chr5:157384037	chr5:157375741~157384950:-
PRAD	cis	rs10515750	0.643	rs10063539	ENSG00000248544.2	CTB-47B11.3	9.08	3.36e-18	2.39e-15	0.73	0.39	Lung function (FEV1/FVC);	chr5:157384666	chr5:157375741~157384950:-
PRAD	cis	rs6517329	0.513	rs2284622	ENSG00000236830.5	CBR3-AS1	9.08	3.36e-18	2.39e-15	0.41	0.39	Schizophrenia;	chr21:36172082	chr21:36131767~36175815:-
PRAD	cis	rs11098499	0.779	rs10011097	ENSG00000245958.5	RP11-33B1.1	-9.08	3.36e-18	2.39e-15	-0.38	-0.39	Corneal astigmatism;	chr4:119389204	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.954	rs7437420	ENSG00000245958.5	RP11-33B1.1	-9.08	3.36e-18	2.39e-15	-0.38	-0.39	Corneal astigmatism;	chr4:119391748	chr4:119454791~119552025:+
PRAD	cis	rs4835473	0.932	rs6827971	ENSG00000251600.4	RP11-673E1.1	-9.08	3.37e-18	2.4e-15	-0.49	-0.39	Immature fraction of reticulocytes;	chr4:143822126	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs4835305	ENSG00000251600.4	RP11-673E1.1	-9.08	3.37e-18	2.4e-15	-0.49	-0.39	Immature fraction of reticulocytes;	chr4:143823646	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs11721700	ENSG00000251600.4	RP11-673E1.1	-9.08	3.37e-18	2.4e-15	-0.49	-0.39	Immature fraction of reticulocytes;	chr4:143824264	chr4:143912331~143982454:+
PRAD	cis	rs4820294	1	rs732856	ENSG00000233360.4	Z83844.1	-9.08	3.38e-18	2.4e-15	-0.5	-0.39	Fat distribution (HIV);	chr22:37664684	chr22:37641832~37658377:-
PRAD	cis	rs2153535	0.518	rs9393054	ENSG00000230939.1	RP11-314C16.1	-9.08	3.38e-18	2.4e-15	-0.48	-0.39	Motion sickness;	chr6:8647209	chr6:8784178~8785445:+
PRAD	cis	rs7811142	0.83	rs78256546	ENSG00000242294.5	STAG3L5P	9.08	3.38e-18	2.41e-15	0.26	0.39	Platelet count;	chr7:100355347	chr7:100336079~100351900:+
PRAD	cis	rs8177376	0.953	rs529328	ENSG00000254905.1	RP11-712L6.7	9.08	3.39e-18	2.41e-15	0.49	0.39	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126263746	chr11:126292922~126294254:-
PRAD	cis	rs10129255	0.5	rs10131875	ENSG00000223648.3	IGHV3-64	9.08	3.39e-18	2.41e-15	0.34	0.39	Kawasaki disease;	chr14:106792798	chr14:106643132~106658258:-
PRAD	cis	rs875971	0.965	rs6971509	ENSG00000237310.1	GS1-124K5.4	-9.08	3.4e-18	2.42e-15	-0.35	-0.39	Aortic root size;	chr7:66249983	chr7:66493706~66495474:+
PRAD	cis	rs8072100	0.905	rs11651766	ENSG00000228782.6	CTD-2026D20.3	9.08	3.41e-18	2.42e-15	0.43	0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47497565	chr17:47450568~47492492:-
PRAD	cis	rs8072100	0.905	rs9901869	ENSG00000228782.6	CTD-2026D20.3	9.08	3.41e-18	2.42e-15	0.43	0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47497840	chr17:47450568~47492492:-
PRAD	cis	rs2274273	0.84	rs72715769	ENSG00000258413.1	RP11-665C16.6	-9.08	3.41e-18	2.42e-15	-0.51	-0.39	Protein biomarker;	chr14:55295711	chr14:55262767~55272075:-
PRAD	cis	rs10129255	0.5	rs11628999	ENSG00000223648.3	IGHV3-64	9.08	3.41e-18	2.43e-15	0.34	0.39	Kawasaki disease;	chr14:106800208	chr14:106643132~106658258:-
PRAD	cis	rs2255336	0.938	rs1478309	ENSG00000245648.1	RP11-277P12.20	9.08	3.42e-18	2.43e-15	0.58	0.39	Blood protein levels;	chr12:10389146	chr12:10363769~10398506:+
PRAD	cis	rs2255336	0.938	rs2045876	ENSG00000245648.1	RP11-277P12.20	9.08	3.42e-18	2.43e-15	0.58	0.39	Blood protein levels;	chr12:10389233	chr12:10363769~10398506:+
PRAD	cis	rs853679	0.657	rs1778483	ENSG00000216901.1	AL022393.7	9.07	3.46e-18	2.46e-15	0.51	0.39	Depression;	chr6:28273214	chr6:28176188~28176674:+
PRAD	cis	rs853679	0.657	rs1778482	ENSG00000216901.1	AL022393.7	9.07	3.46e-18	2.46e-15	0.51	0.39	Depression;	chr6:28273215	chr6:28176188~28176674:+
PRAD	cis	rs6142102	1	rs2378078	ENSG00000276073.1	RP5-1125A11.7	-9.07	3.46e-18	2.46e-15	-0.41	-0.39	Skin pigmentation;	chr20:34126922	chr20:33985617~33988989:-
PRAD	cis	rs2933343	0.649	rs789219	ENSG00000231305.3	RP11-723O4.2	9.07	3.47e-18	2.47e-15	0.37	0.39	IgG glycosylation;	chr3:128873677	chr3:128861313~128871540:-
PRAD	cis	rs2015599	0.623	rs1072724	ENSG00000257176.2	RP11-996F15.2	9.07	3.48e-18	2.47e-15	0.44	0.39	Platelet count;Mean platelet volume;	chr12:29289205	chr12:29280418~29317848:-
PRAD	cis	rs2015599	0.623	rs7358667	ENSG00000257176.2	RP11-996F15.2	9.07	3.48e-18	2.47e-15	0.44	0.39	Platelet count;Mean platelet volume;	chr12:29290236	chr12:29280418~29317848:-
PRAD	cis	rs4835473	0.897	rs6835827	ENSG00000251600.4	RP11-673E1.1	9.07	3.48e-18	2.47e-15	0.49	0.39	Immature fraction of reticulocytes;	chr4:143712803	chr4:143912331~143982454:+
PRAD	cis	rs10262624	0.935	rs4722283	ENSG00000234286.1	AC006026.13	9.07	3.48e-18	2.47e-15	0.44	0.39	Schizophrenia;	chr7:23866595	chr7:23680195~23680786:-
PRAD	cis	rs2274273	0.714	rs7154889	ENSG00000258413.1	RP11-665C16.6	-9.07	3.5e-18	2.48e-15	-0.51	-0.39	Protein biomarker;	chr14:55340167	chr14:55262767~55272075:-
PRAD	cis	rs875971	0.965	rs7794930	ENSG00000237310.1	GS1-124K5.4	-9.07	3.5e-18	2.48e-15	-0.35	-0.39	Aortic root size;	chr7:66313559	chr7:66493706~66495474:+
PRAD	cis	rs2404602	0.716	rs17461634	ENSG00000259422.1	RP11-593F23.1	9.07	3.51e-18	2.49e-15	0.49	0.39	Blood metabolite levels;	chr15:76471766	chr15:76174891~76181486:-
PRAD	cis	rs7772486	0.623	rs735535	ENSG00000235652.6	RP11-545I5.3	-9.07	3.52e-18	2.5e-15	-0.4	-0.39	Lobe attachment (rater-scored or self-reported);	chr6:145715693	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.566	rs735536	ENSG00000235652.6	RP11-545I5.3	-9.07	3.52e-18	2.5e-15	-0.4	-0.39	Lobe attachment (rater-scored or self-reported);	chr6:145715696	chr6:145799409~145886585:+
PRAD	cis	rs67311347	1	rs4973993	ENSG00000223797.4	ENTPD3-AS1	9.07	3.53e-18	2.5e-15	0.36	0.39	Renal cell carcinoma;	chr3:40411469	chr3:40313802~40453329:-
PRAD	cis	rs67311347	1	rs4973994	ENSG00000223797.4	ENTPD3-AS1	9.07	3.53e-18	2.5e-15	0.36	0.39	Renal cell carcinoma;	chr3:40411533	chr3:40313802~40453329:-
PRAD	cis	rs67311347	1	rs9833430	ENSG00000223797.4	ENTPD3-AS1	9.07	3.53e-18	2.5e-15	0.36	0.39	Renal cell carcinoma;	chr3:40417552	chr3:40313802~40453329:-
PRAD	cis	rs67311347	0.784	rs13326389	ENSG00000223797.4	ENTPD3-AS1	9.07	3.53e-18	2.5e-15	0.36	0.39	Renal cell carcinoma;	chr3:40418233	chr3:40313802~40453329:-
PRAD	cis	rs67311347	1	rs12492035	ENSG00000223797.4	ENTPD3-AS1	9.07	3.53e-18	2.5e-15	0.36	0.39	Renal cell carcinoma;	chr3:40425619	chr3:40313802~40453329:-
PRAD	cis	rs67311347	1	rs73078158	ENSG00000223797.4	ENTPD3-AS1	9.07	3.53e-18	2.5e-15	0.36	0.39	Renal cell carcinoma;	chr3:40431076	chr3:40313802~40453329:-
PRAD	cis	rs67311347	1	rs73078164	ENSG00000223797.4	ENTPD3-AS1	9.07	3.53e-18	2.5e-15	0.36	0.39	Renal cell carcinoma;	chr3:40438798	chr3:40313802~40453329:-
PRAD	cis	rs7712401	0.601	rs173480	ENSG00000263432.2	RN7SL689P	9.07	3.53e-18	2.5e-15	0.4	0.39	Mean platelet volume;	chr5:122918436	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.601	rs246265	ENSG00000263432.2	RN7SL689P	9.07	3.53e-18	2.5e-15	0.4	0.39	Mean platelet volume;	chr5:122919255	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.607	rs246270	ENSG00000263432.2	RN7SL689P	9.07	3.53e-18	2.5e-15	0.4	0.39	Mean platelet volume;	chr5:122922954	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.562	rs377316	ENSG00000263432.2	RN7SL689P	9.07	3.53e-18	2.5e-15	0.4	0.39	Mean platelet volume;	chr5:122924180	chr5:123022487~123022783:-
PRAD	cis	rs2348418	0.864	rs7977817	ENSG00000247934.4	RP11-967K21.1	9.07	3.54e-18	2.51e-15	0.36	0.39	Lung function (FEV1);Lung function (FVC);	chr12:28562549	chr12:28163298~28190738:-
PRAD	cis	rs2348418	0.831	rs7977525	ENSG00000247934.4	RP11-967K21.1	9.07	3.54e-18	2.51e-15	0.36	0.39	Lung function (FEV1);Lung function (FVC);	chr12:28562584	chr12:28163298~28190738:-
PRAD	cis	rs2348418	0.864	rs7977850	ENSG00000247934.4	RP11-967K21.1	9.07	3.54e-18	2.51e-15	0.36	0.39	Lung function (FEV1);Lung function (FVC);	chr12:28562715	chr12:28163298~28190738:-
PRAD	cis	rs2348418	0.864	rs11609924	ENSG00000247934.4	RP11-967K21.1	9.07	3.54e-18	2.51e-15	0.36	0.39	Lung function (FEV1);Lung function (FVC);	chr12:28563197	chr12:28163298~28190738:-
PRAD	cis	rs9487094	0.567	rs13196280	ENSG00000260273.1	RP11-425D10.10	9.07	3.56e-18	2.52e-15	0.58	0.39	Height;	chr6:109764163	chr6:109382795~109383666:+
PRAD	cis	rs6452524	0.836	rs10041617	ENSG00000249664.1	CTD-2227C6.2	9.07	3.56e-18	2.53e-15	0.47	0.39	Hypertension (SNP x SNP interaction);	chr5:83096535	chr5:83012285~83013109:-
PRAD	cis	rs11123170	0.529	rs1015755	ENSG00000274877.1	RP11-65I12.1	-9.07	3.59e-18	2.54e-15	-0.61	-0.39	Renal function-related traits (BUN);	chr2:113210730	chr2:113237595~113240825:+
PRAD	cis	rs2348418	0.864	rs2137071	ENSG00000247934.4	RP11-967K21.1	9.07	3.6e-18	2.56e-15	0.36	0.39	Lung function (FEV1);Lung function (FVC);	chr12:28563797	chr12:28163298~28190738:-
PRAD	cis	rs150992	0.57	rs7710032	ENSG00000248489.1	CTD-2007H13.3	-9.07	3.61e-18	2.56e-15	-0.44	-0.39	Body mass index;	chr5:99007501	chr5:98929171~98995013:+
PRAD	cis	rs2255336	0.938	rs2734561	ENSG00000245648.1	RP11-277P12.20	9.07	3.61e-18	2.56e-15	0.57	0.39	Blood protein levels;	chr12:10402386	chr12:10363769~10398506:+
PRAD	cis	rs2348418	0.864	rs7968563	ENSG00000247934.4	RP11-967K21.1	9.07	3.63e-18	2.57e-15	0.36	0.39	Lung function (FEV1);Lung function (FVC);	chr12:28563844	chr12:28163298~28190738:-
PRAD	cis	rs2348418	0.864	rs2137072	ENSG00000247934.4	RP11-967K21.1	9.07	3.63e-18	2.57e-15	0.36	0.39	Lung function (FEV1);Lung function (FVC);	chr12:28563872	chr12:28163298~28190738:-
PRAD	cis	rs4835473	0.932	rs13121861	ENSG00000251600.4	RP11-673E1.1	-9.07	3.64e-18	2.58e-15	-0.49	-0.39	Immature fraction of reticulocytes;	chr4:143814007	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.9	rs4835303	ENSG00000251600.4	RP11-673E1.1	-9.07	3.64e-18	2.58e-15	-0.49	-0.39	Immature fraction of reticulocytes;	chr4:143821533	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs4835034	ENSG00000251600.4	RP11-673E1.1	-9.07	3.64e-18	2.58e-15	-0.49	-0.39	Immature fraction of reticulocytes;	chr4:143821538	chr4:143912331~143982454:+
PRAD	cis	rs9308062	1	rs9308062	ENSG00000273449.1	RP11-218F10.3	-9.07	3.64e-18	2.58e-15	-0.31	-0.39	Small cell lung carcinoma;	chr4:163517048	chr4:163529771~163530697:+
PRAD	cis	rs3779195	0.86	rs12704986	ENSG00000272950.1	RP11-307C18.1	9.07	3.65e-18	2.59e-15	0.6	0.39	Sex hormone-binding globulin levels;	chr7:98357118	chr7:98322853~98323430:+
PRAD	cis	rs3779195	0.858	rs3779196	ENSG00000272950.1	RP11-307C18.1	9.07	3.65e-18	2.59e-15	0.6	0.39	Sex hormone-binding globulin levels;	chr7:98360794	chr7:98322853~98323430:+
PRAD	cis	rs3779195	0.789	rs6965424	ENSG00000272950.1	RP11-307C18.1	9.07	3.65e-18	2.59e-15	0.6	0.39	Sex hormone-binding globulin levels;	chr7:98361813	chr7:98322853~98323430:+
PRAD	cis	rs7189233	0.55	rs17193176	ENSG00000279344.1	RP11-44F14.7	9.07	3.65e-18	2.59e-15	0.36	0.39	Intelligence (multi-trait analysis);	chr16:53484316	chr16:53478957~53481550:-
PRAD	cis	rs2283792	0.764	rs2298432	ENSG00000224086.5	LL22NC03-86G7.1	-9.07	3.66e-18	2.59e-15	-0.47	-0.39	Multiple sclerosis;	chr22:21768900	chr22:21938293~21977632:+
PRAD	cis	rs12817211	0.502	rs7135322	ENSG00000272368.2	RP4-605O3.4	-9.07	3.67e-18	2.6e-15	-0.39	-0.39	Colorectal or endometrial cancer;	chr12:50118065	chr12:50112197~50165618:+
PRAD	cis	rs67311347	1	rs73078169	ENSG00000223797.4	ENTPD3-AS1	9.07	3.68e-18	2.61e-15	0.36	0.39	Renal cell carcinoma;	chr3:40442307	chr3:40313802~40453329:-
PRAD	cis	rs875971	0.895	rs7788984	ENSG00000237310.1	GS1-124K5.4	9.07	3.71e-18	2.63e-15	0.35	0.39	Aortic root size;	chr7:66450629	chr7:66493706~66495474:+
PRAD	cis	rs11098499	0.954	rs10034623	ENSG00000245958.5	RP11-33B1.1	-9.06	3.73e-18	2.64e-15	-0.38	-0.39	Corneal astigmatism;	chr4:119476674	chr4:119454791~119552025:+
PRAD	cis	rs9309711	0.506	rs9284794	ENSG00000225234.1	TRAPPC12-AS1	-9.06	3.75e-18	2.66e-15	-0.4	-0.39	Neurofibrillary tangles;	chr2:3488281	chr2:3481242~3482409:-
PRAD	cis	rs7772486	0.686	rs1292336	ENSG00000235652.6	RP11-545I5.3	-9.06	3.77e-18	2.67e-15	-0.41	-0.39	Lobe attachment (rater-scored or self-reported);	chr6:145646682	chr6:145799409~145886585:+
PRAD	cis	rs2274273	0.84	rs66486619	ENSG00000258413.1	RP11-665C16.6	-9.06	3.78e-18	2.67e-15	-0.5	-0.39	Protein biomarker;	chr14:55402837	chr14:55262767~55272075:-
PRAD	cis	rs67311347	1	rs1123019	ENSG00000223797.4	ENTPD3-AS1	9.06	3.79e-18	2.68e-15	0.36	0.39	Renal cell carcinoma;	chr3:40446789	chr3:40313802~40453329:-
PRAD	cis	rs4927850	1	rs7614767	ENSG00000242086.7	LINC00969	9.06	3.8e-18	2.69e-15	0.34	0.39	Pancreatic cancer;	chr3:196026580	chr3:195658062~195739964:+
PRAD	cis	rs2564921	0.704	rs35671032	ENSG00000242142.1	SERBP1P3	-9.06	3.81e-18	2.69e-15	-0.45	-0.39	Height;	chr3:52972039	chr3:53064283~53065091:-
PRAD	cis	rs2274273	0.837	rs10141552	ENSG00000258413.1	RP11-665C16.6	9.06	3.81e-18	2.7e-15	0.5	0.39	Protein biomarker;	chr14:55279373	chr14:55262767~55272075:-
PRAD	cis	rs2404602	1	rs2120107	ENSG00000259422.1	RP11-593F23.1	9.06	3.82e-18	2.7e-15	0.47	0.39	Blood metabolite levels;	chr15:76577448	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.716	rs284895	ENSG00000259422.1	RP11-593F23.1	-9.06	3.83e-18	2.71e-15	-0.48	-0.39	Blood metabolite levels;	chr15:76458884	chr15:76174891~76181486:-
PRAD	cis	rs11951515	0.663	rs1564198	ENSG00000188850.9	RP11-159F24.2	-9.06	3.83e-18	2.71e-15	-0.47	-0.39	Metabolite levels  (X-11787);	chr5:43338820	chr5:43336164~43348716:+
PRAD	cis	rs4713118	0.621	rs4713132	ENSG00000226314.6	ZNF192P1	-9.06	3.85e-18	2.72e-15	-0.53	-0.39	Parkinson's disease;	chr6:28066257	chr6:28161781~28169594:+
PRAD	cis	rs4713118	0.621	rs4713133	ENSG00000226314.6	ZNF192P1	-9.06	3.85e-18	2.72e-15	-0.53	-0.39	Parkinson's disease;	chr6:28066263	chr6:28161781~28169594:+
PRAD	cis	rs4713118	0.621	rs4713134	ENSG00000226314.6	ZNF192P1	-9.06	3.85e-18	2.72e-15	-0.53	-0.39	Parkinson's disease;	chr6:28066343	chr6:28161781~28169594:+
PRAD	cis	rs4713118	0.621	rs9368548	ENSG00000226314.6	ZNF192P1	-9.06	3.85e-18	2.72e-15	-0.53	-0.39	Parkinson's disease;	chr6:28066959	chr6:28161781~28169594:+
PRAD	cis	rs1075232	1	rs56396205	ENSG00000270055.1	CTD-3092A11.2	-9.06	3.86e-18	2.73e-15	-0.83	-0.39	Survival in colorectal cancer (non-distant metastatic);	chr15:31386182	chr15:30487963~30490313:+
PRAD	cis	rs1075232	1	rs12438318	ENSG00000270055.1	CTD-3092A11.2	-9.06	3.86e-18	2.73e-15	-0.83	-0.39	Survival in colorectal cancer (non-distant metastatic);	chr15:31388242	chr15:30487963~30490313:+
PRAD	cis	rs7811142	1	rs2897358	ENSG00000242294.5	STAG3L5P	9.06	3.91e-18	2.77e-15	0.26	0.39	Platelet count;	chr7:100491017	chr7:100336079~100351900:+
PRAD	cis	rs7811142	1	rs7787620	ENSG00000242294.5	STAG3L5P	9.06	3.91e-18	2.77e-15	0.26	0.39	Platelet count;	chr7:100491611	chr7:100336079~100351900:+
PRAD	cis	rs9326248	0.52	rs236919	ENSG00000280143.1	AP000892.6	9.06	3.91e-18	2.77e-15	0.3	0.39	Blood protein levels;	chr11:117224645	chr11:117204967~117210292:+
PRAD	cis	rs2739330	0.828	rs5760098	ENSG00000235689.1	AP000351.13	9.06	3.92e-18	2.77e-15	0.47	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:24006305~24008258:-
PRAD	cis	rs11159086	0.793	rs1029703	ENSG00000259005.1	RP3-449M8.6	9.06	3.93e-18	2.78e-15	0.5	0.39	Advanced glycation end-product levels;	chr14:74473899	chr14:74474007~74474864:-
PRAD	cis	rs11159086	0.793	rs1029702	ENSG00000259005.1	RP3-449M8.6	9.06	3.93e-18	2.78e-15	0.5	0.39	Advanced glycation end-product levels;	chr14:74473909	chr14:74474007~74474864:-
PRAD	cis	rs875971	0.898	rs6977501	ENSG00000237310.1	GS1-124K5.4	-9.06	3.94e-18	2.78e-15	-0.35	-0.39	Aortic root size;	chr7:66228355	chr7:66493706~66495474:+
PRAD	cis	rs3858145	0.588	rs61854831	ENSG00000233590.1	RP11-153K11.3	-9.06	3.94e-18	2.79e-15	-0.56	-0.39	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68276080	chr10:68233251~68242379:-
PRAD	cis	rs3858145	0.588	rs55888445	ENSG00000233590.1	RP11-153K11.3	-9.06	3.94e-18	2.79e-15	-0.56	-0.39	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68276699	chr10:68233251~68242379:-
PRAD	cis	rs67311347	1	rs9857824	ENSG00000223797.4	ENTPD3-AS1	9.06	3.94e-18	2.79e-15	0.36	0.39	Renal cell carcinoma;	chr3:40417921	chr3:40313802~40453329:-
PRAD	cis	rs2638953	0.888	rs1871152	ENSG00000278733.1	RP11-425D17.1	9.06	3.95e-18	2.79e-15	0.46	0.39	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28226893	chr12:28185625~28186190:-
PRAD	cis	rs9399137	0.561	rs11753985	ENSG00000232876.1	CTA-212D2.2	-9.06	3.95e-18	2.79e-15	-0.5	-0.39	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134959300	chr6:135055033~135060550:+
PRAD	cis	rs4713118	0.869	rs9461405	ENSG00000280107.1	AL022393.9	-9.06	4.01e-18	2.83e-15	-0.49	-0.39	Parkinson's disease;	chr6:27751596	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.869	rs7776351	ENSG00000280107.1	AL022393.9	9.06	4.01e-18	2.83e-15	0.49	0.39	Parkinson's disease;	chr6:27758952	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.869	rs7773070	ENSG00000280107.1	AL022393.9	-9.06	4.01e-18	2.83e-15	-0.49	-0.39	Parkinson's disease;	chr6:27761048	chr6:28170845~28172521:+
PRAD	cis	rs9322193	0.566	rs5024811	ENSG00000216906.2	RP11-350J20.9	-9.06	4.01e-18	2.83e-15	-0.5	-0.39	Lung cancer;	chr6:149924898	chr6:149904243~149906418:+
PRAD	cis	rs853679	0.517	rs868987	ENSG00000226314.6	ZNF192P1	9.06	4.03e-18	2.85e-15	0.53	0.39	Depression;	chr6:28142370	chr6:28161781~28169594:+
PRAD	cis	rs2933343	0.621	rs728838	ENSG00000231305.3	RP11-723O4.2	9.05	4.06e-18	2.87e-15	0.37	0.39	IgG glycosylation;	chr3:128870170	chr3:128861313~128871540:-
PRAD	cis	rs2933343	0.601	rs1680758	ENSG00000231305.3	RP11-723O4.2	9.05	4.06e-18	2.87e-15	0.37	0.39	IgG glycosylation;	chr3:128876054	chr3:128861313~128871540:-
PRAD	cis	rs2933343	0.649	rs789214	ENSG00000231305.3	RP11-723O4.2	9.05	4.06e-18	2.87e-15	0.37	0.39	IgG glycosylation;	chr3:128876152	chr3:128861313~128871540:-
PRAD	cis	rs2933343	0.729	rs789224	ENSG00000231305.3	RP11-723O4.2	9.05	4.06e-18	2.87e-15	0.37	0.39	IgG glycosylation;	chr3:128879388	chr3:128861313~128871540:-
PRAD	cis	rs2933343	0.761	rs789225	ENSG00000231305.3	RP11-723O4.2	9.05	4.06e-18	2.87e-15	0.37	0.39	IgG glycosylation;	chr3:128881386	chr3:128861313~128871540:-
PRAD	cis	rs2933343	0.7	rs789233	ENSG00000231305.3	RP11-723O4.2	9.05	4.06e-18	2.87e-15	0.37	0.39	IgG glycosylation;	chr3:128884307	chr3:128861313~128871540:-
PRAD	cis	rs524281	1	rs547087	ENSG00000255320.1	RP11-755F10.1	-9.05	4.07e-18	2.87e-15	-0.56	-0.39	Electroencephalogram traits;	chr11:66078793	chr11:66244840~66246239:-
PRAD	cis	rs1150668	0.835	rs203869	ENSG00000204709.4	LINC01556	9.05	4.07e-18	2.88e-15	0.48	0.39	Pubertal anthropometrics;	chr6:28073041	chr6:28943877~28944537:+
PRAD	cis	rs2404602	0.716	rs12907805	ENSG00000259422.1	RP11-593F23.1	9.05	4.08e-18	2.88e-15	0.48	0.39	Blood metabolite levels;	chr15:76398265	chr15:76174891~76181486:-
PRAD	cis	rs4835473	0.932	rs2127788	ENSG00000251600.4	RP11-673E1.1	9.05	4.08e-18	2.88e-15	0.49	0.39	Immature fraction of reticulocytes;	chr4:143741996	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs6852195	ENSG00000251600.4	RP11-673E1.1	9.05	4.08e-18	2.88e-15	0.49	0.39	Immature fraction of reticulocytes;	chr4:143742584	chr4:143912331~143982454:+
PRAD	cis	rs1930961	1	rs6004673	ENSG00000272942.1	CTA-246H3.12	-9.05	4.08e-18	2.89e-15	-0.62	-0.39	Bipolar disorder with mood-incongruent psychosis;	chr22:25489386	chr22:25434324~25435070:-
PRAD	cis	rs13217239	0.646	rs7768407	ENSG00000241549.7	GUSBP2	9.05	4.08e-18	2.89e-15	0.43	0.39	Schizophrenia;	chr6:27049016	chr6:26871484~26956554:-
PRAD	cis	rs172166	0.694	rs203876	ENSG00000280107.1	AL022393.9	-9.05	4.09e-18	2.89e-15	-0.47	-0.39	Cardiac Troponin-T levels;	chr6:28078895	chr6:28170845~28172521:+
PRAD	cis	rs172166	0.694	rs203877	ENSG00000280107.1	AL022393.9	-9.05	4.09e-18	2.89e-15	-0.47	-0.39	Cardiac Troponin-T levels;	chr6:28080846	chr6:28170845~28172521:+
PRAD	cis	rs2348418	0.864	rs6487687	ENSG00000247934.4	RP11-967K21.1	9.05	4.09e-18	2.89e-15	0.36	0.39	Lung function (FEV1);Lung function (FVC);	chr12:28558230	chr12:28163298~28190738:-
PRAD	cis	rs741668	0.641	rs9562637	ENSG00000235903.6	CPB2-AS1	-9.05	4.09e-18	2.89e-15	-0.46	-0.39	Cerebrospinal fluid clusterin levels;	chr13:46071410	chr13:46052806~46113332:+
PRAD	cis	rs10170846	0.53	rs56353541	ENSG00000261428.2	RP11-16P6.1	9.05	4.09e-18	2.89e-15	0.52	0.39	Schizophrenia (inflammation and infection response interaction);	chr2:222556468	chr2:222566899~222569719:-
PRAD	cis	rs2274273	0.805	rs28612464	ENSG00000258413.1	RP11-665C16.6	-9.05	4.1e-18	2.89e-15	-0.51	-0.39	Protein biomarker;	chr14:55349693	chr14:55262767~55272075:-
PRAD	cis	rs2274273	0.773	rs28430823	ENSG00000258413.1	RP11-665C16.6	-9.05	4.1e-18	2.89e-15	-0.51	-0.39	Protein biomarker;	chr14:55349842	chr14:55262767~55272075:-
PRAD	cis	rs2274273	0.87	rs17741831	ENSG00000258413.1	RP11-665C16.6	-9.05	4.1e-18	2.89e-15	-0.51	-0.39	Protein biomarker;	chr14:55349997	chr14:55262767~55272075:-
PRAD	cis	rs12220777	1	rs11201297	ENSG00000230091.5	TMEM254-AS1	9.05	4.1e-18	2.9e-15	0.72	0.39	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80033993	chr10:80046860~80078912:-
PRAD	cis	rs524281	0.692	rs2302884	ENSG00000255320.1	RP11-755F10.1	9.05	4.11e-18	2.9e-15	0.58	0.39	Electroencephalogram traits;	chr11:66056613	chr11:66244840~66246239:-
PRAD	cis	rs2348418	0.864	rs7978086	ENSG00000247934.4	RP11-967K21.1	9.05	4.12e-18	2.91e-15	0.36	0.39	Lung function (FEV1);Lung function (FVC);	chr12:28562761	chr12:28163298~28190738:-
PRAD	cis	rs4713118	0.869	rs9366700	ENSG00000280107.1	AL022393.9	-9.05	4.15e-18	2.93e-15	-0.49	-0.39	Parkinson's disease;	chr6:27729172	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.869	rs6456802	ENSG00000280107.1	AL022393.9	-9.05	4.15e-18	2.93e-15	-0.49	-0.39	Parkinson's disease;	chr6:27730576	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.869	rs9393851	ENSG00000280107.1	AL022393.9	-9.05	4.15e-18	2.93e-15	-0.49	-0.39	Parkinson's disease;	chr6:27731802	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.869	rs9461400	ENSG00000280107.1	AL022393.9	-9.05	4.15e-18	2.93e-15	-0.49	-0.39	Parkinson's disease;	chr6:27732780	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.869	rs9295742	ENSG00000280107.1	AL022393.9	-9.05	4.15e-18	2.93e-15	-0.49	-0.39	Parkinson's disease;	chr6:27735053	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.869	rs9461401	ENSG00000280107.1	AL022393.9	-9.05	4.15e-18	2.93e-15	-0.49	-0.39	Parkinson's disease;	chr6:27735512	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.869	rs6914924	ENSG00000280107.1	AL022393.9	-9.05	4.15e-18	2.93e-15	-0.49	-0.39	Parkinson's disease;	chr6:27743751	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.869	rs6930992	ENSG00000280107.1	AL022393.9	-9.05	4.15e-18	2.93e-15	-0.49	-0.39	Parkinson's disease;	chr6:27744341	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.869	rs6901520	ENSG00000280107.1	AL022393.9	-9.05	4.15e-18	2.93e-15	-0.49	-0.39	Parkinson's disease;	chr6:27746796	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.869	rs9295743	ENSG00000280107.1	AL022393.9	-9.05	4.15e-18	2.93e-15	-0.49	-0.39	Parkinson's disease;	chr6:27747323	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.869	rs9283880	ENSG00000280107.1	AL022393.9	-9.05	4.15e-18	2.93e-15	-0.49	-0.39	Parkinson's disease;	chr6:27747464	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.869	rs9283881	ENSG00000280107.1	AL022393.9	-9.05	4.15e-18	2.93e-15	-0.49	-0.39	Parkinson's disease;	chr6:27747476	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.869	rs9283882	ENSG00000280107.1	AL022393.9	-9.05	4.15e-18	2.93e-15	-0.49	-0.39	Parkinson's disease;	chr6:27747479	chr6:28170845~28172521:+
PRAD	cis	rs1185460	0.904	rs1003081	ENSG00000271751.1	RP11-110I1.14	9.05	4.18e-18	2.95e-15	0.54	0.39	Coronary artery disease;	chr11:119043282	chr11:119065263~119065677:-
PRAD	cis	rs9487094	0.614	rs13191444	ENSG00000260273.1	RP11-425D10.10	9.05	4.21e-18	2.97e-15	0.57	0.39	Height;	chr6:109762861	chr6:109382795~109383666:+
PRAD	cis	rs13217239	0.646	rs6937880	ENSG00000241549.7	GUSBP2	9.05	4.21e-18	2.97e-15	0.43	0.39	Schizophrenia;	chr6:27032457	chr6:26871484~26956554:-
PRAD	cis	rs13217239	0.621	rs12527231	ENSG00000241549.7	GUSBP2	9.05	4.21e-18	2.97e-15	0.43	0.39	Schizophrenia;	chr6:27033509	chr6:26871484~26956554:-
PRAD	cis	rs13217239	0.646	rs12523820	ENSG00000241549.7	GUSBP2	9.05	4.21e-18	2.97e-15	0.43	0.39	Schizophrenia;	chr6:27033723	chr6:26871484~26956554:-
PRAD	cis	rs2933343	1	rs789237	ENSG00000261159.1	RP11-723O4.9	9.05	4.22e-18	2.97e-15	0.36	0.39	IgG glycosylation;	chr3:128918118	chr3:128859716~128860526:-
PRAD	cis	rs2274273	0.87	rs8021583	ENSG00000258413.1	RP11-665C16.6	-9.05	4.26e-18	3e-15	-0.5	-0.39	Protein biomarker;	chr14:55282889	chr14:55262767~55272075:-
PRAD	cis	rs7712401	0.601	rs30029	ENSG00000263432.2	RN7SL689P	-9.05	4.26e-18	3e-15	-0.4	-0.39	Mean platelet volume;	chr5:122947475	chr5:123022487~123022783:-
PRAD	cis	rs150992	0.711	rs1069182	ENSG00000248489.1	CTD-2007H13.3	-9.05	4.28e-18	3.02e-15	-0.44	-0.39	Body mass index;	chr5:98806512	chr5:98929171~98995013:+
PRAD	cis	rs150992	0.673	rs992773	ENSG00000248489.1	CTD-2007H13.3	-9.05	4.28e-18	3.02e-15	-0.44	-0.39	Body mass index;	chr5:98808169	chr5:98929171~98995013:+
PRAD	cis	rs11159086	0.793	rs12432412	ENSG00000259005.1	RP3-449M8.6	9.05	4.28e-18	3.02e-15	0.5	0.39	Advanced glycation end-product levels;	chr14:74474294	chr14:74474007~74474864:-
PRAD	cis	rs11159086	0.793	rs1029700	ENSG00000259005.1	RP3-449M8.6	9.05	4.28e-18	3.02e-15	0.5	0.39	Advanced glycation end-product levels;	chr14:74474309	chr14:74474007~74474864:-
PRAD	cis	rs11159086	0.793	rs1029699	ENSG00000259005.1	RP3-449M8.6	9.05	4.28e-18	3.02e-15	0.5	0.39	Advanced glycation end-product levels;	chr14:74474790	chr14:74474007~74474864:-
PRAD	cis	rs67311347	1	rs4571217	ENSG00000223797.4	ENTPD3-AS1	9.05	4.29e-18	3.03e-15	0.36	0.39	Renal cell carcinoma;	chr3:40480482	chr3:40313802~40453329:-
PRAD	cis	rs7829975	0.514	rs2945873	ENSG00000253893.2	FAM85B	-9.05	4.29e-18	3.03e-15	-0.48	-0.39	Mood instability;	chr8:8402935	chr8:8167819~8226614:-
PRAD	cis	rs4713118	0.621	rs9295756	ENSG00000226314.6	ZNF192P1	-9.05	4.3e-18	3.03e-15	-0.53	-0.39	Parkinson's disease;	chr6:28065618	chr6:28161781~28169594:+
PRAD	cis	rs11098499	0.954	rs2389803	ENSG00000245958.5	RP11-33B1.1	9.05	4.3e-18	3.03e-15	0.38	0.39	Corneal astigmatism;	chr4:119472356	chr4:119454791~119552025:+
PRAD	cis	rs13217239	0.646	rs4403259	ENSG00000241549.7	GUSBP2	9.05	4.31e-18	3.04e-15	0.43	0.39	Schizophrenia;	chr6:27029838	chr6:26871484~26956554:-
PRAD	cis	rs11098499	0.866	rs72676074	ENSG00000245958.5	RP11-33B1.1	-9.05	4.33e-18	3.05e-15	-0.38	-0.39	Corneal astigmatism;	chr4:119438686	chr4:119454791~119552025:+
PRAD	cis	rs6700559	0.654	rs2809345	ENSG00000260088.1	RP11-92G12.3	9.05	4.33e-18	3.05e-15	0.48	0.39	Coronary artery disease;	chr1:200627135	chr1:200669507~200694250:+
PRAD	cis	rs2348418	0.864	rs11049716	ENSG00000247934.4	RP11-967K21.1	9.05	4.34e-18	3.06e-15	0.36	0.39	Lung function (FEV1);Lung function (FVC);	chr12:28564713	chr12:28163298~28190738:-
PRAD	cis	rs2348418	0.864	rs7136843	ENSG00000247934.4	RP11-967K21.1	9.05	4.34e-18	3.06e-15	0.36	0.39	Lung function (FEV1);Lung function (FVC);	chr12:28564875	chr12:28163298~28190738:-
PRAD	cis	rs11673344	0.73	rs826314	ENSG00000226686.6	LINC01535	9.04	4.4e-18	3.1e-15	0.53	0.39	Obesity-related traits;	chr19:36959533	chr19:37251912~37265535:+
PRAD	cis	rs67311347	0.826	rs9863679	ENSG00000223797.4	ENTPD3-AS1	9.04	4.41e-18	3.11e-15	0.36	0.39	Renal cell carcinoma;	chr3:40398123	chr3:40313802~40453329:-
PRAD	cis	rs13217239	0.646	rs35691005	ENSG00000241549.7	GUSBP2	9.04	4.43e-18	3.12e-15	0.43	0.39	Schizophrenia;	chr6:27004291	chr6:26871484~26956554:-
PRAD	cis	rs13217239	0.646	rs10946891	ENSG00000241549.7	GUSBP2	9.04	4.43e-18	3.12e-15	0.43	0.39	Schizophrenia;	chr6:27005436	chr6:26871484~26956554:-
PRAD	cis	rs13217239	0.646	rs12201393	ENSG00000241549.7	GUSBP2	9.04	4.43e-18	3.12e-15	0.43	0.39	Schizophrenia;	chr6:27007911	chr6:26871484~26956554:-
PRAD	cis	rs13217239	0.646	rs12209886	ENSG00000241549.7	GUSBP2	9.04	4.43e-18	3.12e-15	0.43	0.39	Schizophrenia;	chr6:27016978	chr6:26871484~26956554:-
PRAD	cis	rs6940638	0.531	rs12211984	ENSG00000241549.7	GUSBP2	9.04	4.43e-18	3.12e-15	0.43	0.39	Intelligence (multi-trait analysis);	chr6:27018275	chr6:26871484~26956554:-
PRAD	cis	rs13217239	0.646	rs10456351	ENSG00000241549.7	GUSBP2	9.04	4.43e-18	3.12e-15	0.43	0.39	Schizophrenia;	chr6:27019013	chr6:26871484~26956554:-
PRAD	cis	rs13217239	0.646	rs10456352	ENSG00000241549.7	GUSBP2	9.04	4.43e-18	3.12e-15	0.43	0.39	Schizophrenia;	chr6:27022579	chr6:26871484~26956554:-
PRAD	cis	rs13217239	0.646	rs4583981	ENSG00000241549.7	GUSBP2	9.04	4.43e-18	3.12e-15	0.43	0.39	Schizophrenia;	chr6:27024244	chr6:26871484~26956554:-
PRAD	cis	rs13217239	0.646	rs10946897	ENSG00000241549.7	GUSBP2	9.04	4.43e-18	3.12e-15	0.43	0.39	Schizophrenia;	chr6:27027472	chr6:26871484~26956554:-
PRAD	cis	rs6452524	0.868	rs1564379	ENSG00000249664.1	CTD-2227C6.2	9.04	4.44e-18	3.13e-15	0.46	0.39	Hypertension (SNP x SNP interaction);	chr5:83082143	chr5:83012285~83013109:-
PRAD	cis	rs3096299	0.933	rs3114848	ENSG00000274627.1	RP11-104N10.2	9.04	4.44e-18	3.13e-15	0.4	0.39	Multiple myeloma (IgH translocation);	chr16:89386363	chr16:89516797~89522217:+
PRAD	cis	rs6723108	0.517	rs6430548	ENSG00000224043.6	CCNT2-AS1	-9.04	4.45e-18	3.13e-15	-0.53	-0.39	Type 2 diabetes;	chr2:134854869	chr2:134735464~134918710:-
PRAD	cis	rs7772486	0.875	rs969694	ENSG00000235652.6	RP11-545I5.3	9.04	4.45e-18	3.14e-15	0.4	0.39	Lobe attachment (rater-scored or self-reported);	chr6:146073519	chr6:145799409~145886585:+
PRAD	cis	rs11673344	0.764	rs474017	ENSG00000226686.6	LINC01535	9.04	4.47e-18	3.15e-15	0.53	0.39	Obesity-related traits;	chr19:36963217	chr19:37251912~37265535:+
PRAD	cis	rs367615	0.537	rs17161729	ENSG00000249476.1	CTD-2587M2.1	-9.04	4.48e-18	3.15e-15	-0.48	-0.39	Colorectal cancer (SNP x SNP interaction);	chr5:109324827	chr5:109237120~109326369:-
PRAD	cis	rs4835473	0.742	rs7695853	ENSG00000251600.4	RP11-673E1.1	9.04	4.48e-18	3.15e-15	0.5	0.39	Immature fraction of reticulocytes;	chr4:143883243	chr4:143912331~143982454:+
PRAD	cis	rs2921073	0.509	rs2976931	ENSG00000253893.2	FAM85B	-9.04	4.49e-18	3.16e-15	-0.49	-0.39	Parkinson's disease;	chr8:8399807	chr8:8167819~8226614:-
PRAD	cis	rs9322193	0.607	rs4870078	ENSG00000216906.2	RP11-350J20.9	-9.04	4.49e-18	3.16e-15	-0.51	-0.39	Lung cancer;	chr6:149880676	chr6:149904243~149906418:+
PRAD	cis	rs2274273	0.905	rs8007620	ENSG00000258413.1	RP11-665C16.6	-9.04	4.5e-18	3.17e-15	-0.5	-0.39	Protein biomarker;	chr14:55119869	chr14:55262767~55272075:-
PRAD	cis	rs2153535	0.561	rs2181194	ENSG00000230939.1	RP11-314C16.1	-9.04	4.51e-18	3.17e-15	-0.48	-0.39	Motion sickness;	chr6:8667318	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.561	rs9505511	ENSG00000230939.1	RP11-314C16.1	-9.04	4.51e-18	3.17e-15	-0.48	-0.39	Motion sickness;	chr6:8667322	chr6:8784178~8785445:+
PRAD	cis	rs67311347	1	rs2371186	ENSG00000223797.4	ENTPD3-AS1	9.04	4.51e-18	3.18e-15	0.36	0.39	Renal cell carcinoma;	chr3:40447222	chr3:40313802~40453329:-
PRAD	cis	rs11098499	0.954	rs59394118	ENSG00000245958.5	RP11-33B1.1	-9.04	4.51e-18	3.18e-15	-0.38	-0.39	Corneal astigmatism;	chr4:119374396	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.865	rs9996417	ENSG00000245958.5	RP11-33B1.1	-9.04	4.51e-18	3.18e-15	-0.38	-0.39	Corneal astigmatism;	chr4:119374707	chr4:119454791~119552025:+
PRAD	cis	rs67311347	1	rs9827461	ENSG00000223797.4	ENTPD3-AS1	9.04	4.52e-18	3.18e-15	0.36	0.39	Renal cell carcinoma;	chr3:40447860	chr3:40313802~40453329:-
PRAD	cis	rs853679	1	rs7740487	ENSG00000280107.1	AL022393.9	-9.04	4.53e-18	3.19e-15	-0.59	-0.39	Depression;	chr6:28248708	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.629	rs203888	ENSG00000219392.1	RP1-265C24.5	-9.04	4.53e-18	3.19e-15	-0.5	-0.39	Parkinson's disease;	chr6:28053811	chr6:28115628~28116551:+
PRAD	cis	rs2638953	0.886	rs10843137	ENSG00000278733.1	RP11-425D17.1	-9.04	4.57e-18	3.22e-15	-0.47	-0.39	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28218788	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs10843138	ENSG00000278733.1	RP11-425D17.1	-9.04	4.57e-18	3.22e-15	-0.47	-0.39	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28219210	chr12:28185625~28186190:-
PRAD	cis	rs6700559	0.81	rs2809344	ENSG00000260088.1	RP11-92G12.3	9.04	4.58e-18	3.22e-15	0.49	0.39	Coronary artery disease;	chr1:200627478	chr1:200669507~200694250:+
PRAD	cis	rs2274273	0.87	rs10139000	ENSG00000258413.1	RP11-665C16.6	-9.04	4.62e-18	3.25e-15	-0.51	-0.39	Protein biomarker;	chr14:55383158	chr14:55262767~55272075:-
PRAD	cis	rs2404602	0.716	rs4079681	ENSG00000259422.1	RP11-593F23.1	9.04	4.63e-18	3.26e-15	0.48	0.39	Blood metabolite levels;	chr15:76402889	chr15:76174891~76181486:-
PRAD	cis	rs2739330	0.828	rs4822454	ENSG00000235689.1	AP000351.13	9.04	4.64e-18	3.26e-15	0.48	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:24006305~24008258:-
PRAD	cis	rs2153535	0.518	rs9392232	ENSG00000230939.1	RP11-314C16.1	-9.04	4.64e-18	3.26e-15	-0.47	-0.39	Motion sickness;	chr6:8636211	chr6:8784178~8785445:+
PRAD	cis	rs875971	1	rs6979382	ENSG00000237310.1	GS1-124K5.4	9.04	4.65e-18	3.27e-15	0.35	0.39	Aortic root size;	chr7:66421388	chr7:66493706~66495474:+
PRAD	cis	rs875971	1	rs6961990	ENSG00000237310.1	GS1-124K5.4	9.04	4.65e-18	3.27e-15	0.35	0.39	Aortic root size;	chr7:66423583	chr7:66493706~66495474:+
PRAD	cis	rs2638953	0.962	rs7980151	ENSG00000278733.1	RP11-425D17.1	-9.04	4.66e-18	3.27e-15	-0.47	-0.39	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28149345	chr12:28185625~28186190:-
PRAD	cis	rs4713118	0.513	rs1225591	ENSG00000280107.1	AL022393.9	-9.04	4.67e-18	3.28e-15	-0.49	-0.39	Parkinson's disease;	chr6:28180974	chr6:28170845~28172521:+
PRAD	cis	rs4718428	0.705	rs2901311	ENSG00000230295.1	RP11-458F8.2	-9.04	4.69e-18	3.3e-15	-0.3	-0.39	Corneal structure;	chr7:66950082	chr7:66880708~66882981:+
PRAD	cis	rs9309473	0.606	rs79234109	ENSG00000163016.8	ALMS1P	9.04	4.7e-18	3.31e-15	0.59	0.39	Metabolite levels;	chr2:73621227	chr2:73644919~73685576:+
PRAD	cis	rs4266144	0.821	rs56237906	ENSG00000244515.1	KRT18P34	-9.04	4.7e-18	3.31e-15	-0.51	-0.39	Coronary artery disease;	chr3:157134684	chr3:157162663~157163932:-
PRAD	cis	rs12701220	0.655	rs34344742	ENSG00000229043.2	AC091729.9	-9.03	4.71e-18	3.31e-15	-0.55	-0.39	Bronchopulmonary dysplasia;	chr7:1109652	chr7:1160374~1165267:+
PRAD	cis	rs2274273	0.87	rs7158768	ENSG00000258413.1	RP11-665C16.6	-9.03	4.72e-18	3.32e-15	-0.51	-0.39	Protein biomarker;	chr14:55296894	chr14:55262767~55272075:-
PRAD	cis	rs2274273	0.87	rs10142547	ENSG00000258413.1	RP11-665C16.6	-9.03	4.72e-18	3.32e-15	-0.51	-0.39	Protein biomarker;	chr14:55297245	chr14:55262767~55272075:-
PRAD	cis	rs7429990	0.901	rs9825114	ENSG00000229759.1	MRPS18AP1	-9.03	4.74e-18	3.33e-15	-0.4	-0.39	Educational attainment (years of education);	chr3:48096592	chr3:48256350~48256938:-
PRAD	cis	rs7429990	0.932	rs6766641	ENSG00000229759.1	MRPS18AP1	-9.03	4.74e-18	3.33e-15	-0.4	-0.39	Educational attainment (years of education);	chr3:48103734	chr3:48256350~48256938:-
PRAD	cis	rs7429990	0.864	rs6777081	ENSG00000229759.1	MRPS18AP1	-9.03	4.74e-18	3.33e-15	-0.4	-0.39	Educational attainment (years of education);	chr3:48114079	chr3:48256350~48256938:-
PRAD	cis	rs4835473	0.932	rs12503900	ENSG00000251600.4	RP11-673E1.1	-9.03	4.77e-18	3.35e-15	-0.5	-0.39	Immature fraction of reticulocytes;	chr4:143812459	chr4:143912331~143982454:+
PRAD	cis	rs2564921	0.654	rs73087044	ENSG00000242142.1	SERBP1P3	-9.03	4.78e-18	3.36e-15	-0.45	-0.39	Height;	chr3:52975027	chr3:53064283~53065091:-
PRAD	cis	rs4820294	1	rs4820294	ENSG00000233360.4	Z83844.1	9.03	4.78e-18	3.36e-15	0.5	0.39	Fat distribution (HIV);	chr22:37675036	chr22:37641832~37658377:-
PRAD	cis	rs4835473	0.897	rs12508285	ENSG00000251600.4	RP11-673E1.1	-9.03	4.79e-18	3.36e-15	-0.5	-0.39	Immature fraction of reticulocytes;	chr4:143792642	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.9	rs7667544	ENSG00000251600.4	RP11-673E1.1	-9.03	4.79e-18	3.36e-15	-0.5	-0.39	Immature fraction of reticulocytes;	chr4:143793802	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs6849896	ENSG00000251600.4	RP11-673E1.1	-9.03	4.79e-18	3.36e-15	-0.5	-0.39	Immature fraction of reticulocytes;	chr4:143794927	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.838	rs35998817	ENSG00000251600.4	RP11-673E1.1	-9.03	4.79e-18	3.36e-15	-0.5	-0.39	Immature fraction of reticulocytes;	chr4:143795355	chr4:143912331~143982454:+
PRAD	cis	rs1075265	0.572	rs2193682	ENSG00000233266.1	HMGB1P31	9.03	4.79e-18	3.37e-15	0.54	0.39	Chronotype;Morning vs. evening chronotype;	chr2:53695119	chr2:54051334~54051760:+
PRAD	cis	rs1062177	1	rs1062177	ENSG00000253921.1	CTB-113P19.3	-9.03	4.81e-18	3.38e-15	-0.52	-0.39	Preschool internalizing problems;	chr5:151805140	chr5:151753992~151767247:+
PRAD	cis	rs2274273	0.87	rs10134339	ENSG00000258413.1	RP11-665C16.6	-9.03	4.83e-18	3.39e-15	-0.51	-0.39	Protein biomarker;	chr14:55347662	chr14:55262767~55272075:-
PRAD	cis	rs2274273	0.87	rs28716725	ENSG00000258413.1	RP11-665C16.6	-9.03	4.83e-18	3.39e-15	-0.51	-0.39	Protein biomarker;	chr14:55349892	chr14:55262767~55272075:-
PRAD	cis	rs7714584	1	rs13361189	ENSG00000197083.10	ZNF300P1	9.03	4.84e-18	3.4e-15	0.62	0.39	Crohn's disease;	chr5:150843825	chr5:150930645~150946289:-
PRAD	cis	rs11951515	1	rs11951515	ENSG00000188850.9	RP11-159F24.2	9.03	4.85e-18	3.4e-15	0.48	0.39	Metabolite levels  (X-11787);	chr5:43382756	chr5:43336164~43348716:+
PRAD	cis	rs2015599	0.623	rs3782505	ENSG00000257176.2	RP11-996F15.2	9.03	4.86e-18	3.41e-15	0.44	0.39	Platelet count;Mean platelet volume;	chr12:29292236	chr12:29280418~29317848:-
PRAD	cis	rs1062177	1	rs2915882	ENSG00000253921.1	CTB-113P19.3	-9.03	4.87e-18	3.42e-15	-0.51	-0.39	Preschool internalizing problems;	chr5:151765875	chr5:151753992~151767247:+
PRAD	cis	rs1062177	1	rs2915880	ENSG00000253921.1	CTB-113P19.3	-9.03	4.87e-18	3.42e-15	-0.51	-0.39	Preschool internalizing problems;	chr5:151767773	chr5:151753992~151767247:+
PRAD	cis	rs34375054	0.573	rs12579211	ENSG00000279233.1	RP11-158L12.4	9.03	4.89e-18	3.43e-15	0.43	0.39	Post bronchodilator FEV1/FVC ratio;	chr12:125163206	chr12:125138245~125141711:+
PRAD	cis	rs2739330	0.828	rs5760099	ENSG00000099984.9	GSTT2	-9.03	4.89e-18	3.43e-15	-0.52	-0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23980123~23983911:+
PRAD	cis	rs2274273	0.87	rs11625001	ENSG00000258413.1	RP11-665C16.6	-9.03	4.91e-18	3.44e-15	-0.5	-0.39	Protein biomarker;	chr14:55291442	chr14:55262767~55272075:-
PRAD	cis	rs2274273	0.837	rs7148171	ENSG00000258413.1	RP11-665C16.6	-9.03	4.92e-18	3.45e-15	-0.51	-0.39	Protein biomarker;	chr14:55304026	chr14:55262767~55272075:-
PRAD	cis	rs2274273	0.87	rs1109170	ENSG00000258413.1	RP11-665C16.6	-9.03	4.92e-18	3.45e-15	-0.51	-0.39	Protein biomarker;	chr14:55319070	chr14:55262767~55272075:-
PRAD	cis	rs2274273	0.837	rs10141483	ENSG00000258413.1	RP11-665C16.6	-9.03	4.92e-18	3.45e-15	-0.51	-0.39	Protein biomarker;	chr14:55320153	chr14:55262767~55272075:-
PRAD	cis	rs2274273	0.837	rs10131913	ENSG00000258413.1	RP11-665C16.6	-9.03	4.92e-18	3.45e-15	-0.51	-0.39	Protein biomarker;	chr14:55320702	chr14:55262767~55272075:-
PRAD	cis	rs2274273	0.901	rs112870553	ENSG00000258413.1	RP11-665C16.6	-9.03	4.92e-18	3.45e-15	-0.51	-0.39	Protein biomarker;	chr14:55323344	chr14:55262767~55272075:-
PRAD	cis	rs2274273	0.84	rs28568813	ENSG00000258413.1	RP11-665C16.6	-9.03	4.92e-18	3.45e-15	-0.51	-0.39	Protein biomarker;	chr14:55327396	chr14:55262767~55272075:-
PRAD	cis	rs673078	0.607	rs7295288	ENSG00000275409.1	RP11-131L12.4	-9.03	4.93e-18	3.46e-15	-0.53	-0.39	Glucose homeostasis traits;	chr12:118418008	chr12:118430147~118430699:+
PRAD	cis	rs11676348	0.808	rs12694430	ENSG00000261338.2	RP11-378A13.1	-9.03	4.94e-18	3.47e-15	-0.43	-0.39	Ulcerative colitis;	chr2:218151076	chr2:218255319~218257366:+
PRAD	cis	rs7429990	0.932	rs11720151	ENSG00000229759.1	MRPS18AP1	-9.03	4.97e-18	3.49e-15	-0.4	-0.39	Educational attainment (years of education);	chr3:48099144	chr3:48256350~48256938:-
PRAD	cis	rs2933343	0.621	rs789249	ENSG00000231305.3	RP11-723O4.2	9.03	4.98e-18	3.49e-15	0.36	0.39	IgG glycosylation;	chr3:128859610	chr3:128861313~128871540:-
PRAD	cis	rs2404602	0.631	rs9646213	ENSG00000259422.1	RP11-593F23.1	9.03	5e-18	3.51e-15	0.48	0.39	Blood metabolite levels;	chr15:76515331	chr15:76174891~76181486:-
PRAD	cis	rs858239	0.669	rs10950940	ENSG00000226816.2	AC005082.12	-9.03	5.01e-18	3.51e-15	-0.45	-0.39	Cerebrospinal fluid biomarker levels;	chr7:23157197	chr7:23206013~23208045:+
PRAD	cis	rs2348418	0.864	rs7304540	ENSG00000247934.4	RP11-967K21.1	9.03	5.02e-18	3.52e-15	0.36	0.39	Lung function (FEV1);Lung function (FVC);	chr12:28560489	chr12:28163298~28190738:-
PRAD	cis	rs2348418	0.864	rs7304776	ENSG00000247934.4	RP11-967K21.1	9.03	5.02e-18	3.52e-15	0.36	0.39	Lung function (FEV1);Lung function (FVC);	chr12:28560634	chr12:28163298~28190738:-
PRAD	cis	rs2348418	0.864	rs11049714	ENSG00000247934.4	RP11-967K21.1	9.03	5.02e-18	3.52e-15	0.36	0.39	Lung function (FEV1);Lung function (FVC);	chr12:28561162	chr12:28163298~28190738:-
PRAD	cis	rs4718428	0.705	rs28648401	ENSG00000230295.1	RP11-458F8.2	-9.03	5.04e-18	3.53e-15	-0.29	-0.39	Corneal structure;	chr7:66902145	chr7:66880708~66882981:+
PRAD	cis	rs4718428	0.607	rs66954441	ENSG00000230295.1	RP11-458F8.2	-9.03	5.04e-18	3.53e-15	-0.29	-0.39	Corneal structure;	chr7:66904222	chr7:66880708~66882981:+
PRAD	cis	rs150992	0.678	rs161950	ENSG00000248489.1	CTD-2007H13.3	-9.03	5.05e-18	3.54e-15	-0.44	-0.39	Body mass index;	chr5:98924533	chr5:98929171~98995013:+
PRAD	cis	rs4722166	0.599	rs7776857	ENSG00000179428.2	AC073072.5	-9.03	5.05e-18	3.54e-15	-0.51	-0.39	Lung cancer;	chr7:22715149	chr7:22725395~22727620:-
PRAD	cis	rs2153535	0.518	rs9505503	ENSG00000230939.1	RP11-314C16.1	-9.03	5.05e-18	3.54e-15	-0.47	-0.39	Motion sickness;	chr6:8638572	chr6:8784178~8785445:+
PRAD	cis	rs2933343	0.621	rs789241	ENSG00000231305.3	RP11-723O4.2	9.03	5.05e-18	3.54e-15	0.37	0.39	IgG glycosylation;	chr3:128866909	chr3:128861313~128871540:-
PRAD	cis	rs2933343	0.649	rs2638845	ENSG00000231305.3	RP11-723O4.2	9.03	5.05e-18	3.54e-15	0.37	0.39	IgG glycosylation;	chr3:128868526	chr3:128861313~128871540:-
PRAD	cis	rs2274273	0.84	rs7159144	ENSG00000258413.1	RP11-665C16.6	-9.03	5.05e-18	3.54e-15	-0.51	-0.39	Protein biomarker;	chr14:55354606	chr14:55262767~55272075:-
PRAD	cis	rs7569084	0.663	rs4671128	ENSG00000281920.1	RP11-418H16.1	9.03	5.06e-18	3.55e-15	0.46	0.39	Sum eosinophil basophil counts;	chr2:65438130	chr2:65623272~65628424:+
PRAD	cis	rs3096299	0.967	rs11648663	ENSG00000274627.1	RP11-104N10.2	9.03	5.07e-18	3.56e-15	0.4	0.39	Multiple myeloma (IgH translocation);	chr16:89399899	chr16:89516797~89522217:+
PRAD	cis	rs2404602	0.716	rs56216512	ENSG00000259422.1	RP11-593F23.1	9.02	5.11e-18	3.58e-15	0.49	0.39	Blood metabolite levels;	chr15:76394595	chr15:76174891~76181486:-
PRAD	cis	rs9399137	0.507	rs4289677	ENSG00000232876.1	CTA-212D2.2	-9.02	5.14e-18	3.6e-15	-0.5	-0.39	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134954347	chr6:135055033~135060550:+
PRAD	cis	rs7945705	0.714	rs2653570	ENSG00000254860.4	TMEM9B-AS1	9.02	5.15e-18	3.61e-15	0.4	0.39	Hemoglobin concentration;	chr11:8966276	chr11:8964675~8977527:+
PRAD	cis	rs7945705	0.747	rs2568020	ENSG00000254860.4	TMEM9B-AS1	9.02	5.15e-18	3.61e-15	0.4	0.39	Hemoglobin concentration;	chr11:8973168	chr11:8964675~8977527:+
PRAD	cis	rs7945705	0.719	rs2012680	ENSG00000254860.4	TMEM9B-AS1	9.02	5.15e-18	3.61e-15	0.4	0.39	Hemoglobin concentration;	chr11:8974512	chr11:8964675~8977527:+
PRAD	cis	rs6991838	0.67	rs13275168	ENSG00000272010.1	CTD-3025N20.3	9.02	5.15e-18	3.61e-15	0.38	0.39	Intelligence (multi-trait analysis);	chr8:65685107	chr8:65591850~65592472:-
PRAD	cis	rs17023223	0.509	rs7542832	ENSG00000231365.4	RP11-418J17.1	-9.02	5.16e-18	3.62e-15	-0.41	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119220106	chr1:119140396~119275973:+
PRAD	cis	rs7567389	0.74	rs1604817	ENSG00000236682.1	AC068282.3	9.02	5.17e-18	3.62e-15	0.49	0.39	Self-rated health;	chr2:127242345	chr2:127389130~127400580:+
PRAD	cis	rs7189233	0.513	rs8044091	ENSG00000279344.1	RP11-44F14.7	9.02	5.2e-18	3.64e-15	0.36	0.39	Intelligence (multi-trait analysis);	chr16:53487086	chr16:53478957~53481550:-
PRAD	cis	rs858239	1	rs199347	ENSG00000226816.2	AC005082.12	9.02	5.2e-18	3.64e-15	0.44	0.39	Cerebrospinal fluid biomarker levels;	chr7:23254127	chr7:23206013~23208045:+
PRAD	cis	rs524281	0.731	rs3814744	ENSG00000255320.1	RP11-755F10.1	9.02	5.22e-18	3.66e-15	0.69	0.39	Electroencephalogram traits;	chr11:66042292	chr11:66244840~66246239:-
PRAD	cis	rs524281	0.648	rs4565902	ENSG00000255320.1	RP11-755F10.1	9.02	5.22e-18	3.66e-15	0.69	0.39	Electroencephalogram traits;	chr11:66042574	chr11:66244840~66246239:-
PRAD	cis	rs2348418	0.831	rs7137119	ENSG00000247934.4	RP11-967K21.1	9.02	5.22e-18	3.66e-15	0.36	0.39	Lung function (FEV1);Lung function (FVC);	chr12:28565058	chr12:28163298~28190738:-
PRAD	cis	rs6430553	0.929	rs1348792	ENSG00000224043.6	CCNT2-AS1	-9.02	5.25e-18	3.68e-15	-0.52	-0.39	Blood metabolite levels;	chr2:134903288	chr2:134735464~134918710:-
PRAD	cis	rs10740039	0.549	rs9414741	ENSG00000254271.1	RP11-131N11.4	-9.02	5.27e-18	3.69e-15	-0.54	-0.39	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60738510	chr10:60734342~60741828:+
PRAD	cis	rs875971	1	rs709597	ENSG00000237310.1	GS1-124K5.4	-9.02	5.27e-18	3.69e-15	-0.35	-0.39	Aortic root size;	chr7:66360996	chr7:66493706~66495474:+
PRAD	cis	rs3762637	0.943	rs9289196	ENSG00000272758.4	RP11-299J3.8	-9.02	5.28e-18	3.7e-15	-0.53	-0.39	LDL cholesterol levels;	chr3:122549659	chr3:122416207~122443180:+
PRAD	cis	rs7189233	0.55	rs4783811	ENSG00000279344.1	RP11-44F14.7	9.02	5.31e-18	3.72e-15	0.35	0.39	Intelligence (multi-trait analysis);	chr16:53449464	chr16:53478957~53481550:-
PRAD	cis	rs6723108	0.581	rs10176573	ENSG00000224043.6	CCNT2-AS1	-9.02	5.31e-18	3.72e-15	-0.53	-0.39	Type 2 diabetes;	chr2:134899901	chr2:134735464~134918710:-
PRAD	cis	rs11673344	0.764	rs826303	ENSG00000226686.6	LINC01535	9.02	5.33e-18	3.73e-15	0.53	0.39	Obesity-related traits;	chr19:36951549	chr19:37251912~37265535:+
PRAD	cis	rs524281	1	rs524281	ENSG00000255320.1	RP11-755F10.1	-9.02	5.34e-18	3.73e-15	-0.54	-0.39	Electroencephalogram traits;	chr11:66119191	chr11:66244840~66246239:-
PRAD	cis	rs4835473	0.897	rs2219912	ENSG00000251600.4	RP11-673E1.1	9.02	5.36e-18	3.75e-15	0.49	0.39	Immature fraction of reticulocytes;	chr4:143707909	chr4:143912331~143982454:+
PRAD	cis	rs11098499	0.863	rs6858592	ENSG00000245958.5	RP11-33B1.1	-9.02	5.36e-18	3.75e-15	-0.38	-0.39	Corneal astigmatism;	chr4:119537537	chr4:119454791~119552025:+
PRAD	cis	rs270601	0.739	rs3900945	ENSG00000233006.5	AC034220.3	9.02	5.36e-18	3.75e-15	0.33	0.39	Acylcarnitine levels;	chr5:132257177	chr5:132311285~132369916:-
PRAD	cis	rs853679	1	rs9986596	ENSG00000280107.1	AL022393.9	-9.02	5.37e-18	3.76e-15	-0.59	-0.39	Depression;	chr6:28251883	chr6:28170845~28172521:+
PRAD	cis	rs524281	0.692	rs10791845	ENSG00000255320.1	RP11-755F10.1	-9.02	5.39e-18	3.77e-15	-0.57	-0.39	Electroencephalogram traits;	chr11:66066869	chr11:66244840~66246239:-
PRAD	cis	rs7772486	0.875	rs1331645	ENSG00000235652.6	RP11-545I5.3	9.02	5.43e-18	3.8e-15	0.39	0.39	Lobe attachment (rater-scored or self-reported);	chr6:146077271	chr6:145799409~145886585:+
PRAD	cis	rs4820294	1	rs41280035	ENSG00000233360.4	Z83844.1	9.02	5.43e-18	3.8e-15	0.5	0.39	Fat distribution (HIV);	chr22:37658031	chr22:37641832~37658377:-
PRAD	cis	rs10129255	0.5	rs11627315	ENSG00000223648.3	IGHV3-64	9.02	5.44e-18	3.8e-15	0.34	0.39	Kawasaki disease;	chr14:106802182	chr14:106643132~106658258:-
PRAD	cis	rs7945705	0.747	rs10840158	ENSG00000254860.4	TMEM9B-AS1	9.02	5.45e-18	3.81e-15	0.4	0.39	Hemoglobin concentration;	chr11:8999350	chr11:8964675~8977527:+
PRAD	cis	rs6991838	0.831	rs11992528	ENSG00000272010.1	CTD-3025N20.3	9.02	5.45e-18	3.81e-15	0.37	0.39	Intelligence (multi-trait analysis);	chr8:65561644	chr8:65591850~65592472:-
PRAD	cis	rs8177376	1	rs8177376	ENSG00000254905.1	RP11-712L6.7	9.02	5.45e-18	3.81e-15	0.49	0.39	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126293717	chr11:126292922~126294254:-
PRAD	cis	rs2933343	0.601	rs1680759	ENSG00000231305.3	RP11-723O4.2	9.02	5.47e-18	3.82e-15	0.36	0.39	IgG glycosylation;	chr3:128876053	chr3:128861313~128871540:-
PRAD	cis	rs2284378	0.506	rs6142059	ENSG00000276073.1	RP5-1125A11.7	-9.02	5.47e-18	3.83e-15	-0.38	-0.39	Breast cancer;	chr20:33956521	chr20:33985617~33988989:-
PRAD	cis	rs7772486	0.686	rs1337839	ENSG00000235652.6	RP11-545I5.3	-9.02	5.49e-18	3.83e-15	-0.4	-0.39	Lobe attachment (rater-scored or self-reported);	chr6:145689103	chr6:145799409~145886585:+
PRAD	cis	rs4835473	0.932	rs17018500	ENSG00000251600.4	RP11-673E1.1	-9.02	5.49e-18	3.84e-15	-0.49	-0.39	Immature fraction of reticulocytes;	chr4:143824849	chr4:143912331~143982454:+
PRAD	cis	rs7772486	0.875	rs2814866	ENSG00000235652.6	RP11-545I5.3	9.01	5.52e-18	3.86e-15	0.39	0.39	Lobe attachment (rater-scored or self-reported);	chr6:146018278	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.875	rs2328712	ENSG00000235652.6	RP11-545I5.3	9.01	5.52e-18	3.86e-15	0.39	0.39	Lobe attachment (rater-scored or self-reported);	chr6:146023427	chr6:145799409~145886585:+
PRAD	cis	rs5769707	0.642	rs4824070	ENSG00000188511.11	C22orf34	9.01	5.55e-18	3.88e-15	0.47	0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49637873	chr22:49414524~49657542:-
PRAD	cis	rs4835473	0.897	rs12505617	ENSG00000251600.4	RP11-673E1.1	9.01	5.56e-18	3.89e-15	0.49	0.39	Immature fraction of reticulocytes;	chr4:143723522	chr4:143912331~143982454:+
PRAD	cis	rs2739330	0.828	rs4822451	ENSG00000099984.9	GSTT2	-9.01	5.57e-18	3.89e-15	-0.52	-0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23980123~23983911:+
PRAD	cis	rs12817211	0.502	rs34167640	ENSG00000272368.2	RP4-605O3.4	-9.01	5.57e-18	3.9e-15	-0.39	-0.39	Colorectal or endometrial cancer;	chr12:50123208	chr12:50112197~50165618:+
PRAD	cis	rs2404602	0.716	rs12437627	ENSG00000259422.1	RP11-593F23.1	9.01	5.59e-18	3.9e-15	0.48	0.39	Blood metabolite levels;	chr15:76552709	chr15:76174891~76181486:-
PRAD	cis	rs7309	0.967	rs3754970	ENSG00000235724.7	AC009299.2	-9.01	5.6e-18	3.91e-15	-0.48	-0.39	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161235325	chr2:161222785~161308303:-
PRAD	cis	rs3858145	0.588	rs7081284	ENSG00000233590.1	RP11-153K11.3	-9.01	5.61e-18	3.92e-15	-0.57	-0.39	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68285035	chr10:68233251~68242379:-
PRAD	cis	rs2980439	0.818	rs2945249	ENSG00000253893.2	FAM85B	-9.01	5.63e-18	3.93e-15	-0.49	-0.39	Neuroticism;	chr8:8237204	chr8:8167819~8226614:-
PRAD	cis	rs8177376	0.953	rs4935964	ENSG00000254905.1	RP11-712L6.7	9.01	5.64e-18	3.94e-15	0.49	0.39	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126285289	chr11:126292922~126294254:-
PRAD	cis	rs8177376	1	rs8177365	ENSG00000254905.1	RP11-712L6.7	9.01	5.64e-18	3.94e-15	0.49	0.39	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126289965	chr11:126292922~126294254:-
PRAD	cis	rs2274273	0.837	rs6573017	ENSG00000258413.1	RP11-665C16.6	-9.01	5.66e-18	3.95e-15	-0.51	-0.39	Protein biomarker;	chr14:55335525	chr14:55262767~55272075:-
PRAD	cis	rs12931792	0.782	rs6565176	ENSG00000183604.13	SMG1P5	9.01	5.67e-18	3.96e-15	0.35	0.39	Tonsillectomy;	chr16:30163605	chr16:30267553~30335374:-
PRAD	cis	rs4718428	0.705	rs10267335	ENSG00000230295.1	RP11-458F8.2	-9.01	5.67e-18	3.96e-15	-0.3	-0.39	Corneal structure;	chr7:66938233	chr7:66880708~66882981:+
PRAD	cis	rs6517329	0.538	rs8126939	ENSG00000236830.5	CBR3-AS1	9.01	5.67e-18	3.96e-15	0.41	0.39	Schizophrenia;	chr21:36140649	chr21:36131767~36175815:-
PRAD	cis	rs6517329	0.538	rs4817781	ENSG00000236830.5	CBR3-AS1	9.01	5.67e-18	3.96e-15	0.41	0.39	Schizophrenia;	chr21:36141298	chr21:36131767~36175815:-
PRAD	cis	rs6517329	0.538	rs4817782	ENSG00000236830.5	CBR3-AS1	9.01	5.67e-18	3.96e-15	0.41	0.39	Schizophrenia;	chr21:36141449	chr21:36131767~36175815:-
PRAD	cis	rs6517329	0.538	rs1056892	ENSG00000236830.5	CBR3-AS1	9.01	5.67e-18	3.96e-15	0.41	0.39	Schizophrenia;	chr21:36146408	chr21:36131767~36175815:-
PRAD	cis	rs875971	1	rs697970	ENSG00000237310.1	GS1-124K5.4	-9.01	5.68e-18	3.96e-15	-0.35	-0.39	Aortic root size;	chr7:66095065	chr7:66493706~66495474:+
PRAD	cis	rs7772486	0.875	rs2748502	ENSG00000235652.6	RP11-545I5.3	9.01	5.69e-18	3.97e-15	0.39	0.39	Lobe attachment (rater-scored or self-reported);	chr6:145977103	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.875	rs2777477	ENSG00000235652.6	RP11-545I5.3	9.01	5.69e-18	3.97e-15	0.39	0.39	Lobe attachment (rater-scored or self-reported);	chr6:145984355	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.875	rs1330939	ENSG00000235652.6	RP11-545I5.3	9.01	5.69e-18	3.97e-15	0.39	0.39	Lobe attachment (rater-scored or self-reported);	chr6:145987382	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.846	rs2492856	ENSG00000235652.6	RP11-545I5.3	9.01	5.69e-18	3.97e-15	0.39	0.39	Lobe attachment (rater-scored or self-reported);	chr6:146002792	chr6:145799409~145886585:+
PRAD	cis	rs9545047	0.604	rs12865187	ENSG00000227676.3	LINC01068	-9.01	5.69e-18	3.97e-15	-0.46	-0.39	Schizophrenia;	chr13:79316469	chr13:79566727~79571436:+
PRAD	cis	rs7772486	0.875	rs2748490	ENSG00000235652.6	RP11-545I5.3	9.01	5.69e-18	3.97e-15	0.39	0.39	Lobe attachment (rater-scored or self-reported);	chr6:146008545	chr6:145799409~145886585:+
PRAD	cis	rs10129255	0.5	rs7157975	ENSG00000223648.3	IGHV3-64	9.01	5.69e-18	3.97e-15	0.34	0.39	Kawasaki disease;	chr14:106804049	chr14:106643132~106658258:-
PRAD	cis	rs2348418	0.831	rs7296538	ENSG00000247934.4	RP11-967K21.1	-9.01	5.71e-18	3.99e-15	-0.36	-0.39	Lung function (FEV1);Lung function (FVC);	chr12:28558850	chr12:28163298~28190738:-
PRAD	cis	rs765787	0.556	rs10851422	ENSG00000259520.4	CTD-2651B20.3	-9.01	5.72e-18	3.99e-15	-0.5	-0.39	Uric acid levels;	chr15:45221540	chr15:45251580~45279251:-
PRAD	cis	rs4853012	0.775	rs12465641	ENSG00000257800.1	FNBP1P1	-9.01	5.73e-18	4e-15	-0.35	-0.39	Gestational age at birth (maternal effect);	chr2:74110588	chr2:74120680~74123218:+
PRAD	cis	rs1075265	0.62	rs2542584	ENSG00000233266.1	HMGB1P31	9.01	5.74e-18	4e-15	0.53	0.39	Chronotype;Morning vs. evening chronotype;	chr2:53782707	chr2:54051334~54051760:+
PRAD	cis	rs2153535	0.518	rs9393051	ENSG00000230939.1	RP11-314C16.1	-9.01	5.77e-18	4.02e-15	-0.47	-0.39	Motion sickness;	chr6:8638726	chr6:8784178~8785445:+
PRAD	cis	rs6570726	0.846	rs6570698	ENSG00000235652.6	RP11-545I5.3	9.01	5.79e-18	4.04e-15	0.4	0.39	Lobe attachment (rater-scored or self-reported);	chr6:145597499	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.846	rs6914304	ENSG00000235652.6	RP11-545I5.3	9.01	5.79e-18	4.04e-15	0.4	0.39	Lobe attachment (rater-scored or self-reported);	chr6:145599881	chr6:145799409~145886585:+
PRAD	cis	rs2274273	0.87	rs59629906	ENSG00000258413.1	RP11-665C16.6	-9.01	5.79e-18	4.04e-15	-0.5	-0.39	Protein biomarker;	chr14:55314471	chr14:55262767~55272075:-
PRAD	cis	rs9918079	0.6	rs61021642	ENSG00000273133.1	RP11-799M12.2	9.01	5.81e-18	4.05e-15	0.51	0.39	Obesity-related traits;	chr4:15575702	chr4:15563698~15564253:-
PRAD	cis	rs9545047	0.604	rs9565487	ENSG00000227676.3	LINC01068	-9.01	5.82e-18	4.06e-15	-0.46	-0.39	Schizophrenia;	chr13:79332742	chr13:79566727~79571436:+
PRAD	cis	rs7829975	0.514	rs2976929	ENSG00000253893.2	FAM85B	-9.01	5.82e-18	4.06e-15	-0.48	-0.39	Mood instability;	chr8:8401202	chr8:8167819~8226614:-
PRAD	cis	rs673078	0.607	rs6490177	ENSG00000275409.1	RP11-131L12.4	-9.01	5.82e-18	4.06e-15	-0.5	-0.39	Glucose homeostasis traits;	chr12:118358280	chr12:118430147~118430699:+
PRAD	cis	rs7211079	0.917	rs8067991	ENSG00000279259.1	RP11-334C17.3	9.01	5.83e-18	4.07e-15	0.42	0.39	Myocardial infarction;	chr17:80145503	chr17:80147250~80148596:+
PRAD	cis	rs7309	0.622	rs4664395	ENSG00000227403.1	AC009299.3	-9.01	5.84e-18	4.07e-15	-0.5	-0.39	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161044790	chr2:161244739~161249050:+
PRAD	cis	rs172166	0.561	rs149976	ENSG00000204709.4	LINC01556	-9.01	5.84e-18	4.07e-15	-0.48	-0.39	Cardiac Troponin-T levels;	chr6:28019998	chr6:28943877~28944537:+
PRAD	cis	rs1062177	0.826	rs2053063	ENSG00000253921.1	CTB-113P19.3	-9.01	5.87e-18	4.09e-15	-0.5	-0.39	Preschool internalizing problems;	chr5:151787203	chr5:151753992~151767247:+
PRAD	cis	rs17361889	0.766	rs17672493	ENSG00000224683.1	RPL36AP29	-9.01	5.88e-18	4.1e-15	-0.45	-0.39	Pediatric bone mineral content (hip);	chr7:16196559	chr7:16208945~16209265:+
PRAD	cis	rs11676348	0.774	rs11683524	ENSG00000261338.2	RP11-378A13.1	-9.01	5.92e-18	4.12e-15	-0.43	-0.39	Ulcerative colitis;	chr2:218119881	chr2:218255319~218257366:+
PRAD	cis	rs7772486	0.686	rs9497395	ENSG00000235652.6	RP11-545I5.3	-9.01	5.92e-18	4.13e-15	-0.4	-0.39	Lobe attachment (rater-scored or self-reported);	chr6:145692456	chr6:145799409~145886585:+
PRAD	cis	rs10262624	1	rs10950973	ENSG00000234286.1	AC006026.13	-9.01	5.92e-18	4.13e-15	-0.44	-0.39	Schizophrenia;	chr7:23877658	chr7:23680195~23680786:-
PRAD	cis	rs10262624	1	rs10950974	ENSG00000234286.1	AC006026.13	-9.01	5.92e-18	4.13e-15	-0.44	-0.39	Schizophrenia;	chr7:23877661	chr7:23680195~23680786:-
PRAD	cis	rs2274273	0.84	rs7144737	ENSG00000258413.1	RP11-665C16.6	-9.01	5.93e-18	4.14e-15	-0.5	-0.39	Protein biomarker;	chr14:55356228	chr14:55262767~55272075:-
PRAD	cis	rs34779708	0.931	rs17582416	ENSG00000230534.5	RP11-297A16.2	9.01	5.94e-18	4.14e-15	0.53	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:34998722	chr10:35098006~35127020:-
PRAD	cis	rs853679	1	rs68141011	ENSG00000280107.1	AL022393.9	-9.01	5.94e-18	4.14e-15	-0.59	-0.39	Depression;	chr6:28250019	chr6:28170845~28172521:+
PRAD	cis	rs853679	1	rs13200462	ENSG00000280107.1	AL022393.9	-9.01	5.94e-18	4.14e-15	-0.59	-0.39	Depression;	chr6:28250421	chr6:28170845~28172521:+
PRAD	cis	rs17023223	0.537	rs2794310	ENSG00000231365.4	RP11-418J17.1	-9	5.94e-18	4.14e-15	-0.4	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119019307	chr1:119140396~119275973:+
PRAD	cis	rs6517329	0.513	rs2187300	ENSG00000236830.5	CBR3-AS1	9	5.95e-18	4.15e-15	0.41	0.39	Schizophrenia;	chr21:36165173	chr21:36131767~36175815:-
PRAD	cis	rs2274273	0.84	rs7153110	ENSG00000258413.1	RP11-665C16.6	-9	5.95e-18	4.15e-15	-0.51	-0.39	Protein biomarker;	chr14:55353910	chr14:55262767~55272075:-
PRAD	cis	rs853679	0.517	rs1904841	ENSG00000226314.6	ZNF192P1	-9	5.95e-18	4.15e-15	-0.53	-0.39	Depression;	chr6:28140307	chr6:28161781~28169594:+
PRAD	cis	rs71403859	0.685	rs12927044	ENSG00000260886.1	TAT-AS1	9	5.96e-18	4.15e-15	0.83	0.39	Post bronchodilator FEV1;	chr16:71896202	chr16:71565789~71578187:+
PRAD	cis	rs6452524	0.967	rs11741420	ENSG00000249664.1	CTD-2227C6.2	9	5.97e-18	4.16e-15	0.46	0.39	Hypertension (SNP x SNP interaction);	chr5:83174913	chr5:83012285~83013109:-
PRAD	cis	rs6452524	0.967	rs4401555	ENSG00000249664.1	CTD-2227C6.2	9	5.97e-18	4.16e-15	0.46	0.39	Hypertension (SNP x SNP interaction);	chr5:83175267	chr5:83012285~83013109:-
PRAD	cis	rs6991838	0.733	rs7822627	ENSG00000272010.1	CTD-3025N20.3	9	6e-18	4.18e-15	0.38	0.39	Intelligence (multi-trait analysis);	chr8:65714139	chr8:65591850~65592472:-
PRAD	cis	rs9322193	0.566	rs3922947	ENSG00000216906.2	RP11-350J20.9	-9	6.08e-18	4.23e-15	-0.5	-0.39	Lung cancer;	chr6:149924856	chr6:149904243~149906418:+
PRAD	cis	rs7712401	0.601	rs193539	ENSG00000263432.2	RN7SL689P	9	6.08e-18	4.24e-15	0.4	0.39	Mean platelet volume;	chr5:122921922	chr5:123022487~123022783:-
PRAD	cis	rs2348418	0.648	rs11049730	ENSG00000247934.4	RP11-967K21.1	9	6.09e-18	4.24e-15	0.37	0.39	Lung function (FEV1);Lung function (FVC);	chr12:28586912	chr12:28163298~28190738:-
PRAD	cis	rs7772486	0.686	rs9403739	ENSG00000235652.6	RP11-545I5.3	-9	6.1e-18	4.25e-15	-0.4	-0.39	Lobe attachment (rater-scored or self-reported);	chr6:145694221	chr6:145799409~145886585:+
PRAD	cis	rs2348418	0.864	rs7960369	ENSG00000247934.4	RP11-967K21.1	9	6.1e-18	4.25e-15	0.36	0.39	Lung function (FEV1);Lung function (FVC);	chr12:28561569	chr12:28163298~28190738:-
PRAD	cis	rs11148252	0.716	rs3803262	ENSG00000278238.1	RP11-245D16.4	-9	6.1e-18	4.25e-15	-0.45	-0.39	Lewy body disease;	chr13:52462263	chr13:52454775~52455331:-
PRAD	cis	rs1075232	1	rs4450360	ENSG00000270055.1	CTD-3092A11.2	-9	6.13e-18	4.27e-15	-0.84	-0.39	Survival in colorectal cancer (non-distant metastatic);	chr15:31389827	chr15:30487963~30490313:+
PRAD	cis	rs1075232	1	rs72722847	ENSG00000270055.1	CTD-3092A11.2	-9	6.13e-18	4.27e-15	-0.84	-0.39	Survival in colorectal cancer (non-distant metastatic);	chr15:31390143	chr15:30487963~30490313:+
PRAD	cis	rs9326248	0.689	rs236916	ENSG00000280143.1	AP000892.6	-9	6.17e-18	4.3e-15	-0.43	-0.39	Blood protein levels;	chr11:117218912	chr11:117204967~117210292:+
PRAD	cis	rs2638953	0.924	rs7973516	ENSG00000278733.1	RP11-425D17.1	-9	6.19e-18	4.31e-15	-0.47	-0.39	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28207523	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.886	rs7973241	ENSG00000278733.1	RP11-425D17.1	-9	6.19e-18	4.31e-15	-0.47	-0.39	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28207583	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs7973656	ENSG00000278733.1	RP11-425D17.1	-9	6.19e-18	4.31e-15	-0.47	-0.39	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28207679	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs7971033	ENSG00000278733.1	RP11-425D17.1	-9	6.19e-18	4.31e-15	-0.47	-0.39	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28208420	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs7956418	ENSG00000278733.1	RP11-425D17.1	-9	6.19e-18	4.31e-15	-0.47	-0.39	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28208566	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs11519094	ENSG00000278733.1	RP11-425D17.1	-9	6.19e-18	4.31e-15	-0.47	-0.39	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28209430	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs11513465	ENSG00000278733.1	RP11-425D17.1	-9	6.19e-18	4.31e-15	-0.47	-0.39	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28209483	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs11513250	ENSG00000278733.1	RP11-425D17.1	-9	6.19e-18	4.31e-15	-0.47	-0.39	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28209500	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs11519330	ENSG00000278733.1	RP11-425D17.1	-9	6.19e-18	4.31e-15	-0.47	-0.39	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28209720	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.85	rs11519331	ENSG00000278733.1	RP11-425D17.1	-9	6.19e-18	4.31e-15	-0.47	-0.39	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28209995	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.888	rs11513466	ENSG00000278733.1	RP11-425D17.1	-9	6.19e-18	4.31e-15	-0.47	-0.39	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28210111	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs7298652	ENSG00000278733.1	RP11-425D17.1	-9	6.19e-18	4.31e-15	-0.47	-0.39	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28210620	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs6487669	ENSG00000278733.1	RP11-425D17.1	-9	6.19e-18	4.31e-15	-0.47	-0.39	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28210827	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs6487671	ENSG00000278733.1	RP11-425D17.1	-9	6.19e-18	4.31e-15	-0.47	-0.39	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28210902	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs11049464	ENSG00000278733.1	RP11-425D17.1	-9	6.19e-18	4.31e-15	-0.47	-0.39	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28211637	chr12:28185625~28186190:-
PRAD	cis	rs524281	0.647	rs2302883	ENSG00000255320.1	RP11-755F10.1	9	6.19e-18	4.31e-15	0.58	0.39	Electroencephalogram traits;	chr11:66057523	chr11:66244840~66246239:-
PRAD	cis	rs3096299	0.933	rs2965934	ENSG00000274627.1	RP11-104N10.2	9	6.21e-18	4.32e-15	0.4	0.39	Multiple myeloma (IgH translocation);	chr16:89414821	chr16:89516797~89522217:+
PRAD	cis	rs4835473	0.932	rs4835013	ENSG00000251600.4	RP11-673E1.1	9	6.23e-18	4.34e-15	0.5	0.39	Immature fraction of reticulocytes;	chr4:143748485	chr4:143912331~143982454:+
PRAD	cis	rs765787	0.53	rs1706834	ENSG00000259520.4	CTD-2651B20.3	9	6.27e-18	4.36e-15	0.48	0.39	Uric acid levels;	chr15:45225656	chr15:45251580~45279251:-
PRAD	cis	rs765787	0.53	rs28524974	ENSG00000259520.4	CTD-2651B20.3	9	6.27e-18	4.36e-15	0.48	0.39	Uric acid levels;	chr15:45251330	chr15:45251580~45279251:-
PRAD	cis	rs7211079	0.957	rs58120535	ENSG00000279259.1	RP11-334C17.3	9	6.3e-18	4.38e-15	0.42	0.39	Myocardial infarction;	chr17:80142225	chr17:80147250~80148596:+
PRAD	cis	rs7727544	0.618	rs2631367	ENSG00000233006.5	AC034220.3	-9	6.31e-18	4.39e-15	-0.34	-0.39	Blood metabolite levels;	chr5:132369766	chr5:132311285~132369916:-
PRAD	cis	rs2739330	0.828	rs5760099	ENSG00000235689.1	AP000351.13	9	6.32e-18	4.4e-15	0.47	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:24006305~24008258:-
PRAD	cis	rs11098499	0.738	rs72918577	ENSG00000245958.5	RP11-33B1.1	-9	6.33e-18	4.41e-15	-0.38	-0.39	Corneal astigmatism;	chr4:119405546	chr4:119454791~119552025:+
PRAD	cis	rs4835473	0.932	rs11730929	ENSG00000251600.4	RP11-673E1.1	-9	6.34e-18	4.41e-15	-0.51	-0.39	Immature fraction of reticulocytes;	chr4:143834795	chr4:143912331~143982454:+
PRAD	cis	rs10246939	0.543	rs11765575	ENSG00000228775.6	WEE2-AS1	9	6.35e-18	4.41e-15	0.47	0.39	Bitter taste perception;	chr7:141838168	chr7:141704338~141738346:-
PRAD	cis	rs1062177	1	rs62377945	ENSG00000253921.1	CTB-113P19.3	-9	6.37e-18	4.43e-15	-0.52	-0.39	Preschool internalizing problems;	chr5:151828443	chr5:151753992~151767247:+
PRAD	cis	rs4835473	0.897	rs7678190	ENSG00000251600.4	RP11-673E1.1	9	6.38e-18	4.43e-15	0.49	0.39	Immature fraction of reticulocytes;	chr4:143722421	chr4:143912331~143982454:+
PRAD	cis	rs11676348	0.873	rs10210012	ENSG00000261338.2	RP11-378A13.1	-9	6.41e-18	4.46e-15	-0.43	-0.39	Ulcerative colitis;	chr2:218148611	chr2:218255319~218257366:+
PRAD	cis	rs11098499	0.909	rs11723757	ENSG00000245958.5	RP11-33B1.1	-8.99	6.42e-18	4.46e-15	-0.38	-0.39	Corneal astigmatism;	chr4:119378514	chr4:119454791~119552025:+
PRAD	cis	rs853679	0.517	rs9393893	ENSG00000226314.6	ZNF192P1	-8.99	6.47e-18	4.49e-15	-0.53	-0.39	Depression;	chr6:28141484	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs4713146	ENSG00000226314.6	ZNF192P1	-8.99	6.47e-18	4.49e-15	-0.53	-0.39	Depression;	chr6:28143758	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs9393894	ENSG00000226314.6	ZNF192P1	-8.99	6.47e-18	4.49e-15	-0.53	-0.39	Depression;	chr6:28144784	chr6:28161781~28169594:+
PRAD	cis	rs6991838	0.67	rs869151	ENSG00000272010.1	CTD-3025N20.3	8.99	6.49e-18	4.51e-15	0.38	0.39	Intelligence (multi-trait analysis);	chr8:65726487	chr8:65591850~65592472:-
PRAD	cis	rs11096990	0.593	rs4580660	ENSG00000249207.1	RP11-360F5.1	-8.99	6.49e-18	4.51e-15	-0.4	-0.39	Cognitive function;	chr4:39152216	chr4:39112677~39126818:-
PRAD	cis	rs2348418	0.864	rs6487689	ENSG00000247934.4	RP11-967K21.1	8.99	6.5e-18	4.51e-15	0.36	0.39	Lung function (FEV1);Lung function (FVC);	chr12:28560101	chr12:28163298~28190738:-
PRAD	cis	rs11673344	0.764	rs547483	ENSG00000226686.6	LINC01535	-8.99	6.55e-18	4.55e-15	-0.53	-0.39	Obesity-related traits;	chr19:36950463	chr19:37251912~37265535:+
PRAD	cis	rs11098499	0.618	rs28491261	ENSG00000245958.5	RP11-33B1.1	-8.99	6.55e-18	4.55e-15	-0.38	-0.39	Corneal astigmatism;	chr4:119373745	chr4:119454791~119552025:+
PRAD	cis	rs7181230	0.885	rs4924413	ENSG00000275636.1	RP11-521C20.5	8.99	6.6e-18	4.58e-15	0.57	0.39	Dehydroepiandrosterone sulphate levels;	chr15:40056496	chr15:40078892~40079347:+
PRAD	cis	rs950169	0.887	rs220333	ENSG00000225151.9	GOLGA2P7	-8.99	6.6e-18	4.58e-15	-0.54	-0.39	Schizophrenia;	chr15:84547902	chr15:84199311~84230136:-
PRAD	cis	rs11098499	0.954	rs9993199	ENSG00000245958.5	RP11-33B1.1	8.99	6.63e-18	4.6e-15	0.39	0.39	Corneal astigmatism;	chr4:119471718	chr4:119454791~119552025:+
PRAD	cis	rs7712401	0.601	rs144597	ENSG00000263432.2	RN7SL689P	8.99	6.63e-18	4.6e-15	0.4	0.39	Mean platelet volume;	chr5:122887537	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.601	rs246282	ENSG00000263432.2	RN7SL689P	8.99	6.63e-18	4.6e-15	0.4	0.39	Mean platelet volume;	chr5:122889910	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.623	rs538424	ENSG00000263432.2	RN7SL689P	8.99	6.63e-18	4.6e-15	0.4	0.39	Mean platelet volume;	chr5:122893068	chr5:123022487~123022783:-
PRAD	cis	rs9545047	0.584	rs1886494	ENSG00000227676.3	LINC01068	-8.99	6.64e-18	4.61e-15	-0.46	-0.39	Schizophrenia;	chr13:79403005	chr13:79566727~79571436:+
PRAD	cis	rs853679	0.76	rs9468317	ENSG00000280107.1	AL022393.9	-8.99	6.65e-18	4.61e-15	-0.54	-0.39	Depression;	chr6:28230678	chr6:28170845~28172521:+
PRAD	cis	rs7189233	0.531	rs17801498	ENSG00000279344.1	RP11-44F14.7	8.99	6.65e-18	4.62e-15	0.35	0.39	Intelligence (multi-trait analysis);	chr16:53479540	chr16:53478957~53481550:-
PRAD	cis	rs2337406	0.789	rs112027230	ENSG00000274576.2	IGHV2-70	-8.99	6.65e-18	4.62e-15	-0.41	-0.39	Alzheimer's disease (late onset);	chr14:106810329	chr14:106770577~106771020:-
PRAD	cis	rs6991838	0.584	rs7463740	ENSG00000200714.1	Y_RNA	-8.99	6.66e-18	4.62e-15	-0.43	-0.39	Intelligence (multi-trait analysis);	chr8:65573950	chr8:65592731~65592820:+
PRAD	cis	rs2153535	0.585	rs9406185	ENSG00000230939.1	RP11-314C16.1	-8.99	6.67e-18	4.63e-15	-0.48	-0.39	Motion sickness;	chr6:8644491	chr6:8784178~8785445:+
PRAD	cis	rs3858145	0.588	rs4142048	ENSG00000233590.1	RP11-153K11.3	-8.99	6.73e-18	4.67e-15	-0.57	-0.39	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68284274	chr10:68233251~68242379:-
PRAD	cis	rs7829975	0.514	rs2920991	ENSG00000253893.2	FAM85B	-8.99	6.74e-18	4.67e-15	-0.48	-0.39	Mood instability;	chr8:8401607	chr8:8167819~8226614:-
PRAD	cis	rs67311347	1	rs11707278	ENSG00000223797.4	ENTPD3-AS1	8.99	6.75e-18	4.68e-15	0.36	0.39	Renal cell carcinoma;	chr3:40445584	chr3:40313802~40453329:-
PRAD	cis	rs2274273	0.87	rs13379169	ENSG00000258413.1	RP11-665C16.6	-8.99	6.76e-18	4.69e-15	-0.51	-0.39	Protein biomarker;	chr14:55274569	chr14:55262767~55272075:-
PRAD	cis	rs4835473	0.932	rs17695238	ENSG00000251600.4	RP11-673E1.1	-8.99	6.76e-18	4.69e-15	-0.51	-0.39	Immature fraction of reticulocytes;	chr4:143820720	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.868	rs35809032	ENSG00000251600.4	RP11-673E1.1	-8.99	6.76e-18	4.69e-15	-0.51	-0.39	Immature fraction of reticulocytes;	chr4:143824797	chr4:143912331~143982454:+
PRAD	cis	rs150992	0.587	rs13179812	ENSG00000248489.1	CTD-2007H13.3	-8.99	6.77e-18	4.69e-15	-0.43	-0.39	Body mass index;	chr5:99021029	chr5:98929171~98995013:+
PRAD	cis	rs17361889	0.766	rs1527221	ENSG00000224683.1	RPL36AP29	8.99	6.77e-18	4.69e-15	0.45	0.39	Pediatric bone mineral content (hip);	chr7:16207470	chr7:16208945~16209265:+
PRAD	cis	rs17023223	0.537	rs17023185	ENSG00000231365.4	RP11-418J17.1	-8.99	6.79e-18	4.71e-15	-0.4	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119068164	chr1:119140396~119275973:+
PRAD	cis	rs17023223	0.509	rs6668960	ENSG00000231365.4	RP11-418J17.1	-8.99	6.79e-18	4.71e-15	-0.4	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119058189	chr1:119140396~119275973:+
PRAD	cis	rs2153535	0.609	rs1328864	ENSG00000230939.1	RP11-314C16.1	-8.99	6.81e-18	4.72e-15	-0.47	-0.39	Motion sickness;	chr6:8656048	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.585	rs9379237	ENSG00000230939.1	RP11-314C16.1	-8.99	6.82e-18	4.73e-15	-0.47	-0.39	Motion sickness;	chr6:8654330	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.585	rs7450731	ENSG00000230939.1	RP11-314C16.1	-8.99	6.82e-18	4.73e-15	-0.47	-0.39	Motion sickness;	chr6:8656501	chr6:8784178~8785445:+
PRAD	cis	rs7811142	0.72	rs112622797	ENSG00000242294.5	STAG3L5P	8.99	6.88e-18	4.77e-15	0.27	0.39	Platelet count;	chr7:100319793	chr7:100336079~100351900:+
PRAD	cis	rs4835473	0.897	rs2590034	ENSG00000251600.4	RP11-673E1.1	8.99	6.89e-18	4.77e-15	0.49	0.39	Immature fraction of reticulocytes;	chr4:143926778	chr4:143912331~143982454:+
PRAD	cis	rs2274273	0.806	rs7146752	ENSG00000258413.1	RP11-665C16.6	-8.99	6.89e-18	4.77e-15	-0.51	-0.39	Protein biomarker;	chr14:55272189	chr14:55262767~55272075:-
PRAD	cis	rs435066	0.525	rs912498	ENSG00000234264.1	DEPDC1-AS1	-8.99	6.89e-18	4.78e-15	-0.55	-0.39	IgG glycosylation;	chr1:68538073	chr1:68496676~68538627:+
PRAD	cis	rs4835473	0.932	rs17763107	ENSG00000251600.4	RP11-673E1.1	-8.99	6.91e-18	4.79e-15	-0.51	-0.39	Immature fraction of reticulocytes;	chr4:143828512	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs17695782	ENSG00000251600.4	RP11-673E1.1	-8.99	6.91e-18	4.79e-15	-0.51	-0.39	Immature fraction of reticulocytes;	chr4:143830311	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs34917094	ENSG00000251600.4	RP11-673E1.1	-8.99	6.91e-18	4.79e-15	-0.51	-0.39	Immature fraction of reticulocytes;	chr4:143832003	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs11736609	ENSG00000251600.4	RP11-673E1.1	-8.99	6.91e-18	4.79e-15	-0.51	-0.39	Immature fraction of reticulocytes;	chr4:143832876	chr4:143912331~143982454:+
PRAD	cis	rs6452524	0.935	rs7703318	ENSG00000249664.1	CTD-2227C6.2	8.99	6.93e-18	4.8e-15	0.45	0.39	Hypertension (SNP x SNP interaction);	chr5:83118234	chr5:83012285~83013109:-
PRAD	cis	rs4835473	0.868	rs62337291	ENSG00000251600.4	RP11-673E1.1	-8.98	7e-18	4.85e-15	-0.49	-0.39	Immature fraction of reticulocytes;	chr4:143807903	chr4:143912331~143982454:+
PRAD	cis	rs8072100	0.967	rs11656855	ENSG00000228782.6	CTD-2026D20.3	-8.98	7.01e-18	4.85e-15	-0.43	-0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47637289	chr17:47450568~47492492:-
PRAD	cis	rs2274273	0.84	rs2341622	ENSG00000258413.1	RP11-665C16.6	-8.98	7.04e-18	4.88e-15	-0.51	-0.39	Protein biomarker;	chr14:55270525	chr14:55262767~55272075:-
PRAD	cis	rs2638953	0.888	rs11610011	ENSG00000278733.1	RP11-425D17.1	-8.98	7.07e-18	4.89e-15	-0.47	-0.39	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28202801	chr12:28185625~28186190:-
PRAD	cis	rs4713118	0.513	rs149954	ENSG00000280107.1	AL022393.9	-8.98	7.08e-18	4.9e-15	-0.47	-0.39	Parkinson's disease;	chr6:28067468	chr6:28170845~28172521:+
PRAD	cis	rs2404602	0.716	rs17460201	ENSG00000259422.1	RP11-593F23.1	-8.98	7.14e-18	4.94e-15	-0.48	-0.39	Blood metabolite levels;	chr15:76381286	chr15:76174891~76181486:-
PRAD	cis	rs3814244	0.933	rs12423194	ENSG00000255733.4	IFNG-AS1	8.98	7.16e-18	4.95e-15	0.4	0.39	Itch intensity from mosquito bite adjusted by bite size;	chr12:68020387	chr12:67989445~68234686:+
PRAD	cis	rs9309473	1	rs6715819	ENSG00000163016.8	ALMS1P	8.98	7.17e-18	4.96e-15	0.49	0.39	Metabolite levels;	chr2:73545182	chr2:73644919~73685576:+
PRAD	cis	rs2274273	0.773	rs8012380	ENSG00000258413.1	RP11-665C16.6	-8.98	7.21e-18	4.98e-15	-0.51	-0.39	Protein biomarker;	chr14:55268292	chr14:55262767~55272075:-
PRAD	cis	rs524281	0.731	rs10791841	ENSG00000255320.1	RP11-755F10.1	8.98	7.26e-18	5.02e-15	0.68	0.39	Electroencephalogram traits;	chr11:66041116	chr11:66244840~66246239:-
PRAD	cis	rs6538678	1	rs6538678	ENSG00000258343.1	RP11-536G4.2	-8.98	7.3e-18	5.04e-15	-0.54	-0.39	Lupus nephritis in systemic lupus erythematosus;	chr12:95867790	chr12:95795345~95858839:-
PRAD	cis	rs2412819	0.571	rs8030536	ENSG00000205771.5	CATSPER2P1	-8.98	7.3e-18	5.05e-15	-0.56	-0.39	Lung cancer;	chr15:43627365	chr15:43726918~43747094:-
PRAD	cis	rs2153535	0.553	rs6932565	ENSG00000230939.1	RP11-314C16.1	-8.98	7.31e-18	5.05e-15	-0.48	-0.39	Motion sickness;	chr6:8644926	chr6:8784178~8785445:+
PRAD	cis	rs3096299	0.838	rs4785561	ENSG00000274627.1	RP11-104N10.2	8.98	7.31e-18	5.05e-15	0.41	0.39	Multiple myeloma (IgH translocation);	chr16:89362644	chr16:89516797~89522217:+
PRAD	cis	rs1576263	0.504	rs1854411	ENSG00000230939.1	RP11-314C16.1	-8.98	7.31e-18	5.05e-15	-0.47	-0.39	Photic sneeze reflex;	chr6:8545771	chr6:8784178~8785445:+
PRAD	cis	rs17361889	0.806	rs1918259	ENSG00000224683.1	RPL36AP29	8.98	7.35e-18	5.08e-15	0.46	0.39	Pediatric bone mineral content (hip);	chr7:16205732	chr7:16208945~16209265:+
PRAD	cis	rs17361889	0.806	rs6961874	ENSG00000224683.1	RPL36AP29	8.98	7.35e-18	5.08e-15	0.46	0.39	Pediatric bone mineral content (hip);	chr7:16207299	chr7:16208945~16209265:+
PRAD	cis	rs8177376	0.861	rs4937119	ENSG00000254905.1	RP11-712L6.7	8.98	7.37e-18	5.09e-15	0.49	0.39	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126297825	chr11:126292922~126294254:-
PRAD	cis	rs10515750	0.643	rs10063413	ENSG00000248544.2	CTB-47B11.3	-8.98	7.39e-18	5.11e-15	-0.72	-0.39	Lung function (FEV1/FVC);	chr5:157384435	chr5:157375741~157384950:-
PRAD	cis	rs3858145	0.588	rs61854837	ENSG00000233590.1	RP11-153K11.3	-8.98	7.43e-18	5.13e-15	-0.58	-0.39	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68282613	chr10:68233251~68242379:-
PRAD	cis	rs1167827	0.68	rs1167796	ENSG00000127957.15	PMS2P3	8.98	7.45e-18	5.15e-15	0.32	0.39	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75543861	chr7:75502930~75528148:-
PRAD	cis	rs7811142	0.83	rs11771936	ENSG00000242294.5	STAG3L5P	8.98	7.45e-18	5.15e-15	0.26	0.39	Platelet count;	chr7:100345660	chr7:100336079~100351900:+
PRAD	cis	rs6723108	0.627	rs62168872	ENSG00000224043.6	CCNT2-AS1	-8.98	7.46e-18	5.15e-15	-0.53	-0.39	Type 2 diabetes;	chr2:134904177	chr2:134735464~134918710:-
PRAD	cis	rs6723108	0.627	rs4954196	ENSG00000224043.6	CCNT2-AS1	-8.98	7.46e-18	5.15e-15	-0.53	-0.39	Type 2 diabetes;	chr2:134904446	chr2:134735464~134918710:-
PRAD	cis	rs6723108	0.627	rs4954197	ENSG00000224043.6	CCNT2-AS1	-8.98	7.46e-18	5.15e-15	-0.53	-0.39	Type 2 diabetes;	chr2:134904674	chr2:134735464~134918710:-
PRAD	cis	rs2739330	0.828	rs4822451	ENSG00000235689.1	AP000351.13	8.98	7.47e-18	5.16e-15	0.47	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:24006305~24008258:-
PRAD	cis	rs2658782	0.724	rs2605629	ENSG00000279684.1	RP11-755E23.2	8.97	7.53e-18	5.2e-15	0.61	0.39	Pulmonary function decline;	chr11:93530871	chr11:93286629~93288903:-
PRAD	cis	rs2581828	0.632	rs891369	ENSG00000242142.1	SERBP1P3	-8.97	7.55e-18	5.21e-15	-0.46	-0.39	Crohn's disease;	chr3:53102535	chr3:53064283~53065091:-
PRAD	cis	rs13217239	0.646	rs7747454	ENSG00000241549.7	GUSBP2	-8.97	7.6e-18	5.24e-15	-0.43	-0.39	Schizophrenia;	chr6:27066474	chr6:26871484~26956554:-
PRAD	cis	rs853679	0.513	rs13437444	ENSG00000219392.1	RP1-265C24.5	-8.97	7.69e-18	5.31e-15	-0.57	-0.39	Depression;	chr6:28103220	chr6:28115628~28116551:+
PRAD	cis	rs1062177	1	rs12654573	ENSG00000253921.1	CTB-113P19.3	-8.97	7.75e-18	5.35e-15	-0.5	-0.39	Preschool internalizing problems;	chr5:151827912	chr5:151753992~151767247:+
PRAD	cis	rs11159086	0.729	rs8015872	ENSG00000259005.1	RP3-449M8.6	8.97	7.75e-18	5.35e-15	0.49	0.39	Advanced glycation end-product levels;	chr14:74475529	chr14:74474007~74474864:-
PRAD	cis	rs11159086	0.793	rs10147316	ENSG00000259005.1	RP3-449M8.6	8.97	7.75e-18	5.35e-15	0.49	0.39	Advanced glycation end-product levels;	chr14:74475688	chr14:74474007~74474864:-
PRAD	cis	rs11159086	0.838	rs10147963	ENSG00000259005.1	RP3-449M8.6	8.97	7.75e-18	5.35e-15	0.49	0.39	Advanced glycation end-product levels;	chr14:74476091	chr14:74474007~74474864:-
PRAD	cis	rs11159086	0.793	rs8021664	ENSG00000259005.1	RP3-449M8.6	8.97	7.75e-18	5.35e-15	0.49	0.39	Advanced glycation end-product levels;	chr14:74476592	chr14:74474007~74474864:-
PRAD	cis	rs11159086	0.793	rs1860108	ENSG00000259005.1	RP3-449M8.6	8.97	7.75e-18	5.35e-15	0.49	0.39	Advanced glycation end-product levels;	chr14:74478562	chr14:74474007~74474864:-
PRAD	cis	rs12220777	1	rs118110670	ENSG00000230091.5	TMEM254-AS1	8.97	7.75e-18	5.35e-15	0.78	0.39	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80032486	chr10:80046860~80078912:-
PRAD	cis	rs950169	0.922	rs11630507	ENSG00000225151.9	GOLGA2P7	-8.97	7.77e-18	5.36e-15	-0.54	-0.39	Schizophrenia;	chr15:84552494	chr15:84199311~84230136:-
PRAD	cis	rs4835473	0.897	rs4054616	ENSG00000251600.4	RP11-673E1.1	8.97	7.77e-18	5.36e-15	0.51	0.39	Immature fraction of reticulocytes;	chr4:143837472	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.897	rs2323325	ENSG00000251600.4	RP11-673E1.1	8.97	7.77e-18	5.36e-15	0.51	0.39	Immature fraction of reticulocytes;	chr4:143837561	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.8	rs4835330	ENSG00000251600.4	RP11-673E1.1	8.97	7.77e-18	5.36e-15	0.51	0.39	Immature fraction of reticulocytes;	chr4:143846303	chr4:143912331~143982454:+
PRAD	cis	rs950169	1	rs1818950	ENSG00000259728.4	LINC00933	8.97	7.77e-18	5.36e-15	0.46	0.39	Schizophrenia;	chr15:84053769	chr15:84570649~84580175:+
PRAD	cis	rs4888378	0.6	rs729109	ENSG00000261783.1	RP11-252K23.2	8.97	7.78e-18	5.37e-15	0.62	0.39	Coronary artery disease;	chr16:75282176	chr16:75379818~75381260:-
PRAD	cis	rs9322193	0.607	rs6557165	ENSG00000216906.2	RP11-350J20.9	-8.97	7.78e-18	5.37e-15	-0.49	-0.39	Lung cancer;	chr6:149906883	chr6:149904243~149906418:+
PRAD	cis	rs9399137	0.507	rs11758774	ENSG00000232876.1	CTA-212D2.2	-8.97	7.79e-18	5.37e-15	-0.5	-0.39	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135062651	chr6:135055033~135060550:+
PRAD	cis	rs748404	0.69	rs1079309	ENSG00000249839.1	AC011330.5	-8.97	7.86e-18	5.42e-15	-0.47	-0.39	Lung cancer;	chr15:43490966	chr15:43663654~43684339:-
PRAD	cis	rs2933343	0.951	rs789218	ENSG00000261159.1	RP11-723O4.9	8.97	7.86e-18	5.42e-15	0.37	0.39	IgG glycosylation;	chr3:128873827	chr3:128859716~128860526:-
PRAD	cis	rs765787	0.53	rs11070444	ENSG00000259520.4	CTD-2651B20.3	-8.97	7.87e-18	5.43e-15	-0.5	-0.39	Uric acid levels;	chr15:45220923	chr15:45251580~45279251:-
PRAD	cis	rs765787	0.53	rs11070445	ENSG00000259520.4	CTD-2651B20.3	-8.97	7.87e-18	5.43e-15	-0.5	-0.39	Uric acid levels;	chr15:45220965	chr15:45251580~45279251:-
PRAD	cis	rs8062405	0.721	rs151181	ENSG00000251417.2	RP11-1348G14.4	-8.97	7.88e-18	5.44e-15	-0.43	-0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28479196	chr16:28802743~28817828:+
PRAD	cis	rs67311347	1	rs66841330	ENSG00000223797.4	ENTPD3-AS1	8.97	7.89e-18	5.44e-15	0.36	0.39	Renal cell carcinoma;	chr3:40489632	chr3:40313802~40453329:-
PRAD	cis	rs11123170	0.543	rs2863242	ENSG00000274877.1	RP11-65I12.1	-8.97	7.89e-18	5.44e-15	-0.61	-0.39	Renal function-related traits (BUN);	chr2:113231659	chr2:113237595~113240825:+
PRAD	cis	rs4835473	0.932	rs6826665	ENSG00000251600.4	RP11-673E1.1	-8.97	7.89e-18	5.44e-15	-0.5	-0.39	Immature fraction of reticulocytes;	chr4:143795140	chr4:143912331~143982454:+
PRAD	cis	rs853679	0.517	rs1904840	ENSG00000226314.6	ZNF192P1	-8.97	7.96e-18	5.49e-15	-0.53	-0.39	Depression;	chr6:28140454	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs9368555	ENSG00000226314.6	ZNF192P1	-8.97	7.96e-18	5.49e-15	-0.53	-0.39	Depression;	chr6:28141189	chr6:28161781~28169594:+
PRAD	cis	rs2274273	0.837	rs6573010	ENSG00000258413.1	RP11-665C16.6	-8.97	7.97e-18	5.49e-15	-0.51	-0.39	Protein biomarker;	chr14:55254874	chr14:55262767~55272075:-
PRAD	cis	rs13217239	0.646	rs9379956	ENSG00000241549.7	GUSBP2	-8.97	7.98e-18	5.5e-15	-0.43	-0.39	Schizophrenia;	chr6:27065956	chr6:26871484~26956554:-
PRAD	cis	rs4835473	0.808	rs62339607	ENSG00000251600.4	RP11-673E1.1	-8.97	7.99e-18	5.51e-15	-0.49	-0.39	Immature fraction of reticulocytes;	chr4:143791474	chr4:143912331~143982454:+
PRAD	cis	rs6991838	0.831	rs4394432	ENSG00000272010.1	CTD-3025N20.3	8.97	8e-18	5.52e-15	0.37	0.39	Intelligence (multi-trait analysis);	chr8:65560939	chr8:65591850~65592472:-
PRAD	cis	rs6991838	0.771	rs13282323	ENSG00000272010.1	CTD-3025N20.3	8.97	8e-18	5.52e-15	0.37	0.39	Intelligence (multi-trait analysis);	chr8:65560557	chr8:65591850~65592472:-
PRAD	cis	rs2933343	0.679	rs789221	ENSG00000231305.3	RP11-723O4.2	8.97	8.01e-18	5.52e-15	0.36	0.39	IgG glycosylation;	chr3:128872782	chr3:128861313~128871540:-
PRAD	cis	rs6847067	0.8	rs2046404	ENSG00000180769.7	WDFY3-AS2	8.97	8.02e-18	5.53e-15	0.41	0.39	Oropharynx cancer;	chr4:84886601	chr4:84965682~85011277:+
PRAD	cis	rs3858145	0.588	rs4142049	ENSG00000233590.1	RP11-153K11.3	-8.97	8.02e-18	5.53e-15	-0.56	-0.39	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68284695	chr10:68233251~68242379:-
PRAD	cis	rs4820294	1	rs7291867	ENSG00000233360.4	Z83844.1	8.97	8.05e-18	5.55e-15	0.5	0.39	Fat distribution (HIV);	chr22:37666105	chr22:37641832~37658377:-
PRAD	cis	rs1185460	1	rs7938944	ENSG00000271751.1	RP11-110I1.14	-8.97	8.09e-18	5.57e-15	-0.54	-0.39	Coronary artery disease;	chr11:119083356	chr11:119065263~119065677:-
PRAD	cis	rs8177376	1	rs655540	ENSG00000254905.1	RP11-712L6.7	8.96	8.11e-18	5.59e-15	0.49	0.39	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126281347	chr11:126292922~126294254:-
PRAD	cis	rs4713118	0.629	rs203889	ENSG00000226314.6	ZNF192P1	-8.96	8.13e-18	5.6e-15	-0.52	-0.39	Parkinson's disease;	chr6:28053997	chr6:28161781~28169594:+
PRAD	cis	rs2274273	0.774	rs17128440	ENSG00000258413.1	RP11-665C16.6	-8.96	8.13e-18	5.6e-15	-0.5	-0.39	Protein biomarker;	chr14:55395194	chr14:55262767~55272075:-
PRAD	cis	rs7811142	0.83	rs11761253	ENSG00000242294.5	STAG3L5P	8.96	8.15e-18	5.62e-15	0.26	0.39	Platelet count;	chr7:100341698	chr7:100336079~100351900:+
PRAD	cis	rs1930961	1	rs6004675	ENSG00000272798.1	CTA-390C10.9	-8.96	8.18e-18	5.63e-15	-0.63	-0.39	Bipolar disorder with mood-incongruent psychosis;	chr22:25493418	chr22:25436312~25436915:+
PRAD	cis	rs10246939	0.543	rs35836873	ENSG00000228775.6	WEE2-AS1	8.96	8.19e-18	5.64e-15	0.47	0.39	Bitter taste perception;	chr7:141844010	chr7:141704338~141738346:-
PRAD	cis	rs10246939	0.543	rs9640358	ENSG00000228775.6	WEE2-AS1	8.96	8.19e-18	5.64e-15	0.47	0.39	Bitter taste perception;	chr7:141844082	chr7:141704338~141738346:-
PRAD	cis	rs4835473	0.897	rs6537167	ENSG00000251600.4	RP11-673E1.1	8.96	8.19e-18	5.64e-15	0.47	0.39	Immature fraction of reticulocytes;	chr4:143691323	chr4:143912331~143982454:+
PRAD	cis	rs2274273	0.87	rs8013713	ENSG00000258413.1	RP11-665C16.6	8.96	8.19e-18	5.64e-15	0.51	0.39	Protein biomarker;	chr14:55374534	chr14:55262767~55272075:-
PRAD	cis	rs7181230	0.885	rs35781999	ENSG00000275636.1	RP11-521C20.5	8.96	8.2e-18	5.65e-15	0.57	0.39	Dehydroepiandrosterone sulphate levels;	chr15:40063205	chr15:40078892~40079347:+
PRAD	cis	rs7181230	0.885	rs28444847	ENSG00000275636.1	RP11-521C20.5	8.96	8.2e-18	5.65e-15	0.57	0.39	Dehydroepiandrosterone sulphate levels;	chr15:40064403	chr15:40078892~40079347:+
PRAD	cis	rs7567389	0.704	rs4662714	ENSG00000236682.1	AC068282.3	8.96	8.22e-18	5.66e-15	0.48	0.39	Self-rated health;	chr2:127237637	chr2:127389130~127400580:+
PRAD	cis	rs853679	0.882	rs4713139	ENSG00000280107.1	AL022393.9	-8.96	8.24e-18	5.68e-15	-0.65	-0.39	Depression;	chr6:28124907	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.882	rs3757188	ENSG00000280107.1	AL022393.9	-8.96	8.24e-18	5.68e-15	-0.65	-0.39	Depression;	chr6:28139579	chr6:28170845~28172521:+
PRAD	cis	rs75422866	0.867	rs73104112	ENSG00000257433.4	RP1-197B17.3	8.96	8.26e-18	5.69e-15	0.73	0.39	Pneumonia;	chr12:47680969	chr12:47706085~47742294:+
PRAD	cis	rs2153535	0.518	rs9328485	ENSG00000230939.1	RP11-314C16.1	-8.96	8.26e-18	5.69e-15	-0.46	-0.39	Motion sickness;	chr6:8524831	chr6:8784178~8785445:+
PRAD	cis	rs3096299	0.9	rs2911258	ENSG00000274627.1	RP11-104N10.2	8.96	8.27e-18	5.69e-15	0.4	0.39	Multiple myeloma (IgH translocation);	chr16:89414352	chr16:89516797~89522217:+
PRAD	cis	rs853679	0.882	rs4713140	ENSG00000280107.1	AL022393.9	-8.96	8.32e-18	5.72e-15	-0.65	-0.39	Depression;	chr6:28129415	chr6:28170845~28172521:+
PRAD	cis	rs950169	0.881	rs150965	ENSG00000225151.9	GOLGA2P7	-8.96	8.32e-18	5.73e-15	-0.55	-0.39	Schizophrenia;	chr15:84537296	chr15:84199311~84230136:-
PRAD	cis	rs2153535	0.536	rs78180822	ENSG00000230939.1	RP11-314C16.1	-8.96	8.32e-18	5.73e-15	-0.47	-0.39	Motion sickness;	chr6:8620941	chr6:8784178~8785445:+
PRAD	cis	rs7189233	0.531	rs11859538	ENSG00000279344.1	RP11-44F14.7	8.96	8.4e-18	5.78e-15	0.35	0.39	Intelligence (multi-trait analysis);	chr16:53463133	chr16:53478957~53481550:-
PRAD	cis	rs7772486	0.846	rs2748496	ENSG00000235652.6	RP11-545I5.3	8.96	8.42e-18	5.79e-15	0.39	0.39	Lobe attachment (rater-scored or self-reported);	chr6:146000693	chr6:145799409~145886585:+
PRAD	cis	rs2564921	0.704	rs62253603	ENSG00000242142.1	SERBP1P3	-8.96	8.43e-18	5.8e-15	-0.45	-0.39	Height;	chr3:52938846	chr3:53064283~53065091:-
PRAD	cis	rs2564921	0.704	rs62253604	ENSG00000242142.1	SERBP1P3	-8.96	8.43e-18	5.8e-15	-0.45	-0.39	Height;	chr3:52941053	chr3:53064283~53065091:-
PRAD	cis	rs9918079	0.6	rs12500587	ENSG00000273133.1	RP11-799M12.2	8.96	8.44e-18	5.8e-15	0.51	0.39	Obesity-related traits;	chr4:15579131	chr4:15563698~15564253:-
PRAD	cis	rs6723108	0.627	rs766271	ENSG00000224043.6	CCNT2-AS1	-8.96	8.44e-18	5.81e-15	-0.54	-0.39	Type 2 diabetes;	chr2:134909561	chr2:134735464~134918710:-
PRAD	cis	rs2274273	0.805	rs10131926	ENSG00000258413.1	RP11-665C16.6	-8.96	8.45e-18	5.81e-15	-0.51	-0.39	Protein biomarker;	chr14:55246528	chr14:55262767~55272075:-
PRAD	cis	rs7849270	0.679	rs10988217	ENSG00000268707.1	RP11-247A12.7	-8.96	8.49e-18	5.84e-15	-0.43	-0.39	Blood metabolite ratios;	chr9:129125837	chr9:129170434~129170940:+
PRAD	cis	rs7189233	0.531	rs1074182	ENSG00000279344.1	RP11-44F14.7	8.96	8.51e-18	5.85e-15	0.36	0.39	Intelligence (multi-trait analysis);	chr16:53437445	chr16:53478957~53481550:-
PRAD	cis	rs5769707	0.706	rs2071903	ENSG00000188511.11	C22orf34	8.96	8.54e-18	5.87e-15	0.45	0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49640869	chr22:49414524~49657542:-
PRAD	cis	rs4835473	0.932	rs9997931	ENSG00000251600.4	RP11-673E1.1	8.96	8.54e-18	5.87e-15	0.48	0.39	Immature fraction of reticulocytes;	chr4:143904601	chr4:143912331~143982454:+
PRAD	cis	rs7772486	0.875	rs56181683	ENSG00000235652.6	RP11-545I5.3	-8.96	8.58e-18	5.9e-15	-0.39	-0.39	Lobe attachment (rater-scored or self-reported);	chr6:145965484	chr6:145799409~145886585:+
PRAD	cis	rs1075232	1	rs72722861	ENSG00000270055.1	CTD-3092A11.2	-8.96	8.61e-18	5.91e-15	-0.8	-0.39	Survival in colorectal cancer (non-distant metastatic);	chr15:31412085	chr15:30487963~30490313:+
PRAD	cis	rs1075232	0.826	rs12438813	ENSG00000270055.1	CTD-3092A11.2	-8.96	8.61e-18	5.91e-15	-0.8	-0.39	Survival in colorectal cancer (non-distant metastatic);	chr15:31413710	chr15:30487963~30490313:+
PRAD	cis	rs1075232	1	rs34959140	ENSG00000270055.1	CTD-3092A11.2	-8.96	8.61e-18	5.91e-15	-0.8	-0.39	Survival in colorectal cancer (non-distant metastatic);	chr15:31433020	chr15:30487963~30490313:+
PRAD	cis	rs3858145	0.588	rs76854765	ENSG00000233590.1	RP11-153K11.3	-8.96	8.62e-18	5.92e-15	-0.56	-0.39	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68277699	chr10:68233251~68242379:-
PRAD	cis	rs10262624	0.935	rs6955725	ENSG00000234286.1	AC006026.13	-8.96	8.65e-18	5.94e-15	-0.45	-0.39	Schizophrenia;	chr7:23865523	chr7:23680195~23680786:-
PRAD	cis	rs10262624	0.935	rs6955884	ENSG00000234286.1	AC006026.13	-8.96	8.65e-18	5.94e-15	-0.45	-0.39	Schizophrenia;	chr7:23865654	chr7:23680195~23680786:-
PRAD	cis	rs524281	0.731	rs1125078	ENSG00000255320.1	RP11-755F10.1	-8.96	8.66e-18	5.95e-15	-0.64	-0.39	Electroencephalogram traits;	chr11:66042404	chr11:66244840~66246239:-
PRAD	cis	rs2412819	0.571	rs8038068	ENSG00000205771.5	CATSPER2P1	-8.96	8.67e-18	5.96e-15	-0.56	-0.39	Lung cancer;	chr15:43622175	chr15:43726918~43747094:-
PRAD	cis	rs2412819	0.571	rs56246169	ENSG00000205771.5	CATSPER2P1	-8.96	8.67e-18	5.96e-15	-0.56	-0.39	Lung cancer;	chr15:43628358	chr15:43726918~43747094:-
PRAD	cis	rs7712401	0.601	rs1990890	ENSG00000263432.2	RN7SL689P	8.96	8.67e-18	5.96e-15	0.4	0.39	Mean platelet volume;	chr5:122847275	chr5:123022487~123022783:-
PRAD	cis	rs7829975	0.514	rs2979151	ENSG00000253893.2	FAM85B	8.96	8.69e-18	5.97e-15	0.48	0.39	Mood instability;	chr8:8400509	chr8:8167819~8226614:-
PRAD	cis	rs1062177	1	rs41494545	ENSG00000253921.1	CTB-113P19.3	8.96	8.73e-18	6e-15	0.52	0.39	Preschool internalizing problems;	chr5:151855533	chr5:151753992~151767247:+
PRAD	cis	rs8177376	1	rs7932766	ENSG00000254905.1	RP11-712L6.7	8.95	8.74e-18	6e-15	0.49	0.39	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126292967	chr11:126292922~126294254:-
PRAD	cis	rs34787248	1	rs34787248	ENSG00000280107.1	AL022393.9	-8.95	8.76e-18	6.02e-15	-0.53	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28230108	chr6:28170845~28172521:+
PRAD	cis	rs7211079	0.957	rs935117	ENSG00000279259.1	RP11-334C17.3	8.95	8.78e-18	6.03e-15	0.42	0.39	Myocardial infarction;	chr17:80141685	chr17:80147250~80148596:+
PRAD	cis	rs9309473	0.687	rs6706409	ENSG00000163016.8	ALMS1P	-8.95	8.81e-18	6.05e-15	-0.46	-0.39	Metabolite levels;	chr2:73379380	chr2:73644919~73685576:+
PRAD	cis	rs4835473	0.897	rs13135627	ENSG00000251600.4	RP11-673E1.1	-8.95	8.85e-18	6.07e-15	-0.5	-0.39	Immature fraction of reticulocytes;	chr4:143691099	chr4:143912331~143982454:+
PRAD	cis	rs1823874	0.924	rs4965542	ENSG00000182397.13	DNM1P46	-8.95	8.85e-18	6.08e-15	-0.37	-0.39	IgG glycosylation;	chr15:99816414	chr15:99790156~99806927:-
PRAD	cis	rs6991838	0.584	rs3765205	ENSG00000200714.1	Y_RNA	-8.95	8.87e-18	6.09e-15	-0.43	-0.39	Intelligence (multi-trait analysis);	chr8:65605251	chr8:65592731~65592820:+
PRAD	cis	rs4713118	0.662	rs9380045	ENSG00000226314.6	ZNF192P1	-8.95	8.88e-18	6.09e-15	-0.52	-0.39	Parkinson's disease;	chr6:28057501	chr6:28161781~28169594:+
PRAD	cis	rs4713118	0.616	rs9348789	ENSG00000226314.6	ZNF192P1	-8.95	8.88e-18	6.09e-15	-0.52	-0.39	Parkinson's disease;	chr6:28057708	chr6:28161781~28169594:+
PRAD	cis	rs4713118	0.662	rs9468274	ENSG00000226314.6	ZNF192P1	-8.95	8.88e-18	6.09e-15	-0.52	-0.39	Parkinson's disease;	chr6:28058299	chr6:28161781~28169594:+
PRAD	cis	rs4713118	0.662	rs9468275	ENSG00000226314.6	ZNF192P1	-8.95	8.88e-18	6.09e-15	-0.52	-0.39	Parkinson's disease;	chr6:28058358	chr6:28161781~28169594:+
PRAD	cis	rs4713118	0.662	rs9468276	ENSG00000226314.6	ZNF192P1	-8.95	8.88e-18	6.09e-15	-0.52	-0.39	Parkinson's disease;	chr6:28059910	chr6:28161781~28169594:+
PRAD	cis	rs4713118	0.662	rs9468277	ENSG00000226314.6	ZNF192P1	-8.95	8.88e-18	6.09e-15	-0.52	-0.39	Parkinson's disease;	chr6:28060612	chr6:28161781~28169594:+
PRAD	cis	rs4713118	0.662	rs9468278	ENSG00000226314.6	ZNF192P1	-8.95	8.88e-18	6.09e-15	-0.52	-0.39	Parkinson's disease;	chr6:28060704	chr6:28161781~28169594:+
PRAD	cis	rs4713118	0.662	rs13218430	ENSG00000226314.6	ZNF192P1	-8.95	8.88e-18	6.09e-15	-0.52	-0.39	Parkinson's disease;	chr6:28062059	chr6:28161781~28169594:+
PRAD	cis	rs2348418	0.864	rs7314984	ENSG00000247934.4	RP11-967K21.1	8.95	8.88e-18	6.1e-15	0.36	0.39	Lung function (FEV1);Lung function (FVC);	chr12:28557936	chr12:28163298~28190738:-
PRAD	cis	rs67311347	1	rs17078813	ENSG00000223797.4	ENTPD3-AS1	8.95	8.89e-18	6.1e-15	0.36	0.39	Renal cell carcinoma;	chr3:40392671	chr3:40313802~40453329:-
PRAD	cis	rs17023223	0.553	rs55696509	ENSG00000231365.4	RP11-418J17.1	-8.95	8.91e-18	6.11e-15	-0.44	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119144033	chr1:119140396~119275973:+
PRAD	cis	rs4835473	0.932	rs13117421	ENSG00000251600.4	RP11-673E1.1	-8.95	9e-18	6.17e-15	-0.51	-0.39	Immature fraction of reticulocytes;	chr4:143769405	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.838	rs34521499	ENSG00000251600.4	RP11-673E1.1	-8.95	9e-18	6.17e-15	-0.51	-0.39	Immature fraction of reticulocytes;	chr4:143777628	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.9	rs34264936	ENSG00000251600.4	RP11-673E1.1	-8.95	9e-18	6.17e-15	-0.51	-0.39	Immature fraction of reticulocytes;	chr4:143780294	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.9	rs13140028	ENSG00000251600.4	RP11-673E1.1	-8.95	9e-18	6.17e-15	-0.51	-0.39	Immature fraction of reticulocytes;	chr4:143782195	chr4:143912331~143982454:+
PRAD	cis	rs150992	0.587	rs4448016	ENSG00000248489.1	CTD-2007H13.3	8.95	9.04e-18	6.2e-15	0.43	0.39	Body mass index;	chr5:99037904	chr5:98929171~98995013:+
PRAD	cis	rs950169	0.84	rs12905223	ENSG00000225151.9	GOLGA2P7	-8.95	9.04e-18	6.2e-15	-0.54	-0.39	Schizophrenia;	chr15:84571037	chr15:84199311~84230136:-
PRAD	cis	rs1501911	0.53	rs162611	ENSG00000248489.1	CTD-2007H13.3	-8.95	9.05e-18	6.21e-15	-0.43	-0.39	Lung function (FEV1/FVC);	chr5:98809801	chr5:98929171~98995013:+
PRAD	cis	rs2933343	0.649	rs728839	ENSG00000231305.3	RP11-723O4.2	8.95	9.08e-18	6.23e-15	0.36	0.39	IgG glycosylation;	chr3:128870516	chr3:128861313~128871540:-
PRAD	cis	rs5769707	0.604	rs1018814	ENSG00000188511.11	C22orf34	8.95	9.09e-18	6.23e-15	0.46	0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49643252	chr22:49414524~49657542:-
PRAD	cis	rs853679	0.723	rs1736904	ENSG00000280107.1	AL022393.9	-8.95	9.14e-18	6.27e-15	-0.52	-0.39	Depression;	chr6:28251492	chr6:28170845~28172521:+
PRAD	cis	rs17361889	0.806	rs62440376	ENSG00000224683.1	RPL36AP29	8.95	9.16e-18	6.28e-15	0.47	0.39	Pediatric bone mineral content (hip);	chr7:16193307	chr7:16208945~16209265:+
PRAD	cis	rs77204473	0.549	rs12280210	ENSG00000254851.1	RP11-109L13.1	8.95	9.18e-18	6.29e-15	0.76	0.39	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117069733	chr11:117135528~117138582:+
PRAD	cis	rs2274273	0.84	rs6573013	ENSG00000258413.1	RP11-665C16.6	-8.95	9.19e-18	6.3e-15	-0.51	-0.39	Protein biomarker;	chr14:55269155	chr14:55262767~55272075:-
PRAD	cis	rs11676348	0.772	rs6738953	ENSG00000261338.2	RP11-378A13.1	-8.95	9.21e-18	6.31e-15	-0.42	-0.39	Ulcerative colitis;	chr2:218085313	chr2:218255319~218257366:+
PRAD	cis	rs4835473	0.932	rs1450235	ENSG00000251600.4	RP11-673E1.1	8.95	9.22e-18	6.32e-15	0.51	0.39	Immature fraction of reticulocytes;	chr4:143782927	chr4:143912331~143982454:+
PRAD	cis	rs1501911	0.53	rs161942	ENSG00000248489.1	CTD-2007H13.3	8.95	9.23e-18	6.33e-15	0.43	0.39	Lung function (FEV1/FVC);	chr5:98868016	chr5:98929171~98995013:+
PRAD	cis	rs748404	0.66	rs690472	ENSG00000249839.1	AC011330.5	-8.95	9.27e-18	6.35e-15	-0.47	-0.39	Lung cancer;	chr15:43472170	chr15:43663654~43684339:-
PRAD	cis	rs4713118	0.662	rs9357060	ENSG00000226314.6	ZNF192P1	-8.95	9.27e-18	6.36e-15	-0.52	-0.39	Parkinson's disease;	chr6:28056708	chr6:28161781~28169594:+
PRAD	cis	rs4713118	0.662	rs9468271	ENSG00000226314.6	ZNF192P1	-8.95	9.27e-18	6.36e-15	-0.52	-0.39	Parkinson's disease;	chr6:28056792	chr6:28161781~28169594:+
PRAD	cis	rs62445005	1	rs62445005	ENSG00000211697.3	TRGV5	8.95	9.31e-18	6.38e-15	0.58	0.39	Shingles;	chr7:38346957	chr7:38343894~38350022:-
PRAD	cis	rs4713118	0.621	rs9295755	ENSG00000226314.6	ZNF192P1	8.95	9.39e-18	6.44e-15	0.52	0.39	Parkinson's disease;	chr6:28065396	chr6:28161781~28169594:+
PRAD	cis	rs8177376	1	rs674218	ENSG00000254905.1	RP11-712L6.7	8.94	9.46e-18	6.48e-15	0.48	0.39	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126239165	chr11:126292922~126294254:-
PRAD	cis	rs8177376	0.861	rs4340064	ENSG00000254905.1	RP11-712L6.7	8.94	9.46e-18	6.48e-15	0.48	0.39	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126242165	chr11:126292922~126294254:-
PRAD	cis	rs8177376	1	rs73017350	ENSG00000254905.1	RP11-712L6.7	8.94	9.46e-18	6.48e-15	0.48	0.39	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126246064	chr11:126292922~126294254:-
PRAD	cis	rs62103177	0.525	rs8086024	ENSG00000261126.6	RP11-795F19.1	-8.94	9.47e-18	6.49e-15	-0.49	-0.39	Opioid sensitivity;	chr18:79986623	chr18:80046900~80095482:+
PRAD	cis	rs7189233	0.531	rs1131220	ENSG00000279344.1	RP11-44F14.7	8.94	9.49e-18	6.5e-15	0.35	0.39	Intelligence (multi-trait analysis);	chr16:53470022	chr16:53478957~53481550:-
PRAD	cis	rs7189233	0.513	rs10748	ENSG00000279344.1	RP11-44F14.7	8.94	9.49e-18	6.5e-15	0.35	0.39	Intelligence (multi-trait analysis);	chr16:53470809	chr16:53478957~53481550:-
PRAD	cis	rs7189233	0.531	rs8045674	ENSG00000279344.1	RP11-44F14.7	8.94	9.49e-18	6.5e-15	0.35	0.39	Intelligence (multi-trait analysis);	chr16:53476024	chr16:53478957~53481550:-
PRAD	cis	rs7811142	0.83	rs1063945	ENSG00000242294.5	STAG3L5P	8.94	9.52e-18	6.52e-15	0.26	0.39	Platelet count;	chr7:100332824	chr7:100336079~100351900:+
PRAD	cis	rs11673344	0.765	rs826296	ENSG00000226686.6	LINC01535	8.94	9.56e-18	6.55e-15	0.52	0.39	Obesity-related traits;	chr19:36947384	chr19:37251912~37265535:+
PRAD	cis	rs11673344	0.764	rs513406	ENSG00000226686.6	LINC01535	8.94	9.56e-18	6.55e-15	0.52	0.39	Obesity-related traits;	chr19:36948245	chr19:37251912~37265535:+
PRAD	cis	rs11673344	0.734	rs496872	ENSG00000226686.6	LINC01535	8.94	9.56e-18	6.55e-15	0.52	0.39	Obesity-related traits;	chr19:36948579	chr19:37251912~37265535:+
PRAD	cis	rs2412819	0.571	rs66903736	ENSG00000205771.5	CATSPER2P1	-8.94	9.59e-18	6.56e-15	-0.56	-0.39	Lung cancer;	chr15:43619435	chr15:43726918~43747094:-
PRAD	cis	rs2412819	0.571	rs66749753	ENSG00000205771.5	CATSPER2P1	-8.94	9.59e-18	6.56e-15	-0.56	-0.39	Lung cancer;	chr15:43619601	chr15:43726918~43747094:-
PRAD	cis	rs4835473	0.801	rs35839125	ENSG00000251600.4	RP11-673E1.1	-8.94	9.6e-18	6.57e-15	-0.49	-0.39	Immature fraction of reticulocytes;	chr4:143792351	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.75	rs12498381	ENSG00000251600.4	RP11-673E1.1	-8.94	9.6e-18	6.57e-15	-0.49	-0.39	Immature fraction of reticulocytes;	chr4:143793928	chr4:143912331~143982454:+
PRAD	cis	rs6991838	0.584	rs7463649	ENSG00000200714.1	Y_RNA	-8.94	9.62e-18	6.58e-15	-0.43	-0.39	Intelligence (multi-trait analysis);	chr8:65573760	chr8:65592731~65592820:+
PRAD	cis	rs6991838	0.584	rs66467166	ENSG00000200714.1	Y_RNA	-8.94	9.62e-18	6.58e-15	-0.43	-0.39	Intelligence (multi-trait analysis);	chr8:65574165	chr8:65592731~65592820:+
PRAD	cis	rs6991838	0.557	rs67685675	ENSG00000200714.1	Y_RNA	-8.94	9.62e-18	6.58e-15	-0.43	-0.39	Intelligence (multi-trait analysis);	chr8:65574371	chr8:65592731~65592820:+
PRAD	cis	rs6991838	0.584	rs66486920	ENSG00000200714.1	Y_RNA	-8.94	9.62e-18	6.58e-15	-0.43	-0.39	Intelligence (multi-trait analysis);	chr8:65574458	chr8:65592731~65592820:+
PRAD	cis	rs6991838	0.584	rs60023200	ENSG00000200714.1	Y_RNA	-8.94	9.62e-18	6.58e-15	-0.43	-0.39	Intelligence (multi-trait analysis);	chr8:65574547	chr8:65592731~65592820:+
PRAD	cis	rs6991838	0.584	rs61083799	ENSG00000200714.1	Y_RNA	-8.94	9.62e-18	6.58e-15	-0.43	-0.39	Intelligence (multi-trait analysis);	chr8:65574868	chr8:65592731~65592820:+
PRAD	cis	rs6991838	0.584	rs4449837	ENSG00000200714.1	Y_RNA	-8.94	9.62e-18	6.58e-15	-0.43	-0.39	Intelligence (multi-trait analysis);	chr8:65575917	chr8:65592731~65592820:+
PRAD	cis	rs2564921	0.73	rs62253602	ENSG00000242142.1	SERBP1P3	-8.94	9.64e-18	6.59e-15	-0.45	-0.39	Height;	chr3:52936861	chr3:53064283~53065091:-
PRAD	cis	rs2153535	0.585	rs7750891	ENSG00000230939.1	RP11-314C16.1	-8.94	9.64e-18	6.59e-15	-0.48	-0.39	Motion sickness;	chr6:8624613	chr6:8784178~8785445:+
PRAD	cis	rs4879677	0.736	rs12379575	ENSG00000260390.1	RP11-575I8.1	-8.94	9.65e-18	6.6e-15	-0.52	-0.39	Gut microbiome composition (summer and winter);	chr9:27639812	chr9:27829276~27844481:+
PRAD	cis	rs2153535	0.585	rs7753781	ENSG00000230939.1	RP11-314C16.1	-8.94	9.65e-18	6.6e-15	-0.47	-0.39	Motion sickness;	chr6:8637268	chr6:8784178~8785445:+
PRAD	cis	rs732716	0.889	rs11666856	ENSG00000267980.1	AC007292.6	-8.94	9.66e-18	6.61e-15	-0.39	-0.39	Mean corpuscular volume;	chr19:4437453	chr19:4363789~4364640:+
PRAD	cis	rs950169	0.922	rs4586394	ENSG00000259728.4	LINC00933	-8.94	9.67e-18	6.61e-15	-0.48	-0.39	Schizophrenia;	chr15:84153633	chr15:84570649~84580175:+
PRAD	cis	rs3858145	0.588	rs731063	ENSG00000233590.1	RP11-153K11.3	8.94	9.71e-18	6.64e-15	0.56	0.39	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68283433	chr10:68233251~68242379:-
PRAD	cis	rs1062177	0.774	rs2964574	ENSG00000253921.1	CTB-113P19.3	-8.94	9.76e-18	6.67e-15	-0.5	-0.39	Preschool internalizing problems;	chr5:151776150	chr5:151753992~151767247:+
PRAD	cis	rs2153535	0.585	rs1328874	ENSG00000230939.1	RP11-314C16.1	-8.94	9.79e-18	6.69e-15	-0.47	-0.39	Motion sickness;	chr6:8621010	chr6:8784178~8785445:+
PRAD	cis	rs2638953	0.924	rs11049437	ENSG00000278733.1	RP11-425D17.1	-8.94	9.84e-18	6.72e-15	-0.46	-0.39	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28196192	chr12:28185625~28186190:-
PRAD	cis	rs6991838	0.584	rs7841652	ENSG00000200714.1	Y_RNA	-8.94	9.88e-18	6.75e-15	-0.43	-0.39	Intelligence (multi-trait analysis);	chr8:65606392	chr8:65592731~65592820:+
PRAD	cis	rs4631830	0.863	rs2926494	ENSG00000230869.1	CTGLF10P	-8.94	9.97e-18	6.81e-15	-0.48	-0.39	Prostate-specific antigen levels;	chr10:46078466	chr10:45678692~45700532:+
PRAD	cis	rs2933343	0.859	rs789245	ENSG00000261159.1	RP11-723O4.9	8.94	9.97e-18	6.81e-15	0.37	0.39	IgG glycosylation;	chr3:128864737	chr3:128859716~128860526:-
PRAD	cis	rs853679	0.76	rs2299029	ENSG00000280107.1	AL022393.9	-8.94	9.99e-18	6.83e-15	-0.53	-0.39	Depression;	chr6:28231053	chr6:28170845~28172521:+
PRAD	cis	rs11159086	0.793	rs11845370	ENSG00000259005.1	RP3-449M8.6	8.94	9.99e-18	6.83e-15	0.49	0.39	Advanced glycation end-product levels;	chr14:74481587	chr14:74474007~74474864:-
PRAD	cis	rs11159086	0.793	rs3784035	ENSG00000259005.1	RP3-449M8.6	8.94	9.99e-18	6.83e-15	0.49	0.39	Advanced glycation end-product levels;	chr14:74482221	chr14:74474007~74474864:-
PRAD	cis	rs11159086	0.793	rs12433382	ENSG00000259005.1	RP3-449M8.6	8.94	9.99e-18	6.83e-15	0.49	0.39	Advanced glycation end-product levels;	chr14:74482940	chr14:74474007~74474864:-
PRAD	cis	rs11159086	0.793	rs10148268	ENSG00000259005.1	RP3-449M8.6	8.94	9.99e-18	6.83e-15	0.49	0.39	Advanced glycation end-product levels;	chr14:74484261	chr14:74474007~74474864:-
PRAD	cis	rs11159086	0.793	rs8015894	ENSG00000259005.1	RP3-449M8.6	8.94	9.99e-18	6.83e-15	0.49	0.39	Advanced glycation end-product levels;	chr14:74491917	chr14:74474007~74474864:-
PRAD	cis	rs172166	0.637	rs1233708	ENSG00000280107.1	AL022393.9	-8.94	1e-17	6.83e-15	-0.48	-0.39	Cardiac Troponin-T levels;	chr6:28205441	chr6:28170845~28172521:+
PRAD	cis	rs11159086	0.793	rs1029701	ENSG00000259005.1	RP3-449M8.6	8.94	1e-17	6.84e-15	0.49	0.39	Advanced glycation end-product levels;	chr14:74474112	chr14:74474007~74474864:-
PRAD	cis	rs2564921	0.704	rs62253606	ENSG00000242142.1	SERBP1P3	-8.94	1e-17	6.86e-15	-0.44	-0.39	Height;	chr3:52949886	chr3:53064283~53065091:-
PRAD	cis	rs2404602	0.716	rs8039545	ENSG00000259422.1	RP11-593F23.1	8.94	1.01e-17	6.91e-15	0.48	0.39	Blood metabolite levels;	chr15:76414906	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.716	rs7164060	ENSG00000259422.1	RP11-593F23.1	8.94	1.01e-17	6.91e-15	0.48	0.39	Blood metabolite levels;	chr15:76415353	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.716	rs7164813	ENSG00000259422.1	RP11-593F23.1	8.94	1.01e-17	6.91e-15	0.48	0.39	Blood metabolite levels;	chr15:76415725	chr15:76174891~76181486:-
PRAD	cis	rs465969	0.744	rs36007392	ENSG00000255389.1	C6orf3	-8.94	1.01e-17	6.92e-15	-0.73	-0.39	Psoriasis;	chr6:111509287	chr6:111599875~111602295:+
PRAD	cis	rs465969	1	rs13197107	ENSG00000255389.1	C6orf3	-8.94	1.01e-17	6.92e-15	-0.73	-0.39	Psoriasis;	chr6:111512031	chr6:111599875~111602295:+
PRAD	cis	rs2153535	0.585	rs1328870	ENSG00000230939.1	RP11-314C16.1	-8.94	1.02e-17	6.94e-15	-0.48	-0.39	Motion sickness;	chr6:8637803	chr6:8784178~8785445:+
PRAD	cis	rs1062177	1	rs17804178	ENSG00000253921.1	CTB-113P19.3	-8.94	1.02e-17	6.95e-15	-0.52	-0.39	Preschool internalizing problems;	chr5:151818168	chr5:151753992~151767247:+
PRAD	cis	rs11673344	0.764	rs826304	ENSG00000226686.6	LINC01535	8.94	1.02e-17	6.95e-15	0.52	0.39	Obesity-related traits;	chr19:36952681	chr19:37251912~37265535:+
PRAD	cis	rs34779708	0.931	rs2505631	ENSG00000230534.5	RP11-297A16.2	-8.93	1.02e-17	6.96e-15	-0.5	-0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35079457	chr10:35098006~35127020:-
PRAD	cis	rs6723108	0.517	rs4954192	ENSG00000224043.6	CCNT2-AS1	-8.93	1.02e-17	6.98e-15	-0.53	-0.39	Type 2 diabetes;	chr2:134875411	chr2:134735464~134918710:-
PRAD	cis	rs9595066	0.627	rs4942287	ENSG00000227258.4	SMIM2-AS1	-8.93	1.03e-17	7e-15	-0.62	-0.39	Schizophrenia;	chr13:44160560	chr13:44110451~44240517:+
PRAD	cis	rs6452524	1	rs2126990	ENSG00000249664.1	CTD-2227C6.2	8.93	1.03e-17	7.02e-15	0.45	0.39	Hypertension (SNP x SNP interaction);	chr5:83161351	chr5:83012285~83013109:-
PRAD	cis	rs853679	0.513	rs9468296	ENSG00000226314.6	ZNF192P1	-8.93	1.03e-17	7.02e-15	-0.52	-0.39	Depression;	chr6:28145952	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs4711164	ENSG00000226314.6	ZNF192P1	-8.93	1.03e-17	7.02e-15	-0.52	-0.39	Depression;	chr6:28147378	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs4711165	ENSG00000226314.6	ZNF192P1	-8.93	1.03e-17	7.02e-15	-0.52	-0.39	Depression;	chr6:28147406	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs4713148	ENSG00000226314.6	ZNF192P1	-8.93	1.03e-17	7.02e-15	-0.52	-0.39	Depression;	chr6:28148143	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs9348794	ENSG00000226314.6	ZNF192P1	-8.93	1.03e-17	7.02e-15	-0.52	-0.39	Depression;	chr6:28149979	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs9295758	ENSG00000226314.6	ZNF192P1	-8.93	1.03e-17	7.02e-15	-0.52	-0.39	Depression;	chr6:28152885	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs17774663	ENSG00000226314.6	ZNF192P1	-8.93	1.03e-17	7.02e-15	-0.52	-0.39	Depression;	chr6:28153120	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs9468298	ENSG00000226314.6	ZNF192P1	-8.93	1.03e-17	7.02e-15	-0.52	-0.39	Depression;	chr6:28154567	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs9295759	ENSG00000226314.6	ZNF192P1	-8.93	1.03e-17	7.02e-15	-0.52	-0.39	Depression;	chr6:28156691	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs9348796	ENSG00000226314.6	ZNF192P1	-8.93	1.03e-17	7.02e-15	-0.52	-0.39	Depression;	chr6:28158424	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs11552219	ENSG00000226314.6	ZNF192P1	-8.93	1.03e-17	7.02e-15	-0.52	-0.39	Depression;	chr6:28159056	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs9380058	ENSG00000226314.6	ZNF192P1	-8.93	1.03e-17	7.02e-15	-0.52	-0.39	Depression;	chr6:28159666	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs9393895	ENSG00000226314.6	ZNF192P1	-8.93	1.03e-17	7.02e-15	-0.52	-0.39	Depression;	chr6:28159843	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs9393896	ENSG00000226314.6	ZNF192P1	-8.93	1.03e-17	7.02e-15	-0.52	-0.39	Depression;	chr6:28159925	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs9393897	ENSG00000226314.6	ZNF192P1	-8.93	1.03e-17	7.02e-15	-0.52	-0.39	Depression;	chr6:28159932	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs9357066	ENSG00000226314.6	ZNF192P1	-8.93	1.03e-17	7.02e-15	-0.52	-0.39	Depression;	chr6:28162053	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs9393898	ENSG00000226314.6	ZNF192P1	-8.93	1.03e-17	7.02e-15	-0.52	-0.39	Depression;	chr6:28162598	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs9368556	ENSG00000226314.6	ZNF192P1	-8.93	1.03e-17	7.02e-15	-0.52	-0.39	Depression;	chr6:28163375	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs9368557	ENSG00000226314.6	ZNF192P1	-8.93	1.03e-17	7.02e-15	-0.52	-0.39	Depression;	chr6:28163759	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs9380059	ENSG00000226314.6	ZNF192P1	-8.93	1.03e-17	7.02e-15	-0.52	-0.39	Depression;	chr6:28164580	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs9380060	ENSG00000226314.6	ZNF192P1	-8.93	1.03e-17	7.02e-15	-0.52	-0.39	Depression;	chr6:28164825	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs35227624	ENSG00000226314.6	ZNF192P1	-8.93	1.03e-17	7.02e-15	-0.52	-0.39	Depression;	chr6:28164948	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs9380061	ENSG00000226314.6	ZNF192P1	-8.93	1.03e-17	7.02e-15	-0.52	-0.39	Depression;	chr6:28165025	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs9368558	ENSG00000226314.6	ZNF192P1	-8.93	1.03e-17	7.02e-15	-0.52	-0.39	Depression;	chr6:28165528	chr6:28161781~28169594:+
PRAD	cis	rs4713118	0.587	rs9393899	ENSG00000226314.6	ZNF192P1	-8.93	1.03e-17	7.02e-15	-0.52	-0.39	Parkinson's disease;	chr6:28165750	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs4713150	ENSG00000226314.6	ZNF192P1	-8.93	1.03e-17	7.02e-15	-0.52	-0.39	Depression;	chr6:28168434	chr6:28161781~28169594:+
PRAD	cis	rs4713118	0.527	rs4713151	ENSG00000226314.6	ZNF192P1	-8.93	1.03e-17	7.02e-15	-0.52	-0.39	Parkinson's disease;	chr6:28168578	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs9393901	ENSG00000226314.6	ZNF192P1	-8.93	1.03e-17	7.02e-15	-0.52	-0.39	Depression;	chr6:28169019	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs3173443	ENSG00000226314.6	ZNF192P1	-8.93	1.03e-17	7.02e-15	-0.52	-0.39	Depression;	chr6:28169249	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs4713152	ENSG00000226314.6	ZNF192P1	-8.93	1.03e-17	7.02e-15	-0.52	-0.39	Depression;	chr6:28169676	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs9348797	ENSG00000226314.6	ZNF192P1	-8.93	1.03e-17	7.02e-15	-0.52	-0.39	Depression;	chr6:28169755	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs9380062	ENSG00000226314.6	ZNF192P1	-8.93	1.03e-17	7.02e-15	-0.52	-0.39	Depression;	chr6:28169791	chr6:28161781~28169594:+
PRAD	cis	rs765787	0.505	rs12593605	ENSG00000259520.4	CTD-2651B20.3	-8.93	1.03e-17	7.04e-15	-0.5	-0.39	Uric acid levels;	chr15:45205250	chr15:45251580~45279251:-
PRAD	cis	rs7181230	0.885	rs4497657	ENSG00000275636.1	RP11-521C20.5	8.93	1.03e-17	7.04e-15	0.56	0.39	Dehydroepiandrosterone sulphate levels;	chr15:40067232	chr15:40078892~40079347:+
PRAD	cis	rs2255336	0.938	rs2617172	ENSG00000245648.1	RP11-277P12.20	8.93	1.03e-17	7.04e-15	0.58	0.39	Blood protein levels;	chr12:10409887	chr12:10363769~10398506:+
PRAD	cis	rs17711722	0.51	rs11767457	ENSG00000237310.1	GS1-124K5.4	8.93	1.04e-17	7.06e-15	0.34	0.39	Calcium levels;	chr7:65825628	chr7:66493706~66495474:+
PRAD	cis	rs7727544	0.606	rs72795121	ENSG00000233006.5	AC034220.3	8.93	1.04e-17	7.06e-15	0.35	0.39	Blood metabolite levels;	chr5:132302631	chr5:132311285~132369916:-
PRAD	cis	rs2882667	0.556	rs6873733	ENSG00000253404.1	AC034243.1	8.93	1.04e-17	7.07e-15	0.48	0.39	Age-related hearing impairment (SNP x SNP interaction);	chr5:139067628	chr5:138744434~138753309:-
PRAD	cis	rs7211079	0.912	rs4889831	ENSG00000279259.1	RP11-334C17.3	8.93	1.04e-17	7.09e-15	0.42	0.39	Myocardial infarction;	chr17:80140854	chr17:80147250~80148596:+
PRAD	cis	rs7569084	0.687	rs6755006	ENSG00000281920.1	RP11-418H16.1	-8.93	1.04e-17	7.09e-15	-0.47	-0.39	Sum eosinophil basophil counts;	chr2:65426008	chr2:65623272~65628424:+
PRAD	cis	rs7569084	0.687	rs6755128	ENSG00000281920.1	RP11-418H16.1	-8.93	1.04e-17	7.09e-15	-0.47	-0.39	Sum eosinophil basophil counts;	chr2:65426065	chr2:65623272~65628424:+
PRAD	cis	rs4713118	0.513	rs9368547	ENSG00000280107.1	AL022393.9	-8.93	1.04e-17	7.1e-15	-0.47	-0.39	Parkinson's disease;	chr6:28060289	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.513	rs183244	ENSG00000280107.1	AL022393.9	-8.93	1.04e-17	7.1e-15	-0.47	-0.39	Parkinson's disease;	chr6:28064060	chr6:28170845~28172521:+
PRAD	cis	rs2255336	0.938	rs2617169	ENSG00000245648.1	RP11-277P12.20	8.93	1.04e-17	7.1e-15	0.58	0.39	Blood protein levels;	chr12:10408225	chr12:10363769~10398506:+
PRAD	cis	rs67311347	0.822	rs9826847	ENSG00000223797.4	ENTPD3-AS1	8.93	1.04e-17	7.1e-15	0.35	0.39	Renal cell carcinoma;	chr3:40303821	chr3:40313802~40453329:-
PRAD	cis	rs7567389	0.74	rs4536600	ENSG00000236682.1	AC068282.3	-8.93	1.04e-17	7.1e-15	-0.48	-0.39	Self-rated health;	chr2:127244996	chr2:127389130~127400580:+
PRAD	cis	rs7727544	0.606	rs10060615	ENSG00000233006.5	AC034220.3	8.93	1.04e-17	7.1e-15	0.34	0.39	Blood metabolite levels;	chr5:132373185	chr5:132311285~132369916:-
PRAD	cis	rs6723108	0.627	rs12469941	ENSG00000224043.6	CCNT2-AS1	8.93	1.04e-17	7.12e-15	0.53	0.39	Type 2 diabetes;	chr2:134872357	chr2:134735464~134918710:-
PRAD	cis	rs9399135	0.773	rs9389263	ENSG00000232876.1	CTA-212D2.2	-8.93	1.05e-17	7.12e-15	-0.5	-0.39	Red blood cell count;	chr6:135079427	chr6:135055033~135060550:+
PRAD	cis	rs748404	0.69	rs2924369	ENSG00000249839.1	AC011330.5	8.93	1.05e-17	7.12e-15	0.47	0.39	Lung cancer;	chr15:43485787	chr15:43663654~43684339:-
PRAD	cis	rs1062177	1	rs2016409	ENSG00000253921.1	CTB-113P19.3	8.93	1.05e-17	7.14e-15	0.52	0.39	Preschool internalizing problems;	chr5:151746763	chr5:151753992~151767247:+
PRAD	cis	rs853679	0.517	rs9468297	ENSG00000226314.6	ZNF192P1	-8.93	1.05e-17	7.15e-15	-0.52	-0.39	Depression;	chr6:28151096	chr6:28161781~28169594:+
PRAD	cis	rs2404602	0.716	rs7179142	ENSG00000259422.1	RP11-593F23.1	8.93	1.05e-17	7.17e-15	0.48	0.39	Blood metabolite levels;	chr15:76405927	chr15:76174891~76181486:-
PRAD	cis	rs2658782	0.724	rs2248020	ENSG00000279684.1	RP11-755E23.2	-8.93	1.06e-17	7.24e-15	-0.59	-0.39	Pulmonary function decline;	chr11:93526799	chr11:93286629~93288903:-
PRAD	cis	rs765787	0.53	rs4514617	ENSG00000259520.4	CTD-2651B20.3	8.93	1.06e-17	7.25e-15	0.47	0.39	Uric acid levels;	chr15:45243241	chr15:45251580~45279251:-
PRAD	cis	rs6700559	0.654	rs66717951	ENSG00000260088.1	RP11-92G12.3	8.93	1.06e-17	7.25e-15	0.48	0.39	Coronary artery disease;	chr1:200626437	chr1:200669507~200694250:+
PRAD	cis	rs6700559	0.654	rs2809346	ENSG00000260088.1	RP11-92G12.3	8.93	1.06e-17	7.25e-15	0.48	0.39	Coronary artery disease;	chr1:200627089	chr1:200669507~200694250:+
PRAD	cis	rs17711722	0.528	rs73138179	ENSG00000228409.4	CCT6P1	-8.93	1.07e-17	7.28e-15	-0.29	-0.39	Calcium levels;	chr7:65829495	chr7:65751142~65763354:+
PRAD	cis	rs10262624	0.901	rs6977550	ENSG00000234286.1	AC006026.13	-8.93	1.07e-17	7.3e-15	-0.44	-0.39	Schizophrenia;	chr7:23865825	chr7:23680195~23680786:-
PRAD	cis	rs9487094	0.614	rs11968978	ENSG00000260273.1	RP11-425D10.10	8.93	1.07e-17	7.3e-15	0.57	0.39	Height;	chr6:109775693	chr6:109382795~109383666:+
PRAD	cis	rs2739330	0.76	rs1007888	ENSG00000206090.4	AP000350.7	8.93	1.07e-17	7.31e-15	0.49	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23939998~23942798:+
PRAD	cis	rs1075265	0.744	rs10203576	ENSG00000233266.1	HMGB1P31	8.93	1.07e-17	7.31e-15	0.53	0.39	Chronotype;Morning vs. evening chronotype;	chr2:54060939	chr2:54051334~54051760:+
PRAD	cis	rs9399137	0.507	rs7768278	ENSG00000232876.1	CTA-212D2.2	-8.93	1.08e-17	7.37e-15	-0.49	-0.39	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134953819	chr6:135055033~135060550:+
PRAD	cis	rs9399137	0.507	rs7748708	ENSG00000232876.1	CTA-212D2.2	-8.93	1.08e-17	7.37e-15	-0.49	-0.39	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134954004	chr6:135055033~135060550:+
PRAD	cis	rs2933343	0.649	rs789216	ENSG00000231305.3	RP11-723O4.2	8.93	1.08e-17	7.37e-15	0.36	0.39	IgG glycosylation;	chr3:128875660	chr3:128861313~128871540:-
PRAD	cis	rs2933343	0.7	rs1680778	ENSG00000231305.3	RP11-723O4.2	8.93	1.08e-17	7.37e-15	0.36	0.39	IgG glycosylation;	chr3:128895342	chr3:128861313~128871540:-
PRAD	cis	rs4879677	0.96	rs9695050	ENSG00000260390.1	RP11-575I8.1	8.93	1.09e-17	7.39e-15	0.51	0.39	Gut microbiome composition (summer and winter);	chr9:27671900	chr9:27829276~27844481:+
PRAD	cis	rs2255336	0.882	rs2246809	ENSG00000245648.1	RP11-277P12.20	8.93	1.09e-17	7.4e-15	0.56	0.39	Blood protein levels;	chr12:10404445	chr12:10363769~10398506:+
PRAD	cis	rs11148252	0.74	rs9526914	ENSG00000278238.1	RP11-245D16.4	-8.93	1.09e-17	7.4e-15	-0.43	-0.39	Lewy body disease;	chr13:52402165	chr13:52454775~52455331:-
PRAD	cis	rs2404602	0.716	rs1946650	ENSG00000259422.1	RP11-593F23.1	8.93	1.09e-17	7.4e-15	0.48	0.39	Blood metabolite levels;	chr15:76556122	chr15:76174891~76181486:-
PRAD	cis	rs17711722	0.522	rs4642526	ENSG00000236529.1	RP13-254B10.1	8.93	1.09e-17	7.41e-15	0.41	0.39	Calcium levels;	chr7:65751755	chr7:65840212~65840596:+
PRAD	cis	rs7712401	0.601	rs246322	ENSG00000263432.2	RN7SL689P	-8.93	1.1e-17	7.48e-15	-0.4	-0.39	Mean platelet volume;	chr5:122971574	chr5:123022487~123022783:-
PRAD	cis	rs17711722	0.51	rs11767457	ENSG00000228409.4	CCT6P1	-8.92	1.1e-17	7.49e-15	-0.29	-0.39	Calcium levels;	chr7:65825628	chr7:65751142~65763354:+
PRAD	cis	rs1501911	0.588	rs819227	ENSG00000248489.1	CTD-2007H13.3	-8.92	1.1e-17	7.5e-15	-0.48	-0.39	Lung function (FEV1/FVC);	chr5:98994161	chr5:98929171~98995013:+
PRAD	cis	rs748404	0.69	rs2244981	ENSG00000249839.1	AC011330.5	-8.92	1.11e-17	7.54e-15	-0.47	-0.39	Lung cancer;	chr15:43460553	chr15:43663654~43684339:-
PRAD	cis	rs2243480	0.706	rs6460257	ENSG00000226824.5	RP4-756H11.3	-8.92	1.11e-17	7.54e-15	-0.65	-0.39	Diabetic kidney disease;	chr7:65731813	chr7:66654538~66669855:+
PRAD	cis	rs7189233	0.571	rs4146344	ENSG00000279344.1	RP11-44F14.7	8.92	1.11e-17	7.56e-15	0.35	0.39	Intelligence (multi-trait analysis);	chr16:53435050	chr16:53478957~53481550:-
PRAD	cis	rs1501911	0.53	rs162149	ENSG00000248489.1	CTD-2007H13.3	8.92	1.11e-17	7.57e-15	0.43	0.39	Lung function (FEV1/FVC);	chr5:98913851	chr5:98929171~98995013:+
PRAD	cis	rs2739330	0.828	rs5760108	ENSG00000235689.1	AP000351.13	8.92	1.12e-17	7.59e-15	0.47	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:24006305~24008258:-
PRAD	cis	rs4713118	0.513	rs149950	ENSG00000280107.1	AL022393.9	-8.92	1.12e-17	7.6e-15	-0.47	-0.39	Parkinson's disease;	chr6:28065261	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.513	rs149951	ENSG00000280107.1	AL022393.9	-8.92	1.12e-17	7.6e-15	-0.47	-0.39	Parkinson's disease;	chr6:28065309	chr6:28170845~28172521:+
PRAD	cis	rs2274273	0.87	rs4597235	ENSG00000258413.1	RP11-665C16.6	-8.92	1.12e-17	7.61e-15	-0.51	-0.39	Protein biomarker;	chr14:55385269	chr14:55262767~55272075:-
PRAD	cis	rs2274273	0.87	rs3825616	ENSG00000258413.1	RP11-665C16.6	-8.92	1.12e-17	7.61e-15	-0.51	-0.39	Protein biomarker;	chr14:55386570	chr14:55262767~55272075:-
PRAD	cis	rs2739330	0.828	rs2877178	ENSG00000235689.1	AP000351.13	8.92	1.13e-17	7.66e-15	0.47	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:24006305~24008258:-
PRAD	cis	rs2739330	0.828	rs2154593	ENSG00000235689.1	AP000351.13	8.92	1.13e-17	7.66e-15	0.47	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:24006305~24008258:-
PRAD	cis	rs2015599	0.549	rs7134796	ENSG00000257176.2	RP11-996F15.2	8.92	1.13e-17	7.66e-15	0.43	0.39	Platelet count;Mean platelet volume;	chr12:29294361	chr12:29280418~29317848:-
PRAD	cis	rs2274273	0.87	rs946059	ENSG00000258413.1	RP11-665C16.6	-8.92	1.13e-17	7.66e-15	-0.51	-0.39	Protein biomarker;	chr14:55380748	chr14:55262767~55272075:-
PRAD	cis	rs2274273	0.87	rs10144345	ENSG00000258413.1	RP11-665C16.6	-8.92	1.13e-17	7.66e-15	-0.51	-0.39	Protein biomarker;	chr14:55381019	chr14:55262767~55272075:-
PRAD	cis	rs2274273	0.87	rs3783650	ENSG00000258413.1	RP11-665C16.6	-8.92	1.13e-17	7.66e-15	-0.51	-0.39	Protein biomarker;	chr14:55382254	chr14:55262767~55272075:-
PRAD	cis	rs4835473	0.832	rs55935372	ENSG00000251600.4	RP11-673E1.1	-8.92	1.13e-17	7.68e-15	-0.5	-0.39	Immature fraction of reticulocytes;	chr4:143700626	chr4:143912331~143982454:+
PRAD	cis	rs2274273	0.87	rs8023197	ENSG00000258413.1	RP11-665C16.6	-8.92	1.13e-17	7.69e-15	-0.51	-0.39	Protein biomarker;	chr14:55300677	chr14:55262767~55272075:-
PRAD	cis	rs58873874	0.522	rs6875379	ENSG00000248544.2	CTB-47B11.3	8.92	1.13e-17	7.7e-15	0.74	0.39	Bipolar disorder (body mass index interaction);	chr5:157391295	chr5:157375741~157384950:-
PRAD	cis	rs3096299	0.967	rs28575874	ENSG00000274627.1	RP11-104N10.2	8.92	1.14e-17	7.72e-15	0.39	0.39	Multiple myeloma (IgH translocation);	chr16:89403482	chr16:89516797~89522217:+
PRAD	cis	rs9389248	0.69	rs6569982	ENSG00000232876.1	CTA-212D2.2	-8.92	1.14e-17	7.72e-15	-0.47	-0.39	High light scatter reticulocyte percentage of red cells;	chr6:134935357	chr6:135055033~135060550:+
PRAD	cis	rs748404	0.66	rs690367	ENSG00000249839.1	AC011330.5	8.92	1.14e-17	7.73e-15	0.47	0.39	Lung cancer;	chr15:43456106	chr15:43663654~43684339:-
PRAD	cis	rs853679	0.542	rs9380063	ENSG00000226314.6	ZNF192P1	-8.92	1.14e-17	7.73e-15	-0.52	-0.39	Depression;	chr6:28170075	chr6:28161781~28169594:+
PRAD	cis	rs10875746	0.556	rs4760619	ENSG00000240399.1	RP1-228P16.1	-8.92	1.14e-17	7.75e-15	-0.43	-0.39	Longevity (90 years and older);	chr12:48106148	chr12:48054813~48055591:-
PRAD	cis	rs6991838	0.765	rs4424306	ENSG00000272010.1	CTD-3025N20.3	8.92	1.14e-17	7.77e-15	0.37	0.39	Intelligence (multi-trait analysis);	chr8:65618674	chr8:65591850~65592472:-
PRAD	cis	rs2933343	0.621	rs789242	ENSG00000231305.3	RP11-723O4.2	8.92	1.15e-17	7.78e-15	0.36	0.39	IgG glycosylation;	chr3:128866864	chr3:128861313~128871540:-
PRAD	cis	rs853679	0.55	rs1150692	ENSG00000219392.1	RP1-265C24.5	-8.92	1.15e-17	7.79e-15	-0.5	-0.39	Depression;	chr6:28206179	chr6:28115628~28116551:+
PRAD	cis	rs2274273	0.934	rs8021940	ENSG00000258413.1	RP11-665C16.6	-8.92	1.15e-17	7.82e-15	-0.51	-0.39	Protein biomarker;	chr14:55252997	chr14:55262767~55272075:-
PRAD	cis	rs853679	0.517	rs9393884	ENSG00000226314.6	ZNF192P1	-8.92	1.15e-17	7.83e-15	-0.52	-0.39	Depression;	chr6:28079011	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs9393887	ENSG00000226314.6	ZNF192P1	-8.92	1.15e-17	7.83e-15	-0.52	-0.39	Depression;	chr6:28091242	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.542	rs9393892	ENSG00000226314.6	ZNF192P1	-8.92	1.15e-17	7.83e-15	-0.52	-0.39	Depression;	chr6:28113616	chr6:28161781~28169594:+
PRAD	cis	rs6430553	0.861	rs12463645	ENSG00000224043.6	CCNT2-AS1	-8.92	1.15e-17	7.83e-15	-0.51	-0.39	Blood metabolite levels;	chr2:134916800	chr2:134735464~134918710:-
PRAD	cis	rs11098499	0.863	rs17050695	ENSG00000245958.5	RP11-33B1.1	-8.92	1.16e-17	7.86e-15	-0.37	-0.39	Corneal astigmatism;	chr4:119568372	chr4:119454791~119552025:+
PRAD	cis	rs5769707	0.656	rs135878	ENSG00000188511.11	C22orf34	8.92	1.16e-17	7.9e-15	0.47	0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49620721	chr22:49414524~49657542:-
PRAD	cis	rs4713118	0.629	rs203889	ENSG00000219392.1	RP1-265C24.5	-8.92	1.17e-17	7.92e-15	-0.49	-0.39	Parkinson's disease;	chr6:28053997	chr6:28115628~28116551:+
PRAD	cis	rs2274273	0.87	rs10149420	ENSG00000258413.1	RP11-665C16.6	-8.92	1.17e-17	7.93e-15	-0.51	-0.39	Protein biomarker;	chr14:55387539	chr14:55262767~55272075:-
PRAD	cis	rs7772486	0.875	rs2748497	ENSG00000235652.6	RP11-545I5.3	8.92	1.17e-17	7.93e-15	0.4	0.39	Lobe attachment (rater-scored or self-reported);	chr6:145998281	chr6:145799409~145886585:+
PRAD	cis	rs853679	0.517	rs9357065	ENSG00000226314.6	ZNF192P1	-8.92	1.17e-17	7.96e-15	-0.52	-0.39	Depression;	chr6:28161802	chr6:28161781~28169594:+
PRAD	cis	rs6723108	0.592	rs10928523	ENSG00000224043.6	CCNT2-AS1	-8.92	1.18e-17	7.97e-15	-0.54	-0.39	Type 2 diabetes;	chr2:134907891	chr2:134735464~134918710:-
PRAD	cis	rs6723108	0.603	rs6733130	ENSG00000224043.6	CCNT2-AS1	-8.92	1.18e-17	7.97e-15	-0.54	-0.39	Type 2 diabetes;	chr2:134908983	chr2:134735464~134918710:-
PRAD	cis	rs6723108	0.627	rs1374288	ENSG00000224043.6	CCNT2-AS1	-8.92	1.18e-17	7.97e-15	-0.54	-0.39	Type 2 diabetes;	chr2:134909483	chr2:134735464~134918710:-
PRAD	cis	rs6723108	0.627	rs1374287	ENSG00000224043.6	CCNT2-AS1	-8.92	1.18e-17	7.97e-15	-0.54	-0.39	Type 2 diabetes;	chr2:134909631	chr2:134735464~134918710:-
PRAD	cis	rs7712401	0.601	rs30045	ENSG00000263432.2	RN7SL689P	8.92	1.18e-17	8.01e-15	0.39	0.39	Mean platelet volume;	chr5:122935924	chr5:123022487~123022783:-
PRAD	cis	rs11159086	0.793	rs17100414	ENSG00000259005.1	RP3-449M8.6	8.92	1.18e-17	8.01e-15	0.49	0.39	Advanced glycation end-product levels;	chr14:74467918	chr14:74474007~74474864:-
PRAD	cis	rs7811142	1	rs7783159	ENSG00000242294.5	STAG3L5P	8.92	1.18e-17	8.02e-15	0.27	0.39	Platelet count;	chr7:100419831	chr7:100336079~100351900:+
PRAD	cis	rs1062177	1	rs12515762	ENSG00000253921.1	CTB-113P19.3	-8.92	1.18e-17	8.03e-15	-0.52	-0.39	Preschool internalizing problems;	chr5:151830361	chr5:151753992~151767247:+
PRAD	cis	rs9322193	0.607	rs9371228	ENSG00000216906.2	RP11-350J20.9	-8.92	1.19e-17	8.05e-15	-0.5	-0.39	Lung cancer;	chr6:149921977	chr6:149904243~149906418:+
PRAD	cis	rs1075265	0.73	rs805391	ENSG00000233266.1	HMGB1P31	-8.91	1.2e-17	8.11e-15	-0.51	-0.39	Chronotype;Morning vs. evening chronotype;	chr2:53877181	chr2:54051334~54051760:+
PRAD	cis	rs2274273	0.686	rs28631821	ENSG00000258413.1	RP11-665C16.6	-8.91	1.2e-17	8.16e-15	-0.51	-0.39	Protein biomarker;	chr14:55379269	chr14:55262767~55272075:-
PRAD	cis	rs6723108	0.603	rs12469411	ENSG00000224043.6	CCNT2-AS1	-8.91	1.2e-17	8.16e-15	-0.54	-0.39	Type 2 diabetes;	chr2:134906986	chr2:134735464~134918710:-
PRAD	cis	rs3814244	0.966	rs10784666	ENSG00000255733.4	IFNG-AS1	-8.91	1.2e-17	8.16e-15	-0.4	-0.39	Itch intensity from mosquito bite adjusted by bite size;	chr12:68021923	chr12:67989445~68234686:+
PRAD	cis	rs3814244	0.966	rs10784667	ENSG00000255733.4	IFNG-AS1	-8.91	1.2e-17	8.16e-15	-0.4	-0.39	Itch intensity from mosquito bite adjusted by bite size;	chr12:68021996	chr12:67989445~68234686:+
PRAD	cis	rs858239	0.899	rs858271	ENSG00000226816.2	AC005082.12	8.91	1.21e-17	8.2e-15	0.44	0.39	Cerebrospinal fluid biomarker levels;	chr7:23238664	chr7:23206013~23208045:+
PRAD	cis	rs7811142	1	rs60478351	ENSG00000242294.5	STAG3L5P	8.91	1.21e-17	8.21e-15	0.26	0.39	Platelet count;	chr7:100491394	chr7:100336079~100351900:+
PRAD	cis	rs13217239	0.646	rs7451149	ENSG00000241549.7	GUSBP2	-8.91	1.22e-17	8.25e-15	-0.43	-0.39	Schizophrenia;	chr6:27089739	chr6:26871484~26956554:-
PRAD	cis	rs4835473	0.9	rs3856989	ENSG00000251600.4	RP11-673E1.1	8.91	1.22e-17	8.25e-15	0.5	0.39	Immature fraction of reticulocytes;	chr4:143921752	chr4:143912331~143982454:+
PRAD	cis	rs950169	1	rs12903820	ENSG00000259728.4	LINC00933	8.91	1.22e-17	8.26e-15	0.46	0.39	Schizophrenia;	chr15:84055068	chr15:84570649~84580175:+
PRAD	cis	rs748404	0.66	rs690446	ENSG00000249839.1	AC011330.5	-8.91	1.22e-17	8.27e-15	-0.47	-0.39	Lung cancer;	chr15:43469066	chr15:43663654~43684339:-
PRAD	cis	rs748404	0.631	rs560191	ENSG00000249839.1	AC011330.5	-8.91	1.22e-17	8.27e-15	-0.47	-0.39	Lung cancer;	chr15:43475576	chr15:43663654~43684339:-
PRAD	cis	rs7772486	0.846	rs2892453	ENSG00000235652.6	RP11-545I5.3	8.91	1.22e-17	8.28e-15	0.39	0.39	Lobe attachment (rater-scored or self-reported);	chr6:146056581	chr6:145799409~145886585:+
PRAD	cis	rs2638953	0.924	rs7957056	ENSG00000278733.1	RP11-425D17.1	-8.91	1.22e-17	8.3e-15	-0.46	-0.39	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28203382	chr12:28185625~28186190:-
PRAD	cis	rs34779708	0.931	rs2490663	ENSG00000230534.5	RP11-297A16.2	-8.91	1.22e-17	8.3e-15	-0.49	-0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35040807	chr10:35098006~35127020:-
PRAD	cis	rs13217239	0.572	rs9379958	ENSG00000241549.7	GUSBP2	-8.91	1.23e-17	8.34e-15	-0.43	-0.39	Schizophrenia;	chr6:27098384	chr6:26871484~26956554:-
PRAD	cis	rs13217239	0.646	rs9393789	ENSG00000241549.7	GUSBP2	-8.91	1.23e-17	8.34e-15	-0.43	-0.39	Schizophrenia;	chr6:27099249	chr6:26871484~26956554:-
PRAD	cis	rs13217239	0.646	rs6456767	ENSG00000241549.7	GUSBP2	-8.91	1.23e-17	8.34e-15	-0.43	-0.39	Schizophrenia;	chr6:27102764	chr6:26871484~26956554:-
PRAD	cis	rs11123170	0.543	rs4849180	ENSG00000274877.1	RP11-65I12.1	-8.91	1.23e-17	8.35e-15	-0.61	-0.39	Renal function-related traits (BUN);	chr2:113227609	chr2:113237595~113240825:+
PRAD	cis	rs11123170	0.543	rs35222158	ENSG00000274877.1	RP11-65I12.1	-8.91	1.23e-17	8.35e-15	-0.61	-0.39	Renal function-related traits (BUN);	chr2:113229052	chr2:113237595~113240825:+
PRAD	cis	rs4835473	0.808	rs6836630	ENSG00000251600.4	RP11-673E1.1	-8.91	1.23e-17	8.36e-15	-0.51	-0.39	Immature fraction of reticulocytes;	chr4:143801068	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs13101541	ENSG00000251600.4	RP11-673E1.1	-8.91	1.23e-17	8.36e-15	-0.51	-0.39	Immature fraction of reticulocytes;	chr4:143806590	chr4:143912331~143982454:+
PRAD	cis	rs2274273	0.837	rs7142857	ENSG00000258413.1	RP11-665C16.6	-8.91	1.24e-17	8.42e-15	-0.51	-0.39	Protein biomarker;	chr14:55237410	chr14:55262767~55272075:-
PRAD	cis	rs6061231	0.834	rs2427311	ENSG00000273619.1	RP5-908M14.9	-8.91	1.25e-17	8.48e-15	-0.26	-0.39	Colorectal cancer;	chr20:62395067	chr20:62386303~62386970:-
PRAD	cis	rs2638953	0.849	rs11049388	ENSG00000278733.1	RP11-425D17.1	-8.91	1.26e-17	8.53e-15	-0.46	-0.39	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28169054	chr12:28185625~28186190:-
PRAD	cis	rs853679	0.55	rs1237875	ENSG00000226314.6	ZNF192P1	8.91	1.26e-17	8.55e-15	0.51	0.39	Depression;	chr6:28205232	chr6:28161781~28169594:+
PRAD	cis	rs6991838	0.584	rs34226237	ENSG00000200714.1	Y_RNA	-8.91	1.27e-17	8.56e-15	-0.42	-0.39	Intelligence (multi-trait analysis);	chr8:65600930	chr8:65592731~65592820:+
PRAD	cis	rs6991838	0.584	rs6994213	ENSG00000200714.1	Y_RNA	-8.91	1.27e-17	8.56e-15	-0.42	-0.39	Intelligence (multi-trait analysis);	chr8:65601497	chr8:65592731~65592820:+
PRAD	cis	rs3814244	0.897	rs4141135	ENSG00000255733.4	IFNG-AS1	8.91	1.27e-17	8.58e-15	0.4	0.39	Itch intensity from mosquito bite adjusted by bite size;	chr12:68025050	chr12:67989445~68234686:+
PRAD	cis	rs7772486	0.875	rs7739418	ENSG00000235652.6	RP11-545I5.3	8.91	1.27e-17	8.58e-15	0.39	0.39	Lobe attachment (rater-scored or self-reported);	chr6:146038052	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.875	rs9390371	ENSG00000235652.6	RP11-545I5.3	8.91	1.27e-17	8.58e-15	0.39	0.39	Lobe attachment (rater-scored or self-reported);	chr6:146042044	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.875	rs6909827	ENSG00000235652.6	RP11-545I5.3	8.91	1.27e-17	8.58e-15	0.39	0.39	Lobe attachment (rater-scored or self-reported);	chr6:146044602	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.875	rs10872582	ENSG00000235652.6	RP11-545I5.3	8.91	1.27e-17	8.58e-15	0.39	0.39	Lobe attachment (rater-scored or self-reported);	chr6:146051925	chr6:145799409~145886585:+
PRAD	cis	rs8062405	0.824	rs153106	ENSG00000251417.2	RP11-1348G14.4	-8.91	1.27e-17	8.6e-15	-0.43	-0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28515576	chr16:28802743~28817828:+
PRAD	cis	rs4835473	0.797	rs34585546	ENSG00000251600.4	RP11-673E1.1	-8.91	1.28e-17	8.64e-15	-0.5	-0.39	Immature fraction of reticulocytes;	chr4:143680693	chr4:143912331~143982454:+
PRAD	cis	rs11159086	0.793	rs11625502	ENSG00000259005.1	RP3-449M8.6	8.91	1.28e-17	8.67e-15	0.49	0.39	Advanced glycation end-product levels;	chr14:74468309	chr14:74474007~74474864:-
PRAD	cis	rs11673344	0.764	rs569371	ENSG00000226686.6	LINC01535	8.9	1.29e-17	8.69e-15	0.52	0.39	Obesity-related traits;	chr19:36963095	chr19:37251912~37265535:+
PRAD	cis	rs6570726	0.791	rs6918814	ENSG00000235652.6	RP11-545I5.3	8.9	1.29e-17	8.71e-15	0.41	0.39	Lobe attachment (rater-scored or self-reported);	chr6:145584892	chr6:145799409~145886585:+
PRAD	cis	rs765787	0.53	rs1648289	ENSG00000259520.4	CTD-2651B20.3	8.9	1.3e-17	8.8e-15	0.47	0.39	Uric acid levels;	chr15:45224296	chr15:45251580~45279251:-
PRAD	cis	rs765787	0.53	rs1648287	ENSG00000259520.4	CTD-2651B20.3	8.9	1.3e-17	8.8e-15	0.47	0.39	Uric acid levels;	chr15:45224758	chr15:45251580~45279251:-
PRAD	cis	rs765787	0.53	rs28526629	ENSG00000259520.4	CTD-2651B20.3	8.9	1.3e-17	8.8e-15	0.47	0.39	Uric acid levels;	chr15:45248264	chr15:45251580~45279251:-
PRAD	cis	rs2638953	0.924	rs11049475	ENSG00000278733.1	RP11-425D17.1	-8.9	1.31e-17	8.82e-15	-0.47	-0.39	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28239731	chr12:28185625~28186190:-
PRAD	cis	rs853679	0.55	rs1150692	ENSG00000226314.6	ZNF192P1	-8.9	1.31e-17	8.82e-15	-0.52	-0.39	Depression;	chr6:28206179	chr6:28161781~28169594:+
PRAD	cis	rs2274273	0.837	rs11625968	ENSG00000258413.1	RP11-665C16.6	-8.9	1.31e-17	8.83e-15	-0.5	-0.39	Protein biomarker;	chr14:55334286	chr14:55262767~55272075:-
PRAD	cis	rs950169	0.92	rs2135551	ENSG00000259728.4	LINC00933	8.9	1.31e-17	8.85e-15	0.46	0.39	Schizophrenia;	chr15:84039099	chr15:84570649~84580175:+
PRAD	cis	rs950169	1	rs12902672	ENSG00000259728.4	LINC00933	8.9	1.31e-17	8.85e-15	0.46	0.39	Schizophrenia;	chr15:84048234	chr15:84570649~84580175:+
PRAD	cis	rs1501911	0.53	rs193072	ENSG00000248489.1	CTD-2007H13.3	8.9	1.31e-17	8.85e-15	0.43	0.39	Lung function (FEV1/FVC);	chr5:98822171	chr5:98929171~98995013:+
PRAD	cis	rs6517329	0.538	rs4816521	ENSG00000236830.5	CBR3-AS1	8.9	1.32e-17	8.89e-15	0.4	0.39	Schizophrenia;	chr21:36138440	chr21:36131767~36175815:-
PRAD	cis	rs17012589	0.639	rs10862968	ENSG00000258815.1	RP11-408B11.2	-8.9	1.32e-17	8.9e-15	-0.53	-0.39	Bone mineral density (Ward's triangle area);	chr12:85320992	chr12:85318060~85342912:+
PRAD	cis	rs17012589	0.639	rs1512735	ENSG00000258815.1	RP11-408B11.2	-8.9	1.32e-17	8.9e-15	-0.53	-0.39	Bone mineral density (Ward's triangle area);	chr12:85322986	chr12:85318060~85342912:+
PRAD	cis	rs17012589	0.592	rs10862969	ENSG00000258815.1	RP11-408B11.2	-8.9	1.32e-17	8.9e-15	-0.53	-0.39	Bone mineral density (Ward's triangle area);	chr12:85324852	chr12:85318060~85342912:+
PRAD	cis	rs11098499	0.697	rs4560394	ENSG00000245958.5	RP11-33B1.1	-8.9	1.32e-17	8.9e-15	-0.38	-0.39	Corneal astigmatism;	chr4:119392280	chr4:119454791~119552025:+
PRAD	cis	rs2255336	0.817	rs12318583	ENSG00000245648.1	RP11-277P12.20	-8.9	1.32e-17	8.92e-15	-0.57	-0.39	Blood protein levels;	chr12:10426485	chr12:10363769~10398506:+
PRAD	cis	rs7829975	0.536	rs2980439	ENSG00000253893.2	FAM85B	-8.9	1.32e-17	8.92e-15	-0.49	-0.39	Mood instability;	chr8:8237348	chr8:8167819~8226614:-
PRAD	cis	rs12220777	0.585	rs11201146	ENSG00000230091.5	TMEM254-AS1	-8.9	1.32e-17	8.93e-15	-0.67	-0.39	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80007581	chr10:80046860~80078912:-
PRAD	cis	rs2638953	0.924	rs4573721	ENSG00000278733.1	RP11-425D17.1	-8.9	1.32e-17	8.93e-15	-0.46	-0.39	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28194746	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs4554927	ENSG00000278733.1	RP11-425D17.1	-8.9	1.32e-17	8.93e-15	-0.46	-0.39	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28194844	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs61920243	ENSG00000278733.1	RP11-425D17.1	-8.9	1.32e-17	8.93e-15	-0.46	-0.39	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195333	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.679	rs7974882	ENSG00000278733.1	RP11-425D17.1	-8.9	1.32e-17	8.93e-15	-0.46	-0.39	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195415	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.679	rs7961395	ENSG00000278733.1	RP11-425D17.1	-8.9	1.32e-17	8.93e-15	-0.46	-0.39	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195420	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs7961407	ENSG00000278733.1	RP11-425D17.1	-8.9	1.32e-17	8.93e-15	-0.46	-0.39	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195482	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs7974904	ENSG00000278733.1	RP11-425D17.1	-8.9	1.32e-17	8.93e-15	-0.46	-0.39	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195491	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs7974979	ENSG00000278733.1	RP11-425D17.1	-8.9	1.32e-17	8.93e-15	-0.46	-0.39	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195496	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs7974701	ENSG00000278733.1	RP11-425D17.1	-8.9	1.32e-17	8.93e-15	-0.46	-0.39	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195579	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.886	rs7961769	ENSG00000278733.1	RP11-425D17.1	-8.9	1.32e-17	8.93e-15	-0.46	-0.39	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195772	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.886	rs61920244	ENSG00000278733.1	RP11-425D17.1	-8.9	1.32e-17	8.93e-15	-0.46	-0.39	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195992	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs34378873	ENSG00000278733.1	RP11-425D17.1	-8.9	1.32e-17	8.93e-15	-0.46	-0.39	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28196124	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs11049438	ENSG00000278733.1	RP11-425D17.1	-8.9	1.32e-17	8.93e-15	-0.46	-0.39	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28196205	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs11049439	ENSG00000278733.1	RP11-425D17.1	-8.9	1.32e-17	8.93e-15	-0.46	-0.39	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28196369	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs11049440	ENSG00000278733.1	RP11-425D17.1	-8.9	1.32e-17	8.93e-15	-0.46	-0.39	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28196474	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs11049441	ENSG00000278733.1	RP11-425D17.1	-8.9	1.32e-17	8.93e-15	-0.46	-0.39	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28196476	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.853	rs11049442	ENSG00000278733.1	RP11-425D17.1	-8.9	1.32e-17	8.93e-15	-0.46	-0.39	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28197211	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs11049443	ENSG00000278733.1	RP11-425D17.1	-8.9	1.32e-17	8.93e-15	-0.46	-0.39	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28197269	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.962	rs60193273	ENSG00000278733.1	RP11-425D17.1	-8.9	1.32e-17	8.93e-15	-0.46	-0.39	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28197638	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs11049446	ENSG00000278733.1	RP11-425D17.1	-8.9	1.32e-17	8.93e-15	-0.46	-0.39	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28197951	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs11049447	ENSG00000278733.1	RP11-425D17.1	-8.9	1.32e-17	8.93e-15	-0.46	-0.39	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28197970	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.886	rs10843123	ENSG00000278733.1	RP11-425D17.1	-8.9	1.32e-17	8.93e-15	-0.46	-0.39	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28198004	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs10843124	ENSG00000278733.1	RP11-425D17.1	-8.9	1.32e-17	8.93e-15	-0.46	-0.39	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28198189	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs11049448	ENSG00000278733.1	RP11-425D17.1	-8.9	1.32e-17	8.93e-15	-0.46	-0.39	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28198975	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs10843126	ENSG00000278733.1	RP11-425D17.1	-8.9	1.32e-17	8.93e-15	-0.46	-0.39	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28199112	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs10843127	ENSG00000278733.1	RP11-425D17.1	-8.9	1.32e-17	8.93e-15	-0.46	-0.39	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28199124	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.85	rs10843128	ENSG00000278733.1	RP11-425D17.1	-8.9	1.32e-17	8.93e-15	-0.46	-0.39	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28199377	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.85	rs10843129	ENSG00000278733.1	RP11-425D17.1	-8.9	1.32e-17	8.93e-15	-0.46	-0.39	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28199378	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs10843130	ENSG00000278733.1	RP11-425D17.1	-8.9	1.32e-17	8.93e-15	-0.46	-0.39	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28199793	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs61920253	ENSG00000278733.1	RP11-425D17.1	-8.9	1.32e-17	8.93e-15	-0.46	-0.39	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28202039	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.888	rs11612143	ENSG00000278733.1	RP11-425D17.1	-8.9	1.32e-17	8.93e-15	-0.46	-0.39	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28202694	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.813	rs11609999	ENSG00000278733.1	RP11-425D17.1	-8.9	1.32e-17	8.93e-15	-0.46	-0.39	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28202721	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs11049453	ENSG00000278733.1	RP11-425D17.1	-8.9	1.32e-17	8.93e-15	-0.46	-0.39	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28202996	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.886	rs7957059	ENSG00000278733.1	RP11-425D17.1	-8.9	1.32e-17	8.93e-15	-0.46	-0.39	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28203390	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.962	rs73261702	ENSG00000278733.1	RP11-425D17.1	-8.9	1.32e-17	8.93e-15	-0.46	-0.39	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28204118	chr12:28185625~28186190:-
PRAD	cis	rs9532669	0.926	rs9594450	ENSG00000176268.5	CYCSP34	8.9	1.33e-17	8.94e-15	0.43	0.39	Cervical cancer;	chr13:40880067	chr13:40863599~40863902:-
PRAD	cis	rs11098499	0.954	rs10006706	ENSG00000245958.5	RP11-33B1.1	-8.9	1.33e-17	8.96e-15	-0.38	-0.39	Corneal astigmatism;	chr4:119487997	chr4:119454791~119552025:+
PRAD	cis	rs853679	0.517	rs4713141	ENSG00000226314.6	ZNF192P1	-8.9	1.33e-17	8.96e-15	-0.52	-0.39	Depression;	chr6:28133900	chr6:28161781~28169594:+
PRAD	cis	rs1501911	0.53	rs162473	ENSG00000248489.1	CTD-2007H13.3	-8.9	1.33e-17	8.98e-15	-0.43	-0.39	Lung function (FEV1/FVC);	chr5:98805276	chr5:98929171~98995013:+
PRAD	cis	rs4713118	0.662	rs9380046	ENSG00000226314.6	ZNF192P1	-8.9	1.34e-17	9.01e-15	-0.52	-0.39	Parkinson's disease;	chr6:28062721	chr6:28161781~28169594:+
PRAD	cis	rs7712401	0.601	rs34126945	ENSG00000263432.2	RN7SL689P	-8.9	1.34e-17	9.06e-15	-0.39	-0.39	Mean platelet volume;	chr5:122994034	chr5:123022487~123022783:-
PRAD	cis	rs6538678	0.746	rs12820313	ENSG00000258343.1	RP11-536G4.2	-8.9	1.35e-17	9.07e-15	-0.51	-0.39	Lupus nephritis in systemic lupus erythematosus;	chr12:95861926	chr12:95795345~95858839:-
PRAD	cis	rs9309473	0.606	rs6759452	ENSG00000163016.8	ALMS1P	8.9	1.35e-17	9.08e-15	0.57	0.39	Metabolite levels;	chr2:73651225	chr2:73644919~73685576:+
PRAD	cis	rs4713118	0.629	rs203890	ENSG00000219392.1	RP1-265C24.5	-8.9	1.35e-17	9.1e-15	-0.5	-0.39	Parkinson's disease;	chr6:28054470	chr6:28115628~28116551:+
PRAD	cis	rs6517329	0.538	rs12483755	ENSG00000236830.5	CBR3-AS1	8.9	1.35e-17	9.11e-15	0.4	0.39	Schizophrenia;	chr21:36136140	chr21:36131767~36175815:-
PRAD	cis	rs6517329	0.538	rs879893	ENSG00000236830.5	CBR3-AS1	8.9	1.35e-17	9.11e-15	0.4	0.39	Schizophrenia;	chr21:36136489	chr21:36131767~36175815:-
PRAD	cis	rs950169	0.919	rs12915589	ENSG00000259728.4	LINC00933	8.9	1.36e-17	9.14e-15	0.46	0.38	Schizophrenia;	chr15:84065712	chr15:84570649~84580175:+
PRAD	cis	rs950169	0.959	rs66801143	ENSG00000259728.4	LINC00933	8.9	1.36e-17	9.14e-15	0.46	0.38	Schizophrenia;	chr15:84067905	chr15:84570649~84580175:+
PRAD	cis	rs950169	1	rs35648189	ENSG00000259728.4	LINC00933	8.9	1.36e-17	9.14e-15	0.46	0.38	Schizophrenia;	chr15:84071996	chr15:84570649~84580175:+
PRAD	cis	rs950169	0.92	rs17300048	ENSG00000259728.4	LINC00933	8.9	1.36e-17	9.14e-15	0.46	0.38	Schizophrenia;	chr15:84080725	chr15:84570649~84580175:+
PRAD	cis	rs12701220	0.655	rs7799656	ENSG00000229043.2	AC091729.9	-8.9	1.37e-17	9.24e-15	-0.56	-0.38	Bronchopulmonary dysplasia;	chr7:1100879	chr7:1160374~1165267:+
PRAD	cis	rs10246939	0.543	rs9640357	ENSG00000228775.6	WEE2-AS1	8.9	1.37e-17	9.24e-15	0.47	0.38	Bitter taste perception;	chr7:141843298	chr7:141704338~141738346:-
PRAD	cis	rs7189233	0.531	rs1072911	ENSG00000279344.1	RP11-44F14.7	8.9	1.37e-17	9.25e-15	0.35	0.38	Intelligence (multi-trait analysis);	chr16:53465813	chr16:53478957~53481550:-
PRAD	cis	rs1930961	1	rs59226697	ENSG00000272977.1	CTA-390C10.10	-8.9	1.37e-17	9.26e-15	-0.75	-0.38	Bipolar disorder with mood-incongruent psychosis;	chr22:25474070	chr22:25476218~25479971:+
PRAD	cis	rs765787	0.505	rs11630884	ENSG00000259520.4	CTD-2651B20.3	8.9	1.38e-17	9.27e-15	0.47	0.38	Uric acid levels;	chr15:45240048	chr15:45251580~45279251:-
PRAD	cis	rs765787	0.53	rs11634794	ENSG00000259520.4	CTD-2651B20.3	8.9	1.38e-17	9.27e-15	0.47	0.38	Uric acid levels;	chr15:45242294	chr15:45251580~45279251:-
PRAD	cis	rs2564921	0.704	rs57916015	ENSG00000242142.1	SERBP1P3	-8.9	1.38e-17	9.28e-15	-0.44	-0.38	Height;	chr3:52971094	chr3:53064283~53065091:-
PRAD	cis	rs4835473	0.897	rs11931330	ENSG00000251600.4	RP11-673E1.1	8.9	1.38e-17	9.28e-15	0.49	0.38	Immature fraction of reticulocytes;	chr4:143970808	chr4:143912331~143982454:+
PRAD	cis	rs11673344	0.764	rs529468	ENSG00000226686.6	LINC01535	8.9	1.38e-17	9.28e-15	0.52	0.38	Obesity-related traits;	chr19:36955298	chr19:37251912~37265535:+
PRAD	cis	rs11673344	0.582	rs114437741	ENSG00000226686.6	LINC01535	8.9	1.38e-17	9.28e-15	0.52	0.38	Obesity-related traits;	chr19:36955379	chr19:37251912~37265535:+
PRAD	cis	rs11673344	0.764	rs524802	ENSG00000226686.6	LINC01535	8.9	1.38e-17	9.28e-15	0.52	0.38	Obesity-related traits;	chr19:36956045	chr19:37251912~37265535:+
PRAD	cis	rs2015599	0.623	rs7964831	ENSG00000257176.2	RP11-996F15.2	-8.9	1.38e-17	9.28e-15	-0.43	-0.38	Platelet count;Mean platelet volume;	chr12:29286655	chr12:29280418~29317848:-
PRAD	cis	rs2348418	0.715	rs1355471	ENSG00000247934.4	RP11-967K21.1	-8.9	1.38e-17	9.28e-15	-0.35	-0.38	Lung function (FEV1);Lung function (FVC);	chr12:28568792	chr12:28163298~28190738:-
PRAD	cis	rs3858145	0.588	rs2305083	ENSG00000233590.1	RP11-153K11.3	-8.89	1.39e-17	9.35e-15	-0.56	-0.38	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68285180	chr10:68233251~68242379:-
PRAD	cis	rs853679	0.517	rs6922063	ENSG00000226314.6	ZNF192P1	-8.89	1.39e-17	9.37e-15	-0.52	-0.38	Depression;	chr6:28126588	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs2275508	ENSG00000226314.6	ZNF192P1	-8.89	1.39e-17	9.37e-15	-0.52	-0.38	Depression;	chr6:28126953	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs9380056	ENSG00000226314.6	ZNF192P1	-8.89	1.4e-17	9.42e-15	-0.52	-0.38	Depression;	chr6:28136698	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs9380057	ENSG00000226314.6	ZNF192P1	-8.89	1.4e-17	9.42e-15	-0.52	-0.38	Depression;	chr6:28136856	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs1947862	ENSG00000226314.6	ZNF192P1	-8.89	1.4e-17	9.42e-15	-0.52	-0.38	Depression;	chr6:28137418	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs6941992	ENSG00000226314.6	ZNF192P1	-8.89	1.4e-17	9.42e-15	-0.52	-0.38	Depression;	chr6:28138363	chr6:28161781~28169594:+
PRAD	cis	rs4713118	0.516	rs4713142	ENSG00000226314.6	ZNF192P1	-8.89	1.4e-17	9.42e-15	-0.52	-0.38	Parkinson's disease;	chr6:28138569	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs4713143	ENSG00000226314.6	ZNF192P1	-8.89	1.4e-17	9.42e-15	-0.52	-0.38	Depression;	chr6:28138981	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs4713144	ENSG00000226314.6	ZNF192P1	-8.89	1.4e-17	9.42e-15	-0.52	-0.38	Depression;	chr6:28139012	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs3757187	ENSG00000226314.6	ZNF192P1	-8.89	1.4e-17	9.42e-15	-0.52	-0.38	Depression;	chr6:28139876	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs3757185	ENSG00000226314.6	ZNF192P1	-8.89	1.4e-17	9.42e-15	-0.52	-0.38	Depression;	chr6:28139998	chr6:28161781~28169594:+
PRAD	cis	rs7923609	0.811	rs3847325	ENSG00000232075.1	MRPL35P2	8.89	1.41e-17	9.48e-15	0.4	0.38	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63571751	chr10:63634317~63634827:-
PRAD	cis	rs3002131	0.604	rs1603742	ENSG00000225265.1	TAF1A-AS1	-8.89	1.41e-17	9.49e-15	-0.66	-0.38	Interleukin-10 levels;	chr1:222571339	chr1:222589825~222593032:+
PRAD	cis	rs4835473	0.798	rs34353812	ENSG00000251600.4	RP11-673E1.1	8.89	1.42e-17	9.53e-15	0.49	0.38	Immature fraction of reticulocytes;	chr4:143973949	chr4:143912331~143982454:+
PRAD	cis	rs741668	0.641	rs9534306	ENSG00000235903.6	CPB2-AS1	8.89	1.42e-17	9.54e-15	0.45	0.38	Cerebrospinal fluid clusterin levels;	chr13:46069100	chr13:46052806~46113332:+
PRAD	cis	rs2564921	0.704	rs17304694	ENSG00000242142.1	SERBP1P3	-8.89	1.42e-17	9.58e-15	-0.45	-0.38	Height;	chr3:53017561	chr3:53064283~53065091:-
PRAD	cis	rs2564921	0.666	rs55796351	ENSG00000242142.1	SERBP1P3	-8.89	1.42e-17	9.58e-15	-0.45	-0.38	Height;	chr3:53020134	chr3:53064283~53065091:-
PRAD	cis	rs17711722	0.503	rs453835	ENSG00000226824.5	RP4-756H11.3	8.89	1.43e-17	9.6e-15	0.5	0.38	Calcium levels;	chr7:66046172	chr7:66654538~66669855:+
PRAD	cis	rs7712401	0.601	rs35479600	ENSG00000263432.2	RN7SL689P	-8.89	1.44e-17	9.68e-15	-0.4	-0.38	Mean platelet volume;	chr5:122988775	chr5:123022487~123022783:-
PRAD	cis	rs9309473	0.687	rs6546827	ENSG00000163016.8	ALMS1P	8.89	1.44e-17	9.71e-15	0.45	0.38	Metabolite levels;	chr2:73379365	chr2:73644919~73685576:+
PRAD	cis	rs9309473	0.718	rs10175529	ENSG00000163016.8	ALMS1P	8.89	1.45e-17	9.75e-15	0.45	0.38	Metabolite levels;	chr2:73378965	chr2:73644919~73685576:+
PRAD	cis	rs6890270	0.634	rs62356569	ENSG00000271828.1	CTD-2310F14.1	8.89	1.46e-17	9.79e-15	0.66	0.38	Breast cancer;	chr5:56963908	chr5:56927874~56929573:+
PRAD	cis	rs7923609	0.811	rs4746204	ENSG00000232075.1	MRPL35P2	8.89	1.46e-17	9.81e-15	0.4	0.38	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63568758	chr10:63634317~63634827:-
PRAD	cis	rs7923609	0.783	rs7907451	ENSG00000232075.1	MRPL35P2	8.89	1.46e-17	9.81e-15	0.4	0.38	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63568980	chr10:63634317~63634827:-
PRAD	cis	rs7923609	0.783	rs7100409	ENSG00000232075.1	MRPL35P2	8.89	1.46e-17	9.81e-15	0.4	0.38	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63570435	chr10:63634317~63634827:-
PRAD	cis	rs7923609	0.703	rs7100413	ENSG00000232075.1	MRPL35P2	8.89	1.46e-17	9.81e-15	0.4	0.38	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63570448	chr10:63634317~63634827:-
PRAD	cis	rs8523	0.836	rs6918936	ENSG00000230314.5	ELOVL2-AS1	8.89	1.47e-17	9.87e-15	0.43	0.38	Red blood cell fatty acid levels;	chr6:10959925	chr6:11043524~11078226:+
PRAD	cis	rs8523	0.836	rs6920247	ENSG00000230314.5	ELOVL2-AS1	8.89	1.47e-17	9.87e-15	0.43	0.38	Red blood cell fatty acid levels;	chr6:10959940	chr6:11043524~11078226:+
PRAD	cis	rs4835473	0.932	rs4835120	ENSG00000251600.4	RP11-673E1.1	8.89	1.47e-17	9.88e-15	0.49	0.38	Immature fraction of reticulocytes;	chr4:143982370	chr4:143912331~143982454:+
PRAD	cis	rs6452524	0.967	rs6897075	ENSG00000249664.1	CTD-2227C6.2	8.89	1.47e-17	9.89e-15	0.45	0.38	Hypertension (SNP x SNP interaction);	chr5:83122959	chr5:83012285~83013109:-
PRAD	cis	rs6452524	0.967	rs10065973	ENSG00000249664.1	CTD-2227C6.2	8.89	1.47e-17	9.89e-15	0.45	0.38	Hypertension (SNP x SNP interaction);	chr5:83123181	chr5:83012285~83013109:-
PRAD	cis	rs6452524	0.967	rs12153441	ENSG00000249664.1	CTD-2227C6.2	8.89	1.47e-17	9.89e-15	0.45	0.38	Hypertension (SNP x SNP interaction);	chr5:83125181	chr5:83012285~83013109:-
PRAD	cis	rs6452524	0.967	rs12152891	ENSG00000249664.1	CTD-2227C6.2	8.89	1.47e-17	9.89e-15	0.45	0.38	Hypertension (SNP x SNP interaction);	chr5:83125217	chr5:83012285~83013109:-
PRAD	cis	rs6452524	0.967	rs6452507	ENSG00000249664.1	CTD-2227C6.2	8.89	1.47e-17	9.89e-15	0.45	0.38	Hypertension (SNP x SNP interaction);	chr5:83125537	chr5:83012285~83013109:-
PRAD	cis	rs6452524	0.967	rs6452508	ENSG00000249664.1	CTD-2227C6.2	8.89	1.47e-17	9.89e-15	0.45	0.38	Hypertension (SNP x SNP interaction);	chr5:83125546	chr5:83012285~83013109:-
PRAD	cis	rs6452524	0.967	rs7717964	ENSG00000249664.1	CTD-2227C6.2	8.89	1.47e-17	9.89e-15	0.45	0.38	Hypertension (SNP x SNP interaction);	chr5:83126323	chr5:83012285~83013109:-
PRAD	cis	rs6723108	0.604	rs2322251	ENSG00000224043.6	CCNT2-AS1	-8.89	1.47e-17	9.9e-15	-0.53	-0.38	Type 2 diabetes;	chr2:134913732	chr2:134735464~134918710:-
PRAD	cis	rs6723108	0.603	rs62168891	ENSG00000224043.6	CCNT2-AS1	-8.89	1.47e-17	9.9e-15	-0.53	-0.38	Type 2 diabetes;	chr2:134914617	chr2:134735464~134918710:-
PRAD	cis	rs34779708	0.706	rs36027395	ENSG00000230534.5	RP11-297A16.2	8.89	1.48e-17	9.93e-15	0.52	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35261395	chr10:35098006~35127020:-
PRAD	cis	rs67311347	0.824	rs59922539	ENSG00000223797.4	ENTPD3-AS1	8.89	1.48e-17	9.96e-15	0.35	0.38	Renal cell carcinoma;	chr3:40295619	chr3:40313802~40453329:-
PRAD	cis	rs853679	0.517	rs17711344	ENSG00000226314.6	ZNF192P1	8.89	1.48e-17	9.96e-15	0.52	0.38	Depression;	chr6:28109824	chr6:28161781~28169594:+
PRAD	cis	rs7727544	0.606	rs11950562	ENSG00000233006.5	AC034220.3	8.89	1.49e-17	1e-14	0.33	0.38	Blood metabolite levels;	chr5:132316836	chr5:132311285~132369916:-
PRAD	cis	rs3002131	0.604	rs2936037	ENSG00000225265.1	TAF1A-AS1	-8.89	1.49e-17	1e-14	-0.62	-0.38	Interleukin-10 levels;	chr1:222575223	chr1:222589825~222593032:+
PRAD	cis	rs3002131	0.604	rs2936035	ENSG00000225265.1	TAF1A-AS1	-8.89	1.49e-17	1e-14	-0.62	-0.38	Interleukin-10 levels;	chr1:222575582	chr1:222589825~222593032:+
PRAD	cis	rs3002131	0.525	rs2936034	ENSG00000225265.1	TAF1A-AS1	-8.89	1.49e-17	1e-14	-0.62	-0.38	Interleukin-10 levels;	chr1:222575661	chr1:222589825~222593032:+
PRAD	cis	rs765787	0.53	rs12910270	ENSG00000259520.4	CTD-2651B20.3	-8.88	1.5e-17	1.01e-14	-0.49	-0.38	Uric acid levels;	chr15:45219888	chr15:45251580~45279251:-
PRAD	cis	rs765787	0.53	rs12440238	ENSG00000259520.4	CTD-2651B20.3	-8.88	1.5e-17	1.01e-14	-0.49	-0.38	Uric acid levels;	chr15:45220707	chr15:45251580~45279251:-
PRAD	cis	rs6991838	0.584	rs4275254	ENSG00000200714.1	Y_RNA	-8.88	1.5e-17	1.01e-14	-0.42	-0.38	Intelligence (multi-trait analysis);	chr8:65589129	chr8:65592731~65592820:+
PRAD	cis	rs150992	0.512	rs161954	ENSG00000248489.1	CTD-2007H13.3	8.88	1.5e-17	1.01e-14	0.43	0.38	Body mass index;	chr5:98920833	chr5:98929171~98995013:+
PRAD	cis	rs11098499	0.909	rs10014719	ENSG00000245958.5	RP11-33B1.1	-8.88	1.5e-17	1.01e-14	-0.38	-0.38	Corneal astigmatism;	chr4:119399560	chr4:119454791~119552025:+
PRAD	cis	rs4835473	0.932	rs10857415	ENSG00000251600.4	RP11-673E1.1	8.88	1.5e-17	1.01e-14	0.49	0.38	Immature fraction of reticulocytes;	chr4:143908753	chr4:143912331~143982454:+
PRAD	cis	rs17711722	0.522	rs62469933	ENSG00000236529.1	RP13-254B10.1	8.88	1.5e-17	1.01e-14	0.4	0.38	Calcium levels;	chr7:65800652	chr7:65840212~65840596:+
PRAD	cis	rs11159086	0.793	rs11621693	ENSG00000259005.1	RP3-449M8.6	8.88	1.5e-17	1.01e-14	0.49	0.38	Advanced glycation end-product levels;	chr14:74472631	chr14:74474007~74474864:-
PRAD	cis	rs7712401	0.601	rs2910136	ENSG00000263432.2	RN7SL689P	-8.88	1.51e-17	1.01e-14	-0.39	-0.38	Mean platelet volume;	chr5:122918322	chr5:123022487~123022783:-
PRAD	cis	rs2153535	0.585	rs9379234	ENSG00000230939.1	RP11-314C16.1	-8.88	1.51e-17	1.02e-14	-0.47	-0.38	Motion sickness;	chr6:8643520	chr6:8784178~8785445:+
PRAD	cis	rs193541	0.545	rs112390044	ENSG00000263432.2	RN7SL689P	-8.88	1.52e-17	1.02e-14	-0.41	-0.38	Glucose homeostasis traits;	chr5:122976307	chr5:123022487~123022783:-
PRAD	cis	rs853679	0.882	rs9468300	ENSG00000280107.1	AL022393.9	-8.88	1.53e-17	1.02e-14	-0.64	-0.38	Depression;	chr6:28159062	chr6:28170845~28172521:+
PRAD	cis	rs150992	0.673	rs161953	ENSG00000248489.1	CTD-2007H13.3	8.88	1.53e-17	1.03e-14	0.43	0.38	Body mass index;	chr5:98921201	chr5:98929171~98995013:+
PRAD	cis	rs150992	0.673	rs161952	ENSG00000248489.1	CTD-2007H13.3	8.88	1.53e-17	1.03e-14	0.43	0.38	Body mass index;	chr5:98921665	chr5:98929171~98995013:+
PRAD	cis	rs7189233	0.531	rs8061398	ENSG00000279344.1	RP11-44F14.7	8.88	1.53e-17	1.03e-14	0.36	0.38	Intelligence (multi-trait analysis);	chr16:53420239	chr16:53478957~53481550:-
PRAD	cis	rs7712401	0.511	rs30068	ENSG00000263432.2	RN7SL689P	8.88	1.53e-17	1.03e-14	0.38	0.38	Mean platelet volume;	chr5:122957914	chr5:123022487~123022783:-
PRAD	cis	rs1075232	0.826	rs12437800	ENSG00000270055.1	CTD-3092A11.2	-8.88	1.53e-17	1.03e-14	-0.81	-0.38	Survival in colorectal cancer (non-distant metastatic);	chr15:31379229	chr15:30487963~30490313:+
PRAD	cis	rs524281	0.731	rs10791838	ENSG00000255320.1	RP11-755F10.1	8.88	1.54e-17	1.03e-14	0.68	0.38	Electroencephalogram traits;	chr11:66022383	chr11:66244840~66246239:-
PRAD	cis	rs853679	0.517	rs12174753	ENSG00000226314.6	ZNF192P1	-8.88	1.54e-17	1.03e-14	-0.52	-0.38	Depression;	chr6:28074687	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs55747925	ENSG00000226314.6	ZNF192P1	-8.88	1.54e-17	1.03e-14	-0.52	-0.38	Depression;	chr6:28076559	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs56310871	ENSG00000226314.6	ZNF192P1	-8.88	1.54e-17	1.03e-14	-0.52	-0.38	Depression;	chr6:28076704	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs34716816	ENSG00000226314.6	ZNF192P1	-8.88	1.54e-17	1.03e-14	-0.52	-0.38	Depression;	chr6:28078391	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs9380049	ENSG00000226314.6	ZNF192P1	-8.88	1.54e-17	1.03e-14	-0.52	-0.38	Depression;	chr6:28080757	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs9380050	ENSG00000226314.6	ZNF192P1	-8.88	1.54e-17	1.03e-14	-0.52	-0.38	Depression;	chr6:28080760	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs9393885	ENSG00000226314.6	ZNF192P1	-8.88	1.54e-17	1.03e-14	-0.52	-0.38	Depression;	chr6:28082231	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs9393886	ENSG00000226314.6	ZNF192P1	-8.88	1.54e-17	1.03e-14	-0.52	-0.38	Depression;	chr6:28082261	chr6:28161781~28169594:+
PRAD	cis	rs4713118	0.515	rs9368549	ENSG00000226314.6	ZNF192P1	-8.88	1.54e-17	1.03e-14	-0.52	-0.38	Parkinson's disease;	chr6:28082269	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs56364346	ENSG00000226314.6	ZNF192P1	-8.88	1.54e-17	1.03e-14	-0.52	-0.38	Depression;	chr6:28082984	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs9357061	ENSG00000226314.6	ZNF192P1	-8.88	1.54e-17	1.03e-14	-0.52	-0.38	Depression;	chr6:28083994	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs9368550	ENSG00000226314.6	ZNF192P1	-8.88	1.54e-17	1.03e-14	-0.52	-0.38	Depression;	chr6:28084025	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.542	rs2295594	ENSG00000226314.6	ZNF192P1	-8.88	1.54e-17	1.03e-14	-0.52	-0.38	Depression;	chr6:28085319	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs2273564	ENSG00000226314.6	ZNF192P1	-8.88	1.54e-17	1.03e-14	-0.52	-0.38	Depression;	chr6:28089816	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs1853097	ENSG00000226314.6	ZNF192P1	-8.88	1.54e-17	1.03e-14	-0.52	-0.38	Depression;	chr6:28090857	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs9393888	ENSG00000226314.6	ZNF192P1	-8.88	1.54e-17	1.03e-14	-0.52	-0.38	Depression;	chr6:28091439	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs3734573	ENSG00000226314.6	ZNF192P1	-8.88	1.54e-17	1.03e-14	-0.52	-0.38	Depression;	chr6:28091659	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs9357063	ENSG00000226314.6	ZNF192P1	-8.88	1.54e-17	1.03e-14	-0.52	-0.38	Depression;	chr6:28092227	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs3823180	ENSG00000226314.6	ZNF192P1	-8.88	1.54e-17	1.03e-14	-0.52	-0.38	Depression;	chr6:28093966	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs9368551	ENSG00000226314.6	ZNF192P1	-8.88	1.54e-17	1.03e-14	-0.52	-0.38	Depression;	chr6:28094014	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs9393890	ENSG00000226314.6	ZNF192P1	-8.88	1.54e-17	1.03e-14	-0.52	-0.38	Depression;	chr6:28096077	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs9366715	ENSG00000226314.6	ZNF192P1	-8.88	1.54e-17	1.03e-14	-0.52	-0.38	Depression;	chr6:28096855	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.598	rs9380054	ENSG00000226314.6	ZNF192P1	-8.88	1.54e-17	1.03e-14	-0.52	-0.38	Depression;	chr6:28099759	chr6:28161781~28169594:+
PRAD	cis	rs4713118	0.547	rs2116981	ENSG00000226314.6	ZNF192P1	-8.88	1.54e-17	1.03e-14	-0.52	-0.38	Parkinson's disease;	chr6:28100173	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs9368552	ENSG00000226314.6	ZNF192P1	-8.88	1.54e-17	1.03e-14	-0.52	-0.38	Depression;	chr6:28100648	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs2281588	ENSG00000226314.6	ZNF192P1	-8.88	1.54e-17	1.03e-14	-0.52	-0.38	Depression;	chr6:28104824	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.542	rs34131763	ENSG00000226314.6	ZNF192P1	-8.88	1.54e-17	1.03e-14	-0.52	-0.38	Depression;	chr6:28107222	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs35193936	ENSG00000226314.6	ZNF192P1	-8.88	1.54e-17	1.03e-14	-0.52	-0.38	Depression;	chr6:28108492	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs36078605	ENSG00000226314.6	ZNF192P1	-8.88	1.54e-17	1.03e-14	-0.52	-0.38	Depression;	chr6:28110254	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs9393891	ENSG00000226314.6	ZNF192P1	-8.88	1.54e-17	1.03e-14	-0.52	-0.38	Depression;	chr6:28111382	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs9468286	ENSG00000226314.6	ZNF192P1	-8.88	1.54e-17	1.03e-14	-0.52	-0.38	Depression;	chr6:28111650	chr6:28161781~28169594:+
PRAD	cis	rs4713118	0.516	rs7739216	ENSG00000226314.6	ZNF192P1	-8.88	1.54e-17	1.03e-14	-0.52	-0.38	Parkinson's disease;	chr6:28112168	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs35512245	ENSG00000226314.6	ZNF192P1	-8.88	1.54e-17	1.03e-14	-0.52	-0.38	Depression;	chr6:28112175	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs9380055	ENSG00000226314.6	ZNF192P1	-8.88	1.54e-17	1.03e-14	-0.52	-0.38	Depression;	chr6:28113851	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs9368553	ENSG00000226314.6	ZNF192P1	-8.88	1.54e-17	1.03e-14	-0.52	-0.38	Depression;	chr6:28114487	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs9368554	ENSG00000226314.6	ZNF192P1	-8.88	1.54e-17	1.03e-14	-0.52	-0.38	Depression;	chr6:28114933	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs4713137	ENSG00000226314.6	ZNF192P1	-8.88	1.54e-17	1.03e-14	-0.52	-0.38	Depression;	chr6:28115743	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs9348793	ENSG00000226314.6	ZNF192P1	-8.88	1.54e-17	1.03e-14	-0.52	-0.38	Depression;	chr6:28116411	chr6:28161781~28169594:+
PRAD	cis	rs4713118	0.586	rs6905516	ENSG00000226314.6	ZNF192P1	-8.88	1.54e-17	1.03e-14	-0.52	-0.38	Parkinson's disease;	chr6:28118700	chr6:28161781~28169594:+
PRAD	cis	rs4713118	0.586	rs6905522	ENSG00000226314.6	ZNF192P1	-8.88	1.54e-17	1.03e-14	-0.52	-0.38	Parkinson's disease;	chr6:28118701	chr6:28161781~28169594:+
PRAD	cis	rs4713118	0.586	rs9468290	ENSG00000226314.6	ZNF192P1	-8.88	1.54e-17	1.03e-14	-0.52	-0.38	Parkinson's disease;	chr6:28119896	chr6:28161781~28169594:+
PRAD	cis	rs2638953	0.924	rs11049415	ENSG00000278733.1	RP11-425D17.1	-8.88	1.54e-17	1.03e-14	-0.46	-0.38	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28190188	chr12:28185625~28186190:-
PRAD	cis	rs4835473	0.736	rs6851661	ENSG00000251600.4	RP11-673E1.1	8.88	1.54e-17	1.03e-14	0.51	0.38	Immature fraction of reticulocytes;	chr4:143850587	chr4:143912331~143982454:+
PRAD	cis	rs2153535	0.585	rs9502734	ENSG00000230939.1	RP11-314C16.1	-8.88	1.55e-17	1.04e-14	-0.47	-0.38	Motion sickness;	chr6:8631618	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.56	rs7750064	ENSG00000230939.1	RP11-314C16.1	-8.88	1.55e-17	1.04e-14	-0.47	-0.38	Motion sickness;	chr6:8632012	chr6:8784178~8785445:+
PRAD	cis	rs853679	0.517	rs9380047	ENSG00000226314.6	ZNF192P1	-8.88	1.55e-17	1.04e-14	-0.52	-0.38	Depression;	chr6:28070115	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs7755442	ENSG00000226314.6	ZNF192P1	-8.88	1.55e-17	1.04e-14	-0.52	-0.38	Depression;	chr6:28071237	chr6:28161781~28169594:+
PRAD	cis	rs2153535	0.585	rs2208540	ENSG00000230939.1	RP11-314C16.1	-8.88	1.55e-17	1.04e-14	-0.47	-0.38	Motion sickness;	chr6:8627147	chr6:8784178~8785445:+
PRAD	cis	rs950169	0.84	rs62019457	ENSG00000225151.9	GOLGA2P7	-8.88	1.55e-17	1.04e-14	-0.53	-0.38	Schizophrenia;	chr15:84558911	chr15:84199311~84230136:-
PRAD	cis	rs6847067	0.8	rs10856851	ENSG00000180769.7	WDFY3-AS2	8.88	1.55e-17	1.04e-14	0.4	0.38	Oropharynx cancer;	chr4:84908450	chr4:84965682~85011277:+
PRAD	cis	rs780096	0.546	rs715326	ENSG00000234072.1	AC074117.10	8.88	1.56e-17	1.05e-14	0.28	0.38	Total body bone mineral density;	chr2:27502894	chr2:27356246~27367622:+
PRAD	cis	rs12220777	1	rs72644213	ENSG00000230091.5	TMEM254-AS1	8.88	1.57e-17	1.05e-14	0.74	0.38	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80023904	chr10:80046860~80078912:-
PRAD	cis	rs172166	0.538	rs149956	ENSG00000204709.4	LINC01556	8.88	1.57e-17	1.05e-14	0.48	0.38	Cardiac Troponin-T levels;	chr6:28068473	chr6:28943877~28944537:+
PRAD	cis	rs2115630	0.691	rs2292462	ENSG00000275120.1	RP11-182J1.17	-8.88	1.58e-17	1.06e-14	-0.44	-0.38	P wave terminal force;	chr15:84657523	chr15:84599434~84606463:-
PRAD	cis	rs111321694	1	rs111321694	ENSG00000271584.1	RP11-89C3.4	8.88	1.59e-17	1.06e-14	0.59	0.38	Educational attainment (years of education);	chr11:111079662	chr11:111091932~111097357:-
PRAD	cis	rs321358	0.895	rs17457076	ENSG00000271584.1	RP11-89C3.4	8.88	1.59e-17	1.06e-14	0.59	0.38	Body mass index;	chr11:111081030	chr11:111091932~111097357:-
PRAD	cis	rs11123170	0.543	rs12472361	ENSG00000274877.1	RP11-65I12.1	-8.88	1.59e-17	1.06e-14	-0.61	-0.38	Renal function-related traits (BUN);	chr2:113223068	chr2:113237595~113240825:+
PRAD	cis	rs6991838	0.584	rs57042777	ENSG00000200714.1	Y_RNA	-8.88	1.6e-17	1.07e-14	-0.42	-0.38	Intelligence (multi-trait analysis);	chr8:65576855	chr8:65592731~65592820:+
PRAD	cis	rs6991838	0.557	rs67046768	ENSG00000200714.1	Y_RNA	-8.88	1.6e-17	1.07e-14	-0.42	-0.38	Intelligence (multi-trait analysis);	chr8:65577486	chr8:65592731~65592820:+
PRAD	cis	rs7772486	0.875	rs9322048	ENSG00000235652.6	RP11-545I5.3	8.88	1.61e-17	1.07e-14	0.39	0.38	Lobe attachment (rater-scored or self-reported);	chr6:146079303	chr6:145799409~145886585:+
PRAD	cis	rs6991838	0.584	rs4388482	ENSG00000200714.1	Y_RNA	-8.88	1.61e-17	1.08e-14	-0.42	-0.38	Intelligence (multi-trait analysis);	chr8:65583968	chr8:65592731~65592820:+
PRAD	cis	rs6991838	0.584	rs4637885	ENSG00000200714.1	Y_RNA	-8.88	1.61e-17	1.08e-14	-0.42	-0.38	Intelligence (multi-trait analysis);	chr8:65584849	chr8:65592731~65592820:+
PRAD	cis	rs6991838	0.556	rs7846527	ENSG00000200714.1	Y_RNA	-8.88	1.61e-17	1.08e-14	-0.42	-0.38	Intelligence (multi-trait analysis);	chr8:65586522	chr8:65592731~65592820:+
PRAD	cis	rs6991838	0.584	rs4320587	ENSG00000200714.1	Y_RNA	-8.88	1.61e-17	1.08e-14	-0.42	-0.38	Intelligence (multi-trait analysis);	chr8:65586991	chr8:65592731~65592820:+
PRAD	cis	rs6991838	0.584	rs35941313	ENSG00000200714.1	Y_RNA	-8.88	1.61e-17	1.08e-14	-0.42	-0.38	Intelligence (multi-trait analysis);	chr8:65587498	chr8:65592731~65592820:+
PRAD	cis	rs6991838	0.557	rs4737222	ENSG00000200714.1	Y_RNA	-8.88	1.61e-17	1.08e-14	-0.42	-0.38	Intelligence (multi-trait analysis);	chr8:65587878	chr8:65592731~65592820:+
PRAD	cis	rs12134133	0.752	rs4844579	ENSG00000274245.1	RP11-357P18.2	8.88	1.61e-17	1.08e-14	0.59	0.38	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207204546	chr1:207372559~207373252:+
PRAD	cis	rs4713118	0.513	rs149955	ENSG00000280107.1	AL022393.9	-8.88	1.61e-17	1.08e-14	-0.47	-0.38	Parkinson's disease;	chr6:28068447	chr6:28170845~28172521:+
PRAD	cis	rs5769707	0.681	rs8137111	ENSG00000188511.11	C22orf34	8.88	1.61e-17	1.08e-14	0.46	0.38	Monocyte percentage of white cells;Monocyte count;	chr22:49650102	chr22:49414524~49657542:-
PRAD	cis	rs11098499	0.954	rs4309825	ENSG00000245958.5	RP11-33B1.1	8.87	1.63e-17	1.09e-14	0.38	0.38	Corneal astigmatism;	chr4:119393726	chr4:119454791~119552025:+
PRAD	cis	rs9399137	0.507	rs7771310	ENSG00000232876.1	CTA-212D2.2	-8.87	1.63e-17	1.09e-14	-0.49	-0.38	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134951397	chr6:135055033~135060550:+
PRAD	cis	rs2638953	0.924	rs12146881	ENSG00000278733.1	RP11-425D17.1	-8.87	1.63e-17	1.09e-14	-0.46	-0.38	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28198436	chr12:28185625~28186190:-
PRAD	cis	rs7945705	0.747	rs2742480	ENSG00000254860.4	TMEM9B-AS1	8.87	1.64e-17	1.1e-14	0.4	0.38	Hemoglobin concentration;	chr11:8971583	chr11:8964675~8977527:+
PRAD	cis	rs5769707	0.681	rs8140095	ENSG00000188511.11	C22orf34	8.87	1.64e-17	1.1e-14	0.46	0.38	Monocyte percentage of white cells;Monocyte count;	chr22:49650147	chr22:49414524~49657542:-
PRAD	cis	rs7189233	0.531	rs9921587	ENSG00000279344.1	RP11-44F14.7	8.87	1.64e-17	1.1e-14	0.35	0.38	Intelligence (multi-trait analysis);	chr16:53441738	chr16:53478957~53481550:-
PRAD	cis	rs62355901	0.545	rs12654176	ENSG00000271828.1	CTD-2310F14.1	8.87	1.65e-17	1.1e-14	0.76	0.38	Breast cancer;	chr5:56762660	chr5:56927874~56929573:+
PRAD	cis	rs4835473	0.864	rs57648439	ENSG00000251600.4	RP11-673E1.1	-8.87	1.65e-17	1.11e-14	-0.49	-0.38	Immature fraction of reticulocytes;	chr4:143691519	chr4:143912331~143982454:+
PRAD	cis	rs853679	0.825	rs8180562	ENSG00000280107.1	AL022393.9	-8.87	1.65e-17	1.11e-14	-0.65	-0.38	Depression;	chr6:28173682	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.882	rs9380064	ENSG00000280107.1	AL022393.9	-8.87	1.65e-17	1.11e-14	-0.65	-0.38	Depression;	chr6:28175340	chr6:28170845~28172521:+
PRAD	cis	rs2739330	0.929	rs5751775	ENSG00000224205.1	AP000351.4	8.87	1.65e-17	1.11e-14	0.48	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23987320~23991421:-
PRAD	cis	rs7923609	0.811	rs10822181	ENSG00000232075.1	MRPL35P2	8.87	1.66e-17	1.11e-14	0.4	0.38	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63565366	chr10:63634317~63634827:-
PRAD	cis	rs2153535	0.518	rs1328868	ENSG00000230939.1	RP11-314C16.1	-8.87	1.66e-17	1.11e-14	-0.46	-0.38	Motion sickness;	chr6:8652345	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.518	rs9505510	ENSG00000230939.1	RP11-314C16.1	-8.87	1.66e-17	1.11e-14	-0.46	-0.38	Motion sickness;	chr6:8657603	chr6:8784178~8785445:+
PRAD	cis	rs2638953	0.924	rs11049399	ENSG00000278733.1	RP11-425D17.1	-8.87	1.66e-17	1.11e-14	-0.46	-0.38	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28174213	chr12:28185625~28186190:-
PRAD	cis	rs2739330	0.828	rs5751770	ENSG00000235689.1	AP000351.13	8.87	1.67e-17	1.12e-14	0.46	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:24006305~24008258:-
PRAD	cis	rs4835473	0.932	rs35017645	ENSG00000251600.4	RP11-673E1.1	-8.87	1.68e-17	1.12e-14	-0.5	-0.38	Immature fraction of reticulocytes;	chr4:143760196	chr4:143912331~143982454:+
PRAD	cis	rs172166	0.637	rs1071893	ENSG00000280107.1	AL022393.9	-8.87	1.68e-17	1.12e-14	-0.47	-0.38	Cardiac Troponin-T levels;	chr6:28199857	chr6:28170845~28172521:+
PRAD	cis	rs6847067	0.8	rs12648852	ENSG00000180769.7	WDFY3-AS2	8.87	1.68e-17	1.12e-14	0.4	0.38	Oropharynx cancer;	chr4:84919080	chr4:84965682~85011277:+
PRAD	cis	rs765787	0.53	rs11636404	ENSG00000259520.4	CTD-2651B20.3	8.87	1.68e-17	1.12e-14	0.47	0.38	Uric acid levels;	chr15:45243663	chr15:45251580~45279251:-
PRAD	cis	rs2638953	0.924	rs1478336	ENSG00000278733.1	RP11-425D17.1	-8.87	1.68e-17	1.12e-14	-0.46	-0.38	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28189186	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs1478335	ENSG00000278733.1	RP11-425D17.1	-8.87	1.68e-17	1.12e-14	-0.46	-0.38	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28189244	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs1478334	ENSG00000278733.1	RP11-425D17.1	-8.87	1.68e-17	1.12e-14	-0.46	-0.38	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28189425	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs11049417	ENSG00000278733.1	RP11-425D17.1	-8.87	1.68e-17	1.12e-14	-0.46	-0.38	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28192152	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs12372059	ENSG00000278733.1	RP11-425D17.1	-8.87	1.68e-17	1.12e-14	-0.46	-0.38	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28192370	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs12372073	ENSG00000278733.1	RP11-425D17.1	-8.87	1.68e-17	1.12e-14	-0.46	-0.38	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28192462	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs56318627	ENSG00000278733.1	RP11-425D17.1	-8.87	1.68e-17	1.12e-14	-0.46	-0.38	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28192719	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.814	rs11049419	ENSG00000278733.1	RP11-425D17.1	-8.87	1.68e-17	1.12e-14	-0.46	-0.38	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28192951	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.85	rs11049420	ENSG00000278733.1	RP11-425D17.1	-8.87	1.68e-17	1.12e-14	-0.46	-0.38	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28193179	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.744	rs11049421	ENSG00000278733.1	RP11-425D17.1	-8.87	1.68e-17	1.12e-14	-0.46	-0.38	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28193324	chr12:28185625~28186190:-
PRAD	cis	rs367615	0.512	rs414724	ENSG00000249476.1	CTD-2587M2.1	8.87	1.69e-17	1.13e-14	0.47	0.38	Colorectal cancer (SNP x SNP interaction);	chr5:109334720	chr5:109237120~109326369:-
PRAD	cis	rs950169	0.922	rs67804993	ENSG00000225151.9	GOLGA2P7	-8.87	1.69e-17	1.13e-14	-0.53	-0.38	Schizophrenia;	chr15:84560799	chr15:84199311~84230136:-
PRAD	cis	rs7772486	0.748	rs2748484	ENSG00000235652.6	RP11-545I5.3	8.87	1.69e-17	1.13e-14	0.39	0.38	Lobe attachment (rater-scored or self-reported);	chr6:146012517	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.846	rs1854901	ENSG00000235652.6	RP11-545I5.3	8.87	1.69e-17	1.13e-14	0.39	0.38	Lobe attachment (rater-scored or self-reported);	chr6:146004549	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.875	rs1960885	ENSG00000235652.6	RP11-545I5.3	8.87	1.69e-17	1.13e-14	0.39	0.38	Lobe attachment (rater-scored or self-reported);	chr6:146004794	chr6:145799409~145886585:+
PRAD	cis	rs7829975	0.624	rs7823056	ENSG00000253893.2	FAM85B	-8.87	1.7e-17	1.13e-14	-0.46	-0.38	Mood instability;	chr8:8525195	chr8:8167819~8226614:-
PRAD	cis	rs11123170	0.543	rs4849178	ENSG00000274877.1	RP11-65I12.1	-8.87	1.7e-17	1.14e-14	-0.61	-0.38	Renal function-related traits (BUN);	chr2:113225031	chr2:113237595~113240825:+
PRAD	cis	rs2638953	0.924	rs10843125	ENSG00000278733.1	RP11-425D17.1	-8.87	1.71e-17	1.14e-14	-0.46	-0.38	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28198308	chr12:28185625~28186190:-
PRAD	cis	rs853679	0.55	rs1233699	ENSG00000226314.6	ZNF192P1	-8.87	1.72e-17	1.15e-14	-0.51	-0.38	Depression;	chr6:28201380	chr6:28161781~28169594:+
PRAD	cis	rs2638953	0.924	rs61920227	ENSG00000278733.1	RP11-425D17.1	-8.87	1.72e-17	1.15e-14	-0.46	-0.38	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28174584	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs11049400	ENSG00000278733.1	RP11-425D17.1	-8.87	1.72e-17	1.15e-14	-0.46	-0.38	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28175051	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs11049401	ENSG00000278733.1	RP11-425D17.1	-8.87	1.72e-17	1.15e-14	-0.46	-0.38	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28175218	chr12:28185625~28186190:-
PRAD	cis	rs2153535	0.518	rs2183113	ENSG00000230939.1	RP11-314C16.1	-8.87	1.72e-17	1.15e-14	-0.46	-0.38	Motion sickness;	chr6:8528305	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.518	rs6597336	ENSG00000230939.1	RP11-314C16.1	-8.87	1.72e-17	1.15e-14	-0.46	-0.38	Motion sickness;	chr6:8530663	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.539	rs4960436	ENSG00000230939.1	RP11-314C16.1	-8.87	1.72e-17	1.15e-14	-0.46	-0.38	Motion sickness;	chr6:8532237	chr6:8784178~8785445:+
PRAD	cis	rs2638953	0.924	rs61920245	ENSG00000278733.1	RP11-425D17.1	-8.87	1.73e-17	1.15e-14	-0.46	-0.38	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28196081	chr12:28185625~28186190:-
PRAD	cis	rs2739330	0.828	rs5760108	ENSG00000224205.1	AP000351.4	8.87	1.73e-17	1.16e-14	0.48	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23987320~23991421:-
PRAD	cis	rs2564921	0.704	rs62253649	ENSG00000242142.1	SERBP1P3	-8.87	1.74e-17	1.16e-14	-0.44	-0.38	Height;	chr3:52967831	chr3:53064283~53065091:-
PRAD	cis	rs11098499	0.58	rs12509234	ENSG00000245958.5	RP11-33B1.1	-8.86	1.74e-17	1.16e-14	-0.38	-0.38	Corneal astigmatism;	chr4:119398279	chr4:119454791~119552025:+
PRAD	cis	rs4835473	0.838	rs6832094	ENSG00000251600.4	RP11-673E1.1	-8.86	1.75e-17	1.16e-14	-0.48	-0.38	Immature fraction of reticulocytes;	chr4:143795388	chr4:143912331~143982454:+
PRAD	cis	rs3809863	0.646	rs9899121	ENSG00000228782.6	CTD-2026D20.3	8.86	1.75e-17	1.17e-14	0.44	0.38	Glaucoma (primary open-angle);	chr17:47317778	chr17:47450568~47492492:-
PRAD	cis	rs2739330	0.828	rs2877178	ENSG00000224205.1	AP000351.4	8.86	1.75e-17	1.17e-14	0.48	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23987320~23991421:-
PRAD	cis	rs2739330	0.828	rs2154593	ENSG00000224205.1	AP000351.4	8.86	1.75e-17	1.17e-14	0.48	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23987320~23991421:-
PRAD	cis	rs7916697	0.52	rs4745957	ENSG00000233590.1	RP11-153K11.3	8.86	1.75e-17	1.17e-14	0.53	0.38	Optic disc area;	chr10:68284945	chr10:68233251~68242379:-
PRAD	cis	rs11159086	0.793	rs28612392	ENSG00000259005.1	RP3-449M8.6	8.86	1.76e-17	1.17e-14	0.49	0.38	Advanced glycation end-product levels;	chr14:74467894	chr14:74474007~74474864:-
PRAD	cis	rs2255336	0.938	rs2617151	ENSG00000245648.1	RP11-277P12.20	8.86	1.77e-17	1.18e-14	0.56	0.38	Blood protein levels;	chr12:10379835	chr12:10363769~10398506:+
PRAD	cis	rs2638953	0.962	rs10843114	ENSG00000278733.1	RP11-425D17.1	-8.86	1.77e-17	1.18e-14	-0.47	-0.38	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28150363	chr12:28185625~28186190:-
PRAD	cis	rs7181230	0.885	rs749748	ENSG00000275636.1	RP11-521C20.5	8.86	1.77e-17	1.18e-14	0.56	0.38	Dehydroepiandrosterone sulphate levels;	chr15:40057708	chr15:40078892~40079347:+
PRAD	cis	rs11159086	0.793	rs10150696	ENSG00000259005.1	RP3-449M8.6	8.86	1.78e-17	1.19e-14	0.49	0.38	Advanced glycation end-product levels;	chr14:74476723	chr14:74474007~74474864:-
PRAD	cis	rs1976403	0.51	rs1697421	ENSG00000227001.3	NBPF2P	8.86	1.78e-17	1.19e-14	0.47	0.38	Liver enzyme levels (alkaline phosphatase);	chr1:21496799	chr1:21424625~21427967:-
PRAD	cis	rs950169	0.84	rs62029595	ENSG00000259728.4	LINC00933	8.86	1.79e-17	1.19e-14	0.46	0.38	Schizophrenia;	chr15:84400603	chr15:84570649~84580175:+
PRAD	cis	rs6723108	0.517	rs6430552	ENSG00000224043.6	CCNT2-AS1	-8.86	1.8e-17	1.2e-14	-0.52	-0.38	Type 2 diabetes;	chr2:134865238	chr2:134735464~134918710:-
PRAD	cis	rs748404	0.66	rs693510	ENSG00000249839.1	AC011330.5	-8.86	1.8e-17	1.2e-14	-0.47	-0.38	Lung cancer;	chr15:43422427	chr15:43663654~43684339:-
PRAD	cis	rs748404	0.66	rs690512	ENSG00000249839.1	AC011330.5	-8.86	1.8e-17	1.2e-14	-0.47	-0.38	Lung cancer;	chr15:43425480	chr15:43663654~43684339:-
PRAD	cis	rs748404	0.66	rs2249952	ENSG00000249839.1	AC011330.5	-8.86	1.8e-17	1.2e-14	-0.47	-0.38	Lung cancer;	chr15:43428335	chr15:43663654~43684339:-
PRAD	cis	rs748404	0.66	rs2439845	ENSG00000249839.1	AC011330.5	-8.86	1.8e-17	1.2e-14	-0.47	-0.38	Lung cancer;	chr15:43430412	chr15:43663654~43684339:-
PRAD	cis	rs748404	0.631	rs2467745	ENSG00000249839.1	AC011330.5	-8.86	1.8e-17	1.2e-14	-0.47	-0.38	Lung cancer;	chr15:43430544	chr15:43663654~43684339:-
PRAD	cis	rs2638953	0.744	rs11049426	ENSG00000278733.1	RP11-425D17.1	-8.86	1.81e-17	1.21e-14	-0.46	-0.38	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28193573	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.886	rs11049429	ENSG00000278733.1	RP11-425D17.1	-8.86	1.81e-17	1.21e-14	-0.46	-0.38	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28194332	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.779	rs11049432	ENSG00000278733.1	RP11-425D17.1	-8.86	1.81e-17	1.21e-14	-0.46	-0.38	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28194454	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.85	rs4284426	ENSG00000278733.1	RP11-425D17.1	-8.86	1.81e-17	1.21e-14	-0.46	-0.38	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28194543	chr12:28185625~28186190:-
PRAD	cis	rs1062177	0.95	rs59580263	ENSG00000253921.1	CTB-113P19.3	-8.86	1.81e-17	1.21e-14	-0.52	-0.38	Preschool internalizing problems;	chr5:151890016	chr5:151753992~151767247:+
PRAD	cis	rs4835473	1	rs4835473	ENSG00000251600.4	RP11-673E1.1	8.86	1.82e-17	1.21e-14	0.49	0.38	Immature fraction of reticulocytes;	chr4:143982419	chr4:143912331~143982454:+
PRAD	cis	rs524281	0.731	rs78578425	ENSG00000255320.1	RP11-755F10.1	8.86	1.82e-17	1.21e-14	0.68	0.38	Electroencephalogram traits;	chr11:66042768	chr11:66244840~66246239:-
PRAD	cis	rs1501911	0.53	rs161933	ENSG00000248489.1	CTD-2007H13.3	8.86	1.82e-17	1.21e-14	0.43	0.38	Lung function (FEV1/FVC);	chr5:98874643	chr5:98929171~98995013:+
PRAD	cis	rs1501911	0.53	rs161938	ENSG00000248489.1	CTD-2007H13.3	8.86	1.82e-17	1.21e-14	0.43	0.38	Lung function (FEV1/FVC);	chr5:98875501	chr5:98929171~98995013:+
PRAD	cis	rs7811142	1	rs7794485	ENSG00000242294.5	STAG3L5P	8.86	1.83e-17	1.22e-14	0.27	0.38	Platelet count;	chr7:100471313	chr7:100336079~100351900:+
PRAD	cis	rs6452524	0.934	rs2940543	ENSG00000249664.1	CTD-2227C6.2	8.86	1.83e-17	1.22e-14	0.45	0.38	Hypertension (SNP x SNP interaction);	chr5:83187297	chr5:83012285~83013109:-
PRAD	cis	rs6452524	0.967	rs2974450	ENSG00000249664.1	CTD-2227C6.2	8.86	1.83e-17	1.22e-14	0.45	0.38	Hypertension (SNP x SNP interaction);	chr5:83187323	chr5:83012285~83013109:-
PRAD	cis	rs6452524	0.967	rs2974449	ENSG00000249664.1	CTD-2227C6.2	8.86	1.83e-17	1.22e-14	0.45	0.38	Hypertension (SNP x SNP interaction);	chr5:83187465	chr5:83012285~83013109:-
PRAD	cis	rs6452524	0.967	rs2662241	ENSG00000249664.1	CTD-2227C6.2	8.86	1.83e-17	1.22e-14	0.45	0.38	Hypertension (SNP x SNP interaction);	chr5:83188774	chr5:83012285~83013109:-
PRAD	cis	rs6452524	0.935	rs2940544	ENSG00000249664.1	CTD-2227C6.2	8.86	1.83e-17	1.22e-14	0.45	0.38	Hypertension (SNP x SNP interaction);	chr5:83189785	chr5:83012285~83013109:-
PRAD	cis	rs6452524	0.967	rs2731865	ENSG00000249664.1	CTD-2227C6.2	8.86	1.83e-17	1.22e-14	0.45	0.38	Hypertension (SNP x SNP interaction);	chr5:83190570	chr5:83012285~83013109:-
PRAD	cis	rs4835473	0.932	rs35055653	ENSG00000251600.4	RP11-673E1.1	-8.86	1.83e-17	1.22e-14	-0.5	-0.38	Immature fraction of reticulocytes;	chr4:143754836	chr4:143912331~143982454:+
PRAD	cis	rs8040855	0.644	rs4635318	ENSG00000259295.5	CSPG4P12	-8.86	1.84e-17	1.23e-14	-0.49	-0.38	Bulimia nervosa;	chr15:85183506	chr15:85191438~85213905:+
PRAD	cis	rs524281	0.731	rs10791840	ENSG00000255320.1	RP11-755F10.1	8.86	1.84e-17	1.23e-14	0.68	0.38	Electroencephalogram traits;	chr11:66035912	chr11:66244840~66246239:-
PRAD	cis	rs853679	0.542	rs6934769	ENSG00000226314.6	ZNF192P1	-8.86	1.85e-17	1.23e-14	-0.52	-0.38	Depression;	chr6:28123153	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs17711801	ENSG00000226314.6	ZNF192P1	-8.86	1.85e-17	1.23e-14	-0.52	-0.38	Depression;	chr6:28124529	chr6:28161781~28169594:+
PRAD	cis	rs4713118	0.527	rs9461433	ENSG00000226314.6	ZNF192P1	-8.86	1.85e-17	1.23e-14	-0.52	-0.38	Parkinson's disease;	chr6:28127394	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs9468292	ENSG00000226314.6	ZNF192P1	-8.86	1.85e-17	1.23e-14	-0.52	-0.38	Depression;	chr6:28127577	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs1947863	ENSG00000226314.6	ZNF192P1	-8.86	1.85e-17	1.23e-14	-0.52	-0.38	Depression;	chr6:28131566	chr6:28161781~28169594:+
PRAD	cis	rs11098499	0.863	rs10004484	ENSG00000245958.5	RP11-33B1.1	-8.86	1.85e-17	1.23e-14	-0.37	-0.38	Corneal astigmatism;	chr4:119521273	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.863	rs1155576	ENSG00000245958.5	RP11-33B1.1	-8.86	1.85e-17	1.23e-14	-0.37	-0.38	Corneal astigmatism;	chr4:119529004	chr4:119454791~119552025:+
PRAD	cis	rs7712401	0.601	rs27976	ENSG00000263432.2	RN7SL689P	-8.86	1.86e-17	1.24e-14	-0.4	-0.38	Mean platelet volume;	chr5:122870765	chr5:123022487~123022783:-
PRAD	cis	rs4835473	0.571	rs1992656	ENSG00000251600.4	RP11-673E1.1	8.86	1.86e-17	1.24e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143855286	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.571	rs1992655	ENSG00000251600.4	RP11-673E1.1	8.86	1.86e-17	1.24e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143855290	chr4:143912331~143982454:+
PRAD	cis	rs853679	0.517	rs1340004	ENSG00000226314.6	ZNF192P1	-8.86	1.86e-17	1.24e-14	-0.52	-0.38	Depression;	chr6:28135913	chr6:28161781~28169594:+
PRAD	cis	rs8177376	0.906	rs8177380	ENSG00000254905.1	RP11-712L6.7	-8.86	1.86e-17	1.24e-14	-0.49	-0.38	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126295671	chr11:126292922~126294254:-
PRAD	cis	rs4835473	0.932	rs4585249	ENSG00000251600.4	RP11-673E1.1	-8.86	1.87e-17	1.24e-14	-0.49	-0.38	Immature fraction of reticulocytes;	chr4:143981173	chr4:143912331~143982454:+
PRAD	cis	rs6991838	0.584	rs4737221	ENSG00000200714.1	Y_RNA	-8.86	1.87e-17	1.24e-14	-0.42	-0.38	Intelligence (multi-trait analysis);	chr8:65569075	chr8:65592731~65592820:+
PRAD	cis	rs7811142	0.779	rs28680963	ENSG00000242294.5	STAG3L5P	8.86	1.87e-17	1.24e-14	0.26	0.38	Platelet count;	chr7:100307852	chr7:100336079~100351900:+
PRAD	cis	rs7923609	0.811	rs12245367	ENSG00000232075.1	MRPL35P2	8.86	1.88e-17	1.25e-14	0.4	0.38	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63561704	chr10:63634317~63634827:-
PRAD	cis	rs7923609	0.811	rs7899657	ENSG00000232075.1	MRPL35P2	8.86	1.88e-17	1.25e-14	0.4	0.38	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63563505	chr10:63634317~63634827:-
PRAD	cis	rs7923609	0.783	rs4746203	ENSG00000232075.1	MRPL35P2	8.86	1.88e-17	1.25e-14	0.4	0.38	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63564237	chr10:63634317~63634827:-
PRAD	cis	rs741668	0.641	rs4942472	ENSG00000235903.6	CPB2-AS1	-8.85	1.89e-17	1.25e-14	-0.46	-0.38	Cerebrospinal fluid clusterin levels;	chr13:46070980	chr13:46052806~46113332:+
PRAD	cis	rs1075265	0.563	rs2692536	ENSG00000233266.1	HMGB1P31	8.85	1.89e-17	1.26e-14	0.52	0.38	Chronotype;Morning vs. evening chronotype;	chr2:53788266	chr2:54051334~54051760:+
PRAD	cis	rs2282300	1	rs12796693	ENSG00000254532.1	RP11-624D11.2	8.85	1.9e-17	1.26e-14	0.52	0.38	Morning vs. evening chronotype;	chr11:30408036	chr11:30044058~30084343:-
PRAD	cis	rs2638953	0.924	rs12368652	ENSG00000278733.1	RP11-425D17.1	-8.85	1.9e-17	1.26e-14	-0.46	-0.38	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28170046	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs11049392	ENSG00000278733.1	RP11-425D17.1	-8.85	1.9e-17	1.26e-14	-0.46	-0.38	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28170256	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs11049394	ENSG00000278733.1	RP11-425D17.1	-8.85	1.9e-17	1.26e-14	-0.46	-0.38	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28170947	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.886	rs11049395	ENSG00000278733.1	RP11-425D17.1	-8.85	1.9e-17	1.26e-14	-0.46	-0.38	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28171087	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.886	rs11049397	ENSG00000278733.1	RP11-425D17.1	-8.85	1.9e-17	1.26e-14	-0.46	-0.38	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28171909	chr12:28185625~28186190:-
PRAD	cis	rs2153535	0.518	rs1998265	ENSG00000230939.1	RP11-314C16.1	-8.85	1.9e-17	1.26e-14	-0.46	-0.38	Motion sickness;	chr6:8651929	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.518	rs9406187	ENSG00000230939.1	RP11-314C16.1	-8.85	1.9e-17	1.26e-14	-0.46	-0.38	Motion sickness;	chr6:8654376	chr6:8784178~8785445:+
PRAD	cis	rs4835473	0.831	rs4452380	ENSG00000251600.4	RP11-673E1.1	8.85	1.9e-17	1.26e-14	0.49	0.38	Immature fraction of reticulocytes;	chr4:143972856	chr4:143912331~143982454:+
PRAD	cis	rs8177376	1	rs17656	ENSG00000254905.1	RP11-712L6.7	8.85	1.91e-17	1.27e-14	0.48	0.38	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126263287	chr11:126292922~126294254:-
PRAD	cis	rs150992	0.711	rs170734	ENSG00000248489.1	CTD-2007H13.3	8.85	1.91e-17	1.27e-14	0.44	0.38	Body mass index;	chr5:98811337	chr5:98929171~98995013:+
PRAD	cis	rs7189233	0.531	rs1362429	ENSG00000279344.1	RP11-44F14.7	8.85	1.91e-17	1.27e-14	0.35	0.38	Intelligence (multi-trait analysis);	chr16:53445172	chr16:53478957~53481550:-
PRAD	cis	rs367615	0.537	rs1965670	ENSG00000249476.1	CTD-2587M2.1	-8.85	1.91e-17	1.27e-14	-0.46	-0.38	Colorectal cancer (SNP x SNP interaction);	chr5:109314097	chr5:109237120~109326369:-
PRAD	cis	rs858239	1	rs199351	ENSG00000226816.2	AC005082.12	8.85	1.92e-17	1.28e-14	0.43	0.38	Cerebrospinal fluid biomarker levels;	chr7:23260430	chr7:23206013~23208045:+
PRAD	cis	rs853679	0.55	rs9295762	ENSG00000226314.6	ZNF192P1	8.85	1.93e-17	1.28e-14	0.51	0.38	Depression;	chr6:28187640	chr6:28161781~28169594:+
PRAD	cis	rs4835473	0.932	rs1973608	ENSG00000251600.4	RP11-673E1.1	8.85	1.94e-17	1.29e-14	0.49	0.38	Immature fraction of reticulocytes;	chr4:143913057	chr4:143912331~143982454:+
PRAD	cis	rs2638953	0.924	rs11049455	ENSG00000278733.1	RP11-425D17.1	-8.85	1.94e-17	1.29e-14	-0.46	-0.38	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28204758	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs11049457	ENSG00000278733.1	RP11-425D17.1	-8.85	1.94e-17	1.29e-14	-0.46	-0.38	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28205050	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.886	rs10843131	ENSG00000278733.1	RP11-425D17.1	-8.85	1.94e-17	1.29e-14	-0.46	-0.38	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28205259	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs10843132	ENSG00000278733.1	RP11-425D17.1	-8.85	1.94e-17	1.29e-14	-0.46	-0.38	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28205348	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs10843133	ENSG00000278733.1	RP11-425D17.1	-8.85	1.94e-17	1.29e-14	-0.46	-0.38	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28205571	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs10843135	ENSG00000278733.1	RP11-425D17.1	-8.85	1.94e-17	1.29e-14	-0.46	-0.38	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28205809	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.886	rs11049458	ENSG00000278733.1	RP11-425D17.1	-8.85	1.94e-17	1.29e-14	-0.46	-0.38	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28205834	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs11049459	ENSG00000278733.1	RP11-425D17.1	-8.85	1.94e-17	1.29e-14	-0.46	-0.38	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28206011	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs11049460	ENSG00000278733.1	RP11-425D17.1	-8.85	1.94e-17	1.29e-14	-0.46	-0.38	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28206021	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs1824767	ENSG00000278733.1	RP11-425D17.1	-8.85	1.94e-17	1.29e-14	-0.46	-0.38	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28206653	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs1824766	ENSG00000278733.1	RP11-425D17.1	-8.85	1.94e-17	1.29e-14	-0.46	-0.38	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28206655	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs1585682	ENSG00000278733.1	RP11-425D17.1	-8.85	1.94e-17	1.29e-14	-0.46	-0.38	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28206841	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.888	rs9645745	ENSG00000278733.1	RP11-425D17.1	-8.85	1.94e-17	1.29e-14	-0.46	-0.38	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28207082	chr12:28185625~28186190:-
PRAD	cis	rs950169	0.922	rs8037078	ENSG00000259728.4	LINC00933	-8.85	1.95e-17	1.29e-14	-0.46	-0.38	Schizophrenia;	chr15:84150119	chr15:84570649~84580175:+
PRAD	cis	rs12220777	1	rs75913297	ENSG00000230091.5	TMEM254-AS1	8.85	1.95e-17	1.29e-14	0.77	0.38	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80030089	chr10:80046860~80078912:-
PRAD	cis	rs4835473	0.8	rs1849117	ENSG00000251600.4	RP11-673E1.1	8.85	1.95e-17	1.3e-14	0.49	0.38	Immature fraction of reticulocytes;	chr4:143989791	chr4:143912331~143982454:+
PRAD	cis	rs7712401	0.601	rs2126935	ENSG00000263432.2	RN7SL689P	-8.85	1.95e-17	1.3e-14	-0.39	-0.38	Mean platelet volume;	chr5:122977876	chr5:123022487~123022783:-
PRAD	cis	rs853679	0.517	rs6932109	ENSG00000226314.6	ZNF192P1	8.85	1.96e-17	1.3e-14	0.52	0.38	Depression;	chr6:28110525	chr6:28161781~28169594:+
PRAD	cis	rs2439831	0.85	rs60883262	ENSG00000249839.1	AC011330.5	-8.85	1.96e-17	1.3e-14	-0.65	-0.38	Lung cancer in ever smokers;	chr15:43784305	chr15:43663654~43684339:-
PRAD	cis	rs2638953	0.924	rs11049409	ENSG00000278733.1	RP11-425D17.1	-8.85	1.96e-17	1.3e-14	-0.46	-0.38	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28182686	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs61920228	ENSG00000278733.1	RP11-425D17.1	-8.85	1.96e-17	1.3e-14	-0.46	-0.38	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28183780	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs7306838	ENSG00000278733.1	RP11-425D17.1	-8.85	1.96e-17	1.3e-14	-0.46	-0.38	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28184449	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs7138173	ENSG00000278733.1	RP11-425D17.1	-8.85	1.96e-17	1.3e-14	-0.46	-0.38	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28184970	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.925	rs11049412	ENSG00000278733.1	RP11-425D17.1	-8.85	1.96e-17	1.3e-14	-0.46	-0.38	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28186199	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs2061758	ENSG00000278733.1	RP11-425D17.1	-8.85	1.96e-17	1.3e-14	-0.46	-0.38	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28186575	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs12366932	ENSG00000278733.1	RP11-425D17.1	-8.85	1.96e-17	1.3e-14	-0.46	-0.38	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28188953	chr12:28185625~28186190:-
PRAD	cis	rs1501911	0.53	rs751878	ENSG00000248489.1	CTD-2007H13.3	8.85	1.98e-17	1.31e-14	0.42	0.38	Lung function (FEV1/FVC);	chr5:98827240	chr5:98929171~98995013:+
PRAD	cis	rs150992	0.609	rs539024	ENSG00000248489.1	CTD-2007H13.3	8.85	1.99e-17	1.32e-14	0.42	0.38	Body mass index;	chr5:98997103	chr5:98929171~98995013:+
PRAD	cis	rs150992	0.532	rs416750	ENSG00000248489.1	CTD-2007H13.3	8.85	1.99e-17	1.32e-14	0.42	0.38	Body mass index;	chr5:98999046	chr5:98929171~98995013:+
PRAD	cis	rs150992	0.609	rs819232	ENSG00000248489.1	CTD-2007H13.3	8.85	1.99e-17	1.32e-14	0.42	0.38	Body mass index;	chr5:98999416	chr5:98929171~98995013:+
PRAD	cis	rs6750795	0.746	rs2916579	ENSG00000181798.2	LINC00471	-8.85	1.99e-17	1.32e-14	-0.45	-0.38	Height;	chr2:231556448	chr2:231508426~231514339:-
PRAD	cis	rs17711722	0.503	rs453835	ENSG00000237310.1	GS1-124K5.4	-8.85	1.99e-17	1.32e-14	-0.34	-0.38	Calcium levels;	chr7:66046172	chr7:66493706~66495474:+
PRAD	cis	rs1062177	0.855	rs62395861	ENSG00000253921.1	CTB-113P19.3	-8.85	2.01e-17	1.33e-14	-0.52	-0.38	Preschool internalizing problems;	chr5:151889709	chr5:151753992~151767247:+
PRAD	cis	rs950169	0.526	rs698620	ENSG00000275120.1	RP11-182J1.17	-8.85	2.01e-17	1.33e-14	-0.44	-0.38	Schizophrenia;	chr15:84633977	chr15:84599434~84606463:-
PRAD	cis	rs4713118	0.662	rs9380045	ENSG00000219392.1	RP1-265C24.5	-8.85	2.02e-17	1.34e-14	-0.49	-0.38	Parkinson's disease;	chr6:28057501	chr6:28115628~28116551:+
PRAD	cis	rs4713118	0.616	rs9348789	ENSG00000219392.1	RP1-265C24.5	-8.85	2.02e-17	1.34e-14	-0.49	-0.38	Parkinson's disease;	chr6:28057708	chr6:28115628~28116551:+
PRAD	cis	rs4713118	0.662	rs9468274	ENSG00000219392.1	RP1-265C24.5	-8.85	2.02e-17	1.34e-14	-0.49	-0.38	Parkinson's disease;	chr6:28058299	chr6:28115628~28116551:+
PRAD	cis	rs4713118	0.662	rs9468275	ENSG00000219392.1	RP1-265C24.5	-8.85	2.02e-17	1.34e-14	-0.49	-0.38	Parkinson's disease;	chr6:28058358	chr6:28115628~28116551:+
PRAD	cis	rs4713118	0.662	rs9468276	ENSG00000219392.1	RP1-265C24.5	-8.85	2.02e-17	1.34e-14	-0.49	-0.38	Parkinson's disease;	chr6:28059910	chr6:28115628~28116551:+
PRAD	cis	rs4713118	0.662	rs9468277	ENSG00000219392.1	RP1-265C24.5	-8.85	2.02e-17	1.34e-14	-0.49	-0.38	Parkinson's disease;	chr6:28060612	chr6:28115628~28116551:+
PRAD	cis	rs4713118	0.662	rs9468278	ENSG00000219392.1	RP1-265C24.5	-8.85	2.02e-17	1.34e-14	-0.49	-0.38	Parkinson's disease;	chr6:28060704	chr6:28115628~28116551:+
PRAD	cis	rs4713118	0.662	rs13218430	ENSG00000219392.1	RP1-265C24.5	-8.85	2.02e-17	1.34e-14	-0.49	-0.38	Parkinson's disease;	chr6:28062059	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.517	rs12332979	ENSG00000226314.6	ZNF192P1	-8.85	2.02e-17	1.34e-14	-0.52	-0.38	Depression;	chr6:28173770	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs67878650	ENSG00000226314.6	ZNF192P1	-8.85	2.02e-17	1.34e-14	-0.52	-0.38	Depression;	chr6:28174809	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.569	rs9348798	ENSG00000226314.6	ZNF192P1	-8.85	2.02e-17	1.34e-14	-0.52	-0.38	Depression;	chr6:28175233	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.517	rs9380065	ENSG00000226314.6	ZNF192P1	-8.85	2.02e-17	1.34e-14	-0.52	-0.38	Depression;	chr6:28176973	chr6:28161781~28169594:+
PRAD	cis	rs950169	0.922	rs12912934	ENSG00000225151.9	GOLGA2P7	-8.85	2.03e-17	1.34e-14	-0.54	-0.38	Schizophrenia;	chr15:84571216	chr15:84199311~84230136:-
PRAD	cis	rs4835473	0.897	rs11735341	ENSG00000251600.4	RP11-673E1.1	-8.84	2.03e-17	1.35e-14	-0.5	-0.38	Immature fraction of reticulocytes;	chr4:143716030	chr4:143912331~143982454:+
PRAD	cis	rs950169	0.84	rs62029595	ENSG00000225151.9	GOLGA2P7	-8.84	2.04e-17	1.35e-14	-0.53	-0.38	Schizophrenia;	chr15:84400603	chr15:84199311~84230136:-
PRAD	cis	rs6723108	0.627	rs766270	ENSG00000224043.6	CCNT2-AS1	-8.84	2.04e-17	1.35e-14	-0.53	-0.38	Type 2 diabetes;	chr2:134909356	chr2:134735464~134918710:-
PRAD	cis	rs2638953	0.924	rs11049444	ENSG00000278733.1	RP11-425D17.1	-8.84	2.05e-17	1.36e-14	-0.46	-0.38	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28197447	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs11049445	ENSG00000278733.1	RP11-425D17.1	-8.84	2.05e-17	1.36e-14	-0.46	-0.38	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28197449	chr12:28185625~28186190:-
PRAD	cis	rs11148252	0.846	rs7333451	ENSG00000278238.1	RP11-245D16.4	-8.84	2.05e-17	1.36e-14	-0.44	-0.38	Lewy body disease;	chr13:52473574	chr13:52454775~52455331:-
PRAD	cis	rs7712401	0.601	rs418562	ENSG00000263432.2	RN7SL689P	-8.84	2.06e-17	1.36e-14	-0.4	-0.38	Mean platelet volume;	chr5:123004567	chr5:123022487~123022783:-
PRAD	cis	rs950169	0.922	rs6603022	ENSG00000259728.4	LINC00933	-8.84	2.06e-17	1.36e-14	-0.46	-0.38	Schizophrenia;	chr15:84161418	chr15:84570649~84580175:+
PRAD	cis	rs6538678	0.712	rs10777748	ENSG00000258343.1	RP11-536G4.2	-8.84	2.06e-17	1.36e-14	-0.51	-0.38	Lupus nephritis in systemic lupus erythematosus;	chr12:95880227	chr12:95795345~95858839:-
PRAD	cis	rs57677839	1	rs57677839	ENSG00000184669.7	OR7E14P	-8.84	2.06e-17	1.37e-14	-0.39	-0.38	Coronary artery disease;	chr11:17006642	chr11:17013998~17053024:+
PRAD	cis	rs1062177	1	rs2964584	ENSG00000253921.1	CTB-113P19.3	-8.84	2.06e-17	1.37e-14	-0.5	-0.38	Preschool internalizing problems;	chr5:151763317	chr5:151753992~151767247:+
PRAD	cis	rs1075265	0.836	rs1421622	ENSG00000233266.1	HMGB1P31	-8.84	2.07e-17	1.37e-14	-0.53	-0.38	Chronotype;Morning vs. evening chronotype;	chr2:54062644	chr2:54051334~54051760:+
PRAD	cis	rs7772486	0.754	rs702323	ENSG00000235652.6	RP11-545I5.3	-8.84	2.07e-17	1.37e-14	-0.4	-0.38	Lobe attachment (rater-scored or self-reported);	chr6:145687138	chr6:145799409~145886585:+
PRAD	cis	rs172166	0.637	rs1225597	ENSG00000280107.1	AL022393.9	-8.84	2.07e-17	1.37e-14	-0.47	-0.38	Cardiac Troponin-T levels;	chr6:28194309	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.882	rs9461432	ENSG00000280107.1	AL022393.9	-8.84	2.08e-17	1.38e-14	-0.64	-0.38	Depression;	chr6:28119105	chr6:28170845~28172521:+
PRAD	cis	rs7115242	0.748	rs1035237	ENSG00000254851.1	RP11-109L13.1	-8.84	2.08e-17	1.38e-14	-0.76	-0.38	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116857134	chr11:117135528~117138582:+
PRAD	cis	rs131777	0.577	rs131748	ENSG00000205559.3	CHKB-AS1	8.84	2.09e-17	1.38e-14	0.39	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50586408	chr22:50583026~50583877:+
PRAD	cis	rs7811142	1	rs7803454	ENSG00000242294.5	STAG3L5P	8.84	2.09e-17	1.38e-14	0.27	0.38	Platelet count;	chr7:100393925	chr7:100336079~100351900:+
PRAD	cis	rs7811142	0.943	rs11769886	ENSG00000242294.5	STAG3L5P	8.84	2.09e-17	1.38e-14	0.27	0.38	Platelet count;	chr7:100400984	chr7:100336079~100351900:+
PRAD	cis	rs1823874	1	rs1823874	ENSG00000182397.13	DNM1P46	-8.84	2.09e-17	1.38e-14	-0.37	-0.38	IgG glycosylation;	chr15:99817230	chr15:99790156~99806927:-
PRAD	cis	rs1062177	0.951	rs2915876	ENSG00000253921.1	CTB-113P19.3	-8.84	2.09e-17	1.38e-14	-0.51	-0.38	Preschool internalizing problems;	chr5:151771184	chr5:151753992~151767247:+
PRAD	cis	rs2638953	0.776	rs11513467	ENSG00000278733.1	RP11-425D17.1	-8.84	2.1e-17	1.39e-14	-0.46	-0.38	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28210252	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.776	rs11519332	ENSG00000278733.1	RP11-425D17.1	-8.84	2.1e-17	1.39e-14	-0.46	-0.38	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28210254	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs7955094	ENSG00000278733.1	RP11-425D17.1	-8.84	2.1e-17	1.39e-14	-0.47	-0.38	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28157097	chr12:28185625~28186190:-
PRAD	cis	rs3096299	0.642	rs12934829	ENSG00000261118.1	RP11-104N10.1	8.84	2.1e-17	1.39e-14	0.38	0.38	Multiple myeloma (IgH translocation);	chr16:89456941	chr16:89492017~89504460:-
PRAD	cis	rs1062177	1	rs2964612	ENSG00000253921.1	CTB-113P19.3	-8.84	2.1e-17	1.39e-14	-0.52	-0.38	Preschool internalizing problems;	chr5:151819189	chr5:151753992~151767247:+
PRAD	cis	rs2348418	0.864	rs2175464	ENSG00000247934.4	RP11-967K21.1	-8.84	2.11e-17	1.39e-14	-0.35	-0.38	Lung function (FEV1);Lung function (FVC);	chr12:28564178	chr12:28163298~28190738:-
PRAD	cis	rs4713118	0.629	rs203890	ENSG00000226314.6	ZNF192P1	-8.84	2.11e-17	1.39e-14	-0.51	-0.38	Parkinson's disease;	chr6:28054470	chr6:28161781~28169594:+
PRAD	cis	rs4835473	0.897	rs7676614	ENSG00000251600.4	RP11-673E1.1	-8.84	2.11e-17	1.4e-14	-0.5	-0.38	Immature fraction of reticulocytes;	chr4:143695213	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.864	rs7681559	ENSG00000251600.4	RP11-673E1.1	-8.84	2.11e-17	1.4e-14	-0.5	-0.38	Immature fraction of reticulocytes;	chr4:143695248	chr4:143912331~143982454:+
PRAD	cis	rs1501911	0.53	rs162150	ENSG00000248489.1	CTD-2007H13.3	8.84	2.11e-17	1.4e-14	0.43	0.38	Lung function (FEV1/FVC);	chr5:98913909	chr5:98929171~98995013:+
PRAD	cis	rs7727544	0.547	rs56083751	ENSG00000233006.5	AC034220.3	8.84	2.12e-17	1.4e-14	0.34	0.38	Blood metabolite levels;	chr5:132328945	chr5:132311285~132369916:-
PRAD	cis	rs8072100	0.967	rs7219303	ENSG00000228782.6	CTD-2026D20.3	-8.84	2.13e-17	1.41e-14	-0.42	-0.38	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47660335	chr17:47450568~47492492:-
PRAD	cis	rs4835473	0.932	rs13129702	ENSG00000251600.4	RP11-673E1.1	8.84	2.13e-17	1.41e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143785132	chr4:143912331~143982454:+
PRAD	cis	rs9389248	0.69	rs6939543	ENSG00000232876.1	CTA-212D2.2	8.84	2.14e-17	1.41e-14	0.48	0.38	High light scatter reticulocyte percentage of red cells;	chr6:134934005	chr6:135055033~135060550:+
PRAD	cis	rs765787	0.53	rs12915804	ENSG00000259520.4	CTD-2651B20.3	-8.84	2.14e-17	1.41e-14	-0.49	-0.38	Uric acid levels;	chr15:45220364	chr15:45251580~45279251:-
PRAD	cis	rs765787	0.556	rs12915965	ENSG00000259520.4	CTD-2651B20.3	-8.84	2.14e-17	1.41e-14	-0.49	-0.38	Uric acid levels;	chr15:45220449	chr15:45251580~45279251:-
PRAD	cis	rs748404	0.66	rs548704	ENSG00000249839.1	AC011330.5	-8.84	2.14e-17	1.41e-14	-0.46	-0.38	Lung cancer;	chr15:43499508	chr15:43663654~43684339:-
PRAD	cis	rs12468226	1	rs3731696	ENSG00000273456.1	RP11-686O6.2	8.84	2.14e-17	1.41e-14	0.53	0.38	Urate levels;	chr2:202567081	chr2:202374932~202375604:-
PRAD	cis	rs748404	0.66	rs509306	ENSG00000249839.1	AC011330.5	-8.84	2.15e-17	1.42e-14	-0.46	-0.38	Lung cancer;	chr15:43422973	chr15:43663654~43684339:-
PRAD	cis	rs2153535	0.585	rs1814213	ENSG00000230939.1	RP11-314C16.1	-8.84	2.16e-17	1.43e-14	-0.48	-0.38	Motion sickness;	chr6:8619632	chr6:8784178~8785445:+
PRAD	cis	rs8523	0.933	rs9368512	ENSG00000230314.5	ELOVL2-AS1	8.84	2.16e-17	1.43e-14	0.43	0.38	Red blood cell fatty acid levels;	chr6:10974799	chr6:11043524~11078226:+
PRAD	cis	rs4835473	0.831	rs1579816	ENSG00000251600.4	RP11-673E1.1	8.84	2.16e-17	1.43e-14	0.5	0.38	Immature fraction of reticulocytes;	chr4:143866772	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs4240334	ENSG00000251600.4	RP11-673E1.1	8.84	2.16e-17	1.43e-14	0.5	0.38	Immature fraction of reticulocytes;	chr4:143871352	chr4:143912331~143982454:+
PRAD	cis	rs950169	0.922	rs11638445	ENSG00000225151.9	GOLGA2P7	-8.84	2.17e-17	1.43e-14	-0.55	-0.38	Schizophrenia;	chr15:84594463	chr15:84199311~84230136:-
PRAD	cis	rs2153535	0.518	rs9392227	ENSG00000230939.1	RP11-314C16.1	-8.84	2.17e-17	1.43e-14	-0.47	-0.38	Motion sickness;	chr6:8581553	chr6:8784178~8785445:+
PRAD	cis	rs10463554	0.927	rs7717343	ENSG00000175749.11	EIF3KP1	8.84	2.18e-17	1.44e-14	0.5	0.38	Parkinson's disease;	chr5:103026279	chr5:103032376~103033031:+
PRAD	cis	rs10463554	0.963	rs7721530	ENSG00000175749.11	EIF3KP1	8.84	2.18e-17	1.44e-14	0.5	0.38	Parkinson's disease;	chr5:103026488	chr5:103032376~103033031:+
PRAD	cis	rs12134133	0.688	rs6540875	ENSG00000274245.1	RP11-357P18.2	8.84	2.18e-17	1.44e-14	0.59	0.38	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207221686	chr1:207372559~207373252:+
PRAD	cis	rs12134133	0.719	rs6696142	ENSG00000274245.1	RP11-357P18.2	8.84	2.18e-17	1.44e-14	0.59	0.38	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207228898	chr1:207372559~207373252:+
PRAD	cis	rs12134133	0.752	rs57003024	ENSG00000274245.1	RP11-357P18.2	8.84	2.18e-17	1.44e-14	0.59	0.38	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207230999	chr1:207372559~207373252:+
PRAD	cis	rs12134133	0.752	rs61821050	ENSG00000274245.1	RP11-357P18.2	8.84	2.18e-17	1.44e-14	0.59	0.38	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207235253	chr1:207372559~207373252:+
PRAD	cis	rs12134133	0.752	rs61821051	ENSG00000274245.1	RP11-357P18.2	8.84	2.18e-17	1.44e-14	0.59	0.38	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207235624	chr1:207372559~207373252:+
PRAD	cis	rs853679	0.517	rs4713145	ENSG00000226314.6	ZNF192P1	-8.84	2.19e-17	1.44e-14	-0.52	-0.38	Depression;	chr6:28139049	chr6:28161781~28169594:+
PRAD	cis	rs9309711	0.666	rs4321399	ENSG00000225234.1	TRAPPC12-AS1	-8.83	2.2e-17	1.45e-14	-0.39	-0.38	Neurofibrillary tangles;	chr2:3477888	chr2:3481242~3482409:-
PRAD	cis	rs4835473	0.932	rs7693772	ENSG00000251600.4	RP11-673E1.1	8.83	2.21e-17	1.46e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143965614	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs4835118	ENSG00000251600.4	RP11-673E1.1	8.83	2.21e-17	1.46e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143981994	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs4835471	ENSG00000251600.4	RP11-673E1.1	8.83	2.21e-17	1.46e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143982153	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.897	rs4835119	ENSG00000251600.4	RP11-673E1.1	8.83	2.21e-17	1.46e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143982210	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs4835472	ENSG00000251600.4	RP11-673E1.1	8.83	2.21e-17	1.46e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143982398	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.897	rs4835474	ENSG00000251600.4	RP11-673E1.1	8.83	2.21e-17	1.46e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143982444	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs6847869	ENSG00000251600.4	RP11-673E1.1	8.83	2.21e-17	1.46e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143982881	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.897	rs6846984	ENSG00000251600.4	RP11-673E1.1	8.83	2.21e-17	1.46e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143983098	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs34617134	ENSG00000251600.4	RP11-673E1.1	8.83	2.21e-17	1.46e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143983606	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.736	rs11724009	ENSG00000251600.4	RP11-673E1.1	8.83	2.21e-17	1.46e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143984291	chr4:143912331~143982454:+
PRAD	cis	rs4323050	0.514	rs28647406	ENSG00000251600.4	RP11-673E1.1	8.83	2.21e-17	1.46e-14	0.48	0.38	High light scatter reticulocyte percentage of red cells;	chr4:143984437	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.604	rs11938387	ENSG00000251600.4	RP11-673E1.1	8.83	2.21e-17	1.46e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143984476	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.798	rs11100829	ENSG00000251600.4	RP11-673E1.1	8.83	2.21e-17	1.46e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143984761	chr4:143912331~143982454:+
PRAD	cis	rs4713118	0.662	rs156744	ENSG00000226314.6	ZNF192P1	-8.83	2.21e-17	1.46e-14	-0.52	-0.38	Parkinson's disease;	chr6:27999496	chr6:28161781~28169594:+
PRAD	cis	rs2115630	0.691	rs8040066	ENSG00000275120.1	RP11-182J1.17	-8.83	2.22e-17	1.46e-14	-0.44	-0.38	P wave terminal force;	chr15:84633234	chr15:84599434~84606463:-
PRAD	cis	rs950169	0.922	rs4842940	ENSG00000259728.4	LINC00933	-8.83	2.22e-17	1.46e-14	-0.46	-0.38	Schizophrenia;	chr15:84162473	chr15:84570649~84580175:+
PRAD	cis	rs950169	0.922	rs4842941	ENSG00000259728.4	LINC00933	-8.83	2.22e-17	1.46e-14	-0.46	-0.38	Schizophrenia;	chr15:84162560	chr15:84570649~84580175:+
PRAD	cis	rs950169	0.922	rs12911223	ENSG00000259728.4	LINC00933	-8.83	2.22e-17	1.46e-14	-0.46	-0.38	Schizophrenia;	chr15:84162919	chr15:84570649~84580175:+
PRAD	cis	rs7849270	1	rs1977447	ENSG00000268707.1	RP11-247A12.7	8.83	2.22e-17	1.46e-14	0.46	0.38	Blood metabolite ratios;	chr9:129105917	chr9:129170434~129170940:+
PRAD	cis	rs7712401	0.645	rs154497	ENSG00000263432.2	RN7SL689P	8.83	2.22e-17	1.46e-14	0.4	0.38	Mean platelet volume;	chr5:122885725	chr5:123022487~123022783:-
PRAD	cis	rs5769707	0.681	rs739236	ENSG00000188511.11	C22orf34	8.83	2.22e-17	1.47e-14	0.46	0.38	Monocyte percentage of white cells;Monocyte count;	chr22:49647954	chr22:49414524~49657542:-
PRAD	cis	rs67311347	0.866	rs56331709	ENSG00000223797.4	ENTPD3-AS1	8.83	2.24e-17	1.47e-14	0.35	0.38	Renal cell carcinoma;	chr3:40315067	chr3:40313802~40453329:-
PRAD	cis	rs67311347	0.824	rs73073561	ENSG00000223797.4	ENTPD3-AS1	8.83	2.24e-17	1.47e-14	0.35	0.38	Renal cell carcinoma;	chr3:40315807	chr3:40313802~40453329:-
PRAD	cis	rs2239557	0.529	rs2041185	ENSG00000259065.1	RP5-1021I20.1	8.83	2.25e-17	1.48e-14	0.49	0.38	Common traits (Other);	chr14:73815387	chr14:73787360~73803270:+
PRAD	cis	rs11098499	0.954	rs17009122	ENSG00000245958.5	RP11-33B1.1	-8.83	2.25e-17	1.48e-14	-0.38	-0.38	Corneal astigmatism;	chr4:119441248	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.505	rs75122014	ENSG00000245958.5	RP11-33B1.1	-8.83	2.25e-17	1.48e-14	-0.38	-0.38	Corneal astigmatism;	chr4:119441271	chr4:119454791~119552025:+
PRAD	cis	rs5769707	0.681	rs739240	ENSG00000188511.11	C22orf34	8.83	2.26e-17	1.49e-14	0.45	0.38	Monocyte percentage of white cells;Monocyte count;	chr22:49658959	chr22:49414524~49657542:-
PRAD	cis	rs7849270	1	rs2768630	ENSG00000268707.1	RP11-247A12.7	8.83	2.26e-17	1.49e-14	0.46	0.38	Blood metabolite ratios;	chr9:129104109	chr9:129170434~129170940:+
PRAD	cis	rs11159086	0.793	rs11850070	ENSG00000259005.1	RP3-449M8.6	8.83	2.27e-17	1.5e-14	0.49	0.38	Advanced glycation end-product levels;	chr14:74487575	chr14:74474007~74474864:-
PRAD	cis	rs11159086	0.793	rs28378078	ENSG00000259005.1	RP3-449M8.6	8.83	2.27e-17	1.5e-14	0.49	0.38	Advanced glycation end-product levels;	chr14:74487940	chr14:74474007~74474864:-
PRAD	cis	rs11159086	0.793	rs9285594	ENSG00000259005.1	RP3-449M8.6	8.83	2.27e-17	1.5e-14	0.49	0.38	Advanced glycation end-product levels;	chr14:74489253	chr14:74474007~74474864:-
PRAD	cis	rs11159086	0.793	rs4903229	ENSG00000259005.1	RP3-449M8.6	8.83	2.27e-17	1.5e-14	0.49	0.38	Advanced glycation end-product levels;	chr14:74489865	chr14:74474007~74474864:-
PRAD	cis	rs11159086	0.793	rs8016972	ENSG00000259005.1	RP3-449M8.6	8.83	2.27e-17	1.5e-14	0.49	0.38	Advanced glycation end-product levels;	chr14:74491833	chr14:74474007~74474864:-
PRAD	cis	rs1075265	0.563	rs2542588	ENSG00000233266.1	HMGB1P31	-8.83	2.27e-17	1.5e-14	-0.52	-0.38	Chronotype;Morning vs. evening chronotype;	chr2:53791787	chr2:54051334~54051760:+
PRAD	cis	rs9341835	0.679	rs9344137	ENSG00000218048.2	RP3-407E4.4	8.83	2.27e-17	1.5e-14	0.43	0.38	Schizophrenia;	chr6:63447059	chr6:63440766~63443580:+
PRAD	cis	rs4835473	0.868	rs5025156	ENSG00000251600.4	RP11-673E1.1	-8.83	2.28e-17	1.5e-14	-0.5	-0.38	Immature fraction of reticulocytes;	chr4:143738025	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs62337619	ENSG00000251600.4	RP11-673E1.1	-8.83	2.28e-17	1.5e-14	-0.5	-0.38	Immature fraction of reticulocytes;	chr4:143742083	chr4:143912331~143982454:+
PRAD	cis	rs4713118	0.581	rs200504	ENSG00000280107.1	AL022393.9	-8.83	2.29e-17	1.51e-14	-0.52	-0.38	Parkinson's disease;	chr6:27818042	chr6:28170845~28172521:+
PRAD	cis	rs4835473	0.932	rs1849136	ENSG00000251600.4	RP11-673E1.1	-8.83	2.3e-17	1.51e-14	-0.5	-0.38	Immature fraction of reticulocytes;	chr4:143912380	chr4:143912331~143982454:+
PRAD	cis	rs853679	0.76	rs11962305	ENSG00000280107.1	AL022393.9	-8.83	2.3e-17	1.52e-14	-0.53	-0.38	Depression;	chr6:28232159	chr6:28170845~28172521:+
PRAD	cis	rs6452524	0.967	rs965674	ENSG00000249664.1	CTD-2227C6.2	8.83	2.3e-17	1.52e-14	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83186765	chr5:83012285~83013109:-
PRAD	cis	rs6452524	0.967	rs2662242	ENSG00000249664.1	CTD-2227C6.2	8.83	2.3e-17	1.52e-14	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83189066	chr5:83012285~83013109:-
PRAD	cis	rs6452524	0.967	rs2731844	ENSG00000249664.1	CTD-2227C6.2	8.83	2.3e-17	1.52e-14	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83192627	chr5:83012285~83013109:-
PRAD	cis	rs6452524	0.901	rs2940540	ENSG00000249664.1	CTD-2227C6.2	8.83	2.3e-17	1.52e-14	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83193004	chr5:83012285~83013109:-
PRAD	cis	rs12931792	0.846	rs9924308	ENSG00000183604.13	SMG1P5	-8.83	2.3e-17	1.52e-14	-0.34	-0.38	Tonsillectomy;	chr16:30143419	chr16:30267553~30335374:-
PRAD	cis	rs321358	0.848	rs78087740	ENSG00000271584.1	RP11-89C3.4	8.83	2.31e-17	1.52e-14	0.59	0.38	Body mass index;	chr11:111079016	chr11:111091932~111097357:-
PRAD	cis	rs321358	0.848	rs73015146	ENSG00000271584.1	RP11-89C3.4	8.83	2.31e-17	1.52e-14	0.59	0.38	Body mass index;	chr11:111079143	chr11:111091932~111097357:-
PRAD	cis	rs8040855	0.542	rs2342122	ENSG00000259295.5	CSPG4P12	-8.83	2.32e-17	1.53e-14	-0.49	-0.38	Bulimia nervosa;	chr15:85185304	chr15:85191438~85213905:+
PRAD	cis	rs4835473	0.932	rs34324222	ENSG00000251600.4	RP11-673E1.1	-8.83	2.32e-17	1.53e-14	-0.5	-0.38	Immature fraction of reticulocytes;	chr4:143784572	chr4:143912331~143982454:+
PRAD	cis	rs11098499	0.954	rs3733520	ENSG00000245958.5	RP11-33B1.1	-8.83	2.33e-17	1.53e-14	-0.38	-0.38	Corneal astigmatism;	chr4:119502325	chr4:119454791~119552025:+
PRAD	cis	rs1979679	0.842	rs11049373	ENSG00000278733.1	RP11-425D17.1	8.83	2.33e-17	1.53e-14	0.49	0.38	Ossification of the posterior longitudinal ligament of the spine;	chr12:28148881	chr12:28185625~28186190:-
PRAD	cis	rs4713118	0.738	rs200465	ENSG00000280107.1	AL022393.9	-8.83	2.33e-17	1.53e-14	-0.48	-0.38	Parkinson's disease;	chr6:27789875	chr6:28170845~28172521:+
PRAD	cis	rs950169	1	rs11638297	ENSG00000259728.4	LINC00933	8.83	2.35e-17	1.54e-14	0.46	0.38	Schizophrenia;	chr15:84113665	chr15:84570649~84580175:+
PRAD	cis	rs9903692	0.954	rs8080662	ENSG00000278765.1	RP5-890E16.5	-8.83	2.35e-17	1.54e-14	-0.58	-0.38	Pulse pressure;	chr17:48113457	chr17:48066704~48067293:-
PRAD	cis	rs4964805	0.657	rs4964813	ENSG00000257681.1	RP11-341G23.4	8.83	2.35e-17	1.55e-14	0.34	0.38	Attention deficit hyperactivity disorder;	chr12:103795776	chr12:103746315~103768858:-
PRAD	cis	rs1062177	1	rs2964585	ENSG00000253921.1	CTB-113P19.3	-8.83	2.36e-17	1.55e-14	-0.51	-0.38	Preschool internalizing problems;	chr5:151762334	chr5:151753992~151767247:+
PRAD	cis	rs1062177	1	rs2964578	ENSG00000253921.1	CTB-113P19.3	-8.83	2.36e-17	1.55e-14	-0.51	-0.38	Preschool internalizing problems;	chr5:151767637	chr5:151753992~151767247:+
PRAD	cis	rs7211079	0.719	rs2289535	ENSG00000279259.1	RP11-334C17.3	8.83	2.37e-17	1.55e-14	0.41	0.38	Myocardial infarction;	chr17:80137650	chr17:80147250~80148596:+
PRAD	cis	rs8062405	0.754	rs149299	ENSG00000251417.2	RP11-1348G14.4	-8.83	2.37e-17	1.56e-14	-0.43	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28473820	chr16:28802743~28817828:+
PRAD	cis	rs812925	0.515	rs1177308	ENSG00000271889.1	RP11-493E12.1	8.82	2.37e-17	1.56e-14	0.42	0.38	Immature fraction of reticulocytes;	chr2:61160119	chr2:61151433~61162105:-
PRAD	cis	rs6452524	1	rs9293334	ENSG00000249664.1	CTD-2227C6.2	8.82	2.38e-17	1.56e-14	0.45	0.38	Hypertension (SNP x SNP interaction);	chr5:83156984	chr5:83012285~83013109:-
PRAD	cis	rs4835473	0.932	rs9308176	ENSG00000251600.4	RP11-673E1.1	-8.82	2.38e-17	1.56e-14	-0.49	-0.38	Immature fraction of reticulocytes;	chr4:144072718	chr4:143912331~143982454:+
PRAD	cis	rs17711722	0.565	rs73372653	ENSG00000236529.1	RP13-254B10.1	8.82	2.39e-17	1.57e-14	0.4	0.38	Calcium levels;	chr7:65977808	chr7:65840212~65840596:+
PRAD	cis	rs524281	0.731	rs6591201	ENSG00000255320.1	RP11-755F10.1	-8.82	2.39e-17	1.57e-14	-0.62	-0.38	Electroencephalogram traits;	chr11:66038499	chr11:66244840~66246239:-
PRAD	cis	rs7772486	0.806	rs2265477	ENSG00000235652.6	RP11-545I5.3	8.82	2.39e-17	1.57e-14	0.39	0.38	Lobe attachment (rater-scored or self-reported);	chr6:145891202	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.806	rs4075695	ENSG00000235652.6	RP11-545I5.3	-8.82	2.39e-17	1.57e-14	-0.39	-0.38	Lobe attachment (rater-scored or self-reported);	chr6:145929823	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.875	rs9403765	ENSG00000235652.6	RP11-545I5.3	-8.82	2.39e-17	1.57e-14	-0.39	-0.38	Lobe attachment (rater-scored or self-reported);	chr6:146046905	chr6:145799409~145886585:+
PRAD	cis	rs2739330	0.587	rs4820571	ENSG00000228039.3	KB-1125A3.10	8.82	2.4e-17	1.57e-14	0.49	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23963780~23964374:+
PRAD	cis	rs9326248	0.516	rs6589577	ENSG00000254851.1	RP11-109L13.1	-8.82	2.4e-17	1.57e-14	-0.82	-0.38	Blood protein levels;	chr11:116879261	chr11:117135528~117138582:+
PRAD	cis	rs875971	1	rs7792762	ENSG00000237310.1	GS1-124K5.4	8.82	2.4e-17	1.58e-14	0.34	0.38	Aortic root size;	chr7:66539151	chr7:66493706~66495474:+
PRAD	cis	rs7189233	0.513	rs2908797	ENSG00000279344.1	RP11-44F14.7	8.82	2.4e-17	1.58e-14	0.36	0.38	Intelligence (multi-trait analysis);	chr16:53395261	chr16:53478957~53481550:-
PRAD	cis	rs11098499	0.779	rs7699346	ENSG00000245958.5	RP11-33B1.1	-8.82	2.41e-17	1.58e-14	-0.38	-0.38	Corneal astigmatism;	chr4:119389387	chr4:119454791~119552025:+
PRAD	cis	rs8072100	0.967	rs8072644	ENSG00000228782.6	CTD-2026D20.3	-8.82	2.41e-17	1.58e-14	-0.42	-0.38	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47575998	chr17:47450568~47492492:-
PRAD	cis	rs34779708	0.649	rs34421369	ENSG00000230534.5	RP11-297A16.2	8.82	2.41e-17	1.58e-14	0.51	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35261347	chr10:35098006~35127020:-
PRAD	cis	rs17711722	0.565	rs73372653	ENSG00000228409.4	CCT6P1	-8.82	2.41e-17	1.58e-14	-0.28	-0.38	Calcium levels;	chr7:65977808	chr7:65751142~65763354:+
PRAD	cis	rs8062405	0.756	rs151182	ENSG00000251417.2	RP11-1348G14.4	-8.82	2.42e-17	1.59e-14	-0.43	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28484431	chr16:28802743~28817828:+
PRAD	cis	rs11951515	0.614	rs7716091	ENSG00000188850.9	RP11-159F24.2	8.82	2.42e-17	1.59e-14	0.46	0.38	Metabolite levels  (X-11787);	chr5:43348156	chr5:43336164~43348716:+
PRAD	cis	rs7712401	0.601	rs385547	ENSG00000263432.2	RN7SL689P	-8.82	2.43e-17	1.59e-14	-0.4	-0.38	Mean platelet volume;	chr5:122986138	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.601	rs454617	ENSG00000263432.2	RN7SL689P	-8.82	2.43e-17	1.59e-14	-0.4	-0.38	Mean platelet volume;	chr5:122986232	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.601	rs436546	ENSG00000263432.2	RN7SL689P	-8.82	2.43e-17	1.59e-14	-0.4	-0.38	Mean platelet volume;	chr5:122987095	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.601	rs397731	ENSG00000263432.2	RN7SL689P	-8.82	2.43e-17	1.59e-14	-0.4	-0.38	Mean platelet volume;	chr5:122987264	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.58	rs35902490	ENSG00000263432.2	RN7SL689P	-8.82	2.43e-17	1.59e-14	-0.4	-0.38	Mean platelet volume;	chr5:122987703	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.562	rs383638	ENSG00000263432.2	RN7SL689P	-8.82	2.43e-17	1.59e-14	-0.4	-0.38	Mean platelet volume;	chr5:122988983	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.562	rs62377399	ENSG00000263432.2	RN7SL689P	-8.82	2.43e-17	1.59e-14	-0.4	-0.38	Mean platelet volume;	chr5:122988984	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.601	rs415534	ENSG00000263432.2	RN7SL689P	-8.82	2.43e-17	1.59e-14	-0.4	-0.38	Mean platelet volume;	chr5:122989606	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.601	rs442911	ENSG00000263432.2	RN7SL689P	-8.82	2.43e-17	1.59e-14	-0.4	-0.38	Mean platelet volume;	chr5:122989856	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.601	rs425573	ENSG00000263432.2	RN7SL689P	-8.82	2.43e-17	1.59e-14	-0.4	-0.38	Mean platelet volume;	chr5:122990313	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.562	rs364723	ENSG00000263432.2	RN7SL689P	-8.82	2.43e-17	1.59e-14	-0.4	-0.38	Mean platelet volume;	chr5:122990769	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.601	rs35847506	ENSG00000263432.2	RN7SL689P	-8.82	2.43e-17	1.59e-14	-0.4	-0.38	Mean platelet volume;	chr5:122991413	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.601	rs390234	ENSG00000263432.2	RN7SL689P	-8.82	2.43e-17	1.59e-14	-0.4	-0.38	Mean platelet volume;	chr5:122995828	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.601	rs4555798	ENSG00000263432.2	RN7SL689P	-8.82	2.43e-17	1.59e-14	-0.4	-0.38	Mean platelet volume;	chr5:122996419	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.601	rs62377424	ENSG00000263432.2	RN7SL689P	-8.82	2.43e-17	1.59e-14	-0.4	-0.38	Mean platelet volume;	chr5:122996627	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.601	rs35699701	ENSG00000263432.2	RN7SL689P	-8.82	2.43e-17	1.59e-14	-0.4	-0.38	Mean platelet volume;	chr5:122998061	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.601	rs35256179	ENSG00000263432.2	RN7SL689P	-8.82	2.43e-17	1.59e-14	-0.4	-0.38	Mean platelet volume;	chr5:122998560	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.601	rs35858098	ENSG00000263432.2	RN7SL689P	-8.82	2.43e-17	1.59e-14	-0.4	-0.38	Mean platelet volume;	chr5:122998670	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.601	rs13155907	ENSG00000263432.2	RN7SL689P	-8.82	2.43e-17	1.59e-14	-0.4	-0.38	Mean platelet volume;	chr5:122998938	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.601	rs62377430	ENSG00000263432.2	RN7SL689P	-8.82	2.43e-17	1.59e-14	-0.4	-0.38	Mean platelet volume;	chr5:122998993	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.601	rs34348084	ENSG00000263432.2	RN7SL689P	-8.82	2.43e-17	1.59e-14	-0.4	-0.38	Mean platelet volume;	chr5:122999419	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.601	rs35334805	ENSG00000263432.2	RN7SL689P	-8.82	2.43e-17	1.59e-14	-0.4	-0.38	Mean platelet volume;	chr5:122999566	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.601	rs448505	ENSG00000263432.2	RN7SL689P	-8.82	2.43e-17	1.59e-14	-0.4	-0.38	Mean platelet volume;	chr5:123000995	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.601	rs13164134	ENSG00000263432.2	RN7SL689P	-8.82	2.43e-17	1.59e-14	-0.4	-0.38	Mean platelet volume;	chr5:123002246	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.601	rs13185741	ENSG00000263432.2	RN7SL689P	-8.82	2.43e-17	1.59e-14	-0.4	-0.38	Mean platelet volume;	chr5:123002315	chr5:123022487~123022783:-
PRAD	cis	rs5769707	0.681	rs6009803	ENSG00000188511.11	C22orf34	8.82	2.43e-17	1.6e-14	0.46	0.38	Monocyte percentage of white cells;Monocyte count;	chr22:49657359	chr22:49414524~49657542:-
PRAD	cis	rs4835473	0.663	rs4835115	ENSG00000251600.4	RP11-673E1.1	8.82	2.43e-17	1.6e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143979308	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.864	rs4257604	ENSG00000251600.4	RP11-673E1.1	8.82	2.43e-17	1.6e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143980261	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs4516663	ENSG00000251600.4	RP11-673E1.1	8.82	2.43e-17	1.6e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143980791	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.8	rs2089839	ENSG00000251600.4	RP11-673E1.1	8.82	2.43e-17	1.6e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143980955	chr4:143912331~143982454:+
PRAD	cis	rs11148252	0.74	rs9596648	ENSG00000278238.1	RP11-245D16.4	8.82	2.43e-17	1.6e-14	0.43	0.38	Lewy body disease;	chr13:52360434	chr13:52454775~52455331:-
PRAD	cis	rs2933343	0.679	rs789254	ENSG00000231305.3	RP11-723O4.2	8.82	2.44e-17	1.6e-14	0.36	0.38	IgG glycosylation;	chr3:128855750	chr3:128861313~128871540:-
PRAD	cis	rs8072100	0.967	rs4794001	ENSG00000228782.6	CTD-2026D20.3	8.82	2.45e-17	1.61e-14	0.42	0.38	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47643483	chr17:47450568~47492492:-
PRAD	cis	rs150992	0.57	rs10050423	ENSG00000248489.1	CTD-2007H13.3	-8.82	2.46e-17	1.61e-14	-0.42	-0.38	Body mass index;	chr5:99006312	chr5:98929171~98995013:+
PRAD	cis	rs2729354	0.768	rs2848635	ENSG00000265566.2	RN7SL605P	-8.82	2.46e-17	1.62e-14	-0.57	-0.38	Blood protein levels;	chr11:57486458	chr11:57528085~57528365:-
PRAD	cis	rs4718428	0.576	rs12698546	ENSG00000230295.1	RP11-458F8.2	-8.82	2.48e-17	1.63e-14	-0.3	-0.38	Corneal structure;	chr7:66801919	chr7:66880708~66882981:+
PRAD	cis	rs17012589	0.639	rs1512733	ENSG00000258815.1	RP11-408B11.2	-8.82	2.49e-17	1.63e-14	-0.52	-0.38	Bone mineral density (Ward's triangle area);	chr12:85300783	chr12:85318060~85342912:+
PRAD	cis	rs6991838	0.798	rs62507575	ENSG00000272010.1	CTD-3025N20.3	8.82	2.49e-17	1.63e-14	0.38	0.38	Intelligence (multi-trait analysis);	chr8:65566486	chr8:65591850~65592472:-
PRAD	cis	rs2638953	0.924	rs11049398	ENSG00000278733.1	RP11-425D17.1	-8.82	2.49e-17	1.64e-14	-0.46	-0.38	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28172371	chr12:28185625~28186190:-
PRAD	cis	rs875971	1	rs709595	ENSG00000237310.1	GS1-124K5.4	8.82	2.51e-17	1.64e-14	0.34	0.38	Aortic root size;	chr7:66352346	chr7:66493706~66495474:+
PRAD	cis	rs875971	1	rs811880	ENSG00000237310.1	GS1-124K5.4	8.82	2.51e-17	1.64e-14	0.34	0.38	Aortic root size;	chr7:66353659	chr7:66493706~66495474:+
PRAD	cis	rs8177376	0.813	rs667627	ENSG00000254905.1	RP11-712L6.7	8.82	2.51e-17	1.65e-14	0.48	0.38	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126277802	chr11:126292922~126294254:-
PRAD	cis	rs7615952	1	rs9289275	ENSG00000171084.14	FAM86JP	8.82	2.52e-17	1.65e-14	0.64	0.38	Blood pressure (smoking interaction);	chr3:125929816	chr3:125916620~125930024:+
PRAD	cis	rs853679	0.76	rs11967137	ENSG00000280107.1	AL022393.9	-8.82	2.52e-17	1.65e-14	-0.52	-0.38	Depression;	chr6:28231986	chr6:28170845~28172521:+
PRAD	cis	rs3858145	0.588	rs78041174	ENSG00000233590.1	RP11-153K11.3	-8.82	2.54e-17	1.66e-14	-0.55	-0.38	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68279014	chr10:68233251~68242379:-
PRAD	cis	rs172166	0.561	rs149971	ENSG00000204709.4	LINC01556	8.82	2.54e-17	1.66e-14	0.48	0.38	Cardiac Troponin-T levels;	chr6:28014374	chr6:28943877~28944537:+
PRAD	cis	rs11098499	0.954	rs3890049	ENSG00000245958.5	RP11-33B1.1	-8.82	2.55e-17	1.67e-14	-0.38	-0.38	Corneal astigmatism;	chr4:119405128	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.954	rs71629403	ENSG00000245958.5	RP11-33B1.1	-8.82	2.55e-17	1.67e-14	-0.38	-0.38	Corneal astigmatism;	chr4:119451412	chr4:119454791~119552025:+
PRAD	cis	rs812925	0.512	rs1729674	ENSG00000271889.1	RP11-493E12.1	8.81	2.56e-17	1.68e-14	0.42	0.38	Immature fraction of reticulocytes;	chr2:61162602	chr2:61151433~61162105:-
PRAD	cis	rs2739330	0.76	rs1007888	ENSG00000272787.1	KB-226F1.2	-8.81	2.57e-17	1.68e-14	-0.41	-0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23969211~23969873:+
PRAD	cis	rs17023223	0.553	rs72691108	ENSG00000231365.4	RP11-418J17.1	-8.81	2.57e-17	1.68e-14	-0.42	-0.38	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119219552	chr1:119140396~119275973:+
PRAD	cis	rs17012589	0.639	rs10779155	ENSG00000258815.1	RP11-408B11.2	-8.81	2.57e-17	1.68e-14	-0.52	-0.38	Bone mineral density (Ward's triangle area);	chr12:85304143	chr12:85318060~85342912:+
PRAD	cis	rs8072100	0.967	rs4239163	ENSG00000228782.6	CTD-2026D20.3	8.81	2.58e-17	1.69e-14	0.42	0.38	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47678588	chr17:47450568~47492492:-
PRAD	cis	rs4835473	0.897	rs2089835	ENSG00000251600.4	RP11-673E1.1	8.81	2.58e-17	1.69e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143965127	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.639	rs28674022	ENSG00000251600.4	RP11-673E1.1	8.81	2.58e-17	1.69e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143966409	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.864	rs28423022	ENSG00000251600.4	RP11-673E1.1	8.81	2.58e-17	1.69e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143966416	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.864	rs35888177	ENSG00000251600.4	RP11-673E1.1	8.81	2.58e-17	1.69e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143966863	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs10033382	ENSG00000251600.4	RP11-673E1.1	8.81	2.58e-17	1.69e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143967103	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs7667092	ENSG00000251600.4	RP11-673E1.1	8.81	2.58e-17	1.69e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143968604	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.897	rs3874	ENSG00000251600.4	RP11-673E1.1	8.81	2.58e-17	1.69e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143968795	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs2323417	ENSG00000251600.4	RP11-673E1.1	8.81	2.58e-17	1.69e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143969108	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.83	rs7692672	ENSG00000251600.4	RP11-673E1.1	8.81	2.58e-17	1.69e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143971048	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.766	rs6537222	ENSG00000251600.4	RP11-673E1.1	8.81	2.58e-17	1.69e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143971459	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.9	rs6537223	ENSG00000251600.4	RP11-673E1.1	8.81	2.58e-17	1.69e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143971541	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.615	rs6857432	ENSG00000251600.4	RP11-673E1.1	8.81	2.58e-17	1.69e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143971912	chr4:143912331~143982454:+
PRAD	cis	rs6991838	0.8	rs11786598	ENSG00000272010.1	CTD-3025N20.3	-8.81	2.58e-17	1.69e-14	-0.38	-0.38	Intelligence (multi-trait analysis);	chr8:65559944	chr8:65591850~65592472:-
PRAD	cis	rs853679	0.585	rs201004	ENSG00000280107.1	AL022393.9	-8.81	2.59e-17	1.69e-14	-0.52	-0.38	Depression;	chr6:27837156	chr6:28170845~28172521:+
PRAD	cis	rs1577917	0.771	rs3812133	ENSG00000203875.9	SNHG5	-8.81	2.59e-17	1.69e-14	-0.48	-0.38	Response to antipsychotic treatment;	chr6:85644693	chr6:85660950~85678736:-
PRAD	cis	rs2638953	0.962	rs10771409	ENSG00000278733.1	RP11-425D17.1	-8.81	2.59e-17	1.69e-14	-0.46	-0.38	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28154129	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.962	rs10771410	ENSG00000278733.1	RP11-425D17.1	-8.81	2.59e-17	1.69e-14	-0.46	-0.38	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28154271	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.962	rs1479492	ENSG00000278733.1	RP11-425D17.1	-8.81	2.59e-17	1.69e-14	-0.46	-0.38	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28155491	chr12:28185625~28186190:-
PRAD	cis	rs1061377	0.501	rs62308278	ENSG00000249207.1	RP11-360F5.1	-8.81	2.6e-17	1.7e-14	-0.4	-0.38	Uric acid levels;	chr4:39161038	chr4:39112677~39126818:-
PRAD	cis	rs1979679	0.842	rs2035271	ENSG00000278733.1	RP11-425D17.1	8.81	2.6e-17	1.7e-14	0.49	0.38	Ossification of the posterior longitudinal ligament of the spine;	chr12:28165638	chr12:28185625~28186190:-
PRAD	cis	rs4835473	0.897	rs1817027	ENSG00000251600.4	RP11-673E1.1	-8.81	2.61e-17	1.71e-14	-0.49	-0.38	Immature fraction of reticulocytes;	chr4:143713336	chr4:143912331~143982454:+
PRAD	cis	rs6452524	0.967	rs4290995	ENSG00000249664.1	CTD-2227C6.2	8.81	2.61e-17	1.71e-14	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83182177	chr5:83012285~83013109:-
PRAD	cis	rs7211079	0.917	rs4243251	ENSG00000279259.1	RP11-334C17.3	8.81	2.61e-17	1.71e-14	0.41	0.38	Myocardial infarction;	chr17:80138811	chr17:80147250~80148596:+
PRAD	cis	rs8523	0.901	rs9468126	ENSG00000230314.5	ELOVL2-AS1	8.81	2.62e-17	1.71e-14	0.42	0.38	Red blood cell fatty acid levels;	chr6:10966308	chr6:11043524~11078226:+
PRAD	cis	rs8062405	0.824	rs240702	ENSG00000251417.2	RP11-1348G14.4	-8.81	2.62e-17	1.71e-14	-0.42	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520032	chr16:28802743~28817828:+
PRAD	cis	rs8523	0.901	rs7774711	ENSG00000230314.5	ELOVL2-AS1	8.81	2.62e-17	1.71e-14	0.42	0.38	Red blood cell fatty acid levels;	chr6:10964788	chr6:11043524~11078226:+
PRAD	cis	rs8523	0.868	rs9295733	ENSG00000230314.5	ELOVL2-AS1	8.81	2.62e-17	1.71e-14	0.42	0.38	Red blood cell fatty acid levels;	chr6:10965214	chr6:11043524~11078226:+
PRAD	cis	rs853679	0.76	rs9393910	ENSG00000280107.1	AL022393.9	-8.81	2.62e-17	1.72e-14	-0.53	-0.38	Depression;	chr6:28240414	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.76	rs9368563	ENSG00000280107.1	AL022393.9	-8.81	2.62e-17	1.72e-14	-0.53	-0.38	Depression;	chr6:28240780	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.76	rs9295768	ENSG00000280107.1	AL022393.9	-8.81	2.62e-17	1.72e-14	-0.53	-0.38	Depression;	chr6:28241324	chr6:28170845~28172521:+
PRAD	cis	rs8177376	1	rs671492	ENSG00000254905.1	RP11-712L6.7	8.81	2.63e-17	1.72e-14	0.48	0.38	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126280025	chr11:126292922~126294254:-
PRAD	cis	rs11098499	0.954	rs12510138	ENSG00000245958.5	RP11-33B1.1	-8.81	2.64e-17	1.73e-14	-0.38	-0.38	Corneal astigmatism;	chr4:119502780	chr4:119454791~119552025:+
PRAD	cis	rs853679	0.517	rs16893666	ENSG00000226314.6	ZNF192P1	8.81	2.64e-17	1.73e-14	0.52	0.38	Depression;	chr6:28086929	chr6:28161781~28169594:+
PRAD	cis	rs4713118	0.662	rs149946	ENSG00000226314.6	ZNF192P1	8.81	2.65e-17	1.73e-14	0.52	0.38	Parkinson's disease;	chr6:28002253	chr6:28161781~28169594:+
PRAD	cis	rs4713118	0.662	rs149947	ENSG00000226314.6	ZNF192P1	-8.81	2.65e-17	1.73e-14	-0.52	-0.38	Parkinson's disease;	chr6:28004655	chr6:28161781~28169594:+
PRAD	cis	rs4713118	0.662	rs149969	ENSG00000226314.6	ZNF192P1	-8.81	2.65e-17	1.73e-14	-0.52	-0.38	Parkinson's disease;	chr6:28009959	chr6:28161781~28169594:+
PRAD	cis	rs2153535	0.518	rs4959493	ENSG00000230939.1	RP11-314C16.1	-8.81	2.65e-17	1.73e-14	-0.46	-0.38	Motion sickness;	chr6:8588503	chr6:8784178~8785445:+
PRAD	cis	rs172166	0.637	rs1233691	ENSG00000280107.1	AL022393.9	-8.81	2.66e-17	1.74e-14	-0.47	-0.38	Cardiac Troponin-T levels;	chr6:28186119	chr6:28170845~28172521:+
PRAD	cis	rs4835473	0.897	rs35599924	ENSG00000251600.4	RP11-673E1.1	8.81	2.67e-17	1.74e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143980602	chr4:143912331~143982454:+
PRAD	cis	rs1930961	1	rs7285549	ENSG00000272798.1	CTA-390C10.9	-8.81	2.67e-17	1.74e-14	-0.61	-0.38	Bipolar disorder with mood-incongruent psychosis;	chr22:25478613	chr22:25436312~25436915:+
PRAD	cis	rs1930961	1	rs5996946	ENSG00000272798.1	CTA-390C10.9	-8.81	2.67e-17	1.74e-14	-0.61	-0.38	Bipolar disorder with mood-incongruent psychosis;	chr22:25480021	chr22:25436312~25436915:+
PRAD	cis	rs1930961	1	rs997873	ENSG00000272798.1	CTA-390C10.9	-8.81	2.67e-17	1.74e-14	-0.61	-0.38	Bipolar disorder with mood-incongruent psychosis;	chr22:25482315	chr22:25436312~25436915:+
PRAD	cis	rs4835473	0.897	rs62337587	ENSG00000251600.4	RP11-673E1.1	-8.81	2.68e-17	1.75e-14	-0.5	-0.38	Immature fraction of reticulocytes;	chr4:143725839	chr4:143912331~143982454:+
PRAD	cis	rs172166	0.637	rs1225592	ENSG00000280107.1	AL022393.9	-8.81	2.7e-17	1.76e-14	-0.47	-0.38	Cardiac Troponin-T levels;	chr6:28182464	chr6:28170845~28172521:+
PRAD	cis	rs9595066	0.667	rs3809350	ENSG00000227258.4	SMIM2-AS1	8.81	2.71e-17	1.76e-14	0.67	0.38	Schizophrenia;	chr13:44162043	chr13:44110451~44240517:+
PRAD	cis	rs172166	0.637	rs1225595	ENSG00000280107.1	AL022393.9	-8.81	2.71e-17	1.77e-14	-0.47	-0.38	Cardiac Troponin-T levels;	chr6:28183562	chr6:28170845~28172521:+
PRAD	cis	rs67311347	1	rs12108041	ENSG00000223797.4	ENTPD3-AS1	8.81	2.71e-17	1.77e-14	0.36	0.38	Renal cell carcinoma;	chr3:40446044	chr3:40313802~40453329:-
PRAD	cis	rs875971	0.522	rs1917563	ENSG00000236529.1	RP13-254B10.1	-8.81	2.71e-17	1.77e-14	-0.4	-0.38	Aortic root size;	chr7:65950660	chr7:65840212~65840596:+
PRAD	cis	rs150992	0.587	rs10040066	ENSG00000248489.1	CTD-2007H13.3	-8.81	2.71e-17	1.77e-14	-0.42	-0.38	Body mass index;	chr5:99001333	chr5:98929171~98995013:+
PRAD	cis	rs150992	0.609	rs4565239	ENSG00000248489.1	CTD-2007H13.3	-8.81	2.71e-17	1.77e-14	-0.42	-0.38	Body mass index;	chr5:99002144	chr5:98929171~98995013:+
PRAD	cis	rs2638953	0.85	rs11049428	ENSG00000278733.1	RP11-425D17.1	-8.81	2.71e-17	1.77e-14	-0.46	-0.38	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28194267	chr12:28185625~28186190:-
PRAD	cis	rs950169	0.922	rs11639244	ENSG00000259728.4	LINC00933	8.81	2.72e-17	1.77e-14	0.46	0.38	Schizophrenia;	chr15:84163898	chr15:84570649~84580175:+
PRAD	cis	rs2739330	0.828	rs5751770	ENSG00000224205.1	AP000351.4	8.81	2.72e-17	1.77e-14	0.47	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23987320~23991421:-
PRAD	cis	rs4713118	0.662	rs9357060	ENSG00000219392.1	RP1-265C24.5	-8.81	2.72e-17	1.78e-14	-0.49	-0.38	Parkinson's disease;	chr6:28056708	chr6:28115628~28116551:+
PRAD	cis	rs4713118	0.662	rs9468271	ENSG00000219392.1	RP1-265C24.5	-8.81	2.72e-17	1.78e-14	-0.49	-0.38	Parkinson's disease;	chr6:28056792	chr6:28115628~28116551:+
PRAD	cis	rs853679	0.55	rs1233707	ENSG00000226314.6	ZNF192P1	-8.81	2.72e-17	1.78e-14	-0.51	-0.38	Depression;	chr6:28205175	chr6:28161781~28169594:+
PRAD	cis	rs2638953	0.886	rs7957503	ENSG00000278733.1	RP11-425D17.1	-8.81	2.73e-17	1.78e-14	-0.46	-0.38	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28203762	chr12:28185625~28186190:-
PRAD	cis	rs524281	0.731	rs10896075	ENSG00000255320.1	RP11-755F10.1	-8.81	2.73e-17	1.78e-14	-0.65	-0.38	Electroencephalogram traits;	chr11:66024742	chr11:66244840~66246239:-
PRAD	cis	rs150992	0.711	rs331918	ENSG00000248489.1	CTD-2007H13.3	8.81	2.73e-17	1.78e-14	0.43	0.38	Body mass index;	chr5:98823040	chr5:98929171~98995013:+
PRAD	cis	rs950169	0.922	rs12910334	ENSG00000225151.9	GOLGA2P7	-8.81	2.73e-17	1.78e-14	-0.54	-0.38	Schizophrenia;	chr15:84403620	chr15:84199311~84230136:-
PRAD	cis	rs3809863	0.602	rs2317677	ENSG00000228782.6	CTD-2026D20.3	8.81	2.74e-17	1.78e-14	0.44	0.38	Glaucoma (primary open-angle);	chr17:47316041	chr17:47450568~47492492:-
PRAD	cis	rs853679	0.699	rs9468318	ENSG00000280107.1	AL022393.9	-8.81	2.74e-17	1.79e-14	-0.53	-0.38	Depression;	chr6:28241753	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.76	rs9357067	ENSG00000280107.1	AL022393.9	-8.81	2.74e-17	1.79e-14	-0.53	-0.38	Depression;	chr6:28242515	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.76	rs967005	ENSG00000280107.1	AL022393.9	-8.81	2.74e-17	1.79e-14	-0.53	-0.38	Depression;	chr6:28242910	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.55	rs1233704	ENSG00000226314.6	ZNF192P1	8.81	2.74e-17	1.79e-14	0.5	0.38	Depression;	chr6:28199145	chr6:28161781~28169594:+
PRAD	cis	rs9341835	0.772	rs4445042	ENSG00000218048.2	RP3-407E4.4	8.81	2.75e-17	1.79e-14	0.42	0.38	Schizophrenia;	chr6:63430092	chr6:63440766~63443580:+
PRAD	cis	rs4835473	0.831	rs10428468	ENSG00000251600.4	RP11-673E1.1	8.81	2.75e-17	1.79e-14	0.49	0.38	Immature fraction of reticulocytes;	chr4:143974104	chr4:143912331~143982454:+
PRAD	cis	rs2015599	0.623	rs10843385	ENSG00000257176.2	RP11-996F15.2	-8.8	2.76e-17	1.8e-14	-0.44	-0.38	Platelet count;Mean platelet volume;	chr12:29323100	chr12:29280418~29317848:-
PRAD	cis	rs2015599	0.601	rs17715086	ENSG00000257176.2	RP11-996F15.2	-8.8	2.76e-17	1.8e-14	-0.44	-0.38	Platelet count;Mean platelet volume;	chr12:29329073	chr12:29280418~29317848:-
PRAD	cis	rs2274273	0.84	rs10467798	ENSG00000258413.1	RP11-665C16.6	-8.8	2.77e-17	1.8e-14	-0.5	-0.38	Protein biomarker;	chr14:55258209	chr14:55262767~55272075:-
PRAD	cis	rs4835473	0.864	rs12507633	ENSG00000251600.4	RP11-673E1.1	8.8	2.77e-17	1.81e-14	0.49	0.38	Immature fraction of reticulocytes;	chr4:143962730	chr4:143912331~143982454:+
PRAD	cis	rs7743045	0.625	rs9387628	ENSG00000253194.1	RP11-351A11.1	-8.8	2.77e-17	1.81e-14	-0.5	-0.38	Mean platelet volume;	chr6:119031853	chr6:118934785~119031541:+
PRAD	cis	rs2439831	0.85	rs7169988	ENSG00000249839.1	AC011330.5	-8.8	2.78e-17	1.81e-14	-0.66	-0.38	Lung cancer in ever smokers;	chr15:43768237	chr15:43663654~43684339:-
PRAD	cis	rs7772486	0.776	rs2265467	ENSG00000235652.6	RP11-545I5.3	8.8	2.79e-17	1.82e-14	0.39	0.38	Lobe attachment (rater-scored or self-reported);	chr6:145897203	chr6:145799409~145886585:+
PRAD	cis	rs2348418	0.515	rs17434556	ENSG00000247934.4	RP11-967K21.1	8.8	2.79e-17	1.82e-14	0.39	0.38	Lung function (FEV1);Lung function (FVC);	chr12:28442760	chr12:28163298~28190738:-
PRAD	cis	rs7772486	0.806	rs4243478	ENSG00000235652.6	RP11-545I5.3	-8.8	2.79e-17	1.82e-14	-0.39	-0.38	Lobe attachment (rater-scored or self-reported);	chr6:145963424	chr6:145799409~145886585:+
PRAD	cis	rs4835473	0.549	rs11940719	ENSG00000251600.4	RP11-673E1.1	8.8	2.79e-17	1.82e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143970855	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs17750042	ENSG00000251600.4	RP11-673E1.1	-8.8	2.79e-17	1.82e-14	-0.5	-0.38	Immature fraction of reticulocytes;	chr4:143726691	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs1375989	ENSG00000251600.4	RP11-673E1.1	-8.8	2.79e-17	1.82e-14	-0.5	-0.38	Immature fraction of reticulocytes;	chr4:143726893	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs35598827	ENSG00000251600.4	RP11-673E1.1	-8.8	2.79e-17	1.82e-14	-0.5	-0.38	Immature fraction of reticulocytes;	chr4:143729605	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs34570929	ENSG00000251600.4	RP11-673E1.1	-8.8	2.79e-17	1.82e-14	-0.5	-0.38	Immature fraction of reticulocytes;	chr4:143730766	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.9	rs17750172	ENSG00000251600.4	RP11-673E1.1	-8.8	2.79e-17	1.82e-14	-0.5	-0.38	Immature fraction of reticulocytes;	chr4:143731094	chr4:143912331~143982454:+
PRAD	cis	rs950169	1	rs11638394	ENSG00000259728.4	LINC00933	8.8	2.8e-17	1.82e-14	0.46	0.38	Schizophrenia;	chr15:84110176	chr15:84570649~84580175:+
PRAD	cis	rs950169	1	rs35658069	ENSG00000259728.4	LINC00933	8.8	2.8e-17	1.82e-14	0.46	0.38	Schizophrenia;	chr15:84111394	chr15:84570649~84580175:+
PRAD	cis	rs12280210	0.557	rs7112937	ENSG00000254851.1	RP11-109L13.1	8.8	2.81e-17	1.83e-14	0.75	0.38	Lobe attachment (rater-scored or self-reported);	chr11:117009740	chr11:117135528~117138582:+
PRAD	cis	rs7772486	0.817	rs2748491	ENSG00000235652.6	RP11-545I5.3	8.8	2.82e-17	1.84e-14	0.38	0.38	Lobe attachment (rater-scored or self-reported);	chr6:146006623	chr6:145799409~145886585:+
PRAD	cis	rs6452524	0.934	rs12153179	ENSG00000249664.1	CTD-2227C6.2	8.8	2.82e-17	1.84e-14	0.45	0.38	Hypertension (SNP x SNP interaction);	chr5:83125109	chr5:83012285~83013109:-
PRAD	cis	rs7772486	0.875	rs2777483	ENSG00000235652.6	RP11-545I5.3	8.8	2.82e-17	1.84e-14	0.38	0.38	Lobe attachment (rater-scored or self-reported);	chr6:146008099	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.875	rs2748485	ENSG00000235652.6	RP11-545I5.3	8.8	2.82e-17	1.84e-14	0.38	0.38	Lobe attachment (rater-scored or self-reported);	chr6:146011285	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.875	rs2207785	ENSG00000235652.6	RP11-545I5.3	8.8	2.82e-17	1.84e-14	0.38	0.38	Lobe attachment (rater-scored or self-reported);	chr6:146011648	chr6:145799409~145886585:+
PRAD	cis	rs9487094	0.567	rs11964864	ENSG00000260273.1	RP11-425D10.10	8.8	2.84e-17	1.85e-14	0.54	0.38	Height;	chr6:109773423	chr6:109382795~109383666:+
PRAD	cis	rs4835473	0.742	rs1838519	ENSG00000251600.4	RP11-673E1.1	8.8	2.84e-17	1.85e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143972242	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.831	rs7689328	ENSG00000251600.4	RP11-673E1.1	8.8	2.84e-17	1.85e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143973768	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.831	rs7694353	ENSG00000251600.4	RP11-673E1.1	8.8	2.84e-17	1.85e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143973787	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.75	rs57610804	ENSG00000251600.4	RP11-673E1.1	8.8	2.84e-17	1.85e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143974341	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs13148097	ENSG00000251600.4	RP11-673E1.1	8.8	2.84e-17	1.85e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143976238	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs28377887	ENSG00000251600.4	RP11-673E1.1	8.8	2.84e-17	1.85e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143977075	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs6826862	ENSG00000251600.4	RP11-673E1.1	8.8	2.84e-17	1.85e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143978180	chr4:143912331~143982454:+
PRAD	cis	rs875971	1	rs4718307	ENSG00000237310.1	GS1-124K5.4	-8.8	2.84e-17	1.85e-14	-0.34	-0.38	Aortic root size;	chr7:66146001	chr7:66493706~66495474:+
PRAD	cis	rs765787	0.53	rs13329228	ENSG00000259520.4	CTD-2651B20.3	8.8	2.84e-17	1.85e-14	0.47	0.38	Uric acid levels;	chr15:45240819	chr15:45251580~45279251:-
PRAD	cis	rs1979679	0.842	rs1841964	ENSG00000278733.1	RP11-425D17.1	-8.8	2.84e-17	1.85e-14	-0.49	-0.38	Ossification of the posterior longitudinal ligament of the spine;	chr12:28190100	chr12:28185625~28186190:-
PRAD	cis	rs17012589	0.589	rs7316291	ENSG00000258815.1	RP11-408B11.2	-8.8	2.84e-17	1.85e-14	-0.52	-0.38	Bone mineral density (Ward's triangle area);	chr12:85305966	chr12:85318060~85342912:+
PRAD	cis	rs9532669	0.926	rs11147823	ENSG00000168852.11	TPTE2P5	-8.8	2.85e-17	1.85e-14	-0.37	-0.38	Cervical cancer;	chr13:40878138	chr13:40822296~40921749:-
PRAD	cis	rs875971	1	rs7801282	ENSG00000237310.1	GS1-124K5.4	-8.8	2.85e-17	1.86e-14	-0.34	-0.38	Aortic root size;	chr7:66148700	chr7:66493706~66495474:+
PRAD	cis	rs8177376	1	rs563011	ENSG00000254905.1	RP11-712L6.7	-8.8	2.86e-17	1.86e-14	-0.48	-0.38	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126281527	chr11:126292922~126294254:-
PRAD	cis	rs11098499	0.697	rs28655325	ENSG00000245958.5	RP11-33B1.1	-8.8	2.87e-17	1.87e-14	-0.38	-0.38	Corneal astigmatism;	chr4:119451844	chr4:119454791~119552025:+
PRAD	cis	rs3002131	0.604	rs3002151	ENSG00000225265.1	TAF1A-AS1	-8.8	2.88e-17	1.87e-14	-0.63	-0.38	Interleukin-10 levels;	chr1:222573225	chr1:222589825~222593032:+
PRAD	cis	rs4631830	0.9	rs10763576	ENSG00000230869.1	CTGLF10P	-8.8	2.89e-17	1.88e-14	-0.47	-0.38	Prostate-specific antigen levels;	chr10:46057009	chr10:45678692~45700532:+
PRAD	cis	rs11676348	0.751	rs6715591	ENSG00000261338.2	RP11-378A13.1	-8.8	2.89e-17	1.88e-14	-0.42	-0.38	Ulcerative colitis;	chr2:218155148	chr2:218255319~218257366:+
PRAD	cis	rs1501911	0.509	rs330421	ENSG00000248489.1	CTD-2007H13.3	8.8	2.9e-17	1.89e-14	0.42	0.38	Lung function (FEV1/FVC);	chr5:98859077	chr5:98929171~98995013:+
PRAD	cis	rs9389248	0.69	rs2064101	ENSG00000232876.1	CTA-212D2.2	8.8	2.91e-17	1.89e-14	0.48	0.38	High light scatter reticulocyte percentage of red cells;	chr6:134929392	chr6:135055033~135060550:+
PRAD	cis	rs950169	1	rs950169	ENSG00000259728.4	LINC00933	8.8	2.91e-17	1.89e-14	0.46	0.38	Schizophrenia;	chr15:84037709	chr15:84570649~84580175:+
PRAD	cis	rs875971	0.505	rs1723275	ENSG00000236529.1	RP13-254B10.1	-8.8	2.92e-17	1.89e-14	-0.4	-0.38	Aortic root size;	chr7:66039646	chr7:65840212~65840596:+
PRAD	cis	rs950169	0.845	rs4106951	ENSG00000259728.4	LINC00933	8.8	2.92e-17	1.9e-14	0.46	0.38	Schizophrenia;	chr15:84164642	chr15:84570649~84580175:+
PRAD	cis	rs17711722	0.522	rs6957759	ENSG00000236529.1	RP13-254B10.1	8.8	2.92e-17	1.9e-14	0.4	0.38	Calcium levels;	chr7:65806798	chr7:65840212~65840596:+
PRAD	cis	rs9389248	0.69	rs2294321	ENSG00000232876.1	CTA-212D2.2	8.8	2.93e-17	1.9e-14	0.48	0.38	High light scatter reticulocyte percentage of red cells;	chr6:134931910	chr6:135055033~135060550:+
PRAD	cis	rs9399135	0.507	rs2072825	ENSG00000232876.1	CTA-212D2.2	8.8	2.93e-17	1.9e-14	0.48	0.38	Red blood cell count;	chr6:134932313	chr6:135055033~135060550:+
PRAD	cis	rs9389248	0.69	rs2072826	ENSG00000232876.1	CTA-212D2.2	8.8	2.93e-17	1.9e-14	0.48	0.38	High light scatter reticulocyte percentage of red cells;	chr6:134932420	chr6:135055033~135060550:+
PRAD	cis	rs11148252	0.846	rs9379	ENSG00000278238.1	RP11-245D16.4	-8.8	2.94e-17	1.91e-14	-0.44	-0.38	Lewy body disease;	chr13:52476344	chr13:52454775~52455331:-
PRAD	cis	rs3096299	0.967	rs3102341	ENSG00000274627.1	RP11-104N10.2	8.8	2.96e-17	1.92e-14	0.39	0.38	Multiple myeloma (IgH translocation);	chr16:89384336	chr16:89516797~89522217:+
PRAD	cis	rs4835473	0.932	rs10025527	ENSG00000251600.4	RP11-673E1.1	8.8	2.96e-17	1.92e-14	0.49	0.38	Immature fraction of reticulocytes;	chr4:143968391	chr4:143912331~143982454:+
PRAD	cis	rs6570726	0.935	rs386344	ENSG00000235652.6	RP11-545I5.3	8.8	2.96e-17	1.92e-14	0.39	0.38	Lobe attachment (rater-scored or self-reported);	chr6:145534486	chr6:145799409~145886585:+
PRAD	cis	rs950169	0.922	rs11631096	ENSG00000225151.9	GOLGA2P7	-8.8	2.97e-17	1.93e-14	-0.53	-0.38	Schizophrenia;	chr15:84557698	chr15:84199311~84230136:-
PRAD	cis	rs2274273	0.905	rs2147961	ENSG00000258413.1	RP11-665C16.6	-8.8	2.97e-17	1.93e-14	-0.5	-0.38	Protein biomarker;	chr14:55118663	chr14:55262767~55272075:-
PRAD	cis	rs1075265	0.553	rs2692532	ENSG00000233266.1	HMGB1P31	8.79	3e-17	1.95e-14	0.52	0.38	Chronotype;Morning vs. evening chronotype;	chr2:53778962	chr2:54051334~54051760:+
PRAD	cis	rs7712401	0.601	rs34707663	ENSG00000263432.2	RN7SL689P	-8.79	3.01e-17	1.95e-14	-0.4	-0.38	Mean platelet volume;	chr5:122984768	chr5:123022487~123022783:-
PRAD	cis	rs812925	0.553	rs1177307	ENSG00000271889.1	RP11-493E12.1	8.79	3.02e-17	1.96e-14	0.42	0.38	Immature fraction of reticulocytes;	chr2:61160253	chr2:61151433~61162105:-
PRAD	cis	rs17608059	0.524	rs9897978	ENSG00000141028.6	CDRT15P1	8.79	3.03e-17	1.96e-14	0.51	0.38	Temperament;	chr17:13996939	chr17:14024514~14025488:+
PRAD	cis	rs11723261	0.621	rs6599307	ENSG00000275426.1	CH17-262A2.1	8.79	3.03e-17	1.97e-14	0.49	0.38	Immune response to smallpox vaccine (IL-6);	chr4:149993	chr4:149738~150317:+
PRAD	cis	rs7189233	0.531	rs6499617	ENSG00000279344.1	RP11-44F14.7	8.79	3.04e-17	1.97e-14	0.35	0.38	Intelligence (multi-trait analysis);	chr16:53433810	chr16:53478957~53481550:-
PRAD	cis	rs7189233	0.531	rs8056349	ENSG00000279344.1	RP11-44F14.7	8.79	3.04e-17	1.97e-14	0.35	0.38	Intelligence (multi-trait analysis);	chr16:53434114	chr16:53478957~53481550:-
PRAD	cis	rs2153535	0.518	rs913571	ENSG00000230939.1	RP11-314C16.1	-8.79	3.04e-17	1.97e-14	-0.46	-0.38	Motion sickness;	chr6:8591095	chr6:8784178~8785445:+
PRAD	cis	rs367615	0.552	rs2963010	ENSG00000249476.1	CTD-2587M2.1	-8.79	3.04e-17	1.98e-14	-0.47	-0.38	Colorectal cancer (SNP x SNP interaction);	chr5:109401342	chr5:109237120~109326369:-
PRAD	cis	rs853679	0.55	rs1233701	ENSG00000226314.6	ZNF192P1	8.79	3.06e-17	1.99e-14	0.51	0.38	Depression;	chr6:28200948	chr6:28161781~28169594:+
PRAD	cis	rs8523	0.901	rs4713103	ENSG00000230314.5	ELOVL2-AS1	8.79	3.06e-17	1.99e-14	0.42	0.38	Red blood cell fatty acid levels;	chr6:10968908	chr6:11043524~11078226:+
PRAD	cis	rs7712401	0.601	rs154496	ENSG00000263432.2	RN7SL689P	8.79	3.08e-17	2e-14	0.39	0.38	Mean platelet volume;	chr5:122886036	chr5:123022487~123022783:-
PRAD	cis	rs950169	1	rs1848093	ENSG00000259728.4	LINC00933	8.79	3.1e-17	2.01e-14	0.46	0.38	Schizophrenia;	chr15:84086775	chr15:84570649~84580175:+
PRAD	cis	rs950169	1	rs12915234	ENSG00000259728.4	LINC00933	8.79	3.1e-17	2.01e-14	0.46	0.38	Schizophrenia;	chr15:84089549	chr15:84570649~84580175:+
PRAD	cis	rs950169	1	rs34751999	ENSG00000259728.4	LINC00933	8.79	3.1e-17	2.01e-14	0.46	0.38	Schizophrenia;	chr15:84089667	chr15:84570649~84580175:+
PRAD	cis	rs950169	0.919	rs17300292	ENSG00000259728.4	LINC00933	8.79	3.1e-17	2.01e-14	0.46	0.38	Schizophrenia;	chr15:84093816	chr15:84570649~84580175:+
PRAD	cis	rs950169	1	rs12916348	ENSG00000259728.4	LINC00933	8.79	3.1e-17	2.01e-14	0.46	0.38	Schizophrenia;	chr15:84096775	chr15:84570649~84580175:+
PRAD	cis	rs950169	1	rs35297609	ENSG00000259728.4	LINC00933	8.79	3.1e-17	2.01e-14	0.46	0.38	Schizophrenia;	chr15:84104144	chr15:84570649~84580175:+
PRAD	cis	rs950169	1	rs62026530	ENSG00000259728.4	LINC00933	8.79	3.1e-17	2.01e-14	0.46	0.38	Schizophrenia;	chr15:84107088	chr15:84570649~84580175:+
PRAD	cis	rs7811142	0.887	rs35111986	ENSG00000242294.5	STAG3L5P	8.79	3.1e-17	2.01e-14	0.27	0.38	Platelet count;	chr7:100402651	chr7:100336079~100351900:+
PRAD	cis	rs524281	1	rs489337	ENSG00000255320.1	RP11-755F10.1	-8.79	3.14e-17	2.03e-14	-0.55	-0.38	Electroencephalogram traits;	chr11:66087090	chr11:66244840~66246239:-
PRAD	cis	rs4713118	0.824	rs2179095	ENSG00000280107.1	AL022393.9	8.79	3.14e-17	2.04e-14	0.48	0.38	Parkinson's disease;	chr6:27783079	chr6:28170845~28172521:+
PRAD	cis	rs6847067	0.8	rs12498637	ENSG00000180769.7	WDFY3-AS2	8.79	3.14e-17	2.04e-14	0.4	0.38	Oropharynx cancer;	chr4:84922800	chr4:84965682~85011277:+
PRAD	cis	rs8062405	0.789	rs240704	ENSG00000251417.2	RP11-1348G14.4	-8.79	3.16e-17	2.05e-14	-0.42	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28518628	chr16:28802743~28817828:+
PRAD	cis	rs7829975	0.591	rs12677543	ENSG00000253893.2	FAM85B	-8.79	3.16e-17	2.05e-14	-0.48	-0.38	Mood instability;	chr8:8786764	chr8:8167819~8226614:-
PRAD	cis	rs7829975	0.593	rs2921051	ENSG00000253893.2	FAM85B	-8.79	3.17e-17	2.05e-14	-0.46	-0.38	Mood instability;	chr8:8462594	chr8:8167819~8226614:-
PRAD	cis	rs8042680	0.522	rs12595616	ENSG00000214432.8	AC068831.10	8.79	3.17e-17	2.05e-14	0.45	0.38	Type 2 diabetes;	chr15:91020283	chr15:91022619~91036611:+
PRAD	cis	rs6061231	0.556	rs6121571	ENSG00000273619.1	RP5-908M14.9	-8.79	3.18e-17	2.06e-14	-0.25	-0.38	Colorectal cancer;	chr20:62402267	chr20:62386303~62386970:-
PRAD	cis	rs9326248	0.53	rs2075292	ENSG00000254851.1	RP11-109L13.1	-8.79	3.18e-17	2.06e-14	-0.77	-0.38	Blood protein levels;	chr11:116861796	chr11:117135528~117138582:+
PRAD	cis	rs9326248	0.53	rs6589575	ENSG00000254851.1	RP11-109L13.1	-8.79	3.18e-17	2.06e-14	-0.77	-0.38	Blood protein levels;	chr11:116862594	chr11:117135528~117138582:+
PRAD	cis	rs9326248	0.53	rs718847	ENSG00000254851.1	RP11-109L13.1	-8.79	3.18e-17	2.06e-14	-0.77	-0.38	Blood protein levels;	chr11:116863430	chr11:117135528~117138582:+
PRAD	cis	rs6452524	0.934	rs1120477	ENSG00000249664.1	CTD-2227C6.2	8.79	3.18e-17	2.06e-14	0.45	0.38	Hypertension (SNP x SNP interaction);	chr5:83127062	chr5:83012285~83013109:-
PRAD	cis	rs6452524	0.934	rs1120478	ENSG00000249664.1	CTD-2227C6.2	8.79	3.18e-17	2.06e-14	0.45	0.38	Hypertension (SNP x SNP interaction);	chr5:83127072	chr5:83012285~83013109:-
PRAD	cis	rs6452524	0.967	rs6452514	ENSG00000249664.1	CTD-2227C6.2	8.79	3.18e-17	2.06e-14	0.45	0.38	Hypertension (SNP x SNP interaction);	chr5:83127627	chr5:83012285~83013109:-
PRAD	cis	rs6452524	0.935	rs6884543	ENSG00000249664.1	CTD-2227C6.2	8.79	3.18e-17	2.06e-14	0.45	0.38	Hypertension (SNP x SNP interaction);	chr5:83127939	chr5:83012285~83013109:-
PRAD	cis	rs4820294	1	rs929039	ENSG00000233360.4	Z83844.1	8.79	3.2e-17	2.07e-14	0.49	0.38	Fat distribution (HIV);	chr22:37675504	chr22:37641832~37658377:-
PRAD	cis	rs6940638	0.513	rs4424065	ENSG00000241549.7	GUSBP2	-8.79	3.2e-17	2.07e-14	-0.43	-0.38	Intelligence (multi-trait analysis);	chr6:27068677	chr6:26871484~26956554:-
PRAD	cis	rs2274273	0.934	rs2341621	ENSG00000258413.1	RP11-665C16.6	-8.79	3.21e-17	2.08e-14	-0.5	-0.38	Protein biomarker;	chr14:55259707	chr14:55262767~55272075:-
PRAD	cis	rs6991838	0.53	rs35038843	ENSG00000200714.1	Y_RNA	-8.78	3.22e-17	2.08e-14	-0.42	-0.38	Intelligence (multi-trait analysis);	chr8:65610263	chr8:65592731~65592820:+
PRAD	cis	rs6991838	0.584	rs4737748	ENSG00000200714.1	Y_RNA	8.78	3.22e-17	2.08e-14	0.42	0.38	Intelligence (multi-trait analysis);	chr8:65613630	chr8:65592731~65592820:+
PRAD	cis	rs6991838	0.55	rs12335006	ENSG00000200714.1	Y_RNA	8.78	3.22e-17	2.08e-14	0.42	0.38	Intelligence (multi-trait analysis);	chr8:65619394	chr8:65592731~65592820:+
PRAD	cis	rs6991838	0.584	rs10957361	ENSG00000200714.1	Y_RNA	8.78	3.22e-17	2.08e-14	0.42	0.38	Intelligence (multi-trait analysis);	chr8:65619626	chr8:65592731~65592820:+
PRAD	cis	rs6991838	0.612	rs12335276	ENSG00000200714.1	Y_RNA	8.78	3.22e-17	2.08e-14	0.42	0.38	Intelligence (multi-trait analysis);	chr8:65619668	chr8:65592731~65592820:+
PRAD	cis	rs6991838	0.612	rs7832407	ENSG00000200714.1	Y_RNA	8.78	3.22e-17	2.08e-14	0.42	0.38	Intelligence (multi-trait analysis);	chr8:65621071	chr8:65592731~65592820:+
PRAD	cis	rs6991838	0.551	rs7007505	ENSG00000200714.1	Y_RNA	8.78	3.22e-17	2.08e-14	0.42	0.38	Intelligence (multi-trait analysis);	chr8:65621719	chr8:65592731~65592820:+
PRAD	cis	rs6991838	0.584	rs7012856	ENSG00000200714.1	Y_RNA	8.78	3.22e-17	2.08e-14	0.42	0.38	Intelligence (multi-trait analysis);	chr8:65622740	chr8:65592731~65592820:+
PRAD	cis	rs6991838	0.55	rs7817112	ENSG00000200714.1	Y_RNA	8.78	3.22e-17	2.08e-14	0.42	0.38	Intelligence (multi-trait analysis);	chr8:65624885	chr8:65592731~65592820:+
PRAD	cis	rs6991838	0.584	rs2048650	ENSG00000200714.1	Y_RNA	8.78	3.22e-17	2.08e-14	0.42	0.38	Intelligence (multi-trait analysis);	chr8:65625664	chr8:65592731~65592820:+
PRAD	cis	rs6991838	0.584	rs4737749	ENSG00000200714.1	Y_RNA	8.78	3.22e-17	2.08e-14	0.42	0.38	Intelligence (multi-trait analysis);	chr8:65627672	chr8:65592731~65592820:+
PRAD	cis	rs6991838	0.584	rs10092109	ENSG00000200714.1	Y_RNA	8.78	3.22e-17	2.08e-14	0.42	0.38	Intelligence (multi-trait analysis);	chr8:65627683	chr8:65592731~65592820:+
PRAD	cis	rs6991838	0.584	rs6997959	ENSG00000200714.1	Y_RNA	8.78	3.22e-17	2.08e-14	0.42	0.38	Intelligence (multi-trait analysis);	chr8:65628247	chr8:65592731~65592820:+
PRAD	cis	rs6991838	0.584	rs7814841	ENSG00000200714.1	Y_RNA	8.78	3.22e-17	2.08e-14	0.42	0.38	Intelligence (multi-trait analysis);	chr8:65629328	chr8:65592731~65592820:+
PRAD	cis	rs6991838	0.584	rs11985628	ENSG00000200714.1	Y_RNA	8.78	3.22e-17	2.08e-14	0.42	0.38	Intelligence (multi-trait analysis);	chr8:65630504	chr8:65592731~65592820:+
PRAD	cis	rs6991838	0.557	rs13266834	ENSG00000200714.1	Y_RNA	8.78	3.22e-17	2.08e-14	0.42	0.38	Intelligence (multi-trait analysis);	chr8:65631303	chr8:65592731~65592820:+
PRAD	cis	rs6991838	0.584	rs13268343	ENSG00000200714.1	Y_RNA	8.78	3.22e-17	2.08e-14	0.42	0.38	Intelligence (multi-trait analysis);	chr8:65631742	chr8:65592731~65592820:+
PRAD	cis	rs6991838	0.584	rs7835313	ENSG00000200714.1	Y_RNA	8.78	3.22e-17	2.08e-14	0.42	0.38	Intelligence (multi-trait analysis);	chr8:65633891	chr8:65592731~65592820:+
PRAD	cis	rs6991838	0.53	rs6472217	ENSG00000200714.1	Y_RNA	8.78	3.22e-17	2.08e-14	0.42	0.38	Intelligence (multi-trait analysis);	chr8:65635496	chr8:65592731~65592820:+
PRAD	cis	rs6991838	0.584	rs6472218	ENSG00000200714.1	Y_RNA	8.78	3.22e-17	2.08e-14	0.42	0.38	Intelligence (multi-trait analysis);	chr8:65635502	chr8:65592731~65592820:+
PRAD	cis	rs6991838	0.584	rs1533285	ENSG00000200714.1	Y_RNA	8.78	3.22e-17	2.08e-14	0.42	0.38	Intelligence (multi-trait analysis);	chr8:65637129	chr8:65592731~65592820:+
PRAD	cis	rs17023223	0.537	rs12081585	ENSG00000231365.4	RP11-418J17.1	-8.78	3.23e-17	2.09e-14	-0.41	-0.38	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119073333	chr1:119140396~119275973:+
PRAD	cis	rs2153535	0.585	rs7765238	ENSG00000230939.1	RP11-314C16.1	8.78	3.24e-17	2.1e-14	0.47	0.38	Motion sickness;	chr6:8632560	chr6:8784178~8785445:+
PRAD	cis	rs875971	1	rs6961717	ENSG00000237310.1	GS1-124K5.4	-8.78	3.25e-17	2.1e-14	-0.34	-0.38	Aortic root size;	chr7:66122550	chr7:66493706~66495474:+
PRAD	cis	rs875971	1	rs2087647	ENSG00000237310.1	GS1-124K5.4	-8.78	3.25e-17	2.1e-14	-0.34	-0.38	Aortic root size;	chr7:66128201	chr7:66493706~66495474:+
PRAD	cis	rs875971	1	rs6958484	ENSG00000237310.1	GS1-124K5.4	-8.78	3.25e-17	2.1e-14	-0.34	-0.38	Aortic root size;	chr7:66134459	chr7:66493706~66495474:+
PRAD	cis	rs7712401	0.601	rs2164773	ENSG00000263432.2	RN7SL689P	-8.78	3.25e-17	2.1e-14	-0.39	-0.38	Mean platelet volume;	chr5:123003222	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.601	rs418229	ENSG00000263432.2	RN7SL689P	-8.78	3.25e-17	2.1e-14	-0.39	-0.38	Mean platelet volume;	chr5:123005969	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.601	rs374403	ENSG00000263432.2	RN7SL689P	-8.78	3.25e-17	2.1e-14	-0.39	-0.38	Mean platelet volume;	chr5:123006018	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.601	rs446782	ENSG00000263432.2	RN7SL689P	-8.78	3.25e-17	2.1e-14	-0.39	-0.38	Mean platelet volume;	chr5:123006173	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.601	rs417268	ENSG00000263432.2	RN7SL689P	-8.78	3.25e-17	2.1e-14	-0.39	-0.38	Mean platelet volume;	chr5:123009317	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.601	rs398142	ENSG00000263432.2	RN7SL689P	-8.78	3.25e-17	2.1e-14	-0.39	-0.38	Mean platelet volume;	chr5:123009881	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.58	rs383262	ENSG00000263432.2	RN7SL689P	-8.78	3.25e-17	2.1e-14	-0.39	-0.38	Mean platelet volume;	chr5:123009989	chr5:123022487~123022783:-
PRAD	cis	rs6452524	0.967	rs4541638	ENSG00000249664.1	CTD-2227C6.2	8.78	3.25e-17	2.1e-14	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83181325	chr5:83012285~83013109:-
PRAD	cis	rs6452524	0.967	rs28360104	ENSG00000249664.1	CTD-2227C6.2	8.78	3.25e-17	2.1e-14	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83181525	chr5:83012285~83013109:-
PRAD	cis	rs6452524	0.934	rs6452512	ENSG00000249664.1	CTD-2227C6.2	8.78	3.25e-17	2.1e-14	0.45	0.38	Hypertension (SNP x SNP interaction);	chr5:83127523	chr5:83012285~83013109:-
PRAD	cis	rs524281	0.731	rs3829937	ENSG00000255320.1	RP11-755F10.1	8.78	3.25e-17	2.1e-14	0.67	0.38	Electroencephalogram traits;	chr11:66020195	chr11:66244840~66246239:-
PRAD	cis	rs7811142	0.779	rs111312383	ENSG00000242294.5	STAG3L5P	8.78	3.26e-17	2.11e-14	0.26	0.38	Platelet count;	chr7:100307702	chr7:100336079~100351900:+
PRAD	cis	rs2638953	0.924	rs10492368	ENSG00000278733.1	RP11-425D17.1	-8.78	3.26e-17	2.11e-14	-0.45	-0.38	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28173941	chr12:28185625~28186190:-
PRAD	cis	rs3858145	0.588	rs736535	ENSG00000233590.1	RP11-153K11.3	-8.78	3.27e-17	2.11e-14	-0.55	-0.38	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68284159	chr10:68233251~68242379:-
PRAD	cis	rs4631830	0.863	rs6481329	ENSG00000230869.1	CTGLF10P	-8.78	3.27e-17	2.12e-14	-0.47	-0.38	Prostate-specific antigen levels;	chr10:46066076	chr10:45678692~45700532:+
PRAD	cis	rs4820294	0.926	rs62236671	ENSG00000233360.4	Z83844.1	8.78	3.28e-17	2.12e-14	0.49	0.38	Fat distribution (HIV);	chr22:37673298	chr22:37641832~37658377:-
PRAD	cis	rs4713118	0.619	rs200486	ENSG00000280107.1	AL022393.9	-8.78	3.28e-17	2.12e-14	-0.52	-0.38	Parkinson's disease;	chr6:27811728	chr6:28170845~28172521:+
PRAD	cis	rs6538678	0.746	rs703693	ENSG00000258343.1	RP11-536G4.2	-8.78	3.28e-17	2.12e-14	-0.52	-0.38	Lupus nephritis in systemic lupus erythematosus;	chr12:95866214	chr12:95795345~95858839:-
PRAD	cis	rs4713118	0.629	rs149899	ENSG00000226314.6	ZNF192P1	-8.78	3.3e-17	2.13e-14	-0.52	-0.38	Parkinson's disease;	chr6:28052201	chr6:28161781~28169594:+
PRAD	cis	rs4713118	0.629	rs172165	ENSG00000226314.6	ZNF192P1	-8.78	3.3e-17	2.13e-14	-0.52	-0.38	Parkinson's disease;	chr6:28053036	chr6:28161781~28169594:+
PRAD	cis	rs4713118	0.597	rs172166	ENSG00000226314.6	ZNF192P1	-8.78	3.3e-17	2.13e-14	-0.52	-0.38	Parkinson's disease;	chr6:28053042	chr6:28161781~28169594:+
PRAD	cis	rs3779195	0.929	rs10953259	ENSG00000272950.1	RP11-307C18.1	-8.78	3.31e-17	2.14e-14	-0.59	-0.38	Sex hormone-binding globulin levels;	chr7:98383795	chr7:98322853~98323430:+
PRAD	cis	rs12468226	0.623	rs12471811	ENSG00000273456.1	RP11-686O6.2	8.78	3.31e-17	2.14e-14	0.56	0.38	Urate levels;	chr2:202586164	chr2:202374932~202375604:-
PRAD	cis	rs4835473	0.932	rs4383567	ENSG00000251600.4	RP11-673E1.1	8.78	3.33e-17	2.15e-14	0.47	0.38	Immature fraction of reticulocytes;	chr4:143788873	chr4:143912331~143982454:+
PRAD	cis	rs1075265	0.611	rs11684084	ENSG00000233266.1	HMGB1P31	8.78	3.34e-17	2.15e-14	0.52	0.38	Chronotype;Morning vs. evening chronotype;	chr2:53695806	chr2:54051334~54051760:+
PRAD	cis	rs6782228	0.628	rs7641584	ENSG00000242551.2	POU5F1P6	-8.78	3.34e-17	2.16e-14	-0.48	-0.38	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128673787	chr3:128674735~128677005:-
PRAD	cis	rs34779708	0.677	rs112355105	ENSG00000230534.5	RP11-297A16.2	8.78	3.35e-17	2.16e-14	0.51	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35261366	chr10:35098006~35127020:-
PRAD	cis	rs875971	1	rs55962648	ENSG00000237310.1	GS1-124K5.4	-8.78	3.37e-17	2.17e-14	-0.34	-0.38	Aortic root size;	chr7:66160764	chr7:66493706~66495474:+
PRAD	cis	rs875971	1	rs2420168	ENSG00000237310.1	GS1-124K5.4	-8.78	3.37e-17	2.17e-14	-0.34	-0.38	Aortic root size;	chr7:66165644	chr7:66493706~66495474:+
PRAD	cis	rs12653946	0.846	rs4975758	ENSG00000249116.1	CTD-2194D22.3	-8.78	3.37e-17	2.18e-14	-0.45	-0.38	Prostate cancer;	chr5:1891060	chr5:1883966~1884649:+
PRAD	cis	rs2638953	0.85	rs11049402	ENSG00000278733.1	RP11-425D17.1	-8.78	3.37e-17	2.18e-14	-0.45	-0.38	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28175974	chr12:28185625~28186190:-
PRAD	cis	rs6517329	0.7	rs11911678	ENSG00000236830.5	CBR3-AS1	8.78	3.38e-17	2.18e-14	0.42	0.38	Schizophrenia;	chr21:36110704	chr21:36131767~36175815:-
PRAD	cis	rs10740039	0.583	rs1904404	ENSG00000254271.1	RP11-131N11.4	-8.78	3.38e-17	2.18e-14	-0.52	-0.38	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60742428	chr10:60734342~60741828:+
PRAD	cis	rs4835473	0.932	rs7697916	ENSG00000251600.4	RP11-673E1.1	-8.78	3.39e-17	2.19e-14	-0.5	-0.38	Immature fraction of reticulocytes;	chr4:143765628	chr4:143912331~143982454:+
PRAD	cis	rs2739330	0.731	rs2000468	ENSG00000206090.4	AP000350.7	8.78	3.4e-17	2.19e-14	0.49	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23939998~23942798:+
PRAD	cis	rs26232	0.521	rs11958562	ENSG00000175749.11	EIF3KP1	8.78	3.4e-17	2.19e-14	0.5	0.38	Rheumatoid arthritis;	chr5:103027357	chr5:103032376~103033031:+
PRAD	cis	rs17012589	0.639	rs7306109	ENSG00000258815.1	RP11-408B11.2	-8.78	3.4e-17	2.2e-14	-0.52	-0.38	Bone mineral density (Ward's triangle area);	chr12:85302787	chr12:85318060~85342912:+
PRAD	cis	rs7829975	0.688	rs6995407	ENSG00000253893.2	FAM85B	-8.78	3.41e-17	2.2e-14	-0.46	-0.38	Mood instability;	chr8:8527137	chr8:8167819~8226614:-
PRAD	cis	rs2255336	0.938	rs1382264	ENSG00000245648.1	RP11-277P12.20	-8.78	3.41e-17	2.2e-14	-0.55	-0.38	Blood protein levels;	chr12:10390740	chr12:10363769~10398506:+
PRAD	cis	rs6452524	0.935	rs3901654	ENSG00000249664.1	CTD-2227C6.2	8.78	3.42e-17	2.2e-14	0.46	0.38	Hypertension (SNP x SNP interaction);	chr5:83110519	chr5:83012285~83013109:-
PRAD	cis	rs6452524	0.935	rs1478480	ENSG00000249664.1	CTD-2227C6.2	8.78	3.42e-17	2.2e-14	0.46	0.38	Hypertension (SNP x SNP interaction);	chr5:83112117	chr5:83012285~83013109:-
PRAD	cis	rs150992	0.517	rs326464	ENSG00000248489.1	CTD-2007H13.3	8.78	3.42e-17	2.21e-14	0.42	0.38	Body mass index;	chr5:98906499	chr5:98929171~98995013:+
PRAD	cis	rs950169	0.922	rs11630760	ENSG00000225151.9	GOLGA2P7	-8.78	3.43e-17	2.21e-14	-0.53	-0.38	Schizophrenia;	chr15:84570106	chr15:84199311~84230136:-
PRAD	cis	rs950169	0.887	rs71395453	ENSG00000225151.9	GOLGA2P7	-8.78	3.43e-17	2.21e-14	-0.53	-0.38	Schizophrenia;	chr15:84570259	chr15:84199311~84230136:-
PRAD	cis	rs950169	0.922	rs11633075	ENSG00000225151.9	GOLGA2P7	-8.78	3.43e-17	2.21e-14	-0.53	-0.38	Schizophrenia;	chr15:84570741	chr15:84199311~84230136:-
PRAD	cis	rs7586673	0.857	rs16845580	ENSG00000227403.1	AC009299.3	-8.78	3.44e-17	2.22e-14	-0.51	-0.38	Intelligence (multi-trait analysis);	chr2:161064373	chr2:161244739~161249050:+
PRAD	cis	rs2638953	0.924	rs1551987	ENSG00000278733.1	RP11-425D17.1	-8.78	3.45e-17	2.22e-14	-0.45	-0.38	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28178761	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs1551986	ENSG00000278733.1	RP11-425D17.1	-8.78	3.45e-17	2.22e-14	-0.45	-0.38	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28178778	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs2078017	ENSG00000278733.1	RP11-425D17.1	-8.78	3.45e-17	2.22e-14	-0.45	-0.38	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28180175	chr12:28185625~28186190:-
PRAD	cis	rs9389248	0.69	rs728030	ENSG00000232876.1	CTA-212D2.2	8.78	3.45e-17	2.22e-14	0.47	0.38	High light scatter reticulocyte percentage of red cells;	chr6:134925156	chr6:135055033~135060550:+
PRAD	cis	rs2153535	0.585	rs9328498	ENSG00000230939.1	RP11-314C16.1	-8.78	3.46e-17	2.23e-14	-0.47	-0.38	Motion sickness;	chr6:8623536	chr6:8784178~8785445:+
PRAD	cis	rs4964805	0.606	rs7312606	ENSG00000257681.1	RP11-341G23.4	8.77	3.48e-17	2.24e-14	0.34	0.38	Attention deficit hyperactivity disorder;	chr12:103794607	chr12:103746315~103768858:-
PRAD	cis	rs4964805	0.581	rs7312825	ENSG00000257681.1	RP11-341G23.4	8.77	3.48e-17	2.24e-14	0.34	0.38	Attention deficit hyperactivity disorder;	chr12:103794610	chr12:103746315~103768858:-
PRAD	cis	rs4964805	0.657	rs11111787	ENSG00000257681.1	RP11-341G23.4	8.77	3.48e-17	2.24e-14	0.34	0.38	Attention deficit hyperactivity disorder;	chr12:103795721	chr12:103746315~103768858:-
PRAD	cis	rs34779708	0.766	rs35308730	ENSG00000230534.5	RP11-297A16.2	8.77	3.49e-17	2.25e-14	0.51	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35260868	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.736	rs34195979	ENSG00000230534.5	RP11-297A16.2	8.77	3.49e-17	2.25e-14	0.51	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35260889	chr10:35098006~35127020:-
PRAD	cis	rs1061377	0.748	rs12649085	ENSG00000249207.1	RP11-360F5.1	-8.77	3.5e-17	2.26e-14	-0.39	-0.38	Uric acid levels;	chr4:39106459	chr4:39112677~39126818:-
PRAD	cis	rs7772486	0.846	rs1474871	ENSG00000235652.6	RP11-545I5.3	8.77	3.51e-17	2.26e-14	0.39	0.38	Lobe attachment (rater-scored or self-reported);	chr6:146085158	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.875	rs6570738	ENSG00000235652.6	RP11-545I5.3	8.77	3.51e-17	2.26e-14	0.39	0.38	Lobe attachment (rater-scored or self-reported);	chr6:146091559	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.875	rs1412080	ENSG00000235652.6	RP11-545I5.3	8.77	3.51e-17	2.26e-14	0.39	0.38	Lobe attachment (rater-scored or self-reported);	chr6:146096168	chr6:145799409~145886585:+
PRAD	cis	rs5769707	0.681	rs4824068	ENSG00000188511.11	C22orf34	8.77	3.53e-17	2.27e-14	0.45	0.38	Monocyte percentage of white cells;Monocyte count;	chr22:49631153	chr22:49414524~49657542:-
PRAD	cis	rs6452524	1	rs4591730	ENSG00000249664.1	CTD-2227C6.2	8.77	3.53e-17	2.27e-14	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83151983	chr5:83012285~83013109:-
PRAD	cis	rs6452524	1	rs1031902	ENSG00000249664.1	CTD-2227C6.2	8.77	3.53e-17	2.27e-14	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83152308	chr5:83012285~83013109:-
PRAD	cis	rs2638953	0.779	rs61920241	ENSG00000278733.1	RP11-425D17.1	-8.77	3.54e-17	2.28e-14	-0.46	-0.38	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195184	chr12:28185625~28186190:-
PRAD	cis	rs1930961	1	rs6004669	ENSG00000272798.1	CTA-390C10.9	-8.77	3.55e-17	2.29e-14	-0.6	-0.38	Bipolar disorder with mood-incongruent psychosis;	chr22:25479836	chr22:25436312~25436915:+
PRAD	cis	rs1930961	1	rs997872	ENSG00000272798.1	CTA-390C10.9	-8.77	3.55e-17	2.29e-14	-0.6	-0.38	Bipolar disorder with mood-incongruent psychosis;	chr22:25482647	chr22:25436312~25436915:+
PRAD	cis	rs6991838	0.702	rs13274205	ENSG00000272010.1	CTD-3025N20.3	8.77	3.55e-17	2.29e-14	0.37	0.38	Intelligence (multi-trait analysis);	chr8:65708124	chr8:65591850~65592472:-
PRAD	cis	rs2412819	0.571	rs7174260	ENSG00000205771.5	CATSPER2P1	-8.77	3.57e-17	2.3e-14	-0.55	-0.38	Lung cancer;	chr15:43751988	chr15:43726918~43747094:-
PRAD	cis	rs17012589	0.639	rs10779158	ENSG00000258815.1	RP11-408B11.2	-8.77	3.57e-17	2.3e-14	-0.52	-0.38	Bone mineral density (Ward's triangle area);	chr12:85330318	chr12:85318060~85342912:+
PRAD	cis	rs526231	0.511	rs7731395	ENSG00000175749.11	EIF3KP1	8.77	3.58e-17	2.3e-14	0.5	0.38	Primary biliary cholangitis;	chr5:103026057	chr5:103032376~103033031:+
PRAD	cis	rs12468226	0.81	rs115255999	ENSG00000273456.1	RP11-686O6.2	8.77	3.58e-17	2.31e-14	0.52	0.38	Urate levels;	chr2:202572326	chr2:202374932~202375604:-
PRAD	cis	rs10463554	0.927	rs34798	ENSG00000175749.11	EIF3KP1	8.77	3.6e-17	2.31e-14	0.59	0.38	Parkinson's disease;	chr5:103090047	chr5:103032376~103033031:+
PRAD	cis	rs1979679	0.842	rs11049380	ENSG00000278733.1	RP11-425D17.1	8.77	3.61e-17	2.32e-14	0.49	0.38	Ossification of the posterior longitudinal ligament of the spine;	chr12:28160904	chr12:28185625~28186190:-
PRAD	cis	rs2282300	1	rs12575085	ENSG00000254532.1	RP11-624D11.2	8.77	3.62e-17	2.33e-14	0.52	0.38	Morning vs. evening chronotype;	chr11:30406715	chr11:30044058~30084343:-
PRAD	cis	rs950169	0.881	rs72750843	ENSG00000225151.9	GOLGA2P7	-8.77	3.63e-17	2.33e-14	-0.54	-0.38	Schizophrenia;	chr15:84592552	chr15:84199311~84230136:-
PRAD	cis	rs8072100	0.967	rs4239162	ENSG00000228782.6	CTD-2026D20.3	8.77	3.63e-17	2.34e-14	0.42	0.38	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47678444	chr17:47450568~47492492:-
PRAD	cis	rs67311347	1	rs9822909	ENSG00000223797.4	ENTPD3-AS1	8.77	3.64e-17	2.34e-14	0.36	0.38	Renal cell carcinoma;	chr3:40415593	chr3:40313802~40453329:-
PRAD	cis	rs11098499	0.954	rs6838814	ENSG00000245958.5	RP11-33B1.1	-8.77	3.64e-17	2.34e-14	-0.38	-0.38	Corneal astigmatism;	chr4:119471288	chr4:119454791~119552025:+
PRAD	cis	rs4713118	0.513	rs149897	ENSG00000280107.1	AL022393.9	-8.77	3.64e-17	2.34e-14	-0.46	-0.38	Parkinson's disease;	chr6:28038872	chr6:28170845~28172521:+
PRAD	cis	rs1930961	1	rs6004667	ENSG00000272798.1	CTA-390C10.9	8.77	3.65e-17	2.35e-14	0.61	0.38	Bipolar disorder with mood-incongruent psychosis;	chr22:25478497	chr22:25436312~25436915:+
PRAD	cis	rs8042680	0.522	rs1867225	ENSG00000214432.8	AC068831.10	-8.77	3.66e-17	2.35e-14	-0.45	-0.38	Type 2 diabetes;	chr15:91020599	chr15:91022619~91036611:+
PRAD	cis	rs2274273	0.87	rs6573009	ENSG00000258413.1	RP11-665C16.6	-8.77	3.66e-17	2.35e-14	-0.5	-0.38	Protein biomarker;	chr14:55215606	chr14:55262767~55272075:-
PRAD	cis	rs7772486	0.875	rs2073287	ENSG00000235652.6	RP11-545I5.3	8.77	3.68e-17	2.37e-14	0.38	0.38	Lobe attachment (rater-scored or self-reported);	chr6:146029128	chr6:145799409~145886585:+
PRAD	cis	rs4964805	0.683	rs12424737	ENSG00000257681.1	RP11-341G23.4	8.77	3.68e-17	2.37e-14	0.34	0.38	Attention deficit hyperactivity disorder;	chr12:103802443	chr12:103746315~103768858:-
PRAD	cis	rs4713118	0.513	rs156734	ENSG00000280107.1	AL022393.9	-8.77	3.7e-17	2.38e-14	-0.46	-0.38	Parkinson's disease;	chr6:28039579	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.662	rs9380046	ENSG00000219392.1	RP1-265C24.5	-8.77	3.7e-17	2.38e-14	-0.49	-0.38	Parkinson's disease;	chr6:28062721	chr6:28115628~28116551:+
PRAD	cis	rs9399135	0.743	rs7745098	ENSG00000232876.1	CTA-212D2.2	-8.77	3.7e-17	2.38e-14	-0.49	-0.38	Red blood cell count;	chr6:135093866	chr6:135055033~135060550:+
PRAD	cis	rs7826238	0.594	rs2948285	ENSG00000253893.2	FAM85B	-8.77	3.72e-17	2.39e-14	-0.48	-0.38	Systolic blood pressure;	chr8:8273016	chr8:8167819~8226614:-
PRAD	cis	rs1823874	0.962	rs12906206	ENSG00000182397.13	DNM1P46	-8.77	3.72e-17	2.39e-14	-0.36	-0.38	IgG glycosylation;	chr15:99818921	chr15:99790156~99806927:-
PRAD	cis	rs7849270	0.76	rs1075650	ENSG00000268707.1	RP11-247A12.7	8.77	3.73e-17	2.4e-14	0.45	0.38	Blood metabolite ratios;	chr9:129176634	chr9:129170434~129170940:+
PRAD	cis	rs853679	0.55	rs1225598	ENSG00000226314.6	ZNF192P1	-8.77	3.74e-17	2.4e-14	-0.51	-0.38	Depression;	chr6:28193021	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.55	rs1150689	ENSG00000226314.6	ZNF192P1	-8.77	3.74e-17	2.4e-14	-0.51	-0.38	Depression;	chr6:28197321	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.55	rs1225599	ENSG00000226314.6	ZNF192P1	-8.77	3.74e-17	2.4e-14	-0.51	-0.38	Depression;	chr6:28197412	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.574	rs1233705	ENSG00000226314.6	ZNF192P1	-8.77	3.74e-17	2.4e-14	-0.51	-0.38	Depression;	chr6:28198669	chr6:28161781~28169594:+
PRAD	cis	rs875971	1	rs6963646	ENSG00000237310.1	GS1-124K5.4	-8.76	3.75e-17	2.41e-14	-0.34	-0.38	Aortic root size;	chr7:66220780	chr7:66493706~66495474:+
PRAD	cis	rs853679	0.517	rs9295761	ENSG00000226314.6	ZNF192P1	-8.76	3.75e-17	2.41e-14	-0.52	-0.38	Depression;	chr6:28180209	chr6:28161781~28169594:+
PRAD	cis	rs4713118	0.662	rs149961	ENSG00000226314.6	ZNF192P1	-8.76	3.75e-17	2.41e-14	-0.52	-0.38	Parkinson's disease;	chr6:28047791	chr6:28161781~28169594:+
PRAD	cis	rs17012589	0.592	rs4761130	ENSG00000258815.1	RP11-408B11.2	-8.76	3.75e-17	2.41e-14	-0.52	-0.38	Bone mineral density (Ward's triangle area);	chr12:85308487	chr12:85318060~85342912:+
PRAD	cis	rs17608059	0.901	rs11078215	ENSG00000141028.6	CDRT15P1	-8.76	3.76e-17	2.42e-14	-0.49	-0.38	Temperament;	chr17:14003617	chr17:14024514~14025488:+
PRAD	cis	rs7712401	0.623	rs426877	ENSG00000263432.2	RN7SL689P	-8.76	3.77e-17	2.42e-14	-0.39	-0.38	Mean platelet volume;	chr5:122978940	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.601	rs34233716	ENSG00000263432.2	RN7SL689P	-8.76	3.77e-17	2.42e-14	-0.39	-0.38	Mean platelet volume;	chr5:122980670	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.54	rs416763	ENSG00000263432.2	RN7SL689P	-8.76	3.77e-17	2.42e-14	-0.39	-0.38	Mean platelet volume;	chr5:122981546	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.601	rs35339188	ENSG00000263432.2	RN7SL689P	-8.76	3.77e-17	2.42e-14	-0.39	-0.38	Mean platelet volume;	chr5:122981990	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.601	rs36099390	ENSG00000263432.2	RN7SL689P	-8.76	3.77e-17	2.42e-14	-0.39	-0.38	Mean platelet volume;	chr5:122982024	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.601	rs35157167	ENSG00000263432.2	RN7SL689P	-8.76	3.77e-17	2.42e-14	-0.39	-0.38	Mean platelet volume;	chr5:122982506	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.601	rs396941	ENSG00000263432.2	RN7SL689P	-8.76	3.77e-17	2.42e-14	-0.39	-0.38	Mean platelet volume;	chr5:122982570	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.58	rs439739	ENSG00000263432.2	RN7SL689P	-8.76	3.77e-17	2.42e-14	-0.39	-0.38	Mean platelet volume;	chr5:122982726	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.601	rs371604	ENSG00000263432.2	RN7SL689P	-8.76	3.77e-17	2.42e-14	-0.39	-0.38	Mean platelet volume;	chr5:122982737	chr5:123022487~123022783:-
PRAD	cis	rs1501911	0.53	rs326468	ENSG00000248489.1	CTD-2007H13.3	8.76	3.77e-17	2.42e-14	0.42	0.38	Lung function (FEV1/FVC);	chr5:98897105	chr5:98929171~98995013:+
PRAD	cis	rs5769707	0.681	rs2071902	ENSG00000188511.11	C22orf34	8.76	3.81e-17	2.44e-14	0.45	0.38	Monocyte percentage of white cells;Monocyte count;	chr22:49640890	chr22:49414524~49657542:-
PRAD	cis	rs1075265	0.836	rs10208233	ENSG00000233266.1	HMGB1P31	8.76	3.83e-17	2.46e-14	0.52	0.38	Chronotype;Morning vs. evening chronotype;	chr2:54066433	chr2:54051334~54051760:+
PRAD	cis	rs7189233	0.531	rs1978337	ENSG00000279344.1	RP11-44F14.7	8.76	3.84e-17	2.46e-14	0.35	0.38	Intelligence (multi-trait analysis);	chr16:53425833	chr16:53478957~53481550:-
PRAD	cis	rs1075232	1	rs12439239	ENSG00000270055.1	CTD-3092A11.2	-8.76	3.85e-17	2.47e-14	-0.79	-0.38	Survival in colorectal cancer (non-distant metastatic);	chr15:31359515	chr15:30487963~30490313:+
PRAD	cis	rs2638953	0.924	rs7957382	ENSG00000278733.1	RP11-425D17.1	8.76	3.87e-17	2.48e-14	0.46	0.38	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28203643	chr12:28185625~28186190:-
PRAD	cis	rs7727544	0.716	rs4594848	ENSG00000233006.5	AC034220.3	8.76	3.88e-17	2.49e-14	0.34	0.38	Blood metabolite levels;	chr5:132250905	chr5:132311285~132369916:-
PRAD	cis	rs853679	1	rs1419183	ENSG00000280107.1	AL022393.9	-8.76	3.89e-17	2.49e-14	-0.57	-0.38	Depression;	chr6:28275017	chr6:28170845~28172521:+
PRAD	cis	rs193541	0.632	rs10037044	ENSG00000263432.2	RN7SL689P	-8.76	3.89e-17	2.49e-14	-0.41	-0.38	Glucose homeostasis traits;	chr5:122787604	chr5:123022487~123022783:-
PRAD	cis	rs4964805	0.657	rs11111783	ENSG00000257681.1	RP11-341G23.4	8.76	3.89e-17	2.5e-14	0.34	0.38	Attention deficit hyperactivity disorder;	chr12:103794745	chr12:103746315~103768858:-
PRAD	cis	rs6452524	1	rs11740478	ENSG00000249664.1	CTD-2227C6.2	8.76	3.89e-17	2.5e-14	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83150567	chr5:83012285~83013109:-
PRAD	cis	rs4927850	0.752	rs7618864	ENSG00000242086.7	LINC00969	8.76	3.91e-17	2.51e-14	0.33	0.38	Pancreatic cancer;	chr3:196022690	chr3:195658062~195739964:+
PRAD	cis	rs150992	0.609	rs7711061	ENSG00000248489.1	CTD-2007H13.3	-8.76	3.91e-17	2.51e-14	-0.41	-0.38	Body mass index;	chr5:99003535	chr5:98929171~98995013:+
PRAD	cis	rs2564921	0.666	rs11130335	ENSG00000242142.1	SERBP1P3	-8.76	3.93e-17	2.52e-14	-0.44	-0.38	Height;	chr3:52989619	chr3:53064283~53065091:-
PRAD	cis	rs11673344	0.704	rs571340	ENSG00000226686.6	LINC01535	8.76	3.93e-17	2.52e-14	0.53	0.38	Obesity-related traits;	chr19:36933981	chr19:37251912~37265535:+
PRAD	cis	rs12049351	0.509	rs7521083	ENSG00000229367.1	HMGN2P19	8.76	3.94e-17	2.52e-14	0.6	0.38	Circulating myeloperoxidase levels (plasma);	chr1:229429457	chr1:229570532~229570796:+
PRAD	cis	rs17012589	0.639	rs10862966	ENSG00000258815.1	RP11-408B11.2	-8.76	3.94e-17	2.52e-14	-0.52	-0.38	Bone mineral density (Ward's triangle area);	chr12:85311477	chr12:85318060~85342912:+
PRAD	cis	rs17711722	0.503	rs453835	ENSG00000228409.4	CCT6P1	8.76	3.95e-17	2.53e-14	0.28	0.38	Calcium levels;	chr7:66046172	chr7:65751142~65763354:+
PRAD	cis	rs4835473	0.932	rs4287958	ENSG00000251600.4	RP11-673E1.1	8.76	3.95e-17	2.53e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143987719	chr4:143912331~143982454:+
PRAD	cis	rs765787	0.53	rs11636395	ENSG00000259520.4	CTD-2651B20.3	8.76	3.95e-17	2.53e-14	0.47	0.38	Uric acid levels;	chr15:45243486	chr15:45251580~45279251:-
PRAD	cis	rs507080	0.769	rs7389	ENSG00000255422.1	AP002954.4	8.76	3.98e-17	2.55e-14	0.47	0.38	Serum metabolite levels;	chr11:118657756	chr11:118704607~118750263:+
PRAD	cis	rs875971	1	rs11974219	ENSG00000237310.1	GS1-124K5.4	-8.76	3.98e-17	2.55e-14	-0.34	-0.38	Aortic root size;	chr7:66182423	chr7:66493706~66495474:+
PRAD	cis	rs875971	1	rs1565531	ENSG00000237310.1	GS1-124K5.4	-8.76	3.98e-17	2.55e-14	-0.34	-0.38	Aortic root size;	chr7:66198126	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.965	rs28682868	ENSG00000237310.1	GS1-124K5.4	-8.76	3.98e-17	2.55e-14	-0.34	-0.38	Aortic root size;	chr7:66224822	chr7:66493706~66495474:+
PRAD	cis	rs150992	0.574	rs2927655	ENSG00000248489.1	CTD-2007H13.3	8.76	3.98e-17	2.55e-14	0.43	0.38	Body mass index;	chr5:98839049	chr5:98929171~98995013:+
PRAD	cis	rs11096990	0.572	rs35040563	ENSG00000249207.1	RP11-360F5.1	-8.76	3.99e-17	2.55e-14	-0.4	-0.38	Cognitive function;	chr4:39154262	chr4:39112677~39126818:-
PRAD	cis	rs7181230	0.885	rs28736699	ENSG00000275636.1	RP11-521C20.5	8.76	3.99e-17	2.56e-14	0.55	0.38	Dehydroepiandrosterone sulphate levels;	chr15:40055234	chr15:40078892~40079347:+
PRAD	cis	rs853679	0.585	rs201001	ENSG00000280107.1	AL022393.9	-8.76	4e-17	2.56e-14	-0.52	-0.38	Depression;	chr6:27841121	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.585	rs201000	ENSG00000280107.1	AL022393.9	-8.76	4e-17	2.56e-14	-0.52	-0.38	Depression;	chr6:27841381	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.723	rs9366718	ENSG00000280107.1	AL022393.9	-8.76	4e-17	2.57e-14	-0.52	-0.38	Depression;	chr6:28237724	chr6:28170845~28172521:+
PRAD	cis	rs2019137	0.868	rs6755639	ENSG00000274877.1	RP11-65I12.1	-8.76	4.03e-17	2.58e-14	-0.48	-0.38	Lymphocyte counts;	chr2:113224233	chr2:113237595~113240825:+
PRAD	cis	rs4964805	0.657	rs1866293	ENSG00000257681.1	RP11-341G23.4	8.76	4.03e-17	2.58e-14	0.34	0.38	Attention deficit hyperactivity disorder;	chr12:103792877	chr12:103746315~103768858:-
PRAD	cis	rs4964805	0.657	rs1866294	ENSG00000257681.1	RP11-341G23.4	8.76	4.03e-17	2.58e-14	0.34	0.38	Attention deficit hyperactivity disorder;	chr12:103793017	chr12:103746315~103768858:-
PRAD	cis	rs4964805	0.71	rs1866296	ENSG00000257681.1	RP11-341G23.4	8.76	4.03e-17	2.58e-14	0.34	0.38	Attention deficit hyperactivity disorder;	chr12:103793314	chr12:103746315~103768858:-
PRAD	cis	rs6452524	0.967	rs2974443	ENSG00000249664.1	CTD-2227C6.2	8.75	4.04e-17	2.58e-14	0.45	0.38	Hypertension (SNP x SNP interaction);	chr5:83184595	chr5:83012285~83013109:-
PRAD	cis	rs6452524	0.967	rs2974441	ENSG00000249664.1	CTD-2227C6.2	8.75	4.04e-17	2.58e-14	0.45	0.38	Hypertension (SNP x SNP interaction);	chr5:83193330	chr5:83012285~83013109:-
PRAD	cis	rs6847067	0.696	rs13114115	ENSG00000180769.7	WDFY3-AS2	8.75	4.05e-17	2.6e-14	0.4	0.38	Oropharynx cancer;	chr4:84911274	chr4:84965682~85011277:+
PRAD	cis	rs8062405	0.756	rs151301	ENSG00000251417.2	RP11-1348G14.4	-8.75	4.06e-17	2.6e-14	-0.43	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28485738	chr16:28802743~28817828:+
PRAD	cis	rs673078	0.607	rs882927	ENSG00000275409.1	RP11-131L12.4	-8.75	4.06e-17	2.6e-14	-0.53	-0.38	Glucose homeostasis traits;	chr12:118406737	chr12:118430147~118430699:+
PRAD	cis	rs950169	1	rs1911155	ENSG00000259728.4	LINC00933	8.75	4.07e-17	2.61e-14	0.45	0.38	Schizophrenia;	chr15:84118883	chr15:84570649~84580175:+
PRAD	cis	rs875971	1	rs875971	ENSG00000237310.1	GS1-124K5.4	-8.75	4.09e-17	2.61e-14	-0.34	-0.38	Aortic root size;	chr7:66152608	chr7:66493706~66495474:+
PRAD	cis	rs9389248	0.69	rs1028314	ENSG00000232876.1	CTA-212D2.2	8.75	4.1e-17	2.62e-14	0.47	0.38	High light scatter reticulocyte percentage of red cells;	chr6:134934572	chr6:135055033~135060550:+
PRAD	cis	rs748404	0.66	rs2467741	ENSG00000249839.1	AC011330.5	-8.75	4.11e-17	2.63e-14	-0.46	-0.38	Lung cancer;	chr15:43450428	chr15:43663654~43684339:-
PRAD	cis	rs11098499	0.954	rs35091806	ENSG00000245958.5	RP11-33B1.1	-8.75	4.11e-17	2.63e-14	-0.38	-0.38	Corneal astigmatism;	chr4:119404374	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.954	rs6846442	ENSG00000245958.5	RP11-33B1.1	-8.75	4.11e-17	2.63e-14	-0.38	-0.38	Corneal astigmatism;	chr4:119405168	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.738	rs34566984	ENSG00000245958.5	RP11-33B1.1	-8.75	4.11e-17	2.63e-14	-0.38	-0.38	Corneal astigmatism;	chr4:119440115	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.738	rs34965784	ENSG00000245958.5	RP11-33B1.1	-8.75	4.11e-17	2.63e-14	-0.38	-0.38	Corneal astigmatism;	chr4:119440431	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.954	rs9685777	ENSG00000245958.5	RP11-33B1.1	-8.75	4.11e-17	2.63e-14	-0.38	-0.38	Corneal astigmatism;	chr4:119444810	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.954	rs71614438	ENSG00000245958.5	RP11-33B1.1	-8.75	4.11e-17	2.63e-14	-0.38	-0.38	Corneal astigmatism;	chr4:119450097	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.954	rs66506550	ENSG00000245958.5	RP11-33B1.1	-8.75	4.11e-17	2.63e-14	-0.38	-0.38	Corneal astigmatism;	chr4:119450290	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.909	rs7659501	ENSG00000245958.5	RP11-33B1.1	-8.75	4.11e-17	2.63e-14	-0.38	-0.38	Corneal astigmatism;	chr4:119450397	chr4:119454791~119552025:+
PRAD	cis	rs11148252	0.846	rs7323666	ENSG00000278238.1	RP11-245D16.4	-8.75	4.12e-17	2.63e-14	-0.44	-0.38	Lewy body disease;	chr13:52431923	chr13:52454775~52455331:-
PRAD	cis	rs321358	0.945	rs10502130	ENSG00000271584.1	RP11-89C3.4	8.75	4.13e-17	2.64e-14	0.59	0.38	Body mass index;	chr11:111107437	chr11:111091932~111097357:-
PRAD	cis	rs321358	0.945	rs73017109	ENSG00000271584.1	RP11-89C3.4	8.75	4.13e-17	2.64e-14	0.59	0.38	Body mass index;	chr11:111108484	chr11:111091932~111097357:-
PRAD	cis	rs321358	0.887	rs1470537	ENSG00000271584.1	RP11-89C3.4	8.75	4.13e-17	2.64e-14	0.59	0.38	Body mass index;	chr11:111109328	chr11:111091932~111097357:-
PRAD	cis	rs321358	0.945	rs12421769	ENSG00000271584.1	RP11-89C3.4	8.75	4.13e-17	2.64e-14	0.59	0.38	Body mass index;	chr11:111109500	chr11:111091932~111097357:-
PRAD	cis	rs321358	0.945	rs73017114	ENSG00000271584.1	RP11-89C3.4	8.75	4.13e-17	2.64e-14	0.59	0.38	Body mass index;	chr11:111111582	chr11:111091932~111097357:-
PRAD	cis	rs321358	0.945	rs17458493	ENSG00000271584.1	RP11-89C3.4	8.75	4.13e-17	2.64e-14	0.59	0.38	Body mass index;	chr11:111112156	chr11:111091932~111097357:-
PRAD	cis	rs321358	0.945	rs17458541	ENSG00000271584.1	RP11-89C3.4	8.75	4.13e-17	2.64e-14	0.59	0.38	Body mass index;	chr11:111113182	chr11:111091932~111097357:-
PRAD	cis	rs321358	0.836	rs17458597	ENSG00000271584.1	RP11-89C3.4	8.75	4.13e-17	2.64e-14	0.59	0.38	Body mass index;	chr11:111113599	chr11:111091932~111097357:-
PRAD	cis	rs321358	0.945	rs73017176	ENSG00000271584.1	RP11-89C3.4	8.75	4.13e-17	2.64e-14	0.59	0.38	Body mass index;	chr11:111113879	chr11:111091932~111097357:-
PRAD	cis	rs321358	0.887	rs80221187	ENSG00000271584.1	RP11-89C3.4	8.75	4.13e-17	2.64e-14	0.59	0.38	Body mass index;	chr11:111113977	chr11:111091932~111097357:-
PRAD	cis	rs321358	0.945	rs73017177	ENSG00000271584.1	RP11-89C3.4	8.75	4.13e-17	2.64e-14	0.59	0.38	Body mass index;	chr11:111114034	chr11:111091932~111097357:-
PRAD	cis	rs321358	0.895	rs73017179	ENSG00000271584.1	RP11-89C3.4	8.75	4.13e-17	2.64e-14	0.59	0.38	Body mass index;	chr11:111114037	chr11:111091932~111097357:-
PRAD	cis	rs321358	0.945	rs1356411	ENSG00000271584.1	RP11-89C3.4	8.75	4.13e-17	2.64e-14	0.59	0.38	Body mass index;	chr11:111115371	chr11:111091932~111097357:-
PRAD	cis	rs321358	0.945	rs17537360	ENSG00000271584.1	RP11-89C3.4	8.75	4.13e-17	2.64e-14	0.59	0.38	Body mass index;	chr11:111116921	chr11:111091932~111097357:-
PRAD	cis	rs321358	0.945	rs17537367	ENSG00000271584.1	RP11-89C3.4	8.75	4.13e-17	2.64e-14	0.59	0.38	Body mass index;	chr11:111117008	chr11:111091932~111097357:-
PRAD	cis	rs321358	0.945	rs17458885	ENSG00000271584.1	RP11-89C3.4	8.75	4.13e-17	2.64e-14	0.59	0.38	Body mass index;	chr11:111117222	chr11:111091932~111097357:-
PRAD	cis	rs321358	0.945	rs7931995	ENSG00000271584.1	RP11-89C3.4	8.75	4.13e-17	2.64e-14	0.59	0.38	Body mass index;	chr11:111117691	chr11:111091932~111097357:-
PRAD	cis	rs11098499	0.954	rs10518331	ENSG00000245958.5	RP11-33B1.1	-8.75	4.13e-17	2.64e-14	-0.38	-0.38	Corneal astigmatism;	chr4:119402440	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.954	rs13133522	ENSG00000245958.5	RP11-33B1.1	-8.75	4.13e-17	2.64e-14	-0.38	-0.38	Corneal astigmatism;	chr4:119403269	chr4:119454791~119552025:+
PRAD	cis	rs812925	0.512	rs7558954	ENSG00000271889.1	RP11-493E12.1	8.75	4.15e-17	2.65e-14	0.42	0.38	Immature fraction of reticulocytes;	chr2:61157771	chr2:61151433~61162105:-
PRAD	cis	rs875971	1	rs1544549	ENSG00000237310.1	GS1-124K5.4	-8.75	4.16e-17	2.65e-14	-0.34	-0.38	Aortic root size;	chr7:66625676	chr7:66493706~66495474:+
PRAD	cis	rs11098499	0.779	rs28495013	ENSG00000245958.5	RP11-33B1.1	-8.75	4.16e-17	2.66e-14	-0.38	-0.38	Corneal astigmatism;	chr4:119454676	chr4:119454791~119552025:+
PRAD	cis	rs1062177	1	rs2915887	ENSG00000253921.1	CTB-113P19.3	-8.75	4.16e-17	2.66e-14	-0.51	-0.38	Preschool internalizing problems;	chr5:151825943	chr5:151753992~151767247:+
PRAD	cis	rs853679	0.506	rs1150693	ENSG00000219392.1	RP1-265C24.5	-8.75	4.16e-17	2.66e-14	-0.5	-0.38	Depression;	chr6:28206812	chr6:28115628~28116551:+
PRAD	cis	rs3096299	0.967	rs2965827	ENSG00000274627.1	RP11-104N10.2	-8.75	4.17e-17	2.66e-14	-0.39	-0.38	Multiple myeloma (IgH translocation);	chr16:89390942	chr16:89516797~89522217:+
PRAD	cis	rs6723108	0.517	rs1530557	ENSG00000224043.6	CCNT2-AS1	8.75	4.17e-17	2.66e-14	0.52	0.38	Type 2 diabetes;	chr2:134849309	chr2:134735464~134918710:-
PRAD	cis	rs11098499	0.779	rs80242894	ENSG00000245958.5	RP11-33B1.1	-8.75	4.18e-17	2.67e-14	-0.38	-0.38	Corneal astigmatism;	chr4:119454597	chr4:119454791~119552025:+
PRAD	cis	rs4835473	0.897	rs13144504	ENSG00000251600.4	RP11-673E1.1	-8.75	4.18e-17	2.67e-14	-0.49	-0.38	Immature fraction of reticulocytes;	chr4:143707402	chr4:143912331~143982454:+
PRAD	cis	rs67311347	0.822	rs11709089	ENSG00000223797.4	ENTPD3-AS1	8.75	4.19e-17	2.68e-14	0.35	0.38	Renal cell carcinoma;	chr3:40309993	chr3:40313802~40453329:-
PRAD	cis	rs67311347	0.866	rs9826419	ENSG00000223797.4	ENTPD3-AS1	8.75	4.19e-17	2.68e-14	0.35	0.38	Renal cell carcinoma;	chr3:40310560	chr3:40313802~40453329:-
PRAD	cis	rs67311347	0.866	rs3214006	ENSG00000223797.4	ENTPD3-AS1	8.75	4.19e-17	2.68e-14	0.35	0.38	Renal cell carcinoma;	chr3:40310643	chr3:40313802~40453329:-
PRAD	cis	rs6570726	0.905	rs430248	ENSG00000235652.6	RP11-545I5.3	8.75	4.21e-17	2.69e-14	0.4	0.38	Lobe attachment (rater-scored or self-reported);	chr6:145552968	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.935	rs406343	ENSG00000235652.6	RP11-545I5.3	8.75	4.21e-17	2.69e-14	0.4	0.38	Lobe attachment (rater-scored or self-reported);	chr6:145553252	chr6:145799409~145886585:+
PRAD	cis	rs3809863	0.602	rs7225700	ENSG00000228782.6	CTD-2026D20.3	8.75	4.21e-17	2.69e-14	0.44	0.38	Glaucoma (primary open-angle);	chr17:47314438	chr17:47450568~47492492:-
PRAD	cis	rs748404	0.66	rs493377	ENSG00000249839.1	AC011330.5	-8.75	4.22e-17	2.7e-14	-0.46	-0.38	Lung cancer;	chr15:43481269	chr15:43663654~43684339:-
PRAD	cis	rs6452524	0.967	rs2974444	ENSG00000249664.1	CTD-2227C6.2	8.75	4.23e-17	2.7e-14	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83185174	chr5:83012285~83013109:-
PRAD	cis	rs6452524	0.967	rs2940542	ENSG00000249664.1	CTD-2227C6.2	8.75	4.23e-17	2.7e-14	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83185734	chr5:83012285~83013109:-
PRAD	cis	rs6570726	0.935	rs408768	ENSG00000235652.6	RP11-545I5.3	8.75	4.24e-17	2.71e-14	0.4	0.38	Lobe attachment (rater-scored or self-reported);	chr6:145550599	chr6:145799409~145886585:+
PRAD	cis	rs12280210	0.557	rs11216225	ENSG00000254851.1	RP11-109L13.1	8.75	4.24e-17	2.71e-14	0.73	0.38	Lobe attachment (rater-scored or self-reported);	chr11:117007298	chr11:117135528~117138582:+
PRAD	cis	rs7712401	0.601	rs442427	ENSG00000263432.2	RN7SL689P	-8.75	4.24e-17	2.71e-14	-0.39	-0.38	Mean platelet volume;	chr5:122986570	chr5:123022487~123022783:-
PRAD	cis	rs4713118	0.824	rs7759217	ENSG00000280107.1	AL022393.9	-8.75	4.24e-17	2.71e-14	-0.48	-0.38	Parkinson's disease;	chr6:27762684	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.784	rs9468219	ENSG00000280107.1	AL022393.9	-8.75	4.24e-17	2.71e-14	-0.48	-0.38	Parkinson's disease;	chr6:27763976	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.824	rs9366702	ENSG00000280107.1	AL022393.9	-8.75	4.24e-17	2.71e-14	-0.48	-0.38	Parkinson's disease;	chr6:27766691	chr6:28170845~28172521:+
PRAD	cis	rs4835473	0.864	rs2323418	ENSG00000251600.4	RP11-673E1.1	8.75	4.24e-17	2.71e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143969141	chr4:143912331~143982454:+
PRAD	cis	rs7772486	0.806	rs2247317	ENSG00000235652.6	RP11-545I5.3	8.75	4.25e-17	2.71e-14	0.39	0.38	Lobe attachment (rater-scored or self-reported);	chr6:145896434	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.776	rs4316025	ENSG00000235652.6	RP11-545I5.3	-8.75	4.25e-17	2.71e-14	-0.39	-0.38	Lobe attachment (rater-scored or self-reported);	chr6:145916896	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.806	rs4075696	ENSG00000235652.6	RP11-545I5.3	-8.75	4.25e-17	2.71e-14	-0.39	-0.38	Lobe attachment (rater-scored or self-reported);	chr6:145929811	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.935	rs407721	ENSG00000235652.6	RP11-545I5.3	8.75	4.27e-17	2.73e-14	0.4	0.38	Lobe attachment (rater-scored or self-reported);	chr6:145550218	chr6:145799409~145886585:+
PRAD	cis	rs2638953	0.924	rs11049471	ENSG00000278733.1	RP11-425D17.1	-8.75	4.28e-17	2.73e-14	-0.45	-0.38	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28228259	chr12:28185625~28186190:-
PRAD	cis	rs62103177	0.525	rs9949598	ENSG00000261126.6	RP11-795F19.1	-8.75	4.29e-17	2.74e-14	-0.48	-0.38	Opioid sensitivity;	chr18:79993037	chr18:80046900~80095482:+
PRAD	cis	rs673078	0.66	rs76842574	ENSG00000275409.1	RP11-131L12.4	-8.75	4.3e-17	2.74e-14	-0.47	-0.38	Glucose homeostasis traits;	chr12:118371789	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.615	rs56324376	ENSG00000275409.1	RP11-131L12.4	-8.75	4.3e-17	2.74e-14	-0.47	-0.38	Glucose homeostasis traits;	chr12:118372134	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.607	rs4766899	ENSG00000275409.1	RP11-131L12.4	-8.75	4.3e-17	2.74e-14	-0.47	-0.38	Glucose homeostasis traits;	chr12:118374888	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.607	rs10850967	ENSG00000275409.1	RP11-131L12.4	-8.75	4.3e-17	2.74e-14	-0.47	-0.38	Glucose homeostasis traits;	chr12:118380072	chr12:118430147~118430699:+
PRAD	cis	rs17361889	0.806	rs17367660	ENSG00000224683.1	RPL36AP29	8.75	4.31e-17	2.75e-14	0.46	0.38	Pediatric bone mineral content (hip);	chr7:16179008	chr7:16208945~16209265:+
PRAD	cis	rs321358	0.945	rs10502129	ENSG00000271584.1	RP11-89C3.4	8.75	4.32e-17	2.76e-14	0.59	0.38	Body mass index;	chr11:111107405	chr11:111091932~111097357:-
PRAD	cis	rs321358	0.945	rs12420595	ENSG00000271584.1	RP11-89C3.4	8.75	4.32e-17	2.76e-14	0.59	0.38	Body mass index;	chr11:111115871	chr11:111091932~111097357:-
PRAD	cis	rs853679	1	rs11965538	ENSG00000280107.1	AL022393.9	-8.75	4.33e-17	2.76e-14	-0.57	-0.38	Depression;	chr6:28272137	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.882	rs2743555	ENSG00000280107.1	AL022393.9	-8.75	4.33e-17	2.76e-14	-0.57	-0.38	Depression;	chr6:28273304	chr6:28170845~28172521:+
PRAD	cis	rs11676348	0.808	rs4674267	ENSG00000261338.2	RP11-378A13.1	-8.75	4.34e-17	2.77e-14	-0.42	-0.38	Ulcerative colitis;	chr2:218181714	chr2:218255319~218257366:+
PRAD	cis	rs4835473	0.897	rs2036880	ENSG00000251600.4	RP11-673E1.1	8.75	4.35e-17	2.77e-14	0.47	0.38	Immature fraction of reticulocytes;	chr4:143907834	chr4:143912331~143982454:+
PRAD	cis	rs2412819	0.52	rs17727763	ENSG00000205771.5	CATSPER2P1	-8.75	4.35e-17	2.77e-14	-0.6	-0.38	Lung cancer;	chr15:43623873	chr15:43726918~43747094:-
PRAD	cis	rs367615	0.512	rs246105	ENSG00000249476.1	CTD-2587M2.1	8.74	4.38e-17	2.79e-14	0.46	0.38	Colorectal cancer (SNP x SNP interaction);	chr5:109337245	chr5:109237120~109326369:-
PRAD	cis	rs1979679	0.842	rs60025108	ENSG00000278733.1	RP11-425D17.1	8.74	4.38e-17	2.79e-14	0.48	0.38	Ossification of the posterior longitudinal ligament of the spine;	chr12:28168238	chr12:28185625~28186190:-
PRAD	cis	rs1979679	0.842	rs7487773	ENSG00000278733.1	RP11-425D17.1	8.74	4.38e-17	2.79e-14	0.48	0.38	Ossification of the posterior longitudinal ligament of the spine;	chr12:28168418	chr12:28185625~28186190:-
PRAD	cis	rs6991838	0.584	rs3812412	ENSG00000200714.1	Y_RNA	8.74	4.39e-17	2.8e-14	0.42	0.38	Intelligence (multi-trait analysis);	chr8:65634857	chr8:65592731~65592820:+
PRAD	cis	rs4835473	0.864	rs4835343	ENSG00000251600.4	RP11-673E1.1	8.74	4.4e-17	2.81e-14	0.5	0.38	Immature fraction of reticulocytes;	chr4:143866038	chr4:143912331~143982454:+
PRAD	cis	rs748404	0.66	rs694725	ENSG00000249839.1	AC011330.5	-8.74	4.41e-17	2.81e-14	-0.46	-0.38	Lung cancer;	chr15:43464012	chr15:43663654~43684339:-
PRAD	cis	rs1930961	1	rs6004671	ENSG00000272798.1	CTA-390C10.9	-8.74	4.42e-17	2.82e-14	-0.61	-0.38	Bipolar disorder with mood-incongruent psychosis;	chr22:25483507	chr22:25436312~25436915:+
PRAD	cis	rs1930961	1	rs6004672	ENSG00000272798.1	CTA-390C10.9	-8.74	4.42e-17	2.82e-14	-0.61	-0.38	Bipolar disorder with mood-incongruent psychosis;	chr22:25485046	chr22:25436312~25436915:+
PRAD	cis	rs6991838	0.584	rs7836349	ENSG00000200714.1	Y_RNA	-8.74	4.44e-17	2.83e-14	-0.42	-0.38	Intelligence (multi-trait analysis);	chr8:65591328	chr8:65592731~65592820:+
PRAD	cis	rs4631830	0.863	rs10826125	ENSG00000230869.1	CTGLF10P	-8.74	4.45e-17	2.83e-14	-0.47	-0.38	Prostate-specific antigen levels;	chr10:46065317	chr10:45678692~45700532:+
PRAD	cis	rs4631830	0.863	rs4554834	ENSG00000230869.1	CTGLF10P	-8.74	4.45e-17	2.83e-14	-0.47	-0.38	Prostate-specific antigen levels;	chr10:46065676	chr10:45678692~45700532:+
PRAD	cis	rs11098499	0.954	rs7654587	ENSG00000245958.5	RP11-33B1.1	-8.74	4.45e-17	2.83e-14	-0.38	-0.38	Corneal astigmatism;	chr4:119467251	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.954	rs11098525	ENSG00000245958.5	RP11-33B1.1	-8.74	4.45e-17	2.83e-14	-0.38	-0.38	Corneal astigmatism;	chr4:119468997	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.821	rs10032151	ENSG00000245958.5	RP11-33B1.1	-8.74	4.45e-17	2.83e-14	-0.38	-0.38	Corneal astigmatism;	chr4:119470473	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.865	rs10032158	ENSG00000245958.5	RP11-33B1.1	-8.74	4.45e-17	2.83e-14	-0.38	-0.38	Corneal astigmatism;	chr4:119470477	chr4:119454791~119552025:+
PRAD	cis	rs6538678	0.895	rs4762637	ENSG00000258343.1	RP11-536G4.2	-8.74	4.45e-17	2.84e-14	-0.51	-0.38	Lupus nephritis in systemic lupus erythematosus;	chr12:95888877	chr12:95795345~95858839:-
PRAD	cis	rs6991838	0.584	rs6993876	ENSG00000200714.1	Y_RNA	8.74	4.45e-17	2.84e-14	0.42	0.38	Intelligence (multi-trait analysis);	chr8:65601240	chr8:65592731~65592820:+
PRAD	cis	rs9903692	0.954	rs11079808	ENSG00000278765.1	RP5-890E16.5	-8.74	4.47e-17	2.85e-14	-0.57	-0.38	Pulse pressure;	chr17:48102870	chr17:48066704~48067293:-
PRAD	cis	rs9903692	0.954	rs8077860	ENSG00000278765.1	RP5-890E16.5	-8.74	4.47e-17	2.85e-14	-0.57	-0.38	Pulse pressure;	chr17:48107973	chr17:48066704~48067293:-
PRAD	cis	rs2015599	0.563	rs11050168	ENSG00000257176.2	RP11-996F15.2	8.74	4.47e-17	2.85e-14	0.43	0.38	Platelet count;Mean platelet volume;	chr12:29273760	chr12:29280418~29317848:-
PRAD	cis	rs11098499	0.865	rs28634456	ENSG00000245958.5	RP11-33B1.1	-8.74	4.47e-17	2.85e-14	-0.38	-0.38	Corneal astigmatism;	chr4:119454623	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.909	rs78332141	ENSG00000245958.5	RP11-33B1.1	-8.74	4.47e-17	2.85e-14	-0.38	-0.38	Corneal astigmatism;	chr4:119454627	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.954	rs2389802	ENSG00000245958.5	RP11-33B1.1	-8.74	4.48e-17	2.85e-14	-0.38	-0.38	Corneal astigmatism;	chr4:119404577	chr4:119454791~119552025:+
PRAD	cis	rs6452524	0.967	rs2731861	ENSG00000249664.1	CTD-2227C6.2	8.74	4.51e-17	2.87e-14	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83189445	chr5:83012285~83013109:-
PRAD	cis	rs507080	0.769	rs745663	ENSG00000255422.1	AP002954.4	-8.74	4.51e-17	2.87e-14	-0.47	-0.38	Serum metabolite levels;	chr11:118658886	chr11:118704607~118750263:+
PRAD	cis	rs11676348	0.808	rs61700947	ENSG00000261338.2	RP11-378A13.1	8.74	4.54e-17	2.89e-14	0.42	0.38	Ulcerative colitis;	chr2:218181448	chr2:218255319~218257366:+
PRAD	cis	rs6723108	0.627	rs4954191	ENSG00000224043.6	CCNT2-AS1	-8.74	4.55e-17	2.9e-14	-0.53	-0.38	Type 2 diabetes;	chr2:134854878	chr2:134735464~134918710:-
PRAD	cis	rs1930961	0.702	rs1930966	ENSG00000272942.1	CTA-246H3.12	-8.74	4.57e-17	2.91e-14	-0.72	-0.38	Bipolar disorder with mood-incongruent psychosis;	chr22:25489737	chr22:25434324~25435070:-
PRAD	cis	rs7811142	0.83	rs28495773	ENSG00000242294.5	STAG3L5P	8.74	4.58e-17	2.91e-14	0.26	0.38	Platelet count;	chr7:100345960	chr7:100336079~100351900:+
PRAD	cis	rs4835473	0.932	rs1849115	ENSG00000251600.4	RP11-673E1.1	8.74	4.59e-17	2.92e-14	0.49	0.38	Immature fraction of reticulocytes;	chr4:143989687	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs1473055	ENSG00000251600.4	RP11-673E1.1	8.74	4.61e-17	2.93e-14	0.49	0.38	Immature fraction of reticulocytes;	chr4:143997714	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs4835126	ENSG00000251600.4	RP11-673E1.1	8.74	4.61e-17	2.93e-14	0.49	0.38	Immature fraction of reticulocytes;	chr4:143997740	chr4:143912331~143982454:+
PRAD	cis	rs11155671	0.546	rs1999633	ENSG00000216906.2	RP11-350J20.9	8.74	4.62e-17	2.94e-14	0.49	0.38	Testicular germ cell tumor;	chr6:149866576	chr6:149904243~149906418:+
PRAD	cis	rs11098499	0.954	rs6820115	ENSG00000245958.5	RP11-33B1.1	-8.74	4.63e-17	2.94e-14	-0.36	-0.38	Corneal astigmatism;	chr4:119477027	chr4:119454791~119552025:+
PRAD	cis	rs7396835	1	rs7396835	ENSG00000254851.1	RP11-109L13.1	-8.74	4.63e-17	2.94e-14	-0.71	-0.38	Quantitative traits;	chr11:116813312	chr11:117135528~117138582:+
PRAD	cis	rs4713118	0.513	rs149989	ENSG00000280107.1	AL022393.9	-8.74	4.64e-17	2.95e-14	-0.46	-0.38	Parkinson's disease;	chr6:28030406	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.513	rs149944	ENSG00000280107.1	AL022393.9	-8.74	4.64e-17	2.95e-14	-0.46	-0.38	Parkinson's disease;	chr6:28035040	chr6:28170845~28172521:+
PRAD	cis	rs1979679	0.842	rs981494	ENSG00000278733.1	RP11-425D17.1	-8.74	4.64e-17	2.95e-14	-0.48	-0.38	Ossification of the posterior longitudinal ligament of the spine;	chr12:28172916	chr12:28185625~28186190:-
PRAD	cis	rs1979679	0.842	rs34043014	ENSG00000278733.1	RP11-425D17.1	8.74	4.65e-17	2.96e-14	0.48	0.38	Ossification of the posterior longitudinal ligament of the spine;	chr12:28171359	chr12:28185625~28186190:-
PRAD	cis	rs1979679	0.842	rs10492370	ENSG00000278733.1	RP11-425D17.1	8.74	4.65e-17	2.96e-14	0.48	0.38	Ossification of the posterior longitudinal ligament of the spine;	chr12:28171900	chr12:28185625~28186190:-
PRAD	cis	rs496547	0.719	rs476246	ENSG00000278376.1	RP11-158I9.8	8.74	4.65e-17	2.96e-14	0.34	0.38	Hip minimal joint space width;	chr11:118747211	chr11:118791254~118793137:+
PRAD	cis	rs6061231	0.761	rs2427312	ENSG00000273619.1	RP5-908M14.9	-8.74	4.66e-17	2.96e-14	-0.32	-0.38	Colorectal cancer;	chr20:62395535	chr20:62386303~62386970:-
PRAD	cis	rs4835473	0.932	rs4125545	ENSG00000251600.4	RP11-673E1.1	8.74	4.67e-17	2.97e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143988650	chr4:143912331~143982454:+
PRAD	cis	rs11098499	0.909	rs11723839	ENSG00000245958.5	RP11-33B1.1	-8.74	4.68e-17	2.98e-14	-0.38	-0.38	Corneal astigmatism;	chr4:119378518	chr4:119454791~119552025:+
PRAD	cis	rs2153535	0.518	rs1328859	ENSG00000230939.1	RP11-314C16.1	-8.74	4.69e-17	2.98e-14	-0.46	-0.38	Motion sickness;	chr6:8562582	chr6:8784178~8785445:+
PRAD	cis	rs2153535	0.518	rs6912560	ENSG00000230939.1	RP11-314C16.1	-8.74	4.69e-17	2.98e-14	-0.46	-0.38	Motion sickness;	chr6:8563878	chr6:8784178~8785445:+
PRAD	cis	rs4713118	0.629	rs203888	ENSG00000226314.6	ZNF192P1	-8.74	4.69e-17	2.98e-14	-0.51	-0.38	Parkinson's disease;	chr6:28053811	chr6:28161781~28169594:+
PRAD	cis	rs11098499	0.954	rs67265404	ENSG00000245958.5	RP11-33B1.1	-8.73	4.7e-17	2.98e-14	-0.38	-0.38	Corneal astigmatism;	chr4:119438115	chr4:119454791~119552025:+
PRAD	cis	rs4713118	0.513	rs149941	ENSG00000280107.1	AL022393.9	-8.73	4.71e-17	2.99e-14	-0.46	-0.38	Parkinson's disease;	chr6:28033255	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.513	rs149942	ENSG00000280107.1	AL022393.9	-8.73	4.71e-17	2.99e-14	-0.46	-0.38	Parkinson's disease;	chr6:28033832	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.513	rs149945	ENSG00000280107.1	AL022393.9	-8.73	4.71e-17	2.99e-14	-0.46	-0.38	Parkinson's disease;	chr6:28035075	chr6:28170845~28172521:+
PRAD	cis	rs12817211	0.502	rs12819883	ENSG00000272368.2	RP4-605O3.4	-8.73	4.71e-17	2.99e-14	-0.38	-0.38	Colorectal or endometrial cancer;	chr12:50140005	chr12:50112197~50165618:+
PRAD	cis	rs4835473	0.618	rs12499429	ENSG00000251600.4	RP11-673E1.1	-8.73	4.72e-17	3e-14	-0.5	-0.38	Immature fraction of reticulocytes;	chr4:143889914	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.801	rs28715976	ENSG00000251600.4	RP11-673E1.1	-8.73	4.72e-17	3e-14	-0.5	-0.38	Immature fraction of reticulocytes;	chr4:143891603	chr4:143912331~143982454:+
PRAD	cis	rs1075265	0.636	rs2193683	ENSG00000233266.1	HMGB1P31	8.73	4.75e-17	3.01e-14	0.52	0.38	Chronotype;Morning vs. evening chronotype;	chr2:53695319	chr2:54051334~54051760:+
PRAD	cis	rs6723108	0.603	rs10166142	ENSG00000224043.6	CCNT2-AS1	-8.73	4.77e-17	3.03e-14	-0.52	-0.38	Type 2 diabetes;	chr2:134952752	chr2:134735464~134918710:-
PRAD	cis	rs6723108	0.603	rs3814354	ENSG00000224043.6	CCNT2-AS1	-8.73	4.77e-17	3.03e-14	-0.52	-0.38	Type 2 diabetes;	chr2:134954087	chr2:134735464~134918710:-
PRAD	cis	rs6723108	0.603	rs3769023	ENSG00000224043.6	CCNT2-AS1	-8.73	4.77e-17	3.03e-14	-0.52	-0.38	Type 2 diabetes;	chr2:134956133	chr2:134735464~134918710:-
PRAD	cis	rs6723108	0.603	rs1947112	ENSG00000224043.6	CCNT2-AS1	-8.73	4.77e-17	3.03e-14	-0.52	-0.38	Type 2 diabetes;	chr2:134958387	chr2:134735464~134918710:-
PRAD	cis	rs673078	0.607	rs2036489	ENSG00000275409.1	RP11-131L12.4	-8.73	4.82e-17	3.06e-14	-0.47	-0.38	Glucose homeostasis traits;	chr12:118364643	chr12:118430147~118430699:+
PRAD	cis	rs56080343	0.688	rs10083190	ENSG00000275409.1	RP11-131L12.4	-8.73	4.82e-17	3.06e-14	-0.47	-0.38	Neuroticism;	chr12:118365385	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.607	rs10082823	ENSG00000275409.1	RP11-131L12.4	-8.73	4.82e-17	3.06e-14	-0.47	-0.38	Glucose homeostasis traits;	chr12:118365386	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.607	rs2062519	ENSG00000275409.1	RP11-131L12.4	-8.73	4.82e-17	3.06e-14	-0.47	-0.38	Glucose homeostasis traits;	chr12:118367577	chr12:118430147~118430699:+
PRAD	cis	rs17361889	0.778	rs56033714	ENSG00000224683.1	RPL36AP29	8.73	4.86e-17	3.09e-14	0.45	0.38	Pediatric bone mineral content (hip);	chr7:16171442	chr7:16208945~16209265:+
PRAD	cis	rs950169	0.922	rs11633534	ENSG00000225151.9	GOLGA2P7	-8.73	4.87e-17	3.09e-14	-0.53	-0.38	Schizophrenia;	chr15:84581411	chr15:84199311~84230136:-
PRAD	cis	rs950169	0.65	rs12902052	ENSG00000225151.9	GOLGA2P7	-8.73	4.87e-17	3.09e-14	-0.53	-0.38	Schizophrenia;	chr15:84582607	chr15:84199311~84230136:-
PRAD	cis	rs4927850	0.752	rs7624460	ENSG00000242086.7	LINC00969	8.73	4.87e-17	3.09e-14	0.33	0.38	Pancreatic cancer;	chr3:196021659	chr3:195658062~195739964:+
PRAD	cis	rs2115630	0.653	rs61394864	ENSG00000275120.1	RP11-182J1.17	-8.73	4.89e-17	3.1e-14	-0.43	-0.38	P wave terminal force;	chr15:84626943	chr15:84599434~84606463:-
PRAD	cis	rs67311347	0.866	rs11712426	ENSG00000223797.4	ENTPD3-AS1	8.73	4.9e-17	3.1e-14	0.34	0.38	Renal cell carcinoma;	chr3:40288831	chr3:40313802~40453329:-
PRAD	cis	rs11098499	0.954	rs12506546	ENSG00000245958.5	RP11-33B1.1	-8.73	4.9e-17	3.11e-14	-0.38	-0.38	Corneal astigmatism;	chr4:119380463	chr4:119454791~119552025:+
PRAD	cis	rs4835473	0.863	rs11735239	ENSG00000251600.4	RP11-673E1.1	-8.73	4.92e-17	3.12e-14	-0.49	-0.38	Immature fraction of reticulocytes;	chr4:143689372	chr4:143912331~143982454:+
PRAD	cis	rs7811142	1	rs2406255	ENSG00000242294.5	STAG3L5P	8.73	4.93e-17	3.12e-14	0.26	0.38	Platelet count;	chr7:100456067	chr7:100336079~100351900:+
PRAD	cis	rs11098499	0.618	rs35265692	ENSG00000245958.5	RP11-33B1.1	-8.73	4.94e-17	3.13e-14	-0.38	-0.38	Corneal astigmatism;	chr4:119403980	chr4:119454791~119552025:+
PRAD	cis	rs67311347	1	rs17078941	ENSG00000223797.4	ENTPD3-AS1	-8.73	4.94e-17	3.13e-14	-0.35	-0.38	Renal cell carcinoma;	chr3:40409397	chr3:40313802~40453329:-
PRAD	cis	rs12142240	0.731	rs6658556	ENSG00000232022.5	FAAHP1	-8.73	4.95e-17	3.14e-14	-0.35	-0.38	Menopause (age at onset);	chr1:46378508	chr1:46432129~46445521:+
PRAD	cis	rs12468226	0.746	rs75987655	ENSG00000273456.1	RP11-686O6.2	8.73	4.95e-17	3.14e-14	0.53	0.38	Urate levels;	chr2:202581913	chr2:202374932~202375604:-
PRAD	cis	rs2739330	0.652	rs2000469	ENSG00000235689.1	AP000351.13	8.73	4.96e-17	3.14e-14	0.47	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:24006305~24008258:-
PRAD	cis	rs4835473	0.897	rs11728121	ENSG00000251600.4	RP11-673E1.1	8.73	4.96e-17	3.15e-14	0.49	0.38	Immature fraction of reticulocytes;	chr4:143707079	chr4:143912331~143982454:+
PRAD	cis	rs8523	0.901	rs1238273	ENSG00000230314.5	ELOVL2-AS1	8.73	5e-17	3.17e-14	0.42	0.38	Red blood cell fatty acid levels;	chr6:10968671	chr6:11043524~11078226:+
PRAD	cis	rs2581828	0.58	rs4687570	ENSG00000242142.1	SERBP1P3	8.73	5e-17	3.17e-14	0.44	0.38	Crohn's disease;	chr3:53136484	chr3:53064283~53065091:-
PRAD	cis	rs11098499	0.909	rs9759478	ENSG00000245958.5	RP11-33B1.1	-8.73	5e-17	3.17e-14	-0.38	-0.38	Corneal astigmatism;	chr4:119446843	chr4:119454791~119552025:+
PRAD	cis	rs4835473	0.932	rs6813011	ENSG00000251600.4	RP11-673E1.1	8.73	5.01e-17	3.18e-14	0.49	0.38	Immature fraction of reticulocytes;	chr4:143914496	chr4:143912331~143982454:+
PRAD	cis	rs6430553	0.929	rs74265413	ENSG00000224043.6	CCNT2-AS1	-8.73	5.02e-17	3.18e-14	-0.51	-0.38	Blood metabolite levels;	chr2:134892083	chr2:134735464~134918710:-
PRAD	cis	rs9368481	0.761	rs6918835	ENSG00000241549.7	GUSBP2	-8.73	5.05e-17	3.2e-14	-0.45	-0.38	Autism spectrum disorder or schizophrenia;	chr6:27050048	chr6:26871484~26956554:-
PRAD	cis	rs2739330	0.587	rs4820571	ENSG00000224205.1	AP000351.4	8.73	5.05e-17	3.2e-14	0.46	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23987320~23991421:-
PRAD	cis	rs2729354	0.729	rs2729353	ENSG00000265566.2	RN7SL605P	-8.73	5.05e-17	3.2e-14	-0.56	-0.38	Blood protein levels;	chr11:57480530	chr11:57528085~57528365:-
PRAD	cis	rs6782228	0.651	rs9852825	ENSG00000242551.2	POU5F1P6	-8.72	5.08e-17	3.22e-14	-0.48	-0.38	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128668514	chr3:128674735~128677005:-
PRAD	cis	rs6782228	0.651	rs9289332	ENSG00000242551.2	POU5F1P6	-8.72	5.08e-17	3.22e-14	-0.48	-0.38	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128669041	chr3:128674735~128677005:-
PRAD	cis	rs6782228	0.606	rs7613073	ENSG00000242551.2	POU5F1P6	-8.72	5.08e-17	3.22e-14	-0.48	-0.38	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128669660	chr3:128674735~128677005:-
PRAD	cis	rs8062405	0.789	rs1968752	ENSG00000259982.1	CDC37P1	8.72	5.09e-17	3.22e-14	0.48	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620264	chr16:28700294~28701540:-
PRAD	cis	rs321358	0.79	rs10502128	ENSG00000271584.1	RP11-89C3.4	8.72	5.1e-17	3.23e-14	0.57	0.38	Body mass index;	chr11:111076827	chr11:111091932~111097357:-
PRAD	cis	rs321358	0.848	rs57168185	ENSG00000271584.1	RP11-89C3.4	8.72	5.1e-17	3.23e-14	0.57	0.38	Body mass index;	chr11:111078120	chr11:111091932~111097357:-
PRAD	cis	rs950169	1	rs79318564	ENSG00000259728.4	LINC00933	8.72	5.1e-17	3.23e-14	0.45	0.38	Schizophrenia;	chr15:84117398	chr15:84570649~84580175:+
PRAD	cis	rs2739330	0.791	rs9612520	ENSG00000272787.1	KB-226F1.2	-8.72	5.11e-17	3.24e-14	-0.41	-0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23969211~23969873:+
PRAD	cis	rs7727544	0.606	rs17622208	ENSG00000233006.5	AC034220.3	8.72	5.12e-17	3.24e-14	0.34	0.38	Blood metabolite levels;	chr5:132381358	chr5:132311285~132369916:-
PRAD	cis	rs2274273	0.837	rs8008119	ENSG00000258413.1	RP11-665C16.6	-8.72	5.15e-17	3.26e-14	-0.49	-0.38	Protein biomarker;	chr14:55364510	chr14:55262767~55272075:-
PRAD	cis	rs6723108	0.603	rs10187990	ENSG00000224043.6	CCNT2-AS1	-8.72	5.15e-17	3.26e-14	-0.52	-0.38	Type 2 diabetes;	chr2:134939987	chr2:134735464~134918710:-
PRAD	cis	rs11083475	1	rs3786837	ENSG00000267892.1	CTD-2540F13.2	8.72	5.17e-17	3.27e-14	0.42	0.38	Heart rate;	chr19:38681402	chr19:38738284~38739863:+
PRAD	cis	rs11098499	0.909	rs71614422	ENSG00000245958.5	RP11-33B1.1	-8.72	5.19e-17	3.28e-14	-0.38	-0.38	Corneal astigmatism;	chr4:119438185	chr4:119454791~119552025:+
PRAD	cis	rs2108622	0.958	rs56340170	ENSG00000267453.5	AC004791.2	-8.72	5.2e-17	3.29e-14	-0.51	-0.38	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871067	chr19:15851993~15864904:-
PRAD	cis	rs4835473	0.838	rs12507468	ENSG00000251600.4	RP11-673E1.1	-8.72	5.2e-17	3.29e-14	-0.5	-0.38	Immature fraction of reticulocytes;	chr4:143908061	chr4:143912331~143982454:+
PRAD	cis	rs7923609	0.776	rs10761785	ENSG00000232075.1	MRPL35P2	-8.72	5.2e-17	3.29e-14	-0.4	-0.38	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63559006	chr10:63634317~63634827:-
PRAD	cis	rs4835473	0.863	rs13146607	ENSG00000251600.4	RP11-673E1.1	-8.72	5.21e-17	3.3e-14	-0.49	-0.38	Immature fraction of reticulocytes;	chr4:143687283	chr4:143912331~143982454:+
PRAD	cis	rs7727544	0.716	rs7701414	ENSG00000233006.5	AC034220.3	8.72	5.22e-17	3.3e-14	0.34	0.38	Blood metabolite levels;	chr5:132250265	chr5:132311285~132369916:-
PRAD	cis	rs2739330	0.627	rs9608219	ENSG00000272787.1	KB-226F1.2	-8.72	5.23e-17	3.31e-14	-0.41	-0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23969211~23969873:+
PRAD	cis	rs7811142	1	rs11761725	ENSG00000242294.5	STAG3L5P	8.72	5.24e-17	3.31e-14	0.26	0.38	Platelet count;	chr7:100442192	chr7:100336079~100351900:+
PRAD	cis	rs6991838	0.733	rs13281981	ENSG00000272010.1	CTD-3025N20.3	8.72	5.25e-17	3.32e-14	0.38	0.38	Intelligence (multi-trait analysis);	chr8:65611649	chr8:65591850~65592472:-
PRAD	cis	rs4835473	0.742	rs6537238	ENSG00000251600.4	RP11-673E1.1	8.72	5.26e-17	3.33e-14	0.49	0.38	Immature fraction of reticulocytes;	chr4:143996463	chr4:143912331~143982454:+
PRAD	cis	rs2274273	0.901	rs10140801	ENSG00000258413.1	RP11-665C16.6	-8.72	5.26e-17	3.33e-14	-0.49	-0.38	Protein biomarker;	chr14:55263686	chr14:55262767~55272075:-
PRAD	cis	rs12701220	0.696	rs12112029	ENSG00000229043.2	AC091729.9	-8.72	5.27e-17	3.33e-14	-0.55	-0.38	Bronchopulmonary dysplasia;	chr7:1098253	chr7:1160374~1165267:+
PRAD	cis	rs875971	0.965	rs9969301	ENSG00000237310.1	GS1-124K5.4	-8.72	5.27e-17	3.33e-14	-0.34	-0.38	Aortic root size;	chr7:66316668	chr7:66493706~66495474:+
PRAD	cis	rs11098499	0.954	rs10017543	ENSG00000245958.5	RP11-33B1.1	-8.72	5.3e-17	3.35e-14	-0.38	-0.38	Corneal astigmatism;	chr4:119400265	chr4:119454791~119552025:+
PRAD	cis	rs1075265	0.547	rs7587217	ENSG00000233266.1	HMGB1P31	8.72	5.3e-17	3.35e-14	0.52	0.38	Chronotype;Morning vs. evening chronotype;	chr2:53675029	chr2:54051334~54051760:+
PRAD	cis	rs1075265	0.933	rs7562055	ENSG00000233266.1	HMGB1P31	8.72	5.31e-17	3.36e-14	0.51	0.38	Chronotype;Morning vs. evening chronotype;	chr2:54112694	chr2:54051334~54051760:+
PRAD	cis	rs4631830	0.72	rs898343	ENSG00000230869.1	CTGLF10P	8.72	5.32e-17	3.36e-14	0.47	0.38	Prostate-specific antigen levels;	chr10:46090419	chr10:45678692~45700532:+
PRAD	cis	rs7712401	0.58	rs10066632	ENSG00000263432.2	RN7SL689P	8.72	5.35e-17	3.38e-14	0.4	0.38	Mean platelet volume;	chr5:123028988	chr5:123022487~123022783:-
PRAD	cis	rs1501911	0.713	rs10479344	ENSG00000248489.1	CTD-2007H13.3	-8.72	5.35e-17	3.38e-14	-0.42	-0.38	Lung function (FEV1/FVC);	chr5:99012676	chr5:98929171~98995013:+
PRAD	cis	rs934734	0.563	rs11126034	ENSG00000204929.10	AC074391.1	-8.72	5.36e-17	3.39e-14	-0.49	-0.38	Rheumatoid arthritis;	chr2:65353087	chr2:65436711~66084639:+
PRAD	cis	rs875971	0.867	rs1002053	ENSG00000237310.1	GS1-124K5.4	-8.72	5.37e-17	3.39e-14	-0.33	-0.38	Aortic root size;	chr7:66333558	chr7:66493706~66495474:+
PRAD	cis	rs875971	1	rs6460292	ENSG00000237310.1	GS1-124K5.4	-8.72	5.37e-17	3.39e-14	-0.33	-0.38	Aortic root size;	chr7:66345088	chr7:66493706~66495474:+
PRAD	cis	rs4835473	0.801	rs999049	ENSG00000251600.4	RP11-673E1.1	-8.72	5.38e-17	3.4e-14	-0.49	-0.38	Immature fraction of reticulocytes;	chr4:143715440	chr4:143912331~143982454:+
PRAD	cis	rs2739330	0.828	rs4820572	ENSG00000224205.1	AP000351.4	8.72	5.38e-17	3.4e-14	0.47	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23987320~23991421:-
PRAD	cis	rs1075265	0.547	rs6743627	ENSG00000233266.1	HMGB1P31	-8.72	5.38e-17	3.4e-14	-0.52	-0.38	Chronotype;Morning vs. evening chronotype;	chr2:53687024	chr2:54051334~54051760:+
PRAD	cis	rs2274273	0.905	rs17128183	ENSG00000258413.1	RP11-665C16.6	8.72	5.39e-17	3.41e-14	0.5	0.38	Protein biomarker;	chr14:55112795	chr14:55262767~55272075:-
PRAD	cis	rs1062177	1	rs12518722	ENSG00000253921.1	CTB-113P19.3	-8.72	5.4e-17	3.41e-14	-0.51	-0.38	Preschool internalizing problems;	chr5:151851899	chr5:151753992~151767247:+
PRAD	cis	rs7189233	0.531	rs13332071	ENSG00000279344.1	RP11-44F14.7	8.72	5.4e-17	3.41e-14	0.35	0.38	Intelligence (multi-trait analysis);	chr16:53409724	chr16:53478957~53481550:-
PRAD	cis	rs2274273	0.967	rs8009670	ENSG00000258413.1	RP11-665C16.6	-8.72	5.42e-17	3.42e-14	-0.5	-0.38	Protein biomarker;	chr14:55116759	chr14:55262767~55272075:-
PRAD	cis	rs6847067	0.8	rs13109918	ENSG00000180769.7	WDFY3-AS2	8.72	5.43e-17	3.43e-14	0.39	0.38	Oropharynx cancer;	chr4:84919619	chr4:84965682~85011277:+
PRAD	cis	rs2274273	0.744	rs8011808	ENSG00000258413.1	RP11-665C16.6	-8.72	5.44e-17	3.43e-14	-0.5	-0.38	Protein biomarker;	chr14:55356626	chr14:55262767~55272075:-
PRAD	cis	rs1075265	0.587	rs2949811	ENSG00000233266.1	HMGB1P31	8.72	5.44e-17	3.44e-14	0.51	0.38	Chronotype;Morning vs. evening chronotype;	chr2:53797028	chr2:54051334~54051760:+
PRAD	cis	rs2274273	0.84	rs10150760	ENSG00000258413.1	RP11-665C16.6	8.72	5.46e-17	3.45e-14	0.49	0.38	Protein biomarker;	chr14:55354830	chr14:55262767~55272075:-
PRAD	cis	rs853679	0.55	rs9295762	ENSG00000272009.1	RP1-313I6.12	8.71	5.52e-17	3.49e-14	0.38	0.38	Depression;	chr6:28187640	chr6:28078792~28081130:-
PRAD	cis	rs1075265	0.522	rs7584474	ENSG00000233266.1	HMGB1P31	8.71	5.53e-17	3.49e-14	0.52	0.38	Chronotype;Morning vs. evening chronotype;	chr2:53674874	chr2:54051334~54051760:+
PRAD	cis	rs440932	1	rs378974	ENSG00000254340.1	RP11-10A14.3	8.71	5.56e-17	3.51e-14	0.46	0.38	High light scatter reticulocyte percentage of red cells;	chr8:9169129	chr8:9141424~9145435:+
PRAD	cis	rs4964805	0.657	rs4964814	ENSG00000257681.1	RP11-341G23.4	-8.71	5.57e-17	3.52e-14	-0.34	-0.38	Attention deficit hyperactivity disorder;	chr12:103795606	chr12:103746315~103768858:-
PRAD	cis	rs5769707	0.681	rs1107514	ENSG00000188511.11	C22orf34	8.71	5.57e-17	3.52e-14	0.46	0.38	Monocyte percentage of white cells;Monocyte count;	chr22:49648735	chr22:49414524~49657542:-
PRAD	cis	rs7811142	1	rs7783550	ENSG00000242294.5	STAG3L5P	-8.71	5.58e-17	3.52e-14	-0.25	-0.38	Platelet count;	chr7:100390182	chr7:100336079~100351900:+
PRAD	cis	rs2729354	0.729	rs2258835	ENSG00000265566.2	RN7SL605P	-8.71	5.61e-17	3.54e-14	-0.58	-0.38	Blood protein levels;	chr11:57476115	chr11:57528085~57528365:-
PRAD	cis	rs6452524	0.967	rs4616871	ENSG00000249664.1	CTD-2227C6.2	8.71	5.62e-17	3.55e-14	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83175271	chr5:83012285~83013109:-
PRAD	cis	rs4713118	0.587	rs61471148	ENSG00000226314.6	ZNF192P1	-8.71	5.63e-17	3.55e-14	-0.51	-0.38	Parkinson's disease;	chr6:28069254	chr6:28161781~28169594:+
PRAD	cis	rs3743772	0.5	rs8045574	ENSG00000279722.1	RP11-44F14.6	-8.71	5.63e-17	3.55e-14	-0.46	-0.38	Depressive symptoms (SSRI exposure interaction);	chr16:53395293	chr16:53487607~53489943:-
PRAD	cis	rs7829975	0.501	rs2980769	ENSG00000253893.2	FAM85B	-8.71	5.63e-17	3.55e-14	-0.46	-0.38	Mood instability;	chr8:8462781	chr8:8167819~8226614:-
PRAD	cis	rs6452524	0.967	rs2974445	ENSG00000249664.1	CTD-2227C6.2	-8.71	5.64e-17	3.56e-14	-0.43	-0.38	Hypertension (SNP x SNP interaction);	chr5:83185561	chr5:83012285~83013109:-
PRAD	cis	rs6061231	0.544	rs2427314	ENSG00000273619.1	RP5-908M14.9	-8.71	5.64e-17	3.56e-14	-0.24	-0.38	Colorectal cancer;	chr20:62398610	chr20:62386303~62386970:-
PRAD	cis	rs2153535	0.518	rs926533	ENSG00000230939.1	RP11-314C16.1	-8.71	5.65e-17	3.56e-14	-0.46	-0.38	Motion sickness;	chr6:8556529	chr6:8784178~8785445:+
PRAD	cis	rs11098499	0.863	rs3775854	ENSG00000245958.5	RP11-33B1.1	-8.71	5.65e-17	3.57e-14	-0.37	-0.38	Corneal astigmatism;	chr4:119550816	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.863	rs6853998	ENSG00000245958.5	RP11-33B1.1	-8.71	5.65e-17	3.57e-14	-0.37	-0.38	Corneal astigmatism;	chr4:119554705	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.863	rs6858777	ENSG00000245958.5	RP11-33B1.1	-8.71	5.65e-17	3.57e-14	-0.37	-0.38	Corneal astigmatism;	chr4:119554811	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.863	rs11731756	ENSG00000245958.5	RP11-33B1.1	-8.71	5.65e-17	3.57e-14	-0.37	-0.38	Corneal astigmatism;	chr4:119557541	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.863	rs34308924	ENSG00000245958.5	RP11-33B1.1	-8.71	5.65e-17	3.57e-14	-0.37	-0.38	Corneal astigmatism;	chr4:119560276	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.863	rs2170276	ENSG00000245958.5	RP11-33B1.1	-8.71	5.65e-17	3.57e-14	-0.37	-0.38	Corneal astigmatism;	chr4:119564669	chr4:119454791~119552025:+
PRAD	cis	rs11676348	0.772	rs11687200	ENSG00000261338.2	RP11-378A13.1	-8.71	5.67e-17	3.58e-14	-0.41	-0.38	Ulcerative colitis;	chr2:218079892	chr2:218255319~218257366:+
PRAD	cis	rs6782228	0.675	rs9841987	ENSG00000242551.2	POU5F1P6	-8.71	5.74e-17	3.62e-14	-0.48	-0.38	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128666299	chr3:128674735~128677005:-
PRAD	cis	rs6782228	0.675	rs56141228	ENSG00000242551.2	POU5F1P6	-8.71	5.74e-17	3.62e-14	-0.48	-0.38	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128667199	chr3:128674735~128677005:-
PRAD	cis	rs10129255	0.5	rs8011115	ENSG00000223648.3	IGHV3-64	8.71	5.74e-17	3.62e-14	0.33	0.38	Kawasaki disease;	chr14:106786292	chr14:106643132~106658258:-
PRAD	cis	rs12142240	0.659	rs72677602	ENSG00000232022.5	FAAHP1	-8.71	5.75e-17	3.62e-14	-0.35	-0.38	Menopause (age at onset);	chr1:46371815	chr1:46432129~46445521:+
PRAD	cis	rs6723108	0.627	rs1374292	ENSG00000224043.6	CCNT2-AS1	-8.71	5.76e-17	3.63e-14	-0.53	-0.38	Type 2 diabetes;	chr2:134896598	chr2:134735464~134918710:-
PRAD	cis	rs11098499	0.909	rs10020034	ENSG00000245958.5	RP11-33B1.1	-8.71	5.78e-17	3.64e-14	-0.37	-0.38	Corneal astigmatism;	chr4:119373176	chr4:119454791~119552025:+
PRAD	cis	rs321358	0.79	rs73015129	ENSG00000271584.1	RP11-89C3.4	8.71	5.78e-17	3.64e-14	0.59	0.38	Body mass index;	chr11:111076157	chr11:111091932~111097357:-
PRAD	cis	rs321358	0.79	rs73015134	ENSG00000271584.1	RP11-89C3.4	8.71	5.78e-17	3.64e-14	0.59	0.38	Body mass index;	chr11:111076520	chr11:111091932~111097357:-
PRAD	cis	rs934734	0.544	rs4671127	ENSG00000204929.10	AC074391.1	8.71	5.79e-17	3.65e-14	0.49	0.38	Rheumatoid arthritis;	chr2:65335836	chr2:65436711~66084639:+
PRAD	cis	rs321358	0.732	rs17535419	ENSG00000271584.1	RP11-89C3.4	8.71	5.82e-17	3.67e-14	0.58	0.38	Body mass index;	chr11:111075357	chr11:111091932~111097357:-
PRAD	cis	rs321358	0.79	rs77820525	ENSG00000271584.1	RP11-89C3.4	8.71	5.82e-17	3.67e-14	0.58	0.38	Body mass index;	chr11:111076697	chr11:111091932~111097357:-
PRAD	cis	rs321358	0.848	rs73015141	ENSG00000271584.1	RP11-89C3.4	8.71	5.82e-17	3.67e-14	0.58	0.38	Body mass index;	chr11:111077556	chr11:111091932~111097357:-
PRAD	cis	rs321358	0.848	rs73015142	ENSG00000271584.1	RP11-89C3.4	8.71	5.82e-17	3.67e-14	0.58	0.38	Body mass index;	chr11:111078647	chr11:111091932~111097357:-
PRAD	cis	rs765787	0.53	rs12323957	ENSG00000259520.4	CTD-2651B20.3	-8.71	5.83e-17	3.67e-14	-0.49	-0.38	Uric acid levels;	chr15:45198575	chr15:45251580~45279251:-
PRAD	cis	rs2108622	0.545	rs59140933	ENSG00000267453.5	AC004791.2	-8.71	5.83e-17	3.67e-14	-0.49	-0.38	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15864498	chr19:15851993~15864904:-
PRAD	cis	rs12701220	0.655	rs9638973	ENSG00000229043.2	AC091729.9	-8.71	5.83e-17	3.68e-14	-0.55	-0.38	Bronchopulmonary dysplasia;	chr7:1094042	chr7:1160374~1165267:+
PRAD	cis	rs8072100	0.581	rs4267364	ENSG00000228782.6	CTD-2026D20.3	8.71	5.84e-17	3.68e-14	0.42	0.38	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47703898	chr17:47450568~47492492:-
PRAD	cis	rs507080	0.697	rs653008	ENSG00000255422.1	AP002954.4	-8.71	5.84e-17	3.68e-14	-0.47	-0.38	Serum metabolite levels;	chr11:118649775	chr11:118704607~118750263:+
PRAD	cis	rs7727544	0.631	rs13357280	ENSG00000233006.5	AC034220.3	8.71	5.84e-17	3.68e-14	0.34	0.38	Blood metabolite levels;	chr5:132264494	chr5:132311285~132369916:-
PRAD	cis	rs4835473	0.9	rs10003922	ENSG00000251600.4	RP11-673E1.1	-8.71	5.86e-17	3.69e-14	-0.5	-0.38	Immature fraction of reticulocytes;	chr4:143921235	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs6852502	ENSG00000251600.4	RP11-673E1.1	8.7	5.9e-17	3.72e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143987174	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.663	rs1511423	ENSG00000251600.4	RP11-673E1.1	8.7	5.9e-17	3.72e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143990136	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.639	rs5029916	ENSG00000251600.4	RP11-673E1.1	8.7	5.9e-17	3.72e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143990684	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs1988206	ENSG00000251600.4	RP11-673E1.1	8.7	5.9e-17	3.72e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143991344	chr4:143912331~143982454:+
PRAD	cis	rs8040855	0.644	rs2342120	ENSG00000259295.5	CSPG4P12	-8.7	5.9e-17	3.72e-14	-0.48	-0.38	Bulimia nervosa;	chr15:85185589	chr15:85191438~85213905:+
PRAD	cis	rs200986	1	rs200986	ENSG00000280107.1	AL022393.9	-8.7	5.91e-17	3.72e-14	-0.47	-0.38	Autism spectrum disorder or schizophrenia;	chr6:27856988	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.539	rs200951	ENSG00000280107.1	AL022393.9	-8.7	5.91e-17	3.72e-14	-0.47	-0.38	Parkinson's disease;	chr6:27868152	chr6:28170845~28172521:+
PRAD	cis	rs8062405	0.824	rs28698667	ENSG00000251417.2	RP11-1348G14.4	-8.7	5.93e-17	3.73e-14	-0.42	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28521750	chr16:28802743~28817828:+
PRAD	cis	rs8062405	0.754	rs62034323	ENSG00000251417.2	RP11-1348G14.4	-8.7	5.93e-17	3.73e-14	-0.42	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525152	chr16:28802743~28817828:+
PRAD	cis	rs8062405	0.824	rs62034324	ENSG00000251417.2	RP11-1348G14.4	-8.7	5.93e-17	3.73e-14	-0.42	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525441	chr16:28802743~28817828:+
PRAD	cis	rs8062405	0.824	rs62034326	ENSG00000251417.2	RP11-1348G14.4	-8.7	5.93e-17	3.73e-14	-0.42	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527972	chr16:28802743~28817828:+
PRAD	cis	rs8062405	0.824	rs4788084	ENSG00000251417.2	RP11-1348G14.4	-8.7	5.93e-17	3.73e-14	-0.42	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28528527	chr16:28802743~28817828:+
PRAD	cis	rs4713118	0.513	rs149972	ENSG00000280107.1	AL022393.9	-8.7	5.93e-17	3.74e-14	-0.46	-0.38	Parkinson's disease;	chr6:28015449	chr6:28170845~28172521:+
PRAD	cis	rs4835473	0.868	rs4350958	ENSG00000251600.4	RP11-673E1.1	8.7	5.94e-17	3.74e-14	0.5	0.38	Immature fraction of reticulocytes;	chr4:143744656	chr4:143912331~143982454:+
PRAD	cis	rs875971	1	rs9986696	ENSG00000237310.1	GS1-124K5.4	-8.7	5.95e-17	3.74e-14	-0.33	-0.38	Aortic root size;	chr7:66239589	chr7:66493706~66495474:+
PRAD	cis	rs2274273	0.773	rs8006525	ENSG00000258413.1	RP11-665C16.6	-8.7	5.95e-17	3.75e-14	-0.5	-0.38	Protein biomarker;	chr14:55346676	chr14:55262767~55272075:-
PRAD	cis	rs2638953	0.924	rs11049405	ENSG00000278733.1	RP11-425D17.1	-8.7	5.95e-17	3.75e-14	-0.45	-0.38	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28181003	chr12:28185625~28186190:-
PRAD	cis	rs4713118	0.824	rs742046	ENSG00000280107.1	AL022393.9	-8.7	5.95e-17	3.75e-14	-0.48	-0.38	Parkinson's disease;	chr6:27771475	chr6:28170845~28172521:+
PRAD	cis	rs5760092	0.572	rs738806	ENSG00000225282.1	AP000350.6	8.7	5.95e-17	3.75e-14	0.56	0.38	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23926900~23929574:+
PRAD	cis	rs4713118	0.513	rs149975	ENSG00000280107.1	AL022393.9	-8.7	6.03e-17	3.79e-14	-0.46	-0.38	Parkinson's disease;	chr6:28018562	chr6:28170845~28172521:+
PRAD	cis	rs6723108	0.627	rs55865348	ENSG00000224043.6	CCNT2-AS1	-8.7	6.05e-17	3.81e-14	-0.52	-0.38	Type 2 diabetes;	chr2:134892235	chr2:134735464~134918710:-
PRAD	cis	rs367615	0.537	rs431669	ENSG00000249476.1	CTD-2587M2.1	8.7	6.06e-17	3.81e-14	0.47	0.38	Colorectal cancer (SNP x SNP interaction);	chr5:109327414	chr5:109237120~109326369:-
PRAD	cis	rs367615	0.537	rs10463600	ENSG00000249476.1	CTD-2587M2.1	8.7	6.06e-17	3.81e-14	0.47	0.38	Colorectal cancer (SNP x SNP interaction);	chr5:109327935	chr5:109237120~109326369:-
PRAD	cis	rs507080	0.733	rs601318	ENSG00000255422.1	AP002954.4	-8.7	6.06e-17	3.81e-14	-0.47	-0.38	Serum metabolite levels;	chr11:118648845	chr11:118704607~118750263:+
PRAD	cis	rs4713118	0.739	rs2893931	ENSG00000280107.1	AL022393.9	-8.7	6.08e-17	3.82e-14	-0.48	-0.38	Parkinson's disease;	chr6:27780231	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.824	rs2092075	ENSG00000280107.1	AL022393.9	-8.7	6.08e-17	3.82e-14	-0.48	-0.38	Parkinson's disease;	chr6:27781551	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.824	rs13211701	ENSG00000280107.1	AL022393.9	-8.7	6.08e-17	3.82e-14	-0.48	-0.38	Parkinson's disease;	chr6:27782300	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.824	rs9468229	ENSG00000280107.1	AL022393.9	-8.7	6.08e-17	3.82e-14	-0.48	-0.38	Parkinson's disease;	chr6:27782307	chr6:28170845~28172521:+
PRAD	cis	rs4964805	0.657	rs73192049	ENSG00000257681.1	RP11-341G23.4	8.7	6.08e-17	3.82e-14	0.34	0.38	Attention deficit hyperactivity disorder;	chr12:103794215	chr12:103746315~103768858:-
PRAD	cis	rs6723108	0.603	rs3814355	ENSG00000224043.6	CCNT2-AS1	-8.7	6.12e-17	3.85e-14	-0.52	-0.38	Type 2 diabetes;	chr2:134953946	chr2:134735464~134918710:-
PRAD	cis	rs2274273	0.84	rs6573014	ENSG00000258413.1	RP11-665C16.6	8.7	6.13e-17	3.86e-14	0.5	0.38	Protein biomarker;	chr14:55269174	chr14:55262767~55272075:-
PRAD	cis	rs11098499	0.909	rs35165976	ENSG00000245958.5	RP11-33B1.1	-8.7	6.14e-17	3.86e-14	-0.38	-0.38	Corneal astigmatism;	chr4:119404475	chr4:119454791~119552025:+
PRAD	cis	rs67311347	1	rs67311347	ENSG00000223797.4	ENTPD3-AS1	8.7	6.15e-17	3.87e-14	0.34	0.38	Renal cell carcinoma;	chr3:40491752	chr3:40313802~40453329:-
PRAD	cis	rs11098499	0.954	rs17006190	ENSG00000245958.5	RP11-33B1.1	-8.7	6.19e-17	3.89e-14	-0.38	-0.38	Corneal astigmatism;	chr4:119497683	chr4:119454791~119552025:+
PRAD	cis	rs3096299	0.967	rs2965830	ENSG00000274627.1	RP11-104N10.2	8.7	6.21e-17	3.9e-14	0.38	0.38	Multiple myeloma (IgH translocation);	chr16:89393882	chr16:89516797~89522217:+
PRAD	cis	rs189798	0.592	rs10111263	ENSG00000254340.1	RP11-10A14.3	-8.7	6.21e-17	3.9e-14	-0.46	-0.38	Myopia (pathological);	chr8:9111923	chr8:9141424~9145435:+
PRAD	cis	rs8062405	0.754	rs28410083	ENSG00000259982.1	CDC37P1	-8.7	6.22e-17	3.91e-14	-0.49	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620039	chr16:28700294~28701540:-
PRAD	cis	rs8062405	0.789	rs1968751	ENSG00000259982.1	CDC37P1	-8.7	6.22e-17	3.91e-14	-0.49	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620438	chr16:28700294~28701540:-
PRAD	cis	rs8040855	0.644	rs7495437	ENSG00000259295.5	CSPG4P12	-8.7	6.22e-17	3.91e-14	-0.48	-0.38	Bulimia nervosa;	chr15:85183059	chr15:85191438~85213905:+
PRAD	cis	rs853679	1	rs2799077	ENSG00000280107.1	AL022393.9	-8.7	6.22e-17	3.91e-14	-0.57	-0.38	Depression;	chr6:28266819	chr6:28170845~28172521:+
PRAD	cis	rs950169	0.922	rs4338765	ENSG00000259728.4	LINC00933	8.7	6.23e-17	3.91e-14	0.46	0.38	Schizophrenia;	chr15:84248084	chr15:84570649~84580175:+
PRAD	cis	rs6452524	1	rs6868817	ENSG00000249664.1	CTD-2227C6.2	8.7	6.23e-17	3.91e-14	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83142287	chr5:83012285~83013109:-
PRAD	cis	rs6452524	0.967	rs10042018	ENSG00000249664.1	CTD-2227C6.2	8.7	6.23e-17	3.91e-14	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83142490	chr5:83012285~83013109:-
PRAD	cis	rs6452524	0.967	rs10036418	ENSG00000249664.1	CTD-2227C6.2	8.7	6.23e-17	3.91e-14	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83142493	chr5:83012285~83013109:-
PRAD	cis	rs6452524	1	rs10055948	ENSG00000249664.1	CTD-2227C6.2	8.7	6.23e-17	3.91e-14	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83143437	chr5:83012285~83013109:-
PRAD	cis	rs6452524	1	rs10037872	ENSG00000249664.1	CTD-2227C6.2	8.7	6.23e-17	3.91e-14	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83144101	chr5:83012285~83013109:-
PRAD	cis	rs3096299	0.967	rs28644774	ENSG00000274627.1	RP11-104N10.2	8.7	6.24e-17	3.92e-14	0.39	0.38	Multiple myeloma (IgH translocation);	chr16:89405773	chr16:89516797~89522217:+
PRAD	cis	rs4964805	0.657	rs11111781	ENSG00000257681.1	RP11-341G23.4	8.7	6.25e-17	3.93e-14	0.34	0.38	Attention deficit hyperactivity disorder;	chr12:103793662	chr12:103746315~103768858:-
PRAD	cis	rs748404	0.66	rs2467742	ENSG00000249839.1	AC011330.5	-8.7	6.27e-17	3.94e-14	-0.46	-0.38	Lung cancer;	chr15:43458039	chr15:43663654~43684339:-
PRAD	cis	rs17711722	0.523	rs313812	ENSG00000236529.1	RP13-254B10.1	-8.7	6.27e-17	3.94e-14	-0.4	-0.38	Calcium levels;	chr7:66040056	chr7:65840212~65840596:+
PRAD	cis	rs12653946	0.811	rs10866527	ENSG00000249116.1	CTD-2194D22.3	-8.7	6.28e-17	3.95e-14	-0.45	-0.38	Prostate cancer;	chr5:1891686	chr5:1883966~1884649:+
PRAD	cis	rs875971	0.964	rs6945019	ENSG00000237310.1	GS1-124K5.4	8.7	6.29e-17	3.95e-14	0.33	0.38	Aortic root size;	chr7:66457471	chr7:66493706~66495474:+
PRAD	cis	rs7712401	0.601	rs154501	ENSG00000263432.2	RN7SL689P	8.7	6.31e-17	3.96e-14	0.39	0.38	Mean platelet volume;	chr5:122875899	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.601	rs246271	ENSG00000263432.2	RN7SL689P	8.7	6.31e-17	3.96e-14	0.39	0.38	Mean platelet volume;	chr5:122877127	chr5:123022487~123022783:-
PRAD	cis	rs7712401	0.601	rs257813	ENSG00000263432.2	RN7SL689P	8.7	6.31e-17	3.96e-14	0.39	0.38	Mean platelet volume;	chr5:122881473	chr5:123022487~123022783:-
PRAD	cis	rs7250849	0.79	rs7259861	ENSG00000273837.1	LLNLR-470E3.1	-8.7	6.34e-17	3.98e-14	-0.61	-0.38	Blood protein levels;	chr19:51657490	chr19:51639478~51639931:-
PRAD	cis	rs7712401	0.58	rs10076327	ENSG00000263432.2	RN7SL689P	8.7	6.34e-17	3.98e-14	0.4	0.38	Mean platelet volume;	chr5:123031652	chr5:123022487~123022783:-
PRAD	cis	rs6452524	0.905	rs10040244	ENSG00000249664.1	CTD-2227C6.2	8.69	6.35e-17	3.99e-14	0.45	0.38	Hypertension (SNP x SNP interaction);	chr5:83089242	chr5:83012285~83013109:-
PRAD	cis	rs6452524	1	rs17284288	ENSG00000249664.1	CTD-2227C6.2	8.69	6.36e-17	4e-14	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83148997	chr5:83012285~83013109:-
PRAD	cis	rs4927850	0.723	rs7630825	ENSG00000242086.7	LINC00969	8.69	6.37e-17	4e-14	0.32	0.38	Pancreatic cancer;	chr3:196026869	chr3:195658062~195739964:+
PRAD	cis	rs507080	0.769	rs527290	ENSG00000255422.1	AP002954.4	-8.69	6.38e-17	4.01e-14	-0.47	-0.38	Serum metabolite levels;	chr11:118644898	chr11:118704607~118750263:+
PRAD	cis	rs9903692	0.954	rs8076380	ENSG00000278765.1	RP5-890E16.5	-8.69	6.39e-17	4.01e-14	-0.57	-0.38	Pulse pressure;	chr17:48113028	chr17:48066704~48067293:-
PRAD	cis	rs9903692	0.754	rs12602948	ENSG00000278765.1	RP5-890E16.5	-8.69	6.39e-17	4.01e-14	-0.57	-0.38	Pulse pressure;	chr17:48113567	chr17:48066704~48067293:-
PRAD	cis	rs9903692	0.908	rs9807087	ENSG00000278765.1	RP5-890E16.5	-8.69	6.39e-17	4.01e-14	-0.57	-0.38	Pulse pressure;	chr17:48126776	chr17:48066704~48067293:-
PRAD	cis	rs9903692	0.954	rs7209730	ENSG00000278765.1	RP5-890E16.5	-8.69	6.39e-17	4.01e-14	-0.57	-0.38	Pulse pressure;	chr17:48130137	chr17:48066704~48067293:-
PRAD	cis	rs5769707	0.681	rs2319346	ENSG00000188511.11	C22orf34	8.69	6.39e-17	4.02e-14	0.45	0.38	Monocyte percentage of white cells;Monocyte count;	chr22:49635992	chr22:49414524~49657542:-
PRAD	cis	rs7712401	0.601	rs404442	ENSG00000263432.2	RN7SL689P	-8.69	6.4e-17	4.02e-14	-0.39	-0.38	Mean platelet volume;	chr5:123009236	chr5:123022487~123022783:-
PRAD	cis	rs67311347	1	rs1466237	ENSG00000223797.4	ENTPD3-AS1	8.69	6.4e-17	4.02e-14	0.33	0.38	Renal cell carcinoma;	chr3:40420535	chr3:40313802~40453329:-
PRAD	cis	rs4713118	0.824	rs9468223	ENSG00000280107.1	AL022393.9	-8.69	6.42e-17	4.03e-14	-0.48	-0.38	Parkinson's disease;	chr6:27772887	chr6:28170845~28172521:+
PRAD	cis	rs875971	0.508	rs6947808	ENSG00000237310.1	GS1-124K5.4	-8.69	6.43e-17	4.04e-14	-0.33	-0.38	Aortic root size;	chr7:66580095	chr7:66493706~66495474:+
PRAD	cis	rs6452524	1	rs62374374	ENSG00000249664.1	CTD-2227C6.2	8.69	6.44e-17	4.04e-14	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83144838	chr5:83012285~83013109:-
PRAD	cis	rs6452524	1	rs1382372	ENSG00000249664.1	CTD-2227C6.2	8.69	6.44e-17	4.04e-14	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83145237	chr5:83012285~83013109:-
PRAD	cis	rs6452524	1	rs1382371	ENSG00000249664.1	CTD-2227C6.2	8.69	6.44e-17	4.04e-14	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83145300	chr5:83012285~83013109:-
PRAD	cis	rs6452524	1	rs1382369	ENSG00000249664.1	CTD-2227C6.2	8.69	6.44e-17	4.04e-14	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83145610	chr5:83012285~83013109:-
PRAD	cis	rs6452524	1	rs2386240	ENSG00000249664.1	CTD-2227C6.2	8.69	6.44e-17	4.04e-14	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83147192	chr5:83012285~83013109:-
PRAD	cis	rs6452524	1	rs9986131	ENSG00000249664.1	CTD-2227C6.2	8.69	6.44e-17	4.04e-14	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83149037	chr5:83012285~83013109:-
PRAD	cis	rs4835473	0.932	rs13129993	ENSG00000251600.4	RP11-673E1.1	-8.69	6.45e-17	4.05e-14	-0.49	-0.38	Immature fraction of reticulocytes;	chr4:143763076	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs1580002	ENSG00000251600.4	RP11-673E1.1	-8.69	6.45e-17	4.05e-14	-0.49	-0.38	Immature fraction of reticulocytes;	chr4:143766507	chr4:143912331~143982454:+
PRAD	cis	rs7131987	0.621	rs6487805	ENSG00000257176.2	RP11-996F15.2	8.69	6.46e-17	4.05e-14	0.41	0.38	QT interval;	chr12:29304617	chr12:29280418~29317848:-
PRAD	cis	rs7945705	0.692	rs2742470	ENSG00000254860.4	TMEM9B-AS1	8.69	6.49e-17	4.07e-14	0.38	0.38	Hemoglobin concentration;	chr11:8982455	chr11:8964675~8977527:+
PRAD	cis	rs367615	0.552	rs7720036	ENSG00000249476.1	CTD-2587M2.1	-8.69	6.5e-17	4.08e-14	-0.47	-0.38	Colorectal cancer (SNP x SNP interaction);	chr5:109374998	chr5:109237120~109326369:-
PRAD	cis	rs12817211	0.502	rs59262224	ENSG00000272368.2	RP4-605O3.4	-8.69	6.52e-17	4.09e-14	-0.38	-0.38	Colorectal or endometrial cancer;	chr12:50117164	chr12:50112197~50165618:+
PRAD	cis	rs7615952	0.8	rs2062773	ENSG00000171084.14	FAM86JP	8.69	6.53e-17	4.1e-14	0.61	0.38	Blood pressure (smoking interaction);	chr3:125920805	chr3:125916620~125930024:+
PRAD	cis	rs7615952	0.799	rs13315434	ENSG00000171084.14	FAM86JP	8.69	6.53e-17	4.1e-14	0.61	0.38	Blood pressure (smoking interaction);	chr3:125922551	chr3:125916620~125930024:+
PRAD	cis	rs6570726	0.846	rs446031	ENSG00000235652.6	RP11-545I5.3	8.69	6.57e-17	4.12e-14	0.39	0.38	Lobe attachment (rater-scored or self-reported);	chr6:145564456	chr6:145799409~145886585:+
PRAD	cis	rs321358	0.895	rs7131434	ENSG00000271584.1	RP11-89C3.4	8.69	6.58e-17	4.13e-14	0.58	0.38	Body mass index;	chr11:111085693	chr11:111091932~111097357:-
PRAD	cis	rs11083475	0.935	rs10416718	ENSG00000267892.1	CTD-2540F13.2	8.69	6.58e-17	4.13e-14	0.41	0.38	Heart rate;	chr19:38756336	chr19:38738284~38739863:+
PRAD	cis	rs11098499	0.863	rs2306456	ENSG00000245958.5	RP11-33B1.1	-8.69	6.59e-17	4.13e-14	-0.37	-0.38	Corneal astigmatism;	chr4:119551267	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.863	rs11947234	ENSG00000245958.5	RP11-33B1.1	-8.69	6.59e-17	4.13e-14	-0.37	-0.38	Corneal astigmatism;	chr4:119553704	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.863	rs11933966	ENSG00000245958.5	RP11-33B1.1	-8.69	6.59e-17	4.13e-14	-0.37	-0.38	Corneal astigmatism;	chr4:119555560	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.863	rs36040693	ENSG00000245958.5	RP11-33B1.1	-8.69	6.59e-17	4.13e-14	-0.37	-0.38	Corneal astigmatism;	chr4:119556461	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.863	rs1552092	ENSG00000245958.5	RP11-33B1.1	-8.69	6.59e-17	4.13e-14	-0.37	-0.38	Corneal astigmatism;	chr4:119567341	chr4:119454791~119552025:+
PRAD	cis	rs4713118	0.696	rs2394002	ENSG00000280107.1	AL022393.9	-8.69	6.61e-17	4.14e-14	-0.48	-0.38	Parkinson's disease;	chr6:27780236	chr6:28170845~28172521:+
PRAD	cis	rs11098499	0.954	rs10008392	ENSG00000245958.5	RP11-33B1.1	-8.69	6.63e-17	4.16e-14	-0.38	-0.38	Corneal astigmatism;	chr4:119397684	chr4:119454791~119552025:+
PRAD	cis	rs4835473	0.897	rs35140014	ENSG00000251600.4	RP11-673E1.1	8.69	6.64e-17	4.16e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143964292	chr4:143912331~143982454:+
PRAD	cis	rs11951515	0.663	rs10039048	ENSG00000188850.9	RP11-159F24.2	8.69	6.67e-17	4.18e-14	0.46	0.38	Metabolite levels  (X-11787);	chr5:43313076	chr5:43336164~43348716:+
PRAD	cis	rs6452524	0.967	rs62374400	ENSG00000249664.1	CTD-2227C6.2	8.69	6.68e-17	4.19e-14	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83177053	chr5:83012285~83013109:-
PRAD	cis	rs6452524	0.967	rs10040363	ENSG00000249664.1	CTD-2227C6.2	8.69	6.68e-17	4.19e-14	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83177826	chr5:83012285~83013109:-
PRAD	cis	rs6452524	0.967	rs10051542	ENSG00000249664.1	CTD-2227C6.2	8.69	6.68e-17	4.19e-14	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83178268	chr5:83012285~83013109:-
PRAD	cis	rs6452524	0.967	rs10051557	ENSG00000249664.1	CTD-2227C6.2	8.69	6.68e-17	4.19e-14	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83178307	chr5:83012285~83013109:-
PRAD	cis	rs875971	1	rs2420820	ENSG00000237310.1	GS1-124K5.4	-8.69	6.7e-17	4.2e-14	-0.34	-0.38	Aortic root size;	chr7:66626920	chr7:66493706~66495474:+
PRAD	cis	rs4713118	0.955	rs9393847	ENSG00000280107.1	AL022393.9	-8.69	6.74e-17	4.22e-14	-0.48	-0.38	Parkinson's disease;	chr6:27720194	chr6:28170845~28172521:+
PRAD	cis	rs875971	1	rs6460296	ENSG00000237310.1	GS1-124K5.4	8.69	6.74e-17	4.22e-14	0.33	0.38	Aortic root size;	chr7:66430152	chr7:66493706~66495474:+
PRAD	cis	rs7923609	0.811	rs3847326	ENSG00000232075.1	MRPL35P2	8.69	6.75e-17	4.23e-14	0.39	0.38	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63572099	chr10:63634317~63634827:-
PRAD	cis	rs748404	0.66	rs518288	ENSG00000249839.1	AC011330.5	-8.69	6.76e-17	4.24e-14	-0.46	-0.38	Lung cancer;	chr15:43471801	chr15:43663654~43684339:-
PRAD	cis	rs4964805	0.632	rs9706225	ENSG00000257681.1	RP11-341G23.4	8.69	6.8e-17	4.26e-14	0.34	0.38	Attention deficit hyperactivity disorder;	chr12:103794308	chr12:103746315~103768858:-
PRAD	cis	rs11951515	0.59	rs7722781	ENSG00000188850.9	RP11-159F24.2	8.69	6.81e-17	4.27e-14	0.46	0.38	Metabolite levels  (X-11787);	chr5:43340913	chr5:43336164~43348716:+
PRAD	cis	rs11098499	0.818	rs55825515	ENSG00000245958.5	RP11-33B1.1	-8.69	6.83e-17	4.28e-14	-0.38	-0.38	Corneal astigmatism;	chr4:119565247	chr4:119454791~119552025:+
PRAD	cis	rs4380275	0.965	rs4315562	ENSG00000272342.1	RP13-539J13.1	8.69	6.84e-17	4.28e-14	0.48	0.38	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:772723	chr2:739588~740164:-
PRAD	cis	rs4380275	1	rs4450634	ENSG00000272342.1	RP13-539J13.1	8.69	6.84e-17	4.28e-14	0.48	0.38	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:773257	chr2:739588~740164:-
PRAD	cis	rs4380275	1	rs4380275	ENSG00000272342.1	RP13-539J13.1	8.69	6.84e-17	4.28e-14	0.48	0.38	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:773278	chr2:739588~740164:-
PRAD	cis	rs4380275	1	rs6548253	ENSG00000272342.1	RP13-539J13.1	8.69	6.84e-17	4.28e-14	0.48	0.38	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:773655	chr2:739588~740164:-
PRAD	cis	rs4380275	1	rs73143802	ENSG00000272342.1	RP13-539J13.1	8.69	6.84e-17	4.28e-14	0.48	0.38	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:773826	chr2:739588~740164:-
PRAD	cis	rs4380275	1	rs4359695	ENSG00000272342.1	RP13-539J13.1	8.69	6.84e-17	4.28e-14	0.48	0.38	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:774214	chr2:739588~740164:-
PRAD	cis	rs4380275	0.931	rs4538239	ENSG00000272342.1	RP13-539J13.1	8.69	6.84e-17	4.28e-14	0.48	0.38	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:774238	chr2:739588~740164:-
PRAD	cis	rs4380275	1	rs7562792	ENSG00000272342.1	RP13-539J13.1	8.69	6.84e-17	4.28e-14	0.48	0.38	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:774469	chr2:739588~740164:-
PRAD	cis	rs7772486	0.743	rs9376955	ENSG00000235652.6	RP11-545I5.3	8.69	6.84e-17	4.28e-14	0.39	0.38	Lobe attachment (rater-scored or self-reported);	chr6:145628268	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.805	rs4896831	ENSG00000235652.6	RP11-545I5.3	8.69	6.84e-17	4.28e-14	0.39	0.38	Lobe attachment (rater-scored or self-reported);	chr6:145638345	chr6:145799409~145886585:+
PRAD	cis	rs853679	1	rs1778511	ENSG00000280107.1	AL022393.9	8.68	6.88e-17	4.31e-14	0.57	0.38	Depression;	chr6:28261633	chr6:28170845~28172521:+
PRAD	cis	rs7615952	0.576	rs2276729	ENSG00000171084.14	FAM86JP	8.68	6.89e-17	4.31e-14	0.59	0.38	Blood pressure (smoking interaction);	chr3:126107371	chr3:125916620~125930024:+
PRAD	cis	rs4835473	0.932	rs3872	ENSG00000251600.4	RP11-673E1.1	8.68	6.9e-17	4.32e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143968788	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.832	rs35398499	ENSG00000251600.4	RP11-673E1.1	-8.68	6.9e-17	4.32e-14	-0.48	-0.38	Immature fraction of reticulocytes;	chr4:143737715	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.832	rs35763177	ENSG00000251600.4	RP11-673E1.1	-8.68	6.9e-17	4.32e-14	-0.48	-0.38	Immature fraction of reticulocytes;	chr4:143737717	chr4:143912331~143982454:+
PRAD	cis	rs950169	0.887	rs35986397	ENSG00000259728.4	LINC00933	8.68	6.92e-17	4.33e-14	0.46	0.38	Schizophrenia;	chr15:84400409	chr15:84570649~84580175:+
PRAD	cis	rs3096299	0.967	rs753852	ENSG00000274627.1	RP11-104N10.2	8.68	6.94e-17	4.34e-14	0.39	0.38	Multiple myeloma (IgH translocation);	chr16:89380011	chr16:89516797~89522217:+
PRAD	cis	rs4835473	0.932	rs1511425	ENSG00000251600.4	RP11-673E1.1	8.68	6.95e-17	4.35e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143985122	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs1849120	ENSG00000251600.4	RP11-673E1.1	8.68	6.95e-17	4.35e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143985337	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs4835476	ENSG00000251600.4	RP11-673E1.1	8.68	6.95e-17	4.35e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143985517	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs1828502	ENSG00000251600.4	RP11-673E1.1	8.68	6.95e-17	4.35e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143985797	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs7668698	ENSG00000251600.4	RP11-673E1.1	8.68	6.95e-17	4.35e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143986333	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs6537231	ENSG00000251600.4	RP11-673E1.1	8.68	6.95e-17	4.35e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143986489	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs1877234	ENSG00000251600.4	RP11-673E1.1	8.68	6.95e-17	4.35e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143986774	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs4260486	ENSG00000251600.4	RP11-673E1.1	8.68	6.95e-17	4.35e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143987556	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.897	rs12649594	ENSG00000251600.4	RP11-673E1.1	8.68	6.95e-17	4.35e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143989307	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.864	rs13101482	ENSG00000251600.4	RP11-673E1.1	8.68	6.95e-17	4.35e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143989463	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.864	rs13135472	ENSG00000251600.4	RP11-673E1.1	8.68	6.95e-17	4.35e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143989465	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs1849118	ENSG00000251600.4	RP11-673E1.1	8.68	6.95e-17	4.35e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143989822	chr4:143912331~143982454:+
PRAD	cis	rs150992	0.587	rs12189335	ENSG00000248489.1	CTD-2007H13.3	-8.68	7.03e-17	4.39e-14	-0.42	-0.38	Body mass index;	chr5:99009311	chr5:98929171~98995013:+
PRAD	cis	rs2739330	0.753	rs4822452	ENSG00000224205.1	AP000351.4	8.68	7.03e-17	4.39e-14	0.47	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23987320~23991421:-
PRAD	cis	rs4835473	0.932	rs13107719	ENSG00000251600.4	RP11-673E1.1	-8.68	7.03e-17	4.39e-14	-0.49	-0.38	Immature fraction of reticulocytes;	chr4:143752034	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.897	rs2323194	ENSG00000251600.4	RP11-673E1.1	-8.68	7.03e-17	4.39e-14	-0.49	-0.38	Immature fraction of reticulocytes;	chr4:143752879	chr4:143912331~143982454:+
PRAD	cis	rs9903692	0.954	rs2051821	ENSG00000278765.1	RP5-890E16.5	8.68	7.03e-17	4.4e-14	0.57	0.38	Pulse pressure;	chr17:48066153	chr17:48066704~48067293:-
PRAD	cis	rs8062405	0.824	rs62034319	ENSG00000251417.2	RP11-1348G14.4	-8.68	7.04e-17	4.4e-14	-0.41	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520867	chr16:28802743~28817828:+
PRAD	cis	rs11098499	0.909	rs28571712	ENSG00000245958.5	RP11-33B1.1	-8.68	7.04e-17	4.4e-14	-0.37	-0.38	Corneal astigmatism;	chr4:119454825	chr4:119454791~119552025:+
PRAD	cis	rs4835473	0.932	rs1450236	ENSG00000251600.4	RP11-673E1.1	-8.68	7.05e-17	4.41e-14	-0.47	-0.38	Immature fraction of reticulocytes;	chr4:143783069	chr4:143912331~143982454:+
PRAD	cis	rs4713118	0.662	rs9393881	ENSG00000226314.6	ZNF192P1	-8.68	7.05e-17	4.41e-14	-0.52	-0.38	Parkinson's disease;	chr6:28055973	chr6:28161781~28169594:+
PRAD	cis	rs6723108	0.627	rs1348790	ENSG00000224043.6	CCNT2-AS1	-8.68	7.11e-17	4.44e-14	-0.53	-0.38	Type 2 diabetes;	chr2:134882405	chr2:134735464~134918710:-
PRAD	cis	rs6723108	0.627	rs4954193	ENSG00000224043.6	CCNT2-AS1	-8.68	7.11e-17	4.44e-14	-0.53	-0.38	Type 2 diabetes;	chr2:134884610	chr2:134735464~134918710:-
PRAD	cis	rs9903692	0.954	rs12936731	ENSG00000278765.1	RP5-890E16.5	8.68	7.13e-17	4.46e-14	0.57	0.38	Pulse pressure;	chr17:48050997	chr17:48066704~48067293:-
PRAD	cis	rs9903692	0.909	rs9899275	ENSG00000278765.1	RP5-890E16.5	8.68	7.13e-17	4.46e-14	0.57	0.38	Pulse pressure;	chr17:48051953	chr17:48066704~48067293:-
PRAD	cis	rs9903692	0.954	rs12450620	ENSG00000278765.1	RP5-890E16.5	8.68	7.13e-17	4.46e-14	0.57	0.38	Pulse pressure;	chr17:48052892	chr17:48066704~48067293:-
PRAD	cis	rs9903692	0.954	rs7212202	ENSG00000278765.1	RP5-890E16.5	8.68	7.13e-17	4.46e-14	0.57	0.38	Pulse pressure;	chr17:48055361	chr17:48066704~48067293:-
PRAD	cis	rs9903692	0.954	rs34750858	ENSG00000278765.1	RP5-890E16.5	8.68	7.13e-17	4.46e-14	0.57	0.38	Pulse pressure;	chr17:48055575	chr17:48066704~48067293:-
PRAD	cis	rs9903692	0.954	rs875065	ENSG00000278765.1	RP5-890E16.5	8.68	7.13e-17	4.46e-14	0.57	0.38	Pulse pressure;	chr17:48062207	chr17:48066704~48067293:-
PRAD	cis	rs9903692	0.954	rs875066	ENSG00000278765.1	RP5-890E16.5	8.68	7.13e-17	4.46e-14	0.57	0.38	Pulse pressure;	chr17:48062370	chr17:48066704~48067293:-
PRAD	cis	rs1979679	0.842	rs2127315	ENSG00000278733.1	RP11-425D17.1	8.68	7.15e-17	4.47e-14	0.48	0.38	Ossification of the posterior longitudinal ligament of the spine;	chr12:28156247	chr12:28185625~28186190:-
PRAD	cis	rs950169	0.92	rs12915390	ENSG00000259728.4	LINC00933	8.68	7.17e-17	4.48e-14	0.45	0.38	Schizophrenia;	chr15:84123317	chr15:84570649~84580175:+
PRAD	cis	rs950169	0.959	rs12902070	ENSG00000259728.4	LINC00933	8.68	7.17e-17	4.48e-14	0.45	0.38	Schizophrenia;	chr15:84124806	chr15:84570649~84580175:+
PRAD	cis	rs8062405	0.721	rs151303	ENSG00000251417.2	RP11-1348G14.4	-8.68	7.18e-17	4.48e-14	-0.43	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28481189	chr16:28802743~28817828:+
PRAD	cis	rs10463554	0.963	rs13340364	ENSG00000175749.11	EIF3KP1	8.68	7.2e-17	4.5e-14	0.49	0.38	Parkinson's disease;	chr5:103003406	chr5:103032376~103033031:+
PRAD	cis	rs748404	0.631	rs2412781	ENSG00000249839.1	AC011330.5	8.68	7.21e-17	4.5e-14	0.46	0.38	Lung cancer;	chr15:43375702	chr15:43663654~43684339:-
PRAD	cis	rs6921919	0.515	rs1339898	ENSG00000216901.1	AL022393.7	8.68	7.21e-17	4.5e-14	0.47	0.38	Autism spectrum disorder or schizophrenia;	chr6:28427729	chr6:28176188~28176674:+
PRAD	cis	rs2933343	0.909	rs1683817	ENSG00000261159.1	RP11-723O4.9	8.68	7.21e-17	4.5e-14	0.36	0.38	IgG glycosylation;	chr3:128932693	chr3:128859716~128860526:-
PRAD	cis	rs4713118	0.866	rs2179094	ENSG00000280107.1	AL022393.9	-8.68	7.22e-17	4.51e-14	-0.47	-0.38	Parkinson's disease;	chr6:27774046	chr6:28170845~28172521:+
PRAD	cis	rs875971	0.508	rs10242423	ENSG00000237310.1	GS1-124K5.4	-8.68	7.22e-17	4.51e-14	-0.33	-0.38	Aortic root size;	chr7:66594188	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.508	rs10253883	ENSG00000237310.1	GS1-124K5.4	-8.68	7.22e-17	4.51e-14	-0.33	-0.38	Aortic root size;	chr7:66596151	chr7:66493706~66495474:+
PRAD	cis	rs2274273	0.868	rs6573007	ENSG00000258413.1	RP11-665C16.6	-8.68	7.23e-17	4.51e-14	-0.5	-0.38	Protein biomarker;	chr14:55159220	chr14:55262767~55272075:-
PRAD	cis	rs11098499	0.731	rs6846966	ENSG00000245958.5	RP11-33B1.1	-8.68	7.23e-17	4.51e-14	-0.36	-0.38	Corneal astigmatism;	chr4:119372053	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.866	rs6847778	ENSG00000245958.5	RP11-33B1.1	-8.68	7.23e-17	4.51e-14	-0.36	-0.38	Corneal astigmatism;	chr4:119372427	chr4:119454791~119552025:+
PRAD	cis	rs11676348	0.741	rs12694425	ENSG00000261338.2	RP11-378A13.1	8.68	7.26e-17	4.53e-14	0.41	0.38	Ulcerative colitis;	chr2:218077590	chr2:218255319~218257366:+
PRAD	cis	rs11098499	0.954	rs10006525	ENSG00000245958.5	RP11-33B1.1	-8.68	7.26e-17	4.53e-14	-0.37	-0.38	Corneal astigmatism;	chr4:119487776	chr4:119454791~119552025:+
PRAD	cis	rs3096299	1	rs3096299	ENSG00000274627.1	RP11-104N10.2	8.68	7.29e-17	4.55e-14	0.39	0.38	Multiple myeloma (IgH translocation);	chr16:89382255	chr16:89516797~89522217:+
PRAD	cis	rs8062405	0.824	rs7191618	ENSG00000251417.2	RP11-1348G14.4	-8.68	7.34e-17	4.58e-14	-0.41	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554346	chr16:28802743~28817828:+
PRAD	cis	rs8062405	0.754	rs3859172	ENSG00000251417.2	RP11-1348G14.4	-8.68	7.34e-17	4.58e-14	-0.41	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554837	chr16:28802743~28817828:+
PRAD	cis	rs7712401	0.601	rs154500	ENSG00000263432.2	RN7SL689P	8.68	7.34e-17	4.58e-14	0.39	0.38	Mean platelet volume;	chr5:122876296	chr5:123022487~123022783:-
PRAD	cis	rs4835473	0.699	rs4835127	ENSG00000251600.4	RP11-673E1.1	8.68	7.35e-17	4.58e-14	0.49	0.38	Immature fraction of reticulocytes;	chr4:143997972	chr4:143912331~143982454:+
PRAD	cis	rs9595066	0.715	rs9567366	ENSG00000227258.4	SMIM2-AS1	-8.68	7.36e-17	4.59e-14	-0.62	-0.38	Schizophrenia;	chr13:44108837	chr13:44110451~44240517:+
PRAD	cis	rs875971	0.964	rs55748098	ENSG00000237310.1	GS1-124K5.4	-8.68	7.36e-17	4.59e-14	-0.33	-0.38	Aortic root size;	chr7:66298631	chr7:66493706~66495474:+
PRAD	cis	rs56145559	1	rs56145559	ENSG00000163016.8	ALMS1P	8.68	7.37e-17	4.6e-14	0.47	0.38	Schizophrenia;	chr2:73396311	chr2:73644919~73685576:+
PRAD	cis	rs12142240	0.698	rs56358525	ENSG00000232022.5	FAAHP1	-8.67	7.42e-17	4.63e-14	-0.35	-0.38	Menopause (age at onset);	chr1:46383848	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.667	rs45524035	ENSG00000232022.5	FAAHP1	-8.67	7.42e-17	4.63e-14	-0.35	-0.38	Menopause (age at onset);	chr1:46397108	chr1:46432129~46445521:+
PRAD	cis	rs17711722	0.565	rs73372653	ENSG00000224316.1	RP11-479O9.2	8.67	7.44e-17	4.64e-14	0.35	0.38	Calcium levels;	chr7:65977808	chr7:65773620~65802067:+
PRAD	cis	rs6991838	0.765	rs10957358	ENSG00000272010.1	CTD-3025N20.3	8.67	7.48e-17	4.66e-14	0.37	0.38	Intelligence (multi-trait analysis);	chr8:65590067	chr8:65591850~65592472:-
PRAD	cis	rs17608059	0.71	rs8080167	ENSG00000141028.6	CDRT15P1	-8.67	7.48e-17	4.66e-14	-0.48	-0.38	Temperament;	chr17:14046511	chr17:14024514~14025488:+
PRAD	cis	rs17608059	0.679	rs9898056	ENSG00000141028.6	CDRT15P1	-8.67	7.48e-17	4.66e-14	-0.48	-0.38	Temperament;	chr17:14048649	chr17:14024514~14025488:+
PRAD	cis	rs853679	0.628	rs9368560	ENSG00000219392.1	RP1-265C24.5	-8.67	7.5e-17	4.68e-14	-0.49	-0.38	Depression;	chr6:28192182	chr6:28115628~28116551:+
PRAD	cis	rs4718428	0.705	rs13220977	ENSG00000230295.1	RP11-458F8.2	8.67	7.53e-17	4.69e-14	0.28	0.38	Corneal structure;	chr7:66872661	chr7:66880708~66882981:+
PRAD	cis	rs12664251	0.809	rs6931074	ENSG00000253194.1	RP11-351A11.1	8.67	7.57e-17	4.72e-14	0.49	0.38	Schizophrenia;	chr6:119020840	chr6:118934785~119031541:+
PRAD	cis	rs6723108	0.627	rs7589297	ENSG00000224043.6	CCNT2-AS1	-8.67	7.57e-17	4.72e-14	-0.52	-0.38	Type 2 diabetes;	chr2:134894829	chr2:134735464~134918710:-
PRAD	cis	rs7712401	0.584	rs28373879	ENSG00000263432.2	RN7SL689P	8.67	7.61e-17	4.74e-14	0.39	0.38	Mean platelet volume;	chr5:123036707	chr5:123022487~123022783:-
PRAD	cis	rs7727544	0.548	rs4705938	ENSG00000233006.5	AC034220.3	8.67	7.62e-17	4.75e-14	0.33	0.38	Blood metabolite levels;	chr5:132358384	chr5:132311285~132369916:-
PRAD	cis	rs17361889	0.766	rs1527220	ENSG00000224683.1	RPL36AP29	8.67	7.64e-17	4.76e-14	0.44	0.38	Pediatric bone mineral content (hip);	chr7:16206354	chr7:16208945~16209265:+
PRAD	cis	rs673078	0.607	rs59594854	ENSG00000275409.1	RP11-131L12.4	-8.67	7.65e-17	4.77e-14	-0.47	-0.38	Glucose homeostasis traits;	chr12:118374000	chr12:118430147~118430699:+
PRAD	cis	rs321358	0.895	rs73015175	ENSG00000271584.1	RP11-89C3.4	8.67	7.66e-17	4.77e-14	0.58	0.38	Body mass index;	chr11:111088593	chr11:111091932~111097357:-
PRAD	cis	rs321358	0.895	rs17536143	ENSG00000271584.1	RP11-89C3.4	8.67	7.66e-17	4.77e-14	0.58	0.38	Body mass index;	chr11:111088619	chr11:111091932~111097357:-
PRAD	cis	rs321358	0.895	rs12419745	ENSG00000271584.1	RP11-89C3.4	8.67	7.66e-17	4.77e-14	0.58	0.38	Body mass index;	chr11:111090741	chr11:111091932~111097357:-
PRAD	cis	rs950169	0.84	rs72748702	ENSG00000259728.4	LINC00933	8.67	7.69e-17	4.79e-14	0.46	0.38	Schizophrenia;	chr15:84246494	chr15:84570649~84580175:+
PRAD	cis	rs11098499	0.908	rs9995234	ENSG00000245958.5	RP11-33B1.1	-8.67	7.72e-17	4.81e-14	-0.39	-0.38	Corneal astigmatism;	chr4:119400672	chr4:119454791~119552025:+
PRAD	cis	rs858239	0.796	rs433395	ENSG00000226816.2	AC005082.12	8.67	7.73e-17	4.81e-14	0.42	0.38	Cerebrospinal fluid biomarker levels;	chr7:23362336	chr7:23206013~23208045:+
PRAD	cis	rs150992	0.587	rs1393210	ENSG00000248489.1	CTD-2007H13.3	-8.67	7.73e-17	4.82e-14	-0.42	-0.38	Body mass index;	chr5:99025892	chr5:98929171~98995013:+
PRAD	cis	rs150992	0.587	rs11242567	ENSG00000248489.1	CTD-2007H13.3	-8.67	7.73e-17	4.82e-14	-0.42	-0.38	Body mass index;	chr5:99028686	chr5:98929171~98995013:+
PRAD	cis	rs7811142	1	rs76913697	ENSG00000242294.5	STAG3L5P	8.67	7.74e-17	4.82e-14	0.25	0.38	Platelet count;	chr7:100405149	chr7:100336079~100351900:+
PRAD	cis	rs950169	0.922	rs17531523	ENSG00000225151.9	GOLGA2P7	-8.67	7.75e-17	4.83e-14	-0.54	-0.38	Schizophrenia;	chr15:84589218	chr15:84199311~84230136:-
PRAD	cis	rs2153535	0.518	rs9379225	ENSG00000230939.1	RP11-314C16.1	-8.67	7.76e-17	4.83e-14	-0.45	-0.38	Motion sickness;	chr6:8566027	chr6:8784178~8785445:+
PRAD	cis	rs11098499	0.954	rs11098526	ENSG00000245958.5	RP11-33B1.1	-8.67	7.77e-17	4.84e-14	-0.37	-0.38	Corneal astigmatism;	chr4:119469204	chr4:119454791~119552025:+
PRAD	cis	rs9487094	0.744	rs12661287	ENSG00000260273.1	RP11-425D10.10	8.67	7.79e-17	4.85e-14	0.54	0.38	Height;	chr6:109732047	chr6:109382795~109383666:+
PRAD	cis	rs6538678	0.895	rs1436124	ENSG00000258343.1	RP11-536G4.2	-8.67	7.83e-17	4.87e-14	-0.51	-0.38	Lupus nephritis in systemic lupus erythematosus;	chr12:95889654	chr12:95795345~95858839:-
PRAD	cis	rs4835473	0.8	rs1849122	ENSG00000251600.4	RP11-673E1.1	8.67	7.84e-17	4.88e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143978699	chr4:143912331~143982454:+
PRAD	cis	rs748404	0.66	rs2444251	ENSG00000249839.1	AC011330.5	-8.67	7.86e-17	4.89e-14	-0.46	-0.38	Lung cancer;	chr15:43496397	chr15:43663654~43684339:-
PRAD	cis	rs12701220	0.553	rs9639882	ENSG00000229043.2	AC091729.9	-8.67	7.9e-17	4.92e-14	-0.55	-0.38	Bronchopulmonary dysplasia;	chr7:1094095	chr7:1160374~1165267:+
PRAD	cis	rs4380275	0.965	rs4375894	ENSG00000272342.1	RP13-539J13.1	8.67	7.94e-17	4.94e-14	0.48	0.38	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:772567	chr2:739588~740164:-
PRAD	cis	rs7688540	0.723	rs80316648	ENSG00000275426.1	CH17-262A2.1	8.66	7.99e-17	4.97e-14	0.54	0.38	Facial morphology (factor 6, height of vermillion lower lip);	chr4:238426	chr4:149738~150317:+
PRAD	cis	rs875971	0.895	rs4718349	ENSG00000237310.1	GS1-124K5.4	8.66	8e-17	4.97e-14	0.33	0.38	Aortic root size;	chr7:66444024	chr7:66493706~66495474:+
PRAD	cis	rs875971	1	rs2042133	ENSG00000237310.1	GS1-124K5.4	8.66	8e-17	4.97e-14	0.33	0.38	Aortic root size;	chr7:66466935	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.964	rs2161065	ENSG00000237310.1	GS1-124K5.4	8.66	8e-17	4.97e-14	0.33	0.38	Aortic root size;	chr7:66467918	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.862	rs12698521	ENSG00000237310.1	GS1-124K5.4	8.66	8e-17	4.97e-14	0.33	0.38	Aortic root size;	chr7:66474502	chr7:66493706~66495474:+
PRAD	cis	rs6452524	0.837	rs1479569	ENSG00000249664.1	CTD-2227C6.2	8.66	8.01e-17	4.98e-14	0.47	0.38	Hypertension (SNP x SNP interaction);	chr5:83081747	chr5:83012285~83013109:-
PRAD	cis	rs11098499	0.908	rs7696649	ENSG00000245958.5	RP11-33B1.1	-8.66	8.03e-17	4.99e-14	-0.37	-0.38	Corneal astigmatism;	chr4:119401022	chr4:119454791~119552025:+
PRAD	cis	rs7569084	1	rs13385171	ENSG00000204929.10	AC074391.1	-8.66	8.06e-17	5.01e-14	-0.47	-0.38	Sum eosinophil basophil counts;	chr2:65434709	chr2:65436711~66084639:+
PRAD	cis	rs12220777	1	rs11201660	ENSG00000230091.5	TMEM254-AS1	-8.66	8.08e-17	5.02e-14	-0.71	-0.38	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80094775	chr10:80046860~80078912:-
PRAD	cis	rs853679	1	rs1679732	ENSG00000280107.1	AL022393.9	8.66	8.09e-17	5.03e-14	0.57	0.38	Depression;	chr6:28253486	chr6:28170845~28172521:+
PRAD	cis	rs853679	1	rs1679709	ENSG00000280107.1	AL022393.9	8.66	8.09e-17	5.03e-14	0.57	0.38	Depression;	chr6:28260564	chr6:28170845~28172521:+
PRAD	cis	rs6452524	0.934	rs10473870	ENSG00000249664.1	CTD-2227C6.2	8.66	8.1e-17	5.03e-14	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83199768	chr5:83012285~83013109:-
PRAD	cis	rs11098499	0.863	rs12508173	ENSG00000245958.5	RP11-33B1.1	-8.66	8.1e-17	5.04e-14	-0.37	-0.38	Corneal astigmatism;	chr4:119397371	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.908	rs12504149	ENSG00000245958.5	RP11-33B1.1	-8.66	8.1e-17	5.04e-14	-0.37	-0.38	Corneal astigmatism;	chr4:119397422	chr4:119454791~119552025:+
PRAD	cis	rs4718428	0.705	rs3800817	ENSG00000230295.1	RP11-458F8.2	-8.66	8.16e-17	5.07e-14	-0.28	-0.38	Corneal structure;	chr7:66798563	chr7:66880708~66882981:+
PRAD	cis	rs673078	0.607	rs2036314	ENSG00000275409.1	RP11-131L12.4	-8.66	8.18e-17	5.08e-14	-0.5	-0.38	Glucose homeostasis traits;	chr12:118367132	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.607	rs61943369	ENSG00000275409.1	RP11-131L12.4	-8.66	8.18e-17	5.08e-14	-0.5	-0.38	Glucose homeostasis traits;	chr12:118368145	chr12:118430147~118430699:+
PRAD	cis	rs2933343	1	rs1680795	ENSG00000261159.1	RP11-723O4.9	8.66	8.19e-17	5.09e-14	0.36	0.38	IgG glycosylation;	chr3:128901545	chr3:128859716~128860526:-
PRAD	cis	rs7727544	0.594	rs10479000	ENSG00000233006.5	AC034220.3	8.66	8.22e-17	5.11e-14	0.34	0.38	Blood metabolite levels;	chr5:132271709	chr5:132311285~132369916:-
PRAD	cis	rs8062405	0.754	rs151179	ENSG00000251417.2	RP11-1348G14.4	-8.66	8.23e-17	5.11e-14	-0.42	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28475735	chr16:28802743~28817828:+
PRAD	cis	rs4835473	0.715	rs1849124	ENSG00000251600.4	RP11-673E1.1	8.66	8.23e-17	5.11e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143978494	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.689	rs1849123	ENSG00000251600.4	RP11-673E1.1	8.66	8.23e-17	5.11e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143978495	chr4:143912331~143982454:+
PRAD	cis	rs2274273	0.87	rs10147434	ENSG00000258413.1	RP11-665C16.6	-8.66	8.26e-17	5.13e-14	-0.49	-0.38	Protein biomarker;	chr14:55208129	chr14:55262767~55272075:-
PRAD	cis	rs7945705	0.747	rs1123936	ENSG00000254860.4	TMEM9B-AS1	8.66	8.32e-17	5.17e-14	0.38	0.38	Hemoglobin concentration;	chr11:8981759	chr11:8964675~8977527:+
PRAD	cis	rs2638953	0.924	rs7307078	ENSG00000278733.1	RP11-425D17.1	-8.66	8.33e-17	5.17e-14	-0.45	-0.38	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28184645	chr12:28185625~28186190:-
PRAD	cis	rs9903692	0.909	rs8078125	ENSG00000278765.1	RP5-890E16.5	8.66	8.33e-17	5.17e-14	0.57	0.38	Pulse pressure;	chr17:48068347	chr17:48066704~48067293:-
PRAD	cis	rs9903692	0.954	rs11651097	ENSG00000278765.1	RP5-890E16.5	8.66	8.33e-17	5.17e-14	0.57	0.38	Pulse pressure;	chr17:48069677	chr17:48066704~48067293:-
PRAD	cis	rs321358	0.945	rs73015196	ENSG00000271584.1	RP11-89C3.4	8.66	8.33e-17	5.17e-14	0.58	0.38	Body mass index;	chr11:111104608	chr11:111091932~111097357:-
PRAD	cis	rs321358	0.945	rs73015199	ENSG00000271584.1	RP11-89C3.4	8.66	8.33e-17	5.17e-14	0.58	0.38	Body mass index;	chr11:111104952	chr11:111091932~111097357:-
PRAD	cis	rs321358	0.945	rs7111445	ENSG00000271584.1	RP11-89C3.4	-8.66	8.33e-17	5.17e-14	-0.58	-0.38	Body mass index;	chr11:111105787	chr11:111091932~111097357:-
PRAD	cis	rs4631830	0.863	rs57263518	ENSG00000230869.1	CTGLF10P	-8.66	8.33e-17	5.17e-14	-0.46	-0.38	Prostate-specific antigen levels;	chr10:46076668	chr10:45678692~45700532:+
PRAD	cis	rs2439831	0.85	rs16950562	ENSG00000249839.1	AC011330.5	-8.66	8.34e-17	5.18e-14	-0.64	-0.38	Lung cancer in ever smokers;	chr15:43744166	chr15:43663654~43684339:-
PRAD	cis	rs2439831	0.85	rs12441861	ENSG00000249839.1	AC011330.5	-8.66	8.34e-17	5.18e-14	-0.64	-0.38	Lung cancer in ever smokers;	chr15:43768685	chr15:43663654~43684339:-
PRAD	cis	rs11098499	0.863	rs12498539	ENSG00000245958.5	RP11-33B1.1	-8.66	8.35e-17	5.18e-14	-0.37	-0.38	Corneal astigmatism;	chr4:119547215	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.863	rs3822194	ENSG00000245958.5	RP11-33B1.1	-8.66	8.35e-17	5.18e-14	-0.37	-0.38	Corneal astigmatism;	chr4:119550493	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.954	rs7436506	ENSG00000245958.5	RP11-33B1.1	-8.66	8.36e-17	5.19e-14	-0.37	-0.38	Corneal astigmatism;	chr4:119472614	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.954	rs10008459	ENSG00000245958.5	RP11-33B1.1	-8.66	8.36e-17	5.19e-14	-0.37	-0.38	Corneal astigmatism;	chr4:119473076	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.909	rs2127821	ENSG00000245958.5	RP11-33B1.1	-8.66	8.36e-17	5.19e-14	-0.37	-0.38	Corneal astigmatism;	chr4:119473380	chr4:119454791~119552025:+
PRAD	cis	rs2739330	0.76	rs5751761	ENSG00000272787.1	KB-226F1.2	8.66	8.36e-17	5.19e-14	0.39	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23969211~23969873:+
PRAD	cis	rs875971	1	rs7781698	ENSG00000237310.1	GS1-124K5.4	8.66	8.36e-17	5.19e-14	0.33	0.38	Aortic root size;	chr7:66431325	chr7:66493706~66495474:+
PRAD	cis	rs6570726	0.837	rs419991	ENSG00000235652.6	RP11-545I5.3	8.66	8.37e-17	5.19e-14	0.39	0.38	Lobe attachment (rater-scored or self-reported);	chr6:145543076	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.875	rs12524077	ENSG00000235652.6	RP11-545I5.3	8.66	8.37e-17	5.19e-14	0.39	0.38	Lobe attachment (rater-scored or self-reported);	chr6:145545197	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.875	rs416243	ENSG00000235652.6	RP11-545I5.3	8.66	8.37e-17	5.19e-14	0.39	0.38	Lobe attachment (rater-scored or self-reported);	chr6:145546945	chr6:145799409~145886585:+
PRAD	cis	rs2243480	1	rs316315	ENSG00000226824.5	RP4-756H11.3	8.66	8.38e-17	5.2e-14	0.64	0.38	Diabetic kidney disease;	chr7:66126218	chr7:66654538~66669855:+
PRAD	cis	rs2274273	0.87	rs1952087	ENSG00000258413.1	RP11-665C16.6	-8.66	8.38e-17	5.2e-14	-0.49	-0.38	Protein biomarker;	chr14:55216493	chr14:55262767~55272075:-
PRAD	cis	rs4835473	0.831	rs4323050	ENSG00000251600.4	RP11-673E1.1	8.66	8.42e-17	5.22e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143992106	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.897	rs4423826	ENSG00000251600.4	RP11-673E1.1	8.66	8.42e-17	5.22e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143992165	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs1849128	ENSG00000251600.4	RP11-673E1.1	8.66	8.42e-17	5.22e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143992582	chr4:143912331~143982454:+
PRAD	cis	rs7811142	0.943	rs10241492	ENSG00000242294.5	STAG3L5P	8.66	8.44e-17	5.23e-14	0.25	0.38	Platelet count;	chr7:100397190	chr7:100336079~100351900:+
PRAD	cis	rs4835473	0.932	rs11100824	ENSG00000251600.4	RP11-673E1.1	8.66	8.45e-17	5.24e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143964845	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.592	rs11100825	ENSG00000251600.4	RP11-673E1.1	8.66	8.45e-17	5.24e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143964903	chr4:143912331~143982454:+
PRAD	cis	rs875971	0.965	rs10267430	ENSG00000237310.1	GS1-124K5.4	-8.66	8.46e-17	5.24e-14	-0.33	-0.38	Aortic root size;	chr7:66278036	chr7:66493706~66495474:+
PRAD	cis	rs875971	1	rs10257427	ENSG00000237310.1	GS1-124K5.4	-8.66	8.46e-17	5.24e-14	-0.33	-0.38	Aortic root size;	chr7:66278221	chr7:66493706~66495474:+
PRAD	cis	rs875971	1	rs10215948	ENSG00000237310.1	GS1-124K5.4	-8.66	8.46e-17	5.24e-14	-0.33	-0.38	Aortic root size;	chr7:66282799	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.964	rs778723	ENSG00000237310.1	GS1-124K5.4	8.66	8.46e-17	5.24e-14	0.33	0.38	Aortic root size;	chr7:66364510	chr7:66493706~66495474:+
PRAD	cis	rs6452524	0.901	rs1842020	ENSG00000249664.1	CTD-2227C6.2	8.66	8.46e-17	5.24e-14	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83125814	chr5:83012285~83013109:-
PRAD	cis	rs7615952	1	rs7616044	ENSG00000171084.14	FAM86JP	8.66	8.49e-17	5.27e-14	0.62	0.38	Blood pressure (smoking interaction);	chr3:125930511	chr3:125916620~125930024:+
PRAD	cis	rs11098499	0.657	rs71614442	ENSG00000245958.5	RP11-33B1.1	-8.66	8.52e-17	5.28e-14	-0.37	-0.38	Corneal astigmatism;	chr4:119458191	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.954	rs2892848	ENSG00000245958.5	RP11-33B1.1	-8.66	8.52e-17	5.28e-14	-0.37	-0.38	Corneal astigmatism;	chr4:119460186	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.697	rs11941899	ENSG00000245958.5	RP11-33B1.1	-8.66	8.52e-17	5.28e-14	-0.37	-0.38	Corneal astigmatism;	chr4:119461603	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.909	rs7681978	ENSG00000245958.5	RP11-33B1.1	-8.66	8.52e-17	5.28e-14	-0.37	-0.38	Corneal astigmatism;	chr4:119462620	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.821	rs28665282	ENSG00000245958.5	RP11-33B1.1	-8.66	8.52e-17	5.28e-14	-0.37	-0.38	Corneal astigmatism;	chr4:119463031	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.738	rs10026493	ENSG00000245958.5	RP11-33B1.1	-8.66	8.52e-17	5.28e-14	-0.37	-0.38	Corneal astigmatism;	chr4:119463039	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.909	rs7681214	ENSG00000245958.5	RP11-33B1.1	-8.66	8.52e-17	5.28e-14	-0.37	-0.38	Corneal astigmatism;	chr4:119464165	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.908	rs28559989	ENSG00000245958.5	RP11-33B1.1	-8.66	8.52e-17	5.28e-14	-0.37	-0.38	Corneal astigmatism;	chr4:119465472	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.909	rs28632018	ENSG00000245958.5	RP11-33B1.1	-8.66	8.52e-17	5.28e-14	-0.37	-0.38	Corneal astigmatism;	chr4:119465575	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.908	rs71614449	ENSG00000245958.5	RP11-33B1.1	-8.66	8.52e-17	5.28e-14	-0.37	-0.38	Corneal astigmatism;	chr4:119465900	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.954	rs35063680	ENSG00000245958.5	RP11-33B1.1	-8.66	8.52e-17	5.28e-14	-0.37	-0.38	Corneal astigmatism;	chr4:119465947	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.954	rs34858317	ENSG00000245958.5	RP11-33B1.1	-8.66	8.52e-17	5.28e-14	-0.37	-0.38	Corneal astigmatism;	chr4:119465955	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.954	rs17046116	ENSG00000245958.5	RP11-33B1.1	-8.66	8.52e-17	5.28e-14	-0.37	-0.38	Corneal astigmatism;	chr4:119466104	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.909	rs17046118	ENSG00000245958.5	RP11-33B1.1	-8.66	8.52e-17	5.28e-14	-0.37	-0.38	Corneal astigmatism;	chr4:119466341	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.954	rs3733519	ENSG00000245958.5	RP11-33B1.1	-8.66	8.54e-17	5.29e-14	-0.38	-0.38	Corneal astigmatism;	chr4:119502293	chr4:119454791~119552025:+
PRAD	cis	rs2439831	0.702	rs8033995	ENSG00000249839.1	AC011330.5	-8.65	8.59e-17	5.32e-14	-0.64	-0.38	Lung cancer in ever smokers;	chr15:43721311	chr15:43663654~43684339:-
PRAD	cis	rs875971	1	rs2220626	ENSG00000237310.1	GS1-124K5.4	-8.65	8.59e-17	5.32e-14	-0.34	-0.38	Aortic root size;	chr7:66081075	chr7:66493706~66495474:+
PRAD	cis	rs11676348	0.774	rs57545959	ENSG00000261338.2	RP11-378A13.1	8.65	8.6e-17	5.33e-14	0.42	0.38	Ulcerative colitis;	chr2:218182995	chr2:218255319~218257366:+
PRAD	cis	rs10463554	0.926	rs5855	ENSG00000175749.11	EIF3KP1	-8.65	8.61e-17	5.33e-14	-0.49	-0.38	Parkinson's disease;	chr5:103029482	chr5:103032376~103033031:+
PRAD	cis	rs10463554	0.926	rs3776858	ENSG00000175749.11	EIF3KP1	8.65	8.62e-17	5.34e-14	0.49	0.38	Parkinson's disease;	chr5:103021790	chr5:103032376~103033031:+
PRAD	cis	rs6570726	0.935	rs585292	ENSG00000235652.6	RP11-545I5.3	8.65	8.64e-17	5.35e-14	0.39	0.38	Lobe attachment (rater-scored or self-reported);	chr6:145541092	chr6:145799409~145886585:+
PRAD	cis	rs4835473	0.932	rs13152443	ENSG00000251600.4	RP11-673E1.1	-8.65	8.69e-17	5.38e-14	-0.48	-0.38	Immature fraction of reticulocytes;	chr4:143742492	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs9685306	ENSG00000251600.4	RP11-673E1.1	-8.65	8.69e-17	5.38e-14	-0.48	-0.38	Immature fraction of reticulocytes;	chr4:143748843	chr4:143912331~143982454:+
PRAD	cis	rs6847067	0.8	rs6531777	ENSG00000180769.7	WDFY3-AS2	8.65	8.7e-17	5.39e-14	0.39	0.38	Oropharynx cancer;	chr4:84943942	chr4:84965682~85011277:+
PRAD	cis	rs12817211	0.502	rs7307230	ENSG00000272368.2	RP4-605O3.4	8.65	8.75e-17	5.42e-14	0.38	0.38	Colorectal or endometrial cancer;	chr12:50118849	chr12:50112197~50165618:+
PRAD	cis	rs34779708	0.733	rs12254018	ENSG00000230534.5	RP11-297A16.2	8.65	8.75e-17	5.42e-14	0.5	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35261713	chr10:35098006~35127020:-
PRAD	cis	rs4835473	0.771	rs4443231	ENSG00000251600.4	RP11-673E1.1	8.65	8.76e-17	5.43e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143979501	chr4:143912331~143982454:+
PRAD	cis	rs2439831	0.85	rs12441127	ENSG00000249839.1	AC011330.5	-8.65	8.76e-17	5.43e-14	-0.64	-0.38	Lung cancer in ever smokers;	chr15:43728977	chr15:43663654~43684339:-
PRAD	cis	rs7598759	0.679	rs6437018	ENSG00000181798.2	LINC00471	-8.65	8.78e-17	5.43e-14	-0.44	-0.38	Noise-induced hearing loss;	chr2:231462980	chr2:231508426~231514339:-
PRAD	cis	rs7598759	0.679	rs6437019	ENSG00000181798.2	LINC00471	-8.65	8.78e-17	5.43e-14	-0.44	-0.38	Noise-induced hearing loss;	chr2:231462996	chr2:231508426~231514339:-
PRAD	cis	rs9399137	0.507	rs7754722	ENSG00000232876.1	CTA-212D2.2	8.65	8.85e-17	5.47e-14	0.48	0.38	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134939165	chr6:135055033~135060550:+
PRAD	cis	rs6723108	0.603	rs1592	ENSG00000224043.6	CCNT2-AS1	-8.65	8.86e-17	5.48e-14	-0.52	-0.38	Type 2 diabetes;	chr2:134964573	chr2:134735464~134918710:-
PRAD	cis	rs7615952	0.932	rs7629977	ENSG00000171084.14	FAM86JP	8.65	8.87e-17	5.49e-14	0.62	0.38	Blood pressure (smoking interaction);	chr3:125930730	chr3:125916620~125930024:+
PRAD	cis	rs1930961	1	rs760555	ENSG00000272798.1	CTA-390C10.9	-8.65	8.88e-17	5.49e-14	-0.6	-0.38	Bipolar disorder with mood-incongruent psychosis;	chr22:25476870	chr22:25436312~25436915:+
PRAD	cis	rs6570726	0.935	rs380433	ENSG00000235652.6	RP11-545I5.3	8.65	8.88e-17	5.5e-14	0.39	0.38	Lobe attachment (rater-scored or self-reported);	chr6:145538465	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.935	rs367643	ENSG00000235652.6	RP11-545I5.3	8.65	8.88e-17	5.5e-14	0.39	0.38	Lobe attachment (rater-scored or self-reported);	chr6:145538466	chr6:145799409~145886585:+
PRAD	cis	rs6723108	0.627	rs2197579	ENSG00000224043.6	CCNT2-AS1	-8.65	8.88e-17	5.5e-14	-0.52	-0.38	Type 2 diabetes;	chr2:134887408	chr2:134735464~134918710:-
PRAD	cis	rs10463554	0.963	rs62362546	ENSG00000175749.11	EIF3KP1	8.65	8.89e-17	5.5e-14	0.49	0.38	Parkinson's disease;	chr5:103015615	chr5:103032376~103033031:+
PRAD	cis	rs5769707	0.681	rs135879	ENSG00000188511.11	C22orf34	8.65	8.92e-17	5.52e-14	0.42	0.38	Monocyte percentage of white cells;Monocyte count;	chr22:49625003	chr22:49414524~49657542:-
PRAD	cis	rs5769707	0.642	rs135880	ENSG00000188511.11	C22orf34	8.65	8.92e-17	5.52e-14	0.42	0.38	Monocyte percentage of white cells;Monocyte count;	chr22:49625006	chr22:49414524~49657542:-
PRAD	cis	rs2274273	0.967	rs1009978	ENSG00000258413.1	RP11-665C16.6	-8.65	8.93e-17	5.53e-14	-0.49	-0.38	Protein biomarker;	chr14:55136343	chr14:55262767~55272075:-
PRAD	cis	rs4835473	0.932	rs12512202	ENSG00000251600.4	RP11-673E1.1	-8.65	8.94e-17	5.53e-14	-0.48	-0.38	Immature fraction of reticulocytes;	chr4:143771248	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs6843671	ENSG00000251600.4	RP11-673E1.1	-8.65	8.94e-17	5.53e-14	-0.48	-0.38	Immature fraction of reticulocytes;	chr4:143772041	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.9	rs35395070	ENSG00000251600.4	RP11-673E1.1	-8.65	8.94e-17	5.53e-14	-0.48	-0.38	Immature fraction of reticulocytes;	chr4:143772283	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.9	rs34614750	ENSG00000251600.4	RP11-673E1.1	-8.65	8.94e-17	5.53e-14	-0.48	-0.38	Immature fraction of reticulocytes;	chr4:143772369	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs35002497	ENSG00000251600.4	RP11-673E1.1	-8.65	8.94e-17	5.53e-14	-0.48	-0.38	Immature fraction of reticulocytes;	chr4:143772952	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.9	rs13119630	ENSG00000251600.4	RP11-673E1.1	-8.65	8.94e-17	5.53e-14	-0.48	-0.38	Immature fraction of reticulocytes;	chr4:143773901	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs1450233	ENSG00000251600.4	RP11-673E1.1	-8.65	8.94e-17	5.53e-14	-0.48	-0.38	Immature fraction of reticulocytes;	chr4:143774710	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs4308330	ENSG00000251600.4	RP11-673E1.1	-8.65	8.94e-17	5.53e-14	-0.48	-0.38	Immature fraction of reticulocytes;	chr4:143774761	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs11725708	ENSG00000251600.4	RP11-673E1.1	-8.65	8.94e-17	5.53e-14	-0.48	-0.38	Immature fraction of reticulocytes;	chr4:143775683	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs17762299	ENSG00000251600.4	RP11-673E1.1	-8.65	8.94e-17	5.53e-14	-0.48	-0.38	Immature fraction of reticulocytes;	chr4:143777196	chr4:143912331~143982454:+
PRAD	cis	rs3743772	0.5	rs4784308	ENSG00000279722.1	RP11-44F14.6	8.65	8.99e-17	5.56e-14	0.46	0.38	Depressive symptoms (SSRI exposure interaction);	chr16:53406387	chr16:53487607~53489943:-
PRAD	cis	rs4713118	0.824	rs9468225	ENSG00000280107.1	AL022393.9	-8.65	8.99e-17	5.56e-14	-0.47	-0.38	Parkinson's disease;	chr6:27777940	chr6:28170845~28172521:+
PRAD	cis	rs5769707	0.605	rs6009791	ENSG00000188511.11	C22orf34	8.65	9e-17	5.56e-14	0.45	0.38	Monocyte percentage of white cells;Monocyte count;	chr22:49631617	chr22:49414524~49657542:-
PRAD	cis	rs5769707	0.667	rs4824069	ENSG00000188511.11	C22orf34	8.65	9e-17	5.56e-14	0.45	0.38	Monocyte percentage of white cells;Monocyte count;	chr22:49636677	chr22:49414524~49657542:-
PRAD	cis	rs6430553	0.929	rs6430547	ENSG00000224043.6	CCNT2-AS1	8.65	9.02e-17	5.58e-14	0.51	0.38	Blood metabolite levels;	chr2:134854852	chr2:134735464~134918710:-
PRAD	cis	rs12817211	0.502	rs11169282	ENSG00000272368.2	RP4-605O3.4	8.65	9.06e-17	5.6e-14	0.38	0.38	Colorectal or endometrial cancer;	chr12:50136188	chr12:50112197~50165618:+
PRAD	cis	rs42648	0.564	rs12154563	ENSG00000227646.6	STEAP2-AS1	-8.65	9.06e-17	5.6e-14	-0.34	-0.38	Homocysteine levels;	chr7:90198912	chr7:89882353~90211635:-
PRAD	cis	rs34779708	0.741	rs34397613	ENSG00000230534.5	RP11-297A16.2	8.65	9.07e-17	5.6e-14	0.51	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35261385	chr10:35098006~35127020:-
PRAD	cis	rs11098499	0.954	rs12502423	ENSG00000245958.5	RP11-33B1.1	-8.65	9.07e-17	5.61e-14	-0.37	-0.38	Corneal astigmatism;	chr4:119503017	chr4:119454791~119552025:+
PRAD	cis	rs2739330	0.703	rs5760112	ENSG00000272787.1	KB-226F1.2	-8.65	9.11e-17	5.63e-14	-0.4	-0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23969211~23969873:+
PRAD	cis	rs8523	1	rs8523	ENSG00000230314.5	ELOVL2-AS1	-8.65	9.12e-17	5.64e-14	-0.41	-0.38	Red blood cell fatty acid levels;	chr6:10980820	chr6:11043524~11078226:+
PRAD	cis	rs7923609	0.871	rs12245149	ENSG00000232075.1	MRPL35P2	8.65	9.14e-17	5.65e-14	0.39	0.38	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63561387	chr10:63634317~63634827:-
PRAD	cis	rs150992	0.688	rs161947	ENSG00000248489.1	CTD-2007H13.3	8.65	9.15e-17	5.65e-14	0.5	0.38	Body mass index;	chr5:98932868	chr5:98929171~98995013:+
PRAD	cis	rs6570726	0.935	rs368848	ENSG00000235652.6	RP11-545I5.3	8.65	9.15e-17	5.66e-14	0.39	0.38	Lobe attachment (rater-scored or self-reported);	chr6:145534145	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.935	rs374000	ENSG00000235652.6	RP11-545I5.3	8.65	9.15e-17	5.66e-14	0.39	0.38	Lobe attachment (rater-scored or self-reported);	chr6:145534154	chr6:145799409~145886585:+
PRAD	cis	rs875971	0.508	rs10950045	ENSG00000237310.1	GS1-124K5.4	-8.65	9.2e-17	5.69e-14	-0.33	-0.38	Aortic root size;	chr7:66601386	chr7:66493706~66495474:+
PRAD	cis	rs801193	0.839	rs6968619	ENSG00000237310.1	GS1-124K5.4	-8.65	9.2e-17	5.69e-14	-0.33	-0.38	Aortic root size;	chr7:66603880	chr7:66493706~66495474:+
PRAD	cis	rs801193	0.839	rs12534943	ENSG00000237310.1	GS1-124K5.4	-8.65	9.2e-17	5.69e-14	-0.33	-0.38	Aortic root size;	chr7:66605533	chr7:66493706~66495474:+
PRAD	cis	rs801193	0.805	rs12532355	ENSG00000237310.1	GS1-124K5.4	-8.65	9.2e-17	5.69e-14	-0.33	-0.38	Aortic root size;	chr7:66605597	chr7:66493706~66495474:+
PRAD	cis	rs8523	0.901	rs9368513	ENSG00000230314.5	ELOVL2-AS1	8.65	9.23e-17	5.71e-14	0.42	0.38	Red blood cell fatty acid levels;	chr6:10975563	chr6:11043524~11078226:+
PRAD	cis	rs4835473	0.864	rs2089837	ENSG00000251600.4	RP11-673E1.1	8.65	9.24e-17	5.71e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143965038	chr4:143912331~143982454:+
PRAD	cis	rs6570726	0.902	rs373321	ENSG00000235652.6	RP11-545I5.3	8.65	9.25e-17	5.71e-14	0.39	0.38	Lobe attachment (rater-scored or self-reported);	chr6:145533014	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.967	rs374728	ENSG00000235652.6	RP11-545I5.3	8.65	9.25e-17	5.71e-14	0.39	0.38	Lobe attachment (rater-scored or self-reported);	chr6:145533462	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.935	rs369214	ENSG00000235652.6	RP11-545I5.3	8.65	9.25e-17	5.71e-14	0.39	0.38	Lobe attachment (rater-scored or self-reported);	chr6:145535573	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.935	rs390252	ENSG00000235652.6	RP11-545I5.3	8.65	9.25e-17	5.71e-14	0.39	0.38	Lobe attachment (rater-scored or self-reported);	chr6:145535760	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.875	rs373313	ENSG00000235652.6	RP11-545I5.3	8.65	9.25e-17	5.71e-14	0.39	0.38	Lobe attachment (rater-scored or self-reported);	chr6:145536655	chr6:145799409~145886585:+
PRAD	cis	rs42648	0.564	rs7777651	ENSG00000227646.6	STEAP2-AS1	-8.64	9.27e-17	5.73e-14	-0.34	-0.38	Homocysteine levels;	chr7:90193030	chr7:89882353~90211635:-
PRAD	cis	rs11148252	0.74	rs9596643	ENSG00000278238.1	RP11-245D16.4	8.64	9.27e-17	5.73e-14	0.42	0.38	Lewy body disease;	chr13:52338245	chr13:52454775~52455331:-
PRAD	cis	rs950169	0.763	rs35372971	ENSG00000225151.9	GOLGA2P7	-8.64	9.32e-17	5.75e-14	-0.52	-0.38	Schizophrenia;	chr15:84387097	chr15:84199311~84230136:-
PRAD	cis	rs673078	0.607	rs4766900	ENSG00000275409.1	RP11-131L12.4	-8.64	9.32e-17	5.75e-14	-0.53	-0.38	Glucose homeostasis traits;	chr12:118375139	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.607	rs884844	ENSG00000275409.1	RP11-131L12.4	-8.64	9.32e-17	5.75e-14	-0.53	-0.38	Glucose homeostasis traits;	chr12:118377033	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.607	rs61943398	ENSG00000275409.1	RP11-131L12.4	-8.64	9.32e-17	5.75e-14	-0.53	-0.38	Glucose homeostasis traits;	chr12:118393280	chr12:118430147~118430699:+
PRAD	cis	rs42648	0.564	rs6465248	ENSG00000227646.6	STEAP2-AS1	-8.64	9.34e-17	5.77e-14	-0.34	-0.38	Homocysteine levels;	chr7:90195426	chr7:89882353~90211635:-
PRAD	cis	rs4713118	0.955	rs34752872	ENSG00000280107.1	AL022393.9	-8.64	9.4e-17	5.8e-14	-0.48	-0.38	Parkinson's disease;	chr6:27715465	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.911	rs2394000	ENSG00000280107.1	AL022393.9	-8.64	9.4e-17	5.8e-14	-0.48	-0.38	Parkinson's disease;	chr6:27719212	chr6:28170845~28172521:+
PRAD	cis	rs2108622	1	rs62107762	ENSG00000267453.5	AC004791.2	-8.64	9.41e-17	5.81e-14	-0.5	-0.38	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871728	chr19:15851993~15864904:-
PRAD	cis	rs17711722	0.565	rs4717276	ENSG00000236529.1	RP13-254B10.1	8.64	9.43e-17	5.82e-14	0.39	0.38	Calcium levels;	chr7:65829754	chr7:65840212~65840596:+
PRAD	cis	rs7712401	0.623	rs26372	ENSG00000263432.2	RN7SL689P	-8.64	9.45e-17	5.83e-14	-0.39	-0.38	Mean platelet volume;	chr5:122870752	chr5:123022487~123022783:-
PRAD	cis	rs673078	0.607	rs61943403	ENSG00000275409.1	RP11-131L12.4	-8.64	9.46e-17	5.83e-14	-0.52	-0.38	Glucose homeostasis traits;	chr12:118399887	chr12:118430147~118430699:+
PRAD	cis	rs17711722	0.528	rs73138179	ENSG00000226824.5	RP4-756H11.3	-8.64	9.47e-17	5.84e-14	-0.49	-0.38	Calcium levels;	chr7:65829495	chr7:66654538~66669855:+
PRAD	cis	rs11676348	0.772	rs11676275	ENSG00000261338.2	RP11-378A13.1	-8.64	9.51e-17	5.86e-14	-0.4	-0.38	Ulcerative colitis;	chr2:218080085	chr2:218255319~218257366:+
PRAD	cis	rs2348418	0.715	rs12307612	ENSG00000247934.4	RP11-967K21.1	8.64	9.52e-17	5.87e-14	0.34	0.38	Lung function (FEV1);Lung function (FVC);	chr12:28566713	chr12:28163298~28190738:-
PRAD	cis	rs2348418	0.715	rs12307709	ENSG00000247934.4	RP11-967K21.1	8.64	9.52e-17	5.87e-14	0.34	0.38	Lung function (FEV1);Lung function (FVC);	chr12:28566767	chr12:28163298~28190738:-
PRAD	cis	rs2348418	0.715	rs11049719	ENSG00000247934.4	RP11-967K21.1	8.64	9.52e-17	5.87e-14	0.34	0.38	Lung function (FEV1);Lung function (FVC);	chr12:28567446	chr12:28163298~28190738:-
PRAD	cis	rs2348418	0.715	rs11049720	ENSG00000247934.4	RP11-967K21.1	8.64	9.52e-17	5.87e-14	0.34	0.38	Lung function (FEV1);Lung function (FVC);	chr12:28567477	chr12:28163298~28190738:-
PRAD	cis	rs2348418	0.715	rs1912782	ENSG00000247934.4	RP11-967K21.1	8.64	9.52e-17	5.87e-14	0.34	0.38	Lung function (FEV1);Lung function (FVC);	chr12:28568774	chr12:28163298~28190738:-
PRAD	cis	rs2348418	0.715	rs10843206	ENSG00000247934.4	RP11-967K21.1	8.64	9.52e-17	5.87e-14	0.34	0.38	Lung function (FEV1);Lung function (FVC);	chr12:28569823	chr12:28163298~28190738:-
PRAD	cis	rs2348418	0.681	rs10843207	ENSG00000247934.4	RP11-967K21.1	8.64	9.52e-17	5.87e-14	0.34	0.38	Lung function (FEV1);Lung function (FVC);	chr12:28569929	chr12:28163298~28190738:-
PRAD	cis	rs2348418	0.715	rs7971717	ENSG00000247934.4	RP11-967K21.1	8.64	9.52e-17	5.87e-14	0.34	0.38	Lung function (FEV1);Lung function (FVC);	chr12:28570087	chr12:28163298~28190738:-
PRAD	cis	rs9341835	0.772	rs4710254	ENSG00000218048.2	RP3-407E4.4	8.64	9.54e-17	5.89e-14	0.41	0.38	Schizophrenia;	chr6:63427704	chr6:63440766~63443580:+
PRAD	cis	rs9341835	0.772	rs9449233	ENSG00000218048.2	RP3-407E4.4	8.64	9.55e-17	5.89e-14	0.41	0.38	Schizophrenia;	chr6:63428329	chr6:63440766~63443580:+
PRAD	cis	rs950169	0.922	rs62021167	ENSG00000225151.9	GOLGA2P7	-8.64	9.55e-17	5.89e-14	-0.53	-0.38	Schizophrenia;	chr15:84574820	chr15:84199311~84230136:-
PRAD	cis	rs9341835	0.772	rs9341841	ENSG00000218048.2	RP3-407E4.4	8.64	9.58e-17	5.9e-14	0.41	0.38	Schizophrenia;	chr6:63425105	chr6:63440766~63443580:+
PRAD	cis	rs9341835	0.772	rs9344090	ENSG00000218048.2	RP3-407E4.4	8.64	9.58e-17	5.9e-14	0.41	0.38	Schizophrenia;	chr6:63425925	chr6:63440766~63443580:+
PRAD	cis	rs12817211	0.524	rs1554845	ENSG00000272368.2	RP4-605O3.4	-8.64	9.58e-17	5.91e-14	-0.38	-0.38	Colorectal or endometrial cancer;	chr12:50129721	chr12:50112197~50165618:+
PRAD	cis	rs950169	0.922	rs67804993	ENSG00000259728.4	LINC00933	8.64	9.6e-17	5.92e-14	0.45	0.38	Schizophrenia;	chr15:84560799	chr15:84570649~84580175:+
PRAD	cis	rs11098499	0.863	rs3822195	ENSG00000245958.5	RP11-33B1.1	-8.64	9.6e-17	5.92e-14	-0.37	-0.38	Corneal astigmatism;	chr4:119550505	chr4:119454791~119552025:+
PRAD	cis	rs11723261	0.527	rs11731581	ENSG00000275426.1	CH17-262A2.1	8.64	9.62e-17	5.93e-14	0.49	0.38	Immune response to smallpox vaccine (IL-6);	chr4:88044	chr4:149738~150317:+
PRAD	cis	rs4964805	0.913	rs12229276	ENSG00000257681.1	RP11-341G23.4	-8.64	9.64e-17	5.94e-14	-0.37	-0.38	Attention deficit hyperactivity disorder;	chr12:103810993	chr12:103746315~103768858:-
PRAD	cis	rs8062405	0.69	rs6498089	ENSG00000259982.1	CDC37P1	-8.64	9.64e-17	5.94e-14	-0.49	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28617979	chr16:28700294~28701540:-
PRAD	cis	rs7189233	0.531	rs8055642	ENSG00000279344.1	RP11-44F14.7	8.64	9.65e-17	5.95e-14	0.34	0.38	Intelligence (multi-trait analysis);	chr16:53503669	chr16:53478957~53481550:-
PRAD	cis	rs11098499	0.863	rs28718422	ENSG00000245958.5	RP11-33B1.1	-8.64	9.67e-17	5.96e-14	-0.37	-0.38	Corneal astigmatism;	chr4:119545149	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.818	rs12498599	ENSG00000245958.5	RP11-33B1.1	-8.64	9.67e-17	5.96e-14	-0.37	-0.38	Corneal astigmatism;	chr4:119547348	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.863	rs10009626	ENSG00000245958.5	RP11-33B1.1	-8.64	9.67e-17	5.96e-14	-0.37	-0.38	Corneal astigmatism;	chr4:119548850	chr4:119454791~119552025:+
PRAD	cis	rs875971	0.929	rs10950041	ENSG00000237310.1	GS1-124K5.4	8.64	9.68e-17	5.97e-14	0.33	0.38	Aortic root size;	chr7:66508888	chr7:66493706~66495474:+
PRAD	cis	rs4380275	0.965	rs4375894	ENSG00000223751.1	AC116609.2	8.64	9.69e-17	5.97e-14	0.48	0.38	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:772567	chr2:742488~747767:+
PRAD	cis	rs4380275	0.965	rs4315562	ENSG00000223751.1	AC116609.2	8.64	9.72e-17	5.98e-14	0.48	0.38	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:772723	chr2:742488~747767:+
PRAD	cis	rs4380275	1	rs4450634	ENSG00000223751.1	AC116609.2	8.64	9.72e-17	5.98e-14	0.48	0.38	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:773257	chr2:742488~747767:+
PRAD	cis	rs4380275	1	rs4380275	ENSG00000223751.1	AC116609.2	8.64	9.72e-17	5.98e-14	0.48	0.38	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:773278	chr2:742488~747767:+
PRAD	cis	rs4380275	1	rs6548253	ENSG00000223751.1	AC116609.2	8.64	9.72e-17	5.98e-14	0.48	0.38	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:773655	chr2:742488~747767:+
PRAD	cis	rs4380275	1	rs73143802	ENSG00000223751.1	AC116609.2	8.64	9.72e-17	5.98e-14	0.48	0.38	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:773826	chr2:742488~747767:+
PRAD	cis	rs4380275	1	rs4359695	ENSG00000223751.1	AC116609.2	8.64	9.72e-17	5.98e-14	0.48	0.38	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:774214	chr2:742488~747767:+
PRAD	cis	rs4380275	0.931	rs4538239	ENSG00000223751.1	AC116609.2	8.64	9.72e-17	5.98e-14	0.48	0.38	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:774238	chr2:742488~747767:+
PRAD	cis	rs4380275	1	rs7562792	ENSG00000223751.1	AC116609.2	8.64	9.72e-17	5.98e-14	0.48	0.38	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:774469	chr2:742488~747767:+
PRAD	cis	rs11098499	0.954	rs12508504	ENSG00000245958.5	RP11-33B1.1	-8.64	9.75e-17	6.01e-14	-0.37	-0.38	Corneal astigmatism;	chr4:119489452	chr4:119454791~119552025:+
PRAD	cis	rs7727544	0.678	rs7735891	ENSG00000233006.5	AC034220.3	8.64	9.76e-17	6.01e-14	0.34	0.38	Blood metabolite levels;	chr5:132261312	chr5:132311285~132369916:-
PRAD	cis	rs7712401	0.541	rs6867714	ENSG00000263432.2	RN7SL689P	8.64	9.76e-17	6.01e-14	0.39	0.38	Mean platelet volume;	chr5:123046364	chr5:123022487~123022783:-
PRAD	cis	rs2980439	0.557	rs2921056	ENSG00000253893.2	FAM85B	-8.64	9.77e-17	6.02e-14	-0.46	-0.38	Neuroticism;	chr8:8461672	chr8:8167819~8226614:-
PRAD	cis	rs7826238	0.524	rs2921055	ENSG00000253893.2	FAM85B	-8.64	9.77e-17	6.02e-14	-0.46	-0.38	Systolic blood pressure;	chr8:8461832	chr8:8167819~8226614:-
PRAD	cis	rs4835473	0.932	rs1877235	ENSG00000251600.4	RP11-673E1.1	-8.64	9.78e-17	6.02e-14	-0.48	-0.38	Immature fraction of reticulocytes;	chr4:143986961	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs4305468	ENSG00000251600.4	RP11-673E1.1	-8.64	9.78e-17	6.02e-14	-0.48	-0.38	Immature fraction of reticulocytes;	chr4:143987315	chr4:143912331~143982454:+
PRAD	cis	rs7772486	0.743	rs9403742	ENSG00000235652.6	RP11-545I5.3	8.64	9.78e-17	6.02e-14	0.38	0.38	Lobe attachment (rater-scored or self-reported);	chr6:145739057	chr6:145799409~145886585:+
PRAD	cis	rs853679	0.766	rs9368561	ENSG00000280107.1	AL022393.9	-8.64	9.79e-17	6.03e-14	-0.64	-0.38	Depression;	chr6:28200565	chr6:28170845~28172521:+
PRAD	cis	rs321358	0.895	rs7950087	ENSG00000271584.1	RP11-89C3.4	-8.64	9.79e-17	6.03e-14	-0.58	-0.38	Body mass index;	chr11:111082536	chr11:111091932~111097357:-
PRAD	cis	rs9903692	0.954	rs2109984	ENSG00000278765.1	RP5-890E16.5	8.64	9.8e-17	6.04e-14	0.56	0.38	Pulse pressure;	chr17:48093737	chr17:48066704~48067293:-
PRAD	cis	rs10875746	0.669	rs61941003	ENSG00000240399.1	RP1-228P16.1	-8.64	9.81e-17	6.04e-14	-0.36	-0.38	Longevity (90 years and older);	chr12:48225842	chr12:48054813~48055591:-
PRAD	cis	rs12899811	0.53	rs11073967	ENSG00000214432.8	AC068831.10	-8.64	9.85e-17	6.06e-14	-0.45	-0.38	Type 2 diabetes;	chr15:91022574	chr15:91022619~91036611:+
PRAD	cis	rs4631830	0.812	rs11593361	ENSG00000230869.1	CTGLF10P	-8.64	9.87e-17	6.07e-14	-0.46	-0.38	Prostate-specific antigen levels;	chr10:46056666	chr10:45678692~45700532:+
PRAD	cis	rs12142240	0.698	rs55670684	ENSG00000232022.5	FAAHP1	-8.64	9.87e-17	6.08e-14	-0.35	-0.38	Menopause (age at onset);	chr1:46369467	chr1:46432129~46445521:+
PRAD	cis	rs4835473	0.8	rs1849134	ENSG00000251600.4	RP11-673E1.1	8.64	9.88e-17	6.08e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143958260	chr4:143912331~143982454:+
PRAD	cis	rs7688540	0.771	rs2353605	ENSG00000275426.1	CH17-262A2.1	8.64	9.9e-17	6.09e-14	0.54	0.38	Facial morphology (factor 6, height of vermillion lower lip);	chr4:225749	chr4:149738~150317:+
PRAD	cis	rs9326248	0.581	rs7106437	ENSG00000280143.1	AP000892.6	8.64	9.9e-17	6.09e-14	0.29	0.38	Blood protein levels;	chr11:117121360	chr11:117204967~117210292:+
PRAD	cis	rs172166	0.561	rs149973	ENSG00000204709.4	LINC01556	8.64	9.92e-17	6.11e-14	0.47	0.38	Cardiac Troponin-T levels;	chr6:28015835	chr6:28943877~28944537:+
PRAD	cis	rs172166	0.561	rs149974	ENSG00000204709.4	LINC01556	8.64	9.92e-17	6.11e-14	0.47	0.38	Cardiac Troponin-T levels;	chr6:28017318	chr6:28943877~28944537:+
PRAD	cis	rs11098499	0.78	rs10013652	ENSG00000245958.5	RP11-33B1.1	-8.64	9.94e-17	6.12e-14	-0.36	-0.38	Corneal astigmatism;	chr4:119371101	chr4:119454791~119552025:+
PRAD	cis	rs4835473	0.897	rs28701142	ENSG00000251600.4	RP11-673E1.1	8.64	9.95e-17	6.12e-14	0.48	0.38	Immature fraction of reticulocytes;	chr4:143945730	chr4:143912331~143982454:+
PRAD	cis	rs6452524	0.901	rs2662238	ENSG00000249664.1	CTD-2227C6.2	8.64	9.97e-17	6.13e-14	0.45	0.38	Hypertension (SNP x SNP interaction);	chr5:83203488	chr5:83012285~83013109:-
PRAD	cis	rs875971	0.929	rs778712	ENSG00000237310.1	GS1-124K5.4	8.64	9.97e-17	6.13e-14	0.33	0.38	Aortic root size;	chr7:66384991	chr7:66493706~66495474:+
PRAD	cis	rs875971	1	rs778710	ENSG00000237310.1	GS1-124K5.4	8.64	9.97e-17	6.13e-14	0.33	0.38	Aortic root size;	chr7:66389847	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.964	rs778708	ENSG00000237310.1	GS1-124K5.4	8.64	9.97e-17	6.13e-14	0.33	0.38	Aortic root size;	chr7:66391332	chr7:66493706~66495474:+
PRAD	cis	rs875971	1	rs778696	ENSG00000237310.1	GS1-124K5.4	8.64	9.97e-17	6.13e-14	0.33	0.38	Aortic root size;	chr7:66405826	chr7:66493706~66495474:+
PRAD	cis	rs875971	1	rs778694	ENSG00000237310.1	GS1-124K5.4	8.64	9.97e-17	6.13e-14	0.33	0.38	Aortic root size;	chr7:66406571	chr7:66493706~66495474:+
PRAD	cis	rs875971	1	rs4718344	ENSG00000237310.1	GS1-124K5.4	8.64	9.97e-17	6.13e-14	0.33	0.38	Aortic root size;	chr7:66409394	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.737	rs7803424	ENSG00000237310.1	GS1-124K5.4	8.64	9.97e-17	6.13e-14	0.33	0.38	Aortic root size;	chr7:66415618	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.83	rs7799834	ENSG00000237310.1	GS1-124K5.4	8.64	9.97e-17	6.13e-14	0.33	0.38	Aortic root size;	chr7:66415707	chr7:66493706~66495474:+
PRAD	cis	rs42648	0.72	rs9655741	ENSG00000227646.6	STEAP2-AS1	-8.63	9.99e-17	6.14e-14	-0.35	-0.38	Homocysteine levels;	chr7:90304560	chr7:89882353~90211635:-
PRAD	cis	rs2980439	0.557	rs2976876	ENSG00000253893.2	FAM85B	-8.63	1e-16	6.16e-14	-0.46	-0.38	Neuroticism;	chr8:8461340	chr8:8167819~8226614:-
PRAD	cis	rs853679	0.55	rs6901017	ENSG00000272009.1	RP1-313I6.12	-8.63	1e-16	6.16e-14	-0.38	-0.38	Depression;	chr6:28184805	chr6:28078792~28081130:-
PRAD	cis	rs9487094	0.567	rs13198879	ENSG00000260273.1	RP11-425D10.10	8.63	1e-16	6.17e-14	0.53	0.38	Height;	chr6:109769861	chr6:109382795~109383666:+
PRAD	cis	rs853679	0.824	rs34712084	ENSG00000280107.1	AL022393.9	-8.63	1e-16	6.17e-14	-0.63	-0.38	Depression;	chr6:28076050	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.824	rs1321505	ENSG00000280107.1	AL022393.9	-8.63	1e-16	6.17e-14	-0.63	-0.38	Depression;	chr6:28085045	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.882	rs9468287	ENSG00000280107.1	AL022393.9	-8.63	1e-16	6.17e-14	-0.63	-0.38	Depression;	chr6:28111963	chr6:28170845~28172521:+
PRAD	cis	rs42648	0.748	rs12673914	ENSG00000227646.6	STEAP2-AS1	-8.63	1.01e-16	6.18e-14	-0.35	-0.38	Homocysteine levels;	chr7:90314075	chr7:89882353~90211635:-
PRAD	cis	rs11123170	0.529	rs35606997	ENSG00000274877.1	RP11-65I12.1	-8.63	1.01e-16	6.19e-14	-0.57	-0.38	Renal function-related traits (BUN);	chr2:113215773	chr2:113237595~113240825:+
PRAD	cis	rs1789	0.786	rs6449161	ENSG00000273133.1	RP11-799M12.2	-8.63	1.01e-16	6.23e-14	-0.49	-0.38	Blood protein levels;	chr4:15691331	chr4:15563698~15564253:-
PRAD	cis	rs4835473	0.932	rs7666368	ENSG00000251600.4	RP11-673E1.1	-8.63	1.01e-16	6.23e-14	-0.47	-0.38	Immature fraction of reticulocytes;	chr4:143785372	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs7690428	ENSG00000251600.4	RP11-673E1.1	-8.63	1.01e-16	6.23e-14	-0.47	-0.38	Immature fraction of reticulocytes;	chr4:143785400	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs34781605	ENSG00000251600.4	RP11-673E1.1	-8.63	1.01e-16	6.23e-14	-0.47	-0.38	Immature fraction of reticulocytes;	chr4:143785486	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.9	rs11100810	ENSG00000251600.4	RP11-673E1.1	-8.63	1.01e-16	6.23e-14	-0.47	-0.38	Immature fraction of reticulocytes;	chr4:143787518	chr4:143912331~143982454:+
PRAD	cis	rs9309711	0.544	rs9309712	ENSG00000225234.1	TRAPPC12-AS1	-8.63	1.02e-16	6.25e-14	-0.38	-0.38	Neurofibrillary tangles;	chr2:3487556	chr2:3481242~3482409:-
PRAD	cis	rs1930961	0.85	rs5996945	ENSG00000271138.1	IGLVIVOR22-1	8.63	1.02e-16	6.26e-14	0.55	0.38	Bipolar disorder with mood-incongruent psychosis;	chr22:25479606	chr22:25437306~25437823:-
PRAD	cis	rs950169	0.922	rs12915832	ENSG00000259728.4	LINC00933	8.63	1.02e-16	6.26e-14	0.45	0.38	Schizophrenia;	chr15:84568226	chr15:84570649~84580175:+
PRAD	cis	rs2439831	0.85	rs10438303	ENSG00000249839.1	AC011330.5	-8.63	1.02e-16	6.27e-14	-0.64	-0.38	Lung cancer in ever smokers;	chr15:43724219	chr15:43663654~43684339:-
PRAD	cis	rs2439831	0.85	rs11070408	ENSG00000249839.1	AC011330.5	-8.63	1.02e-16	6.27e-14	-0.64	-0.38	Lung cancer in ever smokers;	chr15:43742590	chr15:43663654~43684339:-
PRAD	cis	rs2439831	0.85	rs28718261	ENSG00000249839.1	AC011330.5	-8.63	1.02e-16	6.27e-14	-0.64	-0.38	Lung cancer in ever smokers;	chr15:43751595	chr15:43663654~43684339:-
PRAD	cis	rs2439831	0.85	rs7168158	ENSG00000249839.1	AC011330.5	-8.63	1.02e-16	6.27e-14	-0.64	-0.38	Lung cancer in ever smokers;	chr15:43758178	chr15:43663654~43684339:-
PRAD	cis	rs2439831	0.85	rs7174208	ENSG00000249839.1	AC011330.5	-8.63	1.02e-16	6.27e-14	-0.64	-0.38	Lung cancer in ever smokers;	chr15:43760484	chr15:43663654~43684339:-
PRAD	cis	rs2439831	0.85	rs12101756	ENSG00000249839.1	AC011330.5	-8.63	1.02e-16	6.27e-14	-0.64	-0.38	Lung cancer in ever smokers;	chr15:43761689	chr15:43663654~43684339:-
PRAD	cis	rs2439831	0.85	rs12442129	ENSG00000249839.1	AC011330.5	-8.63	1.02e-16	6.27e-14	-0.64	-0.38	Lung cancer in ever smokers;	chr15:43763658	chr15:43663654~43684339:-
PRAD	cis	rs2439831	0.702	rs7175032	ENSG00000249839.1	AC011330.5	-8.63	1.02e-16	6.27e-14	-0.64	-0.38	Lung cancer in ever smokers;	chr15:43768038	chr15:43663654~43684339:-
PRAD	cis	rs2439831	0.85	rs3862142	ENSG00000249839.1	AC011330.5	-8.63	1.02e-16	6.27e-14	-0.64	-0.38	Lung cancer in ever smokers;	chr15:43772608	chr15:43663654~43684339:-
PRAD	cis	rs2439831	0.702	rs2788	ENSG00000249839.1	AC011330.5	-8.63	1.02e-16	6.27e-14	-0.64	-0.38	Lung cancer in ever smokers;	chr15:43772688	chr15:43663654~43684339:-
PRAD	cis	rs2439831	0.85	rs2277531	ENSG00000249839.1	AC011330.5	-8.63	1.02e-16	6.27e-14	-0.64	-0.38	Lung cancer in ever smokers;	chr15:43776871	chr15:43663654~43684339:-
PRAD	cis	rs2439831	0.85	rs28891769	ENSG00000249839.1	AC011330.5	-8.63	1.02e-16	6.27e-14	-0.64	-0.38	Lung cancer in ever smokers;	chr15:43780662	chr15:43663654~43684339:-
PRAD	cis	rs2439831	0.85	rs28578398	ENSG00000249839.1	AC011330.5	-8.63	1.02e-16	6.27e-14	-0.64	-0.38	Lung cancer in ever smokers;	chr15:43782848	chr15:43663654~43684339:-
PRAD	cis	rs950169	0.881	rs34117475	ENSG00000259728.4	LINC00933	8.63	1.02e-16	6.27e-14	0.45	0.38	Schizophrenia;	chr15:84565212	chr15:84570649~84580175:+
PRAD	cis	rs6723108	0.604	rs1374291	ENSG00000224043.6	CCNT2-AS1	-8.63	1.02e-16	6.28e-14	-0.52	-0.38	Type 2 diabetes;	chr2:134896768	chr2:134735464~134918710:-
PRAD	cis	rs10740039	0.548	rs9415607	ENSG00000254271.1	RP11-131N11.4	-8.63	1.03e-16	6.31e-14	-0.52	-0.38	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60737616	chr10:60734342~60741828:+
PRAD	cis	rs1150668	0.768	rs1150716	ENSG00000280107.1	AL022393.9	-8.63	1.03e-16	6.32e-14	-0.45	-0.38	Pubertal anthropometrics;	chr6:28294921	chr6:28170845~28172521:+
PRAD	cis	rs2487048	0.773	rs2472494	ENSG00000226334.1	RP11-217B7.2	-8.63	1.03e-16	6.34e-14	-0.51	-0.38	Intraocular pressure;	chr9:104933258	chr9:104927553~104928892:+
PRAD	cis	rs950169	0.887	rs35986397	ENSG00000225151.9	GOLGA2P7	-8.63	1.03e-16	6.34e-14	-0.53	-0.38	Schizophrenia;	chr15:84400409	chr15:84199311~84230136:-
PRAD	cis	rs2274273	0.84	rs28493647	ENSG00000258413.1	RP11-665C16.6	-8.63	1.03e-16	6.35e-14	-0.48	-0.38	Protein biomarker;	chr14:55357745	chr14:55262767~55272075:-
PRAD	cis	rs2274273	0.84	rs17674463	ENSG00000258413.1	RP11-665C16.6	-8.63	1.03e-16	6.35e-14	-0.48	-0.38	Protein biomarker;	chr14:55358145	chr14:55262767~55272075:-
PRAD	cis	rs875971	1	rs1167411	ENSG00000237310.1	GS1-124K5.4	-8.63	1.04e-16	6.37e-14	-0.34	-0.38	Aortic root size;	chr7:66074277	chr7:66493706~66495474:+
PRAD	cis	rs875971	1	rs1144895	ENSG00000237310.1	GS1-124K5.4	-8.63	1.04e-16	6.37e-14	-0.34	-0.38	Aortic root size;	chr7:66076320	chr7:66493706~66495474:+
PRAD	cis	rs321358	0.945	rs7112932	ENSG00000271584.1	RP11-89C3.4	8.63	1.04e-16	6.38e-14	0.58	0.38	Body mass index;	chr11:111101099	chr11:111091932~111097357:-
PRAD	cis	rs34779708	0.733	rs3853672	ENSG00000230534.5	RP11-297A16.2	8.63	1.04e-16	6.39e-14	0.5	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35260678	chr10:35098006~35127020:-
PRAD	cis	rs12701220	0.655	rs7784403	ENSG00000229043.2	AC091729.9	-8.63	1.04e-16	6.39e-14	-0.52	-0.38	Bronchopulmonary dysplasia;	chr7:1113441	chr7:1160374~1165267:+
PRAD	cis	rs26232	0.52	rs26432	ENSG00000175749.11	EIF3KP1	-8.63	1.04e-16	6.4e-14	-0.49	-0.38	Rheumatoid arthritis;	chr5:103030006	chr5:103032376~103033031:+
PRAD	cis	rs26232	0.583	rs26430	ENSG00000175749.11	EIF3KP1	-8.63	1.04e-16	6.4e-14	-0.49	-0.38	Rheumatoid arthritis;	chr5:103030228	chr5:103032376~103033031:+
PRAD	cis	rs3096299	0.967	rs753853	ENSG00000274627.1	RP11-104N10.2	8.63	1.05e-16	6.42e-14	0.39	0.37	Multiple myeloma (IgH translocation);	chr16:89380117	chr16:89516797~89522217:+
PRAD	cis	rs1062177	1	rs62394155	ENSG00000253921.1	CTB-113P19.3	-8.63	1.06e-16	6.47e-14	-0.5	-0.37	Preschool internalizing problems;	chr5:151868508	chr5:151753992~151767247:+
PRAD	cis	rs1062177	1	rs12653926	ENSG00000253921.1	CTB-113P19.3	-8.63	1.06e-16	6.47e-14	-0.5	-0.37	Preschool internalizing problems;	chr5:151870687	chr5:151753992~151767247:+
PRAD	cis	rs7211079	0.833	rs7220523	ENSG00000279259.1	RP11-334C17.3	8.63	1.06e-16	6.49e-14	0.41	0.37	Myocardial infarction;	chr17:80153896	chr17:80147250~80148596:+
PRAD	cis	rs7211079	0.879	rs7221505	ENSG00000279259.1	RP11-334C17.3	8.63	1.06e-16	6.49e-14	0.41	0.37	Myocardial infarction;	chr17:80154432	chr17:80147250~80148596:+
PRAD	cis	rs9903692	0.954	rs7224014	ENSG00000278765.1	RP5-890E16.5	8.63	1.06e-16	6.5e-14	0.56	0.37	Pulse pressure;	chr17:48073499	chr17:48066704~48067293:-
PRAD	cis	rs9903692	0.954	rs2240122	ENSG00000278765.1	RP5-890E16.5	8.63	1.06e-16	6.5e-14	0.56	0.37	Pulse pressure;	chr17:48075197	chr17:48066704~48067293:-
PRAD	cis	rs9903692	0.738	rs35202025	ENSG00000278765.1	RP5-890E16.5	8.63	1.06e-16	6.5e-14	0.56	0.37	Pulse pressure;	chr17:48075355	chr17:48066704~48067293:-
PRAD	cis	rs9903692	0.954	rs7217496	ENSG00000278765.1	RP5-890E16.5	8.63	1.06e-16	6.5e-14	0.56	0.37	Pulse pressure;	chr17:48076840	chr17:48066704~48067293:-
PRAD	cis	rs9903692	0.954	rs9747001	ENSG00000278765.1	RP5-890E16.5	8.63	1.06e-16	6.5e-14	0.56	0.37	Pulse pressure;	chr17:48077307	chr17:48066704~48067293:-
PRAD	cis	rs9903692	0.909	rs12952163	ENSG00000278765.1	RP5-890E16.5	8.63	1.06e-16	6.5e-14	0.56	0.37	Pulse pressure;	chr17:48082029	chr17:48066704~48067293:-
PRAD	cis	rs9903692	0.648	rs35361214	ENSG00000278765.1	RP5-890E16.5	8.63	1.06e-16	6.5e-14	0.56	0.37	Pulse pressure;	chr17:48087729	chr17:48066704~48067293:-
PRAD	cis	rs9903692	0.697	rs6504024	ENSG00000278765.1	RP5-890E16.5	8.63	1.06e-16	6.5e-14	0.56	0.37	Pulse pressure;	chr17:48088224	chr17:48066704~48067293:-
PRAD	cis	rs9903692	0.779	rs6504025	ENSG00000278765.1	RP5-890E16.5	8.63	1.06e-16	6.5e-14	0.56	0.37	Pulse pressure;	chr17:48088711	chr17:48066704~48067293:-
PRAD	cis	rs42648	0.633	rs11563909	ENSG00000227646.6	STEAP2-AS1	-8.63	1.07e-16	6.55e-14	-0.35	-0.37	Homocysteine levels;	chr7:90306390	chr7:89882353~90211635:-
PRAD	cis	rs3779195	1	rs3779195	ENSG00000272950.1	RP11-307C18.1	-8.62	1.08e-16	6.59e-14	-0.6	-0.37	Sex hormone-binding globulin levels;	chr7:98364050	chr7:98322853~98323430:+
PRAD	cis	rs950169	0.887	rs220333	ENSG00000259728.4	LINC00933	8.62	1.08e-16	6.61e-14	0.45	0.37	Schizophrenia;	chr15:84547902	chr15:84570649~84580175:+
PRAD	cis	rs2274273	0.935	rs8004787	ENSG00000258413.1	RP11-665C16.6	-8.62	1.08e-16	6.62e-14	-0.49	-0.37	Protein biomarker;	chr14:55140648	chr14:55262767~55272075:-
PRAD	cis	rs2274273	0.905	rs2075601	ENSG00000258413.1	RP11-665C16.6	-8.62	1.08e-16	6.62e-14	-0.49	-0.37	Protein biomarker;	chr14:55142516	chr14:55262767~55272075:-
PRAD	cis	rs2274273	0.875	rs2075602	ENSG00000258413.1	RP11-665C16.6	-8.62	1.08e-16	6.62e-14	-0.49	-0.37	Protein biomarker;	chr14:55143056	chr14:55262767~55272075:-
PRAD	cis	rs8062405	0.792	rs12446550	ENSG00000251417.2	RP11-1348G14.4	-8.62	1.09e-16	6.66e-14	-0.41	-0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28532060	chr16:28802743~28817828:+
PRAD	cis	rs4713118	0.662	rs175954	ENSG00000226314.6	ZNF192P1	-8.62	1.09e-16	6.67e-14	-0.51	-0.37	Parkinson's disease;	chr6:28043807	chr6:28161781~28169594:+
PRAD	cis	rs1979679	0.842	rs1118097	ENSG00000278733.1	RP11-425D17.1	8.62	1.09e-16	6.67e-14	0.47	0.37	Ossification of the posterior longitudinal ligament of the spine;	chr12:28177156	chr12:28185625~28186190:-
PRAD	cis	rs67311347	1	rs9874006	ENSG00000223797.4	ENTPD3-AS1	8.62	1.09e-16	6.68e-14	0.33	0.37	Renal cell carcinoma;	chr3:40430105	chr3:40313802~40453329:-
PRAD	cis	rs67311347	1	rs34762643	ENSG00000223797.4	ENTPD3-AS1	8.62	1.09e-16	6.68e-14	0.33	0.37	Renal cell carcinoma;	chr3:40433942	chr3:40313802~40453329:-
PRAD	cis	rs67311347	1	rs9841335	ENSG00000223797.4	ENTPD3-AS1	8.62	1.09e-16	6.68e-14	0.33	0.37	Renal cell carcinoma;	chr3:40434367	chr3:40313802~40453329:-
PRAD	cis	rs67311347	1	rs28434528	ENSG00000223797.4	ENTPD3-AS1	8.62	1.09e-16	6.68e-14	0.33	0.37	Renal cell carcinoma;	chr3:40443402	chr3:40313802~40453329:-
PRAD	cis	rs67311347	1	rs11716675	ENSG00000223797.4	ENTPD3-AS1	8.62	1.09e-16	6.68e-14	0.33	0.37	Renal cell carcinoma;	chr3:40443789	chr3:40313802~40453329:-
PRAD	cis	rs3779195	0.929	rs4268041	ENSG00000272950.1	RP11-307C18.1	-8.62	1.09e-16	6.69e-14	-0.56	-0.37	Sex hormone-binding globulin levels;	chr7:98376226	chr7:98322853~98323430:+
PRAD	cis	rs2153535	0.561	rs9328474	ENSG00000230939.1	RP11-314C16.1	-8.62	1.09e-16	6.7e-14	-0.45	-0.37	Motion sickness;	chr6:8506770	chr6:8784178~8785445:+
PRAD	cis	rs3096299	0.933	rs747485	ENSG00000274627.1	RP11-104N10.2	8.62	1.1e-16	6.71e-14	0.38	0.37	Multiple myeloma (IgH translocation);	chr16:89407686	chr16:89516797~89522217:+
PRAD	cis	rs4835473	0.932	rs66474962	ENSG00000251600.4	RP11-673E1.1	-8.62	1.1e-16	6.72e-14	-0.47	-0.37	Immature fraction of reticulocytes;	chr4:143735145	chr4:143912331~143982454:+
PRAD	cis	rs11098499	0.863	rs2306457	ENSG00000245958.5	RP11-33B1.1	-8.62	1.1e-16	6.72e-14	-0.37	-0.37	Corneal astigmatism;	chr4:119551684	chr4:119454791~119552025:+
PRAD	cis	rs11159086	0.793	rs10136668	ENSG00000259005.1	RP3-449M8.6	8.62	1.1e-16	6.72e-14	0.48	0.37	Advanced glycation end-product levels;	chr14:74492183	chr14:74474007~74474864:-
PRAD	cis	rs2348418	0.864	rs2137073	ENSG00000247934.4	RP11-967K21.1	-8.62	1.1e-16	6.73e-14	-0.35	-0.37	Lung function (FEV1);Lung function (FVC);	chr12:28564151	chr12:28163298~28190738:-
PRAD	cis	rs42648	0.567	rs12669304	ENSG00000227646.6	STEAP2-AS1	-8.62	1.1e-16	6.75e-14	-0.35	-0.37	Homocysteine levels;	chr7:90261726	chr7:89882353~90211635:-
PRAD	cis	rs6570726	0.935	rs366621	ENSG00000235652.6	RP11-545I5.3	8.62	1.1e-16	6.75e-14	0.39	0.37	Lobe attachment (rater-scored or self-reported);	chr6:145540139	chr6:145799409~145886585:+
PRAD	cis	rs1062177	0.756	rs2964592	ENSG00000253921.1	CTB-113P19.3	8.62	1.1e-16	6.75e-14	0.49	0.37	Preschool internalizing problems;	chr5:151736127	chr5:151753992~151767247:+
PRAD	cis	rs6452524	0.935	rs10474081	ENSG00000249664.1	CTD-2227C6.2	8.62	1.1e-16	6.76e-14	0.45	0.37	Hypertension (SNP x SNP interaction);	chr5:83095064	chr5:83012285~83013109:-
PRAD	cis	rs11098499	0.908	rs7695996	ENSG00000245958.5	RP11-33B1.1	-8.62	1.1e-16	6.76e-14	-0.37	-0.37	Corneal astigmatism;	chr4:119400878	chr4:119454791~119552025:+
PRAD	cis	rs7727544	0.716	rs3844312	ENSG00000233006.5	AC034220.3	8.62	1.11e-16	6.78e-14	0.33	0.37	Blood metabolite levels;	chr5:132246663	chr5:132311285~132369916:-
PRAD	cis	rs4718428	0.672	rs13241598	ENSG00000230295.1	RP11-458F8.2	-8.62	1.12e-16	6.83e-14	-0.28	-0.37	Corneal structure;	chr7:66835665	chr7:66880708~66882981:+
PRAD	cis	rs875971	1	rs2077593	ENSG00000237310.1	GS1-124K5.4	8.62	1.12e-16	6.85e-14	0.33	0.37	Aortic root size;	chr7:66427543	chr7:66493706~66495474:+
PRAD	cis	rs875971	1	rs4717292	ENSG00000237310.1	GS1-124K5.4	8.62	1.12e-16	6.85e-14	0.33	0.37	Aortic root size;	chr7:66430611	chr7:66493706~66495474:+
PRAD	cis	rs9341835	0.772	rs9294206	ENSG00000218048.2	RP3-407E4.4	8.62	1.12e-16	6.86e-14	0.41	0.37	Schizophrenia;	chr6:63431296	chr6:63440766~63443580:+
PRAD	cis	rs7727544	0.716	rs11949055	ENSG00000233006.5	AC034220.3	8.62	1.12e-16	6.86e-14	0.33	0.37	Blood metabolite levels;	chr5:132241044	chr5:132311285~132369916:-
PRAD	cis	rs2487048	0.773	rs2472493	ENSG00000226334.1	RP11-217B7.2	-8.62	1.12e-16	6.87e-14	-0.51	-0.37	Intraocular pressure;	chr9:104933567	chr9:104927553~104928892:+
PRAD	cis	rs2274273	0.87	rs7160523	ENSG00000258413.1	RP11-665C16.6	-8.62	1.12e-16	6.87e-14	-0.49	-0.37	Protein biomarker;	chr14:55127842	chr14:55262767~55272075:-
PRAD	cis	rs4631830	0.863	rs2611508	ENSG00000230869.1	CTGLF10P	-8.62	1.12e-16	6.87e-14	-0.46	-0.37	Prostate-specific antigen levels;	chr10:46077775	chr10:45678692~45700532:+
PRAD	cis	rs853679	1	rs6901575	ENSG00000280107.1	AL022393.9	-8.62	1.13e-16	6.88e-14	-0.56	-0.37	Depression;	chr6:28283207	chr6:28170845~28172521:+
PRAD	cis	rs9326248	0.581	rs7120515	ENSG00000280143.1	AP000892.6	8.62	1.13e-16	6.94e-14	0.29	0.37	Blood protein levels;	chr11:117121210	chr11:117204967~117210292:+
PRAD	cis	rs875971	1	rs1167612	ENSG00000237310.1	GS1-124K5.4	-8.62	1.13e-16	6.94e-14	-0.34	-0.37	Aortic root size;	chr7:66102989	chr7:66493706~66495474:+
PRAD	cis	rs934734	0.563	rs1858036	ENSG00000204929.10	AC074391.1	8.62	1.14e-16	6.95e-14	0.48	0.37	Rheumatoid arthritis;	chr2:65371107	chr2:65436711~66084639:+
PRAD	cis	rs934734	0.563	rs1858037	ENSG00000204929.10	AC074391.1	8.62	1.14e-16	6.95e-14	0.48	0.37	Rheumatoid arthritis;	chr2:65371166	chr2:65436711~66084639:+
PRAD	cis	rs9309473	0.687	rs6710659	ENSG00000163016.8	ALMS1P	8.62	1.14e-16	6.95e-14	0.45	0.37	Metabolite levels;	chr2:73380382	chr2:73644919~73685576:+
PRAD	cis	rs875971	0.964	rs697969	ENSG00000237310.1	GS1-124K5.4	-8.62	1.14e-16	6.96e-14	-0.34	-0.37	Aortic root size;	chr7:66093491	chr7:66493706~66495474:+
PRAD	cis	rs875971	1	rs1182882	ENSG00000237310.1	GS1-124K5.4	-8.62	1.14e-16	6.96e-14	-0.34	-0.37	Aortic root size;	chr7:66097076	chr7:66493706~66495474:+
PRAD	cis	rs4835473	0.932	rs1849112	ENSG00000251600.4	RP11-673E1.1	8.62	1.14e-16	6.97e-14	0.48	0.37	Immature fraction of reticulocytes;	chr4:143962502	chr4:143912331~143982454:+
PRAD	cis	rs7615952	1	rs7615952	ENSG00000171084.14	FAM86JP	-8.62	1.14e-16	6.97e-14	-0.62	-0.37	Blood pressure (smoking interaction);	chr3:125930560	chr3:125916620~125930024:+
PRAD	cis	rs853679	0.506	rs1150693	ENSG00000226314.6	ZNF192P1	-8.62	1.14e-16	6.98e-14	-0.51	-0.37	Depression;	chr6:28206812	chr6:28161781~28169594:+
PRAD	cis	rs12817211	0.502	rs7294618	ENSG00000272368.2	RP4-605O3.4	-8.62	1.14e-16	7e-14	-0.38	-0.37	Colorectal or endometrial cancer;	chr12:50119192	chr12:50112197~50165618:+
PRAD	cis	rs12817211	0.502	rs7961112	ENSG00000272368.2	RP4-605O3.4	-8.62	1.14e-16	7e-14	-0.38	-0.37	Colorectal or endometrial cancer;	chr12:50119736	chr12:50112197~50165618:+
PRAD	cis	rs2274273	0.905	rs4652	ENSG00000258413.1	RP11-665C16.6	-8.62	1.15e-16	7e-14	-0.49	-0.37	Protein biomarker;	chr14:55138318	chr14:55262767~55272075:-
PRAD	cis	rs12701220	0.655	rs34696066	ENSG00000229043.2	AC091729.9	-8.62	1.15e-16	7.02e-14	-0.54	-0.37	Bronchopulmonary dysplasia;	chr7:1101283	chr7:1160374~1165267:+
PRAD	cis	rs2108622	0.727	rs7251296	ENSG00000267056.2	AC005336.4	8.62	1.15e-16	7.04e-14	0.51	0.37	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15872926	chr19:15910582~15911824:-
PRAD	cis	rs6452524	0.934	rs1120476	ENSG00000249664.1	CTD-2227C6.2	8.62	1.15e-16	7.04e-14	0.44	0.37	Hypertension (SNP x SNP interaction);	chr5:83126824	chr5:83012285~83013109:-
PRAD	cis	rs11123170	0.529	rs112692022	ENSG00000274877.1	RP11-65I12.1	-8.62	1.15e-16	7.04e-14	-0.57	-0.37	Renal function-related traits (BUN);	chr2:113212605	chr2:113237595~113240825:+
PRAD	cis	rs17361889	0.711	rs1978253	ENSG00000224683.1	RPL36AP29	8.62	1.15e-16	7.04e-14	0.46	0.37	Pediatric bone mineral content (hip);	chr7:16151114	chr7:16208945~16209265:+
PRAD	cis	rs2255336	0.938	rs59906810	ENSG00000245648.1	RP11-277P12.20	-8.62	1.16e-16	7.06e-14	-0.51	-0.37	Blood protein levels;	chr12:10446021	chr12:10363769~10398506:+
PRAD	cis	rs875971	1	rs6957199	ENSG00000237310.1	GS1-124K5.4	8.62	1.16e-16	7.06e-14	0.33	0.37	Aortic root size;	chr7:66513532	chr7:66493706~66495474:+
PRAD	cis	rs7569084	0.522	rs906577	ENSG00000204929.10	AC074391.1	8.62	1.16e-16	7.06e-14	0.48	0.37	Sum eosinophil basophil counts;	chr2:65369523	chr2:65436711~66084639:+
PRAD	cis	rs934734	0.563	rs11126035	ENSG00000204929.10	AC074391.1	8.62	1.16e-16	7.06e-14	0.48	0.37	Rheumatoid arthritis;	chr2:65369932	chr2:65436711~66084639:+
PRAD	cis	rs853679	0.628	rs9368560	ENSG00000226314.6	ZNF192P1	-8.62	1.16e-16	7.08e-14	-0.51	-0.37	Depression;	chr6:28192182	chr6:28161781~28169594:+
PRAD	cis	rs950169	0.724	rs11632668	ENSG00000225151.9	GOLGA2P7	-8.61	1.16e-16	7.08e-14	-0.52	-0.37	Schizophrenia;	chr15:84393989	chr15:84199311~84230136:-
PRAD	cis	rs950169	0.881	rs34591918	ENSG00000225151.9	GOLGA2P7	-8.61	1.16e-16	7.08e-14	-0.52	-0.37	Schizophrenia;	chr15:84396135	chr15:84199311~84230136:-
PRAD	cis	rs950169	0.887	rs12903946	ENSG00000225151.9	GOLGA2P7	-8.61	1.16e-16	7.08e-14	-0.52	-0.37	Schizophrenia;	chr15:84399732	chr15:84199311~84230136:-
PRAD	cis	rs950169	0.887	rs62029593	ENSG00000225151.9	GOLGA2P7	-8.61	1.16e-16	7.08e-14	-0.52	-0.37	Schizophrenia;	chr15:84400482	chr15:84199311~84230136:-
PRAD	cis	rs950169	0.81	rs62029594	ENSG00000225151.9	GOLGA2P7	-8.61	1.16e-16	7.08e-14	-0.52	-0.37	Schizophrenia;	chr15:84400554	chr15:84199311~84230136:-
PRAD	cis	rs950169	0.881	rs62029596	ENSG00000225151.9	GOLGA2P7	-8.61	1.16e-16	7.08e-14	-0.52	-0.37	Schizophrenia;	chr15:84400736	chr15:84199311~84230136:-
PRAD	cis	rs950169	0.881	rs4081123	ENSG00000225151.9	GOLGA2P7	-8.61	1.16e-16	7.08e-14	-0.52	-0.37	Schizophrenia;	chr15:84401537	chr15:84199311~84230136:-
PRAD	cis	rs950169	0.881	rs62029599	ENSG00000225151.9	GOLGA2P7	-8.61	1.16e-16	7.08e-14	-0.52	-0.37	Schizophrenia;	chr15:84401867	chr15:84199311~84230136:-
PRAD	cis	rs950169	0.8	rs4099846	ENSG00000225151.9	GOLGA2P7	-8.61	1.16e-16	7.08e-14	-0.52	-0.37	Schizophrenia;	chr15:84402196	chr15:84199311~84230136:-
PRAD	cis	rs7131987	0.65	rs4331146	ENSG00000257176.2	RP11-996F15.2	-8.61	1.17e-16	7.13e-14	-0.41	-0.37	QT interval;	chr12:29287150	chr12:29280418~29317848:-
PRAD	cis	rs2638953	0.814	rs11049413	ENSG00000278733.1	RP11-425D17.1	-8.61	1.17e-16	7.14e-14	-0.45	-0.37	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28186322	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.85	rs11049414	ENSG00000278733.1	RP11-425D17.1	-8.61	1.17e-16	7.14e-14	-0.45	-0.37	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28186325	chr12:28185625~28186190:-
PRAD	cis	rs11098499	0.863	rs1010739	ENSG00000245958.5	RP11-33B1.1	-8.61	1.17e-16	7.16e-14	-0.37	-0.37	Corneal astigmatism;	chr4:119542316	chr4:119454791~119552025:+
PRAD	cis	rs7772486	0.686	rs9373473	ENSG00000235652.6	RP11-545I5.3	8.61	1.18e-16	7.17e-14	0.38	0.37	Lobe attachment (rater-scored or self-reported);	chr6:145761146	chr6:145799409~145886585:+
PRAD	cis	rs950169	0.922	rs11630507	ENSG00000259728.4	LINC00933	8.61	1.18e-16	7.17e-14	0.45	0.37	Schizophrenia;	chr15:84552494	chr15:84570649~84580175:+
PRAD	cis	rs17711722	0.565	rs4275112	ENSG00000236529.1	RP13-254B10.1	-8.61	1.18e-16	7.19e-14	-0.39	-0.37	Calcium levels;	chr7:65733651	chr7:65840212~65840596:+
PRAD	cis	rs875971	0.895	rs3857684	ENSG00000237310.1	GS1-124K5.4	8.61	1.18e-16	7.19e-14	0.33	0.37	Aortic root size;	chr7:66473171	chr7:66493706~66495474:+
PRAD	cis	rs875971	1	rs12533997	ENSG00000237310.1	GS1-124K5.4	8.61	1.18e-16	7.19e-14	0.33	0.37	Aortic root size;	chr7:66500390	chr7:66493706~66495474:+
PRAD	cis	rs9532669	0.926	rs4628824	ENSG00000168852.11	TPTE2P5	8.61	1.18e-16	7.21e-14	0.36	0.37	Cervical cancer;	chr13:40876217	chr13:40822296~40921749:-
PRAD	cis	rs4835473	0.831	rs4125544	ENSG00000251600.4	RP11-673E1.1	8.61	1.19e-16	7.23e-14	0.48	0.37	Immature fraction of reticulocytes;	chr4:143962542	chr4:143912331~143982454:+
PRAD	cis	rs11951515	0.638	rs10065852	ENSG00000188850.9	RP11-159F24.2	8.61	1.19e-16	7.23e-14	0.45	0.37	Metabolite levels  (X-11787);	chr5:43342063	chr5:43336164~43348716:+
PRAD	cis	rs7615952	0.736	rs11921945	ENSG00000171084.14	FAM86JP	8.61	1.19e-16	7.25e-14	0.6	0.37	Blood pressure (smoking interaction);	chr3:125924876	chr3:125916620~125930024:+
PRAD	cis	rs9532669	0.926	rs7328139	ENSG00000168852.11	TPTE2P5	8.61	1.19e-16	7.28e-14	0.35	0.37	Cervical cancer;	chr13:40862295	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.926	rs7328145	ENSG00000168852.11	TPTE2P5	8.61	1.19e-16	7.28e-14	0.35	0.37	Cervical cancer;	chr13:40862307	chr13:40822296~40921749:-
PRAD	cis	rs6570726	0.935	rs387965	ENSG00000235652.6	RP11-545I5.3	8.61	1.2e-16	7.31e-14	0.39	0.37	Lobe attachment (rater-scored or self-reported);	chr6:145548230	chr6:145799409~145886585:+
PRAD	cis	rs875971	0.522	rs2949690	ENSG00000236529.1	RP13-254B10.1	-8.61	1.2e-16	7.32e-14	-0.39	-0.37	Aortic root size;	chr7:66018255	chr7:65840212~65840596:+
PRAD	cis	rs4835473	0.932	rs34653324	ENSG00000251600.4	RP11-673E1.1	-8.61	1.2e-16	7.34e-14	-0.47	-0.37	Immature fraction of reticulocytes;	chr4:143735058	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs35947648	ENSG00000251600.4	RP11-673E1.1	-8.61	1.2e-16	7.34e-14	-0.47	-0.37	Immature fraction of reticulocytes;	chr4:143735092	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.838	rs35800634	ENSG00000251600.4	RP11-673E1.1	-8.61	1.2e-16	7.34e-14	-0.47	-0.37	Immature fraction of reticulocytes;	chr4:143735199	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.838	rs34505330	ENSG00000251600.4	RP11-673E1.1	-8.61	1.2e-16	7.34e-14	-0.47	-0.37	Immature fraction of reticulocytes;	chr4:143735206	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs4597770	ENSG00000251600.4	RP11-673E1.1	-8.61	1.2e-16	7.34e-14	-0.47	-0.37	Immature fraction of reticulocytes;	chr4:143735239	chr4:143912331~143982454:+
PRAD	cis	rs9309711	0.544	rs9752130	ENSG00000225234.1	TRAPPC12-AS1	-8.61	1.21e-16	7.38e-14	-0.39	-0.37	Neurofibrillary tangles;	chr2:3484731	chr2:3481242~3482409:-
PRAD	cis	rs6723108	0.627	rs2053727	ENSG00000224043.6	CCNT2-AS1	-8.61	1.21e-16	7.4e-14	-0.52	-0.37	Type 2 diabetes;	chr2:134885728	chr2:134735464~134918710:-
PRAD	cis	rs934734	0.563	rs955903	ENSG00000204929.10	AC074391.1	8.61	1.21e-16	7.4e-14	0.48	0.37	Rheumatoid arthritis;	chr2:65348419	chr2:65436711~66084639:+
PRAD	cis	rs7181230	0.885	rs9919974	ENSG00000275636.1	RP11-521C20.5	8.61	1.22e-16	7.41e-14	0.54	0.37	Dehydroepiandrosterone sulphate levels;	chr15:40045261	chr15:40078892~40079347:+
PRAD	cis	rs12142240	0.698	rs13374893	ENSG00000232022.5	FAAHP1	-8.61	1.22e-16	7.41e-14	-0.35	-0.37	Menopause (age at onset);	chr1:46378128	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.621	rs13374968	ENSG00000232022.5	FAAHP1	-8.61	1.22e-16	7.41e-14	-0.35	-0.37	Menopause (age at onset);	chr1:46378236	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs6695043	ENSG00000232022.5	FAAHP1	8.61	1.22e-16	7.41e-14	0.35	0.37	Menopause (age at onset);	chr1:46378858	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs72679807	ENSG00000232022.5	FAAHP1	-8.61	1.22e-16	7.41e-14	-0.35	-0.37	Menopause (age at onset);	chr1:46380818	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs56284503	ENSG00000232022.5	FAAHP1	-8.61	1.22e-16	7.41e-14	-0.35	-0.37	Menopause (age at onset);	chr1:46381455	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs17361915	ENSG00000232022.5	FAAHP1	-8.61	1.22e-16	7.41e-14	-0.35	-0.37	Menopause (age at onset);	chr1:46381649	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.66	rs72890715	ENSG00000232022.5	FAAHP1	-8.61	1.22e-16	7.41e-14	-0.35	-0.37	Menopause (age at onset);	chr1:46386405	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs4372193	ENSG00000232022.5	FAAHP1	-8.61	1.22e-16	7.41e-14	-0.35	-0.37	Menopause (age at onset);	chr1:46387561	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.659	rs111723629	ENSG00000232022.5	FAAHP1	-8.61	1.22e-16	7.41e-14	-0.35	-0.37	Menopause (age at onset);	chr1:46387689	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs3991877	ENSG00000232022.5	FAAHP1	-8.61	1.22e-16	7.41e-14	-0.35	-0.37	Menopause (age at onset);	chr1:46388077	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.659	rs1984491	ENSG00000232022.5	FAAHP1	-8.61	1.22e-16	7.41e-14	-0.35	-0.37	Menopause (age at onset);	chr1:46392935	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs45449893	ENSG00000232022.5	FAAHP1	-8.61	1.22e-16	7.41e-14	-0.35	-0.37	Menopause (age at onset);	chr1:46393352	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs45517837	ENSG00000232022.5	FAAHP1	-8.61	1.22e-16	7.41e-14	-0.35	-0.37	Menopause (age at onset);	chr1:46393553	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs932816	ENSG00000232022.5	FAAHP1	-8.61	1.22e-16	7.41e-14	-0.35	-0.37	Menopause (age at onset);	chr1:46394077	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs72890727	ENSG00000232022.5	FAAHP1	-8.61	1.22e-16	7.41e-14	-0.35	-0.37	Menopause (age at onset);	chr1:46394565	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs6703374	ENSG00000232022.5	FAAHP1	-8.61	1.22e-16	7.41e-14	-0.35	-0.37	Menopause (age at onset);	chr1:46396660	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs6703669	ENSG00000232022.5	FAAHP1	-8.61	1.22e-16	7.41e-14	-0.35	-0.37	Menopause (age at onset);	chr1:46396883	chr1:46432129~46445521:+
PRAD	cis	rs4835473	0.897	rs7662736	ENSG00000251600.4	RP11-673E1.1	8.61	1.22e-16	7.43e-14	0.48	0.37	Immature fraction of reticulocytes;	chr4:143958036	chr4:143912331~143982454:+
PRAD	cis	rs9532669	0.89	rs12865032	ENSG00000168852.11	TPTE2P5	8.61	1.22e-16	7.45e-14	0.36	0.37	Cervical cancer;	chr13:40873801	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.89	rs34123829	ENSG00000168852.11	TPTE2P5	8.61	1.22e-16	7.45e-14	0.36	0.37	Cervical cancer;	chr13:40873808	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.926	rs4488324	ENSG00000168852.11	TPTE2P5	8.61	1.22e-16	7.45e-14	0.36	0.37	Cervical cancer;	chr13:40873864	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.926	rs4288867	ENSG00000168852.11	TPTE2P5	8.61	1.22e-16	7.45e-14	0.36	0.37	Cervical cancer;	chr13:40873880	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.926	rs4415896	ENSG00000168852.11	TPTE2P5	8.61	1.22e-16	7.45e-14	0.36	0.37	Cervical cancer;	chr13:40874001	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.89	rs4415897	ENSG00000168852.11	TPTE2P5	8.61	1.22e-16	7.45e-14	0.36	0.37	Cervical cancer;	chr13:40874035	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.926	rs4389021	ENSG00000168852.11	TPTE2P5	8.61	1.22e-16	7.45e-14	0.36	0.37	Cervical cancer;	chr13:40874209	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.824	rs4628828	ENSG00000168852.11	TPTE2P5	8.61	1.22e-16	7.45e-14	0.36	0.37	Cervical cancer;	chr13:40874369	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.737	rs34354179	ENSG00000168852.11	TPTE2P5	8.61	1.22e-16	7.45e-14	0.36	0.37	Cervical cancer;	chr13:40874424	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.926	rs9594445	ENSG00000168852.11	TPTE2P5	8.61	1.22e-16	7.45e-14	0.36	0.37	Cervical cancer;	chr13:40874859	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.926	rs9594446	ENSG00000168852.11	TPTE2P5	8.61	1.22e-16	7.45e-14	0.36	0.37	Cervical cancer;	chr13:40874863	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.926	rs4402423	ENSG00000168852.11	TPTE2P5	8.61	1.22e-16	7.45e-14	0.36	0.37	Cervical cancer;	chr13:40875010	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.963	rs9532628	ENSG00000168852.11	TPTE2P5	8.61	1.22e-16	7.45e-14	0.36	0.37	Cervical cancer;	chr13:40875172	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.926	rs9532629	ENSG00000168852.11	TPTE2P5	8.61	1.22e-16	7.45e-14	0.36	0.37	Cervical cancer;	chr13:40875193	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.926	rs7491149	ENSG00000168852.11	TPTE2P5	8.61	1.22e-16	7.45e-14	0.36	0.37	Cervical cancer;	chr13:40875216	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.926	rs9532630	ENSG00000168852.11	TPTE2P5	8.61	1.22e-16	7.45e-14	0.36	0.37	Cervical cancer;	chr13:40875472	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.89	rs4306385	ENSG00000168852.11	TPTE2P5	8.61	1.22e-16	7.45e-14	0.36	0.37	Cervical cancer;	chr13:40875641	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.926	rs4406939	ENSG00000168852.11	TPTE2P5	8.61	1.22e-16	7.45e-14	0.36	0.37	Cervical cancer;	chr13:40876108	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.926	rs9532632	ENSG00000168852.11	TPTE2P5	8.61	1.22e-16	7.45e-14	0.36	0.37	Cervical cancer;	chr13:40876309	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.926	rs9532633	ENSG00000168852.11	TPTE2P5	8.61	1.22e-16	7.45e-14	0.36	0.37	Cervical cancer;	chr13:40876332	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.926	rs9532634	ENSG00000168852.11	TPTE2P5	8.61	1.22e-16	7.45e-14	0.36	0.37	Cervical cancer;	chr13:40876369	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.926	rs9532635	ENSG00000168852.11	TPTE2P5	8.61	1.22e-16	7.45e-14	0.36	0.37	Cervical cancer;	chr13:40876397	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.926	rs12428959	ENSG00000168852.11	TPTE2P5	8.61	1.22e-16	7.45e-14	0.36	0.37	Cervical cancer;	chr13:40876638	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.895	rs4942009	ENSG00000168852.11	TPTE2P5	8.61	1.22e-16	7.45e-14	0.36	0.37	Cervical cancer;	chr13:40877243	chr13:40822296~40921749:-
PRAD	cis	rs11098499	0.908	rs11098527	ENSG00000245958.5	RP11-33B1.1	-8.61	1.22e-16	7.45e-14	-0.37	-0.37	Corneal astigmatism;	chr4:119478751	chr4:119454791~119552025:+
PRAD	cis	rs950169	0.8	rs34302901	ENSG00000225151.9	GOLGA2P7	-8.61	1.23e-16	7.46e-14	-0.51	-0.37	Schizophrenia;	chr15:84567712	chr15:84199311~84230136:-
PRAD	cis	rs12701220	0.655	rs6463317	ENSG00000229043.2	AC091729.9	-8.61	1.23e-16	7.46e-14	-0.51	-0.37	Bronchopulmonary dysplasia;	chr7:1119607	chr7:1160374~1165267:+
PRAD	cis	rs6452524	1	rs62374373	ENSG00000249664.1	CTD-2227C6.2	8.61	1.23e-16	7.49e-14	0.43	0.37	Hypertension (SNP x SNP interaction);	chr5:83137389	chr5:83012285~83013109:-
PRAD	cis	rs6452524	1	rs10043018	ENSG00000249664.1	CTD-2227C6.2	8.61	1.23e-16	7.49e-14	0.43	0.37	Hypertension (SNP x SNP interaction);	chr5:83138498	chr5:83012285~83013109:-
PRAD	cis	rs6452524	0.935	rs10037501	ENSG00000249664.1	CTD-2227C6.2	8.61	1.23e-16	7.49e-14	0.43	0.37	Hypertension (SNP x SNP interaction);	chr5:83138722	chr5:83012285~83013109:-
PRAD	cis	rs6452524	0.904	rs6452525	ENSG00000249664.1	CTD-2227C6.2	8.61	1.23e-16	7.49e-14	0.43	0.37	Hypertension (SNP x SNP interaction);	chr5:83138752	chr5:83012285~83013109:-
PRAD	cis	rs6452524	1	rs7716931	ENSG00000249664.1	CTD-2227C6.2	8.61	1.23e-16	7.49e-14	0.43	0.37	Hypertension (SNP x SNP interaction);	chr5:83138856	chr5:83012285~83013109:-
PRAD	cis	rs6452524	1	rs7721416	ENSG00000249664.1	CTD-2227C6.2	8.61	1.23e-16	7.49e-14	0.43	0.37	Hypertension (SNP x SNP interaction);	chr5:83139174	chr5:83012285~83013109:-
PRAD	cis	rs6452524	1	rs6882220	ENSG00000249664.1	CTD-2227C6.2	8.61	1.23e-16	7.49e-14	0.43	0.37	Hypertension (SNP x SNP interaction);	chr5:83139715	chr5:83012285~83013109:-
PRAD	cis	rs6452524	1	rs6452526	ENSG00000249664.1	CTD-2227C6.2	8.61	1.23e-16	7.49e-14	0.43	0.37	Hypertension (SNP x SNP interaction);	chr5:83140992	chr5:83012285~83013109:-
PRAD	cis	rs6452524	1	rs6452527	ENSG00000249664.1	CTD-2227C6.2	8.61	1.23e-16	7.49e-14	0.43	0.37	Hypertension (SNP x SNP interaction);	chr5:83141021	chr5:83012285~83013109:-
PRAD	cis	rs6452524	1	rs10055844	ENSG00000249664.1	CTD-2227C6.2	8.61	1.23e-16	7.49e-14	0.43	0.37	Hypertension (SNP x SNP interaction);	chr5:83141276	chr5:83012285~83013109:-
PRAD	cis	rs6452524	1	rs10077862	ENSG00000249664.1	CTD-2227C6.2	8.61	1.23e-16	7.49e-14	0.43	0.37	Hypertension (SNP x SNP interaction);	chr5:83141322	chr5:83012285~83013109:-
PRAD	cis	rs6452524	1	rs9293332	ENSG00000249664.1	CTD-2227C6.2	8.61	1.23e-16	7.49e-14	0.43	0.37	Hypertension (SNP x SNP interaction);	chr5:83141546	chr5:83012285~83013109:-
PRAD	cis	rs6452524	1	rs6452524	ENSG00000249664.1	CTD-2227C6.2	-8.61	1.23e-16	7.49e-14	-0.43	-0.37	Hypertension (SNP x SNP interaction);	chr5:83137962	chr5:83012285~83013109:-
PRAD	cis	rs7849270	0.801	rs10819475	ENSG00000268707.1	RP11-247A12.7	8.61	1.23e-16	7.49e-14	0.44	0.37	Blood metabolite ratios;	chr9:129168561	chr9:129170434~129170940:+
PRAD	cis	rs7849270	0.76	rs419636	ENSG00000268707.1	RP11-247A12.7	8.61	1.23e-16	7.49e-14	0.44	0.37	Blood metabolite ratios;	chr9:129168998	chr9:129170434~129170940:+
PRAD	cis	rs2153535	0.518	rs6926976	ENSG00000230939.1	RP11-314C16.1	8.61	1.24e-16	7.53e-14	0.46	0.37	Motion sickness;	chr6:8622045	chr6:8784178~8785445:+
PRAD	cis	rs10740039	0.583	rs9415611	ENSG00000254271.1	RP11-131N11.4	-8.61	1.24e-16	7.53e-14	-0.52	-0.37	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60743440	chr10:60734342~60741828:+
PRAD	cis	rs34779708	0.733	rs7081597	ENSG00000230534.5	RP11-297A16.2	8.61	1.24e-16	7.55e-14	0.5	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35257403	chr10:35098006~35127020:-
PRAD	cis	rs5769707	0.616	rs135869	ENSG00000188511.11	C22orf34	8.61	1.24e-16	7.56e-14	0.45	0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49614718	chr22:49414524~49657542:-
PRAD	cis	rs4631830	0.863	rs2611507	ENSG00000230869.1	CTGLF10P	-8.61	1.24e-16	7.57e-14	-0.46	-0.37	Prostate-specific antigen levels;	chr10:46077149	chr10:45678692~45700532:+
PRAD	cis	rs2799081	1	rs2799081	ENSG00000204709.4	LINC01556	8.61	1.25e-16	7.58e-14	0.5	0.37	Myopia;	chr6:28302807	chr6:28943877~28944537:+
PRAD	cis	rs11676348	0.774	rs13397673	ENSG00000261338.2	RP11-378A13.1	-8.6	1.25e-16	7.62e-14	-0.42	-0.37	Ulcerative colitis;	chr2:218183059	chr2:218255319~218257366:+
PRAD	cis	rs6452524	0.935	rs10473868	ENSG00000249664.1	CTD-2227C6.2	8.6	1.25e-16	7.62e-14	0.43	0.37	Hypertension (SNP x SNP interaction);	chr5:83141628	chr5:83012285~83013109:-
PRAD	cis	rs7811142	0.887	rs111972532	ENSG00000242294.5	STAG3L5P	8.6	1.25e-16	7.63e-14	0.26	0.37	Platelet count;	chr7:100471465	chr7:100336079~100351900:+
PRAD	cis	rs67311347	1	rs13324109	ENSG00000223797.4	ENTPD3-AS1	8.6	1.26e-16	7.67e-14	0.33	0.37	Renal cell carcinoma;	chr3:40419276	chr3:40313802~40453329:-
PRAD	cis	rs11159086	0.793	rs10139029	ENSG00000259005.1	RP3-449M8.6	8.6	1.26e-16	7.67e-14	0.48	0.37	Advanced glycation end-product levels;	chr14:74492284	chr14:74474007~74474864:-
PRAD	cis	rs11098499	0.954	rs10518328	ENSG00000245958.5	RP11-33B1.1	-8.6	1.26e-16	7.67e-14	-0.37	-0.37	Corneal astigmatism;	chr4:119480624	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.954	rs6822679	ENSG00000245958.5	RP11-33B1.1	-8.6	1.26e-16	7.67e-14	-0.37	-0.37	Corneal astigmatism;	chr4:119481547	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.954	rs4577559	ENSG00000245958.5	RP11-33B1.1	-8.6	1.26e-16	7.67e-14	-0.37	-0.37	Corneal astigmatism;	chr4:119482888	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.954	rs7656252	ENSG00000245958.5	RP11-33B1.1	-8.6	1.26e-16	7.67e-14	-0.37	-0.37	Corneal astigmatism;	chr4:119483113	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.865	rs28845498	ENSG00000245958.5	RP11-33B1.1	-8.6	1.26e-16	7.67e-14	-0.37	-0.37	Corneal astigmatism;	chr4:119484031	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.865	rs28753180	ENSG00000245958.5	RP11-33B1.1	-8.6	1.26e-16	7.67e-14	-0.37	-0.37	Corneal astigmatism;	chr4:119484212	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.954	rs56270433	ENSG00000245958.5	RP11-33B1.1	-8.6	1.26e-16	7.67e-14	-0.37	-0.37	Corneal astigmatism;	chr4:119484875	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.954	rs7681544	ENSG00000245958.5	RP11-33B1.1	-8.6	1.26e-16	7.67e-14	-0.37	-0.37	Corneal astigmatism;	chr4:119490100	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.954	rs11940028	ENSG00000245958.5	RP11-33B1.1	-8.6	1.26e-16	7.67e-14	-0.37	-0.37	Corneal astigmatism;	chr4:119490752	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.954	rs11935596	ENSG00000245958.5	RP11-33B1.1	-8.6	1.26e-16	7.67e-14	-0.37	-0.37	Corneal astigmatism;	chr4:119491302	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.954	rs12507964	ENSG00000245958.5	RP11-33B1.1	-8.6	1.26e-16	7.67e-14	-0.37	-0.37	Corneal astigmatism;	chr4:119491906	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.909	rs11098530	ENSG00000245958.5	RP11-33B1.1	-8.6	1.26e-16	7.67e-14	-0.37	-0.37	Corneal astigmatism;	chr4:119491999	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.954	rs6834796	ENSG00000245958.5	RP11-33B1.1	-8.6	1.26e-16	7.67e-14	-0.37	-0.37	Corneal astigmatism;	chr4:119493538	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.954	rs11729521	ENSG00000245958.5	RP11-33B1.1	-8.6	1.26e-16	7.67e-14	-0.37	-0.37	Corneal astigmatism;	chr4:119495633	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.954	rs11734241	ENSG00000245958.5	RP11-33B1.1	-8.6	1.26e-16	7.67e-14	-0.37	-0.37	Corneal astigmatism;	chr4:119495717	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.954	rs28685688	ENSG00000245958.5	RP11-33B1.1	-8.6	1.26e-16	7.67e-14	-0.37	-0.37	Corneal astigmatism;	chr4:119499179	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.954	rs7687843	ENSG00000245958.5	RP11-33B1.1	-8.6	1.26e-16	7.67e-14	-0.37	-0.37	Corneal astigmatism;	chr4:119500056	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.954	rs2306455	ENSG00000245958.5	RP11-33B1.1	-8.6	1.26e-16	7.67e-14	-0.37	-0.37	Corneal astigmatism;	chr4:119500814	chr4:119454791~119552025:+
PRAD	cis	rs4835473	0.932	rs11724752	ENSG00000251600.4	RP11-673E1.1	-8.6	1.26e-16	7.68e-14	-0.48	-0.37	Immature fraction of reticulocytes;	chr4:143769473	chr4:143912331~143982454:+
PRAD	cis	rs6452524	1	rs6887846	ENSG00000249664.1	CTD-2227C6.2	-8.6	1.27e-16	7.71e-14	-0.44	-0.37	Hypertension (SNP x SNP interaction);	chr5:83140542	chr5:83012285~83013109:-
PRAD	cis	rs8523	0.774	rs2147041	ENSG00000230314.5	ELOVL2-AS1	-8.6	1.27e-16	7.72e-14	-0.41	-0.37	Red blood cell fatty acid levels;	chr6:11050290	chr6:11043524~11078226:+
PRAD	cis	rs7688540	0.739	rs11729659	ENSG00000275426.1	CH17-262A2.1	8.6	1.27e-16	7.73e-14	0.54	0.37	Facial morphology (factor 6, height of vermillion lower lip);	chr4:243495	chr4:149738~150317:+
PRAD	cis	rs7688540	0.665	rs11731933	ENSG00000275426.1	CH17-262A2.1	8.6	1.27e-16	7.73e-14	0.54	0.37	Facial morphology (factor 6, height of vermillion lower lip);	chr4:245370	chr4:149738~150317:+
PRAD	cis	rs7688540	0.771	rs4549329	ENSG00000275426.1	CH17-262A2.1	8.6	1.27e-16	7.73e-14	0.54	0.37	Facial morphology (factor 6, height of vermillion lower lip);	chr4:245996	chr4:149738~150317:+
PRAD	cis	rs7569084	1	rs7569084	ENSG00000204929.10	AC074391.1	-8.6	1.27e-16	7.74e-14	-0.46	-0.37	Sum eosinophil basophil counts;	chr2:65429835	chr2:65436711~66084639:+
PRAD	cis	rs11676348	0.71	rs11894169	ENSG00000261338.2	RP11-378A13.1	8.6	1.28e-16	7.77e-14	0.42	0.37	Ulcerative colitis;	chr2:218182123	chr2:218255319~218257366:+
PRAD	cis	rs34779708	0.733	rs4007271	ENSG00000230534.5	RP11-297A16.2	8.6	1.28e-16	7.77e-14	0.5	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35257683	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.702	rs4007272	ENSG00000230534.5	RP11-297A16.2	8.6	1.28e-16	7.77e-14	0.5	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35257931	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.733	rs4934740	ENSG00000230534.5	RP11-297A16.2	8.6	1.28e-16	7.77e-14	0.5	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35258213	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.702	rs4244995	ENSG00000230534.5	RP11-297A16.2	8.6	1.28e-16	7.77e-14	0.5	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35258247	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.733	rs4244997	ENSG00000230534.5	RP11-297A16.2	8.6	1.28e-16	7.77e-14	0.5	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35258326	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.733	rs4298846	ENSG00000230534.5	RP11-297A16.2	8.6	1.28e-16	7.77e-14	0.5	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35258452	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.733	rs4391768	ENSG00000230534.5	RP11-297A16.2	8.6	1.28e-16	7.77e-14	0.5	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35258667	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.733	rs7914468	ENSG00000230534.5	RP11-297A16.2	8.6	1.28e-16	7.77e-14	0.5	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35259143	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.733	rs7914560	ENSG00000230534.5	RP11-297A16.2	8.6	1.28e-16	7.77e-14	0.5	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35259171	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.733	rs4444023	ENSG00000230534.5	RP11-297A16.2	8.6	1.28e-16	7.77e-14	0.5	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35259426	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.733	rs12243593	ENSG00000230534.5	RP11-297A16.2	8.6	1.28e-16	7.77e-14	0.5	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35260117	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.733	rs3936502	ENSG00000230534.5	RP11-297A16.2	8.6	1.28e-16	7.77e-14	0.5	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35260290	chr10:35098006~35127020:-
PRAD	cis	rs6452524	1	rs10474093	ENSG00000249664.1	CTD-2227C6.2	8.6	1.28e-16	7.78e-14	0.43	0.37	Hypertension (SNP x SNP interaction);	chr5:83141612	chr5:83012285~83013109:-
PRAD	cis	rs875971	0.964	rs60193905	ENSG00000237310.1	GS1-124K5.4	8.6	1.28e-16	7.8e-14	0.33	0.37	Aortic root size;	chr7:66506273	chr7:66493706~66495474:+
PRAD	cis	rs2404602	0.655	rs10444809	ENSG00000259422.1	RP11-593F23.1	-8.6	1.29e-16	7.81e-14	-0.47	-0.37	Blood metabolite levels;	chr15:76832195	chr15:76174891~76181486:-
PRAD	cis	rs7615952	0.611	rs72979452	ENSG00000171084.14	FAM86JP	8.6	1.29e-16	7.82e-14	0.81	0.37	Blood pressure (smoking interaction);	chr3:126037335	chr3:125916620~125930024:+
PRAD	cis	rs4713118	0.955	rs9368528	ENSG00000280107.1	AL022393.9	-8.6	1.29e-16	7.86e-14	-0.47	-0.37	Parkinson's disease;	chr6:27716019	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.955	rs9368529	ENSG00000280107.1	AL022393.9	-8.6	1.29e-16	7.86e-14	-0.47	-0.37	Parkinson's disease;	chr6:27716852	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.955	rs9380012	ENSG00000280107.1	AL022393.9	-8.6	1.29e-16	7.86e-14	-0.47	-0.37	Parkinson's disease;	chr6:27716875	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.955	rs9468201	ENSG00000280107.1	AL022393.9	-8.6	1.29e-16	7.86e-14	-0.47	-0.37	Parkinson's disease;	chr6:27719256	chr6:28170845~28172521:+
PRAD	cis	rs4631830	0.72	rs2611512	ENSG00000230869.1	CTGLF10P	-8.6	1.3e-16	7.86e-14	-0.46	-0.37	Prostate-specific antigen levels;	chr10:46080288	chr10:45678692~45700532:+
PRAD	cis	rs6723108	0.581	rs1446525	ENSG00000224043.6	CCNT2-AS1	-8.6	1.3e-16	7.87e-14	-0.52	-0.37	Type 2 diabetes;	chr2:134880277	chr2:134735464~134918710:-
PRAD	cis	rs6723108	0.627	rs6430554	ENSG00000224043.6	CCNT2-AS1	-8.6	1.3e-16	7.87e-14	-0.52	-0.37	Type 2 diabetes;	chr2:134880891	chr2:134735464~134918710:-
PRAD	cis	rs2153535	0.518	rs9502728	ENSG00000230939.1	RP11-314C16.1	-8.6	1.3e-16	7.88e-14	-0.45	-0.37	Motion sickness;	chr6:8602710	chr6:8784178~8785445:+
PRAD	cis	rs4835473	0.897	rs7682204	ENSG00000251600.4	RP11-673E1.1	8.6	1.3e-16	7.89e-14	0.48	0.37	Immature fraction of reticulocytes;	chr4:143966306	chr4:143912331~143982454:+
PRAD	cis	rs10463554	0.963	rs6596530	ENSG00000175749.11	EIF3KP1	8.6	1.3e-16	7.9e-14	0.49	0.37	Parkinson's disease;	chr5:103035736	chr5:103032376~103033031:+
PRAD	cis	rs950169	0.724	rs11632668	ENSG00000259728.4	LINC00933	8.6	1.3e-16	7.91e-14	0.45	0.37	Schizophrenia;	chr15:84393989	chr15:84570649~84580175:+
PRAD	cis	rs950169	0.881	rs34591918	ENSG00000259728.4	LINC00933	8.6	1.3e-16	7.91e-14	0.45	0.37	Schizophrenia;	chr15:84396135	chr15:84570649~84580175:+
PRAD	cis	rs950169	0.887	rs12903946	ENSG00000259728.4	LINC00933	8.6	1.3e-16	7.91e-14	0.45	0.37	Schizophrenia;	chr15:84399732	chr15:84570649~84580175:+
PRAD	cis	rs950169	0.887	rs62029593	ENSG00000259728.4	LINC00933	8.6	1.3e-16	7.91e-14	0.45	0.37	Schizophrenia;	chr15:84400482	chr15:84570649~84580175:+
PRAD	cis	rs950169	0.81	rs62029594	ENSG00000259728.4	LINC00933	8.6	1.3e-16	7.91e-14	0.45	0.37	Schizophrenia;	chr15:84400554	chr15:84570649~84580175:+
PRAD	cis	rs950169	0.881	rs62029596	ENSG00000259728.4	LINC00933	8.6	1.3e-16	7.91e-14	0.45	0.37	Schizophrenia;	chr15:84400736	chr15:84570649~84580175:+
PRAD	cis	rs950169	0.881	rs4081123	ENSG00000259728.4	LINC00933	8.6	1.3e-16	7.91e-14	0.45	0.37	Schizophrenia;	chr15:84401537	chr15:84570649~84580175:+
PRAD	cis	rs950169	0.881	rs62029599	ENSG00000259728.4	LINC00933	8.6	1.3e-16	7.91e-14	0.45	0.37	Schizophrenia;	chr15:84401867	chr15:84570649~84580175:+
PRAD	cis	rs950169	0.8	rs4099846	ENSG00000259728.4	LINC00933	8.6	1.3e-16	7.91e-14	0.45	0.37	Schizophrenia;	chr15:84402196	chr15:84570649~84580175:+
PRAD	cis	rs11083475	1	rs2303040	ENSG00000267892.1	CTD-2540F13.2	8.6	1.31e-16	7.92e-14	0.41	0.37	Heart rate;	chr19:38647968	chr19:38738284~38739863:+
PRAD	cis	rs8081395	0.801	rs2665405	ENSG00000266992.1	DHX40P1	-8.6	1.31e-16	7.94e-14	-0.42	-0.37	White blood cell count;	chr17:59797931	chr17:59976009~60002384:-
PRAD	cis	rs1930961	1	rs1930961	ENSG00000272798.1	CTA-390C10.9	-8.6	1.31e-16	7.94e-14	-0.6	-0.37	Bipolar disorder with mood-incongruent psychosis;	chr22:25479298	chr22:25436312~25436915:+
PRAD	cis	rs507080	0.769	rs2077173	ENSG00000255422.1	AP002954.4	-8.6	1.31e-16	7.95e-14	-0.46	-0.37	Serum metabolite levels;	chr11:118621876	chr11:118704607~118750263:+
PRAD	cis	rs4835473	0.618	rs7666297	ENSG00000251600.4	RP11-673E1.1	-8.6	1.31e-16	7.96e-14	-0.49	-0.37	Immature fraction of reticulocytes;	chr4:143999005	chr4:143912331~143982454:+
PRAD	cis	rs7615952	0.611	rs79405914	ENSG00000171084.14	FAM86JP	8.6	1.31e-16	7.96e-14	0.81	0.37	Blood pressure (smoking interaction);	chr3:126004780	chr3:125916620~125930024:+
PRAD	cis	rs9532669	0.89	rs7333274	ENSG00000168852.11	TPTE2P5	8.6	1.32e-16	7.98e-14	0.35	0.37	Cervical cancer;	chr13:40862531	chr13:40822296~40921749:-
PRAD	cis	rs6570726	0.935	rs388394	ENSG00000235652.6	RP11-545I5.3	8.6	1.32e-16	7.99e-14	0.39	0.37	Lobe attachment (rater-scored or self-reported);	chr6:145531553	chr6:145799409~145886585:+
PRAD	cis	rs11083475	1	rs3786839	ENSG00000267892.1	CTD-2540F13.2	8.6	1.32e-16	8e-14	0.4	0.37	Heart rate;	chr19:38691925	chr19:38738284~38739863:+
PRAD	cis	rs875971	1	rs2420591	ENSG00000237310.1	GS1-124K5.4	8.6	1.33e-16	8.05e-14	0.33	0.37	Aortic root size;	chr7:66447394	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.895	rs10755833	ENSG00000237310.1	GS1-124K5.4	8.6	1.33e-16	8.05e-14	0.33	0.37	Aortic root size;	chr7:66448930	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.895	rs12698520	ENSG00000237310.1	GS1-124K5.4	8.6	1.33e-16	8.05e-14	0.33	0.37	Aortic root size;	chr7:66453720	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.895	rs1833495	ENSG00000237310.1	GS1-124K5.4	8.6	1.33e-16	8.05e-14	0.33	0.37	Aortic root size;	chr7:66456608	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.964	rs6945032	ENSG00000237310.1	GS1-124K5.4	8.6	1.33e-16	8.05e-14	0.33	0.37	Aortic root size;	chr7:66457499	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.929	rs12673810	ENSG00000237310.1	GS1-124K5.4	8.6	1.33e-16	8.05e-14	0.33	0.37	Aortic root size;	chr7:66458866	chr7:66493706~66495474:+
PRAD	cis	rs875971	1	rs35149210	ENSG00000237310.1	GS1-124K5.4	8.6	1.33e-16	8.05e-14	0.33	0.37	Aortic root size;	chr7:66464938	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.929	rs34406470	ENSG00000237310.1	GS1-124K5.4	8.6	1.33e-16	8.05e-14	0.33	0.37	Aortic root size;	chr7:66464969	chr7:66493706~66495474:+
PRAD	cis	rs875971	1	rs6961155	ENSG00000237310.1	GS1-124K5.4	8.6	1.33e-16	8.05e-14	0.33	0.37	Aortic root size;	chr7:66468308	chr7:66493706~66495474:+
PRAD	cis	rs875971	1	rs7789768	ENSG00000237310.1	GS1-124K5.4	8.6	1.33e-16	8.05e-14	0.33	0.37	Aortic root size;	chr7:66473993	chr7:66493706~66495474:+
PRAD	cis	rs875971	1	rs1363055	ENSG00000237310.1	GS1-124K5.4	8.6	1.33e-16	8.05e-14	0.33	0.37	Aortic root size;	chr7:66478288	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.964	rs9691480	ENSG00000237310.1	GS1-124K5.4	8.6	1.33e-16	8.05e-14	0.33	0.37	Aortic root size;	chr7:66479319	chr7:66493706~66495474:+
PRAD	cis	rs875971	1	rs7789554	ENSG00000237310.1	GS1-124K5.4	8.6	1.33e-16	8.05e-14	0.33	0.37	Aortic root size;	chr7:66481051	chr7:66493706~66495474:+
PRAD	cis	rs875971	1	rs4717300	ENSG00000237310.1	GS1-124K5.4	8.6	1.33e-16	8.05e-14	0.33	0.37	Aortic root size;	chr7:66482393	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.895	rs1974769	ENSG00000237310.1	GS1-124K5.4	8.6	1.33e-16	8.05e-14	0.33	0.37	Aortic root size;	chr7:66485627	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.895	rs6460300	ENSG00000237310.1	GS1-124K5.4	8.6	1.33e-16	8.05e-14	0.33	0.37	Aortic root size;	chr7:66487937	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.862	rs7803416	ENSG00000237310.1	GS1-124K5.4	8.6	1.33e-16	8.05e-14	0.33	0.37	Aortic root size;	chr7:66489212	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.862	rs1981799	ENSG00000237310.1	GS1-124K5.4	8.6	1.33e-16	8.05e-14	0.33	0.37	Aortic root size;	chr7:66490572	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.964	rs2277911	ENSG00000237310.1	GS1-124K5.4	8.6	1.33e-16	8.05e-14	0.33	0.37	Aortic root size;	chr7:66493638	chr7:66493706~66495474:+
PRAD	cis	rs7712401	0.601	rs386602	ENSG00000263432.2	RN7SL689P	-8.6	1.33e-16	8.05e-14	-0.39	-0.37	Mean platelet volume;	chr5:122986262	chr5:123022487~123022783:-
PRAD	cis	rs3096299	0.933	rs2965823	ENSG00000274627.1	RP11-104N10.2	8.6	1.34e-16	8.09e-14	0.38	0.37	Multiple myeloma (IgH translocation);	chr16:89388516	chr16:89516797~89522217:+
PRAD	cis	rs7727544	0.716	rs6863213	ENSG00000233006.5	AC034220.3	8.6	1.34e-16	8.1e-14	0.33	0.37	Blood metabolite levels;	chr5:132240239	chr5:132311285~132369916:-
PRAD	cis	rs6991838	0.798	rs6994889	ENSG00000200714.1	Y_RNA	8.6	1.34e-16	8.1e-14	0.38	0.37	Intelligence (multi-trait analysis);	chr8:65562547	chr8:65592731~65592820:+
PRAD	cis	rs6723108	0.627	rs1446524	ENSG00000224043.6	CCNT2-AS1	-8.6	1.34e-16	8.11e-14	-0.52	-0.37	Type 2 diabetes;	chr2:134873761	chr2:134735464~134918710:-
PRAD	cis	rs6723108	0.627	rs10928522	ENSG00000224043.6	CCNT2-AS1	-8.6	1.34e-16	8.11e-14	-0.52	-0.37	Type 2 diabetes;	chr2:134875292	chr2:134735464~134918710:-
PRAD	cis	rs4835473	0.868	rs4629390	ENSG00000251600.4	RP11-673E1.1	-8.6	1.34e-16	8.12e-14	-0.47	-0.37	Immature fraction of reticulocytes;	chr4:143735302	chr4:143912331~143982454:+
PRAD	cis	rs875971	1	rs3981131	ENSG00000237310.1	GS1-124K5.4	8.6	1.34e-16	8.14e-14	0.33	0.37	Aortic root size;	chr7:66486690	chr7:66493706~66495474:+
PRAD	cis	rs11098499	0.863	rs6835635	ENSG00000245958.5	RP11-33B1.1	-8.6	1.34e-16	8.14e-14	-0.37	-0.37	Corneal astigmatism;	chr4:119537712	chr4:119454791~119552025:+
PRAD	cis	rs7811142	1	rs11771419	ENSG00000242294.5	STAG3L5P	8.6	1.35e-16	8.15e-14	0.25	0.37	Platelet count;	chr7:100390780	chr7:100336079~100351900:+
PRAD	cis	rs7811142	0.943	rs3900792	ENSG00000242294.5	STAG3L5P	8.6	1.35e-16	8.15e-14	0.25	0.37	Platelet count;	chr7:100406954	chr7:100336079~100351900:+
PRAD	cis	rs7811142	1	rs67471932	ENSG00000242294.5	STAG3L5P	8.6	1.35e-16	8.15e-14	0.25	0.37	Platelet count;	chr7:100412362	chr7:100336079~100351900:+
PRAD	cis	rs7811142	1	rs73161759	ENSG00000242294.5	STAG3L5P	8.6	1.35e-16	8.15e-14	0.25	0.37	Platelet count;	chr7:100412371	chr7:100336079~100351900:+
PRAD	cis	rs7811142	1	rs66632384	ENSG00000242294.5	STAG3L5P	8.6	1.35e-16	8.15e-14	0.25	0.37	Platelet count;	chr7:100421281	chr7:100336079~100351900:+
PRAD	cis	rs7811142	0.943	rs73403312	ENSG00000242294.5	STAG3L5P	8.6	1.35e-16	8.15e-14	0.25	0.37	Platelet count;	chr7:100426530	chr7:100336079~100351900:+
PRAD	cis	rs526231	0.511	rs17154965	ENSG00000175749.11	EIF3KP1	8.59	1.35e-16	8.17e-14	0.51	0.37	Primary biliary cholangitis;	chr5:103023862	chr5:103032376~103033031:+
PRAD	cis	rs6061231	0.701	rs6061505	ENSG00000273619.1	RP5-908M14.9	-8.59	1.35e-16	8.18e-14	-0.23	-0.37	Colorectal cancer;	chr20:62385155	chr20:62386303~62386970:-
PRAD	cis	rs4713118	0.629	rs149899	ENSG00000219392.1	RP1-265C24.5	-8.59	1.35e-16	8.18e-14	-0.49	-0.37	Parkinson's disease;	chr6:28052201	chr6:28115628~28116551:+
PRAD	cis	rs4713118	0.629	rs172165	ENSG00000219392.1	RP1-265C24.5	-8.59	1.35e-16	8.18e-14	-0.49	-0.37	Parkinson's disease;	chr6:28053036	chr6:28115628~28116551:+
PRAD	cis	rs4713118	0.597	rs172166	ENSG00000219392.1	RP1-265C24.5	-8.59	1.35e-16	8.18e-14	-0.49	-0.37	Parkinson's disease;	chr6:28053042	chr6:28115628~28116551:+
PRAD	cis	rs67311347	1	rs6795475	ENSG00000223797.4	ENTPD3-AS1	8.59	1.36e-16	8.22e-14	0.33	0.37	Renal cell carcinoma;	chr3:40447790	chr3:40313802~40453329:-
PRAD	cis	rs11098499	0.909	rs6842762	ENSG00000245958.5	RP11-33B1.1	-8.59	1.36e-16	8.23e-14	-0.37	-0.37	Corneal astigmatism;	chr4:119477081	chr4:119454791~119552025:+
PRAD	cis	rs4835473	0.897	rs17693768	ENSG00000251600.4	RP11-673E1.1	-8.59	1.36e-16	8.23e-14	-0.47	-0.37	Immature fraction of reticulocytes;	chr4:143737503	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.864	rs5015762	ENSG00000251600.4	RP11-673E1.1	-8.59	1.36e-16	8.23e-14	-0.47	-0.37	Immature fraction of reticulocytes;	chr4:143737773	chr4:143912331~143982454:+
PRAD	cis	rs7772486	0.743	rs62433835	ENSG00000235652.6	RP11-545I5.3	-8.59	1.36e-16	8.24e-14	-0.38	-0.37	Lobe attachment (rater-scored or self-reported);	chr6:145711552	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.743	rs2092262	ENSG00000235652.6	RP11-545I5.3	-8.59	1.36e-16	8.24e-14	-0.38	-0.37	Lobe attachment (rater-scored or self-reported);	chr6:145715969	chr6:145799409~145886585:+
PRAD	cis	rs7772486	0.682	rs1337840	ENSG00000235652.6	RP11-545I5.3	-8.59	1.36e-16	8.24e-14	-0.38	-0.37	Lobe attachment (rater-scored or self-reported);	chr6:145721422	chr6:145799409~145886585:+
PRAD	cis	rs17486696	0.655	rs62352418	ENSG00000248771.4	LINC01207	8.59	1.36e-16	8.24e-14	0.65	0.37	Positive affect;	chr4:164759536	chr4:164754064~164803795:+
PRAD	cis	rs6452524	1	rs10474094	ENSG00000249664.1	CTD-2227C6.2	8.59	1.36e-16	8.25e-14	0.43	0.37	Hypertension (SNP x SNP interaction);	chr5:83154678	chr5:83012285~83013109:-
PRAD	cis	rs2439831	0.85	rs28595038	ENSG00000249839.1	AC011330.5	-8.59	1.36e-16	8.26e-14	-0.64	-0.37	Lung cancer in ever smokers;	chr15:43752661	chr15:43663654~43684339:-
PRAD	cis	rs2439831	0.85	rs10163054	ENSG00000249839.1	AC011330.5	-8.59	1.36e-16	8.26e-14	-0.64	-0.37	Lung cancer in ever smokers;	chr15:43755440	chr15:43663654~43684339:-
PRAD	cis	rs950169	0.922	rs12910334	ENSG00000259728.4	LINC00933	8.59	1.37e-16	8.27e-14	0.45	0.37	Schizophrenia;	chr15:84403620	chr15:84570649~84580175:+
PRAD	cis	rs507080	0.769	rs571001	ENSG00000255422.1	AP002954.4	-8.59	1.37e-16	8.3e-14	-0.46	-0.37	Serum metabolite levels;	chr11:118629457	chr11:118704607~118750263:+
PRAD	cis	rs2108622	1	rs55744319	ENSG00000267453.5	AC004791.2	-8.59	1.37e-16	8.31e-14	-0.5	-0.37	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871011	chr19:15851993~15864904:-
PRAD	cis	rs2274273	0.905	rs10134800	ENSG00000258413.1	RP11-665C16.6	-8.59	1.37e-16	8.31e-14	-0.49	-0.37	Protein biomarker;	chr14:55168491	chr14:55262767~55272075:-
PRAD	cis	rs2274273	0.87	rs8018110	ENSG00000258413.1	RP11-665C16.6	-8.59	1.37e-16	8.31e-14	-0.49	-0.37	Protein biomarker;	chr14:55174996	chr14:55262767~55272075:-
PRAD	cis	rs875971	1	rs778726	ENSG00000237310.1	GS1-124K5.4	8.59	1.38e-16	8.33e-14	0.33	0.37	Aortic root size;	chr7:66363744	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.767	rs1695815	ENSG00000237310.1	GS1-124K5.4	8.59	1.38e-16	8.33e-14	0.33	0.37	Aortic root size;	chr7:66366357	chr7:66493706~66495474:+
PRAD	cis	rs875971	1	rs778685	ENSG00000237310.1	GS1-124K5.4	8.59	1.38e-16	8.33e-14	0.33	0.37	Aortic root size;	chr7:66371189	chr7:66493706~66495474:+
PRAD	cis	rs4964805	0.913	rs11111795	ENSG00000257681.1	RP11-341G23.4	8.59	1.38e-16	8.37e-14	0.37	0.37	Attention deficit hyperactivity disorder;	chr12:103811052	chr12:103746315~103768858:-
PRAD	cis	rs6570726	0.935	rs110289	ENSG00000235652.6	RP11-545I5.3	8.59	1.39e-16	8.39e-14	0.39	0.37	Lobe attachment (rater-scored or self-reported);	chr6:145544040	chr6:145799409~145886585:+
PRAD	cis	rs853679	0.55	rs1233707	ENSG00000272009.1	RP1-313I6.12	-8.59	1.39e-16	8.39e-14	-0.37	-0.37	Depression;	chr6:28205175	chr6:28078792~28081130:-
PRAD	cis	rs4713118	0.955	rs9380010	ENSG00000280107.1	AL022393.9	-8.59	1.39e-16	8.4e-14	-0.47	-0.37	Parkinson's disease;	chr6:27715793	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.55	rs1237875	ENSG00000272009.1	RP1-313I6.12	8.59	1.39e-16	8.42e-14	0.37	0.37	Depression;	chr6:28205232	chr6:28078792~28081130:-
PRAD	cis	rs2439831	0.702	rs7171750	ENSG00000249839.1	AC011330.5	-8.59	1.39e-16	8.42e-14	-0.63	-0.37	Lung cancer in ever smokers;	chr15:43733660	chr15:43663654~43684339:-
PRAD	cis	rs673078	0.607	rs7304342	ENSG00000275409.1	RP11-131L12.4	-8.59	1.4e-16	8.43e-14	-0.52	-0.37	Glucose homeostasis traits;	chr12:118390166	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.615	rs61943397	ENSG00000275409.1	RP11-131L12.4	-8.59	1.4e-16	8.43e-14	-0.52	-0.37	Glucose homeostasis traits;	chr12:118390996	chr12:118430147~118430699:+
PRAD	cis	rs6723108	0.517	rs10928520	ENSG00000224043.6	CCNT2-AS1	-8.59	1.4e-16	8.44e-14	-0.51	-0.37	Type 2 diabetes;	chr2:134846613	chr2:134735464~134918710:-
PRAD	cis	rs11083475	1	rs7251903	ENSG00000267892.1	CTD-2540F13.2	8.59	1.4e-16	8.46e-14	0.4	0.37	Heart rate;	chr19:38694171	chr19:38738284~38739863:+
PRAD	cis	rs375066	0.935	rs368089	ENSG00000267058.1	RP11-15A1.3	-8.59	1.4e-16	8.48e-14	-0.31	-0.37	Breast cancer;	chr19:43894932	chr19:43891804~43901805:-
PRAD	cis	rs11098499	0.866	rs10518329	ENSG00000245958.5	RP11-33B1.1	-8.59	1.4e-16	8.49e-14	-0.36	-0.37	Corneal astigmatism;	chr4:119480680	chr4:119454791~119552025:+
PRAD	cis	rs507080	0.769	rs570952	ENSG00000255422.1	AP002954.4	-8.59	1.4e-16	8.49e-14	-0.46	-0.37	Serum metabolite levels;	chr11:118629477	chr11:118704607~118750263:+
PRAD	cis	rs875971	0.929	rs778682	ENSG00000237310.1	GS1-124K5.4	8.59	1.41e-16	8.49e-14	0.33	0.37	Aortic root size;	chr7:66372947	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.964	rs11765965	ENSG00000237310.1	GS1-124K5.4	8.59	1.41e-16	8.49e-14	0.33	0.37	Aortic root size;	chr7:66377234	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.522	rs709604	ENSG00000236529.1	RP13-254B10.1	-8.59	1.41e-16	8.49e-14	-0.39	-0.37	Aortic root size;	chr7:66032447	chr7:65840212~65840596:+
PRAD	cis	rs1075265	0.901	rs9808326	ENSG00000233266.1	HMGB1P31	8.59	1.41e-16	8.5e-14	0.51	0.37	Chronotype;Morning vs. evening chronotype;	chr2:54115971	chr2:54051334~54051760:+
PRAD	cis	rs9341835	0.772	rs9294196	ENSG00000218048.2	RP3-407E4.4	-8.59	1.41e-16	8.51e-14	-0.41	-0.37	Schizophrenia;	chr6:63425288	chr6:63440766~63443580:+
PRAD	cis	rs4713118	0.699	rs573179	ENSG00000226314.6	ZNF192P1	-8.59	1.41e-16	8.51e-14	-0.52	-0.37	Parkinson's disease;	chr6:27881898	chr6:28161781~28169594:+
PRAD	cis	rs11951515	0.626	rs3733768	ENSG00000188850.9	RP11-159F24.2	-8.59	1.41e-16	8.53e-14	-0.45	-0.37	Metabolite levels  (X-11787);	chr5:43296930	chr5:43336164~43348716:+
PRAD	cis	rs7131987	0.65	rs67146951	ENSG00000257176.2	RP11-996F15.2	-8.59	1.42e-16	8.56e-14	-0.41	-0.37	QT interval;	chr12:29297620	chr12:29280418~29317848:-
PRAD	cis	rs2412819	0.545	rs35822148	ENSG00000205771.5	CATSPER2P1	-8.59	1.43e-16	8.61e-14	-0.58	-0.37	Lung cancer;	chr15:43808084	chr15:43726918~43747094:-
PRAD	cis	rs2412819	0.571	rs17727853	ENSG00000205771.5	CATSPER2P1	-8.59	1.43e-16	8.64e-14	-0.54	-0.37	Lung cancer;	chr15:43630299	chr15:43726918~43747094:-
PRAD	cis	rs9309473	0.687	rs11693531	ENSG00000163016.8	ALMS1P	8.59	1.43e-16	8.65e-14	0.45	0.37	Metabolite levels;	chr2:73381486	chr2:73644919~73685576:+
PRAD	cis	rs7131987	0.65	rs3782509	ENSG00000257176.2	RP11-996F15.2	-8.59	1.44e-16	8.68e-14	-0.41	-0.37	QT interval;	chr12:29300845	chr12:29280418~29317848:-
PRAD	cis	rs7115242	0.844	rs645258	ENSG00000254851.1	RP11-109L13.1	-8.59	1.44e-16	8.69e-14	-0.84	-0.37	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116930485	chr11:117135528~117138582:+
PRAD	cis	rs5769707	0.681	rs9616329	ENSG00000188511.11	C22orf34	8.59	1.44e-16	8.69e-14	0.42	0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49632666	chr22:49414524~49657542:-
PRAD	cis	rs11098499	0.909	rs10026736	ENSG00000245958.5	RP11-33B1.1	-8.59	1.45e-16	8.74e-14	-0.37	-0.37	Corneal astigmatism;	chr4:119463167	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.954	rs12499324	ENSG00000245958.5	RP11-33B1.1	-8.59	1.45e-16	8.74e-14	-0.37	-0.37	Corneal astigmatism;	chr4:119472631	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.954	rs9998585	ENSG00000245958.5	RP11-33B1.1	-8.59	1.45e-16	8.74e-14	-0.37	-0.37	Corneal astigmatism;	chr4:119475647	chr4:119454791~119552025:+
PRAD	cis	rs1075265	0.933	rs929734	ENSG00000233266.1	HMGB1P31	8.59	1.45e-16	8.74e-14	0.51	0.37	Chronotype;Morning vs. evening chronotype;	chr2:54111158	chr2:54051334~54051760:+
PRAD	cis	rs950169	0.96	rs35159785	ENSG00000259728.4	LINC00933	8.58	1.45e-16	8.77e-14	0.45	0.37	Schizophrenia;	chr15:84135262	chr15:84570649~84580175:+
PRAD	cis	rs9903692	0.954	rs8065670	ENSG00000278765.1	RP5-890E16.5	-8.58	1.46e-16	8.79e-14	-0.56	-0.37	Pulse pressure;	chr17:48096478	chr17:48066704~48067293:-
PRAD	cis	rs9903692	0.866	rs11079807	ENSG00000278765.1	RP5-890E16.5	-8.58	1.46e-16	8.79e-14	-0.56	-0.37	Pulse pressure;	chr17:48098685	chr17:48066704~48067293:-
PRAD	cis	rs9903692	0.954	rs10853094	ENSG00000278765.1	RP5-890E16.5	-8.58	1.46e-16	8.79e-14	-0.56	-0.37	Pulse pressure;	chr17:48098700	chr17:48066704~48067293:-
PRAD	cis	rs9903692	0.954	rs4794441	ENSG00000278765.1	RP5-890E16.5	-8.58	1.46e-16	8.79e-14	-0.56	-0.37	Pulse pressure;	chr17:48099094	chr17:48066704~48067293:-
PRAD	cis	rs9903692	0.908	rs12950402	ENSG00000278765.1	RP5-890E16.5	-8.58	1.46e-16	8.79e-14	-0.56	-0.37	Pulse pressure;	chr17:48102752	chr17:48066704~48067293:-
PRAD	cis	rs9903692	0.954	rs4794448	ENSG00000278765.1	RP5-890E16.5	-8.58	1.46e-16	8.79e-14	-0.56	-0.37	Pulse pressure;	chr17:48103445	chr17:48066704~48067293:-
PRAD	cis	rs9903692	0.954	rs68175794	ENSG00000278765.1	RP5-890E16.5	-8.58	1.46e-16	8.79e-14	-0.56	-0.37	Pulse pressure;	chr17:48103742	chr17:48066704~48067293:-
PRAD	cis	rs9903692	0.862	rs12943543	ENSG00000278765.1	RP5-890E16.5	-8.58	1.46e-16	8.79e-14	-0.56	-0.37	Pulse pressure;	chr17:48104003	chr17:48066704~48067293:-
PRAD	cis	rs9903692	0.954	rs4794451	ENSG00000278765.1	RP5-890E16.5	-8.58	1.46e-16	8.79e-14	-0.56	-0.37	Pulse pressure;	chr17:48107419	chr17:48066704~48067293:-
PRAD	cis	rs9903692	0.862	rs4794453	ENSG00000278765.1	RP5-890E16.5	-8.58	1.46e-16	8.79e-14	-0.56	-0.37	Pulse pressure;	chr17:48107564	chr17:48066704~48067293:-
PRAD	cis	rs7811142	1	rs67315960	ENSG00000242294.5	STAG3L5P	8.58	1.46e-16	8.81e-14	0.25	0.37	Platelet count;	chr7:100417501	chr7:100336079~100351900:+
PRAD	cis	rs7811142	1	rs11763414	ENSG00000242294.5	STAG3L5P	8.58	1.46e-16	8.81e-14	0.25	0.37	Platelet count;	chr7:100419221	chr7:100336079~100351900:+
PRAD	cis	rs7811142	1	rs67163493	ENSG00000242294.5	STAG3L5P	8.58	1.46e-16	8.81e-14	0.25	0.37	Platelet count;	chr7:100426215	chr7:100336079~100351900:+
PRAD	cis	rs67311347	0.713	rs4974018	ENSG00000223797.4	ENTPD3-AS1	8.58	1.46e-16	8.82e-14	0.34	0.37	Renal cell carcinoma;	chr3:40265928	chr3:40313802~40453329:-
PRAD	cis	rs9326248	0.53	rs6589576	ENSG00000254851.1	RP11-109L13.1	8.58	1.46e-16	8.83e-14	0.73	0.37	Blood protein levels;	chr11:116865072	chr11:117135528~117138582:+
PRAD	cis	rs11098499	0.865	rs9994730	ENSG00000245958.5	RP11-33B1.1	-8.58	1.47e-16	8.84e-14	-0.37	-0.37	Corneal astigmatism;	chr4:119460409	chr4:119454791~119552025:+
PRAD	cis	rs2274273	0.967	rs10147667	ENSG00000258413.1	RP11-665C16.6	8.58	1.47e-16	8.88e-14	0.49	0.37	Protein biomarker;	chr14:55104131	chr14:55262767~55272075:-
PRAD	cis	rs4835473	0.932	rs4835278	ENSG00000251600.4	RP11-673E1.1	-8.58	1.47e-16	8.89e-14	-0.47	-0.37	Immature fraction of reticulocytes;	chr4:143788433	chr4:143912331~143982454:+
PRAD	cis	rs7772486	0.743	rs9390344	ENSG00000235652.6	RP11-545I5.3	-8.58	1.47e-16	8.89e-14	-0.38	-0.37	Lobe attachment (rater-scored or self-reported);	chr6:145691619	chr6:145799409~145886585:+
PRAD	cis	rs8062405	0.573	rs8045689	ENSG00000251417.2	RP11-1348G14.4	8.58	1.47e-16	8.89e-14	0.45	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28976948	chr16:28802743~28817828:+
PRAD	cis	rs67311347	1	rs4973997	ENSG00000223797.4	ENTPD3-AS1	8.58	1.48e-16	8.91e-14	0.33	0.37	Renal cell carcinoma;	chr3:40418654	chr3:40313802~40453329:-
PRAD	cis	rs4835473	0.8	rs1849133	ENSG00000251600.4	RP11-673E1.1	8.58	1.48e-16	8.92e-14	0.48	0.37	Immature fraction of reticulocytes;	chr4:143958262	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.864	rs1849132	ENSG00000251600.4	RP11-673E1.1	8.58	1.48e-16	8.92e-14	0.48	0.37	Immature fraction of reticulocytes;	chr4:143958309	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.9	rs13123407	ENSG00000251600.4	RP11-673E1.1	8.58	1.48e-16	8.92e-14	0.48	0.37	Immature fraction of reticulocytes;	chr4:143958713	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.897	rs61611095	ENSG00000251600.4	RP11-673E1.1	8.58	1.48e-16	8.92e-14	0.48	0.37	Immature fraction of reticulocytes;	chr4:143958802	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.9	rs4835449	ENSG00000251600.4	RP11-673E1.1	8.58	1.48e-16	8.92e-14	0.48	0.37	Immature fraction of reticulocytes;	chr4:143958830	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs1838516	ENSG00000251600.4	RP11-673E1.1	8.58	1.48e-16	8.92e-14	0.48	0.37	Immature fraction of reticulocytes;	chr4:143962082	chr4:143912331~143982454:+
PRAD	cis	rs10875746	0.669	rs11168499	ENSG00000240399.1	RP1-228P16.1	-8.58	1.48e-16	8.92e-14	-0.36	-0.37	Longevity (90 years and older);	chr12:48268887	chr12:48054813~48055591:-
PRAD	cis	rs11951515	0.663	rs10039617	ENSG00000188850.9	RP11-159F24.2	8.58	1.49e-16	8.97e-14	0.46	0.37	Metabolite levels  (X-11787);	chr5:43319250	chr5:43336164~43348716:+
PRAD	cis	rs853679	0.513	rs13437444	ENSG00000272009.1	RP1-313I6.12	-8.58	1.49e-16	8.98e-14	-0.43	-0.37	Depression;	chr6:28103220	chr6:28078792~28081130:-
PRAD	cis	rs11676348	0.712	rs11687434	ENSG00000261338.2	RP11-378A13.1	-8.58	1.49e-16	8.98e-14	-0.4	-0.37	Ulcerative colitis;	chr2:218080420	chr2:218255319~218257366:+
PRAD	cis	rs6452524	0.868	rs1011981	ENSG00000249664.1	CTD-2227C6.2	8.58	1.49e-16	8.98e-14	0.44	0.37	Hypertension (SNP x SNP interaction);	chr5:83097869	chr5:83012285~83013109:-
PRAD	cis	rs6452524	0.868	rs17284218	ENSG00000249664.1	CTD-2227C6.2	8.58	1.49e-16	8.98e-14	0.44	0.37	Hypertension (SNP x SNP interaction);	chr5:83099530	chr5:83012285~83013109:-
PRAD	cis	rs321358	0.945	rs17458235	ENSG00000271584.1	RP11-89C3.4	-8.58	1.49e-16	8.99e-14	-0.57	-0.37	Body mass index;	chr11:111106114	chr11:111091932~111097357:-
PRAD	cis	rs9309473	0.687	rs10165862	ENSG00000163016.8	ALMS1P	8.58	1.49e-16	9e-14	0.44	0.37	Metabolite levels;	chr2:73383615	chr2:73644919~73685576:+
PRAD	cis	rs7598759	0.712	rs6735961	ENSG00000181798.2	LINC00471	-8.58	1.5e-16	9.02e-14	-0.44	-0.37	Noise-induced hearing loss;	chr2:231469703	chr2:231508426~231514339:-
PRAD	cis	rs875971	0.522	rs1701760	ENSG00000236529.1	RP13-254B10.1	8.58	1.5e-16	9.06e-14	0.39	0.37	Aortic root size;	chr7:66008701	chr7:65840212~65840596:+
PRAD	cis	rs7772486	0.754	rs702324	ENSG00000235652.6	RP11-545I5.3	-8.58	1.51e-16	9.09e-14	-0.39	-0.37	Lobe attachment (rater-scored or self-reported);	chr6:145687657	chr6:145799409~145886585:+
PRAD	cis	rs4835473	0.932	rs1849135	ENSG00000251600.4	RP11-673E1.1	-8.58	1.52e-16	9.17e-14	-0.49	-0.37	Immature fraction of reticulocytes;	chr4:143912279	chr4:143912331~143982454:+
PRAD	cis	rs950169	0.84	rs2896002	ENSG00000259728.4	LINC00933	8.58	1.52e-16	9.17e-14	0.46	0.37	Schizophrenia;	chr15:84390423	chr15:84570649~84580175:+
PRAD	cis	rs2115630	0.691	rs61322921	ENSG00000225151.9	GOLGA2P7	8.58	1.53e-16	9.2e-14	0.47	0.37	P wave terminal force;	chr15:84620407	chr15:84199311~84230136:-
PRAD	cis	rs9399135	0.682	rs9402684	ENSG00000232876.1	CTA-212D2.2	-8.58	1.53e-16	9.21e-14	-0.48	-0.37	Red blood cell count;	chr6:135098167	chr6:135055033~135060550:+
PRAD	cis	rs9399135	0.715	rs7743042	ENSG00000232876.1	CTA-212D2.2	-8.58	1.53e-16	9.21e-14	-0.48	-0.37	Red blood cell count;	chr6:135098696	chr6:135055033~135060550:+
PRAD	cis	rs6847067	0.8	rs13141322	ENSG00000180769.7	WDFY3-AS2	8.58	1.53e-16	9.22e-14	0.39	0.37	Oropharynx cancer;	chr4:84911425	chr4:84965682~85011277:+
PRAD	cis	rs2274273	0.805	rs60972460	ENSG00000258413.1	RP11-665C16.6	-8.58	1.53e-16	9.23e-14	-0.5	-0.37	Protein biomarker;	chr14:55105055	chr14:55262767~55272075:-
PRAD	cis	rs2739330	0.76	rs5751760	ENSG00000272787.1	KB-226F1.2	-8.58	1.53e-16	9.24e-14	-0.41	-0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23969211~23969873:+
PRAD	cis	rs2274273	0.967	rs2340931	ENSG00000258413.1	RP11-665C16.6	-8.58	1.54e-16	9.26e-14	-0.48	-0.37	Protein biomarker;	chr14:55150219	chr14:55262767~55272075:-
PRAD	cis	rs11083475	1	rs10421560	ENSG00000267892.1	CTD-2540F13.2	8.58	1.54e-16	9.27e-14	0.4	0.37	Heart rate;	chr19:38695973	chr19:38738284~38739863:+
PRAD	cis	rs11951515	0.626	rs9292871	ENSG00000188850.9	RP11-159F24.2	8.58	1.55e-16	9.3e-14	0.45	0.37	Metabolite levels  (X-11787);	chr5:43304300	chr5:43336164~43348716:+
PRAD	cis	rs11951515	0.577	rs7701391	ENSG00000188850.9	RP11-159F24.2	8.58	1.55e-16	9.3e-14	0.45	0.37	Metabolite levels  (X-11787);	chr5:43306688	chr5:43336164~43348716:+
PRAD	cis	rs9532669	0.926	rs2183144	ENSG00000168852.11	TPTE2P5	-8.58	1.55e-16	9.33e-14	-0.35	-0.37	Cervical cancer;	chr13:40862129	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.926	rs4942003	ENSG00000168852.11	TPTE2P5	8.58	1.56e-16	9.36e-14	0.35	0.37	Cervical cancer;	chr13:40863270	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.89	rs4942004	ENSG00000168852.11	TPTE2P5	8.58	1.56e-16	9.36e-14	0.35	0.37	Cervical cancer;	chr13:40863598	chr13:40822296~40921749:-
PRAD	cis	rs875971	1	rs3735148	ENSG00000237310.1	GS1-124K5.4	8.58	1.56e-16	9.39e-14	0.33	0.37	Aortic root size;	chr7:66506022	chr7:66493706~66495474:+
PRAD	cis	rs9341835	0.74	rs7763834	ENSG00000218048.2	RP3-407E4.4	8.58	1.56e-16	9.39e-14	0.41	0.37	Schizophrenia;	chr6:63439452	chr6:63440766~63443580:+
PRAD	cis	rs2412819	0.571	rs62018900	ENSG00000205771.5	CATSPER2P1	-8.57	1.57e-16	9.42e-14	-0.53	-0.37	Lung cancer;	chr15:43633252	chr15:43726918~43747094:-
PRAD	cis	rs2412819	0.571	rs112667279	ENSG00000205771.5	CATSPER2P1	-8.57	1.57e-16	9.42e-14	-0.53	-0.37	Lung cancer;	chr15:43649258	chr15:43726918~43747094:-
PRAD	cis	rs2933343	0.729	rs789228	ENSG00000231305.3	RP11-723O4.2	8.57	1.57e-16	9.43e-14	0.35	0.37	IgG glycosylation;	chr3:128882207	chr3:128861313~128871540:-
PRAD	cis	rs2933343	0.679	rs789229	ENSG00000231305.3	RP11-723O4.2	8.57	1.57e-16	9.43e-14	0.35	0.37	IgG glycosylation;	chr3:128883683	chr3:128861313~128871540:-
PRAD	cis	rs2933343	0.729	rs789230	ENSG00000231305.3	RP11-723O4.2	8.57	1.57e-16	9.43e-14	0.35	0.37	IgG glycosylation;	chr3:128883715	chr3:128861313~128871540:-
PRAD	cis	rs2933343	0.661	rs2630259	ENSG00000231305.3	RP11-723O4.2	8.57	1.57e-16	9.43e-14	0.35	0.37	IgG glycosylation;	chr3:128887479	chr3:128861313~128871540:-
PRAD	cis	rs2933343	0.729	rs6790091	ENSG00000231305.3	RP11-723O4.2	8.57	1.57e-16	9.43e-14	0.35	0.37	IgG glycosylation;	chr3:128889908	chr3:128861313~128871540:-
PRAD	cis	rs875971	0.964	rs12668936	ENSG00000237310.1	GS1-124K5.4	8.57	1.57e-16	9.45e-14	0.33	0.37	Aortic root size;	chr7:66449417	chr7:66493706~66495474:+
PRAD	cis	rs2019137	0.868	rs3748916	ENSG00000274877.1	RP11-65I12.1	8.57	1.57e-16	9.45e-14	0.47	0.37	Lymphocyte counts;	chr2:113226456	chr2:113237595~113240825:+
PRAD	cis	rs11123170	0.503	rs28679654	ENSG00000274877.1	RP11-65I12.1	-8.57	1.57e-16	9.46e-14	-0.57	-0.37	Renal function-related traits (BUN);	chr2:113210040	chr2:113237595~113240825:+
PRAD	cis	rs507080	0.769	rs11603616	ENSG00000255422.1	AP002954.4	-8.57	1.57e-16	9.46e-14	-0.46	-0.37	Serum metabolite levels;	chr11:118625350	chr11:118704607~118750263:+
PRAD	cis	rs8062405	0.823	rs7202948	ENSG00000251417.2	RP11-1348G14.4	-8.57	1.58e-16	9.51e-14	-0.41	-0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546968	chr16:28802743~28817828:+
PRAD	cis	rs6782228	0.675	rs9813845	ENSG00000242551.2	POU5F1P6	-8.57	1.58e-16	9.51e-14	-0.47	-0.37	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128680780	chr3:128674735~128677005:-
PRAD	cis	rs4835473	0.831	rs1912743	ENSG00000251600.4	RP11-673E1.1	8.57	1.59e-16	9.56e-14	0.48	0.37	Immature fraction of reticulocytes;	chr4:143993705	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.614	rs4487293	ENSG00000251600.4	RP11-673E1.1	8.57	1.59e-16	9.56e-14	0.48	0.37	Immature fraction of reticulocytes;	chr4:143993880	chr4:143912331~143982454:+
PRAD	cis	rs950169	0.922	rs2033284	ENSG00000259728.4	LINC00933	8.57	1.59e-16	9.56e-14	0.45	0.37	Schizophrenia;	chr15:84391575	chr15:84570649~84580175:+
PRAD	cis	rs34375054	0.558	rs12578774	ENSG00000279233.1	RP11-158L12.4	-8.57	1.6e-16	9.59e-14	-0.37	-0.37	Post bronchodilator FEV1/FVC ratio;	chr12:125197215	chr12:125138245~125141711:+
PRAD	cis	rs42648	0.564	rs39284	ENSG00000227646.6	STEAP2-AS1	-8.57	1.6e-16	9.61e-14	-0.34	-0.37	Homocysteine levels;	chr7:90162667	chr7:89882353~90211635:-
PRAD	cis	rs2274273	0.905	rs8007944	ENSG00000258413.1	RP11-665C16.6	-8.57	1.6e-16	9.63e-14	-0.5	-0.37	Protein biomarker;	chr14:55110098	chr14:55262767~55272075:-
PRAD	cis	rs2015599	0.514	rs10843376	ENSG00000257176.2	RP11-996F15.2	8.57	1.6e-16	9.63e-14	0.42	0.37	Platelet count;Mean platelet volume;	chr12:29283651	chr12:29280418~29317848:-
PRAD	cis	rs875971	0.929	rs6970860	ENSG00000237310.1	GS1-124K5.4	8.57	1.6e-16	9.63e-14	0.33	0.37	Aortic root size;	chr7:66511647	chr7:66493706~66495474:+
PRAD	cis	rs10463554	0.89	rs26428	ENSG00000175749.11	EIF3KP1	-8.57	1.6e-16	9.64e-14	-0.48	-0.37	Parkinson's disease;	chr5:103030780	chr5:103032376~103033031:+
PRAD	cis	rs950169	0.84	rs2896002	ENSG00000225151.9	GOLGA2P7	-8.57	1.61e-16	9.66e-14	-0.53	-0.37	Schizophrenia;	chr15:84390423	chr15:84199311~84230136:-
PRAD	cis	rs9532669	0.89	rs9315791	ENSG00000168852.11	TPTE2P5	8.57	1.61e-16	9.67e-14	0.35	0.37	Cervical cancer;	chr13:40863931	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.824	rs9315792	ENSG00000168852.11	TPTE2P5	8.57	1.61e-16	9.67e-14	0.35	0.37	Cervical cancer;	chr13:40863951	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.684	rs7139788	ENSG00000168852.11	TPTE2P5	8.57	1.61e-16	9.67e-14	0.35	0.37	Cervical cancer;	chr13:40864264	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.926	rs7338617	ENSG00000168852.11	TPTE2P5	8.57	1.61e-16	9.67e-14	0.35	0.37	Cervical cancer;	chr13:40870787	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.857	rs6560961	ENSG00000168852.11	TPTE2P5	8.57	1.61e-16	9.67e-14	0.35	0.37	Cervical cancer;	chr13:40870878	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.926	rs6560962	ENSG00000168852.11	TPTE2P5	8.57	1.61e-16	9.67e-14	0.35	0.37	Cervical cancer;	chr13:40870948	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.926	rs1055588	ENSG00000168852.11	TPTE2P5	8.57	1.61e-16	9.67e-14	0.35	0.37	Cervical cancer;	chr13:40871306	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.926	rs3610	ENSG00000168852.11	TPTE2P5	8.57	1.61e-16	9.67e-14	0.35	0.37	Cervical cancer;	chr13:40871334	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.926	rs4942006	ENSG00000168852.11	TPTE2P5	8.57	1.61e-16	9.67e-14	0.35	0.37	Cervical cancer;	chr13:40871862	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.926	rs4942008	ENSG00000168852.11	TPTE2P5	8.57	1.61e-16	9.67e-14	0.35	0.37	Cervical cancer;	chr13:40871989	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.89	rs2039118	ENSG00000168852.11	TPTE2P5	8.57	1.61e-16	9.67e-14	0.35	0.37	Cervical cancer;	chr13:40872260	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.926	rs4356347	ENSG00000168852.11	TPTE2P5	8.57	1.61e-16	9.67e-14	0.35	0.37	Cervical cancer;	chr13:40872516	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.926	rs7982346	ENSG00000168852.11	TPTE2P5	8.57	1.61e-16	9.67e-14	0.35	0.37	Cervical cancer;	chr13:40873273	chr13:40822296~40921749:-
PRAD	cis	rs11148252	0.74	rs9596642	ENSG00000278238.1	RP11-245D16.4	8.57	1.61e-16	9.67e-14	0.42	0.37	Lewy body disease;	chr13:52326744	chr13:52454775~52455331:-
PRAD	cis	rs6452524	0.934	rs12153440	ENSG00000249664.1	CTD-2227C6.2	8.57	1.61e-16	9.7e-14	0.44	0.37	Hypertension (SNP x SNP interaction);	chr5:83125097	chr5:83012285~83013109:-
PRAD	cis	rs9532669	0.926	rs4270044	ENSG00000168852.11	TPTE2P5	8.57	1.62e-16	9.71e-14	0.36	0.37	Cervical cancer;	chr13:40877923	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.926	rs11147824	ENSG00000168852.11	TPTE2P5	8.57	1.62e-16	9.71e-14	0.36	0.37	Cervical cancer;	chr13:40878183	chr13:40822296~40921749:-
PRAD	cis	rs433852	0.718	rs550455	ENSG00000232871.7	SEC1P	-8.57	1.62e-16	9.72e-14	-0.41	-0.37	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;	chr19:48633258	chr19:48638071~48682245:+
PRAD	cis	rs6570726	0.837	rs636894	ENSG00000235652.6	RP11-545I5.3	8.57	1.62e-16	9.74e-14	0.39	0.37	Lobe attachment (rater-scored or self-reported);	chr6:145542986	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.935	rs382910	ENSG00000235652.6	RP11-545I5.3	8.57	1.62e-16	9.74e-14	0.39	0.37	Lobe attachment (rater-scored or self-reported);	chr6:145544805	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.935	rs447818	ENSG00000235652.6	RP11-545I5.3	8.57	1.62e-16	9.74e-14	0.39	0.37	Lobe attachment (rater-scored or self-reported);	chr6:145547860	chr6:145799409~145886585:+
PRAD	cis	rs1062177	0.502	rs10463321	ENSG00000213433.5	RPLP1P6	-8.57	1.63e-16	9.78e-14	-0.48	-0.37	Preschool internalizing problems;	chr5:151944344	chr5:151765859~151766378:-
PRAD	cis	rs42648	0.564	rs13224065	ENSG00000227646.6	STEAP2-AS1	-8.57	1.63e-16	9.79e-14	-0.34	-0.37	Homocysteine levels;	chr7:90173049	chr7:89882353~90211635:-
PRAD	cis	rs42648	0.564	rs6956980	ENSG00000227646.6	STEAP2-AS1	-8.57	1.63e-16	9.79e-14	-0.34	-0.37	Homocysteine levels;	chr7:90174320	chr7:89882353~90211635:-
PRAD	cis	rs42648	0.564	rs11563340	ENSG00000227646.6	STEAP2-AS1	-8.57	1.63e-16	9.79e-14	-0.34	-0.37	Homocysteine levels;	chr7:90180265	chr7:89882353~90211635:-
PRAD	cis	rs42648	0.564	rs39283	ENSG00000227646.6	STEAP2-AS1	-8.57	1.63e-16	9.81e-14	-0.34	-0.37	Homocysteine levels;	chr7:90159492	chr7:89882353~90211635:-
PRAD	cis	rs42648	0.564	rs17863031	ENSG00000227646.6	STEAP2-AS1	-8.57	1.64e-16	9.85e-14	-0.34	-0.37	Homocysteine levels;	chr7:90176499	chr7:89882353~90211635:-
PRAD	cis	rs875971	0.964	rs1643388	ENSG00000237310.1	GS1-124K5.4	8.57	1.65e-16	9.89e-14	0.33	0.37	Aortic root size;	chr7:66379575	chr7:66493706~66495474:+
PRAD	cis	rs875971	1	rs778722	ENSG00000237310.1	GS1-124K5.4	8.57	1.65e-16	9.89e-14	0.33	0.37	Aortic root size;	chr7:66379841	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.964	rs778721	ENSG00000237310.1	GS1-124K5.4	8.57	1.65e-16	9.89e-14	0.33	0.37	Aortic root size;	chr7:66380410	chr7:66493706~66495474:+
PRAD	cis	rs875971	1	rs778706	ENSG00000237310.1	GS1-124K5.4	8.57	1.65e-16	9.89e-14	0.33	0.37	Aortic root size;	chr7:66395437	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.895	rs778700	ENSG00000237310.1	GS1-124K5.4	8.57	1.65e-16	9.89e-14	0.33	0.37	Aortic root size;	chr7:66401463	chr7:66493706~66495474:+
PRAD	cis	rs875971	1	rs778699	ENSG00000237310.1	GS1-124K5.4	8.57	1.65e-16	9.89e-14	0.33	0.37	Aortic root size;	chr7:66403303	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.929	rs778692	ENSG00000237310.1	GS1-124K5.4	8.57	1.65e-16	9.89e-14	0.33	0.37	Aortic root size;	chr7:66407462	chr7:66493706~66495474:+
PRAD	cis	rs875971	1	rs4718343	ENSG00000237310.1	GS1-124K5.4	8.57	1.65e-16	9.89e-14	0.33	0.37	Aortic root size;	chr7:66409301	chr7:66493706~66495474:+
PRAD	cis	rs875971	1	rs1968225	ENSG00000237310.1	GS1-124K5.4	8.57	1.65e-16	9.89e-14	0.33	0.37	Aortic root size;	chr7:66409786	chr7:66493706~66495474:+
PRAD	cis	rs875971	1	rs6460295	ENSG00000237310.1	GS1-124K5.4	8.57	1.65e-16	9.89e-14	0.33	0.37	Aortic root size;	chr7:66417741	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.964	rs6978721	ENSG00000237310.1	GS1-124K5.4	8.57	1.65e-16	9.89e-14	0.33	0.37	Aortic root size;	chr7:66418217	chr7:66493706~66495474:+
PRAD	cis	rs67311347	1	rs6599102	ENSG00000223797.4	ENTPD3-AS1	8.57	1.65e-16	9.89e-14	0.33	0.37	Renal cell carcinoma;	chr3:40426915	chr3:40313802~40453329:-
PRAD	cis	rs9532669	0.926	rs4334153	ENSG00000168852.11	TPTE2P5	8.57	1.65e-16	9.91e-14	0.36	0.37	Cervical cancer;	chr13:40877737	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.926	rs4309270	ENSG00000168852.11	TPTE2P5	8.57	1.65e-16	9.91e-14	0.36	0.37	Cervical cancer;	chr13:40877827	chr13:40822296~40921749:-
PRAD	cis	rs12142240	0.698	rs67200518	ENSG00000232022.5	FAAHP1	-8.57	1.65e-16	9.91e-14	-0.35	-0.37	Menopause (age at onset);	chr1:46370105	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs67941619	ENSG00000232022.5	FAAHP1	-8.57	1.65e-16	9.91e-14	-0.35	-0.37	Menopause (age at onset);	chr1:46372547	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs66483119	ENSG00000232022.5	FAAHP1	-8.57	1.65e-16	9.91e-14	-0.35	-0.37	Menopause (age at onset);	chr1:46372717	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs68012736	ENSG00000232022.5	FAAHP1	-8.57	1.65e-16	9.91e-14	-0.35	-0.37	Menopause (age at onset);	chr1:46373838	chr1:46432129~46445521:+
PRAD	cis	rs4835473	0.864	rs5015761	ENSG00000251600.4	RP11-673E1.1	-8.57	1.65e-16	9.91e-14	-0.47	-0.37	Immature fraction of reticulocytes;	chr4:143737791	chr4:143912331~143982454:+
PRAD	cis	rs4927850	0.829	rs6768483	ENSG00000242086.7	LINC00969	8.57	1.66e-16	9.96e-14	0.35	0.37	Pancreatic cancer;	chr3:196019092	chr3:195658062~195739964:+
PRAD	cis	rs6452524	1	rs10042854	ENSG00000249664.1	CTD-2227C6.2	-8.57	1.66e-16	9.97e-14	-0.43	-0.37	Hypertension (SNP x SNP interaction);	chr5:83143876	chr5:83012285~83013109:-
PRAD	cis	rs367615	0.512	rs814153	ENSG00000249476.1	CTD-2587M2.1	8.57	1.67e-16	9.99e-14	0.47	0.37	Colorectal cancer (SNP x SNP interaction);	chr5:109332128	chr5:109237120~109326369:-
PRAD	cis	rs10875746	0.669	rs10875792	ENSG00000240399.1	RP1-228P16.1	-8.57	1.67e-16	9.99e-14	-0.36	-0.37	Longevity (90 years and older);	chr12:48303640	chr12:48054813~48055591:-
PRAD	cis	rs10875746	0.623	rs10875793	ENSG00000240399.1	RP1-228P16.1	-8.57	1.67e-16	9.99e-14	-0.36	-0.37	Longevity (90 years and older);	chr12:48303647	chr12:48054813~48055591:-
PRAD	cis	rs763567	1	rs2022372	ENSG00000271811.1	RP1-79C4.4	-8.57	1.67e-16	1e-13	-0.43	-0.37	Tonsillectomy;	chr1:170620769	chr1:170667381~170669425:+
PRAD	cis	rs8177376	0.953	rs73017385	ENSG00000254905.1	RP11-712L6.7	8.57	1.67e-16	1e-13	0.49	0.37	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126309680	chr11:126292922~126294254:-
PRAD	cis	rs7131987	0.65	rs10843382	ENSG00000257176.2	RP11-996F15.2	-8.57	1.68e-16	1.01e-13	-0.41	-0.37	QT interval;	chr12:29298788	chr12:29280418~29317848:-
PRAD	cis	rs3096299	0.719	rs2911262	ENSG00000261118.1	RP11-104N10.1	8.57	1.68e-16	1.01e-13	0.36	0.37	Multiple myeloma (IgH translocation);	chr16:89448633	chr16:89492017~89504460:-
PRAD	cis	rs67311347	1	rs9332450	ENSG00000223797.4	ENTPD3-AS1	-8.57	1.68e-16	1.01e-13	-0.33	-0.37	Renal cell carcinoma;	chr3:40416550	chr3:40313802~40453329:-
PRAD	cis	rs875971	1	rs12532998	ENSG00000237310.1	GS1-124K5.4	8.57	1.68e-16	1.01e-13	0.33	0.37	Aortic root size;	chr7:66502472	chr7:66493706~66495474:+
PRAD	cis	rs2243480	1	rs4149468	ENSG00000226824.5	RP4-756H11.3	-8.57	1.68e-16	1.01e-13	-0.74	-0.37	Diabetic kidney disease;	chr7:66360703	chr7:66654538~66669855:+
PRAD	cis	rs9341835	0.772	rs6919709	ENSG00000218048.2	RP3-407E4.4	8.56	1.69e-16	1.01e-13	0.4	0.37	Schizophrenia;	chr6:63429951	chr6:63440766~63443580:+
PRAD	cis	rs11098499	0.954	rs6848389	ENSG00000245958.5	RP11-33B1.1	-8.56	1.69e-16	1.01e-13	-0.37	-0.37	Corneal astigmatism;	chr4:119481467	chr4:119454791~119552025:+
PRAD	cis	rs950169	0.881	rs34117475	ENSG00000225151.9	GOLGA2P7	-8.56	1.69e-16	1.01e-13	-0.52	-0.37	Schizophrenia;	chr15:84565212	chr15:84199311~84230136:-
PRAD	cis	rs2115630	0.691	rs61322921	ENSG00000275120.1	RP11-182J1.17	-8.56	1.69e-16	1.01e-13	-0.43	-0.37	P wave terminal force;	chr15:84620407	chr15:84599434~84606463:-
PRAD	cis	rs2274273	0.905	rs28429419	ENSG00000258413.1	RP11-665C16.6	-8.56	1.69e-16	1.02e-13	-0.5	-0.37	Protein biomarker;	chr14:55108075	chr14:55262767~55272075:-
PRAD	cis	rs1075265	0.933	rs7573491	ENSG00000233266.1	HMGB1P31	8.56	1.7e-16	1.02e-13	0.5	0.37	Chronotype;Morning vs. evening chronotype;	chr2:54115875	chr2:54051334~54051760:+
PRAD	cis	rs1075265	0.933	rs2042143	ENSG00000233266.1	HMGB1P31	8.56	1.7e-16	1.02e-13	0.5	0.37	Chronotype;Morning vs. evening chronotype;	chr2:54116377	chr2:54051334~54051760:+
PRAD	cis	rs4835473	0.932	rs5015760	ENSG00000251600.4	RP11-673E1.1	-8.56	1.7e-16	1.02e-13	-0.47	-0.37	Immature fraction of reticulocytes;	chr4:143737955	chr4:143912331~143982454:+
PRAD	cis	rs7945705	0.747	rs2653605	ENSG00000254860.4	TMEM9B-AS1	8.56	1.7e-16	1.02e-13	0.38	0.37	Hemoglobin concentration;	chr11:8971762	chr11:8964675~8977527:+
PRAD	cis	rs4423214	0.592	rs1790349	ENSG00000254682.1	RP11-660L16.2	-8.56	1.71e-16	1.02e-13	-0.61	-0.37	Vitamin D levels;	chr11:71431304	chr11:71448674~71452157:+
PRAD	cis	rs1075265	0.933	rs11888384	ENSG00000233266.1	HMGB1P31	8.56	1.71e-16	1.03e-13	0.5	0.37	Chronotype;Morning vs. evening chronotype;	chr2:54110984	chr2:54051334~54051760:+
PRAD	cis	rs950169	0.881	rs4842852	ENSG00000259728.4	LINC00933	8.56	1.71e-16	1.03e-13	0.45	0.37	Schizophrenia;	chr15:84387263	chr15:84570649~84580175:+
PRAD	cis	rs950169	0.84	rs4842853	ENSG00000259728.4	LINC00933	8.56	1.71e-16	1.03e-13	0.45	0.37	Schizophrenia;	chr15:84387606	chr15:84570649~84580175:+
PRAD	cis	rs950169	0.922	rs4842946	ENSG00000259728.4	LINC00933	8.56	1.71e-16	1.03e-13	0.45	0.37	Schizophrenia;	chr15:84387633	chr15:84570649~84580175:+
PRAD	cis	rs950169	0.84	rs4842854	ENSG00000259728.4	LINC00933	8.56	1.71e-16	1.03e-13	0.45	0.37	Schizophrenia;	chr15:84387641	chr15:84570649~84580175:+
PRAD	cis	rs950169	0.887	rs3860265	ENSG00000259728.4	LINC00933	8.56	1.71e-16	1.03e-13	0.45	0.37	Schizophrenia;	chr15:84390487	chr15:84570649~84580175:+
PRAD	cis	rs4835473	0.9	rs58106929	ENSG00000251600.4	RP11-673E1.1	8.56	1.72e-16	1.03e-13	0.47	0.37	Immature fraction of reticulocytes;	chr4:143733166	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.9	rs7698963	ENSG00000251600.4	RP11-673E1.1	8.56	1.72e-16	1.03e-13	0.47	0.37	Immature fraction of reticulocytes;	chr4:143733190	chr4:143912331~143982454:+
PRAD	cis	rs12142240	0.698	rs72677596	ENSG00000232022.5	FAAHP1	-8.56	1.73e-16	1.03e-13	-0.35	-0.37	Menopause (age at onset);	chr1:46368258	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs72677600	ENSG00000232022.5	FAAHP1	-8.56	1.73e-16	1.03e-13	-0.35	-0.37	Menopause (age at onset);	chr1:46368777	chr1:46432129~46445521:+
PRAD	cis	rs17023223	0.537	rs12086	ENSG00000231365.4	RP11-418J17.1	-8.56	1.73e-16	1.04e-13	-0.41	-0.37	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119031237	chr1:119140396~119275973:+
PRAD	cis	rs853679	0.628	rs9368560	ENSG00000272009.1	RP1-313I6.12	-8.56	1.73e-16	1.04e-13	-0.38	-0.37	Depression;	chr6:28192182	chr6:28078792~28081130:-
PRAD	cis	rs3743772	0.5	rs11866060	ENSG00000279722.1	RP11-44F14.6	8.56	1.73e-16	1.04e-13	0.46	0.37	Depressive symptoms (SSRI exposure interaction);	chr16:53394937	chr16:53487607~53489943:-
PRAD	cis	rs2337406	0.925	rs873534	ENSG00000274576.2	IGHV2-70	-8.56	1.73e-16	1.04e-13	-0.42	-0.37	Alzheimer's disease (late onset);	chr14:106667423	chr14:106770577~106771020:-
PRAD	cis	rs11098499	0.954	rs10031483	ENSG00000245958.5	RP11-33B1.1	-8.56	1.74e-16	1.04e-13	-0.37	-0.37	Corneal astigmatism;	chr4:119501481	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.954	rs10031665	ENSG00000245958.5	RP11-33B1.1	-8.56	1.74e-16	1.04e-13	-0.37	-0.37	Corneal astigmatism;	chr4:119501697	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.954	rs3733523	ENSG00000245958.5	RP11-33B1.1	-8.56	1.74e-16	1.04e-13	-0.37	-0.37	Corneal astigmatism;	chr4:119502564	chr4:119454791~119552025:+
PRAD	cis	rs12142240	0.698	rs17361887	ENSG00000232022.5	FAAHP1	-8.56	1.74e-16	1.04e-13	-0.35	-0.37	Menopause (age at onset);	chr1:46369103	chr1:46432129~46445521:+
PRAD	cis	rs4713118	0.513	rs202908	ENSG00000280107.1	AL022393.9	-8.56	1.74e-16	1.04e-13	-0.45	-0.37	Parkinson's disease;	chr6:28043773	chr6:28170845~28172521:+
PRAD	cis	rs9532669	0.926	rs4942005	ENSG00000168852.11	TPTE2P5	8.56	1.75e-16	1.05e-13	0.35	0.37	Cervical cancer;	chr13:40871636	chr13:40822296~40921749:-
PRAD	cis	rs12142240	0.698	rs61519400	ENSG00000232022.5	FAAHP1	-8.56	1.75e-16	1.05e-13	-0.35	-0.37	Menopause (age at onset);	chr1:46389626	chr1:46432129~46445521:+
PRAD	cis	rs6452524	0.934	rs6452510	ENSG00000249664.1	CTD-2227C6.2	8.56	1.75e-16	1.05e-13	0.44	0.37	Hypertension (SNP x SNP interaction);	chr5:83127401	chr5:83012285~83013109:-
PRAD	cis	rs4713118	0.869	rs9348775	ENSG00000280107.1	AL022393.9	-8.56	1.75e-16	1.05e-13	-0.46	-0.37	Parkinson's disease;	chr6:27727550	chr6:28170845~28172521:+
PRAD	cis	rs9810089	0.814	rs834305	ENSG00000261758.1	RP11-102M11.2	8.56	1.75e-16	1.05e-13	0.42	0.37	Gestational age at birth (child effect);	chr3:136400512	chr3:136752630~136755780:+
PRAD	cis	rs10771431	0.935	rs1117735	ENSG00000111788.10	RP11-22B23.1	8.56	1.76e-16	1.05e-13	0.37	0.37	Breast size;	chr12:9220132	chr12:9277235~9313241:+
PRAD	cis	rs875971	1	rs6945843	ENSG00000237310.1	GS1-124K5.4	-8.56	1.76e-16	1.05e-13	-0.33	-0.37	Aortic root size;	chr7:66269796	chr7:66493706~66495474:+
PRAD	cis	rs6991838	0.8	rs28547533	ENSG00000272010.1	CTD-3025N20.3	8.56	1.76e-16	1.05e-13	0.36	0.37	Intelligence (multi-trait analysis);	chr8:65559318	chr8:65591850~65592472:-
PRAD	cis	rs6991838	0.8	rs28626262	ENSG00000272010.1	CTD-3025N20.3	8.56	1.76e-16	1.05e-13	0.36	0.37	Intelligence (multi-trait analysis);	chr8:65559335	chr8:65591850~65592472:-
PRAD	cis	rs6991838	0.8	rs28709439	ENSG00000272010.1	CTD-3025N20.3	8.56	1.76e-16	1.05e-13	0.36	0.37	Intelligence (multi-trait analysis);	chr8:65559337	chr8:65591850~65592472:-
PRAD	cis	rs4713118	0.955	rs9468200	ENSG00000280107.1	AL022393.9	-8.56	1.77e-16	1.06e-13	-0.47	-0.37	Parkinson's disease;	chr6:27715284	chr6:28170845~28172521:+
PRAD	cis	rs3745672	1	rs113033627	ENSG00000219665.7	CTD-2006C1.2	-8.56	1.77e-16	1.06e-13	-0.81	-0.37	Multiple sclerosis;	chr19:12055554	chr19:11987617~12046275:+
PRAD	cis	rs11123170	0.569	rs1049137	ENSG00000274877.1	RP11-65I12.1	-8.56	1.77e-16	1.06e-13	-0.59	-0.37	Renal function-related traits (BUN);	chr2:113217533	chr2:113237595~113240825:+
PRAD	cis	rs7727544	0.716	rs4705928	ENSG00000233006.5	AC034220.3	-8.56	1.78e-16	1.06e-13	-0.33	-0.37	Blood metabolite levels;	chr5:132242944	chr5:132311285~132369916:-
PRAD	cis	rs673078	0.607	rs11068919	ENSG00000275409.1	RP11-131L12.4	-8.56	1.78e-16	1.07e-13	-0.49	-0.37	Glucose homeostasis traits;	chr12:118354925	chr12:118430147~118430699:+
PRAD	cis	rs11083475	1	rs9304578	ENSG00000267892.1	CTD-2540F13.2	-8.56	1.79e-16	1.07e-13	-0.4	-0.37	Heart rate;	chr19:38759697	chr19:38738284~38739863:+
PRAD	cis	rs950169	0.81	rs2879976	ENSG00000225151.9	GOLGA2P7	-8.56	1.79e-16	1.07e-13	-0.51	-0.37	Schizophrenia;	chr15:84566347	chr15:84199311~84230136:-
PRAD	cis	rs875971	1	rs12698523	ENSG00000237310.1	GS1-124K5.4	8.56	1.8e-16	1.08e-13	0.33	0.37	Aortic root size;	chr7:66503126	chr7:66493706~66495474:+
PRAD	cis	rs11098499	0.863	rs11098531	ENSG00000245958.5	RP11-33B1.1	-8.56	1.8e-16	1.08e-13	-0.37	-0.37	Corneal astigmatism;	chr4:119543846	chr4:119454791~119552025:+
PRAD	cis	rs858239	0.67	rs6967526	ENSG00000226816.2	AC005082.12	8.55	1.82e-16	1.09e-13	0.42	0.37	Cerebrospinal fluid biomarker levels;	chr7:23119622	chr7:23206013~23208045:+
PRAD	cis	rs2274273	0.84	rs3742569	ENSG00000258413.1	RP11-665C16.6	-8.55	1.83e-16	1.09e-13	-0.48	-0.37	Protein biomarker;	chr14:55351988	chr14:55262767~55272075:-
PRAD	cis	rs9903692	0.657	rs1452665	ENSG00000278765.1	RP5-890E16.5	8.55	1.83e-16	1.09e-13	0.57	0.37	Pulse pressure;	chr17:48219789	chr17:48066704~48067293:-
PRAD	cis	rs34779708	0.702	rs7087150	ENSG00000230534.5	RP11-297A16.2	8.55	1.83e-16	1.09e-13	0.5	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35253210	chr10:35098006~35127020:-
PRAD	cis	rs2086824	0.538	rs4785673	ENSG00000261118.1	RP11-104N10.1	8.55	1.83e-16	1.1e-13	0.35	0.37	Multiple myeloma (IgH translocation);	chr16:89470137	chr16:89492017~89504460:-
PRAD	cis	rs4713118	0.539	rs510987	ENSG00000280107.1	AL022393.9	-8.55	1.84e-16	1.1e-13	-0.47	-0.37	Parkinson's disease;	chr6:27879739	chr6:28170845~28172521:+
PRAD	cis	rs3743772	0.5	rs2388117	ENSG00000279722.1	RP11-44F14.6	8.55	1.84e-16	1.1e-13	0.46	0.37	Depressive symptoms (SSRI exposure interaction);	chr16:53413692	chr16:53487607~53489943:-
PRAD	cis	rs3743772	0.5	rs28415605	ENSG00000279722.1	RP11-44F14.6	8.55	1.84e-16	1.1e-13	0.46	0.37	Depressive symptoms (SSRI exposure interaction);	chr16:53415274	chr16:53487607~53489943:-
PRAD	cis	rs3743772	0.5	rs2160290	ENSG00000279722.1	RP11-44F14.6	8.55	1.84e-16	1.1e-13	0.46	0.37	Depressive symptoms (SSRI exposure interaction);	chr16:53415763	chr16:53487607~53489943:-
PRAD	cis	rs950169	0.881	rs4842852	ENSG00000225151.9	GOLGA2P7	-8.55	1.84e-16	1.1e-13	-0.52	-0.37	Schizophrenia;	chr15:84387263	chr15:84199311~84230136:-
PRAD	cis	rs950169	0.84	rs4842853	ENSG00000225151.9	GOLGA2P7	-8.55	1.84e-16	1.1e-13	-0.52	-0.37	Schizophrenia;	chr15:84387606	chr15:84199311~84230136:-
PRAD	cis	rs950169	0.922	rs4842946	ENSG00000225151.9	GOLGA2P7	-8.55	1.84e-16	1.1e-13	-0.52	-0.37	Schizophrenia;	chr15:84387633	chr15:84199311~84230136:-
PRAD	cis	rs950169	0.84	rs4842854	ENSG00000225151.9	GOLGA2P7	-8.55	1.84e-16	1.1e-13	-0.52	-0.37	Schizophrenia;	chr15:84387641	chr15:84199311~84230136:-
PRAD	cis	rs950169	0.887	rs3860265	ENSG00000225151.9	GOLGA2P7	-8.55	1.84e-16	1.1e-13	-0.52	-0.37	Schizophrenia;	chr15:84390487	chr15:84199311~84230136:-
PRAD	cis	rs4631830	0.72	rs2125770	ENSG00000230869.1	CTGLF10P	-8.55	1.85e-16	1.11e-13	-0.46	-0.37	Prostate-specific antigen levels;	chr10:46080998	chr10:45678692~45700532:+
PRAD	cis	rs2487048	0.804	rs2472496	ENSG00000226334.1	RP11-217B7.2	-8.55	1.86e-16	1.11e-13	-0.5	-0.37	Intraocular pressure;	chr9:104933072	chr9:104927553~104928892:+
PRAD	cis	rs2739330	0.828	rs5760107	ENSG00000224205.1	AP000351.4	8.55	1.86e-16	1.11e-13	0.47	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23987320~23991421:-
PRAD	cis	rs2739330	0.789	rs5760109	ENSG00000224205.1	AP000351.4	8.55	1.86e-16	1.11e-13	0.47	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23987320~23991421:-
PRAD	cis	rs11123170	0.529	rs1015753	ENSG00000274877.1	RP11-65I12.1	-8.55	1.86e-16	1.11e-13	-0.57	-0.37	Renal function-related traits (BUN);	chr2:113211226	chr2:113237595~113240825:+
PRAD	cis	rs6860806	0.507	rs169256	ENSG00000233006.5	AC034220.3	8.55	1.86e-16	1.11e-13	0.39	0.37	Breast cancer;	chr5:132352840	chr5:132311285~132369916:-
PRAD	cis	rs875971	0.965	rs697968	ENSG00000237310.1	GS1-124K5.4	-8.55	1.86e-16	1.11e-13	-0.34	-0.37	Aortic root size;	chr7:66070046	chr7:66493706~66495474:+
PRAD	cis	rs875971	1	rs1183245	ENSG00000237310.1	GS1-124K5.4	-8.55	1.86e-16	1.11e-13	-0.34	-0.37	Aortic root size;	chr7:66076198	chr7:66493706~66495474:+
PRAD	cis	rs875971	1	rs1144894	ENSG00000237310.1	GS1-124K5.4	-8.55	1.86e-16	1.11e-13	-0.34	-0.37	Aortic root size;	chr7:66077907	chr7:66493706~66495474:+
PRAD	cis	rs7712401	0.562	rs384483	ENSG00000263432.2	RN7SL689P	-8.55	1.87e-16	1.11e-13	-0.38	-0.37	Mean platelet volume;	chr5:122925878	chr5:123022487~123022783:-
PRAD	cis	rs3743772	0.5	rs35346613	ENSG00000279722.1	RP11-44F14.6	8.55	1.88e-16	1.12e-13	0.46	0.37	Depressive symptoms (SSRI exposure interaction);	chr16:53408246	chr16:53487607~53489943:-
PRAD	cis	rs3743772	0.5	rs62048485	ENSG00000279722.1	RP11-44F14.6	8.55	1.88e-16	1.12e-13	0.46	0.37	Depressive symptoms (SSRI exposure interaction);	chr16:53414065	chr16:53487607~53489943:-
PRAD	cis	rs3743772	0.5	rs28804772	ENSG00000279722.1	RP11-44F14.6	8.55	1.88e-16	1.12e-13	0.46	0.37	Depressive symptoms (SSRI exposure interaction);	chr16:53411252	chr16:53487607~53489943:-
PRAD	cis	rs2739330	0.828	rs2330635	ENSG00000224205.1	AP000351.4	8.55	1.88e-16	1.12e-13	0.47	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23987320~23991421:-
PRAD	cis	rs950169	0.686	rs12906474	ENSG00000225151.9	GOLGA2P7	-8.55	1.89e-16	1.13e-13	-0.51	-0.37	Schizophrenia;	chr15:84566006	chr15:84199311~84230136:-
PRAD	cis	rs7181230	0.885	rs28826672	ENSG00000275636.1	RP11-521C20.5	8.55	1.89e-16	1.13e-13	0.54	0.37	Dehydroepiandrosterone sulphate levels;	chr15:40068165	chr15:40078892~40079347:+
PRAD	cis	rs17608059	0.566	rs6502327	ENSG00000141028.6	CDRT15P1	-8.55	1.89e-16	1.13e-13	-0.48	-0.37	Temperament;	chr17:14042870	chr17:14024514~14025488:+
PRAD	cis	rs526231	0.511	rs1011453	ENSG00000175749.11	EIF3KP1	8.55	1.9e-16	1.13e-13	0.5	0.37	Primary biliary cholangitis;	chr5:103032323	chr5:103032376~103033031:+
PRAD	cis	rs7739264	0.544	rs6456266	ENSG00000228412.5	RP4-625H18.2	8.55	1.9e-16	1.13e-13	0.44	0.37	Endometriosis;	chr6:19791053	chr6:19802164~19804752:-
PRAD	cis	rs12701220	0.604	rs34904312	ENSG00000229043.2	AC091729.9	-8.55	1.9e-16	1.14e-13	-0.54	-0.37	Bronchopulmonary dysplasia;	chr7:1096247	chr7:1160374~1165267:+
PRAD	cis	rs2108622	0.727	rs62107770	ENSG00000267056.2	AC005336.4	8.55	1.91e-16	1.14e-13	0.51	0.37	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15874615	chr19:15910582~15911824:-
PRAD	cis	rs950169	0.723	rs17589320	ENSG00000259728.4	LINC00933	8.55	1.91e-16	1.14e-13	0.45	0.37	Schizophrenia;	chr15:84251244	chr15:84570649~84580175:+
PRAD	cis	rs950169	0.845	rs4502182	ENSG00000259728.4	LINC00933	8.55	1.91e-16	1.14e-13	0.45	0.37	Schizophrenia;	chr15:84254768	chr15:84570649~84580175:+
PRAD	cis	rs7189233	0.531	rs6499613	ENSG00000279344.1	RP11-44F14.7	8.55	1.91e-16	1.14e-13	0.35	0.37	Intelligence (multi-trait analysis);	chr16:53429506	chr16:53478957~53481550:-
PRAD	cis	rs853679	0.55	rs1233701	ENSG00000272009.1	RP1-313I6.12	8.55	1.91e-16	1.14e-13	0.37	0.37	Depression;	chr6:28200948	chr6:28078792~28081130:-
PRAD	cis	rs12701220	0.582	rs9655452	ENSG00000229043.2	AC091729.9	-8.55	1.91e-16	1.14e-13	-0.55	-0.37	Bronchopulmonary dysplasia;	chr7:1099004	chr7:1160374~1165267:+
PRAD	cis	rs42648	0.748	rs6972119	ENSG00000227646.6	STEAP2-AS1	-8.55	1.91e-16	1.14e-13	-0.34	-0.37	Homocysteine levels;	chr7:90264694	chr7:89882353~90211635:-
PRAD	cis	rs17711722	0.51	rs11767457	ENSG00000226824.5	RP4-756H11.3	-8.55	1.91e-16	1.14e-13	-0.48	-0.37	Calcium levels;	chr7:65825628	chr7:66654538~66669855:+
PRAD	cis	rs67311347	0.544	rs7644181	ENSG00000223797.4	ENTPD3-AS1	-8.55	1.92e-16	1.14e-13	-0.33	-0.37	Renal cell carcinoma;	chr3:40314174	chr3:40313802~40453329:-
PRAD	cis	rs4835473	0.897	rs4835095	ENSG00000251600.4	RP11-673E1.1	8.55	1.92e-16	1.14e-13	0.48	0.37	Immature fraction of reticulocytes;	chr4:143960431	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.831	rs2667353	ENSG00000251600.4	RP11-673E1.1	8.55	1.92e-16	1.14e-13	0.48	0.37	Immature fraction of reticulocytes;	chr4:143960462	chr4:143912331~143982454:+
PRAD	cis	rs3745672	1	rs76403598	ENSG00000219665.7	CTD-2006C1.2	-8.55	1.92e-16	1.15e-13	-0.8	-0.37	Multiple sclerosis;	chr19:12055367	chr19:11987617~12046275:+
PRAD	cis	rs8177376	0.906	rs522486	ENSG00000254905.1	RP11-712L6.7	8.55	1.92e-16	1.15e-13	0.49	0.37	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126190054	chr11:126292922~126294254:-
PRAD	cis	rs11098499	0.954	rs6849561	ENSG00000245958.5	RP11-33B1.1	8.55	1.92e-16	1.15e-13	0.37	0.37	Corneal astigmatism;	chr4:119488539	chr4:119454791~119552025:+
PRAD	cis	rs4713118	0.662	rs149900	ENSG00000226314.6	ZNF192P1	-8.55	1.93e-16	1.15e-13	-0.52	-0.37	Parkinson's disease;	chr6:28046819	chr6:28161781~28169594:+
PRAD	cis	rs524281	0.692	rs11227395	ENSG00000255320.1	RP11-755F10.1	8.55	1.93e-16	1.15e-13	0.55	0.37	Electroencephalogram traits;	chr11:66062166	chr11:66244840~66246239:-
PRAD	cis	rs2274273	0.805	rs7159808	ENSG00000258413.1	RP11-665C16.6	-8.55	1.94e-16	1.15e-13	-0.49	-0.37	Protein biomarker;	chr14:55157609	chr14:55262767~55272075:-
PRAD	cis	rs34779708	0.733	rs12240638	ENSG00000230534.5	RP11-297A16.2	8.55	1.94e-16	1.16e-13	0.5	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35253682	chr10:35098006~35127020:-
PRAD	cis	rs6452524	1	rs6452531	ENSG00000249664.1	CTD-2227C6.2	8.55	1.94e-16	1.16e-13	0.43	0.37	Hypertension (SNP x SNP interaction);	chr5:83170355	chr5:83012285~83013109:-
PRAD	cis	rs12817211	0.524	rs2204683	ENSG00000272368.2	RP4-605O3.4	-8.55	1.95e-16	1.16e-13	-0.37	-0.37	Colorectal or endometrial cancer;	chr12:50128593	chr12:50112197~50165618:+
PRAD	cis	rs875971	0.964	rs6978429	ENSG00000237310.1	GS1-124K5.4	8.55	1.95e-16	1.16e-13	0.33	0.37	Aortic root size;	chr7:66494889	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.929	rs12535036	ENSG00000237310.1	GS1-124K5.4	8.55	1.95e-16	1.16e-13	0.33	0.37	Aortic root size;	chr7:66499076	chr7:66493706~66495474:+
PRAD	cis	rs875971	1	rs6970030	ENSG00000237310.1	GS1-124K5.4	8.55	1.95e-16	1.16e-13	0.33	0.37	Aortic root size;	chr7:66503692	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.928	rs6970357	ENSG00000237310.1	GS1-124K5.4	8.55	1.95e-16	1.16e-13	0.33	0.37	Aortic root size;	chr7:66503891	chr7:66493706~66495474:+
PRAD	cis	rs9601248	0.845	rs1932197	ENSG00000227676.3	LINC01068	8.55	1.95e-16	1.16e-13	0.45	0.37	Major depressive disorder;	chr13:79609218	chr13:79566727~79571436:+
PRAD	cis	rs148406912	1	rs148406912	ENSG00000254851.1	RP11-109L13.1	8.55	1.95e-16	1.16e-13	0.72	0.37	Lobe attachment (rater-scored or self-reported);	chr11:116967001	chr11:117135528~117138582:+
PRAD	cis	rs11098499	0.738	rs28687057	ENSG00000245958.5	RP11-33B1.1	-8.54	1.96e-16	1.17e-13	-0.36	-0.37	Corneal astigmatism;	chr4:119359657	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.775	rs67281037	ENSG00000245958.5	RP11-33B1.1	-8.54	1.96e-16	1.17e-13	-0.36	-0.37	Corneal astigmatism;	chr4:119360002	chr4:119454791~119552025:+
PRAD	cis	rs10028773	0.506	rs12374346	ENSG00000245958.5	RP11-33B1.1	-8.54	1.96e-16	1.17e-13	-0.36	-0.37	Educational attainment;	chr4:119360550	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.866	rs12374244	ENSG00000245958.5	RP11-33B1.1	-8.54	1.96e-16	1.17e-13	-0.36	-0.37	Corneal astigmatism;	chr4:119360817	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.866	rs12374352	ENSG00000245958.5	RP11-33B1.1	-8.54	1.96e-16	1.17e-13	-0.36	-0.37	Corneal astigmatism;	chr4:119360822	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.775	rs10021601	ENSG00000245958.5	RP11-33B1.1	-8.54	1.96e-16	1.17e-13	-0.36	-0.37	Corneal astigmatism;	chr4:119361408	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.866	rs6857892	ENSG00000245958.5	RP11-33B1.1	-8.54	1.96e-16	1.17e-13	-0.36	-0.37	Corneal astigmatism;	chr4:119361541	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.909	rs28581362	ENSG00000245958.5	RP11-33B1.1	-8.54	1.96e-16	1.17e-13	-0.36	-0.37	Corneal astigmatism;	chr4:119362393	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.82	rs12503082	ENSG00000245958.5	RP11-33B1.1	-8.54	1.96e-16	1.17e-13	-0.36	-0.37	Corneal astigmatism;	chr4:119363162	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.866	rs12499602	ENSG00000245958.5	RP11-33B1.1	-8.54	1.96e-16	1.17e-13	-0.36	-0.37	Corneal astigmatism;	chr4:119363232	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.774	rs11098505	ENSG00000245958.5	RP11-33B1.1	-8.54	1.96e-16	1.17e-13	-0.36	-0.37	Corneal astigmatism;	chr4:119363472	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.866	rs13105020	ENSG00000245958.5	RP11-33B1.1	-8.54	1.96e-16	1.17e-13	-0.36	-0.37	Corneal astigmatism;	chr4:119364533	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.866	rs6824111	ENSG00000245958.5	RP11-33B1.1	-8.54	1.96e-16	1.17e-13	-0.36	-0.37	Corneal astigmatism;	chr4:119364813	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.775	rs10029303	ENSG00000245958.5	RP11-33B1.1	-8.54	1.96e-16	1.17e-13	-0.36	-0.37	Corneal astigmatism;	chr4:119365600	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.866	rs9995136	ENSG00000245958.5	RP11-33B1.1	-8.54	1.96e-16	1.17e-13	-0.36	-0.37	Corneal astigmatism;	chr4:119365690	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.866	rs13125526	ENSG00000245958.5	RP11-33B1.1	-8.54	1.96e-16	1.17e-13	-0.36	-0.37	Corneal astigmatism;	chr4:119366864	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.866	rs12513310	ENSG00000245958.5	RP11-33B1.1	-8.54	1.96e-16	1.17e-13	-0.36	-0.37	Corneal astigmatism;	chr4:119366884	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.866	rs12510451	ENSG00000245958.5	RP11-33B1.1	-8.54	1.96e-16	1.17e-13	-0.36	-0.37	Corneal astigmatism;	chr4:119367988	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.774	rs73842616	ENSG00000245958.5	RP11-33B1.1	-8.54	1.96e-16	1.17e-13	-0.36	-0.37	Corneal astigmatism;	chr4:119369528	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.645	rs72676059	ENSG00000245958.5	RP11-33B1.1	-8.54	1.96e-16	1.17e-13	-0.36	-0.37	Corneal astigmatism;	chr4:119369673	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.569	rs55845118	ENSG00000245958.5	RP11-33B1.1	-8.54	1.96e-16	1.17e-13	-0.36	-0.37	Corneal astigmatism;	chr4:119369758	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.866	rs7677068	ENSG00000245958.5	RP11-33B1.1	-8.54	1.96e-16	1.17e-13	-0.36	-0.37	Corneal astigmatism;	chr4:119370549	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.866	rs9991221	ENSG00000245958.5	RP11-33B1.1	-8.54	1.96e-16	1.17e-13	-0.36	-0.37	Corneal astigmatism;	chr4:119370952	chr4:119454791~119552025:+
PRAD	cis	rs496547	0.756	rs562059	ENSG00000278376.1	RP11-158I9.8	-8.54	1.97e-16	1.17e-13	-0.34	-0.37	Hip minimal joint space width;	chr11:118731349	chr11:118791254~118793137:+
PRAD	cis	rs9903692	0.779	rs2285863	ENSG00000278765.1	RP5-890E16.5	8.54	1.97e-16	1.17e-13	0.56	0.37	Pulse pressure;	chr17:48048616	chr17:48066704~48067293:-
PRAD	cis	rs8042680	0.522	rs8026678	ENSG00000214432.8	AC068831.10	-8.54	1.98e-16	1.18e-13	-0.44	-0.37	Type 2 diabetes;	chr15:91018775	chr15:91022619~91036611:+
PRAD	cis	rs66486766	1	rs66486766	ENSG00000259728.4	LINC00933	8.54	1.98e-16	1.18e-13	0.45	0.37	Bipolar disorder lithium response (categorical) or schizophrenia;	chr15:84137308	chr15:84570649~84580175:+
PRAD	cis	rs7811142	1	rs74460138	ENSG00000242294.5	STAG3L5P	8.54	1.98e-16	1.18e-13	0.25	0.37	Platelet count;	chr7:100429716	chr7:100336079~100351900:+
PRAD	cis	rs7811142	1	rs4989959	ENSG00000242294.5	STAG3L5P	8.54	1.98e-16	1.18e-13	0.25	0.37	Platelet count;	chr7:100434665	chr7:100336079~100351900:+
PRAD	cis	rs4835473	0.9	rs10027246	ENSG00000251600.4	RP11-673E1.1	-8.54	1.99e-16	1.18e-13	-0.48	-0.37	Immature fraction of reticulocytes;	chr4:143935069	chr4:143912331~143982454:+
PRAD	cis	rs7615952	0.641	rs6438951	ENSG00000171084.14	FAM86JP	8.54	1.99e-16	1.18e-13	0.58	0.37	Blood pressure (smoking interaction);	chr3:125978156	chr3:125916620~125930024:+
PRAD	cis	rs7829975	0.623	rs10092965	ENSG00000253893.2	FAM85B	-8.54	1.99e-16	1.18e-13	-0.43	-0.37	Mood instability;	chr8:8515975	chr8:8167819~8226614:-
PRAD	cis	rs6570726	0.902	rs396681	ENSG00000235652.6	RP11-545I5.3	8.54	2e-16	1.19e-13	0.39	0.37	Lobe attachment (rater-scored or self-reported);	chr6:145532467	chr6:145799409~145886585:+
PRAD	cis	rs42648	0.536	rs39270	ENSG00000227646.6	STEAP2-AS1	-8.54	2e-16	1.19e-13	-0.33	-0.37	Homocysteine levels;	chr7:90143312	chr7:89882353~90211635:-
PRAD	cis	rs7811142	1	rs11764818	ENSG00000242294.5	STAG3L5P	8.54	2e-16	1.19e-13	0.25	0.37	Platelet count;	chr7:100445432	chr7:100336079~100351900:+
PRAD	cis	rs8177376	0.953	rs3862627	ENSG00000254905.1	RP11-712L6.7	8.54	2.01e-16	1.19e-13	0.48	0.37	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126311697	chr11:126292922~126294254:-
PRAD	cis	rs8177376	0.953	rs73017394	ENSG00000254905.1	RP11-712L6.7	8.54	2.01e-16	1.19e-13	0.48	0.37	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126311952	chr11:126292922~126294254:-
PRAD	cis	rs950169	0.922	rs2033284	ENSG00000225151.9	GOLGA2P7	-8.54	2.01e-16	1.19e-13	-0.52	-0.37	Schizophrenia;	chr15:84391575	chr15:84199311~84230136:-
PRAD	cis	rs12142240	0.698	rs41534051	ENSG00000232022.5	FAAHP1	-8.54	2.02e-16	1.2e-13	-0.34	-0.37	Menopause (age at onset);	chr1:46363062	chr1:46432129~46445521:+
PRAD	cis	rs12817211	0.524	rs7967979	ENSG00000272368.2	RP4-605O3.4	-8.54	2.02e-16	1.2e-13	-0.38	-0.37	Colorectal or endometrial cancer;	chr12:50126893	chr12:50112197~50165618:+
PRAD	cis	rs12817211	0.548	rs2204684	ENSG00000272368.2	RP4-605O3.4	-8.54	2.02e-16	1.2e-13	-0.38	-0.37	Colorectal or endometrial cancer;	chr12:50128689	chr12:50112197~50165618:+
PRAD	cis	rs9309473	0.687	rs6747145	ENSG00000163016.8	ALMS1P	8.54	2.02e-16	1.2e-13	0.44	0.37	Metabolite levels;	chr2:73382049	chr2:73644919~73685576:+
PRAD	cis	rs950169	0.8	rs34302901	ENSG00000259728.4	LINC00933	8.54	2.02e-16	1.2e-13	0.44	0.37	Schizophrenia;	chr15:84567712	chr15:84570649~84580175:+
PRAD	cis	rs4713118	0.955	rs9380011	ENSG00000280107.1	AL022393.9	-8.54	2.02e-16	1.2e-13	-0.47	-0.37	Parkinson's disease;	chr6:27716145	chr6:28170845~28172521:+
PRAD	cis	rs7772486	0.743	rs1292339	ENSG00000235652.6	RP11-545I5.3	-8.54	2.03e-16	1.21e-13	-0.38	-0.37	Lobe attachment (rater-scored or self-reported);	chr6:145645950	chr6:145799409~145886585:+
PRAD	cis	rs10129255	0.5	rs2027902	ENSG00000223648.3	IGHV3-64	8.54	2.04e-16	1.21e-13	0.32	0.37	Kawasaki disease;	chr14:106807157	chr14:106643132~106658258:-
PRAD	cis	rs748404	0.69	rs2467737	ENSG00000249839.1	AC011330.5	-8.54	2.05e-16	1.22e-13	-0.45	-0.37	Lung cancer;	chr15:43444990	chr15:43663654~43684339:-
PRAD	cis	rs748404	0.66	rs2439846	ENSG00000249839.1	AC011330.5	-8.54	2.05e-16	1.22e-13	-0.45	-0.37	Lung cancer;	chr15:43448772	chr15:43663654~43684339:-
PRAD	cis	rs526231	0.511	rs55896090	ENSG00000175749.11	EIF3KP1	8.54	2.05e-16	1.22e-13	0.51	0.37	Primary biliary cholangitis;	chr5:103026300	chr5:103032376~103033031:+
PRAD	cis	rs7189233	0.531	rs7203132	ENSG00000279344.1	RP11-44F14.7	-8.54	2.05e-16	1.22e-13	-0.34	-0.37	Intelligence (multi-trait analysis);	chr16:53395863	chr16:53478957~53481550:-
PRAD	cis	rs67311347	0.713	rs9861194	ENSG00000223797.4	ENTPD3-AS1	8.54	2.06e-16	1.22e-13	0.34	0.37	Renal cell carcinoma;	chr3:40267734	chr3:40313802~40453329:-
PRAD	cis	rs9903692	0.789	rs12601675	ENSG00000278765.1	RP5-890E16.5	-8.54	2.06e-16	1.22e-13	-0.56	-0.37	Pulse pressure;	chr17:48113566	chr17:48066704~48067293:-
PRAD	cis	rs9903692	0.908	rs8066391	ENSG00000278765.1	RP5-890E16.5	-8.54	2.06e-16	1.22e-13	-0.56	-0.37	Pulse pressure;	chr17:48117934	chr17:48066704~48067293:-
PRAD	cis	rs9903692	0.908	rs11079809	ENSG00000278765.1	RP5-890E16.5	-8.54	2.06e-16	1.22e-13	-0.56	-0.37	Pulse pressure;	chr17:48120859	chr17:48066704~48067293:-
PRAD	cis	rs9903692	0.954	rs3744346	ENSG00000278765.1	RP5-890E16.5	-8.54	2.06e-16	1.22e-13	-0.56	-0.37	Pulse pressure;	chr17:48121514	chr17:48066704~48067293:-
PRAD	cis	rs9903692	0.908	rs7222136	ENSG00000278765.1	RP5-890E16.5	-8.54	2.06e-16	1.22e-13	-0.56	-0.37	Pulse pressure;	chr17:48122230	chr17:48066704~48067293:-
PRAD	cis	rs9903692	0.954	rs1010228	ENSG00000278765.1	RP5-890E16.5	-8.54	2.06e-16	1.22e-13	-0.56	-0.37	Pulse pressure;	chr17:48122986	chr17:48066704~48067293:-
PRAD	cis	rs9903692	0.954	rs1860866	ENSG00000278765.1	RP5-890E16.5	-8.54	2.06e-16	1.22e-13	-0.56	-0.37	Pulse pressure;	chr17:48123669	chr17:48066704~48067293:-
PRAD	cis	rs42648	0.564	rs17867585	ENSG00000227646.6	STEAP2-AS1	-8.54	2.07e-16	1.23e-13	-0.34	-0.37	Homocysteine levels;	chr7:90189860	chr7:89882353~90211635:-
PRAD	cis	rs367615	0.512	rs246104	ENSG00000249476.1	CTD-2587M2.1	-8.54	2.07e-16	1.23e-13	-0.47	-0.37	Colorectal cancer (SNP x SNP interaction);	chr5:109365281	chr5:109237120~109326369:-
PRAD	cis	rs11098499	0.866	rs12501602	ENSG00000245958.5	RP11-33B1.1	-8.54	2.08e-16	1.23e-13	-0.36	-0.37	Corneal astigmatism;	chr4:119366780	chr4:119454791~119552025:+
PRAD	cis	rs2439831	0.85	rs28504496	ENSG00000249839.1	AC011330.5	-8.54	2.08e-16	1.24e-13	-0.64	-0.37	Lung cancer in ever smokers;	chr15:43724685	chr15:43663654~43684339:-
PRAD	cis	rs11096990	0.613	rs4974996	ENSG00000249207.1	RP11-360F5.1	-8.54	2.09e-16	1.24e-13	-0.39	-0.37	Cognitive function;	chr4:39225928	chr4:39112677~39126818:-
PRAD	cis	rs9903692	0.909	rs1468270	ENSG00000278765.1	RP5-890E16.5	8.54	2.09e-16	1.24e-13	0.56	0.37	Pulse pressure;	chr17:48047829	chr17:48066704~48067293:-
PRAD	cis	rs812925	0.533	rs60997156	ENSG00000271889.1	RP11-493E12.1	8.54	2.1e-16	1.25e-13	0.41	0.37	Immature fraction of reticulocytes;	chr2:61169404	chr2:61151433~61162105:-
PRAD	cis	rs950169	0.922	rs8037078	ENSG00000225151.9	GOLGA2P7	8.54	2.11e-16	1.25e-13	0.52	0.37	Schizophrenia;	chr15:84150119	chr15:84199311~84230136:-
PRAD	cis	rs1075265	1	rs1075265	ENSG00000233266.1	HMGB1P31	8.53	2.11e-16	1.25e-13	0.5	0.37	Chronotype;Morning vs. evening chronotype;	chr2:54127790	chr2:54051334~54051760:+
PRAD	cis	rs507080	0.769	rs12290522	ENSG00000255422.1	AP002954.4	-8.53	2.11e-16	1.25e-13	-0.46	-0.37	Serum metabolite levels;	chr11:118615610	chr11:118704607~118750263:+
PRAD	cis	rs9532669	0.89	rs35396630	ENSG00000168852.11	TPTE2P5	8.53	2.12e-16	1.25e-13	0.35	0.37	Cervical cancer;	chr13:40863135	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.926	rs4942001	ENSG00000168852.11	TPTE2P5	8.53	2.12e-16	1.25e-13	0.35	0.37	Cervical cancer;	chr13:40863176	chr13:40822296~40921749:-
PRAD	cis	rs6452524	1	rs7710900	ENSG00000249664.1	CTD-2227C6.2	8.53	2.12e-16	1.26e-13	0.43	0.37	Hypertension (SNP x SNP interaction);	chr5:83137201	chr5:83012285~83013109:-
PRAD	cis	rs4380275	1	rs4268954	ENSG00000272342.1	RP13-539J13.1	8.53	2.12e-16	1.26e-13	0.47	0.37	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:772834	chr2:739588~740164:-
PRAD	cis	rs34779708	0.733	rs3936503	ENSG00000230534.5	RP11-297A16.2	-8.53	2.13e-16	1.26e-13	-0.49	-0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35260329	chr10:35098006~35127020:-
PRAD	cis	rs950169	0.922	rs12915832	ENSG00000225151.9	GOLGA2P7	-8.53	2.13e-16	1.26e-13	-0.52	-0.37	Schizophrenia;	chr15:84568226	chr15:84199311~84230136:-
PRAD	cis	rs17711722	0.528	rs73138179	ENSG00000237310.1	GS1-124K5.4	8.53	2.13e-16	1.26e-13	0.33	0.37	Calcium levels;	chr7:65829495	chr7:66493706~66495474:+
PRAD	cis	rs11148252	0.819	rs7336679	ENSG00000278238.1	RP11-245D16.4	-8.53	2.13e-16	1.26e-13	-0.42	-0.37	Lewy body disease;	chr13:52469198	chr13:52454775~52455331:-
PRAD	cis	rs9532669	0.926	rs2324737	ENSG00000168852.11	TPTE2P5	8.53	2.14e-16	1.27e-13	0.35	0.37	Cervical cancer;	chr13:40862808	chr13:40822296~40921749:-
PRAD	cis	rs67311347	1	rs12638199	ENSG00000223797.4	ENTPD3-AS1	8.53	2.14e-16	1.27e-13	0.33	0.37	Renal cell carcinoma;	chr3:40433794	chr3:40313802~40453329:-
PRAD	cis	rs4631830	0.683	rs10763193	ENSG00000230869.1	CTGLF10P	8.53	2.14e-16	1.27e-13	0.46	0.37	Prostate-specific antigen levels;	chr10:46090884	chr10:45678692~45700532:+
PRAD	cis	rs7811142	1	rs6975729	ENSG00000242294.5	STAG3L5P	8.53	2.14e-16	1.27e-13	0.25	0.37	Platelet count;	chr7:100430564	chr7:100336079~100351900:+
PRAD	cis	rs7811142	1	rs1073	ENSG00000242294.5	STAG3L5P	8.53	2.14e-16	1.27e-13	0.25	0.37	Platelet count;	chr7:100433989	chr7:100336079~100351900:+
PRAD	cis	rs7811142	0.887	rs4074838	ENSG00000242294.5	STAG3L5P	8.53	2.14e-16	1.27e-13	0.25	0.37	Platelet count;	chr7:100435042	chr7:100336079~100351900:+
PRAD	cis	rs8062405	0.573	rs7187575	ENSG00000251417.2	RP11-1348G14.4	8.53	2.14e-16	1.27e-13	0.45	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28978780	chr16:28802743~28817828:+
PRAD	cis	rs934734	0.563	rs11684155	ENSG00000204929.10	AC074391.1	8.53	2.14e-16	1.27e-13	0.48	0.37	Rheumatoid arthritis;	chr2:65354166	chr2:65436711~66084639:+
PRAD	cis	rs9601248	0.838	rs2783130	ENSG00000227676.3	LINC01068	-8.53	2.14e-16	1.27e-13	-0.46	-0.37	Major depressive disorder;	chr13:79596025	chr13:79566727~79571436:+
PRAD	cis	rs1075265	0.547	rs7557799	ENSG00000233266.1	HMGB1P31	-8.53	2.14e-16	1.27e-13	-0.51	-0.37	Chronotype;Morning vs. evening chronotype;	chr2:53674760	chr2:54051334~54051760:+
PRAD	cis	rs11763147	1	rs11763147	ENSG00000236529.1	RP13-254B10.1	-8.53	2.15e-16	1.27e-13	-0.39	-0.37	Corneal structure;	chr7:65861834	chr7:65840212~65840596:+
PRAD	cis	rs7811142	1	rs11773661	ENSG00000242294.5	STAG3L5P	8.53	2.15e-16	1.27e-13	0.25	0.37	Platelet count;	chr7:100475446	chr7:100336079~100351900:+
PRAD	cis	rs7811142	0.943	rs66958101	ENSG00000242294.5	STAG3L5P	8.53	2.15e-16	1.27e-13	0.25	0.37	Platelet count;	chr7:100476397	chr7:100336079~100351900:+
PRAD	cis	rs2919917	1	rs1466526	ENSG00000254352.1	RP11-578O24.2	-8.53	2.15e-16	1.27e-13	-0.44	-0.37	Lymphocyte counts;	chr8:78643239	chr8:78723796~78724136:-
PRAD	cis	rs2455601	1	rs2455601	ENSG00000254860.4	TMEM9B-AS1	8.53	2.16e-16	1.28e-13	0.48	0.37	Schizophrenia;	chr11:8877853	chr11:8964675~8977527:+
PRAD	cis	rs7829975	0.623	rs7010753	ENSG00000253893.2	FAM85B	-8.53	2.16e-16	1.28e-13	-0.43	-0.37	Mood instability;	chr8:8516446	chr8:8167819~8226614:-
PRAD	cis	rs950169	0.8	rs4842847	ENSG00000225151.9	GOLGA2P7	-8.53	2.17e-16	1.28e-13	-0.52	-0.37	Schizophrenia;	chr15:84262447	chr15:84199311~84230136:-
PRAD	cis	rs42648	0.748	rs10227385	ENSG00000227646.6	STEAP2-AS1	-8.53	2.17e-16	1.28e-13	-0.34	-0.37	Homocysteine levels;	chr7:90261054	chr7:89882353~90211635:-
PRAD	cis	rs6061231	0.675	rs755726	ENSG00000273619.1	RP5-908M14.9	-8.53	2.17e-16	1.29e-13	-0.23	-0.37	Colorectal cancer;	chr20:62387568	chr20:62386303~62386970:-
PRAD	cis	rs4713118	0.539	rs200988	ENSG00000280107.1	AL022393.9	-8.53	2.18e-16	1.29e-13	-0.46	-0.37	Parkinson's disease;	chr6:27851575	chr6:28170845~28172521:+
PRAD	cis	rs7739264	0.564	rs2223361	ENSG00000228412.5	RP4-625H18.2	8.53	2.19e-16	1.3e-13	0.44	0.37	Endometriosis;	chr6:19790578	chr6:19802164~19804752:-
PRAD	cis	rs7739264	0.564	rs760796	ENSG00000228412.5	RP4-625H18.2	8.53	2.19e-16	1.3e-13	0.44	0.37	Endometriosis;	chr6:19790156	chr6:19802164~19804752:-
PRAD	cis	rs4835473	0.838	rs34819068	ENSG00000251600.4	RP11-673E1.1	-8.53	2.19e-16	1.3e-13	-0.47	-0.37	Immature fraction of reticulocytes;	chr4:143787330	chr4:143912331~143982454:+
PRAD	cis	rs9341835	0.51	rs7745873	ENSG00000218048.2	RP3-407E4.4	8.53	2.2e-16	1.3e-13	0.43	0.37	Schizophrenia;	chr6:63455948	chr6:63440766~63443580:+
PRAD	cis	rs507080	0.769	rs645637	ENSG00000255422.1	AP002954.4	-8.53	2.2e-16	1.3e-13	-0.46	-0.37	Serum metabolite levels;	chr11:118634373	chr11:118704607~118750263:+
PRAD	cis	rs950169	0.922	rs4842940	ENSG00000225151.9	GOLGA2P7	8.53	2.21e-16	1.31e-13	0.52	0.37	Schizophrenia;	chr15:84162473	chr15:84199311~84230136:-
PRAD	cis	rs950169	0.922	rs4842941	ENSG00000225151.9	GOLGA2P7	8.53	2.21e-16	1.31e-13	0.52	0.37	Schizophrenia;	chr15:84162560	chr15:84199311~84230136:-
PRAD	cis	rs950169	0.922	rs12911223	ENSG00000225151.9	GOLGA2P7	8.53	2.21e-16	1.31e-13	0.52	0.37	Schizophrenia;	chr15:84162919	chr15:84199311~84230136:-
PRAD	cis	rs12142240	0.698	rs72677589	ENSG00000232022.5	FAAHP1	-8.53	2.21e-16	1.31e-13	-0.35	-0.37	Menopause (age at onset);	chr1:46352098	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs72677592	ENSG00000232022.5	FAAHP1	-8.53	2.21e-16	1.31e-13	-0.35	-0.37	Menopause (age at onset);	chr1:46352616	chr1:46432129~46445521:+
PRAD	cis	rs11098499	0.865	rs11722183	ENSG00000245958.5	RP11-33B1.1	-8.53	2.22e-16	1.31e-13	-0.36	-0.37	Corneal astigmatism;	chr4:119359442	chr4:119454791~119552025:+
PRAD	cis	rs6452524	1	rs7733354	ENSG00000249664.1	CTD-2227C6.2	8.53	2.22e-16	1.31e-13	0.43	0.37	Hypertension (SNP x SNP interaction);	chr5:83134859	chr5:83012285~83013109:-
PRAD	cis	rs6452524	1	rs4634330	ENSG00000249664.1	CTD-2227C6.2	8.53	2.22e-16	1.31e-13	0.43	0.37	Hypertension (SNP x SNP interaction);	chr5:83134963	chr5:83012285~83013109:-
PRAD	cis	rs6452524	1	rs2386238	ENSG00000249664.1	CTD-2227C6.2	8.53	2.22e-16	1.31e-13	0.43	0.37	Hypertension (SNP x SNP interaction);	chr5:83135266	chr5:83012285~83013109:-
PRAD	cis	rs6452524	1	rs2386239	ENSG00000249664.1	CTD-2227C6.2	8.53	2.22e-16	1.31e-13	0.43	0.37	Hypertension (SNP x SNP interaction);	chr5:83135339	chr5:83012285~83013109:-
PRAD	cis	rs6452524	0.934	rs7700253	ENSG00000249664.1	CTD-2227C6.2	8.53	2.22e-16	1.31e-13	0.43	0.37	Hypertension (SNP x SNP interaction);	chr5:83135510	chr5:83012285~83013109:-
PRAD	cis	rs6452524	1	rs10067439	ENSG00000249664.1	CTD-2227C6.2	8.53	2.22e-16	1.31e-13	0.43	0.37	Hypertension (SNP x SNP interaction);	chr5:83136274	chr5:83012285~83013109:-
PRAD	cis	rs2274273	0.87	rs2016931	ENSG00000258413.1	RP11-665C16.6	-8.53	2.22e-16	1.31e-13	-0.48	-0.37	Protein biomarker;	chr14:55375614	chr14:55262767~55272075:-
PRAD	cis	rs67311347	1	rs2305522	ENSG00000223797.4	ENTPD3-AS1	8.53	2.23e-16	1.32e-13	0.32	0.37	Renal cell carcinoma;	chr3:40387867	chr3:40313802~40453329:-
PRAD	cis	rs2739330	0.76	rs1002286	ENSG00000272787.1	KB-226F1.2	8.53	2.23e-16	1.32e-13	0.4	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23969211~23969873:+
PRAD	cis	rs4835473	0.715	rs4538428	ENSG00000251600.4	RP11-673E1.1	8.53	2.23e-16	1.32e-13	0.48	0.37	Immature fraction of reticulocytes;	chr4:143992751	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.771	rs2175452	ENSG00000251600.4	RP11-673E1.1	8.53	2.23e-16	1.32e-13	0.48	0.37	Immature fraction of reticulocytes;	chr4:143992887	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.8	rs2175451	ENSG00000251600.4	RP11-673E1.1	8.53	2.23e-16	1.32e-13	0.48	0.37	Immature fraction of reticulocytes;	chr4:143992964	chr4:143912331~143982454:+
PRAD	cis	rs4323050	0.51	rs4254715	ENSG00000251600.4	RP11-673E1.1	8.53	2.23e-16	1.32e-13	0.48	0.37	High light scatter reticulocyte percentage of red cells;	chr4:143993140	chr4:143912331~143982454:+
PRAD	cis	rs4323050	0.51	rs4273414	ENSG00000251600.4	RP11-673E1.1	8.53	2.23e-16	1.32e-13	0.48	0.37	High light scatter reticulocyte percentage of red cells;	chr4:143993142	chr4:143912331~143982454:+
PRAD	cis	rs6991838	0.671	rs13251307	ENSG00000272010.1	CTD-3025N20.3	8.53	2.25e-16	1.33e-13	0.36	0.37	Intelligence (multi-trait analysis);	chr8:65664911	chr8:65591850~65592472:-
PRAD	cis	rs6570726	0.935	rs449377	ENSG00000235652.6	RP11-545I5.3	8.53	2.25e-16	1.33e-13	0.39	0.37	Lobe attachment (rater-scored or self-reported);	chr6:145531301	chr6:145799409~145886585:+
PRAD	cis	rs4835473	0.801	rs76574827	ENSG00000251600.4	RP11-673E1.1	-8.53	2.26e-16	1.34e-13	-0.47	-0.37	Immature fraction of reticulocytes;	chr4:143737303	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.832	rs62337616	ENSG00000251600.4	RP11-673E1.1	-8.53	2.26e-16	1.34e-13	-0.47	-0.37	Immature fraction of reticulocytes;	chr4:143737307	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.832	rs66717029	ENSG00000251600.4	RP11-673E1.1	-8.53	2.26e-16	1.34e-13	-0.47	-0.37	Immature fraction of reticulocytes;	chr4:143737318	chr4:143912331~143982454:+
PRAD	cis	rs950169	0.922	rs62028133	ENSG00000259728.4	LINC00933	8.53	2.26e-16	1.34e-13	0.45	0.37	Schizophrenia;	chr15:84250623	chr15:84570649~84580175:+
PRAD	cis	rs4713118	0.715	rs200480	ENSG00000216901.1	AL022393.7	8.53	2.27e-16	1.34e-13	0.48	0.37	Parkinson's disease;	chr6:27805886	chr6:28176188~28176674:+
PRAD	cis	rs7567389	0.744	rs6430934	ENSG00000236682.1	AC068282.3	8.53	2.27e-16	1.34e-13	0.47	0.37	Self-rated health;	chr2:127243257	chr2:127389130~127400580:+
PRAD	cis	rs9341835	0.772	rs9294197	ENSG00000218048.2	RP3-407E4.4	8.52	2.28e-16	1.35e-13	0.41	0.37	Schizophrenia;	chr6:63425743	chr6:63440766~63443580:+
PRAD	cis	rs4713118	0.869	rs2056925	ENSG00000280107.1	AL022393.9	-8.52	2.28e-16	1.35e-13	-0.46	-0.37	Parkinson's disease;	chr6:27723126	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.662	rs175954	ENSG00000219392.1	RP1-265C24.5	-8.52	2.28e-16	1.35e-13	-0.48	-0.37	Parkinson's disease;	chr6:28043807	chr6:28115628~28116551:+
PRAD	cis	rs9532669	0.926	rs4454835	ENSG00000168852.11	TPTE2P5	8.52	2.28e-16	1.35e-13	0.35	0.37	Cervical cancer;	chr13:40928978	chr13:40822296~40921749:-
PRAD	cis	rs4835473	0.808	rs4054643	ENSG00000251600.4	RP11-673E1.1	-8.52	2.28e-16	1.35e-13	-0.47	-0.37	Immature fraction of reticulocytes;	chr4:143787329	chr4:143912331~143982454:+
PRAD	cis	rs496547	0.719	rs472641	ENSG00000278376.1	RP11-158I9.8	-8.52	2.28e-16	1.35e-13	-0.33	-0.37	Hip minimal joint space width;	chr11:118746835	chr11:118791254~118793137:+
PRAD	cis	rs2348418	0.864	rs6487690	ENSG00000247934.4	RP11-967K21.1	8.52	2.29e-16	1.35e-13	0.34	0.37	Lung function (FEV1);Lung function (FVC);	chr12:28560407	chr12:28163298~28190738:-
PRAD	cis	rs42648	0.564	rs259134	ENSG00000227646.6	STEAP2-AS1	-8.52	2.29e-16	1.36e-13	-0.34	-0.37	Homocysteine levels;	chr7:90166538	chr7:89882353~90211635:-
PRAD	cis	rs7811142	1	rs7811142	ENSG00000242294.5	STAG3L5P	8.52	2.3e-16	1.36e-13	0.25	0.37	Platelet count;	chr7:100467820	chr7:100336079~100351900:+
PRAD	cis	rs67311347	0.544	rs2278929	ENSG00000223797.4	ENTPD3-AS1	-8.52	2.3e-16	1.36e-13	-0.32	-0.37	Renal cell carcinoma;	chr3:40309517	chr3:40313802~40453329:-
PRAD	cis	rs9341835	0.74	rs9294198	ENSG00000218048.2	RP3-407E4.4	8.52	2.3e-16	1.36e-13	0.41	0.37	Schizophrenia;	chr6:63427088	chr6:63440766~63443580:+
PRAD	cis	rs67311347	1	rs7648952	ENSG00000223797.4	ENTPD3-AS1	-8.52	2.3e-16	1.36e-13	-0.33	-0.37	Renal cell carcinoma;	chr3:40415547	chr3:40313802~40453329:-
PRAD	cis	rs67311347	1	rs951560	ENSG00000223797.4	ENTPD3-AS1	8.52	2.3e-16	1.36e-13	0.33	0.37	Renal cell carcinoma;	chr3:40421980	chr3:40313802~40453329:-
PRAD	cis	rs526231	0.511	rs55810112	ENSG00000175749.11	EIF3KP1	8.52	2.3e-16	1.36e-13	0.5	0.37	Primary biliary cholangitis;	chr5:103026645	chr5:103032376~103033031:+
PRAD	cis	rs875971	0.505	rs1167385	ENSG00000236529.1	RP13-254B10.1	-8.52	2.31e-16	1.36e-13	-0.39	-0.37	Aortic root size;	chr7:66048321	chr7:65840212~65840596:+
PRAD	cis	rs67311347	1	rs6599094	ENSG00000223797.4	ENTPD3-AS1	8.52	2.31e-16	1.36e-13	0.33	0.37	Renal cell carcinoma;	chr3:40358102	chr3:40313802~40453329:-
PRAD	cis	rs2348418	0.647	rs938081	ENSG00000247934.4	RP11-967K21.1	8.52	2.31e-16	1.37e-13	0.34	0.37	Lung function (FEV1);Lung function (FVC);	chr12:28567680	chr12:28163298~28190738:-
PRAD	cis	rs6452524	0.967	rs11949474	ENSG00000249664.1	CTD-2227C6.2	8.52	2.31e-16	1.37e-13	0.43	0.37	Hypertension (SNP x SNP interaction);	chr5:83179759	chr5:83012285~83013109:-
PRAD	cis	rs9341835	0.772	rs9294202	ENSG00000218048.2	RP3-407E4.4	8.52	2.32e-16	1.37e-13	0.41	0.37	Schizophrenia;	chr6:63429049	chr6:63440766~63443580:+
PRAD	cis	rs4835473	0.808	rs13134564	ENSG00000251600.4	RP11-673E1.1	-8.52	2.33e-16	1.37e-13	-0.47	-0.37	Immature fraction of reticulocytes;	chr4:143738763	chr4:143912331~143982454:+
PRAD	cis	rs2019137	0.901	rs4849176	ENSG00000274877.1	RP11-65I12.1	8.52	2.33e-16	1.38e-13	0.47	0.37	Lymphocyte counts;	chr2:113220359	chr2:113237595~113240825:+
PRAD	cis	rs6430553	0.929	rs6758113	ENSG00000224043.6	CCNT2-AS1	-8.52	2.33e-16	1.38e-13	-0.51	-0.37	Blood metabolite levels;	chr2:134851677	chr2:134735464~134918710:-
PRAD	cis	rs6991838	0.701	rs7829434	ENSG00000272010.1	CTD-3025N20.3	8.52	2.34e-16	1.38e-13	0.36	0.37	Intelligence (multi-trait analysis);	chr8:65716909	chr8:65591850~65592472:-
PRAD	cis	rs853679	1	rs1778508	ENSG00000280107.1	AL022393.9	8.52	2.34e-16	1.38e-13	0.56	0.37	Depression;	chr6:28262103	chr6:28170845~28172521:+
PRAD	cis	rs6847067	0.74	rs111481594	ENSG00000180769.7	WDFY3-AS2	8.52	2.35e-16	1.39e-13	0.39	0.37	Oropharynx cancer;	chr4:84927622	chr4:84965682~85011277:+
PRAD	cis	rs6847067	0.8	rs11730981	ENSG00000180769.7	WDFY3-AS2	8.52	2.35e-16	1.39e-13	0.39	0.37	Oropharynx cancer;	chr4:84928846	chr4:84965682~85011277:+
PRAD	cis	rs6847067	0.8	rs9684737	ENSG00000180769.7	WDFY3-AS2	8.52	2.35e-16	1.39e-13	0.39	0.37	Oropharynx cancer;	chr4:84930812	chr4:84965682~85011277:+
PRAD	cis	rs7772486	0.713	rs2328704	ENSG00000235652.6	RP11-545I5.3	-8.52	2.36e-16	1.39e-13	-0.38	-0.37	Lobe attachment (rater-scored or self-reported);	chr6:145699358	chr6:145799409~145886585:+
PRAD	cis	rs7615952	0.688	rs4422259	ENSG00000171084.14	FAM86JP	8.52	2.36e-16	1.39e-13	0.54	0.37	Blood pressure (smoking interaction);	chr3:125826988	chr3:125916620~125930024:+
PRAD	cis	rs2522056	0.808	rs1016988	ENSG00000233006.5	AC034220.3	-8.52	2.37e-16	1.4e-13	-0.38	-0.37	Fibrinogen;Lymphocyte counts;	chr5:132408882	chr5:132311285~132369916:-
PRAD	cis	rs496547	0.588	rs473298	ENSG00000278376.1	RP11-158I9.8	-8.52	2.37e-16	1.4e-13	-0.33	-0.37	Hip minimal joint space width;	chr11:118808678	chr11:118791254~118793137:+
PRAD	cis	rs4835473	0.808	rs2060652	ENSG00000251600.4	RP11-673E1.1	-8.52	2.37e-16	1.4e-13	-0.47	-0.37	Immature fraction of reticulocytes;	chr4:143739129	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.897	rs2060654	ENSG00000251600.4	RP11-673E1.1	-8.52	2.37e-16	1.4e-13	-0.47	-0.37	Immature fraction of reticulocytes;	chr4:143739155	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs2060655	ENSG00000251600.4	RP11-673E1.1	-8.52	2.37e-16	1.4e-13	-0.47	-0.37	Immature fraction of reticulocytes;	chr4:143739159	chr4:143912331~143982454:+
PRAD	cis	rs6991838	0.733	rs10111844	ENSG00000272010.1	CTD-3025N20.3	8.52	2.38e-16	1.4e-13	0.36	0.37	Intelligence (multi-trait analysis);	chr8:65690374	chr8:65591850~65592472:-
PRAD	cis	rs67311347	1	rs9829800	ENSG00000223797.4	ENTPD3-AS1	8.52	2.38e-16	1.4e-13	0.33	0.37	Renal cell carcinoma;	chr3:40402436	chr3:40313802~40453329:-
PRAD	cis	rs12701220	0.655	rs10215292	ENSG00000229043.2	AC091729.9	-8.52	2.39e-16	1.41e-13	-0.54	-0.37	Bronchopulmonary dysplasia;	chr7:1095627	chr7:1160374~1165267:+
PRAD	cis	rs7598759	0.588	rs6737291	ENSG00000181798.2	LINC00471	-8.52	2.39e-16	1.41e-13	-0.43	-0.37	Noise-induced hearing loss;	chr2:231464848	chr2:231508426~231514339:-
PRAD	cis	rs9903692	0.954	rs12941295	ENSG00000278765.1	RP5-890E16.5	-8.52	2.39e-16	1.41e-13	-0.56	-0.37	Pulse pressure;	chr17:48110825	chr17:48066704~48067293:-
PRAD	cis	rs6430553	0.964	rs56383182	ENSG00000224043.6	CCNT2-AS1	-8.52	2.39e-16	1.41e-13	-0.51	-0.37	Blood metabolite levels;	chr2:134850641	chr2:134735464~134918710:-
PRAD	cis	rs6723108	0.534	rs6430546	ENSG00000224043.6	CCNT2-AS1	-8.52	2.39e-16	1.41e-13	-0.51	-0.37	Type 2 diabetes;	chr2:134851231	chr2:134735464~134918710:-
PRAD	cis	rs6570726	0.935	rs421268	ENSG00000235652.6	RP11-545I5.3	8.52	2.4e-16	1.41e-13	0.39	0.37	Lobe attachment (rater-scored or self-reported);	chr6:145524422	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.935	rs454370	ENSG00000235652.6	RP11-545I5.3	8.52	2.4e-16	1.41e-13	0.39	0.37	Lobe attachment (rater-scored or self-reported);	chr6:145525593	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.935	rs416987	ENSG00000235652.6	RP11-545I5.3	8.52	2.4e-16	1.41e-13	0.39	0.37	Lobe attachment (rater-scored or self-reported);	chr6:145525869	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.905	rs452770	ENSG00000235652.6	RP11-545I5.3	8.52	2.4e-16	1.41e-13	0.39	0.37	Lobe attachment (rater-scored or self-reported);	chr6:145526026	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.935	rs442254	ENSG00000235652.6	RP11-545I5.3	8.52	2.4e-16	1.41e-13	0.39	0.37	Lobe attachment (rater-scored or self-reported);	chr6:145527982	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.846	rs441575	ENSG00000235652.6	RP11-545I5.3	8.52	2.4e-16	1.41e-13	0.39	0.37	Lobe attachment (rater-scored or self-reported);	chr6:145528069	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.935	rs436212	ENSG00000235652.6	RP11-545I5.3	8.52	2.4e-16	1.41e-13	0.39	0.37	Lobe attachment (rater-scored or self-reported);	chr6:145528264	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.935	rs414222	ENSG00000235652.6	RP11-545I5.3	8.52	2.4e-16	1.41e-13	0.39	0.37	Lobe attachment (rater-scored or self-reported);	chr6:145529346	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.935	rs385134	ENSG00000235652.6	RP11-545I5.3	8.52	2.4e-16	1.41e-13	0.39	0.37	Lobe attachment (rater-scored or self-reported);	chr6:145529869	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.935	rs415590	ENSG00000235652.6	RP11-545I5.3	8.52	2.4e-16	1.41e-13	0.39	0.37	Lobe attachment (rater-scored or self-reported);	chr6:145530108	chr6:145799409~145886585:+
PRAD	cis	rs12142240	0.698	rs56049453	ENSG00000232022.5	FAAHP1	-8.52	2.4e-16	1.42e-13	-0.34	-0.37	Menopause (age at onset);	chr1:46369796	chr1:46432129~46445521:+
PRAD	cis	rs1979679	0.842	rs10459091	ENSG00000278733.1	RP11-425D17.1	8.52	2.4e-16	1.42e-13	0.47	0.37	Ossification of the posterior longitudinal ligament of the spine;	chr12:28188383	chr12:28185625~28186190:-
PRAD	cis	rs6430553	0.964	rs60793693	ENSG00000224043.6	CCNT2-AS1	-8.52	2.41e-16	1.42e-13	-0.51	-0.37	Blood metabolite levels;	chr2:134852125	chr2:134735464~134918710:-
PRAD	cis	rs7568498	0.517	rs11678856	ENSG00000227403.1	AC009299.3	8.52	2.41e-16	1.42e-13	0.51	0.37	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);	chr2:161068932	chr2:161244739~161249050:+
PRAD	cis	rs10463554	0.926	rs26429	ENSG00000175749.11	EIF3KP1	-8.52	2.41e-16	1.42e-13	-0.47	-0.37	Parkinson's disease;	chr5:103030349	chr5:103032376~103033031:+
PRAD	cis	rs6452524	1	rs1382364	ENSG00000249664.1	CTD-2227C6.2	8.52	2.41e-16	1.42e-13	0.43	0.37	Hypertension (SNP x SNP interaction);	chr5:83156677	chr5:83012285~83013109:-
PRAD	cis	rs6452524	1	rs1382363	ENSG00000249664.1	CTD-2227C6.2	8.52	2.41e-16	1.42e-13	0.43	0.37	Hypertension (SNP x SNP interaction);	chr5:83156753	chr5:83012285~83013109:-
PRAD	cis	rs6452524	1	rs11741897	ENSG00000249664.1	CTD-2227C6.2	8.52	2.41e-16	1.42e-13	0.43	0.37	Hypertension (SNP x SNP interaction);	chr5:83157246	chr5:83012285~83013109:-
PRAD	cis	rs6452524	1	rs10076000	ENSG00000249664.1	CTD-2227C6.2	8.52	2.41e-16	1.42e-13	0.43	0.37	Hypertension (SNP x SNP interaction);	chr5:83161629	chr5:83012285~83013109:-
PRAD	cis	rs6452524	1	rs13436667	ENSG00000249664.1	CTD-2227C6.2	8.52	2.41e-16	1.42e-13	0.43	0.37	Hypertension (SNP x SNP interaction);	chr5:83168948	chr5:83012285~83013109:-
PRAD	cis	rs6452524	1	rs7726564	ENSG00000249664.1	CTD-2227C6.2	8.52	2.41e-16	1.42e-13	0.43	0.37	Hypertension (SNP x SNP interaction);	chr5:83170274	chr5:83012285~83013109:-
PRAD	cis	rs8062405	0.573	rs11645306	ENSG00000251417.2	RP11-1348G14.4	8.52	2.42e-16	1.43e-13	0.45	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28972615	chr16:28802743~28817828:+
PRAD	cis	rs11098499	0.954	rs3733524	ENSG00000245958.5	RP11-33B1.1	-8.52	2.43e-16	1.43e-13	-0.38	-0.37	Corneal astigmatism;	chr4:119502574	chr4:119454791~119552025:+
PRAD	cis	rs4713118	0.662	rs156744	ENSG00000272009.1	RP1-313I6.12	-8.52	2.43e-16	1.43e-13	-0.38	-0.37	Parkinson's disease;	chr6:27999496	chr6:28078792~28081130:-
PRAD	cis	rs858239	0.965	rs156429	ENSG00000226816.2	AC005082.12	8.52	2.43e-16	1.43e-13	0.41	0.37	Cerebrospinal fluid biomarker levels;	chr7:23266401	chr7:23206013~23208045:+
PRAD	cis	rs67311347	0.955	rs60554147	ENSG00000223797.4	ENTPD3-AS1	8.52	2.43e-16	1.43e-13	0.33	0.37	Renal cell carcinoma;	chr3:40431012	chr3:40313802~40453329:-
PRAD	cis	rs7189233	0.531	rs1861353	ENSG00000279344.1	RP11-44F14.7	8.52	2.44e-16	1.44e-13	0.35	0.37	Intelligence (multi-trait analysis);	chr16:53418169	chr16:53478957~53481550:-
PRAD	cis	rs6570726	0.935	rs384519	ENSG00000235652.6	RP11-545I5.3	8.52	2.44e-16	1.44e-13	0.39	0.37	Lobe attachment (rater-scored or self-reported);	chr6:145524881	chr6:145799409~145886585:+
PRAD	cis	rs507080	0.769	rs483283	ENSG00000255422.1	AP002954.4	-8.52	2.44e-16	1.44e-13	-0.46	-0.37	Serum metabolite levels;	chr11:118635684	chr11:118704607~118750263:+
PRAD	cis	rs7811142	0.945	rs6955362	ENSG00000242294.5	STAG3L5P	8.52	2.44e-16	1.44e-13	0.25	0.37	Platelet count;	chr7:100458543	chr7:100336079~100351900:+
PRAD	cis	rs7811142	1	rs6975514	ENSG00000242294.5	STAG3L5P	8.52	2.44e-16	1.44e-13	0.25	0.37	Platelet count;	chr7:100458597	chr7:100336079~100351900:+
PRAD	cis	rs4713118	0.955	rs9468206	ENSG00000280107.1	AL022393.9	-8.51	2.45e-16	1.44e-13	-0.47	-0.37	Parkinson's disease;	chr6:27722674	chr6:28170845~28172521:+
PRAD	cis	rs7189233	0.55	rs9927982	ENSG00000279344.1	RP11-44F14.7	8.51	2.45e-16	1.44e-13	0.33	0.37	Intelligence (multi-trait analysis);	chr16:53440196	chr16:53478957~53481550:-
PRAD	cis	rs7189233	0.531	rs17800577	ENSG00000279344.1	RP11-44F14.7	8.51	2.45e-16	1.44e-13	0.33	0.37	Intelligence (multi-trait analysis);	chr16:53442892	chr16:53478957~53481550:-
PRAD	cis	rs1061377	1	rs9996285	ENSG00000249685.1	RP11-360F5.3	8.51	2.45e-16	1.44e-13	0.41	0.37	Uric acid levels;	chr4:39130556	chr4:39133913~39135608:+
PRAD	cis	rs10463554	0.963	rs3776859	ENSG00000175749.11	EIF3KP1	8.51	2.46e-16	1.45e-13	0.48	0.37	Parkinson's disease;	chr5:103016330	chr5:103032376~103033031:+
PRAD	cis	rs10463554	0.963	rs17154953	ENSG00000175749.11	EIF3KP1	8.51	2.46e-16	1.45e-13	0.48	0.37	Parkinson's disease;	chr5:103019557	chr5:103032376~103033031:+
PRAD	cis	rs748404	0.66	rs2602141	ENSG00000249839.1	AC011330.5	-8.51	2.46e-16	1.45e-13	-0.45	-0.37	Lung cancer;	chr15:43432448	chr15:43663654~43684339:-
PRAD	cis	rs2638953	0.821	rs7964793	ENSG00000278733.1	RP11-425D17.1	8.51	2.47e-16	1.45e-13	0.46	0.37	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28298776	chr12:28185625~28186190:-
PRAD	cis	rs853679	0.55	rs6901017	ENSG00000226314.6	ZNF192P1	-8.51	2.47e-16	1.45e-13	-0.5	-0.37	Depression;	chr6:28184805	chr6:28161781~28169594:+
PRAD	cis	rs10740039	0.583	rs9415612	ENSG00000254271.1	RP11-131N11.4	-8.51	2.48e-16	1.46e-13	-0.52	-0.37	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60746638	chr10:60734342~60741828:+
PRAD	cis	rs875971	0.508	rs10258739	ENSG00000237310.1	GS1-124K5.4	-8.51	2.49e-16	1.46e-13	-0.33	-0.37	Aortic root size;	chr7:66597948	chr7:66493706~66495474:+
PRAD	cis	rs7586673	0.93	rs6432667	ENSG00000227403.1	AC009299.3	-8.51	2.49e-16	1.46e-13	-0.5	-0.37	Intelligence (multi-trait analysis);	chr2:161048490	chr2:161244739~161249050:+
PRAD	cis	rs7727544	0.581	rs10075801	ENSG00000233006.5	AC034220.3	8.51	2.49e-16	1.46e-13	0.33	0.37	Blood metabolite levels;	chr5:132341949	chr5:132311285~132369916:-
PRAD	cis	rs4713118	0.513	rs149958	ENSG00000280107.1	AL022393.9	-8.51	2.49e-16	1.46e-13	-0.45	-0.37	Parkinson's disease;	chr6:28045839	chr6:28170845~28172521:+
PRAD	cis	rs801193	0.636	rs10233806	ENSG00000237310.1	GS1-124K5.4	-8.51	2.49e-16	1.47e-13	-0.34	-0.37	Aortic root size;	chr7:66653261	chr7:66493706~66495474:+
PRAD	cis	rs2348418	0.639	rs10459087	ENSG00000247934.4	RP11-967K21.1	8.51	2.5e-16	1.47e-13	0.35	0.37	Lung function (FEV1);Lung function (FVC);	chr12:28115904	chr12:28163298~28190738:-
PRAD	cis	rs375066	0.967	rs436249	ENSG00000267058.1	RP11-15A1.3	-8.51	2.5e-16	1.47e-13	-0.31	-0.37	Breast cancer;	chr19:43895413	chr19:43891804~43901805:-
PRAD	cis	rs853679	0.517	rs9380052	ENSG00000226314.6	ZNF192P1	-8.51	2.5e-16	1.47e-13	-0.5	-0.37	Depression;	chr6:28096845	chr6:28161781~28169594:+
PRAD	cis	rs10463554	0.963	rs3776857	ENSG00000175749.11	EIF3KP1	8.51	2.51e-16	1.48e-13	0.49	0.37	Parkinson's disease;	chr5:103022456	chr5:103032376~103033031:+
PRAD	cis	rs2729354	0.52	rs2729377	ENSG00000265566.2	RN7SL605P	-8.51	2.51e-16	1.48e-13	-0.55	-0.37	Blood protein levels;	chr11:57482611	chr11:57528085~57528365:-
PRAD	cis	rs7309	0.622	rs4664396	ENSG00000227403.1	AC009299.3	8.51	2.53e-16	1.49e-13	0.48	0.37	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161045139	chr2:161244739~161249050:+
PRAD	cis	rs12142240	0.698	rs17361936	ENSG00000232022.5	FAAHP1	-8.51	2.53e-16	1.49e-13	-0.34	-0.37	Menopause (age at onset);	chr1:46397221	chr1:46432129~46445521:+
PRAD	cis	rs3779195	0.697	rs13232861	ENSG00000272950.1	RP11-307C18.1	8.51	2.54e-16	1.49e-13	0.57	0.37	Sex hormone-binding globulin levels;	chr7:98299769	chr7:98322853~98323430:+
PRAD	cis	rs7250849	0.565	rs7255319	ENSG00000273837.1	LLNLR-470E3.1	8.51	2.54e-16	1.49e-13	0.53	0.37	Blood protein levels;	chr19:51664653	chr19:51639478~51639931:-
PRAD	cis	rs4835473	0.932	rs2060656	ENSG00000251600.4	RP11-673E1.1	-8.51	2.54e-16	1.5e-13	-0.47	-0.37	Immature fraction of reticulocytes;	chr4:143739330	chr4:143912331~143982454:+
PRAD	cis	rs526231	0.511	rs17155009	ENSG00000175749.11	EIF3KP1	8.51	2.55e-16	1.5e-13	0.5	0.37	Primary biliary cholangitis;	chr5:103038440	chr5:103032376~103033031:+
PRAD	cis	rs26232	0.521	rs67019105	ENSG00000175749.11	EIF3KP1	8.51	2.55e-16	1.5e-13	0.5	0.37	Rheumatoid arthritis;	chr5:103038459	chr5:103032376~103033031:+
PRAD	cis	rs12817211	0.502	rs12369104	ENSG00000272368.2	RP4-605O3.4	-8.51	2.56e-16	1.51e-13	-0.37	-0.37	Colorectal or endometrial cancer;	chr12:50141207	chr12:50112197~50165618:+
PRAD	cis	rs67311347	0.955	rs6599100	ENSG00000223797.4	ENTPD3-AS1	8.51	2.57e-16	1.51e-13	0.32	0.37	Renal cell carcinoma;	chr3:40405871	chr3:40313802~40453329:-
PRAD	cis	rs11951515	0.7	rs7714919	ENSG00000188850.9	RP11-159F24.2	8.51	2.57e-16	1.51e-13	0.45	0.37	Metabolite levels  (X-11787);	chr5:43293248	chr5:43336164~43348716:+
PRAD	cis	rs934734	0.563	rs11673956	ENSG00000204929.10	AC074391.1	8.51	2.58e-16	1.51e-13	0.48	0.37	Rheumatoid arthritis;	chr2:65370523	chr2:65436711~66084639:+
PRAD	cis	rs934734	0.563	rs11673987	ENSG00000204929.10	AC074391.1	8.51	2.58e-16	1.51e-13	0.48	0.37	Rheumatoid arthritis;	chr2:65370537	chr2:65436711~66084639:+
PRAD	cis	rs11098499	0.779	rs10857066	ENSG00000245958.5	RP11-33B1.1	-8.51	2.58e-16	1.52e-13	-0.35	-0.37	Corneal astigmatism;	chr4:119365441	chr4:119454791~119552025:+
PRAD	cis	rs34779708	0.733	rs7086715	ENSG00000230534.5	RP11-297A16.2	8.51	2.59e-16	1.52e-13	0.49	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35252912	chr10:35098006~35127020:-
PRAD	cis	rs496547	0.719	rs1790189	ENSG00000278376.1	RP11-158I9.8	-8.51	2.6e-16	1.53e-13	-0.33	-0.37	Hip minimal joint space width;	chr11:118781617	chr11:118791254~118793137:+
PRAD	cis	rs6538678	0.963	rs11108310	ENSG00000258343.1	RP11-536G4.2	-8.51	2.6e-16	1.53e-13	-0.48	-0.37	Lupus nephritis in systemic lupus erythematosus;	chr12:95864164	chr12:95795345~95858839:-
PRAD	cis	rs11098499	0.82	rs6829903	ENSG00000245958.5	RP11-33B1.1	-8.51	2.61e-16	1.53e-13	-0.37	-0.37	Corneal astigmatism;	chr4:119585729	chr4:119454791~119552025:+
PRAD	cis	rs9309473	0.607	rs6740173	ENSG00000163016.8	ALMS1P	8.51	2.64e-16	1.55e-13	0.44	0.37	Metabolite levels;	chr2:73375138	chr2:73644919~73685576:+
PRAD	cis	rs172166	0.769	rs149965	ENSG00000280107.1	AL022393.9	-8.5	2.66e-16	1.56e-13	-0.46	-0.37	Cardiac Troponin-T levels;	chr6:28050911	chr6:28170845~28172521:+
PRAD	cis	rs11951515	0.663	rs4866820	ENSG00000188850.9	RP11-159F24.2	8.5	2.67e-16	1.57e-13	0.45	0.37	Metabolite levels  (X-11787);	chr5:43353675	chr5:43336164~43348716:+
PRAD	cis	rs7727544	0.606	rs10058074	ENSG00000233006.5	AC034220.3	8.5	2.67e-16	1.57e-13	0.33	0.37	Blood metabolite levels;	chr5:132350453	chr5:132311285~132369916:-
PRAD	cis	rs8062405	0.789	rs2106480	ENSG00000251417.2	RP11-1348G14.4	-8.5	2.67e-16	1.57e-13	-0.4	-0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28526650	chr16:28802743~28817828:+
PRAD	cis	rs2337406	1	rs11850600	ENSG00000274576.2	IGHV2-70	-8.5	2.68e-16	1.58e-13	-0.42	-0.37	Alzheimer's disease (late onset);	chr14:106670765	chr14:106770577~106771020:-
PRAD	cis	rs7811142	1	rs6972167	ENSG00000242294.5	STAG3L5P	8.5	2.69e-16	1.58e-13	0.24	0.37	Platelet count;	chr7:100482390	chr7:100336079~100351900:+
PRAD	cis	rs4835473	0.77	rs4835096	ENSG00000251600.4	RP11-673E1.1	8.5	2.7e-16	1.58e-13	0.47	0.37	Immature fraction of reticulocytes;	chr4:143960685	chr4:143912331~143982454:+
PRAD	cis	rs6847067	0.8	rs4131745	ENSG00000180769.7	WDFY3-AS2	8.5	2.7e-16	1.58e-13	0.39	0.37	Oropharynx cancer;	chr4:84915301	chr4:84965682~85011277:+
PRAD	cis	rs11676348	0.774	rs4672870	ENSG00000261338.2	RP11-378A13.1	-8.5	2.7e-16	1.59e-13	-0.4	-0.37	Ulcerative colitis;	chr2:218077193	chr2:218255319~218257366:+
PRAD	cis	rs853679	0.55	rs1233699	ENSG00000272009.1	RP1-313I6.12	-8.5	2.71e-16	1.59e-13	-0.37	-0.37	Depression;	chr6:28201380	chr6:28078792~28081130:-
PRAD	cis	rs7396835	0.741	rs7396851	ENSG00000254851.1	RP11-109L13.1	8.5	2.72e-16	1.59e-13	0.69	0.37	Quantitative traits;	chr11:116813448	chr11:117135528~117138582:+
PRAD	cis	rs11096990	0.613	rs6840578	ENSG00000249207.1	RP11-360F5.1	-8.5	2.72e-16	1.59e-13	-0.39	-0.37	Cognitive function;	chr4:39206996	chr4:39112677~39126818:-
PRAD	cis	rs11096990	0.613	rs7690414	ENSG00000249207.1	RP11-360F5.1	-8.5	2.72e-16	1.59e-13	-0.39	-0.37	Cognitive function;	chr4:39210669	chr4:39112677~39126818:-
PRAD	cis	rs6452524	0.967	rs7718278	ENSG00000249664.1	CTD-2227C6.2	8.5	2.73e-16	1.6e-13	0.43	0.37	Hypertension (SNP x SNP interaction);	chr5:83126600	chr5:83012285~83013109:-
PRAD	cis	rs34779708	0.733	rs60553075	ENSG00000230534.5	RP11-297A16.2	8.5	2.74e-16	1.61e-13	0.49	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35253534	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.733	rs61449529	ENSG00000230534.5	RP11-297A16.2	8.5	2.74e-16	1.61e-13	0.49	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35254986	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.733	rs59287215	ENSG00000230534.5	RP11-297A16.2	8.5	2.74e-16	1.61e-13	0.49	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35255066	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.702	rs35969476	ENSG00000230534.5	RP11-297A16.2	8.5	2.74e-16	1.61e-13	0.49	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35255390	chr10:35098006~35127020:-
PRAD	cis	rs42648	0.564	rs39267	ENSG00000227646.6	STEAP2-AS1	-8.5	2.75e-16	1.61e-13	-0.33	-0.37	Homocysteine levels;	chr7:90142195	chr7:89882353~90211635:-
PRAD	cis	rs9810089	0.814	rs2688600	ENSG00000261758.1	RP11-102M11.2	8.5	2.75e-16	1.61e-13	0.43	0.37	Gestational age at birth (child effect);	chr3:136533754	chr3:136752630~136755780:+
PRAD	cis	rs9810089	0.777	rs2688601	ENSG00000261758.1	RP11-102M11.2	8.5	2.75e-16	1.61e-13	0.43	0.37	Gestational age at birth (child effect);	chr3:136533759	chr3:136752630~136755780:+
PRAD	cis	rs10463554	0.963	rs61418746	ENSG00000175749.11	EIF3KP1	8.5	2.75e-16	1.61e-13	0.48	0.37	Parkinson's disease;	chr5:103043914	chr5:103032376~103033031:+
PRAD	cis	rs11096990	0.593	rs35937374	ENSG00000249207.1	RP11-360F5.1	-8.5	2.75e-16	1.61e-13	-0.39	-0.37	Cognitive function;	chr4:39184735	chr4:39112677~39126818:-
PRAD	cis	rs11096990	0.574	rs34070258	ENSG00000249207.1	RP11-360F5.1	-8.5	2.75e-16	1.61e-13	-0.39	-0.37	Cognitive function;	chr4:39188132	chr4:39112677~39126818:-
PRAD	cis	rs11096990	0.613	rs35391082	ENSG00000249207.1	RP11-360F5.1	-8.5	2.75e-16	1.61e-13	-0.39	-0.37	Cognitive function;	chr4:39191033	chr4:39112677~39126818:-
PRAD	cis	rs11096990	0.613	rs4974990	ENSG00000249207.1	RP11-360F5.1	-8.5	2.75e-16	1.61e-13	-0.39	-0.37	Cognitive function;	chr4:39191645	chr4:39112677~39126818:-
PRAD	cis	rs8523	0.901	rs2295600	ENSG00000230314.5	ELOVL2-AS1	8.5	2.75e-16	1.61e-13	0.41	0.37	Red blood cell fatty acid levels;	chr6:10962017	chr6:11043524~11078226:+
PRAD	cis	rs12817211	0.502	rs3741562	ENSG00000272368.2	RP4-605O3.4	-8.5	2.76e-16	1.62e-13	-0.37	-0.37	Colorectal or endometrial cancer;	chr12:50135953	chr12:50112197~50165618:+
PRAD	cis	rs4835473	0.932	rs62339580	ENSG00000251600.4	RP11-673E1.1	-8.5	2.77e-16	1.62e-13	-0.47	-0.37	Immature fraction of reticulocytes;	chr4:143785090	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs62339581	ENSG00000251600.4	RP11-673E1.1	-8.5	2.77e-16	1.62e-13	-0.47	-0.37	Immature fraction of reticulocytes;	chr4:143785172	chr4:143912331~143982454:+
PRAD	cis	rs11098499	0.863	rs9884402	ENSG00000245958.5	RP11-33B1.1	-8.5	2.77e-16	1.62e-13	-0.37	-0.37	Corneal astigmatism;	chr4:119568827	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.731	rs9995026	ENSG00000245958.5	RP11-33B1.1	-8.5	2.77e-16	1.62e-13	-0.37	-0.37	Corneal astigmatism;	chr4:119569344	chr4:119454791~119552025:+
PRAD	cis	rs1155848	0.571	rs6563127	ENSG00000227354.5	RBM26-AS1	8.5	2.77e-16	1.62e-13	0.66	0.37	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79642012	chr13:79406309~79424328:+
PRAD	cis	rs496547	0.686	rs540180	ENSG00000278376.1	RP11-158I9.8	-8.5	2.78e-16	1.63e-13	-0.33	-0.37	Hip minimal joint space width;	chr11:118782920	chr11:118791254~118793137:+
PRAD	cis	rs4713118	0.516	rs6931858	ENSG00000226314.6	ZNF192P1	-8.5	2.78e-16	1.63e-13	-0.51	-0.37	Parkinson's disease;	chr6:28110633	chr6:28161781~28169594:+
PRAD	cis	rs9309473	0.607	rs7567017	ENSG00000163016.8	ALMS1P	8.5	2.78e-16	1.63e-13	0.44	0.37	Metabolite levels;	chr2:73369142	chr2:73644919~73685576:+
PRAD	cis	rs9309473	0.607	rs7586361	ENSG00000163016.8	ALMS1P	8.5	2.8e-16	1.64e-13	0.44	0.37	Metabolite levels;	chr2:73374478	chr2:73644919~73685576:+
PRAD	cis	rs7131987	0.65	rs6487808	ENSG00000257176.2	RP11-996F15.2	8.5	2.81e-16	1.64e-13	0.41	0.37	QT interval;	chr12:29310426	chr12:29280418~29317848:-
PRAD	cis	rs12899811	0.512	rs7164916	ENSG00000214432.8	AC068831.10	-8.5	2.81e-16	1.64e-13	-0.44	-0.37	Type 2 diabetes;	chr15:91018216	chr15:91022619~91036611:+
PRAD	cis	rs526231	0.511	rs62362558	ENSG00000175749.11	EIF3KP1	8.5	2.82e-16	1.65e-13	0.5	0.37	Primary biliary cholangitis;	chr5:103032789	chr5:103032376~103033031:+
PRAD	cis	rs526231	0.511	rs4421079	ENSG00000175749.11	EIF3KP1	8.5	2.82e-16	1.65e-13	0.5	0.37	Primary biliary cholangitis;	chr5:103033372	chr5:103032376~103033031:+
PRAD	cis	rs35260072	1	rs35260072	ENSG00000233006.5	AC034220.3	8.5	2.82e-16	1.65e-13	0.34	0.37	Itch intensity from mosquito bite;	chr5:132295159	chr5:132311285~132369916:-
PRAD	cis	rs3096299	0.933	rs2965824	ENSG00000274627.1	RP11-104N10.2	8.5	2.82e-16	1.65e-13	0.37	0.37	Multiple myeloma (IgH translocation);	chr16:89388898	chr16:89516797~89522217:+
PRAD	cis	rs7131987	0.65	rs10843377	ENSG00000257176.2	RP11-996F15.2	8.5	2.82e-16	1.65e-13	0.41	0.37	QT interval;	chr12:29284120	chr12:29280418~29317848:-
PRAD	cis	rs2412819	0.571	rs56226333	ENSG00000205771.5	CATSPER2P1	-8.5	2.83e-16	1.65e-13	-0.53	-0.37	Lung cancer;	chr15:43632410	chr15:43726918~43747094:-
PRAD	cis	rs7598759	0.679	rs6740843	ENSG00000181798.2	LINC00471	-8.5	2.83e-16	1.66e-13	-0.43	-0.37	Noise-induced hearing loss;	chr2:231467428	chr2:231508426~231514339:-
PRAD	cis	rs7598759	0.712	rs6740474	ENSG00000181798.2	LINC00471	-8.5	2.84e-16	1.66e-13	-0.43	-0.37	Noise-induced hearing loss;	chr2:231467120	chr2:231508426~231514339:-
PRAD	cis	rs7598759	0.712	rs6727372	ENSG00000181798.2	LINC00471	-8.5	2.84e-16	1.66e-13	-0.43	-0.37	Noise-induced hearing loss;	chr2:231467195	chr2:231508426~231514339:-
PRAD	cis	rs7598759	0.712	rs6727510	ENSG00000181798.2	LINC00471	-8.5	2.84e-16	1.66e-13	-0.43	-0.37	Noise-induced hearing loss;	chr2:231467305	chr2:231508426~231514339:-
PRAD	cis	rs7598759	0.675	rs6727530	ENSG00000181798.2	LINC00471	-8.5	2.84e-16	1.66e-13	-0.43	-0.37	Noise-induced hearing loss;	chr2:231467347	chr2:231508426~231514339:-
PRAD	cis	rs7598759	0.712	rs10933372	ENSG00000181798.2	LINC00471	-8.5	2.84e-16	1.66e-13	-0.43	-0.37	Noise-induced hearing loss;	chr2:231467614	chr2:231508426~231514339:-
PRAD	cis	rs7598759	0.712	rs997400	ENSG00000181798.2	LINC00471	-8.5	2.84e-16	1.66e-13	-0.43	-0.37	Noise-induced hearing loss;	chr2:231468136	chr2:231508426~231514339:-
PRAD	cis	rs2412819	0.571	rs12900924	ENSG00000205771.5	CATSPER2P1	-8.49	2.85e-16	1.67e-13	-0.55	-0.37	Lung cancer;	chr15:43737329	chr15:43726918~43747094:-
PRAD	cis	rs10463554	0.963	rs17154959	ENSG00000175749.11	EIF3KP1	8.49	2.85e-16	1.67e-13	0.49	0.37	Parkinson's disease;	chr5:103020587	chr5:103032376~103033031:+
PRAD	cis	rs496547	0.721	rs2508570	ENSG00000278376.1	RP11-158I9.8	-8.49	2.86e-16	1.67e-13	-0.33	-0.37	Hip minimal joint space width;	chr11:118807900	chr11:118791254~118793137:+
PRAD	cis	rs496547	0.686	rs591756	ENSG00000278376.1	RP11-158I9.8	-8.49	2.86e-16	1.67e-13	-0.33	-0.37	Hip minimal joint space width;	chr11:118808172	chr11:118791254~118793137:+
PRAD	cis	rs496547	0.686	rs477014	ENSG00000278376.1	RP11-158I9.8	-8.49	2.86e-16	1.67e-13	-0.33	-0.37	Hip minimal joint space width;	chr11:118808277	chr11:118791254~118793137:+
PRAD	cis	rs496547	0.557	rs516719	ENSG00000278376.1	RP11-158I9.8	-8.49	2.86e-16	1.67e-13	-0.33	-0.37	Hip minimal joint space width;	chr11:118808736	chr11:118791254~118793137:+
PRAD	cis	rs42648	0.564	rs11563947	ENSG00000227646.6	STEAP2-AS1	8.49	2.87e-16	1.68e-13	0.33	0.37	Homocysteine levels;	chr7:90179450	chr7:89882353~90211635:-
PRAD	cis	rs11096990	0.593	rs1026235	ENSG00000249207.1	RP11-360F5.1	-8.49	2.87e-16	1.68e-13	-0.38	-0.37	Cognitive function;	chr4:39226629	chr4:39112677~39126818:-
PRAD	cis	rs7211079	0.957	rs8082247	ENSG00000279259.1	RP11-334C17.3	8.49	2.87e-16	1.68e-13	0.41	0.37	Myocardial infarction;	chr17:80141192	chr17:80147250~80148596:+
PRAD	cis	rs4835473	0.643	rs34680080	ENSG00000251600.4	RP11-673E1.1	-8.49	2.88e-16	1.69e-13	-0.47	-0.37	Immature fraction of reticulocytes;	chr4:143797290	chr4:143912331~143982454:+
PRAD	cis	rs7712401	0.601	rs36180885	ENSG00000263432.2	RN7SL689P	-8.49	2.9e-16	1.69e-13	-0.39	-0.37	Mean platelet volume;	chr5:123020708	chr5:123022487~123022783:-
PRAD	cis	rs6847067	0.8	rs12510410	ENSG00000180769.7	WDFY3-AS2	-8.49	2.9e-16	1.69e-13	-0.38	-0.37	Oropharynx cancer;	chr4:84945649	chr4:84965682~85011277:+
PRAD	cis	rs875971	0.522	rs4502988	ENSG00000236529.1	RP13-254B10.1	8.49	2.9e-16	1.7e-13	0.38	0.37	Aortic root size;	chr7:65832759	chr7:65840212~65840596:+
PRAD	cis	rs6921919	0.515	rs1558205	ENSG00000216901.1	AL022393.7	-8.49	2.9e-16	1.7e-13	-0.47	-0.37	Autism spectrum disorder or schizophrenia;	chr6:28414485	chr6:28176188~28176674:+
PRAD	cis	rs17361889	0.738	rs35150436	ENSG00000224683.1	RPL36AP29	8.49	2.91e-16	1.7e-13	0.45	0.37	Pediatric bone mineral content (hip);	chr7:16147313	chr7:16208945~16209265:+
PRAD	cis	rs4835473	0.838	rs56033497	ENSG00000251600.4	RP11-673E1.1	-8.49	2.91e-16	1.7e-13	-0.47	-0.37	Immature fraction of reticulocytes;	chr4:143792341	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs13130345	ENSG00000251600.4	RP11-673E1.1	8.49	2.92e-16	1.7e-13	0.47	0.37	Immature fraction of reticulocytes;	chr4:143920939	chr4:143912331~143982454:+
PRAD	cis	rs7923609	1	rs7916868	ENSG00000232075.1	MRPL35P2	-8.49	2.92e-16	1.71e-13	-0.39	-0.37	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63229171	chr10:63634317~63634827:-
PRAD	cis	rs7849270	0.879	rs10819461	ENSG00000268707.1	RP11-247A12.7	-8.49	2.92e-16	1.71e-13	-0.44	-0.37	Blood metabolite ratios;	chr9:129079608	chr9:129170434~129170940:+
PRAD	cis	rs17361889	0.633	rs1918267	ENSG00000224683.1	RPL36AP29	8.49	2.92e-16	1.71e-13	0.45	0.37	Pediatric bone mineral content (hip);	chr7:16231700	chr7:16208945~16209265:+
PRAD	cis	rs6452524	1	rs4590162	ENSG00000249664.1	CTD-2227C6.2	8.49	2.93e-16	1.71e-13	0.43	0.37	Hypertension (SNP x SNP interaction);	chr5:83145621	chr5:83012285~83013109:-
PRAD	cis	rs12142240	0.698	rs1057533	ENSG00000232022.5	FAAHP1	-8.49	2.94e-16	1.72e-13	-0.34	-0.37	Menopause (age at onset);	chr1:46350164	chr1:46432129~46445521:+
PRAD	cis	rs10463554	0.892	rs13340345	ENSG00000175749.11	EIF3KP1	8.49	2.94e-16	1.72e-13	0.49	0.37	Parkinson's disease;	chr5:103003518	chr5:103032376~103033031:+
PRAD	cis	rs10463554	0.963	rs3776860	ENSG00000175749.11	EIF3KP1	8.49	2.94e-16	1.72e-13	0.49	0.37	Parkinson's disease;	chr5:103014266	chr5:103032376~103033031:+
PRAD	cis	rs11098499	0.866	rs11098506	ENSG00000245958.5	RP11-33B1.1	-8.49	2.96e-16	1.73e-13	-0.36	-0.37	Corneal astigmatism;	chr4:119363816	chr4:119454791~119552025:+
PRAD	cis	rs12908161	1	rs12905057	ENSG00000259728.4	LINC00933	8.49	2.96e-16	1.73e-13	0.46	0.37	Schizophrenia;	chr15:84667534	chr15:84570649~84580175:+
PRAD	cis	rs2933343	0.729	rs789231	ENSG00000231305.3	RP11-723O4.2	8.49	2.97e-16	1.74e-13	0.34	0.37	IgG glycosylation;	chr3:128884004	chr3:128861313~128871540:-
PRAD	cis	rs950169	0.922	rs11631096	ENSG00000259728.4	LINC00933	8.49	2.98e-16	1.74e-13	0.45	0.37	Schizophrenia;	chr15:84557698	chr15:84570649~84580175:+
PRAD	cis	rs5769707	0.632	rs135876	ENSG00000188511.11	C22orf34	8.49	2.99e-16	1.74e-13	0.43	0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49619925	chr22:49414524~49657542:-
PRAD	cis	rs4713118	0.662	rs156744	ENSG00000219392.1	RP1-265C24.5	-8.49	2.99e-16	1.75e-13	-0.48	-0.37	Parkinson's disease;	chr6:27999496	chr6:28115628~28116551:+
PRAD	cis	rs4713118	0.869	rs6922574	ENSG00000280107.1	AL022393.9	-8.49	2.99e-16	1.75e-13	-0.46	-0.37	Parkinson's disease;	chr6:27725224	chr6:28170845~28172521:+
PRAD	cis	rs7712401	0.601	rs30038	ENSG00000263432.2	RN7SL689P	8.49	3.01e-16	1.76e-13	0.38	0.37	Mean platelet volume;	chr5:122941667	chr5:123022487~123022783:-
PRAD	cis	rs17361889	0.752	rs56161298	ENSG00000224683.1	RPL36AP29	8.49	3.01e-16	1.76e-13	0.45	0.37	Pediatric bone mineral content (hip);	chr7:16215537	chr7:16208945~16209265:+
PRAD	cis	rs10771431	0.967	rs7137443	ENSG00000111788.10	RP11-22B23.1	8.49	3.02e-16	1.76e-13	0.37	0.37	Breast size;	chr12:9219433	chr12:9277235~9313241:+
PRAD	cis	rs10771431	0.935	rs1988852	ENSG00000111788.10	RP11-22B23.1	8.49	3.02e-16	1.76e-13	0.37	0.37	Breast size;	chr12:9220266	chr12:9277235~9313241:+
PRAD	cis	rs11676348	0.772	rs10932745	ENSG00000261338.2	RP11-378A13.1	-8.49	3.03e-16	1.77e-13	-0.4	-0.37	Ulcerative colitis;	chr2:218078253	chr2:218255319~218257366:+
PRAD	cis	rs950169	0.922	rs11635505	ENSG00000225151.9	GOLGA2P7	8.49	3.03e-16	1.77e-13	0.51	0.37	Schizophrenia;	chr15:84553803	chr15:84199311~84230136:-
PRAD	cis	rs17711722	0.74	rs7809991	ENSG00000236529.1	RP13-254B10.1	8.49	3.04e-16	1.77e-13	0.38	0.37	Calcium levels;	chr7:65941231	chr7:65840212~65840596:+
PRAD	cis	rs7811142	0.83	rs118119933	ENSG00000242294.5	STAG3L5P	8.49	3.04e-16	1.78e-13	0.26	0.37	Platelet count;	chr7:100341427	chr7:100336079~100351900:+
PRAD	cis	rs673078	0.66	rs11068917	ENSG00000275409.1	RP11-131L12.4	-8.49	3.04e-16	1.78e-13	-0.48	-0.37	Glucose homeostasis traits;	chr12:118353315	chr12:118430147~118430699:+
PRAD	cis	rs150992	0.548	rs12109067	ENSG00000248489.1	CTD-2007H13.3	8.49	3.06e-16	1.78e-13	0.41	0.37	Body mass index;	chr5:99038928	chr5:98929171~98995013:+
PRAD	cis	rs17711722	0.727	rs1880555	ENSG00000236529.1	RP13-254B10.1	8.48	3.06e-16	1.79e-13	0.38	0.37	Calcium levels;	chr7:65967580	chr7:65840212~65840596:+
PRAD	cis	rs10463554	0.963	rs1011454	ENSG00000175749.11	EIF3KP1	8.48	3.07e-16	1.79e-13	0.48	0.37	Parkinson's disease;	chr5:103032551	chr5:103032376~103033031:+
PRAD	cis	rs875971	0.522	rs2008188	ENSG00000236529.1	RP13-254B10.1	8.48	3.08e-16	1.8e-13	0.38	0.37	Aortic root size;	chr7:65964026	chr7:65840212~65840596:+
PRAD	cis	rs748404	0.631	rs7163288	ENSG00000249839.1	AC011330.5	-8.48	3.09e-16	1.8e-13	-0.45	-0.37	Lung cancer;	chr15:43379157	chr15:43663654~43684339:-
PRAD	cis	rs11098499	0.564	rs11098507	ENSG00000245958.5	RP11-33B1.1	-8.48	3.09e-16	1.8e-13	-0.35	-0.37	Corneal astigmatism;	chr4:119367131	chr4:119454791~119552025:+
PRAD	cis	rs2412819	0.545	rs35333173	ENSG00000205771.5	CATSPER2P1	-8.48	3.12e-16	1.82e-13	-0.53	-0.37	Lung cancer;	chr15:43640818	chr15:43726918~43747094:-
PRAD	cis	rs875971	1	rs10244498	ENSG00000237310.1	GS1-124K5.4	8.48	3.14e-16	1.83e-13	0.34	0.37	Aortic root size;	chr7:66651069	chr7:66493706~66495474:+
PRAD	cis	rs4835473	0.838	rs13134571	ENSG00000251600.4	RP11-673E1.1	-8.48	3.14e-16	1.83e-13	-0.47	-0.37	Immature fraction of reticulocytes;	chr4:143738771	chr4:143912331~143982454:+
PRAD	cis	rs801193	0.773	rs801207	ENSG00000237310.1	GS1-124K5.4	-8.48	3.14e-16	1.83e-13	-0.32	-0.37	Aortic root size;	chr7:66555603	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.543	rs801191	ENSG00000237310.1	GS1-124K5.4	-8.48	3.14e-16	1.83e-13	-0.32	-0.37	Aortic root size;	chr7:66567968	chr7:66493706~66495474:+
PRAD	cis	rs4713118	0.513	rs149962	ENSG00000280107.1	AL022393.9	-8.48	3.14e-16	1.83e-13	-0.45	-0.37	Parkinson's disease;	chr6:28048140	chr6:28170845~28172521:+
PRAD	cis	rs17361889	0.778	rs1527198	ENSG00000224683.1	RPL36AP29	-8.48	3.15e-16	1.83e-13	-0.44	-0.37	Pediatric bone mineral content (hip);	chr7:16176520	chr7:16208945~16209265:+
PRAD	cis	rs875971	0.522	rs10807697	ENSG00000236529.1	RP13-254B10.1	8.48	3.16e-16	1.84e-13	0.38	0.37	Aortic root size;	chr7:65951183	chr7:65840212~65840596:+
PRAD	cis	rs10875746	0.579	rs10875778	ENSG00000240399.1	RP1-228P16.1	-8.48	3.17e-16	1.85e-13	-0.36	-0.37	Longevity (90 years and older);	chr12:48230872	chr12:48054813~48055591:-
PRAD	cis	rs10875746	0.669	rs10875779	ENSG00000240399.1	RP1-228P16.1	-8.48	3.17e-16	1.85e-13	-0.36	-0.37	Longevity (90 years and older);	chr12:48236086	chr12:48054813~48055591:-
PRAD	cis	rs7211079	0.843	rs73438138	ENSG00000279259.1	RP11-334C17.3	8.48	3.18e-16	1.85e-13	0.4	0.37	Myocardial infarction;	chr17:80148608	chr17:80147250~80148596:+
PRAD	cis	rs34779708	0.733	rs12777960	ENSG00000230534.5	RP11-297A16.2	8.48	3.19e-16	1.86e-13	0.49	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35252098	chr10:35098006~35127020:-
PRAD	cis	rs2933343	0.621	rs883843	ENSG00000231305.3	RP11-723O4.2	-8.48	3.19e-16	1.86e-13	-0.35	-0.37	IgG glycosylation;	chr3:128848540	chr3:128861313~128871540:-
PRAD	cis	rs11083475	1	rs62121818	ENSG00000267892.1	CTD-2540F13.2	8.48	3.19e-16	1.86e-13	0.4	0.37	Heart rate;	chr19:38677120	chr19:38738284~38739863:+
PRAD	cis	rs77204473	0.557	rs9971422	ENSG00000254851.1	RP11-109L13.1	8.48	3.19e-16	1.86e-13	0.72	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116966657	chr11:117135528~117138582:+
PRAD	cis	rs4713118	0.662	rs149961	ENSG00000219392.1	RP1-265C24.5	-8.48	3.19e-16	1.86e-13	-0.48	-0.37	Parkinson's disease;	chr6:28047791	chr6:28115628~28116551:+
PRAD	cis	rs4835473	0.808	rs11725413	ENSG00000251600.4	RP11-673E1.1	-8.48	3.19e-16	1.86e-13	-0.48	-0.37	Immature fraction of reticulocytes;	chr4:143943366	chr4:143912331~143982454:+
PRAD	cis	rs17711722	0.523	rs365896	ENSG00000236529.1	RP13-254B10.1	-8.48	3.2e-16	1.86e-13	-0.39	-0.37	Calcium levels;	chr7:66045710	chr7:65840212~65840596:+
PRAD	cis	rs6723108	0.517	rs6729702	ENSG00000224043.6	CCNT2-AS1	-8.48	3.2e-16	1.86e-13	-0.51	-0.37	Type 2 diabetes;	chr2:134844586	chr2:134735464~134918710:-
PRAD	cis	rs11098499	0.863	rs58452170	ENSG00000245958.5	RP11-33B1.1	-8.48	3.2e-16	1.86e-13	-0.37	-0.37	Corneal astigmatism;	chr4:119538519	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.863	rs1552095	ENSG00000245958.5	RP11-33B1.1	-8.48	3.2e-16	1.86e-13	-0.37	-0.37	Corneal astigmatism;	chr4:119539151	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.863	rs7678400	ENSG00000245958.5	RP11-33B1.1	-8.48	3.2e-16	1.86e-13	-0.37	-0.37	Corneal astigmatism;	chr4:119540802	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.863	rs1480936	ENSG00000245958.5	RP11-33B1.1	-8.48	3.2e-16	1.86e-13	-0.37	-0.37	Corneal astigmatism;	chr4:119541706	chr4:119454791~119552025:+
PRAD	cis	rs7849270	0.76	rs882616	ENSG00000268707.1	RP11-247A12.7	8.48	3.2e-16	1.86e-13	0.44	0.37	Blood metabolite ratios;	chr9:129178586	chr9:129170434~129170940:+
PRAD	cis	rs2255336	0.938	rs17549004	ENSG00000245648.1	RP11-277P12.20	-8.48	3.21e-16	1.87e-13	-0.6	-0.37	Blood protein levels;	chr12:10410024	chr12:10363769~10398506:+
PRAD	cis	rs10463554	0.892	rs158408	ENSG00000175749.11	EIF3KP1	8.48	3.23e-16	1.88e-13	0.48	0.37	Parkinson's disease;	chr5:103071670	chr5:103032376~103033031:+
PRAD	cis	rs11098499	0.863	rs11098532	ENSG00000245958.5	RP11-33B1.1	-8.48	3.24e-16	1.89e-13	-0.37	-0.37	Corneal astigmatism;	chr4:119569571	chr4:119454791~119552025:+
PRAD	cis	rs131777	0.532	rs131747	ENSG00000205559.3	CHKB-AS1	-8.48	3.24e-16	1.89e-13	-0.37	-0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50586645	chr22:50583026~50583877:+
PRAD	cis	rs4713118	0.513	rs149878	ENSG00000280107.1	AL022393.9	-8.48	3.25e-16	1.89e-13	-0.46	-0.37	Parkinson's disease;	chr6:27910960	chr6:28170845~28172521:+
PRAD	cis	rs2739330	0.796	rs2154594	ENSG00000224205.1	AP000351.4	-8.48	3.26e-16	1.9e-13	-0.46	-0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23987320~23991421:-
PRAD	cis	rs1062177	0.826	rs2915873	ENSG00000253921.1	CTB-113P19.3	-8.48	3.26e-16	1.9e-13	-0.49	-0.37	Preschool internalizing problems;	chr5:151777097	chr5:151753992~151767247:+
PRAD	cis	rs6452524	0.71	rs7708124	ENSG00000249664.1	CTD-2227C6.2	8.48	3.28e-16	1.91e-13	0.43	0.37	Hypertension (SNP x SNP interaction);	chr5:83132035	chr5:83012285~83013109:-
PRAD	cis	rs4713118	0.513	rs156738	ENSG00000280107.1	AL022393.9	-8.47	3.3e-16	1.92e-13	-0.45	-0.37	Parkinson's disease;	chr6:28046247	chr6:28170845~28172521:+
PRAD	cis	rs7131987	0.65	rs16934135	ENSG00000257176.2	RP11-996F15.2	-8.47	3.3e-16	1.92e-13	-0.41	-0.37	QT interval;	chr12:29331030	chr12:29280418~29317848:-
PRAD	cis	rs6452524	1	rs11958314	ENSG00000249664.1	CTD-2227C6.2	8.47	3.31e-16	1.92e-13	0.43	0.37	Hypertension (SNP x SNP interaction);	chr5:83132929	chr5:83012285~83013109:-
PRAD	cis	rs6452524	0.686	rs6452517	ENSG00000249664.1	CTD-2227C6.2	8.47	3.31e-16	1.92e-13	0.43	0.37	Hypertension (SNP x SNP interaction);	chr5:83133041	chr5:83012285~83013109:-
PRAD	cis	rs6452524	0.686	rs6452518	ENSG00000249664.1	CTD-2227C6.2	8.47	3.31e-16	1.92e-13	0.43	0.37	Hypertension (SNP x SNP interaction);	chr5:83133043	chr5:83012285~83013109:-
PRAD	cis	rs6452524	1	rs10069402	ENSG00000249664.1	CTD-2227C6.2	8.47	3.31e-16	1.92e-13	0.43	0.37	Hypertension (SNP x SNP interaction);	chr5:83133776	chr5:83012285~83013109:-
PRAD	cis	rs240993	0.809	rs11153277	ENSG00000230177.1	RP5-1112D6.4	-8.47	3.31e-16	1.92e-13	-0.42	-0.37	Inflammatory skin disease;Psoriasis;	chr6:111259358	chr6:111277932~111278742:+
PRAD	cis	rs10463554	0.963	rs62364875	ENSG00000175749.11	EIF3KP1	8.47	3.31e-16	1.93e-13	0.48	0.37	Parkinson's disease;	chr5:103056486	chr5:103032376~103033031:+
PRAD	cis	rs1150668	0.768	rs1233713	ENSG00000280107.1	AL022393.9	-8.47	3.32e-16	1.93e-13	-0.44	-0.37	Pubertal anthropometrics;	chr6:28230503	chr6:28170845~28172521:+
PRAD	cis	rs875971	1	rs4718357	ENSG00000237310.1	GS1-124K5.4	8.47	3.33e-16	1.93e-13	0.33	0.37	Aortic root size;	chr7:66495891	chr7:66493706~66495474:+
PRAD	cis	rs950169	0.922	rs6603022	ENSG00000225151.9	GOLGA2P7	8.47	3.33e-16	1.93e-13	0.52	0.37	Schizophrenia;	chr15:84161418	chr15:84199311~84230136:-
PRAD	cis	rs8062405	0.72	rs9926245	ENSG00000251417.2	RP11-1348G14.4	-8.47	3.33e-16	1.94e-13	-0.4	-0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544385	chr16:28802743~28817828:+
PRAD	cis	rs34779708	0.643	rs4275563	ENSG00000230534.5	RP11-297A16.2	8.47	3.34e-16	1.94e-13	0.49	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35256358	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.766	rs7913451	ENSG00000230534.5	RP11-297A16.2	8.47	3.34e-16	1.94e-13	0.5	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35262597	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.766	rs7897088	ENSG00000230534.5	RP11-297A16.2	8.47	3.34e-16	1.94e-13	0.5	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35262639	chr10:35098006~35127020:-
PRAD	cis	rs7615952	0.576	rs2276726	ENSG00000171084.14	FAM86JP	8.47	3.35e-16	1.95e-13	0.57	0.37	Blood pressure (smoking interaction);	chr3:126107444	chr3:125916620~125930024:+
PRAD	cis	rs9810089	0.814	rs10804640	ENSG00000261758.1	RP11-102M11.2	8.47	3.35e-16	1.95e-13	0.42	0.37	Gestational age at birth (child effect);	chr3:136446853	chr3:136752630~136755780:+
PRAD	cis	rs7829975	0.511	rs2948286	ENSG00000253893.2	FAM85B	-8.47	3.36e-16	1.95e-13	-0.47	-0.37	Mood instability;	chr8:8272638	chr8:8167819~8226614:-
PRAD	cis	rs6001482	0.638	rs5757574	ENSG00000272779.1	LL22NC03-80A10.6	-8.47	3.37e-16	1.96e-13	-0.44	-0.37	Diastolic blood pressure;	chr22:22231597	chr22:22303224~22310401:+
PRAD	cis	rs4835473	0.897	rs55635947	ENSG00000251600.4	RP11-673E1.1	-8.47	3.39e-16	1.97e-13	-0.47	-0.37	Immature fraction of reticulocytes;	chr4:143736218	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.897	rs56334914	ENSG00000251600.4	RP11-673E1.1	-8.47	3.39e-16	1.97e-13	-0.47	-0.37	Immature fraction of reticulocytes;	chr4:143736291	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.897	rs56324738	ENSG00000251600.4	RP11-673E1.1	-8.47	3.39e-16	1.97e-13	-0.47	-0.37	Immature fraction of reticulocytes;	chr4:143736297	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs55862664	ENSG00000251600.4	RP11-673E1.1	-8.47	3.39e-16	1.97e-13	-0.47	-0.37	Immature fraction of reticulocytes;	chr4:143736311	chr4:143912331~143982454:+
PRAD	cis	rs8062405	0.824	rs4788083	ENSG00000251417.2	RP11-1348G14.4	-8.47	3.4e-16	1.98e-13	-0.4	-0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534128	chr16:28802743~28817828:+
PRAD	cis	rs10463554	0.963	rs1595553	ENSG00000175749.11	EIF3KP1	8.47	3.41e-16	1.98e-13	0.49	0.37	Parkinson's disease;	chr5:103043164	chr5:103032376~103033031:+
PRAD	cis	rs10463554	0.963	rs12655592	ENSG00000175749.11	EIF3KP1	8.47	3.41e-16	1.98e-13	0.49	0.37	Parkinson's disease;	chr5:103043715	chr5:103032376~103033031:+
PRAD	cis	rs10463554	0.963	rs12054848	ENSG00000175749.11	EIF3KP1	8.47	3.41e-16	1.98e-13	0.49	0.37	Parkinson's disease;	chr5:103044736	chr5:103032376~103033031:+
PRAD	cis	rs10463554	0.963	rs11242484	ENSG00000175749.11	EIF3KP1	8.47	3.41e-16	1.98e-13	0.49	0.37	Parkinson's disease;	chr5:103046172	chr5:103032376~103033031:+
PRAD	cis	rs10463554	0.963	rs11242485	ENSG00000175749.11	EIF3KP1	8.47	3.41e-16	1.98e-13	0.49	0.37	Parkinson's disease;	chr5:103046330	chr5:103032376~103033031:+
PRAD	cis	rs10463554	0.892	rs10434791	ENSG00000175749.11	EIF3KP1	8.47	3.41e-16	1.98e-13	0.49	0.37	Parkinson's disease;	chr5:103053768	chr5:103032376~103033031:+
PRAD	cis	rs6452524	1	rs10076271	ENSG00000249664.1	CTD-2227C6.2	8.47	3.41e-16	1.98e-13	0.43	0.37	Hypertension (SNP x SNP interaction);	chr5:83133875	chr5:83012285~83013109:-
PRAD	cis	rs6452524	1	rs10076274	ENSG00000249664.1	CTD-2227C6.2	8.47	3.41e-16	1.98e-13	0.43	0.37	Hypertension (SNP x SNP interaction);	chr5:83133908	chr5:83012285~83013109:-
PRAD	cis	rs6452524	1	rs10061521	ENSG00000249664.1	CTD-2227C6.2	8.47	3.41e-16	1.98e-13	0.43	0.37	Hypertension (SNP x SNP interaction);	chr5:83133936	chr5:83012285~83013109:-
PRAD	cis	rs6452524	1	rs7733151	ENSG00000249664.1	CTD-2227C6.2	8.47	3.41e-16	1.98e-13	0.43	0.37	Hypertension (SNP x SNP interaction);	chr5:83134655	chr5:83012285~83013109:-
PRAD	cis	rs6452524	1	rs7733330	ENSG00000249664.1	CTD-2227C6.2	8.47	3.41e-16	1.98e-13	0.43	0.37	Hypertension (SNP x SNP interaction);	chr5:83134774	chr5:83012285~83013109:-
PRAD	cis	rs858239	1	rs166663	ENSG00000226816.2	AC005082.12	8.47	3.41e-16	1.98e-13	0.42	0.37	Cerebrospinal fluid biomarker levels;	chr7:23277123	chr7:23206013~23208045:+
PRAD	cis	rs1185460	1	rs7127212	ENSG00000271751.1	RP11-110I1.14	8.47	3.42e-16	1.99e-13	0.51	0.37	Coronary artery disease;	chr11:119082492	chr11:119065263~119065677:-
PRAD	cis	rs6570726	0.935	rs434298	ENSG00000235652.6	RP11-545I5.3	8.47	3.42e-16	1.99e-13	0.39	0.37	Lobe attachment (rater-scored or self-reported);	chr6:145525737	chr6:145799409~145886585:+
PRAD	cis	rs9595066	0.627	rs4941486	ENSG00000227258.4	SMIM2-AS1	8.47	3.43e-16	1.99e-13	0.64	0.37	Schizophrenia;	chr13:44175021	chr13:44110451~44240517:+
PRAD	cis	rs526231	0.543	rs4386712	ENSG00000175749.11	EIF3KP1	8.47	3.44e-16	1.99e-13	0.5	0.37	Primary biliary cholangitis;	chr5:103033530	chr5:103032376~103033031:+
PRAD	cis	rs526231	0.511	rs56235607	ENSG00000175749.11	EIF3KP1	8.47	3.44e-16	1.99e-13	0.5	0.37	Primary biliary cholangitis;	chr5:103036902	chr5:103032376~103033031:+
PRAD	cis	rs526231	0.511	rs55741939	ENSG00000175749.11	EIF3KP1	8.47	3.44e-16	1.99e-13	0.5	0.37	Primary biliary cholangitis;	chr5:103036984	chr5:103032376~103033031:+
PRAD	cis	rs10463554	0.963	rs72785733	ENSG00000175749.11	EIF3KP1	8.47	3.44e-16	1.99e-13	0.5	0.37	Parkinson's disease;	chr5:103038488	chr5:103032376~103033031:+
PRAD	cis	rs4713118	0.513	rs149959	ENSG00000280107.1	AL022393.9	-8.47	3.44e-16	2e-13	-0.45	-0.37	Parkinson's disease;	chr6:28046076	chr6:28170845~28172521:+
PRAD	cis	rs10463554	0.927	rs185387	ENSG00000175749.11	EIF3KP1	8.47	3.45e-16	2e-13	0.48	0.37	Parkinson's disease;	chr5:103084315	chr5:103032376~103033031:+
PRAD	cis	rs10463554	0.927	rs257315	ENSG00000175749.11	EIF3KP1	8.47	3.45e-16	2e-13	0.48	0.37	Parkinson's disease;	chr5:103085725	chr5:103032376~103033031:+
PRAD	cis	rs1555322	0.505	rs2254207	ENSG00000126005.14	MMP24-AS1	-8.47	3.45e-16	2e-13	-0.43	-0.37	Attention deficit hyperactivity disorder;	chr20:35269908	chr20:35216462~35278131:-
PRAD	cis	rs11098499	0.954	rs1480931	ENSG00000245958.5	RP11-33B1.1	-8.47	3.45e-16	2.01e-13	-0.37	-0.37	Corneal astigmatism;	chr4:119474654	chr4:119454791~119552025:+
PRAD	cis	rs1075232	1	rs67634762	ENSG00000270055.1	CTD-3092A11.2	-8.47	3.46e-16	2.01e-13	-0.73	-0.37	Survival in colorectal cancer (non-distant metastatic);	chr15:31455852	chr15:30487963~30490313:+
PRAD	cis	rs9341835	0.542	rs4710430	ENSG00000218048.2	RP3-407E4.4	8.47	3.47e-16	2.01e-13	0.43	0.37	Schizophrenia;	chr6:63455439	chr6:63440766~63443580:+
PRAD	cis	rs11951515	0.663	rs6451684	ENSG00000188850.9	RP11-159F24.2	-8.47	3.48e-16	2.02e-13	-0.45	-0.37	Metabolite levels  (X-11787);	chr5:43319545	chr5:43336164~43348716:+
PRAD	cis	rs950169	0.845	rs4106951	ENSG00000225151.9	GOLGA2P7	-8.47	3.49e-16	2.03e-13	-0.52	-0.37	Schizophrenia;	chr15:84164642	chr15:84199311~84230136:-
PRAD	cis	rs9309473	0.687	rs7576824	ENSG00000163016.8	ALMS1P	-8.47	3.49e-16	2.03e-13	-0.45	-0.37	Metabolite levels;	chr2:73384153	chr2:73644919~73685576:+
PRAD	cis	rs11096990	0.593	rs7685619	ENSG00000249207.1	RP11-360F5.1	-8.47	3.49e-16	2.03e-13	-0.39	-0.37	Cognitive function;	chr4:39211779	chr4:39112677~39126818:-
PRAD	cis	rs2739330	0.929	rs5751775	ENSG00000206090.4	AP000350.7	8.47	3.49e-16	2.03e-13	0.47	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23939998~23942798:+
PRAD	cis	rs7432375	0.899	rs6439655	ENSG00000261758.1	RP11-102M11.2	-8.47	3.5e-16	2.03e-13	-0.41	-0.37	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136747757	chr3:136752630~136755780:+
PRAD	cis	rs9341835	0.709	rs9359467	ENSG00000218048.2	RP3-407E4.4	8.47	3.5e-16	2.03e-13	0.41	0.37	Schizophrenia;	chr6:63445070	chr6:63440766~63443580:+
PRAD	cis	rs9341835	0.74	rs4710255	ENSG00000218048.2	RP3-407E4.4	8.47	3.5e-16	2.03e-13	0.41	0.37	Schizophrenia;	chr6:63446363	chr6:63440766~63443580:+
PRAD	cis	rs17711722	1	rs17711722	ENSG00000236529.1	RP13-254B10.1	-8.47	3.51e-16	2.03e-13	-0.38	-0.37	Calcium levels;	chr7:65806210	chr7:65840212~65840596:+
PRAD	cis	rs17711722	0.675	rs6947132	ENSG00000236529.1	RP13-254B10.1	-8.47	3.51e-16	2.03e-13	-0.38	-0.37	Calcium levels;	chr7:65808508	chr7:65840212~65840596:+
PRAD	cis	rs34779708	0.733	rs16935945	ENSG00000230534.5	RP11-297A16.2	8.47	3.51e-16	2.04e-13	0.49	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35251392	chr10:35098006~35127020:-
PRAD	cis	rs7849270	0.842	rs184457	ENSG00000268707.1	RP11-247A12.7	8.47	3.51e-16	2.04e-13	0.44	0.37	Blood metabolite ratios;	chr9:129177740	chr9:129170434~129170940:+
PRAD	cis	rs2980436	1	rs2980436	ENSG00000253893.2	FAM85B	8.47	3.52e-16	2.04e-13	0.49	0.37	Schizophrenia;	chr8:8234503	chr8:8167819~8226614:-
PRAD	cis	rs4835473	0.897	rs35598237	ENSG00000251600.4	RP11-673E1.1	-8.47	3.52e-16	2.04e-13	-0.47	-0.37	Immature fraction of reticulocytes;	chr4:143735961	chr4:143912331~143982454:+
PRAD	cis	rs10463554	0.963	rs34382	ENSG00000175749.11	EIF3KP1	8.47	3.53e-16	2.04e-13	0.49	0.37	Parkinson's disease;	chr5:103060521	chr5:103032376~103033031:+
PRAD	cis	rs10463554	0.963	rs34380	ENSG00000175749.11	EIF3KP1	8.47	3.53e-16	2.04e-13	0.49	0.37	Parkinson's disease;	chr5:103061245	chr5:103032376~103033031:+
PRAD	cis	rs42648	0.518	rs12535435	ENSG00000227646.6	STEAP2-AS1	-8.47	3.53e-16	2.04e-13	-0.33	-0.37	Homocysteine levels;	chr7:90201503	chr7:89882353~90211635:-
PRAD	cis	rs673078	0.607	rs8467	ENSG00000275409.1	RP11-131L12.4	-8.47	3.53e-16	2.05e-13	-0.52	-0.37	Glucose homeostasis traits;	chr12:118417479	chr12:118430147~118430699:+
PRAD	cis	rs5769707	0.632	rs135872	ENSG00000188511.11	C22orf34	8.47	3.54e-16	2.06e-13	0.42	0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49615652	chr22:49414524~49657542:-
PRAD	cis	rs7923609	0.841	rs2163188	ENSG00000232075.1	MRPL35P2	8.46	3.57e-16	2.07e-13	0.39	0.37	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63554951	chr10:63634317~63634827:-
PRAD	cis	rs7923609	0.871	rs2393984	ENSG00000232075.1	MRPL35P2	8.46	3.57e-16	2.07e-13	0.39	0.37	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63555211	chr10:63634317~63634827:-
PRAD	cis	rs7923609	0.871	rs6479905	ENSG00000232075.1	MRPL35P2	8.46	3.57e-16	2.07e-13	0.39	0.37	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63555471	chr10:63634317~63634827:-
PRAD	cis	rs7923609	0.811	rs7919685	ENSG00000232075.1	MRPL35P2	8.46	3.57e-16	2.07e-13	0.39	0.37	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63556040	chr10:63634317~63634827:-
PRAD	cis	rs7923609	0.749	rs12247907	ENSG00000232075.1	MRPL35P2	8.46	3.57e-16	2.07e-13	0.39	0.37	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63557285	chr10:63634317~63634827:-
PRAD	cis	rs7923609	0.746	rs7070761	ENSG00000232075.1	MRPL35P2	8.46	3.57e-16	2.07e-13	0.39	0.37	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63557296	chr10:63634317~63634827:-
PRAD	cis	rs7923609	0.871	rs7898861	ENSG00000232075.1	MRPL35P2	8.46	3.57e-16	2.07e-13	0.39	0.37	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63559918	chr10:63634317~63634827:-
PRAD	cis	rs9545047	0.584	rs12871015	ENSG00000227676.3	LINC01068	-8.46	3.57e-16	2.07e-13	-0.44	-0.37	Schizophrenia;	chr13:79333564	chr13:79566727~79571436:+
PRAD	cis	rs35160687	0.722	rs6728029	ENSG00000273080.1	RP11-301O19.1	-8.46	3.57e-16	2.07e-13	-0.42	-0.37	Night sleep phenotypes;	chr2:86328258	chr2:86195590~86196049:+
PRAD	cis	rs12142240	0.698	rs56344958	ENSG00000232022.5	FAAHP1	-8.46	3.57e-16	2.07e-13	-0.34	-0.37	Menopause (age at onset);	chr1:46348846	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.583	rs5013330	ENSG00000232022.5	FAAHP1	-8.46	3.57e-16	2.07e-13	-0.34	-0.37	Menopause (age at onset);	chr1:46349482	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs17357683	ENSG00000232022.5	FAAHP1	-8.46	3.57e-16	2.07e-13	-0.34	-0.37	Menopause (age at onset);	chr1:46349706	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs6667861	ENSG00000232022.5	FAAHP1	-8.46	3.57e-16	2.07e-13	-0.34	-0.37	Menopause (age at onset);	chr1:46350077	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs1057534	ENSG00000232022.5	FAAHP1	-8.46	3.57e-16	2.07e-13	-0.34	-0.37	Menopause (age at onset);	chr1:46350208	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs1057535	ENSG00000232022.5	FAAHP1	-8.46	3.57e-16	2.07e-13	-0.34	-0.37	Menopause (age at onset);	chr1:46350226	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs1135459	ENSG00000232022.5	FAAHP1	-8.46	3.57e-16	2.07e-13	-0.34	-0.37	Menopause (age at onset);	chr1:46350258	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs1135460	ENSG00000232022.5	FAAHP1	-8.46	3.57e-16	2.07e-13	-0.34	-0.37	Menopause (age at onset);	chr1:46350298	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs1475390	ENSG00000232022.5	FAAHP1	-8.46	3.57e-16	2.07e-13	-0.34	-0.37	Menopause (age at onset);	chr1:46350668	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs1475389	ENSG00000232022.5	FAAHP1	-8.46	3.57e-16	2.07e-13	-0.34	-0.37	Menopause (age at onset);	chr1:46350757	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs1475388	ENSG00000232022.5	FAAHP1	-8.46	3.57e-16	2.07e-13	-0.34	-0.37	Menopause (age at onset);	chr1:46350793	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs57267378	ENSG00000232022.5	FAAHP1	-8.46	3.57e-16	2.07e-13	-0.34	-0.37	Menopause (age at onset);	chr1:46350972	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs58162700	ENSG00000232022.5	FAAHP1	-8.46	3.57e-16	2.07e-13	-0.34	-0.37	Menopause (age at onset);	chr1:46350987	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs966907	ENSG00000232022.5	FAAHP1	-8.46	3.57e-16	2.07e-13	-0.34	-0.37	Menopause (age at onset);	chr1:46351453	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.621	rs66828173	ENSG00000232022.5	FAAHP1	-8.46	3.57e-16	2.07e-13	-0.34	-0.37	Menopause (age at onset);	chr1:46352494	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.659	rs72677591	ENSG00000232022.5	FAAHP1	-8.46	3.57e-16	2.07e-13	-0.34	-0.37	Menopause (age at onset);	chr1:46352547	chr1:46432129~46445521:+
PRAD	cis	rs17608059	0.545	rs736261	ENSG00000141028.6	CDRT15P1	-8.46	3.59e-16	2.08e-13	-0.47	-0.37	Temperament;	chr17:14033087	chr17:14024514~14025488:+
PRAD	cis	rs4927850	0.723	rs7630825	ENSG00000207650.1	MIR570	8.46	3.59e-16	2.08e-13	0.39	0.37	Pancreatic cancer;	chr3:196026869	chr3:195699401~195699497:+
PRAD	cis	rs4713118	0.955	rs9393848	ENSG00000280107.1	AL022393.9	-8.46	3.59e-16	2.08e-13	-0.46	-0.37	Parkinson's disease;	chr6:27720590	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.955	rs9468204	ENSG00000280107.1	AL022393.9	-8.46	3.59e-16	2.08e-13	-0.46	-0.37	Parkinson's disease;	chr6:27721030	chr6:28170845~28172521:+
PRAD	cis	rs950169	0.922	rs4586394	ENSG00000225151.9	GOLGA2P7	8.46	3.6e-16	2.09e-13	0.53	0.37	Schizophrenia;	chr15:84153633	chr15:84199311~84230136:-
PRAD	cis	rs2729354	0.693	rs2584862	ENSG00000265566.2	RN7SL605P	-8.46	3.61e-16	2.09e-13	-0.56	-0.37	Blood protein levels;	chr11:57474483	chr11:57528085~57528365:-
PRAD	cis	rs2933343	0.621	rs6764682	ENSG00000231305.3	RP11-723O4.2	-8.46	3.61e-16	2.09e-13	-0.35	-0.37	IgG glycosylation;	chr3:128849540	chr3:128861313~128871540:-
PRAD	cis	rs950169	0.92	rs2135551	ENSG00000225151.9	GOLGA2P7	-8.46	3.61e-16	2.09e-13	-0.51	-0.37	Schizophrenia;	chr15:84039099	chr15:84199311~84230136:-
PRAD	cis	rs950169	1	rs12902672	ENSG00000225151.9	GOLGA2P7	-8.46	3.61e-16	2.09e-13	-0.51	-0.37	Schizophrenia;	chr15:84048234	chr15:84199311~84230136:-
PRAD	cis	rs11083475	1	rs8107416	ENSG00000267892.1	CTD-2540F13.2	8.46	3.61e-16	2.09e-13	0.4	0.37	Heart rate;	chr19:38747310	chr19:38738284~38739863:+
PRAD	cis	rs4835473	0.897	rs7681903	ENSG00000251600.4	RP11-673E1.1	-8.46	3.61e-16	2.09e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143759326	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.897	rs7656753	ENSG00000251600.4	RP11-673E1.1	-8.46	3.61e-16	2.09e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143759414	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.897	rs7656786	ENSG00000251600.4	RP11-673E1.1	-8.46	3.61e-16	2.09e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143759455	chr4:143912331~143982454:+
PRAD	cis	rs10740039	0.583	rs9415608	ENSG00000254271.1	RP11-131N11.4	-8.46	3.62e-16	2.1e-13	-0.52	-0.37	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60737680	chr10:60734342~60741828:+
PRAD	cis	rs6452524	1	rs6452519	ENSG00000249664.1	CTD-2227C6.2	8.46	3.63e-16	2.1e-13	0.43	0.37	Hypertension (SNP x SNP interaction);	chr5:83133429	chr5:83012285~83013109:-
PRAD	cis	rs8081395	0.801	rs2777895	ENSG00000266992.1	DHX40P1	-8.46	3.63e-16	2.11e-13	-0.41	-0.37	White blood cell count;	chr17:59802249	chr17:59976009~60002384:-
PRAD	cis	rs8081395	0.769	rs12449331	ENSG00000266992.1	DHX40P1	-8.46	3.63e-16	2.11e-13	-0.41	-0.37	White blood cell count;	chr17:59806285	chr17:59976009~60002384:-
PRAD	cis	rs2739330	0.929	rs5751777	ENSG00000206090.4	AP000350.7	8.46	3.64e-16	2.11e-13	0.47	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23939998~23942798:+
PRAD	cis	rs875971	0.522	rs781144	ENSG00000236529.1	RP13-254B10.1	8.46	3.65e-16	2.11e-13	0.38	0.37	Aortic root size;	chr7:65975357	chr7:65840212~65840596:+
PRAD	cis	rs7739264	0.564	rs760794	ENSG00000228412.5	RP4-625H18.2	8.46	3.65e-16	2.12e-13	0.44	0.37	Endometriosis;	chr6:19790329	chr6:19802164~19804752:-
PRAD	cis	rs7829975	0.688	rs13270194	ENSG00000253893.2	FAM85B	-8.46	3.66e-16	2.12e-13	-0.43	-0.37	Mood instability;	chr8:8520592	chr8:8167819~8226614:-
PRAD	cis	rs526231	0.578	rs42860	ENSG00000175749.11	EIF3KP1	8.46	3.66e-16	2.12e-13	0.49	0.37	Primary biliary cholangitis;	chr5:103092414	chr5:103032376~103033031:+
PRAD	cis	rs10463554	0.927	rs34806	ENSG00000175749.11	EIF3KP1	8.46	3.66e-16	2.12e-13	0.49	0.37	Parkinson's disease;	chr5:103092733	chr5:103032376~103033031:+
PRAD	cis	rs875971	0.522	rs1880556	ENSG00000236529.1	RP13-254B10.1	8.46	3.66e-16	2.12e-13	0.38	0.37	Aortic root size;	chr7:65967557	chr7:65840212~65840596:+
PRAD	cis	rs507080	0.769	rs570836	ENSG00000255422.1	AP002954.4	-8.46	3.67e-16	2.13e-13	-0.45	-0.37	Serum metabolite levels;	chr11:118641444	chr11:118704607~118750263:+
PRAD	cis	rs1930961	1	rs6004668	ENSG00000271138.1	IGLVIVOR22-1	8.46	3.68e-16	2.13e-13	0.56	0.37	Bipolar disorder with mood-incongruent psychosis;	chr22:25478535	chr22:25437306~25437823:-
PRAD	cis	rs7826238	0.535	rs2979179	ENSG00000253893.2	FAM85B	-8.46	3.68e-16	2.13e-13	-0.44	-0.37	Systolic blood pressure;	chr8:8462519	chr8:8167819~8226614:-
PRAD	cis	rs7131987	0.65	rs7301398	ENSG00000257176.2	RP11-996F15.2	-8.46	3.68e-16	2.13e-13	-0.4	-0.37	QT interval;	chr12:29302457	chr12:29280418~29317848:-
PRAD	cis	rs7131987	0.65	rs7301188	ENSG00000257176.2	RP11-996F15.2	-8.46	3.68e-16	2.13e-13	-0.4	-0.37	QT interval;	chr12:29302458	chr12:29280418~29317848:-
PRAD	cis	rs6844153	0.887	rs62302535	ENSG00000240005.4	RP11-293A21.1	-8.46	3.7e-16	2.14e-13	-0.52	-0.37	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26957254	chr4:26859806~26860599:-
PRAD	cis	rs10129255	0.536	rs17113249	ENSG00000211972.2	IGHV3-66	8.46	3.71e-16	2.15e-13	0.32	0.37	Kawasaki disease;	chr14:106678273	chr14:106675017~106675544:-
PRAD	cis	rs10129255	0.5	rs2105991	ENSG00000211972.2	IGHV3-66	8.46	3.71e-16	2.15e-13	0.32	0.37	Kawasaki disease;	chr14:106682022	chr14:106675017~106675544:-
PRAD	cis	rs11098499	0.863	rs59732491	ENSG00000245958.5	RP11-33B1.1	-8.46	3.72e-16	2.15e-13	-0.37	-0.37	Corneal astigmatism;	chr4:119568433	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.863	rs11723090	ENSG00000245958.5	RP11-33B1.1	-8.46	3.72e-16	2.15e-13	-0.37	-0.37	Corneal astigmatism;	chr4:119569437	chr4:119454791~119552025:+
PRAD	cis	rs2739330	0.731	rs2000468	ENSG00000272787.1	KB-226F1.2	-8.46	3.73e-16	2.16e-13	-0.4	-0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23969211~23969873:+
PRAD	cis	rs2929278	0.736	rs2412823	ENSG00000249839.1	AC011330.5	8.46	3.76e-16	2.18e-13	0.46	0.37	Schizophrenia;	chr15:43935072	chr15:43663654~43684339:-
PRAD	cis	rs7727544	0.544	rs55722650	ENSG00000233006.5	AC034220.3	8.46	3.77e-16	2.18e-13	0.34	0.37	Blood metabolite levels;	chr5:132271607	chr5:132311285~132369916:-
PRAD	cis	rs9810089	0.786	rs10935183	ENSG00000261758.1	RP11-102M11.2	8.46	3.77e-16	2.18e-13	0.42	0.37	Gestational age at birth (child effect);	chr3:136430297	chr3:136752630~136755780:+
PRAD	cis	rs875971	0.522	rs4718286	ENSG00000236529.1	RP13-254B10.1	8.46	3.77e-16	2.18e-13	0.38	0.37	Aortic root size;	chr7:65827777	chr7:65840212~65840596:+
PRAD	cis	rs17711722	0.585	rs6942660	ENSG00000236529.1	RP13-254B10.1	8.46	3.77e-16	2.18e-13	0.38	0.37	Calcium levels;	chr7:65837419	chr7:65840212~65840596:+
PRAD	cis	rs2015599	0.623	rs7313552	ENSG00000275476.1	RP11-996F15.4	8.46	3.77e-16	2.18e-13	0.4	0.37	Platelet count;Mean platelet volume;	chr12:29277302	chr12:29277397~29277882:-
PRAD	cis	rs2015599	0.584	rs7299283	ENSG00000275476.1	RP11-996F15.4	8.46	3.77e-16	2.18e-13	0.4	0.37	Platelet count;Mean platelet volume;	chr12:29277442	chr12:29277397~29277882:-
PRAD	cis	rs4713118	0.662	rs149946	ENSG00000219392.1	RP1-265C24.5	8.46	3.78e-16	2.18e-13	0.48	0.37	Parkinson's disease;	chr6:28002253	chr6:28115628~28116551:+
PRAD	cis	rs4713118	0.662	rs149947	ENSG00000219392.1	RP1-265C24.5	-8.46	3.78e-16	2.18e-13	-0.48	-0.37	Parkinson's disease;	chr6:28004655	chr6:28115628~28116551:+
PRAD	cis	rs4713118	0.662	rs149969	ENSG00000219392.1	RP1-265C24.5	-8.46	3.78e-16	2.18e-13	-0.48	-0.37	Parkinson's disease;	chr6:28009959	chr6:28115628~28116551:+
PRAD	cis	rs6847067	0.727	rs17009341	ENSG00000180769.7	WDFY3-AS2	8.46	3.78e-16	2.18e-13	0.38	0.37	Oropharynx cancer;	chr4:84923963	chr4:84965682~85011277:+
PRAD	cis	rs853679	0.55	rs1225598	ENSG00000272009.1	RP1-313I6.12	-8.46	3.79e-16	2.19e-13	-0.37	-0.37	Depression;	chr6:28193021	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.55	rs1150689	ENSG00000272009.1	RP1-313I6.12	-8.46	3.79e-16	2.19e-13	-0.37	-0.37	Depression;	chr6:28197321	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.55	rs1225599	ENSG00000272009.1	RP1-313I6.12	-8.46	3.79e-16	2.19e-13	-0.37	-0.37	Depression;	chr6:28197412	chr6:28078792~28081130:-
PRAD	cis	rs853679	0.574	rs1233705	ENSG00000272009.1	RP1-313I6.12	-8.46	3.79e-16	2.19e-13	-0.37	-0.37	Depression;	chr6:28198669	chr6:28078792~28081130:-
PRAD	cis	rs7811142	1	rs11771241	ENSG00000242294.5	STAG3L5P	8.46	3.8e-16	2.2e-13	0.25	0.37	Platelet count;	chr7:100397162	chr7:100336079~100351900:+
PRAD	cis	rs67311347	0.911	rs6773917	ENSG00000223797.4	ENTPD3-AS1	8.46	3.8e-16	2.2e-13	0.33	0.37	Renal cell carcinoma;	chr3:40427763	chr3:40313802~40453329:-
PRAD	cis	rs4835473	0.932	rs1993015	ENSG00000251600.4	RP11-673E1.1	-8.46	3.81e-16	2.2e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143760202	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.9	rs1993016	ENSG00000251600.4	RP11-673E1.1	-8.46	3.81e-16	2.2e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143760217	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs1993017	ENSG00000251600.4	RP11-673E1.1	-8.46	3.81e-16	2.2e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143760285	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.9	rs1375983	ENSG00000251600.4	RP11-673E1.1	-8.46	3.81e-16	2.2e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143760423	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs1375984	ENSG00000251600.4	RP11-673E1.1	-8.46	3.81e-16	2.2e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143760510	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs1375985	ENSG00000251600.4	RP11-673E1.1	-8.46	3.81e-16	2.2e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143760556	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs17018200	ENSG00000251600.4	RP11-673E1.1	-8.46	3.81e-16	2.2e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143760866	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs11100805	ENSG00000251600.4	RP11-673E1.1	-8.46	3.81e-16	2.2e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143760979	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.868	rs56115009	ENSG00000251600.4	RP11-673E1.1	-8.46	3.81e-16	2.2e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143761073	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.9	rs10857406	ENSG00000251600.4	RP11-673E1.1	-8.46	3.81e-16	2.2e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143761216	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs10857407	ENSG00000251600.4	RP11-673E1.1	-8.46	3.81e-16	2.2e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143761226	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs10857408	ENSG00000251600.4	RP11-673E1.1	-8.46	3.81e-16	2.2e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143761333	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.9	rs10857409	ENSG00000251600.4	RP11-673E1.1	-8.46	3.81e-16	2.2e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143761461	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs10857410	ENSG00000251600.4	RP11-673E1.1	-8.46	3.81e-16	2.2e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143761566	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs10857411	ENSG00000251600.4	RP11-673E1.1	-8.46	3.81e-16	2.2e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143761599	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs1006406	ENSG00000251600.4	RP11-673E1.1	-8.46	3.81e-16	2.2e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143761710	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs1562776	ENSG00000251600.4	RP11-673E1.1	-8.46	3.81e-16	2.2e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143761999	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs34697602	ENSG00000251600.4	RP11-673E1.1	-8.46	3.81e-16	2.2e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143762499	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs34618381	ENSG00000251600.4	RP11-673E1.1	-8.46	3.81e-16	2.2e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143762612	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs11100808	ENSG00000251600.4	RP11-673E1.1	-8.46	3.81e-16	2.2e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143762728	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs7661407	ENSG00000251600.4	RP11-673E1.1	-8.46	3.81e-16	2.2e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143762982	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.9	rs4285038	ENSG00000251600.4	RP11-673E1.1	-8.46	3.81e-16	2.2e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143763637	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs1562777	ENSG00000251600.4	RP11-673E1.1	-8.46	3.81e-16	2.2e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143763676	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs1562778	ENSG00000251600.4	RP11-673E1.1	-8.46	3.81e-16	2.2e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143763816	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs1562779	ENSG00000251600.4	RP11-673E1.1	-8.46	3.81e-16	2.2e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143763999	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs1597441	ENSG00000251600.4	RP11-673E1.1	-8.46	3.81e-16	2.2e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143764158	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs1597442	ENSG00000251600.4	RP11-673E1.1	-8.46	3.81e-16	2.2e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143764359	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs1597443	ENSG00000251600.4	RP11-673E1.1	-8.46	3.81e-16	2.2e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143764406	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs1597444	ENSG00000251600.4	RP11-673E1.1	-8.46	3.81e-16	2.2e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143764547	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.9	rs60038202	ENSG00000251600.4	RP11-673E1.1	-8.46	3.81e-16	2.2e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143764662	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs34886773	ENSG00000251600.4	RP11-673E1.1	-8.46	3.81e-16	2.2e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143764678	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs1450230	ENSG00000251600.4	RP11-673E1.1	-8.46	3.81e-16	2.2e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143765118	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.9	rs72946226	ENSG00000251600.4	RP11-673E1.1	-8.46	3.81e-16	2.2e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143765238	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs34230433	ENSG00000251600.4	RP11-673E1.1	-8.46	3.81e-16	2.2e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143765253	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs7696869	ENSG00000251600.4	RP11-673E1.1	-8.46	3.81e-16	2.2e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143765855	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs7698287	ENSG00000251600.4	RP11-673E1.1	-8.46	3.81e-16	2.2e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143765859	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs11721495	ENSG00000251600.4	RP11-673E1.1	-8.46	3.81e-16	2.2e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143767216	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.9	rs7689374	ENSG00000251600.4	RP11-673E1.1	-8.46	3.81e-16	2.2e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143769567	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs6537183	ENSG00000251600.4	RP11-673E1.1	-8.46	3.81e-16	2.2e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143770441	chr4:143912331~143982454:+
PRAD	cis	rs42648	0.693	rs194533	ENSG00000227646.6	STEAP2-AS1	-8.46	3.81e-16	2.2e-13	-0.34	-0.37	Homocysteine levels;	chr7:90241463	chr7:89882353~90211635:-
PRAD	cis	rs2019137	0.936	rs902696	ENSG00000274877.1	RP11-65I12.1	-8.45	3.82e-16	2.21e-13	-0.46	-0.37	Lymphocyte counts;	chr2:113197302	chr2:113237595~113240825:+
PRAD	cis	rs9309473	0.687	rs12465867	ENSG00000163016.8	ALMS1P	8.45	3.83e-16	2.21e-13	0.44	0.37	Metabolite levels;	chr2:73384974	chr2:73644919~73685576:+
PRAD	cis	rs9309473	0.583	rs35885918	ENSG00000163016.8	ALMS1P	8.45	3.83e-16	2.21e-13	0.44	0.37	Metabolite levels;	chr2:73385106	chr2:73644919~73685576:+
PRAD	cis	rs10050311	0.79	rs72667716	ENSG00000251411.1	RP11-397E7.4	-8.45	3.85e-16	2.22e-13	-0.46	-0.37	Insulin-related traits;	chr4:86912775	chr4:86913266~86914817:-
PRAD	cis	rs858239	0.669	rs6461688	ENSG00000226816.2	AC005082.12	8.45	3.85e-16	2.22e-13	0.42	0.37	Cerebrospinal fluid biomarker levels;	chr7:23076996	chr7:23206013~23208045:+
PRAD	cis	rs2739330	0.796	rs5760106	ENSG00000224205.1	AP000351.4	-8.45	3.85e-16	2.22e-13	-0.46	-0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23987320~23991421:-
PRAD	cis	rs4713118	0.699	rs200978	ENSG00000226314.6	ZNF192P1	-8.45	3.85e-16	2.22e-13	-0.51	-0.37	Parkinson's disease;	chr6:27885390	chr6:28161781~28169594:+
PRAD	cis	rs7772486	0.837	rs2474354	ENSG00000235652.6	RP11-545I5.3	8.45	3.85e-16	2.22e-13	0.37	0.37	Lobe attachment (rater-scored or self-reported);	chr6:146002659	chr6:145799409~145886585:+
PRAD	cis	rs5760092	0.572	rs738806	ENSG00000273295.1	AP000350.5	8.45	3.85e-16	2.22e-13	0.5	0.37	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23901432~23907068:-
PRAD	cis	rs34779708	0.733	rs12249814	ENSG00000230534.5	RP11-297A16.2	8.45	3.86e-16	2.23e-13	0.49	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35253829	chr10:35098006~35127020:-
PRAD	cis	rs10463554	0.927	rs158250	ENSG00000175749.11	EIF3KP1	8.45	3.86e-16	2.23e-13	0.48	0.37	Parkinson's disease;	chr5:103071075	chr5:103032376~103033031:+
PRAD	cis	rs10463554	0.927	rs464702	ENSG00000175749.11	EIF3KP1	8.45	3.86e-16	2.23e-13	0.48	0.37	Parkinson's disease;	chr5:103071180	chr5:103032376~103033031:+
PRAD	cis	rs10463554	0.927	rs158396	ENSG00000175749.11	EIF3KP1	8.45	3.86e-16	2.23e-13	0.48	0.37	Parkinson's disease;	chr5:103076015	chr5:103032376~103033031:+
PRAD	cis	rs4835473	0.932	rs11100806	ENSG00000251600.4	RP11-673E1.1	8.45	3.86e-16	2.23e-13	0.47	0.37	Immature fraction of reticulocytes;	chr4:143761006	chr4:143912331~143982454:+
PRAD	cis	rs7131987	0.65	rs11050187	ENSG00000257176.2	RP11-996F15.2	-8.45	3.88e-16	2.24e-13	-0.4	-0.37	QT interval;	chr12:29319943	chr12:29280418~29317848:-
PRAD	cis	rs1979679	0.842	rs35098487	ENSG00000278733.1	RP11-425D17.1	8.45	3.89e-16	2.24e-13	0.47	0.37	Ossification of the posterior longitudinal ligament of the spine;	chr12:28191043	chr12:28185625~28186190:-
PRAD	cis	rs11096990	0.551	rs2060005	ENSG00000249207.1	RP11-360F5.1	-8.45	3.9e-16	2.25e-13	-0.39	-0.37	Cognitive function;	chr4:39160901	chr4:39112677~39126818:-
PRAD	cis	rs10463554	0.927	rs257312	ENSG00000175749.11	EIF3KP1	8.45	3.9e-16	2.25e-13	0.48	0.37	Parkinson's disease;	chr5:103083923	chr5:103032376~103033031:+
PRAD	cis	rs10463554	0.892	rs257313	ENSG00000175749.11	EIF3KP1	8.45	3.9e-16	2.25e-13	0.48	0.37	Parkinson's disease;	chr5:103084943	chr5:103032376~103033031:+
PRAD	cis	rs6847067	0.8	rs12506456	ENSG00000180769.7	WDFY3-AS2	8.45	3.91e-16	2.26e-13	0.38	0.37	Oropharynx cancer;	chr4:84937095	chr4:84965682~85011277:+
PRAD	cis	rs6847067	0.8	rs12503215	ENSG00000180769.7	WDFY3-AS2	8.45	3.91e-16	2.26e-13	0.38	0.37	Oropharynx cancer;	chr4:84937335	chr4:84965682~85011277:+
PRAD	cis	rs7615952	0.688	rs9754526	ENSG00000171084.14	FAM86JP	8.45	3.92e-16	2.26e-13	0.57	0.37	Blood pressure (smoking interaction);	chr3:125824023	chr3:125916620~125930024:+
PRAD	cis	rs950169	0.922	rs62029585	ENSG00000259728.4	LINC00933	8.45	3.93e-16	2.27e-13	0.46	0.37	Schizophrenia;	chr15:84397176	chr15:84570649~84580175:+
PRAD	cis	rs10463554	0.667	rs57714862	ENSG00000175749.11	EIF3KP1	8.45	3.93e-16	2.27e-13	0.48	0.37	Parkinson's disease;	chr5:103047025	chr5:103032376~103033031:+
PRAD	cis	rs7746199	0.736	rs34573979	ENSG00000280107.1	AL022393.9	-8.45	3.93e-16	2.27e-13	-0.75	-0.37	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27512747	chr6:28170845~28172521:+
PRAD	cis	rs4713118	0.662	rs464312	ENSG00000226314.6	ZNF192P1	-8.45	3.94e-16	2.27e-13	-0.49	-0.37	Parkinson's disease;	chr6:27999813	chr6:28161781~28169594:+
PRAD	cis	rs4713118	0.662	rs469228	ENSG00000226314.6	ZNF192P1	-8.45	3.94e-16	2.27e-13	-0.49	-0.37	Parkinson's disease;	chr6:28002926	chr6:28161781~28169594:+
PRAD	cis	rs4713118	0.54	rs469227	ENSG00000226314.6	ZNF192P1	-8.45	3.94e-16	2.27e-13	-0.49	-0.37	Parkinson's disease;	chr6:28002927	chr6:28161781~28169594:+
PRAD	cis	rs4713118	0.662	rs149948	ENSG00000226314.6	ZNF192P1	-8.45	3.94e-16	2.27e-13	-0.49	-0.37	Parkinson's disease;	chr6:28007039	chr6:28161781~28169594:+
PRAD	cis	rs875971	0.505	rs2462573	ENSG00000236529.1	RP13-254B10.1	-8.45	3.94e-16	2.27e-13	-0.38	-0.37	Aortic root size;	chr7:66042405	chr7:65840212~65840596:+
PRAD	cis	rs875971	0.505	rs1167386	ENSG00000236529.1	RP13-254B10.1	-8.45	3.94e-16	2.27e-13	-0.38	-0.37	Aortic root size;	chr7:66048109	chr7:65840212~65840596:+
PRAD	cis	rs853679	0.882	rs9393908	ENSG00000280107.1	AL022393.9	-8.45	3.96e-16	2.28e-13	-0.62	-0.37	Depression;	chr6:28223052	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.882	rs9366717	ENSG00000280107.1	AL022393.9	-8.45	3.96e-16	2.28e-13	-0.62	-0.37	Depression;	chr6:28223279	chr6:28170845~28172521:+
PRAD	cis	rs2946504	0.553	rs2946498	ENSG00000251468.2	RP11-369K16.1	-8.45	3.96e-16	2.28e-13	-0.45	-0.37	Type 2 diabetes;	chr8:12960578	chr8:12958387~12962200:+
PRAD	cis	rs11098499	0.687	rs71610270	ENSG00000245958.5	RP11-33B1.1	-8.45	3.96e-16	2.28e-13	-0.35	-0.37	Corneal astigmatism;	chr4:119366281	chr4:119454791~119552025:+
PRAD	cis	rs875971	0.54	rs1723268	ENSG00000236529.1	RP13-254B10.1	8.45	3.96e-16	2.28e-13	0.38	0.37	Aortic root size;	chr7:66008093	chr7:65840212~65840596:+
PRAD	cis	rs9810089	0.814	rs866758	ENSG00000261758.1	RP11-102M11.2	8.45	3.98e-16	2.29e-13	0.42	0.37	Gestational age at birth (child effect);	chr3:136399028	chr3:136752630~136755780:+
PRAD	cis	rs34779708	0.733	rs7087099	ENSG00000230534.5	RP11-297A16.2	8.45	3.98e-16	2.3e-13	0.49	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35253054	chr10:35098006~35127020:-
PRAD	cis	rs9532669	0.926	rs12428966	ENSG00000168852.11	TPTE2P5	8.45	3.99e-16	2.3e-13	0.35	0.37	Cervical cancer;	chr13:40876552	chr13:40822296~40921749:-
PRAD	cis	rs875971	0.505	rs6955582	ENSG00000236529.1	RP13-254B10.1	8.45	4e-16	2.3e-13	0.38	0.37	Aortic root size;	chr7:65966699	chr7:65840212~65840596:+
PRAD	cis	rs6991838	0.55	rs4737750	ENSG00000200714.1	Y_RNA	8.45	4e-16	2.3e-13	0.4	0.37	Intelligence (multi-trait analysis);	chr8:65638724	chr8:65592731~65592820:+
PRAD	cis	rs9341835	0.681	rs9352960	ENSG00000218048.2	RP3-407E4.4	8.45	4e-16	2.31e-13	0.4	0.37	Schizophrenia;	chr6:63440521	chr6:63440766~63443580:+
PRAD	cis	rs9341835	0.74	rs10755410	ENSG00000218048.2	RP3-407E4.4	8.45	4e-16	2.31e-13	0.4	0.37	Schizophrenia;	chr6:63440784	chr6:63440766~63443580:+
PRAD	cis	rs9341835	0.74	rs9294215	ENSG00000218048.2	RP3-407E4.4	8.45	4e-16	2.31e-13	0.4	0.37	Schizophrenia;	chr6:63441866	chr6:63440766~63443580:+
PRAD	cis	rs760794	0.729	rs2206033	ENSG00000228412.5	RP4-625H18.2	8.45	4.03e-16	2.32e-13	0.43	0.37	Endometriosis;	chr6:19796647	chr6:19802164~19804752:-
PRAD	cis	rs7829975	0.511	rs2955578	ENSG00000253893.2	FAM85B	-8.45	4.04e-16	2.32e-13	-0.46	-0.37	Mood instability;	chr8:8279561	chr8:8167819~8226614:-
PRAD	cis	rs875971	0.522	rs4718285	ENSG00000236529.1	RP13-254B10.1	8.45	4.04e-16	2.32e-13	0.38	0.37	Aortic root size;	chr7:65827018	chr7:65840212~65840596:+
PRAD	cis	rs875971	0.516	rs6945322	ENSG00000236529.1	RP13-254B10.1	8.45	4.04e-16	2.33e-13	0.38	0.37	Aortic root size;	chr7:65871069	chr7:65840212~65840596:+
PRAD	cis	rs17711722	0.701	rs55773927	ENSG00000236529.1	RP13-254B10.1	8.45	4.04e-16	2.33e-13	0.38	0.37	Calcium levels;	chr7:65872915	chr7:65840212~65840596:+
PRAD	cis	rs17711722	0.727	rs35850374	ENSG00000236529.1	RP13-254B10.1	8.45	4.04e-16	2.33e-13	0.38	0.37	Calcium levels;	chr7:65892789	chr7:65840212~65840596:+
PRAD	cis	rs10463554	0.927	rs34811	ENSG00000175749.11	EIF3KP1	8.45	4.05e-16	2.33e-13	0.49	0.37	Parkinson's disease;	chr5:103096117	chr5:103032376~103033031:+
PRAD	cis	rs4835473	0.932	rs6853676	ENSG00000251600.4	RP11-673E1.1	-8.45	4.05e-16	2.33e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143750495	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs6848393	ENSG00000251600.4	RP11-673E1.1	-8.45	4.05e-16	2.33e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143750537	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs971390	ENSG00000251600.4	RP11-673E1.1	-8.45	4.05e-16	2.33e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143751264	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.868	rs971391	ENSG00000251600.4	RP11-673E1.1	-8.45	4.05e-16	2.33e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143751324	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs971392	ENSG00000251600.4	RP11-673E1.1	-8.45	4.05e-16	2.33e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143751384	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.838	rs35978782	ENSG00000251600.4	RP11-673E1.1	-8.45	4.05e-16	2.33e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143751713	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs34060266	ENSG00000251600.4	RP11-673E1.1	-8.45	4.05e-16	2.33e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143751766	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs13139419	ENSG00000251600.4	RP11-673E1.1	-8.45	4.05e-16	2.33e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143751862	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.868	rs13106052	ENSG00000251600.4	RP11-673E1.1	-8.45	4.05e-16	2.33e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143751995	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs13134401	ENSG00000251600.4	RP11-673E1.1	-8.45	4.05e-16	2.33e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143752008	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs13106287	ENSG00000251600.4	RP11-673E1.1	-8.45	4.05e-16	2.33e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143752091	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs13134679	ENSG00000251600.4	RP11-673E1.1	-8.45	4.05e-16	2.33e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143752187	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs13108134	ENSG00000251600.4	RP11-673E1.1	-8.45	4.05e-16	2.33e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143752213	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.9	rs34406317	ENSG00000251600.4	RP11-673E1.1	-8.45	4.05e-16	2.33e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143752237	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs35863996	ENSG00000251600.4	RP11-673E1.1	-8.45	4.05e-16	2.33e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143752260	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs6836896	ENSG00000251600.4	RP11-673E1.1	-8.45	4.05e-16	2.33e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143752404	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs2874983	ENSG00000251600.4	RP11-673E1.1	-8.45	4.05e-16	2.33e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143752589	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs2874984	ENSG00000251600.4	RP11-673E1.1	-8.45	4.05e-16	2.33e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143752622	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.9	rs2323192	ENSG00000251600.4	RP11-673E1.1	-8.45	4.05e-16	2.33e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143752646	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs2323193	ENSG00000251600.4	RP11-673E1.1	-8.45	4.05e-16	2.33e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143752812	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs34152627	ENSG00000251600.4	RP11-673E1.1	-8.45	4.05e-16	2.33e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143753205	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs35670108	ENSG00000251600.4	RP11-673E1.1	-8.45	4.05e-16	2.33e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143753280	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.9	rs6832005	ENSG00000251600.4	RP11-673E1.1	-8.45	4.05e-16	2.33e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143754284	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.838	rs55963933	ENSG00000251600.4	RP11-673E1.1	-8.45	4.05e-16	2.33e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143755048	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.868	rs35243309	ENSG00000251600.4	RP11-673E1.1	-8.45	4.05e-16	2.33e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143755116	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.9	rs34790336	ENSG00000251600.4	RP11-673E1.1	-8.45	4.05e-16	2.33e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143755284	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs35740243	ENSG00000251600.4	RP11-673E1.1	-8.45	4.05e-16	2.33e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143755395	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs4395452	ENSG00000251600.4	RP11-673E1.1	-8.45	4.05e-16	2.33e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143755678	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.741	rs6537180	ENSG00000251600.4	RP11-673E1.1	-8.45	4.05e-16	2.33e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143755984	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.741	rs6537181	ENSG00000251600.4	RP11-673E1.1	-8.45	4.05e-16	2.33e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143755995	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.9	rs6814065	ENSG00000251600.4	RP11-673E1.1	-8.45	4.05e-16	2.33e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143756233	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.9	rs6816347	ENSG00000251600.4	RP11-673E1.1	-8.45	4.05e-16	2.33e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143756674	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.808	rs6847256	ENSG00000251600.4	RP11-673E1.1	-8.45	4.05e-16	2.33e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143757032	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.868	rs57413073	ENSG00000251600.4	RP11-673E1.1	-8.45	4.05e-16	2.33e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143757852	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs34732468	ENSG00000251600.4	RP11-673E1.1	-8.45	4.05e-16	2.33e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143758009	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs12510395	ENSG00000251600.4	RP11-673E1.1	-8.45	4.05e-16	2.33e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143758107	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs12513087	ENSG00000251600.4	RP11-673E1.1	-8.45	4.05e-16	2.33e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143758551	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs12513119	ENSG00000251600.4	RP11-673E1.1	-8.45	4.05e-16	2.33e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143758619	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs12513130	ENSG00000251600.4	RP11-673E1.1	-8.45	4.05e-16	2.33e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143758666	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.868	rs7681891	ENSG00000251600.4	RP11-673E1.1	-8.45	4.05e-16	2.33e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143759289	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.771	rs34069296	ENSG00000251600.4	RP11-673E1.1	-8.45	4.05e-16	2.33e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143759656	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.897	rs7687915	ENSG00000251600.4	RP11-673E1.1	-8.45	4.05e-16	2.33e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143759801	chr4:143912331~143982454:+
PRAD	cis	rs2946504	0.553	rs2977078	ENSG00000251468.2	RP11-369K16.1	-8.45	4.05e-16	2.33e-13	-0.45	-0.37	Type 2 diabetes;	chr8:12959997	chr8:12958387~12962200:+
PRAD	cis	rs11673344	0.667	rs504549	ENSG00000226686.6	LINC01535	8.45	4.05e-16	2.33e-13	0.5	0.37	Obesity-related traits;	chr19:36946299	chr19:37251912~37265535:+
PRAD	cis	rs12817211	0.524	rs10876000	ENSG00000272368.2	RP4-605O3.4	-8.45	4.07e-16	2.34e-13	-0.36	-0.37	Colorectal or endometrial cancer;	chr12:50128431	chr12:50112197~50165618:+
PRAD	cis	rs4964805	0.865	rs3935416	ENSG00000257681.1	RP11-341G23.4	8.45	4.07e-16	2.34e-13	0.36	0.37	Attention deficit hyperactivity disorder;	chr12:103813177	chr12:103746315~103768858:-
PRAD	cis	rs6570726	0.967	rs7772286	ENSG00000235652.6	RP11-545I5.3	-8.45	4.08e-16	2.35e-13	-0.38	-0.37	Lobe attachment (rater-scored or self-reported);	chr6:145609287	chr6:145799409~145886585:+
PRAD	cis	rs6452524	1	rs6452520	ENSG00000249664.1	CTD-2227C6.2	8.45	4.08e-16	2.35e-13	0.43	0.37	Hypertension (SNP x SNP interaction);	chr5:83133452	chr5:83012285~83013109:-
PRAD	cis	rs6452524	1	rs6452521	ENSG00000249664.1	CTD-2227C6.2	8.45	4.08e-16	2.35e-13	0.43	0.37	Hypertension (SNP x SNP interaction);	chr5:83133453	chr5:83012285~83013109:-
PRAD	cis	rs6452524	0.935	rs6452522	ENSG00000249664.1	CTD-2227C6.2	8.45	4.08e-16	2.35e-13	0.43	0.37	Hypertension (SNP x SNP interaction);	chr5:83133471	chr5:83012285~83013109:-
PRAD	cis	rs2337406	0.85	rs11849578	ENSG00000274576.2	IGHV2-70	-8.45	4.09e-16	2.35e-13	-0.42	-0.37	Alzheimer's disease (late onset);	chr14:106670302	chr14:106770577~106771020:-
PRAD	cis	rs9903692	1	rs9903692	ENSG00000278765.1	RP5-890E16.5	8.45	4.09e-16	2.35e-13	0.55	0.37	Pulse pressure;	chr17:48196567	chr17:48066704~48067293:-
PRAD	cis	rs9903692	0.954	rs9909933	ENSG00000278765.1	RP5-890E16.5	8.45	4.09e-16	2.35e-13	0.55	0.37	Pulse pressure;	chr17:48202870	chr17:48066704~48067293:-
PRAD	cis	rs9903692	0.909	rs2325885	ENSG00000278765.1	RP5-890E16.5	8.45	4.09e-16	2.35e-13	0.55	0.37	Pulse pressure;	chr17:48213013	chr17:48066704~48067293:-
PRAD	cis	rs1979679	0.808	rs71452082	ENSG00000278733.1	RP11-425D17.1	8.44	4.12e-16	2.37e-13	0.47	0.37	Ossification of the posterior longitudinal ligament of the spine;	chr12:28221647	chr12:28185625~28186190:-
PRAD	cis	rs1062177	0.756	rs2915826	ENSG00000253921.1	CTB-113P19.3	8.44	4.12e-16	2.37e-13	0.48	0.37	Preschool internalizing problems;	chr5:151740402	chr5:151753992~151767247:+
PRAD	cis	rs1062177	0.756	rs2964587	ENSG00000253921.1	CTB-113P19.3	8.44	4.12e-16	2.37e-13	0.48	0.37	Preschool internalizing problems;	chr5:151740411	chr5:151753992~151767247:+
PRAD	cis	rs2933343	0.729	rs1680780	ENSG00000231305.3	RP11-723O4.2	8.44	4.12e-16	2.37e-13	0.34	0.37	IgG glycosylation;	chr3:128893816	chr3:128861313~128871540:-
PRAD	cis	rs2933343	0.729	rs1680781	ENSG00000231305.3	RP11-723O4.2	8.44	4.12e-16	2.37e-13	0.34	0.37	IgG glycosylation;	chr3:128893987	chr3:128861313~128871540:-
PRAD	cis	rs10875746	0.669	rs11168487	ENSG00000240399.1	RP1-228P16.1	-8.44	4.13e-16	2.37e-13	-0.36	-0.37	Longevity (90 years and older);	chr12:48246926	chr12:48054813~48055591:-
PRAD	cis	rs11098499	0.954	rs17005535	ENSG00000245958.5	RP11-33B1.1	-8.44	4.13e-16	2.37e-13	-0.37	-0.37	Corneal astigmatism;	chr4:119490407	chr4:119454791~119552025:+
PRAD	cis	rs11159086	0.793	rs10139122	ENSG00000259005.1	RP3-449M8.6	8.44	4.13e-16	2.37e-13	0.47	0.37	Advanced glycation end-product levels;	chr14:74492353	chr14:74474007~74474864:-
PRAD	cis	rs17361889	0.645	rs17285792	ENSG00000224683.1	RPL36AP29	8.44	4.15e-16	2.39e-13	0.46	0.37	Pediatric bone mineral content (hip);	chr7:16086578	chr7:16208945~16209265:+
PRAD	cis	rs2412819	0.571	rs4923964	ENSG00000205771.5	CATSPER2P1	8.44	4.16e-16	2.39e-13	0.49	0.37	Lung cancer;	chr15:43722882	chr15:43726918~43747094:-
PRAD	cis	rs6723108	0.603	rs6430555	ENSG00000224043.6	CCNT2-AS1	-8.44	4.16e-16	2.39e-13	-0.51	-0.37	Type 2 diabetes;	chr2:134890089	chr2:134735464~134918710:-
PRAD	cis	rs2439831	0.702	rs2467402	ENSG00000249839.1	AC011330.5	8.44	4.17e-16	2.4e-13	0.6	0.37	Lung cancer in ever smokers;	chr15:43732292	chr15:43663654~43684339:-
PRAD	cis	rs4835473	0.932	rs4835279	ENSG00000251600.4	RP11-673E1.1	-8.44	4.18e-16	2.4e-13	-0.47	-0.37	Immature fraction of reticulocytes;	chr4:143788917	chr4:143912331~143982454:+
PRAD	cis	rs17711722	0.701	rs781143	ENSG00000236529.1	RP13-254B10.1	8.44	4.18e-16	2.4e-13	0.38	0.37	Calcium levels;	chr7:65974892	chr7:65840212~65840596:+
PRAD	cis	rs2638953	0.962	rs10771408	ENSG00000278733.1	RP11-425D17.1	-8.44	4.18e-16	2.4e-13	-0.45	-0.37	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28147679	chr12:28185625~28186190:-
PRAD	cis	rs9368481	0.672	rs3931463	ENSG00000241549.7	GUSBP2	8.44	4.19e-16	2.41e-13	0.42	0.37	Autism spectrum disorder or schizophrenia;	chr6:26972018	chr6:26871484~26956554:-
PRAD	cis	rs9309473	0.607	rs6546826	ENSG00000163016.8	ALMS1P	-8.44	4.2e-16	2.41e-13	-0.44	-0.37	Metabolite levels;	chr2:73372680	chr2:73644919~73685576:+
PRAD	cis	rs12142240	0.698	rs72677599	ENSG00000232022.5	FAAHP1	-8.44	4.2e-16	2.41e-13	-0.34	-0.37	Menopause (age at onset);	chr1:46368579	chr1:46432129~46445521:+
PRAD	cis	rs760794	0.765	rs7759616	ENSG00000228412.5	RP4-625H18.2	8.44	4.2e-16	2.41e-13	0.43	0.37	Endometriosis;	chr6:19794354	chr6:19802164~19804752:-
PRAD	cis	rs7923609	0.812	rs10822184	ENSG00000232075.1	MRPL35P2	8.44	4.2e-16	2.41e-13	0.38	0.37	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63577393	chr10:63634317~63634827:-
PRAD	cis	rs2739330	0.731	rs4822450	ENSG00000272787.1	KB-226F1.2	-8.44	4.2e-16	2.41e-13	-0.4	-0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23969211~23969873:+
PRAD	cis	rs9309473	0.687	rs6706235	ENSG00000163016.8	ALMS1P	8.44	4.21e-16	2.42e-13	0.44	0.37	Metabolite levels;	chr2:73386430	chr2:73644919~73685576:+
PRAD	cis	rs11976180	1	rs1320894	ENSG00000170356.8	OR2A20P	-8.44	4.21e-16	2.42e-13	-0.49	-0.37	Obesity-related traits;	chr7:144054709	chr7:144250045~144252957:-
PRAD	cis	rs11976180	1	rs2951369	ENSG00000170356.8	OR2A20P	-8.44	4.21e-16	2.42e-13	-0.49	-0.37	Obesity-related traits;	chr7:144055545	chr7:144250045~144252957:-
PRAD	cis	rs4963124	0.886	rs10902216	ENSG00000279672.1	CMB9-55F22.1	8.44	4.22e-16	2.43e-13	0.51	0.37	Proteinuria and chronic kidney disease;	chr11:739392	chr11:779617~780755:+
PRAD	cis	rs8042680	0.522	rs10775251	ENSG00000214432.8	AC068831.10	-8.44	4.23e-16	2.43e-13	-0.44	-0.37	Type 2 diabetes;	chr15:91011195	chr15:91022619~91036611:+
PRAD	cis	rs858239	0.636	rs28706766	ENSG00000226816.2	AC005082.12	8.44	4.23e-16	2.43e-13	0.42	0.37	Cerebrospinal fluid biomarker levels;	chr7:23130215	chr7:23206013~23208045:+
PRAD	cis	rs11098499	0.82	rs13128602	ENSG00000245958.5	RP11-33B1.1	8.44	4.23e-16	2.43e-13	0.36	0.37	Corneal astigmatism;	chr4:119538211	chr4:119454791~119552025:+
PRAD	cis	rs801193	0.844	rs732465	ENSG00000237310.1	GS1-124K5.4	8.44	4.25e-16	2.44e-13	0.32	0.37	Aortic root size;	chr7:66533463	chr7:66493706~66495474:+
PRAD	cis	rs4835473	0.932	rs5016160	ENSG00000251600.4	RP11-673E1.1	8.44	4.25e-16	2.44e-13	0.46	0.37	Immature fraction of reticulocytes;	chr4:143738305	chr4:143912331~143982454:+
PRAD	cis	rs875971	0.522	rs7784623	ENSG00000236529.1	RP13-254B10.1	8.44	4.25e-16	2.44e-13	0.38	0.37	Aortic root size;	chr7:65930047	chr7:65840212~65840596:+
PRAD	cis	rs6723108	0.604	rs1893396	ENSG00000224043.6	CCNT2-AS1	-8.44	4.27e-16	2.45e-13	-0.51	-0.37	Type 2 diabetes;	chr2:134841439	chr2:134735464~134918710:-
PRAD	cis	rs6723108	0.603	rs3739030	ENSG00000224043.6	CCNT2-AS1	-8.44	4.27e-16	2.45e-13	-0.51	-0.37	Type 2 diabetes;	chr2:134841811	chr2:134735464~134918710:-
PRAD	cis	rs11098499	0.78	rs7692994	ENSG00000245958.5	RP11-33B1.1	-8.44	4.27e-16	2.45e-13	-0.35	-0.37	Corneal astigmatism;	chr4:119506334	chr4:119454791~119552025:+
PRAD	cis	rs6991838	0.702	rs34496943	ENSG00000272010.1	CTD-3025N20.3	8.44	4.28e-16	2.46e-13	0.37	0.37	Intelligence (multi-trait analysis);	chr8:65676978	chr8:65591850~65592472:-
PRAD	cis	rs6991838	0.733	rs13281090	ENSG00000272010.1	CTD-3025N20.3	8.44	4.28e-16	2.46e-13	0.37	0.37	Intelligence (multi-trait analysis);	chr8:65678244	chr8:65591850~65592472:-
PRAD	cis	rs6991838	0.701	rs17395275	ENSG00000272010.1	CTD-3025N20.3	8.44	4.28e-16	2.46e-13	0.37	0.37	Intelligence (multi-trait analysis);	chr8:65679003	chr8:65591850~65592472:-
PRAD	cis	rs9368481	0.743	rs9368480	ENSG00000241549.7	GUSBP2	8.44	4.29e-16	2.46e-13	0.41	0.37	Autism spectrum disorder or schizophrenia;	chr6:26987971	chr6:26871484~26956554:-
PRAD	cis	rs17711722	0.701	rs781145	ENSG00000236529.1	RP13-254B10.1	8.44	4.29e-16	2.46e-13	0.38	0.37	Calcium levels;	chr7:65975383	chr7:65840212~65840596:+
PRAD	cis	rs17711722	0.727	rs2658585	ENSG00000236529.1	RP13-254B10.1	8.44	4.29e-16	2.46e-13	0.38	0.37	Calcium levels;	chr7:65996954	chr7:65840212~65840596:+
PRAD	cis	rs12142240	0.698	rs1984490	ENSG00000232022.5	FAAHP1	8.44	4.29e-16	2.46e-13	0.34	0.37	Menopause (age at onset);	chr1:46393062	chr1:46432129~46445521:+
PRAD	cis	rs4835473	0.868	rs7683365	ENSG00000251600.4	RP11-673E1.1	-8.44	4.3e-16	2.47e-13	-0.48	-0.37	Immature fraction of reticulocytes;	chr4:143999443	chr4:143912331~143982454:+
PRAD	cis	rs7615952	0.599	rs16834938	ENSG00000171084.14	FAM86JP	8.44	4.31e-16	2.48e-13	0.57	0.37	Blood pressure (smoking interaction);	chr3:125987203	chr3:125916620~125930024:+
PRAD	cis	rs10129255	0.53	rs11624912	ENSG00000211972.2	IGHV3-66	8.44	4.31e-16	2.48e-13	0.32	0.37	Kawasaki disease;	chr14:106673891	chr14:106675017~106675544:-
PRAD	cis	rs4713118	0.662	rs149946	ENSG00000272009.1	RP1-313I6.12	8.44	4.31e-16	2.48e-13	0.37	0.37	Parkinson's disease;	chr6:28002253	chr6:28078792~28081130:-
PRAD	cis	rs4713118	0.662	rs149947	ENSG00000272009.1	RP1-313I6.12	-8.44	4.31e-16	2.48e-13	-0.37	-0.37	Parkinson's disease;	chr6:28004655	chr6:28078792~28081130:-
PRAD	cis	rs4713118	0.662	rs149969	ENSG00000272009.1	RP1-313I6.12	-8.44	4.31e-16	2.48e-13	-0.37	-0.37	Parkinson's disease;	chr6:28009959	chr6:28078792~28081130:-
PRAD	cis	rs875971	0.54	rs4717275	ENSG00000236529.1	RP13-254B10.1	-8.44	4.32e-16	2.48e-13	-0.38	-0.37	Aortic root size;	chr7:65800193	chr7:65840212~65840596:+
PRAD	cis	rs12908161	1	rs58416181	ENSG00000259728.4	LINC00933	8.44	4.32e-16	2.48e-13	0.45	0.37	Schizophrenia;	chr15:84721230	chr15:84570649~84580175:+
PRAD	cis	rs17711722	0.64	rs13237956	ENSG00000236529.1	RP13-254B10.1	8.44	4.32e-16	2.48e-13	0.38	0.37	Calcium levels;	chr7:65853042	chr7:65840212~65840596:+
PRAD	cis	rs7238033	0.624	rs7229967	ENSG00000267193.4	RP11-116O18.3	8.44	4.32e-16	2.48e-13	0.4	0.37	Bladder cancer;	chr18:45732403	chr18:45669367~45747215:-
PRAD	cis	rs11951515	0.568	rs13354903	ENSG00000188850.9	RP11-159F24.2	8.44	4.33e-16	2.49e-13	0.45	0.37	Metabolite levels  (X-11787);	chr5:43331515	chr5:43336164~43348716:+
PRAD	cis	rs2638953	0.888	rs11049407	ENSG00000278733.1	RP11-425D17.1	-8.44	4.33e-16	2.49e-13	-0.44	-0.37	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28181431	chr12:28185625~28186190:-
PRAD	cis	rs950169	0.686	rs12906474	ENSG00000259728.4	LINC00933	8.44	4.34e-16	2.49e-13	0.44	0.37	Schizophrenia;	chr15:84566006	chr15:84570649~84580175:+
PRAD	cis	rs7250849	0.565	rs11883221	ENSG00000273837.1	LLNLR-470E3.1	-8.44	4.34e-16	2.49e-13	-0.53	-0.37	Blood protein levels;	chr19:51665579	chr19:51639478~51639931:-
PRAD	cis	rs7615952	0.866	rs13063119	ENSG00000171084.14	FAM86JP	8.44	4.34e-16	2.49e-13	0.61	0.37	Blood pressure (smoking interaction);	chr3:125925004	chr3:125916620~125930024:+
PRAD	cis	rs34779708	0.733	rs16935948	ENSG00000230534.5	RP11-297A16.2	8.44	4.34e-16	2.49e-13	0.5	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35260820	chr10:35098006~35127020:-
PRAD	cis	rs2404602	0.692	rs2120108	ENSG00000259422.1	RP11-593F23.1	-8.44	4.34e-16	2.49e-13	-0.46	-0.37	Blood metabolite levels;	chr15:76577588	chr15:76174891~76181486:-
PRAD	cis	rs7615952	0.8	rs12489350	ENSG00000171084.14	FAM86JP	8.44	4.35e-16	2.5e-13	0.61	0.37	Blood pressure (smoking interaction);	chr3:125925273	chr3:125916620~125930024:+
PRAD	cis	rs367615	0.552	rs2963025	ENSG00000249476.1	CTD-2587M2.1	-8.44	4.35e-16	2.5e-13	-0.44	-0.37	Colorectal cancer (SNP x SNP interaction);	chr5:109397555	chr5:109237120~109326369:-
PRAD	cis	rs10463554	0.927	rs464720	ENSG00000175749.11	EIF3KP1	8.44	4.35e-16	2.5e-13	0.48	0.37	Parkinson's disease;	chr5:103071183	chr5:103032376~103033031:+
PRAD	cis	rs10463554	0.892	rs158401	ENSG00000175749.11	EIF3KP1	8.44	4.35e-16	2.5e-13	0.48	0.37	Parkinson's disease;	chr5:103079764	chr5:103032376~103033031:+
PRAD	cis	rs6570726	1	rs405622	ENSG00000235652.6	RP11-545I5.3	8.44	4.36e-16	2.5e-13	0.38	0.37	Lobe attachment (rater-scored or self-reported);	chr6:145550761	chr6:145799409~145886585:+
PRAD	cis	rs6570726	1	rs455109	ENSG00000235652.6	RP11-545I5.3	8.44	4.36e-16	2.5e-13	0.38	0.37	Lobe attachment (rater-scored or self-reported);	chr6:145551529	chr6:145799409~145886585:+
PRAD	cis	rs6570726	1	rs373778	ENSG00000235652.6	RP11-545I5.3	8.44	4.36e-16	2.5e-13	0.38	0.37	Lobe attachment (rater-scored or self-reported);	chr6:145552116	chr6:145799409~145886585:+
PRAD	cis	rs12142240	0.698	rs41294476	ENSG00000232022.5	FAAHP1	-8.44	4.37e-16	2.5e-13	-0.34	-0.37	Menopause (age at onset);	chr1:46352702	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs17413694	ENSG00000232022.5	FAAHP1	-8.44	4.37e-16	2.5e-13	-0.34	-0.37	Menopause (age at onset);	chr1:46352744	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs77185326	ENSG00000232022.5	FAAHP1	-8.44	4.37e-16	2.5e-13	-0.34	-0.37	Menopause (age at onset);	chr1:46352745	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs41294478	ENSG00000232022.5	FAAHP1	-8.44	4.37e-16	2.5e-13	-0.34	-0.37	Menopause (age at onset);	chr1:46352770	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs17413701	ENSG00000232022.5	FAAHP1	-8.44	4.37e-16	2.5e-13	-0.34	-0.37	Menopause (age at onset);	chr1:46352780	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs7515598	ENSG00000232022.5	FAAHP1	-8.44	4.37e-16	2.5e-13	-0.34	-0.37	Menopause (age at onset);	chr1:46352807	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.692	rs7529674	ENSG00000232022.5	FAAHP1	-8.44	4.37e-16	2.5e-13	-0.34	-0.37	Menopause (age at onset);	chr1:46352836	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs12385697	ENSG00000232022.5	FAAHP1	-8.44	4.37e-16	2.5e-13	-0.34	-0.37	Menopause (age at onset);	chr1:46353226	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs12385695	ENSG00000232022.5	FAAHP1	-8.44	4.37e-16	2.5e-13	-0.34	-0.37	Menopause (age at onset);	chr1:46353349	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.66	rs6679080	ENSG00000232022.5	FAAHP1	-8.44	4.37e-16	2.5e-13	-0.34	-0.37	Menopause (age at onset);	chr1:46354107	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs6690075	ENSG00000232022.5	FAAHP1	-8.44	4.37e-16	2.5e-13	-0.34	-0.37	Menopause (age at onset);	chr1:46354176	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs6679898	ENSG00000232022.5	FAAHP1	-8.44	4.37e-16	2.5e-13	-0.34	-0.37	Menopause (age at onset);	chr1:46354917	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs10158236	ENSG00000232022.5	FAAHP1	-8.44	4.37e-16	2.5e-13	-0.34	-0.37	Menopause (age at onset);	chr1:46355224	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.667	rs66990604	ENSG00000232022.5	FAAHP1	-8.44	4.37e-16	2.5e-13	-0.34	-0.37	Menopause (age at onset);	chr1:46356401	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs112068407	ENSG00000232022.5	FAAHP1	-8.44	4.37e-16	2.5e-13	-0.34	-0.37	Menopause (age at onset);	chr1:46356619	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.66	rs112560929	ENSG00000232022.5	FAAHP1	-8.44	4.37e-16	2.5e-13	-0.34	-0.37	Menopause (age at onset);	chr1:46356625	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs10158572	ENSG00000232022.5	FAAHP1	-8.44	4.37e-16	2.5e-13	-0.34	-0.37	Menopause (age at onset);	chr1:46356768	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs10158130	ENSG00000232022.5	FAAHP1	-8.44	4.37e-16	2.5e-13	-0.34	-0.37	Menopause (age at onset);	chr1:46356928	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.73	rs56030283	ENSG00000232022.5	FAAHP1	-8.44	4.37e-16	2.5e-13	-0.34	-0.37	Menopause (age at onset);	chr1:46357421	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs55971480	ENSG00000232022.5	FAAHP1	-8.44	4.37e-16	2.5e-13	-0.34	-0.37	Menopause (age at onset);	chr1:46357534	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs66911505	ENSG00000232022.5	FAAHP1	-8.44	4.37e-16	2.5e-13	-0.34	-0.37	Menopause (age at onset);	chr1:46357626	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs72677593	ENSG00000232022.5	FAAHP1	-8.44	4.37e-16	2.5e-13	-0.34	-0.37	Menopause (age at onset);	chr1:46358691	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs72677594	ENSG00000232022.5	FAAHP1	-8.44	4.37e-16	2.5e-13	-0.34	-0.37	Menopause (age at onset);	chr1:46358699	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.66	rs7520497	ENSG00000232022.5	FAAHP1	-8.44	4.37e-16	2.5e-13	-0.34	-0.37	Menopause (age at onset);	chr1:46359247	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.692	rs7532149	ENSG00000232022.5	FAAHP1	-8.44	4.37e-16	2.5e-13	-0.34	-0.37	Menopause (age at onset);	chr1:46359260	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs28578741	ENSG00000232022.5	FAAHP1	-8.44	4.37e-16	2.5e-13	-0.34	-0.37	Menopause (age at onset);	chr1:46359504	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs56063031	ENSG00000232022.5	FAAHP1	-8.44	4.37e-16	2.5e-13	-0.34	-0.37	Menopause (age at onset);	chr1:46359761	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs67276232	ENSG00000232022.5	FAAHP1	-8.44	4.37e-16	2.5e-13	-0.34	-0.37	Menopause (age at onset);	chr1:46359812	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.667	rs55887761	ENSG00000232022.5	FAAHP1	-8.44	4.37e-16	2.5e-13	-0.34	-0.37	Menopause (age at onset);	chr1:46360915	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs9661240	ENSG00000232022.5	FAAHP1	-8.44	4.37e-16	2.5e-13	-0.34	-0.37	Menopause (age at onset);	chr1:46361378	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs1053627	ENSG00000232022.5	FAAHP1	-8.44	4.37e-16	2.5e-13	-0.34	-0.37	Menopause (age at onset);	chr1:46362056	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs1053628	ENSG00000232022.5	FAAHP1	-8.44	4.37e-16	2.5e-13	-0.34	-0.37	Menopause (age at onset);	chr1:46362097	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs6429599	ENSG00000232022.5	FAAHP1	-8.44	4.37e-16	2.5e-13	-0.34	-0.37	Menopause (age at onset);	chr1:46362199	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs17361819	ENSG00000232022.5	FAAHP1	-8.44	4.37e-16	2.5e-13	-0.34	-0.37	Menopause (age at onset);	chr1:46362437	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs67142569	ENSG00000232022.5	FAAHP1	-8.44	4.37e-16	2.5e-13	-0.34	-0.37	Menopause (age at onset);	chr1:46362788	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs17361833	ENSG00000232022.5	FAAHP1	-8.44	4.37e-16	2.5e-13	-0.34	-0.37	Menopause (age at onset);	chr1:46363028	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs17357711	ENSG00000232022.5	FAAHP1	-8.44	4.37e-16	2.5e-13	-0.34	-0.37	Menopause (age at onset);	chr1:46363341	chr1:46432129~46445521:+
PRAD	cis	rs3096299	0.866	rs4238829	ENSG00000274627.1	RP11-104N10.2	8.44	4.37e-16	2.5e-13	0.37	0.37	Multiple myeloma (IgH translocation);	chr16:89395854	chr16:89516797~89522217:+
PRAD	cis	rs2337406	0.925	rs2011167	ENSG00000274576.2	IGHV2-70	-8.44	4.39e-16	2.52e-13	-0.41	-0.37	Alzheimer's disease (late onset);	chr14:106680831	chr14:106770577~106771020:-
PRAD	cis	rs4835473	0.932	rs35300159	ENSG00000251600.4	RP11-673E1.1	-8.44	4.4e-16	2.52e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143751768	chr4:143912331~143982454:+
PRAD	cis	rs7615952	0.736	rs13063122	ENSG00000171084.14	FAM86JP	8.44	4.41e-16	2.53e-13	0.6	0.37	Blood pressure (smoking interaction);	chr3:125925017	chr3:125916620~125930024:+
PRAD	cis	rs7811142	1	rs73161762	ENSG00000242294.5	STAG3L5P	8.44	4.42e-16	2.53e-13	0.26	0.37	Platelet count;	chr7:100417223	chr7:100336079~100351900:+
PRAD	cis	rs2348418	0.715	rs4931083	ENSG00000247934.4	RP11-967K21.1	-8.44	4.43e-16	2.54e-13	-0.33	-0.37	Lung function (FEV1);Lung function (FVC);	chr12:28568952	chr12:28163298~28190738:-
PRAD	cis	rs7727544	0.571	rs12521097	ENSG00000233006.5	AC034220.3	8.43	4.43e-16	2.54e-13	0.32	0.37	Blood metabolite levels;	chr5:132239645	chr5:132311285~132369916:-
PRAD	cis	rs26232	0.526	rs61654927	ENSG00000175749.11	EIF3KP1	8.43	4.45e-16	2.55e-13	0.49	0.37	Rheumatoid arthritis;	chr5:103047021	chr5:103032376~103033031:+
PRAD	cis	rs10463554	0.892	rs59292735	ENSG00000175749.11	EIF3KP1	8.43	4.45e-16	2.55e-13	0.49	0.37	Parkinson's disease;	chr5:103047047	chr5:103032376~103033031:+
PRAD	cis	rs4835473	0.932	rs34525847	ENSG00000251600.4	RP11-673E1.1	-8.43	4.46e-16	2.55e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143734970	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs35277115	ENSG00000251600.4	RP11-673E1.1	-8.43	4.46e-16	2.55e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143735001	chr4:143912331~143982454:+
PRAD	cis	rs34779708	0.733	rs11010146	ENSG00000230534.5	RP11-297A16.2	8.43	4.48e-16	2.56e-13	0.49	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35252633	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.733	rs7083266	ENSG00000230534.5	RP11-297A16.2	8.43	4.48e-16	2.56e-13	0.49	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35252704	chr10:35098006~35127020:-
PRAD	cis	rs11083475	1	rs883394	ENSG00000267892.1	CTD-2540F13.2	8.43	4.48e-16	2.56e-13	0.4	0.37	Heart rate;	chr19:38714973	chr19:38738284~38739863:+
PRAD	cis	rs9368481	0.761	rs4713062	ENSG00000241549.7	GUSBP2	-8.43	4.48e-16	2.56e-13	-0.41	-0.37	Autism spectrum disorder or schizophrenia;	chr6:26980416	chr6:26871484~26956554:-
PRAD	cis	rs7598759	0.712	rs12991636	ENSG00000181798.2	LINC00471	-8.43	4.48e-16	2.57e-13	-0.43	-0.37	Noise-induced hearing loss;	chr2:231468955	chr2:231508426~231514339:-
PRAD	cis	rs858239	0.669	rs1006709	ENSG00000226816.2	AC005082.12	8.43	4.48e-16	2.57e-13	0.41	0.37	Cerebrospinal fluid biomarker levels;	chr7:23100480	chr7:23206013~23208045:+
PRAD	cis	rs6723108	0.603	rs62168897	ENSG00000224043.6	CCNT2-AS1	-8.43	4.48e-16	2.57e-13	-0.5	-0.37	Type 2 diabetes;	chr2:134960427	chr2:134735464~134918710:-
PRAD	cis	rs9368481	0.729	rs9379948	ENSG00000241549.7	GUSBP2	8.43	4.49e-16	2.57e-13	0.41	0.37	Autism spectrum disorder or schizophrenia;	chr6:26977004	chr6:26871484~26956554:-
PRAD	cis	rs2412819	0.571	rs12443084	ENSG00000205771.5	CATSPER2P1	8.43	4.49e-16	2.57e-13	0.49	0.37	Lung cancer;	chr15:43748767	chr15:43726918~43747094:-
PRAD	cis	rs2412819	0.571	rs10163069	ENSG00000205771.5	CATSPER2P1	8.43	4.49e-16	2.57e-13	0.49	0.37	Lung cancer;	chr15:43755372	chr15:43726918~43747094:-
PRAD	cis	rs2929278	0.617	rs3986209	ENSG00000205771.5	CATSPER2P1	8.43	4.49e-16	2.57e-13	0.49	0.37	Schizophrenia;	chr15:43758675	chr15:43726918~43747094:-
PRAD	cis	rs9532669	0.926	rs9532671	ENSG00000168852.11	TPTE2P5	8.43	4.5e-16	2.57e-13	0.35	0.37	Cervical cancer;	chr13:40927761	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.833	rs9532672	ENSG00000168852.11	TPTE2P5	8.43	4.5e-16	2.57e-13	0.35	0.37	Cervical cancer;	chr13:40928285	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.963	rs7324625	ENSG00000168852.11	TPTE2P5	8.43	4.5e-16	2.57e-13	0.35	0.37	Cervical cancer;	chr13:40928606	chr13:40822296~40921749:-
PRAD	cis	rs8062405	0.824	rs4788085	ENSG00000251417.2	RP11-1348G14.4	-8.43	4.5e-16	2.58e-13	-0.4	-0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523682	chr16:28802743~28817828:+
PRAD	cis	rs8062405	0.824	rs28772958	ENSG00000251417.2	RP11-1348G14.4	-8.43	4.5e-16	2.58e-13	-0.4	-0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523984	chr16:28802743~28817828:+
PRAD	cis	rs4835473	0.9	rs10025455	ENSG00000251600.4	RP11-673E1.1	-8.43	4.51e-16	2.58e-13	-0.48	-0.37	Immature fraction of reticulocytes;	chr4:143998417	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.722	rs7666296	ENSG00000251600.4	RP11-673E1.1	-8.43	4.51e-16	2.58e-13	-0.48	-0.37	Immature fraction of reticulocytes;	chr4:143999004	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.722	rs7662277	ENSG00000251600.4	RP11-673E1.1	-8.43	4.51e-16	2.58e-13	-0.48	-0.37	Immature fraction of reticulocytes;	chr4:143999485	chr4:143912331~143982454:+
PRAD	cis	rs11096990	0.634	rs3733287	ENSG00000249207.1	RP11-360F5.1	-8.43	4.51e-16	2.58e-13	-0.39	-0.37	Cognitive function;	chr4:39215732	chr4:39112677~39126818:-
PRAD	cis	rs4835473	0.932	rs2323190	ENSG00000251600.4	RP11-673E1.1	-8.43	4.53e-16	2.59e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143744282	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.9	rs935732	ENSG00000251600.4	RP11-673E1.1	-8.43	4.53e-16	2.59e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143759164	chr4:143912331~143982454:+
PRAD	cis	rs4631830	0.747	rs745180	ENSG00000230869.1	CTGLF10P	8.43	4.54e-16	2.6e-13	0.45	0.37	Prostate-specific antigen levels;	chr10:46091329	chr10:45678692~45700532:+
PRAD	cis	rs321358	1	rs12419222	ENSG00000271584.1	RP11-89C3.4	8.43	4.56e-16	2.61e-13	0.58	0.37	Body mass index;	chr11:111128439	chr11:111091932~111097357:-
PRAD	cis	rs853679	0.55	rs1233704	ENSG00000272009.1	RP1-313I6.12	8.43	4.58e-16	2.62e-13	0.37	0.37	Depression;	chr6:28199145	chr6:28078792~28081130:-
PRAD	cis	rs6046396	1	rs6046396	ENSG00000275142.1	RP5-999L4.2	8.43	4.58e-16	2.62e-13	0.49	0.37	Bipolar disorder and schizophrenia;	chr20:19871859	chr20:19871891~19872284:+
PRAD	cis	rs9326248	0.861	rs11216172	ENSG00000280143.1	AP000892.6	8.43	4.59e-16	2.62e-13	0.34	0.37	Blood protein levels;	chr11:116879162	chr11:117204967~117210292:+
PRAD	cis	rs7772486	0.902	rs2144476	ENSG00000235652.6	RP11-545I5.3	8.43	4.59e-16	2.62e-13	0.37	0.37	Lobe attachment (rater-scored or self-reported);	chr6:146001348	chr6:145799409~145886585:+
PRAD	cis	rs7615952	0.932	rs7630077	ENSG00000171084.14	FAM86JP	8.43	4.61e-16	2.64e-13	0.61	0.37	Blood pressure (smoking interaction);	chr3:125930833	chr3:125916620~125930024:+
PRAD	cis	rs1355223	0.872	rs12802798	ENSG00000271369.1	RP11-350D17.3	-8.43	4.61e-16	2.64e-13	-0.43	-0.37	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34725887	chr11:34709600~34710161:+
PRAD	cis	rs2108622	0.727	rs2158511	ENSG00000267056.2	AC005336.4	8.43	4.62e-16	2.64e-13	0.51	0.37	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15875837	chr19:15910582~15911824:-
PRAD	cis	rs2108622	0.727	rs3093216	ENSG00000267056.2	AC005336.4	8.43	4.62e-16	2.64e-13	0.51	0.37	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15876927	chr19:15910582~15911824:-
PRAD	cis	rs2108622	0.701	rs3093209	ENSG00000267056.2	AC005336.4	8.43	4.62e-16	2.64e-13	0.51	0.37	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15877610	chr19:15910582~15911824:-
PRAD	cis	rs2108622	0.727	rs3093207	ENSG00000267056.2	AC005336.4	8.43	4.62e-16	2.64e-13	0.51	0.37	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15877848	chr19:15910582~15911824:-
PRAD	cis	rs2404602	0.74	rs34924128	ENSG00000259422.1	RP11-593F23.1	8.43	4.62e-16	2.64e-13	0.46	0.37	Blood metabolite levels;	chr15:76672828	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.692	rs67010831	ENSG00000259422.1	RP11-593F23.1	8.43	4.62e-16	2.64e-13	0.46	0.37	Blood metabolite levels;	chr15:76672967	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.655	rs4886824	ENSG00000259422.1	RP11-593F23.1	8.43	4.62e-16	2.64e-13	0.46	0.37	Blood metabolite levels;	chr15:76676915	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.692	rs58361452	ENSG00000259422.1	RP11-593F23.1	8.43	4.62e-16	2.64e-13	0.46	0.37	Blood metabolite levels;	chr15:76681031	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.692	rs8043474	ENSG00000259422.1	RP11-593F23.1	8.43	4.62e-16	2.64e-13	0.46	0.37	Blood metabolite levels;	chr15:76682382	chr15:76174891~76181486:-
PRAD	cis	rs11098499	0.863	rs6833334	ENSG00000245958.5	RP11-33B1.1	-8.43	4.62e-16	2.64e-13	-0.37	-0.37	Corneal astigmatism;	chr4:119583072	chr4:119454791~119552025:+
PRAD	cis	rs6723108	0.627	rs6706537	ENSG00000224043.6	CCNT2-AS1	-8.43	4.64e-16	2.65e-13	-0.51	-0.37	Type 2 diabetes;	chr2:134861412	chr2:134735464~134918710:-
PRAD	cis	rs7712401	0.601	rs154502	ENSG00000263432.2	RN7SL689P	8.43	4.64e-16	2.65e-13	0.38	0.37	Mean platelet volume;	chr5:122871351	chr5:123022487~123022783:-
PRAD	cis	rs10463554	0.927	rs257304	ENSG00000175749.11	EIF3KP1	8.43	4.64e-16	2.65e-13	0.48	0.37	Parkinson's disease;	chr5:103081114	chr5:103032376~103033031:+
PRAD	cis	rs4713118	0.699	rs200969	ENSG00000226314.6	ZNF192P1	-8.43	4.65e-16	2.65e-13	-0.51	-0.37	Parkinson's disease;	chr6:27891675	chr6:28161781~28169594:+
PRAD	cis	rs11098499	0.863	rs13140391	ENSG00000245958.5	RP11-33B1.1	-8.43	4.66e-16	2.66e-13	-0.36	-0.37	Corneal astigmatism;	chr4:119582282	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.863	rs13140409	ENSG00000245958.5	RP11-33B1.1	-8.43	4.66e-16	2.66e-13	-0.36	-0.37	Corneal astigmatism;	chr4:119582305	chr4:119454791~119552025:+
PRAD	cis	rs2638953	0.924	rs11049467	ENSG00000278733.1	RP11-425D17.1	-8.43	4.67e-16	2.67e-13	-0.46	-0.37	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28215602	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs11049468	ENSG00000278733.1	RP11-425D17.1	-8.43	4.67e-16	2.67e-13	-0.46	-0.37	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28215684	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs11049469	ENSG00000278733.1	RP11-425D17.1	-8.43	4.67e-16	2.67e-13	-0.46	-0.37	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28216729	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.886	rs11049470	ENSG00000278733.1	RP11-425D17.1	-8.43	4.67e-16	2.67e-13	-0.46	-0.37	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28221449	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs10843140	ENSG00000278733.1	RP11-425D17.1	-8.43	4.67e-16	2.67e-13	-0.46	-0.37	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28227273	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs11049472	ENSG00000278733.1	RP11-425D17.1	-8.43	4.67e-16	2.67e-13	-0.46	-0.37	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28229772	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.888	rs2061760	ENSG00000278733.1	RP11-425D17.1	-8.43	4.67e-16	2.67e-13	-0.46	-0.37	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28234492	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.886	rs11049474	ENSG00000278733.1	RP11-425D17.1	-8.43	4.67e-16	2.67e-13	-0.46	-0.37	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28235512	chr12:28185625~28186190:-
PRAD	cis	rs67311347	0.956	rs11714871	ENSG00000223797.4	ENTPD3-AS1	8.43	4.67e-16	2.67e-13	0.32	0.37	Renal cell carcinoma;	chr3:40387447	chr3:40313802~40453329:-
PRAD	cis	rs67311347	1	rs2305521	ENSG00000223797.4	ENTPD3-AS1	8.43	4.67e-16	2.67e-13	0.32	0.37	Renal cell carcinoma;	chr3:40387692	chr3:40313802~40453329:-
PRAD	cis	rs12134133	0.752	rs6673080	ENSG00000274245.1	RP11-357P18.2	8.43	4.68e-16	2.67e-13	0.56	0.37	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207216859	chr1:207372559~207373252:+
PRAD	cis	rs950169	0.96	rs12905475	ENSG00000259728.4	LINC00933	8.43	4.68e-16	2.67e-13	0.45	0.37	Schizophrenia;	chr15:84131743	chr15:84570649~84580175:+
PRAD	cis	rs760794	0.729	rs6921786	ENSG00000228412.5	RP4-625H18.2	-8.43	4.68e-16	2.67e-13	-0.43	-0.37	Endometriosis;	chr6:19793785	chr6:19802164~19804752:-
PRAD	cis	rs950169	0.81	rs2879976	ENSG00000259728.4	LINC00933	8.43	4.69e-16	2.68e-13	0.44	0.37	Schizophrenia;	chr15:84566347	chr15:84570649~84580175:+
PRAD	cis	rs7688540	0.771	rs77078697	ENSG00000275426.1	CH17-262A2.1	8.43	4.7e-16	2.68e-13	0.52	0.37	Facial morphology (factor 6, height of vermillion lower lip);	chr4:258259	chr4:149738~150317:+
PRAD	cis	rs7688540	0.771	rs61795006	ENSG00000275426.1	CH17-262A2.1	8.43	4.7e-16	2.68e-13	0.52	0.37	Facial morphology (factor 6, height of vermillion lower lip);	chr4:259812	chr4:149738~150317:+
PRAD	cis	rs7688540	0.771	rs61795007	ENSG00000275426.1	CH17-262A2.1	8.43	4.7e-16	2.68e-13	0.52	0.37	Facial morphology (factor 6, height of vermillion lower lip);	chr4:261475	chr4:149738~150317:+
PRAD	cis	rs9341835	0.593	rs9449297	ENSG00000218048.2	RP3-407E4.4	8.43	4.72e-16	2.7e-13	0.43	0.37	Schizophrenia;	chr6:63454344	chr6:63440766~63443580:+
PRAD	cis	rs2108622	0.683	rs6512067	ENSG00000267056.2	AC005336.4	8.43	4.74e-16	2.7e-13	0.5	0.37	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15872141	chr19:15910582~15911824:-
PRAD	cis	rs7131987	0.718	rs7976961	ENSG00000257176.2	RP11-996F15.2	-8.43	4.74e-16	2.7e-13	-0.4	-0.37	QT interval;	chr12:29310155	chr12:29280418~29317848:-
PRAD	cis	rs17711722	0.701	rs4467826	ENSG00000236529.1	RP13-254B10.1	8.43	4.74e-16	2.71e-13	0.38	0.37	Calcium levels;	chr7:65903721	chr7:65840212~65840596:+
PRAD	cis	rs4380275	1	rs4268954	ENSG00000223751.1	AC116609.2	8.43	4.75e-16	2.71e-13	0.46	0.37	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:772834	chr2:742488~747767:+
PRAD	cis	rs26232	0.583	rs26434	ENSG00000175749.11	EIF3KP1	-8.43	4.75e-16	2.71e-13	-0.5	-0.37	Rheumatoid arthritis;	chr5:103027698	chr5:103032376~103033031:+
PRAD	cis	rs42648	0.536	rs2158747	ENSG00000227646.6	STEAP2-AS1	-8.43	4.75e-16	2.71e-13	-0.33	-0.37	Homocysteine levels;	chr7:90169107	chr7:89882353~90211635:-
PRAD	cis	rs4835473	0.932	rs13119602	ENSG00000251600.4	RP11-673E1.1	-8.43	4.75e-16	2.71e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143736621	chr4:143912331~143982454:+
PRAD	cis	rs1979679	0.842	rs7139154	ENSG00000278733.1	RP11-425D17.1	8.42	4.79e-16	2.73e-13	0.46	0.37	Ossification of the posterior longitudinal ligament of the spine;	chr12:28181603	chr12:28185625~28186190:-
PRAD	cis	rs1979679	0.842	rs11049411	ENSG00000278733.1	RP11-425D17.1	8.42	4.79e-16	2.73e-13	0.46	0.37	Ossification of the posterior longitudinal ligament of the spine;	chr12:28184723	chr12:28185625~28186190:-
PRAD	cis	rs950169	0.84	rs72748702	ENSG00000225151.9	GOLGA2P7	-8.42	4.79e-16	2.73e-13	-0.51	-0.37	Schizophrenia;	chr15:84246494	chr15:84199311~84230136:-
PRAD	cis	rs9309473	0.579	rs6728128	ENSG00000163016.8	ALMS1P	8.42	4.8e-16	2.74e-13	0.44	0.37	Metabolite levels;	chr2:73368854	chr2:73644919~73685576:+
PRAD	cis	rs9309473	0.607	rs7567343	ENSG00000163016.8	ALMS1P	8.42	4.8e-16	2.74e-13	0.44	0.37	Metabolite levels;	chr2:73369477	chr2:73644919~73685576:+
PRAD	cis	rs6570726	0.967	rs6903252	ENSG00000235652.6	RP11-545I5.3	8.42	4.81e-16	2.75e-13	0.38	0.37	Lobe attachment (rater-scored or self-reported);	chr6:145601641	chr6:145799409~145886585:+
PRAD	cis	rs7849270	0.801	rs10819474	ENSG00000268707.1	RP11-247A12.7	-8.42	4.82e-16	2.75e-13	-0.43	-0.37	Blood metabolite ratios;	chr9:129168215	chr9:129170434~129170940:+
PRAD	cis	rs2108622	0.727	rs7254940	ENSG00000267056.2	AC005336.4	8.42	4.83e-16	2.75e-13	0.51	0.37	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15873698	chr19:15910582~15911824:-
PRAD	cis	rs763567	1	rs3903239	ENSG00000271811.1	RP1-79C4.4	-8.42	4.83e-16	2.76e-13	-0.42	-0.37	Tonsillectomy;	chr1:170600176	chr1:170667381~170669425:+
PRAD	cis	rs763567	1	rs12760630	ENSG00000271811.1	RP1-79C4.4	-8.42	4.83e-16	2.76e-13	-0.42	-0.37	Tonsillectomy;	chr1:170600548	chr1:170667381~170669425:+
PRAD	cis	rs763567	0.967	rs7412231	ENSG00000271811.1	RP1-79C4.4	-8.42	4.83e-16	2.76e-13	-0.42	-0.37	Tonsillectomy;	chr1:170601358	chr1:170667381~170669425:+
PRAD	cis	rs763567	1	rs10919437	ENSG00000271811.1	RP1-79C4.4	-8.42	4.83e-16	2.76e-13	-0.42	-0.37	Tonsillectomy;	chr1:170603805	chr1:170667381~170669425:+
PRAD	cis	rs763567	1	rs2206062	ENSG00000271811.1	RP1-79C4.4	-8.42	4.83e-16	2.76e-13	-0.42	-0.37	Tonsillectomy;	chr1:170606966	chr1:170667381~170669425:+
PRAD	cis	rs9309473	0.607	rs7574291	ENSG00000163016.8	ALMS1P	8.42	4.83e-16	2.76e-13	0.44	0.37	Metabolite levels;	chr2:73367813	chr2:73644919~73685576:+
PRAD	cis	rs6844153	0.715	rs73813220	ENSG00000240005.4	RP11-293A21.1	-8.42	4.84e-16	2.76e-13	-0.46	-0.37	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26920224	chr4:26859806~26860599:-
PRAD	cis	rs1062177	0.756	rs2964588	ENSG00000253921.1	CTB-113P19.3	8.42	4.84e-16	2.76e-13	0.48	0.37	Preschool internalizing problems;	chr5:151738825	chr5:151753992~151767247:+
PRAD	cis	rs9810089	0.814	rs696518	ENSG00000261758.1	RP11-102M11.2	8.42	4.85e-16	2.76e-13	0.42	0.37	Gestational age at birth (child effect);	chr3:136401458	chr3:136752630~136755780:+
PRAD	cis	rs4835473	0.771	rs4261935	ENSG00000251600.4	RP11-673E1.1	8.42	4.85e-16	2.76e-13	0.47	0.37	Immature fraction of reticulocytes;	chr4:143979751	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.524	rs4404495	ENSG00000251600.4	RP11-673E1.1	8.42	4.85e-16	2.76e-13	0.47	0.37	Immature fraction of reticulocytes;	chr4:143979791	chr4:143912331~143982454:+
PRAD	cis	rs2274273	0.84	rs6573020	ENSG00000258413.1	RP11-665C16.6	-8.42	4.85e-16	2.77e-13	-0.46	-0.37	Protein biomarker;	chr14:55404734	chr14:55262767~55272075:-
PRAD	cis	rs2412819	0.571	rs28410121	ENSG00000205771.5	CATSPER2P1	8.42	4.85e-16	2.77e-13	0.48	0.37	Lung cancer;	chr15:43777831	chr15:43726918~43747094:-
PRAD	cis	rs950169	1	rs1818950	ENSG00000225151.9	GOLGA2P7	-8.42	4.86e-16	2.77e-13	-0.51	-0.37	Schizophrenia;	chr15:84053769	chr15:84199311~84230136:-
PRAD	cis	rs950169	1	rs12903820	ENSG00000225151.9	GOLGA2P7	-8.42	4.87e-16	2.78e-13	-0.51	-0.37	Schizophrenia;	chr15:84055068	chr15:84199311~84230136:-
PRAD	cis	rs17361889	0.806	rs10487915	ENSG00000224683.1	RPL36AP29	8.42	4.88e-16	2.78e-13	0.43	0.37	Pediatric bone mineral content (hip);	chr7:16189396	chr7:16208945~16209265:+
PRAD	cis	rs950169	1	rs1911155	ENSG00000225151.9	GOLGA2P7	-8.42	4.88e-16	2.78e-13	-0.51	-0.37	Schizophrenia;	chr15:84118883	chr15:84199311~84230136:-
PRAD	cis	rs17361889	0.806	rs1949952	ENSG00000224683.1	RPL36AP29	-8.42	4.89e-16	2.79e-13	-0.42	-0.37	Pediatric bone mineral content (hip);	chr7:16189503	chr7:16208945~16209265:+
PRAD	cis	rs9309473	0.687	rs6748040	ENSG00000163016.8	ALMS1P	-8.42	4.91e-16	2.8e-13	-0.44	-0.37	Metabolite levels;	chr2:73382800	chr2:73644919~73685576:+
PRAD	cis	rs875971	0.522	rs9530	ENSG00000236529.1	RP13-254B10.1	8.42	4.91e-16	2.8e-13	0.39	0.37	Aortic root size;	chr7:65960907	chr7:65840212~65840596:+
PRAD	cis	rs4713118	0.513	rs156739	ENSG00000280107.1	AL022393.9	-8.42	4.92e-16	2.8e-13	-0.45	-0.37	Parkinson's disease;	chr6:28045632	chr6:28170845~28172521:+
PRAD	cis	rs6001482	0.679	rs5757568	ENSG00000272779.1	LL22NC03-80A10.6	-8.42	4.93e-16	2.81e-13	-0.44	-0.37	Diastolic blood pressure;	chr22:22229175	chr22:22303224~22310401:+
PRAD	cis	rs11098499	0.863	rs3822192	ENSG00000245958.5	RP11-33B1.1	-8.42	4.93e-16	2.81e-13	-0.37	-0.37	Corneal astigmatism;	chr4:119524565	chr4:119454791~119552025:+
PRAD	cis	rs4835473	0.897	rs34425128	ENSG00000251600.4	RP11-673E1.1	-8.42	4.93e-16	2.81e-13	-0.48	-0.37	Immature fraction of reticulocytes;	chr4:143725191	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.9	rs35230778	ENSG00000251600.4	RP11-673E1.1	-8.42	4.95e-16	2.81e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143734336	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.9	rs34772566	ENSG00000251600.4	RP11-673E1.1	-8.42	4.95e-16	2.81e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143734355	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.9	rs35419968	ENSG00000251600.4	RP11-673E1.1	-8.42	4.95e-16	2.81e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143734583	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.868	rs66634585	ENSG00000251600.4	RP11-673E1.1	-8.42	4.95e-16	2.81e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143734608	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.868	rs35016507	ENSG00000251600.4	RP11-673E1.1	-8.42	4.95e-16	2.81e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143734617	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.9	rs67600034	ENSG00000251600.4	RP11-673E1.1	-8.42	4.95e-16	2.81e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143734670	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs35655934	ENSG00000251600.4	RP11-673E1.1	-8.42	4.95e-16	2.81e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143734697	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.897	rs35515006	ENSG00000251600.4	RP11-673E1.1	-8.42	4.95e-16	2.81e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143734705	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.838	rs4583708	ENSG00000251600.4	RP11-673E1.1	-8.42	4.95e-16	2.81e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143735610	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs34257944	ENSG00000251600.4	RP11-673E1.1	-8.42	4.95e-16	2.81e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143736443	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs12509642	ENSG00000251600.4	RP11-673E1.1	-8.42	4.95e-16	2.81e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143737080	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.864	rs17750354	ENSG00000251600.4	RP11-673E1.1	-8.42	4.95e-16	2.81e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143737352	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.9	rs5015759	ENSG00000251600.4	RP11-673E1.1	-8.42	4.95e-16	2.81e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143738050	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.9	rs5015758	ENSG00000251600.4	RP11-673E1.1	-8.42	4.95e-16	2.81e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143738052	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.9	rs34569841	ENSG00000251600.4	RP11-673E1.1	-8.42	4.95e-16	2.81e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143738060	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs34950821	ENSG00000251600.4	RP11-673E1.1	-8.42	4.95e-16	2.81e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143738174	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs5016158	ENSG00000251600.4	RP11-673E1.1	-8.42	4.95e-16	2.81e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143738472	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs5016157	ENSG00000251600.4	RP11-673E1.1	-8.42	4.95e-16	2.81e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143738587	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.864	rs67749935	ENSG00000251600.4	RP11-673E1.1	-8.42	4.95e-16	2.81e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143739852	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.9	rs66934100	ENSG00000251600.4	RP11-673E1.1	-8.42	4.95e-16	2.81e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143739872	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs4325971	ENSG00000251600.4	RP11-673E1.1	-8.42	4.95e-16	2.81e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143740167	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs4443230	ENSG00000251600.4	RP11-673E1.1	-8.42	4.95e-16	2.81e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143740372	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs4637344	ENSG00000251600.4	RP11-673E1.1	-8.42	4.95e-16	2.81e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143740434	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs56277406	ENSG00000251600.4	RP11-673E1.1	-8.42	4.95e-16	2.81e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143740620	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs13143879	ENSG00000251600.4	RP11-673E1.1	-8.42	4.95e-16	2.81e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143740901	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs36086465	ENSG00000251600.4	RP11-673E1.1	-8.42	4.95e-16	2.81e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143742738	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs873430	ENSG00000251600.4	RP11-673E1.1	-8.42	4.95e-16	2.81e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143742953	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs873431	ENSG00000251600.4	RP11-673E1.1	-8.42	4.95e-16	2.81e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143743035	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs899903	ENSG00000251600.4	RP11-673E1.1	-8.42	4.95e-16	2.81e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143743551	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.9	rs1375982	ENSG00000251600.4	RP11-673E1.1	-8.42	4.95e-16	2.81e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143745764	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.9	rs4835237	ENSG00000251600.4	RP11-673E1.1	-8.42	4.95e-16	2.81e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143746349	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.9	rs56084616	ENSG00000251600.4	RP11-673E1.1	-8.42	4.95e-16	2.81e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143746697	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.966	rs11722639	ENSG00000251600.4	RP11-673E1.1	-8.42	4.95e-16	2.81e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143746884	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.966	rs11722673	ENSG00000251600.4	RP11-673E1.1	-8.42	4.95e-16	2.81e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143746946	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs6821979	ENSG00000251600.4	RP11-673E1.1	-8.42	4.95e-16	2.81e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143748091	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs6838887	ENSG00000251600.4	RP11-673E1.1	-8.42	4.95e-16	2.81e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143748130	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs1982392	ENSG00000251600.4	RP11-673E1.1	-8.42	4.95e-16	2.81e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143748604	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs1982393	ENSG00000251600.4	RP11-673E1.1	-8.42	4.95e-16	2.81e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143748736	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs9683880	ENSG00000251600.4	RP11-673E1.1	-8.42	4.95e-16	2.81e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143748787	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.9	rs7687976	ENSG00000251600.4	RP11-673E1.1	-8.42	4.95e-16	2.81e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143749171	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.9	rs7683287	ENSG00000251600.4	RP11-673E1.1	-8.42	4.95e-16	2.81e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143749270	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs2218791	ENSG00000251600.4	RP11-673E1.1	-8.42	4.95e-16	2.81e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143749300	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.712	rs2198000	ENSG00000251600.4	RP11-673E1.1	-8.42	4.95e-16	2.81e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143750005	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.9	rs2198002	ENSG00000251600.4	RP11-673E1.1	-8.42	4.95e-16	2.81e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143750028	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs6853460	ENSG00000251600.4	RP11-673E1.1	-8.42	4.95e-16	2.81e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143750392	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs13147386	ENSG00000251600.4	RP11-673E1.1	8.42	4.95e-16	2.81e-13	0.46	0.37	Immature fraction of reticulocytes;	chr4:143736586	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs5015757	ENSG00000251600.4	RP11-673E1.1	8.42	4.95e-16	2.81e-13	0.46	0.37	Immature fraction of reticulocytes;	chr4:143738144	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs13135034	ENSG00000251600.4	RP11-673E1.1	8.42	4.95e-16	2.81e-13	0.46	0.37	Immature fraction of reticulocytes;	chr4:143738247	chr4:143912331~143982454:+
PRAD	cis	rs42648	0.623	rs194505	ENSG00000227646.6	STEAP2-AS1	-8.42	4.95e-16	2.82e-13	-0.33	-0.37	Homocysteine levels;	chr7:90211993	chr7:89882353~90211635:-
PRAD	cis	rs2980439	0.846	rs2980437	ENSG00000253893.2	FAM85B	8.42	4.95e-16	2.82e-13	0.46	0.37	Neuroticism;	chr8:8237241	chr8:8167819~8226614:-
PRAD	cis	rs7615952	0.866	rs6438949	ENSG00000171084.14	FAM86JP	8.42	4.95e-16	2.82e-13	0.62	0.37	Blood pressure (smoking interaction);	chr3:125931221	chr3:125916620~125930024:+
PRAD	cis	rs7178615	1	rs7178615	ENSG00000259471.1	LINC01169	8.42	4.97e-16	2.83e-13	0.51	0.37	Diastolic blood pressure;	chr15:66576734	chr15:66582190~66685794:+
PRAD	cis	rs7772486	0.654	rs4896829	ENSG00000235652.6	RP11-545I5.3	8.42	4.98e-16	2.83e-13	0.38	0.37	Lobe attachment (rater-scored or self-reported);	chr6:145632539	chr6:145799409~145886585:+
PRAD	cis	rs67311347	0.955	rs11719205	ENSG00000223797.4	ENTPD3-AS1	8.42	4.98e-16	2.83e-13	0.32	0.37	Renal cell carcinoma;	chr3:40375767	chr3:40313802~40453329:-
PRAD	cis	rs875971	0.522	rs34973832	ENSG00000236529.1	RP13-254B10.1	8.42	4.99e-16	2.84e-13	0.38	0.37	Aortic root size;	chr7:65931217	chr7:65840212~65840596:+
PRAD	cis	rs4323050	0.546	rs13124157	ENSG00000251600.4	RP11-673E1.1	8.42	4.99e-16	2.84e-13	0.47	0.37	High light scatter reticulocyte percentage of red cells;	chr4:143975741	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs13147170	ENSG00000251600.4	RP11-673E1.1	8.42	4.99e-16	2.84e-13	0.47	0.37	Immature fraction of reticulocytes;	chr4:143975848	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs13147184	ENSG00000251600.4	RP11-673E1.1	8.42	4.99e-16	2.84e-13	0.47	0.37	Immature fraction of reticulocytes;	chr4:143975873	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.8	rs13124170	ENSG00000251600.4	RP11-673E1.1	8.42	4.99e-16	2.84e-13	0.47	0.37	Immature fraction of reticulocytes;	chr4:143975951	chr4:143912331~143982454:+
PRAD	cis	rs6517329	0.6	rs2835279	ENSG00000236830.5	CBR3-AS1	8.42	4.99e-16	2.84e-13	0.39	0.37	Schizophrenia;	chr21:36112905	chr21:36131767~36175815:-
PRAD	cis	rs12142240	1	rs12142240	ENSG00000232022.5	FAAHP1	-8.42	5.01e-16	2.85e-13	-0.35	-0.37	Menopause (age at onset);	chr1:46281629	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.92	rs6697623	ENSG00000232022.5	FAAHP1	-8.42	5.01e-16	2.85e-13	-0.35	-0.37	Menopause (age at onset);	chr1:46291870	chr1:46432129~46445521:+
PRAD	cis	rs4713118	0.869	rs4713121	ENSG00000226314.6	ZNF192P1	-8.42	5.02e-16	2.85e-13	-0.49	-0.37	Parkinson's disease;	chr6:27754285	chr6:28161781~28169594:+
PRAD	cis	rs67311347	1	rs4973878	ENSG00000223797.4	ENTPD3-AS1	8.42	5.02e-16	2.86e-13	0.32	0.37	Renal cell carcinoma;	chr3:40366074	chr3:40313802~40453329:-
PRAD	cis	rs526231	0.511	rs45518833	ENSG00000175749.11	EIF3KP1	8.42	5.03e-16	2.86e-13	0.5	0.37	Primary biliary cholangitis;	chr5:103007286	chr5:103032376~103033031:+
PRAD	cis	rs10463554	0.963	rs34381	ENSG00000175749.11	EIF3KP1	8.42	5.03e-16	2.86e-13	0.49	0.37	Parkinson's disease;	chr5:103060852	chr5:103032376~103033031:+
PRAD	cis	rs950169	0.922	rs4338765	ENSG00000225151.9	GOLGA2P7	-8.42	5.05e-16	2.87e-13	-0.52	-0.37	Schizophrenia;	chr15:84248084	chr15:84199311~84230136:-
PRAD	cis	rs10129255	0.518	rs7143784	ENSG00000211972.2	IGHV3-66	8.42	5.05e-16	2.87e-13	0.32	0.37	Kawasaki disease;	chr14:106687277	chr14:106675017~106675544:-
PRAD	cis	rs950169	0.544	rs2036949	ENSG00000259728.4	LINC00933	8.42	5.06e-16	2.88e-13	0.45	0.37	Schizophrenia;	chr15:84620374	chr15:84570649~84580175:+
PRAD	cis	rs6723108	0.627	rs7593370	ENSG00000224043.6	CCNT2-AS1	8.42	5.07e-16	2.88e-13	0.5	0.37	Type 2 diabetes;	chr2:134865947	chr2:134735464~134918710:-
PRAD	cis	rs9532669	0.963	rs1056824	ENSG00000168852.11	TPTE2P5	8.42	5.07e-16	2.88e-13	0.35	0.37	Cervical cancer;	chr13:40932748	chr13:40822296~40921749:-
PRAD	cis	rs763567	0.81	rs638704	ENSG00000271811.1	RP1-79C4.4	8.42	5.08e-16	2.89e-13	0.42	0.37	Tonsillectomy;	chr1:170629046	chr1:170667381~170669425:+
PRAD	cis	rs17361889	0.752	rs62440374	ENSG00000224683.1	RPL36AP29	8.42	5.09e-16	2.89e-13	0.44	0.37	Pediatric bone mineral content (hip);	chr7:16172290	chr7:16208945~16209265:+
PRAD	cis	rs8177376	0.953	rs73017399	ENSG00000254905.1	RP11-712L6.7	8.42	5.11e-16	2.91e-13	0.48	0.37	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126316417	chr11:126292922~126294254:-
PRAD	cis	rs1355223	0.902	rs865070	ENSG00000271369.1	RP11-350D17.3	-8.42	5.12e-16	2.91e-13	-0.42	-0.37	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34720950	chr11:34709600~34710161:+
PRAD	cis	rs7615952	0.576	rs1127717	ENSG00000171084.14	FAM86JP	8.42	5.12e-16	2.91e-13	0.58	0.37	Blood pressure (smoking interaction);	chr3:126107216	chr3:125916620~125930024:+
PRAD	cis	rs7189233	0.513	rs28759393	ENSG00000279344.1	RP11-44F14.7	8.42	5.12e-16	2.91e-13	0.34	0.37	Intelligence (multi-trait analysis);	chr16:53411446	chr16:53478957~53481550:-
PRAD	cis	rs7189233	0.513	rs1344491	ENSG00000279344.1	RP11-44F14.7	8.42	5.13e-16	2.92e-13	0.34	0.37	Intelligence (multi-trait analysis);	chr16:53405497	chr16:53478957~53481550:-
PRAD	cis	rs11976180	1	rs2951372	ENSG00000170356.8	OR2A20P	-8.41	5.14e-16	2.92e-13	-0.48	-0.37	Obesity-related traits;	chr7:144052410	chr7:144250045~144252957:-
PRAD	cis	rs11976180	1	rs2951368	ENSG00000170356.8	OR2A20P	-8.41	5.14e-16	2.92e-13	-0.48	-0.37	Obesity-related traits;	chr7:144055728	chr7:144250045~144252957:-
PRAD	cis	rs11976180	1	rs2961115	ENSG00000170356.8	OR2A20P	-8.41	5.14e-16	2.92e-13	-0.48	-0.37	Obesity-related traits;	chr7:144056278	chr7:144250045~144252957:-
PRAD	cis	rs7615952	0.599	rs7652883	ENSG00000171084.14	FAM86JP	8.41	5.14e-16	2.92e-13	0.57	0.37	Blood pressure (smoking interaction);	chr3:125989134	chr3:125916620~125930024:+
PRAD	cis	rs7615952	0.688	rs12485622	ENSG00000171084.14	FAM86JP	8.41	5.14e-16	2.92e-13	0.57	0.37	Blood pressure (smoking interaction);	chr3:125991896	chr3:125916620~125930024:+
PRAD	cis	rs7131987	0.65	rs7957339	ENSG00000257176.2	RP11-996F15.2	-8.41	5.14e-16	2.92e-13	-0.4	-0.37	QT interval;	chr12:29303562	chr12:29280418~29317848:-
PRAD	cis	rs42648	0.535	rs10952994	ENSG00000227646.6	STEAP2-AS1	8.41	5.15e-16	2.93e-13	0.33	0.37	Homocysteine levels;	chr7:90124545	chr7:89882353~90211635:-
PRAD	cis	rs10129255	0.5	rs1024350	ENSG00000211972.2	IGHV3-66	8.41	5.16e-16	2.93e-13	0.32	0.37	Kawasaki disease;	chr14:106685105	chr14:106675017~106675544:-
PRAD	cis	rs526231	0.511	rs12109860	ENSG00000175749.11	EIF3KP1	8.41	5.17e-16	2.94e-13	0.5	0.37	Primary biliary cholangitis;	chr5:103057408	chr5:103032376~103033031:+
PRAD	cis	rs950169	0.763	rs35372971	ENSG00000259728.4	LINC00933	8.41	5.18e-16	2.94e-13	0.44	0.37	Schizophrenia;	chr15:84387097	chr15:84570649~84580175:+
PRAD	cis	rs4835473	0.864	rs28609839	ENSG00000251600.4	RP11-673E1.1	-8.41	5.19e-16	2.95e-13	-0.48	-0.37	Immature fraction of reticulocytes;	chr4:143954160	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.9	rs13101531	ENSG00000251600.4	RP11-673E1.1	-8.41	5.2e-16	2.95e-13	-0.48	-0.37	Immature fraction of reticulocytes;	chr4:143982197	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs28668841	ENSG00000251600.4	RP11-673E1.1	-8.41	5.2e-16	2.95e-13	-0.48	-0.37	Immature fraction of reticulocytes;	chr4:143982530	chr4:143912331~143982454:+
PRAD	cis	rs7189233	0.531	rs8063294	ENSG00000279344.1	RP11-44F14.7	8.41	5.22e-16	2.96e-13	0.34	0.37	Intelligence (multi-trait analysis);	chr16:53412845	chr16:53478957~53481550:-
PRAD	cis	rs9903692	0.954	rs9889470	ENSG00000278765.1	RP5-890E16.5	8.41	5.24e-16	2.97e-13	0.56	0.37	Pulse pressure;	chr17:48233713	chr17:48066704~48067293:-
PRAD	cis	rs7432375	0.901	rs35874192	ENSG00000261758.1	RP11-102M11.2	-8.41	5.25e-16	2.98e-13	-0.42	-0.37	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136751162	chr3:136752630~136755780:+
PRAD	cis	rs7432375	0.901	rs900818	ENSG00000261758.1	RP11-102M11.2	-8.41	5.25e-16	2.98e-13	-0.42	-0.37	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136752973	chr3:136752630~136755780:+
PRAD	cis	rs6452524	1	rs1382368	ENSG00000249664.1	CTD-2227C6.2	8.41	5.25e-16	2.98e-13	0.42	0.37	Hypertension (SNP x SNP interaction);	chr5:83155256	chr5:83012285~83013109:-
PRAD	cis	rs6452524	1	rs1382366	ENSG00000249664.1	CTD-2227C6.2	8.41	5.25e-16	2.98e-13	0.42	0.37	Hypertension (SNP x SNP interaction);	chr5:83156352	chr5:83012285~83013109:-
PRAD	cis	rs6452524	1	rs13358361	ENSG00000249664.1	CTD-2227C6.2	8.41	5.25e-16	2.98e-13	0.42	0.37	Hypertension (SNP x SNP interaction);	chr5:83160237	chr5:83012285~83013109:-
PRAD	cis	rs6452524	1	rs6452528	ENSG00000249664.1	CTD-2227C6.2	8.41	5.25e-16	2.98e-13	0.42	0.37	Hypertension (SNP x SNP interaction);	chr5:83162560	chr5:83012285~83013109:-
PRAD	cis	rs6452524	1	rs6864479	ENSG00000249664.1	CTD-2227C6.2	8.41	5.25e-16	2.98e-13	0.42	0.37	Hypertension (SNP x SNP interaction);	chr5:83166421	chr5:83012285~83013109:-
PRAD	cis	rs950169	0.922	rs11639244	ENSG00000225151.9	GOLGA2P7	-8.41	5.25e-16	2.98e-13	-0.51	-0.37	Schizophrenia;	chr15:84163898	chr15:84199311~84230136:-
PRAD	cis	rs812925	0.533	rs35507645	ENSG00000271889.1	RP11-493E12.1	8.41	5.29e-16	2.99e-13	0.4	0.37	Immature fraction of reticulocytes;	chr2:61169631	chr2:61151433~61162105:-
PRAD	cis	rs875971	0.929	rs4122249	ENSG00000237310.1	GS1-124K5.4	8.41	5.32e-16	3.01e-13	0.33	0.37	Aortic root size;	chr7:66455949	chr7:66493706~66495474:+
PRAD	cis	rs950169	1	rs950169	ENSG00000225151.9	GOLGA2P7	-8.41	5.33e-16	3.01e-13	-0.51	-0.37	Schizophrenia;	chr15:84037709	chr15:84199311~84230136:-
PRAD	cis	rs950169	1	rs11638394	ENSG00000225151.9	GOLGA2P7	-8.41	5.34e-16	3.02e-13	-0.51	-0.37	Schizophrenia;	chr15:84110176	chr15:84199311~84230136:-
PRAD	cis	rs950169	1	rs35658069	ENSG00000225151.9	GOLGA2P7	-8.41	5.34e-16	3.02e-13	-0.51	-0.37	Schizophrenia;	chr15:84111394	chr15:84199311~84230136:-
PRAD	cis	rs10463554	0.963	rs6883113	ENSG00000175749.11	EIF3KP1	8.41	5.35e-16	3.02e-13	0.49	0.37	Parkinson's disease;	chr5:103042185	chr5:103032376~103033031:+
PRAD	cis	rs6538678	0.833	rs1898178	ENSG00000258343.1	RP11-536G4.2	-8.41	5.38e-16	3.04e-13	-0.47	-0.37	Lupus nephritis in systemic lupus erythematosus;	chr12:95887554	chr12:95795345~95858839:-
PRAD	cis	rs6538678	0.833	rs1898177	ENSG00000258343.1	RP11-536G4.2	-8.41	5.38e-16	3.04e-13	-0.47	-0.37	Lupus nephritis in systemic lupus erythematosus;	chr12:95887568	chr12:95795345~95858839:-
PRAD	cis	rs875971	1	rs6956179	ENSG00000237310.1	GS1-124K5.4	-8.41	5.4e-16	3.05e-13	-0.32	-0.37	Aortic root size;	chr7:66341672	chr7:66493706~66495474:+
PRAD	cis	rs7615952	0.932	rs6438948	ENSG00000171084.14	FAM86JP	-8.41	5.4e-16	3.05e-13	-0.6	-0.37	Blood pressure (smoking interaction);	chr3:125931202	chr3:125916620~125930024:+
PRAD	cis	rs4722166	0.532	rs4719712	ENSG00000179428.2	AC073072.5	-8.41	5.41e-16	3.06e-13	-0.42	-0.37	Lung cancer;	chr7:22716188	chr7:22725395~22727620:-
PRAD	cis	rs4631830	0.863	rs3101227	ENSG00000230869.1	CTGLF10P	-8.41	5.41e-16	3.06e-13	-0.46	-0.37	Prostate-specific antigen levels;	chr10:46075619	chr10:45678692~45700532:+
PRAD	cis	rs3096299	0.586	rs4572400	ENSG00000261118.1	RP11-104N10.1	8.41	5.44e-16	3.08e-13	0.35	0.37	Multiple myeloma (IgH translocation);	chr16:89467108	chr16:89492017~89504460:-
PRAD	cis	rs853679	0.527	rs213228	ENSG00000216901.1	AL022393.7	8.41	5.44e-16	3.08e-13	0.46	0.37	Depression;	chr6:28363475	chr6:28176188~28176674:+
PRAD	cis	rs6991838	0.831	rs11992528	ENSG00000200714.1	Y_RNA	8.41	5.45e-16	3.08e-13	0.37	0.37	Intelligence (multi-trait analysis);	chr8:65561644	chr8:65592731~65592820:+
PRAD	cis	rs2404602	0.692	rs35138393	ENSG00000259422.1	RP11-593F23.1	8.41	5.45e-16	3.08e-13	0.46	0.37	Blood metabolite levels;	chr15:76685276	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.669	rs12595313	ENSG00000259422.1	RP11-593F23.1	8.41	5.45e-16	3.08e-13	0.46	0.37	Blood metabolite levels;	chr15:76686029	chr15:76174891~76181486:-
PRAD	cis	rs763567	1	rs12755237	ENSG00000271811.1	RP1-79C4.4	-8.41	5.47e-16	3.09e-13	-0.42	-0.37	Tonsillectomy;	chr1:170599573	chr1:170667381~170669425:+
PRAD	cis	rs763567	1	rs12742164	ENSG00000271811.1	RP1-79C4.4	-8.41	5.47e-16	3.09e-13	-0.42	-0.37	Tonsillectomy;	chr1:170599755	chr1:170667381~170669425:+
PRAD	cis	rs763567	1	rs61217505	ENSG00000271811.1	RP1-79C4.4	-8.41	5.47e-16	3.09e-13	-0.42	-0.37	Tonsillectomy;	chr1:170604117	chr1:170667381~170669425:+
PRAD	cis	rs172166	0.516	rs2791333	ENSG00000280107.1	AL022393.9	-8.41	5.47e-16	3.09e-13	-0.44	-0.37	Cardiac Troponin-T levels;	chr6:28143336	chr6:28170845~28172521:+
PRAD	cis	rs801193	0.613	rs2659900	ENSG00000237310.1	GS1-124K5.4	8.41	5.49e-16	3.1e-13	0.34	0.37	Aortic root size;	chr7:66719456	chr7:66493706~66495474:+
PRAD	cis	rs6723108	0.627	rs6430550	ENSG00000224043.6	CCNT2-AS1	-8.41	5.49e-16	3.1e-13	-0.51	-0.37	Type 2 diabetes;	chr2:134858815	chr2:134735464~134918710:-
PRAD	cis	rs7811142	1	rs60257855	ENSG00000242294.5	STAG3L5P	8.41	5.49e-16	3.1e-13	0.25	0.37	Platelet count;	chr7:100429157	chr7:100336079~100351900:+
PRAD	cis	rs950169	0.922	rs62028133	ENSG00000225151.9	GOLGA2P7	-8.41	5.51e-16	3.11e-13	-0.51	-0.37	Schizophrenia;	chr15:84250623	chr15:84199311~84230136:-
PRAD	cis	rs10463554	0.927	rs40061	ENSG00000175749.11	EIF3KP1	8.41	5.52e-16	3.12e-13	0.49	0.37	Parkinson's disease;	chr5:103067412	chr5:103032376~103033031:+
PRAD	cis	rs2255336	0.938	rs2126888	ENSG00000245648.1	RP11-277P12.20	8.41	5.53e-16	3.12e-13	0.55	0.37	Blood protein levels;	chr12:10393789	chr12:10363769~10398506:+
PRAD	cis	rs9532669	0.926	rs8002809	ENSG00000168852.11	TPTE2P5	8.4	5.53e-16	3.13e-13	0.35	0.37	Cervical cancer;	chr13:40872769	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.929	rs7982421	ENSG00000168852.11	TPTE2P5	8.4	5.53e-16	3.13e-13	0.35	0.37	Cervical cancer;	chr13:40872776	chr13:40822296~40921749:-
PRAD	cis	rs67311347	1	rs7636719	ENSG00000223797.4	ENTPD3-AS1	8.4	5.55e-16	3.14e-13	0.32	0.37	Renal cell carcinoma;	chr3:40390593	chr3:40313802~40453329:-
PRAD	cis	rs10463554	0.824	rs34818	ENSG00000175749.11	EIF3KP1	8.4	5.59e-16	3.15e-13	0.5	0.37	Parkinson's disease;	chr5:103100407	chr5:103032376~103033031:+
PRAD	cis	rs8005677	1	rs8014936	ENSG00000257285.4	RP11-298I3.1	8.4	5.6e-16	3.16e-13	0.37	0.37	Cognitive ability (multi-trait analysis);	chr14:22905936	chr14:22929609~22955562:+
PRAD	cis	rs8005677	1	rs8016061	ENSG00000257285.4	RP11-298I3.1	8.4	5.6e-16	3.16e-13	0.37	0.37	Cognitive ability (multi-trait analysis);	chr14:22906600	chr14:22929609~22955562:+
PRAD	cis	rs8005677	1	rs8005677	ENSG00000257285.4	RP11-298I3.1	8.4	5.6e-16	3.16e-13	0.37	0.37	Cognitive ability (multi-trait analysis);	chr14:22907469	chr14:22929609~22955562:+
PRAD	cis	rs2108622	0.727	rs55954696	ENSG00000267056.2	AC005336.4	8.4	5.6e-16	3.16e-13	0.5	0.37	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15870995	chr19:15910582~15911824:-
PRAD	cis	rs2243480	0.708	rs35825036	ENSG00000226824.5	RP4-756H11.3	-8.4	5.61e-16	3.16e-13	-0.73	-0.37	Diabetic kidney disease;	chr7:66521515	chr7:66654538~66669855:+
PRAD	cis	rs763567	0.967	rs1234274	ENSG00000271811.1	RP1-79C4.4	8.4	5.61e-16	3.16e-13	0.42	0.37	Tonsillectomy;	chr1:170627232	chr1:170667381~170669425:+
PRAD	cis	rs12142240	0.698	rs66847432	ENSG00000232022.5	FAAHP1	-8.4	5.62e-16	3.17e-13	-0.34	-0.37	Menopause (age at onset);	chr1:46366341	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.659	rs67547686	ENSG00000232022.5	FAAHP1	-8.4	5.62e-16	3.17e-13	-0.34	-0.37	Menopause (age at onset);	chr1:46366557	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.659	rs17361873	ENSG00000232022.5	FAAHP1	-8.4	5.62e-16	3.17e-13	-0.34	-0.37	Menopause (age at onset);	chr1:46367014	chr1:46432129~46445521:+
PRAD	cis	rs7131987	0.621	rs3782506	ENSG00000257176.2	RP11-996F15.2	8.4	5.64e-16	3.18e-13	0.4	0.37	QT interval;	chr12:29292489	chr12:29280418~29317848:-
PRAD	cis	rs11976180	1	rs6464574	ENSG00000170356.8	OR2A20P	-8.4	5.65e-16	3.19e-13	-0.49	-0.37	Obesity-related traits;	chr7:144051164	chr7:144250045~144252957:-
PRAD	cis	rs526231	0.511	rs11951374	ENSG00000175749.11	EIF3KP1	8.4	5.66e-16	3.19e-13	0.49	0.37	Primary biliary cholangitis;	chr5:103020094	chr5:103032376~103033031:+
PRAD	cis	rs1062177	0.694	rs2915816	ENSG00000253921.1	CTB-113P19.3	8.4	5.67e-16	3.2e-13	0.47	0.37	Preschool internalizing problems;	chr5:151736296	chr5:151753992~151767247:+
PRAD	cis	rs950169	0.84	rs62019457	ENSG00000259728.4	LINC00933	8.4	5.68e-16	3.2e-13	0.43	0.37	Schizophrenia;	chr15:84558911	chr15:84570649~84580175:+
PRAD	cis	rs4835473	0.932	rs36018946	ENSG00000251600.4	RP11-673E1.1	-8.4	5.68e-16	3.2e-13	-0.47	-0.37	Immature fraction of reticulocytes;	chr4:143980942	chr4:143912331~143982454:+
PRAD	cis	rs42648	0.748	rs10226014	ENSG00000227646.6	STEAP2-AS1	8.4	5.68e-16	3.21e-13	0.34	0.37	Homocysteine levels;	chr7:90273219	chr7:89882353~90211635:-
PRAD	cis	rs1501911	0.566	rs709388	ENSG00000248489.1	CTD-2007H13.3	8.4	5.69e-16	3.21e-13	0.46	0.37	Lung function (FEV1/FVC);	chr5:98994037	chr5:98929171~98995013:+
PRAD	cis	rs6452524	1	rs6882179	ENSG00000249664.1	CTD-2227C6.2	8.4	5.7e-16	3.22e-13	0.42	0.37	Hypertension (SNP x SNP interaction);	chr5:83139582	chr5:83012285~83013109:-
PRAD	cis	rs6452524	1	rs7732092	ENSG00000249664.1	CTD-2227C6.2	8.4	5.7e-16	3.22e-13	0.42	0.37	Hypertension (SNP x SNP interaction);	chr5:83141110	chr5:83012285~83013109:-
PRAD	cis	rs11098499	0.73	rs78971550	ENSG00000245958.5	RP11-33B1.1	-8.4	5.71e-16	3.22e-13	-0.36	-0.37	Corneal astigmatism;	chr4:119359886	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.645	rs78422072	ENSG00000245958.5	RP11-33B1.1	-8.4	5.71e-16	3.22e-13	-0.36	-0.37	Corneal astigmatism;	chr4:119359887	chr4:119454791~119552025:+
PRAD	cis	rs9532669	0.963	rs1571116	ENSG00000168852.11	TPTE2P5	8.4	5.71e-16	3.22e-13	0.35	0.37	Cervical cancer;	chr13:40929765	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.963	rs9532673	ENSG00000168852.11	TPTE2P5	8.4	5.71e-16	3.22e-13	0.35	0.37	Cervical cancer;	chr13:40930412	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.89	rs9532676	ENSG00000168852.11	TPTE2P5	8.4	5.71e-16	3.22e-13	0.35	0.37	Cervical cancer;	chr13:40935626	chr13:40822296~40921749:-
PRAD	cis	rs853679	1	rs2799079	ENSG00000280107.1	AL022393.9	-8.4	5.72e-16	3.23e-13	-0.55	-0.37	Depression;	chr6:28267398	chr6:28170845~28172521:+
PRAD	cis	rs1062177	0.901	rs1549622	ENSG00000253921.1	CTB-113P19.3	-8.4	5.74e-16	3.24e-13	-0.5	-0.37	Preschool internalizing problems;	chr5:151886488	chr5:151753992~151767247:+
PRAD	cis	rs1150668	0.699	rs2394049	ENSG00000280107.1	AL022393.9	-8.4	5.74e-16	3.24e-13	-0.44	-0.37	Pubertal anthropometrics;	chr6:28271903	chr6:28170845~28172521:+
PRAD	cis	rs7829975	0.806	rs2428	ENSG00000253893.2	FAM85B	-8.4	5.77e-16	3.25e-13	-0.46	-0.37	Mood instability;	chr8:8783635	chr8:8167819~8226614:-
PRAD	cis	rs2404602	0.619	rs7342603	ENSG00000259422.1	RP11-593F23.1	8.4	5.79e-16	3.26e-13	0.46	0.37	Blood metabolite levels;	chr15:76690284	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.692	rs7350777	ENSG00000259422.1	RP11-593F23.1	8.4	5.79e-16	3.26e-13	0.46	0.37	Blood metabolite levels;	chr15:76693100	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.692	rs35395069	ENSG00000259422.1	RP11-593F23.1	8.4	5.79e-16	3.26e-13	0.46	0.37	Blood metabolite levels;	chr15:76693993	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.692	rs72738889	ENSG00000259422.1	RP11-593F23.1	8.4	5.79e-16	3.26e-13	0.46	0.37	Blood metabolite levels;	chr15:76699722	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.692	rs3816266	ENSG00000259422.1	RP11-593F23.1	8.4	5.79e-16	3.26e-13	0.46	0.37	Blood metabolite levels;	chr15:76701494	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.692	rs2304920	ENSG00000259422.1	RP11-593F23.1	8.4	5.79e-16	3.26e-13	0.46	0.37	Blood metabolite levels;	chr15:76701526	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.692	rs58973160	ENSG00000259422.1	RP11-593F23.1	8.4	5.79e-16	3.26e-13	0.46	0.37	Blood metabolite levels;	chr15:76708001	chr15:76174891~76181486:-
PRAD	cis	rs6847067	0.8	rs6847811	ENSG00000180769.7	WDFY3-AS2	-8.4	5.81e-16	3.27e-13	-0.38	-0.37	Oropharynx cancer;	chr4:84946160	chr4:84965682~85011277:+
PRAD	cis	rs4835473	0.864	rs13145791	ENSG00000251600.4	RP11-673E1.1	-8.4	5.81e-16	3.27e-13	-0.47	-0.37	Immature fraction of reticulocytes;	chr4:143735688	chr4:143912331~143982454:+
PRAD	cis	rs950169	0.919	rs12915589	ENSG00000225151.9	GOLGA2P7	-8.4	5.81e-16	3.27e-13	-0.51	-0.37	Schizophrenia;	chr15:84065712	chr15:84199311~84230136:-
PRAD	cis	rs950169	0.959	rs66801143	ENSG00000225151.9	GOLGA2P7	-8.4	5.81e-16	3.27e-13	-0.51	-0.37	Schizophrenia;	chr15:84067905	chr15:84199311~84230136:-
PRAD	cis	rs950169	1	rs35648189	ENSG00000225151.9	GOLGA2P7	-8.4	5.81e-16	3.27e-13	-0.51	-0.37	Schizophrenia;	chr15:84071996	chr15:84199311~84230136:-
PRAD	cis	rs950169	0.92	rs17300048	ENSG00000225151.9	GOLGA2P7	-8.4	5.81e-16	3.27e-13	-0.51	-0.37	Schizophrenia;	chr15:84080725	chr15:84199311~84230136:-
PRAD	cis	rs950169	1	rs79318564	ENSG00000225151.9	GOLGA2P7	-8.4	5.83e-16	3.28e-13	-0.51	-0.37	Schizophrenia;	chr15:84117398	chr15:84199311~84230136:-
PRAD	cis	rs6921919	0.525	rs16894095	ENSG00000216901.1	AL022393.7	8.4	5.84e-16	3.29e-13	0.47	0.37	Autism spectrum disorder or schizophrenia;	chr6:28422453	chr6:28176188~28176674:+
PRAD	cis	rs812925	0.512	rs1177309	ENSG00000271889.1	RP11-493E12.1	8.4	5.84e-16	3.29e-13	0.4	0.37	Immature fraction of reticulocytes;	chr2:61158113	chr2:61151433~61162105:-
PRAD	cis	rs7432375	0.901	rs1681817	ENSG00000261758.1	RP11-102M11.2	-8.4	5.84e-16	3.29e-13	-0.42	-0.37	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136754886	chr3:136752630~136755780:+
PRAD	cis	rs7432375	0.901	rs6802702	ENSG00000261758.1	RP11-102M11.2	-8.4	5.84e-16	3.29e-13	-0.42	-0.37	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136770721	chr3:136752630~136755780:+
PRAD	cis	rs3096299	0.9	rs4785666	ENSG00000274627.1	RP11-104N10.2	8.4	5.86e-16	3.3e-13	0.37	0.37	Multiple myeloma (IgH translocation);	chr16:89396363	chr16:89516797~89522217:+
PRAD	cis	rs7712401	0.56	rs13168225	ENSG00000263432.2	RN7SL689P	-8.4	5.86e-16	3.3e-13	-0.39	-0.37	Mean platelet volume;	chr5:123011569	chr5:123022487~123022783:-
PRAD	cis	rs1150668	0.699	rs1736895	ENSG00000280107.1	AL022393.9	-8.4	5.87e-16	3.3e-13	-0.44	-0.37	Pubertal anthropometrics;	chr6:28252048	chr6:28170845~28172521:+
PRAD	cis	rs1150668	0.699	rs12214383	ENSG00000280107.1	AL022393.9	8.4	5.87e-16	3.31e-13	0.44	0.37	Pubertal anthropometrics;	chr6:28255953	chr6:28170845~28172521:+
PRAD	cis	rs673078	0.607	rs1060964	ENSG00000275409.1	RP11-131L12.4	-8.4	5.88e-16	3.31e-13	-0.5	-0.37	Glucose homeostasis traits;	chr12:118414906	chr12:118430147~118430699:+
PRAD	cis	rs10875746	0.624	rs11168498	ENSG00000240399.1	RP1-228P16.1	-8.4	5.9e-16	3.32e-13	-0.35	-0.37	Longevity (90 years and older);	chr12:48261305	chr12:48054813~48055591:-
PRAD	cis	rs12908161	1	rs35316992	ENSG00000259728.4	LINC00933	8.4	5.9e-16	3.32e-13	0.45	0.37	Schizophrenia;	chr15:84704902	chr15:84570649~84580175:+
PRAD	cis	rs12908161	1	rs4643294	ENSG00000259728.4	LINC00933	8.4	5.9e-16	3.32e-13	0.45	0.37	Schizophrenia;	chr15:84707022	chr15:84570649~84580175:+
PRAD	cis	rs12908161	1	rs62021219	ENSG00000259728.4	LINC00933	8.4	5.9e-16	3.32e-13	0.45	0.37	Schizophrenia;	chr15:84712928	chr15:84570649~84580175:+
PRAD	cis	rs12908161	1	rs34900908	ENSG00000259728.4	LINC00933	8.4	5.9e-16	3.32e-13	0.45	0.37	Schizophrenia;	chr15:84714368	chr15:84570649~84580175:+
PRAD	cis	rs12908161	1	rs35524990	ENSG00000259728.4	LINC00933	8.4	5.9e-16	3.32e-13	0.45	0.37	Schizophrenia;	chr15:84714972	chr15:84570649~84580175:+
PRAD	cis	rs4835473	0.897	rs17693780	ENSG00000251600.4	RP11-673E1.1	-8.4	5.91e-16	3.32e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143737563	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.897	rs35556180	ENSG00000251600.4	RP11-673E1.1	-8.4	5.91e-16	3.32e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143737595	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.897	rs35377051	ENSG00000251600.4	RP11-673E1.1	-8.4	5.91e-16	3.32e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143737627	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.864	rs17018131	ENSG00000251600.4	RP11-673E1.1	-8.4	5.91e-16	3.32e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143737647	chr4:143912331~143982454:+
PRAD	cis	rs9601248	0.874	rs9545154	ENSG00000227676.3	LINC01068	8.4	5.92e-16	3.33e-13	0.44	0.37	Major depressive disorder;	chr13:79617682	chr13:79566727~79571436:+
PRAD	cis	rs9601248	0.874	rs9545155	ENSG00000227676.3	LINC01068	8.4	5.92e-16	3.33e-13	0.44	0.37	Major depressive disorder;	chr13:79617738	chr13:79566727~79571436:+
PRAD	cis	rs9903692	0.865	rs7220520	ENSG00000278765.1	RP5-890E16.5	8.4	5.92e-16	3.33e-13	0.55	0.37	Pulse pressure;	chr17:48090580	chr17:48066704~48067293:-
PRAD	cis	rs3096299	0.503	rs9925045	ENSG00000261118.1	RP11-104N10.1	8.4	5.93e-16	3.34e-13	0.35	0.37	Multiple myeloma (IgH translocation);	chr16:89490068	chr16:89492017~89504460:-
PRAD	cis	rs950169	0.8	rs4842847	ENSG00000259728.4	LINC00933	8.4	5.93e-16	3.34e-13	0.44	0.37	Schizophrenia;	chr15:84262447	chr15:84570649~84580175:+
PRAD	cis	rs12908161	1	rs11638290	ENSG00000259728.4	LINC00933	8.4	5.95e-16	3.35e-13	0.45	0.37	Schizophrenia;	chr15:84684405	chr15:84570649~84580175:+
PRAD	cis	rs7104764	0.507	rs6598056	ENSG00000277290.1	RP11-326C3.16	8.4	5.95e-16	3.35e-13	0.37	0.37	Menarche (age at onset);	chr11:252283	chr11:243099~243483:-
PRAD	cis	rs6430553	0.929	rs3819121	ENSG00000224043.6	CCNT2-AS1	-8.4	5.95e-16	3.35e-13	-0.49	-0.37	Blood metabolite levels;	chr2:134865290	chr2:134735464~134918710:-
PRAD	cis	rs10463554	0.963	rs62364874	ENSG00000175749.11	EIF3KP1	8.39	5.97e-16	3.36e-13	0.49	0.37	Parkinson's disease;	chr5:103056475	chr5:103032376~103033031:+
PRAD	cis	rs10463554	0.963	rs62364876	ENSG00000175749.11	EIF3KP1	8.39	5.97e-16	3.36e-13	0.49	0.37	Parkinson's disease;	chr5:103058454	chr5:103032376~103033031:+
PRAD	cis	rs10463554	0.963	rs158254	ENSG00000175749.11	EIF3KP1	8.39	5.97e-16	3.36e-13	0.49	0.37	Parkinson's disease;	chr5:103059179	chr5:103032376~103033031:+
PRAD	cis	rs6723108	0.603	rs4953938	ENSG00000224043.6	CCNT2-AS1	8.39	5.97e-16	3.36e-13	0.5	0.37	Type 2 diabetes;	chr2:134937278	chr2:134735464~134918710:-
PRAD	cis	rs4631830	0.72	rs4935573	ENSG00000230869.1	CTGLF10P	8.39	5.97e-16	3.36e-13	0.45	0.37	Prostate-specific antigen levels;	chr10:46091437	chr10:45678692~45700532:+
PRAD	cis	rs9903692	0.909	rs11079806	ENSG00000278765.1	RP5-890E16.5	8.39	5.98e-16	3.36e-13	0.55	0.37	Pulse pressure;	chr17:48065318	chr17:48066704~48067293:-
PRAD	cis	rs801193	0.66	rs10950049	ENSG00000237310.1	GS1-124K5.4	8.39	5.98e-16	3.37e-13	0.33	0.37	Aortic root size;	chr7:66765873	chr7:66493706~66495474:+
PRAD	cis	rs7432375	0.901	rs11919030	ENSG00000261758.1	RP11-102M11.2	8.39	5.99e-16	3.37e-13	0.42	0.37	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136629757	chr3:136752630~136755780:+
PRAD	cis	rs7432375	0.901	rs1017882	ENSG00000261758.1	RP11-102M11.2	8.39	5.99e-16	3.37e-13	0.42	0.37	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136638863	chr3:136752630~136755780:+
PRAD	cis	rs7432375	0.901	rs4521165	ENSG00000261758.1	RP11-102M11.2	-8.39	5.99e-16	3.37e-13	-0.42	-0.37	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136650868	chr3:136752630~136755780:+
PRAD	cis	rs7432375	0.901	rs7618518	ENSG00000261758.1	RP11-102M11.2	-8.39	5.99e-16	3.37e-13	-0.42	-0.37	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136651250	chr3:136752630~136755780:+
PRAD	cis	rs7432375	0.901	rs4038587	ENSG00000261758.1	RP11-102M11.2	-8.39	5.99e-16	3.37e-13	-0.42	-0.37	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136662526	chr3:136752630~136755780:+
PRAD	cis	rs7432375	0.901	rs9836231	ENSG00000261758.1	RP11-102M11.2	-8.39	5.99e-16	3.37e-13	-0.42	-0.37	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136695479	chr3:136752630~136755780:+
PRAD	cis	rs7432375	0.804	rs6764567	ENSG00000261758.1	RP11-102M11.2	-8.39	5.99e-16	3.37e-13	-0.42	-0.37	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136706672	chr3:136752630~136755780:+
PRAD	cis	rs7432375	0.901	rs7616204	ENSG00000261758.1	RP11-102M11.2	-8.39	5.99e-16	3.37e-13	-0.42	-0.37	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136725747	chr3:136752630~136755780:+
PRAD	cis	rs801193	0.66	rs974239	ENSG00000237310.1	GS1-124K5.4	8.39	6.01e-16	3.38e-13	0.33	0.37	Aortic root size;	chr7:66748504	chr7:66493706~66495474:+
PRAD	cis	rs2108622	0.727	rs8102532	ENSG00000267056.2	AC005336.4	8.39	6.01e-16	3.38e-13	0.5	0.37	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869250	chr19:15910582~15911824:-
PRAD	cis	rs964611	0.938	rs8026751	ENSG00000259488.2	RP11-154J22.1	-8.39	6.02e-16	3.38e-13	-0.35	-0.37	Metabolite levels (Pyroglutamine);	chr15:48290648	chr15:48312353~48331856:-
PRAD	cis	rs1075265	0.933	rs7607066	ENSG00000233266.1	HMGB1P31	8.39	6.03e-16	3.39e-13	0.5	0.37	Chronotype;Morning vs. evening chronotype;	chr2:54110054	chr2:54051334~54051760:+
PRAD	cis	rs7131987	0.65	rs7973786	ENSG00000257176.2	RP11-996F15.2	-8.39	6.03e-16	3.39e-13	-0.4	-0.37	QT interval;	chr12:29309811	chr12:29280418~29317848:-
PRAD	cis	rs9287719	0.967	rs7570118	ENSG00000234818.1	AC092687.5	8.39	6.04e-16	3.39e-13	0.44	0.37	Prostate cancer;	chr2:10577881	chr2:10589166~10604830:+
PRAD	cis	rs950169	0.922	rs11635505	ENSG00000259728.4	LINC00933	-8.39	6.05e-16	3.4e-13	-0.44	-0.37	Schizophrenia;	chr15:84553803	chr15:84570649~84580175:+
PRAD	cis	rs875971	0.522	rs6960048	ENSG00000236529.1	RP13-254B10.1	8.39	6.06e-16	3.41e-13	0.38	0.37	Aortic root size;	chr7:65943052	chr7:65840212~65840596:+
PRAD	cis	rs67311347	1	rs9842564	ENSG00000223797.4	ENTPD3-AS1	-8.39	6.08e-16	3.42e-13	-0.32	-0.37	Renal cell carcinoma;	chr3:40364319	chr3:40313802~40453329:-
PRAD	cis	rs7727544	0.716	rs2089855	ENSG00000233006.5	AC034220.3	8.39	6.09e-16	3.42e-13	0.32	0.37	Blood metabolite levels;	chr5:132237836	chr5:132311285~132369916:-
PRAD	cis	rs3096299	0.934	rs9927904	ENSG00000274627.1	RP11-104N10.2	8.39	6.11e-16	3.43e-13	0.37	0.37	Multiple myeloma (IgH translocation);	chr16:89396439	chr16:89516797~89522217:+
PRAD	cis	rs12142240	0.698	rs17361950	ENSG00000232022.5	FAAHP1	-8.39	6.11e-16	3.43e-13	-0.35	-0.37	Menopause (age at onset);	chr1:46398478	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs6683192	ENSG00000232022.5	FAAHP1	-8.39	6.12e-16	3.44e-13	-0.34	-0.37	Menopause (age at onset);	chr1:46364585	chr1:46432129~46445521:+
PRAD	cis	rs801193	0.66	rs2659914	ENSG00000237310.1	GS1-124K5.4	8.39	6.13e-16	3.44e-13	0.33	0.37	Aortic root size;	chr7:66691927	chr7:66493706~66495474:+
PRAD	cis	rs524281	0.731	rs2452682	ENSG00000255320.1	RP11-755F10.1	8.39	6.13e-16	3.44e-13	0.57	0.37	Electroencephalogram traits;	chr11:66045138	chr11:66244840~66246239:-
PRAD	cis	rs1075265	0.935	rs6545384	ENSG00000233266.1	HMGB1P31	8.39	6.13e-16	3.44e-13	0.5	0.37	Chronotype;Morning vs. evening chronotype;	chr2:54073927	chr2:54051334~54051760:+
PRAD	cis	rs9341835	0.741	rs6929702	ENSG00000218048.2	RP3-407E4.4	8.39	6.14e-16	3.45e-13	0.41	0.37	Schizophrenia;	chr6:63434209	chr6:63440766~63443580:+
PRAD	cis	rs1979679	0.842	rs36097532	ENSG00000278733.1	RP11-425D17.1	8.39	6.14e-16	3.45e-13	0.46	0.37	Ossification of the posterior longitudinal ligament of the spine;	chr12:28228557	chr12:28185625~28186190:-
PRAD	cis	rs9601248	0.874	rs4141825	ENSG00000227676.3	LINC01068	8.39	6.17e-16	3.46e-13	0.44	0.37	Major depressive disorder;	chr13:79616713	chr13:79566727~79571436:+
PRAD	cis	rs9601248	0.874	rs9545158	ENSG00000227676.3	LINC01068	8.39	6.18e-16	3.47e-13	0.44	0.37	Major depressive disorder;	chr13:79618771	chr13:79566727~79571436:+
PRAD	cis	rs1555322	0.53	rs2425053	ENSG00000126005.14	MMP24-AS1	-8.39	6.18e-16	3.47e-13	-0.43	-0.37	Attention deficit hyperactivity disorder;	chr20:35294017	chr20:35216462~35278131:-
PRAD	cis	rs9309473	0.583	rs6718864	ENSG00000163016.8	ALMS1P	8.39	6.2e-16	3.48e-13	0.44	0.37	Metabolite levels;	chr2:73347463	chr2:73644919~73685576:+
PRAD	cis	rs12142240	0.77	rs112869704	ENSG00000232022.5	FAAHP1	-8.39	6.21e-16	3.49e-13	-0.35	-0.37	Menopause (age at onset);	chr1:46314613	chr1:46432129~46445521:+
PRAD	cis	rs12134133	0.752	rs6540874	ENSG00000274245.1	RP11-357P18.2	8.39	6.23e-16	3.5e-13	0.55	0.37	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207221638	chr1:207372559~207373252:+
PRAD	cis	rs12134133	0.752	rs6683677	ENSG00000274245.1	RP11-357P18.2	8.39	6.23e-16	3.5e-13	0.55	0.37	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207228335	chr1:207372559~207373252:+
PRAD	cis	rs7598759	0.617	rs6437017	ENSG00000181798.2	LINC00471	-8.39	6.23e-16	3.5e-13	-0.43	-0.37	Noise-induced hearing loss;	chr2:231462873	chr2:231508426~231514339:-
PRAD	cis	rs763567	1	rs1928715	ENSG00000271811.1	RP1-79C4.4	-8.39	6.25e-16	3.51e-13	-0.42	-0.37	Tonsillectomy;	chr1:170598296	chr1:170667381~170669425:+
PRAD	cis	rs12142240	0.731	rs6681857	ENSG00000232022.5	FAAHP1	-8.39	6.26e-16	3.51e-13	-0.34	-0.37	Menopause (age at onset);	chr1:46384452	chr1:46432129~46445521:+
PRAD	cis	rs1355223	0.902	rs1361645	ENSG00000271369.1	RP11-350D17.3	-8.39	6.26e-16	3.52e-13	-0.42	-0.37	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34724838	chr11:34709600~34710161:+
PRAD	cis	rs2412819	0.571	rs11070411	ENSG00000205771.5	CATSPER2P1	8.39	6.26e-16	3.52e-13	0.48	0.37	Lung cancer;	chr15:43766436	chr15:43726918~43747094:-
PRAD	cis	rs67311347	1	rs4246666	ENSG00000223797.4	ENTPD3-AS1	8.39	6.28e-16	3.52e-13	0.32	0.37	Renal cell carcinoma;	chr3:40366179	chr3:40313802~40453329:-
PRAD	cis	rs67311347	1	rs2887995	ENSG00000223797.4	ENTPD3-AS1	8.39	6.28e-16	3.52e-13	0.32	0.37	Renal cell carcinoma;	chr3:40367538	chr3:40313802~40453329:-
PRAD	cis	rs7567389	0.6	rs72845979	ENSG00000236682.1	AC068282.3	-8.39	6.28e-16	3.53e-13	-0.48	-0.37	Self-rated health;	chr2:127338178	chr2:127389130~127400580:+
PRAD	cis	rs7567389	0.534	rs72845982	ENSG00000236682.1	AC068282.3	-8.39	6.28e-16	3.53e-13	-0.48	-0.37	Self-rated health;	chr2:127340994	chr2:127389130~127400580:+
PRAD	cis	rs7567389	0.6	rs11691088	ENSG00000236682.1	AC068282.3	-8.39	6.28e-16	3.53e-13	-0.48	-0.37	Self-rated health;	chr2:127374277	chr2:127389130~127400580:+
PRAD	cis	rs1150668	0.799	rs2142730	ENSG00000280107.1	AL022393.9	-8.39	6.29e-16	3.53e-13	-0.44	-0.37	Pubertal anthropometrics;	chr6:28298372	chr6:28170845~28172521:+
PRAD	cis	rs4835473	0.897	rs11723113	ENSG00000251600.4	RP11-673E1.1	8.39	6.3e-16	3.53e-13	0.46	0.37	Immature fraction of reticulocytes;	chr4:143707283	chr4:143912331~143982454:+
PRAD	cis	rs8523	0.901	rs68148747	ENSG00000230314.5	ELOVL2-AS1	8.39	6.32e-16	3.54e-13	0.4	0.37	Red blood cell fatty acid levels;	chr6:10966787	chr6:11043524~11078226:+
PRAD	cis	rs8523	0.901	rs9393818	ENSG00000230314.5	ELOVL2-AS1	8.39	6.32e-16	3.54e-13	0.4	0.37	Red blood cell fatty acid levels;	chr6:10967685	chr6:11043524~11078226:+
PRAD	cis	rs10078	0.898	rs2241598	ENSG00000221990.4	EXOC3-AS1	-8.39	6.32e-16	3.54e-13	-0.35	-0.37	Fat distribution (HIV);	chr5:438449	chr5:441498~443160:-
PRAD	cis	rs8040855	0.621	rs6496796	ENSG00000259295.5	CSPG4P12	-8.39	6.32e-16	3.55e-13	-0.47	-0.37	Bulimia nervosa;	chr15:85183617	chr15:85191438~85213905:+
PRAD	cis	rs950169	1	rs1848093	ENSG00000225151.9	GOLGA2P7	-8.39	6.36e-16	3.57e-13	-0.51	-0.37	Schizophrenia;	chr15:84086775	chr15:84199311~84230136:-
PRAD	cis	rs950169	1	rs12915234	ENSG00000225151.9	GOLGA2P7	-8.39	6.36e-16	3.57e-13	-0.51	-0.37	Schizophrenia;	chr15:84089549	chr15:84199311~84230136:-
PRAD	cis	rs950169	1	rs34751999	ENSG00000225151.9	GOLGA2P7	-8.39	6.36e-16	3.57e-13	-0.51	-0.37	Schizophrenia;	chr15:84089667	chr15:84199311~84230136:-
PRAD	cis	rs950169	0.919	rs17300292	ENSG00000225151.9	GOLGA2P7	-8.39	6.36e-16	3.57e-13	-0.51	-0.37	Schizophrenia;	chr15:84093816	chr15:84199311~84230136:-
PRAD	cis	rs950169	1	rs12916348	ENSG00000225151.9	GOLGA2P7	-8.39	6.36e-16	3.57e-13	-0.51	-0.37	Schizophrenia;	chr15:84096775	chr15:84199311~84230136:-
PRAD	cis	rs950169	1	rs35297609	ENSG00000225151.9	GOLGA2P7	-8.39	6.36e-16	3.57e-13	-0.51	-0.37	Schizophrenia;	chr15:84104144	chr15:84199311~84230136:-
PRAD	cis	rs950169	1	rs62026530	ENSG00000225151.9	GOLGA2P7	-8.39	6.36e-16	3.57e-13	-0.51	-0.37	Schizophrenia;	chr15:84107088	chr15:84199311~84230136:-
PRAD	cis	rs193541	0.556	rs30024	ENSG00000263432.2	RN7SL689P	8.39	6.37e-16	3.57e-13	0.39	0.37	Glucose homeostasis traits;	chr5:122949465	chr5:123022487~123022783:-
PRAD	cis	rs193541	0.632	rs30023	ENSG00000263432.2	RN7SL689P	8.39	6.37e-16	3.57e-13	0.39	0.37	Glucose homeostasis traits;	chr5:122949604	chr5:123022487~123022783:-
PRAD	cis	rs6570726	0.967	rs373704	ENSG00000235652.6	RP11-545I5.3	8.39	6.37e-16	3.57e-13	0.38	0.37	Lobe attachment (rater-scored or self-reported);	chr6:145539482	chr6:145799409~145886585:+
PRAD	cis	rs2412819	0.597	rs7181912	ENSG00000205771.5	CATSPER2P1	8.39	6.39e-16	3.58e-13	0.49	0.37	Lung cancer;	chr15:43770676	chr15:43726918~43747094:-
PRAD	cis	rs950169	0.723	rs17589320	ENSG00000225151.9	GOLGA2P7	-8.38	6.42e-16	3.6e-13	-0.51	-0.37	Schizophrenia;	chr15:84251244	chr15:84199311~84230136:-
PRAD	cis	rs950169	0.845	rs4502182	ENSG00000225151.9	GOLGA2P7	-8.38	6.42e-16	3.6e-13	-0.51	-0.37	Schizophrenia;	chr15:84254768	chr15:84199311~84230136:-
PRAD	cis	rs801193	0.66	rs4610622	ENSG00000237310.1	GS1-124K5.4	8.38	6.43e-16	3.6e-13	0.33	0.37	Aortic root size;	chr7:66759510	chr7:66493706~66495474:+
PRAD	cis	rs12908161	0.959	rs34028043	ENSG00000259728.4	LINC00933	8.38	6.44e-16	3.61e-13	0.45	0.37	Schizophrenia;	chr15:84688354	chr15:84570649~84580175:+
PRAD	cis	rs12908161	0.959	rs34784022	ENSG00000259728.4	LINC00933	8.38	6.44e-16	3.61e-13	0.45	0.37	Schizophrenia;	chr15:84688675	chr15:84570649~84580175:+
PRAD	cis	rs12908161	0.959	rs12908699	ENSG00000259728.4	LINC00933	8.38	6.44e-16	3.61e-13	0.45	0.37	Schizophrenia;	chr15:84697172	chr15:84570649~84580175:+
PRAD	cis	rs2337406	0.714	rs2337463	ENSG00000274576.2	IGHV2-70	-8.38	6.45e-16	3.62e-13	-0.38	-0.37	Alzheimer's disease (late onset);	chr14:106816066	chr14:106770577~106771020:-
PRAD	cis	rs4835473	0.932	rs13139738	ENSG00000251600.4	RP11-673E1.1	-8.38	6.47e-16	3.62e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143738828	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs17018165	ENSG00000251600.4	RP11-673E1.1	-8.38	6.47e-16	3.62e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143738849	chr4:143912331~143982454:+
PRAD	cis	rs17361889	0.711	rs17358277	ENSG00000224683.1	RPL36AP29	8.38	6.48e-16	3.63e-13	0.45	0.37	Pediatric bone mineral content (hip);	chr7:16093695	chr7:16208945~16209265:+
PRAD	cis	rs17361889	0.596	rs17286418	ENSG00000224683.1	RPL36AP29	8.38	6.48e-16	3.63e-13	0.45	0.37	Pediatric bone mineral content (hip);	chr7:16097894	chr7:16208945~16209265:+
PRAD	cis	rs17361889	0.711	rs3857709	ENSG00000224683.1	RPL36AP29	8.38	6.48e-16	3.63e-13	0.45	0.37	Pediatric bone mineral content (hip);	chr7:16100477	chr7:16208945~16209265:+
PRAD	cis	rs17361889	0.685	rs62442360	ENSG00000224683.1	RPL36AP29	8.38	6.48e-16	3.63e-13	0.45	0.37	Pediatric bone mineral content (hip);	chr7:16103664	chr7:16208945~16209265:+
PRAD	cis	rs42648	0.642	rs11771963	ENSG00000227646.6	STEAP2-AS1	-8.38	6.51e-16	3.65e-13	-0.33	-0.37	Homocysteine levels;	chr7:90258273	chr7:89882353~90211635:-
PRAD	cis	rs2638953	0.886	rs11049465	ENSG00000278733.1	RP11-425D17.1	-8.38	6.52e-16	3.65e-13	-0.46	-0.37	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28212086	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs7980441	ENSG00000278733.1	RP11-425D17.1	-8.38	6.52e-16	3.65e-13	-0.46	-0.37	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28214748	chr12:28185625~28186190:-
PRAD	cis	rs9810089	0.814	rs73226190	ENSG00000261758.1	RP11-102M11.2	8.38	6.52e-16	3.65e-13	0.42	0.37	Gestational age at birth (child effect);	chr3:136494468	chr3:136752630~136755780:+
PRAD	cis	rs2108622	0.727	rs8104311	ENSG00000267056.2	AC005336.4	8.38	6.53e-16	3.65e-13	0.5	0.37	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871950	chr19:15910582~15911824:-
PRAD	cis	rs763567	1	rs763567	ENSG00000271811.1	RP1-79C4.4	-8.38	6.54e-16	3.66e-13	-0.43	-0.37	Tonsillectomy;	chr1:170596864	chr1:170667381~170669425:+
PRAD	cis	rs6570726	0.935	rs371744	ENSG00000235652.6	RP11-545I5.3	8.38	6.55e-16	3.67e-13	0.38	0.37	Lobe attachment (rater-scored or self-reported);	chr6:145519888	chr6:145799409~145886585:+
PRAD	cis	rs10463554	0.927	rs257317	ENSG00000175749.11	EIF3KP1	8.38	6.56e-16	3.67e-13	0.47	0.37	Parkinson's disease;	chr5:103086881	chr5:103032376~103033031:+
PRAD	cis	rs10463554	0.927	rs34373	ENSG00000175749.11	EIF3KP1	8.38	6.57e-16	3.68e-13	0.49	0.37	Parkinson's disease;	chr5:103068590	chr5:103032376~103033031:+
PRAD	cis	rs10463554	0.927	rs158253	ENSG00000175749.11	EIF3KP1	8.38	6.57e-16	3.68e-13	0.49	0.37	Parkinson's disease;	chr5:103069502	chr5:103032376~103033031:+
PRAD	cis	rs10463554	0.892	rs158252	ENSG00000175749.11	EIF3KP1	8.38	6.57e-16	3.68e-13	0.49	0.37	Parkinson's disease;	chr5:103070546	chr5:103032376~103033031:+
PRAD	cis	rs10463554	0.927	rs154369	ENSG00000175749.11	EIF3KP1	8.38	6.57e-16	3.68e-13	0.49	0.37	Parkinson's disease;	chr5:103071140	chr5:103032376~103033031:+
PRAD	cis	rs10463554	0.892	rs158246	ENSG00000175749.11	EIF3KP1	8.38	6.57e-16	3.68e-13	0.49	0.37	Parkinson's disease;	chr5:103073145	chr5:103032376~103033031:+
PRAD	cis	rs10463554	0.927	rs158245	ENSG00000175749.11	EIF3KP1	8.38	6.57e-16	3.68e-13	0.49	0.37	Parkinson's disease;	chr5:103073801	chr5:103032376~103033031:+
PRAD	cis	rs10463554	0.857	rs158397	ENSG00000175749.11	EIF3KP1	8.38	6.57e-16	3.68e-13	0.49	0.37	Parkinson's disease;	chr5:103076497	chr5:103032376~103033031:+
PRAD	cis	rs10463554	0.927	rs158399	ENSG00000175749.11	EIF3KP1	8.38	6.57e-16	3.68e-13	0.49	0.37	Parkinson's disease;	chr5:103077564	chr5:103032376~103033031:+
PRAD	cis	rs10463554	0.927	rs158404	ENSG00000175749.11	EIF3KP1	8.38	6.57e-16	3.68e-13	0.49	0.37	Parkinson's disease;	chr5:103080206	chr5:103032376~103033031:+
PRAD	cis	rs6570726	0.905	rs421032	ENSG00000235652.6	RP11-545I5.3	8.38	6.61e-16	3.7e-13	0.38	0.37	Lobe attachment (rater-scored or self-reported);	chr6:145506635	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.935	rs9390329	ENSG00000235652.6	RP11-545I5.3	8.38	6.61e-16	3.7e-13	0.38	0.37	Lobe attachment (rater-scored or self-reported);	chr6:145506890	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.902	rs406979	ENSG00000235652.6	RP11-545I5.3	8.38	6.61e-16	3.7e-13	0.38	0.37	Lobe attachment (rater-scored or self-reported);	chr6:145517847	chr6:145799409~145886585:+
PRAD	cis	rs7899628	1	rs7899628	ENSG00000276742.1	RP11-500G22.4	-8.38	6.62e-16	3.71e-13	-0.47	-0.37	Breast cancer;	chr10:121904429	chr10:121956782~121957098:+
PRAD	cis	rs6538678	0.929	rs10777744	ENSG00000258343.1	RP11-536G4.2	-8.38	6.63e-16	3.71e-13	-0.47	-0.37	Lupus nephritis in systemic lupus erythematosus;	chr12:95864561	chr12:95795345~95858839:-
PRAD	cis	rs12908161	1	rs35808647	ENSG00000259728.4	LINC00933	8.38	6.63e-16	3.71e-13	0.45	0.37	Schizophrenia;	chr15:84834210	chr15:84570649~84580175:+
PRAD	cis	rs2153535	0.585	rs1328858	ENSG00000230939.1	RP11-314C16.1	8.38	6.64e-16	3.72e-13	0.45	0.37	Motion sickness;	chr6:8563218	chr6:8784178~8785445:+
PRAD	cis	rs801193	0.66	rs1016265	ENSG00000237310.1	GS1-124K5.4	8.38	6.65e-16	3.72e-13	0.33	0.37	Aortic root size;	chr7:66749580	chr7:66493706~66495474:+
PRAD	cis	rs4964805	0.632	rs11111782	ENSG00000257681.1	RP11-341G23.4	-8.38	6.65e-16	3.72e-13	-0.33	-0.37	Attention deficit hyperactivity disorder;	chr12:103794698	chr12:103746315~103768858:-
PRAD	cis	rs12701220	0.655	rs11489405	ENSG00000229043.2	AC091729.9	-8.38	6.65e-16	3.72e-13	-0.54	-0.37	Bronchopulmonary dysplasia;	chr7:1100256	chr7:1160374~1165267:+
PRAD	cis	rs11083475	0.967	rs28624276	ENSG00000267892.1	CTD-2540F13.2	8.38	6.68e-16	3.74e-13	0.39	0.37	Heart rate;	chr19:38712257	chr19:38738284~38739863:+
PRAD	cis	rs6847067	0.8	rs72664952	ENSG00000180769.7	WDFY3-AS2	8.38	6.71e-16	3.75e-13	0.38	0.37	Oropharynx cancer;	chr4:84925938	chr4:84965682~85011277:+
PRAD	cis	rs10129255	0.5	rs10143242	ENSG00000211972.2	IGHV3-66	8.38	6.72e-16	3.76e-13	0.32	0.37	Kawasaki disease;	chr14:106681814	chr14:106675017~106675544:-
PRAD	cis	rs1062177	0.826	rs2915822	ENSG00000253921.1	CTB-113P19.3	8.38	6.73e-16	3.76e-13	0.48	0.37	Preschool internalizing problems;	chr5:151751340	chr5:151753992~151767247:+
PRAD	cis	rs950169	0.92	rs12915390	ENSG00000225151.9	GOLGA2P7	-8.38	6.73e-16	3.76e-13	-0.51	-0.37	Schizophrenia;	chr15:84123317	chr15:84199311~84230136:-
PRAD	cis	rs950169	0.959	rs12902070	ENSG00000225151.9	GOLGA2P7	-8.38	6.73e-16	3.76e-13	-0.51	-0.37	Schizophrenia;	chr15:84124806	chr15:84199311~84230136:-
PRAD	cis	rs3096299	0.967	rs28689480	ENSG00000274627.1	RP11-104N10.2	8.38	6.74e-16	3.77e-13	0.38	0.37	Multiple myeloma (IgH translocation);	chr16:89393685	chr16:89516797~89522217:+
PRAD	cis	rs6452524	0.967	rs12186460	ENSG00000249664.1	CTD-2227C6.2	8.38	6.76e-16	3.78e-13	0.44	0.37	Hypertension (SNP x SNP interaction);	chr5:83123950	chr5:83012285~83013109:-
PRAD	cis	rs4722166	0.597	rs2002792	ENSG00000179428.2	AC073072.5	-8.38	6.76e-16	3.78e-13	-0.42	-0.37	Lung cancer;	chr7:22724226	chr7:22725395~22727620:-
PRAD	cis	rs7615952	0.576	rs4646759	ENSG00000171084.14	FAM86JP	8.38	6.78e-16	3.79e-13	0.59	0.37	Blood pressure (smoking interaction);	chr3:126104103	chr3:125916620~125930024:+
PRAD	cis	rs367615	0.552	rs10042721	ENSG00000249476.1	CTD-2587M2.1	-8.38	6.82e-16	3.81e-13	-0.44	-0.37	Colorectal cancer (SNP x SNP interaction);	chr5:109378269	chr5:109237120~109326369:-
PRAD	cis	rs2404602	0.716	rs1125932	ENSG00000259422.1	RP11-593F23.1	8.38	6.82e-16	3.81e-13	0.45	0.37	Blood metabolite levels;	chr15:76528199	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.716	rs66754747	ENSG00000259422.1	RP11-593F23.1	8.38	6.82e-16	3.81e-13	0.45	0.37	Blood metabolite levels;	chr15:76536227	chr15:76174891~76181486:-
PRAD	cis	rs5769707	0.609	rs135861	ENSG00000188511.11	C22orf34	8.38	6.82e-16	3.81e-13	0.42	0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49604470	chr22:49414524~49657542:-
PRAD	cis	rs6860806	0.507	rs2631372	ENSG00000233006.5	AC034220.3	8.38	6.83e-16	3.82e-13	0.35	0.37	Breast cancer;	chr5:132367886	chr5:132311285~132369916:-
PRAD	cis	rs11096990	0.613	rs2060805	ENSG00000249207.1	RP11-360F5.1	-8.38	6.85e-16	3.82e-13	-0.38	-0.37	Cognitive function;	chr4:39232788	chr4:39112677~39126818:-
PRAD	cis	rs6538678	0.929	rs10745733	ENSG00000258343.1	RP11-536G4.2	-8.38	6.87e-16	3.84e-13	-0.47	-0.37	Lupus nephritis in systemic lupus erythematosus;	chr12:95868728	chr12:95795345~95858839:-
PRAD	cis	rs6538678	0.926	rs10745734	ENSG00000258343.1	RP11-536G4.2	-8.38	6.87e-16	3.84e-13	-0.47	-0.37	Lupus nephritis in systemic lupus erythematosus;	chr12:95868936	chr12:95795345~95858839:-
PRAD	cis	rs11976180	1	rs2951364	ENSG00000170356.8	OR2A20P	-8.38	6.87e-16	3.84e-13	-0.48	-0.37	Obesity-related traits;	chr7:144057390	chr7:144250045~144252957:-
PRAD	cis	rs150992	0.609	rs366353	ENSG00000248489.1	CTD-2007H13.3	-8.38	6.87e-16	3.84e-13	-0.4	-0.37	Body mass index;	chr5:98995663	chr5:98929171~98995013:+
PRAD	cis	rs8062405	0.573	rs7140	ENSG00000251417.2	RP11-1348G14.4	8.38	6.88e-16	3.84e-13	0.44	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28984436	chr16:28802743~28817828:+
PRAD	cis	rs11098499	0.863	rs1480940	ENSG00000245958.5	RP11-33B1.1	-8.38	6.88e-16	3.84e-13	-0.36	-0.37	Corneal astigmatism;	chr4:119536527	chr4:119454791~119552025:+
PRAD	cis	rs950169	1	rs11638297	ENSG00000225151.9	GOLGA2P7	-8.38	6.89e-16	3.85e-13	-0.51	-0.37	Schizophrenia;	chr15:84113665	chr15:84199311~84230136:-
PRAD	cis	rs1355223	0.872	rs7116409	ENSG00000271369.1	RP11-350D17.3	-8.38	6.9e-16	3.85e-13	-0.42	-0.37	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34729460	chr11:34709600~34710161:+
PRAD	cis	rs6750795	0.746	rs1667301	ENSG00000181798.2	LINC00471	-8.37	6.92e-16	3.86e-13	-0.43	-0.37	Height;	chr2:231559006	chr2:231508426~231514339:-
PRAD	cis	rs12908161	0.96	rs34452033	ENSG00000259728.4	LINC00933	8.37	6.96e-16	3.89e-13	0.45	0.37	Schizophrenia;	chr15:84678762	chr15:84570649~84580175:+
PRAD	cis	rs7712401	0.584	rs4836382	ENSG00000263432.2	RN7SL689P	8.37	6.98e-16	3.89e-13	0.37	0.37	Mean platelet volume;	chr5:123040946	chr5:123022487~123022783:-
PRAD	cis	rs7615952	0.599	rs6803160	ENSG00000171084.14	FAM86JP	8.37	6.98e-16	3.9e-13	0.57	0.37	Blood pressure (smoking interaction);	chr3:125990711	chr3:125916620~125930024:+
PRAD	cis	rs950169	0.959	rs12911210	ENSG00000225151.9	GOLGA2P7	-8.37	7e-16	3.91e-13	-0.51	-0.37	Schizophrenia;	chr15:84123331	chr15:84199311~84230136:-
PRAD	cis	rs875971	1	rs6958271	ENSG00000237310.1	GS1-124K5.4	8.37	7.02e-16	3.92e-13	0.33	0.37	Aortic root size;	chr7:66514344	chr7:66493706~66495474:+
PRAD	cis	rs875971	1	rs6958277	ENSG00000237310.1	GS1-124K5.4	8.37	7.02e-16	3.92e-13	0.33	0.37	Aortic root size;	chr7:66514362	chr7:66493706~66495474:+
PRAD	cis	rs17608059	0.611	rs62052300	ENSG00000141028.6	CDRT15P1	-8.37	7.06e-16	3.94e-13	-0.47	-0.37	Temperament;	chr17:14013482	chr17:14024514~14025488:+
PRAD	cis	rs4835473	0.932	rs13133444	ENSG00000251600.4	RP11-673E1.1	8.37	7.07e-16	3.94e-13	0.46	0.37	Immature fraction of reticulocytes;	chr4:143738191	chr4:143912331~143982454:+
PRAD	cis	rs6538678	0.929	rs7962359	ENSG00000258343.1	RP11-536G4.2	-8.37	7.08e-16	3.95e-13	-0.47	-0.37	Lupus nephritis in systemic lupus erythematosus;	chr12:95862566	chr12:95795345~95858839:-
PRAD	cis	rs67311347	0.911	rs9849224	ENSG00000223797.4	ENTPD3-AS1	8.37	7.08e-16	3.95e-13	0.32	0.37	Renal cell carcinoma;	chr3:40351071	chr3:40313802~40453329:-
PRAD	cis	rs67311347	1	rs2168111	ENSG00000223797.4	ENTPD3-AS1	8.37	7.08e-16	3.95e-13	0.32	0.37	Renal cell carcinoma;	chr3:40353834	chr3:40313802~40453329:-
PRAD	cis	rs67311347	1	rs9834052	ENSG00000223797.4	ENTPD3-AS1	8.37	7.08e-16	3.95e-13	0.32	0.37	Renal cell carcinoma;	chr3:40357569	chr3:40313802~40453329:-
PRAD	cis	rs2404602	0.692	rs8024476	ENSG00000259422.1	RP11-593F23.1	8.37	7.09e-16	3.95e-13	0.46	0.37	Blood metabolite levels;	chr15:76691613	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.692	rs7163397	ENSG00000259422.1	RP11-593F23.1	8.37	7.09e-16	3.96e-13	0.46	0.37	Blood metabolite levels;	chr15:76647974	chr15:76174891~76181486:-
PRAD	cis	rs950169	0.58	rs11635597	ENSG00000259728.4	LINC00933	8.37	7.11e-16	3.96e-13	0.44	0.37	Schizophrenia;	chr15:84622468	chr15:84570649~84580175:+
PRAD	cis	rs1150668	0.799	rs7206	ENSG00000280107.1	AL022393.9	-8.37	7.11e-16	3.97e-13	-0.44	-0.37	Pubertal anthropometrics;	chr6:28233360	chr6:28170845~28172521:+
PRAD	cis	rs11098499	0.863	rs7669520	ENSG00000245958.5	RP11-33B1.1	-8.37	7.13e-16	3.97e-13	-0.36	-0.37	Corneal astigmatism;	chr4:119594123	chr4:119454791~119552025:+
PRAD	cis	rs17608059	0.545	rs9944522	ENSG00000141028.6	CDRT15P1	-8.37	7.18e-16	4e-13	-0.47	-0.37	Temperament;	chr17:14015466	chr17:14024514~14025488:+
PRAD	cis	rs1062177	0.826	rs1549920	ENSG00000253921.1	CTB-113P19.3	-8.37	7.2e-16	4.01e-13	-0.48	-0.37	Preschool internalizing problems;	chr5:151761283	chr5:151753992~151767247:+
PRAD	cis	rs2412819	0.545	rs3862143	ENSG00000205771.5	CATSPER2P1	8.37	7.22e-16	4.02e-13	0.49	0.37	Lung cancer;	chr15:43779282	chr15:43726918~43747094:-
PRAD	cis	rs2015599	0.645	rs12578931	ENSG00000257176.2	RP11-996F15.2	-8.37	7.24e-16	4.03e-13	-0.42	-0.37	Platelet count;Mean platelet volume;	chr12:29358608	chr12:29280418~29317848:-
PRAD	cis	rs2015599	0.623	rs4931174	ENSG00000257176.2	RP11-996F15.2	-8.37	7.24e-16	4.03e-13	-0.42	-0.37	Platelet count;Mean platelet volume;	chr12:29360545	chr12:29280418~29317848:-
PRAD	cis	rs2015599	0.623	rs1006410	ENSG00000275476.1	RP11-996F15.4	8.37	7.24e-16	4.03e-13	0.4	0.37	Platelet count;Mean platelet volume;	chr12:29282682	chr12:29277397~29277882:-
PRAD	cis	rs9601248	0.874	rs2093621	ENSG00000227676.3	LINC01068	8.37	7.24e-16	4.03e-13	0.44	0.37	Major depressive disorder;	chr13:79613953	chr13:79566727~79571436:+
PRAD	cis	rs9601248	0.874	rs2093620	ENSG00000227676.3	LINC01068	8.37	7.24e-16	4.03e-13	0.44	0.37	Major depressive disorder;	chr13:79613954	chr13:79566727~79571436:+
PRAD	cis	rs4835473	0.932	rs2323191	ENSG00000251600.4	RP11-673E1.1	-8.37	7.24e-16	4.04e-13	-0.46	-0.37	Immature fraction of reticulocytes;	chr4:143744472	chr4:143912331~143982454:+
PRAD	cis	rs67311347	0.544	rs12633295	ENSG00000223797.4	ENTPD3-AS1	-8.37	7.26e-16	4.05e-13	-0.32	-0.37	Renal cell carcinoma;	chr3:40293801	chr3:40313802~40453329:-
PRAD	cis	rs11148252	0.744	rs4884354	ENSG00000278238.1	RP11-245D16.4	-8.37	7.26e-16	4.05e-13	-0.41	-0.37	Lewy body disease;	chr13:52443339	chr13:52454775~52455331:-
PRAD	cis	rs6538678	0.864	rs10777749	ENSG00000258343.1	RP11-536G4.2	-8.37	7.27e-16	4.05e-13	-0.45	-0.37	Lupus nephritis in systemic lupus erythematosus;	chr12:95883182	chr12:95795345~95858839:-
PRAD	cis	rs7688540	0.771	rs7674560	ENSG00000275426.1	CH17-262A2.1	8.37	7.28e-16	4.05e-13	0.52	0.37	Facial morphology (factor 6, height of vermillion lower lip);	chr4:269530	chr4:149738~150317:+
PRAD	cis	rs8081395	0.836	rs2063353	ENSG00000266992.1	DHX40P1	-8.37	7.3e-16	4.07e-13	-0.41	-0.37	White blood cell count;	chr17:59811831	chr17:59976009~60002384:-
PRAD	cis	rs2439831	0.85	rs8023458	ENSG00000249839.1	AC011330.5	-8.37	7.32e-16	4.08e-13	-0.63	-0.37	Lung cancer in ever smokers;	chr15:43788741	chr15:43663654~43684339:-
PRAD	cis	rs34375054	0.573	rs12581813	ENSG00000279233.1	RP11-158L12.4	8.37	7.35e-16	4.09e-13	0.41	0.37	Post bronchodilator FEV1/FVC ratio;	chr12:125171856	chr12:125138245~125141711:+
PRAD	cis	rs1075265	0.901	rs2048749	ENSG00000233266.1	HMGB1P31	8.37	7.36e-16	4.1e-13	0.49	0.37	Chronotype;Morning vs. evening chronotype;	chr2:54130483	chr2:54051334~54051760:+
PRAD	cis	rs6723108	0.604	rs6430551	ENSG00000224043.6	CCNT2-AS1	-8.37	7.38e-16	4.11e-13	-0.5	-0.37	Type 2 diabetes;	chr2:134863986	chr2:134735464~134918710:-
PRAD	cis	rs67311347	0.955	rs6773383	ENSG00000223797.4	ENTPD3-AS1	8.37	7.39e-16	4.11e-13	0.32	0.37	Renal cell carcinoma;	chr3:40335921	chr3:40313802~40453329:-
PRAD	cis	rs858239	1	rs156407	ENSG00000226816.2	AC005082.12	8.37	7.39e-16	4.11e-13	0.41	0.37	Cerebrospinal fluid biomarker levels;	chr7:23276020	chr7:23206013~23208045:+
PRAD	cis	rs2739330	0.76	rs5760095	ENSG00000272787.1	KB-226F1.2	-8.37	7.4e-16	4.12e-13	-0.39	-0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23969211~23969873:+
PRAD	cis	rs4631830	0.863	rs7081532	ENSG00000230869.1	CTGLF10P	-8.37	7.41e-16	4.12e-13	-0.45	-0.37	Prostate-specific antigen levels;	chr10:46069729	chr10:45678692~45700532:+
PRAD	cis	rs42648	0.596	rs194511	ENSG00000227646.6	STEAP2-AS1	-8.37	7.41e-16	4.13e-13	-0.33	-0.37	Homocysteine levels;	chr7:90217413	chr7:89882353~90211635:-
PRAD	cis	rs193541	0.632	rs30036	ENSG00000263432.2	RN7SL689P	8.37	7.42e-16	4.13e-13	0.39	0.37	Glucose homeostasis traits;	chr5:122942565	chr5:123022487~123022783:-
PRAD	cis	rs17361889	0.727	rs62440394	ENSG00000224683.1	RPL36AP29	8.36	7.44e-16	4.14e-13	0.42	0.37	Pediatric bone mineral content (hip);	chr7:16215008	chr7:16208945~16209265:+
PRAD	cis	rs6570726	0.935	rs400968	ENSG00000235652.6	RP11-545I5.3	8.36	7.51e-16	4.18e-13	0.38	0.37	Lobe attachment (rater-scored or self-reported);	chr6:145498582	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.935	rs391820	ENSG00000235652.6	RP11-545I5.3	8.36	7.51e-16	4.18e-13	0.38	0.37	Lobe attachment (rater-scored or self-reported);	chr6:145500148	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.875	rs1883407	ENSG00000235652.6	RP11-545I5.3	8.36	7.51e-16	4.18e-13	0.38	0.37	Lobe attachment (rater-scored or self-reported);	chr6:145502296	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.935	rs367612	ENSG00000235652.6	RP11-545I5.3	8.36	7.51e-16	4.18e-13	0.38	0.37	Lobe attachment (rater-scored or self-reported);	chr6:145507851	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.905	rs375692	ENSG00000235652.6	RP11-545I5.3	8.36	7.51e-16	4.18e-13	0.38	0.37	Lobe attachment (rater-scored or self-reported);	chr6:145519232	chr6:145799409~145886585:+
PRAD	cis	rs193541	0.586	rs11241662	ENSG00000263432.2	RN7SL689P	-8.36	7.53e-16	4.19e-13	-0.39	-0.37	Glucose homeostasis traits;	chr5:122846280	chr5:123022487~123022783:-
PRAD	cis	rs7429990	0.965	rs4599334	ENSG00000229759.1	MRPS18AP1	-8.36	7.54e-16	4.19e-13	-0.37	-0.37	Educational attainment (years of education);	chr3:48024910	chr3:48256350~48256938:-
PRAD	cis	rs6723108	0.627	rs4954187	ENSG00000224043.6	CCNT2-AS1	-8.36	7.54e-16	4.2e-13	-0.51	-0.37	Type 2 diabetes;	chr2:134842848	chr2:134735464~134918710:-
PRAD	cis	rs5769707	0.609	rs739247	ENSG00000188511.11	C22orf34	8.36	7.56e-16	4.2e-13	0.43	0.36	Monocyte percentage of white cells;Monocyte count;	chr22:49603009	chr22:49414524~49657542:-
PRAD	cis	rs42648	0.596	rs194524	ENSG00000227646.6	STEAP2-AS1	-8.36	7.56e-16	4.2e-13	-0.33	-0.36	Homocysteine levels;	chr7:90232518	chr7:89882353~90211635:-
PRAD	cis	rs6847067	0.8	rs11097026	ENSG00000180769.7	WDFY3-AS2	-8.36	7.56e-16	4.21e-13	-0.38	-0.36	Oropharynx cancer;	chr4:84882454	chr4:84965682~85011277:+
PRAD	cis	rs7829975	0.564	rs2921060	ENSG00000253893.2	FAM85B	8.36	7.58e-16	4.21e-13	0.45	0.36	Mood instability;	chr8:8460307	chr8:8167819~8226614:-
PRAD	cis	rs4835473	0.932	rs7683686	ENSG00000251600.4	RP11-673E1.1	-8.36	7.65e-16	4.25e-13	-0.44	-0.36	Immature fraction of reticulocytes;	chr4:143784352	chr4:143912331~143982454:+
PRAD	cis	rs858239	0.669	rs1990365	ENSG00000226816.2	AC005082.12	8.36	7.66e-16	4.26e-13	0.42	0.36	Cerebrospinal fluid biomarker levels;	chr7:23076347	chr7:23206013~23208045:+
PRAD	cis	rs4835473	0.669	rs56112476	ENSG00000251600.4	RP11-673E1.1	-8.36	7.68e-16	4.27e-13	-0.49	-0.36	Immature fraction of reticulocytes;	chr4:143948716	chr4:143912331~143982454:+
PRAD	cis	rs526231	0.511	rs10434792	ENSG00000175749.11	EIF3KP1	8.36	7.69e-16	4.27e-13	0.5	0.36	Primary biliary cholangitis;	chr5:103053898	chr5:103032376~103033031:+
PRAD	cis	rs526231	0.511	rs10434793	ENSG00000175749.11	EIF3KP1	8.36	7.69e-16	4.27e-13	0.5	0.36	Primary biliary cholangitis;	chr5:103054111	chr5:103032376~103033031:+
PRAD	cis	rs4835473	0.932	rs34683160	ENSG00000251600.4	RP11-673E1.1	-8.36	7.7e-16	4.28e-13	-0.46	-0.36	Immature fraction of reticulocytes;	chr4:143765227	chr4:143912331~143982454:+
PRAD	cis	rs11976180	1	rs1320893	ENSG00000170356.8	OR2A20P	-8.36	7.73e-16	4.3e-13	-0.47	-0.36	Obesity-related traits;	chr7:144055019	chr7:144250045~144252957:-
PRAD	cis	rs2946504	0.822	rs2977095	ENSG00000251468.2	RP11-369K16.1	8.36	7.73e-16	4.3e-13	0.44	0.36	Type 2 diabetes;	chr8:12947706	chr8:12958387~12962200:+
PRAD	cis	rs367615	0.552	rs2115511	ENSG00000249476.1	CTD-2587M2.1	-8.36	7.75e-16	4.31e-13	-0.44	-0.36	Colorectal cancer (SNP x SNP interaction);	chr5:109389702	chr5:109237120~109326369:-
PRAD	cis	rs4713118	0.868	rs2893928	ENSG00000226314.6	ZNF192P1	-8.36	7.79e-16	4.33e-13	-0.51	-0.36	Parkinson's disease;	chr6:27770651	chr6:28161781~28169594:+
PRAD	cis	rs6430553	0.964	rs1530556	ENSG00000224043.6	CCNT2-AS1	-8.36	7.79e-16	4.33e-13	-0.5	-0.36	Blood metabolite levels;	chr2:134842164	chr2:134735464~134918710:-
PRAD	cis	rs26232	0.551	rs26431	ENSG00000175749.11	EIF3KP1	-8.36	7.79e-16	4.33e-13	-0.49	-0.36	Rheumatoid arthritis;	chr5:103030090	chr5:103032376~103033031:+
PRAD	cis	rs7615952	0.688	rs12638224	ENSG00000171084.14	FAM86JP	8.36	7.83e-16	4.35e-13	0.56	0.36	Blood pressure (smoking interaction);	chr3:125822477	chr3:125916620~125930024:+
PRAD	cis	rs7712401	0.623	rs7723798	ENSG00000263432.2	RN7SL689P	8.36	7.83e-16	4.35e-13	0.37	0.36	Mean platelet volume;	chr5:123034022	chr5:123022487~123022783:-
PRAD	cis	rs9309473	0.607	rs6720094	ENSG00000163016.8	ALMS1P	8.36	7.83e-16	4.35e-13	0.43	0.36	Metabolite levels;	chr2:73360948	chr2:73644919~73685576:+
PRAD	cis	rs7240205	0.724	rs6508447	ENSG00000275805.1	RP11-349H17.2	8.36	7.85e-16	4.36e-13	0.43	0.36	Breast cancer;	chr18:26552657	chr18:26565723~26575626:-
PRAD	cis	rs11098499	0.866	rs7665125	ENSG00000245958.5	RP11-33B1.1	-8.36	7.87e-16	4.37e-13	-0.36	-0.36	Corneal astigmatism;	chr4:119480924	chr4:119454791~119552025:+
PRAD	cis	rs2980439	0.87	rs2945230	ENSG00000253893.2	FAM85B	-8.36	7.88e-16	4.38e-13	-0.45	-0.36	Neuroticism;	chr8:8252414	chr8:8167819~8226614:-
PRAD	cis	rs7615952	0.641	rs12491577	ENSG00000171084.14	FAM86JP	8.36	7.89e-16	4.38e-13	0.57	0.36	Blood pressure (smoking interaction);	chr3:126012288	chr3:125916620~125930024:+
PRAD	cis	rs2337406	1	rs17095456	ENSG00000274576.2	IGHV2-70	-8.36	7.94e-16	4.41e-13	-0.4	-0.36	Alzheimer's disease (late onset);	chr14:106676559	chr14:106770577~106771020:-
PRAD	cis	rs4835473	0.808	rs2060653	ENSG00000251600.4	RP11-673E1.1	-8.36	7.95e-16	4.41e-13	-0.46	-0.36	Immature fraction of reticulocytes;	chr4:143739132	chr4:143912331~143982454:+
PRAD	cis	rs1789	0.786	rs6414768	ENSG00000273133.1	RP11-799M12.2	-8.36	7.96e-16	4.42e-13	-0.48	-0.36	Blood protein levels;	chr4:15693740	chr4:15563698~15564253:-
PRAD	cis	rs2404602	0.669	rs12148877	ENSG00000259422.1	RP11-593F23.1	8.36	7.97e-16	4.42e-13	0.46	0.36	Blood metabolite levels;	chr15:76627618	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.692	rs12902452	ENSG00000259422.1	RP11-593F23.1	8.36	7.97e-16	4.42e-13	0.46	0.36	Blood metabolite levels;	chr15:76629124	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.692	rs34478400	ENSG00000259422.1	RP11-593F23.1	8.36	7.97e-16	4.42e-13	0.46	0.36	Blood metabolite levels;	chr15:76631169	chr15:76174891~76181486:-
PRAD	cis	rs1075265	0.547	rs3770406	ENSG00000233266.1	HMGB1P31	8.35	8.04e-16	4.46e-13	0.51	0.36	Chronotype;Morning vs. evening chronotype;	chr2:53691108	chr2:54051334~54051760:+
PRAD	cis	rs4835473	0.932	rs13103072	ENSG00000251600.4	RP11-673E1.1	-8.35	8.09e-16	4.49e-13	-0.48	-0.36	Immature fraction of reticulocytes;	chr4:143952116	chr4:143912331~143982454:+
PRAD	cis	rs2019137	0.936	rs3811059	ENSG00000274877.1	RP11-65I12.1	8.35	8.11e-16	4.5e-13	0.46	0.36	Lymphocyte counts;	chr2:113204494	chr2:113237595~113240825:+
PRAD	cis	rs2019137	0.936	rs12620738	ENSG00000274877.1	RP11-65I12.1	8.35	8.11e-16	4.5e-13	0.46	0.36	Lymphocyte counts;	chr2:113206162	chr2:113237595~113240825:+
PRAD	cis	rs9287719	0.967	rs7355649	ENSG00000234818.1	AC092687.5	8.35	8.13e-16	4.51e-13	0.44	0.36	Prostate cancer;	chr2:10607968	chr2:10589166~10604830:+
PRAD	cis	rs67311347	1	rs10510708	ENSG00000223797.4	ENTPD3-AS1	8.35	8.14e-16	4.51e-13	0.32	0.36	Renal cell carcinoma;	chr3:40363279	chr3:40313802~40453329:-
PRAD	cis	rs1062177	0.756	rs2915817	ENSG00000253921.1	CTB-113P19.3	8.35	8.15e-16	4.52e-13	0.48	0.36	Preschool internalizing problems;	chr5:151735956	chr5:151753992~151767247:+
PRAD	cis	rs507080	0.922	rs654792	ENSG00000255422.1	AP002954.4	8.35	8.17e-16	4.53e-13	0.45	0.36	Serum metabolite levels;	chr11:118682287	chr11:118704607~118750263:+
PRAD	cis	rs4713118	0.955	rs9468203	ENSG00000280107.1	AL022393.9	-8.35	8.18e-16	4.54e-13	-0.46	-0.36	Parkinson's disease;	chr6:27720888	chr6:28170845~28172521:+
PRAD	cis	rs9309473	0.607	rs1403412	ENSG00000163016.8	ALMS1P	8.35	8.2e-16	4.55e-13	0.44	0.36	Metabolite levels;	chr2:73370964	chr2:73644919~73685576:+
PRAD	cis	rs6517329	0.565	rs73374920	ENSG00000236830.5	CBR3-AS1	8.35	8.22e-16	4.55e-13	0.38	0.36	Schizophrenia;	chr21:36170687	chr21:36131767~36175815:-
PRAD	cis	rs2404602	0.692	rs35498563	ENSG00000259422.1	RP11-593F23.1	8.35	8.24e-16	4.57e-13	0.45	0.36	Blood metabolite levels;	chr15:76666527	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.692	rs55676827	ENSG00000259422.1	RP11-593F23.1	8.35	8.24e-16	4.57e-13	0.45	0.36	Blood metabolite levels;	chr15:76669375	chr15:76174891~76181486:-
PRAD	cis	rs4713118	0.662	rs149900	ENSG00000219392.1	RP1-265C24.5	-8.35	8.27e-16	4.58e-13	-0.49	-0.36	Parkinson's disease;	chr6:28046819	chr6:28115628~28116551:+
PRAD	cis	rs4722166	0.532	rs4719713	ENSG00000179428.2	AC073072.5	-8.35	8.27e-16	4.58e-13	-0.42	-0.36	Lung cancer;	chr7:22719192	chr7:22725395~22727620:-
PRAD	cis	rs9309473	0.555	rs2901437	ENSG00000163016.8	ALMS1P	8.35	8.28e-16	4.59e-13	0.44	0.36	Metabolite levels;	chr2:73369896	chr2:73644919~73685576:+
PRAD	cis	rs9309473	0.579	rs1852644	ENSG00000163016.8	ALMS1P	8.35	8.28e-16	4.59e-13	0.44	0.36	Metabolite levels;	chr2:73370590	chr2:73644919~73685576:+
PRAD	cis	rs9810089	0.758	rs12492510	ENSG00000261758.1	RP11-102M11.2	8.35	8.3e-16	4.6e-13	0.42	0.36	Gestational age at birth (child effect);	chr3:136432789	chr3:136752630~136755780:+
PRAD	cis	rs2739330	0.791	rs4822458	ENSG00000272787.1	KB-226F1.2	-8.35	8.3e-16	4.6e-13	-0.39	-0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23969211~23969873:+
PRAD	cis	rs10740039	0.583	rs2127353	ENSG00000254271.1	RP11-131N11.4	-8.35	8.3e-16	4.6e-13	-0.51	-0.36	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60750206	chr10:60734342~60741828:+
PRAD	cis	rs4835473	0.864	rs13117932	ENSG00000251600.4	RP11-673E1.1	-8.35	8.35e-16	4.62e-13	-0.46	-0.36	Immature fraction of reticulocytes;	chr4:143735873	chr4:143912331~143982454:+
PRAD	cis	rs12142240	0.667	rs12062	ENSG00000232022.5	FAAHP1	8.35	8.36e-16	4.63e-13	0.34	0.36	Menopause (age at onset);	chr1:46364775	chr1:46432129~46445521:+
PRAD	cis	rs10463554	0.963	rs67068617	ENSG00000175749.11	EIF3KP1	8.35	8.36e-16	4.63e-13	0.49	0.36	Parkinson's disease;	chr5:103039977	chr5:103032376~103033031:+
PRAD	cis	rs11976180	1	rs2951363	ENSG00000170356.8	OR2A20P	-8.35	8.36e-16	4.63e-13	-0.48	-0.36	Obesity-related traits;	chr7:144057631	chr7:144250045~144252957:-
PRAD	cis	rs7615952	0.599	rs2270986	ENSG00000171084.14	FAM86JP	8.35	8.38e-16	4.64e-13	0.57	0.36	Blood pressure (smoking interaction);	chr3:125982256	chr3:125916620~125930024:+
PRAD	cis	rs7615952	0.599	rs12496921	ENSG00000171084.14	FAM86JP	8.35	8.38e-16	4.64e-13	0.57	0.36	Blood pressure (smoking interaction);	chr3:125983105	chr3:125916620~125930024:+
PRAD	cis	rs6452524	1	rs2126988	ENSG00000249664.1	CTD-2227C6.2	8.35	8.4e-16	4.65e-13	0.42	0.36	Hypertension (SNP x SNP interaction);	chr5:83146496	chr5:83012285~83013109:-
PRAD	cis	rs7615952	0.576	rs2276727	ENSG00000171084.14	FAM86JP	8.35	8.41e-16	4.66e-13	0.58	0.36	Blood pressure (smoking interaction);	chr3:126107400	chr3:125916620~125930024:+
PRAD	cis	rs10463554	0.927	rs158403	ENSG00000175749.11	EIF3KP1	8.35	8.41e-16	4.66e-13	0.49	0.36	Parkinson's disease;	chr5:103080064	chr5:103032376~103033031:+
PRAD	cis	rs7615952	0.512	rs34085484	ENSG00000171084.14	FAM86JP	8.35	8.44e-16	4.67e-13	0.56	0.36	Blood pressure (smoking interaction);	chr3:125825343	chr3:125916620~125930024:+
PRAD	cis	rs7615952	0.608	rs35668111	ENSG00000171084.14	FAM86JP	8.35	8.44e-16	4.67e-13	0.56	0.36	Blood pressure (smoking interaction);	chr3:125825792	chr3:125916620~125930024:+
PRAD	cis	rs11096990	0.613	rs12505690	ENSG00000249207.1	RP11-360F5.1	-8.35	8.44e-16	4.67e-13	-0.38	-0.36	Cognitive function;	chr4:39167425	chr4:39112677~39126818:-
PRAD	cis	rs4835473	0.618	rs12499907	ENSG00000251600.4	RP11-673E1.1	-8.35	8.44e-16	4.67e-13	-0.48	-0.36	Immature fraction of reticulocytes;	chr4:143999748	chr4:143912331~143982454:+
PRAD	cis	rs1061377	1	rs35437629	ENSG00000249685.1	RP11-360F5.3	8.35	8.44e-16	4.67e-13	0.41	0.36	Uric acid levels;	chr4:39131712	chr4:39133913~39135608:+
PRAD	cis	rs1061377	1	rs7657926	ENSG00000249685.1	RP11-360F5.3	8.35	8.44e-16	4.67e-13	0.41	0.36	Uric acid levels;	chr4:39132443	chr4:39133913~39135608:+
PRAD	cis	rs1061377	1	rs11096982	ENSG00000249685.1	RP11-360F5.3	8.35	8.44e-16	4.67e-13	0.41	0.36	Uric acid levels;	chr4:39133247	chr4:39133913~39135608:+
PRAD	cis	rs1061377	1	rs11727875	ENSG00000249685.1	RP11-360F5.3	8.35	8.44e-16	4.67e-13	0.41	0.36	Uric acid levels;	chr4:39133699	chr4:39133913~39135608:+
PRAD	cis	rs8062405	0.789	rs28676837	ENSG00000259982.1	CDC37P1	-8.35	8.44e-16	4.67e-13	-0.47	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28615742	chr16:28700294~28701540:-
PRAD	cis	rs4927850	0.709	rs6783079	ENSG00000242086.7	LINC00969	8.35	8.45e-16	4.68e-13	0.34	0.36	Pancreatic cancer;	chr3:195925837	chr3:195658062~195739964:+
PRAD	cis	rs4927850	0.709	rs6765762	ENSG00000242086.7	LINC00969	8.35	8.45e-16	4.68e-13	0.34	0.36	Pancreatic cancer;	chr3:195925980	chr3:195658062~195739964:+
PRAD	cis	rs7182621	0.515	rs3803416	ENSG00000259363.4	CTD-2054N24.2	-8.35	8.46e-16	4.68e-13	-0.41	-0.36	Colonoscopy-negative controls vs population controls;	chr15:99788855	chr15:99807023~99877148:+
PRAD	cis	rs6538678	0.929	rs10735336	ENSG00000258343.1	RP11-536G4.2	-8.35	8.48e-16	4.69e-13	-0.47	-0.36	Lupus nephritis in systemic lupus erythematosus;	chr12:95869661	chr12:95795345~95858839:-
PRAD	cis	rs1150668	0.799	rs1150707	ENSG00000280107.1	AL022393.9	-8.35	8.48e-16	4.69e-13	-0.44	-0.36	Pubertal anthropometrics;	chr6:28229827	chr6:28170845~28172521:+
PRAD	cis	rs875971	0.54	rs736270	ENSG00000236529.1	RP13-254B10.1	8.35	8.51e-16	4.71e-13	0.38	0.36	Aortic root size;	chr7:65963835	chr7:65840212~65840596:+
PRAD	cis	rs7615952	0.575	rs35949599	ENSG00000171084.14	FAM86JP	8.34	8.62e-16	4.77e-13	0.56	0.36	Blood pressure (smoking interaction);	chr3:125825359	chr3:125916620~125930024:+
PRAD	cis	rs17361889	0.727	rs1527208	ENSG00000224683.1	RPL36AP29	8.34	8.63e-16	4.77e-13	0.42	0.36	Pediatric bone mineral content (hip);	chr7:16241218	chr7:16208945~16209265:+
PRAD	cis	rs12142240	0.698	rs6696777	ENSG00000232022.5	FAAHP1	-8.34	8.66e-16	4.79e-13	-0.34	-0.36	Menopause (age at onset);	chr1:46345298	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs6697123	ENSG00000232022.5	FAAHP1	-8.34	8.66e-16	4.79e-13	-0.34	-0.36	Menopause (age at onset);	chr1:46345638	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs67487250	ENSG00000232022.5	FAAHP1	-8.34	8.66e-16	4.79e-13	-0.34	-0.36	Menopause (age at onset);	chr1:46345661	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs112089006	ENSG00000232022.5	FAAHP1	-8.34	8.66e-16	4.79e-13	-0.34	-0.36	Menopause (age at onset);	chr1:46346688	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs72677585	ENSG00000232022.5	FAAHP1	-8.34	8.66e-16	4.79e-13	-0.34	-0.36	Menopause (age at onset);	chr1:46346702	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs17357676	ENSG00000232022.5	FAAHP1	-8.34	8.66e-16	4.79e-13	-0.34	-0.36	Menopause (age at onset);	chr1:46346772	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs17361791	ENSG00000232022.5	FAAHP1	-8.34	8.66e-16	4.79e-13	-0.34	-0.36	Menopause (age at onset);	chr1:46346847	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.66	rs72886903	ENSG00000232022.5	FAAHP1	-8.34	8.66e-16	4.79e-13	-0.34	-0.36	Menopause (age at onset);	chr1:46348188	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs68112720	ENSG00000232022.5	FAAHP1	-8.34	8.66e-16	4.79e-13	-0.34	-0.36	Menopause (age at onset);	chr1:46348216	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs72677587	ENSG00000232022.5	FAAHP1	-8.34	8.66e-16	4.79e-13	-0.34	-0.36	Menopause (age at onset);	chr1:46348310	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs17361812	ENSG00000232022.5	FAAHP1	-8.34	8.66e-16	4.79e-13	-0.34	-0.36	Menopause (age at onset);	chr1:46348336	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs66575205	ENSG00000232022.5	FAAHP1	-8.34	8.66e-16	4.79e-13	-0.34	-0.36	Menopause (age at onset);	chr1:46348420	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs72886911	ENSG00000232022.5	FAAHP1	-8.34	8.66e-16	4.79e-13	-0.34	-0.36	Menopause (age at onset);	chr1:46348680	chr1:46432129~46445521:+
PRAD	cis	rs2404602	0.679	rs12900494	ENSG00000259422.1	RP11-593F23.1	8.34	8.69e-16	4.8e-13	0.46	0.36	Blood metabolite levels;	chr15:76620163	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.716	rs7169394	ENSG00000259422.1	RP11-593F23.1	8.34	8.69e-16	4.8e-13	0.46	0.36	Blood metabolite levels;	chr15:76620933	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.692	rs55729975	ENSG00000259422.1	RP11-593F23.1	8.34	8.7e-16	4.81e-13	0.45	0.36	Blood metabolite levels;	chr15:76510885	chr15:76174891~76181486:-
PRAD	cis	rs4835473	0.932	rs1849113	ENSG00000251600.4	RP11-673E1.1	-8.34	8.73e-16	4.82e-13	-0.46	-0.36	Immature fraction of reticulocytes;	chr4:143962512	chr4:143912331~143982454:+
PRAD	cis	rs950169	0.922	rs12906983	ENSG00000225151.9	GOLGA2P7	-8.34	8.73e-16	4.82e-13	-0.51	-0.36	Schizophrenia;	chr15:84262270	chr15:84199311~84230136:-
PRAD	cis	rs4835473	0.897	rs34380794	ENSG00000251600.4	RP11-673E1.1	-8.34	8.77e-16	4.85e-13	-0.47	-0.36	Immature fraction of reticulocytes;	chr4:143735800	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.75	rs56372690	ENSG00000251600.4	RP11-673E1.1	-8.34	8.77e-16	4.85e-13	-0.47	-0.36	Immature fraction of reticulocytes;	chr4:143735816	chr4:143912331~143982454:+
PRAD	cis	rs1555322	0.53	rs8122819	ENSG00000126005.14	MMP24-AS1	-8.34	8.78e-16	4.85e-13	-0.43	-0.36	Attention deficit hyperactivity disorder;	chr20:35293783	chr20:35216462~35278131:-
PRAD	cis	rs1062177	0.756	rs2964589	ENSG00000253921.1	CTB-113P19.3	8.34	8.81e-16	4.87e-13	0.48	0.36	Preschool internalizing problems;	chr5:151738628	chr5:151753992~151767247:+
PRAD	cis	rs8005677	1	rs1956880	ENSG00000257285.4	RP11-298I3.1	8.34	8.82e-16	4.87e-13	0.37	0.36	Cognitive ability (multi-trait analysis);	chr14:22924798	chr14:22929609~22955562:+
PRAD	cis	rs42648	0.596	rs194518	ENSG00000227646.6	STEAP2-AS1	-8.34	8.83e-16	4.87e-13	-0.33	-0.36	Homocysteine levels;	chr7:90223835	chr7:89882353~90211635:-
PRAD	cis	rs42648	0.596	rs194520	ENSG00000227646.6	STEAP2-AS1	-8.34	8.83e-16	4.87e-13	-0.33	-0.36	Homocysteine levels;	chr7:90225132	chr7:89882353~90211635:-
PRAD	cis	rs2108622	0.727	rs62106155	ENSG00000267056.2	AC005336.4	8.34	8.83e-16	4.88e-13	0.5	0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869550	chr19:15910582~15911824:-
PRAD	cis	rs2108622	0.727	rs62106157	ENSG00000267056.2	AC005336.4	8.34	8.83e-16	4.88e-13	0.5	0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869638	chr19:15910582~15911824:-
PRAD	cis	rs2108622	0.727	rs62106158	ENSG00000267056.2	AC005336.4	8.34	8.83e-16	4.88e-13	0.5	0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869682	chr19:15910582~15911824:-
PRAD	cis	rs2108622	0.727	rs7256877	ENSG00000267056.2	AC005336.4	8.34	8.83e-16	4.88e-13	0.5	0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869873	chr19:15910582~15911824:-
PRAD	cis	rs2108622	0.727	rs7253873	ENSG00000267056.2	AC005336.4	8.34	8.83e-16	4.88e-13	0.5	0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15870090	chr19:15910582~15911824:-
PRAD	cis	rs2108622	0.559	rs7252638	ENSG00000267056.2	AC005336.4	8.34	8.83e-16	4.88e-13	0.5	0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15870215	chr19:15910582~15911824:-
PRAD	cis	rs2108622	0.727	rs7253684	ENSG00000267056.2	AC005336.4	8.34	8.83e-16	4.88e-13	0.5	0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15870316	chr19:15910582~15911824:-
PRAD	cis	rs2739330	0.734	rs2000467	ENSG00000272787.1	KB-226F1.2	8.34	8.83e-16	4.88e-13	0.4	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23969211~23969873:+
PRAD	cis	rs4713118	0.629	rs203887	ENSG00000280107.1	AL022393.9	-8.34	8.85e-16	4.88e-13	-0.51	-0.36	Parkinson's disease;	chr6:28053491	chr6:28170845~28172521:+
PRAD	cis	rs763567	1	rs6677540	ENSG00000271811.1	RP1-79C4.4	-8.34	8.88e-16	4.9e-13	-0.42	-0.36	Tonsillectomy;	chr1:170614370	chr1:170667381~170669425:+
PRAD	cis	rs7684253	1	rs7684253	ENSG00000269949.1	RP11-738E22.3	8.34	8.89e-16	4.91e-13	0.42	0.36	Migraine;	chr4:56861145	chr4:56960927~56961373:-
PRAD	cis	rs5769707	0.681	rs4622843	ENSG00000188511.11	C22orf34	8.34	8.9e-16	4.91e-13	0.41	0.36	Monocyte percentage of white cells;Monocyte count;	chr22:49643268	chr22:49414524~49657542:-
PRAD	cis	rs7916697	0.52	rs12265247	ENSG00000233590.1	RP11-153K11.3	-8.34	8.92e-16	4.93e-13	-0.5	-0.36	Optic disc area;	chr10:68278641	chr10:68233251~68242379:-
PRAD	cis	rs2282300	1	rs2282300	ENSG00000254532.1	RP11-624D11.2	8.34	8.92e-16	4.93e-13	0.51	0.36	Morning vs. evening chronotype;	chr11:30414038	chr11:30044058~30084343:-
PRAD	cis	rs6723108	0.627	rs6430549	ENSG00000224043.6	CCNT2-AS1	-8.34	8.95e-16	4.94e-13	-0.5	-0.36	Type 2 diabetes;	chr2:134858776	chr2:134735464~134918710:-
PRAD	cis	rs6723108	0.627	rs1446523	ENSG00000224043.6	CCNT2-AS1	-8.34	8.95e-16	4.94e-13	-0.5	-0.36	Type 2 diabetes;	chr2:134859051	chr2:134735464~134918710:-
PRAD	cis	rs7923609	0.841	rs10761786	ENSG00000232075.1	MRPL35P2	-8.34	9.02e-16	4.98e-13	-0.38	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63576447	chr10:63634317~63634827:-
PRAD	cis	rs2019137	0.967	rs895412	ENSG00000274877.1	RP11-65I12.1	8.34	9.05e-16	4.99e-13	0.46	0.36	Lymphocyte counts;	chr2:113216387	chr2:113237595~113240825:+
PRAD	cis	rs12220777	0.892	rs7083787	ENSG00000230091.5	TMEM254-AS1	8.34	9.06e-16	5e-13	0.7	0.36	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80029185	chr10:80046860~80078912:-
PRAD	cis	rs4631830	0.9	rs11006274	ENSG00000230869.1	CTGLF10P	8.34	9.07e-16	5.01e-13	0.45	0.36	Prostate-specific antigen levels;	chr10:46055531	chr10:45678692~45700532:+
PRAD	cis	rs2019137	1	rs2019137	ENSG00000274877.1	RP11-65I12.1	8.34	9.07e-16	5.01e-13	0.46	0.36	Lymphocyte counts;	chr2:113216055	chr2:113237595~113240825:+
PRAD	cis	rs77204473	0.557	rs7111854	ENSG00000254851.1	RP11-109L13.1	8.34	9.08e-16	5.01e-13	0.69	0.36	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116906110	chr11:117135528~117138582:+
PRAD	cis	rs9341835	0.518	rs9361816	ENSG00000218048.2	RP3-407E4.4	8.34	9.13e-16	5.04e-13	0.42	0.36	Schizophrenia;	chr6:63464534	chr6:63440766~63443580:+
PRAD	cis	rs11951515	0.663	rs11743622	ENSG00000188850.9	RP11-159F24.2	8.34	9.14e-16	5.04e-13	0.44	0.36	Metabolite levels  (X-11787);	chr5:43351501	chr5:43336164~43348716:+
PRAD	cis	rs10463554	0.927	rs12055075	ENSG00000175749.11	EIF3KP1	8.34	9.15e-16	5.05e-13	0.49	0.36	Parkinson's disease;	chr5:103044553	chr5:103032376~103033031:+
PRAD	cis	rs11098499	0.82	rs11737395	ENSG00000245958.5	RP11-33B1.1	-8.34	9.17e-16	5.06e-13	-0.36	-0.36	Corneal astigmatism;	chr4:119599549	chr4:119454791~119552025:+
PRAD	cis	rs1075265	0.572	rs62139835	ENSG00000233266.1	HMGB1P31	8.34	9.19e-16	5.07e-13	0.49	0.36	Chronotype;Morning vs. evening chronotype;	chr2:53682307	chr2:54051334~54051760:+
PRAD	cis	rs12142240	0.698	rs56130131	ENSG00000232022.5	FAAHP1	-8.33	9.26e-16	5.11e-13	-0.34	-0.36	Menopause (age at onset);	chr1:46395634	chr1:46432129~46445521:+
PRAD	cis	rs2337406	1	rs78857163	ENSG00000274576.2	IGHV2-70	-8.33	9.29e-16	5.12e-13	-0.4	-0.36	Alzheimer's disease (late onset);	chr14:106707435	chr14:106770577~106771020:-
PRAD	cis	rs2617170	0.883	rs2086099	ENSG00000245648.1	RP11-277P12.20	8.33	9.3e-16	5.13e-13	0.44	0.36	Behcet's disease;	chr12:10373939	chr12:10363769~10398506:+
PRAD	cis	rs9368481	0.761	rs7775041	ENSG00000241549.7	GUSBP2	-8.33	9.33e-16	5.14e-13	-0.41	-0.36	Autism spectrum disorder or schizophrenia;	chr6:27041733	chr6:26871484~26956554:-
PRAD	cis	rs2581828	0.618	rs6792345	ENSG00000242142.1	SERBP1P3	-8.33	9.34e-16	5.15e-13	-0.43	-0.36	Crohn's disease;	chr3:53131178	chr3:53064283~53065091:-
PRAD	cis	rs2581828	0.618	rs6792363	ENSG00000242142.1	SERBP1P3	-8.33	9.34e-16	5.15e-13	-0.43	-0.36	Crohn's disease;	chr3:53131247	chr3:53064283~53065091:-
PRAD	cis	rs2581828	0.618	rs6445565	ENSG00000242142.1	SERBP1P3	-8.33	9.34e-16	5.15e-13	-0.43	-0.36	Crohn's disease;	chr3:53131448	chr3:53064283~53065091:-
PRAD	cis	rs2581828	0.591	rs6445566	ENSG00000242142.1	SERBP1P3	-8.33	9.34e-16	5.15e-13	-0.43	-0.36	Crohn's disease;	chr3:53131611	chr3:53064283~53065091:-
PRAD	cis	rs2581828	0.618	rs13319872	ENSG00000242142.1	SERBP1P3	-8.33	9.34e-16	5.15e-13	-0.43	-0.36	Crohn's disease;	chr3:53132082	chr3:53064283~53065091:-
PRAD	cis	rs2581828	0.618	rs9828221	ENSG00000242142.1	SERBP1P3	-8.33	9.34e-16	5.15e-13	-0.43	-0.36	Crohn's disease;	chr3:53132643	chr3:53064283~53065091:-
PRAD	cis	rs763567	0.967	rs6690642	ENSG00000271811.1	RP1-79C4.4	-8.33	9.34e-16	5.15e-13	-0.42	-0.36	Tonsillectomy;	chr1:170614803	chr1:170667381~170669425:+
PRAD	cis	rs1075265	0.933	rs2287642	ENSG00000233266.1	HMGB1P31	8.33	9.38e-16	5.17e-13	0.49	0.36	Chronotype;Morning vs. evening chronotype;	chr2:54108447	chr2:54051334~54051760:+
PRAD	cis	rs2638953	0.924	rs12320545	ENSG00000278733.1	RP11-425D17.1	8.33	9.42e-16	5.19e-13	0.44	0.36	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28248047	chr12:28185625~28186190:-
PRAD	cis	rs6723108	0.603	rs6708336	ENSG00000224043.6	CCNT2-AS1	-8.33	9.43e-16	5.2e-13	-0.5	-0.36	Type 2 diabetes;	chr2:134961562	chr2:134735464~134918710:-
PRAD	cis	rs10463554	0.857	rs34376	ENSG00000175749.11	EIF3KP1	8.33	9.43e-16	5.2e-13	0.49	0.36	Parkinson's disease;	chr5:103065409	chr5:103032376~103033031:+
PRAD	cis	rs10463554	0.927	rs34375	ENSG00000175749.11	EIF3KP1	8.33	9.43e-16	5.2e-13	0.49	0.36	Parkinson's disease;	chr5:103065419	chr5:103032376~103033031:+
PRAD	cis	rs6570726	0.935	rs432086	ENSG00000235652.6	RP11-545I5.3	-8.33	9.46e-16	5.21e-13	-0.38	-0.36	Lobe attachment (rater-scored or self-reported);	chr6:145520457	chr6:145799409~145886585:+
PRAD	cis	rs62103177	0.535	rs62101568	ENSG00000261126.6	RP11-795F19.1	8.33	9.47e-16	5.22e-13	0.47	0.36	Opioid sensitivity;	chr18:80176788	chr18:80046900~80095482:+
PRAD	cis	rs2638953	0.924	rs12372372	ENSG00000278733.1	RP11-425D17.1	-8.33	9.48e-16	5.22e-13	-0.45	-0.36	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28147877	chr12:28185625~28186190:-
PRAD	cis	rs1061377	1	rs1897136	ENSG00000249685.1	RP11-360F5.3	8.33	9.51e-16	5.24e-13	0.41	0.36	Uric acid levels;	chr4:39131242	chr4:39133913~39135608:+
PRAD	cis	rs1061377	1	rs1897137	ENSG00000249685.1	RP11-360F5.3	8.33	9.51e-16	5.24e-13	0.41	0.36	Uric acid levels;	chr4:39131387	chr4:39133913~39135608:+
PRAD	cis	rs1061377	1	rs7681116	ENSG00000249685.1	RP11-360F5.3	8.33	9.51e-16	5.24e-13	0.41	0.36	Uric acid levels;	chr4:39133015	chr4:39133913~39135608:+
PRAD	cis	rs9309473	0.583	rs6546822	ENSG00000163016.8	ALMS1P	8.33	9.52e-16	5.24e-13	0.44	0.36	Metabolite levels;	chr2:73347970	chr2:73644919~73685576:+
PRAD	cis	rs150992	0.587	rs11949103	ENSG00000248489.1	CTD-2007H13.3	-8.33	9.56e-16	5.26e-13	-0.4	-0.36	Body mass index;	chr5:99011939	chr5:98929171~98995013:+
PRAD	cis	rs1155848	0.571	rs6563125	ENSG00000227354.5	RBM26-AS1	8.33	9.56e-16	5.27e-13	0.65	0.36	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79630618	chr13:79406309~79424328:+
PRAD	cis	rs1155848	0.571	rs58739959	ENSG00000227354.5	RBM26-AS1	8.33	9.56e-16	5.27e-13	0.65	0.36	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79633468	chr13:79406309~79424328:+
PRAD	cis	rs2404602	0.692	rs4886503	ENSG00000259422.1	RP11-593F23.1	-8.33	9.57e-16	5.27e-13	-0.45	-0.36	Blood metabolite levels;	chr15:76816533	chr15:76174891~76181486:-
PRAD	cis	rs1930961	1	rs6004673	ENSG00000272798.1	CTA-390C10.9	-8.33	9.59e-16	5.28e-13	-0.58	-0.36	Bipolar disorder with mood-incongruent psychosis;	chr22:25489386	chr22:25436312~25436915:+
PRAD	cis	rs8523	0.838	rs17675322	ENSG00000230314.5	ELOVL2-AS1	8.33	9.6e-16	5.28e-13	0.4	0.36	Red blood cell fatty acid levels;	chr6:11058952	chr6:11043524~11078226:+
PRAD	cis	rs8523	0.697	rs59542081	ENSG00000230314.5	ELOVL2-AS1	8.33	9.6e-16	5.28e-13	0.4	0.36	Red blood cell fatty acid levels;	chr6:11058976	chr6:11043524~11078226:+
PRAD	cis	rs8523	0.697	rs57549068	ENSG00000230314.5	ELOVL2-AS1	8.33	9.6e-16	5.28e-13	0.4	0.36	Red blood cell fatty acid levels;	chr6:11058977	chr6:11043524~11078226:+
PRAD	cis	rs5769707	0.632	rs135871	ENSG00000188511.11	C22orf34	8.33	9.66e-16	5.32e-13	0.43	0.36	Monocyte percentage of white cells;Monocyte count;	chr22:49615321	chr22:49414524~49657542:-
PRAD	cis	rs2439831	0.85	rs16963953	ENSG00000249839.1	AC011330.5	-8.33	9.68e-16	5.33e-13	-0.63	-0.36	Lung cancer in ever smokers;	chr15:43789521	chr15:43663654~43684339:-
PRAD	cis	rs2581828	0.618	rs9868406	ENSG00000242142.1	SERBP1P3	-8.33	9.68e-16	5.33e-13	-0.43	-0.36	Crohn's disease;	chr3:53130177	chr3:53064283~53065091:-
PRAD	cis	rs17012589	0.639	rs7486483	ENSG00000258815.1	RP11-408B11.2	8.33	9.68e-16	5.33e-13	0.5	0.36	Bone mineral density (Ward's triangle area);	chr12:85288532	chr12:85318060~85342912:+
PRAD	cis	rs17012589	0.639	rs6539889	ENSG00000258815.1	RP11-408B11.2	8.33	9.68e-16	5.33e-13	0.5	0.36	Bone mineral density (Ward's triangle area);	chr12:85288880	chr12:85318060~85342912:+
PRAD	cis	rs4835473	0.9	rs4257605	ENSG00000251600.4	RP11-673E1.1	-8.33	9.71e-16	5.35e-13	-0.46	-0.36	Immature fraction of reticulocytes;	chr4:143740081	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs4498094	ENSG00000251600.4	RP11-673E1.1	-8.33	9.71e-16	5.35e-13	-0.46	-0.36	Immature fraction of reticulocytes;	chr4:143740097	chr4:143912331~143982454:+
PRAD	cis	rs8523	0.933	rs66464172	ENSG00000230314.5	ELOVL2-AS1	8.33	9.73e-16	5.35e-13	0.4	0.36	Red blood cell fatty acid levels;	chr6:10978785	chr6:11043524~11078226:+
PRAD	cis	rs10463554	0.824	rs427430	ENSG00000175749.11	EIF3KP1	8.33	9.73e-16	5.35e-13	0.5	0.36	Parkinson's disease;	chr5:103096320	chr5:103032376~103033031:+
PRAD	cis	rs1789	0.872	rs4333182	ENSG00000273133.1	RP11-799M12.2	-8.33	9.76e-16	5.37e-13	-0.48	-0.36	Blood protein levels;	chr4:15683089	chr4:15563698~15564253:-
PRAD	cis	rs193541	0.617	rs2045628	ENSG00000263432.2	RN7SL689P	8.33	9.77e-16	5.37e-13	0.39	0.36	Glucose homeostasis traits;	chr5:122759459	chr5:123022487~123022783:-
PRAD	cis	rs1501911	0.566	rs709387	ENSG00000248489.1	CTD-2007H13.3	8.33	9.8e-16	5.39e-13	0.45	0.36	Lung function (FEV1/FVC);	chr5:98994337	chr5:98929171~98995013:+
PRAD	cis	rs1501911	0.588	rs709386	ENSG00000248489.1	CTD-2007H13.3	8.33	9.8e-16	5.39e-13	0.45	0.36	Lung function (FEV1/FVC);	chr5:98994346	chr5:98929171~98995013:+
PRAD	cis	rs9532669	0.926	rs9532657	ENSG00000168852.11	TPTE2P5	-8.33	9.85e-16	5.42e-13	-0.34	-0.36	Cervical cancer;	chr13:40918208	chr13:40822296~40921749:-
PRAD	cis	rs34779708	0.801	rs12098720	ENSG00000230534.5	RP11-297A16.2	8.33	9.86e-16	5.42e-13	0.49	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35249755	chr10:35098006~35127020:-
PRAD	cis	rs34779708	0.801	rs34592588	ENSG00000230534.5	RP11-297A16.2	8.33	9.86e-16	5.42e-13	0.49	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35251206	chr10:35098006~35127020:-
PRAD	cis	rs12908161	1	rs12908161	ENSG00000259728.4	LINC00933	8.33	9.86e-16	5.42e-13	0.45	0.36	Schizophrenia;	chr15:84664594	chr15:84570649~84580175:+
PRAD	cis	rs4835473	0.932	rs4615131	ENSG00000251600.4	RP11-673E1.1	-8.33	9.87e-16	5.42e-13	-0.46	-0.36	Immature fraction of reticulocytes;	chr4:143740295	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs4499657	ENSG00000251600.4	RP11-673E1.1	-8.33	9.87e-16	5.42e-13	-0.46	-0.36	Immature fraction of reticulocytes;	chr4:143740316	chr4:143912331~143982454:+
PRAD	cis	rs75422866	0.867	rs73111258	ENSG00000274902.1	RP1-197B17.4	8.33	9.94e-16	5.46e-13	0.95	0.36	Pneumonia;	chr12:47597313	chr12:47731908~47732351:+
PRAD	cis	rs75422866	0.867	rs117388682	ENSG00000274902.1	RP1-197B17.4	8.33	9.94e-16	5.46e-13	0.95	0.36	Pneumonia;	chr12:47599713	chr12:47731908~47732351:+
PRAD	cis	rs75422866	0.867	rs79113930	ENSG00000274902.1	RP1-197B17.4	8.33	9.94e-16	5.46e-13	0.95	0.36	Pneumonia;	chr12:47600628	chr12:47731908~47732351:+
PRAD	cis	rs748404	0.631	rs6493083	ENSG00000249839.1	AC011330.5	-8.33	9.95e-16	5.47e-13	-0.45	-0.36	Lung cancer;	chr15:43345787	chr15:43663654~43684339:-
PRAD	cis	rs9287719	0.967	rs7563894	ENSG00000234818.1	AC092687.5	8.33	9.95e-16	5.47e-13	0.43	0.36	Prostate cancer;	chr2:10614523	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs7566767	ENSG00000234818.1	AC092687.5	8.33	9.95e-16	5.47e-13	0.43	0.36	Prostate cancer;	chr2:10614537	chr2:10589166~10604830:+
PRAD	cis	rs2404602	0.692	rs34272342	ENSG00000259422.1	RP11-593F23.1	8.32	9.96e-16	5.47e-13	0.45	0.36	Blood metabolite levels;	chr15:76719935	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.692	rs1471780	ENSG00000259422.1	RP11-593F23.1	8.32	9.96e-16	5.47e-13	0.45	0.36	Blood metabolite levels;	chr15:76734185	chr15:76174891~76181486:-
PRAD	cis	rs367615	0.552	rs2963024	ENSG00000249476.1	CTD-2587M2.1	-8.32	9.98e-16	5.48e-13	-0.43	-0.36	Colorectal cancer (SNP x SNP interaction);	chr5:109395072	chr5:109237120~109326369:-
PRAD	cis	rs1150668	0.699	rs13408	ENSG00000280107.1	AL022393.9	-8.32	1e-15	5.49e-13	-0.44	-0.36	Pubertal anthropometrics;	chr6:28244970	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.666	rs200956	ENSG00000226314.6	ZNF192P1	-8.32	1e-15	5.5e-13	-0.53	-0.36	Depression;	chr6:27871968	chr6:28161781~28169594:+
PRAD	cis	rs17711722	0.522	rs4642526	ENSG00000237310.1	GS1-124K5.4	8.32	1e-15	5.5e-13	0.31	0.36	Calcium levels;	chr7:65751755	chr7:66493706~66495474:+
PRAD	cis	rs2015599	0.623	rs2288128	ENSG00000275476.1	RP11-996F15.4	8.32	1e-15	5.5e-13	0.4	0.36	Platelet count;Mean platelet volume;	chr12:29316054	chr12:29277397~29277882:-
PRAD	cis	rs2015599	0.584	rs2288129	ENSG00000275476.1	RP11-996F15.4	8.32	1e-15	5.5e-13	0.4	0.36	Platelet count;Mean platelet volume;	chr12:29316355	chr12:29277397~29277882:-
PRAD	cis	rs9287719	0.967	rs6432112	ENSG00000234818.1	AC092687.5	-8.32	1.01e-15	5.53e-13	-0.43	-0.36	Prostate cancer;	chr2:10604748	chr2:10589166~10604830:+
PRAD	cis	rs8005677	1	rs11157930	ENSG00000257285.4	RP11-298I3.1	8.32	1.01e-15	5.54e-13	0.37	0.36	Cognitive ability (multi-trait analysis);	chr14:22933962	chr14:22929609~22955562:+
PRAD	cis	rs8005677	0.962	rs11157931	ENSG00000257285.4	RP11-298I3.1	8.32	1.01e-15	5.54e-13	0.37	0.36	Cognitive ability (multi-trait analysis);	chr14:22933984	chr14:22929609~22955562:+
PRAD	cis	rs6847067	0.794	rs11732309	ENSG00000180769.7	WDFY3-AS2	-8.32	1.01e-15	5.54e-13	-0.38	-0.36	Oropharynx cancer;	chr4:85012150	chr4:84965682~85011277:+
PRAD	cis	rs8005677	0.962	rs8003934	ENSG00000257285.4	RP11-298I3.1	8.32	1.01e-15	5.54e-13	0.37	0.36	Cognitive ability (multi-trait analysis);	chr14:22931933	chr14:22929609~22955562:+
PRAD	cis	rs6538678	0.864	rs4762249	ENSG00000258343.1	RP11-536G4.2	8.32	1.01e-15	5.54e-13	0.46	0.36	Lupus nephritis in systemic lupus erythematosus;	chr12:95884183	chr12:95795345~95858839:-
PRAD	cis	rs9287719	0.967	rs6712304	ENSG00000234818.1	AC092687.5	8.32	1.02e-15	5.57e-13	0.43	0.36	Prostate cancer;	chr2:10614249	chr2:10589166~10604830:+
PRAD	cis	rs4835473	0.708	rs7655939	ENSG00000251600.4	RP11-673E1.1	8.32	1.02e-15	5.58e-13	0.47	0.36	Immature fraction of reticulocytes;	chr4:143956889	chr4:143912331~143982454:+
PRAD	cis	rs496547	0.654	rs688161	ENSG00000278376.1	RP11-158I9.8	-8.32	1.02e-15	5.58e-13	-0.33	-0.36	Hip minimal joint space width;	chr11:118807001	chr11:118791254~118793137:+
PRAD	cis	rs4718428	0.705	rs11028	ENSG00000230295.1	RP11-458F8.2	-8.32	1.02e-15	5.58e-13	-0.27	-0.36	Corneal structure;	chr7:66811230	chr7:66880708~66882981:+
PRAD	cis	rs11098499	0.909	rs10017335	ENSG00000245958.5	RP11-33B1.1	8.32	1.02e-15	5.58e-13	0.36	0.36	Corneal astigmatism;	chr4:119460368	chr4:119454791~119552025:+
PRAD	cis	rs7829975	0.688	rs7837587	ENSG00000253893.2	FAM85B	-8.32	1.02e-15	5.59e-13	-0.42	-0.36	Mood instability;	chr8:8521482	chr8:8167819~8226614:-
PRAD	cis	rs4835473	0.9	rs35906127	ENSG00000251600.4	RP11-673E1.1	-8.32	1.02e-15	5.61e-13	-0.46	-0.36	Immature fraction of reticulocytes;	chr4:143734400	chr4:143912331~143982454:+
PRAD	cis	rs763567	0.967	rs10919444	ENSG00000271811.1	RP1-79C4.4	-8.32	1.03e-15	5.63e-13	-0.42	-0.36	Tonsillectomy;	chr1:170612493	chr1:170667381~170669425:+
PRAD	cis	rs2015599	0.623	rs10843385	ENSG00000275476.1	RP11-996F15.4	-8.32	1.03e-15	5.64e-13	-0.4	-0.36	Platelet count;Mean platelet volume;	chr12:29323100	chr12:29277397~29277882:-
PRAD	cis	rs2015599	0.601	rs17715086	ENSG00000275476.1	RP11-996F15.4	-8.32	1.03e-15	5.64e-13	-0.4	-0.36	Platelet count;Mean platelet volume;	chr12:29329073	chr12:29277397~29277882:-
PRAD	cis	rs8062405	0.789	rs28480369	ENSG00000259982.1	CDC37P1	-8.32	1.04e-15	5.69e-13	-0.47	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28615683	chr16:28700294~28701540:-
PRAD	cis	rs2028414	0.512	rs2247712	ENSG00000258701.1	LINC00638	8.32	1.04e-15	5.69e-13	0.56	0.36	IgG glycosylation;	chr14:104893490	chr14:104821201~104823718:+
PRAD	cis	rs11098499	0.863	rs10019674	ENSG00000245958.5	RP11-33B1.1	8.32	1.04e-15	5.69e-13	0.37	0.36	Corneal astigmatism;	chr4:119522334	chr4:119454791~119552025:+
PRAD	cis	rs1062177	0.756	rs2915815	ENSG00000253921.1	CTB-113P19.3	8.32	1.04e-15	5.7e-13	0.48	0.36	Preschool internalizing problems;	chr5:151736322	chr5:151753992~151767247:+
PRAD	cis	rs2153535	0.518	rs9285977	ENSG00000230939.1	RP11-314C16.1	-8.32	1.04e-15	5.71e-13	-0.44	-0.36	Motion sickness;	chr6:8572052	chr6:8784178~8785445:+
PRAD	cis	rs2015599	0.623	rs7964831	ENSG00000275476.1	RP11-996F15.4	-8.32	1.05e-15	5.73e-13	-0.39	-0.36	Platelet count;Mean platelet volume;	chr12:29286655	chr12:29277397~29277882:-
PRAD	cis	rs4631830	0.72	rs12412140	ENSG00000230869.1	CTGLF10P	8.32	1.05e-15	5.74e-13	0.45	0.36	Prostate-specific antigen levels;	chr10:46091845	chr10:45678692~45700532:+
PRAD	cis	rs4713118	0.662	rs149901	ENSG00000226314.6	ZNF192P1	-8.32	1.05e-15	5.76e-13	-0.49	-0.36	Parkinson's disease;	chr6:27997725	chr6:28161781~28169594:+
PRAD	cis	rs526231	0.543	rs158395	ENSG00000175749.11	EIF3KP1	8.32	1.05e-15	5.77e-13	0.5	0.36	Primary biliary cholangitis;	chr5:103075685	chr5:103032376~103033031:+
PRAD	cis	rs526231	0.543	rs158400	ENSG00000175749.11	EIF3KP1	8.32	1.05e-15	5.77e-13	0.5	0.36	Primary biliary cholangitis;	chr5:103077628	chr5:103032376~103033031:+
PRAD	cis	rs526231	0.543	rs257302	ENSG00000175749.11	EIF3KP1	8.32	1.05e-15	5.77e-13	0.5	0.36	Primary biliary cholangitis;	chr5:103080426	chr5:103032376~103033031:+
PRAD	cis	rs526231	0.543	rs257303	ENSG00000175749.11	EIF3KP1	8.32	1.05e-15	5.77e-13	0.5	0.36	Primary biliary cholangitis;	chr5:103081023	chr5:103032376~103033031:+
PRAD	cis	rs9287719	0.839	rs11683335	ENSG00000234818.1	AC092687.5	8.32	1.05e-15	5.77e-13	0.43	0.36	Prostate cancer;	chr2:10616539	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs10929688	ENSG00000234818.1	AC092687.5	8.32	1.06e-15	5.78e-13	0.43	0.36	Prostate cancer;	chr2:10616524	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs715247	ENSG00000234818.1	AC092687.5	8.32	1.06e-15	5.79e-13	0.43	0.36	Prostate cancer;	chr2:10596165	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs715246	ENSG00000234818.1	AC092687.5	8.32	1.06e-15	5.79e-13	0.43	0.36	Prostate cancer;	chr2:10596229	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs2010073	ENSG00000234818.1	AC092687.5	8.32	1.06e-15	5.79e-13	0.43	0.36	Prostate cancer;	chr2:10596352	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs2010080	ENSG00000234818.1	AC092687.5	8.32	1.06e-15	5.79e-13	0.43	0.36	Prostate cancer;	chr2:10596426	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.901	rs6432109	ENSG00000234818.1	AC092687.5	8.32	1.06e-15	5.79e-13	0.43	0.36	Prostate cancer;	chr2:10596695	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs7592691	ENSG00000234818.1	AC092687.5	8.32	1.06e-15	5.79e-13	0.43	0.36	Prostate cancer;	chr2:10597300	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.934	rs6432110	ENSG00000234818.1	AC092687.5	8.32	1.06e-15	5.79e-13	0.43	0.36	Prostate cancer;	chr2:10597892	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs7605461	ENSG00000234818.1	AC092687.5	8.32	1.06e-15	5.79e-13	0.43	0.36	Prostate cancer;	chr2:10598008	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs7593496	ENSG00000234818.1	AC092687.5	8.32	1.06e-15	5.79e-13	0.43	0.36	Prostate cancer;	chr2:10598050	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs7608498	ENSG00000234818.1	AC092687.5	8.32	1.06e-15	5.79e-13	0.43	0.36	Prostate cancer;	chr2:10598302	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs7582775	ENSG00000234818.1	AC092687.5	8.32	1.06e-15	5.79e-13	0.43	0.36	Prostate cancer;	chr2:10598323	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs6750891	ENSG00000234818.1	AC092687.5	8.32	1.06e-15	5.79e-13	0.43	0.36	Prostate cancer;	chr2:10598437	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs6733416	ENSG00000234818.1	AC092687.5	8.32	1.06e-15	5.79e-13	0.43	0.36	Prostate cancer;	chr2:10598558	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs6751398	ENSG00000234818.1	AC092687.5	8.32	1.06e-15	5.79e-13	0.43	0.36	Prostate cancer;	chr2:10598846	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs4519489	ENSG00000234818.1	AC092687.5	8.32	1.06e-15	5.79e-13	0.43	0.36	Prostate cancer;	chr2:10598961	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs4453662	ENSG00000234818.1	AC092687.5	8.32	1.06e-15	5.79e-13	0.43	0.36	Prostate cancer;	chr2:10599002	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.901	rs13034017	ENSG00000234818.1	AC092687.5	8.32	1.06e-15	5.79e-13	0.43	0.36	Prostate cancer;	chr2:10599466	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs13034061	ENSG00000234818.1	AC092687.5	8.32	1.06e-15	5.79e-13	0.43	0.36	Prostate cancer;	chr2:10599525	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.935	rs7600495	ENSG00000234818.1	AC092687.5	8.32	1.06e-15	5.79e-13	0.43	0.36	Prostate cancer;	chr2:10599674	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs7600587	ENSG00000234818.1	AC092687.5	8.32	1.06e-15	5.79e-13	0.43	0.36	Prostate cancer;	chr2:10599725	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.839	rs7600695	ENSG00000234818.1	AC092687.5	8.32	1.06e-15	5.79e-13	0.43	0.36	Prostate cancer;	chr2:10599819	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs7587114	ENSG00000234818.1	AC092687.5	8.32	1.06e-15	5.79e-13	0.43	0.36	Prostate cancer;	chr2:10599837	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs7600728	ENSG00000234818.1	AC092687.5	8.32	1.06e-15	5.79e-13	0.43	0.36	Prostate cancer;	chr2:10599873	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs7600820	ENSG00000234818.1	AC092687.5	8.32	1.06e-15	5.79e-13	0.43	0.36	Prostate cancer;	chr2:10599918	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs7587231	ENSG00000234818.1	AC092687.5	8.32	1.06e-15	5.79e-13	0.43	0.36	Prostate cancer;	chr2:10599967	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs4668691	ENSG00000234818.1	AC092687.5	8.32	1.06e-15	5.79e-13	0.43	0.36	Prostate cancer;	chr2:10600368	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.934	rs10181806	ENSG00000234818.1	AC092687.5	8.32	1.06e-15	5.79e-13	0.43	0.36	Prostate cancer;	chr2:10601015	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs11687023	ENSG00000234818.1	AC092687.5	8.32	1.06e-15	5.79e-13	0.43	0.36	Prostate cancer;	chr2:10601286	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs10454738	ENSG00000234818.1	AC092687.5	8.32	1.06e-15	5.79e-13	0.43	0.36	Prostate cancer;	chr2:10601923	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs6706542	ENSG00000234818.1	AC092687.5	8.32	1.06e-15	5.79e-13	0.43	0.36	Prostate cancer;	chr2:10602365	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs2287061	ENSG00000234818.1	AC092687.5	8.32	1.06e-15	5.79e-13	0.43	0.36	Prostate cancer;	chr2:10603027	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs2287062	ENSG00000234818.1	AC092687.5	8.32	1.06e-15	5.79e-13	0.43	0.36	Prostate cancer;	chr2:10603065	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.935	rs1309	ENSG00000234818.1	AC092687.5	8.32	1.06e-15	5.79e-13	0.43	0.36	Prostate cancer;	chr2:10603420	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs3815521	ENSG00000234818.1	AC092687.5	8.32	1.06e-15	5.79e-13	0.43	0.36	Prostate cancer;	chr2:10603528	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs10929686	ENSG00000234818.1	AC092687.5	8.32	1.06e-15	5.79e-13	0.43	0.36	Prostate cancer;	chr2:10603579	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs4613248	ENSG00000234818.1	AC092687.5	8.32	1.06e-15	5.79e-13	0.43	0.36	Prostate cancer;	chr2:10603925	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs10191883	ENSG00000234818.1	AC092687.5	8.32	1.06e-15	5.79e-13	0.43	0.36	Prostate cancer;	chr2:10604010	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.934	rs4629131	ENSG00000234818.1	AC092687.5	8.32	1.06e-15	5.79e-13	0.43	0.36	Prostate cancer;	chr2:10604033	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.901	rs4555317	ENSG00000234818.1	AC092687.5	8.32	1.06e-15	5.79e-13	0.43	0.36	Prostate cancer;	chr2:10604121	chr2:10589166~10604830:+
PRAD	cis	rs9368481	0.761	rs12661756	ENSG00000241549.7	GUSBP2	8.32	1.06e-15	5.81e-13	0.41	0.36	Autism spectrum disorder or schizophrenia;	chr6:27035704	chr6:26871484~26956554:-
PRAD	cis	rs10463554	0.927	rs56361326	ENSG00000175749.11	EIF3KP1	8.32	1.06e-15	5.82e-13	0.47	0.36	Parkinson's disease;	chr5:103054184	chr5:103032376~103033031:+
PRAD	cis	rs10463554	0.927	rs34800	ENSG00000175749.11	EIF3KP1	8.32	1.06e-15	5.82e-13	0.5	0.36	Parkinson's disease;	chr5:103090799	chr5:103032376~103033031:+
PRAD	cis	rs10463554	0.927	rs34802	ENSG00000175749.11	EIF3KP1	8.32	1.06e-15	5.82e-13	0.5	0.36	Parkinson's disease;	chr5:103091301	chr5:103032376~103033031:+
PRAD	cis	rs526231	0.508	rs34805	ENSG00000175749.11	EIF3KP1	8.32	1.06e-15	5.82e-13	0.5	0.36	Primary biliary cholangitis;	chr5:103092608	chr5:103032376~103033031:+
PRAD	cis	rs10463554	0.927	rs34810	ENSG00000175749.11	EIF3KP1	8.32	1.06e-15	5.82e-13	0.5	0.36	Parkinson's disease;	chr5:103095045	chr5:103032376~103033031:+
PRAD	cis	rs5769707	0.616	rs6009786	ENSG00000188511.11	C22orf34	8.32	1.06e-15	5.82e-13	0.42	0.36	Monocyte percentage of white cells;Monocyte count;	chr22:49621497	chr22:49414524~49657542:-
PRAD	cis	rs2108622	0.958	rs79400241	ENSG00000267453.5	AC004791.2	-8.32	1.07e-15	5.83e-13	-0.49	-0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15873592	chr19:15851993~15864904:-
PRAD	cis	rs9287719	0.967	rs4669596	ENSG00000234818.1	AC092687.5	8.32	1.07e-15	5.83e-13	0.43	0.36	Prostate cancer;	chr2:10580446	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs4284804	ENSG00000234818.1	AC092687.5	8.32	1.07e-15	5.83e-13	0.43	0.36	Prostate cancer;	chr2:10581998	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.935	rs10803723	ENSG00000234818.1	AC092687.5	8.32	1.07e-15	5.83e-13	0.43	0.36	Prostate cancer;	chr2:10582751	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.935	rs6751075	ENSG00000234818.1	AC092687.5	8.32	1.07e-15	5.83e-13	0.43	0.36	Prostate cancer;	chr2:10583420	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs12622765	ENSG00000234818.1	AC092687.5	8.32	1.07e-15	5.83e-13	0.43	0.36	Prostate cancer;	chr2:10588205	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs759402	ENSG00000234818.1	AC092687.5	8.32	1.07e-15	5.83e-13	0.43	0.36	Prostate cancer;	chr2:10589428	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs759403	ENSG00000234818.1	AC092687.5	8.32	1.07e-15	5.83e-13	0.43	0.36	Prostate cancer;	chr2:10589771	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs11674433	ENSG00000234818.1	AC092687.5	8.32	1.07e-15	5.83e-13	0.43	0.36	Prostate cancer;	chr2:10590713	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs2024431	ENSG00000234818.1	AC092687.5	8.32	1.07e-15	5.83e-13	0.43	0.36	Prostate cancer;	chr2:10591201	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs10929682	ENSG00000234818.1	AC092687.5	8.32	1.07e-15	5.83e-13	0.43	0.36	Prostate cancer;	chr2:10592063	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.901	rs10210859	ENSG00000234818.1	AC092687.5	8.32	1.07e-15	5.83e-13	0.43	0.36	Prostate cancer;	chr2:10593803	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs4555318	ENSG00000234818.1	AC092687.5	8.32	1.07e-15	5.83e-13	0.43	0.36	Prostate cancer;	chr2:10604169	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.934	rs4622695	ENSG00000234818.1	AC092687.5	8.32	1.07e-15	5.83e-13	0.43	0.36	Prostate cancer;	chr2:10604201	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.934	rs6432111	ENSG00000234818.1	AC092687.5	8.32	1.07e-15	5.83e-13	0.43	0.36	Prostate cancer;	chr2:10604494	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs6432114	ENSG00000234818.1	AC092687.5	8.32	1.07e-15	5.83e-13	0.43	0.36	Prostate cancer;	chr2:10604804	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.87	rs728135	ENSG00000234818.1	AC092687.5	8.32	1.07e-15	5.83e-13	0.43	0.36	Prostate cancer;	chr2:10605006	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs963831	ENSG00000234818.1	AC092687.5	8.32	1.07e-15	5.83e-13	0.43	0.36	Prostate cancer;	chr2:10605058	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs728134	ENSG00000234818.1	AC092687.5	8.32	1.07e-15	5.83e-13	0.43	0.36	Prostate cancer;	chr2:10605061	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs2884233	ENSG00000234818.1	AC092687.5	8.32	1.07e-15	5.83e-13	0.43	0.36	Prostate cancer;	chr2:10605177	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.839	rs12692415	ENSG00000234818.1	AC092687.5	8.32	1.07e-15	5.83e-13	0.43	0.36	Prostate cancer;	chr2:10605348	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.934	rs12692416	ENSG00000234818.1	AC092687.5	8.32	1.07e-15	5.83e-13	0.43	0.36	Prostate cancer;	chr2:10605501	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs12692417	ENSG00000234818.1	AC092687.5	8.32	1.07e-15	5.83e-13	0.43	0.36	Prostate cancer;	chr2:10605592	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.934	rs12692418	ENSG00000234818.1	AC092687.5	8.32	1.07e-15	5.83e-13	0.43	0.36	Prostate cancer;	chr2:10605744	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs6755548	ENSG00000234818.1	AC092687.5	8.32	1.07e-15	5.83e-13	0.43	0.36	Prostate cancer;	chr2:10606000	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs6761678	ENSG00000234818.1	AC092687.5	8.32	1.07e-15	5.83e-13	0.43	0.36	Prostate cancer;	chr2:10606215	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs6759100	ENSG00000234818.1	AC092687.5	8.32	1.07e-15	5.83e-13	0.43	0.36	Prostate cancer;	chr2:10606584	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs6759714	ENSG00000234818.1	AC092687.5	8.32	1.07e-15	5.83e-13	0.43	0.36	Prostate cancer;	chr2:10607081	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs6744854	ENSG00000234818.1	AC092687.5	8.32	1.07e-15	5.83e-13	0.43	0.36	Prostate cancer;	chr2:10607120	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs6759740	ENSG00000234818.1	AC092687.5	8.32	1.07e-15	5.83e-13	0.43	0.36	Prostate cancer;	chr2:10607145	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs6709466	ENSG00000234818.1	AC092687.5	8.32	1.07e-15	5.83e-13	0.43	0.36	Prostate cancer;	chr2:10608131	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs6719701	ENSG00000234818.1	AC092687.5	8.32	1.07e-15	5.83e-13	0.43	0.36	Prostate cancer;	chr2:10608157	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.934	rs6432115	ENSG00000234818.1	AC092687.5	8.32	1.07e-15	5.83e-13	0.43	0.36	Prostate cancer;	chr2:10608217	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs6432116	ENSG00000234818.1	AC092687.5	8.32	1.07e-15	5.83e-13	0.43	0.36	Prostate cancer;	chr2:10608489	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs2110776	ENSG00000234818.1	AC092687.5	8.32	1.07e-15	5.83e-13	0.43	0.36	Prostate cancer;	chr2:10608684	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs2110778	ENSG00000234818.1	AC092687.5	8.32	1.07e-15	5.83e-13	0.43	0.36	Prostate cancer;	chr2:10608844	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs6432117	ENSG00000234818.1	AC092687.5	8.32	1.07e-15	5.83e-13	0.43	0.36	Prostate cancer;	chr2:10609233	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs6432118	ENSG00000234818.1	AC092687.5	8.32	1.07e-15	5.83e-13	0.43	0.36	Prostate cancer;	chr2:10609315	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.935	rs728283	ENSG00000234818.1	AC092687.5	8.32	1.07e-15	5.83e-13	0.43	0.36	Prostate cancer;	chr2:10609964	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs728282	ENSG00000234818.1	AC092687.5	8.32	1.07e-15	5.83e-13	0.43	0.36	Prostate cancer;	chr2:10610177	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs728281	ENSG00000234818.1	AC092687.5	8.32	1.07e-15	5.83e-13	0.43	0.36	Prostate cancer;	chr2:10610229	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.934	rs6721510	ENSG00000234818.1	AC092687.5	8.32	1.07e-15	5.83e-13	0.43	0.36	Prostate cancer;	chr2:10610920	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs6721514	ENSG00000234818.1	AC092687.5	8.32	1.07e-15	5.83e-13	0.43	0.36	Prostate cancer;	chr2:10610936	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.934	rs6706763	ENSG00000234818.1	AC092687.5	8.32	1.07e-15	5.83e-13	0.43	0.36	Prostate cancer;	chr2:10611281	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs10203664	ENSG00000234818.1	AC092687.5	8.32	1.07e-15	5.83e-13	0.43	0.36	Prostate cancer;	chr2:10612251	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.934	rs10201077	ENSG00000234818.1	AC092687.5	8.32	1.07e-15	5.83e-13	0.43	0.36	Prostate cancer;	chr2:10612300	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs9287720	ENSG00000234818.1	AC092687.5	8.32	1.07e-15	5.83e-13	0.43	0.36	Prostate cancer;	chr2:10612538	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.87	rs10167676	ENSG00000234818.1	AC092687.5	8.32	1.07e-15	5.83e-13	0.43	0.36	Prostate cancer;	chr2:10613014	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs12995159	ENSG00000234818.1	AC092687.5	8.32	1.07e-15	5.83e-13	0.43	0.36	Prostate cancer;	chr2:10613197	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs12995602	ENSG00000234818.1	AC092687.5	8.32	1.07e-15	5.83e-13	0.43	0.36	Prostate cancer;	chr2:10613416	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs6432119	ENSG00000234818.1	AC092687.5	8.32	1.07e-15	5.83e-13	0.43	0.36	Prostate cancer;	chr2:10613561	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs6432120	ENSG00000234818.1	AC092687.5	8.32	1.07e-15	5.83e-13	0.43	0.36	Prostate cancer;	chr2:10613645	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs6432121	ENSG00000234818.1	AC092687.5	8.32	1.07e-15	5.83e-13	0.43	0.36	Prostate cancer;	chr2:10613678	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs6432122	ENSG00000234818.1	AC092687.5	8.32	1.07e-15	5.83e-13	0.43	0.36	Prostate cancer;	chr2:10613718	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs6712406	ENSG00000234818.1	AC092687.5	8.32	1.07e-15	5.83e-13	0.43	0.36	Prostate cancer;	chr2:10614294	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs10195802	ENSG00000234818.1	AC092687.5	8.32	1.07e-15	5.83e-13	0.43	0.36	Prostate cancer;	chr2:10614406	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs7566875	ENSG00000234818.1	AC092687.5	8.32	1.07e-15	5.83e-13	0.43	0.36	Prostate cancer;	chr2:10614666	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.934	rs4371336	ENSG00000234818.1	AC092687.5	8.32	1.07e-15	5.83e-13	0.43	0.36	Prostate cancer;	chr2:10615597	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs4405729	ENSG00000234818.1	AC092687.5	8.32	1.07e-15	5.83e-13	0.43	0.36	Prostate cancer;	chr2:10615653	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.934	rs6710033	ENSG00000234818.1	AC092687.5	8.32	1.07e-15	5.83e-13	0.43	0.36	Prostate cancer;	chr2:10617551	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs4669598	ENSG00000234818.1	AC092687.5	8.32	1.07e-15	5.83e-13	0.43	0.36	Prostate cancer;	chr2:10617712	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs4669599	ENSG00000234818.1	AC092687.5	8.32	1.07e-15	5.83e-13	0.43	0.36	Prostate cancer;	chr2:10617903	chr2:10589166~10604830:+
PRAD	cis	rs8081395	0.801	rs12938273	ENSG00000266992.1	DHX40P1	-8.32	1.07e-15	5.83e-13	-0.41	-0.36	White blood cell count;	chr17:59824291	chr17:59976009~60002384:-
PRAD	cis	rs8081395	0.836	rs1292061	ENSG00000266992.1	DHX40P1	-8.32	1.07e-15	5.83e-13	-0.41	-0.36	White blood cell count;	chr17:59833869	chr17:59976009~60002384:-
PRAD	cis	rs11096990	0.634	rs7666632	ENSG00000249207.1	RP11-360F5.1	-8.32	1.07e-15	5.84e-13	-0.38	-0.36	Cognitive function;	chr4:39238568	chr4:39112677~39126818:-
PRAD	cis	rs5769707	0.632	rs135877	ENSG00000188511.11	C22orf34	8.32	1.07e-15	5.85e-13	0.43	0.36	Monocyte percentage of white cells;Monocyte count;	chr22:49620354	chr22:49414524~49657542:-
PRAD	cis	rs11098499	0.909	rs79026312	ENSG00000245958.5	RP11-33B1.1	-8.31	1.07e-15	5.86e-13	-0.36	-0.36	Corneal astigmatism;	chr4:119519522	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.909	rs35111518	ENSG00000245958.5	RP11-33B1.1	-8.31	1.07e-15	5.86e-13	-0.36	-0.36	Corneal astigmatism;	chr4:119519527	chr4:119454791~119552025:+
PRAD	cis	rs9341835	0.593	rs9361779	ENSG00000218048.2	RP3-407E4.4	8.31	1.08e-15	5.88e-13	0.42	0.36	Schizophrenia;	chr6:63449159	chr6:63440766~63443580:+
PRAD	cis	rs9341835	0.53	rs7742595	ENSG00000218048.2	RP3-407E4.4	8.31	1.08e-15	5.89e-13	0.42	0.36	Schizophrenia;	chr6:63451828	chr6:63440766~63443580:+
PRAD	cis	rs9341835	0.593	rs9449291	ENSG00000218048.2	RP3-407E4.4	8.31	1.08e-15	5.89e-13	0.42	0.36	Schizophrenia;	chr6:63453048	chr6:63440766~63443580:+
PRAD	cis	rs7916697	0.52	rs12246624	ENSG00000233590.1	RP11-153K11.3	-8.31	1.08e-15	5.9e-13	-0.5	-0.36	Optic disc area;	chr10:68276805	chr10:68233251~68242379:-
PRAD	cis	rs7923609	0.967	rs7085018	ENSG00000232075.1	MRPL35P2	-8.31	1.08e-15	5.9e-13	-0.38	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63526907	chr10:63634317~63634827:-
PRAD	cis	rs748404	0.631	rs7167882	ENSG00000249839.1	AC011330.5	-8.31	1.08e-15	5.9e-13	-0.44	-0.36	Lung cancer;	chr15:43386465	chr15:43663654~43684339:-
PRAD	cis	rs9287719	0.967	rs10203785	ENSG00000234818.1	AC092687.5	8.31	1.08e-15	5.91e-13	0.43	0.36	Prostate cancer;	chr2:10612382	chr2:10589166~10604830:+
PRAD	cis	rs2404602	0.692	rs10444858	ENSG00000259422.1	RP11-593F23.1	8.31	1.08e-15	5.91e-13	0.45	0.36	Blood metabolite levels;	chr15:76670163	chr15:76174891~76181486:-
PRAD	cis	rs6921919	0.848	rs9468350	ENSG00000216901.1	AL022393.7	8.31	1.08e-15	5.91e-13	0.51	0.36	Autism spectrum disorder or schizophrenia;	chr6:28351330	chr6:28176188~28176674:+
PRAD	cis	rs8081395	0.836	rs1295926	ENSG00000266992.1	DHX40P1	-8.31	1.08e-15	5.92e-13	-0.41	-0.36	White blood cell count;	chr17:59832012	chr17:59976009~60002384:-
PRAD	cis	rs9287719	1	rs9679122	ENSG00000234818.1	AC092687.5	8.31	1.09e-15	5.95e-13	0.43	0.36	Prostate cancer;	chr2:10611584	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs9679581	ENSG00000234818.1	AC092687.5	8.31	1.09e-15	5.95e-13	0.43	0.36	Prostate cancer;	chr2:10611610	chr2:10589166~10604830:+
PRAD	cis	rs17361889	0.633	rs17359183	ENSG00000224683.1	RPL36AP29	8.31	1.09e-15	5.96e-13	0.44	0.36	Pediatric bone mineral content (hip);	chr7:16123149	chr7:16208945~16209265:+
PRAD	cis	rs17361889	0.711	rs17359294	ENSG00000224683.1	RPL36AP29	8.31	1.09e-15	5.96e-13	0.44	0.36	Pediatric bone mineral content (hip);	chr7:16124889	chr7:16208945~16209265:+
PRAD	cis	rs4835473	0.932	rs6858195	ENSG00000251600.4	RP11-673E1.1	-8.31	1.09e-15	5.96e-13	-0.46	-0.36	Immature fraction of reticulocytes;	chr4:143768444	chr4:143912331~143982454:+
PRAD	cis	rs357618	1	rs357625	ENSG00000260581.1	CTB-113P19.4	8.31	1.09e-15	5.97e-13	0.45	0.36	Basophil percentage of white cells;	chr5:151469313	chr5:151652275~151655449:+
PRAD	cis	rs1355223	0.902	rs1578622	ENSG00000271369.1	RP11-350D17.3	-8.31	1.09e-15	5.97e-13	-0.42	-0.36	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34704368	chr11:34709600~34710161:+
PRAD	cis	rs2255336	0.938	rs2733840	ENSG00000245648.1	RP11-277P12.20	8.31	1.09e-15	5.97e-13	0.54	0.36	Blood protein levels;	chr12:10393326	chr12:10363769~10398506:+
PRAD	cis	rs131777	0.526	rs86337	ENSG00000205559.3	CHKB-AS1	-8.31	1.1e-15	6e-13	-0.37	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50582239	chr22:50583026~50583877:+
PRAD	cis	rs10050311	0.79	rs61651372	ENSG00000251411.1	RP11-397E7.4	-8.31	1.1e-15	6.01e-13	-0.45	-0.36	Insulin-related traits;	chr4:86912903	chr4:86913266~86914817:-
PRAD	cis	rs7615952	0.576	rs4646748	ENSG00000171084.14	FAM86JP	8.31	1.1e-15	6.02e-13	0.58	0.36	Blood pressure (smoking interaction);	chr3:126107486	chr3:125916620~125930024:+
PRAD	cis	rs6051080	1	rs6051080	ENSG00000274973.1	RP13-401N8.7	-8.31	1.1e-15	6.02e-13	-0.42	-0.36	Colorectal or endometrial cancer;	chr20:25995038	chr20:25845497~25845862:+
PRAD	cis	rs964611	0.872	rs72623972	ENSG00000259488.2	RP11-154J22.1	-8.31	1.1e-15	6.02e-13	-0.35	-0.36	Metabolite levels (Pyroglutamine);	chr15:48294797	chr15:48312353~48331856:-
PRAD	cis	rs6538678	0.864	rs10777747	ENSG00000258343.1	RP11-536G4.2	-8.31	1.11e-15	6.04e-13	-0.46	-0.36	Lupus nephritis in systemic lupus erythematosus;	chr12:95870192	chr12:95795345~95858839:-
PRAD	cis	rs11148252	0.846	rs7985262	ENSG00000278238.1	RP11-245D16.4	-8.31	1.11e-15	6.04e-13	-0.41	-0.36	Lewy body disease;	chr13:52423026	chr13:52454775~52455331:-
PRAD	cis	rs11148252	0.846	rs4886077	ENSG00000278238.1	RP11-245D16.4	-8.31	1.11e-15	6.04e-13	-0.41	-0.36	Lewy body disease;	chr13:52424562	chr13:52454775~52455331:-
PRAD	cis	rs11148252	0.846	rs8001624	ENSG00000278238.1	RP11-245D16.4	-8.31	1.11e-15	6.04e-13	-0.41	-0.36	Lewy body disease;	chr13:52428860	chr13:52454775~52455331:-
PRAD	cis	rs1062177	0.756	rs2915827	ENSG00000253921.1	CTB-113P19.3	8.31	1.11e-15	6.06e-13	0.48	0.36	Preschool internalizing problems;	chr5:151740144	chr5:151753992~151767247:+
PRAD	cis	rs853679	0.517	rs4713135	ENSG00000226314.6	ZNF192P1	-8.31	1.11e-15	6.06e-13	-0.5	-0.36	Depression;	chr6:28071808	chr6:28161781~28169594:+
PRAD	cis	rs950169	0.922	rs4842939	ENSG00000259728.4	LINC00933	-8.31	1.11e-15	6.07e-13	-0.45	-0.36	Schizophrenia;	chr15:84159214	chr15:84570649~84580175:+
PRAD	cis	rs10771431	1	rs11611670	ENSG00000111788.10	RP11-22B23.1	8.31	1.11e-15	6.07e-13	0.36	0.36	Breast size;	chr12:9232939	chr12:9277235~9313241:+
PRAD	cis	rs763567	0.933	rs623752	ENSG00000271811.1	RP1-79C4.4	8.31	1.12e-15	6.09e-13	0.41	0.36	Tonsillectomy;	chr1:170649150	chr1:170667381~170669425:+
PRAD	cis	rs950169	0.92	rs11637666	ENSG00000259728.4	LINC00933	8.31	1.12e-15	6.1e-13	0.46	0.36	Schizophrenia;	chr15:84035122	chr15:84570649~84580175:+
PRAD	cis	rs2581828	0.618	rs6784207	ENSG00000242142.1	SERBP1P3	-8.31	1.12e-15	6.14e-13	-0.43	-0.36	Crohn's disease;	chr3:53133458	chr3:53064283~53065091:-
PRAD	cis	rs8523	0.774	rs6456810	ENSG00000230314.5	ELOVL2-AS1	8.31	1.12e-15	6.14e-13	0.4	0.36	Red blood cell fatty acid levels;	chr6:11052185	chr6:11043524~11078226:+
PRAD	cis	rs496547	0.686	rs2508916	ENSG00000278376.1	RP11-158I9.8	-8.31	1.13e-15	6.14e-13	-0.32	-0.36	Hip minimal joint space width;	chr11:118783942	chr11:118791254~118793137:+
PRAD	cis	rs7829975	0.511	rs1401390	ENSG00000253893.2	FAM85B	-8.31	1.13e-15	6.14e-13	-0.46	-0.36	Mood instability;	chr8:8278888	chr8:8167819~8226614:-
PRAD	cis	rs193541	0.632	rs119449	ENSG00000263432.2	RN7SL689P	8.31	1.13e-15	6.18e-13	0.39	0.36	Glucose homeostasis traits;	chr5:122948046	chr5:123022487~123022783:-
PRAD	cis	rs2980439	0.556	rs2921059	ENSG00000253893.2	FAM85B	-8.31	1.13e-15	6.18e-13	-0.45	-0.36	Neuroticism;	chr8:8460377	chr8:8167819~8226614:-
PRAD	cis	rs193541	0.632	rs6595413	ENSG00000263432.2	RN7SL689P	8.31	1.14e-15	6.19e-13	0.39	0.36	Glucose homeostasis traits;	chr5:122821254	chr5:123022487~123022783:-
PRAD	cis	rs193541	0.632	rs1363200	ENSG00000263432.2	RN7SL689P	8.31	1.14e-15	6.19e-13	0.39	0.36	Glucose homeostasis traits;	chr5:122828107	chr5:123022487~123022783:-
PRAD	cis	rs193541	0.593	rs1035372	ENSG00000263432.2	RN7SL689P	8.31	1.14e-15	6.19e-13	0.39	0.36	Glucose homeostasis traits;	chr5:122833753	chr5:123022487~123022783:-
PRAD	cis	rs801193	0.636	rs2659895	ENSG00000237310.1	GS1-124K5.4	8.31	1.14e-15	6.23e-13	0.33	0.36	Aortic root size;	chr7:66731484	chr7:66493706~66495474:+
PRAD	cis	rs11096990	0.613	rs9997015	ENSG00000249207.1	RP11-360F5.1	8.31	1.14e-15	6.23e-13	0.37	0.36	Cognitive function;	chr4:39222677	chr4:39112677~39126818:-
PRAD	cis	rs858239	0.67	rs3807452	ENSG00000226816.2	AC005082.12	-8.31	1.15e-15	6.28e-13	-0.41	-0.36	Cerebrospinal fluid biomarker levels;	chr7:23122462	chr7:23206013~23208045:+
PRAD	cis	rs7916697	0.52	rs10762201	ENSG00000233590.1	RP11-153K11.3	8.31	1.15e-15	6.28e-13	0.5	0.36	Optic disc area;	chr10:68280354	chr10:68233251~68242379:-
PRAD	cis	rs270601	0.721	rs270621	ENSG00000233006.5	AC034220.3	8.3	1.15e-15	6.28e-13	0.32	0.36	Acylcarnitine levels;	chr5:132270128	chr5:132311285~132369916:-
PRAD	cis	rs4842666	0.85	rs11105328	ENSG00000258302.2	RP11-981P6.1	8.3	1.16e-15	6.29e-13	0.44	0.36	Blood pressure;	chr12:89548613	chr12:89561129~89594878:+
PRAD	cis	rs7746199	0.736	rs13195636	ENSG00000280107.1	AL022393.9	-8.3	1.16e-15	6.29e-13	-0.74	-0.36	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27541714	chr6:28170845~28172521:+
PRAD	cis	rs6570726	1	rs444564	ENSG00000235652.6	RP11-545I5.3	8.3	1.16e-15	6.3e-13	0.38	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145538659	chr6:145799409~145886585:+
PRAD	cis	rs2108622	0.727	rs62106156	ENSG00000267056.2	AC005336.4	8.3	1.16e-15	6.31e-13	0.5	0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869614	chr19:15910582~15911824:-
PRAD	cis	rs4835473	0.932	rs1597445	ENSG00000251600.4	RP11-673E1.1	-8.3	1.16e-15	6.31e-13	-0.46	-0.36	Immature fraction of reticulocytes;	chr4:143768543	chr4:143912331~143982454:+
PRAD	cis	rs6570726	1	rs404229	ENSG00000235652.6	RP11-545I5.3	8.3	1.16e-15	6.32e-13	0.38	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145547064	chr6:145799409~145886585:+
PRAD	cis	rs12142240	0.698	rs72885198	ENSG00000232022.5	FAAHP1	-8.3	1.16e-15	6.33e-13	-0.34	-0.36	Menopause (age at onset);	chr1:46347216	chr1:46432129~46445521:+
PRAD	cis	rs3779195	0.929	rs2906184	ENSG00000272950.1	RP11-307C18.1	-8.3	1.17e-15	6.35e-13	-0.57	-0.36	Sex hormone-binding globulin levels;	chr7:98310675	chr7:98322853~98323430:+
PRAD	cis	rs7131987	0.621	rs57803026	ENSG00000257176.2	RP11-996F15.2	-8.3	1.17e-15	6.35e-13	-0.4	-0.36	QT interval;	chr12:29344573	chr12:29280418~29317848:-
PRAD	cis	rs7131987	0.617	rs3764953	ENSG00000257176.2	RP11-996F15.2	-8.3	1.17e-15	6.35e-13	-0.4	-0.36	QT interval;	chr12:29349303	chr12:29280418~29317848:-
PRAD	cis	rs67311347	0.544	rs60329764	ENSG00000223797.4	ENTPD3-AS1	-8.3	1.17e-15	6.37e-13	-0.31	-0.36	Renal cell carcinoma;	chr3:40293130	chr3:40313802~40453329:-
PRAD	cis	rs193541	0.632	rs4835896	ENSG00000263432.2	RN7SL689P	-8.3	1.17e-15	6.37e-13	-0.39	-0.36	Glucose homeostasis traits;	chr5:122785545	chr5:123022487~123022783:-
PRAD	cis	rs193541	0.632	rs7729834	ENSG00000263432.2	RN7SL689P	8.3	1.17e-15	6.37e-13	0.39	0.36	Glucose homeostasis traits;	chr5:122786464	chr5:123022487~123022783:-
PRAD	cis	rs193541	0.632	rs1903260	ENSG00000263432.2	RN7SL689P	8.3	1.17e-15	6.37e-13	0.39	0.36	Glucose homeostasis traits;	chr5:122799493	chr5:123022487~123022783:-
PRAD	cis	rs2404602	0.692	rs67570291	ENSG00000259422.1	RP11-593F23.1	8.3	1.17e-15	6.37e-13	0.45	0.36	Blood metabolite levels;	chr15:76728161	chr15:76174891~76181486:-
PRAD	cis	rs6991838	0.771	rs13282323	ENSG00000200714.1	Y_RNA	8.3	1.17e-15	6.38e-13	0.37	0.36	Intelligence (multi-trait analysis);	chr8:65560557	chr8:65592731~65592820:+
PRAD	cis	rs6991838	0.831	rs4394432	ENSG00000200714.1	Y_RNA	8.3	1.17e-15	6.38e-13	0.37	0.36	Intelligence (multi-trait analysis);	chr8:65560939	chr8:65592731~65592820:+
PRAD	cis	rs8523	0.774	rs6920155	ENSG00000230314.5	ELOVL2-AS1	8.3	1.17e-15	6.39e-13	0.39	0.36	Red blood cell fatty acid levels;	chr6:11047723	chr6:11043524~11078226:+
PRAD	cis	rs367615	0.552	rs2416210	ENSG00000249476.1	CTD-2587M2.1	-8.3	1.17e-15	6.39e-13	-0.44	-0.36	Colorectal cancer (SNP x SNP interaction);	chr5:109405436	chr5:109237120~109326369:-
PRAD	cis	rs4722166	0.568	rs1880241	ENSG00000179428.2	AC073072.5	-8.3	1.18e-15	6.41e-13	-0.4	-0.36	Lung cancer;	chr7:22719850	chr7:22725395~22727620:-
PRAD	cis	rs1355223	0.902	rs1901831	ENSG00000271369.1	RP11-350D17.3	-8.3	1.18e-15	6.42e-13	-0.42	-0.36	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34703628	chr11:34709600~34710161:+
PRAD	cis	rs2404602	0.716	rs8030411	ENSG00000259422.1	RP11-593F23.1	8.3	1.18e-15	6.43e-13	0.45	0.36	Blood metabolite levels;	chr15:76407514	chr15:76174891~76181486:-
PRAD	cis	rs4835473	0.868	rs1822841	ENSG00000251600.4	RP11-673E1.1	8.3	1.18e-15	6.44e-13	0.47	0.36	Immature fraction of reticulocytes;	chr4:143921485	chr4:143912331~143982454:+
PRAD	cis	rs4722166	0.532	rs1404008	ENSG00000179428.2	AC073072.5	-8.3	1.18e-15	6.44e-13	-0.42	-0.36	Lung cancer;	chr7:22716381	chr7:22725395~22727620:-
PRAD	cis	rs6452524	1	rs7716962	ENSG00000249664.1	CTD-2227C6.2	8.3	1.19e-15	6.47e-13	0.42	0.36	Hypertension (SNP x SNP interaction);	chr5:83138913	chr5:83012285~83013109:-
PRAD	cis	rs10078	1	rs10078	ENSG00000221990.4	EXOC3-AS1	8.3	1.19e-15	6.48e-13	0.33	0.36	Fat distribution (HIV);	chr5:437987	chr5:441498~443160:-
PRAD	cis	rs172166	0.516	rs2622322	ENSG00000280107.1	AL022393.9	-8.3	1.19e-15	6.49e-13	-0.43	-0.36	Cardiac Troponin-T levels;	chr6:28149665	chr6:28170845~28172521:+
PRAD	cis	rs2108622	0.727	rs12609900	ENSG00000267056.2	AC005336.4	8.3	1.19e-15	6.49e-13	0.5	0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871604	chr19:15910582~15911824:-
PRAD	cis	rs2108622	0.727	rs62107763	ENSG00000267056.2	AC005336.4	8.3	1.19e-15	6.49e-13	0.5	0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871788	chr19:15910582~15911824:-
PRAD	cis	rs2108622	0.727	rs62107764	ENSG00000267056.2	AC005336.4	8.3	1.19e-15	6.49e-13	0.5	0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871848	chr19:15910582~15911824:-
PRAD	cis	rs2108622	0.727	rs76984410	ENSG00000267056.2	AC005336.4	8.3	1.19e-15	6.49e-13	0.5	0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871890	chr19:15910582~15911824:-
PRAD	cis	rs2108622	0.727	rs77780918	ENSG00000267056.2	AC005336.4	8.3	1.19e-15	6.49e-13	0.5	0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871897	chr19:15910582~15911824:-
PRAD	cis	rs2108622	0.727	rs8101038	ENSG00000267056.2	AC005336.4	8.3	1.19e-15	6.49e-13	0.5	0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15872054	chr19:15910582~15911824:-
PRAD	cis	rs42648	0.667	rs2157793	ENSG00000227646.6	STEAP2-AS1	-8.3	1.19e-15	6.49e-13	-0.33	-0.36	Homocysteine levels;	chr7:90251040	chr7:89882353~90211635:-
PRAD	cis	rs10800713	0.56	rs10919967	ENSG00000260088.1	RP11-92G12.3	8.3	1.2e-15	6.52e-13	0.55	0.36	Tandem gait;	chr1:200533543	chr1:200669507~200694250:+
PRAD	cis	rs34375054	0.573	rs12811438	ENSG00000279233.1	RP11-158L12.4	8.3	1.2e-15	6.52e-13	0.4	0.36	Post bronchodilator FEV1/FVC ratio;	chr12:125168944	chr12:125138245~125141711:+
PRAD	cis	rs7615952	0.558	rs17334039	ENSG00000171084.14	FAM86JP	8.3	1.2e-15	6.53e-13	0.55	0.36	Blood pressure (smoking interaction);	chr3:125821465	chr3:125916620~125930024:+
PRAD	cis	rs2404602	0.716	rs4886813	ENSG00000259422.1	RP11-593F23.1	-8.3	1.2e-15	6.54e-13	-0.45	-0.36	Blood metabolite levels;	chr15:76545880	chr15:76174891~76181486:-
PRAD	cis	rs4713118	0.662	rs9380045	ENSG00000272009.1	RP1-313I6.12	-8.3	1.21e-15	6.55e-13	-0.37	-0.36	Parkinson's disease;	chr6:28057501	chr6:28078792~28081130:-
PRAD	cis	rs4713118	0.616	rs9348789	ENSG00000272009.1	RP1-313I6.12	-8.3	1.21e-15	6.55e-13	-0.37	-0.36	Parkinson's disease;	chr6:28057708	chr6:28078792~28081130:-
PRAD	cis	rs4713118	0.662	rs9468274	ENSG00000272009.1	RP1-313I6.12	-8.3	1.21e-15	6.55e-13	-0.37	-0.36	Parkinson's disease;	chr6:28058299	chr6:28078792~28081130:-
PRAD	cis	rs4713118	0.662	rs9468275	ENSG00000272009.1	RP1-313I6.12	-8.3	1.21e-15	6.55e-13	-0.37	-0.36	Parkinson's disease;	chr6:28058358	chr6:28078792~28081130:-
PRAD	cis	rs4713118	0.662	rs9468276	ENSG00000272009.1	RP1-313I6.12	-8.3	1.21e-15	6.55e-13	-0.37	-0.36	Parkinson's disease;	chr6:28059910	chr6:28078792~28081130:-
PRAD	cis	rs4713118	0.662	rs9468277	ENSG00000272009.1	RP1-313I6.12	-8.3	1.21e-15	6.55e-13	-0.37	-0.36	Parkinson's disease;	chr6:28060612	chr6:28078792~28081130:-
PRAD	cis	rs4713118	0.662	rs9468278	ENSG00000272009.1	RP1-313I6.12	-8.3	1.21e-15	6.55e-13	-0.37	-0.36	Parkinson's disease;	chr6:28060704	chr6:28078792~28081130:-
PRAD	cis	rs4713118	0.662	rs13218430	ENSG00000272009.1	RP1-313I6.12	-8.3	1.21e-15	6.55e-13	-0.37	-0.36	Parkinson's disease;	chr6:28062059	chr6:28078792~28081130:-
PRAD	cis	rs26232	0.583	rs154258	ENSG00000175749.11	EIF3KP1	-8.3	1.21e-15	6.56e-13	-0.49	-0.36	Rheumatoid arthritis;	chr5:103027919	chr5:103032376~103033031:+
PRAD	cis	rs12142240	0.698	rs6684274	ENSG00000232022.5	FAAHP1	8.3	1.21e-15	6.58e-13	0.34	0.36	Menopause (age at onset);	chr1:46345170	chr1:46432129~46445521:+
PRAD	cis	rs7829975	0.688	rs7826654	ENSG00000253893.2	FAM85B	-8.3	1.21e-15	6.58e-13	-0.42	-0.36	Mood instability;	chr8:8521596	chr8:8167819~8226614:-
PRAD	cis	rs7829975	0.688	rs7826660	ENSG00000253893.2	FAM85B	-8.3	1.21e-15	6.58e-13	-0.42	-0.36	Mood instability;	chr8:8521597	chr8:8167819~8226614:-
PRAD	cis	rs11098499	0.657	rs10434028	ENSG00000245958.5	RP11-33B1.1	-8.3	1.21e-15	6.58e-13	-0.35	-0.36	Corneal astigmatism;	chr4:119373309	chr4:119454791~119552025:+
PRAD	cis	rs17711722	0.51	rs11767457	ENSG00000224316.1	RP11-479O9.2	8.3	1.21e-15	6.59e-13	0.34	0.36	Calcium levels;	chr7:65825628	chr7:65773620~65802067:+
PRAD	cis	rs1150668	0.799	rs9301	ENSG00000280107.1	AL022393.9	-8.3	1.21e-15	6.59e-13	-0.44	-0.36	Pubertal anthropometrics;	chr6:28324929	chr6:28170845~28172521:+
PRAD	cis	rs1150668	0.799	rs853684	ENSG00000280107.1	AL022393.9	-8.3	1.21e-15	6.59e-13	-0.44	-0.36	Pubertal anthropometrics;	chr6:28326773	chr6:28170845~28172521:+
PRAD	cis	rs950169	0.922	rs11630760	ENSG00000259728.4	LINC00933	8.3	1.22e-15	6.6e-13	0.44	0.36	Schizophrenia;	chr15:84570106	chr15:84570649~84580175:+
PRAD	cis	rs950169	0.887	rs71395453	ENSG00000259728.4	LINC00933	8.3	1.22e-15	6.6e-13	0.44	0.36	Schizophrenia;	chr15:84570259	chr15:84570649~84580175:+
PRAD	cis	rs950169	0.922	rs11633075	ENSG00000259728.4	LINC00933	8.3	1.22e-15	6.6e-13	0.44	0.36	Schizophrenia;	chr15:84570741	chr15:84570649~84580175:+
PRAD	cis	rs8081395	0.801	rs2665404	ENSG00000266992.1	DHX40P1	8.3	1.22e-15	6.62e-13	0.41	0.36	White blood cell count;	chr17:59798035	chr17:59976009~60002384:-
PRAD	cis	rs1062177	0.826	rs2915879	ENSG00000253921.1	CTB-113P19.3	-8.3	1.22e-15	6.62e-13	-0.46	-0.36	Preschool internalizing problems;	chr5:151767881	chr5:151753992~151767247:+
PRAD	cis	rs11083475	1	rs10406778	ENSG00000267892.1	CTD-2540F13.2	8.3	1.22e-15	6.62e-13	0.39	0.36	Heart rate;	chr19:38679833	chr19:38738284~38739863:+
PRAD	cis	rs7615952	0.673	rs3811677	ENSG00000171084.14	FAM86JP	8.3	1.22e-15	6.63e-13	0.61	0.36	Blood pressure (smoking interaction);	chr3:125929237	chr3:125916620~125930024:+
PRAD	cis	rs7615952	0.932	rs3811679	ENSG00000171084.14	FAM86JP	8.3	1.22e-15	6.63e-13	0.61	0.36	Blood pressure (smoking interaction);	chr3:125929440	chr3:125916620~125930024:+
PRAD	cis	rs1729407	0.814	rs2071521	ENSG00000254851.1	RP11-109L13.1	8.3	1.23e-15	6.66e-13	0.48	0.36	Apolipoprotein A-IV levels;	chr11:116827132	chr11:117135528~117138582:+
PRAD	cis	rs950169	0.922	rs62029585	ENSG00000225151.9	GOLGA2P7	-8.3	1.23e-15	6.67e-13	-0.52	-0.36	Schizophrenia;	chr15:84397176	chr15:84199311~84230136:-
PRAD	cis	rs3096299	0.935	rs3102387	ENSG00000274627.1	RP11-104N10.2	8.3	1.23e-15	6.68e-13	0.37	0.36	Multiple myeloma (IgH translocation);	chr16:89365868	chr16:89516797~89522217:+
PRAD	cis	rs6452524	1	rs6863300	ENSG00000249664.1	CTD-2227C6.2	8.29	1.24e-15	6.76e-13	0.42	0.36	Hypertension (SNP x SNP interaction);	chr5:83139629	chr5:83012285~83013109:-
PRAD	cis	rs7238033	0.624	rs7230298	ENSG00000267193.4	RP11-116O18.3	-8.29	1.25e-15	6.76e-13	-0.39	-0.36	Bladder cancer;	chr18:45732554	chr18:45669367~45747215:-
PRAD	cis	rs8177376	0.906	rs1613842	ENSG00000254905.1	RP11-712L6.7	8.29	1.25e-15	6.77e-13	0.46	0.36	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126326015	chr11:126292922~126294254:-
PRAD	cis	rs8177376	0.906	rs1695739	ENSG00000254905.1	RP11-712L6.7	8.29	1.25e-15	6.77e-13	0.46	0.36	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126326280	chr11:126292922~126294254:-
PRAD	cis	rs4835473	0.932	rs7696106	ENSG00000251600.4	RP11-673E1.1	-8.29	1.25e-15	6.79e-13	-0.46	-0.36	Immature fraction of reticulocytes;	chr4:143765454	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.932	rs7680045	ENSG00000251600.4	RP11-673E1.1	-8.29	1.25e-15	6.79e-13	-0.46	-0.36	Immature fraction of reticulocytes;	chr4:143765470	chr4:143912331~143982454:+
PRAD	cis	rs1729407	0.659	rs2542050	ENSG00000254851.1	RP11-109L13.1	-8.29	1.25e-15	6.8e-13	-0.48	-0.36	Apolipoprotein A-IV levels;	chr11:116826401	chr11:117135528~117138582:+
PRAD	cis	rs1729407	0.565	rs2849173	ENSG00000254851.1	RP11-109L13.1	-8.29	1.25e-15	6.8e-13	-0.48	-0.36	Apolipoprotein A-IV levels;	chr11:116826605	chr11:117135528~117138582:+
PRAD	cis	rs7772486	0.869	rs2777473	ENSG00000235652.6	RP11-545I5.3	8.29	1.25e-15	6.81e-13	0.37	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145980358	chr6:145799409~145886585:+
PRAD	cis	rs6539288	0.901	rs2041894	ENSG00000260329.1	RP11-412D9.4	-8.29	1.26e-15	6.82e-13	-0.32	-0.36	Total body bone mineral density;	chr12:106956389	chr12:106954029~106955497:-
PRAD	cis	rs9487605	1	rs9487605	ENSG00000271789.1	RP5-1112D6.7	-8.29	1.26e-15	6.84e-13	-0.44	-0.36	Inflammatory skin disease;	chr6:111261682	chr6:111297126~111298510:+
PRAD	cis	rs7712401	0.546	rs10044921	ENSG00000263432.2	RN7SL689P	8.29	1.26e-15	6.84e-13	0.37	0.36	Mean platelet volume;	chr5:122843662	chr5:123022487~123022783:-
PRAD	cis	rs5769707	0.609	rs2007024	ENSG00000188511.11	C22orf34	8.29	1.26e-15	6.86e-13	0.42	0.36	Monocyte percentage of white cells;Monocyte count;	chr22:49595167	chr22:49414524~49657542:-
PRAD	cis	rs7181230	0.848	rs62004114	ENSG00000275636.1	RP11-521C20.5	8.29	1.26e-15	6.86e-13	0.54	0.36	Dehydroepiandrosterone sulphate levels;	chr15:40041154	chr15:40078892~40079347:+
PRAD	cis	rs7181230	0.848	rs75509561	ENSG00000275636.1	RP11-521C20.5	8.29	1.26e-15	6.86e-13	0.54	0.36	Dehydroepiandrosterone sulphate levels;	chr15:40041268	chr15:40078892~40079347:+
PRAD	cis	rs7181230	0.848	rs7497289	ENSG00000275636.1	RP11-521C20.5	8.29	1.26e-15	6.86e-13	0.54	0.36	Dehydroepiandrosterone sulphate levels;	chr15:40041456	chr15:40078892~40079347:+
PRAD	cis	rs7181230	0.848	rs1010879	ENSG00000275636.1	RP11-521C20.5	8.29	1.26e-15	6.86e-13	0.54	0.36	Dehydroepiandrosterone sulphate levels;	chr15:40041714	chr15:40078892~40079347:+
PRAD	cis	rs526231	0.511	rs58344084	ENSG00000175749.11	EIF3KP1	8.29	1.26e-15	6.86e-13	0.5	0.36	Primary biliary cholangitis;	chr5:103042508	chr5:103032376~103033031:+
PRAD	cis	rs10875746	0.669	rs11168510	ENSG00000240399.1	RP1-228P16.1	-8.29	1.27e-15	6.89e-13	-0.35	-0.36	Longevity (90 years and older);	chr12:48291772	chr12:48054813~48055591:-
PRAD	cis	rs763567	0.967	rs1952675	ENSG00000271811.1	RP1-79C4.4	-8.29	1.27e-15	6.9e-13	-0.42	-0.36	Tonsillectomy;	chr1:170613434	chr1:170667381~170669425:+
PRAD	cis	rs12142240	0.698	rs72886907	ENSG00000232022.5	FAAHP1	-8.29	1.27e-15	6.9e-13	-0.34	-0.36	Menopause (age at onset);	chr1:46348593	chr1:46432129~46445521:+
PRAD	cis	rs2581828	0.608	rs9868263	ENSG00000242142.1	SERBP1P3	-8.29	1.27e-15	6.92e-13	-0.43	-0.36	Crohn's disease;	chr3:53130078	chr3:53064283~53065091:-
PRAD	cis	rs4713118	0.539	rs200967	ENSG00000280107.1	AL022393.9	-8.29	1.28e-15	6.92e-13	-0.46	-0.36	Parkinson's disease;	chr6:27894349	chr6:28170845~28172521:+
PRAD	cis	rs6782228	0.565	rs67445542	ENSG00000242551.2	POU5F1P6	-8.29	1.28e-15	6.92e-13	-0.45	-0.36	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611683	chr3:128674735~128677005:-
PRAD	cis	rs11098499	0.909	rs73842633	ENSG00000245958.5	RP11-33B1.1	-8.29	1.28e-15	6.94e-13	-0.37	-0.36	Corneal astigmatism;	chr4:119454309	chr4:119454791~119552025:+
PRAD	cis	rs274567	0.599	rs11242110	ENSG00000233006.5	AC034220.3	-8.29	1.29e-15	6.97e-13	-0.32	-0.36	Blood metabolite levels;	chr5:132408085	chr5:132311285~132369916:-
PRAD	cis	rs7567389	0.6	rs3732209	ENSG00000236682.1	AC068282.3	-8.29	1.29e-15	6.98e-13	-0.47	-0.36	Self-rated health;	chr2:127322230	chr2:127389130~127400580:+
PRAD	cis	rs1075265	0.791	rs1833498	ENSG00000233266.1	HMGB1P31	8.29	1.29e-15	6.98e-13	0.49	0.36	Chronotype;Morning vs. evening chronotype;	chr2:54080801	chr2:54051334~54051760:+
PRAD	cis	rs4722166	1	rs4722166	ENSG00000179428.2	AC073072.5	-8.29	1.29e-15	6.99e-13	-0.46	-0.36	Lung cancer;	chr7:22699143	chr7:22725395~22727620:-
PRAD	cis	rs4631830	0.832	rs2843554	ENSG00000230869.1	CTGLF10P	-8.29	1.29e-15	6.99e-13	-0.45	-0.36	Prostate-specific antigen levels;	chr10:46071961	chr10:45678692~45700532:+
PRAD	cis	rs79349575	0.716	rs595767	ENSG00000248278.1	SUMO2P17	8.29	1.29e-15	7.01e-13	0.41	0.36	Type 2 diabetes;	chr17:48880625	chr17:48874860~48908983:-
PRAD	cis	rs12142240	0.698	rs17357759	ENSG00000232022.5	FAAHP1	-8.29	1.29e-15	7.01e-13	-0.33	-0.36	Menopause (age at onset);	chr1:46366862	chr1:46432129~46445521:+
PRAD	cis	rs2522056	0.808	rs7704457	ENSG00000233006.5	AC034220.3	8.29	1.29e-15	7.01e-13	0.37	0.36	Fibrinogen;Lymphocyte counts;	chr5:132409098	chr5:132311285~132369916:-
PRAD	cis	rs9532669	0.963	rs4600338	ENSG00000168852.11	TPTE2P5	8.29	1.29e-15	7.01e-13	0.34	0.36	Cervical cancer;	chr13:40925175	chr13:40822296~40921749:-
PRAD	cis	rs4835473	0.771	rs4835097	ENSG00000251600.4	RP11-673E1.1	8.29	1.29e-15	7.01e-13	0.47	0.36	Immature fraction of reticulocytes;	chr4:143960687	chr4:143912331~143982454:+
PRAD	cis	rs26232	0.521	rs3776856	ENSG00000175749.11	EIF3KP1	8.29	1.29e-15	7.02e-13	0.49	0.36	Rheumatoid arthritis;	chr5:103023102	chr5:103032376~103033031:+
PRAD	cis	rs67311347	1	rs897117	ENSG00000223797.4	ENTPD3-AS1	-8.29	1.3e-15	7.02e-13	-0.32	-0.36	Renal cell carcinoma;	chr3:40395803	chr3:40313802~40453329:-
PRAD	cis	rs2739330	0.828	rs4822454	ENSG00000224205.1	AP000351.4	8.29	1.3e-15	7.03e-13	0.45	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23987320~23991421:-
PRAD	cis	rs11846409	0.86	rs1858692	ENSG00000274576.2	IGHV2-70	8.29	1.3e-15	7.03e-13	0.4	0.36	Rheumatic heart disease;	chr14:106622776	chr14:106770577~106771020:-
PRAD	cis	rs1930961	0.702	rs6004684	ENSG00000100058.11	CRYBB2P1	-8.29	1.3e-15	7.03e-13	-0.77	-0.36	Bipolar disorder with mood-incongruent psychosis;	chr22:25503972	chr22:25448105~25520854:+
PRAD	cis	rs2404602	0.692	rs1116535	ENSG00000259422.1	RP11-593F23.1	-8.29	1.3e-15	7.03e-13	-0.45	-0.36	Blood metabolite levels;	chr15:76717173	chr15:76174891~76181486:-
PRAD	cis	rs2906856	0.526	rs2906852	ENSG00000255733.4	IFNG-AS1	8.29	1.3e-15	7.03e-13	0.41	0.36	Mosquito bite size;	chr12:67985701	chr12:67989445~68234686:+
PRAD	cis	rs4927850	0.666	rs4927853	ENSG00000242086.7	LINC00969	8.29	1.3e-15	7.04e-13	0.34	0.36	Pancreatic cancer;	chr3:196025182	chr3:195658062~195739964:+
PRAD	cis	rs4722166	0.532	rs6461662	ENSG00000179428.2	AC073072.5	-8.29	1.3e-15	7.04e-13	-0.42	-0.36	Lung cancer;	chr7:22717470	chr7:22725395~22727620:-
PRAD	cis	rs7772486	0.902	rs2748500	ENSG00000235652.6	RP11-545I5.3	8.29	1.3e-15	7.04e-13	0.37	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145993716	chr6:145799409~145886585:+
PRAD	cis	rs11976180	1	rs6464574	ENSG00000273234.1	OR2A13P	-8.29	1.3e-15	7.06e-13	-0.44	-0.36	Obesity-related traits;	chr7:144051164	chr7:144142009~144142938:+
PRAD	cis	rs9326248	0.581	rs10892072	ENSG00000280143.1	AP000892.6	8.29	1.31e-15	7.08e-13	0.28	0.36	Blood protein levels;	chr11:117089597	chr11:117204967~117210292:+
PRAD	cis	rs6538678	0.864	rs7308921	ENSG00000258343.1	RP11-536G4.2	8.29	1.31e-15	7.08e-13	0.46	0.36	Lupus nephritis in systemic lupus erythematosus;	chr12:95870757	chr12:95795345~95858839:-
PRAD	cis	rs2933343	0.7	rs1683779	ENSG00000231305.3	RP11-723O4.2	8.29	1.31e-15	7.08e-13	0.34	0.36	IgG glycosylation;	chr3:128923205	chr3:128861313~128871540:-
PRAD	cis	rs2412819	0.545	rs17795279	ENSG00000205771.5	CATSPER2P1	8.29	1.31e-15	7.09e-13	0.51	0.36	Lung cancer;	chr15:43637180	chr15:43726918~43747094:-
PRAD	cis	rs801193	0.66	rs2659897	ENSG00000237310.1	GS1-124K5.4	-8.29	1.31e-15	7.09e-13	-0.33	-0.36	Aortic root size;	chr7:66722728	chr7:66493706~66495474:+
PRAD	cis	rs4835473	0.932	rs13134327	ENSG00000251600.4	RP11-673E1.1	8.29	1.31e-15	7.1e-13	0.46	0.36	Immature fraction of reticulocytes;	chr4:143738642	chr4:143912331~143982454:+
PRAD	cis	rs2108622	0.727	rs9305069	ENSG00000267056.2	AC005336.4	8.29	1.31e-15	7.1e-13	0.5	0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15872576	chr19:15910582~15911824:-
PRAD	cis	rs17486696	0.51	rs10009649	ENSG00000248771.4	LINC01207	8.29	1.32e-15	7.14e-13	0.62	0.36	Positive affect;	chr4:164761828	chr4:164754064~164803795:+
PRAD	cis	rs1912483	0.505	rs3760372	ENSG00000228782.6	CTD-2026D20.3	8.29	1.32e-15	7.15e-13	0.44	0.36	Coronary artery disease;	chr17:47302636	chr17:47450568~47492492:-
PRAD	cis	rs1979679	0.842	rs7316299	ENSG00000278733.1	RP11-425D17.1	8.29	1.32e-15	7.15e-13	0.47	0.36	Ossification of the posterior longitudinal ligament of the spine;	chr12:28179757	chr12:28185625~28186190:-
PRAD	cis	rs6142102	0.812	rs6120440	ENSG00000276073.1	RP5-1125A11.7	8.29	1.32e-15	7.17e-13	0.46	0.36	Skin pigmentation;	chr20:33929779	chr20:33985617~33988989:-
PRAD	cis	rs875971	0.522	rs1617484	ENSG00000236529.1	RP13-254B10.1	8.29	1.33e-15	7.18e-13	0.37	0.36	Aortic root size;	chr7:65998108	chr7:65840212~65840596:+
PRAD	cis	rs4835473	0.9	rs35311036	ENSG00000251600.4	RP11-673E1.1	-8.28	1.34e-15	7.23e-13	-0.46	-0.36	Immature fraction of reticulocytes;	chr4:143734397	chr4:143912331~143982454:+
PRAD	cis	rs7772486	0.902	rs1331643	ENSG00000235652.6	RP11-545I5.3	8.28	1.34e-15	7.25e-13	0.37	0.36	Lobe attachment (rater-scored or self-reported);	chr6:146077737	chr6:145799409~145886585:+
PRAD	cis	rs1426063	1	rs10030850	ENSG00000249717.1	RP11-44F21.3	8.28	1.34e-15	7.25e-13	0.64	0.36	QT interval;	chr4:75099199	chr4:74955974~74970362:-
PRAD	cis	rs1426063	1	rs9993589	ENSG00000249717.1	RP11-44F21.3	8.28	1.34e-15	7.25e-13	0.64	0.36	QT interval;	chr4:75099556	chr4:74955974~74970362:-
PRAD	cis	rs1979679	0.842	rs10459090	ENSG00000278733.1	RP11-425D17.1	8.28	1.34e-15	7.25e-13	0.46	0.36	Ossification of the posterior longitudinal ligament of the spine;	chr12:28188207	chr12:28185625~28186190:-
PRAD	cis	rs7569084	0.566	rs7584295	ENSG00000204929.10	AC074391.1	8.28	1.34e-15	7.25e-13	0.46	0.36	Sum eosinophil basophil counts;	chr2:65353940	chr2:65436711~66084639:+
PRAD	cis	rs934734	0.563	rs11695373	ENSG00000204929.10	AC074391.1	8.28	1.34e-15	7.25e-13	0.46	0.36	Rheumatoid arthritis;	chr2:65354066	chr2:65436711~66084639:+
PRAD	cis	rs8523	0.804	rs7752895	ENSG00000230314.5	ELOVL2-AS1	8.28	1.34e-15	7.25e-13	0.4	0.36	Red blood cell fatty acid levels;	chr6:11064547	chr6:11043524~11078226:+
PRAD	cis	rs9287719	0.967	rs6721739	ENSG00000234818.1	AC092687.5	-8.28	1.34e-15	7.27e-13	-0.43	-0.36	Prostate cancer;	chr2:10611120	chr2:10589166~10604830:+
PRAD	cis	rs7615952	0.688	rs17334074	ENSG00000171084.14	FAM86JP	-8.28	1.34e-15	7.28e-13	-0.55	-0.36	Blood pressure (smoking interaction);	chr3:125821617	chr3:125916620~125930024:+
PRAD	cis	rs10822145	1	rs10822145	ENSG00000232075.1	MRPL35P2	-8.28	1.35e-15	7.3e-13	-0.38	-0.36	Triglycerides;	chr10:63174788	chr10:63634317~63634827:-
PRAD	cis	rs11096990	0.634	rs10010352	ENSG00000249207.1	RP11-360F5.1	-8.28	1.35e-15	7.32e-13	-0.38	-0.36	Cognitive function;	chr4:39240657	chr4:39112677~39126818:-
PRAD	cis	rs7569084	0.663	rs10190233	ENSG00000281920.1	RP11-418H16.1	-8.28	1.36e-15	7.35e-13	-0.44	-0.36	Sum eosinophil basophil counts;	chr2:65413095	chr2:65623272~65628424:+
PRAD	cis	rs526231	0.511	rs3756582	ENSG00000175749.11	EIF3KP1	8.28	1.36e-15	7.38e-13	0.49	0.36	Primary biliary cholangitis;	chr5:103003848	chr5:103032376~103033031:+
PRAD	cis	rs526231	0.511	rs1826673	ENSG00000175749.11	EIF3KP1	8.28	1.36e-15	7.38e-13	0.49	0.36	Primary biliary cholangitis;	chr5:103010212	chr5:103032376~103033031:+
PRAD	cis	rs526231	0.511	rs62362545	ENSG00000175749.11	EIF3KP1	8.28	1.36e-15	7.38e-13	0.49	0.36	Primary biliary cholangitis;	chr5:103011748	chr5:103032376~103033031:+
PRAD	cis	rs526231	0.511	rs3910557	ENSG00000175749.11	EIF3KP1	8.28	1.36e-15	7.38e-13	0.49	0.36	Primary biliary cholangitis;	chr5:103014767	chr5:103032376~103033031:+
PRAD	cis	rs526231	0.511	rs2288389	ENSG00000175749.11	EIF3KP1	8.28	1.36e-15	7.38e-13	0.49	0.36	Primary biliary cholangitis;	chr5:103018104	chr5:103032376~103033031:+
PRAD	cis	rs2019137	0.936	rs4849169	ENSG00000274877.1	RP11-65I12.1	8.28	1.37e-15	7.41e-13	0.45	0.36	Lymphocyte counts;	chr2:113196080	chr2:113237595~113240825:+
PRAD	cis	rs8523	0.901	rs1225737	ENSG00000230314.5	ELOVL2-AS1	8.28	1.37e-15	7.43e-13	0.4	0.36	Red blood cell fatty acid levels;	chr6:10982419	chr6:11043524~11078226:+
PRAD	cis	rs2638953	0.924	rs11049410	ENSG00000278733.1	RP11-425D17.1	-8.28	1.38e-15	7.45e-13	-0.46	-0.36	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28183438	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs11049418	ENSG00000278733.1	RP11-425D17.1	-8.28	1.38e-15	7.45e-13	-0.46	-0.36	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28192154	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs12367188	ENSG00000278733.1	RP11-425D17.1	-8.28	1.38e-15	7.45e-13	-0.46	-0.36	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28192511	chr12:28185625~28186190:-
PRAD	cis	rs7104764	0.507	rs7121085	ENSG00000277290.1	RP11-326C3.16	-8.28	1.38e-15	7.46e-13	-0.37	-0.36	Menarche (age at onset);	chr11:258523	chr11:243099~243483:-
PRAD	cis	rs7104764	0.507	rs7111364	ENSG00000277290.1	RP11-326C3.16	-8.28	1.38e-15	7.46e-13	-0.37	-0.36	Menarche (age at onset);	chr11:258542	chr11:243099~243483:-
PRAD	cis	rs1075265	0.87	rs10207537	ENSG00000233266.1	HMGB1P31	8.28	1.38e-15	7.46e-13	0.49	0.36	Chronotype;Morning vs. evening chronotype;	chr2:54101700	chr2:54051334~54051760:+
PRAD	cis	rs10463554	0.927	rs34799	ENSG00000175749.11	EIF3KP1	8.28	1.38e-15	7.47e-13	0.5	0.36	Parkinson's disease;	chr5:103090498	chr5:103032376~103033031:+
PRAD	cis	rs7829975	0.511	rs1543238	ENSG00000253893.2	FAM85B	-8.28	1.38e-15	7.47e-13	-0.45	-0.36	Mood instability;	chr8:8277287	chr8:8167819~8226614:-
PRAD	cis	rs75422866	0.764	rs67408202	ENSG00000257433.4	RP1-197B17.3	8.28	1.39e-15	7.49e-13	0.78	0.36	Pneumonia;	chr12:47713564	chr12:47706085~47742294:+
PRAD	cis	rs75422866	0.867	rs57848393	ENSG00000257433.4	RP1-197B17.3	8.28	1.39e-15	7.49e-13	0.78	0.36	Pneumonia;	chr12:47714734	chr12:47706085~47742294:+
PRAD	cis	rs6452524	0.901	rs12514607	ENSG00000249664.1	CTD-2227C6.2	-8.28	1.39e-15	7.51e-13	-0.44	-0.36	Hypertension (SNP x SNP interaction);	chr5:83209710	chr5:83012285~83013109:-
PRAD	cis	rs2348418	0.647	rs10843210	ENSG00000247934.4	RP11-967K21.1	8.28	1.39e-15	7.51e-13	0.33	0.36	Lung function (FEV1);Lung function (FVC);	chr12:28575800	chr12:28163298~28190738:-
PRAD	cis	rs4927850	0.752	rs7618864	ENSG00000207650.1	MIR570	8.28	1.39e-15	7.51e-13	0.38	0.36	Pancreatic cancer;	chr3:196022690	chr3:195699401~195699497:+
PRAD	cis	rs9309711	0.56	rs6548164	ENSG00000225234.1	TRAPPC12-AS1	8.28	1.39e-15	7.51e-13	0.35	0.36	Neurofibrillary tangles;	chr2:3468894	chr2:3481242~3482409:-
PRAD	cis	rs10463554	0.856	rs26427	ENSG00000175749.11	EIF3KP1	-8.28	1.4e-15	7.54e-13	-0.46	-0.36	Parkinson's disease;	chr5:103031079	chr5:103032376~103033031:+
PRAD	cis	rs2404602	0.692	rs35195096	ENSG00000259422.1	RP11-593F23.1	8.28	1.4e-15	7.55e-13	0.45	0.36	Blood metabolite levels;	chr15:76646106	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.692	rs34287706	ENSG00000259422.1	RP11-593F23.1	8.28	1.4e-15	7.55e-13	0.45	0.36	Blood metabolite levels;	chr15:76650061	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.669	rs12438540	ENSG00000259422.1	RP11-593F23.1	8.28	1.4e-15	7.55e-13	0.45	0.36	Blood metabolite levels;	chr15:76650872	chr15:76174891~76181486:-
PRAD	cis	rs7131987	0.65	rs10843384	ENSG00000257176.2	RP11-996F15.2	-8.28	1.4e-15	7.56e-13	-0.4	-0.36	QT interval;	chr12:29319476	chr12:29280418~29317848:-
PRAD	cis	rs7131987	0.65	rs11050188	ENSG00000257176.2	RP11-996F15.2	-8.28	1.4e-15	7.56e-13	-0.4	-0.36	QT interval;	chr12:29320175	chr12:29280418~29317848:-
PRAD	cis	rs7131987	0.683	rs12366505	ENSG00000257176.2	RP11-996F15.2	-8.28	1.4e-15	7.56e-13	-0.4	-0.36	QT interval;	chr12:29321177	chr12:29280418~29317848:-
PRAD	cis	rs7131987	0.65	rs12366527	ENSG00000257176.2	RP11-996F15.2	-8.28	1.4e-15	7.56e-13	-0.4	-0.36	QT interval;	chr12:29321323	chr12:29280418~29317848:-
PRAD	cis	rs7131987	0.65	rs7311912	ENSG00000257176.2	RP11-996F15.2	-8.28	1.4e-15	7.56e-13	-0.4	-0.36	QT interval;	chr12:29322770	chr12:29280418~29317848:-
PRAD	cis	rs375066	0.901	rs1050054	ENSG00000267058.1	RP11-15A1.3	-8.28	1.4e-15	7.56e-13	-0.3	-0.36	Breast cancer;	chr19:43872529	chr19:43891804~43901805:-
PRAD	cis	rs7211079	0.879	rs66693363	ENSG00000279259.1	RP11-334C17.3	8.28	1.4e-15	7.56e-13	0.4	0.36	Myocardial infarction;	chr17:80155136	chr17:80147250~80148596:+
PRAD	cis	rs2404602	0.692	rs1838048	ENSG00000259422.1	RP11-593F23.1	8.28	1.4e-15	7.58e-13	0.45	0.36	Blood metabolite levels;	chr15:76639338	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.692	rs56193230	ENSG00000259422.1	RP11-593F23.1	8.28	1.4e-15	7.58e-13	0.45	0.36	Blood metabolite levels;	chr15:76642131	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.692	rs35077207	ENSG00000259422.1	RP11-593F23.1	8.28	1.4e-15	7.58e-13	0.45	0.36	Blood metabolite levels;	chr15:76642965	chr15:76174891~76181486:-
PRAD	cis	rs8005677	1	rs2295685	ENSG00000257285.4	RP11-298I3.1	8.28	1.41e-15	7.6e-13	0.36	0.36	Cognitive ability (multi-trait analysis);	chr14:22928944	chr14:22929609~22955562:+
PRAD	cis	rs8005677	1	rs4982710	ENSG00000257285.4	RP11-298I3.1	8.28	1.41e-15	7.6e-13	0.36	0.36	Cognitive ability (multi-trait analysis);	chr14:22929693	chr14:22929609~22955562:+
PRAD	cis	rs8005677	1	rs7145494	ENSG00000257285.4	RP11-298I3.1	8.28	1.41e-15	7.6e-13	0.36	0.36	Cognitive ability (multi-trait analysis);	chr14:22930581	chr14:22929609~22955562:+
PRAD	cis	rs8005677	1	rs7155857	ENSG00000257285.4	RP11-298I3.1	8.28	1.41e-15	7.6e-13	0.36	0.36	Cognitive ability (multi-trait analysis);	chr14:22930850	chr14:22929609~22955562:+
PRAD	cis	rs2337406	0.925	rs76288499	ENSG00000274576.2	IGHV2-70	-8.28	1.41e-15	7.61e-13	-0.4	-0.36	Alzheimer's disease (late onset);	chr14:106686309	chr14:106770577~106771020:-
PRAD	cis	rs9309473	0.718	rs6546829	ENSG00000163016.8	ALMS1P	8.28	1.41e-15	7.61e-13	0.44	0.36	Metabolite levels;	chr2:73386661	chr2:73644919~73685576:+
PRAD	cis	rs1355223	0.902	rs1588353	ENSG00000271369.1	RP11-350D17.3	-8.28	1.41e-15	7.63e-13	-0.42	-0.36	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34709267	chr11:34709600~34710161:+
PRAD	cis	rs6723108	0.603	rs1374289	ENSG00000224043.6	CCNT2-AS1	8.28	1.41e-15	7.63e-13	0.5	0.36	Type 2 diabetes;	chr2:134936809	chr2:134735464~134918710:-
PRAD	cis	rs4713118	0.662	rs149900	ENSG00000272009.1	RP1-313I6.12	-8.28	1.41e-15	7.64e-13	-0.38	-0.36	Parkinson's disease;	chr6:28046819	chr6:28078792~28081130:-
PRAD	cis	rs763567	0.933	rs608930	ENSG00000271811.1	RP1-79C4.4	8.28	1.42e-15	7.65e-13	0.41	0.36	Tonsillectomy;	chr1:170648165	chr1:170667381~170669425:+
PRAD	cis	rs6538678	0.777	rs10745736	ENSG00000258343.1	RP11-536G4.2	-8.28	1.42e-15	7.65e-13	-0.47	-0.36	Lupus nephritis in systemic lupus erythematosus;	chr12:95889308	chr12:95795345~95858839:-
PRAD	cis	rs34779708	0.801	rs12246600	ENSG00000230534.5	RP11-297A16.2	8.28	1.42e-15	7.67e-13	0.48	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35249193	chr10:35098006~35127020:-
PRAD	cis	rs2638953	0.924	rs11049416	ENSG00000278733.1	RP11-425D17.1	8.28	1.42e-15	7.67e-13	0.46	0.36	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28190305	chr12:28185625~28186190:-
PRAD	cis	rs9903692	0.954	rs6847	ENSG00000278765.1	RP5-890E16.5	-8.28	1.42e-15	7.67e-13	-0.54	-0.36	Pulse pressure;	chr17:48070445	chr17:48066704~48067293:-
PRAD	cis	rs11083475	0.935	rs12460849	ENSG00000267892.1	CTD-2540F13.2	8.28	1.43e-15	7.69e-13	0.4	0.36	Heart rate;	chr19:38653244	chr19:38738284~38739863:+
PRAD	cis	rs17361889	0.752	rs4721485	ENSG00000224683.1	RPL36AP29	8.28	1.43e-15	7.69e-13	0.42	0.36	Pediatric bone mineral content (hip);	chr7:16242848	chr7:16208945~16209265:+
PRAD	cis	rs9532669	0.926	rs4942007	ENSG00000168852.11	TPTE2P5	8.28	1.43e-15	7.7e-13	0.34	0.36	Cervical cancer;	chr13:40871887	chr13:40822296~40921749:-
PRAD	cis	rs763567	0.967	rs736791	ENSG00000271811.1	RP1-79C4.4	-8.28	1.43e-15	7.7e-13	-0.42	-0.36	Tonsillectomy;	chr1:170617174	chr1:170667381~170669425:+
PRAD	cis	rs1061377	0.965	rs10018622	ENSG00000249685.1	RP11-360F5.3	8.28	1.43e-15	7.7e-13	0.4	0.36	Uric acid levels;	chr4:39133944	chr4:39133913~39135608:+
PRAD	cis	rs7567389	0.535	rs4150416	ENSG00000236682.1	AC068282.3	8.28	1.43e-15	7.72e-13	0.45	0.36	Self-rated health;	chr2:127288972	chr2:127389130~127400580:+
PRAD	cis	rs8005677	1	rs1956881	ENSG00000257285.4	RP11-298I3.1	8.28	1.43e-15	7.74e-13	0.36	0.36	Cognitive ability (multi-trait analysis);	chr14:22924860	chr14:22929609~22955562:+
PRAD	cis	rs8005677	0.962	rs10130756	ENSG00000257285.4	RP11-298I3.1	8.28	1.43e-15	7.74e-13	0.36	0.36	Cognitive ability (multi-trait analysis);	chr14:22927391	chr14:22929609~22955562:+
PRAD	cis	rs17772222	1	rs17772288	ENSG00000258983.2	RP11-507K2.2	8.28	1.44e-15	7.74e-13	0.52	0.36	Coronary artery calcification;	chr14:88361022	chr14:88499334~88515502:+
PRAD	cis	rs1555322	0.53	rs6058224	ENSG00000126005.14	MMP24-AS1	-8.27	1.44e-15	7.75e-13	-0.42	-0.36	Attention deficit hyperactivity disorder;	chr20:35293971	chr20:35216462~35278131:-
PRAD	cis	rs9309473	0.607	rs1522926	ENSG00000163016.8	ALMS1P	8.27	1.44e-15	7.76e-13	0.43	0.36	Metabolite levels;	chr2:73364113	chr2:73644919~73685576:+
PRAD	cis	rs7615952	0.599	rs1875683	ENSG00000171084.14	FAM86JP	8.27	1.44e-15	7.78e-13	0.57	0.36	Blood pressure (smoking interaction);	chr3:126013638	chr3:125916620~125930024:+
PRAD	cis	rs7829975	0.688	rs7827182	ENSG00000253893.2	FAM85B	-8.27	1.44e-15	7.78e-13	-0.42	-0.36	Mood instability;	chr8:8522961	chr8:8167819~8226614:-
PRAD	cis	rs6921919	0.789	rs1119211	ENSG00000216901.1	AL022393.7	-8.27	1.45e-15	7.8e-13	-0.5	-0.36	Autism spectrum disorder or schizophrenia;	chr6:28341359	chr6:28176188~28176674:+
PRAD	cis	rs6723108	0.517	rs3739029	ENSG00000224043.6	CCNT2-AS1	-8.27	1.45e-15	7.8e-13	-0.5	-0.36	Type 2 diabetes;	chr2:134841837	chr2:134735464~134918710:-
PRAD	cis	rs270601	0.721	rs162894	ENSG00000233006.5	AC034220.3	8.27	1.45e-15	7.8e-13	0.32	0.36	Acylcarnitine levels;	chr5:132276179	chr5:132311285~132369916:-
PRAD	cis	rs7615952	0.611	rs114419739	ENSG00000171084.14	FAM86JP	8.27	1.45e-15	7.82e-13	0.75	0.36	Blood pressure (smoking interaction);	chr3:126003647	chr3:125916620~125930024:+
PRAD	cis	rs11096990	0.593	rs35552004	ENSG00000249207.1	RP11-360F5.1	-8.27	1.45e-15	7.83e-13	-0.38	-0.36	Cognitive function;	chr4:39170914	chr4:39112677~39126818:-
PRAD	cis	rs11096990	0.552	rs7655170	ENSG00000249207.1	RP11-360F5.1	-8.27	1.45e-15	7.83e-13	-0.38	-0.36	Cognitive function;	chr4:39171984	chr4:39112677~39126818:-
PRAD	cis	rs67311347	0.955	rs73080163	ENSG00000223797.4	ENTPD3-AS1	8.27	1.45e-15	7.84e-13	0.33	0.36	Renal cell carcinoma;	chr3:40491570	chr3:40313802~40453329:-
PRAD	cis	rs67311347	1	rs73080165	ENSG00000223797.4	ENTPD3-AS1	8.27	1.45e-15	7.84e-13	0.33	0.36	Renal cell carcinoma;	chr3:40491571	chr3:40313802~40453329:-
PRAD	cis	rs2404602	0.679	rs12908421	ENSG00000259422.1	RP11-593F23.1	8.27	1.45e-15	7.84e-13	0.46	0.36	Blood metabolite levels;	chr15:76589453	chr15:76174891~76181486:-
PRAD	cis	rs2015599	0.623	rs1072724	ENSG00000275476.1	RP11-996F15.4	8.27	1.46e-15	7.84e-13	0.39	0.36	Platelet count;Mean platelet volume;	chr12:29289205	chr12:29277397~29277882:-
PRAD	cis	rs2015599	0.623	rs7358667	ENSG00000275476.1	RP11-996F15.4	8.27	1.46e-15	7.84e-13	0.39	0.36	Platelet count;Mean platelet volume;	chr12:29290236	chr12:29277397~29277882:-
PRAD	cis	rs1061377	1	rs12646251	ENSG00000249685.1	RP11-360F5.3	8.27	1.46e-15	7.84e-13	0.41	0.36	Uric acid levels;	chr4:39132751	chr4:39133913~39135608:+
PRAD	cis	rs6570726	0.967	rs441364	ENSG00000235652.6	RP11-545I5.3	8.27	1.46e-15	7.86e-13	0.38	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145532526	chr6:145799409~145886585:+
PRAD	cis	rs357618	0.965	rs187180	ENSG00000260581.1	CTB-113P19.4	8.27	1.46e-15	7.88e-13	0.44	0.36	Basophil percentage of white cells;	chr5:151468434	chr5:151652275~151655449:+
PRAD	cis	rs12142240	0.959	rs12137934	ENSG00000232022.5	FAAHP1	-8.27	1.47e-15	7.91e-13	-0.34	-0.36	Menopause (age at onset);	chr1:46263241	chr1:46432129~46445521:+
PRAD	cis	rs4713118	0.662	rs149901	ENSG00000219392.1	RP1-265C24.5	-8.27	1.47e-15	7.92e-13	-0.46	-0.36	Parkinson's disease;	chr6:27997725	chr6:28115628~28116551:+
PRAD	cis	rs526231	0.543	rs34377	ENSG00000175749.11	EIF3KP1	8.27	1.47e-15	7.93e-13	0.5	0.36	Primary biliary cholangitis;	chr5:103064852	chr5:103032376~103033031:+
PRAD	cis	rs6782228	0.675	rs2253151	ENSG00000242551.2	POU5F1P6	-8.27	1.47e-15	7.94e-13	-0.45	-0.36	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611294	chr3:128674735~128677005:-
PRAD	cis	rs748404	0.587	rs690276	ENSG00000249839.1	AC011330.5	-8.27	1.48e-15	7.95e-13	-0.44	-0.36	Lung cancer;	chr15:43412360	chr15:43663654~43684339:-
PRAD	cis	rs4713118	0.513	rs200971	ENSG00000280107.1	AL022393.9	-8.27	1.48e-15	7.96e-13	-0.45	-0.36	Parkinson's disease;	chr6:27891126	chr6:28170845~28172521:+
PRAD	cis	rs42648	0.693	rs3747800	ENSG00000227646.6	STEAP2-AS1	-8.27	1.48e-15	7.97e-13	-0.33	-0.36	Homocysteine levels;	chr7:90270174	chr7:89882353~90211635:-
PRAD	cis	rs6991838	0.673	rs7462352	ENSG00000200714.1	Y_RNA	8.27	1.48e-15	7.98e-13	0.37	0.36	Intelligence (multi-trait analysis);	chr8:65584378	chr8:65592731~65592820:+
PRAD	cis	rs801193	0.591	rs9986881	ENSG00000237310.1	GS1-124K5.4	8.27	1.48e-15	7.99e-13	0.32	0.36	Aortic root size;	chr7:66708053	chr7:66493706~66495474:+
PRAD	cis	rs4631830	0.72	rs7090326	ENSG00000230869.1	CTGLF10P	-8.27	1.48e-15	7.99e-13	-0.44	-0.36	Prostate-specific antigen levels;	chr10:46092447	chr10:45678692~45700532:+
PRAD	cis	rs8062405	0.573	rs6565300	ENSG00000251417.2	RP11-1348G14.4	-8.27	1.48e-15	7.99e-13	-0.43	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28981728	chr16:28802743~28817828:+
PRAD	cis	rs4631830	0.72	rs2843560	ENSG00000230869.1	CTGLF10P	8.27	1.49e-15	8.03e-13	0.44	0.36	Prostate-specific antigen levels;	chr10:46083693	chr10:45678692~45700532:+
PRAD	cis	rs7615952	0.641	rs7618515	ENSG00000171084.14	FAM86JP	8.27	1.49e-15	8.05e-13	0.57	0.36	Blood pressure (smoking interaction);	chr3:126071735	chr3:125916620~125930024:+
PRAD	cis	rs7432375	0.901	rs4408829	ENSG00000261758.1	RP11-102M11.2	-8.27	1.5e-15	8.07e-13	-0.42	-0.36	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136685841	chr3:136752630~136755780:+
PRAD	cis	rs7772486	0.902	rs2777480	ENSG00000235652.6	RP11-545I5.3	8.27	1.5e-15	8.07e-13	0.37	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145988847	chr6:145799409~145886585:+
PRAD	cis	rs17428076	0.836	rs57718990	ENSG00000228389.1	AC068039.4	-8.27	1.5e-15	8.08e-13	-0.46	-0.36	Myopia;	chr2:171806104	chr2:171773482~171775844:+
PRAD	cis	rs6921919	0.583	rs2027361	ENSG00000216901.1	AL022393.7	8.27	1.51e-15	8.1e-13	0.46	0.36	Autism spectrum disorder or schizophrenia;	chr6:28420531	chr6:28176188~28176674:+
PRAD	cis	rs6921919	0.583	rs4642462	ENSG00000216901.1	AL022393.7	8.27	1.51e-15	8.1e-13	0.46	0.36	Autism spectrum disorder or schizophrenia;	chr6:28421474	chr6:28176188~28176674:+
PRAD	cis	rs9341835	0.518	rs9350929	ENSG00000218048.2	RP3-407E4.4	8.27	1.51e-15	8.1e-13	0.42	0.36	Schizophrenia;	chr6:63465763	chr6:63440766~63443580:+
PRAD	cis	rs9341835	0.518	rs6942342	ENSG00000218048.2	RP3-407E4.4	8.27	1.51e-15	8.1e-13	0.42	0.36	Schizophrenia;	chr6:63466542	chr6:63440766~63443580:+
PRAD	cis	rs7923609	0.967	rs7082470	ENSG00000232075.1	MRPL35P2	-8.27	1.51e-15	8.11e-13	-0.38	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63517266	chr10:63634317~63634827:-
PRAD	cis	rs7923609	0.846	rs7075901	ENSG00000232075.1	MRPL35P2	-8.27	1.51e-15	8.11e-13	-0.38	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63521234	chr10:63634317~63634827:-
PRAD	cis	rs2439831	0.867	rs2447208	ENSG00000205771.5	CATSPER2P1	-8.27	1.51e-15	8.11e-13	-0.57	-0.36	Lung cancer in ever smokers;	chr15:43641697	chr15:43726918~43747094:-
PRAD	cis	rs8062405	0.722	rs28729187	ENSG00000259982.1	CDC37P1	-8.27	1.51e-15	8.12e-13	-0.47	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28615645	chr16:28700294~28701540:-
PRAD	cis	rs3745672	1	rs7248680	ENSG00000219665.7	CTD-2006C1.2	8.27	1.52e-15	8.16e-13	0.75	0.36	Multiple sclerosis;	chr19:12054955	chr19:11987617~12046275:+
PRAD	cis	rs7615952	0.688	rs12638240	ENSG00000171084.14	FAM86JP	8.27	1.52e-15	8.17e-13	0.55	0.36	Blood pressure (smoking interaction);	chr3:125822395	chr3:125916620~125930024:+
PRAD	cis	rs375066	0.935	rs4803662	ENSG00000267058.1	RP11-15A1.3	-8.27	1.52e-15	8.17e-13	-0.3	-0.36	Breast cancer;	chr19:43855412	chr19:43891804~43901805:-
PRAD	cis	rs3096299	0.606	rs4785674	ENSG00000274627.1	RP11-104N10.2	8.27	1.52e-15	8.18e-13	0.38	0.36	Multiple myeloma (IgH translocation);	chr16:89470205	chr16:89516797~89522217:+
PRAD	cis	rs7615952	0.576	rs6780025	ENSG00000171084.14	FAM86JP	8.27	1.52e-15	8.19e-13	0.58	0.36	Blood pressure (smoking interaction);	chr3:126096781	chr3:125916620~125930024:+
PRAD	cis	rs7615952	0.576	rs6804482	ENSG00000171084.14	FAM86JP	8.27	1.52e-15	8.19e-13	0.58	0.36	Blood pressure (smoking interaction);	chr3:126096919	chr3:125916620~125930024:+
PRAD	cis	rs7615952	0.576	rs12497295	ENSG00000171084.14	FAM86JP	8.27	1.52e-15	8.19e-13	0.58	0.36	Blood pressure (smoking interaction);	chr3:126099807	chr3:125916620~125930024:+
PRAD	cis	rs7615952	0.512	rs4646765	ENSG00000171084.14	FAM86JP	8.27	1.52e-15	8.19e-13	0.58	0.36	Blood pressure (smoking interaction);	chr3:126101864	chr3:125916620~125930024:+
PRAD	cis	rs7615952	0.576	rs4646763	ENSG00000171084.14	FAM86JP	8.27	1.52e-15	8.19e-13	0.58	0.36	Blood pressure (smoking interaction);	chr3:126103286	chr3:125916620~125930024:+
PRAD	cis	rs11098499	0.863	rs1383532	ENSG00000245958.5	RP11-33B1.1	8.27	1.52e-15	8.19e-13	0.36	0.36	Corneal astigmatism;	chr4:119513249	chr4:119454791~119552025:+
PRAD	cis	rs2404602	0.692	rs35557205	ENSG00000259422.1	RP11-593F23.1	8.27	1.52e-15	8.19e-13	0.46	0.36	Blood metabolite levels;	chr15:76838370	chr15:76174891~76181486:-
PRAD	cis	rs6921919	0.583	rs35560946	ENSG00000216901.1	AL022393.7	8.27	1.52e-15	8.19e-13	0.46	0.36	Autism spectrum disorder or schizophrenia;	chr6:28427660	chr6:28176188~28176674:+
PRAD	cis	rs2348418	0.639	rs11049350	ENSG00000247934.4	RP11-967K21.1	-8.27	1.52e-15	8.19e-13	-0.35	-0.36	Lung function (FEV1);Lung function (FVC);	chr12:28113042	chr12:28163298~28190738:-
PRAD	cis	rs72627509	0.904	rs3796529	ENSG00000269949.1	RP11-738E22.3	8.27	1.53e-15	8.24e-13	0.52	0.36	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56931248	chr4:56960927~56961373:-
PRAD	cis	rs2274273	0.588	rs2297816	ENSG00000258413.1	RP11-665C16.6	-8.27	1.54e-15	8.29e-13	-0.48	-0.36	Protein biomarker;	chr14:55366320	chr14:55262767~55272075:-
PRAD	cis	rs240993	1	rs240993	ENSG00000230177.1	RP5-1112D6.4	-8.26	1.55e-15	8.31e-13	-0.43	-0.36	Inflammatory skin disease;Psoriasis;	chr6:111352511	chr6:111277932~111278742:+
PRAD	cis	rs9532669	1	rs9532669	ENSG00000168852.11	TPTE2P5	8.26	1.55e-15	8.34e-13	0.34	0.36	Cervical cancer;	chr13:40927414	chr13:40822296~40921749:-
PRAD	cis	rs3745672	1	rs7246419	ENSG00000219665.7	CTD-2006C1.2	-8.26	1.55e-15	8.34e-13	-0.77	-0.36	Multiple sclerosis;	chr19:12051897	chr19:11987617~12046275:+
PRAD	cis	rs6921919	0.789	rs13210258	ENSG00000216901.1	AL022393.7	8.26	1.55e-15	8.35e-13	0.5	0.36	Autism spectrum disorder or schizophrenia;	chr6:28340894	chr6:28176188~28176674:+
PRAD	cis	rs2243480	1	rs778704	ENSG00000226824.5	RP4-756H11.3	-8.26	1.56e-15	8.36e-13	-0.73	-0.36	Diabetic kidney disease;	chr7:66398480	chr7:66654538~66669855:+
PRAD	cis	rs2243480	0.901	rs778693	ENSG00000226824.5	RP4-756H11.3	-8.26	1.56e-15	8.36e-13	-0.73	-0.36	Diabetic kidney disease;	chr7:66407358	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs778691	ENSG00000226824.5	RP4-756H11.3	-8.26	1.56e-15	8.36e-13	-0.73	-0.36	Diabetic kidney disease;	chr7:66408105	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs13235972	ENSG00000226824.5	RP4-756H11.3	-8.26	1.56e-15	8.36e-13	-0.73	-0.36	Diabetic kidney disease;	chr7:66418618	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs34192067	ENSG00000226824.5	RP4-756H11.3	-8.26	1.56e-15	8.36e-13	-0.73	-0.36	Diabetic kidney disease;	chr7:66422670	chr7:66654538~66669855:+
PRAD	cis	rs2243480	0.901	rs34807232	ENSG00000226824.5	RP4-756H11.3	-8.26	1.56e-15	8.36e-13	-0.73	-0.36	Diabetic kidney disease;	chr7:66500146	chr7:66654538~66669855:+
PRAD	cis	rs2243480	0.901	rs35823062	ENSG00000226824.5	RP4-756H11.3	-8.26	1.56e-15	8.36e-13	-0.73	-0.36	Diabetic kidney disease;	chr7:66500834	chr7:66654538~66669855:+
PRAD	cis	rs4835473	0.932	rs12512649	ENSG00000251600.4	RP11-673E1.1	-8.26	1.56e-15	8.38e-13	-0.46	-0.36	Immature fraction of reticulocytes;	chr4:143736745	chr4:143912331~143982454:+
PRAD	cis	rs7727544	0.526	rs17516457	ENSG00000233006.5	AC034220.3	8.26	1.56e-15	8.39e-13	0.33	0.36	Blood metabolite levels;	chr5:132254694	chr5:132311285~132369916:-
PRAD	cis	rs853679	0.607	rs13199772	ENSG00000280107.1	AL022393.9	-8.26	1.56e-15	8.4e-13	-0.72	-0.36	Depression;	chr6:27866307	chr6:28170845~28172521:+
PRAD	cis	rs321358	0.943	rs17537987	ENSG00000271584.1	RP11-89C3.4	8.26	1.56e-15	8.4e-13	0.56	0.36	Body mass index;	chr11:111134144	chr11:111091932~111097357:-
PRAD	cis	rs321358	1	rs73019218	ENSG00000271584.1	RP11-89C3.4	8.26	1.56e-15	8.4e-13	0.56	0.36	Body mass index;	chr11:111134521	chr11:111091932~111097357:-
PRAD	cis	rs4631830	0.869	rs7896437	ENSG00000230869.1	CTGLF10P	-8.26	1.57e-15	8.41e-13	-0.45	-0.36	Prostate-specific antigen levels;	chr10:46066229	chr10:45678692~45700532:+
PRAD	cis	rs7615952	0.512	rs1077621	ENSG00000171084.14	FAM86JP	8.26	1.57e-15	8.42e-13	0.58	0.36	Blood pressure (smoking interaction);	chr3:126100956	chr3:125916620~125930024:+
PRAD	cis	rs2243480	0.901	rs12530490	ENSG00000226824.5	RP4-756H11.3	8.26	1.57e-15	8.42e-13	0.73	0.36	Diabetic kidney disease;	chr7:66226660	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs7778911	ENSG00000226824.5	RP4-756H11.3	8.26	1.57e-15	8.42e-13	0.73	0.36	Diabetic kidney disease;	chr7:66229519	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs1979823	ENSG00000226824.5	RP4-756H11.3	8.26	1.57e-15	8.42e-13	0.73	0.36	Diabetic kidney disease;	chr7:66239626	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs4718334	ENSG00000226824.5	RP4-756H11.3	8.26	1.57e-15	8.42e-13	0.73	0.36	Diabetic kidney disease;	chr7:66324467	chr7:66654538~66669855:+
PRAD	cis	rs2243480	0.908	rs1532573	ENSG00000226824.5	RP4-756H11.3	8.26	1.57e-15	8.42e-13	0.73	0.36	Diabetic kidney disease;	chr7:66333815	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs778729	ENSG00000226824.5	RP4-756H11.3	-8.26	1.57e-15	8.42e-13	-0.73	-0.36	Diabetic kidney disease;	chr7:66359432	chr7:66654538~66669855:+
PRAD	cis	rs2243480	0.901	rs778687	ENSG00000226824.5	RP4-756H11.3	-8.26	1.57e-15	8.42e-13	-0.73	-0.36	Diabetic kidney disease;	chr7:66370832	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs778679	ENSG00000226824.5	RP4-756H11.3	-8.26	1.57e-15	8.42e-13	-0.73	-0.36	Diabetic kidney disease;	chr7:66375924	chr7:66654538~66669855:+
PRAD	cis	rs858239	1	rs156425	ENSG00000226816.2	AC005082.12	-8.26	1.57e-15	8.45e-13	-0.4	-0.36	Cerebrospinal fluid biomarker levels;	chr7:23269500	chr7:23206013~23208045:+
PRAD	cis	rs367615	0.552	rs3828603	ENSG00000249476.1	CTD-2587M2.1	-8.26	1.57e-15	8.45e-13	-0.44	-0.36	Colorectal cancer (SNP x SNP interaction);	chr5:109376367	chr5:109237120~109326369:-
PRAD	cis	rs7746199	0.736	rs13202291	ENSG00000280107.1	AL022393.9	-8.26	1.57e-15	8.46e-13	-0.73	-0.36	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731078	chr6:28170845~28172521:+
PRAD	cis	rs7746199	0.736	rs17750424	ENSG00000280107.1	AL022393.9	-8.26	1.57e-15	8.46e-13	-0.73	-0.36	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27733343	chr6:28170845~28172521:+
PRAD	cis	rs7746199	0.736	rs13193542	ENSG00000280107.1	AL022393.9	-8.26	1.57e-15	8.46e-13	-0.73	-0.36	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27734646	chr6:28170845~28172521:+
PRAD	cis	rs7746199	0.736	rs13193480	ENSG00000280107.1	AL022393.9	-8.26	1.57e-15	8.46e-13	-0.73	-0.36	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27734782	chr6:28170845~28172521:+
PRAD	cis	rs7746199	0.673	rs72847313	ENSG00000280107.1	AL022393.9	-8.26	1.57e-15	8.46e-13	-0.73	-0.36	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27762303	chr6:28170845~28172521:+
PRAD	cis	rs7746199	0.611	rs17750747	ENSG00000280107.1	AL022393.9	-8.26	1.57e-15	8.46e-13	-0.73	-0.36	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27762555	chr6:28170845~28172521:+
PRAD	cis	rs12220777	1	rs12220777	ENSG00000230091.5	TMEM254-AS1	-8.26	1.58e-15	8.47e-13	-0.7	-0.36	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80028348	chr10:80046860~80078912:-
PRAD	cis	rs526231	0.511	rs3776861	ENSG00000175749.11	EIF3KP1	8.26	1.58e-15	8.48e-13	0.48	0.36	Primary biliary cholangitis;	chr5:103013958	chr5:103032376~103033031:+
PRAD	cis	rs13201294	1	rs13201294	ENSG00000280107.1	AL022393.9	-8.26	1.59e-15	8.53e-13	-0.67	-0.36	Squamous cell lung carcinoma;	chr6:27588362	chr6:28170845~28172521:+
PRAD	cis	rs11118620	0.622	rs11118618	ENSG00000257551.1	HLX-AS1	8.26	1.59e-15	8.55e-13	0.52	0.36	Heart failure;	chr1:220838204	chr1:220832763~220880140:-
PRAD	cis	rs526231	0.543	rs34801	ENSG00000175749.11	EIF3KP1	8.26	1.59e-15	8.56e-13	0.5	0.36	Primary biliary cholangitis;	chr5:103090809	chr5:103032376~103033031:+
PRAD	cis	rs875971	0.564	rs313804	ENSG00000237310.1	GS1-124K5.4	8.26	1.6e-15	8.59e-13	0.31	0.36	Aortic root size;	chr7:66049635	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.662	rs448725	ENSG00000237310.1	GS1-124K5.4	8.26	1.6e-15	8.59e-13	0.31	0.36	Aortic root size;	chr7:66049641	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.658	rs432667	ENSG00000237310.1	GS1-124K5.4	8.26	1.6e-15	8.59e-13	0.31	0.36	Aortic root size;	chr7:66049646	chr7:66493706~66495474:+
PRAD	cis	rs6570726	0.935	rs392014	ENSG00000235652.6	RP11-545I5.3	8.26	1.6e-15	8.61e-13	0.37	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145522555	chr6:145799409~145886585:+
PRAD	cis	rs6570726	1	rs436066	ENSG00000235652.6	RP11-545I5.3	8.26	1.6e-15	8.61e-13	0.37	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145525991	chr6:145799409~145886585:+
PRAD	cis	rs6570726	1	rs441477	ENSG00000235652.6	RP11-545I5.3	8.26	1.6e-15	8.61e-13	0.37	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145527107	chr6:145799409~145886585:+
PRAD	cis	rs1150668	0.83	rs213240	ENSG00000280107.1	AL022393.9	-8.26	1.61e-15	8.62e-13	-0.44	-0.36	Pubertal anthropometrics;	chr6:28348098	chr6:28170845~28172521:+
PRAD	cis	rs7615952	0.641	rs7632497	ENSG00000171084.14	FAM86JP	8.26	1.61e-15	8.62e-13	0.57	0.36	Blood pressure (smoking interaction);	chr3:126064243	chr3:125916620~125930024:+
PRAD	cis	rs7615952	0.641	rs12487875	ENSG00000171084.14	FAM86JP	8.26	1.61e-15	8.62e-13	0.57	0.36	Blood pressure (smoking interaction);	chr3:126068381	chr3:125916620~125930024:+
PRAD	cis	rs42648	0.792	rs4236517	ENSG00000227646.6	STEAP2-AS1	-8.26	1.62e-15	8.68e-13	-0.34	-0.36	Homocysteine levels;	chr7:90334151	chr7:89882353~90211635:-
PRAD	cis	rs1150668	0.699	rs1531681	ENSG00000280107.1	AL022393.9	-8.26	1.62e-15	8.69e-13	-0.43	-0.36	Pubertal anthropometrics;	chr6:28259100	chr6:28170845~28172521:+
PRAD	cis	rs10129255	0.518	rs10150460	ENSG00000211972.2	IGHV3-66	-8.26	1.62e-15	8.7e-13	-0.32	-0.36	Kawasaki disease;	chr14:106677179	chr14:106675017~106675544:-
PRAD	cis	rs853679	1	rs6905391	ENSG00000280107.1	AL022393.9	-8.26	1.63e-15	8.73e-13	-0.54	-0.36	Depression;	chr6:28294909	chr6:28170845~28172521:+
PRAD	cis	rs2274273	0.588	rs7158791	ENSG00000258413.1	RP11-665C16.6	-8.26	1.63e-15	8.73e-13	-0.49	-0.36	Protein biomarker;	chr14:55361889	chr14:55262767~55272075:-
PRAD	cis	rs2274273	0.588	rs11158037	ENSG00000258413.1	RP11-665C16.6	-8.26	1.63e-15	8.73e-13	-0.49	-0.36	Protein biomarker;	chr14:55365434	chr14:55262767~55272075:-
PRAD	cis	rs496547	0.719	rs598373	ENSG00000278376.1	RP11-158I9.8	-8.26	1.63e-15	8.73e-13	-0.33	-0.36	Hip minimal joint space width;	chr11:118793668	chr11:118791254~118793137:+
PRAD	cis	rs801193	0.66	rs1962050	ENSG00000237310.1	GS1-124K5.4	-8.26	1.63e-15	8.73e-13	-0.33	-0.36	Aortic root size;	chr7:66775021	chr7:66493706~66495474:+
PRAD	cis	rs1355223	0.902	rs1258464	ENSG00000271369.1	RP11-350D17.3	-8.26	1.64e-15	8.78e-13	-0.42	-0.36	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34709949	chr11:34709600~34710161:+
PRAD	cis	rs9532669	0.89	rs9532627	ENSG00000168852.11	TPTE2P5	8.26	1.64e-15	8.78e-13	0.34	0.36	Cervical cancer;	chr13:40874811	chr13:40822296~40921749:-
PRAD	cis	rs62388641	0.547	rs4513844	ENSG00000272279.1	RP11-157J24.2	-8.26	1.64e-15	8.79e-13	-0.46	-0.36	Daytime sleep phenotypes;	chr6:1551747	chr6:1528364~1528911:-
PRAD	cis	rs71403859	0.554	rs12373065	ENSG00000260886.1	TAT-AS1	8.26	1.64e-15	8.79e-13	0.67	0.36	Post bronchodilator FEV1;	chr16:71836129	chr16:71565789~71578187:+
PRAD	cis	rs6452524	0.967	rs62372752	ENSG00000249664.1	CTD-2227C6.2	8.26	1.64e-15	8.8e-13	0.42	0.36	Hypertension (SNP x SNP interaction);	chr5:83134239	chr5:83012285~83013109:-
PRAD	cis	rs375066	0.901	rs372491	ENSG00000267058.1	RP11-15A1.3	-8.26	1.64e-15	8.81e-13	-0.3	-0.36	Breast cancer;	chr19:43897641	chr19:43891804~43901805:-
PRAD	cis	rs375066	0.868	rs453950	ENSG00000267058.1	RP11-15A1.3	-8.26	1.64e-15	8.81e-13	-0.3	-0.36	Breast cancer;	chr19:43898903	chr19:43891804~43901805:-
PRAD	cis	rs375066	0.934	rs440784	ENSG00000267058.1	RP11-15A1.3	-8.26	1.64e-15	8.81e-13	-0.3	-0.36	Breast cancer;	chr19:43900190	chr19:43891804~43901805:-
PRAD	cis	rs375066	0.901	rs374307	ENSG00000267058.1	RP11-15A1.3	-8.26	1.64e-15	8.81e-13	-0.3	-0.36	Breast cancer;	chr19:43900246	chr19:43891804~43901805:-
PRAD	cis	rs375066	0.967	rs441344	ENSG00000267058.1	RP11-15A1.3	-8.26	1.64e-15	8.81e-13	-0.3	-0.36	Breast cancer;	chr19:43900530	chr19:43891804~43901805:-
PRAD	cis	rs375066	0.935	rs398099	ENSG00000267058.1	RP11-15A1.3	-8.26	1.64e-15	8.81e-13	-0.3	-0.36	Breast cancer;	chr19:43901129	chr19:43891804~43901805:-
PRAD	cis	rs375066	0.935	rs385321	ENSG00000267058.1	RP11-15A1.3	-8.26	1.64e-15	8.81e-13	-0.3	-0.36	Breast cancer;	chr19:43901135	chr19:43891804~43901805:-
PRAD	cis	rs375066	0.935	rs448823	ENSG00000267058.1	RP11-15A1.3	-8.26	1.64e-15	8.81e-13	-0.3	-0.36	Breast cancer;	chr19:43902139	chr19:43891804~43901805:-
PRAD	cis	rs375066	0.868	rs448829	ENSG00000267058.1	RP11-15A1.3	-8.26	1.64e-15	8.81e-13	-0.3	-0.36	Breast cancer;	chr19:43902169	chr19:43891804~43901805:-
PRAD	cis	rs375066	0.967	rs376328	ENSG00000267058.1	RP11-15A1.3	-8.26	1.64e-15	8.81e-13	-0.3	-0.36	Breast cancer;	chr19:43903335	chr19:43891804~43901805:-
PRAD	cis	rs375066	0.935	rs365556	ENSG00000267058.1	RP11-15A1.3	-8.26	1.64e-15	8.81e-13	-0.3	-0.36	Breast cancer;	chr19:43904047	chr19:43891804~43901805:-
PRAD	cis	rs375066	0.901	rs451945	ENSG00000267058.1	RP11-15A1.3	-8.26	1.64e-15	8.81e-13	-0.3	-0.36	Breast cancer;	chr19:43904601	chr19:43891804~43901805:-
PRAD	cis	rs375066	0.934	rs454813	ENSG00000267058.1	RP11-15A1.3	-8.26	1.64e-15	8.81e-13	-0.3	-0.36	Breast cancer;	chr19:43904821	chr19:43891804~43901805:-
PRAD	cis	rs375066	0.967	rs417400	ENSG00000267058.1	RP11-15A1.3	-8.26	1.64e-15	8.81e-13	-0.3	-0.36	Breast cancer;	chr19:43906694	chr19:43891804~43901805:-
PRAD	cis	rs375066	0.901	rs376457	ENSG00000267058.1	RP11-15A1.3	-8.26	1.64e-15	8.81e-13	-0.3	-0.36	Breast cancer;	chr19:43908605	chr19:43891804~43901805:-
PRAD	cis	rs375066	0.935	rs430667	ENSG00000267058.1	RP11-15A1.3	-8.26	1.64e-15	8.81e-13	-0.3	-0.36	Breast cancer;	chr19:43909101	chr19:43891804~43901805:-
PRAD	cis	rs375066	0.935	rs398964	ENSG00000267058.1	RP11-15A1.3	-8.26	1.64e-15	8.81e-13	-0.3	-0.36	Breast cancer;	chr19:43909732	chr19:43891804~43901805:-
PRAD	cis	rs375066	0.935	rs439665	ENSG00000267058.1	RP11-15A1.3	-8.26	1.64e-15	8.81e-13	-0.3	-0.36	Breast cancer;	chr19:43910315	chr19:43891804~43901805:-
PRAD	cis	rs7615952	0.599	rs6766327	ENSG00000171084.14	FAM86JP	8.26	1.64e-15	8.81e-13	0.57	0.36	Blood pressure (smoking interaction);	chr3:126004834	chr3:125916620~125930024:+
PRAD	cis	rs12908161	0.959	rs17534709	ENSG00000259728.4	LINC00933	8.26	1.65e-15	8.82e-13	0.45	0.36	Schizophrenia;	chr15:84771166	chr15:84570649~84580175:+
PRAD	cis	rs7712401	0.502	rs30066	ENSG00000263432.2	RN7SL689P	8.26	1.65e-15	8.85e-13	0.39	0.36	Mean platelet volume;	chr5:122958007	chr5:123022487~123022783:-
PRAD	cis	rs2153535	0.518	rs9328473	ENSG00000230939.1	RP11-314C16.1	-8.26	1.65e-15	8.85e-13	-0.44	-0.36	Motion sickness;	chr6:8487092	chr6:8784178~8785445:+
PRAD	cis	rs193541	0.632	rs7735618	ENSG00000263432.2	RN7SL689P	8.26	1.66e-15	8.87e-13	0.39	0.36	Glucose homeostasis traits;	chr5:122840550	chr5:123022487~123022783:-
PRAD	cis	rs375066	0.935	rs384522	ENSG00000267058.1	RP11-15A1.3	-8.26	1.66e-15	8.88e-13	-0.3	-0.36	Breast cancer;	chr19:43900892	chr19:43891804~43901805:-
PRAD	cis	rs6539288	0.901	rs4964506	ENSG00000260329.1	RP11-412D9.4	-8.26	1.66e-15	8.89e-13	-0.32	-0.36	Total body bone mineral density;	chr12:106953307	chr12:106954029~106955497:-
PRAD	cis	rs6539288	0.901	rs4964507	ENSG00000260329.1	RP11-412D9.4	-8.26	1.66e-15	8.89e-13	-0.32	-0.36	Total body bone mineral density;	chr12:106954979	chr12:106954029~106955497:-
PRAD	cis	rs6539288	0.835	rs2041893	ENSG00000260329.1	RP11-412D9.4	-8.26	1.66e-15	8.89e-13	-0.32	-0.36	Total body bone mineral density;	chr12:106956598	chr12:106954029~106955497:-
PRAD	cis	rs736801	0.704	rs56399423	ENSG00000233006.5	AC034220.3	8.25	1.66e-15	8.91e-13	0.33	0.36	Mosquito bite size;Breast cancer;	chr5:132336964	chr5:132311285~132369916:-
PRAD	cis	rs42648	0.693	rs2106274	ENSG00000227646.6	STEAP2-AS1	-8.25	1.67e-15	8.93e-13	-0.33	-0.36	Homocysteine levels;	chr7:90251234	chr7:89882353~90211635:-
PRAD	cis	rs950169	0.58	rs4603535	ENSG00000259728.4	LINC00933	8.25	1.67e-15	8.94e-13	0.43	0.36	Schizophrenia;	chr15:84630641	chr15:84570649~84580175:+
PRAD	cis	rs950169	0.541	rs10795	ENSG00000259728.4	LINC00933	8.25	1.67e-15	8.94e-13	0.43	0.36	Schizophrenia;	chr15:84634066	chr15:84570649~84580175:+
PRAD	cis	rs950169	0.58	rs36126054	ENSG00000259728.4	LINC00933	8.25	1.67e-15	8.94e-13	0.43	0.36	Schizophrenia;	chr15:84634492	chr15:84570649~84580175:+
PRAD	cis	rs950169	0.58	rs1061737	ENSG00000259728.4	LINC00933	8.25	1.67e-15	8.94e-13	0.43	0.36	Schizophrenia;	chr15:84640559	chr15:84570649~84580175:+
PRAD	cis	rs2946504	0.628	rs2946510	ENSG00000251468.2	RP11-369K16.1	-8.25	1.68e-15	8.98e-13	-0.43	-0.36	Type 2 diabetes;	chr8:12950371	chr8:12958387~12962200:+
PRAD	cis	rs8005677	1	rs4982712	ENSG00000257285.4	RP11-298I3.1	8.25	1.68e-15	9e-13	0.36	0.36	Cognitive ability (multi-trait analysis);	chr14:22934519	chr14:22929609~22955562:+
PRAD	cis	rs4660456	0.504	rs542214	ENSG00000237899.1	RP4-739H11.3	8.25	1.68e-15	9.02e-13	0.51	0.36	Platelet count;	chr1:40632806	chr1:40669089~40687588:-
PRAD	cis	rs4927850	0.752	rs7624460	ENSG00000207650.1	MIR570	8.25	1.69e-15	9.02e-13	0.38	0.36	Pancreatic cancer;	chr3:196021659	chr3:195699401~195699497:+
PRAD	cis	rs10463554	0.927	rs34795	ENSG00000175749.11	EIF3KP1	8.25	1.69e-15	9.04e-13	0.5	0.36	Parkinson's disease;	chr5:103088716	chr5:103032376~103033031:+
PRAD	cis	rs10463554	0.927	rs34796	ENSG00000175749.11	EIF3KP1	8.25	1.69e-15	9.04e-13	0.5	0.36	Parkinson's disease;	chr5:103088725	chr5:103032376~103033031:+
PRAD	cis	rs4835473	0.932	rs11721523	ENSG00000251600.4	RP11-673E1.1	-8.25	1.69e-15	9.05e-13	-0.46	-0.36	Immature fraction of reticulocytes;	chr4:143767301	chr4:143912331~143982454:+
PRAD	cis	rs4713118	0.669	rs200997	ENSG00000280107.1	AL022393.9	-8.25	1.69e-15	9.06e-13	-0.44	-0.36	Parkinson's disease;	chr6:27844037	chr6:28170845~28172521:+
PRAD	cis	rs2337406	0.714	rs7145254	ENSG00000274576.2	IGHV2-70	-8.25	1.69e-15	9.07e-13	-0.38	-0.36	Alzheimer's disease (late onset);	chr14:106817783	chr14:106770577~106771020:-
PRAD	cis	rs10181042	0.581	rs1177285	ENSG00000271889.1	RP11-493E12.1	8.25	1.7e-15	9.08e-13	0.41	0.36	Crohn's disease;	chr2:61123002	chr2:61151433~61162105:-
PRAD	cis	rs7567389	0.504	rs1568278	ENSG00000236682.1	AC068282.3	-8.25	1.7e-15	9.08e-13	-0.48	-0.36	Self-rated health;	chr2:127432619	chr2:127389130~127400580:+
PRAD	cis	rs12142240	0.698	rs17361763	ENSG00000232022.5	FAAHP1	-8.25	1.7e-15	9.08e-13	-0.33	-0.36	Menopause (age at onset);	chr1:46344998	chr1:46432129~46445521:+
PRAD	cis	rs7131987	0.621	rs11050181	ENSG00000257176.2	RP11-996F15.2	-8.25	1.7e-15	9.08e-13	-0.39	-0.36	QT interval;	chr12:29314736	chr12:29280418~29317848:-
PRAD	cis	rs7923609	0.934	rs7923544	ENSG00000232075.1	MRPL35P2	-8.25	1.7e-15	9.08e-13	-0.38	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63422496	chr10:63634317~63634827:-
PRAD	cis	rs7238033	0.624	rs17674709	ENSG00000267193.4	RP11-116O18.3	8.25	1.7e-15	9.09e-13	0.39	0.36	Bladder cancer;	chr18:45731415	chr18:45669367~45747215:-
PRAD	cis	rs7238033	0.602	rs10460034	ENSG00000267193.4	RP11-116O18.3	8.25	1.7e-15	9.09e-13	0.39	0.36	Bladder cancer;	chr18:45731434	chr18:45669367~45747215:-
PRAD	cis	rs7238033	0.624	rs8099449	ENSG00000267193.4	RP11-116O18.3	8.25	1.7e-15	9.09e-13	0.39	0.36	Bladder cancer;	chr18:45731731	chr18:45669367~45747215:-
PRAD	cis	rs2283792	0.646	rs9610317	ENSG00000224086.5	LL22NC03-86G7.1	-8.25	1.71e-15	9.13e-13	-0.45	-0.36	Multiple sclerosis;	chr22:21785601	chr22:21938293~21977632:+
PRAD	cis	rs7746199	0.736	rs13209332	ENSG00000280107.1	AL022393.9	-8.25	1.71e-15	9.14e-13	-0.73	-0.36	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27552973	chr6:28170845~28172521:+
PRAD	cis	rs7746199	0.736	rs10484399	ENSG00000280107.1	AL022393.9	-8.25	1.71e-15	9.14e-13	-0.73	-0.36	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27566749	chr6:28170845~28172521:+
PRAD	cis	rs7746199	0.736	rs34105070	ENSG00000280107.1	AL022393.9	-8.25	1.71e-15	9.14e-13	-0.73	-0.36	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27593026	chr6:28170845~28172521:+
PRAD	cis	rs7746199	0.673	rs72845046	ENSG00000280107.1	AL022393.9	-8.25	1.71e-15	9.14e-13	-0.73	-0.36	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27607489	chr6:28170845~28172521:+
PRAD	cis	rs7746199	0.736	rs67652222	ENSG00000280107.1	AL022393.9	-8.25	1.71e-15	9.14e-13	-0.73	-0.36	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27618441	chr6:28170845~28172521:+
PRAD	cis	rs7746199	0.736	rs34038546	ENSG00000280107.1	AL022393.9	-8.25	1.71e-15	9.14e-13	-0.73	-0.36	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27639881	chr6:28170845~28172521:+
PRAD	cis	rs141342723	1	rs141342723	ENSG00000280107.1	AL022393.9	-8.25	1.71e-15	9.14e-13	-0.73	-0.36	Autism spectrum disorder or schizophrenia;	chr6:27654305	chr6:28170845~28172521:+
PRAD	cis	rs7746199	0.736	rs34543938	ENSG00000280107.1	AL022393.9	-8.25	1.71e-15	9.14e-13	-0.73	-0.36	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27656861	chr6:28170845~28172521:+
PRAD	cis	rs45509595	0.556	rs34409918	ENSG00000280107.1	AL022393.9	-8.25	1.71e-15	9.14e-13	-0.73	-0.36	Breast cancer;	chr6:27717569	chr6:28170845~28172521:+
PRAD	cis	rs7746199	0.736	rs13212318	ENSG00000280107.1	AL022393.9	-8.25	1.71e-15	9.14e-13	-0.73	-0.36	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27721062	chr6:28170845~28172521:+
PRAD	cis	rs2404602	0.692	rs8037005	ENSG00000259422.1	RP11-593F23.1	8.25	1.72e-15	9.19e-13	0.45	0.36	Blood metabolite levels;	chr15:76658768	chr15:76174891~76181486:-
PRAD	cis	rs6142102	0.59	rs6059691	ENSG00000276073.1	RP5-1125A11.7	8.25	1.73e-15	9.24e-13	0.36	0.36	Skin pigmentation;	chr20:34149161	chr20:33985617~33988989:-
PRAD	cis	rs9341835	0.709	rs4358600	ENSG00000218048.2	RP3-407E4.4	8.25	1.73e-15	9.25e-13	0.4	0.36	Schizophrenia;	chr6:63443314	chr6:63440766~63443580:+
PRAD	cis	rs240993	0.909	rs240991	ENSG00000230177.1	RP5-1112D6.4	-8.25	1.75e-15	9.32e-13	-0.43	-0.36	Inflammatory skin disease;Psoriasis;	chr6:111346971	chr6:111277932~111278742:+
PRAD	cis	rs2745572	0.557	rs2745569	ENSG00000272279.1	RP11-157J24.2	-8.25	1.75e-15	9.34e-13	-0.46	-0.36	Intraocular pressure;Glaucoma (primary open-angle);Glaucoma (high intraocular pressure);	chr6:1547396	chr6:1528364~1528911:-
PRAD	cis	rs10463554	0.963	rs257115	ENSG00000175749.11	EIF3KP1	8.25	1.76e-15	9.37e-13	0.47	0.36	Parkinson's disease;	chr5:103196107	chr5:103032376~103033031:+
PRAD	cis	rs6001482	0.573	rs4990163	ENSG00000272779.1	LL22NC03-80A10.6	-8.25	1.76e-15	9.38e-13	-0.43	-0.36	Diastolic blood pressure;	chr22:22233778	chr22:22303224~22310401:+
PRAD	cis	rs6723108	0.559	rs1942051	ENSG00000224043.6	CCNT2-AS1	-8.25	1.76e-15	9.4e-13	-0.51	-0.36	Type 2 diabetes;	chr2:134846120	chr2:134735464~134918710:-
PRAD	cis	rs6723108	0.627	rs10928519	ENSG00000224043.6	CCNT2-AS1	-8.25	1.76e-15	9.4e-13	-0.51	-0.36	Type 2 diabetes;	chr2:134846389	chr2:134735464~134918710:-
PRAD	cis	rs4631830	0.863	rs2843550	ENSG00000230869.1	CTGLF10P	-8.25	1.76e-15	9.41e-13	-0.45	-0.36	Prostate-specific antigen levels;	chr10:46074370	chr10:45678692~45700532:+
PRAD	cis	rs17012589	0.639	rs1512732	ENSG00000258815.1	RP11-408B11.2	-8.25	1.77e-15	9.43e-13	-0.5	-0.36	Bone mineral density (Ward's triangle area);	chr12:85295173	chr12:85318060~85342912:+
PRAD	cis	rs7923609	0.841	rs7920036	ENSG00000232075.1	MRPL35P2	-8.25	1.77e-15	9.44e-13	-0.38	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63534100	chr10:63634317~63634827:-
PRAD	cis	rs964611	0.938	rs8039653	ENSG00000259488.2	RP11-154J22.1	-8.25	1.77e-15	9.45e-13	-0.35	-0.36	Metabolite levels (Pyroglutamine);	chr15:48280438	chr15:48312353~48331856:-
PRAD	cis	rs7746199	0.736	rs56405707	ENSG00000280107.1	AL022393.9	-8.25	1.77e-15	9.45e-13	-0.73	-0.36	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27672467	chr6:28170845~28172521:+
PRAD	cis	rs7746199	0.736	rs13210634	ENSG00000280107.1	AL022393.9	-8.25	1.77e-15	9.45e-13	-0.73	-0.36	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27678713	chr6:28170845~28172521:+
PRAD	cis	rs7746199	0.736	rs13215275	ENSG00000280107.1	AL022393.9	-8.25	1.77e-15	9.45e-13	-0.73	-0.36	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27679730	chr6:28170845~28172521:+
PRAD	cis	rs7746199	0.736	rs17749927	ENSG00000280107.1	AL022393.9	-8.25	1.77e-15	9.45e-13	-0.73	-0.36	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27702197	chr6:28170845~28172521:+
PRAD	cis	rs7746199	0.736	rs13192965	ENSG00000280107.1	AL022393.9	-8.25	1.77e-15	9.45e-13	-0.73	-0.36	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27704046	chr6:28170845~28172521:+
PRAD	cis	rs4631830	0.863	rs2843549	ENSG00000230869.1	CTGLF10P	-8.25	1.77e-15	9.45e-13	-0.45	-0.36	Prostate-specific antigen levels;	chr10:46074575	chr10:45678692~45700532:+
PRAD	cis	rs7923609	0.902	rs7897379	ENSG00000232075.1	MRPL35P2	-8.25	1.78e-15	9.48e-13	-0.38	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63541965	chr10:63634317~63634827:-
PRAD	cis	rs763567	0.933	rs531007	ENSG00000271811.1	RP1-79C4.4	8.25	1.78e-15	9.48e-13	0.41	0.36	Tonsillectomy;	chr1:170649241	chr1:170667381~170669425:+
PRAD	cis	rs6921919	0.789	rs6456814	ENSG00000216901.1	AL022393.7	8.25	1.78e-15	9.49e-13	0.5	0.36	Autism spectrum disorder or schizophrenia;	chr6:28338035	chr6:28176188~28176674:+
PRAD	cis	rs10463554	0.927	rs468844	ENSG00000175749.11	EIF3KP1	8.25	1.78e-15	9.51e-13	0.5	0.36	Parkinson's disease;	chr5:103087872	chr5:103032376~103033031:+
PRAD	cis	rs10463554	0.927	rs469094	ENSG00000175749.11	EIF3KP1	8.25	1.78e-15	9.51e-13	0.5	0.36	Parkinson's disease;	chr5:103087875	chr5:103032376~103033031:+
PRAD	cis	rs2404602	0.716	rs2404737	ENSG00000259422.1	RP11-593F23.1	8.25	1.78e-15	9.52e-13	0.45	0.36	Blood metabolite levels;	chr15:76579876	chr15:76174891~76181486:-
PRAD	cis	rs9368481	0.645	rs10456350	ENSG00000241549.7	GUSBP2	8.24	1.79e-15	9.54e-13	0.41	0.36	Autism spectrum disorder or schizophrenia;	chr6:27007802	chr6:26871484~26956554:-
PRAD	cis	rs75422866	0.764	rs67201012	ENSG00000257433.4	RP1-197B17.3	8.24	1.8e-15	9.58e-13	0.78	0.36	Pneumonia;	chr12:47715881	chr12:47706085~47742294:+
PRAD	cis	rs7115242	0.567	rs10047462	ENSG00000254851.1	RP11-109L13.1	-8.24	1.8e-15	9.59e-13	-0.79	-0.36	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116851325	chr11:117135528~117138582:+
PRAD	cis	rs4835473	0.9	rs13137885	ENSG00000251600.4	RP11-673E1.1	-8.24	1.8e-15	9.6e-13	-0.46	-0.36	Immature fraction of reticulocytes;	chr4:143734212	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.9	rs13105550	ENSG00000251600.4	RP11-673E1.1	-8.24	1.8e-15	9.6e-13	-0.46	-0.36	Immature fraction of reticulocytes;	chr4:143734220	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.9	rs13105571	ENSG00000251600.4	RP11-673E1.1	-8.24	1.8e-15	9.6e-13	-0.46	-0.36	Immature fraction of reticulocytes;	chr4:143734241	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.9	rs36083417	ENSG00000251600.4	RP11-673E1.1	-8.24	1.8e-15	9.6e-13	-0.46	-0.36	Immature fraction of reticulocytes;	chr4:143734253	chr4:143912331~143982454:+
PRAD	cis	rs6570726	1	rs374464	ENSG00000235652.6	RP11-545I5.3	8.24	1.81e-15	9.63e-13	0.37	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145525543	chr6:145799409~145886585:+
PRAD	cis	rs6570726	1	rs450076	ENSG00000235652.6	RP11-545I5.3	8.24	1.81e-15	9.63e-13	0.37	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145526519	chr6:145799409~145886585:+
PRAD	cis	rs2522056	1	rs11242113	ENSG00000233006.5	AC034220.3	-8.24	1.81e-15	9.63e-13	-0.35	-0.36	Fibrinogen;Lymphocyte counts;	chr5:132441542	chr5:132311285~132369916:-
PRAD	cis	rs9287719	0.967	rs6748036	ENSG00000234818.1	AC092687.5	8.24	1.81e-15	9.64e-13	0.43	0.36	Prostate cancer;	chr2:10577363	chr2:10589166~10604830:+
PRAD	cis	rs6847067	0.794	rs10856852	ENSG00000180769.7	WDFY3-AS2	8.24	1.81e-15	9.65e-13	0.38	0.36	Oropharynx cancer;	chr4:84976382	chr4:84965682~85011277:+
PRAD	cis	rs2243480	1	rs313813	ENSG00000226824.5	RP4-756H11.3	-8.24	1.82e-15	9.71e-13	-0.7	-0.36	Diabetic kidney disease;	chr7:66038513	chr7:66654538~66669855:+
PRAD	cis	rs4631830	0.863	rs4486572	ENSG00000230869.1	CTGLF10P	-8.24	1.82e-15	9.72e-13	-0.45	-0.36	Prostate-specific antigen levels;	chr10:46064017	chr10:45678692~45700532:+
PRAD	cis	rs7432375	0.901	rs7648531	ENSG00000261758.1	RP11-102M11.2	-8.24	1.82e-15	9.72e-13	-0.41	-0.36	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136743381	chr3:136752630~136755780:+
PRAD	cis	rs12908161	1	rs60957376	ENSG00000259728.4	LINC00933	8.24	1.82e-15	9.72e-13	0.44	0.36	Schizophrenia;	chr15:84737561	chr15:84570649~84580175:+
PRAD	cis	rs3096299	0.746	rs9931120	ENSG00000261118.1	RP11-104N10.1	8.24	1.83e-15	9.74e-13	0.35	0.36	Multiple myeloma (IgH translocation);	chr16:89434949	chr16:89492017~89504460:-
PRAD	cis	rs6847067	0.8	rs4624645	ENSG00000180769.7	WDFY3-AS2	8.24	1.83e-15	9.76e-13	0.38	0.36	Oropharynx cancer;	chr4:84963222	chr4:84965682~85011277:+
PRAD	cis	rs2745572	0.538	rs4587210	ENSG00000272279.1	RP11-157J24.2	8.24	1.83e-15	9.77e-13	0.46	0.36	Intraocular pressure;Glaucoma (primary open-angle);Glaucoma (high intraocular pressure);	chr6:1542956	chr6:1528364~1528911:-
PRAD	cis	rs67311347	0.955	rs1129200	ENSG00000223797.4	ENTPD3-AS1	8.24	1.84e-15	9.78e-13	0.33	0.36	Renal cell carcinoma;	chr3:40490766	chr3:40313802~40453329:-
PRAD	cis	rs748404	0.587	rs9920879	ENSG00000249839.1	AC011330.5	-8.24	1.84e-15	9.81e-13	-0.44	-0.36	Lung cancer;	chr15:43347572	chr15:43663654~43684339:-
PRAD	cis	rs748404	0.631	rs7166812	ENSG00000249839.1	AC011330.5	-8.24	1.84e-15	9.81e-13	-0.44	-0.36	Lung cancer;	chr15:43352562	chr15:43663654~43684339:-
PRAD	cis	rs748404	0.631	rs1133395	ENSG00000249839.1	AC011330.5	-8.24	1.84e-15	9.81e-13	-0.44	-0.36	Lung cancer;	chr15:43358186	chr15:43663654~43684339:-
PRAD	cis	rs11098499	0.866	rs3756156	ENSG00000245958.5	RP11-33B1.1	-8.24	1.85e-15	9.84e-13	-0.36	-0.36	Corneal astigmatism;	chr4:119603686	chr4:119454791~119552025:+
PRAD	cis	rs67311347	1	rs6762251	ENSG00000223797.4	ENTPD3-AS1	-8.24	1.85e-15	9.85e-13	-0.32	-0.36	Renal cell carcinoma;	chr3:40489645	chr3:40313802~40453329:-
PRAD	cis	rs6452524	0.967	rs1031901	ENSG00000249664.1	CTD-2227C6.2	8.24	1.85e-15	9.86e-13	0.43	0.36	Hypertension (SNP x SNP interaction);	chr5:83147904	chr5:83012285~83013109:-
PRAD	cis	rs2933343	0.7	rs6787833	ENSG00000231305.3	RP11-723O4.2	8.24	1.85e-15	9.87e-13	0.34	0.36	IgG glycosylation;	chr3:128937341	chr3:128861313~128871540:-
PRAD	cis	rs9368481	0.761	rs3931464	ENSG00000241549.7	GUSBP2	8.24	1.86e-15	9.88e-13	0.41	0.36	Autism spectrum disorder or schizophrenia;	chr6:26972077	chr6:26871484~26956554:-
PRAD	cis	rs193541	0.632	rs246276	ENSG00000263432.2	RN7SL689P	8.24	1.86e-15	9.88e-13	0.39	0.36	Glucose homeostasis traits;	chr5:122904262	chr5:123022487~123022783:-
PRAD	cis	rs4631830	0.733	rs4512771	ENSG00000230869.1	CTGLF10P	-8.24	1.86e-15	9.89e-13	-0.45	-0.36	Prostate-specific antigen levels;	chr10:46054916	chr10:45678692~45700532:+
PRAD	cis	rs11096990	0.634	rs4975001	ENSG00000249207.1	RP11-360F5.1	8.24	1.86e-15	9.9e-13	0.37	0.36	Cognitive function;	chr4:39264844	chr4:39112677~39126818:-
PRAD	cis	rs7238033	0.581	rs7229753	ENSG00000267193.4	RP11-116O18.3	8.24	1.86e-15	9.91e-13	0.39	0.36	Bladder cancer;	chr18:45732495	chr18:45669367~45747215:-
PRAD	cis	rs6452524	0.901	rs1039786	ENSG00000249664.1	CTD-2227C6.2	8.24	1.87e-15	9.94e-13	0.42	0.36	Hypertension (SNP x SNP interaction);	chr5:83204222	chr5:83012285~83013109:-
PRAD	cis	rs9368481	0.761	rs9348746	ENSG00000241549.7	GUSBP2	-8.24	1.87e-15	9.94e-13	-0.4	-0.36	Autism spectrum disorder or schizophrenia;	chr6:27002578	chr6:26871484~26956554:-
PRAD	cis	rs853679	0.55	rs1150692	ENSG00000272009.1	RP1-313I6.12	-8.24	1.87e-15	9.96e-13	-0.36	-0.36	Depression;	chr6:28206179	chr6:28078792~28081130:-
PRAD	cis	rs950169	0.922	rs12912934	ENSG00000259728.4	LINC00933	8.24	1.88e-15	9.98e-13	0.44	0.36	Schizophrenia;	chr15:84571216	chr15:84570649~84580175:+
PRAD	cis	rs9532669	0.926	rs6560963	ENSG00000168852.11	TPTE2P5	8.24	1.88e-15	9.98e-13	0.35	0.36	Cervical cancer;	chr13:40871126	chr13:40822296~40921749:-
PRAD	cis	rs2015599	0.623	rs3782505	ENSG00000275476.1	RP11-996F15.4	8.24	1.88e-15	9.99e-13	0.39	0.36	Platelet count;Mean platelet volume;	chr12:29292236	chr12:29277397~29277882:-
PRAD	cis	rs2404602	0.669	rs8036703	ENSG00000259422.1	RP11-593F23.1	8.24	1.88e-15	9.99e-13	0.45	0.36	Blood metabolite levels;	chr15:76658699	chr15:76174891~76181486:-
PRAD	cis	rs9309473	0.583	rs6709853	ENSG00000163016.8	ALMS1P	8.24	1.88e-15	9.99e-13	0.43	0.36	Metabolite levels;	chr2:73348937	chr2:73644919~73685576:+
PRAD	cis	rs7923609	0.74	rs10761784	ENSG00000232075.1	MRPL35P2	-8.24	1.88e-15	1e-12	-0.38	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63548990	chr10:63634317~63634827:-
PRAD	cis	rs9532669	0.926	rs2324742	ENSG00000168852.11	TPTE2P5	8.24	1.88e-15	1e-12	0.35	0.36	Cervical cancer;	chr13:40919059	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.857	rs9594455	ENSG00000168852.11	TPTE2P5	8.24	1.88e-15	1e-12	0.35	0.36	Cervical cancer;	chr13:40919452	chr13:40822296~40921749:-
PRAD	cis	rs950169	0.92	rs11637666	ENSG00000225151.9	GOLGA2P7	-8.24	1.88e-15	1e-12	-0.53	-0.36	Schizophrenia;	chr15:84035122	chr15:84199311~84230136:-
PRAD	cis	rs2108622	0.683	rs56228205	ENSG00000267056.2	AC005336.4	8.24	1.88e-15	1e-12	0.49	0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871163	chr19:15910582~15911824:-
PRAD	cis	rs56114371	0.568	rs200468	ENSG00000280107.1	AL022393.9	-8.24	1.89e-15	1e-12	-0.49	-0.36	Breast cancer;	chr6:27790076	chr6:28170845~28172521:+
PRAD	cis	rs4835473	0.932	rs5016159	ENSG00000251600.4	RP11-673E1.1	8.24	1.89e-15	1e-12	0.46	0.36	Immature fraction of reticulocytes;	chr4:143738362	chr4:143912331~143982454:+
PRAD	cis	rs11976180	1	rs2961144	ENSG00000170356.8	OR2A20P	8.24	1.89e-15	1e-12	0.48	0.36	Obesity-related traits;	chr7:144050777	chr7:144250045~144252957:-
PRAD	cis	rs763567	0.935	rs1234275	ENSG00000271811.1	RP1-79C4.4	-8.24	1.89e-15	1e-12	-0.42	-0.36	Tonsillectomy;	chr1:170627117	chr1:170667381~170669425:+
PRAD	cis	rs1150668	0.764	rs9368565	ENSG00000280107.1	AL022393.9	8.24	1.89e-15	1e-12	0.44	0.36	Pubertal anthropometrics;	chr6:28377433	chr6:28170845~28172521:+
PRAD	cis	rs1150668	0.796	rs1052215	ENSG00000280107.1	AL022393.9	8.24	1.89e-15	1e-12	0.44	0.36	Pubertal anthropometrics;	chr6:28380381	chr6:28170845~28172521:+
PRAD	cis	rs11676348	0.712	rs12694426	ENSG00000261338.2	RP11-378A13.1	-8.24	1.89e-15	1.01e-12	-0.39	-0.36	Ulcerative colitis;	chr2:218077628	chr2:218255319~218257366:+
PRAD	cis	rs9309473	0.607	rs2421488	ENSG00000163016.8	ALMS1P	8.24	1.89e-15	1.01e-12	0.43	0.36	Metabolite levels;	chr2:73363497	chr2:73644919~73685576:+
PRAD	cis	rs9287719	0.967	rs4669593	ENSG00000234818.1	AC092687.5	8.24	1.9e-15	1.01e-12	0.43	0.36	Prostate cancer;	chr2:10561782	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs3814388	ENSG00000234818.1	AC092687.5	8.24	1.9e-15	1.01e-12	0.43	0.36	Prostate cancer;	chr2:10561973	chr2:10589166~10604830:+
PRAD	cis	rs914615	0.552	rs4460629	ENSG00000160766.13	GBAP1	-8.24	1.9e-15	1.01e-12	-0.37	-0.36	Urinary albumin-to-creatinine ratio;	chr1:155162859	chr1:155213821~155227422:-
PRAD	cis	rs2933343	0.621	rs4927921	ENSG00000231305.3	RP11-723O4.2	-8.24	1.9e-15	1.01e-12	-0.34	-0.36	IgG glycosylation;	chr3:128850025	chr3:128861313~128871540:-
PRAD	cis	rs8081395	0.801	rs2645479	ENSG00000266992.1	DHX40P1	8.24	1.91e-15	1.01e-12	0.4	0.36	White blood cell count;	chr17:59843171	chr17:59976009~60002384:-
PRAD	cis	rs7598759	0.679	rs10202701	ENSG00000181798.2	LINC00471	8.24	1.91e-15	1.01e-12	0.43	0.36	Noise-induced hearing loss;	chr2:231463970	chr2:231508426~231514339:-
PRAD	cis	rs8005677	1	rs4982709	ENSG00000257285.4	RP11-298I3.1	8.24	1.91e-15	1.02e-12	0.36	0.36	Cognitive ability (multi-trait analysis);	chr14:22925490	chr14:22929609~22955562:+
PRAD	cis	rs7238033	0.624	rs9946832	ENSG00000267193.4	RP11-116O18.3	8.24	1.91e-15	1.02e-12	0.39	0.36	Bladder cancer;	chr18:45732825	chr18:45669367~45747215:-
PRAD	cis	rs7238033	0.624	rs9946998	ENSG00000267193.4	RP11-116O18.3	8.24	1.91e-15	1.02e-12	0.39	0.36	Bladder cancer;	chr18:45732857	chr18:45669367~45747215:-
PRAD	cis	rs7238033	0.624	rs9949609	ENSG00000267193.4	RP11-116O18.3	8.24	1.91e-15	1.02e-12	0.39	0.36	Bladder cancer;	chr18:45733163	chr18:45669367~45747215:-
PRAD	cis	rs7238033	0.624	rs8096571	ENSG00000267193.4	RP11-116O18.3	8.24	1.91e-15	1.02e-12	0.39	0.36	Bladder cancer;	chr18:45734508	chr18:45669367~45747215:-
PRAD	cis	rs7829975	0.688	rs6601703	ENSG00000253893.2	FAM85B	-8.23	1.93e-15	1.02e-12	-0.42	-0.36	Mood instability;	chr8:8522714	chr8:8167819~8226614:-
PRAD	cis	rs10129255	0.5	rs4774008	ENSG00000211972.2	IGHV3-66	8.23	1.93e-15	1.03e-12	0.32	0.36	Kawasaki disease;	chr14:106681273	chr14:106675017~106675544:-
PRAD	cis	rs10129255	0.5	rs9324092	ENSG00000211972.2	IGHV3-66	-8.23	1.93e-15	1.03e-12	-0.32	-0.36	Kawasaki disease;	chr14:106683806	chr14:106675017~106675544:-
PRAD	cis	rs6921919	0.609	rs36018474	ENSG00000216901.1	AL022393.7	8.23	1.93e-15	1.03e-12	0.46	0.36	Autism spectrum disorder or schizophrenia;	chr6:28417752	chr6:28176188~28176674:+
PRAD	cis	rs6921919	0.583	rs13201726	ENSG00000216901.1	AL022393.7	8.23	1.93e-15	1.03e-12	0.46	0.36	Autism spectrum disorder or schizophrenia;	chr6:28417774	chr6:28176188~28176674:+
PRAD	cis	rs2581828	0.608	rs9830353	ENSG00000242142.1	SERBP1P3	-8.23	1.94e-15	1.03e-12	-0.43	-0.36	Crohn's disease;	chr3:53129937	chr3:53064283~53065091:-
PRAD	cis	rs10875746	0.669	rs10875772	ENSG00000240399.1	RP1-228P16.1	-8.23	1.94e-15	1.03e-12	-0.35	-0.36	Longevity (90 years and older);	chr12:48215770	chr12:48054813~48055591:-
PRAD	cis	rs4631830	0.832	rs2611513	ENSG00000230869.1	CTGLF10P	8.23	1.95e-15	1.04e-12	0.44	0.36	Prostate-specific antigen levels;	chr10:46080365	chr10:45678692~45700532:+
PRAD	cis	rs150992	0.505	rs167798	ENSG00000248489.1	CTD-2007H13.3	8.23	1.95e-15	1.04e-12	0.46	0.36	Body mass index;	chr5:98972150	chr5:98929171~98995013:+
PRAD	cis	rs9326248	0.559	rs12808524	ENSG00000280143.1	AP000892.6	8.23	1.96e-15	1.04e-12	0.27	0.36	Blood protein levels;	chr11:117020277	chr11:117204967~117210292:+
PRAD	cis	rs193541	0.632	rs6878609	ENSG00000263432.2	RN7SL689P	8.23	1.96e-15	1.04e-12	0.39	0.36	Glucose homeostasis traits;	chr5:122759854	chr5:123022487~123022783:-
PRAD	cis	rs7432375	0.933	rs6791142	ENSG00000261758.1	RP11-102M11.2	8.23	1.96e-15	1.04e-12	0.41	0.36	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136658535	chr3:136752630~136755780:+
PRAD	cis	rs10463554	0.892	rs34830	ENSG00000175749.11	EIF3KP1	8.23	1.96e-15	1.04e-12	0.49	0.36	Parkinson's disease;	chr5:103108349	chr5:103032376~103033031:+
PRAD	cis	rs10463554	0.963	rs257319	ENSG00000175749.11	EIF3KP1	8.23	1.96e-15	1.04e-12	0.49	0.36	Parkinson's disease;	chr5:103110123	chr5:103032376~103033031:+
PRAD	cis	rs10463554	0.927	rs39666	ENSG00000175749.11	EIF3KP1	8.23	1.96e-15	1.04e-12	0.49	0.36	Parkinson's disease;	chr5:103111423	chr5:103032376~103033031:+
PRAD	cis	rs10463554	0.927	rs34769	ENSG00000175749.11	EIF3KP1	8.23	1.96e-15	1.04e-12	0.49	0.36	Parkinson's disease;	chr5:103111523	chr5:103032376~103033031:+
PRAD	cis	rs10463554	0.892	rs464591	ENSG00000175749.11	EIF3KP1	8.23	1.96e-15	1.04e-12	0.49	0.36	Parkinson's disease;	chr5:103111600	chr5:103032376~103033031:+
PRAD	cis	rs10463554	0.963	rs34772	ENSG00000175749.11	EIF3KP1	8.23	1.96e-15	1.04e-12	0.49	0.36	Parkinson's disease;	chr5:103114808	chr5:103032376~103033031:+
PRAD	cis	rs17711722	0.528	rs73138179	ENSG00000236529.1	RP13-254B10.1	8.23	1.96e-15	1.04e-12	0.39	0.36	Calcium levels;	chr7:65829495	chr7:65840212~65840596:+
PRAD	cis	rs5769707	0.554	rs10854876	ENSG00000188511.11	C22orf34	8.23	1.97e-15	1.04e-12	0.42	0.36	Monocyte percentage of white cells;Monocyte count;	chr22:49616922	chr22:49414524~49657542:-
PRAD	cis	rs11098499	0.82	rs28394116	ENSG00000245958.5	RP11-33B1.1	-8.23	1.97e-15	1.04e-12	-0.35	-0.36	Corneal astigmatism;	chr4:119603128	chr4:119454791~119552025:+
PRAD	cis	rs7739264	0.602	rs6925511	ENSG00000228412.5	RP4-625H18.2	-8.23	1.97e-15	1.05e-12	-0.43	-0.36	Endometriosis;	chr6:19773322	chr6:19802164~19804752:-
PRAD	cis	rs2348418	0.639	rs10459086	ENSG00000247934.4	RP11-967K21.1	-8.23	1.97e-15	1.05e-12	-0.34	-0.36	Lung function (FEV1);Lung function (FVC);	chr12:28115511	chr12:28163298~28190738:-
PRAD	cis	rs7396835	0.866	rs6589571	ENSG00000254851.1	RP11-109L13.1	-8.23	1.97e-15	1.05e-12	-0.69	-0.36	Quantitative traits;	chr11:116809702	chr11:117135528~117138582:+
PRAD	cis	rs9368481	0.678	rs62402024	ENSG00000241549.7	GUSBP2	8.23	1.97e-15	1.05e-12	0.41	0.36	Autism spectrum disorder or schizophrenia;	chr6:26956197	chr6:26871484~26956554:-
PRAD	cis	rs7739264	0.563	rs9465516	ENSG00000228412.5	RP4-625H18.2	8.23	1.98e-15	1.05e-12	0.43	0.36	Endometriosis;	chr6:19771767	chr6:19802164~19804752:-
PRAD	cis	rs375066	0.935	rs426534	ENSG00000267058.1	RP11-15A1.3	-8.23	1.98e-15	1.05e-12	-0.3	-0.36	Breast cancer;	chr19:43908431	chr19:43891804~43901805:-
PRAD	cis	rs4713118	0.662	rs9393881	ENSG00000272009.1	RP1-313I6.12	-8.23	1.98e-15	1.05e-12	-0.38	-0.36	Parkinson's disease;	chr6:28055973	chr6:28078792~28081130:-
PRAD	cis	rs4713118	0.662	rs9393881	ENSG00000219392.1	RP1-265C24.5	-8.23	1.98e-15	1.05e-12	-0.48	-0.36	Parkinson's disease;	chr6:28055973	chr6:28115628~28116551:+
PRAD	cis	rs1185460	0.547	rs34150933	ENSG00000271751.1	RP11-110I1.14	8.23	1.98e-15	1.05e-12	0.48	0.36	Coronary artery disease;	chr11:119040329	chr11:119065263~119065677:-
PRAD	cis	rs9532669	0.89	rs9525417	ENSG00000168852.11	TPTE2P5	8.23	1.98e-15	1.05e-12	0.35	0.36	Cervical cancer;	chr13:40878431	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.89	rs9532638	ENSG00000168852.11	TPTE2P5	8.23	1.98e-15	1.05e-12	0.35	0.36	Cervical cancer;	chr13:40878471	chr13:40822296~40921749:-
PRAD	cis	rs12142240	0.66	rs72885163	ENSG00000232022.5	FAAHP1	-8.23	1.98e-15	1.05e-12	-0.33	-0.36	Menopause (age at onset);	chr1:46341445	chr1:46432129~46445521:+
PRAD	cis	rs6001482	0.727	rs5757616	ENSG00000272779.1	LL22NC03-80A10.6	-8.23	1.99e-15	1.06e-12	-0.44	-0.36	Diastolic blood pressure;	chr22:22240095	chr22:22303224~22310401:+
PRAD	cis	rs2243480	1	rs6964245	ENSG00000226824.5	RP4-756H11.3	8.23	1.99e-15	1.06e-12	0.72	0.36	Diabetic kidney disease;	chr7:66253730	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs10807701	ENSG00000226824.5	RP4-756H11.3	8.23	1.99e-15	1.06e-12	0.72	0.36	Diabetic kidney disease;	chr7:66259699	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs1499613	ENSG00000226824.5	RP4-756H11.3	8.23	1.99e-15	1.06e-12	0.72	0.36	Diabetic kidney disease;	chr7:66265873	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs1553174	ENSG00000226824.5	RP4-756H11.3	8.23	1.99e-15	1.06e-12	0.72	0.36	Diabetic kidney disease;	chr7:66266207	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs10950032	ENSG00000226824.5	RP4-756H11.3	8.23	1.99e-15	1.06e-12	0.72	0.36	Diabetic kidney disease;	chr7:66273604	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs6958420	ENSG00000226824.5	RP4-756H11.3	8.23	1.99e-15	1.06e-12	0.72	0.36	Diabetic kidney disease;	chr7:66286184	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs1392104	ENSG00000226824.5	RP4-756H11.3	8.23	1.99e-15	1.06e-12	0.72	0.36	Diabetic kidney disease;	chr7:66294120	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs4718333	ENSG00000226824.5	RP4-756H11.3	8.23	1.99e-15	1.06e-12	0.72	0.36	Diabetic kidney disease;	chr7:66307771	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs7792391	ENSG00000226824.5	RP4-756H11.3	8.23	1.99e-15	1.06e-12	0.72	0.36	Diabetic kidney disease;	chr7:66308442	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs10247526	ENSG00000226824.5	RP4-756H11.3	8.23	1.99e-15	1.06e-12	0.72	0.36	Diabetic kidney disease;	chr7:66315709	chr7:66654538~66669855:+
PRAD	cis	rs2015599	0.563	rs11050168	ENSG00000275476.1	RP11-996F15.4	8.23	1.99e-15	1.06e-12	0.4	0.36	Platelet count;Mean platelet volume;	chr12:29273760	chr12:29277397~29277882:-
PRAD	cis	rs9309473	0.607	rs2421489	ENSG00000163016.8	ALMS1P	8.23	1.99e-15	1.06e-12	0.43	0.36	Metabolite levels;	chr2:73366320	chr2:73644919~73685576:+
PRAD	cis	rs748404	0.676	rs4401024	ENSG00000249839.1	AC011330.5	-8.23	2e-15	1.06e-12	-0.44	-0.36	Lung cancer;	chr15:43358137	chr15:43663654~43684339:-
PRAD	cis	rs748404	0.631	rs6493086	ENSG00000249839.1	AC011330.5	-8.23	2e-15	1.06e-12	-0.44	-0.36	Lung cancer;	chr15:43363196	chr15:43663654~43684339:-
PRAD	cis	rs12142240	0.698	rs68083747	ENSG00000232022.5	FAAHP1	-8.23	2e-15	1.06e-12	-0.33	-0.36	Menopause (age at onset);	chr1:46341744	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs66972124	ENSG00000232022.5	FAAHP1	-8.23	2e-15	1.06e-12	-0.33	-0.36	Menopause (age at onset);	chr1:46341773	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs17357621	ENSG00000232022.5	FAAHP1	-8.23	2e-15	1.06e-12	-0.33	-0.36	Menopause (age at onset);	chr1:46342025	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs56909107	ENSG00000232022.5	FAAHP1	-8.23	2e-15	1.06e-12	-0.33	-0.36	Menopause (age at onset);	chr1:46342552	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs41293285	ENSG00000232022.5	FAAHP1	-8.23	2e-15	1.06e-12	-0.33	-0.36	Menopause (age at onset);	chr1:46342754	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs17357628	ENSG00000232022.5	FAAHP1	-8.23	2e-15	1.06e-12	-0.33	-0.36	Menopause (age at onset);	chr1:46342790	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs17357635	ENSG00000232022.5	FAAHP1	-8.23	2e-15	1.06e-12	-0.33	-0.36	Menopause (age at onset);	chr1:46342996	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs68191463	ENSG00000232022.5	FAAHP1	-8.23	2e-15	1.06e-12	-0.33	-0.36	Menopause (age at onset);	chr1:46343023	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.667	rs41293287	ENSG00000232022.5	FAAHP1	-8.23	2e-15	1.06e-12	-0.33	-0.36	Menopause (age at onset);	chr1:46343180	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.628	rs56126529	ENSG00000232022.5	FAAHP1	-8.23	2e-15	1.06e-12	-0.33	-0.36	Menopause (age at onset);	chr1:46343188	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs7525309	ENSG00000232022.5	FAAHP1	-8.23	2e-15	1.06e-12	-0.33	-0.36	Menopause (age at onset);	chr1:46343353	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs7548675	ENSG00000232022.5	FAAHP1	-8.23	2e-15	1.06e-12	-0.33	-0.36	Menopause (age at onset);	chr1:46343649	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs7515284	ENSG00000232022.5	FAAHP1	-8.23	2e-15	1.06e-12	-0.33	-0.36	Menopause (age at onset);	chr1:46343747	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs41294456	ENSG00000232022.5	FAAHP1	-8.23	2e-15	1.06e-12	-0.33	-0.36	Menopause (age at onset);	chr1:46344110	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs66516678	ENSG00000232022.5	FAAHP1	-8.23	2e-15	1.06e-12	-0.33	-0.36	Menopause (age at onset);	chr1:46344440	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs41294458	ENSG00000232022.5	FAAHP1	-8.23	2e-15	1.06e-12	-0.33	-0.36	Menopause (age at onset);	chr1:46344632	chr1:46432129~46445521:+
PRAD	cis	rs6723108	0.627	rs2053726	ENSG00000224043.6	CCNT2-AS1	-8.23	2e-15	1.06e-12	-0.5	-0.36	Type 2 diabetes;	chr2:134852584	chr2:134735464~134918710:-
PRAD	cis	rs11098499	0.863	rs1383533	ENSG00000245958.5	RP11-33B1.1	-8.23	2e-15	1.06e-12	-0.35	-0.36	Corneal astigmatism;	chr4:119513421	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.863	rs2291185	ENSG00000245958.5	RP11-33B1.1	-8.23	2e-15	1.06e-12	-0.35	-0.36	Corneal astigmatism;	chr4:119513678	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.863	rs10030660	ENSG00000245958.5	RP11-33B1.1	-8.23	2e-15	1.06e-12	-0.35	-0.36	Corneal astigmatism;	chr4:119515549	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.863	rs13149407	ENSG00000245958.5	RP11-33B1.1	-8.23	2e-15	1.06e-12	-0.35	-0.36	Corneal astigmatism;	chr4:119516670	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.863	rs34868248	ENSG00000245958.5	RP11-33B1.1	-8.23	2e-15	1.06e-12	-0.35	-0.36	Corneal astigmatism;	chr4:119521275	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.863	rs3733525	ENSG00000245958.5	RP11-33B1.1	-8.23	2e-15	1.06e-12	-0.35	-0.36	Corneal astigmatism;	chr4:119525893	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.863	rs3775847	ENSG00000245958.5	RP11-33B1.1	-8.23	2e-15	1.06e-12	-0.35	-0.36	Corneal astigmatism;	chr4:119526487	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.863	rs3775848	ENSG00000245958.5	RP11-33B1.1	-8.23	2e-15	1.06e-12	-0.35	-0.36	Corneal astigmatism;	chr4:119526569	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.863	rs10013305	ENSG00000245958.5	RP11-33B1.1	-8.23	2e-15	1.06e-12	-0.35	-0.36	Corneal astigmatism;	chr4:119529269	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.863	rs3775849	ENSG00000245958.5	RP11-33B1.1	-8.23	2e-15	1.06e-12	-0.35	-0.36	Corneal astigmatism;	chr4:119529753	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.818	rs7688802	ENSG00000245958.5	RP11-33B1.1	-8.23	2e-15	1.06e-12	-0.35	-0.36	Corneal astigmatism;	chr4:119530513	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.863	rs7695620	ENSG00000245958.5	RP11-33B1.1	-8.23	2e-15	1.06e-12	-0.35	-0.36	Corneal astigmatism;	chr4:119531621	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.863	rs12502389	ENSG00000245958.5	RP11-33B1.1	-8.23	2e-15	1.06e-12	-0.35	-0.36	Corneal astigmatism;	chr4:119533036	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.821	rs3775852	ENSG00000245958.5	RP11-33B1.1	-8.23	2e-15	1.06e-12	-0.35	-0.36	Corneal astigmatism;	chr4:119533401	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.82	rs6534140	ENSG00000245958.5	RP11-33B1.1	-8.23	2e-15	1.06e-12	-0.35	-0.36	Corneal astigmatism;	chr4:119534156	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.863	rs7657849	ENSG00000245958.5	RP11-33B1.1	-8.23	2e-15	1.06e-12	-0.35	-0.36	Corneal astigmatism;	chr4:119534339	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.863	rs10034450	ENSG00000245958.5	RP11-33B1.1	-8.23	2e-15	1.06e-12	-0.35	-0.36	Corneal astigmatism;	chr4:119534494	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.863	rs1480939	ENSG00000245958.5	RP11-33B1.1	-8.23	2e-15	1.06e-12	-0.35	-0.36	Corneal astigmatism;	chr4:119535772	chr4:119454791~119552025:+
PRAD	cis	rs9393777	0.92	rs34150729	ENSG00000280107.1	AL022393.9	-8.23	2e-15	1.06e-12	-0.72	-0.36	Intelligence (multi-trait analysis);	chr6:27420975	chr6:28170845~28172521:+
PRAD	cis	rs9393777	0.92	rs13191227	ENSG00000280107.1	AL022393.9	-8.23	2e-15	1.06e-12	-0.72	-0.36	Intelligence (multi-trait analysis);	chr6:27422336	chr6:28170845~28172521:+
PRAD	cis	rs12142240	0.738	rs41293275	ENSG00000232022.5	FAAHP1	-8.23	2.01e-15	1.06e-12	-0.33	-0.36	Menopause (age at onset);	chr1:46340757	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.738	rs17361749	ENSG00000232022.5	FAAHP1	-8.23	2.01e-15	1.06e-12	-0.33	-0.36	Menopause (age at onset);	chr1:46340808	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.738	rs41293277	ENSG00000232022.5	FAAHP1	-8.23	2.01e-15	1.06e-12	-0.33	-0.36	Menopause (age at onset);	chr1:46340878	chr1:46432129~46445521:+
PRAD	cis	rs2243480	1	rs10807702	ENSG00000226824.5	RP4-756H11.3	-8.23	2.01e-15	1.06e-12	-0.72	-0.36	Diabetic kidney disease;	chr7:66302856	chr7:66654538~66669855:+
PRAD	cis	rs1075265	0.933	rs7560947	ENSG00000233266.1	HMGB1P31	8.23	2.01e-15	1.06e-12	0.49	0.36	Chronotype;Morning vs. evening chronotype;	chr2:54087473	chr2:54051334~54051760:+
PRAD	cis	rs2404602	0.716	rs67204011	ENSG00000259422.1	RP11-593F23.1	8.23	2.01e-15	1.06e-12	0.45	0.36	Blood metabolite levels;	chr15:76554214	chr15:76174891~76181486:-
PRAD	cis	rs2019137	0.936	rs2305133	ENSG00000274877.1	RP11-65I12.1	8.23	2.02e-15	1.07e-12	0.45	0.36	Lymphocyte counts;	chr2:113199244	chr2:113237595~113240825:+
PRAD	cis	rs2019137	0.936	rs12612729	ENSG00000274877.1	RP11-65I12.1	8.23	2.02e-15	1.07e-12	0.45	0.36	Lymphocyte counts;	chr2:113199471	chr2:113237595~113240825:+
PRAD	cis	rs2019137	0.936	rs731834	ENSG00000274877.1	RP11-65I12.1	8.23	2.02e-15	1.07e-12	0.45	0.36	Lymphocyte counts;	chr2:113199621	chr2:113237595~113240825:+
PRAD	cis	rs6570726	0.935	rs447247	ENSG00000235652.6	RP11-545I5.3	8.23	2.02e-15	1.07e-12	0.38	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145491542	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.935	rs369458	ENSG00000235652.6	RP11-545I5.3	8.23	2.02e-15	1.07e-12	0.38	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145491673	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.935	rs906774	ENSG00000235652.6	RP11-545I5.3	8.23	2.02e-15	1.07e-12	0.38	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145492634	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.935	rs366308	ENSG00000235652.6	RP11-545I5.3	8.23	2.02e-15	1.07e-12	0.38	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145493396	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.935	rs384806	ENSG00000235652.6	RP11-545I5.3	8.23	2.02e-15	1.07e-12	0.38	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145493753	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.935	rs385185	ENSG00000235652.6	RP11-545I5.3	8.23	2.02e-15	1.07e-12	0.38	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145493856	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.935	rs384453	ENSG00000235652.6	RP11-545I5.3	8.23	2.02e-15	1.07e-12	0.38	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145494009	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.935	rs372378	ENSG00000235652.6	RP11-545I5.3	8.23	2.02e-15	1.07e-12	0.38	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145495091	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.905	rs388728	ENSG00000235652.6	RP11-545I5.3	8.23	2.02e-15	1.07e-12	0.38	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145495283	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.935	rs12663204	ENSG00000235652.6	RP11-545I5.3	8.23	2.02e-15	1.07e-12	0.38	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145497237	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.935	rs12663205	ENSG00000235652.6	RP11-545I5.3	8.23	2.02e-15	1.07e-12	0.38	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145497242	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.935	rs12663211	ENSG00000235652.6	RP11-545I5.3	8.23	2.02e-15	1.07e-12	0.38	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145497291	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.934	rs430003	ENSG00000235652.6	RP11-545I5.3	8.23	2.02e-15	1.07e-12	0.38	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145498370	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.935	rs395948	ENSG00000235652.6	RP11-545I5.3	8.23	2.02e-15	1.07e-12	0.38	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145499049	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.935	rs452552	ENSG00000235652.6	RP11-545I5.3	8.23	2.02e-15	1.07e-12	0.38	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145499645	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.935	rs451349	ENSG00000235652.6	RP11-545I5.3	8.23	2.02e-15	1.07e-12	0.38	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145499758	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.905	rs406799	ENSG00000235652.6	RP11-545I5.3	8.23	2.02e-15	1.07e-12	0.38	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145500701	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.935	rs1883406	ENSG00000235652.6	RP11-545I5.3	8.23	2.02e-15	1.07e-12	0.38	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145502069	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.87	rs370653	ENSG00000235652.6	RP11-545I5.3	8.23	2.02e-15	1.07e-12	0.38	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145502506	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.935	rs391524	ENSG00000235652.6	RP11-545I5.3	8.23	2.02e-15	1.07e-12	0.38	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145502708	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.935	rs429306	ENSG00000235652.6	RP11-545I5.3	8.23	2.02e-15	1.07e-12	0.38	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145505880	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.935	rs428659	ENSG00000235652.6	RP11-545I5.3	8.23	2.02e-15	1.07e-12	0.38	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145505903	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.935	rs376991	ENSG00000235652.6	RP11-545I5.3	8.23	2.02e-15	1.07e-12	0.38	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145506937	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.935	rs401888	ENSG00000235652.6	RP11-545I5.3	8.23	2.02e-15	1.07e-12	0.38	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145510399	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.935	rs414646	ENSG00000235652.6	RP11-545I5.3	8.23	2.02e-15	1.07e-12	0.38	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145510549	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.935	rs454614	ENSG00000235652.6	RP11-545I5.3	8.23	2.02e-15	1.07e-12	0.38	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145511497	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.846	rs411468	ENSG00000235652.6	RP11-545I5.3	8.23	2.02e-15	1.07e-12	0.38	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145511656	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.935	rs425731	ENSG00000235652.6	RP11-545I5.3	8.23	2.02e-15	1.07e-12	0.38	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145513015	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.935	rs421690	ENSG00000235652.6	RP11-545I5.3	8.23	2.02e-15	1.07e-12	0.38	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145513458	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.935	rs399169	ENSG00000235652.6	RP11-545I5.3	8.23	2.02e-15	1.07e-12	0.38	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145515217	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.935	rs422540	ENSG00000235652.6	RP11-545I5.3	8.23	2.02e-15	1.07e-12	0.38	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145516679	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.935	rs408723	ENSG00000235652.6	RP11-545I5.3	8.23	2.02e-15	1.07e-12	0.38	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145517399	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.935	rs425717	ENSG00000235652.6	RP11-545I5.3	8.23	2.02e-15	1.07e-12	0.38	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145517484	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.935	rs409121	ENSG00000235652.6	RP11-545I5.3	8.23	2.02e-15	1.07e-12	0.38	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145518657	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.935	rs424263	ENSG00000235652.6	RP11-545I5.3	8.23	2.02e-15	1.07e-12	0.38	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145518937	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.905	rs419575	ENSG00000235652.6	RP11-545I5.3	8.23	2.02e-15	1.07e-12	0.38	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145519038	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.935	rs409725	ENSG00000235652.6	RP11-545I5.3	8.23	2.02e-15	1.07e-12	0.38	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145519204	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.935	rs386823	ENSG00000235652.6	RP11-545I5.3	8.23	2.02e-15	1.07e-12	0.38	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145520229	chr6:145799409~145886585:+
PRAD	cis	rs172166	0.516	rs1150670	ENSG00000280107.1	AL022393.9	-8.23	2.02e-15	1.07e-12	-0.43	-0.36	Cardiac Troponin-T levels;	chr6:28162781	chr6:28170845~28172521:+
PRAD	cis	rs172166	0.516	rs2021826	ENSG00000280107.1	AL022393.9	-8.23	2.02e-15	1.07e-12	-0.43	-0.36	Cardiac Troponin-T levels;	chr6:28164978	chr6:28170845~28172521:+
PRAD	cis	rs1552244	0.554	rs4488814	ENSG00000206567.8	AC022007.5	8.23	2.03e-15	1.07e-12	0.39	0.36	Alzheimer's disease;	chr3:9960716	chr3:10006418~10011209:-
PRAD	cis	rs7396835	0.8	rs6589572	ENSG00000254851.1	RP11-109L13.1	-8.23	2.03e-15	1.07e-12	-0.69	-0.36	Quantitative traits;	chr11:116810847	chr11:117135528~117138582:+
PRAD	cis	rs7396835	0.866	rs7927820	ENSG00000254851.1	RP11-109L13.1	-8.23	2.03e-15	1.07e-12	-0.69	-0.36	Quantitative traits;	chr11:116811440	chr11:117135528~117138582:+
PRAD	cis	rs6723108	0.517	rs1530555	ENSG00000224043.6	CCNT2-AS1	-8.23	2.03e-15	1.07e-12	-0.5	-0.36	Type 2 diabetes;	chr2:134842169	chr2:134735464~134918710:-
PRAD	cis	rs6570726	0.818	rs398812	ENSG00000235652.6	RP11-545I5.3	8.23	2.03e-15	1.07e-12	0.38	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145496135	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.935	rs446242	ENSG00000235652.6	RP11-545I5.3	8.23	2.03e-15	1.08e-12	0.38	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145522730	chr6:145799409~145886585:+
PRAD	cis	rs11723261	0.664	rs4627799	ENSG00000275426.1	CH17-262A2.1	8.23	2.04e-15	1.08e-12	0.47	0.36	Immune response to smallpox vaccine (IL-6);	chr4:138608	chr4:149738~150317:+
PRAD	cis	rs4713118	0.629	rs203890	ENSG00000272009.1	RP1-313I6.12	-8.23	2.04e-15	1.08e-12	-0.36	-0.36	Parkinson's disease;	chr6:28054470	chr6:28078792~28081130:-
PRAD	cis	rs6570726	0.935	rs453609	ENSG00000235652.6	RP11-545I5.3	8.23	2.04e-15	1.08e-12	0.38	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145491196	chr6:145799409~145886585:+
PRAD	cis	rs7211079	0.879	rs72852522	ENSG00000279259.1	RP11-334C17.3	8.23	2.05e-15	1.08e-12	0.39	0.36	Myocardial infarction;	chr17:80157691	chr17:80147250~80148596:+
PRAD	cis	rs17711722	0.522	rs6957759	ENSG00000237310.1	GS1-124K5.4	8.23	2.05e-15	1.08e-12	0.31	0.36	Calcium levels;	chr7:65806798	chr7:66493706~66495474:+
PRAD	cis	rs72627509	0.857	rs2227901	ENSG00000269949.1	RP11-738E22.3	-8.23	2.05e-15	1.09e-12	-0.51	-0.36	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56932023	chr4:56960927~56961373:-
PRAD	cis	rs950169	0.922	rs4842939	ENSG00000225151.9	GOLGA2P7	8.23	2.06e-15	1.09e-12	0.51	0.36	Schizophrenia;	chr15:84159214	chr15:84199311~84230136:-
PRAD	cis	rs2617170	0.885	rs2617150	ENSG00000245648.1	RP11-277P12.20	8.23	2.06e-15	1.09e-12	0.43	0.36	Behcet's disease;	chr12:10376435	chr12:10363769~10398506:+
PRAD	cis	rs2617170	0.883	rs2733851	ENSG00000245648.1	RP11-277P12.20	8.23	2.06e-15	1.09e-12	0.43	0.36	Behcet's disease;	chr12:10376498	chr12:10363769~10398506:+
PRAD	cis	rs6723108	0.603	rs56271357	ENSG00000224043.6	CCNT2-AS1	-8.22	2.07e-15	1.09e-12	-0.49	-0.36	Type 2 diabetes;	chr2:134963145	chr2:134735464~134918710:-
PRAD	cis	rs950169	0.922	rs12906983	ENSG00000259728.4	LINC00933	8.22	2.07e-15	1.09e-12	0.44	0.36	Schizophrenia;	chr15:84262270	chr15:84570649~84580175:+
PRAD	cis	rs12908161	1	rs11632465	ENSG00000259728.4	LINC00933	8.22	2.07e-15	1.1e-12	0.44	0.36	Schizophrenia;	chr15:84738814	chr15:84570649~84580175:+
PRAD	cis	rs7615952	0.599	rs12486459	ENSG00000171084.14	FAM86JP	8.22	2.07e-15	1.1e-12	0.58	0.36	Blood pressure (smoking interaction);	chr3:126022622	chr3:125916620~125930024:+
PRAD	cis	rs7615952	0.599	rs67575510	ENSG00000171084.14	FAM86JP	8.22	2.07e-15	1.1e-12	0.58	0.36	Blood pressure (smoking interaction);	chr3:126023512	chr3:125916620~125930024:+
PRAD	cis	rs6570726	0.935	rs379164	ENSG00000235652.6	RP11-545I5.3	8.22	2.07e-15	1.1e-12	0.38	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145507957	chr6:145799409~145886585:+
PRAD	cis	rs2739330	0.828	rs2186366	ENSG00000224205.1	AP000351.4	-8.22	2.08e-15	1.1e-12	-0.45	-0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23987320~23991421:-
PRAD	cis	rs1150668	0.835	rs1233696	ENSG00000280107.1	AL022393.9	-8.22	2.08e-15	1.1e-12	-0.43	-0.36	Pubertal anthropometrics;	chr6:28175232	chr6:28170845~28172521:+
PRAD	cis	rs2019137	0.905	rs2276561	ENSG00000274877.1	RP11-65I12.1	8.22	2.08e-15	1.1e-12	0.45	0.36	Lymphocyte counts;	chr2:113198794	chr2:113237595~113240825:+
PRAD	cis	rs4835473	0.864	rs56084830	ENSG00000251600.4	RP11-673E1.1	-8.22	2.08e-15	1.1e-12	-0.49	-0.36	Immature fraction of reticulocytes;	chr4:143791943	chr4:143912331~143982454:+
PRAD	cis	rs12612619	0.724	rs7355650	ENSG00000229122.1	AGBL5-IT1	-8.22	2.09e-15	1.11e-12	-0.38	-0.36	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27022607	chr2:27061038~27061815:+
PRAD	cis	rs1355223	0.902	rs4465347	ENSG00000271369.1	RP11-350D17.3	-8.22	2.1e-15	1.11e-12	-0.41	-0.36	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34705786	chr11:34709600~34710161:+
PRAD	cis	rs7746199	0.736	rs13212093	ENSG00000280107.1	AL022393.9	-8.22	2.1e-15	1.11e-12	-0.73	-0.36	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27638937	chr6:28170845~28172521:+
PRAD	cis	rs2404602	0.692	rs66866130	ENSG00000259422.1	RP11-593F23.1	8.22	2.1e-15	1.11e-12	0.45	0.36	Blood metabolite levels;	chr15:76836233	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.692	rs35170561	ENSG00000259422.1	RP11-593F23.1	8.22	2.1e-15	1.11e-12	0.45	0.36	Blood metabolite levels;	chr15:76838354	chr15:76174891~76181486:-
PRAD	cis	rs950169	0.881	rs150965	ENSG00000259728.4	LINC00933	8.22	2.1e-15	1.11e-12	0.44	0.36	Schizophrenia;	chr15:84537296	chr15:84570649~84580175:+
PRAD	cis	rs1355223	0.902	rs34610590	ENSG00000271369.1	RP11-350D17.3	-8.22	2.1e-15	1.11e-12	-0.41	-0.36	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34703893	chr11:34709600~34710161:+
PRAD	cis	rs2933343	0.7	rs883602	ENSG00000231305.3	RP11-723O4.2	8.22	2.1e-15	1.11e-12	0.33	0.36	IgG glycosylation;	chr3:128935109	chr3:128861313~128871540:-
PRAD	cis	rs9368481	0.761	rs9379952	ENSG00000241549.7	GUSBP2	-8.22	2.1e-15	1.11e-12	-0.4	-0.36	Autism spectrum disorder or schizophrenia;	chr6:27020121	chr6:26871484~26956554:-
PRAD	cis	rs375066	0.935	rs10406290	ENSG00000267058.1	RP11-15A1.3	-8.22	2.11e-15	1.11e-12	-0.3	-0.36	Breast cancer;	chr19:43874725	chr19:43891804~43901805:-
PRAD	cis	rs526231	0.511	rs6881612	ENSG00000175749.11	EIF3KP1	8.22	2.11e-15	1.11e-12	0.49	0.36	Primary biliary cholangitis;	chr5:103041309	chr5:103032376~103033031:+
PRAD	cis	rs11846409	0.872	rs74091715	ENSG00000274576.2	IGHV2-70	-8.22	2.11e-15	1.11e-12	-0.39	-0.36	Rheumatic heart disease;	chr14:106637731	chr14:106770577~106771020:-
PRAD	cis	rs11846409	0.932	rs74091721	ENSG00000274576.2	IGHV2-70	-8.22	2.11e-15	1.11e-12	-0.39	-0.36	Rheumatic heart disease;	chr14:106638262	chr14:106770577~106771020:-
PRAD	cis	rs7615952	0.641	rs12495947	ENSG00000171084.14	FAM86JP	8.22	2.12e-15	1.12e-12	0.57	0.36	Blood pressure (smoking interaction);	chr3:126052855	chr3:125916620~125930024:+
PRAD	cis	rs7615952	0.641	rs6805074	ENSG00000171084.14	FAM86JP	8.22	2.12e-15	1.12e-12	0.57	0.36	Blood pressure (smoking interaction);	chr3:126053431	chr3:125916620~125930024:+
PRAD	cis	rs7615952	0.641	rs4422257	ENSG00000171084.14	FAM86JP	8.22	2.12e-15	1.12e-12	0.57	0.36	Blood pressure (smoking interaction);	chr3:126055520	chr3:125916620~125930024:+
PRAD	cis	rs7615952	0.641	rs66520539	ENSG00000171084.14	FAM86JP	8.22	2.12e-15	1.12e-12	0.57	0.36	Blood pressure (smoking interaction);	chr3:126061531	chr3:125916620~125930024:+
PRAD	cis	rs7615952	0.641	rs12488180	ENSG00000171084.14	FAM86JP	8.22	2.12e-15	1.12e-12	0.57	0.36	Blood pressure (smoking interaction);	chr3:126063393	chr3:125916620~125930024:+
PRAD	cis	rs801193	0.591	rs2707839	ENSG00000237310.1	GS1-124K5.4	8.22	2.12e-15	1.12e-12	0.33	0.36	Aortic root size;	chr7:66728097	chr7:66493706~66495474:+
PRAD	cis	rs2581828	0.618	rs1560332	ENSG00000242142.1	SERBP1P3	8.22	2.12e-15	1.12e-12	0.42	0.36	Crohn's disease;	chr3:53130787	chr3:53064283~53065091:-
PRAD	cis	rs11123170	0.542	rs28522253	ENSG00000274877.1	RP11-65I12.1	-8.22	2.13e-15	1.13e-12	-0.54	-0.36	Renal function-related traits (BUN);	chr2:113209810	chr2:113237595~113240825:+
PRAD	cis	rs193541	0.632	rs26370	ENSG00000263432.2	RN7SL689P	8.22	2.13e-15	1.13e-12	0.39	0.36	Glucose homeostasis traits;	chr5:122899497	chr5:123022487~123022783:-
PRAD	cis	rs11098499	0.863	rs1010740	ENSG00000245958.5	RP11-33B1.1	8.22	2.14e-15	1.13e-12	0.36	0.36	Corneal astigmatism;	chr4:119542254	chr4:119454791~119552025:+
PRAD	cis	rs11951515	0.626	rs6863360	ENSG00000188850.9	RP11-159F24.2	8.22	2.14e-15	1.13e-12	0.44	0.36	Metabolite levels  (X-11787);	chr5:43298413	chr5:43336164~43348716:+
PRAD	cis	rs11148252	0.74	rs7981050	ENSG00000278238.1	RP11-245D16.4	-8.22	2.14e-15	1.13e-12	-0.4	-0.36	Lewy body disease;	chr13:52181014	chr13:52454775~52455331:-
PRAD	cis	rs526231	0.512	rs34797	ENSG00000175749.11	EIF3KP1	8.22	2.14e-15	1.13e-12	0.5	0.36	Primary biliary cholangitis;	chr5:103090023	chr5:103032376~103033031:+
PRAD	cis	rs4713118	0.505	rs156740	ENSG00000204709.4	LINC01556	8.22	2.15e-15	1.13e-12	0.45	0.36	Parkinson's disease;	chr6:27992657	chr6:28943877~28944537:+
PRAD	cis	rs2638953	0.924	rs11049454	ENSG00000278733.1	RP11-425D17.1	-8.22	2.15e-15	1.14e-12	-0.45	-0.36	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28204755	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs10843134	ENSG00000278733.1	RP11-425D17.1	-8.22	2.15e-15	1.14e-12	-0.45	-0.36	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28205710	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs1824768	ENSG00000278733.1	RP11-425D17.1	-8.22	2.15e-15	1.14e-12	-0.45	-0.36	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28206530	chr12:28185625~28186190:-
PRAD	cis	rs2283792	0.624	rs2876981	ENSG00000224086.5	LL22NC03-86G7.1	-8.22	2.15e-15	1.14e-12	-0.45	-0.36	Multiple sclerosis;	chr22:21851322	chr22:21938293~21977632:+
PRAD	cis	rs10463554	0.927	rs34821	ENSG00000175749.11	EIF3KP1	8.22	2.15e-15	1.14e-12	0.49	0.36	Parkinson's disease;	chr5:103101913	chr5:103032376~103033031:+
PRAD	cis	rs4631830	0.832	rs2337711	ENSG00000230869.1	CTGLF10P	8.22	2.16e-15	1.14e-12	0.46	0.36	Prostate-specific antigen levels;	chr10:46091218	chr10:45678692~45700532:+
PRAD	cis	rs17711722	0.523	rs313812	ENSG00000224316.1	RP11-479O9.2	-8.22	2.16e-15	1.14e-12	-0.34	-0.36	Calcium levels;	chr7:66040056	chr7:65773620~65802067:+
PRAD	cis	rs17361889	0.671	rs73071825	ENSG00000224683.1	RPL36AP29	8.22	2.17e-15	1.14e-12	0.44	0.36	Pediatric bone mineral content (hip);	chr7:16109442	chr7:16208945~16209265:+
PRAD	cis	rs9532669	0.889	rs7339089	ENSG00000168852.11	TPTE2P5	8.22	2.17e-15	1.14e-12	0.34	0.36	Cervical cancer;	chr13:40863790	chr13:40822296~40921749:-
PRAD	cis	rs1729407	0.814	rs2542051	ENSG00000254851.1	RP11-109L13.1	8.22	2.17e-15	1.14e-12	0.48	0.36	Apolipoprotein A-IV levels;	chr11:116827022	chr11:117135528~117138582:+
PRAD	cis	rs11976180	1	rs6464573	ENSG00000170356.8	OR2A20P	8.22	2.17e-15	1.15e-12	0.48	0.36	Obesity-related traits;	chr7:144051005	chr7:144250045~144252957:-
PRAD	cis	rs7131987	0.683	rs3782511	ENSG00000257176.2	RP11-996F15.2	-8.22	2.18e-15	1.15e-12	-0.4	-0.36	QT interval;	chr12:29343291	chr12:29280418~29317848:-
PRAD	cis	rs7586673	0.866	rs747003	ENSG00000227403.1	AC009299.3	8.22	2.18e-15	1.15e-12	0.48	0.36	Intelligence (multi-trait analysis);	chr2:161059898	chr2:161244739~161249050:+
PRAD	cis	rs440932	0.565	rs19334	ENSG00000254340.1	RP11-10A14.3	8.22	2.18e-15	1.15e-12	0.44	0.36	High light scatter reticulocyte percentage of red cells;	chr8:9152396	chr8:9141424~9145435:+
PRAD	cis	rs11096990	0.634	rs6531702	ENSG00000249207.1	RP11-360F5.1	-8.22	2.18e-15	1.15e-12	-0.37	-0.36	Cognitive function;	chr4:39273774	chr4:39112677~39126818:-
PRAD	cis	rs2348418	0.639	rs2347595	ENSG00000247934.4	RP11-967K21.1	-8.22	2.19e-15	1.15e-12	-0.35	-0.36	Lung function (FEV1);Lung function (FVC);	chr12:28109947	chr12:28163298~28190738:-
PRAD	cis	rs7923609	0.841	rs10822186	ENSG00000232075.1	MRPL35P2	-8.22	2.19e-15	1.15e-12	-0.38	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63590623	chr10:63634317~63634827:-
PRAD	cis	rs1800795	0.599	rs1546762	ENSG00000179428.2	AC073072.5	-8.22	2.2e-15	1.16e-12	-0.41	-0.36	Cerebrospinal fluid clusterin levels in APOEe4- carriers;	chr7:22717884	chr7:22725395~22727620:-
PRAD	cis	rs4722166	0.532	rs1546763	ENSG00000179428.2	AC073072.5	-8.22	2.2e-15	1.16e-12	-0.41	-0.36	Lung cancer;	chr7:22718224	chr7:22725395~22727620:-
PRAD	cis	rs1355223	0.902	rs2185700	ENSG00000271369.1	RP11-350D17.3	-8.22	2.2e-15	1.16e-12	-0.41	-0.36	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34702657	chr11:34709600~34710161:+
PRAD	cis	rs72627509	0.951	rs6554401	ENSG00000269949.1	RP11-738E22.3	8.22	2.2e-15	1.16e-12	0.52	0.36	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56959170	chr4:56960927~56961373:-
PRAD	cis	rs11096990	0.634	rs4975002	ENSG00000249207.1	RP11-360F5.1	8.22	2.21e-15	1.16e-12	0.37	0.36	Cognitive function;	chr4:39286733	chr4:39112677~39126818:-
PRAD	cis	rs4713118	0.662	rs9357060	ENSG00000272009.1	RP1-313I6.12	-8.22	2.21e-15	1.16e-12	-0.36	-0.36	Parkinson's disease;	chr6:28056708	chr6:28078792~28081130:-
PRAD	cis	rs4713118	0.662	rs9468271	ENSG00000272009.1	RP1-313I6.12	-8.22	2.21e-15	1.16e-12	-0.36	-0.36	Parkinson's disease;	chr6:28056792	chr6:28078792~28081130:-
PRAD	cis	rs375066	0.935	rs417699	ENSG00000267058.1	RP11-15A1.3	-8.22	2.22e-15	1.17e-12	-0.3	-0.36	Breast cancer;	chr19:43913423	chr19:43891804~43901805:-
PRAD	cis	rs7615952	0.599	rs67566088	ENSG00000171084.14	FAM86JP	8.21	2.23e-15	1.17e-12	0.57	0.36	Blood pressure (smoking interaction);	chr3:126050130	chr3:125916620~125930024:+
PRAD	cis	rs2108622	0.785	rs3093199	ENSG00000267056.2	AC005336.4	8.21	2.24e-15	1.18e-12	0.5	0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15879061	chr19:15910582~15911824:-
PRAD	cis	rs9287719	0.967	rs6735074	ENSG00000234818.1	AC092687.5	-8.21	2.24e-15	1.18e-12	-0.43	-0.36	Prostate cancer;	chr2:10594640	chr2:10589166~10604830:+
PRAD	cis	rs7615952	0.599	rs60847438	ENSG00000171084.14	FAM86JP	8.21	2.24e-15	1.18e-12	0.58	0.36	Blood pressure (smoking interaction);	chr3:126027162	chr3:125916620~125930024:+
PRAD	cis	rs7615952	0.534	rs1503072	ENSG00000171084.14	FAM86JP	8.21	2.24e-15	1.18e-12	0.58	0.36	Blood pressure (smoking interaction);	chr3:126035848	chr3:125916620~125930024:+
PRAD	cis	rs7615952	0.599	rs7631268	ENSG00000171084.14	FAM86JP	8.21	2.24e-15	1.18e-12	0.58	0.36	Blood pressure (smoking interaction);	chr3:126036821	chr3:125916620~125930024:+
PRAD	cis	rs6921919	0.583	rs4254981	ENSG00000216901.1	AL022393.7	8.21	2.25e-15	1.18e-12	0.46	0.36	Autism spectrum disorder or schizophrenia;	chr6:28403625	chr6:28176188~28176674:+
PRAD	cis	rs6921919	0.525	rs6929825	ENSG00000216901.1	AL022393.7	8.21	2.25e-15	1.18e-12	0.46	0.36	Autism spectrum disorder or schizophrenia;	chr6:28411182	chr6:28176188~28176674:+
PRAD	cis	rs6921919	0.583	rs35599905	ENSG00000216901.1	AL022393.7	8.21	2.25e-15	1.18e-12	0.46	0.36	Autism spectrum disorder or schizophrenia;	chr6:28411886	chr6:28176188~28176674:+
PRAD	cis	rs6921919	0.583	rs1124131	ENSG00000216901.1	AL022393.7	8.21	2.25e-15	1.18e-12	0.46	0.36	Autism spectrum disorder or schizophrenia;	chr6:28412471	chr6:28176188~28176674:+
PRAD	cis	rs6921919	0.583	rs6899389	ENSG00000216901.1	AL022393.7	8.21	2.25e-15	1.18e-12	0.46	0.36	Autism spectrum disorder or schizophrenia;	chr6:28413363	chr6:28176188~28176674:+
PRAD	cis	rs6921919	0.583	rs6922374	ENSG00000216901.1	AL022393.7	8.21	2.25e-15	1.18e-12	0.46	0.36	Autism spectrum disorder or schizophrenia;	chr6:28413495	chr6:28176188~28176674:+
PRAD	cis	rs6921919	0.583	rs6899603	ENSG00000216901.1	AL022393.7	8.21	2.25e-15	1.18e-12	0.46	0.36	Autism spectrum disorder or schizophrenia;	chr6:28413528	chr6:28176188~28176674:+
PRAD	cis	rs6921919	0.583	rs6922429	ENSG00000216901.1	AL022393.7	8.21	2.25e-15	1.18e-12	0.46	0.36	Autism spectrum disorder or schizophrenia;	chr6:28413568	chr6:28176188~28176674:+
PRAD	cis	rs6921919	0.583	rs6922169	ENSG00000216901.1	AL022393.7	8.21	2.25e-15	1.18e-12	0.46	0.36	Autism spectrum disorder or schizophrenia;	chr6:28415155	chr6:28176188~28176674:+
PRAD	cis	rs2274273	0.967	rs8013027	ENSG00000258413.1	RP11-665C16.6	-8.21	2.25e-15	1.19e-12	-0.45	-0.36	Protein biomarker;	chr14:55144222	chr14:55262767~55272075:-
PRAD	cis	rs950169	0.959	rs12911210	ENSG00000259728.4	LINC00933	8.21	2.25e-15	1.19e-12	0.43	0.36	Schizophrenia;	chr15:84123331	chr15:84570649~84580175:+
PRAD	cis	rs7567389	0.564	rs10209483	ENSG00000236682.1	AC068282.3	8.21	2.25e-15	1.19e-12	0.47	0.36	Self-rated health;	chr2:127401061	chr2:127389130~127400580:+
PRAD	cis	rs34864796	0.547	rs200476	ENSG00000280107.1	AL022393.9	-8.21	2.26e-15	1.19e-12	-0.49	-0.36	Lung function (FEV1/FVC);Lung function (FVC);Lung function (FEV1);	chr6:27800570	chr6:28170845~28172521:+
PRAD	cis	rs56114371	0.53	rs169262	ENSG00000280107.1	AL022393.9	-8.21	2.26e-15	1.19e-12	-0.49	-0.36	Breast cancer;	chr6:27803112	chr6:28170845~28172521:+
PRAD	cis	rs465969	0.744	rs3851228	ENSG00000255389.1	C6orf3	8.21	2.26e-15	1.19e-12	0.65	0.36	Psoriasis;	chr6:111526988	chr6:111599875~111602295:+
PRAD	cis	rs6847067	0.763	rs7654035	ENSG00000180769.7	WDFY3-AS2	8.21	2.27e-15	1.19e-12	0.37	0.36	Oropharynx cancer;	chr4:84956971	chr4:84965682~85011277:+
PRAD	cis	rs6847067	0.8	rs7694949	ENSG00000180769.7	WDFY3-AS2	8.21	2.27e-15	1.19e-12	0.37	0.36	Oropharynx cancer;	chr4:84959676	chr4:84965682~85011277:+
PRAD	cis	rs6847067	0.8	rs7661609	ENSG00000180769.7	WDFY3-AS2	8.21	2.27e-15	1.19e-12	0.37	0.36	Oropharynx cancer;	chr4:84961696	chr4:84965682~85011277:+
PRAD	cis	rs964611	0.938	rs7174204	ENSG00000259488.2	RP11-154J22.1	-8.21	2.28e-15	1.2e-12	-0.34	-0.36	Metabolite levels (Pyroglutamine);	chr15:48286949	chr15:48312353~48331856:-
PRAD	cis	rs9368481	0.729	rs10946881	ENSG00000241549.7	GUSBP2	8.21	2.28e-15	1.2e-12	0.41	0.36	Autism spectrum disorder or schizophrenia;	chr6:26946832	chr6:26871484~26956554:-
PRAD	cis	rs2117029	0.737	rs34436857	ENSG00000258017.1	RP11-386G11.10	-8.21	2.29e-15	1.2e-12	-0.51	-0.36	Intelligence (multi-trait analysis);	chr12:49045738	chr12:49127782~49147869:+
PRAD	cis	rs995000	0.783	rs6686331	ENSG00000235545.1	RP11-230B22.1	-8.21	2.29e-15	1.21e-12	-0.48	-0.36	Triglyceride levels;	chr1:62716464	chr1:62688482~62710694:+
PRAD	cis	rs42648	0.535	rs39198	ENSG00000227646.6	STEAP2-AS1	-8.21	2.3e-15	1.21e-12	-0.32	-0.36	Homocysteine levels;	chr7:90104504	chr7:89882353~90211635:-
PRAD	cis	rs3096299	0.503	rs9940093	ENSG00000261118.1	RP11-104N10.1	8.21	2.31e-15	1.21e-12	0.35	0.36	Multiple myeloma (IgH translocation);	chr16:89492297	chr16:89492017~89504460:-
PRAD	cis	rs1528149	0.93	rs62440852	ENSG00000224683.1	RPL36AP29	8.21	2.31e-15	1.21e-12	0.44	0.36	Sitting height ratio;	chr7:16077294	chr7:16208945~16209265:+
PRAD	cis	rs1528149	0.93	rs17357511	ENSG00000224683.1	RPL36AP29	8.21	2.31e-15	1.21e-12	0.44	0.36	Sitting height ratio;	chr7:16077339	chr7:16208945~16209265:+
PRAD	cis	rs3096299	0.874	rs3102342	ENSG00000274627.1	RP11-104N10.2	8.21	2.32e-15	1.22e-12	0.37	0.36	Multiple myeloma (IgH translocation);	chr16:89385167	chr16:89516797~89522217:+
PRAD	cis	rs6921919	0.559	rs13210866	ENSG00000216901.1	AL022393.7	8.21	2.32e-15	1.22e-12	0.46	0.36	Autism spectrum disorder or schizophrenia;	chr6:28416065	chr6:28176188~28176674:+
PRAD	cis	rs4713118	0.866	rs9468217	ENSG00000226314.6	ZNF192P1	-8.21	2.32e-15	1.22e-12	-0.48	-0.36	Parkinson's disease;	chr6:27758688	chr6:28161781~28169594:+
PRAD	cis	rs4713118	0.911	rs9295746	ENSG00000226314.6	ZNF192P1	-8.21	2.32e-15	1.22e-12	-0.48	-0.36	Parkinson's disease;	chr6:27762285	chr6:28161781~28169594:+
PRAD	cis	rs193541	0.632	rs30063	ENSG00000263432.2	RN7SL689P	8.21	2.33e-15	1.23e-12	0.38	0.36	Glucose homeostasis traits;	chr5:122959998	chr5:123022487~123022783:-
PRAD	cis	rs4835473	0.932	rs12505628	ENSG00000251600.4	RP11-673E1.1	-8.21	2.33e-15	1.23e-12	-0.46	-0.36	Immature fraction of reticulocytes;	chr4:143758468	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.9	rs12505663	ENSG00000251600.4	RP11-673E1.1	-8.21	2.33e-15	1.23e-12	-0.46	-0.36	Immature fraction of reticulocytes;	chr4:143758491	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.868	rs12513078	ENSG00000251600.4	RP11-673E1.1	-8.21	2.33e-15	1.23e-12	-0.46	-0.36	Immature fraction of reticulocytes;	chr4:143758494	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.9	rs12505665	ENSG00000251600.4	RP11-673E1.1	-8.21	2.33e-15	1.23e-12	-0.46	-0.36	Immature fraction of reticulocytes;	chr4:143758515	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.9	rs12509716	ENSG00000251600.4	RP11-673E1.1	-8.21	2.33e-15	1.23e-12	-0.46	-0.36	Immature fraction of reticulocytes;	chr4:143758520	chr4:143912331~143982454:+
PRAD	cis	rs42648	0.508	rs39204	ENSG00000227646.6	STEAP2-AS1	-8.21	2.34e-15	1.23e-12	-0.32	-0.36	Homocysteine levels;	chr7:90105004	chr7:89882353~90211635:-
PRAD	cis	rs9309473	0.607	rs1851546	ENSG00000163016.8	ALMS1P	8.21	2.34e-15	1.23e-12	0.43	0.36	Metabolite levels;	chr2:73363999	chr2:73644919~73685576:+
PRAD	cis	rs2274273	0.564	rs3783649	ENSG00000258413.1	RP11-665C16.6	-8.21	2.34e-15	1.23e-12	-0.48	-0.36	Protein biomarker;	chr14:55367692	chr14:55262767~55272075:-
PRAD	cis	rs1075265	0.868	rs4671872	ENSG00000233266.1	HMGB1P31	8.21	2.35e-15	1.23e-12	0.48	0.36	Chronotype;Morning vs. evening chronotype;	chr2:54134035	chr2:54051334~54051760:+
PRAD	cis	rs4835473	0.712	rs12509607	ENSG00000251600.4	RP11-673E1.1	-8.21	2.35e-15	1.23e-12	-0.46	-0.36	Immature fraction of reticulocytes;	chr4:143736894	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.712	rs12498218	ENSG00000251600.4	RP11-673E1.1	-8.21	2.35e-15	1.23e-12	-0.46	-0.36	Immature fraction of reticulocytes;	chr4:143736900	chr4:143912331~143982454:+
PRAD	cis	rs4925386	0.808	rs1760073	ENSG00000273619.1	RP5-908M14.9	8.21	2.36e-15	1.24e-12	0.22	0.36	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62351050	chr20:62386303~62386970:-
PRAD	cis	rs2015599	0.623	rs12581107	ENSG00000257176.2	RP11-996F15.2	-8.21	2.36e-15	1.24e-12	-0.41	-0.36	Platelet count;Mean platelet volume;	chr12:29352358	chr12:29280418~29317848:-
PRAD	cis	rs42648	0.617	rs11563435	ENSG00000227646.6	STEAP2-AS1	-8.21	2.37e-15	1.24e-12	-0.33	-0.36	Homocysteine levels;	chr7:90270893	chr7:89882353~90211635:-
PRAD	cis	rs453301	0.682	rs2929308	ENSG00000253893.2	FAM85B	8.21	2.37e-15	1.25e-12	0.45	0.36	Joint mobility (Beighton score);	chr8:9226611	chr8:8167819~8226614:-
PRAD	cis	rs10771431	1	rs10771431	ENSG00000111788.10	RP11-22B23.1	8.21	2.37e-15	1.25e-12	0.35	0.36	Breast size;	chr12:9228263	chr12:9277235~9313241:+
PRAD	cis	rs2404602	0.692	rs59088060	ENSG00000259422.1	RP11-593F23.1	8.21	2.37e-15	1.25e-12	0.45	0.36	Blood metabolite levels;	chr15:76567633	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.716	rs12902174	ENSG00000259422.1	RP11-593F23.1	8.21	2.37e-15	1.25e-12	0.45	0.36	Blood metabolite levels;	chr15:76571199	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.716	rs12438077	ENSG00000259422.1	RP11-593F23.1	8.21	2.37e-15	1.25e-12	0.45	0.36	Blood metabolite levels;	chr15:76571260	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.716	rs12441550	ENSG00000259422.1	RP11-593F23.1	8.21	2.37e-15	1.25e-12	0.45	0.36	Blood metabolite levels;	chr15:76571341	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.716	rs1874944	ENSG00000259422.1	RP11-593F23.1	8.21	2.37e-15	1.25e-12	0.45	0.36	Blood metabolite levels;	chr15:76571587	chr15:76174891~76181486:-
PRAD	cis	rs7238033	0.624	rs10460036	ENSG00000267193.4	RP11-116O18.3	8.21	2.38e-15	1.25e-12	0.39	0.36	Bladder cancer;	chr18:45731601	chr18:45669367~45747215:-
PRAD	cis	rs6570726	0.935	rs413916	ENSG00000235652.6	RP11-545I5.3	8.21	2.38e-15	1.25e-12	0.38	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145510264	chr6:145799409~145886585:+
PRAD	cis	rs12612619	0.732	rs11126857	ENSG00000229122.1	AGBL5-IT1	-8.21	2.38e-15	1.25e-12	-0.37	-0.36	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27074889	chr2:27061038~27061815:+
PRAD	cis	rs433852	0.718	rs386551	ENSG00000232871.7	SEC1P	-8.21	2.38e-15	1.25e-12	-0.39	-0.36	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;	chr19:48635029	chr19:48638071~48682245:+
PRAD	cis	rs3096299	0.933	rs28608022	ENSG00000274627.1	RP11-104N10.2	8.2	2.39e-15	1.26e-12	0.36	0.36	Multiple myeloma (IgH translocation);	chr16:89387884	chr16:89516797~89522217:+
PRAD	cis	rs2933343	0.649	rs1683786	ENSG00000231305.3	RP11-723O4.2	8.2	2.39e-15	1.26e-12	0.34	0.36	IgG glycosylation;	chr3:128908109	chr3:128861313~128871540:-
PRAD	cis	rs7829975	0.511	rs2921028	ENSG00000253893.2	FAM85B	-8.2	2.39e-15	1.26e-12	-0.44	-0.36	Mood instability;	chr8:8482967	chr8:8167819~8226614:-
PRAD	cis	rs496547	0.686	rs487728	ENSG00000278376.1	RP11-158I9.8	-8.2	2.4e-15	1.26e-12	-0.32	-0.36	Hip minimal joint space width;	chr11:118750785	chr11:118791254~118793137:+
PRAD	cis	rs321358	1	rs73019214	ENSG00000271584.1	RP11-89C3.4	8.2	2.41e-15	1.26e-12	0.56	0.36	Body mass index;	chr11:111131680	chr11:111091932~111097357:-
PRAD	cis	rs10050311	0.79	rs17751557	ENSG00000251411.1	RP11-397E7.4	-8.2	2.41e-15	1.26e-12	-0.44	-0.36	Insulin-related traits;	chr4:86913454	chr4:86913266~86914817:-
PRAD	cis	rs858239	0.862	rs1728292	ENSG00000226816.2	AC005082.12	8.2	2.41e-15	1.26e-12	0.4	0.36	Cerebrospinal fluid biomarker levels;	chr7:23223855	chr7:23206013~23208045:+
PRAD	cis	rs1150668	0.796	rs1005125	ENSG00000280107.1	AL022393.9	-8.2	2.41e-15	1.27e-12	-0.43	-0.36	Pubertal anthropometrics;	chr6:28399578	chr6:28170845~28172521:+
PRAD	cis	rs367615	0.552	rs2963023	ENSG00000249476.1	CTD-2587M2.1	-8.2	2.41e-15	1.27e-12	-0.44	-0.36	Colorectal cancer (SNP x SNP interaction);	chr5:109394369	chr5:109237120~109326369:-
PRAD	cis	rs4925386	0.808	rs1741634	ENSG00000273619.1	RP5-908M14.9	8.2	2.42e-15	1.27e-12	0.22	0.36	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62350923	chr20:62386303~62386970:-
PRAD	cis	rs853679	0.506	rs1150693	ENSG00000272009.1	RP1-313I6.12	-8.2	2.43e-15	1.28e-12	-0.37	-0.36	Depression;	chr6:28206812	chr6:28078792~28081130:-
PRAD	cis	rs2404602	0.692	rs4442773	ENSG00000259422.1	RP11-593F23.1	8.2	2.43e-15	1.28e-12	0.45	0.36	Blood metabolite levels;	chr15:76739292	chr15:76174891~76181486:-
PRAD	cis	rs2019137	0.936	rs3828189	ENSG00000274877.1	RP11-65I12.1	8.2	2.43e-15	1.28e-12	0.45	0.36	Lymphocyte counts;	chr2:113196919	chr2:113237595~113240825:+
PRAD	cis	rs7429990	0.901	rs6442091	ENSG00000229759.1	MRPS18AP1	-8.2	2.43e-15	1.28e-12	-0.37	-0.36	Educational attainment (years of education);	chr3:48001568	chr3:48256350~48256938:-
PRAD	cis	rs7429990	0.965	rs4858810	ENSG00000229759.1	MRPS18AP1	-8.2	2.43e-15	1.28e-12	-0.37	-0.36	Educational attainment (years of education);	chr3:48002247	chr3:48256350~48256938:-
PRAD	cis	rs7429990	0.965	rs4296617	ENSG00000229759.1	MRPS18AP1	-8.2	2.43e-15	1.28e-12	-0.37	-0.36	Educational attainment (years of education);	chr3:48026818	chr3:48256350~48256938:-
PRAD	cis	rs9309473	0.554	rs4330127	ENSG00000163016.8	ALMS1P	8.2	2.43e-15	1.28e-12	0.43	0.36	Metabolite levels;	chr2:73354192	chr2:73644919~73685576:+
PRAD	cis	rs2108622	0.727	rs3093193	ENSG00000267056.2	AC005336.4	8.2	2.43e-15	1.28e-12	0.5	0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15881104	chr19:15910582~15911824:-
PRAD	cis	rs9368481	0.7	rs6911401	ENSG00000241549.7	GUSBP2	8.2	2.44e-15	1.28e-12	0.41	0.36	Autism spectrum disorder or schizophrenia;	chr6:26945435	chr6:26871484~26956554:-
PRAD	cis	rs11098499	0.863	rs7664986	ENSG00000245958.5	RP11-33B1.1	-8.2	2.44e-15	1.28e-12	-0.35	-0.36	Corneal astigmatism;	chr4:119508797	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.818	rs10008791	ENSG00000245958.5	RP11-33B1.1	-8.2	2.44e-15	1.28e-12	-0.35	-0.36	Corneal astigmatism;	chr4:119510314	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.863	rs11736416	ENSG00000245958.5	RP11-33B1.1	-8.2	2.44e-15	1.28e-12	-0.35	-0.36	Corneal astigmatism;	chr4:119510506	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.863	rs3775845	ENSG00000245958.5	RP11-33B1.1	-8.2	2.44e-15	1.28e-12	-0.35	-0.36	Corneal astigmatism;	chr4:119511292	chr4:119454791~119552025:+
PRAD	cis	rs7250849	0.688	rs78019331	ENSG00000273837.1	LLNLR-470E3.1	-8.2	2.44e-15	1.28e-12	-0.54	-0.36	Blood protein levels;	chr19:51658484	chr19:51639478~51639931:-
PRAD	cis	rs2015599	0.54	rs12301475	ENSG00000257176.2	RP11-996F15.2	8.2	2.44e-15	1.28e-12	0.41	0.36	Platelet count;Mean platelet volume;	chr12:29253144	chr12:29280418~29317848:-
PRAD	cis	rs321358	1	rs321352	ENSG00000271584.1	RP11-89C3.4	8.2	2.45e-15	1.28e-12	0.55	0.36	Body mass index;	chr11:111123001	chr11:111091932~111097357:-
PRAD	cis	rs321358	1	rs167683	ENSG00000271584.1	RP11-89C3.4	8.2	2.45e-15	1.28e-12	0.55	0.36	Body mass index;	chr11:111123131	chr11:111091932~111097357:-
PRAD	cis	rs4927850	0.958	rs1975582	ENSG00000207650.1	MIR570	8.2	2.46e-15	1.29e-12	0.38	0.36	Pancreatic cancer;	chr3:196024568	chr3:195699401~195699497:+
PRAD	cis	rs11148252	0.846	rs13431	ENSG00000278238.1	RP11-245D16.4	-8.2	2.46e-15	1.29e-12	-0.41	-0.36	Lewy body disease;	chr13:52413342	chr13:52454775~52455331:-
PRAD	cis	rs11148252	0.846	rs1056335	ENSG00000278238.1	RP11-245D16.4	-8.2	2.46e-15	1.29e-12	-0.41	-0.36	Lewy body disease;	chr13:52415728	chr13:52454775~52455331:-
PRAD	cis	rs2019137	0.967	rs902695	ENSG00000274877.1	RP11-65I12.1	8.2	2.47e-15	1.3e-12	0.45	0.36	Lymphocyte counts;	chr2:113197497	chr2:113237595~113240825:+
PRAD	cis	rs67311347	0.866	rs1454491	ENSG00000223797.4	ENTPD3-AS1	8.2	2.48e-15	1.3e-12	0.32	0.36	Renal cell carcinoma;	chr3:40311156	chr3:40313802~40453329:-
PRAD	cis	rs875971	0.54	rs781152	ENSG00000236529.1	RP13-254B10.1	8.2	2.48e-15	1.3e-12	0.38	0.36	Aortic root size;	chr7:66014585	chr7:65840212~65840596:+
PRAD	cis	rs17711722	0.727	rs781151	ENSG00000236529.1	RP13-254B10.1	8.2	2.48e-15	1.3e-12	0.38	0.36	Calcium levels;	chr7:66014891	chr7:65840212~65840596:+
PRAD	cis	rs357618	1	rs357627	ENSG00000260581.1	CTB-113P19.4	8.2	2.48e-15	1.3e-12	0.44	0.36	Basophil percentage of white cells;	chr5:151470699	chr5:151652275~151655449:+
PRAD	cis	rs357618	1	rs357628	ENSG00000260581.1	CTB-113P19.4	8.2	2.48e-15	1.3e-12	0.44	0.36	Basophil percentage of white cells;	chr5:151470791	chr5:151652275~151655449:+
PRAD	cis	rs357618	1	rs165352	ENSG00000260581.1	CTB-113P19.4	8.2	2.48e-15	1.3e-12	0.44	0.36	Basophil percentage of white cells;	chr5:151476546	chr5:151652275~151655449:+
PRAD	cis	rs357618	1	rs165353	ENSG00000260581.1	CTB-113P19.4	8.2	2.48e-15	1.3e-12	0.44	0.36	Basophil percentage of white cells;	chr5:151477196	chr5:151652275~151655449:+
PRAD	cis	rs10875746	0.551	rs12322347	ENSG00000240399.1	RP1-228P16.1	-8.2	2.48e-15	1.3e-12	-0.35	-0.36	Longevity (90 years and older);	chr12:48313915	chr12:48054813~48055591:-
PRAD	cis	rs10875746	0.551	rs12322348	ENSG00000240399.1	RP1-228P16.1	-8.2	2.48e-15	1.3e-12	-0.35	-0.36	Longevity (90 years and older);	chr12:48313916	chr12:48054813~48055591:-
PRAD	cis	rs9287719	0.967	rs6432126	ENSG00000234818.1	AC092687.5	8.2	2.49e-15	1.3e-12	0.43	0.36	Prostate cancer;	chr2:10616975	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.904	rs55738250	ENSG00000234818.1	AC092687.5	8.2	2.49e-15	1.3e-12	0.43	0.36	Prostate cancer;	chr2:10617006	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs10167129	ENSG00000234818.1	AC092687.5	8.2	2.49e-15	1.3e-12	0.43	0.36	Prostate cancer;	chr2:10618449	chr2:10589166~10604830:+
PRAD	cis	rs72627509	0.857	rs56155140	ENSG00000269949.1	RP11-738E22.3	8.2	2.49e-15	1.3e-12	0.52	0.36	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56958285	chr4:56960927~56961373:-
PRAD	cis	rs12908161	0.96	rs17599989	ENSG00000259728.4	LINC00933	8.2	2.49e-15	1.3e-12	0.44	0.36	Schizophrenia;	chr15:84742305	chr15:84570649~84580175:+
PRAD	cis	rs10463554	0.927	rs34824	ENSG00000175749.11	EIF3KP1	8.2	2.5e-15	1.31e-12	0.49	0.36	Parkinson's disease;	chr5:103103227	chr5:103032376~103033031:+
PRAD	cis	rs10463554	0.927	rs34825	ENSG00000175749.11	EIF3KP1	8.2	2.5e-15	1.31e-12	0.49	0.36	Parkinson's disease;	chr5:103103614	chr5:103032376~103033031:+
PRAD	cis	rs10463554	0.963	rs34826	ENSG00000175749.11	EIF3KP1	8.2	2.5e-15	1.31e-12	0.49	0.36	Parkinson's disease;	chr5:103106044	chr5:103032376~103033031:+
PRAD	cis	rs950169	0.544	rs62021193	ENSG00000259728.4	LINC00933	8.2	2.5e-15	1.31e-12	0.43	0.36	Schizophrenia;	chr15:84627352	chr15:84570649~84580175:+
PRAD	cis	rs950169	0.58	rs17598114	ENSG00000259728.4	LINC00933	8.2	2.5e-15	1.31e-12	0.43	0.36	Schizophrenia;	chr15:84628086	chr15:84570649~84580175:+
PRAD	cis	rs950169	0.58	rs17532346	ENSG00000259728.4	LINC00933	8.2	2.5e-15	1.31e-12	0.43	0.36	Schizophrenia;	chr15:84628264	chr15:84570649~84580175:+
PRAD	cis	rs10050311	0.79	rs76583174	ENSG00000251411.1	RP11-397E7.4	-8.2	2.51e-15	1.31e-12	-0.45	-0.36	Insulin-related traits;	chr4:86917234	chr4:86913266~86914817:-
PRAD	cis	rs2404602	0.716	rs7174953	ENSG00000259422.1	RP11-593F23.1	8.2	2.51e-15	1.32e-12	0.45	0.36	Blood metabolite levels;	chr15:76614506	chr15:76174891~76181486:-
PRAD	cis	rs4835473	0.742	rs7654409	ENSG00000251600.4	RP11-673E1.1	8.2	2.51e-15	1.32e-12	0.46	0.36	Immature fraction of reticulocytes;	chr4:143956842	chr4:143912331~143982454:+
PRAD	cis	rs7923609	1	rs1935	ENSG00000232075.1	MRPL35P2	-8.2	2.52e-15	1.32e-12	-0.38	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63168063	chr10:63634317~63634827:-
PRAD	cis	rs9341835	0.518	rs2758237	ENSG00000218048.2	RP3-407E4.4	-8.2	2.52e-15	1.32e-12	-0.42	-0.36	Schizophrenia;	chr6:63508392	chr6:63440766~63443580:+
PRAD	cis	rs9341835	0.518	rs2622294	ENSG00000218048.2	RP3-407E4.4	-8.2	2.52e-15	1.32e-12	-0.42	-0.36	Schizophrenia;	chr6:63508411	chr6:63440766~63443580:+
PRAD	cis	rs9341835	0.518	rs2622293	ENSG00000218048.2	RP3-407E4.4	-8.2	2.52e-15	1.32e-12	-0.42	-0.36	Schizophrenia;	chr6:63508586	chr6:63440766~63443580:+
PRAD	cis	rs9341835	0.511	rs1744146	ENSG00000218048.2	RP3-407E4.4	-8.2	2.52e-15	1.32e-12	-0.42	-0.36	Schizophrenia;	chr6:63511964	chr6:63440766~63443580:+
PRAD	cis	rs11676348	0.772	rs12694427	ENSG00000261338.2	RP11-378A13.1	-8.2	2.53e-15	1.32e-12	-0.39	-0.36	Ulcerative colitis;	chr2:218080322	chr2:218255319~218257366:+
PRAD	cis	rs6570726	0.935	rs411641	ENSG00000235652.6	RP11-545I5.3	8.2	2.53e-15	1.32e-12	0.38	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145506396	chr6:145799409~145886585:+
PRAD	cis	rs9532669	0.963	rs1056835	ENSG00000168852.11	TPTE2P5	8.2	2.53e-15	1.33e-12	0.35	0.36	Cervical cancer;	chr13:40932585	chr13:40822296~40921749:-
PRAD	cis	rs4865169	0.595	rs9998008	ENSG00000269949.1	RP11-738E22.3	8.2	2.54e-15	1.33e-12	0.41	0.36	Breast cancer;	chr4:56899886	chr4:56960927~56961373:-
PRAD	cis	rs11951515	0.663	rs4866826	ENSG00000188850.9	RP11-159F24.2	8.2	2.55e-15	1.33e-12	0.44	0.36	Metabolite levels  (X-11787);	chr5:43359554	chr5:43336164~43348716:+
PRAD	cis	rs13113518	0.729	rs12641881	ENSG00000249700.7	SRD5A3-AS1	8.2	2.56e-15	1.34e-12	0.5	0.36	Height;	chr4:55401306	chr4:55363971~55395847:-
PRAD	cis	rs2243480	1	rs1499614	ENSG00000226824.5	RP4-756H11.3	-8.2	2.56e-15	1.34e-12	-0.72	-0.36	Diabetic kidney disease;	chr7:66265811	chr7:66654538~66669855:+
PRAD	cis	rs7567389	0.504	rs2069898	ENSG00000236682.1	AC068282.3	-8.2	2.56e-15	1.34e-12	-0.48	-0.36	Self-rated health;	chr2:127416651	chr2:127389130~127400580:+
PRAD	cis	rs8062405	0.573	rs7187575	ENSG00000259982.1	CDC37P1	-8.19	2.57e-15	1.34e-12	-0.52	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28978780	chr16:28700294~28701540:-
PRAD	cis	rs748404	0.578	rs2278856	ENSG00000249839.1	AC011330.5	-8.19	2.57e-15	1.35e-12	-0.44	-0.36	Lung cancer;	chr15:43339158	chr15:43663654~43684339:-
PRAD	cis	rs10463554	0.963	rs257318	ENSG00000175749.11	EIF3KP1	8.19	2.57e-15	1.35e-12	0.47	0.36	Parkinson's disease;	chr5:103109766	chr5:103032376~103033031:+
PRAD	cis	rs10463554	0.963	rs40322	ENSG00000175749.11	EIF3KP1	8.19	2.57e-15	1.35e-12	0.47	0.36	Parkinson's disease;	chr5:103111253	chr5:103032376~103033031:+
PRAD	cis	rs10463554	0.963	rs34773	ENSG00000175749.11	EIF3KP1	8.19	2.57e-15	1.35e-12	0.47	0.36	Parkinson's disease;	chr5:103114872	chr5:103032376~103033031:+
PRAD	cis	rs11083475	1	rs7252589	ENSG00000267892.1	CTD-2540F13.2	8.19	2.58e-15	1.35e-12	0.39	0.36	Heart rate;	chr19:38680268	chr19:38738284~38739863:+
PRAD	cis	rs1729407	0.649	rs2849176	ENSG00000254851.1	RP11-109L13.1	8.19	2.58e-15	1.35e-12	0.47	0.36	Apolipoprotein A-IV levels;	chr11:116826205	chr11:117135528~117138582:+
PRAD	cis	rs7923609	0.871	rs10761787	ENSG00000232075.1	MRPL35P2	-8.19	2.59e-15	1.35e-12	-0.37	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63593995	chr10:63634317~63634827:-
PRAD	cis	rs2283792	0.646	rs9610271	ENSG00000224086.5	LL22NC03-86G7.1	-8.19	2.59e-15	1.35e-12	-0.44	-0.36	Multiple sclerosis;	chr22:21758238	chr22:21938293~21977632:+
PRAD	cis	rs9287719	0.967	rs6432113	ENSG00000234818.1	AC092687.5	-8.19	2.6e-15	1.36e-12	-0.43	-0.36	Prostate cancer;	chr2:10604763	chr2:10589166~10604830:+
PRAD	cis	rs34375054	0.573	rs35698828	ENSG00000279233.1	RP11-158L12.4	8.19	2.61e-15	1.36e-12	0.4	0.36	Post bronchodilator FEV1/FVC ratio;	chr12:125174057	chr12:125138245~125141711:+
PRAD	cis	rs10050311	0.79	rs17751427	ENSG00000251411.1	RP11-397E7.4	-8.19	2.61e-15	1.36e-12	-0.45	-0.36	Insulin-related traits;	chr4:86909939	chr4:86913266~86914817:-
PRAD	cis	rs11098499	0.863	rs6534139	ENSG00000245958.5	RP11-33B1.1	8.19	2.61e-15	1.37e-12	0.35	0.36	Corneal astigmatism;	chr4:119528301	chr4:119454791~119552025:+
PRAD	cis	rs9532669	0.89	rs11619117	ENSG00000168852.11	TPTE2P5	8.19	2.61e-15	1.37e-12	0.34	0.36	Cervical cancer;	chr13:40880020	chr13:40822296~40921749:-
PRAD	cis	rs2739330	0.796	rs1006771	ENSG00000235689.1	AP000351.13	8.19	2.62e-15	1.37e-12	0.43	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:24006305~24008258:-
PRAD	cis	rs9287719	0.967	rs4470306	ENSG00000234818.1	AC092687.5	8.19	2.62e-15	1.37e-12	0.43	0.36	Prostate cancer;	chr2:10603872	chr2:10589166~10604830:+
PRAD	cis	rs357618	0.931	rs394736	ENSG00000260581.1	CTB-113P19.4	8.19	2.62e-15	1.37e-12	0.44	0.36	Basophil percentage of white cells;	chr5:151467948	chr5:151652275~151655449:+
PRAD	cis	rs357618	0.965	rs357621	ENSG00000260581.1	CTB-113P19.4	8.19	2.62e-15	1.37e-12	0.44	0.36	Basophil percentage of white cells;	chr5:151467993	chr5:151652275~151655449:+
PRAD	cis	rs357618	1	rs193299	ENSG00000260581.1	CTB-113P19.4	8.19	2.62e-15	1.37e-12	0.44	0.36	Basophil percentage of white cells;	chr5:151468094	chr5:151652275~151655449:+
PRAD	cis	rs357618	1	rs357622	ENSG00000260581.1	CTB-113P19.4	8.19	2.62e-15	1.37e-12	0.44	0.36	Basophil percentage of white cells;	chr5:151468844	chr5:151652275~151655449:+
PRAD	cis	rs357618	1	rs357623	ENSG00000260581.1	CTB-113P19.4	8.19	2.62e-15	1.37e-12	0.44	0.36	Basophil percentage of white cells;	chr5:151468939	chr5:151652275~151655449:+
PRAD	cis	rs357618	1	rs357624	ENSG00000260581.1	CTB-113P19.4	8.19	2.62e-15	1.37e-12	0.44	0.36	Basophil percentage of white cells;	chr5:151469140	chr5:151652275~151655449:+
PRAD	cis	rs4713118	0.662	rs464312	ENSG00000219392.1	RP1-265C24.5	-8.19	2.62e-15	1.37e-12	-0.46	-0.36	Parkinson's disease;	chr6:27999813	chr6:28115628~28116551:+
PRAD	cis	rs4713118	0.662	rs469228	ENSG00000219392.1	RP1-265C24.5	-8.19	2.62e-15	1.37e-12	-0.46	-0.36	Parkinson's disease;	chr6:28002926	chr6:28115628~28116551:+
PRAD	cis	rs4713118	0.54	rs469227	ENSG00000219392.1	RP1-265C24.5	-8.19	2.62e-15	1.37e-12	-0.46	-0.36	Parkinson's disease;	chr6:28002927	chr6:28115628~28116551:+
PRAD	cis	rs4713118	0.662	rs149948	ENSG00000219392.1	RP1-265C24.5	-8.19	2.62e-15	1.37e-12	-0.46	-0.36	Parkinson's disease;	chr6:28007039	chr6:28115628~28116551:+
PRAD	cis	rs17711722	0.565	rs4275112	ENSG00000164669.11	INTS4P1	8.19	2.62e-15	1.37e-12	0.45	0.36	Calcium levels;	chr7:65733651	chr7:65141225~65234216:+
PRAD	cis	rs172166	0.538	rs1150686	ENSG00000280107.1	AL022393.9	-8.19	2.63e-15	1.37e-12	-0.43	-0.36	Cardiac Troponin-T levels;	chr6:28193493	chr6:28170845~28172521:+
PRAD	cis	rs1150688	1	rs1150688	ENSG00000280107.1	AL022393.9	-8.19	2.63e-15	1.37e-12	-0.43	-0.36	Autism spectrum disorder or schizophrenia;	chr6:28195002	chr6:28170845~28172521:+
PRAD	cis	rs2739330	0.685	rs4822453	ENSG00000206090.4	AP000350.7	8.19	2.63e-15	1.38e-12	0.45	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23939998~23942798:+
PRAD	cis	rs7615952	0.641	rs61048217	ENSG00000171084.14	FAM86JP	8.19	2.64e-15	1.38e-12	0.58	0.36	Blood pressure (smoking interaction);	chr3:126089062	chr3:125916620~125930024:+
PRAD	cis	rs7615952	0.641	rs60839048	ENSG00000171084.14	FAM86JP	8.19	2.64e-15	1.38e-12	0.58	0.36	Blood pressure (smoking interaction);	chr3:126089095	chr3:125916620~125930024:+
PRAD	cis	rs7615952	0.641	rs7640158	ENSG00000171084.14	FAM86JP	8.19	2.64e-15	1.38e-12	0.58	0.36	Blood pressure (smoking interaction);	chr3:126089168	chr3:125916620~125930024:+
PRAD	cis	rs7615952	0.641	rs2365019	ENSG00000171084.14	FAM86JP	8.19	2.64e-15	1.38e-12	0.58	0.36	Blood pressure (smoking interaction);	chr3:126089292	chr3:125916620~125930024:+
PRAD	cis	rs2404602	0.692	rs36070630	ENSG00000259422.1	RP11-593F23.1	8.19	2.65e-15	1.38e-12	0.45	0.36	Blood metabolite levels;	chr15:76656918	chr15:76174891~76181486:-
PRAD	cis	rs172166	0.516	rs1225618	ENSG00000280107.1	AL022393.9	-8.19	2.65e-15	1.38e-12	-0.42	-0.36	Cardiac Troponin-T levels;	chr6:28161935	chr6:28170845~28172521:+
PRAD	cis	rs7500321	1	rs7500321	ENSG00000259982.1	CDC37P1	-8.19	2.65e-15	1.39e-12	-0.51	-0.36	Intelligence (multi-trait analysis);	chr16:28965699	chr16:28700294~28701540:-
PRAD	cis	rs6452524	0.967	rs2974448	ENSG00000249664.1	CTD-2227C6.2	8.19	2.66e-15	1.39e-12	0.42	0.36	Hypertension (SNP x SNP interaction);	chr5:83190937	chr5:83012285~83013109:-
PRAD	cis	rs7500321	1	rs7500321	ENSG00000251417.2	RP11-1348G14.4	8.19	2.66e-15	1.39e-12	0.44	0.36	Intelligence (multi-trait analysis);	chr16:28965699	chr16:28802743~28817828:+
PRAD	cis	rs17361889	0.671	rs987932	ENSG00000224683.1	RPL36AP29	8.19	2.66e-15	1.39e-12	0.43	0.36	Pediatric bone mineral content (hip);	chr7:16114696	chr7:16208945~16209265:+
PRAD	cis	rs17361889	0.632	rs987934	ENSG00000224683.1	RPL36AP29	8.19	2.66e-15	1.39e-12	0.43	0.36	Pediatric bone mineral content (hip);	chr7:16115124	chr7:16208945~16209265:+
PRAD	cis	rs4664293	0.51	rs72961735	ENSG00000226266.5	AC009961.3	8.19	2.66e-15	1.39e-12	0.48	0.36	Monocyte percentage of white cells;	chr2:159708009	chr2:159670708~159712435:-
PRAD	cis	rs741668	0.759	rs12428399	ENSG00000235903.6	CPB2-AS1	8.19	2.66e-15	1.39e-12	0.48	0.36	Cerebrospinal fluid clusterin levels;	chr13:46060804	chr13:46052806~46113332:+
PRAD	cis	rs17711722	0.528	rs73138179	ENSG00000224316.1	RP11-479O9.2	8.19	2.67e-15	1.4e-12	0.34	0.36	Calcium levels;	chr7:65829495	chr7:65773620~65802067:+
PRAD	cis	rs8523	0.804	rs4711171	ENSG00000230314.5	ELOVL2-AS1	8.19	2.68e-15	1.4e-12	0.39	0.36	Red blood cell fatty acid levels;	chr6:11074114	chr6:11043524~11078226:+
PRAD	cis	rs7712401	0.691	rs62377436	ENSG00000263432.2	RN7SL689P	-8.19	2.68e-15	1.4e-12	-0.37	-0.36	Mean platelet volume;	chr5:123018007	chr5:123022487~123022783:-
PRAD	cis	rs2739330	0.685	rs4822453	ENSG00000272787.1	KB-226F1.2	-8.19	2.68e-15	1.4e-12	-0.38	-0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23969211~23969873:+
PRAD	cis	rs9309473	0.632	rs6546825	ENSG00000163016.8	ALMS1P	8.19	2.68e-15	1.4e-12	0.43	0.36	Metabolite levels;	chr2:73365125	chr2:73644919~73685576:+
PRAD	cis	rs748404	0.631	rs3809482	ENSG00000249839.1	AC011330.5	-8.19	2.69e-15	1.4e-12	-0.44	-0.36	Lung cancer;	chr15:43369604	chr15:43663654~43684339:-
PRAD	cis	rs7131987	0.622	rs7294598	ENSG00000257176.2	RP11-996F15.2	8.19	2.7e-15	1.41e-12	0.39	0.36	QT interval;	chr12:29379056	chr12:29280418~29317848:-
PRAD	cis	rs193541	0.642	rs42538	ENSG00000263432.2	RN7SL689P	8.19	2.7e-15	1.41e-12	0.38	0.36	Glucose homeostasis traits;	chr5:122956657	chr5:123022487~123022783:-
PRAD	cis	rs193541	0.632	rs39821	ENSG00000263432.2	RN7SL689P	8.19	2.7e-15	1.41e-12	0.38	0.36	Glucose homeostasis traits;	chr5:122959777	chr5:123022487~123022783:-
PRAD	cis	rs9368481	1	rs9368481	ENSG00000241549.7	GUSBP2	-8.19	2.71e-15	1.41e-12	-0.4	-0.36	Autism spectrum disorder or schizophrenia;	chr6:26993982	chr6:26871484~26956554:-
PRAD	cis	rs9368481	0.554	rs2754603	ENSG00000241549.7	GUSBP2	-8.19	2.71e-15	1.41e-12	-0.4	-0.36	Autism spectrum disorder or schizophrenia;	chr6:26997360	chr6:26871484~26956554:-
PRAD	cis	rs9368481	0.761	rs9357028	ENSG00000241549.7	GUSBP2	-8.19	2.71e-15	1.41e-12	-0.4	-0.36	Autism spectrum disorder or schizophrenia;	chr6:26999445	chr6:26871484~26956554:-
PRAD	cis	rs7567389	1	rs7567389	ENSG00000236682.1	AC068282.3	8.19	2.71e-15	1.42e-12	0.45	0.36	Self-rated health;	chr2:127225069	chr2:127389130~127400580:+
PRAD	cis	rs2617170	0.922	rs1049172	ENSG00000245648.1	RP11-277P12.20	8.19	2.72e-15	1.42e-12	0.43	0.36	Behcet's disease;	chr12:10373141	chr12:10363769~10398506:+
PRAD	cis	rs1552244	0.554	rs2272119	ENSG00000206567.8	AC022007.5	-8.19	2.72e-15	1.42e-12	-0.4	-0.36	Alzheimer's disease;	chr3:10007668	chr3:10006418~10011209:-
PRAD	cis	rs1552244	0.608	rs9837460	ENSG00000206567.8	AC022007.5	-8.19	2.72e-15	1.42e-12	-0.4	-0.36	Alzheimer's disease;	chr3:10008238	chr3:10006418~10011209:-
PRAD	cis	rs1552244	0.554	rs28667821	ENSG00000206567.8	AC022007.5	-8.19	2.72e-15	1.42e-12	-0.4	-0.36	Alzheimer's disease;	chr3:10009083	chr3:10006418~10011209:-
PRAD	cis	rs1552244	0.543	rs28719585	ENSG00000206567.8	AC022007.5	-8.19	2.72e-15	1.42e-12	-0.4	-0.36	Alzheimer's disease;	chr3:10009129	chr3:10006418~10011209:-
PRAD	cis	rs1552244	0.554	rs7349576	ENSG00000206567.8	AC022007.5	-8.19	2.72e-15	1.42e-12	-0.4	-0.36	Alzheimer's disease;	chr3:10009209	chr3:10006418~10011209:-
PRAD	cis	rs6921919	0.583	rs6928771	ENSG00000216901.1	AL022393.7	8.19	2.74e-15	1.43e-12	0.45	0.36	Autism spectrum disorder or schizophrenia;	chr6:28407432	chr6:28176188~28176674:+
PRAD	cis	rs7772486	0.681	rs9390343	ENSG00000235652.6	RP11-545I5.3	-8.19	2.75e-15	1.43e-12	-0.37	-0.36	Lobe attachment (rater-scored or self-reported);	chr6:145689391	chr6:145799409~145886585:+
PRAD	cis	rs11846409	0.818	rs2516909	ENSG00000274576.2	IGHV2-70	8.19	2.75e-15	1.43e-12	0.39	0.36	Rheumatic heart disease;	chr14:106630317	chr14:106770577~106771020:-
PRAD	cis	rs2638953	0.962	rs11049370	ENSG00000278733.1	RP11-425D17.1	-8.18	2.76e-15	1.44e-12	-0.44	-0.36	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28146904	chr12:28185625~28186190:-
PRAD	cis	rs2412819	0.571	rs2930531	ENSG00000205771.5	CATSPER2P1	8.18	2.77e-15	1.44e-12	0.49	0.36	Lung cancer;	chr15:43829372	chr15:43726918~43747094:-
PRAD	cis	rs6517329	0.933	rs12151967	ENSG00000236830.5	CBR3-AS1	8.18	2.78e-15	1.45e-12	0.37	0.36	Schizophrenia;	chr21:36111456	chr21:36131767~36175815:-
PRAD	cis	rs6723108	0.627	rs6430545	ENSG00000224043.6	CCNT2-AS1	8.18	2.79e-15	1.45e-12	0.5	0.36	Type 2 diabetes;	chr2:134845031	chr2:134735464~134918710:-
PRAD	cis	rs748404	0.604	rs2278857	ENSG00000249839.1	AC011330.5	-8.18	2.79e-15	1.45e-12	-0.44	-0.36	Lung cancer;	chr15:43340351	chr15:43663654~43684339:-
PRAD	cis	rs7615952	0.736	rs9866347	ENSG00000171084.14	FAM86JP	8.18	2.79e-15	1.45e-12	0.66	0.36	Blood pressure (smoking interaction);	chr3:125951082	chr3:125916620~125930024:+
PRAD	cis	rs42648	0.819	rs2285399	ENSG00000227646.6	STEAP2-AS1	-8.18	2.8e-15	1.46e-12	-0.33	-0.36	Homocysteine levels;	chr7:90340564	chr7:89882353~90211635:-
PRAD	cis	rs2617170	0.922	rs1351113	ENSG00000245648.1	RP11-277P12.20	-8.18	2.8e-15	1.46e-12	-0.43	-0.36	Behcet's disease;	chr12:10373045	chr12:10363769~10398506:+
PRAD	cis	rs2337406	0.714	rs115401799	ENSG00000274576.2	IGHV2-70	-8.18	2.81e-15	1.46e-12	-0.4	-0.36	Alzheimer's disease (late onset);	chr14:106813739	chr14:106770577~106771020:-
PRAD	cis	rs17711722	0.565	rs73372653	ENSG00000275400.1	RP4-756H11.5	-8.18	2.81e-15	1.46e-12	-0.32	-0.36	Calcium levels;	chr7:65977808	chr7:66553805~66554199:-
PRAD	cis	rs72627509	0.629	rs1718824	ENSG00000269949.1	RP11-738E22.3	-8.18	2.81e-15	1.46e-12	-0.48	-0.36	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:57037581	chr4:56960927~56961373:-
PRAD	cis	rs2638953	0.924	rs11049369	ENSG00000278733.1	RP11-425D17.1	-8.18	2.81e-15	1.46e-12	-0.44	-0.36	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28146543	chr12:28185625~28186190:-
PRAD	cis	rs12142240	0.845	rs4313342	ENSG00000232022.5	FAAHP1	-8.18	2.82e-15	1.47e-12	-0.34	-0.36	Menopause (age at onset);	chr1:46336232	chr1:46432129~46445521:+
PRAD	cis	rs12931792	0.712	rs4787495	ENSG00000183604.13	SMG1P5	-8.18	2.84e-15	1.48e-12	-0.31	-0.36	Tonsillectomy;	chr16:30154404	chr16:30267553~30335374:-
PRAD	cis	rs11098499	0.954	rs10017371	ENSG00000245958.5	RP11-33B1.1	-8.18	2.85e-15	1.48e-12	-0.36	-0.36	Corneal astigmatism;	chr4:119372621	chr4:119454791~119552025:+
PRAD	cis	rs2739330	0.892	rs5751776	ENSG00000206090.4	AP000350.7	8.18	2.86e-15	1.49e-12	0.45	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23939998~23942798:+
PRAD	cis	rs8523	0.804	rs9295763	ENSG00000230314.5	ELOVL2-AS1	8.18	2.86e-15	1.49e-12	0.39	0.36	Red blood cell fatty acid levels;	chr6:11044959	chr6:11043524~11078226:+
PRAD	cis	rs8523	0.774	rs9295764	ENSG00000230314.5	ELOVL2-AS1	8.18	2.86e-15	1.49e-12	0.39	0.36	Red blood cell fatty acid levels;	chr6:11044963	chr6:11043524~11078226:+
PRAD	cis	rs7923609	0.869	rs9971352	ENSG00000232075.1	MRPL35P2	-8.18	2.86e-15	1.49e-12	-0.38	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63505348	chr10:63634317~63634827:-
PRAD	cis	rs2274273	0.588	rs58296156	ENSG00000258413.1	RP11-665C16.6	-8.18	2.87e-15	1.49e-12	-0.48	-0.36	Protein biomarker;	chr14:55361609	chr14:55262767~55272075:-
PRAD	cis	rs2019137	0.836	rs4848318	ENSG00000274877.1	RP11-65I12.1	8.18	2.87e-15	1.49e-12	0.45	0.36	Lymphocyte counts;	chr2:113196375	chr2:113237595~113240825:+
PRAD	cis	rs2019137	0.936	rs2241978	ENSG00000274877.1	RP11-65I12.1	8.18	2.87e-15	1.49e-12	0.45	0.36	Lymphocyte counts;	chr2:113196429	chr2:113237595~113240825:+
PRAD	cis	rs2019137	0.936	rs3828188	ENSG00000274877.1	RP11-65I12.1	8.18	2.87e-15	1.49e-12	0.45	0.36	Lymphocyte counts;	chr2:113196670	chr2:113237595~113240825:+
PRAD	cis	rs9532669	0.926	rs4600337	ENSG00000168852.11	TPTE2P5	8.18	2.87e-15	1.49e-12	0.35	0.36	Cervical cancer;	chr13:40879564	chr13:40822296~40921749:-
PRAD	cis	rs10463554	0.892	rs34816	ENSG00000175749.11	EIF3KP1	8.18	2.87e-15	1.49e-12	0.49	0.36	Parkinson's disease;	chr5:103098941	chr5:103032376~103033031:+
PRAD	cis	rs1150668	0.796	rs1124132	ENSG00000280107.1	AL022393.9	-8.18	2.88e-15	1.5e-12	-0.43	-0.36	Pubertal anthropometrics;	chr6:28412544	chr6:28170845~28172521:+
PRAD	cis	rs1150668	0.796	rs2531832	ENSG00000280107.1	AL022393.9	-8.18	2.88e-15	1.5e-12	-0.43	-0.36	Pubertal anthropometrics;	chr6:28421445	chr6:28170845~28172521:+
PRAD	cis	rs12908161	1	rs17601029	ENSG00000259728.4	LINC00933	8.18	2.88e-15	1.5e-12	0.44	0.36	Schizophrenia;	chr15:84804478	chr15:84570649~84580175:+
PRAD	cis	rs440932	1	rs440932	ENSG00000254340.1	RP11-10A14.3	8.18	2.89e-15	1.5e-12	0.43	0.36	High light scatter reticulocyte percentage of red cells;	chr8:9169419	chr8:9141424~9145435:+
PRAD	cis	rs2404602	0.716	rs67920045	ENSG00000259422.1	RP11-593F23.1	8.18	2.89e-15	1.5e-12	0.45	0.36	Blood metabolite levels;	chr15:76507743	chr15:76174891~76181486:-
PRAD	cis	rs1062177	0.724	rs2915828	ENSG00000253921.1	CTB-113P19.3	8.18	2.89e-15	1.5e-12	0.47	0.36	Preschool internalizing problems;	chr5:151738560	chr5:151753992~151767247:+
PRAD	cis	rs1062177	0.724	rs2964590	ENSG00000253921.1	CTB-113P19.3	8.18	2.89e-15	1.5e-12	0.47	0.36	Preschool internalizing problems;	chr5:151738585	chr5:151753992~151767247:+
PRAD	cis	rs4835473	0.868	rs1828503	ENSG00000251600.4	RP11-673E1.1	-8.18	2.89e-15	1.5e-12	-0.47	-0.36	Immature fraction of reticulocytes;	chr4:143993354	chr4:143912331~143982454:+
PRAD	cis	rs11096990	0.656	rs7686161	ENSG00000249207.1	RP11-360F5.1	8.18	2.9e-15	1.51e-12	0.37	0.36	Cognitive function;	chr4:39283201	chr4:39112677~39126818:-
PRAD	cis	rs10463554	0.889	rs34822	ENSG00000175749.11	EIF3KP1	8.18	2.91e-15	1.51e-12	0.47	0.36	Parkinson's disease;	chr5:103102007	chr5:103032376~103033031:+
PRAD	cis	rs2638953	0.924	rs11524516	ENSG00000278733.1	RP11-425D17.1	-8.18	2.91e-15	1.51e-12	-0.46	-0.36	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28209517	chr12:28185625~28186190:-
PRAD	cis	rs7829975	0.564	rs2921057	ENSG00000253893.2	FAM85B	-8.18	2.92e-15	1.52e-12	-0.44	-0.36	Mood instability;	chr8:8461157	chr8:8167819~8226614:-
PRAD	cis	rs7131987	0.65	rs7954871	ENSG00000257176.2	RP11-996F15.2	-8.18	2.93e-15	1.52e-12	-0.39	-0.36	QT interval;	chr12:29306799	chr12:29280418~29317848:-
PRAD	cis	rs964611	1	rs964611	ENSG00000259488.2	RP11-154J22.1	-8.18	2.93e-15	1.52e-12	-0.38	-0.36	Metabolite levels (Pyroglutamine);	chr15:48305317	chr15:48312353~48331856:-
PRAD	cis	rs1150668	0.799	rs1736891	ENSG00000280107.1	AL022393.9	-8.18	2.94e-15	1.53e-12	-0.44	-0.36	Pubertal anthropometrics;	chr6:28219323	chr6:28170845~28172521:+
PRAD	cis	rs3779195	0.627	rs6950023	ENSG00000272950.1	RP11-307C18.1	8.18	2.96e-15	1.54e-12	0.57	0.36	Sex hormone-binding globulin levels;	chr7:98286323	chr7:98322853~98323430:+
PRAD	cis	rs3779195	0.627	rs6967728	ENSG00000272950.1	RP11-307C18.1	8.18	2.96e-15	1.54e-12	0.57	0.36	Sex hormone-binding globulin levels;	chr7:98286325	chr7:98322853~98323430:+
PRAD	cis	rs11976180	1	rs1919951	ENSG00000170356.8	OR2A20P	-8.18	2.96e-15	1.54e-12	-0.48	-0.36	Obesity-related traits;	chr7:144071798	chr7:144250045~144252957:-
PRAD	cis	rs2638953	0.886	rs11049393	ENSG00000278733.1	RP11-425D17.1	-8.17	2.97e-15	1.54e-12	-0.45	-0.36	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28170273	chr12:28185625~28186190:-
PRAD	cis	rs1075265	0.901	rs1058320	ENSG00000233266.1	HMGB1P31	8.17	2.97e-15	1.54e-12	0.49	0.36	Chronotype;Morning vs. evening chronotype;	chr2:54085016	chr2:54051334~54051760:+
PRAD	cis	rs9532669	0.857	rs9525427	ENSG00000168852.11	TPTE2P5	8.17	2.97e-15	1.54e-12	0.34	0.36	Cervical cancer;	chr13:40918029	chr13:40822296~40921749:-
PRAD	cis	rs9309473	0.607	rs4641966	ENSG00000163016.8	ALMS1P	8.17	2.97e-15	1.54e-12	0.43	0.36	Metabolite levels;	chr2:73363678	chr2:73644919~73685576:+
PRAD	cis	rs4631830	0.863	rs2611489	ENSG00000230869.1	CTGLF10P	-8.17	2.98e-15	1.54e-12	-0.44	-0.36	Prostate-specific antigen levels;	chr10:46070933	chr10:45678692~45700532:+
PRAD	cis	rs4927850	0.957	rs4927851	ENSG00000207650.1	MIR570	8.17	2.98e-15	1.55e-12	0.38	0.36	Pancreatic cancer;	chr3:196024982	chr3:195699401~195699497:+
PRAD	cis	rs4927850	0.918	rs4361313	ENSG00000207650.1	MIR570	8.17	2.98e-15	1.55e-12	0.38	0.36	Pancreatic cancer;	chr3:196025389	chr3:195699401~195699497:+
PRAD	cis	rs2933343	0.7	rs1683787	ENSG00000231305.3	RP11-723O4.2	-8.17	2.99e-15	1.55e-12	-0.34	-0.36	IgG glycosylation;	chr3:128908178	chr3:128861313~128871540:-
PRAD	cis	rs8523	0.804	rs6900220	ENSG00000230314.5	ELOVL2-AS1	8.17	2.99e-15	1.55e-12	0.39	0.36	Red blood cell fatty acid levels;	chr6:11064905	chr6:11043524~11078226:+
PRAD	cis	rs9309473	0.607	rs6716776	ENSG00000163016.8	ALMS1P	8.17	3e-15	1.55e-12	0.43	0.36	Metabolite levels;	chr2:73360585	chr2:73644919~73685576:+
PRAD	cis	rs7772486	0.774	rs6930181	ENSG00000235652.6	RP11-545I5.3	-8.17	3e-15	1.56e-12	-0.37	-0.36	Lobe attachment (rater-scored or self-reported);	chr6:145859838	chr6:145799409~145886585:+
PRAD	cis	rs62402013	1	rs62402013	ENSG00000241549.7	GUSBP2	8.17	3e-15	1.56e-12	0.41	0.36	Schizophrenia;	chr6:26947221	chr6:26871484~26956554:-
PRAD	cis	rs73607972	0.778	rs55662133	ENSG00000275191.1	RP11-36I17.2	-8.17	3e-15	1.56e-12	-0.55	-0.36	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53612761	chr16:53628256~53628816:-
PRAD	cis	rs12908161	1	rs12911736	ENSG00000259728.4	LINC00933	8.17	3.02e-15	1.57e-12	0.43	0.36	Schizophrenia;	chr15:84696777	chr15:84570649~84580175:+
PRAD	cis	rs10129255	0.518	rs2006284	ENSG00000211972.2	IGHV3-66	8.17	3.02e-15	1.57e-12	0.32	0.36	Kawasaki disease;	chr14:106676185	chr14:106675017~106675544:-
PRAD	cis	rs524281	0.731	rs2430979	ENSG00000255320.1	RP11-755F10.1	-8.17	3.02e-15	1.57e-12	-0.56	-0.36	Electroencephalogram traits;	chr11:66045912	chr11:66244840~66246239:-
PRAD	cis	rs4713118	0.662	rs175954	ENSG00000272009.1	RP1-313I6.12	-8.17	3.02e-15	1.57e-12	-0.36	-0.36	Parkinson's disease;	chr6:28043807	chr6:28078792~28081130:-
PRAD	cis	rs2404602	0.692	rs34181263	ENSG00000259422.1	RP11-593F23.1	8.17	3.03e-15	1.57e-12	0.44	0.36	Blood metabolite levels;	chr15:76773047	chr15:76174891~76181486:-
PRAD	cis	rs496547	0.686	rs524590	ENSG00000278376.1	RP11-158I9.8	-8.17	3.03e-15	1.57e-12	-0.32	-0.36	Hip minimal joint space width;	chr11:118769354	chr11:118791254~118793137:+
PRAD	cis	rs9309473	0.607	rs11686504	ENSG00000163016.8	ALMS1P	8.17	3.04e-15	1.57e-12	0.43	0.36	Metabolite levels;	chr2:73352684	chr2:73644919~73685576:+
PRAD	cis	rs7567389	0.6	rs11679414	ENSG00000236682.1	AC068282.3	-8.17	3.04e-15	1.58e-12	-0.47	-0.36	Self-rated health;	chr2:127393427	chr2:127389130~127400580:+
PRAD	cis	rs357618	1	rs357629	ENSG00000260581.1	CTB-113P19.4	-8.17	3.04e-15	1.58e-12	-0.44	-0.36	Basophil percentage of white cells;	chr5:151471385	chr5:151652275~151655449:+
PRAD	cis	rs9532669	0.926	rs4555012	ENSG00000168852.11	TPTE2P5	8.17	3.05e-15	1.58e-12	0.35	0.36	Cervical cancer;	chr13:40879997	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.926	rs12871420	ENSG00000168852.11	TPTE2P5	8.17	3.05e-15	1.58e-12	0.35	0.36	Cervical cancer;	chr13:40880034	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.926	rs12871735	ENSG00000168852.11	TPTE2P5	8.17	3.05e-15	1.58e-12	0.35	0.36	Cervical cancer;	chr13:40880169	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.926	rs12871895	ENSG00000168852.11	TPTE2P5	8.17	3.05e-15	1.58e-12	0.35	0.36	Cervical cancer;	chr13:40880189	chr13:40822296~40921749:-
PRAD	cis	rs2581828	0.646	rs28501212	ENSG00000242142.1	SERBP1P3	-8.17	3.05e-15	1.58e-12	-0.42	-0.36	Crohn's disease;	chr3:53129041	chr3:53064283~53065091:-
PRAD	cis	rs950169	0.58	rs11634322	ENSG00000259728.4	LINC00933	8.17	3.05e-15	1.58e-12	0.43	0.36	Schizophrenia;	chr15:84628978	chr15:84570649~84580175:+
PRAD	cis	rs950169	0.58	rs11636189	ENSG00000259728.4	LINC00933	8.17	3.05e-15	1.58e-12	0.43	0.36	Schizophrenia;	chr15:84650323	chr15:84570649~84580175:+
PRAD	cis	rs950169	0.58	rs35516100	ENSG00000259728.4	LINC00933	8.17	3.05e-15	1.58e-12	0.43	0.36	Schizophrenia;	chr15:84652199	chr15:84570649~84580175:+
PRAD	cis	rs950169	0.58	rs62021208	ENSG00000259728.4	LINC00933	8.17	3.05e-15	1.58e-12	0.43	0.36	Schizophrenia;	chr15:84653013	chr15:84570649~84580175:+
PRAD	cis	rs1979679	0.842	rs4931730	ENSG00000278733.1	RP11-425D17.1	8.17	3.05e-15	1.58e-12	0.46	0.36	Ossification of the posterior longitudinal ligament of the spine;	chr12:28146343	chr12:28185625~28186190:-
PRAD	cis	rs1134634	0.52	rs4698403	ENSG00000273133.1	RP11-799M12.2	-8.17	3.05e-15	1.58e-12	-0.47	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15628204	chr4:15563698~15564253:-
PRAD	cis	rs1134634	0.52	rs73127647	ENSG00000273133.1	RP11-799M12.2	-8.17	3.05e-15	1.58e-12	-0.47	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15639969	chr4:15563698~15564253:-
PRAD	cis	rs7746199	0.736	rs58616630	ENSG00000280107.1	AL022393.9	-8.17	3.07e-15	1.59e-12	-0.73	-0.36	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27506936	chr6:28170845~28172521:+
PRAD	cis	rs10129255	0.576	rs2157616	ENSG00000211972.2	IGHV3-66	8.17	3.07e-15	1.59e-12	0.31	0.36	Kawasaki disease;	chr14:106767802	chr14:106675017~106675544:-
PRAD	cis	rs4713118	0.911	rs9461406	ENSG00000226314.6	ZNF192P1	8.17	3.08e-15	1.59e-12	0.48	0.36	Parkinson's disease;	chr6:27751985	chr6:28161781~28169594:+
PRAD	cis	rs7250849	0.736	rs12459542	ENSG00000273837.1	LLNLR-470E3.1	-8.17	3.08e-15	1.6e-12	-0.53	-0.36	Blood protein levels;	chr19:51660025	chr19:51639478~51639931:-
PRAD	cis	rs2933343	0.7	rs876754	ENSG00000231305.3	RP11-723O4.2	8.17	3.09e-15	1.6e-12	0.33	0.36	IgG glycosylation;	chr3:128908910	chr3:128861313~128871540:-
PRAD	cis	rs9341835	0.518	rs6939983	ENSG00000218048.2	RP3-407E4.4	8.17	3.09e-15	1.6e-12	0.41	0.36	Schizophrenia;	chr6:63463311	chr6:63440766~63443580:+
PRAD	cis	rs950169	0.96	rs35159785	ENSG00000225151.9	GOLGA2P7	-8.17	3.09e-15	1.6e-12	-0.5	-0.36	Schizophrenia;	chr15:84135262	chr15:84199311~84230136:-
PRAD	cis	rs9341835	0.518	rs9344168	ENSG00000218048.2	RP3-407E4.4	8.17	3.1e-15	1.6e-12	0.41	0.36	Schizophrenia;	chr6:63459777	chr6:63440766~63443580:+
PRAD	cis	rs17361889	0.711	rs17287882	ENSG00000224683.1	RPL36AP29	8.17	3.1e-15	1.6e-12	0.43	0.36	Pediatric bone mineral content (hip);	chr7:16139249	chr7:16208945~16209265:+
PRAD	cis	rs6844153	1	rs57686546	ENSG00000240005.4	RP11-293A21.1	-8.17	3.1e-15	1.61e-12	-0.51	-0.36	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26915162	chr4:26859806~26860599:-
PRAD	cis	rs17711722	0.522	rs62469933	ENSG00000237310.1	GS1-124K5.4	8.17	3.1e-15	1.61e-12	0.31	0.36	Calcium levels;	chr7:65800652	chr7:66493706~66495474:+
PRAD	cis	rs7688540	0.61	rs6830496	ENSG00000275426.1	CH17-262A2.1	8.17	3.11e-15	1.61e-12	0.52	0.36	Facial morphology (factor 6, height of vermillion lower lip);	chr4:221985	chr4:149738~150317:+
PRAD	cis	rs193541	0.632	rs1460040	ENSG00000263432.2	RN7SL689P	8.17	3.11e-15	1.61e-12	0.38	0.36	Glucose homeostasis traits;	chr5:122769537	chr5:123022487~123022783:-
PRAD	cis	rs4664293	0.801	rs7590595	ENSG00000226266.5	AC009961.3	-8.17	3.12e-15	1.62e-12	-0.48	-0.36	Monocyte percentage of white cells;	chr2:159715198	chr2:159670708~159712435:-
PRAD	cis	rs9309473	0.632	rs6706179	ENSG00000163016.8	ALMS1P	8.17	3.13e-15	1.62e-12	0.43	0.36	Metabolite levels;	chr2:73351449	chr2:73644919~73685576:+
PRAD	cis	rs8005677	1	rs1043209	ENSG00000257285.4	RP11-298I3.1	-8.17	3.14e-15	1.62e-12	-0.36	-0.36	Cognitive ability (multi-trait analysis);	chr14:22904777	chr14:22929609~22955562:+
PRAD	cis	rs7712401	0.562	rs2407403	ENSG00000263432.2	RN7SL689P	8.17	3.14e-15	1.62e-12	0.37	0.36	Mean platelet volume;	chr5:122838336	chr5:123022487~123022783:-
PRAD	cis	rs6921919	0.583	rs16894108	ENSG00000216901.1	AL022393.7	8.17	3.14e-15	1.62e-12	0.45	0.36	Autism spectrum disorder or schizophrenia;	chr6:28434013	chr6:28176188~28176674:+
PRAD	cis	rs7569084	0.687	rs963539	ENSG00000281920.1	RP11-418H16.1	-8.17	3.15e-15	1.63e-12	-0.44	-0.36	Sum eosinophil basophil counts;	chr2:65421413	chr2:65623272~65628424:+
PRAD	cis	rs17772222	0.958	rs74074098	ENSG00000258983.2	RP11-507K2.2	8.17	3.15e-15	1.63e-12	0.51	0.36	Coronary artery calcification;	chr14:88484213	chr14:88499334~88515502:+
PRAD	cis	rs2404602	0.692	rs12910734	ENSG00000259422.1	RP11-593F23.1	8.17	3.16e-15	1.63e-12	0.45	0.36	Blood metabolite levels;	chr15:76857590	chr15:76174891~76181486:-
PRAD	cis	rs1729407	0.695	rs1263176	ENSG00000254851.1	RP11-109L13.1	-8.17	3.16e-15	1.64e-12	-0.47	-0.36	Apolipoprotein A-IV levels;	chr11:116819407	chr11:117135528~117138582:+
PRAD	cis	rs9532669	0.926	rs12872288	ENSG00000168852.11	TPTE2P5	8.17	3.17e-15	1.64e-12	0.35	0.36	Cervical cancer;	chr13:40880268	chr13:40822296~40921749:-
PRAD	cis	rs6921919	0.583	rs6928773	ENSG00000216901.1	AL022393.7	8.17	3.18e-15	1.65e-12	0.45	0.36	Autism spectrum disorder or schizophrenia;	chr6:28407433	chr6:28176188~28176674:+
PRAD	cis	rs1150668	0.83	rs2023493	ENSG00000280107.1	AL022393.9	-8.17	3.18e-15	1.65e-12	-0.43	-0.36	Pubertal anthropometrics;	chr6:28432385	chr6:28170845~28172521:+
PRAD	cis	rs9341835	0.51	rs2622284	ENSG00000218048.2	RP3-407E4.4	-8.17	3.19e-15	1.65e-12	-0.41	-0.36	Schizophrenia;	chr6:63483667	chr6:63440766~63443580:+
PRAD	cis	rs67311347	0.866	rs2371183	ENSG00000223797.4	ENTPD3-AS1	-8.16	3.19e-15	1.65e-12	-0.32	-0.36	Renal cell carcinoma;	chr3:40292756	chr3:40313802~40453329:-
PRAD	cis	rs6538678	0.833	rs10859966	ENSG00000258343.1	RP11-536G4.2	8.16	3.2e-15	1.65e-12	0.45	0.36	Lupus nephritis in systemic lupus erythematosus;	chr12:95859597	chr12:95795345~95858839:-
PRAD	cis	rs6001482	0.656	rs1894237	ENSG00000272779.1	LL22NC03-80A10.6	-8.16	3.21e-15	1.66e-12	-0.43	-0.36	Diastolic blood pressure;	chr22:22235546	chr22:22303224~22310401:+
PRAD	cis	rs2337406	1	rs1961901	ENSG00000274576.2	IGHV2-70	-8.16	3.21e-15	1.66e-12	-0.38	-0.36	Alzheimer's disease (late onset);	chr14:106680856	chr14:106770577~106771020:-
PRAD	cis	rs2337406	1	rs4774172	ENSG00000274576.2	IGHV2-70	-8.16	3.21e-15	1.66e-12	-0.38	-0.36	Alzheimer's disease (late onset);	chr14:106681320	chr14:106770577~106771020:-
PRAD	cis	rs2283792	0.646	rs7292584	ENSG00000224086.5	LL22NC03-86G7.1	-8.16	3.22e-15	1.66e-12	-0.44	-0.36	Multiple sclerosis;	chr22:21768458	chr22:21938293~21977632:+
PRAD	cis	rs6545883	0.524	rs2694619	ENSG00000271889.1	RP11-493E12.1	-8.16	3.22e-15	1.67e-12	-0.39	-0.36	Tuberculosis;	chr2:61309766	chr2:61151433~61162105:-
PRAD	cis	rs193541	0.593	rs246309	ENSG00000263432.2	RN7SL689P	8.16	3.23e-15	1.67e-12	0.38	0.36	Glucose homeostasis traits;	chr5:122934024	chr5:123022487~123022783:-
PRAD	cis	rs13134327	0.513	rs7679687	ENSG00000251600.4	RP11-673E1.1	-8.16	3.24e-15	1.67e-12	-0.48	-0.36	Glycated hemoglobin levels;	chr4:144024031	chr4:143912331~143982454:+
PRAD	cis	rs172166	0.61	rs276369	ENSG00000204709.4	LINC01556	8.16	3.24e-15	1.68e-12	0.45	0.36	Cardiac Troponin-T levels;	chr6:27951465	chr6:28943877~28944537:+
PRAD	cis	rs67311347	0.91	rs7617361	ENSG00000223797.4	ENTPD3-AS1	8.16	3.24e-15	1.68e-12	0.31	0.36	Renal cell carcinoma;	chr3:40331768	chr3:40313802~40453329:-
PRAD	cis	rs42648	0.507	rs4397318	ENSG00000227646.6	STEAP2-AS1	8.16	3.24e-15	1.68e-12	0.32	0.36	Homocysteine levels;	chr7:90098955	chr7:89882353~90211635:-
PRAD	cis	rs6844153	0.887	rs60890366	ENSG00000240005.4	RP11-293A21.1	-8.16	3.25e-15	1.68e-12	-0.48	-0.36	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26938615	chr4:26859806~26860599:-
PRAD	cis	rs6723108	0.627	rs10432371	ENSG00000224043.6	CCNT2-AS1	-8.16	3.25e-15	1.68e-12	-0.5	-0.36	Type 2 diabetes;	chr2:134852176	chr2:134735464~134918710:-
PRAD	cis	rs4713118	0.629	rs203888	ENSG00000272009.1	RP1-313I6.12	-8.16	3.26e-15	1.68e-12	-0.36	-0.36	Parkinson's disease;	chr6:28053811	chr6:28078792~28081130:-
PRAD	cis	rs7569084	0.663	rs6546150	ENSG00000281920.1	RP11-418H16.1	-8.16	3.26e-15	1.69e-12	-0.44	-0.36	Sum eosinophil basophil counts;	chr2:65415066	chr2:65623272~65628424:+
PRAD	cis	rs11098499	0.863	rs13134665	ENSG00000245958.5	RP11-33B1.1	-8.16	3.27e-15	1.69e-12	-0.35	-0.36	Corneal astigmatism;	chr4:119505275	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.863	rs3775843	ENSG00000245958.5	RP11-33B1.1	-8.16	3.27e-15	1.69e-12	-0.35	-0.36	Corneal astigmatism;	chr4:119506689	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.863	rs3775844	ENSG00000245958.5	RP11-33B1.1	-8.16	3.27e-15	1.69e-12	-0.35	-0.36	Corneal astigmatism;	chr4:119506878	chr4:119454791~119552025:+
PRAD	cis	rs375066	0.806	rs415168	ENSG00000267058.1	RP11-15A1.3	-8.16	3.28e-15	1.69e-12	-0.3	-0.36	Breast cancer;	chr19:43898422	chr19:43891804~43901805:-
PRAD	cis	rs11083475	1	rs56113315	ENSG00000267892.1	CTD-2540F13.2	8.16	3.29e-15	1.7e-12	0.39	0.36	Heart rate;	chr19:38693526	chr19:38738284~38739863:+
PRAD	cis	rs2581828	0.618	rs9824325	ENSG00000242142.1	SERBP1P3	-8.16	3.31e-15	1.71e-12	-0.42	-0.36	Crohn's disease;	chr3:53132494	chr3:53064283~53065091:-
PRAD	cis	rs950169	0.84	rs12905223	ENSG00000259728.4	LINC00933	8.16	3.33e-15	1.72e-12	0.43	0.36	Schizophrenia;	chr15:84571037	chr15:84570649~84580175:+
PRAD	cis	rs6723108	0.627	rs4954189	ENSG00000224043.6	CCNT2-AS1	-8.16	3.33e-15	1.72e-12	-0.5	-0.36	Type 2 diabetes;	chr2:134849763	chr2:134735464~134918710:-
PRAD	cis	rs10463554	0.927	rs257308	ENSG00000175749.11	EIF3KP1	8.16	3.34e-15	1.72e-12	0.48	0.36	Parkinson's disease;	chr5:103082557	chr5:103032376~103033031:+
PRAD	cis	rs10463554	0.927	rs257311	ENSG00000175749.11	EIF3KP1	8.16	3.34e-15	1.72e-12	0.48	0.36	Parkinson's disease;	chr5:103083394	chr5:103032376~103033031:+
PRAD	cis	rs10463554	0.927	rs257314	ENSG00000175749.11	EIF3KP1	8.16	3.34e-15	1.72e-12	0.48	0.36	Parkinson's disease;	chr5:103085391	chr5:103032376~103033031:+
PRAD	cis	rs72627509	0.904	rs56281640	ENSG00000269949.1	RP11-738E22.3	8.16	3.35e-15	1.73e-12	0.51	0.36	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56899650	chr4:56960927~56961373:-
PRAD	cis	rs673078	0.607	rs17441061	ENSG00000275409.1	RP11-131L12.4	-8.16	3.35e-15	1.73e-12	-0.51	-0.36	Glucose homeostasis traits;	chr12:118409847	chr12:118430147~118430699:+
PRAD	cis	rs2337406	1	rs7145172	ENSG00000274576.2	IGHV2-70	-8.16	3.35e-15	1.73e-12	-0.38	-0.36	Alzheimer's disease (late onset);	chr14:106704924	chr14:106770577~106771020:-
PRAD	cis	rs4631830	0.9	rs9787697	ENSG00000230869.1	CTGLF10P	-8.16	3.35e-15	1.73e-12	-0.44	-0.36	Prostate-specific antigen levels;	chr10:46062446	chr10:45678692~45700532:+
PRAD	cis	rs4631830	0.9	rs4630241	ENSG00000230869.1	CTGLF10P	-8.16	3.35e-15	1.73e-12	-0.44	-0.36	Prostate-specific antigen levels;	chr10:46063071	chr10:45678692~45700532:+
PRAD	cis	rs62355901	0.545	rs12657172	ENSG00000271828.1	CTD-2310F14.1	8.16	3.36e-15	1.73e-12	0.76	0.36	Breast cancer;	chr5:56768280	chr5:56927874~56929573:+
PRAD	cis	rs12939005	1	rs12939005	ENSG00000275710.1	RP11-257O5.4	-8.16	3.36e-15	1.73e-12	-0.54	-0.36	Large artery stroke;	chr17:54909123	chr17:54964474~54964679:+
PRAD	cis	rs4631830	0.9	rs10763534	ENSG00000230869.1	CTGLF10P	-8.16	3.37e-15	1.74e-12	-0.44	-0.36	Prostate-specific antigen levels;	chr10:46060902	chr10:45678692~45700532:+
PRAD	cis	rs34779708	0.733	rs7070778	ENSG00000230534.5	RP11-297A16.2	8.16	3.37e-15	1.74e-12	0.48	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35252760	chr10:35098006~35127020:-
PRAD	cis	rs4713118	0.868	rs760587	ENSG00000226314.6	ZNF192P1	-8.16	3.38e-15	1.74e-12	-0.49	-0.36	Parkinson's disease;	chr6:27772521	chr6:28161781~28169594:+
PRAD	cis	rs7945705	0.747	rs1980429	ENSG00000254860.4	TMEM9B-AS1	8.16	3.38e-15	1.74e-12	0.37	0.36	Hemoglobin concentration;	chr11:8988927	chr11:8964675~8977527:+
PRAD	cis	rs853679	0.599	rs188015	ENSG00000280107.1	AL022393.9	-8.16	3.38e-15	1.74e-12	-0.64	-0.36	Depression;	chr6:27909668	chr6:28170845~28172521:+
PRAD	cis	rs17711722	0.51	rs11767457	ENSG00000236529.1	RP13-254B10.1	8.16	3.39e-15	1.74e-12	0.38	0.36	Calcium levels;	chr7:65825628	chr7:65840212~65840596:+
PRAD	cis	rs72627509	0.904	rs781663	ENSG00000269949.1	RP11-738E22.3	8.16	3.39e-15	1.75e-12	0.51	0.36	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56915588	chr4:56960927~56961373:-
PRAD	cis	rs2015599	0.549	rs7134796	ENSG00000275476.1	RP11-996F15.4	8.16	3.4e-15	1.75e-12	0.39	0.36	Platelet count;Mean platelet volume;	chr12:29294361	chr12:29277397~29277882:-
PRAD	cis	rs7615952	0.599	rs2279821	ENSG00000171084.14	FAM86JP	8.16	3.42e-15	1.76e-12	0.57	0.36	Blood pressure (smoking interaction);	chr3:126015465	chr3:125916620~125930024:+
PRAD	cis	rs7429990	0.901	rs7431567	ENSG00000229759.1	MRPS18AP1	-8.16	3.42e-15	1.76e-12	-0.37	-0.36	Educational attainment (years of education);	chr3:47986342	chr3:48256350~48256938:-
PRAD	cis	rs375066	0.935	rs397913	ENSG00000267058.1	RP11-15A1.3	8.16	3.42e-15	1.76e-12	0.3	0.36	Breast cancer;	chr19:43894788	chr19:43891804~43901805:-
PRAD	cis	rs875971	0.793	rs460678	ENSG00000237310.1	GS1-124K5.4	8.15	3.43e-15	1.77e-12	0.31	0.36	Aortic root size;	chr7:66062213	chr7:66493706~66495474:+
PRAD	cis	rs7615952	0.576	rs66671308	ENSG00000171084.14	FAM86JP	8.15	3.43e-15	1.77e-12	0.57	0.36	Blood pressure (smoking interaction);	chr3:126074683	chr3:125916620~125930024:+
PRAD	cis	rs2638953	0.924	rs10843139	ENSG00000278733.1	RP11-425D17.1	-8.15	3.44e-15	1.77e-12	-0.46	-0.36	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28227160	chr12:28185625~28186190:-
PRAD	cis	rs2108622	0.701	rs118144071	ENSG00000267056.2	AC005336.4	8.15	3.45e-15	1.78e-12	0.49	0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15868384	chr19:15910582~15911824:-
PRAD	cis	rs11920570	0.526	rs3828362	ENSG00000272758.4	RP11-299J3.8	8.15	3.45e-15	1.78e-12	0.39	0.36	Resting heart rate;	chr3:122412930	chr3:122416207~122443180:+
PRAD	cis	rs9532669	0.75	rs9532598	ENSG00000168852.11	TPTE2P5	8.15	3.45e-15	1.78e-12	0.35	0.36	Cervical cancer;	chr13:40860627	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.611	rs9532599	ENSG00000168852.11	TPTE2P5	8.15	3.45e-15	1.78e-12	0.35	0.36	Cervical cancer;	chr13:40860633	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.571	rs9525405	ENSG00000168852.11	TPTE2P5	8.15	3.45e-15	1.78e-12	0.35	0.36	Cervical cancer;	chr13:40860638	chr13:40822296~40921749:-
PRAD	cis	rs4631830	0.9	rs7920517	ENSG00000230869.1	CTGLF10P	-8.15	3.46e-15	1.78e-12	-0.44	-0.36	Prostate-specific antigen levels;	chr10:46063201	chr10:45678692~45700532:+
PRAD	cis	rs12220777	1	rs11201799	ENSG00000230091.5	TMEM254-AS1	-8.15	3.48e-15	1.79e-12	-0.66	-0.36	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80122198	chr10:80046860~80078912:-
PRAD	cis	rs150992	0.504	rs152036	ENSG00000248489.1	CTD-2007H13.3	8.15	3.48e-15	1.79e-12	0.47	0.36	Body mass index;	chr5:98981729	chr5:98929171~98995013:+
PRAD	cis	rs67311347	1	rs67680017	ENSG00000223797.4	ENTPD3-AS1	8.15	3.48e-15	1.79e-12	0.33	0.36	Renal cell carcinoma;	chr3:40491673	chr3:40313802~40453329:-
PRAD	cis	rs12908161	0.959	rs2175567	ENSG00000259728.4	LINC00933	8.15	3.49e-15	1.79e-12	0.43	0.36	Schizophrenia;	chr15:84657715	chr15:84570649~84580175:+
PRAD	cis	rs7829975	0.617	rs4841071	ENSG00000253893.2	FAM85B	-8.15	3.5e-15	1.8e-12	-0.43	-0.36	Mood instability;	chr8:8933634	chr8:8167819~8226614:-
PRAD	cis	rs7923609	0.936	rs10761778	ENSG00000232075.1	MRPL35P2	-8.15	3.51e-15	1.8e-12	-0.38	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63514022	chr10:63634317~63634827:-
PRAD	cis	rs950169	0.84	rs35522895	ENSG00000225151.9	GOLGA2P7	-8.15	3.51e-15	1.8e-12	-0.52	-0.36	Schizophrenia;	chr15:84259297	chr15:84199311~84230136:-
PRAD	cis	rs6539288	0.739	rs1053050	ENSG00000260329.1	RP11-412D9.4	-8.15	3.51e-15	1.81e-12	-0.31	-0.36	Total body bone mineral density;	chr12:106973446	chr12:106954029~106955497:-
PRAD	cis	rs17711722	0.503	rs453835	ENSG00000236529.1	RP13-254B10.1	-8.15	3.52e-15	1.81e-12	-0.38	-0.36	Calcium levels;	chr7:66046172	chr7:65840212~65840596:+
PRAD	cis	rs375066	0.935	rs367283	ENSG00000267058.1	RP11-15A1.3	-8.15	3.54e-15	1.82e-12	-0.3	-0.36	Breast cancer;	chr19:43901975	chr19:43891804~43901805:-
PRAD	cis	rs12908161	0.92	rs35738019	ENSG00000259728.4	LINC00933	8.15	3.54e-15	1.82e-12	0.44	0.36	Schizophrenia;	chr15:84736979	chr15:84570649~84580175:+
PRAD	cis	rs12908161	1	rs34570071	ENSG00000259728.4	LINC00933	8.15	3.54e-15	1.82e-12	0.44	0.36	Schizophrenia;	chr15:84736981	chr15:84570649~84580175:+
PRAD	cis	rs950169	0.58	rs11630887	ENSG00000259728.4	LINC00933	8.15	3.54e-15	1.82e-12	0.43	0.36	Schizophrenia;	chr15:84649784	chr15:84570649~84580175:+
PRAD	cis	rs6847067	0.763	rs56194765	ENSG00000180769.7	WDFY3-AS2	8.15	3.54e-15	1.82e-12	0.37	0.36	Oropharynx cancer;	chr4:85004309	chr4:84965682~85011277:+
PRAD	cis	rs465969	1	rs1407644	ENSG00000255389.1	C6orf3	8.15	3.55e-15	1.82e-12	0.73	0.36	Psoriasis;	chr6:111480895	chr6:111599875~111602295:+
PRAD	cis	rs2337406	1	rs11850709	ENSG00000274576.2	IGHV2-70	-8.15	3.55e-15	1.82e-12	-0.38	-0.36	Alzheimer's disease (late onset);	chr14:106670844	chr14:106770577~106771020:-
PRAD	cis	rs9532669	0.926	rs2875421	ENSG00000168852.11	TPTE2P5	8.15	3.55e-15	1.83e-12	0.34	0.36	Cervical cancer;	chr13:40936536	chr13:40822296~40921749:-
PRAD	cis	rs11098499	0.82	rs2389885	ENSG00000245958.5	RP11-33B1.1	-8.15	3.56e-15	1.83e-12	-0.36	-0.36	Corneal astigmatism;	chr4:119612776	chr4:119454791~119552025:+
PRAD	cis	rs12612619	0.677	rs3754733	ENSG00000229122.1	AGBL5-IT1	8.15	3.56e-15	1.83e-12	0.37	0.36	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27026377	chr2:27061038~27061815:+
PRAD	cis	rs875971	0.83	rs587360	ENSG00000237310.1	GS1-124K5.4	8.15	3.6e-15	1.85e-12	0.31	0.36	Aortic root size;	chr7:66057711	chr7:66493706~66495474:+
PRAD	cis	rs10853057	1	rs10853057	ENSG00000214174.7	AMZ2P1	8.15	3.61e-15	1.85e-12	0.61	0.36	White matter microstructure (global fractional anisotropy);	chr17:65001905	chr17:64966550~64975576:-
PRAD	cis	rs6921919	0.583	rs3800328	ENSG00000216901.1	AL022393.7	8.15	3.62e-15	1.86e-12	0.45	0.36	Autism spectrum disorder or schizophrenia;	chr6:28423066	chr6:28176188~28176674:+
PRAD	cis	rs6921919	0.583	rs740622	ENSG00000216901.1	AL022393.7	8.15	3.62e-15	1.86e-12	0.45	0.36	Autism spectrum disorder or schizophrenia;	chr6:28430514	chr6:28176188~28176674:+
PRAD	cis	rs526231	0.511	rs158402	ENSG00000175749.11	EIF3KP1	8.15	3.62e-15	1.86e-12	0.48	0.36	Primary biliary cholangitis;	chr5:103079821	chr5:103032376~103033031:+
PRAD	cis	rs4713118	0.662	rs149970	ENSG00000226314.6	ZNF192P1	-8.15	3.63e-15	1.87e-12	-0.48	-0.36	Parkinson's disease;	chr6:28012442	chr6:28161781~28169594:+
PRAD	cis	rs11096990	0.634	rs2276888	ENSG00000249207.1	RP11-360F5.1	8.15	3.63e-15	1.87e-12	0.37	0.36	Cognitive function;	chr4:39278287	chr4:39112677~39126818:-
PRAD	cis	rs875971	0.964	rs160635	ENSG00000237310.1	GS1-124K5.4	8.15	3.64e-15	1.87e-12	0.31	0.36	Aortic root size;	chr7:66063931	chr7:66493706~66495474:+
PRAD	cis	rs321358	0.895	rs17536059	ENSG00000271584.1	RP11-89C3.4	-8.15	3.64e-15	1.87e-12	-0.51	-0.36	Body mass index;	chr11:111086611	chr11:111091932~111097357:-
PRAD	cis	rs508487	0.537	rs5072	ENSG00000254851.1	RP11-109L13.1	-8.15	3.64e-15	1.87e-12	-0.85	-0.36	Cardiovascular disease risk factors;Triglyceride levels;	chr11:116836867	chr11:117135528~117138582:+
PRAD	cis	rs9393777	0.92	rs13207689	ENSG00000280107.1	AL022393.9	-8.15	3.65e-15	1.88e-12	-0.71	-0.36	Intelligence (multi-trait analysis);	chr6:27401925	chr6:28170845~28172521:+
PRAD	cis	rs200972	1	rs200972	ENSG00000280107.1	AL022393.9	-8.15	3.66e-15	1.88e-12	-0.44	-0.36	Urinary tract infection frequency;	chr6:27891059	chr6:28170845~28172521:+
PRAD	cis	rs12908161	1	rs12903134	ENSG00000259728.4	LINC00933	8.15	3.67e-15	1.88e-12	0.44	0.36	Schizophrenia;	chr15:84794468	chr15:84570649~84580175:+
PRAD	cis	rs12908161	1	rs35726233	ENSG00000259728.4	LINC00933	8.15	3.67e-15	1.88e-12	0.44	0.36	Schizophrenia;	chr15:84794569	chr15:84570649~84580175:+
PRAD	cis	rs5769707	0.632	rs5770601	ENSG00000188511.11	C22orf34	8.15	3.67e-15	1.89e-12	0.43	0.36	Monocyte percentage of white cells;Monocyte count;	chr22:49628255	chr22:49414524~49657542:-
PRAD	cis	rs12142240	0.638	rs6662982	ENSG00000232022.5	FAAHP1	-8.15	3.68e-15	1.89e-12	-0.34	-0.36	Menopause (age at onset);	chr1:46411508	chr1:46432129~46445521:+
PRAD	cis	rs12908161	0.96	rs62019463	ENSG00000259728.4	LINC00933	8.15	3.68e-15	1.89e-12	0.44	0.36	Schizophrenia;	chr15:84744856	chr15:84570649~84580175:+
PRAD	cis	rs12908161	1	rs62019464	ENSG00000259728.4	LINC00933	8.15	3.68e-15	1.89e-12	0.44	0.36	Schizophrenia;	chr15:84751238	chr15:84570649~84580175:+
PRAD	cis	rs4266144	1	rs12487629	ENSG00000244515.1	KRT18P34	-8.15	3.68e-15	1.89e-12	-0.44	-0.36	Coronary artery disease;	chr3:157134416	chr3:157162663~157163932:-
PRAD	cis	rs7923609	0.967	rs3999089	ENSG00000232075.1	MRPL35P2	8.14	3.7e-15	1.9e-12	0.38	0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63444048	chr10:63634317~63634827:-
PRAD	cis	rs1355223	0.902	rs1597962	ENSG00000271369.1	RP11-350D17.3	-8.14	3.71e-15	1.91e-12	-0.41	-0.36	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34705625	chr11:34709600~34710161:+
PRAD	cis	rs10463554	0.963	rs40093	ENSG00000175749.11	EIF3KP1	8.14	3.72e-15	1.91e-12	0.47	0.36	Parkinson's disease;	chr5:103104121	chr5:103032376~103033031:+
PRAD	cis	rs17012589	0.639	rs12315575	ENSG00000258815.1	RP11-408B11.2	8.14	3.73e-15	1.91e-12	0.49	0.36	Bone mineral density (Ward's triangle area);	chr12:85276558	chr12:85318060~85342912:+
PRAD	cis	rs17012589	0.696	rs4076027	ENSG00000258815.1	RP11-408B11.2	8.14	3.73e-15	1.91e-12	0.49	0.36	Bone mineral density (Ward's triangle area);	chr12:85278029	chr12:85318060~85342912:+
PRAD	cis	rs10463554	0.963	rs34771	ENSG00000175749.11	EIF3KP1	8.14	3.74e-15	1.92e-12	0.47	0.36	Parkinson's disease;	chr5:103114713	chr5:103032376~103033031:+
PRAD	cis	rs7772486	0.902	rs1125462	ENSG00000235652.6	RP11-545I5.3	8.14	3.75e-15	1.92e-12	0.36	0.36	Lobe attachment (rater-scored or self-reported);	chr6:146096696	chr6:145799409~145886585:+
PRAD	cis	rs240993	0.715	rs7776346	ENSG00000230177.1	RP5-1112D6.4	8.14	3.75e-15	1.92e-12	0.44	0.36	Inflammatory skin disease;Psoriasis;	chr6:111540162	chr6:111277932~111278742:+
PRAD	cis	rs2404602	0.716	rs2404736	ENSG00000259422.1	RP11-593F23.1	8.14	3.75e-15	1.93e-12	0.45	0.36	Blood metabolite levels;	chr15:76583602	chr15:76174891~76181486:-
PRAD	cis	rs1930961	1	rs6004675	ENSG00000271138.1	IGLVIVOR22-1	-8.14	3.75e-15	1.93e-12	-0.55	-0.36	Bipolar disorder with mood-incongruent psychosis;	chr22:25493418	chr22:25437306~25437823:-
PRAD	cis	rs10463554	0.889	rs34775	ENSG00000175749.11	EIF3KP1	8.14	3.76e-15	1.93e-12	0.49	0.36	Parkinson's disease;	chr5:103115572	chr5:103032376~103033031:+
PRAD	cis	rs10463554	0.927	rs34776	ENSG00000175749.11	EIF3KP1	8.14	3.76e-15	1.93e-12	0.49	0.36	Parkinson's disease;	chr5:103116090	chr5:103032376~103033031:+
PRAD	cis	rs10463554	0.667	rs34782	ENSG00000175749.11	EIF3KP1	8.14	3.76e-15	1.93e-12	0.49	0.36	Parkinson's disease;	chr5:103118766	chr5:103032376~103033031:+
PRAD	cis	rs4722166	0.532	rs4719711	ENSG00000179428.2	AC073072.5	8.14	3.76e-15	1.93e-12	0.41	0.36	Lung cancer;	chr7:22716069	chr7:22725395~22727620:-
PRAD	cis	rs1528149	0.93	rs2389581	ENSG00000224683.1	RPL36AP29	8.14	3.77e-15	1.93e-12	0.44	0.36	Sitting height ratio;	chr7:16078546	chr7:16208945~16209265:+
PRAD	cis	rs5769707	0.706	rs763128	ENSG00000188511.11	C22orf34	8.14	3.77e-15	1.93e-12	0.41	0.36	Monocyte percentage of white cells;Monocyte count;	chr22:49624397	chr22:49414524~49657542:-
PRAD	cis	rs6570726	0.935	rs380883	ENSG00000235652.6	RP11-545I5.3	8.14	3.77e-15	1.93e-12	0.38	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145501856	chr6:145799409~145886585:+
PRAD	cis	rs7432375	1	rs940174	ENSG00000261758.1	RP11-102M11.2	8.14	3.77e-15	1.93e-12	0.41	0.36	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136590868	chr3:136752630~136755780:+
PRAD	cis	rs10129255	0.517	rs11625572	ENSG00000211970.3	IGHV4-61	-8.14	3.77e-15	1.94e-12	-0.34	-0.36	Kawasaki disease;	chr14:106656426	chr14:106639119~106639657:-
PRAD	cis	rs321358	1	rs429803	ENSG00000271584.1	RP11-89C3.4	8.14	3.79e-15	1.94e-12	0.54	0.36	Body mass index;	chr11:111132263	chr11:111091932~111097357:-
PRAD	cis	rs321358	0.943	rs402820	ENSG00000271584.1	RP11-89C3.4	8.14	3.79e-15	1.94e-12	0.54	0.36	Body mass index;	chr11:111132480	chr11:111091932~111097357:-
PRAD	cis	rs10875746	0.669	rs2279464	ENSG00000240399.1	RP1-228P16.1	-8.14	3.79e-15	1.95e-12	-0.35	-0.36	Longevity (90 years and older);	chr12:48296626	chr12:48054813~48055591:-
PRAD	cis	rs6452524	0.967	rs2662243	ENSG00000249664.1	CTD-2227C6.2	8.14	3.8e-15	1.95e-12	0.43	0.36	Hypertension (SNP x SNP interaction);	chr5:83192630	chr5:83012285~83013109:-
PRAD	cis	rs6452524	0.935	rs2731846	ENSG00000249664.1	CTD-2227C6.2	8.14	3.8e-15	1.95e-12	0.43	0.36	Hypertension (SNP x SNP interaction);	chr5:83193781	chr5:83012285~83013109:-
PRAD	cis	rs72627509	0.629	rs1277313	ENSG00000269949.1	RP11-738E22.3	-8.14	3.81e-15	1.95e-12	-0.48	-0.36	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:57037782	chr4:56960927~56961373:-
PRAD	cis	rs7727544	0.716	rs7720230	ENSG00000233006.5	AC034220.3	8.14	3.82e-15	1.96e-12	0.32	0.36	Blood metabolite levels;	chr5:132256712	chr5:132311285~132369916:-
PRAD	cis	rs875971	0.8	rs427557	ENSG00000237310.1	GS1-124K5.4	8.14	3.82e-15	1.96e-12	0.31	0.36	Aortic root size;	chr7:66054263	chr7:66493706~66495474:+
PRAD	cis	rs10463554	0.963	rs32850	ENSG00000175749.11	EIF3KP1	8.14	3.82e-15	1.96e-12	0.46	0.36	Parkinson's disease;	chr5:103134325	chr5:103032376~103033031:+
PRAD	cis	rs2638953	0.924	rs11049403	ENSG00000278733.1	RP11-425D17.1	-8.14	3.82e-15	1.96e-12	-0.45	-0.36	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28177105	chr12:28185625~28186190:-
PRAD	cis	rs2404602	0.692	rs12911902	ENSG00000259422.1	RP11-593F23.1	8.14	3.83e-15	1.96e-12	0.44	0.36	Blood metabolite levels;	chr15:76761234	chr15:76174891~76181486:-
PRAD	cis	rs375066	0.901	rs376069	ENSG00000267058.1	RP11-15A1.3	-8.14	3.84e-15	1.97e-12	-0.3	-0.36	Breast cancer;	chr19:43913143	chr19:43891804~43901805:-
PRAD	cis	rs17711722	0.565	rs4717276	ENSG00000164669.11	INTS4P1	-8.14	3.84e-15	1.97e-12	-0.44	-0.36	Calcium levels;	chr7:65829754	chr7:65141225~65234216:+
PRAD	cis	rs17361889	0.752	rs1918266	ENSG00000224683.1	RPL36AP29	-8.14	3.85e-15	1.97e-12	-0.43	-0.36	Pediatric bone mineral content (hip);	chr7:16231996	chr7:16208945~16209265:+
PRAD	cis	rs7923609	0.902	rs10740136	ENSG00000232075.1	MRPL35P2	-8.14	3.85e-15	1.97e-12	-0.37	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63569862	chr10:63634317~63634827:-
PRAD	cis	rs10463554	0.927	rs257316	ENSG00000175749.11	EIF3KP1	-8.14	3.85e-15	1.97e-12	-0.48	-0.36	Parkinson's disease;	chr5:103086739	chr5:103032376~103033031:+
PRAD	cis	rs2337406	0.85	rs4774179	ENSG00000274576.2	IGHV2-70	-8.14	3.85e-15	1.98e-12	-0.39	-0.36	Alzheimer's disease (late onset);	chr14:106700837	chr14:106770577~106771020:-
PRAD	cis	rs3096299	0.933	rs3096297	ENSG00000274627.1	RP11-104N10.2	8.14	3.86e-15	1.98e-12	0.37	0.36	Multiple myeloma (IgH translocation);	chr16:89386747	chr16:89516797~89522217:+
PRAD	cis	rs6545883	0.524	rs17482440	ENSG00000271889.1	RP11-493E12.1	-8.14	3.86e-15	1.98e-12	-0.39	-0.36	Tuberculosis;	chr2:61321722	chr2:61151433~61162105:-
PRAD	cis	rs67311347	0.635	rs62261855	ENSG00000223797.4	ENTPD3-AS1	8.14	3.87e-15	1.98e-12	0.34	0.36	Renal cell carcinoma;	chr3:40253447	chr3:40313802~40453329:-
PRAD	cis	rs1062177	0.756	rs2964591	ENSG00000253921.1	CTB-113P19.3	8.14	3.87e-15	1.98e-12	0.46	0.36	Preschool internalizing problems;	chr5:151737836	chr5:151753992~151767247:+
PRAD	cis	rs6452524	1	rs7738033	ENSG00000249664.1	CTD-2227C6.2	8.14	3.88e-15	1.99e-12	0.43	0.36	Hypertension (SNP x SNP interaction);	chr5:83135470	chr5:83012285~83013109:-
PRAD	cis	rs6452524	1	rs6860239	ENSG00000249664.1	CTD-2227C6.2	8.14	3.88e-15	1.99e-12	0.43	0.36	Hypertension (SNP x SNP interaction);	chr5:83136022	chr5:83012285~83013109:-
PRAD	cis	rs7746199	0.736	rs13202295	ENSG00000280107.1	AL022393.9	-8.14	3.88e-15	1.99e-12	-0.73	-0.36	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731058	chr6:28170845~28172521:+
PRAD	cis	rs66486766	1	rs66486766	ENSG00000225151.9	GOLGA2P7	-8.14	3.89e-15	1.99e-12	-0.5	-0.36	Bipolar disorder lithium response (categorical) or schizophrenia;	chr15:84137308	chr15:84199311~84230136:-
PRAD	cis	rs6517329	0.649	rs4817776	ENSG00000236830.5	CBR3-AS1	8.14	3.89e-15	1.99e-12	0.38	0.36	Schizophrenia;	chr21:36121124	chr21:36131767~36175815:-
PRAD	cis	rs6430553	0.964	rs10496731	ENSG00000224043.6	CCNT2-AS1	-8.14	3.9e-15	2e-12	-0.49	-0.36	Blood metabolite levels;	chr2:134840058	chr2:134735464~134918710:-
PRAD	cis	rs8042680	0.688	rs4244883	ENSG00000214432.8	AC068831.10	-8.14	3.91e-15	2e-12	-0.43	-0.36	Type 2 diabetes;	chr15:91003267	chr15:91022619~91036611:+
PRAD	cis	rs7115242	0.92	rs6589574	ENSG00000254851.1	RP11-109L13.1	-8.14	3.91e-15	2e-12	-0.84	-0.36	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116859922	chr11:117135528~117138582:+
PRAD	cis	rs10875746	0.537	rs4760625	ENSG00000240399.1	RP1-228P16.1	-8.14	3.93e-15	2.01e-12	-0.35	-0.36	Longevity (90 years and older);	chr12:48279960	chr12:48054813~48055591:-
PRAD	cis	rs964611	1	rs7168752	ENSG00000259488.2	RP11-154J22.1	-8.14	3.94e-15	2.02e-12	-0.39	-0.36	Metabolite levels (Pyroglutamine);	chr15:48308583	chr15:48312353~48331856:-
PRAD	cis	rs964611	1	rs79040993	ENSG00000259488.2	RP11-154J22.1	-8.14	3.94e-15	2.02e-12	-0.39	-0.36	Metabolite levels (Pyroglutamine);	chr15:48309949	chr15:48312353~48331856:-
PRAD	cis	rs2108622	0.683	rs111388185	ENSG00000267056.2	AC005336.4	8.14	3.94e-15	2.02e-12	0.49	0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866604	chr19:15910582~15911824:-
PRAD	cis	rs2108622	0.683	rs112571591	ENSG00000267056.2	AC005336.4	8.14	3.94e-15	2.02e-12	0.49	0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866635	chr19:15910582~15911824:-
PRAD	cis	rs2108622	0.647	rs111427692	ENSG00000267056.2	AC005336.4	8.14	3.94e-15	2.02e-12	0.49	0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866669	chr19:15910582~15911824:-
PRAD	cis	rs2108622	0.727	rs12609468	ENSG00000267056.2	AC005336.4	8.14	3.94e-15	2.02e-12	0.49	0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867004	chr19:15910582~15911824:-
PRAD	cis	rs2108622	0.727	rs12610967	ENSG00000267056.2	AC005336.4	8.14	3.94e-15	2.02e-12	0.49	0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867119	chr19:15910582~15911824:-
PRAD	cis	rs2108622	0.711	rs12609820	ENSG00000267056.2	AC005336.4	8.14	3.94e-15	2.02e-12	0.49	0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867247	chr19:15910582~15911824:-
PRAD	cis	rs2108622	0.668	rs62106153	ENSG00000267056.2	AC005336.4	8.14	3.94e-15	2.02e-12	0.49	0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867697	chr19:15910582~15911824:-
PRAD	cis	rs2108622	0.727	rs12611242	ENSG00000267056.2	AC005336.4	8.14	3.94e-15	2.02e-12	0.49	0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867754	chr19:15910582~15911824:-
PRAD	cis	rs2108622	0.727	rs12611308	ENSG00000267056.2	AC005336.4	8.14	3.94e-15	2.02e-12	0.49	0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867776	chr19:15910582~15911824:-
PRAD	cis	rs2108622	0.727	rs12610189	ENSG00000267056.2	AC005336.4	8.14	3.94e-15	2.02e-12	0.49	0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867831	chr19:15910582~15911824:-
PRAD	cis	rs2108622	0.711	rs113343664	ENSG00000267056.2	AC005336.4	8.14	3.94e-15	2.02e-12	0.49	0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15868183	chr19:15910582~15911824:-
PRAD	cis	rs950169	0.58	rs11634320	ENSG00000259728.4	LINC00933	-8.14	3.95e-15	2.02e-12	-0.42	-0.36	Schizophrenia;	chr15:84628952	chr15:84570649~84580175:+
PRAD	cis	rs8005677	1	rs10148215	ENSG00000257285.4	RP11-298I3.1	8.14	3.96e-15	2.02e-12	0.36	0.36	Cognitive ability (multi-trait analysis);	chr14:22913136	chr14:22929609~22955562:+
PRAD	cis	rs9532669	0.926	rs9532654	ENSG00000168852.11	TPTE2P5	8.13	3.96e-15	2.03e-12	0.34	0.36	Cervical cancer;	chr13:40909812	chr13:40822296~40921749:-
PRAD	cis	rs4664293	0.51	rs66589863	ENSG00000226266.5	AC009961.3	8.13	3.96e-15	2.03e-12	0.48	0.36	Monocyte percentage of white cells;	chr2:159649684	chr2:159670708~159712435:-
PRAD	cis	rs8081395	0.836	rs2150879	ENSG00000266992.1	DHX40P1	-8.13	3.96e-15	2.03e-12	-0.4	-0.36	White blood cell count;	chr17:59781849	chr17:59976009~60002384:-
PRAD	cis	rs12142240	1	rs12146051	ENSG00000232022.5	FAAHP1	-8.13	3.96e-15	2.03e-12	-0.34	-0.36	Menopause (age at onset);	chr1:46277280	chr1:46432129~46445521:+
PRAD	cis	rs748404	0.697	rs493177	ENSG00000205771.5	CATSPER2P1	-8.13	3.97e-15	2.03e-12	-0.38	-0.36	Lung cancer;	chr15:43251060	chr15:43726918~43747094:-
PRAD	cis	rs964611	0.748	rs61248772	ENSG00000259488.2	RP11-154J22.1	-8.13	3.98e-15	2.04e-12	-0.38	-0.36	Metabolite levels (Pyroglutamine);	chr15:48306529	chr15:48312353~48331856:-
PRAD	cis	rs9309473	0.607	rs10198301	ENSG00000163016.8	ALMS1P	8.13	3.98e-15	2.04e-12	0.43	0.36	Metabolite levels;	chr2:73354472	chr2:73644919~73685576:+
PRAD	cis	rs7923609	0.902	rs10733793	ENSG00000232075.1	MRPL35P2	-8.13	3.98e-15	2.04e-12	-0.37	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63564049	chr10:63634317~63634827:-
PRAD	cis	rs7923609	0.902	rs10822182	ENSG00000232075.1	MRPL35P2	-8.13	3.98e-15	2.04e-12	-0.37	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63565718	chr10:63634317~63634827:-
PRAD	cis	rs7923609	0.902	rs4633333	ENSG00000232075.1	MRPL35P2	-8.13	3.98e-15	2.04e-12	-0.37	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63568779	chr10:63634317~63634827:-
PRAD	cis	rs9810089	0.843	rs834304	ENSG00000261758.1	RP11-102M11.2	8.13	3.98e-15	2.04e-12	0.41	0.36	Gestational age at birth (child effect);	chr3:136392816	chr3:136752630~136755780:+
PRAD	cis	rs10463554	0.892	rs257305	ENSG00000175749.11	EIF3KP1	8.13	4.01e-15	2.05e-12	0.48	0.36	Parkinson's disease;	chr5:103081533	chr5:103032376~103033031:+
PRAD	cis	rs10463554	0.927	rs257306	ENSG00000175749.11	EIF3KP1	8.13	4.01e-15	2.05e-12	0.48	0.36	Parkinson's disease;	chr5:103081770	chr5:103032376~103033031:+
PRAD	cis	rs10463554	0.892	rs257307	ENSG00000175749.11	EIF3KP1	8.13	4.01e-15	2.05e-12	0.48	0.36	Parkinson's disease;	chr5:103081805	chr5:103032376~103033031:+
PRAD	cis	rs1979679	1	rs1979679	ENSG00000278733.1	RP11-425D17.1	8.13	4.01e-15	2.05e-12	0.47	0.36	Ossification of the posterior longitudinal ligament of the spine;	chr12:28253582	chr12:28185625~28186190:-
PRAD	cis	rs1979679	1	rs11049487	ENSG00000278733.1	RP11-425D17.1	8.13	4.01e-15	2.05e-12	0.47	0.36	Ossification of the posterior longitudinal ligament of the spine;	chr12:28254157	chr12:28185625~28186190:-
PRAD	cis	rs1979679	0.842	rs4931727	ENSG00000278733.1	RP11-425D17.1	8.13	4.01e-15	2.05e-12	0.45	0.36	Ossification of the posterior longitudinal ligament of the spine;	chr12:28146186	chr12:28185625~28186190:-
PRAD	cis	rs858239	0.669	rs6461687	ENSG00000226816.2	AC005082.12	8.13	4.04e-15	2.07e-12	0.41	0.36	Cerebrospinal fluid biomarker levels;	chr7:23076961	chr7:23206013~23208045:+
PRAD	cis	rs6844153	0.68	rs11729927	ENSG00000240005.4	RP11-293A21.1	-8.13	4.05e-15	2.07e-12	-0.44	-0.36	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26922178	chr4:26859806~26860599:-
PRAD	cis	rs964611	0.935	rs76749119	ENSG00000259488.2	RP11-154J22.1	-8.13	4.05e-15	2.07e-12	-0.39	-0.36	Metabolite levels (Pyroglutamine);	chr15:48312868	chr15:48312353~48331856:-
PRAD	cis	rs964611	1	rs74012001	ENSG00000259488.2	RP11-154J22.1	-8.13	4.05e-15	2.07e-12	-0.39	-0.36	Metabolite levels (Pyroglutamine);	chr15:48313011	chr15:48312353~48331856:-
PRAD	cis	rs7397814	0.558	rs4764447	ENSG00000278635.1	CTD-2318O12.1	8.13	4.06e-15	2.08e-12	0.36	0.36	IgG glycosylation;	chr12:9426513	chr12:9415641~9416718:+
PRAD	cis	rs42648	0.755	rs1557650	ENSG00000227646.6	STEAP2-AS1	-8.13	4.07e-15	2.08e-12	-0.33	-0.36	Homocysteine levels;	chr7:90342242	chr7:89882353~90211635:-
PRAD	cis	rs7615952	0.741	rs13314845	ENSG00000171084.14	FAM86JP	8.13	4.09e-15	2.09e-12	0.59	0.36	Blood pressure (smoking interaction);	chr3:125925939	chr3:125916620~125930024:+
PRAD	cis	rs7615952	0.733	rs13314847	ENSG00000171084.14	FAM86JP	8.13	4.09e-15	2.09e-12	0.59	0.36	Blood pressure (smoking interaction);	chr3:125925945	chr3:125916620~125930024:+
PRAD	cis	rs7615952	0.932	rs13086087	ENSG00000171084.14	FAM86JP	8.13	4.09e-15	2.09e-12	0.59	0.36	Blood pressure (smoking interaction);	chr3:125927438	chr3:125916620~125930024:+
PRAD	cis	rs7615952	0.8	rs13086460	ENSG00000171084.14	FAM86JP	8.13	4.09e-15	2.09e-12	0.59	0.36	Blood pressure (smoking interaction);	chr3:125927574	chr3:125916620~125930024:+
PRAD	cis	rs7615952	0.866	rs1976459	ENSG00000171084.14	FAM86JP	8.13	4.09e-15	2.09e-12	0.59	0.36	Blood pressure (smoking interaction);	chr3:125928643	chr3:125916620~125930024:+
PRAD	cis	rs72627509	0.904	rs7687767	ENSG00000269949.1	RP11-738E22.3	-8.13	4.13e-15	2.11e-12	-0.51	-0.36	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56958766	chr4:56960927~56961373:-
PRAD	cis	rs4266144	1	rs4561781	ENSG00000244515.1	KRT18P34	8.13	4.13e-15	2.11e-12	0.43	0.36	Coronary artery disease;	chr3:157135154	chr3:157162663~157163932:-
PRAD	cis	rs6517329	0.576	rs7283730	ENSG00000236830.5	CBR3-AS1	8.13	4.13e-15	2.11e-12	0.38	0.36	Schizophrenia;	chr21:36123076	chr21:36131767~36175815:-
PRAD	cis	rs35828350	1	rs35828350	ENSG00000259728.4	LINC00933	8.13	4.14e-15	2.12e-12	0.44	0.36	Autism spectrum disorder or schizophrenia;	chr15:84812610	chr15:84570649~84580175:+
PRAD	cis	rs12908161	0.92	rs35758837	ENSG00000259728.4	LINC00933	8.13	4.16e-15	2.13e-12	0.44	0.36	Schizophrenia;	chr15:84768151	chr15:84570649~84580175:+
PRAD	cis	rs12908161	1	rs36033486	ENSG00000259728.4	LINC00933	8.13	4.16e-15	2.13e-12	0.44	0.36	Schizophrenia;	chr15:84776461	chr15:84570649~84580175:+
PRAD	cis	rs12908161	1	rs12908549	ENSG00000259728.4	LINC00933	8.13	4.16e-15	2.13e-12	0.44	0.36	Schizophrenia;	chr15:84779120	chr15:84570649~84580175:+
PRAD	cis	rs11096990	0.613	rs4974995	ENSG00000249207.1	RP11-360F5.1	8.13	4.16e-15	2.13e-12	0.37	0.36	Cognitive function;	chr4:39216503	chr4:39112677~39126818:-
PRAD	cis	rs8523	0.804	rs3798720	ENSG00000230314.5	ELOVL2-AS1	8.13	4.17e-15	2.13e-12	0.39	0.36	Red blood cell fatty acid levels;	chr6:11039769	chr6:11043524~11078226:+
PRAD	cis	rs11148252	0.508	rs11148260	ENSG00000278238.1	RP11-245D16.4	-8.13	4.18e-15	2.13e-12	-0.38	-0.36	Lewy body disease;	chr13:52588508	chr13:52454775~52455331:-
PRAD	cis	rs9287719	0.967	rs12467642	ENSG00000234818.1	AC092687.5	8.13	4.18e-15	2.13e-12	0.42	0.36	Prostate cancer;	chr2:10621358	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs12464908	ENSG00000234818.1	AC092687.5	8.13	4.18e-15	2.13e-12	0.42	0.36	Prostate cancer;	chr2:10621370	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs7563816	ENSG00000234818.1	AC092687.5	8.13	4.18e-15	2.13e-12	0.42	0.36	Prostate cancer;	chr2:10623274	chr2:10589166~10604830:+
PRAD	cis	rs7923609	0.934	rs10761771	ENSG00000232075.1	MRPL35P2	-8.13	4.19e-15	2.14e-12	-0.38	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63470404	chr10:63634317~63634827:-
PRAD	cis	rs7923609	0.869	rs10733792	ENSG00000232075.1	MRPL35P2	-8.13	4.19e-15	2.14e-12	-0.38	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63472779	chr10:63634317~63634827:-
PRAD	cis	rs7923609	0.838	rs7909960	ENSG00000232075.1	MRPL35P2	-8.13	4.19e-15	2.14e-12	-0.38	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63479417	chr10:63634317~63634827:-
PRAD	cis	rs7923609	0.967	rs7915779	ENSG00000232075.1	MRPL35P2	-8.13	4.19e-15	2.14e-12	-0.38	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63484484	chr10:63634317~63634827:-
PRAD	cis	rs7923609	0.967	rs2393977	ENSG00000232075.1	MRPL35P2	-8.13	4.19e-15	2.14e-12	-0.38	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63487849	chr10:63634317~63634827:-
PRAD	cis	rs7923609	0.905	rs10740129	ENSG00000232075.1	MRPL35P2	-8.13	4.19e-15	2.14e-12	-0.38	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63491048	chr10:63634317~63634827:-
PRAD	cis	rs7923609	0.967	rs10509189	ENSG00000232075.1	MRPL35P2	-8.13	4.19e-15	2.14e-12	-0.38	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63504366	chr10:63634317~63634827:-
PRAD	cis	rs7923609	0.967	rs4486511	ENSG00000232075.1	MRPL35P2	-8.13	4.19e-15	2.14e-12	-0.38	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63504506	chr10:63634317~63634827:-
PRAD	cis	rs7567389	0.677	rs7607907	ENSG00000236682.1	AC068282.3	8.13	4.19e-15	2.14e-12	0.46	0.36	Self-rated health;	chr2:127386710	chr2:127389130~127400580:+
PRAD	cis	rs7746199	0.736	rs35848276	ENSG00000280107.1	AL022393.9	-8.13	4.2e-15	2.14e-12	-0.73	-0.36	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27553317	chr6:28170845~28172521:+
PRAD	cis	rs12142240	0.738	rs10489769	ENSG00000232022.5	FAAHP1	-8.13	4.2e-15	2.14e-12	-0.33	-0.36	Menopause (age at onset);	chr1:46341031	chr1:46432129~46445521:+
PRAD	cis	rs1134634	0.52	rs872678	ENSG00000273133.1	RP11-799M12.2	-8.13	4.21e-15	2.15e-12	-0.47	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15654075	chr4:15563698~15564253:-
PRAD	cis	rs853679	0.607	rs13199906	ENSG00000280107.1	AL022393.9	-8.13	4.21e-15	2.15e-12	-0.72	-0.36	Depression;	chr6:27866361	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.607	rs17763089	ENSG00000280107.1	AL022393.9	-8.13	4.21e-15	2.15e-12	-0.72	-0.36	Depression;	chr6:27867440	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.546	rs17695758	ENSG00000280107.1	AL022393.9	-8.13	4.21e-15	2.15e-12	-0.72	-0.36	Depression;	chr6:27869405	chr6:28170845~28172521:+
PRAD	cis	rs1061377	1	rs9990742	ENSG00000249685.1	RP11-360F5.3	8.13	4.22e-15	2.15e-12	0.4	0.36	Uric acid levels;	chr4:39119794	chr4:39133913~39135608:+
PRAD	cis	rs526231	0.578	rs34794	ENSG00000175749.11	EIF3KP1	8.13	4.23e-15	2.16e-12	0.5	0.36	Primary biliary cholangitis;	chr5:103087664	chr5:103032376~103033031:+
PRAD	cis	rs7727544	0.669	rs113823725	ENSG00000233006.5	AC034220.3	8.13	4.24e-15	2.16e-12	0.31	0.36	Blood metabolite levels;	chr5:132227808	chr5:132311285~132369916:-
PRAD	cis	rs7923609	0.967	rs7912893	ENSG00000232075.1	MRPL35P2	-8.13	4.24e-15	2.16e-12	-0.38	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63402240	chr10:63634317~63634827:-
PRAD	cis	rs7923609	0.967	rs7896783	ENSG00000232075.1	MRPL35P2	-8.13	4.24e-15	2.16e-12	-0.38	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63402393	chr10:63634317~63634827:-
PRAD	cis	rs7923609	0.967	rs10761762	ENSG00000232075.1	MRPL35P2	-8.13	4.24e-15	2.16e-12	-0.38	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63424957	chr10:63634317~63634827:-
PRAD	cis	rs7923609	0.934	rs10761763	ENSG00000232075.1	MRPL35P2	-8.13	4.24e-15	2.16e-12	-0.38	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63428558	chr10:63634317~63634827:-
PRAD	cis	rs7923609	0.967	rs10761766	ENSG00000232075.1	MRPL35P2	-8.13	4.24e-15	2.16e-12	-0.38	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63430567	chr10:63634317~63634827:-
PRAD	cis	rs7923609	0.967	rs3740331	ENSG00000232075.1	MRPL35P2	-8.13	4.24e-15	2.16e-12	-0.38	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63432528	chr10:63634317~63634827:-
PRAD	cis	rs7923609	0.967	rs3956912	ENSG00000232075.1	MRPL35P2	-8.13	4.24e-15	2.16e-12	-0.38	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63446121	chr10:63634317~63634827:-
PRAD	cis	rs7923609	0.967	rs10509186	ENSG00000232075.1	MRPL35P2	-8.13	4.24e-15	2.16e-12	-0.38	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63447258	chr10:63634317~63634827:-
PRAD	cis	rs7923609	0.967	rs7085621	ENSG00000232075.1	MRPL35P2	-8.13	4.24e-15	2.16e-12	-0.38	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63449166	chr10:63634317~63634827:-
PRAD	cis	rs7923609	0.936	rs10740125	ENSG00000232075.1	MRPL35P2	-8.13	4.24e-15	2.16e-12	-0.38	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63449849	chr10:63634317~63634827:-
PRAD	cis	rs7923609	0.967	rs10740126	ENSG00000232075.1	MRPL35P2	-8.13	4.24e-15	2.16e-12	-0.38	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63451175	chr10:63634317~63634827:-
PRAD	cis	rs321358	1	rs419633	ENSG00000271584.1	RP11-89C3.4	8.13	4.24e-15	2.16e-12	0.54	0.36	Body mass index;	chr11:111132187	chr11:111091932~111097357:-
PRAD	cis	rs1134634	0.52	rs7682586	ENSG00000273133.1	RP11-799M12.2	-8.13	4.25e-15	2.16e-12	-0.47	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15624620	chr4:15563698~15564253:-
PRAD	cis	rs8523	0.933	rs1225717	ENSG00000230314.5	ELOVL2-AS1	-8.13	4.25e-15	2.17e-12	-0.4	-0.36	Red blood cell fatty acid levels;	chr6:10978007	chr6:11043524~11078226:+
PRAD	cis	rs12142240	0.738	rs67545510	ENSG00000232022.5	FAAHP1	-8.13	4.26e-15	2.17e-12	-0.33	-0.36	Menopause (age at onset);	chr1:46340570	chr1:46432129~46445521:+
PRAD	cis	rs12142240	0.698	rs41293273	ENSG00000232022.5	FAAHP1	-8.13	4.26e-15	2.17e-12	-0.33	-0.36	Menopause (age at onset);	chr1:46340721	chr1:46432129~46445521:+
PRAD	cis	rs1552244	0.554	rs13081079	ENSG00000206567.8	AC022007.5	-8.12	4.26e-15	2.17e-12	-0.39	-0.36	Alzheimer's disease;	chr3:10014664	chr3:10006418~10011209:-
PRAD	cis	rs4713118	0.662	rs9380046	ENSG00000272009.1	RP1-313I6.12	-8.12	4.26e-15	2.17e-12	-0.36	-0.36	Parkinson's disease;	chr6:28062721	chr6:28078792~28081130:-
PRAD	cis	rs6001482	0.679	rs1475928	ENSG00000272779.1	LL22NC03-80A10.6	-8.12	4.28e-15	2.18e-12	-0.42	-0.36	Diastolic blood pressure;	chr22:22236137	chr22:22303224~22310401:+
PRAD	cis	rs6001482	0.679	rs6001528	ENSG00000272779.1	LL22NC03-80A10.6	-8.12	4.28e-15	2.18e-12	-0.42	-0.36	Diastolic blood pressure;	chr22:22236511	chr22:22303224~22310401:+
PRAD	cis	rs12908161	0.92	rs12904605	ENSG00000259728.4	LINC00933	8.12	4.29e-15	2.18e-12	0.43	0.36	Schizophrenia;	chr15:84658188	chr15:84570649~84580175:+
PRAD	cis	rs34779708	0.801	rs12255409	ENSG00000230534.5	RP11-297A16.2	8.12	4.29e-15	2.18e-12	0.48	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35246497	chr10:35098006~35127020:-
PRAD	cis	rs4927850	1	rs7627706	ENSG00000207650.1	MIR570	8.12	4.3e-15	2.19e-12	0.38	0.36	Pancreatic cancer;	chr3:196026482	chr3:195699401~195699497:+
PRAD	cis	rs4927850	0.881	rs7630489	ENSG00000207650.1	MIR570	8.12	4.3e-15	2.19e-12	0.38	0.36	Pancreatic cancer;	chr3:196026530	chr3:195699401~195699497:+
PRAD	cis	rs4927850	1	rs7627868	ENSG00000207650.1	MIR570	8.12	4.3e-15	2.19e-12	0.38	0.36	Pancreatic cancer;	chr3:196026602	chr3:195699401~195699497:+
PRAD	cis	rs4835473	0.932	rs12512652	ENSG00000251600.4	RP11-673E1.1	-8.12	4.3e-15	2.19e-12	-0.45	-0.36	Immature fraction of reticulocytes;	chr4:143736787	chr4:143912331~143982454:+
PRAD	cis	rs375066	0.935	rs423765	ENSG00000267058.1	RP11-15A1.3	-8.12	4.3e-15	2.19e-12	-0.3	-0.36	Breast cancer;	chr19:43912047	chr19:43891804~43901805:-
PRAD	cis	rs6452524	0.967	rs6452509	ENSG00000249664.1	CTD-2227C6.2	8.12	4.32e-15	2.2e-12	0.42	0.36	Hypertension (SNP x SNP interaction);	chr5:83125564	chr5:83012285~83013109:-
PRAD	cis	rs9309473	0.607	rs7573719	ENSG00000163016.8	ALMS1P	8.12	4.33e-15	2.2e-12	0.42	0.36	Metabolite levels;	chr2:73355858	chr2:73644919~73685576:+
PRAD	cis	rs1134634	0.52	rs10008889	ENSG00000273133.1	RP11-799M12.2	-8.12	4.34e-15	2.21e-12	-0.47	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15622896	chr4:15563698~15564253:-
PRAD	cis	rs4835473	0.618	rs7685385	ENSG00000251600.4	RP11-673E1.1	-8.12	4.35e-15	2.21e-12	-0.48	-0.36	Immature fraction of reticulocytes;	chr4:144029851	chr4:143912331~143982454:+
PRAD	cis	rs2581828	0.646	rs9867023	ENSG00000242142.1	SERBP1P3	8.12	4.35e-15	2.21e-12	0.42	0.36	Crohn's disease;	chr3:53126116	chr3:53064283~53065091:-
PRAD	cis	rs673078	0.607	rs61943404	ENSG00000275409.1	RP11-131L12.4	-8.12	4.36e-15	2.22e-12	-0.51	-0.36	Glucose homeostasis traits;	chr12:118402062	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.607	rs7136676	ENSG00000275409.1	RP11-131L12.4	-8.12	4.36e-15	2.22e-12	-0.51	-0.36	Glucose homeostasis traits;	chr12:118403605	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.607	rs17441033	ENSG00000275409.1	RP11-131L12.4	-8.12	4.36e-15	2.22e-12	-0.51	-0.36	Glucose homeostasis traits;	chr12:118404101	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.562	rs61943405	ENSG00000275409.1	RP11-131L12.4	-8.12	4.36e-15	2.22e-12	-0.51	-0.36	Glucose homeostasis traits;	chr12:118405030	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.607	rs61943406	ENSG00000275409.1	RP11-131L12.4	-8.12	4.36e-15	2.22e-12	-0.51	-0.36	Glucose homeostasis traits;	chr12:118405767	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.607	rs17441075	ENSG00000275409.1	RP11-131L12.4	-8.12	4.36e-15	2.22e-12	-0.51	-0.36	Glucose homeostasis traits;	chr12:118410542	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.607	rs965524	ENSG00000275409.1	RP11-131L12.4	-8.12	4.36e-15	2.22e-12	-0.51	-0.36	Glucose homeostasis traits;	chr12:118412361	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.607	rs74685643	ENSG00000275409.1	RP11-131L12.4	-8.12	4.36e-15	2.22e-12	-0.51	-0.36	Glucose homeostasis traits;	chr12:118412761	chr12:118430147~118430699:+
PRAD	cis	rs9368481	0.729	rs9379950	ENSG00000241549.7	GUSBP2	-8.12	4.36e-15	2.22e-12	-0.4	-0.36	Autism spectrum disorder or schizophrenia;	chr6:26993769	chr6:26871484~26956554:-
PRAD	cis	rs9532669	0.89	rs2324738	ENSG00000168852.11	TPTE2P5	8.12	4.36e-15	2.22e-12	0.34	0.36	Cervical cancer;	chr13:40925242	chr13:40822296~40921749:-
PRAD	cis	rs2274273	0.588	rs7154831	ENSG00000258413.1	RP11-665C16.6	-8.12	4.36e-15	2.22e-12	-0.48	-0.36	Protein biomarker;	chr14:55357247	chr14:55262767~55272075:-
PRAD	cis	rs4664293	0.51	rs66537229	ENSG00000226266.5	AC009961.3	8.12	4.37e-15	2.22e-12	0.48	0.36	Monocyte percentage of white cells;	chr2:159624095	chr2:159670708~159712435:-
PRAD	cis	rs4664293	0.51	rs66571608	ENSG00000226266.5	AC009961.3	8.12	4.37e-15	2.22e-12	0.48	0.36	Monocyte percentage of white cells;	chr2:159635851	chr2:159670708~159712435:-
PRAD	cis	rs2108622	0.711	rs113059233	ENSG00000267056.2	AC005336.4	8.12	4.37e-15	2.22e-12	0.49	0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866558	chr19:15910582~15911824:-
PRAD	cis	rs9368481	0.761	rs4358615	ENSG00000241549.7	GUSBP2	8.12	4.38e-15	2.23e-12	0.4	0.36	Autism spectrum disorder or schizophrenia;	chr6:27030788	chr6:26871484~26956554:-
PRAD	cis	rs1355223	0.902	rs7102625	ENSG00000271369.1	RP11-350D17.3	8.12	4.39e-15	2.23e-12	0.41	0.36	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34718170	chr11:34709600~34710161:+
PRAD	cis	rs8062405	0.573	rs11645306	ENSG00000259982.1	CDC37P1	-8.12	4.4e-15	2.24e-12	-0.51	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28972615	chr16:28700294~28701540:-
PRAD	cis	rs10463554	0.927	rs34820	ENSG00000175749.11	EIF3KP1	8.12	4.41e-15	2.25e-12	0.46	0.36	Parkinson's disease;	chr5:103101164	chr5:103032376~103033031:+
PRAD	cis	rs1075265	0.901	rs7591194	ENSG00000233266.1	HMGB1P31	-8.12	4.44e-15	2.26e-12	-0.48	-0.36	Chronotype;Morning vs. evening chronotype;	chr2:54086699	chr2:54051334~54051760:+
PRAD	cis	rs6921919	0.583	rs6908137	ENSG00000216901.1	AL022393.7	8.12	4.44e-15	2.26e-12	0.46	0.36	Autism spectrum disorder or schizophrenia;	chr6:28402616	chr6:28176188~28176674:+
PRAD	cis	rs17711722	0.565	rs4717276	ENSG00000237310.1	GS1-124K5.4	8.12	4.45e-15	2.27e-12	0.31	0.36	Calcium levels;	chr7:65829754	chr7:66493706~66495474:+
PRAD	cis	rs6847067	0.965	rs67045782	ENSG00000180769.7	WDFY3-AS2	8.12	4.46e-15	2.27e-12	0.37	0.36	Oropharynx cancer;	chr4:84859429	chr4:84965682~85011277:+
PRAD	cis	rs7250849	0.529	rs16982912	ENSG00000273837.1	LLNLR-470E3.1	-8.12	4.46e-15	2.27e-12	-0.51	-0.36	Blood protein levels;	chr19:51661874	chr19:51639478~51639931:-
PRAD	cis	rs45509595	0.841	rs17751184	ENSG00000280107.1	AL022393.9	-8.12	4.48e-15	2.28e-12	-0.72	-0.36	Breast cancer;	chr6:27807250	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.607	rs67101035	ENSG00000280107.1	AL022393.9	-8.12	4.48e-15	2.28e-12	-0.72	-0.36	Depression;	chr6:27831109	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.556	rs34706883	ENSG00000280107.1	AL022393.9	-8.12	4.48e-15	2.28e-12	-0.72	-0.36	Depression;	chr6:27837477	chr6:28170845~28172521:+
PRAD	cis	rs67340775	0.748	rs13212651	ENSG00000280107.1	AL022393.9	-8.12	4.48e-15	2.28e-12	-0.72	-0.36	Lung cancer in ever smokers;	chr6:27839207	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.546	rs35819751	ENSG00000280107.1	AL022393.9	-8.12	4.48e-15	2.28e-12	-0.72	-0.36	Depression;	chr6:27842791	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.607	rs13194781	ENSG00000280107.1	AL022393.9	-8.12	4.48e-15	2.28e-12	-0.72	-0.36	Depression;	chr6:27847861	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.546	rs36116761	ENSG00000280107.1	AL022393.9	-8.12	4.48e-15	2.28e-12	-0.72	-0.36	Depression;	chr6:27850704	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.546	rs34194357	ENSG00000280107.1	AL022393.9	-8.12	4.48e-15	2.28e-12	-0.72	-0.36	Depression;	chr6:27850757	chr6:28170845~28172521:+
PRAD	cis	rs2404602	0.669	rs12441484	ENSG00000259422.1	RP11-593F23.1	8.12	4.5e-15	2.29e-12	0.44	0.36	Blood metabolite levels;	chr15:76817534	chr15:76174891~76181486:-
PRAD	cis	rs4713118	0.662	rs149970	ENSG00000219392.1	RP1-265C24.5	-8.12	4.53e-15	2.3e-12	-0.46	-0.36	Parkinson's disease;	chr6:28012442	chr6:28115628~28116551:+
PRAD	cis	rs7567389	0.6	rs7590030	ENSG00000236682.1	AC068282.3	8.12	4.53e-15	2.3e-12	0.47	0.36	Self-rated health;	chr2:127298391	chr2:127389130~127400580:+
PRAD	cis	rs4722166	0.532	rs1880242	ENSG00000179428.2	AC073072.5	8.12	4.54e-15	2.31e-12	0.41	0.36	Lung cancer;	chr7:22719988	chr7:22725395~22727620:-
PRAD	cis	rs6570726	0.935	rs377130	ENSG00000235652.6	RP11-545I5.3	8.12	4.55e-15	2.31e-12	0.37	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145515496	chr6:145799409~145886585:+
PRAD	cis	rs7923609	0.934	rs10822153	ENSG00000232075.1	MRPL35P2	-8.12	4.56e-15	2.31e-12	-0.37	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63297053	chr10:63634317~63634827:-
PRAD	cis	rs8042680	0.688	rs11073964	ENSG00000214432.8	AC068831.10	-8.12	4.56e-15	2.32e-12	-0.42	-0.36	Type 2 diabetes;	chr15:91000531	chr15:91022619~91036611:+
PRAD	cis	rs6844153	0.752	rs58968032	ENSG00000240005.4	RP11-293A21.1	-8.12	4.56e-15	2.32e-12	-0.45	-0.36	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26884674	chr4:26859806~26860599:-
PRAD	cis	rs7712401	0.765	rs4349713	ENSG00000263432.2	RN7SL689P	8.11	4.59e-15	2.33e-12	0.35	0.36	Mean platelet volume;	chr5:123055931	chr5:123022487~123022783:-
PRAD	cis	rs2243480	0.803	rs13224048	ENSG00000226824.5	RP4-756H11.3	-8.11	4.59e-15	2.33e-12	-0.71	-0.36	Diabetic kidney disease;	chr7:66528779	chr7:66654538~66669855:+
PRAD	cis	rs4713118	0.868	rs7756968	ENSG00000226314.6	ZNF192P1	-8.11	4.6e-15	2.33e-12	-0.48	-0.36	Parkinson's disease;	chr6:27767175	chr6:28161781~28169594:+
PRAD	cis	rs4713118	0.826	rs2893929	ENSG00000226314.6	ZNF192P1	-8.11	4.6e-15	2.33e-12	-0.48	-0.36	Parkinson's disease;	chr6:27770953	chr6:28161781~28169594:+
PRAD	cis	rs4713118	0.666	rs4140646	ENSG00000226314.6	ZNF192P1	-8.11	4.6e-15	2.33e-12	-0.48	-0.36	Parkinson's disease;	chr6:27771022	chr6:28161781~28169594:+
PRAD	cis	rs4713118	0.666	rs2893930	ENSG00000226314.6	ZNF192P1	-8.11	4.6e-15	2.33e-12	-0.48	-0.36	Parkinson's disease;	chr6:27771027	chr6:28161781~28169594:+
PRAD	cis	rs4713118	0.868	rs742047	ENSG00000226314.6	ZNF192P1	-8.11	4.6e-15	2.33e-12	-0.48	-0.36	Parkinson's disease;	chr6:27771601	chr6:28161781~28169594:+
PRAD	cis	rs4713118	0.629	rs203889	ENSG00000272009.1	RP1-313I6.12	-8.11	4.6e-15	2.34e-12	-0.36	-0.36	Parkinson's disease;	chr6:28053997	chr6:28078792~28081130:-
PRAD	cis	rs62355901	0.552	rs16886128	ENSG00000271828.1	CTD-2310F14.1	8.11	4.62e-15	2.34e-12	0.78	0.36	Breast cancer;	chr5:56702258	chr5:56927874~56929573:+
PRAD	cis	rs11096990	0.679	rs6531707	ENSG00000249207.1	RP11-360F5.1	8.11	4.62e-15	2.35e-12	0.37	0.36	Cognitive function;	chr4:39296064	chr4:39112677~39126818:-
PRAD	cis	rs2439831	0.85	rs2957637	ENSG00000205771.5	CATSPER2P1	-8.11	4.63e-15	2.35e-12	-0.57	-0.36	Lung cancer in ever smokers;	chr15:43658920	chr15:43726918~43747094:-
PRAD	cis	rs72627509	0.857	rs781658	ENSG00000269949.1	RP11-738E22.3	8.11	4.63e-15	2.35e-12	0.51	0.36	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56913401	chr4:56960927~56961373:-
PRAD	cis	rs6921919	0.789	rs11970439	ENSG00000204709.4	LINC01556	8.11	4.63e-15	2.35e-12	0.51	0.36	Autism spectrum disorder or schizophrenia;	chr6:28335687	chr6:28943877~28944537:+
PRAD	cis	rs11976180	1	rs1320894	ENSG00000273234.1	OR2A13P	-8.11	4.63e-15	2.35e-12	-0.43	-0.36	Obesity-related traits;	chr7:144054709	chr7:144142009~144142938:+
PRAD	cis	rs11976180	1	rs2951369	ENSG00000273234.1	OR2A13P	-8.11	4.63e-15	2.35e-12	-0.43	-0.36	Obesity-related traits;	chr7:144055545	chr7:144142009~144142938:+
PRAD	cis	rs172166	0.61	rs156737	ENSG00000280107.1	AL022393.9	-8.11	4.64e-15	2.36e-12	-0.43	-0.36	Cardiac Troponin-T levels;	chr6:27927435	chr6:28170845~28172521:+
PRAD	cis	rs26232	0.521	rs40508	ENSG00000175749.11	EIF3KP1	8.11	4.65e-15	2.36e-12	0.49	0.36	Rheumatoid arthritis;	chr5:103108234	chr5:103032376~103033031:+
PRAD	cis	rs10463554	0.759	rs461609	ENSG00000175749.11	EIF3KP1	8.11	4.65e-15	2.36e-12	0.49	0.36	Parkinson's disease;	chr5:103111601	chr5:103032376~103033031:+
PRAD	cis	rs4631830	0.932	rs4581397	ENSG00000230869.1	CTGLF10P	-8.11	4.65e-15	2.36e-12	-0.44	-0.36	Prostate-specific antigen levels;	chr10:46063455	chr10:45678692~45700532:+
PRAD	cis	rs673078	0.66	rs17619932	ENSG00000275409.1	RP11-131L12.4	-8.11	4.66e-15	2.36e-12	-0.46	-0.36	Glucose homeostasis traits;	chr12:118352228	chr12:118430147~118430699:+
PRAD	cis	rs2933343	0.7	rs2624910	ENSG00000231305.3	RP11-723O4.2	8.11	4.66e-15	2.36e-12	0.33	0.36	IgG glycosylation;	chr3:128931432	chr3:128861313~128871540:-
PRAD	cis	rs6921919	0.583	rs6907950	ENSG00000216901.1	AL022393.7	8.11	4.67e-15	2.37e-12	0.45	0.36	Autism spectrum disorder or schizophrenia;	chr6:28402469	chr6:28176188~28176674:+
PRAD	cis	rs2243480	0.901	rs778730	ENSG00000226824.5	RP4-756H11.3	-8.11	4.68e-15	2.37e-12	-0.71	-0.36	Diabetic kidney disease;	chr7:66358338	chr7:66654538~66669855:+
PRAD	cis	rs2404602	0.692	rs60658665	ENSG00000259422.1	RP11-593F23.1	8.11	4.68e-15	2.37e-12	0.44	0.36	Blood metabolite levels;	chr15:76750167	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.692	rs12910382	ENSG00000259422.1	RP11-593F23.1	8.11	4.68e-15	2.37e-12	0.44	0.36	Blood metabolite levels;	chr15:76761101	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.692	rs4383105	ENSG00000259422.1	RP11-593F23.1	8.11	4.68e-15	2.37e-12	0.44	0.36	Blood metabolite levels;	chr15:76763169	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.692	rs7174673	ENSG00000259422.1	RP11-593F23.1	8.11	4.68e-15	2.37e-12	0.44	0.36	Blood metabolite levels;	chr15:76779657	chr15:76174891~76181486:-
PRAD	cis	rs9532669	0.926	rs7997560	ENSG00000168852.11	TPTE2P5	8.11	4.68e-15	2.37e-12	0.35	0.36	Cervical cancer;	chr13:40878723	chr13:40822296~40921749:-
PRAD	cis	rs357618	1	rs357620	ENSG00000260581.1	CTB-113P19.4	8.11	4.73e-15	2.4e-12	0.44	0.36	Basophil percentage of white cells;	chr5:151467560	chr5:151652275~151655449:+
PRAD	cis	rs2412819	0.571	rs4923965	ENSG00000205771.5	CATSPER2P1	8.11	4.73e-15	2.4e-12	0.49	0.36	Lung cancer;	chr15:43790232	chr15:43726918~43747094:-
PRAD	cis	rs2412819	0.571	rs4644832	ENSG00000205771.5	CATSPER2P1	8.11	4.73e-15	2.4e-12	0.49	0.36	Lung cancer;	chr15:43792507	chr15:43726918~43747094:-
PRAD	cis	rs1134634	0.52	rs12645849	ENSG00000273133.1	RP11-799M12.2	-8.11	4.74e-15	2.4e-12	-0.47	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15627457	chr4:15563698~15564253:-
PRAD	cis	rs1134634	0.52	rs10022610	ENSG00000273133.1	RP11-799M12.2	-8.11	4.74e-15	2.4e-12	-0.47	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15635864	chr4:15563698~15564253:-
PRAD	cis	rs7923609	1	rs4400684	ENSG00000232075.1	MRPL35P2	-8.11	4.75e-15	2.41e-12	-0.37	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63252927	chr10:63634317~63634827:-
PRAD	cis	rs7923609	0.967	rs4454603	ENSG00000232075.1	MRPL35P2	-8.11	4.75e-15	2.41e-12	-0.37	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63252990	chr10:63634317~63634827:-
PRAD	cis	rs7923609	1	rs4595427	ENSG00000232075.1	MRPL35P2	-8.11	4.75e-15	2.41e-12	-0.37	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63253184	chr10:63634317~63634827:-
PRAD	cis	rs7923609	0.936	rs4405189	ENSG00000232075.1	MRPL35P2	-8.11	4.75e-15	2.41e-12	-0.37	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63254175	chr10:63634317~63634827:-
PRAD	cis	rs11096990	0.634	rs2381371	ENSG00000249207.1	RP11-360F5.1	-8.11	4.75e-15	2.41e-12	-0.37	-0.36	Cognitive function;	chr4:39271414	chr4:39112677~39126818:-
PRAD	cis	rs11096990	0.634	rs2381372	ENSG00000249207.1	RP11-360F5.1	-8.11	4.75e-15	2.41e-12	-0.37	-0.36	Cognitive function;	chr4:39271471	chr4:39112677~39126818:-
PRAD	cis	rs10875746	0.624	rs7297298	ENSG00000240399.1	RP1-228P16.1	-8.11	4.77e-15	2.42e-12	-0.34	-0.36	Longevity (90 years and older);	chr12:48278523	chr12:48054813~48055591:-
PRAD	cis	rs9287719	0.649	rs58633964	ENSG00000234818.1	AC092687.5	8.11	4.77e-15	2.42e-12	0.44	0.36	Prostate cancer;	chr2:10596256	chr2:10589166~10604830:+
PRAD	cis	rs8005677	1	rs8006396	ENSG00000257285.4	RP11-298I3.1	8.11	4.77e-15	2.42e-12	0.36	0.36	Cognitive ability (multi-trait analysis);	chr14:22911641	chr14:22929609~22955562:+
PRAD	cis	rs8005677	1	rs4981446	ENSG00000257285.4	RP11-298I3.1	8.11	4.77e-15	2.42e-12	0.36	0.36	Cognitive ability (multi-trait analysis);	chr14:22912204	chr14:22929609~22955562:+
PRAD	cis	rs8005677	1	rs4982706	ENSG00000257285.4	RP11-298I3.1	8.11	4.77e-15	2.42e-12	0.36	0.36	Cognitive ability (multi-trait analysis);	chr14:22912488	chr14:22929609~22955562:+
PRAD	cis	rs11096990	0.593	rs7662880	ENSG00000249207.1	RP11-360F5.1	8.11	4.79e-15	2.43e-12	0.37	0.36	Cognitive function;	chr4:39283604	chr4:39112677~39126818:-
PRAD	cis	rs8005677	0.926	rs34344888	ENSG00000257285.4	RP11-298I3.1	8.11	4.79e-15	2.43e-12	0.36	0.36	Cognitive ability (multi-trait analysis);	chr14:22918376	chr14:22929609~22955562:+
PRAD	cis	rs8005677	0.962	rs34917191	ENSG00000257285.4	RP11-298I3.1	8.11	4.79e-15	2.43e-12	0.36	0.36	Cognitive ability (multi-trait analysis);	chr14:22918419	chr14:22929609~22955562:+
PRAD	cis	rs8005677	1	rs1951119	ENSG00000257285.4	RP11-298I3.1	8.11	4.79e-15	2.43e-12	0.36	0.36	Cognitive ability (multi-trait analysis);	chr14:22919117	chr14:22929609~22955562:+
PRAD	cis	rs8005677	1	rs2295683	ENSG00000257285.4	RP11-298I3.1	8.11	4.79e-15	2.43e-12	0.36	0.36	Cognitive ability (multi-trait analysis);	chr14:22919173	chr14:22929609~22955562:+
PRAD	cis	rs8005677	1	rs4981449	ENSG00000257285.4	RP11-298I3.1	8.11	4.79e-15	2.43e-12	0.36	0.36	Cognitive ability (multi-trait analysis);	chr14:22919662	chr14:22929609~22955562:+
PRAD	cis	rs11096990	0.634	rs17431358	ENSG00000249207.1	RP11-360F5.1	8.11	4.79e-15	2.43e-12	0.37	0.36	Cognitive function;	chr4:39275676	chr4:39112677~39126818:-
PRAD	cis	rs11096990	0.634	rs12648082	ENSG00000249207.1	RP11-360F5.1	8.11	4.79e-15	2.43e-12	0.37	0.36	Cognitive function;	chr4:39278104	chr4:39112677~39126818:-
PRAD	cis	rs7916697	0.626	rs3858146	ENSG00000233590.1	RP11-153K11.3	-8.11	4.8e-15	2.43e-12	-0.47	-0.36	Optic disc area;	chr10:68253493	chr10:68233251~68242379:-
PRAD	cis	rs2274273	0.624	rs8015211	ENSG00000258413.1	RP11-665C16.6	-8.11	4.8e-15	2.43e-12	-0.48	-0.36	Protein biomarker;	chr14:55374729	chr14:55262767~55272075:-
PRAD	cis	rs1729407	0.625	rs2727789	ENSG00000254851.1	RP11-109L13.1	-8.11	4.8e-15	2.43e-12	-0.47	-0.36	Apolipoprotein A-IV levels;	chr11:116826171	chr11:117135528~117138582:+
PRAD	cis	rs1729407	0.632	rs2071523	ENSG00000254851.1	RP11-109L13.1	-8.11	4.82e-15	2.44e-12	-0.47	-0.36	Apolipoprotein A-IV levels;	chr11:116826628	chr11:117135528~117138582:+
PRAD	cis	rs1979679	0.801	rs7977538	ENSG00000278733.1	RP11-425D17.1	8.11	4.82e-15	2.44e-12	0.46	0.36	Ossification of the posterior longitudinal ligament of the spine;	chr12:28143503	chr12:28185625~28186190:-
PRAD	cis	rs1979679	0.801	rs1965280	ENSG00000278733.1	RP11-425D17.1	8.11	4.82e-15	2.44e-12	0.46	0.36	Ossification of the posterior longitudinal ligament of the spine;	chr12:28143639	chr12:28185625~28186190:-
PRAD	cis	rs11083475	1	rs10418728	ENSG00000267892.1	CTD-2540F13.2	8.11	4.84e-15	2.45e-12	0.38	0.36	Heart rate;	chr19:38756662	chr19:38738284~38739863:+
PRAD	cis	rs1134634	0.52	rs75099653	ENSG00000273133.1	RP11-799M12.2	-8.11	4.84e-15	2.45e-12	-0.47	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15626397	chr4:15563698~15564253:-
PRAD	cis	rs375066	0.868	rs368079	ENSG00000267058.1	RP11-15A1.3	-8.11	4.85e-15	2.45e-12	-0.3	-0.36	Breast cancer;	chr19:43889204	chr19:43891804~43901805:-
PRAD	cis	rs72627509	0.951	rs17087335	ENSG00000269949.1	RP11-738E22.3	8.11	4.87e-15	2.47e-12	0.51	0.36	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56972417	chr4:56960927~56961373:-
PRAD	cis	rs2337406	1	rs78631692	ENSG00000274576.2	IGHV2-70	-8.11	4.9e-15	2.48e-12	-0.4	-0.36	Alzheimer's disease (late onset);	chr14:106709371	chr14:106770577~106771020:-
PRAD	cis	rs10129255	0.5	rs4774189	ENSG00000211972.2	IGHV3-66	8.11	4.9e-15	2.48e-12	0.31	0.36	Kawasaki disease;	chr14:106768275	chr14:106675017~106675544:-
PRAD	cis	rs11096990	0.634	rs12651217	ENSG00000249207.1	RP11-360F5.1	-8.11	4.9e-15	2.48e-12	-0.37	-0.36	Cognitive function;	chr4:39271964	chr4:39112677~39126818:-
PRAD	cis	rs7615952	0.599	rs6779141	ENSG00000171084.14	FAM86JP	8.11	4.91e-15	2.49e-12	0.56	0.36	Blood pressure (smoking interaction);	chr3:125991152	chr3:125916620~125930024:+
PRAD	cis	rs7250849	0.688	rs16982907	ENSG00000273837.1	LLNLR-470E3.1	-8.11	4.91e-15	2.49e-12	-0.52	-0.36	Blood protein levels;	chr19:51659782	chr19:51639478~51639931:-
PRAD	cis	rs6570726	0.935	rs397418	ENSG00000235652.6	RP11-545I5.3	8.1	4.94e-15	2.5e-12	0.37	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145521226	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.935	rs419854	ENSG00000235652.6	RP11-545I5.3	8.1	4.94e-15	2.5e-12	0.37	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145522949	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.935	rs365658	ENSG00000235652.6	RP11-545I5.3	8.1	4.94e-15	2.5e-12	0.37	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145523452	chr6:145799409~145886585:+
PRAD	cis	rs2243480	0.908	rs2460431	ENSG00000226824.5	RP4-756H11.3	8.1	4.95e-15	2.5e-12	0.7	0.36	Diabetic kidney disease;	chr7:66157859	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs4718309	ENSG00000226824.5	RP4-756H11.3	8.1	4.95e-15	2.5e-12	0.7	0.36	Diabetic kidney disease;	chr7:66162777	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs6460274	ENSG00000226824.5	RP4-756H11.3	8.1	4.95e-15	2.5e-12	0.7	0.36	Diabetic kidney disease;	chr7:66163497	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs7787230	ENSG00000226824.5	RP4-756H11.3	8.1	4.95e-15	2.5e-12	0.7	0.36	Diabetic kidney disease;	chr7:66164112	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs316318	ENSG00000226824.5	RP4-756H11.3	-8.1	4.95e-15	2.5e-12	-0.7	-0.36	Diabetic kidney disease;	chr7:66147917	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs316317	ENSG00000226824.5	RP4-756H11.3	-8.1	4.95e-15	2.5e-12	-0.7	-0.36	Diabetic kidney disease;	chr7:66148650	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs316304	ENSG00000226824.5	RP4-756H11.3	-8.1	4.95e-15	2.5e-12	-0.7	-0.36	Diabetic kidney disease;	chr7:66151907	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs2465120	ENSG00000226824.5	RP4-756H11.3	-8.1	4.95e-15	2.5e-12	-0.7	-0.36	Diabetic kidney disease;	chr7:66155987	chr7:66654538~66669855:+
PRAD	cis	rs2404602	0.692	rs12904198	ENSG00000259422.1	RP11-593F23.1	8.1	4.95e-15	2.5e-12	0.44	0.36	Blood metabolite levels;	chr15:76854637	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.692	rs2137307	ENSG00000259422.1	RP11-593F23.1	8.1	4.95e-15	2.5e-12	0.44	0.36	Blood metabolite levels;	chr15:76856679	chr15:76174891~76181486:-
PRAD	cis	rs9532669	0.926	rs4941995	ENSG00000168852.11	TPTE2P5	8.1	4.95e-15	2.51e-12	0.35	0.36	Cervical cancer;	chr13:40850117	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.926	rs9315789	ENSG00000168852.11	TPTE2P5	8.1	4.95e-15	2.51e-12	0.35	0.36	Cervical cancer;	chr13:40852898	chr13:40822296~40921749:-
PRAD	cis	rs526231	0.543	rs42431	ENSG00000175749.11	EIF3KP1	-8.1	4.96e-15	2.51e-12	-0.48	-0.36	Primary biliary cholangitis;	chr5:103064359	chr5:103032376~103033031:+
PRAD	cis	rs6061231	0.74	rs11698650	ENSG00000273619.1	RP5-908M14.9	-8.1	4.97e-15	2.51e-12	-0.22	-0.36	Colorectal cancer;	chr20:62383318	chr20:62386303~62386970:-
PRAD	cis	rs7615952	0.932	rs1976458	ENSG00000171084.14	FAM86JP	8.1	4.98e-15	2.52e-12	0.59	0.36	Blood pressure (smoking interaction);	chr3:125928669	chr3:125916620~125930024:+
PRAD	cis	rs2243480	1	rs437889	ENSG00000226824.5	RP4-756H11.3	-8.1	4.98e-15	2.52e-12	-0.71	-0.36	Diabetic kidney disease;	chr7:66044247	chr7:66654538~66669855:+
PRAD	cis	rs2243480	0.711	rs2420172	ENSG00000226824.5	RP4-756H11.3	8.1	4.98e-15	2.52e-12	0.7	0.36	Diabetic kidney disease;	chr7:66170354	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs2420171	ENSG00000226824.5	RP4-756H11.3	8.1	4.98e-15	2.52e-12	0.7	0.36	Diabetic kidney disease;	chr7:66172773	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs6974723	ENSG00000226824.5	RP4-756H11.3	8.1	4.98e-15	2.52e-12	0.7	0.36	Diabetic kidney disease;	chr7:66172952	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs9769882	ENSG00000226824.5	RP4-756H11.3	8.1	4.98e-15	2.52e-12	0.7	0.36	Diabetic kidney disease;	chr7:66177938	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs6966322	ENSG00000226824.5	RP4-756H11.3	8.1	4.98e-15	2.52e-12	0.7	0.36	Diabetic kidney disease;	chr7:66181767	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs4145008	ENSG00000226824.5	RP4-756H11.3	8.1	4.98e-15	2.52e-12	0.7	0.36	Diabetic kidney disease;	chr7:66182524	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs4718315	ENSG00000226824.5	RP4-756H11.3	8.1	4.98e-15	2.52e-12	0.7	0.36	Diabetic kidney disease;	chr7:66183554	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs4718316	ENSG00000226824.5	RP4-756H11.3	8.1	4.98e-15	2.52e-12	0.7	0.36	Diabetic kidney disease;	chr7:66183744	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs1873494	ENSG00000226824.5	RP4-756H11.3	8.1	4.98e-15	2.52e-12	0.7	0.36	Diabetic kidney disease;	chr7:66184912	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs6959002	ENSG00000226824.5	RP4-756H11.3	8.1	4.98e-15	2.52e-12	0.7	0.36	Diabetic kidney disease;	chr7:66185509	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs1546059	ENSG00000226824.5	RP4-756H11.3	8.1	4.98e-15	2.52e-12	0.7	0.36	Diabetic kidney disease;	chr7:66189722	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs2420170	ENSG00000226824.5	RP4-756H11.3	8.1	4.98e-15	2.52e-12	0.7	0.36	Diabetic kidney disease;	chr7:66191066	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs6958289	ENSG00000226824.5	RP4-756H11.3	8.1	4.98e-15	2.52e-12	0.7	0.36	Diabetic kidney disease;	chr7:66192124	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs7804223	ENSG00000226824.5	RP4-756H11.3	8.1	4.98e-15	2.52e-12	0.7	0.36	Diabetic kidney disease;	chr7:66199572	chr7:66654538~66669855:+
PRAD	cis	rs67311347	1	rs7612015	ENSG00000223797.4	ENTPD3-AS1	8.1	4.99e-15	2.52e-12	0.31	0.36	Renal cell carcinoma;	chr3:40358483	chr3:40313802~40453329:-
PRAD	cis	rs34375054	0.573	rs12581367	ENSG00000279233.1	RP11-158L12.4	8.1	4.99e-15	2.52e-12	0.38	0.36	Post bronchodilator FEV1/FVC ratio;	chr12:125170095	chr12:125138245~125141711:+
PRAD	cis	rs2404602	0.655	rs8028294	ENSG00000259422.1	RP11-593F23.1	8.1	5e-15	2.53e-12	0.44	0.36	Blood metabolite levels;	chr15:76792536	chr15:76174891~76181486:-
PRAD	cis	rs1979679	0.842	rs4931729	ENSG00000278733.1	RP11-425D17.1	8.1	5e-15	2.53e-12	0.45	0.36	Ossification of the posterior longitudinal ligament of the spine;	chr12:28146306	chr12:28185625~28186190:-
PRAD	cis	rs9393777	0.844	rs72839477	ENSG00000280107.1	AL022393.9	-8.1	5.01e-15	2.53e-12	-0.74	-0.36	Intelligence (multi-trait analysis);	chr6:27359221	chr6:28170845~28172521:+
PRAD	cis	rs4631830	0.863	rs10826127	ENSG00000230869.1	CTGLF10P	-8.1	5.01e-15	2.53e-12	-0.44	-0.36	Prostate-specific antigen levels;	chr10:46065065	chr10:45678692~45700532:+
PRAD	cis	rs7916697	0.626	rs3858145	ENSG00000233590.1	RP11-153K11.3	-8.1	5.03e-15	2.54e-12	-0.47	-0.36	Optic disc area;	chr10:68252081	chr10:68233251~68242379:-
PRAD	cis	rs11976180	1	rs11975942	ENSG00000273234.1	OR2A13P	-8.1	5.05e-15	2.55e-12	-0.44	-0.36	Obesity-related traits;	chr7:144043487	chr7:144142009~144142938:+
PRAD	cis	rs638893	1	rs73005500	ENSG00000278376.1	RP11-158I9.8	8.1	5.05e-15	2.55e-12	0.45	0.36	Vitiligo;	chr11:118826666	chr11:118791254~118793137:+
PRAD	cis	rs4713118	0.868	rs9468220	ENSG00000226314.6	ZNF192P1	8.1	5.06e-15	2.56e-12	0.48	0.36	Parkinson's disease;	chr6:27765197	chr6:28161781~28169594:+
PRAD	cis	rs673078	0.562	rs56347775	ENSG00000275409.1	RP11-131L12.4	-8.1	5.08e-15	2.56e-12	-0.51	-0.36	Glucose homeostasis traits;	chr12:118438002	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.607	rs61943451	ENSG00000275409.1	RP11-131L12.4	-8.1	5.08e-15	2.56e-12	-0.51	-0.36	Glucose homeostasis traits;	chr12:118438929	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.518	rs61943452	ENSG00000275409.1	RP11-131L12.4	-8.1	5.08e-15	2.56e-12	-0.51	-0.36	Glucose homeostasis traits;	chr12:118438990	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.607	rs61943454	ENSG00000275409.1	RP11-131L12.4	-8.1	5.08e-15	2.56e-12	-0.51	-0.36	Glucose homeostasis traits;	chr12:118439140	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.517	rs61943455	ENSG00000275409.1	RP11-131L12.4	-8.1	5.08e-15	2.56e-12	-0.51	-0.36	Glucose homeostasis traits;	chr12:118439414	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.607	rs73207566	ENSG00000275409.1	RP11-131L12.4	-8.1	5.08e-15	2.56e-12	-0.51	-0.36	Glucose homeostasis traits;	chr12:118439471	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.607	rs2393416	ENSG00000275409.1	RP11-131L12.4	-8.1	5.08e-15	2.56e-12	-0.51	-0.36	Glucose homeostasis traits;	chr12:118439968	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.56	rs4406856	ENSG00000275409.1	RP11-131L12.4	-8.1	5.08e-15	2.56e-12	-0.51	-0.36	Glucose homeostasis traits;	chr12:118440094	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.607	rs4457791	ENSG00000275409.1	RP11-131L12.4	-8.1	5.08e-15	2.56e-12	-0.51	-0.36	Glucose homeostasis traits;	chr12:118440144	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.607	rs61943456	ENSG00000275409.1	RP11-131L12.4	-8.1	5.08e-15	2.56e-12	-0.51	-0.36	Glucose homeostasis traits;	chr12:118440326	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.607	rs17513006	ENSG00000275409.1	RP11-131L12.4	-8.1	5.08e-15	2.56e-12	-0.51	-0.36	Glucose homeostasis traits;	chr12:118440383	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.56	rs61943457	ENSG00000275409.1	RP11-131L12.4	-8.1	5.08e-15	2.56e-12	-0.51	-0.36	Glucose homeostasis traits;	chr12:118440487	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.562	rs55883417	ENSG00000275409.1	RP11-131L12.4	-8.1	5.08e-15	2.56e-12	-0.51	-0.36	Glucose homeostasis traits;	chr12:118440801	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.607	rs55842338	ENSG00000275409.1	RP11-131L12.4	-8.1	5.08e-15	2.56e-12	-0.51	-0.36	Glucose homeostasis traits;	chr12:118441259	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.518	rs17441251	ENSG00000275409.1	RP11-131L12.4	-8.1	5.08e-15	2.56e-12	-0.51	-0.36	Glucose homeostasis traits;	chr12:118441361	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.607	rs17513013	ENSG00000275409.1	RP11-131L12.4	-8.1	5.08e-15	2.56e-12	-0.51	-0.36	Glucose homeostasis traits;	chr12:118442070	chr12:118430147~118430699:+
PRAD	cis	rs357618	1	rs357618	ENSG00000260581.1	CTB-113P19.4	8.1	5.1e-15	2.57e-12	0.44	0.35	Basophil percentage of white cells;	chr5:151467051	chr5:151652275~151655449:+
PRAD	cis	rs8040855	0.86	rs6496775	ENSG00000259295.5	CSPG4P12	-8.1	5.11e-15	2.58e-12	-0.48	-0.35	Bulimia nervosa;	chr15:85164910	chr15:85191438~85213905:+
PRAD	cis	rs375066	0.935	rs396973	ENSG00000267058.1	RP11-15A1.3	8.1	5.11e-15	2.58e-12	0.29	0.35	Breast cancer;	chr19:43895154	chr19:43891804~43901805:-
PRAD	cis	rs10463554	0.926	rs34778	ENSG00000175749.11	EIF3KP1	8.1	5.12e-15	2.58e-12	0.47	0.35	Parkinson's disease;	chr5:103116852	chr5:103032376~103033031:+
PRAD	cis	rs10463554	0.963	rs26524	ENSG00000175749.11	EIF3KP1	8.1	5.12e-15	2.58e-12	0.47	0.35	Parkinson's disease;	chr5:103120600	chr5:103032376~103033031:+
PRAD	cis	rs8040855	0.825	rs3964197	ENSG00000259295.5	CSPG4P12	8.1	5.13e-15	2.59e-12	0.45	0.35	Bulimia nervosa;	chr15:85178681	chr15:85191438~85213905:+
PRAD	cis	rs853679	1	rs1936365	ENSG00000280107.1	AL022393.9	8.1	5.14e-15	2.59e-12	0.53	0.35	Depression;	chr6:28300675	chr6:28170845~28172521:+
PRAD	cis	rs72627509	0.857	rs55762216	ENSG00000269949.1	RP11-738E22.3	8.1	5.14e-15	2.6e-12	0.52	0.35	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56899565	chr4:56960927~56961373:-
PRAD	cis	rs11083475	0.935	rs28488032	ENSG00000267892.1	CTD-2540F13.2	8.1	5.15e-15	2.6e-12	0.38	0.35	Heart rate;	chr19:38712248	chr19:38738284~38739863:+
PRAD	cis	rs8062405	0.573	rs8045689	ENSG00000259982.1	CDC37P1	-8.1	5.16e-15	2.6e-12	-0.51	-0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28976948	chr16:28700294~28701540:-
PRAD	cis	rs6991838	0.8	rs11786598	ENSG00000200714.1	Y_RNA	-8.1	5.18e-15	2.61e-12	-0.37	-0.35	Intelligence (multi-trait analysis);	chr8:65559944	chr8:65592731~65592820:+
PRAD	cis	rs7238033	0.56	rs8083653	ENSG00000267193.4	RP11-116O18.3	8.1	5.19e-15	2.62e-12	0.39	0.35	Bladder cancer;	chr18:45735062	chr18:45669367~45747215:-
PRAD	cis	rs9287719	0.967	rs1541573	ENSG00000234818.1	AC092687.5	8.1	5.21e-15	2.63e-12	0.43	0.35	Prostate cancer;	chr2:10633259	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.967	rs1541574	ENSG00000234818.1	AC092687.5	8.1	5.21e-15	2.63e-12	0.43	0.35	Prostate cancer;	chr2:10633382	chr2:10589166~10604830:+
PRAD	cis	rs1061377	1	rs13182	ENSG00000249685.1	RP11-360F5.3	8.1	5.22e-15	2.63e-12	0.4	0.35	Uric acid levels;	chr4:39121293	chr4:39133913~39135608:+
PRAD	cis	rs9532669	0.89	rs9532593	ENSG00000168852.11	TPTE2P5	8.1	5.22e-15	2.63e-12	0.35	0.35	Cervical cancer;	chr13:40847717	chr13:40822296~40921749:-
PRAD	cis	rs6921919	0.583	rs9468370	ENSG00000216901.1	AL022393.7	8.1	5.22e-15	2.63e-12	0.45	0.35	Autism spectrum disorder or schizophrenia;	chr6:28401163	chr6:28176188~28176674:+
PRAD	cis	rs7250849	0.565	rs73052857	ENSG00000273837.1	LLNLR-470E3.1	-8.1	5.22e-15	2.63e-12	-0.53	-0.35	Blood protein levels;	chr19:51661182	chr19:51639478~51639931:-
PRAD	cis	rs2522056	1	rs2106854	ENSG00000233006.5	AC034220.3	-8.1	5.23e-15	2.63e-12	-0.35	-0.35	Fibrinogen;Lymphocyte counts;	chr5:132433482	chr5:132311285~132369916:-
PRAD	cis	rs2412819	0.571	rs2930529	ENSG00000205771.5	CATSPER2P1	8.1	5.24e-15	2.64e-12	0.49	0.35	Lung cancer;	chr15:43819467	chr15:43726918~43747094:-
PRAD	cis	rs62103177	0.568	rs2365388	ENSG00000261126.6	RP11-795F19.1	8.1	5.25e-15	2.64e-12	0.47	0.35	Opioid sensitivity;	chr18:80215819	chr18:80046900~80095482:+
PRAD	cis	rs75422866	0.867	rs73104163	ENSG00000274902.1	RP1-197B17.4	8.1	5.25e-15	2.65e-12	0.95	0.35	Pneumonia;	chr12:47706187	chr12:47731908~47732351:+
PRAD	cis	rs75422866	1	rs12423045	ENSG00000274902.1	RP1-197B17.4	8.1	5.25e-15	2.65e-12	0.95	0.35	Pneumonia;	chr12:47706275	chr12:47731908~47732351:+
PRAD	cis	rs9532669	0.857	rs7327018	ENSG00000168852.11	TPTE2P5	8.1	5.26e-15	2.65e-12	0.35	0.35	Cervical cancer;	chr13:40856376	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.926	rs7327315	ENSG00000168852.11	TPTE2P5	8.1	5.26e-15	2.65e-12	0.35	0.35	Cervical cancer;	chr13:40856383	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.926	rs7327059	ENSG00000168852.11	TPTE2P5	8.1	5.26e-15	2.65e-12	0.35	0.35	Cervical cancer;	chr13:40856458	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.926	rs9594433	ENSG00000168852.11	TPTE2P5	8.1	5.26e-15	2.65e-12	0.35	0.35	Cervical cancer;	chr13:40856935	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.926	rs9525403	ENSG00000168852.11	TPTE2P5	8.1	5.26e-15	2.65e-12	0.35	0.35	Cervical cancer;	chr13:40858292	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.926	rs7318768	ENSG00000168852.11	TPTE2P5	8.1	5.26e-15	2.65e-12	0.35	0.35	Cervical cancer;	chr13:40859140	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.926	rs4942000	ENSG00000168852.11	TPTE2P5	8.1	5.26e-15	2.65e-12	0.35	0.35	Cervical cancer;	chr13:40859979	chr13:40822296~40921749:-
PRAD	cis	rs763567	0.967	rs473832	ENSG00000271811.1	RP1-79C4.4	8.1	5.26e-15	2.65e-12	0.41	0.35	Tonsillectomy;	chr1:170640049	chr1:170667381~170669425:+
PRAD	cis	rs4723738	0.693	rs6462818	ENSG00000227191.5	TRGC2	8.1	5.26e-15	2.65e-12	0.44	0.35	Treatment response for severe sepsis;	chr7:38211435	chr7:38239580~38368091:-
PRAD	cis	rs150992	0.507	rs377731	ENSG00000248489.1	CTD-2007H13.3	8.1	5.27e-15	2.66e-12	0.38	0.35	Body mass index;	chr5:98996535	chr5:98929171~98995013:+
PRAD	cis	rs853679	1	rs10456362	ENSG00000280107.1	AL022393.9	8.09	5.31e-15	2.68e-12	0.56	0.35	Depression;	chr6:28254038	chr6:28170845~28172521:+
PRAD	cis	rs3096299	0.504	rs4785574	ENSG00000261118.1	RP11-104N10.1	8.09	5.33e-15	2.68e-12	0.35	0.35	Multiple myeloma (IgH translocation);	chr16:89502467	chr16:89492017~89504460:-
PRAD	cis	rs10463554	0.926	rs26433	ENSG00000175749.11	EIF3KP1	8.09	5.33e-15	2.69e-12	0.44	0.35	Parkinson's disease;	chr5:103028154	chr5:103032376~103033031:+
PRAD	cis	rs7429990	0.965	rs7642590	ENSG00000229759.1	MRPS18AP1	-8.09	5.33e-15	2.69e-12	-0.37	-0.35	Educational attainment (years of education);	chr3:48058260	chr3:48256350~48256938:-
PRAD	cis	rs2404602	0.669	rs9788684	ENSG00000259422.1	RP11-593F23.1	8.09	5.33e-15	2.69e-12	0.44	0.35	Blood metabolite levels;	chr15:76902497	chr15:76174891~76181486:-
PRAD	cis	rs950169	0.84	rs35522895	ENSG00000259728.4	LINC00933	8.09	5.34e-15	2.69e-12	0.44	0.35	Schizophrenia;	chr15:84259297	chr15:84570649~84580175:+
PRAD	cis	rs763567	0.967	rs593560	ENSG00000271811.1	RP1-79C4.4	8.09	5.34e-15	2.69e-12	0.41	0.35	Tonsillectomy;	chr1:170646776	chr1:170667381~170669425:+
PRAD	cis	rs4927850	1	rs6799572	ENSG00000207650.1	MIR570	8.09	5.35e-15	2.69e-12	0.38	0.35	Pancreatic cancer;	chr3:196013537	chr3:195699401~195699497:+
PRAD	cis	rs950169	0.58	rs11633762	ENSG00000259728.4	LINC00933	8.09	5.35e-15	2.7e-12	0.43	0.35	Schizophrenia;	chr15:84643921	chr15:84570649~84580175:+
PRAD	cis	rs853679	0.527	rs1997660	ENSG00000204709.4	LINC01556	8.09	5.35e-15	2.7e-12	0.46	0.35	Depression;	chr6:28301886	chr6:28943877~28944537:+
PRAD	cis	rs2933343	0.7	rs2249514	ENSG00000231305.3	RP11-723O4.2	8.09	5.36e-15	2.7e-12	0.33	0.35	IgG glycosylation;	chr3:128924969	chr3:128861313~128871540:-
PRAD	cis	rs2933343	0.7	rs2630257	ENSG00000231305.3	RP11-723O4.2	8.09	5.36e-15	2.7e-12	0.33	0.35	IgG glycosylation;	chr3:128925172	chr3:128861313~128871540:-
PRAD	cis	rs2933343	0.729	rs1680785	ENSG00000231305.3	RP11-723O4.2	8.09	5.36e-15	2.7e-12	0.33	0.35	IgG glycosylation;	chr3:128925973	chr3:128861313~128871540:-
PRAD	cis	rs2933343	0.729	rs1680786	ENSG00000231305.3	RP11-723O4.2	8.09	5.36e-15	2.7e-12	0.33	0.35	IgG glycosylation;	chr3:128925997	chr3:128861313~128871540:-
PRAD	cis	rs9532669	0.926	rs9532659	ENSG00000168852.11	TPTE2P5	8.09	5.36e-15	2.7e-12	0.34	0.35	Cervical cancer;	chr13:40920380	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.89	rs9594457	ENSG00000168852.11	TPTE2P5	8.09	5.36e-15	2.7e-12	0.34	0.35	Cervical cancer;	chr13:40920439	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.926	rs9594458	ENSG00000168852.11	TPTE2P5	8.09	5.36e-15	2.7e-12	0.34	0.35	Cervical cancer;	chr13:40920448	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.926	rs9590562	ENSG00000168852.11	TPTE2P5	8.09	5.36e-15	2.7e-12	0.34	0.35	Cervical cancer;	chr13:40920503	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.963	rs12857052	ENSG00000168852.11	TPTE2P5	8.09	5.36e-15	2.7e-12	0.34	0.35	Cervical cancer;	chr13:40920831	chr13:40822296~40921749:-
PRAD	cis	rs62355901	0.545	rs6882255	ENSG00000271828.1	CTD-2310F14.1	8.09	5.38e-15	2.71e-12	0.67	0.35	Breast cancer;	chr5:56762344	chr5:56927874~56929573:+
PRAD	cis	rs8005677	1	rs8006409	ENSG00000257285.4	RP11-298I3.1	8.09	5.39e-15	2.71e-12	0.36	0.35	Cognitive ability (multi-trait analysis);	chr14:22927302	chr14:22929609~22955562:+
PRAD	cis	rs321358	1	rs321355	ENSG00000271584.1	RP11-89C3.4	8.09	5.4e-15	2.72e-12	0.54	0.35	Body mass index;	chr11:111124273	chr11:111091932~111097357:-
PRAD	cis	rs6430553	0.894	rs6730306	ENSG00000224043.6	CCNT2-AS1	-8.09	5.4e-15	2.72e-12	-0.49	-0.35	Blood metabolite levels;	chr2:134851597	chr2:134735464~134918710:-
PRAD	cis	rs2439831	0.85	rs16965120	ENSG00000249839.1	AC011330.5	-8.09	5.41e-15	2.72e-12	-0.6	-0.35	Lung cancer in ever smokers;	chr15:43808144	chr15:43663654~43684339:-
PRAD	cis	rs9532669	0.963	rs2324739	ENSG00000168852.11	TPTE2P5	8.09	5.42e-15	2.73e-12	0.34	0.35	Cervical cancer;	chr13:40925479	chr13:40822296~40921749:-
PRAD	cis	rs7829975	0.688	rs7817376	ENSG00000253893.2	FAM85B	8.09	5.43e-15	2.73e-12	0.42	0.35	Mood instability;	chr8:8523020	chr8:8167819~8226614:-
PRAD	cis	rs1979679	0.879	rs55996833	ENSG00000278733.1	RP11-425D17.1	8.09	5.43e-15	2.73e-12	0.47	0.35	Ossification of the posterior longitudinal ligament of the spine;	chr12:28313303	chr12:28185625~28186190:-
PRAD	cis	rs7923609	1	rs4379723	ENSG00000232075.1	MRPL35P2	-8.09	5.43e-15	2.74e-12	-0.37	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63203689	chr10:63634317~63634827:-
PRAD	cis	rs7923609	1	rs10822149	ENSG00000232075.1	MRPL35P2	-8.09	5.43e-15	2.74e-12	-0.37	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63227652	chr10:63634317~63634827:-
PRAD	cis	rs7923609	1	rs10761727	ENSG00000232075.1	MRPL35P2	-8.09	5.43e-15	2.74e-12	-0.37	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63235733	chr10:63634317~63634827:-
PRAD	cis	rs7923609	0.967	rs10761729	ENSG00000232075.1	MRPL35P2	-8.09	5.43e-15	2.74e-12	-0.37	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63235844	chr10:63634317~63634827:-
PRAD	cis	rs7923609	1	rs4399232	ENSG00000232075.1	MRPL35P2	-8.09	5.43e-15	2.74e-12	-0.37	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63239730	chr10:63634317~63634827:-
PRAD	cis	rs1528149	0.856	rs6952865	ENSG00000224683.1	RPL36AP29	8.09	5.44e-15	2.74e-12	0.44	0.35	Sitting height ratio;	chr7:16082239	chr7:16208945~16209265:+
PRAD	cis	rs375066	0.967	rs8104290	ENSG00000267058.1	RP11-15A1.3	-8.09	5.45e-15	2.74e-12	-0.29	-0.35	Breast cancer;	chr19:43863186	chr19:43891804~43901805:-
PRAD	cis	rs375066	0.934	rs2191564	ENSG00000267058.1	RP11-15A1.3	-8.09	5.45e-15	2.74e-12	-0.29	-0.35	Breast cancer;	chr19:43863459	chr19:43891804~43901805:-
PRAD	cis	rs375066	0.935	rs11673020	ENSG00000267058.1	RP11-15A1.3	-8.09	5.45e-15	2.74e-12	-0.29	-0.35	Breast cancer;	chr19:43870479	chr19:43891804~43901805:-
PRAD	cis	rs375066	0.935	rs10414702	ENSG00000267058.1	RP11-15A1.3	-8.09	5.45e-15	2.74e-12	-0.29	-0.35	Breast cancer;	chr19:43876384	chr19:43891804~43901805:-
PRAD	cis	rs375066	0.935	rs10421518	ENSG00000267058.1	RP11-15A1.3	-8.09	5.45e-15	2.74e-12	-0.29	-0.35	Breast cancer;	chr19:43877134	chr19:43891804~43901805:-
PRAD	cis	rs375066	0.87	rs7258418	ENSG00000267058.1	RP11-15A1.3	-8.09	5.45e-15	2.74e-12	-0.29	-0.35	Breast cancer;	chr19:43878931	chr19:43891804~43901805:-
PRAD	cis	rs853679	1	rs853694	ENSG00000280107.1	AL022393.9	-8.09	5.45e-15	2.74e-12	-0.53	-0.35	Depression;	chr6:28311323	chr6:28170845~28172521:+
PRAD	cis	rs964611	0.882	rs6493316	ENSG00000259488.2	RP11-154J22.1	-8.09	5.46e-15	2.75e-12	-0.33	-0.35	Metabolite levels (Pyroglutamine);	chr15:48275280	chr15:48312353~48331856:-
PRAD	cis	rs10463554	1	rs6879788	ENSG00000175749.11	EIF3KP1	8.09	5.48e-15	2.76e-12	0.45	0.35	Parkinson's disease;	chr5:102978353	chr5:103032376~103033031:+
PRAD	cis	rs7916697	0.626	rs61854803	ENSG00000233590.1	RP11-153K11.3	-8.09	5.5e-15	2.76e-12	-0.46	-0.35	Optic disc area;	chr10:68254881	chr10:68233251~68242379:-
PRAD	cis	rs2404602	0.692	rs4641709	ENSG00000259422.1	RP11-593F23.1	-8.09	5.52e-15	2.77e-12	-0.44	-0.35	Blood metabolite levels;	chr15:76755395	chr15:76174891~76181486:-
PRAD	cis	rs72627509	0.68	rs66790703	ENSG00000269949.1	RP11-738E22.3	8.09	5.53e-15	2.78e-12	0.51	0.35	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56907742	chr4:56960927~56961373:-
PRAD	cis	rs9532669	0.824	rs4941998	ENSG00000168852.11	TPTE2P5	8.09	5.53e-15	2.78e-12	0.35	0.35	Cervical cancer;	chr13:40859901	chr13:40822296~40921749:-
PRAD	cis	rs9287719	0.967	rs10206225	ENSG00000234818.1	AC092687.5	8.09	5.54e-15	2.78e-12	0.42	0.35	Prostate cancer;	chr2:10618531	chr2:10589166~10604830:+
PRAD	cis	rs62355900	0.636	rs12654584	ENSG00000271828.1	CTD-2310F14.1	8.09	5.55e-15	2.79e-12	0.67	0.35	Endometriosis;	chr5:56762588	chr5:56927874~56929573:+
PRAD	cis	rs3745672	0.59	rs10401283	ENSG00000219665.7	CTD-2006C1.2	-8.09	5.56e-15	2.79e-12	-0.7	-0.35	Multiple sclerosis;	chr19:12056538	chr19:11987617~12046275:+
PRAD	cis	rs3745672	0.59	rs75275742	ENSG00000219665.7	CTD-2006C1.2	-8.09	5.56e-15	2.79e-12	-0.7	-0.35	Multiple sclerosis;	chr19:12057582	chr19:11987617~12046275:+
PRAD	cis	rs3745672	0.59	rs10409622	ENSG00000219665.7	CTD-2006C1.2	-8.09	5.56e-15	2.79e-12	-0.7	-0.35	Multiple sclerosis;	chr19:12057935	chr19:11987617~12046275:+
PRAD	cis	rs881375	0.934	rs2159778	ENSG00000226752.6	PSMD5-AS1	-8.09	5.57e-15	2.8e-12	-0.42	-0.35	Rheumatoid arthritis;	chr9:120915851	chr9:120824828~120854385:+
PRAD	cis	rs11096990	0.634	rs6531703	ENSG00000249207.1	RP11-360F5.1	8.09	5.58e-15	2.8e-12	0.37	0.35	Cognitive function;	chr4:39281786	chr4:39112677~39126818:-
PRAD	cis	rs321358	1	rs321359	ENSG00000271584.1	RP11-89C3.4	8.09	5.59e-15	2.81e-12	0.54	0.35	Body mass index;	chr11:111125257	chr11:111091932~111097357:-
PRAD	cis	rs321358	1	rs321360	ENSG00000271584.1	RP11-89C3.4	8.09	5.59e-15	2.81e-12	0.54	0.35	Body mass index;	chr11:111125346	chr11:111091932~111097357:-
PRAD	cis	rs321358	1	rs321361	ENSG00000271584.1	RP11-89C3.4	8.09	5.59e-15	2.81e-12	0.54	0.35	Body mass index;	chr11:111125495	chr11:111091932~111097357:-
PRAD	cis	rs321358	1	rs321362	ENSG00000271584.1	RP11-89C3.4	8.09	5.59e-15	2.81e-12	0.54	0.35	Body mass index;	chr11:111125754	chr11:111091932~111097357:-
PRAD	cis	rs321358	1	rs321363	ENSG00000271584.1	RP11-89C3.4	8.09	5.59e-15	2.81e-12	0.54	0.35	Body mass index;	chr11:111125929	chr11:111091932~111097357:-
PRAD	cis	rs321358	1	rs321366	ENSG00000271584.1	RP11-89C3.4	8.09	5.59e-15	2.81e-12	0.54	0.35	Body mass index;	chr11:111128003	chr11:111091932~111097357:-
PRAD	cis	rs321358	1	rs321368	ENSG00000271584.1	RP11-89C3.4	8.09	5.59e-15	2.81e-12	0.54	0.35	Body mass index;	chr11:111129033	chr11:111091932~111097357:-
PRAD	cis	rs321358	1	rs321369	ENSG00000271584.1	RP11-89C3.4	8.09	5.59e-15	2.81e-12	0.54	0.35	Body mass index;	chr11:111129797	chr11:111091932~111097357:-
PRAD	cis	rs321358	1	rs321370	ENSG00000271584.1	RP11-89C3.4	8.09	5.59e-15	2.81e-12	0.54	0.35	Body mass index;	chr11:111129959	chr11:111091932~111097357:-
PRAD	cis	rs736801	0.729	rs1050152	ENSG00000233006.5	AC034220.3	8.09	5.59e-15	2.81e-12	0.32	0.35	Mosquito bite size;Breast cancer;	chr5:132340627	chr5:132311285~132369916:-
PRAD	cis	rs17711722	0.653	rs2460421	ENSG00000237310.1	GS1-124K5.4	-8.09	5.6e-15	2.81e-12	-0.31	-0.35	Calcium levels;	chr7:66026136	chr7:66493706~66495474:+
PRAD	cis	rs11976180	1	rs11976037	ENSG00000273234.1	OR2A13P	-8.09	5.6e-15	2.81e-12	-0.43	-0.35	Obesity-related traits;	chr7:144043931	chr7:144142009~144142938:+
PRAD	cis	rs11098499	0.82	rs28578366	ENSG00000245958.5	RP11-33B1.1	8.09	5.6e-15	2.81e-12	0.35	0.35	Corneal astigmatism;	chr4:119615750	chr4:119454791~119552025:+
PRAD	cis	rs2153535	0.518	rs6925765	ENSG00000230939.1	RP11-314C16.1	-8.09	5.62e-15	2.82e-12	-0.43	-0.35	Motion sickness;	chr6:8566471	chr6:8784178~8785445:+
PRAD	cis	rs9287719	0.967	rs6727768	ENSG00000234818.1	AC092687.5	8.09	5.62e-15	2.82e-12	0.42	0.35	Prostate cancer;	chr2:10617353	chr2:10589166~10604830:+
PRAD	cis	rs11096990	0.634	rs11096988	ENSG00000249207.1	RP11-360F5.1	-8.09	5.63e-15	2.83e-12	-0.37	-0.35	Cognitive function;	chr4:39264081	chr4:39112677~39126818:-
PRAD	cis	rs2933343	0.7	rs1683777	ENSG00000231305.3	RP11-723O4.2	8.09	5.64e-15	2.83e-12	0.33	0.35	IgG glycosylation;	chr3:128906037	chr3:128861313~128871540:-
PRAD	cis	rs2933343	0.7	rs1680788	ENSG00000231305.3	RP11-723O4.2	8.09	5.64e-15	2.83e-12	0.33	0.35	IgG glycosylation;	chr3:128906475	chr3:128861313~128871540:-
PRAD	cis	rs9287719	0.967	rs12464817	ENSG00000234818.1	AC092687.5	8.09	5.66e-15	2.84e-12	0.42	0.35	Prostate cancer;	chr2:10567086	chr2:10589166~10604830:+
PRAD	cis	rs9287719	1	rs9287719	ENSG00000234818.1	AC092687.5	8.09	5.66e-15	2.84e-12	0.42	0.35	Prostate cancer;	chr2:10570604	chr2:10589166~10604830:+
PRAD	cis	rs2337406	0.925	rs873533	ENSG00000274576.2	IGHV2-70	-8.08	5.68e-15	2.85e-12	-0.38	-0.35	Alzheimer's disease (late onset);	chr14:106667442	chr14:106770577~106771020:-
PRAD	cis	rs7923609	1	rs7070296	ENSG00000232075.1	MRPL35P2	-8.08	5.7e-15	2.86e-12	-0.37	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63310678	chr10:63634317~63634827:-
PRAD	cis	rs7923609	1	rs10761742	ENSG00000232075.1	MRPL35P2	-8.08	5.7e-15	2.86e-12	-0.37	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63325288	chr10:63634317~63634827:-
PRAD	cis	rs375066	0.935	rs373168	ENSG00000267058.1	RP11-15A1.3	-8.08	5.7e-15	2.86e-12	-0.3	-0.35	Breast cancer;	chr19:43926717	chr19:43891804~43901805:-
PRAD	cis	rs2243480	1	rs2707844	ENSG00000226824.5	RP4-756H11.3	-8.08	5.71e-15	2.86e-12	-0.7	-0.35	Diabetic kidney disease;	chr7:66594522	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs1796220	ENSG00000226824.5	RP4-756H11.3	-8.08	5.71e-15	2.86e-12	-0.7	-0.35	Diabetic kidney disease;	chr7:66597113	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs2707831	ENSG00000226824.5	RP4-756H11.3	-8.08	5.71e-15	2.86e-12	-0.7	-0.35	Diabetic kidney disease;	chr7:66597524	chr7:66654538~66669855:+
PRAD	cis	rs2581828	0.659	rs4282053	ENSG00000242142.1	SERBP1P3	-8.08	5.71e-15	2.87e-12	-0.42	-0.35	Crohn's disease;	chr3:53107949	chr3:53064283~53065091:-
PRAD	cis	rs2581828	0.659	rs9845352	ENSG00000242142.1	SERBP1P3	-8.08	5.71e-15	2.87e-12	-0.42	-0.35	Crohn's disease;	chr3:53108205	chr3:53064283~53065091:-
PRAD	cis	rs2581828	0.659	rs9845484	ENSG00000242142.1	SERBP1P3	-8.08	5.71e-15	2.87e-12	-0.42	-0.35	Crohn's disease;	chr3:53108240	chr3:53064283~53065091:-
PRAD	cis	rs7429990	0.965	rs4858887	ENSG00000229759.1	MRPS18AP1	-8.08	5.73e-15	2.87e-12	-0.36	-0.35	Educational attainment (years of education);	chr3:48050527	chr3:48256350~48256938:-
PRAD	cis	rs7189233	0.531	rs8043918	ENSG00000279344.1	RP11-44F14.7	8.08	5.73e-15	2.87e-12	0.33	0.35	Intelligence (multi-trait analysis);	chr16:53479121	chr16:53478957~53481550:-
PRAD	cis	rs2739330	0.652	rs2000469	ENSG00000272787.1	KB-226F1.2	-8.08	5.73e-15	2.87e-12	-0.39	-0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23969211~23969873:+
PRAD	cis	rs67311347	0.577	rs1317217	ENSG00000223797.4	ENTPD3-AS1	8.08	5.73e-15	2.88e-12	0.33	0.35	Renal cell carcinoma;	chr3:40230206	chr3:40313802~40453329:-
PRAD	cis	rs2933343	0.7	rs789239	ENSG00000231305.3	RP11-723O4.2	8.08	5.74e-15	2.88e-12	0.33	0.35	IgG glycosylation;	chr3:128914965	chr3:128861313~128871540:-
PRAD	cis	rs2933343	0.7	rs789238	ENSG00000231305.3	RP11-723O4.2	8.08	5.74e-15	2.88e-12	0.33	0.35	IgG glycosylation;	chr3:128917872	chr3:128861313~128871540:-
PRAD	cis	rs7923609	1	rs10761723	ENSG00000232075.1	MRPL35P2	-8.08	5.74e-15	2.88e-12	-0.37	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63195821	chr10:63634317~63634827:-
PRAD	cis	rs11083475	1	rs979971	ENSG00000267892.1	CTD-2540F13.2	8.08	5.75e-15	2.88e-12	0.39	0.35	Heart rate;	chr19:38653604	chr19:38738284~38739863:+
PRAD	cis	rs7727544	0.716	rs72793283	ENSG00000233006.5	AC034220.3	8.08	5.77e-15	2.89e-12	0.31	0.35	Blood metabolite levels;	chr5:132231248	chr5:132311285~132369916:-
PRAD	cis	rs7727544	0.716	rs11955347	ENSG00000233006.5	AC034220.3	8.08	5.77e-15	2.89e-12	0.31	0.35	Blood metabolite levels;	chr5:132232231	chr5:132311285~132369916:-
PRAD	cis	rs7727544	0.647	rs72793280	ENSG00000233006.5	AC034220.3	8.08	5.78e-15	2.9e-12	0.31	0.35	Blood metabolite levels;	chr5:132227207	chr5:132311285~132369916:-
PRAD	cis	rs7923609	0.875	rs10761741	ENSG00000232075.1	MRPL35P2	-8.08	5.79e-15	2.9e-12	-0.37	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63306426	chr10:63634317~63634827:-
PRAD	cis	rs2243480	1	rs160643	ENSG00000226824.5	RP4-756H11.3	-8.08	5.8e-15	2.91e-12	-0.67	-0.35	Diabetic kidney disease;	chr7:66093235	chr7:66654538~66669855:+
PRAD	cis	rs9810089	0.843	rs11717954	ENSG00000261758.1	RP11-102M11.2	8.08	5.8e-15	2.91e-12	0.41	0.35	Gestational age at birth (child effect);	chr3:136393267	chr3:136752630~136755780:+
PRAD	cis	rs9393777	0.92	rs13196692	ENSG00000280107.1	AL022393.9	-8.08	5.81e-15	2.91e-12	-0.71	-0.35	Intelligence (multi-trait analysis);	chr6:27411340	chr6:28170845~28172521:+
PRAD	cis	rs2243480	1	rs13237037	ENSG00000226824.5	RP4-756H11.3	-8.08	5.83e-15	2.92e-12	-0.71	-0.35	Diabetic kidney disease;	chr7:66532895	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs1796228	ENSG00000226824.5	RP4-756H11.3	-8.08	5.83e-15	2.92e-12	-0.71	-0.35	Diabetic kidney disease;	chr7:66568097	chr7:66654538~66669855:+
PRAD	cis	rs2015599	0.56	rs3948497	ENSG00000275476.1	RP11-996F15.4	-8.08	5.85e-15	2.93e-12	-0.39	-0.35	Platelet count;Mean platelet volume;	chr12:29247552	chr12:29277397~29277882:-
PRAD	cis	rs2933343	0.729	rs1680794	ENSG00000231305.3	RP11-723O4.2	8.08	5.86e-15	2.94e-12	0.33	0.35	IgG glycosylation;	chr3:128901547	chr3:128861313~128871540:-
PRAD	cis	rs10129255	0.5	rs2027903	ENSG00000211972.2	IGHV3-66	8.08	5.87e-15	2.94e-12	0.31	0.35	Kawasaki disease;	chr14:106807047	chr14:106675017~106675544:-
PRAD	cis	rs853679	1	rs735765	ENSG00000280107.1	AL022393.9	-8.08	5.89e-15	2.95e-12	-0.57	-0.35	Depression;	chr6:28202519	chr6:28170845~28172521:+
PRAD	cis	rs11098499	0.754	rs1980025	ENSG00000245958.5	RP11-33B1.1	8.08	5.89e-15	2.95e-12	0.33	0.35	Corneal astigmatism;	chr4:119331651	chr4:119454791~119552025:+
PRAD	cis	rs7250849	0.565	rs73052859	ENSG00000273837.1	LLNLR-470E3.1	-8.08	5.89e-15	2.95e-12	-0.52	-0.35	Blood protein levels;	chr19:51661210	chr19:51639478~51639931:-
PRAD	cis	rs7250849	0.565	rs73052861	ENSG00000273837.1	LLNLR-470E3.1	-8.08	5.89e-15	2.95e-12	-0.52	-0.35	Blood protein levels;	chr19:51661217	chr19:51639478~51639931:-
PRAD	cis	rs9810089	0.814	rs864437	ENSG00000261758.1	RP11-102M11.2	8.08	5.9e-15	2.95e-12	0.4	0.35	Gestational age at birth (child effect);	chr3:136401067	chr3:136752630~136755780:+
PRAD	cis	rs6001482	0.679	rs8142710	ENSG00000272779.1	LL22NC03-80A10.6	-8.08	5.91e-15	2.96e-12	-0.43	-0.35	Diastolic blood pressure;	chr22:22233044	chr22:22303224~22310401:+
PRAD	cis	rs12908161	1	rs12910012	ENSG00000259728.4	LINC00933	8.08	5.93e-15	2.97e-12	0.44	0.35	Schizophrenia;	chr15:84755431	chr15:84570649~84580175:+
PRAD	cis	rs12908161	1	rs12899981	ENSG00000259728.4	LINC00933	8.08	5.93e-15	2.97e-12	0.44	0.35	Schizophrenia;	chr15:84759142	chr15:84570649~84580175:+
PRAD	cis	rs6452524	0.868	rs10079372	ENSG00000249664.1	CTD-2227C6.2	8.08	5.94e-15	2.97e-12	0.43	0.35	Hypertension (SNP x SNP interaction);	chr5:83117113	chr5:83012285~83013109:-
PRAD	cis	rs11096990	0.634	rs12648793	ENSG00000249207.1	RP11-360F5.1	8.08	5.97e-15	2.99e-12	0.36	0.35	Cognitive function;	chr4:39284473	chr4:39112677~39126818:-
PRAD	cis	rs4266144	0.926	rs4368453	ENSG00000244515.1	KRT18P34	-8.08	5.97e-15	2.99e-12	-0.44	-0.35	Coronary artery disease;	chr3:157134352	chr3:157162663~157163932:-
PRAD	cis	rs7432375	0.901	rs1729951	ENSG00000261758.1	RP11-102M11.2	-8.08	5.97e-15	2.99e-12	-0.41	-0.35	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136781891	chr3:136752630~136755780:+
PRAD	cis	rs2933343	0.672	rs1872545	ENSG00000231305.3	RP11-723O4.2	8.08	5.99e-15	3e-12	0.33	0.35	IgG glycosylation;	chr3:128926196	chr3:128861313~128871540:-
PRAD	cis	rs2638953	0.924	rs11049476	ENSG00000278733.1	RP11-425D17.1	-8.08	6e-15	3e-12	-0.43	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28244242	chr12:28185625~28186190:-
PRAD	cis	rs2404602	0.692	rs55864032	ENSG00000259422.1	RP11-593F23.1	8.08	6e-15	3e-12	0.44	0.35	Blood metabolite levels;	chr15:76830207	chr15:76174891~76181486:-
PRAD	cis	rs858239	0.699	rs858260	ENSG00000226816.2	AC005082.12	8.08	6.01e-15	3.01e-12	0.41	0.35	Cerebrospinal fluid biomarker levels;	chr7:23173315	chr7:23206013~23208045:+
PRAD	cis	rs4835473	0.932	rs4835455	ENSG00000251600.4	RP11-673E1.1	8.08	6.02e-15	3.02e-12	0.43	0.35	Immature fraction of reticulocytes;	chr4:143962290	chr4:143912331~143982454:+
PRAD	cis	rs853679	0.599	rs156743	ENSG00000280107.1	AL022393.9	-8.08	6.04e-15	3.02e-12	-0.64	-0.35	Depression;	chr6:27999311	chr6:28170845~28172521:+
PRAD	cis	rs375066	0.935	rs430308	ENSG00000267058.1	RP11-15A1.3	-8.08	6.07e-15	3.04e-12	-0.29	-0.35	Breast cancer;	chr19:43896223	chr19:43891804~43901805:-
PRAD	cis	rs1729407	0.709	rs2098453	ENSG00000254851.1	RP11-109L13.1	-8.08	6.07e-15	3.04e-12	-0.46	-0.35	Apolipoprotein A-IV levels;	chr11:116825964	chr11:117135528~117138582:+
PRAD	cis	rs1979679	0.842	rs12049916	ENSG00000278733.1	RP11-425D17.1	8.08	6.08e-15	3.04e-12	0.47	0.35	Ossification of the posterior longitudinal ligament of the spine;	chr12:28207052	chr12:28185625~28186190:-
PRAD	cis	rs10800713	0.56	rs10800706	ENSG00000260088.1	RP11-92G12.3	-8.08	6.09e-15	3.05e-12	-0.55	-0.35	Tandem gait;	chr1:200526967	chr1:200669507~200694250:+
PRAD	cis	rs4713118	0.868	rs35069907	ENSG00000226314.6	ZNF192P1	-8.08	6.09e-15	3.05e-12	-0.48	-0.35	Parkinson's disease;	chr6:27778913	chr6:28161781~28169594:+
PRAD	cis	rs62355901	0.545	rs72756091	ENSG00000271828.1	CTD-2310F14.1	8.08	6.09e-15	3.05e-12	0.76	0.35	Breast cancer;	chr5:56765903	chr5:56927874~56929573:+
PRAD	cis	rs7121800	0.632	rs7114662	ENSG00000242353.1	RP4-710M3.1	-8.07	6.11e-15	3.06e-12	-0.39	-0.35	Pit-and-Fissure caries;	chr11:30507967	chr11:30368148~30368646:+
PRAD	cis	rs9467773	0.62	rs1027203	ENSG00000241549.7	GUSBP2	8.07	6.12e-15	3.06e-12	0.38	0.35	Intelligence (multi-trait analysis);	chr6:26639104	chr6:26871484~26956554:-
PRAD	cis	rs9467773	0.595	rs2172007	ENSG00000241549.7	GUSBP2	8.07	6.12e-15	3.06e-12	0.38	0.35	Intelligence (multi-trait analysis);	chr6:26639549	chr6:26871484~26956554:-
PRAD	cis	rs375066	0.935	rs108775	ENSG00000267058.1	RP11-15A1.3	-8.07	6.13e-15	3.06e-12	-0.29	-0.35	Breast cancer;	chr19:43901770	chr19:43891804~43901805:-
PRAD	cis	rs193541	0.593	rs154517	ENSG00000263432.2	RN7SL689P	8.07	6.13e-15	3.06e-12	0.38	0.35	Glucose homeostasis traits;	chr5:122854130	chr5:123022487~123022783:-
PRAD	cis	rs193541	0.632	rs152038	ENSG00000263432.2	RN7SL689P	8.07	6.13e-15	3.06e-12	0.38	0.35	Glucose homeostasis traits;	chr5:122860151	chr5:123022487~123022783:-
PRAD	cis	rs914615	0.552	rs12752585	ENSG00000160766.13	GBAP1	-8.07	6.13e-15	3.07e-12	-0.36	-0.35	Urinary albumin-to-creatinine ratio;	chr1:155162930	chr1:155213821~155227422:-
PRAD	cis	rs7923609	0.967	rs7920058	ENSG00000232075.1	MRPL35P2	-8.07	6.13e-15	3.07e-12	-0.37	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63534164	chr10:63634317~63634827:-
PRAD	cis	rs1552244	0.554	rs6786636	ENSG00000206567.8	AC022007.5	-8.07	6.14e-15	3.07e-12	-0.4	-0.35	Alzheimer's disease;	chr3:10004019	chr3:10006418~10011209:-
PRAD	cis	rs1552244	0.554	rs6762702	ENSG00000206567.8	AC022007.5	-8.07	6.14e-15	3.07e-12	-0.4	-0.35	Alzheimer's disease;	chr3:10014105	chr3:10006418~10011209:-
PRAD	cis	rs2243480	1	rs402418	ENSG00000226824.5	RP4-756H11.3	-8.07	6.14e-15	3.07e-12	-0.71	-0.35	Diabetic kidney disease;	chr7:66044482	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs431318	ENSG00000226824.5	RP4-756H11.3	-8.07	6.14e-15	3.07e-12	-0.71	-0.35	Diabetic kidney disease;	chr7:66046610	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs313803	ENSG00000226824.5	RP4-756H11.3	-8.07	6.14e-15	3.07e-12	-0.71	-0.35	Diabetic kidney disease;	chr7:66049744	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs313802	ENSG00000226824.5	RP4-756H11.3	-8.07	6.14e-15	3.07e-12	-0.71	-0.35	Diabetic kidney disease;	chr7:66051386	chr7:66654538~66669855:+
PRAD	cis	rs2243480	0.803	rs403089	ENSG00000226824.5	RP4-756H11.3	-8.07	6.14e-15	3.07e-12	-0.71	-0.35	Diabetic kidney disease;	chr7:66052736	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs458291	ENSG00000226824.5	RP4-756H11.3	-8.07	6.14e-15	3.07e-12	-0.71	-0.35	Diabetic kidney disease;	chr7:66055492	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.83	rs427575	ENSG00000237310.1	GS1-124K5.4	8.07	6.17e-15	3.09e-12	0.31	0.35	Aortic root size;	chr7:66054232	chr7:66493706~66495474:+
PRAD	cis	rs4713118	0.699	rs573179	ENSG00000219392.1	RP1-265C24.5	-8.07	6.17e-15	3.09e-12	-0.47	-0.35	Parkinson's disease;	chr6:27881898	chr6:28115628~28116551:+
PRAD	cis	rs4713118	1	rs4713118	ENSG00000280107.1	AL022393.9	-8.07	6.18e-15	3.09e-12	-0.45	-0.35	Parkinson's disease;	chr6:27709015	chr6:28170845~28172521:+
PRAD	cis	rs4713118	1	rs13215072	ENSG00000280107.1	AL022393.9	-8.07	6.18e-15	3.09e-12	-0.45	-0.35	Parkinson's disease;	chr6:27709949	chr6:28170845~28172521:+
PRAD	cis	rs2337406	0.714	rs8022729	ENSG00000274576.2	IGHV2-70	8.07	6.18e-15	3.09e-12	0.37	0.35	Alzheimer's disease (late onset);	chr14:106816928	chr14:106770577~106771020:-
PRAD	cis	rs7739264	0.602	rs6916251	ENSG00000228412.5	RP4-625H18.2	8.07	6.2e-15	3.1e-12	0.42	0.35	Endometriosis;	chr6:19760984	chr6:19802164~19804752:-
PRAD	cis	rs17361889	0.656	rs2058269	ENSG00000224683.1	RPL36AP29	8.07	6.23e-15	3.11e-12	0.4	0.35	Pediatric bone mineral content (hip);	chr7:16193629	chr7:16208945~16209265:+
PRAD	cis	rs375066	0.935	rs396874	ENSG00000267058.1	RP11-15A1.3	-8.07	6.23e-15	3.12e-12	-0.29	-0.35	Breast cancer;	chr19:43893073	chr19:43891804~43901805:-
PRAD	cis	rs375066	0.935	rs397346	ENSG00000267058.1	RP11-15A1.3	-8.07	6.23e-15	3.12e-12	-0.29	-0.35	Breast cancer;	chr19:43894963	chr19:43891804~43901805:-
PRAD	cis	rs673078	0.607	rs7132753	ENSG00000275409.1	RP11-131L12.4	-8.07	6.24e-15	3.12e-12	-0.51	-0.35	Glucose homeostasis traits;	chr12:118420383	chr12:118430147~118430699:+
PRAD	cis	rs2255336	0.657	rs11053765	ENSG00000245648.1	RP11-277P12.20	8.07	6.24e-15	3.12e-12	0.58	0.35	Blood protein levels;	chr12:10351365	chr12:10363769~10398506:+
PRAD	cis	rs4664293	0.51	rs3903306	ENSG00000226266.5	AC009961.3	8.07	6.27e-15	3.13e-12	0.48	0.35	Monocyte percentage of white cells;	chr2:159592171	chr2:159670708~159712435:-
PRAD	cis	rs6921919	0.583	rs740621	ENSG00000216901.1	AL022393.7	8.07	6.27e-15	3.13e-12	0.45	0.35	Autism spectrum disorder or schizophrenia;	chr6:28430010	chr6:28176188~28176674:+
PRAD	cis	rs11096990	0.656	rs9993224	ENSG00000249207.1	RP11-360F5.1	8.07	6.27e-15	3.13e-12	0.36	0.35	Cognitive function;	chr4:39298578	chr4:39112677~39126818:-
PRAD	cis	rs2243480	1	rs316330	ENSG00000226824.5	RP4-756H11.3	-8.07	6.28e-15	3.14e-12	-0.7	-0.35	Diabetic kidney disease;	chr7:66140385	chr7:66654538~66669855:+
PRAD	cis	rs17711722	0.503	rs453835	ENSG00000224316.1	RP11-479O9.2	-8.07	6.28e-15	3.14e-12	-0.34	-0.35	Calcium levels;	chr7:66046172	chr7:65773620~65802067:+
PRAD	cis	rs8081395	0.805	rs1295927	ENSG00000266992.1	DHX40P1	8.07	6.29e-15	3.14e-12	0.39	0.35	White blood cell count;	chr17:59852174	chr17:59976009~60002384:-
PRAD	cis	rs2243480	1	rs431076	ENSG00000226824.5	RP4-756H11.3	-8.07	6.3e-15	3.15e-12	-0.7	-0.35	Diabetic kidney disease;	chr7:66135333	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs2460422	ENSG00000226824.5	RP4-756H11.3	-8.07	6.3e-15	3.15e-12	-0.7	-0.35	Diabetic kidney disease;	chr7:66136518	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs316334	ENSG00000226824.5	RP4-756H11.3	-8.07	6.3e-15	3.15e-12	-0.7	-0.35	Diabetic kidney disease;	chr7:66137139	chr7:66654538~66669855:+
PRAD	cis	rs9532669	0.889	rs6560964	ENSG00000168852.11	TPTE2P5	8.07	6.31e-15	3.15e-12	0.34	0.35	Cervical cancer;	chr13:40871132	chr13:40822296~40921749:-
PRAD	cis	rs11098499	0.863	rs3822190	ENSG00000245958.5	RP11-33B1.1	-8.07	6.32e-15	3.16e-12	-0.35	-0.35	Corneal astigmatism;	chr4:119506943	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.863	rs3822191	ENSG00000245958.5	RP11-33B1.1	-8.07	6.32e-15	3.16e-12	-0.35	-0.35	Corneal astigmatism;	chr4:119506946	chr4:119454791~119552025:+
PRAD	cis	rs763567	0.904	rs544478	ENSG00000271811.1	RP1-79C4.4	8.07	6.33e-15	3.16e-12	0.4	0.35	Tonsillectomy;	chr1:170644901	chr1:170667381~170669425:+
PRAD	cis	rs2243480	1	rs316326	ENSG00000226824.5	RP4-756H11.3	-8.07	6.34e-15	3.16e-12	-0.7	-0.35	Diabetic kidney disease;	chr7:66144466	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs316325	ENSG00000226824.5	RP4-756H11.3	-8.07	6.34e-15	3.16e-12	-0.7	-0.35	Diabetic kidney disease;	chr7:66144531	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs316321	ENSG00000226824.5	RP4-756H11.3	-8.07	6.34e-15	3.16e-12	-0.7	-0.35	Diabetic kidney disease;	chr7:66146626	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs316327	ENSG00000226824.5	RP4-756H11.3	8.07	6.34e-15	3.16e-12	0.7	0.35	Diabetic kidney disease;	chr7:66144214	chr7:66654538~66669855:+
PRAD	cis	rs4664293	0.51	rs890096	ENSG00000226266.5	AC009961.3	8.07	6.34e-15	3.17e-12	0.47	0.35	Monocyte percentage of white cells;	chr2:159604849	chr2:159670708~159712435:-
PRAD	cis	rs4664293	0.51	rs747707	ENSG00000226266.5	AC009961.3	8.07	6.34e-15	3.17e-12	0.47	0.35	Monocyte percentage of white cells;	chr2:159609003	chr2:159670708~159712435:-
PRAD	cis	rs2243480	0.908	rs313822	ENSG00000226824.5	RP4-756H11.3	-8.07	6.36e-15	3.17e-12	-0.7	-0.35	Diabetic kidney disease;	chr7:66108952	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs313824	ENSG00000226824.5	RP4-756H11.3	-8.07	6.36e-15	3.17e-12	-0.7	-0.35	Diabetic kidney disease;	chr7:66116220	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs186378	ENSG00000226824.5	RP4-756H11.3	-8.07	6.36e-15	3.17e-12	-0.7	-0.35	Diabetic kidney disease;	chr7:66117071	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs160637	ENSG00000226824.5	RP4-756H11.3	-8.07	6.36e-15	3.17e-12	-0.7	-0.35	Diabetic kidney disease;	chr7:66119331	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs422164	ENSG00000226824.5	RP4-756H11.3	-8.07	6.36e-15	3.17e-12	-0.7	-0.35	Diabetic kidney disease;	chr7:66121618	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs316313	ENSG00000226824.5	RP4-756H11.3	-8.07	6.36e-15	3.17e-12	-0.7	-0.35	Diabetic kidney disease;	chr7:66128561	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs316312	ENSG00000226824.5	RP4-756H11.3	-8.07	6.36e-15	3.17e-12	-0.7	-0.35	Diabetic kidney disease;	chr7:66131504	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs419603	ENSG00000226824.5	RP4-756H11.3	-8.07	6.36e-15	3.17e-12	-0.7	-0.35	Diabetic kidney disease;	chr7:66132354	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs387676	ENSG00000226824.5	RP4-756H11.3	-8.07	6.36e-15	3.17e-12	-0.7	-0.35	Diabetic kidney disease;	chr7:66133233	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs13310597	ENSG00000226824.5	RP4-756H11.3	-8.07	6.36e-15	3.17e-12	-0.7	-0.35	Diabetic kidney disease;	chr7:66133553	chr7:66654538~66669855:+
PRAD	cis	rs17711722	0.565	rs4275112	ENSG00000237310.1	GS1-124K5.4	-8.07	6.36e-15	3.18e-12	-0.3	-0.35	Calcium levels;	chr7:65733651	chr7:66493706~66495474:+
PRAD	cis	rs11096990	0.634	rs1057807	ENSG00000249207.1	RP11-360F5.1	8.07	6.37e-15	3.18e-12	0.37	0.35	Cognitive function;	chr4:39287853	chr4:39112677~39126818:-
PRAD	cis	rs858239	1	rs199357	ENSG00000226816.2	AC005082.12	-8.07	6.39e-15	3.19e-12	-0.39	-0.35	Cerebrospinal fluid biomarker levels;	chr7:23248690	chr7:23206013~23208045:+
PRAD	cis	rs2243480	0.764	rs2460423	ENSG00000226824.5	RP4-756H11.3	-8.07	6.4e-15	3.2e-12	-0.7	-0.35	Diabetic kidney disease;	chr7:66136229	chr7:66654538~66669855:+
PRAD	cis	rs526231	0.543	rs34808	ENSG00000175749.11	EIF3KP1	8.07	6.41e-15	3.2e-12	0.5	0.35	Primary biliary cholangitis;	chr5:103093484	chr5:103032376~103033031:+
PRAD	cis	rs526231	0.543	rs34809	ENSG00000175749.11	EIF3KP1	8.07	6.41e-15	3.2e-12	0.5	0.35	Primary biliary cholangitis;	chr5:103094413	chr5:103032376~103033031:+
PRAD	cis	rs193541	0.632	rs2407402	ENSG00000263432.2	RN7SL689P	8.07	6.42e-15	3.2e-12	0.38	0.35	Glucose homeostasis traits;	chr5:122771410	chr5:123022487~123022783:-
PRAD	cis	rs10129255	0.5	rs8021941	ENSG00000211972.2	IGHV3-66	8.07	6.42e-15	3.2e-12	0.31	0.35	Kawasaki disease;	chr14:106781490	chr14:106675017~106675544:-
PRAD	cis	rs10129255	0.5	rs10142931	ENSG00000211972.2	IGHV3-66	8.07	6.42e-15	3.2e-12	0.31	0.35	Kawasaki disease;	chr14:106782288	chr14:106675017~106675544:-
PRAD	cis	rs881375	0.9	rs2241003	ENSG00000226752.6	PSMD5-AS1	-8.07	6.44e-15	3.21e-12	-0.41	-0.35	Rheumatoid arthritis;	chr9:120904499	chr9:120824828~120854385:+
PRAD	cis	rs4713118	0.588	rs200994	ENSG00000226314.6	ZNF192P1	8.07	6.46e-15	3.22e-12	0.48	0.35	Parkinson's disease;	chr6:27846035	chr6:28161781~28169594:+
PRAD	cis	rs2115630	0.653	rs61394864	ENSG00000225151.9	GOLGA2P7	8.07	6.46e-15	3.22e-12	0.44	0.35	P wave terminal force;	chr15:84626943	chr15:84199311~84230136:-
PRAD	cis	rs172166	0.516	rs1225710	ENSG00000280107.1	AL022393.9	8.07	6.46e-15	3.22e-12	0.42	0.35	Cardiac Troponin-T levels;	chr6:28132862	chr6:28170845~28172521:+
PRAD	cis	rs11096990	0.576	rs2008679	ENSG00000249207.1	RP11-360F5.1	8.07	6.48e-15	3.23e-12	0.37	0.35	Cognitive function;	chr4:39266385	chr4:39112677~39126818:-
PRAD	cis	rs4631830	0.863	rs2843546	ENSG00000230869.1	CTGLF10P	-8.07	6.48e-15	3.23e-12	-0.44	-0.35	Prostate-specific antigen levels;	chr10:46077134	chr10:45678692~45700532:+
PRAD	cis	rs6545883	0.507	rs6545855	ENSG00000271889.1	RP11-493E12.1	-8.07	6.48e-15	3.23e-12	-0.38	-0.35	Tuberculosis;	chr2:61305725	chr2:61151433~61162105:-
PRAD	cis	rs1789	0.706	rs7696938	ENSG00000273133.1	RP11-799M12.2	8.07	6.49e-15	3.24e-12	0.5	0.35	Blood protein levels;	chr4:15701954	chr4:15563698~15564253:-
PRAD	cis	rs6545883	0.507	rs10169662	ENSG00000271889.1	RP11-493E12.1	-8.07	6.49e-15	3.24e-12	-0.39	-0.35	Tuberculosis;	chr2:61280801	chr2:61151433~61162105:-
PRAD	cis	rs193541	0.632	rs154512	ENSG00000263432.2	RN7SL689P	8.06	6.56e-15	3.27e-12	0.38	0.35	Glucose homeostasis traits;	chr5:122859345	chr5:123022487~123022783:-
PRAD	cis	rs193541	0.555	rs2438151	ENSG00000263432.2	RN7SL689P	8.06	6.56e-15	3.27e-12	0.38	0.35	Glucose homeostasis traits;	chr5:122863502	chr5:123022487~123022783:-
PRAD	cis	rs3745672	0.59	rs10411299	ENSG00000219665.7	CTD-2006C1.2	-8.06	6.57e-15	3.27e-12	-0.72	-0.35	Multiple sclerosis;	chr19:12058348	chr19:11987617~12046275:+
PRAD	cis	rs3745672	0.59	rs79343210	ENSG00000219665.7	CTD-2006C1.2	-8.06	6.57e-15	3.27e-12	-0.72	-0.35	Multiple sclerosis;	chr19:12058908	chr19:11987617~12046275:+
PRAD	cis	rs3745672	0.59	rs79219764	ENSG00000219665.7	CTD-2006C1.2	-8.06	6.57e-15	3.27e-12	-0.72	-0.35	Multiple sclerosis;	chr19:12059147	chr19:11987617~12046275:+
PRAD	cis	rs3745672	0.59	rs79770870	ENSG00000219665.7	CTD-2006C1.2	-8.06	6.57e-15	3.27e-12	-0.72	-0.35	Multiple sclerosis;	chr19:12064543	chr19:11987617~12046275:+
PRAD	cis	rs1134634	0.52	rs28419165	ENSG00000273133.1	RP11-799M12.2	-8.06	6.58e-15	3.28e-12	-0.48	-0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15587722	chr4:15563698~15564253:-
PRAD	cis	rs9903692	0.954	rs9899461	ENSG00000278765.1	RP5-890E16.5	-8.06	6.59e-15	3.28e-12	-0.54	-0.35	Pulse pressure;	chr17:48051991	chr17:48066704~48067293:-
PRAD	cis	rs2946504	0.861	rs2946501	ENSG00000251468.2	RP11-369K16.1	8.06	6.6e-15	3.29e-12	0.44	0.35	Type 2 diabetes;	chr8:12955922	chr8:12958387~12962200:+
PRAD	cis	rs6921919	0.583	rs7740351	ENSG00000216901.1	AL022393.7	8.06	6.63e-15	3.3e-12	0.45	0.35	Autism spectrum disorder or schizophrenia;	chr6:28431635	chr6:28176188~28176674:+
PRAD	cis	rs7131987	0.683	rs7954278	ENSG00000257176.2	RP11-996F15.2	-8.06	6.64e-15	3.31e-12	-0.39	-0.35	QT interval;	chr12:29306357	chr12:29280418~29317848:-
PRAD	cis	rs67311347	0.544	rs12635762	ENSG00000223797.4	ENTPD3-AS1	-8.06	6.65e-15	3.31e-12	-0.31	-0.35	Renal cell carcinoma;	chr3:40291268	chr3:40313802~40453329:-
PRAD	cis	rs2522056	0.808	rs17771891	ENSG00000233006.5	AC034220.3	8.06	6.69e-15	3.33e-12	0.36	0.35	Fibrinogen;Lymphocyte counts;	chr5:132408510	chr5:132311285~132369916:-
PRAD	cis	rs9399135	0.627	rs6930223	ENSG00000232876.1	CTA-212D2.2	-8.06	6.69e-15	3.33e-12	-0.45	-0.35	Red blood cell count;	chr6:135103065	chr6:135055033~135060550:+
PRAD	cis	rs2243480	1	rs313820	ENSG00000226824.5	RP4-756H11.3	-8.06	6.73e-15	3.35e-12	-0.7	-0.35	Diabetic kidney disease;	chr7:66109479	chr7:66654538~66669855:+
PRAD	cis	rs4713118	1	rs1139226	ENSG00000280107.1	AL022393.9	-8.06	6.73e-15	3.35e-12	-0.45	-0.35	Parkinson's disease;	chr6:27707511	chr6:28170845~28172521:+
PRAD	cis	rs4713118	1	rs9468195	ENSG00000280107.1	AL022393.9	-8.06	6.73e-15	3.35e-12	-0.45	-0.35	Parkinson's disease;	chr6:27708530	chr6:28170845~28172521:+
PRAD	cis	rs11096990	0.634	rs7564	ENSG00000249207.1	RP11-360F5.1	8.06	6.74e-15	3.36e-12	0.36	0.35	Cognitive function;	chr4:39285702	chr4:39112677~39126818:-
PRAD	cis	rs11096990	0.613	rs1451821	ENSG00000249207.1	RP11-360F5.1	8.06	6.74e-15	3.36e-12	0.37	0.35	Cognitive function;	chr4:39178797	chr4:39112677~39126818:-
PRAD	cis	rs12142240	0.698	rs6659228	ENSG00000232022.5	FAAHP1	-8.06	6.74e-15	3.36e-12	-0.33	-0.35	Menopause (age at onset);	chr1:46345355	chr1:46432129~46445521:+
PRAD	cis	rs2243480	1	rs427044	ENSG00000226824.5	RP4-756H11.3	-8.06	6.75e-15	3.36e-12	-0.7	-0.35	Diabetic kidney disease;	chr7:66043558	chr7:66654538~66669855:+
PRAD	cis	rs4631830	0.737	rs7071471	ENSG00000230869.1	CTGLF10P	8.06	6.8e-15	3.38e-12	0.44	0.35	Prostate-specific antigen levels;	chr10:46092487	chr10:45678692~45700532:+
PRAD	cis	rs11951515	0.502	rs9292874	ENSG00000188850.9	RP11-159F24.2	8.06	6.81e-15	3.39e-12	0.43	0.35	Metabolite levels  (X-11787);	chr5:43355250	chr5:43336164~43348716:+
PRAD	cis	rs7923609	0.778	rs7075195	ENSG00000232075.1	MRPL35P2	-8.06	6.83e-15	3.4e-12	-0.37	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63290899	chr10:63634317~63634827:-
PRAD	cis	rs11096990	0.656	rs3733284	ENSG00000249207.1	RP11-360F5.1	8.06	6.83e-15	3.4e-12	0.36	0.35	Cognitive function;	chr4:39299714	chr4:39112677~39126818:-
PRAD	cis	rs17711722	0.523	rs365896	ENSG00000275400.1	RP4-756H11.5	8.06	6.85e-15	3.41e-12	0.32	0.35	Calcium levels;	chr7:66045710	chr7:66553805~66554199:-
PRAD	cis	rs62355901	0.509	rs116154674	ENSG00000271828.1	CTD-2310F14.1	8.06	6.86e-15	3.41e-12	0.78	0.35	Breast cancer;	chr5:56710833	chr5:56927874~56929573:+
PRAD	cis	rs7923609	0.935	rs10995477	ENSG00000232075.1	MRPL35P2	-8.06	6.87e-15	3.42e-12	-0.37	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63250912	chr10:63634317~63634827:-
PRAD	cis	rs7829975	0.711	rs12682352	ENSG00000253893.2	FAM85B	-8.06	6.87e-15	3.42e-12	-0.45	-0.35	Mood instability;	chr8:8788736	chr8:8167819~8226614:-
PRAD	cis	rs6951245	0.554	rs118191017	ENSG00000229043.2	AC091729.9	-8.06	6.88e-15	3.42e-12	-0.48	-0.35	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1116210	chr7:1160374~1165267:+
PRAD	cis	rs5769707	0.632	rs1476037	ENSG00000188511.11	C22orf34	8.06	6.89e-15	3.43e-12	0.4	0.35	Monocyte percentage of white cells;Monocyte count;	chr22:49597729	chr22:49414524~49657542:-
PRAD	cis	rs12908161	1	rs56864281	ENSG00000259728.4	LINC00933	8.06	6.91e-15	3.44e-12	0.43	0.35	Schizophrenia;	chr15:84814418	chr15:84570649~84580175:+
PRAD	cis	rs13113518	0.729	rs13120134	ENSG00000249700.7	SRD5A3-AS1	8.06	6.92e-15	3.44e-12	0.48	0.35	Height;	chr4:55415153	chr4:55363971~55395847:-
PRAD	cis	rs858239	1	rs156421	ENSG00000226816.2	AC005082.12	8.06	6.94e-15	3.45e-12	0.4	0.35	Cerebrospinal fluid biomarker levels;	chr7:23272868	chr7:23206013~23208045:+
PRAD	cis	rs9399137	0.507	rs4896118	ENSG00000232876.1	CTA-212D2.2	8.06	6.95e-15	3.45e-12	0.45	0.35	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134954927	chr6:135055033~135060550:+
PRAD	cis	rs6921919	0.583	rs2071965	ENSG00000216901.1	AL022393.7	8.06	6.95e-15	3.45e-12	0.45	0.35	Autism spectrum disorder or schizophrenia;	chr6:28435448	chr6:28176188~28176674:+
PRAD	cis	rs6545883	0.524	rs4599092	ENSG00000271889.1	RP11-493E12.1	-8.06	6.96e-15	3.46e-12	-0.39	-0.35	Tuberculosis;	chr2:61271833	chr2:61151433~61162105:-
PRAD	cis	rs375066	0.935	rs408549	ENSG00000267058.1	RP11-15A1.3	-8.06	6.98e-15	3.47e-12	-0.29	-0.35	Breast cancer;	chr19:43921467	chr19:43891804~43901805:-
PRAD	cis	rs375066	0.935	rs398388	ENSG00000267058.1	RP11-15A1.3	-8.06	6.98e-15	3.47e-12	-0.29	-0.35	Breast cancer;	chr19:43921530	chr19:43891804~43901805:-
PRAD	cis	rs375066	0.935	rs403137	ENSG00000267058.1	RP11-15A1.3	-8.06	6.98e-15	3.47e-12	-0.29	-0.35	Breast cancer;	chr19:43923474	chr19:43891804~43901805:-
PRAD	cis	rs375066	0.869	rs379785	ENSG00000267058.1	RP11-15A1.3	-8.06	6.98e-15	3.47e-12	-0.29	-0.35	Breast cancer;	chr19:43923949	chr19:43891804~43901805:-
PRAD	cis	rs375066	0.935	rs428505	ENSG00000267058.1	RP11-15A1.3	-8.06	6.98e-15	3.47e-12	-0.29	-0.35	Breast cancer;	chr19:43924759	chr19:43891804~43901805:-
PRAD	cis	rs375066	0.935	rs367741	ENSG00000267058.1	RP11-15A1.3	-8.06	6.98e-15	3.47e-12	-0.29	-0.35	Breast cancer;	chr19:43925028	chr19:43891804~43901805:-
PRAD	cis	rs11096990	0.634	rs10019594	ENSG00000249207.1	RP11-360F5.1	8.06	6.98e-15	3.47e-12	0.36	0.35	Cognitive function;	chr4:39287127	chr4:39112677~39126818:-
PRAD	cis	rs11096990	0.656	rs3796513	ENSG00000249207.1	RP11-360F5.1	8.06	6.98e-15	3.47e-12	0.36	0.35	Cognitive function;	chr4:39289462	chr4:39112677~39126818:-
PRAD	cis	rs11096990	0.634	rs10029074	ENSG00000249207.1	RP11-360F5.1	8.06	6.98e-15	3.47e-12	0.36	0.35	Cognitive function;	chr4:39290882	chr4:39112677~39126818:-
PRAD	cis	rs11096990	0.634	rs1564710	ENSG00000249207.1	RP11-360F5.1	8.06	6.98e-15	3.47e-12	0.36	0.35	Cognitive function;	chr4:39291178	chr4:39112677~39126818:-
PRAD	cis	rs11096990	0.634	rs2839765	ENSG00000249207.1	RP11-360F5.1	8.06	6.98e-15	3.47e-12	0.36	0.35	Cognitive function;	chr4:39293933	chr4:39112677~39126818:-
PRAD	cis	rs11096990	0.634	rs6815855	ENSG00000249207.1	RP11-360F5.1	8.06	6.98e-15	3.47e-12	0.36	0.35	Cognitive function;	chr4:39294926	chr4:39112677~39126818:-
PRAD	cis	rs375066	0.935	rs387689	ENSG00000267058.1	RP11-15A1.3	-8.06	6.99e-15	3.47e-12	-0.29	-0.35	Breast cancer;	chr19:43915959	chr19:43891804~43901805:-
PRAD	cis	rs375066	0.935	rs398193	ENSG00000267058.1	RP11-15A1.3	-8.06	6.99e-15	3.47e-12	-0.29	-0.35	Breast cancer;	chr19:43916268	chr19:43891804~43901805:-
PRAD	cis	rs375066	0.868	rs378112	ENSG00000267058.1	RP11-15A1.3	-8.06	6.99e-15	3.47e-12	-0.29	-0.35	Breast cancer;	chr19:43917777	chr19:43891804~43901805:-
PRAD	cis	rs375066	0.868	rs378109	ENSG00000267058.1	RP11-15A1.3	-8.06	6.99e-15	3.47e-12	-0.29	-0.35	Breast cancer;	chr19:43917785	chr19:43891804~43901805:-
PRAD	cis	rs375066	0.935	rs450308	ENSG00000267058.1	RP11-15A1.3	-8.06	6.99e-15	3.47e-12	-0.29	-0.35	Breast cancer;	chr19:43918206	chr19:43891804~43901805:-
PRAD	cis	rs375066	0.935	rs424729	ENSG00000267058.1	RP11-15A1.3	-8.06	6.99e-15	3.47e-12	-0.29	-0.35	Breast cancer;	chr19:43918650	chr19:43891804~43901805:-
PRAD	cis	rs375066	0.935	rs423320	ENSG00000267058.1	RP11-15A1.3	-8.06	6.99e-15	3.47e-12	-0.29	-0.35	Breast cancer;	chr19:43918830	chr19:43891804~43901805:-
PRAD	cis	rs375066	0.935	rs423752	ENSG00000267058.1	RP11-15A1.3	-8.06	6.99e-15	3.47e-12	-0.29	-0.35	Breast cancer;	chr19:43919043	chr19:43891804~43901805:-
PRAD	cis	rs7923609	0.756	rs7080386	ENSG00000232075.1	MRPL35P2	-8.06	7e-15	3.48e-12	-0.37	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63288546	chr10:63634317~63634827:-
PRAD	cis	rs10129255	0.518	rs28378320	ENSG00000211972.2	IGHV3-66	8.06	7.01e-15	3.48e-12	0.31	0.35	Kawasaki disease;	chr14:106808609	chr14:106675017~106675544:-
PRAD	cis	rs11951515	0.663	rs7704588	ENSG00000188850.9	RP11-159F24.2	8.06	7.02e-15	3.49e-12	0.43	0.35	Metabolite levels  (X-11787);	chr5:43358657	chr5:43336164~43348716:+
PRAD	cis	rs1552244	0.554	rs17050704	ENSG00000206567.8	AC022007.5	-8.06	7.03e-15	3.49e-12	-0.39	-0.35	Alzheimer's disease;	chr3:10004050	chr3:10006418~10011209:-
PRAD	cis	rs1552244	0.554	rs34883592	ENSG00000206567.8	AC022007.5	-8.06	7.03e-15	3.49e-12	-0.39	-0.35	Alzheimer's disease;	chr3:10004481	chr3:10006418~10011209:-
PRAD	cis	rs1552244	0.554	rs17050705	ENSG00000206567.8	AC022007.5	-8.06	7.03e-15	3.49e-12	-0.39	-0.35	Alzheimer's disease;	chr3:10004714	chr3:10006418~10011209:-
PRAD	cis	rs1552244	0.554	rs2272120	ENSG00000206567.8	AC022007.5	-8.06	7.03e-15	3.49e-12	-0.39	-0.35	Alzheimer's disease;	chr3:10005019	chr3:10006418~10011209:-
PRAD	cis	rs1552244	0.554	rs13079240	ENSG00000206567.8	AC022007.5	-8.06	7.03e-15	3.49e-12	-0.39	-0.35	Alzheimer's disease;	chr3:10005562	chr3:10006418~10011209:-
PRAD	cis	rs1552244	0.554	rs2272121	ENSG00000206567.8	AC022007.5	-8.06	7.03e-15	3.49e-12	-0.39	-0.35	Alzheimer's disease;	chr3:10005996	chr3:10006418~10011209:-
PRAD	cis	rs1552244	0.554	rs3732965	ENSG00000206567.8	AC022007.5	-8.06	7.03e-15	3.49e-12	-0.39	-0.35	Alzheimer's disease;	chr3:10007076	chr3:10006418~10011209:-
PRAD	cis	rs1552244	0.554	rs3732964	ENSG00000206567.8	AC022007.5	-8.06	7.03e-15	3.49e-12	-0.39	-0.35	Alzheimer's disease;	chr3:10007155	chr3:10006418~10011209:-
PRAD	cis	rs1552244	0.554	rs3732963	ENSG00000206567.8	AC022007.5	-8.06	7.03e-15	3.49e-12	-0.39	-0.35	Alzheimer's disease;	chr3:10007201	chr3:10006418~10011209:-
PRAD	cis	rs1552244	0.608	rs3732962	ENSG00000206567.8	AC022007.5	-8.06	7.03e-15	3.49e-12	-0.39	-0.35	Alzheimer's disease;	chr3:10007267	chr3:10006418~10011209:-
PRAD	cis	rs1552244	0.554	rs2272118	ENSG00000206567.8	AC022007.5	-8.06	7.03e-15	3.49e-12	-0.39	-0.35	Alzheimer's disease;	chr3:10007603	chr3:10006418~10011209:-
PRAD	cis	rs1552244	0.554	rs58020561	ENSG00000206567.8	AC022007.5	-8.06	7.03e-15	3.49e-12	-0.39	-0.35	Alzheimer's disease;	chr3:10012998	chr3:10006418~10011209:-
PRAD	cis	rs9467773	0.523	rs2498399	ENSG00000241549.7	GUSBP2	8.05	7.04e-15	3.49e-12	0.38	0.35	Intelligence (multi-trait analysis);	chr6:26795343	chr6:26871484~26956554:-
PRAD	cis	rs6545883	0.524	rs12713435	ENSG00000271889.1	RP11-493E12.1	-8.05	7.04e-15	3.5e-12	-0.39	-0.35	Tuberculosis;	chr2:61272654	chr2:61151433~61162105:-
PRAD	cis	rs6570726	0.967	rs439017	ENSG00000235652.6	RP11-545I5.3	8.05	7.04e-15	3.5e-12	0.37	0.35	Lobe attachment (rater-scored or self-reported);	chr6:145484987	chr6:145799409~145886585:+
PRAD	cis	rs4631830	0.9	rs7914347	ENSG00000230869.1	CTGLF10P	-8.05	7.07e-15	3.51e-12	-0.44	-0.35	Prostate-specific antigen levels;	chr10:46058391	chr10:45678692~45700532:+
PRAD	cis	rs4631830	0.869	rs4131357	ENSG00000230869.1	CTGLF10P	-8.05	7.07e-15	3.51e-12	-0.44	-0.35	Prostate-specific antigen levels;	chr10:46058530	chr10:45678692~45700532:+
PRAD	cis	rs9309473	0.583	rs6713196	ENSG00000163016.8	ALMS1P	8.05	7.07e-15	3.51e-12	0.43	0.35	Metabolite levels;	chr2:73349277	chr2:73644919~73685576:+
PRAD	cis	rs11098499	0.691	rs10028773	ENSG00000245958.5	RP11-33B1.1	8.05	7.07e-15	3.51e-12	0.32	0.35	Corneal astigmatism;	chr4:119344104	chr4:119454791~119552025:+
PRAD	cis	rs7746199	0.736	rs35037868	ENSG00000280107.1	AL022393.9	-8.05	7.08e-15	3.51e-12	-0.73	-0.35	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27791336	chr6:28170845~28172521:+
PRAD	cis	rs2243480	1	rs313814	ENSG00000226824.5	RP4-756H11.3	-8.05	7.1e-15	3.52e-12	-0.71	-0.35	Diabetic kidney disease;	chr7:66038306	chr7:66654538~66669855:+
PRAD	cis	rs2739330	0.796	rs1006771	ENSG00000272787.1	KB-226F1.2	-8.05	7.11e-15	3.53e-12	-0.38	-0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23969211~23969873:+
PRAD	cis	rs763567	0.845	rs539045	ENSG00000271811.1	RP1-79C4.4	8.05	7.11e-15	3.53e-12	0.4	0.35	Tonsillectomy;	chr1:170638940	chr1:170667381~170669425:+
PRAD	cis	rs11096990	0.634	rs6531706	ENSG00000249207.1	RP11-360F5.1	8.05	7.12e-15	3.53e-12	0.36	0.35	Cognitive function;	chr4:39294547	chr4:39112677~39126818:-
PRAD	cis	rs964611	1	rs74011998	ENSG00000259488.2	RP11-154J22.1	-8.05	7.13e-15	3.54e-12	-0.38	-0.35	Metabolite levels (Pyroglutamine);	chr15:48304516	chr15:48312353~48331856:-
PRAD	cis	rs357618	0.897	rs357630	ENSG00000260581.1	CTB-113P19.4	8.05	7.14e-15	3.54e-12	0.43	0.35	Basophil percentage of white cells;	chr5:151471697	chr5:151652275~151655449:+
PRAD	cis	rs1555322	0.505	rs591590	ENSG00000279253.1	RP4-614O4.13	8.05	7.14e-15	3.55e-12	0.42	0.35	Attention deficit hyperactivity disorder;	chr20:35278225	chr20:35262727~35264187:-
PRAD	cis	rs4713118	0.662	rs4713120	ENSG00000216901.1	AL022393.7	8.05	7.15e-15	3.55e-12	0.45	0.35	Parkinson's disease;	chr6:27754056	chr6:28176188~28176674:+
PRAD	cis	rs9532669	0.926	rs9532640	ENSG00000168852.11	TPTE2P5	8.05	7.17e-15	3.55e-12	0.35	0.35	Cervical cancer;	chr13:40880628	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.89	rs9532641	ENSG00000168852.11	TPTE2P5	8.05	7.17e-15	3.55e-12	0.35	0.35	Cervical cancer;	chr13:40880648	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.926	rs9532643	ENSG00000168852.11	TPTE2P5	8.05	7.17e-15	3.55e-12	0.35	0.35	Cervical cancer;	chr13:40880800	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.963	rs9532644	ENSG00000168852.11	TPTE2P5	8.05	7.17e-15	3.55e-12	0.35	0.35	Cervical cancer;	chr13:40880860	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.926	rs9532645	ENSG00000168852.11	TPTE2P5	8.05	7.17e-15	3.55e-12	0.35	0.35	Cervical cancer;	chr13:40880898	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.926	rs9532646	ENSG00000168852.11	TPTE2P5	8.05	7.17e-15	3.55e-12	0.35	0.35	Cervical cancer;	chr13:40880989	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.926	rs9525419	ENSG00000168852.11	TPTE2P5	8.05	7.17e-15	3.55e-12	0.35	0.35	Cervical cancer;	chr13:40881047	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.926	rs9532647	ENSG00000168852.11	TPTE2P5	8.05	7.17e-15	3.55e-12	0.35	0.35	Cervical cancer;	chr13:40881799	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.89	rs9525420	ENSG00000168852.11	TPTE2P5	8.05	7.17e-15	3.55e-12	0.35	0.35	Cervical cancer;	chr13:40882628	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.926	rs7324383	ENSG00000168852.11	TPTE2P5	8.05	7.17e-15	3.55e-12	0.35	0.35	Cervical cancer;	chr13:40882754	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.926	rs9532648	ENSG00000168852.11	TPTE2P5	8.05	7.17e-15	3.55e-12	0.35	0.35	Cervical cancer;	chr13:40882795	chr13:40822296~40921749:-
PRAD	cis	rs2404602	0.692	rs12911174	ENSG00000259422.1	RP11-593F23.1	8.05	7.17e-15	3.56e-12	0.44	0.35	Blood metabolite levels;	chr15:76857602	chr15:76174891~76181486:-
PRAD	cis	rs6452524	0.967	rs62374399	ENSG00000249664.1	CTD-2227C6.2	8.05	7.18e-15	3.56e-12	0.41	0.35	Hypertension (SNP x SNP interaction);	chr5:83176051	chr5:83012285~83013109:-
PRAD	cis	rs950169	0.922	rs62021167	ENSG00000259728.4	LINC00933	8.05	7.18e-15	3.56e-12	0.43	0.35	Schizophrenia;	chr15:84574820	chr15:84570649~84580175:+
PRAD	cis	rs12908161	0.959	rs1051168	ENSG00000259728.4	LINC00933	8.05	7.2e-15	3.57e-12	0.42	0.35	Schizophrenia;	chr15:84657289	chr15:84570649~84580175:+
PRAD	cis	rs9532669	0.926	rs9566582	ENSG00000168852.11	TPTE2P5	8.05	7.2e-15	3.57e-12	0.35	0.35	Cervical cancer;	chr13:40852121	chr13:40822296~40921749:-
PRAD	cis	rs4713118	0.662	rs149961	ENSG00000272009.1	RP1-313I6.12	-8.05	7.2e-15	3.57e-12	-0.36	-0.35	Parkinson's disease;	chr6:28047791	chr6:28078792~28081130:-
PRAD	cis	rs2933343	0.7	rs789240	ENSG00000231305.3	RP11-723O4.2	8.05	7.23e-15	3.58e-12	0.33	0.35	IgG glycosylation;	chr3:128911792	chr3:128861313~128871540:-
PRAD	cis	rs9368481	0.761	rs9357030	ENSG00000241549.7	GUSBP2	-8.05	7.25e-15	3.59e-12	-0.4	-0.35	Autism spectrum disorder or schizophrenia;	chr6:27017247	chr6:26871484~26956554:-
PRAD	cis	rs3858145	0.5	rs4633337	ENSG00000233590.1	RP11-153K11.3	8.05	7.27e-15	3.6e-12	0.53	0.35	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68285970	chr10:68233251~68242379:-
PRAD	cis	rs1930961	0.702	rs8141065	ENSG00000272942.1	CTA-246H3.12	8.05	7.28e-15	3.61e-12	0.67	0.35	Bipolar disorder with mood-incongruent psychosis;	chr22:25489221	chr22:25434324~25435070:-
PRAD	cis	rs2638953	0.924	rs79712894	ENSG00000278733.1	RP11-425D17.1	-8.05	7.29e-15	3.61e-12	-0.45	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28239400	chr12:28185625~28186190:-
PRAD	cis	rs11098499	0.82	rs13122709	ENSG00000245958.5	RP11-33B1.1	-8.05	7.29e-15	3.61e-12	-0.35	-0.35	Corneal astigmatism;	chr4:119634201	chr4:119454791~119552025:+
PRAD	cis	rs193541	0.53	rs1466371	ENSG00000263432.2	RN7SL689P	8.05	7.3e-15	3.62e-12	0.37	0.35	Glucose homeostasis traits;	chr5:122748093	chr5:123022487~123022783:-
PRAD	cis	rs1979679	0.918	rs11049513	ENSG00000278733.1	RP11-425D17.1	8.05	7.3e-15	3.62e-12	0.47	0.35	Ossification of the posterior longitudinal ligament of the spine;	chr12:28297218	chr12:28185625~28186190:-
PRAD	cis	rs748404	0.631	rs11070399	ENSG00000249839.1	AC011330.5	-8.05	7.3e-15	3.62e-12	-0.43	-0.35	Lung cancer;	chr15:43354149	chr15:43663654~43684339:-
PRAD	cis	rs4266144	1	rs4266144	ENSG00000244515.1	KRT18P34	-8.05	7.31e-15	3.62e-12	-0.43	-0.35	Coronary artery disease;	chr3:157134803	chr3:157162663~157163932:-
PRAD	cis	rs6452524	0.967	rs62374401	ENSG00000249664.1	CTD-2227C6.2	8.05	7.31e-15	3.62e-12	0.42	0.35	Hypertension (SNP x SNP interaction);	chr5:83177159	chr5:83012285~83013109:-
PRAD	cis	rs526231	0.543	rs246913	ENSG00000175749.11	EIF3KP1	8.05	7.33e-15	3.63e-12	0.5	0.35	Primary biliary cholangitis;	chr5:103224669	chr5:103032376~103033031:+
PRAD	cis	rs6991838	0.798	rs62507575	ENSG00000200714.1	Y_RNA	8.05	7.33e-15	3.63e-12	0.37	0.35	Intelligence (multi-trait analysis);	chr8:65566486	chr8:65592731~65592820:+
PRAD	cis	rs812925	0.511	rs11886950	ENSG00000271889.1	RP11-493E12.1	8.05	7.35e-15	3.64e-12	0.39	0.35	Immature fraction of reticulocytes;	chr2:61172182	chr2:61151433~61162105:-
PRAD	cis	rs6517329	0.6	rs6517330	ENSG00000236830.5	CBR3-AS1	8.05	7.38e-15	3.65e-12	0.38	0.35	Schizophrenia;	chr21:36117163	chr21:36131767~36175815:-
PRAD	cis	rs4835473	0.838	rs4271960	ENSG00000251600.4	RP11-673E1.1	-8.05	7.39e-15	3.66e-12	-0.45	-0.35	Immature fraction of reticulocytes;	chr4:143763591	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.808	rs2323198	ENSG00000251600.4	RP11-673E1.1	-8.05	7.39e-15	3.66e-12	-0.45	-0.35	Immature fraction of reticulocytes;	chr4:143763595	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.9	rs2323199	ENSG00000251600.4	RP11-673E1.1	-8.05	7.39e-15	3.66e-12	-0.45	-0.35	Immature fraction of reticulocytes;	chr4:143763606	chr4:143912331~143982454:+
PRAD	cis	rs8177376	0.834	rs12287976	ENSG00000254905.1	RP11-712L6.7	8.05	7.4e-15	3.67e-12	0.42	0.35	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126302693	chr11:126292922~126294254:-
PRAD	cis	rs7916697	0.593	rs3740587	ENSG00000233590.1	RP11-153K11.3	8.05	7.4e-15	3.67e-12	0.47	0.35	Optic disc area;	chr10:68261045	chr10:68233251~68242379:-
PRAD	cis	rs9532669	0.926	rs7997536	ENSG00000168852.11	TPTE2P5	8.05	7.44e-15	3.69e-12	0.35	0.35	Cervical cancer;	chr13:40878685	chr13:40822296~40921749:-
PRAD	cis	rs5769707	0.632	rs6009782	ENSG00000188511.11	C22orf34	8.05	7.45e-15	3.69e-12	0.4	0.35	Monocyte percentage of white cells;Monocyte count;	chr22:49617164	chr22:49414524~49657542:-
PRAD	cis	rs5769707	0.592	rs6009783	ENSG00000188511.11	C22orf34	8.05	7.45e-15	3.69e-12	0.4	0.35	Monocyte percentage of white cells;Monocyte count;	chr22:49617353	chr22:49414524~49657542:-
PRAD	cis	rs4664293	0.51	rs6731277	ENSG00000226266.5	AC009961.3	8.05	7.46e-15	3.69e-12	0.47	0.35	Monocyte percentage of white cells;	chr2:159610606	chr2:159670708~159712435:-
PRAD	cis	rs7923609	0.905	rs7088799	ENSG00000232075.1	MRPL35P2	-8.05	7.46e-15	3.69e-12	-0.37	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63256414	chr10:63634317~63634827:-
PRAD	cis	rs7923609	0.846	rs7098181	ENSG00000232075.1	MRPL35P2	-8.05	7.46e-15	3.69e-12	-0.37	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63267383	chr10:63634317~63634827:-
PRAD	cis	rs7923609	0.846	rs10761731	ENSG00000232075.1	MRPL35P2	-8.05	7.46e-15	3.69e-12	-0.37	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63267850	chr10:63634317~63634827:-
PRAD	cis	rs7923609	0.846	rs9787438	ENSG00000232075.1	MRPL35P2	-8.05	7.46e-15	3.69e-12	-0.37	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63278270	chr10:63634317~63634827:-
PRAD	cis	rs2243480	1	rs2257790	ENSG00000226824.5	RP4-756H11.3	-8.05	7.49e-15	3.71e-12	-0.69	-0.35	Diabetic kidney disease;	chr7:66135463	chr7:66654538~66669855:+
PRAD	cis	rs7923609	0.812	rs10761753	ENSG00000232075.1	MRPL35P2	-8.05	7.5e-15	3.71e-12	-0.37	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63402143	chr10:63634317~63634827:-
PRAD	cis	rs12468226	1	rs7587234	ENSG00000273456.1	RP11-686O6.2	8.05	7.55e-15	3.74e-12	0.49	0.35	Urate levels;	chr2:202351699	chr2:202374932~202375604:-
PRAD	cis	rs2243480	1	rs160639	ENSG00000226824.5	RP4-756H11.3	-8.04	7.57e-15	3.74e-12	-0.69	-0.35	Diabetic kidney disease;	chr7:66115000	chr7:66654538~66669855:+
PRAD	cis	rs7746199	0.673	rs35501037	ENSG00000280107.1	AL022393.9	-8.04	7.58e-15	3.75e-12	-0.71	-0.35	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27771787	chr6:28170845~28172521:+
PRAD	cis	rs6570726	0.935	rs430561	ENSG00000235652.6	RP11-545I5.3	8.04	7.64e-15	3.78e-12	0.37	0.35	Lobe attachment (rater-scored or self-reported);	chr6:145492004	chr6:145799409~145886585:+
PRAD	cis	rs763567	0.845	rs492804	ENSG00000271811.1	RP1-79C4.4	8.04	7.65e-15	3.78e-12	0.41	0.35	Tonsillectomy;	chr1:170643121	chr1:170667381~170669425:+
PRAD	cis	rs7586673	0.866	rs7579662	ENSG00000227403.1	AC009299.3	-8.04	7.67e-15	3.79e-12	-0.47	-0.35	Intelligence (multi-trait analysis);	chr2:161059299	chr2:161244739~161249050:+
PRAD	cis	rs2412819	0.597	rs2412821	ENSG00000205771.5	CATSPER2P1	-8.04	7.68e-15	3.8e-12	-0.48	-0.35	Lung cancer;	chr15:43864966	chr15:43726918~43747094:-
PRAD	cis	rs6545883	0.524	rs7561697	ENSG00000271889.1	RP11-493E12.1	-8.04	7.68e-15	3.8e-12	-0.38	-0.35	Tuberculosis;	chr2:61292030	chr2:61151433~61162105:-
PRAD	cis	rs2337406	1	rs4774173	ENSG00000274576.2	IGHV2-70	-8.04	7.71e-15	3.81e-12	-0.37	-0.35	Alzheimer's disease (late onset);	chr14:106682029	chr14:106770577~106771020:-
PRAD	cis	rs7923609	0.87	rs10822156	ENSG00000232075.1	MRPL35P2	-8.04	7.72e-15	3.81e-12	-0.37	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63320967	chr10:63634317~63634827:-
PRAD	cis	rs7923609	0.841	rs10740131	ENSG00000232075.1	MRPL35P2	-8.04	7.73e-15	3.82e-12	-0.38	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63511728	chr10:63634317~63634827:-
PRAD	cis	rs7923609	0.846	rs7073753	ENSG00000232075.1	MRPL35P2	-8.04	7.74e-15	3.82e-12	-0.37	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63303060	chr10:63634317~63634827:-
PRAD	cis	rs2243480	1	rs316307	ENSG00000226824.5	RP4-756H11.3	-8.04	7.76e-15	3.83e-12	-0.7	-0.35	Diabetic kidney disease;	chr7:66105184	chr7:66654538~66669855:+
PRAD	cis	rs1075232	1	rs12437749	ENSG00000270055.1	CTD-3092A11.2	-8.04	7.76e-15	3.83e-12	-0.72	-0.35	Survival in colorectal cancer (non-distant metastatic);	chr15:31357685	chr15:30487963~30490313:+
PRAD	cis	rs6921919	0.583	rs9468367	ENSG00000216901.1	AL022393.7	8.04	7.76e-15	3.83e-12	0.45	0.35	Autism spectrum disorder or schizophrenia;	chr6:28392469	chr6:28176188~28176674:+
PRAD	cis	rs10463554	0.526	rs114525197	ENSG00000175749.11	EIF3KP1	8.04	7.78e-15	3.84e-12	0.49	0.35	Parkinson's disease;	chr5:103107341	chr5:103032376~103033031:+
PRAD	cis	rs4631830	0.9	rs10763588	ENSG00000230869.1	CTGLF10P	-8.04	7.78e-15	3.84e-12	-0.44	-0.35	Prostate-specific antigen levels;	chr10:46056060	chr10:45678692~45700532:+
PRAD	cis	rs2243480	1	rs316322	ENSG00000226824.5	RP4-756H11.3	-8.04	7.78e-15	3.84e-12	-0.7	-0.35	Diabetic kidney disease;	chr7:66146246	chr7:66654538~66669855:+
PRAD	cis	rs193541	0.632	rs173481	ENSG00000263432.2	RN7SL689P	8.04	7.78e-15	3.84e-12	0.38	0.35	Glucose homeostasis traits;	chr5:122918857	chr5:123022487~123022783:-
PRAD	cis	rs193541	0.632	rs430069	ENSG00000263432.2	RN7SL689P	8.04	7.78e-15	3.84e-12	0.38	0.35	Glucose homeostasis traits;	chr5:122927656	chr5:123022487~123022783:-
PRAD	cis	rs881375	0.692	rs2072438	ENSG00000226752.6	PSMD5-AS1	-8.04	7.79e-15	3.85e-12	-0.41	-0.35	Rheumatoid arthritis;	chr9:120889023	chr9:120824828~120854385:+
PRAD	cis	rs9309473	0.687	rs11126399	ENSG00000163016.8	ALMS1P	8.04	7.8e-15	3.85e-12	0.43	0.35	Metabolite levels;	chr2:73386213	chr2:73644919~73685576:+
PRAD	cis	rs950169	0.526	rs698620	ENSG00000225151.9	GOLGA2P7	8.04	7.8e-15	3.85e-12	0.44	0.35	Schizophrenia;	chr15:84633977	chr15:84199311~84230136:-
PRAD	cis	rs673078	0.607	rs61943443	ENSG00000275409.1	RP11-131L12.4	-8.04	7.81e-15	3.86e-12	-0.51	-0.35	Glucose homeostasis traits;	chr12:118416602	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.607	rs7305647	ENSG00000275409.1	RP11-131L12.4	-8.04	7.81e-15	3.86e-12	-0.51	-0.35	Glucose homeostasis traits;	chr12:118417761	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.607	rs61943444	ENSG00000275409.1	RP11-131L12.4	-8.04	7.81e-15	3.86e-12	-0.51	-0.35	Glucose homeostasis traits;	chr12:118421641	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.607	rs73207504	ENSG00000275409.1	RP11-131L12.4	-8.04	7.81e-15	3.86e-12	-0.51	-0.35	Glucose homeostasis traits;	chr12:118427914	chr12:118430147~118430699:+
PRAD	cis	rs875971	0.83	rs427973	ENSG00000237310.1	GS1-124K5.4	8.04	7.82e-15	3.86e-12	0.31	0.35	Aortic root size;	chr7:66061661	chr7:66493706~66495474:+
PRAD	cis	rs1729407	0.706	rs595049	ENSG00000254851.1	RP11-109L13.1	-8.04	7.82e-15	3.86e-12	-0.47	-0.35	Apolipoprotein A-IV levels;	chr11:116828729	chr11:117135528~117138582:+
PRAD	cis	rs9309473	0.583	rs6705203	ENSG00000163016.8	ALMS1P	8.04	7.82e-15	3.86e-12	0.43	0.35	Metabolite levels;	chr2:73347472	chr2:73644919~73685576:+
PRAD	cis	rs11951515	0.6	rs60207549	ENSG00000188850.9	RP11-159F24.2	-8.04	7.83e-15	3.87e-12	-0.43	-0.35	Metabolite levels  (X-11787);	chr5:43272846	chr5:43336164~43348716:+
PRAD	cis	rs9595066	0.548	rs9562537	ENSG00000227258.4	SMIM2-AS1	8.04	7.9e-15	3.9e-12	0.64	0.35	Schizophrenia;	chr13:44181651	chr13:44110451~44240517:+
PRAD	cis	rs375066	0.935	rs406968	ENSG00000267058.1	RP11-15A1.3	-8.04	7.91e-15	3.9e-12	-0.29	-0.35	Breast cancer;	chr19:43914191	chr19:43891804~43901805:-
PRAD	cis	rs2581828	0.609	rs73088342	ENSG00000242142.1	SERBP1P3	-8.04	7.95e-15	3.92e-12	-0.42	-0.35	Crohn's disease;	chr3:53117648	chr3:53064283~53065091:-
PRAD	cis	rs4713118	0.505	rs156740	ENSG00000280107.1	AL022393.9	-8.04	7.96e-15	3.93e-12	-0.42	-0.35	Parkinson's disease;	chr6:27992657	chr6:28170845~28172521:+
PRAD	cis	rs11018904	0.906	rs12793836	ENSG00000280385.1	AP000648.5	-8.04	7.98e-15	3.94e-12	-0.5	-0.35	Intelligence (multi-trait analysis);	chr11:90220325	chr11:90193614~90198120:+
PRAD	cis	rs1426063	0.748	rs7654088	ENSG00000260265.1	RP11-44F21.5	-8.04	7.98e-15	3.94e-12	-0.5	-0.35	QT interval;	chr4:75107103	chr4:75081702~75084717:-
PRAD	cis	rs2337406	0.641	rs10133227	ENSG00000274576.2	IGHV2-70	8.04	8.01e-15	3.95e-12	0.37	0.35	Alzheimer's disease (late onset);	chr14:106814260	chr14:106770577~106771020:-
PRAD	cis	rs763567	0.967	rs654461	ENSG00000271811.1	RP1-79C4.4	8.04	8.01e-15	3.95e-12	0.41	0.35	Tonsillectomy;	chr1:170644709	chr1:170667381~170669425:+
PRAD	cis	rs193541	0.593	rs30042	ENSG00000263432.2	RN7SL689P	8.04	8.02e-15	3.96e-12	0.38	0.35	Glucose homeostasis traits;	chr5:122936946	chr5:123022487~123022783:-
PRAD	cis	rs673078	0.607	rs73207564	ENSG00000275409.1	RP11-131L12.4	-8.04	8.03e-15	3.96e-12	-0.5	-0.35	Glucose homeostasis traits;	chr12:118429566	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.607	rs61943447	ENSG00000275409.1	RP11-131L12.4	-8.04	8.03e-15	3.96e-12	-0.5	-0.35	Glucose homeostasis traits;	chr12:118430598	chr12:118430147~118430699:+
PRAD	cis	rs6921919	0.789	rs6912584	ENSG00000216901.1	AL022393.7	8.04	8.04e-15	3.97e-12	0.5	0.35	Autism spectrum disorder or schizophrenia;	chr6:28341813	chr6:28176188~28176674:+
PRAD	cis	rs4266144	0.558	rs4680339	ENSG00000244515.1	KRT18P34	8.04	8.06e-15	3.97e-12	0.4	0.35	Coronary artery disease;	chr3:157117630	chr3:157162663~157163932:-
PRAD	cis	rs673078	0.607	rs7137055	ENSG00000275409.1	RP11-131L12.4	-8.04	8.08e-15	3.98e-12	-0.5	-0.35	Glucose homeostasis traits;	chr12:118395030	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.607	rs7137184	ENSG00000275409.1	RP11-131L12.4	-8.04	8.08e-15	3.98e-12	-0.5	-0.35	Glucose homeostasis traits;	chr12:118395163	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.562	rs4767672	ENSG00000275409.1	RP11-131L12.4	-8.04	8.08e-15	3.98e-12	-0.5	-0.35	Glucose homeostasis traits;	chr12:118397048	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.607	rs73205594	ENSG00000275409.1	RP11-131L12.4	-8.04	8.08e-15	3.98e-12	-0.5	-0.35	Glucose homeostasis traits;	chr12:118397168	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.607	rs61943400	ENSG00000275409.1	RP11-131L12.4	-8.04	8.08e-15	3.98e-12	-0.5	-0.35	Glucose homeostasis traits;	chr12:118398236	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.607	rs61943401	ENSG00000275409.1	RP11-131L12.4	-8.04	8.08e-15	3.98e-12	-0.5	-0.35	Glucose homeostasis traits;	chr12:118398527	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.607	rs61943402	ENSG00000275409.1	RP11-131L12.4	-8.04	8.08e-15	3.98e-12	-0.5	-0.35	Glucose homeostasis traits;	chr12:118398808	chr12:118430147~118430699:+
PRAD	cis	rs367615	0.552	rs2963022	ENSG00000249476.1	CTD-2587M2.1	-8.04	8.08e-15	3.98e-12	-0.44	-0.35	Colorectal cancer (SNP x SNP interaction);	chr5:109391484	chr5:109237120~109326369:-
PRAD	cis	rs5769707	0.656	rs135875	ENSG00000188511.11	C22orf34	8.03	8.12e-15	4e-12	0.4	0.35	Monocyte percentage of white cells;Monocyte count;	chr22:49618771	chr22:49414524~49657542:-
PRAD	cis	rs7746199	0.736	rs34965299	ENSG00000280107.1	AL022393.9	-8.03	8.14e-15	4.01e-12	-0.7	-0.35	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27554077	chr6:28170845~28172521:+
PRAD	cis	rs7746199	0.736	rs34064842	ENSG00000280107.1	AL022393.9	-8.03	8.14e-15	4.01e-12	-0.7	-0.35	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27720846	chr6:28170845~28172521:+
PRAD	cis	rs524281	0.692	rs2452681	ENSG00000255320.1	RP11-755F10.1	-8.03	8.16e-15	4.02e-12	-0.49	-0.35	Electroencephalogram traits;	chr11:66047371	chr11:66244840~66246239:-
PRAD	cis	rs375066	0.935	rs425221	ENSG00000267058.1	RP11-15A1.3	8.03	8.17e-15	4.03e-12	0.29	0.35	Breast cancer;	chr19:43914392	chr19:43891804~43901805:-
PRAD	cis	rs375066	0.935	rs388706	ENSG00000267058.1	RP11-15A1.3	-8.03	8.17e-15	4.03e-12	-0.29	-0.35	Breast cancer;	chr19:43914541	chr19:43891804~43901805:-
PRAD	cis	rs2412819	0.571	rs2930530	ENSG00000205771.5	CATSPER2P1	8.03	8.18e-15	4.03e-12	0.48	0.35	Lung cancer;	chr15:43823268	chr15:43726918~43747094:-
PRAD	cis	rs9532669	0.963	rs9315794	ENSG00000168852.11	TPTE2P5	8.03	8.19e-15	4.04e-12	0.34	0.35	Cervical cancer;	chr13:40939489	chr13:40822296~40921749:-
PRAD	cis	rs9309473	0.528	rs11126396	ENSG00000163016.8	ALMS1P	8.03	8.19e-15	4.04e-12	0.43	0.35	Metabolite levels;	chr2:73338015	chr2:73644919~73685576:+
PRAD	cis	rs6921919	0.583	rs2041230	ENSG00000216901.1	AL022393.7	8.03	8.21e-15	4.05e-12	0.45	0.35	Autism spectrum disorder or schizophrenia;	chr6:28397738	chr6:28176188~28176674:+
PRAD	cis	rs858239	1	rs199348	ENSG00000226816.2	AC005082.12	8.03	8.22e-15	4.05e-12	0.4	0.35	Cerebrospinal fluid biomarker levels;	chr7:23253479	chr7:23206013~23208045:+
PRAD	cis	rs858239	0.932	rs199355	ENSG00000226816.2	AC005082.12	8.03	8.22e-15	4.05e-12	0.4	0.35	Cerebrospinal fluid biomarker levels;	chr7:23256914	chr7:23206013~23208045:+
PRAD	cis	rs2115630	0.691	rs8040066	ENSG00000225151.9	GOLGA2P7	8.03	8.23e-15	4.05e-12	0.44	0.35	P wave terminal force;	chr15:84633234	chr15:84199311~84230136:-
PRAD	cis	rs9287719	0.837	rs4233883	ENSG00000234818.1	AC092687.5	8.03	8.25e-15	4.07e-12	0.43	0.35	Prostate cancer;	chr2:10615470	chr2:10589166~10604830:+
PRAD	cis	rs2274273	0.648	rs58553156	ENSG00000258413.1	RP11-665C16.6	-8.03	8.25e-15	4.07e-12	-0.46	-0.35	Protein biomarker;	chr14:55115976	chr14:55262767~55272075:-
PRAD	cis	rs748404	0.578	rs4547312	ENSG00000249839.1	AC011330.5	-8.03	8.28e-15	4.08e-12	-0.43	-0.35	Lung cancer;	chr15:43339940	chr15:43663654~43684339:-
PRAD	cis	rs1979679	0.879	rs980920	ENSG00000278733.1	RP11-425D17.1	8.03	8.31e-15	4.09e-12	0.47	0.35	Ossification of the posterior longitudinal ligament of the spine;	chr12:28316178	chr12:28185625~28186190:-
PRAD	cis	rs673078	0.607	rs17440942	ENSG00000275409.1	RP11-131L12.4	8.03	8.32e-15	4.1e-12	0.51	0.35	Glucose homeostasis traits;	chr12:118394030	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.607	rs61943388	ENSG00000275409.1	RP11-131L12.4	-8.03	8.32e-15	4.1e-12	-0.51	-0.35	Glucose homeostasis traits;	chr12:118374590	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.607	rs61943389	ENSG00000275409.1	RP11-131L12.4	-8.03	8.32e-15	4.1e-12	-0.51	-0.35	Glucose homeostasis traits;	chr12:118377467	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.607	rs7299040	ENSG00000275409.1	RP11-131L12.4	-8.03	8.32e-15	4.1e-12	-0.51	-0.35	Glucose homeostasis traits;	chr12:118380660	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.607	rs7968011	ENSG00000275409.1	RP11-131L12.4	-8.03	8.32e-15	4.1e-12	-0.51	-0.35	Glucose homeostasis traits;	chr12:118382001	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.607	rs61943399	ENSG00000275409.1	RP11-131L12.4	-8.03	8.32e-15	4.1e-12	-0.51	-0.35	Glucose homeostasis traits;	chr12:118393628	chr12:118430147~118430699:+
PRAD	cis	rs6991838	0.8	rs28547533	ENSG00000200714.1	Y_RNA	8.03	8.32e-15	4.1e-12	0.36	0.35	Intelligence (multi-trait analysis);	chr8:65559318	chr8:65592731~65592820:+
PRAD	cis	rs6991838	0.8	rs28626262	ENSG00000200714.1	Y_RNA	8.03	8.32e-15	4.1e-12	0.36	0.35	Intelligence (multi-trait analysis);	chr8:65559335	chr8:65592731~65592820:+
PRAD	cis	rs6991838	0.8	rs28709439	ENSG00000200714.1	Y_RNA	8.03	8.32e-15	4.1e-12	0.36	0.35	Intelligence (multi-trait analysis);	chr8:65559337	chr8:65592731~65592820:+
PRAD	cis	rs75422866	0.867	rs35044089	ENSG00000280054.1	RP1-197B17.7	8.03	8.33e-15	4.1e-12	0.86	0.35	Pneumonia;	chr12:47610881	chr12:47728151~47730598:-
PRAD	cis	rs75422866	0.867	rs78912815	ENSG00000280054.1	RP1-197B17.7	8.03	8.33e-15	4.1e-12	0.86	0.35	Pneumonia;	chr12:47612065	chr12:47728151~47730598:-
PRAD	cis	rs2404602	0.716	rs4886817	ENSG00000259422.1	RP11-593F23.1	8.03	8.34e-15	4.11e-12	0.44	0.35	Blood metabolite levels;	chr15:76585361	chr15:76174891~76181486:-
PRAD	cis	rs801193	0.548	rs2659904	ENSG00000237310.1	GS1-124K5.4	8.03	8.35e-15	4.11e-12	0.32	0.35	Aortic root size;	chr7:66713615	chr7:66493706~66495474:+
PRAD	cis	rs6921919	0.789	rs6912584	ENSG00000204709.4	LINC01556	8.03	8.35e-15	4.11e-12	0.5	0.35	Autism spectrum disorder or schizophrenia;	chr6:28341813	chr6:28943877~28944537:+
PRAD	cis	rs2581828	0.646	rs6783748	ENSG00000242142.1	SERBP1P3	-8.03	8.37e-15	4.12e-12	-0.42	-0.35	Crohn's disease;	chr3:53119415	chr3:53064283~53065091:-
PRAD	cis	rs2404602	0.692	rs57178708	ENSG00000259422.1	RP11-593F23.1	8.03	8.37e-15	4.12e-12	0.44	0.35	Blood metabolite levels;	chr15:76611728	chr15:76174891~76181486:-
PRAD	cis	rs2617170	0.845	rs1049174	ENSG00000245648.1	RP11-277P12.20	8.03	8.38e-15	4.12e-12	0.42	0.35	Behcet's disease;	chr12:10372766	chr12:10363769~10398506:+
PRAD	cis	rs9532669	0.963	rs4941391	ENSG00000168852.11	TPTE2P5	8.03	8.39e-15	4.13e-12	0.34	0.35	Cervical cancer;	chr13:40939787	chr13:40822296~40921749:-
PRAD	cis	rs763567	0.933	rs588837	ENSG00000271811.1	RP1-79C4.4	8.03	8.4e-15	4.13e-12	0.4	0.35	Tonsillectomy;	chr1:170653968	chr1:170667381~170669425:+
PRAD	cis	rs6545883	0.56	rs11677776	ENSG00000271889.1	RP11-493E12.1	-8.03	8.4e-15	4.13e-12	-0.38	-0.35	Tuberculosis;	chr2:61275978	chr2:61151433~61162105:-
PRAD	cis	rs4723738	0.729	rs10226230	ENSG00000227191.5	TRGC2	-8.03	8.41e-15	4.14e-12	-0.44	-0.35	Treatment response for severe sepsis;	chr7:38229691	chr7:38239580~38368091:-
PRAD	cis	rs673078	0.607	rs17440893	ENSG00000275409.1	RP11-131L12.4	-8.03	8.41e-15	4.14e-12	-0.5	-0.35	Glucose homeostasis traits;	chr12:118362532	chr12:118430147~118430699:+
PRAD	cis	rs150992	0.504	rs11745405	ENSG00000248489.1	CTD-2007H13.3	-8.03	8.42e-15	4.14e-12	-0.43	-0.35	Body mass index;	chr5:99047700	chr5:98929171~98995013:+
PRAD	cis	rs4631830	0.869	rs11006207	ENSG00000230869.1	CTGLF10P	-8.03	8.42e-15	4.14e-12	-0.44	-0.35	Prostate-specific antigen levels;	chr10:46057646	chr10:45678692~45700532:+
PRAD	cis	rs7429990	0.87	rs13089844	ENSG00000229759.1	MRPS18AP1	-8.03	8.42e-15	4.14e-12	-0.36	-0.35	Educational attainment (years of education);	chr3:48098741	chr3:48256350~48256938:-
PRAD	cis	rs7429990	0.932	rs12493348	ENSG00000229759.1	MRPS18AP1	-8.03	8.42e-15	4.14e-12	-0.36	-0.35	Educational attainment (years of education);	chr3:48102048	chr3:48256350~48256938:-
PRAD	cis	rs7429990	0.932	rs12486714	ENSG00000229759.1	MRPS18AP1	-8.03	8.42e-15	4.14e-12	-0.36	-0.35	Educational attainment (years of education);	chr3:48107210	chr3:48256350~48256938:-
PRAD	cis	rs7429990	0.932	rs2361684	ENSG00000229759.1	MRPS18AP1	-8.03	8.42e-15	4.14e-12	-0.36	-0.35	Educational attainment (years of education);	chr3:48111128	chr3:48256350~48256938:-
PRAD	cis	rs367615	0.506	rs246102	ENSG00000249476.1	CTD-2587M2.1	-8.03	8.45e-15	4.16e-12	-0.43	-0.35	Colorectal cancer (SNP x SNP interaction);	chr5:109363994	chr5:109237120~109326369:-
PRAD	cis	rs6479901	0.843	rs9414802	ENSG00000232075.1	MRPL35P2	8.03	8.45e-15	4.16e-12	0.43	0.35	Intelligence (multi-trait analysis);	chr10:63391622	chr10:63634317~63634827:-
PRAD	cis	rs6452524	0.804	rs1478481	ENSG00000249664.1	CTD-2227C6.2	8.03	8.46e-15	4.16e-12	0.44	0.35	Hypertension (SNP x SNP interaction);	chr5:83111286	chr5:83012285~83013109:-
PRAD	cis	rs11096990	0.593	rs6531700	ENSG00000249207.1	RP11-360F5.1	8.03	8.47e-15	4.16e-12	0.37	0.35	Cognitive function;	chr4:39269265	chr4:39112677~39126818:-
PRAD	cis	rs17711722	0.522	rs6957759	ENSG00000224316.1	RP11-479O9.2	8.03	8.47e-15	4.17e-12	0.33	0.35	Calcium levels;	chr7:65806798	chr7:65773620~65802067:+
PRAD	cis	rs11096990	0.634	rs6829064	ENSG00000249207.1	RP11-360F5.1	8.03	8.47e-15	4.17e-12	0.36	0.35	Cognitive function;	chr4:39290192	chr4:39112677~39126818:-
PRAD	cis	rs2412819	0.571	rs678084	ENSG00000205771.5	CATSPER2P1	8.03	8.5e-15	4.18e-12	0.48	0.35	Lung cancer;	chr15:43828361	chr15:43726918~43747094:-
PRAD	cis	rs11096990	0.656	rs2123027	ENSG00000249207.1	RP11-360F5.1	8.03	8.5e-15	4.18e-12	0.36	0.35	Cognitive function;	chr4:39289493	chr4:39112677~39126818:-
PRAD	cis	rs9287719	0.935	rs61424402	ENSG00000234818.1	AC092687.5	8.03	8.51e-15	4.18e-12	0.42	0.35	Prostate cancer;	chr2:10618245	chr2:10589166~10604830:+
PRAD	cis	rs10875746	0.669	rs61940962	ENSG00000240399.1	RP1-228P16.1	-8.03	8.51e-15	4.19e-12	-0.34	-0.35	Longevity (90 years and older);	chr12:48201694	chr12:48054813~48055591:-
PRAD	cis	rs11846409	0.789	rs34917868	ENSG00000274576.2	IGHV2-70	-8.03	8.51e-15	4.19e-12	-0.39	-0.35	Rheumatic heart disease;	chr14:106618321	chr14:106770577~106771020:-
PRAD	cis	rs2980439	0.818	rs2948294	ENSG00000253893.2	FAM85B	-8.03	8.52e-15	4.19e-12	-0.45	-0.35	Neuroticism;	chr8:8237439	chr8:8167819~8226614:-
PRAD	cis	rs6517329	0.649	rs2409758	ENSG00000236830.5	CBR3-AS1	8.03	8.54e-15	4.2e-12	0.38	0.35	Schizophrenia;	chr21:36118357	chr21:36131767~36175815:-
PRAD	cis	rs526231	0.543	rs34779	ENSG00000175749.11	EIF3KP1	8.03	8.57e-15	4.21e-12	0.49	0.35	Primary biliary cholangitis;	chr5:103117064	chr5:103032376~103033031:+
PRAD	cis	rs526231	0.547	rs34780	ENSG00000175749.11	EIF3KP1	8.03	8.57e-15	4.21e-12	0.49	0.35	Primary biliary cholangitis;	chr5:103117853	chr5:103032376~103033031:+
PRAD	cis	rs10463554	0.759	rs34781	ENSG00000175749.11	EIF3KP1	8.03	8.57e-15	4.21e-12	0.49	0.35	Parkinson's disease;	chr5:103118735	chr5:103032376~103033031:+
PRAD	cis	rs11976180	1	rs1919949	ENSG00000170356.8	OR2A20P	-8.03	8.6e-15	4.23e-12	-0.47	-0.35	Obesity-related traits;	chr7:144070630	chr7:144250045~144252957:-
PRAD	cis	rs9640161	0.789	rs3735172	ENSG00000261305.1	RP4-584D14.7	-8.03	8.61e-15	4.23e-12	-0.38	-0.35	Blood protein levels;Circulating chemerin levels;	chr7:150331869	chr7:150341771~150342607:+
PRAD	cis	rs7567389	0.719	rs4662718	ENSG00000236682.1	AC068282.3	8.03	8.63e-15	4.24e-12	0.48	0.35	Self-rated health;	chr2:127257791	chr2:127389130~127400580:+
PRAD	cis	rs6570726	0.935	rs419847	ENSG00000235652.6	RP11-545I5.3	8.03	8.64e-15	4.25e-12	0.37	0.35	Lobe attachment (rater-scored or self-reported);	chr6:145506142	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.935	rs419850	ENSG00000235652.6	RP11-545I5.3	8.03	8.64e-15	4.25e-12	0.37	0.35	Lobe attachment (rater-scored or self-reported);	chr6:145506145	chr6:145799409~145886585:+
PRAD	cis	rs2337406	1	rs7145100	ENSG00000274576.2	IGHV2-70	-8.03	8.66e-15	4.25e-12	-0.38	-0.35	Alzheimer's disease (late onset);	chr14:106704673	chr14:106770577~106771020:-
PRAD	cis	rs7567389	0.719	rs4150499	ENSG00000236682.1	AC068282.3	8.03	8.69e-15	4.27e-12	0.47	0.35	Self-rated health;	chr2:127271216	chr2:127389130~127400580:+
PRAD	cis	rs2522056	1	rs1003533	ENSG00000233006.5	AC034220.3	-8.03	8.69e-15	4.27e-12	-0.34	-0.35	Fibrinogen;Lymphocyte counts;	chr5:132419959	chr5:132311285~132369916:-
PRAD	cis	rs11976180	0.953	rs2951355	ENSG00000170356.8	OR2A20P	-8.03	8.7e-15	4.27e-12	-0.47	-0.35	Obesity-related traits;	chr7:144063469	chr7:144250045~144252957:-
PRAD	cis	rs11976180	1	rs2951354	ENSG00000170356.8	OR2A20P	-8.03	8.7e-15	4.27e-12	-0.47	-0.35	Obesity-related traits;	chr7:144063908	chr7:144250045~144252957:-
PRAD	cis	rs11976180	1	rs2961125	ENSG00000170356.8	OR2A20P	-8.03	8.7e-15	4.27e-12	-0.47	-0.35	Obesity-related traits;	chr7:144064677	chr7:144250045~144252957:-
PRAD	cis	rs11976180	1	rs2961126	ENSG00000170356.8	OR2A20P	-8.03	8.7e-15	4.27e-12	-0.47	-0.35	Obesity-related traits;	chr7:144065643	chr7:144250045~144252957:-
PRAD	cis	rs11976180	0.953	rs2961127	ENSG00000170356.8	OR2A20P	-8.03	8.7e-15	4.27e-12	-0.47	-0.35	Obesity-related traits;	chr7:144065644	chr7:144250045~144252957:-
PRAD	cis	rs11976180	1	rs1919948	ENSG00000170356.8	OR2A20P	-8.03	8.7e-15	4.27e-12	-0.47	-0.35	Obesity-related traits;	chr7:144065750	chr7:144250045~144252957:-
PRAD	cis	rs11976180	1	rs2961128	ENSG00000170356.8	OR2A20P	-8.03	8.7e-15	4.27e-12	-0.47	-0.35	Obesity-related traits;	chr7:144066390	chr7:144250045~144252957:-
PRAD	cis	rs11976180	1	rs2371248	ENSG00000170356.8	OR2A20P	-8.03	8.7e-15	4.27e-12	-0.47	-0.35	Obesity-related traits;	chr7:144067096	chr7:144250045~144252957:-
PRAD	cis	rs11976180	1	rs1533268	ENSG00000170356.8	OR2A20P	-8.03	8.7e-15	4.27e-12	-0.47	-0.35	Obesity-related traits;	chr7:144069265	chr7:144250045~144252957:-
PRAD	cis	rs11976180	1	rs1533267	ENSG00000170356.8	OR2A20P	-8.03	8.7e-15	4.27e-12	-0.47	-0.35	Obesity-related traits;	chr7:144069347	chr7:144250045~144252957:-
PRAD	cis	rs11976180	1	rs1533266	ENSG00000170356.8	OR2A20P	-8.03	8.7e-15	4.27e-12	-0.47	-0.35	Obesity-related traits;	chr7:144069621	chr7:144250045~144252957:-
PRAD	cis	rs6517329	0.649	rs7282480	ENSG00000236830.5	CBR3-AS1	8.03	8.7e-15	4.27e-12	0.38	0.35	Schizophrenia;	chr21:36119262	chr21:36131767~36175815:-
PRAD	cis	rs6142102	0.527	rs1015362	ENSG00000276073.1	RP5-1125A11.7	8.03	8.71e-15	4.28e-12	0.36	0.35	Skin pigmentation;	chr20:34150806	chr20:33985617~33988989:-
PRAD	cis	rs9287719	0.934	rs6727884	ENSG00000234818.1	AC092687.5	-8.03	8.71e-15	4.28e-12	-0.42	-0.35	Prostate cancer;	chr2:10617431	chr2:10589166~10604830:+
PRAD	cis	rs6921919	0.583	rs3734563	ENSG00000216901.1	AL022393.7	8.03	8.71e-15	4.28e-12	0.45	0.35	Autism spectrum disorder or schizophrenia;	chr6:28381948	chr6:28176188~28176674:+
PRAD	cis	rs6921919	0.583	rs1591913	ENSG00000216901.1	AL022393.7	8.03	8.71e-15	4.28e-12	0.45	0.35	Autism spectrum disorder or schizophrenia;	chr6:28383951	chr6:28176188~28176674:+
PRAD	cis	rs4835473	0.591	rs6822129	ENSG00000251600.4	RP11-673E1.1	-8.02	8.73e-15	4.29e-12	-0.47	-0.35	Immature fraction of reticulocytes;	chr4:144058755	chr4:143912331~143982454:+
PRAD	cis	rs673078	0.607	rs11068926	ENSG00000275409.1	RP11-131L12.4	-8.02	8.75e-15	4.3e-12	-0.47	-0.35	Glucose homeostasis traits;	chr12:118367320	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.607	rs4442583	ENSG00000275409.1	RP11-131L12.4	-8.02	8.75e-15	4.3e-12	-0.47	-0.35	Glucose homeostasis traits;	chr12:118367914	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.607	rs61943370	ENSG00000275409.1	RP11-131L12.4	-8.02	8.75e-15	4.3e-12	-0.47	-0.35	Glucose homeostasis traits;	chr12:118369469	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.607	rs61943371	ENSG00000275409.1	RP11-131L12.4	-8.02	8.75e-15	4.3e-12	-0.47	-0.35	Glucose homeostasis traits;	chr12:118369600	chr12:118430147~118430699:+
PRAD	cis	rs2404602	0.692	rs12595586	ENSG00000259422.1	RP11-593F23.1	8.02	8.76e-15	4.3e-12	0.44	0.35	Blood metabolite levels;	chr15:76879869	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.692	rs4360890	ENSG00000259422.1	RP11-593F23.1	8.02	8.76e-15	4.3e-12	0.44	0.35	Blood metabolite levels;	chr15:76880954	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.669	rs12916324	ENSG00000259422.1	RP11-593F23.1	8.02	8.76e-15	4.3e-12	0.44	0.35	Blood metabolite levels;	chr15:76887262	chr15:76174891~76181486:-
PRAD	cis	rs4664293	0.546	rs72956113	ENSG00000226266.5	AC009961.3	8.02	8.77e-15	4.31e-12	0.48	0.35	Monocyte percentage of white cells;	chr2:159631132	chr2:159670708~159712435:-
PRAD	cis	rs7688540	0.723	rs7687112	ENSG00000275426.1	CH17-262A2.1	8.02	8.77e-15	4.31e-12	0.5	0.35	Facial morphology (factor 6, height of vermillion lower lip);	chr4:249767	chr4:149738~150317:+
PRAD	cis	rs853679	0.599	rs149990	ENSG00000280107.1	AL022393.9	-8.02	8.79e-15	4.31e-12	-0.64	-0.35	Depression;	chr6:28030480	chr6:28170845~28172521:+
PRAD	cis	rs1061377	1	rs9997089	ENSG00000249685.1	RP11-360F5.3	8.02	8.79e-15	4.31e-12	0.39	0.35	Uric acid levels;	chr4:39119263	chr4:39133913~39135608:+
PRAD	cis	rs1061377	1	rs28465556	ENSG00000249685.1	RP11-360F5.3	8.02	8.79e-15	4.31e-12	0.39	0.35	Uric acid levels;	chr4:39119569	chr4:39133913~39135608:+
PRAD	cis	rs1061377	1	rs9990755	ENSG00000249685.1	RP11-360F5.3	8.02	8.79e-15	4.31e-12	0.39	0.35	Uric acid levels;	chr4:39119819	chr4:39133913~39135608:+
PRAD	cis	rs1061377	1	rs7676008	ENSG00000249685.1	RP11-360F5.3	8.02	8.79e-15	4.31e-12	0.39	0.35	Uric acid levels;	chr4:39120154	chr4:39133913~39135608:+
PRAD	cis	rs1061377	1	rs7655122	ENSG00000249685.1	RP11-360F5.3	8.02	8.79e-15	4.31e-12	0.39	0.35	Uric acid levels;	chr4:39120396	chr4:39133913~39135608:+
PRAD	cis	rs1061377	0.932	rs35464499	ENSG00000249685.1	RP11-360F5.3	8.02	8.79e-15	4.31e-12	0.39	0.35	Uric acid levels;	chr4:39127670	chr4:39133913~39135608:+
PRAD	cis	rs4722166	0.598	rs4722178	ENSG00000179428.2	AC073072.5	-8.02	8.81e-15	4.32e-12	-0.4	-0.35	Lung cancer;	chr7:22759031	chr7:22725395~22727620:-
PRAD	cis	rs375066	0.901	rs1978723	ENSG00000267058.1	RP11-15A1.3	8.02	8.81e-15	4.32e-12	0.29	0.35	Breast cancer;	chr19:43879648	chr19:43891804~43901805:-
PRAD	cis	rs72627509	0.951	rs72627508	ENSG00000269949.1	RP11-738E22.3	8.02	8.85e-15	4.34e-12	0.51	0.35	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56965398	chr4:56960927~56961373:-
PRAD	cis	rs440932	0.757	rs330943	ENSG00000254340.1	RP11-10A14.3	8.02	8.86e-15	4.34e-12	0.43	0.35	High light scatter reticulocyte percentage of red cells;	chr8:9163516	chr8:9141424~9145435:+
PRAD	cis	rs1563304	1	rs1563304	ENSG00000214401.4	KANSL1-AS1	8.02	8.86e-15	4.35e-12	0.63	0.35	Neuroticism;	chr17:46797087	chr17:46193576~46196723:+
PRAD	cis	rs2581828	0.646	rs9757079	ENSG00000242142.1	SERBP1P3	-8.02	8.86e-15	4.35e-12	-0.41	-0.35	Crohn's disease;	chr3:53121142	chr3:53064283~53065091:-
PRAD	cis	rs2337406	0.925	rs11851094	ENSG00000274576.2	IGHV2-70	-8.02	8.89e-15	4.36e-12	-0.37	-0.35	Alzheimer's disease (late onset);	chr14:106688967	chr14:106770577~106771020:-
PRAD	cis	rs11083475	1	rs16972767	ENSG00000267892.1	CTD-2540F13.2	8.02	8.91e-15	4.37e-12	0.38	0.35	Heart rate;	chr19:38662404	chr19:38738284~38739863:+
PRAD	cis	rs62355901	0.599	rs62355875	ENSG00000271828.1	CTD-2310F14.1	8.02	8.92e-15	4.37e-12	0.77	0.35	Breast cancer;	chr5:56729353	chr5:56927874~56929573:+
PRAD	cis	rs62355901	0.599	rs62355876	ENSG00000271828.1	CTD-2310F14.1	8.02	8.92e-15	4.37e-12	0.77	0.35	Breast cancer;	chr5:56729373	chr5:56927874~56929573:+
PRAD	cis	rs11083475	0.967	rs7254100	ENSG00000267892.1	CTD-2540F13.2	8.02	8.95e-15	4.39e-12	0.38	0.35	Heart rate;	chr19:38682846	chr19:38738284~38739863:+
PRAD	cis	rs4713118	0.699	rs200969	ENSG00000219392.1	RP1-265C24.5	-8.02	8.96e-15	4.39e-12	-0.47	-0.35	Parkinson's disease;	chr6:27891675	chr6:28115628~28116551:+
PRAD	cis	rs2337406	1	rs17113257	ENSG00000274576.2	IGHV2-70	-8.02	8.97e-15	4.4e-12	-0.37	-0.35	Alzheimer's disease (late onset);	chr14:106679574	chr14:106770577~106771020:-
PRAD	cis	rs2581828	0.632	rs73088322	ENSG00000242142.1	SERBP1P3	-8.02	8.98e-15	4.4e-12	-0.42	-0.35	Crohn's disease;	chr3:53107500	chr3:53064283~53065091:-
PRAD	cis	rs2581828	0.659	rs73088327	ENSG00000242142.1	SERBP1P3	-8.02	8.98e-15	4.4e-12	-0.42	-0.35	Crohn's disease;	chr3:53107533	chr3:53064283~53065091:-
PRAD	cis	rs10463554	0.963	rs26817	ENSG00000175749.11	EIF3KP1	-8.02	9e-15	4.41e-12	-0.45	-0.35	Parkinson's disease;	chr5:103204665	chr5:103032376~103033031:+
PRAD	cis	rs6545883	0.56	rs11677775	ENSG00000271889.1	RP11-493E12.1	-8.02	9.01e-15	4.42e-12	-0.38	-0.35	Tuberculosis;	chr2:61275975	chr2:61151433~61162105:-
PRAD	cis	rs10463554	0.963	rs34829	ENSG00000175749.11	EIF3KP1	8.02	9.03e-15	4.42e-12	0.45	0.35	Parkinson's disease;	chr5:103108260	chr5:103032376~103033031:+
PRAD	cis	rs2337406	1	rs1858677	ENSG00000274576.2	IGHV2-70	-8.02	9.03e-15	4.43e-12	-0.38	-0.35	Alzheimer's disease (late onset);	chr14:106706828	chr14:106770577~106771020:-
PRAD	cis	rs1061377	1	rs2890659	ENSG00000249685.1	RP11-360F5.3	8.02	9.03e-15	4.43e-12	0.39	0.35	Uric acid levels;	chr4:39125401	chr4:39133913~39135608:+
PRAD	cis	rs4664293	0.801	rs7589771	ENSG00000226266.5	AC009961.3	-8.02	9.04e-15	4.43e-12	-0.47	-0.35	Monocyte percentage of white cells;	chr2:159727621	chr2:159670708~159712435:-
PRAD	cis	rs2243480	0.711	rs2460426	ENSG00000226824.5	RP4-756H11.3	8.02	9.06e-15	4.44e-12	0.7	0.35	Diabetic kidney disease;	chr7:66158142	chr7:66654538~66669855:+
PRAD	cis	rs9532669	0.963	rs4343141	ENSG00000168852.11	TPTE2P5	8.02	9.08e-15	4.45e-12	0.34	0.35	Cervical cancer;	chr13:40940497	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.963	rs3887418	ENSG00000168852.11	TPTE2P5	8.02	9.08e-15	4.45e-12	0.34	0.35	Cervical cancer;	chr13:40940560	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.926	rs1056820	ENSG00000168852.11	TPTE2P5	8.02	9.08e-15	4.45e-12	0.34	0.35	Cervical cancer;	chr13:40941150	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.926	rs9532678	ENSG00000168852.11	TPTE2P5	8.02	9.08e-15	4.45e-12	0.34	0.35	Cervical cancer;	chr13:40941862	chr13:40822296~40921749:-
PRAD	cis	rs7238033	0.647	rs8095657	ENSG00000267193.4	RP11-116O18.3	8.02	9.09e-15	4.46e-12	0.38	0.35	Bladder cancer;	chr18:45734580	chr18:45669367~45747215:-
PRAD	cis	rs2337406	1	rs17112416	ENSG00000274576.2	IGHV2-70	8.02	9.1e-15	4.46e-12	0.39	0.35	Alzheimer's disease (late onset);	chr14:106686773	chr14:106770577~106771020:-
PRAD	cis	rs3096299	0.9	rs4785663	ENSG00000274627.1	RP11-104N10.2	8.02	9.13e-15	4.47e-12	0.36	0.35	Multiple myeloma (IgH translocation);	chr16:89368480	chr16:89516797~89522217:+
PRAD	cis	rs1979679	0.918	rs11049529	ENSG00000278733.1	RP11-425D17.1	8.02	9.18e-15	4.49e-12	0.46	0.35	Ossification of the posterior longitudinal ligament of the spine;	chr12:28318571	chr12:28185625~28186190:-
PRAD	cis	rs8091660	0.929	rs3744827	ENSG00000278983.1	RP11-426J5.3	-8.02	9.18e-15	4.5e-12	-0.44	-0.35	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48569572	chr18:48564795~48568342:+
PRAD	cis	rs7916697	0.593	rs7912895	ENSG00000233590.1	RP11-153K11.3	-8.02	9.2e-15	4.5e-12	-0.46	-0.35	Optic disc area;	chr10:68261741	chr10:68233251~68242379:-
PRAD	cis	rs1930961	0.702	rs6004684	ENSG00000272942.1	CTA-246H3.12	8.02	9.21e-15	4.51e-12	0.75	0.35	Bipolar disorder with mood-incongruent psychosis;	chr22:25503972	chr22:25434324~25435070:-
PRAD	cis	rs2581828	0.646	rs9878875	ENSG00000242142.1	SERBP1P3	-8.02	9.21e-15	4.51e-12	-0.41	-0.35	Crohn's disease;	chr3:53122851	chr3:53064283~53065091:-
PRAD	cis	rs2581828	0.646	rs12630819	ENSG00000242142.1	SERBP1P3	-8.02	9.21e-15	4.51e-12	-0.41	-0.35	Crohn's disease;	chr3:53123286	chr3:53064283~53065091:-
PRAD	cis	rs2581828	0.646	rs12638996	ENSG00000242142.1	SERBP1P3	-8.02	9.21e-15	4.51e-12	-0.41	-0.35	Crohn's disease;	chr3:53123530	chr3:53064283~53065091:-
PRAD	cis	rs2581828	0.646	rs9861233	ENSG00000242142.1	SERBP1P3	-8.02	9.21e-15	4.51e-12	-0.41	-0.35	Crohn's disease;	chr3:53124815	chr3:53064283~53065091:-
PRAD	cis	rs2581828	0.646	rs6769931	ENSG00000242142.1	SERBP1P3	-8.02	9.21e-15	4.51e-12	-0.41	-0.35	Crohn's disease;	chr3:53126177	chr3:53064283~53065091:-
PRAD	cis	rs2581828	0.646	rs6809973	ENSG00000242142.1	SERBP1P3	-8.02	9.21e-15	4.51e-12	-0.41	-0.35	Crohn's disease;	chr3:53126200	chr3:53064283~53065091:-
PRAD	cis	rs2581828	0.608	rs6769944	ENSG00000242142.1	SERBP1P3	-8.02	9.21e-15	4.51e-12	-0.41	-0.35	Crohn's disease;	chr3:53126227	chr3:53064283~53065091:-
PRAD	cis	rs2581828	0.646	rs9858469	ENSG00000242142.1	SERBP1P3	-8.02	9.21e-15	4.51e-12	-0.41	-0.35	Crohn's disease;	chr3:53128390	chr3:53064283~53065091:-
PRAD	cis	rs2581828	0.646	rs9820324	ENSG00000242142.1	SERBP1P3	-8.02	9.21e-15	4.51e-12	-0.41	-0.35	Crohn's disease;	chr3:53128429	chr3:53064283~53065091:-
PRAD	cis	rs11098499	0.908	rs1002152	ENSG00000245958.5	RP11-33B1.1	-8.02	9.22e-15	4.52e-12	-0.35	-0.35	Corneal astigmatism;	chr4:119352232	chr4:119454791~119552025:+
PRAD	cis	rs748404	0.631	rs8042688	ENSG00000249839.1	AC011330.5	-8.02	9.22e-15	4.52e-12	-0.43	-0.35	Lung cancer;	chr15:43346327	chr15:43663654~43684339:-
PRAD	cis	rs748404	0.631	rs4296223	ENSG00000249839.1	AC011330.5	-8.02	9.22e-15	4.52e-12	-0.43	-0.35	Lung cancer;	chr15:43353048	chr15:43663654~43684339:-
PRAD	cis	rs748404	0.631	rs6493084	ENSG00000249839.1	AC011330.5	-8.02	9.22e-15	4.52e-12	-0.43	-0.35	Lung cancer;	chr15:43355429	chr15:43663654~43684339:-
PRAD	cis	rs748404	0.631	rs12905772	ENSG00000249839.1	AC011330.5	-8.02	9.22e-15	4.52e-12	-0.43	-0.35	Lung cancer;	chr15:43356246	chr15:43663654~43684339:-
PRAD	cis	rs2274273	0.624	rs67412516	ENSG00000258413.1	RP11-665C16.6	-8.02	9.23e-15	4.52e-12	-0.47	-0.35	Protein biomarker;	chr14:55386519	chr14:55262767~55272075:-
PRAD	cis	rs12928939	0.815	rs10500560	ENSG00000260886.1	TAT-AS1	8.02	9.25e-15	4.53e-12	0.49	0.35	Post bronchodilator FEV1;	chr16:71647250	chr16:71565789~71578187:+
PRAD	cis	rs11976180	1	rs1919950	ENSG00000170356.8	OR2A20P	-8.02	9.26e-15	4.53e-12	-0.47	-0.35	Obesity-related traits;	chr7:144070805	chr7:144250045~144252957:-
PRAD	cis	rs6921919	0.583	rs9461459	ENSG00000216901.1	AL022393.7	8.02	9.26e-15	4.53e-12	0.45	0.35	Autism spectrum disorder or schizophrenia;	chr6:28394139	chr6:28176188~28176674:+
PRAD	cis	rs6921919	0.583	rs28360638	ENSG00000216901.1	AL022393.7	8.02	9.26e-15	4.53e-12	0.45	0.35	Autism spectrum disorder or schizophrenia;	chr6:28394552	chr6:28176188~28176674:+
PRAD	cis	rs6921919	0.583	rs9468368	ENSG00000216901.1	AL022393.7	8.02	9.26e-15	4.53e-12	0.45	0.35	Autism spectrum disorder or schizophrenia;	chr6:28397172	chr6:28176188~28176674:+
PRAD	cis	rs6921919	0.609	rs1005127	ENSG00000216901.1	AL022393.7	8.02	9.26e-15	4.53e-12	0.45	0.35	Autism spectrum disorder or schizophrenia;	chr6:28399881	chr6:28176188~28176674:+
PRAD	cis	rs853679	0.515	rs4580862	ENSG00000216901.1	AL022393.7	8.02	9.26e-15	4.53e-12	0.45	0.35	Depression;	chr6:28399886	chr6:28176188~28176674:+
PRAD	cis	rs6921919	0.583	rs4357130	ENSG00000216901.1	AL022393.7	8.02	9.26e-15	4.53e-12	0.45	0.35	Autism spectrum disorder or schizophrenia;	chr6:28399906	chr6:28176188~28176674:+
PRAD	cis	rs6921919	0.583	rs11755942	ENSG00000216901.1	AL022393.7	8.02	9.26e-15	4.53e-12	0.45	0.35	Autism spectrum disorder or schizophrenia;	chr6:28401760	chr6:28176188~28176674:+
PRAD	cis	rs321358	1	rs321358	ENSG00000271584.1	RP11-89C3.4	8.02	9.27e-15	4.54e-12	0.53	0.35	Body mass index;	chr11:111125247	chr11:111091932~111097357:-
PRAD	cis	rs321358	1	rs321353	ENSG00000271584.1	RP11-89C3.4	-8.02	9.27e-15	4.54e-12	-0.53	-0.35	Body mass index;	chr11:111123841	chr11:111091932~111097357:-
PRAD	cis	rs950169	0.579	rs881983	ENSG00000225151.9	GOLGA2P7	-8.02	9.29e-15	4.55e-12	-0.52	-0.35	Schizophrenia;	chr15:83978556	chr15:84199311~84230136:-
PRAD	cis	rs4664293	0.967	rs12999124	ENSG00000226266.5	AC009961.3	-8.02	9.29e-15	4.55e-12	-0.46	-0.35	Monocyte percentage of white cells;	chr2:159674817	chr2:159670708~159712435:-
PRAD	cis	rs75422866	0.717	rs73113159	ENSG00000280054.1	RP1-197B17.7	8.02	9.29e-15	4.55e-12	0.86	0.35	Pneumonia;	chr12:47631318	chr12:47728151~47730598:-
PRAD	cis	rs75422866	0.717	rs73113161	ENSG00000280054.1	RP1-197B17.7	8.02	9.29e-15	4.55e-12	0.86	0.35	Pneumonia;	chr12:47632361	chr12:47728151~47730598:-
PRAD	cis	rs75422866	0.867	rs117022227	ENSG00000280054.1	RP1-197B17.7	8.02	9.29e-15	4.55e-12	0.86	0.35	Pneumonia;	chr12:47633282	chr12:47728151~47730598:-
PRAD	cis	rs75422866	1	rs73102120	ENSG00000280054.1	RP1-197B17.7	8.02	9.29e-15	4.55e-12	0.86	0.35	Pneumonia;	chr12:47637280	chr12:47728151~47730598:-
PRAD	cis	rs75422866	0.867	rs12422974	ENSG00000280054.1	RP1-197B17.7	8.02	9.29e-15	4.55e-12	0.86	0.35	Pneumonia;	chr12:47644559	chr12:47728151~47730598:-
PRAD	cis	rs75422866	0.867	rs73102127	ENSG00000280054.1	RP1-197B17.7	8.02	9.29e-15	4.55e-12	0.86	0.35	Pneumonia;	chr12:47645341	chr12:47728151~47730598:-
PRAD	cis	rs75422866	0.867	rs73102140	ENSG00000280054.1	RP1-197B17.7	8.02	9.29e-15	4.55e-12	0.86	0.35	Pneumonia;	chr12:47647497	chr12:47728151~47730598:-
PRAD	cis	rs75422866	0.867	rs73102148	ENSG00000280054.1	RP1-197B17.7	8.02	9.29e-15	4.55e-12	0.86	0.35	Pneumonia;	chr12:47648013	chr12:47728151~47730598:-
PRAD	cis	rs75422866	0.867	rs73102151	ENSG00000280054.1	RP1-197B17.7	8.02	9.29e-15	4.55e-12	0.86	0.35	Pneumonia;	chr12:47648023	chr12:47728151~47730598:-
PRAD	cis	rs75422866	0.867	rs73102166	ENSG00000280054.1	RP1-197B17.7	8.02	9.29e-15	4.55e-12	0.86	0.35	Pneumonia;	chr12:47653769	chr12:47728151~47730598:-
PRAD	cis	rs75422866	0.867	rs73102168	ENSG00000280054.1	RP1-197B17.7	8.02	9.29e-15	4.55e-12	0.86	0.35	Pneumonia;	chr12:47654010	chr12:47728151~47730598:-
PRAD	cis	rs75422866	0.867	rs73102171	ENSG00000280054.1	RP1-197B17.7	8.02	9.29e-15	4.55e-12	0.86	0.35	Pneumonia;	chr12:47656077	chr12:47728151~47730598:-
PRAD	cis	rs75422866	0.867	rs76100981	ENSG00000280054.1	RP1-197B17.7	8.02	9.29e-15	4.55e-12	0.86	0.35	Pneumonia;	chr12:47660092	chr12:47728151~47730598:-
PRAD	cis	rs75422866	0.867	rs73102188	ENSG00000280054.1	RP1-197B17.7	8.02	9.29e-15	4.55e-12	0.86	0.35	Pneumonia;	chr12:47662993	chr12:47728151~47730598:-
PRAD	cis	rs75422866	0.867	rs73102195	ENSG00000280054.1	RP1-197B17.7	8.02	9.29e-15	4.55e-12	0.86	0.35	Pneumonia;	chr12:47666309	chr12:47728151~47730598:-
PRAD	cis	rs75422866	0.867	rs73102201	ENSG00000280054.1	RP1-197B17.7	8.02	9.29e-15	4.55e-12	0.86	0.35	Pneumonia;	chr12:47669269	chr12:47728151~47730598:-
PRAD	cis	rs75422866	0.867	rs73104103	ENSG00000280054.1	RP1-197B17.7	8.02	9.29e-15	4.55e-12	0.86	0.35	Pneumonia;	chr12:47669604	chr12:47728151~47730598:-
PRAD	cis	rs75422866	0.867	rs73104104	ENSG00000280054.1	RP1-197B17.7	8.02	9.29e-15	4.55e-12	0.86	0.35	Pneumonia;	chr12:47671986	chr12:47728151~47730598:-
PRAD	cis	rs75422866	0.867	rs73104111	ENSG00000280054.1	RP1-197B17.7	8.02	9.29e-15	4.55e-12	0.86	0.35	Pneumonia;	chr12:47673994	chr12:47728151~47730598:-
PRAD	cis	rs75422866	0.867	rs73104115	ENSG00000280054.1	RP1-197B17.7	8.02	9.29e-15	4.55e-12	0.86	0.35	Pneumonia;	chr12:47684843	chr12:47728151~47730598:-
PRAD	cis	rs75422866	0.867	rs73104116	ENSG00000280054.1	RP1-197B17.7	8.02	9.29e-15	4.55e-12	0.86	0.35	Pneumonia;	chr12:47685023	chr12:47728151~47730598:-
PRAD	cis	rs75422866	0.867	rs73104138	ENSG00000280054.1	RP1-197B17.7	8.02	9.29e-15	4.55e-12	0.86	0.35	Pneumonia;	chr12:47692302	chr12:47728151~47730598:-
PRAD	cis	rs75422866	0.717	rs73104143	ENSG00000280054.1	RP1-197B17.7	8.02	9.29e-15	4.55e-12	0.86	0.35	Pneumonia;	chr12:47693449	chr12:47728151~47730598:-
PRAD	cis	rs75422866	0.867	rs73104144	ENSG00000280054.1	RP1-197B17.7	8.02	9.29e-15	4.55e-12	0.86	0.35	Pneumonia;	chr12:47694390	chr12:47728151~47730598:-
PRAD	cis	rs75422866	0.867	rs73104148	ENSG00000280054.1	RP1-197B17.7	8.02	9.29e-15	4.55e-12	0.86	0.35	Pneumonia;	chr12:47696732	chr12:47728151~47730598:-
PRAD	cis	rs75422866	0.867	rs73104152	ENSG00000280054.1	RP1-197B17.7	8.02	9.29e-15	4.55e-12	0.86	0.35	Pneumonia;	chr12:47699091	chr12:47728151~47730598:-
PRAD	cis	rs75422866	0.867	rs73104155	ENSG00000280054.1	RP1-197B17.7	8.02	9.29e-15	4.55e-12	0.86	0.35	Pneumonia;	chr12:47700790	chr12:47728151~47730598:-
PRAD	cis	rs526231	0.543	rs34807	ENSG00000175749.11	EIF3KP1	8.02	9.3e-15	4.55e-12	0.49	0.35	Primary biliary cholangitis;	chr5:103092818	chr5:103032376~103033031:+
PRAD	cis	rs4842666	0.915	rs117742247	ENSG00000258302.2	RP11-981P6.1	8.02	9.3e-15	4.55e-12	0.45	0.35	Blood pressure;	chr12:89597536	chr12:89561129~89594878:+
PRAD	cis	rs10463554	0.759	rs34815	ENSG00000175749.11	EIF3KP1	8.02	9.31e-15	4.55e-12	0.49	0.35	Parkinson's disease;	chr5:103098561	chr5:103032376~103033031:+
PRAD	cis	rs193541	0.632	rs154504	ENSG00000263432.2	RN7SL689P	8.02	9.32e-15	4.56e-12	0.38	0.35	Glucose homeostasis traits;	chr5:122868391	chr5:123022487~123022783:-
PRAD	cis	rs2412819	0.597	rs514311	ENSG00000205771.5	CATSPER2P1	-8.02	9.32e-15	4.56e-12	-0.48	-0.35	Lung cancer;	chr15:43869376	chr15:43726918~43747094:-
PRAD	cis	rs2412819	0.571	rs2729494	ENSG00000205771.5	CATSPER2P1	8.02	9.32e-15	4.56e-12	0.48	0.35	Lung cancer;	chr15:43837395	chr15:43726918~43747094:-
PRAD	cis	rs2412819	0.571	rs528764	ENSG00000205771.5	CATSPER2P1	8.02	9.32e-15	4.56e-12	0.48	0.35	Lung cancer;	chr15:43838650	chr15:43726918~43747094:-
PRAD	cis	rs2412819	0.571	rs495880	ENSG00000205771.5	CATSPER2P1	8.02	9.32e-15	4.56e-12	0.48	0.35	Lung cancer;	chr15:43855067	chr15:43726918~43747094:-
PRAD	cis	rs7688540	0.713	rs12511388	ENSG00000275426.1	CH17-262A2.1	8.02	9.33e-15	4.56e-12	0.5	0.35	Facial morphology (factor 6, height of vermillion lower lip);	chr4:303758	chr4:149738~150317:+
PRAD	cis	rs11096990	0.634	rs7659894	ENSG00000249207.1	RP11-360F5.1	8.02	9.36e-15	4.58e-12	0.37	0.35	Cognitive function;	chr4:39282815	chr4:39112677~39126818:-
PRAD	cis	rs6921919	0.609	rs67211468	ENSG00000216901.1	AL022393.7	8.01	9.39e-15	4.59e-12	0.45	0.35	Autism spectrum disorder or schizophrenia;	chr6:28424210	chr6:28176188~28176674:+
PRAD	cis	rs2581828	0.646	rs13433700	ENSG00000242142.1	SERBP1P3	-8.01	9.41e-15	4.6e-12	-0.41	-0.35	Crohn's disease;	chr3:53113870	chr3:53064283~53065091:-
PRAD	cis	rs853679	0.599	rs149943	ENSG00000280107.1	AL022393.9	-8.01	9.42e-15	4.61e-12	-0.63	-0.35	Depression;	chr6:28034610	chr6:28170845~28172521:+
PRAD	cis	rs2243480	1	rs316332	ENSG00000226824.5	RP4-756H11.3	-8.01	9.43e-15	4.61e-12	-0.69	-0.35	Diabetic kidney disease;	chr7:66139312	chr7:66654538~66669855:+
PRAD	cis	rs2255336	0.938	rs12578507	ENSG00000245648.1	RP11-277P12.20	-8.01	9.47e-15	4.63e-12	-0.53	-0.35	Blood protein levels;	chr12:10470396	chr12:10363769~10398506:+
PRAD	cis	rs2404602	0.692	rs12594556	ENSG00000259422.1	RP11-593F23.1	8.01	9.47e-15	4.63e-12	0.44	0.35	Blood metabolite levels;	chr15:76873022	chr15:76174891~76181486:-
PRAD	cis	rs11976180	1	rs13243677	ENSG00000170356.8	OR2A20P	-8.01	9.49e-15	4.64e-12	-0.47	-0.35	Obesity-related traits;	chr7:144049479	chr7:144250045~144252957:-
PRAD	cis	rs2522056	1	rs10900807	ENSG00000233006.5	AC034220.3	-8.01	9.52e-15	4.65e-12	-0.36	-0.35	Fibrinogen;Lymphocyte counts;	chr5:132421788	chr5:132311285~132369916:-
PRAD	cis	rs6546847	0.531	rs2567601	ENSG00000163016.8	ALMS1P	8.01	9.53e-15	4.66e-12	0.51	0.35	Urinary metabolites (H-NMR features);	chr2:73758040	chr2:73644919~73685576:+
PRAD	cis	rs6546847	0.531	rs2567603	ENSG00000163016.8	ALMS1P	8.01	9.53e-15	4.66e-12	0.51	0.35	Urinary metabolites (H-NMR features);	chr2:73758998	chr2:73644919~73685576:+
PRAD	cis	rs1061377	1	rs35116118	ENSG00000249685.1	RP11-360F5.3	8.01	9.53e-15	4.66e-12	0.39	0.35	Uric acid levels;	chr4:39127293	chr4:39133913~39135608:+
PRAD	cis	rs12142240	0.698	rs12385696	ENSG00000232022.5	FAAHP1	-8.01	9.55e-15	4.66e-12	-0.33	-0.35	Menopause (age at onset);	chr1:46353164	chr1:46432129~46445521:+
PRAD	cis	rs1075232	1	rs72722829	ENSG00000270055.1	CTD-3092A11.2	-8.01	9.55e-15	4.66e-12	-0.72	-0.35	Survival in colorectal cancer (non-distant metastatic);	chr15:31346911	chr15:30487963~30490313:+
PRAD	cis	rs1075232	1	rs16956707	ENSG00000270055.1	CTD-3092A11.2	-8.01	9.55e-15	4.66e-12	-0.72	-0.35	Survival in colorectal cancer (non-distant metastatic);	chr15:31349430	chr15:30487963~30490313:+
PRAD	cis	rs193541	0.632	rs2910135	ENSG00000263432.2	RN7SL689P	8.01	9.57e-15	4.67e-12	0.37	0.35	Glucose homeostasis traits;	chr5:122894095	chr5:123022487~123022783:-
PRAD	cis	rs763567	0.933	rs567328	ENSG00000271811.1	RP1-79C4.4	8.01	9.57e-15	4.68e-12	0.4	0.35	Tonsillectomy;	chr1:170644728	chr1:170667381~170669425:+
PRAD	cis	rs1979679	0.918	rs786711	ENSG00000278733.1	RP11-425D17.1	8.01	9.58e-15	4.68e-12	0.45	0.35	Ossification of the posterior longitudinal ligament of the spine;	chr12:28406330	chr12:28185625~28186190:-
PRAD	cis	rs10463554	1	rs10463554	ENSG00000175749.11	EIF3KP1	8.01	9.58e-15	4.68e-12	0.44	0.35	Parkinson's disease;	chr5:102983270	chr5:103032376~103033031:+
PRAD	cis	rs75422866	0.867	rs73113139	ENSG00000280054.1	RP1-197B17.7	8.01	9.6e-15	4.69e-12	0.86	0.35	Pneumonia;	chr12:47622826	chr12:47728151~47730598:-
PRAD	cis	rs9326248	0.581	rs10892063	ENSG00000280143.1	AP000892.6	8.01	9.62e-15	4.7e-12	0.27	0.35	Blood protein levels;	chr11:117025439	chr11:117204967~117210292:+
PRAD	cis	rs2286503	0.839	rs2240726	ENSG00000228649.7	AC005682.5	8.01	9.63e-15	4.7e-12	0.4	0.35	Fibrinogen;	chr7:22813516	chr7:22854178~22861579:+
PRAD	cis	rs3096299	0.933	rs2965938	ENSG00000261118.1	RP11-104N10.1	8.01	9.63e-15	4.7e-12	0.35	0.35	Multiple myeloma (IgH translocation);	chr16:89424928	chr16:89492017~89504460:-
PRAD	cis	rs4835473	0.838	rs10024263	ENSG00000251600.4	RP11-673E1.1	8.01	9.64e-15	4.71e-12	0.46	0.35	Immature fraction of reticulocytes;	chr4:144038174	chr4:143912331~143982454:+
PRAD	cis	rs7923609	0.967	rs10761751	ENSG00000232075.1	MRPL35P2	-8.01	9.65e-15	4.71e-12	-0.37	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63395125	chr10:63634317~63634827:-
PRAD	cis	rs75422866	0.867	rs35044089	ENSG00000274902.1	RP1-197B17.4	8.01	9.69e-15	4.73e-12	0.91	0.35	Pneumonia;	chr12:47610881	chr12:47731908~47732351:+
PRAD	cis	rs75422866	0.867	rs78912815	ENSG00000274902.1	RP1-197B17.4	8.01	9.69e-15	4.73e-12	0.91	0.35	Pneumonia;	chr12:47612065	chr12:47731908~47732351:+
PRAD	cis	rs1061377	1	rs10027813	ENSG00000249685.1	RP11-360F5.3	8.01	9.71e-15	4.74e-12	0.39	0.35	Uric acid levels;	chr4:39119818	chr4:39133913~39135608:+
PRAD	cis	rs2404602	0.692	rs7169663	ENSG00000259422.1	RP11-593F23.1	8.01	9.72e-15	4.74e-12	0.44	0.35	Blood metabolite levels;	chr15:76900502	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.692	rs35999717	ENSG00000259422.1	RP11-593F23.1	8.01	9.72e-15	4.74e-12	0.44	0.35	Blood metabolite levels;	chr15:76901026	chr15:76174891~76181486:-
PRAD	cis	rs3096299	0.935	rs3114890	ENSG00000274627.1	RP11-104N10.2	8.01	9.73e-15	4.75e-12	0.36	0.35	Multiple myeloma (IgH translocation);	chr16:89383138	chr16:89516797~89522217:+
PRAD	cis	rs2274273	0.624	rs3783651	ENSG00000258413.1	RP11-665C16.6	-8.01	9.74e-15	4.75e-12	-0.47	-0.35	Protein biomarker;	chr14:55384255	chr14:55262767~55272075:-
PRAD	cis	rs2638953	0.886	rs10492369	ENSG00000278733.1	RP11-425D17.1	8.01	9.78e-15	4.77e-12	0.44	0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28172185	chr12:28185625~28186190:-
PRAD	cis	rs375066	0.935	rs371875	ENSG00000267058.1	RP11-15A1.3	-8.01	9.81e-15	4.79e-12	-0.3	-0.35	Breast cancer;	chr19:43889105	chr19:43891804~43901805:-
PRAD	cis	rs11098499	0.863	rs7699064	ENSG00000245958.5	RP11-33B1.1	8.01	9.81e-15	4.79e-12	0.35	0.35	Corneal astigmatism;	chr4:119507154	chr4:119454791~119552025:+
PRAD	cis	rs1015362	0.869	rs6088411	ENSG00000276073.1	RP5-1125A11.7	8.01	9.84e-15	4.8e-12	0.36	0.35	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:34152101	chr20:33985617~33988989:-
PRAD	cis	rs1075265	0.901	rs1118618	ENSG00000233266.1	HMGB1P31	8.01	9.85e-15	4.8e-12	0.48	0.35	Chronotype;Morning vs. evening chronotype;	chr2:54099333	chr2:54051334~54051760:+
PRAD	cis	rs2274273	0.837	rs8011329	ENSG00000258413.1	RP11-665C16.6	-8.01	9.85e-15	4.81e-12	-0.45	-0.35	Protein biomarker;	chr14:55210537	chr14:55262767~55272075:-
PRAD	cis	rs2337406	1	rs61268362	ENSG00000274576.2	IGHV2-70	-8.01	9.85e-15	4.81e-12	-0.41	-0.35	Alzheimer's disease (late onset);	chr14:106697010	chr14:106770577~106771020:-
PRAD	cis	rs2337406	0.85	rs8014460	ENSG00000274576.2	IGHV2-70	-8.01	9.85e-15	4.81e-12	-0.41	-0.35	Alzheimer's disease (late onset);	chr14:106697140	chr14:106770577~106771020:-
PRAD	cis	rs7923609	0.905	rs7092784	ENSG00000232075.1	MRPL35P2	-8.01	9.87e-15	4.81e-12	-0.37	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63454989	chr10:63634317~63634827:-
PRAD	cis	rs7429990	0.896	rs7427648	ENSG00000229759.1	MRPS18AP1	-8.01	9.87e-15	4.82e-12	-0.36	-0.35	Educational attainment (years of education);	chr3:48116749	chr3:48256350~48256938:-
PRAD	cis	rs1061377	0.965	rs7677729	ENSG00000249685.1	RP11-360F5.3	8.01	9.89e-15	4.82e-12	0.39	0.35	Uric acid levels;	chr4:39120370	chr4:39133913~39135608:+
PRAD	cis	rs1061377	1	rs3796511	ENSG00000249685.1	RP11-360F5.3	8.01	9.89e-15	4.82e-12	0.39	0.35	Uric acid levels;	chr4:39120586	chr4:39133913~39135608:+
PRAD	cis	rs1061377	1	rs3733274	ENSG00000249685.1	RP11-360F5.3	8.01	9.89e-15	4.82e-12	0.39	0.35	Uric acid levels;	chr4:39120957	chr4:39133913~39135608:+
PRAD	cis	rs1061377	1	rs1982009	ENSG00000249685.1	RP11-360F5.3	8.01	9.89e-15	4.82e-12	0.39	0.35	Uric acid levels;	chr4:39123253	chr4:39133913~39135608:+
PRAD	cis	rs1061377	0.965	rs1138494	ENSG00000249685.1	RP11-360F5.3	8.01	9.89e-15	4.82e-12	0.39	0.35	Uric acid levels;	chr4:39123315	chr4:39133913~39135608:+
PRAD	cis	rs1061377	0.965	rs1046655	ENSG00000249685.1	RP11-360F5.3	8.01	9.89e-15	4.82e-12	0.39	0.35	Uric acid levels;	chr4:39126127	chr4:39133913~39135608:+
PRAD	cis	rs1061377	1	rs7694760	ENSG00000249685.1	RP11-360F5.3	8.01	9.89e-15	4.82e-12	0.39	0.35	Uric acid levels;	chr4:39126481	chr4:39133913~39135608:+
PRAD	cis	rs1061377	1	rs34771104	ENSG00000249685.1	RP11-360F5.3	8.01	9.89e-15	4.82e-12	0.39	0.35	Uric acid levels;	chr4:39127432	chr4:39133913~39135608:+
PRAD	cis	rs1061377	0.965	rs11728058	ENSG00000249685.1	RP11-360F5.3	8.01	9.89e-15	4.82e-12	0.39	0.35	Uric acid levels;	chr4:39128224	chr4:39133913~39135608:+
PRAD	cis	rs1061377	1	rs17508864	ENSG00000249685.1	RP11-360F5.3	8.01	9.89e-15	4.82e-12	0.39	0.35	Uric acid levels;	chr4:39129025	chr4:39133913~39135608:+
PRAD	cis	rs12899811	0.53	rs7162685	ENSG00000214432.8	AC068831.10	-8.01	9.91e-15	4.83e-12	-0.42	-0.35	Type 2 diabetes;	chr15:91023632	chr15:91022619~91036611:+
PRAD	cis	rs3096299	0.9	rs744327	ENSG00000274627.1	RP11-104N10.2	8.01	9.92e-15	4.84e-12	0.36	0.35	Multiple myeloma (IgH translocation);	chr16:89372862	chr16:89516797~89522217:+
PRAD	cis	rs2522056	0.932	rs2522064	ENSG00000233006.5	AC034220.3	-8.01	9.94e-15	4.84e-12	-0.35	-0.35	Fibrinogen;Lymphocyte counts;	chr5:132470796	chr5:132311285~132369916:-
PRAD	cis	rs9532669	0.963	rs9562238	ENSG00000168852.11	TPTE2P5	8.01	9.97e-15	4.86e-12	0.34	0.35	Cervical cancer;	chr13:40924785	chr13:40822296~40921749:-
PRAD	cis	rs11096990	0.634	rs11947159	ENSG00000249207.1	RP11-360F5.1	8.01	9.97e-15	4.86e-12	0.36	0.35	Cognitive function;	chr4:39286900	chr4:39112677~39126818:-
PRAD	cis	rs7923609	0.936	rs10822160	ENSG00000232075.1	MRPL35P2	-8.01	1e-14	4.88e-12	-0.37	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63353036	chr10:63634317~63634827:-
PRAD	cis	rs2108622	0.649	rs113055956	ENSG00000267056.2	AC005336.4	8.01	1e-14	4.88e-12	0.49	0.35	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866502	chr19:15910582~15911824:-
PRAD	cis	rs17772222	0.876	rs12587528	ENSG00000258983.2	RP11-507K2.2	8.01	1e-14	4.89e-12	0.51	0.35	Coronary artery calcification;	chr14:88487652	chr14:88499334~88515502:+
PRAD	cis	rs9287719	0.901	rs55861579	ENSG00000234818.1	AC092687.5	8.01	1e-14	4.89e-12	0.42	0.35	Prostate cancer;	chr2:10623214	chr2:10589166~10604830:+
PRAD	cis	rs2255336	0.938	rs4548707	ENSG00000245648.1	RP11-277P12.20	-8.01	1e-14	4.89e-12	-0.51	-0.35	Blood protein levels;	chr12:10467634	chr12:10363769~10398506:+
PRAD	cis	rs2274273	0.624	rs7152390	ENSG00000258413.1	RP11-665C16.6	-8.01	1e-14	4.89e-12	-0.47	-0.35	Protein biomarker;	chr14:55344983	chr14:55262767~55272075:-
PRAD	cis	rs2274273	0.588	rs9919923	ENSG00000258413.1	RP11-665C16.6	-8.01	1e-14	4.89e-12	-0.47	-0.35	Protein biomarker;	chr14:55347181	chr14:55262767~55272075:-
PRAD	cis	rs2274273	0.588	rs9919932	ENSG00000258413.1	RP11-665C16.6	-8.01	1e-14	4.89e-12	-0.47	-0.35	Protein biomarker;	chr14:55347362	chr14:55262767~55272075:-
PRAD	cis	rs7615952	0.932	rs13314869	ENSG00000171084.14	FAM86JP	8.01	1e-14	4.9e-12	0.58	0.35	Blood pressure (smoking interaction);	chr3:125925826	chr3:125916620~125930024:+
PRAD	cis	rs193541	0.632	rs34486978	ENSG00000263432.2	RN7SL689P	-8	1.01e-14	4.9e-12	-0.38	-0.35	Glucose homeostasis traits;	chr5:122976848	chr5:123022487~123022783:-
PRAD	cis	rs17711722	0.522	rs62469933	ENSG00000224316.1	RP11-479O9.2	8	1.01e-14	4.9e-12	0.33	0.35	Calcium levels;	chr7:65800652	chr7:65773620~65802067:+
PRAD	cis	rs72627509	0.951	rs72606404	ENSG00000269949.1	RP11-738E22.3	8	1.01e-14	4.91e-12	0.51	0.35	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56975047	chr4:56960927~56961373:-
PRAD	cis	rs6545883	0.524	rs778159	ENSG00000271889.1	RP11-493E12.1	-8	1.01e-14	4.92e-12	-0.39	-0.35	Tuberculosis;	chr2:61329609	chr2:61151433~61162105:-
PRAD	cis	rs526231	0.543	rs246909	ENSG00000175749.11	EIF3KP1	8	1.01e-14	4.94e-12	0.49	0.35	Primary biliary cholangitis;	chr5:103227976	chr5:103032376~103033031:+
PRAD	cis	rs526231	0.543	rs246906	ENSG00000175749.11	EIF3KP1	8	1.01e-14	4.94e-12	0.49	0.35	Primary biliary cholangitis;	chr5:103230770	chr5:103032376~103033031:+
PRAD	cis	rs526231	0.543	rs62362884	ENSG00000175749.11	EIF3KP1	8	1.01e-14	4.94e-12	0.49	0.35	Primary biliary cholangitis;	chr5:103231754	chr5:103032376~103033031:+
PRAD	cis	rs9309473	0.607	rs12478346	ENSG00000163016.8	ALMS1P	8	1.01e-14	4.94e-12	0.43	0.35	Metabolite levels;	chr2:73357232	chr2:73644919~73685576:+
PRAD	cis	rs6782228	0.675	rs4443194	ENSG00000242551.2	POU5F1P6	-8	1.02e-14	4.95e-12	-0.45	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128664603	chr3:128674735~128677005:-
PRAD	cis	rs6782228	0.675	rs4857918	ENSG00000242551.2	POU5F1P6	-8	1.02e-14	4.95e-12	-0.45	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128665117	chr3:128674735~128677005:-
PRAD	cis	rs375066	0.868	rs370190	ENSG00000267058.1	RP11-15A1.3	-8	1.02e-14	4.95e-12	-0.29	-0.35	Breast cancer;	chr19:43920102	chr19:43891804~43901805:-
PRAD	cis	rs375066	0.935	rs413093	ENSG00000267058.1	RP11-15A1.3	-8	1.02e-14	4.95e-12	-0.29	-0.35	Breast cancer;	chr19:43922113	chr19:43891804~43901805:-
PRAD	cis	rs2348418	0.67	rs10843098	ENSG00000247934.4	RP11-967K21.1	-8	1.02e-14	4.95e-12	-0.34	-0.35	Lung function (FEV1);Lung function (FVC);	chr12:28116709	chr12:28163298~28190738:-
PRAD	cis	rs375066	1	rs375066	ENSG00000267058.1	RP11-15A1.3	-8	1.02e-14	4.95e-12	-0.29	-0.35	Breast cancer;	chr19:43919418	chr19:43891804~43901805:-
PRAD	cis	rs6847067	0.794	rs7663580	ENSG00000180769.7	WDFY3-AS2	8	1.02e-14	4.98e-12	0.37	0.35	Oropharynx cancer;	chr4:85007163	chr4:84965682~85011277:+
PRAD	cis	rs2348418	0.639	rs61301264	ENSG00000247934.4	RP11-967K21.1	-8	1.02e-14	4.98e-12	-0.33	-0.35	Lung function (FEV1);Lung function (FVC);	chr12:28112922	chr12:28163298~28190738:-
PRAD	cis	rs3096299	0.967	rs7205785	ENSG00000274627.1	RP11-104N10.2	8	1.02e-14	4.98e-12	0.36	0.35	Multiple myeloma (IgH translocation);	chr16:89392576	chr16:89516797~89522217:+
PRAD	cis	rs9309473	0.583	rs11126397	ENSG00000163016.8	ALMS1P	8	1.02e-14	4.99e-12	0.42	0.35	Metabolite levels;	chr2:73361605	chr2:73644919~73685576:+
PRAD	cis	rs2739330	0.76	rs5751761	ENSG00000206090.4	AP000350.7	-8	1.02e-14	4.99e-12	-0.43	-0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23939998~23942798:+
PRAD	cis	rs2274273	0.624	rs8014477	ENSG00000258413.1	RP11-665C16.6	8	1.03e-14	5.01e-12	0.47	0.35	Protein biomarker;	chr14:55374759	chr14:55262767~55272075:-
PRAD	cis	rs75422866	0.867	rs73102125	ENSG00000274902.1	RP1-197B17.4	8	1.03e-14	5.02e-12	0.87	0.35	Pneumonia;	chr12:47637869	chr12:47731908~47732351:+
PRAD	cis	rs75422866	0.867	rs12426849	ENSG00000274902.1	RP1-197B17.4	8	1.03e-14	5.02e-12	0.87	0.35	Pneumonia;	chr12:47638975	chr12:47731908~47732351:+
PRAD	cis	rs75422866	0.867	rs117950951	ENSG00000274902.1	RP1-197B17.4	8	1.03e-14	5.02e-12	0.87	0.35	Pneumonia;	chr12:47639794	chr12:47731908~47732351:+
PRAD	cis	rs75422866	0.867	rs7954764	ENSG00000274902.1	RP1-197B17.4	8	1.03e-14	5.02e-12	0.87	0.35	Pneumonia;	chr12:47641136	chr12:47731908~47732351:+
PRAD	cis	rs11976180	1	rs2951364	ENSG00000273234.1	OR2A13P	-8	1.03e-14	5.02e-12	-0.42	-0.35	Obesity-related traits;	chr7:144057390	chr7:144142009~144142938:+
PRAD	cis	rs6921919	0.583	rs9468355	ENSG00000216901.1	AL022393.7	8	1.03e-14	5.02e-12	0.48	0.35	Autism spectrum disorder or schizophrenia;	chr6:28374100	chr6:28176188~28176674:+
PRAD	cis	rs1979679	0.76	rs16932640	ENSG00000278733.1	RP11-425D17.1	8	1.04e-14	5.04e-12	0.45	0.35	Ossification of the posterior longitudinal ligament of the spine;	chr12:28142034	chr12:28185625~28186190:-
PRAD	cis	rs10463554	1	rs3776862	ENSG00000175749.11	EIF3KP1	8	1.04e-14	5.05e-12	0.45	0.35	Parkinson's disease;	chr5:102996017	chr5:103032376~103033031:+
PRAD	cis	rs9532669	0.511	rs3783164	ENSG00000176268.5	CYCSP34	-8	1.04e-14	5.05e-12	-0.38	-0.35	Cervical cancer;	chr13:40806227	chr13:40863599~40863902:-
PRAD	cis	rs1979679	0.842	rs7138497	ENSG00000278733.1	RP11-425D17.1	8	1.04e-14	5.06e-12	0.44	0.35	Ossification of the posterior longitudinal ligament of the spine;	chr12:28242918	chr12:28185625~28186190:-
PRAD	cis	rs6539288	0.901	rs4964505	ENSG00000260329.1	RP11-412D9.4	-8	1.04e-14	5.06e-12	-0.31	-0.35	Total body bone mineral density;	chr12:106948062	chr12:106954029~106955497:-
PRAD	cis	rs10078	0.848	rs890985	ENSG00000221990.4	EXOC3-AS1	8	1.04e-14	5.06e-12	0.35	0.35	Fat distribution (HIV);	chr5:479631	chr5:441498~443160:-
PRAD	cis	rs7429990	0.901	rs7374482	ENSG00000229759.1	MRPS18AP1	-8	1.04e-14	5.07e-12	-0.36	-0.35	Educational attainment (years of education);	chr3:48126900	chr3:48256350~48256938:-
PRAD	cis	rs2243480	1	rs6964530	ENSG00000226824.5	RP4-756H11.3	8	1.05e-14	5.08e-12	0.7	0.35	Diabetic kidney disease;	chr7:66253864	chr7:66654538~66669855:+
PRAD	cis	rs6504950	0.579	rs17712917	ENSG00000275710.1	RP11-257O5.4	8	1.05e-14	5.09e-12	0.54	0.35	Breast cancer;	chr17:55194004	chr17:54964474~54964679:+
PRAD	cis	rs7923609	0.934	rs10761756	ENSG00000232075.1	MRPL35P2	-8	1.05e-14	5.09e-12	-0.37	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63412568	chr10:63634317~63634827:-
PRAD	cis	rs7923609	0.967	rs10761758	ENSG00000232075.1	MRPL35P2	-8	1.05e-14	5.09e-12	-0.37	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63412987	chr10:63634317~63634827:-
PRAD	cis	rs7923609	0.967	rs7909269	ENSG00000232075.1	MRPL35P2	-8	1.05e-14	5.09e-12	-0.37	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63418006	chr10:63634317~63634827:-
PRAD	cis	rs62355901	0.551	rs60856350	ENSG00000271828.1	CTD-2310F14.1	8	1.05e-14	5.1e-12	0.77	0.35	Breast cancer;	chr5:56727093	chr5:56927874~56929573:+
PRAD	cis	rs11096990	0.656	rs4580661	ENSG00000249207.1	RP11-360F5.1	8	1.05e-14	5.1e-12	0.36	0.35	Cognitive function;	chr4:39294730	chr4:39112677~39126818:-
PRAD	cis	rs4631830	0.965	rs7070301	ENSG00000230869.1	CTGLF10P	-8	1.05e-14	5.11e-12	-0.44	-0.35	Prostate-specific antigen levels;	chr10:46052752	chr10:45678692~45700532:+
PRAD	cis	rs6545883	0.524	rs2463101	ENSG00000271889.1	RP11-493E12.1	-8	1.05e-14	5.12e-12	-0.38	-0.35	Tuberculosis;	chr2:61347287	chr2:61151433~61162105:-
PRAD	cis	rs4664293	0.528	rs56027129	ENSG00000226266.5	AC009961.3	8	1.05e-14	5.12e-12	0.47	0.35	Monocyte percentage of white cells;	chr2:159600091	chr2:159670708~159712435:-
PRAD	cis	rs42648	0.591	rs11770630	ENSG00000227646.6	STEAP2-AS1	-8	1.06e-14	5.14e-12	-0.32	-0.35	Homocysteine levels;	chr7:90175927	chr7:89882353~90211635:-
PRAD	cis	rs1185460	1	rs15818	ENSG00000271751.1	RP11-110I1.14	-8	1.06e-14	5.15e-12	-0.49	-0.35	Coronary artery disease;	chr11:119081463	chr11:119065263~119065677:-
PRAD	cis	rs72627509	1	rs57265257	ENSG00000269949.1	RP11-738E22.3	8	1.06e-14	5.15e-12	0.51	0.35	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56973114	chr4:56960927~56961373:-
PRAD	cis	rs193541	0.593	rs154499	ENSG00000263432.2	RN7SL689P	8	1.06e-14	5.16e-12	0.37	0.35	Glucose homeostasis traits;	chr5:122883971	chr5:123022487~123022783:-
PRAD	cis	rs763567	0.817	rs598993	ENSG00000271811.1	RP1-79C4.4	8	1.07e-14	5.19e-12	0.4	0.35	Tonsillectomy;	chr1:170634981	chr1:170667381~170669425:+
PRAD	cis	rs763567	0.935	rs541557	ENSG00000271811.1	RP1-79C4.4	8	1.07e-14	5.19e-12	0.4	0.35	Tonsillectomy;	chr1:170635797	chr1:170667381~170669425:+
PRAD	cis	rs526231	0.543	rs40092	ENSG00000175749.11	EIF3KP1	8	1.07e-14	5.19e-12	0.49	0.35	Primary biliary cholangitis;	chr5:103088509	chr5:103032376~103033031:+
PRAD	cis	rs11976180	1	rs2951353	ENSG00000170356.8	OR2A20P	-8	1.07e-14	5.21e-12	-0.47	-0.35	Obesity-related traits;	chr7:144064023	chr7:144250045~144252957:-
PRAD	cis	rs11976180	1	rs2371247	ENSG00000170356.8	OR2A20P	-8	1.07e-14	5.21e-12	-0.47	-0.35	Obesity-related traits;	chr7:144067086	chr7:144250045~144252957:-
PRAD	cis	rs75422866	0.867	rs73113139	ENSG00000274902.1	RP1-197B17.4	8	1.07e-14	5.22e-12	0.91	0.35	Pneumonia;	chr12:47622826	chr12:47731908~47732351:+
PRAD	cis	rs2348418	0.67	rs4035202	ENSG00000247934.4	RP11-967K21.1	-8	1.08e-14	5.23e-12	-0.34	-0.35	Lung function (FEV1);Lung function (FVC);	chr12:28118015	chr12:28163298~28190738:-
PRAD	cis	rs7727544	0.716	rs10058655	ENSG00000233006.5	AC034220.3	8	1.08e-14	5.24e-12	0.31	0.35	Blood metabolite levels;	chr5:132235203	chr5:132311285~132369916:-
PRAD	cis	rs11976180	1	rs2961120	ENSG00000273234.1	OR2A13P	-7.99	1.08e-14	5.24e-12	-0.42	-0.35	Obesity-related traits;	chr7:144059492	chr7:144142009~144142938:+
PRAD	cis	rs11976180	1	rs2951360	ENSG00000273234.1	OR2A13P	-7.99	1.08e-14	5.24e-12	-0.42	-0.35	Obesity-related traits;	chr7:144060256	chr7:144142009~144142938:+
PRAD	cis	rs2439831	0.702	rs3759791	ENSG00000249839.1	AC011330.5	-7.99	1.08e-14	5.25e-12	-0.6	-0.35	Lung cancer in ever smokers;	chr15:43798600	chr15:43663654~43684339:-
PRAD	cis	rs526231	0.543	rs27698	ENSG00000175749.11	EIF3KP1	-7.99	1.08e-14	5.25e-12	-0.48	-0.35	Primary biliary cholangitis;	chr5:103190474	chr5:103032376~103033031:+
PRAD	cis	rs673078	0.607	rs61943392	ENSG00000275409.1	RP11-131L12.4	-7.99	1.08e-14	5.25e-12	-0.51	-0.35	Glucose homeostasis traits;	chr12:118382618	chr12:118430147~118430699:+
PRAD	cis	rs9309473	0.607	rs6546824	ENSG00000163016.8	ALMS1P	7.99	1.08e-14	5.26e-12	0.42	0.35	Metabolite levels;	chr2:73360203	chr2:73644919~73685576:+
PRAD	cis	rs10463554	0.655	rs152138	ENSG00000175749.11	EIF3KP1	7.99	1.08e-14	5.26e-12	0.47	0.35	Parkinson's disease;	chr5:103223727	chr5:103032376~103033031:+
PRAD	cis	rs3020264	0.669	rs7005662	ENSG00000271743.1	CTD-2541M15.3	7.99	1.09e-14	5.27e-12	0.4	0.35	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks);	chr8:6619105	chr8:6615604~6617198:-
PRAD	cis	rs2015599	0.56	rs3948497	ENSG00000257176.2	RP11-996F15.2	-7.99	1.09e-14	5.27e-12	-0.4	-0.35	Platelet count;Mean platelet volume;	chr12:29247552	chr12:29280418~29317848:-
PRAD	cis	rs4631830	0.863	rs2249986	ENSG00000230869.1	CTGLF10P	-7.99	1.09e-14	5.28e-12	-0.43	-0.35	Prostate-specific antigen levels;	chr10:46074138	chr10:45678692~45700532:+
PRAD	cis	rs673078	0.66	rs17512609	ENSG00000275409.1	RP11-131L12.4	-7.99	1.09e-14	5.29e-12	-0.5	-0.35	Glucose homeostasis traits;	chr12:118354072	chr12:118430147~118430699:+
PRAD	cis	rs17428076	0.793	rs7584258	ENSG00000228389.1	AC068039.4	-7.99	1.09e-14	5.3e-12	-0.45	-0.35	Myopia;	chr2:171803326	chr2:171773482~171775844:+
PRAD	cis	rs11018904	0.906	rs10501713	ENSG00000280385.1	AP000648.5	-7.99	1.1e-14	5.31e-12	-0.5	-0.35	Intelligence (multi-trait analysis);	chr11:90219845	chr11:90193614~90198120:+
PRAD	cis	rs12928939	0.815	rs1345868	ENSG00000260886.1	TAT-AS1	7.99	1.1e-14	5.32e-12	0.48	0.35	Post bronchodilator FEV1;	chr16:71635721	chr16:71565789~71578187:+
PRAD	cis	rs2439831	0.867	rs2447211	ENSG00000205771.5	CATSPER2P1	-7.99	1.1e-14	5.34e-12	-0.56	-0.35	Lung cancer in ever smokers;	chr15:43644153	chr15:43726918~43747094:-
PRAD	cis	rs6921919	0.789	rs11970439	ENSG00000216901.1	AL022393.7	7.99	1.1e-14	5.34e-12	0.5	0.35	Autism spectrum disorder or schizophrenia;	chr6:28335687	chr6:28176188~28176674:+
PRAD	cis	rs4664293	0.801	rs6432552	ENSG00000226266.5	AC009961.3	-7.99	1.1e-14	5.36e-12	-0.47	-0.35	Monocyte percentage of white cells;	chr2:159717613	chr2:159670708~159712435:-
PRAD	cis	rs193541	0.632	rs168913	ENSG00000263432.2	RN7SL689P	7.99	1.11e-14	5.37e-12	0.37	0.35	Glucose homeostasis traits;	chr5:122890098	chr5:123022487~123022783:-
PRAD	cis	rs7772486	0.774	rs2247571	ENSG00000235652.6	RP11-545I5.3	7.99	1.11e-14	5.37e-12	0.36	0.35	Lobe attachment (rater-scored or self-reported);	chr6:145898397	chr6:145799409~145886585:+
PRAD	cis	rs2439831	0.764	rs2447193	ENSG00000205771.5	CATSPER2P1	-7.99	1.11e-14	5.37e-12	-0.56	-0.35	Lung cancer in ever smokers;	chr15:43637535	chr15:43726918~43747094:-
PRAD	cis	rs2439831	0.571	rs2470121	ENSG00000205771.5	CATSPER2P1	-7.99	1.11e-14	5.37e-12	-0.56	-0.35	Lung cancer in ever smokers;	chr15:43645420	chr15:43726918~43747094:-
PRAD	cis	rs11096990	0.634	rs7654501	ENSG00000249207.1	RP11-360F5.1	7.99	1.11e-14	5.38e-12	0.36	0.35	Cognitive function;	chr4:39282364	chr4:39112677~39126818:-
PRAD	cis	rs17608059	0.566	rs17676459	ENSG00000141028.6	CDRT15P1	-7.99	1.11e-14	5.39e-12	-0.45	-0.35	Temperament;	chr17:14007198	chr17:14024514~14025488:+
PRAD	cis	rs4674676	1	rs4674676	ENSG00000261428.2	RP11-16P6.1	7.99	1.12e-14	5.4e-12	0.6	0.35	Chin dimples;	chr2:222664393	chr2:222566899~222569719:-
PRAD	cis	rs11096990	0.656	rs6531710	ENSG00000249207.1	RP11-360F5.1	7.99	1.12e-14	5.42e-12	0.36	0.35	Cognitive function;	chr4:39300658	chr4:39112677~39126818:-
PRAD	cis	rs4631830	0.832	rs1585378	ENSG00000230869.1	CTGLF10P	-7.99	1.12e-14	5.42e-12	-0.43	-0.35	Prostate-specific antigen levels;	chr10:46072609	chr10:45678692~45700532:+
PRAD	cis	rs12908161	1	rs35630683	ENSG00000259728.4	LINC00933	7.99	1.12e-14	5.43e-12	0.43	0.35	Schizophrenia;	chr15:84806000	chr15:84570649~84580175:+
PRAD	cis	rs8062405	0.789	rs1968752	ENSG00000251417.2	RP11-1348G14.4	-7.99	1.12e-14	5.43e-12	-0.38	-0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620264	chr16:28802743~28817828:+
PRAD	cis	rs7240205	0.657	rs1111207	ENSG00000275805.1	RP11-349H17.2	-7.99	1.12e-14	5.44e-12	-0.42	-0.35	Breast cancer;	chr18:26545893	chr18:26565723~26575626:-
PRAD	cis	rs7240205	0.657	rs1111208	ENSG00000275805.1	RP11-349H17.2	-7.99	1.12e-14	5.44e-12	-0.42	-0.35	Breast cancer;	chr18:26545901	chr18:26565723~26575626:-
PRAD	cis	rs75422866	0.717	rs73113159	ENSG00000274902.1	RP1-197B17.4	7.99	1.13e-14	5.45e-12	0.91	0.35	Pneumonia;	chr12:47631318	chr12:47731908~47732351:+
PRAD	cis	rs75422866	0.717	rs73113161	ENSG00000274902.1	RP1-197B17.4	7.99	1.13e-14	5.45e-12	0.91	0.35	Pneumonia;	chr12:47632361	chr12:47731908~47732351:+
PRAD	cis	rs75422866	0.867	rs117022227	ENSG00000274902.1	RP1-197B17.4	7.99	1.13e-14	5.45e-12	0.91	0.35	Pneumonia;	chr12:47633282	chr12:47731908~47732351:+
PRAD	cis	rs75422866	1	rs73102120	ENSG00000274902.1	RP1-197B17.4	7.99	1.13e-14	5.45e-12	0.91	0.35	Pneumonia;	chr12:47637280	chr12:47731908~47732351:+
PRAD	cis	rs75422866	0.867	rs12422974	ENSG00000274902.1	RP1-197B17.4	7.99	1.13e-14	5.45e-12	0.91	0.35	Pneumonia;	chr12:47644559	chr12:47731908~47732351:+
PRAD	cis	rs75422866	0.867	rs73102127	ENSG00000274902.1	RP1-197B17.4	7.99	1.13e-14	5.45e-12	0.91	0.35	Pneumonia;	chr12:47645341	chr12:47731908~47732351:+
PRAD	cis	rs75422866	0.867	rs73102140	ENSG00000274902.1	RP1-197B17.4	7.99	1.13e-14	5.45e-12	0.91	0.35	Pneumonia;	chr12:47647497	chr12:47731908~47732351:+
PRAD	cis	rs75422866	0.867	rs73102148	ENSG00000274902.1	RP1-197B17.4	7.99	1.13e-14	5.45e-12	0.91	0.35	Pneumonia;	chr12:47648013	chr12:47731908~47732351:+
PRAD	cis	rs75422866	0.867	rs73102151	ENSG00000274902.1	RP1-197B17.4	7.99	1.13e-14	5.45e-12	0.91	0.35	Pneumonia;	chr12:47648023	chr12:47731908~47732351:+
PRAD	cis	rs75422866	0.867	rs73102166	ENSG00000274902.1	RP1-197B17.4	7.99	1.13e-14	5.45e-12	0.91	0.35	Pneumonia;	chr12:47653769	chr12:47731908~47732351:+
PRAD	cis	rs75422866	0.867	rs73102168	ENSG00000274902.1	RP1-197B17.4	7.99	1.13e-14	5.45e-12	0.91	0.35	Pneumonia;	chr12:47654010	chr12:47731908~47732351:+
PRAD	cis	rs75422866	0.867	rs73102171	ENSG00000274902.1	RP1-197B17.4	7.99	1.13e-14	5.45e-12	0.91	0.35	Pneumonia;	chr12:47656077	chr12:47731908~47732351:+
PRAD	cis	rs75422866	0.867	rs76100981	ENSG00000274902.1	RP1-197B17.4	7.99	1.13e-14	5.45e-12	0.91	0.35	Pneumonia;	chr12:47660092	chr12:47731908~47732351:+
PRAD	cis	rs75422866	0.867	rs73102188	ENSG00000274902.1	RP1-197B17.4	7.99	1.13e-14	5.45e-12	0.91	0.35	Pneumonia;	chr12:47662993	chr12:47731908~47732351:+
PRAD	cis	rs75422866	0.867	rs73102195	ENSG00000274902.1	RP1-197B17.4	7.99	1.13e-14	5.45e-12	0.91	0.35	Pneumonia;	chr12:47666309	chr12:47731908~47732351:+
PRAD	cis	rs75422866	0.867	rs73102201	ENSG00000274902.1	RP1-197B17.4	7.99	1.13e-14	5.45e-12	0.91	0.35	Pneumonia;	chr12:47669269	chr12:47731908~47732351:+
PRAD	cis	rs75422866	0.867	rs73104103	ENSG00000274902.1	RP1-197B17.4	7.99	1.13e-14	5.45e-12	0.91	0.35	Pneumonia;	chr12:47669604	chr12:47731908~47732351:+
PRAD	cis	rs75422866	0.867	rs73104104	ENSG00000274902.1	RP1-197B17.4	7.99	1.13e-14	5.45e-12	0.91	0.35	Pneumonia;	chr12:47671986	chr12:47731908~47732351:+
PRAD	cis	rs75422866	0.867	rs73104111	ENSG00000274902.1	RP1-197B17.4	7.99	1.13e-14	5.45e-12	0.91	0.35	Pneumonia;	chr12:47673994	chr12:47731908~47732351:+
PRAD	cis	rs75422866	0.867	rs73104115	ENSG00000274902.1	RP1-197B17.4	7.99	1.13e-14	5.45e-12	0.91	0.35	Pneumonia;	chr12:47684843	chr12:47731908~47732351:+
PRAD	cis	rs75422866	0.867	rs73104116	ENSG00000274902.1	RP1-197B17.4	7.99	1.13e-14	5.45e-12	0.91	0.35	Pneumonia;	chr12:47685023	chr12:47731908~47732351:+
PRAD	cis	rs75422866	0.867	rs73104138	ENSG00000274902.1	RP1-197B17.4	7.99	1.13e-14	5.45e-12	0.91	0.35	Pneumonia;	chr12:47692302	chr12:47731908~47732351:+
PRAD	cis	rs75422866	0.717	rs73104143	ENSG00000274902.1	RP1-197B17.4	7.99	1.13e-14	5.45e-12	0.91	0.35	Pneumonia;	chr12:47693449	chr12:47731908~47732351:+
PRAD	cis	rs75422866	0.867	rs73104144	ENSG00000274902.1	RP1-197B17.4	7.99	1.13e-14	5.45e-12	0.91	0.35	Pneumonia;	chr12:47694390	chr12:47731908~47732351:+
PRAD	cis	rs75422866	0.867	rs73104148	ENSG00000274902.1	RP1-197B17.4	7.99	1.13e-14	5.45e-12	0.91	0.35	Pneumonia;	chr12:47696732	chr12:47731908~47732351:+
PRAD	cis	rs75422866	0.867	rs73104152	ENSG00000274902.1	RP1-197B17.4	7.99	1.13e-14	5.45e-12	0.91	0.35	Pneumonia;	chr12:47699091	chr12:47731908~47732351:+
PRAD	cis	rs75422866	0.867	rs73104155	ENSG00000274902.1	RP1-197B17.4	7.99	1.13e-14	5.45e-12	0.91	0.35	Pneumonia;	chr12:47700790	chr12:47731908~47732351:+
PRAD	cis	rs11976180	1	rs13226728	ENSG00000170356.8	OR2A20P	-7.99	1.13e-14	5.46e-12	-0.46	-0.35	Obesity-related traits;	chr7:144049485	chr7:144250045~144252957:-
PRAD	cis	rs2412819	0.571	rs6493090	ENSG00000205771.5	CATSPER2P1	7.99	1.13e-14	5.47e-12	0.48	0.35	Lung cancer;	chr15:43792084	chr15:43726918~43747094:-
PRAD	cis	rs6504950	0.579	rs8075983	ENSG00000275710.1	RP11-257O5.4	7.99	1.13e-14	5.47e-12	0.54	0.35	Breast cancer;	chr17:55194557	chr17:54964474~54964679:+
PRAD	cis	rs4722166	0.532	rs6963866	ENSG00000179428.2	AC073072.5	-7.99	1.13e-14	5.48e-12	-0.41	-0.35	Lung cancer;	chr7:22717722	chr7:22725395~22727620:-
PRAD	cis	rs1552244	0.608	rs2075310	ENSG00000206567.8	AC022007.5	-7.99	1.13e-14	5.48e-12	-0.39	-0.35	Alzheimer's disease;	chr3:10025967	chr3:10006418~10011209:-
PRAD	cis	rs5760092	0.755	rs4585126	ENSG00000206090.4	AP000350.7	-7.99	1.13e-14	5.49e-12	-0.49	-0.35	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23939998~23942798:+
PRAD	cis	rs4664293	0.967	rs13032135	ENSG00000226266.5	AC009961.3	-7.99	1.14e-14	5.5e-12	-0.46	-0.35	Monocyte percentage of white cells;	chr2:159675588	chr2:159670708~159712435:-
PRAD	cis	rs11976180	1	rs2961119	ENSG00000170356.8	OR2A20P	-7.99	1.14e-14	5.52e-12	-0.47	-0.35	Obesity-related traits;	chr7:144058759	chr7:144250045~144252957:-
PRAD	cis	rs9810089	0.903	rs7427564	ENSG00000261758.1	RP11-102M11.2	7.99	1.15e-14	5.54e-12	0.4	0.35	Gestational age at birth (child effect);	chr3:136555593	chr3:136752630~136755780:+
PRAD	cis	rs10751647	0.804	rs3809112	ENSG00000251661.3	RP11-326C3.11	-7.99	1.15e-14	5.55e-12	-0.4	-0.35	Monocyte count;	chr11:307036	chr11:318640~325631:+
PRAD	cis	rs9309473	0.528	rs11126395	ENSG00000163016.8	ALMS1P	7.99	1.15e-14	5.58e-12	0.43	0.35	Metabolite levels;	chr2:73337836	chr2:73644919~73685576:+
PRAD	cis	rs9309473	0.528	rs11898362	ENSG00000163016.8	ALMS1P	7.99	1.15e-14	5.58e-12	0.43	0.35	Metabolite levels;	chr2:73338165	chr2:73644919~73685576:+
PRAD	cis	rs6479901	0.895	rs10761722	ENSG00000232075.1	MRPL35P2	-7.99	1.16e-14	5.59e-12	-0.42	-0.35	Intelligence (multi-trait analysis);	chr10:63195287	chr10:63634317~63634827:-
PRAD	cis	rs1134634	0.52	rs4280723	ENSG00000273133.1	RP11-799M12.2	7.99	1.16e-14	5.59e-12	0.46	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15574095	chr4:15563698~15564253:-
PRAD	cis	rs1031391	0.716	rs10772416	ENSG00000247157.5	LINC01252	-7.99	1.16e-14	5.59e-12	-0.48	-0.35	Bitter taste perception;	chr12:11017488	chr12:11548030~11590369:+
PRAD	cis	rs72627509	1	rs72627509	ENSG00000269949.1	RP11-738E22.3	7.98	1.16e-14	5.61e-12	0.51	0.35	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56972885	chr4:56960927~56961373:-
PRAD	cis	rs881375	0.715	rs10985073	ENSG00000226752.6	PSMD5-AS1	-7.98	1.16e-14	5.62e-12	-0.41	-0.35	Rheumatoid arthritis;	chr9:120881577	chr9:120824828~120854385:+
PRAD	cis	rs2153535	0.518	rs9328493	ENSG00000230939.1	RP11-314C16.1	-7.98	1.16e-14	5.62e-12	-0.42	-0.35	Motion sickness;	chr6:8569066	chr6:8784178~8785445:+
PRAD	cis	rs8177376	0.906	rs240559	ENSG00000254905.1	RP11-712L6.7	7.98	1.16e-14	5.63e-12	0.44	0.35	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126321217	chr11:126292922~126294254:-
PRAD	cis	rs58873874	0.737	rs78738433	ENSG00000251405.2	CTB-109A12.1	7.98	1.17e-14	5.64e-12	0.89	0.35	Bipolar disorder (body mass index interaction);	chr5:157386503	chr5:157362615~157460078:-
PRAD	cis	rs1789	0.706	rs8180240	ENSG00000273133.1	RP11-799M12.2	-7.98	1.17e-14	5.65e-12	-0.5	-0.35	Blood protein levels;	chr4:15699952	chr4:15563698~15564253:-
PRAD	cis	rs10800713	0.56	rs10919965	ENSG00000260088.1	RP11-92G12.3	-7.98	1.17e-14	5.67e-12	-0.53	-0.35	Tandem gait;	chr1:200532134	chr1:200669507~200694250:+
PRAD	cis	rs853679	1	rs853685	ENSG00000280107.1	AL022393.9	-7.98	1.17e-14	5.67e-12	-0.53	-0.35	Depression;	chr6:28321008	chr6:28170845~28172521:+
PRAD	cis	rs17608059	0.566	rs5005684	ENSG00000141028.6	CDRT15P1	-7.98	1.17e-14	5.68e-12	-0.45	-0.35	Temperament;	chr17:14007316	chr17:14024514~14025488:+
PRAD	cis	rs72627509	0.904	rs17081933	ENSG00000269949.1	RP11-738E22.3	7.98	1.18e-14	5.68e-12	0.5	0.35	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56956703	chr4:56960927~56961373:-
PRAD	cis	rs6921919	0.583	rs7759191	ENSG00000216901.1	AL022393.7	7.98	1.18e-14	5.69e-12	0.45	0.35	Autism spectrum disorder or schizophrenia;	chr6:28385657	chr6:28176188~28176674:+
PRAD	cis	rs2439831	0.867	rs11856184	ENSG00000205771.5	CATSPER2P1	-7.98	1.18e-14	5.7e-12	-0.57	-0.35	Lung cancer in ever smokers;	chr15:43626964	chr15:43726918~43747094:-
PRAD	cis	rs2439831	0.867	rs2927072	ENSG00000205771.5	CATSPER2P1	-7.98	1.18e-14	5.7e-12	-0.57	-0.35	Lung cancer in ever smokers;	chr15:43630200	chr15:43726918~43747094:-
PRAD	cis	rs2439831	0.867	rs2920781	ENSG00000205771.5	CATSPER2P1	-7.98	1.18e-14	5.7e-12	-0.57	-0.35	Lung cancer in ever smokers;	chr15:43632484	chr15:43726918~43747094:-
PRAD	cis	rs73186030	0.546	rs55780469	ENSG00000272758.4	RP11-299J3.8	7.98	1.18e-14	5.71e-12	0.48	0.35	Serum parathyroid hormone levels;	chr3:122388590	chr3:122416207~122443180:+
PRAD	cis	rs17361889	0.727	rs1527209	ENSG00000224683.1	RPL36AP29	7.98	1.18e-14	5.72e-12	0.42	0.35	Pediatric bone mineral content (hip);	chr7:16241462	chr7:16208945~16209265:+
PRAD	cis	rs9810089	0.903	rs7432375	ENSG00000261758.1	RP11-102M11.2	7.98	1.19e-14	5.75e-12	0.4	0.35	Gestational age at birth (child effect);	chr3:136569563	chr3:136752630~136755780:+
PRAD	cis	rs9810089	0.903	rs10935185	ENSG00000261758.1	RP11-102M11.2	7.98	1.19e-14	5.75e-12	0.4	0.35	Gestational age at birth (child effect);	chr3:136571687	chr3:136752630~136755780:+
PRAD	cis	rs4664293	0.51	rs1968343	ENSG00000226266.5	AC009961.3	7.98	1.19e-14	5.77e-12	0.47	0.35	Monocyte percentage of white cells;	chr2:159712247	chr2:159670708~159712435:-
PRAD	cis	rs62355901	0.599	rs12655060	ENSG00000271828.1	CTD-2310F14.1	7.98	1.19e-14	5.77e-12	0.77	0.35	Breast cancer;	chr5:56720808	chr5:56927874~56929573:+
PRAD	cis	rs11976180	1	rs2961132	ENSG00000170356.8	OR2A20P	-7.98	1.2e-14	5.78e-12	-0.47	-0.35	Obesity-related traits;	chr7:144071035	chr7:144250045~144252957:-
PRAD	cis	rs853679	0.527	rs853690	ENSG00000204709.4	LINC01556	7.98	1.2e-14	5.8e-12	0.45	0.35	Depression;	chr6:28317705	chr6:28943877~28944537:+
PRAD	cis	rs6517329	0.649	rs2242798	ENSG00000236830.5	CBR3-AS1	7.98	1.2e-14	5.81e-12	0.37	0.35	Schizophrenia;	chr21:36120583	chr21:36131767~36175815:-
PRAD	cis	rs4631830	0.72	rs12763717	ENSG00000230869.1	CTGLF10P	7.98	1.2e-14	5.81e-12	0.44	0.35	Prostate-specific antigen levels;	chr10:46094948	chr10:45678692~45700532:+
PRAD	cis	rs11976180	1	rs1320893	ENSG00000273234.1	OR2A13P	-7.98	1.21e-14	5.82e-12	-0.41	-0.35	Obesity-related traits;	chr7:144055019	chr7:144142009~144142938:+
PRAD	cis	rs72627509	0.904	rs58408429	ENSG00000269949.1	RP11-738E22.3	7.98	1.21e-14	5.82e-12	0.5	0.35	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56903658	chr4:56960927~56961373:-
PRAD	cis	rs72627509	0.767	rs6853156	ENSG00000269949.1	RP11-738E22.3	7.98	1.21e-14	5.82e-12	0.5	0.35	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56908677	chr4:56960927~56961373:-
PRAD	cis	rs11096990	0.634	rs17754	ENSG00000249207.1	RP11-360F5.1	-7.98	1.21e-14	5.83e-12	-0.36	-0.35	Cognitive function;	chr4:39287688	chr4:39112677~39126818:-
PRAD	cis	rs1061377	1	rs7685468	ENSG00000249685.1	RP11-360F5.3	7.98	1.21e-14	5.83e-12	0.39	0.35	Uric acid levels;	chr4:39116649	chr4:39133913~39135608:+
PRAD	cis	rs526231	0.543	rs257310	ENSG00000175749.11	EIF3KP1	7.98	1.21e-14	5.84e-12	0.48	0.35	Primary biliary cholangitis;	chr5:103083149	chr5:103032376~103033031:+
PRAD	cis	rs17711722	0.565	rs4717276	ENSG00000224316.1	RP11-479O9.2	7.98	1.21e-14	5.84e-12	0.33	0.35	Calcium levels;	chr7:65829754	chr7:65773620~65802067:+
PRAD	cis	rs4927850	0.881	rs7624638	ENSG00000207650.1	MIR570	7.98	1.21e-14	5.84e-12	0.37	0.35	Pancreatic cancer;	chr3:196021858	chr3:195699401~195699497:+
PRAD	cis	rs4927850	1	rs10881564	ENSG00000207650.1	MIR570	7.98	1.21e-14	5.84e-12	0.37	0.35	Pancreatic cancer;	chr3:196023455	chr3:195699401~195699497:+
PRAD	cis	rs62355901	0.545	rs57850701	ENSG00000271828.1	CTD-2310F14.1	7.98	1.21e-14	5.85e-12	0.76	0.35	Breast cancer;	chr5:56728529	chr5:56927874~56929573:+
PRAD	cis	rs7923609	1	rs7923609	ENSG00000232075.1	MRPL35P2	-7.98	1.21e-14	5.85e-12	-0.37	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63374062	chr10:63634317~63634827:-
PRAD	cis	rs7923609	0.934	rs2893919	ENSG00000232075.1	MRPL35P2	-7.98	1.21e-14	5.85e-12	-0.37	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63375018	chr10:63634317~63634827:-
PRAD	cis	rs7923609	0.967	rs2393966	ENSG00000232075.1	MRPL35P2	-7.98	1.21e-14	5.85e-12	-0.37	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63375054	chr10:63634317~63634827:-
PRAD	cis	rs4927850	1	rs7625570	ENSG00000207650.1	MIR570	7.98	1.21e-14	5.86e-12	0.37	0.35	Pancreatic cancer;	chr3:196020527	chr3:195699401~195699497:+
PRAD	cis	rs2412819	0.597	rs541871	ENSG00000205771.5	CATSPER2P1	-7.98	1.22e-14	5.87e-12	-0.48	-0.35	Lung cancer;	chr15:43868656	chr15:43726918~43747094:-
PRAD	cis	rs2522056	1	rs62385693	ENSG00000233006.5	AC034220.3	-7.98	1.22e-14	5.87e-12	-0.34	-0.35	Fibrinogen;Lymphocyte counts;	chr5:132437982	chr5:132311285~132369916:-
PRAD	cis	rs673078	0.607	rs73207578	ENSG00000275409.1	RP11-131L12.4	-7.98	1.22e-14	5.89e-12	-0.5	-0.35	Glucose homeostasis traits;	chr12:118447080	chr12:118430147~118430699:+
PRAD	cis	rs11096990	0.656	rs2066786	ENSG00000249207.1	RP11-360F5.1	-7.98	1.22e-14	5.89e-12	-0.36	-0.35	Cognitive function;	chr4:39300409	chr4:39112677~39126818:-
PRAD	cis	rs62388641	0.547	rs2317966	ENSG00000272279.1	RP11-157J24.2	-7.98	1.22e-14	5.9e-12	-0.44	-0.35	Daytime sleep phenotypes;	chr6:1550651	chr6:1528364~1528911:-
PRAD	cis	rs193541	0.632	rs154503	ENSG00000263432.2	RN7SL689P	7.98	1.22e-14	5.91e-12	0.38	0.35	Glucose homeostasis traits;	chr5:122868804	chr5:123022487~123022783:-
PRAD	cis	rs11096990	0.634	rs11736790	ENSG00000249207.1	RP11-360F5.1	-7.98	1.23e-14	5.91e-12	-0.36	-0.35	Cognitive function;	chr4:39254704	chr4:39112677~39126818:-
PRAD	cis	rs6844153	0.887	rs3792685	ENSG00000240005.4	RP11-293A21.1	-7.98	1.23e-14	5.94e-12	-0.48	-0.35	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26957585	chr4:26859806~26860599:-
PRAD	cis	rs2243480	0.831	rs57294491	ENSG00000226824.5	RP4-756H11.3	7.98	1.23e-14	5.94e-12	0.7	0.35	Diabetic kidney disease;	chr7:66219914	chr7:66654538~66669855:+
PRAD	cis	rs950169	0.649	rs12911612	ENSG00000225151.9	GOLGA2P7	-7.98	1.24e-14	5.96e-12	-0.51	-0.35	Schizophrenia;	chr15:84022262	chr15:84199311~84230136:-
PRAD	cis	rs950169	0.649	rs12905952	ENSG00000225151.9	GOLGA2P7	-7.98	1.24e-14	5.96e-12	-0.51	-0.35	Schizophrenia;	chr15:84022509	chr15:84199311~84230136:-
PRAD	cis	rs950169	0.61	rs34529571	ENSG00000225151.9	GOLGA2P7	-7.98	1.24e-14	5.96e-12	-0.51	-0.35	Schizophrenia;	chr15:84023055	chr15:84199311~84230136:-
PRAD	cis	rs73186030	0.546	rs73188388	ENSG00000272758.4	RP11-299J3.8	7.98	1.24e-14	5.97e-12	0.48	0.35	Serum parathyroid hormone levels;	chr3:122399229	chr3:122416207~122443180:+
PRAD	cis	rs12928939	0.815	rs8049163	ENSG00000260886.1	TAT-AS1	7.98	1.24e-14	6e-12	0.47	0.35	Post bronchodilator FEV1;	chr16:71685450	chr16:71565789~71578187:+
PRAD	cis	rs7923609	1	rs12355784	ENSG00000232075.1	MRPL35P2	-7.97	1.24e-14	6e-12	-0.37	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63361805	chr10:63634317~63634827:-
PRAD	cis	rs2153535	0.518	rs9406181	ENSG00000230939.1	RP11-314C16.1	-7.97	1.24e-14	6e-12	-0.42	-0.35	Motion sickness;	chr6:8569069	chr6:8784178~8785445:+
PRAD	cis	rs673078	0.607	rs2055534	ENSG00000275409.1	RP11-131L12.4	-7.97	1.25e-14	6.01e-12	-0.5	-0.35	Glucose homeostasis traits;	chr12:118386527	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.607	rs56157623	ENSG00000275409.1	RP11-131L12.4	-7.97	1.25e-14	6.01e-12	-0.5	-0.35	Glucose homeostasis traits;	chr12:118388162	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.607	rs4767669	ENSG00000275409.1	RP11-131L12.4	-7.97	1.25e-14	6.01e-12	-0.5	-0.35	Glucose homeostasis traits;	chr12:118390651	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.607	rs4767670	ENSG00000275409.1	RP11-131L12.4	-7.97	1.25e-14	6.01e-12	-0.5	-0.35	Glucose homeostasis traits;	chr12:118390737	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.607	rs950288	ENSG00000275409.1	RP11-131L12.4	-7.97	1.25e-14	6.01e-12	-0.5	-0.35	Glucose homeostasis traits;	chr12:118392201	chr12:118430147~118430699:+
PRAD	cis	rs34375054	0.573	rs12831151	ENSG00000279233.1	RP11-158L12.4	7.97	1.25e-14	6.02e-12	0.38	0.35	Post bronchodilator FEV1/FVC ratio;	chr12:125171717	chr12:125138245~125141711:+
PRAD	cis	rs7829975	0.593	rs2921077	ENSG00000253893.2	FAM85B	-7.97	1.25e-14	6.04e-12	-0.43	-0.35	Mood instability;	chr8:8446992	chr8:8167819~8226614:-
PRAD	cis	rs172166	0.61	rs276369	ENSG00000280107.1	AL022393.9	-7.97	1.26e-14	6.06e-12	-0.42	-0.35	Cardiac Troponin-T levels;	chr6:27951465	chr6:28170845~28172521:+
PRAD	cis	rs375066	0.901	rs368316	ENSG00000267058.1	RP11-15A1.3	-7.97	1.26e-14	6.08e-12	-0.3	-0.35	Breast cancer;	chr19:43927742	chr19:43891804~43901805:-
PRAD	cis	rs7772486	0.742	rs4896851	ENSG00000235652.6	RP11-545I5.3	-7.97	1.27e-14	6.09e-12	-0.36	-0.35	Lobe attachment (rater-scored or self-reported);	chr6:145957823	chr6:145799409~145886585:+
PRAD	cis	rs2286503	0.839	rs2240728	ENSG00000228649.7	AC005682.5	7.97	1.27e-14	6.1e-12	0.4	0.35	Fibrinogen;	chr7:22812880	chr7:22854178~22861579:+
PRAD	cis	rs2286503	0.839	rs1054471	ENSG00000228649.7	AC005682.5	7.97	1.27e-14	6.1e-12	0.4	0.35	Fibrinogen;	chr7:22813024	chr7:22854178~22861579:+
PRAD	cis	rs4713118	0.868	rs10484401	ENSG00000226314.6	ZNF192P1	7.97	1.27e-14	6.1e-12	0.47	0.35	Parkinson's disease;	chr6:27778811	chr6:28161781~28169594:+
PRAD	cis	rs2337406	1	rs11845269	ENSG00000274576.2	IGHV2-70	-7.97	1.27e-14	6.13e-12	-0.37	-0.35	Alzheimer's disease (late onset);	chr14:106683851	chr14:106770577~106771020:-
PRAD	cis	rs7714584	1	rs59043558	ENSG00000197083.10	ZNF300P1	7.97	1.27e-14	6.13e-12	0.6	0.35	Crohn's disease;	chr5:150955100	chr5:150930645~150946289:-
PRAD	cis	rs193541	0.632	rs415417	ENSG00000263432.2	RN7SL689P	-7.97	1.27e-14	6.13e-12	-0.37	-0.35	Glucose homeostasis traits;	chr5:122987189	chr5:123022487~123022783:-
PRAD	cis	rs193541	0.632	rs62377425	ENSG00000263432.2	RN7SL689P	-7.97	1.27e-14	6.13e-12	-0.37	-0.35	Glucose homeostasis traits;	chr5:122996930	chr5:123022487~123022783:-
PRAD	cis	rs193541	0.632	rs34714850	ENSG00000263432.2	RN7SL689P	-7.97	1.27e-14	6.13e-12	-0.37	-0.35	Glucose homeostasis traits;	chr5:122997000	chr5:123022487~123022783:-
PRAD	cis	rs673078	0.607	rs61943391	ENSG00000275409.1	RP11-131L12.4	-7.97	1.28e-14	6.18e-12	-0.5	-0.35	Glucose homeostasis traits;	chr12:118382603	chr12:118430147~118430699:+
PRAD	cis	rs1528149	0.866	rs1528147	ENSG00000224683.1	RPL36AP29	7.97	1.28e-14	6.18e-12	0.44	0.35	Sitting height ratio;	chr7:16073898	chr7:16208945~16209265:+
PRAD	cis	rs1528149	0.93	rs17357253	ENSG00000224683.1	RPL36AP29	7.97	1.28e-14	6.18e-12	0.44	0.35	Sitting height ratio;	chr7:16074339	chr7:16208945~16209265:+
PRAD	cis	rs7396835	0.866	rs6589570	ENSG00000254851.1	RP11-109L13.1	-7.97	1.29e-14	6.2e-12	-0.69	-0.35	Quantitative traits;	chr11:116804578	chr11:117135528~117138582:+
PRAD	cis	rs2274273	0.624	rs7150234	ENSG00000258413.1	RP11-665C16.6	-7.97	1.29e-14	6.2e-12	-0.48	-0.35	Protein biomarker;	chr14:55335463	chr14:55262767~55272075:-
PRAD	cis	rs11096990	0.634	rs3733281	ENSG00000249207.1	RP11-360F5.1	7.97	1.29e-14	6.21e-12	0.36	0.35	Cognitive function;	chr4:39270293	chr4:39112677~39126818:-
PRAD	cis	rs17711722	0.522	rs62469933	ENSG00000164669.11	INTS4P1	-7.97	1.29e-14	6.22e-12	-0.44	-0.35	Calcium levels;	chr7:65800652	chr7:65141225~65234216:+
PRAD	cis	rs2404602	0.669	rs17464903	ENSG00000259422.1	RP11-593F23.1	7.97	1.3e-14	6.23e-12	0.43	0.35	Blood metabolite levels;	chr15:76903145	chr15:76174891~76181486:-
PRAD	cis	rs4927850	1	rs7614767	ENSG00000207650.1	MIR570	7.97	1.3e-14	6.25e-12	0.37	0.35	Pancreatic cancer;	chr3:196026580	chr3:195699401~195699497:+
PRAD	cis	rs321358	1	rs321365	ENSG00000271584.1	RP11-89C3.4	7.97	1.3e-14	6.27e-12	0.53	0.35	Body mass index;	chr11:111126676	chr11:111091932~111097357:-
PRAD	cis	rs34375054	1	rs3751178	ENSG00000279233.1	RP11-158L12.4	-7.97	1.31e-14	6.28e-12	-0.33	-0.35	Post bronchodilator FEV1/FVC ratio;	chr12:125179811	chr12:125138245~125141711:+
PRAD	cis	rs11096990	0.656	rs6531709	ENSG00000249207.1	RP11-360F5.1	7.97	1.31e-14	6.31e-12	0.36	0.35	Cognitive function;	chr4:39300629	chr4:39112677~39126818:-
PRAD	cis	rs6539288	0.901	rs4964193	ENSG00000260329.1	RP11-412D9.4	-7.97	1.31e-14	6.31e-12	-0.31	-0.35	Total body bone mineral density;	chr12:106927970	chr12:106954029~106955497:-
PRAD	cis	rs7429990	0.932	rs13085054	ENSG00000229759.1	MRPS18AP1	-7.97	1.31e-14	6.32e-12	-0.35	-0.35	Educational attainment (years of education);	chr3:48092647	chr3:48256350~48256938:-
PRAD	cis	rs11098499	0.532	rs4833624	ENSG00000245958.5	RP11-33B1.1	-7.97	1.31e-14	6.32e-12	-0.34	-0.35	Corneal astigmatism;	chr4:119664342	chr4:119454791~119552025:+
PRAD	cis	rs1355223	0.902	rs836467	ENSG00000271369.1	RP11-350D17.3	-7.97	1.32e-14	6.33e-12	-0.4	-0.35	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34715885	chr11:34709600~34710161:+
PRAD	cis	rs34779708	0.733	rs4102764	ENSG00000230534.5	RP11-297A16.2	7.97	1.32e-14	6.34e-12	0.47	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35256464	chr10:35098006~35127020:-
PRAD	cis	rs4664293	0.967	rs1346325	ENSG00000226266.5	AC009961.3	-7.97	1.32e-14	6.35e-12	-0.45	-0.35	Monocyte percentage of white cells;	chr2:159685995	chr2:159670708~159712435:-
PRAD	cis	rs4664293	0.967	rs35975814	ENSG00000226266.5	AC009961.3	-7.97	1.32e-14	6.35e-12	-0.45	-0.35	Monocyte percentage of white cells;	chr2:159691280	chr2:159670708~159712435:-
PRAD	cis	rs172166	0.561	rs149976	ENSG00000280107.1	AL022393.9	7.97	1.32e-14	6.35e-12	0.41	0.35	Cardiac Troponin-T levels;	chr6:28019998	chr6:28170845~28172521:+
PRAD	cis	rs1061377	0.861	rs35739603	ENSG00000249685.1	RP11-360F5.3	7.97	1.32e-14	6.36e-12	0.4	0.35	Uric acid levels;	chr4:39107938	chr4:39133913~39135608:+
PRAD	cis	rs11098499	0.722	rs1814814	ENSG00000245958.5	RP11-33B1.1	-7.97	1.33e-14	6.38e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119336969	chr4:119454791~119552025:+
PRAD	cis	rs12468226	1	rs13426118	ENSG00000273456.1	RP11-686O6.2	7.97	1.33e-14	6.39e-12	0.42	0.35	Urate levels;	chr2:202390762	chr2:202374932~202375604:-
PRAD	cis	rs11123170	0.542	rs11123169	ENSG00000274877.1	RP11-65I12.1	7.97	1.33e-14	6.39e-12	0.49	0.35	Renal function-related traits (BUN);	chr2:113209498	chr2:113237595~113240825:+
PRAD	cis	rs62355901	0.505	rs16886257	ENSG00000271828.1	CTD-2310F14.1	7.97	1.33e-14	6.39e-12	0.8	0.35	Breast cancer;	chr5:56766994	chr5:56927874~56929573:+
PRAD	cis	rs526231	0.543	rs158244	ENSG00000175749.11	EIF3KP1	7.97	1.33e-14	6.4e-12	0.48	0.35	Primary biliary cholangitis;	chr5:103075062	chr5:103032376~103033031:+
PRAD	cis	rs964611	0.882	rs16960737	ENSG00000259488.2	RP11-154J22.1	-7.97	1.33e-14	6.4e-12	-0.33	-0.35	Metabolite levels (Pyroglutamine);	chr15:48299863	chr15:48312353~48331856:-
PRAD	cis	rs7634476	1	rs7634476	ENSG00000261758.1	RP11-102M11.2	-7.97	1.33e-14	6.4e-12	-0.4	-0.35	Neuroticism;	chr3:136679545	chr3:136752630~136755780:+
PRAD	cis	rs6782228	0.585	rs9841161	ENSG00000242551.2	POU5F1P6	-7.97	1.33e-14	6.41e-12	-0.44	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128613027	chr3:128674735~128677005:-
PRAD	cis	rs6782228	0.606	rs2712405	ENSG00000242551.2	POU5F1P6	-7.97	1.33e-14	6.41e-12	-0.44	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128613239	chr3:128674735~128677005:-
PRAD	cis	rs11096990	0.613	rs6829660	ENSG00000249207.1	RP11-360F5.1	-7.96	1.34e-14	6.42e-12	-0.37	-0.35	Cognitive function;	chr4:39280943	chr4:39112677~39126818:-
PRAD	cis	rs7432375	1	rs10935186	ENSG00000261758.1	RP11-102M11.2	7.96	1.34e-14	6.45e-12	0.4	0.35	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136627364	chr3:136752630~136755780:+
PRAD	cis	rs7432375	0.933	rs55970317	ENSG00000261758.1	RP11-102M11.2	7.96	1.34e-14	6.45e-12	0.4	0.35	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136634351	chr3:136752630~136755780:+
PRAD	cis	rs7432375	0.966	rs6808312	ENSG00000261758.1	RP11-102M11.2	-7.96	1.34e-14	6.45e-12	-0.4	-0.35	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136652662	chr3:136752630~136755780:+
PRAD	cis	rs7432375	1	rs6439649	ENSG00000261758.1	RP11-102M11.2	-7.96	1.34e-14	6.45e-12	-0.4	-0.35	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136652849	chr3:136752630~136755780:+
PRAD	cis	rs6903823	0.527	rs4713158	ENSG00000204709.4	LINC01556	7.96	1.35e-14	6.47e-12	0.45	0.35	Pulmonary function;	chr6:28309994	chr6:28943877~28944537:+
PRAD	cis	rs950169	0.58	rs4603535	ENSG00000275120.1	RP11-182J1.17	7.96	1.36e-14	6.54e-12	0.45	0.35	Schizophrenia;	chr15:84630641	chr15:84599434~84606463:-
PRAD	cis	rs950169	0.541	rs10795	ENSG00000275120.1	RP11-182J1.17	7.96	1.36e-14	6.54e-12	0.45	0.35	Schizophrenia;	chr15:84634066	chr15:84599434~84606463:-
PRAD	cis	rs950169	0.58	rs36126054	ENSG00000275120.1	RP11-182J1.17	7.96	1.36e-14	6.54e-12	0.45	0.35	Schizophrenia;	chr15:84634492	chr15:84599434~84606463:-
PRAD	cis	rs950169	0.58	rs1061737	ENSG00000275120.1	RP11-182J1.17	7.96	1.36e-14	6.54e-12	0.45	0.35	Schizophrenia;	chr15:84640559	chr15:84599434~84606463:-
PRAD	cis	rs11118620	0.853	rs12037861	ENSG00000257551.1	HLX-AS1	7.96	1.37e-14	6.56e-12	0.45	0.35	Heart failure;	chr1:220864835	chr1:220832763~220880140:-
PRAD	cis	rs3096299	0.967	rs2911257	ENSG00000261118.1	RP11-104N10.1	7.96	1.37e-14	6.57e-12	0.34	0.35	Multiple myeloma (IgH translocation);	chr16:89417726	chr16:89492017~89504460:-
PRAD	cis	rs526231	0.511	rs73179850	ENSG00000175749.11	EIF3KP1	7.96	1.37e-14	6.57e-12	0.48	0.35	Primary biliary cholangitis;	chr5:103012873	chr5:103032376~103033031:+
PRAD	cis	rs1979679	0.918	rs1586867	ENSG00000278733.1	RP11-425D17.1	7.96	1.37e-14	6.58e-12	0.45	0.35	Ossification of the posterior longitudinal ligament of the spine;	chr12:28368345	chr12:28185625~28186190:-
PRAD	cis	rs10740039	0.583	rs9415613	ENSG00000254271.1	RP11-131N11.4	-7.96	1.37e-14	6.59e-12	-0.52	-0.35	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60747636	chr10:60734342~60741828:+
PRAD	cis	rs524281	0.506	rs512421	ENSG00000255320.1	RP11-755F10.1	7.96	1.38e-14	6.61e-12	0.51	0.35	Electroencephalogram traits;	chr11:66217697	chr11:66244840~66246239:-
PRAD	cis	rs6782228	0.606	rs2253144	ENSG00000242551.2	POU5F1P6	7.96	1.38e-14	6.62e-12	0.44	0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611077	chr3:128674735~128677005:-
PRAD	cis	rs6921919	0.525	rs11760133	ENSG00000216901.1	AL022393.7	7.96	1.38e-14	6.65e-12	0.45	0.35	Autism spectrum disorder or schizophrenia;	chr6:28418962	chr6:28176188~28176674:+
PRAD	cis	rs435066	0.633	rs1924532	ENSG00000234264.1	DEPDC1-AS1	-7.96	1.39e-14	6.65e-12	-0.52	-0.35	IgG glycosylation;	chr1:68547621	chr1:68496676~68538627:+
PRAD	cis	rs435066	0.633	rs1924531	ENSG00000234264.1	DEPDC1-AS1	-7.96	1.39e-14	6.65e-12	-0.52	-0.35	IgG glycosylation;	chr1:68547729	chr1:68496676~68538627:+
PRAD	cis	rs435066	0.633	rs1924530	ENSG00000234264.1	DEPDC1-AS1	-7.96	1.39e-14	6.65e-12	-0.52	-0.35	IgG glycosylation;	chr1:68548361	chr1:68496676~68538627:+
PRAD	cis	rs435066	0.633	rs2419644	ENSG00000234264.1	DEPDC1-AS1	-7.96	1.39e-14	6.65e-12	-0.52	-0.35	IgG glycosylation;	chr1:68556116	chr1:68496676~68538627:+
PRAD	cis	rs11976180	1	rs2951308	ENSG00000170356.8	OR2A20P	7.96	1.39e-14	6.65e-12	0.47	0.35	Obesity-related traits;	chr7:144070056	chr7:144250045~144252957:-
PRAD	cis	rs8523	0.901	rs3798707	ENSG00000230314.5	ELOVL2-AS1	7.96	1.39e-14	6.68e-12	0.39	0.35	Red blood cell fatty acid levels;	chr6:10991702	chr6:11043524~11078226:+
PRAD	cis	rs1979679	0.837	rs2881860	ENSG00000278733.1	RP11-425D17.1	7.96	1.39e-14	6.69e-12	0.45	0.35	Ossification of the posterior longitudinal ligament of the spine;	chr12:28363268	chr12:28185625~28186190:-
PRAD	cis	rs10463554	1	rs6596529	ENSG00000175749.11	EIF3KP1	7.96	1.4e-14	6.69e-12	0.44	0.35	Parkinson's disease;	chr5:102981338	chr5:103032376~103033031:+
PRAD	cis	rs10463554	0.963	rs10463555	ENSG00000175749.11	EIF3KP1	7.96	1.4e-14	6.69e-12	0.44	0.35	Parkinson's disease;	chr5:102983333	chr5:103032376~103033031:+
PRAD	cis	rs2581828	0.58	rs9872260	ENSG00000242142.1	SERBP1P3	-7.96	1.4e-14	6.71e-12	-0.41	-0.35	Crohn's disease;	chr3:53136158	chr3:53064283~53065091:-
PRAD	cis	rs11976180	1	rs2961118	ENSG00000170356.8	OR2A20P	-7.96	1.4e-14	6.71e-12	-0.46	-0.35	Obesity-related traits;	chr7:144058350	chr7:144250045~144252957:-
PRAD	cis	rs11976180	1	rs2371244	ENSG00000170356.8	OR2A20P	-7.96	1.4e-14	6.71e-12	-0.46	-0.35	Obesity-related traits;	chr7:144060518	chr7:144250045~144252957:-
PRAD	cis	rs11976180	1	rs4726669	ENSG00000170356.8	OR2A20P	-7.96	1.4e-14	6.71e-12	-0.46	-0.35	Obesity-related traits;	chr7:144061098	chr7:144250045~144252957:-
PRAD	cis	rs193541	0.632	rs400207	ENSG00000263432.2	RN7SL689P	-7.96	1.4e-14	6.72e-12	-0.37	-0.35	Glucose homeostasis traits;	chr5:122982802	chr5:123022487~123022783:-
PRAD	cis	rs1134634	0.52	rs28522268	ENSG00000273133.1	RP11-799M12.2	-7.96	1.4e-14	6.72e-12	-0.47	-0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15601844	chr4:15563698~15564253:-
PRAD	cis	rs6517329	0.649	rs11088338	ENSG00000236830.5	CBR3-AS1	7.96	1.4e-14	6.74e-12	0.37	0.35	Schizophrenia;	chr21:36122719	chr21:36131767~36175815:-
PRAD	cis	rs853679	0.527	rs707907	ENSG00000204709.4	LINC01556	7.96	1.41e-14	6.74e-12	0.45	0.35	Depression;	chr6:28323463	chr6:28943877~28944537:+
PRAD	cis	rs9309473	0.528	rs7573275	ENSG00000163016.8	ALMS1P	7.96	1.41e-14	6.77e-12	0.44	0.35	Metabolite levels;	chr2:73325414	chr2:73644919~73685576:+
PRAD	cis	rs2739330	0.791	rs4822458	ENSG00000228039.3	KB-1125A3.10	7.96	1.41e-14	6.77e-12	0.45	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23963780~23964374:+
PRAD	cis	rs8091660	0.929	rs11082685	ENSG00000278983.1	RP11-426J5.3	7.96	1.42e-14	6.79e-12	0.44	0.35	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48566806	chr18:48564795~48568342:+
PRAD	cis	rs2739330	0.627	rs9608219	ENSG00000228039.3	KB-1125A3.10	7.96	1.42e-14	6.81e-12	0.45	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23963780~23964374:+
PRAD	cis	rs2274273	0.6	rs10131730	ENSG00000258413.1	RP11-665C16.6	-7.96	1.42e-14	6.82e-12	-0.47	-0.35	Protein biomarker;	chr14:55373374	chr14:55262767~55272075:-
PRAD	cis	rs2274273	0.624	rs12050123	ENSG00000258413.1	RP11-665C16.6	-7.96	1.42e-14	6.82e-12	-0.47	-0.35	Protein biomarker;	chr14:55373668	chr14:55262767~55272075:-
PRAD	cis	rs2274273	0.624	rs10132453	ENSG00000258413.1	RP11-665C16.6	-7.96	1.42e-14	6.82e-12	-0.47	-0.35	Protein biomarker;	chr14:55374133	chr14:55262767~55272075:-
PRAD	cis	rs2274273	0.624	rs8014540	ENSG00000258413.1	RP11-665C16.6	-7.96	1.42e-14	6.82e-12	-0.47	-0.35	Protein biomarker;	chr14:55374970	chr14:55262767~55272075:-
PRAD	cis	rs10463554	0.889	rs246908	ENSG00000175749.11	EIF3KP1	7.96	1.43e-14	6.83e-12	0.47	0.35	Parkinson's disease;	chr5:103228476	chr5:103032376~103033031:+
PRAD	cis	rs10463554	0.853	rs246907	ENSG00000175749.11	EIF3KP1	7.96	1.43e-14	6.83e-12	0.47	0.35	Parkinson's disease;	chr5:103230577	chr5:103032376~103033031:+
PRAD	cis	rs11096990	0.634	rs745642	ENSG00000249207.1	RP11-360F5.1	7.96	1.43e-14	6.84e-12	0.36	0.35	Cognitive function;	chr4:39279642	chr4:39112677~39126818:-
PRAD	cis	rs11096990	0.634	rs2086752	ENSG00000249207.1	RP11-360F5.1	7.96	1.43e-14	6.84e-12	0.36	0.35	Cognitive function;	chr4:39280486	chr4:39112677~39126818:-
PRAD	cis	rs11096990	0.594	rs2381373	ENSG00000249207.1	RP11-360F5.1	7.96	1.43e-14	6.84e-12	0.36	0.35	Cognitive function;	chr4:39280683	chr4:39112677~39126818:-
PRAD	cis	rs11096990	0.634	rs6531704	ENSG00000249207.1	RP11-360F5.1	7.96	1.43e-14	6.84e-12	0.36	0.35	Cognitive function;	chr4:39282126	chr4:39112677~39126818:-
PRAD	cis	rs5769707	0.568	rs2011097	ENSG00000188511.11	C22orf34	7.96	1.43e-14	6.85e-12	0.4	0.35	Monocyte percentage of white cells;Monocyte count;	chr22:49624421	chr22:49414524~49657542:-
PRAD	cis	rs1043099	0.912	rs2041199	ENSG00000279699.1	RP1-102K2.9	-7.96	1.43e-14	6.85e-12	-0.54	-0.35	Rheumatoid arthritis;	chr22:30336247	chr22:30275215~30276951:-
PRAD	cis	rs6452524	1	rs10068099	ENSG00000249664.1	CTD-2227C6.2	7.96	1.43e-14	6.86e-12	0.41	0.35	Hypertension (SNP x SNP interaction);	chr5:83161373	chr5:83012285~83013109:-
PRAD	cis	rs10129255	0.5	rs1974468	ENSG00000211972.2	IGHV3-66	7.96	1.43e-14	6.86e-12	0.31	0.35	Kawasaki disease;	chr14:106686149	chr14:106675017~106675544:-
PRAD	cis	rs13631	0.965	rs9411307	ENSG00000268996.3	MAN1B1-AS1	7.96	1.43e-14	6.87e-12	0.35	0.35	Cerebrospinal fluid biomarker levels;	chr9:137100495	chr9:137084946~137086817:-
PRAD	cis	rs526231	0.543	rs34785	ENSG00000175749.11	EIF3KP1	7.96	1.43e-14	6.87e-12	0.48	0.35	Primary biliary cholangitis;	chr5:103122399	chr5:103032376~103033031:+
PRAD	cis	rs526231	0.578	rs34786	ENSG00000175749.11	EIF3KP1	7.96	1.43e-14	6.87e-12	0.48	0.35	Primary biliary cholangitis;	chr5:103122409	chr5:103032376~103033031:+
PRAD	cis	rs526231	0.543	rs34787	ENSG00000175749.11	EIF3KP1	7.96	1.43e-14	6.87e-12	0.48	0.35	Primary biliary cholangitis;	chr5:103123199	chr5:103032376~103033031:+
PRAD	cis	rs526231	0.543	rs34789	ENSG00000175749.11	EIF3KP1	7.96	1.43e-14	6.87e-12	0.48	0.35	Primary biliary cholangitis;	chr5:103125035	chr5:103032376~103033031:+
PRAD	cis	rs526231	0.543	rs34791	ENSG00000175749.11	EIF3KP1	7.96	1.43e-14	6.87e-12	0.48	0.35	Primary biliary cholangitis;	chr5:103126400	chr5:103032376~103033031:+
PRAD	cis	rs526231	0.543	rs26525	ENSG00000175749.11	EIF3KP1	7.96	1.43e-14	6.87e-12	0.48	0.35	Primary biliary cholangitis;	chr5:103129219	chr5:103032376~103033031:+
PRAD	cis	rs526231	0.543	rs32851	ENSG00000175749.11	EIF3KP1	7.96	1.43e-14	6.87e-12	0.48	0.35	Primary biliary cholangitis;	chr5:103132967	chr5:103032376~103033031:+
PRAD	cis	rs8523	0.901	rs2295602	ENSG00000230314.5	ELOVL2-AS1	7.95	1.44e-14	6.88e-12	0.39	0.35	Red blood cell fatty acid levels;	chr6:11005609	chr6:11043524~11078226:+
PRAD	cis	rs6921919	0.583	rs1054372	ENSG00000216901.1	AL022393.7	7.95	1.45e-14	6.92e-12	0.45	0.35	Autism spectrum disorder or schizophrenia;	chr6:28368965	chr6:28176188~28176674:+
PRAD	cis	rs6921919	0.583	rs9468354	ENSG00000216901.1	AL022393.7	7.95	1.45e-14	6.92e-12	0.45	0.35	Autism spectrum disorder or schizophrenia;	chr6:28370024	chr6:28176188~28176674:+
PRAD	cis	rs6921919	0.583	rs7773051	ENSG00000216901.1	AL022393.7	7.95	1.45e-14	6.92e-12	0.45	0.35	Autism spectrum disorder or schizophrenia;	chr6:28372539	chr6:28176188~28176674:+
PRAD	cis	rs6921919	0.583	rs12697938	ENSG00000216901.1	AL022393.7	7.95	1.45e-14	6.92e-12	0.45	0.35	Autism spectrum disorder or schizophrenia;	chr6:28373322	chr6:28176188~28176674:+
PRAD	cis	rs6921919	0.583	rs13437294	ENSG00000216901.1	AL022393.7	7.95	1.45e-14	6.92e-12	0.45	0.35	Autism spectrum disorder or schizophrenia;	chr6:28373758	chr6:28176188~28176674:+
PRAD	cis	rs6921919	0.609	rs9468357	ENSG00000216901.1	AL022393.7	7.95	1.45e-14	6.92e-12	0.45	0.35	Autism spectrum disorder or schizophrenia;	chr6:28374276	chr6:28176188~28176674:+
PRAD	cis	rs6921919	0.583	rs34513104	ENSG00000216901.1	AL022393.7	7.95	1.45e-14	6.92e-12	0.45	0.35	Autism spectrum disorder or schizophrenia;	chr6:28375566	chr6:28176188~28176674:+
PRAD	cis	rs6921919	0.583	rs9461456	ENSG00000216901.1	AL022393.7	7.95	1.45e-14	6.92e-12	0.45	0.35	Autism spectrum disorder or schizophrenia;	chr6:28376039	chr6:28176188~28176674:+
PRAD	cis	rs6921919	0.525	rs9468360	ENSG00000216901.1	AL022393.7	7.95	1.45e-14	6.92e-12	0.45	0.35	Autism spectrum disorder or schizophrenia;	chr6:28376661	chr6:28176188~28176674:+
PRAD	cis	rs6921919	0.583	rs16894021	ENSG00000216901.1	AL022393.7	7.95	1.45e-14	6.92e-12	0.45	0.35	Autism spectrum disorder or schizophrenia;	chr6:28377249	chr6:28176188~28176674:+
PRAD	cis	rs6921919	0.583	rs11751693	ENSG00000216901.1	AL022393.7	7.95	1.45e-14	6.92e-12	0.45	0.35	Autism spectrum disorder or schizophrenia;	chr6:28377306	chr6:28176188~28176674:+
PRAD	cis	rs6921919	0.583	rs7749736	ENSG00000216901.1	AL022393.7	7.95	1.45e-14	6.92e-12	0.45	0.35	Autism spectrum disorder or schizophrenia;	chr6:28378254	chr6:28176188~28176674:+
PRAD	cis	rs6921919	0.525	rs9468361	ENSG00000216901.1	AL022393.7	7.95	1.45e-14	6.92e-12	0.45	0.35	Autism spectrum disorder or schizophrenia;	chr6:28378541	chr6:28176188~28176674:+
PRAD	cis	rs6921919	0.583	rs7775132	ENSG00000216901.1	AL022393.7	7.95	1.45e-14	6.92e-12	0.45	0.35	Autism spectrum disorder or schizophrenia;	chr6:28379236	chr6:28176188~28176674:+
PRAD	cis	rs12468226	1	rs6739198	ENSG00000273456.1	RP11-686O6.2	7.95	1.45e-14	6.93e-12	0.43	0.35	Urate levels;	chr2:202492273	chr2:202374932~202375604:-
PRAD	cis	rs12468226	1	rs7565875	ENSG00000273456.1	RP11-686O6.2	7.95	1.45e-14	6.93e-12	0.43	0.35	Urate levels;	chr2:202516412	chr2:202374932~202375604:-
PRAD	cis	rs8523	0.901	rs9295752	ENSG00000230314.5	ELOVL2-AS1	7.95	1.45e-14	6.95e-12	0.39	0.35	Red blood cell fatty acid levels;	chr6:11010567	chr6:11043524~11078226:+
PRAD	cis	rs8523	0.901	rs953413	ENSG00000230314.5	ELOVL2-AS1	7.95	1.45e-14	6.95e-12	0.39	0.35	Red blood cell fatty acid levels;	chr6:11012626	chr6:11043524~11078226:+
PRAD	cis	rs375066	0.935	rs384329	ENSG00000267058.1	RP11-15A1.3	-7.95	1.45e-14	6.96e-12	-0.29	-0.35	Breast cancer;	chr19:43919829	chr19:43891804~43901805:-
PRAD	cis	rs12908161	1	rs35960805	ENSG00000259728.4	LINC00933	7.95	1.46e-14	6.97e-12	0.43	0.35	Schizophrenia;	chr15:84800749	chr15:84570649~84580175:+
PRAD	cis	rs12908161	1	rs12912388	ENSG00000259728.4	LINC00933	7.95	1.46e-14	6.97e-12	0.43	0.35	Schizophrenia;	chr15:84801319	chr15:84570649~84580175:+
PRAD	cis	rs4664293	1	rs11676412	ENSG00000226266.5	AC009961.3	-7.95	1.46e-14	6.99e-12	-0.46	-0.35	Monocyte percentage of white cells;	chr2:159651560	chr2:159670708~159712435:-
PRAD	cis	rs853679	0.527	rs9468333	ENSG00000204709.4	LINC01556	7.95	1.46e-14	7.01e-12	0.45	0.35	Depression;	chr6:28303421	chr6:28943877~28944537:+
PRAD	cis	rs11096990	0.634	rs746678	ENSG00000249207.1	RP11-360F5.1	7.95	1.46e-14	7.01e-12	0.36	0.35	Cognitive function;	chr4:39279035	chr4:39112677~39126818:-
PRAD	cis	rs4927850	1	rs4927704	ENSG00000207650.1	MIR570	7.95	1.47e-14	7.02e-12	0.38	0.35	Pancreatic cancer;	chr3:196011357	chr3:195699401~195699497:+
PRAD	cis	rs4927850	1	rs4927848	ENSG00000207650.1	MIR570	7.95	1.47e-14	7.02e-12	0.38	0.35	Pancreatic cancer;	chr3:196011535	chr3:195699401~195699497:+
PRAD	cis	rs1134634	0.52	rs28661857	ENSG00000273133.1	RP11-799M12.2	-7.95	1.47e-14	7.02e-12	-0.47	-0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15589842	chr4:15563698~15564253:-
PRAD	cis	rs4713118	0.629	rs149899	ENSG00000272009.1	RP1-313I6.12	-7.95	1.47e-14	7.05e-12	-0.36	-0.35	Parkinson's disease;	chr6:28052201	chr6:28078792~28081130:-
PRAD	cis	rs4713118	0.629	rs172165	ENSG00000272009.1	RP1-313I6.12	-7.95	1.47e-14	7.05e-12	-0.36	-0.35	Parkinson's disease;	chr6:28053036	chr6:28078792~28081130:-
PRAD	cis	rs4713118	0.597	rs172166	ENSG00000272009.1	RP1-313I6.12	-7.95	1.47e-14	7.05e-12	-0.36	-0.35	Parkinson's disease;	chr6:28053042	chr6:28078792~28081130:-
PRAD	cis	rs673078	0.607	rs17512644	ENSG00000275409.1	RP11-131L12.4	-7.95	1.47e-14	7.05e-12	-0.5	-0.35	Glucose homeostasis traits;	chr12:118359963	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.607	rs17512652	ENSG00000275409.1	RP11-131L12.4	-7.95	1.47e-14	7.05e-12	-0.5	-0.35	Glucose homeostasis traits;	chr12:118361278	chr12:118430147~118430699:+
PRAD	cis	rs4266144	0.569	rs729257	ENSG00000244515.1	KRT18P34	-7.95	1.48e-14	7.06e-12	-0.4	-0.35	Coronary artery disease;	chr3:157111034	chr3:157162663~157163932:-
PRAD	cis	rs6921919	0.583	rs7764722	ENSG00000216901.1	AL022393.7	7.95	1.48e-14	7.1e-12	0.45	0.35	Autism spectrum disorder or schizophrenia;	chr6:28386756	chr6:28176188~28176674:+
PRAD	cis	rs11976180	1	rs2951372	ENSG00000273234.1	OR2A13P	-7.95	1.48e-14	7.1e-12	-0.42	-0.35	Obesity-related traits;	chr7:144052410	chr7:144142009~144142938:+
PRAD	cis	rs11976180	1	rs2951368	ENSG00000273234.1	OR2A13P	-7.95	1.48e-14	7.1e-12	-0.42	-0.35	Obesity-related traits;	chr7:144055728	chr7:144142009~144142938:+
PRAD	cis	rs11976180	1	rs2961115	ENSG00000273234.1	OR2A13P	-7.95	1.48e-14	7.1e-12	-0.42	-0.35	Obesity-related traits;	chr7:144056278	chr7:144142009~144142938:+
PRAD	cis	rs950169	0.579	rs12912716	ENSG00000225151.9	GOLGA2P7	-7.95	1.49e-14	7.11e-12	-0.51	-0.35	Schizophrenia;	chr15:83995511	chr15:84199311~84230136:-
PRAD	cis	rs950169	0.579	rs12913054	ENSG00000225151.9	GOLGA2P7	-7.95	1.49e-14	7.11e-12	-0.51	-0.35	Schizophrenia;	chr15:83995704	chr15:84199311~84230136:-
PRAD	cis	rs4927850	0.958	rs2044599	ENSG00000207650.1	MIR570	7.95	1.49e-14	7.11e-12	0.38	0.35	Pancreatic cancer;	chr3:196009869	chr3:195699401~195699497:+
PRAD	cis	rs7829975	0.606	rs10112585	ENSG00000253893.2	FAM85B	7.95	1.49e-14	7.12e-12	0.43	0.35	Mood instability;	chr8:8937520	chr8:8167819~8226614:-
PRAD	cis	rs4631830	0.965	rs4306255	ENSG00000230869.1	CTGLF10P	-7.95	1.49e-14	7.14e-12	-0.44	-0.35	Prostate-specific antigen levels;	chr10:46053378	chr10:45678692~45700532:+
PRAD	cis	rs6061231	0.755	rs11699160	ENSG00000273619.1	RP5-908M14.9	-7.95	1.49e-14	7.14e-12	-0.22	-0.35	Colorectal cancer;	chr20:62383595	chr20:62386303~62386970:-
PRAD	cis	rs10022462	0.933	rs10516806	ENSG00000246375.2	RP11-10L7.1	7.95	1.5e-14	7.16e-12	0.37	0.35	Breast cancer;Blood metabolite levels;	chr4:88325062	chr4:88284942~88331421:+
PRAD	cis	rs9467773	0.595	rs13207371	ENSG00000241549.7	GUSBP2	7.95	1.5e-14	7.17e-12	0.38	0.35	Intelligence (multi-trait analysis);	chr6:26590846	chr6:26871484~26956554:-
PRAD	cis	rs1061377	0.965	rs3733275	ENSG00000249685.1	RP11-360F5.3	7.95	1.5e-14	7.18e-12	0.39	0.35	Uric acid levels;	chr4:39121077	chr4:39133913~39135608:+
PRAD	cis	rs6545883	0.507	rs4411680	ENSG00000271889.1	RP11-493E12.1	-7.95	1.5e-14	7.18e-12	-0.38	-0.35	Tuberculosis;	chr2:61356970	chr2:61151433~61162105:-
PRAD	cis	rs2015599	0.54	rs12301475	ENSG00000275476.1	RP11-996F15.4	7.95	1.5e-14	7.19e-12	0.38	0.35	Platelet count;Mean platelet volume;	chr12:29253144	chr12:29277397~29277882:-
PRAD	cis	rs17428076	0.836	rs3770455	ENSG00000228389.1	AC068039.4	-7.95	1.51e-14	7.19e-12	-0.45	-0.35	Myopia;	chr2:171811385	chr2:171773482~171775844:+
PRAD	cis	rs2015599	0.514	rs10843376	ENSG00000275476.1	RP11-996F15.4	7.95	1.51e-14	7.2e-12	0.38	0.35	Platelet count;Mean platelet volume;	chr12:29283651	chr12:29277397~29277882:-
PRAD	cis	rs2439831	0.702	rs2467402	ENSG00000205771.5	CATSPER2P1	7.95	1.51e-14	7.22e-12	0.51	0.35	Lung cancer in ever smokers;	chr15:43732292	chr15:43726918~43747094:-
PRAD	cis	rs4664293	0.934	rs4380179	ENSG00000226266.5	AC009961.3	-7.95	1.52e-14	7.25e-12	-0.45	-0.35	Monocyte percentage of white cells;	chr2:159685064	chr2:159670708~159712435:-
PRAD	cis	rs4664293	0.967	rs10803758	ENSG00000226266.5	AC009961.3	-7.95	1.52e-14	7.25e-12	-0.45	-0.35	Monocyte percentage of white cells;	chr2:159691708	chr2:159670708~159712435:-
PRAD	cis	rs67311347	1	rs1119179	ENSG00000223797.4	ENTPD3-AS1	-7.95	1.52e-14	7.25e-12	-0.32	-0.35	Renal cell carcinoma;	chr3:40383438	chr3:40313802~40453329:-
PRAD	cis	rs4664293	1	rs10184034	ENSG00000226266.5	AC009961.3	-7.95	1.52e-14	7.27e-12	-0.46	-0.35	Monocyte percentage of white cells;	chr2:159648916	chr2:159670708~159712435:-
PRAD	cis	rs4664293	1	rs4664293	ENSG00000226266.5	AC009961.3	-7.95	1.52e-14	7.27e-12	-0.46	-0.35	Monocyte percentage of white cells;	chr2:159649241	chr2:159670708~159712435:-
PRAD	cis	rs4664293	1	rs10193402	ENSG00000226266.5	AC009961.3	-7.95	1.52e-14	7.27e-12	-0.46	-0.35	Monocyte percentage of white cells;	chr2:159651271	chr2:159670708~159712435:-
PRAD	cis	rs950169	0.58	rs11634320	ENSG00000275120.1	RP11-182J1.17	-7.95	1.52e-14	7.28e-12	-0.44	-0.35	Schizophrenia;	chr15:84628952	chr15:84599434~84606463:-
PRAD	cis	rs61774743	0.557	rs4359027	ENSG00000229901.1	RP11-399E6.4	-7.95	1.53e-14	7.29e-12	-0.33	-0.35	Intelligence (multi-trait analysis);	chr1:41382624	chr1:41375004~41375669:-
PRAD	cis	rs12928939	0.815	rs7185575	ENSG00000260886.1	TAT-AS1	7.95	1.53e-14	7.29e-12	0.48	0.35	Post bronchodilator FEV1;	chr16:71638666	chr16:71565789~71578187:+
PRAD	cis	rs7923609	1	rs10822163	ENSG00000232075.1	MRPL35P2	-7.95	1.53e-14	7.31e-12	-0.37	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63364338	chr10:63634317~63634827:-
PRAD	cis	rs7923609	0.967	rs6479896	ENSG00000232075.1	MRPL35P2	-7.95	1.53e-14	7.31e-12	-0.37	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63367072	chr10:63634317~63634827:-
PRAD	cis	rs10761750	1	rs10761750	ENSG00000232075.1	MRPL35P2	-7.95	1.53e-14	7.31e-12	-0.37	-0.35	Vascular endothelial growth factor levels;	chr10:63368859	chr10:63634317~63634827:-
PRAD	cis	rs950169	0.58	rs11634322	ENSG00000275120.1	RP11-182J1.17	7.95	1.53e-14	7.33e-12	0.45	0.35	Schizophrenia;	chr15:84628978	chr15:84599434~84606463:-
PRAD	cis	rs950169	0.58	rs11636189	ENSG00000275120.1	RP11-182J1.17	7.95	1.53e-14	7.33e-12	0.45	0.35	Schizophrenia;	chr15:84650323	chr15:84599434~84606463:-
PRAD	cis	rs950169	0.58	rs35516100	ENSG00000275120.1	RP11-182J1.17	7.95	1.53e-14	7.33e-12	0.45	0.35	Schizophrenia;	chr15:84652199	chr15:84599434~84606463:-
PRAD	cis	rs950169	0.58	rs62021208	ENSG00000275120.1	RP11-182J1.17	7.95	1.53e-14	7.33e-12	0.45	0.35	Schizophrenia;	chr15:84653013	chr15:84599434~84606463:-
PRAD	cis	rs11976180	1	rs11976037	ENSG00000170356.8	OR2A20P	-7.94	1.54e-14	7.35e-12	-0.47	-0.35	Obesity-related traits;	chr7:144043931	chr7:144250045~144252957:-
PRAD	cis	rs6061231	0.631	rs2427318	ENSG00000273619.1	RP5-908M14.9	-7.94	1.54e-14	7.35e-12	-0.22	-0.35	Colorectal cancer;	chr20:62400671	chr20:62386303~62386970:-
PRAD	cis	rs12653946	0.846	rs10866528	ENSG00000249116.1	CTD-2194D22.3	-7.94	1.54e-14	7.36e-12	-0.41	-0.35	Prostate cancer;	chr5:1891707	chr5:1883966~1884649:+
PRAD	cis	rs11951515	0.626	rs10805671	ENSG00000188850.9	RP11-159F24.2	7.94	1.54e-14	7.36e-12	0.43	0.35	Metabolite levels  (X-11787);	chr5:43271445	chr5:43336164~43348716:+
PRAD	cis	rs7665147	1	rs7665147	ENSG00000269949.1	RP11-738E22.3	7.94	1.55e-14	7.42e-12	0.5	0.35	Platelet count;	chr4:56901161	chr4:56960927~56961373:-
PRAD	cis	rs1979679	0.918	rs1586868	ENSG00000278733.1	RP11-425D17.1	7.94	1.56e-14	7.44e-12	0.45	0.35	Ossification of the posterior longitudinal ligament of the spine;	chr12:28368176	chr12:28185625~28186190:-
PRAD	cis	rs6452524	1	rs67683443	ENSG00000249664.1	CTD-2227C6.2	7.94	1.56e-14	7.44e-12	0.41	0.35	Hypertension (SNP x SNP interaction);	chr5:83167884	chr5:83012285~83013109:-
PRAD	cis	rs1061377	1	rs9998867	ENSG00000249685.1	RP11-360F5.3	7.94	1.57e-14	7.46e-12	0.39	0.35	Uric acid levels;	chr4:39117542	chr4:39133913~39135608:+
PRAD	cis	rs1061377	1	rs2381284	ENSG00000249685.1	RP11-360F5.3	7.94	1.57e-14	7.46e-12	0.39	0.35	Uric acid levels;	chr4:39117976	chr4:39133913~39135608:+
PRAD	cis	rs1134634	0.52	rs10034328	ENSG00000273133.1	RP11-799M12.2	-7.94	1.57e-14	7.48e-12	-0.47	-0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15616764	chr4:15563698~15564253:-
PRAD	cis	rs12612619	0.732	rs11681562	ENSG00000272148.1	RP11-195B17.1	7.94	1.57e-14	7.5e-12	0.42	0.35	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27027735	chr2:27062428~27062907:-
PRAD	cis	rs2564921	0.513	rs12638195	ENSG00000242142.1	SERBP1P3	-7.94	1.57e-14	7.5e-12	-0.41	-0.35	Height;	chr3:52842623	chr3:53064283~53065091:-
PRAD	cis	rs193541	0.564	rs407230	ENSG00000263432.2	RN7SL689P	-7.94	1.57e-14	7.5e-12	-0.37	-0.35	Glucose homeostasis traits;	chr5:123010032	chr5:123022487~123022783:-
PRAD	cis	rs881375	0.654	rs10760126	ENSG00000226752.6	PSMD5-AS1	-7.94	1.58e-14	7.53e-12	-0.41	-0.35	Rheumatoid arthritis;	chr9:120900340	chr9:120824828~120854385:+
PRAD	cis	rs881375	0.678	rs7031752	ENSG00000226752.6	PSMD5-AS1	-7.94	1.58e-14	7.53e-12	-0.41	-0.35	Rheumatoid arthritis;	chr9:120901204	chr9:120824828~120854385:+
PRAD	cis	rs881375	0.678	rs4836834	ENSG00000226752.6	PSMD5-AS1	-7.94	1.58e-14	7.53e-12	-0.41	-0.35	Rheumatoid arthritis;	chr9:120903623	chr9:120824828~120854385:+
PRAD	cis	rs10463554	0.963	rs28301	ENSG00000175749.11	EIF3KP1	7.94	1.58e-14	7.54e-12	0.46	0.35	Parkinson's disease;	chr5:103105778	chr5:103032376~103033031:+
PRAD	cis	rs10463554	0.963	rs34828	ENSG00000175749.11	EIF3KP1	7.94	1.58e-14	7.54e-12	0.46	0.35	Parkinson's disease;	chr5:103107209	chr5:103032376~103033031:+
PRAD	cis	rs10875746	0.669	rs17122812	ENSG00000240399.1	RP1-228P16.1	-7.94	1.58e-14	7.54e-12	-0.34	-0.35	Longevity (90 years and older);	chr12:48203270	chr12:48054813~48055591:-
PRAD	cis	rs8177376	0.906	rs487450	ENSG00000254905.1	RP11-712L6.7	7.94	1.58e-14	7.54e-12	0.47	0.35	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126188474	chr11:126292922~126294254:-
PRAD	cis	rs2348418	0.67	rs1824919	ENSG00000247934.4	RP11-967K21.1	-7.94	1.59e-14	7.58e-12	-0.33	-0.35	Lung function (FEV1);Lung function (FVC);	chr12:28118449	chr12:28163298~28190738:-
PRAD	cis	rs2348418	0.67	rs899504	ENSG00000247934.4	RP11-967K21.1	-7.94	1.59e-14	7.58e-12	-0.33	-0.35	Lung function (FEV1);Lung function (FVC);	chr12:28118723	chr12:28163298~28190738:-
PRAD	cis	rs10463554	1	rs3776864	ENSG00000175749.11	EIF3KP1	7.94	1.59e-14	7.59e-12	0.46	0.35	Parkinson's disease;	chr5:102992164	chr5:103032376~103033031:+
PRAD	cis	rs950169	0.545	rs4842841	ENSG00000225151.9	GOLGA2P7	-7.94	1.59e-14	7.59e-12	-0.51	-0.35	Schizophrenia;	chr15:83972373	chr15:84199311~84230136:-
PRAD	cis	rs73186030	0.546	rs55857899	ENSG00000272758.4	RP11-299J3.8	7.94	1.59e-14	7.59e-12	0.48	0.35	Serum parathyroid hormone levels;	chr3:122390705	chr3:122416207~122443180:+
PRAD	cis	rs73186030	0.546	rs73188320	ENSG00000272758.4	RP11-299J3.8	7.94	1.59e-14	7.59e-12	0.48	0.35	Serum parathyroid hormone levels;	chr3:122391694	chr3:122416207~122443180:+
PRAD	cis	rs73186030	0.546	rs73188327	ENSG00000272758.4	RP11-299J3.8	7.94	1.59e-14	7.59e-12	0.48	0.35	Serum parathyroid hormone levels;	chr3:122394819	chr3:122416207~122443180:+
PRAD	cis	rs7829975	0.623	rs10087493	ENSG00000253893.2	FAM85B	7.94	1.59e-14	7.59e-12	0.42	0.35	Mood instability;	chr8:8516047	chr8:8167819~8226614:-
PRAD	cis	rs9467773	0.572	rs62394558	ENSG00000241549.7	GUSBP2	7.94	1.6e-14	7.61e-12	0.38	0.35	Intelligence (multi-trait analysis);	chr6:26604422	chr6:26871484~26956554:-
PRAD	cis	rs673078	0.607	rs61944661	ENSG00000275409.1	RP11-131L12.4	-7.94	1.6e-14	7.62e-12	-0.5	-0.35	Glucose homeostasis traits;	chr12:118445514	chr12:118430147~118430699:+
PRAD	cis	rs9532669	0.963	rs4942012	ENSG00000168852.11	TPTE2P5	7.94	1.61e-14	7.65e-12	0.33	0.35	Cervical cancer;	chr13:40939112	chr13:40822296~40921749:-
PRAD	cis	rs6452524	0.806	rs10078084	ENSG00000249664.1	CTD-2227C6.2	7.94	1.61e-14	7.65e-12	0.42	0.35	Hypertension (SNP x SNP interaction);	chr5:83106588	chr5:83012285~83013109:-
PRAD	cis	rs6452524	0.868	rs11750836	ENSG00000249664.1	CTD-2227C6.2	7.94	1.61e-14	7.65e-12	0.42	0.35	Hypertension (SNP x SNP interaction);	chr5:83107368	chr5:83012285~83013109:-
PRAD	cis	rs950169	0.58	rs11633762	ENSG00000275120.1	RP11-182J1.17	7.94	1.61e-14	7.66e-12	0.45	0.35	Schizophrenia;	chr15:84643921	chr15:84599434~84606463:-
PRAD	cis	rs17428076	0.514	rs3821095	ENSG00000228389.1	AC068039.4	7.94	1.61e-14	7.67e-12	0.39	0.35	Myopia;	chr2:171827496	chr2:171773482~171775844:+
PRAD	cis	rs6539288	0.865	rs2888893	ENSG00000260329.1	RP11-412D9.4	-7.94	1.61e-14	7.68e-12	-0.31	-0.35	Total body bone mineral density;	chr12:106944853	chr12:106954029~106955497:-
PRAD	cis	rs7923609	0.967	rs7095571	ENSG00000232075.1	MRPL35P2	-7.94	1.61e-14	7.68e-12	-0.37	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63391199	chr10:63634317~63634827:-
PRAD	cis	rs12594515	0.591	rs35554150	ENSG00000273972.1	CTD-2306A12.1	-7.94	1.62e-14	7.69e-12	-0.41	-0.35	Weight;Waist circumference;	chr15:45698100	chr15:45702640~45703183:+
PRAD	cis	rs7923609	1	rs10822161	ENSG00000232075.1	MRPL35P2	-7.94	1.62e-14	7.7e-12	-0.37	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63358443	chr10:63634317~63634827:-
PRAD	cis	rs6674176	0.569	rs34830883	ENSG00000237950.1	RP11-7O11.3	7.94	1.62e-14	7.73e-12	0.41	0.35	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43939667	chr1:43944370~43946551:-
PRAD	cis	rs12928939	0.859	rs11670	ENSG00000260886.1	TAT-AS1	7.94	1.63e-14	7.76e-12	0.49	0.35	Post bronchodilator FEV1;	chr16:71645124	chr16:71565789~71578187:+
PRAD	cis	rs7432375	0.966	rs7618871	ENSG00000261758.1	RP11-102M11.2	-7.94	1.63e-14	7.78e-12	-0.4	-0.35	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136681578	chr3:136752630~136755780:+
PRAD	cis	rs6782228	0.606	rs2712404	ENSG00000242551.2	POU5F1P6	7.94	1.64e-14	7.8e-12	0.44	0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128613836	chr3:128674735~128677005:-
PRAD	cis	rs3096299	0.967	rs2911255	ENSG00000261118.1	RP11-104N10.1	7.94	1.64e-14	7.81e-12	0.35	0.35	Multiple myeloma (IgH translocation);	chr16:89420729	chr16:89492017~89504460:-
PRAD	cis	rs11096990	0.656	rs2123028	ENSG00000249207.1	RP11-360F5.1	7.94	1.64e-14	7.81e-12	0.36	0.35	Cognitive function;	chr4:39301859	chr4:39112677~39126818:-
PRAD	cis	rs17711722	0.523	rs313812	ENSG00000164669.11	INTS4P1	7.94	1.64e-14	7.82e-12	0.44	0.35	Calcium levels;	chr7:66040056	chr7:65141225~65234216:+
PRAD	cis	rs4631830	0.863	rs3123078	ENSG00000230869.1	CTGLF10P	7.94	1.64e-14	7.82e-12	0.42	0.35	Prostate-specific antigen levels;	chr10:46070851	chr10:45678692~45700532:+
PRAD	cis	rs1912483	0.545	rs35161461	ENSG00000228782.6	CTD-2026D20.3	7.94	1.65e-14	7.84e-12	0.43	0.35	Coronary artery disease;	chr17:47324391	chr17:47450568~47492492:-
PRAD	cis	rs67311347	0.544	rs13097602	ENSG00000223797.4	ENTPD3-AS1	-7.93	1.66e-14	7.88e-12	-0.31	-0.35	Renal cell carcinoma;	chr3:40297756	chr3:40313802~40453329:-
PRAD	cis	rs2581828	0.58	rs6799837	ENSG00000242142.1	SERBP1P3	-7.93	1.66e-14	7.88e-12	-0.41	-0.35	Crohn's disease;	chr3:53133838	chr3:53064283~53065091:-
PRAD	cis	rs2581828	0.58	rs57514626	ENSG00000242142.1	SERBP1P3	-7.93	1.66e-14	7.88e-12	-0.41	-0.35	Crohn's disease;	chr3:53135286	chr3:53064283~53065091:-
PRAD	cis	rs2581828	0.58	rs61296683	ENSG00000242142.1	SERBP1P3	-7.93	1.66e-14	7.88e-12	-0.41	-0.35	Crohn's disease;	chr3:53135307	chr3:53064283~53065091:-
PRAD	cis	rs2581828	0.58	rs9867590	ENSG00000242142.1	SERBP1P3	-7.93	1.66e-14	7.88e-12	-0.41	-0.35	Crohn's disease;	chr3:53135635	chr3:53064283~53065091:-
PRAD	cis	rs2581828	0.58	rs9834111	ENSG00000242142.1	SERBP1P3	-7.93	1.66e-14	7.88e-12	-0.41	-0.35	Crohn's disease;	chr3:53136028	chr3:53064283~53065091:-
PRAD	cis	rs2581828	0.58	rs9817467	ENSG00000242142.1	SERBP1P3	-7.93	1.66e-14	7.88e-12	-0.41	-0.35	Crohn's disease;	chr3:53136609	chr3:53064283~53065091:-
PRAD	cis	rs2581828	0.58	rs9845021	ENSG00000242142.1	SERBP1P3	-7.93	1.66e-14	7.88e-12	-0.41	-0.35	Crohn's disease;	chr3:53138096	chr3:53064283~53065091:-
PRAD	cis	rs4713118	0.513	rs2294480	ENSG00000216901.1	AL022393.7	7.93	1.66e-14	7.89e-12	0.45	0.35	Parkinson's disease;	chr6:27616182	chr6:28176188~28176674:+
PRAD	cis	rs853679	1	rs853679	ENSG00000280107.1	AL022393.9	-7.93	1.66e-14	7.91e-12	-0.52	-0.35	Depression;	chr6:28329086	chr6:28170845~28172521:+
PRAD	cis	rs853679	1	rs853678	ENSG00000280107.1	AL022393.9	-7.93	1.66e-14	7.91e-12	-0.52	-0.35	Depression;	chr6:28329536	chr6:28170845~28172521:+
PRAD	cis	rs801193	0.844	rs2244022	ENSG00000237310.1	GS1-124K5.4	7.93	1.66e-14	7.91e-12	0.31	0.35	Aortic root size;	chr7:66737443	chr7:66493706~66495474:+
PRAD	cis	rs12594515	0.548	rs12912226	ENSG00000273972.1	CTD-2306A12.1	-7.93	1.66e-14	7.91e-12	-0.41	-0.35	Weight;Waist circumference;	chr15:45693510	chr15:45702640~45703183:+
PRAD	cis	rs2617170	0.922	rs2733852	ENSG00000245648.1	RP11-277P12.20	-7.93	1.66e-14	7.92e-12	-0.43	-0.35	Behcet's disease;	chr12:10375969	chr12:10363769~10398506:+
PRAD	cis	rs7181230	0.922	rs4924410	ENSG00000275636.1	RP11-521C20.5	-7.93	1.67e-14	7.93e-12	-0.49	-0.35	Dehydroepiandrosterone sulphate levels;	chr15:40047293	chr15:40078892~40079347:+
PRAD	cis	rs7739264	0.544	rs7750533	ENSG00000228412.5	RP4-625H18.2	7.93	1.67e-14	7.93e-12	0.42	0.35	Endometriosis;	chr6:19804565	chr6:19802164~19804752:-
PRAD	cis	rs17012589	0.639	rs12810608	ENSG00000258815.1	RP11-408B11.2	7.93	1.68e-14	7.98e-12	0.48	0.35	Bone mineral density (Ward's triangle area);	chr12:85280929	chr12:85318060~85342912:+
PRAD	cis	rs11159086	1	rs4903232	ENSG00000259005.1	RP3-449M8.6	7.93	1.68e-14	7.98e-12	0.47	0.35	Advanced glycation end-product levels;	chr14:74496585	chr14:74474007~74474864:-
PRAD	cis	rs9467773	0.572	rs13213953	ENSG00000241549.7	GUSBP2	7.93	1.68e-14	8e-12	0.38	0.35	Intelligence (multi-trait analysis);	chr6:26594306	chr6:26871484~26956554:-
PRAD	cis	rs4927850	1	rs4927850	ENSG00000207650.1	MIR570	-7.93	1.69e-14	8.03e-12	-0.37	-0.35	Pancreatic cancer;	chr3:196024759	chr3:195699401~195699497:+
PRAD	cis	rs4664293	0.934	rs7604482	ENSG00000226266.5	AC009961.3	-7.93	1.69e-14	8.04e-12	-0.45	-0.35	Monocyte percentage of white cells;	chr2:159657315	chr2:159670708~159712435:-
PRAD	cis	rs4664293	0.967	rs10176436	ENSG00000226266.5	AC009961.3	-7.93	1.69e-14	8.04e-12	-0.45	-0.35	Monocyte percentage of white cells;	chr2:159658883	chr2:159670708~159712435:-
PRAD	cis	rs4664293	0.967	rs7559127	ENSG00000226266.5	AC009961.3	-7.93	1.69e-14	8.04e-12	-0.45	-0.35	Monocyte percentage of white cells;	chr2:159659424	chr2:159670708~159712435:-
PRAD	cis	rs6751744	0.514	rs12386214	ENSG00000226266.5	AC009961.3	-7.93	1.69e-14	8.04e-12	-0.45	-0.35	Dysphagia;	chr2:159675012	chr2:159670708~159712435:-
PRAD	cis	rs4664293	0.932	rs4665104	ENSG00000226266.5	AC009961.3	-7.93	1.69e-14	8.04e-12	-0.45	-0.35	Monocyte percentage of white cells;	chr2:159675847	chr2:159670708~159712435:-
PRAD	cis	rs4664293	0.967	rs7595639	ENSG00000226266.5	AC009961.3	-7.93	1.69e-14	8.04e-12	-0.45	-0.35	Monocyte percentage of white cells;	chr2:159676533	chr2:159670708~159712435:-
PRAD	cis	rs17711722	0.565	rs4275112	ENSG00000224316.1	RP11-479O9.2	-7.93	1.69e-14	8.04e-12	-0.32	-0.35	Calcium levels;	chr7:65733651	chr7:65773620~65802067:+
PRAD	cis	rs7923609	0.936	rs10761779	ENSG00000232075.1	MRPL35P2	-7.93	1.69e-14	8.04e-12	-0.37	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63515167	chr10:63634317~63634827:-
PRAD	cis	rs964611	0.882	rs66823218	ENSG00000259488.2	RP11-154J22.1	-7.93	1.69e-14	8.06e-12	-0.33	-0.35	Metabolite levels (Pyroglutamine);	chr15:48299886	chr15:48312353~48331856:-
PRAD	cis	rs8040855	0.894	rs6496770	ENSG00000259295.5	CSPG4P12	-7.93	1.7e-14	8.06e-12	-0.46	-0.35	Bulimia nervosa;	chr15:85161890	chr15:85191438~85213905:+
PRAD	cis	rs526231	0.543	rs34379	ENSG00000175749.11	EIF3KP1	-7.93	1.7e-14	8.07e-12	-0.47	-0.35	Primary biliary cholangitis;	chr5:103062994	chr5:103032376~103033031:+
PRAD	cis	rs6847067	0.794	rs9790649	ENSG00000180769.7	WDFY3-AS2	7.93	1.7e-14	8.08e-12	0.37	0.35	Oropharynx cancer;	chr4:85032830	chr4:84965682~85011277:+
PRAD	cis	rs62355900	0.627	rs9292123	ENSG00000271828.1	CTD-2310F14.1	7.93	1.7e-14	8.08e-12	0.68	0.35	Endometriosis;	chr5:56807982	chr5:56927874~56929573:+
PRAD	cis	rs1930961	1	rs7285549	ENSG00000271138.1	IGLVIVOR22-1	-7.93	1.7e-14	8.09e-12	-0.53	-0.35	Bipolar disorder with mood-incongruent psychosis;	chr22:25478613	chr22:25437306~25437823:-
PRAD	cis	rs1930961	1	rs5996946	ENSG00000271138.1	IGLVIVOR22-1	-7.93	1.7e-14	8.09e-12	-0.53	-0.35	Bipolar disorder with mood-incongruent psychosis;	chr22:25480021	chr22:25437306~25437823:-
PRAD	cis	rs1930961	1	rs997873	ENSG00000271138.1	IGLVIVOR22-1	-7.93	1.7e-14	8.09e-12	-0.53	-0.35	Bipolar disorder with mood-incongruent psychosis;	chr22:25482315	chr22:25437306~25437823:-
PRAD	cis	rs6061231	0.631	rs2427310	ENSG00000273619.1	RP5-908M14.9	-7.93	1.71e-14	8.1e-12	-0.22	-0.35	Colorectal cancer;	chr20:62394873	chr20:62386303~62386970:-
PRAD	cis	rs13113518	0.595	rs13120635	ENSG00000249700.7	SRD5A3-AS1	7.93	1.71e-14	8.11e-12	0.48	0.35	Height;	chr4:55361200	chr4:55363971~55395847:-
PRAD	cis	rs964611	1	rs1820492	ENSG00000259488.2	RP11-154J22.1	7.93	1.71e-14	8.12e-12	0.33	0.35	Metabolite levels (Pyroglutamine);	chr15:48311230	chr15:48312353~48331856:-
PRAD	cis	rs6517329	0.61	rs11088339	ENSG00000236830.5	CBR3-AS1	7.93	1.71e-14	8.13e-12	0.37	0.35	Schizophrenia;	chr21:36126696	chr21:36131767~36175815:-
PRAD	cis	rs1426063	1	rs10029141	ENSG00000249717.1	RP11-44F21.3	7.93	1.72e-14	8.15e-12	0.61	0.35	QT interval;	chr4:75097437	chr4:74955974~74970362:-
PRAD	cis	rs673078	0.607	rs17441172	ENSG00000275409.1	RP11-131L12.4	7.93	1.73e-14	8.21e-12	0.5	0.35	Glucose homeostasis traits;	chr12:118430456	chr12:118430147~118430699:+
PRAD	cis	rs11976180	1	rs6464573	ENSG00000273234.1	OR2A13P	7.93	1.73e-14	8.23e-12	0.42	0.35	Obesity-related traits;	chr7:144051005	chr7:144142009~144142938:+
PRAD	cis	rs950169	0.545	rs4354897	ENSG00000225151.9	GOLGA2P7	-7.93	1.74e-14	8.24e-12	-0.51	-0.35	Schizophrenia;	chr15:83976219	chr15:84199311~84230136:-
PRAD	cis	rs72627509	0.638	rs7658601	ENSG00000269949.1	RP11-738E22.3	7.93	1.75e-14	8.32e-12	0.51	0.35	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56915181	chr4:56960927~56961373:-
PRAD	cis	rs7250849	0.529	rs73052877	ENSG00000273837.1	LLNLR-470E3.1	-7.93	1.76e-14	8.33e-12	-0.51	-0.35	Blood protein levels;	chr19:51662744	chr19:51639478~51639931:-
PRAD	cis	rs1061377	1	rs7685082	ENSG00000249685.1	RP11-360F5.3	7.93	1.76e-14	8.34e-12	0.39	0.35	Uric acid levels;	chr4:39116472	chr4:39133913~39135608:+
PRAD	cis	rs1061377	1	rs7664078	ENSG00000249685.1	RP11-360F5.3	7.93	1.76e-14	8.34e-12	0.39	0.35	Uric acid levels;	chr4:39116583	chr4:39133913~39135608:+
PRAD	cis	rs1061377	1	rs9998481	ENSG00000249685.1	RP11-360F5.3	7.93	1.76e-14	8.34e-12	0.39	0.35	Uric acid levels;	chr4:39117215	chr4:39133913~39135608:+
PRAD	cis	rs3858145	0.588	rs10998059	ENSG00000233590.1	RP11-153K11.3	7.93	1.76e-14	8.34e-12	0.49	0.35	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68302750	chr10:68233251~68242379:-
PRAD	cis	rs7429990	0.828	rs10446426	ENSG00000229759.1	MRPS18AP1	-7.93	1.76e-14	8.35e-12	-0.36	-0.35	Educational attainment (years of education);	chr3:48129031	chr3:48256350~48256938:-
PRAD	cis	rs7712401	0.765	rs10079941	ENSG00000263432.2	RN7SL689P	7.93	1.76e-14	8.35e-12	0.35	0.35	Mean platelet volume;	chr5:123045668	chr5:123022487~123022783:-
PRAD	cis	rs526231	0.543	rs34832	ENSG00000175749.11	EIF3KP1	7.93	1.76e-14	8.35e-12	0.49	0.35	Primary biliary cholangitis;	chr5:103108891	chr5:103032376~103033031:+
PRAD	cis	rs526231	0.543	rs34770	ENSG00000175749.11	EIF3KP1	7.93	1.76e-14	8.35e-12	0.49	0.35	Primary biliary cholangitis;	chr5:103111942	chr5:103032376~103033031:+
PRAD	cis	rs2337406	1	rs79452530	ENSG00000274576.2	IGHV2-70	-7.93	1.77e-14	8.38e-12	-0.38	-0.35	Alzheimer's disease (late onset);	chr14:106699992	chr14:106770577~106771020:-
PRAD	cis	rs2337406	1	rs17113276	ENSG00000274576.2	IGHV2-70	7.93	1.77e-14	8.38e-12	0.37	0.35	Alzheimer's disease (late onset);	chr14:106683485	chr14:106770577~106771020:-
PRAD	cis	rs2243480	1	rs160646	ENSG00000226824.5	RP4-756H11.3	-7.93	1.77e-14	8.39e-12	-0.69	-0.35	Diabetic kidney disease;	chr7:66091293	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs465359	ENSG00000226824.5	RP4-756H11.3	-7.93	1.77e-14	8.39e-12	-0.69	-0.35	Diabetic kidney disease;	chr7:66093177	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs462853	ENSG00000226824.5	RP4-756H11.3	-7.93	1.77e-14	8.39e-12	-0.69	-0.35	Diabetic kidney disease;	chr7:66093180	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs160644	ENSG00000226824.5	RP4-756H11.3	-7.93	1.77e-14	8.39e-12	-0.69	-0.35	Diabetic kidney disease;	chr7:66093199	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs160642	ENSG00000226824.5	RP4-756H11.3	-7.93	1.77e-14	8.39e-12	-0.69	-0.35	Diabetic kidney disease;	chr7:66093386	chr7:66654538~66669855:+
PRAD	cis	rs2243480	0.614	rs34032527	ENSG00000226824.5	RP4-756H11.3	-7.93	1.77e-14	8.39e-12	-0.69	-0.35	Diabetic kidney disease;	chr7:66100154	chr7:66654538~66669855:+
PRAD	cis	rs964611	0.808	rs35405890	ENSG00000259488.2	RP11-154J22.1	-7.93	1.77e-14	8.4e-12	-0.33	-0.35	Metabolite levels (Pyroglutamine);	chr15:48299070	chr15:48312353~48331856:-
PRAD	cis	rs950169	0.614	rs12911536	ENSG00000225151.9	GOLGA2P7	-7.92	1.77e-14	8.41e-12	-0.51	-0.35	Schizophrenia;	chr15:84004278	chr15:84199311~84230136:-
PRAD	cis	rs9309473	0.632	rs7599076	ENSG00000163016.8	ALMS1P	7.92	1.78e-14	8.42e-12	0.42	0.35	Metabolite levels;	chr2:73358391	chr2:73644919~73685576:+
PRAD	cis	rs9326248	0.603	rs7396061	ENSG00000280143.1	AP000892.6	7.92	1.78e-14	8.43e-12	0.27	0.35	Blood protein levels;	chr11:116880158	chr11:117204967~117210292:+
PRAD	cis	rs7567389	0.677	rs72845975	ENSG00000236682.1	AC068282.3	-7.92	1.78e-14	8.45e-12	-0.46	-0.35	Self-rated health;	chr2:127328698	chr2:127389130~127400580:+
PRAD	cis	rs4713118	0.699	rs200978	ENSG00000219392.1	RP1-265C24.5	-7.92	1.79e-14	8.47e-12	-0.46	-0.35	Parkinson's disease;	chr6:27885390	chr6:28115628~28116551:+
PRAD	cis	rs673078	0.607	rs7958551	ENSG00000275409.1	RP11-131L12.4	-7.92	1.79e-14	8.5e-12	-0.5	-0.35	Glucose homeostasis traits;	chr12:118442585	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.607	rs7958652	ENSG00000275409.1	RP11-131L12.4	-7.92	1.79e-14	8.5e-12	-0.5	-0.35	Glucose homeostasis traits;	chr12:118442630	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.607	rs111607725	ENSG00000275409.1	RP11-131L12.4	-7.92	1.79e-14	8.5e-12	-0.5	-0.35	Glucose homeostasis traits;	chr12:118442957	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.607	rs76809232	ENSG00000275409.1	RP11-131L12.4	-7.92	1.79e-14	8.5e-12	-0.5	-0.35	Glucose homeostasis traits;	chr12:118444979	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.607	rs61944660	ENSG00000275409.1	RP11-131L12.4	-7.92	1.79e-14	8.5e-12	-0.5	-0.35	Glucose homeostasis traits;	chr12:118445326	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.607	rs61944662	ENSG00000275409.1	RP11-131L12.4	-7.92	1.79e-14	8.5e-12	-0.5	-0.35	Glucose homeostasis traits;	chr12:118445520	chr12:118430147~118430699:+
PRAD	cis	rs11098499	0.863	rs3775841	ENSG00000245958.5	RP11-33B1.1	-7.92	1.8e-14	8.52e-12	-0.34	-0.35	Corneal astigmatism;	chr4:119504622	chr4:119454791~119552025:+
PRAD	cis	rs2274273	0.6	rs10134317	ENSG00000258413.1	RP11-665C16.6	-7.92	1.8e-14	8.53e-12	-0.47	-0.35	Protein biomarker;	chr14:55326730	chr14:55262767~55272075:-
PRAD	cis	rs2274273	0.624	rs67795323	ENSG00000258413.1	RP11-665C16.6	-7.92	1.8e-14	8.53e-12	-0.47	-0.35	Protein biomarker;	chr14:55331115	chr14:55262767~55272075:-
PRAD	cis	rs2274273	0.624	rs8005450	ENSG00000258413.1	RP11-665C16.6	-7.92	1.8e-14	8.53e-12	-0.47	-0.35	Protein biomarker;	chr14:55332447	chr14:55262767~55272075:-
PRAD	cis	rs12908161	1	rs17600551	ENSG00000259728.4	LINC00933	7.92	1.8e-14	8.54e-12	0.42	0.35	Schizophrenia;	chr15:84776027	chr15:84570649~84580175:+
PRAD	cis	rs12908161	1	rs62019469	ENSG00000259728.4	LINC00933	7.92	1.8e-14	8.54e-12	0.42	0.35	Schizophrenia;	chr15:84777989	chr15:84570649~84580175:+
PRAD	cis	rs853679	0.556	rs45509595	ENSG00000280107.1	AL022393.9	-7.92	1.81e-14	8.57e-12	-0.71	-0.35	Depression;	chr6:27873148	chr6:28170845~28172521:+
PRAD	cis	rs1043099	0.912	rs5749066	ENSG00000279699.1	RP1-102K2.9	-7.92	1.82e-14	8.6e-12	-0.54	-0.35	Rheumatoid arthritis;	chr22:30340922	chr22:30275215~30276951:-
PRAD	cis	rs1043099	0.912	rs5753080	ENSG00000279699.1	RP1-102K2.9	-7.92	1.82e-14	8.6e-12	-0.54	-0.35	Rheumatoid arthritis;	chr22:30342748	chr22:30275215~30276951:-
PRAD	cis	rs62355901	0.505	rs12657615	ENSG00000271828.1	CTD-2310F14.1	7.92	1.82e-14	8.62e-12	0.79	0.35	Breast cancer;	chr5:56768306	chr5:56927874~56929573:+
PRAD	cis	rs375066	0.934	rs411803	ENSG00000267058.1	RP11-15A1.3	7.92	1.82e-14	8.62e-12	0.29	0.35	Breast cancer;	chr19:43928688	chr19:43891804~43901805:-
PRAD	cis	rs673078	0.607	rs61943367	ENSG00000275409.1	RP11-131L12.4	-7.92	1.82e-14	8.63e-12	-0.5	-0.35	Glucose homeostasis traits;	chr12:118366316	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.607	rs61943368	ENSG00000275409.1	RP11-131L12.4	-7.92	1.82e-14	8.63e-12	-0.5	-0.35	Glucose homeostasis traits;	chr12:118366568	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.607	rs61943385	ENSG00000275409.1	RP11-131L12.4	-7.92	1.82e-14	8.63e-12	-0.5	-0.35	Glucose homeostasis traits;	chr12:118370339	chr12:118430147~118430699:+
PRAD	cis	rs9810089	0.903	rs711975	ENSG00000261758.1	RP11-102M11.2	7.92	1.82e-14	8.63e-12	0.4	0.35	Gestational age at birth (child effect);	chr3:136517066	chr3:136752630~136755780:+
PRAD	cis	rs6921919	0.848	rs6903652	ENSG00000216901.1	AL022393.7	7.92	1.83e-14	8.65e-12	0.49	0.35	Autism spectrum disorder or schizophrenia;	chr6:28354343	chr6:28176188~28176674:+
PRAD	cis	rs1555322	0.53	rs6060341	ENSG00000279253.1	RP4-614O4.13	7.92	1.83e-14	8.65e-12	0.41	0.35	Attention deficit hyperactivity disorder;	chr20:35275830	chr20:35262727~35264187:-
PRAD	cis	rs6003958	1	rs6003958	ENSG00000228039.3	KB-1125A3.10	-7.92	1.83e-14	8.67e-12	-0.54	-0.35	S-phenylmercapturic acid levels in smokers;	chr22:23921902	chr22:23963780~23964374:+
PRAD	cis	rs5760092	0.755	rs6003959	ENSG00000228039.3	KB-1125A3.10	-7.92	1.83e-14	8.67e-12	-0.54	-0.35	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23922208	chr22:23963780~23964374:+
PRAD	cis	rs7238033	0.602	rs8088163	ENSG00000267193.4	RP11-116O18.3	7.92	1.84e-14	8.71e-12	0.38	0.35	Bladder cancer;	chr18:45729844	chr18:45669367~45747215:-
PRAD	cis	rs7238033	0.624	rs8090908	ENSG00000267193.4	RP11-116O18.3	7.92	1.84e-14	8.71e-12	0.38	0.35	Bladder cancer;	chr18:45730222	chr18:45669367~45747215:-
PRAD	cis	rs6847067	0.794	rs12498787	ENSG00000180769.7	WDFY3-AS2	7.92	1.84e-14	8.71e-12	0.37	0.35	Oropharynx cancer;	chr4:85024761	chr4:84965682~85011277:+
PRAD	cis	rs7923609	1	rs7910927	ENSG00000232075.1	MRPL35P2	-7.92	1.84e-14	8.72e-12	-0.37	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63379150	chr10:63634317~63634827:-
PRAD	cis	rs1061377	0.803	rs6857761	ENSG00000249685.1	RP11-360F5.3	7.92	1.87e-14	8.83e-12	0.39	0.35	Uric acid levels;	chr4:39118353	chr4:39133913~39135608:+
PRAD	cis	rs2439831	0.85	rs694985	ENSG00000249839.1	AC011330.5	-7.92	1.87e-14	8.84e-12	-0.58	-0.35	Lung cancer in ever smokers;	chr15:43521189	chr15:43663654~43684339:-
PRAD	cis	rs5760092	0.572	rs738806	ENSG00000218537.1	MIF-AS1	7.92	1.87e-14	8.84e-12	0.53	0.35	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23894426~23898930:-
PRAD	cis	rs5760092	0.755	rs915589	ENSG00000228039.3	KB-1125A3.10	-7.92	1.87e-14	8.86e-12	-0.55	-0.35	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23963780~23964374:+
PRAD	cis	rs526231	0.543	rs152137	ENSG00000175749.11	EIF3KP1	7.92	1.87e-14	8.86e-12	0.5	0.35	Primary biliary cholangitis;	chr5:103224362	chr5:103032376~103033031:+
PRAD	cis	rs6539288	0.739	rs7302653	ENSG00000260329.1	RP11-412D9.4	-7.92	1.87e-14	8.86e-12	-0.31	-0.35	Total body bone mineral density;	chr12:106979744	chr12:106954029~106955497:-
PRAD	cis	rs2243480	1	rs2533288	ENSG00000226824.5	RP4-756H11.3	-7.92	1.88e-14	8.87e-12	-0.69	-0.35	Diabetic kidney disease;	chr7:66591724	chr7:66654538~66669855:+
PRAD	cis	rs12142240	0.698	rs17361805	ENSG00000232022.5	FAAHP1	-7.92	1.88e-14	8.9e-12	-0.32	-0.35	Menopause (age at onset);	chr1:46348295	chr1:46432129~46445521:+
PRAD	cis	rs1979679	0.918	rs10771427	ENSG00000278733.1	RP11-425D17.1	7.92	1.88e-14	8.91e-12	0.45	0.35	Ossification of the posterior longitudinal ligament of the spine;	chr12:28452493	chr12:28185625~28186190:-
PRAD	cis	rs7238033	0.624	rs16978469	ENSG00000267193.4	RP11-116O18.3	7.92	1.89e-14	8.92e-12	0.37	0.35	Bladder cancer;	chr18:45725820	chr18:45669367~45747215:-
PRAD	cis	rs1150668	0.745	rs213238	ENSG00000280107.1	AL022393.9	-7.92	1.89e-14	8.94e-12	-0.42	-0.35	Pubertal anthropometrics;	chr6:28354216	chr6:28170845~28172521:+
PRAD	cis	rs1528149	0.856	rs60333130	ENSG00000224683.1	RPL36AP29	7.92	1.89e-14	8.94e-12	0.43	0.35	Sitting height ratio;	chr7:16059809	chr7:16208945~16209265:+
PRAD	cis	rs11098499	1	rs1011054	ENSG00000245958.5	RP11-33B1.1	7.92	1.9e-14	8.96e-12	0.35	0.35	Corneal astigmatism;	chr4:119281232	chr4:119454791~119552025:+
PRAD	cis	rs6782228	0.606	rs9828893	ENSG00000242551.2	POU5F1P6	-7.92	1.9e-14	8.96e-12	-0.44	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128614082	chr3:128674735~128677005:-
PRAD	cis	rs858239	0.932	rs1728320	ENSG00000226816.2	AC005082.12	7.92	1.9e-14	8.98e-12	0.4	0.35	Cerebrospinal fluid biomarker levels;	chr7:23280170	chr7:23206013~23208045:+
PRAD	cis	rs2243480	0.708	rs13242216	ENSG00000226824.5	RP4-756H11.3	-7.92	1.9e-14	8.98e-12	-0.71	-0.35	Diabetic kidney disease;	chr7:66433290	chr7:66654538~66669855:+
PRAD	cis	rs2243480	0.615	rs34363376	ENSG00000226824.5	RP4-756H11.3	-7.92	1.9e-14	8.98e-12	-0.71	-0.35	Diabetic kidney disease;	chr7:66474549	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs67536397	ENSG00000226824.5	RP4-756H11.3	-7.92	1.9e-14	8.98e-12	-0.71	-0.35	Diabetic kidney disease;	chr7:66482930	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs58669269	ENSG00000226824.5	RP4-756H11.3	-7.92	1.9e-14	8.98e-12	-0.71	-0.35	Diabetic kidney disease;	chr7:66486966	chr7:66654538~66669855:+
PRAD	cis	rs526231	0.543	rs6880911	ENSG00000175749.11	EIF3KP1	7.91	1.91e-14	9.01e-12	0.47	0.35	Primary biliary cholangitis;	chr5:102971767	chr5:103032376~103033031:+
PRAD	cis	rs526231	0.543	rs6881225	ENSG00000175749.11	EIF3KP1	7.91	1.91e-14	9.01e-12	0.47	0.35	Primary biliary cholangitis;	chr5:102971888	chr5:103032376~103033031:+
PRAD	cis	rs7567389	0.677	rs11680949	ENSG00000236682.1	AC068282.3	-7.91	1.91e-14	9.03e-12	-0.46	-0.35	Self-rated health;	chr2:127365986	chr2:127389130~127400580:+
PRAD	cis	rs7712401	0.58	rs4288111	ENSG00000263432.2	RN7SL689P	-7.91	1.91e-14	9.04e-12	-0.35	-0.35	Mean platelet volume;	chr5:123052487	chr5:123022487~123022783:-
PRAD	cis	rs4631830	0.9	rs10763546	ENSG00000230869.1	CTGLF10P	-7.91	1.92e-14	9.06e-12	-0.43	-0.35	Prostate-specific antigen levels;	chr10:46059423	chr10:45678692~45700532:+
PRAD	cis	rs1426063	1	rs11941556	ENSG00000249717.1	RP11-44F21.3	7.91	1.92e-14	9.06e-12	0.61	0.35	QT interval;	chr4:75093825	chr4:74955974~74970362:-
PRAD	cis	rs1426063	1	rs10022814	ENSG00000249717.1	RP11-44F21.3	7.91	1.92e-14	9.06e-12	0.61	0.35	QT interval;	chr4:75094704	chr4:74955974~74970362:-
PRAD	cis	rs5760092	0.627	rs6519489	ENSG00000228039.3	KB-1125A3.10	-7.91	1.92e-14	9.06e-12	-0.55	-0.35	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919659	chr22:23963780~23964374:+
PRAD	cis	rs7238033	0.641	rs11877028	ENSG00000267193.4	RP11-116O18.3	7.91	1.92e-14	9.08e-12	0.38	0.35	Bladder cancer;	chr18:45737901	chr18:45669367~45747215:-
PRAD	cis	rs526231	0.543	rs34784	ENSG00000175749.11	EIF3KP1	7.91	1.92e-14	9.08e-12	0.48	0.35	Primary biliary cholangitis;	chr5:103121626	chr5:103032376~103033031:+
PRAD	cis	rs526231	0.543	rs32849	ENSG00000175749.11	EIF3KP1	7.91	1.92e-14	9.08e-12	0.48	0.35	Primary biliary cholangitis;	chr5:103134339	chr5:103032376~103033031:+
PRAD	cis	rs11098499	0.82	rs28535956	ENSG00000245958.5	RP11-33B1.1	7.91	1.93e-14	9.1e-12	0.34	0.35	Corneal astigmatism;	chr4:119615703	chr4:119454791~119552025:+
PRAD	cis	rs12922040	0.701	rs12149912	ENSG00000263335.1	AF001548.5	-7.91	1.93e-14	9.11e-12	-0.37	-0.35	Serum uric acid levels in response to allopurinol in gout;	chr16:15774798	chr16:15726674~15732993:+
PRAD	cis	rs10463554	0.889	rs246911	ENSG00000175749.11	EIF3KP1	7.91	1.93e-14	9.11e-12	0.46	0.35	Parkinson's disease;	chr5:103227502	chr5:103032376~103033031:+
PRAD	cis	rs2581828	0.646	rs3796351	ENSG00000242142.1	SERBP1P3	7.91	1.93e-14	9.14e-12	0.41	0.35	Crohn's disease;	chr3:53122049	chr3:53064283~53065091:-
PRAD	cis	rs12931792	0.712	rs2887799	ENSG00000183604.13	SMG1P5	7.91	1.94e-14	9.15e-12	0.3	0.35	Tonsillectomy;	chr16:30152512	chr16:30267553~30335374:-
PRAD	cis	rs7567389	0.71	rs72848615	ENSG00000236682.1	AC068282.3	-7.91	1.94e-14	9.15e-12	-0.46	-0.35	Self-rated health;	chr2:127376022	chr2:127389130~127400580:+
PRAD	cis	rs2946504	0.906	rs2946511	ENSG00000251468.2	RP11-369K16.1	7.91	1.94e-14	9.15e-12	0.42	0.35	Type 2 diabetes;	chr8:12949796	chr8:12958387~12962200:+
PRAD	cis	rs6539288	0.705	rs1053051	ENSG00000260329.1	RP11-412D9.4	-7.91	1.94e-14	9.16e-12	-0.3	-0.35	Total body bone mineral density;	chr12:106973447	chr12:106954029~106955497:-
PRAD	cis	rs2337406	1	rs3858878	ENSG00000274576.2	IGHV2-70	-7.91	1.94e-14	9.18e-12	-0.36	-0.35	Alzheimer's disease (late onset);	chr14:106688061	chr14:106770577~106771020:-
PRAD	cis	rs1528149	0.93	rs62440849	ENSG00000224683.1	RPL36AP29	7.91	1.95e-14	9.21e-12	0.43	0.35	Sitting height ratio;	chr7:16072349	chr7:16208945~16209265:+
PRAD	cis	rs2115630	0.645	rs2292463	ENSG00000225151.9	GOLGA2P7	7.91	1.95e-14	9.21e-12	0.44	0.35	P wave terminal force;	chr15:84632519	chr15:84199311~84230136:-
PRAD	cis	rs6844153	0.68	rs61047003	ENSG00000240005.4	RP11-293A21.1	-7.91	1.95e-14	9.21e-12	-0.41	-0.35	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26937139	chr4:26859806~26860599:-
PRAD	cis	rs67311347	0.549	rs60249586	ENSG00000223797.4	ENTPD3-AS1	7.91	1.95e-14	9.22e-12	0.31	0.35	Renal cell carcinoma;	chr3:40205168	chr3:40313802~40453329:-
PRAD	cis	rs858239	0.665	rs6964665	ENSG00000226816.2	AC005082.12	7.91	1.96e-14	9.24e-12	0.41	0.35	Cerebrospinal fluid biomarker levels;	chr7:23171733	chr7:23206013~23208045:+
PRAD	cis	rs4722166	0.598	rs35658589	ENSG00000179428.2	AC073072.5	-7.91	1.96e-14	9.25e-12	-0.4	-0.35	Lung cancer;	chr7:22760816	chr7:22725395~22727620:-
PRAD	cis	rs17711722	0.565	rs73372653	ENSG00000164669.11	INTS4P1	-7.91	1.96e-14	9.26e-12	-0.44	-0.35	Calcium levels;	chr7:65977808	chr7:65141225~65234216:+
PRAD	cis	rs62355901	0.545	rs56008823	ENSG00000271828.1	CTD-2310F14.1	7.91	1.96e-14	9.27e-12	0.75	0.35	Breast cancer;	chr5:56772187	chr5:56927874~56929573:+
PRAD	cis	rs9341835	0.51	rs12196062	ENSG00000218048.2	RP3-407E4.4	7.91	1.97e-14	9.28e-12	0.41	0.35	Schizophrenia;	chr6:63457887	chr6:63440766~63443580:+
PRAD	cis	rs6921919	0.583	rs7764737	ENSG00000216901.1	AL022393.7	7.91	1.97e-14	9.28e-12	0.44	0.35	Autism spectrum disorder or schizophrenia;	chr6:28386838	chr6:28176188~28176674:+
PRAD	cis	rs6921919	0.583	rs9461458	ENSG00000216901.1	AL022393.7	7.91	1.97e-14	9.28e-12	0.44	0.35	Autism spectrum disorder or schizophrenia;	chr6:28388098	chr6:28176188~28176674:+
PRAD	cis	rs6921919	0.609	rs9468365	ENSG00000216901.1	AL022393.7	7.91	1.97e-14	9.28e-12	0.44	0.35	Autism spectrum disorder or schizophrenia;	chr6:28390189	chr6:28176188~28176674:+
PRAD	cis	rs6921919	0.583	rs1361385	ENSG00000216901.1	AL022393.7	7.91	1.97e-14	9.28e-12	0.44	0.35	Autism spectrum disorder or schizophrenia;	chr6:28390543	chr6:28176188~28176674:+
PRAD	cis	rs6921919	0.583	rs1416918	ENSG00000216901.1	AL022393.7	7.91	1.97e-14	9.28e-12	0.44	0.35	Autism spectrum disorder or schizophrenia;	chr6:28390558	chr6:28176188~28176674:+
PRAD	cis	rs7923609	0.902	rs10822158	ENSG00000232075.1	MRPL35P2	-7.91	1.97e-14	9.3e-12	-0.37	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63334623	chr10:63634317~63634827:-
PRAD	cis	rs7923609	0.846	rs10740115	ENSG00000232075.1	MRPL35P2	-7.91	1.97e-14	9.3e-12	-0.37	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63335230	chr10:63634317~63634827:-
PRAD	cis	rs7923609	0.846	rs10740116	ENSG00000232075.1	MRPL35P2	-7.91	1.97e-14	9.3e-12	-0.37	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63335232	chr10:63634317~63634827:-
PRAD	cis	rs673078	0.607	rs61944664	ENSG00000275409.1	RP11-131L12.4	-7.91	1.97e-14	9.31e-12	-0.5	-0.35	Glucose homeostasis traits;	chr12:118447145	chr12:118430147~118430699:+
PRAD	cis	rs11976180	1	rs11976180	ENSG00000273234.1	OR2A13P	-7.91	1.98e-14	9.32e-12	-0.42	-0.35	Obesity-related traits;	chr7:144044487	chr7:144142009~144142938:+
PRAD	cis	rs11018904	0.861	rs4589254	ENSG00000280385.1	AP000648.5	7.91	1.98e-14	9.34e-12	0.49	0.35	Intelligence (multi-trait analysis);	chr11:90230187	chr11:90193614~90198120:+
PRAD	cis	rs11096990	0.6	rs6835337	ENSG00000249207.1	RP11-360F5.1	7.91	1.98e-14	9.35e-12	0.36	0.35	Cognitive function;	chr4:39281189	chr4:39112677~39126818:-
PRAD	cis	rs950169	0.614	rs12903883	ENSG00000225151.9	GOLGA2P7	-7.91	1.98e-14	9.36e-12	-0.51	-0.35	Schizophrenia;	chr15:84011801	chr15:84199311~84230136:-
PRAD	cis	rs9326248	0.59	rs2542063	ENSG00000280143.1	AP000892.6	7.91	1.99e-14	9.39e-12	0.29	0.35	Blood protein levels;	chr11:116814051	chr11:117204967~117210292:+
PRAD	cis	rs881375	0.678	rs10760125	ENSG00000226752.6	PSMD5-AS1	-7.91	1.99e-14	9.39e-12	-0.4	-0.35	Rheumatoid arthritis;	chr9:120900312	chr9:120824828~120854385:+
PRAD	cis	rs881375	0.678	rs9886724	ENSG00000226752.6	PSMD5-AS1	-7.91	1.99e-14	9.39e-12	-0.4	-0.35	Rheumatoid arthritis;	chr9:120902741	chr9:120824828~120854385:+
PRAD	cis	rs881375	0.631	rs10739577	ENSG00000226752.6	PSMD5-AS1	-7.91	1.99e-14	9.39e-12	-0.4	-0.35	Rheumatoid arthritis;	chr9:120906576	chr9:120824828~120854385:+
PRAD	cis	rs11332131	1	rs11332131	ENSG00000266992.1	DHX40P1	7.91	2e-14	9.42e-12	0.39	0.35	Platelet distribution width;	chr17:59849031	chr17:59976009~60002384:-
PRAD	cis	rs2243480	1	rs316329	ENSG00000226824.5	RP4-756H11.3	-7.91	2e-14	9.43e-12	-0.68	-0.35	Diabetic kidney disease;	chr7:66143429	chr7:66654538~66669855:+
PRAD	cis	rs526231	0.543	rs26820	ENSG00000175749.11	EIF3KP1	7.91	2e-14	9.45e-12	0.48	0.35	Primary biliary cholangitis;	chr5:103192391	chr5:103032376~103033031:+
PRAD	cis	rs17361889	0.671	rs1527201	ENSG00000224683.1	RPL36AP29	-7.91	2.01e-14	9.47e-12	-0.42	-0.35	Pediatric bone mineral content (hip);	chr7:16111403	chr7:16208945~16209265:+
PRAD	cis	rs526231	0.575	rs26822	ENSG00000175749.11	EIF3KP1	7.91	2.01e-14	9.48e-12	0.49	0.35	Primary biliary cholangitis;	chr5:103183094	chr5:103032376~103033031:+
PRAD	cis	rs4664293	0.585	rs35081473	ENSG00000226266.5	AC009961.3	7.91	2.01e-14	9.48e-12	0.46	0.35	Monocyte percentage of white cells;	chr2:159679970	chr2:159670708~159712435:-
PRAD	cis	rs4664293	0.605	rs7556888	ENSG00000226266.5	AC009961.3	7.91	2.01e-14	9.48e-12	0.46	0.35	Monocyte percentage of white cells;	chr2:159683750	chr2:159670708~159712435:-
PRAD	cis	rs673078	0.607	rs73207573	ENSG00000275409.1	RP11-131L12.4	-7.91	2.01e-14	9.48e-12	-0.5	-0.35	Glucose homeostasis traits;	chr12:118444664	chr12:118430147~118430699:+
PRAD	cis	rs42648	0.748	rs10225744	ENSG00000227646.6	STEAP2-AS1	-7.91	2.03e-14	9.58e-12	-0.32	-0.35	Homocysteine levels;	chr7:90316689	chr7:89882353~90211635:-
PRAD	cis	rs7238033	0.663	rs11082467	ENSG00000267193.4	RP11-116O18.3	7.91	2.03e-14	9.59e-12	0.38	0.35	Bladder cancer;	chr18:45738679	chr18:45669367~45747215:-
PRAD	cis	rs7181230	0.885	rs8026641	ENSG00000275636.1	RP11-521C20.5	-7.91	2.04e-14	9.61e-12	-0.48	-0.35	Dehydroepiandrosterone sulphate levels;	chr15:40046660	chr15:40078892~40079347:+
PRAD	cis	rs10875746	0.551	rs11168536	ENSG00000240399.1	RP1-228P16.1	-7.91	2.04e-14	9.62e-12	-0.34	-0.35	Longevity (90 years and older);	chr12:48351268	chr12:48054813~48055591:-
PRAD	cis	rs4631830	0.863	rs4935162	ENSG00000230869.1	CTGLF10P	-7.91	2.04e-14	9.62e-12	-0.42	-0.35	Prostate-specific antigen levels;	chr10:46070123	chr10:45678692~45700532:+
PRAD	cis	rs995000	0.868	rs1168113	ENSG00000235545.1	RP11-230B22.1	-7.91	2.04e-14	9.62e-12	-0.46	-0.35	Triglyceride levels;	chr1:62690427	chr1:62688482~62710694:+
PRAD	cis	rs7772486	0.712	rs6570726	ENSG00000235652.6	RP11-545I5.3	7.91	2.04e-14	9.62e-12	0.36	0.35	Lobe attachment (rater-scored or self-reported);	chr6:145838324	chr6:145799409~145886585:+
PRAD	cis	rs11976180	1	rs1540894	ENSG00000273234.1	OR2A13P	-7.91	2.04e-14	9.62e-12	-0.42	-0.35	Obesity-related traits;	chr7:144070583	chr7:144142009~144142938:+
PRAD	cis	rs1555322	0.53	rs2297789	ENSG00000279253.1	RP4-614O4.13	-7.9	2.05e-14	9.65e-12	-0.41	-0.35	Attention deficit hyperactivity disorder;	chr20:35279445	chr20:35262727~35264187:-
PRAD	cis	rs13631	1	rs13631	ENSG00000268996.3	MAN1B1-AS1	7.9	2.05e-14	9.65e-12	0.36	0.35	Cerebrospinal fluid biomarker levels;	chr9:137111750	chr9:137084946~137086817:-
PRAD	cis	rs7923609	1	rs4310508	ENSG00000232075.1	MRPL35P2	-7.9	2.05e-14	9.65e-12	-0.37	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63378813	chr10:63634317~63634827:-
PRAD	cis	rs1555322	0.53	rs2425047	ENSG00000279253.1	RP4-614O4.13	7.9	2.05e-14	9.66e-12	0.41	0.35	Attention deficit hyperactivity disorder;	chr20:35283872	chr20:35262727~35264187:-
PRAD	cis	rs7567389	0.677	rs6757492	ENSG00000236682.1	AC068282.3	7.9	2.05e-14	9.66e-12	0.46	0.35	Self-rated health;	chr2:127237756	chr2:127389130~127400580:+
PRAD	cis	rs8040855	0.93	rs6496767	ENSG00000259295.5	CSPG4P12	-7.9	2.05e-14	9.68e-12	-0.46	-0.35	Bulimia nervosa;	chr15:85159522	chr15:85191438~85213905:+
PRAD	cis	rs4927850	1	rs7630875	ENSG00000207650.1	MIR570	7.9	2.06e-14	9.7e-12	0.37	0.35	Pancreatic cancer;	chr3:196026895	chr3:195699401~195699497:+
PRAD	cis	rs4266144	0.581	rs1806867	ENSG00000244515.1	KRT18P34	-7.9	2.06e-14	9.72e-12	-0.41	-0.35	Coronary artery disease;	chr3:157110513	chr3:157162663~157163932:-
PRAD	cis	rs3096299	0.606	rs2965946	ENSG00000274627.1	RP11-104N10.2	7.9	2.07e-14	9.77e-12	0.37	0.35	Multiple myeloma (IgH translocation);	chr16:89450204	chr16:89516797~89522217:+
PRAD	cis	rs1043099	0.912	rs737950	ENSG00000279699.1	RP1-102K2.9	-7.9	2.08e-14	9.77e-12	-0.54	-0.35	Rheumatoid arthritis;	chr22:30361306	chr22:30275215~30276951:-
PRAD	cis	rs1043099	0.871	rs5749078	ENSG00000279699.1	RP1-102K2.9	-7.9	2.08e-14	9.77e-12	-0.54	-0.35	Rheumatoid arthritis;	chr22:30365077	chr22:30275215~30276951:-
PRAD	cis	rs8081395	0.834	rs11650106	ENSG00000266992.1	DHX40P1	-7.9	2.08e-14	9.79e-12	-0.39	-0.35	White blood cell count;	chr17:59772890	chr17:59976009~60002384:-
PRAD	cis	rs11083475	1	rs12462270	ENSG00000267892.1	CTD-2540F13.2	7.9	2.08e-14	9.8e-12	0.38	0.35	Heart rate;	chr19:38710848	chr19:38738284~38739863:+
PRAD	cis	rs11083475	1	rs2279144	ENSG00000267892.1	CTD-2540F13.2	7.9	2.08e-14	9.8e-12	0.38	0.35	Heart rate;	chr19:38711141	chr19:38738284~38739863:+
PRAD	cis	rs1979679	0.918	rs786712	ENSG00000278733.1	RP11-425D17.1	7.9	2.08e-14	9.8e-12	0.45	0.35	Ossification of the posterior longitudinal ligament of the spine;	chr12:28399664	chr12:28185625~28186190:-
PRAD	cis	rs6061231	0.631	rs927133	ENSG00000273619.1	RP5-908M14.9	-7.9	2.08e-14	9.82e-12	-0.22	-0.35	Colorectal cancer;	chr20:62397053	chr20:62386303~62386970:-
PRAD	cis	rs72627509	0.904	rs12645070	ENSG00000269949.1	RP11-738E22.3	7.9	2.09e-14	9.83e-12	0.5	0.35	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56903940	chr4:56960927~56961373:-
PRAD	cis	rs5760092	0.755	rs11090298	ENSG00000228039.3	KB-1125A3.10	-7.9	2.09e-14	9.83e-12	-0.54	-0.35	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919874	chr22:23963780~23964374:+
PRAD	cis	rs9595066	0.712	rs4391951	ENSG00000227258.4	SMIM2-AS1	-7.9	2.09e-14	9.85e-12	-0.57	-0.35	Schizophrenia;	chr13:44180935	chr13:44110451~44240517:+
PRAD	cis	rs13113518	0.812	rs12648271	ENSG00000249700.7	SRD5A3-AS1	7.9	2.09e-14	9.86e-12	0.48	0.35	Height;	chr4:55501955	chr4:55363971~55395847:-
PRAD	cis	rs1552244	0.507	rs6443274	ENSG00000206567.8	AC022007.5	-7.9	2.1e-14	9.87e-12	-0.39	-0.35	Alzheimer's disease;	chr3:9953604	chr3:10006418~10011209:-
PRAD	cis	rs1061377	1	rs6829450	ENSG00000249685.1	RP11-360F5.3	7.9	2.11e-14	9.91e-12	0.39	0.35	Uric acid levels;	chr4:39114721	chr4:39133913~39135608:+
PRAD	cis	rs75422866	0.867	rs73111258	ENSG00000280054.1	RP1-197B17.7	7.9	2.11e-14	9.92e-12	0.86	0.35	Pneumonia;	chr12:47597313	chr12:47728151~47730598:-
PRAD	cis	rs75422866	0.867	rs117388682	ENSG00000280054.1	RP1-197B17.7	7.9	2.11e-14	9.92e-12	0.86	0.35	Pneumonia;	chr12:47599713	chr12:47728151~47730598:-
PRAD	cis	rs75422866	0.867	rs79113930	ENSG00000280054.1	RP1-197B17.7	7.9	2.11e-14	9.92e-12	0.86	0.35	Pneumonia;	chr12:47600628	chr12:47728151~47730598:-
PRAD	cis	rs2739330	0.791	rs9612520	ENSG00000228039.3	KB-1125A3.10	7.9	2.11e-14	9.93e-12	0.45	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23963780~23964374:+
PRAD	cis	rs73186030	0.546	rs67931976	ENSG00000272758.4	RP11-299J3.8	7.9	2.11e-14	9.94e-12	0.48	0.35	Serum parathyroid hormone levels;	chr3:122386868	chr3:122416207~122443180:+
PRAD	cis	rs2564921	0.57	rs3821831	ENSG00000242142.1	SERBP1P3	-7.9	2.12e-14	9.96e-12	-0.4	-0.35	Height;	chr3:52819385	chr3:53064283~53065091:-
PRAD	cis	rs11148252	0.583	rs9536048	ENSG00000278238.1	RP11-245D16.4	-7.9	2.12e-14	9.97e-12	-0.43	-0.35	Lewy body disease;	chr13:52384653	chr13:52454775~52455331:-
PRAD	cis	rs9326248	0.581	rs10892061	ENSG00000280143.1	AP000892.6	7.9	2.12e-14	9.97e-12	0.26	0.35	Blood protein levels;	chr11:117015398	chr11:117204967~117210292:+
PRAD	cis	rs2337406	1	rs10459466	ENSG00000274576.2	IGHV2-70	-7.9	2.12e-14	9.97e-12	-0.39	-0.35	Alzheimer's disease (late onset);	chr14:106689255	chr14:106770577~106771020:-
PRAD	cis	rs673078	0.607	rs4254101	ENSG00000275409.1	RP11-131L12.4	-7.9	2.12e-14	9.98e-12	-0.5	-0.35	Glucose homeostasis traits;	chr12:118445877	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.607	rs4622305	ENSG00000275409.1	RP11-131L12.4	-7.9	2.12e-14	9.98e-12	-0.5	-0.35	Glucose homeostasis traits;	chr12:118445912	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.607	rs73207575	ENSG00000275409.1	RP11-131L12.4	-7.9	2.12e-14	9.98e-12	-0.5	-0.35	Glucose homeostasis traits;	chr12:118446711	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.607	rs61944663	ENSG00000275409.1	RP11-131L12.4	-7.9	2.12e-14	9.98e-12	-0.5	-0.35	Glucose homeostasis traits;	chr12:118446886	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.607	rs73207577	ENSG00000275409.1	RP11-131L12.4	-7.9	2.12e-14	9.98e-12	-0.5	-0.35	Glucose homeostasis traits;	chr12:118447012	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.607	rs73207579	ENSG00000275409.1	RP11-131L12.4	-7.9	2.12e-14	9.98e-12	-0.5	-0.35	Glucose homeostasis traits;	chr12:118447123	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.607	rs7969871	ENSG00000275409.1	RP11-131L12.4	-7.9	2.12e-14	9.98e-12	-0.5	-0.35	Glucose homeostasis traits;	chr12:118447331	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.56	rs7970361	ENSG00000275409.1	RP11-131L12.4	-7.9	2.12e-14	9.98e-12	-0.5	-0.35	Glucose homeostasis traits;	chr12:118447723	chr12:118430147~118430699:+
PRAD	cis	rs7923609	0.967	rs10761752	ENSG00000232075.1	MRPL35P2	-7.9	2.13e-14	1e-11	-0.37	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63400561	chr10:63634317~63634827:-
PRAD	cis	rs853679	0.713	rs200991	ENSG00000226314.6	ZNF192P1	7.9	2.14e-14	1e-11	0.52	0.35	Depression;	chr6:27847716	chr6:28161781~28169594:+
PRAD	cis	rs1061377	0.965	rs7669376	ENSG00000249685.1	RP11-360F5.3	7.9	2.14e-14	1.01e-11	0.39	0.35	Uric acid levels;	chr4:39116717	chr4:39133913~39135608:+
PRAD	cis	rs7238033	0.624	rs8087241	ENSG00000267193.4	RP11-116O18.3	7.9	2.14e-14	1.01e-11	0.38	0.35	Bladder cancer;	chr18:45729738	chr18:45669367~45747215:-
PRAD	cis	rs2522056	1	rs7730247	ENSG00000233006.5	AC034220.3	-7.9	2.15e-14	1.01e-11	-0.34	-0.35	Fibrinogen;Lymphocyte counts;	chr5:132445596	chr5:132311285~132369916:-
PRAD	cis	rs72627509	0.904	rs17081935	ENSG00000269949.1	RP11-738E22.3	7.9	2.15e-14	1.01e-11	0.51	0.35	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56957310	chr4:56960927~56961373:-
PRAD	cis	rs11976180	1	rs2961144	ENSG00000273234.1	OR2A13P	7.9	2.15e-14	1.01e-11	0.42	0.35	Obesity-related traits;	chr7:144050777	chr7:144142009~144142938:+
PRAD	cis	rs1426063	0.748	rs10005117	ENSG00000260265.1	RP11-44F21.5	7.9	2.15e-14	1.01e-11	0.5	0.35	QT interval;	chr4:75108281	chr4:75081702~75084717:-
PRAD	cis	rs12130219	1	rs34428306	ENSG00000237975.5	FLG-AS1	7.9	2.16e-14	1.01e-11	0.53	0.35	Inflammatory skin disease;	chr1:152211840	chr1:152168125~152445456:+
PRAD	cis	rs11846409	0.587	rs1806881	ENSG00000274576.2	IGHV2-70	7.9	2.16e-14	1.02e-11	0.37	0.35	Rheumatic heart disease;	chr14:106650770	chr14:106770577~106771020:-
PRAD	cis	rs1800795	0.553	rs1524099	ENSG00000179428.2	AC073072.5	-7.9	2.16e-14	1.02e-11	-0.42	-0.35	Cerebrospinal fluid clusterin levels in APOEe4- carriers;	chr7:22742038	chr7:22725395~22727620:-
PRAD	cis	rs1061377	1	rs10026775	ENSG00000249685.1	RP11-360F5.3	7.9	2.17e-14	1.02e-11	0.39	0.35	Uric acid levels;	chr4:39115155	chr4:39133913~39135608:+
PRAD	cis	rs1061377	1	rs3733276	ENSG00000249685.1	RP11-360F5.3	7.9	2.17e-14	1.02e-11	0.39	0.35	Uric acid levels;	chr4:39115291	chr4:39133913~39135608:+
PRAD	cis	rs1061377	1	rs3733277	ENSG00000249685.1	RP11-360F5.3	7.9	2.17e-14	1.02e-11	0.39	0.35	Uric acid levels;	chr4:39115483	chr4:39133913~39135608:+
PRAD	cis	rs1061377	1	rs3733278	ENSG00000249685.1	RP11-360F5.3	7.9	2.17e-14	1.02e-11	0.39	0.35	Uric acid levels;	chr4:39115615	chr4:39133913~39135608:+
PRAD	cis	rs1061377	1	rs3733279	ENSG00000249685.1	RP11-360F5.3	7.9	2.17e-14	1.02e-11	0.39	0.35	Uric acid levels;	chr4:39115625	chr4:39133913~39135608:+
PRAD	cis	rs1061377	1	rs10018049	ENSG00000249685.1	RP11-360F5.3	7.9	2.17e-14	1.02e-11	0.39	0.35	Uric acid levels;	chr4:39115781	chr4:39133913~39135608:+
PRAD	cis	rs1134634	0.52	rs13121363	ENSG00000273133.1	RP11-799M12.2	7.9	2.17e-14	1.02e-11	0.46	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15567369	chr4:15563698~15564253:-
PRAD	cis	rs1134634	0.52	rs13116304	ENSG00000273133.1	RP11-799M12.2	7.9	2.17e-14	1.02e-11	0.46	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15567523	chr4:15563698~15564253:-
PRAD	cis	rs1555322	0.53	rs932562	ENSG00000279253.1	RP4-614O4.13	-7.9	2.17e-14	1.02e-11	-0.41	-0.35	Attention deficit hyperactivity disorder;	chr20:35283507	chr20:35262727~35264187:-
PRAD	cis	rs950169	0.579	rs62027818	ENSG00000225151.9	GOLGA2P7	-7.9	2.18e-14	1.02e-11	-0.51	-0.35	Schizophrenia;	chr15:83992393	chr15:84199311~84230136:-
PRAD	cis	rs4631830	0.72	rs11599333	ENSG00000230869.1	CTGLF10P	7.9	2.18e-14	1.02e-11	0.43	0.35	Prostate-specific antigen levels;	chr10:46096167	chr10:45678692~45700532:+
PRAD	cis	rs6921919	0.609	rs9461455	ENSG00000216901.1	AL022393.7	7.9	2.18e-14	1.02e-11	0.44	0.35	Autism spectrum disorder or schizophrenia;	chr6:28361954	chr6:28176188~28176674:+
PRAD	cis	rs6061231	0.561	rs67072353	ENSG00000273619.1	RP5-908M14.9	-7.9	2.18e-14	1.03e-11	-0.28	-0.35	Colorectal cancer;	chr20:62365646	chr20:62386303~62386970:-
PRAD	cis	rs7567389	0.677	rs72845976	ENSG00000236682.1	AC068282.3	-7.9	2.19e-14	1.03e-11	-0.46	-0.35	Self-rated health;	chr2:127328864	chr2:127389130~127400580:+
PRAD	cis	rs1061377	1	rs9999327	ENSG00000249685.1	RP11-360F5.3	7.9	2.19e-14	1.03e-11	0.39	0.35	Uric acid levels;	chr4:39110111	chr4:39133913~39135608:+
PRAD	cis	rs1061377	0.965	rs6833654	ENSG00000249685.1	RP11-360F5.3	7.9	2.19e-14	1.03e-11	0.39	0.35	Uric acid levels;	chr4:39110701	chr4:39133913~39135608:+
PRAD	cis	rs1061377	1	rs1036037	ENSG00000249685.1	RP11-360F5.3	7.9	2.19e-14	1.03e-11	0.39	0.35	Uric acid levels;	chr4:39111272	chr4:39133913~39135608:+
PRAD	cis	rs1061377	1	rs1036038	ENSG00000249685.1	RP11-360F5.3	7.9	2.19e-14	1.03e-11	0.39	0.35	Uric acid levels;	chr4:39111383	chr4:39133913~39135608:+
PRAD	cis	rs1061377	1	rs1560396	ENSG00000249685.1	RP11-360F5.3	7.9	2.19e-14	1.03e-11	0.39	0.35	Uric acid levels;	chr4:39112092	chr4:39133913~39135608:+
PRAD	cis	rs1061377	1	rs1560397	ENSG00000249685.1	RP11-360F5.3	7.9	2.19e-14	1.03e-11	0.39	0.35	Uric acid levels;	chr4:39112265	chr4:39133913~39135608:+
PRAD	cis	rs1061377	1	rs2381285	ENSG00000249685.1	RP11-360F5.3	7.9	2.19e-14	1.03e-11	0.39	0.35	Uric acid levels;	chr4:39112775	chr4:39133913~39135608:+
PRAD	cis	rs1061377	1	rs2163272	ENSG00000249685.1	RP11-360F5.3	7.9	2.19e-14	1.03e-11	0.39	0.35	Uric acid levels;	chr4:39112790	chr4:39133913~39135608:+
PRAD	cis	rs1061377	1	rs2163273	ENSG00000249685.1	RP11-360F5.3	7.9	2.19e-14	1.03e-11	0.39	0.35	Uric acid levels;	chr4:39112835	chr4:39133913~39135608:+
PRAD	cis	rs1061377	1	rs62310332	ENSG00000249685.1	RP11-360F5.3	7.9	2.19e-14	1.03e-11	0.39	0.35	Uric acid levels;	chr4:39112939	chr4:39133913~39135608:+
PRAD	cis	rs1061377	0.965	rs3796510	ENSG00000249685.1	RP11-360F5.3	7.9	2.19e-14	1.03e-11	0.39	0.35	Uric acid levels;	chr4:39113309	chr4:39133913~39135608:+
PRAD	cis	rs1061377	1	rs10030904	ENSG00000249685.1	RP11-360F5.3	7.9	2.19e-14	1.03e-11	0.39	0.35	Uric acid levels;	chr4:39113603	chr4:39133913~39135608:+
PRAD	cis	rs1061377	0.932	rs6855118	ENSG00000249685.1	RP11-360F5.3	7.9	2.19e-14	1.03e-11	0.39	0.35	Uric acid levels;	chr4:39114322	chr4:39133913~39135608:+
PRAD	cis	rs1061377	1	rs6829234	ENSG00000249685.1	RP11-360F5.3	7.9	2.19e-14	1.03e-11	0.39	0.35	Uric acid levels;	chr4:39114586	chr4:39133913~39135608:+
PRAD	cis	rs1061377	1	rs6812540	ENSG00000249685.1	RP11-360F5.3	7.9	2.19e-14	1.03e-11	0.39	0.35	Uric acid levels;	chr4:39114803	chr4:39133913~39135608:+
PRAD	cis	rs3096299	0.781	rs2965819	ENSG00000261118.1	RP11-104N10.1	-7.9	2.19e-14	1.03e-11	-0.33	-0.35	Multiple myeloma (IgH translocation);	chr16:89434622	chr16:89492017~89504460:-
PRAD	cis	rs2337406	0.539	rs2583292	ENSG00000274576.2	IGHV2-70	-7.89	2.19e-14	1.03e-11	-0.37	-0.35	Alzheimer's disease (late onset);	chr14:106649040	chr14:106770577~106771020:-
PRAD	cis	rs6844153	0.887	rs62302533	ENSG00000240005.4	RP11-293A21.1	-7.89	2.2e-14	1.03e-11	-0.47	-0.35	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26955309	chr4:26859806~26860599:-
PRAD	cis	rs3096299	0.583	rs2965949	ENSG00000274627.1	RP11-104N10.2	7.89	2.2e-14	1.03e-11	0.37	0.35	Multiple myeloma (IgH translocation);	chr16:89454044	chr16:89516797~89522217:+
PRAD	cis	rs7829975	0.711	rs4481596	ENSG00000253893.2	FAM85B	-7.89	2.2e-14	1.03e-11	-0.44	-0.35	Mood instability;	chr8:8846820	chr8:8167819~8226614:-
PRAD	cis	rs524281	0.729	rs12790034	ENSG00000255320.1	RP11-755F10.1	-7.89	2.2e-14	1.03e-11	-0.56	-0.35	Electroencephalogram traits;	chr11:66018268	chr11:66244840~66246239:-
PRAD	cis	rs6844153	0.68	rs6833053	ENSG00000240005.4	RP11-293A21.1	-7.89	2.2e-14	1.03e-11	-0.43	-0.35	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26870838	chr4:26859806~26860599:-
PRAD	cis	rs950169	0.58	rs2271431	ENSG00000275120.1	RP11-182J1.17	7.89	2.2e-14	1.03e-11	0.44	0.35	Schizophrenia;	chr15:84646233	chr15:84599434~84606463:-
PRAD	cis	rs1134634	0.52	rs7661102	ENSG00000273133.1	RP11-799M12.2	-7.89	2.2e-14	1.03e-11	-0.47	-0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15596914	chr4:15563698~15564253:-
PRAD	cis	rs1134634	0.52	rs56041141	ENSG00000273133.1	RP11-799M12.2	-7.89	2.2e-14	1.03e-11	-0.47	-0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15598222	chr4:15563698~15564253:-
PRAD	cis	rs9532669	0.853	rs9315795	ENSG00000168852.11	TPTE2P5	7.89	2.21e-14	1.04e-11	0.33	0.35	Cervical cancer;	chr13:40943382	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.963	rs3764056	ENSG00000168852.11	TPTE2P5	7.89	2.21e-14	1.04e-11	0.33	0.35	Cervical cancer;	chr13:40943849	chr13:40822296~40921749:-
PRAD	cis	rs11098499	0.863	rs13136462	ENSG00000245958.5	RP11-33B1.1	-7.89	2.21e-14	1.04e-11	-0.34	-0.35	Corneal astigmatism;	chr4:119622018	chr4:119454791~119552025:+
PRAD	cis	rs11118620	0.81	rs4587570	ENSG00000257551.1	HLX-AS1	7.89	2.21e-14	1.04e-11	0.45	0.35	Heart failure;	chr1:220860693	chr1:220832763~220880140:-
PRAD	cis	rs6539288	0.901	rs7974499	ENSG00000260329.1	RP11-412D9.4	-7.89	2.21e-14	1.04e-11	-0.31	-0.35	Total body bone mineral density;	chr12:106947607	chr12:106954029~106955497:-
PRAD	cis	rs10463554	1	rs17154893	ENSG00000175749.11	EIF3KP1	7.89	2.22e-14	1.04e-11	0.44	0.35	Parkinson's disease;	chr5:102980902	chr5:103032376~103033031:+
PRAD	cis	rs7429990	0.932	rs11130155	ENSG00000229759.1	MRPS18AP1	-7.89	2.23e-14	1.05e-11	-0.35	-0.35	Educational attainment (years of education);	chr3:48098938	chr3:48256350~48256938:-
PRAD	cis	rs7429990	0.901	rs6442102	ENSG00000229759.1	MRPS18AP1	-7.89	2.23e-14	1.05e-11	-0.35	-0.35	Educational attainment (years of education);	chr3:48111072	chr3:48256350~48256938:-
PRAD	cis	rs7429990	0.803	rs11714518	ENSG00000229759.1	MRPS18AP1	-7.89	2.23e-14	1.05e-11	-0.35	-0.35	Educational attainment (years of education);	chr3:48115145	chr3:48256350~48256938:-
PRAD	cis	rs1061377	0.513	rs2566166	ENSG00000249207.1	RP11-360F5.1	7.89	2.23e-14	1.05e-11	0.41	0.35	Uric acid levels;	chr4:39148404	chr4:39112677~39126818:-
PRAD	cis	rs3096299	0.933	rs2930219	ENSG00000261118.1	RP11-104N10.1	7.89	2.23e-14	1.05e-11	0.34	0.35	Multiple myeloma (IgH translocation);	chr16:89425641	chr16:89492017~89504460:-
PRAD	cis	rs638893	0.617	rs7933007	ENSG00000278376.1	RP11-158I9.8	7.89	2.23e-14	1.05e-11	0.36	0.35	Vitiligo;	chr11:118859960	chr11:118791254~118793137:+
PRAD	cis	rs11976180	1	rs11975942	ENSG00000170356.8	OR2A20P	-7.89	2.23e-14	1.05e-11	-0.47	-0.35	Obesity-related traits;	chr7:144043487	chr7:144250045~144252957:-
PRAD	cis	rs7688540	0.771	rs61792114	ENSG00000275426.1	CH17-262A2.1	7.89	2.24e-14	1.05e-11	0.5	0.35	Facial morphology (factor 6, height of vermillion lower lip);	chr4:295350	chr4:149738~150317:+
PRAD	cis	rs17711722	0.653	rs2460421	ENSG00000236529.1	RP13-254B10.1	-7.89	2.24e-14	1.05e-11	-0.37	-0.35	Calcium levels;	chr7:66026136	chr7:65840212~65840596:+
PRAD	cis	rs9287719	0.781	rs12472807	ENSG00000234818.1	AC092687.5	7.89	2.24e-14	1.05e-11	0.42	0.35	Prostate cancer;	chr2:10641479	chr2:10589166~10604830:+
PRAD	cis	rs62355901	0.509	rs10461615	ENSG00000271828.1	CTD-2310F14.1	7.89	2.24e-14	1.05e-11	0.77	0.35	Breast cancer;	chr5:56715913	chr5:56927874~56929573:+
PRAD	cis	rs9326248	0.559	rs10892064	ENSG00000280143.1	AP000892.6	7.89	2.24e-14	1.05e-11	0.26	0.35	Blood protein levels;	chr11:117025837	chr11:117204967~117210292:+
PRAD	cis	rs9326248	0.539	rs10892065	ENSG00000280143.1	AP000892.6	7.89	2.24e-14	1.05e-11	0.26	0.35	Blood protein levels;	chr11:117026308	chr11:117204967~117210292:+
PRAD	cis	rs4664293	0.967	rs7597482	ENSG00000226266.5	AC009961.3	-7.89	2.25e-14	1.06e-11	-0.45	-0.35	Monocyte percentage of white cells;	chr2:159690580	chr2:159670708~159712435:-
PRAD	cis	rs4664293	0.967	rs7597488	ENSG00000226266.5	AC009961.3	-7.89	2.25e-14	1.06e-11	-0.45	-0.35	Monocyte percentage of white cells;	chr2:159690585	chr2:159670708~159712435:-
PRAD	cis	rs4664293	0.902	rs13391919	ENSG00000226266.5	AC009961.3	-7.89	2.25e-14	1.06e-11	-0.45	-0.35	Monocyte percentage of white cells;	chr2:159703649	chr2:159670708~159712435:-
PRAD	cis	rs8523	0.901	rs61624919	ENSG00000230314.5	ELOVL2-AS1	7.89	2.26e-14	1.06e-11	0.38	0.35	Red blood cell fatty acid levels;	chr6:10997590	chr6:11043524~11078226:+
PRAD	cis	rs6603134	0.502	rs10405582	ENSG00000267939.1	CTD-2325M2.1	-7.89	2.26e-14	1.06e-11	-0.4	-0.35	Blood protein levels;	chr19:8038654	chr19:8008729~8016025:+
PRAD	cis	rs9287719	0.81	rs1990612	ENSG00000234818.1	AC092687.5	7.89	2.26e-14	1.06e-11	0.42	0.35	Prostate cancer;	chr2:10641818	chr2:10589166~10604830:+
PRAD	cis	rs61774743	0.521	rs60144015	ENSG00000229901.1	RP11-399E6.4	-7.89	2.26e-14	1.06e-11	-0.33	-0.35	Intelligence (multi-trait analysis);	chr1:41379574	chr1:41375004~41375669:-
PRAD	cis	rs9287719	0.81	rs7601748	ENSG00000234818.1	AC092687.5	7.89	2.26e-14	1.06e-11	0.42	0.35	Prostate cancer;	chr2:10645320	chr2:10589166~10604830:+
PRAD	cis	rs1528149	1	rs1528149	ENSG00000224683.1	RPL36AP29	7.89	2.26e-14	1.06e-11	0.43	0.35	Sitting height ratio;	chr7:16067733	chr7:16208945~16209265:+
PRAD	cis	rs2108622	0.527	rs67617968	ENSG00000267056.2	AC005336.4	7.89	2.27e-14	1.06e-11	0.47	0.35	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866755	chr19:15910582~15911824:-
PRAD	cis	rs10129255	0.556	rs8010005	ENSG00000211972.2	IGHV3-66	7.89	2.27e-14	1.06e-11	0.3	0.35	Kawasaki disease;	chr14:106777987	chr14:106675017~106675544:-
PRAD	cis	rs10129255	0.556	rs6576224	ENSG00000211972.2	IGHV3-66	7.89	2.27e-14	1.06e-11	0.3	0.35	Kawasaki disease;	chr14:106777997	chr14:106675017~106675544:-
PRAD	cis	rs2638953	0.888	rs1871152	ENSG00000247934.4	RP11-967K21.1	7.89	2.27e-14	1.07e-11	0.34	0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28226893	chr12:28163298~28190738:-
PRAD	cis	rs6061231	0.571	rs482010	ENSG00000273619.1	RP5-908M14.9	7.89	2.28e-14	1.07e-11	0.22	0.35	Colorectal cancer;	chr20:62352495	chr20:62386303~62386970:-
PRAD	cis	rs1043099	0.912	rs5753071	ENSG00000279699.1	RP1-102K2.9	-7.89	2.28e-14	1.07e-11	-0.53	-0.35	Rheumatoid arthritis;	chr22:30330837	chr22:30275215~30276951:-
PRAD	cis	rs1043099	0.912	rs10376	ENSG00000279699.1	RP1-102K2.9	-7.89	2.28e-14	1.07e-11	-0.53	-0.35	Rheumatoid arthritis;	chr22:30332367	chr22:30275215~30276951:-
PRAD	cis	rs6603134	0.502	rs10405588	ENSG00000267939.1	CTD-2325M2.1	-7.89	2.29e-14	1.07e-11	-0.4	-0.35	Blood protein levels;	chr19:8038663	chr19:8008729~8016025:+
PRAD	cis	rs526231	0.543	rs7714539	ENSG00000175749.11	EIF3KP1	7.89	2.29e-14	1.07e-11	0.47	0.35	Primary biliary cholangitis;	chr5:102993174	chr5:103032376~103033031:+
PRAD	cis	rs526231	0.543	rs60633061	ENSG00000175749.11	EIF3KP1	7.89	2.29e-14	1.07e-11	0.47	0.35	Primary biliary cholangitis;	chr5:102994345	chr5:103032376~103033031:+
PRAD	cis	rs1009647	0.656	rs10147254	ENSG00000258413.1	RP11-665C16.6	-7.89	2.29e-14	1.07e-11	-0.47	-0.35	Testicular germ cell tumor;	chr14:55383597	chr14:55262767~55272075:-
PRAD	cis	rs240993	0.715	rs7752418	ENSG00000230177.1	RP5-1112D6.4	7.89	2.29e-14	1.08e-11	0.43	0.35	Inflammatory skin disease;Psoriasis;	chr6:111466682	chr6:111277932~111278742:+
PRAD	cis	rs150992	0.571	rs34488	ENSG00000248489.1	CTD-2007H13.3	7.89	2.3e-14	1.08e-11	0.44	0.35	Body mass index;	chr5:98977773	chr5:98929171~98995013:+
PRAD	cis	rs150992	0.536	rs179053	ENSG00000248489.1	CTD-2007H13.3	7.89	2.3e-14	1.08e-11	0.44	0.35	Body mass index;	chr5:98979890	chr5:98929171~98995013:+
PRAD	cis	rs150992	0.536	rs161729	ENSG00000248489.1	CTD-2007H13.3	7.89	2.3e-14	1.08e-11	0.44	0.35	Body mass index;	chr5:98982477	chr5:98929171~98995013:+
PRAD	cis	rs150992	0.536	rs161730	ENSG00000248489.1	CTD-2007H13.3	7.89	2.3e-14	1.08e-11	0.44	0.35	Body mass index;	chr5:98982631	chr5:98929171~98995013:+
PRAD	cis	rs6600671	0.693	rs1853731	ENSG00000223345.3	HIST2H2BA	7.89	2.3e-14	1.08e-11	0.42	0.35	Hip geometry;	chr1:121510262	chr1:121108210~121117257:-
PRAD	cis	rs2946504	0.861	rs2977085	ENSG00000251468.2	RP11-369K16.1	-7.89	2.3e-14	1.08e-11	-0.44	-0.35	Type 2 diabetes;	chr8:12956237	chr8:12958387~12962200:+
PRAD	cis	rs7829975	0.593	rs2979241	ENSG00000253893.2	FAM85B	-7.89	2.3e-14	1.08e-11	-0.42	-0.35	Mood instability;	chr8:8445843	chr8:8167819~8226614:-
PRAD	cis	rs914615	0.552	rs11264339	ENSG00000160766.13	GBAP1	7.89	2.3e-14	1.08e-11	0.35	0.35	Urinary albumin-to-creatinine ratio;	chr1:155168172	chr1:155213821~155227422:-
PRAD	cis	rs867371	0.82	rs12443224	ENSG00000278603.1	RP13-608F4.5	7.89	2.31e-14	1.08e-11	0.46	0.35	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82203269	chr15:82472203~82472426:+
PRAD	cis	rs6847067	0.929	rs1484660	ENSG00000180769.7	WDFY3-AS2	7.89	2.31e-14	1.08e-11	0.36	0.35	Oropharynx cancer;	chr4:84861028	chr4:84965682~85011277:+
PRAD	cis	rs2638953	0.925	rs11049491	ENSG00000278733.1	RP11-425D17.1	-7.89	2.32e-14	1.09e-11	-0.44	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28262340	chr12:28185625~28186190:-
PRAD	cis	rs6061231	0.597	rs624313	ENSG00000273619.1	RP5-908M14.9	7.89	2.32e-14	1.09e-11	0.22	0.35	Colorectal cancer;	chr20:62352356	chr20:62386303~62386970:-
PRAD	cis	rs1185460	1	rs4614	ENSG00000271751.1	RP11-110I1.14	-7.89	2.32e-14	1.09e-11	-0.48	-0.35	Coronary artery disease;	chr11:119081661	chr11:119065263~119065677:-
PRAD	cis	rs321358	1	rs321357	ENSG00000271584.1	RP11-89C3.4	7.89	2.32e-14	1.09e-11	0.53	0.35	Body mass index;	chr11:111125002	chr11:111091932~111097357:-
PRAD	cis	rs7429990	0.932	rs936428	ENSG00000229759.1	MRPS18AP1	-7.89	2.33e-14	1.09e-11	-0.35	-0.35	Educational attainment (years of education);	chr3:48125791	chr3:48256350~48256938:-
PRAD	cis	rs7727544	0.654	rs4705849	ENSG00000233006.5	AC034220.3	7.89	2.33e-14	1.09e-11	0.3	0.35	Blood metabolite levels;	chr5:132223506	chr5:132311285~132369916:-
PRAD	cis	rs67340775	0.541	rs200965	ENSG00000280107.1	AL022393.9	-7.89	2.33e-14	1.09e-11	-0.56	-0.35	Lung cancer in ever smokers;	chr6:27898606	chr6:28170845~28172521:+
PRAD	cis	rs67340775	0.541	rs200964	ENSG00000280107.1	AL022393.9	-7.89	2.33e-14	1.09e-11	-0.56	-0.35	Lung cancer in ever smokers;	chr6:27899165	chr6:28170845~28172521:+
PRAD	cis	rs507080	0.501	rs625735	ENSG00000255422.1	AP002954.4	-7.89	2.34e-14	1.1e-11	-0.4	-0.35	Serum metabolite levels;	chr11:118704710	chr11:118704607~118750263:+
PRAD	cis	rs6603134	0.502	rs10411185	ENSG00000267939.1	CTD-2325M2.1	-7.89	2.34e-14	1.1e-11	-0.4	-0.35	Blood protein levels;	chr19:8038997	chr19:8008729~8016025:+
PRAD	cis	rs6001482	0.679	rs1894238	ENSG00000272779.1	LL22NC03-80A10.6	-7.89	2.34e-14	1.1e-11	-0.42	-0.35	Diastolic blood pressure;	chr22:22235704	chr22:22303224~22310401:+
PRAD	cis	rs9326248	0.515	rs2727793	ENSG00000280143.1	AP000892.6	7.89	2.34e-14	1.1e-11	0.3	0.35	Blood protein levels;	chr11:116812658	chr11:117204967~117210292:+
PRAD	cis	rs7181230	1	rs28587891	ENSG00000275636.1	RP11-521C20.5	7.89	2.35e-14	1.1e-11	0.45	0.35	Dehydroepiandrosterone sulphate levels;	chr15:40072905	chr15:40078892~40079347:+
PRAD	cis	rs8523	0.901	rs9380025	ENSG00000230314.5	ELOVL2-AS1	7.88	2.35e-14	1.1e-11	0.38	0.35	Red blood cell fatty acid levels;	chr6:11010841	chr6:11043524~11078226:+
PRAD	cis	rs62355901	0.599	rs12656399	ENSG00000271828.1	CTD-2310F14.1	7.88	2.35e-14	1.1e-11	0.77	0.35	Breast cancer;	chr5:56731016	chr5:56927874~56929573:+
PRAD	cis	rs62355901	0.551	rs72756073	ENSG00000271828.1	CTD-2310F14.1	7.88	2.35e-14	1.1e-11	0.77	0.35	Breast cancer;	chr5:56732554	chr5:56927874~56929573:+
PRAD	cis	rs62355901	0.551	rs61103728	ENSG00000271828.1	CTD-2310F14.1	7.88	2.35e-14	1.1e-11	0.77	0.35	Breast cancer;	chr5:56733066	chr5:56927874~56929573:+
PRAD	cis	rs67311347	0.506	rs55962832	ENSG00000223797.4	ENTPD3-AS1	7.88	2.35e-14	1.1e-11	0.32	0.35	Renal cell carcinoma;	chr3:40202960	chr3:40313802~40453329:-
PRAD	cis	rs10463554	0.963	rs34774	ENSG00000175749.11	EIF3KP1	7.88	2.36e-14	1.1e-11	0.46	0.35	Parkinson's disease;	chr5:103115116	chr5:103032376~103033031:+
PRAD	cis	rs10463554	0.963	rs34777	ENSG00000175749.11	EIF3KP1	7.88	2.36e-14	1.1e-11	0.46	0.35	Parkinson's disease;	chr5:103116554	chr5:103032376~103033031:+
PRAD	cis	rs2243480	0.803	rs36127118	ENSG00000226824.5	RP4-756H11.3	-7.88	2.36e-14	1.1e-11	-0.68	-0.35	Diabetic kidney disease;	chr7:66100518	chr7:66654538~66669855:+
PRAD	cis	rs440932	1	rs365309	ENSG00000254340.1	RP11-10A14.3	-7.88	2.36e-14	1.11e-11	-0.41	-0.35	High light scatter reticulocyte percentage of red cells;	chr8:9169430	chr8:9141424~9145435:+
PRAD	cis	rs17711722	0.523	rs365896	ENSG00000164669.11	INTS4P1	7.88	2.37e-14	1.11e-11	0.43	0.35	Calcium levels;	chr7:66045710	chr7:65141225~65234216:+
PRAD	cis	rs2337406	0.587	rs11624678	ENSG00000274576.2	IGHV2-70	7.88	2.37e-14	1.11e-11	0.38	0.35	Alzheimer's disease (late onset);	chr14:106650408	chr14:106770577~106771020:-
PRAD	cis	rs9640161	0.75	rs73170185	ENSG00000261305.1	RP4-584D14.7	7.88	2.38e-14	1.11e-11	0.39	0.35	Blood protein levels;Circulating chemerin levels;	chr7:150333102	chr7:150341771~150342607:+
PRAD	cis	rs964611	0.882	rs8025164	ENSG00000259488.2	RP11-154J22.1	7.88	2.38e-14	1.11e-11	0.36	0.35	Metabolite levels (Pyroglutamine);	chr15:48346517	chr15:48312353~48331856:-
PRAD	cis	rs11096990	0.634	rs1451818	ENSG00000249207.1	RP11-360F5.1	-7.88	2.38e-14	1.11e-11	-0.36	-0.35	Cognitive function;	chr4:39257151	chr4:39112677~39126818:-
PRAD	cis	rs3020264	0.579	rs2454517	ENSG00000271743.1	CTD-2541M15.3	-7.88	2.39e-14	1.12e-11	-0.41	-0.35	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks);	chr8:6616237	chr8:6615604~6617198:-
PRAD	cis	rs2274273	0.588	rs17675223	ENSG00000258413.1	RP11-665C16.6	-7.88	2.39e-14	1.12e-11	-0.47	-0.35	Protein biomarker;	chr14:55395518	chr14:55262767~55272075:-
PRAD	cis	rs4835473	0.932	rs1375986	ENSG00000251600.4	RP11-673E1.1	-7.88	2.39e-14	1.12e-11	-0.44	-0.35	Immature fraction of reticulocytes;	chr4:143746048	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.868	rs35420625	ENSG00000251600.4	RP11-673E1.1	-7.88	2.39e-14	1.12e-11	-0.44	-0.35	Immature fraction of reticulocytes;	chr4:143746089	chr4:143912331~143982454:+
PRAD	cis	rs4835473	0.9	rs4835009	ENSG00000251600.4	RP11-673E1.1	-7.88	2.39e-14	1.12e-11	-0.44	-0.35	Immature fraction of reticulocytes;	chr4:143746130	chr4:143912331~143982454:+
PRAD	cis	rs950169	0.579	rs11633088	ENSG00000225151.9	GOLGA2P7	7.88	2.39e-14	1.12e-11	0.5	0.35	Schizophrenia;	chr15:84003429	chr15:84199311~84230136:-
PRAD	cis	rs526231	0.543	rs75913944	ENSG00000175749.11	EIF3KP1	7.88	2.4e-14	1.12e-11	0.48	0.35	Primary biliary cholangitis;	chr5:103143799	chr5:103032376~103033031:+
PRAD	cis	rs1061377	0.722	rs34803689	ENSG00000249685.1	RP11-360F5.3	7.88	2.4e-14	1.12e-11	0.39	0.35	Uric acid levels;	chr4:39116665	chr4:39133913~39135608:+
PRAD	cis	rs62355901	0.545	rs16886256	ENSG00000271828.1	CTD-2310F14.1	-7.88	2.41e-14	1.12e-11	-0.64	-0.35	Breast cancer;	chr5:56765737	chr5:56927874~56929573:+
PRAD	cis	rs6570726	0.967	rs365515	ENSG00000235652.6	RP11-545I5.3	-7.88	2.41e-14	1.12e-11	-0.36	-0.35	Lobe attachment (rater-scored or self-reported);	chr6:145481697	chr6:145799409~145886585:+
PRAD	cis	rs7727544	0.716	rs72793278	ENSG00000233006.5	AC034220.3	7.88	2.41e-14	1.13e-11	0.3	0.35	Blood metabolite levels;	chr5:132225679	chr5:132311285~132369916:-
PRAD	cis	rs11976180	1	rs1540894	ENSG00000170356.8	OR2A20P	-7.88	2.42e-14	1.13e-11	-0.46	-0.35	Obesity-related traits;	chr7:144070583	chr7:144250045~144252957:-
PRAD	cis	rs11976180	1	rs2951308	ENSG00000273234.1	OR2A13P	7.88	2.43e-14	1.13e-11	0.42	0.35	Obesity-related traits;	chr7:144070056	chr7:144142009~144142938:+
PRAD	cis	rs867186	0.535	rs2275274	ENSG00000126005.14	MMP24-AS1	-7.88	2.43e-14	1.13e-11	-0.59	-0.35	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35269741	chr20:35216462~35278131:-
PRAD	cis	rs9640161	0.75	rs3800780	ENSG00000261305.1	RP4-584D14.7	7.88	2.43e-14	1.14e-11	0.39	0.35	Blood protein levels;Circulating chemerin levels;	chr7:150330195	chr7:150341771~150342607:+
PRAD	cis	rs1555322	0.53	rs2275275	ENSG00000279253.1	RP4-614O4.13	-7.88	2.43e-14	1.14e-11	-0.41	-0.35	Attention deficit hyperactivity disorder;	chr20:35284508	chr20:35262727~35264187:-
PRAD	cis	rs8091660	0.929	rs4939780	ENSG00000278983.1	RP11-426J5.3	7.88	2.43e-14	1.14e-11	0.43	0.35	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48568873	chr18:48564795~48568342:+
PRAD	cis	rs9326248	0.731	rs90192	ENSG00000280143.1	AP000892.6	7.88	2.44e-14	1.14e-11	0.36	0.35	Blood protein levels;	chr11:117188631	chr11:117204967~117210292:+
PRAD	cis	rs526231	0.511	rs34823	ENSG00000175749.11	EIF3KP1	-7.88	2.44e-14	1.14e-11	-0.48	-0.35	Primary biliary cholangitis;	chr5:103102587	chr5:103032376~103033031:+
PRAD	cis	rs494459	0.657	rs614554	ENSG00000278376.1	RP11-158I9.8	-7.88	2.45e-14	1.15e-11	-0.29	-0.35	Height;	chr11:118764443	chr11:118791254~118793137:+
PRAD	cis	rs10463554	0.963	rs154355	ENSG00000175749.11	EIF3KP1	7.88	2.45e-14	1.15e-11	0.46	0.35	Parkinson's disease;	chr5:103163177	chr5:103032376~103033031:+
PRAD	cis	rs26232	0.517	rs154356	ENSG00000175749.11	EIF3KP1	7.88	2.45e-14	1.15e-11	0.46	0.35	Rheumatoid arthritis;	chr5:103163440	chr5:103032376~103033031:+
PRAD	cis	rs10129255	0.518	rs8010020	ENSG00000211972.2	IGHV3-66	7.88	2.46e-14	1.15e-11	0.3	0.35	Kawasaki disease;	chr14:106778016	chr14:106675017~106675544:-
PRAD	cis	rs10129255	0.5	rs6576225	ENSG00000211972.2	IGHV3-66	7.88	2.46e-14	1.15e-11	0.3	0.35	Kawasaki disease;	chr14:106778120	chr14:106675017~106675544:-
PRAD	cis	rs10129255	0.5	rs6576226	ENSG00000211972.2	IGHV3-66	7.88	2.46e-14	1.15e-11	0.3	0.35	Kawasaki disease;	chr14:106778135	chr14:106675017~106675544:-
PRAD	cis	rs10463554	1	rs11949145	ENSG00000175749.11	EIF3KP1	7.88	2.47e-14	1.15e-11	0.44	0.35	Parkinson's disease;	chr5:102994552	chr5:103032376~103033031:+
PRAD	cis	rs17772222	0.958	rs2297128	ENSG00000258983.2	RP11-507K2.2	7.88	2.47e-14	1.15e-11	0.49	0.35	Coronary artery calcification;	chr14:88469910	chr14:88499334~88515502:+
PRAD	cis	rs12701220	0.553	rs13245507	ENSG00000229043.2	AC091729.9	-7.88	2.47e-14	1.16e-11	-0.51	-0.35	Bronchopulmonary dysplasia;	chr7:1124058	chr7:1160374~1165267:+
PRAD	cis	rs2274273	0.624	rs7147247	ENSG00000258413.1	RP11-665C16.6	-7.88	2.48e-14	1.16e-11	-0.47	-0.35	Protein biomarker;	chr14:55310995	chr14:55262767~55272075:-
PRAD	cis	rs9326248	0.581	rs4938331	ENSG00000280143.1	AP000892.6	7.88	2.49e-14	1.16e-11	0.26	0.35	Blood protein levels;	chr11:117059966	chr11:117204967~117210292:+
PRAD	cis	rs9326248	0.51	rs4938332	ENSG00000280143.1	AP000892.6	7.88	2.49e-14	1.16e-11	0.26	0.35	Blood protein levels;	chr11:117060082	chr11:117204967~117210292:+
PRAD	cis	rs9326248	0.581	rs6589590	ENSG00000280143.1	AP000892.6	7.88	2.49e-14	1.16e-11	0.26	0.35	Blood protein levels;	chr11:117065365	chr11:117204967~117210292:+
PRAD	cis	rs9810089	0.868	rs4630889	ENSG00000261758.1	RP11-102M11.2	7.88	2.49e-14	1.16e-11	0.4	0.35	Gestational age at birth (child effect);	chr3:136559409	chr3:136752630~136755780:+
PRAD	cis	rs5760092	0.618	rs5996631	ENSG00000224205.1	AP000351.4	-7.88	2.5e-14	1.17e-11	-0.48	-0.35	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23987320~23991421:-
PRAD	cis	rs11976180	1	rs2961120	ENSG00000170356.8	OR2A20P	-7.88	2.51e-14	1.17e-11	-0.46	-0.35	Obesity-related traits;	chr7:144059492	chr7:144250045~144252957:-
PRAD	cis	rs11976180	1	rs2951360	ENSG00000170356.8	OR2A20P	-7.88	2.51e-14	1.17e-11	-0.46	-0.35	Obesity-related traits;	chr7:144060256	chr7:144250045~144252957:-
PRAD	cis	rs9341835	0.618	rs1779747	ENSG00000218048.2	RP3-407E4.4	-7.88	2.51e-14	1.17e-11	-0.39	-0.35	Schizophrenia;	chr6:63431195	chr6:63440766~63443580:+
PRAD	cis	rs6847067	0.732	rs13124246	ENSG00000180769.7	WDFY3-AS2	7.88	2.52e-14	1.17e-11	0.36	0.35	Oropharynx cancer;	chr4:84974368	chr4:84965682~85011277:+
PRAD	cis	rs2337406	1	rs11849532	ENSG00000274576.2	IGHV2-70	-7.88	2.52e-14	1.17e-11	-0.37	-0.35	Alzheimer's disease (late onset);	chr14:106669877	chr14:106770577~106771020:-
PRAD	cis	rs17711722	0.523	rs365896	ENSG00000224316.1	RP11-479O9.2	-7.87	2.53e-14	1.18e-11	-0.32	-0.35	Calcium levels;	chr7:66045710	chr7:65773620~65802067:+
PRAD	cis	rs1043099	0.912	rs740219	ENSG00000279699.1	RP1-102K2.9	-7.87	2.55e-14	1.19e-11	-0.53	-0.35	Rheumatoid arthritis;	chr22:30318695	chr22:30275215~30276951:-
PRAD	cis	rs17772222	0.837	rs1864748	ENSG00000258983.2	RP11-507K2.2	7.87	2.55e-14	1.19e-11	0.5	0.35	Coronary artery calcification;	chr14:88488847	chr14:88499334~88515502:+
PRAD	cis	rs673078	0.607	rs17512763	ENSG00000275409.1	RP11-131L12.4	-7.87	2.56e-14	1.2e-11	-0.48	-0.35	Glucose homeostasis traits;	chr12:118400974	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.607	rs61944669	ENSG00000275409.1	RP11-131L12.4	-7.87	2.58e-14	1.2e-11	-0.49	-0.35	Glucose homeostasis traits;	chr12:118448530	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.607	rs61944670	ENSG00000275409.1	RP11-131L12.4	-7.87	2.58e-14	1.2e-11	-0.49	-0.35	Glucose homeostasis traits;	chr12:118448697	chr12:118430147~118430699:+
PRAD	cis	rs2255336	0.817	rs4764430	ENSG00000245648.1	RP11-277P12.20	7.87	2.58e-14	1.2e-11	0.51	0.35	Blood protein levels;	chr12:10365209	chr12:10363769~10398506:+
PRAD	cis	rs2115630	0.846	rs8024538	ENSG00000275120.1	RP11-182J1.17	-7.87	2.58e-14	1.2e-11	-0.41	-0.35	P wave terminal force;	chr15:84825188	chr15:84599434~84606463:-
PRAD	cis	rs4927850	1	rs10881563	ENSG00000207650.1	MIR570	7.87	2.58e-14	1.2e-11	0.37	0.35	Pancreatic cancer;	chr3:196023354	chr3:195699401~195699497:+
PRAD	cis	rs10129255	0.518	rs8009594	ENSG00000211972.2	IGHV3-66	7.87	2.59e-14	1.21e-11	0.3	0.35	Kawasaki disease;	chr14:106777494	chr14:106675017~106675544:-
PRAD	cis	rs6570726	0.967	rs9497316	ENSG00000235652.6	RP11-545I5.3	-7.87	2.59e-14	1.21e-11	-0.36	-0.35	Lobe attachment (rater-scored or self-reported);	chr6:145471251	chr6:145799409~145886585:+
PRAD	cis	rs9516	0.544	rs681179	ENSG00000254974.1	RP11-702H23.2	7.87	2.59e-14	1.21e-11	0.44	0.35	Facial morphology (factor 15, philtrum width);	chr11:74475791	chr11:74485580~74486051:-
PRAD	cis	rs1930961	1	rs6004669	ENSG00000271138.1	IGLVIVOR22-1	-7.87	2.61e-14	1.21e-11	-0.52	-0.35	Bipolar disorder with mood-incongruent psychosis;	chr22:25479836	chr22:25437306~25437823:-
PRAD	cis	rs1930961	1	rs997872	ENSG00000271138.1	IGLVIVOR22-1	-7.87	2.61e-14	1.21e-11	-0.52	-0.35	Bipolar disorder with mood-incongruent psychosis;	chr22:25482647	chr22:25437306~25437823:-
PRAD	cis	rs673078	0.607	rs56080343	ENSG00000275409.1	RP11-131L12.4	-7.87	2.61e-14	1.22e-11	-0.44	-0.35	Glucose homeostasis traits;	chr12:118439113	chr12:118430147~118430699:+
PRAD	cis	rs964611	0.882	rs12442530	ENSG00000259488.2	RP11-154J22.1	-7.87	2.62e-14	1.22e-11	-0.33	-0.35	Metabolite levels (Pyroglutamine);	chr15:48288376	chr15:48312353~48331856:-
PRAD	cis	rs26232	0.521	rs3776855	ENSG00000175749.11	EIF3KP1	7.87	2.63e-14	1.22e-11	0.48	0.35	Rheumatoid arthritis;	chr5:103023111	chr5:103032376~103033031:+
PRAD	cis	rs1155848	0.571	rs7983556	ENSG00000227354.5	RBM26-AS1	7.87	2.63e-14	1.23e-11	0.59	0.35	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79608777	chr13:79406309~79424328:+
PRAD	cis	rs2117029	0.767	rs11168838	ENSG00000258017.1	RP11-386G11.10	-7.87	2.63e-14	1.23e-11	-0.51	-0.35	Intelligence (multi-trait analysis);	chr12:49061223	chr12:49127782~49147869:+
PRAD	cis	rs12817211	0.549	rs6580728	ENSG00000272368.2	RP4-605O3.4	-7.87	2.64e-14	1.23e-11	-0.35	-0.35	Colorectal or endometrial cancer;	chr12:50147344	chr12:50112197~50165618:+
PRAD	cis	rs6061231	0.518	rs639836	ENSG00000273619.1	RP5-908M14.9	7.87	2.64e-14	1.23e-11	0.22	0.35	Colorectal cancer;	chr20:62351167	chr20:62386303~62386970:-
PRAD	cis	rs7238033	0.686	rs3819177	ENSG00000267193.4	RP11-116O18.3	7.87	2.64e-14	1.23e-11	0.38	0.35	Bladder cancer;	chr18:45736145	chr18:45669367~45747215:-
PRAD	cis	rs10875746	0.551	rs1471998	ENSG00000240399.1	RP1-228P16.1	-7.87	2.65e-14	1.23e-11	-0.33	-0.35	Longevity (90 years and older);	chr12:48318219	chr12:48054813~48055591:-
PRAD	cis	rs10875746	0.551	rs2054904	ENSG00000240399.1	RP1-228P16.1	-7.87	2.65e-14	1.23e-11	-0.33	-0.35	Longevity (90 years and older);	chr12:48330571	chr12:48054813~48055591:-
PRAD	cis	rs11083475	1	rs10415219	ENSG00000267892.1	CTD-2540F13.2	7.87	2.65e-14	1.24e-11	0.37	0.35	Heart rate;	chr19:38659595	chr19:38738284~38739863:+
PRAD	cis	rs494459	0.838	rs581045	ENSG00000278376.1	RP11-158I9.8	-7.87	2.66e-14	1.24e-11	-0.29	-0.35	Height;	chr11:118761813	chr11:118791254~118793137:+
PRAD	cis	rs56080343	0.808	rs1045552	ENSG00000275409.1	RP11-131L12.4	-7.87	2.67e-14	1.24e-11	-0.49	-0.35	Neuroticism;	chr12:118417678	chr12:118430147~118430699:+
PRAD	cis	rs12594515	0.548	rs55932467	ENSG00000273972.1	CTD-2306A12.1	-7.87	2.68e-14	1.25e-11	-0.42	-0.35	Weight;Waist circumference;	chr15:45704926	chr15:45702640~45703183:+
PRAD	cis	rs17361889	0.711	rs1120230	ENSG00000224683.1	RPL36AP29	7.87	2.68e-14	1.25e-11	0.41	0.35	Pediatric bone mineral content (hip);	chr7:16110992	chr7:16208945~16209265:+
PRAD	cis	rs11159086	0.793	rs1029701	ENSG00000270000.1	RP3-449M8.9	7.87	2.69e-14	1.25e-11	0.52	0.35	Advanced glycation end-product levels;	chr14:74474112	chr14:74471930~74472360:-
PRAD	cis	rs7567389	0.677	rs61422716	ENSG00000236682.1	AC068282.3	-7.87	2.7e-14	1.25e-11	-0.46	-0.35	Self-rated health;	chr2:127330075	chr2:127389130~127400580:+
PRAD	cis	rs7567389	0.677	rs10496661	ENSG00000236682.1	AC068282.3	-7.87	2.7e-14	1.25e-11	-0.46	-0.35	Self-rated health;	chr2:127332568	chr2:127389130~127400580:+
PRAD	cis	rs7567389	0.677	rs11680877	ENSG00000236682.1	AC068282.3	-7.87	2.7e-14	1.25e-11	-0.46	-0.35	Self-rated health;	chr2:127332874	chr2:127389130~127400580:+
PRAD	cis	rs7567389	0.677	rs72846002	ENSG00000236682.1	AC068282.3	-7.87	2.7e-14	1.25e-11	-0.46	-0.35	Self-rated health;	chr2:127360571	chr2:127389130~127400580:+
PRAD	cis	rs7567389	0.677	rs72848604	ENSG00000236682.1	AC068282.3	-7.87	2.7e-14	1.25e-11	-0.46	-0.35	Self-rated health;	chr2:127362542	chr2:127389130~127400580:+
PRAD	cis	rs10463554	0.963	rs32840	ENSG00000175749.11	EIF3KP1	7.87	2.71e-14	1.26e-11	0.45	0.35	Parkinson's disease;	chr5:103143446	chr5:103032376~103033031:+
PRAD	cis	rs2638953	0.962	rs9300176	ENSG00000278733.1	RP11-425D17.1	7.86	2.71e-14	1.26e-11	0.4	0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28368584	chr12:28185625~28186190:-
PRAD	cis	rs2243480	1	rs4718317	ENSG00000226824.5	RP4-756H11.3	7.86	2.71e-14	1.26e-11	0.68	0.35	Diabetic kidney disease;	chr7:66183914	chr7:66654538~66669855:+
PRAD	cis	rs6545883	0.501	rs935860	ENSG00000271889.1	RP11-493E12.1	7.86	2.72e-14	1.26e-11	0.38	0.35	Tuberculosis;	chr2:61179426	chr2:61151433~61162105:-
PRAD	cis	rs526231	0.543	rs62362544	ENSG00000175749.11	EIF3KP1	7.86	2.72e-14	1.27e-11	0.47	0.35	Primary biliary cholangitis;	chr5:102998543	chr5:103032376~103033031:+
PRAD	cis	rs17428076	0.793	rs12622772	ENSG00000228389.1	AC068039.4	-7.86	2.73e-14	1.27e-11	-0.44	-0.35	Myopia;	chr2:171769227	chr2:171773482~171775844:+
PRAD	cis	rs435066	0.633	rs4607932	ENSG00000234264.1	DEPDC1-AS1	-7.86	2.73e-14	1.27e-11	-0.51	-0.35	IgG glycosylation;	chr1:68571661	chr1:68496676~68538627:+
PRAD	cis	rs435066	0.633	rs6694172	ENSG00000234264.1	DEPDC1-AS1	-7.86	2.73e-14	1.27e-11	-0.51	-0.35	IgG glycosylation;	chr1:68573694	chr1:68496676~68538627:+
PRAD	cis	rs11096990	0.634	rs6852967	ENSG00000249207.1	RP11-360F5.1	7.86	2.73e-14	1.27e-11	0.36	0.35	Cognitive function;	chr4:39281526	chr4:39112677~39126818:-
PRAD	cis	rs11148252	0.508	rs6561671	ENSG00000278238.1	RP11-245D16.4	-7.86	2.73e-14	1.27e-11	-0.36	-0.35	Lewy body disease;	chr13:52608179	chr13:52454775~52455331:-
PRAD	cis	rs2274273	0.624	rs10141396	ENSG00000258413.1	RP11-665C16.6	-7.86	2.73e-14	1.27e-11	-0.47	-0.35	Protein biomarker;	chr14:55350207	chr14:55262767~55272075:-
PRAD	cis	rs964611	0.882	rs12594698	ENSG00000259488.2	RP11-154J22.1	-7.86	2.74e-14	1.27e-11	-0.33	-0.35	Metabolite levels (Pyroglutamine);	chr15:48282759	chr15:48312353~48331856:-
PRAD	cis	rs11118620	0.81	rs1603047	ENSG00000257551.1	HLX-AS1	7.86	2.74e-14	1.27e-11	0.45	0.35	Heart failure;	chr1:220849953	chr1:220832763~220880140:-
PRAD	cis	rs11118620	1	rs11118620	ENSG00000257551.1	HLX-AS1	7.86	2.74e-14	1.27e-11	0.45	0.35	Heart failure;	chr1:220855166	chr1:220832763~220880140:-
PRAD	cis	rs1979679	0.918	rs7314502	ENSG00000278733.1	RP11-425D17.1	-7.86	2.75e-14	1.28e-11	-0.44	-0.35	Ossification of the posterior longitudinal ligament of the spine;	chr12:28462300	chr12:28185625~28186190:-
PRAD	cis	rs1023500	0.573	rs133380	ENSG00000205702.9	CYP2D7	7.86	2.76e-14	1.28e-11	0.26	0.35	Schizophrenia;	chr22:42072906	chr22:42140203~42144577:-
PRAD	cis	rs12908161	1	rs11637142	ENSG00000259728.4	LINC00933	7.86	2.76e-14	1.28e-11	0.42	0.35	Schizophrenia;	chr15:84752696	chr15:84570649~84580175:+
PRAD	cis	rs526231	0.543	rs34765	ENSG00000175749.11	EIF3KP1	7.86	2.76e-14	1.28e-11	0.48	0.35	Primary biliary cholangitis;	chr5:103171160	chr5:103032376~103033031:+
PRAD	cis	rs526231	0.543	rs183752	ENSG00000175749.11	EIF3KP1	7.86	2.76e-14	1.28e-11	0.48	0.35	Primary biliary cholangitis;	chr5:103172108	chr5:103032376~103033031:+
PRAD	cis	rs6517329	0.624	rs4817774	ENSG00000236830.5	CBR3-AS1	7.86	2.76e-14	1.28e-11	0.36	0.35	Schizophrenia;	chr21:36112344	chr21:36131767~36175815:-
PRAD	cis	rs10129255	0.589	rs78599641	ENSG00000211970.3	IGHV4-61	-7.86	2.77e-14	1.29e-11	-0.33	-0.35	Kawasaki disease;	chr14:106637576	chr14:106639119~106639657:-
PRAD	cis	rs12908161	0.959	rs11637728	ENSG00000259728.4	LINC00933	7.86	2.77e-14	1.29e-11	0.41	0.35	Schizophrenia;	chr15:84660161	chr15:84570649~84580175:+
PRAD	cis	rs9467773	0.534	rs34453863	ENSG00000241549.7	GUSBP2	7.86	2.77e-14	1.29e-11	0.38	0.35	Intelligence (multi-trait analysis);	chr6:26627777	chr6:26871484~26956554:-
PRAD	cis	rs853679	0.527	rs853683	ENSG00000204709.4	LINC01556	7.86	2.77e-14	1.29e-11	0.45	0.35	Depression;	chr6:28327262	chr6:28943877~28944537:+
PRAD	cis	rs2638953	0.962	rs61922969	ENSG00000278733.1	RP11-425D17.1	-7.86	2.78e-14	1.29e-11	-0.45	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28261721	chr12:28185625~28186190:-
PRAD	cis	rs9287719	0.781	rs6714795	ENSG00000234818.1	AC092687.5	7.86	2.78e-14	1.29e-11	0.41	0.35	Prostate cancer;	chr2:10619008	chr2:10589166~10604830:+
PRAD	cis	rs1061377	0.513	rs2711994	ENSG00000249207.1	RP11-360F5.1	7.86	2.78e-14	1.29e-11	0.41	0.35	Uric acid levels;	chr4:39148121	chr4:39112677~39126818:-
PRAD	cis	rs8523	0.838	rs3778167	ENSG00000230314.5	ELOVL2-AS1	7.86	2.79e-14	1.29e-11	0.38	0.35	Red blood cell fatty acid levels;	chr6:11033235	chr6:11043524~11078226:+
PRAD	cis	rs9326248	0.574	rs1263173	ENSG00000280143.1	AP000892.6	7.86	2.79e-14	1.3e-11	0.29	0.35	Blood protein levels;	chr11:116810292	chr11:117204967~117210292:+
PRAD	cis	rs964611	0.882	rs4775749	ENSG00000259488.2	RP11-154J22.1	7.86	2.8e-14	1.3e-11	0.35	0.35	Metabolite levels (Pyroglutamine);	chr15:48350064	chr15:48312353~48331856:-
PRAD	cis	rs9326248	0.581	rs11216242	ENSG00000280143.1	AP000892.6	7.86	2.8e-14	1.3e-11	0.26	0.35	Blood protein levels;	chr11:117030833	chr11:117204967~117210292:+
PRAD	cis	rs9326248	0.581	rs12804122	ENSG00000280143.1	AP000892.6	7.86	2.8e-14	1.3e-11	0.26	0.35	Blood protein levels;	chr11:117031900	chr11:117204967~117210292:+
PRAD	cis	rs67180937	0.921	rs35700460	ENSG00000272750.1	RP11-378J18.8	-7.86	2.81e-14	1.31e-11	-0.46	-0.35	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222638065	chr1:222658867~222661512:-
PRAD	cis	rs526231	0.543	rs246900	ENSG00000175749.11	EIF3KP1	7.86	2.82e-14	1.31e-11	0.48	0.35	Primary biliary cholangitis;	chr5:103198928	chr5:103032376~103033031:+
PRAD	cis	rs7829975	0.564	rs2976855	ENSG00000253893.2	FAM85B	-7.86	2.83e-14	1.31e-11	-0.42	-0.35	Mood instability;	chr8:8444284	chr8:8167819~8226614:-
PRAD	cis	rs12130219	1	rs12130219	ENSG00000237975.5	FLG-AS1	7.86	2.83e-14	1.31e-11	0.53	0.35	Inflammatory skin disease;	chr1:152189630	chr1:152168125~152445456:+
PRAD	cis	rs12130219	1	rs1552994	ENSG00000237975.5	FLG-AS1	7.86	2.83e-14	1.31e-11	0.53	0.35	Inflammatory skin disease;	chr1:152198985	chr1:152168125~152445456:+
PRAD	cis	rs12130219	1	rs12733173	ENSG00000237975.5	FLG-AS1	7.86	2.83e-14	1.31e-11	0.53	0.35	Inflammatory skin disease;	chr1:152201496	chr1:152168125~152445456:+
PRAD	cis	rs7923609	0.846	rs10761739	ENSG00000232075.1	MRPL35P2	7.86	2.83e-14	1.31e-11	0.37	0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63302248	chr10:63634317~63634827:-
PRAD	cis	rs17428076	0.836	rs12053046	ENSG00000228389.1	AC068039.4	-7.86	2.84e-14	1.32e-11	-0.45	-0.35	Myopia;	chr2:171816889	chr2:171773482~171775844:+
PRAD	cis	rs1979679	0.918	rs1533142	ENSG00000278733.1	RP11-425D17.1	-7.86	2.84e-14	1.32e-11	-0.45	-0.35	Ossification of the posterior longitudinal ligament of the spine;	chr12:28461206	chr12:28185625~28186190:-
PRAD	cis	rs11159086	1	rs11159086	ENSG00000259005.1	RP3-449M8.6	7.86	2.84e-14	1.32e-11	0.47	0.35	Advanced glycation end-product levels;	chr14:74495572	chr14:74474007~74474864:-
PRAD	cis	rs494459	0.838	rs555639	ENSG00000278376.1	RP11-158I9.8	7.86	2.85e-14	1.32e-11	0.29	0.35	Height;	chr11:118758322	chr11:118791254~118793137:+
PRAD	cis	rs10875746	0.551	rs10875799	ENSG00000240399.1	RP1-228P16.1	-7.86	2.87e-14	1.33e-11	-0.34	-0.35	Longevity (90 years and older);	chr12:48347096	chr12:48054813~48055591:-
PRAD	cis	rs1979679	0.918	rs10771429	ENSG00000278733.1	RP11-425D17.1	-7.86	2.87e-14	1.33e-11	-0.45	-0.35	Ossification of the posterior longitudinal ligament of the spine;	chr12:28468573	chr12:28185625~28186190:-
PRAD	cis	rs62355900	0.627	rs72758096	ENSG00000271828.1	CTD-2310F14.1	7.86	2.88e-14	1.34e-11	0.72	0.35	Endometriosis;	chr5:56870367	chr5:56927874~56929573:+
PRAD	cis	rs7727544	0.716	rs4705926	ENSG00000233006.5	AC034220.3	7.86	2.89e-14	1.34e-11	0.3	0.35	Blood metabolite levels;	chr5:132226065	chr5:132311285~132369916:-
PRAD	cis	rs6545883	0.507	rs34668697	ENSG00000271889.1	RP11-493E12.1	-7.86	2.89e-14	1.34e-11	-0.38	-0.35	Tuberculosis;	chr2:61341214	chr2:61151433~61162105:-
PRAD	cis	rs4664293	0.967	rs3940435	ENSG00000226266.5	AC009961.3	-7.85	2.91e-14	1.35e-11	-0.45	-0.35	Monocyte percentage of white cells;	chr2:159638272	chr2:159670708~159712435:-
PRAD	cis	rs11976180	0.953	rs2951355	ENSG00000273234.1	OR2A13P	-7.85	2.91e-14	1.35e-11	-0.42	-0.35	Obesity-related traits;	chr7:144063469	chr7:144142009~144142938:+
PRAD	cis	rs11976180	1	rs2951354	ENSG00000273234.1	OR2A13P	-7.85	2.91e-14	1.35e-11	-0.42	-0.35	Obesity-related traits;	chr7:144063908	chr7:144142009~144142938:+
PRAD	cis	rs11976180	1	rs2961125	ENSG00000273234.1	OR2A13P	-7.85	2.91e-14	1.35e-11	-0.42	-0.35	Obesity-related traits;	chr7:144064677	chr7:144142009~144142938:+
PRAD	cis	rs11976180	1	rs2961126	ENSG00000273234.1	OR2A13P	-7.85	2.91e-14	1.35e-11	-0.42	-0.35	Obesity-related traits;	chr7:144065643	chr7:144142009~144142938:+
PRAD	cis	rs11976180	0.953	rs2961127	ENSG00000273234.1	OR2A13P	-7.85	2.91e-14	1.35e-11	-0.42	-0.35	Obesity-related traits;	chr7:144065644	chr7:144142009~144142938:+
PRAD	cis	rs11976180	1	rs1919948	ENSG00000273234.1	OR2A13P	-7.85	2.91e-14	1.35e-11	-0.42	-0.35	Obesity-related traits;	chr7:144065750	chr7:144142009~144142938:+
PRAD	cis	rs11976180	1	rs2961128	ENSG00000273234.1	OR2A13P	-7.85	2.91e-14	1.35e-11	-0.42	-0.35	Obesity-related traits;	chr7:144066390	chr7:144142009~144142938:+
PRAD	cis	rs11976180	1	rs2371248	ENSG00000273234.1	OR2A13P	-7.85	2.91e-14	1.35e-11	-0.42	-0.35	Obesity-related traits;	chr7:144067096	chr7:144142009~144142938:+
PRAD	cis	rs11976180	1	rs1533268	ENSG00000273234.1	OR2A13P	-7.85	2.91e-14	1.35e-11	-0.42	-0.35	Obesity-related traits;	chr7:144069265	chr7:144142009~144142938:+
PRAD	cis	rs11976180	1	rs1533267	ENSG00000273234.1	OR2A13P	-7.85	2.91e-14	1.35e-11	-0.42	-0.35	Obesity-related traits;	chr7:144069347	chr7:144142009~144142938:+
PRAD	cis	rs11976180	1	rs1533266	ENSG00000273234.1	OR2A13P	-7.85	2.91e-14	1.35e-11	-0.42	-0.35	Obesity-related traits;	chr7:144069621	chr7:144142009~144142938:+
PRAD	cis	rs7923609	0.846	rs7090111	ENSG00000232075.1	MRPL35P2	-7.85	2.92e-14	1.35e-11	-0.36	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63318234	chr10:63634317~63634827:-
PRAD	cis	rs12817211	0.549	rs7398567	ENSG00000272368.2	RP4-605O3.4	7.85	2.92e-14	1.35e-11	0.35	0.35	Colorectal or endometrial cancer;	chr12:50157375	chr12:50112197~50165618:+
PRAD	cis	rs1061377	1	rs36090629	ENSG00000249685.1	RP11-360F5.3	7.85	2.92e-14	1.35e-11	0.39	0.35	Uric acid levels;	chr4:39137195	chr4:39133913~39135608:+
PRAD	cis	rs1061377	0.87	rs73238544	ENSG00000249685.1	RP11-360F5.3	7.85	2.92e-14	1.35e-11	0.39	0.35	Uric acid levels;	chr4:39137343	chr4:39133913~39135608:+
PRAD	cis	rs2404602	0.692	rs58889902	ENSG00000259422.1	RP11-593F23.1	7.85	2.92e-14	1.35e-11	0.43	0.35	Blood metabolite levels;	chr15:76880729	chr15:76174891~76181486:-
PRAD	cis	rs526231	0.543	rs34767	ENSG00000175749.11	EIF3KP1	7.85	2.93e-14	1.36e-11	0.49	0.35	Primary biliary cholangitis;	chr5:103153807	chr5:103032376~103033031:+
PRAD	cis	rs4266144	0.544	rs7340627	ENSG00000244515.1	KRT18P34	-7.85	2.94e-14	1.36e-11	-0.4	-0.35	Coronary artery disease;	chr3:157114604	chr3:157162663~157163932:-
PRAD	cis	rs8040855	0.965	rs1961276	ENSG00000259295.5	CSPG4P12	7.85	2.95e-14	1.37e-11	0.44	0.35	Bulimia nervosa;	chr15:85170986	chr15:85191438~85213905:+
PRAD	cis	rs1061377	1	rs7673299	ENSG00000249685.1	RP11-360F5.3	7.85	2.95e-14	1.37e-11	0.39	0.35	Uric acid levels;	chr4:39109138	chr4:39133913~39135608:+
PRAD	cis	rs67311347	0.577	rs11129870	ENSG00000223797.4	ENTPD3-AS1	7.85	2.95e-14	1.37e-11	0.32	0.35	Renal cell carcinoma;	chr3:40218915	chr3:40313802~40453329:-
PRAD	cis	rs2364543	0.624	rs61774752	ENSG00000229901.1	RP11-399E6.4	-7.85	2.97e-14	1.38e-11	-0.33	-0.35	Intelligence (multi-trait analysis);	chr1:41381352	chr1:41375004~41375669:-
PRAD	cis	rs950169	0.614	rs12911536	ENSG00000259728.4	LINC00933	7.85	2.97e-14	1.38e-11	0.44	0.35	Schizophrenia;	chr15:84004278	chr15:84570649~84580175:+
PRAD	cis	rs17711722	0.523	rs313812	ENSG00000237310.1	GS1-124K5.4	-7.85	2.98e-14	1.38e-11	-0.3	-0.35	Calcium levels;	chr7:66040056	chr7:66493706~66495474:+
PRAD	cis	rs10510102	0.608	rs4752607	ENSG00000276742.1	RP11-500G22.4	-7.85	2.99e-14	1.38e-11	-0.47	-0.35	Breast cancer;	chr10:121835426	chr10:121956782~121957098:+
PRAD	cis	rs2638953	0.962	rs11049488	ENSG00000278733.1	RP11-425D17.1	-7.85	2.99e-14	1.38e-11	-0.44	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28259439	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.962	rs57618147	ENSG00000278733.1	RP11-425D17.1	-7.85	2.99e-14	1.38e-11	-0.44	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28259902	chr12:28185625~28186190:-
PRAD	cis	rs11159086	0.941	rs11846588	ENSG00000259005.1	RP3-449M8.6	7.85	2.99e-14	1.39e-11	0.48	0.35	Advanced glycation end-product levels;	chr14:74505398	chr14:74474007~74474864:-
PRAD	cis	rs10129255	0.5	rs6576231	ENSG00000211972.2	IGHV3-66	7.85	2.99e-14	1.39e-11	0.3	0.35	Kawasaki disease;	chr14:106783693	chr14:106675017~106675544:-
PRAD	cis	rs6921919	0.848	rs6903652	ENSG00000204709.4	LINC01556	7.85	3.01e-14	1.39e-11	0.49	0.35	Autism spectrum disorder or schizophrenia;	chr6:28354343	chr6:28943877~28944537:+
PRAD	cis	rs9532669	0.963	rs9532681	ENSG00000168852.11	TPTE2P5	7.85	3.02e-14	1.4e-11	0.33	0.35	Cervical cancer;	chr13:40951633	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.926	rs4516083	ENSG00000168852.11	TPTE2P5	7.85	3.02e-14	1.4e-11	0.33	0.35	Cervical cancer;	chr13:40951783	chr13:40822296~40921749:-
PRAD	cis	rs12928939	0.815	rs34731378	ENSG00000260886.1	TAT-AS1	7.85	3.02e-14	1.4e-11	0.46	0.35	Post bronchodilator FEV1;	chr16:71711845	chr16:71565789~71578187:+
PRAD	cis	rs17711722	0.522	rs4642526	ENSG00000224316.1	RP11-479O9.2	7.85	3.02e-14	1.4e-11	0.32	0.35	Calcium levels;	chr7:65751755	chr7:65773620~65802067:+
PRAD	cis	rs6603134	0.502	rs6603133	ENSG00000267939.1	CTD-2325M2.1	-7.85	3.02e-14	1.4e-11	-0.4	-0.35	Blood protein levels;	chr19:8038352	chr19:8008729~8016025:+
PRAD	cis	rs673078	0.607	rs7309484	ENSG00000275409.1	RP11-131L12.4	-7.85	3.03e-14	1.4e-11	-0.49	-0.35	Glucose homeostasis traits;	chr12:118400833	chr12:118430147~118430699:+
PRAD	cis	rs6991838	1	rs6991838	ENSG00000272010.1	CTD-3025N20.3	-7.85	3.04e-14	1.41e-11	-0.34	-0.35	Intelligence (multi-trait analysis);	chr8:65558727	chr8:65591850~65592472:-
PRAD	cis	rs71403859	0.504	rs12926413	ENSG00000260886.1	TAT-AS1	7.85	3.05e-14	1.41e-11	0.65	0.35	Post bronchodilator FEV1;	chr16:71938422	chr16:71565789~71578187:+
PRAD	cis	rs12468226	0.938	rs12463937	ENSG00000273456.1	RP11-686O6.2	7.85	3.05e-14	1.41e-11	0.47	0.35	Urate levels;	chr2:202246543	chr2:202374932~202375604:-
PRAD	cis	rs67311347	0.577	rs11712626	ENSG00000223797.4	ENTPD3-AS1	7.85	3.05e-14	1.41e-11	0.32	0.35	Renal cell carcinoma;	chr3:40218436	chr3:40313802~40453329:-
PRAD	cis	rs42648	0.596	rs6465251	ENSG00000227646.6	STEAP2-AS1	-7.85	3.05e-14	1.41e-11	-0.31	-0.35	Homocysteine levels;	chr7:90218567	chr7:89882353~90211635:-
PRAD	cis	rs42648	0.596	rs194513	ENSG00000227646.6	STEAP2-AS1	-7.85	3.05e-14	1.41e-11	-0.31	-0.35	Homocysteine levels;	chr7:90220856	chr7:89882353~90211635:-
PRAD	cis	rs6921919	0.848	rs6903823	ENSG00000216901.1	AL022393.7	7.85	3.06e-14	1.41e-11	0.49	0.35	Autism spectrum disorder or schizophrenia;	chr6:28354519	chr6:28176188~28176674:+
PRAD	cis	rs6921919	0.848	rs56131013	ENSG00000204709.4	LINC01556	7.85	3.06e-14	1.41e-11	0.49	0.35	Autism spectrum disorder or schizophrenia;	chr6:28352900	chr6:28943877~28944537:+
PRAD	cis	rs1930961	1	rs6004667	ENSG00000271138.1	IGLVIVOR22-1	7.85	3.06e-14	1.41e-11	0.53	0.35	Bipolar disorder with mood-incongruent psychosis;	chr22:25478497	chr22:25437306~25437823:-
PRAD	cis	rs2274273	0.624	rs66551709	ENSG00000258413.1	RP11-665C16.6	-7.85	3.06e-14	1.41e-11	-0.46	-0.35	Protein biomarker;	chr14:55324304	chr14:55262767~55272075:-
PRAD	cis	rs1134634	0.52	rs4393989	ENSG00000273133.1	RP11-799M12.2	-7.85	3.07e-14	1.42e-11	-0.46	-0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15614276	chr4:15563698~15564253:-
PRAD	cis	rs1134634	0.52	rs10003739	ENSG00000273133.1	RP11-799M12.2	-7.85	3.07e-14	1.42e-11	-0.46	-0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15617063	chr4:15563698~15564253:-
PRAD	cis	rs950169	0.512	rs4374136	ENSG00000225151.9	GOLGA2P7	-7.85	3.07e-14	1.42e-11	-0.51	-0.35	Schizophrenia;	chr15:83976255	chr15:84199311~84230136:-
PRAD	cis	rs9810089	0.934	rs66691851	ENSG00000261758.1	RP11-102M11.2	7.85	3.07e-14	1.42e-11	0.39	0.35	Gestational age at birth (child effect);	chr3:136435986	chr3:136752630~136755780:+
PRAD	cis	rs2404602	0.692	rs12913810	ENSG00000259422.1	RP11-593F23.1	7.85	3.07e-14	1.42e-11	0.43	0.35	Blood metabolite levels;	chr15:76874334	chr15:76174891~76181486:-
PRAD	cis	rs62103177	0.564	rs1864529	ENSG00000261126.6	RP11-795F19.1	-7.85	3.07e-14	1.42e-11	-0.45	-0.35	Opioid sensitivity;	chr18:79988975	chr18:80046900~80095482:+
PRAD	cis	rs12817211	0.549	rs10783338	ENSG00000272368.2	RP4-605O3.4	7.85	3.07e-14	1.42e-11	0.35	0.35	Colorectal or endometrial cancer;	chr12:50158746	chr12:50112197~50165618:+
PRAD	cis	rs2108622	1	rs62107762	ENSG00000267056.2	AC005336.4	7.85	3.08e-14	1.42e-11	0.49	0.35	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871728	chr19:15910582~15911824:-
PRAD	cis	rs150992	0.536	rs10479348	ENSG00000248489.1	CTD-2007H13.3	-7.85	3.08e-14	1.42e-11	-0.45	-0.35	Body mass index;	chr5:99013022	chr5:98929171~98995013:+
PRAD	cis	rs9287719	0.967	rs6744599	ENSG00000234818.1	AC092687.5	-7.85	3.08e-14	1.42e-11	-0.42	-0.35	Prostate cancer;	chr2:10606887	chr2:10589166~10604830:+
PRAD	cis	rs10463554	1	rs1593842	ENSG00000175749.11	EIF3KP1	7.85	3.1e-14	1.43e-11	0.44	0.35	Parkinson's disease;	chr5:102999018	chr5:103032376~103033031:+
PRAD	cis	rs11083475	1	rs56365761	ENSG00000267892.1	CTD-2540F13.2	7.85	3.11e-14	1.44e-11	0.38	0.35	Heart rate;	chr19:38657463	chr19:38738284~38739863:+
PRAD	cis	rs2274273	0.624	rs7150763	ENSG00000258413.1	RP11-665C16.6	-7.84	3.12e-14	1.44e-11	-0.46	-0.35	Protein biomarker;	chr14:55373083	chr14:55262767~55272075:-
PRAD	cis	rs950169	0.614	rs12903883	ENSG00000259728.4	LINC00933	7.84	3.12e-14	1.44e-11	0.44	0.35	Schizophrenia;	chr15:84011801	chr15:84570649~84580175:+
PRAD	cis	rs2522056	0.935	rs1981524	ENSG00000233006.5	AC034220.3	-7.84	3.13e-14	1.45e-11	-0.34	-0.35	Fibrinogen;Lymphocyte counts;	chr5:132420814	chr5:132311285~132369916:-
PRAD	cis	rs4845570	1	rs6673002	ENSG00000268288.1	RP11-98D18.16	-7.84	3.13e-14	1.45e-11	-0.52	-0.35	Coronary artery disease;	chr1:151770799	chr1:151766486~151767000:-
PRAD	cis	rs2638953	0.962	rs716687	ENSG00000278733.1	RP11-425D17.1	-7.84	3.13e-14	1.45e-11	-0.44	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28261517	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.962	rs11049495	ENSG00000278733.1	RP11-425D17.1	-7.84	3.13e-14	1.45e-11	-0.44	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28264795	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.962	rs11049496	ENSG00000278733.1	RP11-425D17.1	-7.84	3.13e-14	1.45e-11	-0.44	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28267327	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.819	rs10843146	ENSG00000278733.1	RP11-425D17.1	-7.84	3.13e-14	1.45e-11	-0.44	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28268352	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.962	rs2172299	ENSG00000278733.1	RP11-425D17.1	-7.84	3.13e-14	1.45e-11	-0.44	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28280180	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.962	rs11049503	ENSG00000278733.1	RP11-425D17.1	-7.84	3.13e-14	1.45e-11	-0.44	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28282714	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.962	rs61922974	ENSG00000278733.1	RP11-425D17.1	-7.84	3.13e-14	1.45e-11	-0.44	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28283302	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.962	rs61922975	ENSG00000278733.1	RP11-425D17.1	-7.84	3.13e-14	1.45e-11	-0.44	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28283705	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.962	rs61922976	ENSG00000278733.1	RP11-425D17.1	-7.84	3.13e-14	1.45e-11	-0.44	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28283837	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.962	rs61922977	ENSG00000278733.1	RP11-425D17.1	-7.84	3.13e-14	1.45e-11	-0.44	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28286889	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.962	rs11049505	ENSG00000278733.1	RP11-425D17.1	-7.84	3.13e-14	1.45e-11	-0.44	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28288087	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs11049507	ENSG00000278733.1	RP11-425D17.1	-7.84	3.13e-14	1.45e-11	-0.44	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28289554	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.962	rs11049509	ENSG00000278733.1	RP11-425D17.1	-7.84	3.13e-14	1.45e-11	-0.44	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28290055	chr12:28185625~28186190:-
PRAD	cis	rs8040855	0.965	rs4843027	ENSG00000259295.5	CSPG4P12	-7.84	3.14e-14	1.45e-11	-0.44	-0.35	Bulimia nervosa;	chr15:85171892	chr15:85191438~85213905:+
PRAD	cis	rs4664293	0.967	rs1006192	ENSG00000226266.5	AC009961.3	-7.84	3.15e-14	1.45e-11	-0.45	-0.35	Monocyte percentage of white cells;	chr2:159711078	chr2:159670708~159712435:-
PRAD	cis	rs17711722	0.51	rs11767457	ENSG00000234585.5	CCT6P3	7.84	3.15e-14	1.45e-11	0.27	0.35	Calcium levels;	chr7:65825628	chr7:65038354~65074713:+
PRAD	cis	rs4713118	0.628	rs9295740	ENSG00000280107.1	AL022393.9	-7.84	3.15e-14	1.46e-11	-0.47	-0.35	Parkinson's disease;	chr6:27721723	chr6:28170845~28172521:+
PRAD	cis	rs526231	0.543	rs26523	ENSG00000175749.11	EIF3KP1	7.84	3.16e-14	1.46e-11	0.48	0.35	Primary biliary cholangitis;	chr5:103120550	chr5:103032376~103033031:+
PRAD	cis	rs9393777	0.92	rs67859638	ENSG00000280107.1	AL022393.9	-7.84	3.17e-14	1.46e-11	-0.72	-0.35	Intelligence (multi-trait analysis);	chr6:27390199	chr6:28170845~28172521:+
PRAD	cis	rs4664293	0.801	rs7607143	ENSG00000226266.5	AC009961.3	-7.84	3.17e-14	1.46e-11	-0.46	-0.35	Monocyte percentage of white cells;	chr2:159728250	chr2:159670708~159712435:-
PRAD	cis	rs4664293	0.833	rs10170336	ENSG00000226266.5	AC009961.3	-7.84	3.17e-14	1.46e-11	-0.46	-0.35	Monocyte percentage of white cells;	chr2:159732832	chr2:159670708~159712435:-
PRAD	cis	rs1979679	0.801	rs1463571	ENSG00000278733.1	RP11-425D17.1	7.84	3.18e-14	1.47e-11	0.44	0.35	Ossification of the posterior longitudinal ligament of the spine;	chr12:28144514	chr12:28185625~28186190:-
PRAD	cis	rs1979679	0.918	rs786707	ENSG00000278733.1	RP11-425D17.1	7.84	3.18e-14	1.47e-11	0.45	0.35	Ossification of the posterior longitudinal ligament of the spine;	chr12:28420714	chr12:28185625~28186190:-
PRAD	cis	rs638893	1	rs113641235	ENSG00000278376.1	RP11-158I9.8	7.84	3.18e-14	1.47e-11	0.44	0.35	Vitiligo;	chr11:118829555	chr11:118791254~118793137:+
PRAD	cis	rs2404602	0.669	rs17367297	ENSG00000259422.1	RP11-593F23.1	7.84	3.19e-14	1.47e-11	0.43	0.35	Blood metabolite levels;	chr15:76865685	chr15:76174891~76181486:-
PRAD	cis	rs881375	0.678	rs10760128	ENSG00000226752.6	PSMD5-AS1	-7.84	3.19e-14	1.47e-11	-0.4	-0.35	Rheumatoid arthritis;	chr9:120934047	chr9:120824828~120854385:+
PRAD	cis	rs1799949	0.929	rs799906	ENSG00000267002.1	RP11-242D8.1	7.84	3.2e-14	1.48e-11	0.32	0.35	Menopause (age at onset);	chr17:43126099	chr17:43164183~43170403:-
PRAD	cis	rs1799949	0.965	rs799908	ENSG00000267002.1	RP11-242D8.1	7.84	3.2e-14	1.48e-11	0.32	0.35	Menopause (age at onset);	chr17:43126899	chr17:43164183~43170403:-
PRAD	cis	rs1799949	0.93	rs1554063	ENSG00000267002.1	RP11-242D8.1	7.84	3.2e-14	1.48e-11	0.32	0.35	Menopause (age at onset);	chr17:43135128	chr17:43164183~43170403:-
PRAD	cis	rs11083475	1	rs11083475	ENSG00000267892.1	CTD-2540F13.2	7.84	3.2e-14	1.48e-11	0.37	0.35	Heart rate;	chr19:38697472	chr19:38738284~38739863:+
PRAD	cis	rs526231	0.543	rs34766	ENSG00000175749.11	EIF3KP1	7.84	3.21e-14	1.48e-11	0.48	0.35	Primary biliary cholangitis;	chr5:103175219	chr5:103032376~103033031:+
PRAD	cis	rs7899628	1	rs7899628	ENSG00000226864.1	ATE1-AS1	-7.84	3.22e-14	1.48e-11	-0.47	-0.34	Breast cancer;	chr10:121904429	chr10:121928312~121951965:+
PRAD	cis	rs7923609	0.875	rs10740118	ENSG00000232075.1	MRPL35P2	7.84	3.22e-14	1.49e-11	0.36	0.34	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63341447	chr10:63634317~63634827:-
PRAD	cis	rs12817211	0.549	rs7972465	ENSG00000272368.2	RP4-605O3.4	7.84	3.23e-14	1.49e-11	0.35	0.34	Colorectal or endometrial cancer;	chr12:50152342	chr12:50112197~50165618:+
PRAD	cis	rs2729354	0.502	rs2848641	ENSG00000265566.2	RN7SL605P	-7.84	3.23e-14	1.49e-11	-0.45	-0.34	Blood protein levels;	chr11:57495595	chr11:57528085~57528365:-
PRAD	cis	rs11976180	1	rs2951363	ENSG00000273234.1	OR2A13P	-7.84	3.24e-14	1.49e-11	-0.41	-0.34	Obesity-related traits;	chr7:144057631	chr7:144142009~144142938:+
PRAD	cis	rs1930961	1	rs6004671	ENSG00000271138.1	IGLVIVOR22-1	-7.84	3.24e-14	1.5e-11	-0.53	-0.34	Bipolar disorder with mood-incongruent psychosis;	chr22:25483507	chr22:25437306~25437823:-
PRAD	cis	rs1930961	1	rs6004672	ENSG00000271138.1	IGLVIVOR22-1	-7.84	3.24e-14	1.5e-11	-0.53	-0.34	Bipolar disorder with mood-incongruent psychosis;	chr22:25485046	chr22:25437306~25437823:-
PRAD	cis	rs71403859	0.504	rs35203704	ENSG00000260886.1	TAT-AS1	7.84	3.26e-14	1.5e-11	0.66	0.34	Post bronchodilator FEV1;	chr16:71925758	chr16:71565789~71578187:+
PRAD	cis	rs9467773	0.62	rs2504567	ENSG00000241549.7	GUSBP2	7.84	3.26e-14	1.5e-11	0.36	0.34	Intelligence (multi-trait analysis);	chr6:26662692	chr6:26871484~26956554:-
PRAD	cis	rs950169	0.544	rs62021193	ENSG00000275120.1	RP11-182J1.17	7.84	3.26e-14	1.5e-11	0.44	0.34	Schizophrenia;	chr15:84627352	chr15:84599434~84606463:-
PRAD	cis	rs950169	0.58	rs17598114	ENSG00000275120.1	RP11-182J1.17	7.84	3.26e-14	1.5e-11	0.44	0.34	Schizophrenia;	chr15:84628086	chr15:84599434~84606463:-
PRAD	cis	rs950169	0.58	rs17532346	ENSG00000275120.1	RP11-182J1.17	7.84	3.26e-14	1.5e-11	0.44	0.34	Schizophrenia;	chr15:84628264	chr15:84599434~84606463:-
PRAD	cis	rs435066	0.633	rs2093860	ENSG00000234264.1	DEPDC1-AS1	-7.84	3.26e-14	1.5e-11	-0.51	-0.34	IgG glycosylation;	chr1:68552348	chr1:68496676~68538627:+
PRAD	cis	rs435066	0.633	rs1924526	ENSG00000234264.1	DEPDC1-AS1	-7.84	3.26e-14	1.5e-11	-0.51	-0.34	IgG glycosylation;	chr1:68559407	chr1:68496676~68538627:+
PRAD	cis	rs435066	0.594	rs999335	ENSG00000234264.1	DEPDC1-AS1	-7.84	3.26e-14	1.5e-11	-0.51	-0.34	IgG glycosylation;	chr1:68568078	chr1:68496676~68538627:+
PRAD	cis	rs1499614	1	rs2659913	ENSG00000226824.5	RP4-756H11.3	-7.84	3.28e-14	1.51e-11	-0.69	-0.34	Gout;	chr7:66692349	chr7:66654538~66669855:+
PRAD	cis	rs1499614	1	rs2659911	ENSG00000226824.5	RP4-756H11.3	-7.84	3.28e-14	1.51e-11	-0.69	-0.34	Gout;	chr7:66693433	chr7:66654538~66669855:+
PRAD	cis	rs1499614	1	rs2707838	ENSG00000226824.5	RP4-756H11.3	-7.84	3.28e-14	1.51e-11	-0.69	-0.34	Gout;	chr7:66694214	chr7:66654538~66669855:+
PRAD	cis	rs1499614	1	rs60326618	ENSG00000226824.5	RP4-756H11.3	-7.84	3.28e-14	1.51e-11	-0.69	-0.34	Gout;	chr7:66701371	chr7:66654538~66669855:+
PRAD	cis	rs1499614	1	rs2707830	ENSG00000226824.5	RP4-756H11.3	-7.84	3.28e-14	1.51e-11	-0.69	-0.34	Gout;	chr7:66702658	chr7:66654538~66669855:+
PRAD	cis	rs1499614	1	rs2707828	ENSG00000226824.5	RP4-756H11.3	-7.84	3.28e-14	1.51e-11	-0.69	-0.34	Gout;	chr7:66706390	chr7:66654538~66669855:+
PRAD	cis	rs1499614	0.803	rs1922723	ENSG00000226824.5	RP4-756H11.3	-7.84	3.28e-14	1.51e-11	-0.69	-0.34	Gout;	chr7:66710076	chr7:66654538~66669855:+
PRAD	cis	rs1499614	1	rs2659903	ENSG00000226824.5	RP4-756H11.3	-7.84	3.28e-14	1.51e-11	-0.69	-0.34	Gout;	chr7:66715944	chr7:66654538~66669855:+
PRAD	cis	rs1499614	1	rs2141924	ENSG00000226824.5	RP4-756H11.3	-7.84	3.28e-14	1.51e-11	-0.69	-0.34	Gout;	chr7:66721259	chr7:66654538~66669855:+
PRAD	cis	rs1499614	0.901	rs2178742	ENSG00000226824.5	RP4-756H11.3	-7.84	3.28e-14	1.51e-11	-0.69	-0.34	Gout;	chr7:66732812	chr7:66654538~66669855:+
PRAD	cis	rs2337406	0.85	rs75196489	ENSG00000274576.2	IGHV2-70	-7.84	3.29e-14	1.52e-11	-0.38	-0.34	Alzheimer's disease (late onset);	chr14:106699438	chr14:106770577~106771020:-
PRAD	cis	rs1061377	1	rs3796509	ENSG00000249685.1	RP11-360F5.3	7.84	3.29e-14	1.52e-11	0.39	0.34	Uric acid levels;	chr4:39108566	chr4:39133913~39135608:+
PRAD	cis	rs17711722	0.522	rs6957759	ENSG00000164669.11	INTS4P1	-7.84	3.29e-14	1.52e-11	-0.43	-0.34	Calcium levels;	chr7:65806798	chr7:65141225~65234216:+
PRAD	cis	rs2108622	0.958	rs79400241	ENSG00000267056.2	AC005336.4	7.84	3.3e-14	1.52e-11	0.49	0.34	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15873592	chr19:15910582~15911824:-
PRAD	cis	rs2638953	0.924	rs1841962	ENSG00000247934.4	RP11-967K21.1	7.84	3.3e-14	1.52e-11	0.34	0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28220919	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.924	rs7969582	ENSG00000247934.4	RP11-967K21.1	7.84	3.3e-14	1.52e-11	0.34	0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28236725	chr12:28163298~28190738:-
PRAD	cis	rs8523	0.671	rs60376022	ENSG00000230314.5	ELOVL2-AS1	7.84	3.3e-14	1.52e-11	0.38	0.34	Red blood cell fatty acid levels;	chr6:11027716	chr6:11043524~11078226:+
PRAD	cis	rs10129255	0.5	rs6576230	ENSG00000211972.2	IGHV3-66	7.84	3.3e-14	1.52e-11	0.3	0.34	Kawasaki disease;	chr14:106778539	chr14:106675017~106675544:-
PRAD	cis	rs10129255	0.518	rs11847766	ENSG00000211972.2	IGHV3-66	7.84	3.3e-14	1.52e-11	0.3	0.34	Kawasaki disease;	chr14:106779186	chr14:106675017~106675544:-
PRAD	cis	rs17711722	0.523	rs313812	ENSG00000275400.1	RP4-756H11.5	7.84	3.3e-14	1.52e-11	0.31	0.34	Calcium levels;	chr7:66040056	chr7:66553805~66554199:-
PRAD	cis	rs75422866	0.867	rs75568526	ENSG00000280054.1	RP1-197B17.7	7.84	3.31e-14	1.53e-11	0.83	0.34	Pneumonia;	chr12:47649718	chr12:47728151~47730598:-
PRAD	cis	rs75422866	0.867	rs116302411	ENSG00000280054.1	RP1-197B17.7	7.84	3.31e-14	1.53e-11	0.83	0.34	Pneumonia;	chr12:47649788	chr12:47728151~47730598:-
PRAD	cis	rs964611	0.882	rs3784616	ENSG00000259488.2	RP11-154J22.1	-7.84	3.32e-14	1.53e-11	-0.33	-0.34	Metabolite levels (Pyroglutamine);	chr15:48278381	chr15:48312353~48331856:-
PRAD	cis	rs11083475	0.967	rs2287729	ENSG00000267892.1	CTD-2540F13.2	7.84	3.32e-14	1.53e-11	0.37	0.34	Heart rate;	chr19:38704674	chr19:38738284~38739863:+
PRAD	cis	rs12928939	0.769	rs12445161	ENSG00000260886.1	TAT-AS1	7.84	3.32e-14	1.53e-11	0.46	0.34	Post bronchodilator FEV1;	chr16:71708025	chr16:71565789~71578187:+
PRAD	cis	rs853679	0.769	rs17720293	ENSG00000280107.1	AL022393.9	-7.84	3.34e-14	1.54e-11	-0.62	-0.34	Depression;	chr6:28246920	chr6:28170845~28172521:+
PRAD	cis	rs1061377	1	rs28607301	ENSG00000249685.1	RP11-360F5.3	7.84	3.34e-14	1.54e-11	0.39	0.34	Uric acid levels;	chr4:39136460	chr4:39133913~39135608:+
PRAD	cis	rs1499614	1	rs1882655	ENSG00000226824.5	RP4-756H11.3	7.83	3.34e-14	1.54e-11	0.69	0.34	Gout;	chr7:66682070	chr7:66654538~66669855:+
PRAD	cis	rs1499614	0.831	rs3800822	ENSG00000226824.5	RP4-756H11.3	7.83	3.34e-14	1.54e-11	0.69	0.34	Gout;	chr7:66682162	chr7:66654538~66669855:+
PRAD	cis	rs1499614	1	rs1638731	ENSG00000226824.5	RP4-756H11.3	-7.83	3.34e-14	1.54e-11	-0.69	-0.34	Gout;	chr7:66679692	chr7:66654538~66669855:+
PRAD	cis	rs9362426	0.503	rs6454609	ENSG00000218793.1	RP3-382I10.3	-7.83	3.34e-14	1.54e-11	-0.43	-0.34	Depressive episodes in bipolar disorder;	chr6:87396310	chr6:87441165~87442146:-
PRAD	cis	rs2946504	0.861	rs2954171	ENSG00000251468.2	RP11-369K16.1	-7.83	3.35e-14	1.54e-11	-0.44	-0.34	Type 2 diabetes;	chr8:12956087	chr8:12958387~12962200:+
PRAD	cis	rs6001482	0.679	rs5995706	ENSG00000272779.1	LL22NC03-80A10.6	-7.83	3.35e-14	1.54e-11	-0.42	-0.34	Diastolic blood pressure;	chr22:22236371	chr22:22303224~22310401:+
PRAD	cis	rs6001482	0.702	rs7286018	ENSG00000272779.1	LL22NC03-80A10.6	-7.83	3.35e-14	1.54e-11	-0.42	-0.34	Diastolic blood pressure;	chr22:22236464	chr22:22303224~22310401:+
PRAD	cis	rs270601	0.69	rs162904	ENSG00000233006.5	AC034220.3	-7.83	3.36e-14	1.54e-11	-0.3	-0.34	Acylcarnitine levels;	chr5:132260091	chr5:132311285~132369916:-
PRAD	cis	rs7923609	0.812	rs10822155	ENSG00000232075.1	MRPL35P2	-7.83	3.37e-14	1.55e-11	-0.36	-0.34	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63311455	chr10:63634317~63634827:-
PRAD	cis	rs8042680	1	rs11853024	ENSG00000214432.8	AC068831.10	-7.83	3.37e-14	1.55e-11	-0.41	-0.34	Type 2 diabetes;	chr15:90971567	chr15:91022619~91036611:+
PRAD	cis	rs8042680	0.915	rs7166743	ENSG00000214432.8	AC068831.10	-7.83	3.37e-14	1.55e-11	-0.41	-0.34	Type 2 diabetes;	chr15:90971584	chr15:91022619~91036611:+
PRAD	cis	rs4266144	0.558	rs7623382	ENSG00000244515.1	KRT18P34	-7.83	3.38e-14	1.55e-11	-0.4	-0.34	Coronary artery disease;	chr3:157115105	chr3:157162663~157163932:-
PRAD	cis	rs881375	0.967	rs10733648	ENSG00000226752.6	PSMD5-AS1	-7.83	3.38e-14	1.55e-11	-0.41	-0.34	Rheumatoid arthritis;	chr9:120938501	chr9:120824828~120854385:+
PRAD	cis	rs914615	0.507	rs4971085	ENSG00000160766.13	GBAP1	-7.83	3.38e-14	1.55e-11	-0.35	-0.34	Urinary albumin-to-creatinine ratio;	chr1:155165746	chr1:155213821~155227422:-
PRAD	cis	rs914615	0.552	rs11264337	ENSG00000160766.13	GBAP1	-7.83	3.38e-14	1.55e-11	-0.35	-0.34	Urinary albumin-to-creatinine ratio;	chr1:155165974	chr1:155213821~155227422:-
PRAD	cis	rs914615	0.529	rs11264338	ENSG00000160766.13	GBAP1	-7.83	3.38e-14	1.55e-11	-0.35	-0.34	Urinary albumin-to-creatinine ratio;	chr1:155166081	chr1:155213821~155227422:-
PRAD	cis	rs2638953	0.962	rs12370271	ENSG00000278733.1	RP11-425D17.1	-7.83	3.39e-14	1.56e-11	-0.44	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28313840	chr12:28185625~28186190:-
PRAD	cis	rs2348418	0.639	rs2881788	ENSG00000247934.4	RP11-967K21.1	-7.83	3.39e-14	1.56e-11	-0.33	-0.34	Lung function (FEV1);Lung function (FVC);	chr12:28119641	chr12:28163298~28190738:-
PRAD	cis	rs2337406	0.929	rs11847182	ENSG00000274576.2	IGHV2-70	-7.83	3.4e-14	1.57e-11	-0.4	-0.34	Alzheimer's disease (late onset);	chr14:106697724	chr14:106770577~106771020:-
PRAD	cis	rs75422866	0.867	rs73113117	ENSG00000280054.1	RP1-197B17.7	7.83	3.42e-14	1.57e-11	0.83	0.34	Pneumonia;	chr12:47617299	chr12:47728151~47730598:-
PRAD	cis	rs75422866	0.867	rs73113143	ENSG00000280054.1	RP1-197B17.7	7.83	3.42e-14	1.57e-11	0.83	0.34	Pneumonia;	chr12:47623060	chr12:47728151~47730598:-
PRAD	cis	rs13113518	0.729	rs11133377	ENSG00000249700.7	SRD5A3-AS1	7.83	3.42e-14	1.58e-11	0.49	0.34	Height;	chr4:55413708	chr4:55363971~55395847:-
PRAD	cis	rs2255336	0.748	rs60110638	ENSG00000245648.1	RP11-277P12.20	-7.83	3.42e-14	1.58e-11	-0.47	-0.34	Blood protein levels;	chr12:10444712	chr12:10363769~10398506:+
PRAD	cis	rs2946504	0.822	rs2977097	ENSG00000251468.2	RP11-369K16.1	7.83	3.43e-14	1.58e-11	0.42	0.34	Type 2 diabetes;	chr8:12946592	chr8:12958387~12962200:+
PRAD	cis	rs172166	0.56	rs203878	ENSG00000280107.1	AL022393.9	-7.83	3.44e-14	1.58e-11	-0.41	-0.34	Cardiac Troponin-T levels;	chr6:28081218	chr6:28170845~28172521:+
PRAD	cis	rs9467773	0.596	rs2451750	ENSG00000241549.7	GUSBP2	7.83	3.45e-14	1.58e-11	0.36	0.34	Intelligence (multi-trait analysis);	chr6:26646351	chr6:26871484~26956554:-
PRAD	cis	rs9467773	0.596	rs2451751	ENSG00000241549.7	GUSBP2	7.83	3.45e-14	1.58e-11	0.36	0.34	Intelligence (multi-trait analysis);	chr6:26646486	chr6:26871484~26956554:-
PRAD	cis	rs9467773	0.62	rs2504600	ENSG00000241549.7	GUSBP2	7.83	3.45e-14	1.58e-11	0.36	0.34	Intelligence (multi-trait analysis);	chr6:26648106	chr6:26871484~26956554:-
PRAD	cis	rs9467773	0.62	rs2130657	ENSG00000241549.7	GUSBP2	7.83	3.45e-14	1.58e-11	0.36	0.34	Intelligence (multi-trait analysis);	chr6:26650598	chr6:26871484~26956554:-
PRAD	cis	rs12908161	0.959	rs3748376	ENSG00000259728.4	LINC00933	7.83	3.45e-14	1.59e-11	0.43	0.34	Schizophrenia;	chr15:84785121	chr15:84570649~84580175:+
PRAD	cis	rs1949733	0.628	rs1543246	ENSG00000205959.3	RP11-689P11.2	-7.83	3.45e-14	1.59e-11	-0.37	-0.34	Response to antineoplastic agents;	chr4:8503182	chr4:8482270~8512610:+
PRAD	cis	rs2638953	0.962	rs11049533	ENSG00000278733.1	RP11-425D17.1	-7.83	3.45e-14	1.59e-11	-0.45	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28327471	chr12:28185625~28186190:-
PRAD	cis	rs673078	0.607	rs61944671	ENSG00000275409.1	RP11-131L12.4	-7.83	3.46e-14	1.59e-11	-0.49	-0.34	Glucose homeostasis traits;	chr12:118450046	chr12:118430147~118430699:+
PRAD	cis	rs10129255	0.518	rs12590732	ENSG00000211972.2	IGHV3-66	-7.83	3.47e-14	1.6e-11	-0.3	-0.34	Kawasaki disease;	chr14:106779612	chr14:106675017~106675544:-
PRAD	cis	rs321358	1	rs321356	ENSG00000271584.1	RP11-89C3.4	-7.83	3.47e-14	1.6e-11	-0.52	-0.34	Body mass index;	chr11:111124957	chr11:111091932~111097357:-
PRAD	cis	rs6061231	0.631	rs2427317	ENSG00000273619.1	RP5-908M14.9	-7.83	3.48e-14	1.6e-11	-0.21	-0.34	Colorectal cancer;	chr20:62400669	chr20:62386303~62386970:-
PRAD	cis	rs2243480	1	rs464895	ENSG00000226824.5	RP4-756H11.3	-7.83	3.48e-14	1.6e-11	-0.69	-0.34	Diabetic kidney disease;	chr7:66062119	chr7:66654538~66669855:+
PRAD	cis	rs4664293	0.51	rs2042781	ENSG00000226266.5	AC009961.3	7.83	3.49e-14	1.6e-11	0.47	0.34	Monocyte percentage of white cells;	chr2:159789899	chr2:159670708~159712435:-
PRAD	cis	rs10463554	1	rs12659870	ENSG00000175749.11	EIF3KP1	7.83	3.49e-14	1.6e-11	0.44	0.34	Parkinson's disease;	chr5:103000867	chr5:103032376~103033031:+
PRAD	cis	rs10463554	0.963	rs1552916	ENSG00000175749.11	EIF3KP1	7.83	3.49e-14	1.6e-11	0.44	0.34	Parkinson's disease;	chr5:103002036	chr5:103032376~103033031:+
PRAD	cis	rs2243480	1	rs160633	ENSG00000226824.5	RP4-756H11.3	-7.83	3.49e-14	1.6e-11	-0.69	-0.34	Diabetic kidney disease;	chr7:66063241	chr7:66654538~66669855:+
PRAD	cis	rs5850	0.602	rs1005786	ENSG00000226816.2	AC005082.12	7.83	3.49e-14	1.6e-11	0.4	0.34	Blood protein levels;	chr7:23106218	chr7:23206013~23208045:+
PRAD	cis	rs736801	0.78	rs2188962	ENSG00000233006.5	AC034220.3	7.83	3.5e-14	1.61e-11	0.31	0.34	Mosquito bite size;Breast cancer;	chr5:132435113	chr5:132311285~132369916:-
PRAD	cis	rs224278	0.51	rs1888967	ENSG00000238280.1	RP11-436D10.3	-7.83	3.5e-14	1.61e-11	-0.44	-0.34	Ewing sarcoma;	chr10:62819700	chr10:62793562~62805887:-
PRAD	cis	rs10129255	0.5	rs8022547	ENSG00000211972.2	IGHV3-66	7.83	3.5e-14	1.61e-11	0.3	0.34	Kawasaki disease;	chr14:106781985	chr14:106675017~106675544:-
PRAD	cis	rs10129255	0.518	rs8004895	ENSG00000211972.2	IGHV3-66	7.83	3.5e-14	1.61e-11	0.3	0.34	Kawasaki disease;	chr14:106785139	chr14:106675017~106675544:-
PRAD	cis	rs4664293	0.51	rs2113861	ENSG00000226266.5	AC009961.3	7.83	3.5e-14	1.61e-11	0.46	0.34	Monocyte percentage of white cells;	chr2:159585233	chr2:159670708~159712435:-
PRAD	cis	rs17711722	0.522	rs4642526	ENSG00000164669.11	INTS4P1	-7.83	3.5e-14	1.61e-11	-0.43	-0.34	Calcium levels;	chr7:65751755	chr7:65141225~65234216:+
PRAD	cis	rs7923609	1	rs7073746	ENSG00000232075.1	MRPL35P2	-7.83	3.51e-14	1.61e-11	-0.37	-0.34	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63144311	chr10:63634317~63634827:-
PRAD	cis	rs2638953	0.889	rs2045887	ENSG00000278733.1	RP11-425D17.1	-7.83	3.51e-14	1.61e-11	-0.44	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28270825	chr12:28185625~28186190:-
PRAD	cis	rs11083475	1	rs3745859	ENSG00000267892.1	CTD-2540F13.2	7.83	3.51e-14	1.61e-11	0.37	0.34	Heart rate;	chr19:38706105	chr19:38738284~38739863:+
PRAD	cis	rs17772222	0.958	rs2274737	ENSG00000258983.2	RP11-507K2.2	7.83	3.52e-14	1.62e-11	0.49	0.34	Coronary artery calcification;	chr14:88469307	chr14:88499334~88515502:+
PRAD	cis	rs10129255	0.5	rs59939897	ENSG00000211972.2	IGHV3-66	7.83	3.52e-14	1.62e-11	0.3	0.34	Kawasaki disease;	chr14:106783414	chr14:106675017~106675544:-
PRAD	cis	rs10129255	0.5	rs12101190	ENSG00000211972.2	IGHV3-66	7.83	3.52e-14	1.62e-11	0.3	0.34	Kawasaki disease;	chr14:106784149	chr14:106675017~106675544:-
PRAD	cis	rs6600671	0.719	rs9728991	ENSG00000223345.3	HIST2H2BA	7.83	3.52e-14	1.62e-11	0.42	0.34	Hip geometry;	chr1:121522281	chr1:121108210~121117257:-
PRAD	cis	rs2337406	0.706	rs74090742	ENSG00000274576.2	IGHV2-70	-7.83	3.52e-14	1.62e-11	-0.4	-0.34	Alzheimer's disease (late onset);	chr14:106696601	chr14:106770577~106771020:-
PRAD	cis	rs950169	0.922	rs17531523	ENSG00000259728.4	LINC00933	7.83	3.53e-14	1.62e-11	0.42	0.34	Schizophrenia;	chr15:84589218	chr15:84570649~84580175:+
PRAD	cis	rs62355901	0.653	rs16886206	ENSG00000271828.1	CTD-2310F14.1	7.83	3.54e-14	1.63e-11	0.75	0.34	Breast cancer;	chr5:56742321	chr5:56927874~56929573:+
PRAD	cis	rs6991838	0.584	rs10089708	ENSG00000200714.1	Y_RNA	7.83	3.54e-14	1.63e-11	0.38	0.34	Intelligence (multi-trait analysis);	chr8:65642927	chr8:65592731~65592820:+
PRAD	cis	rs7923609	0.846	rs7896518	ENSG00000232075.1	MRPL35P2	-7.83	3.55e-14	1.63e-11	-0.36	-0.34	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63344740	chr10:63634317~63634827:-
PRAD	cis	rs494459	0.838	rs488219	ENSG00000278376.1	RP11-158I9.8	-7.83	3.56e-14	1.64e-11	-0.29	-0.34	Height;	chr11:118749988	chr11:118791254~118793137:+
PRAD	cis	rs42648	0.569	rs110360	ENSG00000227646.6	STEAP2-AS1	-7.83	3.57e-14	1.64e-11	-0.31	-0.34	Homocysteine levels;	chr7:90227294	chr7:89882353~90211635:-
PRAD	cis	rs11098499	0.532	rs12512646	ENSG00000245958.5	RP11-33B1.1	-7.83	3.57e-14	1.64e-11	-0.33	-0.34	Corneal astigmatism;	chr4:119664578	chr4:119454791~119552025:+
PRAD	cis	rs964611	0.816	rs1426722	ENSG00000259488.2	RP11-154J22.1	-7.83	3.58e-14	1.65e-11	-0.32	-0.34	Metabolite levels (Pyroglutamine);	chr15:48277212	chr15:48312353~48331856:-
PRAD	cis	rs7181230	1	rs9972424	ENSG00000275636.1	RP11-521C20.5	7.82	3.59e-14	1.65e-11	0.45	0.34	Dehydroepiandrosterone sulphate levels;	chr15:40073650	chr15:40078892~40079347:+
PRAD	cis	rs4845570	1	rs3790514	ENSG00000268288.1	RP11-98D18.16	7.82	3.59e-14	1.65e-11	0.52	0.34	Coronary artery disease;	chr1:151771692	chr1:151766486~151767000:-
PRAD	cis	rs10129255	0.536	rs10142951	ENSG00000211972.2	IGHV3-66	7.82	3.59e-14	1.65e-11	0.3	0.34	Kawasaki disease;	chr14:106782337	chr14:106675017~106675544:-
PRAD	cis	rs2439831	0.85	rs3816792	ENSG00000249839.1	AC011330.5	7.82	3.6e-14	1.65e-11	0.58	0.34	Lung cancer in ever smokers;	chr15:43824788	chr15:43663654~43684339:-
PRAD	cis	rs12142240	0.731	rs12385693	ENSG00000232022.5	FAAHP1	-7.82	3.6e-14	1.65e-11	-0.33	-0.34	Menopause (age at onset);	chr1:46353249	chr1:46432129~46445521:+
PRAD	cis	rs10463554	0.853	rs458598	ENSG00000175749.11	EIF3KP1	7.82	3.61e-14	1.66e-11	0.46	0.34	Parkinson's disease;	chr5:103233677	chr5:103032376~103033031:+
PRAD	cis	rs950169	0.58	rs11635597	ENSG00000275120.1	RP11-182J1.17	7.82	3.62e-14	1.66e-11	0.45	0.34	Schizophrenia;	chr15:84622468	chr15:84599434~84606463:-
PRAD	cis	rs10129255	0.5	rs7161740	ENSG00000211972.2	IGHV3-66	7.82	3.62e-14	1.66e-11	0.3	0.34	Kawasaki disease;	chr14:106776119	chr14:106675017~106675544:-
PRAD	cis	rs10129255	0.556	rs6576222	ENSG00000211972.2	IGHV3-66	7.82	3.62e-14	1.66e-11	0.3	0.34	Kawasaki disease;	chr14:106776442	chr14:106675017~106675544:-
PRAD	cis	rs10129255	0.536	rs6576223	ENSG00000211972.2	IGHV3-66	7.82	3.62e-14	1.66e-11	0.3	0.34	Kawasaki disease;	chr14:106776448	chr14:106675017~106675544:-
PRAD	cis	rs10129255	0.5	rs988134	ENSG00000211972.2	IGHV3-66	7.82	3.62e-14	1.66e-11	0.3	0.34	Kawasaki disease;	chr14:106776698	chr14:106675017~106675544:-
PRAD	cis	rs10129255	0.5	rs988133	ENSG00000211972.2	IGHV3-66	7.82	3.62e-14	1.66e-11	0.3	0.34	Kawasaki disease;	chr14:106776724	chr14:106675017~106675544:-
PRAD	cis	rs914615	0.552	rs7556304	ENSG00000160766.13	GBAP1	-7.82	3.62e-14	1.66e-11	-0.35	-0.34	Urinary albumin-to-creatinine ratio;	chr1:155167033	chr1:155213821~155227422:-
PRAD	cis	rs914615	0.552	rs4421576	ENSG00000160766.13	GBAP1	-7.82	3.62e-14	1.66e-11	-0.35	-0.34	Urinary albumin-to-creatinine ratio;	chr1:155169734	chr1:155213821~155227422:-
PRAD	cis	rs950169	0.649	rs12911612	ENSG00000259728.4	LINC00933	7.82	3.63e-14	1.66e-11	0.43	0.34	Schizophrenia;	chr15:84022262	chr15:84570649~84580175:+
PRAD	cis	rs950169	0.649	rs12905952	ENSG00000259728.4	LINC00933	7.82	3.63e-14	1.66e-11	0.43	0.34	Schizophrenia;	chr15:84022509	chr15:84570649~84580175:+
PRAD	cis	rs950169	0.61	rs34529571	ENSG00000259728.4	LINC00933	7.82	3.63e-14	1.66e-11	0.43	0.34	Schizophrenia;	chr15:84023055	chr15:84570649~84580175:+
PRAD	cis	rs6847067	0.794	rs11732347	ENSG00000180769.7	WDFY3-AS2	7.82	3.63e-14	1.67e-11	0.36	0.34	Oropharynx cancer;	chr4:85012297	chr4:84965682~85011277:+
PRAD	cis	rs42648	0.596	rs194523	ENSG00000227646.6	STEAP2-AS1	-7.82	3.64e-14	1.67e-11	-0.31	-0.34	Homocysteine levels;	chr7:90231260	chr7:89882353~90211635:-
PRAD	cis	rs1979679	0.918	rs10843187	ENSG00000278733.1	RP11-425D17.1	-7.82	3.64e-14	1.67e-11	-0.45	-0.34	Ossification of the posterior longitudinal ligament of the spine;	chr12:28483586	chr12:28185625~28186190:-
PRAD	cis	rs881375	0.631	rs2416808	ENSG00000226752.6	PSMD5-AS1	-7.82	3.65e-14	1.67e-11	-0.4	-0.34	Rheumatoid arthritis;	chr9:120944005	chr9:120824828~120854385:+
PRAD	cis	rs914615	0.552	rs4276914	ENSG00000160766.13	GBAP1	-7.82	3.65e-14	1.67e-11	-0.35	-0.34	Urinary albumin-to-creatinine ratio;	chr1:155169753	chr1:155213821~155227422:-
PRAD	cis	rs914615	0.552	rs4971088	ENSG00000160766.13	GBAP1	-7.82	3.65e-14	1.67e-11	-0.35	-0.34	Urinary albumin-to-creatinine ratio;	chr1:155170407	chr1:155213821~155227422:-
PRAD	cis	rs914615	0.552	rs4971089	ENSG00000160766.13	GBAP1	-7.82	3.65e-14	1.67e-11	-0.35	-0.34	Urinary albumin-to-creatinine ratio;	chr1:155170451	chr1:155213821~155227422:-
PRAD	cis	rs7829975	0.714	rs12544992	ENSG00000253893.2	FAM85B	-7.82	3.66e-14	1.68e-11	-0.44	-0.34	Mood instability;	chr8:8804171	chr8:8167819~8226614:-
PRAD	cis	rs4266144	0.544	rs13080798	ENSG00000244515.1	KRT18P34	-7.82	3.67e-14	1.68e-11	-0.4	-0.34	Coronary artery disease;	chr3:157114612	chr3:157162663~157163932:-
PRAD	cis	rs1912483	0.505	rs11079772	ENSG00000228782.6	CTD-2026D20.3	-7.82	3.67e-14	1.68e-11	-0.41	-0.34	Coronary artery disease;	chr17:47316373	chr17:47450568~47492492:-
PRAD	cis	rs1552244	0.554	rs6443275	ENSG00000206567.8	AC022007.5	-7.82	3.68e-14	1.69e-11	-0.38	-0.34	Alzheimer's disease;	chr3:9967135	chr3:10006418~10011209:-
PRAD	cis	rs881375	0.678	rs10985102	ENSG00000226752.6	PSMD5-AS1	-7.82	3.69e-14	1.69e-11	-0.4	-0.34	Rheumatoid arthritis;	chr9:120945219	chr9:120824828~120854385:+
PRAD	cis	rs748404	0.631	rs28702649	ENSG00000249839.1	AC011330.5	-7.82	3.69e-14	1.69e-11	-0.43	-0.34	Lung cancer;	chr15:43356431	chr15:43663654~43684339:-
PRAD	cis	rs6603134	0.502	rs10406511	ENSG00000267939.1	CTD-2325M2.1	-7.82	3.69e-14	1.69e-11	-0.4	-0.34	Blood protein levels;	chr19:8039061	chr19:8008729~8016025:+
PRAD	cis	rs6844153	0.887	rs62302532	ENSG00000240005.4	RP11-293A21.1	-7.82	3.7e-14	1.7e-11	-0.47	-0.34	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26947150	chr4:26859806~26860599:-
PRAD	cis	rs6844153	0.887	rs6448488	ENSG00000240005.4	RP11-293A21.1	-7.82	3.7e-14	1.7e-11	-0.47	-0.34	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26949365	chr4:26859806~26860599:-
PRAD	cis	rs112721625	1	rs112721625	ENSG00000266992.1	DHX40P1	7.82	3.7e-14	1.7e-11	0.39	0.34	Monocyte count;	chr17:59850066	chr17:59976009~60002384:-
PRAD	cis	rs9640161	0.711	rs3800781	ENSG00000261305.1	RP4-584D14.7	7.82	3.71e-14	1.7e-11	0.39	0.34	Blood protein levels;Circulating chemerin levels;	chr7:150330235	chr7:150341771~150342607:+
PRAD	cis	rs7567389	0.534	rs2069904	ENSG00000236682.1	AC068282.3	-7.82	3.71e-14	1.7e-11	-0.46	-0.34	Self-rated health;	chr2:127418203	chr2:127389130~127400580:+
PRAD	cis	rs7567389	0.504	rs41280570	ENSG00000236682.1	AC068282.3	-7.82	3.71e-14	1.7e-11	-0.46	-0.34	Self-rated health;	chr2:127418654	chr2:127389130~127400580:+
PRAD	cis	rs950169	0.58	rs11630887	ENSG00000275120.1	RP11-182J1.17	7.82	3.71e-14	1.7e-11	0.44	0.34	Schizophrenia;	chr15:84649784	chr15:84599434~84606463:-
PRAD	cis	rs3096299	0.606	rs2965960	ENSG00000274627.1	RP11-104N10.2	7.82	3.72e-14	1.7e-11	0.36	0.34	Multiple myeloma (IgH translocation);	chr16:89475387	chr16:89516797~89522217:+
PRAD	cis	rs6921919	0.551	rs13201753	ENSG00000216901.1	AL022393.7	7.82	3.72e-14	1.7e-11	0.44	0.34	Autism spectrum disorder or schizophrenia;	chr6:28363351	chr6:28176188~28176674:+
PRAD	cis	rs1061377	1	rs4974931	ENSG00000249685.1	RP11-360F5.3	7.82	3.72e-14	1.71e-11	0.39	0.34	Uric acid levels;	chr4:39108896	chr4:39133913~39135608:+
PRAD	cis	rs673078	0.607	rs2393418	ENSG00000275409.1	RP11-131L12.4	-7.82	3.73e-14	1.71e-11	-0.49	-0.34	Glucose homeostasis traits;	chr12:118445995	chr12:118430147~118430699:+
PRAD	cis	rs10463554	0.824	rs60588319	ENSG00000175749.11	EIF3KP1	7.82	3.74e-14	1.71e-11	0.45	0.34	Parkinson's disease;	chr5:102988656	chr5:103032376~103033031:+
PRAD	cis	rs8040855	0.794	rs4843024	ENSG00000259295.5	CSPG4P12	-7.82	3.74e-14	1.71e-11	-0.46	-0.34	Bulimia nervosa;	chr15:85162669	chr15:85191438~85213905:+
PRAD	cis	rs964611	0.882	rs7175172	ENSG00000259488.2	RP11-154J22.1	-7.82	3.75e-14	1.72e-11	-0.33	-0.34	Metabolite levels (Pyroglutamine);	chr15:48280021	chr15:48312353~48331856:-
PRAD	cis	rs10463554	0.963	rs27970	ENSG00000175749.11	EIF3KP1	7.82	3.75e-14	1.72e-11	0.46	0.34	Parkinson's disease;	chr5:103151019	chr5:103032376~103033031:+
PRAD	cis	rs748404	0.578	rs512628	ENSG00000249839.1	AC011330.5	-7.82	3.76e-14	1.72e-11	-0.43	-0.34	Lung cancer;	chr15:43326536	chr15:43663654~43684339:-
PRAD	cis	rs1552244	0.554	rs6768339	ENSG00000206567.8	AC022007.5	7.82	3.77e-14	1.73e-11	0.38	0.34	Alzheimer's disease;	chr3:9964395	chr3:10006418~10011209:-
PRAD	cis	rs2274273	0.529	rs10131562	ENSG00000258413.1	RP11-665C16.6	-7.82	3.77e-14	1.73e-11	-0.46	-0.34	Protein biomarker;	chr14:55380297	chr14:55262767~55272075:-
PRAD	cis	rs7238033	0.624	rs11877062	ENSG00000267193.4	RP11-116O18.3	7.82	3.78e-14	1.73e-11	0.37	0.34	Bladder cancer;	chr18:45727281	chr18:45669367~45747215:-
PRAD	cis	rs2115630	0.645	rs3825877	ENSG00000225151.9	GOLGA2P7	7.82	3.79e-14	1.74e-11	0.43	0.34	P wave terminal force;	chr15:84631400	chr15:84199311~84230136:-
PRAD	cis	rs2115630	0.645	rs3825878	ENSG00000225151.9	GOLGA2P7	7.82	3.79e-14	1.74e-11	0.43	0.34	P wave terminal force;	chr15:84631524	chr15:84199311~84230136:-
PRAD	cis	rs11018904	0.906	rs17227345	ENSG00000280385.1	AP000648.5	7.82	3.8e-14	1.74e-11	0.49	0.34	Intelligence (multi-trait analysis);	chr11:90221517	chr11:90193614~90198120:+
PRAD	cis	rs74024059	1	rs335725	ENSG00000260685.1	RP11-326L17.1	-7.82	3.81e-14	1.74e-11	-0.99	-0.34	Red blood cell count;Hematocrit;	chr15:75936291	chr15:75950464~75951144:-
PRAD	cis	rs9549328	0.731	rs2873371	ENSG00000267868.1	RP11-120K24.3	7.82	3.81e-14	1.75e-11	0.42	0.34	Systolic blood pressure;	chr13:112961928	chr13:112964835~112966131:-
PRAD	cis	rs2638953	0.925	rs11049510	ENSG00000278733.1	RP11-425D17.1	-7.82	3.82e-14	1.75e-11	-0.44	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28290839	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.962	rs61922978	ENSG00000278733.1	RP11-425D17.1	-7.82	3.82e-14	1.75e-11	-0.44	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28292075	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.962	rs12372448	ENSG00000278733.1	RP11-425D17.1	-7.82	3.82e-14	1.75e-11	-0.44	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28293956	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.925	rs11049511	ENSG00000278733.1	RP11-425D17.1	-7.82	3.82e-14	1.75e-11	-0.44	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28294393	chr12:28185625~28186190:-
PRAD	cis	rs11133665	0.683	rs7719875	ENSG00000249201.2	CTD-3080P12.3	7.82	3.83e-14	1.75e-11	0.37	0.34	Urinary metabolites;	chr5:1189973	chr5:1173141~1178605:-
PRAD	cis	rs6844153	1	rs6844153	ENSG00000240005.4	RP11-293A21.1	-7.82	3.83e-14	1.75e-11	-0.49	-0.34	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26942692	chr4:26859806~26860599:-
PRAD	cis	rs4664293	0.967	rs13397722	ENSG00000226266.5	AC009961.3	-7.82	3.84e-14	1.76e-11	-0.46	-0.34	Monocyte percentage of white cells;	chr2:159659140	chr2:159670708~159712435:-
PRAD	cis	rs4664293	0.934	rs1365800	ENSG00000226266.5	AC009961.3	-7.82	3.84e-14	1.76e-11	-0.46	-0.34	Monocyte percentage of white cells;	chr2:159699112	chr2:159670708~159712435:-
PRAD	cis	rs8062405	0.558	rs231976	ENSG00000259982.1	CDC37P1	7.82	3.84e-14	1.76e-11	0.43	0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534266	chr16:28700294~28701540:-
PRAD	cis	rs12908161	0.959	rs34342559	ENSG00000259728.4	LINC00933	7.81	3.85e-14	1.76e-11	0.42	0.34	Schizophrenia;	chr15:84788040	chr15:84570649~84580175:+
PRAD	cis	rs12908161	0.959	rs62019472	ENSG00000259728.4	LINC00933	7.81	3.85e-14	1.76e-11	0.42	0.34	Schizophrenia;	chr15:84788262	chr15:84570649~84580175:+
PRAD	cis	rs12908161	0.959	rs35557864	ENSG00000259728.4	LINC00933	7.81	3.85e-14	1.76e-11	0.42	0.34	Schizophrenia;	chr15:84788398	chr15:84570649~84580175:+
PRAD	cis	rs5769707	0.609	rs2071890	ENSG00000188511.11	C22orf34	7.81	3.85e-14	1.76e-11	0.38	0.34	Monocyte percentage of white cells;Monocyte count;	chr22:49607643	chr22:49414524~49657542:-
PRAD	cis	rs2255336	0.873	rs11053806	ENSG00000245648.1	RP11-277P12.20	-7.81	3.86e-14	1.77e-11	-0.52	-0.34	Blood protein levels;	chr12:10455822	chr12:10363769~10398506:+
PRAD	cis	rs2108622	1	rs2108622	ENSG00000267453.5	AC004791.2	-7.81	3.87e-14	1.77e-11	-0.47	-0.34	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15879621	chr19:15851993~15864904:-
PRAD	cis	rs881375	0.678	rs10760129	ENSG00000226752.6	PSMD5-AS1	-7.81	3.87e-14	1.77e-11	-0.4	-0.34	Rheumatoid arthritis;	chr9:120937905	chr9:120824828~120854385:+
PRAD	cis	rs10740039	0.729	rs6479728	ENSG00000254271.1	RP11-131N11.4	-7.81	3.88e-14	1.77e-11	-0.47	-0.34	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60731043	chr10:60734342~60741828:+
PRAD	cis	rs42648	0.564	rs6975005	ENSG00000227646.6	STEAP2-AS1	7.81	3.88e-14	1.77e-11	0.3	0.34	Homocysteine levels;	chr7:90197414	chr7:89882353~90211635:-
PRAD	cis	rs42648	0.564	rs12155202	ENSG00000227646.6	STEAP2-AS1	-7.81	3.88e-14	1.77e-11	-0.3	-0.34	Homocysteine levels;	chr7:90198810	chr7:89882353~90211635:-
PRAD	cis	rs1979679	0.719	rs11049489	ENSG00000278733.1	RP11-425D17.1	7.81	3.89e-14	1.78e-11	0.45	0.34	Ossification of the posterior longitudinal ligament of the spine;	chr12:28259482	chr12:28185625~28186190:-
PRAD	cis	rs2243480	1	rs781142	ENSG00000226824.5	RP4-756H11.3	-7.81	3.89e-14	1.78e-11	-0.66	-0.34	Diabetic kidney disease;	chr7:65973791	chr7:66654538~66669855:+
PRAD	cis	rs2117029	0.767	rs12580349	ENSG00000258017.1	RP11-386G11.10	7.81	3.89e-14	1.78e-11	0.48	0.34	Intelligence (multi-trait analysis);	chr12:49042941	chr12:49127782~49147869:+
PRAD	cis	rs4845570	0.92	rs10788809	ENSG00000268288.1	RP11-98D18.16	-7.81	3.9e-14	1.78e-11	-0.53	-0.34	Coronary artery disease;	chr1:151788316	chr1:151766486~151767000:-
PRAD	cis	rs10463554	0.963	rs257294	ENSG00000175749.11	EIF3KP1	7.81	3.9e-14	1.79e-11	0.45	0.34	Parkinson's disease;	chr5:103131563	chr5:103032376~103033031:+
PRAD	cis	rs62355901	0.599	rs10513090	ENSG00000271828.1	CTD-2310F14.1	-7.81	3.91e-14	1.79e-11	-0.74	-0.34	Breast cancer;	chr5:56758238	chr5:56927874~56929573:+
PRAD	cis	rs4845570	1	rs7416415	ENSG00000268288.1	RP11-98D18.16	-7.81	3.92e-14	1.79e-11	-0.53	-0.34	Coronary artery disease;	chr1:151785322	chr1:151766486~151767000:-
PRAD	cis	rs853679	1	rs6901575	ENSG00000226314.6	ZNF192P1	-7.81	3.92e-14	1.79e-11	-0.54	-0.34	Depression;	chr6:28283207	chr6:28161781~28169594:+
PRAD	cis	rs10463554	0.927	rs34831	ENSG00000175749.11	EIF3KP1	7.81	3.95e-14	1.81e-11	0.46	0.34	Parkinson's disease;	chr5:103108385	chr5:103032376~103033031:+
PRAD	cis	rs526231	0.511	rs27896	ENSG00000175749.11	EIF3KP1	7.81	3.96e-14	1.81e-11	0.48	0.34	Primary biliary cholangitis;	chr5:103152867	chr5:103032376~103033031:+
PRAD	cis	rs7567389	0.638	rs12105051	ENSG00000236682.1	AC068282.3	7.81	3.98e-14	1.82e-11	0.46	0.34	Self-rated health;	chr2:127232601	chr2:127389130~127400580:+
PRAD	cis	rs6545883	0.524	rs2694618	ENSG00000271889.1	RP11-493E12.1	7.81	3.98e-14	1.82e-11	0.38	0.34	Tuberculosis;	chr2:61309849	chr2:61151433~61162105:-
PRAD	cis	rs1930961	1	rs760555	ENSG00000271138.1	IGLVIVOR22-1	-7.81	3.98e-14	1.82e-11	-0.52	-0.34	Bipolar disorder with mood-incongruent psychosis;	chr22:25476870	chr22:25437306~25437823:-
PRAD	cis	rs62355900	0.627	rs3736430	ENSG00000271828.1	CTD-2310F14.1	7.81	4e-14	1.83e-11	0.71	0.34	Endometriosis;	chr5:56884653	chr5:56927874~56929573:+
PRAD	cis	rs34524635	1	rs34524635	ENSG00000232075.1	MRPL35P2	-7.81	4e-14	1.83e-11	-0.36	-0.34	Vascular endothelial growth factor levels;	chr10:63501417	chr10:63634317~63634827:-
PRAD	cis	rs172166	0.538	rs149956	ENSG00000280107.1	AL022393.9	-7.81	4.01e-14	1.83e-11	-0.41	-0.34	Cardiac Troponin-T levels;	chr6:28068473	chr6:28170845~28172521:+
PRAD	cis	rs526231	0.543	rs28025	ENSG00000175749.11	EIF3KP1	7.81	4.02e-14	1.84e-11	0.48	0.34	Primary biliary cholangitis;	chr5:103201678	chr5:103032376~103033031:+
PRAD	cis	rs9532669	0.963	rs3736953	ENSG00000168852.11	TPTE2P5	7.81	4.03e-14	1.84e-11	0.33	0.34	Cervical cancer;	chr13:40951450	chr13:40822296~40921749:-
PRAD	cis	rs4664293	0.967	rs9646765	ENSG00000226266.5	AC009961.3	-7.81	4.03e-14	1.84e-11	-0.45	-0.34	Monocyte percentage of white cells;	chr2:159709137	chr2:159670708~159712435:-
PRAD	cis	rs2243480	0.901	rs778732	ENSG00000226824.5	RP4-756H11.3	-7.81	4.04e-14	1.85e-11	-0.69	-0.34	Diabetic kidney disease;	chr7:66357373	chr7:66654538~66669855:+
PRAD	cis	rs12908161	0.92	rs12904605	ENSG00000275120.1	RP11-182J1.17	7.81	4.05e-14	1.85e-11	0.44	0.34	Schizophrenia;	chr15:84658188	chr15:84599434~84606463:-
PRAD	cis	rs11148252	0.5	rs342768	ENSG00000278238.1	RP11-245D16.4	-7.81	4.05e-14	1.85e-11	-0.36	-0.34	Lewy body disease;	chr13:52634747	chr13:52454775~52455331:-
PRAD	cis	rs42648	0.564	rs6465249	ENSG00000227646.6	STEAP2-AS1	-7.81	4.05e-14	1.85e-11	-0.3	-0.34	Homocysteine levels;	chr7:90195439	chr7:89882353~90211635:-
PRAD	cis	rs2439831	1	rs527921	ENSG00000205771.5	CATSPER2P1	7.81	4.05e-14	1.85e-11	0.5	0.34	Lung cancer in ever smokers;	chr15:43478218	chr15:43726918~43747094:-
PRAD	cis	rs2638953	0.962	rs11049493	ENSG00000278733.1	RP11-425D17.1	-7.81	4.06e-14	1.85e-11	-0.44	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28263115	chr12:28185625~28186190:-
PRAD	cis	rs858239	0.712	rs200717	ENSG00000226816.2	AC005082.12	7.81	4.07e-14	1.86e-11	0.38	0.34	Cerebrospinal fluid biomarker levels;	chr7:23352652	chr7:23206013~23208045:+
PRAD	cis	rs42648	0.564	rs7777170	ENSG00000227646.6	STEAP2-AS1	-7.81	4.07e-14	1.86e-11	-0.3	-0.34	Homocysteine levels;	chr7:90192968	chr7:89882353~90211635:-
PRAD	cis	rs42648	0.564	rs7777282	ENSG00000227646.6	STEAP2-AS1	-7.81	4.07e-14	1.86e-11	-0.3	-0.34	Homocysteine levels;	chr7:90192991	chr7:89882353~90211635:-
PRAD	cis	rs35491132	1	rs35491132	ENSG00000280107.1	AL022393.9	-7.81	4.07e-14	1.86e-11	-0.67	-0.34	Urinary tract infection frequency;	chr6:27559449	chr6:28170845~28172521:+
PRAD	cis	rs881375	0.678	rs10760130	ENSG00000226752.6	PSMD5-AS1	-7.81	4.08e-14	1.86e-11	-0.4	-0.34	Rheumatoid arthritis;	chr9:120939712	chr9:120824828~120854385:+
PRAD	cis	rs1979679	0.959	rs75757272	ENSG00000278733.1	RP11-425D17.1	7.81	4.09e-14	1.87e-11	0.48	0.34	Ossification of the posterior longitudinal ligament of the spine;	chr12:28251809	chr12:28185625~28186190:-
PRAD	cis	rs17772222	0.958	rs1123421	ENSG00000258983.2	RP11-507K2.2	7.81	4.1e-14	1.87e-11	0.49	0.34	Coronary artery calcification;	chr14:88524651	chr14:88499334~88515502:+
PRAD	cis	rs8523	0.901	rs1321536	ENSG00000230314.5	ELOVL2-AS1	7.8	4.13e-14	1.88e-11	0.38	0.34	Red blood cell fatty acid levels;	chr6:11018579	chr6:11043524~11078226:+
PRAD	cis	rs465969	1	rs13208890	ENSG00000255389.1	C6orf3	-7.8	4.13e-14	1.88e-11	-0.69	-0.34	Psoriasis;	chr6:111500620	chr6:111599875~111602295:+
PRAD	cis	rs9640161	0.659	rs7806429	ENSG00000261305.1	RP4-584D14.7	7.8	4.13e-14	1.88e-11	0.36	0.34	Blood protein levels;Circulating chemerin levels;	chr7:150316304	chr7:150341771~150342607:+
PRAD	cis	rs11976180	1	rs2961119	ENSG00000273234.1	OR2A13P	-7.8	4.14e-14	1.89e-11	-0.41	-0.34	Obesity-related traits;	chr7:144058759	chr7:144142009~144142938:+
PRAD	cis	rs853679	1	rs1419183	ENSG00000226314.6	ZNF192P1	-7.8	4.15e-14	1.89e-11	-0.54	-0.34	Depression;	chr6:28275017	chr6:28161781~28169594:+
PRAD	cis	rs2243480	0.803	rs423187	ENSG00000226824.5	RP4-756H11.3	-7.8	4.15e-14	1.89e-11	-0.7	-0.34	Diabetic kidney disease;	chr7:66044512	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs466983	ENSG00000226824.5	RP4-756H11.3	-7.8	4.15e-14	1.89e-11	-0.7	-0.34	Diabetic kidney disease;	chr7:66055509	chr7:66654538~66669855:+
PRAD	cis	rs3096299	0.503	rs4785677	ENSG00000261118.1	RP11-104N10.1	7.8	4.15e-14	1.89e-11	0.33	0.34	Multiple myeloma (IgH translocation);	chr16:89488693	chr16:89492017~89504460:-
PRAD	cis	rs1499614	1	rs2707840	ENSG00000226824.5	RP4-756H11.3	-7.8	4.16e-14	1.9e-11	-0.69	-0.34	Gout;	chr7:66693028	chr7:66654538~66669855:+
PRAD	cis	rs2348418	0.639	rs41505151	ENSG00000247934.4	RP11-967K21.1	7.8	4.17e-14	1.9e-11	0.33	0.34	Lung function (FEV1);Lung function (FVC);	chr12:28112651	chr12:28163298~28190738:-
PRAD	cis	rs10463554	0.963	rs26821	ENSG00000175749.11	EIF3KP1	7.8	4.17e-14	1.9e-11	0.46	0.34	Parkinson's disease;	chr5:103184699	chr5:103032376~103033031:+
PRAD	cis	rs17428076	0.556	rs12692976	ENSG00000228389.1	AC068039.4	7.8	4.17e-14	1.9e-11	0.39	0.34	Myopia;	chr2:171827893	chr2:171773482~171775844:+
PRAD	cis	rs8091660	0.929	rs12606093	ENSG00000278983.1	RP11-426J5.3	7.8	4.17e-14	1.9e-11	0.43	0.34	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48550924	chr18:48564795~48568342:+
PRAD	cis	rs2243480	0.708	rs781141	ENSG00000226824.5	RP4-756H11.3	-7.8	4.17e-14	1.9e-11	-0.66	-0.34	Diabetic kidney disease;	chr7:65973566	chr7:66654538~66669855:+
PRAD	cis	rs10129255	0.5	rs34326748	ENSG00000211972.2	IGHV3-66	7.8	4.18e-14	1.91e-11	0.3	0.34	Kawasaki disease;	chr14:106782523	chr14:106675017~106675544:-
PRAD	cis	rs10129255	0.5	rs10143385	ENSG00000211972.2	IGHV3-66	7.8	4.18e-14	1.91e-11	0.3	0.34	Kawasaki disease;	chr14:106782559	chr14:106675017~106675544:-
PRAD	cis	rs6504950	0.579	rs9907270	ENSG00000275710.1	RP11-257O5.4	7.8	4.18e-14	1.91e-11	0.51	0.34	Breast cancer;	chr17:55189054	chr17:54964474~54964679:+
PRAD	cis	rs1979679	0.918	rs7977429	ENSG00000278733.1	RP11-425D17.1	7.8	4.18e-14	1.91e-11	0.44	0.34	Ossification of the posterior longitudinal ligament of the spine;	chr12:28370376	chr12:28185625~28186190:-
PRAD	cis	rs1979679	0.918	rs11049562	ENSG00000278733.1	RP11-425D17.1	7.8	4.18e-14	1.91e-11	0.44	0.34	Ossification of the posterior longitudinal ligament of the spine;	chr12:28375576	chr12:28185625~28186190:-
PRAD	cis	rs9467773	0.62	rs2451711	ENSG00000241549.7	GUSBP2	7.8	4.18e-14	1.91e-11	0.36	0.34	Intelligence (multi-trait analysis);	chr6:26662882	chr6:26871484~26956554:-
PRAD	cis	rs11098499	0.69	rs34818745	ENSG00000245958.5	RP11-33B1.1	-7.8	4.18e-14	1.91e-11	-0.34	-0.34	Corneal astigmatism;	chr4:119335900	chr4:119454791~119552025:+
PRAD	cis	rs17012589	0.667	rs7486805	ENSG00000258815.1	RP11-408B11.2	7.8	4.19e-14	1.91e-11	0.47	0.34	Bone mineral density (Ward's triangle area);	chr12:85271591	chr12:85318060~85342912:+
PRAD	cis	rs2243480	1	rs12698509	ENSG00000226824.5	RP4-756H11.3	-7.8	4.19e-14	1.91e-11	-0.65	-0.34	Diabetic kidney disease;	chr7:65953889	chr7:66654538~66669855:+
PRAD	cis	rs853679	0.527	rs9461443	ENSG00000226314.6	ZNF192P1	-7.8	4.19e-14	1.91e-11	-0.47	-0.34	Depression;	chr6:28226851	chr6:28161781~28169594:+
PRAD	cis	rs17608059	0.611	rs2108591	ENSG00000141028.6	CDRT15P1	-7.8	4.21e-14	1.92e-11	-0.45	-0.34	Temperament;	chr17:14019308	chr17:14024514~14025488:+
PRAD	cis	rs494459	0.838	rs632124	ENSG00000278376.1	RP11-158I9.8	-7.8	4.22e-14	1.92e-11	-0.29	-0.34	Height;	chr11:118742526	chr11:118791254~118793137:+
PRAD	cis	rs2638953	0.924	rs17801436	ENSG00000278733.1	RP11-425D17.1	-7.8	4.22e-14	1.92e-11	-0.43	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28165421	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs11049385	ENSG00000278733.1	RP11-425D17.1	-7.8	4.22e-14	1.92e-11	-0.43	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28167559	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs11049387	ENSG00000278733.1	RP11-425D17.1	-7.8	4.22e-14	1.92e-11	-0.43	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28167609	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.886	rs12371462	ENSG00000278733.1	RP11-425D17.1	-7.8	4.22e-14	1.92e-11	-0.43	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28168770	chr12:28185625~28186190:-
PRAD	cis	rs1979679	0.673	rs12229872	ENSG00000278733.1	RP11-425D17.1	7.8	4.22e-14	1.92e-11	0.45	0.34	Ossification of the posterior longitudinal ligament of the spine;	chr12:28137845	chr12:28185625~28186190:-
PRAD	cis	rs1134634	0.52	rs28528670	ENSG00000273133.1	RP11-799M12.2	-7.8	4.22e-14	1.92e-11	-0.46	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15591295	chr4:15563698~15564253:-
PRAD	cis	rs10129255	1	rs10129407	ENSG00000223648.3	IGHV3-64	7.8	4.22e-14	1.92e-11	0.34	0.34	Kawasaki disease;	chr14:106767956	chr14:106643132~106658258:-
PRAD	cis	rs10875746	0.551	rs3751273	ENSG00000240399.1	RP1-228P16.1	-7.8	4.24e-14	1.93e-11	-0.34	-0.34	Longevity (90 years and older);	chr12:48345655	chr12:48054813~48055591:-
PRAD	cis	rs9467773	0.62	rs1490488	ENSG00000241549.7	GUSBP2	7.8	4.24e-14	1.93e-11	0.36	0.34	Intelligence (multi-trait analysis);	chr6:26614580	chr6:26871484~26956554:-
PRAD	cis	rs9467773	0.62	rs2494692	ENSG00000241549.7	GUSBP2	7.8	4.24e-14	1.93e-11	0.36	0.34	Intelligence (multi-trait analysis);	chr6:26614995	chr6:26871484~26956554:-
PRAD	cis	rs6991838	0.733	rs13281981	ENSG00000200714.1	Y_RNA	7.8	4.26e-14	1.94e-11	0.36	0.34	Intelligence (multi-trait analysis);	chr8:65611649	chr8:65592731~65592820:+
PRAD	cis	rs1061377	1	rs4974998	ENSG00000249685.1	RP11-360F5.3	7.8	4.26e-14	1.94e-11	0.39	0.34	Uric acid levels;	chr4:39109129	chr4:39133913~39135608:+
PRAD	cis	rs1043099	0.871	rs10427610	ENSG00000279699.1	RP1-102K2.9	-7.8	4.27e-14	1.94e-11	-0.53	-0.34	Rheumatoid arthritis;	chr22:30352229	chr22:30275215~30276951:-
PRAD	cis	rs62355901	0.551	rs12659430	ENSG00000271828.1	CTD-2310F14.1	7.8	4.28e-14	1.95e-11	0.76	0.34	Breast cancer;	chr5:56736792	chr5:56927874~56929573:+
PRAD	cis	rs62355901	0.599	rs62355881	ENSG00000271828.1	CTD-2310F14.1	7.8	4.28e-14	1.95e-11	0.76	0.34	Breast cancer;	chr5:56737266	chr5:56927874~56929573:+
PRAD	cis	rs67311347	1	rs9835219	ENSG00000223797.4	ENTPD3-AS1	7.8	4.28e-14	1.95e-11	0.31	0.34	Renal cell carcinoma;	chr3:40382602	chr3:40313802~40453329:-
PRAD	cis	rs67311347	1	rs7642552	ENSG00000223797.4	ENTPD3-AS1	7.8	4.28e-14	1.95e-11	0.31	0.34	Renal cell carcinoma;	chr3:40383325	chr3:40313802~40453329:-
PRAD	cis	rs2337406	0.587	rs916547	ENSG00000274576.2	IGHV2-70	-7.8	4.29e-14	1.95e-11	-0.37	-0.34	Alzheimer's disease (late onset);	chr14:106646735	chr14:106770577~106771020:-
PRAD	cis	rs11083475	1	rs3786845	ENSG00000267892.1	CTD-2540F13.2	7.8	4.3e-14	1.96e-11	0.37	0.34	Heart rate;	chr19:38704443	chr19:38738284~38739863:+
PRAD	cis	rs193541	0.53	rs2045626	ENSG00000263432.2	RN7SL689P	7.8	4.31e-14	1.96e-11	0.37	0.34	Glucose homeostasis traits;	chr5:122745558	chr5:123022487~123022783:-
PRAD	cis	rs881375	0.967	rs7046108	ENSG00000226752.6	PSMD5-AS1	7.8	4.32e-14	1.96e-11	0.41	0.34	Rheumatoid arthritis;	chr9:120898061	chr9:120824828~120854385:+
PRAD	cis	rs1185460	0.565	rs10892325	ENSG00000271751.1	RP11-110I1.14	7.8	4.33e-14	1.97e-11	0.46	0.34	Coronary artery disease;	chr11:119041992	chr11:119065263~119065677:-
PRAD	cis	rs7945705	0.712	rs61876274	ENSG00000254860.4	TMEM9B-AS1	-7.8	4.33e-14	1.97e-11	-0.36	-0.34	Hemoglobin concentration;	chr11:8997643	chr11:8964675~8977527:+
PRAD	cis	rs4664293	0.605	rs12991516	ENSG00000226266.5	AC009961.3	-7.8	4.33e-14	1.97e-11	-0.46	-0.34	Monocyte percentage of white cells;	chr2:159585554	chr2:159670708~159712435:-
PRAD	cis	rs2236295	1	rs2236295	ENSG00000238280.1	RP11-436D10.3	-7.8	4.34e-14	1.98e-11	-0.45	-0.34	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr10:62805132	chr10:62793562~62805887:-
PRAD	cis	rs6479891	0.908	rs11818738	ENSG00000232075.1	MRPL35P2	7.8	4.35e-14	1.98e-11	0.6	0.34	Arthritis (juvenile idiopathic);	chr10:63604971	chr10:63634317~63634827:-
PRAD	cis	rs6479901	1	rs10740133	ENSG00000232075.1	MRPL35P2	-7.8	4.35e-14	1.98e-11	-0.42	-0.34	Intelligence (multi-trait analysis);	chr10:63517676	chr10:63634317~63634827:-
PRAD	cis	rs11976180	1	rs1919951	ENSG00000273234.1	OR2A13P	-7.8	4.36e-14	1.98e-11	-0.41	-0.34	Obesity-related traits;	chr7:144071798	chr7:144142009~144142938:+
PRAD	cis	rs2638953	0.64	rs1511549	ENSG00000278733.1	RP11-425D17.1	-7.8	4.36e-14	1.98e-11	-0.4	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28578968	chr12:28185625~28186190:-
PRAD	cis	rs2115630	0.645	rs6496284	ENSG00000225151.9	GOLGA2P7	7.8	4.36e-14	1.99e-11	0.44	0.34	P wave terminal force;	chr15:84635039	chr15:84199311~84230136:-
PRAD	cis	rs67311347	0.713	rs73073505	ENSG00000223797.4	ENTPD3-AS1	7.8	4.37e-14	1.99e-11	0.32	0.34	Renal cell carcinoma;	chr3:40269202	chr3:40313802~40453329:-
PRAD	cis	rs4845570	0.92	rs6694952	ENSG00000268288.1	RP11-98D18.16	-7.8	4.37e-14	1.99e-11	-0.52	-0.34	Coronary artery disease;	chr1:151787655	chr1:151766486~151767000:-
PRAD	cis	rs4845570	1	rs1054479	ENSG00000268288.1	RP11-98D18.16	7.8	4.38e-14	1.99e-11	0.52	0.34	Coronary artery disease;	chr1:151773603	chr1:151766486~151767000:-
PRAD	cis	rs9467773	0.869	rs1796521	ENSG00000124549.13	BTN2A3P	-7.8	4.39e-14	2e-11	-0.31	-0.34	Intelligence (multi-trait analysis);	chr6:26421164	chr6:26421391~26432383:+
PRAD	cis	rs2115630	0.691	rs2292462	ENSG00000225151.9	GOLGA2P7	7.8	4.41e-14	2.01e-11	0.43	0.34	P wave terminal force;	chr15:84657523	chr15:84199311~84230136:-
PRAD	cis	rs7829975	0.533	rs1039917	ENSG00000253893.2	FAM85B	-7.8	4.42e-14	2.01e-11	-0.45	-0.34	Mood instability;	chr8:8861340	chr8:8167819~8226614:-
PRAD	cis	rs2638953	0.64	rs1511548	ENSG00000278733.1	RP11-425D17.1	-7.8	4.42e-14	2.01e-11	-0.4	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28579057	chr12:28185625~28186190:-
PRAD	cis	rs9467773	0.62	rs2498351	ENSG00000241549.7	GUSBP2	7.8	4.42e-14	2.01e-11	0.36	0.34	Intelligence (multi-trait analysis);	chr6:26659414	chr6:26871484~26956554:-
PRAD	cis	rs9467773	0.62	rs2504566	ENSG00000241549.7	GUSBP2	7.8	4.42e-14	2.01e-11	0.36	0.34	Intelligence (multi-trait analysis);	chr6:26660260	chr6:26871484~26956554:-
PRAD	cis	rs11976180	1	rs2961117	ENSG00000170356.8	OR2A20P	-7.79	4.42e-14	2.01e-11	-0.46	-0.34	Obesity-related traits;	chr7:144058160	chr7:144250045~144252957:-
PRAD	cis	rs7829975	0.774	rs13259216	ENSG00000253893.2	FAM85B	-7.79	4.43e-14	2.01e-11	-0.44	-0.34	Mood instability;	chr8:8816091	chr8:8167819~8226614:-
PRAD	cis	rs8040855	0.965	rs11073990	ENSG00000259295.5	CSPG4P12	7.79	4.43e-14	2.01e-11	0.43	0.34	Bulimia nervosa;	chr15:85168070	chr15:85191438~85213905:+
PRAD	cis	rs853679	0.599	rs202906	ENSG00000280107.1	AL022393.9	7.79	4.43e-14	2.02e-11	0.61	0.34	Depression;	chr6:28043874	chr6:28170845~28172521:+
PRAD	cis	rs2412819	0.545	rs654276	ENSG00000205771.5	CATSPER2P1	7.79	4.43e-14	2.02e-11	0.49	0.34	Lung cancer;	chr15:43798656	chr15:43726918~43747094:-
PRAD	cis	rs2439831	0.717	rs28495368	ENSG00000205771.5	CATSPER2P1	-7.79	4.46e-14	2.03e-11	-0.55	-0.34	Lung cancer in ever smokers;	chr15:43603444	chr15:43726918~43747094:-
PRAD	cis	rs524281	0.506	rs560393	ENSG00000255320.1	RP11-755F10.1	7.79	4.47e-14	2.03e-11	0.5	0.34	Electroencephalogram traits;	chr11:66238006	chr11:66244840~66246239:-
PRAD	cis	rs6545883	0.507	rs12617371	ENSG00000271889.1	RP11-493E12.1	-7.79	4.47e-14	2.03e-11	-0.38	-0.34	Tuberculosis;	chr2:61341999	chr2:61151433~61162105:-
PRAD	cis	rs2286503	0.839	rs4722189	ENSG00000228649.7	AC005682.5	7.79	4.48e-14	2.04e-11	0.39	0.34	Fibrinogen;	chr7:22820855	chr7:22854178~22861579:+
PRAD	cis	rs6479901	0.947	rs7082076	ENSG00000232075.1	MRPL35P2	-7.79	4.49e-14	2.04e-11	-0.42	-0.34	Intelligence (multi-trait analysis);	chr10:63517185	chr10:63634317~63634827:-
PRAD	cis	rs2243480	0.901	rs13237344	ENSG00000226824.5	RP4-756H11.3	-7.79	4.49e-14	2.04e-11	-0.71	-0.34	Diabetic kidney disease;	chr7:66557269	chr7:66654538~66669855:+
PRAD	cis	rs1979679	0.918	rs1257741	ENSG00000278733.1	RP11-425D17.1	7.79	4.51e-14	2.05e-11	0.45	0.34	Ossification of the posterior longitudinal ligament of the spine;	chr12:28381636	chr12:28185625~28186190:-
PRAD	cis	rs7923609	0.818	rs10822159	ENSG00000232075.1	MRPL35P2	-7.79	4.53e-14	2.06e-11	-0.36	-0.34	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63336490	chr10:63634317~63634827:-
PRAD	cis	rs10411161	1	rs8106929	ENSG00000269483.1	AC006272.1	7.79	4.55e-14	2.07e-11	0.48	0.34	Breast cancer;	chr19:51865214	chr19:51839924~51843324:-
PRAD	cis	rs2286503	0.809	rs4719716	ENSG00000228649.7	AC005682.5	7.79	4.55e-14	2.07e-11	0.39	0.34	Fibrinogen;	chr7:22821750	chr7:22854178~22861579:+
PRAD	cis	rs1061377	1	rs4974997	ENSG00000249685.1	RP11-360F5.3	7.79	4.57e-14	2.07e-11	0.39	0.34	Uric acid levels;	chr4:39109151	chr4:39133913~39135608:+
PRAD	cis	rs12612619	0.732	rs11681562	ENSG00000229122.1	AGBL5-IT1	7.79	4.58e-14	2.08e-11	0.36	0.34	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27027735	chr2:27061038~27061815:+
PRAD	cis	rs524281	0.506	rs2298466	ENSG00000255320.1	RP11-755F10.1	7.79	4.58e-14	2.08e-11	0.5	0.34	Electroencephalogram traits;	chr11:66243809	chr11:66244840~66246239:-
PRAD	cis	rs9532669	0.926	rs4254182	ENSG00000168852.11	TPTE2P5	7.79	4.6e-14	2.09e-11	0.33	0.34	Cervical cancer;	chr13:40879120	chr13:40822296~40921749:-
PRAD	cis	rs6991838	0.584	rs6991731	ENSG00000200714.1	Y_RNA	7.79	4.61e-14	2.09e-11	0.38	0.34	Intelligence (multi-trait analysis);	chr8:65643232	chr8:65592731~65592820:+
PRAD	cis	rs4631830	0.828	rs10763567	ENSG00000230869.1	CTGLF10P	7.79	4.61e-14	2.09e-11	0.42	0.34	Prostate-specific antigen levels;	chr10:46057653	chr10:45678692~45700532:+
PRAD	cis	rs1150668	0.83	rs2531831	ENSG00000280107.1	AL022393.9	-7.79	4.61e-14	2.09e-11	-0.4	-0.34	Pubertal anthropometrics;	chr6:28420988	chr6:28170845~28172521:+
PRAD	cis	rs9326248	0.559	rs4938334	ENSG00000280143.1	AP000892.6	7.79	4.61e-14	2.09e-11	0.26	0.34	Blood protein levels;	chr11:117060326	chr11:117204967~117210292:+
PRAD	cis	rs17428076	0.793	rs72881938	ENSG00000228389.1	AC068039.4	-7.79	4.61e-14	2.09e-11	-0.44	-0.34	Myopia;	chr2:171772242	chr2:171773482~171775844:+
PRAD	cis	rs1150668	0.835	rs203869	ENSG00000280107.1	AL022393.9	-7.79	4.61e-14	2.1e-11	-0.4	-0.34	Pubertal anthropometrics;	chr6:28073041	chr6:28170845~28172521:+
PRAD	cis	rs8062405	0.573	rs7140	ENSG00000259982.1	CDC37P1	-7.79	4.62e-14	2.1e-11	-0.48	-0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28984436	chr16:28700294~28701540:-
PRAD	cis	rs9532669	0.926	rs7322399	ENSG00000168852.11	TPTE2P5	7.79	4.62e-14	2.1e-11	0.33	0.34	Cervical cancer;	chr13:40952511	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.926	rs7322097	ENSG00000168852.11	TPTE2P5	7.79	4.62e-14	2.1e-11	0.33	0.34	Cervical cancer;	chr13:40952513	chr13:40822296~40921749:-
PRAD	cis	rs6844153	0.938	rs16878655	ENSG00000240005.4	RP11-293A21.1	7.79	4.64e-14	2.11e-11	0.5	0.34	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26964655	chr4:26859806~26860599:-
PRAD	cis	rs4664293	0.528	rs72960224	ENSG00000226266.5	AC009961.3	7.79	4.65e-14	2.11e-11	0.45	0.34	Monocyte percentage of white cells;	chr2:159563993	chr2:159670708~159712435:-
PRAD	cis	rs12928939	0.815	rs12448022	ENSG00000260886.1	TAT-AS1	7.79	4.65e-14	2.11e-11	0.45	0.34	Post bronchodilator FEV1;	chr16:71690466	chr16:71565789~71578187:+
PRAD	cis	rs9467773	0.62	rs2101582	ENSG00000241549.7	GUSBP2	7.79	4.65e-14	2.11e-11	0.36	0.34	Intelligence (multi-trait analysis);	chr6:26622506	chr6:26871484~26956554:-
PRAD	cis	rs6782228	1	rs11711038	ENSG00000242551.2	POU5F1P6	7.79	4.67e-14	2.12e-11	0.49	0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128675467	chr3:128674735~128677005:-
PRAD	cis	rs853679	1	rs11965538	ENSG00000226314.6	ZNF192P1	-7.79	4.67e-14	2.12e-11	-0.54	-0.34	Depression;	chr6:28272137	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.882	rs2743555	ENSG00000226314.6	ZNF192P1	-7.79	4.67e-14	2.12e-11	-0.54	-0.34	Depression;	chr6:28273304	chr6:28161781~28169594:+
PRAD	cis	rs440932	0.887	rs398801	ENSG00000254340.1	RP11-10A14.3	-7.79	4.67e-14	2.12e-11	-0.42	-0.34	High light scatter reticulocyte percentage of red cells;	chr8:9174194	chr8:9141424~9145435:+
PRAD	cis	rs6001482	0.662	rs6001526	ENSG00000272779.1	LL22NC03-80A10.6	-7.79	4.68e-14	2.12e-11	-0.41	-0.34	Diastolic blood pressure;	chr22:22234518	chr22:22303224~22310401:+
PRAD	cis	rs6921919	0.848	rs56131013	ENSG00000216901.1	AL022393.7	7.79	4.68e-14	2.12e-11	0.48	0.34	Autism spectrum disorder or schizophrenia;	chr6:28352900	chr6:28176188~28176674:+
PRAD	cis	rs9467773	0.596	rs3001369	ENSG00000241549.7	GUSBP2	7.79	4.68e-14	2.12e-11	0.36	0.34	Intelligence (multi-trait analysis);	chr6:26670741	chr6:26871484~26956554:-
PRAD	cis	rs7923609	0.967	rs10740134	ENSG00000232075.1	MRPL35P2	-7.79	4.68e-14	2.12e-11	-0.36	-0.34	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63555673	chr10:63634317~63634827:-
PRAD	cis	rs867186	0.535	rs6058220	ENSG00000126005.14	MMP24-AS1	-7.79	4.69e-14	2.13e-11	-0.58	-0.34	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35271461	chr20:35216462~35278131:-
PRAD	cis	rs858239	0.6	rs4321896	ENSG00000226816.2	AC005082.12	7.79	4.69e-14	2.13e-11	0.39	0.34	Cerebrospinal fluid biomarker levels;	chr7:23088437	chr7:23206013~23208045:+
PRAD	cis	rs1043099	0.871	rs9619104	ENSG00000279699.1	RP1-102K2.9	-7.79	4.69e-14	2.13e-11	-0.53	-0.34	Rheumatoid arthritis;	chr22:30378351	chr22:30275215~30276951:-
PRAD	cis	rs17361889	0.671	rs4282466	ENSG00000224683.1	RPL36AP29	7.79	4.69e-14	2.13e-11	0.41	0.34	Pediatric bone mineral content (hip);	chr7:16111878	chr7:16208945~16209265:+
PRAD	cis	rs2638953	0.925	rs17432330	ENSG00000278733.1	RP11-425D17.1	-7.79	4.69e-14	2.13e-11	-0.44	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28292336	chr12:28185625~28186190:-
PRAD	cis	rs11846409	0.932	rs10151046	ENSG00000274576.2	IGHV2-70	-7.79	4.7e-14	2.13e-11	-0.36	-0.34	Rheumatic heart disease;	chr14:106633095	chr14:106770577~106771020:-
PRAD	cis	rs2243480	1	rs1267820	ENSG00000226824.5	RP4-756H11.3	-7.79	4.7e-14	2.13e-11	-0.71	-0.34	Diabetic kidney disease;	chr7:66585308	chr7:66654538~66669855:+
PRAD	cis	rs2117029	0.767	rs3741622	ENSG00000258017.1	RP11-386G11.10	-7.79	4.7e-14	2.13e-11	-0.49	-0.34	Intelligence (multi-trait analysis);	chr12:49032195	chr12:49127782~49147869:+
PRAD	cis	rs9532669	0.889	rs1989252	ENSG00000168852.11	TPTE2P5	-7.79	4.7e-14	2.13e-11	-0.33	-0.34	Cervical cancer;	chr13:40911532	chr13:40822296~40921749:-
PRAD	cis	rs9467773	0.595	rs12525810	ENSG00000241549.7	GUSBP2	7.79	4.71e-14	2.14e-11	0.37	0.34	Intelligence (multi-trait analysis);	chr6:26623283	chr6:26871484~26956554:-
PRAD	cis	rs1061377	1	rs12499266	ENSG00000249685.1	RP11-360F5.3	-7.79	4.72e-14	2.14e-11	-0.38	-0.34	Uric acid levels;	chr4:39118133	chr4:39133913~39135608:+
PRAD	cis	rs4722166	0.532	rs6963591	ENSG00000179428.2	AC073072.5	7.79	4.72e-14	2.14e-11	0.4	0.34	Lung cancer;	chr7:22717651	chr7:22725395~22727620:-
PRAD	cis	rs7746199	0.736	rs17693963	ENSG00000280107.1	AL022393.9	-7.79	4.74e-14	2.15e-11	-0.64	-0.34	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27742386	chr6:28170845~28172521:+
PRAD	cis	rs10875746	0.669	rs11168516	ENSG00000240399.1	RP1-228P16.1	-7.79	4.74e-14	2.15e-11	-0.32	-0.34	Longevity (90 years and older);	chr12:48308282	chr12:48054813~48055591:-
PRAD	cis	rs1799949	1	rs11652332	ENSG00000267002.1	RP11-242D8.1	7.78	4.75e-14	2.15e-11	0.32	0.34	Menopause (age at onset);	chr17:43143472	chr17:43164183~43170403:-
PRAD	cis	rs2404602	0.692	rs12437733	ENSG00000259422.1	RP11-593F23.1	7.78	4.75e-14	2.16e-11	0.43	0.34	Blood metabolite levels;	chr15:76863221	chr15:76174891~76181486:-
PRAD	cis	rs526231	0.543	rs8488	ENSG00000175749.11	EIF3KP1	7.78	4.75e-14	2.16e-11	0.48	0.34	Primary biliary cholangitis;	chr5:103203051	chr5:103032376~103033031:+
PRAD	cis	rs6142102	0.607	rs6088408	ENSG00000276073.1	RP5-1125A11.7	7.78	4.77e-14	2.16e-11	0.38	0.34	Skin pigmentation;	chr20:34146800	chr20:33985617~33988989:-
PRAD	cis	rs9532669	0.89	rs4941999	ENSG00000168852.11	TPTE2P5	7.78	4.78e-14	2.17e-11	0.34	0.34	Cervical cancer;	chr13:40859926	chr13:40822296~40921749:-
PRAD	cis	rs8062405	0.69	rs6498089	ENSG00000251417.2	RP11-1348G14.4	7.78	4.79e-14	2.17e-11	0.38	0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28617979	chr16:28802743~28817828:+
PRAD	cis	rs2739330	0.731	rs4822450	ENSG00000228039.3	KB-1125A3.10	7.78	4.8e-14	2.18e-11	0.44	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23963780~23964374:+
PRAD	cis	rs950169	0.922	rs11633534	ENSG00000259728.4	LINC00933	7.78	4.8e-14	2.18e-11	0.42	0.34	Schizophrenia;	chr15:84581411	chr15:84570649~84580175:+
PRAD	cis	rs950169	0.65	rs12902052	ENSG00000259728.4	LINC00933	7.78	4.8e-14	2.18e-11	0.42	0.34	Schizophrenia;	chr15:84582607	chr15:84570649~84580175:+
PRAD	cis	rs12612619	0.677	rs3754733	ENSG00000272148.1	RP11-195B17.1	7.78	4.81e-14	2.18e-11	0.41	0.34	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27026377	chr2:27062428~27062907:-
PRAD	cis	rs9467773	0.525	rs1535274	ENSG00000241549.7	GUSBP2	7.78	4.83e-14	2.19e-11	0.37	0.34	Intelligence (multi-trait analysis);	chr6:26520519	chr6:26871484~26956554:-
PRAD	cis	rs9467773	0.565	rs6925047	ENSG00000241549.7	GUSBP2	7.78	4.83e-14	2.19e-11	0.37	0.34	Intelligence (multi-trait analysis);	chr6:26521207	chr6:26871484~26956554:-
PRAD	cis	rs9467773	0.565	rs4343916	ENSG00000241549.7	GUSBP2	7.78	4.83e-14	2.19e-11	0.37	0.34	Intelligence (multi-trait analysis);	chr6:26522447	chr6:26871484~26956554:-
PRAD	cis	rs9362426	0.526	rs7773804	ENSG00000218793.1	RP3-382I10.3	7.78	4.83e-14	2.19e-11	0.42	0.34	Depressive episodes in bipolar disorder;	chr6:87406432	chr6:87441165~87442146:-
PRAD	cis	rs2739330	0.76	rs1007888	ENSG00000228039.3	KB-1125A3.10	7.78	4.84e-14	2.19e-11	0.44	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23963780~23964374:+
PRAD	cis	rs1552244	0.554	rs6762397	ENSG00000206567.8	AC022007.5	-7.78	4.85e-14	2.2e-11	-0.38	-0.34	Alzheimer's disease;	chr3:9966156	chr3:10006418~10011209:-
PRAD	cis	rs853679	0.546	rs13213986	ENSG00000225595.2	XXbac-BPG308K3.6	7.78	4.86e-14	2.2e-11	0.78	0.34	Depression;	chr6:28390232	chr6:28859625~28864630:-
PRAD	cis	rs853679	0.546	rs34546986	ENSG00000225595.2	XXbac-BPG308K3.6	7.78	4.86e-14	2.2e-11	0.78	0.34	Depression;	chr6:28394532	chr6:28859625~28864630:-
PRAD	cis	rs853679	0.546	rs34871267	ENSG00000225595.2	XXbac-BPG308K3.6	7.78	4.86e-14	2.2e-11	0.78	0.34	Depression;	chr6:28396455	chr6:28859625~28864630:-
PRAD	cis	rs853679	0.546	rs35883476	ENSG00000225595.2	XXbac-BPG308K3.6	7.78	4.86e-14	2.2e-11	0.78	0.34	Depression;	chr6:28400731	chr6:28859625~28864630:-
PRAD	cis	rs1979679	0.744	rs2348236	ENSG00000278733.1	RP11-425D17.1	-7.78	4.87e-14	2.2e-11	-0.45	-0.34	Ossification of the posterior longitudinal ligament of the spine;	chr12:28441640	chr12:28185625~28186190:-
PRAD	cis	rs1134634	0.52	rs4698408	ENSG00000273133.1	RP11-799M12.2	-7.78	4.87e-14	2.2e-11	-0.45	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15657425	chr4:15563698~15564253:-
PRAD	cis	rs1979679	0.918	rs2348234	ENSG00000278733.1	RP11-425D17.1	7.78	4.87e-14	2.21e-11	0.44	0.34	Ossification of the posterior longitudinal ligament of the spine;	chr12:28354126	chr12:28185625~28186190:-
PRAD	cis	rs1979679	0.918	rs78500430	ENSG00000278733.1	RP11-425D17.1	7.78	4.87e-14	2.21e-11	0.44	0.34	Ossification of the posterior longitudinal ligament of the spine;	chr12:28369828	chr12:28185625~28186190:-
PRAD	cis	rs2236295	0.597	rs7477765	ENSG00000238280.1	RP11-436D10.3	-7.78	4.88e-14	2.21e-11	-0.44	-0.34	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr10:62831984	chr10:62793562~62805887:-
PRAD	cis	rs1426063	0.614	rs78046076	ENSG00000260265.1	RP11-44F21.5	7.78	4.89e-14	2.21e-11	0.79	0.34	QT interval;	chr4:75091818	chr4:75081702~75084717:-
PRAD	cis	rs1426063	0.614	rs74670563	ENSG00000260265.1	RP11-44F21.5	7.78	4.89e-14	2.21e-11	0.79	0.34	QT interval;	chr4:75094656	chr4:75081702~75084717:-
PRAD	cis	rs1426063	0.614	rs115338890	ENSG00000260265.1	RP11-44F21.5	7.78	4.89e-14	2.21e-11	0.79	0.34	QT interval;	chr4:75094719	chr4:75081702~75084717:-
PRAD	cis	rs1426063	0.541	rs116304289	ENSG00000260265.1	RP11-44F21.5	7.78	4.89e-14	2.21e-11	0.79	0.34	QT interval;	chr4:75095072	chr4:75081702~75084717:-
PRAD	cis	rs1426063	0.614	rs76204704	ENSG00000260265.1	RP11-44F21.5	7.78	4.89e-14	2.21e-11	0.79	0.34	QT interval;	chr4:75097804	chr4:75081702~75084717:-
PRAD	cis	rs1426063	0.614	rs80030693	ENSG00000260265.1	RP11-44F21.5	7.78	4.89e-14	2.21e-11	0.79	0.34	QT interval;	chr4:75099929	chr4:75081702~75084717:-
PRAD	cis	rs964611	0.882	rs7179027	ENSG00000259488.2	RP11-154J22.1	-7.78	4.89e-14	2.22e-11	-0.32	-0.34	Metabolite levels (Pyroglutamine);	chr15:48287279	chr15:48312353~48331856:-
PRAD	cis	rs7923609	0.967	rs2393986	ENSG00000232075.1	MRPL35P2	-7.78	4.9e-14	2.22e-11	-0.36	-0.34	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63560246	chr10:63634317~63634827:-
PRAD	cis	rs1552244	0.554	rs7638846	ENSG00000206567.8	AC022007.5	-7.78	4.91e-14	2.22e-11	-0.38	-0.34	Alzheimer's disease;	chr3:10006917	chr3:10006418~10011209:-
PRAD	cis	rs12612619	0.732	rs6547401	ENSG00000229122.1	AGBL5-IT1	7.78	4.91e-14	2.22e-11	0.35	0.34	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27061977	chr2:27061038~27061815:+
PRAD	cis	rs8040855	0.965	rs6496766	ENSG00000259295.5	CSPG4P12	-7.78	4.93e-14	2.23e-11	-0.43	-0.34	Bulimia nervosa;	chr15:85159144	chr15:85191438~85213905:+
PRAD	cis	rs8040855	1	rs6496768	ENSG00000259295.5	CSPG4P12	-7.78	4.93e-14	2.23e-11	-0.43	-0.34	Bulimia nervosa;	chr15:85159701	chr15:85191438~85213905:+
PRAD	cis	rs4845570	1	rs6683364	ENSG00000268288.1	RP11-98D18.16	7.78	4.93e-14	2.23e-11	0.52	0.34	Coronary artery disease;	chr1:151773726	chr1:151766486~151767000:-
PRAD	cis	rs1150668	0.796	rs213236	ENSG00000280107.1	AL022393.9	-7.78	4.93e-14	2.23e-11	-0.4	-0.34	Pubertal anthropometrics;	chr6:28356620	chr6:28170845~28172521:+
PRAD	cis	rs12612619	0.677	rs2053386	ENSG00000272148.1	RP11-195B17.1	7.78	4.94e-14	2.23e-11	0.41	0.34	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27021844	chr2:27062428~27062907:-
PRAD	cis	rs8062405	0.755	rs62031607	ENSG00000251417.2	RP11-1348G14.4	-7.78	4.95e-14	2.24e-11	-0.39	-0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620209	chr16:28802743~28817828:+
PRAD	cis	rs9467773	0.62	rs2451737	ENSG00000241549.7	GUSBP2	7.78	4.96e-14	2.25e-11	0.36	0.34	Intelligence (multi-trait analysis);	chr6:26618813	chr6:26871484~26956554:-
PRAD	cis	rs9467773	0.596	rs2494693	ENSG00000241549.7	GUSBP2	7.78	4.96e-14	2.25e-11	0.36	0.34	Intelligence (multi-trait analysis);	chr6:26618998	chr6:26871484~26956554:-
PRAD	cis	rs9467773	0.62	rs2494694	ENSG00000241549.7	GUSBP2	7.78	4.96e-14	2.25e-11	0.36	0.34	Intelligence (multi-trait analysis);	chr6:26619100	chr6:26871484~26956554:-
PRAD	cis	rs9467773	0.595	rs2451736	ENSG00000241549.7	GUSBP2	7.78	4.96e-14	2.25e-11	0.36	0.34	Intelligence (multi-trait analysis);	chr6:26620316	chr6:26871484~26956554:-
PRAD	cis	rs9467773	0.62	rs2494696	ENSG00000241549.7	GUSBP2	7.78	4.96e-14	2.25e-11	0.36	0.34	Intelligence (multi-trait analysis);	chr6:26620666	chr6:26871484~26956554:-
PRAD	cis	rs9467773	0.62	rs2101581	ENSG00000241549.7	GUSBP2	7.78	4.96e-14	2.25e-11	0.36	0.34	Intelligence (multi-trait analysis);	chr6:26622541	chr6:26871484~26956554:-
PRAD	cis	rs9467773	0.62	rs2451732	ENSG00000241549.7	GUSBP2	-7.78	4.96e-14	2.25e-11	-0.36	-0.34	Intelligence (multi-trait analysis);	chr6:26622676	chr6:26871484~26956554:-
PRAD	cis	rs9467773	0.62	rs2451731	ENSG00000241549.7	GUSBP2	7.78	4.96e-14	2.25e-11	0.36	0.34	Intelligence (multi-trait analysis);	chr6:26624594	chr6:26871484~26956554:-
PRAD	cis	rs9467773	0.62	rs9295701	ENSG00000241549.7	GUSBP2	7.78	4.96e-14	2.25e-11	0.36	0.34	Intelligence (multi-trait analysis);	chr6:26627280	chr6:26871484~26956554:-
PRAD	cis	rs9467773	0.62	rs2494700	ENSG00000241549.7	GUSBP2	7.78	4.96e-14	2.25e-11	0.36	0.34	Intelligence (multi-trait analysis);	chr6:26631078	chr6:26871484~26956554:-
PRAD	cis	rs9467773	0.584	rs1021372	ENSG00000241549.7	GUSBP2	7.78	4.96e-14	2.25e-11	0.36	0.34	Intelligence (multi-trait analysis);	chr6:26632216	chr6:26871484~26956554:-
PRAD	cis	rs9467773	0.583	rs1021373	ENSG00000241549.7	GUSBP2	7.78	4.96e-14	2.25e-11	0.36	0.34	Intelligence (multi-trait analysis);	chr6:26632229	chr6:26871484~26956554:-
PRAD	cis	rs9467773	0.62	rs2451744	ENSG00000241549.7	GUSBP2	7.78	4.96e-14	2.25e-11	0.36	0.34	Intelligence (multi-trait analysis);	chr6:26633235	chr6:26871484~26956554:-
PRAD	cis	rs9467773	0.62	rs2494701	ENSG00000241549.7	GUSBP2	7.78	4.96e-14	2.25e-11	0.36	0.34	Intelligence (multi-trait analysis);	chr6:26634204	chr6:26871484~26956554:-
PRAD	cis	rs9467773	0.62	rs1027204	ENSG00000241549.7	GUSBP2	7.78	4.96e-14	2.25e-11	0.36	0.34	Intelligence (multi-trait analysis);	chr6:26639385	chr6:26871484~26956554:-
PRAD	cis	rs9467773	0.62	rs2504592	ENSG00000241549.7	GUSBP2	7.78	4.96e-14	2.25e-11	0.36	0.34	Intelligence (multi-trait analysis);	chr6:26640723	chr6:26871484~26956554:-
PRAD	cis	rs9467773	0.62	rs2504599	ENSG00000241549.7	GUSBP2	7.78	4.96e-14	2.25e-11	0.36	0.34	Intelligence (multi-trait analysis);	chr6:26640832	chr6:26871484~26956554:-
PRAD	cis	rs9467773	0.62	rs2504540	ENSG00000241549.7	GUSBP2	7.78	4.96e-14	2.25e-11	0.36	0.34	Intelligence (multi-trait analysis);	chr6:26641398	chr6:26871484~26956554:-
PRAD	cis	rs150992	0.53	rs2927646	ENSG00000248489.1	CTD-2007H13.3	7.78	4.97e-14	2.25e-11	0.36	0.34	Body mass index;	chr5:98989462	chr5:98929171~98995013:+
PRAD	cis	rs42648	0.869	rs1134956	ENSG00000227646.6	STEAP2-AS1	-7.78	4.98e-14	2.26e-11	-0.31	-0.34	Homocysteine levels;	chr7:90309366	chr7:89882353~90211635:-
PRAD	cis	rs57481061	1	rs57481061	ENSG00000258302.2	RP11-981P6.1	7.78	4.99e-14	2.26e-11	0.42	0.34	Coronary artery disease;	chr12:89625401	chr12:89561129~89594878:+
PRAD	cis	rs4631830	0.896	rs7088225	ENSG00000230869.1	CTGLF10P	7.78	4.99e-14	2.26e-11	0.42	0.34	Prostate-specific antigen levels;	chr10:46073702	chr10:45678692~45700532:+
PRAD	cis	rs11976180	1	rs7777389	ENSG00000170356.8	OR2A20P	-7.78	4.99e-14	2.26e-11	-0.46	-0.34	Obesity-related traits;	chr7:144047709	chr7:144250045~144252957:-
PRAD	cis	rs11976180	1	rs67239267	ENSG00000170356.8	OR2A20P	-7.78	4.99e-14	2.26e-11	-0.46	-0.34	Obesity-related traits;	chr7:144048023	chr7:144250045~144252957:-
PRAD	cis	rs494459	0.838	rs2510897	ENSG00000278376.1	RP11-158I9.8	-7.78	5e-14	2.26e-11	-0.29	-0.34	Height;	chr11:118773873	chr11:118791254~118793137:+
PRAD	cis	rs9549328	0.731	rs7983602	ENSG00000267868.1	RP11-120K24.3	7.78	5e-14	2.26e-11	0.41	0.34	Systolic blood pressure;	chr13:112966168	chr13:112964835~112966131:-
PRAD	cis	rs9309473	0.528	rs2091022	ENSG00000163016.8	ALMS1P	7.78	5.01e-14	2.27e-11	0.42	0.34	Metabolite levels;	chr2:73337442	chr2:73644919~73685576:+
PRAD	cis	rs42648	0.596	rs194507	ENSG00000227646.6	STEAP2-AS1	7.78	5.01e-14	2.27e-11	0.31	0.34	Homocysteine levels;	chr7:90214246	chr7:89882353~90211635:-
PRAD	cis	rs17361889	0.778	rs1527219	ENSG00000224683.1	RPL36AP29	7.78	5.03e-14	2.28e-11	0.4	0.34	Pediatric bone mineral content (hip);	chr7:16206127	chr7:16208945~16209265:+
PRAD	cis	rs494459	0.838	rs1784543	ENSG00000278376.1	RP11-158I9.8	-7.78	5.05e-14	2.28e-11	-0.29	-0.34	Height;	chr11:118760944	chr11:118791254~118793137:+
PRAD	cis	rs75422866	0.867	rs73113117	ENSG00000274902.1	RP1-197B17.4	7.78	5.06e-14	2.29e-11	0.88	0.34	Pneumonia;	chr12:47617299	chr12:47731908~47732351:+
PRAD	cis	rs75422866	0.867	rs73113143	ENSG00000274902.1	RP1-197B17.4	7.78	5.06e-14	2.29e-11	0.88	0.34	Pneumonia;	chr12:47623060	chr12:47731908~47732351:+
PRAD	cis	rs964611	0.882	rs7179535	ENSG00000259488.2	RP11-154J22.1	-7.78	5.06e-14	2.29e-11	-0.32	-0.34	Metabolite levels (Pyroglutamine);	chr15:48287507	chr15:48312353~48331856:-
PRAD	cis	rs995000	0.868	rs9787151	ENSG00000235545.1	RP11-230B22.1	-7.78	5.08e-14	2.3e-11	-0.46	-0.34	Triglyceride levels;	chr1:62713467	chr1:62688482~62710694:+
PRAD	cis	rs995000	0.868	rs9787156	ENSG00000235545.1	RP11-230B22.1	-7.78	5.08e-14	2.3e-11	-0.46	-0.34	Triglyceride levels;	chr1:62713541	chr1:62688482~62710694:+
PRAD	cis	rs240993	0.812	rs6568677	ENSG00000230177.1	RP5-1112D6.4	-7.77	5.09e-14	2.3e-11	-0.43	-0.34	Inflammatory skin disease;Psoriasis;	chr6:111392099	chr6:111277932~111278742:+
PRAD	cis	rs6847067	0.929	rs12511112	ENSG00000180769.7	WDFY3-AS2	-7.77	5.11e-14	2.31e-11	-0.36	-0.34	Oropharynx cancer;	chr4:84754946	chr4:84965682~85011277:+
PRAD	cis	rs7238033	0.609	rs28898869	ENSG00000267193.4	RP11-116O18.3	7.77	5.12e-14	2.31e-11	0.37	0.34	Bladder cancer;	chr18:45735626	chr18:45669367~45747215:-
PRAD	cis	rs1426063	0.614	rs78681370	ENSG00000260265.1	RP11-44F21.5	7.77	5.13e-14	2.32e-11	0.79	0.34	QT interval;	chr4:75081556	chr4:75081702~75084717:-
PRAD	cis	rs1426063	0.614	rs17000212	ENSG00000260265.1	RP11-44F21.5	7.77	5.13e-14	2.32e-11	0.79	0.34	QT interval;	chr4:75081611	chr4:75081702~75084717:-
PRAD	cis	rs1426063	0.614	rs77018380	ENSG00000260265.1	RP11-44F21.5	7.77	5.13e-14	2.32e-11	0.79	0.34	QT interval;	chr4:75081621	chr4:75081702~75084717:-
PRAD	cis	rs1426063	0.614	rs75846524	ENSG00000260265.1	RP11-44F21.5	7.77	5.13e-14	2.32e-11	0.79	0.34	QT interval;	chr4:75083172	chr4:75081702~75084717:-
PRAD	cis	rs1426063	0.614	rs76325897	ENSG00000260265.1	RP11-44F21.5	7.77	5.13e-14	2.32e-11	0.79	0.34	QT interval;	chr4:75084747	chr4:75081702~75084717:-
PRAD	cis	rs1426063	0.614	rs76093954	ENSG00000260265.1	RP11-44F21.5	7.77	5.13e-14	2.32e-11	0.79	0.34	QT interval;	chr4:75087994	chr4:75081702~75084717:-
PRAD	cis	rs1426063	0.614	rs114977200	ENSG00000260265.1	RP11-44F21.5	7.77	5.13e-14	2.32e-11	0.79	0.34	QT interval;	chr4:75088736	chr4:75081702~75084717:-
PRAD	cis	rs1426063	0.614	rs77625282	ENSG00000260265.1	RP11-44F21.5	7.77	5.13e-14	2.32e-11	0.79	0.34	QT interval;	chr4:75089646	chr4:75081702~75084717:-
PRAD	cis	rs1426063	0.614	rs75112697	ENSG00000260265.1	RP11-44F21.5	7.77	5.13e-14	2.32e-11	0.79	0.34	QT interval;	chr4:75089725	chr4:75081702~75084717:-
PRAD	cis	rs1426063	0.614	rs7684790	ENSG00000260265.1	RP11-44F21.5	7.77	5.13e-14	2.32e-11	0.79	0.34	QT interval;	chr4:75090873	chr4:75081702~75084717:-
PRAD	cis	rs1426063	0.614	rs7671634	ENSG00000260265.1	RP11-44F21.5	7.77	5.13e-14	2.32e-11	0.79	0.34	QT interval;	chr4:75090883	chr4:75081702~75084717:-
PRAD	cis	rs1426063	0.614	rs6534447	ENSG00000260265.1	RP11-44F21.5	-7.77	5.13e-14	2.32e-11	-0.79	-0.34	QT interval;	chr4:75080682	chr4:75081702~75084717:-
PRAD	cis	rs17711722	0.523	rs365896	ENSG00000237310.1	GS1-124K5.4	-7.77	5.15e-14	2.33e-11	-0.29	-0.34	Calcium levels;	chr7:66045710	chr7:66493706~66495474:+
PRAD	cis	rs673078	0.571	rs17440823	ENSG00000275409.1	RP11-131L12.4	-7.77	5.16e-14	2.33e-11	-0.49	-0.34	Glucose homeostasis traits;	chr12:118353023	chr12:118430147~118430699:+
PRAD	cis	rs1043099	0.871	rs2108093	ENSG00000279699.1	RP1-102K2.9	-7.77	5.17e-14	2.33e-11	-0.53	-0.34	Rheumatoid arthritis;	chr22:30283398	chr22:30275215~30276951:-
PRAD	cis	rs1185460	0.565	rs584115	ENSG00000271751.1	RP11-110I1.14	7.77	5.17e-14	2.33e-11	0.47	0.34	Coronary artery disease;	chr11:119068169	chr11:119065263~119065677:-
PRAD	cis	rs12817211	0.549	rs7138945	ENSG00000272368.2	RP4-605O3.4	-7.77	5.18e-14	2.34e-11	-0.35	-0.34	Colorectal or endometrial cancer;	chr12:50145636	chr12:50112197~50165618:+
PRAD	cis	rs10875746	0.551	rs3185921	ENSG00000240399.1	RP1-228P16.1	-7.77	5.2e-14	2.35e-11	-0.34	-0.34	Longevity (90 years and older);	chr12:48340948	chr12:48054813~48055591:-
PRAD	cis	rs6847067	0.759	rs4533765	ENSG00000180769.7	WDFY3-AS2	7.77	5.22e-14	2.36e-11	0.35	0.34	Oropharynx cancer;	chr4:84994417	chr4:84965682~85011277:+
PRAD	cis	rs526231	0.543	rs34783	ENSG00000175749.11	EIF3KP1	7.77	5.22e-14	2.36e-11	0.48	0.34	Primary biliary cholangitis;	chr5:103121337	chr5:103032376~103033031:+
PRAD	cis	rs526231	0.512	rs28022	ENSG00000175749.11	EIF3KP1	7.77	5.22e-14	2.36e-11	0.48	0.34	Primary biliary cholangitis;	chr5:103128663	chr5:103032376~103033031:+
PRAD	cis	rs6847067	0.794	rs12640378	ENSG00000180769.7	WDFY3-AS2	-7.77	5.23e-14	2.36e-11	-0.36	-0.34	Oropharynx cancer;	chr4:85028969	chr4:84965682~85011277:+
PRAD	cis	rs2617170	0.922	rs1600128	ENSG00000245648.1	RP11-277P12.20	7.77	5.24e-14	2.37e-11	0.41	0.34	Behcet's disease;	chr12:10383559	chr12:10363769~10398506:+
PRAD	cis	rs2617170	0.922	rs1904123	ENSG00000245648.1	RP11-277P12.20	7.77	5.24e-14	2.37e-11	0.41	0.34	Behcet's disease;	chr12:10385181	chr12:10363769~10398506:+
PRAD	cis	rs4713118	0.869	rs10214440	ENSG00000226314.6	ZNF192P1	-7.77	5.24e-14	2.37e-11	-0.45	-0.34	Parkinson's disease;	chr6:27734661	chr6:28161781~28169594:+
PRAD	cis	rs4713118	0.869	rs6902689	ENSG00000226314.6	ZNF192P1	-7.77	5.24e-14	2.37e-11	-0.45	-0.34	Parkinson's disease;	chr6:27741662	chr6:28161781~28169594:+
PRAD	cis	rs4713118	0.869	rs9468214	ENSG00000226314.6	ZNF192P1	-7.77	5.24e-14	2.37e-11	-0.45	-0.34	Parkinson's disease;	chr6:27745520	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.599	rs149949	ENSG00000280107.1	AL022393.9	-7.77	5.27e-14	2.38e-11	-0.62	-0.34	Depression;	chr6:28043738	chr6:28170845~28172521:+
PRAD	cis	rs4664293	0.528	rs12466650	ENSG00000226266.5	AC009961.3	7.77	5.29e-14	2.38e-11	0.46	0.34	Monocyte percentage of white cells;	chr2:159552252	chr2:159670708~159712435:-
PRAD	cis	rs950169	0.922	rs11638445	ENSG00000259728.4	LINC00933	7.77	5.29e-14	2.39e-11	0.42	0.34	Schizophrenia;	chr15:84594463	chr15:84570649~84580175:+
PRAD	cis	rs10050311	0.858	rs1010902	ENSG00000251411.1	RP11-397E7.4	-7.77	5.29e-14	2.39e-11	-0.44	-0.34	Insulin-related traits;	chr4:86898002	chr4:86913266~86914817:-
PRAD	cis	rs950169	0.614	rs765524	ENSG00000225151.9	GOLGA2P7	-7.77	5.3e-14	2.39e-11	-0.5	-0.34	Schizophrenia;	chr15:84013030	chr15:84199311~84230136:-
PRAD	cis	rs75422866	0.867	rs75568526	ENSG00000274902.1	RP1-197B17.4	7.77	5.3e-14	2.39e-11	0.88	0.34	Pneumonia;	chr12:47649718	chr12:47731908~47732351:+
PRAD	cis	rs75422866	0.867	rs116302411	ENSG00000274902.1	RP1-197B17.4	7.77	5.3e-14	2.39e-11	0.88	0.34	Pneumonia;	chr12:47649788	chr12:47731908~47732351:+
PRAD	cis	rs2243480	1	rs313831	ENSG00000226824.5	RP4-756H11.3	-7.77	5.32e-14	2.4e-11	-0.68	-0.34	Diabetic kidney disease;	chr7:66086239	chr7:66654538~66669855:+
PRAD	cis	rs2255336	0.938	rs12298043	ENSG00000245648.1	RP11-277P12.20	-7.77	5.33e-14	2.4e-11	-0.52	-0.34	Blood protein levels;	chr12:10456883	chr12:10363769~10398506:+
PRAD	cis	rs6547741	0.904	rs2384659	ENSG00000234072.1	AC074117.10	7.77	5.34e-14	2.41e-11	0.25	0.34	Oral cavity cancer;	chr2:27633926	chr2:27356246~27367622:+
PRAD	cis	rs7829975	0.509	rs7838674	ENSG00000253893.2	FAM85B	7.77	5.34e-14	2.41e-11	0.43	0.34	Mood instability;	chr8:8939563	chr8:8167819~8226614:-
PRAD	cis	rs7211079	0.879	rs61357240	ENSG00000279259.1	RP11-334C17.3	7.77	5.37e-14	2.42e-11	0.38	0.34	Myocardial infarction;	chr17:80157976	chr17:80147250~80148596:+
PRAD	cis	rs2404602	0.655	rs4886507	ENSG00000259422.1	RP11-593F23.1	7.77	5.38e-14	2.43e-11	0.43	0.34	Blood metabolite levels;	chr15:76917353	chr15:76174891~76181486:-
PRAD	cis	rs526231	0.543	rs3776863	ENSG00000175749.11	EIF3KP1	7.77	5.38e-14	2.43e-11	0.46	0.34	Primary biliary cholangitis;	chr5:102992165	chr5:103032376~103033031:+
PRAD	cis	rs526231	0.543	rs17154913	ENSG00000175749.11	EIF3KP1	7.77	5.38e-14	2.43e-11	0.46	0.34	Primary biliary cholangitis;	chr5:102992786	chr5:103032376~103033031:+
PRAD	cis	rs10463554	0.727	rs34768	ENSG00000175749.11	EIF3KP1	7.77	5.41e-14	2.44e-11	0.48	0.34	Parkinson's disease;	chr5:103155798	chr5:103032376~103033031:+
PRAD	cis	rs9287719	0.781	rs6714413	ENSG00000234818.1	AC092687.5	7.77	5.41e-14	2.44e-11	0.41	0.34	Prostate cancer;	chr2:10618733	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.753	rs2018512	ENSG00000234818.1	AC092687.5	7.77	5.41e-14	2.44e-11	0.41	0.34	Prostate cancer;	chr2:10619153	chr2:10589166~10604830:+
PRAD	cis	rs2404602	0.692	rs3110382	ENSG00000259422.1	RP11-593F23.1	-7.77	5.42e-14	2.44e-11	-0.42	-0.34	Blood metabolite levels;	chr15:76856347	chr15:76174891~76181486:-
PRAD	cis	rs12908161	0.96	rs62019463	ENSG00000275120.1	RP11-182J1.17	7.77	5.42e-14	2.44e-11	0.45	0.34	Schizophrenia;	chr15:84744856	chr15:84599434~84606463:-
PRAD	cis	rs12908161	1	rs62019464	ENSG00000275120.1	RP11-182J1.17	7.77	5.42e-14	2.44e-11	0.45	0.34	Schizophrenia;	chr15:84751238	chr15:84599434~84606463:-
PRAD	cis	rs2933343	0.729	rs813732	ENSG00000231305.3	RP11-723O4.2	7.77	5.42e-14	2.44e-11	0.32	0.34	IgG glycosylation;	chr3:128900514	chr3:128861313~128871540:-
PRAD	cis	rs6452524	0.78	rs2386237	ENSG00000249664.1	CTD-2227C6.2	7.77	5.44e-14	2.45e-11	0.41	0.34	Hypertension (SNP x SNP interaction);	chr5:83101852	chr5:83012285~83013109:-
PRAD	cis	rs2522056	0.932	rs1012793	ENSG00000233006.5	AC034220.3	-7.77	5.45e-14	2.46e-11	-0.33	-0.34	Fibrinogen;Lymphocyte counts;	chr5:132445653	chr5:132311285~132369916:-
PRAD	cis	rs1043099	0.912	rs4823085	ENSG00000279699.1	RP1-102K2.9	-7.76	5.46e-14	2.46e-11	-0.53	-0.34	Rheumatoid arthritis;	chr22:30290237	chr22:30275215~30276951:-
PRAD	cis	rs2522056	1	rs2057655	ENSG00000233006.5	AC034220.3	7.76	5.46e-14	2.46e-11	0.34	0.34	Fibrinogen;Lymphocyte counts;	chr5:132471932	chr5:132311285~132369916:-
PRAD	cis	rs9309473	0.632	rs11885217	ENSG00000163016.8	ALMS1P	7.76	5.46e-14	2.46e-11	0.42	0.34	Metabolite levels;	chr2:73326080	chr2:73644919~73685576:+
PRAD	cis	rs1150668	0.799	rs1150705	ENSG00000280107.1	AL022393.9	-7.76	5.47e-14	2.47e-11	-0.41	-0.34	Pubertal anthropometrics;	chr6:28226008	chr6:28170845~28172521:+
PRAD	cis	rs17711722	0.522	rs62469933	ENSG00000275400.1	RP4-756H11.5	-7.76	5.47e-14	2.47e-11	-0.31	-0.34	Calcium levels;	chr7:65800652	chr7:66553805~66554199:-
PRAD	cis	rs17012589	0.503	rs6539886	ENSG00000258815.1	RP11-408B11.2	7.76	5.47e-14	2.47e-11	0.47	0.34	Bone mineral density (Ward's triangle area);	chr12:85248096	chr12:85318060~85342912:+
PRAD	cis	rs17012589	0.531	rs11116753	ENSG00000258815.1	RP11-408B11.2	7.76	5.47e-14	2.47e-11	0.47	0.34	Bone mineral density (Ward's triangle area);	chr12:85249731	chr12:85318060~85342912:+
PRAD	cis	rs17012589	0.667	rs7488598	ENSG00000258815.1	RP11-408B11.2	7.76	5.47e-14	2.47e-11	0.47	0.34	Bone mineral density (Ward's triangle area);	chr12:85254032	chr12:85318060~85342912:+
PRAD	cis	rs673078	0.607	rs7967900	ENSG00000275409.1	RP11-131L12.4	7.76	5.49e-14	2.47e-11	0.49	0.34	Glucose homeostasis traits;	chr12:118381902	chr12:118430147~118430699:+
PRAD	cis	rs7238033	0.602	rs3819178	ENSG00000267193.4	RP11-116O18.3	7.76	5.5e-14	2.48e-11	0.37	0.34	Bladder cancer;	chr18:45730880	chr18:45669367~45747215:-
PRAD	cis	rs8091660	0.893	rs1567656	ENSG00000278983.1	RP11-426J5.3	-7.76	5.52e-14	2.48e-11	-0.42	-0.34	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48568420	chr18:48564795~48568342:+
PRAD	cis	rs12612619	0.732	rs11679681	ENSG00000229122.1	AGBL5-IT1	7.76	5.53e-14	2.49e-11	0.35	0.34	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27075611	chr2:27061038~27061815:+
PRAD	cis	rs2638953	0.924	rs11049478	ENSG00000278733.1	RP11-425D17.1	-7.76	5.54e-14	2.49e-11	-0.44	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28244827	chr12:28185625~28186190:-
PRAD	cis	rs11976180	1	rs1919949	ENSG00000273234.1	OR2A13P	-7.76	5.54e-14	2.49e-11	-0.41	-0.34	Obesity-related traits;	chr7:144070630	chr7:144142009~144142938:+
PRAD	cis	rs2337406	1	rs75651733	ENSG00000274576.2	IGHV2-70	-7.76	5.55e-14	2.5e-11	-0.38	-0.34	Alzheimer's disease (late onset);	chr14:106701309	chr14:106770577~106771020:-
PRAD	cis	rs11098499	0.532	rs4504231	ENSG00000245958.5	RP11-33B1.1	-7.76	5.55e-14	2.5e-11	-0.34	-0.34	Corneal astigmatism;	chr4:119665736	chr4:119454791~119552025:+
PRAD	cis	rs6479891	0.908	rs61853655	ENSG00000232075.1	MRPL35P2	7.76	5.57e-14	2.51e-11	0.57	0.34	Arthritis (juvenile idiopathic);	chr10:63570645	chr10:63634317~63634827:-
PRAD	cis	rs2617170	0.922	rs2086098	ENSG00000245648.1	RP11-277P12.20	7.76	5.59e-14	2.51e-11	0.42	0.34	Behcet's disease;	chr12:10373949	chr12:10363769~10398506:+
PRAD	cis	rs62355901	0.653	rs62355882	ENSG00000271828.1	CTD-2310F14.1	7.76	5.59e-14	2.51e-11	0.74	0.34	Breast cancer;	chr5:56749283	chr5:56927874~56929573:+
PRAD	cis	rs10463554	0.963	rs26816	ENSG00000175749.11	EIF3KP1	7.76	5.59e-14	2.52e-11	0.45	0.34	Parkinson's disease;	chr5:103204821	chr5:103032376~103033031:+
PRAD	cis	rs1979679	0.918	rs2169755	ENSG00000278733.1	RP11-425D17.1	7.76	5.6e-14	2.52e-11	0.44	0.34	Ossification of the posterior longitudinal ligament of the spine;	chr12:28338224	chr12:28185625~28186190:-
PRAD	cis	rs4713118	0.662	rs149901	ENSG00000272009.1	RP1-313I6.12	-7.76	5.61e-14	2.52e-11	-0.34	-0.34	Parkinson's disease;	chr6:27997725	chr6:28078792~28081130:-
PRAD	cis	rs1426063	0.614	rs115690958	ENSG00000260265.1	RP11-44F21.5	7.76	5.61e-14	2.52e-11	0.8	0.34	QT interval;	chr4:75078364	chr4:75081702~75084717:-
PRAD	cis	rs9467773	0.511	rs11755443	ENSG00000241549.7	GUSBP2	7.76	5.64e-14	2.54e-11	0.38	0.34	Intelligence (multi-trait analysis);	chr6:26923824	chr6:26871484~26956554:-
PRAD	cis	rs1043099	0.912	rs929454	ENSG00000279699.1	RP1-102K2.9	7.76	5.65e-14	2.54e-11	0.53	0.34	Rheumatoid arthritis;	chr22:30296364	chr22:30275215~30276951:-
PRAD	cis	rs12468226	1	rs16839077	ENSG00000273456.1	RP11-686O6.2	7.76	5.66e-14	2.55e-11	0.47	0.34	Urate levels;	chr2:202343970	chr2:202374932~202375604:-
PRAD	cis	rs10463554	0.963	rs26261	ENSG00000175749.11	EIF3KP1	7.76	5.66e-14	2.55e-11	0.45	0.34	Parkinson's disease;	chr5:103209992	chr5:103032376~103033031:+
PRAD	cis	rs9467773	0.62	rs2504571	ENSG00000241549.7	GUSBP2	7.76	5.67e-14	2.55e-11	0.36	0.34	Intelligence (multi-trait analysis);	chr6:26643207	chr6:26871484~26956554:-
PRAD	cis	rs526231	0.575	rs55652053	ENSG00000175749.11	EIF3KP1	7.76	5.68e-14	2.55e-11	0.47	0.34	Primary biliary cholangitis;	chr5:103001466	chr5:103032376~103033031:+
PRAD	cis	rs2439831	0.867	rs2447211	ENSG00000249839.1	AC011330.5	-7.76	5.69e-14	2.56e-11	-0.6	-0.34	Lung cancer in ever smokers;	chr15:43644153	chr15:43663654~43684339:-
PRAD	cis	rs6847067	0.683	rs12640811	ENSG00000180769.7	WDFY3-AS2	7.76	5.69e-14	2.56e-11	0.36	0.34	Oropharynx cancer;	chr4:85011514	chr4:84965682~85011277:+
PRAD	cis	rs2439831	0.85	rs8032649	ENSG00000249839.1	AC011330.5	7.76	5.71e-14	2.57e-11	0.59	0.34	Lung cancer in ever smokers;	chr15:43842724	chr15:43663654~43684339:-
PRAD	cis	rs8042680	1	rs12593261	ENSG00000214432.8	AC068831.10	-7.76	5.72e-14	2.57e-11	-0.41	-0.34	Type 2 diabetes;	chr15:90977089	chr15:91022619~91036611:+
PRAD	cis	rs12908161	1	rs11637142	ENSG00000275120.1	RP11-182J1.17	7.76	5.72e-14	2.57e-11	0.44	0.34	Schizophrenia;	chr15:84752696	chr15:84599434~84606463:-
PRAD	cis	rs2337406	1	rs17113331	ENSG00000274576.2	IGHV2-70	-7.76	5.72e-14	2.57e-11	-0.37	-0.34	Alzheimer's disease (late onset);	chr14:106703843	chr14:106770577~106771020:-
PRAD	cis	rs6539288	0.739	rs4964511	ENSG00000260329.1	RP11-412D9.4	-7.76	5.73e-14	2.58e-11	-0.3	-0.34	Total body bone mineral density;	chr12:106966468	chr12:106954029~106955497:-
PRAD	cis	rs2412819	0.559	rs8040336	ENSG00000205771.5	CATSPER2P1	-7.76	5.74e-14	2.58e-11	-0.37	-0.34	Lung cancer;	chr15:43761419	chr15:43726918~43747094:-
PRAD	cis	rs1979679	0.918	rs10771430	ENSG00000278733.1	RP11-425D17.1	-7.76	5.75e-14	2.59e-11	-0.45	-0.34	Ossification of the posterior longitudinal ligament of the spine;	chr12:28470505	chr12:28185625~28186190:-
PRAD	cis	rs55665837	1	rs4412729	ENSG00000251991.1	RNU7-49P	7.76	5.76e-14	2.59e-11	0.38	0.34	Vitamin D levels;	chr11:14417454	chr11:14478892~14478953:+
PRAD	cis	rs12928939	0.727	rs8053623	ENSG00000260886.1	TAT-AS1	7.76	5.76e-14	2.59e-11	0.45	0.34	Post bronchodilator FEV1;	chr16:71613626	chr16:71565789~71578187:+
PRAD	cis	rs2638953	0.962	rs10506029	ENSG00000278733.1	RP11-425D17.1	-7.76	5.76e-14	2.59e-11	-0.44	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28320302	chr12:28185625~28186190:-
PRAD	cis	rs9326248	0.581	rs11216267	ENSG00000280143.1	AP000892.6	7.76	5.77e-14	2.59e-11	0.26	0.34	Blood protein levels;	chr11:117081676	chr11:117204967~117210292:+
PRAD	cis	rs172166	0.561	rs149973	ENSG00000280107.1	AL022393.9	-7.76	5.79e-14	2.6e-11	-0.4	-0.34	Cardiac Troponin-T levels;	chr6:28015835	chr6:28170845~28172521:+
PRAD	cis	rs172166	0.561	rs149974	ENSG00000280107.1	AL022393.9	-7.76	5.79e-14	2.6e-11	-0.4	-0.34	Cardiac Troponin-T levels;	chr6:28017318	chr6:28170845~28172521:+
PRAD	cis	rs62355901	0.545	rs2113084	ENSG00000271828.1	CTD-2310F14.1	7.76	5.79e-14	2.6e-11	0.74	0.34	Breast cancer;	chr5:56737844	chr5:56927874~56929573:+
PRAD	cis	rs494459	0.688	rs1048040	ENSG00000278376.1	RP11-158I9.8	-7.76	5.81e-14	2.61e-11	-0.29	-0.34	Height;	chr11:118747911	chr11:118791254~118793137:+
PRAD	cis	rs2117029	0.767	rs11614738	ENSG00000258017.1	RP11-386G11.10	-7.76	5.84e-14	2.62e-11	-0.49	-0.34	Intelligence (multi-trait analysis);	chr12:49030833	chr12:49127782~49147869:+
PRAD	cis	rs4266144	0.558	rs34696078	ENSG00000244515.1	KRT18P34	-7.76	5.84e-14	2.62e-11	-0.4	-0.34	Coronary artery disease;	chr3:157114875	chr3:157162663~157163932:-
PRAD	cis	rs2255336	0.938	rs61917750	ENSG00000245648.1	RP11-277P12.20	-7.75	5.86e-14	2.63e-11	-0.51	-0.34	Blood protein levels;	chr12:10480824	chr12:10363769~10398506:+
PRAD	cis	rs2255336	0.938	rs7953692	ENSG00000245648.1	RP11-277P12.20	-7.75	5.86e-14	2.63e-11	-0.51	-0.34	Blood protein levels;	chr12:10482432	chr12:10363769~10398506:+
PRAD	cis	rs10463554	1	rs12656131	ENSG00000175749.11	EIF3KP1	-7.75	5.86e-14	2.63e-11	-0.44	-0.34	Parkinson's disease;	chr5:102990174	chr5:103032376~103033031:+
PRAD	cis	rs6479901	0.895	rs907	ENSG00000232075.1	MRPL35P2	-7.75	5.86e-14	2.63e-11	-0.41	-0.34	Intelligence (multi-trait analysis);	chr10:63176919	chr10:63634317~63634827:-
PRAD	cis	rs2439831	0.85	rs2228368	ENSG00000249839.1	AC011330.5	-7.75	5.89e-14	2.65e-11	-0.59	-0.34	Lung cancer in ever smokers;	chr15:43809812	chr15:43663654~43684339:-
PRAD	cis	rs881375	0.967	rs876445	ENSG00000226752.6	PSMD5-AS1	-7.75	5.91e-14	2.65e-11	-0.41	-0.34	Rheumatoid arthritis;	chr9:120914824	chr9:120824828~120854385:+
PRAD	cis	rs881375	0.967	rs2109895	ENSG00000226752.6	PSMD5-AS1	-7.75	5.91e-14	2.65e-11	-0.41	-0.34	Rheumatoid arthritis;	chr9:120915549	chr9:120824828~120854385:+
PRAD	cis	rs526231	0.543	rs246915	ENSG00000175749.11	EIF3KP1	7.75	5.91e-14	2.65e-11	0.48	0.34	Primary biliary cholangitis;	chr5:103222343	chr5:103032376~103033031:+
PRAD	cis	rs2676071	0.862	rs12148576	ENSG00000259446.4	RP11-489D6.2	7.75	5.93e-14	2.66e-11	0.47	0.34	Periodontitis (Mean PAL);	chr15:33309108	chr15:33303657~33310659:-
PRAD	cis	rs12468226	0.938	rs3731700	ENSG00000273456.1	RP11-686O6.2	7.75	5.95e-14	2.67e-11	0.47	0.34	Urate levels;	chr2:202291213	chr2:202374932~202375604:-
PRAD	cis	rs12468226	0.938	rs12464254	ENSG00000273456.1	RP11-686O6.2	7.75	5.95e-14	2.67e-11	0.47	0.34	Urate levels;	chr2:202301641	chr2:202374932~202375604:-
PRAD	cis	rs12468226	0.938	rs12471060	ENSG00000273456.1	RP11-686O6.2	7.75	5.95e-14	2.67e-11	0.47	0.34	Urate levels;	chr2:202309597	chr2:202374932~202375604:-
PRAD	cis	rs12468226	0.938	rs80315897	ENSG00000273456.1	RP11-686O6.2	7.75	5.95e-14	2.67e-11	0.47	0.34	Urate levels;	chr2:202318044	chr2:202374932~202375604:-
PRAD	cis	rs10129255	0.518	rs8009612	ENSG00000211972.2	IGHV3-66	7.75	5.95e-14	2.67e-11	0.3	0.34	Kawasaki disease;	chr14:106777510	chr14:106675017~106675544:-
PRAD	cis	rs55665837	1	rs2305305	ENSG00000251991.1	RNU7-49P	7.75	5.96e-14	2.67e-11	0.37	0.34	Vitamin D levels;	chr11:14519396	chr11:14478892~14478953:+
PRAD	cis	rs6001482	0.638	rs5757569	ENSG00000272779.1	LL22NC03-80A10.6	-7.75	5.99e-14	2.69e-11	-0.41	-0.34	Diastolic blood pressure;	chr22:22230282	chr22:22303224~22310401:+
PRAD	cis	rs853679	0.506	rs1150711	ENSG00000204709.4	LINC01556	7.75	5.99e-14	2.69e-11	0.44	0.34	Depression;	chr6:28240757	chr6:28943877~28944537:+
PRAD	cis	rs2255336	0.81	rs7976624	ENSG00000245648.1	RP11-277P12.20	7.75	5.99e-14	2.69e-11	0.56	0.34	Blood protein levels;	chr12:10359392	chr12:10363769~10398506:+
PRAD	cis	rs6570726	0.902	rs4895678	ENSG00000235652.6	RP11-545I5.3	7.75	6.01e-14	2.7e-11	0.36	0.34	Lobe attachment (rater-scored or self-reported);	chr6:145614374	chr6:145799409~145886585:+
PRAD	cis	rs1499614	1	rs2707832	ENSG00000226824.5	RP4-756H11.3	-7.75	6.01e-14	2.7e-11	-0.68	-0.34	Gout;	chr7:66671562	chr7:66654538~66669855:+
PRAD	cis	rs4713118	0.786	rs200503	ENSG00000226314.6	ZNF192P1	-7.75	6.02e-14	2.7e-11	-0.45	-0.34	Parkinson's disease;	chr6:27818104	chr6:28161781~28169594:+
PRAD	cis	rs11159086	1	rs3759745	ENSG00000259005.1	RP3-449M8.6	7.75	6.04e-14	2.71e-11	0.46	0.34	Advanced glycation end-product levels;	chr14:74495967	chr14:74474007~74474864:-
PRAD	cis	rs172166	0.561	rs149971	ENSG00000280107.1	AL022393.9	-7.75	6.04e-14	2.71e-11	-0.41	-0.34	Cardiac Troponin-T levels;	chr6:28014374	chr6:28170845~28172521:+
PRAD	cis	rs6025590	1	rs6025590	ENSG00000124097.7	HMGB1P1	-7.75	6.04e-14	2.71e-11	-0.43	-0.34	Obesity-related traits;	chr20:57495449	chr20:57488392~57489027:-
PRAD	cis	rs17711722	0.565	rs4717276	ENSG00000275400.1	RP4-756H11.5	-7.75	6.04e-14	2.71e-11	-0.31	-0.34	Calcium levels;	chr7:65829754	chr7:66553805~66554199:-
PRAD	cis	rs950173	1	rs13000153	ENSG00000228389.1	AC068039.4	7.75	6.04e-14	2.71e-11	0.6	0.34	Hippocampal volume;	chr2:171729557	chr2:171773482~171775844:+
PRAD	cis	rs9467773	0.62	rs2504565	ENSG00000241549.7	GUSBP2	7.75	6.05e-14	2.71e-11	0.36	0.34	Intelligence (multi-trait analysis);	chr6:26656662	chr6:26871484~26956554:-
PRAD	cis	rs62355901	0.599	rs62355899	ENSG00000271828.1	CTD-2310F14.1	7.75	6.06e-14	2.72e-11	0.73	0.34	Breast cancer;	chr5:56754638	chr5:56927874~56929573:+
PRAD	cis	rs4713118	0.505	rs276371	ENSG00000280107.1	AL022393.9	-7.75	6.07e-14	2.72e-11	-0.41	-0.34	Parkinson's disease;	chr6:27942930	chr6:28170845~28172521:+
PRAD	cis	rs4722166	0.598	rs7804146	ENSG00000179428.2	AC073072.5	-7.75	6.1e-14	2.73e-11	-0.39	-0.34	Lung cancer;	chr7:22761310	chr7:22725395~22727620:-
PRAD	cis	rs7829975	0.582	rs448231	ENSG00000253893.2	FAM85B	7.75	6.12e-14	2.74e-11	0.41	0.34	Mood instability;	chr8:8932549	chr8:8167819~8226614:-
PRAD	cis	rs8523	0.774	rs115367234	ENSG00000230314.5	ELOVL2-AS1	7.75	6.13e-14	2.75e-11	0.36	0.34	Red blood cell fatty acid levels;	chr6:11044425	chr6:11043524~11078226:+
PRAD	cis	rs7238033	0.624	rs7233769	ENSG00000267193.4	RP11-116O18.3	7.75	6.13e-14	2.75e-11	0.37	0.34	Bladder cancer;	chr18:45726716	chr18:45669367~45747215:-
PRAD	cis	rs7238033	0.624	rs7234310	ENSG00000267193.4	RP11-116O18.3	7.75	6.13e-14	2.75e-11	0.37	0.34	Bladder cancer;	chr18:45726828	chr18:45669367~45747215:-
PRAD	cis	rs7238033	0.624	rs11877086	ENSG00000267193.4	RP11-116O18.3	7.75	6.13e-14	2.75e-11	0.37	0.34	Bladder cancer;	chr18:45727373	chr18:45669367~45747215:-
PRAD	cis	rs7238033	0.624	rs9304321	ENSG00000267193.4	RP11-116O18.3	7.75	6.13e-14	2.75e-11	0.37	0.34	Bladder cancer;	chr18:45728223	chr18:45669367~45747215:-
PRAD	cis	rs7238033	0.624	rs9304322	ENSG00000267193.4	RP11-116O18.3	7.75	6.13e-14	2.75e-11	0.37	0.34	Bladder cancer;	chr18:45728233	chr18:45669367~45747215:-
PRAD	cis	rs7238033	0.624	rs9304323	ENSG00000267193.4	RP11-116O18.3	7.75	6.13e-14	2.75e-11	0.37	0.34	Bladder cancer;	chr18:45728350	chr18:45669367~45747215:-
PRAD	cis	rs7238033	0.56	rs2170974	ENSG00000267193.4	RP11-116O18.3	7.75	6.13e-14	2.75e-11	0.37	0.34	Bladder cancer;	chr18:45728845	chr18:45669367~45747215:-
PRAD	cis	rs7238033	0.624	rs9967412	ENSG00000267193.4	RP11-116O18.3	7.75	6.13e-14	2.75e-11	0.37	0.34	Bladder cancer;	chr18:45728924	chr18:45669367~45747215:-
PRAD	cis	rs7238033	0.624	rs4479340	ENSG00000267193.4	RP11-116O18.3	7.75	6.13e-14	2.75e-11	0.37	0.34	Bladder cancer;	chr18:45728990	chr18:45669367~45747215:-
PRAD	cis	rs7238033	0.624	rs4316845	ENSG00000267193.4	RP11-116O18.3	7.75	6.13e-14	2.75e-11	0.37	0.34	Bladder cancer;	chr18:45729170	chr18:45669367~45747215:-
PRAD	cis	rs7238033	0.624	rs4310958	ENSG00000267193.4	RP11-116O18.3	7.75	6.13e-14	2.75e-11	0.37	0.34	Bladder cancer;	chr18:45729390	chr18:45669367~45747215:-
PRAD	cis	rs62355900	0.627	rs61243567	ENSG00000271828.1	CTD-2310F14.1	7.75	6.14e-14	2.75e-11	0.72	0.34	Endometriosis;	chr5:56867986	chr5:56927874~56929573:+
PRAD	cis	rs1799949	0.929	rs799905	ENSG00000267002.1	RP11-242D8.1	7.75	6.15e-14	2.75e-11	0.32	0.34	Menopause (age at onset);	chr17:43125170	chr17:43164183~43170403:-
PRAD	cis	rs7829975	0.659	rs4382480	ENSG00000253893.2	FAM85B	-7.75	6.16e-14	2.76e-11	-0.43	-0.34	Mood instability;	chr8:8863963	chr8:8167819~8226614:-
PRAD	cis	rs853679	0.607	rs200489	ENSG00000280107.1	AL022393.9	-7.75	6.17e-14	2.76e-11	-0.61	-0.34	Depression;	chr6:27830479	chr6:28170845~28172521:+
PRAD	cis	rs67311347	0.635	rs73071706	ENSG00000223797.4	ENTPD3-AS1	7.75	6.17e-14	2.76e-11	0.32	0.34	Renal cell carcinoma;	chr3:40246699	chr3:40313802~40453329:-
PRAD	cis	rs67311347	0.668	rs73071710	ENSG00000223797.4	ENTPD3-AS1	7.75	6.17e-14	2.76e-11	0.32	0.34	Renal cell carcinoma;	chr3:40247096	chr3:40313802~40453329:-
PRAD	cis	rs62355900	0.636	rs62355907	ENSG00000271828.1	CTD-2310F14.1	7.75	6.17e-14	2.76e-11	0.73	0.34	Endometriosis;	chr5:56775503	chr5:56927874~56929573:+
PRAD	cis	rs2274273	0.624	rs7157308	ENSG00000258413.1	RP11-665C16.6	-7.75	6.18e-14	2.77e-11	-0.46	-0.34	Protein biomarker;	chr14:55315325	chr14:55262767~55272075:-
PRAD	cis	rs73607972	0.593	rs4784321	ENSG00000275191.1	RP11-36I17.2	-7.75	6.19e-14	2.77e-11	-0.47	-0.34	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53602497	chr16:53628256~53628816:-
PRAD	cis	rs4718428	0.96	rs6460317	ENSG00000232546.1	RP11-458F8.1	-7.75	6.19e-14	2.77e-11	-0.26	-0.34	Corneal structure;	chr7:66925268	chr7:66848496~66858136:+
PRAD	cis	rs4266144	0.544	rs6805781	ENSG00000244515.1	KRT18P34	7.75	6.19e-14	2.77e-11	0.39	0.34	Coronary artery disease;	chr3:157112780	chr3:157162663~157163932:-
PRAD	cis	rs6479901	0.841	rs10822148	ENSG00000232075.1	MRPL35P2	-7.75	6.2e-14	2.78e-11	-0.41	-0.34	Intelligence (multi-trait analysis);	chr10:63219487	chr10:63634317~63634827:-
PRAD	cis	rs17711722	0.522	rs6957759	ENSG00000275400.1	RP4-756H11.5	-7.75	6.2e-14	2.78e-11	-0.31	-0.34	Calcium levels;	chr7:65806798	chr7:66553805~66554199:-
PRAD	cis	rs9467773	0.869	rs742090	ENSG00000124549.13	BTN2A3P	-7.75	6.2e-14	2.78e-11	-0.3	-0.34	Intelligence (multi-trait analysis);	chr6:26415409	chr6:26421391~26432383:+
PRAD	cis	rs73186030	0.546	rs67818421	ENSG00000272758.4	RP11-299J3.8	7.75	6.2e-14	2.78e-11	0.46	0.34	Serum parathyroid hormone levels;	chr3:122389871	chr3:122416207~122443180:+
PRAD	cis	rs73186030	0.546	rs9857972	ENSG00000272758.4	RP11-299J3.8	7.75	6.2e-14	2.78e-11	0.46	0.34	Serum parathyroid hormone levels;	chr3:122390602	chr3:122416207~122443180:+
PRAD	cis	rs2337406	0.704	rs1858679	ENSG00000274576.2	IGHV2-70	-7.75	6.23e-14	2.79e-11	-0.37	-0.34	Alzheimer's disease (late onset);	chr14:106706726	chr14:106770577~106771020:-
PRAD	cis	rs6844153	0.823	rs12642922	ENSG00000240005.4	RP11-293A21.1	-7.75	6.23e-14	2.79e-11	-0.48	-0.34	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:27025996	chr4:26859806~26860599:-
PRAD	cis	rs9467773	0.62	rs2451741	ENSG00000241549.7	GUSBP2	7.75	6.24e-14	2.79e-11	0.35	0.34	Intelligence (multi-trait analysis);	chr6:26629176	chr6:26871484~26956554:-
PRAD	cis	rs6570726	0.905	rs377143	ENSG00000235652.6	RP11-545I5.3	7.75	6.26e-14	2.8e-11	0.36	0.34	Lobe attachment (rater-scored or self-reported);	chr6:145513084	chr6:145799409~145886585:+
PRAD	cis	rs8091660	0.929	rs12456253	ENSG00000278983.1	RP11-426J5.3	-7.74	6.27e-14	2.81e-11	-0.43	-0.34	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48550603	chr18:48564795~48568342:+
PRAD	cis	rs12908161	1	rs56864281	ENSG00000275120.1	RP11-182J1.17	7.74	6.27e-14	2.81e-11	0.45	0.34	Schizophrenia;	chr15:84814418	chr15:84599434~84606463:-
PRAD	cis	rs881375	0.678	rs7021049	ENSG00000226752.6	PSMD5-AS1	-7.74	6.29e-14	2.81e-11	-0.39	-0.34	Rheumatoid arthritis;	chr9:120921704	chr9:120824828~120854385:+
PRAD	cis	rs2439831	0.85	rs7183809	ENSG00000249839.1	AC011330.5	-7.74	6.29e-14	2.81e-11	-0.58	-0.34	Lung cancer in ever smokers;	chr15:43828670	chr15:43663654~43684339:-
PRAD	cis	rs2439831	0.85	rs3759790	ENSG00000249839.1	AC011330.5	-7.74	6.29e-14	2.81e-11	-0.58	-0.34	Lung cancer in ever smokers;	chr15:43828832	chr15:43663654~43684339:-
PRAD	cis	rs9467773	0.869	rs1796520	ENSG00000124549.13	BTN2A3P	-7.74	6.3e-14	2.82e-11	-0.3	-0.34	Intelligence (multi-trait analysis);	chr6:26410572	chr6:26421391~26432383:+
PRAD	cis	rs673078	0.607	rs61943393	ENSG00000275409.1	RP11-131L12.4	-7.74	6.31e-14	2.82e-11	-0.5	-0.34	Glucose homeostasis traits;	chr12:118383650	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.607	rs73205576	ENSG00000275409.1	RP11-131L12.4	-7.74	6.31e-14	2.82e-11	-0.5	-0.34	Glucose homeostasis traits;	chr12:118384268	chr12:118430147~118430699:+
PRAD	cis	rs11083475	1	rs979972	ENSG00000267892.1	CTD-2540F13.2	7.74	6.32e-14	2.83e-11	0.37	0.34	Heart rate;	chr19:38653527	chr19:38738284~38739863:+
PRAD	cis	rs2439831	0.85	rs3825783	ENSG00000205771.5	CATSPER2P1	-7.74	6.33e-14	2.83e-11	-0.53	-0.34	Lung cancer in ever smokers;	chr15:43810111	chr15:43726918~43747094:-
PRAD	cis	rs3096299	0.933	rs28608022	ENSG00000261118.1	RP11-104N10.1	7.74	6.34e-14	2.83e-11	0.33	0.34	Multiple myeloma (IgH translocation);	chr16:89387884	chr16:89492017~89504460:-
PRAD	cis	rs3096299	0.9	rs2911258	ENSG00000261118.1	RP11-104N10.1	7.74	6.34e-14	2.84e-11	0.34	0.34	Multiple myeloma (IgH translocation);	chr16:89414352	chr16:89492017~89504460:-
PRAD	cis	rs496547	0.719	rs472641	ENSG00000255239.1	AP002954.6	7.74	6.34e-14	2.84e-11	0.46	0.34	Hip minimal joint space width;	chr11:118746835	chr11:118688039~118690600:-
PRAD	cis	rs853679	0.538	rs13199081	ENSG00000204709.4	LINC01556	7.74	6.35e-14	2.84e-11	0.47	0.34	Depression;	chr6:28364057	chr6:28943877~28944537:+
PRAD	cis	rs10129255	0.5	rs2105989	ENSG00000211972.2	IGHV3-66	7.74	6.35e-14	2.84e-11	0.3	0.34	Kawasaki disease;	chr14:106682199	chr14:106675017~106675544:-
PRAD	cis	rs2617170	0.885	rs7975996	ENSG00000245648.1	RP11-277P12.20	7.74	6.36e-14	2.84e-11	0.42	0.34	Behcet's disease;	chr12:10372324	chr12:10363769~10398506:+
PRAD	cis	rs6991838	0.765	rs10957358	ENSG00000200714.1	Y_RNA	7.74	6.38e-14	2.85e-11	0.36	0.34	Intelligence (multi-trait analysis);	chr8:65590067	chr8:65592731~65592820:+
PRAD	cis	rs9640161	0.659	rs77354576	ENSG00000261305.1	RP4-584D14.7	7.74	6.39e-14	2.86e-11	0.36	0.34	Blood protein levels;Circulating chemerin levels;	chr7:150316211	chr7:150341771~150342607:+
PRAD	cis	rs1134634	0.52	rs11932730	ENSG00000273133.1	RP11-799M12.2	7.74	6.39e-14	2.86e-11	0.45	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15564135	chr4:15563698~15564253:-
PRAD	cis	rs6570726	0.967	rs403584	ENSG00000235652.6	RP11-545I5.3	7.74	6.4e-14	2.86e-11	0.36	0.34	Lobe attachment (rater-scored or self-reported);	chr6:145485874	chr6:145799409~145886585:+
PRAD	cis	rs11083475	0.967	rs13343794	ENSG00000267892.1	CTD-2540F13.2	7.74	6.43e-14	2.87e-11	0.36	0.34	Heart rate;	chr19:38688631	chr19:38738284~38739863:+
PRAD	cis	rs6570726	0.905	rs1355146	ENSG00000235652.6	RP11-545I5.3	-7.74	6.43e-14	2.87e-11	-0.36	-0.34	Lobe attachment (rater-scored or self-reported);	chr6:145460605	chr6:145799409~145886585:+
PRAD	cis	rs9287719	0.746	rs6742448	ENSG00000234818.1	AC092687.5	7.74	6.43e-14	2.87e-11	0.41	0.34	Prostate cancer;	chr2:10619000	chr2:10589166~10604830:+
PRAD	cis	rs9287719	0.781	rs6732671	ENSG00000234818.1	AC092687.5	7.74	6.43e-14	2.87e-11	0.41	0.34	Prostate cancer;	chr2:10619023	chr2:10589166~10604830:+
PRAD	cis	rs62355901	0.545	rs6895844	ENSG00000271828.1	CTD-2310F14.1	7.74	6.44e-14	2.88e-11	0.63	0.34	Breast cancer;	chr5:56762113	chr5:56927874~56929573:+
PRAD	cis	rs2243480	1	rs313832	ENSG00000226824.5	RP4-756H11.3	-7.74	6.45e-14	2.88e-11	-0.68	-0.34	Diabetic kidney disease;	chr7:66085904	chr7:66654538~66669855:+
PRAD	cis	rs7181230	1	rs28620926	ENSG00000275636.1	RP11-521C20.5	7.74	6.45e-14	2.88e-11	0.47	0.34	Dehydroepiandrosterone sulphate levels;	chr15:40064970	chr15:40078892~40079347:+
PRAD	cis	rs12188164	0.965	rs77101200	ENSG00000221990.4	EXOC3-AS1	7.74	6.46e-14	2.89e-11	0.28	0.34	Cystic fibrosis severity;	chr5:442944	chr5:441498~443160:-
PRAD	cis	rs7567389	0.677	rs4662720	ENSG00000236682.1	AC068282.3	7.74	6.46e-14	2.89e-11	0.46	0.34	Self-rated health;	chr2:127319031	chr2:127389130~127400580:+
PRAD	cis	rs12908161	0.959	rs12906348	ENSG00000275120.1	RP11-182J1.17	7.74	6.47e-14	2.89e-11	0.44	0.34	Schizophrenia;	chr15:84786190	chr15:84599434~84606463:-
PRAD	cis	rs6452524	1	rs7349753	ENSG00000249664.1	CTD-2227C6.2	7.74	6.49e-14	2.9e-11	0.4	0.34	Hypertension (SNP x SNP interaction);	chr5:83165632	chr5:83012285~83013109:-
PRAD	cis	rs2255336	0.702	rs7964772	ENSG00000245648.1	RP11-277P12.20	7.74	6.49e-14	2.9e-11	0.54	0.34	Blood protein levels;	chr12:10367498	chr12:10363769~10398506:+
PRAD	cis	rs2153535	0.764	rs12190361	ENSG00000230939.1	RP11-314C16.1	7.74	6.51e-14	2.91e-11	0.41	0.34	Motion sickness;	chr6:8377079	chr6:8784178~8785445:+
PRAD	cis	rs875971	0.545	rs73378304	ENSG00000226824.5	RP4-756H11.3	-7.74	6.51e-14	2.91e-11	-0.5	-0.34	Aortic root size;	chr7:66175760	chr7:66654538~66669855:+
PRAD	cis	rs12908161	1	rs12903134	ENSG00000275120.1	RP11-182J1.17	7.74	6.51e-14	2.91e-11	0.45	0.34	Schizophrenia;	chr15:84794468	chr15:84599434~84606463:-
PRAD	cis	rs12908161	1	rs35726233	ENSG00000275120.1	RP11-182J1.17	7.74	6.51e-14	2.91e-11	0.45	0.34	Schizophrenia;	chr15:84794569	chr15:84599434~84606463:-
PRAD	cis	rs494459	0.964	rs576283	ENSG00000255422.1	AP002954.4	-7.74	6.51e-14	2.91e-11	-0.39	-0.34	Height;	chr11:118703185	chr11:118704607~118750263:+
PRAD	cis	rs494459	0.929	rs627391	ENSG00000255422.1	AP002954.4	-7.74	6.51e-14	2.91e-11	-0.39	-0.34	Height;	chr11:118703207	chr11:118704607~118750263:+
PRAD	cis	rs2243480	1	rs316315	ENSG00000273142.1	RP11-458F8.4	7.74	6.53e-14	2.91e-11	0.33	0.34	Diabetic kidney disease;	chr7:66126218	chr7:66902857~66906297:+
PRAD	cis	rs6570726	0.967	rs450973	ENSG00000235652.6	RP11-545I5.3	7.74	6.54e-14	2.92e-11	0.36	0.34	Lobe attachment (rater-scored or self-reported);	chr6:145541929	chr6:145799409~145886585:+
PRAD	cis	rs881375	0.933	rs4837804	ENSG00000226752.6	PSMD5-AS1	-7.74	6.55e-14	2.92e-11	-0.4	-0.34	Rheumatoid arthritis;	chr9:120943026	chr9:120824828~120854385:+
PRAD	cis	rs881375	0.967	rs7039505	ENSG00000226752.6	PSMD5-AS1	-7.74	6.55e-14	2.92e-11	-0.4	-0.34	Rheumatoid arthritis;	chr9:120943667	chr9:120824828~120854385:+
PRAD	cis	rs950173	1	rs950173	ENSG00000228389.1	AC068039.4	7.74	6.56e-14	2.93e-11	0.62	0.34	Hippocampal volume;	chr2:171713909	chr2:171773482~171775844:+
PRAD	cis	rs6025590	0.791	rs2182970	ENSG00000124097.7	HMGB1P1	-7.74	6.56e-14	2.93e-11	-0.42	-0.34	Obesity-related traits;	chr20:57496597	chr20:57488392~57489027:-
PRAD	cis	rs12468226	0.873	rs79071680	ENSG00000273456.1	RP11-686O6.2	7.74	6.56e-14	2.93e-11	0.47	0.34	Urate levels;	chr2:202191520	chr2:202374932~202375604:-
PRAD	cis	rs12468226	0.873	rs79860867	ENSG00000273456.1	RP11-686O6.2	7.74	6.56e-14	2.93e-11	0.47	0.34	Urate levels;	chr2:202192397	chr2:202374932~202375604:-
PRAD	cis	rs62355901	0.545	rs62355938	ENSG00000271828.1	CTD-2310F14.1	7.74	6.57e-14	2.93e-11	0.73	0.34	Breast cancer;	chr5:56798887	chr5:56927874~56929573:+
PRAD	cis	rs62355900	0.627	rs1862620	ENSG00000271828.1	CTD-2310F14.1	7.74	6.57e-14	2.93e-11	0.73	0.34	Endometriosis;	chr5:56802543	chr5:56927874~56929573:+
PRAD	cis	rs995000	0.868	rs6682423	ENSG00000235545.1	RP11-230B22.1	-7.74	6.59e-14	2.94e-11	-0.46	-0.34	Triglyceride levels;	chr1:62705392	chr1:62688482~62710694:+
PRAD	cis	rs995000	0.868	rs6666816	ENSG00000235545.1	RP11-230B22.1	-7.74	6.59e-14	2.94e-11	-0.46	-0.34	Triglyceride levels;	chr1:62705528	chr1:62688482~62710694:+
PRAD	cis	rs995000	0.868	rs880694	ENSG00000235545.1	RP11-230B22.1	-7.74	6.59e-14	2.94e-11	-0.46	-0.34	Triglyceride levels;	chr1:62707613	chr1:62688482~62710694:+
PRAD	cis	rs4664293	0.528	rs12477092	ENSG00000226266.5	AC009961.3	7.74	6.6e-14	2.95e-11	0.45	0.34	Monocyte percentage of white cells;	chr2:159577170	chr2:159670708~159712435:-
PRAD	cis	rs1979679	0.918	rs7135922	ENSG00000278733.1	RP11-425D17.1	-7.74	6.61e-14	2.95e-11	-0.45	-0.34	Ossification of the posterior longitudinal ligament of the spine;	chr12:28469148	chr12:28185625~28186190:-
PRAD	cis	rs321358	1	rs73003503	ENSG00000271584.1	RP11-89C3.4	7.74	6.61e-14	2.95e-11	0.52	0.34	Body mass index;	chr11:111158360	chr11:111091932~111097357:-
PRAD	cis	rs6570726	0.967	rs9403706	ENSG00000235652.6	RP11-545I5.3	-7.74	6.61e-14	2.95e-11	-0.36	-0.34	Lobe attachment (rater-scored or self-reported);	chr6:145474051	chr6:145799409~145886585:+
PRAD	cis	rs736801	0.78	rs12521868	ENSG00000233006.5	AC034220.3	-7.74	6.62e-14	2.96e-11	-0.32	-0.34	Mosquito bite size;Breast cancer;	chr5:132448701	chr5:132311285~132369916:-
PRAD	cis	rs9532669	0.926	rs4942014	ENSG00000168852.11	TPTE2P5	7.74	6.63e-14	2.96e-11	0.32	0.34	Cervical cancer;	chr13:40966366	chr13:40822296~40921749:-
PRAD	cis	rs11118620	0.853	rs11118622	ENSG00000257551.1	HLX-AS1	7.74	6.63e-14	2.96e-11	0.44	0.34	Heart failure;	chr1:220868833	chr1:220832763~220880140:-
PRAD	cis	rs6001482	0.679	rs5750786	ENSG00000272779.1	LL22NC03-80A10.6	-7.74	6.64e-14	2.96e-11	-0.41	-0.34	Diastolic blood pressure;	chr22:22235358	chr22:22303224~22310401:+
PRAD	cis	rs8081395	0.651	rs1292067	ENSG00000266992.1	DHX40P1	-7.74	6.64e-14	2.96e-11	-0.38	-0.34	White blood cell count;	chr17:59853285	chr17:59976009~60002384:-
PRAD	cis	rs12928939	0.774	rs7205340	ENSG00000260886.1	TAT-AS1	-7.74	6.65e-14	2.97e-11	-0.44	-0.34	Post bronchodilator FEV1;	chr16:71611767	chr16:71565789~71578187:+
PRAD	cis	rs853679	0.546	rs483143	ENSG00000280107.1	AL022393.9	-7.74	6.66e-14	2.97e-11	-0.61	-0.34	Depression;	chr6:27878966	chr6:28170845~28172521:+
PRAD	cis	rs12612619	0.732	rs1078809	ENSG00000229122.1	AGBL5-IT1	7.74	6.67e-14	2.97e-11	0.35	0.34	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27066047	chr2:27061038~27061815:+
PRAD	cis	rs12612619	0.732	rs10865461	ENSG00000229122.1	AGBL5-IT1	7.74	6.67e-14	2.97e-11	0.35	0.34	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27069783	chr2:27061038~27061815:+
PRAD	cis	rs6545883	0.507	rs2123111	ENSG00000271889.1	RP11-493E12.1	-7.74	6.69e-14	2.98e-11	-0.37	-0.34	Tuberculosis;	chr2:61223319	chr2:61151433~61162105:-
PRAD	cis	rs67340775	0.541	rs200979	ENSG00000280107.1	AL022393.9	-7.74	6.69e-14	2.99e-11	-0.53	-0.34	Lung cancer in ever smokers;	chr6:27884579	chr6:28170845~28172521:+
PRAD	cis	rs67340775	0.541	rs169287	ENSG00000280107.1	AL022393.9	-7.74	6.69e-14	2.99e-11	-0.53	-0.34	Lung cancer in ever smokers;	chr6:27886982	chr6:28170845~28172521:+
PRAD	cis	rs67340775	0.541	rs200975	ENSG00000280107.1	AL022393.9	-7.74	6.69e-14	2.99e-11	-0.53	-0.34	Lung cancer in ever smokers;	chr6:27887847	chr6:28170845~28172521:+
PRAD	cis	rs67340775	0.541	rs200974	ENSG00000280107.1	AL022393.9	-7.74	6.69e-14	2.99e-11	-0.53	-0.34	Lung cancer in ever smokers;	chr6:27888067	chr6:28170845~28172521:+
PRAD	cis	rs4664293	0.528	rs1549386	ENSG00000226266.5	AC009961.3	7.74	6.7e-14	2.99e-11	0.45	0.34	Monocyte percentage of white cells;	chr2:159558015	chr2:159670708~159712435:-
PRAD	cis	rs6940116	1	rs6940116	ENSG00000280107.1	AL022393.9	-7.74	6.7e-14	2.99e-11	-0.48	-0.34	Intelligence (multi-trait analysis);Autism spectrum disorder or schizophrenia;	chr6:27740953	chr6:28170845~28172521:+
PRAD	cis	rs1185460	0.565	rs657685	ENSG00000271751.1	RP11-110I1.14	7.74	6.71e-14	2.99e-11	0.46	0.34	Coronary artery disease;	chr11:119042272	chr11:119065263~119065677:-
PRAD	cis	rs6546847	0.531	rs2567602	ENSG00000163016.8	ALMS1P	7.74	6.71e-14	2.99e-11	0.51	0.34	Urinary metabolites (H-NMR features);	chr2:73758409	chr2:73644919~73685576:+
PRAD	cis	rs1552244	0.608	rs6764807	ENSG00000206567.8	AC022007.5	-7.74	6.72e-14	3e-11	-0.38	-0.34	Alzheimer's disease;	chr3:9957119	chr3:10006418~10011209:-
PRAD	cis	rs1552244	0.554	rs34391585	ENSG00000206567.8	AC022007.5	-7.74	6.72e-14	3e-11	-0.38	-0.34	Alzheimer's disease;	chr3:9957524	chr3:10006418~10011209:-
PRAD	cis	rs1552244	0.515	rs7613004	ENSG00000206567.8	AC022007.5	-7.74	6.72e-14	3e-11	-0.38	-0.34	Alzheimer's disease;	chr3:9958229	chr3:10006418~10011209:-
PRAD	cis	rs12908161	0.959	rs34342559	ENSG00000275120.1	RP11-182J1.17	7.73	6.73e-14	3e-11	0.45	0.34	Schizophrenia;	chr15:84788040	chr15:84599434~84606463:-
PRAD	cis	rs12908161	0.959	rs62019472	ENSG00000275120.1	RP11-182J1.17	7.73	6.73e-14	3e-11	0.45	0.34	Schizophrenia;	chr15:84788262	chr15:84599434~84606463:-
PRAD	cis	rs12908161	0.959	rs35557864	ENSG00000275120.1	RP11-182J1.17	7.73	6.73e-14	3e-11	0.45	0.34	Schizophrenia;	chr15:84788398	chr15:84599434~84606463:-
PRAD	cis	rs6921919	0.789	rs17301128	ENSG00000216901.1	AL022393.7	7.73	6.75e-14	3.01e-11	0.49	0.34	Autism spectrum disorder or schizophrenia;	chr6:28340257	chr6:28176188~28176674:+
PRAD	cis	rs11018904	0.906	rs36177012	ENSG00000280385.1	AP000648.5	-7.73	6.75e-14	3.01e-11	-0.48	-0.34	Intelligence (multi-trait analysis);	chr11:90200151	chr11:90193614~90198120:+
PRAD	cis	rs11018904	0.906	rs7925507	ENSG00000280385.1	AP000648.5	-7.73	6.75e-14	3.01e-11	-0.48	-0.34	Intelligence (multi-trait analysis);	chr11:90206978	chr11:90193614~90198120:+
PRAD	cis	rs11018904	0.861	rs12786959	ENSG00000280385.1	AP000648.5	-7.73	6.75e-14	3.01e-11	-0.48	-0.34	Intelligence (multi-trait analysis);	chr11:90210508	chr11:90193614~90198120:+
PRAD	cis	rs11018904	0.861	rs12787117	ENSG00000280385.1	AP000648.5	-7.73	6.75e-14	3.01e-11	-0.48	-0.34	Intelligence (multi-trait analysis);	chr11:90210513	chr11:90193614~90198120:+
PRAD	cis	rs11018904	0.817	rs11601793	ENSG00000280385.1	AP000648.5	-7.73	6.75e-14	3.01e-11	-0.48	-0.34	Intelligence (multi-trait analysis);	chr11:90213186	chr11:90193614~90198120:+
PRAD	cis	rs11018904	0.906	rs35129016	ENSG00000280385.1	AP000648.5	-7.73	6.75e-14	3.01e-11	-0.48	-0.34	Intelligence (multi-trait analysis);	chr11:90215521	chr11:90193614~90198120:+
PRAD	cis	rs6603134	0.502	rs10406540	ENSG00000267939.1	CTD-2325M2.1	-7.73	6.76e-14	3.02e-11	-0.39	-0.34	Blood protein levels;	chr19:8039113	chr19:8008729~8016025:+
PRAD	cis	rs673078	0.562	rs61944672	ENSG00000275409.1	RP11-131L12.4	-7.73	6.78e-14	3.02e-11	-0.5	-0.34	Glucose homeostasis traits;	chr12:118450123	chr12:118430147~118430699:+
PRAD	cis	rs62355901	0.545	rs58774999	ENSG00000271828.1	CTD-2310F14.1	7.73	6.78e-14	3.02e-11	0.73	0.34	Breast cancer;	chr5:56798018	chr5:56927874~56929573:+
PRAD	cis	rs2274273	0.624	rs7151754	ENSG00000258413.1	RP11-665C16.6	-7.73	6.78e-14	3.02e-11	-0.46	-0.34	Protein biomarker;	chr14:55321783	chr14:55262767~55272075:-
PRAD	cis	rs10875746	0.551	rs2054903	ENSG00000240399.1	RP1-228P16.1	-7.73	6.78e-14	3.03e-11	-0.33	-0.34	Longevity (90 years and older);	chr12:48330710	chr12:48054813~48055591:-
PRAD	cis	rs881375	0.933	rs4837799	ENSG00000226752.6	PSMD5-AS1	-7.73	6.79e-14	3.03e-11	-0.41	-0.34	Rheumatoid arthritis;	chr9:120906048	chr9:120824828~120854385:+
PRAD	cis	rs6991838	0.584	rs7842085	ENSG00000200714.1	Y_RNA	7.73	6.82e-14	3.04e-11	0.38	0.34	Intelligence (multi-trait analysis);	chr8:65636787	chr8:65592731~65592820:+
PRAD	cis	rs9640161	0.75	rs4395803	ENSG00000261305.1	RP4-584D14.7	7.73	6.83e-14	3.04e-11	0.38	0.34	Blood protein levels;Circulating chemerin levels;	chr7:150328278	chr7:150341771~150342607:+
PRAD	cis	rs7739264	0.602	rs2223362	ENSG00000228412.5	RP4-625H18.2	7.73	6.83e-14	3.04e-11	0.4	0.34	Endometriosis;	chr6:19777940	chr6:19802164~19804752:-
PRAD	cis	rs42648	0.536	rs13242882	ENSG00000227646.6	STEAP2-AS1	-7.73	6.83e-14	3.04e-11	-0.31	-0.34	Homocysteine levels;	chr7:90170739	chr7:89882353~90211635:-
PRAD	cis	rs42648	0.535	rs6978118	ENSG00000227646.6	STEAP2-AS1	-7.73	6.83e-14	3.04e-11	-0.31	-0.34	Homocysteine levels;	chr7:90170927	chr7:89882353~90211635:-
PRAD	cis	rs42648	0.564	rs7783739	ENSG00000227646.6	STEAP2-AS1	-7.73	6.83e-14	3.04e-11	-0.31	-0.34	Homocysteine levels;	chr7:90172473	chr7:89882353~90211635:-
PRAD	cis	rs42648	0.564	rs10257064	ENSG00000227646.6	STEAP2-AS1	-7.73	6.83e-14	3.04e-11	-0.31	-0.34	Homocysteine levels;	chr7:90173282	chr7:89882353~90211635:-
PRAD	cis	rs42648	0.564	rs11563564	ENSG00000227646.6	STEAP2-AS1	-7.73	6.83e-14	3.04e-11	-0.31	-0.34	Homocysteine levels;	chr7:90187387	chr7:89882353~90211635:-
PRAD	cis	rs6603134	0.502	rs6603131	ENSG00000267939.1	CTD-2325M2.1	-7.73	6.84e-14	3.05e-11	-0.39	-0.34	Blood protein levels;	chr19:8037873	chr19:8008729~8016025:+
PRAD	cis	rs2638953	0.924	rs7955118	ENSG00000278733.1	RP11-425D17.1	-7.73	6.86e-14	3.06e-11	-0.44	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28157159	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs7955237	ENSG00000278733.1	RP11-425D17.1	-7.73	6.86e-14	3.06e-11	-0.44	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28157272	chr12:28185625~28186190:-
PRAD	cis	rs507080	0.501	rs494459	ENSG00000255422.1	AP002954.4	7.73	6.87e-14	3.06e-11	0.39	0.34	Serum metabolite levels;	chr11:118703966	chr11:118704607~118750263:+
PRAD	cis	rs507080	0.524	rs524409	ENSG00000255422.1	AP002954.4	-7.73	6.87e-14	3.06e-11	-0.39	-0.34	Serum metabolite levels;	chr11:118703602	chr11:118704607~118750263:+
PRAD	cis	rs507080	0.501	rs626645	ENSG00000255422.1	AP002954.4	-7.73	6.87e-14	3.06e-11	-0.39	-0.34	Serum metabolite levels;	chr11:118704471	chr11:118704607~118750263:+
PRAD	cis	rs7429990	0.932	rs7630685	ENSG00000229759.1	MRPS18AP1	-7.73	6.87e-14	3.06e-11	-0.35	-0.34	Educational attainment (years of education);	chr3:48089680	chr3:48256350~48256938:-
PRAD	cis	rs9532669	0.889	rs7333447	ENSG00000168852.11	TPTE2P5	7.73	6.88e-14	3.07e-11	0.32	0.34	Cervical cancer;	chr13:40917586	chr13:40822296~40921749:-
PRAD	cis	rs62355901	0.599	rs12657013	ENSG00000271828.1	CTD-2310F14.1	7.73	6.89e-14	3.07e-11	0.73	0.34	Breast cancer;	chr5:56739441	chr5:56927874~56929573:+
PRAD	cis	rs526231	0.543	rs27361	ENSG00000175749.11	EIF3KP1	7.73	6.91e-14	3.08e-11	0.47	0.34	Primary biliary cholangitis;	chr5:103213266	chr5:103032376~103033031:+
PRAD	cis	rs10463554	0.75	rs26257	ENSG00000175749.11	EIF3KP1	7.73	6.91e-14	3.08e-11	0.47	0.34	Parkinson's disease;	chr5:103214830	chr5:103032376~103033031:+
PRAD	cis	rs2286503	0.839	rs2270108	ENSG00000228649.7	AC005682.5	7.73	6.93e-14	3.09e-11	0.38	0.34	Fibrinogen;	chr7:22822512	chr7:22854178~22861579:+
PRAD	cis	rs2286503	0.839	rs2270107	ENSG00000228649.7	AC005682.5	7.73	6.93e-14	3.09e-11	0.38	0.34	Fibrinogen;	chr7:22822564	chr7:22854178~22861579:+
PRAD	cis	rs2286503	0.839	rs2270105	ENSG00000228649.7	AC005682.5	7.73	6.93e-14	3.09e-11	0.38	0.34	Fibrinogen;	chr7:22822848	chr7:22854178~22861579:+
PRAD	cis	rs2286503	0.839	rs2270103	ENSG00000228649.7	AC005682.5	7.73	6.93e-14	3.09e-11	0.38	0.34	Fibrinogen;	chr7:22823103	chr7:22854178~22861579:+
PRAD	cis	rs12928939	0.769	rs1056303	ENSG00000260886.1	TAT-AS1	7.73	6.93e-14	3.09e-11	0.46	0.34	Post bronchodilator FEV1;	chr16:71636163	chr16:71565789~71578187:+
PRAD	cis	rs6479901	0.947	rs10740123	ENSG00000232075.1	MRPL35P2	-7.73	6.94e-14	3.09e-11	-0.41	-0.34	Intelligence (multi-trait analysis);	chr10:63404755	chr10:63634317~63634827:-
PRAD	cis	rs6479901	0.947	rs10995530	ENSG00000232075.1	MRPL35P2	-7.73	6.94e-14	3.09e-11	-0.41	-0.34	Intelligence (multi-trait analysis);	chr10:63419654	chr10:63634317~63634827:-
PRAD	cis	rs6479901	0.947	rs10761767	ENSG00000232075.1	MRPL35P2	-7.73	6.94e-14	3.09e-11	-0.41	-0.34	Intelligence (multi-trait analysis);	chr10:63432671	chr10:63634317~63634827:-
PRAD	cis	rs6479901	0.947	rs10761768	ENSG00000232075.1	MRPL35P2	-7.73	6.94e-14	3.09e-11	-0.41	-0.34	Intelligence (multi-trait analysis);	chr10:63434369	chr10:63634317~63634827:-
PRAD	cis	rs6479901	0.947	rs12573212	ENSG00000232075.1	MRPL35P2	-7.73	6.94e-14	3.09e-11	-0.41	-0.34	Intelligence (multi-trait analysis);	chr10:63458665	chr10:63634317~63634827:-
PRAD	cis	rs6479901	0.947	rs7074735	ENSG00000232075.1	MRPL35P2	-7.73	6.94e-14	3.09e-11	-0.41	-0.34	Intelligence (multi-trait analysis);	chr10:63459519	chr10:63634317~63634827:-
PRAD	cis	rs6479901	0.802	rs7075205	ENSG00000232075.1	MRPL35P2	-7.73	6.94e-14	3.09e-11	-0.41	-0.34	Intelligence (multi-trait analysis);	chr10:63459834	chr10:63634317~63634827:-
PRAD	cis	rs6479901	0.947	rs10995540	ENSG00000232075.1	MRPL35P2	-7.73	6.94e-14	3.09e-11	-0.41	-0.34	Intelligence (multi-trait analysis);	chr10:63460170	chr10:63634317~63634827:-
PRAD	cis	rs6479901	0.894	rs1061259	ENSG00000232075.1	MRPL35P2	-7.73	6.94e-14	3.09e-11	-0.41	-0.34	Intelligence (multi-trait analysis);	chr10:63465484	chr10:63634317~63634827:-
PRAD	cis	rs6479901	0.947	rs10995541	ENSG00000232075.1	MRPL35P2	-7.73	6.94e-14	3.09e-11	-0.41	-0.34	Intelligence (multi-trait analysis);	chr10:63473575	chr10:63634317~63634827:-
PRAD	cis	rs6479901	0.894	rs10761773	ENSG00000232075.1	MRPL35P2	-7.73	6.94e-14	3.09e-11	-0.41	-0.34	Intelligence (multi-trait analysis);	chr10:63480322	chr10:63634317~63634827:-
PRAD	cis	rs6479901	0.894	rs2393978	ENSG00000232075.1	MRPL35P2	-7.73	6.94e-14	3.09e-11	-0.41	-0.34	Intelligence (multi-trait analysis);	chr10:63482050	chr10:63634317~63634827:-
PRAD	cis	rs6479901	0.895	rs10822173	ENSG00000232075.1	MRPL35P2	-7.73	6.94e-14	3.09e-11	-0.41	-0.34	Intelligence (multi-trait analysis);	chr10:63483842	chr10:63634317~63634827:-
PRAD	cis	rs6479901	0.947	rs7085862	ENSG00000232075.1	MRPL35P2	-7.73	6.94e-14	3.09e-11	-0.41	-0.34	Intelligence (multi-trait analysis);	chr10:63486687	chr10:63634317~63634827:-
PRAD	cis	rs6479901	0.894	rs9919452	ENSG00000232075.1	MRPL35P2	-7.73	6.94e-14	3.09e-11	-0.41	-0.34	Intelligence (multi-trait analysis);	chr10:63488812	chr10:63634317~63634827:-
PRAD	cis	rs6479901	0.947	rs10761776	ENSG00000232075.1	MRPL35P2	-7.73	6.94e-14	3.09e-11	-0.41	-0.34	Intelligence (multi-trait analysis);	chr10:63491217	chr10:63634317~63634827:-
PRAD	cis	rs6479901	0.947	rs7910662	ENSG00000232075.1	MRPL35P2	-7.73	6.94e-14	3.09e-11	-0.41	-0.34	Intelligence (multi-trait analysis);	chr10:63493940	chr10:63634317~63634827:-
PRAD	cis	rs6479901	0.624	rs10822175	ENSG00000232075.1	MRPL35P2	-7.73	6.94e-14	3.09e-11	-0.41	-0.34	Intelligence (multi-trait analysis);	chr10:63495414	chr10:63634317~63634827:-
PRAD	cis	rs6479901	0.947	rs7097698	ENSG00000232075.1	MRPL35P2	-7.73	6.94e-14	3.09e-11	-0.41	-0.34	Intelligence (multi-trait analysis);	chr10:63513635	chr10:63634317~63634827:-
PRAD	cis	rs6479901	0.947	rs7068144	ENSG00000232075.1	MRPL35P2	-7.73	6.94e-14	3.09e-11	-0.41	-0.34	Intelligence (multi-trait analysis);	chr10:63514500	chr10:63634317~63634827:-
PRAD	cis	rs6545883	0.524	rs2593631	ENSG00000271889.1	RP11-493E12.1	-7.73	6.95e-14	3.09e-11	-0.38	-0.34	Tuberculosis;	chr2:61345151	chr2:61151433~61162105:-
PRAD	cis	rs6545883	0.542	rs2593628	ENSG00000271889.1	RP11-493E12.1	-7.73	6.95e-14	3.09e-11	-0.38	-0.34	Tuberculosis;	chr2:61346152	chr2:61151433~61162105:-
PRAD	cis	rs6479901	0.947	rs10822179	ENSG00000232075.1	MRPL35P2	-7.73	6.97e-14	3.1e-11	-0.41	-0.34	Intelligence (multi-trait analysis);	chr10:63520404	chr10:63634317~63634827:-
PRAD	cis	rs950169	0.544	rs2036949	ENSG00000275120.1	RP11-182J1.17	7.73	6.98e-14	3.1e-11	0.44	0.34	Schizophrenia;	chr15:84620374	chr15:84599434~84606463:-
PRAD	cis	rs2236295	0.618	rs224285	ENSG00000238280.1	RP11-436D10.3	7.73	6.99e-14	3.11e-11	0.43	0.34	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr10:62825050	chr10:62793562~62805887:-
PRAD	cis	rs3096299	0.967	rs2911256	ENSG00000261118.1	RP11-104N10.1	7.73	7e-14	3.12e-11	0.33	0.34	Multiple myeloma (IgH translocation);	chr16:89418688	chr16:89492017~89504460:-
PRAD	cis	rs4713118	0.869	rs9283883	ENSG00000226314.6	ZNF192P1	-7.73	7e-14	3.12e-11	-0.45	-0.34	Parkinson's disease;	chr6:27747691	chr6:28161781~28169594:+
PRAD	cis	rs1552244	0.554	rs59465469	ENSG00000206567.8	AC022007.5	-7.73	7.02e-14	3.12e-11	-0.38	-0.34	Alzheimer's disease;	chr3:9949116	chr3:10006418~10011209:-
PRAD	cis	rs496547	0.686	rs487728	ENSG00000255239.1	AP002954.6	7.73	7.02e-14	3.13e-11	0.45	0.34	Hip minimal joint space width;	chr11:118750785	chr11:118688039~118690600:-
PRAD	cis	rs11083475	1	rs3786848	ENSG00000267892.1	CTD-2540F13.2	7.73	7.03e-14	3.13e-11	0.37	0.34	Heart rate;	chr19:38716689	chr19:38738284~38739863:+
PRAD	cis	rs11083475	1	rs8111746	ENSG00000267892.1	CTD-2540F13.2	7.73	7.03e-14	3.13e-11	0.37	0.34	Heart rate;	chr19:38722219	chr19:38738284~38739863:+
PRAD	cis	rs11083475	1	rs3786851	ENSG00000267892.1	CTD-2540F13.2	7.73	7.03e-14	3.13e-11	0.37	0.34	Heart rate;	chr19:38724693	chr19:38738284~38739863:+
PRAD	cis	rs6545883	0.507	rs2442025	ENSG00000271889.1	RP11-493E12.1	-7.73	7.04e-14	3.13e-11	-0.38	-0.34	Tuberculosis;	chr2:61344310	chr2:61151433~61162105:-
PRAD	cis	rs8062405	0.754	rs28410083	ENSG00000251417.2	RP11-1348G14.4	7.73	7.06e-14	3.14e-11	0.38	0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620039	chr16:28802743~28817828:+
PRAD	cis	rs8062405	0.789	rs1968751	ENSG00000251417.2	RP11-1348G14.4	7.73	7.06e-14	3.14e-11	0.38	0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620438	chr16:28802743~28817828:+
PRAD	cis	rs1979679	0.801	rs2881787	ENSG00000278733.1	RP11-425D17.1	-7.73	7.06e-14	3.14e-11	-0.43	-0.34	Ossification of the posterior longitudinal ligament of the spine;	chr12:28145489	chr12:28185625~28186190:-
PRAD	cis	rs6570726	0.967	rs413880	ENSG00000235652.6	RP11-545I5.3	7.73	7.06e-14	3.14e-11	0.36	0.34	Lobe attachment (rater-scored or self-reported);	chr6:145483686	chr6:145799409~145886585:+
PRAD	cis	rs11098499	0.955	rs13129661	ENSG00000245958.5	RP11-33B1.1	-7.73	7.07e-14	3.14e-11	-0.33	-0.34	Corneal astigmatism;	chr4:119231754	chr4:119454791~119552025:+
PRAD	cis	rs7238033	0.624	rs12455090	ENSG00000267193.4	RP11-116O18.3	-7.73	7.07e-14	3.14e-11	-0.37	-0.34	Bladder cancer;	chr18:45733402	chr18:45669367~45747215:-
PRAD	cis	rs2638953	0.925	rs11049520	ENSG00000278733.1	RP11-425D17.1	-7.73	7.07e-14	3.14e-11	-0.43	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28310656	chr12:28185625~28186190:-
PRAD	cis	rs748404	0.697	rs1095389	ENSG00000205771.5	CATSPER2P1	-7.73	7.08e-14	3.15e-11	-0.37	-0.34	Lung cancer;	chr15:43274473	chr15:43726918~43747094:-
PRAD	cis	rs6479901	0.894	rs10740124	ENSG00000232075.1	MRPL35P2	-7.73	7.08e-14	3.15e-11	-0.41	-0.34	Intelligence (multi-trait analysis);	chr10:63426034	chr10:63634317~63634827:-
PRAD	cis	rs6921919	0.778	rs67381177	ENSG00000225595.2	XXbac-BPG308K3.6	7.73	7.09e-14	3.15e-11	0.78	0.34	Autism spectrum disorder or schizophrenia;	chr6:28444164	chr6:28859625~28864630:-
PRAD	cis	rs9467773	0.583	rs2498380	ENSG00000241549.7	GUSBP2	-7.73	7.09e-14	3.15e-11	-0.36	-0.34	Intelligence (multi-trait analysis);	chr6:26643768	chr6:26871484~26956554:-
PRAD	cis	rs6921919	0.673	rs13201681	ENSG00000225595.2	XXbac-BPG308K3.6	7.73	7.12e-14	3.17e-11	0.78	0.34	Autism spectrum disorder or schizophrenia;	chr6:28426903	chr6:28859625~28864630:-
PRAD	cis	rs6991838	0.765	rs4424306	ENSG00000200714.1	Y_RNA	7.73	7.13e-14	3.17e-11	0.35	0.34	Intelligence (multi-trait analysis);	chr8:65618674	chr8:65592731~65592820:+
PRAD	cis	rs8040855	1	rs8040855	ENSG00000259295.5	CSPG4P12	-7.73	7.15e-14	3.18e-11	-0.43	-0.34	Bulimia nervosa;	chr15:85155976	chr15:85191438~85213905:+
PRAD	cis	rs6674176	0.597	rs4660262	ENSG00000237950.1	RP11-7O11.3	7.73	7.17e-14	3.19e-11	0.38	0.34	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43916852	chr1:43944370~43946551:-
PRAD	cis	rs10463554	0.853	rs257309	ENSG00000175749.11	EIF3KP1	7.73	7.17e-14	3.19e-11	0.42	0.34	Parkinson's disease;	chr5:103082900	chr5:103032376~103033031:+
PRAD	cis	rs10129255	0.5	rs8014529	ENSG00000211972.2	IGHV3-66	7.73	7.17e-14	3.19e-11	0.3	0.34	Kawasaki disease;	chr14:106784065	chr14:106675017~106675544:-
PRAD	cis	rs67311347	1	rs112619360	ENSG00000223797.4	ENTPD3-AS1	7.73	7.19e-14	3.2e-11	0.31	0.34	Renal cell carcinoma;	chr3:40391154	chr3:40313802~40453329:-
PRAD	cis	rs1979679	0.918	rs10843176	ENSG00000278733.1	RP11-425D17.1	-7.72	7.2e-14	3.2e-11	-0.45	-0.34	Ossification of the posterior longitudinal ligament of the spine;	chr12:28454984	chr12:28185625~28186190:-
PRAD	cis	rs2933343	0.63	rs75824035	ENSG00000231305.3	RP11-723O4.2	7.72	7.21e-14	3.2e-11	0.32	0.34	IgG glycosylation;	chr3:128934142	chr3:128861313~128871540:-
PRAD	cis	rs6570726	0.902	rs9390326	ENSG00000235652.6	RP11-545I5.3	-7.72	7.21e-14	3.21e-11	-0.36	-0.34	Lobe attachment (rater-scored or self-reported);	chr6:145470086	chr6:145799409~145886585:+
PRAD	cis	rs10510102	0.608	rs4077606	ENSG00000276742.1	RP11-500G22.4	-7.72	7.24e-14	3.22e-11	-0.47	-0.34	Breast cancer;	chr10:121849907	chr10:121956782~121957098:+
PRAD	cis	rs6921919	0.562	rs13198809	ENSG00000225595.2	XXbac-BPG308K3.6	7.72	7.24e-14	3.22e-11	0.75	0.34	Autism spectrum disorder or schizophrenia;	chr6:28355925	chr6:28859625~28864630:-
PRAD	cis	rs10129255	0.5	rs8006888	ENSG00000211972.2	IGHV3-66	7.72	7.25e-14	3.22e-11	0.29	0.34	Kawasaki disease;	chr14:106782219	chr14:106675017~106675544:-
PRAD	cis	rs12653946	0.846	rs4975758	ENSG00000248994.1	RP11-259O2.1	-7.72	7.27e-14	3.23e-11	-0.4	-0.34	Prostate cancer;	chr5:1891060	chr5:1933863~1959176:+
PRAD	cis	rs6547741	0.816	rs10201652	ENSG00000234072.1	AC074117.10	-7.72	7.27e-14	3.23e-11	-0.26	-0.34	Oral cavity cancer;	chr2:27651465	chr2:27356246~27367622:+
PRAD	cis	rs6547741	0.788	rs7595739	ENSG00000234072.1	AC074117.10	-7.72	7.27e-14	3.23e-11	-0.26	-0.34	Oral cavity cancer;	chr2:27651696	chr2:27356246~27367622:+
PRAD	cis	rs7567389	0.504	rs13030463	ENSG00000236682.1	AC068282.3	-7.72	7.28e-14	3.23e-11	-0.46	-0.34	Self-rated health;	chr2:127431295	chr2:127389130~127400580:+
PRAD	cis	rs2255336	0.938	rs12315123	ENSG00000245648.1	RP11-277P12.20	-7.72	7.28e-14	3.24e-11	-0.51	-0.34	Blood protein levels;	chr12:10481540	chr12:10363769~10398506:+
PRAD	cis	rs8062405	0.573	rs6565300	ENSG00000259982.1	CDC37P1	7.72	7.29e-14	3.24e-11	0.48	0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28981728	chr16:28700294~28701540:-
PRAD	cis	rs8091660	1	rs8091660	ENSG00000278983.1	RP11-426J5.3	7.72	7.31e-14	3.25e-11	0.43	0.34	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48561565	chr18:48564795~48568342:+
PRAD	cis	rs853679	0.546	rs34676049	ENSG00000225595.2	XXbac-BPG308K3.6	7.72	7.31e-14	3.25e-11	0.8	0.34	Depression;	chr6:28485841	chr6:28859625~28864630:-
PRAD	cis	rs10463554	0.892	rs62362519	ENSG00000175749.11	EIF3KP1	7.72	7.31e-14	3.25e-11	0.45	0.34	Parkinson's disease;	chr5:102965759	chr5:103032376~103033031:+
PRAD	cis	rs10463554	0.853	rs2241565	ENSG00000175749.11	EIF3KP1	7.72	7.31e-14	3.25e-11	0.45	0.34	Parkinson's disease;	chr5:102966233	chr5:103032376~103033031:+
PRAD	cis	rs1799810	0.523	rs11683986	ENSG00000236682.1	AC068282.3	7.72	7.32e-14	3.25e-11	0.45	0.34	Self-rated health;	chr2:127438822	chr2:127389130~127400580:+
PRAD	cis	rs10463554	0.889	rs246912	ENSG00000175749.11	EIF3KP1	7.72	7.33e-14	3.25e-11	0.46	0.34	Parkinson's disease;	chr5:103225140	chr5:103032376~103033031:+
PRAD	cis	rs2638953	0.889	rs11049481	ENSG00000278733.1	RP11-425D17.1	-7.72	7.33e-14	3.26e-11	-0.43	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28252087	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.962	rs11049482	ENSG00000278733.1	RP11-425D17.1	-7.72	7.33e-14	3.26e-11	-0.43	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28252088	chr12:28185625~28186190:-
PRAD	cis	rs17711722	0.565	rs4275112	ENSG00000275400.1	RP4-756H11.5	7.72	7.36e-14	3.27e-11	0.31	0.34	Calcium levels;	chr7:65733651	chr7:66553805~66554199:-
PRAD	cis	rs526231	0.511	rs28062	ENSG00000175749.11	EIF3KP1	7.72	7.36e-14	3.27e-11	0.47	0.34	Primary biliary cholangitis;	chr5:103204500	chr5:103032376~103033031:+
PRAD	cis	rs5760092	0.618	rs4461358	ENSG00000224205.1	AP000351.4	-7.72	7.37e-14	3.27e-11	-0.47	-0.34	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23917919	chr22:23987320~23991421:-
PRAD	cis	rs6479901	0.947	rs7083823	ENSG00000232075.1	MRPL35P2	-7.72	7.37e-14	3.27e-11	-0.41	-0.34	Intelligence (multi-trait analysis);	chr10:63510912	chr10:63634317~63634827:-
PRAD	cis	rs8042680	1	rs4544218	ENSG00000214432.8	AC068831.10	-7.72	7.37e-14	3.27e-11	-0.41	-0.34	Type 2 diabetes;	chr15:90977143	chr15:91022619~91036611:+
PRAD	cis	rs11098499	0.663	rs9996501	ENSG00000245958.5	RP11-33B1.1	-7.72	7.38e-14	3.28e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119317763	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.697	rs28458294	ENSG00000245958.5	RP11-33B1.1	-7.72	7.38e-14	3.28e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119317769	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.663	rs28369503	ENSG00000245958.5	RP11-33B1.1	-7.72	7.38e-14	3.28e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119317770	chr4:119454791~119552025:+
PRAD	cis	rs507080	0.501	rs637563	ENSG00000255422.1	AP002954.4	-7.72	7.38e-14	3.28e-11	-0.39	-0.34	Serum metabolite levels;	chr11:118704770	chr11:118704607~118750263:+
PRAD	cis	rs1552244	0.554	rs2272122	ENSG00000206567.8	AC022007.5	-7.72	7.38e-14	3.28e-11	-0.38	-0.34	Alzheimer's disease;	chr3:10006291	chr3:10006418~10011209:-
PRAD	cis	rs1150668	0.796	rs728122	ENSG00000280107.1	AL022393.9	-7.72	7.38e-14	3.28e-11	-0.4	-0.34	Pubertal anthropometrics;	chr6:28431347	chr6:28170845~28172521:+
PRAD	cis	rs12908161	1	rs12910012	ENSG00000275120.1	RP11-182J1.17	7.72	7.41e-14	3.29e-11	0.45	0.34	Schizophrenia;	chr15:84755431	chr15:84599434~84606463:-
PRAD	cis	rs12908161	1	rs12899981	ENSG00000275120.1	RP11-182J1.17	7.72	7.41e-14	3.29e-11	0.45	0.34	Schizophrenia;	chr15:84759142	chr15:84599434~84606463:-
PRAD	cis	rs2439831	0.867	rs3101443	ENSG00000249839.1	AC011330.5	-7.72	7.43e-14	3.3e-11	-0.6	-0.34	Lung cancer in ever smokers;	chr15:43620174	chr15:43663654~43684339:-
PRAD	cis	rs12908161	1	rs17600551	ENSG00000275120.1	RP11-182J1.17	7.72	7.44e-14	3.3e-11	0.44	0.34	Schizophrenia;	chr15:84776027	chr15:84599434~84606463:-
PRAD	cis	rs12908161	1	rs62019469	ENSG00000275120.1	RP11-182J1.17	7.72	7.44e-14	3.3e-11	0.44	0.34	Schizophrenia;	chr15:84777989	chr15:84599434~84606463:-
PRAD	cis	rs11083475	1	rs10403540	ENSG00000267892.1	CTD-2540F13.2	7.72	7.45e-14	3.31e-11	0.37	0.34	Heart rate;	chr19:38714206	chr19:38738284~38739863:+
PRAD	cis	rs6723108	0.627	rs3814358	ENSG00000224043.6	CCNT2-AS1	-7.72	7.45e-14	3.31e-11	-0.47	-0.34	Type 2 diabetes;	chr2:134866438	chr2:134735464~134918710:-
PRAD	cis	rs1134634	0.52	rs741180	ENSG00000273133.1	RP11-799M12.2	-7.72	7.46e-14	3.31e-11	-0.45	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15561787	chr4:15563698~15564253:-
PRAD	cis	rs2739330	0.734	rs2000467	ENSG00000224205.1	AP000351.4	-7.72	7.46e-14	3.31e-11	-0.42	-0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23987320~23991421:-
PRAD	cis	rs6479901	0.793	rs7070693	ENSG00000232075.1	MRPL35P2	-7.72	7.47e-14	3.31e-11	-0.42	-0.34	Intelligence (multi-trait analysis);	chr10:63256402	chr10:63634317~63634827:-
PRAD	cis	rs6991838	0.612	rs7842162	ENSG00000200714.1	Y_RNA	7.72	7.48e-14	3.32e-11	0.38	0.34	Intelligence (multi-trait analysis);	chr8:65644057	chr8:65592731~65592820:+
PRAD	cis	rs9341835	0.525	rs2253430	ENSG00000218048.2	RP3-407E4.4	7.72	7.5e-14	3.33e-11	0.38	0.34	Schizophrenia;	chr6:63276607	chr6:63440766~63443580:+
PRAD	cis	rs673078	0.66	rs6490175	ENSG00000275409.1	RP11-131L12.4	-7.72	7.51e-14	3.33e-11	-0.44	-0.34	Glucose homeostasis traits;	chr12:118293559	chr12:118430147~118430699:+
PRAD	cis	rs6991838	0.806	rs11781358	ENSG00000272010.1	CTD-3025N20.3	7.72	7.51e-14	3.33e-11	0.34	0.34	Intelligence (multi-trait analysis);	chr8:65557691	chr8:65591850~65592472:-
PRAD	cis	rs2980439	0.607	rs2980419	ENSG00000253893.2	FAM85B	-7.72	7.52e-14	3.33e-11	-0.43	-0.34	Neuroticism;	chr8:8256619	chr8:8167819~8226614:-
PRAD	cis	rs13631	0.928	rs9411308	ENSG00000268996.3	MAN1B1-AS1	7.72	7.52e-14	3.33e-11	0.34	0.34	Cerebrospinal fluid biomarker levels;	chr9:137105663	chr9:137084946~137086817:-
PRAD	cis	rs12908161	1	rs35808647	ENSG00000275120.1	RP11-182J1.17	7.72	7.53e-14	3.34e-11	0.45	0.34	Schizophrenia;	chr15:84834210	chr15:84599434~84606463:-
PRAD	cis	rs2274273	0.624	rs11848456	ENSG00000258413.1	RP11-665C16.6	-7.72	7.53e-14	3.34e-11	-0.46	-0.34	Protein biomarker;	chr14:55288674	chr14:55262767~55272075:-
PRAD	cis	rs2274273	0.624	rs11848575	ENSG00000258413.1	RP11-665C16.6	-7.72	7.53e-14	3.34e-11	-0.46	-0.34	Protein biomarker;	chr14:55289070	chr14:55262767~55272075:-
PRAD	cis	rs2274273	0.624	rs67386901	ENSG00000258413.1	RP11-665C16.6	-7.72	7.53e-14	3.34e-11	-0.46	-0.34	Protein biomarker;	chr14:55290646	chr14:55262767~55272075:-
PRAD	cis	rs2274273	0.624	rs7140628	ENSG00000258413.1	RP11-665C16.6	-7.72	7.53e-14	3.34e-11	-0.46	-0.34	Protein biomarker;	chr14:55293963	chr14:55262767~55272075:-
PRAD	cis	rs2274273	0.624	rs68138420	ENSG00000258413.1	RP11-665C16.6	-7.72	7.53e-14	3.34e-11	-0.46	-0.34	Protein biomarker;	chr14:55311249	chr14:55262767~55272075:-
PRAD	cis	rs2274273	0.624	rs4580079	ENSG00000258413.1	RP11-665C16.6	-7.72	7.53e-14	3.34e-11	-0.46	-0.34	Protein biomarker;	chr14:55313648	chr14:55262767~55272075:-
PRAD	cis	rs11976180	1	rs2961117	ENSG00000273234.1	OR2A13P	-7.72	7.54e-14	3.34e-11	-0.41	-0.34	Obesity-related traits;	chr7:144058160	chr7:144142009~144142938:+
PRAD	cis	rs748404	0.697	rs505249	ENSG00000205771.5	CATSPER2P1	-7.72	7.55e-14	3.35e-11	-0.37	-0.34	Lung cancer;	chr15:43267762	chr15:43726918~43747094:-
PRAD	cis	rs7829975	0.606	rs11776838	ENSG00000253893.2	FAM85B	7.72	7.57e-14	3.35e-11	0.42	0.34	Mood instability;	chr8:8937291	chr8:8167819~8226614:-
PRAD	cis	rs17772222	0.682	rs1864744	ENSG00000258983.2	RP11-507K2.2	-7.72	7.57e-14	3.35e-11	-0.44	-0.34	Coronary artery calcification;	chr14:88484662	chr14:88499334~88515502:+
PRAD	cis	rs9467773	0.62	rs2451738	ENSG00000241549.7	GUSBP2	-7.72	7.58e-14	3.36e-11	-0.36	-0.34	Intelligence (multi-trait analysis);	chr6:26618231	chr6:26871484~26956554:-
PRAD	cis	rs526231	0.543	rs34804	ENSG00000175749.11	EIF3KP1	7.72	7.58e-14	3.36e-11	0.49	0.34	Primary biliary cholangitis;	chr5:103092535	chr5:103032376~103033031:+
PRAD	cis	rs172166	0.637	rs1071893	ENSG00000204709.4	LINC01556	7.72	7.59e-14	3.37e-11	0.44	0.34	Cardiac Troponin-T levels;	chr6:28199857	chr6:28943877~28944537:+
PRAD	cis	rs2274273	1	rs67098772	ENSG00000258413.1	RP11-665C16.6	-7.72	7.6e-14	3.37e-11	-0.44	-0.34	Protein biomarker;	chr14:55128524	chr14:55262767~55272075:-
PRAD	cis	rs9467773	0.62	rs9467810	ENSG00000241549.7	GUSBP2	7.72	7.6e-14	3.37e-11	0.35	0.34	Intelligence (multi-trait analysis);	chr6:26608033	chr6:26871484~26956554:-
PRAD	cis	rs17772222	0.958	rs1816372	ENSG00000258983.2	RP11-507K2.2	7.72	7.61e-14	3.37e-11	0.49	0.34	Coronary artery calcification;	chr14:88507033	chr14:88499334~88515502:+
PRAD	cis	rs494459	0.838	rs607125	ENSG00000278376.1	RP11-158I9.8	-7.72	7.61e-14	3.37e-11	-0.29	-0.34	Height;	chr11:118746590	chr11:118791254~118793137:+
PRAD	cis	rs6782228	0.606	rs10048945	ENSG00000242551.2	POU5F1P6	-7.72	7.61e-14	3.37e-11	-0.43	-0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128690837	chr3:128674735~128677005:-
PRAD	cis	rs853679	1	rs2799077	ENSG00000226314.6	ZNF192P1	-7.72	7.63e-14	3.38e-11	-0.53	-0.34	Depression;	chr6:28266819	chr6:28161781~28169594:+
PRAD	cis	rs2274273	0.588	rs9323285	ENSG00000258413.1	RP11-665C16.6	7.72	7.65e-14	3.39e-11	0.46	0.34	Protein biomarker;	chr14:55397111	chr14:55262767~55272075:-
PRAD	cis	rs2274273	1	rs67805055	ENSG00000258413.1	RP11-665C16.6	-7.72	7.66e-14	3.39e-11	-0.44	-0.34	Protein biomarker;	chr14:55120834	chr14:55262767~55272075:-
PRAD	cis	rs2274273	1	rs3825613	ENSG00000258413.1	RP11-665C16.6	-7.72	7.66e-14	3.39e-11	-0.44	-0.34	Protein biomarker;	chr14:55126454	chr14:55262767~55272075:-
PRAD	cis	rs2019137	0.589	rs7560701	ENSG00000274877.1	RP11-65I12.1	-7.72	7.66e-14	3.39e-11	-0.44	-0.34	Lymphocyte counts;	chr2:113269305	chr2:113237595~113240825:+
PRAD	cis	rs853679	0.545	rs35949109	ENSG00000280107.1	AL022393.9	-7.72	7.69e-14	3.41e-11	-0.62	-0.34	Depression;	chr6:28058148	chr6:28170845~28172521:+
PRAD	cis	rs12908161	0.959	rs3748376	ENSG00000275120.1	RP11-182J1.17	7.72	7.7e-14	3.41e-11	0.45	0.34	Schizophrenia;	chr15:84785121	chr15:84599434~84606463:-
PRAD	cis	rs7567389	0.677	rs72845991	ENSG00000236682.1	AC068282.3	-7.71	7.73e-14	3.42e-11	-0.45	-0.34	Self-rated health;	chr2:127350331	chr2:127389130~127400580:+
PRAD	cis	rs7567389	0.671	rs11692990	ENSG00000236682.1	AC068282.3	-7.71	7.73e-14	3.42e-11	-0.45	-0.34	Self-rated health;	chr2:127354614	chr2:127389130~127400580:+
PRAD	cis	rs748404	0.697	rs493444	ENSG00000205771.5	CATSPER2P1	-7.71	7.74e-14	3.43e-11	-0.37	-0.34	Lung cancer;	chr15:43274272	chr15:43726918~43747094:-
PRAD	cis	rs10463554	1	rs56372231	ENSG00000175749.11	EIF3KP1	7.71	7.77e-14	3.44e-11	0.43	0.34	Parkinson's disease;	chr5:102986201	chr5:103032376~103033031:+
PRAD	cis	rs2638953	0.777	rs11049363	ENSG00000278733.1	RP11-425D17.1	-7.71	7.77e-14	3.44e-11	-0.46	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28136270	chr12:28185625~28186190:-
PRAD	cis	rs9393777	0.92	rs34071253	ENSG00000280107.1	AL022393.9	-7.71	7.78e-14	3.45e-11	-0.64	-0.34	Intelligence (multi-trait analysis);	chr6:27424023	chr6:28170845~28172521:+
PRAD	cis	rs1061377	0.965	rs12504238	ENSG00000249685.1	RP11-360F5.3	7.71	7.79e-14	3.45e-11	0.39	0.34	Uric acid levels;	chr4:39142824	chr4:39133913~39135608:+
PRAD	cis	rs4631830	0.72	rs2125771	ENSG00000230869.1	CTGLF10P	-7.71	7.79e-14	3.45e-11	-0.42	-0.34	Prostate-specific antigen levels;	chr10:46088865	chr10:45678692~45700532:+
PRAD	cis	rs11098499	0.754	rs1814813	ENSG00000245958.5	RP11-33B1.1	7.71	7.81e-14	3.46e-11	0.32	0.34	Corneal astigmatism;	chr4:119337052	chr4:119454791~119552025:+
PRAD	cis	rs73607972	0.66	rs9923447	ENSG00000275191.1	RP11-36I17.2	-7.71	7.83e-14	3.47e-11	-0.47	-0.34	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53609191	chr16:53628256~53628816:-
PRAD	cis	rs7238033	0.663	rs17675121	ENSG00000267193.4	RP11-116O18.3	7.71	7.85e-14	3.47e-11	0.36	0.34	Bladder cancer;	chr18:45738220	chr18:45669367~45747215:-
PRAD	cis	rs11846409	0.86	rs4774167	ENSG00000274576.2	IGHV2-70	-7.71	7.85e-14	3.47e-11	-0.37	-0.34	Rheumatic heart disease;	chr14:106619987	chr14:106770577~106771020:-
PRAD	cis	rs10129255	0.642	rs11624918	ENSG00000211970.3	IGHV4-61	-7.71	7.85e-14	3.47e-11	-0.33	-0.34	Kawasaki disease;	chr14:106664672	chr14:106639119~106639657:-
PRAD	cis	rs6479901	0.841	rs10761721	ENSG00000232075.1	MRPL35P2	-7.71	7.87e-14	3.48e-11	-0.41	-0.34	Intelligence (multi-trait analysis);	chr10:63178644	chr10:63634317~63634827:-
PRAD	cis	rs6479901	0.895	rs3211105	ENSG00000232075.1	MRPL35P2	-7.71	7.87e-14	3.48e-11	-0.41	-0.34	Intelligence (multi-trait analysis);	chr10:63185604	chr10:63634317~63634827:-
PRAD	cis	rs12468226	0.938	rs16841867	ENSG00000273456.1	RP11-686O6.2	7.71	7.88e-14	3.49e-11	0.47	0.34	Urate levels;	chr2:202303512	chr2:202374932~202375604:-
PRAD	cis	rs12468226	0.938	rs79117531	ENSG00000273456.1	RP11-686O6.2	7.71	7.88e-14	3.49e-11	0.47	0.34	Urate levels;	chr2:202307690	chr2:202374932~202375604:-
PRAD	cis	rs12468226	0.938	rs16839065	ENSG00000273456.1	RP11-686O6.2	7.71	7.88e-14	3.49e-11	0.47	0.34	Urate levels;	chr2:202308774	chr2:202374932~202375604:-
PRAD	cis	rs12468226	0.938	rs114922024	ENSG00000273456.1	RP11-686O6.2	7.71	7.88e-14	3.49e-11	0.47	0.34	Urate levels;	chr2:202315958	chr2:202374932~202375604:-
PRAD	cis	rs12468226	0.938	rs77261109	ENSG00000273456.1	RP11-686O6.2	7.71	7.88e-14	3.49e-11	0.47	0.34	Urate levels;	chr2:202316233	chr2:202374932~202375604:-
PRAD	cis	rs12468226	0.938	rs12466003	ENSG00000273456.1	RP11-686O6.2	7.71	7.88e-14	3.49e-11	0.47	0.34	Urate levels;	chr2:202317317	chr2:202374932~202375604:-
PRAD	cis	rs12468226	0.938	rs76501067	ENSG00000273456.1	RP11-686O6.2	7.71	7.88e-14	3.49e-11	0.47	0.34	Urate levels;	chr2:202318042	chr2:202374932~202375604:-
PRAD	cis	rs12908161	0.92	rs35758837	ENSG00000275120.1	RP11-182J1.17	7.71	7.88e-14	3.49e-11	0.45	0.34	Schizophrenia;	chr15:84768151	chr15:84599434~84606463:-
PRAD	cis	rs12908161	1	rs36033486	ENSG00000275120.1	RP11-182J1.17	7.71	7.88e-14	3.49e-11	0.45	0.34	Schizophrenia;	chr15:84776461	chr15:84599434~84606463:-
PRAD	cis	rs12908161	1	rs12908549	ENSG00000275120.1	RP11-182J1.17	7.71	7.88e-14	3.49e-11	0.45	0.34	Schizophrenia;	chr15:84779120	chr15:84599434~84606463:-
PRAD	cis	rs12908161	0.959	rs1051168	ENSG00000275120.1	RP11-182J1.17	7.71	7.9e-14	3.49e-11	0.43	0.34	Schizophrenia;	chr15:84657289	chr15:84599434~84606463:-
PRAD	cis	rs2638953	0.924	rs11049386	ENSG00000278733.1	RP11-425D17.1	-7.71	7.9e-14	3.49e-11	-0.43	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28167603	chr12:28185625~28186190:-
PRAD	cis	rs6452524	0.836	rs4343818	ENSG00000249664.1	CTD-2227C6.2	7.71	7.91e-14	3.5e-11	0.42	0.34	Hypertension (SNP x SNP interaction);	chr5:83205603	chr5:83012285~83013109:-
PRAD	cis	rs240993	0.715	rs7742724	ENSG00000230177.1	RP5-1112D6.4	7.71	7.91e-14	3.5e-11	0.4	0.34	Inflammatory skin disease;Psoriasis;	chr6:111517816	chr6:111277932~111278742:+
PRAD	cis	rs9309473	0.607	rs10196402	ENSG00000163016.8	ALMS1P	7.71	7.91e-14	3.5e-11	0.42	0.34	Metabolite levels;	chr2:73344953	chr2:73644919~73685576:+
PRAD	cis	rs17361889	0.752	rs62440451	ENSG00000224683.1	RPL36AP29	7.71	7.92e-14	3.5e-11	0.4	0.34	Pediatric bone mineral content (hip);	chr7:16259676	chr7:16208945~16209265:+
PRAD	cis	rs9640161	0.659	rs7788316	ENSG00000261305.1	RP4-584D14.7	7.71	7.92e-14	3.51e-11	0.37	0.34	Blood protein levels;Circulating chemerin levels;	chr7:150316906	chr7:150341771~150342607:+
PRAD	cis	rs6908034	0.66	rs7746588	ENSG00000228412.5	RP4-625H18.2	7.71	7.93e-14	3.51e-11	0.66	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19804409	chr6:19802164~19804752:-
PRAD	cis	rs6908034	0.66	rs7750716	ENSG00000228412.5	RP4-625H18.2	7.71	7.93e-14	3.51e-11	0.66	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19804608	chr6:19802164~19804752:-
PRAD	cis	rs2439831	0.85	rs28590651	ENSG00000249839.1	AC011330.5	-7.71	7.95e-14	3.52e-11	-0.58	-0.34	Lung cancer in ever smokers;	chr15:43820818	chr15:43663654~43684339:-
PRAD	cis	rs673078	0.607	rs17440956	ENSG00000275409.1	RP11-131L12.4	7.71	7.96e-14	3.52e-11	0.49	0.34	Glucose homeostasis traits;	chr12:118394639	chr12:118430147~118430699:+
PRAD	cis	rs17711722	0.522	rs4642526	ENSG00000275400.1	RP4-756H11.5	-7.71	7.97e-14	3.53e-11	-0.31	-0.34	Calcium levels;	chr7:65751755	chr7:66553805~66554199:-
PRAD	cis	rs1426063	1	rs10026801	ENSG00000249717.1	RP11-44F21.3	7.71	7.98e-14	3.53e-11	0.57	0.34	QT interval;	chr4:75103167	chr4:74955974~74970362:-
PRAD	cis	rs9341835	0.525	rs1723518	ENSG00000218048.2	RP3-407E4.4	-7.71	8e-14	3.54e-11	-0.38	-0.34	Schizophrenia;	chr6:63274355	chr6:63440766~63443580:+
PRAD	cis	rs7829975	0.714	rs7823757	ENSG00000253893.2	FAM85B	-7.71	8.01e-14	3.54e-11	-0.43	-0.34	Mood instability;	chr8:8812667	chr8:8167819~8226614:-
PRAD	cis	rs42648	0.564	rs11763820	ENSG00000227646.6	STEAP2-AS1	-7.71	8.03e-14	3.55e-11	-0.3	-0.34	Homocysteine levels;	chr7:90189631	chr7:89882353~90211635:-
PRAD	cis	rs42648	0.564	rs6465244	ENSG00000227646.6	STEAP2-AS1	-7.71	8.03e-14	3.55e-11	-0.3	-0.34	Homocysteine levels;	chr7:90191568	chr7:89882353~90211635:-
PRAD	cis	rs8062405	0.755	rs56209193	ENSG00000251417.2	RP11-1348G14.4	-7.71	8.04e-14	3.55e-11	-0.38	-0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574315	chr16:28802743~28817828:+
PRAD	cis	rs193541	0.545	rs12518979	ENSG00000263432.2	RN7SL689P	-7.71	8.04e-14	3.55e-11	-0.36	-0.34	Glucose homeostasis traits;	chr5:122846092	chr5:123022487~123022783:-
PRAD	cis	rs435066	0.633	rs912499	ENSG00000234264.1	DEPDC1-AS1	-7.71	8.06e-14	3.56e-11	-0.5	-0.34	IgG glycosylation;	chr1:68537899	chr1:68496676~68538627:+
PRAD	cis	rs12612619	0.732	rs11679069	ENSG00000229122.1	AGBL5-IT1	7.71	8.06e-14	3.56e-11	0.35	0.34	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27047443	chr2:27061038~27061815:+
PRAD	cis	rs2638953	0.962	rs11049514	ENSG00000278733.1	RP11-425D17.1	-7.71	8.08e-14	3.57e-11	-0.44	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28299461	chr12:28185625~28186190:-
PRAD	cis	rs853679	0.546	rs36092177	ENSG00000225595.2	XXbac-BPG308K3.6	7.71	8.1e-14	3.58e-11	0.75	0.34	Depression;	chr6:28390030	chr6:28859625~28864630:-
PRAD	cis	rs853679	0.546	rs2232429	ENSG00000225595.2	XXbac-BPG308K3.6	7.71	8.1e-14	3.58e-11	0.75	0.34	Depression;	chr6:28391855	chr6:28859625~28864630:-
PRAD	cis	rs853679	0.546	rs2232426	ENSG00000225595.2	XXbac-BPG308K3.6	7.71	8.1e-14	3.58e-11	0.75	0.34	Depression;	chr6:28392882	chr6:28859625~28864630:-
PRAD	cis	rs853679	0.546	rs2232423	ENSG00000225595.2	XXbac-BPG308K3.6	7.71	8.1e-14	3.58e-11	0.75	0.34	Depression;	chr6:28398374	chr6:28859625~28864630:-
PRAD	cis	rs11098499	0.954	rs11098524	ENSG00000245958.5	RP11-33B1.1	-7.71	8.12e-14	3.59e-11	-0.33	-0.34	Corneal astigmatism;	chr4:119468877	chr4:119454791~119552025:+
PRAD	cis	rs853679	0.567	rs1005126	ENSG00000204709.4	LINC01556	7.71	8.14e-14	3.6e-11	0.47	0.34	Depression;	chr6:28399846	chr6:28943877~28944537:+
PRAD	cis	rs6545883	0.507	rs62149712	ENSG00000271889.1	RP11-493E12.1	-7.71	8.15e-14	3.6e-11	-0.37	-0.34	Tuberculosis;	chr2:61374137	chr2:61151433~61162105:-
PRAD	cis	rs858239	0.669	rs12539467	ENSG00000226816.2	AC005082.12	7.71	8.15e-14	3.6e-11	0.4	0.34	Cerebrospinal fluid biomarker levels;	chr7:23076240	chr7:23206013~23208045:+
PRAD	cis	rs56114371	0.53	rs9348774	ENSG00000280107.1	AL022393.9	-7.71	8.16e-14	3.61e-11	-0.46	-0.34	Breast cancer;	chr6:27721151	chr6:28170845~28172521:+
PRAD	cis	rs2274273	0.624	rs72717738	ENSG00000258413.1	RP11-665C16.6	-7.71	8.16e-14	3.61e-11	-0.46	-0.34	Protein biomarker;	chr14:55376043	chr14:55262767~55272075:-
PRAD	cis	rs638893	0.673	rs538645	ENSG00000278376.1	RP11-158I9.8	7.71	8.2e-14	3.62e-11	0.34	0.34	Vitiligo;	chr11:118840360	chr11:118791254~118793137:+
PRAD	cis	rs853679	0.567	rs3799499	ENSG00000204709.4	LINC01556	7.71	8.2e-14	3.62e-11	0.47	0.34	Depression;	chr6:28386473	chr6:28943877~28944537:+
PRAD	cis	rs853679	0.567	rs2232427	ENSG00000204709.4	LINC01556	7.71	8.2e-14	3.62e-11	0.47	0.34	Depression;	chr6:28391932	chr6:28943877~28944537:+
PRAD	cis	rs6565180	0.962	rs6565182	ENSG00000183604.13	SMG1P5	-7.71	8.21e-14	3.63e-11	-0.33	-0.34	Tonsillectomy;	chr16:30363060	chr16:30267553~30335374:-
PRAD	cis	rs1799949	0.965	rs33961729	ENSG00000267002.1	RP11-242D8.1	7.71	8.22e-14	3.63e-11	0.32	0.34	Menopause (age at onset);	chr17:43135907	chr17:43164183~43170403:-
PRAD	cis	rs1799949	1	rs11657835	ENSG00000267002.1	RP11-242D8.1	7.71	8.22e-14	3.63e-11	0.32	0.34	Menopause (age at onset);	chr17:43139936	chr17:43164183~43170403:-
PRAD	cis	rs1799949	1	rs1135214	ENSG00000267002.1	RP11-242D8.1	7.71	8.22e-14	3.63e-11	0.32	0.34	Menopause (age at onset);	chr17:43140306	chr17:43164183~43170403:-
PRAD	cis	rs1799949	1	rs4793212	ENSG00000267002.1	RP11-242D8.1	7.71	8.22e-14	3.63e-11	0.32	0.34	Menopause (age at onset);	chr17:43150733	chr17:43164183~43170403:-
PRAD	cis	rs1799949	1	rs34534709	ENSG00000267002.1	RP11-242D8.1	7.71	8.22e-14	3.63e-11	0.32	0.34	Menopause (age at onset);	chr17:43150923	chr17:43164183~43170403:-
PRAD	cis	rs1799949	1	rs34059614	ENSG00000267002.1	RP11-242D8.1	7.71	8.22e-14	3.63e-11	0.32	0.34	Menopause (age at onset);	chr17:43151054	chr17:43164183~43170403:-
PRAD	cis	rs2739330	0.685	rs4822453	ENSG00000099984.9	GSTT2	-7.71	8.23e-14	3.63e-11	-0.44	-0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23980123~23983911:+
PRAD	cis	rs853679	0.546	rs200954	ENSG00000280107.1	AL022393.9	-7.71	8.23e-14	3.63e-11	-0.6	-0.34	Depression;	chr6:27870986	chr6:28170845~28172521:+
PRAD	cis	rs6061231	0.546	rs482220	ENSG00000273619.1	RP5-908M14.9	7.71	8.23e-14	3.63e-11	0.22	0.34	Colorectal cancer;	chr20:62352426	chr20:62386303~62386970:-
PRAD	cis	rs4845570	1	rs6681093	ENSG00000268288.1	RP11-98D18.16	7.71	8.24e-14	3.64e-11	0.55	0.34	Coronary artery disease;	chr1:151782808	chr1:151766486~151767000:-
PRAD	cis	rs7829975	0.714	rs11777085	ENSG00000253893.2	FAM85B	-7.71	8.24e-14	3.64e-11	-0.44	-0.34	Mood instability;	chr8:8814919	chr8:8167819~8226614:-
PRAD	cis	rs8177376	0.861	rs604255	ENSG00000254905.1	RP11-712L6.7	7.71	8.25e-14	3.64e-11	0.43	0.34	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126327131	chr11:126292922~126294254:-
PRAD	cis	rs1150668	0.796	rs2531825	ENSG00000280107.1	AL022393.9	-7.7	8.28e-14	3.66e-11	-0.4	-0.34	Pubertal anthropometrics;	chr6:28381487	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.546	rs200948	ENSG00000280107.1	AL022393.9	-7.7	8.3e-14	3.66e-11	-0.6	-0.34	Depression;	chr6:27867494	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.546	rs200950	ENSG00000280107.1	AL022393.9	-7.7	8.3e-14	3.66e-11	-0.6	-0.34	Depression;	chr6:27867994	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.546	rs200952	ENSG00000280107.1	AL022393.9	-7.7	8.3e-14	3.66e-11	-0.6	-0.34	Depression;	chr6:27869198	chr6:28170845~28172521:+
PRAD	cis	rs748404	0.697	rs530188	ENSG00000205771.5	CATSPER2P1	-7.7	8.3e-14	3.66e-11	-0.37	-0.34	Lung cancer;	chr15:43253116	chr15:43726918~43747094:-
PRAD	cis	rs748404	0.697	rs475227	ENSG00000205771.5	CATSPER2P1	-7.7	8.3e-14	3.66e-11	-0.37	-0.34	Lung cancer;	chr15:43254248	chr15:43726918~43747094:-
PRAD	cis	rs12612619	0.652	rs2011616	ENSG00000272148.1	RP11-195B17.1	-7.7	8.32e-14	3.67e-11	-0.41	-0.34	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27079693	chr2:27062428~27062907:-
PRAD	cis	rs964611	0.882	rs60899194	ENSG00000259488.2	RP11-154J22.1	-7.7	8.32e-14	3.67e-11	-0.32	-0.34	Metabolite levels (Pyroglutamine);	chr15:48290763	chr15:48312353~48331856:-
PRAD	cis	rs3096299	0.967	rs2965827	ENSG00000261118.1	RP11-104N10.1	-7.7	8.33e-14	3.68e-11	-0.33	-0.34	Multiple myeloma (IgH translocation);	chr16:89390942	chr16:89492017~89504460:-
PRAD	cis	rs2404602	0.536	rs17364330	ENSG00000259422.1	RP11-593F23.1	7.7	8.34e-14	3.68e-11	0.42	0.34	Blood metabolite levels;	chr15:76473044	chr15:76174891~76181486:-
PRAD	cis	rs5769707	0.542	rs739242	ENSG00000188511.11	C22orf34	7.7	8.36e-14	3.69e-11	0.4	0.34	Monocyte percentage of white cells;Monocyte count;	chr22:49663468	chr22:49414524~49657542:-
PRAD	cis	rs5769707	0.521	rs7285764	ENSG00000188511.11	C22orf34	7.7	8.36e-14	3.69e-11	0.4	0.34	Monocyte percentage of white cells;Monocyte count;	chr22:49664913	chr22:49414524~49657542:-
PRAD	cis	rs5769707	0.521	rs9616715	ENSG00000188511.11	C22orf34	7.7	8.36e-14	3.69e-11	0.4	0.34	Monocyte percentage of white cells;Monocyte count;	chr22:49664934	chr22:49414524~49657542:-
PRAD	cis	rs5769707	0.521	rs6009805	ENSG00000188511.11	C22orf34	7.7	8.36e-14	3.69e-11	0.4	0.34	Monocyte percentage of white cells;Monocyte count;	chr22:49665067	chr22:49414524~49657542:-
PRAD	cis	rs5769707	0.521	rs6009807	ENSG00000188511.11	C22orf34	7.7	8.36e-14	3.69e-11	0.4	0.34	Monocyte percentage of white cells;Monocyte count;	chr22:49665274	chr22:49414524~49657542:-
PRAD	cis	rs2638953	0.962	rs11049484	ENSG00000278733.1	RP11-425D17.1	-7.7	8.37e-14	3.69e-11	-0.43	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28252254	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.962	rs11049485	ENSG00000278733.1	RP11-425D17.1	-7.7	8.37e-14	3.69e-11	-0.43	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28252522	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.962	rs10843143	ENSG00000278733.1	RP11-425D17.1	-7.7	8.37e-14	3.69e-11	-0.43	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28253484	chr12:28185625~28186190:-
PRAD	cis	rs4664293	1	rs6753181	ENSG00000226266.5	AC009961.3	-7.7	8.37e-14	3.69e-11	-0.44	-0.34	Monocyte percentage of white cells;	chr2:159635927	chr2:159670708~159712435:-
PRAD	cis	rs2243480	1	rs781156	ENSG00000226824.5	RP4-756H11.3	-7.7	8.4e-14	3.7e-11	-0.66	-0.34	Diabetic kidney disease;	chr7:66014154	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs451396	ENSG00000226824.5	RP4-756H11.3	-7.7	8.4e-14	3.7e-11	-0.66	-0.34	Diabetic kidney disease;	chr7:66019087	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs1715235	ENSG00000226824.5	RP4-756H11.3	-7.7	8.4e-14	3.7e-11	-0.66	-0.34	Diabetic kidney disease;	chr7:66023407	chr7:66654538~66669855:+
PRAD	cis	rs6570726	0.967	rs373527	ENSG00000235652.6	RP11-545I5.3	7.7	8.4e-14	3.7e-11	0.36	0.34	Lobe attachment (rater-scored or self-reported);	chr6:145480725	chr6:145799409~145886585:+
PRAD	cis	rs3096299	0.967	rs28575874	ENSG00000261118.1	RP11-104N10.1	7.7	8.4e-14	3.71e-11	0.33	0.34	Multiple myeloma (IgH translocation);	chr16:89403482	chr16:89492017~89504460:-
PRAD	cis	rs2739330	0.731	rs5751792	ENSG00000272787.1	KB-226F1.2	-7.7	8.42e-14	3.71e-11	-0.36	-0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23969211~23969873:+
PRAD	cis	rs2739330	0.761	rs5760176	ENSG00000272787.1	KB-226F1.2	7.7	8.42e-14	3.71e-11	0.36	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23969211~23969873:+
PRAD	cis	rs17361889	0.778	rs6963052	ENSG00000224683.1	RPL36AP29	7.7	8.42e-14	3.71e-11	0.39	0.34	Pediatric bone mineral content (hip);	chr7:16171904	chr7:16208945~16209265:+
PRAD	cis	rs2243480	1	rs1964692	ENSG00000226824.5	RP4-756H11.3	-7.7	8.42e-14	3.72e-11	-0.66	-0.34	Diabetic kidney disease;	chr7:65989196	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs1723267	ENSG00000226824.5	RP4-756H11.3	-7.7	8.42e-14	3.72e-11	-0.66	-0.34	Diabetic kidney disease;	chr7:66008327	chr7:66654538~66669855:+
PRAD	cis	rs17361889	0.778	rs2214626	ENSG00000224683.1	RPL36AP29	7.7	8.43e-14	3.72e-11	0.41	0.34	Pediatric bone mineral content (hip);	chr7:16276027	chr7:16208945~16209265:+
PRAD	cis	rs17772222	0.958	rs76559451	ENSG00000258983.2	RP11-507K2.2	7.7	8.43e-14	3.72e-11	0.49	0.34	Coronary artery calcification;	chr14:88523193	chr14:88499334~88515502:+
PRAD	cis	rs17772222	0.958	rs12436326	ENSG00000258983.2	RP11-507K2.2	7.7	8.43e-14	3.72e-11	0.49	0.34	Coronary artery calcification;	chr14:88533632	chr14:88499334~88515502:+
PRAD	cis	rs17772222	0.958	rs17203789	ENSG00000258983.2	RP11-507K2.2	7.7	8.43e-14	3.72e-11	0.49	0.34	Coronary artery calcification;	chr14:88541362	chr14:88499334~88515502:+
PRAD	cis	rs6847067	0.8	rs10029496	ENSG00000180769.7	WDFY3-AS2	7.7	8.44e-14	3.72e-11	0.36	0.34	Oropharynx cancer;	chr4:84903079	chr4:84965682~85011277:+
PRAD	cis	rs12612619	0.677	rs2053386	ENSG00000229122.1	AGBL5-IT1	7.7	8.45e-14	3.73e-11	0.36	0.34	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27021844	chr2:27061038~27061815:+
PRAD	cis	rs2439831	0.85	rs3736180	ENSG00000249839.1	AC011330.5	-7.7	8.46e-14	3.73e-11	-0.59	-0.34	Lung cancer in ever smokers;	chr15:43814426	chr15:43663654~43684339:-
PRAD	cis	rs2933343	0.729	rs1683780	ENSG00000231305.3	RP11-723O4.2	7.7	8.48e-14	3.74e-11	0.31	0.34	IgG glycosylation;	chr3:128921396	chr3:128861313~128871540:-
PRAD	cis	rs858239	0.6	rs6967475	ENSG00000226816.2	AC005082.12	7.7	8.48e-14	3.74e-11	0.39	0.34	Cerebrospinal fluid biomarker levels;	chr7:23089363	chr7:23206013~23208045:+
PRAD	cis	rs74024059	1	rs74024043	ENSG00000260685.1	RP11-326L17.1	7.7	8.53e-14	3.76e-11	0.91	0.34	Red blood cell count;Hematocrit;	chr15:75988539	chr15:75950464~75951144:-
PRAD	cis	rs1043099	0.571	rs5749082	ENSG00000279699.1	RP1-102K2.9	-7.7	8.54e-14	3.76e-11	-0.43	-0.34	Rheumatoid arthritis;	chr22:30374614	chr22:30275215~30276951:-
PRAD	cis	rs2274273	0.624	rs10143136	ENSG00000258413.1	RP11-665C16.6	-7.7	8.55e-14	3.77e-11	-0.46	-0.34	Protein biomarker;	chr14:55276810	chr14:55262767~55272075:-
PRAD	cis	rs7429990	0.932	rs6442101	ENSG00000229759.1	MRPS18AP1	-7.7	8.57e-14	3.78e-11	-0.35	-0.34	Educational attainment (years of education);	chr3:48089403	chr3:48256350~48256938:-
PRAD	cis	rs12468226	1	rs113877751	ENSG00000273456.1	RP11-686O6.2	7.7	8.6e-14	3.79e-11	0.46	0.34	Urate levels;	chr2:202329998	chr2:202374932~202375604:-
PRAD	cis	rs12468226	0.935	rs113021930	ENSG00000273456.1	RP11-686O6.2	7.7	8.6e-14	3.79e-11	0.46	0.34	Urate levels;	chr2:202330448	chr2:202374932~202375604:-
PRAD	cis	rs12468226	1	rs113491584	ENSG00000273456.1	RP11-686O6.2	7.7	8.6e-14	3.79e-11	0.46	0.34	Urate levels;	chr2:202331724	chr2:202374932~202375604:-
PRAD	cis	rs12468226	1	rs112306637	ENSG00000273456.1	RP11-686O6.2	7.7	8.6e-14	3.79e-11	0.46	0.34	Urate levels;	chr2:202334195	chr2:202374932~202375604:-
PRAD	cis	rs12468226	1	rs111252524	ENSG00000273456.1	RP11-686O6.2	7.7	8.6e-14	3.79e-11	0.46	0.34	Urate levels;	chr2:202334465	chr2:202374932~202375604:-
PRAD	cis	rs12468226	1	rs112753638	ENSG00000273456.1	RP11-686O6.2	7.7	8.6e-14	3.79e-11	0.46	0.34	Urate levels;	chr2:202334496	chr2:202374932~202375604:-
PRAD	cis	rs12468226	0.935	rs113188021	ENSG00000273456.1	RP11-686O6.2	7.7	8.6e-14	3.79e-11	0.46	0.34	Urate levels;	chr2:202336237	chr2:202374932~202375604:-
PRAD	cis	rs12468226	1	rs6731027	ENSG00000273456.1	RP11-686O6.2	7.7	8.6e-14	3.79e-11	0.46	0.34	Urate levels;	chr2:202337443	chr2:202374932~202375604:-
PRAD	cis	rs12908161	1	rs35630683	ENSG00000275120.1	RP11-182J1.17	7.7	8.63e-14	3.8e-11	0.44	0.34	Schizophrenia;	chr15:84806000	chr15:84599434~84606463:-
PRAD	cis	rs10463554	0.892	rs1561404	ENSG00000175749.11	EIF3KP1	7.7	8.65e-14	3.81e-11	0.45	0.34	Parkinson's disease;	chr5:102963647	chr5:103032376~103033031:+
PRAD	cis	rs12931792	0.712	rs56399904	ENSG00000183604.13	SMG1P5	7.7	8.66e-14	3.81e-11	0.29	0.34	Tonsillectomy;	chr16:30154862	chr16:30267553~30335374:-
PRAD	cis	rs10510102	0.608	rs4486560	ENSG00000276742.1	RP11-500G22.4	7.7	8.66e-14	3.81e-11	0.46	0.34	Breast cancer;	chr10:121844840	chr10:121956782~121957098:+
PRAD	cis	rs6479901	0.895	rs1904296	ENSG00000232075.1	MRPL35P2	-7.7	8.67e-14	3.82e-11	-0.41	-0.34	Intelligence (multi-trait analysis);	chr10:63173019	chr10:63634317~63634827:-
PRAD	cis	rs748404	0.65	rs556851	ENSG00000205771.5	CATSPER2P1	-7.7	8.67e-14	3.82e-11	-0.37	-0.34	Lung cancer;	chr15:43279021	chr15:43726918~43747094:-
PRAD	cis	rs748404	0.697	rs567357	ENSG00000205771.5	CATSPER2P1	-7.7	8.67e-14	3.82e-11	-0.37	-0.34	Lung cancer;	chr15:43279192	chr15:43726918~43747094:-
PRAD	cis	rs10129255	0.518	rs10136903	ENSG00000211972.2	IGHV3-66	7.7	8.69e-14	3.82e-11	0.29	0.34	Kawasaki disease;	chr14:106778866	chr14:106675017~106675544:-
PRAD	cis	rs995000	0.868	rs4409689	ENSG00000235545.1	RP11-230B22.1	7.7	8.7e-14	3.83e-11	0.45	0.34	Triglyceride levels;	chr1:62711694	chr1:62688482~62710694:+
PRAD	cis	rs1150668	0.796	rs9468372	ENSG00000280107.1	AL022393.9	-7.7	8.7e-14	3.83e-11	-0.4	-0.34	Pubertal anthropometrics;	chr6:28411584	chr6:28170845~28172521:+
PRAD	cis	rs2638953	0.962	rs11049515	ENSG00000278733.1	RP11-425D17.1	-7.7	8.7e-14	3.83e-11	-0.43	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28299564	chr12:28185625~28186190:-
PRAD	cis	rs2638953	1	rs11049516	ENSG00000278733.1	RP11-425D17.1	-7.7	8.7e-14	3.83e-11	-0.43	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28299649	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.962	rs61922979	ENSG00000278733.1	RP11-425D17.1	-7.7	8.7e-14	3.83e-11	-0.43	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28301218	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.962	rs11049517	ENSG00000278733.1	RP11-425D17.1	-7.7	8.7e-14	3.83e-11	-0.43	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28301627	chr12:28185625~28186190:-
PRAD	cis	rs11098499	1	rs13116504	ENSG00000245958.5	RP11-33B1.1	-7.7	8.71e-14	3.84e-11	-0.33	-0.34	Corneal astigmatism;	chr4:119288257	chr4:119454791~119552025:+
PRAD	cis	rs7829975	0.617	rs4841072	ENSG00000253893.2	FAM85B	7.7	8.73e-14	3.84e-11	0.41	0.34	Mood instability;	chr8:8933743	chr8:8167819~8226614:-
PRAD	cis	rs9341835	0.583	rs2753062	ENSG00000218048.2	RP3-407E4.4	7.7	8.75e-14	3.85e-11	0.38	0.34	Schizophrenia;	chr6:63421905	chr6:63440766~63443580:+
PRAD	cis	rs3096299	0.967	rs3102341	ENSG00000261118.1	RP11-104N10.1	7.7	8.78e-14	3.86e-11	0.34	0.34	Multiple myeloma (IgH translocation);	chr16:89384336	chr16:89492017~89504460:-
PRAD	cis	rs6991838	0.765	rs6472219	ENSG00000200714.1	Y_RNA	7.7	8.79e-14	3.87e-11	0.35	0.34	Intelligence (multi-trait analysis);	chr8:65644487	chr8:65592731~65592820:+
PRAD	cis	rs2243480	0.908	rs4718273	ENSG00000226824.5	RP4-756H11.3	7.7	8.8e-14	3.87e-11	0.66	0.34	Diabetic kidney disease;	chr7:65751112	chr7:66654538~66669855:+
PRAD	cis	rs4713118	0.614	rs9380007	ENSG00000216901.1	AL022393.7	7.7	8.8e-14	3.87e-11	0.44	0.34	Parkinson's disease;	chr6:27692729	chr6:28176188~28176674:+
PRAD	cis	rs4718428	0.924	rs6971897	ENSG00000232546.1	RP11-458F8.1	-7.7	8.8e-14	3.87e-11	-0.26	-0.34	Corneal structure;	chr7:66947787	chr7:66848496~66858136:+
PRAD	cis	rs6545883	0.507	rs12478192	ENSG00000271889.1	RP11-493E12.1	-7.7	8.81e-14	3.88e-11	-0.37	-0.34	Tuberculosis;	chr2:61364040	chr2:61151433~61162105:-
PRAD	cis	rs6545883	0.524	rs12992614	ENSG00000271889.1	RP11-493E12.1	-7.7	8.81e-14	3.88e-11	-0.37	-0.34	Tuberculosis;	chr2:61365941	chr2:61151433~61162105:-
PRAD	cis	rs13113518	0.783	rs12504300	ENSG00000249700.7	SRD5A3-AS1	7.7	8.83e-14	3.89e-11	0.47	0.34	Height;	chr4:55482360	chr4:55363971~55395847:-
PRAD	cis	rs4713118	0.786	rs200502	ENSG00000226314.6	ZNF192P1	-7.7	8.84e-14	3.89e-11	-0.45	-0.34	Parkinson's disease;	chr6:27820284	chr6:28161781~28169594:+
PRAD	cis	rs2638953	0.962	rs11049524	ENSG00000278733.1	RP11-425D17.1	-7.7	8.84e-14	3.89e-11	-0.43	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28311956	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.962	rs11049525	ENSG00000278733.1	RP11-425D17.1	-7.7	8.84e-14	3.89e-11	-0.43	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28313227	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.962	rs12371974	ENSG00000278733.1	RP11-425D17.1	-7.7	8.84e-14	3.89e-11	-0.43	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28313969	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.962	rs11049526	ENSG00000278733.1	RP11-425D17.1	-7.7	8.84e-14	3.89e-11	-0.43	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28314751	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.962	rs11049527	ENSG00000278733.1	RP11-425D17.1	-7.7	8.84e-14	3.89e-11	-0.43	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28317667	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.925	rs11049528	ENSG00000278733.1	RP11-425D17.1	-7.7	8.84e-14	3.89e-11	-0.43	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28317914	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.962	rs10843153	ENSG00000278733.1	RP11-425D17.1	-7.7	8.84e-14	3.89e-11	-0.43	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28319168	chr12:28185625~28186190:-
PRAD	cis	rs853679	0.546	rs175597	ENSG00000280107.1	AL022393.9	-7.7	8.86e-14	3.9e-11	-0.6	-0.34	Depression;	chr6:27842848	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.546	rs200989	ENSG00000280107.1	AL022393.9	-7.7	8.86e-14	3.9e-11	-0.6	-0.34	Depression;	chr6:27848664	chr6:28170845~28172521:+
PRAD	cis	rs1552244	0.608	rs7615408	ENSG00000206567.8	AC022007.5	-7.69	8.89e-14	3.91e-11	-0.38	-0.34	Alzheimer's disease;	chr3:9958502	chr3:10006418~10011209:-
PRAD	cis	rs853679	0.546	rs35016036	ENSG00000225595.2	XXbac-BPG308K3.6	7.69	8.9e-14	3.91e-11	0.75	0.34	Depression;	chr6:28347103	chr6:28859625~28864630:-
PRAD	cis	rs853679	0.546	rs35744819	ENSG00000225595.2	XXbac-BPG308K3.6	7.69	8.9e-14	3.91e-11	0.75	0.34	Depression;	chr6:28350554	chr6:28859625~28864630:-
PRAD	cis	rs10463554	0.818	rs2241564	ENSG00000175749.11	EIF3KP1	7.69	8.92e-14	3.92e-11	0.45	0.34	Parkinson's disease;	chr5:102966547	chr5:103032376~103033031:+
PRAD	cis	rs1799949	0.965	rs799910	ENSG00000267002.1	RP11-242D8.1	7.69	8.95e-14	3.94e-11	0.32	0.34	Menopause (age at onset);	chr17:43127544	chr17:43164183~43170403:-
PRAD	cis	rs736801	0.808	rs72797306	ENSG00000233006.5	AC034220.3	7.69	8.96e-14	3.94e-11	0.31	0.34	Mosquito bite size;Breast cancer;	chr5:132465058	chr5:132311285~132369916:-
PRAD	cis	rs62103177	0.564	rs2115996	ENSG00000261126.6	RP11-795F19.1	7.69	8.97e-14	3.94e-11	0.49	0.34	Opioid sensitivity;	chr18:79941007	chr18:80046900~80095482:+
PRAD	cis	rs4664293	0.899	rs7588710	ENSG00000226266.5	AC009961.3	-7.69	8.97e-14	3.95e-11	-0.45	-0.34	Monocyte percentage of white cells;	chr2:159673011	chr2:159670708~159712435:-
PRAD	cis	rs4664293	0.967	rs4665103	ENSG00000226266.5	AC009961.3	-7.69	8.97e-14	3.95e-11	-0.45	-0.34	Monocyte percentage of white cells;	chr2:159675801	chr2:159670708~159712435:-
PRAD	cis	rs853679	1	rs1778511	ENSG00000226314.6	ZNF192P1	7.69	8.99e-14	3.95e-11	0.53	0.34	Depression;	chr6:28261633	chr6:28161781~28169594:+
PRAD	cis	rs9640161	0.789	rs2373751	ENSG00000261305.1	RP4-584D14.7	7.69	9e-14	3.96e-11	0.39	0.34	Blood protein levels;Circulating chemerin levels;	chr7:150324510	chr7:150341771~150342607:+
PRAD	cis	rs9640161	0.636	rs56190213	ENSG00000261305.1	RP4-584D14.7	7.69	9e-14	3.96e-11	0.39	0.34	Blood protein levels;Circulating chemerin levels;	chr7:150328631	chr7:150341771~150342607:+
PRAD	cis	rs950169	0.58	rs2271431	ENSG00000259728.4	LINC00933	7.69	9e-14	3.96e-11	0.4	0.34	Schizophrenia;	chr15:84646233	chr15:84570649~84580175:+
PRAD	cis	rs2108622	1	rs55744319	ENSG00000267056.2	AC005336.4	7.69	9.01e-14	3.96e-11	0.48	0.34	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871011	chr19:15910582~15911824:-
PRAD	cis	rs673078	1	rs673078	ENSG00000275409.1	RP11-131L12.4	7.69	9.02e-14	3.96e-11	0.44	0.34	Glucose homeostasis traits;	chr12:118353636	chr12:118430147~118430699:+
PRAD	cis	rs881375	0.967	rs1930780	ENSG00000226752.6	PSMD5-AS1	-7.69	9.03e-14	3.97e-11	-0.4	-0.34	Rheumatoid arthritis;	chr9:120923941	chr9:120824828~120854385:+
PRAD	cis	rs1555322	0.53	rs2425042	ENSG00000279253.1	RP4-614O4.13	-7.69	9.03e-14	3.97e-11	-0.41	-0.34	Attention deficit hyperactivity disorder;	chr20:35278092	chr20:35262727~35264187:-
PRAD	cis	rs2933343	0.951	rs9871612	ENSG00000261159.1	RP11-723O4.9	7.69	9.04e-14	3.97e-11	0.33	0.34	IgG glycosylation;	chr3:128851559	chr3:128859716~128860526:-
PRAD	cis	rs12468226	1	rs16839090	ENSG00000273456.1	RP11-686O6.2	7.69	9.05e-14	3.98e-11	0.46	0.34	Urate levels;	chr2:202348338	chr2:202374932~202375604:-
PRAD	cis	rs12468226	1	rs13389798	ENSG00000273456.1	RP11-686O6.2	7.69	9.06e-14	3.98e-11	0.46	0.34	Urate levels;	chr2:202348370	chr2:202374932~202375604:-
PRAD	cis	rs17772222	0.917	rs10143767	ENSG00000258983.2	RP11-507K2.2	7.69	9.07e-14	3.99e-11	0.49	0.34	Coronary artery calcification;	chr14:88514867	chr14:88499334~88515502:+
PRAD	cis	rs1043099	0.571	rs757869	ENSG00000279699.1	RP1-102K2.9	-7.69	9.08e-14	3.99e-11	-0.43	-0.34	Rheumatoid arthritis;	chr22:30368464	chr22:30275215~30276951:-
PRAD	cis	rs4664293	0.51	rs57575372	ENSG00000226266.5	AC009961.3	7.69	9.09e-14	3.99e-11	0.45	0.34	Monocyte percentage of white cells;	chr2:159569253	chr2:159670708~159712435:-
PRAD	cis	rs56114371	0.53	rs9357045	ENSG00000280107.1	AL022393.9	-7.69	9.11e-14	4e-11	-0.47	-0.34	Breast cancer;	chr6:27721148	chr6:28170845~28172521:+
PRAD	cis	rs964611	0.938	rs12050648	ENSG00000259488.2	RP11-154J22.1	-7.69	9.12e-14	4e-11	-0.32	-0.34	Metabolite levels (Pyroglutamine);	chr15:48297544	chr15:48312353~48331856:-
PRAD	cis	rs2638953	0.962	rs10843151	ENSG00000278733.1	RP11-425D17.1	-7.69	9.12e-14	4.01e-11	-0.43	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28318386	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.962	rs10843152	ENSG00000278733.1	RP11-425D17.1	-7.69	9.12e-14	4.01e-11	-0.43	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28319090	chr12:28185625~28186190:-
PRAD	cis	rs11098499	0.554	rs2175381	ENSG00000245958.5	RP11-33B1.1	-7.69	9.13e-14	4.01e-11	-0.31	-0.34	Corneal astigmatism;	chr4:119344812	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.599	rs3864142	ENSG00000245958.5	RP11-33B1.1	-7.69	9.13e-14	4.01e-11	-0.31	-0.34	Corneal astigmatism;	chr4:119345036	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.605	rs6833140	ENSG00000245958.5	RP11-33B1.1	-7.69	9.13e-14	4.01e-11	-0.31	-0.34	Corneal astigmatism;	chr4:119345667	chr4:119454791~119552025:+
PRAD	cis	rs17608059	0.545	rs9915045	ENSG00000141028.6	CDRT15P1	-7.69	9.15e-14	4.02e-11	-0.44	-0.34	Temperament;	chr17:13999319	chr17:14024514~14025488:+
PRAD	cis	rs9393777	0.92	rs13212562	ENSG00000280107.1	AL022393.9	-7.69	9.18e-14	4.03e-11	-0.6	-0.34	Intelligence (multi-trait analysis);	chr6:27332531	chr6:28170845~28172521:+
PRAD	cis	rs2243480	1	rs316331	ENSG00000226824.5	RP4-756H11.3	7.69	9.19e-14	4.04e-11	0.68	0.34	Diabetic kidney disease;	chr7:66139635	chr7:66654538~66669855:+
PRAD	cis	rs1552244	0.554	rs6800204	ENSG00000206567.8	AC022007.5	-7.69	9.21e-14	4.05e-11	-0.38	-0.34	Alzheimer's disease;	chr3:9953720	chr3:10006418~10011209:-
PRAD	cis	rs1552244	0.554	rs6762594	ENSG00000206567.8	AC022007.5	-7.69	9.21e-14	4.05e-11	-0.38	-0.34	Alzheimer's disease;	chr3:9953832	chr3:10006418~10011209:-
PRAD	cis	rs881375	0.902	rs2900180	ENSG00000226752.6	PSMD5-AS1	-7.69	9.22e-14	4.05e-11	-0.4	-0.34	Rheumatoid arthritis;	chr9:120944104	chr9:120824828~120854385:+
PRAD	cis	rs9467773	0.62	rs2494716	ENSG00000241549.7	GUSBP2	7.69	9.23e-14	4.05e-11	0.36	0.34	Intelligence (multi-trait analysis);	chr6:26662508	chr6:26871484~26956554:-
PRAD	cis	rs526231	0.543	rs62362541	ENSG00000175749.11	EIF3KP1	7.69	9.23e-14	4.05e-11	0.45	0.34	Primary biliary cholangitis;	chr5:102986744	chr5:103032376~103033031:+
PRAD	cis	rs17012589	0.667	rs12320670	ENSG00000258815.1	RP11-408B11.2	7.69	9.24e-14	4.06e-11	0.46	0.34	Bone mineral density (Ward's triangle area);	chr12:85217232	chr12:85318060~85342912:+
PRAD	cis	rs17012589	0.592	rs7488285	ENSG00000258815.1	RP11-408B11.2	7.69	9.24e-14	4.06e-11	0.46	0.34	Bone mineral density (Ward's triangle area);	chr12:85226723	chr12:85318060~85342912:+
PRAD	cis	rs17012589	0.667	rs67463599	ENSG00000258815.1	RP11-408B11.2	7.69	9.24e-14	4.06e-11	0.46	0.34	Bone mineral density (Ward's triangle area);	chr12:85234755	chr12:85318060~85342912:+
PRAD	cis	rs17012589	0.667	rs1159869	ENSG00000258815.1	RP11-408B11.2	7.69	9.24e-14	4.06e-11	0.46	0.34	Bone mineral density (Ward's triangle area);	chr12:85235463	chr12:85318060~85342912:+
PRAD	cis	rs17012589	0.667	rs1159868	ENSG00000258815.1	RP11-408B11.2	7.69	9.24e-14	4.06e-11	0.46	0.34	Bone mineral density (Ward's triangle area);	chr12:85235677	chr12:85318060~85342912:+
PRAD	cis	rs17012589	0.695	rs7315741	ENSG00000258815.1	RP11-408B11.2	7.69	9.24e-14	4.06e-11	0.46	0.34	Bone mineral density (Ward's triangle area);	chr12:85237507	chr12:85318060~85342912:+
PRAD	cis	rs11976180	1	rs2951353	ENSG00000273234.1	OR2A13P	-7.69	9.24e-14	4.06e-11	-0.41	-0.34	Obesity-related traits;	chr7:144064023	chr7:144142009~144142938:+
PRAD	cis	rs11976180	1	rs2371247	ENSG00000273234.1	OR2A13P	-7.69	9.24e-14	4.06e-11	-0.41	-0.34	Obesity-related traits;	chr7:144067086	chr7:144142009~144142938:+
PRAD	cis	rs881375	0.967	rs10739579	ENSG00000226752.6	PSMD5-AS1	-7.69	9.24e-14	4.06e-11	-0.4	-0.34	Rheumatoid arthritis;	chr9:120932510	chr9:120824828~120854385:+
PRAD	cis	rs6921919	0.806	rs213230	ENSG00000216901.1	AL022393.7	7.69	9.25e-14	4.06e-11	0.46	0.34	Autism spectrum disorder or schizophrenia;	chr6:28362487	chr6:28176188~28176674:+
PRAD	cis	rs62355900	0.627	rs16886449	ENSG00000271828.1	CTD-2310F14.1	7.69	9.27e-14	4.07e-11	0.72	0.34	Endometriosis;	chr5:56880479	chr5:56927874~56929573:+
PRAD	cis	rs62355900	0.627	rs895380	ENSG00000271828.1	CTD-2310F14.1	7.69	9.27e-14	4.07e-11	0.72	0.34	Endometriosis;	chr5:56881321	chr5:56927874~56929573:+
PRAD	cis	rs62355900	0.627	rs16886463	ENSG00000271828.1	CTD-2310F14.1	7.69	9.27e-14	4.07e-11	0.72	0.34	Endometriosis;	chr5:56883514	chr5:56927874~56929573:+
PRAD	cis	rs62355900	0.627	rs62358106	ENSG00000271828.1	CTD-2310F14.1	7.69	9.27e-14	4.07e-11	0.72	0.34	Endometriosis;	chr5:56885542	chr5:56927874~56929573:+
PRAD	cis	rs62355900	0.627	rs3817119	ENSG00000271828.1	CTD-2310F14.1	7.69	9.27e-14	4.07e-11	0.72	0.34	Endometriosis;	chr5:56887916	chr5:56927874~56929573:+
PRAD	cis	rs736801	0.808	rs72797303	ENSG00000233006.5	AC034220.3	7.69	9.28e-14	4.07e-11	0.31	0.34	Mosquito bite size;Breast cancer;	chr5:132460471	chr5:132311285~132369916:-
PRAD	cis	rs964611	1	rs8037626	ENSG00000259488.2	RP11-154J22.1	-7.69	9.29e-14	4.07e-11	-0.35	-0.34	Metabolite levels (Pyroglutamine);	chr15:48314149	chr15:48312353~48331856:-
PRAD	cis	rs4925386	1	rs1889201	ENSG00000273619.1	RP5-908M14.9	7.69	9.31e-14	4.09e-11	0.21	0.34	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62348019	chr20:62386303~62386970:-
PRAD	cis	rs2243480	1	rs781157	ENSG00000226824.5	RP4-756H11.3	-7.69	9.32e-14	4.09e-11	-0.65	-0.34	Diabetic kidney disease;	chr7:66013324	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs781149	ENSG00000226824.5	RP4-756H11.3	-7.69	9.32e-14	4.09e-11	-0.65	-0.34	Diabetic kidney disease;	chr7:66016297	chr7:66654538~66669855:+
PRAD	cis	rs2243480	0.901	rs58207111	ENSG00000226824.5	RP4-756H11.3	-7.69	9.32e-14	4.09e-11	-0.65	-0.34	Diabetic kidney disease;	chr7:66021736	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs1167613	ENSG00000226824.5	RP4-756H11.3	-7.69	9.32e-14	4.09e-11	-0.65	-0.34	Diabetic kidney disease;	chr7:66022452	chr7:66654538~66669855:+
PRAD	cis	rs4845570	1	rs4845356	ENSG00000268288.1	RP11-98D18.16	-7.69	9.33e-14	4.09e-11	-0.5	-0.34	Coronary artery disease;	chr1:151786747	chr1:151766486~151767000:-
PRAD	cis	rs2243480	1	rs1039664	ENSG00000226824.5	RP4-756H11.3	-7.69	9.33e-14	4.09e-11	-0.65	-0.34	Diabetic kidney disease;	chr7:65984729	chr7:66654538~66669855:+
PRAD	cis	rs2243480	0.901	rs2456483	ENSG00000226824.5	RP4-756H11.3	-7.69	9.33e-14	4.09e-11	-0.65	-0.34	Diabetic kidney disease;	chr7:65996588	chr7:66654538~66669855:+
PRAD	cis	rs2243480	0.901	rs2949697	ENSG00000226824.5	RP4-756H11.3	-7.69	9.33e-14	4.09e-11	-0.65	-0.34	Diabetic kidney disease;	chr7:65999249	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs1701750	ENSG00000226824.5	RP4-756H11.3	-7.69	9.33e-14	4.09e-11	-0.65	-0.34	Diabetic kidney disease;	chr7:66002158	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs1701758	ENSG00000226824.5	RP4-756H11.3	-7.69	9.33e-14	4.09e-11	-0.65	-0.34	Diabetic kidney disease;	chr7:66005214	chr7:66654538~66669855:+
PRAD	cis	rs2243480	0.901	rs1701759	ENSG00000226824.5	RP4-756H11.3	-7.69	9.33e-14	4.09e-11	-0.65	-0.34	Diabetic kidney disease;	chr7:66005945	chr7:66654538~66669855:+
PRAD	cis	rs193541	0.53	rs9327272	ENSG00000263432.2	RN7SL689P	7.69	9.35e-14	4.1e-11	0.37	0.34	Glucose homeostasis traits;	chr5:122737853	chr5:123022487~123022783:-
PRAD	cis	rs763567	0.935	rs2988392	ENSG00000271811.1	RP1-79C4.4	7.69	9.35e-14	4.1e-11	0.39	0.34	Tonsillectomy;	chr1:170647214	chr1:170667381~170669425:+
PRAD	cis	rs2255336	0.81	rs7959328	ENSG00000245648.1	RP11-277P12.20	7.69	9.35e-14	4.1e-11	0.56	0.34	Blood protein levels;	chr12:10361467	chr12:10363769~10398506:+
PRAD	cis	rs12612619	0.732	rs10432697	ENSG00000229122.1	AGBL5-IT1	7.69	9.38e-14	4.12e-11	0.35	0.34	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27049184	chr2:27061038~27061815:+
PRAD	cis	rs17428076	0.831	rs55957712	ENSG00000228389.1	AC068039.4	-7.69	9.4e-14	4.12e-11	-0.44	-0.34	Myopia;	chr2:171731446	chr2:171773482~171775844:+
PRAD	cis	rs8091660	0.929	rs2175564	ENSG00000278983.1	RP11-426J5.3	7.69	9.43e-14	4.13e-11	0.42	0.34	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48570838	chr18:48564795~48568342:+
PRAD	cis	rs11083475	1	rs883433	ENSG00000267892.1	CTD-2540F13.2	-7.69	9.43e-14	4.13e-11	-0.36	-0.34	Heart rate;	chr19:38715648	chr19:38738284~38739863:+
PRAD	cis	rs6570726	0.967	rs1396648	ENSG00000235652.6	RP11-545I5.3	-7.69	9.43e-14	4.14e-11	-0.36	-0.34	Lobe attachment (rater-scored or self-reported);	chr6:145464112	chr6:145799409~145886585:+
PRAD	cis	rs10463554	0.963	rs187427	ENSG00000175749.11	EIF3KP1	7.69	9.44e-14	4.14e-11	0.45	0.34	Parkinson's disease;	chr5:103177102	chr5:103032376~103033031:+
PRAD	cis	rs853679	0.567	rs6905380	ENSG00000204709.4	LINC01556	7.69	9.45e-14	4.14e-11	0.47	0.34	Depression;	chr6:28407125	chr6:28943877~28944537:+
PRAD	cis	rs11098499	0.73	rs12505735	ENSG00000245958.5	RP11-33B1.1	-7.69	9.46e-14	4.15e-11	-0.34	-0.34	Corneal astigmatism;	chr4:119611801	chr4:119454791~119552025:+
PRAD	cis	rs7916697	0.593	rs10762198	ENSG00000233590.1	RP11-153K11.3	7.69	9.47e-14	4.15e-11	0.45	0.34	Optic disc area;	chr10:68263296	chr10:68233251~68242379:-
PRAD	cis	rs1979679	0.766	rs11049365	ENSG00000278733.1	RP11-425D17.1	7.68	9.53e-14	4.18e-11	0.46	0.34	Ossification of the posterior longitudinal ligament of the spine;	chr12:28138401	chr12:28185625~28186190:-
PRAD	cis	rs42648	0.935	rs42624	ENSG00000227646.6	STEAP2-AS1	-7.68	9.53e-14	4.18e-11	-0.31	-0.34	Homocysteine levels;	chr7:90328227	chr7:89882353~90211635:-
PRAD	cis	rs12612619	0.732	rs7560144	ENSG00000272148.1	RP11-195B17.1	7.68	9.56e-14	4.19e-11	0.4	0.34	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27057592	chr2:27062428~27062907:-
PRAD	cis	rs1555322	0.53	rs2425044	ENSG00000279253.1	RP4-614O4.13	-7.68	9.58e-14	4.2e-11	-0.41	-0.34	Attention deficit hyperactivity disorder;	chr20:35281932	chr20:35262727~35264187:-
PRAD	cis	rs964611	0.872	rs11855410	ENSG00000259488.2	RP11-154J22.1	-7.68	9.59e-14	4.2e-11	-0.34	-0.34	Metabolite levels (Pyroglutamine);	chr15:48301657	chr15:48312353~48331856:-
PRAD	cis	rs45509595	0.841	rs200501	ENSG00000280107.1	AL022393.9	-7.68	9.6e-14	4.21e-11	-0.6	-0.34	Breast cancer;	chr6:27821164	chr6:28170845~28172521:+
PRAD	cis	rs2439831	0.867	rs11856184	ENSG00000249839.1	AC011330.5	-7.68	9.62e-14	4.21e-11	-0.61	-0.34	Lung cancer in ever smokers;	chr15:43626964	chr15:43663654~43684339:-
PRAD	cis	rs2439831	0.867	rs2927072	ENSG00000249839.1	AC011330.5	-7.68	9.62e-14	4.21e-11	-0.61	-0.34	Lung cancer in ever smokers;	chr15:43630200	chr15:43663654~43684339:-
PRAD	cis	rs2439831	0.867	rs2920781	ENSG00000249839.1	AC011330.5	-7.68	9.62e-14	4.21e-11	-0.61	-0.34	Lung cancer in ever smokers;	chr15:43632484	chr15:43663654~43684339:-
PRAD	cis	rs7829975	0.511	rs2980426	ENSG00000253893.2	FAM85B	-7.68	9.64e-14	4.22e-11	-0.42	-0.34	Mood instability;	chr8:8288087	chr8:8167819~8226614:-
PRAD	cis	rs853679	0.567	rs9969098	ENSG00000204709.4	LINC01556	7.68	9.64e-14	4.22e-11	0.47	0.34	Depression;	chr6:28430971	chr6:28943877~28944537:+
PRAD	cis	rs8031584	0.541	rs1983459	ENSG00000270015.1	RP11-540B6.6	-7.68	9.66e-14	4.23e-11	-0.29	-0.34	Huntington's disease progression;	chr15:30916546	chr15:30926514~30928407:+
PRAD	cis	rs17772222	0.917	rs2004329	ENSG00000258983.2	RP11-507K2.2	7.68	9.66e-14	4.23e-11	0.48	0.34	Coronary artery calcification;	chr14:88532965	chr14:88499334~88515502:+
PRAD	cis	rs6847067	0.794	rs4626191	ENSG00000180769.7	WDFY3-AS2	7.68	9.72e-14	4.26e-11	0.35	0.34	Oropharynx cancer;	chr4:85015526	chr4:84965682~85011277:+
PRAD	cis	rs7121800	0.962	rs1336515	ENSG00000242353.1	RP4-710M3.1	-7.68	9.74e-14	4.27e-11	-0.35	-0.34	Pit-and-Fissure caries;	chr11:30503157	chr11:30368148~30368646:+
PRAD	cis	rs2274273	0.624	rs7154796	ENSG00000258413.1	RP11-665C16.6	-7.68	9.81e-14	4.3e-11	-0.46	-0.34	Protein biomarker;	chr14:55304740	chr14:55262767~55272075:-
PRAD	cis	rs2286503	0.78	rs981792	ENSG00000228649.7	AC005682.5	7.68	9.83e-14	4.3e-11	0.38	0.34	Fibrinogen;	chr7:22822020	chr7:22854178~22861579:+
PRAD	cis	rs61774743	0.557	rs4660192	ENSG00000229901.1	RP11-399E6.4	-7.68	9.84e-14	4.31e-11	-0.33	-0.34	Intelligence (multi-trait analysis);	chr1:41376678	chr1:41375004~41375669:-
PRAD	cis	rs2243480	1	rs34136756	ENSG00000226824.5	RP4-756H11.3	-7.68	9.84e-14	4.31e-11	-0.64	-0.34	Diabetic kidney disease;	chr7:65916269	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs34933526	ENSG00000226824.5	RP4-756H11.3	-7.68	9.84e-14	4.31e-11	-0.64	-0.34	Diabetic kidney disease;	chr7:65918212	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs6949812	ENSG00000226824.5	RP4-756H11.3	-7.68	9.84e-14	4.31e-11	-0.64	-0.34	Diabetic kidney disease;	chr7:65922114	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs6970243	ENSG00000226824.5	RP4-756H11.3	-7.68	9.84e-14	4.31e-11	-0.64	-0.34	Diabetic kidney disease;	chr7:65923503	chr7:66654538~66669855:+
PRAD	cis	rs2243480	0.708	rs35310401	ENSG00000226824.5	RP4-756H11.3	-7.68	9.84e-14	4.31e-11	-0.64	-0.34	Diabetic kidney disease;	chr7:65925372	chr7:66654538~66669855:+
PRAD	cis	rs2243480	0.901	rs35087093	ENSG00000226824.5	RP4-756H11.3	-7.68	9.84e-14	4.31e-11	-0.64	-0.34	Diabetic kidney disease;	chr7:65940221	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs35046236	ENSG00000226824.5	RP4-756H11.3	-7.68	9.84e-14	4.31e-11	-0.64	-0.34	Diabetic kidney disease;	chr7:65943626	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs36068983	ENSG00000226824.5	RP4-756H11.3	-7.68	9.84e-14	4.31e-11	-0.64	-0.34	Diabetic kidney disease;	chr7:65944004	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs68189316	ENSG00000226824.5	RP4-756H11.3	-7.68	9.84e-14	4.31e-11	-0.64	-0.34	Diabetic kidney disease;	chr7:65944182	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs937108	ENSG00000226824.5	RP4-756H11.3	-7.68	9.84e-14	4.31e-11	-0.64	-0.34	Diabetic kidney disease;	chr7:65963465	chr7:66654538~66669855:+
PRAD	cis	rs2243480	0.711	rs1626926	ENSG00000226824.5	RP4-756H11.3	-7.68	9.84e-14	4.31e-11	-0.64	-0.34	Diabetic kidney disease;	chr7:65970805	chr7:66654538~66669855:+
PRAD	cis	rs2243480	0.831	rs7806717	ENSG00000226824.5	RP4-756H11.3	7.68	9.84e-14	4.31e-11	0.64	0.34	Diabetic kidney disease;	chr7:65928187	chr7:66654538~66669855:+
PRAD	cis	rs1555322	0.53	rs7004	ENSG00000279253.1	RP4-614O4.13	-7.68	9.85e-14	4.31e-11	-0.41	-0.34	Attention deficit hyperactivity disorder;	chr20:35278950	chr20:35262727~35264187:-
PRAD	cis	rs6570726	1	rs6570699	ENSG00000235652.6	RP11-545I5.3	7.68	9.85e-14	4.31e-11	0.36	0.34	Lobe attachment (rater-scored or self-reported);	chr6:145599596	chr6:145799409~145886585:+
PRAD	cis	rs6570726	1	rs1935615	ENSG00000235652.6	RP11-545I5.3	7.68	9.85e-14	4.31e-11	0.36	0.34	Lobe attachment (rater-scored or self-reported);	chr6:145599981	chr6:145799409~145886585:+
PRAD	cis	rs12612619	0.732	rs11126857	ENSG00000272148.1	RP11-195B17.1	-7.68	9.87e-14	4.32e-11	-0.4	-0.34	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27074889	chr2:27062428~27062907:-
PRAD	cis	rs17772222	0.727	rs3179969	ENSG00000258983.2	RP11-507K2.2	7.68	9.88e-14	4.32e-11	0.44	0.34	Coronary artery calcification;	chr14:88396185	chr14:88499334~88515502:+
PRAD	cis	rs9362426	0.608	rs9444494	ENSG00000218793.1	RP3-382I10.3	7.68	9.89e-14	4.33e-11	0.44	0.34	Depressive episodes in bipolar disorder;	chr6:87409283	chr6:87441165~87442146:-
PRAD	cis	rs7829975	0.572	rs7005000	ENSG00000253893.2	FAM85B	7.68	9.9e-14	4.33e-11	0.42	0.34	Mood instability;	chr8:8939092	chr8:8167819~8226614:-
PRAD	cis	rs10759883	0.539	rs609296	ENSG00000175611.10	LINC00476	7.68	9.92e-14	4.34e-11	0.44	0.34	Nicotine dependence;	chr9:95973604	chr9:95759231~95875977:-
PRAD	cis	rs2243480	0.901	rs313808	ENSG00000226824.5	RP4-756H11.3	-7.68	9.92e-14	4.34e-11	-0.65	-0.34	Diabetic kidney disease;	chr7:66034886	chr7:66654538~66669855:+
PRAD	cis	rs496547	0.686	rs2508916	ENSG00000255239.1	AP002954.6	7.68	9.93e-14	4.34e-11	0.45	0.34	Hip minimal joint space width;	chr11:118783942	chr11:118688039~118690600:-
PRAD	cis	rs1563304	1	rs1563304	ENSG00000262500.1	RP11-259G18.2	7.68	9.93e-14	4.35e-11	0.57	0.34	Neuroticism;	chr17:46797087	chr17:46243606~46245044:+
PRAD	cis	rs7829975	0.774	rs35431455	ENSG00000253893.2	FAM85B	-7.68	9.93e-14	4.35e-11	-0.43	-0.34	Mood instability;	chr8:8816226	chr8:8167819~8226614:-
PRAD	cis	rs638893	0.617	rs4938558	ENSG00000278376.1	RP11-158I9.8	-7.68	9.98e-14	4.37e-11	-0.34	-0.34	Vitiligo;	chr11:118847220	chr11:118791254~118793137:+
PRAD	cis	rs8523	0.901	rs1570069	ENSG00000230314.5	ELOVL2-AS1	7.68	1e-13	4.37e-11	0.37	0.34	Red blood cell fatty acid levels;	chr6:11017592	chr6:11043524~11078226:+
PRAD	cis	rs9326248	0.53	rs7940310	ENSG00000280143.1	AP000892.6	7.68	1e-13	4.38e-11	0.4	0.34	Blood protein levels;	chr11:117153765	chr11:117204967~117210292:+
PRAD	cis	rs853679	0.567	rs13209596	ENSG00000204709.4	LINC01556	7.68	1e-13	4.39e-11	0.47	0.34	Depression;	chr6:28428413	chr6:28943877~28944537:+
PRAD	cis	rs7121800	0.962	rs11031119	ENSG00000242353.1	RP4-710M3.1	-7.68	1e-13	4.39e-11	-0.35	-0.34	Pit-and-Fissure caries;	chr11:30504226	chr11:30368148~30368646:+
PRAD	cis	rs17428076	0.836	rs57775770	ENSG00000228389.1	AC068039.4	-7.68	1.01e-13	4.4e-11	-0.44	-0.34	Myopia;	chr2:171831221	chr2:171773482~171775844:+
PRAD	cis	rs2243480	1	rs35396113	ENSG00000226824.5	RP4-756H11.3	-7.68	1.01e-13	4.4e-11	-0.66	-0.34	Diabetic kidney disease;	chr7:66030474	chr7:66654538~66669855:+
PRAD	cis	rs881375	0.933	rs2239657	ENSG00000226752.6	PSMD5-AS1	7.68	1.01e-13	4.41e-11	0.4	0.34	Rheumatoid arthritis;	chr9:120909242	chr9:120824828~120854385:+
PRAD	cis	rs7238033	0.663	rs11082468	ENSG00000267193.4	RP11-116O18.3	7.68	1.01e-13	4.41e-11	0.36	0.34	Bladder cancer;	chr18:45741063	chr18:45669367~45747215:-
PRAD	cis	rs748404	0.697	rs1814323	ENSG00000205771.5	CATSPER2P1	7.68	1.01e-13	4.41e-11	0.37	0.34	Lung cancer;	chr15:43271039	chr15:43726918~43747094:-
PRAD	cis	rs35828350	1	rs35828350	ENSG00000275120.1	RP11-182J1.17	7.68	1.01e-13	4.42e-11	0.44	0.34	Autism spectrum disorder or schizophrenia;	chr15:84812610	chr15:84599434~84606463:-
PRAD	cis	rs6479901	0.895	rs10761746	ENSG00000232075.1	MRPL35P2	-7.68	1.01e-13	4.43e-11	-0.41	-0.34	Intelligence (multi-trait analysis);	chr10:63345134	chr10:63634317~63634827:-
PRAD	cis	rs801193	0.591	rs9986881	ENSG00000228409.4	CCT6P1	-7.68	1.01e-13	4.43e-11	-0.26	-0.34	Aortic root size;	chr7:66708053	chr7:65751142~65763354:+
PRAD	cis	rs2599510	0.811	rs176410	ENSG00000276334.1	AL133243.1	-7.68	1.01e-13	4.43e-11	-0.37	-0.34	Interleukin-18 levels;	chr2:32418369	chr2:32521927~32523547:+
PRAD	cis	rs55665837	1	rs11023215	ENSG00000251991.1	RNU7-49P	7.68	1.01e-13	4.43e-11	0.36	0.34	Vitamin D levels;	chr11:14415424	chr11:14478892~14478953:+
PRAD	cis	rs9640161	0.75	rs11764936	ENSG00000261305.1	RP4-584D14.7	7.68	1.01e-13	4.43e-11	0.38	0.34	Blood protein levels;Circulating chemerin levels;	chr7:150328826	chr7:150341771~150342607:+
PRAD	cis	rs6545883	0.507	rs4672427	ENSG00000271889.1	RP11-493E12.1	-7.68	1.02e-13	4.44e-11	-0.36	-0.34	Tuberculosis;	chr2:61242115	chr2:61151433~61162105:-
PRAD	cis	rs7238033	0.663	rs11877630	ENSG00000267193.4	RP11-116O18.3	7.68	1.02e-13	4.44e-11	0.36	0.34	Bladder cancer;	chr18:45738012	chr18:45669367~45747215:-
PRAD	cis	rs74024059	1	rs2593281	ENSG00000260685.1	RP11-326L17.1	7.68	1.02e-13	4.45e-11	0.9	0.34	Red blood cell count;Hematocrit;	chr15:75860847	chr15:75950464~75951144:-
PRAD	cis	rs74024059	0.661	rs2604403	ENSG00000260685.1	RP11-326L17.1	7.68	1.02e-13	4.45e-11	0.9	0.34	Red blood cell count;Hematocrit;	chr15:75861341	chr15:75950464~75951144:-
PRAD	cis	rs853679	0.55	rs34477097	ENSG00000226314.6	ZNF192P1	-7.67	1.02e-13	4.45e-11	-0.46	-0.34	Depression;	chr6:28229408	chr6:28161781~28169594:+
PRAD	cis	rs2255336	0.938	rs61917723	ENSG00000245648.1	RP11-277P12.20	-7.67	1.02e-13	4.46e-11	-0.51	-0.34	Blood protein levels;	chr12:10472728	chr12:10363769~10398506:+
PRAD	cis	rs8523	0.901	rs7743830	ENSG00000230314.5	ELOVL2-AS1	7.67	1.02e-13	4.46e-11	0.37	0.34	Red blood cell fatty acid levels;	chr6:11013987	chr6:11043524~11078226:+
PRAD	cis	rs11976180	1	rs2961134	ENSG00000273234.1	OR2A13P	-7.67	1.02e-13	4.46e-11	-0.41	-0.34	Obesity-related traits;	chr7:144073969	chr7:144142009~144142938:+
PRAD	cis	rs881375	0.933	rs7031096	ENSG00000226752.6	PSMD5-AS1	-7.67	1.02e-13	4.47e-11	-0.4	-0.34	Rheumatoid arthritis;	chr9:120932664	chr9:120824828~120854385:+
PRAD	cis	rs881375	0.967	rs10739580	ENSG00000226752.6	PSMD5-AS1	-7.67	1.02e-13	4.47e-11	-0.4	-0.34	Rheumatoid arthritis;	chr9:120933004	chr9:120824828~120854385:+
PRAD	cis	rs853679	0.657	rs1778483	ENSG00000204709.4	LINC01556	7.67	1.02e-13	4.47e-11	0.45	0.34	Depression;	chr6:28273214	chr6:28943877~28944537:+
PRAD	cis	rs853679	0.657	rs1778482	ENSG00000204709.4	LINC01556	7.67	1.02e-13	4.47e-11	0.45	0.34	Depression;	chr6:28273215	chr6:28943877~28944537:+
PRAD	cis	rs2243480	1	rs1723270	ENSG00000226824.5	RP4-756H11.3	-7.67	1.02e-13	4.48e-11	-0.66	-0.34	Diabetic kidney disease;	chr7:66004843	chr7:66654538~66669855:+
PRAD	cis	rs12701220	0.504	rs12702092	ENSG00000229043.2	AC091729.9	-7.67	1.03e-13	4.49e-11	-0.52	-0.34	Bronchopulmonary dysplasia;	chr7:1106232	chr7:1160374~1165267:+
PRAD	cis	rs950169	0.881	rs72750843	ENSG00000259728.4	LINC00933	7.67	1.03e-13	4.49e-11	0.42	0.34	Schizophrenia;	chr15:84592552	chr15:84570649~84580175:+
PRAD	cis	rs62355901	0.599	rs751990	ENSG00000271828.1	CTD-2310F14.1	7.67	1.03e-13	4.5e-11	0.71	0.34	Breast cancer;	chr5:56743292	chr5:56927874~56929573:+
PRAD	cis	rs12928939	0.769	rs34680964	ENSG00000260886.1	TAT-AS1	7.67	1.03e-13	4.51e-11	0.46	0.34	Post bronchodilator FEV1;	chr16:71624691	chr16:71565789~71578187:+
PRAD	cis	rs10463554	0.892	rs1837256	ENSG00000175749.11	EIF3KP1	7.67	1.03e-13	4.52e-11	0.45	0.34	Parkinson's disease;	chr5:102968852	chr5:103032376~103033031:+
PRAD	cis	rs4722166	0.598	rs4722179	ENSG00000179428.2	AC073072.5	-7.67	1.03e-13	4.52e-11	-0.39	-0.34	Lung cancer;	chr7:22764242	chr7:22725395~22727620:-
PRAD	cis	rs2255336	0.808	rs59611026	ENSG00000245648.1	RP11-277P12.20	-7.67	1.03e-13	4.52e-11	-0.46	-0.34	Blood protein levels;	chr12:10445387	chr12:10363769~10398506:+
PRAD	cis	rs7567389	0.599	rs6430938	ENSG00000236682.1	AC068282.3	7.67	1.04e-13	4.52e-11	0.44	0.34	Self-rated health;	chr2:127405047	chr2:127389130~127400580:+
PRAD	cis	rs2274273	0.967	rs67756714	ENSG00000258413.1	RP11-665C16.6	-7.67	1.04e-13	4.52e-11	-0.43	-0.34	Protein biomarker;	chr14:55123105	chr14:55262767~55272075:-
PRAD	cis	rs763567	0.835	rs503706	ENSG00000271811.1	RP1-79C4.4	7.67	1.04e-13	4.53e-11	0.38	0.34	Tonsillectomy;	chr1:170665943	chr1:170667381~170669425:+
PRAD	cis	rs12928939	0.815	rs11648483	ENSG00000260886.1	TAT-AS1	7.67	1.04e-13	4.53e-11	0.45	0.34	Post bronchodilator FEV1;	chr16:71673495	chr16:71565789~71578187:+
PRAD	cis	rs6570726	1	rs1935617	ENSG00000235652.6	RP11-545I5.3	7.67	1.04e-13	4.54e-11	0.36	0.34	Lobe attachment (rater-scored or self-reported);	chr6:145622190	chr6:145799409~145886585:+
PRAD	cis	rs240993	0.809	rs11153277	ENSG00000271789.1	RP5-1112D6.7	-7.67	1.04e-13	4.54e-11	-0.4	-0.34	Inflammatory skin disease;Psoriasis;	chr6:111259358	chr6:111297126~111298510:+
PRAD	cis	rs7739264	0.602	rs1121384	ENSG00000228412.5	RP4-625H18.2	7.67	1.04e-13	4.55e-11	0.4	0.34	Endometriosis;	chr6:19771276	chr6:19802164~19804752:-
PRAD	cis	rs12468226	0.938	rs4675274	ENSG00000273456.1	RP11-686O6.2	-7.67	1.04e-13	4.56e-11	-0.45	-0.34	Urate levels;	chr2:202243145	chr2:202374932~202375604:-
PRAD	cis	rs748404	0.697	rs572959	ENSG00000205771.5	CATSPER2P1	-7.67	1.05e-13	4.57e-11	-0.37	-0.34	Lung cancer;	chr15:43258304	chr15:43726918~43747094:-
PRAD	cis	rs748404	0.697	rs554001	ENSG00000205771.5	CATSPER2P1	-7.67	1.05e-13	4.57e-11	-0.37	-0.34	Lung cancer;	chr15:43259721	chr15:43726918~43747094:-
PRAD	cis	rs748404	0.697	rs501884	ENSG00000205771.5	CATSPER2P1	-7.67	1.05e-13	4.57e-11	-0.37	-0.34	Lung cancer;	chr15:43261784	chr15:43726918~43747094:-
PRAD	cis	rs748404	0.697	rs504417	ENSG00000205771.5	CATSPER2P1	-7.67	1.05e-13	4.57e-11	-0.37	-0.34	Lung cancer;	chr15:43262028	chr15:43726918~43747094:-
PRAD	cis	rs748404	0.723	rs560134	ENSG00000205771.5	CATSPER2P1	-7.67	1.05e-13	4.57e-11	-0.37	-0.34	Lung cancer;	chr15:43263501	chr15:43726918~43747094:-
PRAD	cis	rs2436845	0.603	rs2513923	ENSG00000253320.4	KB-1507C5.2	-7.67	1.05e-13	4.57e-11	-0.41	-0.34	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102813207	chr8:102864300~102977876:+
PRAD	cis	rs56080343	0.515	rs73222056	ENSG00000275759.1	RP11-131L12.3	-7.67	1.05e-13	4.57e-11	-0.57	-0.34	Neuroticism;	chr12:118215875	chr12:118428281~118428870:+
PRAD	cis	rs881375	1	rs6478484	ENSG00000226752.6	PSMD5-AS1	-7.67	1.05e-13	4.57e-11	-0.41	-0.34	Rheumatoid arthritis;	chr9:120890102	chr9:120824828~120854385:+
PRAD	cis	rs9516	0.544	rs664679	ENSG00000254974.1	RP11-702H23.2	7.67	1.05e-13	4.57e-11	0.43	0.34	Facial morphology (factor 15, philtrum width);	chr11:74475254	chr11:74485580~74486051:-
PRAD	cis	rs881375	0.678	rs10118357	ENSG00000226752.6	PSMD5-AS1	-7.67	1.05e-13	4.58e-11	-0.39	-0.34	Rheumatoid arthritis;	chr9:120917790	chr9:120824828~120854385:+
PRAD	cis	rs8042680	0.688	rs2386584	ENSG00000214432.8	AC068831.10	-7.67	1.05e-13	4.59e-11	-0.41	-0.34	Type 2 diabetes;	chr15:90996342	chr15:91022619~91036611:+
PRAD	cis	rs12908161	0.959	rs17534709	ENSG00000275120.1	RP11-182J1.17	7.67	1.05e-13	4.6e-11	0.45	0.34	Schizophrenia;	chr15:84771166	chr15:84599434~84606463:-
PRAD	cis	rs2286503	0.839	rs10276099	ENSG00000228649.7	AC005682.5	7.67	1.06e-13	4.61e-11	0.38	0.34	Fibrinogen;	chr7:22823331	chr7:22854178~22861579:+
PRAD	cis	rs6951245	0.554	rs76243429	ENSG00000229043.2	AC091729.9	-7.67	1.06e-13	4.61e-11	-0.48	-0.34	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1112907	chr7:1160374~1165267:+
PRAD	cis	rs12612619	0.732	rs7560144	ENSG00000229122.1	AGBL5-IT1	7.67	1.06e-13	4.61e-11	0.35	0.34	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27057592	chr2:27061038~27061815:+
PRAD	cis	rs2739330	0.76	rs5760095	ENSG00000228039.3	KB-1125A3.10	7.67	1.06e-13	4.62e-11	0.44	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23963780~23964374:+
PRAD	cis	rs75422866	0.867	rs73102125	ENSG00000280054.1	RP1-197B17.7	7.67	1.06e-13	4.63e-11	0.79	0.34	Pneumonia;	chr12:47637869	chr12:47728151~47730598:-
PRAD	cis	rs75422866	0.867	rs12426849	ENSG00000280054.1	RP1-197B17.7	7.67	1.06e-13	4.63e-11	0.79	0.34	Pneumonia;	chr12:47638975	chr12:47728151~47730598:-
PRAD	cis	rs75422866	0.867	rs117950951	ENSG00000280054.1	RP1-197B17.7	7.67	1.06e-13	4.63e-11	0.79	0.34	Pneumonia;	chr12:47639794	chr12:47728151~47730598:-
PRAD	cis	rs75422866	0.867	rs7954764	ENSG00000280054.1	RP1-197B17.7	7.67	1.06e-13	4.63e-11	0.79	0.34	Pneumonia;	chr12:47641136	chr12:47728151~47730598:-
PRAD	cis	rs526231	0.511	rs10515341	ENSG00000175749.11	EIF3KP1	7.67	1.06e-13	4.63e-11	0.46	0.34	Primary biliary cholangitis;	chr5:102981413	chr5:103032376~103033031:+
PRAD	cis	rs526231	0.575	rs10463990	ENSG00000175749.11	EIF3KP1	7.67	1.06e-13	4.63e-11	0.46	0.34	Primary biliary cholangitis;	chr5:102981714	chr5:103032376~103033031:+
PRAD	cis	rs9467773	0.595	rs13207371	ENSG00000124549.13	BTN2A3P	7.67	1.06e-13	4.64e-11	0.3	0.34	Intelligence (multi-trait analysis);	chr6:26590846	chr6:26421391~26432383:+
PRAD	cis	rs9393777	0.92	rs35716472	ENSG00000280107.1	AL022393.9	-7.67	1.06e-13	4.64e-11	-0.64	-0.34	Intelligence (multi-trait analysis);	chr6:27438828	chr6:28170845~28172521:+
PRAD	cis	rs6908034	0.556	rs7750703	ENSG00000228412.5	RP4-625H18.2	7.67	1.06e-13	4.64e-11	0.66	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19804583	chr6:19802164~19804752:-
PRAD	cis	rs375066	0.935	rs407731	ENSG00000267058.1	RP11-15A1.3	7.67	1.07e-13	4.65e-11	0.28	0.34	Breast cancer;	chr19:43913925	chr19:43891804~43901805:-
PRAD	cis	rs741668	0.795	rs1041167	ENSG00000235903.6	CPB2-AS1	7.67	1.07e-13	4.66e-11	0.45	0.34	Cerebrospinal fluid clusterin levels;	chr13:46046000	chr13:46052806~46113332:+
PRAD	cis	rs2243480	1	rs78803505	ENSG00000226824.5	RP4-756H11.3	-7.67	1.07e-13	4.66e-11	-0.64	-0.34	Diabetic kidney disease;	chr7:65917585	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs34577383	ENSG00000226824.5	RP4-756H11.3	-7.67	1.07e-13	4.66e-11	-0.64	-0.34	Diabetic kidney disease;	chr7:65920739	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs55895244	ENSG00000226824.5	RP4-756H11.3	-7.67	1.07e-13	4.66e-11	-0.64	-0.34	Diabetic kidney disease;	chr7:65922691	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs7795242	ENSG00000226824.5	RP4-756H11.3	-7.67	1.07e-13	4.66e-11	-0.64	-0.34	Diabetic kidney disease;	chr7:65925107	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs2177703	ENSG00000226824.5	RP4-756H11.3	-7.67	1.07e-13	4.66e-11	-0.64	-0.34	Diabetic kidney disease;	chr7:65926730	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs35432774	ENSG00000226824.5	RP4-756H11.3	-7.67	1.07e-13	4.66e-11	-0.64	-0.34	Diabetic kidney disease;	chr7:65928032	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs56985706	ENSG00000226824.5	RP4-756H11.3	-7.67	1.07e-13	4.66e-11	-0.64	-0.34	Diabetic kidney disease;	chr7:65929575	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs60683927	ENSG00000226824.5	RP4-756H11.3	-7.67	1.07e-13	4.66e-11	-0.64	-0.34	Diabetic kidney disease;	chr7:65929781	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs58062456	ENSG00000226824.5	RP4-756H11.3	-7.67	1.07e-13	4.66e-11	-0.64	-0.34	Diabetic kidney disease;	chr7:65929865	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs34529418	ENSG00000226824.5	RP4-756H11.3	-7.67	1.07e-13	4.66e-11	-0.64	-0.34	Diabetic kidney disease;	chr7:65938222	chr7:66654538~66669855:+
PRAD	cis	rs2243480	0.803	rs34804747	ENSG00000226824.5	RP4-756H11.3	-7.67	1.07e-13	4.66e-11	-0.64	-0.34	Diabetic kidney disease;	chr7:65947955	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs11538349	ENSG00000226824.5	RP4-756H11.3	-7.67	1.07e-13	4.66e-11	-0.64	-0.34	Diabetic kidney disease;	chr7:65956884	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs35542501	ENSG00000226824.5	RP4-756H11.3	-7.67	1.07e-13	4.66e-11	-0.64	-0.34	Diabetic kidney disease;	chr7:65966228	chr7:66654538~66669855:+
PRAD	cis	rs2274273	0.624	rs11158034	ENSG00000258413.1	RP11-665C16.6	-7.67	1.07e-13	4.67e-11	-0.45	-0.34	Protein biomarker;	chr14:55286842	chr14:55262767~55272075:-
PRAD	cis	rs7568498	0.517	rs197261	ENSG00000227403.1	AC009299.3	7.67	1.07e-13	4.67e-11	0.48	0.34	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);	chr2:161048312	chr2:161244739~161249050:+
PRAD	cis	rs17012589	0.667	rs4761127	ENSG00000258815.1	RP11-408B11.2	7.67	1.07e-13	4.67e-11	0.46	0.34	Bone mineral density (Ward's triangle area);	chr12:85267595	chr12:85318060~85342912:+
PRAD	cis	rs6600671	0.692	rs11249430	ENSG00000223345.3	HIST2H2BA	7.67	1.07e-13	4.68e-11	0.41	0.34	Hip geometry;	chr1:121547115	chr1:121108210~121117257:-
PRAD	cis	rs853679	0.567	rs13196606	ENSG00000204709.4	LINC01556	7.67	1.08e-13	4.68e-11	0.47	0.34	Depression;	chr6:28402301	chr6:28943877~28944537:+
PRAD	cis	rs1134634	0.52	rs4280724	ENSG00000273133.1	RP11-799M12.2	-7.67	1.08e-13	4.7e-11	-0.45	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15574128	chr4:15563698~15564253:-
PRAD	cis	rs6569038	0.557	rs9401118	ENSG00000253194.1	RP11-351A11.1	-7.67	1.08e-13	4.7e-11	-0.42	-0.34	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:119053584	chr6:118934785~119031541:+
PRAD	cis	rs3096299	0.838	rs4785561	ENSG00000261118.1	RP11-104N10.1	7.67	1.08e-13	4.72e-11	0.34	0.34	Multiple myeloma (IgH translocation);	chr16:89362644	chr16:89492017~89504460:-
PRAD	cis	rs2439831	0.85	rs28564774	ENSG00000205771.5	CATSPER2P1	-7.67	1.09e-13	4.73e-11	-0.53	-0.34	Lung cancer in ever smokers;	chr15:43833277	chr15:43726918~43747094:-
PRAD	cis	rs2439831	0.85	rs12441984	ENSG00000205771.5	CATSPER2P1	-7.67	1.09e-13	4.73e-11	-0.53	-0.34	Lung cancer in ever smokers;	chr15:43834087	chr15:43726918~43747094:-
PRAD	cis	rs2439831	0.85	rs28707214	ENSG00000205771.5	CATSPER2P1	-7.67	1.09e-13	4.73e-11	-0.53	-0.34	Lung cancer in ever smokers;	chr15:43839425	chr15:43726918~43747094:-
PRAD	cis	rs741668	0.759	rs73188488	ENSG00000235903.6	CPB2-AS1	7.67	1.09e-13	4.73e-11	0.45	0.34	Cerebrospinal fluid clusterin levels;	chr13:46050849	chr13:46052806~46113332:+
PRAD	cis	rs964611	0.882	rs75094472	ENSG00000259488.2	RP11-154J22.1	-7.67	1.09e-13	4.74e-11	-0.35	-0.34	Metabolite levels (Pyroglutamine);	chr15:48351917	chr15:48312353~48331856:-
PRAD	cis	rs853679	0.567	rs7740429	ENSG00000204709.4	LINC01556	7.67	1.09e-13	4.74e-11	0.47	0.34	Depression;	chr6:28431469	chr6:28943877~28944537:+
PRAD	cis	rs7829975	0.593	rs2921061	ENSG00000253893.2	FAM85B	-7.66	1.09e-13	4.76e-11	-0.42	-0.34	Mood instability;	chr8:8460105	chr8:8167819~8226614:-
PRAD	cis	rs7731783	1	rs7731783	ENSG00000247679.2	RP11-1277A3.1	7.66	1.09e-13	4.76e-11	0.31	0.34	Methadone dose in opioid dependence;	chr5:177633311	chr5:177611253~177619754:+
PRAD	cis	rs34119086	1	rs34119086	ENSG00000225595.2	XXbac-BPG308K3.6	7.66	1.1e-13	4.77e-11	0.78	0.34	Breast cancer;	chr6:28594471	chr6:28859625~28864630:-
PRAD	cis	rs6844153	1	rs7655686	ENSG00000240005.4	RP11-293A21.1	-7.66	1.1e-13	4.77e-11	-0.49	-0.34	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26897955	chr4:26859806~26860599:-
PRAD	cis	rs9393800	0.56	rs7745613	ENSG00000230314.5	ELOVL2-AS1	7.66	1.1e-13	4.78e-11	0.41	0.34	Menopause (age at onset);	chr6:10957700	chr6:11043524~11078226:+
PRAD	cis	rs7739264	0.564	rs7750725	ENSG00000228412.5	RP4-625H18.2	7.66	1.1e-13	4.78e-11	0.4	0.34	Endometriosis;	chr6:19804666	chr6:19802164~19804752:-
PRAD	cis	rs12188164	0.965	rs72717435	ENSG00000221990.4	EXOC3-AS1	7.66	1.1e-13	4.79e-11	0.28	0.34	Cystic fibrosis severity;	chr5:448087	chr5:441498~443160:-
PRAD	cis	rs673078	0.66	rs9943819	ENSG00000275409.1	RP11-131L12.4	-7.66	1.1e-13	4.79e-11	-0.44	-0.34	Glucose homeostasis traits;	chr12:118298917	chr12:118430147~118430699:+
PRAD	cis	rs10463554	0.963	rs6889592	ENSG00000175749.11	EIF3KP1	7.66	1.1e-13	4.79e-11	0.43	0.34	Parkinson's disease;	chr5:102978235	chr5:103032376~103033031:+
PRAD	cis	rs4713118	0.662	rs464312	ENSG00000272009.1	RP1-313I6.12	-7.66	1.11e-13	4.81e-11	-0.34	-0.34	Parkinson's disease;	chr6:27999813	chr6:28078792~28081130:-
PRAD	cis	rs4713118	0.662	rs469228	ENSG00000272009.1	RP1-313I6.12	-7.66	1.11e-13	4.81e-11	-0.34	-0.34	Parkinson's disease;	chr6:28002926	chr6:28078792~28081130:-
PRAD	cis	rs4713118	0.54	rs469227	ENSG00000272009.1	RP1-313I6.12	-7.66	1.11e-13	4.81e-11	-0.34	-0.34	Parkinson's disease;	chr6:28002927	chr6:28078792~28081130:-
PRAD	cis	rs4713118	0.662	rs149948	ENSG00000272009.1	RP1-313I6.12	-7.66	1.11e-13	4.81e-11	-0.34	-0.34	Parkinson's disease;	chr6:28007039	chr6:28078792~28081130:-
PRAD	cis	rs6751744	0.513	rs10173538	ENSG00000226266.5	AC009961.3	-7.66	1.11e-13	4.81e-11	-0.44	-0.34	Dysphagia;	chr2:159712765	chr2:159670708~159712435:-
PRAD	cis	rs526231	0.543	rs152123	ENSG00000175749.11	EIF3KP1	-7.66	1.11e-13	4.83e-11	-0.49	-0.34	Primary biliary cholangitis;	chr5:103196218	chr5:103032376~103033031:+
PRAD	cis	rs8062405	0.723	rs4788077	ENSG00000251417.2	RP11-1348G14.4	-7.66	1.11e-13	4.83e-11	-0.38	-0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558443	chr16:28802743~28817828:+
PRAD	cis	rs6547741	1	rs6547741	ENSG00000234072.1	AC074117.10	7.66	1.11e-13	4.84e-11	0.25	0.34	Oral cavity cancer;	chr2:27633057	chr2:27356246~27367622:+
PRAD	cis	rs6547741	1	rs4666007	ENSG00000234072.1	AC074117.10	7.66	1.11e-13	4.84e-11	0.25	0.34	Oral cavity cancer;	chr2:27633628	chr2:27356246~27367622:+
PRAD	cis	rs6547741	1	rs1528402	ENSG00000234072.1	AC074117.10	7.66	1.11e-13	4.84e-11	0.25	0.34	Oral cavity cancer;	chr2:27634650	chr2:27356246~27367622:+
PRAD	cis	rs6479901	0.895	rs10761728	ENSG00000232075.1	MRPL35P2	-7.66	1.11e-13	4.84e-11	-0.41	-0.34	Intelligence (multi-trait analysis);	chr10:63235808	chr10:63634317~63634827:-
PRAD	cis	rs853679	0.546	rs200949	ENSG00000280107.1	AL022393.9	-7.66	1.12e-13	4.85e-11	-0.57	-0.34	Depression;	chr6:27867657	chr6:28170845~28172521:+
PRAD	cis	rs6904897	0.538	rs4639353	ENSG00000232876.1	CTA-212D2.2	7.66	1.12e-13	4.85e-11	0.43	0.34	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr6:134903190	chr6:135055033~135060550:+
PRAD	cis	rs2638953	0.962	rs7303747	ENSG00000278733.1	RP11-425D17.1	-7.66	1.12e-13	4.85e-11	-0.43	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28241969	chr12:28185625~28186190:-
PRAD	cis	rs11148252	0.716	rs1887360	ENSG00000278238.1	RP11-245D16.4	-7.66	1.13e-13	4.89e-11	-0.4	-0.34	Lewy body disease;	chr13:52205031	chr13:52454775~52455331:-
PRAD	cis	rs2243480	1	rs35058610	ENSG00000226824.5	RP4-756H11.3	-7.66	1.13e-13	4.89e-11	-0.64	-0.34	Diabetic kidney disease;	chr7:65925938	chr7:66654538~66669855:+
PRAD	cis	rs496547	0.686	rs524590	ENSG00000255239.1	AP002954.6	7.66	1.13e-13	4.91e-11	0.45	0.34	Hip minimal joint space width;	chr11:118769354	chr11:118688039~118690600:-
PRAD	cis	rs2436845	0.627	rs2436861	ENSG00000253320.4	KB-1507C5.2	-7.66	1.13e-13	4.91e-11	-0.41	-0.34	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102812625	chr8:102864300~102977876:+
PRAD	cis	rs9467773	0.62	rs9461275	ENSG00000241549.7	GUSBP2	7.66	1.13e-13	4.91e-11	0.35	0.34	Intelligence (multi-trait analysis);	chr6:26590573	chr6:26871484~26956554:-
PRAD	cis	rs9467773	0.62	rs6925087	ENSG00000241549.7	GUSBP2	7.66	1.13e-13	4.91e-11	0.35	0.34	Intelligence (multi-trait analysis);	chr6:26592625	chr6:26871484~26956554:-
PRAD	cis	rs9467773	0.62	rs4368798	ENSG00000241549.7	GUSBP2	7.66	1.13e-13	4.91e-11	0.35	0.34	Intelligence (multi-trait analysis);	chr6:26593243	chr6:26871484~26956554:-
PRAD	cis	rs9467773	0.62	rs9461276	ENSG00000241549.7	GUSBP2	7.66	1.13e-13	4.91e-11	0.35	0.34	Intelligence (multi-trait analysis);	chr6:26594940	chr6:26871484~26956554:-
PRAD	cis	rs9362426	0.639	rs9450674	ENSG00000218793.1	RP3-382I10.3	7.66	1.13e-13	4.91e-11	0.44	0.34	Depressive episodes in bipolar disorder;	chr6:87411202	chr6:87441165~87442146:-
PRAD	cis	rs11976180	1	rs11976180	ENSG00000170356.8	OR2A20P	-7.66	1.13e-13	4.91e-11	-0.46	-0.34	Obesity-related traits;	chr7:144044487	chr7:144250045~144252957:-
PRAD	cis	rs9326248	0.581	rs10892053	ENSG00000280143.1	AP000892.6	7.66	1.13e-13	4.92e-11	0.26	0.34	Blood protein levels;	chr11:116986287	chr11:117204967~117210292:+
PRAD	cis	rs853679	1	rs853676	ENSG00000280107.1	AL022393.9	-7.66	1.13e-13	4.92e-11	-0.52	-0.34	Depression;	chr6:28331910	chr6:28170845~28172521:+
PRAD	cis	rs4925386	1	rs4925386	ENSG00000273619.1	RP5-908M14.9	-7.66	1.13e-13	4.92e-11	-0.21	-0.34	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62345988	chr20:62386303~62386970:-
PRAD	cis	rs6539288	0.745	rs2041895	ENSG00000260329.1	RP11-412D9.4	-7.66	1.14e-13	4.93e-11	-0.29	-0.34	Total body bone mineral density;	chr12:106956310	chr12:106954029~106955497:-
PRAD	cis	rs673078	0.66	rs6490173	ENSG00000275409.1	RP11-131L12.4	-7.66	1.14e-13	4.93e-11	-0.44	-0.34	Glucose homeostasis traits;	chr12:118278637	chr12:118430147~118430699:+
PRAD	cis	rs11098499	0.78	rs12504773	ENSG00000245958.5	RP11-33B1.1	-7.66	1.14e-13	4.94e-11	-0.34	-0.34	Corneal astigmatism;	chr4:119640994	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.78	rs7680914	ENSG00000245958.5	RP11-33B1.1	-7.66	1.14e-13	4.94e-11	-0.34	-0.34	Corneal astigmatism;	chr4:119641898	chr4:119454791~119552025:+
PRAD	cis	rs2015599	0.56	rs11050147	ENSG00000257176.2	RP11-996F15.2	-7.66	1.14e-13	4.94e-11	-0.39	-0.34	Platelet count;Mean platelet volume;	chr12:29242746	chr12:29280418~29317848:-
PRAD	cis	rs2108622	0.958	rs56340170	ENSG00000267056.2	AC005336.4	7.66	1.14e-13	4.94e-11	0.48	0.34	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871067	chr19:15910582~15911824:-
PRAD	cis	rs6904897	0.563	rs6569976	ENSG00000232876.1	CTA-212D2.2	-7.66	1.14e-13	4.94e-11	-0.42	-0.34	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr6:134903615	chr6:135055033~135060550:+
PRAD	cis	rs1499614	0.901	rs3936	ENSG00000226824.5	RP4-756H11.3	-7.66	1.14e-13	4.96e-11	-0.68	-0.34	Gout;	chr7:66661502	chr7:66654538~66669855:+
PRAD	cis	rs7567389	0.677	rs7556675	ENSG00000236682.1	AC068282.3	7.66	1.14e-13	4.97e-11	0.46	0.34	Self-rated health;	chr2:127296171	chr2:127389130~127400580:+
PRAD	cis	rs7567389	0.677	rs10850	ENSG00000236682.1	AC068282.3	7.66	1.14e-13	4.97e-11	0.46	0.34	Self-rated health;	chr2:127306369	chr2:127389130~127400580:+
PRAD	cis	rs2243480	1	rs313799	ENSG00000226824.5	RP4-756H11.3	-7.66	1.15e-13	4.98e-11	-0.65	-0.34	Diabetic kidney disease;	chr7:66029343	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs313807	ENSG00000226824.5	RP4-756H11.3	-7.66	1.15e-13	4.98e-11	-0.65	-0.34	Diabetic kidney disease;	chr7:66034494	chr7:66654538~66669855:+
PRAD	cis	rs964611	0.882	rs67904691	ENSG00000259488.2	RP11-154J22.1	-7.66	1.15e-13	4.98e-11	-0.32	-0.34	Metabolite levels (Pyroglutamine);	chr15:48295386	chr15:48312353~48331856:-
PRAD	cis	rs62355901	0.505	rs62356561	ENSG00000271828.1	CTD-2310F14.1	7.66	1.15e-13	4.98e-11	0.68	0.34	Breast cancer;	chr5:56933826	chr5:56927874~56929573:+
PRAD	cis	rs1528149	0.836	rs740823	ENSG00000224683.1	RPL36AP29	7.66	1.15e-13	4.99e-11	0.41	0.34	Sitting height ratio;	chr7:16062778	chr7:16208945~16209265:+
PRAD	cis	rs9532669	0.963	rs7989303	ENSG00000168852.11	TPTE2P5	7.66	1.15e-13	5e-11	0.32	0.34	Cervical cancer;	chr13:40950087	chr13:40822296~40921749:-
PRAD	cis	rs2274273	1	rs2147972	ENSG00000258413.1	RP11-665C16.6	-7.66	1.15e-13	5e-11	-0.43	-0.34	Protein biomarker;	chr14:55131312	chr14:55262767~55272075:-
PRAD	cis	rs2274273	1	rs4644	ENSG00000258413.1	RP11-665C16.6	-7.66	1.15e-13	5e-11	-0.43	-0.34	Protein biomarker;	chr14:55138217	chr14:55262767~55272075:-
PRAD	cis	rs2274273	1	rs2075603	ENSG00000258413.1	RP11-665C16.6	-7.66	1.15e-13	5e-11	-0.43	-0.34	Protein biomarker;	chr14:55143237	chr14:55262767~55272075:-
PRAD	cis	rs10028773	0.7	rs7671797	ENSG00000245958.5	RP11-33B1.1	-7.66	1.15e-13	5e-11	-0.32	-0.34	Educational attainment;	chr4:119327002	chr4:119454791~119552025:+
PRAD	cis	rs875971	0.522	rs1701760	ENSG00000237310.1	GS1-124K5.4	7.66	1.15e-13	5.01e-11	0.29	0.34	Aortic root size;	chr7:66008701	chr7:66493706~66495474:+
PRAD	cis	rs8062405	0.755	rs7186573	ENSG00000251417.2	RP11-1348G14.4	-7.66	1.16e-13	5.01e-11	-0.37	-0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576068	chr16:28802743~28817828:+
PRAD	cis	rs7567389	0.677	rs72845997	ENSG00000236682.1	AC068282.3	-7.66	1.16e-13	5.02e-11	-0.45	-0.34	Self-rated health;	chr2:127352506	chr2:127389130~127400580:+
PRAD	cis	rs881375	0.967	rs2416805	ENSG00000226752.6	PSMD5-AS1	-7.66	1.16e-13	5.02e-11	-0.41	-0.34	Rheumatoid arthritis;	chr9:120914204	chr9:120824828~120854385:+
PRAD	cis	rs853679	0.567	rs16894106	ENSG00000204709.4	LINC01556	7.66	1.16e-13	5.03e-11	0.47	0.34	Depression;	chr6:28432562	chr6:28943877~28944537:+
PRAD	cis	rs1075265	0.933	rs918357	ENSG00000233266.1	HMGB1P31	7.66	1.16e-13	5.03e-11	0.44	0.34	Chronotype;Morning vs. evening chronotype;	chr2:54108826	chr2:54051334~54051760:+
PRAD	cis	rs7916697	0.947	rs7916410	ENSG00000233590.1	RP11-153K11.3	7.66	1.16e-13	5.04e-11	0.46	0.34	Optic disc area;	chr10:68235910	chr10:68233251~68242379:-
PRAD	cis	rs6750795	0.641	rs10933375	ENSG00000181798.2	LINC00471	7.66	1.16e-13	5.04e-11	0.45	0.34	Height;	chr2:231502585	chr2:231508426~231514339:-
PRAD	cis	rs11096990	0.634	rs2062229	ENSG00000249207.1	RP11-360F5.1	-7.66	1.17e-13	5.06e-11	-0.35	-0.34	Cognitive function;	chr4:39285146	chr4:39112677~39126818:-
PRAD	cis	rs6847067	0.628	rs4464556	ENSG00000180769.7	WDFY3-AS2	-7.65	1.17e-13	5.08e-11	-0.36	-0.34	Oropharynx cancer;	chr4:84873781	chr4:84965682~85011277:+
PRAD	cis	rs4774565	0.84	rs4775880	ENSG00000244879.4	GABPB1-AS1	7.65	1.17e-13	5.08e-11	0.31	0.34	Breast cancer;	chr15:50383621	chr15:50354959~50372202:+
PRAD	cis	rs6782228	0.606	rs6775270	ENSG00000242551.2	POU5F1P6	-7.65	1.17e-13	5.09e-11	-0.43	-0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128684655	chr3:128674735~128677005:-
PRAD	cis	rs2274273	0.624	rs7159824	ENSG00000258413.1	RP11-665C16.6	-7.65	1.18e-13	5.1e-11	-0.46	-0.34	Protein biomarker;	chr14:55305818	chr14:55262767~55272075:-
PRAD	cis	rs9309473	0.528	rs10191517	ENSG00000163016.8	ALMS1P	7.65	1.18e-13	5.11e-11	0.41	0.34	Metabolite levels;	chr2:73331275	chr2:73644919~73685576:+
PRAD	cis	rs8042680	0.911	rs1443256	ENSG00000214432.8	AC068831.10	-7.65	1.18e-13	5.11e-11	-0.41	-0.34	Type 2 diabetes;	chr15:90972785	chr15:91022619~91036611:+
PRAD	cis	rs8042680	1	rs8037254	ENSG00000214432.8	AC068831.10	-7.65	1.18e-13	5.11e-11	-0.41	-0.34	Type 2 diabetes;	chr15:90976869	chr15:91022619~91036611:+
PRAD	cis	rs494459	0.838	rs567680	ENSG00000278376.1	RP11-158I9.8	-7.65	1.18e-13	5.12e-11	-0.29	-0.34	Height;	chr11:118737823	chr11:118791254~118793137:+
PRAD	cis	rs7829975	0.714	rs4841040	ENSG00000253893.2	FAM85B	-7.65	1.18e-13	5.13e-11	-0.43	-0.34	Mood instability;	chr8:8797017	chr8:8167819~8226614:-
PRAD	cis	rs733592	0.931	rs765260	ENSG00000240399.1	RP1-228P16.1	-7.65	1.18e-13	5.13e-11	-0.28	-0.34	Plateletcrit;	chr12:48038153	chr12:48054813~48055591:-
PRAD	cis	rs2286503	0.65	rs1990279	ENSG00000226329.2	AC005682.6	7.65	1.19e-13	5.14e-11	0.35	0.34	Fibrinogen;	chr7:22851123	chr7:22863874~22881350:-
PRAD	cis	rs2638953	0.962	rs10843150	ENSG00000278733.1	RP11-425D17.1	7.65	1.19e-13	5.15e-11	0.43	0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28304869	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.962	rs11049518	ENSG00000278733.1	RP11-425D17.1	-7.65	1.19e-13	5.15e-11	-0.43	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28303728	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.962	rs3782517	ENSG00000278733.1	RP11-425D17.1	-7.65	1.19e-13	5.15e-11	-0.43	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28310254	chr12:28185625~28186190:-
PRAD	cis	rs8042680	1	rs4508401	ENSG00000214432.8	AC068831.10	-7.65	1.19e-13	5.16e-11	-0.41	-0.34	Type 2 diabetes;	chr15:90971491	chr15:91022619~91036611:+
PRAD	cis	rs11098499	1	rs35643470	ENSG00000245958.5	RP11-33B1.1	-7.65	1.19e-13	5.17e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119263793	chr4:119454791~119552025:+
PRAD	cis	rs4631830	0.72	rs11004422	ENSG00000230869.1	CTGLF10P	7.65	1.19e-13	5.17e-11	0.42	0.34	Prostate-specific antigen levels;	chr10:46097486	chr10:45678692~45700532:+
PRAD	cis	rs4631830	0.72	rs11004415	ENSG00000230869.1	CTGLF10P	7.65	1.19e-13	5.17e-11	0.42	0.34	Prostate-specific antigen levels;	chr10:46097641	chr10:45678692~45700532:+
PRAD	cis	rs4631830	0.683	rs11004409	ENSG00000230869.1	CTGLF10P	7.65	1.19e-13	5.17e-11	0.42	0.34	Prostate-specific antigen levels;	chr10:46097803	chr10:45678692~45700532:+
PRAD	cis	rs7567389	0.719	rs4150404	ENSG00000236682.1	AC068282.3	7.65	1.19e-13	5.17e-11	0.46	0.34	Self-rated health;	chr2:127292424	chr2:127389130~127400580:+
PRAD	cis	rs3858145	0.505	rs12765827	ENSG00000233590.1	RP11-153K11.3	7.65	1.19e-13	5.18e-11	0.51	0.34	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68286821	chr10:68233251~68242379:-
PRAD	cis	rs2115630	0.645	rs4842978	ENSG00000225151.9	GOLGA2P7	7.65	1.2e-13	5.19e-11	0.42	0.34	P wave terminal force;	chr15:84654022	chr15:84199311~84230136:-
PRAD	cis	rs2115630	0.645	rs1107179	ENSG00000225151.9	GOLGA2P7	-7.65	1.2e-13	5.19e-11	-0.42	-0.34	P wave terminal force;	chr15:84655131	chr15:84199311~84230136:-
PRAD	cis	rs10463554	0.553	rs72785712	ENSG00000175749.11	EIF3KP1	7.65	1.2e-13	5.2e-11	0.45	0.34	Parkinson's disease;	chr5:102988693	chr5:103032376~103033031:+
PRAD	cis	rs7615952	0.515	rs7637246	ENSG00000171084.14	FAM86JP	7.65	1.2e-13	5.2e-11	0.54	0.34	Blood pressure (smoking interaction);	chr3:125959863	chr3:125916620~125930024:+
PRAD	cis	rs6570726	1	rs951143	ENSG00000235652.6	RP11-545I5.3	7.65	1.2e-13	5.21e-11	0.36	0.34	Lobe attachment (rater-scored or self-reported);	chr6:145611440	chr6:145799409~145886585:+
PRAD	cis	rs2638953	0.85	rs10843111	ENSG00000278733.1	RP11-425D17.1	-7.65	1.2e-13	5.21e-11	-0.44	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28141022	chr12:28185625~28186190:-
PRAD	cis	rs6847067	0.794	rs4470615	ENSG00000180769.7	WDFY3-AS2	7.65	1.2e-13	5.22e-11	0.35	0.34	Oropharynx cancer;	chr4:85034218	chr4:84965682~85011277:+
PRAD	cis	rs12928939	0.774	rs7192860	ENSG00000260886.1	TAT-AS1	7.65	1.21e-13	5.22e-11	0.46	0.34	Post bronchodilator FEV1;	chr16:71609719	chr16:71565789~71578187:+
PRAD	cis	rs2638953	1	rs2638953	ENSG00000278733.1	RP11-425D17.1	7.65	1.21e-13	5.23e-11	0.4	0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28381482	chr12:28185625~28186190:-
PRAD	cis	rs7567389	0.719	rs4150402	ENSG00000236682.1	AC068282.3	-7.65	1.21e-13	5.23e-11	-0.45	-0.34	Self-rated health;	chr2:127292558	chr2:127389130~127400580:+
PRAD	cis	rs12612619	0.732	rs3754734	ENSG00000229122.1	AGBL5-IT1	7.65	1.21e-13	5.23e-11	0.35	0.34	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27076730	chr2:27061038~27061815:+
PRAD	cis	rs2255336	0.684	rs6416265	ENSG00000245648.1	RP11-277P12.20	7.65	1.21e-13	5.23e-11	0.54	0.34	Blood protein levels;	chr12:10344268	chr12:10363769~10398506:+
PRAD	cis	rs6782228	0.606	rs7650156	ENSG00000242551.2	POU5F1P6	-7.65	1.21e-13	5.25e-11	-0.42	-0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128642712	chr3:128674735~128677005:-
PRAD	cis	rs75422866	0.541	rs61918136	ENSG00000257433.4	RP1-197B17.3	7.65	1.21e-13	5.26e-11	0.64	0.34	Pneumonia;	chr12:47566798	chr12:47706085~47742294:+
PRAD	cis	rs1881744	0.588	rs78808618	ENSG00000257433.4	RP1-197B17.3	7.65	1.21e-13	5.26e-11	0.64	0.34	Metabolite levels (HVA/5-HIAA ratio);	chr12:47567624	chr12:47706085~47742294:+
PRAD	cis	rs2946504	0.861	rs2946502	ENSG00000251468.2	RP11-369K16.1	-7.65	1.22e-13	5.26e-11	-0.43	-0.34	Type 2 diabetes;	chr8:12955445	chr8:12958387~12962200:+
PRAD	cis	rs1799949	0.93	rs33968979	ENSG00000267002.1	RP11-242D8.1	7.65	1.22e-13	5.27e-11	0.31	0.34	Menopause (age at onset);	chr17:43145975	chr17:43164183~43170403:-
PRAD	cis	rs1799949	1	rs12952790	ENSG00000267002.1	RP11-242D8.1	7.65	1.22e-13	5.27e-11	0.31	0.34	Menopause (age at onset);	chr17:43147590	chr17:43164183~43170403:-
PRAD	cis	rs1799949	1	rs12950607	ENSG00000267002.1	RP11-242D8.1	7.65	1.22e-13	5.27e-11	0.31	0.34	Menopause (age at onset);	chr17:43147911	chr17:43164183~43170403:-
PRAD	cis	rs1799949	1	rs11079056	ENSG00000267002.1	RP11-242D8.1	7.65	1.22e-13	5.27e-11	0.31	0.34	Menopause (age at onset);	chr17:43148782	chr17:43164183~43170403:-
PRAD	cis	rs1799949	1	rs12936816	ENSG00000267002.1	RP11-242D8.1	7.65	1.22e-13	5.27e-11	0.31	0.34	Menopause (age at onset);	chr17:43149692	chr17:43164183~43170403:-
PRAD	cis	rs4925386	1	rs4925389	ENSG00000273619.1	RP5-908M14.9	7.65	1.22e-13	5.27e-11	0.21	0.34	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62347456	chr20:62386303~62386970:-
PRAD	cis	rs12908161	1	rs58416181	ENSG00000275120.1	RP11-182J1.17	7.65	1.22e-13	5.3e-11	0.44	0.34	Schizophrenia;	chr15:84721230	chr15:84599434~84606463:-
PRAD	cis	rs193541	0.53	rs6595405	ENSG00000263432.2	RN7SL689P	7.65	1.23e-13	5.3e-11	0.36	0.34	Glucose homeostasis traits;	chr5:122749050	chr5:123022487~123022783:-
PRAD	cis	rs2638953	0.925	rs11049549	ENSG00000278733.1	RP11-425D17.1	-7.65	1.23e-13	5.31e-11	-0.42	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28357808	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.853	rs3782515	ENSG00000278733.1	RP11-425D17.1	-7.65	1.23e-13	5.31e-11	-0.43	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28310511	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.962	rs11049521	ENSG00000278733.1	RP11-425D17.1	-7.65	1.23e-13	5.31e-11	-0.43	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28310976	chr12:28185625~28186190:-
PRAD	cis	rs2274273	1	rs72718804	ENSG00000258413.1	RP11-665C16.6	-7.65	1.23e-13	5.31e-11	-0.43	-0.34	Protein biomarker;	chr14:55163892	chr14:55262767~55272075:-
PRAD	cis	rs2337406	0.778	rs58113768	ENSG00000274576.2	IGHV2-70	-7.65	1.23e-13	5.32e-11	-0.38	-0.34	Alzheimer's disease (late onset);	chr14:106700213	chr14:106770577~106771020:-
PRAD	cis	rs6479891	0.908	rs4746201	ENSG00000232075.1	MRPL35P2	7.65	1.23e-13	5.33e-11	0.55	0.34	Arthritis (juvenile idiopathic);	chr10:63562621	chr10:63634317~63634827:-
PRAD	cis	rs7916697	0.54	rs4551651	ENSG00000233590.1	RP11-153K11.3	-7.65	1.24e-13	5.34e-11	-0.45	-0.34	Optic disc area;	chr10:68264772	chr10:68233251~68242379:-
PRAD	cis	rs1355223	0.902	rs34875830	ENSG00000271369.1	RP11-350D17.3	-7.65	1.24e-13	5.35e-11	-0.39	-0.34	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34700658	chr11:34709600~34710161:+
PRAD	cis	rs138024639	1	rs138024639	ENSG00000225595.2	XXbac-BPG308K3.6	7.65	1.24e-13	5.35e-11	0.78	0.34	Breast cancer;	chr6:28468244	chr6:28859625~28864630:-
PRAD	cis	rs853679	0.546	rs55690788	ENSG00000225595.2	XXbac-BPG308K3.6	7.65	1.24e-13	5.35e-11	0.78	0.34	Depression;	chr6:28468368	chr6:28859625~28864630:-
PRAD	cis	rs13191038	1	rs13191038	ENSG00000225595.2	XXbac-BPG308K3.6	7.65	1.24e-13	5.35e-11	0.78	0.34	Urinary tract infection frequency;	chr6:28515140	chr6:28859625~28864630:-
PRAD	cis	rs853679	0.567	rs7774981	ENSG00000204709.4	LINC01556	7.65	1.24e-13	5.35e-11	0.47	0.34	Depression;	chr6:28379133	chr6:28943877~28944537:+
PRAD	cis	rs853679	0.567	rs7754960	ENSG00000204709.4	LINC01556	7.65	1.24e-13	5.35e-11	0.47	0.34	Depression;	chr6:28379168	chr6:28943877~28944537:+
PRAD	cis	rs2439831	0.867	rs3101443	ENSG00000205771.5	CATSPER2P1	-7.65	1.24e-13	5.36e-11	-0.54	-0.34	Lung cancer in ever smokers;	chr15:43620174	chr15:43726918~43747094:-
PRAD	cis	rs11603023	0.569	rs573905	ENSG00000255422.1	AP002954.4	-7.65	1.24e-13	5.37e-11	-0.38	-0.34	Cholesterol, total;	chr11:118701558	chr11:118704607~118750263:+
PRAD	cis	rs2274273	1	rs66871576	ENSG00000258413.1	RP11-665C16.6	-7.65	1.24e-13	5.37e-11	-0.43	-0.34	Protein biomarker;	chr14:55162332	chr14:55262767~55272075:-
PRAD	cis	rs2274273	0.563	rs79163357	ENSG00000258413.1	RP11-665C16.6	-7.65	1.24e-13	5.37e-11	-0.46	-0.34	Protein biomarker;	chr14:55271731	chr14:55262767~55272075:-
PRAD	cis	rs853679	0.546	rs13213152	ENSG00000225595.2	XXbac-BPG308K3.6	7.65	1.24e-13	5.38e-11	0.76	0.34	Depression;	chr6:28381921	chr6:28859625~28864630:-
PRAD	cis	rs2739330	0.732	rs5760175	ENSG00000272787.1	KB-226F1.2	-7.65	1.25e-13	5.39e-11	-0.36	-0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23969211~23969873:+
PRAD	cis	rs964611	0.882	rs7182177	ENSG00000259488.2	RP11-154J22.1	-7.65	1.25e-13	5.39e-11	-0.34	-0.34	Metabolite levels (Pyroglutamine);	chr15:48354357	chr15:48312353~48331856:-
PRAD	cis	rs853679	0.607	rs66868086	ENSG00000280107.1	AL022393.9	-7.64	1.25e-13	5.41e-11	-0.69	-0.34	Depression;	chr6:27898124	chr6:28170845~28172521:+
PRAD	cis	rs17361889	0.752	rs6974124	ENSG00000224683.1	RPL36AP29	7.64	1.25e-13	5.41e-11	0.4	0.34	Pediatric bone mineral content (hip);	chr7:16234495	chr7:16208945~16209265:+
PRAD	cis	rs10853057	0.717	rs4791242	ENSG00000214174.7	AMZ2P1	-7.64	1.25e-13	5.41e-11	-0.55	-0.34	White matter microstructure (global fractional anisotropy);	chr17:65061533	chr17:64966550~64975576:-
PRAD	cis	rs2274273	0.84	rs10142448	ENSG00000258413.1	RP11-665C16.6	7.64	1.25e-13	5.41e-11	0.42	0.34	Protein biomarker;	chr14:55371390	chr14:55262767~55272075:-
PRAD	cis	rs2638953	0.962	rs11049537	ENSG00000278733.1	RP11-425D17.1	-7.64	1.26e-13	5.45e-11	-0.43	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28331239	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.962	rs11049530	ENSG00000278733.1	RP11-425D17.1	-7.64	1.27e-13	5.47e-11	-0.43	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28322220	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.962	rs11049531	ENSG00000278733.1	RP11-425D17.1	-7.64	1.27e-13	5.47e-11	-0.43	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28322797	chr12:28185625~28186190:-
PRAD	cis	rs2638953	1	rs11049532	ENSG00000278733.1	RP11-425D17.1	-7.64	1.27e-13	5.47e-11	-0.43	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28323979	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.925	rs10843154	ENSG00000278733.1	RP11-425D17.1	-7.64	1.27e-13	5.47e-11	-0.43	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28326824	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.889	rs10843155	ENSG00000278733.1	RP11-425D17.1	-7.64	1.27e-13	5.47e-11	-0.43	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28334920	chr12:28185625~28186190:-
PRAD	cis	rs7746199	0.736	rs72845070	ENSG00000280107.1	AL022393.9	-7.64	1.27e-13	5.49e-11	-0.69	-0.34	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27700521	chr6:28170845~28172521:+
PRAD	cis	rs6844153	0.887	rs6835631	ENSG00000240005.4	RP11-293A21.1	7.64	1.27e-13	5.49e-11	0.45	0.34	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26946864	chr4:26859806~26860599:-
PRAD	cis	rs3096299	0.606	rs4785573	ENSG00000274627.1	RP11-104N10.2	7.64	1.27e-13	5.5e-11	0.36	0.34	Multiple myeloma (IgH translocation);	chr16:89498995	chr16:89516797~89522217:+
PRAD	cis	rs2274273	0.624	rs10129505	ENSG00000258413.1	RP11-665C16.6	-7.64	1.28e-13	5.51e-11	-0.46	-0.34	Protein biomarker;	chr14:55309657	chr14:55262767~55272075:-
PRAD	cis	rs2274273	0.6	rs35112084	ENSG00000258413.1	RP11-665C16.6	-7.64	1.28e-13	5.51e-11	-0.46	-0.34	Protein biomarker;	chr14:55314382	chr14:55262767~55272075:-
PRAD	cis	rs2274273	0.624	rs1972221	ENSG00000258413.1	RP11-665C16.6	-7.64	1.28e-13	5.51e-11	-0.46	-0.34	Protein biomarker;	chr14:55318663	chr14:55262767~55272075:-
PRAD	cis	rs11098499	0.754	rs2036857	ENSG00000245958.5	RP11-33B1.1	-7.64	1.28e-13	5.52e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119328085	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.754	rs2036856	ENSG00000245958.5	RP11-33B1.1	-7.64	1.28e-13	5.52e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119328133	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.754	rs4443261	ENSG00000245958.5	RP11-33B1.1	-7.64	1.28e-13	5.52e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119328146	chr4:119454791~119552025:+
PRAD	cis	rs995000	0.868	rs1168107	ENSG00000235545.1	RP11-230B22.1	-7.64	1.28e-13	5.52e-11	-0.45	-0.34	Triglyceride levels;	chr1:62695502	chr1:62688482~62710694:+
PRAD	cis	rs6844153	0.887	rs62302474	ENSG00000240005.4	RP11-293A21.1	-7.64	1.28e-13	5.52e-11	-0.49	-0.34	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26909118	chr4:26859806~26860599:-
PRAD	cis	rs7829975	0.714	rs6994038	ENSG00000253893.2	FAM85B	-7.64	1.28e-13	5.52e-11	-0.43	-0.34	Mood instability;	chr8:8803028	chr8:8167819~8226614:-
PRAD	cis	rs1979679	0.879	rs1002863	ENSG00000278733.1	RP11-425D17.1	-7.64	1.28e-13	5.52e-11	-0.45	-0.34	Ossification of the posterior longitudinal ligament of the spine;	chr12:28500768	chr12:28185625~28186190:-
PRAD	cis	rs6479901	0.841	rs10733787	ENSG00000232075.1	MRPL35P2	-7.64	1.29e-13	5.55e-11	-0.41	-0.34	Intelligence (multi-trait analysis);	chr10:63147078	chr10:63634317~63634827:-
PRAD	cis	rs6479901	0.67	rs12240740	ENSG00000232075.1	MRPL35P2	-7.64	1.29e-13	5.55e-11	-0.41	-0.34	Intelligence (multi-trait analysis);	chr10:63147478	chr10:63634317~63634827:-
PRAD	cis	rs217727	0.818	rs2525883	ENSG00000226416.1	MRPL23-AS1	7.64	1.29e-13	5.56e-11	0.47	0.34	Breast cancer;	chr11:2000750	chr11:1983237~1989920:-
PRAD	cis	rs10463554	0.892	rs1560040	ENSG00000175749.11	EIF3KP1	7.64	1.29e-13	5.56e-11	0.45	0.34	Parkinson's disease;	chr5:102964363	chr5:103032376~103033031:+
PRAD	cis	rs2243480	1	rs4718269	ENSG00000226824.5	RP4-756H11.3	7.64	1.29e-13	5.57e-11	0.66	0.34	Diabetic kidney disease;	chr7:65735810	chr7:66654538~66669855:+
PRAD	cis	rs9640161	0.659	rs7781827	ENSG00000261305.1	RP4-584D14.7	7.64	1.29e-13	5.58e-11	0.36	0.34	Blood protein levels;Circulating chemerin levels;	chr7:150311769	chr7:150341771~150342607:+
PRAD	cis	rs881375	0.9	rs1930786	ENSG00000226752.6	PSMD5-AS1	-7.64	1.29e-13	5.58e-11	-0.4	-0.34	Rheumatoid arthritis;	chr9:120929191	chr9:120824828~120854385:+
PRAD	cis	rs881375	0.967	rs7864019	ENSG00000226752.6	PSMD5-AS1	-7.64	1.29e-13	5.58e-11	-0.4	-0.34	Rheumatoid arthritis;	chr9:120930590	chr9:120824828~120854385:+
PRAD	cis	rs2278034	0.516	rs9829709	ENSG00000273009.1	RP11-352G9.1	7.64	1.3e-13	5.59e-11	0.31	0.34	Bronchopulmonary dysplasia;	chr3:195889802	chr3:195913078~195913683:-
PRAD	cis	rs1799949	1	rs8176083	ENSG00000267002.1	RP11-242D8.1	7.64	1.3e-13	5.59e-11	0.32	0.34	Menopause (age at onset);	chr17:43123134	chr17:43164183~43170403:-
PRAD	cis	rs2243480	1	rs958550	ENSG00000226824.5	RP4-756H11.3	7.64	1.3e-13	5.59e-11	0.67	0.34	Diabetic kidney disease;	chr7:66170692	chr7:66654538~66669855:+
PRAD	cis	rs3096299	0.967	rs2911253	ENSG00000261118.1	RP11-104N10.1	7.64	1.3e-13	5.6e-11	0.33	0.34	Multiple myeloma (IgH translocation);	chr16:89422179	chr16:89492017~89504460:-
PRAD	cis	rs12612619	0.761	rs34732613	ENSG00000229122.1	AGBL5-IT1	7.64	1.3e-13	5.6e-11	0.35	0.34	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27031928	chr2:27061038~27061815:+
PRAD	cis	rs11976180	1	rs2961118	ENSG00000273234.1	OR2A13P	-7.64	1.3e-13	5.61e-11	-0.4	-0.34	Obesity-related traits;	chr7:144058350	chr7:144142009~144142938:+
PRAD	cis	rs11976180	1	rs2371244	ENSG00000273234.1	OR2A13P	-7.64	1.3e-13	5.61e-11	-0.4	-0.34	Obesity-related traits;	chr7:144060518	chr7:144142009~144142938:+
PRAD	cis	rs11976180	1	rs4726669	ENSG00000273234.1	OR2A13P	-7.64	1.3e-13	5.61e-11	-0.4	-0.34	Obesity-related traits;	chr7:144061098	chr7:144142009~144142938:+
PRAD	cis	rs9341835	0.525	rs1711893	ENSG00000218048.2	RP3-407E4.4	-7.64	1.3e-13	5.61e-11	-0.37	-0.34	Schizophrenia;	chr6:63272985	chr6:63440766~63443580:+
PRAD	cis	rs6860806	1	rs6860806	ENSG00000233006.5	AC034220.3	-7.64	1.3e-13	5.62e-11	-0.29	-0.34	Breast cancer;	chr5:132304843	chr5:132311285~132369916:-
PRAD	cis	rs9640161	0.617	rs56019796	ENSG00000261305.1	RP4-584D14.7	7.64	1.3e-13	5.62e-11	0.36	0.34	Blood protein levels;Circulating chemerin levels;	chr7:150312137	chr7:150341771~150342607:+
PRAD	cis	rs2255336	0.81	rs7139147	ENSG00000245648.1	RP11-277P12.20	7.64	1.31e-13	5.65e-11	0.56	0.34	Blood protein levels;	chr12:10361956	chr12:10363769~10398506:+
PRAD	cis	rs853679	1	rs9986596	ENSG00000226314.6	ZNF192P1	-7.64	1.31e-13	5.65e-11	-0.53	-0.34	Depression;	chr6:28251883	chr6:28161781~28169594:+
PRAD	cis	rs1426063	0.748	rs6534607	ENSG00000260265.1	RP11-44F21.5	7.64	1.31e-13	5.65e-11	0.48	0.34	QT interval;	chr4:75106366	chr4:75081702~75084717:-
PRAD	cis	rs11098499	1	rs10029750	ENSG00000245958.5	RP11-33B1.1	-7.64	1.31e-13	5.66e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119251388	chr4:119454791~119552025:+
PRAD	cis	rs6545883	0.524	rs811871	ENSG00000271889.1	RP11-493E12.1	-7.64	1.31e-13	5.67e-11	-0.37	-0.34	Tuberculosis;	chr2:61350814	chr2:61151433~61162105:-
PRAD	cis	rs494459	0.838	rs566733	ENSG00000278376.1	RP11-158I9.8	-7.64	1.31e-13	5.67e-11	-0.29	-0.34	Height;	chr11:118737916	chr11:118791254~118793137:+
PRAD	cis	rs853679	1	rs68141011	ENSG00000226314.6	ZNF192P1	-7.64	1.31e-13	5.67e-11	-0.54	-0.34	Depression;	chr6:28250019	chr6:28161781~28169594:+
PRAD	cis	rs853679	1	rs13200462	ENSG00000226314.6	ZNF192P1	-7.64	1.31e-13	5.67e-11	-0.54	-0.34	Depression;	chr6:28250421	chr6:28161781~28169594:+
PRAD	cis	rs6782228	0.606	rs4857861	ENSG00000242551.2	POU5F1P6	-7.64	1.31e-13	5.67e-11	-0.42	-0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128687924	chr3:128674735~128677005:-
PRAD	cis	rs6782228	0.606	rs4857919	ENSG00000242551.2	POU5F1P6	-7.64	1.31e-13	5.67e-11	-0.42	-0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128688652	chr3:128674735~128677005:-
PRAD	cis	rs9467773	0.511	rs17278688	ENSG00000241549.7	GUSBP2	7.64	1.31e-13	5.67e-11	0.38	0.34	Intelligence (multi-trait analysis);	chr6:26922357	chr6:26871484~26956554:-
PRAD	cis	rs673078	0.607	rs17441214	ENSG00000275409.1	RP11-131L12.4	-7.64	1.32e-13	5.68e-11	-0.5	-0.34	Glucose homeostasis traits;	chr12:118436721	chr12:118430147~118430699:+
PRAD	cis	rs6452524	0.775	rs10071579	ENSG00000249664.1	CTD-2227C6.2	7.64	1.32e-13	5.69e-11	0.41	0.34	Hypertension (SNP x SNP interaction);	chr5:83113925	chr5:83012285~83013109:-
PRAD	cis	rs45509595	0.822	rs200484	ENSG00000280107.1	AL022393.9	-7.64	1.32e-13	5.69e-11	-0.59	-0.34	Breast cancer;	chr6:27807896	chr6:28170845~28172521:+
PRAD	cis	rs45509595	0.841	rs9368531	ENSG00000280107.1	AL022393.9	-7.64	1.32e-13	5.69e-11	-0.59	-0.34	Breast cancer;	chr6:27814094	chr6:28170845~28172521:+
PRAD	cis	rs45509595	0.749	rs401763	ENSG00000280107.1	AL022393.9	-7.64	1.32e-13	5.69e-11	-0.59	-0.34	Breast cancer;	chr6:27814750	chr6:28170845~28172521:+
PRAD	cis	rs45509595	0.659	rs390764	ENSG00000280107.1	AL022393.9	-7.64	1.32e-13	5.69e-11	-0.59	-0.34	Breast cancer;	chr6:27814757	chr6:28170845~28172521:+
PRAD	cis	rs45509595	0.841	rs401754	ENSG00000280107.1	AL022393.9	-7.64	1.32e-13	5.69e-11	-0.59	-0.34	Breast cancer;	chr6:27814760	chr6:28170845~28172521:+
PRAD	cis	rs45509595	0.841	rs2747054	ENSG00000280107.1	AL022393.9	-7.64	1.32e-13	5.69e-11	-0.59	-0.34	Breast cancer;	chr6:27815581	chr6:28170845~28172521:+
PRAD	cis	rs7829975	0.511	rs2976902	ENSG00000253893.2	FAM85B	-7.64	1.32e-13	5.7e-11	-0.41	-0.34	Mood instability;	chr8:8483595	chr8:8167819~8226614:-
PRAD	cis	rs3096299	0.933	rs2965939	ENSG00000261118.1	RP11-104N10.1	7.64	1.32e-13	5.7e-11	0.34	0.34	Multiple myeloma (IgH translocation);	chr16:89426635	chr16:89492017~89504460:-
PRAD	cis	rs3096299	0.967	rs2965932	ENSG00000274627.1	RP11-104N10.2	-7.64	1.32e-13	5.7e-11	-0.36	-0.34	Multiple myeloma (IgH translocation);	chr16:89410643	chr16:89516797~89522217:+
PRAD	cis	rs1552244	0.554	rs3846169	ENSG00000206567.8	AC022007.5	7.64	1.33e-13	5.72e-11	0.37	0.34	Alzheimer's disease;	chr3:9955370	chr3:10006418~10011209:-
PRAD	cis	rs6479901	0.895	rs67963837	ENSG00000232075.1	MRPL35P2	-7.64	1.33e-13	5.72e-11	-0.41	-0.34	Intelligence (multi-trait analysis);	chr10:63247111	chr10:63634317~63634827:-
PRAD	cis	rs1075265	0.508	rs12621225	ENSG00000233266.1	HMGB1P31	7.64	1.33e-13	5.72e-11	0.47	0.34	Chronotype;Morning vs. evening chronotype;	chr2:53710040	chr2:54051334~54051760:+
PRAD	cis	rs4713118	0.662	rs149970	ENSG00000272009.1	RP1-313I6.12	-7.64	1.33e-13	5.72e-11	-0.34	-0.34	Parkinson's disease;	chr6:28012442	chr6:28078792~28081130:-
PRAD	cis	rs1799949	0.931	rs34410138	ENSG00000267002.1	RP11-242D8.1	7.64	1.33e-13	5.73e-11	0.32	0.34	Menopause (age at onset);	chr17:43127753	chr17:43164183~43170403:-
PRAD	cis	rs12928939	0.815	rs12446005	ENSG00000260886.1	TAT-AS1	7.64	1.33e-13	5.73e-11	0.46	0.34	Post bronchodilator FEV1;	chr16:71621132	chr16:71565789~71578187:+
PRAD	cis	rs6570726	0.875	rs368744	ENSG00000235652.6	RP11-545I5.3	7.64	1.33e-13	5.73e-11	0.36	0.34	Lobe attachment (rater-scored or self-reported);	chr6:145491486	chr6:145799409~145886585:+
PRAD	cis	rs7238033	0.663	rs11660575	ENSG00000267193.4	RP11-116O18.3	7.64	1.33e-13	5.73e-11	0.37	0.34	Bladder cancer;	chr18:45740473	chr18:45669367~45747215:-
PRAD	cis	rs13113518	0.557	rs13142096	ENSG00000249700.7	SRD5A3-AS1	7.64	1.33e-13	5.75e-11	0.47	0.34	Height;	chr4:55566291	chr4:55363971~55395847:-
PRAD	cis	rs10463554	0.824	rs3776868	ENSG00000175749.11	EIF3KP1	7.64	1.33e-13	5.75e-11	0.44	0.34	Parkinson's disease;	chr5:102963012	chr5:103032376~103033031:+
PRAD	cis	rs526231	0.575	rs66730942	ENSG00000175749.11	EIF3KP1	7.64	1.34e-13	5.75e-11	0.46	0.34	Primary biliary cholangitis;	chr5:102971075	chr5:103032376~103033031:+
PRAD	cis	rs526231	0.575	rs62362524	ENSG00000175749.11	EIF3KP1	7.64	1.34e-13	5.75e-11	0.46	0.34	Primary biliary cholangitis;	chr5:102978523	chr5:103032376~103033031:+
PRAD	cis	rs2739330	0.703	rs5760112	ENSG00000228039.3	KB-1125A3.10	7.64	1.34e-13	5.75e-11	0.44	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23963780~23964374:+
PRAD	cis	rs526231	0.511	rs26255	ENSG00000175749.11	EIF3KP1	7.64	1.34e-13	5.77e-11	0.47	0.34	Primary biliary cholangitis;	chr5:103218399	chr5:103032376~103033031:+
PRAD	cis	rs526231	0.543	rs246916	ENSG00000175749.11	EIF3KP1	7.64	1.34e-13	5.77e-11	0.47	0.34	Primary biliary cholangitis;	chr5:103221814	chr5:103032376~103033031:+
PRAD	cis	rs11018904	0.906	rs55685917	ENSG00000280385.1	AP000648.5	-7.63	1.34e-13	5.78e-11	-0.48	-0.34	Intelligence (multi-trait analysis);	chr11:90231197	chr11:90193614~90198120:+
PRAD	cis	rs11018904	0.906	rs35286339	ENSG00000280385.1	AP000648.5	-7.63	1.34e-13	5.78e-11	-0.48	-0.34	Intelligence (multi-trait analysis);	chr11:90232511	chr11:90193614~90198120:+
PRAD	cis	rs853679	1	rs7740487	ENSG00000226314.6	ZNF192P1	-7.63	1.34e-13	5.79e-11	-0.53	-0.34	Depression;	chr6:28248708	chr6:28161781~28169594:+
PRAD	cis	rs2337406	1	rs74090714	ENSG00000274576.2	IGHV2-70	-7.63	1.34e-13	5.79e-11	-0.36	-0.34	Alzheimer's disease (late onset);	chr14:106691225	chr14:106770577~106771020:-
PRAD	cis	rs881375	1	rs10760121	ENSG00000226752.6	PSMD5-AS1	-7.63	1.35e-13	5.8e-11	-0.4	-0.34	Rheumatoid arthritis;	chr9:120885637	chr9:120824828~120854385:+
PRAD	cis	rs58873874	0.737	rs80320835	ENSG00000251405.2	CTB-109A12.1	7.63	1.35e-13	5.81e-11	0.88	0.34	Bipolar disorder (body mass index interaction);	chr5:157389887	chr5:157362615~157460078:-
PRAD	cis	rs172166	0.637	rs1225597	ENSG00000204709.4	LINC01556	7.63	1.35e-13	5.83e-11	0.43	0.34	Cardiac Troponin-T levels;	chr6:28194309	chr6:28943877~28944537:+
PRAD	cis	rs2638953	0.962	rs3825246	ENSG00000278733.1	RP11-425D17.1	-7.63	1.35e-13	5.83e-11	-0.43	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28310186	chr12:28185625~28186190:-
PRAD	cis	rs12612619	0.732	rs1053609	ENSG00000229122.1	AGBL5-IT1	7.63	1.35e-13	5.83e-11	0.35	0.34	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27070282	chr2:27061038~27061815:+
PRAD	cis	rs2439831	0.85	rs7169322	ENSG00000205771.5	CATSPER2P1	-7.63	1.35e-13	5.83e-11	-0.53	-0.34	Lung cancer in ever smokers;	chr15:43838816	chr15:43726918~43747094:-
PRAD	cis	rs2439831	0.85	rs28413704	ENSG00000205771.5	CATSPER2P1	-7.63	1.35e-13	5.83e-11	-0.53	-0.34	Lung cancer in ever smokers;	chr15:43856229	chr15:43726918~43747094:-
PRAD	cis	rs2439831	0.702	rs9989313	ENSG00000205771.5	CATSPER2P1	-7.63	1.35e-13	5.83e-11	-0.53	-0.34	Lung cancer in ever smokers;	chr15:43860619	chr15:43726918~43747094:-
PRAD	cis	rs6847067	0.965	rs2046402	ENSG00000180769.7	WDFY3-AS2	7.63	1.35e-13	5.83e-11	0.35	0.34	Oropharynx cancer;	chr4:84841232	chr4:84965682~85011277:+
PRAD	cis	rs10028773	0.6	rs4001390	ENSG00000245958.5	RP11-33B1.1	-7.63	1.36e-13	5.84e-11	-0.31	-0.34	Educational attainment;	chr4:119344628	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.691	rs2136911	ENSG00000245958.5	RP11-33B1.1	-7.63	1.36e-13	5.84e-11	-0.31	-0.34	Corneal astigmatism;	chr4:119344704	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.779	rs6815934	ENSG00000245958.5	RP11-33B1.1	-7.63	1.36e-13	5.84e-11	-0.31	-0.34	Corneal astigmatism;	chr4:119346155	chr4:119454791~119552025:+
PRAD	cis	rs10028773	0.568	rs6838457	ENSG00000245958.5	RP11-33B1.1	-7.63	1.36e-13	5.84e-11	-0.31	-0.34	Educational attainment;	chr4:119346212	chr4:119454791~119552025:+
PRAD	cis	rs17361889	0.727	rs61282805	ENSG00000224683.1	RPL36AP29	7.63	1.36e-13	5.84e-11	0.39	0.34	Pediatric bone mineral content (hip);	chr7:16236981	chr7:16208945~16209265:+
PRAD	cis	rs914615	0.508	rs4971079	ENSG00000160766.13	GBAP1	-7.63	1.36e-13	5.84e-11	-0.34	-0.34	Urinary albumin-to-creatinine ratio;	chr1:155157915	chr1:155213821~155227422:-
PRAD	cis	rs2522056	0.808	rs2706373	ENSG00000233006.5	AC034220.3	-7.63	1.36e-13	5.85e-11	-0.34	-0.34	Fibrinogen;Lymphocyte counts;	chr5:132468564	chr5:132311285~132369916:-
PRAD	cis	rs2522056	1	rs2522062	ENSG00000233006.5	AC034220.3	-7.63	1.36e-13	5.85e-11	-0.34	-0.34	Fibrinogen;Lymphocyte counts;	chr5:132469724	chr5:132311285~132369916:-
PRAD	cis	rs2522056	1	rs2522063	ENSG00000233006.5	AC034220.3	-7.63	1.36e-13	5.85e-11	-0.34	-0.34	Fibrinogen;Lymphocyte counts;	chr5:132469899	chr5:132311285~132369916:-
PRAD	cis	rs2522056	1	rs2706379	ENSG00000233006.5	AC034220.3	-7.63	1.36e-13	5.85e-11	-0.34	-0.34	Fibrinogen;Lymphocyte counts;	chr5:132470043	chr5:132311285~132369916:-
PRAD	cis	rs12908161	0.959	rs2175567	ENSG00000275120.1	RP11-182J1.17	7.63	1.36e-13	5.86e-11	0.43	0.34	Schizophrenia;	chr15:84657715	chr15:84599434~84606463:-
PRAD	cis	rs6479901	0.947	rs6479897	ENSG00000232075.1	MRPL35P2	-7.63	1.36e-13	5.86e-11	-0.41	-0.34	Intelligence (multi-trait analysis);	chr10:63376868	chr10:63634317~63634827:-
PRAD	cis	rs12468226	1	rs58288071	ENSG00000273456.1	RP11-686O6.2	7.63	1.36e-13	5.87e-11	0.47	0.34	Urate levels;	chr2:202350016	chr2:202374932~202375604:-
PRAD	cis	rs2439831	0.85	rs16977798	ENSG00000249839.1	AC011330.5	-7.63	1.37e-13	5.89e-11	-0.58	-0.34	Lung cancer in ever smokers;	chr15:43859750	chr15:43663654~43684339:-
PRAD	cis	rs172166	0.637	rs1233691	ENSG00000204709.4	LINC01556	7.63	1.37e-13	5.9e-11	0.43	0.34	Cardiac Troponin-T levels;	chr6:28186119	chr6:28943877~28944537:+
PRAD	cis	rs2274273	0.624	rs7151581	ENSG00000258413.1	RP11-665C16.6	7.63	1.37e-13	5.91e-11	0.45	0.34	Protein biomarker;	chr14:55321727	chr14:55262767~55272075:-
PRAD	cis	rs9341835	0.608	rs2800017	ENSG00000218048.2	RP3-407E4.4	-7.63	1.37e-13	5.91e-11	-0.38	-0.34	Schizophrenia;	chr6:63448172	chr6:63440766~63443580:+
PRAD	cis	rs6847067	0.929	rs72664934	ENSG00000180769.7	WDFY3-AS2	7.63	1.37e-13	5.91e-11	0.35	0.34	Oropharynx cancer;	chr4:84859500	chr4:84965682~85011277:+
PRAD	cis	rs7567389	0.677	rs72848616	ENSG00000236682.1	AC068282.3	-7.63	1.37e-13	5.91e-11	-0.44	-0.34	Self-rated health;	chr2:127377521	chr2:127389130~127400580:+
PRAD	cis	rs7567389	0.71	rs72848618	ENSG00000236682.1	AC068282.3	-7.63	1.37e-13	5.91e-11	-0.44	-0.34	Self-rated health;	chr2:127377749	chr2:127389130~127400580:+
PRAD	cis	rs7238033	0.624	rs10432193	ENSG00000267193.4	RP11-116O18.3	7.63	1.38e-13	5.92e-11	0.37	0.34	Bladder cancer;	chr18:45727107	chr18:45669367~45747215:-
PRAD	cis	rs1043099	1	rs1043099	ENSG00000279699.1	RP1-102K2.9	-7.63	1.38e-13	5.92e-11	-0.52	-0.34	Rheumatoid arthritis;	chr22:30285268	chr22:30275215~30276951:-
PRAD	cis	rs4845570	1	rs4845570	ENSG00000268288.1	RP11-98D18.16	-7.63	1.38e-13	5.92e-11	-0.5	-0.34	Coronary artery disease;	chr1:151786628	chr1:151766486~151767000:-
PRAD	cis	rs12908161	0.96	rs11633450	ENSG00000259728.4	LINC00933	7.63	1.38e-13	5.93e-11	0.42	0.34	Schizophrenia;	chr15:84764056	chr15:84570649~84580175:+
PRAD	cis	rs6479901	0.895	rs7082066	ENSG00000232075.1	MRPL35P2	-7.63	1.38e-13	5.93e-11	-0.41	-0.34	Intelligence (multi-trait analysis);	chr10:63239211	chr10:63634317~63634827:-
PRAD	cis	rs9549328	0.7	rs2185001	ENSG00000267868.1	RP11-120K24.3	7.63	1.38e-13	5.94e-11	0.41	0.34	Systolic blood pressure;	chr13:112962055	chr13:112964835~112966131:-
PRAD	cis	rs2108622	1	rs2108622	ENSG00000267056.2	AC005336.4	7.63	1.38e-13	5.94e-11	0.48	0.34	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15879621	chr19:15910582~15911824:-
PRAD	cis	rs2739330	0.76	rs1002286	ENSG00000228039.3	KB-1125A3.10	-7.63	1.38e-13	5.94e-11	-0.44	-0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23963780~23964374:+
PRAD	cis	rs42648	0.935	rs42621	ENSG00000227646.6	STEAP2-AS1	-7.63	1.38e-13	5.95e-11	-0.31	-0.34	Homocysteine levels;	chr7:90327170	chr7:89882353~90211635:-
PRAD	cis	rs42648	0.905	rs42622	ENSG00000227646.6	STEAP2-AS1	-7.63	1.38e-13	5.95e-11	-0.31	-0.34	Homocysteine levels;	chr7:90327510	chr7:89882353~90211635:-
PRAD	cis	rs10463554	0.963	rs26253	ENSG00000175749.11	EIF3KP1	7.63	1.38e-13	5.95e-11	0.44	0.34	Parkinson's disease;	chr5:103221266	chr5:103032376~103033031:+
PRAD	cis	rs780096	1	rs780095	ENSG00000234072.1	AC074117.10	-7.63	1.38e-13	5.96e-11	-0.26	-0.34	Total body bone mineral density;	chr2:27518238	chr2:27356246~27367622:+
PRAD	cis	rs853679	0.527	rs213228	ENSG00000204709.4	LINC01556	7.63	1.39e-13	5.96e-11	0.43	0.34	Depression;	chr6:28363475	chr6:28943877~28944537:+
PRAD	cis	rs42648	0.564	rs1541428	ENSG00000227646.6	STEAP2-AS1	-7.63	1.39e-13	5.97e-11	-0.3	-0.34	Homocysteine levels;	chr7:90206965	chr7:89882353~90211635:-
PRAD	cis	rs9810089	1	rs1279831	ENSG00000261758.1	RP11-102M11.2	7.63	1.39e-13	5.97e-11	0.39	0.34	Gestational age at birth (child effect);	chr3:136214422	chr3:136752630~136755780:+
PRAD	cis	rs453301	0.624	rs2979265	ENSG00000253893.2	FAM85B	-7.63	1.39e-13	5.98e-11	-0.43	-0.34	Joint mobility (Beighton score);	chr8:9001207	chr8:8167819~8226614:-
PRAD	cis	rs6545883	0.507	rs59981505	ENSG00000271889.1	RP11-493E12.1	-7.63	1.39e-13	5.99e-11	-0.37	-0.34	Tuberculosis;	chr2:61353394	chr2:61151433~61162105:-
PRAD	cis	rs1150668	0.83	rs2859365	ENSG00000280107.1	AL022393.9	7.63	1.4e-13	6e-11	0.4	0.34	Pubertal anthropometrics;	chr6:28423688	chr6:28170845~28172521:+
PRAD	cis	rs12612619	0.696	rs11678188	ENSG00000229122.1	AGBL5-IT1	7.63	1.4e-13	6e-11	0.35	0.34	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27024964	chr2:27061038~27061815:+
PRAD	cis	rs7238033	0.663	rs11665385	ENSG00000267193.4	RP11-116O18.3	-7.63	1.4e-13	6.02e-11	-0.37	-0.34	Bladder cancer;	chr18:45738781	chr18:45669367~45747215:-
PRAD	cis	rs9640161	0.658	rs57888387	ENSG00000261305.1	RP4-584D14.7	7.63	1.4e-13	6.03e-11	0.38	0.34	Blood protein levels;Circulating chemerin levels;	chr7:150307155	chr7:150341771~150342607:+
PRAD	cis	rs6547741	0.967	rs4665986	ENSG00000234072.1	AC074117.10	7.63	1.41e-13	6.04e-11	0.25	0.34	Oral cavity cancer;	chr2:27532301	chr2:27356246~27367622:+
PRAD	cis	rs2439831	0.85	rs3825783	ENSG00000249839.1	AC011330.5	-7.63	1.41e-13	6.04e-11	-0.58	-0.34	Lung cancer in ever smokers;	chr15:43810111	chr15:43663654~43684339:-
PRAD	cis	rs7739264	0.644	rs7753263	ENSG00000228412.5	RP4-625H18.2	7.63	1.41e-13	6.04e-11	0.41	0.34	Endometriosis;	chr6:19823021	chr6:19802164~19804752:-
PRAD	cis	rs193541	0.53	rs2125857	ENSG00000263432.2	RN7SL689P	7.63	1.41e-13	6.05e-11	0.36	0.34	Glucose homeostasis traits;	chr5:122747461	chr5:123022487~123022783:-
PRAD	cis	rs12612619	0.732	rs3754734	ENSG00000272148.1	RP11-195B17.1	7.63	1.41e-13	6.06e-11	0.4	0.34	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27076730	chr2:27062428~27062907:-
PRAD	cis	rs4664293	0.967	rs2357526	ENSG00000226266.5	AC009961.3	7.63	1.41e-13	6.06e-11	0.44	0.34	Monocyte percentage of white cells;	chr2:159668085	chr2:159670708~159712435:-
PRAD	cis	rs6479901	0.894	rs10761748	ENSG00000232075.1	MRPL35P2	-7.63	1.41e-13	6.07e-11	-0.41	-0.34	Intelligence (multi-trait analysis);	chr10:63350216	chr10:63634317~63634827:-
PRAD	cis	rs6479901	0.846	rs7082926	ENSG00000232075.1	MRPL35P2	-7.63	1.41e-13	6.07e-11	-0.41	-0.34	Intelligence (multi-trait analysis);	chr10:63355771	chr10:63634317~63634827:-
PRAD	cis	rs881375	0.967	rs1008382	ENSG00000226752.6	PSMD5-AS1	-7.63	1.41e-13	6.07e-11	-0.4	-0.34	Rheumatoid arthritis;	chr9:120918977	chr9:120824828~120854385:+
PRAD	cis	rs12488721	1	rs12488721	ENSG00000261758.1	RP11-102M11.2	7.63	1.41e-13	6.08e-11	0.39	0.34	Neuroticism;	chr3:136273803	chr3:136752630~136755780:+
PRAD	cis	rs9810089	0.934	rs684195	ENSG00000261758.1	RP11-102M11.2	7.63	1.41e-13	6.08e-11	0.39	0.34	Gestational age at birth (child effect);	chr3:136274757	chr3:136752630~136755780:+
PRAD	cis	rs9810089	0.934	rs1279949	ENSG00000261758.1	RP11-102M11.2	7.63	1.41e-13	6.08e-11	0.39	0.34	Gestational age at birth (child effect);	chr3:136278028	chr3:136752630~136755780:+
PRAD	cis	rs9810089	0.814	rs1279424	ENSG00000261758.1	RP11-102M11.2	7.63	1.41e-13	6.08e-11	0.39	0.34	Gestational age at birth (child effect);	chr3:136288491	chr3:136752630~136755780:+
PRAD	cis	rs858239	0.6	rs13438188	ENSG00000226816.2	AC005082.12	-7.63	1.41e-13	6.08e-11	-0.38	-0.34	Cerebrospinal fluid biomarker levels;	chr7:23104578	chr7:23206013~23208045:+
PRAD	cis	rs7191700	0.673	rs12325495	ENSG00000263080.1	RP11-485G7.5	7.63	1.42e-13	6.08e-11	0.41	0.34	Multiple sclerosis;	chr16:11324471	chr16:11341809~11345211:-
PRAD	cis	rs1552244	0.554	rs3846167	ENSG00000206567.8	AC022007.5	-7.63	1.42e-13	6.08e-11	-0.37	-0.34	Alzheimer's disease;	chr3:9954742	chr3:10006418~10011209:-
PRAD	cis	rs881375	1	rs6478486	ENSG00000226752.6	PSMD5-AS1	-7.63	1.42e-13	6.08e-11	-0.4	-0.34	Rheumatoid arthritis;	chr9:120893051	chr9:120824828~120854385:+
PRAD	cis	rs881375	1	rs7037140	ENSG00000226752.6	PSMD5-AS1	-7.63	1.42e-13	6.08e-11	-0.4	-0.34	Rheumatoid arthritis;	chr9:120894049	chr9:120824828~120854385:+
PRAD	cis	rs881375	0.967	rs1860823	ENSG00000226752.6	PSMD5-AS1	-7.63	1.42e-13	6.08e-11	-0.4	-0.34	Rheumatoid arthritis;	chr9:120897026	chr9:120824828~120854385:+
PRAD	cis	rs881375	0.967	rs1860824	ENSG00000226752.6	PSMD5-AS1	-7.63	1.42e-13	6.08e-11	-0.4	-0.34	Rheumatoid arthritis;	chr9:120897061	chr9:120824828~120854385:+
PRAD	cis	rs881375	0.967	rs7875829	ENSG00000226752.6	PSMD5-AS1	-7.63	1.42e-13	6.08e-11	-0.4	-0.34	Rheumatoid arthritis;	chr9:120898120	chr9:120824828~120854385:+
PRAD	cis	rs881375	0.867	rs10818484	ENSG00000226752.6	PSMD5-AS1	-7.63	1.42e-13	6.08e-11	-0.4	-0.34	Rheumatoid arthritis;	chr9:120898916	chr9:120824828~120854385:+
PRAD	cis	rs881375	0.933	rs7859805	ENSG00000226752.6	PSMD5-AS1	-7.63	1.42e-13	6.08e-11	-0.4	-0.34	Rheumatoid arthritis;	chr9:120901845	chr9:120824828~120854385:+
PRAD	cis	rs881375	0.933	rs10818485	ENSG00000226752.6	PSMD5-AS1	-7.63	1.42e-13	6.08e-11	-0.4	-0.34	Rheumatoid arthritis;	chr9:120905538	chr9:120824828~120854385:+
PRAD	cis	rs881375	0.967	rs10435843	ENSG00000226752.6	PSMD5-AS1	-7.63	1.42e-13	6.08e-11	-0.4	-0.34	Rheumatoid arthritis;	chr9:120905755	chr9:120824828~120854385:+
PRAD	cis	rs881375	0.967	rs10435844	ENSG00000226752.6	PSMD5-AS1	-7.63	1.42e-13	6.08e-11	-0.4	-0.34	Rheumatoid arthritis;	chr9:120905921	chr9:120824828~120854385:+
PRAD	cis	rs881375	0.967	rs7848332	ENSG00000226752.6	PSMD5-AS1	-7.63	1.42e-13	6.08e-11	-0.4	-0.34	Rheumatoid arthritis;	chr9:120907218	chr9:120824828~120854385:+
PRAD	cis	rs881375	0.967	rs2239658	ENSG00000226752.6	PSMD5-AS1	-7.63	1.42e-13	6.08e-11	-0.4	-0.34	Rheumatoid arthritis;	chr9:120909559	chr9:120824828~120854385:+
PRAD	cis	rs7688540	0.771	rs10027325	ENSG00000275426.1	CH17-262A2.1	7.63	1.42e-13	6.09e-11	0.47	0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:288819	chr4:149738~150317:+
PRAD	cis	rs7688540	0.771	rs1986557	ENSG00000275426.1	CH17-262A2.1	7.63	1.42e-13	6.09e-11	0.47	0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:289329	chr4:149738~150317:+
PRAD	cis	rs9810089	0.934	rs1153877	ENSG00000261758.1	RP11-102M11.2	7.63	1.42e-13	6.1e-11	0.39	0.34	Gestational age at birth (child effect);	chr3:136286083	chr3:136752630~136755780:+
PRAD	cis	rs11976180	1	rs13243677	ENSG00000273234.1	OR2A13P	-7.63	1.42e-13	6.1e-11	-0.4	-0.34	Obesity-related traits;	chr7:144049479	chr7:144142009~144142938:+
PRAD	cis	rs435066	0.633	rs6663232	ENSG00000234264.1	DEPDC1-AS1	7.63	1.42e-13	6.11e-11	0.49	0.34	IgG glycosylation;	chr1:68541658	chr1:68496676~68538627:+
PRAD	cis	rs7238033	0.663	rs8086631	ENSG00000267193.4	RP11-116O18.3	7.63	1.42e-13	6.11e-11	0.37	0.34	Bladder cancer;	chr18:45741477	chr18:45669367~45747215:-
PRAD	cis	rs2404602	0.563	rs12914005	ENSG00000259422.1	RP11-593F23.1	7.63	1.43e-13	6.12e-11	0.41	0.34	Blood metabolite levels;	chr15:76473326	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.536	rs7163946	ENSG00000259422.1	RP11-593F23.1	7.63	1.43e-13	6.12e-11	0.41	0.34	Blood metabolite levels;	chr15:76473708	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.536	rs7165025	ENSG00000259422.1	RP11-593F23.1	7.63	1.43e-13	6.12e-11	0.41	0.34	Blood metabolite levels;	chr15:76474093	chr15:76174891~76181486:-
PRAD	cis	rs2404602	0.536	rs1587381	ENSG00000259422.1	RP11-593F23.1	7.63	1.43e-13	6.12e-11	0.41	0.34	Blood metabolite levels;	chr15:76477279	chr15:76174891~76181486:-
PRAD	cis	rs2274273	0.624	rs7155954	ENSG00000258413.1	RP11-665C16.6	-7.63	1.43e-13	6.12e-11	-0.46	-0.34	Protein biomarker;	chr14:55284225	chr14:55262767~55272075:-
PRAD	cis	rs12612619	0.732	rs11680096	ENSG00000229122.1	AGBL5-IT1	7.63	1.43e-13	6.13e-11	0.35	0.34	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27050703	chr2:27061038~27061815:+
PRAD	cis	rs4664293	1	rs2357382	ENSG00000226266.5	AC009961.3	-7.63	1.43e-13	6.13e-11	-0.44	-0.34	Monocyte percentage of white cells;	chr2:159636614	chr2:159670708~159712435:-
PRAD	cis	rs1134634	0.52	rs7665390	ENSG00000273133.1	RP11-799M12.2	-7.63	1.43e-13	6.14e-11	-0.45	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15576115	chr4:15563698~15564253:-
PRAD	cis	rs7238033	0.641	rs8086499	ENSG00000267193.4	RP11-116O18.3	7.63	1.43e-13	6.14e-11	0.37	0.34	Bladder cancer;	chr18:45741447	chr18:45669367~45747215:-
PRAD	cis	rs7238033	0.663	rs12454680	ENSG00000267193.4	RP11-116O18.3	7.63	1.43e-13	6.14e-11	0.37	0.34	Bladder cancer;	chr18:45741452	chr18:45669367~45747215:-
PRAD	cis	rs17772222	0.958	rs891750	ENSG00000258983.2	RP11-507K2.2	7.63	1.43e-13	6.14e-11	0.49	0.34	Coronary artery calcification;	chr14:88550856	chr14:88499334~88515502:+
PRAD	cis	rs17772222	0.958	rs891749	ENSG00000258983.2	RP11-507K2.2	7.63	1.43e-13	6.14e-11	0.49	0.34	Coronary artery calcification;	chr14:88550893	chr14:88499334~88515502:+
PRAD	cis	rs435066	0.633	rs11209316	ENSG00000234264.1	DEPDC1-AS1	-7.63	1.43e-13	6.15e-11	-0.5	-0.34	IgG glycosylation;	chr1:68530362	chr1:68496676~68538627:+
PRAD	cis	rs435066	0.595	rs1924537	ENSG00000234264.1	DEPDC1-AS1	-7.63	1.43e-13	6.15e-11	-0.5	-0.34	IgG glycosylation;	chr1:68532087	chr1:68496676~68538627:+
PRAD	cis	rs435066	0.594	rs1924535	ENSG00000234264.1	DEPDC1-AS1	-7.63	1.43e-13	6.15e-11	-0.5	-0.34	IgG glycosylation;	chr1:68532771	chr1:68496676~68538627:+
PRAD	cis	rs2439831	0.85	rs28513374	ENSG00000205771.5	CATSPER2P1	-7.63	1.43e-13	6.15e-11	-0.53	-0.34	Lung cancer in ever smokers;	chr15:43833297	chr15:43726918~43747094:-
PRAD	cis	rs10463554	0.963	rs11955683	ENSG00000175749.11	EIF3KP1	7.63	1.43e-13	6.16e-11	0.43	0.34	Parkinson's disease;	chr5:102990992	chr5:103032376~103033031:+
PRAD	cis	rs2439831	0.85	rs3736180	ENSG00000205771.5	CATSPER2P1	-7.63	1.44e-13	6.16e-11	-0.53	-0.34	Lung cancer in ever smokers;	chr15:43814426	chr15:43726918~43747094:-
PRAD	cis	rs2255336	0.938	rs10161486	ENSG00000245648.1	RP11-277P12.20	-7.63	1.44e-13	6.16e-11	-0.51	-0.34	Blood protein levels;	chr12:10457167	chr12:10363769~10398506:+
PRAD	cis	rs2255336	0.938	rs73070924	ENSG00000245648.1	RP11-277P12.20	-7.63	1.44e-13	6.16e-11	-0.51	-0.34	Blood protein levels;	chr12:10457386	chr12:10363769~10398506:+
PRAD	cis	rs4713118	0.629	rs203887	ENSG00000219392.1	RP1-265C24.5	-7.62	1.44e-13	6.17e-11	-0.47	-0.34	Parkinson's disease;	chr6:28053491	chr6:28115628~28116551:+
PRAD	cis	rs1799949	0.965	rs33925201	ENSG00000267002.1	RP11-242D8.1	7.62	1.44e-13	6.17e-11	0.31	0.34	Menopause (age at onset);	chr17:43128665	chr17:43164183~43170403:-
PRAD	cis	rs2274273	0.588	rs2880103	ENSG00000258413.1	RP11-665C16.6	-7.62	1.44e-13	6.17e-11	-0.46	-0.34	Protein biomarker;	chr14:55271114	chr14:55262767~55272075:-
PRAD	cis	rs2274273	0.553	rs56166765	ENSG00000258413.1	RP11-665C16.6	-7.62	1.44e-13	6.17e-11	-0.46	-0.34	Protein biomarker;	chr14:55271300	chr14:55262767~55272075:-
PRAD	cis	rs526231	0.575	rs62362523	ENSG00000175749.11	EIF3KP1	7.62	1.44e-13	6.18e-11	0.45	0.34	Primary biliary cholangitis;	chr5:102977979	chr5:103032376~103033031:+
PRAD	cis	rs748404	0.697	rs513970	ENSG00000205771.5	CATSPER2P1	-7.62	1.44e-13	6.18e-11	-0.37	-0.34	Lung cancer;	chr15:43287368	chr15:43726918~43747094:-
PRAD	cis	rs12908161	0.959	rs11637728	ENSG00000275120.1	RP11-182J1.17	7.62	1.44e-13	6.19e-11	0.43	0.34	Schizophrenia;	chr15:84660161	chr15:84599434~84606463:-
PRAD	cis	rs1043099	0.912	rs4339043	ENSG00000279699.1	RP1-102K2.9	7.62	1.45e-13	6.21e-11	0.52	0.34	Rheumatoid arthritis;	chr22:30339919	chr22:30275215~30276951:-
PRAD	cis	rs2638953	0.889	rs11049538	ENSG00000278733.1	RP11-425D17.1	-7.62	1.45e-13	6.22e-11	-0.43	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28335801	chr12:28185625~28186190:-
PRAD	cis	rs733592	0.56	rs61918773	ENSG00000240399.1	RP1-228P16.1	-7.62	1.45e-13	6.22e-11	-0.27	-0.34	Plateletcrit;	chr12:48027991	chr12:48054813~48055591:-
PRAD	cis	rs11159086	0.793	rs28612392	ENSG00000270000.1	RP3-449M8.9	7.62	1.45e-13	6.23e-11	0.51	0.34	Advanced glycation end-product levels;	chr14:74467894	chr14:74471930~74472360:-
PRAD	cis	rs6565180	0.962	rs11642676	ENSG00000183604.13	SMG1P5	-7.62	1.46e-13	6.25e-11	-0.33	-0.34	Tonsillectomy;	chr16:30360334	chr16:30267553~30335374:-
PRAD	cis	rs2015599	0.645	rs12578931	ENSG00000275476.1	RP11-996F15.4	-7.62	1.46e-13	6.26e-11	-0.37	-0.34	Platelet count;Mean platelet volume;	chr12:29358608	chr12:29277397~29277882:-
PRAD	cis	rs2015599	0.623	rs4931174	ENSG00000275476.1	RP11-996F15.4	-7.62	1.46e-13	6.26e-11	-0.37	-0.34	Platelet count;Mean platelet volume;	chr12:29360545	chr12:29277397~29277882:-
PRAD	cis	rs4664293	1	rs10432413	ENSG00000226266.5	AC009961.3	-7.62	1.46e-13	6.26e-11	-0.46	-0.34	Monocyte percentage of white cells;	chr2:159639243	chr2:159670708~159712435:-
PRAD	cis	rs9309473	0.607	rs7560272	ENSG00000163016.8	ALMS1P	7.62	1.46e-13	6.27e-11	0.41	0.34	Metabolite levels;	chr2:73334357	chr2:73644919~73685576:+
PRAD	cis	rs8523	0.901	rs4532436	ENSG00000230314.5	ELOVL2-AS1	7.62	1.47e-13	6.29e-11	0.37	0.34	Red blood cell fatty acid levels;	chr6:10983738	chr6:11043524~11078226:+
PRAD	cis	rs9549328	0.577	rs4907477	ENSG00000267868.1	RP11-120K24.3	7.62	1.47e-13	6.3e-11	0.41	0.34	Systolic blood pressure;	chr13:112964170	chr13:112964835~112966131:-
PRAD	cis	rs9549328	0.577	rs4907478	ENSG00000267868.1	RP11-120K24.3	7.62	1.47e-13	6.3e-11	0.41	0.34	Systolic blood pressure;	chr13:112964173	chr13:112964835~112966131:-
PRAD	cis	rs9549328	0.577	rs4907571	ENSG00000267868.1	RP11-120K24.3	7.62	1.47e-13	6.3e-11	0.41	0.34	Systolic blood pressure;	chr13:112964182	chr13:112964835~112966131:-
PRAD	cis	rs74024059	1	rs2655137	ENSG00000260685.1	RP11-326L17.1	7.62	1.47e-13	6.31e-11	0.89	0.34	Red blood cell count;Hematocrit;	chr15:75869557	chr15:75950464~75951144:-
PRAD	cis	rs74024059	1	rs2604405	ENSG00000260685.1	RP11-326L17.1	7.62	1.47e-13	6.31e-11	0.89	0.34	Red blood cell count;Hematocrit;	chr15:75869788	chr15:75950464~75951144:-
PRAD	cis	rs74024059	0.661	rs2460801	ENSG00000260685.1	RP11-326L17.1	-7.62	1.47e-13	6.31e-11	-0.89	-0.34	Red blood cell count;Hematocrit;	chr15:75872007	chr15:75950464~75951144:-
PRAD	cis	rs736801	0.808	rs2248116	ENSG00000233006.5	AC034220.3	-7.62	1.47e-13	6.32e-11	-0.31	-0.34	Mosquito bite size;Breast cancer;	chr5:132468655	chr5:132311285~132369916:-
PRAD	cis	rs67311347	0.521	rs6769540	ENSG00000223797.4	ENTPD3-AS1	7.62	1.47e-13	6.32e-11	0.3	0.34	Renal cell carcinoma;	chr3:40316413	chr3:40313802~40453329:-
PRAD	cis	rs526231	0.543	rs152134	ENSG00000175749.11	EIF3KP1	7.62	1.47e-13	6.32e-11	0.47	0.34	Primary biliary cholangitis;	chr5:103176745	chr5:103032376~103033031:+
PRAD	cis	rs4664293	0.903	rs10185155	ENSG00000226266.5	AC009961.3	-7.62	1.48e-13	6.34e-11	-0.45	-0.34	Monocyte percentage of white cells;	chr2:159696717	chr2:159670708~159712435:-
PRAD	cis	rs2439831	0.85	rs28513374	ENSG00000249839.1	AC011330.5	-7.62	1.48e-13	6.34e-11	-0.58	-0.34	Lung cancer in ever smokers;	chr15:43833297	chr15:43663654~43684339:-
PRAD	cis	rs9341835	0.608	rs2076874	ENSG00000218048.2	RP3-407E4.4	7.62	1.48e-13	6.34e-11	0.37	0.34	Schizophrenia;	chr6:63443786	chr6:63440766~63443580:+
PRAD	cis	rs9341835	0.525	rs12663017	ENSG00000218048.2	RP3-407E4.4	7.62	1.48e-13	6.35e-11	0.38	0.34	Schizophrenia;	chr6:63275703	chr6:63440766~63443580:+
PRAD	cis	rs853679	0.546	rs35353359	ENSG00000225595.2	XXbac-BPG308K3.6	7.62	1.48e-13	6.36e-11	0.74	0.34	Depression;	chr6:28356601	chr6:28859625~28864630:-
PRAD	cis	rs9532669	0.89	rs35073784	ENSG00000168852.11	TPTE2P5	7.62	1.48e-13	6.36e-11	0.32	0.34	Cervical cancer;	chr13:40993428	chr13:40822296~40921749:-
PRAD	cis	rs17361889	0.778	rs56279207	ENSG00000224683.1	RPL36AP29	7.62	1.49e-13	6.37e-11	0.4	0.34	Pediatric bone mineral content (hip);	chr7:16275559	chr7:16208945~16209265:+
PRAD	cis	rs77204473	0.655	rs11216183	ENSG00000254851.1	RP11-109L13.1	7.62	1.49e-13	6.4e-11	0.67	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116910829	chr11:117135528~117138582:+
PRAD	cis	rs526231	0.543	rs26819	ENSG00000175749.11	EIF3KP1	7.62	1.49e-13	6.4e-11	0.47	0.34	Primary biliary cholangitis;	chr5:103193700	chr5:103032376~103033031:+
PRAD	cis	rs526231	0.615	rs26818	ENSG00000175749.11	EIF3KP1	7.62	1.49e-13	6.4e-11	0.47	0.34	Primary biliary cholangitis;	chr5:103194018	chr5:103032376~103033031:+
PRAD	cis	rs7115242	0.702	rs672058	ENSG00000254851.1	RP11-109L13.1	-7.62	1.49e-13	6.4e-11	-0.58	-0.34	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116893305	chr11:117135528~117138582:+
PRAD	cis	rs2243480	0.901	rs57126451	ENSG00000226824.5	RP4-756H11.3	-7.62	1.5e-13	6.4e-11	-0.64	-0.34	Diabetic kidney disease;	chr7:65951319	chr7:66654538~66669855:+
PRAD	cis	rs6452524	0.901	rs72767146	ENSG00000249664.1	CTD-2227C6.2	7.62	1.5e-13	6.43e-11	0.4	0.34	Hypertension (SNP x SNP interaction);	chr5:83126365	chr5:83012285~83013109:-
PRAD	cis	rs6452524	0.868	rs11746977	ENSG00000249664.1	CTD-2227C6.2	7.62	1.5e-13	6.43e-11	0.41	0.34	Hypertension (SNP x SNP interaction);	chr5:83085581	chr5:83012285~83013109:-
PRAD	cis	rs6001482	0.702	rs9623126	ENSG00000272779.1	LL22NC03-80A10.6	-7.62	1.5e-13	6.44e-11	-0.41	-0.34	Diastolic blood pressure;	chr22:22234624	chr22:22303224~22310401:+
PRAD	cis	rs858239	0.6	rs6461692	ENSG00000226816.2	AC005082.12	7.62	1.5e-13	6.44e-11	0.38	0.34	Cerebrospinal fluid biomarker levels;	chr7:23100076	chr7:23206013~23208045:+
PRAD	cis	rs11098499	0.754	rs2036860	ENSG00000245958.5	RP11-33B1.1	-7.62	1.51e-13	6.45e-11	-0.31	-0.34	Corneal astigmatism;	chr4:119327779	chr4:119454791~119552025:+
PRAD	cis	rs4664293	0.718	rs4477859	ENSG00000226266.5	AC009961.3	7.62	1.51e-13	6.46e-11	0.43	0.34	Monocyte percentage of white cells;	chr2:159738616	chr2:159670708~159712435:-
PRAD	cis	rs55665837	1	rs34980103	ENSG00000251991.1	RNU7-49P	7.62	1.52e-13	6.5e-11	0.36	0.34	Vitamin D levels;	chr11:14491339	chr11:14478892~14478953:+
PRAD	cis	rs6782228	0.509	rs4481172	ENSG00000242551.2	POU5F1P6	-7.62	1.52e-13	6.5e-11	-0.42	-0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128653814	chr3:128674735~128677005:-
PRAD	cis	rs6547741	1	rs6718128	ENSG00000234072.1	AC074117.10	-7.62	1.52e-13	6.51e-11	-0.25	-0.34	Oral cavity cancer;	chr2:27610885	chr2:27356246~27367622:+
PRAD	cis	rs17608059	0.634	rs10852819	ENSG00000141028.6	CDRT15P1	-7.62	1.52e-13	6.52e-11	-0.43	-0.34	Temperament;	chr17:14018109	chr17:14024514~14025488:+
PRAD	cis	rs2439831	0.85	rs28684672	ENSG00000249839.1	AC011330.5	-7.62	1.52e-13	6.52e-11	-0.58	-0.34	Lung cancer in ever smokers;	chr15:43815464	chr15:43663654~43684339:-
PRAD	cis	rs2243480	1	rs410128	ENSG00000226824.5	RP4-756H11.3	-7.62	1.52e-13	6.52e-11	-0.69	-0.34	Diabetic kidney disease;	chr7:66138186	chr7:66654538~66669855:+
PRAD	cis	rs964611	0.882	rs8040405	ENSG00000259488.2	RP11-154J22.1	-7.62	1.52e-13	6.52e-11	-0.32	-0.34	Metabolite levels (Pyroglutamine);	chr15:48280640	chr15:48312353~48331856:-
PRAD	cis	rs17428076	0.831	rs3736499	ENSG00000228389.1	AC068039.4	-7.62	1.53e-13	6.53e-11	-0.44	-0.34	Myopia;	chr2:171833908	chr2:171773482~171775844:+
PRAD	cis	rs9810089	0.843	rs696081	ENSG00000261758.1	RP11-102M11.2	-7.62	1.53e-13	6.53e-11	-0.38	-0.34	Gestational age at birth (child effect);	chr3:136328347	chr3:136752630~136755780:+
PRAD	cis	rs853679	0.546	rs13214023	ENSG00000225595.2	XXbac-BPG308K3.6	-7.62	1.53e-13	6.53e-11	-0.74	-0.34	Depression;	chr6:28364364	chr6:28859625~28864630:-
PRAD	cis	rs453301	0.624	rs6987558	ENSG00000253893.2	FAM85B	-7.62	1.53e-13	6.54e-11	-0.42	-0.34	Joint mobility (Beighton score);	chr8:9005011	chr8:8167819~8226614:-
PRAD	cis	rs763567	0.935	rs580487	ENSG00000271811.1	RP1-79C4.4	7.62	1.53e-13	6.56e-11	0.38	0.34	Tonsillectomy;	chr1:170640484	chr1:170667381~170669425:+
PRAD	cis	rs741668	0.759	rs3736943	ENSG00000235903.6	CPB2-AS1	7.62	1.53e-13	6.56e-11	0.45	0.34	Cerebrospinal fluid clusterin levels;	chr13:46044936	chr13:46052806~46113332:+
PRAD	cis	rs741668	0.795	rs17600555	ENSG00000235903.6	CPB2-AS1	7.62	1.53e-13	6.56e-11	0.45	0.34	Cerebrospinal fluid clusterin levels;	chr13:46049527	chr13:46052806~46113332:+
PRAD	cis	rs741668	0.795	rs7324938	ENSG00000235903.6	CPB2-AS1	7.62	1.53e-13	6.56e-11	0.45	0.34	Cerebrospinal fluid clusterin levels;	chr13:46049937	chr13:46052806~46113332:+
PRAD	cis	rs673078	0.66	rs2280711	ENSG00000275409.1	RP11-131L12.4	-7.62	1.54e-13	6.58e-11	-0.45	-0.34	Glucose homeostasis traits;	chr12:118212149	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.615	rs73222058	ENSG00000275409.1	RP11-131L12.4	-7.62	1.54e-13	6.58e-11	-0.45	-0.34	Glucose homeostasis traits;	chr12:118221066	chr12:118430147~118430699:+
PRAD	cis	rs1061377	0.965	rs12511857	ENSG00000249685.1	RP11-360F5.3	7.62	1.54e-13	6.58e-11	0.39	0.34	Uric acid levels;	chr4:39143252	chr4:39133913~39135608:+
PRAD	cis	rs6674176	0.66	rs11210936	ENSG00000237950.1	RP11-7O11.3	7.61	1.54e-13	6.59e-11	0.37	0.34	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43925766	chr1:43944370~43946551:-
PRAD	cis	rs8031584	0.56	rs1056118	ENSG00000270015.1	RP11-540B6.6	7.61	1.54e-13	6.59e-11	0.29	0.34	Huntington's disease progression;	chr15:30911583	chr15:30926514~30928407:+
PRAD	cis	rs11098499	0.754	rs66900435	ENSG00000245958.5	RP11-33B1.1	-7.61	1.54e-13	6.59e-11	-0.31	-0.34	Corneal astigmatism;	chr4:119328270	chr4:119454791~119552025:+
PRAD	cis	rs12908161	0.959	rs12906348	ENSG00000259728.4	LINC00933	7.61	1.55e-13	6.63e-11	0.41	0.34	Schizophrenia;	chr15:84786190	chr15:84570649~84580175:+
PRAD	cis	rs17772222	0.958	rs10134008	ENSG00000258983.2	RP11-507K2.2	7.61	1.55e-13	6.65e-11	0.49	0.34	Coronary artery calcification;	chr14:88549183	chr14:88499334~88515502:+
PRAD	cis	rs2933343	0.729	rs6767104	ENSG00000231305.3	RP11-723O4.2	-7.61	1.56e-13	6.66e-11	-0.31	-0.34	IgG glycosylation;	chr3:128929274	chr3:128861313~128871540:-
PRAD	cis	rs7916697	0.578	rs4745951	ENSG00000233590.1	RP11-153K11.3	7.61	1.56e-13	6.66e-11	0.47	0.34	Optic disc area;	chr10:68236867	chr10:68233251~68242379:-
PRAD	cis	rs1979679	1	rs6487672	ENSG00000278733.1	RP11-425D17.1	7.61	1.56e-13	6.67e-11	0.44	0.34	Ossification of the posterior longitudinal ligament of the spine;	chr12:28270413	chr12:28185625~28186190:-
PRAD	cis	rs8062405	0.755	rs56272201	ENSG00000251417.2	RP11-1348G14.4	-7.61	1.56e-13	6.67e-11	-0.38	-0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569364	chr16:28802743~28817828:+
PRAD	cis	rs8062405	0.755	rs62034355	ENSG00000251417.2	RP11-1348G14.4	-7.61	1.56e-13	6.67e-11	-0.38	-0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569717	chr16:28802743~28817828:+
PRAD	cis	rs55665837	1	rs10766182	ENSG00000251991.1	RNU7-49P	7.61	1.56e-13	6.67e-11	0.36	0.34	Vitamin D levels;	chr11:14477990	chr11:14478892~14478953:+
PRAD	cis	rs55665837	0.961	rs11023237	ENSG00000251991.1	RNU7-49P	7.61	1.56e-13	6.67e-11	0.36	0.34	Vitamin D levels;	chr11:14478788	chr11:14478892~14478953:+
PRAD	cis	rs55665837	1	rs10466412	ENSG00000251991.1	RNU7-49P	7.61	1.56e-13	6.67e-11	0.36	0.34	Vitamin D levels;	chr11:14483643	chr11:14478892~14478953:+
PRAD	cis	rs55665837	1	rs12364959	ENSG00000251991.1	RNU7-49P	7.61	1.56e-13	6.67e-11	0.36	0.34	Vitamin D levels;	chr11:14485889	chr11:14478892~14478953:+
PRAD	cis	rs7121800	0.962	rs11031113	ENSG00000242353.1	RP4-710M3.1	7.61	1.56e-13	6.68e-11	0.35	0.34	Pit-and-Fissure caries;	chr11:30494410	chr11:30368148~30368646:+
PRAD	cis	rs881375	0.867	rs6478487	ENSG00000226752.6	PSMD5-AS1	-7.61	1.56e-13	6.68e-11	-0.4	-0.34	Rheumatoid arthritis;	chr9:120910499	chr9:120824828~120854385:+
PRAD	cis	rs11098499	0.662	rs13108589	ENSG00000245958.5	RP11-33B1.1	-7.61	1.56e-13	6.69e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119346947	chr4:119454791~119552025:+
PRAD	cis	rs62103177	0.564	rs11874805	ENSG00000261126.6	RP11-795F19.1	7.61	1.57e-13	6.69e-11	0.47	0.34	Opioid sensitivity;	chr18:79937110	chr18:80046900~80095482:+
PRAD	cis	rs853679	0.607	rs13199649	ENSG00000280107.1	AL022393.9	-7.61	1.57e-13	6.7e-11	-0.69	-0.34	Depression;	chr6:27901014	chr6:28170845~28172521:+
PRAD	cis	rs8062405	0.69	rs762634	ENSG00000251417.2	RP11-1348G14.4	-7.61	1.57e-13	6.7e-11	-0.38	-0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28592014	chr16:28802743~28817828:+
PRAD	cis	rs55665837	1	rs10832278	ENSG00000251991.1	RNU7-49P	7.61	1.57e-13	6.71e-11	0.37	0.34	Vitamin D levels;	chr11:14475073	chr11:14478892~14478953:+
PRAD	cis	rs2274273	0.624	rs78205412	ENSG00000258413.1	RP11-665C16.6	-7.61	1.57e-13	6.71e-11	-0.45	-0.34	Protein biomarker;	chr14:55314532	chr14:55262767~55272075:-
PRAD	cis	rs853679	0.513	rs13437444	ENSG00000226314.6	ZNF192P1	-7.61	1.57e-13	6.73e-11	-0.52	-0.34	Depression;	chr6:28103220	chr6:28161781~28169594:+
PRAD	cis	rs11976180	1	rs2961134	ENSG00000170356.8	OR2A20P	-7.61	1.58e-13	6.76e-11	-0.45	-0.34	Obesity-related traits;	chr7:144073969	chr7:144250045~144252957:-
PRAD	cis	rs6547741	1	rs6737921	ENSG00000234072.1	AC074117.10	7.61	1.58e-13	6.77e-11	0.25	0.34	Oral cavity cancer;	chr2:27616240	chr2:27356246~27367622:+
PRAD	cis	rs6547741	1	rs6756238	ENSG00000234072.1	AC074117.10	7.61	1.58e-13	6.77e-11	0.25	0.34	Oral cavity cancer;	chr2:27618438	chr2:27356246~27367622:+
PRAD	cis	rs6480314	0.636	rs77760458	ENSG00000233590.1	RP11-153K11.3	-7.61	1.59e-13	6.78e-11	-0.57	-0.34	Optic nerve measurement (disc area);	chr10:68244248	chr10:68233251~68242379:-
PRAD	cis	rs881375	1	rs1953126	ENSG00000226752.6	PSMD5-AS1	-7.61	1.59e-13	6.78e-11	-0.4	-0.34	Rheumatoid arthritis;	chr9:120878222	chr9:120824828~120854385:+
PRAD	cis	rs2439831	0.85	rs28684672	ENSG00000205771.5	CATSPER2P1	-7.61	1.59e-13	6.78e-11	-0.53	-0.34	Lung cancer in ever smokers;	chr15:43815464	chr15:43726918~43747094:-
PRAD	cis	rs9467773	0.836	rs1624440	ENSG00000124549.13	BTN2A3P	-7.61	1.59e-13	6.78e-11	-0.3	-0.34	Intelligence (multi-trait analysis);	chr6:26433101	chr6:26421391~26432383:+
PRAD	cis	rs10463554	0.892	rs1438687	ENSG00000175749.11	EIF3KP1	7.61	1.59e-13	6.79e-11	0.44	0.34	Parkinson's disease;	chr5:102968792	chr5:103032376~103033031:+
PRAD	cis	rs11098499	0.821	rs56155624	ENSG00000245958.5	RP11-33B1.1	-7.61	1.59e-13	6.79e-11	-0.34	-0.34	Corneal astigmatism;	chr4:119369871	chr4:119454791~119552025:+
PRAD	cis	rs8081395	0.775	rs2645482	ENSG00000266992.1	DHX40P1	7.61	1.59e-13	6.8e-11	0.38	0.34	White blood cell count;	chr17:59865754	chr17:59976009~60002384:-
PRAD	cis	rs8081395	0.805	rs2645485	ENSG00000266992.1	DHX40P1	7.61	1.59e-13	6.8e-11	0.38	0.34	White blood cell count;	chr17:59866920	chr17:59976009~60002384:-
PRAD	cis	rs375066	0.935	rs429027	ENSG00000267058.1	RP11-15A1.3	-7.61	1.6e-13	6.82e-11	-0.28	-0.34	Breast cancer;	chr19:43891337	chr19:43891804~43901805:-
PRAD	cis	rs9810089	0.708	rs711977	ENSG00000261758.1	RP11-102M11.2	7.61	1.6e-13	6.84e-11	0.39	0.34	Gestational age at birth (child effect);	chr3:136508545	chr3:136752630~136755780:+
PRAD	cis	rs4664293	0.967	rs13020365	ENSG00000226266.5	AC009961.3	-7.61	1.6e-13	6.84e-11	-0.44	-0.34	Monocyte percentage of white cells;	chr2:159619893	chr2:159670708~159712435:-
PRAD	cis	rs4664293	1	rs13014418	ENSG00000226266.5	AC009961.3	-7.61	1.6e-13	6.84e-11	-0.44	-0.34	Monocyte percentage of white cells;	chr2:159627174	chr2:159670708~159712435:-
PRAD	cis	rs7238033	0.641	rs56044725	ENSG00000267193.4	RP11-116O18.3	7.61	1.6e-13	6.85e-11	0.37	0.34	Bladder cancer;	chr18:45741598	chr18:45669367~45747215:-
PRAD	cis	rs6547741	1	rs11127071	ENSG00000234072.1	AC074117.10	7.61	1.6e-13	6.85e-11	0.25	0.34	Oral cavity cancer;	chr2:27615191	chr2:27356246~27367622:+
PRAD	cis	rs11098499	0.754	rs7672594	ENSG00000245958.5	RP11-33B1.1	-7.61	1.61e-13	6.85e-11	-0.31	-0.34	Corneal astigmatism;	chr4:119327388	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.754	rs7672778	ENSG00000245958.5	RP11-33B1.1	-7.61	1.61e-13	6.85e-11	-0.31	-0.34	Corneal astigmatism;	chr4:119327430	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.754	rs12513083	ENSG00000245958.5	RP11-33B1.1	-7.61	1.61e-13	6.85e-11	-0.31	-0.34	Corneal astigmatism;	chr4:119328457	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.754	rs12509621	ENSG00000245958.5	RP11-33B1.1	-7.61	1.61e-13	6.85e-11	-0.31	-0.34	Corneal astigmatism;	chr4:119328505	chr4:119454791~119552025:+
PRAD	cis	rs74024059	1	rs335678	ENSG00000260685.1	RP11-326L17.1	7.61	1.61e-13	6.86e-11	0.9	0.34	Red blood cell count;Hematocrit;	chr15:75929595	chr15:75950464~75951144:-
PRAD	cis	rs75422866	0.85	rs73111212	ENSG00000280054.1	RP1-197B17.7	7.61	1.61e-13	6.86e-11	0.93	0.34	Pneumonia;	chr12:47577638	chr12:47728151~47730598:-
PRAD	cis	rs75422866	0.85	rs73111216	ENSG00000280054.1	RP1-197B17.7	7.61	1.61e-13	6.86e-11	0.93	0.34	Pneumonia;	chr12:47577671	chr12:47728151~47730598:-
PRAD	cis	rs75422866	0.85	rs73111217	ENSG00000280054.1	RP1-197B17.7	7.61	1.61e-13	6.86e-11	0.93	0.34	Pneumonia;	chr12:47577693	chr12:47728151~47730598:-
PRAD	cis	rs12188164	0.965	rs1056465	ENSG00000221990.4	EXOC3-AS1	7.61	1.61e-13	6.86e-11	0.28	0.34	Cystic fibrosis severity;	chr5:442323	chr5:441498~443160:-
PRAD	cis	rs12188164	0.965	rs56146525	ENSG00000221990.4	EXOC3-AS1	7.61	1.61e-13	6.86e-11	0.28	0.34	Cystic fibrosis severity;	chr5:442456	chr5:441498~443160:-
PRAD	cis	rs11098499	0.754	rs9991959	ENSG00000245958.5	RP11-33B1.1	7.61	1.61e-13	6.88e-11	0.31	0.34	Corneal astigmatism;	chr4:119332618	chr4:119454791~119552025:+
PRAD	cis	rs3096299	0.967	rs16965692	ENSG00000261118.1	RP11-104N10.1	7.61	1.61e-13	6.89e-11	0.33	0.34	Multiple myeloma (IgH translocation);	chr16:89405074	chr16:89492017~89504460:-
PRAD	cis	rs3096299	0.566	rs4129126	ENSG00000274627.1	RP11-104N10.2	7.61	1.61e-13	6.89e-11	0.36	0.34	Multiple myeloma (IgH translocation);	chr16:89495067	chr16:89516797~89522217:+
PRAD	cis	rs11098499	0.535	rs10005542	ENSG00000245958.5	RP11-33B1.1	-7.61	1.62e-13	6.91e-11	-0.31	-0.34	Corneal astigmatism;	chr4:119347147	chr4:119454791~119552025:+
PRAD	cis	rs2739330	0.652	rs2000469	ENSG00000224205.1	AP000351.4	7.61	1.62e-13	6.91e-11	0.42	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23987320~23991421:-
PRAD	cis	rs12468226	0.938	rs115418918	ENSG00000273456.1	RP11-686O6.2	7.61	1.62e-13	6.91e-11	0.46	0.34	Urate levels;	chr2:202315145	chr2:202374932~202375604:-
PRAD	cis	rs9810089	0.934	rs10935184	ENSG00000261758.1	RP11-102M11.2	7.61	1.62e-13	6.91e-11	0.38	0.34	Gestational age at birth (child effect);	chr3:136434626	chr3:136752630~136755780:+
PRAD	cis	rs7429990	0.965	rs7651237	ENSG00000229759.1	MRPS18AP1	-7.61	1.62e-13	6.91e-11	-0.37	-0.34	Educational attainment (years of education);	chr3:48064038	chr3:48256350~48256938:-
PRAD	cis	rs9309473	0.583	rs11899517	ENSG00000163016.8	ALMS1P	7.61	1.62e-13	6.93e-11	0.4	0.34	Metabolite levels;	chr2:73346133	chr2:73644919~73685576:+
PRAD	cis	rs6479901	0.947	rs10761755	ENSG00000232075.1	MRPL35P2	-7.61	1.63e-13	6.94e-11	-0.41	-0.34	Intelligence (multi-trait analysis);	chr10:63412212	chr10:63634317~63634827:-
PRAD	cis	rs6479901	0.895	rs10761757	ENSG00000232075.1	MRPL35P2	-7.61	1.63e-13	6.94e-11	-0.41	-0.34	Intelligence (multi-trait analysis);	chr10:63412790	chr10:63634317~63634827:-
PRAD	cis	rs6479901	0.846	rs10761761	ENSG00000232075.1	MRPL35P2	-7.61	1.63e-13	6.94e-11	-0.41	-0.34	Intelligence (multi-trait analysis);	chr10:63419398	chr10:63634317~63634827:-
PRAD	cis	rs2243480	1	rs59794892	ENSG00000226824.5	RP4-756H11.3	-7.61	1.63e-13	6.95e-11	-0.64	-0.34	Diabetic kidney disease;	chr7:65950886	chr7:66654538~66669855:+
PRAD	cis	rs2243480	0.803	rs36004293	ENSG00000226824.5	RP4-756H11.3	-7.61	1.63e-13	6.95e-11	-0.64	-0.34	Diabetic kidney disease;	chr7:65951525	chr7:66654538~66669855:+
PRAD	cis	rs2243480	0.803	rs35268390	ENSG00000226824.5	RP4-756H11.3	-7.61	1.63e-13	6.95e-11	-0.64	-0.34	Diabetic kidney disease;	chr7:65951549	chr7:66654538~66669855:+
PRAD	cis	rs1426063	0.541	rs58959724	ENSG00000260265.1	RP11-44F21.5	7.61	1.63e-13	6.96e-11	0.79	0.34	QT interval;	chr4:75073543	chr4:75081702~75084717:-
PRAD	cis	rs2439831	0.867	rs2447196	ENSG00000205771.5	CATSPER2P1	7.61	1.63e-13	6.97e-11	0.52	0.34	Lung cancer in ever smokers;	chr15:43601620	chr15:43726918~43747094:-
PRAD	cis	rs2739330	0.731	rs2000468	ENSG00000228039.3	KB-1125A3.10	7.61	1.64e-13	6.98e-11	0.44	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23963780~23964374:+
PRAD	cis	rs12612619	0.732	rs11126836	ENSG00000229122.1	AGBL5-IT1	7.61	1.64e-13	6.99e-11	0.35	0.34	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27050260	chr2:27061038~27061815:+
PRAD	cis	rs11098499	0.754	rs10213554	ENSG00000245958.5	RP11-33B1.1	7.61	1.64e-13	7e-11	0.31	0.34	Corneal astigmatism;	chr4:119339630	chr4:119454791~119552025:+
PRAD	cis	rs9341835	0.584	rs1741801	ENSG00000218048.2	RP3-407E4.4	7.61	1.64e-13	7.01e-11	0.38	0.34	Schizophrenia;	chr6:63435470	chr6:63440766~63443580:+
PRAD	cis	rs11159086	1	rs4903233	ENSG00000259005.1	RP3-449M8.6	7.61	1.65e-13	7.02e-11	0.45	0.34	Advanced glycation end-product levels;	chr14:74497291	chr14:74474007~74474864:-
PRAD	cis	rs964611	0.882	rs11854679	ENSG00000259488.2	RP11-154J22.1	-7.61	1.65e-13	7.03e-11	-0.32	-0.34	Metabolite levels (Pyroglutamine);	chr15:48265376	chr15:48312353~48331856:-
PRAD	cis	rs55665837	1	rs2305306	ENSG00000251991.1	RNU7-49P	7.6	1.65e-13	7.06e-11	0.37	0.34	Vitamin D levels;	chr11:14513453	chr11:14478892~14478953:+
PRAD	cis	rs812925	0.555	rs12616433	ENSG00000271889.1	RP11-493E12.1	7.6	1.66e-13	7.07e-11	0.37	0.34	Immature fraction of reticulocytes;	chr2:61469353	chr2:61151433~61162105:-
PRAD	cis	rs6921919	0.583	rs16894060	ENSG00000216901.1	AL022393.7	7.6	1.66e-13	7.07e-11	0.44	0.34	Autism spectrum disorder or schizophrenia;	chr6:28394694	chr6:28176188~28176674:+
PRAD	cis	rs7191700	0.674	rs12597893	ENSG00000263080.1	RP11-485G7.5	7.6	1.66e-13	7.08e-11	0.4	0.34	Multiple sclerosis;	chr16:11332474	chr16:11341809~11345211:-
PRAD	cis	rs6782228	0.527	rs7426806	ENSG00000242551.2	POU5F1P6	-7.6	1.66e-13	7.09e-11	-0.42	-0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694087	chr3:128674735~128677005:-
PRAD	cis	rs6782228	0.527	rs6767383	ENSG00000242551.2	POU5F1P6	-7.6	1.66e-13	7.09e-11	-0.42	-0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694744	chr3:128674735~128677005:-
PRAD	cis	rs6782228	0.509	rs6780447	ENSG00000242551.2	POU5F1P6	-7.6	1.66e-13	7.09e-11	-0.42	-0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694965	chr3:128674735~128677005:-
PRAD	cis	rs2439831	0.764	rs2447193	ENSG00000249839.1	AC011330.5	-7.6	1.67e-13	7.1e-11	-0.59	-0.34	Lung cancer in ever smokers;	chr15:43637535	chr15:43663654~43684339:-
PRAD	cis	rs2439831	0.571	rs2470121	ENSG00000249839.1	AC011330.5	-7.6	1.67e-13	7.1e-11	-0.59	-0.34	Lung cancer in ever smokers;	chr15:43645420	chr15:43663654~43684339:-
PRAD	cis	rs733592	0.507	rs7299704	ENSG00000240399.1	RP1-228P16.1	7.6	1.67e-13	7.11e-11	0.27	0.34	Plateletcrit;	chr12:48050705	chr12:48054813~48055591:-
PRAD	cis	rs2255336	0.938	rs9651850	ENSG00000245648.1	RP11-277P12.20	-7.6	1.67e-13	7.13e-11	-0.51	-0.34	Blood protein levels;	chr12:10490533	chr12:10363769~10398506:+
PRAD	cis	rs2255336	0.873	rs12301897	ENSG00000245648.1	RP11-277P12.20	-7.6	1.67e-13	7.13e-11	-0.51	-0.34	Blood protein levels;	chr12:10491974	chr12:10363769~10398506:+
PRAD	cis	rs6844153	0.938	rs12646473	ENSG00000240005.4	RP11-293A21.1	-7.6	1.67e-13	7.14e-11	-0.48	-0.34	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26873833	chr4:26859806~26860599:-
PRAD	cis	rs848490	0.894	rs17233275	ENSG00000214293.7	APTR	7.6	1.68e-13	7.15e-11	0.35	0.34	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77680725	chr7:77657660~77696265:-
PRAD	cis	rs6847067	0.794	rs34239067	ENSG00000180769.7	WDFY3-AS2	7.6	1.68e-13	7.16e-11	0.35	0.34	Oropharynx cancer;	chr4:85030551	chr4:84965682~85011277:+
PRAD	cis	rs10463554	0.963	rs26254	ENSG00000175749.11	EIF3KP1	7.6	1.68e-13	7.16e-11	0.45	0.34	Parkinson's disease;	chr5:103221158	chr5:103032376~103033031:+
PRAD	cis	rs12049351	0.511	rs7524626	ENSG00000229367.1	HMGN2P19	7.6	1.69e-13	7.19e-11	0.56	0.34	Circulating myeloperoxidase levels (plasma);	chr1:229430783	chr1:229570532~229570796:+
PRAD	cis	rs964611	0.882	rs11629707	ENSG00000259488.2	RP11-154J22.1	7.6	1.69e-13	7.19e-11	0.34	0.34	Metabolite levels (Pyroglutamine);	chr15:48348148	chr15:48312353~48331856:-
PRAD	cis	rs763567	0.9	rs525489	ENSG00000271811.1	RP1-79C4.4	7.6	1.69e-13	7.19e-11	0.38	0.34	Tonsillectomy;	chr1:170665861	chr1:170667381~170669425:+
PRAD	cis	rs17361889	1	rs17361889	ENSG00000224683.1	RPL36AP29	7.6	1.69e-13	7.2e-11	0.45	0.34	Pediatric bone mineral content (hip);	chr7:16264454	chr7:16208945~16209265:+
PRAD	cis	rs6723108	0.626	rs1530559	ENSG00000224043.6	CCNT2-AS1	7.6	1.69e-13	7.2e-11	0.47	0.34	Type 2 diabetes;	chr2:134998059	chr2:134735464~134918710:-
PRAD	cis	rs1426063	1	rs28515115	ENSG00000249717.1	RP11-44F21.3	7.6	1.69e-13	7.2e-11	0.56	0.34	QT interval;	chr4:75101904	chr4:74955974~74970362:-
PRAD	cis	rs113835537	0.529	rs7943327	ENSG00000255517.5	CTD-3074O7.5	-7.6	1.69e-13	7.21e-11	-0.34	-0.34	Airway imaging phenotypes;	chr11:66489110	chr11:66473490~66480233:-
PRAD	cis	rs3096299	0.9	rs3114867	ENSG00000261118.1	RP11-104N10.1	7.6	1.69e-13	7.21e-11	0.33	0.34	Multiple myeloma (IgH translocation);	chr16:89362559	chr16:89492017~89504460:-
PRAD	cis	rs12468226	0.938	rs80282360	ENSG00000273456.1	RP11-686O6.2	7.6	1.7e-13	7.24e-11	0.46	0.34	Urate levels;	chr2:202275121	chr2:202374932~202375604:-
PRAD	cis	rs1185460	0.547	rs667584	ENSG00000271751.1	RP11-110I1.14	7.6	1.7e-13	7.24e-11	0.45	0.34	Coronary artery disease;	chr11:119040834	chr11:119065263~119065677:-
PRAD	cis	rs1499614	0.803	rs1796229	ENSG00000226824.5	RP4-756H11.3	-7.6	1.7e-13	7.24e-11	-0.67	-0.34	Gout;	chr7:66654674	chr7:66654538~66669855:+
PRAD	cis	rs55665837	1	rs11023246	ENSG00000251991.1	RNU7-49P	7.6	1.7e-13	7.26e-11	0.36	0.34	Vitamin D levels;	chr11:14515410	chr11:14478892~14478953:+
PRAD	cis	rs193541	0.564	rs62377434	ENSG00000263432.2	RN7SL689P	-7.6	1.71e-13	7.26e-11	-0.36	-0.34	Glucose homeostasis traits;	chr5:123004874	chr5:123022487~123022783:-
PRAD	cis	rs11976180	1	rs1919950	ENSG00000273234.1	OR2A13P	-7.6	1.71e-13	7.29e-11	-0.41	-0.34	Obesity-related traits;	chr7:144070805	chr7:144142009~144142938:+
PRAD	cis	rs55665837	1	rs10832254	ENSG00000251991.1	RNU7-49P	7.6	1.71e-13	7.3e-11	0.36	0.34	Vitamin D levels;	chr11:14413152	chr11:14478892~14478953:+
PRAD	cis	rs55665837	1	rs11023214	ENSG00000251991.1	RNU7-49P	7.6	1.71e-13	7.3e-11	0.36	0.34	Vitamin D levels;	chr11:14414713	chr11:14478892~14478953:+
PRAD	cis	rs4713118	0.715	rs200480	ENSG00000280107.1	AL022393.9	-7.6	1.71e-13	7.3e-11	-0.41	-0.34	Parkinson's disease;	chr6:27805886	chr6:28170845~28172521:+
PRAD	cis	rs673078	0.66	rs61946063	ENSG00000275409.1	RP11-131L12.4	-7.6	1.71e-13	7.3e-11	-0.44	-0.34	Glucose homeostasis traits;	chr12:118294448	chr12:118430147~118430699:+
PRAD	cis	rs7923609	1	rs2393969	ENSG00000232075.1	MRPL35P2	-7.6	1.71e-13	7.3e-11	-0.35	-0.34	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63380680	chr10:63634317~63634827:-
PRAD	cis	rs1061377	1	rs56119980	ENSG00000249685.1	RP11-360F5.3	7.6	1.72e-13	7.3e-11	0.38	0.34	Uric acid levels;	chr4:39139390	chr4:39133913~39135608:+
PRAD	cis	rs2933343	0.649	rs789219	ENSG00000261159.1	RP11-723O4.9	7.6	1.72e-13	7.31e-11	0.29	0.34	IgG glycosylation;	chr3:128873677	chr3:128859716~128860526:-
PRAD	cis	rs6452524	0.868	rs10045104	ENSG00000249664.1	CTD-2227C6.2	7.6	1.72e-13	7.32e-11	0.41	0.34	Hypertension (SNP x SNP interaction);	chr5:83116543	chr5:83012285~83013109:-
PRAD	cis	rs6479891	0.908	rs16918603	ENSG00000232075.1	MRPL35P2	7.6	1.72e-13	7.33e-11	0.56	0.34	Arthritis (juvenile idiopathic);	chr10:63561712	chr10:63634317~63634827:-
PRAD	cis	rs6847067	0.672	rs1838038	ENSG00000180769.7	WDFY3-AS2	7.6	1.72e-13	7.33e-11	0.38	0.34	Oropharynx cancer;	chr4:84649211	chr4:84965682~85011277:+
PRAD	cis	rs2274273	0.967	rs17832359	ENSG00000258413.1	RP11-665C16.6	-7.6	1.72e-13	7.34e-11	-0.43	-0.34	Protein biomarker;	chr14:55149223	chr14:55262767~55272075:-
PRAD	cis	rs2274273	1	rs11621351	ENSG00000258413.1	RP11-665C16.6	-7.6	1.72e-13	7.34e-11	-0.43	-0.34	Protein biomarker;	chr14:55150022	chr14:55262767~55272075:-
PRAD	cis	rs6782228	0.585	rs6774515	ENSG00000242551.2	POU5F1P6	-7.6	1.73e-13	7.34e-11	-0.42	-0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128697035	chr3:128674735~128677005:-
PRAD	cis	rs6782228	0.565	rs12695509	ENSG00000242551.2	POU5F1P6	-7.6	1.73e-13	7.34e-11	-0.42	-0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128698201	chr3:128674735~128677005:-
PRAD	cis	rs172166	0.585	rs149963	ENSG00000280107.1	AL022393.9	-7.6	1.73e-13	7.36e-11	-0.4	-0.34	Cardiac Troponin-T levels;	chr6:28049354	chr6:28170845~28172521:+
PRAD	cis	rs1799949	0.896	rs8176086	ENSG00000267002.1	RP11-242D8.1	7.6	1.73e-13	7.36e-11	0.31	0.34	Menopause (age at onset);	chr17:43122761	chr17:43164183~43170403:-
PRAD	cis	rs1799949	0.93	rs3765640	ENSG00000267002.1	RP11-242D8.1	7.6	1.73e-13	7.36e-11	0.31	0.34	Menopause (age at onset);	chr17:43124230	chr17:43164183~43170403:-
PRAD	cis	rs1799949	1	rs8176077	ENSG00000267002.1	RP11-242D8.1	7.6	1.73e-13	7.36e-11	0.31	0.34	Menopause (age at onset);	chr17:43124331	chr17:43164183~43170403:-
PRAD	cis	rs1799949	1	rs11655505	ENSG00000267002.1	RP11-242D8.1	7.6	1.73e-13	7.36e-11	0.31	0.34	Menopause (age at onset);	chr17:43126360	chr17:43164183~43170403:-
PRAD	cis	rs1799949	0.965	rs4793204	ENSG00000267002.1	RP11-242D8.1	7.6	1.73e-13	7.36e-11	0.31	0.34	Menopause (age at onset);	chr17:43127281	chr17:43164183~43170403:-
PRAD	cis	rs1799949	0.965	rs12947782	ENSG00000267002.1	RP11-242D8.1	7.6	1.73e-13	7.36e-11	0.31	0.34	Menopause (age at onset);	chr17:43127865	chr17:43164183~43170403:-
PRAD	cis	rs1799949	1	rs33945274	ENSG00000267002.1	RP11-242D8.1	7.6	1.73e-13	7.36e-11	0.31	0.34	Menopause (age at onset);	chr17:43128056	chr17:43164183~43170403:-
PRAD	cis	rs1799949	1	rs11653069	ENSG00000267002.1	RP11-242D8.1	7.6	1.73e-13	7.36e-11	0.31	0.34	Menopause (age at onset);	chr17:43131360	chr17:43164183~43170403:-
PRAD	cis	rs1799949	0.965	rs33988650	ENSG00000267002.1	RP11-242D8.1	7.6	1.73e-13	7.36e-11	0.31	0.34	Menopause (age at onset);	chr17:43135863	chr17:43164183~43170403:-
PRAD	cis	rs1799949	1	rs11656097	ENSG00000267002.1	RP11-242D8.1	7.6	1.73e-13	7.36e-11	0.31	0.34	Menopause (age at onset);	chr17:43138596	chr17:43164183~43170403:-
PRAD	cis	rs1799949	1	rs11658754	ENSG00000267002.1	RP11-242D8.1	7.6	1.73e-13	7.36e-11	0.31	0.34	Menopause (age at onset);	chr17:43140722	chr17:43164183~43170403:-
PRAD	cis	rs881375	1	rs10117059	ENSG00000226752.6	PSMD5-AS1	-7.6	1.73e-13	7.36e-11	-0.4	-0.34	Rheumatoid arthritis;	chr9:120891199	chr9:120824828~120854385:+
PRAD	cis	rs3096299	0.933	rs3114848	ENSG00000261118.1	RP11-104N10.1	7.6	1.73e-13	7.36e-11	0.33	0.34	Multiple myeloma (IgH translocation);	chr16:89386363	chr16:89492017~89504460:-
PRAD	cis	rs1930961	1	rs1930961	ENSG00000271138.1	IGLVIVOR22-1	-7.6	1.73e-13	7.36e-11	-0.51	-0.34	Bipolar disorder with mood-incongruent psychosis;	chr22:25479298	chr22:25437306~25437823:-
PRAD	cis	rs55665837	1	rs11023216	ENSG00000251991.1	RNU7-49P	7.6	1.73e-13	7.36e-11	0.36	0.34	Vitamin D levels;	chr11:14415607	chr11:14478892~14478953:+
PRAD	cis	rs853679	0.585	rs201004	ENSG00000226314.6	ZNF192P1	-7.6	1.73e-13	7.37e-11	-0.48	-0.34	Depression;	chr6:27837156	chr6:28161781~28169594:+
PRAD	cis	rs8062405	0.789	rs28480369	ENSG00000251417.2	RP11-1348G14.4	7.6	1.73e-13	7.38e-11	0.37	0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28615683	chr16:28802743~28817828:+
PRAD	cis	rs42648	0.935	rs2188232	ENSG00000227646.6	STEAP2-AS1	-7.6	1.74e-13	7.39e-11	-0.31	-0.34	Homocysteine levels;	chr7:90329000	chr7:89882353~90211635:-
PRAD	cis	rs42648	0.935	rs2188233	ENSG00000227646.6	STEAP2-AS1	-7.6	1.74e-13	7.39e-11	-0.31	-0.34	Homocysteine levels;	chr7:90329001	chr7:89882353~90211635:-
PRAD	cis	rs1061377	0.76	rs7678457	ENSG00000249685.1	RP11-360F5.3	7.6	1.74e-13	7.39e-11	0.38	0.34	Uric acid levels;	chr4:39136041	chr4:39133913~39135608:+
PRAD	cis	rs12188164	0.931	rs115554641	ENSG00000221990.4	EXOC3-AS1	7.6	1.74e-13	7.39e-11	0.28	0.34	Cystic fibrosis severity;	chr5:443121	chr5:441498~443160:-
PRAD	cis	rs12188164	0.965	rs11739543	ENSG00000221990.4	EXOC3-AS1	7.6	1.74e-13	7.39e-11	0.28	0.34	Cystic fibrosis severity;	chr5:443561	chr5:441498~443160:-
PRAD	cis	rs12188164	0.965	rs72717430	ENSG00000221990.4	EXOC3-AS1	7.6	1.74e-13	7.39e-11	0.28	0.34	Cystic fibrosis severity;	chr5:444387	chr5:441498~443160:-
PRAD	cis	rs12188164	0.93	rs72717436	ENSG00000221990.4	EXOC3-AS1	7.6	1.74e-13	7.39e-11	0.28	0.34	Cystic fibrosis severity;	chr5:448176	chr5:441498~443160:-
PRAD	cis	rs12188164	0.965	rs72717438	ENSG00000221990.4	EXOC3-AS1	7.6	1.74e-13	7.39e-11	0.28	0.34	Cystic fibrosis severity;	chr5:448548	chr5:441498~443160:-
PRAD	cis	rs12188164	0.93	rs72717440	ENSG00000221990.4	EXOC3-AS1	7.6	1.74e-13	7.39e-11	0.28	0.34	Cystic fibrosis severity;	chr5:449586	chr5:441498~443160:-
PRAD	cis	rs9810089	0.967	rs10935177	ENSG00000261758.1	RP11-102M11.2	-7.6	1.74e-13	7.4e-11	-0.39	-0.34	Gestational age at birth (child effect);	chr3:136132235	chr3:136752630~136755780:+
PRAD	cis	rs12468226	0.938	rs10931993	ENSG00000273456.1	RP11-686O6.2	7.6	1.74e-13	7.42e-11	0.45	0.34	Urate levels;	chr2:202243017	chr2:202374932~202375604:-
PRAD	cis	rs6547741	0.752	rs7562863	ENSG00000234072.1	AC074117.10	-7.6	1.74e-13	7.42e-11	-0.26	-0.34	Oral cavity cancer;	chr2:27669827	chr2:27356246~27367622:+
PRAD	cis	rs1799949	1	rs2175957	ENSG00000267002.1	RP11-242D8.1	7.6	1.75e-13	7.43e-11	0.31	0.34	Menopause (age at onset);	chr17:43134805	chr17:43164183~43170403:-
PRAD	cis	rs9810089	0.934	rs570621	ENSG00000261758.1	RP11-102M11.2	7.6	1.75e-13	7.46e-11	0.39	0.34	Gestational age at birth (child effect);	chr3:136281901	chr3:136752630~136755780:+
PRAD	cis	rs6921919	0.848	rs6903823	ENSG00000204709.4	LINC01556	7.6	1.76e-13	7.48e-11	0.47	0.34	Autism spectrum disorder or schizophrenia;	chr6:28354519	chr6:28943877~28944537:+
PRAD	cis	rs12999373	0.501	rs2867134	ENSG00000272342.1	RP13-539J13.1	-7.59	1.76e-13	7.5e-11	-0.43	-0.34	Response to fenofibrate (adiponectin levels);Uric acid levels;	chr2:697499	chr2:739588~740164:-
PRAD	cis	rs733592	0.524	rs10875741	ENSG00000240399.1	RP1-228P16.1	-7.59	1.77e-13	7.53e-11	-0.27	-0.34	Plateletcrit;	chr12:48099139	chr12:48054813~48055591:-
PRAD	cis	rs733592	0.507	rs7304428	ENSG00000240399.1	RP1-228P16.1	-7.59	1.77e-13	7.53e-11	-0.27	-0.34	Plateletcrit;	chr12:48100492	chr12:48054813~48055591:-
PRAD	cis	rs733592	0.524	rs10875744	ENSG00000240399.1	RP1-228P16.1	7.59	1.77e-13	7.53e-11	0.27	0.34	Plateletcrit;	chr12:48104657	chr12:48054813~48055591:-
PRAD	cis	rs7916697	0.626	rs3858144	ENSG00000233590.1	RP11-153K11.3	-7.59	1.77e-13	7.53e-11	-0.44	-0.34	Optic disc area;	chr10:68251597	chr10:68233251~68242379:-
PRAD	cis	rs6570726	0.967	rs418662	ENSG00000235652.6	RP11-545I5.3	7.59	1.77e-13	7.54e-11	0.35	0.34	Lobe attachment (rater-scored or self-reported);	chr6:145527696	chr6:145799409~145886585:+
PRAD	cis	rs2933343	0.649	rs728839	ENSG00000261159.1	RP11-723O4.9	7.59	1.78e-13	7.56e-11	0.29	0.34	IgG glycosylation;	chr3:128870516	chr3:128859716~128860526:-
PRAD	cis	rs453301	0.653	rs1562211	ENSG00000253893.2	FAM85B	7.59	1.78e-13	7.56e-11	0.42	0.34	Joint mobility (Beighton score);	chr8:9044914	chr8:8167819~8226614:-
PRAD	cis	rs3020736	0.5	rs764481	ENSG00000205702.9	CYP2D7	-7.59	1.79e-13	7.59e-11	-0.26	-0.34	Autism spectrum disorder or schizophrenia;	chr22:42122422	chr22:42140203~42144577:-
PRAD	cis	rs62355900	0.627	rs16886403	ENSG00000271828.1	CTD-2310F14.1	7.59	1.79e-13	7.59e-11	0.71	0.34	Endometriosis;	chr5:56843419	chr5:56927874~56929573:+
PRAD	cis	rs1150668	0.796	rs2247002	ENSG00000280107.1	AL022393.9	-7.59	1.79e-13	7.6e-11	-0.39	-0.34	Pubertal anthropometrics;	chr6:28430174	chr6:28170845~28172521:+
PRAD	cis	rs9362426	0.503	rs34977536	ENSG00000218793.1	RP3-382I10.3	7.59	1.79e-13	7.6e-11	0.41	0.34	Depressive episodes in bipolar disorder;	chr6:87402650	chr6:87441165~87442146:-
PRAD	cis	rs9467773	0.869	rs9295689	ENSG00000124549.13	BTN2A3P	7.59	1.79e-13	7.61e-11	0.3	0.34	Intelligence (multi-trait analysis);	chr6:26455583	chr6:26421391~26432383:+
PRAD	cis	rs67340775	0.541	rs200968	ENSG00000280107.1	AL022393.9	-7.59	1.79e-13	7.62e-11	-0.52	-0.34	Lung cancer in ever smokers;	chr6:27891790	chr6:28170845~28172521:+
PRAD	cis	rs67340775	0.541	rs200966	ENSG00000280107.1	AL022393.9	-7.59	1.79e-13	7.62e-11	-0.52	-0.34	Lung cancer in ever smokers;	chr6:27894374	chr6:28170845~28172521:+
PRAD	cis	rs10129255	0.957	rs8014696	ENSG00000223648.3	IGHV3-64	-7.59	1.79e-13	7.62e-11	-0.33	-0.34	Kawasaki disease;	chr14:106769752	chr14:106643132~106658258:-
PRAD	cis	rs733592	0.507	rs3825403	ENSG00000240399.1	RP1-228P16.1	-7.59	1.8e-13	7.66e-11	-0.27	-0.34	Plateletcrit;	chr12:48063376	chr12:48054813~48055591:-
PRAD	cis	rs11168351	0.591	rs4258439	ENSG00000240399.1	RP1-228P16.1	-7.59	1.8e-13	7.66e-11	-0.27	-0.34	Bipolar disorder and schizophrenia;	chr12:48074869	chr12:48054813~48055591:-
PRAD	cis	rs733592	0.507	rs10747529	ENSG00000240399.1	RP1-228P16.1	-7.59	1.8e-13	7.66e-11	-0.27	-0.34	Plateletcrit;	chr12:48079586	chr12:48054813~48055591:-
PRAD	cis	rs733592	0.507	rs56129148	ENSG00000240399.1	RP1-228P16.1	-7.59	1.8e-13	7.66e-11	-0.27	-0.34	Plateletcrit;	chr12:48091747	chr12:48054813~48055591:-
PRAD	cis	rs11098499	0.789	rs9991166	ENSG00000245958.5	RP11-33B1.1	-7.59	1.8e-13	7.66e-11	-0.31	-0.34	Corneal astigmatism;	chr4:119316696	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.708	rs10005237	ENSG00000245958.5	RP11-33B1.1	-7.59	1.8e-13	7.66e-11	-0.31	-0.34	Corneal astigmatism;	chr4:119316742	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.754	rs878372	ENSG00000245958.5	RP11-33B1.1	-7.59	1.8e-13	7.66e-11	-0.31	-0.34	Corneal astigmatism;	chr4:119317625	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.754	rs10213267	ENSG00000245958.5	RP11-33B1.1	-7.59	1.8e-13	7.66e-11	-0.31	-0.34	Corneal astigmatism;	chr4:119317919	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.754	rs10212775	ENSG00000245958.5	RP11-33B1.1	-7.59	1.8e-13	7.66e-11	-0.31	-0.34	Corneal astigmatism;	chr4:119318089	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.754	rs11732087	ENSG00000245958.5	RP11-33B1.1	-7.59	1.8e-13	7.66e-11	-0.31	-0.34	Corneal astigmatism;	chr4:119318676	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.754	rs2964	ENSG00000245958.5	RP11-33B1.1	-7.59	1.8e-13	7.66e-11	-0.31	-0.34	Corneal astigmatism;	chr4:119318976	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.754	rs1511025	ENSG00000245958.5	RP11-33B1.1	-7.59	1.8e-13	7.66e-11	-0.31	-0.34	Corneal astigmatism;	chr4:119319083	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.754	rs12510269	ENSG00000245958.5	RP11-33B1.1	-7.59	1.8e-13	7.66e-11	-0.31	-0.34	Corneal astigmatism;	chr4:119320491	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.754	rs12506610	ENSG00000245958.5	RP11-33B1.1	-7.59	1.8e-13	7.66e-11	-0.31	-0.34	Corneal astigmatism;	chr4:119320504	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.743	rs10003567	ENSG00000245958.5	RP11-33B1.1	-7.59	1.8e-13	7.66e-11	-0.31	-0.34	Corneal astigmatism;	chr4:119320519	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.754	rs10006259	ENSG00000245958.5	RP11-33B1.1	-7.59	1.8e-13	7.66e-11	-0.31	-0.34	Corneal astigmatism;	chr4:119320990	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.754	rs28652763	ENSG00000245958.5	RP11-33B1.1	-7.59	1.8e-13	7.66e-11	-0.31	-0.34	Corneal astigmatism;	chr4:119321157	chr4:119454791~119552025:+
PRAD	cis	rs2439831	0.85	rs2957637	ENSG00000249839.1	AC011330.5	-7.59	1.81e-13	7.67e-11	-0.59	-0.34	Lung cancer in ever smokers;	chr15:43658920	chr15:43663654~43684339:-
PRAD	cis	rs12612619	0.732	rs1866655	ENSG00000229122.1	AGBL5-IT1	-7.59	1.81e-13	7.68e-11	-0.35	-0.34	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26985999	chr2:27061038~27061815:+
PRAD	cis	rs56114371	0.777	rs200481	ENSG00000280107.1	AL022393.9	-7.59	1.81e-13	7.7e-11	-0.58	-0.34	Breast cancer;	chr6:27806054	chr6:28170845~28172521:+
PRAD	cis	rs12701220	0.553	rs34062359	ENSG00000229043.2	AC091729.9	-7.59	1.82e-13	7.71e-11	-0.52	-0.34	Bronchopulmonary dysplasia;	chr7:1099440	chr7:1160374~1165267:+
PRAD	cis	rs172166	0.637	rs1225595	ENSG00000204709.4	LINC01556	7.59	1.82e-13	7.72e-11	0.43	0.34	Cardiac Troponin-T levels;	chr6:28183562	chr6:28943877~28944537:+
PRAD	cis	rs42648	0.564	rs10270950	ENSG00000227646.6	STEAP2-AS1	-7.59	1.82e-13	7.73e-11	-0.3	-0.34	Homocysteine levels;	chr7:90177982	chr7:89882353~90211635:-
PRAD	cis	rs2255336	0.938	rs61610254	ENSG00000245648.1	RP11-277P12.20	-7.59	1.82e-13	7.73e-11	-0.45	-0.34	Blood protein levels;	chr12:10446176	chr12:10363769~10398506:+
PRAD	cis	rs2933343	0.621	rs728838	ENSG00000261159.1	RP11-723O4.9	7.59	1.82e-13	7.73e-11	0.29	0.34	IgG glycosylation;	chr3:128870170	chr3:128859716~128860526:-
PRAD	cis	rs2933343	0.601	rs1680758	ENSG00000261159.1	RP11-723O4.9	7.59	1.82e-13	7.73e-11	0.29	0.34	IgG glycosylation;	chr3:128876054	chr3:128859716~128860526:-
PRAD	cis	rs2933343	0.649	rs789214	ENSG00000261159.1	RP11-723O4.9	7.59	1.82e-13	7.73e-11	0.29	0.34	IgG glycosylation;	chr3:128876152	chr3:128859716~128860526:-
PRAD	cis	rs2933343	0.729	rs789224	ENSG00000261159.1	RP11-723O4.9	7.59	1.82e-13	7.73e-11	0.29	0.34	IgG glycosylation;	chr3:128879388	chr3:128859716~128860526:-
PRAD	cis	rs2933343	0.761	rs789225	ENSG00000261159.1	RP11-723O4.9	7.59	1.82e-13	7.73e-11	0.29	0.34	IgG glycosylation;	chr3:128881386	chr3:128859716~128860526:-
PRAD	cis	rs2933343	0.7	rs789233	ENSG00000261159.1	RP11-723O4.9	7.59	1.82e-13	7.73e-11	0.29	0.34	IgG glycosylation;	chr3:128884307	chr3:128859716~128860526:-
PRAD	cis	rs5760092	0.618	rs5996631	ENSG00000206090.4	AP000350.7	-7.59	1.83e-13	7.75e-11	-0.48	-0.34	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23939998~23942798:+
PRAD	cis	rs6479901	0.895	rs10733788	ENSG00000232075.1	MRPL35P2	-7.59	1.83e-13	7.76e-11	-0.41	-0.34	Intelligence (multi-trait analysis);	chr10:63158105	chr10:63634317~63634827:-
PRAD	cis	rs2439831	0.85	rs60883262	ENSG00000205771.5	CATSPER2P1	-7.59	1.84e-13	7.79e-11	-0.51	-0.34	Lung cancer in ever smokers;	chr15:43784305	chr15:43726918~43747094:-
PRAD	cis	rs55665837	1	rs12792120	ENSG00000251991.1	RNU7-49P	7.59	1.84e-13	7.8e-11	0.36	0.34	Vitamin D levels;	chr11:14447897	chr11:14478892~14478953:+
PRAD	cis	rs11098499	0.754	rs9999724	ENSG00000245958.5	RP11-33B1.1	-7.59	1.84e-13	7.81e-11	-0.31	-0.34	Corneal astigmatism;	chr4:119318789	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.754	rs714899	ENSG00000245958.5	RP11-33B1.1	-7.59	1.84e-13	7.81e-11	-0.31	-0.34	Corneal astigmatism;	chr4:119321880	chr4:119454791~119552025:+
PRAD	cis	rs11018904	0.817	rs11606060	ENSG00000280385.1	AP000648.5	-7.59	1.85e-13	7.83e-11	-0.48	-0.34	Intelligence (multi-trait analysis);	chr11:90195429	chr11:90193614~90198120:+
PRAD	cis	rs11018904	0.906	rs11603498	ENSG00000280385.1	AP000648.5	-7.59	1.85e-13	7.83e-11	-0.48	-0.34	Intelligence (multi-trait analysis);	chr11:90195615	chr11:90193614~90198120:+
PRAD	cis	rs9393777	0.777	rs56114371	ENSG00000280107.1	AL022393.9	-7.59	1.85e-13	7.84e-11	-0.69	-0.34	Intelligence (multi-trait analysis);	chr6:27307055	chr6:28170845~28172521:+
PRAD	cis	rs914615	0.508	rs7535292	ENSG00000160766.13	GBAP1	-7.59	1.85e-13	7.86e-11	-0.34	-0.34	Urinary albumin-to-creatinine ratio;	chr1:155155273	chr1:155213821~155227422:-
PRAD	cis	rs858239	0.6	rs4628176	ENSG00000226816.2	AC005082.12	7.59	1.85e-13	7.86e-11	0.38	0.34	Cerebrospinal fluid biomarker levels;	chr7:23102947	chr7:23206013~23208045:+
PRAD	cis	rs858239	0.6	rs10488077	ENSG00000226816.2	AC005082.12	7.59	1.85e-13	7.86e-11	0.38	0.34	Cerebrospinal fluid biomarker levels;	chr7:23104563	chr7:23206013~23208045:+
PRAD	cis	rs62355901	0.505	rs12655082	ENSG00000271828.1	CTD-2310F14.1	7.59	1.86e-13	7.88e-11	0.67	0.34	Breast cancer;	chr5:56930384	chr5:56927874~56929573:+
PRAD	cis	rs12612619	0.732	rs11897106	ENSG00000272148.1	RP11-195B17.1	-7.59	1.87e-13	7.91e-11	-0.4	-0.34	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26973431	chr2:27062428~27062907:-
PRAD	cis	rs858239	0.6	rs61292332	ENSG00000226816.2	AC005082.12	7.59	1.87e-13	7.91e-11	0.38	0.34	Cerebrospinal fluid biomarker levels;	chr7:23092243	chr7:23206013~23208045:+
PRAD	cis	rs9467773	0.62	rs3800303	ENSG00000241549.7	GUSBP2	7.59	1.87e-13	7.92e-11	0.35	0.34	Intelligence (multi-trait analysis);	chr6:26597960	chr6:26871484~26956554:-
PRAD	cis	rs9810089	0.934	rs696520	ENSG00000261758.1	RP11-102M11.2	7.59	1.87e-13	7.93e-11	0.38	0.34	Gestational age at birth (child effect);	chr3:136338019	chr3:136752630~136755780:+
PRAD	cis	rs3096299	0.933	rs2965823	ENSG00000261118.1	RP11-104N10.1	7.59	1.88e-13	7.96e-11	0.32	0.34	Multiple myeloma (IgH translocation);	chr16:89388516	chr16:89492017~89504460:-
PRAD	cis	rs2439831	0.85	rs28564774	ENSG00000249839.1	AC011330.5	-7.59	1.88e-13	7.99e-11	-0.58	-0.34	Lung cancer in ever smokers;	chr15:43833277	chr15:43663654~43684339:-
PRAD	cis	rs2439831	0.85	rs12441984	ENSG00000249839.1	AC011330.5	-7.59	1.88e-13	7.99e-11	-0.58	-0.34	Lung cancer in ever smokers;	chr15:43834087	chr15:43663654~43684339:-
PRAD	cis	rs2439831	0.85	rs28707214	ENSG00000249839.1	AC011330.5	-7.59	1.88e-13	7.99e-11	-0.58	-0.34	Lung cancer in ever smokers;	chr15:43839425	chr15:43663654~43684339:-
PRAD	cis	rs964611	0.935	rs2291341	ENSG00000259488.2	RP11-154J22.1	-7.59	1.89e-13	8e-11	-0.34	-0.34	Metabolite levels (Pyroglutamine);	chr15:48291640	chr15:48312353~48331856:-
PRAD	cis	rs6570726	0.811	rs375873	ENSG00000235652.6	RP11-545I5.3	7.59	1.89e-13	8e-11	0.36	0.34	Lobe attachment (rater-scored or self-reported);	chr6:145491235	chr6:145799409~145886585:+
PRAD	cis	rs858239	0.571	rs6953020	ENSG00000226816.2	AC005082.12	7.59	1.89e-13	8e-11	0.38	0.34	Cerebrospinal fluid biomarker levels;	chr7:23132513	chr7:23206013~23208045:+
PRAD	cis	rs13126694	0.75	rs2346782	ENSG00000248429.4	RP11-597D13.9	7.58	1.89e-13	8.02e-11	0.35	0.34	Blood osmolality (transformed sodium);	chr4:158147143	chr4:158170752~158202877:+
PRAD	cis	rs1501911	0.509	rs330422	ENSG00000248489.1	CTD-2007H13.3	7.58	1.89e-13	8.03e-11	0.37	0.34	Lung function (FEV1/FVC);	chr5:98859184	chr5:98929171~98995013:+
PRAD	cis	rs950169	0.579	rs12912716	ENSG00000259728.4	LINC00933	7.58	1.9e-13	8.03e-11	0.42	0.34	Schizophrenia;	chr15:83995511	chr15:84570649~84580175:+
PRAD	cis	rs950169	0.579	rs12913054	ENSG00000259728.4	LINC00933	7.58	1.9e-13	8.03e-11	0.42	0.34	Schizophrenia;	chr15:83995704	chr15:84570649~84580175:+
PRAD	cis	rs6674176	0.66	rs3791112	ENSG00000237950.1	RP11-7O11.3	7.58	1.9e-13	8.03e-11	0.37	0.34	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43913576	chr1:43944370~43946551:-
PRAD	cis	rs950169	0.96	rs12905475	ENSG00000225151.9	GOLGA2P7	-7.58	1.9e-13	8.04e-11	-0.48	-0.34	Schizophrenia;	chr15:84131743	chr15:84199311~84230136:-
PRAD	cis	rs2255336	0.81	rs10772267	ENSG00000245648.1	RP11-277P12.20	7.58	1.9e-13	8.05e-11	0.54	0.34	Blood protein levels;	chr12:10357969	chr12:10363769~10398506:+
PRAD	cis	rs526231	0.543	rs246901	ENSG00000175749.11	EIF3KP1	7.58	1.9e-13	8.05e-11	0.49	0.34	Primary biliary cholangitis;	chr5:103248477	chr5:103032376~103033031:+
PRAD	cis	rs673078	0.607	rs7312555	ENSG00000275409.1	RP11-131L12.4	-7.58	1.9e-13	8.07e-11	-0.5	-0.33	Glucose homeostasis traits;	chr12:118414120	chr12:118430147~118430699:+
PRAD	cis	rs3096299	0.967	rs2965937	ENSG00000261118.1	RP11-104N10.1	7.58	1.91e-13	8.07e-11	0.33	0.33	Multiple myeloma (IgH translocation);	chr16:89422371	chr16:89492017~89504460:-
PRAD	cis	rs7567389	0.637	rs4150421	ENSG00000236682.1	AC068282.3	7.58	1.91e-13	8.07e-11	0.45	0.33	Self-rated health;	chr2:127287354	chr2:127389130~127400580:+
PRAD	cis	rs858239	0.601	rs6969733	ENSG00000226816.2	AC005082.12	7.58	1.91e-13	8.08e-11	0.38	0.33	Cerebrospinal fluid biomarker levels;	chr7:23128758	chr7:23206013~23208045:+
PRAD	cis	rs858239	0.601	rs4440529	ENSG00000226816.2	AC005082.12	7.58	1.91e-13	8.08e-11	0.38	0.33	Cerebrospinal fluid biomarker levels;	chr7:23129132	chr7:23206013~23208045:+
PRAD	cis	rs7429990	0.932	rs6803741	ENSG00000229759.1	MRPS18AP1	-7.58	1.91e-13	8.11e-11	-0.35	-0.33	Educational attainment (years of education);	chr3:48082050	chr3:48256350~48256938:-
PRAD	cis	rs733592	0.507	rs10875739	ENSG00000240399.1	RP1-228P16.1	7.58	1.92e-13	8.11e-11	0.28	0.33	Plateletcrit;	chr12:48087136	chr12:48054813~48055591:-
PRAD	cis	rs3020736	0.5	rs4147641	ENSG00000205702.9	CYP2D7	-7.58	1.92e-13	8.14e-11	-0.26	-0.33	Autism spectrum disorder or schizophrenia;	chr22:42086498	chr22:42140203~42144577:-
PRAD	cis	rs3020736	0.5	rs4147640	ENSG00000205702.9	CYP2D7	-7.58	1.92e-13	8.14e-11	-0.26	-0.33	Autism spectrum disorder or schizophrenia;	chr22:42089288	chr22:42140203~42144577:-
PRAD	cis	rs3020736	0.5	rs1801311	ENSG00000205702.9	CYP2D7	-7.58	1.92e-13	8.14e-11	-0.26	-0.33	Autism spectrum disorder or schizophrenia;	chr22:42090719	chr22:42140203~42144577:-
PRAD	cis	rs1023500	0.507	rs6002600	ENSG00000205702.9	CYP2D7	-7.58	1.92e-13	8.14e-11	-0.26	-0.33	Schizophrenia;	chr22:42092902	chr22:42140203~42144577:-
PRAD	cis	rs3020736	0.5	rs6002604	ENSG00000205702.9	CYP2D7	-7.58	1.92e-13	8.14e-11	-0.26	-0.33	Autism spectrum disorder or schizophrenia;	chr22:42097077	chr22:42140203~42144577:-
PRAD	cis	rs3020736	0.5	rs5996109	ENSG00000205702.9	CYP2D7	-7.58	1.92e-13	8.14e-11	-0.26	-0.33	Autism spectrum disorder or schizophrenia;	chr22:42097094	chr22:42140203~42144577:-
PRAD	cis	rs3020736	0.5	rs5996110	ENSG00000205702.9	CYP2D7	-7.58	1.92e-13	8.14e-11	-0.26	-0.33	Autism spectrum disorder or schizophrenia;	chr22:42097763	chr22:42140203~42144577:-
PRAD	cis	rs3020736	0.5	rs9620026	ENSG00000205702.9	CYP2D7	-7.58	1.92e-13	8.14e-11	-0.26	-0.33	Autism spectrum disorder or schizophrenia;	chr22:42102574	chr22:42140203~42144577:-
PRAD	cis	rs3020736	0.5	rs28791586	ENSG00000205702.9	CYP2D7	-7.58	1.92e-13	8.14e-11	-0.26	-0.33	Autism spectrum disorder or schizophrenia;	chr22:42104479	chr22:42140203~42144577:-
PRAD	cis	rs3020736	0.5	rs2839708	ENSG00000205702.9	CYP2D7	-7.58	1.92e-13	8.14e-11	-0.26	-0.33	Autism spectrum disorder or schizophrenia;	chr22:42104741	chr22:42140203~42144577:-
PRAD	cis	rs3020736	0.5	rs6519306	ENSG00000205702.9	CYP2D7	-7.58	1.92e-13	8.14e-11	-0.26	-0.33	Autism spectrum disorder or schizophrenia;	chr22:42105213	chr22:42140203~42144577:-
PRAD	cis	rs2274273	1	rs57970196	ENSG00000258413.1	RP11-665C16.6	-7.58	1.93e-13	8.15e-11	-0.43	-0.33	Protein biomarker;	chr14:55133687	chr14:55262767~55272075:-
PRAD	cis	rs10170846	0.626	rs9288575	ENSG00000261428.2	RP11-16P6.1	7.58	1.93e-13	8.15e-11	0.57	0.33	Schizophrenia (inflammation and infection response interaction);	chr2:222630414	chr2:222566899~222569719:-
PRAD	cis	rs875971	0.54	rs1723268	ENSG00000237310.1	GS1-124K5.4	7.58	1.93e-13	8.16e-11	0.28	0.33	Aortic root size;	chr7:66008093	chr7:66493706~66495474:+
PRAD	cis	rs12928939	0.723	rs71403864	ENSG00000260886.1	TAT-AS1	7.58	1.93e-13	8.16e-11	0.45	0.33	Post bronchodilator FEV1;	chr16:71661127	chr16:71565789~71578187:+
PRAD	cis	rs12142240	0.698	rs79490411	ENSG00000232022.5	FAAHP1	-7.58	1.94e-13	8.2e-11	-0.32	-0.33	Menopause (age at onset);	chr1:46347896	chr1:46432129~46445521:+
PRAD	cis	rs6570726	0.905	rs442435	ENSG00000235652.6	RP11-545I5.3	7.58	1.95e-13	8.24e-11	0.36	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145494423	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.905	rs396492	ENSG00000235652.6	RP11-545I5.3	7.58	1.95e-13	8.24e-11	0.36	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145495044	chr6:145799409~145886585:+
PRAD	cis	rs6570726	0.935	rs7757387	ENSG00000235652.6	RP11-545I5.3	7.58	1.95e-13	8.24e-11	0.36	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145495590	chr6:145799409~145886585:+
PRAD	cis	rs2638953	0.962	rs9645730	ENSG00000278733.1	RP11-425D17.1	-7.58	1.95e-13	8.24e-11	-0.43	-0.33	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28317151	chr12:28185625~28186190:-
PRAD	cis	rs673078	0.66	rs7136216	ENSG00000275409.1	RP11-131L12.4	-7.58	1.95e-13	8.27e-11	-0.45	-0.33	Glucose homeostasis traits;	chr12:118170475	chr12:118430147~118430699:+
PRAD	cis	rs6479901	0.895	rs7092139	ENSG00000232075.1	MRPL35P2	-7.58	1.96e-13	8.27e-11	-0.41	-0.33	Intelligence (multi-trait analysis);	chr10:63306540	chr10:63634317~63634827:-
PRAD	cis	rs6479901	1	rs7092539	ENSG00000232075.1	MRPL35P2	-7.58	1.96e-13	8.27e-11	-0.41	-0.33	Intelligence (multi-trait analysis);	chr10:63306749	chr10:63634317~63634827:-
PRAD	cis	rs853679	1	rs1679732	ENSG00000226314.6	ZNF192P1	7.58	1.96e-13	8.28e-11	0.53	0.33	Depression;	chr6:28253486	chr6:28161781~28169594:+
PRAD	cis	rs853679	1	rs1679709	ENSG00000226314.6	ZNF192P1	7.58	1.96e-13	8.28e-11	0.53	0.33	Depression;	chr6:28260564	chr6:28161781~28169594:+
PRAD	cis	rs11098499	0.661	rs10015965	ENSG00000245958.5	RP11-33B1.1	-7.58	1.96e-13	8.29e-11	-0.31	-0.33	Corneal astigmatism;	chr4:119347082	chr4:119454791~119552025:+
PRAD	cis	rs12612619	0.724	rs7355650	ENSG00000272148.1	RP11-195B17.1	-7.58	1.96e-13	8.31e-11	-0.41	-0.33	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27022607	chr2:27062428~27062907:-
PRAD	cis	rs62355901	0.505	rs12657396	ENSG00000271828.1	CTD-2310F14.1	7.58	1.98e-13	8.35e-11	0.67	0.33	Breast cancer;	chr5:56930778	chr5:56927874~56929573:+
PRAD	cis	rs7829975	0.742	rs7832968	ENSG00000253893.2	FAM85B	-7.58	1.98e-13	8.37e-11	-0.43	-0.33	Mood instability;	chr8:8795379	chr8:8167819~8226614:-
PRAD	cis	rs12612619	0.732	rs893790	ENSG00000229122.1	AGBL5-IT1	-7.58	1.98e-13	8.39e-11	-0.35	-0.33	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26978989	chr2:27061038~27061815:+
PRAD	cis	rs4460629	0.905	rs4971077	ENSG00000160766.13	GBAP1	-7.58	1.98e-13	8.39e-11	-0.34	-0.33	Serum magnesium levels;	chr1:155156241	chr1:155213821~155227422:-
PRAD	cis	rs11098499	0.722	rs10006192	ENSG00000245958.5	RP11-33B1.1	-7.58	1.99e-13	8.39e-11	-0.31	-0.33	Corneal astigmatism;	chr4:119341867	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.615	rs28551750	ENSG00000245958.5	RP11-33B1.1	-7.58	1.99e-13	8.39e-11	-0.31	-0.33	Corneal astigmatism;	chr4:119343746	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.691	rs9995716	ENSG00000245958.5	RP11-33B1.1	-7.58	1.99e-13	8.39e-11	-0.31	-0.33	Corneal astigmatism;	chr4:119343841	chr4:119454791~119552025:+
PRAD	cis	rs7104764	0.507	rs6598054	ENSG00000277290.1	RP11-326C3.16	7.58	1.99e-13	8.4e-11	0.33	0.33	Menarche (age at onset);	chr11:254010	chr11:243099~243483:-
PRAD	cis	rs496547	0.756	rs562059	ENSG00000255239.1	AP002954.6	7.58	1.99e-13	8.4e-11	0.45	0.33	Hip minimal joint space width;	chr11:118731349	chr11:118688039~118690600:-
PRAD	cis	rs853679	0.546	rs35017208	ENSG00000225595.2	XXbac-BPG308K3.6	7.58	1.99e-13	8.42e-11	0.74	0.33	Depression;	chr6:28377505	chr6:28859625~28864630:-
PRAD	cis	rs881375	0.967	rs2109896	ENSG00000226752.6	PSMD5-AS1	-7.58	2e-13	8.44e-11	-0.4	-0.33	Rheumatoid arthritis;	chr9:120920828	chr9:120824828~120854385:+
PRAD	cis	rs494459	0.838	rs12796102	ENSG00000278376.1	RP11-158I9.8	-7.58	2e-13	8.44e-11	-0.28	-0.33	Height;	chr11:118791319	chr11:118791254~118793137:+
PRAD	cis	rs6547741	1	rs6547740	ENSG00000234072.1	AC074117.10	7.58	2e-13	8.44e-11	0.25	0.33	Oral cavity cancer;	chr2:27631502	chr2:27356246~27367622:+
PRAD	cis	rs3020736	0.5	rs11090076	ENSG00000205702.9	CYP2D7	-7.58	2e-13	8.45e-11	-0.26	-0.33	Autism spectrum disorder or schizophrenia;	chr22:42118186	chr22:42140203~42144577:-
PRAD	cis	rs2255336	0.938	rs73070926	ENSG00000245648.1	RP11-277P12.20	-7.58	2e-13	8.47e-11	-0.5	-0.33	Blood protein levels;	chr12:10459717	chr12:10363769~10398506:+
PRAD	cis	rs2255336	0.938	rs7298494	ENSG00000245648.1	RP11-277P12.20	-7.58	2e-13	8.47e-11	-0.5	-0.33	Blood protein levels;	chr12:10460666	chr12:10363769~10398506:+
PRAD	cis	rs2638953	0.962	rs11049540	ENSG00000278733.1	RP11-425D17.1	-7.58	2e-13	8.47e-11	-0.42	-0.33	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28337959	chr12:28185625~28186190:-
PRAD	cis	rs6001482	0.686	rs9623125	ENSG00000272779.1	LL22NC03-80A10.6	-7.58	2e-13	8.47e-11	-0.4	-0.33	Diastolic blood pressure;	chr22:22234600	chr22:22303224~22310401:+
PRAD	cis	rs11159086	0.793	rs12432412	ENSG00000270000.1	RP3-449M8.9	7.58	2.01e-13	8.5e-11	0.51	0.33	Advanced glycation end-product levels;	chr14:74474294	chr14:74471930~74472360:-
PRAD	cis	rs11159086	0.793	rs1029700	ENSG00000270000.1	RP3-449M8.9	7.58	2.01e-13	8.5e-11	0.51	0.33	Advanced glycation end-product levels;	chr14:74474309	chr14:74471930~74472360:-
PRAD	cis	rs11159086	0.793	rs1029699	ENSG00000270000.1	RP3-449M8.9	7.58	2.01e-13	8.5e-11	0.51	0.33	Advanced glycation end-product levels;	chr14:74474790	chr14:74471930~74472360:-
PRAD	cis	rs6545883	0.542	rs10177225	ENSG00000271889.1	RP11-493E12.1	-7.58	2.01e-13	8.51e-11	-0.36	-0.33	Tuberculosis;	chr2:61367363	chr2:61151433~61162105:-
PRAD	cis	rs9810089	0.843	rs650326	ENSG00000261758.1	RP11-102M11.2	7.58	2.02e-13	8.52e-11	0.38	0.33	Gestational age at birth (child effect);	chr3:136318865	chr3:136752630~136755780:+
PRAD	cis	rs10028773	0.666	rs12498657	ENSG00000245958.5	RP11-33B1.1	-7.58	2.02e-13	8.52e-11	-0.31	-0.33	Educational attainment;	chr4:119341711	chr4:119454791~119552025:+
PRAD	cis	rs42648	0.869	rs42609	ENSG00000227646.6	STEAP2-AS1	-7.58	2.02e-13	8.53e-11	-0.31	-0.33	Homocysteine levels;	chr7:90320541	chr7:89882353~90211635:-
PRAD	cis	rs9393777	0.92	rs72839445	ENSG00000280107.1	AL022393.9	-7.58	2.02e-13	8.54e-11	-0.71	-0.33	Intelligence (multi-trait analysis);	chr6:27281907	chr6:28170845~28172521:+
PRAD	cis	rs12928939	0.815	rs61753635	ENSG00000260886.1	TAT-AS1	7.57	2.02e-13	8.54e-11	0.46	0.33	Post bronchodilator FEV1;	chr16:71626501	chr16:71565789~71578187:+
PRAD	cis	rs9309473	0.528	rs6546820	ENSG00000163016.8	ALMS1P	7.57	2.02e-13	8.55e-11	0.4	0.33	Metabolite levels;	chr2:73326269	chr2:73644919~73685576:+
PRAD	cis	rs11673344	0.528	rs578655	ENSG00000226686.6	LINC01535	7.57	2.03e-13	8.56e-11	0.43	0.33	Obesity-related traits;	chr19:36919855	chr19:37251912~37265535:+
PRAD	cis	rs321358	1	rs73021573	ENSG00000271584.1	RP11-89C3.4	7.57	2.03e-13	8.58e-11	0.51	0.33	Body mass index;	chr11:111155508	chr11:111091932~111097357:-
PRAD	cis	rs321358	1	rs73003511	ENSG00000271584.1	RP11-89C3.4	7.57	2.03e-13	8.58e-11	0.51	0.33	Body mass index;	chr11:111160478	chr11:111091932~111097357:-
PRAD	cis	rs321358	1	rs73003514	ENSG00000271584.1	RP11-89C3.4	7.57	2.03e-13	8.58e-11	0.51	0.33	Body mass index;	chr11:111160605	chr11:111091932~111097357:-
PRAD	cis	rs12653946	0.811	rs10866527	ENSG00000248994.1	RP11-259O2.1	-7.57	2.03e-13	8.59e-11	-0.4	-0.33	Prostate cancer;	chr5:1891686	chr5:1933863~1959176:+
PRAD	cis	rs74024059	1	rs13379955	ENSG00000260685.1	RP11-326L17.1	7.57	2.04e-13	8.6e-11	0.89	0.33	Red blood cell count;Hematocrit;	chr15:75981114	chr15:75950464~75951144:-
PRAD	cis	rs74024059	1	rs74024038	ENSG00000260685.1	RP11-326L17.1	7.57	2.04e-13	8.6e-11	0.89	0.33	Red blood cell count;Hematocrit;	chr15:75981920	chr15:75950464~75951144:-
PRAD	cis	rs4713118	0.869	rs7776351	ENSG00000226314.6	ZNF192P1	7.57	2.04e-13	8.6e-11	0.44	0.33	Parkinson's disease;	chr6:27758952	chr6:28161781~28169594:+
PRAD	cis	rs4713118	0.869	rs9461405	ENSG00000226314.6	ZNF192P1	-7.57	2.04e-13	8.6e-11	-0.44	-0.33	Parkinson's disease;	chr6:27751596	chr6:28161781~28169594:+
PRAD	cis	rs4713118	0.869	rs7773070	ENSG00000226314.6	ZNF192P1	-7.57	2.04e-13	8.6e-11	-0.44	-0.33	Parkinson's disease;	chr6:27761048	chr6:28161781~28169594:+
PRAD	cis	rs67311347	0.524	rs11129869	ENSG00000223797.4	ENTPD3-AS1	7.57	2.04e-13	8.6e-11	0.31	0.33	Renal cell carcinoma;	chr3:40218247	chr3:40313802~40453329:-
PRAD	cis	rs2243480	1	rs12698509	ENSG00000273142.1	RP11-458F8.4	-7.57	2.04e-13	8.61e-11	-0.36	-0.33	Diabetic kidney disease;	chr7:65953889	chr7:66902857~66906297:+
PRAD	cis	rs748404	0.697	rs530683	ENSG00000205771.5	CATSPER2P1	7.57	2.04e-13	8.61e-11	0.36	0.33	Lung cancer;	chr15:43276801	chr15:43726918~43747094:-
PRAD	cis	rs748404	0.697	rs473554	ENSG00000205771.5	CATSPER2P1	-7.57	2.04e-13	8.61e-11	-0.36	-0.33	Lung cancer;	chr15:43276009	chr15:43726918~43747094:-
PRAD	cis	rs11159086	1	rs8006909	ENSG00000259005.1	RP3-449M8.6	7.57	2.04e-13	8.61e-11	0.46	0.33	Advanced glycation end-product levels;	chr14:74478085	chr14:74474007~74474864:-
PRAD	cis	rs12612619	0.732	rs2289360	ENSG00000229122.1	AGBL5-IT1	7.57	2.04e-13	8.63e-11	0.35	0.33	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27079297	chr2:27061038~27061815:+
PRAD	cis	rs8062405	0.789	rs28676837	ENSG00000251417.2	RP11-1348G14.4	7.57	2.05e-13	8.63e-11	0.37	0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28615742	chr16:28802743~28817828:+
PRAD	cis	rs964611	0.882	rs56308793	ENSG00000259488.2	RP11-154J22.1	-7.57	2.05e-13	8.64e-11	-0.34	-0.33	Metabolite levels (Pyroglutamine);	chr15:48350611	chr15:48312353~48331856:-
PRAD	cis	rs6600671	0.691	rs6600662	ENSG00000223345.3	HIST2H2BA	7.57	2.05e-13	8.64e-11	0.41	0.33	Hip geometry;	chr1:121488992	chr1:121108210~121117257:-
PRAD	cis	rs6570726	0.935	rs398060	ENSG00000235652.6	RP11-545I5.3	-7.57	2.05e-13	8.65e-11	-0.35	-0.33	Lobe attachment (rater-scored or self-reported);	chr6:145520379	chr6:145799409~145886585:+
PRAD	cis	rs10129255	0.957	rs10150241	ENSG00000223648.3	IGHV3-64	-7.57	2.05e-13	8.66e-11	-0.33	-0.33	Kawasaki disease;	chr14:106775945	chr14:106643132~106658258:-
PRAD	cis	rs8040855	0.894	rs4843023	ENSG00000259295.5	CSPG4P12	-7.57	2.05e-13	8.66e-11	-0.42	-0.33	Bulimia nervosa;	chr15:85162641	chr15:85191438~85213905:+
PRAD	cis	rs10463554	0.892	rs1898673	ENSG00000175749.11	EIF3KP1	7.57	2.05e-13	8.66e-11	0.45	0.33	Parkinson's disease;	chr5:102957676	chr5:103032376~103033031:+
PRAD	cis	rs4722166	0.598	rs4722180	ENSG00000179428.2	AC073072.5	-7.57	2.06e-13	8.7e-11	-0.38	-0.33	Lung cancer;	chr7:22765453	chr7:22725395~22727620:-
PRAD	cis	rs1501911	0.588	rs709389	ENSG00000248489.1	CTD-2007H13.3	7.57	2.06e-13	8.7e-11	0.4	0.33	Lung function (FEV1/FVC);	chr5:98994011	chr5:98929171~98995013:+
PRAD	cis	rs9532669	0.926	rs4356344	ENSG00000168852.11	TPTE2P5	7.57	2.06e-13	8.7e-11	0.34	0.33	Cervical cancer;	chr13:40874086	chr13:40822296~40921749:-
PRAD	cis	rs950169	0.579	rs11633088	ENSG00000259728.4	LINC00933	-7.57	2.07e-13	8.71e-11	-0.42	-0.33	Schizophrenia;	chr15:84003429	chr15:84570649~84580175:+
PRAD	cis	rs6480314	0.542	rs1007848	ENSG00000233590.1	RP11-153K11.3	-7.57	2.07e-13	8.71e-11	-0.55	-0.33	Optic nerve measurement (disc area);	chr10:68258549	chr10:68233251~68242379:-
PRAD	cis	rs6480314	0.542	rs61854807	ENSG00000233590.1	RP11-153K11.3	-7.57	2.07e-13	8.71e-11	-0.55	-0.33	Optic nerve measurement (disc area);	chr10:68258948	chr10:68233251~68242379:-
PRAD	cis	rs6480314	0.616	rs12571093	ENSG00000233590.1	RP11-153K11.3	-7.57	2.07e-13	8.71e-11	-0.55	-0.33	Optic nerve measurement (disc area);	chr10:68259614	chr10:68233251~68242379:-
PRAD	cis	rs6480314	0.542	rs7476012	ENSG00000233590.1	RP11-153K11.3	-7.57	2.07e-13	8.71e-11	-0.55	-0.33	Optic nerve measurement (disc area);	chr10:68259950	chr10:68233251~68242379:-
PRAD	cis	rs6480314	0.542	rs2120902	ENSG00000233590.1	RP11-153K11.3	-7.57	2.07e-13	8.71e-11	-0.55	-0.33	Optic nerve measurement (disc area);	chr10:68260465	chr10:68233251~68242379:-
PRAD	cis	rs12571093	0.773	rs4142047	ENSG00000233590.1	RP11-153K11.3	-7.57	2.07e-13	8.71e-11	-0.55	-0.33	Optic nerve measurement (disc area);	chr10:68261498	chr10:68233251~68242379:-
PRAD	cis	rs6480314	0.542	rs61854809	ENSG00000233590.1	RP11-153K11.3	-7.57	2.07e-13	8.71e-11	-0.55	-0.33	Optic nerve measurement (disc area);	chr10:68262847	chr10:68233251~68242379:-
PRAD	cis	rs6480314	0.542	rs61854810	ENSG00000233590.1	RP11-153K11.3	-7.57	2.07e-13	8.71e-11	-0.55	-0.33	Optic nerve measurement (disc area);	chr10:68264139	chr10:68233251~68242379:-
PRAD	cis	rs6480314	0.542	rs4592311	ENSG00000233590.1	RP11-153K11.3	-7.57	2.07e-13	8.71e-11	-0.55	-0.33	Optic nerve measurement (disc area);	chr10:68268492	chr10:68233251~68242379:-
PRAD	cis	rs6480314	0.542	rs79081413	ENSG00000233590.1	RP11-153K11.3	-7.57	2.07e-13	8.71e-11	-0.55	-0.33	Optic nerve measurement (disc area);	chr10:68268746	chr10:68233251~68242379:-
PRAD	cis	rs6480314	0.542	rs17231630	ENSG00000233590.1	RP11-153K11.3	-7.57	2.07e-13	8.71e-11	-0.55	-0.33	Optic nerve measurement (disc area);	chr10:68268960	chr10:68233251~68242379:-
PRAD	cis	rs6480314	0.542	rs61854816	ENSG00000233590.1	RP11-153K11.3	-7.57	2.07e-13	8.71e-11	-0.55	-0.33	Optic nerve measurement (disc area);	chr10:68269051	chr10:68233251~68242379:-
PRAD	cis	rs6480314	0.542	rs10998044	ENSG00000233590.1	RP11-153K11.3	-7.57	2.07e-13	8.71e-11	-0.55	-0.33	Optic nerve measurement (disc area);	chr10:68269508	chr10:68233251~68242379:-
PRAD	cis	rs6480314	0.542	rs10998045	ENSG00000233590.1	RP11-153K11.3	-7.57	2.07e-13	8.71e-11	-0.55	-0.33	Optic nerve measurement (disc area);	chr10:68269626	chr10:68233251~68242379:-
PRAD	cis	rs6480314	0.542	rs10998046	ENSG00000233590.1	RP11-153K11.3	-7.57	2.07e-13	8.71e-11	-0.55	-0.33	Optic nerve measurement (disc area);	chr10:68269641	chr10:68233251~68242379:-
PRAD	cis	rs6480314	0.542	rs17231637	ENSG00000233590.1	RP11-153K11.3	7.57	2.07e-13	8.71e-11	0.55	0.33	Optic nerve measurement (disc area);	chr10:68270137	chr10:68233251~68242379:-
PRAD	cis	rs6480314	0.542	rs61854824	ENSG00000233590.1	RP11-153K11.3	-7.57	2.07e-13	8.71e-11	-0.55	-0.33	Optic nerve measurement (disc area);	chr10:68270438	chr10:68233251~68242379:-
PRAD	cis	rs6480314	0.542	rs12572954	ENSG00000233590.1	RP11-153K11.3	-7.57	2.07e-13	8.71e-11	-0.55	-0.33	Optic nerve measurement (disc area);	chr10:68270766	chr10:68233251~68242379:-
PRAD	cis	rs6480314	0.542	rs12572967	ENSG00000233590.1	RP11-153K11.3	-7.57	2.07e-13	8.71e-11	-0.55	-0.33	Optic nerve measurement (disc area);	chr10:68270873	chr10:68233251~68242379:-
PRAD	cis	rs6480314	0.542	rs12572960	ENSG00000233590.1	RP11-153K11.3	-7.57	2.07e-13	8.71e-11	-0.55	-0.33	Optic nerve measurement (disc area);	chr10:68270966	chr10:68233251~68242379:-
PRAD	cis	rs12571093	0.803	rs2241969	ENSG00000233590.1	RP11-153K11.3	-7.57	2.07e-13	8.71e-11	-0.55	-0.33	Optic nerve measurement (disc area);	chr10:68271253	chr10:68233251~68242379:-
PRAD	cis	rs12571093	0.803	rs61854825	ENSG00000233590.1	RP11-153K11.3	-7.57	2.07e-13	8.71e-11	-0.55	-0.33	Optic nerve measurement (disc area);	chr10:68271535	chr10:68233251~68242379:-
PRAD	cis	rs12571093	0.803	rs61854826	ENSG00000233590.1	RP11-153K11.3	-7.57	2.07e-13	8.71e-11	-0.55	-0.33	Optic nerve measurement (disc area);	chr10:68271801	chr10:68233251~68242379:-
PRAD	cis	rs12571093	0.803	rs17297418	ENSG00000233590.1	RP11-153K11.3	7.57	2.07e-13	8.71e-11	0.55	0.33	Optic nerve measurement (disc area);	chr10:68271894	chr10:68233251~68242379:-
PRAD	cis	rs12571093	0.803	rs36103935	ENSG00000233590.1	RP11-153K11.3	-7.57	2.07e-13	8.71e-11	-0.55	-0.33	Optic nerve measurement (disc area);	chr10:68273171	chr10:68233251~68242379:-
PRAD	cis	rs12571093	0.803	rs61854829	ENSG00000233590.1	RP11-153K11.3	-7.57	2.07e-13	8.71e-11	-0.55	-0.33	Optic nerve measurement (disc area);	chr10:68273286	chr10:68233251~68242379:-
PRAD	cis	rs78456975	0.574	rs13412980	ENSG00000231482.2	AC141930.2	-7.57	2.07e-13	8.72e-11	-0.45	-0.33	Placebo response in major depressive disorder (% change in symptom score);	chr2:1541459	chr2:1572554~1580311:-
PRAD	cis	rs12468226	0.873	rs12470401	ENSG00000273456.1	RP11-686O6.2	7.57	2.08e-13	8.76e-11	0.46	0.33	Urate levels;	chr2:202236436	chr2:202374932~202375604:-
PRAD	cis	rs6570726	1	rs386678	ENSG00000235652.6	RP11-545I5.3	7.57	2.08e-13	8.78e-11	0.35	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145547874	chr6:145799409~145886585:+
PRAD	cis	rs9640161	0.711	rs55881542	ENSG00000261305.1	RP4-584D14.7	7.57	2.09e-13	8.79e-11	0.38	0.33	Blood protein levels;Circulating chemerin levels;	chr7:150328645	chr7:150341771~150342607:+
PRAD	cis	rs1799949	1	rs2292595	ENSG00000267002.1	RP11-242D8.1	7.57	2.09e-13	8.8e-11	0.31	0.33	Menopause (age at onset);	chr17:43138657	chr17:43164183~43170403:-
PRAD	cis	rs748404	0.697	rs498227	ENSG00000205771.5	CATSPER2P1	-7.57	2.09e-13	8.8e-11	-0.36	-0.33	Lung cancer;	chr15:43280854	chr15:43726918~43747094:-
PRAD	cis	rs3020736	0.5	rs6002601	ENSG00000205702.9	CYP2D7	-7.57	2.09e-13	8.8e-11	-0.26	-0.33	Autism spectrum disorder or schizophrenia;	chr22:42093054	chr22:42140203~42144577:-
PRAD	cis	rs2638953	0.962	rs10843171	ENSG00000278733.1	RP11-425D17.1	-7.57	2.1e-13	8.86e-11	-0.4	-0.33	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28435583	chr12:28185625~28186190:-
PRAD	cis	rs79349575	0.655	rs62078384	ENSG00000248278.1	SUMO2P17	7.57	2.11e-13	8.88e-11	0.39	0.33	Type 2 diabetes;	chr17:48967101	chr17:48874860~48908983:-
PRAD	cis	rs79349575	0.756	rs62078385	ENSG00000248278.1	SUMO2P17	7.57	2.11e-13	8.88e-11	0.39	0.33	Type 2 diabetes;	chr17:48967647	chr17:48874860~48908983:-
PRAD	cis	rs9467773	0.595	rs7767847	ENSG00000241549.7	GUSBP2	7.57	2.12e-13	8.92e-11	0.35	0.33	Intelligence (multi-trait analysis);	chr6:26597665	chr6:26871484~26956554:-
PRAD	cis	rs6782228	1	rs6775011	ENSG00000242551.2	POU5F1P6	7.57	2.12e-13	8.93e-11	0.47	0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128677640	chr3:128674735~128677005:-
PRAD	cis	rs2243480	1	rs6964530	ENSG00000273142.1	RP11-458F8.4	7.57	2.13e-13	8.95e-11	0.38	0.33	Diabetic kidney disease;	chr7:66253864	chr7:66902857~66906297:+
PRAD	cis	rs9341835	0.525	rs1320102	ENSG00000218048.2	RP3-407E4.4	7.57	2.13e-13	8.97e-11	0.38	0.33	Schizophrenia;	chr6:63276830	chr6:63440766~63443580:+
PRAD	cis	rs812925	0.537	rs10196146	ENSG00000271889.1	RP11-493E12.1	-7.57	2.13e-13	8.99e-11	-0.37	-0.33	Immature fraction of reticulocytes;	chr2:61378244	chr2:61151433~61162105:-
PRAD	cis	rs1426063	1	rs1426063	ENSG00000249717.1	RP11-44F21.3	-7.57	2.14e-13	8.99e-11	-0.55	-0.33	QT interval;	chr4:75105711	chr4:74955974~74970362:-
PRAD	cis	rs964611	0.575	rs11070640	ENSG00000259488.2	RP11-154J22.1	7.57	2.14e-13	9.01e-11	0.33	0.33	Metabolite levels (Pyroglutamine);	chr15:48387502	chr15:48312353~48331856:-
PRAD	cis	rs2933343	0.601	rs1680759	ENSG00000261159.1	RP11-723O4.9	7.57	2.14e-13	9.02e-11	0.29	0.33	IgG glycosylation;	chr3:128876053	chr3:128859716~128860526:-
PRAD	cis	rs9341835	0.525	rs2347256	ENSG00000218048.2	RP3-407E4.4	7.57	2.14e-13	9.03e-11	0.38	0.33	Schizophrenia;	chr6:63277570	chr6:63440766~63443580:+
PRAD	cis	rs17428076	0.836	rs12622895	ENSG00000228389.1	AC068039.4	7.57	2.14e-13	9.03e-11	0.43	0.33	Myopia;	chr2:171829794	chr2:171773482~171775844:+
PRAD	cis	rs881375	1	rs4323544	ENSG00000226752.6	PSMD5-AS1	-7.57	2.15e-13	9.04e-11	-0.4	-0.33	Rheumatoid arthritis;	chr9:120885099	chr9:120824828~120854385:+
PRAD	cis	rs881375	0.967	rs2270231	ENSG00000226752.6	PSMD5-AS1	-7.57	2.15e-13	9.04e-11	-0.4	-0.33	Rheumatoid arthritis;	chr9:120888704	chr9:120824828~120854385:+
PRAD	cis	rs881375	1	rs881375	ENSG00000226752.6	PSMD5-AS1	-7.57	2.15e-13	9.04e-11	-0.4	-0.33	Rheumatoid arthritis;	chr9:120890620	chr9:120824828~120854385:+
PRAD	cis	rs736801	0.607	rs11746555	ENSG00000233006.5	AC034220.3	7.57	2.15e-13	9.04e-11	0.3	0.33	Mosquito bite size;Breast cancer;	chr5:132391341	chr5:132311285~132369916:-
PRAD	cis	rs881375	1	rs10818480	ENSG00000226752.6	PSMD5-AS1	-7.57	2.15e-13	9.06e-11	-0.4	-0.33	Rheumatoid arthritis;	chr9:120880892	chr9:120824828~120854385:+
PRAD	cis	rs2933343	0.679	rs1091938	ENSG00000231305.3	RP11-723O4.2	7.57	2.16e-13	9.08e-11	0.31	0.33	IgG glycosylation;	chr3:128918182	chr3:128861313~128871540:-
PRAD	cis	rs3020736	0.5	rs6002614	ENSG00000205702.9	CYP2D7	-7.57	2.16e-13	9.09e-11	-0.26	-0.33	Autism spectrum disorder or schizophrenia;	chr22:42105798	chr22:42140203~42144577:-
PRAD	cis	rs3020736	0.5	rs2413669	ENSG00000205702.9	CYP2D7	-7.57	2.16e-13	9.09e-11	-0.26	-0.33	Autism spectrum disorder or schizophrenia;	chr22:42111744	chr22:42140203~42144577:-
PRAD	cis	rs3020736	0.5	rs6002618	ENSG00000205702.9	CYP2D7	-7.57	2.16e-13	9.09e-11	-0.26	-0.33	Autism spectrum disorder or schizophrenia;	chr22:42111855	chr22:42140203~42144577:-
PRAD	cis	rs1023500	0.551	rs61665536	ENSG00000205702.9	CYP2D7	-7.57	2.16e-13	9.09e-11	-0.26	-0.33	Schizophrenia;	chr22:42116609	chr22:42140203~42144577:-
PRAD	cis	rs3020736	0.5	rs2413672	ENSG00000205702.9	CYP2D7	-7.57	2.16e-13	9.09e-11	-0.26	-0.33	Autism spectrum disorder or schizophrenia;	chr22:42117257	chr22:42140203~42144577:-
PRAD	cis	rs3020736	0.5	rs6002623	ENSG00000205702.9	CYP2D7	-7.57	2.16e-13	9.09e-11	-0.26	-0.33	Autism spectrum disorder or schizophrenia;	chr22:42117757	chr22:42140203~42144577:-
PRAD	cis	rs3020736	0.5	rs8138678	ENSG00000205702.9	CYP2D7	-7.57	2.16e-13	9.09e-11	-0.26	-0.33	Autism spectrum disorder or schizophrenia;	chr22:42120225	chr22:42140203~42144577:-
PRAD	cis	rs3020736	0.519	rs5996116	ENSG00000205702.9	CYP2D7	-7.57	2.16e-13	9.09e-11	-0.26	-0.33	Autism spectrum disorder or schizophrenia;	chr22:42121488	chr22:42140203~42144577:-
PRAD	cis	rs10129255	0.957	rs12589190	ENSG00000223648.3	IGHV3-64	7.56	2.17e-13	9.13e-11	0.33	0.33	Kawasaki disease;	chr14:106783079	chr14:106643132~106658258:-
PRAD	cis	rs853679	0.585	rs201001	ENSG00000226314.6	ZNF192P1	-7.56	2.17e-13	9.15e-11	-0.48	-0.33	Depression;	chr6:27841121	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.585	rs201000	ENSG00000226314.6	ZNF192P1	-7.56	2.17e-13	9.15e-11	-0.48	-0.33	Depression;	chr6:27841381	chr6:28161781~28169594:+
PRAD	cis	rs7598759	0.584	rs4973409	ENSG00000181798.2	LINC00471	-7.56	2.18e-13	9.16e-11	-0.41	-0.33	Noise-induced hearing loss;	chr2:231447160	chr2:231508426~231514339:-
PRAD	cis	rs853679	1	rs1778508	ENSG00000226314.6	ZNF192P1	7.56	2.18e-13	9.16e-11	0.53	0.33	Depression;	chr6:28262103	chr6:28161781~28169594:+
PRAD	cis	rs11098499	0.754	rs28643450	ENSG00000245958.5	RP11-33B1.1	-7.56	2.18e-13	9.17e-11	-0.31	-0.33	Corneal astigmatism;	chr4:119324087	chr4:119454791~119552025:+
PRAD	cis	rs7567389	0.719	rs1011019	ENSG00000236682.1	AC068282.3	7.56	2.18e-13	9.19e-11	0.45	0.33	Self-rated health;	chr2:127279984	chr2:127389130~127400580:+
PRAD	cis	rs6480314	0.542	rs61854804	ENSG00000233590.1	RP11-153K11.3	-7.56	2.19e-13	9.22e-11	-0.54	-0.33	Optic nerve measurement (disc area);	chr10:68255819	chr10:68233251~68242379:-
PRAD	cis	rs763567	0.9	rs473133	ENSG00000271811.1	RP1-79C4.4	7.56	2.19e-13	9.23e-11	0.38	0.33	Tonsillectomy;	chr1:170666938	chr1:170667381~170669425:+
PRAD	cis	rs6479901	0.895	rs10740119	ENSG00000232075.1	MRPL35P2	-7.56	2.2e-13	9.26e-11	-0.4	-0.33	Intelligence (multi-trait analysis);	chr10:63365477	chr10:63634317~63634827:-
PRAD	cis	rs6479901	0.894	rs10822165	ENSG00000232075.1	MRPL35P2	-7.56	2.2e-13	9.26e-11	-0.4	-0.33	Intelligence (multi-trait analysis);	chr10:63387199	chr10:63634317~63634827:-
PRAD	cis	rs9532669	0.963	rs9532662	ENSG00000168852.11	TPTE2P5	7.56	2.2e-13	9.27e-11	0.32	0.33	Cervical cancer;	chr13:40926215	chr13:40822296~40921749:-
PRAD	cis	rs11951515	0.546	rs13187876	ENSG00000188850.9	RP11-159F24.2	7.56	2.2e-13	9.27e-11	0.41	0.33	Metabolite levels  (X-11787);	chr5:43367552	chr5:43336164~43348716:+
PRAD	cis	rs6904897	0.563	rs9321479	ENSG00000232876.1	CTA-212D2.2	7.56	2.22e-13	9.32e-11	0.41	0.33	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr6:134912771	chr6:135055033~135060550:+
PRAD	cis	rs67311347	0.544	rs9864601	ENSG00000223797.4	ENTPD3-AS1	7.56	2.22e-13	9.32e-11	0.29	0.33	Renal cell carcinoma;	chr3:40303827	chr3:40313802~40453329:-
PRAD	cis	rs858239	0.601	rs2141307	ENSG00000226816.2	AC005082.12	7.56	2.23e-13	9.36e-11	0.39	0.33	Cerebrospinal fluid biomarker levels;	chr7:23151805	chr7:23206013~23208045:+
PRAD	cis	rs12701220	0.52	rs7803208	ENSG00000229043.2	AC091729.9	-7.56	2.23e-13	9.37e-11	-0.44	-0.33	Bronchopulmonary dysplasia;	chr7:1122448	chr7:1160374~1165267:+
PRAD	cis	rs748404	0.697	rs574065	ENSG00000205771.5	CATSPER2P1	7.56	2.23e-13	9.37e-11	0.36	0.33	Lung cancer;	chr15:43258457	chr15:43726918~43747094:-
PRAD	cis	rs10129255	1	rs10129255	ENSG00000223648.3	IGHV3-64	-7.56	2.23e-13	9.38e-11	-0.33	-0.33	Kawasaki disease;	chr14:106767970	chr14:106643132~106658258:-
PRAD	cis	rs2243480	1	rs73150014	ENSG00000226824.5	RP4-756H11.3	-7.56	2.23e-13	9.38e-11	-0.65	-0.33	Diabetic kidney disease;	chr7:65985932	chr7:66654538~66669855:+
PRAD	cis	rs4664293	0.51	rs12469374	ENSG00000226266.5	AC009961.3	7.56	2.23e-13	9.38e-11	0.45	0.33	Monocyte percentage of white cells;	chr2:159720393	chr2:159670708~159712435:-
PRAD	cis	rs9532669	0.926	rs2324747	ENSG00000168852.11	TPTE2P5	7.56	2.24e-13	9.43e-11	0.32	0.33	Cervical cancer;	chr13:40988883	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.926	rs9525439	ENSG00000168852.11	TPTE2P5	7.56	2.24e-13	9.43e-11	0.32	0.33	Cervical cancer;	chr13:40992645	chr13:40822296~40921749:-
PRAD	cis	rs11098499	0.754	rs1511017	ENSG00000245958.5	RP11-33B1.1	-7.56	2.25e-13	9.44e-11	-0.31	-0.33	Corneal astigmatism;	chr4:119329650	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.789	rs12498994	ENSG00000245958.5	RP11-33B1.1	-7.56	2.25e-13	9.44e-11	-0.31	-0.33	Corneal astigmatism;	chr4:119329663	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.754	rs12507565	ENSG00000245958.5	RP11-33B1.1	-7.56	2.25e-13	9.44e-11	-0.31	-0.33	Corneal astigmatism;	chr4:119329966	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.826	rs12511640	ENSG00000245958.5	RP11-33B1.1	-7.56	2.25e-13	9.44e-11	-0.31	-0.33	Corneal astigmatism;	chr4:119330093	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.754	rs1980026	ENSG00000245958.5	RP11-33B1.1	-7.56	2.25e-13	9.44e-11	-0.31	-0.33	Corneal astigmatism;	chr4:119330488	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.722	rs28713555	ENSG00000245958.5	RP11-33B1.1	-7.56	2.25e-13	9.44e-11	-0.31	-0.33	Corneal astigmatism;	chr4:119330840	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.743	rs11098501	ENSG00000245958.5	RP11-33B1.1	-7.56	2.25e-13	9.44e-11	-0.31	-0.33	Corneal astigmatism;	chr4:119330862	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.754	rs11098502	ENSG00000245958.5	RP11-33B1.1	-7.56	2.25e-13	9.44e-11	-0.31	-0.33	Corneal astigmatism;	chr4:119330908	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.708	rs11732686	ENSG00000245958.5	RP11-33B1.1	-7.56	2.25e-13	9.44e-11	-0.31	-0.33	Corneal astigmatism;	chr4:119331175	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.754	rs11724409	ENSG00000245958.5	RP11-33B1.1	-7.56	2.25e-13	9.44e-11	-0.31	-0.33	Corneal astigmatism;	chr4:119331206	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.789	rs1980024	ENSG00000245958.5	RP11-33B1.1	-7.56	2.25e-13	9.44e-11	-0.31	-0.33	Corneal astigmatism;	chr4:119331892	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.754	rs34425882	ENSG00000245958.5	RP11-33B1.1	-7.56	2.25e-13	9.44e-11	-0.31	-0.33	Corneal astigmatism;	chr4:119332022	chr4:119454791~119552025:+
PRAD	cis	rs67311347	1	rs72861689	ENSG00000223797.4	ENTPD3-AS1	7.56	2.25e-13	9.44e-11	0.3	0.33	Renal cell carcinoma;	chr3:40394399	chr3:40313802~40453329:-
PRAD	cis	rs1134634	0.52	rs2041671	ENSG00000273133.1	RP11-799M12.2	-7.56	2.25e-13	9.46e-11	-0.44	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15550575	chr4:15563698~15564253:-
PRAD	cis	rs8031584	0.541	rs2959037	ENSG00000270015.1	RP11-540B6.6	7.56	2.25e-13	9.46e-11	0.29	0.33	Huntington's disease progression;	chr15:30925961	chr15:30926514~30928407:+
PRAD	cis	rs8031584	0.505	rs2959036	ENSG00000270015.1	RP11-540B6.6	7.56	2.25e-13	9.46e-11	0.29	0.33	Huntington's disease progression;	chr15:30927539	chr15:30926514~30928407:+
PRAD	cis	rs8031584	0.541	rs2955777	ENSG00000270015.1	RP11-540B6.6	7.56	2.25e-13	9.46e-11	0.29	0.33	Huntington's disease progression;	chr15:30927585	chr15:30926514~30928407:+
PRAD	cis	rs4713118	0.869	rs9366700	ENSG00000226314.6	ZNF192P1	-7.56	2.25e-13	9.46e-11	-0.44	-0.33	Parkinson's disease;	chr6:27729172	chr6:28161781~28169594:+
PRAD	cis	rs4713118	0.869	rs6456802	ENSG00000226314.6	ZNF192P1	-7.56	2.25e-13	9.46e-11	-0.44	-0.33	Parkinson's disease;	chr6:27730576	chr6:28161781~28169594:+
PRAD	cis	rs4713118	0.869	rs9393851	ENSG00000226314.6	ZNF192P1	-7.56	2.25e-13	9.46e-11	-0.44	-0.33	Parkinson's disease;	chr6:27731802	chr6:28161781~28169594:+
PRAD	cis	rs4713118	0.869	rs9461400	ENSG00000226314.6	ZNF192P1	-7.56	2.25e-13	9.46e-11	-0.44	-0.33	Parkinson's disease;	chr6:27732780	chr6:28161781~28169594:+
PRAD	cis	rs4713118	0.869	rs9295742	ENSG00000226314.6	ZNF192P1	-7.56	2.25e-13	9.46e-11	-0.44	-0.33	Parkinson's disease;	chr6:27735053	chr6:28161781~28169594:+
PRAD	cis	rs4713118	0.869	rs9461401	ENSG00000226314.6	ZNF192P1	-7.56	2.25e-13	9.46e-11	-0.44	-0.33	Parkinson's disease;	chr6:27735512	chr6:28161781~28169594:+
PRAD	cis	rs4713118	0.869	rs6914924	ENSG00000226314.6	ZNF192P1	-7.56	2.25e-13	9.46e-11	-0.44	-0.33	Parkinson's disease;	chr6:27743751	chr6:28161781~28169594:+
PRAD	cis	rs4713118	0.869	rs6930992	ENSG00000226314.6	ZNF192P1	-7.56	2.25e-13	9.46e-11	-0.44	-0.33	Parkinson's disease;	chr6:27744341	chr6:28161781~28169594:+
PRAD	cis	rs4713118	0.869	rs6901520	ENSG00000226314.6	ZNF192P1	-7.56	2.25e-13	9.46e-11	-0.44	-0.33	Parkinson's disease;	chr6:27746796	chr6:28161781~28169594:+
PRAD	cis	rs4713118	0.869	rs9295743	ENSG00000226314.6	ZNF192P1	-7.56	2.25e-13	9.46e-11	-0.44	-0.33	Parkinson's disease;	chr6:27747323	chr6:28161781~28169594:+
PRAD	cis	rs4713118	0.869	rs9283880	ENSG00000226314.6	ZNF192P1	-7.56	2.25e-13	9.46e-11	-0.44	-0.33	Parkinson's disease;	chr6:27747464	chr6:28161781~28169594:+
PRAD	cis	rs4713118	0.869	rs9283881	ENSG00000226314.6	ZNF192P1	-7.56	2.25e-13	9.46e-11	-0.44	-0.33	Parkinson's disease;	chr6:27747476	chr6:28161781~28169594:+
PRAD	cis	rs4713118	0.869	rs9283882	ENSG00000226314.6	ZNF192P1	-7.56	2.25e-13	9.46e-11	-0.44	-0.33	Parkinson's disease;	chr6:27747479	chr6:28161781~28169594:+
PRAD	cis	rs11159086	0.793	rs11625502	ENSG00000270000.1	RP3-449M8.9	7.56	2.25e-13	9.46e-11	0.5	0.33	Advanced glycation end-product levels;	chr14:74468309	chr14:74471930~74472360:-
PRAD	cis	rs875971	0.522	rs4502988	ENSG00000237310.1	GS1-124K5.4	7.56	2.25e-13	9.46e-11	0.28	0.33	Aortic root size;	chr7:65832759	chr7:66493706~66495474:+
PRAD	cis	rs11159086	0.793	rs10139122	ENSG00000270000.1	RP3-449M8.9	7.56	2.26e-13	9.5e-11	0.51	0.33	Advanced glycation end-product levels;	chr14:74492353	chr14:74471930~74472360:-
PRAD	cis	rs79349575	0.783	rs903567	ENSG00000248278.1	SUMO2P17	7.56	2.26e-13	9.5e-11	0.38	0.33	Type 2 diabetes;	chr17:48902956	chr17:48874860~48908983:-
PRAD	cis	rs79349575	0.783	rs62075818	ENSG00000248278.1	SUMO2P17	7.56	2.26e-13	9.5e-11	0.38	0.33	Type 2 diabetes;	chr17:48904965	chr17:48874860~48908983:-
PRAD	cis	rs79349575	0.783	rs9912829	ENSG00000248278.1	SUMO2P17	7.56	2.26e-13	9.5e-11	0.38	0.33	Type 2 diabetes;	chr17:48905387	chr17:48874860~48908983:-
PRAD	cis	rs79349575	0.783	rs62075820	ENSG00000248278.1	SUMO2P17	7.56	2.26e-13	9.5e-11	0.38	0.33	Type 2 diabetes;	chr17:48905809	chr17:48874860~48908983:-
PRAD	cis	rs79349575	0.783	rs4294857	ENSG00000248278.1	SUMO2P17	7.56	2.26e-13	9.5e-11	0.38	0.33	Type 2 diabetes;	chr17:48906029	chr17:48874860~48908983:-
PRAD	cis	rs79349575	0.783	rs61576918	ENSG00000248278.1	SUMO2P17	7.56	2.26e-13	9.5e-11	0.38	0.33	Type 2 diabetes;	chr17:48908231	chr17:48874860~48908983:-
PRAD	cis	rs79349575	0.729	rs62075824	ENSG00000248278.1	SUMO2P17	7.56	2.26e-13	9.5e-11	0.38	0.33	Type 2 diabetes;	chr17:48909317	chr17:48874860~48908983:-
PRAD	cis	rs79349575	0.749	rs46521	ENSG00000248278.1	SUMO2P17	7.56	2.26e-13	9.5e-11	0.38	0.33	Type 2 diabetes;	chr17:48911167	chr17:48874860~48908983:-
PRAD	cis	rs79349575	0.749	rs318093	ENSG00000248278.1	SUMO2P17	7.56	2.26e-13	9.5e-11	0.38	0.33	Type 2 diabetes;	chr17:48911992	chr17:48874860~48908983:-
PRAD	cis	rs79349575	0.745	rs170319	ENSG00000248278.1	SUMO2P17	7.56	2.26e-13	9.5e-11	0.38	0.33	Type 2 diabetes;	chr17:48914169	chr17:48874860~48908983:-
PRAD	cis	rs79349575	0.783	rs318090	ENSG00000248278.1	SUMO2P17	7.56	2.26e-13	9.5e-11	0.38	0.33	Type 2 diabetes;	chr17:48914390	chr17:48874860~48908983:-
PRAD	cis	rs79349575	0.721	rs3744608	ENSG00000248278.1	SUMO2P17	7.56	2.26e-13	9.5e-11	0.38	0.33	Type 2 diabetes;	chr17:48915871	chr17:48874860~48908983:-
PRAD	cis	rs79349575	0.651	rs4378658	ENSG00000248278.1	SUMO2P17	7.56	2.26e-13	9.5e-11	0.38	0.33	Type 2 diabetes;	chr17:48916008	chr17:48874860~48908983:-
PRAD	cis	rs79349575	0.783	rs12453374	ENSG00000248278.1	SUMO2P17	7.56	2.26e-13	9.5e-11	0.38	0.33	Type 2 diabetes;	chr17:48917484	chr17:48874860~48908983:-
PRAD	cis	rs79349575	0.783	rs12453394	ENSG00000248278.1	SUMO2P17	7.56	2.26e-13	9.5e-11	0.38	0.33	Type 2 diabetes;	chr17:48917608	chr17:48874860~48908983:-
PRAD	cis	rs79349575	0.811	rs12601072	ENSG00000248278.1	SUMO2P17	7.56	2.26e-13	9.5e-11	0.38	0.33	Type 2 diabetes;	chr17:48920636	chr17:48874860~48908983:-
PRAD	cis	rs79349575	0.749	rs58838744	ENSG00000248278.1	SUMO2P17	7.56	2.26e-13	9.5e-11	0.38	0.33	Type 2 diabetes;	chr17:48921540	chr17:48874860~48908983:-
PRAD	cis	rs79349575	0.811	rs60708039	ENSG00000248278.1	SUMO2P17	7.56	2.26e-13	9.5e-11	0.38	0.33	Type 2 diabetes;	chr17:48922011	chr17:48874860~48908983:-
PRAD	cis	rs79349575	0.783	rs55771415	ENSG00000248278.1	SUMO2P17	7.56	2.26e-13	9.5e-11	0.38	0.33	Type 2 diabetes;	chr17:48922575	chr17:48874860~48908983:-
PRAD	cis	rs79349575	0.783	rs2088139	ENSG00000248278.1	SUMO2P17	7.56	2.26e-13	9.5e-11	0.38	0.33	Type 2 diabetes;	chr17:48922748	chr17:48874860~48908983:-
PRAD	cis	rs79349575	0.783	rs4793991	ENSG00000248278.1	SUMO2P17	7.56	2.26e-13	9.5e-11	0.38	0.33	Type 2 diabetes;	chr17:48924439	chr17:48874860~48908983:-
PRAD	cis	rs79349575	0.715	rs62075844	ENSG00000248278.1	SUMO2P17	7.56	2.26e-13	9.5e-11	0.38	0.33	Type 2 diabetes;	chr17:48925027	chr17:48874860~48908983:-
PRAD	cis	rs79349575	0.749	rs957557	ENSG00000248278.1	SUMO2P17	7.56	2.26e-13	9.5e-11	0.38	0.33	Type 2 diabetes;	chr17:48925859	chr17:48874860~48908983:-
PRAD	cis	rs17711722	0.74	rs7809991	ENSG00000237310.1	GS1-124K5.4	7.56	2.26e-13	9.5e-11	0.28	0.33	Calcium levels;	chr7:65941231	chr7:66493706~66495474:+
PRAD	cis	rs435066	0.633	rs12057928	ENSG00000234264.1	DEPDC1-AS1	-7.56	2.27e-13	9.52e-11	-0.49	-0.33	IgG glycosylation;	chr1:68530371	chr1:68496676~68538627:+
PRAD	cis	rs10129255	0.957	rs10137980	ENSG00000223648.3	IGHV3-64	7.56	2.27e-13	9.52e-11	0.33	0.33	Kawasaki disease;	chr14:106775735	chr14:106643132~106658258:-
PRAD	cis	rs10129255	0.957	rs10141052	ENSG00000223648.3	IGHV3-64	7.56	2.27e-13	9.52e-11	0.33	0.33	Kawasaki disease;	chr14:106776528	chr14:106643132~106658258:-
PRAD	cis	rs10129255	0.957	rs10141009	ENSG00000223648.3	IGHV3-64	7.56	2.27e-13	9.52e-11	0.33	0.33	Kawasaki disease;	chr14:106776695	chr14:106643132~106658258:-
PRAD	cis	rs10129255	0.912	rs6576227	ENSG00000223648.3	IGHV3-64	7.56	2.27e-13	9.52e-11	0.33	0.33	Kawasaki disease;	chr14:106778202	chr14:106643132~106658258:-
PRAD	cis	rs10129255	0.957	rs6576228	ENSG00000223648.3	IGHV3-64	7.56	2.27e-13	9.52e-11	0.33	0.33	Kawasaki disease;	chr14:106778401	chr14:106643132~106658258:-
PRAD	cis	rs10129255	0.957	rs12590799	ENSG00000223648.3	IGHV3-64	7.56	2.27e-13	9.52e-11	0.33	0.33	Kawasaki disease;	chr14:106779713	chr14:106643132~106658258:-
PRAD	cis	rs10129255	0.957	rs10136781	ENSG00000223648.3	IGHV3-64	7.56	2.27e-13	9.52e-11	0.33	0.33	Kawasaki disease;	chr14:106780451	chr14:106643132~106658258:-
PRAD	cis	rs10129255	0.957	rs8022165	ENSG00000223648.3	IGHV3-64	7.56	2.27e-13	9.52e-11	0.33	0.33	Kawasaki disease;	chr14:106781682	chr14:106643132~106658258:-
PRAD	cis	rs10129255	0.917	rs8022493	ENSG00000223648.3	IGHV3-64	7.56	2.27e-13	9.52e-11	0.33	0.33	Kawasaki disease;	chr14:106781820	chr14:106643132~106658258:-
PRAD	cis	rs6479901	0.895	rs10822157	ENSG00000232075.1	MRPL35P2	-7.56	2.27e-13	9.52e-11	-0.4	-0.33	Intelligence (multi-trait analysis);	chr10:63329720	chr10:63634317~63634827:-
PRAD	cis	rs11098499	0.754	rs1546503	ENSG00000245958.5	RP11-33B1.1	-7.56	2.27e-13	9.54e-11	-0.31	-0.33	Corneal astigmatism;	chr4:119320012	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.708	rs1546506	ENSG00000245958.5	RP11-33B1.1	-7.56	2.27e-13	9.54e-11	-0.31	-0.33	Corneal astigmatism;	chr4:119320085	chr4:119454791~119552025:+
PRAD	cis	rs7829975	0.582	rs6982832	ENSG00000253893.2	FAM85B	7.56	2.29e-13	9.59e-11	0.41	0.33	Mood instability;	chr8:8934707	chr8:8167819~8226614:-
PRAD	cis	rs875971	0.522	rs2008188	ENSG00000237310.1	GS1-124K5.4	7.56	2.29e-13	9.61e-11	0.28	0.33	Aortic root size;	chr7:65964026	chr7:66493706~66495474:+
PRAD	cis	rs79349575	0.783	rs318095	ENSG00000248278.1	SUMO2P17	7.56	2.3e-13	9.63e-11	0.38	0.33	Type 2 diabetes;	chr17:48897372	chr17:48874860~48908983:-
PRAD	cis	rs79349575	0.783	rs318096	ENSG00000248278.1	SUMO2P17	7.56	2.3e-13	9.63e-11	0.38	0.33	Type 2 diabetes;	chr17:48898008	chr17:48874860~48908983:-
PRAD	cis	rs79349575	0.777	rs28517720	ENSG00000248278.1	SUMO2P17	7.56	2.3e-13	9.63e-11	0.38	0.33	Type 2 diabetes;	chr17:48899394	chr17:48874860~48908983:-
PRAD	cis	rs79349575	0.756	rs2643361	ENSG00000248278.1	SUMO2P17	7.56	2.3e-13	9.63e-11	0.38	0.33	Type 2 diabetes;	chr17:48900100	chr17:48874860~48908983:-
PRAD	cis	rs79349575	0.749	rs2546491	ENSG00000248278.1	SUMO2P17	7.56	2.3e-13	9.63e-11	0.38	0.33	Type 2 diabetes;	chr17:48900554	chr17:48874860~48908983:-
PRAD	cis	rs79349575	0.783	rs962272	ENSG00000248278.1	SUMO2P17	7.56	2.3e-13	9.63e-11	0.38	0.33	Type 2 diabetes;	chr17:48900921	chr17:48874860~48908983:-
PRAD	cis	rs6479901	0.947	rs7358191	ENSG00000232075.1	MRPL35P2	-7.56	2.3e-13	9.66e-11	-0.41	-0.33	Intelligence (multi-trait analysis);	chr10:63519028	chr10:63634317~63634827:-
PRAD	cis	rs6479901	0.947	rs7358152	ENSG00000232075.1	MRPL35P2	-7.56	2.3e-13	9.66e-11	-0.41	-0.33	Intelligence (multi-trait analysis);	chr10:63519138	chr10:63634317~63634827:-
PRAD	cis	rs853679	0.607	rs34788973	ENSG00000280107.1	AL022393.9	-7.56	2.31e-13	9.67e-11	-0.68	-0.33	Depression;	chr6:27911422	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.607	rs61742093	ENSG00000280107.1	AL022393.9	-7.56	2.31e-13	9.67e-11	-0.68	-0.33	Depression;	chr6:27912204	chr6:28170845~28172521:+
PRAD	cis	rs748404	0.697	rs471122	ENSG00000205771.5	CATSPER2P1	7.56	2.31e-13	9.68e-11	0.36	0.33	Lung cancer;	chr15:43266376	chr15:43726918~43747094:-
PRAD	cis	rs6565180	0.962	rs35480350	ENSG00000183604.13	SMG1P5	-7.56	2.31e-13	9.69e-11	-0.33	-0.33	Tonsillectomy;	chr16:30354718	chr16:30267553~30335374:-
PRAD	cis	rs10463554	0.853	rs2432177	ENSG00000175749.11	EIF3KP1	7.56	2.32e-13	9.71e-11	0.44	0.33	Parkinson's disease;	chr5:103236172	chr5:103032376~103033031:+
PRAD	cis	rs2243480	1	rs1638734	ENSG00000226824.5	RP4-756H11.3	-7.56	2.32e-13	9.71e-11	-0.68	-0.33	Diabetic kidney disease;	chr7:66632552	chr7:66654538~66669855:+
PRAD	cis	rs11976180	1	rs7777389	ENSG00000273234.1	OR2A13P	-7.56	2.32e-13	9.71e-11	-0.4	-0.33	Obesity-related traits;	chr7:144047709	chr7:144142009~144142938:+
PRAD	cis	rs11976180	1	rs67239267	ENSG00000273234.1	OR2A13P	-7.56	2.32e-13	9.71e-11	-0.4	-0.33	Obesity-related traits;	chr7:144048023	chr7:144142009~144142938:+
PRAD	cis	rs1061377	1	rs7675782	ENSG00000249685.1	RP11-360F5.3	7.56	2.32e-13	9.72e-11	0.37	0.33	Uric acid levels;	chr4:39120048	chr4:39133913~39135608:+
PRAD	cis	rs853679	0.506	rs1150693	ENSG00000204709.4	LINC01556	7.56	2.32e-13	9.72e-11	0.46	0.33	Depression;	chr6:28206812	chr6:28943877~28944537:+
PRAD	cis	rs4664293	0.867	rs1427329	ENSG00000226266.5	AC009961.3	-7.55	2.32e-13	9.74e-11	-0.44	-0.33	Monocyte percentage of white cells;	chr2:159748301	chr2:159670708~159712435:-
PRAD	cis	rs7829975	0.582	rs6983150	ENSG00000253893.2	FAM85B	7.55	2.33e-13	9.75e-11	0.41	0.33	Mood instability;	chr8:8934916	chr8:8167819~8226614:-
PRAD	cis	rs13631	0.894	rs7856589	ENSG00000268996.3	MAN1B1-AS1	-7.55	2.33e-13	9.76e-11	-0.34	-0.33	Cerebrospinal fluid biomarker levels;	chr9:137109469	chr9:137084946~137086817:-
PRAD	cis	rs11098499	0.754	rs17595608	ENSG00000245958.5	RP11-33B1.1	-7.55	2.33e-13	9.78e-11	-0.31	-0.33	Corneal astigmatism;	chr4:119329351	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.754	rs1980027	ENSG00000245958.5	RP11-33B1.1	-7.55	2.33e-13	9.78e-11	-0.31	-0.33	Corneal astigmatism;	chr4:119330422	chr4:119454791~119552025:+
PRAD	cis	rs11098499	1	rs28374891	ENSG00000245958.5	RP11-33B1.1	-7.55	2.34e-13	9.8e-11	-0.32	-0.33	Corneal astigmatism;	chr4:119262395	chr4:119454791~119552025:+
PRAD	cis	rs75422866	0.558	rs73104190	ENSG00000257433.4	RP1-197B17.3	7.55	2.34e-13	9.81e-11	0.7	0.33	Pneumonia;	chr12:47716040	chr12:47706085~47742294:+
PRAD	cis	rs4664293	0.967	rs13000070	ENSG00000226266.5	AC009961.3	-7.55	2.34e-13	9.81e-11	-0.44	-0.33	Monocyte percentage of white cells;	chr2:159669263	chr2:159670708~159712435:-
PRAD	cis	rs853679	0.546	rs200995	ENSG00000280107.1	AL022393.9	7.55	2.35e-13	9.84e-11	0.58	0.33	Depression;	chr6:27845916	chr6:28170845~28172521:+
PRAD	cis	rs10050311	0.79	rs17012132	ENSG00000251411.1	RP11-397E7.4	-7.55	2.35e-13	9.85e-11	-0.47	-0.33	Insulin-related traits;	chr4:86860135	chr4:86913266~86914817:-
PRAD	cis	rs79349575	0.749	rs12601672	ENSG00000248278.1	SUMO2P17	7.55	2.35e-13	9.86e-11	0.38	0.33	Type 2 diabetes;	chr17:48929131	chr17:48874860~48908983:-
PRAD	cis	rs79349575	0.783	rs17635252	ENSG00000248278.1	SUMO2P17	7.55	2.35e-13	9.86e-11	0.38	0.33	Type 2 diabetes;	chr17:48929588	chr17:48874860~48908983:-
PRAD	cis	rs875971	0.522	rs10807697	ENSG00000237310.1	GS1-124K5.4	7.55	2.36e-13	9.91e-11	0.28	0.33	Aortic root size;	chr7:65951183	chr7:66493706~66495474:+
PRAD	cis	rs172166	0.637	rs1225592	ENSG00000204709.4	LINC01556	7.55	2.37e-13	9.91e-11	0.43	0.33	Cardiac Troponin-T levels;	chr6:28182464	chr6:28943877~28944537:+
PRAD	cis	rs9326248	0.581	rs10790167	ENSG00000280143.1	AP000892.6	7.55	2.37e-13	9.92e-11	0.25	0.33	Blood protein levels;	chr11:116930227	chr11:117204967~117210292:+
PRAD	cis	rs17772222	0.637	rs7161660	ENSG00000258983.2	RP11-507K2.2	7.55	2.37e-13	9.94e-11	0.43	0.33	Coronary artery calcification;	chr14:88471832	chr14:88499334~88515502:+
PRAD	cis	rs17772222	0.682	rs2297129	ENSG00000258983.2	RP11-507K2.2	7.55	2.37e-13	9.94e-11	0.43	0.33	Coronary artery calcification;	chr14:88469581	chr14:88499334~88515502:+
PRAD	cis	rs17772222	0.682	rs61542857	ENSG00000258983.2	RP11-507K2.2	7.55	2.37e-13	9.94e-11	0.43	0.33	Coronary artery calcification;	chr14:88470358	chr14:88499334~88515502:+
PRAD	cis	rs17772222	0.682	rs7141363	ENSG00000258983.2	RP11-507K2.2	7.55	2.37e-13	9.94e-11	0.43	0.33	Coronary artery calcification;	chr14:88471879	chr14:88499334~88515502:+
PRAD	cis	rs2274273	0.624	rs10146637	ENSG00000258413.1	RP11-665C16.6	-7.55	2.38e-13	9.95e-11	-0.45	-0.33	Protein biomarker;	chr14:55278092	chr14:55262767~55272075:-
PRAD	cis	rs1499614	1	rs1267818	ENSG00000226824.5	RP4-756H11.3	-7.55	2.38e-13	9.95e-11	-0.68	-0.33	Gout;	chr7:66642037	chr7:66654538~66669855:+
PRAD	cis	rs1499614	1	rs1267817	ENSG00000226824.5	RP4-756H11.3	-7.55	2.38e-13	9.95e-11	-0.68	-0.33	Gout;	chr7:66645053	chr7:66654538~66669855:+
PRAD	cis	rs2933343	0.621	rs789241	ENSG00000261159.1	RP11-723O4.9	7.55	2.38e-13	9.96e-11	0.29	0.33	IgG glycosylation;	chr3:128866909	chr3:128859716~128860526:-
PRAD	cis	rs2933343	0.649	rs2638845	ENSG00000261159.1	RP11-723O4.9	7.55	2.38e-13	9.96e-11	0.29	0.33	IgG glycosylation;	chr3:128868526	chr3:128859716~128860526:-
PRAD	cis	rs10129255	0.957	rs11846893	ENSG00000223648.3	IGHV3-64	7.55	2.39e-13	1e-10	0.33	0.33	Kawasaki disease;	chr14:106779068	chr14:106643132~106658258:-
PRAD	cis	rs12612619	0.696	rs11678188	ENSG00000272148.1	RP11-195B17.1	7.55	2.39e-13	1e-10	0.4	0.33	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27024964	chr2:27062428~27062907:-
PRAD	cis	rs6452524	0.868	rs62372714	ENSG00000249664.1	CTD-2227C6.2	7.55	2.39e-13	1e-10	0.4	0.33	Hypertension (SNP x SNP interaction);	chr5:83095449	chr5:83012285~83013109:-
PRAD	cis	rs67311347	0.544	rs9833640	ENSG00000223797.4	ENTPD3-AS1	7.55	2.39e-13	1e-10	0.29	0.33	Renal cell carcinoma;	chr3:40313450	chr3:40313802~40453329:-
PRAD	cis	rs67311347	0.544	rs6762121	ENSG00000223797.4	ENTPD3-AS1	7.55	2.39e-13	1e-10	0.29	0.33	Renal cell carcinoma;	chr3:40313822	chr3:40313802~40453329:-
PRAD	cis	rs67311347	0.544	rs6787516	ENSG00000223797.4	ENTPD3-AS1	7.55	2.39e-13	1e-10	0.29	0.33	Renal cell carcinoma;	chr3:40314125	chr3:40313802~40453329:-
PRAD	cis	rs67311347	0.524	rs7649168	ENSG00000223797.4	ENTPD3-AS1	7.55	2.39e-13	1e-10	0.29	0.33	Renal cell carcinoma;	chr3:40314667	chr3:40313802~40453329:-
PRAD	cis	rs11098499	0.691	rs9996644	ENSG00000245958.5	RP11-33B1.1	-7.55	2.4e-13	1e-10	-0.31	-0.33	Corneal astigmatism;	chr4:119317722	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.691	rs9996494	ENSG00000245958.5	RP11-33B1.1	-7.55	2.4e-13	1e-10	-0.31	-0.33	Corneal astigmatism;	chr4:119317725	chr4:119454791~119552025:+
PRAD	cis	rs736801	0.74	rs12515180	ENSG00000233006.5	AC034220.3	7.55	2.4e-13	1e-10	0.31	0.33	Mosquito bite size;Breast cancer;	chr5:132449992	chr5:132311285~132369916:-
PRAD	cis	rs736801	0.78	rs11951091	ENSG00000233006.5	AC034220.3	7.55	2.4e-13	1e-10	0.31	0.33	Mosquito bite size;Breast cancer;	chr5:132450903	chr5:132311285~132369916:-
PRAD	cis	rs1426063	0.858	rs6823982	ENSG00000249717.1	RP11-44F21.3	7.55	2.4e-13	1e-10	0.55	0.33	QT interval;	chr4:75084961	chr4:74955974~74970362:-
PRAD	cis	rs10463554	0.892	rs32842	ENSG00000175749.11	EIF3KP1	7.55	2.4e-13	1.01e-10	0.44	0.33	Parkinson's disease;	chr5:103142298	chr5:103032376~103033031:+
PRAD	cis	rs6674176	0.597	rs12127737	ENSG00000237950.1	RP11-7O11.3	7.55	2.41e-13	1.01e-10	0.38	0.33	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43936893	chr1:43944370~43946551:-
PRAD	cis	rs17711722	0.727	rs1880555	ENSG00000237310.1	GS1-124K5.4	7.55	2.41e-13	1.01e-10	0.28	0.33	Calcium levels;	chr7:65967580	chr7:66493706~66495474:+
PRAD	cis	rs6480314	0.542	rs7079054	ENSG00000233590.1	RP11-153K11.3	-7.55	2.41e-13	1.01e-10	-0.55	-0.33	Optic nerve measurement (disc area);	chr10:68266404	chr10:68233251~68242379:-
PRAD	cis	rs6480314	0.542	rs12570281	ENSG00000233590.1	RP11-153K11.3	-7.55	2.41e-13	1.01e-10	-0.55	-0.33	Optic nerve measurement (disc area);	chr10:68267237	chr10:68233251~68242379:-
PRAD	cis	rs6480314	0.542	rs61854813	ENSG00000233590.1	RP11-153K11.3	-7.55	2.41e-13	1.01e-10	-0.55	-0.33	Optic nerve measurement (disc area);	chr10:68267464	chr10:68233251~68242379:-
PRAD	cis	rs12571093	0.803	rs61854814	ENSG00000233590.1	RP11-153K11.3	-7.55	2.41e-13	1.01e-10	-0.55	-0.33	Optic nerve measurement (disc area);	chr10:68267639	chr10:68233251~68242379:-
PRAD	cis	rs881375	0.967	rs758959	ENSG00000226752.6	PSMD5-AS1	-7.55	2.41e-13	1.01e-10	-0.4	-0.33	Rheumatoid arthritis;	chr9:120914421	chr9:120824828~120854385:+
PRAD	cis	rs6600671	0.764	rs6600673	ENSG00000223345.3	HIST2H2BA	7.55	2.41e-13	1.01e-10	0.4	0.33	Hip geometry;	chr1:121426988	chr1:121108210~121117257:-
PRAD	cis	rs2676071	0.858	rs2670946	ENSG00000259446.4	RP11-489D6.2	-7.55	2.41e-13	1.01e-10	-0.44	-0.33	Periodontitis (Mean PAL);	chr15:33306691	chr15:33303657~33310659:-
PRAD	cis	rs9640161	0.617	rs73170169	ENSG00000261305.1	RP4-584D14.7	7.55	2.42e-13	1.01e-10	0.38	0.33	Blood protein levels;Circulating chemerin levels;	chr7:150310947	chr7:150341771~150342607:+
PRAD	cis	rs8031584	0.56	rs7171208	ENSG00000270015.1	RP11-540B6.6	7.55	2.42e-13	1.01e-10	0.29	0.33	Huntington's disease progression;	chr15:30906726	chr15:30926514~30928407:+
PRAD	cis	rs17428076	0.793	rs3770449	ENSG00000228389.1	AC068039.4	-7.55	2.42e-13	1.01e-10	-0.43	-0.33	Myopia;	chr2:171835538	chr2:171773482~171775844:+
PRAD	cis	rs9601248	0.838	rs6563121	ENSG00000227676.3	LINC01068	-7.55	2.42e-13	1.01e-10	-0.4	-0.33	Major depressive disorder;	chr13:79600865	chr13:79566727~79571436:+
PRAD	cis	rs440932	0.717	rs330944	ENSG00000254340.1	RP11-10A14.3	7.55	2.43e-13	1.02e-10	0.4	0.33	High light scatter reticulocyte percentage of red cells;	chr8:9163783	chr8:9141424~9145435:+
PRAD	cis	rs1555322	0.53	rs2425043	ENSG00000279253.1	RP4-614O4.13	-7.55	2.44e-13	1.02e-10	-0.39	-0.33	Attention deficit hyperactivity disorder;	chr20:35280899	chr20:35262727~35264187:-
PRAD	cis	rs2439831	0.702	rs8033995	ENSG00000205771.5	CATSPER2P1	-7.55	2.44e-13	1.02e-10	-0.52	-0.33	Lung cancer in ever smokers;	chr15:43721311	chr15:43726918~43747094:-
PRAD	cis	rs12701220	0.522	rs1881116	ENSG00000229043.2	AC091729.9	-7.55	2.45e-13	1.02e-10	-0.42	-0.33	Bronchopulmonary dysplasia;	chr7:1014322	chr7:1160374~1165267:+
PRAD	cis	rs8062405	0.69	rs62034351	ENSG00000251417.2	RP11-1348G14.4	-7.55	2.45e-13	1.02e-10	-0.38	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554168	chr16:28802743~28817828:+
PRAD	cis	rs6001482	0.702	rs5757581	ENSG00000272779.1	LL22NC03-80A10.6	7.55	2.45e-13	1.02e-10	0.4	0.33	Diastolic blood pressure;	chr22:22234220	chr22:22303224~22310401:+
PRAD	cis	rs7615952	0.599	rs66532274	ENSG00000171084.14	FAM86JP	7.55	2.46e-13	1.03e-10	0.5	0.33	Blood pressure (smoking interaction);	chr3:126013002	chr3:125916620~125930024:+
PRAD	cis	rs2286503	0.839	rs4722188	ENSG00000228649.7	AC005682.5	7.55	2.46e-13	1.03e-10	0.37	0.33	Fibrinogen;	chr7:22820592	chr7:22854178~22861579:+
PRAD	cis	rs11098499	0.955	rs56386062	ENSG00000245958.5	RP11-33B1.1	-7.55	2.46e-13	1.03e-10	-0.32	-0.33	Corneal astigmatism;	chr4:119233980	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.955	rs4145951	ENSG00000245958.5	RP11-33B1.1	-7.55	2.46e-13	1.03e-10	-0.32	-0.33	Corneal astigmatism;	chr4:119234662	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.955	rs35916640	ENSG00000245958.5	RP11-33B1.1	-7.55	2.46e-13	1.03e-10	-0.32	-0.33	Corneal astigmatism;	chr4:119234697	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.955	rs13114751	ENSG00000245958.5	RP11-33B1.1	-7.55	2.46e-13	1.03e-10	-0.32	-0.33	Corneal astigmatism;	chr4:119235462	chr4:119454791~119552025:+
PRAD	cis	rs9467773	0.933	rs35355150	ENSG00000124549.13	BTN2A3P	7.55	2.46e-13	1.03e-10	0.3	0.33	Intelligence (multi-trait analysis);	chr6:26525811	chr6:26421391~26432383:+
PRAD	cis	rs2638953	0.962	rs10843158	ENSG00000278733.1	RP11-425D17.1	7.55	2.47e-13	1.03e-10	0.42	0.33	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28354259	chr12:28185625~28186190:-
PRAD	cis	rs8062405	0.722	rs28729187	ENSG00000251417.2	RP11-1348G14.4	7.55	2.47e-13	1.03e-10	0.37	0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28615645	chr16:28802743~28817828:+
PRAD	cis	rs1023500	0.573	rs8135801	ENSG00000205702.9	CYP2D7	-7.55	2.47e-13	1.03e-10	-0.26	-0.33	Schizophrenia;	chr22:42079564	chr22:42140203~42144577:-
PRAD	cis	rs1023500	0.573	rs1807494	ENSG00000205702.9	CYP2D7	-7.55	2.47e-13	1.03e-10	-0.26	-0.33	Schizophrenia;	chr22:42078134	chr22:42140203~42144577:-
PRAD	cis	rs9640161	0.659	rs59572505	ENSG00000261305.1	RP4-584D14.7	7.55	2.48e-13	1.04e-10	0.37	0.33	Blood protein levels;Circulating chemerin levels;	chr7:150317897	chr7:150341771~150342607:+
PRAD	cis	rs673078	0.66	rs61945219	ENSG00000275409.1	RP11-131L12.4	-7.55	2.48e-13	1.04e-10	-0.45	-0.33	Glucose homeostasis traits;	chr12:118272916	chr12:118430147~118430699:+
PRAD	cis	rs12612619	0.732	rs13021112	ENSG00000229122.1	AGBL5-IT1	7.55	2.48e-13	1.04e-10	0.35	0.33	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27036926	chr2:27061038~27061815:+
PRAD	cis	rs11159086	0.793	rs1029703	ENSG00000270000.1	RP3-449M8.9	7.54	2.48e-13	1.04e-10	0.5	0.33	Advanced glycation end-product levels;	chr14:74473899	chr14:74471930~74472360:-
PRAD	cis	rs11159086	0.793	rs1029702	ENSG00000270000.1	RP3-449M8.9	7.54	2.48e-13	1.04e-10	0.5	0.33	Advanced glycation end-product levels;	chr14:74473909	chr14:74471930~74472360:-
PRAD	cis	rs1023500	0.573	rs133382	ENSG00000205702.9	CYP2D7	7.54	2.49e-13	1.04e-10	0.26	0.33	Schizophrenia;	chr22:42075770	chr22:42140203~42144577:-
PRAD	cis	rs10129255	0.5	rs11627315	ENSG00000211972.2	IGHV3-66	7.54	2.49e-13	1.04e-10	0.29	0.33	Kawasaki disease;	chr14:106802182	chr14:106675017~106675544:-
PRAD	cis	rs10463554	0.963	rs11242483	ENSG00000175749.11	EIF3KP1	7.54	2.49e-13	1.04e-10	0.42	0.33	Parkinson's disease;	chr5:102988062	chr5:103032376~103033031:+
PRAD	cis	rs4631830	0.6	rs11004324	ENSG00000230869.1	CTGLF10P	-7.54	2.5e-13	1.04e-10	-0.47	-0.33	Prostate-specific antigen levels;	chr10:46099199	chr10:45678692~45700532:+
PRAD	cis	rs42648	0.869	rs2027965	ENSG00000227646.6	STEAP2-AS1	-7.54	2.5e-13	1.04e-10	-0.3	-0.33	Homocysteine levels;	chr7:90283199	chr7:89882353~90211635:-
PRAD	cis	rs67311347	0.577	rs2371129	ENSG00000223797.4	ENTPD3-AS1	-7.54	2.5e-13	1.04e-10	-0.31	-0.33	Renal cell carcinoma;	chr3:40206902	chr3:40313802~40453329:-
PRAD	cis	rs2337406	0.925	rs10131226	ENSG00000274576.2	IGHV2-70	-7.54	2.5e-13	1.04e-10	-0.37	-0.33	Alzheimer's disease (late onset);	chr14:106665764	chr14:106770577~106771020:-
PRAD	cis	rs964611	0.938	rs8032357	ENSG00000259488.2	RP11-154J22.1	-7.54	2.51e-13	1.05e-10	-0.35	-0.33	Metabolite levels (Pyroglutamine);	chr15:48326622	chr15:48312353~48331856:-
PRAD	cis	rs67311347	0.544	rs9814779	ENSG00000223797.4	ENTPD3-AS1	7.54	2.51e-13	1.05e-10	0.29	0.33	Renal cell carcinoma;	chr3:40298940	chr3:40313802~40453329:-
PRAD	cis	rs11846409	0.86	rs61686131	ENSG00000274576.2	IGHV2-70	-7.54	2.52e-13	1.05e-10	-0.35	-0.33	Rheumatic heart disease;	chr14:106631568	chr14:106770577~106771020:-
PRAD	cis	rs1979679	0.877	rs6487684	ENSG00000278733.1	RP11-425D17.1	-7.54	2.52e-13	1.05e-10	-0.45	-0.33	Ossification of the posterior longitudinal ligament of the spine;	chr12:28490280	chr12:28185625~28186190:-
PRAD	cis	rs12468226	0.873	rs59293950	ENSG00000273456.1	RP11-686O6.2	7.54	2.52e-13	1.05e-10	0.46	0.33	Urate levels;	chr2:202214069	chr2:202374932~202375604:-
PRAD	cis	rs12468226	0.873	rs12472035	ENSG00000273456.1	RP11-686O6.2	7.54	2.52e-13	1.05e-10	0.46	0.33	Urate levels;	chr2:202221970	chr2:202374932~202375604:-
PRAD	cis	rs2108622	0.545	rs59140933	ENSG00000267056.2	AC005336.4	7.54	2.53e-13	1.05e-10	0.45	0.33	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15864498	chr19:15910582~15911824:-
PRAD	cis	rs73081554	0.611	rs4681851	ENSG00000272360.1	RP11-359I18.5	-7.54	2.53e-13	1.05e-10	-0.54	-0.33	Rheumatoid arthritis;	chr3:58410164	chr3:58490830~58491291:-
PRAD	cis	rs2439831	0.85	rs12440573	ENSG00000249839.1	AC011330.5	-7.54	2.53e-13	1.06e-10	-0.58	-0.33	Lung cancer in ever smokers;	chr15:43816799	chr15:43663654~43684339:-
PRAD	cis	rs2404602	0.632	rs34338978	ENSG00000259422.1	RP11-593F23.1	7.54	2.53e-13	1.06e-10	0.42	0.33	Blood metabolite levels;	chr15:76934464	chr15:76174891~76181486:-
PRAD	cis	rs17012589	0.522	rs10862970	ENSG00000258815.1	RP11-408B11.2	-7.54	2.53e-13	1.06e-10	-0.45	-0.33	Bone mineral density (Ward's triangle area);	chr12:85335961	chr12:85318060~85342912:+
PRAD	cis	rs6452524	0.836	rs1015440	ENSG00000249664.1	CTD-2227C6.2	7.54	2.54e-13	1.06e-10	0.41	0.33	Hypertension (SNP x SNP interaction);	chr5:83202986	chr5:83012285~83013109:-
PRAD	cis	rs10463554	0.927	rs55641526	ENSG00000175749.11	EIF3KP1	7.54	2.54e-13	1.06e-10	0.44	0.33	Parkinson's disease;	chr5:102915301	chr5:103032376~103033031:+
PRAD	cis	rs673078	0.607	rs4767671	ENSG00000275409.1	RP11-131L12.4	-7.54	2.54e-13	1.06e-10	-0.49	-0.33	Glucose homeostasis traits;	chr12:118396038	chr12:118430147~118430699:+
PRAD	cis	rs1061377	1	rs1061377	ENSG00000249685.1	RP11-360F5.3	7.54	2.54e-13	1.06e-10	0.37	0.33	Uric acid levels;	chr4:39123130	chr4:39133913~39135608:+
PRAD	cis	rs1061377	1	rs13109200	ENSG00000249685.1	RP11-360F5.3	7.54	2.54e-13	1.06e-10	0.37	0.33	Uric acid levels;	chr4:39124396	chr4:39133913~39135608:+
PRAD	cis	rs1061377	1	rs13144374	ENSG00000249685.1	RP11-360F5.3	7.54	2.54e-13	1.06e-10	0.37	0.33	Uric acid levels;	chr4:39128859	chr4:39133913~39135608:+
PRAD	cis	rs11673344	0.528	rs573294	ENSG00000226686.6	LINC01535	7.54	2.55e-13	1.06e-10	0.43	0.33	Obesity-related traits;	chr19:36919260	chr19:37251912~37265535:+
PRAD	cis	rs11673344	0.528	rs579452	ENSG00000226686.6	LINC01535	7.54	2.55e-13	1.06e-10	0.43	0.33	Obesity-related traits;	chr19:36919936	chr19:37251912~37265535:+
PRAD	cis	rs11673344	0.528	rs491326	ENSG00000226686.6	LINC01535	7.54	2.55e-13	1.06e-10	0.43	0.33	Obesity-related traits;	chr19:36920037	chr19:37251912~37265535:+
PRAD	cis	rs11673344	0.528	rs563786	ENSG00000226686.6	LINC01535	7.54	2.55e-13	1.06e-10	0.43	0.33	Obesity-related traits;	chr19:36922012	chr19:37251912~37265535:+
PRAD	cis	rs853679	0.567	rs16894091	ENSG00000204709.4	LINC01556	-7.54	2.55e-13	1.06e-10	-0.46	-0.33	Depression;	chr6:28422360	chr6:28943877~28944537:+
PRAD	cis	rs2933343	0.729	rs813945	ENSG00000231305.3	RP11-723O4.2	7.54	2.55e-13	1.07e-10	0.31	0.33	IgG glycosylation;	chr3:128942094	chr3:128861313~128871540:-
PRAD	cis	rs1150668	0.796	rs213237	ENSG00000280107.1	AL022393.9	-7.54	2.56e-13	1.07e-10	-0.39	-0.33	Pubertal anthropometrics;	chr6:28356161	chr6:28170845~28172521:+
PRAD	cis	rs12612619	0.761	rs7606840	ENSG00000229122.1	AGBL5-IT1	7.54	2.57e-13	1.07e-10	0.35	0.33	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27020496	chr2:27061038~27061815:+
PRAD	cis	rs8072100	0.837	rs8070463	ENSG00000228782.6	CTD-2026D20.3	7.54	2.57e-13	1.07e-10	0.36	0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47691470	chr17:47450568~47492492:-
PRAD	cis	rs2236295	0.814	rs1848797	ENSG00000238280.1	RP11-436D10.3	-7.54	2.57e-13	1.07e-10	-0.42	-0.33	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr10:62793174	chr10:62793562~62805887:-
PRAD	cis	rs12432203	1	rs72622442	ENSG00000258479.4	LINC00640	7.54	2.57e-13	1.07e-10	0.62	0.33	Cancer;	chr14:51278150	chr14:51333393~51365557:+
PRAD	cis	rs240993	0.715	rs9400483	ENSG00000230177.1	RP5-1112D6.4	7.54	2.57e-13	1.07e-10	0.42	0.33	Inflammatory skin disease;Psoriasis;	chr6:111535073	chr6:111277932~111278742:+
PRAD	cis	rs10935480	0.904	rs13065271	ENSG00000239445.4	ST3GAL6-AS1	-7.54	2.58e-13	1.07e-10	-0.41	-0.33	Blood protein levels;	chr3:98715649	chr3:98714330~98732651:-
PRAD	cis	rs1930961	1	rs6004673	ENSG00000271138.1	IGLVIVOR22-1	-7.54	2.58e-13	1.07e-10	-0.51	-0.33	Bipolar disorder with mood-incongruent psychosis;	chr22:25489386	chr22:25437306~25437823:-
PRAD	cis	rs1185460	0.547	rs666741	ENSG00000271751.1	RP11-110I1.14	7.54	2.58e-13	1.08e-10	0.45	0.33	Coronary artery disease;	chr11:119040640	chr11:119065263~119065677:-
PRAD	cis	rs12612619	0.732	rs4665366	ENSG00000229122.1	AGBL5-IT1	-7.54	2.58e-13	1.08e-10	-0.34	-0.33	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26989728	chr2:27061038~27061815:+
PRAD	cis	rs2255336	0.81	rs10743886	ENSG00000245648.1	RP11-277P12.20	7.54	2.58e-13	1.08e-10	0.54	0.33	Blood protein levels;	chr12:10359063	chr12:10363769~10398506:+
PRAD	cis	rs3096299	0.809	rs2911264	ENSG00000261118.1	RP11-104N10.1	7.54	2.59e-13	1.08e-10	0.33	0.33	Multiple myeloma (IgH translocation);	chr16:89432864	chr16:89492017~89504460:-
PRAD	cis	rs11098499	0.913	rs35271032	ENSG00000245958.5	RP11-33B1.1	-7.54	2.59e-13	1.08e-10	-0.32	-0.33	Corneal astigmatism;	chr4:119235504	chr4:119454791~119552025:+
PRAD	cis	rs2404602	0.536	rs12915248	ENSG00000259422.1	RP11-593F23.1	7.54	2.6e-13	1.08e-10	0.41	0.33	Blood metabolite levels;	chr15:76473274	chr15:76174891~76181486:-
PRAD	cis	rs9640161	0.659	rs17837498	ENSG00000261305.1	RP4-584D14.7	7.54	2.6e-13	1.08e-10	0.36	0.33	Blood protein levels;Circulating chemerin levels;	chr7:150312590	chr7:150341771~150342607:+
PRAD	cis	rs67311347	0.544	rs13098483	ENSG00000223797.4	ENTPD3-AS1	7.54	2.6e-13	1.08e-10	0.29	0.33	Renal cell carcinoma;	chr3:40301252	chr3:40313802~40453329:-
PRAD	cis	rs79349575	0.783	rs4255820	ENSG00000248278.1	SUMO2P17	7.54	2.6e-13	1.08e-10	0.38	0.33	Type 2 diabetes;	chr17:48919221	chr17:48874860~48908983:-
PRAD	cis	rs881375	0.715	rs11794516	ENSG00000226752.6	PSMD5-AS1	-7.54	2.61e-13	1.09e-10	-0.39	-0.33	Rheumatoid arthritis;	chr9:120877952	chr9:120824828~120854385:+
PRAD	cis	rs17486696	0.51	rs17678924	ENSG00000248771.4	LINC01207	-7.54	2.61e-13	1.09e-10	-0.71	-0.33	Positive affect;	chr4:164770667	chr4:164754064~164803795:+
PRAD	cis	rs6479901	0.895	rs10740113	ENSG00000232075.1	MRPL35P2	-7.54	2.61e-13	1.09e-10	-0.41	-0.33	Intelligence (multi-trait analysis);	chr10:63322516	chr10:63634317~63634827:-
PRAD	cis	rs6479901	0.895	rs10740114	ENSG00000232075.1	MRPL35P2	-7.54	2.61e-13	1.09e-10	-0.41	-0.33	Intelligence (multi-trait analysis);	chr10:63322659	chr10:63634317~63634827:-
PRAD	cis	rs881375	0.933	rs1548784	ENSG00000226752.6	PSMD5-AS1	-7.54	2.62e-13	1.09e-10	-0.39	-0.33	Rheumatoid arthritis;	chr9:120923002	chr9:120824828~120854385:+
PRAD	cis	rs881375	0.967	rs7034492	ENSG00000226752.6	PSMD5-AS1	-7.54	2.62e-13	1.09e-10	-0.39	-0.33	Rheumatoid arthritis;	chr9:120924933	chr9:120824828~120854385:+
PRAD	cis	rs881375	0.967	rs7034653	ENSG00000226752.6	PSMD5-AS1	-7.54	2.62e-13	1.09e-10	-0.39	-0.33	Rheumatoid arthritis;	chr9:120925094	chr9:120824828~120854385:+
PRAD	cis	rs6565180	1	rs11646130	ENSG00000183604.13	SMG1P5	-7.54	2.62e-13	1.09e-10	-0.33	-0.33	Tonsillectomy;	chr16:30365638	chr16:30267553~30335374:-
PRAD	cis	rs7567389	0.719	rs6430936	ENSG00000236682.1	AC068282.3	7.54	2.62e-13	1.09e-10	0.45	0.33	Self-rated health;	chr2:127250110	chr2:127389130~127400580:+
PRAD	cis	rs9309711	0.961	rs11686236	ENSG00000225234.1	TRAPPC12-AS1	-7.54	2.62e-13	1.09e-10	-0.37	-0.33	Neurofibrillary tangles;	chr2:3467778	chr2:3481242~3482409:-
PRAD	cis	rs1023500	0.573	rs133378	ENSG00000205702.9	CYP2D7	7.54	2.63e-13	1.09e-10	0.26	0.33	Schizophrenia;	chr22:42071691	chr22:42140203~42144577:-
PRAD	cis	rs4664293	0.631	rs13019272	ENSG00000226266.5	AC009961.3	-7.54	2.63e-13	1.1e-10	-0.43	-0.33	Monocyte percentage of white cells;	chr2:159802352	chr2:159670708~159712435:-
PRAD	cis	rs9810089	0.843	rs556788	ENSG00000261758.1	RP11-102M11.2	7.54	2.63e-13	1.1e-10	0.38	0.33	Gestational age at birth (child effect);	chr3:136308707	chr3:136752630~136755780:+
PRAD	cis	rs17361889	0.752	rs34750529	ENSG00000224683.1	RPL36AP29	7.54	2.63e-13	1.1e-10	0.4	0.33	Pediatric bone mineral content (hip);	chr7:16236950	chr7:16208945~16209265:+
PRAD	cis	rs7238033	0.663	rs11877720	ENSG00000267193.4	RP11-116O18.3	7.54	2.64e-13	1.1e-10	0.36	0.33	Bladder cancer;	chr18:45738290	chr18:45669367~45747215:-
PRAD	cis	rs79349575	0.749	rs519537	ENSG00000248278.1	SUMO2P17	7.54	2.65e-13	1.1e-10	0.38	0.33	Type 2 diabetes;	chr17:48893778	chr17:48874860~48908983:-
PRAD	cis	rs79349575	0.783	rs832410	ENSG00000248278.1	SUMO2P17	7.54	2.65e-13	1.1e-10	0.38	0.33	Type 2 diabetes;	chr17:48895503	chr17:48874860~48908983:-
PRAD	cis	rs2404602	0.655	rs3829489	ENSG00000259422.1	RP11-593F23.1	7.54	2.65e-13	1.1e-10	0.42	0.33	Blood metabolite levels;	chr15:76930915	chr15:76174891~76181486:-
PRAD	cis	rs11098499	1	rs6849889	ENSG00000245958.5	RP11-33B1.1	-7.54	2.65e-13	1.1e-10	-0.32	-0.33	Corneal astigmatism;	chr4:119265193	chr4:119454791~119552025:+
PRAD	cis	rs17428076	0.874	rs72885529	ENSG00000228389.1	AC068039.4	-7.54	2.65e-13	1.1e-10	-0.43	-0.33	Myopia;	chr2:171827522	chr2:171773482~171775844:+
PRAD	cis	rs17428076	0.874	rs72885532	ENSG00000228389.1	AC068039.4	-7.54	2.65e-13	1.1e-10	-0.43	-0.33	Myopia;	chr2:171827523	chr2:171773482~171775844:+
PRAD	cis	rs4664293	1	rs6432542	ENSG00000226266.5	AC009961.3	-7.54	2.66e-13	1.11e-10	-0.44	-0.33	Monocyte percentage of white cells;	chr2:159624025	chr2:159670708~159712435:-
PRAD	cis	rs7567389	0.573	rs11541137	ENSG00000236682.1	AC068282.3	-7.54	2.66e-13	1.11e-10	-0.45	-0.33	Self-rated health;	chr2:127388195	chr2:127389130~127400580:+
PRAD	cis	rs1799949	0.965	rs799912	ENSG00000267002.1	RP11-242D8.1	7.53	2.66e-13	1.11e-10	0.31	0.33	Menopause (age at onset);	chr17:43105117	chr17:43164183~43170403:-
PRAD	cis	rs2617170	0.922	rs2617149	ENSG00000245648.1	RP11-277P12.20	-7.53	2.66e-13	1.11e-10	-0.4	-0.33	Behcet's disease;	chr12:10375734	chr12:10363769~10398506:+
PRAD	cis	rs7945705	0.747	rs2568045	ENSG00000254860.4	TMEM9B-AS1	7.53	2.67e-13	1.11e-10	0.34	0.33	Hemoglobin concentration;	chr11:8982513	chr11:8964675~8977527:+
PRAD	cis	rs6570726	0.934	rs9484995	ENSG00000235652.6	RP11-545I5.3	-7.53	2.67e-13	1.11e-10	-0.35	-0.33	Lobe attachment (rater-scored or self-reported);	chr6:145459978	chr6:145799409~145886585:+
PRAD	cis	rs6539288	0.933	rs1822736	ENSG00000260329.1	RP11-412D9.4	7.53	2.67e-13	1.11e-10	0.29	0.33	Total body bone mineral density;	chr12:106915481	chr12:106954029~106955497:-
PRAD	cis	rs1185460	0.565	rs1182922	ENSG00000271751.1	RP11-110I1.14	7.53	2.67e-13	1.11e-10	0.45	0.33	Coronary artery disease;	chr11:119062148	chr11:119065263~119065677:-
PRAD	cis	rs881375	0.9	rs1008383	ENSG00000226752.6	PSMD5-AS1	-7.53	2.68e-13	1.12e-10	-0.4	-0.33	Rheumatoid arthritis;	chr9:120921301	chr9:120824828~120854385:+
PRAD	cis	rs7567389	0.719	rs4150476	ENSG00000236682.1	AC068282.3	7.53	2.69e-13	1.12e-10	0.45	0.33	Self-rated health;	chr2:127275246	chr2:127389130~127400580:+
PRAD	cis	rs7567389	0.719	rs4150471	ENSG00000236682.1	AC068282.3	7.53	2.69e-13	1.12e-10	0.45	0.33	Self-rated health;	chr2:127276963	chr2:127389130~127400580:+
PRAD	cis	rs11159086	1	rs8006958	ENSG00000259005.1	RP3-449M8.6	7.53	2.69e-13	1.12e-10	0.46	0.33	Advanced glycation end-product levels;	chr14:74478148	chr14:74474007~74474864:-
PRAD	cis	rs2638953	0.962	rs12371059	ENSG00000278733.1	RP11-425D17.1	-7.53	2.69e-13	1.12e-10	-0.43	-0.33	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28375375	chr12:28185625~28186190:-
PRAD	cis	rs9532669	0.926	rs9532693	ENSG00000168852.11	TPTE2P5	7.53	2.69e-13	1.12e-10	0.32	0.33	Cervical cancer;	chr13:40980557	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.926	rs2324748	ENSG00000168852.11	TPTE2P5	7.53	2.69e-13	1.12e-10	0.32	0.33	Cervical cancer;	chr13:40989452	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.926	rs4245311	ENSG00000168852.11	TPTE2P5	7.53	2.69e-13	1.12e-10	0.32	0.33	Cervical cancer;	chr13:40990003	chr13:40822296~40921749:-
PRAD	cis	rs9532669	0.89	rs9594473	ENSG00000168852.11	TPTE2P5	7.53	2.69e-13	1.12e-10	0.32	0.33	Cervical cancer;	chr13:40997997	chr13:40822296~40921749:-
PRAD	cis	rs2439831	0.717	rs2447198	ENSG00000205771.5	CATSPER2P1	-7.53	2.69e-13	1.12e-10	-0.54	-0.33	Lung cancer in ever smokers;	chr15:43602920	chr15:43726918~43747094:-
PRAD	cis	rs4842666	0.915	rs73437338	ENSG00000258302.2	RP11-981P6.1	7.53	2.69e-13	1.12e-10	0.41	0.33	Blood pressure;	chr12:89660842	chr12:89561129~89594878:+
PRAD	cis	rs2638953	0.962	rs11049550	ENSG00000278733.1	RP11-425D17.1	-7.53	2.7e-13	1.12e-10	-0.42	-0.33	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28358591	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.962	rs11049552	ENSG00000278733.1	RP11-425D17.1	-7.53	2.7e-13	1.12e-10	-0.42	-0.33	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28361466	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.962	rs11049553	ENSG00000278733.1	RP11-425D17.1	-7.53	2.7e-13	1.12e-10	-0.42	-0.33	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28361611	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.962	rs11049554	ENSG00000278733.1	RP11-425D17.1	-7.53	2.7e-13	1.12e-10	-0.42	-0.33	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28362819	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.962	rs12371222	ENSG00000278733.1	RP11-425D17.1	-7.53	2.7e-13	1.12e-10	-0.42	-0.33	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28363245	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.962	rs11049555	ENSG00000278733.1	RP11-425D17.1	-7.53	2.7e-13	1.12e-10	-0.42	-0.33	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28364919	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.962	rs11049556	ENSG00000278733.1	RP11-425D17.1	-7.53	2.7e-13	1.12e-10	-0.42	-0.33	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28365626	chr12:28185625~28186190:-
PRAD	cis	rs853679	0.55	rs1150692	ENSG00000204709.4	LINC01556	7.53	2.7e-13	1.12e-10	0.45	0.33	Depression;	chr6:28206179	chr6:28943877~28944537:+
PRAD	cis	rs10895987	0.531	rs11227118	ENSG00000254614.2	AP003068.23	7.53	2.7e-13	1.12e-10	0.44	0.33	Blood protein levels;	chr11:65093183	chr11:65177606~65181834:-
PRAD	cis	rs10895987	0.531	rs11227120	ENSG00000254614.2	AP003068.23	7.53	2.7e-13	1.12e-10	0.44	0.33	Blood protein levels;	chr11:65097387	chr11:65177606~65181834:-
PRAD	cis	rs79349575	0.721	rs9904645	ENSG00000248278.1	SUMO2P17	7.53	2.7e-13	1.13e-10	0.38	0.33	Type 2 diabetes;	chr17:48892303	chr17:48874860~48908983:-
PRAD	cis	rs6782228	0.606	rs7627549	ENSG00000242551.2	POU5F1P6	-7.53	2.71e-13	1.13e-10	-0.41	-0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128634236	chr3:128674735~128677005:-
PRAD	cis	rs6782228	0.606	rs1697	ENSG00000242551.2	POU5F1P6	-7.53	2.71e-13	1.13e-10	-0.41	-0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128638009	chr3:128674735~128677005:-
PRAD	cis	rs673078	0.607	rs55929628	ENSG00000275409.1	RP11-131L12.4	-7.53	2.71e-13	1.13e-10	-0.5	-0.33	Glucose homeostasis traits;	chr12:118371332	chr12:118430147~118430699:+
PRAD	cis	rs2243480	1	rs56016656	ENSG00000226824.5	RP4-756H11.3	-7.53	2.71e-13	1.13e-10	-0.64	-0.33	Diabetic kidney disease;	chr7:65918494	chr7:66654538~66669855:+
PRAD	cis	rs2243480	0.803	rs55700941	ENSG00000226824.5	RP4-756H11.3	-7.53	2.71e-13	1.13e-10	-0.64	-0.33	Diabetic kidney disease;	chr7:65924813	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs56291018	ENSG00000226824.5	RP4-756H11.3	-7.53	2.71e-13	1.13e-10	-0.64	-0.33	Diabetic kidney disease;	chr7:65925352	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs36033484	ENSG00000226824.5	RP4-756H11.3	-7.53	2.71e-13	1.13e-10	-0.64	-0.33	Diabetic kidney disease;	chr7:65925571	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs34560516	ENSG00000226824.5	RP4-756H11.3	-7.53	2.71e-13	1.13e-10	-0.64	-0.33	Diabetic kidney disease;	chr7:65939105	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs34970380	ENSG00000226824.5	RP4-756H11.3	-7.53	2.71e-13	1.13e-10	-0.64	-0.33	Diabetic kidney disease;	chr7:65966506	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs4718270	ENSG00000226824.5	RP4-756H11.3	-7.53	2.72e-13	1.13e-10	-0.64	-0.33	Diabetic kidney disease;	chr7:65737415	chr7:66654538~66669855:+
PRAD	cis	rs11159086	0.793	rs11621693	ENSG00000270000.1	RP3-449M8.9	7.53	2.73e-13	1.13e-10	0.5	0.33	Advanced glycation end-product levels;	chr14:74472631	chr14:74471930~74472360:-
PRAD	cis	rs9326248	0.52	rs1446105	ENSG00000280143.1	AP000892.6	7.53	2.73e-13	1.14e-10	0.25	0.33	Blood protein levels;	chr11:116927828	chr11:117204967~117210292:+
PRAD	cis	rs17711722	0.528	rs73138179	ENSG00000234585.5	CCT6P3	7.53	2.74e-13	1.14e-10	0.26	0.33	Calcium levels;	chr7:65829495	chr7:65038354~65074713:+
PRAD	cis	rs2337406	0.85	rs10131280	ENSG00000274576.2	IGHV2-70	-7.53	2.75e-13	1.14e-10	-0.36	-0.33	Alzheimer's disease (late onset);	chr14:106665591	chr14:106770577~106771020:-
PRAD	cis	rs2243480	1	rs160655	ENSG00000226824.5	RP4-756H11.3	-7.53	2.76e-13	1.15e-10	-0.66	-0.33	Diabetic kidney disease;	chr7:66068227	chr7:66654538~66669855:+
PRAD	cis	rs2243480	0.803	rs160649	ENSG00000226824.5	RP4-756H11.3	-7.53	2.76e-13	1.15e-10	-0.66	-0.33	Diabetic kidney disease;	chr7:66078212	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs160648	ENSG00000226824.5	RP4-756H11.3	-7.53	2.76e-13	1.15e-10	-0.66	-0.33	Diabetic kidney disease;	chr7:66078397	chr7:66654538~66669855:+
PRAD	cis	rs853679	0.546	rs34295134	ENSG00000280107.1	AL022393.9	-7.53	2.76e-13	1.15e-10	-0.59	-0.33	Depression;	chr6:27860373	chr6:28170845~28172521:+
PRAD	cis	rs1355223	0.902	rs11605785	ENSG00000271369.1	RP11-350D17.3	-7.53	2.76e-13	1.15e-10	-0.39	-0.33	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34729840	chr11:34709600~34710161:+
PRAD	cis	rs494459	0.691	rs607472	ENSG00000278376.1	RP11-158I9.8	-7.53	2.77e-13	1.15e-10	-0.28	-0.33	Height;	chr11:118809363	chr11:118791254~118793137:+
PRAD	cis	rs6452524	0.868	rs10057303	ENSG00000249664.1	CTD-2227C6.2	7.53	2.77e-13	1.15e-10	0.4	0.33	Hypertension (SNP x SNP interaction);	chr5:83098564	chr5:83012285~83013109:-
PRAD	cis	rs6452524	0.868	rs2386235	ENSG00000249664.1	CTD-2227C6.2	7.53	2.77e-13	1.15e-10	0.4	0.33	Hypertension (SNP x SNP interaction);	chr5:83101452	chr5:83012285~83013109:-
PRAD	cis	rs853679	0.567	rs6905380	ENSG00000216901.1	AL022393.7	7.53	2.78e-13	1.15e-10	0.46	0.33	Depression;	chr6:28407125	chr6:28176188~28176674:+
PRAD	cis	rs6480314	0.542	rs61854811	ENSG00000233590.1	RP11-153K11.3	-7.53	2.78e-13	1.15e-10	-0.55	-0.33	Optic nerve measurement (disc area);	chr10:68264474	chr10:68233251~68242379:-
PRAD	cis	rs79349575	0.594	rs1985785	ENSG00000248278.1	SUMO2P17	7.53	2.78e-13	1.15e-10	0.38	0.33	Type 2 diabetes;	chr17:48890426	chr17:48874860~48908983:-
PRAD	cis	rs79349575	0.685	rs1124829	ENSG00000248278.1	SUMO2P17	7.53	2.78e-13	1.15e-10	0.38	0.33	Type 2 diabetes;	chr17:48890435	chr17:48874860~48908983:-
PRAD	cis	rs79349575	0.721	rs1008834	ENSG00000248278.1	SUMO2P17	7.53	2.78e-13	1.15e-10	0.38	0.33	Type 2 diabetes;	chr17:48890646	chr17:48874860~48908983:-
PRAD	cis	rs55665837	1	rs11023227	ENSG00000251991.1	RNU7-49P	7.53	2.78e-13	1.15e-10	0.36	0.33	Vitamin D levels;	chr11:14437541	chr11:14478892~14478953:+
PRAD	cis	rs496547	0.686	rs540180	ENSG00000255239.1	AP002954.6	7.53	2.78e-13	1.16e-10	0.44	0.33	Hip minimal joint space width;	chr11:118782920	chr11:118688039~118690600:-
PRAD	cis	rs6479901	0.895	rs7916224	ENSG00000232075.1	MRPL35P2	-7.53	2.79e-13	1.16e-10	-0.41	-0.33	Intelligence (multi-trait analysis);	chr10:63144843	chr10:63634317~63634827:-
PRAD	cis	rs12612619	0.732	rs10432697	ENSG00000272148.1	RP11-195B17.1	7.53	2.79e-13	1.16e-10	0.4	0.33	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27049184	chr2:27062428~27062907:-
PRAD	cis	rs875971	0.522	rs2949690	ENSG00000237310.1	GS1-124K5.4	-7.53	2.79e-13	1.16e-10	-0.28	-0.33	Aortic root size;	chr7:66018255	chr7:66493706~66495474:+
PRAD	cis	rs6951245	0.554	rs58210047	ENSG00000229043.2	AC091729.9	-7.53	2.79e-13	1.16e-10	-0.48	-0.33	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1109745	chr7:1160374~1165267:+
PRAD	cis	rs11098499	0.562	rs58583086	ENSG00000245958.5	RP11-33B1.1	7.53	2.79e-13	1.16e-10	0.31	0.33	Corneal astigmatism;	chr4:119635207	chr4:119454791~119552025:+
PRAD	cis	rs79349575	0.87	rs12941262	ENSG00000248278.1	SUMO2P17	7.53	2.79e-13	1.16e-10	0.38	0.33	Type 2 diabetes;	chr17:48889675	chr17:48874860~48908983:-
PRAD	cis	rs79349575	0.778	rs12950328	ENSG00000248278.1	SUMO2P17	7.53	2.79e-13	1.16e-10	0.38	0.33	Type 2 diabetes;	chr17:48889699	chr17:48874860~48908983:-
PRAD	cis	rs858239	0.537	rs2286272	ENSG00000226816.2	AC005082.12	7.53	2.79e-13	1.16e-10	0.39	0.33	Cerebrospinal fluid biomarker levels;	chr7:23184748	chr7:23206013~23208045:+
PRAD	cis	rs858239	0.537	rs6955115	ENSG00000226816.2	AC005082.12	7.53	2.79e-13	1.16e-10	0.39	0.33	Cerebrospinal fluid biomarker levels;	chr7:23187525	chr7:23206013~23208045:+
PRAD	cis	rs2933343	0.621	rs789249	ENSG00000261159.1	RP11-723O4.9	7.53	2.8e-13	1.16e-10	0.29	0.33	IgG glycosylation;	chr3:128859610	chr3:128859716~128860526:-
PRAD	cis	rs73081554	0.611	rs35975336	ENSG00000272360.1	RP11-359I18.5	-7.53	2.8e-13	1.16e-10	-0.54	-0.33	Rheumatoid arthritis;	chr3:58465907	chr3:58490830~58491291:-
PRAD	cis	rs11098499	0.566	rs7664440	ENSG00000245958.5	RP11-33B1.1	-7.53	2.8e-13	1.16e-10	-0.34	-0.33	Corneal astigmatism;	chr4:119657385	chr4:119454791~119552025:+
PRAD	cis	rs8523	0.901	rs3798711	ENSG00000230314.5	ELOVL2-AS1	-7.53	2.81e-13	1.16e-10	-0.36	-0.33	Red blood cell fatty acid levels;	chr6:11002577	chr6:11043524~11078226:+
PRAD	cis	rs11018904	0.906	rs61903722	ENSG00000280385.1	AP000648.5	-7.53	2.81e-13	1.16e-10	-0.48	-0.33	Intelligence (multi-trait analysis);	chr11:90233874	chr11:90193614~90198120:+
PRAD	cis	rs11976180	1	rs2961132	ENSG00000273234.1	OR2A13P	-7.53	2.81e-13	1.17e-10	-0.4	-0.33	Obesity-related traits;	chr7:144071035	chr7:144142009~144142938:+
PRAD	cis	rs950169	0.579	rs62027818	ENSG00000259728.4	LINC00933	7.53	2.81e-13	1.17e-10	0.42	0.33	Schizophrenia;	chr15:83992393	chr15:84570649~84580175:+
PRAD	cis	rs6452524	0.836	rs62372713	ENSG00000249664.1	CTD-2227C6.2	7.53	2.82e-13	1.17e-10	0.4	0.33	Hypertension (SNP x SNP interaction);	chr5:83090635	chr5:83012285~83013109:-
PRAD	cis	rs12908161	0.96	rs17599989	ENSG00000275120.1	RP11-182J1.17	7.53	2.82e-13	1.17e-10	0.43	0.33	Schizophrenia;	chr15:84742305	chr15:84599434~84606463:-
PRAD	cis	rs1043099	0.912	rs4820008	ENSG00000279699.1	RP1-102K2.9	-7.53	2.82e-13	1.17e-10	-0.52	-0.33	Rheumatoid arthritis;	chr22:30353352	chr22:30275215~30276951:-
PRAD	cis	rs6782228	0.585	rs2811492	ENSG00000242551.2	POU5F1P6	-7.53	2.82e-13	1.17e-10	-0.41	-0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128637436	chr3:128674735~128677005:-
PRAD	cis	rs10463554	0.895	rs3733939	ENSG00000175749.11	EIF3KP1	7.53	2.83e-13	1.17e-10	0.41	0.33	Parkinson's disease;	chr5:102974462	chr5:103032376~103033031:+
PRAD	cis	rs10875746	0.669	rs1021313	ENSG00000240399.1	RP1-228P16.1	-7.53	2.84e-13	1.18e-10	-0.31	-0.33	Longevity (90 years and older);	chr12:48244258	chr12:48054813~48055591:-
PRAD	cis	rs1355223	0.902	rs1453380	ENSG00000271369.1	RP11-350D17.3	-7.52	2.85e-13	1.18e-10	-0.38	-0.33	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34682135	chr11:34709600~34710161:+
PRAD	cis	rs9640161	0.789	rs4554381	ENSG00000261305.1	RP4-584D14.7	7.52	2.86e-13	1.19e-10	0.37	0.33	Blood protein levels;Circulating chemerin levels;	chr7:150328478	chr7:150341771~150342607:+
PRAD	cis	rs2439831	0.85	rs7169322	ENSG00000249839.1	AC011330.5	-7.52	2.86e-13	1.19e-10	-0.58	-0.33	Lung cancer in ever smokers;	chr15:43838816	chr15:43663654~43684339:-
PRAD	cis	rs2439831	0.85	rs28413704	ENSG00000249839.1	AC011330.5	-7.52	2.86e-13	1.19e-10	-0.58	-0.33	Lung cancer in ever smokers;	chr15:43856229	chr15:43663654~43684339:-
PRAD	cis	rs2439831	0.702	rs9989313	ENSG00000249839.1	AC011330.5	-7.52	2.86e-13	1.19e-10	-0.58	-0.33	Lung cancer in ever smokers;	chr15:43860619	chr15:43663654~43684339:-
PRAD	cis	rs2243480	1	rs35058610	ENSG00000273142.1	RP11-458F8.4	-7.52	2.87e-13	1.19e-10	-0.36	-0.33	Diabetic kidney disease;	chr7:65925938	chr7:66902857~66906297:+
PRAD	cis	rs17428076	0.874	rs12614709	ENSG00000228389.1	AC068039.4	-7.52	2.87e-13	1.19e-10	-0.43	-0.33	Myopia;	chr2:171824362	chr2:171773482~171775844:+
PRAD	cis	rs17428076	0.874	rs17581347	ENSG00000228389.1	AC068039.4	-7.52	2.87e-13	1.19e-10	-0.43	-0.33	Myopia;	chr2:171826091	chr2:171773482~171775844:+
PRAD	cis	rs17428076	0.874	rs17581361	ENSG00000228389.1	AC068039.4	-7.52	2.87e-13	1.19e-10	-0.43	-0.33	Myopia;	chr2:171826102	chr2:171773482~171775844:+
PRAD	cis	rs17428076	0.874	rs62182372	ENSG00000228389.1	AC068039.4	-7.52	2.87e-13	1.19e-10	-0.43	-0.33	Myopia;	chr2:171827977	chr2:171773482~171775844:+
PRAD	cis	rs67311347	0.521	rs2887963	ENSG00000223797.4	ENTPD3-AS1	-7.52	2.88e-13	1.19e-10	-0.29	-0.33	Renal cell carcinoma;	chr3:40201975	chr3:40313802~40453329:-
PRAD	cis	rs62103177	0.608	rs59300126	ENSG00000261126.6	RP11-795F19.1	7.52	2.88e-13	1.19e-10	0.46	0.33	Opioid sensitivity;	chr18:79934439	chr18:80046900~80095482:+
PRAD	cis	rs11846409	0.799	rs2583330	ENSG00000274576.2	IGHV2-70	7.52	2.88e-13	1.19e-10	0.36	0.33	Rheumatic heart disease;	chr14:106621051	chr14:106770577~106771020:-
PRAD	cis	rs12468226	0.873	rs78798541	ENSG00000273456.1	RP11-686O6.2	7.52	2.89e-13	1.2e-10	0.46	0.33	Urate levels;	chr2:202194708	chr2:202374932~202375604:-
PRAD	cis	rs6547741	1	rs4665381	ENSG00000234072.1	AC074117.10	7.52	2.89e-13	1.2e-10	0.25	0.33	Oral cavity cancer;	chr2:27534283	chr2:27356246~27367622:+
PRAD	cis	rs6479901	0.895	rs1579045	ENSG00000232075.1	MRPL35P2	-7.52	2.89e-13	1.2e-10	-0.4	-0.33	Intelligence (multi-trait analysis);	chr10:63210688	chr10:63634317~63634827:-
PRAD	cis	rs6479901	0.895	rs7920159	ENSG00000232075.1	MRPL35P2	-7.52	2.89e-13	1.2e-10	-0.4	-0.33	Intelligence (multi-trait analysis);	chr10:63212416	chr10:63634317~63634827:-
PRAD	cis	rs8523	0.744	rs9348807	ENSG00000230314.5	ELOVL2-AS1	7.52	2.9e-13	1.2e-10	0.36	0.33	Red blood cell fatty acid levels;	chr6:11082089	chr6:11043524~11078226:+
PRAD	cis	rs8523	0.774	rs12526913	ENSG00000230314.5	ELOVL2-AS1	7.52	2.9e-13	1.2e-10	0.36	0.33	Red blood cell fatty acid levels;	chr6:11082691	chr6:11043524~11078226:+
PRAD	cis	rs964611	0.872	rs60820695	ENSG00000259488.2	RP11-154J22.1	-7.52	2.91e-13	1.21e-10	-0.34	-0.33	Metabolite levels (Pyroglutamine);	chr15:48292686	chr15:48312353~48331856:-
PRAD	cis	rs7849270	0.801	rs6478868	ENSG00000268707.1	RP11-247A12.7	7.52	2.91e-13	1.21e-10	0.39	0.33	Blood metabolite ratios;	chr9:129164813	chr9:129170434~129170940:+
PRAD	cis	rs55665837	1	rs55665837	ENSG00000251991.1	RNU7-49P	7.52	2.91e-13	1.21e-10	0.36	0.33	Vitamin D levels;	chr11:14473503	chr11:14478892~14478953:+
PRAD	cis	rs12571093	0.803	rs2241970	ENSG00000233590.1	RP11-153K11.3	7.52	2.92e-13	1.21e-10	0.55	0.33	Optic nerve measurement (disc area);	chr10:68271310	chr10:68233251~68242379:-
PRAD	cis	rs6480314	0.542	rs17297383	ENSG00000233590.1	RP11-153K11.3	-7.52	2.92e-13	1.21e-10	-0.55	-0.33	Optic nerve measurement (disc area);	chr10:68269106	chr10:68233251~68242379:-
PRAD	cis	rs673078	0.66	rs61943365	ENSG00000275409.1	RP11-131L12.4	-7.52	2.92e-13	1.21e-10	-0.44	-0.33	Glucose homeostasis traits;	chr12:118339166	chr12:118430147~118430699:+
PRAD	cis	rs6921919	1	rs6921919	ENSG00000216901.1	AL022393.7	7.52	2.93e-13	1.21e-10	0.48	0.33	Autism spectrum disorder or schizophrenia;	chr6:28357424	chr6:28176188~28176674:+
PRAD	cis	rs12468226	0.938	rs114177656	ENSG00000273456.1	RP11-686O6.2	7.52	2.93e-13	1.21e-10	0.45	0.33	Urate levels;	chr2:202291596	chr2:202374932~202375604:-
PRAD	cis	rs6782228	0.565	rs11719239	ENSG00000242551.2	POU5F1P6	-7.52	2.93e-13	1.21e-10	-0.41	-0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128700211	chr3:128674735~128677005:-
PRAD	cis	rs6782228	0.606	rs2001950	ENSG00000242551.2	POU5F1P6	-7.52	2.93e-13	1.21e-10	-0.41	-0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128700913	chr3:128674735~128677005:-
PRAD	cis	rs2034650	0.506	rs1984793	ENSG00000223313.1	RNU6-516P	7.52	2.93e-13	1.22e-10	0.4	0.33	Interstitial lung disease;	chr15:40407172	chr15:40529570~40529673:+
PRAD	cis	rs7772486	0.743	rs111332144	ENSG00000235652.6	RP11-545I5.3	-7.52	2.94e-13	1.22e-10	-0.35	-0.33	Lobe attachment (rater-scored or self-reported);	chr6:145735545	chr6:145799409~145886585:+
PRAD	cis	rs964611	0.882	rs12909148	ENSG00000259488.2	RP11-154J22.1	7.52	2.94e-13	1.22e-10	0.34	0.33	Metabolite levels (Pyroglutamine);	chr15:48356800	chr15:48312353~48331856:-
PRAD	cis	rs6479901	0.894	rs4518976	ENSG00000232075.1	MRPL35P2	-7.52	2.95e-13	1.22e-10	-0.41	-0.33	Intelligence (multi-trait analysis);	chr10:63319017	chr10:63634317~63634827:-
PRAD	cis	rs2638953	0.962	rs10506032	ENSG00000278733.1	RP11-425D17.1	-7.52	2.95e-13	1.22e-10	-0.42	-0.33	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28384177	chr12:28185625~28186190:-
PRAD	cis	rs858239	0.537	rs10279691	ENSG00000226816.2	AC005082.12	7.52	2.95e-13	1.22e-10	0.39	0.33	Cerebrospinal fluid biomarker levels;	chr7:23188768	chr7:23206013~23208045:+
PRAD	cis	rs6479901	0.895	rs7897326	ENSG00000232075.1	MRPL35P2	-7.52	2.95e-13	1.22e-10	-0.4	-0.33	Intelligence (multi-trait analysis);	chr10:63306059	chr10:63634317~63634827:-
PRAD	cis	rs6782228	0.585	rs3122175	ENSG00000242551.2	POU5F1P6	-7.52	2.96e-13	1.22e-10	-0.41	-0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128642433	chr3:128674735~128677005:-
PRAD	cis	rs6782228	0.606	rs2811497	ENSG00000242551.2	POU5F1P6	-7.52	2.96e-13	1.22e-10	-0.41	-0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128644489	chr3:128674735~128677005:-
PRAD	cis	rs11098499	0.754	rs4107728	ENSG00000245958.5	RP11-33B1.1	-7.52	2.97e-13	1.23e-10	-0.31	-0.33	Corneal astigmatism;	chr4:119332755	chr4:119454791~119552025:+
PRAD	cis	rs9640161	0.636	rs3735171	ENSG00000261305.1	RP4-584D14.7	7.52	2.97e-13	1.23e-10	0.37	0.33	Blood protein levels;Circulating chemerin levels;	chr7:150336793	chr7:150341771~150342607:+
PRAD	cis	rs2243480	1	rs160652	ENSG00000226824.5	RP4-756H11.3	-7.52	2.98e-13	1.23e-10	-0.67	-0.33	Diabetic kidney disease;	chr7:66073444	chr7:66654538~66669855:+
PRAD	cis	rs73607972	0.74	rs66961852	ENSG00000275191.1	RP11-36I17.2	-7.52	2.98e-13	1.23e-10	-0.52	-0.33	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53587476	chr16:53628256~53628816:-
PRAD	cis	rs6991838	0.701	rs7829434	ENSG00000200714.1	Y_RNA	7.52	2.98e-13	1.23e-10	0.34	0.33	Intelligence (multi-trait analysis);	chr8:65716909	chr8:65592731~65592820:+
PRAD	cis	rs2439831	0.85	rs68079546	ENSG00000249839.1	AC011330.5	-7.52	2.99e-13	1.24e-10	-0.57	-0.33	Lung cancer in ever smokers;	chr15:43844759	chr15:43663654~43684339:-
PRAD	cis	rs2439831	0.85	rs56909447	ENSG00000249839.1	AC011330.5	-7.52	2.99e-13	1.24e-10	-0.57	-0.33	Lung cancer in ever smokers;	chr15:43845420	chr15:43663654~43684339:-
PRAD	cis	rs2439831	0.85	rs28476182	ENSG00000249839.1	AC011330.5	-7.52	2.99e-13	1.24e-10	-0.57	-0.33	Lung cancer in ever smokers;	chr15:43847445	chr15:43663654~43684339:-
PRAD	cis	rs2439831	0.85	rs28696802	ENSG00000249839.1	AC011330.5	-7.52	2.99e-13	1.24e-10	-0.57	-0.33	Lung cancer in ever smokers;	chr15:43848197	chr15:43663654~43684339:-
PRAD	cis	rs11098499	1	rs12506395	ENSG00000245958.5	RP11-33B1.1	-7.52	3.01e-13	1.24e-10	-0.32	-0.33	Corneal astigmatism;	chr4:119263939	chr4:119454791~119552025:+
PRAD	cis	rs638893	0.617	rs4938565	ENSG00000278376.1	RP11-158I9.8	7.52	3.01e-13	1.25e-10	0.34	0.33	Vitiligo;	chr11:118850289	chr11:118791254~118793137:+
PRAD	cis	rs524281	0.692	rs2254388	ENSG00000255320.1	RP11-755F10.1	-7.52	3.02e-13	1.25e-10	-0.46	-0.33	Electroencephalogram traits;	chr11:66070128	chr11:66244840~66246239:-
PRAD	cis	rs2243480	1	rs160643	ENSG00000273142.1	RP11-458F8.4	-7.52	3.02e-13	1.25e-10	-0.36	-0.33	Diabetic kidney disease;	chr7:66093235	chr7:66902857~66906297:+
PRAD	cis	rs11098499	0.955	rs1511015	ENSG00000245958.5	RP11-33B1.1	-7.52	3.03e-13	1.25e-10	-0.32	-0.33	Corneal astigmatism;	chr4:119249318	chr4:119454791~119552025:+
PRAD	cis	rs7567389	0.719	rs6733478	ENSG00000236682.1	AC068282.3	7.52	3.03e-13	1.25e-10	0.45	0.33	Self-rated health;	chr2:127238413	chr2:127389130~127400580:+
PRAD	cis	rs812925	0.537	rs778139	ENSG00000271889.1	RP11-493E12.1	-7.52	3.03e-13	1.25e-10	-0.36	-0.33	Immature fraction of reticulocytes;	chr2:61457429	chr2:61151433~61162105:-
PRAD	cis	rs10129255	1	rs4612959	ENSG00000223648.3	IGHV3-64	7.52	3.04e-13	1.26e-10	0.33	0.33	Kawasaki disease;	chr14:106767055	chr14:106643132~106658258:-
PRAD	cis	rs6674176	0.597	rs9326136	ENSG00000237950.1	RP11-7O11.3	-7.52	3.04e-13	1.26e-10	-0.36	-0.33	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43924720	chr1:43944370~43946551:-
PRAD	cis	rs9362426	0.503	rs6454622	ENSG00000218793.1	RP3-382I10.3	7.51	3.05e-13	1.26e-10	0.41	0.33	Depressive episodes in bipolar disorder;	chr6:87424793	chr6:87441165~87442146:-
PRAD	cis	rs12439619	0.508	rs11856561	ENSG00000255769.6	GOLGA2P10	-7.51	3.05e-13	1.26e-10	-0.39	-0.33	Intelligence (multi-trait analysis);	chr15:82161415	chr15:82472993~82513950:-
PRAD	cis	rs9341835	0.584	rs2622286	ENSG00000218048.2	RP3-407E4.4	7.51	3.07e-13	1.27e-10	0.37	0.33	Schizophrenia;	chr6:63440162	chr6:63440766~63443580:+
PRAD	cis	rs9341835	0.584	rs2622307	ENSG00000218048.2	RP3-407E4.4	7.51	3.07e-13	1.27e-10	0.37	0.33	Schizophrenia;	chr6:63442144	chr6:63440766~63443580:+
PRAD	cis	rs9341835	0.584	rs2096346	ENSG00000218048.2	RP3-407E4.4	7.51	3.07e-13	1.27e-10	0.37	0.33	Schizophrenia;	chr6:63443109	chr6:63440766~63443580:+
PRAD	cis	rs12432203	1	rs59302370	ENSG00000258479.4	LINC00640	7.51	3.07e-13	1.27e-10	0.61	0.33	Cancer;	chr14:51273225	chr14:51333393~51365557:+
PRAD	cis	rs12432203	1	rs58700439	ENSG00000258479.4	LINC00640	7.51	3.07e-13	1.27e-10	0.61	0.33	Cancer;	chr14:51273703	chr14:51333393~51365557:+
PRAD	cis	rs12571093	0.656	rs3858147	ENSG00000233590.1	RP11-153K11.3	-7.51	3.07e-13	1.27e-10	-0.53	-0.33	Optic nerve measurement (disc area);	chr10:68253507	chr10:68233251~68242379:-
PRAD	cis	rs12439619	0.53	rs7162177	ENSG00000255769.6	GOLGA2P10	-7.51	3.08e-13	1.27e-10	-0.39	-0.33	Intelligence (multi-trait analysis);	chr15:82181728	chr15:82472993~82513950:-
PRAD	cis	rs9640161	0.659	rs11974980	ENSG00000261305.1	RP4-584D14.7	7.51	3.08e-13	1.27e-10	0.36	0.33	Blood protein levels;Circulating chemerin levels;	chr7:150312749	chr7:150341771~150342607:+
PRAD	cis	rs9640161	0.659	rs11975886	ENSG00000261305.1	RP4-584D14.7	7.51	3.08e-13	1.27e-10	0.36	0.33	Blood protein levels;Circulating chemerin levels;	chr7:150313273	chr7:150341771~150342607:+
PRAD	cis	rs964611	0.751	rs58922278	ENSG00000259488.2	RP11-154J22.1	-7.51	3.09e-13	1.28e-10	-0.32	-0.33	Metabolite levels (Pyroglutamine);	chr15:48257357	chr15:48312353~48331856:-
PRAD	cis	rs4713118	0.513	rs149954	ENSG00000220721.1	OR1F12	7.51	3.1e-13	1.28e-10	0.38	0.33	Parkinson's disease;	chr6:28067468	chr6:28073316~28074233:+
PRAD	cis	rs324126	0.527	rs17780009	ENSG00000277977.1	CTD-3018O17.5	-7.51	3.1e-13	1.28e-10	-0.42	-0.33	Colonoscopy-negative controls vs population controls;	chr19:52370365	chr19:52392659~52392755:+
PRAD	cis	rs7487075	0.78	rs10785624	ENSG00000274723.1	RP11-618L22.1	7.51	3.1e-13	1.28e-10	0.39	0.33	Itch intensity from mosquito bite;	chr12:46373004	chr12:46970504~46972155:+
PRAD	cis	rs7487075	0.78	rs2279559	ENSG00000274723.1	RP11-618L22.1	7.51	3.1e-13	1.28e-10	0.39	0.33	Itch intensity from mosquito bite;	chr12:46373392	chr12:46970504~46972155:+
PRAD	cis	rs7829975	0.606	rs7819827	ENSG00000253893.2	FAM85B	7.51	3.11e-13	1.29e-10	0.42	0.33	Mood instability;	chr8:8939545	chr8:8167819~8226614:-
PRAD	cis	rs6674176	0.597	rs3762422	ENSG00000237950.1	RP11-7O11.3	7.51	3.11e-13	1.29e-10	0.37	0.33	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43934860	chr1:43944370~43946551:-
PRAD	cis	rs6844153	0.877	rs10939146	ENSG00000240005.4	RP11-293A21.1	-7.51	3.12e-13	1.29e-10	-0.49	-0.33	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26978399	chr4:26859806~26860599:-
PRAD	cis	rs6991838	0.671	rs13251307	ENSG00000200714.1	Y_RNA	7.51	3.13e-13	1.29e-10	0.35	0.33	Intelligence (multi-trait analysis);	chr8:65664911	chr8:65592731~65592820:+
PRAD	cis	rs67311347	0.544	rs4974047	ENSG00000223797.4	ENTPD3-AS1	7.51	3.13e-13	1.29e-10	0.29	0.33	Renal cell carcinoma;	chr3:40298162	chr3:40313802~40453329:-
PRAD	cis	rs7829975	0.714	rs11784052	ENSG00000253893.2	FAM85B	-7.51	3.15e-13	1.3e-10	-0.43	-0.33	Mood instability;	chr8:8814452	chr8:8167819~8226614:-
PRAD	cis	rs61774743	0.636	rs1892423	ENSG00000229901.1	RP11-399E6.4	-7.51	3.16e-13	1.3e-10	-0.32	-0.33	Intelligence (multi-trait analysis);	chr1:41383668	chr1:41375004~41375669:-
PRAD	cis	rs61774743	0.681	rs10889959	ENSG00000229901.1	RP11-399E6.4	-7.51	3.16e-13	1.3e-10	-0.32	-0.33	Intelligence (multi-trait analysis);	chr1:41384063	chr1:41375004~41375669:-
PRAD	cis	rs4631830	0.72	rs2012677	ENSG00000230869.1	CTGLF10P	-7.51	3.16e-13	1.3e-10	-0.41	-0.33	Prostate-specific antigen levels;	chr10:46091025	chr10:45678692~45700532:+
PRAD	cis	rs11098499	0.754	rs7672372	ENSG00000245958.5	RP11-33B1.1	-7.51	3.16e-13	1.3e-10	-0.31	-0.33	Corneal astigmatism;	chr4:119327251	chr4:119454791~119552025:+
PRAD	cis	rs55665837	1	rs12295888	ENSG00000251991.1	RNU7-49P	7.51	3.16e-13	1.3e-10	0.36	0.33	Vitamin D levels;	chr11:14428985	chr11:14478892~14478953:+
PRAD	cis	rs6674176	0.66	rs2108202	ENSG00000237950.1	RP11-7O11.3	-7.51	3.17e-13	1.31e-10	-0.37	-0.33	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43930114	chr1:43944370~43946551:-
PRAD	cis	rs1426063	1	rs17000242	ENSG00000249717.1	RP11-44F21.3	7.51	3.17e-13	1.31e-10	0.55	0.33	QT interval;	chr4:75103857	chr4:74955974~74970362:-
PRAD	cis	rs1426063	1	rs7666371	ENSG00000249717.1	RP11-44F21.3	7.51	3.17e-13	1.31e-10	0.55	0.33	QT interval;	chr4:75104325	chr4:74955974~74970362:-
PRAD	cis	rs1426063	1	rs6829858	ENSG00000249717.1	RP11-44F21.3	7.51	3.17e-13	1.31e-10	0.55	0.33	QT interval;	chr4:75105202	chr4:74955974~74970362:-
PRAD	cis	rs881375	1	rs1609810	ENSG00000226752.6	PSMD5-AS1	-7.51	3.18e-13	1.31e-10	-0.4	-0.33	Rheumatoid arthritis;	chr9:120880073	chr9:120824828~120854385:+
PRAD	cis	rs55665837	1	rs10047429	ENSG00000251991.1	RNU7-49P	7.51	3.18e-13	1.31e-10	0.36	0.33	Vitamin D levels;	chr11:14417486	chr11:14478892~14478953:+
PRAD	cis	rs55665837	1	rs10047457	ENSG00000251991.1	RNU7-49P	7.51	3.18e-13	1.31e-10	0.36	0.33	Vitamin D levels;	chr11:14417913	chr11:14478892~14478953:+
PRAD	cis	rs55665837	1	rs12283797	ENSG00000251991.1	RNU7-49P	7.51	3.18e-13	1.31e-10	0.36	0.33	Vitamin D levels;	chr11:14420716	chr11:14478892~14478953:+
PRAD	cis	rs55665837	1	rs10832256	ENSG00000251991.1	RNU7-49P	7.51	3.18e-13	1.31e-10	0.36	0.33	Vitamin D levels;	chr11:14421329	chr11:14478892~14478953:+
PRAD	cis	rs55665837	1	rs10832257	ENSG00000251991.1	RNU7-49P	7.51	3.18e-13	1.31e-10	0.36	0.33	Vitamin D levels;	chr11:14421770	chr11:14478892~14478953:+
PRAD	cis	rs55665837	0.961	rs12795972	ENSG00000251991.1	RNU7-49P	7.51	3.18e-13	1.31e-10	0.36	0.33	Vitamin D levels;	chr11:14422229	chr11:14478892~14478953:+
PRAD	cis	rs55665837	1	rs12287715	ENSG00000251991.1	RNU7-49P	7.51	3.18e-13	1.31e-10	0.36	0.33	Vitamin D levels;	chr11:14423029	chr11:14478892~14478953:+
PRAD	cis	rs55665837	0.922	rs12287212	ENSG00000251991.1	RNU7-49P	7.51	3.18e-13	1.31e-10	0.36	0.33	Vitamin D levels;	chr11:14428315	chr11:14478892~14478953:+
PRAD	cis	rs55665837	1	rs12295723	ENSG00000251991.1	RNU7-49P	7.51	3.18e-13	1.31e-10	0.36	0.33	Vitamin D levels;	chr11:14428655	chr11:14478892~14478953:+
PRAD	cis	rs55665837	1	rs12288873	ENSG00000251991.1	RNU7-49P	7.51	3.18e-13	1.31e-10	0.36	0.33	Vitamin D levels;	chr11:14428919	chr11:14478892~14478953:+
PRAD	cis	rs55665837	1	rs34382046	ENSG00000251991.1	RNU7-49P	7.51	3.18e-13	1.31e-10	0.36	0.33	Vitamin D levels;	chr11:14429772	chr11:14478892~14478953:+
PRAD	cis	rs55665837	1	rs7945167	ENSG00000251991.1	RNU7-49P	7.51	3.18e-13	1.31e-10	0.36	0.33	Vitamin D levels;	chr11:14430274	chr11:14478892~14478953:+
PRAD	cis	rs55665837	0.961	rs60622588	ENSG00000251991.1	RNU7-49P	7.51	3.18e-13	1.31e-10	0.36	0.33	Vitamin D levels;	chr11:14435452	chr11:14478892~14478953:+
PRAD	cis	rs55665837	1	rs11023223	ENSG00000251991.1	RNU7-49P	7.51	3.18e-13	1.31e-10	0.36	0.33	Vitamin D levels;	chr11:14435566	chr11:14478892~14478953:+
PRAD	cis	rs55665837	1	rs11023224	ENSG00000251991.1	RNU7-49P	7.51	3.18e-13	1.31e-10	0.36	0.33	Vitamin D levels;	chr11:14436193	chr11:14478892~14478953:+
PRAD	cis	rs55665837	0.961	rs11023226	ENSG00000251991.1	RNU7-49P	7.51	3.18e-13	1.31e-10	0.36	0.33	Vitamin D levels;	chr11:14437271	chr11:14478892~14478953:+
PRAD	cis	rs55665837	1	rs10832264	ENSG00000251991.1	RNU7-49P	7.51	3.18e-13	1.31e-10	0.36	0.33	Vitamin D levels;	chr11:14438436	chr11:14478892~14478953:+
PRAD	cis	rs55665837	1	rs11023229	ENSG00000251991.1	RNU7-49P	7.51	3.18e-13	1.31e-10	0.36	0.33	Vitamin D levels;	chr11:14439455	chr11:14478892~14478953:+
PRAD	cis	rs55665837	1	rs12276938	ENSG00000251991.1	RNU7-49P	7.51	3.18e-13	1.31e-10	0.36	0.33	Vitamin D levels;	chr11:14441942	chr11:14478892~14478953:+
PRAD	cis	rs55665837	1	rs10832268	ENSG00000251991.1	RNU7-49P	7.51	3.18e-13	1.31e-10	0.36	0.33	Vitamin D levels;	chr11:14443522	chr11:14478892~14478953:+
PRAD	cis	rs55665837	1	rs10832269	ENSG00000251991.1	RNU7-49P	7.51	3.18e-13	1.31e-10	0.36	0.33	Vitamin D levels;	chr11:14443523	chr11:14478892~14478953:+
PRAD	cis	rs55665837	1	rs10832271	ENSG00000251991.1	RNU7-49P	7.51	3.18e-13	1.31e-10	0.36	0.33	Vitamin D levels;	chr11:14445373	chr11:14478892~14478953:+
PRAD	cis	rs55665837	1	rs10832275	ENSG00000251991.1	RNU7-49P	7.51	3.18e-13	1.31e-10	0.36	0.33	Vitamin D levels;	chr11:14456678	chr11:14478892~14478953:+
PRAD	cis	rs1185460	0.565	rs540261	ENSG00000271751.1	RP11-110I1.14	7.51	3.18e-13	1.31e-10	0.45	0.33	Coronary artery disease;	chr11:119076924	chr11:119065263~119065677:-
PRAD	cis	rs13126694	0.778	rs6814979	ENSG00000248429.4	RP11-597D13.9	-7.51	3.19e-13	1.32e-10	-0.33	-0.33	Blood osmolality (transformed sodium);	chr4:158135798	chr4:158170752~158202877:+
PRAD	cis	rs2522056	1	rs2706383	ENSG00000233006.5	AC034220.3	-7.51	3.19e-13	1.32e-10	-0.34	-0.33	Fibrinogen;Lymphocyte counts;	chr5:132456710	chr5:132311285~132369916:-
PRAD	cis	rs12188164	0.965	rs41282625	ENSG00000221990.4	EXOC3-AS1	7.51	3.19e-13	1.32e-10	0.28	0.33	Cystic fibrosis severity;	chr5:475511	chr5:441498~443160:-
PRAD	cis	rs10050311	0.858	rs1985944	ENSG00000251411.1	RP11-397E7.4	-7.51	3.2e-13	1.32e-10	-0.43	-0.33	Insulin-related traits;	chr4:86898130	chr4:86913266~86914817:-
PRAD	cis	rs17428076	0.874	rs12619041	ENSG00000228389.1	AC068039.4	7.51	3.21e-13	1.32e-10	0.43	0.33	Myopia;	chr2:171744206	chr2:171773482~171775844:+
PRAD	cis	rs75422866	0.51	rs73104197	ENSG00000257433.4	RP1-197B17.3	7.51	3.22e-13	1.33e-10	0.7	0.33	Pneumonia;	chr12:47717273	chr12:47706085~47742294:+
PRAD	cis	rs3096299	0.933	rs2965934	ENSG00000261118.1	RP11-104N10.1	7.51	3.22e-13	1.33e-10	0.33	0.33	Multiple myeloma (IgH translocation);	chr16:89414821	chr16:89492017~89504460:-
PRAD	cis	rs10050311	0.79	rs55831707	ENSG00000251411.1	RP11-397E7.4	-7.51	3.22e-13	1.33e-10	-0.43	-0.33	Insulin-related traits;	chr4:86918376	chr4:86913266~86914817:-
PRAD	cis	rs6991838	0.733	rs10111844	ENSG00000200714.1	Y_RNA	7.51	3.22e-13	1.33e-10	0.34	0.33	Intelligence (multi-trait analysis);	chr8:65690374	chr8:65592731~65592820:+
PRAD	cis	rs2243480	1	rs4149468	ENSG00000273142.1	RP11-458F8.4	-7.51	3.23e-13	1.33e-10	-0.37	-0.33	Diabetic kidney disease;	chr7:66360703	chr7:66902857~66906297:+
PRAD	cis	rs67311347	0.544	rs9821440	ENSG00000223797.4	ENTPD3-AS1	7.51	3.24e-13	1.33e-10	0.29	0.33	Renal cell carcinoma;	chr3:40300856	chr3:40313802~40453329:-
PRAD	cis	rs67311347	0.544	rs9868700	ENSG00000223797.4	ENTPD3-AS1	7.51	3.24e-13	1.33e-10	0.29	0.33	Renal cell carcinoma;	chr3:40303917	chr3:40313802~40453329:-
PRAD	cis	rs11098499	0.754	rs17049949	ENSG00000245958.5	RP11-33B1.1	-7.51	3.24e-13	1.34e-10	-0.31	-0.33	Corneal astigmatism;	chr4:119334135	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.865	rs10213221	ENSG00000245958.5	RP11-33B1.1	-7.51	3.24e-13	1.34e-10	-0.31	-0.33	Corneal astigmatism;	chr4:119334771	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.754	rs7689729	ENSG00000245958.5	RP11-33B1.1	-7.51	3.24e-13	1.34e-10	-0.31	-0.33	Corneal astigmatism;	chr4:119335037	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.865	rs3956464	ENSG00000245958.5	RP11-33B1.1	-7.51	3.24e-13	1.34e-10	-0.31	-0.33	Corneal astigmatism;	chr4:119335609	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.619	rs28502463	ENSG00000245958.5	RP11-33B1.1	-7.51	3.24e-13	1.34e-10	-0.31	-0.33	Corneal astigmatism;	chr4:119335868	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.648	rs2002047	ENSG00000245958.5	RP11-33B1.1	-7.51	3.24e-13	1.34e-10	-0.31	-0.33	Corneal astigmatism;	chr4:119336073	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.775	rs2002049	ENSG00000245958.5	RP11-33B1.1	-7.51	3.24e-13	1.34e-10	-0.31	-0.33	Corneal astigmatism;	chr4:119336262	chr4:119454791~119552025:+
PRAD	cis	rs27432	0.608	rs2927619	ENSG00000248734.2	CTD-2260A17.1	7.51	3.24e-13	1.34e-10	0.35	0.33	Psoriasis vulgaris;	chr5:96847014	chr5:96784777~96785999:+
PRAD	cis	rs6001482	0.702	rs5757586	ENSG00000272779.1	LL22NC03-80A10.6	-7.51	3.25e-13	1.34e-10	-0.4	-0.33	Diastolic blood pressure;	chr22:22234458	chr22:22303224~22310401:+
PRAD	cis	rs3096299	0.967	rs11648663	ENSG00000261118.1	RP11-104N10.1	7.51	3.26e-13	1.34e-10	0.32	0.33	Multiple myeloma (IgH translocation);	chr16:89399899	chr16:89492017~89504460:-
PRAD	cis	rs526231	0.543	rs72785717	ENSG00000175749.11	EIF3KP1	7.5	3.27e-13	1.35e-10	0.47	0.33	Primary biliary cholangitis;	chr5:102997401	chr5:103032376~103033031:+
PRAD	cis	rs7396835	0.537	rs10892035	ENSG00000280143.1	AP000892.6	7.5	3.27e-13	1.35e-10	0.33	0.33	Quantitative traits;	chr11:116824222	chr11:117204967~117210292:+
PRAD	cis	rs67311347	0.544	rs13062243	ENSG00000223797.4	ENTPD3-AS1	7.5	3.27e-13	1.35e-10	0.29	0.33	Renal cell carcinoma;	chr3:40295298	chr3:40313802~40453329:-
PRAD	cis	rs67311347	0.544	rs12054197	ENSG00000223797.4	ENTPD3-AS1	7.5	3.27e-13	1.35e-10	0.29	0.33	Renal cell carcinoma;	chr3:40296071	chr3:40313802~40453329:-
PRAD	cis	rs3096299	0.933	rs2965824	ENSG00000261118.1	RP11-104N10.1	7.5	3.28e-13	1.35e-10	0.32	0.33	Multiple myeloma (IgH translocation);	chr16:89388898	chr16:89492017~89504460:-
PRAD	cis	rs17772222	0.682	rs8017689	ENSG00000258983.2	RP11-507K2.2	7.5	3.29e-13	1.35e-10	0.43	0.33	Coronary artery calcification;	chr14:88483442	chr14:88499334~88515502:+
PRAD	cis	rs17772222	0.682	rs28371093	ENSG00000258983.2	RP11-507K2.2	7.5	3.29e-13	1.35e-10	0.43	0.33	Coronary artery calcification;	chr14:88486112	chr14:88499334~88515502:+
PRAD	cis	rs17772222	0.655	rs10150594	ENSG00000258983.2	RP11-507K2.2	7.5	3.29e-13	1.35e-10	0.43	0.33	Coronary artery calcification;	chr14:88489613	chr14:88499334~88515502:+
PRAD	cis	rs9640161	0.702	rs1962004	ENSG00000261305.1	RP4-584D14.7	7.5	3.29e-13	1.35e-10	0.39	0.33	Blood protein levels;Circulating chemerin levels;	chr7:150323292	chr7:150341771~150342607:+
PRAD	cis	rs10129255	1	rs10129319	ENSG00000223648.3	IGHV3-64	7.5	3.29e-13	1.35e-10	0.33	0.33	Kawasaki disease;	chr14:106767996	chr14:106643132~106658258:-
PRAD	cis	rs12612619	0.732	rs3806520	ENSG00000229122.1	AGBL5-IT1	7.5	3.29e-13	1.36e-10	0.34	0.33	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27053334	chr2:27061038~27061815:+
PRAD	cis	rs853679	0.527	rs1997660	ENSG00000280107.1	AL022393.9	-7.5	3.3e-13	1.36e-10	-0.41	-0.33	Depression;	chr6:28301886	chr6:28170845~28172521:+
PRAD	cis	rs6547741	0.967	rs4665999	ENSG00000234072.1	AC074117.10	7.5	3.3e-13	1.36e-10	0.25	0.33	Oral cavity cancer;	chr2:27611577	chr2:27356246~27367622:+
PRAD	cis	rs2688482	0.512	rs3103954	ENSG00000224769.1	AC069213.1	7.5	3.3e-13	1.36e-10	0.54	0.33	Lung disease severity in cystic fibrosis;	chr3:195789759	chr3:195614947~195620233:+
PRAD	cis	rs1075232	1	rs4450360	ENSG00000215302.7	CTD-3092A11.1	-7.5	3.3e-13	1.36e-10	-0.77	-0.33	Survival in colorectal cancer (non-distant metastatic);	chr15:31389827	chr15:30470779~30507623:+
PRAD	cis	rs1075232	1	rs72722847	ENSG00000215302.7	CTD-3092A11.1	-7.5	3.3e-13	1.36e-10	-0.77	-0.33	Survival in colorectal cancer (non-distant metastatic);	chr15:31390143	chr15:30470779~30507623:+
PRAD	cis	rs9467773	1	rs9467783	ENSG00000124549.13	BTN2A3P	7.5	3.3e-13	1.36e-10	0.29	0.33	Intelligence (multi-trait analysis);	chr6:26542666	chr6:26421391~26432383:+
PRAD	cis	rs11098499	0.754	rs12711071	ENSG00000245958.5	RP11-33B1.1	-7.5	3.3e-13	1.36e-10	-0.31	-0.33	Corneal astigmatism;	chr4:119319779	chr4:119454791~119552025:+
PRAD	cis	rs2115630	0.641	rs11073613	ENSG00000275120.1	RP11-182J1.17	-7.5	3.3e-13	1.36e-10	-0.38	-0.33	P wave terminal force;	chr15:84642662	chr15:84599434~84606463:-
PRAD	cis	rs12908161	1	rs60957376	ENSG00000275120.1	RP11-182J1.17	7.5	3.31e-13	1.36e-10	0.43	0.33	Schizophrenia;	chr15:84737561	chr15:84599434~84606463:-
PRAD	cis	rs4845570	1	rs7542898	ENSG00000268288.1	RP11-98D18.16	7.5	3.31e-13	1.37e-10	0.51	0.33	Coronary artery disease;	chr1:151781146	chr1:151766486~151767000:-
PRAD	cis	rs9329221	0.502	rs11777364	ENSG00000261451.1	RP11-981G7.1	7.5	3.32e-13	1.37e-10	0.43	0.33	Neuroticism;	chr8:10431036	chr8:10433672~10438312:+
PRAD	cis	rs733592	0.56	rs2158515	ENSG00000240399.1	RP1-228P16.1	-7.5	3.33e-13	1.37e-10	-0.27	-0.33	Plateletcrit;	chr12:48113885	chr12:48054813~48055591:-
PRAD	cis	rs736801	0.74	rs17622378	ENSG00000233006.5	AC034220.3	7.5	3.33e-13	1.37e-10	0.31	0.33	Mosquito bite size;Breast cancer;	chr5:132442760	chr5:132311285~132369916:-
PRAD	cis	rs10050311	0.858	rs72667703	ENSG00000251411.1	RP11-397E7.4	-7.5	3.34e-13	1.38e-10	-0.43	-0.33	Insulin-related traits;	chr4:86891825	chr4:86913266~86914817:-
PRAD	cis	rs7829975	0.567	rs6601273	ENSG00000253893.2	FAM85B	7.5	3.34e-13	1.38e-10	0.42	0.33	Mood instability;	chr8:8939009	chr8:8167819~8226614:-
PRAD	cis	rs8005677	0.828	rs12589539	ENSG00000257285.4	RP11-298I3.1	7.5	3.34e-13	1.38e-10	0.33	0.33	Cognitive ability (multi-trait analysis);	chr14:22927471	chr14:22929609~22955562:+
PRAD	cis	rs9810089	0.872	rs527888	ENSG00000261758.1	RP11-102M11.2	7.5	3.34e-13	1.38e-10	0.38	0.33	Gestational age at birth (child effect);	chr3:136312516	chr3:136752630~136755780:+
PRAD	cis	rs17772222	0.682	rs3783889	ENSG00000258983.2	RP11-507K2.2	7.5	3.35e-13	1.38e-10	0.43	0.33	Coronary artery calcification;	chr14:88475637	chr14:88499334~88515502:+
PRAD	cis	rs7739264	0.564	rs1155100	ENSG00000228412.5	RP4-625H18.2	7.5	3.35e-13	1.38e-10	0.4	0.33	Endometriosis;	chr6:19804134	chr6:19802164~19804752:-
PRAD	cis	rs4713118	0.513	rs149950	ENSG00000220721.1	OR1F12	7.5	3.35e-13	1.38e-10	0.38	0.33	Parkinson's disease;	chr6:28065261	chr6:28073316~28074233:+
PRAD	cis	rs4713118	0.513	rs149951	ENSG00000220721.1	OR1F12	7.5	3.35e-13	1.38e-10	0.38	0.33	Parkinson's disease;	chr6:28065309	chr6:28073316~28074233:+
PRAD	cis	rs10875746	0.587	rs9788082	ENSG00000240399.1	RP1-228P16.1	-7.5	3.36e-13	1.38e-10	-0.32	-0.33	Longevity (90 years and older);	chr12:48358273	chr12:48054813~48055591:-
PRAD	cis	rs748404	0.723	rs512431	ENSG00000205771.5	CATSPER2P1	7.5	3.36e-13	1.38e-10	0.36	0.33	Lung cancer;	chr15:43249741	chr15:43726918~43747094:-
PRAD	cis	rs2243480	1	rs383402	ENSG00000226824.5	RP4-756H11.3	7.5	3.37e-13	1.39e-10	0.65	0.33	Diabetic kidney disease;	chr7:66121666	chr7:66654538~66669855:+
PRAD	cis	rs11673344	0.528	rs476194	ENSG00000226686.6	LINC01535	7.5	3.37e-13	1.39e-10	0.43	0.33	Obesity-related traits;	chr19:36919831	chr19:37251912~37265535:+
PRAD	cis	rs2243480	1	rs34136756	ENSG00000273142.1	RP11-458F8.4	-7.5	3.38e-13	1.39e-10	-0.36	-0.33	Diabetic kidney disease;	chr7:65916269	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs34933526	ENSG00000273142.1	RP11-458F8.4	-7.5	3.38e-13	1.39e-10	-0.36	-0.33	Diabetic kidney disease;	chr7:65918212	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs6949812	ENSG00000273142.1	RP11-458F8.4	-7.5	3.38e-13	1.39e-10	-0.36	-0.33	Diabetic kidney disease;	chr7:65922114	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs6970243	ENSG00000273142.1	RP11-458F8.4	-7.5	3.38e-13	1.39e-10	-0.36	-0.33	Diabetic kidney disease;	chr7:65923503	chr7:66902857~66906297:+
PRAD	cis	rs2243480	0.708	rs35310401	ENSG00000273142.1	RP11-458F8.4	-7.5	3.38e-13	1.39e-10	-0.36	-0.33	Diabetic kidney disease;	chr7:65925372	chr7:66902857~66906297:+
PRAD	cis	rs2243480	0.901	rs35087093	ENSG00000273142.1	RP11-458F8.4	-7.5	3.38e-13	1.39e-10	-0.36	-0.33	Diabetic kidney disease;	chr7:65940221	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs35046236	ENSG00000273142.1	RP11-458F8.4	-7.5	3.38e-13	1.39e-10	-0.36	-0.33	Diabetic kidney disease;	chr7:65943626	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs36068983	ENSG00000273142.1	RP11-458F8.4	-7.5	3.38e-13	1.39e-10	-0.36	-0.33	Diabetic kidney disease;	chr7:65944004	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs68189316	ENSG00000273142.1	RP11-458F8.4	-7.5	3.38e-13	1.39e-10	-0.36	-0.33	Diabetic kidney disease;	chr7:65944182	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs937108	ENSG00000273142.1	RP11-458F8.4	-7.5	3.38e-13	1.39e-10	-0.36	-0.33	Diabetic kidney disease;	chr7:65963465	chr7:66902857~66906297:+
PRAD	cis	rs2243480	0.711	rs1626926	ENSG00000273142.1	RP11-458F8.4	-7.5	3.38e-13	1.39e-10	-0.36	-0.33	Diabetic kidney disease;	chr7:65970805	chr7:66902857~66906297:+
PRAD	cis	rs2243480	0.831	rs7806717	ENSG00000273142.1	RP11-458F8.4	7.5	3.38e-13	1.39e-10	0.36	0.33	Diabetic kidney disease;	chr7:65928187	chr7:66902857~66906297:+
PRAD	cis	rs17711722	0.565	rs73372653	ENSG00000237310.1	GS1-124K5.4	7.5	3.38e-13	1.39e-10	0.29	0.33	Calcium levels;	chr7:65977808	chr7:66493706~66495474:+
PRAD	cis	rs1134634	0.52	rs11943107	ENSG00000273133.1	RP11-799M12.2	-7.5	3.39e-13	1.4e-10	-0.44	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15573042	chr4:15563698~15564253:-
PRAD	cis	rs638893	0.617	rs4938561	ENSG00000278376.1	RP11-158I9.8	-7.5	3.39e-13	1.4e-10	-0.34	-0.33	Vitiligo;	chr11:118847776	chr11:118791254~118793137:+
PRAD	cis	rs11098499	0.604	rs2389882	ENSG00000245958.5	RP11-33B1.1	-7.5	3.4e-13	1.4e-10	-0.34	-0.33	Corneal astigmatism;	chr4:119645578	chr4:119454791~119552025:+
PRAD	cis	rs6847067	0.965	rs4529041	ENSG00000180769.7	WDFY3-AS2	7.5	3.4e-13	1.4e-10	0.35	0.33	Oropharynx cancer;	chr4:84700259	chr4:84965682~85011277:+
PRAD	cis	rs6547741	1	rs1080060	ENSG00000234072.1	AC074117.10	7.5	3.4e-13	1.4e-10	0.25	0.33	Oral cavity cancer;	chr2:27545941	chr2:27356246~27367622:+
PRAD	cis	rs6547741	1	rs6749052	ENSG00000234072.1	AC074117.10	7.5	3.4e-13	1.4e-10	0.25	0.33	Oral cavity cancer;	chr2:27550012	chr2:27356246~27367622:+
PRAD	cis	rs6547741	1	rs6706610	ENSG00000234072.1	AC074117.10	7.5	3.4e-13	1.4e-10	0.25	0.33	Oral cavity cancer;	chr2:27555224	chr2:27356246~27367622:+
PRAD	cis	rs12742923	0.534	rs323962	ENSG00000236268.4	LINC01361	-7.5	3.4e-13	1.4e-10	-0.44	-0.33	HIV-associated dementia;	chr1:83152534	chr1:82973882~82986208:-
PRAD	cis	rs2638953	0.85	rs61920210	ENSG00000278733.1	RP11-425D17.1	-7.5	3.41e-13	1.4e-10	-0.43	-0.33	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28144951	chr12:28185625~28186190:-
PRAD	cis	rs6782228	1	rs12495411	ENSG00000242551.2	POU5F1P6	7.5	3.41e-13	1.4e-10	0.46	0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128676852	chr3:128674735~128677005:-
PRAD	cis	rs6547741	1	rs10165098	ENSG00000234072.1	AC074117.10	7.5	3.41e-13	1.4e-10	0.25	0.33	Oral cavity cancer;	chr2:27573659	chr2:27356246~27367622:+
PRAD	cis	rs6547741	0.967	rs4665995	ENSG00000234072.1	AC074117.10	7.5	3.41e-13	1.4e-10	0.25	0.33	Oral cavity cancer;	chr2:27590960	chr2:27356246~27367622:+
PRAD	cis	rs6547741	0.967	rs4665996	ENSG00000234072.1	AC074117.10	7.5	3.41e-13	1.4e-10	0.25	0.33	Oral cavity cancer;	chr2:27591476	chr2:27356246~27367622:+
PRAD	cis	rs6547741	1	rs13026621	ENSG00000234072.1	AC074117.10	7.5	3.42e-13	1.41e-10	0.25	0.33	Oral cavity cancer;	chr2:27584757	chr2:27356246~27367622:+
PRAD	cis	rs17428076	0.793	rs56275355	ENSG00000228389.1	AC068039.4	-7.5	3.43e-13	1.41e-10	-0.43	-0.33	Myopia;	chr2:171853670	chr2:171773482~171775844:+
PRAD	cis	rs736801	0.808	rs2522057	ENSG00000233006.5	AC034220.3	7.5	3.43e-13	1.41e-10	0.3	0.33	Mosquito bite size;Breast cancer;	chr5:132466255	chr5:132311285~132369916:-
PRAD	cis	rs1799949	1	rs8077486	ENSG00000267002.1	RP11-242D8.1	7.5	3.43e-13	1.41e-10	0.31	0.33	Menopause (age at onset);	chr17:43060788	chr17:43164183~43170403:-
PRAD	cis	rs858239	0.632	rs1985769	ENSG00000226816.2	AC005082.12	7.5	3.43e-13	1.41e-10	0.37	0.33	Cerebrospinal fluid biomarker levels;	chr7:23082887	chr7:23206013~23208045:+
PRAD	cis	rs858239	0.6	rs28499396	ENSG00000226816.2	AC005082.12	7.5	3.43e-13	1.41e-10	0.37	0.33	Cerebrospinal fluid biomarker levels;	chr7:23084479	chr7:23206013~23208045:+
PRAD	cis	rs858239	0.6	rs7789237	ENSG00000226816.2	AC005082.12	7.5	3.43e-13	1.41e-10	0.37	0.33	Cerebrospinal fluid biomarker levels;	chr7:23085094	chr7:23206013~23208045:+
PRAD	cis	rs6061231	0.63	rs62196294	ENSG00000273619.1	RP5-908M14.9	-7.5	3.43e-13	1.41e-10	-0.21	-0.33	Colorectal cancer;	chr20:62398376	chr20:62386303~62386970:-
PRAD	cis	rs2638953	0.893	rs7969086	ENSG00000278733.1	RP11-425D17.1	7.5	3.44e-13	1.41e-10	0.38	0.33	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28507273	chr12:28185625~28186190:-
PRAD	cis	rs950169	0.579	rs881983	ENSG00000259728.4	LINC00933	7.5	3.46e-13	1.42e-10	0.42	0.33	Schizophrenia;	chr15:83978556	chr15:84570649~84580175:+
PRAD	cis	rs1552244	0.554	rs55847233	ENSG00000206567.8	AC022007.5	-7.5	3.47e-13	1.42e-10	-0.37	-0.33	Alzheimer's disease;	chr3:9949417	chr3:10006418~10011209:-
PRAD	cis	rs6452524	1	rs10080123	ENSG00000249664.1	CTD-2227C6.2	-7.5	3.47e-13	1.43e-10	-0.39	-0.33	Hypertension (SNP x SNP interaction);	chr5:83165447	chr5:83012285~83013109:-
PRAD	cis	rs79349575	0.721	rs2291725	ENSG00000248278.1	SUMO2P17	7.5	3.48e-13	1.43e-10	0.38	0.33	Type 2 diabetes;	chr17:48961770	chr17:48874860~48908983:-
PRAD	cis	rs17361889	0.727	rs17458603	ENSG00000224683.1	RPL36AP29	7.5	3.49e-13	1.43e-10	0.39	0.33	Pediatric bone mineral content (hip);	chr7:16239968	chr7:16208945~16209265:+
PRAD	cis	rs2439831	0.867	rs496584	ENSG00000249839.1	AC011330.5	-7.49	3.49e-13	1.44e-10	-0.57	-0.33	Lung cancer in ever smokers;	chr15:43539725	chr15:43663654~43684339:-
PRAD	cis	rs6479901	0.894	rs10761732	ENSG00000232075.1	MRPL35P2	-7.49	3.5e-13	1.44e-10	-0.41	-0.33	Intelligence (multi-trait analysis);	chr10:63268497	chr10:63634317~63634827:-
PRAD	cis	rs6479901	0.793	rs10761733	ENSG00000232075.1	MRPL35P2	-7.49	3.5e-13	1.44e-10	-0.41	-0.33	Intelligence (multi-trait analysis);	chr10:63275024	chr10:63634317~63634827:-
PRAD	cis	rs9362426	0.608	rs9450682	ENSG00000218793.1	RP3-382I10.3	-7.49	3.5e-13	1.44e-10	-0.43	-0.33	Depressive episodes in bipolar disorder;	chr6:87438084	chr6:87441165~87442146:-
PRAD	cis	rs12908161	1	rs35960805	ENSG00000275120.1	RP11-182J1.17	7.49	3.5e-13	1.44e-10	0.44	0.33	Schizophrenia;	chr15:84800749	chr15:84599434~84606463:-
PRAD	cis	rs12908161	1	rs12912388	ENSG00000275120.1	RP11-182J1.17	7.49	3.5e-13	1.44e-10	0.44	0.33	Schizophrenia;	chr15:84801319	chr15:84599434~84606463:-
PRAD	cis	rs3096299	1	rs3096299	ENSG00000261118.1	RP11-104N10.1	7.49	3.5e-13	1.44e-10	0.33	0.33	Multiple myeloma (IgH translocation);	chr16:89382255	chr16:89492017~89504460:-
PRAD	cis	rs75920871	0.528	rs4388921	ENSG00000254851.1	RP11-109L13.1	7.49	3.51e-13	1.44e-10	0.46	0.33	Subjective well-being;	chr11:117106062	chr11:117135528~117138582:+
PRAD	cis	rs6539288	0.933	rs6539291	ENSG00000260329.1	RP11-412D9.4	-7.49	3.51e-13	1.44e-10	-0.29	-0.33	Total body bone mineral density;	chr12:106916033	chr12:106954029~106955497:-
PRAD	cis	rs673078	0.66	rs17586342	ENSG00000275409.1	RP11-131L12.4	-7.49	3.52e-13	1.44e-10	-0.45	-0.33	Glucose homeostasis traits;	chr12:118162399	chr12:118430147~118430699:+
PRAD	cis	rs881375	0.967	rs1930781	ENSG00000226752.6	PSMD5-AS1	-7.49	3.52e-13	1.45e-10	-0.39	-0.33	Rheumatoid arthritis;	chr9:120925556	chr9:120824828~120854385:+
PRAD	cis	rs881375	0.967	rs2416806	ENSG00000226752.6	PSMD5-AS1	-7.49	3.52e-13	1.45e-10	-0.39	-0.33	Rheumatoid arthritis;	chr9:120928014	chr9:120824828~120854385:+
PRAD	cis	rs881375	0.933	rs7028641	ENSG00000226752.6	PSMD5-AS1	-7.49	3.52e-13	1.45e-10	-0.39	-0.33	Rheumatoid arthritis;	chr9:120928863	chr9:120824828~120854385:+
PRAD	cis	rs1789	0.592	rs1558572	ENSG00000273133.1	RP11-799M12.2	-7.49	3.52e-13	1.45e-10	-0.46	-0.33	Blood protein levels;	chr4:15537121	chr4:15563698~15564253:-
PRAD	cis	rs853679	0.546	rs200490	ENSG00000280107.1	AL022393.9	-7.49	3.52e-13	1.45e-10	-0.59	-0.33	Depression;	chr6:27829157	chr6:28170845~28172521:+
PRAD	cis	rs7829975	0.573	rs7842359	ENSG00000253893.2	FAM85B	7.49	3.52e-13	1.45e-10	0.42	0.33	Mood instability;	chr8:8939568	chr8:8167819~8226614:-
PRAD	cis	rs673078	0.562	rs61944668	ENSG00000275409.1	RP11-131L12.4	-7.49	3.52e-13	1.45e-10	-0.49	-0.33	Glucose homeostasis traits;	chr12:118448446	chr12:118430147~118430699:+
PRAD	cis	rs45509595	0.841	rs200485	ENSG00000280107.1	AL022393.9	-7.49	3.53e-13	1.45e-10	-0.58	-0.33	Breast cancer;	chr6:27807919	chr6:28170845~28172521:+
PRAD	cis	rs2015599	0.623	rs12581107	ENSG00000275476.1	RP11-996F15.4	-7.49	3.53e-13	1.45e-10	-0.37	-0.33	Platelet count;Mean platelet volume;	chr12:29352358	chr12:29277397~29277882:-
PRAD	cis	rs375066	0.935	rs388685	ENSG00000267058.1	RP11-15A1.3	-7.49	3.53e-13	1.45e-10	-0.28	-0.33	Breast cancer;	chr19:43914528	chr19:43891804~43901805:-
PRAD	cis	rs79349575	0.783	rs4793992	ENSG00000248278.1	SUMO2P17	7.49	3.53e-13	1.45e-10	0.37	0.33	Type 2 diabetes;	chr17:48930845	chr17:48874860~48908983:-
PRAD	cis	rs6674176	0.597	rs6671164	ENSG00000237950.1	RP11-7O11.3	7.49	3.54e-13	1.45e-10	0.38	0.33	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43937817	chr1:43944370~43946551:-
PRAD	cis	rs881375	0.967	rs1008381	ENSG00000226752.6	PSMD5-AS1	-7.49	3.54e-13	1.45e-10	-0.4	-0.33	Rheumatoid arthritis;	chr9:120918838	chr9:120824828~120854385:+
PRAD	cis	rs55665837	0.961	rs12576926	ENSG00000251991.1	RNU7-49P	7.49	3.54e-13	1.45e-10	0.36	0.33	Vitamin D levels;	chr11:14458746	chr11:14478892~14478953:+
PRAD	cis	rs34435647	1	rs34435647	ENSG00000226266.5	AC009961.3	-7.49	3.54e-13	1.45e-10	-0.44	-0.33	Neutrophil percentage of white cells;Granulocyte percentage of myeloid white cells;	chr2:159661779	chr2:159670708~159712435:-
PRAD	cis	rs3790515	1	rs3790515	ENSG00000249602.1	RP11-98D18.3	-7.49	3.56e-13	1.46e-10	-0.55	-0.33	Depressive symptoms (SSRI exposure interaction);	chr1:151813896	chr1:151763384~151769501:-
PRAD	cis	rs6547741	1	rs7604798	ENSG00000234072.1	AC074117.10	7.49	3.56e-13	1.46e-10	0.25	0.33	Oral cavity cancer;	chr2:27602073	chr2:27356246~27367622:+
PRAD	cis	rs6547741	1	rs6547734	ENSG00000234072.1	AC074117.10	7.49	3.56e-13	1.46e-10	0.25	0.33	Oral cavity cancer;	chr2:27608123	chr2:27356246~27367622:+
PRAD	cis	rs8062405	0.723	rs113208333	ENSG00000251417.2	RP11-1348G14.4	-7.49	3.57e-13	1.46e-10	-0.38	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28594839	chr16:28802743~28817828:+
PRAD	cis	rs9326248	0.569	rs10892082	ENSG00000280143.1	AP000892.6	7.49	3.57e-13	1.46e-10	0.4	0.33	Blood protein levels;	chr11:117168609	chr11:117204967~117210292:+
PRAD	cis	rs6547741	1	rs1972669	ENSG00000234072.1	AC074117.10	7.49	3.57e-13	1.47e-10	0.25	0.33	Oral cavity cancer;	chr2:27544240	chr2:27356246~27367622:+
PRAD	cis	rs6547741	1	rs6750943	ENSG00000234072.1	AC074117.10	7.49	3.57e-13	1.47e-10	0.25	0.33	Oral cavity cancer;	chr2:27555037	chr2:27356246~27367622:+
PRAD	cis	rs2439831	0.85	rs28524541	ENSG00000249839.1	AC011330.5	-7.49	3.58e-13	1.47e-10	-0.57	-0.33	Lung cancer in ever smokers;	chr15:43832633	chr15:43663654~43684339:-
PRAD	cis	rs7829975	0.714	rs60315134	ENSG00000253893.2	FAM85B	-7.49	3.58e-13	1.47e-10	-0.42	-0.33	Mood instability;	chr8:8813089	chr8:8167819~8226614:-
PRAD	cis	rs10935480	0.935	rs4857414	ENSG00000239445.4	ST3GAL6-AS1	-7.49	3.59e-13	1.47e-10	-0.42	-0.33	Blood protein levels;	chr3:98713715	chr3:98714330~98732651:-
PRAD	cis	rs6547741	1	rs10205364	ENSG00000234072.1	AC074117.10	7.49	3.59e-13	1.47e-10	0.25	0.33	Oral cavity cancer;	chr2:27571366	chr2:27356246~27367622:+
PRAD	cis	rs853679	0.607	rs35030260	ENSG00000225595.2	XXbac-BPG308K3.6	7.49	3.59e-13	1.47e-10	0.73	0.33	Depression;	chr6:28337731	chr6:28859625~28864630:-
PRAD	cis	rs853679	0.607	rs13217619	ENSG00000225595.2	XXbac-BPG308K3.6	7.49	3.59e-13	1.47e-10	0.73	0.33	Depression;	chr6:28338894	chr6:28859625~28864630:-
PRAD	cis	rs673078	0.66	rs61945190	ENSG00000275409.1	RP11-131L12.4	-7.49	3.59e-13	1.47e-10	-0.49	-0.33	Glucose homeostasis traits;	chr12:118231345	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.66	rs7977403	ENSG00000275409.1	RP11-131L12.4	-7.49	3.59e-13	1.47e-10	-0.49	-0.33	Glucose homeostasis traits;	chr12:118233446	chr12:118430147~118430699:+
PRAD	cis	rs11096990	0.656	rs7693837	ENSG00000249207.1	RP11-360F5.1	-7.49	3.61e-13	1.48e-10	-0.35	-0.33	Cognitive function;	chr4:39301481	chr4:39112677~39126818:-
PRAD	cis	rs17772222	0.682	rs2274736	ENSG00000258983.2	RP11-507K2.2	7.49	3.61e-13	1.48e-10	0.43	0.33	Coronary artery calcification;	chr14:88472308	chr14:88499334~88515502:+
PRAD	cis	rs2439831	0.85	rs16977798	ENSG00000205771.5	CATSPER2P1	-7.49	3.61e-13	1.48e-10	-0.52	-0.33	Lung cancer in ever smokers;	chr15:43859750	chr15:43726918~43747094:-
PRAD	cis	rs9640161	0.663	rs1916932	ENSG00000261305.1	RP4-584D14.7	7.49	3.61e-13	1.48e-10	0.37	0.33	Blood protein levels;Circulating chemerin levels;	chr7:150324555	chr7:150341771~150342607:+
PRAD	cis	rs9640161	0.75	rs59211922	ENSG00000261305.1	RP4-584D14.7	7.49	3.61e-13	1.48e-10	0.37	0.33	Blood protein levels;Circulating chemerin levels;	chr7:150326701	chr7:150341771~150342607:+
PRAD	cis	rs9640161	0.711	rs60268791	ENSG00000261305.1	RP4-584D14.7	7.49	3.61e-13	1.48e-10	0.37	0.33	Blood protein levels;Circulating chemerin levels;	chr7:150326711	chr7:150341771~150342607:+
PRAD	cis	rs6479901	0.947	rs10159609	ENSG00000232075.1	MRPL35P2	-7.49	3.61e-13	1.48e-10	-0.4	-0.33	Intelligence (multi-trait analysis);	chr10:63461168	chr10:63634317~63634827:-
PRAD	cis	rs6479901	0.947	rs7915680	ENSG00000232075.1	MRPL35P2	-7.49	3.61e-13	1.48e-10	-0.4	-0.33	Intelligence (multi-trait analysis);	chr10:63484544	chr10:63634317~63634827:-
PRAD	cis	rs6479901	0.947	rs9971294	ENSG00000232075.1	MRPL35P2	-7.49	3.61e-13	1.48e-10	-0.4	-0.33	Intelligence (multi-trait analysis);	chr10:63503108	chr10:63634317~63634827:-
PRAD	cis	rs67311347	0.544	rs1454492	ENSG00000223797.4	ENTPD3-AS1	7.49	3.62e-13	1.48e-10	0.29	0.33	Renal cell carcinoma;	chr3:40311393	chr3:40313802~40453329:-
PRAD	cis	rs10050311	0.858	rs72667705	ENSG00000251411.1	RP11-397E7.4	-7.49	3.62e-13	1.49e-10	-0.41	-0.33	Insulin-related traits;	chr4:86892986	chr4:86913266~86914817:-
PRAD	cis	rs67311347	0.503	rs11719968	ENSG00000223797.4	ENTPD3-AS1	7.49	3.63e-13	1.49e-10	0.31	0.33	Renal cell carcinoma;	chr3:40200109	chr3:40313802~40453329:-
PRAD	cis	rs35264875	0.851	rs72930621	ENSG00000259799.1	RP11-554A11.9	7.49	3.63e-13	1.49e-10	0.44	0.33	Blond vs. brown hair color;	chr11:69099277	chr11:69155910~69159752:+
PRAD	cis	rs11159086	0.729	rs8015872	ENSG00000270000.1	RP3-449M8.9	7.49	3.64e-13	1.49e-10	0.5	0.33	Advanced glycation end-product levels;	chr14:74475529	chr14:74471930~74472360:-
PRAD	cis	rs11159086	0.793	rs10147316	ENSG00000270000.1	RP3-449M8.9	7.49	3.64e-13	1.49e-10	0.5	0.33	Advanced glycation end-product levels;	chr14:74475688	chr14:74471930~74472360:-
PRAD	cis	rs11159086	0.838	rs10147963	ENSG00000270000.1	RP3-449M8.9	7.49	3.64e-13	1.49e-10	0.5	0.33	Advanced glycation end-product levels;	chr14:74476091	chr14:74471930~74472360:-
PRAD	cis	rs11159086	0.793	rs8021664	ENSG00000270000.1	RP3-449M8.9	7.49	3.64e-13	1.49e-10	0.5	0.33	Advanced glycation end-product levels;	chr14:74476592	chr14:74471930~74472360:-
PRAD	cis	rs11159086	0.793	rs1860108	ENSG00000270000.1	RP3-449M8.9	7.49	3.64e-13	1.49e-10	0.5	0.33	Advanced glycation end-product levels;	chr14:74478562	chr14:74471930~74472360:-
PRAD	cis	rs79349575	0.783	rs58591767	ENSG00000248278.1	SUMO2P17	7.49	3.64e-13	1.49e-10	0.38	0.33	Type 2 diabetes;	chr17:48948714	chr17:48874860~48908983:-
PRAD	cis	rs79349575	0.783	rs59270107	ENSG00000248278.1	SUMO2P17	7.49	3.64e-13	1.49e-10	0.38	0.33	Type 2 diabetes;	chr17:48948823	chr17:48874860~48908983:-
PRAD	cis	rs79349575	0.783	rs62078370	ENSG00000248278.1	SUMO2P17	7.49	3.64e-13	1.49e-10	0.38	0.33	Type 2 diabetes;	chr17:48949474	chr17:48874860~48908983:-
PRAD	cis	rs79349575	0.783	rs11079844	ENSG00000248278.1	SUMO2P17	7.49	3.64e-13	1.49e-10	0.38	0.33	Type 2 diabetes;	chr17:48950972	chr17:48874860~48908983:-
PRAD	cis	rs79349575	0.783	rs62078372	ENSG00000248278.1	SUMO2P17	7.49	3.64e-13	1.49e-10	0.38	0.33	Type 2 diabetes;	chr17:48951627	chr17:48874860~48908983:-
PRAD	cis	rs79349575	0.783	rs12602933	ENSG00000248278.1	SUMO2P17	7.49	3.64e-13	1.49e-10	0.38	0.33	Type 2 diabetes;	chr17:48951918	chr17:48874860~48908983:-
PRAD	cis	rs79349575	0.783	rs4794003	ENSG00000248278.1	SUMO2P17	7.49	3.64e-13	1.49e-10	0.38	0.33	Type 2 diabetes;	chr17:48952542	chr17:48874860~48908983:-
PRAD	cis	rs79349575	0.783	rs12602746	ENSG00000248278.1	SUMO2P17	7.49	3.64e-13	1.49e-10	0.38	0.33	Type 2 diabetes;	chr17:48954379	chr17:48874860~48908983:-
PRAD	cis	rs12188164	0.762	rs11745923	ENSG00000221990.4	EXOC3-AS1	7.49	3.65e-13	1.5e-10	0.28	0.33	Cystic fibrosis severity;	chr5:475293	chr5:441498~443160:-
PRAD	cis	rs853679	0.607	rs67998226	ENSG00000280107.1	AL022393.9	-7.49	3.66e-13	1.5e-10	-0.62	-0.33	Depression;	chr6:28270281	chr6:28170845~28172521:+
PRAD	cis	rs2933343	0.533	rs13086121	ENSG00000231305.3	RP11-723O4.2	7.49	3.66e-13	1.5e-10	0.31	0.33	IgG glycosylation;	chr3:128985447	chr3:128861313~128871540:-
PRAD	cis	rs74024059	1	rs2648435	ENSG00000260685.1	RP11-326L17.1	7.49	3.66e-13	1.5e-10	0.95	0.33	Red blood cell count;Hematocrit;	chr15:75927424	chr15:75950464~75951144:-
PRAD	cis	rs4713118	0.513	rs9368547	ENSG00000220721.1	OR1F12	7.49	3.66e-13	1.5e-10	0.38	0.33	Parkinson's disease;	chr6:28060289	chr6:28073316~28074233:+
PRAD	cis	rs4713118	0.513	rs183244	ENSG00000220721.1	OR1F12	7.49	3.66e-13	1.5e-10	0.38	0.33	Parkinson's disease;	chr6:28064060	chr6:28073316~28074233:+
PRAD	cis	rs217727	0.524	rs7483477	ENSG00000226416.1	MRPL23-AS1	-7.49	3.66e-13	1.5e-10	-0.4	-0.33	Breast cancer;	chr11:1899025	chr11:1983237~1989920:-
PRAD	cis	rs17361889	0.698	rs1528136	ENSG00000224683.1	RPL36AP29	-7.49	3.66e-13	1.5e-10	-0.41	-0.33	Pediatric bone mineral content (hip);	chr7:16090018	chr7:16208945~16209265:+
PRAD	cis	rs2255336	0.817	rs7310643	ENSG00000245648.1	RP11-277P12.20	7.49	3.66e-13	1.5e-10	0.52	0.33	Blood protein levels;	chr12:10365501	chr12:10363769~10398506:+
PRAD	cis	rs67311347	0.544	rs2278930	ENSG00000223797.4	ENTPD3-AS1	7.49	3.67e-13	1.5e-10	0.29	0.33	Renal cell carcinoma;	chr3:40309601	chr3:40313802~40453329:-
PRAD	cis	rs673078	0.66	rs11068910	ENSG00000275409.1	RP11-131L12.4	-7.49	3.68e-13	1.51e-10	-0.43	-0.33	Glucose homeostasis traits;	chr12:118336076	chr12:118430147~118430699:+
PRAD	cis	rs2638953	0.962	rs11049539	ENSG00000278733.1	RP11-425D17.1	-7.49	3.68e-13	1.51e-10	-0.42	-0.33	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28335953	chr12:28185625~28186190:-
PRAD	cis	rs11763147	1	rs11763147	ENSG00000237310.1	GS1-124K5.4	-7.49	3.68e-13	1.51e-10	-0.28	-0.33	Corneal structure;	chr7:65861834	chr7:66493706~66495474:+
PRAD	cis	rs6547741	1	rs1919125	ENSG00000234072.1	AC074117.10	7.49	3.69e-13	1.51e-10	0.25	0.33	Oral cavity cancer;	chr2:27578536	chr2:27356246~27367622:+
PRAD	cis	rs6547741	1	rs1919126	ENSG00000234072.1	AC074117.10	7.49	3.69e-13	1.51e-10	0.25	0.33	Oral cavity cancer;	chr2:27578551	chr2:27356246~27367622:+
PRAD	cis	rs5760092	0.618	rs4461358	ENSG00000206090.4	AP000350.7	-7.49	3.7e-13	1.51e-10	-0.47	-0.33	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23917919	chr22:23939998~23942798:+
PRAD	cis	rs736801	0.808	rs4705950	ENSG00000233006.5	AC034220.3	7.49	3.7e-13	1.51e-10	0.31	0.33	Mosquito bite size;Breast cancer;	chr5:132457594	chr5:132311285~132369916:-
PRAD	cis	rs17772222	0.637	rs879932	ENSG00000258983.2	RP11-507K2.2	7.49	3.7e-13	1.52e-10	0.43	0.33	Coronary artery calcification;	chr14:88479247	chr14:88499334~88515502:+
PRAD	cis	rs673078	0.66	rs7974718	ENSG00000275409.1	RP11-131L12.4	-7.49	3.71e-13	1.52e-10	-0.45	-0.33	Glucose homeostasis traits;	chr12:118243258	chr12:118430147~118430699:+
PRAD	cis	rs6782228	0.606	rs2811500	ENSG00000242551.2	POU5F1P6	-7.49	3.71e-13	1.52e-10	-0.41	-0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128647413	chr3:128674735~128677005:-
PRAD	cis	rs780096	0.778	rs780094	ENSG00000234072.1	AC074117.10	7.49	3.72e-13	1.52e-10	0.26	0.33	Total body bone mineral density;	chr2:27518370	chr2:27356246~27367622:+
PRAD	cis	rs79349575	0.783	rs62075838	ENSG00000248278.1	SUMO2P17	7.49	3.72e-13	1.52e-10	0.37	0.33	Type 2 diabetes;	chr17:48919070	chr17:48874860~48908983:-
PRAD	cis	rs79349575	0.783	rs62075839	ENSG00000248278.1	SUMO2P17	7.49	3.72e-13	1.52e-10	0.37	0.33	Type 2 diabetes;	chr17:48919072	chr17:48874860~48908983:-
PRAD	cis	rs5760092	0.755	rs4585126	ENSG00000224205.1	AP000351.4	-7.49	3.73e-13	1.53e-10	-0.45	-0.33	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23987320~23991421:-
PRAD	cis	rs6539288	0.899	rs6539290	ENSG00000260329.1	RP11-412D9.4	-7.48	3.74e-13	1.53e-10	-0.29	-0.33	Total body bone mineral density;	chr12:106915871	chr12:106954029~106955497:-
PRAD	cis	rs494459	0.726	rs1784300	ENSG00000278376.1	RP11-158I9.8	-7.48	3.74e-13	1.53e-10	-0.28	-0.33	Height;	chr11:118808920	chr11:118791254~118793137:+
PRAD	cis	rs858239	0.6	rs6461691	ENSG00000226816.2	AC005082.12	7.48	3.74e-13	1.53e-10	0.38	0.33	Cerebrospinal fluid biomarker levels;	chr7:23099726	chr7:23206013~23208045:+
PRAD	cis	rs2243480	1	rs6460260	ENSG00000226824.5	RP4-756H11.3	7.48	3.75e-13	1.54e-10	0.66	0.33	Diabetic kidney disease;	chr7:65750468	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs6460261	ENSG00000226824.5	RP4-756H11.3	7.48	3.75e-13	1.54e-10	0.66	0.33	Diabetic kidney disease;	chr7:65750593	chr7:66654538~66669855:+
PRAD	cis	rs9362426	0.639	rs5009694	ENSG00000218793.1	RP3-382I10.3	7.48	3.76e-13	1.54e-10	0.42	0.33	Depressive episodes in bipolar disorder;	chr6:87422150	chr6:87441165~87442146:-
PRAD	cis	rs9362426	0.608	rs6912875	ENSG00000218793.1	RP3-382I10.3	7.48	3.76e-13	1.54e-10	0.42	0.33	Depressive episodes in bipolar disorder;	chr6:87423785	chr6:87441165~87442146:-
PRAD	cis	rs10875746	0.669	rs11168496	ENSG00000240399.1	RP1-228P16.1	-7.48	3.78e-13	1.54e-10	-0.3	-0.33	Longevity (90 years and older);	chr12:48257072	chr12:48054813~48055591:-
PRAD	cis	rs2522056	1	rs2522050	ENSG00000233006.5	AC034220.3	-7.48	3.79e-13	1.55e-10	-0.34	-0.33	Fibrinogen;Lymphocyte counts;	chr5:132460917	chr5:132311285~132369916:-
PRAD	cis	rs10875746	0.624	rs10875777	ENSG00000240399.1	RP1-228P16.1	-7.48	3.79e-13	1.55e-10	-0.31	-0.33	Longevity (90 years and older);	chr12:48228288	chr12:48054813~48055591:-
PRAD	cis	rs11098499	0.954	rs1546505	ENSG00000245958.5	RP11-33B1.1	-7.48	3.8e-13	1.55e-10	-0.33	-0.33	Corneal astigmatism;	chr4:119320069	chr4:119454791~119552025:+
PRAD	cis	rs8040855	0.931	rs11855471	ENSG00000259295.5	CSPG4P12	-7.48	3.8e-13	1.55e-10	-0.42	-0.33	Bulimia nervosa;	chr15:85175976	chr15:85191438~85213905:+
PRAD	cis	rs10875746	0.669	rs61941006	ENSG00000240399.1	RP1-228P16.1	-7.48	3.8e-13	1.55e-10	-0.31	-0.33	Longevity (90 years and older);	chr12:48237350	chr12:48054813~48055591:-
PRAD	cis	rs9810089	0.843	rs1279086	ENSG00000261758.1	RP11-102M11.2	7.48	3.8e-13	1.55e-10	0.38	0.33	Gestational age at birth (child effect);	chr3:136319732	chr3:136752630~136755780:+
PRAD	cis	rs10760123	1	rs10760123	ENSG00000226752.6	PSMD5-AS1	-7.48	3.8e-13	1.56e-10	-0.4	-0.33	Allergic disease (asthma, hay fever or eczema);	chr9:120888256	chr9:120824828~120854385:+
PRAD	cis	rs12188164	0.965	rs11743639	ENSG00000221990.4	EXOC3-AS1	7.48	3.81e-13	1.56e-10	0.28	0.33	Cystic fibrosis severity;	chr5:450595	chr5:441498~443160:-
PRAD	cis	rs12188164	0.965	rs11745789	ENSG00000221990.4	EXOC3-AS1	7.48	3.81e-13	1.56e-10	0.28	0.33	Cystic fibrosis severity;	chr5:450662	chr5:441498~443160:-
PRAD	cis	rs12188164	0.965	rs11744539	ENSG00000221990.4	EXOC3-AS1	7.48	3.81e-13	1.56e-10	0.28	0.33	Cystic fibrosis severity;	chr5:451310	chr5:441498~443160:-
PRAD	cis	rs8177376	0.727	rs589442	ENSG00000254905.1	RP11-712L6.7	7.48	3.81e-13	1.56e-10	0.4	0.33	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126328101	chr11:126292922~126294254:-
PRAD	cis	rs10463554	0.963	rs26262	ENSG00000175749.11	EIF3KP1	7.48	3.82e-13	1.56e-10	0.44	0.33	Parkinson's disease;	chr5:103209462	chr5:103032376~103033031:+
PRAD	cis	rs10129255	0.785	rs10150044	ENSG00000223648.3	IGHV3-64	7.48	3.82e-13	1.56e-10	0.32	0.33	Kawasaki disease;	chr14:106775695	chr14:106643132~106658258:-
PRAD	cis	rs6480314	0.636	rs61854797	ENSG00000233590.1	RP11-153K11.3	-7.48	3.83e-13	1.56e-10	-0.57	-0.33	Optic nerve measurement (disc area);	chr10:68245854	chr10:68233251~68242379:-
PRAD	cis	rs858239	0.601	rs764533	ENSG00000226816.2	AC005082.12	7.48	3.83e-13	1.57e-10	0.37	0.33	Cerebrospinal fluid biomarker levels;	chr7:23114256	chr7:23206013~23208045:+
PRAD	cis	rs10463554	0.895	rs3756583	ENSG00000175749.11	EIF3KP1	7.48	3.84e-13	1.57e-10	0.4	0.33	Parkinson's disease;	chr5:102998340	chr5:103032376~103033031:+
PRAD	cis	rs6479901	0.841	rs72837019	ENSG00000232075.1	MRPL35P2	-7.48	3.84e-13	1.57e-10	-0.4	-0.33	Intelligence (multi-trait analysis);	chr10:63427258	chr10:63634317~63634827:-
PRAD	cis	rs6479901	0.947	rs10761764	ENSG00000232075.1	MRPL35P2	-7.48	3.84e-13	1.57e-10	-0.4	-0.33	Intelligence (multi-trait analysis);	chr10:63429143	chr10:63634317~63634827:-
PRAD	cis	rs6479901	0.846	rs7917169	ENSG00000232075.1	MRPL35P2	-7.48	3.84e-13	1.57e-10	-0.4	-0.33	Intelligence (multi-trait analysis);	chr10:63433181	chr10:63634317~63634827:-
PRAD	cis	rs6479901	0.895	rs10822172	ENSG00000232075.1	MRPL35P2	-7.48	3.84e-13	1.57e-10	-0.4	-0.33	Intelligence (multi-trait analysis);	chr10:63455478	chr10:63634317~63634827:-
PRAD	cis	rs79349575	0.783	rs56046215	ENSG00000248278.1	SUMO2P17	7.48	3.85e-13	1.57e-10	0.37	0.33	Type 2 diabetes;	chr17:48931395	chr17:48874860~48908983:-
PRAD	cis	rs995000	0.931	rs1168036	ENSG00000235545.1	RP11-230B22.1	-7.48	3.85e-13	1.57e-10	-0.44	-0.33	Triglyceride levels;	chr1:62497063	chr1:62688482~62710694:+
PRAD	cis	rs995000	0.899	rs1168027	ENSG00000235545.1	RP11-230B22.1	-7.48	3.85e-13	1.57e-10	-0.44	-0.33	Triglyceride levels;	chr1:62504513	chr1:62688482~62710694:+
PRAD	cis	rs995000	0.931	rs1168042	ENSG00000235545.1	RP11-230B22.1	-7.48	3.85e-13	1.57e-10	-0.44	-0.33	Triglyceride levels;	chr1:62508479	chr1:62688482~62710694:+
PRAD	cis	rs6547741	1	rs2384654	ENSG00000234072.1	AC074117.10	7.48	3.85e-13	1.57e-10	0.24	0.33	Oral cavity cancer;	chr2:27624497	chr2:27356246~27367622:+
PRAD	cis	rs11098499	0.698	rs4422403	ENSG00000245958.5	RP11-33B1.1	-7.48	3.86e-13	1.58e-10	-0.3	-0.33	Corneal astigmatism;	chr4:119337039	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.569	rs10023641	ENSG00000245958.5	RP11-33B1.1	-7.48	3.86e-13	1.58e-10	-0.3	-0.33	Corneal astigmatism;	chr4:119337255	chr4:119454791~119552025:+
PRAD	cis	rs9341835	0.642	rs1723535	ENSG00000218048.2	RP3-407E4.4	7.48	3.86e-13	1.58e-10	0.37	0.33	Schizophrenia;	chr6:63426981	chr6:63440766~63443580:+
PRAD	cis	rs10129255	0.5	rs10131875	ENSG00000211972.2	IGHV3-66	7.48	3.87e-13	1.58e-10	0.29	0.33	Kawasaki disease;	chr14:106792798	chr14:106675017~106675544:-
PRAD	cis	rs6921919	0.515	rs1558205	ENSG00000204709.4	LINC01556	-7.48	3.88e-13	1.58e-10	-0.42	-0.33	Autism spectrum disorder or schizophrenia;	chr6:28414485	chr6:28943877~28944537:+
PRAD	cis	rs11098499	0.955	rs35197422	ENSG00000245958.5	RP11-33B1.1	-7.48	3.9e-13	1.59e-10	-0.32	-0.33	Corneal astigmatism;	chr4:119248159	chr4:119454791~119552025:+
PRAD	cis	rs3096299	0.874	rs3102342	ENSG00000261118.1	RP11-104N10.1	7.48	3.9e-13	1.59e-10	0.33	0.33	Multiple myeloma (IgH translocation);	chr16:89385167	chr16:89492017~89504460:-
PRAD	cis	rs10129255	0.957	rs12590667	ENSG00000223648.3	IGHV3-64	-7.48	3.9e-13	1.59e-10	-0.32	-0.33	Kawasaki disease;	chr14:106779223	chr14:106643132~106658258:-
PRAD	cis	rs42648	0.508	rs39201	ENSG00000227646.6	STEAP2-AS1	7.48	3.9e-13	1.59e-10	0.3	0.33	Homocysteine levels;	chr7:90104790	chr7:89882353~90211635:-
PRAD	cis	rs897984	0.647	rs8060857	ENSG00000279196.1	RP11-1072A3.3	-7.48	3.9e-13	1.59e-10	-0.36	-0.33	Dementia with Lewy bodies;	chr16:30991399	chr16:30984630~30988270:-
PRAD	cis	rs79349575	0.749	rs1057902	ENSG00000248278.1	SUMO2P17	7.48	3.91e-13	1.59e-10	0.38	0.33	Type 2 diabetes;	chr17:48928226	chr17:48874860~48908983:-
PRAD	cis	rs496547	0.719	rs1790189	ENSG00000255239.1	AP002954.6	7.48	3.91e-13	1.59e-10	0.44	0.33	Hip minimal joint space width;	chr11:118781617	chr11:118688039~118690600:-
PRAD	cis	rs812925	0.502	rs778150	ENSG00000271889.1	RP11-493E12.1	-7.48	3.91e-13	1.6e-10	-0.36	-0.33	Immature fraction of reticulocytes;	chr2:61381237	chr2:61151433~61162105:-
PRAD	cis	rs6452524	0.868	rs17205699	ENSG00000249664.1	CTD-2227C6.2	7.48	3.92e-13	1.6e-10	0.4	0.33	Hypertension (SNP x SNP interaction);	chr5:83098479	chr5:83012285~83013109:-
PRAD	cis	rs17772222	0.682	rs7142053	ENSG00000258983.2	RP11-507K2.2	7.48	3.94e-13	1.61e-10	0.43	0.33	Coronary artery calcification;	chr14:88511594	chr14:88499334~88515502:+
PRAD	cis	rs4927850	1	rs10881563	ENSG00000231464.1	AC024937.4	7.48	3.94e-13	1.61e-10	0.4	0.33	Pancreatic cancer;	chr3:196023354	chr3:195996738~195998233:+
PRAD	cis	rs858239	0.601	rs11984129	ENSG00000226816.2	AC005082.12	7.48	3.95e-13	1.61e-10	0.37	0.33	Cerebrospinal fluid biomarker levels;	chr7:23113058	chr7:23206013~23208045:+
PRAD	cis	rs2278034	0.502	rs3747672	ENSG00000273009.1	RP11-352G9.1	7.48	3.95e-13	1.61e-10	0.3	0.33	Bronchopulmonary dysplasia;	chr3:195885163	chr3:195913078~195913683:-
PRAD	cis	rs12468226	0.938	rs6435139	ENSG00000273456.1	RP11-686O6.2	-7.48	3.95e-13	1.61e-10	-0.44	-0.33	Urate levels;	chr2:202255145	chr2:202374932~202375604:-
PRAD	cis	rs11096990	0.634	rs60016848	ENSG00000249207.1	RP11-360F5.1	7.48	3.95e-13	1.61e-10	0.35	0.33	Cognitive function;	chr4:39281436	chr4:39112677~39126818:-
PRAD	cis	rs11096990	0.577	rs6830736	ENSG00000249207.1	RP11-360F5.1	7.48	3.95e-13	1.61e-10	0.35	0.33	Cognitive function;	chr4:39281467	chr4:39112677~39126818:-
PRAD	cis	rs11096990	0.634	rs6854358	ENSG00000249207.1	RP11-360F5.1	7.48	3.95e-13	1.61e-10	0.35	0.33	Cognitive function;	chr4:39281492	chr4:39112677~39126818:-
PRAD	cis	rs12612619	0.704	rs3769139	ENSG00000229122.1	AGBL5-IT1	7.48	3.95e-13	1.61e-10	0.34	0.33	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27092846	chr2:27061038~27061815:+
PRAD	cis	rs12612619	0.695	rs4665935	ENSG00000229122.1	AGBL5-IT1	-7.48	3.97e-13	1.62e-10	-0.34	-0.33	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27007024	chr2:27061038~27061815:+
PRAD	cis	rs9532669	0.819	rs9532652	ENSG00000168852.11	TPTE2P5	7.48	3.98e-13	1.62e-10	0.34	0.33	Cervical cancer;	chr13:40903300	chr13:40822296~40921749:-
PRAD	cis	rs7826238	0.566	rs2945886	ENSG00000253893.2	FAM85B	-7.48	3.99e-13	1.63e-10	-0.41	-0.33	Systolic blood pressure;	chr8:8290748	chr8:8167819~8226614:-
PRAD	cis	rs995000	0.868	rs1168102	ENSG00000235545.1	RP11-230B22.1	-7.48	3.99e-13	1.63e-10	-0.44	-0.33	Triglyceride levels;	chr1:62662034	chr1:62688482~62710694:+
PRAD	cis	rs995000	0.931	rs2479464	ENSG00000235545.1	RP11-230B22.1	-7.48	3.99e-13	1.63e-10	-0.44	-0.33	Triglyceride levels;	chr1:62665320	chr1:62688482~62710694:+
PRAD	cis	rs995000	0.931	rs1168132	ENSG00000235545.1	RP11-230B22.1	-7.48	3.99e-13	1.63e-10	-0.44	-0.33	Triglyceride levels;	chr1:62667797	chr1:62688482~62710694:+
PRAD	cis	rs4460629	0.901	rs4745	ENSG00000160766.13	GBAP1	7.48	3.99e-13	1.63e-10	0.34	0.33	Serum magnesium levels;	chr1:155133751	chr1:155213821~155227422:-
PRAD	cis	rs4845570	0.85	rs4618976	ENSG00000268288.1	RP11-98D18.16	-7.47	4.01e-13	1.63e-10	-0.51	-0.33	Coronary artery disease;	chr1:151794112	chr1:151766486~151767000:-
PRAD	cis	rs17772222	0.74	rs10138002	ENSG00000258983.2	RP11-507K2.2	-7.47	4.01e-13	1.64e-10	-0.44	-0.33	Coronary artery calcification;	chr14:88510071	chr14:88499334~88515502:+
PRAD	cis	rs2739330	0.76	rs5751760	ENSG00000228039.3	KB-1125A3.10	7.47	4.02e-13	1.64e-10	0.43	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23963780~23964374:+
PRAD	cis	rs7727544	0.647	rs7721882	ENSG00000233006.5	AC034220.3	7.47	4.02e-13	1.64e-10	0.3	0.33	Blood metabolite levels;	chr5:132083255	chr5:132311285~132369916:-
PRAD	cis	rs4664293	0.867	rs7579206	ENSG00000226266.5	AC009961.3	-7.47	4.03e-13	1.64e-10	-0.44	-0.33	Monocyte percentage of white cells;	chr2:159715992	chr2:159670708~159712435:-
PRAD	cis	rs2439831	0.867	rs2614811	ENSG00000249839.1	AC011330.5	-7.47	4.03e-13	1.64e-10	-0.59	-0.33	Lung cancer in ever smokers;	chr15:43621289	chr15:43663654~43684339:-
PRAD	cis	rs75422866	0.867	rs73104163	ENSG00000280054.1	RP1-197B17.7	7.47	4.03e-13	1.64e-10	0.83	0.33	Pneumonia;	chr12:47706187	chr12:47728151~47730598:-
PRAD	cis	rs75422866	1	rs12423045	ENSG00000280054.1	RP1-197B17.7	7.47	4.03e-13	1.64e-10	0.83	0.33	Pneumonia;	chr12:47706275	chr12:47728151~47730598:-
PRAD	cis	rs9640161	0.75	rs11769348	ENSG00000261305.1	RP4-584D14.7	-7.47	4.04e-13	1.65e-10	-0.37	-0.33	Blood protein levels;Circulating chemerin levels;	chr7:150329664	chr7:150341771~150342607:+
PRAD	cis	rs858239	0.539	rs10254544	ENSG00000226816.2	AC005082.12	7.47	4.04e-13	1.65e-10	0.39	0.33	Cerebrospinal fluid biomarker levels;	chr7:23180616	chr7:23206013~23208045:+
PRAD	cis	rs17012589	0.502	rs1877481	ENSG00000258815.1	RP11-408B11.2	-7.47	4.05e-13	1.65e-10	-0.45	-0.33	Bone mineral density (Ward's triangle area);	chr12:85352383	chr12:85318060~85342912:+
PRAD	cis	rs995000	0.931	rs1168098	ENSG00000235545.1	RP11-230B22.1	-7.47	4.05e-13	1.65e-10	-0.44	-0.33	Triglyceride levels;	chr1:62655623	chr1:62688482~62710694:+
PRAD	cis	rs995000	0.899	rs1168099	ENSG00000235545.1	RP11-230B22.1	-7.47	4.05e-13	1.65e-10	-0.44	-0.33	Triglyceride levels;	chr1:62657188	chr1:62688482~62710694:+
PRAD	cis	rs673078	0.517	rs73205578	ENSG00000275409.1	RP11-131L12.4	-7.47	4.05e-13	1.65e-10	-0.49	-0.33	Glucose homeostasis traits;	chr12:118385113	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.66	rs73205579	ENSG00000275409.1	RP11-131L12.4	-7.47	4.05e-13	1.65e-10	-0.49	-0.33	Glucose homeostasis traits;	chr12:118385125	chr12:118430147~118430699:+
PRAD	cis	rs9595066	0.627	rs4432167	ENSG00000227258.4	SMIM2-AS1	-7.47	4.05e-13	1.65e-10	-0.53	-0.33	Schizophrenia;	chr13:44178225	chr13:44110451~44240517:+
PRAD	cis	rs10129255	0.5	rs11628999	ENSG00000211972.2	IGHV3-66	7.47	4.06e-13	1.65e-10	0.29	0.33	Kawasaki disease;	chr14:106800208	chr14:106675017~106675544:-
PRAD	cis	rs7727544	0.564	rs3852206	ENSG00000233006.5	AC034220.3	7.47	4.06e-13	1.66e-10	0.3	0.33	Blood metabolite levels;	chr5:132079743	chr5:132311285~132369916:-
PRAD	cis	rs2439831	0.85	rs28524541	ENSG00000205771.5	CATSPER2P1	-7.47	4.07e-13	1.66e-10	-0.51	-0.33	Lung cancer in ever smokers;	chr15:43832633	chr15:43726918~43747094:-
PRAD	cis	rs67311347	0.544	rs35112505	ENSG00000223797.4	ENTPD3-AS1	7.47	4.07e-13	1.66e-10	0.29	0.33	Renal cell carcinoma;	chr3:40295584	chr3:40313802~40453329:-
PRAD	cis	rs67311347	0.544	rs67533651	ENSG00000223797.4	ENTPD3-AS1	7.47	4.07e-13	1.66e-10	0.29	0.33	Renal cell carcinoma;	chr3:40296876	chr3:40313802~40453329:-
PRAD	cis	rs12701220	0.503	rs12531999	ENSG00000229043.2	AC091729.9	-7.47	4.07e-13	1.66e-10	-0.5	-0.33	Bronchopulmonary dysplasia;	chr7:1141965	chr7:1160374~1165267:+
PRAD	cis	rs2299587	0.527	rs7843715	ENSG00000253671.1	RP11-806O11.1	-7.47	4.07e-13	1.66e-10	-0.32	-0.33	Economic and political preferences;	chr8:17876017	chr8:17808941~17820868:+
PRAD	cis	rs2274273	0.624	rs66464079	ENSG00000258413.1	RP11-665C16.6	-7.47	4.08e-13	1.66e-10	-0.45	-0.33	Protein biomarker;	chr14:55299446	chr14:55262767~55272075:-
PRAD	cis	rs11951515	0.663	rs4866741	ENSG00000188850.9	RP11-159F24.2	7.47	4.09e-13	1.66e-10	0.41	0.33	Metabolite levels  (X-11787);	chr5:43369791	chr5:43336164~43348716:+
PRAD	cis	rs6480314	0.542	rs7078967	ENSG00000233590.1	RP11-153K11.3	-7.47	4.09e-13	1.67e-10	-0.54	-0.33	Optic nerve measurement (disc area);	chr10:68266564	chr10:68233251~68242379:-
PRAD	cis	rs2404602	0.536	rs11072599	ENSG00000259422.1	RP11-593F23.1	7.47	4.1e-13	1.67e-10	0.4	0.33	Blood metabolite levels;	chr15:76482167	chr15:76174891~76181486:-
PRAD	cis	rs42648	0.869	rs1015402	ENSG00000227646.6	STEAP2-AS1	-7.47	4.1e-13	1.67e-10	-0.3	-0.33	Homocysteine levels;	chr7:90283955	chr7:89882353~90211635:-
PRAD	cis	rs67311347	0.568	rs9864544	ENSG00000223797.4	ENTPD3-AS1	7.47	4.12e-13	1.68e-10	0.29	0.33	Renal cell carcinoma;	chr3:40294713	chr3:40313802~40453329:-
PRAD	cis	rs375066	0.935	rs421512	ENSG00000267058.1	RP11-15A1.3	-7.47	4.13e-13	1.68e-10	-0.28	-0.33	Breast cancer;	chr19:43911428	chr19:43891804~43901805:-
PRAD	cis	rs2836950	0.509	rs11088466	ENSG00000255568.3	BRWD1-AS2	-7.47	4.14e-13	1.68e-10	-0.27	-0.33	Menarche (age at onset);	chr21:39208091	chr21:39313935~39314962:+
PRAD	cis	rs17772222	0.839	rs2274735	ENSG00000258983.2	RP11-507K2.2	7.47	4.14e-13	1.68e-10	0.43	0.33	Coronary artery calcification;	chr14:88505414	chr14:88499334~88515502:+
PRAD	cis	rs494459	0.756	rs570806	ENSG00000278376.1	RP11-158I9.8	-7.47	4.14e-13	1.69e-10	-0.28	-0.33	Height;	chr11:118786602	chr11:118791254~118793137:+
PRAD	cis	rs995000	0.931	rs1168097	ENSG00000235545.1	RP11-230B22.1	-7.47	4.15e-13	1.69e-10	-0.44	-0.33	Triglyceride levels;	chr1:62654700	chr1:62688482~62710694:+
PRAD	cis	rs9315786	0.924	rs7323436	ENSG00000176268.5	CYCSP34	-7.47	4.16e-13	1.69e-10	-0.35	-0.33	Neutrophil percentage of granulocytes;	chr13:40776843	chr13:40863599~40863902:-
PRAD	cis	rs11098499	0.913	rs11098496	ENSG00000245958.5	RP11-33B1.1	-7.47	4.17e-13	1.7e-10	-0.32	-0.33	Corneal astigmatism;	chr4:119246311	chr4:119454791~119552025:+
PRAD	cis	rs73186030	0.687	rs55636509	ENSG00000272758.4	RP11-299J3.8	7.47	4.18e-13	1.7e-10	0.49	0.33	Serum parathyroid hormone levels;	chr3:122351816	chr3:122416207~122443180:+
PRAD	cis	rs858239	0.6	rs10235786	ENSG00000226816.2	AC005082.12	7.47	4.18e-13	1.7e-10	0.37	0.33	Cerebrospinal fluid biomarker levels;	chr7:23100321	chr7:23206013~23208045:+
PRAD	cis	rs11976180	1	rs13226728	ENSG00000273234.1	OR2A13P	-7.47	4.18e-13	1.7e-10	-0.39	-0.33	Obesity-related traits;	chr7:144049485	chr7:144142009~144142938:+
PRAD	cis	rs2638953	0.924	rs12369144	ENSG00000278733.1	RP11-425D17.1	-7.47	4.18e-13	1.7e-10	-0.42	-0.33	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28341109	chr12:28185625~28186190:-
PRAD	cis	rs9467773	1	rs6922824	ENSG00000124549.13	BTN2A3P	-7.47	4.2e-13	1.71e-10	-0.29	-0.33	Intelligence (multi-trait analysis);	chr6:26553587	chr6:26421391~26432383:+
PRAD	cis	rs1552244	0.554	rs9878047	ENSG00000206567.8	AC022007.5	-7.47	4.23e-13	1.72e-10	-0.37	-0.33	Alzheimer's disease;	chr3:9943773	chr3:10006418~10011209:-
PRAD	cis	rs950169	0.512	rs4374136	ENSG00000259728.4	LINC00933	7.47	4.24e-13	1.72e-10	0.42	0.33	Schizophrenia;	chr15:83976255	chr15:84570649~84580175:+
PRAD	cis	rs9810089	0.843	rs518972	ENSG00000261758.1	RP11-102M11.2	7.47	4.26e-13	1.73e-10	0.38	0.33	Gestational age at birth (child effect);	chr3:136320426	chr3:136752630~136755780:+
PRAD	cis	rs2638953	0.962	rs11049621	ENSG00000278733.1	RP11-425D17.1	-7.47	4.26e-13	1.73e-10	-0.39	-0.33	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28456074	chr12:28185625~28186190:-
PRAD	cis	rs7829975	0.714	rs4840362	ENSG00000253893.2	FAM85B	7.47	4.26e-13	1.73e-10	0.41	0.33	Mood instability;	chr8:8812572	chr8:8167819~8226614:-
PRAD	cis	rs780096	0.56	rs4665972	ENSG00000234072.1	AC074117.10	-7.47	4.27e-13	1.74e-10	-0.26	-0.33	Total body bone mineral density;	chr2:27375230	chr2:27356246~27367622:+
PRAD	cis	rs853679	0.567	rs7740429	ENSG00000216901.1	AL022393.7	7.47	4.28e-13	1.74e-10	0.46	0.33	Depression;	chr6:28431469	chr6:28176188~28176674:+
PRAD	cis	rs2404602	0.655	rs34748201	ENSG00000259422.1	RP11-593F23.1	7.46	4.28e-13	1.74e-10	0.42	0.33	Blood metabolite levels;	chr15:76929189	chr15:76174891~76181486:-
PRAD	cis	rs7121800	0.888	rs34344304	ENSG00000242353.1	RP4-710M3.1	-7.46	4.28e-13	1.74e-10	-0.34	-0.33	Pit-and-Fissure caries;	chr11:30491046	chr11:30368148~30368646:+
PRAD	cis	rs10895987	0.531	rs2282498	ENSG00000254614.2	AP003068.23	7.46	4.28e-13	1.74e-10	0.44	0.33	Blood protein levels;	chr11:65088514	chr11:65177606~65181834:-
PRAD	cis	rs673078	0.66	rs61945176	ENSG00000275409.1	RP11-131L12.4	-7.46	4.29e-13	1.74e-10	-0.45	-0.33	Glucose homeostasis traits;	chr12:118204735	chr12:118430147~118430699:+
PRAD	cis	rs6674176	0.561	rs12127226	ENSG00000237950.1	RP11-7O11.3	7.46	4.29e-13	1.74e-10	0.37	0.33	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43929637	chr1:43944370~43946551:-
PRAD	cis	rs2041895	0.565	rs10861679	ENSG00000260329.1	RP11-412D9.4	-7.46	4.29e-13	1.74e-10	-0.32	-0.33	Glaucoma (low intraocular pressure);	chr12:106929137	chr12:106954029~106955497:-
PRAD	cis	rs9532669	0.889	rs7320344	ENSG00000168852.11	TPTE2P5	7.46	4.3e-13	1.75e-10	0.34	0.33	Cervical cancer;	chr13:40885502	chr13:40822296~40921749:-
PRAD	cis	rs72615157	0.664	rs6953580	ENSG00000242294.5	STAG3L5P	7.46	4.3e-13	1.75e-10	0.21	0.33	Lung function (FEV1/FVC);	chr7:100227652	chr7:100336079~100351900:+
PRAD	cis	rs2243480	1	rs78803505	ENSG00000273142.1	RP11-458F8.4	-7.46	4.31e-13	1.75e-10	-0.36	-0.33	Diabetic kidney disease;	chr7:65917585	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs34577383	ENSG00000273142.1	RP11-458F8.4	-7.46	4.31e-13	1.75e-10	-0.36	-0.33	Diabetic kidney disease;	chr7:65920739	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs55895244	ENSG00000273142.1	RP11-458F8.4	-7.46	4.31e-13	1.75e-10	-0.36	-0.33	Diabetic kidney disease;	chr7:65922691	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs7795242	ENSG00000273142.1	RP11-458F8.4	-7.46	4.31e-13	1.75e-10	-0.36	-0.33	Diabetic kidney disease;	chr7:65925107	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs2177703	ENSG00000273142.1	RP11-458F8.4	-7.46	4.31e-13	1.75e-10	-0.36	-0.33	Diabetic kidney disease;	chr7:65926730	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs35432774	ENSG00000273142.1	RP11-458F8.4	-7.46	4.31e-13	1.75e-10	-0.36	-0.33	Diabetic kidney disease;	chr7:65928032	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs56985706	ENSG00000273142.1	RP11-458F8.4	-7.46	4.31e-13	1.75e-10	-0.36	-0.33	Diabetic kidney disease;	chr7:65929575	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs60683927	ENSG00000273142.1	RP11-458F8.4	-7.46	4.31e-13	1.75e-10	-0.36	-0.33	Diabetic kidney disease;	chr7:65929781	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs58062456	ENSG00000273142.1	RP11-458F8.4	-7.46	4.31e-13	1.75e-10	-0.36	-0.33	Diabetic kidney disease;	chr7:65929865	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs34529418	ENSG00000273142.1	RP11-458F8.4	-7.46	4.31e-13	1.75e-10	-0.36	-0.33	Diabetic kidney disease;	chr7:65938222	chr7:66902857~66906297:+
PRAD	cis	rs2243480	0.803	rs34804747	ENSG00000273142.1	RP11-458F8.4	-7.46	4.31e-13	1.75e-10	-0.36	-0.33	Diabetic kidney disease;	chr7:65947955	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs11538349	ENSG00000273142.1	RP11-458F8.4	-7.46	4.31e-13	1.75e-10	-0.36	-0.33	Diabetic kidney disease;	chr7:65956884	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs35542501	ENSG00000273142.1	RP11-458F8.4	-7.46	4.31e-13	1.75e-10	-0.36	-0.33	Diabetic kidney disease;	chr7:65966228	chr7:66902857~66906297:+
PRAD	cis	rs2255336	0.578	rs7965744	ENSG00000245648.1	RP11-277P12.20	-7.46	4.31e-13	1.75e-10	-0.48	-0.33	Blood protein levels;	chr12:10367580	chr12:10363769~10398506:+
PRAD	cis	rs2067615	0.542	rs10861654	ENSG00000260329.1	RP11-412D9.4	-7.46	4.31e-13	1.75e-10	-0.28	-0.33	Heart rate;	chr12:106729118	chr12:106954029~106955497:-
PRAD	cis	rs6001482	0.647	rs8140302	ENSG00000272779.1	LL22NC03-80A10.6	-7.46	4.31e-13	1.75e-10	-0.4	-0.33	Diastolic blood pressure;	chr22:22234843	chr22:22303224~22310401:+
PRAD	cis	rs2439831	0.717	rs28495368	ENSG00000249839.1	AC011330.5	-7.46	4.32e-13	1.75e-10	-0.58	-0.33	Lung cancer in ever smokers;	chr15:43603444	chr15:43663654~43684339:-
PRAD	cis	rs8062405	0.69	rs4787458	ENSG00000251417.2	RP11-1348G14.4	-7.46	4.33e-13	1.76e-10	-0.39	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28519966	chr16:28802743~28817828:+
PRAD	cis	rs673078	0.571	rs7963464	ENSG00000275409.1	RP11-131L12.4	-7.46	4.33e-13	1.76e-10	-0.45	-0.33	Glucose homeostasis traits;	chr12:118264924	chr12:118430147~118430699:+
PRAD	cis	rs7829975	0.606	rs6422352	ENSG00000253893.2	FAM85B	7.46	4.34e-13	1.76e-10	0.41	0.33	Mood instability;	chr8:8936683	chr8:8167819~8226614:-
PRAD	cis	rs7829975	0.606	rs891570	ENSG00000253893.2	FAM85B	7.46	4.34e-13	1.76e-10	0.41	0.33	Mood instability;	chr8:8936944	chr8:8167819~8226614:-
PRAD	cis	rs4631830	0.72	rs2611475	ENSG00000230869.1	CTGLF10P	-7.46	4.34e-13	1.76e-10	-0.41	-0.33	Prostate-specific antigen levels;	chr10:46092644	chr10:45678692~45700532:+
PRAD	cis	rs74024059	1	rs335717	ENSG00000260685.1	RP11-326L17.1	-7.46	4.34e-13	1.76e-10	-0.9	-0.33	Red blood cell count;Hematocrit;	chr15:75889181	chr15:75950464~75951144:-
PRAD	cis	rs2638953	0.962	rs11049541	ENSG00000278733.1	RP11-425D17.1	-7.46	4.35e-13	1.77e-10	-0.42	-0.33	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28341781	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.889	rs11049543	ENSG00000278733.1	RP11-425D17.1	-7.46	4.35e-13	1.77e-10	-0.42	-0.33	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28342124	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.962	rs11049544	ENSG00000278733.1	RP11-425D17.1	-7.46	4.35e-13	1.77e-10	-0.42	-0.33	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28342348	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.889	rs10843157	ENSG00000278733.1	RP11-425D17.1	-7.46	4.35e-13	1.77e-10	-0.42	-0.33	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28346417	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.962	rs11049548	ENSG00000278733.1	RP11-425D17.1	-7.46	4.35e-13	1.77e-10	-0.42	-0.33	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28350789	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.962	rs10843159	ENSG00000278733.1	RP11-425D17.1	-7.46	4.35e-13	1.77e-10	-0.42	-0.33	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28354597	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.962	rs11049558	ENSG00000278733.1	RP11-425D17.1	-7.46	4.35e-13	1.77e-10	-0.42	-0.33	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28371438	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.925	rs11049563	ENSG00000278733.1	RP11-425D17.1	-7.46	4.35e-13	1.77e-10	-0.42	-0.33	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28376041	chr12:28185625~28186190:-
PRAD	cis	rs875971	0.522	rs9530	ENSG00000237310.1	GS1-124K5.4	7.46	4.35e-13	1.77e-10	0.29	0.33	Aortic root size;	chr7:65960907	chr7:66493706~66495474:+
PRAD	cis	rs950169	0.545	rs4354897	ENSG00000259728.4	LINC00933	7.46	4.35e-13	1.77e-10	0.42	0.33	Schizophrenia;	chr15:83976219	chr15:84570649~84580175:+
PRAD	cis	rs9640161	0.789	rs10952250	ENSG00000261305.1	RP4-584D14.7	7.46	4.36e-13	1.77e-10	0.36	0.33	Blood protein levels;Circulating chemerin levels;	chr7:150328877	chr7:150341771~150342607:+
PRAD	cis	rs62355901	0.505	rs56984944	ENSG00000271828.1	CTD-2310F14.1	7.46	4.36e-13	1.77e-10	0.7	0.33	Breast cancer;	chr5:56927671	chr5:56927874~56929573:+
PRAD	cis	rs2638953	0.925	rs11049545	ENSG00000278733.1	RP11-425D17.1	-7.46	4.36e-13	1.77e-10	-0.42	-0.33	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28344965	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.962	rs11049547	ENSG00000278733.1	RP11-425D17.1	-7.46	4.36e-13	1.77e-10	-0.42	-0.33	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28346945	chr12:28185625~28186190:-
PRAD	cis	rs2243480	1	rs2462569	ENSG00000226824.5	RP4-756H11.3	7.46	4.36e-13	1.77e-10	0.63	0.33	Diabetic kidney disease;	chr7:66009859	chr7:66654538~66669855:+
PRAD	cis	rs9595066	0.627	rs2246432	ENSG00000227258.4	SMIM2-AS1	-7.46	4.37e-13	1.77e-10	-0.53	-0.33	Schizophrenia;	chr13:44182648	chr13:44110451~44240517:+
PRAD	cis	rs11098499	0.954	rs6857105	ENSG00000245958.5	RP11-33B1.1	-7.46	4.37e-13	1.77e-10	-0.33	-0.33	Corneal astigmatism;	chr4:119301143	chr4:119454791~119552025:+
PRAD	cis	rs2638953	0.893	rs10843192	ENSG00000278733.1	RP11-425D17.1	-7.46	4.37e-13	1.77e-10	-0.38	-0.33	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28508756	chr12:28185625~28186190:-
PRAD	cis	rs12612619	0.732	rs1866654	ENSG00000229122.1	AGBL5-IT1	7.46	4.37e-13	1.77e-10	0.34	0.33	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27040254	chr2:27061038~27061815:+
PRAD	cis	rs4631830	0.9	rs7075009	ENSG00000230869.1	CTGLF10P	-7.46	4.38e-13	1.78e-10	-0.42	-0.33	Prostate-specific antigen levels;	chr10:46051679	chr10:45678692~45700532:+
PRAD	cis	rs6480314	0.636	rs61854782	ENSG00000233590.1	RP11-153K11.3	-7.46	4.39e-13	1.78e-10	-0.54	-0.33	Optic nerve measurement (disc area);	chr10:68231992	chr10:68233251~68242379:-
PRAD	cis	rs2599510	0.811	rs2710628	ENSG00000276334.1	AL133243.1	7.46	4.4e-13	1.78e-10	0.37	0.33	Interleukin-18 levels;	chr2:32533286	chr2:32521927~32523547:+
PRAD	cis	rs736801	0.836	rs2522052	ENSG00000233006.5	AC034220.3	-7.46	4.41e-13	1.79e-10	-0.3	-0.33	Mosquito bite size;Breast cancer;	chr5:132462795	chr5:132311285~132369916:-
PRAD	cis	rs736801	0.808	rs2706403	ENSG00000233006.5	AC034220.3	-7.46	4.41e-13	1.79e-10	-0.3	-0.33	Mosquito bite size;Breast cancer;	chr5:132463320	chr5:132311285~132369916:-
PRAD	cis	rs736801	0.754	rs2706336	ENSG00000233006.5	AC034220.3	-7.46	4.41e-13	1.79e-10	-0.3	-0.33	Mosquito bite size;Breast cancer;	chr5:132464269	chr5:132311285~132369916:-
PRAD	cis	rs3858145	0.546	rs7912806	ENSG00000233590.1	RP11-153K11.3	7.46	4.41e-13	1.79e-10	0.46	0.33	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68296578	chr10:68233251~68242379:-
PRAD	cis	rs7772486	0.712	rs1292335	ENSG00000235652.6	RP11-545I5.3	7.46	4.42e-13	1.79e-10	0.35	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145646741	chr6:145799409~145886585:+
PRAD	cis	rs2933343	0.729	rs1683816	ENSG00000231305.3	RP11-723O4.2	-7.46	4.42e-13	1.79e-10	-0.29	-0.33	IgG glycosylation;	chr3:128932352	chr3:128861313~128871540:-
PRAD	cis	rs12928939	0.637	rs8046629	ENSG00000260886.1	TAT-AS1	7.46	4.43e-13	1.8e-10	0.46	0.33	Post bronchodilator FEV1;	chr16:71609213	chr16:71565789~71578187:+
PRAD	cis	rs10129255	0.5	rs8011115	ENSG00000211972.2	IGHV3-66	7.46	4.43e-13	1.8e-10	0.28	0.33	Kawasaki disease;	chr14:106786292	chr14:106675017~106675544:-
PRAD	cis	rs11098499	1	rs11726229	ENSG00000245958.5	RP11-33B1.1	-7.46	4.43e-13	1.8e-10	-0.32	-0.33	Corneal astigmatism;	chr4:119290425	chr4:119454791~119552025:+
PRAD	cis	rs2439831	0.85	rs7183809	ENSG00000205771.5	CATSPER2P1	-7.46	4.44e-13	1.8e-10	-0.51	-0.33	Lung cancer in ever smokers;	chr15:43828670	chr15:43726918~43747094:-
PRAD	cis	rs2439831	0.85	rs3759790	ENSG00000205771.5	CATSPER2P1	-7.46	4.44e-13	1.8e-10	-0.51	-0.33	Lung cancer in ever smokers;	chr15:43828832	chr15:43726918~43747094:-
PRAD	cis	rs2276314	1	rs9956938	ENSG00000278986.1	RP11-723J4.3	-7.46	4.44e-13	1.8e-10	-0.42	-0.33	Endometriosis;Drug-induced torsades de pointes;	chr18:35987098	chr18:35972151~35973916:+
PRAD	cis	rs2439831	0.85	rs68079546	ENSG00000205771.5	CATSPER2P1	-7.46	4.45e-13	1.8e-10	-0.51	-0.33	Lung cancer in ever smokers;	chr15:43844759	chr15:43726918~43747094:-
PRAD	cis	rs2439831	0.85	rs56909447	ENSG00000205771.5	CATSPER2P1	-7.46	4.45e-13	1.8e-10	-0.51	-0.33	Lung cancer in ever smokers;	chr15:43845420	chr15:43726918~43747094:-
PRAD	cis	rs2439831	0.85	rs28476182	ENSG00000205771.5	CATSPER2P1	-7.46	4.45e-13	1.8e-10	-0.51	-0.33	Lung cancer in ever smokers;	chr15:43847445	chr15:43726918~43747094:-
PRAD	cis	rs2439831	0.85	rs28696802	ENSG00000205771.5	CATSPER2P1	-7.46	4.45e-13	1.8e-10	-0.51	-0.33	Lung cancer in ever smokers;	chr15:43848197	chr15:43726918~43747094:-
PRAD	cis	rs3096299	0.967	rs753852	ENSG00000261118.1	RP11-104N10.1	7.46	4.45e-13	1.81e-10	0.33	0.33	Multiple myeloma (IgH translocation);	chr16:89380011	chr16:89492017~89504460:-
PRAD	cis	rs858239	0.6	rs10266123	ENSG00000226816.2	AC005082.12	7.46	4.45e-13	1.81e-10	0.38	0.33	Cerebrospinal fluid biomarker levels;	chr7:23096868	chr7:23206013~23208045:+
PRAD	cis	rs7727544	0.625	rs3864277	ENSG00000233006.5	AC034220.3	7.46	4.47e-13	1.81e-10	0.3	0.33	Blood metabolite levels;	chr5:132084556	chr5:132311285~132369916:-
PRAD	cis	rs7727544	0.647	rs6898270	ENSG00000233006.5	AC034220.3	7.46	4.47e-13	1.81e-10	0.3	0.33	Blood metabolite levels;	chr5:132085497	chr5:132311285~132369916:-
PRAD	cis	rs11098499	0.954	rs12505469	ENSG00000245958.5	RP11-33B1.1	-7.46	4.48e-13	1.82e-10	-0.33	-0.33	Corneal astigmatism;	chr4:119328430	chr4:119454791~119552025:+
PRAD	cis	rs79349575	0.783	rs28409394	ENSG00000248278.1	SUMO2P17	7.46	4.48e-13	1.82e-10	0.37	0.33	Type 2 diabetes;	chr17:48920756	chr17:48874860~48908983:-
PRAD	cis	rs42648	0.564	rs10224488	ENSG00000227646.6	STEAP2-AS1	-7.46	4.49e-13	1.82e-10	-0.29	-0.33	Homocysteine levels;	chr7:90180947	chr7:89882353~90211635:-
PRAD	cis	rs2439831	0.85	rs12440573	ENSG00000205771.5	CATSPER2P1	-7.46	4.49e-13	1.82e-10	-0.52	-0.33	Lung cancer in ever smokers;	chr15:43816799	chr15:43726918~43747094:-
PRAD	cis	rs6991838	0.806	rs17302392	ENSG00000272010.1	CTD-3025N20.3	7.46	4.49e-13	1.82e-10	0.33	0.33	Intelligence (multi-trait analysis);	chr8:65551073	chr8:65591850~65592472:-
PRAD	cis	rs673078	0.66	rs61945180	ENSG00000275409.1	RP11-131L12.4	-7.46	4.5e-13	1.82e-10	-0.49	-0.33	Glucose homeostasis traits;	chr12:118216335	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.66	rs61945181	ENSG00000275409.1	RP11-131L12.4	-7.46	4.5e-13	1.82e-10	-0.49	-0.33	Glucose homeostasis traits;	chr12:118216651	chr12:118430147~118430699:+
PRAD	cis	rs11098499	0.691	rs12510133	ENSG00000245958.5	RP11-33B1.1	-7.46	4.51e-13	1.83e-10	-0.3	-0.33	Corneal astigmatism;	chr4:119350189	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.754	rs12506487	ENSG00000245958.5	RP11-33B1.1	-7.46	4.51e-13	1.83e-10	-0.3	-0.33	Corneal astigmatism;	chr4:119350206	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.691	rs12502524	ENSG00000245958.5	RP11-33B1.1	-7.46	4.51e-13	1.83e-10	-0.3	-0.33	Corneal astigmatism;	chr4:119350259	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.691	rs28396837	ENSG00000245958.5	RP11-33B1.1	-7.46	4.51e-13	1.83e-10	-0.3	-0.33	Corneal astigmatism;	chr4:119350386	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.629	rs28369518	ENSG00000245958.5	RP11-33B1.1	-7.46	4.51e-13	1.83e-10	-0.3	-0.33	Corneal astigmatism;	chr4:119350475	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.722	rs10025925	ENSG00000245958.5	RP11-33B1.1	-7.46	4.51e-13	1.83e-10	-0.3	-0.33	Corneal astigmatism;	chr4:119350589	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.731	rs10015579	ENSG00000245958.5	RP11-33B1.1	-7.46	4.51e-13	1.83e-10	-0.3	-0.33	Corneal astigmatism;	chr4:119350647	chr4:119454791~119552025:+
PRAD	cis	rs2836950	0.52	rs8133927	ENSG00000255568.3	BRWD1-AS2	-7.46	4.51e-13	1.83e-10	-0.27	-0.33	Menarche (age at onset);	chr21:39318035	chr21:39313935~39314962:+
PRAD	cis	rs2836950	0.52	rs8133928	ENSG00000255568.3	BRWD1-AS2	-7.46	4.51e-13	1.83e-10	-0.27	-0.33	Menarche (age at onset);	chr21:39318037	chr21:39313935~39314962:+
PRAD	cis	rs7829975	0.742	rs12547493	ENSG00000253893.2	FAM85B	7.46	4.51e-13	1.83e-10	0.44	0.33	Mood instability;	chr8:8804024	chr8:8167819~8226614:-
PRAD	cis	rs73186030	0.764	rs66508963	ENSG00000272758.4	RP11-299J3.8	7.46	4.52e-13	1.83e-10	0.48	0.33	Serum parathyroid hormone levels;	chr3:122365682	chr3:122416207~122443180:+
PRAD	cis	rs73186030	0.764	rs55744726	ENSG00000272758.4	RP11-299J3.8	7.46	4.52e-13	1.83e-10	0.48	0.33	Serum parathyroid hormone levels;	chr3:122368907	chr3:122416207~122443180:+
PRAD	cis	rs73186030	0.764	rs73186095	ENSG00000272758.4	RP11-299J3.8	7.46	4.52e-13	1.83e-10	0.48	0.33	Serum parathyroid hormone levels;	chr3:122372769	chr3:122416207~122443180:+
PRAD	cis	rs73186030	0.764	rs67446552	ENSG00000272758.4	RP11-299J3.8	7.46	4.52e-13	1.83e-10	0.48	0.33	Serum parathyroid hormone levels;	chr3:122377448	chr3:122416207~122443180:+
PRAD	cis	rs73186030	0.764	rs67706840	ENSG00000272758.4	RP11-299J3.8	7.46	4.52e-13	1.83e-10	0.48	0.33	Serum parathyroid hormone levels;	chr3:122377717	chr3:122416207~122443180:+
PRAD	cis	rs73186030	0.764	rs16833078	ENSG00000272758.4	RP11-299J3.8	7.46	4.52e-13	1.83e-10	0.48	0.33	Serum parathyroid hormone levels;	chr3:122380747	chr3:122416207~122443180:+
PRAD	cis	rs10129255	0.957	rs7493713	ENSG00000223648.3	IGHV3-64	7.46	4.53e-13	1.83e-10	0.33	0.33	Kawasaki disease;	chr14:106783685	chr14:106643132~106658258:-
PRAD	cis	rs10129255	0.912	rs35468694	ENSG00000223648.3	IGHV3-64	7.46	4.53e-13	1.83e-10	0.33	0.33	Kawasaki disease;	chr14:106784199	chr14:106643132~106658258:-
PRAD	cis	rs10129255	0.957	rs8019272	ENSG00000223648.3	IGHV3-64	7.46	4.53e-13	1.83e-10	0.33	0.33	Kawasaki disease;	chr14:106784709	chr14:106643132~106658258:-
PRAD	cis	rs17428076	0.874	rs62182373	ENSG00000228389.1	AC068039.4	-7.46	4.54e-13	1.84e-10	-0.43	-0.33	Myopia;	chr2:171829045	chr2:171773482~171775844:+
PRAD	cis	rs2243480	1	rs7794661	ENSG00000226824.5	RP4-756H11.3	-7.46	4.54e-13	1.84e-10	-0.63	-0.33	Diabetic kidney disease;	chr7:65924743	chr7:66654538~66669855:+
PRAD	cis	rs964611	0.938	rs12592155	ENSG00000259488.2	RP11-154J22.1	-7.46	4.54e-13	1.84e-10	-0.36	-0.33	Metabolite levels (Pyroglutamine);	chr15:48331303	chr15:48312353~48331856:-
PRAD	cis	rs736801	0.808	rs2706396	ENSG00000233006.5	AC034220.3	-7.46	4.55e-13	1.84e-10	-0.3	-0.33	Mosquito bite size;Breast cancer;	chr5:132461117	chr5:132311285~132369916:-
PRAD	cis	rs638893	0.617	rs2156750	ENSG00000278376.1	RP11-158I9.8	-7.45	4.58e-13	1.85e-10	-0.34	-0.33	Vitiligo;	chr11:118848545	chr11:118791254~118793137:+
PRAD	cis	rs638893	0.561	rs2156749	ENSG00000278376.1	RP11-158I9.8	-7.45	4.58e-13	1.85e-10	-0.34	-0.33	Vitiligo;	chr11:118848696	chr11:118791254~118793137:+
PRAD	cis	rs3096299	0.934	rs9927904	ENSG00000261118.1	RP11-104N10.1	7.45	4.58e-13	1.85e-10	0.32	0.33	Multiple myeloma (IgH translocation);	chr16:89396439	chr16:89492017~89504460:-
PRAD	cis	rs6539288	0.901	rs1444580	ENSG00000260329.1	RP11-412D9.4	-7.45	4.58e-13	1.86e-10	-0.29	-0.33	Total body bone mineral density;	chr12:106920780	chr12:106954029~106955497:-
PRAD	cis	rs2274273	0.967	rs11622740	ENSG00000258413.1	RP11-665C16.6	-7.45	4.6e-13	1.86e-10	-0.42	-0.33	Protein biomarker;	chr14:55151126	chr14:55262767~55272075:-
PRAD	cis	rs1799949	0.965	rs9897425	ENSG00000267002.1	RP11-242D8.1	7.45	4.61e-13	1.87e-10	0.31	0.33	Menopause (age at onset);	chr17:43352811	chr17:43164183~43170403:-
PRAD	cis	rs673078	0.66	rs73205551	ENSG00000275409.1	RP11-131L12.4	-7.45	4.61e-13	1.87e-10	-0.43	-0.33	Glucose homeostasis traits;	chr12:118330808	chr12:118430147~118430699:+
PRAD	cis	rs763567	0.935	rs639652	ENSG00000271811.1	RP1-79C4.4	7.45	4.61e-13	1.87e-10	0.38	0.33	Tonsillectomy;	chr1:170643732	chr1:170667381~170669425:+
PRAD	cis	rs8072100	0.805	rs67919208	ENSG00000228782.6	CTD-2026D20.3	7.45	4.62e-13	1.87e-10	0.36	0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47694507	chr17:47450568~47492492:-
PRAD	cis	rs72615157	0.612	rs7786505	ENSG00000242294.5	STAG3L5P	7.45	4.64e-13	1.88e-10	0.21	0.33	Lung function (FEV1/FVC);	chr7:100219962	chr7:100336079~100351900:+
PRAD	cis	rs17772222	0.74	rs7143642	ENSG00000258983.2	RP11-507K2.2	7.45	4.65e-13	1.88e-10	0.44	0.33	Coronary artery calcification;	chr14:88507616	chr14:88499334~88515502:+
PRAD	cis	rs9810089	0.967	rs7372313	ENSG00000261758.1	RP11-102M11.2	7.45	4.65e-13	1.88e-10	0.38	0.33	Gestational age at birth (child effect);	chr3:136154116	chr3:136752630~136755780:+
PRAD	cis	rs11098499	0.575	rs907204	ENSG00000245958.5	RP11-33B1.1	-7.45	4.66e-13	1.88e-10	-0.31	-0.33	Corneal astigmatism;	chr4:119317499	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.575	rs907205	ENSG00000245958.5	RP11-33B1.1	-7.45	4.66e-13	1.88e-10	-0.31	-0.33	Corneal astigmatism;	chr4:119317509	chr4:119454791~119552025:+
PRAD	cis	rs12612619	0.732	rs1053609	ENSG00000272148.1	RP11-195B17.1	7.45	4.66e-13	1.89e-10	0.39	0.33	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27070282	chr2:27062428~27062907:-
PRAD	cis	rs2712381	0.797	rs62270806	ENSG00000242551.2	POU5F1P6	-7.45	4.67e-13	1.89e-10	-0.41	-0.33	Monocyte count;	chr3:128657426	chr3:128674735~128677005:-
PRAD	cis	rs67311347	0.568	rs57287242	ENSG00000223797.4	ENTPD3-AS1	7.45	4.67e-13	1.89e-10	0.29	0.33	Renal cell carcinoma;	chr3:40294047	chr3:40313802~40453329:-
PRAD	cis	rs2439831	0.85	rs10438303	ENSG00000205771.5	CATSPER2P1	-7.45	4.68e-13	1.89e-10	-0.51	-0.33	Lung cancer in ever smokers;	chr15:43724219	chr15:43726918~43747094:-
PRAD	cis	rs2439831	0.85	rs11070408	ENSG00000205771.5	CATSPER2P1	-7.45	4.68e-13	1.89e-10	-0.51	-0.33	Lung cancer in ever smokers;	chr15:43742590	chr15:43726918~43747094:-
PRAD	cis	rs2439831	0.85	rs28718261	ENSG00000205771.5	CATSPER2P1	-7.45	4.68e-13	1.89e-10	-0.51	-0.33	Lung cancer in ever smokers;	chr15:43751595	chr15:43726918~43747094:-
PRAD	cis	rs2439831	0.85	rs7168158	ENSG00000205771.5	CATSPER2P1	-7.45	4.68e-13	1.89e-10	-0.51	-0.33	Lung cancer in ever smokers;	chr15:43758178	chr15:43726918~43747094:-
PRAD	cis	rs2439831	0.85	rs7174208	ENSG00000205771.5	CATSPER2P1	-7.45	4.68e-13	1.89e-10	-0.51	-0.33	Lung cancer in ever smokers;	chr15:43760484	chr15:43726918~43747094:-
PRAD	cis	rs2439831	0.85	rs12101756	ENSG00000205771.5	CATSPER2P1	-7.45	4.68e-13	1.89e-10	-0.51	-0.33	Lung cancer in ever smokers;	chr15:43761689	chr15:43726918~43747094:-
PRAD	cis	rs2439831	0.85	rs12442129	ENSG00000205771.5	CATSPER2P1	-7.45	4.68e-13	1.89e-10	-0.51	-0.33	Lung cancer in ever smokers;	chr15:43763658	chr15:43726918~43747094:-
PRAD	cis	rs2439831	0.702	rs7175032	ENSG00000205771.5	CATSPER2P1	-7.45	4.68e-13	1.89e-10	-0.51	-0.33	Lung cancer in ever smokers;	chr15:43768038	chr15:43726918~43747094:-
PRAD	cis	rs2439831	0.85	rs3862142	ENSG00000205771.5	CATSPER2P1	-7.45	4.68e-13	1.89e-10	-0.51	-0.33	Lung cancer in ever smokers;	chr15:43772608	chr15:43726918~43747094:-
PRAD	cis	rs2439831	0.702	rs2788	ENSG00000205771.5	CATSPER2P1	-7.45	4.68e-13	1.89e-10	-0.51	-0.33	Lung cancer in ever smokers;	chr15:43772688	chr15:43726918~43747094:-
PRAD	cis	rs2439831	0.85	rs2277531	ENSG00000205771.5	CATSPER2P1	-7.45	4.68e-13	1.89e-10	-0.51	-0.33	Lung cancer in ever smokers;	chr15:43776871	chr15:43726918~43747094:-
PRAD	cis	rs2439831	0.85	rs28891769	ENSG00000205771.5	CATSPER2P1	-7.45	4.68e-13	1.89e-10	-0.51	-0.33	Lung cancer in ever smokers;	chr15:43780662	chr15:43726918~43747094:-
PRAD	cis	rs2439831	0.85	rs28578398	ENSG00000205771.5	CATSPER2P1	-7.45	4.68e-13	1.89e-10	-0.51	-0.33	Lung cancer in ever smokers;	chr15:43782848	chr15:43726918~43747094:-
PRAD	cis	rs6003958	1	rs6003958	ENSG00000206090.4	AP000350.7	-7.45	4.68e-13	1.89e-10	-0.5	-0.33	S-phenylmercapturic acid levels in smokers;	chr22:23921902	chr22:23939998~23942798:+
PRAD	cis	rs5760092	0.755	rs6003959	ENSG00000206090.4	AP000350.7	-7.45	4.68e-13	1.89e-10	-0.5	-0.33	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23922208	chr22:23939998~23942798:+
PRAD	cis	rs2337406	0.587	rs2516886	ENSG00000274576.2	IGHV2-70	7.45	4.69e-13	1.9e-10	0.34	0.33	Alzheimer's disease (late onset);	chr14:106649674	chr14:106770577~106771020:-
PRAD	cis	rs11098499	0.644	rs3986377	ENSG00000245958.5	RP11-33B1.1	-7.45	4.69e-13	1.9e-10	-0.3	-0.33	Corneal astigmatism;	chr4:119339115	chr4:119454791~119552025:+
PRAD	cis	rs10463554	0.895	rs12656561	ENSG00000175749.11	EIF3KP1	7.45	4.69e-13	1.9e-10	0.4	0.33	Parkinson's disease;	chr5:102989988	chr5:103032376~103033031:+
PRAD	cis	rs10028773	0.7	rs7690338	ENSG00000245958.5	RP11-33B1.1	-7.45	4.71e-13	1.9e-10	-0.31	-0.33	Educational attainment;	chr4:119335313	chr4:119454791~119552025:+
PRAD	cis	rs13126694	0.75	rs6833295	ENSG00000248429.4	RP11-597D13.9	7.45	4.71e-13	1.91e-10	0.35	0.33	Blood osmolality (transformed sodium);	chr4:158143520	chr4:158170752~158202877:+
PRAD	cis	rs6479901	0.793	rs10822154	ENSG00000232075.1	MRPL35P2	-7.45	4.71e-13	1.91e-10	-0.4	-0.33	Intelligence (multi-trait analysis);	chr10:63299284	chr10:63634317~63634827:-
PRAD	cis	rs1707322	0.656	rs3014210	ENSG00000280836.1	AL355480.1	7.45	4.71e-13	1.91e-10	0.42	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45600936	chr1:45581219~45581321:-
PRAD	cis	rs11098499	0.874	rs13139045	ENSG00000245958.5	RP11-33B1.1	-7.45	4.72e-13	1.91e-10	-0.32	-0.33	Corneal astigmatism;	chr4:119247433	chr4:119454791~119552025:+
PRAD	cis	rs1061377	0.513	rs2566162	ENSG00000249207.1	RP11-360F5.1	-7.45	4.72e-13	1.91e-10	-0.4	-0.33	Uric acid levels;	chr4:39126453	chr4:39112677~39126818:-
PRAD	cis	rs2522056	1	rs6874639	ENSG00000233006.5	AC034220.3	7.45	4.72e-13	1.91e-10	0.32	0.33	Fibrinogen;Lymphocyte counts;	chr5:132443024	chr5:132311285~132369916:-
PRAD	cis	rs853679	0.567	rs13209596	ENSG00000216901.1	AL022393.7	7.45	4.73e-13	1.91e-10	0.45	0.33	Depression;	chr6:28428413	chr6:28176188~28176674:+
PRAD	cis	rs6847067	0.794	rs6531782	ENSG00000180769.7	WDFY3-AS2	-7.45	4.73e-13	1.91e-10	-0.34	-0.33	Oropharynx cancer;	chr4:85007246	chr4:84965682~85011277:+
PRAD	cis	rs9810089	0.843	rs838202	ENSG00000261758.1	RP11-102M11.2	7.45	4.74e-13	1.92e-10	0.38	0.33	Gestational age at birth (child effect);	chr3:136316375	chr3:136752630~136755780:+
PRAD	cis	rs9810089	0.843	rs681783	ENSG00000261758.1	RP11-102M11.2	7.45	4.74e-13	1.92e-10	0.38	0.33	Gestational age at birth (child effect);	chr3:136316461	chr3:136752630~136755780:+
PRAD	cis	rs73607972	0.877	rs66646415	ENSG00000275191.1	RP11-36I17.2	-7.45	4.74e-13	1.92e-10	-0.5	-0.33	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53572317	chr16:53628256~53628816:-
PRAD	cis	rs4664293	1	rs6745766	ENSG00000226266.5	AC009961.3	-7.45	4.75e-13	1.92e-10	-0.43	-0.33	Monocyte percentage of white cells;	chr2:159598284	chr2:159670708~159712435:-
PRAD	cis	rs17012589	0.502	rs1913133	ENSG00000258815.1	RP11-408B11.2	-7.45	4.76e-13	1.92e-10	-0.44	-0.33	Bone mineral density (Ward's triangle area);	chr12:85351103	chr12:85318060~85342912:+
PRAD	cis	rs4927850	1	rs4927704	ENSG00000231464.1	AC024937.4	7.45	4.8e-13	1.94e-10	0.4	0.33	Pancreatic cancer;	chr3:196011357	chr3:195996738~195998233:+
PRAD	cis	rs4927850	1	rs4927848	ENSG00000231464.1	AC024937.4	7.45	4.8e-13	1.94e-10	0.4	0.33	Pancreatic cancer;	chr3:196011535	chr3:195996738~195998233:+
PRAD	cis	rs73081554	0.611	rs4681852	ENSG00000272360.1	RP11-359I18.5	-7.45	4.81e-13	1.94e-10	-0.54	-0.33	Rheumatoid arthritis;	chr3:58423446	chr3:58490830~58491291:-
PRAD	cis	rs6782228	0.606	rs6787559	ENSG00000242551.2	POU5F1P6	-7.45	4.82e-13	1.95e-10	-0.41	-0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128662243	chr3:128674735~128677005:-
PRAD	cis	rs6782228	0.606	rs2001703	ENSG00000242551.2	POU5F1P6	-7.45	4.82e-13	1.95e-10	-0.41	-0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128664254	chr3:128674735~128677005:-
PRAD	cis	rs11098499	0.954	rs878373	ENSG00000245958.5	RP11-33B1.1	-7.45	4.83e-13	1.95e-10	-0.33	-0.33	Corneal astigmatism;	chr4:119316329	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.954	rs10006877	ENSG00000245958.5	RP11-33B1.1	-7.45	4.83e-13	1.95e-10	-0.33	-0.33	Corneal astigmatism;	chr4:119321638	chr4:119454791~119552025:+
PRAD	cis	rs2274273	0.686	rs2182207	ENSG00000258413.1	RP11-665C16.6	-7.45	4.83e-13	1.95e-10	-0.46	-0.33	Protein biomarker;	chr14:55123085	chr14:55262767~55272075:-
PRAD	cis	rs2274273	0.71	rs67395212	ENSG00000258413.1	RP11-665C16.6	-7.45	4.83e-13	1.95e-10	-0.46	-0.33	Protein biomarker;	chr14:55125221	chr14:55262767~55272075:-
PRAD	cis	rs9326248	0.53	rs7112513	ENSG00000280143.1	AP000892.6	7.45	4.83e-13	1.95e-10	0.39	0.33	Blood protein levels;	chr11:117166645	chr11:117204967~117210292:+
PRAD	cis	rs6480314	0.542	rs61854805	ENSG00000233590.1	RP11-153K11.3	-7.45	4.83e-13	1.95e-10	-0.54	-0.33	Optic nerve measurement (disc area);	chr10:68255826	chr10:68233251~68242379:-
PRAD	cis	rs73186030	0.764	rs4491840	ENSG00000272758.4	RP11-299J3.8	7.45	4.84e-13	1.95e-10	0.48	0.33	Serum parathyroid hormone levels;	chr3:122361900	chr3:122416207~122443180:+
PRAD	cis	rs113835537	0.529	rs2277302	ENSG00000255517.5	CTD-3074O7.5	-7.45	4.84e-13	1.95e-10	-0.33	-0.33	Airway imaging phenotypes;	chr11:66473411	chr11:66473490~66480233:-
PRAD	cis	rs673078	0.66	rs75752792	ENSG00000275409.1	RP11-131L12.4	-7.45	4.84e-13	1.95e-10	-0.49	-0.33	Glucose homeostasis traits;	chr12:118187005	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.66	rs75571641	ENSG00000275409.1	RP11-131L12.4	-7.45	4.84e-13	1.95e-10	-0.49	-0.33	Glucose homeostasis traits;	chr12:118187012	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.66	rs17512177	ENSG00000275409.1	RP11-131L12.4	-7.45	4.84e-13	1.95e-10	-0.49	-0.33	Glucose homeostasis traits;	chr12:118192335	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.66	rs17512198	ENSG00000275409.1	RP11-131L12.4	-7.45	4.84e-13	1.95e-10	-0.49	-0.33	Glucose homeostasis traits;	chr12:118194217	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.66	rs10507286	ENSG00000275409.1	RP11-131L12.4	-7.45	4.84e-13	1.95e-10	-0.49	-0.33	Glucose homeostasis traits;	chr12:118197101	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.66	rs61945183	ENSG00000275409.1	RP11-131L12.4	-7.45	4.84e-13	1.95e-10	-0.49	-0.33	Glucose homeostasis traits;	chr12:118221966	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.66	rs16948193	ENSG00000275409.1	RP11-131L12.4	-7.45	4.84e-13	1.95e-10	-0.49	-0.33	Glucose homeostasis traits;	chr12:118227115	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.66	rs61945187	ENSG00000275409.1	RP11-131L12.4	-7.45	4.84e-13	1.95e-10	-0.49	-0.33	Glucose homeostasis traits;	chr12:118228989	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.66	rs73205512	ENSG00000275409.1	RP11-131L12.4	-7.45	4.84e-13	1.95e-10	-0.49	-0.33	Glucose homeostasis traits;	chr12:118235770	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.66	rs61945206	ENSG00000275409.1	RP11-131L12.4	-7.45	4.84e-13	1.95e-10	-0.49	-0.33	Glucose homeostasis traits;	chr12:118238295	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.66	rs7970481	ENSG00000275409.1	RP11-131L12.4	-7.45	4.84e-13	1.95e-10	-0.49	-0.33	Glucose homeostasis traits;	chr12:118242112	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.66	rs7973455	ENSG00000275409.1	RP11-131L12.4	-7.45	4.84e-13	1.95e-10	-0.49	-0.33	Glucose homeostasis traits;	chr12:118247490	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.66	rs58113338	ENSG00000275409.1	RP11-131L12.4	-7.45	4.84e-13	1.95e-10	-0.49	-0.33	Glucose homeostasis traits;	chr12:118251335	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.615	rs16948204	ENSG00000275409.1	RP11-131L12.4	-7.45	4.84e-13	1.95e-10	-0.49	-0.33	Glucose homeostasis traits;	chr12:118258252	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.66	rs7303417	ENSG00000275409.1	RP11-131L12.4	-7.45	4.84e-13	1.95e-10	-0.49	-0.33	Glucose homeostasis traits;	chr12:118258859	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.66	rs7965350	ENSG00000275409.1	RP11-131L12.4	-7.45	4.84e-13	1.95e-10	-0.49	-0.33	Glucose homeostasis traits;	chr12:118266710	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.66	rs17433217	ENSG00000275409.1	RP11-131L12.4	-7.45	4.84e-13	1.95e-10	-0.49	-0.33	Glucose homeostasis traits;	chr12:118269076	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.66	rs73205526	ENSG00000275409.1	RP11-131L12.4	-7.45	4.84e-13	1.95e-10	-0.49	-0.33	Glucose homeostasis traits;	chr12:118273172	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.66	rs56708462	ENSG00000275409.1	RP11-131L12.4	-7.45	4.84e-13	1.95e-10	-0.49	-0.33	Glucose homeostasis traits;	chr12:118284135	chr12:118430147~118430699:+
PRAD	cis	rs673078	0.66	rs7962185	ENSG00000275409.1	RP11-131L12.4	-7.45	4.84e-13	1.95e-10	-0.49	-0.33	Glucose homeostasis traits;	chr12:118287842	chr12:118430147~118430699:+
PRAD	cis	rs12612619	0.732	rs2304681	ENSG00000272148.1	RP11-195B17.1	-7.45	4.85e-13	1.96e-10	-0.39	-0.33	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27092384	chr2:27062428~27062907:-
PRAD	cis	rs12612619	0.677	rs67100745	ENSG00000229122.1	AGBL5-IT1	7.45	4.85e-13	1.96e-10	0.35	0.33	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27027882	chr2:27061038~27061815:+
PRAD	cis	rs11159086	0.793	rs11845370	ENSG00000270000.1	RP3-449M8.9	7.45	4.85e-13	1.96e-10	0.5	0.33	Advanced glycation end-product levels;	chr14:74481587	chr14:74471930~74472360:-
PRAD	cis	rs11159086	0.793	rs3784035	ENSG00000270000.1	RP3-449M8.9	7.45	4.85e-13	1.96e-10	0.5	0.33	Advanced glycation end-product levels;	chr14:74482221	chr14:74471930~74472360:-
PRAD	cis	rs11159086	0.793	rs12433382	ENSG00000270000.1	RP3-449M8.9	7.45	4.85e-13	1.96e-10	0.5	0.33	Advanced glycation end-product levels;	chr14:74482940	chr14:74471930~74472360:-
PRAD	cis	rs11159086	0.793	rs10148268	ENSG00000270000.1	RP3-449M8.9	7.45	4.85e-13	1.96e-10	0.5	0.33	Advanced glycation end-product levels;	chr14:74484261	chr14:74471930~74472360:-
PRAD	cis	rs11159086	0.793	rs8015894	ENSG00000270000.1	RP3-449M8.9	7.45	4.85e-13	1.96e-10	0.5	0.33	Advanced glycation end-product levels;	chr14:74491917	chr14:74471930~74472360:-
PRAD	cis	rs12571093	0.803	rs61854839	ENSG00000233590.1	RP11-153K11.3	-7.45	4.87e-13	1.97e-10	-0.55	-0.33	Optic nerve measurement (disc area);	chr10:68284859	chr10:68233251~68242379:-
PRAD	cis	rs6674176	0.66	rs6801	ENSG00000237950.1	RP11-7O11.3	-7.45	4.87e-13	1.97e-10	-0.36	-0.33	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43930974	chr1:43944370~43946551:-
PRAD	cis	rs10463554	0.857	rs3776871	ENSG00000175749.11	EIF3KP1	7.45	4.87e-13	1.97e-10	0.43	0.33	Parkinson's disease;	chr5:102956507	chr5:103032376~103033031:+
PRAD	cis	rs8042680	0.784	rs6496747	ENSG00000214432.8	AC068831.10	-7.45	4.87e-13	1.97e-10	-0.4	-0.33	Type 2 diabetes;	chr15:90993397	chr15:91022619~91036611:+
PRAD	cis	rs987724	0.512	rs9842198	ENSG00000240875.4	LINC00886	-7.45	4.87e-13	1.97e-10	-0.38	-0.33	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156821415	chr3:156747346~156817062:-
PRAD	cis	rs914615	0.508	rs4390169	ENSG00000160766.13	GBAP1	7.45	4.88e-13	1.97e-10	0.33	0.33	Urinary albumin-to-creatinine ratio;	chr1:155133578	chr1:155213821~155227422:-
PRAD	cis	rs2455601	0.679	rs2653559	ENSG00000254860.4	TMEM9B-AS1	7.45	4.88e-13	1.97e-10	0.4	0.33	Schizophrenia;	chr11:8878847	chr11:8964675~8977527:+
PRAD	cis	rs673078	0.607	rs11068906	ENSG00000275409.1	RP11-131L12.4	-7.45	4.88e-13	1.97e-10	-0.44	-0.33	Glucose homeostasis traits;	chr12:118315098	chr12:118430147~118430699:+
PRAD	cis	rs11098499	0.955	rs6815725	ENSG00000245958.5	RP11-33B1.1	-7.45	4.88e-13	1.97e-10	-0.32	-0.33	Corneal astigmatism;	chr4:119237255	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.955	rs1551	ENSG00000245958.5	RP11-33B1.1	-7.45	4.88e-13	1.97e-10	-0.32	-0.33	Corneal astigmatism;	chr4:119237345	chr4:119454791~119552025:+
PRAD	cis	rs9467773	1	rs1884946	ENSG00000124549.13	BTN2A3P	7.45	4.88e-13	1.97e-10	0.29	0.33	Intelligence (multi-trait analysis);	chr6:26545080	chr6:26421391~26432383:+
PRAD	cis	rs11159086	0.793	rs17100414	ENSG00000270000.1	RP3-449M8.9	7.45	4.89e-13	1.97e-10	0.5	0.33	Advanced glycation end-product levels;	chr14:74467918	chr14:74471930~74472360:-
PRAD	cis	rs6921919	0.515	rs1339898	ENSG00000204709.4	LINC01556	7.44	4.9e-13	1.98e-10	0.42	0.33	Autism spectrum disorder or schizophrenia;	chr6:28427729	chr6:28943877~28944537:+
PRAD	cis	rs46522	0.585	rs79049364	ENSG00000248278.1	SUMO2P17	7.44	4.9e-13	1.98e-10	0.38	0.33	Coronary heart disease;	chr17:48937629	chr17:48874860~48908983:-
PRAD	cis	rs79349575	0.811	rs80032154	ENSG00000248278.1	SUMO2P17	7.44	4.9e-13	1.98e-10	0.38	0.33	Type 2 diabetes;	chr17:48937630	chr17:48874860~48908983:-
PRAD	cis	rs2439831	0.85	rs28504496	ENSG00000205771.5	CATSPER2P1	-7.44	4.91e-13	1.98e-10	-0.51	-0.33	Lung cancer in ever smokers;	chr15:43724685	chr15:43726918~43747094:-
PRAD	cis	rs2439831	0.867	rs2447208	ENSG00000249839.1	AC011330.5	-7.44	4.91e-13	1.98e-10	-0.57	-0.33	Lung cancer in ever smokers;	chr15:43641697	chr15:43663654~43684339:-
PRAD	cis	rs79349575	0.811	rs1057897	ENSG00000248278.1	SUMO2P17	7.44	4.92e-13	1.98e-10	0.37	0.33	Type 2 diabetes;	chr17:48928147	chr17:48874860~48908983:-
PRAD	cis	rs9640161	0.75	rs3735173	ENSG00000261305.1	RP4-584D14.7	7.44	4.92e-13	1.99e-10	0.36	0.33	Blood protein levels;Circulating chemerin levels;	chr7:150323437	chr7:150341771~150342607:+
PRAD	cis	rs7567389	0.719	rs6744237	ENSG00000236682.1	AC068282.3	7.44	4.92e-13	1.99e-10	0.45	0.33	Self-rated health;	chr2:127246469	chr2:127389130~127400580:+
PRAD	cis	rs11098499	0.955	rs11944880	ENSG00000245958.5	RP11-33B1.1	7.44	4.93e-13	1.99e-10	0.32	0.33	Corneal astigmatism;	chr4:119238179	chr4:119454791~119552025:+
PRAD	cis	rs9595066	0.627	rs4394973	ENSG00000227258.4	SMIM2-AS1	-7.44	4.93e-13	1.99e-10	-0.53	-0.33	Schizophrenia;	chr13:44179173	chr13:44110451~44240517:+
PRAD	cis	rs995000	0.895	rs11208001	ENSG00000235545.1	RP11-230B22.1	7.44	4.93e-13	1.99e-10	0.44	0.33	Triglyceride levels;	chr1:62664760	chr1:62688482~62710694:+
PRAD	cis	rs858239	0.6	rs10233039	ENSG00000226816.2	AC005082.12	7.44	4.94e-13	1.99e-10	0.37	0.33	Cerebrospinal fluid biomarker levels;	chr7:23103494	chr7:23206013~23208045:+
PRAD	cis	rs6782228	0.606	rs6439135	ENSG00000242551.2	POU5F1P6	-7.44	4.94e-13	1.99e-10	-0.41	-0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128639790	chr3:128674735~128677005:-
PRAD	cis	rs9467773	0.549	rs9461273	ENSG00000241549.7	GUSBP2	-7.44	4.95e-13	2e-10	-0.35	-0.33	Intelligence (multi-trait analysis);	chr6:26584298	chr6:26871484~26956554:-
PRAD	cis	rs6430553	0.929	rs6714498	ENSG00000224043.6	CCNT2-AS1	7.44	4.95e-13	2e-10	0.45	0.33	Blood metabolite levels;	chr2:134893196	chr2:134735464~134918710:-
PRAD	cis	rs4664293	0.747	rs7600347	ENSG00000226266.5	AC009961.3	-7.44	4.96e-13	2e-10	-0.45	-0.33	Monocyte percentage of white cells;	chr2:159800981	chr2:159670708~159712435:-
PRAD	cis	rs2439831	0.85	rs12441127	ENSG00000205771.5	CATSPER2P1	-7.44	4.96e-13	2e-10	-0.51	-0.33	Lung cancer in ever smokers;	chr15:43728977	chr15:43726918~43747094:-
PRAD	cis	rs62103177	0.535	rs4799109	ENSG00000261126.6	RP11-795F19.1	7.44	4.96e-13	2e-10	0.47	0.33	Opioid sensitivity;	chr18:79915188	chr18:80046900~80095482:+
PRAD	cis	rs9467773	1	rs9295695	ENSG00000124549.13	BTN2A3P	-7.44	4.96e-13	2e-10	-0.29	-0.33	Intelligence (multi-trait analysis);	chr6:26528022	chr6:26421391~26432383:+
PRAD	cis	rs9467773	1	rs9467779	ENSG00000124549.13	BTN2A3P	-7.44	4.96e-13	2e-10	-0.29	-0.33	Intelligence (multi-trait analysis);	chr6:26536459	chr6:26421391~26432383:+
PRAD	cis	rs9467773	1	rs9393731	ENSG00000124549.13	BTN2A3P	7.44	4.96e-13	2e-10	0.29	0.33	Intelligence (multi-trait analysis);	chr6:26529146	chr6:26421391~26432383:+
PRAD	cis	rs9467773	1	rs11756120	ENSG00000124549.13	BTN2A3P	7.44	4.96e-13	2e-10	0.29	0.33	Intelligence (multi-trait analysis);	chr6:26529580	chr6:26421391~26432383:+
PRAD	cis	rs9467773	1	rs9393732	ENSG00000124549.13	BTN2A3P	7.44	4.96e-13	2e-10	0.29	0.33	Intelligence (multi-trait analysis);	chr6:26530670	chr6:26421391~26432383:+
PRAD	cis	rs9467773	0.967	rs9358954	ENSG00000124549.13	BTN2A3P	7.44	4.96e-13	2e-10	0.29	0.33	Intelligence (multi-trait analysis);	chr6:26530950	chr6:26421391~26432383:+
PRAD	cis	rs9467773	1	rs28558133	ENSG00000124549.13	BTN2A3P	7.44	4.96e-13	2e-10	0.29	0.33	Intelligence (multi-trait analysis);	chr6:26531205	chr6:26421391~26432383:+
PRAD	cis	rs9467773	1	rs1321480	ENSG00000124549.13	BTN2A3P	7.44	4.96e-13	2e-10	0.29	0.33	Intelligence (multi-trait analysis);	chr6:26532514	chr6:26421391~26432383:+
PRAD	cis	rs9467773	1	rs10946834	ENSG00000124549.13	BTN2A3P	7.44	4.96e-13	2e-10	0.29	0.33	Intelligence (multi-trait analysis);	chr6:26533436	chr6:26421391~26432383:+
PRAD	cis	rs9467773	1	rs10946835	ENSG00000124549.13	BTN2A3P	7.44	4.96e-13	2e-10	0.29	0.33	Intelligence (multi-trait analysis);	chr6:26533529	chr6:26421391~26432383:+
PRAD	cis	rs9467773	1	rs9467778	ENSG00000124549.13	BTN2A3P	7.44	4.96e-13	2e-10	0.29	0.33	Intelligence (multi-trait analysis);	chr6:26534515	chr6:26421391~26432383:+
PRAD	cis	rs9467773	1	rs2393670	ENSG00000124549.13	BTN2A3P	7.44	4.96e-13	2e-10	0.29	0.33	Intelligence (multi-trait analysis);	chr6:26535313	chr6:26421391~26432383:+
PRAD	cis	rs9467773	1	rs1321481	ENSG00000124549.13	BTN2A3P	7.44	4.96e-13	2e-10	0.29	0.33	Intelligence (multi-trait analysis);	chr6:26537982	chr6:26421391~26432383:+
PRAD	cis	rs9467773	1	rs4713008	ENSG00000124549.13	BTN2A3P	7.44	4.96e-13	2e-10	0.29	0.33	Intelligence (multi-trait analysis);	chr6:26538040	chr6:26421391~26432383:+
PRAD	cis	rs9467773	0.967	rs6932865	ENSG00000124549.13	BTN2A3P	7.44	4.96e-13	2e-10	0.29	0.33	Intelligence (multi-trait analysis);	chr6:26539938	chr6:26421391~26432383:+
PRAD	cis	rs9467773	1	rs6933176	ENSG00000124549.13	BTN2A3P	7.44	4.96e-13	2e-10	0.29	0.33	Intelligence (multi-trait analysis);	chr6:26539950	chr6:26421391~26432383:+
PRAD	cis	rs9467773	1	rs9467782	ENSG00000124549.13	BTN2A3P	7.44	4.96e-13	2e-10	0.29	0.33	Intelligence (multi-trait analysis);	chr6:26542545	chr6:26421391~26432383:+
PRAD	cis	rs9467773	0.935	rs9461270	ENSG00000124549.13	BTN2A3P	7.44	4.96e-13	2e-10	0.29	0.33	Intelligence (multi-trait analysis);	chr6:26543882	chr6:26421391~26432383:+
PRAD	cis	rs35160687	0.712	rs11691726	ENSG00000273080.1	RP11-301O19.1	-7.44	4.97e-13	2e-10	-0.37	-0.33	Night sleep phenotypes;	chr2:86267147	chr2:86195590~86196049:+
PRAD	cis	rs9601248	0.967	rs9545145	ENSG00000227676.3	LINC01068	-7.44	4.98e-13	2.01e-10	-0.39	-0.33	Major depressive disorder;	chr13:79599625	chr13:79566727~79571436:+
PRAD	cis	rs12908161	0.959	rs61074241	ENSG00000259728.4	LINC00933	7.44	4.99e-13	2.01e-10	0.43	0.33	Schizophrenia;	chr15:84790165	chr15:84570649~84580175:+
PRAD	cis	rs67180937	0.884	rs2291832	ENSG00000272750.1	RP11-378J18.8	-7.44	4.99e-13	2.01e-10	-0.43	-0.33	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222653139	chr1:222658867~222661512:-
PRAD	cis	rs35158675	1	rs35158675	ENSG00000272750.1	RP11-378J18.8	-7.44	4.99e-13	2.01e-10	-0.43	-0.33	Coronary artery disease;	chr1:222656208	chr1:222658867~222661512:-
PRAD	cis	rs67180937	0.922	rs1133220	ENSG00000272750.1	RP11-378J18.8	-7.44	4.99e-13	2.01e-10	-0.43	-0.33	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222661461	chr1:222658867~222661512:-
PRAD	cis	rs67180937	0.961	rs17465940	ENSG00000272750.1	RP11-378J18.8	-7.44	4.99e-13	2.01e-10	-0.43	-0.33	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222663654	chr1:222658867~222661512:-
PRAD	cis	rs67180937	0.922	rs17465982	ENSG00000272750.1	RP11-378J18.8	-7.44	4.99e-13	2.01e-10	-0.43	-0.33	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222664597	chr1:222658867~222661512:-
PRAD	cis	rs7615952	0.515	rs4267608	ENSG00000171084.14	FAM86JP	7.44	5e-13	2.02e-10	0.51	0.33	Blood pressure (smoking interaction);	chr3:125961657	chr3:125916620~125930024:+
PRAD	cis	rs6479901	0.512	rs11817169	ENSG00000232075.1	MRPL35P2	7.44	5e-13	2.02e-10	0.56	0.33	Intelligence (multi-trait analysis);	chr10:63596549	chr10:63634317~63634827:-
PRAD	cis	rs11098499	0.913	rs10010696	ENSG00000245958.5	RP11-33B1.1	-7.44	5.01e-13	2.02e-10	-0.32	-0.33	Corneal astigmatism;	chr4:119243148	chr4:119454791~119552025:+
PRAD	cis	rs5760092	0.755	rs11090298	ENSG00000206090.4	AP000350.7	-7.44	5.02e-13	2.02e-10	-0.5	-0.33	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919874	chr22:23939998~23942798:+
PRAD	cis	rs11098499	0.644	rs7676296	ENSG00000245958.5	RP11-33B1.1	-7.44	5.02e-13	2.02e-10	-0.31	-0.33	Corneal astigmatism;	chr4:119634532	chr4:119454791~119552025:+
PRAD	cis	rs4664293	0.967	rs12611922	ENSG00000226266.5	AC009961.3	-7.44	5.02e-13	2.02e-10	-0.43	-0.33	Monocyte percentage of white cells;	chr2:159606238	chr2:159670708~159712435:-
PRAD	cis	rs17012589	0.502	rs10862971	ENSG00000258815.1	RP11-408B11.2	7.44	5.03e-13	2.03e-10	0.44	0.33	Bone mineral density (Ward's triangle area);	chr12:85342699	chr12:85318060~85342912:+
PRAD	cis	rs1799949	1	rs8176133	ENSG00000267002.1	RP11-242D8.1	7.44	5.03e-13	2.03e-10	0.31	0.33	Menopause (age at onset);	chr17:43105441	chr17:43164183~43170403:-
PRAD	cis	rs9640161	0.789	rs60283368	ENSG00000261305.1	RP4-584D14.7	7.44	5.03e-13	2.03e-10	0.36	0.33	Blood protein levels;Circulating chemerin levels;	chr7:150326169	chr7:150341771~150342607:+
PRAD	cis	rs67311347	0.544	rs6769627	ENSG00000223797.4	ENTPD3-AS1	7.44	5.04e-13	2.03e-10	0.29	0.33	Renal cell carcinoma;	chr3:40286354	chr3:40313802~40453329:-
PRAD	cis	rs6991838	0.67	rs13275168	ENSG00000200714.1	Y_RNA	7.44	5.05e-13	2.03e-10	0.34	0.33	Intelligence (multi-trait analysis);	chr8:65685107	chr8:65592731~65592820:+
PRAD	cis	rs2041895	0.527	rs10861681	ENSG00000260329.1	RP11-412D9.4	-7.44	5.05e-13	2.04e-10	-0.32	-0.33	Glaucoma (low intraocular pressure);	chr12:106940484	chr12:106954029~106955497:-
PRAD	cis	rs6570726	0.902	rs973855	ENSG00000235652.6	RP11-545I5.3	-7.44	5.07e-13	2.04e-10	-0.35	-0.33	Lobe attachment (rater-scored or self-reported);	chr6:145460714	chr6:145799409~145886585:+
PRAD	cis	rs11098499	0.691	rs17009144	ENSG00000245958.5	RP11-33B1.1	7.44	5.08e-13	2.05e-10	0.3	0.33	Corneal astigmatism;	chr4:119349640	chr4:119454791~119552025:+
PRAD	cis	rs7829975	0.572	rs28730413	ENSG00000253893.2	FAM85B	7.44	5.09e-13	2.05e-10	0.41	0.33	Mood instability;	chr8:8937937	chr8:8167819~8226614:-
PRAD	cis	rs673078	0.607	rs16948230	ENSG00000275409.1	RP11-131L12.4	-7.44	5.09e-13	2.05e-10	-0.48	-0.33	Glucose homeostasis traits;	chr12:118277086	chr12:118430147~118430699:+
PRAD	cis	rs2337406	0.778	rs56965016	ENSG00000274576.2	IGHV2-70	-7.44	5.09e-13	2.05e-10	-0.36	-0.33	Alzheimer's disease (late onset);	chr14:106656649	chr14:106770577~106771020:-
PRAD	cis	rs2337406	0.778	rs56658355	ENSG00000274576.2	IGHV2-70	-7.44	5.09e-13	2.05e-10	-0.36	-0.33	Alzheimer's disease (late onset);	chr14:106662151	chr14:106770577~106771020:-
PRAD	cis	rs6782228	0.606	rs6807019	ENSG00000242551.2	POU5F1P6	-7.44	5.1e-13	2.06e-10	-0.41	-0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128687091	chr3:128674735~128677005:-
PRAD	cis	rs6504622	0.902	rs1052586	ENSG00000262879.4	RP11-156P1.3	-7.44	5.1e-13	2.06e-10	-0.35	-0.33	Orofacial clefts;	chr17:46941097	chr17:46984045~47100323:-
PRAD	cis	rs2439831	0.85	rs8023458	ENSG00000205771.5	CATSPER2P1	-7.44	5.1e-13	2.06e-10	-0.51	-0.33	Lung cancer in ever smokers;	chr15:43788741	chr15:43726918~43747094:-
PRAD	cis	rs1426063	0.858	rs7666182	ENSG00000249717.1	RP11-44F21.3	7.44	5.11e-13	2.06e-10	0.54	0.33	QT interval;	chr4:75090989	chr4:74955974~74970362:-
PRAD	cis	rs2439831	0.85	rs28595038	ENSG00000205771.5	CATSPER2P1	-7.44	5.11e-13	2.06e-10	-0.51	-0.33	Lung cancer in ever smokers;	chr15:43752661	chr15:43726918~43747094:-
PRAD	cis	rs2439831	0.85	rs10163054	ENSG00000205771.5	CATSPER2P1	-7.44	5.11e-13	2.06e-10	-0.51	-0.33	Lung cancer in ever smokers;	chr15:43755440	chr15:43726918~43747094:-
PRAD	cis	rs6921919	0.789	rs17301128	ENSG00000204709.4	LINC01556	7.44	5.11e-13	2.06e-10	0.47	0.33	Autism spectrum disorder or schizophrenia;	chr6:28340257	chr6:28943877~28944537:+
PRAD	cis	rs2015599	0.56	rs11050147	ENSG00000275476.1	RP11-996F15.4	-7.44	5.11e-13	2.06e-10	-0.37	-0.33	Platelet count;Mean platelet volume;	chr12:29242746	chr12:29277397~29277882:-
PRAD	cis	rs8177376	0.681	rs678422	ENSG00000254905.1	RP11-712L6.7	7.44	5.12e-13	2.06e-10	0.39	0.33	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126330009	chr11:126292922~126294254:-
PRAD	cis	rs67311347	0.544	rs9864664	ENSG00000223797.4	ENTPD3-AS1	7.44	5.12e-13	2.06e-10	0.29	0.33	Renal cell carcinoma;	chr3:40294735	chr3:40313802~40453329:-
PRAD	cis	rs17772222	0.74	rs4390529	ENSG00000258983.2	RP11-507K2.2	7.44	5.12e-13	2.06e-10	0.44	0.33	Coronary artery calcification;	chr14:88510853	chr14:88499334~88515502:+
PRAD	cis	rs17772222	0.771	rs4516145	ENSG00000258983.2	RP11-507K2.2	7.44	5.12e-13	2.06e-10	0.44	0.33	Coronary artery calcification;	chr14:88510953	chr14:88499334~88515502:+
PRAD	cis	rs77204473	0.744	rs2269399	ENSG00000254851.1	RP11-109L13.1	7.44	5.13e-13	2.06e-10	0.73	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117195637	chr11:117135528~117138582:+
PRAD	cis	rs9810089	1	rs1278493	ENSG00000261758.1	RP11-102M11.2	-7.44	5.13e-13	2.06e-10	-0.38	-0.33	Gestational age at birth (child effect);	chr3:136095167	chr3:136752630~136755780:+
PRAD	cis	rs507080	0.501	rs516503	ENSG00000255422.1	AP002954.4	-7.44	5.13e-13	2.07e-10	-0.39	-0.33	Serum metabolite levels;	chr11:118709639	chr11:118704607~118750263:+
PRAD	cis	rs1799949	0.965	rs2236762	ENSG00000267002.1	RP11-242D8.1	7.44	5.14e-13	2.07e-10	0.31	0.33	Menopause (age at onset);	chr17:43074658	chr17:43164183~43170403:-
PRAD	cis	rs7826238	0.509	rs2948288	ENSG00000253893.2	FAM85B	-7.44	5.15e-13	2.07e-10	-0.41	-0.33	Systolic blood pressure;	chr8:8257782	chr8:8167819~8226614:-
PRAD	cis	rs2638953	0.85	rs10843112	ENSG00000278733.1	RP11-425D17.1	-7.44	5.15e-13	2.07e-10	-0.42	-0.33	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28144614	chr12:28185625~28186190:-
PRAD	cis	rs2836950	0.501	rs13047518	ENSG00000255568.3	BRWD1-AS2	-7.44	5.16e-13	2.08e-10	-0.27	-0.33	Menarche (age at onset);	chr21:39335381	chr21:39313935~39314962:+
PRAD	cis	rs12999373	0.501	rs11127496	ENSG00000272342.1	RP13-539J13.1	7.44	5.16e-13	2.08e-10	0.43	0.33	Response to fenofibrate (adiponectin levels);Uric acid levels;	chr2:694063	chr2:739588~740164:-
PRAD	cis	rs10129255	0.912	rs8009135	ENSG00000223648.3	IGHV3-64	7.44	5.18e-13	2.08e-10	0.32	0.33	Kawasaki disease;	chr14:106777528	chr14:106643132~106658258:-
PRAD	cis	rs638893	0.617	rs4938564	ENSG00000278376.1	RP11-158I9.8	-7.44	5.19e-13	2.09e-10	-0.34	-0.33	Vitiligo;	chr11:118849881	chr11:118791254~118793137:+
PRAD	cis	rs638893	0.617	rs11217059	ENSG00000278376.1	RP11-158I9.8	-7.44	5.19e-13	2.09e-10	-0.34	-0.33	Vitiligo;	chr11:118852378	chr11:118791254~118793137:+
PRAD	cis	rs638893	0.617	rs7103314	ENSG00000278376.1	RP11-158I9.8	-7.44	5.19e-13	2.09e-10	-0.34	-0.33	Vitiligo;	chr11:118852828	chr11:118791254~118793137:+
PRAD	cis	rs7945705	0.692	rs11042149	ENSG00000254860.4	TMEM9B-AS1	7.44	5.19e-13	2.09e-10	0.33	0.33	Hemoglobin concentration;	chr11:8989190	chr11:8964675~8977527:+
PRAD	cis	rs7945705	0.747	rs11042150	ENSG00000254860.4	TMEM9B-AS1	7.44	5.19e-13	2.09e-10	0.33	0.33	Hemoglobin concentration;	chr11:8989272	chr11:8964675~8977527:+
PRAD	cis	rs733592	0.524	rs10875727	ENSG00000240399.1	RP1-228P16.1	-7.44	5.19e-13	2.09e-10	-0.27	-0.33	Plateletcrit;	chr12:48032360	chr12:48054813~48055591:-
PRAD	cis	rs1979679	0.879	rs2061759	ENSG00000278733.1	RP11-425D17.1	7.44	5.19e-13	2.09e-10	0.43	0.33	Ossification of the posterior longitudinal ligament of the spine;	chr12:28310394	chr12:28185625~28186190:-
PRAD	cis	rs8031584	0.541	rs2955797	ENSG00000270015.1	RP11-540B6.6	7.44	5.2e-13	2.09e-10	0.28	0.33	Huntington's disease progression;	chr15:30918778	chr15:30926514~30928407:+
PRAD	cis	rs6001482	0.523	rs5757595	ENSG00000272779.1	LL22NC03-80A10.6	-7.44	5.21e-13	2.1e-10	-0.4	-0.33	Diastolic blood pressure;	chr22:22235017	chr22:22303224~22310401:+
PRAD	cis	rs858239	0.6	rs59073109	ENSG00000226816.2	AC005082.12	7.44	5.23e-13	2.1e-10	0.37	0.33	Cerebrospinal fluid biomarker levels;	chr7:23093607	chr7:23206013~23208045:+
PRAD	cis	rs858239	0.6	rs7788821	ENSG00000226816.2	AC005082.12	7.44	5.23e-13	2.1e-10	0.37	0.33	Cerebrospinal fluid biomarker levels;	chr7:23094026	chr7:23206013~23208045:+
PRAD	cis	rs858239	0.6	rs6956595	ENSG00000226816.2	AC005082.12	7.44	5.23e-13	2.1e-10	0.37	0.33	Cerebrospinal fluid biomarker levels;	chr7:23094637	chr7:23206013~23208045:+
PRAD	cis	rs9532669	0.89	rs1543589	ENSG00000168852.11	TPTE2P5	7.43	5.25e-13	2.11e-10	0.32	0.33	Cervical cancer;	chr13:40999064	chr13:40822296~40921749:-
PRAD	cis	rs853679	0.607	rs34166054	ENSG00000280107.1	AL022393.9	-7.43	5.25e-13	2.11e-10	-0.67	-0.33	Depression;	chr6:28098023	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.556	rs34588114	ENSG00000280107.1	AL022393.9	-7.43	5.25e-13	2.11e-10	-0.67	-0.33	Depression;	chr6:28112850	chr6:28170845~28172521:+
PRAD	cis	rs73607972	0.877	rs67786703	ENSG00000275191.1	RP11-36I17.2	-7.43	5.26e-13	2.12e-10	-0.5	-0.33	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53572427	chr16:53628256~53628816:-
PRAD	cis	rs8062405	0.691	rs743590	ENSG00000251417.2	RP11-1348G14.4	-7.43	5.26e-13	2.12e-10	-0.37	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28596909	chr16:28802743~28817828:+
PRAD	cis	rs6539288	0.933	rs10861673	ENSG00000260329.1	RP11-412D9.4	-7.43	5.27e-13	2.12e-10	-0.29	-0.33	Total body bone mineral density;	chr12:106906293	chr12:106954029~106955497:-
PRAD	cis	rs2015599	0.623	rs3782510	ENSG00000257176.2	RP11-996F15.2	7.43	5.27e-13	2.12e-10	0.36	0.33	Platelet count;Mean platelet volume;	chr12:29301176	chr12:29280418~29317848:-
PRAD	cis	rs4664293	0.836	rs73967923	ENSG00000226266.5	AC009961.3	-7.43	5.27e-13	2.12e-10	-0.45	-0.33	Monocyte percentage of white cells;	chr2:159801754	chr2:159670708~159712435:-
PRAD	cis	rs62355900	0.627	rs61141156	ENSG00000271828.1	CTD-2310F14.1	7.43	5.29e-13	2.13e-10	0.69	0.33	Endometriosis;	chr5:56842951	chr5:56927874~56929573:+
PRAD	cis	rs62355900	0.627	rs58151318	ENSG00000271828.1	CTD-2310F14.1	7.43	5.29e-13	2.13e-10	0.69	0.33	Endometriosis;	chr5:56843355	chr5:56927874~56929573:+
PRAD	cis	rs62355900	0.627	rs16886407	ENSG00000271828.1	CTD-2310F14.1	7.43	5.29e-13	2.13e-10	0.69	0.33	Endometriosis;	chr5:56845540	chr5:56927874~56929573:+
PRAD	cis	rs62355900	0.627	rs16886419	ENSG00000271828.1	CTD-2310F14.1	7.43	5.29e-13	2.13e-10	0.69	0.33	Endometriosis;	chr5:56847034	chr5:56927874~56929573:+
PRAD	cis	rs62355901	0.545	rs1862621	ENSG00000271828.1	CTD-2310F14.1	7.43	5.29e-13	2.13e-10	0.69	0.33	Breast cancer;	chr5:56847332	chr5:56927874~56929573:+
PRAD	cis	rs62355900	0.627	rs62358076	ENSG00000271828.1	CTD-2310F14.1	7.43	5.29e-13	2.13e-10	0.69	0.33	Endometriosis;	chr5:56848189	chr5:56927874~56929573:+
PRAD	cis	rs62355900	0.627	rs16886424	ENSG00000271828.1	CTD-2310F14.1	7.43	5.29e-13	2.13e-10	0.69	0.33	Endometriosis;	chr5:56850866	chr5:56927874~56929573:+
PRAD	cis	rs62355900	0.627	rs16886429	ENSG00000271828.1	CTD-2310F14.1	7.43	5.29e-13	2.13e-10	0.69	0.33	Endometriosis;	chr5:56857265	chr5:56927874~56929573:+
PRAD	cis	rs62355900	0.627	rs62358104	ENSG00000271828.1	CTD-2310F14.1	7.43	5.29e-13	2.13e-10	0.69	0.33	Endometriosis;	chr5:56863344	chr5:56927874~56929573:+
PRAD	cis	rs11846409	0.86	rs4774166	ENSG00000274576.2	IGHV2-70	-7.43	5.3e-13	2.13e-10	-0.36	-0.33	Rheumatic heart disease;	chr14:106619598	chr14:106770577~106771020:-
PRAD	cis	rs10875746	0.625	rs2898065	ENSG00000240399.1	RP1-228P16.1	-7.43	5.3e-13	2.13e-10	-0.3	-0.33	Longevity (90 years and older);	chr12:48250836	chr12:48054813~48055591:-
PRAD	cis	rs9309711	0.883	rs13429373	ENSG00000225234.1	TRAPPC12-AS1	-7.43	5.32e-13	2.14e-10	-0.37	-0.33	Neurofibrillary tangles;	chr2:3473243	chr2:3481242~3482409:-
PRAD	cis	rs42648	0.869	rs10266179	ENSG00000227646.6	STEAP2-AS1	-7.43	5.34e-13	2.14e-10	-0.3	-0.33	Homocysteine levels;	chr7:90280668	chr7:89882353~90211635:-
PRAD	cis	rs7121800	0.962	rs12417588	ENSG00000242353.1	RP4-710M3.1	-7.43	5.34e-13	2.15e-10	-0.34	-0.33	Pit-and-Fissure caries;	chr11:30500116	chr11:30368148~30368646:+
PRAD	cis	rs7121800	0.962	rs4923641	ENSG00000242353.1	RP4-710M3.1	-7.43	5.34e-13	2.15e-10	-0.34	-0.33	Pit-and-Fissure caries;	chr11:30501598	chr11:30368148~30368646:+
PRAD	cis	rs2933343	0.679	rs789221	ENSG00000261159.1	RP11-723O4.9	7.43	5.35e-13	2.15e-10	0.29	0.33	IgG glycosylation;	chr3:128872782	chr3:128859716~128860526:-
PRAD	cis	rs673078	0.607	rs7294498	ENSG00000275409.1	RP11-131L12.4	-7.43	5.35e-13	2.15e-10	-0.43	-0.33	Glucose homeostasis traits;	chr12:118321680	chr12:118430147~118430699:+
PRAD	cis	rs9640161	0.702	rs11765692	ENSG00000261305.1	RP4-584D14.7	7.43	5.35e-13	2.15e-10	0.36	0.33	Blood protein levels;Circulating chemerin levels;	chr7:150329478	chr7:150341771~150342607:+
PRAD	cis	rs7615952	0.599	rs12485717	ENSG00000171084.14	FAM86JP	-7.43	5.35e-13	2.15e-10	-0.51	-0.33	Blood pressure (smoking interaction);	chr3:125988232	chr3:125916620~125930024:+
PRAD	cis	rs62355901	0.505	rs55698001	ENSG00000271828.1	CTD-2310F14.1	7.43	5.37e-13	2.16e-10	0.73	0.33	Breast cancer;	chr5:56949313	chr5:56927874~56929573:+
PRAD	cis	rs42648	0.869	rs1015404	ENSG00000227646.6	STEAP2-AS1	-7.43	5.38e-13	2.16e-10	-0.3	-0.33	Homocysteine levels;	chr7:90284632	chr7:89882353~90211635:-
PRAD	cis	rs6782228	0.606	rs2811488	ENSG00000242551.2	POU5F1P6	-7.43	5.38e-13	2.16e-10	-0.41	-0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128617674	chr3:128674735~128677005:-
PRAD	cis	rs6782228	0.606	rs2712381	ENSG00000242551.2	POU5F1P6	-7.43	5.38e-13	2.16e-10	-0.41	-0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619757	chr3:128674735~128677005:-
PRAD	cis	rs6782228	0.606	rs1127030	ENSG00000242551.2	POU5F1P6	-7.43	5.38e-13	2.16e-10	-0.41	-0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128620110	chr3:128674735~128677005:-
PRAD	cis	rs6782228	0.606	rs2712419	ENSG00000242551.2	POU5F1P6	-7.43	5.38e-13	2.16e-10	-0.41	-0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128622053	chr3:128674735~128677005:-
PRAD	cis	rs6782228	0.606	rs2712417	ENSG00000242551.2	POU5F1P6	-7.43	5.38e-13	2.16e-10	-0.41	-0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128626336	chr3:128674735~128677005:-
PRAD	cis	rs6844153	1	rs4557251	ENSG00000240005.4	RP11-293A21.1	-7.43	5.38e-13	2.16e-10	-0.49	-0.33	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26848285	chr4:26859806~26860599:-
PRAD	cis	rs17772222	0.74	rs10138309	ENSG00000258983.2	RP11-507K2.2	7.43	5.39e-13	2.17e-10	0.44	0.33	Coronary artery calcification;	chr14:88510352	chr14:88499334~88515502:+
PRAD	cis	rs7567389	0.671	rs72845993	ENSG00000236682.1	AC068282.3	-7.43	5.39e-13	2.17e-10	-0.43	-0.33	Self-rated health;	chr2:127351025	chr2:127389130~127400580:+
PRAD	cis	rs7181230	1	rs7181230	ENSG00000275636.1	RP11-521C20.5	7.43	5.4e-13	2.17e-10	0.44	0.33	Dehydroepiandrosterone sulphate levels;	chr15:40068540	chr15:40078892~40079347:+
PRAD	cis	rs2933343	0.679	rs789254	ENSG00000261159.1	RP11-723O4.9	7.43	5.4e-13	2.17e-10	0.29	0.33	IgG glycosylation;	chr3:128855750	chr3:128859716~128860526:-
PRAD	cis	rs9467773	0.967	rs7753565	ENSG00000124549.13	BTN2A3P	7.43	5.41e-13	2.17e-10	0.29	0.33	Intelligence (multi-trait analysis);	chr6:26559784	chr6:26421391~26432383:+
PRAD	cis	rs2243480	0.901	rs57126451	ENSG00000273142.1	RP11-458F8.4	-7.43	5.43e-13	2.18e-10	-0.36	-0.33	Diabetic kidney disease;	chr7:65951319	chr7:66902857~66906297:+
PRAD	cis	rs853679	0.628	rs9368560	ENSG00000204709.4	LINC01556	7.43	5.44e-13	2.18e-10	0.45	0.33	Depression;	chr6:28192182	chr6:28943877~28944537:+
PRAD	cis	rs10463554	0.892	rs11952337	ENSG00000175749.11	EIF3KP1	7.43	5.45e-13	2.19e-10	0.42	0.33	Parkinson's disease;	chr5:102928043	chr5:103032376~103033031:+
PRAD	cis	rs10463554	0.892	rs6871715	ENSG00000175749.11	EIF3KP1	7.43	5.45e-13	2.19e-10	0.42	0.33	Parkinson's disease;	chr5:102930398	chr5:103032376~103033031:+
PRAD	cis	rs812925	0.537	rs10208769	ENSG00000271889.1	RP11-493E12.1	-7.43	5.45e-13	2.19e-10	-0.36	-0.33	Immature fraction of reticulocytes;	chr2:61378479	chr2:61151433~61162105:-
PRAD	cis	rs73186030	0.687	rs16833080	ENSG00000272758.4	RP11-299J3.8	-7.43	5.46e-13	2.19e-10	-0.47	-0.33	Serum parathyroid hormone levels;	chr3:122382060	chr3:122416207~122443180:+
PRAD	cis	rs1979679	0.766	rs7299798	ENSG00000278733.1	RP11-425D17.1	-7.43	5.47e-13	2.2e-10	-0.43	-0.33	Ossification of the posterior longitudinal ligament of the spine;	chr12:28559224	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.671	rs10843101	ENSG00000278733.1	RP11-425D17.1	-7.43	5.48e-13	2.2e-10	-0.44	-0.33	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28117129	chr12:28185625~28186190:-
PRAD	cis	rs67340775	0.834	rs13218875	ENSG00000280107.1	AL022393.9	-7.43	5.49e-13	2.2e-10	-0.67	-0.33	Lung cancer in ever smokers;	chr6:27916234	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.607	rs67040724	ENSG00000280107.1	AL022393.9	-7.43	5.49e-13	2.2e-10	-0.67	-0.33	Depression;	chr6:27937731	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.607	rs67662114	ENSG00000280107.1	AL022393.9	-7.43	5.49e-13	2.2e-10	-0.67	-0.33	Depression;	chr6:27964523	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.607	rs13216117	ENSG00000280107.1	AL022393.9	-7.43	5.49e-13	2.2e-10	-0.67	-0.33	Depression;	chr6:27970706	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.607	rs36101351	ENSG00000280107.1	AL022393.9	-7.43	5.49e-13	2.2e-10	-0.67	-0.33	Depression;	chr6:27975591	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.607	rs28360499	ENSG00000280107.1	AL022393.9	-7.43	5.49e-13	2.2e-10	-0.67	-0.33	Depression;	chr6:27977618	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.546	rs71537572	ENSG00000280107.1	AL022393.9	-7.43	5.49e-13	2.2e-10	-0.67	-0.33	Depression;	chr6:28002937	chr6:28170845~28172521:+
PRAD	cis	rs812925	0.537	rs2593620	ENSG00000271889.1	RP11-493E12.1	-7.43	5.5e-13	2.21e-10	-0.36	-0.33	Immature fraction of reticulocytes;	chr2:61386126	chr2:61151433~61162105:-
PRAD	cis	rs964611	0.938	rs12592157	ENSG00000259488.2	RP11-154J22.1	-7.43	5.52e-13	2.21e-10	-0.36	-0.33	Metabolite levels (Pyroglutamine);	chr15:48331327	chr15:48312353~48331856:-
PRAD	cis	rs4631830	0.896	rs7077830	ENSG00000230869.1	CTGLF10P	7.43	5.52e-13	2.22e-10	0.4	0.33	Prostate-specific antigen levels;	chr10:46073546	chr10:45678692~45700532:+
PRAD	cis	rs6847067	0.894	rs72664926	ENSG00000180769.7	WDFY3-AS2	7.43	5.53e-13	2.22e-10	0.34	0.33	Oropharynx cancer;	chr4:84827743	chr4:84965682~85011277:+
PRAD	cis	rs6921919	0.789	rs6456814	ENSG00000204709.4	LINC01556	7.43	5.54e-13	2.22e-10	0.46	0.33	Autism spectrum disorder or schizophrenia;	chr6:28338035	chr6:28943877~28944537:+
PRAD	cis	rs7615952	0.599	rs6438953	ENSG00000171084.14	FAM86JP	7.43	5.54e-13	2.22e-10	0.49	0.33	Blood pressure (smoking interaction);	chr3:126006108	chr3:125916620~125930024:+
PRAD	cis	rs7615952	0.599	rs1044215	ENSG00000171084.14	FAM86JP	7.43	5.54e-13	2.22e-10	0.49	0.33	Blood pressure (smoking interaction);	chr3:126006716	chr3:125916620~125930024:+
PRAD	cis	rs2739330	0.685	rs4822453	ENSG00000228039.3	KB-1125A3.10	7.43	5.54e-13	2.22e-10	0.42	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23963780~23964374:+
PRAD	cis	rs79349575	0.783	rs12603969	ENSG00000248278.1	SUMO2P17	7.43	5.55e-13	2.23e-10	0.38	0.33	Type 2 diabetes;	chr17:48957057	chr17:48874860~48908983:-
PRAD	cis	rs79349575	0.783	rs12601955	ENSG00000248278.1	SUMO2P17	7.43	5.55e-13	2.23e-10	0.38	0.33	Type 2 diabetes;	chr17:48957058	chr17:48874860~48908983:-
PRAD	cis	rs16886181	0.512	rs12652988	ENSG00000271828.1	CTD-2310F14.1	7.43	5.56e-13	2.23e-10	0.75	0.33	Breast cancer (early onset);	chr5:56739539	chr5:56927874~56929573:+
PRAD	cis	rs2255336	0.81	rs7956385	ENSG00000245648.1	RP11-277P12.20	7.43	5.56e-13	2.23e-10	0.55	0.33	Blood protein levels;	chr12:10361398	chr12:10363769~10398506:+
PRAD	cis	rs6921919	0.789	rs13210258	ENSG00000204709.4	LINC01556	7.43	5.56e-13	2.23e-10	0.46	0.33	Autism spectrum disorder or schizophrenia;	chr6:28340894	chr6:28943877~28944537:+
PRAD	cis	rs367615	0.506	rs2914684	ENSG00000249476.1	CTD-2587M2.1	-7.43	5.56e-13	2.23e-10	-0.4	-0.33	Colorectal cancer (SNP x SNP interaction);	chr5:109439409	chr5:109237120~109326369:-
PRAD	cis	rs10129255	0.5	rs7157975	ENSG00000211972.2	IGHV3-66	7.43	5.58e-13	2.24e-10	0.28	0.33	Kawasaki disease;	chr14:106804049	chr14:106675017~106675544:-
PRAD	cis	rs79349575	0.783	rs15563	ENSG00000248278.1	SUMO2P17	7.43	5.58e-13	2.24e-10	0.37	0.33	Type 2 diabetes;	chr17:48927831	chr17:48874860~48908983:-
PRAD	cis	rs2439831	0.85	rs16963953	ENSG00000205771.5	CATSPER2P1	-7.43	5.58e-13	2.24e-10	-0.51	-0.33	Lung cancer in ever smokers;	chr15:43789521	chr15:43726918~43747094:-
PRAD	cis	rs1061377	1	rs1036036	ENSG00000249685.1	RP11-360F5.3	7.43	5.58e-13	2.24e-10	0.37	0.33	Uric acid levels;	chr4:39111104	chr4:39133913~39135608:+
PRAD	cis	rs9326248	0.53	rs11216171	ENSG00000280143.1	AP000892.6	7.43	5.58e-13	2.24e-10	0.29	0.33	Blood protein levels;	chr11:116878397	chr11:117204967~117210292:+
PRAD	cis	rs6991838	0.67	rs869151	ENSG00000200714.1	Y_RNA	7.43	5.58e-13	2.24e-10	0.34	0.33	Intelligence (multi-trait analysis);	chr8:65726487	chr8:65592731~65592820:+
PRAD	cis	rs2439831	0.85	rs8042868	ENSG00000249839.1	AC011330.5	-7.42	5.6e-13	2.25e-10	-0.56	-0.33	Lung cancer in ever smokers;	chr15:43647444	chr15:43663654~43684339:-
PRAD	cis	rs1979679	0.918	rs3858544	ENSG00000278733.1	RP11-425D17.1	-7.42	5.61e-13	2.25e-10	-0.42	-0.33	Ossification of the posterior longitudinal ligament of the spine;	chr12:28442911	chr12:28185625~28186190:-
PRAD	cis	rs10875746	0.551	rs1471997	ENSG00000240399.1	RP1-228P16.1	-7.42	5.62e-13	2.25e-10	-0.31	-0.33	Longevity (90 years and older);	chr12:48329812	chr12:48054813~48055591:-
PRAD	cis	rs748404	0.697	rs555001	ENSG00000205771.5	CATSPER2P1	-7.42	5.62e-13	2.25e-10	-0.35	-0.33	Lung cancer;	chr15:43253530	chr15:43726918~43747094:-
PRAD	cis	rs748404	0.697	rs475261	ENSG00000205771.5	CATSPER2P1	-7.42	5.62e-13	2.25e-10	-0.35	-0.33	Lung cancer;	chr15:43254258	chr15:43726918~43747094:-
PRAD	cis	rs853679	0.546	rs200981	ENSG00000280107.1	AL022393.9	-7.42	5.67e-13	2.27e-10	-0.58	-0.33	Depression;	chr6:27865396	chr6:28170845~28172521:+
PRAD	cis	rs12612619	0.732	rs13021112	ENSG00000272148.1	RP11-195B17.1	7.42	5.67e-13	2.27e-10	0.4	0.33	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27036926	chr2:27062428~27062907:-
PRAD	cis	rs9362426	0.608	rs6454613	ENSG00000218793.1	RP3-382I10.3	7.42	5.67e-13	2.27e-10	0.42	0.33	Depressive episodes in bipolar disorder;	chr6:87402271	chr6:87441165~87442146:-
PRAD	cis	rs9362426	0.579	rs9362428	ENSG00000218793.1	RP3-382I10.3	-7.42	5.67e-13	2.27e-10	-0.42	-0.33	Depressive episodes in bipolar disorder;	chr6:87397697	chr6:87441165~87442146:-
PRAD	cis	rs9362426	0.608	rs6454611	ENSG00000218793.1	RP3-382I10.3	-7.42	5.67e-13	2.27e-10	-0.42	-0.33	Depressive episodes in bipolar disorder;	chr6:87400387	chr6:87441165~87442146:-
PRAD	cis	rs526231	0.511	rs17154942	ENSG00000175749.11	EIF3KP1	-7.42	5.68e-13	2.27e-10	-0.46	-0.33	Primary biliary cholangitis;	chr5:103017014	chr5:103032376~103033031:+
PRAD	cis	rs526231	0.543	rs62362521	ENSG00000175749.11	EIF3KP1	7.42	5.68e-13	2.27e-10	0.45	0.33	Primary biliary cholangitis;	chr5:102970357	chr5:103032376~103033031:+
PRAD	cis	rs526231	0.575	rs12652973	ENSG00000175749.11	EIF3KP1	7.42	5.68e-13	2.27e-10	0.45	0.33	Primary biliary cholangitis;	chr5:102970618	chr5:103032376~103033031:+
PRAD	cis	rs73607972	0.935	rs16952396	ENSG00000275191.1	RP11-36I17.2	-7.42	5.68e-13	2.28e-10	-0.53	-0.33	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53616751	chr16:53628256~53628816:-
PRAD	cis	rs11098499	0.644	rs28787668	ENSG00000245958.5	RP11-33B1.1	-7.42	5.69e-13	2.28e-10	-0.31	-0.33	Corneal astigmatism;	chr4:119633532	chr4:119454791~119552025:+
PRAD	cis	rs375066	0.935	rs425217	ENSG00000267058.1	RP11-15A1.3	-7.42	5.7e-13	2.28e-10	-0.28	-0.33	Breast cancer;	chr19:43889823	chr19:43891804~43901805:-
PRAD	cis	rs375066	0.935	rs422457	ENSG00000267058.1	RP11-15A1.3	-7.42	5.7e-13	2.28e-10	-0.28	-0.33	Breast cancer;	chr19:43905259	chr19:43891804~43901805:-
PRAD	cis	rs10463554	0.892	rs66759661	ENSG00000175749.11	EIF3KP1	7.42	5.71e-13	2.29e-10	0.43	0.33	Parkinson's disease;	chr5:102925894	chr5:103032376~103033031:+
PRAD	cis	rs10463554	0.892	rs6872442	ENSG00000175749.11	EIF3KP1	7.42	5.71e-13	2.29e-10	0.43	0.33	Parkinson's disease;	chr5:102930818	chr5:103032376~103033031:+
PRAD	cis	rs62355901	0.505	rs62356567	ENSG00000271828.1	CTD-2310F14.1	7.42	5.71e-13	2.29e-10	0.73	0.33	Breast cancer;	chr5:56953442	chr5:56927874~56929573:+
PRAD	cis	rs9640161	0.742	rs11767726	ENSG00000261305.1	RP4-584D14.7	-7.42	5.74e-13	2.3e-10	-0.36	-0.33	Blood protein levels;Circulating chemerin levels;	chr7:150321007	chr7:150341771~150342607:+
PRAD	cis	rs2638953	0.962	rs61920565	ENSG00000278733.1	RP11-425D17.1	-7.42	5.75e-13	2.3e-10	-0.41	-0.33	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28377192	chr12:28185625~28186190:-
PRAD	cis	rs858239	0.601	rs6461702	ENSG00000226816.2	AC005082.12	7.42	5.78e-13	2.31e-10	0.39	0.33	Cerebrospinal fluid biomarker levels;	chr7:23209654	chr7:23206013~23208045:+
PRAD	cis	rs10129255	0.646	rs55995061	ENSG00000211970.3	IGHV4-61	-7.42	5.78e-13	2.32e-10	-0.3	-0.33	Kawasaki disease;	chr14:106799309	chr14:106639119~106639657:-
PRAD	cis	rs6539288	0.933	rs10861672	ENSG00000260329.1	RP11-412D9.4	-7.42	5.78e-13	2.32e-10	-0.29	-0.33	Total body bone mineral density;	chr12:106906222	chr12:106954029~106955497:-
PRAD	cis	rs7829975	0.714	rs59046059	ENSG00000253893.2	FAM85B	-7.42	5.79e-13	2.32e-10	-0.42	-0.33	Mood instability;	chr8:8813226	chr8:8167819~8226614:-
PRAD	cis	rs673078	0.66	rs17440364	ENSG00000275409.1	RP11-131L12.4	-7.42	5.79e-13	2.32e-10	-0.48	-0.33	Glucose homeostasis traits;	chr12:118186613	chr12:118430147~118430699:+
PRAD	cis	rs9467773	0.549	rs9467805	ENSG00000241549.7	GUSBP2	7.42	5.79e-13	2.32e-10	0.35	0.33	Intelligence (multi-trait analysis);	chr6:26583138	chr6:26871484~26956554:-
PRAD	cis	rs7429990	0.965	rs62260764	ENSG00000229759.1	MRPS18AP1	7.42	5.8e-13	2.32e-10	0.37	0.33	Educational attainment (years of education);	chr3:47949010	chr3:48256350~48256938:-
PRAD	cis	rs4631830	1	rs4631830	ENSG00000230869.1	CTGLF10P	-7.42	5.8e-13	2.32e-10	-0.4	-0.33	Prostate-specific antigen levels;	chr10:46052478	chr10:45678692~45700532:+
PRAD	cis	rs4631830	0.72	rs2611471	ENSG00000230869.1	CTGLF10P	-7.42	5.8e-13	2.32e-10	-0.41	-0.33	Prostate-specific antigen levels;	chr10:46092263	chr10:45678692~45700532:+
PRAD	cis	rs4631830	0.72	rs113082846	ENSG00000230869.1	CTGLF10P	-7.42	5.8e-13	2.32e-10	-0.41	-0.33	Prostate-specific antigen levels;	chr10:46093020	chr10:45678692~45700532:+
PRAD	cis	rs2255336	0.616	rs6488285	ENSG00000245648.1	RP11-277P12.20	7.42	5.8e-13	2.32e-10	0.52	0.33	Blood protein levels;	chr12:10366107	chr12:10363769~10398506:+
PRAD	cis	rs2255336	0.608	rs7957681	ENSG00000245648.1	RP11-277P12.20	7.42	5.8e-13	2.32e-10	0.52	0.33	Blood protein levels;	chr12:10366223	chr12:10363769~10398506:+
PRAD	cis	rs2255336	0.608	rs7958658	ENSG00000245648.1	RP11-277P12.20	7.42	5.8e-13	2.32e-10	0.52	0.33	Blood protein levels;	chr12:10366229	chr12:10363769~10398506:+
PRAD	cis	rs2638953	0.962	rs61920564	ENSG00000278733.1	RP11-425D17.1	-7.42	5.8e-13	2.32e-10	-0.42	-0.33	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28357000	chr12:28185625~28186190:-
PRAD	cis	rs12612619	0.732	rs1866654	ENSG00000272148.1	RP11-195B17.1	7.42	5.81e-13	2.33e-10	0.39	0.33	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27040254	chr2:27062428~27062907:-
PRAD	cis	rs67311347	0.544	rs7644643	ENSG00000223797.4	ENTPD3-AS1	-7.42	5.81e-13	2.33e-10	-0.29	-0.33	Renal cell carcinoma;	chr3:40308718	chr3:40313802~40453329:-
PRAD	cis	rs10129255	0.5	rs8004923	ENSG00000211972.2	IGHV3-66	7.42	5.85e-13	2.34e-10	0.28	0.33	Kawasaki disease;	chr14:106785926	chr14:106675017~106675544:-
PRAD	cis	rs10129255	0.5	rs6576232	ENSG00000211972.2	IGHV3-66	7.42	5.85e-13	2.34e-10	0.28	0.33	Kawasaki disease;	chr14:106787090	chr14:106675017~106675544:-
PRAD	cis	rs2836950	0.501	rs2056844	ENSG00000255568.3	BRWD1-AS2	-7.42	5.86e-13	2.35e-10	-0.27	-0.33	Menarche (age at onset);	chr21:39298534	chr21:39313935~39314962:+
PRAD	cis	rs6844153	1	rs74895929	ENSG00000240005.4	RP11-293A21.1	-7.42	5.86e-13	2.35e-10	-0.47	-0.33	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26846035	chr4:26859806~26860599:-
PRAD	cis	rs853679	0.607	rs71559070	ENSG00000280107.1	AL022393.9	-7.42	5.87e-13	2.35e-10	-0.67	-0.33	Depression;	chr6:28071151	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.607	rs35902873	ENSG00000280107.1	AL022393.9	-7.42	5.87e-13	2.35e-10	-0.67	-0.33	Depression;	chr6:28091171	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.607	rs13197574	ENSG00000280107.1	AL022393.9	-7.42	5.87e-13	2.35e-10	-0.67	-0.33	Depression;	chr6:28092461	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.607	rs34662244	ENSG00000280107.1	AL022393.9	-7.42	5.87e-13	2.35e-10	-0.67	-0.33	Depression;	chr6:28106103	chr6:28170845~28172521:+
PRAD	cis	rs35952432	1	rs35952432	ENSG00000280107.1	AL022393.9	-7.42	5.87e-13	2.35e-10	-0.67	-0.33	Lung cancer;	chr6:28107123	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.607	rs13203816	ENSG00000280107.1	AL022393.9	-7.42	5.87e-13	2.35e-10	-0.67	-0.33	Depression;	chr6:28111820	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.546	rs34371502	ENSG00000280107.1	AL022393.9	-7.42	5.87e-13	2.35e-10	-0.67	-0.33	Depression;	chr6:28113980	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.607	rs66886492	ENSG00000280107.1	AL022393.9	-7.42	5.87e-13	2.35e-10	-0.67	-0.33	Depression;	chr6:28121953	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.607	rs35345226	ENSG00000280107.1	AL022393.9	-7.42	5.87e-13	2.35e-10	-0.67	-0.33	Depression;	chr6:28123802	chr6:28170845~28172521:+
PRAD	cis	rs1061377	0.862	rs12508577	ENSG00000249685.1	RP11-360F5.3	7.42	5.88e-13	2.35e-10	0.38	0.33	Uric acid levels;	chr4:39107779	chr4:39133913~39135608:+
PRAD	cis	rs193541	0.621	rs898391	ENSG00000263432.2	RN7SL689P	7.42	5.89e-13	2.36e-10	0.35	0.33	Glucose homeostasis traits;	chr5:122746471	chr5:123022487~123022783:-
PRAD	cis	rs881375	0.933	rs7021206	ENSG00000226752.6	PSMD5-AS1	7.42	5.9e-13	2.36e-10	0.39	0.33	Rheumatoid arthritis;	chr9:120921879	chr9:120824828~120854385:+
PRAD	cis	rs1979679	0.801	rs6487686	ENSG00000278733.1	RP11-425D17.1	-7.42	5.9e-13	2.36e-10	-0.44	-0.33	Ossification of the posterior longitudinal ligament of the spine;	chr12:28548362	chr12:28185625~28186190:-
PRAD	cis	rs995000	0.868	rs1168114	ENSG00000235545.1	RP11-230B22.1	7.42	5.9e-13	2.36e-10	0.44	0.33	Triglyceride levels;	chr1:62690372	chr1:62688482~62710694:+
PRAD	cis	rs4664293	0.836	rs13421392	ENSG00000226266.5	AC009961.3	-7.42	5.91e-13	2.36e-10	-0.46	-0.33	Monocyte percentage of white cells;	chr2:159801785	chr2:159670708~159712435:-
PRAD	cis	rs79349575	0.715	rs55724082	ENSG00000248278.1	SUMO2P17	7.42	5.93e-13	2.37e-10	0.37	0.33	Type 2 diabetes;	chr17:48940517	chr17:48874860~48908983:-
PRAD	cis	rs62355901	0.505	rs72758017	ENSG00000271828.1	CTD-2310F14.1	7.42	5.93e-13	2.37e-10	0.74	0.33	Breast cancer;	chr5:56797732	chr5:56927874~56929573:+
PRAD	cis	rs9341835	0.51	rs2250179	ENSG00000218048.2	RP3-407E4.4	7.42	5.94e-13	2.38e-10	0.38	0.33	Schizophrenia;	chr6:63464654	chr6:63440766~63443580:+
PRAD	cis	rs17674580	0.582	rs3745006	ENSG00000267193.4	RP11-116O18.3	7.42	5.95e-13	2.38e-10	0.36	0.33	Bladder cancer;	chr18:45749625	chr18:45669367~45747215:-
PRAD	cis	rs3745672	0.661	rs10408992	ENSG00000219665.7	CTD-2006C1.2	-7.42	5.96e-13	2.38e-10	-0.73	-0.33	Multiple sclerosis;	chr19:11984973	chr19:11987617~12046275:+
PRAD	cis	rs2243480	1	rs7794661	ENSG00000273142.1	RP11-458F8.4	-7.42	5.97e-13	2.39e-10	-0.36	-0.33	Diabetic kidney disease;	chr7:65924743	chr7:66902857~66906297:+
PRAD	cis	rs10463554	0.892	rs2195272	ENSG00000175749.11	EIF3KP1	7.42	5.97e-13	2.39e-10	0.43	0.33	Parkinson's disease;	chr5:102959800	chr5:103032376~103033031:+
PRAD	cis	rs12468226	0.938	rs3843338	ENSG00000273456.1	RP11-686O6.2	-7.42	5.97e-13	2.39e-10	-0.44	-0.33	Urate levels;	chr2:202246102	chr2:202374932~202375604:-
PRAD	cis	rs9393777	0.92	rs34150729	ENSG00000226314.6	ZNF192P1	-7.42	5.98e-13	2.39e-10	-0.68	-0.33	Intelligence (multi-trait analysis);	chr6:27420975	chr6:28161781~28169594:+
PRAD	cis	rs9393777	0.92	rs13191227	ENSG00000226314.6	ZNF192P1	-7.42	5.98e-13	2.39e-10	-0.68	-0.33	Intelligence (multi-trait analysis);	chr6:27422336	chr6:28161781~28169594:+
PRAD	cis	rs6991838	0.733	rs7822627	ENSG00000200714.1	Y_RNA	7.42	5.98e-13	2.39e-10	0.34	0.33	Intelligence (multi-trait analysis);	chr8:65714139	chr8:65592731~65592820:+
PRAD	cis	rs17772222	0.74	rs11159857	ENSG00000258983.2	RP11-507K2.2	7.42	5.98e-13	2.39e-10	0.44	0.33	Coronary artery calcification;	chr14:88510796	chr14:88499334~88515502:+
PRAD	cis	rs17772222	0.74	rs4594187	ENSG00000258983.2	RP11-507K2.2	7.42	5.98e-13	2.39e-10	0.44	0.33	Coronary artery calcification;	chr14:88511071	chr14:88499334~88515502:+
PRAD	cis	rs17772222	0.74	rs4514599	ENSG00000258983.2	RP11-507K2.2	7.42	5.98e-13	2.39e-10	0.44	0.33	Coronary artery calcification;	chr14:88511083	chr14:88499334~88515502:+
PRAD	cis	rs17772222	0.74	rs61975276	ENSG00000258983.2	RP11-507K2.2	7.42	5.98e-13	2.39e-10	0.44	0.33	Coronary artery calcification;	chr14:88511193	chr14:88499334~88515502:+
PRAD	cis	rs17772222	0.74	rs61975277	ENSG00000258983.2	RP11-507K2.2	7.42	5.98e-13	2.39e-10	0.44	0.33	Coronary artery calcification;	chr14:88511202	chr14:88499334~88515502:+
PRAD	cis	rs17772222	0.74	rs73317739	ENSG00000258983.2	RP11-507K2.2	7.42	5.98e-13	2.39e-10	0.44	0.33	Coronary artery calcification;	chr14:88511400	chr14:88499334~88515502:+
PRAD	cis	rs17772222	0.696	rs28666030	ENSG00000258983.2	RP11-507K2.2	7.42	5.98e-13	2.39e-10	0.44	0.33	Coronary artery calcification;	chr14:88511463	chr14:88499334~88515502:+
PRAD	cis	rs17772222	0.74	rs28493481	ENSG00000258983.2	RP11-507K2.2	7.42	5.98e-13	2.39e-10	0.44	0.33	Coronary artery calcification;	chr14:88511491	chr14:88499334~88515502:+
PRAD	cis	rs6480314	0.636	rs7914274	ENSG00000233590.1	RP11-153K11.3	-7.42	5.98e-13	2.39e-10	-0.55	-0.33	Optic nerve measurement (disc area);	chr10:68240300	chr10:68233251~68242379:-
PRAD	cis	rs17674580	0.582	rs7359740	ENSG00000267193.4	RP11-116O18.3	7.42	5.99e-13	2.39e-10	0.36	0.33	Bladder cancer;	chr18:45753948	chr18:45669367~45747215:-
PRAD	cis	rs2243480	1	rs781142	ENSG00000273142.1	RP11-458F8.4	-7.42	5.99e-13	2.39e-10	-0.36	-0.33	Diabetic kidney disease;	chr7:65973791	chr7:66902857~66906297:+
PRAD	cis	rs4713118	0.513	rs149955	ENSG00000220721.1	OR1F12	7.41	6.01e-13	2.4e-10	0.38	0.33	Parkinson's disease;	chr6:28068447	chr6:28073316~28074233:+
PRAD	cis	rs1799949	1	rs4793236	ENSG00000267002.1	RP11-242D8.1	7.41	6.02e-13	2.4e-10	0.31	0.33	Menopause (age at onset);	chr17:43359072	chr17:43164183~43170403:-
PRAD	cis	rs7238033	0.62	rs11082469	ENSG00000267193.4	RP11-116O18.3	7.41	6.02e-13	2.41e-10	0.35	0.33	Bladder cancer;	chr18:45741304	chr18:45669367~45747215:-
PRAD	cis	rs853679	0.546	rs200996	ENSG00000280107.1	AL022393.9	-7.41	6.03e-13	2.41e-10	-0.58	-0.33	Depression;	chr6:27844050	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.546	rs200990	ENSG00000280107.1	AL022393.9	-7.41	6.03e-13	2.41e-10	-0.58	-0.33	Depression;	chr6:27848045	chr6:28170845~28172521:+
PRAD	cis	rs9601248	1	rs9601248	ENSG00000227676.3	LINC01068	-7.41	6.04e-13	2.41e-10	-0.39	-0.33	Major depressive disorder;	chr13:79594869	chr13:79566727~79571436:+
PRAD	cis	rs17711722	0.565	rs4717276	ENSG00000234585.5	CCT6P3	7.41	6.04e-13	2.41e-10	0.25	0.33	Calcium levels;	chr7:65829754	chr7:65038354~65074713:+
PRAD	cis	rs11846409	0.872	rs2516914	ENSG00000274576.2	IGHV2-70	7.41	6.04e-13	2.42e-10	0.34	0.33	Rheumatic heart disease;	chr14:106629835	chr14:106770577~106771020:-
PRAD	cis	rs4865169	0.595	rs4865165	ENSG00000269949.1	RP11-738E22.3	-7.41	6.05e-13	2.42e-10	-0.38	-0.33	Breast cancer;	chr4:56899380	chr4:56960927~56961373:-
PRAD	cis	rs11098499	0.913	rs67073020	ENSG00000245958.5	RP11-33B1.1	-7.41	6.06e-13	2.42e-10	-0.32	-0.33	Corneal astigmatism;	chr4:119231402	chr4:119454791~119552025:+
PRAD	cis	rs6844153	0.627	rs11730235	ENSG00000240005.4	RP11-293A21.1	-7.41	6.08e-13	2.43e-10	-0.41	-0.33	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26922822	chr4:26859806~26860599:-
PRAD	cis	rs2933343	0.649	rs789216	ENSG00000261159.1	RP11-723O4.9	7.41	6.08e-13	2.43e-10	0.29	0.33	IgG glycosylation;	chr3:128875660	chr3:128859716~128860526:-
PRAD	cis	rs2933343	0.7	rs1680778	ENSG00000261159.1	RP11-723O4.9	7.41	6.08e-13	2.43e-10	0.29	0.33	IgG glycosylation;	chr3:128895342	chr3:128859716~128860526:-
PRAD	cis	rs748404	0.697	rs546170	ENSG00000205771.5	CATSPER2P1	-7.41	6.08e-13	2.43e-10	-0.35	-0.33	Lung cancer;	chr15:43272651	chr15:43726918~43747094:-
PRAD	cis	rs9532669	0.926	rs9532691	ENSG00000168852.11	TPTE2P5	-7.41	6.09e-13	2.43e-10	-0.31	-0.33	Cervical cancer;	chr13:40969358	chr13:40822296~40921749:-
PRAD	cis	rs67311347	0.544	rs2278927	ENSG00000223797.4	ENTPD3-AS1	7.41	6.09e-13	2.43e-10	0.29	0.33	Renal cell carcinoma;	chr3:40308956	chr3:40313802~40453329:-
PRAD	cis	rs13113518	0.678	rs7663650	ENSG00000249700.7	SRD5A3-AS1	-7.41	6.09e-13	2.43e-10	-0.4	-0.33	Height;	chr4:55364952	chr4:55363971~55395847:-
PRAD	cis	rs853679	1	rs2799079	ENSG00000226314.6	ZNF192P1	-7.41	6.1e-13	2.44e-10	-0.51	-0.33	Depression;	chr6:28267398	chr6:28161781~28169594:+
PRAD	cis	rs8523	0.779	rs1323739	ENSG00000230314.5	ELOVL2-AS1	-7.41	6.11e-13	2.44e-10	-0.36	-0.33	Red blood cell fatty acid levels;	chr6:11004328	chr6:11043524~11078226:+
PRAD	cis	rs9640161	0.658	rs60467296	ENSG00000261305.1	RP4-584D14.7	7.41	6.12e-13	2.44e-10	0.36	0.33	Blood protein levels;Circulating chemerin levels;	chr7:150318382	chr7:150341771~150342607:+
PRAD	cis	rs6921919	0.789	rs1119211	ENSG00000204709.4	LINC01556	-7.41	6.12e-13	2.44e-10	-0.46	-0.33	Autism spectrum disorder or schizophrenia;	chr6:28341359	chr6:28943877~28944537:+
PRAD	cis	rs9341835	0.518	rs6924479	ENSG00000218048.2	RP3-407E4.4	7.41	6.12e-13	2.44e-10	0.37	0.33	Schizophrenia;	chr6:63464035	chr6:63440766~63443580:+
PRAD	cis	rs1426063	1	rs10033857	ENSG00000249717.1	RP11-44F21.3	7.41	6.12e-13	2.44e-10	0.55	0.33	QT interval;	chr4:75103208	chr4:74955974~74970362:-
PRAD	cis	rs6479901	0.895	rs7918743	ENSG00000232075.1	MRPL35P2	-7.41	6.12e-13	2.44e-10	-0.4	-0.33	Intelligence (multi-trait analysis);	chr10:63333302	chr10:63634317~63634827:-
PRAD	cis	rs5769707	0.521	rs6009810	ENSG00000188511.11	C22orf34	7.41	6.12e-13	2.44e-10	0.38	0.33	Monocyte percentage of white cells;Monocyte count;	chr22:49665892	chr22:49414524~49657542:-
PRAD	cis	rs35264875	0.851	rs7933746	ENSG00000259799.1	RP11-554A11.9	7.41	6.13e-13	2.45e-10	0.39	0.33	Blond vs. brown hair color;	chr11:69100254	chr11:69155910~69159752:+
PRAD	cis	rs79349575	0.783	rs2112617	ENSG00000248278.1	SUMO2P17	7.41	6.14e-13	2.45e-10	0.37	0.33	Type 2 diabetes;	chr17:48899763	chr17:48874860~48908983:-
PRAD	cis	rs6480314	0.573	rs12573244	ENSG00000233590.1	RP11-153K11.3	-7.41	6.14e-13	2.45e-10	-0.55	-0.33	Optic nerve measurement (disc area);	chr10:68241488	chr10:68233251~68242379:-
PRAD	cis	rs6480314	0.542	rs11814858	ENSG00000233590.1	RP11-153K11.3	-7.41	6.14e-13	2.45e-10	-0.55	-0.33	Optic nerve measurement (disc area);	chr10:68241950	chr10:68233251~68242379:-
PRAD	cis	rs6480314	0.636	rs61854788	ENSG00000233590.1	RP11-153K11.3	-7.41	6.14e-13	2.45e-10	-0.55	-0.33	Optic nerve measurement (disc area);	chr10:68241980	chr10:68233251~68242379:-
PRAD	cis	rs2067615	0.579	rs7975576	ENSG00000260329.1	RP11-412D9.4	-7.41	6.14e-13	2.45e-10	-0.28	-0.33	Heart rate;	chr12:106738723	chr12:106954029~106955497:-
PRAD	cis	rs1023500	0.529	rs133375	ENSG00000205702.9	CYP2D7	7.41	6.14e-13	2.45e-10	0.25	0.33	Schizophrenia;	chr22:42070505	chr22:42140203~42144577:-
PRAD	cis	rs1134634	0.52	rs73125606	ENSG00000273133.1	RP11-799M12.2	-7.41	6.15e-13	2.45e-10	-0.44	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15545691	chr4:15563698~15564253:-
PRAD	cis	rs10129255	0.957	rs8009638	ENSG00000223648.3	IGHV3-64	7.41	6.16e-13	2.46e-10	0.32	0.33	Kawasaki disease;	chr14:106777570	chr14:106643132~106658258:-
PRAD	cis	rs7238033	0.663	rs7234986	ENSG00000267193.4	RP11-116O18.3	7.41	6.16e-13	2.46e-10	0.35	0.33	Bladder cancer;	chr18:45740639	chr18:45669367~45747215:-
PRAD	cis	rs17674580	0.604	rs9954521	ENSG00000267193.4	RP11-116O18.3	7.41	6.17e-13	2.46e-10	0.36	0.33	Bladder cancer;	chr18:45750931	chr18:45669367~45747215:-
PRAD	cis	rs17674580	0.604	rs3087560	ENSG00000267193.4	RP11-116O18.3	7.41	6.17e-13	2.46e-10	0.36	0.33	Bladder cancer;	chr18:45752290	chr18:45669367~45747215:-
PRAD	cis	rs17674580	0.582	rs3178156	ENSG00000267193.4	RP11-116O18.3	7.41	6.17e-13	2.46e-10	0.36	0.33	Bladder cancer;	chr18:45752515	chr18:45669367~45747215:-
PRAD	cis	rs375066	0.901	rs438517	ENSG00000267058.1	RP11-15A1.3	-7.41	6.17e-13	2.46e-10	-0.28	-0.33	Breast cancer;	chr19:43915506	chr19:43891804~43901805:-
PRAD	cis	rs375066	0.935	rs446674	ENSG00000267058.1	RP11-15A1.3	-7.41	6.17e-13	2.46e-10	-0.28	-0.33	Breast cancer;	chr19:43916855	chr19:43891804~43901805:-
PRAD	cis	rs2243480	1	rs56016656	ENSG00000273142.1	RP11-458F8.4	-7.41	6.19e-13	2.47e-10	-0.36	-0.33	Diabetic kidney disease;	chr7:65918494	chr7:66902857~66906297:+
PRAD	cis	rs2243480	0.803	rs55700941	ENSG00000273142.1	RP11-458F8.4	-7.41	6.19e-13	2.47e-10	-0.36	-0.33	Diabetic kidney disease;	chr7:65924813	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs56291018	ENSG00000273142.1	RP11-458F8.4	-7.41	6.19e-13	2.47e-10	-0.36	-0.33	Diabetic kidney disease;	chr7:65925352	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs36033484	ENSG00000273142.1	RP11-458F8.4	-7.41	6.19e-13	2.47e-10	-0.36	-0.33	Diabetic kidney disease;	chr7:65925571	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs34560516	ENSG00000273142.1	RP11-458F8.4	-7.41	6.19e-13	2.47e-10	-0.36	-0.33	Diabetic kidney disease;	chr7:65939105	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs34970380	ENSG00000273142.1	RP11-458F8.4	-7.41	6.19e-13	2.47e-10	-0.36	-0.33	Diabetic kidney disease;	chr7:65966506	chr7:66902857~66906297:+
PRAD	cis	rs2439831	0.85	rs9944216	ENSG00000249839.1	AC011330.5	7.41	6.2e-13	2.47e-10	0.57	0.33	Lung cancer in ever smokers;	chr15:43868575	chr15:43663654~43684339:-
PRAD	cis	rs10129255	0.517	rs11625572	ENSG00000223648.3	IGHV3-64	7.41	6.2e-13	2.47e-10	0.34	0.33	Kawasaki disease;	chr14:106656426	chr14:106643132~106658258:-
PRAD	cis	rs2933343	0.553	rs789212	ENSG00000231305.3	RP11-723O4.2	7.41	6.2e-13	2.47e-10	0.3	0.33	IgG glycosylation;	chr3:128968069	chr3:128861313~128871540:-
PRAD	cis	rs42648	0.935	rs42635	ENSG00000227646.6	STEAP2-AS1	-7.41	6.2e-13	2.47e-10	-0.3	-0.33	Homocysteine levels;	chr7:90336884	chr7:89882353~90211635:-
PRAD	cis	rs10129255	0.957	rs6576233	ENSG00000211970.3	IGHV4-61	-7.41	6.21e-13	2.48e-10	-0.3	-0.33	Kawasaki disease;	chr14:106787239	chr14:106639119~106639657:-
PRAD	cis	rs113835537	0.529	rs3892818	ENSG00000255517.5	CTD-3074O7.5	-7.41	6.22e-13	2.48e-10	-0.33	-0.33	Airway imaging phenotypes;	chr11:66472720	chr11:66473490~66480233:-
PRAD	cis	rs12612619	0.668	rs2304682	ENSG00000272148.1	RP11-195B17.1	7.41	6.22e-13	2.48e-10	0.4	0.33	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27084901	chr2:27062428~27062907:-
PRAD	cis	rs79349575	0.783	rs4399576	ENSG00000248278.1	SUMO2P17	7.41	6.22e-13	2.48e-10	0.37	0.33	Type 2 diabetes;	chr17:48932473	chr17:48874860~48908983:-
PRAD	cis	rs79349575	0.687	rs12602179	ENSG00000248278.1	SUMO2P17	7.41	6.22e-13	2.48e-10	0.37	0.33	Type 2 diabetes;	chr17:48932672	chr17:48874860~48908983:-
PRAD	cis	rs79349575	0.783	rs17708633	ENSG00000248278.1	SUMO2P17	7.41	6.22e-13	2.48e-10	0.37	0.33	Type 2 diabetes;	chr17:48934258	chr17:48874860~48908983:-
PRAD	cis	rs79349575	0.783	rs9747646	ENSG00000248278.1	SUMO2P17	7.41	6.22e-13	2.48e-10	0.37	0.33	Type 2 diabetes;	chr17:48939520	chr17:48874860~48908983:-
PRAD	cis	rs79349575	0.783	rs62075852	ENSG00000248278.1	SUMO2P17	7.41	6.22e-13	2.48e-10	0.37	0.33	Type 2 diabetes;	chr17:48939814	chr17:48874860~48908983:-
PRAD	cis	rs79349575	0.783	rs12601858	ENSG00000248278.1	SUMO2P17	7.41	6.22e-13	2.48e-10	0.37	0.33	Type 2 diabetes;	chr17:48940115	chr17:48874860~48908983:-
PRAD	cis	rs79349575	0.749	rs8182364	ENSG00000248278.1	SUMO2P17	7.41	6.22e-13	2.48e-10	0.37	0.33	Type 2 diabetes;	chr17:48940663	chr17:48874860~48908983:-
PRAD	cis	rs79349575	0.681	rs56080003	ENSG00000248278.1	SUMO2P17	7.41	6.22e-13	2.48e-10	0.37	0.33	Type 2 diabetes;	chr17:48941687	chr17:48874860~48908983:-
PRAD	cis	rs79349575	0.783	rs4793995	ENSG00000248278.1	SUMO2P17	7.41	6.22e-13	2.48e-10	0.37	0.33	Type 2 diabetes;	chr17:48942037	chr17:48874860~48908983:-
PRAD	cis	rs79349575	0.783	rs4793996	ENSG00000248278.1	SUMO2P17	7.41	6.22e-13	2.48e-10	0.37	0.33	Type 2 diabetes;	chr17:48942235	chr17:48874860~48908983:-
PRAD	cis	rs79349575	0.715	rs4793997	ENSG00000248278.1	SUMO2P17	7.41	6.22e-13	2.48e-10	0.37	0.33	Type 2 diabetes;	chr17:48942310	chr17:48874860~48908983:-
PRAD	cis	rs79349575	0.783	rs4793998	ENSG00000248278.1	SUMO2P17	7.41	6.22e-13	2.48e-10	0.37	0.33	Type 2 diabetes;	chr17:48942537	chr17:48874860~48908983:-
PRAD	cis	rs79349575	0.749	rs2270574	ENSG00000248278.1	SUMO2P17	7.41	6.22e-13	2.48e-10	0.37	0.33	Type 2 diabetes;	chr17:48944908	chr17:48874860~48908983:-
PRAD	cis	rs79349575	0.783	rs4794000	ENSG00000248278.1	SUMO2P17	7.41	6.22e-13	2.48e-10	0.37	0.33	Type 2 diabetes;	chr17:48945393	chr17:48874860~48908983:-
PRAD	cis	rs6547741	0.935	rs4666004	ENSG00000234072.1	AC074117.10	7.41	6.25e-13	2.49e-10	0.25	0.33	Oral cavity cancer;	chr2:27632185	chr2:27356246~27367622:+
PRAD	cis	rs6951245	0.554	rs2070118	ENSG00000229043.2	AC091729.9	-7.41	6.26e-13	2.49e-10	-0.47	-0.33	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1092869	chr7:1160374~1165267:+
PRAD	cis	rs12908161	0.92	rs35738019	ENSG00000275120.1	RP11-182J1.17	7.41	6.27e-13	2.5e-10	0.43	0.33	Schizophrenia;	chr15:84736979	chr15:84599434~84606463:-
PRAD	cis	rs12908161	1	rs34570071	ENSG00000275120.1	RP11-182J1.17	7.41	6.27e-13	2.5e-10	0.43	0.33	Schizophrenia;	chr15:84736981	chr15:84599434~84606463:-
PRAD	cis	rs12468226	1	rs16824599	ENSG00000273456.1	RP11-686O6.2	7.41	6.27e-13	2.5e-10	0.47	0.33	Urate levels;	chr2:202358243	chr2:202374932~202375604:-
PRAD	cis	rs995000	0.895	rs1168124	ENSG00000235545.1	RP11-230B22.1	-7.41	6.27e-13	2.5e-10	-0.44	-0.33	Triglyceride levels;	chr1:62674059	chr1:62688482~62710694:+
PRAD	cis	rs12468226	0.938	rs57571703	ENSG00000273456.1	RP11-686O6.2	7.41	6.28e-13	2.5e-10	0.45	0.33	Urate levels;	chr2:202281997	chr2:202374932~202375604:-
PRAD	cis	rs4925386	0.681	rs2427295	ENSG00000273619.1	RP5-908M14.9	-7.41	6.29e-13	2.51e-10	-0.23	-0.33	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62352375	chr20:62386303~62386970:-
PRAD	cis	rs7567389	0.719	rs1504135	ENSG00000236682.1	AC068282.3	7.41	6.3e-13	2.51e-10	0.45	0.33	Self-rated health;	chr2:127245675	chr2:127389130~127400580:+
PRAD	cis	rs8005677	0.798	rs4982711	ENSG00000257285.4	RP11-298I3.1	7.41	6.31e-13	2.51e-10	0.33	0.33	Cognitive ability (multi-trait analysis);	chr14:22929781	chr14:22929609~22955562:+
PRAD	cis	rs9326248	0.559	rs482371	ENSG00000280143.1	AP000892.6	7.41	6.32e-13	2.52e-10	0.25	0.33	Blood protein levels;	chr11:116881447	chr11:117204967~117210292:+
PRAD	cis	rs6539288	0.899	rs7956807	ENSG00000260329.1	RP11-412D9.4	-7.41	6.32e-13	2.52e-10	-0.28	-0.33	Total body bone mineral density;	chr12:106906748	chr12:106954029~106955497:-
PRAD	cis	rs6539288	0.899	rs7298423	ENSG00000260329.1	RP11-412D9.4	-7.41	6.32e-13	2.52e-10	-0.28	-0.33	Total body bone mineral density;	chr12:106908202	chr12:106954029~106955497:-
PRAD	cis	rs987724	0.531	rs12492804	ENSG00000240875.4	LINC00886	-7.41	6.32e-13	2.52e-10	-0.37	-0.33	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156814356	chr3:156747346~156817062:-
PRAD	cis	rs987724	0.592	rs12497539	ENSG00000240875.4	LINC00886	-7.41	6.32e-13	2.52e-10	-0.37	-0.33	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156816148	chr3:156747346~156817062:-
PRAD	cis	rs987724	0.571	rs59717073	ENSG00000240875.4	LINC00886	-7.41	6.32e-13	2.52e-10	-0.37	-0.33	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156816456	chr3:156747346~156817062:-
PRAD	cis	rs7637701	0.818	rs11717133	ENSG00000240875.4	LINC00886	-7.41	6.32e-13	2.52e-10	-0.37	-0.33	Breast cancer;	chr3:156816792	chr3:156747346~156817062:-
PRAD	cis	rs8062405	0.54	rs151226	ENSG00000259982.1	CDC37P1	7.41	6.32e-13	2.52e-10	0.41	0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28538502	chr16:28700294~28701540:-
PRAD	cis	rs9810089	0.676	rs526574	ENSG00000261758.1	RP11-102M11.2	7.41	6.33e-13	2.52e-10	0.37	0.33	Gestational age at birth (child effect);	chr3:136384507	chr3:136752630~136755780:+
PRAD	cis	rs17772222	0.682	rs2401751	ENSG00000258983.2	RP11-507K2.2	-7.41	6.34e-13	2.53e-10	-0.43	-0.33	Coronary artery calcification;	chr14:88480278	chr14:88499334~88515502:+
PRAD	cis	rs9828933	0.832	rs2292662	ENSG00000280620.1	SCAANT1	7.41	6.34e-13	2.53e-10	0.5	0.33	Type 2 diabetes;	chr3:63911539	chr3:63911518~63911772:-
PRAD	cis	rs12612619	0.732	rs6547401	ENSG00000272148.1	RP11-195B17.1	7.41	6.37e-13	2.54e-10	0.39	0.33	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27061977	chr2:27062428~27062907:-
PRAD	cis	rs2522056	1	rs886286	ENSG00000233006.5	AC034220.3	-7.41	6.37e-13	2.54e-10	-0.34	-0.33	Fibrinogen;Lymphocyte counts;	chr5:132459905	chr5:132311285~132369916:-
PRAD	cis	rs2522056	1	rs757105	ENSG00000233006.5	AC034220.3	-7.41	6.37e-13	2.54e-10	-0.34	-0.33	Fibrinogen;Lymphocyte counts;	chr5:132459971	chr5:132311285~132369916:-
PRAD	cis	rs2522056	1	rs2522047	ENSG00000233006.5	AC034220.3	-7.41	6.37e-13	2.54e-10	-0.34	-0.33	Fibrinogen;Lymphocyte counts;	chr5:132460190	chr5:132311285~132369916:-
PRAD	cis	rs2522056	1	rs2706393	ENSG00000233006.5	AC034220.3	-7.41	6.37e-13	2.54e-10	-0.34	-0.33	Fibrinogen;Lymphocyte counts;	chr5:132460375	chr5:132311285~132369916:-
PRAD	cis	rs2522056	1	rs2706395	ENSG00000233006.5	AC034220.3	-7.41	6.37e-13	2.54e-10	-0.34	-0.33	Fibrinogen;Lymphocyte counts;	chr5:132461111	chr5:132311285~132369916:-
PRAD	cis	rs7615952	0.576	rs17523380	ENSG00000171084.14	FAM86JP	7.41	6.38e-13	2.54e-10	0.45	0.33	Blood pressure (smoking interaction);	chr3:126084031	chr3:125916620~125930024:+
PRAD	cis	rs638893	0.617	rs7116715	ENSG00000278376.1	RP11-158I9.8	-7.41	6.39e-13	2.54e-10	-0.34	-0.33	Vitiligo;	chr11:118849033	chr11:118791254~118793137:+
PRAD	cis	rs2274273	0.588	rs7155054	ENSG00000258413.1	RP11-665C16.6	-7.41	6.39e-13	2.55e-10	-0.44	-0.33	Protein biomarker;	chr14:55283944	chr14:55262767~55272075:-
PRAD	cis	rs1501911	0.545	rs4703345	ENSG00000248489.1	CTD-2007H13.3	-7.41	6.4e-13	2.55e-10	-0.43	-0.33	Lung function (FEV1/FVC);	chr5:99016679	chr5:98929171~98995013:+
PRAD	cis	rs56114371	0.777	rs200482	ENSG00000280107.1	AL022393.9	-7.41	6.41e-13	2.55e-10	-0.57	-0.33	Breast cancer;	chr6:27806126	chr6:28170845~28172521:+
PRAD	cis	rs858239	0.6	rs7776644	ENSG00000226816.2	AC005082.12	7.41	6.41e-13	2.55e-10	0.37	0.33	Cerebrospinal fluid biomarker levels;	chr7:23079688	chr7:23206013~23208045:+
PRAD	cis	rs10875746	0.669	rs4760701	ENSG00000240399.1	RP1-228P16.1	-7.41	6.41e-13	2.55e-10	-0.3	-0.33	Longevity (90 years and older);	chr12:48304735	chr12:48054813~48055591:-
PRAD	cis	rs67340775	0.541	rs200973	ENSG00000280107.1	AL022393.9	-7.4	6.42e-13	2.56e-10	-0.51	-0.33	Lung cancer in ever smokers;	chr6:27890643	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.882	rs9380069	ENSG00000280107.1	AL022393.9	-7.4	6.42e-13	2.56e-10	-0.51	-0.33	Depression;	chr6:28235522	chr6:28170845~28172521:+
PRAD	cis	rs62355901	0.505	rs61193961	ENSG00000271828.1	CTD-2310F14.1	7.4	6.44e-13	2.56e-10	0.74	0.33	Breast cancer;	chr5:56792343	chr5:56927874~56929573:+
PRAD	cis	rs1799949	0.965	rs799917	ENSG00000267002.1	RP11-242D8.1	7.4	6.44e-13	2.56e-10	0.31	0.33	Menopause (age at onset);	chr17:43092919	chr17:43164183~43170403:-
PRAD	cis	rs9467773	1	rs12526680	ENSG00000124549.13	BTN2A3P	7.4	6.44e-13	2.56e-10	0.29	0.33	Intelligence (multi-trait analysis);	chr6:26550726	chr6:26421391~26432383:+
PRAD	cis	rs12908161	1	rs17601029	ENSG00000275120.1	RP11-182J1.17	7.4	6.44e-13	2.57e-10	0.43	0.33	Schizophrenia;	chr15:84804478	chr15:84599434~84606463:-
PRAD	cis	rs875971	0.619	rs2302918	ENSG00000237310.1	GS1-124K5.4	7.4	6.45e-13	2.57e-10	0.28	0.33	Aortic root size;	chr7:66535945	chr7:66493706~66495474:+
PRAD	cis	rs987724	0.592	rs1430410	ENSG00000240875.4	LINC00886	-7.4	6.45e-13	2.57e-10	-0.37	-0.33	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156807773	chr3:156747346~156817062:-
PRAD	cis	rs1043099	0.912	rs4820831	ENSG00000279699.1	RP1-102K2.9	7.4	6.48e-13	2.58e-10	0.51	0.33	Rheumatoid arthritis;	chr22:30315454	chr22:30275215~30276951:-
PRAD	cis	rs1134634	0.52	rs16892140	ENSG00000273133.1	RP11-799M12.2	-7.4	6.48e-13	2.58e-10	-0.44	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15546927	chr4:15563698~15564253:-
PRAD	cis	rs12612619	0.732	rs11679681	ENSG00000272148.1	RP11-195B17.1	7.4	6.48e-13	2.58e-10	0.39	0.33	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27075611	chr2:27062428~27062907:-
PRAD	cis	rs2638953	0.886	rs10843137	ENSG00000247934.4	RP11-967K21.1	-7.4	6.49e-13	2.58e-10	-0.33	-0.33	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28218788	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.924	rs10843138	ENSG00000247934.4	RP11-967K21.1	-7.4	6.49e-13	2.58e-10	-0.33	-0.33	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28219210	chr12:28163298~28190738:-
PRAD	cis	rs7916697	0.898	rs1900005	ENSG00000233590.1	RP11-153K11.3	7.4	6.5e-13	2.59e-10	0.45	0.33	Optic disc area;	chr10:68238298	chr10:68233251~68242379:-
PRAD	cis	rs6539288	0.933	rs6539289	ENSG00000260329.1	RP11-412D9.4	7.4	6.51e-13	2.59e-10	0.28	0.33	Total body bone mineral density;	chr12:106915538	chr12:106954029~106955497:-
PRAD	cis	rs8040855	0.86	rs7172266	ENSG00000259295.5	CSPG4P12	-7.4	6.52e-13	2.59e-10	-0.42	-0.33	Bulimia nervosa;	chr15:85172982	chr15:85191438~85213905:+
PRAD	cis	rs2243480	1	rs313798	ENSG00000226824.5	RP4-756H11.3	-7.4	6.52e-13	2.59e-10	-0.65	-0.33	Diabetic kidney disease;	chr7:66028044	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs313809	ENSG00000226824.5	RP4-756H11.3	-7.4	6.52e-13	2.59e-10	-0.65	-0.33	Diabetic kidney disease;	chr7:66034996	chr7:66654538~66669855:+
PRAD	cis	rs56114371	0.53	rs2056923	ENSG00000280107.1	AL022393.9	-7.4	6.52e-13	2.6e-10	-0.46	-0.33	Breast cancer;	chr6:27722160	chr6:28170845~28172521:+
PRAD	cis	rs3096299	0.967	rs753853	ENSG00000261118.1	RP11-104N10.1	7.4	6.53e-13	2.6e-10	0.33	0.33	Multiple myeloma (IgH translocation);	chr16:89380117	chr16:89492017~89504460:-
PRAD	cis	rs6480314	0.542	rs7894859	ENSG00000233590.1	RP11-153K11.3	-7.4	6.54e-13	2.6e-10	-0.55	-0.33	Optic nerve measurement (disc area);	chr10:68234620	chr10:68233251~68242379:-
PRAD	cis	rs9640161	0.75	rs3735167	ENSG00000261305.1	RP4-584D14.7	7.4	6.55e-13	2.61e-10	0.38	0.33	Blood protein levels;Circulating chemerin levels;	chr7:150342466	chr7:150341771~150342607:+
PRAD	cis	rs733592	0.524	rs10875726	ENSG00000240399.1	RP1-228P16.1	-7.4	6.56e-13	2.61e-10	-0.27	-0.33	Plateletcrit;	chr12:48032209	chr12:48054813~48055591:-
PRAD	cis	rs1979679	0.879	rs1581630	ENSG00000278733.1	RP11-425D17.1	-7.4	6.56e-13	2.61e-10	-0.43	-0.33	Ossification of the posterior longitudinal ligament of the spine;	chr12:28466378	chr12:28185625~28186190:-
PRAD	cis	rs67311347	0.577	rs2887951	ENSG00000223797.4	ENTPD3-AS1	7.4	6.57e-13	2.61e-10	0.3	0.33	Renal cell carcinoma;	chr3:40240613	chr3:40313802~40453329:-
PRAD	cis	rs10028773	0.556	rs4473640	ENSG00000245958.5	RP11-33B1.1	-7.4	6.57e-13	2.61e-10	-0.3	-0.33	Educational attainment;	chr4:119339282	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.691	rs10010355	ENSG00000245958.5	RP11-33B1.1	-7.4	6.57e-13	2.61e-10	-0.3	-0.33	Corneal astigmatism;	chr4:119339888	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.691	rs9307471	ENSG00000245958.5	RP11-33B1.1	-7.4	6.57e-13	2.61e-10	-0.3	-0.33	Corneal astigmatism;	chr4:119340107	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.644	rs17517414	ENSG00000245958.5	RP11-33B1.1	-7.4	6.57e-13	2.61e-10	-0.3	-0.33	Corneal astigmatism;	chr4:119340946	chr4:119454791~119552025:+
PRAD	cis	rs6952407	1	rs6952407	ENSG00000237310.1	GS1-124K5.4	-7.4	6.57e-13	2.61e-10	-0.29	-0.33	Cotinine glucuronidation;	chr7:66580525	chr7:66493706~66495474:+
PRAD	cis	rs858239	0.601	rs6461693	ENSG00000226816.2	AC005082.12	-7.4	6.58e-13	2.62e-10	-0.37	-0.33	Cerebrospinal fluid biomarker levels;	chr7:23120514	chr7:23206013~23208045:+
PRAD	cis	rs9467773	1	rs1321479	ENSG00000124549.13	BTN2A3P	-7.4	6.58e-13	2.62e-10	-0.28	-0.33	Intelligence (multi-trait analysis);	chr6:26501669	chr6:26421391~26432383:+
PRAD	cis	rs2243480	1	rs781150	ENSG00000226824.5	RP4-756H11.3	-7.4	6.59e-13	2.62e-10	-0.65	-0.33	Diabetic kidney disease;	chr7:66015986	chr7:66654538~66669855:+
PRAD	cis	rs4664293	0.585	rs13019325	ENSG00000226266.5	AC009961.3	7.4	6.6e-13	2.62e-10	0.43	0.33	Monocyte percentage of white cells;	chr2:159772479	chr2:159670708~159712435:-
PRAD	cis	rs6547741	0.935	rs2384626	ENSG00000234072.1	AC074117.10	7.4	6.6e-13	2.62e-10	0.25	0.33	Oral cavity cancer;	chr2:27550781	chr2:27356246~27367622:+
PRAD	cis	rs6547741	0.935	rs6761095	ENSG00000234072.1	AC074117.10	7.4	6.6e-13	2.62e-10	0.25	0.33	Oral cavity cancer;	chr2:27555143	chr2:27356246~27367622:+
PRAD	cis	rs55665837	1	rs7121171	ENSG00000251991.1	RNU7-49P	7.4	6.61e-13	2.63e-10	0.35	0.33	Vitamin D levels;	chr11:14424874	chr11:14478892~14478953:+
PRAD	cis	rs11846409	0.932	rs28378201	ENSG00000274576.2	IGHV2-70	-7.4	6.61e-13	2.63e-10	-0.34	-0.33	Rheumatic heart disease;	chr14:106637262	chr14:106770577~106771020:-
PRAD	cis	rs2243480	1	rs906134	ENSG00000226824.5	RP4-756H11.3	-7.4	6.61e-13	2.63e-10	-0.65	-0.33	Diabetic kidney disease;	chr7:65979301	chr7:66654538~66669855:+
PRAD	cis	rs2933343	0.621	rs789242	ENSG00000261159.1	RP11-723O4.9	7.4	6.62e-13	2.63e-10	0.29	0.33	IgG glycosylation;	chr3:128866864	chr3:128859716~128860526:-
PRAD	cis	rs79349575	0.756	rs4793605	ENSG00000248278.1	SUMO2P17	7.4	6.63e-13	2.64e-10	0.37	0.33	Type 2 diabetes;	chr17:48958507	chr17:48874860~48908983:-
PRAD	cis	rs4927850	0.666	rs4927853	ENSG00000207650.1	MIR570	7.4	6.63e-13	2.64e-10	0.37	0.33	Pancreatic cancer;	chr3:196025182	chr3:195699401~195699497:+
PRAD	cis	rs7916410	0.512	rs61854783	ENSG00000233590.1	RP11-153K11.3	-7.4	6.65e-13	2.64e-10	-0.52	-0.33	Optic disc area;	chr10:68236307	chr10:68233251~68242379:-
PRAD	cis	rs4713118	0.614	rs9468209	ENSG00000216901.1	AL022393.7	7.4	6.65e-13	2.65e-10	0.42	0.33	Parkinson's disease;	chr6:27726642	chr6:28176188~28176674:+
PRAD	cis	rs4927850	0.829	rs6768483	ENSG00000207650.1	MIR570	7.4	6.66e-13	2.65e-10	0.38	0.33	Pancreatic cancer;	chr3:196019092	chr3:195699401~195699497:+
PRAD	cis	rs2638953	0.79	rs4357727	ENSG00000247934.4	RP11-967K21.1	7.4	6.66e-13	2.65e-10	0.32	0.33	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28291989	chr12:28163298~28190738:-
PRAD	cis	rs10050311	0.858	rs55698195	ENSG00000251411.1	RP11-397E7.4	-7.4	6.66e-13	2.65e-10	-0.42	-0.33	Insulin-related traits;	chr4:86872297	chr4:86913266~86914817:-
PRAD	cis	rs10463554	0.857	rs3776873	ENSG00000175749.11	EIF3KP1	7.4	6.67e-13	2.65e-10	0.43	0.33	Parkinson's disease;	chr5:102946768	chr5:103032376~103033031:+
PRAD	cis	rs6951245	0.554	rs10246354	ENSG00000229043.2	AC091729.9	-7.4	6.68e-13	2.66e-10	-0.47	-0.33	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1092820	chr7:1160374~1165267:+
PRAD	cis	rs9532669	0.926	rs9525438	ENSG00000168852.11	TPTE2P5	7.4	6.68e-13	2.66e-10	0.31	0.33	Cervical cancer;	chr13:40964123	chr13:40822296~40921749:-
PRAD	cis	rs6480314	0.542	rs17231644	ENSG00000233590.1	RP11-153K11.3	7.4	6.7e-13	2.66e-10	0.55	0.33	Optic nerve measurement (disc area);	chr10:68270301	chr10:68233251~68242379:-
PRAD	cis	rs10129255	0.5	rs2027902	ENSG00000211972.2	IGHV3-66	7.4	6.7e-13	2.66e-10	0.28	0.33	Kawasaki disease;	chr14:106807157	chr14:106675017~106675544:-
PRAD	cis	rs8062405	0.755	rs17640009	ENSG00000251417.2	RP11-1348G14.4	-7.4	6.71e-13	2.67e-10	-0.37	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28584379	chr16:28802743~28817828:+
PRAD	cis	rs12701220	0.503	rs13222294	ENSG00000229043.2	AC091729.9	-7.4	6.71e-13	2.67e-10	-0.49	-0.33	Bronchopulmonary dysplasia;	chr7:1133333	chr7:1160374~1165267:+
PRAD	cis	rs9810089	0.708	rs619605	ENSG00000261758.1	RP11-102M11.2	7.4	6.71e-13	2.67e-10	0.38	0.33	Gestational age at birth (child effect);	chr3:136368170	chr3:136752630~136755780:+
PRAD	cis	rs9362426	0.639	rs35332886	ENSG00000218793.1	RP3-382I10.3	7.4	6.73e-13	2.68e-10	0.42	0.33	Depressive episodes in bipolar disorder;	chr6:87431346	chr6:87441165~87442146:-
PRAD	cis	rs17772222	0.74	rs11847417	ENSG00000258983.2	RP11-507K2.2	-7.4	6.73e-13	2.68e-10	-0.44	-0.33	Coronary artery calcification;	chr14:88510606	chr14:88499334~88515502:+
PRAD	cis	rs12908161	1	rs11632465	ENSG00000275120.1	RP11-182J1.17	7.4	6.75e-13	2.68e-10	0.43	0.33	Schizophrenia;	chr15:84738814	chr15:84599434~84606463:-
PRAD	cis	rs858239	0.632	rs6952947	ENSG00000226816.2	AC005082.12	-7.4	6.76e-13	2.69e-10	-0.37	-0.33	Cerebrospinal fluid biomarker levels;	chr7:23081423	chr7:23206013~23208045:+
PRAD	cis	rs12468226	0.938	rs116601501	ENSG00000273456.1	RP11-686O6.2	7.4	6.76e-13	2.69e-10	0.45	0.33	Urate levels;	chr2:202274567	chr2:202374932~202375604:-
PRAD	cis	rs12468226	0.938	rs76658848	ENSG00000273456.1	RP11-686O6.2	7.4	6.76e-13	2.69e-10	0.45	0.33	Urate levels;	chr2:202275548	chr2:202374932~202375604:-
PRAD	cis	rs12468226	0.938	rs78928733	ENSG00000273456.1	RP11-686O6.2	7.4	6.76e-13	2.69e-10	0.45	0.33	Urate levels;	chr2:202283787	chr2:202374932~202375604:-
PRAD	cis	rs12468226	0.938	rs77062060	ENSG00000273456.1	RP11-686O6.2	7.4	6.76e-13	2.69e-10	0.45	0.33	Urate levels;	chr2:202285639	chr2:202374932~202375604:-
PRAD	cis	rs11098499	0.913	rs68128210	ENSG00000245958.5	RP11-33B1.1	-7.4	6.77e-13	2.69e-10	-0.33	-0.33	Corneal astigmatism;	chr4:119216664	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.913	rs13126596	ENSG00000245958.5	RP11-33B1.1	-7.4	6.77e-13	2.69e-10	-0.33	-0.33	Corneal astigmatism;	chr4:119219574	chr4:119454791~119552025:+
PRAD	cis	rs2243480	0.708	rs781141	ENSG00000273142.1	RP11-458F8.4	-7.4	6.79e-13	2.7e-10	-0.36	-0.33	Diabetic kidney disease;	chr7:65973566	chr7:66902857~66906297:+
PRAD	cis	rs11846409	0.86	rs59055020	ENSG00000274576.2	IGHV2-70	-7.4	6.79e-13	2.7e-10	-0.34	-0.33	Rheumatic heart disease;	chr14:106631573	chr14:106770577~106771020:-
PRAD	cis	rs748404	0.723	rs573169	ENSG00000205771.5	CATSPER2P1	-7.4	6.8e-13	2.7e-10	-0.35	-0.33	Lung cancer;	chr15:43258383	chr15:43726918~43747094:-
PRAD	cis	rs748404	0.697	rs524547	ENSG00000205771.5	CATSPER2P1	-7.4	6.8e-13	2.7e-10	-0.35	-0.33	Lung cancer;	chr15:43258825	chr15:43726918~43747094:-
PRAD	cis	rs748404	0.697	rs564946	ENSG00000205771.5	CATSPER2P1	-7.4	6.8e-13	2.7e-10	-0.35	-0.33	Lung cancer;	chr15:43264074	chr15:43726918~43747094:-
PRAD	cis	rs748404	0.723	rs565658	ENSG00000205771.5	CATSPER2P1	-7.4	6.8e-13	2.7e-10	-0.35	-0.33	Lung cancer;	chr15:43264109	chr15:43726918~43747094:-
PRAD	cis	rs748404	0.697	rs579651	ENSG00000205771.5	CATSPER2P1	-7.4	6.8e-13	2.7e-10	-0.35	-0.33	Lung cancer;	chr15:43266178	chr15:43726918~43747094:-
PRAD	cis	rs748404	0.697	rs473016	ENSG00000205771.5	CATSPER2P1	-7.4	6.8e-13	2.7e-10	-0.35	-0.33	Lung cancer;	chr15:43266625	chr15:43726918~43747094:-
PRAD	cis	rs2439831	0.867	rs2614811	ENSG00000205771.5	CATSPER2P1	-7.4	6.81e-13	2.7e-10	-0.53	-0.33	Lung cancer in ever smokers;	chr15:43621289	chr15:43726918~43747094:-
PRAD	cis	rs17772222	0.74	rs10150311	ENSG00000258983.2	RP11-507K2.2	7.4	6.83e-13	2.71e-10	0.42	0.33	Coronary artery calcification;	chr14:88510128	chr14:88499334~88515502:+
PRAD	cis	rs2117029	0.727	rs10875910	ENSG00000258017.1	RP11-386G11.10	-7.4	6.83e-13	2.71e-10	-0.47	-0.33	Intelligence (multi-trait analysis);	chr12:49008610	chr12:49127782~49147869:+
PRAD	cis	rs6479901	0.947	rs10761780	ENSG00000232075.1	MRPL35P2	-7.4	6.83e-13	2.71e-10	-0.4	-0.33	Intelligence (multi-trait analysis);	chr10:63524272	chr10:63634317~63634827:-
PRAD	cis	rs12908161	1	rs12911736	ENSG00000275120.1	RP11-182J1.17	7.4	6.84e-13	2.72e-10	0.42	0.33	Schizophrenia;	chr15:84696777	chr15:84599434~84606463:-
PRAD	cis	rs9532669	0.926	rs9594450	ENSG00000168852.11	TPTE2P5	7.4	6.84e-13	2.72e-10	0.34	0.33	Cervical cancer;	chr13:40880067	chr13:40822296~40921749:-
PRAD	cis	rs17772222	0.74	rs61975278	ENSG00000258983.2	RP11-507K2.2	7.4	6.85e-13	2.72e-10	0.44	0.33	Coronary artery calcification;	chr14:88511223	chr14:88499334~88515502:+
PRAD	cis	rs7916697	0.947	rs4745950	ENSG00000233590.1	RP11-153K11.3	7.39	6.86e-13	2.72e-10	0.45	0.33	Optic disc area;	chr10:68236698	chr10:68233251~68242379:-
PRAD	cis	rs875971	0.522	rs1917563	ENSG00000237310.1	GS1-124K5.4	-7.39	6.87e-13	2.73e-10	-0.28	-0.33	Aortic root size;	chr7:65950660	chr7:66493706~66495474:+
PRAD	cis	rs172166	0.694	rs1225716	ENSG00000219392.1	RP1-265C24.5	-7.39	6.89e-13	2.74e-10	-0.4	-0.33	Cardiac Troponin-T levels;	chr6:28145968	chr6:28115628~28116551:+
PRAD	cis	rs4713118	0.512	rs2622319	ENSG00000219392.1	RP1-265C24.5	-7.39	6.89e-13	2.74e-10	-0.4	-0.33	Parkinson's disease;	chr6:28152623	chr6:28115628~28116551:+
PRAD	cis	rs7598759	0.966	rs6754426	ENSG00000181798.2	LINC00471	-7.39	6.9e-13	2.74e-10	-0.39	-0.33	Noise-induced hearing loss;	chr2:231458068	chr2:231508426~231514339:-
PRAD	cis	rs733592	0.507	rs7138917	ENSG00000240399.1	RP1-228P16.1	-7.39	6.91e-13	2.74e-10	-0.27	-0.33	Plateletcrit;	chr12:48061472	chr12:48054813~48055591:-
PRAD	cis	rs367615	0.506	rs2914680	ENSG00000249476.1	CTD-2587M2.1	-7.39	6.91e-13	2.74e-10	-0.39	-0.33	Colorectal cancer (SNP x SNP interaction);	chr5:109451445	chr5:109237120~109326369:-
PRAD	cis	rs6539288	0.677	rs4964509	ENSG00000260329.1	RP11-412D9.4	-7.39	6.92e-13	2.75e-10	-0.29	-0.33	Total body bone mineral density;	chr12:106963280	chr12:106954029~106955497:-
PRAD	cis	rs10411161	0.935	rs8107422	ENSG00000269483.1	AC006272.1	7.39	6.92e-13	2.75e-10	0.48	0.33	Breast cancer;	chr19:51865522	chr19:51839924~51843324:-
PRAD	cis	rs2243480	1	rs59794892	ENSG00000273142.1	RP11-458F8.4	-7.39	6.93e-13	2.75e-10	-0.35	-0.33	Diabetic kidney disease;	chr7:65950886	chr7:66902857~66906297:+
PRAD	cis	rs2243480	0.803	rs36004293	ENSG00000273142.1	RP11-458F8.4	-7.39	6.93e-13	2.75e-10	-0.35	-0.33	Diabetic kidney disease;	chr7:65951525	chr7:66902857~66906297:+
PRAD	cis	rs2243480	0.803	rs35268390	ENSG00000273142.1	RP11-458F8.4	-7.39	6.93e-13	2.75e-10	-0.35	-0.33	Diabetic kidney disease;	chr7:65951549	chr7:66902857~66906297:+
PRAD	cis	rs8062405	0.755	rs7193402	ENSG00000251417.2	RP11-1348G14.4	-7.39	6.94e-13	2.75e-10	-0.36	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574806	chr16:28802743~28817828:+
PRAD	cis	rs8062405	0.755	rs62034358	ENSG00000251417.2	RP11-1348G14.4	-7.39	6.94e-13	2.75e-10	-0.36	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576276	chr16:28802743~28817828:+
PRAD	cis	rs6539288	0.933	rs4964497	ENSG00000260329.1	RP11-412D9.4	-7.39	6.94e-13	2.76e-10	-0.28	-0.33	Total body bone mineral density;	chr12:106910711	chr12:106954029~106955497:-
PRAD	cis	rs7615952	0.599	rs2333408	ENSG00000171084.14	FAM86JP	7.39	6.97e-13	2.77e-10	0.5	0.33	Blood pressure (smoking interaction);	chr3:126013255	chr3:125916620~125930024:+
PRAD	cis	rs4972806	0.849	rs2857541	ENSG00000226363.3	HAGLROS	-7.39	6.97e-13	2.77e-10	-0.37	-0.33	IgG glycosylation;	chr2:176164358	chr2:176177717~176179008:+
PRAD	cis	rs375066	0.935	rs432454	ENSG00000267058.1	RP11-15A1.3	-7.39	6.97e-13	2.77e-10	-0.28	-0.33	Breast cancer;	chr19:43894679	chr19:43891804~43901805:-
PRAD	cis	rs6547741	1	rs4666009	ENSG00000234072.1	AC074117.10	7.39	6.98e-13	2.77e-10	0.24	0.33	Oral cavity cancer;	chr2:27635125	chr2:27356246~27367622:+
PRAD	cis	rs10050311	0.858	rs1010903	ENSG00000251411.1	RP11-397E7.4	-7.39	6.99e-13	2.77e-10	-0.42	-0.33	Insulin-related traits;	chr4:86898040	chr4:86913266~86914817:-
PRAD	cis	rs35264875	0.898	rs72928701	ENSG00000259799.1	RP11-554A11.9	7.39	6.99e-13	2.77e-10	0.44	0.33	Blond vs. brown hair color;	chr11:69094096	chr11:69155910~69159752:+
PRAD	cis	rs35264875	0.898	rs55648928	ENSG00000259799.1	RP11-554A11.9	7.39	6.99e-13	2.77e-10	0.44	0.33	Blond vs. brown hair color;	chr11:69094123	chr11:69155910~69159752:+
PRAD	cis	rs35264875	0.898	rs56140802	ENSG00000259799.1	RP11-554A11.9	7.39	6.99e-13	2.77e-10	0.44	0.33	Blond vs. brown hair color;	chr11:69094163	chr11:69155910~69159752:+
PRAD	cis	rs6539288	0.899	rs4964192	ENSG00000260329.1	RP11-412D9.4	-7.39	6.99e-13	2.77e-10	-0.28	-0.33	Total body bone mineral density;	chr12:106915014	chr12:106954029~106955497:-
PRAD	cis	rs11018904	0.861	rs61903723	ENSG00000280385.1	AP000648.5	-7.39	6.99e-13	2.77e-10	-0.47	-0.33	Intelligence (multi-trait analysis);	chr11:90235078	chr11:90193614~90198120:+
PRAD	cis	rs6539288	0.899	rs2053206	ENSG00000260329.1	RP11-412D9.4	-7.39	6.99e-13	2.77e-10	-0.28	-0.33	Total body bone mineral density;	chr12:106912401	chr12:106954029~106955497:-
PRAD	cis	rs6539288	0.933	rs2053205	ENSG00000260329.1	RP11-412D9.4	-7.39	6.99e-13	2.77e-10	-0.28	-0.33	Total body bone mineral density;	chr12:106912489	chr12:106954029~106955497:-
PRAD	cis	rs6539288	0.933	rs759605	ENSG00000260329.1	RP11-412D9.4	-7.39	6.99e-13	2.77e-10	-0.28	-0.33	Total body bone mineral density;	chr12:106913401	chr12:106954029~106955497:-
PRAD	cis	rs6539288	0.933	rs759604	ENSG00000260329.1	RP11-412D9.4	-7.39	6.99e-13	2.77e-10	-0.28	-0.33	Total body bone mineral density;	chr12:106913518	chr12:106954029~106955497:-
PRAD	cis	rs6539288	0.899	rs759603	ENSG00000260329.1	RP11-412D9.4	-7.39	6.99e-13	2.77e-10	-0.28	-0.33	Total body bone mineral density;	chr12:106913613	chr12:106954029~106955497:-
PRAD	cis	rs6539288	0.933	rs2075289	ENSG00000260329.1	RP11-412D9.4	-7.39	6.99e-13	2.77e-10	-0.28	-0.33	Total body bone mineral density;	chr12:106913860	chr12:106954029~106955497:-
PRAD	cis	rs10463554	0.892	rs72783889	ENSG00000175749.11	EIF3KP1	7.39	7.01e-13	2.78e-10	0.43	0.33	Parkinson's disease;	chr5:102938835	chr5:103032376~103033031:+
PRAD	cis	rs10463554	0.892	rs72783890	ENSG00000175749.11	EIF3KP1	7.39	7.01e-13	2.78e-10	0.43	0.33	Parkinson's disease;	chr5:102938836	chr5:103032376~103033031:+
PRAD	cis	rs812925	0.519	rs2694638	ENSG00000271889.1	RP11-493E12.1	-7.39	7.02e-13	2.78e-10	-0.36	-0.33	Immature fraction of reticulocytes;	chr2:61408228	chr2:61151433~61162105:-
PRAD	cis	rs9467773	0.62	rs1027203	ENSG00000124549.13	BTN2A3P	7.39	7.02e-13	2.78e-10	0.29	0.33	Intelligence (multi-trait analysis);	chr6:26639104	chr6:26421391~26432383:+
PRAD	cis	rs9467773	0.595	rs2172007	ENSG00000124549.13	BTN2A3P	7.39	7.02e-13	2.78e-10	0.29	0.33	Intelligence (multi-trait analysis);	chr6:26639549	chr6:26421391~26432383:+
PRAD	cis	rs3096299	0.935	rs3102387	ENSG00000261118.1	RP11-104N10.1	7.39	7.02e-13	2.78e-10	0.33	0.33	Multiple myeloma (IgH translocation);	chr16:89365868	chr16:89492017~89504460:-
PRAD	cis	rs780096	0.814	rs780093	ENSG00000234072.1	AC074117.10	-7.39	7.03e-13	2.79e-10	-0.26	-0.33	Total body bone mineral density;	chr2:27519736	chr2:27356246~27367622:+
PRAD	cis	rs12612619	0.732	rs1078809	ENSG00000272148.1	RP11-195B17.1	7.39	7.04e-13	2.79e-10	0.39	0.33	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27066047	chr2:27062428~27062907:-
PRAD	cis	rs12612619	0.732	rs10865461	ENSG00000272148.1	RP11-195B17.1	7.39	7.04e-13	2.79e-10	0.39	0.33	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27069783	chr2:27062428~27062907:-
PRAD	cis	rs11098499	0.909	rs28555550	ENSG00000245958.5	RP11-33B1.1	-7.39	7.04e-13	2.79e-10	-0.32	-0.33	Corneal astigmatism;	chr4:119289885	chr4:119454791~119552025:+
PRAD	cis	rs11098499	1	rs28419773	ENSG00000245958.5	RP11-33B1.1	-7.39	7.04e-13	2.79e-10	-0.32	-0.33	Corneal astigmatism;	chr4:119289906	chr4:119454791~119552025:+
PRAD	cis	rs9467773	1	rs9986382	ENSG00000124549.13	BTN2A3P	7.39	7.07e-13	2.8e-10	0.28	0.33	Intelligence (multi-trait analysis);	chr6:26550391	chr6:26421391~26432383:+
PRAD	cis	rs9467773	0.967	rs6941022	ENSG00000124549.13	BTN2A3P	7.39	7.07e-13	2.8e-10	0.28	0.33	Intelligence (multi-trait analysis);	chr6:26553303	chr6:26421391~26432383:+
PRAD	cis	rs9467773	1	rs2224380	ENSG00000124549.13	BTN2A3P	7.39	7.07e-13	2.8e-10	0.28	0.33	Intelligence (multi-trait analysis);	chr6:26553715	chr6:26421391~26432383:+
PRAD	cis	rs9467773	1	rs9461271	ENSG00000124549.13	BTN2A3P	7.39	7.07e-13	2.8e-10	0.28	0.33	Intelligence (multi-trait analysis);	chr6:26554740	chr6:26421391~26432383:+
PRAD	cis	rs9467773	1	rs6930120	ENSG00000124549.13	BTN2A3P	7.39	7.07e-13	2.8e-10	0.28	0.33	Intelligence (multi-trait analysis);	chr6:26555256	chr6:26421391~26432383:+
PRAD	cis	rs9467773	1	rs9467787	ENSG00000124549.13	BTN2A3P	7.39	7.07e-13	2.8e-10	0.28	0.33	Intelligence (multi-trait analysis);	chr6:26556541	chr6:26421391~26432383:+
PRAD	cis	rs9467773	1	rs767471	ENSG00000124549.13	BTN2A3P	7.39	7.07e-13	2.8e-10	0.28	0.33	Intelligence (multi-trait analysis);	chr6:26557626	chr6:26421391~26432383:+
PRAD	cis	rs9467773	1	rs6940053	ENSG00000124549.13	BTN2A3P	7.39	7.07e-13	2.8e-10	0.28	0.33	Intelligence (multi-trait analysis);	chr6:26561894	chr6:26421391~26432383:+
PRAD	cis	rs6951245	0.58	rs77101766	ENSG00000229043.2	AC091729.9	-7.39	7.07e-13	2.8e-10	-0.48	-0.33	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1082802	chr7:1160374~1165267:+
PRAD	cis	rs6479901	0.789	rs7081614	ENSG00000232075.1	MRPL35P2	-7.39	7.1e-13	2.81e-10	-0.4	-0.33	Intelligence (multi-trait analysis);	chr10:63252088	chr10:63634317~63634827:-
PRAD	cis	rs9467773	1	rs10484442	ENSG00000124549.13	BTN2A3P	7.39	7.1e-13	2.81e-10	0.29	0.33	Intelligence (multi-trait analysis);	chr6:26555651	chr6:26421391~26432383:+
PRAD	cis	rs8062405	0.755	rs4788073	ENSG00000251417.2	RP11-1348G14.4	-7.39	7.1e-13	2.81e-10	-0.36	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28583228	chr16:28802743~28817828:+
PRAD	cis	rs8062405	0.755	rs55792032	ENSG00000251417.2	RP11-1348G14.4	-7.39	7.1e-13	2.81e-10	-0.36	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28588090	chr16:28802743~28817828:+
PRAD	cis	rs4984778	0.717	rs2738892	ENSG00000260182.1	RP11-616M22.5	7.39	7.1e-13	2.81e-10	0.46	0.33	Blood protein levels;	chr16:1218758	chr16:1257339~1258074:+
PRAD	cis	rs812925	0.502	rs2053750	ENSG00000271889.1	RP11-493E12.1	-7.39	7.1e-13	2.82e-10	-0.36	-0.33	Immature fraction of reticulocytes;	chr2:61429138	chr2:61151433~61162105:-
PRAD	cis	rs1799949	1	rs4793231	ENSG00000267002.1	RP11-242D8.1	7.39	7.14e-13	2.83e-10	0.31	0.33	Menopause (age at onset);	chr17:43350101	chr17:43164183~43170403:-
PRAD	cis	rs4927850	0.958	rs2044599	ENSG00000231464.1	AC024937.4	7.39	7.14e-13	2.83e-10	0.4	0.33	Pancreatic cancer;	chr3:196009869	chr3:195996738~195998233:+
PRAD	cis	rs287982	1	rs287975	ENSG00000269973.1	RP11-95D17.1	-7.39	7.14e-13	2.83e-10	-0.32	-0.33	Nonsyndromic cleft lip with cleft palate;	chr2:9829346	chr2:9936360~9939590:+
PRAD	cis	rs6479901	0.895	rs7902187	ENSG00000232075.1	MRPL35P2	-7.39	7.15e-13	2.83e-10	-0.4	-0.33	Intelligence (multi-trait analysis);	chr10:63333375	chr10:63634317~63634827:-
PRAD	cis	rs375066	0.935	rs399098	ENSG00000267058.1	RP11-15A1.3	-7.39	7.16e-13	2.84e-10	-0.28	-0.33	Breast cancer;	chr19:43914672	chr19:43891804~43901805:-
PRAD	cis	rs62355901	0.556	rs2897972	ENSG00000271828.1	CTD-2310F14.1	7.39	7.16e-13	2.84e-10	0.75	0.33	Breast cancer;	chr5:56750525	chr5:56927874~56929573:+
PRAD	cis	rs7121800	0.962	rs10835675	ENSG00000242353.1	RP4-710M3.1	-7.39	7.16e-13	2.84e-10	-0.34	-0.33	Pit-and-Fissure caries;	chr11:30498306	chr11:30368148~30368646:+
PRAD	cis	rs10895987	0.531	rs7943007	ENSG00000254614.2	AP003068.23	-7.39	7.17e-13	2.84e-10	-0.44	-0.33	Blood protein levels;	chr11:65089626	chr11:65177606~65181834:-
PRAD	cis	rs10028773	0.515	rs9994651	ENSG00000245958.5	RP11-33B1.1	-7.39	7.18e-13	2.85e-10	-0.31	-0.33	Educational attainment;	chr4:119666648	chr4:119454791~119552025:+
PRAD	cis	rs2836950	0.501	rs11088470	ENSG00000255568.3	BRWD1-AS2	-7.39	7.19e-13	2.85e-10	-0.27	-0.33	Menarche (age at onset);	chr21:39317236	chr21:39313935~39314962:+
PRAD	cis	rs2836950	0.501	rs2836983	ENSG00000255568.3	BRWD1-AS2	-7.39	7.19e-13	2.85e-10	-0.27	-0.33	Menarche (age at onset);	chr21:39317410	chr21:39313935~39314962:+
PRAD	cis	rs2836950	0.565	rs7279497	ENSG00000255568.3	BRWD1-AS2	7.39	7.2e-13	2.85e-10	0.27	0.33	Menarche (age at onset);	chr21:39159380	chr21:39313935~39314962:+
PRAD	cis	rs1979679	0.918	rs7312574	ENSG00000278733.1	RP11-425D17.1	-7.39	7.22e-13	2.86e-10	-0.43	-0.33	Ossification of the posterior longitudinal ligament of the spine;	chr12:28514977	chr12:28185625~28186190:-
PRAD	cis	rs853679	1	rs6905391	ENSG00000226314.6	ZNF192P1	-7.39	7.23e-13	2.87e-10	-0.51	-0.33	Depression;	chr6:28294909	chr6:28161781~28169594:+
PRAD	cis	rs73081554	0.611	rs13071861	ENSG00000272360.1	RP11-359I18.5	-7.39	7.23e-13	2.87e-10	-0.53	-0.33	Rheumatoid arthritis;	chr3:58385605	chr3:58490830~58491291:-
PRAD	cis	rs7829975	0.667	rs1877119	ENSG00000253893.2	FAM85B	-7.39	7.24e-13	2.87e-10	-0.43	-0.33	Mood instability;	chr8:8849687	chr8:8167819~8226614:-
PRAD	cis	rs67180937	0.885	rs2133187	ENSG00000272750.1	RP11-378J18.8	-7.39	7.24e-13	2.87e-10	-0.43	-0.33	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222640383	chr1:222658867~222661512:-
PRAD	cis	rs858239	0.537	rs6942981	ENSG00000226816.2	AC005082.12	7.39	7.25e-13	2.87e-10	0.38	0.33	Cerebrospinal fluid biomarker levels;	chr7:23191929	chr7:23206013~23208045:+
PRAD	cis	rs2243480	1	rs35820085	ENSG00000226824.5	RP4-756H11.3	-7.39	7.26e-13	2.88e-10	-0.65	-0.33	Diabetic kidney disease;	chr7:65977771	chr7:66654538~66669855:+
PRAD	cis	rs858239	0.6	rs10256359	ENSG00000226816.2	AC005082.12	7.39	7.3e-13	2.89e-10	0.37	0.33	Cerebrospinal fluid biomarker levels;	chr7:23084258	chr7:23206013~23208045:+
PRAD	cis	rs67311347	0.544	rs2123998	ENSG00000223797.4	ENTPD3-AS1	-7.39	7.3e-13	2.89e-10	-0.29	-0.33	Renal cell carcinoma;	chr3:40317514	chr3:40313802~40453329:-
PRAD	cis	rs67311347	0.544	rs1902073	ENSG00000223797.4	ENTPD3-AS1	7.39	7.32e-13	2.9e-10	0.28	0.33	Renal cell carcinoma;	chr3:40292006	chr3:40313802~40453329:-
PRAD	cis	rs74024059	1	rs2454210	ENSG00000260685.1	RP11-326L17.1	7.39	7.33e-13	2.9e-10	0.93	0.33	Red blood cell count;Hematocrit;	chr15:76021856	chr15:75950464~75951144:-
PRAD	cis	rs2255336	0.706	rs4415856	ENSG00000245648.1	RP11-277P12.20	-7.38	7.34e-13	2.91e-10	-0.44	-0.33	Blood protein levels;	chr12:10448069	chr12:10363769~10398506:+
PRAD	cis	rs4713118	0.581	rs200504	ENSG00000226314.6	ZNF192P1	-7.38	7.35e-13	2.91e-10	-0.47	-0.33	Parkinson's disease;	chr6:27818042	chr6:28161781~28169594:+
PRAD	cis	rs950169	0.519	rs7237	ENSG00000259728.4	LINC00933	7.38	7.35e-13	2.91e-10	0.39	0.33	Schizophrenia;	chr15:84643346	chr15:84570649~84580175:+
PRAD	cis	rs2638953	0.707	rs11049711	ENSG00000247934.4	RP11-967K21.1	-7.38	7.36e-13	2.91e-10	-0.33	-0.33	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28553171	chr12:28163298~28190738:-
PRAD	cis	rs858239	0.508	rs10242104	ENSG00000226816.2	AC005082.12	7.38	7.36e-13	2.92e-10	0.38	0.33	Cerebrospinal fluid biomarker levels;	chr7:23180831	chr7:23206013~23208045:+
PRAD	cis	rs2836950	0.565	rs7278297	ENSG00000255568.3	BRWD1-AS2	-7.38	7.39e-13	2.92e-10	-0.27	-0.33	Menarche (age at onset);	chr21:39253826	chr21:39313935~39314962:+
PRAD	cis	rs1799949	0.965	rs7212284	ENSG00000267002.1	RP11-242D8.1	7.38	7.42e-13	2.94e-10	0.31	0.33	Menopause (age at onset);	chr17:43053924	chr17:43164183~43170403:-
PRAD	cis	rs193541	0.501	rs3943379	ENSG00000263432.2	RN7SL689P	7.38	7.42e-13	2.94e-10	0.36	0.33	Glucose homeostasis traits;	chr5:122720442	chr5:123022487~123022783:-
PRAD	cis	rs193541	0.502	rs2061511	ENSG00000263432.2	RN7SL689P	7.38	7.42e-13	2.94e-10	0.36	0.33	Glucose homeostasis traits;	chr5:122721032	chr5:123022487~123022783:-
PRAD	cis	rs77204473	0.744	rs2170317	ENSG00000254851.1	RP11-109L13.1	7.38	7.45e-13	2.95e-10	0.72	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117200024	chr11:117135528~117138582:+
PRAD	cis	rs11083475	1	rs1808382	ENSG00000267892.1	CTD-2540F13.2	7.38	7.45e-13	2.95e-10	0.35	0.33	Heart rate;	chr19:38660394	chr19:38738284~38739863:+
PRAD	cis	rs42648	0.935	rs42627	ENSG00000227646.6	STEAP2-AS1	-7.38	7.46e-13	2.95e-10	-0.3	-0.33	Homocysteine levels;	chr7:90332562	chr7:89882353~90211635:-
PRAD	cis	rs17772222	0.655	rs7160717	ENSG00000258983.2	RP11-507K2.2	7.38	7.47e-13	2.96e-10	0.42	0.33	Coronary artery calcification;	chr14:88498232	chr14:88499334~88515502:+
PRAD	cis	rs6480314	0.636	rs61854790	ENSG00000233590.1	RP11-153K11.3	-7.38	7.48e-13	2.96e-10	-0.55	-0.33	Optic nerve measurement (disc area);	chr10:68242491	chr10:68233251~68242379:-
PRAD	cis	rs897984	0.762	rs2054213	ENSG00000279196.1	RP11-1072A3.3	-7.38	7.5e-13	2.97e-10	-0.35	-0.33	Dementia with Lewy bodies;	chr16:30960489	chr16:30984630~30988270:-
PRAD	cis	rs6479901	0.895	rs7073932	ENSG00000232075.1	MRPL35P2	-7.38	7.51e-13	2.97e-10	-0.4	-0.33	Intelligence (multi-trait analysis);	chr10:63350160	chr10:63634317~63634827:-
PRAD	cis	rs6479901	0.947	rs7083356	ENSG00000232075.1	MRPL35P2	-7.38	7.51e-13	2.97e-10	-0.4	-0.33	Intelligence (multi-trait analysis);	chr10:63356028	chr10:63634317~63634827:-
PRAD	cis	rs357618	1	rs165351	ENSG00000260581.1	CTB-113P19.4	7.38	7.51e-13	2.97e-10	0.4	0.33	Basophil percentage of white cells;	chr5:151475320	chr5:151652275~151655449:+
PRAD	cis	rs893363	0.636	rs4687587	ENSG00000271916.1	RP11-884K10.6	7.38	7.51e-13	2.97e-10	0.38	0.33	Axial length;	chr3:53815483	chr3:53797764~53798019:-
PRAD	cis	rs172166	0.637	rs1233708	ENSG00000204709.4	LINC01556	7.38	7.52e-13	2.97e-10	0.43	0.33	Cardiac Troponin-T levels;	chr6:28205441	chr6:28943877~28944537:+
PRAD	cis	rs6452524	0.901	rs4571449	ENSG00000249664.1	CTD-2227C6.2	7.38	7.54e-13	2.98e-10	0.39	0.33	Hypertension (SNP x SNP interaction);	chr5:83175392	chr5:83012285~83013109:-
PRAD	cis	rs12908161	0.959	rs34028043	ENSG00000275120.1	RP11-182J1.17	7.38	7.55e-13	2.98e-10	0.43	0.33	Schizophrenia;	chr15:84688354	chr15:84599434~84606463:-
PRAD	cis	rs12908161	0.959	rs34784022	ENSG00000275120.1	RP11-182J1.17	7.38	7.55e-13	2.98e-10	0.43	0.33	Schizophrenia;	chr15:84688675	chr15:84599434~84606463:-
PRAD	cis	rs12908161	0.959	rs12908699	ENSG00000275120.1	RP11-182J1.17	7.38	7.55e-13	2.98e-10	0.43	0.33	Schizophrenia;	chr15:84697172	chr15:84599434~84606463:-
PRAD	cis	rs853679	0.546	rs200977	ENSG00000280107.1	AL022393.9	-7.38	7.56e-13	2.99e-10	-0.59	-0.33	Depression;	chr6:27886523	chr6:28170845~28172521:+
PRAD	cis	rs6921919	1	rs35875412	ENSG00000204709.4	LINC01556	7.38	7.62e-13	3.01e-10	0.48	0.33	Autism spectrum disorder or schizophrenia;	chr6:28364041	chr6:28943877~28944537:+
PRAD	cis	rs42648	0.935	rs42629	ENSG00000227646.6	STEAP2-AS1	-7.38	7.63e-13	3.01e-10	-0.3	-0.33	Homocysteine levels;	chr7:90334010	chr7:89882353~90211635:-
PRAD	cis	rs7428	0.527	rs1061782	ENSG00000246575.2	AC093162.5	-7.38	7.67e-13	3.03e-10	-0.24	-0.33	Ear protrusion;	chr2:85319492	chr2:85315041~85316529:+
PRAD	cis	rs2638953	0.925	rs7312201	ENSG00000278733.1	RP11-425D17.1	-7.38	7.67e-13	3.03e-10	-0.41	-0.33	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28417885	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.962	rs11049585	ENSG00000278733.1	RP11-425D17.1	-7.38	7.67e-13	3.03e-10	-0.41	-0.33	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28417957	chr12:28185625~28186190:-
PRAD	cis	rs6547741	0.904	rs2384628	ENSG00000234072.1	AC074117.10	7.38	7.69e-13	3.04e-10	0.24	0.33	Oral cavity cancer;	chr2:27551835	chr2:27356246~27367622:+
PRAD	cis	rs4925386	0.625	rs3810550	ENSG00000273619.1	RP5-908M14.9	-7.38	7.69e-13	3.04e-10	-0.25	-0.33	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62337061	chr20:62386303~62386970:-
PRAD	cis	rs113835537	0.529	rs79798028	ENSG00000255517.5	CTD-3074O7.5	-7.38	7.69e-13	3.04e-10	-0.33	-0.33	Airway imaging phenotypes;	chr11:66431891	chr11:66473490~66480233:-
PRAD	cis	rs113835537	0.529	rs2279865	ENSG00000255517.5	CTD-3074O7.5	-7.38	7.69e-13	3.04e-10	-0.33	-0.33	Airway imaging phenotypes;	chr11:66435554	chr11:66473490~66480233:-
PRAD	cis	rs113835537	0.502	rs7104378	ENSG00000255517.5	CTD-3074O7.5	-7.38	7.69e-13	3.04e-10	-0.33	-0.33	Airway imaging phenotypes;	chr11:66449204	chr11:66473490~66480233:-
PRAD	cis	rs8042680	1	rs12898311	ENSG00000214432.8	AC068831.10	-7.38	7.69e-13	3.04e-10	-0.4	-0.33	Type 2 diabetes;	chr15:90974550	chr15:91022619~91036611:+
PRAD	cis	rs8042680	1	rs8031915	ENSG00000214432.8	AC068831.10	-7.38	7.69e-13	3.04e-10	-0.4	-0.33	Type 2 diabetes;	chr15:90976061	chr15:91022619~91036611:+
PRAD	cis	rs8042680	0.868	rs12595029	ENSG00000214432.8	AC068831.10	-7.38	7.69e-13	3.04e-10	-0.4	-0.33	Type 2 diabetes;	chr15:90976929	chr15:91022619~91036611:+
PRAD	cis	rs42648	0.869	rs12374728	ENSG00000227646.6	STEAP2-AS1	-7.38	7.7e-13	3.04e-10	-0.3	-0.33	Homocysteine levels;	chr7:90312570	chr7:89882353~90211635:-
PRAD	cis	rs11098499	0.644	rs10050092	ENSG00000245958.5	RP11-33B1.1	-7.38	7.71e-13	3.04e-10	-0.31	-0.33	Corneal astigmatism;	chr4:119610930	chr4:119454791~119552025:+
PRAD	cis	rs995000	0.868	rs11208007	ENSG00000235545.1	RP11-230B22.1	7.38	7.73e-13	3.05e-10	0.44	0.33	Triglyceride levels;	chr1:62710412	chr1:62688482~62710694:+
PRAD	cis	rs11159086	0.793	rs10150696	ENSG00000270000.1	RP3-449M8.9	7.38	7.75e-13	3.06e-10	0.49	0.33	Advanced glycation end-product levels;	chr14:74476723	chr14:74471930~74472360:-
PRAD	cis	rs10411161	1	rs10414104	ENSG00000269483.1	AC006272.1	7.38	7.75e-13	3.06e-10	0.48	0.33	Breast cancer;	chr19:51864879	chr19:51839924~51843324:-
PRAD	cis	rs11098499	0.913	rs56122576	ENSG00000245958.5	RP11-33B1.1	-7.38	7.75e-13	3.06e-10	-0.33	-0.33	Corneal astigmatism;	chr4:119208181	chr4:119454791~119552025:+
PRAD	cis	rs17428076	0.793	rs3770448	ENSG00000228389.1	AC068039.4	-7.38	7.75e-13	3.06e-10	-0.42	-0.33	Myopia;	chr2:171835755	chr2:171773482~171775844:+
PRAD	cis	rs9302635	0.515	rs36033103	ENSG00000260886.1	TAT-AS1	7.38	7.76e-13	3.06e-10	0.67	0.33	Blood protein levels;	chr16:72108139	chr16:71565789~71578187:+
PRAD	cis	rs957448	1	rs12679345	ENSG00000253704.1	RP11-267M23.4	7.38	7.76e-13	3.07e-10	0.38	0.33	Nonsyndromic cleft lip with cleft palate;	chr8:94552305	chr8:94553722~94569745:+
PRAD	cis	rs881375	0.967	rs1014529	ENSG00000226752.6	PSMD5-AS1	-7.38	7.77e-13	3.07e-10	-0.39	-0.33	Rheumatoid arthritis;	chr9:120922665	chr9:120824828~120854385:+
PRAD	cis	rs1979679	0.659	rs11049461	ENSG00000278733.1	RP11-425D17.1	7.38	7.77e-13	3.07e-10	0.46	0.33	Ossification of the posterior longitudinal ligament of the spine;	chr12:28207688	chr12:28185625~28186190:-
PRAD	cis	rs1440410	0.835	rs4594668	ENSG00000250326.1	RP11-284M14.1	7.38	7.77e-13	3.07e-10	0.34	0.33	Ischemic stroke;	chr4:143129293	chr4:142933195~143184861:-
PRAD	cis	rs10463554	0.856	rs257293	ENSG00000175749.11	EIF3KP1	7.38	7.78e-13	3.07e-10	0.41	0.33	Parkinson's disease;	chr5:103159824	chr5:103032376~103033031:+
PRAD	cis	rs8523	0.744	rs57896541	ENSG00000230314.5	ELOVL2-AS1	7.38	7.78e-13	3.07e-10	0.36	0.33	Red blood cell fatty acid levels;	chr6:11074784	chr6:11043524~11078226:+
PRAD	cis	rs6782228	0.606	rs2811490	ENSG00000242551.2	POU5F1P6	-7.38	7.79e-13	3.07e-10	-0.4	-0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128632912	chr3:128674735~128677005:-
PRAD	cis	rs9810089	1	rs9810089	ENSG00000261758.1	RP11-102M11.2	-7.38	7.79e-13	3.08e-10	-0.38	-0.33	Gestational age at birth (child effect);	chr3:136088767	chr3:136752630~136755780:+
PRAD	cis	rs853679	0.76	rs9393909	ENSG00000280107.1	AL022393.9	7.38	7.82e-13	3.09e-10	0.48	0.33	Depression;	chr6:28239422	chr6:28170845~28172521:+
PRAD	cis	rs995000	0.931	rs1168044	ENSG00000235545.1	RP11-230B22.1	-7.38	7.83e-13	3.09e-10	-0.43	-0.33	Triglyceride levels;	chr1:62511887	chr1:62688482~62710694:+
PRAD	cis	rs17772222	0.74	rs10138139	ENSG00000258983.2	RP11-507K2.2	7.37	7.86e-13	3.1e-10	0.43	0.33	Coronary artery calcification;	chr14:88510027	chr14:88499334~88515502:+
PRAD	cis	rs172166	0.694	rs188105	ENSG00000219392.1	RP1-265C24.5	-7.37	7.86e-13	3.1e-10	-0.4	-0.33	Cardiac Troponin-T levels;	chr6:28103615	chr6:28115628~28116551:+
PRAD	cis	rs67180937	0.961	rs17163358	ENSG00000272750.1	RP11-378J18.8	-7.37	7.87e-13	3.1e-10	-0.42	-0.33	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222647297	chr1:222658867~222661512:-
PRAD	cis	rs6539288	0.933	rs10778513	ENSG00000260329.1	RP11-412D9.4	-7.37	7.88e-13	3.11e-10	-0.28	-0.33	Total body bone mineral density;	chr12:106908405	chr12:106954029~106955497:-
PRAD	cis	rs733592	1	rs733592	ENSG00000240399.1	RP1-228P16.1	-7.37	7.88e-13	3.11e-10	-0.27	-0.33	Plateletcrit;	chr12:48035993	chr12:48054813~48055591:-
PRAD	cis	rs10463554	0.927	rs6862616	ENSG00000175749.11	EIF3KP1	7.37	7.9e-13	3.12e-10	0.42	0.33	Parkinson's disease;	chr5:102910334	chr5:103032376~103033031:+
PRAD	cis	rs67180937	0.961	rs2133189	ENSG00000272750.1	RP11-378J18.8	-7.37	7.91e-13	3.12e-10	-0.43	-0.33	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222641100	chr1:222658867~222661512:-
PRAD	cis	rs2676071	1	rs2676071	ENSG00000259446.4	RP11-489D6.2	-7.37	7.92e-13	3.13e-10	-0.43	-0.33	Periodontitis (Mean PAL);	chr15:33304875	chr15:33303657~33310659:-
PRAD	cis	rs17772222	0.653	rs1346996	ENSG00000258983.2	RP11-507K2.2	7.37	7.92e-13	3.13e-10	0.43	0.33	Coronary artery calcification;	chr14:88507174	chr14:88499334~88515502:+
PRAD	cis	rs597539	0.518	rs35093305	ENSG00000261625.1	RP11-554A11.4	-7.37	7.92e-13	3.13e-10	-0.31	-0.33	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68963260	chr11:69000765~69002048:-
PRAD	cis	rs55665837	1	rs3923294	ENSG00000251991.1	RNU7-49P	7.37	7.93e-13	3.13e-10	0.35	0.33	Vitamin D levels;	chr11:14419856	chr11:14478892~14478953:+
PRAD	cis	rs1979679	0.766	rs10843202	ENSG00000278733.1	RP11-425D17.1	-7.37	7.93e-13	3.13e-10	-0.42	-0.33	Ossification of the posterior longitudinal ligament of the spine;	chr12:28563111	chr12:28185625~28186190:-
PRAD	cis	rs4660456	0.597	rs7518568	ENSG00000237899.1	RP4-739H11.3	7.37	7.94e-13	3.13e-10	0.42	0.33	Platelet count;	chr1:40708508	chr1:40669089~40687588:-
PRAD	cis	rs995000	0.899	rs1781212	ENSG00000235545.1	RP11-230B22.1	-7.37	7.94e-13	3.13e-10	-0.43	-0.33	Triglyceride levels;	chr1:62511748	chr1:62688482~62710694:+
PRAD	cis	rs10463554	0.927	rs11952361	ENSG00000175749.11	EIF3KP1	7.37	7.94e-13	3.13e-10	0.42	0.33	Parkinson's disease;	chr5:102952216	chr5:103032376~103033031:+
PRAD	cis	rs11098499	1	rs7659194	ENSG00000245958.5	RP11-33B1.1	-7.37	7.95e-13	3.13e-10	-0.32	-0.33	Corneal astigmatism;	chr4:119285992	chr4:119454791~119552025:+
PRAD	cis	rs10411161	1	rs10402727	ENSG00000269483.1	AC006272.1	7.37	7.96e-13	3.14e-10	0.48	0.33	Breast cancer;	chr19:51867126	chr19:51839924~51843324:-
PRAD	cis	rs10411161	1	rs10409331	ENSG00000269483.1	AC006272.1	7.37	7.96e-13	3.14e-10	0.48	0.33	Breast cancer;	chr19:51867709	chr19:51839924~51843324:-
PRAD	cis	rs10463554	0.892	rs3776874	ENSG00000175749.11	EIF3KP1	7.37	7.96e-13	3.14e-10	0.43	0.33	Parkinson's disease;	chr5:102946613	chr5:103032376~103033031:+
PRAD	cis	rs67180937	0.961	rs17163363	ENSG00000272750.1	RP11-378J18.8	-7.37	7.97e-13	3.14e-10	-0.43	-0.33	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222655362	chr1:222658867~222661512:-
PRAD	cis	rs67180937	0.921	rs2291834	ENSG00000272750.1	RP11-378J18.8	-7.37	7.97e-13	3.14e-10	-0.43	-0.33	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222658953	chr1:222658867~222661512:-
PRAD	cis	rs67180937	0.849	rs4575092	ENSG00000272750.1	RP11-378J18.8	-7.37	7.97e-13	3.14e-10	-0.43	-0.33	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222661161	chr1:222658867~222661512:-
PRAD	cis	rs12612619	0.659	rs12997235	ENSG00000229122.1	AGBL5-IT1	-7.37	7.97e-13	3.14e-10	-0.34	-0.33	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27006211	chr2:27061038~27061815:+
PRAD	cis	rs9467773	0.967	rs6456732	ENSG00000124549.13	BTN2A3P	7.37	7.99e-13	3.15e-10	0.28	0.33	Intelligence (multi-trait analysis);	chr6:26514217	chr6:26421391~26432383:+
PRAD	cis	rs6547741	0.717	rs2178197	ENSG00000234072.1	AC074117.10	7.37	7.99e-13	3.15e-10	0.25	0.33	Oral cavity cancer;	chr2:27637684	chr2:27356246~27367622:+
PRAD	cis	rs6840258	0.547	rs2053771	ENSG00000251411.1	RP11-397E7.4	-7.37	7.99e-13	3.15e-10	-0.42	-0.33	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86937396	chr4:86913266~86914817:-
PRAD	cis	rs4664293	0.51	rs72961751	ENSG00000226266.5	AC009961.3	7.37	8e-13	3.16e-10	0.44	0.33	Monocyte percentage of white cells;	chr2:159738067	chr2:159670708~159712435:-
PRAD	cis	rs12612619	0.732	rs11679069	ENSG00000272148.1	RP11-195B17.1	7.37	8e-13	3.16e-10	0.39	0.33	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27047443	chr2:27062428~27062907:-
PRAD	cis	rs8062405	0.755	rs2077031	ENSG00000251417.2	RP11-1348G14.4	-7.37	8.01e-13	3.16e-10	-0.37	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28591847	chr16:28802743~28817828:+
PRAD	cis	rs995000	0.931	rs12074528	ENSG00000235545.1	RP11-230B22.1	-7.37	8.01e-13	3.16e-10	-0.43	-0.33	Triglyceride levels;	chr1:62545200	chr1:62688482~62710694:+
PRAD	cis	rs10463554	0.892	rs17154860	ENSG00000175749.11	EIF3KP1	7.37	8.01e-13	3.16e-10	0.43	0.33	Parkinson's disease;	chr5:102955441	chr5:103032376~103033031:+
PRAD	cis	rs6940116	1	rs6940116	ENSG00000226314.6	ZNF192P1	-7.37	8.01e-13	3.16e-10	-0.49	-0.33	Intelligence (multi-trait analysis);Autism spectrum disorder or schizophrenia;	chr6:27740953	chr6:28161781~28169594:+
PRAD	cis	rs2638953	0.886	rs11049572	ENSG00000278733.1	RP11-425D17.1	-7.37	8.01e-13	3.16e-10	-0.41	-0.33	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28397268	chr12:28185625~28186190:-
PRAD	cis	rs2274273	1	rs10149435	ENSG00000258413.1	RP11-665C16.6	-7.37	8.03e-13	3.17e-10	-0.42	-0.33	Protein biomarker;	chr14:55160771	chr14:55262767~55272075:-
PRAD	cis	rs172166	0.694	rs1150666	ENSG00000219392.1	RP1-265C24.5	-7.37	8.04e-13	3.17e-10	-0.4	-0.33	Cardiac Troponin-T levels;	chr6:28156150	chr6:28115628~28116551:+
PRAD	cis	rs10129255	0.957	rs28887506	ENSG00000223648.3	IGHV3-64	7.37	8.04e-13	3.17e-10	0.34	0.33	Kawasaki disease;	chr14:106785589	chr14:106643132~106658258:-
PRAD	cis	rs11846409	1	rs11846409	ENSG00000274576.2	IGHV2-70	-7.37	8.05e-13	3.17e-10	-0.34	-0.33	Rheumatic heart disease;	chr14:106645692	chr14:106770577~106771020:-
PRAD	cis	rs17772222	1	rs17772222	ENSG00000258983.2	RP11-507K2.2	-7.37	8.06e-13	3.18e-10	-0.48	-0.33	Coronary artery calcification;	chr14:88360138	chr14:88499334~88515502:+
PRAD	cis	rs6539288	0.933	rs1444583	ENSG00000260329.1	RP11-412D9.4	7.37	8.06e-13	3.18e-10	0.28	0.33	Total body bone mineral density;	chr12:106919068	chr12:106954029~106955497:-
PRAD	cis	rs11098499	0.913	rs10006304	ENSG00000245958.5	RP11-33B1.1	-7.37	8.08e-13	3.18e-10	-0.33	-0.33	Corneal astigmatism;	chr4:119203150	chr4:119454791~119552025:+
PRAD	cis	rs2522056	0.935	rs757104	ENSG00000233006.5	AC034220.3	-7.37	8.09e-13	3.19e-10	-0.34	-0.33	Fibrinogen;Lymphocyte counts;	chr5:132459537	chr5:132311285~132369916:-
PRAD	cis	rs1799949	0.894	rs71367985	ENSG00000267002.1	RP11-242D8.1	7.37	8.11e-13	3.2e-10	0.31	0.33	Menopause (age at onset);	chr17:43222443	chr17:43164183~43170403:-
PRAD	cis	rs2522056	1	rs2405528	ENSG00000233006.5	AC034220.3	-7.37	8.13e-13	3.2e-10	-0.34	-0.33	Fibrinogen;Lymphocyte counts;	chr5:132458606	chr5:132311285~132369916:-
PRAD	cis	rs9532669	0.926	rs9532689	ENSG00000168852.11	TPTE2P5	7.37	8.15e-13	3.21e-10	0.31	0.33	Cervical cancer;	chr13:40957990	chr13:40822296~40921749:-
PRAD	cis	rs42648	0.869	rs1015403	ENSG00000227646.6	STEAP2-AS1	-7.37	8.17e-13	3.22e-10	-0.3	-0.33	Homocysteine levels;	chr7:90284388	chr7:89882353~90211635:-
PRAD	cis	rs42648	0.869	rs12704518	ENSG00000227646.6	STEAP2-AS1	-7.37	8.17e-13	3.22e-10	-0.3	-0.33	Homocysteine levels;	chr7:90285074	chr7:89882353~90211635:-
PRAD	cis	rs42648	0.777	rs4728878	ENSG00000227646.6	STEAP2-AS1	-7.37	8.17e-13	3.22e-10	-0.3	-0.33	Homocysteine levels;	chr7:90294918	chr7:89882353~90211635:-
PRAD	cis	rs42648	0.837	rs13239439	ENSG00000227646.6	STEAP2-AS1	-7.37	8.17e-13	3.22e-10	-0.3	-0.33	Homocysteine levels;	chr7:90295086	chr7:89882353~90211635:-
PRAD	cis	rs42648	0.837	rs7786771	ENSG00000227646.6	STEAP2-AS1	-7.37	8.17e-13	3.22e-10	-0.3	-0.33	Homocysteine levels;	chr7:90295453	chr7:89882353~90211635:-
PRAD	cis	rs987724	0.592	rs1430411	ENSG00000240875.4	LINC00886	-7.37	8.18e-13	3.22e-10	-0.37	-0.33	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156807607	chr3:156747346~156817062:-
PRAD	cis	rs9467773	1	rs9357010	ENSG00000124549.13	BTN2A3P	7.37	8.19e-13	3.23e-10	0.28	0.33	Intelligence (multi-trait analysis);	chr6:26527717	chr6:26421391~26432383:+
PRAD	cis	rs853679	0.546	rs200953	ENSG00000280107.1	AL022393.9	-7.37	8.2e-13	3.23e-10	-0.58	-0.33	Depression;	chr6:27869489	chr6:28170845~28172521:+
PRAD	cis	rs6539288	0.803	rs4479083	ENSG00000260329.1	RP11-412D9.4	-7.37	8.21e-13	3.23e-10	-0.28	-0.33	Total body bone mineral density;	chr12:106927467	chr12:106954029~106955497:-
PRAD	cis	rs6539288	0.933	rs6539285	ENSG00000260329.1	RP11-412D9.4	-7.37	8.22e-13	3.24e-10	-0.28	-0.33	Total body bone mineral density;	chr12:106903683	chr12:106954029~106955497:-
PRAD	cis	rs6539288	0.866	rs6539286	ENSG00000260329.1	RP11-412D9.4	-7.37	8.22e-13	3.24e-10	-0.28	-0.33	Total body bone mineral density;	chr12:106903845	chr12:106954029~106955497:-
PRAD	cis	rs6539288	0.899	rs6539287	ENSG00000260329.1	RP11-412D9.4	-7.37	8.22e-13	3.24e-10	-0.28	-0.33	Total body bone mineral density;	chr12:106903872	chr12:106954029~106955497:-
PRAD	cis	rs638893	0.588	rs4936440	ENSG00000278376.1	RP11-158I9.8	-7.37	8.22e-13	3.24e-10	-0.33	-0.33	Vitiligo;	chr11:118849975	chr11:118791254~118793137:+
PRAD	cis	rs9326248	0.559	rs1269329	ENSG00000280143.1	AP000892.6	7.37	8.22e-13	3.24e-10	0.25	0.33	Blood protein levels;	chr11:116884325	chr11:117204967~117210292:+
PRAD	cis	rs1799949	1	rs9646417	ENSG00000267002.1	RP11-242D8.1	7.37	8.22e-13	3.24e-10	0.31	0.33	Menopause (age at onset);	chr17:43346885	chr17:43164183~43170403:-
PRAD	cis	rs1799949	1	rs1545764	ENSG00000267002.1	RP11-242D8.1	7.37	8.22e-13	3.24e-10	0.31	0.33	Menopause (age at onset);	chr17:43347197	chr17:43164183~43170403:-
PRAD	cis	rs1799949	1	rs9646412	ENSG00000267002.1	RP11-242D8.1	7.37	8.22e-13	3.24e-10	0.31	0.33	Menopause (age at onset);	chr17:43348525	chr17:43164183~43170403:-
PRAD	cis	rs995000	0.965	rs1168046	ENSG00000235545.1	RP11-230B22.1	-7.37	8.23e-13	3.24e-10	-0.43	-0.33	Triglyceride levels;	chr1:62518022	chr1:62688482~62710694:+
PRAD	cis	rs3096299	0.838	rs3102376	ENSG00000274627.1	RP11-104N10.2	7.37	8.24e-13	3.24e-10	0.32	0.33	Multiple myeloma (IgH translocation);	chr16:89336065	chr16:89516797~89522217:+
PRAD	cis	rs6904897	0.563	rs4896117	ENSG00000232876.1	CTA-212D2.2	7.37	8.25e-13	3.25e-10	0.41	0.33	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr6:134908262	chr6:135055033~135060550:+
PRAD	cis	rs897984	0.721	rs28360557	ENSG00000279196.1	RP11-1072A3.3	-7.37	8.25e-13	3.25e-10	-0.35	-0.33	Dementia with Lewy bodies;	chr16:30971939	chr16:30984630~30988270:-
PRAD	cis	rs3096299	0.606	rs8052103	ENSG00000274627.1	RP11-104N10.2	-7.37	8.25e-13	3.25e-10	-0.36	-0.33	Multiple myeloma (IgH translocation);	chr16:89474835	chr16:89516797~89522217:+
PRAD	cis	rs881375	0.934	rs1468671	ENSG00000226752.6	PSMD5-AS1	-7.37	8.26e-13	3.25e-10	-0.4	-0.33	Rheumatoid arthritis;	chr9:120895224	chr9:120824828~120854385:+
PRAD	cis	rs6539288	0.803	rs7305715	ENSG00000260329.1	RP11-412D9.4	-7.37	8.28e-13	3.26e-10	-0.28	-0.33	Total body bone mineral density;	chr12:106932774	chr12:106954029~106955497:-
PRAD	cis	rs6539288	0.803	rs2374651	ENSG00000260329.1	RP11-412D9.4	-7.37	8.28e-13	3.26e-10	-0.28	-0.33	Total body bone mineral density;	chr12:106934346	chr12:106954029~106955497:-
PRAD	cis	rs9467773	0.901	rs1407045	ENSG00000124549.13	BTN2A3P	7.37	8.29e-13	3.26e-10	0.29	0.33	Intelligence (multi-trait analysis);	chr6:26475927	chr6:26421391~26432383:+
PRAD	cis	rs11098499	0.909	rs1546504	ENSG00000245958.5	RP11-33B1.1	-7.37	8.3e-13	3.27e-10	-0.32	-0.33	Corneal astigmatism;	chr4:119320024	chr4:119454791~119552025:+
PRAD	cis	rs6860806	0.661	rs6871350	ENSG00000233006.5	AC034220.3	7.37	8.31e-13	3.27e-10	0.28	0.33	Breast cancer;	chr5:132244527	chr5:132311285~132369916:-
PRAD	cis	rs10935480	1	rs10935480	ENSG00000239445.4	ST3GAL6-AS1	-7.37	8.34e-13	3.28e-10	-0.41	-0.33	Blood protein levels;	chr3:98713142	chr3:98714330~98732651:-
PRAD	cis	rs2836950	0.585	rs1029004	ENSG00000255568.3	BRWD1-AS2	-7.37	8.35e-13	3.28e-10	-0.27	-0.33	Menarche (age at onset);	chr21:39243417	chr21:39313935~39314962:+
PRAD	cis	rs2337406	0.587	rs2583291	ENSG00000274576.2	IGHV2-70	7.37	8.37e-13	3.3e-10	0.34	0.33	Alzheimer's disease (late onset);	chr14:106649293	chr14:106770577~106771020:-
PRAD	cis	rs12908161	1	rs12908161	ENSG00000275120.1	RP11-182J1.17	7.36	8.4e-13	3.3e-10	0.43	0.33	Schizophrenia;	chr15:84664594	chr15:84599434~84606463:-
PRAD	cis	rs4664293	0.867	rs7594329	ENSG00000226266.5	AC009961.3	-7.36	8.4e-13	3.31e-10	-0.43	-0.33	Monocyte percentage of white cells;	chr2:159716207	chr2:159670708~159712435:-
PRAD	cis	rs4664293	0.867	rs7582124	ENSG00000226266.5	AC009961.3	-7.36	8.4e-13	3.31e-10	-0.43	-0.33	Monocyte percentage of white cells;	chr2:159716326	chr2:159670708~159712435:-
PRAD	cis	rs9532669	0.926	rs9532690	ENSG00000168852.11	TPTE2P5	7.36	8.41e-13	3.31e-10	0.31	0.33	Cervical cancer;	chr13:40968654	chr13:40822296~40921749:-
PRAD	cis	rs4664293	0.605	rs890095	ENSG00000226266.5	AC009961.3	7.36	8.41e-13	3.31e-10	0.43	0.33	Monocyte percentage of white cells;	chr2:159604708	chr2:159670708~159712435:-
PRAD	cis	rs2638953	0.924	rs12368652	ENSG00000247934.4	RP11-967K21.1	-7.36	8.42e-13	3.31e-10	-0.33	-0.33	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28170046	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.924	rs11049392	ENSG00000247934.4	RP11-967K21.1	-7.36	8.42e-13	3.31e-10	-0.33	-0.33	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28170256	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.924	rs11049394	ENSG00000247934.4	RP11-967K21.1	-7.36	8.42e-13	3.31e-10	-0.33	-0.33	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28170947	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.886	rs11049395	ENSG00000247934.4	RP11-967K21.1	-7.36	8.42e-13	3.31e-10	-0.33	-0.33	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28171087	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.886	rs11049397	ENSG00000247934.4	RP11-967K21.1	-7.36	8.42e-13	3.31e-10	-0.33	-0.33	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28171909	chr12:28163298~28190738:-
PRAD	cis	rs8042680	1	rs6496743	ENSG00000214432.8	AC068831.10	-7.36	8.42e-13	3.31e-10	-0.4	-0.33	Type 2 diabetes;	chr15:90985128	chr15:91022619~91036611:+
PRAD	cis	rs957448	1	rs1055800	ENSG00000253704.1	RP11-267M23.4	-7.36	8.42e-13	3.31e-10	-0.38	-0.33	Nonsyndromic cleft lip with cleft palate;	chr8:94510810	chr8:94553722~94569745:+
PRAD	cis	rs881375	0.967	rs1930778	ENSG00000226752.6	PSMD5-AS1	-7.36	8.45e-13	3.32e-10	-0.38	-0.33	Rheumatoid arthritis;	chr9:120879091	chr9:120824828~120854385:+
PRAD	cis	rs881375	1	rs10760118	ENSG00000226752.6	PSMD5-AS1	-7.36	8.45e-13	3.32e-10	-0.38	-0.33	Rheumatoid arthritis;	chr9:120879338	chr9:120824828~120854385:+
PRAD	cis	rs858239	0.632	rs7811903	ENSG00000226816.2	AC005082.12	7.36	8.45e-13	3.32e-10	0.37	0.33	Cerebrospinal fluid biomarker levels;	chr7:23079437	chr7:23206013~23208045:+
PRAD	cis	rs12468226	0.873	rs60722019	ENSG00000273456.1	RP11-686O6.2	7.36	8.45e-13	3.32e-10	0.44	0.33	Urate levels;	chr2:202282060	chr2:202374932~202375604:-
PRAD	cis	rs12468226	0.873	rs6761131	ENSG00000273456.1	RP11-686O6.2	-7.36	8.47e-13	3.33e-10	-0.44	-0.33	Urate levels;	chr2:202237675	chr2:202374932~202375604:-
PRAD	cis	rs1043099	0.571	rs5753111	ENSG00000279699.1	RP1-102K2.9	-7.36	8.47e-13	3.33e-10	-0.42	-0.33	Rheumatoid arthritis;	chr22:30383222	chr22:30275215~30276951:-
PRAD	cis	rs2638953	0.924	rs7973516	ENSG00000247934.4	RP11-967K21.1	-7.36	8.47e-13	3.33e-10	-0.33	-0.33	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28207523	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.886	rs7973241	ENSG00000247934.4	RP11-967K21.1	-7.36	8.47e-13	3.33e-10	-0.33	-0.33	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28207583	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.924	rs7973656	ENSG00000247934.4	RP11-967K21.1	-7.36	8.47e-13	3.33e-10	-0.33	-0.33	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28207679	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.924	rs7971033	ENSG00000247934.4	RP11-967K21.1	-7.36	8.47e-13	3.33e-10	-0.33	-0.33	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28208420	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.924	rs7956418	ENSG00000247934.4	RP11-967K21.1	-7.36	8.47e-13	3.33e-10	-0.33	-0.33	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28208566	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.924	rs11519094	ENSG00000247934.4	RP11-967K21.1	-7.36	8.47e-13	3.33e-10	-0.33	-0.33	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28209430	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.924	rs11513465	ENSG00000247934.4	RP11-967K21.1	-7.36	8.47e-13	3.33e-10	-0.33	-0.33	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28209483	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.924	rs11513250	ENSG00000247934.4	RP11-967K21.1	-7.36	8.47e-13	3.33e-10	-0.33	-0.33	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28209500	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.924	rs11519330	ENSG00000247934.4	RP11-967K21.1	-7.36	8.47e-13	3.33e-10	-0.33	-0.33	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28209720	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.85	rs11519331	ENSG00000247934.4	RP11-967K21.1	-7.36	8.47e-13	3.33e-10	-0.33	-0.33	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28209995	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.888	rs11513466	ENSG00000247934.4	RP11-967K21.1	-7.36	8.47e-13	3.33e-10	-0.33	-0.33	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28210111	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.924	rs7298652	ENSG00000247934.4	RP11-967K21.1	-7.36	8.47e-13	3.33e-10	-0.33	-0.33	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28210620	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.924	rs6487669	ENSG00000247934.4	RP11-967K21.1	-7.36	8.47e-13	3.33e-10	-0.33	-0.33	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28210827	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.924	rs6487671	ENSG00000247934.4	RP11-967K21.1	-7.36	8.47e-13	3.33e-10	-0.33	-0.33	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28210902	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.924	rs11049464	ENSG00000247934.4	RP11-967K21.1	-7.36	8.47e-13	3.33e-10	-0.33	-0.33	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28211637	chr12:28163298~28190738:-
PRAD	cis	rs10463554	0.927	rs62362489	ENSG00000175749.11	EIF3KP1	7.36	8.49e-13	3.34e-10	0.42	0.33	Parkinson's disease;	chr5:102909841	chr5:103032376~103033031:+
PRAD	cis	rs2455601	0.744	rs11042107	ENSG00000254860.4	TMEM9B-AS1	7.36	8.5e-13	3.34e-10	0.41	0.33	Schizophrenia;	chr11:8884324	chr11:8964675~8977527:+
PRAD	cis	rs897984	0.762	rs4889599	ENSG00000279196.1	RP11-1072A3.3	-7.36	8.52e-13	3.35e-10	-0.35	-0.33	Dementia with Lewy bodies;	chr16:30957268	chr16:30984630~30988270:-
PRAD	cis	rs897984	0.721	rs2305884	ENSG00000279196.1	RP11-1072A3.3	-7.36	8.52e-13	3.35e-10	-0.35	-0.33	Dementia with Lewy bodies;	chr16:30959420	chr16:30984630~30988270:-
PRAD	cis	rs780096	0.967	rs1260334	ENSG00000234072.1	AC074117.10	-7.36	8.52e-13	3.35e-10	-0.25	-0.33	Total body bone mineral density;	chr2:27525730	chr2:27356246~27367622:+
PRAD	cis	rs2439831	0.867	rs496584	ENSG00000205771.5	CATSPER2P1	-7.36	8.52e-13	3.35e-10	-0.51	-0.33	Lung cancer in ever smokers;	chr15:43539725	chr15:43726918~43747094:-
PRAD	cis	rs42648	0.869	rs3810891	ENSG00000227646.6	STEAP2-AS1	-7.36	8.53e-13	3.35e-10	-0.3	-0.33	Homocysteine levels;	chr7:90279537	chr7:89882353~90211635:-
PRAD	cis	rs17772222	0.74	rs10150986	ENSG00000258983.2	RP11-507K2.2	7.36	8.54e-13	3.35e-10	0.44	0.33	Coronary artery calcification;	chr14:88517326	chr14:88499334~88515502:+
PRAD	cis	rs897984	0.759	rs13708	ENSG00000279196.1	RP11-1072A3.3	-7.36	8.55e-13	3.36e-10	-0.35	-0.33	Dementia with Lewy bodies;	chr16:30989488	chr16:30984630~30988270:-
PRAD	cis	rs71386933	0.543	rs36114735	ENSG00000260886.1	TAT-AS1	7.36	8.55e-13	3.36e-10	0.62	0.33	Post bronchodilator FEV1;	chr16:71983784	chr16:71565789~71578187:+
PRAD	cis	rs5760092	0.755	rs11090298	ENSG00000224205.1	AP000351.4	-7.36	8.56e-13	3.36e-10	-0.48	-0.33	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919874	chr22:23987320~23991421:-
PRAD	cis	rs4722166	0.704	rs4321884	ENSG00000179428.2	AC073072.5	-7.36	8.57e-13	3.37e-10	-0.36	-0.33	Lung cancer;	chr7:22701840	chr7:22725395~22727620:-
PRAD	cis	rs2255336	0.579	rs10772262	ENSG00000245648.1	RP11-277P12.20	7.36	8.57e-13	3.37e-10	0.57	0.33	Blood protein levels;	chr12:10341279	chr12:10363769~10398506:+
PRAD	cis	rs4660456	0.596	rs1534956	ENSG00000237899.1	RP4-739H11.3	7.36	8.57e-13	3.37e-10	0.42	0.33	Platelet count;	chr1:40720771	chr1:40669089~40687588:-
PRAD	cis	rs17772222	0.917	rs61984708	ENSG00000258983.2	RP11-507K2.2	7.36	8.58e-13	3.37e-10	0.46	0.33	Coronary artery calcification;	chr14:88565523	chr14:88499334~88515502:+
PRAD	cis	rs2638953	0.893	rs10771432	ENSG00000278733.1	RP11-425D17.1	-7.36	8.59e-13	3.37e-10	-0.38	-0.33	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28507798	chr12:28185625~28186190:-
PRAD	cis	rs11098499	0.955	rs11931312	ENSG00000245958.5	RP11-33B1.1	-7.36	8.59e-13	3.37e-10	-0.32	-0.33	Corneal astigmatism;	chr4:119237868	chr4:119454791~119552025:+
PRAD	cis	rs453301	0.597	rs7001187	ENSG00000254340.1	RP11-10A14.3	-7.36	8.6e-13	3.38e-10	-0.39	-0.33	Joint mobility (Beighton score);	chr8:8935272	chr8:9141424~9145435:+
PRAD	cis	rs12612619	0.732	rs11680096	ENSG00000272148.1	RP11-195B17.1	7.36	8.6e-13	3.38e-10	0.4	0.33	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27050703	chr2:27062428~27062907:-
PRAD	cis	rs17772222	0.74	rs3783885	ENSG00000258983.2	RP11-507K2.2	7.36	8.63e-13	3.39e-10	0.43	0.33	Coronary artery calcification;	chr14:88510714	chr14:88499334~88515502:+
PRAD	cis	rs11846409	0.86	rs17112419	ENSG00000274576.2	IGHV2-70	-7.36	8.63e-13	3.39e-10	-0.34	-0.33	Rheumatic heart disease;	chr14:106633260	chr14:106770577~106771020:-
PRAD	cis	rs11098499	1	rs11098500	ENSG00000245958.5	RP11-33B1.1	-7.36	8.66e-13	3.4e-10	-0.32	-0.33	Corneal astigmatism;	chr4:119298084	chr4:119454791~119552025:+
PRAD	cis	rs2255336	0.578	rs7980379	ENSG00000245648.1	RP11-277P12.20	7.36	8.69e-13	3.41e-10	0.47	0.33	Blood protein levels;	chr12:10367591	chr12:10363769~10398506:+
PRAD	cis	rs2337406	0.538	rs10141701	ENSG00000274576.2	IGHV2-70	-7.36	8.74e-13	3.43e-10	-0.34	-0.33	Alzheimer's disease (late onset);	chr14:106633467	chr14:106770577~106771020:-
PRAD	cis	rs9393777	0.92	rs34196306	ENSG00000280107.1	AL022393.9	-7.36	8.75e-13	3.43e-10	-0.74	-0.33	Intelligence (multi-trait analysis);	chr6:27457865	chr6:28170845~28172521:+
PRAD	cis	rs858239	0.6	rs10241208	ENSG00000226816.2	AC005082.12	7.36	8.75e-13	3.44e-10	0.37	0.33	Cerebrospinal fluid biomarker levels;	chr7:23105295	chr7:23206013~23208045:+
PRAD	cis	rs17772222	0.917	rs77382318	ENSG00000258983.2	RP11-507K2.2	7.36	8.75e-13	3.44e-10	0.47	0.33	Coronary artery calcification;	chr14:88355785	chr14:88499334~88515502:+
PRAD	cis	rs1979679	0.879	rs2638950	ENSG00000278733.1	RP11-425D17.1	7.36	8.75e-13	3.44e-10	0.42	0.33	Ossification of the posterior longitudinal ligament of the spine;	chr12:28398634	chr12:28185625~28186190:-
PRAD	cis	rs2274273	0.686	rs68083077	ENSG00000258413.1	RP11-665C16.6	-7.36	8.76e-13	3.44e-10	-0.45	-0.33	Protein biomarker;	chr14:55107710	chr14:55262767~55272075:-
PRAD	cis	rs2274273	0.686	rs17253695	ENSG00000258413.1	RP11-665C16.6	7.36	8.76e-13	3.44e-10	0.45	0.33	Protein biomarker;	chr14:55107892	chr14:55262767~55272075:-
PRAD	cis	rs6479901	0.947	rs10822167	ENSG00000232075.1	MRPL35P2	-7.36	8.76e-13	3.44e-10	-0.4	-0.33	Intelligence (multi-trait analysis);	chr10:63398991	chr10:63634317~63634827:-
PRAD	cis	rs6479901	1	rs6479901	ENSG00000232075.1	MRPL35P2	-7.36	8.76e-13	3.44e-10	-0.4	-0.33	Intelligence (multi-trait analysis);	chr10:63421016	chr10:63634317~63634827:-
PRAD	cis	rs853679	0.882	rs4713140	ENSG00000226314.6	ZNF192P1	-7.36	8.79e-13	3.45e-10	-0.57	-0.33	Depression;	chr6:28129415	chr6:28161781~28169594:+
PRAD	cis	rs17772222	0.74	rs61984675	ENSG00000258983.2	RP11-507K2.2	7.36	8.82e-13	3.46e-10	0.43	0.33	Coronary artery calcification;	chr14:88511236	chr14:88499334~88515502:+
PRAD	cis	rs853679	0.567	rs16894106	ENSG00000216901.1	AL022393.7	7.36	8.85e-13	3.47e-10	0.45	0.33	Depression;	chr6:28432562	chr6:28176188~28176674:+
PRAD	cis	rs11098499	0.955	rs13113112	ENSG00000245958.5	RP11-33B1.1	-7.36	8.85e-13	3.47e-10	-0.32	-0.33	Corneal astigmatism;	chr4:119234885	chr4:119454791~119552025:+
PRAD	cis	rs12612619	0.732	rs3806520	ENSG00000272148.1	RP11-195B17.1	7.36	8.85e-13	3.47e-10	0.39	0.33	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27053334	chr2:27062428~27062907:-
PRAD	cis	rs853679	0.546	rs493161	ENSG00000280107.1	AL022393.9	-7.36	8.88e-13	3.48e-10	-0.59	-0.33	Depression;	chr6:27882936	chr6:28170845~28172521:+
PRAD	cis	rs8062405	0.558	rs151228	ENSG00000259982.1	CDC37P1	7.36	8.89e-13	3.49e-10	0.41	0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28551705	chr16:28700294~28701540:-
PRAD	cis	rs780096	0.967	rs1260333	ENSG00000234072.1	AC074117.10	-7.36	8.92e-13	3.5e-10	-0.25	-0.33	Total body bone mineral density;	chr2:27525757	chr2:27356246~27367622:+
PRAD	cis	rs987724	0.592	rs9858861	ENSG00000240875.4	LINC00886	-7.35	8.98e-13	3.52e-10	-0.37	-0.33	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156824848	chr3:156747346~156817062:-
PRAD	cis	rs6480314	0.831	rs1900009	ENSG00000233590.1	RP11-153K11.3	-7.35	9.01e-13	3.53e-10	-0.53	-0.33	Optic nerve measurement (disc area);	chr10:68217940	chr10:68233251~68242379:-
PRAD	cis	rs5758511	0.514	rs5758610	ENSG00000227370.1	RP4-669P10.19	7.35	9.01e-13	3.53e-10	0.36	0.33	Birth weight;	chr22:42151418	chr22:42132543~42132998:+
PRAD	cis	rs496547	0.719	rs476246	ENSG00000255239.1	AP002954.6	-7.35	9.01e-13	3.53e-10	-0.44	-0.33	Hip minimal joint space width;	chr11:118747211	chr11:118688039~118690600:-
PRAD	cis	rs172166	0.611	rs203882	ENSG00000219392.1	RP1-265C24.5	-7.35	9.01e-13	3.53e-10	-0.4	-0.33	Cardiac Troponin-T levels;	chr6:28110724	chr6:28115628~28116551:+
PRAD	cis	rs172166	0.694	rs1770131	ENSG00000219392.1	RP1-265C24.5	-7.35	9.01e-13	3.53e-10	-0.4	-0.33	Cardiac Troponin-T levels;	chr6:28118635	chr6:28115628~28116551:+
PRAD	cis	rs17772222	1	rs79579293	ENSG00000258983.2	RP11-507K2.2	7.35	9.03e-13	3.54e-10	0.47	0.33	Coronary artery calcification;	chr14:88355724	chr14:88499334~88515502:+
PRAD	cis	rs6539288	0.77	rs1468908	ENSG00000260329.1	RP11-412D9.4	-7.35	9.03e-13	3.54e-10	-0.28	-0.33	Total body bone mineral density;	chr12:106904539	chr12:106954029~106955497:-
PRAD	cis	rs6539288	0.933	rs1470380	ENSG00000260329.1	RP11-412D9.4	-7.35	9.03e-13	3.54e-10	-0.28	-0.33	Total body bone mineral density;	chr12:106904961	chr12:106954029~106955497:-
PRAD	cis	rs1930961	0.702	rs1930966	ENSG00000272798.1	CTA-390C10.9	-7.35	9.04e-13	3.54e-10	-0.63	-0.33	Bipolar disorder with mood-incongruent psychosis;	chr22:25489737	chr22:25436312~25436915:+
PRAD	cis	rs12468226	1	rs7597469	ENSG00000273456.1	RP11-686O6.2	7.35	9.05e-13	3.55e-10	0.44	0.33	Urate levels;	chr2:202329547	chr2:202374932~202375604:-
PRAD	cis	rs2617170	0.961	rs2734565	ENSG00000245648.1	RP11-277P12.20	7.35	9.05e-13	3.55e-10	0.39	0.33	Behcet's disease;	chr12:10407992	chr12:10363769~10398506:+
PRAD	cis	rs17772222	0.682	rs28711639	ENSG00000258983.2	RP11-507K2.2	7.35	9.05e-13	3.55e-10	0.43	0.33	Coronary artery calcification;	chr14:88482277	chr14:88499334~88515502:+
PRAD	cis	rs9810089	0.802	rs833861	ENSG00000261758.1	RP11-102M11.2	7.35	9.06e-13	3.55e-10	0.37	0.33	Gestational age at birth (child effect);	chr3:136512225	chr3:136752630~136755780:+
PRAD	cis	rs1426063	0.858	rs11936768	ENSG00000249717.1	RP11-44F21.3	7.35	9.06e-13	3.55e-10	0.54	0.33	QT interval;	chr4:75084506	chr4:74955974~74970362:-
PRAD	cis	rs1426063	0.858	rs72662426	ENSG00000249717.1	RP11-44F21.3	7.35	9.06e-13	3.55e-10	0.54	0.33	QT interval;	chr4:75084828	chr4:74955974~74970362:-
PRAD	cis	rs1426063	0.858	rs6837969	ENSG00000249717.1	RP11-44F21.3	7.35	9.06e-13	3.55e-10	0.54	0.33	QT interval;	chr4:75085005	chr4:74955974~74970362:-
PRAD	cis	rs1426063	0.858	rs6843217	ENSG00000249717.1	RP11-44F21.3	7.35	9.06e-13	3.55e-10	0.54	0.33	QT interval;	chr4:75085201	chr4:74955974~74970362:-
PRAD	cis	rs74024059	1	rs335713	ENSG00000260685.1	RP11-326L17.1	-7.35	9.07e-13	3.55e-10	-0.86	-0.33	Red blood cell count;Hematocrit;	chr15:75890608	chr15:75950464~75951144:-
PRAD	cis	rs74024059	1	rs335710	ENSG00000260685.1	RP11-326L17.1	-7.35	9.07e-13	3.55e-10	-0.86	-0.33	Red blood cell count;Hematocrit;	chr15:75892780	chr15:75950464~75951144:-
PRAD	cis	rs62355901	0.505	rs62356565	ENSG00000271828.1	CTD-2310F14.1	7.35	9.07e-13	3.55e-10	0.65	0.33	Breast cancer;	chr5:56948139	chr5:56927874~56929573:+
PRAD	cis	rs2067615	0.56	rs4964485	ENSG00000260329.1	RP11-412D9.4	-7.35	9.08e-13	3.56e-10	-0.27	-0.33	Heart rate;	chr12:106728174	chr12:106954029~106955497:-
PRAD	cis	rs11098499	0.955	rs1397608	ENSG00000245958.5	RP11-33B1.1	-7.35	9.09e-13	3.56e-10	-0.32	-0.33	Corneal astigmatism;	chr4:119240589	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.955	rs7685268	ENSG00000245958.5	RP11-33B1.1	-7.35	9.09e-13	3.56e-10	-0.32	-0.33	Corneal astigmatism;	chr4:119241033	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.955	rs7684942	ENSG00000245958.5	RP11-33B1.1	-7.35	9.09e-13	3.56e-10	-0.32	-0.33	Corneal astigmatism;	chr4:119241046	chr4:119454791~119552025:+
PRAD	cis	rs453301	0.598	rs1025395	ENSG00000253893.2	FAM85B	-7.35	9.1e-13	3.57e-10	-0.41	-0.33	Joint mobility (Beighton score);	chr8:8979093	chr8:8167819~8226614:-
PRAD	cis	rs2439831	0.85	rs61390361	ENSG00000249839.1	AC011330.5	-7.35	9.11e-13	3.57e-10	-0.58	-0.33	Lung cancer in ever smokers;	chr15:43867644	chr15:43663654~43684339:-
PRAD	cis	rs2439831	0.85	rs11856795	ENSG00000249839.1	AC011330.5	-7.35	9.11e-13	3.57e-10	-0.58	-0.33	Lung cancer in ever smokers;	chr15:43868384	chr15:43663654~43684339:-
PRAD	cis	rs11098499	1	rs13435802	ENSG00000245958.5	RP11-33B1.1	7.35	9.12e-13	3.57e-10	0.32	0.33	Corneal astigmatism;	chr4:119256805	chr4:119454791~119552025:+
PRAD	cis	rs7746199	0.736	rs34573979	ENSG00000226314.6	ZNF192P1	-7.35	9.14e-13	3.58e-10	-0.69	-0.33	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27512747	chr6:28161781~28169594:+
PRAD	cis	rs897984	0.684	rs6950	ENSG00000279196.1	RP11-1072A3.3	-7.35	9.16e-13	3.59e-10	-0.35	-0.33	Dementia with Lewy bodies;	chr16:30984348	chr16:30984630~30988270:-
PRAD	cis	rs897984	0.645	rs9938550	ENSG00000279196.1	RP11-1072A3.3	-7.35	9.16e-13	3.59e-10	-0.35	-0.33	Dementia with Lewy bodies;	chr16:30987821	chr16:30984630~30988270:-
PRAD	cis	rs897984	0.762	rs2305880	ENSG00000279196.1	RP11-1072A3.3	-7.35	9.16e-13	3.59e-10	-0.35	-0.33	Dementia with Lewy bodies;	chr16:30988141	chr16:30984630~30988270:-
PRAD	cis	rs6547741	0.816	rs7560847	ENSG00000234072.1	AC074117.10	-7.35	9.18e-13	3.59e-10	-0.25	-0.33	Oral cavity cancer;	chr2:27659833	chr2:27356246~27367622:+
PRAD	cis	rs42648	0.869	rs42617	ENSG00000227646.6	STEAP2-AS1	-7.35	9.19e-13	3.6e-10	-0.3	-0.33	Homocysteine levels;	chr7:90322732	chr7:89882353~90211635:-
PRAD	cis	rs79349575	0.594	rs62078375	ENSG00000248278.1	SUMO2P17	7.35	9.2e-13	3.6e-10	0.37	0.33	Type 2 diabetes;	chr17:48957612	chr17:48874860~48908983:-
PRAD	cis	rs67311347	0.544	rs4974040	ENSG00000223797.4	ENTPD3-AS1	7.35	9.23e-13	3.61e-10	0.28	0.33	Renal cell carcinoma;	chr3:40289568	chr3:40313802~40453329:-
PRAD	cis	rs9640161	0.789	rs3735174	ENSG00000261305.1	RP4-584D14.7	7.35	9.23e-13	3.61e-10	0.36	0.33	Blood protein levels;Circulating chemerin levels;	chr7:150323400	chr7:150341771~150342607:+
PRAD	cis	rs6921919	1	rs6922111	ENSG00000216901.1	AL022393.7	7.35	9.25e-13	3.62e-10	0.47	0.33	Autism spectrum disorder or schizophrenia;	chr6:28357531	chr6:28176188~28176674:+
PRAD	cis	rs17772222	0.958	rs60213984	ENSG00000258983.2	RP11-507K2.2	7.35	9.26e-13	3.62e-10	0.48	0.33	Coronary artery calcification;	chr14:88401473	chr14:88499334~88515502:+
PRAD	cis	rs2638953	0.925	rs11049567	ENSG00000278733.1	RP11-425D17.1	7.35	9.27e-13	3.63e-10	0.41	0.33	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28385502	chr12:28185625~28186190:-
PRAD	cis	rs6003958	1	rs6003958	ENSG00000224205.1	AP000351.4	-7.35	9.28e-13	3.63e-10	-0.48	-0.33	S-phenylmercapturic acid levels in smokers;	chr22:23921902	chr22:23987320~23991421:-
PRAD	cis	rs5760092	0.755	rs6003959	ENSG00000224205.1	AP000351.4	-7.35	9.28e-13	3.63e-10	-0.48	-0.33	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23922208	chr22:23987320~23991421:-
PRAD	cis	rs17772222	0.74	rs7160471	ENSG00000258983.2	RP11-507K2.2	7.35	9.29e-13	3.64e-10	0.43	0.33	Coronary artery calcification;	chr14:88507241	chr14:88499334~88515502:+
PRAD	cis	rs17772222	0.74	rs9323830	ENSG00000258983.2	RP11-507K2.2	7.35	9.29e-13	3.64e-10	0.43	0.33	Coronary artery calcification;	chr14:88507260	chr14:88499334~88515502:+
PRAD	cis	rs17772222	0.74	rs7160647	ENSG00000258983.2	RP11-507K2.2	7.35	9.29e-13	3.64e-10	0.43	0.33	Coronary artery calcification;	chr14:88507340	chr14:88499334~88515502:+
PRAD	cis	rs2439831	0.85	rs16950562	ENSG00000205771.5	CATSPER2P1	-7.35	9.3e-13	3.64e-10	-0.51	-0.33	Lung cancer in ever smokers;	chr15:43744166	chr15:43726918~43747094:-
PRAD	cis	rs2439831	0.85	rs12441861	ENSG00000205771.5	CATSPER2P1	-7.35	9.3e-13	3.64e-10	-0.51	-0.33	Lung cancer in ever smokers;	chr15:43768685	chr15:43726918~43747094:-
PRAD	cis	rs10206020	0.885	rs13411553	ENSG00000231482.2	AC141930.2	-7.35	9.3e-13	3.64e-10	-0.37	-0.33	IgG glycosylation;	chr2:1570246	chr2:1572554~1580311:-
PRAD	cis	rs964611	0.938	rs12592330	ENSG00000259488.2	RP11-154J22.1	7.35	9.31e-13	3.64e-10	0.35	0.33	Metabolite levels (Pyroglutamine);	chr15:48353083	chr15:48312353~48331856:-
PRAD	cis	rs9467773	0.649	rs2145318	ENSG00000124549.13	BTN2A3P	7.35	9.34e-13	3.65e-10	0.29	0.33	Intelligence (multi-trait analysis);	chr6:26496375	chr6:26421391~26432383:+
PRAD	cis	rs35264875	0.851	rs72930611	ENSG00000259799.1	RP11-554A11.9	7.35	9.41e-13	3.68e-10	0.43	0.33	Blond vs. brown hair color;	chr11:69096191	chr11:69155910~69159752:+
PRAD	cis	rs17772222	1	rs12589480	ENSG00000258983.2	RP11-507K2.2	7.35	9.43e-13	3.69e-10	0.48	0.33	Coronary artery calcification;	chr14:88414926	chr14:88499334~88515502:+
PRAD	cis	rs3813579	1	rs3813579	ENSG00000261390.4	RP11-345M22.2	-7.35	9.43e-13	3.69e-10	-0.38	-0.33	Thyroid volume;	chr16:79715379	chr16:79715232~79770563:-
PRAD	cis	rs2676071	0.858	rs2670945	ENSG00000259446.4	RP11-489D6.2	-7.35	9.43e-13	3.69e-10	-0.43	-0.33	Periodontitis (Mean PAL);	chr15:33307207	chr15:33303657~33310659:-
PRAD	cis	rs2638953	0.821	rs7964793	ENSG00000247934.4	RP11-967K21.1	7.35	9.45e-13	3.7e-10	0.34	0.33	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28298776	chr12:28163298~28190738:-
PRAD	cis	rs72615157	0.613	rs56089143	ENSG00000242294.5	STAG3L5P	7.35	9.46e-13	3.7e-10	0.2	0.33	Lung function (FEV1/FVC);	chr7:100222221	chr7:100336079~100351900:+
PRAD	cis	rs9467773	0.935	rs1884947	ENSG00000124549.13	BTN2A3P	7.35	9.46e-13	3.7e-10	0.29	0.33	Intelligence (multi-trait analysis);	chr6:26553045	chr6:26421391~26432383:+
PRAD	cis	rs8005677	0.828	rs4981450	ENSG00000257285.4	RP11-298I3.1	7.35	9.46e-13	3.7e-10	0.32	0.33	Cognitive ability (multi-trait analysis);	chr14:22920095	chr14:22929609~22955562:+
PRAD	cis	rs440932	0.747	rs330946	ENSG00000254340.1	RP11-10A14.3	7.35	9.47e-13	3.7e-10	0.39	0.33	High light scatter reticulocyte percentage of red cells;	chr8:9164667	chr8:9141424~9145435:+
PRAD	cis	rs67311347	0.544	rs6804545	ENSG00000223797.4	ENTPD3-AS1	7.35	9.47e-13	3.7e-10	0.29	0.33	Renal cell carcinoma;	chr3:40312549	chr3:40313802~40453329:-
PRAD	cis	rs2243480	1	rs1723270	ENSG00000273142.1	RP11-458F8.4	-7.35	9.47e-13	3.7e-10	-0.36	-0.33	Diabetic kidney disease;	chr7:66004843	chr7:66902857~66906297:+
PRAD	cis	rs1799949	0.965	rs4793230	ENSG00000267002.1	RP11-242D8.1	7.35	9.47e-13	3.7e-10	0.31	0.33	Menopause (age at onset);	chr17:43350035	chr17:43164183~43170403:-
PRAD	cis	rs853679	0.607	rs13199772	ENSG00000226314.6	ZNF192P1	-7.35	9.48e-13	3.71e-10	-0.68	-0.33	Depression;	chr6:27866307	chr6:28161781~28169594:+
PRAD	cis	rs42648	0.869	rs6970376	ENSG00000227646.6	STEAP2-AS1	7.35	9.52e-13	3.72e-10	0.3	0.33	Homocysteine levels;	chr7:90308772	chr7:89882353~90211635:-
PRAD	cis	rs42648	0.869	rs6948139	ENSG00000227646.6	STEAP2-AS1	-7.35	9.52e-13	3.72e-10	-0.3	-0.33	Homocysteine levels;	chr7:90308467	chr7:89882353~90211635:-
PRAD	cis	rs42648	0.837	rs6970750	ENSG00000227646.6	STEAP2-AS1	-7.35	9.52e-13	3.72e-10	-0.3	-0.33	Homocysteine levels;	chr7:90308877	chr7:89882353~90211635:-
PRAD	cis	rs4660456	0.572	rs1008204	ENSG00000237899.1	RP4-739H11.3	7.35	9.53e-13	3.72e-10	0.42	0.33	Platelet count;	chr1:40700189	chr1:40669089~40687588:-
PRAD	cis	rs780096	0.967	rs1313566	ENSG00000234072.1	AC074117.10	-7.35	9.54e-13	3.73e-10	-0.25	-0.33	Total body bone mineral density;	chr2:27526037	chr2:27356246~27367622:+
PRAD	cis	rs9309711	0.961	rs35067331	ENSG00000225234.1	TRAPPC12-AS1	-7.35	9.56e-13	3.74e-10	-0.36	-0.33	Neurofibrillary tangles;	chr2:3470314	chr2:3481242~3482409:-
PRAD	cis	rs2836950	0.527	rs2836958	ENSG00000255568.3	BRWD1-AS2	-7.35	9.56e-13	3.74e-10	-0.27	-0.33	Menarche (age at onset);	chr21:39251600	chr21:39313935~39314962:+
PRAD	cis	rs17361889	1	rs6968510	ENSG00000224683.1	RPL36AP29	7.35	9.56e-13	3.74e-10	0.42	0.33	Pediatric bone mineral content (hip);	chr7:16263370	chr7:16208945~16209265:+
PRAD	cis	rs1552244	0.554	rs3774207	ENSG00000206567.8	AC022007.5	-7.35	9.57e-13	3.74e-10	-0.37	-0.33	Alzheimer's disease;	chr3:9943972	chr3:10006418~10011209:-
PRAD	cis	rs74024059	0.661	rs335684	ENSG00000260685.1	RP11-326L17.1	7.35	9.58e-13	3.75e-10	0.86	0.33	Red blood cell count;Hematocrit;	chr15:75901963	chr15:75950464~75951144:-
PRAD	cis	rs2348418	0.639	rs7969946	ENSG00000247934.4	RP11-967K21.1	-7.34	9.62e-13	3.76e-10	-0.32	-0.33	Lung function (FEV1);Lung function (FVC);	chr12:28111814	chr12:28163298~28190738:-
PRAD	cis	rs7567389	0.719	rs6738690	ENSG00000236682.1	AC068282.3	7.34	9.63e-13	3.76e-10	0.45	0.33	Self-rated health;	chr2:127235149	chr2:127389130~127400580:+
PRAD	cis	rs9393777	0.92	rs35768595	ENSG00000280107.1	AL022393.9	-7.34	9.67e-13	3.78e-10	-0.69	-0.33	Intelligence (multi-trait analysis);	chr6:27174125	chr6:28170845~28172521:+
PRAD	cis	rs1823874	0.72	rs1993296	ENSG00000182397.13	DNM1P46	-7.34	9.67e-13	3.78e-10	-0.31	-0.33	IgG glycosylation;	chr15:99823383	chr15:99790156~99806927:-
PRAD	cis	rs7429990	0.965	rs2166770	ENSG00000229759.1	MRPS18AP1	7.34	9.67e-13	3.78e-10	0.34	0.33	Educational attainment (years of education);	chr3:47964183	chr3:48256350~48256938:-
PRAD	cis	rs853679	0.607	rs72846794	ENSG00000280107.1	AL022393.9	-7.34	9.69e-13	3.79e-10	-0.67	-0.33	Depression;	chr6:28169721	chr6:28170845~28172521:+
PRAD	cis	rs858239	0.601	rs7805206	ENSG00000226816.2	AC005082.12	7.34	9.72e-13	3.8e-10	0.37	0.33	Cerebrospinal fluid biomarker levels;	chr7:23120591	chr7:23206013~23208045:+
PRAD	cis	rs3096299	0.967	rs2965830	ENSG00000261118.1	RP11-104N10.1	7.34	9.79e-13	3.82e-10	0.32	0.33	Multiple myeloma (IgH translocation);	chr16:89393882	chr16:89492017~89504460:-
PRAD	cis	rs2581828	0.539	rs114317830	ENSG00000242142.1	SERBP1P3	-7.34	9.79e-13	3.82e-10	-0.39	-0.33	Crohn's disease;	chr3:53126253	chr3:53064283~53065091:-
PRAD	cis	rs2581828	0.539	rs114670283	ENSG00000242142.1	SERBP1P3	-7.34	9.79e-13	3.82e-10	-0.39	-0.33	Crohn's disease;	chr3:53126254	chr3:53064283~53065091:-
PRAD	cis	rs12908161	1	rs11638290	ENSG00000275120.1	RP11-182J1.17	7.34	9.8e-13	3.83e-10	0.42	0.33	Schizophrenia;	chr15:84684405	chr15:84599434~84606463:-
PRAD	cis	rs2638953	0.671	rs7969830	ENSG00000278733.1	RP11-425D17.1	-7.34	9.81e-13	3.83e-10	-0.44	-0.33	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28111770	chr12:28185625~28186190:-
PRAD	cis	rs8062405	0.755	rs12447461	ENSG00000251417.2	RP11-1348G14.4	-7.34	9.82e-13	3.84e-10	-0.36	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28571620	chr16:28802743~28817828:+
PRAD	cis	rs9435732	1	rs9435732	ENSG00000235241.1	RP11-108M9.5	7.34	9.87e-13	3.85e-10	0.46	0.33	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:16981663	chr1:16889095~16889602:+
PRAD	cis	rs564343	0.765	rs1558974	ENSG00000255320.1	RP11-755F10.1	7.34	9.87e-13	3.86e-10	0.44	0.33	Obesity (early onset extreme);	chr11:66110303	chr11:66244840~66246239:-
PRAD	cis	rs9393777	0.92	rs13207689	ENSG00000226314.6	ZNF192P1	-7.34	9.88e-13	3.86e-10	-0.68	-0.33	Intelligence (multi-trait analysis);	chr6:27401925	chr6:28161781~28169594:+
PRAD	cis	rs62355900	0.627	rs59715006	ENSG00000271828.1	CTD-2310F14.1	7.34	9.88e-13	3.86e-10	0.68	0.33	Endometriosis;	chr5:56899820	chr5:56927874~56929573:+
PRAD	cis	rs62355900	0.627	rs61663138	ENSG00000271828.1	CTD-2310F14.1	7.34	9.88e-13	3.86e-10	0.68	0.33	Endometriosis;	chr5:56899946	chr5:56927874~56929573:+
PRAD	cis	rs11098499	0.57	rs6832740	ENSG00000245958.5	RP11-33B1.1	-7.34	9.88e-13	3.86e-10	-0.31	-0.33	Corneal astigmatism;	chr4:119624981	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.644	rs6855918	ENSG00000245958.5	RP11-33B1.1	-7.34	9.88e-13	3.86e-10	-0.31	-0.33	Corneal astigmatism;	chr4:119625144	chr4:119454791~119552025:+
PRAD	cis	rs10463554	0.892	rs10463988	ENSG00000175749.11	EIF3KP1	7.34	9.89e-13	3.86e-10	0.43	0.33	Parkinson's disease;	chr5:102913595	chr5:103032376~103033031:+
PRAD	cis	rs4664293	0.585	rs10460301	ENSG00000226266.5	AC009961.3	7.34	9.89e-13	3.86e-10	0.43	0.33	Monocyte percentage of white cells;	chr2:159778566	chr2:159670708~159712435:-
PRAD	cis	rs12908161	1	rs12905057	ENSG00000275120.1	RP11-182J1.17	7.34	9.9e-13	3.86e-10	0.43	0.33	Schizophrenia;	chr15:84667534	chr15:84599434~84606463:-
PRAD	cis	rs858239	0.6	rs7341483	ENSG00000226816.2	AC005082.12	-7.34	9.9e-13	3.87e-10	-0.37	-0.33	Cerebrospinal fluid biomarker levels;	chr7:23088038	chr7:23206013~23208045:+
PRAD	cis	rs4713118	0.629	rs203887	ENSG00000226314.6	ZNF192P1	-7.34	9.91e-13	3.87e-10	-0.48	-0.33	Parkinson's disease;	chr6:28053491	chr6:28161781~28169594:+
PRAD	cis	rs8062405	0.757	rs2411453	ENSG00000251417.2	RP11-1348G14.4	7.34	9.91e-13	3.87e-10	0.36	0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620700	chr16:28802743~28817828:+
PRAD	cis	rs3217810	1	rs3217810	ENSG00000256164.1	CCND2-AS1	-7.34	9.92e-13	3.87e-10	-0.48	-0.33	Colorectal cancer;	chr12:4279105	chr12:4248765~4276184:-
PRAD	cis	rs453301	0.624	rs2288673	ENSG00000253893.2	FAM85B	-7.34	9.93e-13	3.87e-10	-0.42	-0.33	Joint mobility (Beighton score);	chr8:9002766	chr8:8167819~8226614:-
PRAD	cis	rs3020736	0.5	rs6002605	ENSG00000205702.9	CYP2D7	-7.34	9.94e-13	3.88e-10	-0.25	-0.33	Autism spectrum disorder or schizophrenia;	chr22:42098331	chr22:42140203~42144577:-
PRAD	cis	rs2243480	1	rs35396113	ENSG00000273142.1	RP11-458F8.4	-7.34	9.98e-13	3.9e-10	-0.36	-0.33	Diabetic kidney disease;	chr7:66030474	chr7:66902857~66906297:+
PRAD	cis	rs11098499	0.697	rs35280960	ENSG00000245958.5	RP11-33B1.1	-7.34	9.99e-13	3.9e-10	-0.31	-0.33	Corneal astigmatism;	chr4:119335904	chr4:119454791~119552025:+
PRAD	cis	rs6547741	1	rs76784350	ENSG00000234072.1	AC074117.10	7.34	9.99e-13	3.9e-10	0.24	0.33	Oral cavity cancer;	chr2:27541411	chr2:27356246~27367622:+
PRAD	cis	rs6840258	0.547	rs72667721	ENSG00000251411.1	RP11-397E7.4	-7.34	1e-12	3.9e-10	-0.42	-0.33	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86919644	chr4:86913266~86914817:-
PRAD	cis	rs10050311	0.79	rs4693154	ENSG00000251411.1	RP11-397E7.4	-7.34	1e-12	3.9e-10	-0.42	-0.33	Insulin-related traits;	chr4:86922109	chr4:86913266~86914817:-
PRAD	cis	rs17012589	0.571	rs10862974	ENSG00000258815.1	RP11-408B11.2	-7.34	1e-12	3.91e-10	-0.44	-0.33	Bone mineral density (Ward's triangle area);	chr12:85355194	chr12:85318060~85342912:+
PRAD	cis	rs2274273	0.967	rs10137409	ENSG00000258413.1	RP11-665C16.6	-7.34	1e-12	3.91e-10	-0.41	-0.33	Protein biomarker;	chr14:55144723	chr14:55262767~55272075:-
PRAD	cis	rs2274273	1	rs7140872	ENSG00000258413.1	RP11-665C16.6	-7.34	1e-12	3.91e-10	-0.41	-0.33	Protein biomarker;	chr14:55146026	chr14:55262767~55272075:-
PRAD	cis	rs2274273	1	rs7493394	ENSG00000258413.1	RP11-665C16.6	-7.34	1e-12	3.91e-10	-0.41	-0.33	Protein biomarker;	chr14:55151037	chr14:55262767~55272075:-
PRAD	cis	rs2274273	1	rs15870	ENSG00000258413.1	RP11-665C16.6	-7.34	1e-12	3.91e-10	-0.41	-0.33	Protein biomarker;	chr14:55152593	chr14:55262767~55272075:-
PRAD	cis	rs4713118	0.824	rs9468225	ENSG00000226314.6	ZNF192P1	-7.34	1e-12	3.91e-10	-0.43	-0.33	Parkinson's disease;	chr6:27777940	chr6:28161781~28169594:+
PRAD	cis	rs6452524	0.87	rs2174976	ENSG00000249664.1	CTD-2227C6.2	7.34	1e-12	3.91e-10	0.39	0.33	Hypertension (SNP x SNP interaction);	chr5:83197136	chr5:83012285~83013109:-
PRAD	cis	rs2337406	0.538	rs2015470	ENSG00000274576.2	IGHV2-70	-7.34	1e-12	3.91e-10	-0.33	-0.33	Alzheimer's disease (late onset);	chr14:106631885	chr14:106770577~106771020:-
PRAD	cis	rs6547741	1	rs1528404	ENSG00000234072.1	AC074117.10	-7.34	1.01e-12	3.93e-10	-0.24	-0.33	Oral cavity cancer;	chr2:27623736	chr2:27356246~27367622:+
PRAD	cis	rs9467773	0.967	rs1535276	ENSG00000124549.13	BTN2A3P	7.34	1.01e-12	3.93e-10	0.28	0.33	Intelligence (multi-trait analysis);	chr6:26520713	chr6:26421391~26432383:+
PRAD	cis	rs4713118	0.911	rs9461406	ENSG00000219392.1	RP1-265C24.5	7.34	1.01e-12	3.94e-10	0.42	0.33	Parkinson's disease;	chr6:27751985	chr6:28115628~28116551:+
PRAD	cis	rs4713118	0.619	rs200486	ENSG00000226314.6	ZNF192P1	-7.34	1.01e-12	3.94e-10	-0.46	-0.33	Parkinson's disease;	chr6:27811728	chr6:28161781~28169594:+
PRAD	cis	rs494459	0.733	rs556437	ENSG00000278376.1	RP11-158I9.8	-7.34	1.01e-12	3.94e-10	-0.28	-0.33	Height;	chr11:118835044	chr11:118791254~118793137:+
PRAD	cis	rs17253792	0.822	rs28409547	ENSG00000186615.9	KTN1-AS1	-7.34	1.01e-12	3.94e-10	-0.57	-0.33	Putamen volume;	chr14:55581108	chr14:55499278~55580110:-
PRAD	cis	rs17253792	0.822	rs28478195	ENSG00000186615.9	KTN1-AS1	-7.34	1.01e-12	3.94e-10	-0.57	-0.33	Putamen volume;	chr14:55581133	chr14:55499278~55580110:-
PRAD	cis	rs10463554	0.892	rs66505956	ENSG00000175749.11	EIF3KP1	7.34	1.01e-12	3.95e-10	0.42	0.33	Parkinson's disease;	chr5:102943853	chr5:103032376~103033031:+
PRAD	cis	rs9467773	1	rs6910899	ENSG00000124549.13	BTN2A3P	7.34	1.01e-12	3.95e-10	0.28	0.33	Intelligence (multi-trait analysis);	chr6:26524111	chr6:26421391~26432383:+
PRAD	cis	rs9467773	0.967	rs9461267	ENSG00000124549.13	BTN2A3P	7.34	1.01e-12	3.95e-10	0.28	0.33	Intelligence (multi-trait analysis);	chr6:26525227	chr6:26421391~26432383:+
PRAD	cis	rs9467773	0.967	rs1056347	ENSG00000124549.13	BTN2A3P	7.34	1.01e-12	3.95e-10	0.28	0.33	Intelligence (multi-trait analysis);	chr6:26527296	chr6:26421391~26432383:+
PRAD	cis	rs9467773	1	rs4713006	ENSG00000124549.13	BTN2A3P	7.34	1.02e-12	3.98e-10	0.28	0.33	Intelligence (multi-trait analysis);	chr6:26519644	chr6:26421391~26432383:+
PRAD	cis	rs9467773	0.967	rs6924865	ENSG00000124549.13	BTN2A3P	7.34	1.02e-12	3.98e-10	0.28	0.33	Intelligence (multi-trait analysis);	chr6:26521125	chr6:26421391~26432383:+
PRAD	cis	rs9467773	1	rs6925703	ENSG00000124549.13	BTN2A3P	7.34	1.02e-12	3.98e-10	0.28	0.33	Intelligence (multi-trait analysis);	chr6:26521361	chr6:26421391~26432383:+
PRAD	cis	rs11159086	0.793	rs11850070	ENSG00000270000.1	RP3-449M8.9	7.34	1.02e-12	3.98e-10	0.49	0.33	Advanced glycation end-product levels;	chr14:74487575	chr14:74471930~74472360:-
PRAD	cis	rs11159086	0.793	rs28378078	ENSG00000270000.1	RP3-449M8.9	7.34	1.02e-12	3.98e-10	0.49	0.33	Advanced glycation end-product levels;	chr14:74487940	chr14:74471930~74472360:-
PRAD	cis	rs11159086	0.793	rs9285594	ENSG00000270000.1	RP3-449M8.9	7.34	1.02e-12	3.98e-10	0.49	0.33	Advanced glycation end-product levels;	chr14:74489253	chr14:74471930~74472360:-
PRAD	cis	rs11159086	0.793	rs4903229	ENSG00000270000.1	RP3-449M8.9	7.34	1.02e-12	3.98e-10	0.49	0.33	Advanced glycation end-product levels;	chr14:74489865	chr14:74471930~74472360:-
PRAD	cis	rs11159086	0.793	rs8016972	ENSG00000270000.1	RP3-449M8.9	7.34	1.02e-12	3.98e-10	0.49	0.33	Advanced glycation end-product levels;	chr14:74491833	chr14:74471930~74472360:-
PRAD	cis	rs6547741	0.935	rs4260197	ENSG00000234072.1	AC074117.10	-7.34	1.02e-12	3.98e-10	-0.25	-0.33	Oral cavity cancer;	chr2:27571283	chr2:27356246~27367622:+
PRAD	cis	rs79349575	0.783	rs1994970	ENSG00000248278.1	SUMO2P17	-7.34	1.02e-12	3.99e-10	-0.38	-0.33	Type 2 diabetes;	chr17:48936765	chr17:48874860~48908983:-
PRAD	cis	rs12468226	0.938	rs56684065	ENSG00000273456.1	RP11-686O6.2	7.33	1.02e-12	3.99e-10	0.45	0.33	Urate levels;	chr2:202289528	chr2:202374932~202375604:-
PRAD	cis	rs12468226	0.938	rs1474001	ENSG00000273456.1	RP11-686O6.2	7.33	1.02e-12	3.99e-10	0.45	0.33	Urate levels;	chr2:202290230	chr2:202374932~202375604:-
PRAD	cis	rs12468226	0.938	rs76664732	ENSG00000273456.1	RP11-686O6.2	7.33	1.02e-12	3.99e-10	0.45	0.33	Urate levels;	chr2:202296298	chr2:202374932~202375604:-
PRAD	cis	rs375066	0.901	rs12977303	ENSG00000267058.1	RP11-15A1.3	-7.33	1.03e-12	4e-10	-0.28	-0.33	Breast cancer;	chr19:43873517	chr19:43891804~43901805:-
PRAD	cis	rs2638953	0.925	rs11049584	ENSG00000278733.1	RP11-425D17.1	-7.33	1.03e-12	4.01e-10	-0.42	-0.33	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28417879	chr12:28185625~28186190:-
PRAD	cis	rs61774743	0.681	rs10749805	ENSG00000229901.1	RP11-399E6.4	-7.33	1.03e-12	4.01e-10	-0.31	-0.33	Intelligence (multi-trait analysis);	chr1:41384510	chr1:41375004~41375669:-
PRAD	cis	rs55665837	1	rs12804549	ENSG00000251991.1	RNU7-49P	7.33	1.03e-12	4.03e-10	0.35	0.33	Vitamin D levels;	chr11:14416212	chr11:14478892~14478953:+
PRAD	cis	rs1799949	0.864	rs60309406	ENSG00000267002.1	RP11-242D8.1	7.33	1.04e-12	4.04e-10	0.31	0.33	Menopause (age at onset);	chr17:43358297	chr17:43164183~43170403:-
PRAD	cis	rs6674176	0.66	rs6680421	ENSG00000237950.1	RP11-7O11.3	-7.33	1.04e-12	4.05e-10	-0.37	-0.33	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43943297	chr1:43944370~43946551:-
PRAD	cis	rs10050311	0.79	rs72667724	ENSG00000251411.1	RP11-397E7.4	-7.33	1.04e-12	4.06e-10	-0.42	-0.33	Insulin-related traits;	chr4:86929931	chr4:86913266~86914817:-
PRAD	cis	rs2033711	0.87	rs1465789	ENSG00000269473.1	CTD-2619J13.19	7.33	1.04e-12	4.06e-10	0.36	0.33	Uric acid clearance;	chr19:58434689	chr19:58440448~58445849:+
PRAD	cis	rs9918079	0.884	rs11728037	ENSG00000273133.1	RP11-799M12.2	-7.33	1.05e-12	4.08e-10	-0.51	-0.33	Obesity-related traits;	chr4:15593275	chr4:15563698~15564253:-
PRAD	cis	rs6539288	0.933	rs1037012	ENSG00000260329.1	RP11-412D9.4	-7.33	1.05e-12	4.09e-10	-0.28	-0.33	Total body bone mineral density;	chr12:106908899	chr12:106954029~106955497:-
PRAD	cis	rs2739330	0.892	rs4822455	ENSG00000206090.4	AP000350.7	7.33	1.05e-12	4.09e-10	0.42	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23939998~23942798:+
PRAD	cis	rs853679	0.527	rs9468333	ENSG00000280107.1	AL022393.9	-7.33	1.05e-12	4.09e-10	-0.4	-0.33	Depression;	chr6:28303421	chr6:28170845~28172521:+
PRAD	cis	rs7615952	0.515	rs4441610	ENSG00000171084.14	FAM86JP	7.33	1.05e-12	4.09e-10	0.49	0.33	Blood pressure (smoking interaction);	chr3:125962464	chr3:125916620~125930024:+
PRAD	cis	rs6751744	0.513	rs7563368	ENSG00000226266.5	AC009961.3	7.33	1.06e-12	4.11e-10	0.42	0.33	Dysphagia;	chr2:159600564	chr2:159670708~159712435:-
PRAD	cis	rs2276314	0.857	rs62101376	ENSG00000278986.1	RP11-723J4.3	-7.33	1.06e-12	4.11e-10	-0.4	-0.33	Endometriosis;Drug-induced torsades de pointes;	chr18:36002992	chr18:35972151~35973916:+
PRAD	cis	rs150992	0.603	rs161732	ENSG00000248489.1	CTD-2007H13.3	-7.33	1.06e-12	4.11e-10	-0.41	-0.33	Body mass index;	chr5:98941418	chr5:98929171~98995013:+
PRAD	cis	rs17772222	0.74	rs10143744	ENSG00000258983.2	RP11-507K2.2	7.33	1.06e-12	4.13e-10	0.43	0.32	Coronary artery calcification;	chr14:88508073	chr14:88499334~88515502:+
PRAD	cis	rs17772222	0.74	rs1999177	ENSG00000258983.2	RP11-507K2.2	7.33	1.06e-12	4.13e-10	0.43	0.32	Coronary artery calcification;	chr14:88508298	chr14:88499334~88515502:+
PRAD	cis	rs17772222	0.74	rs1999176	ENSG00000258983.2	RP11-507K2.2	7.33	1.06e-12	4.13e-10	0.43	0.32	Coronary artery calcification;	chr14:88508371	chr14:88499334~88515502:+
PRAD	cis	rs17772222	0.74	rs1864747	ENSG00000258983.2	RP11-507K2.2	7.33	1.06e-12	4.13e-10	0.43	0.32	Coronary artery calcification;	chr14:88508523	chr14:88499334~88515502:+
PRAD	cis	rs17772222	0.74	rs7151164	ENSG00000258983.2	RP11-507K2.2	7.33	1.06e-12	4.13e-10	0.43	0.32	Coronary artery calcification;	chr14:88509329	chr14:88499334~88515502:+
PRAD	cis	rs17772222	0.74	rs12433026	ENSG00000258983.2	RP11-507K2.2	7.33	1.06e-12	4.13e-10	0.43	0.32	Coronary artery calcification;	chr14:88509495	chr14:88499334~88515502:+
PRAD	cis	rs4972806	0.776	rs2072589	ENSG00000226363.3	HAGLROS	-7.33	1.06e-12	4.13e-10	-0.36	-0.32	IgG glycosylation;	chr2:176178143	chr2:176177717~176179008:+
PRAD	cis	rs172166	0.769	rs149965	ENSG00000220721.1	OR1F12	7.33	1.06e-12	4.13e-10	0.38	0.32	Cardiac Troponin-T levels;	chr6:28050911	chr6:28073316~28074233:+
PRAD	cis	rs62355900	0.627	rs16886400	ENSG00000271828.1	CTD-2310F14.1	7.33	1.06e-12	4.14e-10	0.68	0.32	Endometriosis;	chr5:56841605	chr5:56927874~56929573:+
PRAD	cis	rs995000	0.899	rs7518497	ENSG00000235545.1	RP11-230B22.1	-7.33	1.06e-12	4.14e-10	-0.44	-0.32	Triglyceride levels;	chr1:62712025	chr1:62688482~62710694:+
PRAD	cis	rs7429990	0.965	rs1550914	ENSG00000229759.1	MRPS18AP1	7.33	1.06e-12	4.14e-10	0.33	0.32	Educational attainment (years of education);	chr3:47953678	chr3:48256350~48256938:-
PRAD	cis	rs9640161	0.742	rs2108852	ENSG00000261305.1	RP4-584D14.7	7.33	1.07e-12	4.15e-10	0.36	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150322539	chr7:150341771~150342607:+
PRAD	cis	rs9640161	0.742	rs2108851	ENSG00000261305.1	RP4-584D14.7	7.33	1.07e-12	4.15e-10	0.36	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150322545	chr7:150341771~150342607:+
PRAD	cis	rs897984	0.762	rs11150601	ENSG00000279196.1	RP11-1072A3.3	-7.33	1.07e-12	4.15e-10	-0.35	-0.32	Dementia with Lewy bodies;	chr16:30966478	chr16:30984630~30988270:-
PRAD	cis	rs240993	0.812	rs383022	ENSG00000230177.1	RP5-1112D6.4	-7.33	1.07e-12	4.15e-10	-0.41	-0.32	Inflammatory skin disease;Psoriasis;	chr6:111382506	chr6:111277932~111278742:+
PRAD	cis	rs526231	0.543	rs171558	ENSG00000175749.11	EIF3KP1	7.33	1.07e-12	4.15e-10	0.46	0.32	Primary biliary cholangitis;	chr5:103242193	chr5:103032376~103033031:+
PRAD	cis	rs172166	0.694	rs1631552	ENSG00000219392.1	RP1-265C24.5	-7.33	1.07e-12	4.15e-10	-0.4	-0.32	Cardiac Troponin-T levels;	chr6:28121921	chr6:28115628~28116551:+
PRAD	cis	rs6860806	0.661	rs2136188	ENSG00000233006.5	AC034220.3	-7.33	1.07e-12	4.16e-10	-0.28	-0.32	Breast cancer;	chr5:132241821	chr5:132311285~132369916:-
PRAD	cis	rs6452524	0.836	rs11949301	ENSG00000249664.1	CTD-2227C6.2	-7.33	1.07e-12	4.16e-10	-0.4	-0.32	Hypertension (SNP x SNP interaction);	chr5:83209334	chr5:83012285~83013109:-
PRAD	cis	rs2274273	1	rs2274273	ENSG00000258413.1	RP11-665C16.6	7.33	1.07e-12	4.16e-10	0.41	0.32	Protein biomarker;	chr14:55147918	chr14:55262767~55272075:-
PRAD	cis	rs11098499	1	rs11098499	ENSG00000245958.5	RP11-33B1.1	-7.33	1.07e-12	4.17e-10	-0.32	-0.32	Corneal astigmatism;	chr4:119266456	chr4:119454791~119552025:+
PRAD	cis	rs4664293	0.867	rs7606046	ENSG00000226266.5	AC009961.3	-7.33	1.07e-12	4.17e-10	-0.43	-0.32	Monocyte percentage of white cells;	chr2:159719647	chr2:159670708~159712435:-
PRAD	cis	rs9467773	1	rs6940188	ENSG00000124549.13	BTN2A3P	7.33	1.07e-12	4.17e-10	0.28	0.32	Intelligence (multi-trait analysis);	chr6:26561801	chr6:26421391~26432383:+
PRAD	cis	rs1799949	0.965	rs1842147	ENSG00000267002.1	RP11-242D8.1	7.33	1.07e-12	4.17e-10	0.31	0.32	Menopause (age at onset);	chr17:43357824	chr17:43164183~43170403:-
PRAD	cis	rs62355901	0.545	rs16886263	ENSG00000271828.1	CTD-2310F14.1	-7.33	1.07e-12	4.18e-10	-0.67	-0.32	Breast cancer;	chr5:56769680	chr5:56927874~56929573:+
PRAD	cis	rs10208712	0.509	rs1437691	ENSG00000229550.1	AC012445.1	7.33	1.07e-12	4.18e-10	0.39	0.32	Restless legs syndrome;	chr2:4066433	chr2:4136644~4140731:-
PRAD	cis	rs853679	0.607	rs13217984	ENSG00000280107.1	AL022393.9	-7.33	1.07e-12	4.18e-10	-0.67	-0.32	Depression;	chr6:28171932	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.556	rs67297533	ENSG00000280107.1	AL022393.9	-7.33	1.07e-12	4.18e-10	-0.67	-0.32	Depression;	chr6:28173475	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.505	rs35781323	ENSG00000280107.1	AL022393.9	-7.33	1.07e-12	4.18e-10	-0.67	-0.32	Depression;	chr6:28177054	chr6:28170845~28172521:+
PRAD	cis	rs875971	0.638	rs6960778	ENSG00000237310.1	GS1-124K5.4	-7.33	1.08e-12	4.2e-10	-0.29	-0.32	Aortic root size;	chr7:66606610	chr7:66493706~66495474:+
PRAD	cis	rs853679	0.607	rs35749575	ENSG00000280107.1	AL022393.9	-7.33	1.08e-12	4.2e-10	-0.66	-0.32	Depression;	chr6:28147040	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.607	rs72846780	ENSG00000280107.1	AL022393.9	-7.33	1.08e-12	4.2e-10	-0.66	-0.32	Depression;	chr6:28151277	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.607	rs13205911	ENSG00000280107.1	AL022393.9	-7.33	1.08e-12	4.2e-10	-0.66	-0.32	Depression;	chr6:28156336	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.607	rs13197176	ENSG00000280107.1	AL022393.9	-7.33	1.08e-12	4.2e-10	-0.66	-0.32	Depression;	chr6:28161454	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.607	rs13201308	ENSG00000280107.1	AL022393.9	-7.33	1.08e-12	4.2e-10	-0.66	-0.32	Depression;	chr6:28162311	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.607	rs34765154	ENSG00000280107.1	AL022393.9	-7.33	1.08e-12	4.2e-10	-0.66	-0.32	Depression;	chr6:28162672	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.607	rs34505829	ENSG00000280107.1	AL022393.9	-7.33	1.08e-12	4.2e-10	-0.66	-0.32	Depression;	chr6:28165461	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.607	rs35098436	ENSG00000280107.1	AL022393.9	-7.33	1.08e-12	4.2e-10	-0.66	-0.32	Depression;	chr6:28166443	chr6:28170845~28172521:+
PRAD	cis	rs638893	0.588	rs4938566	ENSG00000278376.1	RP11-158I9.8	-7.33	1.08e-12	4.2e-10	-0.33	-0.32	Vitiligo;	chr11:118850480	chr11:118791254~118793137:+
PRAD	cis	rs638893	0.617	rs4938567	ENSG00000278376.1	RP11-158I9.8	-7.33	1.08e-12	4.2e-10	-0.33	-0.32	Vitiligo;	chr11:118850540	chr11:118791254~118793137:+
PRAD	cis	rs2581828	0.618	rs9838517	ENSG00000242142.1	SERBP1P3	-7.33	1.09e-12	4.22e-10	-0.38	-0.32	Crohn's disease;	chr3:53110347	chr3:53064283~53065091:-
PRAD	cis	rs113835537	0.529	rs7950407	ENSG00000255517.5	CTD-3074O7.5	-7.33	1.09e-12	4.22e-10	-0.33	-0.32	Airway imaging phenotypes;	chr11:66490535	chr11:66473490~66480233:-
PRAD	cis	rs11098499	0.644	rs10009566	ENSG00000245958.5	RP11-33B1.1	-7.33	1.09e-12	4.22e-10	-0.3	-0.32	Corneal astigmatism;	chr4:119637453	chr4:119454791~119552025:+
PRAD	cis	rs6539288	0.834	rs1545097	ENSG00000260329.1	RP11-412D9.4	-7.33	1.09e-12	4.22e-10	-0.28	-0.32	Total body bone mineral density;	chr12:106919918	chr12:106954029~106955497:-
PRAD	cis	rs6539288	0.899	rs6539292	ENSG00000260329.1	RP11-412D9.4	-7.33	1.09e-12	4.22e-10	-0.28	-0.32	Total body bone mineral density;	chr12:106919935	chr12:106954029~106955497:-
PRAD	cis	rs2638953	0.925	rs11049491	ENSG00000247934.4	RP11-967K21.1	-7.33	1.09e-12	4.23e-10	-0.35	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28262340	chr12:28163298~28190738:-
PRAD	cis	rs2243480	1	rs2707844	ENSG00000273142.1	RP11-458F8.4	-7.33	1.09e-12	4.24e-10	-0.37	-0.32	Diabetic kidney disease;	chr7:66594522	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs1796220	ENSG00000273142.1	RP11-458F8.4	-7.33	1.09e-12	4.24e-10	-0.37	-0.32	Diabetic kidney disease;	chr7:66597113	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs2707831	ENSG00000273142.1	RP11-458F8.4	-7.33	1.09e-12	4.24e-10	-0.37	-0.32	Diabetic kidney disease;	chr7:66597524	chr7:66902857~66906297:+
PRAD	cis	rs42648	0.869	rs3810890	ENSG00000227646.6	STEAP2-AS1	-7.33	1.09e-12	4.25e-10	-0.3	-0.32	Homocysteine levels;	chr7:90279519	chr7:89882353~90211635:-
PRAD	cis	rs42648	0.837	rs10262603	ENSG00000227646.6	STEAP2-AS1	-7.33	1.09e-12	4.25e-10	-0.3	-0.32	Homocysteine levels;	chr7:90280128	chr7:89882353~90211635:-
PRAD	cis	rs35264875	0.796	rs72930637	ENSG00000259799.1	RP11-554A11.9	7.33	1.1e-12	4.25e-10	0.45	0.32	Blond vs. brown hair color;	chr11:69102499	chr11:69155910~69159752:+
PRAD	cis	rs7646881	0.812	rs74618709	ENSG00000240207.5	RP11-379F4.4	-7.33	1.1e-12	4.25e-10	-0.31	-0.32	Tetralogy of Fallot;	chr3:158737492	chr3:158732263~158784070:+
PRAD	cis	rs3096299	0.9	rs4785666	ENSG00000261118.1	RP11-104N10.1	7.32	1.1e-12	4.26e-10	0.32	0.32	Multiple myeloma (IgH translocation);	chr16:89396363	chr16:89492017~89504460:-
PRAD	cis	rs9399135	0.507	rs7766963	ENSG00000232876.1	CTA-212D2.2	7.32	1.1e-12	4.26e-10	0.41	0.32	Red blood cell count;	chr6:135111745	chr6:135055033~135060550:+
PRAD	cis	rs4713118	0.513	rs149959	ENSG00000220721.1	OR1F12	7.32	1.1e-12	4.26e-10	0.38	0.32	Parkinson's disease;	chr6:28046076	chr6:28073316~28074233:+
PRAD	cis	rs45509595	0.841	rs370155	ENSG00000280107.1	AL022393.9	-7.32	1.1e-12	4.27e-10	-0.56	-0.32	Breast cancer;	chr6:27814253	chr6:28170845~28172521:+
PRAD	cis	rs4925386	0.681	rs2427296	ENSG00000273619.1	RP5-908M14.9	-7.32	1.1e-12	4.28e-10	-0.23	-0.32	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62352419	chr20:62386303~62386970:-
PRAD	cis	rs8177376	0.727	rs586566	ENSG00000254905.1	RP11-712L6.7	7.32	1.1e-12	4.28e-10	0.39	0.32	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126329723	chr11:126292922~126294254:-
PRAD	cis	rs8177376	0.727	rs667469	ENSG00000254905.1	RP11-712L6.7	7.32	1.1e-12	4.28e-10	0.39	0.32	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126330171	chr11:126292922~126294254:-
PRAD	cis	rs8177376	0.727	rs4937121	ENSG00000254905.1	RP11-712L6.7	7.32	1.1e-12	4.28e-10	0.39	0.32	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126330659	chr11:126292922~126294254:-
PRAD	cis	rs6539288	1	rs6539288	ENSG00000260329.1	RP11-412D9.4	-7.32	1.1e-12	4.28e-10	-0.28	-0.32	Total body bone mineral density;	chr12:106904084	chr12:106954029~106955497:-
PRAD	cis	rs9467773	1	rs9467773	ENSG00000124549.13	BTN2A3P	7.32	1.1e-12	4.29e-10	0.28	0.32	Intelligence (multi-trait analysis);	chr6:26498198	chr6:26421391~26432383:+
PRAD	cis	rs9467773	1	rs6926629	ENSG00000124549.13	BTN2A3P	7.32	1.1e-12	4.29e-10	0.28	0.32	Intelligence (multi-trait analysis);	chr6:26499675	chr6:26421391~26432383:+
PRAD	cis	rs9467773	1	rs6903973	ENSG00000124549.13	BTN2A3P	7.32	1.1e-12	4.29e-10	0.28	0.32	Intelligence (multi-trait analysis);	chr6:26499714	chr6:26421391~26432383:+
PRAD	cis	rs9467773	1	rs2255070	ENSG00000124549.13	BTN2A3P	7.32	1.1e-12	4.29e-10	0.28	0.32	Intelligence (multi-trait analysis);	chr6:26501549	chr6:26421391~26432383:+
PRAD	cis	rs9467773	0.844	rs2393669	ENSG00000124549.13	BTN2A3P	7.32	1.1e-12	4.29e-10	0.28	0.32	Intelligence (multi-trait analysis);	chr6:26503645	chr6:26421391~26432383:+
PRAD	cis	rs9467773	1	rs9461259	ENSG00000124549.13	BTN2A3P	7.32	1.1e-12	4.29e-10	0.28	0.32	Intelligence (multi-trait analysis);	chr6:26504607	chr6:26421391~26432383:+
PRAD	cis	rs9467773	1	rs9467774	ENSG00000124549.13	BTN2A3P	7.32	1.1e-12	4.29e-10	0.28	0.32	Intelligence (multi-trait analysis);	chr6:26504808	chr6:26421391~26432383:+
PRAD	cis	rs9467773	1	rs3736781	ENSG00000124549.13	BTN2A3P	7.32	1.1e-12	4.29e-10	0.28	0.32	Intelligence (multi-trait analysis);	chr6:26505134	chr6:26421391~26432383:+
PRAD	cis	rs9467773	1	rs3736782	ENSG00000124549.13	BTN2A3P	7.32	1.1e-12	4.29e-10	0.28	0.32	Intelligence (multi-trait analysis);	chr6:26505175	chr6:26421391~26432383:+
PRAD	cis	rs9467773	1	rs2208331	ENSG00000124549.13	BTN2A3P	7.32	1.1e-12	4.29e-10	0.28	0.32	Intelligence (multi-trait analysis);	chr6:26507091	chr6:26421391~26432383:+
PRAD	cis	rs9467773	1	rs9393728	ENSG00000124549.13	BTN2A3P	7.32	1.1e-12	4.29e-10	0.28	0.32	Intelligence (multi-trait analysis);	chr6:26509102	chr6:26421391~26432383:+
PRAD	cis	rs9467773	1	rs1056667	ENSG00000124549.13	BTN2A3P	7.32	1.1e-12	4.29e-10	0.28	0.32	Intelligence (multi-trait analysis);	chr6:26510336	chr6:26421391~26432383:+
PRAD	cis	rs74024059	1	rs334923	ENSG00000260685.1	RP11-326L17.1	7.32	1.11e-12	4.29e-10	0.85	0.32	Red blood cell count;Hematocrit;	chr15:76041072	chr15:75950464~75951144:-
PRAD	cis	rs748404	0.65	rs518234	ENSG00000205771.5	CATSPER2P1	-7.32	1.11e-12	4.29e-10	-0.35	-0.32	Lung cancer;	chr15:43281223	chr15:43726918~43747094:-
PRAD	cis	rs748404	0.65	rs518261	ENSG00000205771.5	CATSPER2P1	-7.32	1.11e-12	4.29e-10	-0.35	-0.32	Lung cancer;	chr15:43281231	chr15:43726918~43747094:-
PRAD	cis	rs11098499	0.644	rs7693919	ENSG00000245958.5	RP11-33B1.1	-7.32	1.11e-12	4.3e-10	-0.31	-0.32	Corneal astigmatism;	chr4:119619416	chr4:119454791~119552025:+
PRAD	cis	rs897984	0.762	rs7204459	ENSG00000279196.1	RP11-1072A3.3	-7.32	1.11e-12	4.3e-10	-0.35	-0.32	Dementia with Lewy bodies;	chr16:30972891	chr16:30984630~30988270:-
PRAD	cis	rs897984	0.762	rs4889604	ENSG00000279196.1	RP11-1072A3.3	-7.32	1.11e-12	4.3e-10	-0.35	-0.32	Dementia with Lewy bodies;	chr16:30974673	chr16:30984630~30988270:-
PRAD	cis	rs172166	0.694	rs203893	ENSG00000219392.1	RP1-265C24.5	-7.32	1.11e-12	4.3e-10	-0.4	-0.32	Cardiac Troponin-T levels;	chr6:28094288	chr6:28115628~28116551:+
PRAD	cis	rs172166	0.652	rs476167	ENSG00000219392.1	RP1-265C24.5	-7.32	1.11e-12	4.3e-10	-0.4	-0.32	Cardiac Troponin-T levels;	chr6:28098110	chr6:28115628~28116551:+
PRAD	cis	rs172166	0.694	rs203892	ENSG00000219392.1	RP1-265C24.5	-7.32	1.11e-12	4.3e-10	-0.4	-0.32	Cardiac Troponin-T levels;	chr6:28099418	chr6:28115628~28116551:+
PRAD	cis	rs1426063	0.858	rs11931653	ENSG00000249717.1	RP11-44F21.3	7.32	1.11e-12	4.31e-10	0.54	0.32	QT interval;	chr4:75080856	chr4:74955974~74970362:-
PRAD	cis	rs1426063	0.858	rs55775471	ENSG00000249717.1	RP11-44F21.3	7.32	1.11e-12	4.31e-10	0.54	0.32	QT interval;	chr4:75081074	chr4:74955974~74970362:-
PRAD	cis	rs1426063	0.858	rs9990627	ENSG00000249717.1	RP11-44F21.3	7.32	1.11e-12	4.31e-10	0.54	0.32	QT interval;	chr4:75081244	chr4:74955974~74970362:-
PRAD	cis	rs1426063	0.858	rs10026994	ENSG00000249717.1	RP11-44F21.3	7.32	1.11e-12	4.31e-10	0.54	0.32	QT interval;	chr4:75081551	chr4:74955974~74970362:-
PRAD	cis	rs1426063	0.858	rs6830936	ENSG00000249717.1	RP11-44F21.3	7.32	1.11e-12	4.31e-10	0.54	0.32	QT interval;	chr4:75083952	chr4:74955974~74970362:-
PRAD	cis	rs1134634	0.52	rs10025837	ENSG00000273133.1	RP11-799M12.2	-7.32	1.11e-12	4.31e-10	-0.44	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15548362	chr4:15563698~15564253:-
PRAD	cis	rs62355900	0.627	rs62355941	ENSG00000271828.1	CTD-2310F14.1	7.32	1.11e-12	4.31e-10	0.68	0.32	Endometriosis;	chr5:56807871	chr5:56927874~56929573:+
PRAD	cis	rs11098499	0.604	rs10022185	ENSG00000245958.5	RP11-33B1.1	-7.32	1.11e-12	4.32e-10	-0.34	-0.32	Corneal astigmatism;	chr4:119650610	chr4:119454791~119552025:+
PRAD	cis	rs4664293	1	rs10204535	ENSG00000226266.5	AC009961.3	-7.32	1.11e-12	4.33e-10	-0.42	-0.32	Monocyte percentage of white cells;	chr2:159607181	chr2:159670708~159712435:-
PRAD	cis	rs1799949	1	rs11651341	ENSG00000267002.1	RP11-242D8.1	7.32	1.12e-12	4.33e-10	0.31	0.32	Menopause (age at onset);	chr17:43350693	chr17:43164183~43170403:-
PRAD	cis	rs1799949	1	rs34572725	ENSG00000267002.1	RP11-242D8.1	7.32	1.12e-12	4.33e-10	0.31	0.32	Menopause (age at onset);	chr17:43351298	chr17:43164183~43170403:-
PRAD	cis	rs1799949	1	rs4534897	ENSG00000267002.1	RP11-242D8.1	7.32	1.12e-12	4.33e-10	0.31	0.32	Menopause (age at onset);	chr17:43354440	chr17:43164183~43170403:-
PRAD	cis	rs2274273	1	rs3742566	ENSG00000258413.1	RP11-665C16.6	-7.32	1.12e-12	4.34e-10	-0.41	-0.32	Protein biomarker;	chr14:55129121	chr14:55262767~55272075:-
PRAD	cis	rs2274273	1	rs1047556	ENSG00000258413.1	RP11-665C16.6	-7.32	1.12e-12	4.34e-10	-0.41	-0.32	Protein biomarker;	chr14:55133564	chr14:55262767~55272075:-
PRAD	cis	rs75422866	0.51	rs35784744	ENSG00000257433.4	RP1-197B17.3	7.32	1.12e-12	4.35e-10	0.67	0.32	Pneumonia;	chr12:47729646	chr12:47706085~47742294:+
PRAD	cis	rs75422866	0.541	rs12425816	ENSG00000257433.4	RP1-197B17.3	7.32	1.12e-12	4.35e-10	0.67	0.32	Pneumonia;	chr12:47731419	chr12:47706085~47742294:+
PRAD	cis	rs3020736	0.5	rs6002616	ENSG00000205702.9	CYP2D7	-7.32	1.12e-12	4.35e-10	-0.25	-0.32	Autism spectrum disorder or schizophrenia;	chr22:42108675	chr22:42140203~42144577:-
PRAD	cis	rs3020736	0.5	rs7364293	ENSG00000205702.9	CYP2D7	-7.32	1.12e-12	4.35e-10	-0.25	-0.32	Autism spectrum disorder or schizophrenia;	chr22:42110366	chr22:42140203~42144577:-
PRAD	cis	rs6539288	0.933	rs4964498	ENSG00000260329.1	RP11-412D9.4	-7.32	1.12e-12	4.35e-10	-0.28	-0.32	Total body bone mineral density;	chr12:106912945	chr12:106954029~106955497:-
PRAD	cis	rs4713118	0.869	rs6922574	ENSG00000226314.6	ZNF192P1	-7.32	1.12e-12	4.36e-10	-0.43	-0.32	Parkinson's disease;	chr6:27725224	chr6:28161781~28169594:+
PRAD	cis	rs950169	0.545	rs4842841	ENSG00000259728.4	LINC00933	7.32	1.12e-12	4.36e-10	0.41	0.32	Schizophrenia;	chr15:83972373	chr15:84570649~84580175:+
PRAD	cis	rs7727544	0.684	rs272874	ENSG00000233006.5	AC034220.3	-7.32	1.12e-12	4.36e-10	-0.32	-0.32	Blood metabolite levels;	chr5:132339353	chr5:132311285~132369916:-
PRAD	cis	rs11098499	1	rs3749591	ENSG00000245958.5	RP11-33B1.1	-7.32	1.13e-12	4.36e-10	-0.32	-0.32	Corneal astigmatism;	chr4:119292875	chr4:119454791~119552025:+
PRAD	cis	rs2274273	0.624	rs8003279	ENSG00000258413.1	RP11-665C16.6	-7.32	1.13e-12	4.38e-10	-0.45	-0.32	Protein biomarker;	chr14:55397412	chr14:55262767~55272075:-
PRAD	cis	rs8523	0.779	rs67580629	ENSG00000230314.5	ELOVL2-AS1	7.32	1.13e-12	4.39e-10	0.35	0.32	Red blood cell fatty acid levels;	chr6:11005793	chr6:11043524~11078226:+
PRAD	cis	rs9326248	0.559	rs573549	ENSG00000280143.1	AP000892.6	7.32	1.14e-12	4.41e-10	0.25	0.32	Blood protein levels;	chr11:116865963	chr11:117204967~117210292:+
PRAD	cis	rs6921919	0.848	rs9468350	ENSG00000204709.4	LINC01556	7.32	1.14e-12	4.41e-10	0.46	0.32	Autism spectrum disorder or schizophrenia;	chr6:28351330	chr6:28943877~28944537:+
PRAD	cis	rs67311347	0.544	rs6599088	ENSG00000223797.4	ENTPD3-AS1	7.32	1.14e-12	4.42e-10	0.28	0.32	Renal cell carcinoma;	chr3:40287797	chr3:40313802~40453329:-
PRAD	cis	rs67311347	0.544	rs9877105	ENSG00000223797.4	ENTPD3-AS1	7.32	1.14e-12	4.42e-10	0.28	0.32	Renal cell carcinoma;	chr3:40291875	chr3:40313802~40453329:-
PRAD	cis	rs113835537	0.529	rs4930378	ENSG00000255517.5	CTD-3074O7.5	-7.32	1.14e-12	4.43e-10	-0.33	-0.32	Airway imaging phenotypes;	chr11:66488044	chr11:66473490~66480233:-
PRAD	cis	rs897984	0.762	rs897986	ENSG00000279196.1	RP11-1072A3.3	-7.32	1.14e-12	4.43e-10	-0.35	-0.32	Dementia with Lewy bodies;	chr16:30969581	chr16:30984630~30988270:-
PRAD	cis	rs67311347	0.544	rs2887965	ENSG00000223797.4	ENTPD3-AS1	-7.32	1.14e-12	4.43e-10	-0.28	-0.32	Renal cell carcinoma;	chr3:40292663	chr3:40313802~40453329:-
PRAD	cis	rs11083475	1	rs3786835	ENSG00000267892.1	CTD-2540F13.2	7.32	1.15e-12	4.44e-10	0.35	0.32	Heart rate;	chr19:38665240	chr19:38738284~38739863:+
PRAD	cis	rs6479901	0.841	rs6479889	ENSG00000232075.1	MRPL35P2	-7.32	1.15e-12	4.45e-10	-0.39	-0.32	Intelligence (multi-trait analysis);	chr10:63228867	chr10:63634317~63634827:-
PRAD	cis	rs9640161	0.75	rs11765644	ENSG00000261305.1	RP4-584D14.7	7.32	1.15e-12	4.45e-10	0.37	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150329250	chr7:150341771~150342607:+
PRAD	cis	rs812925	0.502	rs13028833	ENSG00000271889.1	RP11-493E12.1	-7.32	1.15e-12	4.46e-10	-0.35	-0.32	Immature fraction of reticulocytes;	chr2:61417194	chr2:61151433~61162105:-
PRAD	cis	rs597539	0.58	rs7935851	ENSG00000261625.1	RP11-554A11.4	-7.32	1.15e-12	4.46e-10	-0.3	-0.32	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68963653	chr11:69000765~69002048:-
PRAD	cis	rs995000	0.965	rs10889332	ENSG00000235545.1	RP11-230B22.1	-7.32	1.15e-12	4.47e-10	-0.43	-0.32	Triglyceride levels;	chr1:62485187	chr1:62688482~62710694:+
PRAD	cis	rs1501911	0.509	rs692759	ENSG00000248489.1	CTD-2007H13.3	-7.32	1.15e-12	4.47e-10	-0.36	-0.32	Lung function (FEV1/FVC);	chr5:98856841	chr5:98929171~98995013:+
PRAD	cis	rs2337406	0.587	rs2516889	ENSG00000274576.2	IGHV2-70	7.32	1.15e-12	4.47e-10	0.34	0.32	Alzheimer's disease (late onset);	chr14:106648903	chr14:106770577~106771020:-
PRAD	cis	rs2412819	0.571	rs514255	ENSG00000205771.5	CATSPER2P1	-7.32	1.15e-12	4.47e-10	-0.45	-0.32	Lung cancer;	chr15:43893134	chr15:43726918~43747094:-
PRAD	cis	rs17674580	0.582	rs11662680	ENSG00000267193.4	RP11-116O18.3	-7.32	1.16e-12	4.48e-10	-0.36	-0.32	Bladder cancer;	chr18:45753220	chr18:45669367~45747215:-
PRAD	cis	rs8005677	0.77	rs56180741	ENSG00000257285.4	RP11-298I3.1	7.32	1.16e-12	4.48e-10	0.33	0.32	Cognitive ability (multi-trait analysis);	chr14:22908037	chr14:22929609~22955562:+
PRAD	cis	rs7487075	0.93	rs11183468	ENSG00000274723.1	RP11-618L22.1	7.32	1.16e-12	4.49e-10	0.38	0.32	Itch intensity from mosquito bite;	chr12:46412478	chr12:46970504~46972155:+
PRAD	cis	rs12612619	0.732	rs11680032	ENSG00000272148.1	RP11-195B17.1	7.32	1.16e-12	4.49e-10	0.39	0.32	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26975280	chr2:27062428~27062907:-
PRAD	cis	rs2638953	0.924	rs11049444	ENSG00000247934.4	RP11-967K21.1	-7.32	1.16e-12	4.5e-10	-0.33	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28197447	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.924	rs11049445	ENSG00000247934.4	RP11-967K21.1	-7.32	1.16e-12	4.5e-10	-0.33	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28197449	chr12:28163298~28190738:-
PRAD	cis	rs6479901	0.947	rs7909692	ENSG00000232075.1	MRPL35P2	-7.32	1.16e-12	4.5e-10	-0.39	-0.32	Intelligence (multi-trait analysis);	chr10:63368517	chr10:63634317~63634827:-
PRAD	cis	rs4713118	0.955	rs9393847	ENSG00000226314.6	ZNF192P1	-7.32	1.16e-12	4.51e-10	-0.43	-0.32	Parkinson's disease;	chr6:27720194	chr6:28161781~28169594:+
PRAD	cis	rs10129255	0.957	rs10142918	ENSG00000223648.3	IGHV3-64	7.32	1.17e-12	4.52e-10	0.33	0.32	Kawasaki disease;	chr14:106782206	chr14:106643132~106658258:-
PRAD	cis	rs10129255	0.957	rs10142859	ENSG00000223648.3	IGHV3-64	7.32	1.17e-12	4.52e-10	0.33	0.32	Kawasaki disease;	chr14:106782238	chr14:106643132~106658258:-
PRAD	cis	rs853679	0.607	rs13207345	ENSG00000225595.2	XXbac-BPG308K3.6	7.32	1.17e-12	4.52e-10	0.71	0.32	Depression;	chr6:28297795	chr6:28859625~28864630:-
PRAD	cis	rs853679	0.607	rs72854513	ENSG00000225595.2	XXbac-BPG308K3.6	7.32	1.17e-12	4.52e-10	0.71	0.32	Depression;	chr6:28298177	chr6:28859625~28864630:-
PRAD	cis	rs853679	0.607	rs56189111	ENSG00000225595.2	XXbac-BPG308K3.6	7.32	1.17e-12	4.52e-10	0.71	0.32	Depression;	chr6:28304196	chr6:28859625~28864630:-
PRAD	cis	rs853679	0.607	rs35072899	ENSG00000225595.2	XXbac-BPG308K3.6	7.32	1.17e-12	4.52e-10	0.71	0.32	Depression;	chr6:28313764	chr6:28859625~28864630:-
PRAD	cis	rs17428076	0.793	rs3765166	ENSG00000228389.1	AC068039.4	-7.32	1.17e-12	4.53e-10	-0.42	-0.32	Myopia;	chr2:171837270	chr2:171773482~171775844:+
PRAD	cis	rs17428076	0.793	rs3765167	ENSG00000228389.1	AC068039.4	-7.32	1.17e-12	4.53e-10	-0.42	-0.32	Myopia;	chr2:171837434	chr2:171773482~171775844:+
PRAD	cis	rs853679	0.607	rs56075693	ENSG00000225595.2	XXbac-BPG308K3.6	7.31	1.17e-12	4.54e-10	0.71	0.32	Depression;	chr6:28322551	chr6:28859625~28864630:-
PRAD	cis	rs853679	0.607	rs34218844	ENSG00000225595.2	XXbac-BPG308K3.6	7.31	1.17e-12	4.54e-10	0.71	0.32	Depression;	chr6:28322870	chr6:28859625~28864630:-
PRAD	cis	rs9309711	0.922	rs11679058	ENSG00000225234.1	TRAPPC12-AS1	-7.31	1.17e-12	4.54e-10	-0.36	-0.32	Neurofibrillary tangles;	chr2:3480042	chr2:3481242~3482409:-
PRAD	cis	rs897984	0.721	rs4889525	ENSG00000279196.1	RP11-1072A3.3	-7.31	1.17e-12	4.55e-10	-0.35	-0.32	Dementia with Lewy bodies;	chr16:30978537	chr16:30984630~30988270:-
PRAD	cis	rs2034650	0.544	rs11070272	ENSG00000223313.1	RNU6-516P	7.31	1.17e-12	4.55e-10	0.4	0.32	Interstitial lung disease;	chr15:40433064	chr15:40529570~40529673:+
PRAD	cis	rs11159086	1	rs11159087	ENSG00000259005.1	RP3-449M8.6	7.31	1.18e-12	4.55e-10	0.47	0.32	Advanced glycation end-product levels;	chr14:74504671	chr14:74474007~74474864:-
PRAD	cis	rs67180937	0.921	rs17163360	ENSG00000272750.1	RP11-378J18.8	-7.31	1.18e-12	4.56e-10	-0.42	-0.32	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222647448	chr1:222658867~222661512:-
PRAD	cis	rs67180937	0.961	rs17465637	ENSG00000272750.1	RP11-378J18.8	7.31	1.18e-12	4.56e-10	0.42	0.32	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222650187	chr1:222658867~222661512:-
PRAD	cis	rs67180937	1	rs67180937	ENSG00000272750.1	RP11-378J18.8	-7.31	1.18e-12	4.56e-10	-0.42	-0.32	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222650401	chr1:222658867~222661512:-
PRAD	cis	rs67180937	0.961	rs17011681	ENSG00000272750.1	RP11-378J18.8	-7.31	1.18e-12	4.56e-10	-0.42	-0.32	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222651746	chr1:222658867~222661512:-
PRAD	cis	rs67180937	0.922	rs10495198	ENSG00000272750.1	RP11-378J18.8	-7.31	1.18e-12	4.56e-10	-0.42	-0.32	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222652375	chr1:222658867~222661512:-
PRAD	cis	rs1065852	0.817	rs5758608	ENSG00000227370.1	RP4-669P10.19	7.31	1.18e-12	4.56e-10	0.36	0.32	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42151238	chr22:42132543~42132998:+
PRAD	cis	rs5758511	0.514	rs5758609	ENSG00000227370.1	RP4-669P10.19	7.31	1.18e-12	4.56e-10	0.36	0.32	Birth weight;	chr22:42151326	chr22:42132543~42132998:+
PRAD	cis	rs11846409	0.86	rs74091720	ENSG00000274576.2	IGHV2-70	-7.31	1.18e-12	4.57e-10	-0.33	-0.32	Rheumatic heart disease;	chr14:106638192	chr14:106770577~106771020:-
PRAD	cis	rs9918079	1	rs9918079	ENSG00000273133.1	RP11-799M12.2	7.31	1.18e-12	4.58e-10	0.51	0.32	Obesity-related traits;	chr4:15543787	chr4:15563698~15564253:-
PRAD	cis	rs733592	1	rs1859440	ENSG00000240399.1	RP1-228P16.1	-7.31	1.18e-12	4.58e-10	-0.27	-0.32	Plateletcrit;	chr12:48033546	chr12:48054813~48055591:-
PRAD	cis	rs453301	0.657	rs36056437	ENSG00000254340.1	RP11-10A14.3	-7.31	1.18e-12	4.58e-10	-0.38	-0.32	Joint mobility (Beighton score);	chr8:8935355	chr8:9141424~9145435:+
PRAD	cis	rs736801	0.808	rs6866614	ENSG00000233006.5	AC034220.3	-7.31	1.18e-12	4.58e-10	-0.3	-0.32	Mosquito bite size;Breast cancer;	chr5:132451445	chr5:132311285~132369916:-
PRAD	cis	rs6479901	0.947	rs10740128	ENSG00000232075.1	MRPL35P2	-7.31	1.19e-12	4.59e-10	-0.4	-0.32	Intelligence (multi-trait analysis);	chr10:63490783	chr10:63634317~63634827:-
PRAD	cis	rs375066	0.935	rs376032	ENSG00000267058.1	RP11-15A1.3	-7.31	1.19e-12	4.59e-10	-0.28	-0.32	Breast cancer;	chr19:43903412	chr19:43891804~43901805:-
PRAD	cis	rs2276314	1	rs9304153	ENSG00000278986.1	RP11-723J4.3	-7.31	1.19e-12	4.59e-10	-0.41	-0.32	Endometriosis;Drug-induced torsades de pointes;	chr18:35982187	chr18:35972151~35973916:+
PRAD	cis	rs2276314	1	rs9304154	ENSG00000278986.1	RP11-723J4.3	-7.31	1.19e-12	4.59e-10	-0.41	-0.32	Endometriosis;Drug-induced torsades de pointes;	chr18:35982264	chr18:35972151~35973916:+
PRAD	cis	rs7121800	0.632	rs7944883	ENSG00000242353.1	RP4-710M3.1	-7.31	1.19e-12	4.6e-10	-0.35	-0.32	Pit-and-Fissure caries;	chr11:30509936	chr11:30368148~30368646:+
PRAD	cis	rs6480314	0.542	rs4403687	ENSG00000233590.1	RP11-153K11.3	-7.31	1.19e-12	4.6e-10	-0.53	-0.32	Optic nerve measurement (disc area);	chr10:68268295	chr10:68233251~68242379:-
PRAD	cis	rs2638953	0.64	rs11049729	ENSG00000278733.1	RP11-425D17.1	7.31	1.19e-12	4.6e-10	0.41	0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28586694	chr12:28185625~28186190:-
PRAD	cis	rs853679	0.607	rs13204012	ENSG00000225595.2	XXbac-BPG308K3.6	7.31	1.19e-12	4.61e-10	0.71	0.32	Depression;	chr6:28233753	chr6:28859625~28864630:-
PRAD	cis	rs853679	0.607	rs13205211	ENSG00000225595.2	XXbac-BPG308K3.6	7.31	1.19e-12	4.61e-10	0.71	0.32	Depression;	chr6:28235278	chr6:28859625~28864630:-
PRAD	cis	rs3020736	0.5	rs4147638	ENSG00000205702.9	CYP2D7	-7.31	1.19e-12	4.62e-10	-0.25	-0.32	Autism spectrum disorder or schizophrenia;	chr22:42091896	chr22:42140203~42144577:-
PRAD	cis	rs897984	0.762	rs12931046	ENSG00000279196.1	RP11-1072A3.3	-7.31	1.19e-12	4.62e-10	-0.35	-0.32	Dementia with Lewy bodies;	chr16:30975823	chr16:30984630~30988270:-
PRAD	cis	rs2933343	0.553	rs35979399	ENSG00000231305.3	RP11-723O4.2	7.31	1.19e-12	4.62e-10	0.3	0.32	IgG glycosylation;	chr3:128978470	chr3:128861313~128871540:-
PRAD	cis	rs9400467	0.528	rs17539197	ENSG00000271789.1	RP5-1112D6.7	-7.31	1.2e-12	4.63e-10	-0.36	-0.32	Amino acid levels;Blood metabolite levels;	chr6:111447968	chr6:111297126~111298510:+
PRAD	cis	rs62034325	0.697	rs710410	ENSG00000251417.2	RP11-1348G14.4	-7.31	1.2e-12	4.64e-10	-0.37	-0.32	Body mass index;	chr16:28592021	chr16:28802743~28817828:+
PRAD	cis	rs2638953	0.924	rs11049437	ENSG00000247934.4	RP11-967K21.1	-7.31	1.2e-12	4.64e-10	-0.33	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28196192	chr12:28163298~28190738:-
PRAD	cis	rs11098499	0.754	rs1849457	ENSG00000245958.5	RP11-33B1.1	-7.31	1.21e-12	4.68e-10	-0.31	-0.32	Corneal astigmatism;	chr4:119333200	chr4:119454791~119552025:+
PRAD	cis	rs2599510	0.783	rs2710630	ENSG00000276334.1	AL133243.1	-7.31	1.21e-12	4.68e-10	-0.37	-0.32	Interleukin-18 levels;	chr2:32540930	chr2:32521927~32523547:+
PRAD	cis	rs12612619	0.652	rs2011616	ENSG00000229122.1	AGBL5-IT1	-7.31	1.21e-12	4.69e-10	-0.34	-0.32	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27079693	chr2:27061038~27061815:+
PRAD	cis	rs4713118	0.539	rs200988	ENSG00000219392.1	RP1-265C24.5	-7.31	1.22e-12	4.7e-10	-0.41	-0.32	Parkinson's disease;	chr6:27851575	chr6:28115628~28116551:+
PRAD	cis	rs10129255	0.957	rs10140904	ENSG00000223648.3	IGHV3-64	7.31	1.22e-12	4.7e-10	0.32	0.32	Kawasaki disease;	chr14:106776558	chr14:106643132~106658258:-
PRAD	cis	rs270601	0.633	rs733300	ENSG00000233006.5	AC034220.3	7.31	1.22e-12	4.71e-10	0.28	0.32	Acylcarnitine levels;	chr5:132236550	chr5:132311285~132369916:-
PRAD	cis	rs12653946	0.846	rs10866528	ENSG00000248994.1	RP11-259O2.1	-7.31	1.22e-12	4.72e-10	-0.38	-0.32	Prostate cancer;	chr5:1891707	chr5:1933863~1959176:+
PRAD	cis	rs35160687	0.712	rs11674249	ENSG00000273080.1	RP11-301O19.1	-7.31	1.22e-12	4.72e-10	-0.36	-0.32	Night sleep phenotypes;	chr2:86270283	chr2:86195590~86196049:+
PRAD	cis	rs9467773	0.933	rs2024970	ENSG00000124549.13	BTN2A3P	7.31	1.22e-12	4.73e-10	0.29	0.32	Intelligence (multi-trait analysis);	chr6:26497292	chr6:26421391~26432383:+
PRAD	cis	rs1134634	0.52	rs1473166	ENSG00000273133.1	RP11-799M12.2	-7.31	1.22e-12	4.73e-10	-0.44	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15555868	chr4:15563698~15564253:-
PRAD	cis	rs10514928	1	rs10514928	ENSG00000228782.6	CTD-2026D20.3	-7.31	1.22e-12	4.73e-10	-0.69	-0.32	Left atrial antero-posterior diameter;	chr17:47426173	chr17:47450568~47492492:-
PRAD	cis	rs858239	0.6	rs7799422	ENSG00000226816.2	AC005082.12	7.31	1.23e-12	4.74e-10	0.37	0.32	Cerebrospinal fluid biomarker levels;	chr7:23088794	chr7:23206013~23208045:+
PRAD	cis	rs2638953	0.925	rs7967281	ENSG00000278733.1	RP11-425D17.1	-7.31	1.23e-12	4.74e-10	-0.4	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28397843	chr12:28185625~28186190:-
PRAD	cis	rs9532669	0.926	rs9525418	ENSG00000168852.11	TPTE2P5	-7.31	1.23e-12	4.74e-10	-0.34	-0.32	Cervical cancer;	chr13:40879081	chr13:40822296~40921749:-
PRAD	cis	rs2274273	0.638	rs11622636	ENSG00000258413.1	RP11-665C16.6	-7.31	1.23e-12	4.75e-10	-0.45	-0.32	Protein biomarker;	chr14:55181122	chr14:55262767~55272075:-
PRAD	cis	rs12612619	0.761	rs7606840	ENSG00000272148.1	RP11-195B17.1	7.31	1.23e-12	4.76e-10	0.39	0.32	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27020496	chr2:27062428~27062907:-
PRAD	cis	rs853679	0.882	rs9468300	ENSG00000226314.6	ZNF192P1	-7.31	1.24e-12	4.77e-10	-0.57	-0.32	Depression;	chr6:28159062	chr6:28161781~28169594:+
PRAD	cis	rs380904	0.926	rs7842979	ENSG00000254859.1	RP11-661A12.5	-7.31	1.24e-12	4.78e-10	-0.44	-0.32	Venous thromboembolism (SNP x SNP interaction);	chr8:143519726	chr8:143541973~143549729:-
PRAD	cis	rs1426063	0.668	rs6534595	ENSG00000260265.1	RP11-44F21.5	7.31	1.24e-12	4.78e-10	0.47	0.32	QT interval;	chr4:75104432	chr4:75081702~75084717:-
PRAD	cis	rs2274273	0.686	rs66531545	ENSG00000258413.1	RP11-665C16.6	-7.31	1.24e-12	4.79e-10	-0.45	-0.32	Protein biomarker;	chr14:55120742	chr14:55262767~55272075:-
PRAD	cis	rs17772222	1	rs17698817	ENSG00000258983.2	RP11-507K2.2	7.31	1.24e-12	4.8e-10	0.47	0.32	Coronary artery calcification;	chr14:88356632	chr14:88499334~88515502:+
PRAD	cis	rs2436845	0.603	rs2679753	ENSG00000253320.4	KB-1507C5.2	-7.31	1.25e-12	4.81e-10	-0.4	-0.32	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102855232	chr8:102864300~102977876:+
PRAD	cis	rs4664293	0.836	rs4665118	ENSG00000226266.5	AC009961.3	-7.31	1.25e-12	4.82e-10	-0.44	-0.32	Monocyte percentage of white cells;	chr2:159802938	chr2:159670708~159712435:-
PRAD	cis	rs1499614	1	rs2707840	ENSG00000273142.1	RP11-458F8.4	-7.31	1.25e-12	4.82e-10	-0.37	-0.32	Gout;	chr7:66693028	chr7:66902857~66906297:+
PRAD	cis	rs1862618	0.573	rs1550821	ENSG00000271828.1	CTD-2310F14.1	-7.31	1.25e-12	4.82e-10	-0.54	-0.32	Initial pursuit acceleration;	chr5:56946496	chr5:56927874~56929573:+
PRAD	cis	rs6539288	0.933	rs1037011	ENSG00000260329.1	RP11-412D9.4	-7.31	1.25e-12	4.83e-10	-0.28	-0.32	Total body bone mineral density;	chr12:106909000	chr12:106954029~106955497:-
PRAD	cis	rs35160687	0.712	rs7560886	ENSG00000273080.1	RP11-301O19.1	-7.31	1.25e-12	4.83e-10	-0.36	-0.32	Night sleep phenotypes;	chr2:86265907	chr2:86195590~86196049:+
PRAD	cis	rs875971	0.66	rs801193	ENSG00000237310.1	GS1-124K5.4	-7.31	1.25e-12	4.83e-10	-0.28	-0.32	Aortic root size;	chr7:66565625	chr7:66493706~66495474:+
PRAD	cis	rs853679	0.882	rs4713139	ENSG00000226314.6	ZNF192P1	-7.3	1.25e-12	4.84e-10	-0.56	-0.32	Depression;	chr6:28124907	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.882	rs3757188	ENSG00000226314.6	ZNF192P1	-7.3	1.25e-12	4.84e-10	-0.56	-0.32	Depression;	chr6:28139579	chr6:28161781~28169594:+
PRAD	cis	rs2638953	0.671	rs11049352	ENSG00000278733.1	RP11-425D17.1	-7.3	1.26e-12	4.85e-10	-0.44	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28113832	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.671	rs10843097	ENSG00000278733.1	RP11-425D17.1	-7.3	1.26e-12	4.85e-10	-0.44	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28114106	chr12:28185625~28186190:-
PRAD	cis	rs4660456	0.619	rs753753	ENSG00000237899.1	RP4-739H11.3	-7.3	1.26e-12	4.85e-10	-0.41	-0.32	Platelet count;	chr1:40771716	chr1:40669089~40687588:-
PRAD	cis	rs950169	0.614	rs765524	ENSG00000259728.4	LINC00933	7.3	1.26e-12	4.85e-10	0.41	0.32	Schizophrenia;	chr15:84013030	chr15:84570649~84580175:+
PRAD	cis	rs7191700	0.644	rs12149160	ENSG00000262703.1	RP11-485G7.6	-7.3	1.26e-12	4.85e-10	-0.31	-0.32	Multiple sclerosis;	chr16:11345446	chr16:11348143~11349321:-
PRAD	cis	rs2274273	1	rs7142704	ENSG00000258413.1	RP11-665C16.6	-7.3	1.26e-12	4.85e-10	-0.41	-0.32	Protein biomarker;	chr14:55163885	chr14:55262767~55272075:-
PRAD	cis	rs240993	0.909	rs11153279	ENSG00000271789.1	RP5-1112D6.7	7.3	1.26e-12	4.87e-10	0.39	0.32	Inflammatory skin disease;Psoriasis;	chr6:111266063	chr6:111297126~111298510:+
PRAD	cis	rs7945705	0.747	rs1980428	ENSG00000254860.4	TMEM9B-AS1	-7.3	1.26e-12	4.87e-10	-0.33	-0.32	Hemoglobin concentration;	chr11:8988950	chr11:8964675~8977527:+
PRAD	cis	rs4664293	0.764	rs10195287	ENSG00000226266.5	AC009961.3	-7.3	1.26e-12	4.88e-10	-0.42	-0.32	Monocyte percentage of white cells;	chr2:159604967	chr2:159670708~159712435:-
PRAD	cis	rs9362426	0.608	rs6940716	ENSG00000218793.1	RP3-382I10.3	7.3	1.26e-12	4.88e-10	0.42	0.32	Depressive episodes in bipolar disorder;	chr6:87433261	chr6:87441165~87442146:-
PRAD	cis	rs172166	0.611	rs203883	ENSG00000219392.1	RP1-265C24.5	-7.3	1.27e-12	4.88e-10	-0.4	-0.32	Cardiac Troponin-T levels;	chr6:28110578	chr6:28115628~28116551:+
PRAD	cis	rs17711722	0.565	rs73372653	ENSG00000234585.5	CCT6P3	7.3	1.27e-12	4.88e-10	0.25	0.32	Calcium levels;	chr7:65977808	chr7:65038354~65074713:+
PRAD	cis	rs995000	0.931	rs1168047	ENSG00000235545.1	RP11-230B22.1	-7.3	1.27e-12	4.89e-10	-0.43	-0.32	Triglyceride levels;	chr1:62518080	chr1:62688482~62710694:+
PRAD	cis	rs11846409	0.932	rs2015469	ENSG00000274576.2	IGHV2-70	-7.3	1.27e-12	4.9e-10	-0.33	-0.32	Rheumatic heart disease;	chr14:106631857	chr14:106770577~106771020:-
PRAD	cis	rs11846409	0.932	rs56167903	ENSG00000274576.2	IGHV2-70	-7.3	1.27e-12	4.9e-10	-0.33	-0.32	Rheumatic heart disease;	chr14:106632070	chr14:106770577~106771020:-
PRAD	cis	rs11846409	0.86	rs10150951	ENSG00000274576.2	IGHV2-70	-7.3	1.27e-12	4.9e-10	-0.33	-0.32	Rheumatic heart disease;	chr14:106632988	chr14:106770577~106771020:-
PRAD	cis	rs11846409	0.932	rs2583329	ENSG00000274576.2	IGHV2-70	7.3	1.27e-12	4.9e-10	0.33	0.32	Rheumatic heart disease;	chr14:106632971	chr14:106770577~106771020:-
PRAD	cis	rs7429990	0.965	rs34750113	ENSG00000229759.1	MRPS18AP1	7.3	1.27e-12	4.9e-10	0.34	0.32	Educational attainment (years of education);	chr3:47944902	chr3:48256350~48256938:-
PRAD	cis	rs453301	0.631	rs13250781	ENSG00000254340.1	RP11-10A14.3	-7.3	1.27e-12	4.91e-10	-0.38	-0.32	Joint mobility (Beighton score);	chr8:8935833	chr8:9141424~9145435:+
PRAD	cis	rs4713118	0.869	rs9348775	ENSG00000226314.6	ZNF192P1	-7.3	1.27e-12	4.92e-10	-0.42	-0.32	Parkinson's disease;	chr6:27727550	chr6:28161781~28169594:+
PRAD	cis	rs2638953	0.671	rs10843102	ENSG00000278733.1	RP11-425D17.1	7.3	1.27e-12	4.92e-10	0.43	0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28119368	chr12:28185625~28186190:-
PRAD	cis	rs5758511	0.514	rs5751228	ENSG00000227370.1	RP4-669P10.19	7.3	1.28e-12	4.92e-10	0.36	0.32	Birth weight;	chr22:42148767	chr22:42132543~42132998:+
PRAD	cis	rs853679	0.567	rs9969098	ENSG00000216901.1	AL022393.7	7.3	1.28e-12	4.93e-10	0.45	0.32	Depression;	chr6:28430971	chr6:28176188~28176674:+
PRAD	cis	rs1134634	0.52	rs3822298	ENSG00000273133.1	RP11-799M12.2	-7.3	1.28e-12	4.94e-10	-0.43	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15554780	chr4:15563698~15564253:-
PRAD	cis	rs11846409	0.932	rs74091728	ENSG00000274576.2	IGHV2-70	-7.3	1.28e-12	4.95e-10	-0.33	-0.32	Rheumatic heart disease;	chr14:106638762	chr14:106770577~106771020:-
PRAD	cis	rs11846409	0.932	rs28617526	ENSG00000274576.2	IGHV2-70	-7.3	1.28e-12	4.95e-10	-0.34	-0.32	Rheumatic heart disease;	chr14:106637322	chr14:106770577~106771020:-
PRAD	cis	rs496547	0.654	rs688161	ENSG00000255239.1	AP002954.6	7.3	1.29e-12	4.96e-10	0.43	0.32	Hip minimal joint space width;	chr11:118807001	chr11:118688039~118690600:-
PRAD	cis	rs17772222	0.74	rs1864746	ENSG00000258983.2	RP11-507K2.2	7.3	1.29e-12	4.98e-10	0.43	0.32	Coronary artery calcification;	chr14:88508455	chr14:88499334~88515502:+
PRAD	cis	rs6860806	0.631	rs4705931	ENSG00000233006.5	AC034220.3	7.3	1.29e-12	4.98e-10	0.27	0.32	Breast cancer;	chr5:132252652	chr5:132311285~132369916:-
PRAD	cis	rs8177376	0.727	rs240552	ENSG00000254905.1	RP11-712L6.7	7.3	1.29e-12	4.98e-10	0.39	0.32	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126333818	chr11:126292922~126294254:-
PRAD	cis	rs2933343	0.533	rs11915889	ENSG00000231305.3	RP11-723O4.2	7.3	1.29e-12	4.98e-10	0.3	0.32	IgG glycosylation;	chr3:128982023	chr3:128861313~128871540:-
PRAD	cis	rs858239	0.6	rs2003555	ENSG00000226816.2	AC005082.12	7.3	1.29e-12	4.98e-10	0.37	0.32	Cerebrospinal fluid biomarker levels;	chr7:23083296	chr7:23206013~23208045:+
PRAD	cis	rs858239	0.6	rs7784929	ENSG00000226816.2	AC005082.12	7.3	1.29e-12	4.98e-10	0.37	0.32	Cerebrospinal fluid biomarker levels;	chr7:23084658	chr7:23206013~23208045:+
PRAD	cis	rs4845570	1	rs11585294	ENSG00000268288.1	RP11-98D18.16	7.3	1.29e-12	4.99e-10	0.53	0.32	Coronary artery disease;	chr1:151797411	chr1:151766486~151767000:-
PRAD	cis	rs17772222	0.682	rs28482235	ENSG00000258983.2	RP11-507K2.2	7.3	1.3e-12	4.99e-10	0.42	0.32	Coronary artery calcification;	chr14:88472857	chr14:88499334~88515502:+
PRAD	cis	rs4842666	0.915	rs2681472	ENSG00000258302.2	RP11-981P6.1	7.3	1.3e-12	5e-10	0.39	0.32	Blood pressure;	chr12:89615182	chr12:89561129~89594878:+
PRAD	cis	rs2243480	0.901	rs778730	ENSG00000273142.1	RP11-458F8.4	-7.3	1.3e-12	5e-10	-0.37	-0.32	Diabetic kidney disease;	chr7:66358338	chr7:66902857~66906297:+
PRAD	cis	rs8005677	0.798	rs61977741	ENSG00000257285.4	RP11-298I3.1	7.3	1.3e-12	5.01e-10	0.32	0.32	Cognitive ability (multi-trait analysis);	chr14:22931770	chr14:22929609~22955562:+
PRAD	cis	rs8005677	0.798	rs4982713	ENSG00000257285.4	RP11-298I3.1	7.3	1.3e-12	5.01e-10	0.32	0.32	Cognitive ability (multi-trait analysis);	chr14:22934893	chr14:22929609~22955562:+
PRAD	cis	rs8005677	0.798	rs35615180	ENSG00000257285.4	RP11-298I3.1	7.3	1.3e-12	5.01e-10	0.32	0.32	Cognitive ability (multi-trait analysis);	chr14:22935180	chr14:22929609~22955562:+
PRAD	cis	rs2638953	0.962	rs12372172	ENSG00000278733.1	RP11-425D17.1	-7.3	1.3e-12	5.02e-10	-0.41	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28419945	chr12:28185625~28186190:-
PRAD	cis	rs1499614	1	rs2659913	ENSG00000273142.1	RP11-458F8.4	-7.3	1.3e-12	5.02e-10	-0.37	-0.32	Gout;	chr7:66692349	chr7:66902857~66906297:+
PRAD	cis	rs1499614	1	rs2659911	ENSG00000273142.1	RP11-458F8.4	-7.3	1.3e-12	5.02e-10	-0.37	-0.32	Gout;	chr7:66693433	chr7:66902857~66906297:+
PRAD	cis	rs1499614	1	rs2707838	ENSG00000273142.1	RP11-458F8.4	-7.3	1.3e-12	5.02e-10	-0.37	-0.32	Gout;	chr7:66694214	chr7:66902857~66906297:+
PRAD	cis	rs1499614	1	rs60326618	ENSG00000273142.1	RP11-458F8.4	-7.3	1.3e-12	5.02e-10	-0.37	-0.32	Gout;	chr7:66701371	chr7:66902857~66906297:+
PRAD	cis	rs1499614	1	rs2707830	ENSG00000273142.1	RP11-458F8.4	-7.3	1.3e-12	5.02e-10	-0.37	-0.32	Gout;	chr7:66702658	chr7:66902857~66906297:+
PRAD	cis	rs1499614	1	rs2707828	ENSG00000273142.1	RP11-458F8.4	-7.3	1.3e-12	5.02e-10	-0.37	-0.32	Gout;	chr7:66706390	chr7:66902857~66906297:+
PRAD	cis	rs1499614	0.803	rs1922723	ENSG00000273142.1	RP11-458F8.4	-7.3	1.3e-12	5.02e-10	-0.37	-0.32	Gout;	chr7:66710076	chr7:66902857~66906297:+
PRAD	cis	rs1499614	1	rs2659903	ENSG00000273142.1	RP11-458F8.4	-7.3	1.3e-12	5.02e-10	-0.37	-0.32	Gout;	chr7:66715944	chr7:66902857~66906297:+
PRAD	cis	rs1499614	1	rs2141924	ENSG00000273142.1	RP11-458F8.4	-7.3	1.3e-12	5.02e-10	-0.37	-0.32	Gout;	chr7:66721259	chr7:66902857~66906297:+
PRAD	cis	rs1499614	0.901	rs2178742	ENSG00000273142.1	RP11-458F8.4	-7.3	1.3e-12	5.02e-10	-0.37	-0.32	Gout;	chr7:66732812	chr7:66902857~66906297:+
PRAD	cis	rs995000	0.868	rs10889357	ENSG00000235545.1	RP11-230B22.1	7.3	1.3e-12	5.02e-10	0.44	0.32	Triglyceride levels;	chr1:62694611	chr1:62688482~62710694:+
PRAD	cis	rs995000	0.899	rs12136083	ENSG00000235545.1	RP11-230B22.1	7.3	1.3e-12	5.02e-10	0.44	0.32	Triglyceride levels;	chr1:62697402	chr1:62688482~62710694:+
PRAD	cis	rs9326248	0.581	rs10502222	ENSG00000280143.1	AP000892.6	7.3	1.3e-12	5.02e-10	0.24	0.32	Blood protein levels;	chr11:116963014	chr11:117204967~117210292:+
PRAD	cis	rs9326248	0.559	rs10892052	ENSG00000280143.1	AP000892.6	7.3	1.3e-12	5.02e-10	0.24	0.32	Blood protein levels;	chr11:116963597	chr11:117204967~117210292:+
PRAD	cis	rs9467773	0.935	rs11752946	ENSG00000124549.13	BTN2A3P	7.3	1.3e-12	5.03e-10	0.29	0.32	Intelligence (multi-trait analysis);	chr6:26560136	chr6:26421391~26432383:+
PRAD	cis	rs1555322	0.505	rs639763	ENSG00000279253.1	RP4-614O4.13	-7.3	1.31e-12	5.03e-10	-0.4	-0.32	Attention deficit hyperactivity disorder;	chr20:35274101	chr20:35262727~35264187:-
PRAD	cis	rs1075232	1	rs56396205	ENSG00000215302.7	CTD-3092A11.1	-7.3	1.31e-12	5.04e-10	-0.74	-0.32	Survival in colorectal cancer (non-distant metastatic);	chr15:31386182	chr15:30470779~30507623:+
PRAD	cis	rs1075232	1	rs12438318	ENSG00000215302.7	CTD-3092A11.1	-7.3	1.31e-12	5.04e-10	-0.74	-0.32	Survival in colorectal cancer (non-distant metastatic);	chr15:31388242	chr15:30470779~30507623:+
PRAD	cis	rs7746199	0.668	rs7749305	ENSG00000280107.1	AL022393.9	-7.3	1.31e-12	5.04e-10	-0.6	-0.32	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27478787	chr6:28170845~28172521:+
PRAD	cis	rs7746199	0.668	rs34864796	ENSG00000280107.1	AL022393.9	-7.3	1.31e-12	5.04e-10	-0.6	-0.32	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27492144	chr6:28170845~28172521:+
PRAD	cis	rs1426063	0.858	rs10004802	ENSG00000249717.1	RP11-44F21.3	7.3	1.31e-12	5.04e-10	0.54	0.32	QT interval;	chr4:75084413	chr4:74955974~74970362:-
PRAD	cis	rs526231	0.543	rs7709726	ENSG00000175749.11	EIF3KP1	-7.3	1.31e-12	5.04e-10	-0.41	-0.32	Primary biliary cholangitis;	chr5:102991759	chr5:103032376~103033031:+
PRAD	cis	rs10129255	0.957	rs8009464	ENSG00000223648.3	IGHV3-64	7.3	1.31e-12	5.05e-10	0.32	0.32	Kawasaki disease;	chr14:106777611	chr14:106643132~106658258:-
PRAD	cis	rs2439831	0.867	rs2447196	ENSG00000249839.1	AC011330.5	7.3	1.32e-12	5.06e-10	0.55	0.32	Lung cancer in ever smokers;	chr15:43601620	chr15:43663654~43684339:-
PRAD	cis	rs4842666	0.831	rs11105337	ENSG00000258302.2	RP11-981P6.1	7.3	1.32e-12	5.08e-10	0.41	0.32	Blood pressure;	chr12:89599730	chr12:89561129~89594878:+
PRAD	cis	rs9467773	0.967	rs9295694	ENSG00000124549.13	BTN2A3P	7.3	1.32e-12	5.09e-10	0.28	0.32	Intelligence (multi-trait analysis);	chr6:26512766	chr6:26421391~26432383:+
PRAD	cis	rs9467773	0.967	rs9467775	ENSG00000124549.13	BTN2A3P	7.3	1.32e-12	5.09e-10	0.28	0.32	Intelligence (multi-trait analysis);	chr6:26513207	chr6:26421391~26432383:+
PRAD	cis	rs9467773	1	rs9393729	ENSG00000124549.13	BTN2A3P	7.3	1.32e-12	5.09e-10	0.28	0.32	Intelligence (multi-trait analysis);	chr6:26513938	chr6:26421391~26432383:+
PRAD	cis	rs11098499	0.754	rs10212714	ENSG00000245958.5	RP11-33B1.1	-7.3	1.32e-12	5.09e-10	-0.31	-0.32	Corneal astigmatism;	chr4:119333147	chr4:119454791~119552025:+
PRAD	cis	rs6847067	0.794	rs7675324	ENSG00000180769.7	WDFY3-AS2	7.3	1.33e-12	5.1e-10	0.34	0.32	Oropharynx cancer;	chr4:85021460	chr4:84965682~85011277:+
PRAD	cis	rs2739330	0.734	rs2000467	ENSG00000206090.4	AP000350.7	-7.3	1.33e-12	5.1e-10	-0.41	-0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23939998~23942798:+
PRAD	cis	rs9326248	0.581	rs6589582	ENSG00000280143.1	AP000892.6	7.3	1.33e-12	5.11e-10	0.24	0.32	Blood protein levels;	chr11:116958484	chr11:117204967~117210292:+
PRAD	cis	rs6751744	0.513	rs6738215	ENSG00000226266.5	AC009961.3	-7.3	1.33e-12	5.11e-10	-0.42	-0.32	Dysphagia;	chr2:159596794	chr2:159670708~159712435:-
PRAD	cis	rs7746199	0.736	rs56405707	ENSG00000226314.6	ZNF192P1	-7.3	1.33e-12	5.12e-10	-0.68	-0.32	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27672467	chr6:28161781~28169594:+
PRAD	cis	rs7746199	0.736	rs13210634	ENSG00000226314.6	ZNF192P1	-7.3	1.33e-12	5.12e-10	-0.68	-0.32	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27678713	chr6:28161781~28169594:+
PRAD	cis	rs7746199	0.736	rs13215275	ENSG00000226314.6	ZNF192P1	-7.3	1.33e-12	5.12e-10	-0.68	-0.32	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27679730	chr6:28161781~28169594:+
PRAD	cis	rs7746199	0.736	rs17749927	ENSG00000226314.6	ZNF192P1	-7.3	1.33e-12	5.12e-10	-0.68	-0.32	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27702197	chr6:28161781~28169594:+
PRAD	cis	rs7746199	0.736	rs13192965	ENSG00000226314.6	ZNF192P1	-7.3	1.33e-12	5.12e-10	-0.68	-0.32	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27704046	chr6:28161781~28169594:+
PRAD	cis	rs11846409	0.932	rs61233250	ENSG00000274576.2	IGHV2-70	-7.3	1.33e-12	5.12e-10	-0.33	-0.32	Rheumatic heart disease;	chr14:106634072	chr14:106770577~106771020:-
PRAD	cis	rs11846409	0.932	rs60659763	ENSG00000274576.2	IGHV2-70	-7.3	1.33e-12	5.12e-10	-0.33	-0.32	Rheumatic heart disease;	chr14:106634172	chr14:106770577~106771020:-
PRAD	cis	rs11846409	0.932	rs57080270	ENSG00000274576.2	IGHV2-70	-7.3	1.33e-12	5.12e-10	-0.33	-0.32	Rheumatic heart disease;	chr14:106634215	chr14:106770577~106771020:-
PRAD	cis	rs11846409	0.932	rs60917084	ENSG00000274576.2	IGHV2-70	-7.3	1.33e-12	5.12e-10	-0.33	-0.32	Rheumatic heart disease;	chr14:106634621	chr14:106770577~106771020:-
PRAD	cis	rs12612619	0.732	rs11126836	ENSG00000272148.1	RP11-195B17.1	7.3	1.33e-12	5.13e-10	0.38	0.32	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27050260	chr2:27062428~27062907:-
PRAD	cis	rs6480314	0.636	rs61854792	ENSG00000233590.1	RP11-153K11.3	-7.3	1.33e-12	5.13e-10	-0.54	-0.32	Optic nerve measurement (disc area);	chr10:68243902	chr10:68233251~68242379:-
PRAD	cis	rs62355901	0.505	rs72759712	ENSG00000271828.1	CTD-2310F14.1	7.3	1.33e-12	5.14e-10	0.72	0.32	Breast cancer;	chr5:56906519	chr5:56927874~56929573:+
PRAD	cis	rs6951245	0.554	rs75075857	ENSG00000229043.2	AC091729.9	-7.3	1.34e-12	5.14e-10	-0.45	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1100662	chr7:1160374~1165267:+
PRAD	cis	rs1426063	1	rs10022563	ENSG00000249717.1	RP11-44F21.3	7.29	1.34e-12	5.15e-10	0.54	0.32	QT interval;	chr4:75100989	chr4:74955974~74970362:-
PRAD	cis	rs12468226	0.873	rs3181153	ENSG00000273456.1	RP11-686O6.2	-7.29	1.34e-12	5.16e-10	-0.43	-0.32	Urate levels;	chr2:202205155	chr2:202374932~202375604:-
PRAD	cis	rs13068223	0.568	rs7636965	ENSG00000243926.1	TIPARP-AS1	7.29	1.34e-12	5.16e-10	0.3	0.32	Age-related hearing impairment (SNP x SNP interaction);	chr3:156700615	chr3:156671862~156674378:-
PRAD	cis	rs4713118	0.824	rs742046	ENSG00000226314.6	ZNF192P1	-7.29	1.34e-12	5.17e-10	-0.43	-0.32	Parkinson's disease;	chr6:27771475	chr6:28161781~28169594:+
PRAD	cis	rs11098499	0.908	rs2017057	ENSG00000245958.5	RP11-33B1.1	-7.29	1.34e-12	5.17e-10	-0.32	-0.32	Corneal astigmatism;	chr4:119336556	chr4:119454791~119552025:+
PRAD	cis	rs6479901	0.895	rs10822162	ENSG00000232075.1	MRPL35P2	-7.29	1.34e-12	5.17e-10	-0.39	-0.32	Intelligence (multi-trait analysis);	chr10:63364320	chr10:63634317~63634827:-
PRAD	cis	rs8177376	0.727	rs651983	ENSG00000254905.1	RP11-712L6.7	7.29	1.34e-12	5.17e-10	0.39	0.32	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126331343	chr11:126292922~126294254:-
PRAD	cis	rs8177376	0.727	rs651922	ENSG00000254905.1	RP11-712L6.7	7.29	1.34e-12	5.17e-10	0.39	0.32	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126331395	chr11:126292922~126294254:-
PRAD	cis	rs8177376	0.727	rs616360	ENSG00000254905.1	RP11-712L6.7	7.29	1.34e-12	5.17e-10	0.39	0.32	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126331508	chr11:126292922~126294254:-
PRAD	cis	rs8177376	0.727	rs651034	ENSG00000254905.1	RP11-712L6.7	7.29	1.34e-12	5.17e-10	0.39	0.32	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126331563	chr11:126292922~126294254:-
PRAD	cis	rs3020736	0.5	rs8143153	ENSG00000205702.9	CYP2D7	-7.29	1.34e-12	5.17e-10	-0.25	-0.32	Autism spectrum disorder or schizophrenia;	chr22:42119633	chr22:42140203~42144577:-
PRAD	cis	rs75422866	0.85	rs73111212	ENSG00000274902.1	RP1-197B17.4	7.29	1.35e-12	5.18e-10	0.95	0.32	Pneumonia;	chr12:47577638	chr12:47731908~47732351:+
PRAD	cis	rs75422866	0.85	rs73111216	ENSG00000274902.1	RP1-197B17.4	7.29	1.35e-12	5.18e-10	0.95	0.32	Pneumonia;	chr12:47577671	chr12:47731908~47732351:+
PRAD	cis	rs75422866	0.85	rs73111217	ENSG00000274902.1	RP1-197B17.4	7.29	1.35e-12	5.18e-10	0.95	0.32	Pneumonia;	chr12:47577693	chr12:47731908~47732351:+
PRAD	cis	rs9595908	0.865	rs497255	ENSG00000212293.1	SNORA16	-7.29	1.35e-12	5.19e-10	-0.4	-0.32	Body mass index;	chr13:32424754	chr13:32420390~32420516:-
PRAD	cis	rs2739330	0.796	rs1006771	ENSG00000224205.1	AP000351.4	7.29	1.35e-12	5.2e-10	0.4	0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23987320~23991421:-
PRAD	cis	rs7567389	0.51	rs6755028	ENSG00000236682.1	AC068282.3	7.29	1.35e-12	5.2e-10	0.43	0.32	Self-rated health;	chr2:127437866	chr2:127389130~127400580:+
PRAD	cis	rs995000	0.931	rs1168021	ENSG00000235545.1	RP11-230B22.1	-7.29	1.36e-12	5.22e-10	-0.43	-0.32	Triglyceride levels;	chr1:62544229	chr1:62688482~62710694:+
PRAD	cis	rs995000	0.965	rs1179765	ENSG00000235545.1	RP11-230B22.1	-7.29	1.36e-12	5.22e-10	-0.43	-0.32	Triglyceride levels;	chr1:62544439	chr1:62688482~62710694:+
PRAD	cis	rs995000	0.931	rs11207986	ENSG00000235545.1	RP11-230B22.1	-7.29	1.36e-12	5.22e-10	-0.43	-0.32	Triglyceride levels;	chr1:62552499	chr1:62688482~62710694:+
PRAD	cis	rs9640161	0.742	rs2159236	ENSG00000261305.1	RP4-584D14.7	7.29	1.36e-12	5.22e-10	0.36	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150320125	chr7:150341771~150342607:+
PRAD	cis	rs8062405	0.755	rs4788076	ENSG00000251417.2	RP11-1348G14.4	-7.29	1.36e-12	5.22e-10	-0.36	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558684	chr16:28802743~28817828:+
PRAD	cis	rs4660456	0.572	rs7519348	ENSG00000237899.1	RP4-739H11.3	-7.29	1.36e-12	5.23e-10	-0.41	-0.32	Platelet count;	chr1:40694532	chr1:40669089~40687588:-
PRAD	cis	rs7115242	0.8	rs7131536	ENSG00000280143.1	AP000892.6	7.29	1.36e-12	5.23e-10	0.39	0.32	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117128730	chr11:117204967~117210292:+
PRAD	cis	rs453301	0.631	rs28572014	ENSG00000254340.1	RP11-10A14.3	-7.29	1.36e-12	5.24e-10	-0.39	-0.32	Joint mobility (Beighton score);	chr8:8936097	chr8:9141424~9145435:+
PRAD	cis	rs2243480	1	rs2533288	ENSG00000273142.1	RP11-458F8.4	-7.29	1.36e-12	5.24e-10	-0.37	-0.32	Diabetic kidney disease;	chr7:66591724	chr7:66902857~66906297:+
PRAD	cis	rs2948294	0.588	rs4840913	ENSG00000253893.2	FAM85B	-7.29	1.36e-12	5.25e-10	-0.42	-0.32	Red cell distribution width;	chr8:8259384	chr8:8167819~8226614:-
PRAD	cis	rs9640161	0.711	rs3735170	ENSG00000261305.1	RP4-584D14.7	7.29	1.37e-12	5.25e-10	0.36	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150337095	chr7:150341771~150342607:+
PRAD	cis	rs9640161	0.75	rs3735169	ENSG00000261305.1	RP4-584D14.7	7.29	1.37e-12	5.25e-10	0.36	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150337289	chr7:150341771~150342607:+
PRAD	cis	rs1355223	0.902	rs704744	ENSG00000271369.1	RP11-350D17.3	-7.29	1.37e-12	5.25e-10	-0.38	-0.32	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34715014	chr11:34709600~34710161:+
PRAD	cis	rs1355223	0.902	rs836466	ENSG00000271369.1	RP11-350D17.3	-7.29	1.37e-12	5.25e-10	-0.38	-0.32	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34715819	chr11:34709600~34710161:+
PRAD	cis	rs1355223	0.902	rs1773910	ENSG00000271369.1	RP11-350D17.3	-7.29	1.37e-12	5.25e-10	-0.38	-0.32	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34719706	chr11:34709600~34710161:+
PRAD	cis	rs1355223	0.902	rs1539251	ENSG00000271369.1	RP11-350D17.3	-7.29	1.37e-12	5.25e-10	-0.38	-0.32	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34721225	chr11:34709600~34710161:+
PRAD	cis	rs1355223	0.902	rs836462	ENSG00000271369.1	RP11-350D17.3	-7.29	1.37e-12	5.25e-10	-0.38	-0.32	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34721716	chr11:34709600~34710161:+
PRAD	cis	rs1355223	0.902	rs1773908	ENSG00000271369.1	RP11-350D17.3	-7.29	1.37e-12	5.25e-10	-0.38	-0.32	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34721833	chr11:34709600~34710161:+
PRAD	cis	rs1355223	0.902	rs860712	ENSG00000271369.1	RP11-350D17.3	-7.29	1.37e-12	5.25e-10	-0.38	-0.32	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34721947	chr11:34709600~34710161:+
PRAD	cis	rs67180937	0.844	rs35626308	ENSG00000272750.1	RP11-378J18.8	-7.29	1.37e-12	5.25e-10	-0.43	-0.32	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222643014	chr1:222658867~222661512:-
PRAD	cis	rs875971	0.642	rs35526611	ENSG00000237310.1	GS1-124K5.4	-7.29	1.37e-12	5.26e-10	-0.28	-0.32	Aortic root size;	chr7:66629021	chr7:66493706~66495474:+
PRAD	cis	rs2034650	0.544	rs661488	ENSG00000223313.1	RNU6-516P	7.29	1.37e-12	5.26e-10	0.39	0.32	Interstitial lung disease;	chr15:40429221	chr15:40529570~40529673:+
PRAD	cis	rs4984778	0.75	rs7198064	ENSG00000260182.1	RP11-616M22.5	7.29	1.37e-12	5.26e-10	0.45	0.32	Blood protein levels;	chr16:1222472	chr16:1257339~1258074:+
PRAD	cis	rs853679	0.567	rs7774981	ENSG00000216901.1	AL022393.7	7.29	1.37e-12	5.27e-10	0.45	0.32	Depression;	chr6:28379133	chr6:28176188~28176674:+
PRAD	cis	rs853679	0.567	rs7754960	ENSG00000216901.1	AL022393.7	7.29	1.37e-12	5.27e-10	0.45	0.32	Depression;	chr6:28379168	chr6:28176188~28176674:+
PRAD	cis	rs673078	0.66	rs16948234	ENSG00000275409.1	RP11-131L12.4	7.29	1.37e-12	5.28e-10	0.47	0.32	Glucose homeostasis traits;	chr12:118282464	chr12:118430147~118430699:+
PRAD	cis	rs6479901	0.895	rs10740112	ENSG00000232075.1	MRPL35P2	-7.29	1.37e-12	5.28e-10	-0.39	-0.32	Intelligence (multi-trait analysis);	chr10:63322315	chr10:63634317~63634827:-
PRAD	cis	rs516805	0.748	rs502252	ENSG00000279453.1	RP3-425C14.4	-7.29	1.37e-12	5.28e-10	-0.29	-0.32	Lymphocyte counts;	chr6:122436330	chr6:122436789~122439223:-
PRAD	cis	rs516805	0.706	rs577049	ENSG00000279453.1	RP3-425C14.4	-7.29	1.37e-12	5.28e-10	-0.29	-0.32	Lymphocyte counts;	chr6:122438204	chr6:122436789~122439223:-
PRAD	cis	rs516805	0.748	rs577838	ENSG00000279453.1	RP3-425C14.4	-7.29	1.37e-12	5.28e-10	-0.29	-0.32	Lymphocyte counts;	chr6:122438270	chr6:122436789~122439223:-
PRAD	cis	rs12439619	0.508	rs8042665	ENSG00000255769.6	GOLGA2P10	-7.29	1.38e-12	5.29e-10	-0.38	-0.32	Intelligence (multi-trait analysis);	chr15:82189008	chr15:82472993~82513950:-
PRAD	cis	rs8062405	0.755	rs4788074	ENSG00000251417.2	RP11-1348G14.4	7.29	1.38e-12	5.29e-10	0.36	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582276	chr16:28802743~28817828:+
PRAD	cis	rs853679	0.607	rs34878803	ENSG00000280107.1	AL022393.9	-7.29	1.38e-12	5.3e-10	-0.61	-0.32	Depression;	chr6:28282402	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.607	rs34396849	ENSG00000280107.1	AL022393.9	-7.29	1.38e-12	5.3e-10	-0.61	-0.32	Depression;	chr6:28283178	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.607	rs13211507	ENSG00000280107.1	AL022393.9	-7.29	1.38e-12	5.3e-10	-0.61	-0.32	Depression;	chr6:28289600	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.607	rs34691223	ENSG00000280107.1	AL022393.9	-7.29	1.38e-12	5.3e-10	-0.61	-0.32	Depression;	chr6:28290431	chr6:28170845~28172521:+
PRAD	cis	rs6847067	0.683	rs13118671	ENSG00000180769.7	WDFY3-AS2	7.29	1.38e-12	5.31e-10	0.36	0.32	Oropharynx cancer;	chr4:84850272	chr4:84965682~85011277:+
PRAD	cis	rs995000	0.931	rs1690766	ENSG00000235545.1	RP11-230B22.1	-7.29	1.39e-12	5.33e-10	-0.43	-0.32	Triglyceride levels;	chr1:62521618	chr1:62688482~62710694:+
PRAD	cis	rs995000	0.899	rs11577840	ENSG00000235545.1	RP11-230B22.1	-7.29	1.39e-12	5.33e-10	-0.43	-0.32	Triglyceride levels;	chr1:62525698	chr1:62688482~62710694:+
PRAD	cis	rs995000	0.839	rs12403207	ENSG00000235545.1	RP11-230B22.1	-7.29	1.39e-12	5.33e-10	-0.43	-0.32	Triglyceride levels;	chr1:62527949	chr1:62688482~62710694:+
PRAD	cis	rs17772222	0.74	rs11845147	ENSG00000258983.2	RP11-507K2.2	7.29	1.39e-12	5.34e-10	0.43	0.32	Coronary artery calcification;	chr14:88502804	chr14:88499334~88515502:+
PRAD	cis	rs858239	0.539	rs6461695	ENSG00000226816.2	AC005082.12	7.29	1.39e-12	5.34e-10	0.37	0.32	Cerebrospinal fluid biomarker levels;	chr7:23158165	chr7:23206013~23208045:+
PRAD	cis	rs2638953	0.924	rs11049398	ENSG00000247934.4	RP11-967K21.1	-7.29	1.39e-12	5.35e-10	-0.32	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28172371	chr12:28163298~28190738:-
PRAD	cis	rs6782228	0.606	rs58977394	ENSG00000242551.2	POU5F1P6	-7.29	1.39e-12	5.35e-10	-0.4	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619074	chr3:128674735~128677005:-
PRAD	cis	rs7829975	0.742	rs1533058	ENSG00000253893.2	FAM85B	-7.29	1.39e-12	5.36e-10	-0.41	-0.32	Mood instability;	chr8:8827680	chr8:8167819~8226614:-
PRAD	cis	rs1799949	0.965	rs4793233	ENSG00000267002.1	RP11-242D8.1	7.29	1.4e-12	5.36e-10	0.31	0.32	Menopause (age at onset);	chr17:43358069	chr17:43164183~43170403:-
PRAD	cis	rs1799949	0.965	rs4793234	ENSG00000267002.1	RP11-242D8.1	7.29	1.4e-12	5.36e-10	0.31	0.32	Menopause (age at onset);	chr17:43358815	chr17:43164183~43170403:-
PRAD	cis	rs2243480	1	rs958550	ENSG00000273142.1	RP11-458F8.4	7.29	1.4e-12	5.37e-10	0.37	0.32	Diabetic kidney disease;	chr7:66170692	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs73150014	ENSG00000273142.1	RP11-458F8.4	-7.29	1.4e-12	5.37e-10	-0.36	-0.32	Diabetic kidney disease;	chr7:65985932	chr7:66902857~66906297:+
PRAD	cis	rs12432203	0.915	rs76084602	ENSG00000258479.4	LINC00640	7.29	1.4e-12	5.37e-10	0.59	0.32	Cancer;	chr14:51277141	chr14:51333393~51365557:+
PRAD	cis	rs4664293	0.867	rs7565297	ENSG00000226266.5	AC009961.3	-7.29	1.4e-12	5.38e-10	-0.43	-0.32	Monocyte percentage of white cells;	chr2:159716008	chr2:159670708~159712435:-
PRAD	cis	rs995000	0.931	rs1168020	ENSG00000235545.1	RP11-230B22.1	-7.29	1.4e-12	5.39e-10	-0.43	-0.32	Triglyceride levels;	chr1:62544285	chr1:62688482~62710694:+
PRAD	cis	rs995000	0.931	rs11207984	ENSG00000235545.1	RP11-230B22.1	-7.29	1.4e-12	5.39e-10	-0.43	-0.32	Triglyceride levels;	chr1:62547725	chr1:62688482~62710694:+
PRAD	cis	rs995000	0.899	rs11207985	ENSG00000235545.1	RP11-230B22.1	-7.29	1.4e-12	5.39e-10	-0.43	-0.32	Triglyceride levels;	chr1:62548115	chr1:62688482~62710694:+
PRAD	cis	rs9467773	1	rs10214634	ENSG00000124549.13	BTN2A3P	7.29	1.41e-12	5.4e-10	0.28	0.32	Intelligence (multi-trait analysis);	chr6:26564354	chr6:26421391~26432383:+
PRAD	cis	rs9467773	0.873	rs9295698	ENSG00000124549.13	BTN2A3P	7.29	1.41e-12	5.4e-10	0.28	0.32	Intelligence (multi-trait analysis);	chr6:26565871	chr6:26421391~26432383:+
PRAD	cis	rs1023500	0.573	rs2269524	ENSG00000205702.9	CYP2D7	-7.29	1.41e-12	5.41e-10	-0.25	-0.32	Schizophrenia;	chr22:42079699	chr22:42140203~42144577:-
PRAD	cis	rs1023500	0.573	rs6002592	ENSG00000205702.9	CYP2D7	-7.29	1.41e-12	5.41e-10	-0.25	-0.32	Schizophrenia;	chr22:42080750	chr22:42140203~42144577:-
PRAD	cis	rs1075232	1	rs9672214	ENSG00000215302.7	CTD-3092A11.1	-7.29	1.41e-12	5.41e-10	-0.74	-0.32	Survival in colorectal cancer (non-distant metastatic);	chr15:31385572	chr15:30470779~30507623:+
PRAD	cis	rs875971	0.619	rs10278371	ENSG00000237310.1	GS1-124K5.4	-7.29	1.41e-12	5.42e-10	-0.28	-0.32	Aortic root size;	chr7:66586553	chr7:66493706~66495474:+
PRAD	cis	rs6782228	0.606	rs2811489	ENSG00000242551.2	POU5F1P6	7.29	1.42e-12	5.44e-10	0.4	0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128618528	chr3:128674735~128677005:-
PRAD	cis	rs5760092	0.627	rs6519489	ENSG00000224205.1	AP000351.4	-7.29	1.42e-12	5.44e-10	-0.48	-0.32	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919659	chr22:23987320~23991421:-
PRAD	cis	rs4713118	0.824	rs7759217	ENSG00000226314.6	ZNF192P1	-7.29	1.42e-12	5.46e-10	-0.43	-0.32	Parkinson's disease;	chr6:27762684	chr6:28161781~28169594:+
PRAD	cis	rs4713118	0.784	rs9468219	ENSG00000226314.6	ZNF192P1	-7.29	1.42e-12	5.46e-10	-0.43	-0.32	Parkinson's disease;	chr6:27763976	chr6:28161781~28169594:+
PRAD	cis	rs4713118	0.824	rs9366702	ENSG00000226314.6	ZNF192P1	-7.29	1.42e-12	5.46e-10	-0.43	-0.32	Parkinson's disease;	chr6:27766691	chr6:28161781~28169594:+
PRAD	cis	rs2034650	0.544	rs2289331	ENSG00000223313.1	RNU6-516P	7.29	1.42e-12	5.46e-10	0.39	0.32	Interstitial lung disease;	chr15:40407739	chr15:40529570~40529673:+
PRAD	cis	rs1023500	0.573	rs4822088	ENSG00000205702.9	CYP2D7	7.29	1.43e-12	5.47e-10	0.25	0.32	Schizophrenia;	chr22:42074585	chr22:42140203~42144577:-
PRAD	cis	rs9393777	0.92	rs13196692	ENSG00000226314.6	ZNF192P1	-7.29	1.43e-12	5.47e-10	-0.67	-0.32	Intelligence (multi-trait analysis);	chr6:27411340	chr6:28161781~28169594:+
PRAD	cis	rs35160687	0.712	rs6738585	ENSG00000273080.1	RP11-301O19.1	-7.28	1.43e-12	5.49e-10	-0.36	-0.32	Night sleep phenotypes;	chr2:86283161	chr2:86195590~86196049:+
PRAD	cis	rs35160687	0.712	rs6725234	ENSG00000273080.1	RP11-301O19.1	-7.28	1.43e-12	5.49e-10	-0.36	-0.32	Night sleep phenotypes;	chr2:86283165	chr2:86195590~86196049:+
PRAD	cis	rs934734	0.673	rs6742215	ENSG00000204929.10	AC074391.1	7.28	1.43e-12	5.5e-10	0.4	0.32	Rheumatoid arthritis;	chr2:65463362	chr2:65436711~66084639:+
PRAD	cis	rs6921919	0.832	rs17312661	ENSG00000204709.4	LINC01556	7.28	1.43e-12	5.5e-10	0.52	0.32	Autism spectrum disorder or schizophrenia;	chr6:28332559	chr6:28943877~28944537:+
PRAD	cis	rs17265703	0.524	rs12107092	ENSG00000272758.4	RP11-299J3.8	7.28	1.43e-12	5.5e-10	0.43	0.32	Phosphorus levels;	chr3:122405001	chr3:122416207~122443180:+
PRAD	cis	rs6782228	0.509	rs2811495	ENSG00000242551.2	POU5F1P6	-7.28	1.44e-12	5.51e-10	-0.4	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128641114	chr3:128674735~128677005:-
PRAD	cis	rs6782228	0.565	rs2811496	ENSG00000242551.2	POU5F1P6	-7.28	1.44e-12	5.51e-10	-0.4	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128641115	chr3:128674735~128677005:-
PRAD	cis	rs2638953	1	rs2638953	ENSG00000247934.4	RP11-967K21.1	7.28	1.44e-12	5.51e-10	0.32	0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28381482	chr12:28163298~28190738:-
PRAD	cis	rs995000	0.931	rs1168050	ENSG00000235545.1	RP11-230B22.1	-7.28	1.44e-12	5.51e-10	-0.43	-0.32	Triglyceride levels;	chr1:62521284	chr1:62688482~62710694:+
PRAD	cis	rs995000	0.931	rs1781195	ENSG00000235545.1	RP11-230B22.1	-7.28	1.44e-12	5.51e-10	-0.43	-0.32	Triglyceride levels;	chr1:62523301	chr1:62688482~62710694:+
PRAD	cis	rs995000	0.931	rs1627591	ENSG00000235545.1	RP11-230B22.1	-7.28	1.44e-12	5.51e-10	-0.43	-0.32	Triglyceride levels;	chr1:62524136	chr1:62688482~62710694:+
PRAD	cis	rs2034650	0.544	rs600791	ENSG00000223313.1	RNU6-516P	7.28	1.44e-12	5.52e-10	0.39	0.32	Interstitial lung disease;	chr15:40428868	chr15:40529570~40529673:+
PRAD	cis	rs11159086	0.793	rs10136668	ENSG00000270000.1	RP3-449M8.9	7.28	1.44e-12	5.52e-10	0.49	0.32	Advanced glycation end-product levels;	chr14:74492183	chr14:74471930~74472360:-
PRAD	cis	rs2522056	1	rs2522054	ENSG00000233006.5	AC034220.3	-7.28	1.44e-12	5.53e-10	-0.33	-0.32	Fibrinogen;Lymphocyte counts;	chr5:132463834	chr5:132311285~132369916:-
PRAD	cis	rs2522056	1	rs2706339	ENSG00000233006.5	AC034220.3	-7.28	1.44e-12	5.53e-10	-0.33	-0.32	Fibrinogen;Lymphocyte counts;	chr5:132464413	chr5:132311285~132369916:-
PRAD	cis	rs2933343	0.553	rs35076317	ENSG00000231305.3	RP11-723O4.2	7.28	1.44e-12	5.54e-10	0.3	0.32	IgG glycosylation;	chr3:128996692	chr3:128861313~128871540:-
PRAD	cis	rs11098499	0.754	rs10518300	ENSG00000245958.5	RP11-33B1.1	7.28	1.45e-12	5.55e-10	0.3	0.32	Corneal astigmatism;	chr4:119328344	chr4:119454791~119552025:+
PRAD	cis	rs75920871	0.557	rs7123336	ENSG00000254851.1	RP11-109L13.1	7.28	1.45e-12	5.55e-10	0.43	0.32	Subjective well-being;	chr11:116912103	chr11:117135528~117138582:+
PRAD	cis	rs75422866	0.51	rs73105829	ENSG00000257433.4	RP1-197B17.3	7.28	1.45e-12	5.55e-10	0.67	0.32	Pneumonia;	chr12:47734162	chr12:47706085~47742294:+
PRAD	cis	rs1355223	0.902	rs12801509	ENSG00000271369.1	RP11-350D17.3	-7.28	1.45e-12	5.56e-10	-0.38	-0.32	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34725789	chr11:34709600~34710161:+
PRAD	cis	rs3096299	0.9	rs4785663	ENSG00000261118.1	RP11-104N10.1	7.28	1.45e-12	5.57e-10	0.32	0.32	Multiple myeloma (IgH translocation);	chr16:89368480	chr16:89492017~89504460:-
PRAD	cis	rs35160687	0.712	rs11675942	ENSG00000273080.1	RP11-301O19.1	-7.28	1.45e-12	5.57e-10	-0.36	-0.32	Night sleep phenotypes;	chr2:86280565	chr2:86195590~86196049:+
PRAD	cis	rs35160687	0.688	rs4832033	ENSG00000273080.1	RP11-301O19.1	-7.28	1.45e-12	5.57e-10	-0.36	-0.32	Night sleep phenotypes;	chr2:86281640	chr2:86195590~86196049:+
PRAD	cis	rs8523	0.774	rs61390967	ENSG00000230314.5	ELOVL2-AS1	7.28	1.45e-12	5.57e-10	0.36	0.32	Red blood cell fatty acid levels;	chr6:11074967	chr6:11043524~11078226:+
PRAD	cis	rs1020064	0.636	rs2679876	ENSG00000235319.1	AC012360.4	-7.28	1.46e-12	5.58e-10	-0.41	-0.32	AIDS;	chr2:105321650	chr2:105324210~105330529:+
PRAD	cis	rs780096	0.846	rs6547692	ENSG00000234072.1	AC074117.10	-7.28	1.46e-12	5.59e-10	-0.25	-0.32	Total body bone mineral density;	chr2:27512105	chr2:27356246~27367622:+
PRAD	cis	rs453301	0.653	rs11784393	ENSG00000253893.2	FAM85B	-7.28	1.46e-12	5.59e-10	-0.4	-0.32	Joint mobility (Beighton score);	chr8:9045624	chr8:8167819~8226614:-
PRAD	cis	rs67311347	0.577	rs1880763	ENSG00000223797.4	ENTPD3-AS1	-7.28	1.47e-12	5.63e-10	-0.29	-0.32	Renal cell carcinoma;	chr3:40241764	chr3:40313802~40453329:-
PRAD	cis	rs12701220	0.503	rs12702024	ENSG00000229043.2	AC091729.9	-7.28	1.47e-12	5.63e-10	-0.51	-0.32	Bronchopulmonary dysplasia;	chr7:1090184	chr7:1160374~1165267:+
PRAD	cis	rs7429990	0.965	rs7430879	ENSG00000229759.1	MRPS18AP1	-7.28	1.47e-12	5.63e-10	-0.33	-0.32	Educational attainment (years of education);	chr3:47997224	chr3:48256350~48256938:-
PRAD	cis	rs7429990	0.932	rs4293721	ENSG00000229759.1	MRPS18AP1	-7.28	1.47e-12	5.63e-10	-0.33	-0.32	Educational attainment (years of education);	chr3:48003647	chr3:48256350~48256938:-
PRAD	cis	rs7429990	0.965	rs11130154	ENSG00000229759.1	MRPS18AP1	-7.28	1.47e-12	5.63e-10	-0.33	-0.32	Educational attainment (years of education);	chr3:48027752	chr3:48256350~48256938:-
PRAD	cis	rs7429990	0.965	rs5012971	ENSG00000229759.1	MRPS18AP1	-7.28	1.47e-12	5.63e-10	-0.33	-0.32	Educational attainment (years of education);	chr3:48033057	chr3:48256350~48256938:-
PRAD	cis	rs7429990	0.813	rs7637622	ENSG00000229759.1	MRPS18AP1	-7.28	1.47e-12	5.63e-10	-0.33	-0.32	Educational attainment (years of education);	chr3:48051561	chr3:48256350~48256938:-
PRAD	cis	rs7429990	0.965	rs7627645	ENSG00000229759.1	MRPS18AP1	-7.28	1.47e-12	5.63e-10	-0.33	-0.32	Educational attainment (years of education);	chr3:48051643	chr3:48256350~48256938:-
PRAD	cis	rs496547	0.721	rs2508570	ENSG00000255239.1	AP002954.6	7.28	1.47e-12	5.63e-10	0.43	0.32	Hip minimal joint space width;	chr11:118807900	chr11:118688039~118690600:-
PRAD	cis	rs496547	0.686	rs591756	ENSG00000255239.1	AP002954.6	7.28	1.47e-12	5.63e-10	0.43	0.32	Hip minimal joint space width;	chr11:118808172	chr11:118688039~118690600:-
PRAD	cis	rs496547	0.686	rs477014	ENSG00000255239.1	AP002954.6	7.28	1.47e-12	5.63e-10	0.43	0.32	Hip minimal joint space width;	chr11:118808277	chr11:118688039~118690600:-
PRAD	cis	rs496547	0.557	rs516719	ENSG00000255239.1	AP002954.6	7.28	1.47e-12	5.63e-10	0.43	0.32	Hip minimal joint space width;	chr11:118808736	chr11:118688039~118690600:-
PRAD	cis	rs2638953	0.924	rs4573721	ENSG00000247934.4	RP11-967K21.1	-7.28	1.48e-12	5.65e-10	-0.33	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28194746	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.924	rs4554927	ENSG00000247934.4	RP11-967K21.1	-7.28	1.48e-12	5.65e-10	-0.33	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28194844	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.924	rs61920243	ENSG00000247934.4	RP11-967K21.1	-7.28	1.48e-12	5.65e-10	-0.33	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195333	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.679	rs7974882	ENSG00000247934.4	RP11-967K21.1	-7.28	1.48e-12	5.65e-10	-0.33	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195415	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.679	rs7961395	ENSG00000247934.4	RP11-967K21.1	-7.28	1.48e-12	5.65e-10	-0.33	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195420	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.924	rs7961407	ENSG00000247934.4	RP11-967K21.1	-7.28	1.48e-12	5.65e-10	-0.33	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195482	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.924	rs7974904	ENSG00000247934.4	RP11-967K21.1	-7.28	1.48e-12	5.65e-10	-0.33	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195491	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.924	rs7974979	ENSG00000247934.4	RP11-967K21.1	-7.28	1.48e-12	5.65e-10	-0.33	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195496	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.924	rs7974701	ENSG00000247934.4	RP11-967K21.1	-7.28	1.48e-12	5.65e-10	-0.33	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195579	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.886	rs7961769	ENSG00000247934.4	RP11-967K21.1	-7.28	1.48e-12	5.65e-10	-0.33	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195772	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.886	rs61920244	ENSG00000247934.4	RP11-967K21.1	-7.28	1.48e-12	5.65e-10	-0.33	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195992	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.924	rs34378873	ENSG00000247934.4	RP11-967K21.1	-7.28	1.48e-12	5.65e-10	-0.33	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28196124	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.924	rs11049438	ENSG00000247934.4	RP11-967K21.1	-7.28	1.48e-12	5.65e-10	-0.33	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28196205	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.924	rs11049439	ENSG00000247934.4	RP11-967K21.1	-7.28	1.48e-12	5.65e-10	-0.33	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28196369	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.924	rs11049440	ENSG00000247934.4	RP11-967K21.1	-7.28	1.48e-12	5.65e-10	-0.33	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28196474	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.924	rs11049441	ENSG00000247934.4	RP11-967K21.1	-7.28	1.48e-12	5.65e-10	-0.33	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28196476	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.853	rs11049442	ENSG00000247934.4	RP11-967K21.1	-7.28	1.48e-12	5.65e-10	-0.33	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28197211	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.924	rs11049443	ENSG00000247934.4	RP11-967K21.1	-7.28	1.48e-12	5.65e-10	-0.33	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28197269	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.962	rs60193273	ENSG00000247934.4	RP11-967K21.1	-7.28	1.48e-12	5.65e-10	-0.33	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28197638	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.924	rs11049446	ENSG00000247934.4	RP11-967K21.1	-7.28	1.48e-12	5.65e-10	-0.33	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28197951	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.924	rs11049447	ENSG00000247934.4	RP11-967K21.1	-7.28	1.48e-12	5.65e-10	-0.33	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28197970	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.886	rs10843123	ENSG00000247934.4	RP11-967K21.1	-7.28	1.48e-12	5.65e-10	-0.33	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28198004	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.924	rs10843124	ENSG00000247934.4	RP11-967K21.1	-7.28	1.48e-12	5.65e-10	-0.33	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28198189	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.924	rs11049448	ENSG00000247934.4	RP11-967K21.1	-7.28	1.48e-12	5.65e-10	-0.33	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28198975	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.924	rs10843126	ENSG00000247934.4	RP11-967K21.1	-7.28	1.48e-12	5.65e-10	-0.33	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28199112	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.924	rs10843127	ENSG00000247934.4	RP11-967K21.1	-7.28	1.48e-12	5.65e-10	-0.33	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28199124	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.85	rs10843128	ENSG00000247934.4	RP11-967K21.1	-7.28	1.48e-12	5.65e-10	-0.33	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28199377	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.85	rs10843129	ENSG00000247934.4	RP11-967K21.1	-7.28	1.48e-12	5.65e-10	-0.33	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28199378	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.924	rs10843130	ENSG00000247934.4	RP11-967K21.1	-7.28	1.48e-12	5.65e-10	-0.33	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28199793	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.924	rs61920253	ENSG00000247934.4	RP11-967K21.1	-7.28	1.48e-12	5.65e-10	-0.33	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28202039	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.888	rs11612143	ENSG00000247934.4	RP11-967K21.1	-7.28	1.48e-12	5.65e-10	-0.33	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28202694	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.813	rs11609999	ENSG00000247934.4	RP11-967K21.1	-7.28	1.48e-12	5.65e-10	-0.33	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28202721	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.924	rs11049453	ENSG00000247934.4	RP11-967K21.1	-7.28	1.48e-12	5.65e-10	-0.33	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28202996	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.886	rs7957059	ENSG00000247934.4	RP11-967K21.1	-7.28	1.48e-12	5.65e-10	-0.33	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28203390	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.962	rs73261702	ENSG00000247934.4	RP11-967K21.1	-7.28	1.48e-12	5.65e-10	-0.33	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28204118	chr12:28163298~28190738:-
PRAD	cis	rs526231	0.578	rs10515337	ENSG00000175749.11	EIF3KP1	-7.28	1.48e-12	5.66e-10	-0.43	-0.32	Primary biliary cholangitis;	chr5:102965664	chr5:103032376~103033031:+
PRAD	cis	rs2638953	0.815	rs11049684	ENSG00000278733.1	RP11-425D17.1	-7.28	1.48e-12	5.66e-10	-0.4	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28512426	chr12:28185625~28186190:-
PRAD	cis	rs9810089	0.749	rs664088	ENSG00000261758.1	RP11-102M11.2	7.28	1.48e-12	5.67e-10	0.37	0.32	Gestational age at birth (child effect);	chr3:136318144	chr3:136752630~136755780:+
PRAD	cis	rs2243480	1	rs709607	ENSG00000226824.5	RP4-756H11.3	7.28	1.48e-12	5.68e-10	0.63	0.32	Diabetic kidney disease;	chr7:65984554	chr7:66654538~66669855:+
PRAD	cis	rs6847067	0.8	rs7699226	ENSG00000180769.7	WDFY3-AS2	7.28	1.48e-12	5.68e-10	0.35	0.32	Oropharynx cancer;	chr4:84956408	chr4:84965682~85011277:+
PRAD	cis	rs17772222	1	rs61977058	ENSG00000258983.2	RP11-507K2.2	7.28	1.48e-12	5.68e-10	0.47	0.32	Coronary artery calcification;	chr14:88415571	chr14:88499334~88515502:+
PRAD	cis	rs8005677	0.828	rs35085068	ENSG00000257285.4	RP11-298I3.1	7.28	1.49e-12	5.69e-10	0.32	0.32	Cognitive ability (multi-trait analysis);	chr14:22940700	chr14:22929609~22955562:+
PRAD	cis	rs8005677	0.828	rs57822749	ENSG00000257285.4	RP11-298I3.1	7.28	1.49e-12	5.69e-10	0.32	0.32	Cognitive ability (multi-trait analysis);	chr14:22940758	chr14:22929609~22955562:+
PRAD	cis	rs8005677	0.828	rs4981451	ENSG00000257285.4	RP11-298I3.1	7.28	1.49e-12	5.69e-10	0.32	0.32	Cognitive ability (multi-trait analysis);	chr14:22941072	chr14:22929609~22955562:+
PRAD	cis	rs8005677	0.798	rs4536383	ENSG00000257285.4	RP11-298I3.1	7.28	1.49e-12	5.69e-10	0.32	0.32	Cognitive ability (multi-trait analysis);	chr14:22941717	chr14:22929609~22955562:+
PRAD	cis	rs8005677	0.828	rs34584578	ENSG00000257285.4	RP11-298I3.1	7.28	1.49e-12	5.69e-10	0.32	0.32	Cognitive ability (multi-trait analysis);	chr14:22942481	chr14:22929609~22955562:+
PRAD	cis	rs2274273	1	rs6573006	ENSG00000258413.1	RP11-665C16.6	-7.28	1.49e-12	5.69e-10	-0.41	-0.32	Protein biomarker;	chr14:55143714	chr14:55262767~55272075:-
PRAD	cis	rs964611	0.882	rs7170447	ENSG00000259488.2	RP11-154J22.1	7.28	1.49e-12	5.7e-10	0.31	0.32	Metabolite levels (Pyroglutamine);	chr15:48361245	chr15:48312353~48331856:-
PRAD	cis	rs1799949	0.93	rs4584865	ENSG00000267002.1	RP11-242D8.1	7.28	1.49e-12	5.71e-10	0.3	0.32	Menopause (age at onset);	chr17:43347551	chr17:43164183~43170403:-
PRAD	cis	rs6479891	0.908	rs16918638	ENSG00000232075.1	MRPL35P2	7.28	1.49e-12	5.71e-10	0.53	0.32	Arthritis (juvenile idiopathic);	chr10:63583371	chr10:63634317~63634827:-
PRAD	cis	rs12432203	1	rs61685874	ENSG00000258479.4	LINC00640	7.28	1.49e-12	5.71e-10	0.59	0.32	Cancer;	chr14:51279300	chr14:51333393~51365557:+
PRAD	cis	rs2067615	0.579	rs1073261	ENSG00000260329.1	RP11-412D9.4	-7.28	1.5e-12	5.73e-10	-0.27	-0.32	Heart rate;	chr12:106742164	chr12:106954029~106955497:-
PRAD	cis	rs4713118	0.955	rs34752872	ENSG00000226314.6	ZNF192P1	-7.28	1.5e-12	5.74e-10	-0.43	-0.32	Parkinson's disease;	chr6:27715465	chr6:28161781~28169594:+
PRAD	cis	rs4713118	0.911	rs2394000	ENSG00000226314.6	ZNF192P1	-7.28	1.5e-12	5.74e-10	-0.43	-0.32	Parkinson's disease;	chr6:27719212	chr6:28161781~28169594:+
PRAD	cis	rs1355223	0.902	rs2226113	ENSG00000271369.1	RP11-350D17.3	-7.28	1.5e-12	5.74e-10	-0.38	-0.32	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34724742	chr11:34709600~34710161:+
PRAD	cis	rs1552244	0.554	rs6796411	ENSG00000206567.8	AC022007.5	-7.28	1.5e-12	5.75e-10	-0.36	-0.32	Alzheimer's disease;	chr3:9968997	chr3:10006418~10011209:-
PRAD	cis	rs853679	0.607	rs13208096	ENSG00000225595.2	XXbac-BPG308K3.6	7.28	1.51e-12	5.76e-10	0.7	0.32	Depression;	chr6:28257533	chr6:28859625~28864630:-
PRAD	cis	rs853679	0.825	rs8180562	ENSG00000226314.6	ZNF192P1	-7.28	1.51e-12	5.77e-10	-0.57	-0.32	Depression;	chr6:28173682	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.882	rs9380064	ENSG00000226314.6	ZNF192P1	-7.28	1.51e-12	5.77e-10	-0.57	-0.32	Depression;	chr6:28175340	chr6:28161781~28169594:+
PRAD	cis	rs35264875	0.808	rs921675	ENSG00000259799.1	RP11-554A11.9	-7.28	1.52e-12	5.79e-10	-0.38	-0.32	Blond vs. brown hair color;	chr11:69101566	chr11:69155910~69159752:+
PRAD	cis	rs1799949	1	rs35956818	ENSG00000267002.1	RP11-242D8.1	7.28	1.52e-12	5.79e-10	0.3	0.32	Menopause (age at onset);	chr17:43345617	chr17:43164183~43170403:-
PRAD	cis	rs270601	0.683	rs81598	ENSG00000233006.5	AC034220.3	7.28	1.52e-12	5.8e-10	0.28	0.32	Acylcarnitine levels;	chr5:132252267	chr5:132311285~132369916:-
PRAD	cis	rs2067615	0.579	rs1922435	ENSG00000260329.1	RP11-412D9.4	-7.28	1.52e-12	5.8e-10	-0.27	-0.32	Heart rate;	chr12:106688677	chr12:106954029~106955497:-
PRAD	cis	rs2911132	0.628	rs2032890	ENSG00000248734.2	CTD-2260A17.1	7.28	1.52e-12	5.8e-10	0.37	0.32	Urate levels (BMI interaction);	chr5:96785448	chr5:96784777~96785999:+
PRAD	cis	rs2274273	1	rs61508494	ENSG00000258413.1	RP11-665C16.6	-7.28	1.52e-12	5.81e-10	-0.41	-0.32	Protein biomarker;	chr14:55120579	chr14:55262767~55272075:-
PRAD	cis	rs17772222	0.682	rs10132554	ENSG00000258983.2	RP11-507K2.2	7.28	1.52e-12	5.81e-10	0.42	0.32	Coronary artery calcification;	chr14:88473090	chr14:88499334~88515502:+
PRAD	cis	rs2638953	0.815	rs10843188	ENSG00000278733.1	RP11-425D17.1	-7.28	1.52e-12	5.81e-10	-0.37	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28504200	chr12:28185625~28186190:-
PRAD	cis	rs12439619	0.508	rs8023960	ENSG00000255769.6	GOLGA2P10	-7.28	1.52e-12	5.81e-10	-0.37	-0.32	Intelligence (multi-trait analysis);	chr15:82206704	chr15:82472993~82513950:-
PRAD	cis	rs17772222	1	rs12589467	ENSG00000258983.2	RP11-507K2.2	7.28	1.52e-12	5.81e-10	0.46	0.32	Coronary artery calcification;	chr14:88357239	chr14:88499334~88515502:+
PRAD	cis	rs2034650	0.544	rs2289330	ENSG00000223313.1	RNU6-516P	7.28	1.52e-12	5.82e-10	0.4	0.32	Interstitial lung disease;	chr15:40412906	chr15:40529570~40529673:+
PRAD	cis	rs17012589	0.695	rs1354839	ENSG00000258815.1	RP11-408B11.2	7.28	1.53e-12	5.84e-10	0.44	0.32	Bone mineral density (Ward's triangle area);	chr12:85209753	chr12:85318060~85342912:+
PRAD	cis	rs964611	1	rs16960758	ENSG00000259488.2	RP11-154J22.1	-7.27	1.53e-12	5.84e-10	-0.34	-0.32	Metabolite levels (Pyroglutamine);	chr15:48314955	chr15:48312353~48331856:-
PRAD	cis	rs12280210	0.557	rs12284696	ENSG00000254851.1	RP11-109L13.1	7.27	1.53e-12	5.84e-10	0.66	0.32	Lobe attachment (rater-scored or self-reported);	chr11:117008803	chr11:117135528~117138582:+
PRAD	cis	rs6993244	1	rs6993244	ENSG00000253893.2	FAM85B	-7.27	1.53e-12	5.85e-10	-0.41	-0.32	Mean corpuscular hemoglobin;	chr8:9005549	chr8:8167819~8226614:-
PRAD	cis	rs875971	0.522	rs34973832	ENSG00000237310.1	GS1-124K5.4	7.27	1.53e-12	5.85e-10	0.27	0.32	Aortic root size;	chr7:65931217	chr7:66493706~66495474:+
PRAD	cis	rs853679	0.527	rs853690	ENSG00000280107.1	AL022393.9	-7.27	1.53e-12	5.86e-10	-0.4	-0.32	Depression;	chr6:28317705	chr6:28170845~28172521:+
PRAD	cis	rs10206020	0.885	rs11886082	ENSG00000231482.2	AC141930.2	-7.27	1.53e-12	5.86e-10	-0.38	-0.32	IgG glycosylation;	chr2:1572911	chr2:1572554~1580311:-
PRAD	cis	rs1499614	1	rs1882655	ENSG00000273142.1	RP11-458F8.4	7.27	1.54e-12	5.87e-10	0.37	0.32	Gout;	chr7:66682070	chr7:66902857~66906297:+
PRAD	cis	rs1499614	0.831	rs3800822	ENSG00000273142.1	RP11-458F8.4	7.27	1.54e-12	5.87e-10	0.37	0.32	Gout;	chr7:66682162	chr7:66902857~66906297:+
PRAD	cis	rs1499614	1	rs1638731	ENSG00000273142.1	RP11-458F8.4	-7.27	1.54e-12	5.87e-10	-0.37	-0.32	Gout;	chr7:66679692	chr7:66902857~66906297:+
PRAD	cis	rs1499614	0.901	rs3936	ENSG00000273142.1	RP11-458F8.4	-7.27	1.54e-12	5.87e-10	-0.37	-0.32	Gout;	chr7:66661502	chr7:66902857~66906297:+
PRAD	cis	rs6860806	0.661	rs6890009	ENSG00000233006.5	AC034220.3	7.27	1.54e-12	5.88e-10	0.27	0.32	Breast cancer;	chr5:132244340	chr5:132311285~132369916:-
PRAD	cis	rs853679	0.607	rs33932084	ENSG00000225595.2	XXbac-BPG308K3.6	7.27	1.54e-12	5.88e-10	0.7	0.32	Depression;	chr6:28301047	chr6:28859625~28864630:-
PRAD	cis	rs6860806	0.661	rs3763112	ENSG00000233006.5	AC034220.3	7.27	1.54e-12	5.88e-10	0.28	0.32	Breast cancer;	chr5:132250787	chr5:132311285~132369916:-
PRAD	cis	rs2638953	0.671	rs11049357	ENSG00000278733.1	RP11-425D17.1	-7.27	1.54e-12	5.9e-10	-0.43	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28119856	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.853	rs17433981	ENSG00000278733.1	RP11-425D17.1	-7.27	1.54e-12	5.9e-10	-0.41	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28393634	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.962	rs12366617	ENSG00000278733.1	RP11-425D17.1	-7.27	1.54e-12	5.9e-10	-0.41	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28395726	chr12:28185625~28186190:-
PRAD	cis	rs17711722	0.701	rs4467826	ENSG00000237310.1	GS1-124K5.4	7.27	1.55e-12	5.9e-10	0.27	0.32	Calcium levels;	chr7:65903721	chr7:66493706~66495474:+
PRAD	cis	rs10129255	0.701	rs2005643	ENSG00000211970.3	IGHV4-61	-7.27	1.55e-12	5.92e-10	-0.3	-0.32	Kawasaki disease;	chr14:106676288	chr14:106639119~106639657:-
PRAD	cis	rs2638953	0.962	rs11049586	ENSG00000278733.1	RP11-425D17.1	-7.27	1.55e-12	5.92e-10	-0.4	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28418028	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.962	rs11049588	ENSG00000278733.1	RP11-425D17.1	-7.27	1.55e-12	5.92e-10	-0.4	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28418628	chr12:28185625~28186190:-
PRAD	cis	rs6452524	0.869	rs10051155	ENSG00000249664.1	CTD-2227C6.2	7.27	1.55e-12	5.92e-10	0.39	0.32	Hypertension (SNP x SNP interaction);	chr5:83160851	chr5:83012285~83013109:-
PRAD	cis	rs6452524	0.935	rs10043698	ENSG00000249664.1	CTD-2227C6.2	7.27	1.55e-12	5.92e-10	0.39	0.32	Hypertension (SNP x SNP interaction);	chr5:83169100	chr5:83012285~83013109:-
PRAD	cis	rs2676071	0.858	rs2670947	ENSG00000259446.4	RP11-489D6.2	7.27	1.55e-12	5.93e-10	0.42	0.32	Periodontitis (Mean PAL);	chr15:33306649	chr15:33303657~33310659:-
PRAD	cis	rs10463554	0.856	rs26260	ENSG00000175749.11	EIF3KP1	7.27	1.55e-12	5.93e-10	0.4	0.32	Parkinson's disease;	chr5:103211493	chr5:103032376~103033031:+
PRAD	cis	rs673078	0.66	rs12229607	ENSG00000275409.1	RP11-131L12.4	-7.27	1.55e-12	5.93e-10	-0.44	-0.32	Glucose homeostasis traits;	chr12:118338333	chr12:118430147~118430699:+
PRAD	cis	rs453301	0.606	rs7462373	ENSG00000254340.1	RP11-10A14.3	-7.27	1.56e-12	5.94e-10	-0.38	-0.32	Joint mobility (Beighton score);	chr8:9041808	chr8:9141424~9145435:+
PRAD	cis	rs17361889	0.711	rs7782485	ENSG00000224683.1	RPL36AP29	7.27	1.56e-12	5.94e-10	0.39	0.32	Pediatric bone mineral content (hip);	chr7:16272940	chr7:16208945~16209265:+
PRAD	cis	rs2274273	1	rs8011834	ENSG00000258413.1	RP11-665C16.6	-7.27	1.57e-12	5.99e-10	-0.41	-0.32	Protein biomarker;	chr14:55159259	chr14:55262767~55272075:-
PRAD	cis	rs12817211	0.536	rs3184122	ENSG00000272368.2	RP4-605O3.4	-7.27	1.57e-12	5.99e-10	-0.33	-0.32	Colorectal or endometrial cancer;	chr12:50176344	chr12:50112197~50165618:+
PRAD	cis	rs1065852	0.906	rs5751227	ENSG00000227370.1	RP4-669P10.19	7.27	1.57e-12	6.01e-10	0.36	0.32	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42146152	chr22:42132543~42132998:+
PRAD	cis	rs853679	0.607	rs201002	ENSG00000280107.1	AL022393.9	-7.27	1.58e-12	6.01e-10	-0.57	-0.32	Depression;	chr6:27840414	chr6:28170845~28172521:+
PRAD	cis	rs7829975	0.682	rs7013471	ENSG00000253893.2	FAM85B	7.27	1.58e-12	6.01e-10	0.42	0.32	Mood instability;	chr8:8829815	chr8:8167819~8226614:-
PRAD	cis	rs9601248	0.841	rs9545146	ENSG00000227676.3	LINC01068	-7.27	1.58e-12	6.03e-10	-0.38	-0.32	Major depressive disorder;	chr13:79601471	chr13:79566727~79571436:+
PRAD	cis	rs2836950	0.565	rs8130320	ENSG00000255568.3	BRWD1-AS2	-7.27	1.58e-12	6.03e-10	-0.26	-0.32	Menarche (age at onset);	chr21:39208332	chr21:39313935~39314962:+
PRAD	cis	rs11098499	0.604	rs2389887	ENSG00000245958.5	RP11-33B1.1	-7.27	1.58e-12	6.03e-10	-0.34	-0.32	Corneal astigmatism;	chr4:119649489	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.604	rs34278750	ENSG00000245958.5	RP11-33B1.1	-7.27	1.58e-12	6.03e-10	-0.34	-0.32	Corneal astigmatism;	chr4:119649981	chr4:119454791~119552025:+
PRAD	cis	rs995000	0.931	rs2131926	ENSG00000235545.1	RP11-230B22.1	-7.27	1.58e-12	6.04e-10	-0.42	-0.32	Triglyceride levels;	chr1:62560340	chr1:62688482~62710694:+
PRAD	cis	rs995000	0.931	rs10889343	ENSG00000235545.1	RP11-230B22.1	-7.27	1.58e-12	6.04e-10	-0.42	-0.32	Triglyceride levels;	chr1:62560758	chr1:62688482~62710694:+
PRAD	cis	rs995000	0.931	rs12062275	ENSG00000235545.1	RP11-230B22.1	-7.27	1.59e-12	6.05e-10	-0.43	-0.32	Triglyceride levels;	chr1:62526234	chr1:62688482~62710694:+
PRAD	cis	rs12468226	0.938	rs10166594	ENSG00000273456.1	RP11-686O6.2	7.27	1.59e-12	6.06e-10	0.42	0.32	Urate levels;	chr2:202250262	chr2:202374932~202375604:-
PRAD	cis	rs1799949	0.965	rs34633610	ENSG00000267002.1	RP11-242D8.1	7.27	1.59e-12	6.07e-10	0.31	0.32	Menopause (age at onset);	chr17:43342017	chr17:43164183~43170403:-
PRAD	cis	rs1799949	0.965	rs11654051	ENSG00000267002.1	RP11-242D8.1	7.27	1.59e-12	6.07e-10	0.31	0.32	Menopause (age at onset);	chr17:43342288	chr17:43164183~43170403:-
PRAD	cis	rs1799949	0.93	rs56729776	ENSG00000267002.1	RP11-242D8.1	7.27	1.59e-12	6.07e-10	0.31	0.32	Menopause (age at onset);	chr17:43344763	chr17:43164183~43170403:-
PRAD	cis	rs858239	0.601	rs10224327	ENSG00000226816.2	AC005082.12	7.27	1.59e-12	6.08e-10	0.37	0.32	Cerebrospinal fluid biomarker levels;	chr7:23122201	chr7:23206013~23208045:+
PRAD	cis	rs667920	0.573	rs9682783	ENSG00000273486.1	RP11-731C17.2	7.27	1.6e-12	6.09e-10	0.42	0.32	Coronary artery disease;	chr3:136820847	chr3:136837338~136839021:-
PRAD	cis	rs2067615	0.579	rs10861657	ENSG00000260329.1	RP11-412D9.4	-7.27	1.6e-12	6.1e-10	-0.27	-0.32	Heart rate;	chr12:106737536	chr12:106954029~106955497:-
PRAD	cis	rs12188164	0.932	rs2230437	ENSG00000221990.4	EXOC3-AS1	7.27	1.6e-12	6.1e-10	0.27	0.32	Cystic fibrosis severity;	chr5:476238	chr5:441498~443160:-
PRAD	cis	rs673078	0.66	rs11068908	ENSG00000275409.1	RP11-131L12.4	-7.27	1.6e-12	6.1e-10	-0.44	-0.32	Glucose homeostasis traits;	chr12:118327265	chr12:118430147~118430699:+
PRAD	cis	rs12701220	0.503	rs12702047	ENSG00000229043.2	AC091729.9	-7.27	1.6e-12	6.11e-10	-0.52	-0.32	Bronchopulmonary dysplasia;	chr7:1093084	chr7:1160374~1165267:+
PRAD	cis	rs453301	0.653	rs2956244	ENSG00000254340.1	RP11-10A14.3	7.27	1.6e-12	6.11e-10	0.4	0.32	Joint mobility (Beighton score);	chr8:9027656	chr8:9141424~9145435:+
PRAD	cis	rs270601	0.633	rs4535443	ENSG00000233006.5	AC034220.3	7.27	1.6e-12	6.12e-10	0.28	0.32	Acylcarnitine levels;	chr5:132236868	chr5:132311285~132369916:-
PRAD	cis	rs11838725	1	rs11838725	ENSG00000176268.5	CYCSP34	7.27	1.61e-12	6.13e-10	0.34	0.32	CSF tryptophan concentration in tuberculous meningitis;	chr13:41096949	chr13:40863599~40863902:-
PRAD	cis	rs7688540	0.723	rs9684973	ENSG00000275426.1	CH17-262A2.1	7.27	1.61e-12	6.13e-10	0.44	0.32	Facial morphology (factor 6, height of vermillion lower lip);	chr4:245032	chr4:149738~150317:+
PRAD	cis	rs853679	0.546	rs35656932	ENSG00000280107.1	AL022393.9	-7.27	1.61e-12	6.13e-10	-0.65	-0.32	Depression;	chr6:28223510	chr6:28170845~28172521:+
PRAD	cis	rs6991838	0.702	rs34496943	ENSG00000200714.1	Y_RNA	7.27	1.61e-12	6.13e-10	0.34	0.32	Intelligence (multi-trait analysis);	chr8:65676978	chr8:65592731~65592820:+
PRAD	cis	rs6991838	0.733	rs13281090	ENSG00000200714.1	Y_RNA	7.27	1.61e-12	6.13e-10	0.34	0.32	Intelligence (multi-trait analysis);	chr8:65678244	chr8:65592731~65592820:+
PRAD	cis	rs6991838	0.701	rs17395275	ENSG00000200714.1	Y_RNA	7.27	1.61e-12	6.13e-10	0.34	0.32	Intelligence (multi-trait analysis);	chr8:65679003	chr8:65592731~65592820:+
PRAD	cis	rs17772222	1	rs55722539	ENSG00000258983.2	RP11-507K2.2	7.27	1.61e-12	6.14e-10	0.48	0.32	Coronary artery calcification;	chr14:88411691	chr14:88499334~88515502:+
PRAD	cis	rs8523	0.774	rs1321535	ENSG00000230314.5	ELOVL2-AS1	7.27	1.61e-12	6.15e-10	0.35	0.32	Red blood cell fatty acid levels;	chr6:11075793	chr6:11043524~11078226:+
PRAD	cis	rs8523	0.715	rs12665478	ENSG00000230314.5	ELOVL2-AS1	7.27	1.61e-12	6.15e-10	0.35	0.32	Red blood cell fatty acid levels;	chr6:11080592	chr6:11043524~11078226:+
PRAD	cis	rs67340775	0.541	rs200965	ENSG00000219392.1	RP1-265C24.5	-7.27	1.61e-12	6.15e-10	-0.52	-0.32	Lung cancer in ever smokers;	chr6:27898606	chr6:28115628~28116551:+
PRAD	cis	rs67340775	0.541	rs200964	ENSG00000219392.1	RP1-265C24.5	-7.27	1.61e-12	6.15e-10	-0.52	-0.32	Lung cancer in ever smokers;	chr6:27899165	chr6:28115628~28116551:+
PRAD	cis	rs56114371	0.777	rs200483	ENSG00000280107.1	AL022393.9	-7.27	1.62e-12	6.17e-10	-0.56	-0.32	Breast cancer;	chr6:27807046	chr6:28170845~28172521:+
PRAD	cis	rs1823913	1	rs68014803	ENSG00000280083.1	RP11-317J9.1	-7.27	1.62e-12	6.18e-10	-0.41	-0.32	Obesity-related traits;	chr2:191241877	chr2:191154118~191156070:-
PRAD	cis	rs55894132	1	rs55894132	ENSG00000257285.4	RP11-298I3.1	7.27	1.62e-12	6.18e-10	0.32	0.32	Intelligence (multi-trait analysis);	chr14:22939628	chr14:22929609~22955562:+
PRAD	cis	rs2439831	0.702	rs7171750	ENSG00000205771.5	CATSPER2P1	-7.27	1.62e-12	6.19e-10	-0.49	-0.32	Lung cancer in ever smokers;	chr15:43733660	chr15:43726918~43747094:-
PRAD	cis	rs2836950	0.501	rs35994303	ENSG00000255568.3	BRWD1-AS2	-7.27	1.63e-12	6.2e-10	-0.27	-0.32	Menarche (age at onset);	chr21:39314094	chr21:39313935~39314962:+
PRAD	cis	rs995000	0.899	rs10889356	ENSG00000235545.1	RP11-230B22.1	7.27	1.63e-12	6.2e-10	0.43	0.32	Triglyceride levels;	chr1:62689678	chr1:62688482~62710694:+
PRAD	cis	rs2638953	0.853	rs3926041	ENSG00000278733.1	RP11-425D17.1	-7.27	1.63e-12	6.2e-10	-0.39	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28461776	chr12:28185625~28186190:-
PRAD	cis	rs270601	0.661	rs10036208	ENSG00000233006.5	AC034220.3	7.27	1.63e-12	6.21e-10	0.28	0.32	Acylcarnitine levels;	chr5:132235630	chr5:132311285~132369916:-
PRAD	cis	rs7487075	0.78	rs10785624	ENSG00000257261.4	RP11-96H19.1	7.27	1.63e-12	6.22e-10	0.4	0.32	Itch intensity from mosquito bite;	chr12:46373004	chr12:46383679~46876159:+
PRAD	cis	rs7487075	0.78	rs2279559	ENSG00000257261.4	RP11-96H19.1	7.27	1.63e-12	6.22e-10	0.4	0.32	Itch intensity from mosquito bite;	chr12:46373392	chr12:46383679~46876159:+
PRAD	cis	rs200986	1	rs200986	ENSG00000219392.1	RP1-265C24.5	-7.26	1.63e-12	6.22e-10	-0.41	-0.32	Autism spectrum disorder or schizophrenia;	chr6:27856988	chr6:28115628~28116551:+
PRAD	cis	rs4713118	0.539	rs200951	ENSG00000219392.1	RP1-265C24.5	-7.26	1.63e-12	6.22e-10	-0.41	-0.32	Parkinson's disease;	chr6:27868152	chr6:28115628~28116551:+
PRAD	cis	rs755249	0.73	rs3916164	ENSG00000237624.1	OXCT2P1	7.26	1.63e-12	6.23e-10	0.42	0.32	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39604267	chr1:39514956~39516490:+
PRAD	cis	rs7646881	0.812	rs7635704	ENSG00000240207.5	RP11-379F4.4	-7.26	1.64e-12	6.23e-10	-0.31	-0.32	Tetralogy of Fallot;	chr3:158741931	chr3:158732263~158784070:+
PRAD	cis	rs6539288	0.803	rs7307895	ENSG00000260329.1	RP11-412D9.4	-7.26	1.64e-12	6.24e-10	-0.28	-0.32	Total body bone mineral density;	chr12:106938348	chr12:106954029~106955497:-
PRAD	cis	rs875971	0.66	rs1860468	ENSG00000237310.1	GS1-124K5.4	-7.26	1.64e-12	6.26e-10	-0.28	-0.32	Aortic root size;	chr7:66642265	chr7:66493706~66495474:+
PRAD	cis	rs12908161	1	rs35316992	ENSG00000275120.1	RP11-182J1.17	7.26	1.65e-12	6.27e-10	0.42	0.32	Schizophrenia;	chr15:84704902	chr15:84599434~84606463:-
PRAD	cis	rs12908161	1	rs4643294	ENSG00000275120.1	RP11-182J1.17	7.26	1.65e-12	6.27e-10	0.42	0.32	Schizophrenia;	chr15:84707022	chr15:84599434~84606463:-
PRAD	cis	rs12908161	1	rs62021219	ENSG00000275120.1	RP11-182J1.17	7.26	1.65e-12	6.27e-10	0.42	0.32	Schizophrenia;	chr15:84712928	chr15:84599434~84606463:-
PRAD	cis	rs12908161	1	rs34900908	ENSG00000275120.1	RP11-182J1.17	7.26	1.65e-12	6.27e-10	0.42	0.32	Schizophrenia;	chr15:84714368	chr15:84599434~84606463:-
PRAD	cis	rs12908161	1	rs35524990	ENSG00000275120.1	RP11-182J1.17	7.26	1.65e-12	6.27e-10	0.42	0.32	Schizophrenia;	chr15:84714972	chr15:84599434~84606463:-
PRAD	cis	rs995000	0.931	rs2131925	ENSG00000235545.1	RP11-230B22.1	-7.26	1.65e-12	6.29e-10	-0.43	-0.32	Triglyceride levels;	chr1:62560271	chr1:62688482~62710694:+
PRAD	cis	rs1023500	0.573	rs133370	ENSG00000205702.9	CYP2D7	7.26	1.65e-12	6.3e-10	0.25	0.32	Schizophrenia;	chr22:42069256	chr22:42140203~42144577:-
PRAD	cis	rs17772222	1	rs2295135	ENSG00000258983.2	RP11-507K2.2	7.26	1.66e-12	6.31e-10	0.48	0.32	Coronary artery calcification;	chr14:88427866	chr14:88499334~88515502:+
PRAD	cis	rs6479891	0.908	rs11817901	ENSG00000232075.1	MRPL35P2	7.26	1.66e-12	6.31e-10	0.53	0.32	Arthritis (juvenile idiopathic);	chr10:63580123	chr10:63634317~63634827:-
PRAD	cis	rs11098499	0.675	rs11098534	ENSG00000245958.5	RP11-33B1.1	-7.26	1.66e-12	6.32e-10	-0.3	-0.32	Corneal astigmatism;	chr4:119635617	chr4:119454791~119552025:+
PRAD	cis	rs6479901	0.895	rs9629895	ENSG00000232075.1	MRPL35P2	-7.26	1.66e-12	6.32e-10	-0.39	-0.32	Intelligence (multi-trait analysis);	chr10:63363027	chr10:63634317~63634827:-
PRAD	cis	rs7567389	0.785	rs4150474	ENSG00000236682.1	AC068282.3	7.26	1.66e-12	6.33e-10	0.43	0.32	Self-rated health;	chr2:127275751	chr2:127389130~127400580:+
PRAD	cis	rs5769707	0.521	rs5769719	ENSG00000188511.11	C22orf34	7.26	1.66e-12	6.33e-10	0.38	0.32	Monocyte percentage of white cells;Monocyte count;	chr22:49668453	chr22:49414524~49657542:-
PRAD	cis	rs5769707	0.521	rs5769720	ENSG00000188511.11	C22orf34	7.26	1.66e-12	6.33e-10	0.38	0.32	Monocyte percentage of white cells;Monocyte count;	chr22:49668485	chr22:49414524~49657542:-
PRAD	cis	rs5769707	0.521	rs5770633	ENSG00000188511.11	C22orf34	7.26	1.66e-12	6.33e-10	0.38	0.32	Monocyte percentage of white cells;Monocyte count;	chr22:49668779	chr22:49414524~49657542:-
PRAD	cis	rs11159086	0.793	rs10139029	ENSG00000270000.1	RP3-449M8.9	7.26	1.66e-12	6.33e-10	0.49	0.32	Advanced glycation end-product levels;	chr14:74492284	chr14:74471930~74472360:-
PRAD	cis	rs1023500	0.551	rs133371	ENSG00000205702.9	CYP2D7	7.26	1.67e-12	6.34e-10	0.25	0.32	Schizophrenia;	chr22:42069570	chr22:42140203~42144577:-
PRAD	cis	rs1023500	0.573	rs133374	ENSG00000205702.9	CYP2D7	7.26	1.67e-12	6.34e-10	0.25	0.32	Schizophrenia;	chr22:42069937	chr22:42140203~42144577:-
PRAD	cis	rs3096299	0.933	rs889576	ENSG00000274627.1	RP11-104N10.2	-7.26	1.67e-12	6.35e-10	-0.33	-0.32	Multiple myeloma (IgH translocation);	chr16:89363245	chr16:89516797~89522217:+
PRAD	cis	rs2836950	0.545	rs8132424	ENSG00000255568.3	BRWD1-AS2	7.26	1.67e-12	6.36e-10	0.27	0.32	Menarche (age at onset);	chr21:39212486	chr21:39313935~39314962:+
PRAD	cis	rs1823913	0.927	rs35092718	ENSG00000280083.1	RP11-317J9.1	-7.26	1.67e-12	6.37e-10	-0.4	-0.32	Obesity-related traits;	chr2:191243882	chr2:191154118~191156070:-
PRAD	cis	rs17772222	0.958	rs61579615	ENSG00000258983.2	RP11-507K2.2	7.26	1.68e-12	6.38e-10	0.47	0.32	Coronary artery calcification;	chr14:88400054	chr14:88499334~88515502:+
PRAD	cis	rs1979679	0.578	rs2127316	ENSG00000278733.1	RP11-425D17.1	7.26	1.68e-12	6.38e-10	0.41	0.32	Ossification of the posterior longitudinal ligament of the spine;	chr12:28121472	chr12:28185625~28186190:-
PRAD	cis	rs6951245	0.554	rs4724294	ENSG00000229043.2	AC091729.9	-7.26	1.68e-12	6.39e-10	-0.45	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1100059	chr7:1160374~1165267:+
PRAD	cis	rs12612619	0.704	rs7602823	ENSG00000272148.1	RP11-195B17.1	-7.26	1.68e-12	6.39e-10	-0.39	-0.32	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27086538	chr2:27062428~27062907:-
PRAD	cis	rs7772486	0.84	rs2814864	ENSG00000235652.6	RP11-545I5.3	7.26	1.68e-12	6.39e-10	0.33	0.32	Lobe attachment (rater-scored or self-reported);	chr6:146023910	chr6:145799409~145886585:+
PRAD	cis	rs4631830	0.657	rs2611502	ENSG00000230869.1	CTGLF10P	-7.26	1.68e-12	6.39e-10	-0.4	-0.32	Prostate-specific antigen levels;	chr10:46095521	chr10:45678692~45700532:+
PRAD	cis	rs149866169	1	rs149866169	ENSG00000280107.1	AL022393.9	-7.26	1.68e-12	6.4e-10	-0.6	-0.32	Subjective well-being (multi-trait analysis);Lung cancer;Neuroticism (multi-trait analysis);Lung cancer in ever smokers;Squamous cell lung carcinoma;	chr6:27473944	chr6:28170845~28172521:+
PRAD	cis	rs17772222	1	rs3814855	ENSG00000258983.2	RP11-507K2.2	7.26	1.68e-12	6.4e-10	0.47	0.32	Coronary artery calcification;	chr14:88467016	chr14:88499334~88515502:+
PRAD	cis	rs7746199	0.736	rs13209332	ENSG00000226314.6	ZNF192P1	-7.26	1.69e-12	6.42e-10	-0.68	-0.32	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27552973	chr6:28161781~28169594:+
PRAD	cis	rs7746199	0.736	rs10484399	ENSG00000226314.6	ZNF192P1	-7.26	1.69e-12	6.42e-10	-0.68	-0.32	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27566749	chr6:28161781~28169594:+
PRAD	cis	rs7746199	0.736	rs34105070	ENSG00000226314.6	ZNF192P1	-7.26	1.69e-12	6.42e-10	-0.68	-0.32	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27593026	chr6:28161781~28169594:+
PRAD	cis	rs7746199	0.673	rs72845046	ENSG00000226314.6	ZNF192P1	-7.26	1.69e-12	6.42e-10	-0.68	-0.32	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27607489	chr6:28161781~28169594:+
PRAD	cis	rs7746199	0.736	rs67652222	ENSG00000226314.6	ZNF192P1	-7.26	1.69e-12	6.42e-10	-0.68	-0.32	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27618441	chr6:28161781~28169594:+
PRAD	cis	rs7746199	0.736	rs34038546	ENSG00000226314.6	ZNF192P1	-7.26	1.69e-12	6.42e-10	-0.68	-0.32	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27639881	chr6:28161781~28169594:+
PRAD	cis	rs141342723	1	rs141342723	ENSG00000226314.6	ZNF192P1	-7.26	1.69e-12	6.42e-10	-0.68	-0.32	Autism spectrum disorder or schizophrenia;	chr6:27654305	chr6:28161781~28169594:+
PRAD	cis	rs7746199	0.736	rs34543938	ENSG00000226314.6	ZNF192P1	-7.26	1.69e-12	6.42e-10	-0.68	-0.32	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27656861	chr6:28161781~28169594:+
PRAD	cis	rs45509595	0.556	rs34409918	ENSG00000226314.6	ZNF192P1	-7.26	1.69e-12	6.42e-10	-0.68	-0.32	Breast cancer;	chr6:27717569	chr6:28161781~28169594:+
PRAD	cis	rs7746199	0.736	rs13212318	ENSG00000226314.6	ZNF192P1	-7.26	1.69e-12	6.42e-10	-0.68	-0.32	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27721062	chr6:28161781~28169594:+
PRAD	cis	rs3745672	1	rs73510930	ENSG00000219665.7	CTD-2006C1.2	-7.26	1.69e-12	6.42e-10	-0.73	-0.32	Multiple sclerosis;	chr19:11980947	chr19:11987617~12046275:+
PRAD	cis	rs2274273	0.686	rs57033289	ENSG00000258413.1	RP11-665C16.6	-7.26	1.69e-12	6.43e-10	-0.45	-0.32	Protein biomarker;	chr14:55156599	chr14:55262767~55272075:-
PRAD	cis	rs2274273	0.686	rs11624679	ENSG00000258413.1	RP11-665C16.6	-7.26	1.69e-12	6.43e-10	-0.45	-0.32	Protein biomarker;	chr14:55157526	chr14:55262767~55272075:-
PRAD	cis	rs7131987	0.65	rs11050208	ENSG00000257176.2	RP11-996F15.2	-7.26	1.69e-12	6.43e-10	-0.36	-0.32	QT interval;	chr12:29357436	chr12:29280418~29317848:-
PRAD	cis	rs2243480	0.711	rs2420172	ENSG00000273142.1	RP11-458F8.4	7.26	1.69e-12	6.44e-10	0.36	0.32	Diabetic kidney disease;	chr7:66170354	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs2420171	ENSG00000273142.1	RP11-458F8.4	7.26	1.69e-12	6.44e-10	0.36	0.32	Diabetic kidney disease;	chr7:66172773	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs6974723	ENSG00000273142.1	RP11-458F8.4	7.26	1.69e-12	6.44e-10	0.36	0.32	Diabetic kidney disease;	chr7:66172952	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs9769882	ENSG00000273142.1	RP11-458F8.4	7.26	1.69e-12	6.44e-10	0.36	0.32	Diabetic kidney disease;	chr7:66177938	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs6966322	ENSG00000273142.1	RP11-458F8.4	7.26	1.69e-12	6.44e-10	0.36	0.32	Diabetic kidney disease;	chr7:66181767	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs4145008	ENSG00000273142.1	RP11-458F8.4	7.26	1.69e-12	6.44e-10	0.36	0.32	Diabetic kidney disease;	chr7:66182524	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs4718315	ENSG00000273142.1	RP11-458F8.4	7.26	1.69e-12	6.44e-10	0.36	0.32	Diabetic kidney disease;	chr7:66183554	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs4718316	ENSG00000273142.1	RP11-458F8.4	7.26	1.69e-12	6.44e-10	0.36	0.32	Diabetic kidney disease;	chr7:66183744	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs1873494	ENSG00000273142.1	RP11-458F8.4	7.26	1.69e-12	6.44e-10	0.36	0.32	Diabetic kidney disease;	chr7:66184912	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs6959002	ENSG00000273142.1	RP11-458F8.4	7.26	1.69e-12	6.44e-10	0.36	0.32	Diabetic kidney disease;	chr7:66185509	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs1546059	ENSG00000273142.1	RP11-458F8.4	7.26	1.69e-12	6.44e-10	0.36	0.32	Diabetic kidney disease;	chr7:66189722	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs2420170	ENSG00000273142.1	RP11-458F8.4	7.26	1.69e-12	6.44e-10	0.36	0.32	Diabetic kidney disease;	chr7:66191066	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs6958289	ENSG00000273142.1	RP11-458F8.4	7.26	1.69e-12	6.44e-10	0.36	0.32	Diabetic kidney disease;	chr7:66192124	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs7804223	ENSG00000273142.1	RP11-458F8.4	7.26	1.69e-12	6.44e-10	0.36	0.32	Diabetic kidney disease;	chr7:66199572	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs34193460	ENSG00000226824.5	RP4-756H11.3	-7.26	1.69e-12	6.44e-10	-0.63	-0.32	Diabetic kidney disease;	chr7:65928123	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs57057549	ENSG00000226824.5	RP4-756H11.3	-7.26	1.69e-12	6.44e-10	-0.63	-0.32	Diabetic kidney disease;	chr7:65940751	chr7:66654538~66669855:+
PRAD	cis	rs2243480	0.808	rs12698508	ENSG00000226824.5	RP4-756H11.3	-7.26	1.69e-12	6.44e-10	-0.63	-0.32	Diabetic kidney disease;	chr7:65946971	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs2961102	ENSG00000226824.5	RP4-756H11.3	-7.26	1.69e-12	6.44e-10	-0.63	-0.32	Diabetic kidney disease;	chr7:65959671	chr7:66654538~66669855:+
PRAD	cis	rs2243480	0.901	rs73148097	ENSG00000226824.5	RP4-756H11.3	-7.26	1.69e-12	6.44e-10	-0.63	-0.32	Diabetic kidney disease;	chr7:65966800	chr7:66654538~66669855:+
PRAD	cis	rs9640161	0.789	rs2098053	ENSG00000261305.1	RP4-584D14.7	7.26	1.69e-12	6.44e-10	0.37	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150346116	chr7:150341771~150342607:+
PRAD	cis	rs9640161	0.673	rs34489187	ENSG00000261305.1	RP4-584D14.7	7.26	1.69e-12	6.44e-10	0.37	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150347290	chr7:150341771~150342607:+
PRAD	cis	rs9601248	0.51	rs9601250	ENSG00000227676.3	LINC01068	7.26	1.7e-12	6.45e-10	0.39	0.32	Major depressive disorder;	chr13:79614567	chr13:79566727~79571436:+
PRAD	cis	rs4728142	0.525	rs4731534	ENSG00000275106.1	RP11-309L24.10	-7.26	1.7e-12	6.46e-10	-0.4	-0.32	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128965540	chr7:128952527~128953316:-
PRAD	cis	rs13068223	0.562	rs346003	ENSG00000243926.1	TIPARP-AS1	-7.26	1.71e-12	6.48e-10	-0.3	-0.32	Age-related hearing impairment (SNP x SNP interaction);	chr3:156705283	chr3:156671862~156674378:-
PRAD	cis	rs2243480	0.901	rs2900904	ENSG00000226824.5	RP4-756H11.3	-7.26	1.71e-12	6.48e-10	-0.63	-0.32	Diabetic kidney disease;	chr7:65739282	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs67728539	ENSG00000273142.1	RP11-458F8.4	-7.26	1.71e-12	6.49e-10	-0.35	-0.32	Diabetic kidney disease;	chr7:65913137	chr7:66902857~66906297:+
PRAD	cis	rs853679	0.766	rs9368561	ENSG00000226314.6	ZNF192P1	-7.26	1.71e-12	6.49e-10	-0.58	-0.32	Depression;	chr6:28200565	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.55	rs34477097	ENSG00000204709.4	LINC01556	7.26	1.71e-12	6.49e-10	0.44	0.32	Depression;	chr6:28229408	chr6:28943877~28944537:+
PRAD	cis	rs2243480	0.831	rs57294491	ENSG00000273142.1	RP11-458F8.4	7.26	1.71e-12	6.49e-10	0.36	0.32	Diabetic kidney disease;	chr7:66219914	chr7:66902857~66906297:+
PRAD	cis	rs1499614	0.803	rs1796229	ENSG00000273142.1	RP11-458F8.4	-7.26	1.71e-12	6.49e-10	-0.37	-0.32	Gout;	chr7:66654674	chr7:66902857~66906297:+
PRAD	cis	rs875971	0.522	rs6960048	ENSG00000237310.1	GS1-124K5.4	7.26	1.71e-12	6.52e-10	0.27	0.32	Aortic root size;	chr7:65943052	chr7:66493706~66495474:+
PRAD	cis	rs1799949	1	rs16941	ENSG00000267002.1	RP11-242D8.1	7.26	1.72e-12	6.52e-10	0.31	0.32	Menopause (age at onset);	chr17:43092418	chr17:43164183~43170403:-
PRAD	cis	rs12612619	0.695	rs11126806	ENSG00000229122.1	AGBL5-IT1	-7.26	1.72e-12	6.54e-10	-0.34	-0.32	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27002276	chr2:27061038~27061815:+
PRAD	cis	rs6782228	0.527	rs2712371	ENSG00000242551.2	POU5F1P6	-7.26	1.72e-12	6.54e-10	-0.4	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128627371	chr3:128674735~128677005:-
PRAD	cis	rs6903823	0.527	rs4713158	ENSG00000280107.1	AL022393.9	-7.26	1.73e-12	6.55e-10	-0.4	-0.32	Pulmonary function;	chr6:28309994	chr6:28170845~28172521:+
PRAD	cis	rs736801	0.569	rs12517950	ENSG00000233006.5	AC034220.3	7.26	1.73e-12	6.56e-10	0.29	0.32	Mosquito bite size;Breast cancer;	chr5:132395634	chr5:132311285~132369916:-
PRAD	cis	rs8177376	0.727	rs658614	ENSG00000254905.1	RP11-712L6.7	7.26	1.73e-12	6.56e-10	0.39	0.32	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126328096	chr11:126292922~126294254:-
PRAD	cis	rs995000	0.839	rs1168034	ENSG00000235545.1	RP11-230B22.1	-7.26	1.73e-12	6.57e-10	-0.42	-0.32	Triglyceride levels;	chr1:62498243	chr1:62688482~62710694:+
PRAD	cis	rs42648	0.837	rs12375075	ENSG00000227646.6	STEAP2-AS1	-7.26	1.73e-12	6.57e-10	-0.29	-0.32	Homocysteine levels;	chr7:90311017	chr7:89882353~90211635:-
PRAD	cis	rs893363	0.517	rs9836592	ENSG00000271916.1	RP11-884K10.6	-7.26	1.73e-12	6.57e-10	-0.38	-0.32	Axial length;	chr3:53821056	chr3:53797764~53798019:-
PRAD	cis	rs172166	0.694	rs203884	ENSG00000220721.1	OR1F12	7.26	1.73e-12	6.57e-10	0.38	0.32	Cardiac Troponin-T levels;	chr6:28109596	chr6:28073316~28074233:+
PRAD	cis	rs6452524	0.804	rs2048215	ENSG00000249664.1	CTD-2227C6.2	-7.26	1.73e-12	6.59e-10	-0.4	-0.32	Hypertension (SNP x SNP interaction);	chr5:83208589	chr5:83012285~83013109:-
PRAD	cis	rs6452524	0.836	rs62374402	ENSG00000249664.1	CTD-2227C6.2	7.26	1.73e-12	6.59e-10	0.4	0.32	Hypertension (SNP x SNP interaction);	chr5:83207343	chr5:83012285~83013109:-
PRAD	cis	rs2439831	0.681	rs956391	ENSG00000249839.1	AC011330.5	7.26	1.74e-12	6.59e-10	0.49	0.32	Lung cancer in ever smokers;	chr15:43325295	chr15:43663654~43684339:-
PRAD	cis	rs42648	0.837	rs10262472	ENSG00000227646.6	STEAP2-AS1	-7.26	1.74e-12	6.59e-10	-0.29	-0.32	Homocysteine levels;	chr7:90271069	chr7:89882353~90211635:-
PRAD	cis	rs17253792	0.822	rs10137340	ENSG00000186615.9	KTN1-AS1	-7.26	1.74e-12	6.6e-10	-0.55	-0.32	Putamen volume;	chr14:55584271	chr14:55499278~55580110:-
PRAD	cis	rs2243480	1	rs6964245	ENSG00000273142.1	RP11-458F8.4	7.26	1.74e-12	6.61e-10	0.37	0.32	Diabetic kidney disease;	chr7:66253730	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs10807701	ENSG00000273142.1	RP11-458F8.4	7.26	1.74e-12	6.61e-10	0.37	0.32	Diabetic kidney disease;	chr7:66259699	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs1499613	ENSG00000273142.1	RP11-458F8.4	7.26	1.74e-12	6.61e-10	0.37	0.32	Diabetic kidney disease;	chr7:66265873	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs1553174	ENSG00000273142.1	RP11-458F8.4	7.26	1.74e-12	6.61e-10	0.37	0.32	Diabetic kidney disease;	chr7:66266207	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs10950032	ENSG00000273142.1	RP11-458F8.4	7.26	1.74e-12	6.61e-10	0.37	0.32	Diabetic kidney disease;	chr7:66273604	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs6958420	ENSG00000273142.1	RP11-458F8.4	7.26	1.74e-12	6.61e-10	0.37	0.32	Diabetic kidney disease;	chr7:66286184	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs1392104	ENSG00000273142.1	RP11-458F8.4	7.26	1.74e-12	6.61e-10	0.37	0.32	Diabetic kidney disease;	chr7:66294120	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs4718333	ENSG00000273142.1	RP11-458F8.4	7.26	1.74e-12	6.61e-10	0.37	0.32	Diabetic kidney disease;	chr7:66307771	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs7792391	ENSG00000273142.1	RP11-458F8.4	7.26	1.74e-12	6.61e-10	0.37	0.32	Diabetic kidney disease;	chr7:66308442	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs10247526	ENSG00000273142.1	RP11-458F8.4	7.26	1.74e-12	6.61e-10	0.37	0.32	Diabetic kidney disease;	chr7:66315709	chr7:66902857~66906297:+
PRAD	cis	rs733592	0.929	rs4760678	ENSG00000240399.1	RP1-228P16.1	-7.26	1.74e-12	6.61e-10	-0.27	-0.32	Plateletcrit;	chr12:48067798	chr12:48054813~48055591:-
PRAD	cis	rs2439831	0.85	rs7179388	ENSG00000205771.5	CATSPER2P1	-7.26	1.74e-12	6.62e-10	-0.5	-0.32	Lung cancer in ever smokers;	chr15:43831747	chr15:43726918~43747094:-
PRAD	cis	rs2439831	0.702	rs16977724	ENSG00000205771.5	CATSPER2P1	-7.26	1.74e-12	6.62e-10	-0.5	-0.32	Lung cancer in ever smokers;	chr15:43859101	chr15:43726918~43747094:-
PRAD	cis	rs987724	0.571	rs7641929	ENSG00000240875.4	LINC00886	-7.26	1.74e-12	6.62e-10	-0.37	-0.32	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156811605	chr3:156747346~156817062:-
PRAD	cis	rs10206020	0.885	rs6720923	ENSG00000231482.2	AC141930.2	-7.25	1.75e-12	6.63e-10	-0.37	-0.32	IgG glycosylation;	chr2:1570425	chr2:1572554~1580311:-
PRAD	cis	rs10206020	0.885	rs6720797	ENSG00000231482.2	AC141930.2	-7.25	1.75e-12	6.63e-10	-0.37	-0.32	IgG glycosylation;	chr2:1570568	chr2:1572554~1580311:-
PRAD	cis	rs6479901	0.947	rs10822150	ENSG00000232075.1	MRPL35P2	-7.25	1.75e-12	6.64e-10	-0.4	-0.32	Intelligence (multi-trait analysis);	chr10:63257736	chr10:63634317~63634827:-
PRAD	cis	rs6479901	0.895	rs4417159	ENSG00000232075.1	MRPL35P2	-7.25	1.75e-12	6.64e-10	-0.4	-0.32	Intelligence (multi-trait analysis);	chr10:63285938	chr10:63634317~63634827:-
PRAD	cis	rs6479901	0.947	rs10995493	ENSG00000232075.1	MRPL35P2	-7.25	1.75e-12	6.64e-10	-0.4	-0.32	Intelligence (multi-trait analysis);	chr10:63287266	chr10:63634317~63634827:-
PRAD	cis	rs1011728	0.566	rs7306333	ENSG00000258815.1	RP11-408B11.2	7.25	1.75e-12	6.64e-10	0.44	0.32	Bone mineral density (Ward's triangle area);	chr12:85335854	chr12:85318060~85342912:+
PRAD	cis	rs2638953	0.962	rs11049488	ENSG00000247934.4	RP11-967K21.1	-7.25	1.75e-12	6.64e-10	-0.34	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28259439	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.962	rs57618147	ENSG00000247934.4	RP11-967K21.1	-7.25	1.75e-12	6.64e-10	-0.34	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28259902	chr12:28163298~28190738:-
PRAD	cis	rs73186030	0.764	rs6438725	ENSG00000272758.4	RP11-299J3.8	7.25	1.75e-12	6.65e-10	0.46	0.32	Serum parathyroid hormone levels;	chr3:122369259	chr3:122416207~122443180:+
PRAD	cis	rs73186030	0.764	rs9881201	ENSG00000272758.4	RP11-299J3.8	7.25	1.75e-12	6.65e-10	0.46	0.32	Serum parathyroid hormone levels;	chr3:122375838	chr3:122416207~122443180:+
PRAD	cis	rs2638953	0.924	rs12146881	ENSG00000247934.4	RP11-967K21.1	-7.25	1.76e-12	6.66e-10	-0.33	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28198436	chr12:28163298~28190738:-
PRAD	cis	rs2243480	0.908	rs2460431	ENSG00000273142.1	RP11-458F8.4	7.25	1.76e-12	6.69e-10	0.36	0.32	Diabetic kidney disease;	chr7:66157859	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs4718309	ENSG00000273142.1	RP11-458F8.4	7.25	1.76e-12	6.69e-10	0.36	0.32	Diabetic kidney disease;	chr7:66162777	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs6460274	ENSG00000273142.1	RP11-458F8.4	7.25	1.76e-12	6.69e-10	0.36	0.32	Diabetic kidney disease;	chr7:66163497	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs7787230	ENSG00000273142.1	RP11-458F8.4	7.25	1.76e-12	6.69e-10	0.36	0.32	Diabetic kidney disease;	chr7:66164112	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs316318	ENSG00000273142.1	RP11-458F8.4	-7.25	1.76e-12	6.69e-10	-0.36	-0.32	Diabetic kidney disease;	chr7:66147917	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs316317	ENSG00000273142.1	RP11-458F8.4	-7.25	1.76e-12	6.69e-10	-0.36	-0.32	Diabetic kidney disease;	chr7:66148650	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs316304	ENSG00000273142.1	RP11-458F8.4	-7.25	1.76e-12	6.69e-10	-0.36	-0.32	Diabetic kidney disease;	chr7:66151907	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs2465120	ENSG00000273142.1	RP11-458F8.4	-7.25	1.76e-12	6.69e-10	-0.36	-0.32	Diabetic kidney disease;	chr7:66155987	chr7:66902857~66906297:+
PRAD	cis	rs853679	0.55	rs1233704	ENSG00000204709.4	LINC01556	-7.25	1.77e-12	6.7e-10	-0.43	-0.32	Depression;	chr6:28199145	chr6:28943877~28944537:+
PRAD	cis	rs6782228	0.527	rs2811491	ENSG00000242551.2	POU5F1P6	-7.25	1.77e-12	6.71e-10	-0.4	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128635107	chr3:128674735~128677005:-
PRAD	cis	rs964611	0.882	rs16960809	ENSG00000259488.2	RP11-154J22.1	7.25	1.77e-12	6.71e-10	0.33	0.32	Metabolite levels (Pyroglutamine);	chr15:48354318	chr15:48312353~48331856:-
PRAD	cis	rs12922040	0.651	rs35288467	ENSG00000263335.1	AF001548.5	-7.25	1.77e-12	6.72e-10	-0.35	-0.32	Serum uric acid levels in response to allopurinol in gout;	chr16:15773097	chr16:15726674~15732993:+
PRAD	cis	rs2115630	0.875	rs8039472	ENSG00000225151.9	GOLGA2P7	7.25	1.77e-12	6.72e-10	0.42	0.32	P wave terminal force;	chr15:84818413	chr15:84199311~84230136:-
PRAD	cis	rs10875746	0.669	rs10783244	ENSG00000240399.1	RP1-228P16.1	-7.25	1.78e-12	6.74e-10	-0.3	-0.32	Longevity (90 years and older);	chr12:48271206	chr12:48054813~48055591:-
PRAD	cis	rs11846409	0.932	rs73378158	ENSG00000274576.2	IGHV2-70	-7.25	1.78e-12	6.74e-10	-0.32	-0.32	Rheumatic heart disease;	chr14:106638433	chr14:106770577~106771020:-
PRAD	cis	rs875971	0.638	rs6460305	ENSG00000237310.1	GS1-124K5.4	-7.25	1.78e-12	6.74e-10	-0.28	-0.32	Aortic root size;	chr7:66595421	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.66	rs10272357	ENSG00000237310.1	GS1-124K5.4	-7.25	1.78e-12	6.74e-10	-0.28	-0.32	Aortic root size;	chr7:66598087	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.66	rs1860470	ENSG00000237310.1	GS1-124K5.4	-7.25	1.78e-12	6.75e-10	-0.28	-0.32	Aortic root size;	chr7:66638707	chr7:66493706~66495474:+
PRAD	cis	rs4713118	0.824	rs9468223	ENSG00000226314.6	ZNF192P1	-7.25	1.78e-12	6.75e-10	-0.43	-0.32	Parkinson's disease;	chr6:27772887	chr6:28161781~28169594:+
PRAD	cis	rs2274273	0.686	rs2296489	ENSG00000258413.1	RP11-665C16.6	-7.25	1.78e-12	6.76e-10	-0.45	-0.32	Protein biomarker;	chr14:55158259	chr14:55262767~55272075:-
PRAD	cis	rs2243480	0.711	rs2460426	ENSG00000273142.1	RP11-458F8.4	7.25	1.78e-12	6.76e-10	0.36	0.32	Diabetic kidney disease;	chr7:66158142	chr7:66902857~66906297:+
PRAD	cis	rs11098499	1	rs58601355	ENSG00000245958.5	RP11-33B1.1	-7.25	1.78e-12	6.76e-10	-0.32	-0.32	Corneal astigmatism;	chr4:119265212	chr4:119454791~119552025:+
PRAD	cis	rs7746199	0.736	rs13212093	ENSG00000226314.6	ZNF192P1	-7.25	1.78e-12	6.76e-10	-0.68	-0.32	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27638937	chr6:28161781~28169594:+
PRAD	cis	rs875971	0.66	rs3764903	ENSG00000237310.1	GS1-124K5.4	-7.25	1.79e-12	6.77e-10	-0.28	-0.32	Aortic root size;	chr7:66633495	chr7:66493706~66495474:+
PRAD	cis	rs4664293	1	rs6432540	ENSG00000226266.5	AC009961.3	-7.25	1.79e-12	6.77e-10	-0.42	-0.32	Monocyte percentage of white cells;	chr2:159594192	chr2:159670708~159712435:-
PRAD	cis	rs848490	0.674	rs4727461	ENSG00000214293.7	APTR	7.25	1.79e-12	6.77e-10	0.33	0.32	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77691071	chr7:77657660~77696265:-
PRAD	cis	rs6951245	0.554	rs11544331	ENSG00000229043.2	AC091729.9	-7.25	1.79e-12	6.77e-10	-0.46	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1091775	chr7:1160374~1165267:+
PRAD	cis	rs8062405	0.54	rs480400	ENSG00000259982.1	CDC37P1	7.25	1.79e-12	6.78e-10	0.41	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28563294	chr16:28700294~28701540:-
PRAD	cis	rs2638953	0.707	rs11049711	ENSG00000278733.1	RP11-425D17.1	-7.25	1.79e-12	6.79e-10	-0.39	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28553171	chr12:28185625~28186190:-
PRAD	cis	rs7746199	0.736	rs35848276	ENSG00000226314.6	ZNF192P1	-7.25	1.79e-12	6.79e-10	-0.69	-0.32	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27553317	chr6:28161781~28169594:+
PRAD	cis	rs4845570	1	rs3811415	ENSG00000268288.1	RP11-98D18.16	7.25	1.79e-12	6.79e-10	0.53	0.32	Coronary artery disease;	chr1:151791291	chr1:151766486~151767000:-
PRAD	cis	rs11846409	0.872	rs2956482	ENSG00000274576.2	IGHV2-70	7.25	1.79e-12	6.8e-10	0.34	0.32	Rheumatic heart disease;	chr14:106630013	chr14:106770577~106771020:-
PRAD	cis	rs8062405	0.755	rs17707300	ENSG00000251417.2	RP11-1348G14.4	-7.25	1.8e-12	6.81e-10	-0.35	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582026	chr16:28802743~28817828:+
PRAD	cis	rs3096299	0.9	rs744327	ENSG00000261118.1	RP11-104N10.1	7.25	1.8e-12	6.82e-10	0.31	0.32	Multiple myeloma (IgH translocation);	chr16:89372862	chr16:89492017~89504460:-
PRAD	cis	rs995000	0.899	rs1002687	ENSG00000235545.1	RP11-230B22.1	-7.25	1.8e-12	6.82e-10	-0.42	-0.32	Triglyceride levels;	chr1:62498066	chr1:62688482~62710694:+
PRAD	cis	rs1799949	1	rs4793197	ENSG00000267002.1	RP11-242D8.1	7.25	1.8e-12	6.84e-10	0.3	0.32	Menopause (age at onset);	chr17:43079885	chr17:43164183~43170403:-
PRAD	cis	rs853679	0.607	rs68188794	ENSG00000280107.1	AL022393.9	-7.25	1.8e-12	6.84e-10	-0.68	-0.32	Depression;	chr6:28112999	chr6:28170845~28172521:+
PRAD	cis	rs995000	0.899	rs11207976	ENSG00000235545.1	RP11-230B22.1	7.25	1.81e-12	6.86e-10	0.42	0.32	Triglyceride levels;	chr1:62511080	chr1:62688482~62710694:+
PRAD	cis	rs4842666	0.915	rs12579302	ENSG00000258302.2	RP11-981P6.1	-7.25	1.82e-12	6.88e-10	-0.39	-0.32	Blood pressure;	chr12:89656726	chr12:89561129~89594878:+
PRAD	cis	rs11846409	0.521	rs10143547	ENSG00000274576.2	IGHV2-70	-7.25	1.82e-12	6.89e-10	-0.34	-0.32	Rheumatic heart disease;	chr14:106644638	chr14:106770577~106771020:-
PRAD	cis	rs4713118	0.513	rs149962	ENSG00000220721.1	OR1F12	7.25	1.82e-12	6.91e-10	0.37	0.32	Parkinson's disease;	chr6:28048140	chr6:28073316~28074233:+
PRAD	cis	rs8062405	0.723	rs762633	ENSG00000251417.2	RP11-1348G14.4	-7.25	1.82e-12	6.91e-10	-0.36	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597020	chr16:28802743~28817828:+
PRAD	cis	rs2439831	0.681	rs28578454	ENSG00000249839.1	AC011330.5	-7.25	1.82e-12	6.91e-10	-0.52	-0.32	Lung cancer in ever smokers;	chr15:43310834	chr15:43663654~43684339:-
PRAD	cis	rs2638953	0.924	rs11049416	ENSG00000247934.4	RP11-967K21.1	7.25	1.82e-12	6.91e-10	0.34	0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28190305	chr12:28163298~28190738:-
PRAD	cis	rs9467773	1	rs4871	ENSG00000124549.13	BTN2A3P	7.25	1.83e-12	6.94e-10	0.28	0.32	Intelligence (multi-trait analysis);	chr6:26545404	chr6:26421391~26432383:+
PRAD	cis	rs1799949	0.536	rs4793227	ENSG00000267002.1	RP11-242D8.1	7.25	1.83e-12	6.94e-10	0.3	0.32	Menopause (age at onset);	chr17:43334882	chr17:43164183~43170403:-
PRAD	cis	rs10463554	0.856	rs257292	ENSG00000175749.11	EIF3KP1	7.25	1.83e-12	6.95e-10	0.4	0.32	Parkinson's disease;	chr5:103159047	chr5:103032376~103033031:+
PRAD	cis	rs270601	0.71	rs371709	ENSG00000233006.5	AC034220.3	7.25	1.84e-12	6.95e-10	0.28	0.32	Acylcarnitine levels;	chr5:132247547	chr5:132311285~132369916:-
PRAD	cis	rs8177376	0.727	rs240555	ENSG00000254905.1	RP11-712L6.7	7.25	1.84e-12	6.96e-10	0.38	0.32	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126332190	chr11:126292922~126294254:-
PRAD	cis	rs73186030	0.764	rs2332179	ENSG00000272758.4	RP11-299J3.8	7.25	1.84e-12	6.98e-10	0.46	0.32	Serum parathyroid hormone levels;	chr3:122360583	chr3:122416207~122443180:+
PRAD	cis	rs7569084	1	rs7583469	ENSG00000204929.10	AC074391.1	7.25	1.84e-12	6.98e-10	0.43	0.32	Sum eosinophil basophil counts;	chr2:65424222	chr2:65436711~66084639:+
PRAD	cis	rs2274273	0.638	rs67416413	ENSG00000258413.1	RP11-665C16.6	-7.25	1.84e-12	6.98e-10	-0.45	-0.32	Protein biomarker;	chr14:55235545	chr14:55262767~55272075:-
PRAD	cis	rs2274273	0.615	rs67008693	ENSG00000258413.1	RP11-665C16.6	-7.25	1.84e-12	6.98e-10	-0.45	-0.32	Protein biomarker;	chr14:55235975	chr14:55262767~55272075:-
PRAD	cis	rs2274273	0.638	rs17672364	ENSG00000258413.1	RP11-665C16.6	-7.25	1.84e-12	6.98e-10	-0.45	-0.32	Protein biomarker;	chr14:55239186	chr14:55262767~55272075:-
PRAD	cis	rs8005677	0.828	rs2295682	ENSG00000257285.4	RP11-298I3.1	7.25	1.84e-12	6.98e-10	0.32	0.32	Cognitive ability (multi-trait analysis);	chr14:22905653	chr14:22929609~22955562:+
PRAD	cis	rs6479891	0.915	rs16918601	ENSG00000232075.1	MRPL35P2	7.25	1.84e-12	6.98e-10	0.51	0.32	Arthritis (juvenile idiopathic);	chr10:63561291	chr10:63634317~63634827:-
PRAD	cis	rs2638953	0.924	rs10843125	ENSG00000247934.4	RP11-967K21.1	-7.25	1.85e-12	6.99e-10	-0.33	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28198308	chr12:28163298~28190738:-
PRAD	cis	rs35264875	0.95	rs35337391	ENSG00000259799.1	RP11-554A11.9	7.25	1.85e-12	7.01e-10	0.43	0.32	Blond vs. brown hair color;	chr11:69086544	chr11:69155910~69159752:+
PRAD	cis	rs6479901	0.841	rs7913332	ENSG00000232075.1	MRPL35P2	-7.25	1.85e-12	7.01e-10	-0.39	-0.32	Intelligence (multi-trait analysis);	chr10:63293890	chr10:63634317~63634827:-
PRAD	cis	rs6479901	0.895	rs7093899	ENSG00000232075.1	MRPL35P2	-7.25	1.85e-12	7.01e-10	-0.39	-0.32	Intelligence (multi-trait analysis);	chr10:63294576	chr10:63634317~63634827:-
PRAD	cis	rs7487075	0.78	rs12307969	ENSG00000274723.1	RP11-618L22.1	7.25	1.85e-12	7.02e-10	0.37	0.32	Itch intensity from mosquito bite;	chr12:46365274	chr12:46970504~46972155:+
PRAD	cis	rs4664293	0.867	rs2059698	ENSG00000226266.5	AC009961.3	7.25	1.86e-12	7.03e-10	0.44	0.32	Monocyte percentage of white cells;	chr2:159785905	chr2:159670708~159712435:-
PRAD	cis	rs934734	0.673	rs7575614	ENSG00000204929.10	AC074391.1	7.25	1.86e-12	7.03e-10	0.4	0.32	Rheumatoid arthritis;	chr2:65462666	chr2:65436711~66084639:+
PRAD	cis	rs1707322	0.721	rs6699418	ENSG00000280836.1	AL355480.1	-7.25	1.86e-12	7.03e-10	-0.4	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634509	chr1:45581219~45581321:-
PRAD	cis	rs1707322	0.721	rs4431884	ENSG00000280836.1	AL355480.1	-7.25	1.86e-12	7.03e-10	-0.4	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45635651	chr1:45581219~45581321:-
PRAD	cis	rs1707322	0.65	rs4660879	ENSG00000280836.1	AL355480.1	-7.25	1.86e-12	7.03e-10	-0.4	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45639729	chr1:45581219~45581321:-
PRAD	cis	rs12534093	0.602	rs11765452	ENSG00000234286.1	AC006026.13	-7.24	1.87e-12	7.06e-10	-0.37	-0.32	Infant length;Height;	chr7:23542936	chr7:23680195~23680786:-
PRAD	cis	rs1799949	1	rs4793194	ENSG00000267002.1	RP11-242D8.1	7.24	1.87e-12	7.06e-10	0.3	0.32	Menopause (age at onset);	chr17:43066316	chr17:43164183~43170403:-
PRAD	cis	rs42648	0.869	rs10234301	ENSG00000227646.6	STEAP2-AS1	-7.24	1.87e-12	7.07e-10	-0.29	-0.32	Homocysteine levels;	chr7:90288964	chr7:89882353~90211635:-
PRAD	cis	rs42648	0.869	rs6973816	ENSG00000227646.6	STEAP2-AS1	-7.24	1.87e-12	7.07e-10	-0.29	-0.32	Homocysteine levels;	chr7:90291758	chr7:89882353~90211635:-
PRAD	cis	rs42648	0.837	rs4728879	ENSG00000227646.6	STEAP2-AS1	-7.24	1.87e-12	7.07e-10	-0.29	-0.32	Homocysteine levels;	chr7:90294923	chr7:89882353~90211635:-
PRAD	cis	rs853679	0.546	rs13195291	ENSG00000280107.1	AL022393.9	-7.24	1.87e-12	7.08e-10	-0.65	-0.32	Depression;	chr6:28201463	chr6:28170845~28172521:+
PRAD	cis	rs2243480	1	rs7456042	ENSG00000226824.5	RP4-756H11.3	-7.24	1.88e-12	7.1e-10	-0.62	-0.32	Diabetic kidney disease;	chr7:65834791	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs34703416	ENSG00000226824.5	RP4-756H11.3	-7.24	1.88e-12	7.1e-10	-0.62	-0.32	Diabetic kidney disease;	chr7:65835655	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs73142121	ENSG00000226824.5	RP4-756H11.3	-7.24	1.88e-12	7.1e-10	-0.62	-0.32	Diabetic kidney disease;	chr7:65846219	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs34702770	ENSG00000226824.5	RP4-756H11.3	-7.24	1.88e-12	7.1e-10	-0.62	-0.32	Diabetic kidney disease;	chr7:65879836	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs34637256	ENSG00000226824.5	RP4-756H11.3	-7.24	1.88e-12	7.1e-10	-0.62	-0.32	Diabetic kidney disease;	chr7:65895144	chr7:66654538~66669855:+
PRAD	cis	rs7428	0.527	rs7608892	ENSG00000246575.2	AC093162.5	7.24	1.88e-12	7.11e-10	0.24	0.32	Ear protrusion;	chr2:85315595	chr2:85315041~85316529:+
PRAD	cis	rs71386933	0.509	rs34400689	ENSG00000260886.1	TAT-AS1	7.24	1.88e-12	7.11e-10	0.58	0.32	Post bronchodilator FEV1;	chr16:71969555	chr16:71565789~71578187:+
PRAD	cis	rs11098499	0.604	rs17051352	ENSG00000245958.5	RP11-33B1.1	-7.24	1.88e-12	7.12e-10	-0.34	-0.32	Corneal astigmatism;	chr4:119660272	chr4:119454791~119552025:+
PRAD	cis	rs526231	0.578	rs59323174	ENSG00000175749.11	EIF3KP1	7.24	1.88e-12	7.12e-10	0.43	0.32	Primary biliary cholangitis;	chr5:102932165	chr5:103032376~103033031:+
PRAD	cis	rs2274273	0.638	rs58269011	ENSG00000258413.1	RP11-665C16.6	-7.24	1.88e-12	7.13e-10	-0.45	-0.32	Protein biomarker;	chr14:55217670	chr14:55262767~55272075:-
PRAD	cis	rs143626010	1	rs143626010	ENSG00000251417.2	RP11-1348G14.4	-7.24	1.89e-12	7.14e-10	-0.36	-0.32	Mosquito bite size;	chr16:28528081	chr16:28802743~28817828:+
PRAD	cis	rs2067615	0.56	rs10431462	ENSG00000260329.1	RP11-412D9.4	-7.24	1.89e-12	7.15e-10	-0.27	-0.32	Heart rate;	chr12:106712768	chr12:106954029~106955497:-
PRAD	cis	rs1061377	0.513	rs2712000	ENSG00000249207.1	RP11-360F5.1	-7.24	1.9e-12	7.18e-10	-0.38	-0.32	Uric acid levels;	chr4:39135462	chr4:39112677~39126818:-
PRAD	cis	rs2115630	0.875	rs8039472	ENSG00000275120.1	RP11-182J1.17	-7.24	1.9e-12	7.18e-10	-0.39	-0.32	P wave terminal force;	chr15:84818413	chr15:84599434~84606463:-
PRAD	cis	rs367615	0.506	rs1428932	ENSG00000249476.1	CTD-2587M2.1	-7.24	1.9e-12	7.2e-10	-0.39	-0.32	Colorectal cancer (SNP x SNP interaction);	chr5:109456778	chr5:109237120~109326369:-
PRAD	cis	rs12612619	0.704	rs7602823	ENSG00000229122.1	AGBL5-IT1	-7.24	1.9e-12	7.2e-10	-0.34	-0.32	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27086538	chr2:27061038~27061815:+
PRAD	cis	rs9506514	0.509	rs9509294	ENSG00000222726.1	RNU2-7P	-7.24	1.91e-12	7.2e-10	-0.33	-0.32	Coronary artery calcification;	chr13:20600506	chr13:20612161~20612338:+
PRAD	cis	rs172166	0.694	rs2791332	ENSG00000204709.4	LINC01556	7.24	1.91e-12	7.22e-10	0.42	0.32	Cardiac Troponin-T levels;	chr6:28141010	chr6:28943877~28944537:+
PRAD	cis	rs7772486	0.811	rs2777475	ENSG00000235652.6	RP11-545I5.3	7.24	1.91e-12	7.22e-10	0.34	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145983467	chr6:145799409~145886585:+
PRAD	cis	rs453301	0.653	rs7005133	ENSG00000254340.1	RP11-10A14.3	7.24	1.91e-12	7.23e-10	0.39	0.32	Joint mobility (Beighton score);	chr8:9043712	chr8:9141424~9145435:+
PRAD	cis	rs853679	0.607	rs34950484	ENSG00000280107.1	AL022393.9	-7.24	1.92e-12	7.25e-10	-0.61	-0.32	Depression;	chr6:28310911	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.607	rs34661125	ENSG00000280107.1	AL022393.9	-7.24	1.92e-12	7.25e-10	-0.61	-0.32	Depression;	chr6:28314117	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.607	rs13190888	ENSG00000280107.1	AL022393.9	-7.24	1.92e-12	7.25e-10	-0.61	-0.32	Depression;	chr6:28318208	chr6:28170845~28172521:+
PRAD	cis	rs2599510	0.783	rs2568464	ENSG00000276334.1	AL133243.1	-7.24	1.92e-12	7.26e-10	-0.36	-0.32	Interleukin-18 levels;	chr2:32623591	chr2:32521927~32523547:+
PRAD	cis	rs2274273	1	rs7160110	ENSG00000258413.1	RP11-665C16.6	-7.24	1.93e-12	7.28e-10	-0.41	-0.32	Protein biomarker;	chr14:55127917	chr14:55262767~55272075:-
PRAD	cis	rs11098499	0.954	rs11722872	ENSG00000245958.5	RP11-33B1.1	-7.24	1.94e-12	7.31e-10	-0.32	-0.32	Corneal astigmatism;	chr4:119311875	chr4:119454791~119552025:+
PRAD	cis	rs17361889	0.634	rs1527210	ENSG00000224683.1	RPL36AP29	7.24	1.94e-12	7.31e-10	0.37	0.32	Pediatric bone mineral content (hip);	chr7:16236056	chr7:16208945~16209265:+
PRAD	cis	rs875971	0.558	rs4433015	ENSG00000236529.1	RP13-254B10.1	-7.24	1.94e-12	7.33e-10	-0.35	-0.32	Aortic root size;	chr7:66174736	chr7:65840212~65840596:+
PRAD	cis	rs12612619	0.732	rs722911	ENSG00000229122.1	AGBL5-IT1	7.24	1.94e-12	7.34e-10	0.33	0.32	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26988344	chr2:27061038~27061815:+
PRAD	cis	rs7429990	0.93	rs7374516	ENSG00000229759.1	MRPS18AP1	7.24	1.94e-12	7.34e-10	0.33	0.32	Educational attainment (years of education);	chr3:47961150	chr3:48256350~48256938:-
PRAD	cis	rs2439831	0.85	rs3816792	ENSG00000205771.5	CATSPER2P1	7.24	1.94e-12	7.34e-10	0.49	0.32	Lung cancer in ever smokers;	chr15:43824788	chr15:43726918~43747094:-
PRAD	cis	rs2638953	0.924	rs11049455	ENSG00000247934.4	RP11-967K21.1	-7.24	1.94e-12	7.34e-10	-0.33	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28204758	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.924	rs11049457	ENSG00000247934.4	RP11-967K21.1	-7.24	1.94e-12	7.34e-10	-0.33	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28205050	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.886	rs10843131	ENSG00000247934.4	RP11-967K21.1	-7.24	1.94e-12	7.34e-10	-0.33	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28205259	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.924	rs10843132	ENSG00000247934.4	RP11-967K21.1	-7.24	1.94e-12	7.34e-10	-0.33	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28205348	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.924	rs10843133	ENSG00000247934.4	RP11-967K21.1	-7.24	1.94e-12	7.34e-10	-0.33	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28205571	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.924	rs10843135	ENSG00000247934.4	RP11-967K21.1	-7.24	1.94e-12	7.34e-10	-0.33	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28205809	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.886	rs11049458	ENSG00000247934.4	RP11-967K21.1	-7.24	1.94e-12	7.34e-10	-0.33	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28205834	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.924	rs11049459	ENSG00000247934.4	RP11-967K21.1	-7.24	1.94e-12	7.34e-10	-0.33	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28206011	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.924	rs11049460	ENSG00000247934.4	RP11-967K21.1	-7.24	1.94e-12	7.34e-10	-0.33	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28206021	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.924	rs1824767	ENSG00000247934.4	RP11-967K21.1	-7.24	1.94e-12	7.34e-10	-0.33	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28206653	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.924	rs1824766	ENSG00000247934.4	RP11-967K21.1	-7.24	1.94e-12	7.34e-10	-0.33	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28206655	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.924	rs1585682	ENSG00000247934.4	RP11-967K21.1	-7.24	1.94e-12	7.34e-10	-0.33	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28206841	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.888	rs9645745	ENSG00000247934.4	RP11-967K21.1	-7.24	1.94e-12	7.34e-10	-0.33	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28207082	chr12:28163298~28190738:-
PRAD	cis	rs7131987	0.621	rs6487805	ENSG00000275476.1	RP11-996F15.4	7.24	1.95e-12	7.35e-10	0.34	0.32	QT interval;	chr12:29304617	chr12:29277397~29277882:-
PRAD	cis	rs2638953	0.924	rs11049620	ENSG00000278733.1	RP11-425D17.1	-7.24	1.95e-12	7.35e-10	-0.4	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28454698	chr12:28185625~28186190:-
PRAD	cis	rs6452524	0.839	rs28745307	ENSG00000249664.1	CTD-2227C6.2	7.24	1.95e-12	7.37e-10	0.39	0.32	Hypertension (SNP x SNP interaction);	chr5:83122099	chr5:83012285~83013109:-
PRAD	cis	rs6452524	0.746	rs28745311	ENSG00000249664.1	CTD-2227C6.2	7.24	1.95e-12	7.37e-10	0.39	0.32	Hypertension (SNP x SNP interaction);	chr5:83123030	chr5:83012285~83013109:-
PRAD	cis	rs9467773	1	rs6456733	ENSG00000124549.13	BTN2A3P	7.24	1.96e-12	7.38e-10	0.28	0.32	Intelligence (multi-trait analysis);	chr6:26566576	chr6:26421391~26432383:+
PRAD	cis	rs9467773	1	rs6456734	ENSG00000124549.13	BTN2A3P	7.24	1.96e-12	7.38e-10	0.28	0.32	Intelligence (multi-trait analysis);	chr6:26566737	chr6:26421391~26432383:+
PRAD	cis	rs9467773	1	rs1535277	ENSG00000124549.13	BTN2A3P	7.24	1.96e-12	7.38e-10	0.28	0.32	Intelligence (multi-trait analysis);	chr6:26567574	chr6:26421391~26432383:+
PRAD	cis	rs9467773	1	rs1884948	ENSG00000124549.13	BTN2A3P	7.24	1.96e-12	7.38e-10	0.28	0.32	Intelligence (multi-trait analysis);	chr6:26567760	chr6:26421391~26432383:+
PRAD	cis	rs9467773	1	rs1884949	ENSG00000124549.13	BTN2A3P	7.24	1.96e-12	7.38e-10	0.28	0.32	Intelligence (multi-trait analysis);	chr6:26567839	chr6:26421391~26432383:+
PRAD	cis	rs9467773	1	rs9467796	ENSG00000124549.13	BTN2A3P	7.24	1.96e-12	7.38e-10	0.28	0.32	Intelligence (multi-trait analysis);	chr6:26568183	chr6:26421391~26432383:+
PRAD	cis	rs9467773	1	rs9467797	ENSG00000124549.13	BTN2A3P	7.24	1.96e-12	7.38e-10	0.28	0.32	Intelligence (multi-trait analysis);	chr6:26568245	chr6:26421391~26432383:+
PRAD	cis	rs9467773	1	rs1078679	ENSG00000124549.13	BTN2A3P	7.24	1.96e-12	7.38e-10	0.28	0.32	Intelligence (multi-trait analysis);	chr6:26568513	chr6:26421391~26432383:+
PRAD	cis	rs1185460	0.546	rs474201	ENSG00000271751.1	RP11-110I1.14	-7.24	1.96e-12	7.4e-10	-0.44	-0.32	Coronary artery disease;	chr11:119087519	chr11:119065263~119065677:-
PRAD	cis	rs17772222	1	rs7145588	ENSG00000258983.2	RP11-507K2.2	7.24	1.96e-12	7.4e-10	0.46	0.32	Coronary artery calcification;	chr14:88360452	chr14:88499334~88515502:+
PRAD	cis	rs17772222	1	rs61977049	ENSG00000258983.2	RP11-507K2.2	7.24	1.96e-12	7.4e-10	0.46	0.32	Coronary artery calcification;	chr14:88360656	chr14:88499334~88515502:+
PRAD	cis	rs17772222	1	rs12587386	ENSG00000258983.2	RP11-507K2.2	7.24	1.96e-12	7.4e-10	0.46	0.32	Coronary artery calcification;	chr14:88361420	chr14:88499334~88515502:+
PRAD	cis	rs4713118	0.513	rs156738	ENSG00000220721.1	OR1F12	7.24	1.96e-12	7.4e-10	0.37	0.32	Parkinson's disease;	chr6:28046247	chr6:28073316~28074233:+
PRAD	cis	rs2255336	0.671	rs7301582	ENSG00000245648.1	RP11-277P12.20	-7.24	1.96e-12	7.41e-10	-0.43	-0.32	Blood protein levels;	chr12:10449091	chr12:10363769~10398506:+
PRAD	cis	rs1799949	1	rs8176145	ENSG00000267002.1	RP11-242D8.1	7.24	1.96e-12	7.41e-10	0.3	0.32	Menopause (age at onset);	chr17:43097077	chr17:43164183~43170403:-
PRAD	cis	rs1799949	0.965	rs8176140	ENSG00000267002.1	RP11-242D8.1	7.24	1.96e-12	7.41e-10	0.3	0.32	Menopause (age at onset);	chr17:43099629	chr17:43164183~43170403:-
PRAD	cis	rs4842666	0.915	rs111478946	ENSG00000258302.2	RP11-981P6.1	7.24	1.97e-12	7.43e-10	0.39	0.32	Blood pressure;	chr12:89665065	chr12:89561129~89594878:+
PRAD	cis	rs516805	0.59	rs13371	ENSG00000279453.1	RP3-425C14.4	-7.24	1.97e-12	7.44e-10	-0.29	-0.32	Lymphocyte counts;	chr6:122443881	chr6:122436789~122439223:-
PRAD	cis	rs75422866	0.51	rs75424057	ENSG00000257433.4	RP1-197B17.3	7.24	1.97e-12	7.44e-10	0.67	0.32	Pneumonia;	chr12:47737294	chr12:47706085~47742294:+
PRAD	cis	rs9467773	0.935	rs1056668	ENSG00000124549.13	BTN2A3P	7.24	1.98e-12	7.45e-10	0.29	0.32	Intelligence (multi-trait analysis);	chr6:26510377	chr6:26421391~26432383:+
PRAD	cis	rs17772222	1	rs17772064	ENSG00000258983.2	RP11-507K2.2	7.24	1.98e-12	7.46e-10	0.46	0.32	Coronary artery calcification;	chr14:88356527	chr14:88499334~88515502:+
PRAD	cis	rs1061377	0.513	rs6840214	ENSG00000249207.1	RP11-360F5.1	7.24	1.98e-12	7.47e-10	0.38	0.32	Uric acid levels;	chr4:39118999	chr4:39112677~39126818:-
PRAD	cis	rs1799949	0.965	rs799916	ENSG00000267002.1	RP11-242D8.1	-7.24	1.98e-12	7.48e-10	-0.3	-0.32	Menopause (age at onset);	chr17:43091173	chr17:43164183~43170403:-
PRAD	cis	rs6844153	0.941	rs75656258	ENSG00000240005.4	RP11-293A21.1	-7.24	1.98e-12	7.49e-10	-0.45	-0.32	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26843577	chr4:26859806~26860599:-
PRAD	cis	rs9543976	0.925	rs2876706	ENSG00000261553.4	RP11-29G8.3	7.24	1.99e-12	7.49e-10	0.51	0.32	Diabetic retinopathy;	chr13:75612169	chr13:75549773~75807120:+
PRAD	cis	rs2243480	0.803	rs35480979	ENSG00000226824.5	RP4-756H11.3	-7.24	1.99e-12	7.49e-10	-0.62	-0.32	Diabetic kidney disease;	chr7:65892097	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs35391607	ENSG00000226824.5	RP4-756H11.3	-7.24	1.99e-12	7.49e-10	-0.62	-0.32	Diabetic kidney disease;	chr7:65895842	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs13220979	ENSG00000226824.5	RP4-756H11.3	-7.24	1.99e-12	7.49e-10	-0.62	-0.32	Diabetic kidney disease;	chr7:65898217	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs34974928	ENSG00000226824.5	RP4-756H11.3	-7.24	1.99e-12	7.49e-10	-0.62	-0.32	Diabetic kidney disease;	chr7:65899019	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs67728539	ENSG00000226824.5	RP4-756H11.3	-7.24	1.99e-12	7.49e-10	-0.62	-0.32	Diabetic kidney disease;	chr7:65913137	chr7:66654538~66669855:+
PRAD	cis	rs9467773	1	rs6932156	ENSG00000124549.13	BTN2A3P	7.24	1.99e-12	7.5e-10	0.28	0.32	Intelligence (multi-trait analysis);	chr6:26571278	chr6:26421391~26432383:+
PRAD	cis	rs9467773	1	rs6924838	ENSG00000124549.13	BTN2A3P	7.24	1.99e-12	7.5e-10	0.28	0.32	Intelligence (multi-trait analysis);	chr6:26571528	chr6:26421391~26432383:+
PRAD	cis	rs2638953	0.924	rs7957056	ENSG00000247934.4	RP11-967K21.1	-7.24	1.99e-12	7.51e-10	-0.32	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28203382	chr12:28163298~28190738:-
PRAD	cis	rs55665837	1	rs10832276	ENSG00000251991.1	RNU7-49P	7.24	1.99e-12	7.51e-10	0.34	0.32	Vitamin D levels;	chr11:14461728	chr11:14478892~14478953:+
PRAD	cis	rs4664293	0.769	rs10171236	ENSG00000226266.5	AC009961.3	-7.23	1.99e-12	7.51e-10	-0.43	-0.32	Monocyte percentage of white cells;	chr2:159729752	chr2:159670708~159712435:-
PRAD	cis	rs9400467	0.528	rs457492	ENSG00000271789.1	RP5-1112D6.7	-7.23	1.99e-12	7.51e-10	-0.36	-0.32	Amino acid levels;Blood metabolite levels;	chr6:111320647	chr6:111297126~111298510:+
PRAD	cis	rs8005677	0.828	rs8016027	ENSG00000257285.4	RP11-298I3.1	7.23	1.99e-12	7.52e-10	0.32	0.32	Cognitive ability (multi-trait analysis);	chr14:22950944	chr14:22929609~22955562:+
PRAD	cis	rs2617170	0.961	rs1841958	ENSG00000245648.1	RP11-277P12.20	7.23	2e-12	7.53e-10	0.39	0.32	Behcet's disease;	chr12:10409490	chr12:10363769~10398506:+
PRAD	cis	rs2739330	0.796	rs1006771	ENSG00000206090.4	AP000350.7	7.23	2e-12	7.55e-10	0.4	0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23939998~23942798:+
PRAD	cis	rs8062405	0.755	rs111693583	ENSG00000251417.2	RP11-1348G14.4	-7.23	2.01e-12	7.57e-10	-0.36	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28572289	chr16:28802743~28817828:+
PRAD	cis	rs1075232	0.826	rs12437800	ENSG00000215302.7	CTD-3092A11.1	-7.23	2.01e-12	7.57e-10	-0.73	-0.32	Survival in colorectal cancer (non-distant metastatic);	chr15:31379229	chr15:30470779~30507623:+
PRAD	cis	rs964611	0.882	rs12148465	ENSG00000259488.2	RP11-154J22.1	7.23	2.01e-12	7.58e-10	0.31	0.32	Metabolite levels (Pyroglutamine);	chr15:48368261	chr15:48312353~48331856:-
PRAD	cis	rs8062405	0.755	rs4149398	ENSG00000251417.2	RP11-1348G14.4	-7.23	2.01e-12	7.58e-10	-0.36	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597617	chr16:28802743~28817828:+
PRAD	cis	rs7746199	0.736	rs13202291	ENSG00000226314.6	ZNF192P1	-7.23	2.01e-12	7.59e-10	-0.68	-0.32	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731078	chr6:28161781~28169594:+
PRAD	cis	rs7746199	0.736	rs17750424	ENSG00000226314.6	ZNF192P1	-7.23	2.01e-12	7.59e-10	-0.68	-0.32	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27733343	chr6:28161781~28169594:+
PRAD	cis	rs7746199	0.736	rs13193542	ENSG00000226314.6	ZNF192P1	-7.23	2.01e-12	7.59e-10	-0.68	-0.32	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27734646	chr6:28161781~28169594:+
PRAD	cis	rs7746199	0.736	rs13193480	ENSG00000226314.6	ZNF192P1	-7.23	2.01e-12	7.59e-10	-0.68	-0.32	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27734782	chr6:28161781~28169594:+
PRAD	cis	rs7746199	0.673	rs72847313	ENSG00000226314.6	ZNF192P1	-7.23	2.01e-12	7.59e-10	-0.68	-0.32	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27762303	chr6:28161781~28169594:+
PRAD	cis	rs7746199	0.611	rs17750747	ENSG00000226314.6	ZNF192P1	-7.23	2.01e-12	7.59e-10	-0.68	-0.32	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27762555	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.556	rs13197633	ENSG00000280107.1	AL022393.9	-7.23	2.02e-12	7.61e-10	-0.65	-0.32	Depression;	chr6:28206979	chr6:28170845~28172521:+
PRAD	cis	rs17711722	0.522	rs6957759	ENSG00000234585.5	CCT6P3	7.23	2.02e-12	7.61e-10	0.25	0.32	Calcium levels;	chr7:65806798	chr7:65038354~65074713:+
PRAD	cis	rs1979679	0.686	rs4348940	ENSG00000278733.1	RP11-425D17.1	-7.23	2.02e-12	7.62e-10	-0.45	-0.32	Ossification of the posterior longitudinal ligament of the spine;	chr12:28437804	chr12:28185625~28186190:-
PRAD	cis	rs853679	0.599	rs13193295	ENSG00000280107.1	AL022393.9	-7.23	2.02e-12	7.63e-10	-0.66	-0.32	Depression;	chr6:28035450	chr6:28170845~28172521:+
PRAD	cis	rs1962636	1	rs1962636	ENSG00000260306.1	RP11-645C24.5	-7.23	2.03e-12	7.64e-10	-0.34	-0.32	Schizophrenia;	chr16:22053074	chr16:21794095~21795759:-
PRAD	cis	rs875971	0.545	rs6969224	ENSG00000226824.5	RP4-756H11.3	-7.23	2.03e-12	7.65e-10	-0.48	-0.32	Aortic root size;	chr7:66370011	chr7:66654538~66669855:+
PRAD	cis	rs867371	0.82	rs7164362	ENSG00000278603.1	RP13-608F4.5	7.23	2.03e-12	7.66e-10	0.43	0.32	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82194401	chr15:82472203~82472426:+
PRAD	cis	rs2243480	1	rs34815098	ENSG00000226824.5	RP4-756H11.3	-7.23	2.03e-12	7.66e-10	-0.62	-0.32	Diabetic kidney disease;	chr7:65827267	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs4548056	ENSG00000226824.5	RP4-756H11.3	-7.23	2.03e-12	7.66e-10	-0.62	-0.32	Diabetic kidney disease;	chr7:65833886	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs35735127	ENSG00000226824.5	RP4-756H11.3	-7.23	2.03e-12	7.66e-10	-0.62	-0.32	Diabetic kidney disease;	chr7:65835436	chr7:66654538~66669855:+
PRAD	cis	rs2243480	0.901	rs35256305	ENSG00000226824.5	RP4-756H11.3	-7.23	2.03e-12	7.66e-10	-0.62	-0.32	Diabetic kidney disease;	chr7:65841418	chr7:66654538~66669855:+
PRAD	cis	rs2243480	0.803	rs34004500	ENSG00000226824.5	RP4-756H11.3	-7.23	2.03e-12	7.66e-10	-0.62	-0.32	Diabetic kidney disease;	chr7:65847191	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs35825738	ENSG00000226824.5	RP4-756H11.3	-7.23	2.03e-12	7.66e-10	-0.62	-0.32	Diabetic kidney disease;	chr7:65853040	chr7:66654538~66669855:+
PRAD	cis	rs1979679	0.766	rs10843197	ENSG00000278733.1	RP11-425D17.1	-7.23	2.03e-12	7.66e-10	-0.42	-0.32	Ossification of the posterior longitudinal ligament of the spine;	chr12:28518308	chr12:28185625~28186190:-
PRAD	cis	rs1799949	1	rs16940	ENSG00000267002.1	RP11-242D8.1	7.23	2.04e-12	7.67e-10	0.31	0.32	Menopause (age at onset);	chr17:43093220	chr17:43164183~43170403:-
PRAD	cis	rs10050311	0.858	rs76283582	ENSG00000251411.1	RP11-397E7.4	-7.23	2.04e-12	7.68e-10	-0.4	-0.32	Insulin-related traits;	chr4:86878202	chr4:86913266~86914817:-
PRAD	cis	rs10206020	0.842	rs7609325	ENSG00000231482.2	AC141930.2	-7.23	2.04e-12	7.68e-10	-0.37	-0.32	IgG glycosylation;	chr2:1570946	chr2:1572554~1580311:-
PRAD	cis	rs10206020	0.842	rs7590900	ENSG00000231482.2	AC141930.2	-7.23	2.04e-12	7.68e-10	-0.37	-0.32	IgG glycosylation;	chr2:1571130	chr2:1572554~1580311:-
PRAD	cis	rs78456975	0.527	rs7590743	ENSG00000231482.2	AC141930.2	-7.23	2.04e-12	7.68e-10	-0.37	-0.32	Placebo response in major depressive disorder (% change in symptom score);	chr2:1571276	chr2:1572554~1580311:-
PRAD	cis	rs78456975	0.527	rs7590742	ENSG00000231482.2	AC141930.2	-7.23	2.04e-12	7.68e-10	-0.37	-0.32	Placebo response in major depressive disorder (% change in symptom score);	chr2:1571277	chr2:1572554~1580311:-
PRAD	cis	rs6951245	0.638	rs4720486	ENSG00000229043.2	AC091729.9	-7.23	2.04e-12	7.69e-10	-0.45	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1107128	chr7:1160374~1165267:+
PRAD	cis	rs9467773	0.935	rs4573	ENSG00000124549.13	BTN2A3P	7.23	2.05e-12	7.7e-10	0.29	0.32	Intelligence (multi-trait analysis);	chr6:26546580	chr6:26421391~26432383:+
PRAD	cis	rs7429990	0.932	rs2166772	ENSG00000229759.1	MRPS18AP1	-7.23	2.05e-12	7.71e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:48006384	chr3:48256350~48256938:-
PRAD	cis	rs875971	0.66	rs10281080	ENSG00000237310.1	GS1-124K5.4	-7.23	2.05e-12	7.73e-10	-0.28	-0.32	Aortic root size;	chr7:66577454	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.66	rs10950044	ENSG00000237310.1	GS1-124K5.4	-7.23	2.05e-12	7.73e-10	-0.28	-0.32	Aortic root size;	chr7:66577989	chr7:66493706~66495474:+
PRAD	cis	rs4713118	0.738	rs200465	ENSG00000226314.6	ZNF192P1	-7.23	2.06e-12	7.75e-10	-0.42	-0.32	Parkinson's disease;	chr6:27789875	chr6:28161781~28169594:+
PRAD	cis	rs1799949	0.965	rs8176310	ENSG00000267002.1	RP11-242D8.1	7.23	2.06e-12	7.75e-10	0.31	0.32	Menopause (age at onset);	chr17:43047896	chr17:43164183~43170403:-
PRAD	cis	rs2638953	0.962	rs11494780	ENSG00000278733.1	RP11-425D17.1	-7.23	2.07e-12	7.78e-10	-0.4	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28402269	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.962	rs11049574	ENSG00000278733.1	RP11-425D17.1	-7.23	2.07e-12	7.78e-10	-0.4	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28406130	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.962	rs10506033	ENSG00000278733.1	RP11-425D17.1	-7.23	2.07e-12	7.78e-10	-0.4	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28415032	chr12:28185625~28186190:-
PRAD	cis	rs2676071	0.767	rs2676077	ENSG00000259446.4	RP11-489D6.2	-7.23	2.07e-12	7.79e-10	-0.44	-0.32	Periodontitis (Mean PAL);	chr15:33313100	chr15:33303657~33310659:-
PRAD	cis	rs516805	0.63	rs499825	ENSG00000279453.1	RP3-425C14.4	-7.23	2.08e-12	7.81e-10	-0.29	-0.32	Lymphocyte counts;	chr6:122454050	chr6:122436789~122439223:-
PRAD	cis	rs853679	0.769	rs7752448	ENSG00000280107.1	AL022393.9	-7.23	2.08e-12	7.82e-10	-0.52	-0.32	Depression;	chr6:28333322	chr6:28170845~28172521:+
PRAD	cis	rs881375	0.935	rs7034390	ENSG00000226752.6	PSMD5-AS1	-7.23	2.08e-12	7.82e-10	-0.38	-0.32	Rheumatoid arthritis;	chr9:120884210	chr9:120824828~120854385:+
PRAD	cis	rs11098499	0.955	rs35434465	ENSG00000245958.5	RP11-33B1.1	-7.23	2.08e-12	7.84e-10	-0.32	-0.32	Corneal astigmatism;	chr4:119248223	chr4:119454791~119552025:+
PRAD	cis	rs7727544	0.507	rs9791170	ENSG00000233006.5	AC034220.3	7.23	2.08e-12	7.84e-10	0.27	0.32	Blood metabolite levels;	chr5:132233934	chr5:132311285~132369916:-
PRAD	cis	rs2276314	1	rs4799835	ENSG00000278986.1	RP11-723J4.3	-7.23	2.09e-12	7.85e-10	-0.41	-0.32	Endometriosis;Drug-induced torsades de pointes;	chr18:35991305	chr18:35972151~35973916:+
PRAD	cis	rs11336847	1	rs11336847	ENSG00000234072.1	AC074117.10	-7.23	2.09e-12	7.87e-10	-0.25	-0.32	Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;	chr2:27526126	chr2:27356246~27367622:+
PRAD	cis	rs71636778	0.509	rs35021342	ENSG00000260063.1	RP5-968P14.2	-7.23	2.09e-12	7.88e-10	-0.64	-0.32	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26759736	chr1:26692132~26694131:-
PRAD	cis	rs71636778	0.509	rs34201939	ENSG00000260063.1	RP5-968P14.2	-7.23	2.09e-12	7.88e-10	-0.64	-0.32	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26767220	chr1:26692132~26694131:-
PRAD	cis	rs7429990	0.965	rs7649981	ENSG00000229759.1	MRPS18AP1	7.23	2.1e-12	7.89e-10	0.33	0.32	Educational attainment (years of education);	chr3:47957847	chr3:48256350~48256938:-
PRAD	cis	rs4664293	0.867	rs2114626	ENSG00000226266.5	AC009961.3	7.23	2.1e-12	7.91e-10	0.43	0.32	Monocyte percentage of white cells;	chr2:159783459	chr2:159670708~159712435:-
PRAD	cis	rs812925	0.537	rs778146	ENSG00000271889.1	RP11-493E12.1	-7.23	2.11e-12	7.93e-10	-0.35	-0.32	Immature fraction of reticulocytes;	chr2:61379340	chr2:61151433~61162105:-
PRAD	cis	rs1799949	0.896	rs35908185	ENSG00000267002.1	RP11-242D8.1	7.23	2.11e-12	7.93e-10	0.3	0.32	Menopause (age at onset);	chr17:43103094	chr17:43164183~43170403:-
PRAD	cis	rs1799949	0.93	rs66499067	ENSG00000267002.1	RP11-242D8.1	7.23	2.11e-12	7.93e-10	0.31	0.32	Menopause (age at onset);	chr17:43096467	chr17:43164183~43170403:-
PRAD	cis	rs6844153	1	rs74642474	ENSG00000240005.4	RP11-293A21.1	-7.23	2.12e-12	7.96e-10	-0.48	-0.32	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26854979	chr4:26859806~26860599:-
PRAD	cis	rs17772222	0.917	rs61977053	ENSG00000258983.2	RP11-507K2.2	7.23	2.12e-12	7.97e-10	0.48	0.32	Coronary artery calcification;	chr14:88380876	chr14:88499334~88515502:+
PRAD	cis	rs287982	1	rs1119633	ENSG00000269973.1	RP11-95D17.1	-7.23	2.12e-12	7.97e-10	-0.31	-0.32	Nonsyndromic cleft lip with cleft palate;	chr2:9827403	chr2:9936360~9939590:+
PRAD	cis	rs287982	0.935	rs1119632	ENSG00000269973.1	RP11-95D17.1	-7.23	2.12e-12	7.97e-10	-0.31	-0.32	Nonsyndromic cleft lip with cleft palate;	chr2:9827535	chr2:9936360~9939590:+
PRAD	cis	rs995000	0.868	rs1168029	ENSG00000235545.1	RP11-230B22.1	-7.23	2.12e-12	7.99e-10	-0.42	-0.32	Triglyceride levels;	chr1:62503731	chr1:62688482~62710694:+
PRAD	cis	rs17772222	1	rs60310240	ENSG00000258983.2	RP11-507K2.2	7.22	2.13e-12	8e-10	0.46	0.32	Coronary artery calcification;	chr14:88356365	chr14:88499334~88515502:+
PRAD	cis	rs6547741	0.874	rs28381983	ENSG00000234072.1	AC074117.10	7.22	2.13e-12	8.01e-10	0.24	0.32	Oral cavity cancer;	chr2:27581565	chr2:27356246~27367622:+
PRAD	cis	rs2799081	1	rs2799081	ENSG00000280107.1	AL022393.9	-7.22	2.14e-12	8.03e-10	-0.41	-0.32	Myopia;	chr6:28302807	chr6:28170845~28172521:+
PRAD	cis	rs12612619	0.704	rs3769139	ENSG00000272148.1	RP11-195B17.1	7.22	2.14e-12	8.04e-10	0.38	0.32	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27092846	chr2:27062428~27062907:-
PRAD	cis	rs7598759	0.594	rs7558903	ENSG00000181798.2	LINC00471	-7.22	2.14e-12	8.05e-10	-0.41	-0.32	Noise-induced hearing loss;	chr2:231448776	chr2:231508426~231514339:-
PRAD	cis	rs1949733	0.666	rs3103070	ENSG00000205959.3	RP11-689P11.2	7.22	2.14e-12	8.06e-10	0.36	0.32	Response to antineoplastic agents;	chr4:8507098	chr4:8482270~8512610:+
PRAD	cis	rs7746199	0.736	rs13195636	ENSG00000226314.6	ZNF192P1	-7.22	2.15e-12	8.07e-10	-0.68	-0.32	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27541714	chr6:28161781~28169594:+
PRAD	cis	rs7746199	0.736	rs13202295	ENSG00000226314.6	ZNF192P1	-7.22	2.15e-12	8.07e-10	-0.69	-0.32	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731058	chr6:28161781~28169594:+
PRAD	cis	rs9326248	0.581	rs7120963	ENSG00000280143.1	AP000892.6	-7.22	2.15e-12	8.08e-10	-0.24	-0.32	Blood protein levels;	chr11:116959545	chr11:117204967~117210292:+
PRAD	cis	rs11098499	0.535	rs7671759	ENSG00000245958.5	RP11-33B1.1	-7.22	2.15e-12	8.09e-10	-0.31	-0.32	Corneal astigmatism;	chr4:119326939	chr4:119454791~119552025:+
PRAD	cis	rs12612619	0.732	rs11688708	ENSG00000272148.1	RP11-195B17.1	7.22	2.15e-12	8.09e-10	0.38	0.32	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26976740	chr2:27062428~27062907:-
PRAD	cis	rs375066	0.935	rs454559	ENSG00000267058.1	RP11-15A1.3	-7.22	2.15e-12	8.1e-10	-0.27	-0.32	Breast cancer;	chr19:43924968	chr19:43891804~43901805:-
PRAD	cis	rs4713118	0.824	rs2179095	ENSG00000226314.6	ZNF192P1	7.22	2.15e-12	8.1e-10	0.42	0.32	Parkinson's disease;	chr6:27783079	chr6:28161781~28169594:+
PRAD	cis	rs6479901	0.947	rs10761781	ENSG00000232075.1	MRPL35P2	7.22	2.15e-12	8.1e-10	0.39	0.32	Intelligence (multi-trait analysis);	chr10:63524843	chr10:63634317~63634827:-
PRAD	cis	rs2274273	0.662	rs67958555	ENSG00000258413.1	RP11-665C16.6	-7.22	2.16e-12	8.11e-10	-0.45	-0.32	Protein biomarker;	chr14:55204148	chr14:55262767~55272075:-
PRAD	cis	rs2274273	0.662	rs67092614	ENSG00000258413.1	RP11-665C16.6	-7.22	2.16e-12	8.11e-10	-0.45	-0.32	Protein biomarker;	chr14:55205337	chr14:55262767~55272075:-
PRAD	cis	rs2274273	0.615	rs17672058	ENSG00000258413.1	RP11-665C16.6	-7.22	2.16e-12	8.11e-10	-0.45	-0.32	Protein biomarker;	chr14:55206676	chr14:55262767~55272075:-
PRAD	cis	rs2274273	0.662	rs67215571	ENSG00000258413.1	RP11-665C16.6	-7.22	2.16e-12	8.11e-10	-0.45	-0.32	Protein biomarker;	chr14:55207005	chr14:55262767~55272075:-
PRAD	cis	rs2638953	0.676	rs11049727	ENSG00000278733.1	RP11-425D17.1	-7.22	2.16e-12	8.13e-10	-0.4	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28584864	chr12:28185625~28186190:-
PRAD	cis	rs7429990	0.965	rs2053767	ENSG00000229759.1	MRPS18AP1	7.22	2.16e-12	8.13e-10	0.33	0.32	Educational attainment (years of education);	chr3:47958184	chr3:48256350~48256938:-
PRAD	cis	rs6452524	0.935	rs72767160	ENSG00000249664.1	CTD-2227C6.2	7.22	2.16e-12	8.13e-10	0.39	0.32	Hypertension (SNP x SNP interaction);	chr5:83161102	chr5:83012285~83013109:-
PRAD	cis	rs6452524	0.935	rs5000997	ENSG00000249664.1	CTD-2227C6.2	7.22	2.16e-12	8.13e-10	0.39	0.32	Hypertension (SNP x SNP interaction);	chr5:83164248	chr5:83012285~83013109:-
PRAD	cis	rs6452524	0.935	rs6887915	ENSG00000249664.1	CTD-2227C6.2	7.22	2.16e-12	8.13e-10	0.39	0.32	Hypertension (SNP x SNP interaction);	chr5:83170837	chr5:83012285~83013109:-
PRAD	cis	rs995000	0.931	rs4915840	ENSG00000235545.1	RP11-230B22.1	-7.22	2.17e-12	8.15e-10	-0.42	-0.32	Triglyceride levels;	chr1:62533924	chr1:62688482~62710694:+
PRAD	cis	rs995000	0.868	rs1168017	ENSG00000235545.1	RP11-230B22.1	-7.22	2.17e-12	8.15e-10	-0.42	-0.32	Triglyceride levels;	chr1:62536880	chr1:62688482~62710694:+
PRAD	cis	rs995000	0.931	rs7548877	ENSG00000235545.1	RP11-230B22.1	-7.22	2.17e-12	8.15e-10	-0.42	-0.32	Triglyceride levels;	chr1:62540279	chr1:62688482~62710694:+
PRAD	cis	rs995000	0.965	rs1168023	ENSG00000235545.1	RP11-230B22.1	-7.22	2.17e-12	8.15e-10	-0.42	-0.32	Triglyceride levels;	chr1:62540924	chr1:62688482~62710694:+
PRAD	cis	rs71636778	0.509	rs57217461	ENSG00000260063.1	RP5-968P14.2	-7.22	2.17e-12	8.17e-10	-0.66	-0.32	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26701425	chr1:26692132~26694131:-
PRAD	cis	rs11018904	0.608	rs35700249	ENSG00000280385.1	AP000648.5	-7.22	2.18e-12	8.17e-10	-0.52	-0.32	Intelligence (multi-trait analysis);	chr11:90198759	chr11:90193614~90198120:+
PRAD	cis	rs11098499	1	rs6837898	ENSG00000245958.5	RP11-33B1.1	-7.22	2.18e-12	8.17e-10	-0.32	-0.32	Corneal astigmatism;	chr4:119257999	chr4:119454791~119552025:+
PRAD	cis	rs4845570	1	rs6659705	ENSG00000268288.1	RP11-98D18.16	7.22	2.18e-12	8.19e-10	0.5	0.32	Coronary artery disease;	chr1:151797274	chr1:151766486~151767000:-
PRAD	cis	rs17772222	1	rs74071851	ENSG00000258983.2	RP11-507K2.2	7.22	2.18e-12	8.19e-10	0.48	0.32	Coronary artery calcification;	chr14:88415858	chr14:88499334~88515502:+
PRAD	cis	rs6479891	1	rs12414796	ENSG00000232075.1	MRPL35P2	7.22	2.19e-12	8.21e-10	0.49	0.32	Arthritis (juvenile idiopathic);	chr10:63543327	chr10:63634317~63634827:-
PRAD	cis	rs1799949	1	rs8176220	ENSG00000267002.1	RP11-242D8.1	7.22	2.19e-12	8.21e-10	0.3	0.32	Menopause (age at onset);	chr17:43070445	chr17:43164183~43170403:-
PRAD	cis	rs1799949	1	rs1799966	ENSG00000267002.1	RP11-242D8.1	7.22	2.19e-12	8.21e-10	0.3	0.32	Menopause (age at onset);	chr17:43071077	chr17:43164183~43170403:-
PRAD	cis	rs240993	0.715	rs6920798	ENSG00000230177.1	RP5-1112D6.4	7.22	2.19e-12	8.22e-10	0.39	0.32	Inflammatory skin disease;Psoriasis;	chr6:111526074	chr6:111277932~111278742:+
PRAD	cis	rs7646881	0.812	rs7624161	ENSG00000240207.5	RP11-379F4.4	-7.22	2.19e-12	8.22e-10	-0.31	-0.32	Tetralogy of Fallot;	chr3:158742125	chr3:158732263~158784070:+
PRAD	cis	rs7646881	0.812	rs113166116	ENSG00000240207.5	RP11-379F4.4	-7.22	2.19e-12	8.22e-10	-0.31	-0.32	Tetralogy of Fallot;	chr3:158742467	chr3:158732263~158784070:+
PRAD	cis	rs172166	0.694	rs203876	ENSG00000219392.1	RP1-265C24.5	-7.22	2.19e-12	8.24e-10	-0.39	-0.32	Cardiac Troponin-T levels;	chr6:28078895	chr6:28115628~28116551:+
PRAD	cis	rs172166	0.694	rs203877	ENSG00000219392.1	RP1-265C24.5	-7.22	2.19e-12	8.24e-10	-0.39	-0.32	Cardiac Troponin-T levels;	chr6:28080846	chr6:28115628~28116551:+
PRAD	cis	rs7208859	0.673	rs9895815	ENSG00000266490.1	CTD-2349P21.9	7.22	2.2e-12	8.25e-10	0.45	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811015	chr17:30792372~30792833:+
PRAD	cis	rs17826219	0.706	rs73271850	ENSG00000266490.1	CTD-2349P21.9	7.22	2.2e-12	8.25e-10	0.45	0.32	Body mass index;	chr17:30815122	chr17:30792372~30792833:+
PRAD	cis	rs17826219	0.636	rs79565452	ENSG00000266490.1	CTD-2349P21.9	7.22	2.2e-12	8.25e-10	0.45	0.32	Body mass index;	chr17:30815823	chr17:30792372~30792833:+
PRAD	cis	rs7208859	0.623	rs7208088	ENSG00000266490.1	CTD-2349P21.9	7.22	2.2e-12	8.25e-10	0.45	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816649	chr17:30792372~30792833:+
PRAD	cis	rs6480314	0.831	rs11813170	ENSG00000233590.1	RP11-153K11.3	-7.22	2.2e-12	8.26e-10	-0.53	-0.32	Optic nerve measurement (disc area);	chr10:68215366	chr10:68233251~68242379:-
PRAD	cis	rs9309473	0.607	rs7604588	ENSG00000163016.8	ALMS1P	7.22	2.21e-12	8.29e-10	0.39	0.32	Metabolite levels;	chr2:73344289	chr2:73644919~73685576:+
PRAD	cis	rs7429990	0.965	rs184388	ENSG00000229759.1	MRPS18AP1	7.22	2.21e-12	8.3e-10	0.33	0.32	Educational attainment (years of education);	chr3:47898136	chr3:48256350~48256938:-
PRAD	cis	rs7429990	0.965	rs319696	ENSG00000229759.1	MRPS18AP1	7.22	2.21e-12	8.3e-10	0.33	0.32	Educational attainment (years of education);	chr3:47902371	chr3:48256350~48256938:-
PRAD	cis	rs7429990	0.93	rs71323371	ENSG00000229759.1	MRPS18AP1	7.22	2.21e-12	8.3e-10	0.33	0.32	Educational attainment (years of education);	chr3:47904327	chr3:48256350~48256938:-
PRAD	cis	rs7429990	0.932	rs34025851	ENSG00000229759.1	MRPS18AP1	7.22	2.21e-12	8.3e-10	0.33	0.32	Educational attainment (years of education);	chr3:47912243	chr3:48256350~48256938:-
PRAD	cis	rs2299587	0.554	rs7815429	ENSG00000253671.1	RP11-806O11.1	-7.22	2.21e-12	8.31e-10	-0.32	-0.32	Economic and political preferences;	chr8:17879848	chr8:17808941~17820868:+
PRAD	cis	rs1858037	0.867	rs871974	ENSG00000281920.1	RP11-418H16.1	-7.22	2.21e-12	8.31e-10	-0.39	-0.32	Rheumatoid arthritis;	chr2:65330153	chr2:65623272~65628424:+
PRAD	cis	rs4664293	0.836	rs4516379	ENSG00000226266.5	AC009961.3	-7.22	2.21e-12	8.31e-10	-0.44	-0.32	Monocyte percentage of white cells;	chr2:159808892	chr2:159670708~159712435:-
PRAD	cis	rs1355223	0.902	rs1258470	ENSG00000271369.1	RP11-350D17.3	7.22	2.22e-12	8.33e-10	0.37	0.32	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34707718	chr11:34709600~34710161:+
PRAD	cis	rs995000	0.899	rs1168032	ENSG00000235545.1	RP11-230B22.1	-7.22	2.22e-12	8.34e-10	-0.42	-0.32	Triglyceride levels;	chr1:62502076	chr1:62688482~62710694:+
PRAD	cis	rs995000	0.899	rs1168031	ENSG00000235545.1	RP11-230B22.1	-7.22	2.22e-12	8.34e-10	-0.42	-0.32	Triglyceride levels;	chr1:62502316	chr1:62688482~62710694:+
PRAD	cis	rs995000	0.899	rs1168030	ENSG00000235545.1	RP11-230B22.1	-7.22	2.22e-12	8.34e-10	-0.42	-0.32	Triglyceride levels;	chr1:62502820	chr1:62688482~62710694:+
PRAD	cis	rs995000	0.839	rs1168028	ENSG00000235545.1	RP11-230B22.1	-7.22	2.22e-12	8.34e-10	-0.42	-0.32	Triglyceride levels;	chr1:62503760	chr1:62688482~62710694:+
PRAD	cis	rs995000	0.839	rs1168026	ENSG00000235545.1	RP11-230B22.1	-7.22	2.22e-12	8.34e-10	-0.42	-0.32	Triglyceride levels;	chr1:62505325	chr1:62688482~62710694:+
PRAD	cis	rs2638953	0.962	rs716687	ENSG00000247934.4	RP11-967K21.1	-7.22	2.22e-12	8.34e-10	-0.34	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28261517	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.962	rs11049495	ENSG00000247934.4	RP11-967K21.1	-7.22	2.22e-12	8.34e-10	-0.34	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28264795	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.962	rs11049496	ENSG00000247934.4	RP11-967K21.1	-7.22	2.22e-12	8.34e-10	-0.34	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28267327	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.819	rs10843146	ENSG00000247934.4	RP11-967K21.1	-7.22	2.22e-12	8.34e-10	-0.34	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28268352	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.962	rs2172299	ENSG00000247934.4	RP11-967K21.1	-7.22	2.22e-12	8.34e-10	-0.34	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28280180	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.962	rs11049503	ENSG00000247934.4	RP11-967K21.1	-7.22	2.22e-12	8.34e-10	-0.34	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28282714	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.962	rs61922974	ENSG00000247934.4	RP11-967K21.1	-7.22	2.22e-12	8.34e-10	-0.34	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28283302	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.962	rs61922975	ENSG00000247934.4	RP11-967K21.1	-7.22	2.22e-12	8.34e-10	-0.34	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28283705	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.962	rs61922976	ENSG00000247934.4	RP11-967K21.1	-7.22	2.22e-12	8.34e-10	-0.34	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28283837	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.962	rs61922977	ENSG00000247934.4	RP11-967K21.1	-7.22	2.22e-12	8.34e-10	-0.34	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28286889	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.962	rs11049505	ENSG00000247934.4	RP11-967K21.1	-7.22	2.22e-12	8.34e-10	-0.34	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28288087	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.924	rs11049507	ENSG00000247934.4	RP11-967K21.1	-7.22	2.22e-12	8.34e-10	-0.34	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28289554	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.962	rs11049509	ENSG00000247934.4	RP11-967K21.1	-7.22	2.22e-12	8.34e-10	-0.34	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28290055	chr12:28163298~28190738:-
PRAD	cis	rs875971	0.66	rs7807930	ENSG00000237310.1	GS1-124K5.4	-7.22	2.23e-12	8.35e-10	-0.28	-0.32	Aortic root size;	chr7:66622178	chr7:66493706~66495474:+
PRAD	cis	rs2436845	0.651	rs2513912	ENSG00000253320.4	KB-1507C5.2	7.22	2.23e-12	8.38e-10	0.38	0.32	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102809260	chr8:102864300~102977876:+
PRAD	cis	rs6565180	0.888	rs12447833	ENSG00000183604.13	SMG1P5	7.22	2.24e-12	8.39e-10	0.31	0.32	Tonsillectomy;	chr16:30378993	chr16:30267553~30335374:-
PRAD	cis	rs12612619	0.761	rs34732613	ENSG00000272148.1	RP11-195B17.1	7.22	2.24e-12	8.4e-10	0.39	0.32	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27031928	chr2:27062428~27062907:-
PRAD	cis	rs6480314	0.831	rs2166221	ENSG00000233590.1	RP11-153K11.3	7.22	2.24e-12	8.42e-10	0.51	0.32	Optic nerve measurement (disc area);	chr10:68222541	chr10:68233251~68242379:-
PRAD	cis	rs74024059	1	rs334951	ENSG00000260685.1	RP11-326L17.1	7.22	2.25e-12	8.42e-10	0.91	0.32	Red blood cell count;Hematocrit;	chr15:76008654	chr15:75950464~75951144:-
PRAD	cis	rs74024059	1	rs334947	ENSG00000260685.1	RP11-326L17.1	7.22	2.25e-12	8.42e-10	0.91	0.32	Red blood cell count;Hematocrit;	chr15:76015498	chr15:75950464~75951144:-
PRAD	cis	rs2638953	0.853	rs2141203	ENSG00000278733.1	RP11-425D17.1	-7.22	2.25e-12	8.43e-10	-0.39	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28461928	chr12:28185625~28186190:-
PRAD	cis	rs9309473	0.519	rs6730785	ENSG00000163016.8	ALMS1P	-7.22	2.25e-12	8.43e-10	-0.36	-0.32	Metabolite levels;	chr2:73415275	chr2:73644919~73685576:+
PRAD	cis	rs9543976	1	rs3818355	ENSG00000261553.4	RP11-29G8.3	7.22	2.25e-12	8.43e-10	0.51	0.32	Diabetic retinopathy;	chr13:75622731	chr13:75549773~75807120:+
PRAD	cis	rs853679	0.607	rs13208096	ENSG00000280107.1	AL022393.9	-7.22	2.25e-12	8.43e-10	-0.64	-0.32	Depression;	chr6:28257533	chr6:28170845~28172521:+
PRAD	cis	rs1707322	0.686	rs2991977	ENSG00000280836.1	AL355480.1	7.22	2.25e-12	8.43e-10	0.4	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45588011	chr1:45581219~45581321:-
PRAD	cis	rs1707322	0.656	rs2991981	ENSG00000280836.1	AL355480.1	7.22	2.25e-12	8.43e-10	0.4	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45591472	chr1:45581219~45581321:-
PRAD	cis	rs10129255	0.913	rs10140943	ENSG00000223648.3	IGHV3-64	7.22	2.25e-12	8.44e-10	0.33	0.32	Kawasaki disease;	chr14:106767441	chr14:106643132~106658258:-
PRAD	cis	rs7428	0.527	rs1053560	ENSG00000246575.2	AC093162.5	7.22	2.25e-12	8.45e-10	0.24	0.32	Ear protrusion;	chr2:85319069	chr2:85315041~85316529:+
PRAD	cis	rs9326248	0.581	rs7120706	ENSG00000280143.1	AP000892.6	-7.22	2.25e-12	8.45e-10	-0.24	-0.32	Blood protein levels;	chr11:116959371	chr11:117204967~117210292:+
PRAD	cis	rs7428	0.527	rs4832164	ENSG00000246575.2	AC093162.5	7.22	2.26e-12	8.46e-10	0.24	0.32	Ear protrusion;	chr2:85319809	chr2:85315041~85316529:+
PRAD	cis	rs9595908	0.865	rs2761365	ENSG00000212293.1	SNORA16	-7.22	2.26e-12	8.46e-10	-0.4	-0.32	Body mass index;	chr13:32437687	chr13:32420390~32420516:-
PRAD	cis	rs9595908	0.827	rs2761366	ENSG00000212293.1	SNORA16	-7.22	2.26e-12	8.46e-10	-0.4	-0.32	Body mass index;	chr13:32437735	chr13:32420390~32420516:-
PRAD	cis	rs17772222	0.755	rs12435019	ENSG00000258983.2	RP11-507K2.2	7.22	2.26e-12	8.47e-10	0.43	0.32	Coronary artery calcification;	chr14:88365074	chr14:88499334~88515502:+
PRAD	cis	rs1799949	1	rs4793229	ENSG00000267002.1	RP11-242D8.1	-7.22	2.26e-12	8.47e-10	-0.3	-0.32	Menopause (age at onset);	chr17:43340966	chr17:43164183~43170403:-
PRAD	cis	rs995000	0.931	rs10889344	ENSG00000235545.1	RP11-230B22.1	-7.22	2.26e-12	8.47e-10	-0.42	-0.32	Triglyceride levels;	chr1:62568270	chr1:62688482~62710694:+
PRAD	cis	rs995000	0.899	rs6696502	ENSG00000235545.1	RP11-230B22.1	-7.22	2.26e-12	8.47e-10	-0.42	-0.32	Triglyceride levels;	chr1:62573862	chr1:62688482~62710694:+
PRAD	cis	rs995000	0.931	rs11207990	ENSG00000235545.1	RP11-230B22.1	-7.22	2.26e-12	8.47e-10	-0.42	-0.32	Triglyceride levels;	chr1:62575415	chr1:62688482~62710694:+
PRAD	cis	rs995000	0.895	rs1472257	ENSG00000235545.1	RP11-230B22.1	-7.22	2.26e-12	8.47e-10	-0.42	-0.32	Triglyceride levels;	chr1:62576455	chr1:62688482~62710694:+
PRAD	cis	rs812925	0.537	rs2463097	ENSG00000271889.1	RP11-493E12.1	-7.22	2.26e-12	8.48e-10	-0.35	-0.32	Immature fraction of reticulocytes;	chr2:61387166	chr2:61151433~61162105:-
PRAD	cis	rs17772222	1	rs17124700	ENSG00000258983.2	RP11-507K2.2	7.22	2.27e-12	8.49e-10	0.47	0.32	Coronary artery calcification;	chr14:88439285	chr14:88499334~88515502:+
PRAD	cis	rs964611	0.872	rs17350938	ENSG00000259488.2	RP11-154J22.1	-7.22	2.27e-12	8.51e-10	-0.37	-0.32	Metabolite levels (Pyroglutamine);	chr15:48297784	chr15:48312353~48331856:-
PRAD	cis	rs4927850	1	rs4927850	ENSG00000231464.1	AC024937.4	-7.22	2.27e-12	8.51e-10	-0.38	-0.32	Pancreatic cancer;	chr3:196024759	chr3:195996738~195998233:+
PRAD	cis	rs172166	0.694	rs1150666	ENSG00000204709.4	LINC01556	7.21	2.27e-12	8.52e-10	0.42	0.32	Cardiac Troponin-T levels;	chr6:28156150	chr6:28943877~28944537:+
PRAD	cis	rs9543976	1	rs7989568	ENSG00000261553.4	RP11-29G8.3	7.21	2.27e-12	8.53e-10	0.5	0.32	Diabetic retinopathy;	chr13:75581428	chr13:75549773~75807120:+
PRAD	cis	rs995000	0.931	rs1168015	ENSG00000235545.1	RP11-230B22.1	-7.21	2.28e-12	8.53e-10	-0.42	-0.32	Triglyceride levels;	chr1:62530375	chr1:62688482~62710694:+
PRAD	cis	rs1979679	0.808	rs10843115	ENSG00000278733.1	RP11-425D17.1	7.21	2.28e-12	8.53e-10	0.39	0.32	Ossification of the posterior longitudinal ligament of the spine;	chr12:28154784	chr12:28185625~28186190:-
PRAD	cis	rs2274273	1	rs1009977	ENSG00000258413.1	RP11-665C16.6	-7.21	2.28e-12	8.54e-10	-0.41	-0.32	Protein biomarker;	chr14:55136284	chr14:55262767~55272075:-
PRAD	cis	rs995000	0.899	rs10889340	ENSG00000235545.1	RP11-230B22.1	-7.21	2.29e-12	8.57e-10	-0.43	-0.32	Triglyceride levels;	chr1:62546400	chr1:62688482~62710694:+
PRAD	cis	rs12612619	0.732	rs722911	ENSG00000272148.1	RP11-195B17.1	7.21	2.29e-12	8.57e-10	0.38	0.32	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26988344	chr2:27062428~27062907:-
PRAD	cis	rs41307935	0.908	rs12739212	ENSG00000260063.1	RP5-968P14.2	-7.21	2.29e-12	8.58e-10	-0.65	-0.32	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26724087	chr1:26692132~26694131:-
PRAD	cis	rs964611	0.935	rs8029972	ENSG00000259488.2	RP11-154J22.1	-7.21	2.29e-12	8.58e-10	-0.37	-0.32	Metabolite levels (Pyroglutamine);	chr15:48285970	chr15:48312353~48331856:-
PRAD	cis	rs5769707	0.521	rs739244	ENSG00000188511.11	C22orf34	7.21	2.29e-12	8.58e-10	0.38	0.32	Monocyte percentage of white cells;Monocyte count;	chr22:49666510	chr22:49414524~49657542:-
PRAD	cis	rs853679	0.527	rs9461443	ENSG00000219392.1	RP1-265C24.5	-7.21	2.29e-12	8.59e-10	-0.42	-0.32	Depression;	chr6:28226851	chr6:28115628~28116551:+
PRAD	cis	rs1823913	0.927	rs1454761	ENSG00000280083.1	RP11-317J9.1	-7.21	2.29e-12	8.6e-10	-0.41	-0.32	Obesity-related traits;	chr2:191237092	chr2:191154118~191156070:-
PRAD	cis	rs760794	0.666	rs7773816	ENSG00000228412.5	RP4-625H18.2	7.21	2.3e-12	8.6e-10	0.4	0.32	Endometriosis;	chr6:19823201	chr6:19802164~19804752:-
PRAD	cis	rs1799949	1	rs67060599	ENSG00000267002.1	RP11-242D8.1	7.21	2.3e-12	8.6e-10	0.31	0.32	Menopause (age at onset);	chr17:43103085	chr17:43164183~43170403:-
PRAD	cis	rs3745672	0.661	rs111940377	ENSG00000219665.7	CTD-2006C1.2	-7.21	2.3e-12	8.63e-10	-0.69	-0.32	Multiple sclerosis;	chr19:11985052	chr19:11987617~12046275:+
PRAD	cis	rs875971	0.638	rs10249404	ENSG00000237310.1	GS1-124K5.4	-7.21	2.31e-12	8.64e-10	-0.28	-0.32	Aortic root size;	chr7:66581737	chr7:66493706~66495474:+
PRAD	cis	rs2243480	1	rs316322	ENSG00000273142.1	RP11-458F8.4	-7.21	2.31e-12	8.64e-10	-0.36	-0.32	Diabetic kidney disease;	chr7:66146246	chr7:66902857~66906297:+
PRAD	cis	rs4713118	0.513	rs149958	ENSG00000220721.1	OR1F12	7.21	2.31e-12	8.64e-10	0.37	0.32	Parkinson's disease;	chr6:28045839	chr6:28073316~28074233:+
PRAD	cis	rs17772222	0.715	rs10139921	ENSG00000258983.2	RP11-507K2.2	7.21	2.31e-12	8.65e-10	0.47	0.32	Coronary artery calcification;	chr14:88468512	chr14:88499334~88515502:+
PRAD	cis	rs2274273	0.638	rs9919921	ENSG00000258413.1	RP11-665C16.6	-7.21	2.32e-12	8.68e-10	-0.45	-0.32	Protein biomarker;	chr14:55228787	chr14:55262767~55272075:-
PRAD	cis	rs9595908	0.865	rs499966	ENSG00000212293.1	SNORA16	-7.21	2.32e-12	8.68e-10	-0.4	-0.32	Body mass index;	chr13:32424473	chr13:32420390~32420516:-
PRAD	cis	rs12612619	0.621	rs4665943	ENSG00000229122.1	AGBL5-IT1	-7.21	2.32e-12	8.69e-10	-0.36	-0.32	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27073017	chr2:27061038~27061815:+
PRAD	cis	rs78456975	0.506	rs13402886	ENSG00000231482.2	AC141930.2	-7.21	2.32e-12	8.7e-10	-0.37	-0.32	Placebo response in major depressive disorder (% change in symptom score);	chr2:1571576	chr2:1572554~1580311:-
PRAD	cis	rs8062405	0.723	rs35175818	ENSG00000251417.2	RP11-1348G14.4	-7.21	2.33e-12	8.72e-10	-0.36	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597425	chr16:28802743~28817828:+
PRAD	cis	rs8062405	0.723	rs62031562	ENSG00000251417.2	RP11-1348G14.4	-7.21	2.33e-12	8.72e-10	-0.36	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28598008	chr16:28802743~28817828:+
PRAD	cis	rs2933343	0.621	rs6764682	ENSG00000261159.1	RP11-723O4.9	-7.21	2.33e-12	8.72e-10	-0.28	-0.32	IgG glycosylation;	chr3:128849540	chr3:128859716~128860526:-
PRAD	cis	rs733592	0.965	rs1978161	ENSG00000240399.1	RP1-228P16.1	-7.21	2.33e-12	8.73e-10	-0.26	-0.32	Plateletcrit;	chr12:48073938	chr12:48054813~48055591:-
PRAD	cis	rs2274273	0.967	rs2094102	ENSG00000258413.1	RP11-665C16.6	-7.21	2.34e-12	8.76e-10	-0.41	-0.32	Protein biomarker;	chr14:55124380	chr14:55262767~55272075:-
PRAD	cis	rs9467773	1	rs6925895	ENSG00000124549.13	BTN2A3P	7.21	2.34e-12	8.76e-10	0.28	0.32	Intelligence (multi-trait analysis);	chr6:26571937	chr6:26421391~26432383:+
PRAD	cis	rs4713118	0.866	rs9468217	ENSG00000219392.1	RP1-265C24.5	-7.21	2.34e-12	8.77e-10	-0.41	-0.32	Parkinson's disease;	chr6:27758688	chr6:28115628~28116551:+
PRAD	cis	rs4713118	0.911	rs9295746	ENSG00000219392.1	RP1-265C24.5	-7.21	2.34e-12	8.77e-10	-0.41	-0.32	Parkinson's disease;	chr6:27762285	chr6:28115628~28116551:+
PRAD	cis	rs6844153	1	rs57663175	ENSG00000240005.4	RP11-293A21.1	-7.21	2.35e-12	8.78e-10	-0.45	-0.32	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26917770	chr4:26859806~26860599:-
PRAD	cis	rs17711722	1	rs17711722	ENSG00000237310.1	GS1-124K5.4	-7.21	2.35e-12	8.78e-10	-0.27	-0.32	Calcium levels;	chr7:65806210	chr7:66493706~66495474:+
PRAD	cis	rs17711722	0.675	rs6947132	ENSG00000237310.1	GS1-124K5.4	-7.21	2.35e-12	8.78e-10	-0.27	-0.32	Calcium levels;	chr7:65808508	chr7:66493706~66495474:+
PRAD	cis	rs12908161	0.959	rs61074241	ENSG00000275120.1	RP11-182J1.17	7.21	2.35e-12	8.79e-10	0.45	0.32	Schizophrenia;	chr15:84790165	chr15:84599434~84606463:-
PRAD	cis	rs75422866	0.51	rs73105818	ENSG00000257433.4	RP1-197B17.3	7.21	2.36e-12	8.81e-10	0.67	0.32	Pneumonia;	chr12:47726538	chr12:47706085~47742294:+
PRAD	cis	rs75422866	0.51	rs73105819	ENSG00000257433.4	RP1-197B17.3	7.21	2.36e-12	8.81e-10	0.67	0.32	Pneumonia;	chr12:47727190	chr12:47706085~47742294:+
PRAD	cis	rs79349575	0.716	rs46522	ENSG00000248278.1	SUMO2P17	7.21	2.36e-12	8.83e-10	0.37	0.32	Type 2 diabetes;	chr17:48911235	chr17:48874860~48908983:-
PRAD	cis	rs11098499	0.722	rs17595727	ENSG00000245958.5	RP11-33B1.1	7.21	2.36e-12	8.83e-10	0.3	0.32	Corneal astigmatism;	chr4:119340919	chr4:119454791~119552025:+
PRAD	cis	rs9640161	0.789	rs2159234	ENSG00000261305.1	RP4-584D14.7	7.21	2.36e-12	8.84e-10	0.36	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150323333	chr7:150341771~150342607:+
PRAD	cis	rs9640161	0.702	rs3735175	ENSG00000261305.1	RP4-584D14.7	7.21	2.36e-12	8.84e-10	0.36	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150323368	chr7:150341771~150342607:+
PRAD	cis	rs7772486	0.774	rs2748503	ENSG00000235652.6	RP11-545I5.3	7.21	2.36e-12	8.84e-10	0.33	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145973906	chr6:145799409~145886585:+
PRAD	cis	rs12612619	0.732	rs1440044	ENSG00000272148.1	RP11-195B17.1	7.21	2.37e-12	8.85e-10	0.38	0.32	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27004086	chr2:27062428~27062907:-
PRAD	cis	rs2638953	0.814	rs10843164	ENSG00000278733.1	RP11-425D17.1	-7.21	2.37e-12	8.85e-10	-0.4	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28416781	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs11049583	ENSG00000278733.1	RP11-425D17.1	-7.21	2.37e-12	8.85e-10	-0.4	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28417238	chr12:28185625~28186190:-
PRAD	cis	rs4664293	1	rs12692554	ENSG00000226266.5	AC009961.3	-7.21	2.37e-12	8.85e-10	-0.42	-0.32	Monocyte percentage of white cells;	chr2:159594777	chr2:159670708~159712435:-
PRAD	cis	rs17772222	1	rs1955599	ENSG00000258983.2	RP11-507K2.2	7.21	2.37e-12	8.87e-10	0.46	0.32	Coronary artery calcification;	chr14:88358788	chr14:88499334~88515502:+
PRAD	cis	rs17772222	1	rs1955600	ENSG00000258983.2	RP11-507K2.2	7.21	2.37e-12	8.87e-10	0.46	0.32	Coronary artery calcification;	chr14:88359040	chr14:88499334~88515502:+
PRAD	cis	rs853679	0.527	rs9461443	ENSG00000204709.4	LINC01556	7.21	2.38e-12	8.88e-10	0.44	0.32	Depression;	chr6:28226851	chr6:28943877~28944537:+
PRAD	cis	rs7429990	0.965	rs9811277	ENSG00000229759.1	MRPS18AP1	7.21	2.38e-12	8.9e-10	0.33	0.32	Educational attainment (years of education);	chr3:47970148	chr3:48256350~48256938:-
PRAD	cis	rs7429990	0.965	rs9814961	ENSG00000229759.1	MRPS18AP1	7.21	2.38e-12	8.9e-10	0.33	0.32	Educational attainment (years of education);	chr3:47976127	chr3:48256350~48256938:-
PRAD	cis	rs7429990	0.965	rs6770467	ENSG00000229759.1	MRPS18AP1	-7.21	2.38e-12	8.9e-10	-0.33	-0.32	Educational attainment (years of education);	chr3:47977742	chr3:48256350~48256938:-
PRAD	cis	rs7429990	0.932	rs6770477	ENSG00000229759.1	MRPS18AP1	-7.21	2.38e-12	8.9e-10	-0.33	-0.32	Educational attainment (years of education);	chr3:47977768	chr3:48256350~48256938:-
PRAD	cis	rs7429990	0.965	rs28637561	ENSG00000229759.1	MRPS18AP1	-7.21	2.38e-12	8.9e-10	-0.33	-0.32	Educational attainment (years of education);	chr3:47979528	chr3:48256350~48256938:-
PRAD	cis	rs7429990	0.965	rs7427418	ENSG00000229759.1	MRPS18AP1	-7.21	2.38e-12	8.9e-10	-0.33	-0.32	Educational attainment (years of education);	chr3:47981217	chr3:48256350~48256938:-
PRAD	cis	rs7429990	0.965	rs13075795	ENSG00000229759.1	MRPS18AP1	-7.21	2.38e-12	8.9e-10	-0.33	-0.32	Educational attainment (years of education);	chr3:47983139	chr3:48256350~48256938:-
PRAD	cis	rs7429990	0.965	rs7431572	ENSG00000229759.1	MRPS18AP1	-7.21	2.38e-12	8.9e-10	-0.33	-0.32	Educational attainment (years of education);	chr3:47986361	chr3:48256350~48256938:-
PRAD	cis	rs7429990	0.965	rs13074973	ENSG00000229759.1	MRPS18AP1	-7.21	2.38e-12	8.9e-10	-0.33	-0.32	Educational attainment (years of education);	chr3:47986654	chr3:48256350~48256938:-
PRAD	cis	rs7429990	0.965	rs7430913	ENSG00000229759.1	MRPS18AP1	-7.21	2.38e-12	8.9e-10	-0.33	-0.32	Educational attainment (years of education);	chr3:47990867	chr3:48256350~48256938:-
PRAD	cis	rs875971	0.505	rs1167385	ENSG00000237310.1	GS1-124K5.4	-7.21	2.38e-12	8.9e-10	-0.27	-0.32	Aortic root size;	chr7:66048321	chr7:66493706~66495474:+
PRAD	cis	rs858239	0.568	rs6970694	ENSG00000226816.2	AC005082.12	7.21	2.38e-12	8.91e-10	0.38	0.32	Cerebrospinal fluid biomarker levels;	chr7:23211209	chr7:23206013~23208045:+
PRAD	cis	rs12612619	0.732	rs7585410	ENSG00000272148.1	RP11-195B17.1	7.21	2.39e-12	8.94e-10	0.38	0.32	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26979252	chr2:27062428~27062907:-
PRAD	cis	rs5760092	0.755	rs915589	ENSG00000224205.1	AP000351.4	-7.21	2.4e-12	8.96e-10	-0.48	-0.32	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23987320~23991421:-
PRAD	cis	rs8062405	0.755	rs62034325	ENSG00000251417.2	RP11-1348G14.4	-7.21	2.4e-12	8.97e-10	-0.36	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527319	chr16:28802743~28817828:+
PRAD	cis	rs7309	0.622	rs4664396	ENSG00000235724.7	AC009299.2	7.21	2.4e-12	8.99e-10	0.38	0.32	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161045139	chr2:161222785~161308303:-
PRAD	cis	rs1023500	0.573	rs133377	ENSG00000205702.9	CYP2D7	7.21	2.41e-12	8.99e-10	0.25	0.32	Schizophrenia;	chr22:42070946	chr22:42140203~42144577:-
PRAD	cis	rs2638953	0.924	rs11049471	ENSG00000247934.4	RP11-967K21.1	-7.21	2.41e-12	9.01e-10	-0.32	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28228259	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.815	rs11049680	ENSG00000278733.1	RP11-425D17.1	-7.21	2.41e-12	9.01e-10	-0.4	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28508436	chr12:28185625~28186190:-
PRAD	cis	rs9532669	0.926	rs7329302	ENSG00000168852.11	TPTE2P5	-7.21	2.41e-12	9.01e-10	-0.31	-0.32	Cervical cancer;	chr13:40962396	chr13:40822296~40921749:-
PRAD	cis	rs2638953	0.962	rs10506034	ENSG00000278733.1	RP11-425D17.1	-7.21	2.41e-12	9.01e-10	-0.4	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28442363	chr12:28185625~28186190:-
PRAD	cis	rs995000	0.965	rs11207981	ENSG00000235545.1	RP11-230B22.1	-7.21	2.41e-12	9.02e-10	-0.42	-0.32	Triglyceride levels;	chr1:62540416	chr1:62688482~62710694:+
PRAD	cis	rs853679	0.882	rs9461432	ENSG00000226314.6	ZNF192P1	-7.21	2.41e-12	9.02e-10	-0.56	-0.32	Depression;	chr6:28119105	chr6:28161781~28169594:+
PRAD	cis	rs79349575	0.756	rs3848460	ENSG00000248278.1	SUMO2P17	-7.21	2.42e-12	9.03e-10	-0.36	-0.32	Type 2 diabetes;	chr17:48969752	chr17:48874860~48908983:-
PRAD	cis	rs6860806	0.661	rs334902	ENSG00000233006.5	AC034220.3	7.21	2.42e-12	9.03e-10	0.27	0.32	Breast cancer;	chr5:132250866	chr5:132311285~132369916:-
PRAD	cis	rs4713118	0.539	rs200967	ENSG00000219392.1	RP1-265C24.5	-7.21	2.42e-12	9.04e-10	-0.4	-0.32	Parkinson's disease;	chr6:27894349	chr6:28115628~28116551:+
PRAD	cis	rs1799949	1	rs8176234	ENSG00000267002.1	RP11-242D8.1	7.21	2.42e-12	9.04e-10	0.3	0.32	Menopause (age at onset);	chr17:43067763	chr17:43164183~43170403:-
PRAD	cis	rs1799949	1	rs8176233	ENSG00000267002.1	RP11-242D8.1	7.21	2.42e-12	9.04e-10	0.3	0.32	Menopause (age at onset);	chr17:43067787	chr17:43164183~43170403:-
PRAD	cis	rs1707322	0.721	rs10789468	ENSG00000280836.1	AL355480.1	-7.21	2.42e-12	9.04e-10	-0.4	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45658886	chr1:45581219~45581321:-
PRAD	cis	rs4664293	0.707	rs7563956	ENSG00000226266.5	AC009961.3	7.21	2.42e-12	9.04e-10	0.42	0.32	Monocyte percentage of white cells;	chr2:159815943	chr2:159670708~159712435:-
PRAD	cis	rs287982	0.935	rs287978	ENSG00000269973.1	RP11-95D17.1	7.2	2.44e-12	9.1e-10	0.31	0.32	Nonsyndromic cleft lip with cleft palate;	chr2:9830405	chr2:9936360~9939590:+
PRAD	cis	rs2638953	0.776	rs11513467	ENSG00000247934.4	RP11-967K21.1	-7.2	2.44e-12	9.11e-10	-0.32	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28210252	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.776	rs11519332	ENSG00000247934.4	RP11-967K21.1	-7.2	2.44e-12	9.11e-10	-0.32	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28210254	chr12:28163298~28190738:-
PRAD	cis	rs4713118	0.696	rs2394002	ENSG00000226314.6	ZNF192P1	-7.2	2.45e-12	9.13e-10	-0.42	-0.32	Parkinson's disease;	chr6:27780236	chr6:28161781~28169594:+
PRAD	cis	rs9393777	0.844	rs72839477	ENSG00000226314.6	ZNF192P1	-7.2	2.45e-12	9.16e-10	-0.7	-0.32	Intelligence (multi-trait analysis);	chr6:27359221	chr6:28161781~28169594:+
PRAD	cis	rs3096299	0.566	rs4129126	ENSG00000261118.1	RP11-104N10.1	7.2	2.45e-12	9.16e-10	0.33	0.32	Multiple myeloma (IgH translocation);	chr16:89495067	chr16:89492017~89504460:-
PRAD	cis	rs2067615	0.579	rs6539283	ENSG00000260329.1	RP11-412D9.4	-7.2	2.46e-12	9.17e-10	-0.27	-0.32	Heart rate;	chr12:106829211	chr12:106954029~106955497:-
PRAD	cis	rs765787	0.53	rs12909987	ENSG00000259520.4	CTD-2651B20.3	7.2	2.46e-12	9.17e-10	0.4	0.32	Uric acid levels;	chr15:45220009	chr15:45251580~45279251:-
PRAD	cis	rs2638953	0.888	rs11610011	ENSG00000247934.4	RP11-967K21.1	-7.2	2.46e-12	9.18e-10	-0.32	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28202801	chr12:28163298~28190738:-
PRAD	cis	rs4728142	0.604	rs4731536	ENSG00000275106.1	RP11-309L24.10	-7.2	2.46e-12	9.19e-10	-0.4	-0.32	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129000239	chr7:128952527~128953316:-
PRAD	cis	rs875971	0.545	rs12671152	ENSG00000226824.5	RP4-756H11.3	-7.2	2.47e-12	9.21e-10	-0.49	-0.32	Aortic root size;	chr7:66311140	chr7:66654538~66669855:+
PRAD	cis	rs853679	0.567	rs3799499	ENSG00000216901.1	AL022393.7	7.2	2.47e-12	9.21e-10	0.44	0.32	Depression;	chr6:28386473	chr6:28176188~28176674:+
PRAD	cis	rs853679	0.567	rs2232427	ENSG00000216901.1	AL022393.7	7.2	2.47e-12	9.21e-10	0.44	0.32	Depression;	chr6:28391932	chr6:28176188~28176674:+
PRAD	cis	rs17772222	1	rs12433464	ENSG00000258983.2	RP11-507K2.2	7.2	2.47e-12	9.22e-10	0.45	0.32	Coronary artery calcification;	chr14:88357671	chr14:88499334~88515502:+
PRAD	cis	rs9640161	0.75	rs11538922	ENSG00000261305.1	RP4-584D14.7	7.2	2.47e-12	9.23e-10	0.36	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150338094	chr7:150341771~150342607:+
PRAD	cis	rs7916697	1	rs7916697	ENSG00000233590.1	RP11-153K11.3	7.2	2.47e-12	9.23e-10	0.43	0.32	Optic disc area;	chr10:68232096	chr10:68233251~68242379:-
PRAD	cis	rs6847067	0.8	rs6833661	ENSG00000180769.7	WDFY3-AS2	7.2	2.48e-12	9.23e-10	0.34	0.32	Oropharynx cancer;	chr4:84917942	chr4:84965682~85011277:+
PRAD	cis	rs1355223	0.902	rs12802120	ENSG00000271369.1	RP11-350D17.3	-7.2	2.48e-12	9.24e-10	-0.38	-0.32	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34726103	chr11:34709600~34710161:+
PRAD	cis	rs1858037	0.867	rs6727013	ENSG00000281920.1	RP11-418H16.1	7.2	2.48e-12	9.24e-10	0.39	0.32	Rheumatoid arthritis;	chr2:65331241	chr2:65623272~65628424:+
PRAD	cis	rs17428076	0.837	rs72889848	ENSG00000228389.1	AC068039.4	-7.2	2.48e-12	9.24e-10	-0.42	-0.32	Myopia;	chr2:171670728	chr2:171773482~171775844:+
PRAD	cis	rs6840258	0.607	rs56023922	ENSG00000251411.1	RP11-397E7.4	-7.2	2.48e-12	9.26e-10	-0.41	-0.32	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86994934	chr4:86913266~86914817:-
PRAD	cis	rs2638953	0.815	rs11049682	ENSG00000278733.1	RP11-425D17.1	-7.2	2.49e-12	9.27e-10	-0.39	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28509062	chr12:28185625~28186190:-
PRAD	cis	rs516805	0.706	rs1339533	ENSG00000279453.1	RP3-425C14.4	-7.2	2.49e-12	9.27e-10	-0.3	-0.32	Lymphocyte counts;	chr6:122348687	chr6:122436789~122439223:-
PRAD	cis	rs6547741	0.935	rs4666005	ENSG00000234072.1	AC074117.10	7.2	2.49e-12	9.28e-10	0.24	0.32	Oral cavity cancer;	chr2:27632372	chr2:27356246~27367622:+
PRAD	cis	rs1023500	0.551	rs2859438	ENSG00000205702.9	CYP2D7	7.2	2.49e-12	9.29e-10	0.25	0.32	Schizophrenia;	chr22:42070976	chr22:42140203~42144577:-
PRAD	cis	rs964611	0.882	rs12441867	ENSG00000259488.2	RP11-154J22.1	7.2	2.49e-12	9.29e-10	0.32	0.32	Metabolite levels (Pyroglutamine);	chr15:48343856	chr15:48312353~48331856:-
PRAD	cis	rs964611	0.882	rs11629725	ENSG00000259488.2	RP11-154J22.1	7.2	2.49e-12	9.29e-10	0.32	0.32	Metabolite levels (Pyroglutamine);	chr15:48347986	chr15:48312353~48331856:-
PRAD	cis	rs10411161	1	rs4514789	ENSG00000269483.1	AC006272.1	7.2	2.49e-12	9.29e-10	0.47	0.32	Breast cancer;	chr19:51862401	chr19:51839924~51843324:-
PRAD	cis	rs1799949	1	rs8176242	ENSG00000267002.1	RP11-242D8.1	7.2	2.49e-12	9.3e-10	0.31	0.32	Menopause (age at onset);	chr17:43065857	chr17:43164183~43170403:-
PRAD	cis	rs2243480	1	rs10807702	ENSG00000273142.1	RP11-458F8.4	-7.2	2.5e-12	9.3e-10	-0.36	-0.32	Diabetic kidney disease;	chr7:66302856	chr7:66902857~66906297:+
PRAD	cis	rs995000	0.899	rs1781221	ENSG00000235545.1	RP11-230B22.1	-7.2	2.5e-12	9.31e-10	-0.42	-0.32	Triglyceride levels;	chr1:62541171	chr1:62688482~62710694:+
PRAD	cis	rs995000	0.931	rs1184547	ENSG00000235545.1	RP11-230B22.1	-7.2	2.5e-12	9.31e-10	-0.42	-0.32	Triglyceride levels;	chr1:62541557	chr1:62688482~62710694:+
PRAD	cis	rs995000	0.965	rs1168022	ENSG00000235545.1	RP11-230B22.1	-7.2	2.5e-12	9.31e-10	-0.42	-0.32	Triglyceride levels;	chr1:62542050	chr1:62688482~62710694:+
PRAD	cis	rs17772222	0.71	rs1028455	ENSG00000258983.2	RP11-507K2.2	7.2	2.5e-12	9.32e-10	0.43	0.32	Coronary artery calcification;	chr14:88363631	chr14:88499334~88515502:+
PRAD	cis	rs748404	0.697	rs491804	ENSG00000205771.5	CATSPER2P1	-7.2	2.51e-12	9.35e-10	-0.34	-0.32	Lung cancer;	chr15:43268627	chr15:43726918~43747094:-
PRAD	cis	rs2638953	0.779	rs61920241	ENSG00000247934.4	RP11-967K21.1	-7.2	2.51e-12	9.36e-10	-0.32	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195184	chr12:28163298~28190738:-
PRAD	cis	rs853679	0.567	rs1005126	ENSG00000216901.1	AL022393.7	7.2	2.52e-12	9.39e-10	0.44	0.32	Depression;	chr6:28399846	chr6:28176188~28176674:+
PRAD	cis	rs2638953	0.925	rs10843166	ENSG00000278733.1	RP11-425D17.1	-7.2	2.52e-12	9.39e-10	-0.4	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28422811	chr12:28185625~28186190:-
PRAD	cis	rs2243480	1	rs316327	ENSG00000273142.1	RP11-458F8.4	7.2	2.52e-12	9.4e-10	0.36	0.32	Diabetic kidney disease;	chr7:66144214	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs316326	ENSG00000273142.1	RP11-458F8.4	-7.2	2.52e-12	9.4e-10	-0.36	-0.32	Diabetic kidney disease;	chr7:66144466	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs316325	ENSG00000273142.1	RP11-458F8.4	-7.2	2.52e-12	9.4e-10	-0.36	-0.32	Diabetic kidney disease;	chr7:66144531	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs316321	ENSG00000273142.1	RP11-458F8.4	-7.2	2.52e-12	9.4e-10	-0.36	-0.32	Diabetic kidney disease;	chr7:66146626	chr7:66902857~66906297:+
PRAD	cis	rs897984	0.806	rs9319588	ENSG00000279196.1	RP11-1072A3.3	-7.2	2.52e-12	9.4e-10	-0.34	-0.32	Dementia with Lewy bodies;	chr16:30919662	chr16:30984630~30988270:-
PRAD	cis	rs42648	0.905	rs42641	ENSG00000227646.6	STEAP2-AS1	-7.2	2.53e-12	9.41e-10	-0.29	-0.32	Homocysteine levels;	chr7:90343450	chr7:89882353~90211635:-
PRAD	cis	rs42648	0.935	rs42644	ENSG00000227646.6	STEAP2-AS1	-7.2	2.53e-12	9.41e-10	-0.29	-0.32	Homocysteine levels;	chr7:90345550	chr7:89882353~90211635:-
PRAD	cis	rs853679	0.607	rs13199906	ENSG00000226314.6	ZNF192P1	-7.2	2.53e-12	9.42e-10	-0.68	-0.32	Depression;	chr6:27866361	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.607	rs17763089	ENSG00000226314.6	ZNF192P1	-7.2	2.53e-12	9.42e-10	-0.68	-0.32	Depression;	chr6:27867440	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.546	rs17695758	ENSG00000226314.6	ZNF192P1	-7.2	2.53e-12	9.42e-10	-0.68	-0.32	Depression;	chr6:27869405	chr6:28161781~28169594:+
PRAD	cis	rs11603691	1	rs117981067	ENSG00000254662.1	RP11-872D17.4	-7.2	2.53e-12	9.44e-10	-0.73	-0.32	Low high density lipoprotein cholesterol levels;	chr11:57296638	chr11:57325603~57327958:+
PRAD	cis	rs539096	0.5	rs2906457	ENSG00000237950.1	RP11-7O11.3	7.2	2.53e-12	9.44e-10	0.35	0.32	Intelligence (multi-trait analysis);	chr1:43872903	chr1:43944370~43946551:-
PRAD	cis	rs4842666	0.834	rs2681492	ENSG00000258302.2	RP11-981P6.1	7.2	2.53e-12	9.44e-10	0.39	0.32	Blood pressure;	chr12:89619312	chr12:89561129~89594878:+
PRAD	cis	rs79349575	0.715	rs11657238	ENSG00000248278.1	SUMO2P17	7.2	2.54e-12	9.44e-10	0.36	0.32	Type 2 diabetes;	chr17:48908272	chr17:48874860~48908983:-
PRAD	cis	rs6991838	0.725	rs6995134	ENSG00000272010.1	CTD-3025N20.3	7.2	2.54e-12	9.45e-10	0.32	0.32	Intelligence (multi-trait analysis);	chr8:65555472	chr8:65591850~65592472:-
PRAD	cis	rs4728142	0.584	rs7796963	ENSG00000275106.1	RP11-309L24.10	-7.2	2.54e-12	9.46e-10	-0.4	-0.32	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128988947	chr7:128952527~128953316:-
PRAD	cis	rs12612619	0.677	rs67100745	ENSG00000272148.1	RP11-195B17.1	7.2	2.54e-12	9.46e-10	0.39	0.32	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27027882	chr2:27062428~27062907:-
PRAD	cis	rs6539288	0.933	rs10746070	ENSG00000260329.1	RP11-412D9.4	-7.2	2.54e-12	9.47e-10	-0.28	-0.32	Total body bone mineral density;	chr12:106910681	chr12:106954029~106955497:-
PRAD	cis	rs1979679	0.578	rs1993936	ENSG00000278733.1	RP11-425D17.1	7.2	2.55e-12	9.48e-10	0.41	0.32	Ossification of the posterior longitudinal ligament of the spine;	chr12:28120979	chr12:28185625~28186190:-
PRAD	cis	rs12612619	0.732	rs2304681	ENSG00000229122.1	AGBL5-IT1	-7.2	2.56e-12	9.53e-10	-0.33	-0.32	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27092384	chr2:27061038~27061815:+
PRAD	cis	rs4728142	0.604	rs6969930	ENSG00000275106.1	RP11-309L24.10	-7.2	2.56e-12	9.53e-10	-0.4	-0.32	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128990259	chr7:128952527~128953316:-
PRAD	cis	rs853679	0.556	rs13200214	ENSG00000280107.1	AL022393.9	-7.2	2.56e-12	9.53e-10	-0.65	-0.32	Depression;	chr6:28049472	chr6:28170845~28172521:+
PRAD	cis	rs7131987	0.65	rs4331146	ENSG00000275476.1	RP11-996F15.4	-7.2	2.56e-12	9.55e-10	-0.34	-0.32	QT interval;	chr12:29287150	chr12:29277397~29277882:-
PRAD	cis	rs780096	1	rs780096	ENSG00000234072.1	AC074117.10	-7.2	2.57e-12	9.57e-10	-0.25	-0.32	Total body bone mineral density;	chr2:27518205	chr2:27356246~27367622:+
PRAD	cis	rs45509595	0.841	rs17751184	ENSG00000226314.6	ZNF192P1	-7.2	2.57e-12	9.58e-10	-0.68	-0.32	Breast cancer;	chr6:27807250	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.607	rs67101035	ENSG00000226314.6	ZNF192P1	-7.2	2.57e-12	9.58e-10	-0.68	-0.32	Depression;	chr6:27831109	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.556	rs34706883	ENSG00000226314.6	ZNF192P1	-7.2	2.57e-12	9.58e-10	-0.68	-0.32	Depression;	chr6:27837477	chr6:28161781~28169594:+
PRAD	cis	rs67340775	0.748	rs13212651	ENSG00000226314.6	ZNF192P1	-7.2	2.57e-12	9.58e-10	-0.68	-0.32	Lung cancer in ever smokers;	chr6:27839207	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.546	rs35819751	ENSG00000226314.6	ZNF192P1	-7.2	2.57e-12	9.58e-10	-0.68	-0.32	Depression;	chr6:27842791	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.607	rs13194781	ENSG00000226314.6	ZNF192P1	-7.2	2.57e-12	9.58e-10	-0.68	-0.32	Depression;	chr6:27847861	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.546	rs36116761	ENSG00000226314.6	ZNF192P1	-7.2	2.57e-12	9.58e-10	-0.68	-0.32	Depression;	chr6:27850704	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.546	rs34194357	ENSG00000226314.6	ZNF192P1	-7.2	2.57e-12	9.58e-10	-0.68	-0.32	Depression;	chr6:27850757	chr6:28161781~28169594:+
PRAD	cis	rs1499614	1	rs2707832	ENSG00000273142.1	RP11-458F8.4	-7.2	2.58e-12	9.59e-10	-0.36	-0.32	Gout;	chr7:66671562	chr7:66902857~66906297:+
PRAD	cis	rs4664293	0.74	rs12464577	ENSG00000226266.5	AC009961.3	7.2	2.58e-12	9.61e-10	0.42	0.32	Monocyte percentage of white cells;	chr2:159816321	chr2:159670708~159712435:-
PRAD	cis	rs2243480	0.908	rs55876148	ENSG00000273142.1	RP11-458F8.4	-7.2	2.58e-12	9.61e-10	-0.35	-0.32	Diabetic kidney disease;	chr7:65914813	chr7:66902857~66906297:+
PRAD	cis	rs1823874	0.72	rs7162911	ENSG00000182397.13	DNM1P46	-7.2	2.58e-12	9.61e-10	-0.31	-0.32	IgG glycosylation;	chr15:99814845	chr15:99790156~99806927:-
PRAD	cis	rs10050311	0.585	rs113536481	ENSG00000251411.1	RP11-397E7.4	-7.2	2.58e-12	9.62e-10	-0.42	-0.32	Insulin-related traits;	chr4:86943979	chr4:86913266~86914817:-
PRAD	cis	rs10266483	0.654	rs6962076	ENSG00000271550.1	BNIP3P11	-7.2	2.58e-12	9.62e-10	-0.45	-0.32	Response to statin therapy;	chr7:64559214	chr7:64678954~64687393:-
PRAD	cis	rs6991838	0.584	rs2175810	ENSG00000200714.1	Y_RNA	-7.2	2.59e-12	9.63e-10	-0.35	-0.32	Intelligence (multi-trait analysis);	chr8:65643583	chr8:65592731~65592820:+
PRAD	cis	rs875971	0.66	rs10263935	ENSG00000237310.1	GS1-124K5.4	7.2	2.59e-12	9.63e-10	0.27	0.32	Aortic root size;	chr7:66631041	chr7:66493706~66495474:+
PRAD	cis	rs853679	0.55	rs1233699	ENSG00000204709.4	LINC01556	7.2	2.59e-12	9.63e-10	0.42	0.32	Depression;	chr6:28201380	chr6:28943877~28944537:+
PRAD	cis	rs867371	0.929	rs1045508	ENSG00000278603.1	RP13-608F4.5	-7.2	2.59e-12	9.64e-10	-0.42	-0.32	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82157565	chr15:82472203~82472426:+
PRAD	cis	rs12612619	0.704	rs10185736	ENSG00000229122.1	AGBL5-IT1	-7.19	2.59e-12	9.66e-10	-0.33	-0.32	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27098356	chr2:27061038~27061815:+
PRAD	cis	rs11976180	0.569	rs12703565	ENSG00000170356.8	OR2A20P	-7.19	2.6e-12	9.67e-10	-0.53	-0.32	Obesity-related traits;	chr7:144057308	chr7:144250045~144252957:-
PRAD	cis	rs875971	0.54	rs4717275	ENSG00000237310.1	GS1-124K5.4	-7.19	2.6e-12	9.67e-10	-0.27	-0.32	Aortic root size;	chr7:65800193	chr7:66493706~66495474:+
PRAD	cis	rs4842666	0.915	rs6538195	ENSG00000258302.2	RP11-981P6.1	7.19	2.6e-12	9.68e-10	0.39	0.32	Blood pressure;	chr12:89668599	chr12:89561129~89594878:+
PRAD	cis	rs6569038	0.669	rs2884078	ENSG00000253194.1	RP11-351A11.1	-7.19	2.6e-12	9.69e-10	-0.41	-0.32	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:119065019	chr6:118934785~119031541:+
PRAD	cis	rs516805	0.781	rs502103	ENSG00000279453.1	RP3-425C14.4	-7.19	2.61e-12	9.7e-10	-0.29	-0.32	Lymphocyte counts;	chr6:122446062	chr6:122436789~122439223:-
PRAD	cis	rs6782228	1	rs6801509	ENSG00000242551.2	POU5F1P6	7.19	2.61e-12	9.7e-10	0.46	0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128645426	chr3:128674735~128677005:-
PRAD	cis	rs2243480	1	rs1499614	ENSG00000273142.1	RP11-458F8.4	-7.19	2.61e-12	9.72e-10	-0.36	-0.32	Diabetic kidney disease;	chr7:66265811	chr7:66902857~66906297:+
PRAD	cis	rs2836950	0.545	rs2836956	ENSG00000255568.3	BRWD1-AS2	7.19	2.61e-12	9.72e-10	0.26	0.32	Menarche (age at onset);	chr21:39251092	chr21:39313935~39314962:+
PRAD	cis	rs2243480	1	rs778729	ENSG00000273142.1	RP11-458F8.4	-7.19	2.61e-12	9.72e-10	-0.36	-0.32	Diabetic kidney disease;	chr7:66359432	chr7:66902857~66906297:+
PRAD	cis	rs2243480	0.901	rs778687	ENSG00000273142.1	RP11-458F8.4	-7.19	2.61e-12	9.72e-10	-0.36	-0.32	Diabetic kidney disease;	chr7:66370832	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs778679	ENSG00000273142.1	RP11-458F8.4	-7.19	2.61e-12	9.72e-10	-0.36	-0.32	Diabetic kidney disease;	chr7:66375924	chr7:66902857~66906297:+
PRAD	cis	rs2243480	0.901	rs12530490	ENSG00000273142.1	RP11-458F8.4	7.19	2.61e-12	9.72e-10	0.36	0.32	Diabetic kidney disease;	chr7:66226660	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs7778911	ENSG00000273142.1	RP11-458F8.4	7.19	2.61e-12	9.72e-10	0.36	0.32	Diabetic kidney disease;	chr7:66229519	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs1979823	ENSG00000273142.1	RP11-458F8.4	7.19	2.61e-12	9.72e-10	0.36	0.32	Diabetic kidney disease;	chr7:66239626	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs4718334	ENSG00000273142.1	RP11-458F8.4	7.19	2.61e-12	9.72e-10	0.36	0.32	Diabetic kidney disease;	chr7:66324467	chr7:66902857~66906297:+
PRAD	cis	rs2243480	0.908	rs1532573	ENSG00000273142.1	RP11-458F8.4	7.19	2.61e-12	9.72e-10	0.36	0.32	Diabetic kidney disease;	chr7:66333815	chr7:66902857~66906297:+
PRAD	cis	rs11098499	0.644	rs34835603	ENSG00000245958.5	RP11-33B1.1	-7.19	2.62e-12	9.76e-10	-0.3	-0.32	Corneal astigmatism;	chr4:119632273	chr4:119454791~119552025:+
PRAD	cis	rs11098499	0.615	rs28850368	ENSG00000245958.5	RP11-33B1.1	-7.19	2.62e-12	9.76e-10	-0.3	-0.32	Corneal astigmatism;	chr4:119633158	chr4:119454791~119552025:+
PRAD	cis	rs736801	0.569	rs11748193	ENSG00000233006.5	AC034220.3	7.19	2.62e-12	9.76e-10	0.29	0.32	Mosquito bite size;Breast cancer;	chr5:132389637	chr5:132311285~132369916:-
PRAD	cis	rs4925386	0.681	rs2427294	ENSG00000273619.1	RP5-908M14.9	-7.19	2.63e-12	9.77e-10	-0.23	-0.32	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62352201	chr20:62386303~62386970:-
PRAD	cis	rs6539247	0.527	rs10778456	ENSG00000257890.1	RP11-114F10.2	-7.19	2.63e-12	9.77e-10	-0.37	-0.32	Attention function in attention deficit hyperactive disorder;	chr12:106054524	chr12:106050961~106058254:-
PRAD	cis	rs2274273	0.662	rs67588230	ENSG00000258413.1	RP11-665C16.6	-7.19	2.63e-12	9.79e-10	-0.45	-0.32	Protein biomarker;	chr14:55200312	chr14:55262767~55272075:-
PRAD	cis	rs2274273	0.662	rs4040064	ENSG00000258413.1	RP11-665C16.6	-7.19	2.63e-12	9.79e-10	-0.45	-0.32	Protein biomarker;	chr14:55211370	chr14:55262767~55272075:-
PRAD	cis	rs4927850	1	rs7625570	ENSG00000231464.1	AC024937.4	7.19	2.64e-12	9.81e-10	0.38	0.32	Pancreatic cancer;	chr3:196020527	chr3:195996738~195998233:+
PRAD	cis	rs2638953	0.861	rs11049685	ENSG00000247934.4	RP11-967K21.1	-7.19	2.64e-12	9.82e-10	-0.31	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28512775	chr12:28163298~28190738:-
PRAD	cis	rs71636778	0.509	rs36053809	ENSG00000260063.1	RP5-968P14.2	-7.19	2.65e-12	9.84e-10	-0.65	-0.32	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26756602	chr1:26692132~26694131:-
PRAD	cis	rs875971	0.522	rs709604	ENSG00000237310.1	GS1-124K5.4	-7.19	2.65e-12	9.86e-10	-0.27	-0.32	Aortic root size;	chr7:66032447	chr7:66493706~66495474:+
PRAD	cis	rs2439831	0.85	rs28590651	ENSG00000205771.5	CATSPER2P1	-7.19	2.65e-12	9.87e-10	-0.49	-0.32	Lung cancer in ever smokers;	chr15:43820818	chr15:43726918~43747094:-
PRAD	cis	rs2337406	0.925	rs4774188	ENSG00000274576.2	IGHV2-70	-7.19	2.66e-12	9.9e-10	-0.37	-0.32	Alzheimer's disease (late onset);	chr14:106767918	chr14:106770577~106771020:-
PRAD	cis	rs496547	0.588	rs473298	ENSG00000255239.1	AP002954.6	7.19	2.67e-12	9.94e-10	0.43	0.32	Hip minimal joint space width;	chr11:118808678	chr11:118688039~118690600:-
PRAD	cis	rs6479891	1	rs4469774	ENSG00000232075.1	MRPL35P2	7.19	2.67e-12	9.95e-10	0.49	0.32	Arthritis (juvenile idiopathic);	chr10:63550017	chr10:63634317~63634827:-
PRAD	cis	rs2638953	0.604	rs10843100	ENSG00000278733.1	RP11-425D17.1	-7.19	2.68e-12	9.95e-10	-0.42	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28117101	chr12:28185625~28186190:-
PRAD	cis	rs10463554	0.856	rs2432169	ENSG00000175749.11	EIF3KP1	7.19	2.68e-12	9.97e-10	0.4	0.32	Parkinson's disease;	chr5:103179056	chr5:103032376~103033031:+
PRAD	cis	rs875971	0.522	rs4718286	ENSG00000237310.1	GS1-124K5.4	7.19	2.69e-12	9.99e-10	0.27	0.32	Aortic root size;	chr7:65827777	chr7:66493706~66495474:+
PRAD	cis	rs17711722	0.585	rs6942660	ENSG00000237310.1	GS1-124K5.4	7.19	2.69e-12	9.99e-10	0.27	0.32	Calcium levels;	chr7:65837419	chr7:66493706~66495474:+
PRAD	cis	rs12432203	1	rs61064202	ENSG00000258479.4	LINC00640	7.19	2.69e-12	9.99e-10	0.59	0.32	Cancer;	chr14:51280349	chr14:51333393~51365557:+
PRAD	cis	rs6547741	0.775	rs11692692	ENSG00000234072.1	AC074117.10	-7.19	2.69e-12	9.99e-10	-0.25	-0.32	Oral cavity cancer;	chr2:27638840	chr2:27356246~27367622:+
PRAD	cis	rs11846409	0.932	rs73378155	ENSG00000274576.2	IGHV2-70	-7.19	2.69e-12	9.99e-10	-0.32	-0.32	Rheumatic heart disease;	chr14:106637840	chr14:106770577~106771020:-
PRAD	cis	rs995000	0.931	rs1168013	ENSG00000235545.1	RP11-230B22.1	7.19	2.69e-12	9.99e-10	0.43	0.32	Triglyceride levels;	chr1:62531167	chr1:62688482~62710694:+
PRAD	cis	rs964611	0.575	rs11636267	ENSG00000259488.2	RP11-154J22.1	7.19	2.69e-12	1e-09	0.32	0.32	Metabolite levels (Pyroglutamine);	chr15:48387795	chr15:48312353~48331856:-
PRAD	cis	rs875971	0.522	rs4718285	ENSG00000237310.1	GS1-124K5.4	7.19	2.69e-12	1e-09	0.27	0.32	Aortic root size;	chr7:65827018	chr7:66493706~66495474:+
PRAD	cis	rs5758511	0.514	rs5758580	ENSG00000227370.1	RP4-669P10.19	7.19	2.7e-12	1e-09	0.35	0.32	Birth weight;	chr22:42097871	chr22:42132543~42132998:+
PRAD	cis	rs8177376	0.727	rs601985	ENSG00000254905.1	RP11-712L6.7	7.19	2.71e-12	1.01e-09	0.38	0.32	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126327662	chr11:126292922~126294254:-
PRAD	cis	rs11846409	0.86	rs73378154	ENSG00000274576.2	IGHV2-70	-7.19	2.71e-12	1.01e-09	-0.33	-0.32	Rheumatic heart disease;	chr14:106637687	chr14:106770577~106771020:-
PRAD	cis	rs4713118	0.513	rs156739	ENSG00000220721.1	OR1F12	7.19	2.71e-12	1.01e-09	0.37	0.32	Parkinson's disease;	chr6:28045632	chr6:28073316~28074233:+
PRAD	cis	rs9309711	0.922	rs13385119	ENSG00000225234.1	TRAPPC12-AS1	-7.19	2.71e-12	1.01e-09	-0.35	-0.32	Neurofibrillary tangles;	chr2:3480750	chr2:3481242~3482409:-
PRAD	cis	rs875971	0.522	rs7784623	ENSG00000237310.1	GS1-124K5.4	7.19	2.72e-12	1.01e-09	0.27	0.32	Aortic root size;	chr7:65930047	chr7:66493706~66495474:+
PRAD	cis	rs1799949	0.965	rs6503726	ENSG00000267002.1	RP11-242D8.1	7.19	2.72e-12	1.01e-09	0.3	0.32	Menopause (age at onset);	chr17:43132725	chr17:43164183~43170403:-
PRAD	cis	rs13113518	0.812	rs12500686	ENSG00000249700.7	SRD5A3-AS1	7.19	2.72e-12	1.01e-09	0.43	0.32	Height;	chr4:55457922	chr4:55363971~55395847:-
PRAD	cis	rs10129255	0.957	rs11846893	ENSG00000211970.3	IGHV4-61	-7.19	2.73e-12	1.01e-09	-0.29	-0.32	Kawasaki disease;	chr14:106779068	chr14:106639119~106639657:-
PRAD	cis	rs10129255	0.957	rs12589190	ENSG00000211970.3	IGHV4-61	-7.19	2.73e-12	1.02e-09	-0.29	-0.32	Kawasaki disease;	chr14:106783079	chr14:106639119~106639657:-
PRAD	cis	rs150992	0.603	rs326481	ENSG00000248489.1	CTD-2007H13.3	7.19	2.74e-12	1.02e-09	0.4	0.32	Body mass index;	chr5:98949581	chr5:98929171~98995013:+
PRAD	cis	rs7829975	0.517	rs12542733	ENSG00000253893.2	FAM85B	7.19	2.74e-12	1.02e-09	0.38	0.32	Mood instability;	chr8:8967348	chr8:8167819~8226614:-
PRAD	cis	rs2638953	0.924	rs11049569	ENSG00000278733.1	RP11-425D17.1	-7.19	2.74e-12	1.02e-09	-0.4	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28386823	chr12:28185625~28186190:-
PRAD	cis	rs875971	0.516	rs6945322	ENSG00000237310.1	GS1-124K5.4	7.19	2.74e-12	1.02e-09	0.27	0.32	Aortic root size;	chr7:65871069	chr7:66493706~66495474:+
PRAD	cis	rs17711722	0.701	rs55773927	ENSG00000237310.1	GS1-124K5.4	7.19	2.74e-12	1.02e-09	0.27	0.32	Calcium levels;	chr7:65872915	chr7:66493706~66495474:+
PRAD	cis	rs17711722	0.727	rs35850374	ENSG00000237310.1	GS1-124K5.4	7.19	2.74e-12	1.02e-09	0.27	0.32	Calcium levels;	chr7:65892789	chr7:66493706~66495474:+
PRAD	cis	rs11098499	0.874	rs28452522	ENSG00000245958.5	RP11-33B1.1	-7.19	2.74e-12	1.02e-09	-0.33	-0.32	Corneal astigmatism;	chr4:119189629	chr4:119454791~119552025:+
PRAD	cis	rs17711722	0.64	rs13237956	ENSG00000237310.1	GS1-124K5.4	7.19	2.75e-12	1.02e-09	0.27	0.32	Calcium levels;	chr7:65853042	chr7:66493706~66495474:+
PRAD	cis	rs2638953	0.853	rs11049670	ENSG00000278733.1	RP11-425D17.1	7.19	2.76e-12	1.03e-09	0.39	0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28499342	chr12:28185625~28186190:-
PRAD	cis	rs1799949	1	rs11649954	ENSG00000267002.1	RP11-242D8.1	7.19	2.77e-12	1.03e-09	0.3	0.32	Menopause (age at onset);	chr17:43342667	chr17:43164183~43170403:-
PRAD	cis	rs1799949	1	rs1824889	ENSG00000267002.1	RP11-242D8.1	7.19	2.77e-12	1.03e-09	0.3	0.32	Menopause (age at onset);	chr17:43344508	chr17:43164183~43170403:-
PRAD	cis	rs7746199	0.736	rs35037868	ENSG00000226314.6	ZNF192P1	-7.18	2.77e-12	1.03e-09	-0.69	-0.32	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27791336	chr6:28161781~28169594:+
PRAD	cis	rs748404	0.697	rs531910	ENSG00000205771.5	CATSPER2P1	-7.18	2.77e-12	1.03e-09	-0.34	-0.32	Lung cancer;	chr15:43268409	chr15:43726918~43747094:-
PRAD	cis	rs748404	0.697	rs492743	ENSG00000205771.5	CATSPER2P1	-7.18	2.77e-12	1.03e-09	-0.34	-0.32	Lung cancer;	chr15:43268747	chr15:43726918~43747094:-
PRAD	cis	rs2638953	0.893	rs10843192	ENSG00000247934.4	RP11-967K21.1	-7.18	2.77e-12	1.03e-09	-0.31	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28508756	chr12:28163298~28190738:-
PRAD	cis	rs7829975	0.626	rs907183	ENSG00000253893.2	FAM85B	7.18	2.78e-12	1.03e-09	0.4	0.32	Mood instability;	chr8:8872251	chr8:8167819~8226614:-
PRAD	cis	rs12468226	0.938	rs116109808	ENSG00000273456.1	RP11-686O6.2	7.18	2.78e-12	1.03e-09	0.44	0.32	Urate levels;	chr2:202287356	chr2:202374932~202375604:-
PRAD	cis	rs12468226	0.873	rs78175596	ENSG00000273456.1	RP11-686O6.2	7.18	2.78e-12	1.03e-09	0.44	0.32	Urate levels;	chr2:202287993	chr2:202374932~202375604:-
PRAD	cis	rs12468226	0.938	rs74454549	ENSG00000273456.1	RP11-686O6.2	7.18	2.78e-12	1.03e-09	0.44	0.32	Urate levels;	chr2:202288044	chr2:202374932~202375604:-
PRAD	cis	rs853679	0.538	rs13199081	ENSG00000216901.1	AL022393.7	7.18	2.78e-12	1.03e-09	0.44	0.32	Depression;	chr6:28364057	chr6:28176188~28176674:+
PRAD	cis	rs7615952	0.736	rs9862893	ENSG00000171084.14	FAM86JP	7.18	2.79e-12	1.04e-09	0.57	0.32	Blood pressure (smoking interaction);	chr3:125968131	chr3:125916620~125930024:+
PRAD	cis	rs10129255	0.642	rs11624918	ENSG00000223648.3	IGHV3-64	7.18	2.79e-12	1.04e-09	0.34	0.32	Kawasaki disease;	chr14:106664672	chr14:106643132~106658258:-
PRAD	cis	rs75422866	0.51	rs73105803	ENSG00000257433.4	RP1-197B17.3	7.18	2.8e-12	1.04e-09	0.66	0.32	Pneumonia;	chr12:47722135	chr12:47706085~47742294:+
PRAD	cis	rs75422866	0.51	rs73105812	ENSG00000257433.4	RP1-197B17.3	7.18	2.8e-12	1.04e-09	0.66	0.32	Pneumonia;	chr12:47724404	chr12:47706085~47742294:+
PRAD	cis	rs75422866	0.51	rs74733564	ENSG00000257433.4	RP1-197B17.3	7.18	2.8e-12	1.04e-09	0.66	0.32	Pneumonia;	chr12:47724644	chr12:47706085~47742294:+
PRAD	cis	rs75422866	0.51	rs73105814	ENSG00000257433.4	RP1-197B17.3	7.18	2.8e-12	1.04e-09	0.66	0.32	Pneumonia;	chr12:47725817	chr12:47706085~47742294:+
PRAD	cis	rs4713118	0.513	rs200971	ENSG00000219392.1	RP1-265C24.5	-7.18	2.8e-12	1.04e-09	-0.4	-0.32	Parkinson's disease;	chr6:27891126	chr6:28115628~28116551:+
PRAD	cis	rs9467773	0.838	rs3734540	ENSG00000124549.13	BTN2A3P	7.18	2.8e-12	1.04e-09	0.28	0.32	Intelligence (multi-trait analysis);	chr6:26463093	chr6:26421391~26432383:+
PRAD	cis	rs848490	0.674	rs17807185	ENSG00000214293.7	APTR	7.18	2.8e-12	1.04e-09	0.33	0.32	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77678978	chr7:77657660~77696265:-
PRAD	cis	rs881375	0.715	rs7858209	ENSG00000226752.6	PSMD5-AS1	-7.18	2.81e-12	1.04e-09	-0.37	-0.32	Rheumatoid arthritis;	chr9:120883482	chr9:120824828~120854385:+
PRAD	cis	rs881375	0.715	rs10760119	ENSG00000226752.6	PSMD5-AS1	-7.18	2.81e-12	1.04e-09	-0.37	-0.32	Rheumatoid arthritis;	chr9:120883782	chr9:120824828~120854385:+
PRAD	cis	rs516805	0.924	rs809770	ENSG00000279453.1	RP3-425C14.4	-7.18	2.82e-12	1.05e-09	-0.25	-0.32	Lymphocyte counts;	chr6:122440061	chr6:122436789~122439223:-
PRAD	cis	rs17711722	0.565	rs4275112	ENSG00000234585.5	CCT6P3	-7.18	2.82e-12	1.05e-09	-0.24	-0.32	Calcium levels;	chr7:65733651	chr7:65038354~65074713:+
PRAD	cis	rs2739330	0.76	rs5751761	ENSG00000228039.3	KB-1125A3.10	-7.18	2.82e-12	1.05e-09	-0.4	-0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23963780~23964374:+
PRAD	cis	rs4925386	0.921	rs11204472	ENSG00000273619.1	RP5-908M14.9	7.18	2.82e-12	1.05e-09	0.2	0.32	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62345831	chr20:62386303~62386970:-
PRAD	cis	rs12468226	0.873	rs76552560	ENSG00000273456.1	RP11-686O6.2	7.18	2.82e-12	1.05e-09	0.44	0.32	Urate levels;	chr2:202173123	chr2:202374932~202375604:-
PRAD	cis	rs2638953	0.962	rs11049493	ENSG00000247934.4	RP11-967K21.1	-7.18	2.83e-12	1.05e-09	-0.34	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28263115	chr12:28163298~28190738:-
PRAD	cis	rs9467773	0.572	rs13213953	ENSG00000124549.13	BTN2A3P	7.18	2.83e-12	1.05e-09	0.28	0.32	Intelligence (multi-trait analysis);	chr6:26594306	chr6:26421391~26432383:+
PRAD	cis	rs2033711	0.755	rs4801587	ENSG00000269473.1	CTD-2619J13.19	7.18	2.83e-12	1.05e-09	0.35	0.32	Uric acid clearance;	chr19:58425312	chr19:58440448~58445849:+
PRAD	cis	rs12821008	1	rs12821008	ENSG00000258017.1	RP11-386G11.10	-7.18	2.83e-12	1.05e-09	-0.45	-0.32	Bone mineral density;	chr12:49080822	chr12:49127782~49147869:+
PRAD	cis	rs17428076	0.874	rs17615262	ENSG00000228389.1	AC068039.4	-7.18	2.84e-12	1.05e-09	-0.41	-0.32	Myopia;	chr2:171826971	chr2:171773482~171775844:+
PRAD	cis	rs9393777	0.841	rs13207082	ENSG00000280107.1	AL022393.9	-7.18	2.84e-12	1.05e-09	-0.65	-0.32	Intelligence (multi-trait analysis);	chr6:27283600	chr6:28170845~28172521:+
PRAD	cis	rs2439831	0.85	rs12702	ENSG00000249839.1	AC011330.5	7.18	2.84e-12	1.05e-09	0.41	0.32	Lung cancer in ever smokers;	chr15:43801729	chr15:43663654~43684339:-
PRAD	cis	rs5758511	0.514	rs5751221	ENSG00000227370.1	RP4-669P10.19	7.18	2.84e-12	1.05e-09	0.35	0.32	Birth weight;	chr22:42120362	chr22:42132543~42132998:+
PRAD	cis	rs42648	0.869	rs42611	ENSG00000227646.6	STEAP2-AS1	-7.18	2.84e-12	1.05e-09	-0.29	-0.32	Homocysteine levels;	chr7:90320746	chr7:89882353~90211635:-
PRAD	cis	rs6921919	0.945	rs16901847	ENSG00000204709.4	LINC01556	7.18	2.85e-12	1.05e-09	0.47	0.32	Autism spectrum disorder or schizophrenia;	chr6:28408074	chr6:28943877~28944537:+
PRAD	cis	rs10129255	1	rs10141557	ENSG00000223648.3	IGHV3-64	7.18	2.85e-12	1.06e-09	0.33	0.32	Kawasaki disease;	chr14:106767990	chr14:106643132~106658258:-
PRAD	cis	rs9640161	0.789	rs1464751	ENSG00000261305.1	RP4-584D14.7	7.18	2.87e-12	1.06e-09	0.35	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150324193	chr7:150341771~150342607:+
PRAD	cis	rs10129255	0.957	rs8009073	ENSG00000223648.3	IGHV3-64	7.18	2.87e-12	1.06e-09	0.32	0.32	Kawasaki disease;	chr14:106777278	chr14:106643132~106658258:-
PRAD	cis	rs881375	0.715	rs10818482	ENSG00000226752.6	PSMD5-AS1	7.18	2.87e-12	1.06e-09	0.37	0.32	Rheumatoid arthritis;	chr9:120885807	chr9:120824828~120854385:+
PRAD	cis	rs17711722	0.701	rs781143	ENSG00000237310.1	GS1-124K5.4	7.18	2.87e-12	1.06e-09	0.27	0.32	Calcium levels;	chr7:65974892	chr7:66493706~66495474:+
PRAD	cis	rs2337406	0.85	rs1858678	ENSG00000274576.2	IGHV2-70	-7.18	2.87e-12	1.06e-09	-0.38	-0.32	Alzheimer's disease (late onset);	chr14:106706790	chr14:106770577~106771020:-
PRAD	cis	rs2286503	0.78	rs2240727	ENSG00000228649.7	AC005682.5	7.18	2.88e-12	1.07e-09	0.37	0.32	Fibrinogen;	chr7:22812893	chr7:22854178~22861579:+
PRAD	cis	rs6517329	0.932	rs4817775	ENSG00000236830.5	CBR3-AS1	7.18	2.88e-12	1.07e-09	0.33	0.32	Schizophrenia;	chr21:36112764	chr21:36131767~36175815:-
PRAD	cis	rs8062405	0.755	rs1074631	ENSG00000251417.2	RP11-1348G14.4	7.18	2.88e-12	1.07e-09	0.36	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28542787	chr16:28802743~28817828:+
PRAD	cis	rs10875746	0.669	rs11168459	ENSG00000240399.1	RP1-228P16.1	-7.18	2.88e-12	1.07e-09	-0.3	-0.32	Longevity (90 years and older);	chr12:48202458	chr12:48054813~48055591:-
PRAD	cis	rs12432203	1	rs4635253	ENSG00000258479.4	LINC00640	7.18	2.88e-12	1.07e-09	0.59	0.32	Cancer;	chr14:51275112	chr14:51333393~51365557:+
PRAD	cis	rs12432203	1	rs72622441	ENSG00000258479.4	LINC00640	7.18	2.88e-12	1.07e-09	0.59	0.32	Cancer;	chr14:51275647	chr14:51333393~51365557:+
PRAD	cis	rs858239	0.899	rs10085838	ENSG00000226816.2	AC005082.12	7.18	2.88e-12	1.07e-09	0.37	0.32	Cerebrospinal fluid biomarker levels;	chr7:23258796	chr7:23206013~23208045:+
PRAD	cis	rs1799949	1	rs8176202	ENSG00000267002.1	RP11-242D8.1	7.18	2.88e-12	1.07e-09	0.3	0.32	Menopause (age at onset);	chr17:43078211	chr17:43164183~43170403:-
PRAD	cis	rs2274273	0.662	rs2147970	ENSG00000258413.1	RP11-665C16.6	-7.18	2.88e-12	1.07e-09	-0.45	-0.32	Protein biomarker;	chr14:55193499	chr14:55262767~55272075:-
PRAD	cis	rs2274273	0.662	rs66476033	ENSG00000258413.1	RP11-665C16.6	-7.18	2.88e-12	1.07e-09	-0.45	-0.32	Protein biomarker;	chr14:55194145	chr14:55262767~55272075:-
PRAD	cis	rs2274273	0.662	rs2094436	ENSG00000258413.1	RP11-665C16.6	-7.18	2.88e-12	1.07e-09	-0.45	-0.32	Protein biomarker;	chr14:55194777	chr14:55262767~55272075:-
PRAD	cis	rs9640161	0.742	rs2108854	ENSG00000261305.1	RP4-584D14.7	-7.18	2.89e-12	1.07e-09	-0.35	-0.32	Blood protein levels;Circulating chemerin levels;	chr7:150320319	chr7:150341771~150342607:+
PRAD	cis	rs2337406	0.587	rs10139664	ENSG00000274576.2	IGHV2-70	-7.18	2.89e-12	1.07e-09	-0.33	-0.32	Alzheimer's disease (late onset);	chr14:106647254	chr14:106770577~106771020:-
PRAD	cis	rs2337406	0.587	rs10129888	ENSG00000274576.2	IGHV2-70	-7.18	2.89e-12	1.07e-09	-0.33	-0.32	Alzheimer's disease (late onset);	chr14:106647421	chr14:106770577~106771020:-
PRAD	cis	rs964611	0.935	rs74011994	ENSG00000259488.2	RP11-154J22.1	-7.18	2.89e-12	1.07e-09	-0.37	-0.32	Metabolite levels (Pyroglutamine);	chr15:48283226	chr15:48312353~48331856:-
PRAD	cis	rs9640161	0.75	rs1983440	ENSG00000261305.1	RP4-584D14.7	7.18	2.89e-12	1.07e-09	0.36	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150326852	chr7:150341771~150342607:+
PRAD	cis	rs6539288	0.901	rs11113143	ENSG00000260329.1	RP11-412D9.4	-7.18	2.89e-12	1.07e-09	-0.28	-0.32	Total body bone mineral density;	chr12:106910081	chr12:106954029~106955497:-
PRAD	cis	rs17711722	0.701	rs781145	ENSG00000237310.1	GS1-124K5.4	7.18	2.89e-12	1.07e-09	0.27	0.32	Calcium levels;	chr7:65975383	chr7:66493706~66495474:+
PRAD	cis	rs17711722	0.727	rs2658585	ENSG00000237310.1	GS1-124K5.4	7.18	2.89e-12	1.07e-09	0.27	0.32	Calcium levels;	chr7:65996954	chr7:66493706~66495474:+
PRAD	cis	rs17772222	1	rs11159856	ENSG00000258983.2	RP11-507K2.2	7.18	2.9e-12	1.07e-09	0.47	0.32	Coronary artery calcification;	chr14:88417585	chr14:88499334~88515502:+
PRAD	cis	rs17772222	0.917	rs17124652	ENSG00000258983.2	RP11-507K2.2	7.18	2.9e-12	1.07e-09	0.47	0.32	Coronary artery calcification;	chr14:88424384	chr14:88499334~88515502:+
PRAD	cis	rs17772222	0.876	rs4375590	ENSG00000258983.2	RP11-507K2.2	7.18	2.9e-12	1.07e-09	0.47	0.32	Coronary artery calcification;	chr14:88451334	chr14:88499334~88515502:+
PRAD	cis	rs673078	0.571	rs7954330	ENSG00000275409.1	RP11-131L12.4	-7.18	2.9e-12	1.07e-09	-0.48	-0.32	Glucose homeostasis traits;	chr12:118275284	chr12:118430147~118430699:+
PRAD	cis	rs995000	0.931	rs11207979	ENSG00000235545.1	RP11-230B22.1	7.18	2.9e-12	1.07e-09	0.42	0.32	Triglyceride levels;	chr1:62517323	chr1:62688482~62710694:+
PRAD	cis	rs4927850	0.957	rs4927851	ENSG00000231464.1	AC024937.4	7.18	2.9e-12	1.07e-09	0.38	0.32	Pancreatic cancer;	chr3:196024982	chr3:195996738~195998233:+
PRAD	cis	rs4927850	0.918	rs4361313	ENSG00000231464.1	AC024937.4	7.18	2.9e-12	1.07e-09	0.38	0.32	Pancreatic cancer;	chr3:196025389	chr3:195996738~195998233:+
PRAD	cis	rs172166	0.694	rs1225716	ENSG00000204709.4	LINC01556	7.18	2.9e-12	1.07e-09	0.41	0.32	Cardiac Troponin-T levels;	chr6:28145968	chr6:28943877~28944537:+
PRAD	cis	rs4713118	0.512	rs2622319	ENSG00000204709.4	LINC01556	7.18	2.9e-12	1.07e-09	0.41	0.32	Parkinson's disease;	chr6:28152623	chr6:28943877~28944537:+
PRAD	cis	rs13113518	0.678	rs13149568	ENSG00000249700.7	SRD5A3-AS1	7.18	2.9e-12	1.07e-09	0.42	0.32	Height;	chr4:55370412	chr4:55363971~55395847:-
PRAD	cis	rs1707322	0.686	rs3014251	ENSG00000280836.1	AL355480.1	7.18	2.91e-12	1.08e-09	0.4	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45611756	chr1:45581219~45581321:-
PRAD	cis	rs853679	0.527	rs707907	ENSG00000280107.1	AL022393.9	-7.18	2.91e-12	1.08e-09	-0.39	-0.32	Depression;	chr6:28323463	chr6:28170845~28172521:+
PRAD	cis	rs2921073	0.605	rs2976933	ENSG00000253893.2	FAM85B	-7.18	2.92e-12	1.08e-09	-0.4	-0.32	Parkinson's disease;	chr8:8397365	chr8:8167819~8226614:-
PRAD	cis	rs1799949	0.965	rs8070179	ENSG00000267002.1	RP11-242D8.1	7.18	2.92e-12	1.08e-09	0.3	0.32	Menopause (age at onset);	chr17:43050671	chr17:43164183~43170403:-
PRAD	cis	rs17275866	0.963	rs873371	ENSG00000248174.4	RP11-148L24.1	7.18	2.93e-12	1.08e-09	0.45	0.32	Chin dimples;	chr4:174148404	chr4:174094660~174220398:-
PRAD	cis	rs1499614	1	rs1267818	ENSG00000273142.1	RP11-458F8.4	-7.18	2.93e-12	1.08e-09	-0.37	-0.32	Gout;	chr7:66642037	chr7:66902857~66906297:+
PRAD	cis	rs1499614	1	rs1267817	ENSG00000273142.1	RP11-458F8.4	-7.18	2.93e-12	1.08e-09	-0.37	-0.32	Gout;	chr7:66645053	chr7:66902857~66906297:+
PRAD	cis	rs4927850	1	rs7627706	ENSG00000231464.1	AC024937.4	7.18	2.93e-12	1.08e-09	0.38	0.32	Pancreatic cancer;	chr3:196026482	chr3:195996738~195998233:+
PRAD	cis	rs4927850	0.881	rs7630489	ENSG00000231464.1	AC024937.4	7.18	2.93e-12	1.08e-09	0.38	0.32	Pancreatic cancer;	chr3:196026530	chr3:195996738~195998233:+
PRAD	cis	rs4927850	1	rs7627868	ENSG00000231464.1	AC024937.4	7.18	2.93e-12	1.08e-09	0.38	0.32	Pancreatic cancer;	chr3:196026602	chr3:195996738~195998233:+
PRAD	cis	rs881375	0.678	rs10739581	ENSG00000226752.6	PSMD5-AS1	-7.18	2.93e-12	1.08e-09	-0.36	-0.32	Rheumatoid arthritis;	chr9:120934593	chr9:120824828~120854385:+
PRAD	cis	rs11976180	0.569	rs12703565	ENSG00000244198.4	RP4-545C24.1	-7.18	2.93e-12	1.09e-09	-0.52	-0.32	Obesity-related traits;	chr7:144057308	chr7:144194858~144280547:+
PRAD	cis	rs875971	0.505	rs1723275	ENSG00000237310.1	GS1-124K5.4	-7.18	2.93e-12	1.09e-09	-0.27	-0.32	Aortic root size;	chr7:66039646	chr7:66493706~66495474:+
PRAD	cis	rs496547	0.719	rs598373	ENSG00000255239.1	AP002954.6	7.18	2.93e-12	1.09e-09	0.43	0.32	Hip minimal joint space width;	chr11:118793668	chr11:118688039~118690600:-
PRAD	cis	rs9810089	0.835	rs6791611	ENSG00000261758.1	RP11-102M11.2	-7.18	2.93e-12	1.09e-09	-0.37	-0.32	Gestational age at birth (child effect);	chr3:136441748	chr3:136752630~136755780:+
PRAD	cis	rs4927850	0.958	rs1975582	ENSG00000231464.1	AC024937.4	7.18	2.94e-12	1.09e-09	0.38	0.32	Pancreatic cancer;	chr3:196024568	chr3:195996738~195998233:+
PRAD	cis	rs2581828	0.618	rs7615099	ENSG00000242142.1	SERBP1P3	-7.18	2.94e-12	1.09e-09	-0.37	-0.32	Crohn's disease;	chr3:53109885	chr3:53064283~53065091:-
PRAD	cis	rs2243480	1	rs4718317	ENSG00000273142.1	RP11-458F8.4	7.18	2.94e-12	1.09e-09	0.36	0.32	Diabetic kidney disease;	chr7:66183914	chr7:66902857~66906297:+
PRAD	cis	rs853679	0.607	rs67340775	ENSG00000225595.2	XXbac-BPG308K3.6	7.18	2.95e-12	1.09e-09	0.66	0.32	Depression;	chr6:28336607	chr6:28859625~28864630:-
PRAD	cis	rs2067615	0.56	rs12298717	ENSG00000260329.1	RP11-412D9.4	7.18	2.95e-12	1.09e-09	0.27	0.32	Heart rate;	chr12:106706105	chr12:106954029~106955497:-
PRAD	cis	rs2638953	0.853	rs11049679	ENSG00000278733.1	RP11-425D17.1	-7.18	2.95e-12	1.09e-09	-0.39	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28508161	chr12:28185625~28186190:-
PRAD	cis	rs1355223	0.844	rs12809046	ENSG00000271369.1	RP11-350D17.3	-7.17	2.96e-12	1.09e-09	-0.38	-0.32	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34726714	chr11:34709600~34710161:+
PRAD	cis	rs2439831	0.85	rs7169988	ENSG00000205771.5	CATSPER2P1	-7.17	2.96e-12	1.09e-09	-0.5	-0.32	Lung cancer in ever smokers;	chr15:43768237	chr15:43726918~43747094:-
PRAD	cis	rs7191700	0.578	rs243324	ENSG00000263080.1	RP11-485G7.5	7.17	2.96e-12	1.09e-09	0.37	0.32	Multiple sclerosis;	chr16:11261113	chr16:11341809~11345211:-
PRAD	cis	rs5758511	0.514	rs5751211	ENSG00000227370.1	RP4-669P10.19	7.17	2.96e-12	1.09e-09	0.35	0.32	Birth weight;	chr22:42090052	chr22:42132543~42132998:+
PRAD	cis	rs5758511	0.514	rs3985938	ENSG00000227370.1	RP4-669P10.19	7.17	2.96e-12	1.09e-09	0.35	0.32	Birth weight;	chr22:42115723	chr22:42132543~42132998:+
PRAD	cis	rs5758511	0.514	rs5758586	ENSG00000227370.1	RP4-669P10.19	7.17	2.96e-12	1.09e-09	0.35	0.32	Birth weight;	chr22:42121467	chr22:42132543~42132998:+
PRAD	cis	rs5758511	0.514	rs5751222	ENSG00000227370.1	RP4-669P10.19	7.17	2.96e-12	1.09e-09	0.35	0.32	Birth weight;	chr22:42121918	chr22:42132543~42132998:+
PRAD	cis	rs1862618	0.525	rs2662021	ENSG00000271828.1	CTD-2310F14.1	-7.17	2.96e-12	1.09e-09	-0.55	-0.32	Initial pursuit acceleration;	chr5:56965864	chr5:56927874~56929573:+
PRAD	cis	rs6565180	0.963	rs4787642	ENSG00000183604.13	SMG1P5	-7.17	2.96e-12	1.09e-09	-0.3	-0.32	Tonsillectomy;	chr16:30348087	chr16:30267553~30335374:-
PRAD	cis	rs3096299	0.933	rs747485	ENSG00000261118.1	RP11-104N10.1	7.17	2.97e-12	1.1e-09	0.31	0.32	Multiple myeloma (IgH translocation);	chr16:89407686	chr16:89492017~89504460:-
PRAD	cis	rs6860806	0.632	rs4330455	ENSG00000233006.5	AC034220.3	7.17	2.97e-12	1.1e-09	0.27	0.32	Breast cancer;	chr5:132250656	chr5:132311285~132369916:-
PRAD	cis	rs853679	0.527	rs853683	ENSG00000280107.1	AL022393.9	-7.17	2.97e-12	1.1e-09	-0.39	-0.32	Depression;	chr6:28327262	chr6:28170845~28172521:+
PRAD	cis	rs6844153	0.752	rs28497454	ENSG00000240005.4	RP11-293A21.1	-7.17	2.98e-12	1.1e-09	-0.38	-0.32	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26906230	chr4:26859806~26860599:-
PRAD	cis	rs8103278	0.507	rs4802276	ENSG00000267395.4	AC074212.6	-7.17	2.98e-12	1.1e-09	-0.28	-0.32	Coronary artery disease;	chr19:45757490	chr19:45767796~45772504:+
PRAD	cis	rs11846409	0.652	rs10143549	ENSG00000274576.2	IGHV2-70	-7.17	2.98e-12	1.1e-09	-0.32	-0.32	Rheumatic heart disease;	chr14:106644643	chr14:106770577~106771020:-
PRAD	cis	rs4718428	1	rs4718421	ENSG00000232546.1	RP11-458F8.1	-7.17	2.99e-12	1.1e-09	-0.24	-0.32	Corneal structure;	chr7:66885313	chr7:66848496~66858136:+
PRAD	cis	rs2276314	0.857	rs28540805	ENSG00000278986.1	RP11-723J4.3	-7.17	2.99e-12	1.11e-09	-0.4	-0.32	Endometriosis;Drug-induced torsades de pointes;	chr18:36062012	chr18:35972151~35973916:+
PRAD	cis	rs853679	0.607	rs34243448	ENSG00000280107.1	AL022393.9	-7.17	2.99e-12	1.11e-09	-0.64	-0.32	Depression;	chr6:28225324	chr6:28170845~28172521:+
PRAD	cis	rs9467773	0.523	rs2498399	ENSG00000124549.13	BTN2A3P	7.17	2.99e-12	1.11e-09	0.28	0.32	Intelligence (multi-trait analysis);	chr6:26795343	chr6:26421391~26432383:+
PRAD	cis	rs11603691	1	rs2155232	ENSG00000254662.1	RP11-872D17.4	-7.17	3e-12	1.11e-09	-0.69	-0.32	Low high density lipoprotein cholesterol levels;	chr11:57273904	chr11:57325603~57327958:+
PRAD	cis	rs453301	0.592	rs4841084	ENSG00000254340.1	RP11-10A14.3	7.17	3e-12	1.11e-09	0.39	0.32	Joint mobility (Beighton score);	chr8:9026395	chr8:9141424~9145435:+
PRAD	cis	rs2638953	0.962	rs11049621	ENSG00000247934.4	RP11-967K21.1	-7.17	3e-12	1.11e-09	-0.31	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28456074	chr12:28163298~28190738:-
PRAD	cis	rs9309711	0.922	rs13431788	ENSG00000225234.1	TRAPPC12-AS1	-7.17	3.01e-12	1.11e-09	-0.35	-0.32	Neurofibrillary tangles;	chr2:3479141	chr2:3481242~3482409:-
PRAD	cis	rs9640161	0.673	rs11773351	ENSG00000261305.1	RP4-584D14.7	7.17	3.01e-12	1.11e-09	0.37	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150333874	chr7:150341771~150342607:+
PRAD	cis	rs71636778	0.509	rs12743862	ENSG00000260063.1	RP5-968P14.2	-7.17	3.01e-12	1.11e-09	-0.64	-0.32	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26701730	chr1:26692132~26694131:-
PRAD	cis	rs71636778	0.509	rs35041418	ENSG00000260063.1	RP5-968P14.2	-7.17	3.01e-12	1.11e-09	-0.64	-0.32	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26722492	chr1:26692132~26694131:-
PRAD	cis	rs1062177	0.547	rs2915818	ENSG00000253921.1	CTB-113P19.3	7.17	3.01e-12	1.11e-09	0.41	0.32	Preschool internalizing problems;	chr5:151735729	chr5:151753992~151767247:+
PRAD	cis	rs9543976	1	rs9565177	ENSG00000261553.4	RP11-29G8.3	-7.17	3.02e-12	1.12e-09	-0.51	-0.32	Diabetic retinopathy;	chr13:75621267	chr13:75549773~75807120:+
PRAD	cis	rs2243480	1	rs316330	ENSG00000273142.1	RP11-458F8.4	-7.17	3.02e-12	1.12e-09	-0.36	-0.32	Diabetic kidney disease;	chr7:66140385	chr7:66902857~66906297:+
PRAD	cis	rs1799949	1	rs35330014	ENSG00000267002.1	RP11-242D8.1	7.17	3.02e-12	1.12e-09	0.3	0.32	Menopause (age at onset);	chr17:43060530	chr17:43164183~43170403:-
PRAD	cis	rs11098499	0.955	rs1511018	ENSG00000245958.5	RP11-33B1.1	-7.17	3.03e-12	1.12e-09	-0.31	-0.32	Corneal astigmatism;	chr4:119240425	chr4:119454791~119552025:+
PRAD	cis	rs1440410	0.93	rs4618266	ENSG00000250326.1	RP11-284M14.1	-7.17	3.03e-12	1.12e-09	-0.33	-0.32	Ischemic stroke;	chr4:143114974	chr4:142933195~143184861:-
PRAD	cis	rs2033711	0.87	rs4801583	ENSG00000269473.1	CTD-2619J13.19	7.17	3.04e-12	1.12e-09	0.35	0.32	Uric acid clearance;	chr19:58407038	chr19:58440448~58445849:+
PRAD	cis	rs8005677	0.828	rs12437151	ENSG00000257285.4	RP11-298I3.1	7.17	3.04e-12	1.12e-09	0.32	0.32	Cognitive ability (multi-trait analysis);	chr14:22903704	chr14:22929609~22955562:+
PRAD	cis	rs7739264	0.602	rs9350179	ENSG00000228412.5	RP4-625H18.2	7.17	3.04e-12	1.12e-09	0.38	0.32	Endometriosis;	chr6:19763864	chr6:19802164~19804752:-
PRAD	cis	rs2243480	0.803	rs13224048	ENSG00000273142.1	RP11-458F8.4	-7.17	3.05e-12	1.13e-09	-0.36	-0.32	Diabetic kidney disease;	chr7:66528779	chr7:66902857~66906297:+
PRAD	cis	rs494459	0.838	rs555649	ENSG00000278376.1	RP11-158I9.8	-7.17	3.05e-12	1.13e-09	-0.27	-0.32	Height;	chr11:118781100	chr11:118791254~118793137:+
PRAD	cis	rs11098499	0.955	rs1511019	ENSG00000245958.5	RP11-33B1.1	-7.17	3.05e-12	1.13e-09	-0.32	-0.32	Corneal astigmatism;	chr4:119244852	chr4:119454791~119552025:+
PRAD	cis	rs875971	0.545	rs11770063	ENSG00000226824.5	RP4-756H11.3	-7.17	3.06e-12	1.13e-09	-0.48	-0.32	Aortic root size;	chr7:66318029	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.545	rs3936065	ENSG00000226824.5	RP4-756H11.3	-7.17	3.06e-12	1.13e-09	-0.48	-0.32	Aortic root size;	chr7:66325577	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.545	rs4718335	ENSG00000226824.5	RP4-756H11.3	-7.17	3.06e-12	1.13e-09	-0.48	-0.32	Aortic root size;	chr7:66339619	chr7:66654538~66669855:+
PRAD	cis	rs1555322	0.53	rs2250205	ENSG00000279253.1	RP4-614O4.13	-7.17	3.06e-12	1.13e-09	-0.39	-0.32	Attention deficit hyperactivity disorder;	chr20:35280121	chr20:35262727~35264187:-
PRAD	cis	rs995000	0.931	rs1168018	ENSG00000235545.1	RP11-230B22.1	-7.17	3.06e-12	1.13e-09	-0.42	-0.32	Triglyceride levels;	chr1:62535449	chr1:62688482~62710694:+
PRAD	cis	rs3096299	0.967	rs28644774	ENSG00000261118.1	RP11-104N10.1	7.17	3.07e-12	1.13e-09	0.31	0.32	Multiple myeloma (IgH translocation);	chr16:89405773	chr16:89492017~89504460:-
PRAD	cis	rs6951245	0.529	rs10262070	ENSG00000229043.2	AC091729.9	-7.17	3.07e-12	1.13e-09	-0.45	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1102102	chr7:1160374~1165267:+
PRAD	cis	rs9393777	0.764	rs35565446	ENSG00000280107.1	AL022393.9	-7.17	3.07e-12	1.13e-09	-0.67	-0.32	Intelligence (multi-trait analysis);	chr6:27177562	chr6:28170845~28172521:+
PRAD	cis	rs875971	0.545	rs6970498	ENSG00000226824.5	RP4-756H11.3	-7.17	3.07e-12	1.13e-09	-0.48	-0.32	Aortic root size;	chr7:66275908	chr7:66654538~66669855:+
PRAD	cis	rs17428076	0.837	rs62182430	ENSG00000228389.1	AC068039.4	-7.17	3.08e-12	1.13e-09	-0.41	-0.32	Myopia;	chr2:171916327	chr2:171773482~171775844:+
PRAD	cis	rs1355223	0.902	rs11603774	ENSG00000271369.1	RP11-350D17.3	-7.17	3.08e-12	1.14e-09	-0.37	-0.32	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34711344	chr11:34709600~34710161:+
PRAD	cis	rs7429990	0.901	rs7433678	ENSG00000229759.1	MRPS18AP1	-7.17	3.08e-12	1.14e-09	-0.32	-0.32	Educational attainment (years of education);	chr3:47995588	chr3:48256350~48256938:-
PRAD	cis	rs7429990	0.965	rs4392441	ENSG00000229759.1	MRPS18AP1	-7.17	3.08e-12	1.14e-09	-0.32	-0.32	Educational attainment (years of education);	chr3:48036211	chr3:48256350~48256938:-
PRAD	cis	rs1799949	0.93	rs3092987	ENSG00000267002.1	RP11-242D8.1	7.17	3.08e-12	1.14e-09	0.3	0.32	Menopause (age at onset);	chr17:43070706	chr17:43164183~43170403:-
PRAD	cis	rs1023500	0.573	rs2413666	ENSG00000205702.9	CYP2D7	7.17	3.08e-12	1.14e-09	0.25	0.32	Schizophrenia;	chr22:42063618	chr22:42140203~42144577:-
PRAD	cis	rs172166	0.694	rs2791332	ENSG00000219392.1	RP1-265C24.5	-7.17	3.09e-12	1.14e-09	-0.39	-0.32	Cardiac Troponin-T levels;	chr6:28141010	chr6:28115628~28116551:+
PRAD	cis	rs12468226	0.817	rs6722588	ENSG00000273456.1	RP11-686O6.2	-7.17	3.09e-12	1.14e-09	-0.43	-0.32	Urate levels;	chr2:202187163	chr2:202374932~202375604:-
PRAD	cis	rs2243480	1	rs13237037	ENSG00000273142.1	RP11-458F8.4	-7.17	3.1e-12	1.14e-09	-0.36	-0.32	Diabetic kidney disease;	chr7:66532895	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs1796228	ENSG00000273142.1	RP11-458F8.4	-7.17	3.1e-12	1.14e-09	-0.36	-0.32	Diabetic kidney disease;	chr7:66568097	chr7:66902857~66906297:+
PRAD	cis	rs516805	0.748	rs562616	ENSG00000279453.1	RP3-425C14.4	-7.17	3.1e-12	1.14e-09	-0.29	-0.32	Lymphocyte counts;	chr6:122467041	chr6:122436789~122439223:-
PRAD	cis	rs2439831	1	rs7173487	ENSG00000249839.1	AC011330.5	-7.17	3.1e-12	1.14e-09	-0.52	-0.32	Lung cancer in ever smokers;	chr15:43458041	chr15:43663654~43684339:-
PRAD	cis	rs6921919	0.887	rs16894116	ENSG00000204709.4	LINC01556	7.17	3.1e-12	1.14e-09	0.47	0.32	Autism spectrum disorder or schizophrenia;	chr6:28447190	chr6:28943877~28944537:+
PRAD	cis	rs2638953	0.924	rs11049582	ENSG00000278733.1	RP11-425D17.1	-7.17	3.1e-12	1.14e-09	-0.4	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28416392	chr12:28185625~28186190:-
PRAD	cis	rs4713118	0.739	rs2893931	ENSG00000226314.6	ZNF192P1	-7.17	3.1e-12	1.14e-09	-0.42	-0.32	Parkinson's disease;	chr6:27780231	chr6:28161781~28169594:+
PRAD	cis	rs4713118	0.824	rs2092075	ENSG00000226314.6	ZNF192P1	-7.17	3.1e-12	1.14e-09	-0.42	-0.32	Parkinson's disease;	chr6:27781551	chr6:28161781~28169594:+
PRAD	cis	rs4713118	0.824	rs13211701	ENSG00000226314.6	ZNF192P1	-7.17	3.1e-12	1.14e-09	-0.42	-0.32	Parkinson's disease;	chr6:27782300	chr6:28161781~28169594:+
PRAD	cis	rs4713118	0.824	rs9468229	ENSG00000226314.6	ZNF192P1	-7.17	3.1e-12	1.14e-09	-0.42	-0.32	Parkinson's disease;	chr6:27782307	chr6:28161781~28169594:+
PRAD	cis	rs8005677	0.828	rs3794452	ENSG00000257285.4	RP11-298I3.1	7.17	3.11e-12	1.15e-09	0.32	0.32	Cognitive ability (multi-trait analysis);	chr14:22917473	chr14:22929609~22955562:+
PRAD	cis	rs2836950	0.509	rs4816618	ENSG00000255568.3	BRWD1-AS2	-7.17	3.11e-12	1.15e-09	-0.26	-0.32	Menarche (age at onset);	chr21:39227603	chr21:39313935~39314962:+
PRAD	cis	rs2836950	0.527	rs2836948	ENSG00000255568.3	BRWD1-AS2	-7.17	3.11e-12	1.15e-09	-0.26	-0.32	Menarche (age at onset);	chr21:39227751	chr21:39313935~39314962:+
PRAD	cis	rs6547741	0.844	rs9678851	ENSG00000234072.1	AC074117.10	-7.17	3.11e-12	1.15e-09	-0.25	-0.32	Oral cavity cancer;	chr2:27664167	chr2:27356246~27367622:+
PRAD	cis	rs6452524	0.904	rs10474095	ENSG00000249664.1	CTD-2227C6.2	7.17	3.12e-12	1.15e-09	0.39	0.32	Hypertension (SNP x SNP interaction);	chr5:83154887	chr5:83012285~83013109:-
PRAD	cis	rs1011728	0.523	rs7299938	ENSG00000258815.1	RP11-408B11.2	-7.17	3.12e-12	1.15e-09	-0.42	-0.32	Bone mineral density (Ward's triangle area);	chr12:85337780	chr12:85318060~85342912:+
PRAD	cis	rs1134634	0.52	rs2160044	ENSG00000273133.1	RP11-799M12.2	-7.17	3.13e-12	1.15e-09	-0.43	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15556720	chr4:15563698~15564253:-
PRAD	cis	rs2243480	1	rs778704	ENSG00000273142.1	RP11-458F8.4	-7.17	3.13e-12	1.15e-09	-0.36	-0.32	Diabetic kidney disease;	chr7:66398480	chr7:66902857~66906297:+
PRAD	cis	rs2243480	0.901	rs778693	ENSG00000273142.1	RP11-458F8.4	-7.17	3.13e-12	1.15e-09	-0.36	-0.32	Diabetic kidney disease;	chr7:66407358	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs778691	ENSG00000273142.1	RP11-458F8.4	-7.17	3.13e-12	1.15e-09	-0.36	-0.32	Diabetic kidney disease;	chr7:66408105	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs13235972	ENSG00000273142.1	RP11-458F8.4	-7.17	3.13e-12	1.15e-09	-0.36	-0.32	Diabetic kidney disease;	chr7:66418618	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs34192067	ENSG00000273142.1	RP11-458F8.4	-7.17	3.13e-12	1.15e-09	-0.36	-0.32	Diabetic kidney disease;	chr7:66422670	chr7:66902857~66906297:+
PRAD	cis	rs2243480	0.901	rs34807232	ENSG00000273142.1	RP11-458F8.4	-7.17	3.13e-12	1.15e-09	-0.36	-0.32	Diabetic kidney disease;	chr7:66500146	chr7:66902857~66906297:+
PRAD	cis	rs2243480	0.901	rs35823062	ENSG00000273142.1	RP11-458F8.4	-7.17	3.13e-12	1.15e-09	-0.36	-0.32	Diabetic kidney disease;	chr7:66500834	chr7:66902857~66906297:+
PRAD	cis	rs516805	0.706	rs541551	ENSG00000279453.1	RP3-425C14.4	-7.17	3.13e-12	1.16e-09	-0.29	-0.32	Lymphocyte counts;	chr6:122462736	chr6:122436789~122439223:-
PRAD	cis	rs2638953	0.853	rs10506036	ENSG00000278733.1	RP11-425D17.1	7.17	3.14e-12	1.16e-09	0.39	0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28497632	chr12:28185625~28186190:-
PRAD	cis	rs2033711	0.837	rs3764535	ENSG00000269473.1	CTD-2619J13.19	7.17	3.14e-12	1.16e-09	0.35	0.32	Uric acid clearance;	chr19:58417685	chr19:58440448~58445849:+
PRAD	cis	rs4660261	0.545	rs803682	ENSG00000237950.1	RP11-7O11.3	7.17	3.14e-12	1.16e-09	0.35	0.32	Intelligence (multi-trait analysis);	chr1:43896951	chr1:43944370~43946551:-
PRAD	cis	rs2276314	0.857	rs28379448	ENSG00000278986.1	RP11-723J4.3	-7.17	3.14e-12	1.16e-09	-0.39	-0.32	Endometriosis;Drug-induced torsades de pointes;	chr18:36024401	chr18:35972151~35973916:+
PRAD	cis	rs8523	0.774	rs60273772	ENSG00000230314.5	ELOVL2-AS1	7.17	3.15e-12	1.16e-09	0.35	0.32	Red blood cell fatty acid levels;	chr6:11074919	chr6:11043524~11078226:+
PRAD	cis	rs2439831	0.85	rs8032649	ENSG00000205771.5	CATSPER2P1	7.17	3.15e-12	1.16e-09	0.5	0.32	Lung cancer in ever smokers;	chr15:43842724	chr15:43726918~43747094:-
PRAD	cis	rs7260598	0.792	rs11670331	ENSG00000268442.1	CTD-2027I19.2	7.17	3.16e-12	1.16e-09	0.55	0.32	Response to taxane treatment (placlitaxel);	chr19:24155040	chr19:24162370~24163425:-
PRAD	cis	rs7260598	0.792	rs11671489	ENSG00000268442.1	CTD-2027I19.2	7.17	3.16e-12	1.16e-09	0.55	0.32	Response to taxane treatment (placlitaxel);	chr19:24156070	chr19:24162370~24163425:-
PRAD	cis	rs7260598	0.792	rs60773823	ENSG00000268442.1	CTD-2027I19.2	7.17	3.16e-12	1.16e-09	0.55	0.32	Response to taxane treatment (placlitaxel);	chr19:24156730	chr19:24162370~24163425:-
PRAD	cis	rs7260598	0.792	rs10500223	ENSG00000268442.1	CTD-2027I19.2	7.17	3.16e-12	1.16e-09	0.55	0.32	Response to taxane treatment (placlitaxel);	chr19:24163222	chr19:24162370~24163425:-
PRAD	cis	rs7260598	0.792	rs17620029	ENSG00000268442.1	CTD-2027I19.2	7.17	3.16e-12	1.16e-09	0.55	0.32	Response to taxane treatment (placlitaxel);	chr19:24171510	chr19:24162370~24163425:-
PRAD	cis	rs995000	0.64	rs4915853	ENSG00000235545.1	RP11-230B22.1	-7.16	3.16e-12	1.17e-09	-0.4	-0.32	Triglyceride levels;	chr1:62725906	chr1:62688482~62710694:+
PRAD	cis	rs875971	0.577	rs34888281	ENSG00000236529.1	RP13-254B10.1	-7.16	3.16e-12	1.17e-09	-0.35	-0.32	Aortic root size;	chr7:66120784	chr7:65840212~65840596:+
PRAD	cis	rs2067615	0.579	rs10861655	ENSG00000260329.1	RP11-412D9.4	7.16	3.17e-12	1.17e-09	0.27	0.32	Heart rate;	chr12:106735641	chr12:106954029~106955497:-
PRAD	cis	rs5760092	0.627	rs6519489	ENSG00000206090.4	AP000350.7	-7.16	3.17e-12	1.17e-09	-0.49	-0.32	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919659	chr22:23939998~23942798:+
PRAD	cis	rs6951245	0.554	rs11761322	ENSG00000229043.2	AC091729.9	-7.16	3.17e-12	1.17e-09	-0.45	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1112021	chr7:1160374~1165267:+
PRAD	cis	rs8177376	0.727	rs645852	ENSG00000254905.1	RP11-712L6.7	7.16	3.17e-12	1.17e-09	0.38	0.32	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126327509	chr11:126292922~126294254:-
PRAD	cis	rs8177376	0.727	rs646775	ENSG00000254905.1	RP11-712L6.7	7.16	3.17e-12	1.17e-09	0.38	0.32	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126327704	chr11:126292922~126294254:-
PRAD	cis	rs6539247	0.509	rs2374584	ENSG00000257890.1	RP11-114F10.2	-7.16	3.17e-12	1.17e-09	-0.37	-0.32	Attention function in attention deficit hyperactive disorder;	chr12:106052210	chr12:106050961~106058254:-
PRAD	cis	rs172166	0.694	rs536704	ENSG00000204709.4	LINC01556	7.16	3.17e-12	1.17e-09	0.41	0.32	Cardiac Troponin-T levels;	chr6:28124825	chr6:28943877~28944537:+
PRAD	cis	rs995000	0.899	rs1168045	ENSG00000235545.1	RP11-230B22.1	-7.16	3.17e-12	1.17e-09	-0.42	-0.32	Triglyceride levels;	chr1:62517220	chr1:62688482~62710694:+
PRAD	cis	rs7131987	0.65	rs67146951	ENSG00000275476.1	RP11-996F15.4	-7.16	3.17e-12	1.17e-09	-0.34	-0.32	QT interval;	chr12:29297620	chr12:29277397~29277882:-
PRAD	cis	rs7429990	0.965	rs1060407	ENSG00000229759.1	MRPS18AP1	7.16	3.18e-12	1.17e-09	0.33	0.32	Educational attainment (years of education);	chr3:47916547	chr3:48256350~48256938:-
PRAD	cis	rs853679	0.556	rs13200214	ENSG00000225595.2	XXbac-BPG308K3.6	7.16	3.18e-12	1.17e-09	0.71	0.32	Depression;	chr6:28049472	chr6:28859625~28864630:-
PRAD	cis	rs867371	0.826	rs2047678	ENSG00000278603.1	RP13-608F4.5	7.16	3.18e-12	1.17e-09	0.42	0.32	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82205857	chr15:82472203~82472426:+
PRAD	cis	rs6951245	0.554	rs79367977	ENSG00000229043.2	AC091729.9	-7.16	3.18e-12	1.17e-09	-0.45	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1113021	chr7:1160374~1165267:+
PRAD	cis	rs881375	0.678	rs10818488	ENSG00000226752.6	PSMD5-AS1	-7.16	3.18e-12	1.17e-09	-0.36	-0.32	Rheumatoid arthritis;	chr9:120942809	chr9:120824828~120854385:+
PRAD	cis	rs7567389	0.719	rs4662713	ENSG00000236682.1	AC068282.3	7.16	3.19e-12	1.17e-09	0.44	0.32	Self-rated health;	chr2:127236527	chr2:127389130~127400580:+
PRAD	cis	rs9640161	0.742	rs2159235	ENSG00000261305.1	RP4-584D14.7	7.16	3.19e-12	1.18e-09	0.35	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150320139	chr7:150341771~150342607:+
PRAD	cis	rs4713118	0.866	rs2179094	ENSG00000226314.6	ZNF192P1	-7.16	3.2e-12	1.18e-09	-0.42	-0.32	Parkinson's disease;	chr6:27774046	chr6:28161781~28169594:+
PRAD	cis	rs2243480	1	rs781156	ENSG00000273142.1	RP11-458F8.4	-7.16	3.2e-12	1.18e-09	-0.35	-0.32	Diabetic kidney disease;	chr7:66014154	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs451396	ENSG00000273142.1	RP11-458F8.4	-7.16	3.2e-12	1.18e-09	-0.35	-0.32	Diabetic kidney disease;	chr7:66019087	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs1715235	ENSG00000273142.1	RP11-458F8.4	-7.16	3.2e-12	1.18e-09	-0.35	-0.32	Diabetic kidney disease;	chr7:66023407	chr7:66902857~66906297:+
PRAD	cis	rs6860806	0.661	rs4705927	ENSG00000233006.5	AC034220.3	7.16	3.2e-12	1.18e-09	0.27	0.32	Breast cancer;	chr5:132242915	chr5:132311285~132369916:-
PRAD	cis	rs2638953	0.64	rs11049721	ENSG00000278733.1	RP11-425D17.1	-7.16	3.2e-12	1.18e-09	-0.39	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28573743	chr12:28185625~28186190:-
PRAD	cis	rs172166	0.694	rs9295760	ENSG00000204709.4	LINC01556	7.16	3.21e-12	1.18e-09	0.41	0.32	Cardiac Troponin-T levels;	chr6:28179607	chr6:28943877~28944537:+
PRAD	cis	rs12554020	1	rs4552973	ENSG00000227603.1	RP11-165J3.6	7.16	3.21e-12	1.18e-09	0.42	0.32	Schizophrenia;	chr9:93539437	chr9:93435332~93437121:-
PRAD	cis	rs964611	0.786	rs10519169	ENSG00000259488.2	RP11-154J22.1	-7.16	3.22e-12	1.18e-09	-0.31	-0.32	Metabolite levels (Pyroglutamine);	chr15:48372829	chr15:48312353~48331856:-
PRAD	cis	rs2638953	0.924	rs10843162	ENSG00000278733.1	RP11-425D17.1	-7.16	3.22e-12	1.19e-09	-0.4	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28410985	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs11049579	ENSG00000278733.1	RP11-425D17.1	-7.16	3.22e-12	1.19e-09	-0.4	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28414693	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs10843163	ENSG00000278733.1	RP11-425D17.1	-7.16	3.22e-12	1.19e-09	-0.4	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28415541	chr12:28185625~28186190:-
PRAD	cis	rs4927850	1	rs7614767	ENSG00000231464.1	AC024937.4	7.16	3.23e-12	1.19e-09	0.38	0.32	Pancreatic cancer;	chr3:196026580	chr3:195996738~195998233:+
PRAD	cis	rs2638953	0.924	rs11049399	ENSG00000247934.4	RP11-967K21.1	-7.16	3.23e-12	1.19e-09	-0.32	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28174213	chr12:28163298~28190738:-
PRAD	cis	rs12612619	0.627	rs13391244	ENSG00000229122.1	AGBL5-IT1	-7.16	3.23e-12	1.19e-09	-0.35	-0.32	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27064741	chr2:27061038~27061815:+
PRAD	cis	rs7826238	0.72	rs12546760	ENSG00000253893.2	FAM85B	7.16	3.23e-12	1.19e-09	0.37	0.32	Systolic blood pressure;	chr8:8517326	chr8:8167819~8226614:-
PRAD	cis	rs4713118	0.628	rs12179134	ENSG00000280107.1	AL022393.9	-7.16	3.23e-12	1.19e-09	-0.45	-0.32	Parkinson's disease;	chr6:27707690	chr6:28170845~28172521:+
PRAD	cis	rs2638953	0.924	rs11049475	ENSG00000247934.4	RP11-967K21.1	-7.16	3.24e-12	1.19e-09	-0.32	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28239731	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.962	rs11049570	ENSG00000278733.1	RP11-425D17.1	-7.16	3.25e-12	1.19e-09	-0.41	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28390218	chr12:28185625~28186190:-
PRAD	cis	rs995000	0.931	rs10889354	ENSG00000235545.1	RP11-230B22.1	7.16	3.25e-12	1.2e-09	0.42	0.32	Triglyceride levels;	chr1:62663411	chr1:62688482~62710694:+
PRAD	cis	rs875971	0.522	rs1968127	ENSG00000237310.1	GS1-124K5.4	-7.16	3.25e-12	1.2e-09	-0.28	-0.32	Aortic root size;	chr7:66591816	chr7:66493706~66495474:+
PRAD	cis	rs10129255	0.957	rs61997760	ENSG00000223648.3	IGHV3-64	7.16	3.26e-12	1.2e-09	0.32	0.32	Kawasaki disease;	chr14:106716993	chr14:106643132~106658258:-
PRAD	cis	rs287982	0.8	rs9973905	ENSG00000269973.1	RP11-95D17.1	-7.16	3.26e-12	1.2e-09	-0.31	-0.32	Nonsyndromic cleft lip with cleft palate;	chr2:9820726	chr2:9936360~9939590:+
PRAD	cis	rs17772222	0.916	rs77306894	ENSG00000258983.2	RP11-507K2.2	7.16	3.26e-12	1.2e-09	0.47	0.32	Coronary artery calcification;	chr14:88494507	chr14:88499334~88515502:+
PRAD	cis	rs4664293	0.867	rs6761145	ENSG00000226266.5	AC009961.3	-7.16	3.26e-12	1.2e-09	-0.43	-0.32	Monocyte percentage of white cells;	chr2:159725673	chr2:159670708~159712435:-
PRAD	cis	rs4664293	0.867	rs6732987	ENSG00000226266.5	AC009961.3	-7.16	3.26e-12	1.2e-09	-0.43	-0.32	Monocyte percentage of white cells;	chr2:159725918	chr2:159670708~159712435:-
PRAD	cis	rs4664293	0.867	rs7589941	ENSG00000226266.5	AC009961.3	-7.16	3.26e-12	1.2e-09	-0.43	-0.32	Monocyte percentage of white cells;	chr2:159727589	chr2:159670708~159712435:-
PRAD	cis	rs2638953	0.671	rs10843099	ENSG00000278733.1	RP11-425D17.1	-7.16	3.27e-12	1.2e-09	-0.43	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28116901	chr12:28185625~28186190:-
PRAD	cis	rs1862618	0.573	rs832532	ENSG00000271828.1	CTD-2310F14.1	7.16	3.27e-12	1.2e-09	0.55	0.32	Initial pursuit acceleration;	chr5:56926111	chr5:56927874~56929573:+
PRAD	cis	rs1858037	0.867	rs4671658	ENSG00000281920.1	RP11-418H16.1	-7.16	3.27e-12	1.2e-09	-0.39	-0.32	Rheumatoid arthritis;	chr2:65334258	chr2:65623272~65628424:+
PRAD	cis	rs4664293	0.565	rs10165197	ENSG00000226266.5	AC009961.3	7.16	3.27e-12	1.2e-09	0.41	0.32	Monocyte percentage of white cells;	chr2:159537137	chr2:159670708~159712435:-
PRAD	cis	rs858239	0.601	rs10278700	ENSG00000226816.2	AC005082.12	7.16	3.27e-12	1.2e-09	0.36	0.32	Cerebrospinal fluid biomarker levels;	chr7:23120910	chr7:23206013~23208045:+
PRAD	cis	rs858239	0.601	rs10263110	ENSG00000226816.2	AC005082.12	7.16	3.27e-12	1.2e-09	0.36	0.32	Cerebrospinal fluid biomarker levels;	chr7:23120932	chr7:23206013~23208045:+
PRAD	cis	rs1789	0.592	rs1125378	ENSG00000273133.1	RP11-799M12.2	-7.16	3.28e-12	1.21e-09	-0.43	-0.32	Blood protein levels;	chr4:15538867	chr4:15563698~15564253:-
PRAD	cis	rs4972806	0.849	rs1542180	ENSG00000226363.3	HAGLROS	-7.16	3.28e-12	1.21e-09	-0.36	-0.32	IgG glycosylation;	chr2:176164039	chr2:176177717~176179008:+
PRAD	cis	rs12468226	0.873	rs6435138	ENSG00000273456.1	RP11-686O6.2	-7.16	3.29e-12	1.21e-09	-0.42	-0.32	Urate levels;	chr2:202234310	chr2:202374932~202375604:-
PRAD	cis	rs62355900	0.627	rs62355943	ENSG00000271828.1	CTD-2310F14.1	7.16	3.29e-12	1.21e-09	0.67	0.32	Endometriosis;	chr5:56814472	chr5:56927874~56929573:+
PRAD	cis	rs62355900	0.627	rs72758038	ENSG00000271828.1	CTD-2310F14.1	7.16	3.29e-12	1.21e-09	0.67	0.32	Endometriosis;	chr5:56814857	chr5:56927874~56929573:+
PRAD	cis	rs1020064	0.636	rs2679883	ENSG00000235319.1	AC012360.4	-7.16	3.29e-12	1.21e-09	-0.4	-0.32	AIDS;	chr2:105333211	chr2:105324210~105330529:+
PRAD	cis	rs7131987	0.65	rs10843382	ENSG00000275476.1	RP11-996F15.4	-7.16	3.29e-12	1.21e-09	-0.34	-0.32	QT interval;	chr12:29298788	chr12:29277397~29277882:-
PRAD	cis	rs987724	0.551	rs1835372	ENSG00000240875.4	LINC00886	-7.16	3.3e-12	1.21e-09	-0.36	-0.32	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156801238	chr3:156747346~156817062:-
PRAD	cis	rs12612619	0.704	rs11680633	ENSG00000229122.1	AGBL5-IT1	7.16	3.3e-12	1.21e-09	0.33	0.32	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27001341	chr2:27061038~27061815:+
PRAD	cis	rs9467773	1	rs9467791	ENSG00000124549.13	BTN2A3P	-7.16	3.3e-12	1.21e-09	-0.28	-0.32	Intelligence (multi-trait analysis);	chr6:26562258	chr6:26421391~26432383:+
PRAD	cis	rs17772222	0.674	rs112788894	ENSG00000258983.2	RP11-507K2.2	7.16	3.31e-12	1.22e-09	0.47	0.32	Coronary artery calcification;	chr14:88442850	chr14:88499334~88515502:+
PRAD	cis	rs200972	1	rs200972	ENSG00000219392.1	RP1-265C24.5	-7.16	3.31e-12	1.22e-09	-0.39	-0.32	Urinary tract infection frequency;	chr6:27891059	chr6:28115628~28116551:+
PRAD	cis	rs4728142	0.604	rs2272347	ENSG00000275106.1	RP11-309L24.10	7.16	3.32e-12	1.22e-09	0.4	0.32	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128979361	chr7:128952527~128953316:-
PRAD	cis	rs9532669	0.926	rs11147831	ENSG00000168852.11	TPTE2P5	7.16	3.32e-12	1.22e-09	0.3	0.32	Cervical cancer;	chr13:40978593	chr13:40822296~40921749:-
PRAD	cis	rs11098499	0.604	rs12642411	ENSG00000245958.5	RP11-33B1.1	-7.16	3.32e-12	1.22e-09	-0.33	-0.32	Corneal astigmatism;	chr4:119659370	chr4:119454791~119552025:+
PRAD	cis	rs4718428	1	rs4718428	ENSG00000232546.1	RP11-458F8.1	-7.16	3.33e-12	1.22e-09	-0.24	-0.32	Corneal structure;	chr7:66956459	chr7:66848496~66858136:+
PRAD	cis	rs2033711	0.84	rs3764533	ENSG00000269473.1	CTD-2619J13.19	7.16	3.33e-12	1.23e-09	0.34	0.32	Uric acid clearance;	chr19:58417827	chr19:58440448~58445849:+
PRAD	cis	rs6921919	0.945	rs7765989	ENSG00000204709.4	LINC01556	7.16	3.34e-12	1.23e-09	0.47	0.32	Autism spectrum disorder or schizophrenia;	chr6:28432518	chr6:28943877~28944537:+
PRAD	cis	rs7121800	0.888	rs16920802	ENSG00000242353.1	RP4-710M3.1	7.16	3.34e-12	1.23e-09	0.33	0.32	Pit-and-Fissure caries;	chr11:30490926	chr11:30368148~30368646:+
PRAD	cis	rs875971	0.545	rs73146609	ENSG00000226824.5	RP4-756H11.3	-7.16	3.34e-12	1.23e-09	-0.48	-0.32	Aortic root size;	chr7:66302477	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.545	rs2173571	ENSG00000226824.5	RP4-756H11.3	-7.16	3.34e-12	1.23e-09	-0.48	-0.32	Aortic root size;	chr7:66305392	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs1723269	ENSG00000226824.5	RP4-756H11.3	-7.16	3.34e-12	1.23e-09	-0.63	-0.32	Diabetic kidney disease;	chr7:66007799	chr7:66654538~66669855:+
PRAD	cis	rs10463554	0.889	rs246899	ENSG00000175749.11	EIF3KP1	7.16	3.35e-12	1.23e-09	0.43	0.32	Parkinson's disease;	chr5:103241438	chr5:103032376~103033031:+
PRAD	cis	rs2911132	1	rs2911131	ENSG00000248734.2	CTD-2260A17.1	-7.16	3.35e-12	1.23e-09	-0.34	-0.32	Urate levels (BMI interaction);	chr5:96850246	chr5:96784777~96785999:+
PRAD	cis	rs875971	0.505	rs2462573	ENSG00000237310.1	GS1-124K5.4	-7.16	3.35e-12	1.23e-09	-0.27	-0.32	Aortic root size;	chr7:66042405	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.505	rs1167386	ENSG00000237310.1	GS1-124K5.4	-7.16	3.35e-12	1.23e-09	-0.27	-0.32	Aortic root size;	chr7:66048109	chr7:66493706~66495474:+
PRAD	cis	rs4842666	0.915	rs11105352	ENSG00000258302.2	RP11-981P6.1	7.16	3.36e-12	1.23e-09	0.39	0.32	Blood pressure;	chr12:89632685	chr12:89561129~89594878:+
PRAD	cis	rs4842666	0.915	rs11105353	ENSG00000258302.2	RP11-981P6.1	7.16	3.36e-12	1.23e-09	0.39	0.32	Blood pressure;	chr12:89632686	chr12:89561129~89594878:+
PRAD	cis	rs4842666	0.915	rs11105354	ENSG00000258302.2	RP11-981P6.1	7.16	3.36e-12	1.23e-09	0.39	0.32	Blood pressure;	chr12:89632746	chr12:89561129~89594878:+
PRAD	cis	rs1707322	0.686	rs2050376	ENSG00000280836.1	AL355480.1	-7.16	3.36e-12	1.23e-09	-0.4	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45612958	chr1:45581219~45581321:-
PRAD	cis	rs8062405	0.755	rs4788080	ENSG00000251417.2	RP11-1348G14.4	-7.16	3.36e-12	1.23e-09	-0.35	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546760	chr16:28802743~28817828:+
PRAD	cis	rs8062405	0.723	rs4788079	ENSG00000251417.2	RP11-1348G14.4	-7.16	3.36e-12	1.23e-09	-0.35	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548042	chr16:28802743~28817828:+
PRAD	cis	rs8062405	0.755	rs4787456	ENSG00000251417.2	RP11-1348G14.4	-7.16	3.36e-12	1.23e-09	-0.35	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548252	chr16:28802743~28817828:+
PRAD	cis	rs8062405	0.755	rs4788078	ENSG00000251417.2	RP11-1348G14.4	-7.16	3.36e-12	1.23e-09	-0.35	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548660	chr16:28802743~28817828:+
PRAD	cis	rs8062405	0.755	rs62034350	ENSG00000251417.2	RP11-1348G14.4	-7.16	3.36e-12	1.23e-09	-0.35	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28550935	chr16:28802743~28817828:+
PRAD	cis	rs2638953	0.79	rs4357727	ENSG00000278733.1	RP11-425D17.1	7.16	3.37e-12	1.24e-09	0.37	0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28291989	chr12:28185625~28186190:-
PRAD	cis	rs858239	0.698	rs4265084	ENSG00000226816.2	AC005082.12	7.16	3.37e-12	1.24e-09	0.36	0.32	Cerebrospinal fluid biomarker levels;	chr7:23367621	chr7:23206013~23208045:+
PRAD	cis	rs4713118	0.629	rs203887	ENSG00000272009.1	RP1-313I6.12	-7.15	3.37e-12	1.24e-09	-0.35	-0.32	Parkinson's disease;	chr6:28053491	chr6:28078792~28081130:-
PRAD	cis	rs6539288	0.933	rs7961366	ENSG00000260329.1	RP11-412D9.4	-7.15	3.38e-12	1.24e-09	-0.28	-0.32	Total body bone mineral density;	chr12:106902263	chr12:106954029~106955497:-
PRAD	cis	rs2836950	0.501	rs2836980	ENSG00000255568.3	BRWD1-AS2	-7.15	3.38e-12	1.24e-09	-0.26	-0.32	Menarche (age at onset);	chr21:39315692	chr21:39313935~39314962:+
PRAD	cis	rs516805	0.748	rs492250	ENSG00000279453.1	RP3-425C14.4	-7.15	3.39e-12	1.24e-09	-0.29	-0.32	Lymphocyte counts;	chr6:122421808	chr6:122436789~122439223:-
PRAD	cis	rs516805	0.748	rs9320872	ENSG00000279453.1	RP3-425C14.4	-7.15	3.39e-12	1.24e-09	-0.29	-0.32	Lymphocyte counts;	chr6:122425438	chr6:122436789~122439223:-
PRAD	cis	rs516805	0.63	rs505749	ENSG00000279453.1	RP3-425C14.4	-7.15	3.39e-12	1.24e-09	-0.29	-0.32	Lymphocyte counts;	chr6:122425751	chr6:122436789~122439223:-
PRAD	cis	rs881375	0.669	rs73541868	ENSG00000226752.6	PSMD5-AS1	-7.15	3.39e-12	1.24e-09	-0.37	-0.32	Rheumatoid arthritis;	chr9:120876986	chr9:120824828~120854385:+
PRAD	cis	rs11148252	0.514	rs1886539	ENSG00000278238.1	RP11-245D16.4	-7.15	3.39e-12	1.25e-09	-0.35	-0.32	Lewy body disease;	chr13:52151955	chr13:52454775~52455331:-
PRAD	cis	rs172166	0.694	rs203884	ENSG00000219392.1	RP1-265C24.5	-7.15	3.39e-12	1.25e-09	-0.4	-0.32	Cardiac Troponin-T levels;	chr6:28109596	chr6:28115628~28116551:+
PRAD	cis	rs17012589	0.502	rs10746340	ENSG00000258815.1	RP11-408B11.2	-7.15	3.39e-12	1.25e-09	-0.42	-0.32	Bone mineral density (Ward's triangle area);	chr12:85336611	chr12:85318060~85342912:+
PRAD	cis	rs1355223	1	rs1396883	ENSG00000271369.1	RP11-350D17.3	-7.15	3.4e-12	1.25e-09	-0.38	-0.32	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34735900	chr11:34709600~34710161:+
PRAD	cis	rs10129255	0.957	rs11847726	ENSG00000223648.3	IGHV3-64	7.15	3.4e-12	1.25e-09	0.32	0.32	Kawasaki disease;	chr14:106779116	chr14:106643132~106658258:-
PRAD	cis	rs10129255	0.957	rs12590735	ENSG00000223648.3	IGHV3-64	7.15	3.4e-12	1.25e-09	0.32	0.32	Kawasaki disease;	chr14:106779660	chr14:106643132~106658258:-
PRAD	cis	rs2638953	0.888	rs10843189	ENSG00000278733.1	RP11-425D17.1	-7.15	3.4e-12	1.25e-09	-0.39	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28506985	chr12:28185625~28186190:-
PRAD	cis	rs7569084	1	rs7569084	ENSG00000281920.1	RP11-418H16.1	-7.15	3.4e-12	1.25e-09	-0.35	-0.32	Sum eosinophil basophil counts;	chr2:65429835	chr2:65623272~65628424:+
PRAD	cis	rs1799949	0.965	rs8176193	ENSG00000267002.1	RP11-242D8.1	7.15	3.4e-12	1.25e-09	0.3	0.32	Menopause (age at onset);	chr17:43079499	chr17:43164183~43170403:-
PRAD	cis	rs8177376	0.681	rs240548	ENSG00000254905.1	RP11-712L6.7	7.15	3.41e-12	1.25e-09	0.38	0.32	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126335072	chr11:126292922~126294254:-
PRAD	cis	rs12432203	1	rs72622439	ENSG00000258479.4	LINC00640	7.15	3.41e-12	1.25e-09	0.59	0.32	Cancer;	chr14:51270230	chr14:51333393~51365557:+
PRAD	cis	rs12432203	1	rs72622440	ENSG00000258479.4	LINC00640	7.15	3.41e-12	1.25e-09	0.59	0.32	Cancer;	chr14:51270473	chr14:51333393~51365557:+
PRAD	cis	rs12432203	1	rs4444247	ENSG00000258479.4	LINC00640	7.15	3.41e-12	1.25e-09	0.59	0.32	Cancer;	chr14:51273916	chr14:51333393~51365557:+
PRAD	cis	rs35264875	1	rs35264875	ENSG00000259799.1	RP11-554A11.9	7.15	3.42e-12	1.25e-09	0.42	0.32	Blond vs. brown hair color;	chr11:69078931	chr11:69155910~69159752:+
PRAD	cis	rs10129255	0.957	rs10137980	ENSG00000211970.3	IGHV4-61	-7.15	3.42e-12	1.25e-09	-0.29	-0.32	Kawasaki disease;	chr14:106775735	chr14:106639119~106639657:-
PRAD	cis	rs10129255	0.957	rs10141052	ENSG00000211970.3	IGHV4-61	-7.15	3.42e-12	1.25e-09	-0.29	-0.32	Kawasaki disease;	chr14:106776528	chr14:106639119~106639657:-
PRAD	cis	rs10129255	0.957	rs10141009	ENSG00000211970.3	IGHV4-61	-7.15	3.42e-12	1.25e-09	-0.29	-0.32	Kawasaki disease;	chr14:106776695	chr14:106639119~106639657:-
PRAD	cis	rs10129255	0.912	rs6576227	ENSG00000211970.3	IGHV4-61	-7.15	3.42e-12	1.25e-09	-0.29	-0.32	Kawasaki disease;	chr14:106778202	chr14:106639119~106639657:-
PRAD	cis	rs10129255	0.957	rs6576228	ENSG00000211970.3	IGHV4-61	-7.15	3.42e-12	1.25e-09	-0.29	-0.32	Kawasaki disease;	chr14:106778401	chr14:106639119~106639657:-
PRAD	cis	rs10129255	0.957	rs12590799	ENSG00000211970.3	IGHV4-61	-7.15	3.42e-12	1.25e-09	-0.29	-0.32	Kawasaki disease;	chr14:106779713	chr14:106639119~106639657:-
PRAD	cis	rs10129255	0.957	rs10136781	ENSG00000211970.3	IGHV4-61	-7.15	3.42e-12	1.25e-09	-0.29	-0.32	Kawasaki disease;	chr14:106780451	chr14:106639119~106639657:-
PRAD	cis	rs10129255	0.957	rs8022165	ENSG00000211970.3	IGHV4-61	-7.15	3.42e-12	1.25e-09	-0.29	-0.32	Kawasaki disease;	chr14:106781682	chr14:106639119~106639657:-
PRAD	cis	rs10129255	0.917	rs8022493	ENSG00000211970.3	IGHV4-61	-7.15	3.42e-12	1.25e-09	-0.29	-0.32	Kawasaki disease;	chr14:106781820	chr14:106639119~106639657:-
PRAD	cis	rs2836950	0.545	rs11701805	ENSG00000255568.3	BRWD1-AS2	-7.15	3.42e-12	1.25e-09	-0.26	-0.32	Menarche (age at onset);	chr21:39246757	chr21:39313935~39314962:+
PRAD	cis	rs9326248	0.539	rs10892058	ENSG00000280143.1	AP000892.6	7.15	3.42e-12	1.25e-09	0.24	0.32	Blood protein levels;	chr11:117005905	chr11:117204967~117210292:+
PRAD	cis	rs9326248	0.52	rs7127881	ENSG00000280143.1	AP000892.6	7.15	3.42e-12	1.25e-09	0.24	0.32	Blood protein levels;	chr11:117010082	chr11:117204967~117210292:+
PRAD	cis	rs453301	0.571	rs2929454	ENSG00000253893.2	FAM85B	7.15	3.42e-12	1.26e-09	0.39	0.32	Joint mobility (Beighton score);	chr8:9226344	chr8:8167819~8226614:-
PRAD	cis	rs2638953	0.889	rs2045887	ENSG00000247934.4	RP11-967K21.1	-7.15	3.43e-12	1.26e-09	-0.34	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28270825	chr12:28163298~28190738:-
PRAD	cis	rs10129255	0.957	rs8009638	ENSG00000211970.3	IGHV4-61	-7.15	3.43e-12	1.26e-09	-0.29	-0.32	Kawasaki disease;	chr14:106777570	chr14:106639119~106639657:-
PRAD	cis	rs9467773	0.549	rs9467805	ENSG00000124549.13	BTN2A3P	7.15	3.43e-12	1.26e-09	0.27	0.32	Intelligence (multi-trait analysis);	chr6:26583138	chr6:26421391~26432383:+
PRAD	cis	rs172166	0.694	rs188105	ENSG00000204709.4	LINC01556	7.15	3.43e-12	1.26e-09	0.41	0.32	Cardiac Troponin-T levels;	chr6:28103615	chr6:28943877~28944537:+
PRAD	cis	rs10129255	0.646	rs55995061	ENSG00000223648.3	IGHV3-64	7.15	3.43e-12	1.26e-09	0.31	0.32	Kawasaki disease;	chr14:106799309	chr14:106643132~106658258:-
PRAD	cis	rs539096	0.5	rs2527776	ENSG00000237950.1	RP11-7O11.3	7.15	3.44e-12	1.26e-09	0.35	0.32	Intelligence (multi-trait analysis);	chr1:43879620	chr1:43944370~43946551:-
PRAD	cis	rs539096	0.5	rs803678	ENSG00000237950.1	RP11-7O11.3	7.15	3.44e-12	1.26e-09	0.35	0.32	Intelligence (multi-trait analysis);	chr1:43885226	chr1:43944370~43946551:-
PRAD	cis	rs8062405	0.722	rs3785354	ENSG00000251417.2	RP11-1348G14.4	-7.15	3.44e-12	1.26e-09	-0.35	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28539346	chr16:28802743~28817828:+
PRAD	cis	rs8062405	0.755	rs4787457	ENSG00000251417.2	RP11-1348G14.4	-7.15	3.44e-12	1.26e-09	-0.35	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544079	chr16:28802743~28817828:+
PRAD	cis	rs7927592	0.789	rs2291467	ENSG00000212093.1	AP000807.1	7.15	3.44e-12	1.26e-09	0.37	0.32	Total body bone mineral density;	chr11:68449288	chr11:68506083~68506166:-
PRAD	cis	rs1707322	0.721	rs11211181	ENSG00000280836.1	AL355480.1	-7.15	3.45e-12	1.26e-09	-0.39	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45771128	chr1:45581219~45581321:-
PRAD	cis	rs875971	0.66	rs10215132	ENSG00000237310.1	GS1-124K5.4	-7.15	3.45e-12	1.26e-09	-0.28	-0.32	Aortic root size;	chr7:66589419	chr7:66493706~66495474:+
PRAD	cis	rs2243480	0.708	rs35825036	ENSG00000273142.1	RP11-458F8.4	-7.15	3.46e-12	1.27e-09	-0.36	-0.32	Diabetic kidney disease;	chr7:66521515	chr7:66902857~66906297:+
PRAD	cis	rs4631830	0.695	rs11004584	ENSG00000230869.1	CTGLF10P	-7.15	3.46e-12	1.27e-09	-0.39	-0.32	Prostate-specific antigen levels;	chr10:46095734	chr10:45678692~45700532:+
PRAD	cis	rs2033711	0.87	rs7409473	ENSG00000269473.1	CTD-2619J13.19	7.15	3.46e-12	1.27e-09	0.34	0.32	Uric acid clearance;	chr19:58427798	chr19:58440448~58445849:+
PRAD	cis	rs2033711	0.87	rs7408188	ENSG00000269473.1	CTD-2619J13.19	7.15	3.46e-12	1.27e-09	0.34	0.32	Uric acid clearance;	chr19:58428022	chr19:58440448~58445849:+
PRAD	cis	rs73186030	0.764	rs56236741	ENSG00000272758.4	RP11-299J3.8	7.15	3.47e-12	1.27e-09	0.46	0.32	Serum parathyroid hormone levels;	chr3:122379136	chr3:122416207~122443180:+
PRAD	cis	rs957448	1	rs12679345	ENSG00000253175.1	RP11-267M23.6	7.15	3.47e-12	1.27e-09	0.39	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94552305	chr8:94565036~94565715:+
PRAD	cis	rs2638953	0.853	rs10843179	ENSG00000278733.1	RP11-425D17.1	7.15	3.48e-12	1.27e-09	0.39	0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28462125	chr12:28185625~28186190:-
PRAD	cis	rs995000	0.931	rs1748197	ENSG00000235545.1	RP11-230B22.1	7.15	3.48e-12	1.27e-09	0.42	0.32	Triglyceride levels;	chr1:62590441	chr1:62688482~62710694:+
PRAD	cis	rs995000	0.931	rs2366636	ENSG00000235545.1	RP11-230B22.1	7.15	3.48e-12	1.27e-09	0.42	0.32	Triglyceride levels;	chr1:62590999	chr1:62688482~62710694:+
PRAD	cis	rs995000	0.931	rs1748199	ENSG00000235545.1	RP11-230B22.1	7.15	3.48e-12	1.27e-09	0.42	0.32	Triglyceride levels;	chr1:62591465	chr1:62688482~62710694:+
PRAD	cis	rs17361889	0.727	rs1295129	ENSG00000224683.1	RPL36AP29	-7.15	3.48e-12	1.28e-09	-0.37	-0.32	Pediatric bone mineral content (hip);	chr7:16277030	chr7:16208945~16209265:+
PRAD	cis	rs6547741	0.844	rs55826602	ENSG00000234072.1	AC074117.10	-7.15	3.48e-12	1.28e-09	-0.25	-0.32	Oral cavity cancer;	chr2:27640585	chr2:27356246~27367622:+
PRAD	cis	rs853679	0.76	rs9468317	ENSG00000226314.6	ZNF192P1	-7.15	3.49e-12	1.28e-09	-0.46	-0.32	Depression;	chr6:28230678	chr6:28161781~28169594:+
PRAD	cis	rs7208859	0.778	rs6505219	ENSG00000263531.1	RP13-753N3.1	7.15	3.49e-12	1.28e-09	0.52	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30938603	chr17:30863921~30864940:-
PRAD	cis	rs2033711	0.87	rs11084545	ENSG00000269473.1	CTD-2619J13.19	7.15	3.5e-12	1.28e-09	0.35	0.32	Uric acid clearance;	chr19:58440326	chr19:58440448~58445849:+
PRAD	cis	rs2033711	0.87	rs7259841	ENSG00000269473.1	CTD-2619J13.19	7.15	3.5e-12	1.28e-09	0.35	0.32	Uric acid clearance;	chr19:58439756	chr19:58440448~58445849:+
PRAD	cis	rs2286503	0.78	rs1304431	ENSG00000228649.7	AC005682.5	7.15	3.5e-12	1.28e-09	0.36	0.32	Fibrinogen;	chr7:22825793	chr7:22854178~22861579:+
PRAD	cis	rs6479901	0.841	rs1904297	ENSG00000232075.1	MRPL35P2	-7.15	3.51e-12	1.28e-09	-0.39	-0.32	Intelligence (multi-trait analysis);	chr10:63255428	chr10:63634317~63634827:-
PRAD	cis	rs2638953	0.924	rs2272361	ENSG00000247934.4	RP11-967K21.1	-7.15	3.51e-12	1.29e-09	-0.31	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28450037	chr12:28163298~28190738:-
PRAD	cis	rs7487075	0.93	rs4076484	ENSG00000274723.1	RP11-618L22.1	7.15	3.52e-12	1.29e-09	0.37	0.32	Itch intensity from mosquito bite;	chr12:46440129	chr12:46970504~46972155:+
PRAD	cis	rs7487075	0.823	rs34472481	ENSG00000274723.1	RP11-618L22.1	7.15	3.52e-12	1.29e-09	0.37	0.32	Itch intensity from mosquito bite;	chr12:46442565	chr12:46970504~46972155:+
PRAD	cis	rs4728142	0.604	rs10954215	ENSG00000275106.1	RP11-309L24.10	-7.15	3.52e-12	1.29e-09	-0.4	-0.32	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129005459	chr7:128952527~128953316:-
PRAD	cis	rs6547741	0.844	rs7586655	ENSG00000234072.1	AC074117.10	-7.15	3.52e-12	1.29e-09	-0.25	-0.32	Oral cavity cancer;	chr2:27692792	chr2:27356246~27367622:+
PRAD	cis	rs748404	0.697	rs546722	ENSG00000205771.5	CATSPER2P1	-7.15	3.53e-12	1.29e-09	-0.35	-0.32	Lung cancer;	chr15:43288621	chr15:43726918~43747094:-
PRAD	cis	rs1023500	0.551	rs133355	ENSG00000205702.9	CYP2D7	7.15	3.53e-12	1.29e-09	0.25	0.32	Schizophrenia;	chr22:42044281	chr22:42140203~42144577:-
PRAD	cis	rs9640161	0.789	rs1464752	ENSG00000261305.1	RP4-584D14.7	7.15	3.53e-12	1.29e-09	0.35	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150324195	chr7:150341771~150342607:+
PRAD	cis	rs9640161	0.789	rs1464753	ENSG00000261305.1	RP4-584D14.7	7.15	3.53e-12	1.29e-09	0.35	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150324261	chr7:150341771~150342607:+
PRAD	cis	rs2638953	0.893	rs7969086	ENSG00000247934.4	RP11-967K21.1	7.15	3.53e-12	1.29e-09	0.31	0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28507273	chr12:28163298~28190738:-
PRAD	cis	rs760794	0.533	rs2206034	ENSG00000228412.5	RP4-625H18.2	7.15	3.54e-12	1.3e-09	0.38	0.32	Endometriosis;	chr6:19796632	chr6:19802164~19804752:-
PRAD	cis	rs858239	0.536	rs6961109	ENSG00000226816.2	AC005082.12	7.15	3.54e-12	1.3e-09	0.37	0.32	Cerebrospinal fluid biomarker levels;	chr7:23212794	chr7:23206013~23208045:+
PRAD	cis	rs42648	0.869	rs42613	ENSG00000227646.6	STEAP2-AS1	-7.15	3.54e-12	1.3e-09	-0.29	-0.32	Homocysteine levels;	chr7:90320989	chr7:89882353~90211635:-
PRAD	cis	rs42648	0.837	rs42615	ENSG00000227646.6	STEAP2-AS1	-7.15	3.54e-12	1.3e-09	-0.29	-0.32	Homocysteine levels;	chr7:90321187	chr7:89882353~90211635:-
PRAD	cis	rs812925	0.519	rs2922089	ENSG00000271889.1	RP11-493E12.1	-7.15	3.55e-12	1.3e-09	-0.35	-0.32	Immature fraction of reticulocytes;	chr2:61397994	chr2:61151433~61162105:-
PRAD	cis	rs812925	0.519	rs2694627	ENSG00000271889.1	RP11-493E12.1	-7.15	3.55e-12	1.3e-09	-0.35	-0.32	Immature fraction of reticulocytes;	chr2:61398371	chr2:61151433~61162105:-
PRAD	cis	rs2243480	1	rs1638734	ENSG00000273142.1	RP11-458F8.4	-7.15	3.56e-12	1.3e-09	-0.37	-0.32	Diabetic kidney disease;	chr7:66632552	chr7:66902857~66906297:+
PRAD	cis	rs12571093	0.773	rs61854802	ENSG00000233590.1	RP11-153K11.3	-7.15	3.56e-12	1.3e-09	-0.53	-0.32	Optic nerve measurement (disc area);	chr10:68249815	chr10:68233251~68242379:-
PRAD	cis	rs35264875	1	rs72928636	ENSG00000259799.1	RP11-554A11.9	7.15	3.56e-12	1.3e-09	0.42	0.32	Blond vs. brown hair color;	chr11:69080918	chr11:69155910~69159752:+
PRAD	cis	rs35264875	1	rs72928644	ENSG00000259799.1	RP11-554A11.9	7.15	3.56e-12	1.3e-09	0.42	0.32	Blond vs. brown hair color;	chr11:69082377	chr11:69155910~69159752:+
PRAD	cis	rs35264875	1	rs1542334	ENSG00000259799.1	RP11-554A11.9	7.15	3.56e-12	1.3e-09	0.42	0.32	Blond vs. brown hair color;	chr11:69083305	chr11:69155910~69159752:+
PRAD	cis	rs35264875	1	rs72928652	ENSG00000259799.1	RP11-554A11.9	7.15	3.56e-12	1.3e-09	0.42	0.32	Blond vs. brown hair color;	chr11:69084079	chr11:69155910~69159752:+
PRAD	cis	rs287982	0.932	rs9973577	ENSG00000269973.1	RP11-95D17.1	-7.15	3.56e-12	1.3e-09	-0.31	-0.32	Nonsyndromic cleft lip with cleft palate;	chr2:9820574	chr2:9936360~9939590:+
PRAD	cis	rs964611	0.808	rs2279369	ENSG00000259488.2	RP11-154J22.1	-7.15	3.56e-12	1.3e-09	-0.37	-0.32	Metabolite levels (Pyroglutamine);	chr15:48250133	chr15:48312353~48331856:-
PRAD	cis	rs7560272	0.682	rs2421546	ENSG00000163016.8	ALMS1P	-7.15	3.57e-12	1.3e-09	-0.36	-0.32	Schizophrenia;	chr2:73413949	chr2:73644919~73685576:+
PRAD	cis	rs1862618	0.573	rs2034245	ENSG00000271828.1	CTD-2310F14.1	-7.15	3.57e-12	1.31e-09	-0.54	-0.32	Initial pursuit acceleration;	chr5:56947858	chr5:56927874~56929573:+
PRAD	cis	rs4972806	0.814	rs1446575	ENSG00000226363.3	HAGLROS	-7.15	3.57e-12	1.31e-09	-0.36	-0.32	IgG glycosylation;	chr2:176183073	chr2:176177717~176179008:+
PRAD	cis	rs2067615	0.579	rs12312782	ENSG00000260329.1	RP11-412D9.4	-7.15	3.57e-12	1.31e-09	-0.27	-0.32	Heart rate;	chr12:106741869	chr12:106954029~106955497:-
PRAD	cis	rs6903823	0.508	rs1778484	ENSG00000280107.1	AL022393.9	-7.15	3.58e-12	1.31e-09	-0.38	-0.32	Pulmonary function;	chr6:28273021	chr6:28170845~28172521:+
PRAD	cis	rs1799949	1	rs1060915	ENSG00000267002.1	RP11-242D8.1	7.15	3.58e-12	1.31e-09	0.3	0.32	Menopause (age at onset);	chr17:43082453	chr17:43164183~43170403:-
PRAD	cis	rs2638953	0.924	rs7957382	ENSG00000247934.4	RP11-967K21.1	7.15	3.58e-12	1.31e-09	0.32	0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28203643	chr12:28163298~28190738:-
PRAD	cis	rs2243480	1	rs313813	ENSG00000273142.1	RP11-458F8.4	-7.15	3.59e-12	1.31e-09	-0.35	-0.32	Diabetic kidney disease;	chr7:66038513	chr7:66902857~66906297:+
PRAD	cis	rs4713118	0.955	rs9368528	ENSG00000219392.1	RP1-265C24.5	-7.15	3.59e-12	1.31e-09	-0.4	-0.32	Parkinson's disease;	chr6:27716019	chr6:28115628~28116551:+
PRAD	cis	rs4713118	0.955	rs9368529	ENSG00000219392.1	RP1-265C24.5	-7.15	3.59e-12	1.31e-09	-0.4	-0.32	Parkinson's disease;	chr6:27716852	chr6:28115628~28116551:+
PRAD	cis	rs4713118	0.955	rs9380012	ENSG00000219392.1	RP1-265C24.5	-7.15	3.59e-12	1.31e-09	-0.4	-0.32	Parkinson's disease;	chr6:27716875	chr6:28115628~28116551:+
PRAD	cis	rs4713118	0.955	rs9468201	ENSG00000219392.1	RP1-265C24.5	-7.15	3.59e-12	1.31e-09	-0.4	-0.32	Parkinson's disease;	chr6:27719256	chr6:28115628~28116551:+
PRAD	cis	rs2243480	1	rs1964692	ENSG00000273142.1	RP11-458F8.4	-7.15	3.6e-12	1.32e-09	-0.35	-0.32	Diabetic kidney disease;	chr7:65989196	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs1723267	ENSG00000273142.1	RP11-458F8.4	-7.15	3.6e-12	1.32e-09	-0.35	-0.32	Diabetic kidney disease;	chr7:66008327	chr7:66902857~66906297:+
PRAD	cis	rs2638953	0.962	rs61922969	ENSG00000247934.4	RP11-967K21.1	-7.14	3.6e-12	1.32e-09	-0.34	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28261721	chr12:28163298~28190738:-
PRAD	cis	rs6844153	1	rs80197589	ENSG00000240005.4	RP11-293A21.1	-7.14	3.6e-12	1.32e-09	-0.44	-0.32	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26887030	chr4:26859806~26860599:-
PRAD	cis	rs150992	0.603	rs246251	ENSG00000248489.1	CTD-2007H13.3	7.14	3.61e-12	1.32e-09	0.4	0.32	Body mass index;	chr5:98942362	chr5:98929171~98995013:+
PRAD	cis	rs12432203	1	rs72622436	ENSG00000258479.4	LINC00640	7.14	3.61e-12	1.32e-09	0.59	0.32	Cancer;	chr14:51268725	chr14:51333393~51365557:+
PRAD	cis	rs12432203	1	rs72622437	ENSG00000258479.4	LINC00640	7.14	3.61e-12	1.32e-09	0.59	0.32	Cancer;	chr14:51268990	chr14:51333393~51365557:+
PRAD	cis	rs4664293	0.769	rs1365798	ENSG00000226266.5	AC009961.3	7.14	3.61e-12	1.32e-09	0.43	0.32	Monocyte percentage of white cells;	chr2:159795853	chr2:159670708~159712435:-
PRAD	cis	rs4664293	0.867	rs3771718	ENSG00000226266.5	AC009961.3	-7.14	3.61e-12	1.32e-09	-0.42	-0.32	Monocyte percentage of white cells;	chr2:159780397	chr2:159670708~159712435:-
PRAD	cis	rs10411161	1	rs8109345	ENSG00000269483.1	AC006272.1	7.14	3.62e-12	1.32e-09	0.47	0.32	Breast cancer;	chr19:51861680	chr19:51839924~51843324:-
PRAD	cis	rs10411161	1	rs8108583	ENSG00000269483.1	AC006272.1	7.14	3.62e-12	1.32e-09	0.47	0.32	Breast cancer;	chr19:51861724	chr19:51839924~51843324:-
PRAD	cis	rs853679	1	rs1936365	ENSG00000226314.6	ZNF192P1	7.14	3.63e-12	1.33e-09	0.5	0.32	Depression;	chr6:28300675	chr6:28161781~28169594:+
PRAD	cis	rs7260598	0.792	rs73021461	ENSG00000268442.1	CTD-2027I19.2	7.14	3.64e-12	1.33e-09	0.55	0.32	Response to taxane treatment (placlitaxel);	chr19:24140154	chr19:24162370~24163425:-
PRAD	cis	rs10463554	0.892	rs17154859	ENSG00000175749.11	EIF3KP1	-7.14	3.64e-12	1.33e-09	-0.41	-0.32	Parkinson's disease;	chr5:102955208	chr5:103032376~103033031:+
PRAD	cis	rs2243480	1	rs34193460	ENSG00000273142.1	RP11-458F8.4	-7.14	3.64e-12	1.33e-09	-0.35	-0.32	Diabetic kidney disease;	chr7:65928123	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs57057549	ENSG00000273142.1	RP11-458F8.4	-7.14	3.64e-12	1.33e-09	-0.35	-0.32	Diabetic kidney disease;	chr7:65940751	chr7:66902857~66906297:+
PRAD	cis	rs2243480	0.808	rs12698508	ENSG00000273142.1	RP11-458F8.4	-7.14	3.64e-12	1.33e-09	-0.35	-0.32	Diabetic kidney disease;	chr7:65946971	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs2961102	ENSG00000273142.1	RP11-458F8.4	-7.14	3.64e-12	1.33e-09	-0.35	-0.32	Diabetic kidney disease;	chr7:65959671	chr7:66902857~66906297:+
PRAD	cis	rs2243480	0.901	rs73148097	ENSG00000273142.1	RP11-458F8.4	-7.14	3.64e-12	1.33e-09	-0.35	-0.32	Diabetic kidney disease;	chr7:65966800	chr7:66902857~66906297:+
PRAD	cis	rs7727544	0.507	rs11741341	ENSG00000233006.5	AC034220.3	7.14	3.65e-12	1.33e-09	0.27	0.32	Blood metabolite levels;	chr5:132234525	chr5:132311285~132369916:-
PRAD	cis	rs2067615	0.579	rs10778509	ENSG00000260329.1	RP11-412D9.4	-7.14	3.65e-12	1.33e-09	-0.27	-0.32	Heart rate;	chr12:106769140	chr12:106954029~106955497:-
PRAD	cis	rs995000	0.965	rs1690761	ENSG00000235545.1	RP11-230B22.1	-7.14	3.65e-12	1.33e-09	-0.42	-0.32	Triglyceride levels;	chr1:62490191	chr1:62688482~62710694:+
PRAD	cis	rs4927850	1	rs6799572	ENSG00000231464.1	AC024937.4	7.14	3.66e-12	1.34e-09	0.39	0.32	Pancreatic cancer;	chr3:196013537	chr3:195996738~195998233:+
PRAD	cis	rs2276314	0.947	rs16967319	ENSG00000278986.1	RP11-723J4.3	-7.14	3.66e-12	1.34e-09	-0.4	-0.32	Endometriosis;Drug-induced torsades de pointes;	chr18:35993562	chr18:35972151~35973916:+
PRAD	cis	rs6479901	0.895	rs7909555	ENSG00000232075.1	MRPL35P2	-7.14	3.67e-12	1.34e-09	-0.39	-0.32	Intelligence (multi-trait analysis);	chr10:63273348	chr10:63634317~63634827:-
PRAD	cis	rs10411161	1	rs8111316	ENSG00000269483.1	AC006272.1	7.14	3.67e-12	1.34e-09	0.48	0.32	Breast cancer;	chr19:51865816	chr19:51839924~51843324:-
PRAD	cis	rs875971	0.545	rs316305	ENSG00000226824.5	RP4-756H11.3	7.14	3.68e-12	1.34e-09	0.47	0.32	Aortic root size;	chr7:66152984	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.545	rs316306	ENSG00000226824.5	RP4-756H11.3	7.14	3.68e-12	1.34e-09	0.47	0.32	Aortic root size;	chr7:66153687	chr7:66654538~66669855:+
PRAD	cis	rs7615952	0.599	rs6438955	ENSG00000171084.14	FAM86JP	7.14	3.68e-12	1.34e-09	0.49	0.32	Blood pressure (smoking interaction);	chr3:126011490	chr3:125916620~125930024:+
PRAD	cis	rs12612619	0.732	rs11680032	ENSG00000229122.1	AGBL5-IT1	7.14	3.68e-12	1.34e-09	0.33	0.32	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26975280	chr2:27061038~27061815:+
PRAD	cis	rs6903823	0.508	rs1150726	ENSG00000280107.1	AL022393.9	-7.14	3.7e-12	1.35e-09	-0.38	-0.32	Pulmonary function;	chr6:28275265	chr6:28170845~28172521:+
PRAD	cis	rs12612619	0.732	rs11897106	ENSG00000229122.1	AGBL5-IT1	-7.14	3.7e-12	1.35e-09	-0.33	-0.32	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26973431	chr2:27061038~27061815:+
PRAD	cis	rs6991838	0.751	rs35553155	ENSG00000272010.1	CTD-3025N20.3	7.14	3.7e-12	1.35e-09	0.32	0.32	Intelligence (multi-trait analysis);	chr8:65551232	chr8:65591850~65592472:-
PRAD	cis	rs6991838	0.806	rs35024820	ENSG00000272010.1	CTD-3025N20.3	7.14	3.7e-12	1.35e-09	0.32	0.32	Intelligence (multi-trait analysis);	chr8:65551296	chr8:65591850~65592472:-
PRAD	cis	rs435066	0.633	rs6682188	ENSG00000234264.1	DEPDC1-AS1	-7.14	3.7e-12	1.35e-09	-0.46	-0.32	IgG glycosylation;	chr1:68518711	chr1:68496676~68538627:+
PRAD	cis	rs995000	0.931	rs10889339	ENSG00000235545.1	RP11-230B22.1	-7.14	3.7e-12	1.35e-09	-0.42	-0.32	Triglyceride levels;	chr1:62546385	chr1:62688482~62710694:+
PRAD	cis	rs995000	0.931	rs11207983	ENSG00000235545.1	RP11-230B22.1	-7.14	3.7e-12	1.35e-09	-0.42	-0.32	Triglyceride levels;	chr1:62546436	chr1:62688482~62710694:+
PRAD	cis	rs1707322	0.721	rs56255771	ENSG00000280836.1	AL355480.1	-7.14	3.71e-12	1.35e-09	-0.39	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45758647	chr1:45581219~45581321:-
PRAD	cis	rs957448	1	rs1055800	ENSG00000253175.1	RP11-267M23.6	-7.14	3.71e-12	1.35e-09	-0.39	-0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94510810	chr8:94565036~94565715:+
PRAD	cis	rs995000	0.868	rs10889360	ENSG00000235545.1	RP11-230B22.1	7.14	3.72e-12	1.36e-09	0.43	0.32	Triglyceride levels;	chr1:62708247	chr1:62688482~62710694:+
PRAD	cis	rs7309	0.622	rs4664395	ENSG00000235724.7	AC009299.2	-7.14	3.72e-12	1.36e-09	-0.38	-0.32	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161044790	chr2:161222785~161308303:-
PRAD	cis	rs2436845	0.627	rs1991928	ENSG00000253320.4	KB-1507C5.2	-7.14	3.72e-12	1.36e-09	-0.39	-0.32	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102860863	chr8:102864300~102977876:+
PRAD	cis	rs11846409	0.799	rs10467899	ENSG00000274576.2	IGHV2-70	-7.14	3.73e-12	1.36e-09	-0.33	-0.32	Rheumatic heart disease;	chr14:106644012	chr14:106770577~106771020:-
PRAD	cis	rs75422866	0.764	rs73104177	ENSG00000274902.1	RP1-197B17.4	7.14	3.73e-12	1.36e-09	0.89	0.32	Pneumonia;	chr12:47713550	chr12:47731908~47732351:+
PRAD	cis	rs853679	1	rs853694	ENSG00000226314.6	ZNF192P1	-7.14	3.73e-12	1.36e-09	-0.5	-0.32	Depression;	chr6:28311323	chr6:28161781~28169594:+
PRAD	cis	rs2836950	0.501	rs2836984	ENSG00000255568.3	BRWD1-AS2	-7.14	3.74e-12	1.36e-09	-0.27	-0.32	Menarche (age at onset);	chr21:39329023	chr21:39313935~39314962:+
PRAD	cis	rs10411161	1	rs8108477	ENSG00000269483.1	AC006272.1	7.14	3.75e-12	1.37e-09	0.47	0.32	Breast cancer;	chr19:51861649	chr19:51839924~51843324:-
PRAD	cis	rs858239	0.601	rs12539331	ENSG00000226816.2	AC005082.12	7.14	3.76e-12	1.37e-09	0.36	0.32	Cerebrospinal fluid biomarker levels;	chr7:23111711	chr7:23206013~23208045:+
PRAD	cis	rs858239	0.601	rs6980224	ENSG00000226816.2	AC005082.12	7.14	3.76e-12	1.37e-09	0.36	0.32	Cerebrospinal fluid biomarker levels;	chr7:23109518	chr7:23206013~23208045:+
PRAD	cis	rs1799949	1	rs2037075	ENSG00000267002.1	RP11-242D8.1	7.14	3.77e-12	1.38e-09	0.3	0.32	Menopause (age at onset);	chr17:43153809	chr17:43164183~43170403:-
PRAD	cis	rs77204473	0.744	rs3781985	ENSG00000254851.1	RP11-109L13.1	7.14	3.77e-12	1.38e-09	0.71	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117194350	chr11:117135528~117138582:+
PRAD	cis	rs77204473	0.744	rs11606480	ENSG00000254851.1	RP11-109L13.1	7.14	3.77e-12	1.38e-09	0.71	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117194817	chr11:117135528~117138582:+
PRAD	cis	rs12817211	0.536	rs9364	ENSG00000272368.2	RP4-605O3.4	7.14	3.78e-12	1.38e-09	0.33	0.32	Colorectal or endometrial cancer;	chr12:50176736	chr12:50112197~50165618:+
PRAD	cis	rs34245511	1	rs34245511	ENSG00000272368.2	RP4-605O3.4	-7.14	3.78e-12	1.38e-09	-0.33	-0.32	Colorectal cancer;	chr12:50179650	chr12:50112197~50165618:+
PRAD	cis	rs9640161	0.789	rs6964110	ENSG00000261305.1	RP4-584D14.7	7.14	3.78e-12	1.38e-09	0.34	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150344747	chr7:150341771~150342607:+
PRAD	cis	rs75422866	0.764	rs73104184	ENSG00000274902.1	RP1-197B17.4	7.14	3.78e-12	1.38e-09	0.88	0.32	Pneumonia;	chr12:47715623	chr12:47731908~47732351:+
PRAD	cis	rs75422866	0.764	rs73104188	ENSG00000274902.1	RP1-197B17.4	7.14	3.78e-12	1.38e-09	0.88	0.32	Pneumonia;	chr12:47715885	chr12:47731908~47732351:+
PRAD	cis	rs8042680	0.955	rs2034084	ENSG00000214432.8	AC068831.10	-7.14	3.79e-12	1.38e-09	-0.38	-0.32	Type 2 diabetes;	chr15:90963509	chr15:91022619~91036611:+
PRAD	cis	rs8081395	0.707	rs1024637	ENSG00000266992.1	DHX40P1	-7.14	3.79e-12	1.38e-09	-0.35	-0.32	White blood cell count;	chr17:59961532	chr17:59976009~60002384:-
PRAD	cis	rs995000	0.931	rs1167996	ENSG00000235545.1	RP11-230B22.1	-7.14	3.8e-12	1.38e-09	-0.42	-0.32	Triglyceride levels;	chr1:62462126	chr1:62688482~62710694:+
PRAD	cis	rs1185460	0.546	rs592190	ENSG00000271751.1	RP11-110I1.14	7.14	3.8e-12	1.38e-09	0.43	0.32	Coronary artery disease;	chr11:119084604	chr11:119065263~119065677:-
PRAD	cis	rs7772486	0.777	rs1546966	ENSG00000235652.6	RP11-545I5.3	7.14	3.8e-12	1.38e-09	0.33	0.32	Lobe attachment (rater-scored or self-reported);	chr6:146064882	chr6:145799409~145886585:+
PRAD	cis	rs7429990	0.965	rs9846062	ENSG00000229759.1	MRPS18AP1	7.14	3.8e-12	1.39e-09	0.32	0.32	Educational attainment (years of education);	chr3:47957476	chr3:48256350~48256938:-
PRAD	cis	rs12612619	0.732	rs2289360	ENSG00000272148.1	RP11-195B17.1	7.14	3.8e-12	1.39e-09	0.38	0.32	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27079297	chr2:27062428~27062907:-
PRAD	cis	rs6452524	0.87	rs12152892	ENSG00000249664.1	CTD-2227C6.2	7.14	3.81e-12	1.39e-09	0.39	0.32	Hypertension (SNP x SNP interaction);	chr5:83125110	chr5:83012285~83013109:-
PRAD	cis	rs875971	0.66	rs801192	ENSG00000237310.1	GS1-124K5.4	-7.14	3.81e-12	1.39e-09	-0.28	-0.32	Aortic root size;	chr7:66566965	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.66	rs801190	ENSG00000237310.1	GS1-124K5.4	-7.14	3.81e-12	1.39e-09	-0.28	-0.32	Aortic root size;	chr7:66568046	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.66	rs3857686	ENSG00000237310.1	GS1-124K5.4	-7.14	3.81e-12	1.39e-09	-0.28	-0.32	Aortic root size;	chr7:66571204	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.545	rs4718325	ENSG00000226824.5	RP4-756H11.3	-7.14	3.81e-12	1.39e-09	-0.48	-0.32	Aortic root size;	chr7:66215323	chr7:66654538~66669855:+
PRAD	cis	rs673078	0.66	rs16948197	ENSG00000275409.1	RP11-131L12.4	7.14	3.82e-12	1.39e-09	0.46	0.32	Glucose homeostasis traits;	chr12:118239135	chr12:118430147~118430699:+
PRAD	cis	rs12612619	0.732	rs1440044	ENSG00000229122.1	AGBL5-IT1	7.14	3.83e-12	1.39e-09	0.32	0.32	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27004086	chr2:27061038~27061815:+
PRAD	cis	rs8062405	0.69	rs7187604	ENSG00000251417.2	RP11-1348G14.4	-7.14	3.83e-12	1.4e-09	-0.35	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554632	chr16:28802743~28817828:+
PRAD	cis	rs673078	0.66	rs17440336	ENSG00000275409.1	RP11-131L12.4	7.14	3.84e-12	1.4e-09	0.45	0.32	Glucose homeostasis traits;	chr12:118163305	chr12:118430147~118430699:+
PRAD	cis	rs6844153	0.752	rs73811400	ENSG00000240005.4	RP11-293A21.1	-7.14	3.84e-12	1.4e-09	-0.38	-0.32	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26887701	chr4:26859806~26860599:-
PRAD	cis	rs1799949	0.965	rs9646413	ENSG00000267002.1	RP11-242D8.1	7.14	3.84e-12	1.4e-09	0.3	0.32	Menopause (age at onset);	chr17:43348789	chr17:43164183~43170403:-
PRAD	cis	rs516805	0.673	rs561953	ENSG00000279453.1	RP3-425C14.4	-7.13	3.85e-12	1.4e-09	-0.29	-0.32	Lymphocyte counts;	chr6:122440341	chr6:122436789~122439223:-
PRAD	cis	rs12908161	0.96	rs34452033	ENSG00000275120.1	RP11-182J1.17	7.13	3.86e-12	1.4e-09	0.42	0.32	Schizophrenia;	chr15:84678762	chr15:84599434~84606463:-
PRAD	cis	rs6844153	1	rs74356465	ENSG00000240005.4	RP11-293A21.1	-7.13	3.86e-12	1.4e-09	-0.44	-0.32	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26902405	chr4:26859806~26860599:-
PRAD	cis	rs7428	0.527	rs1554110	ENSG00000246575.2	AC093162.5	7.13	3.86e-12	1.4e-09	0.24	0.32	Ear protrusion;	chr2:85320840	chr2:85315041~85316529:+
PRAD	cis	rs7428	0.545	rs7572750	ENSG00000246575.2	AC093162.5	7.13	3.86e-12	1.4e-09	0.24	0.32	Ear protrusion;	chr2:85325063	chr2:85315041~85316529:+
PRAD	cis	rs78579487	1	rs78579487	ENSG00000240875.4	LINC00886	-7.13	3.86e-12	1.41e-09	-0.36	-0.32	Breast cancer;	chr3:156800879	chr3:156747346~156817062:-
PRAD	cis	rs6479901	0.846	rs7907462	ENSG00000232075.1	MRPL35P2	-7.13	3.87e-12	1.41e-09	-0.39	-0.32	Intelligence (multi-trait analysis);	chr10:63295773	chr10:63634317~63634827:-
PRAD	cis	rs2638953	0.925	rs11049597	ENSG00000278733.1	RP11-425D17.1	-7.13	3.88e-12	1.41e-09	-0.4	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28433584	chr12:28185625~28186190:-
PRAD	cis	rs763567	0.869	rs680084	ENSG00000271811.1	RP1-79C4.4	7.13	3.88e-12	1.41e-09	0.36	0.32	Tonsillectomy;	chr1:170659114	chr1:170667381~170669425:+
PRAD	cis	rs7428	0.527	rs7607284	ENSG00000246575.2	AC093162.5	7.13	3.89e-12	1.42e-09	0.24	0.32	Ear protrusion;	chr2:85320253	chr2:85315041~85316529:+
PRAD	cis	rs7428	0.527	rs4459734	ENSG00000246575.2	AC093162.5	7.13	3.89e-12	1.42e-09	0.24	0.32	Ear protrusion;	chr2:85320306	chr2:85315041~85316529:+
PRAD	cis	rs875971	0.66	rs7807944	ENSG00000237310.1	GS1-124K5.4	-7.13	3.89e-12	1.42e-09	-0.28	-0.32	Aortic root size;	chr7:66622208	chr7:66493706~66495474:+
PRAD	cis	rs10028773	0.515	rs9994488	ENSG00000245958.5	RP11-33B1.1	-7.13	3.89e-12	1.42e-09	-0.3	-0.32	Educational attainment;	chr4:119666626	chr4:119454791~119552025:+
PRAD	cis	rs10129255	0.719	rs7156660	ENSG00000211970.3	IGHV4-61	-7.13	3.89e-12	1.42e-09	-0.29	-0.32	Kawasaki disease;	chr14:106673171	chr14:106639119~106639657:-
PRAD	cis	rs6496932	0.802	rs10163187	ENSG00000218052.5	ADAMTS7P4	7.13	3.9e-12	1.42e-09	0.38	0.32	Central corneal thickness;Corneal structure;	chr15:85327287	chr15:85255369~85330334:-
PRAD	cis	rs12701220	0.522	rs12701455	ENSG00000229043.2	AC091729.9	-7.13	3.9e-12	1.42e-09	-0.4	-0.32	Bronchopulmonary dysplasia;	chr7:1015773	chr7:1160374~1165267:+
PRAD	cis	rs2067615	0.56	rs10467028	ENSG00000260329.1	RP11-412D9.4	-7.13	3.9e-12	1.42e-09	-0.27	-0.32	Heart rate;	chr12:106682627	chr12:106954029~106955497:-
PRAD	cis	rs853679	0.55	rs1237875	ENSG00000204709.4	LINC01556	-7.13	3.9e-12	1.42e-09	-0.42	-0.32	Depression;	chr6:28205232	chr6:28943877~28944537:+
PRAD	cis	rs9640161	0.742	rs2108853	ENSG00000261305.1	RP4-584D14.7	7.13	3.91e-12	1.42e-09	0.35	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150320500	chr7:150341771~150342607:+
PRAD	cis	rs9287719	0.556	rs10168351	ENSG00000243819.4	RN7SL832P	7.13	3.91e-12	1.42e-09	0.31	0.32	Prostate cancer;	chr2:10596684	chr2:10690344~10692099:+
PRAD	cis	rs9287719	0.578	rs10168852	ENSG00000243819.4	RN7SL832P	7.13	3.91e-12	1.42e-09	0.31	0.32	Prostate cancer;	chr2:10606197	chr2:10690344~10692099:+
PRAD	cis	rs2243480	0.901	rs313808	ENSG00000273142.1	RP11-458F8.4	-7.13	3.91e-12	1.42e-09	-0.35	-0.32	Diabetic kidney disease;	chr7:66034886	chr7:66902857~66906297:+
PRAD	cis	rs9309473	0.607	rs58962779	ENSG00000163016.8	ALMS1P	7.13	3.91e-12	1.42e-09	0.39	0.32	Metabolite levels;	chr2:73328673	chr2:73644919~73685576:+
PRAD	cis	rs964611	0.654	rs968852	ENSG00000259488.2	RP11-154J22.1	7.13	3.92e-12	1.43e-09	0.31	0.32	Metabolite levels (Pyroglutamine);	chr15:48375604	chr15:48312353~48331856:-
PRAD	cis	rs867371	0.929	rs7173852	ENSG00000278603.1	RP13-608F4.5	7.13	3.92e-12	1.43e-09	0.41	0.32	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82169512	chr15:82472203~82472426:+
PRAD	cis	rs875971	0.66	rs79009421	ENSG00000237310.1	GS1-124K5.4	-7.13	3.93e-12	1.43e-09	-0.28	-0.32	Aortic root size;	chr7:66603522	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.66	rs6460308	ENSG00000237310.1	GS1-124K5.4	-7.13	3.93e-12	1.43e-09	-0.28	-0.32	Aortic root size;	chr7:66619753	chr7:66493706~66495474:+
PRAD	cis	rs10875746	0.669	rs11168508	ENSG00000240399.1	RP1-228P16.1	-7.13	3.93e-12	1.43e-09	-0.29	-0.32	Longevity (90 years and older);	chr12:48289728	chr12:48054813~48055591:-
PRAD	cis	rs875971	0.54	rs35510581	ENSG00000236529.1	RP13-254B10.1	-7.13	3.93e-12	1.43e-09	-0.34	-0.32	Aortic root size;	chr7:66113790	chr7:65840212~65840596:+
PRAD	cis	rs4972806	0.814	rs2113560	ENSG00000226363.3	HAGLROS	-7.13	3.94e-12	1.43e-09	-0.36	-0.32	IgG glycosylation;	chr2:176166258	chr2:176177717~176179008:+
PRAD	cis	rs964611	0.938	rs1820494	ENSG00000259488.2	RP11-154J22.1	7.13	3.94e-12	1.43e-09	0.3	0.32	Metabolite levels (Pyroglutamine);	chr15:48310977	chr15:48312353~48331856:-
PRAD	cis	rs964611	0.882	rs1820491	ENSG00000259488.2	RP11-154J22.1	7.13	3.94e-12	1.43e-09	0.3	0.32	Metabolite levels (Pyroglutamine);	chr15:48311245	chr15:48312353~48331856:-
PRAD	cis	rs73186030	0.546	rs6791616	ENSG00000272758.4	RP11-299J3.8	7.13	3.95e-12	1.44e-09	0.42	0.32	Serum parathyroid hormone levels;	chr3:122388388	chr3:122416207~122443180:+
PRAD	cis	rs8114671	0.562	rs6119536	ENSG00000269202.1	RP4-614O4.12	7.13	3.96e-12	1.44e-09	0.31	0.32	Height;	chr20:34862238	chr20:35201747~35203288:-
PRAD	cis	rs2067615	0.542	rs7133161	ENSG00000260329.1	RP11-412D9.4	-7.13	3.96e-12	1.44e-09	-0.27	-0.32	Heart rate;	chr12:106745762	chr12:106954029~106955497:-
PRAD	cis	rs12922040	1	rs12922040	ENSG00000263335.1	AF001548.5	-7.13	3.96e-12	1.44e-09	-0.34	-0.32	Serum uric acid levels in response to allopurinol in gout;	chr16:15775609	chr16:15726674~15732993:+
PRAD	cis	rs875971	0.545	rs73142233	ENSG00000226824.5	RP4-756H11.3	-7.13	3.96e-12	1.44e-09	-0.48	-0.32	Aortic root size;	chr7:66221293	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs313799	ENSG00000273142.1	RP11-458F8.4	-7.13	3.96e-12	1.44e-09	-0.35	-0.32	Diabetic kidney disease;	chr7:66029343	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs313807	ENSG00000273142.1	RP11-458F8.4	-7.13	3.96e-12	1.44e-09	-0.35	-0.32	Diabetic kidney disease;	chr7:66034494	chr7:66902857~66906297:+
PRAD	cis	rs516805	0.924	rs476215	ENSG00000279453.1	RP3-425C14.4	-7.13	3.97e-12	1.44e-09	-0.25	-0.32	Lymphocyte counts;	chr6:122440739	chr6:122436789~122439223:-
PRAD	cis	rs10129255	0.912	rs8009135	ENSG00000211970.3	IGHV4-61	-7.13	3.97e-12	1.44e-09	-0.29	-0.32	Kawasaki disease;	chr14:106777528	chr14:106639119~106639657:-
PRAD	cis	rs3745672	1	rs7359981	ENSG00000219665.7	CTD-2006C1.2	-7.13	3.97e-12	1.44e-09	-0.72	-0.32	Multiple sclerosis;	chr19:11980844	chr19:11987617~12046275:+
PRAD	cis	rs3745672	0.661	rs10084150	ENSG00000219665.7	CTD-2006C1.2	-7.13	3.97e-12	1.44e-09	-0.72	-0.32	Multiple sclerosis;	chr19:11983108	chr19:11987617~12046275:+
PRAD	cis	rs2243480	1	rs160646	ENSG00000273142.1	RP11-458F8.4	-7.13	3.97e-12	1.44e-09	-0.36	-0.32	Diabetic kidney disease;	chr7:66091293	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs465359	ENSG00000273142.1	RP11-458F8.4	-7.13	3.97e-12	1.44e-09	-0.36	-0.32	Diabetic kidney disease;	chr7:66093177	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs462853	ENSG00000273142.1	RP11-458F8.4	-7.13	3.97e-12	1.44e-09	-0.36	-0.32	Diabetic kidney disease;	chr7:66093180	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs160644	ENSG00000273142.1	RP11-458F8.4	-7.13	3.97e-12	1.44e-09	-0.36	-0.32	Diabetic kidney disease;	chr7:66093199	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs160642	ENSG00000273142.1	RP11-458F8.4	-7.13	3.97e-12	1.44e-09	-0.36	-0.32	Diabetic kidney disease;	chr7:66093386	chr7:66902857~66906297:+
PRAD	cis	rs2243480	0.614	rs34032527	ENSG00000273142.1	RP11-458F8.4	-7.13	3.97e-12	1.44e-09	-0.36	-0.32	Diabetic kidney disease;	chr7:66100154	chr7:66902857~66906297:+
PRAD	cis	rs6840360	0.582	rs6535796	ENSG00000278978.1	RP11-164P12.5	-7.13	3.97e-12	1.44e-09	-0.36	-0.32	Intelligence (multi-trait analysis);	chr4:151383576	chr4:151669786~151670503:+
PRAD	cis	rs35264875	0.846	rs72930625	ENSG00000259799.1	RP11-554A11.9	7.13	3.98e-12	1.45e-09	0.44	0.32	Blond vs. brown hair color;	chr11:69099652	chr11:69155910~69159752:+
PRAD	cis	rs35264875	0.846	rs72930627	ENSG00000259799.1	RP11-554A11.9	7.13	3.98e-12	1.45e-09	0.44	0.32	Blond vs. brown hair color;	chr11:69099653	chr11:69155910~69159752:+
PRAD	cis	rs240993	0.715	rs4947122	ENSG00000230177.1	RP5-1112D6.4	-7.13	3.98e-12	1.45e-09	-0.38	-0.32	Inflammatory skin disease;Psoriasis;	chr6:111548887	chr6:111277932~111278742:+
PRAD	cis	rs6674176	0.66	rs12726706	ENSG00000237950.1	RP11-7O11.3	7.13	3.98e-12	1.45e-09	0.36	0.32	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43934270	chr1:43944370~43946551:-
PRAD	cis	rs35264875	1	rs7110274	ENSG00000259799.1	RP11-554A11.9	7.13	3.99e-12	1.45e-09	0.42	0.32	Blond vs. brown hair color;	chr11:69075236	chr11:69155910~69159752:+
PRAD	cis	rs10129255	0.957	rs10150241	ENSG00000211970.3	IGHV4-61	7.13	3.99e-12	1.45e-09	0.29	0.32	Kawasaki disease;	chr14:106775945	chr14:106639119~106639657:-
PRAD	cis	rs7580658	0.724	rs7568261	ENSG00000236682.1	AC068282.3	-7.13	3.99e-12	1.45e-09	-0.39	-0.32	Protein C levels;	chr2:127359748	chr2:127389130~127400580:+
PRAD	cis	rs853679	0.607	rs35001169	ENSG00000280107.1	AL022393.9	-7.13	4e-12	1.45e-09	-0.64	-0.32	Depression;	chr6:28219854	chr6:28170845~28172521:+
PRAD	cis	rs6452524	0.901	rs12188673	ENSG00000249664.1	CTD-2227C6.2	7.13	4e-12	1.45e-09	0.39	0.32	Hypertension (SNP x SNP interaction);	chr5:83126268	chr5:83012285~83013109:-
PRAD	cis	rs848490	0.674	rs7803449	ENSG00000214293.7	APTR	7.13	4e-12	1.45e-09	0.33	0.32	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77679660	chr7:77657660~77696265:-
PRAD	cis	rs1355223	0.902	rs12802323	ENSG00000271369.1	RP11-350D17.3	-7.13	4e-12	1.45e-09	-0.38	-0.32	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34726192	chr11:34709600~34710161:+
PRAD	cis	rs1355223	0.902	rs7121272	ENSG00000271369.1	RP11-350D17.3	-7.13	4e-12	1.45e-09	-0.38	-0.32	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34731015	chr11:34709600~34710161:+
PRAD	cis	rs858239	0.602	rs6953996	ENSG00000226816.2	AC005082.12	7.13	4e-12	1.45e-09	0.37	0.32	Cerebrospinal fluid biomarker levels;	chr7:23136327	chr7:23206013~23208045:+
PRAD	cis	rs7208859	0.623	rs7220999	ENSG00000266490.1	CTD-2349P21.9	7.13	4.01e-12	1.46e-09	0.45	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822280	chr17:30792372~30792833:+
PRAD	cis	rs7208859	0.623	rs55638872	ENSG00000266490.1	CTD-2349P21.9	7.13	4.01e-12	1.46e-09	0.45	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822534	chr17:30792372~30792833:+
PRAD	cis	rs7208859	0.623	rs9899268	ENSG00000266490.1	CTD-2349P21.9	7.13	4.01e-12	1.46e-09	0.45	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30823237	chr17:30792372~30792833:+
PRAD	cis	rs1799949	1	rs8176273	ENSG00000267002.1	RP11-242D8.1	7.13	4.01e-12	1.46e-09	0.31	0.32	Menopause (age at onset);	chr17:43059636	chr17:43164183~43170403:-
PRAD	cis	rs1799949	1	rs8176269	ENSG00000267002.1	RP11-242D8.1	7.13	4.01e-12	1.46e-09	0.31	0.32	Menopause (age at onset);	chr17:43061609	chr17:43164183~43170403:-
PRAD	cis	rs1799949	1	rs8176265	ENSG00000267002.1	RP11-242D8.1	7.13	4.01e-12	1.46e-09	0.31	0.32	Menopause (age at onset);	chr17:43061979	chr17:43164183~43170403:-
PRAD	cis	rs6480314	0.831	rs17538164	ENSG00000233590.1	RP11-153K11.3	7.13	4.01e-12	1.46e-09	0.52	0.32	Optic nerve measurement (disc area);	chr10:68215920	chr10:68233251~68242379:-
PRAD	cis	rs6569038	0.669	rs17513308	ENSG00000253194.1	RP11-351A11.1	7.13	4.01e-12	1.46e-09	0.41	0.32	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:119061186	chr6:118934785~119031541:+
PRAD	cis	rs8005677	0.828	rs712486	ENSG00000257285.4	RP11-298I3.1	7.13	4.01e-12	1.46e-09	0.32	0.32	Cognitive ability (multi-trait analysis);	chr14:22955832	chr14:22929609~22955562:+
PRAD	cis	rs10206020	0.885	rs11899557	ENSG00000231482.2	AC141930.2	-7.13	4.02e-12	1.46e-09	-0.36	-0.32	IgG glycosylation;	chr2:1572351	chr2:1572554~1580311:-
PRAD	cis	rs10206020	0.885	rs6746052	ENSG00000231482.2	AC141930.2	-7.13	4.02e-12	1.46e-09	-0.36	-0.32	IgG glycosylation;	chr2:1573039	chr2:1572554~1580311:-
PRAD	cis	rs10206020	0.885	rs13388254	ENSG00000231482.2	AC141930.2	-7.13	4.02e-12	1.46e-09	-0.36	-0.32	IgG glycosylation;	chr2:1573437	chr2:1572554~1580311:-
PRAD	cis	rs1799949	0.965	rs8176322	ENSG00000267002.1	RP11-242D8.1	7.13	4.02e-12	1.46e-09	0.3	0.32	Menopause (age at onset);	chr17:43043756	chr17:43164183~43170403:-
PRAD	cis	rs8042680	1	rs8042680	ENSG00000214432.8	AC068831.10	7.13	4.03e-12	1.46e-09	0.38	0.32	Type 2 diabetes;	chr15:90978107	chr15:91022619~91036611:+
PRAD	cis	rs2638953	0.924	rs61920245	ENSG00000247934.4	RP11-967K21.1	-7.13	4.03e-12	1.46e-09	-0.32	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28196081	chr12:28163298~28190738:-
PRAD	cis	rs526231	0.578	rs6876278	ENSG00000175749.11	EIF3KP1	7.13	4.03e-12	1.46e-09	0.43	0.32	Primary biliary cholangitis;	chr5:102913842	chr5:103032376~103033031:+
PRAD	cis	rs964611	0.882	rs11629805	ENSG00000259488.2	RP11-154J22.1	7.13	4.03e-12	1.46e-09	0.31	0.32	Metabolite levels (Pyroglutamine);	chr15:48363267	chr15:48312353~48331856:-
PRAD	cis	rs964611	0.882	rs11070636	ENSG00000259488.2	RP11-154J22.1	7.13	4.03e-12	1.46e-09	0.31	0.32	Metabolite levels (Pyroglutamine);	chr15:48364720	chr15:48312353~48331856:-
PRAD	cis	rs964611	0.882	rs11070637	ENSG00000259488.2	RP11-154J22.1	7.13	4.03e-12	1.46e-09	0.31	0.32	Metabolite levels (Pyroglutamine);	chr15:48364881	chr15:48312353~48331856:-
PRAD	cis	rs964611	0.882	rs12439526	ENSG00000259488.2	RP11-154J22.1	7.13	4.03e-12	1.46e-09	0.31	0.32	Metabolite levels (Pyroglutamine);	chr15:48366050	chr15:48312353~48331856:-
PRAD	cis	rs6903823	0.508	rs1150724	ENSG00000280107.1	AL022393.9	-7.13	4.03e-12	1.47e-09	-0.38	-0.32	Pulmonary function;	chr6:28282459	chr6:28170845~28172521:+
PRAD	cis	rs11976180	0.517	rs6949375	ENSG00000170356.8	OR2A20P	-7.13	4.03e-12	1.47e-09	-0.52	-0.32	Obesity-related traits;	chr7:144076758	chr7:144250045~144252957:-
PRAD	cis	rs875971	0.545	rs1796222	ENSG00000226824.5	RP4-756H11.3	7.13	4.04e-12	1.47e-09	0.47	0.32	Aortic root size;	chr7:66592167	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.545	rs2420612	ENSG00000226824.5	RP4-756H11.3	-7.13	4.05e-12	1.47e-09	-0.47	-0.32	Aortic root size;	chr7:66536825	chr7:66654538~66669855:+
PRAD	cis	rs2067615	0.579	rs10861663	ENSG00000260329.1	RP11-412D9.4	-7.13	4.05e-12	1.47e-09	-0.27	-0.32	Heart rate;	chr12:106789811	chr12:106954029~106955497:-
PRAD	cis	rs4713118	0.955	rs9380011	ENSG00000219392.1	RP1-265C24.5	-7.13	4.05e-12	1.47e-09	-0.4	-0.32	Parkinson's disease;	chr6:27716145	chr6:28115628~28116551:+
PRAD	cis	rs1355223	0.816	rs2136506	ENSG00000271369.1	RP11-350D17.3	-7.13	4.05e-12	1.47e-09	-0.38	-0.32	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34726713	chr11:34709600~34710161:+
PRAD	cis	rs1355223	0.902	rs10501134	ENSG00000271369.1	RP11-350D17.3	-7.13	4.05e-12	1.47e-09	-0.38	-0.32	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34727590	chr11:34709600~34710161:+
PRAD	cis	rs1355223	0.902	rs7130325	ENSG00000271369.1	RP11-350D17.3	-7.13	4.05e-12	1.47e-09	-0.38	-0.32	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34729412	chr11:34709600~34710161:+
PRAD	cis	rs1440410	0.897	rs9999826	ENSG00000250326.1	RP11-284M14.1	-7.13	4.05e-12	1.47e-09	-0.33	-0.32	Ischemic stroke;	chr4:143115304	chr4:142933195~143184861:-
PRAD	cis	rs2243480	1	rs1404147	ENSG00000226824.5	RP4-756H11.3	-7.13	4.06e-12	1.47e-09	-0.59	-0.32	Diabetic kidney disease;	chr7:65799537	chr7:66654538~66669855:+
PRAD	cis	rs435066	0.676	rs1555655	ENSG00000234264.1	DEPDC1-AS1	-7.13	4.06e-12	1.47e-09	-0.46	-0.32	IgG glycosylation;	chr1:68515932	chr1:68496676~68538627:+
PRAD	cis	rs2034650	0.563	rs12914315	ENSG00000223313.1	RNU6-516P	-7.13	4.06e-12	1.47e-09	-0.38	-0.32	Interstitial lung disease;	chr15:40421679	chr15:40529570~40529673:+
PRAD	cis	rs875971	0.545	rs73142245	ENSG00000226824.5	RP4-756H11.3	-7.13	4.06e-12	1.47e-09	-0.48	-0.32	Aortic root size;	chr7:66226662	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.502	rs11769702	ENSG00000226824.5	RP4-756H11.3	-7.13	4.06e-12	1.47e-09	-0.48	-0.32	Aortic root size;	chr7:66255529	chr7:66654538~66669855:+
PRAD	cis	rs10463554	0.746	rs6876072	ENSG00000175749.11	EIF3KP1	7.13	4.07e-12	1.48e-09	0.42	0.32	Parkinson's disease;	chr5:103251872	chr5:103032376~103033031:+
PRAD	cis	rs6547741	0.935	rs12714204	ENSG00000234072.1	AC074117.10	7.13	4.08e-12	1.48e-09	0.24	0.32	Oral cavity cancer;	chr2:27564673	chr2:27356246~27367622:+
PRAD	cis	rs2638953	0.962	rs11049599	ENSG00000278733.1	RP11-425D17.1	-7.13	4.08e-12	1.48e-09	-0.4	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28437218	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.962	rs79708115	ENSG00000278733.1	RP11-425D17.1	-7.13	4.08e-12	1.48e-09	-0.4	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28440784	chr12:28185625~28186190:-
PRAD	cis	rs2243480	1	rs781157	ENSG00000273142.1	RP11-458F8.4	-7.13	4.08e-12	1.48e-09	-0.35	-0.32	Diabetic kidney disease;	chr7:66013324	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs781149	ENSG00000273142.1	RP11-458F8.4	-7.13	4.08e-12	1.48e-09	-0.35	-0.32	Diabetic kidney disease;	chr7:66016297	chr7:66902857~66906297:+
PRAD	cis	rs2243480	0.901	rs58207111	ENSG00000273142.1	RP11-458F8.4	-7.13	4.08e-12	1.48e-09	-0.35	-0.32	Diabetic kidney disease;	chr7:66021736	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs1167613	ENSG00000273142.1	RP11-458F8.4	-7.13	4.08e-12	1.48e-09	-0.35	-0.32	Diabetic kidney disease;	chr7:66022452	chr7:66902857~66906297:+
PRAD	cis	rs6480314	0.831	rs6480317	ENSG00000233590.1	RP11-153K11.3	7.13	4.08e-12	1.48e-09	0.5	0.32	Optic nerve measurement (disc area);	chr10:68216837	chr10:68233251~68242379:-
PRAD	cis	rs8062405	0.755	rs12445823	ENSG00000251417.2	RP11-1348G14.4	-7.13	4.09e-12	1.48e-09	-0.35	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576728	chr16:28802743~28817828:+
PRAD	cis	rs8062405	0.723	rs12445744	ENSG00000251417.2	RP11-1348G14.4	-7.13	4.09e-12	1.48e-09	-0.35	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28577074	chr16:28802743~28817828:+
PRAD	cis	rs8062405	0.755	rs4787455	ENSG00000251417.2	RP11-1348G14.4	-7.13	4.09e-12	1.48e-09	-0.35	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28578134	chr16:28802743~28817828:+
PRAD	cis	rs4845570	1	rs11586946	ENSG00000268288.1	RP11-98D18.16	7.13	4.09e-12	1.49e-09	0.51	0.32	Coronary artery disease;	chr1:151797330	chr1:151766486~151767000:-
PRAD	cis	rs2638953	0.886	rs11049594	ENSG00000278733.1	RP11-425D17.1	7.13	4.1e-12	1.49e-09	0.4	0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28430368	chr12:28185625~28186190:-
PRAD	cis	rs853679	0.824	rs34712084	ENSG00000226314.6	ZNF192P1	-7.12	4.1e-12	1.49e-09	-0.56	-0.32	Depression;	chr6:28076050	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.824	rs1321505	ENSG00000226314.6	ZNF192P1	-7.12	4.1e-12	1.49e-09	-0.56	-0.32	Depression;	chr6:28085045	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.882	rs9468287	ENSG00000226314.6	ZNF192P1	-7.12	4.1e-12	1.49e-09	-0.56	-0.32	Depression;	chr6:28111963	chr6:28161781~28169594:+
PRAD	cis	rs853679	0.55	rs1233707	ENSG00000204709.4	LINC01556	7.12	4.11e-12	1.49e-09	0.42	0.32	Depression;	chr6:28205175	chr6:28943877~28944537:+
PRAD	cis	rs673078	0.607	rs61946067	ENSG00000275409.1	RP11-131L12.4	-7.12	4.11e-12	1.49e-09	-0.48	-0.32	Glucose homeostasis traits;	chr12:118303152	chr12:118430147~118430699:+
PRAD	cis	rs412050	0.895	rs240065	ENSG00000224086.5	LL22NC03-86G7.1	-7.12	4.11e-12	1.49e-09	-0.5	-0.32	Attention deficit hyperactivity disorder;	chr22:21941747	chr22:21938293~21977632:+
PRAD	cis	rs412050	0.895	rs6000236	ENSG00000224086.5	LL22NC03-86G7.1	-7.12	4.11e-12	1.49e-09	-0.5	-0.32	Attention deficit hyperactivity disorder;	chr22:21942087	chr22:21938293~21977632:+
PRAD	cis	rs11668609	0.938	rs8110507	ENSG00000268442.1	CTD-2027I19.2	7.12	4.11e-12	1.49e-09	0.43	0.32	Response to taxane treatment (docetaxel);	chr19:24099470	chr19:24162370~24163425:-
PRAD	cis	rs10875746	0.669	rs10875770	ENSG00000240399.1	RP1-228P16.1	-7.12	4.11e-12	1.49e-09	-0.29	-0.32	Longevity (90 years and older);	chr12:48206737	chr12:48054813~48055591:-
PRAD	cis	rs7429990	0.965	rs35199727	ENSG00000229759.1	MRPS18AP1	7.12	4.11e-12	1.49e-09	0.33	0.32	Educational attainment (years of education);	chr3:47905218	chr3:48256350~48256938:-
PRAD	cis	rs7429990	0.965	rs11707679	ENSG00000229759.1	MRPS18AP1	7.12	4.11e-12	1.49e-09	0.33	0.32	Educational attainment (years of education);	chr3:47915016	chr3:48256350~48256938:-
PRAD	cis	rs71636778	0.509	rs35615194	ENSG00000260063.1	RP5-968P14.2	-7.12	4.12e-12	1.49e-09	-0.64	-0.32	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26791680	chr1:26692132~26694131:-
PRAD	cis	rs71636778	0.509	rs35583548	ENSG00000260063.1	RP5-968P14.2	-7.12	4.12e-12	1.49e-09	-0.64	-0.32	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26813658	chr1:26692132~26694131:-
PRAD	cis	rs4713118	0.955	rs9468203	ENSG00000219392.1	RP1-265C24.5	-7.12	4.13e-12	1.5e-09	-0.4	-0.32	Parkinson's disease;	chr6:27720888	chr6:28115628~28116551:+
PRAD	cis	rs858239	0.601	rs764534	ENSG00000226816.2	AC005082.12	7.12	4.13e-12	1.5e-09	0.36	0.32	Cerebrospinal fluid biomarker levels;	chr7:23114316	chr7:23206013~23208045:+
PRAD	cis	rs858239	0.601	rs2068459	ENSG00000226816.2	AC005082.12	7.12	4.13e-12	1.5e-09	0.36	0.32	Cerebrospinal fluid biomarker levels;	chr7:23114694	chr7:23206013~23208045:+
PRAD	cis	rs858239	0.601	rs73272053	ENSG00000226816.2	AC005082.12	7.12	4.13e-12	1.5e-09	0.36	0.32	Cerebrospinal fluid biomarker levels;	chr7:23115906	chr7:23206013~23208045:+
PRAD	cis	rs4728142	0.604	rs7807018	ENSG00000275106.1	RP11-309L24.10	-7.12	4.14e-12	1.5e-09	-0.4	-0.32	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129000134	chr7:128952527~128953316:-
PRAD	cis	rs9309711	0.813	rs11690865	ENSG00000225234.1	TRAPPC12-AS1	-7.12	4.14e-12	1.5e-09	-0.34	-0.32	Neurofibrillary tangles;	chr2:3468179	chr2:3481242~3482409:-
PRAD	cis	rs853679	0.76	rs2299029	ENSG00000226314.6	ZNF192P1	-7.12	4.14e-12	1.5e-09	-0.46	-0.32	Depression;	chr6:28231053	chr6:28161781~28169594:+
PRAD	cis	rs7746199	0.736	rs58616630	ENSG00000226314.6	ZNF192P1	-7.12	4.14e-12	1.5e-09	-0.67	-0.32	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27506936	chr6:28161781~28169594:+
PRAD	cis	rs6847067	0.683	rs11097028	ENSG00000180769.7	WDFY3-AS2	-7.12	4.14e-12	1.5e-09	-0.35	-0.32	Oropharynx cancer;	chr4:84948630	chr4:84965682~85011277:+
PRAD	cis	rs9287719	0.601	rs12995465	ENSG00000243819.4	RN7SL832P	7.12	4.14e-12	1.5e-09	0.31	0.32	Prostate cancer;	chr2:10576702	chr2:10690344~10692099:+
PRAD	cis	rs9287719	0.614	rs10929678	ENSG00000243819.4	RN7SL832P	7.12	4.15e-12	1.5e-09	0.31	0.32	Prostate cancer;	chr2:10582969	chr2:10690344~10692099:+
PRAD	cis	rs9287719	0.601	rs6751436	ENSG00000243819.4	RN7SL832P	7.12	4.15e-12	1.5e-09	0.31	0.32	Prostate cancer;	chr2:10583736	chr2:10690344~10692099:+
PRAD	cis	rs9287719	0.578	rs13425171	ENSG00000243819.4	RN7SL832P	7.12	4.15e-12	1.5e-09	0.31	0.32	Prostate cancer;	chr2:10591840	chr2:10690344~10692099:+
PRAD	cis	rs4713118	0.869	rs2056925	ENSG00000226314.6	ZNF192P1	-7.12	4.16e-12	1.51e-09	-0.41	-0.32	Parkinson's disease;	chr6:27723126	chr6:28161781~28169594:+
PRAD	cis	rs1799949	0.683	rs55737636	ENSG00000267002.1	RP11-242D8.1	7.12	4.16e-12	1.51e-09	0.29	0.32	Menopause (age at onset);	chr17:43112722	chr17:43164183~43170403:-
PRAD	cis	rs875971	0.502	rs1796227	ENSG00000226824.5	RP4-756H11.3	7.12	4.18e-12	1.52e-09	0.47	0.32	Aortic root size;	chr7:66622032	chr7:66654538~66669855:+
PRAD	cis	rs8103278	0.507	rs2041975	ENSG00000267395.4	AC074212.6	-7.12	4.19e-12	1.52e-09	-0.28	-0.32	Coronary artery disease;	chr19:45735297	chr19:45767796~45772504:+
PRAD	cis	rs4713118	0.786	rs200503	ENSG00000219392.1	RP1-265C24.5	-7.12	4.19e-12	1.52e-09	-0.4	-0.32	Parkinson's disease;	chr6:27818104	chr6:28115628~28116551:+
PRAD	cis	rs10206020	0.885	rs11887527	ENSG00000231482.2	AC141930.2	-7.12	4.19e-12	1.52e-09	-0.36	-0.32	IgG glycosylation;	chr2:1574308	chr2:1572554~1580311:-
PRAD	cis	rs10206020	0.885	rs11885392	ENSG00000231482.2	AC141930.2	-7.12	4.19e-12	1.52e-09	-0.36	-0.32	IgG glycosylation;	chr2:1574410	chr2:1572554~1580311:-
PRAD	cis	rs11668609	0.81	rs10407383	ENSG00000268442.1	CTD-2027I19.2	7.12	4.2e-12	1.52e-09	0.44	0.32	Response to taxane treatment (docetaxel);	chr19:24134099	chr19:24162370~24163425:-
PRAD	cis	rs1185460	0.546	rs589925	ENSG00000271751.1	RP11-110I1.14	7.12	4.22e-12	1.53e-09	0.43	0.32	Coronary artery disease;	chr11:119084969	chr11:119065263~119065677:-
PRAD	cis	rs12468226	0.679	rs6435133	ENSG00000273456.1	RP11-686O6.2	-7.12	4.23e-12	1.53e-09	-0.42	-0.32	Urate levels;	chr2:202209237	chr2:202374932~202375604:-
PRAD	cis	rs12468226	0.817	rs12693965	ENSG00000273456.1	RP11-686O6.2	-7.12	4.23e-12	1.53e-09	-0.42	-0.32	Urate levels;	chr2:202210188	chr2:202374932~202375604:-
PRAD	cis	rs12468226	0.873	rs3769817	ENSG00000273456.1	RP11-686O6.2	-7.12	4.23e-12	1.53e-09	-0.42	-0.32	Urate levels;	chr2:202214584	chr2:202374932~202375604:-
PRAD	cis	rs12468226	0.873	rs6435134	ENSG00000273456.1	RP11-686O6.2	-7.12	4.23e-12	1.53e-09	-0.42	-0.32	Urate levels;	chr2:202214857	chr2:202374932~202375604:-
PRAD	cis	rs12468226	0.817	rs6435135	ENSG00000273456.1	RP11-686O6.2	-7.12	4.23e-12	1.53e-09	-0.42	-0.32	Urate levels;	chr2:202217469	chr2:202374932~202375604:-
PRAD	cis	rs3096299	0.781	rs3102381	ENSG00000274627.1	RP11-104N10.2	7.12	4.23e-12	1.53e-09	0.32	0.32	Multiple myeloma (IgH translocation);	chr16:89343312	chr16:89516797~89522217:+
PRAD	cis	rs62355900	0.627	rs58292679	ENSG00000271828.1	CTD-2310F14.1	7.12	4.26e-12	1.54e-09	0.66	0.32	Endometriosis;	chr5:56839989	chr5:56927874~56929573:+
PRAD	cis	rs6903823	0.508	rs1150726	ENSG00000204709.4	LINC01556	7.12	4.26e-12	1.54e-09	0.4	0.32	Pulmonary function;	chr6:28275265	chr6:28943877~28944537:+
PRAD	cis	rs453301	0.598	rs1025395	ENSG00000254340.1	RP11-10A14.3	7.12	4.26e-12	1.54e-09	0.39	0.32	Joint mobility (Beighton score);	chr8:8979093	chr8:9141424~9145435:+
PRAD	cis	rs287982	0.8	rs13429581	ENSG00000269973.1	RP11-95D17.1	-7.12	4.26e-12	1.54e-09	-0.31	-0.32	Nonsyndromic cleft lip with cleft palate;	chr2:9823314	chr2:9936360~9939590:+
PRAD	cis	rs875971	0.545	rs316328	ENSG00000226824.5	RP4-756H11.3	7.12	4.26e-12	1.54e-09	0.45	0.32	Aortic root size;	chr7:66143851	chr7:66654538~66669855:+
PRAD	cis	rs4713118	0.955	rs9468200	ENSG00000226314.6	ZNF192P1	-7.12	4.26e-12	1.54e-09	-0.42	-0.32	Parkinson's disease;	chr6:27715284	chr6:28161781~28169594:+
PRAD	cis	rs8040855	0.599	rs6496791	ENSG00000259295.5	CSPG4P12	-7.12	4.27e-12	1.55e-09	-0.39	-0.32	Bulimia nervosa;	chr15:85182428	chr15:85191438~85213905:+
PRAD	cis	rs4972806	0.849	rs2113561	ENSG00000226363.3	HAGLROS	-7.12	4.27e-12	1.55e-09	-0.36	-0.32	IgG glycosylation;	chr2:176166197	chr2:176177717~176179008:+
PRAD	cis	rs7829975	0.84	rs572366	ENSG00000253893.2	FAM85B	-7.12	4.27e-12	1.55e-09	-0.39	-0.32	Mood instability;	chr8:8721284	chr8:8167819~8226614:-
PRAD	cis	rs853679	0.556	rs45509595	ENSG00000226314.6	ZNF192P1	-7.12	4.29e-12	1.55e-09	-0.68	-0.32	Depression;	chr6:27873148	chr6:28161781~28169594:+
PRAD	cis	rs3096299	0.967	rs28689480	ENSG00000261118.1	RP11-104N10.1	7.12	4.29e-12	1.55e-09	0.31	0.32	Multiple myeloma (IgH translocation);	chr16:89393685	chr16:89492017~89504460:-
PRAD	cis	rs6517329	0.899	rs2835281	ENSG00000236830.5	CBR3-AS1	-7.12	4.29e-12	1.55e-09	-0.32	-0.32	Schizophrenia;	chr21:36117592	chr21:36131767~36175815:-
PRAD	cis	rs1979679	0.682	rs4359252	ENSG00000278733.1	RP11-425D17.1	-7.12	4.3e-12	1.56e-09	-0.45	-0.32	Ossification of the posterior longitudinal ligament of the spine;	chr12:28434298	chr12:28185625~28186190:-
PRAD	cis	rs7621025	0.5	rs16844241	ENSG00000273486.1	RP11-731C17.2	-7.12	4.3e-12	1.56e-09	-0.42	-0.32	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136916329	chr3:136837338~136839021:-
PRAD	cis	rs11098499	0.954	rs1022145	ENSG00000245958.5	RP11-33B1.1	-7.12	4.3e-12	1.56e-09	-0.32	-0.32	Corneal astigmatism;	chr4:119309824	chr4:119454791~119552025:+
PRAD	cis	rs673078	0.66	rs11068891	ENSG00000275409.1	RP11-131L12.4	7.12	4.3e-12	1.56e-09	0.42	0.32	Glucose homeostasis traits;	chr12:118259814	chr12:118430147~118430699:+
PRAD	cis	rs2034650	0.525	rs11790	ENSG00000223313.1	RNU6-516P	7.12	4.3e-12	1.56e-09	0.38	0.32	Interstitial lung disease;	chr15:40420538	chr15:40529570~40529673:+
PRAD	cis	rs11049611	0.504	rs11049431	ENSG00000278733.1	RP11-425D17.1	-7.12	4.31e-12	1.56e-09	-0.45	-0.32	Height;	chr12:28194449	chr12:28185625~28186190:-
PRAD	cis	rs1729407	0.786	rs5096	ENSG00000254851.1	RP11-109L13.1	-7.12	4.31e-12	1.56e-09	-0.43	-0.32	Apolipoprotein A-IV levels;	chr11:116822379	chr11:117135528~117138582:+
PRAD	cis	rs301901	0.683	rs34485458	ENSG00000250155.1	CTD-2353F22.1	-7.12	4.33e-12	1.57e-09	-0.36	-0.32	Height;	chr5:36861889	chr5:36666214~36725195:-
PRAD	cis	rs494459	0.838	rs555649	ENSG00000255422.1	AP002954.4	-7.12	4.34e-12	1.57e-09	-0.36	-0.32	Height;	chr11:118781100	chr11:118704607~118750263:+
PRAD	cis	rs11098499	0.644	rs3806808	ENSG00000245958.5	RP11-33B1.1	-7.12	4.35e-12	1.57e-09	-0.3	-0.32	Corneal astigmatism;	chr4:119629930	chr4:119454791~119552025:+
PRAD	cis	rs367615	0.506	rs2963013	ENSG00000249476.1	CTD-2587M2.1	-7.12	4.36e-12	1.58e-09	-0.38	-0.32	Colorectal cancer (SNP x SNP interaction);	chr5:109440110	chr5:109237120~109326369:-
PRAD	cis	rs1015362	0.581	rs4911373	ENSG00000276073.1	RP5-1125A11.7	-7.12	4.36e-12	1.58e-09	-0.4	-0.32	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:33920952	chr20:33985617~33988989:-
PRAD	cis	rs2638953	0.815	rs11049683	ENSG00000278733.1	RP11-425D17.1	-7.12	4.37e-12	1.58e-09	-0.39	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28509597	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.815	rs10843193	ENSG00000278733.1	RP11-425D17.1	-7.12	4.37e-12	1.58e-09	-0.39	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28509763	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.853	rs7485676	ENSG00000278733.1	RP11-425D17.1	-7.12	4.37e-12	1.58e-09	-0.39	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28510734	chr12:28185625~28186190:-
PRAD	cis	rs172166	0.694	rs536704	ENSG00000219392.1	RP1-265C24.5	-7.12	4.37e-12	1.58e-09	-0.39	-0.32	Cardiac Troponin-T levels;	chr6:28124825	chr6:28115628~28116551:+
PRAD	cis	rs17674580	0.541	rs9951207	ENSG00000267193.4	RP11-116O18.3	7.12	4.38e-12	1.58e-09	0.35	0.32	Bladder cancer;	chr18:45758661	chr18:45669367~45747215:-
PRAD	cis	rs6921919	1	rs6921919	ENSG00000204709.4	LINC01556	7.12	4.38e-12	1.58e-09	0.45	0.32	Autism spectrum disorder or schizophrenia;	chr6:28357424	chr6:28943877~28944537:+
PRAD	cis	rs2638953	0.924	rs61920227	ENSG00000247934.4	RP11-967K21.1	-7.11	4.38e-12	1.59e-09	-0.32	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28174584	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.924	rs11049400	ENSG00000247934.4	RP11-967K21.1	-7.11	4.38e-12	1.59e-09	-0.32	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28175051	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.924	rs11049401	ENSG00000247934.4	RP11-967K21.1	-7.11	4.38e-12	1.59e-09	-0.32	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28175218	chr12:28163298~28190738:-
PRAD	cis	rs17674580	0.582	rs9947769	ENSG00000267193.4	RP11-116O18.3	7.11	4.39e-12	1.59e-09	0.35	0.32	Bladder cancer;	chr18:45757602	chr18:45669367~45747215:-
PRAD	cis	rs12612619	0.732	rs13032059	ENSG00000229122.1	AGBL5-IT1	7.11	4.39e-12	1.59e-09	0.32	0.32	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27010921	chr2:27061038~27061815:+
PRAD	cis	rs12612619	0.732	rs13032100	ENSG00000229122.1	AGBL5-IT1	7.11	4.39e-12	1.59e-09	0.32	0.32	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27010991	chr2:27061038~27061815:+
PRAD	cis	rs1020064	0.636	rs1529974	ENSG00000235319.1	AC012360.4	-7.11	4.4e-12	1.59e-09	-0.4	-0.32	AIDS;	chr2:105311539	chr2:105324210~105330529:+
PRAD	cis	rs6479901	0.841	rs10465990	ENSG00000232075.1	MRPL35P2	-7.11	4.41e-12	1.59e-09	-0.38	-0.32	Intelligence (multi-trait analysis);	chr10:63200776	chr10:63634317~63634827:-
PRAD	cis	rs6479901	0.793	rs4335432	ENSG00000232075.1	MRPL35P2	-7.11	4.41e-12	1.59e-09	-0.38	-0.32	Intelligence (multi-trait analysis);	chr10:63226057	chr10:63634317~63634827:-
PRAD	cis	rs2638953	0.777	rs11049681	ENSG00000278733.1	RP11-425D17.1	-7.11	4.41e-12	1.6e-09	-0.39	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28508722	chr12:28185625~28186190:-
PRAD	cis	rs8523	0.779	rs2236212	ENSG00000230314.5	ELOVL2-AS1	-7.11	4.42e-12	1.6e-09	-0.35	-0.32	Red blood cell fatty acid levels;	chr6:10994782	chr6:11043524~11078226:+
PRAD	cis	rs73607972	0.501	rs4784317	ENSG00000275191.1	RP11-36I17.2	-7.11	4.42e-12	1.6e-09	-0.49	-0.32	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53552273	chr16:53628256~53628816:-
PRAD	cis	rs17428076	0.874	rs62182374	ENSG00000228389.1	AC068039.4	-7.11	4.42e-12	1.6e-09	-0.41	-0.32	Myopia;	chr2:171829172	chr2:171773482~171775844:+
PRAD	cis	rs2638953	0.671	rs10771406	ENSG00000278733.1	RP11-425D17.1	-7.11	4.42e-12	1.6e-09	-0.43	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28117513	chr12:28185625~28186190:-
PRAD	cis	rs4925386	0.959	rs4925385	ENSG00000273619.1	RP5-908M14.9	7.11	4.42e-12	1.6e-09	0.2	0.32	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62345568	chr20:62386303~62386970:-
PRAD	cis	rs4664293	0.836	rs13016015	ENSG00000226266.5	AC009961.3	-7.11	4.43e-12	1.6e-09	-0.42	-0.32	Monocyte percentage of white cells;	chr2:159790018	chr2:159670708~159712435:-
PRAD	cis	rs858239	0.601	rs6948469	ENSG00000226816.2	AC005082.12	7.11	4.43e-12	1.6e-09	0.36	0.32	Cerebrospinal fluid biomarker levels;	chr7:23135147	chr7:23206013~23208045:+
PRAD	cis	rs995000	0.931	rs624660	ENSG00000235545.1	RP11-230B22.1	7.11	4.44e-12	1.6e-09	0.42	0.32	Triglyceride levels;	chr1:62454717	chr1:62688482~62710694:+
PRAD	cis	rs11148252	0.514	rs9526843	ENSG00000278238.1	RP11-245D16.4	-7.11	4.44e-12	1.6e-09	-0.35	-0.32	Lewy body disease;	chr13:52155921	chr13:52454775~52455331:-
PRAD	cis	rs9287719	0.601	rs12692412	ENSG00000243819.4	RN7SL832P	-7.11	4.44e-12	1.61e-09	-0.31	-0.32	Prostate cancer;	chr2:10579928	chr2:10690344~10692099:+
PRAD	cis	rs1799949	1	rs16942	ENSG00000267002.1	RP11-242D8.1	7.11	4.45e-12	1.61e-09	0.3	0.32	Menopause (age at onset);	chr17:43091983	chr17:43164183~43170403:-
PRAD	cis	rs17428076	0.831	rs3821093	ENSG00000228389.1	AC068039.4	-7.11	4.46e-12	1.61e-09	-0.41	-0.32	Myopia;	chr2:171838077	chr2:171773482~171775844:+
PRAD	cis	rs7208859	0.623	rs56018041	ENSG00000266490.1	CTD-2349P21.9	7.11	4.46e-12	1.61e-09	0.44	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732967	chr17:30792372~30792833:+
PRAD	cis	rs77204473	0.744	rs2301174	ENSG00000254851.1	RP11-109L13.1	7.11	4.47e-12	1.62e-09	0.73	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117192993	chr11:117135528~117138582:+
PRAD	cis	rs6452524	0.904	rs10473867	ENSG00000249664.1	CTD-2227C6.2	7.11	4.48e-12	1.62e-09	0.38	0.32	Hypertension (SNP x SNP interaction);	chr5:83141613	chr5:83012285~83013109:-
PRAD	cis	rs995000	0.839	rs12090886	ENSG00000235545.1	RP11-230B22.1	-7.11	4.48e-12	1.62e-09	-0.42	-0.32	Triglyceride levels;	chr1:62515769	chr1:62688482~62710694:+
PRAD	cis	rs172166	0.611	rs203882	ENSG00000204709.4	LINC01556	7.11	4.49e-12	1.62e-09	0.41	0.32	Cardiac Troponin-T levels;	chr6:28110724	chr6:28943877~28944537:+
PRAD	cis	rs172166	0.694	rs1770131	ENSG00000204709.4	LINC01556	7.11	4.49e-12	1.62e-09	0.41	0.32	Cardiac Troponin-T levels;	chr6:28118635	chr6:28943877~28944537:+
PRAD	cis	rs875971	0.522	rs781144	ENSG00000237310.1	GS1-124K5.4	7.11	4.49e-12	1.62e-09	0.27	0.32	Aortic root size;	chr7:65975357	chr7:66493706~66495474:+
PRAD	cis	rs2638953	0.886	rs11049576	ENSG00000278733.1	RP11-425D17.1	-7.11	4.49e-12	1.62e-09	-0.4	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28412347	chr12:28185625~28186190:-
PRAD	cis	rs858239	0.541	rs4624924	ENSG00000226816.2	AC005082.12	7.11	4.49e-12	1.62e-09	0.36	0.32	Cerebrospinal fluid biomarker levels;	chr7:23129224	chr7:23206013~23208045:+
PRAD	cis	rs6903823	0.508	rs1778484	ENSG00000204709.4	LINC01556	7.11	4.5e-12	1.63e-09	0.4	0.32	Pulmonary function;	chr6:28273021	chr6:28943877~28944537:+
PRAD	cis	rs2439831	0.702	rs3759791	ENSG00000205771.5	CATSPER2P1	-7.11	4.51e-12	1.63e-09	-0.49	-0.32	Lung cancer in ever smokers;	chr15:43798600	chr15:43726918~43747094:-
PRAD	cis	rs1043099	0.731	rs5763923	ENSG00000279699.1	RP1-102K2.9	-7.11	4.52e-12	1.63e-09	-0.46	-0.32	Rheumatoid arthritis;	chr22:30279228	chr22:30275215~30276951:-
PRAD	cis	rs6496044	0.507	rs62022863	ENSG00000202081.1	RNU6-1280P	-7.11	4.52e-12	1.63e-09	-0.38	-0.32	Interstitial lung disease;	chr15:85618822	chr15:85651522~85651628:-
PRAD	cis	rs73186030	0.764	rs9834317	ENSG00000272758.4	RP11-299J3.8	7.11	4.53e-12	1.63e-09	0.45	0.32	Serum parathyroid hormone levels;	chr3:122370512	chr3:122416207~122443180:+
PRAD	cis	rs875971	0.638	rs35986979	ENSG00000237310.1	GS1-124K5.4	-7.11	4.53e-12	1.64e-09	-0.28	-0.32	Aortic root size;	chr7:66624003	chr7:66493706~66495474:+
PRAD	cis	rs6847067	1	rs1385263	ENSG00000180769.7	WDFY3-AS2	7.11	4.54e-12	1.64e-09	0.33	0.32	Oropharynx cancer;	chr4:84783821	chr4:84965682~85011277:+
PRAD	cis	rs6847067	0.683	rs7695054	ENSG00000180769.7	WDFY3-AS2	7.11	4.54e-12	1.64e-09	0.35	0.32	Oropharynx cancer;	chr4:84841867	chr4:84965682~85011277:+
PRAD	cis	rs1707322	0.721	rs10890343	ENSG00000280836.1	AL355480.1	-7.11	4.55e-12	1.64e-09	-0.39	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692250	chr1:45581219~45581321:-
PRAD	cis	rs875971	0.545	rs6979636	ENSG00000226824.5	RP4-756H11.3	-7.11	4.56e-12	1.64e-09	-0.47	-0.32	Aortic root size;	chr7:66276638	chr7:66654538~66669855:+
PRAD	cis	rs9309473	0.5	rs11126402	ENSG00000163016.8	ALMS1P	7.11	4.56e-12	1.65e-09	0.35	0.32	Metabolite levels;	chr2:73549455	chr2:73644919~73685576:+
PRAD	cis	rs8049040	0.609	rs11866859	ENSG00000260886.1	TAT-AS1	7.11	4.56e-12	1.65e-09	0.39	0.32	Blood protein levels;	chr16:71444985	chr16:71565789~71578187:+
PRAD	cis	rs9640161	0.742	rs11983355	ENSG00000261305.1	RP4-584D14.7	7.11	4.57e-12	1.65e-09	0.35	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150319608	chr7:150341771~150342607:+
PRAD	cis	rs6496044	0.507	rs7175731	ENSG00000202081.1	RNU6-1280P	-7.11	4.57e-12	1.65e-09	-0.38	-0.32	Interstitial lung disease;	chr15:85611115	chr15:85651522~85651628:-
PRAD	cis	rs2243480	1	rs1039664	ENSG00000273142.1	RP11-458F8.4	-7.11	4.58e-12	1.65e-09	-0.35	-0.32	Diabetic kidney disease;	chr7:65984729	chr7:66902857~66906297:+
PRAD	cis	rs2243480	0.901	rs2456483	ENSG00000273142.1	RP11-458F8.4	-7.11	4.58e-12	1.65e-09	-0.35	-0.32	Diabetic kidney disease;	chr7:65996588	chr7:66902857~66906297:+
PRAD	cis	rs2243480	0.901	rs2949697	ENSG00000273142.1	RP11-458F8.4	-7.11	4.58e-12	1.65e-09	-0.35	-0.32	Diabetic kidney disease;	chr7:65999249	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs1701750	ENSG00000273142.1	RP11-458F8.4	-7.11	4.58e-12	1.65e-09	-0.35	-0.32	Diabetic kidney disease;	chr7:66002158	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs1701758	ENSG00000273142.1	RP11-458F8.4	-7.11	4.58e-12	1.65e-09	-0.35	-0.32	Diabetic kidney disease;	chr7:66005214	chr7:66902857~66906297:+
PRAD	cis	rs2243480	0.901	rs1701759	ENSG00000273142.1	RP11-458F8.4	-7.11	4.58e-12	1.65e-09	-0.35	-0.32	Diabetic kidney disease;	chr7:66005945	chr7:66902857~66906297:+
PRAD	cis	rs853679	0.567	rs16894091	ENSG00000216901.1	AL022393.7	-7.11	4.59e-12	1.65e-09	-0.43	-0.32	Depression;	chr6:28422360	chr6:28176188~28176674:+
PRAD	cis	rs1707322	0.721	rs10890333	ENSG00000280836.1	AL355480.1	-7.11	4.59e-12	1.66e-09	-0.4	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634650	chr1:45581219~45581321:-
PRAD	cis	rs7621025	0.5	rs71630059	ENSG00000273486.1	RP11-731C17.2	-7.11	4.6e-12	1.66e-09	-0.44	-0.32	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136862769	chr3:136837338~136839021:-
PRAD	cis	rs2836950	0.502	rs2150411	ENSG00000255568.3	BRWD1-AS2	-7.11	4.6e-12	1.66e-09	-0.26	-0.32	Menarche (age at onset);	chr21:39202626	chr21:39313935~39314962:+
PRAD	cis	rs7260598	0.71	rs10423819	ENSG00000268442.1	CTD-2027I19.2	7.11	4.6e-12	1.66e-09	0.44	0.32	Response to taxane treatment (placlitaxel);	chr19:24153857	chr19:24162370~24163425:-
PRAD	cis	rs2361701	0.636	rs1982244	ENSG00000279259.1	RP11-334C17.3	7.11	4.6e-12	1.66e-09	0.37	0.32	IgG glycosylation;	chr17:80095149	chr17:80147250~80148596:+
PRAD	cis	rs10875746	0.669	rs10431526	ENSG00000240399.1	RP1-228P16.1	-7.11	4.6e-12	1.66e-09	-0.29	-0.32	Longevity (90 years and older);	chr12:48296360	chr12:48054813~48055591:-
PRAD	cis	rs13068223	0.84	rs1469536	ENSG00000243926.1	TIPARP-AS1	7.11	4.62e-12	1.67e-09	0.29	0.32	Age-related hearing impairment (SNP x SNP interaction);	chr3:156710038	chr3:156671862~156674378:-
PRAD	cis	rs1799949	0.965	rs9911630	ENSG00000267002.1	RP11-242D8.1	7.11	4.62e-12	1.67e-09	0.3	0.32	Menopause (age at onset);	chr17:43036325	chr17:43164183~43170403:-
PRAD	cis	rs853679	0.607	rs13207345	ENSG00000280107.1	AL022393.9	-7.11	4.62e-12	1.67e-09	-0.64	-0.32	Depression;	chr6:28297795	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.607	rs72854513	ENSG00000280107.1	AL022393.9	-7.11	4.62e-12	1.67e-09	-0.64	-0.32	Depression;	chr6:28298177	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.607	rs56189111	ENSG00000280107.1	AL022393.9	-7.11	4.62e-12	1.67e-09	-0.64	-0.32	Depression;	chr6:28304196	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.607	rs35072899	ENSG00000280107.1	AL022393.9	-7.11	4.62e-12	1.67e-09	-0.64	-0.32	Depression;	chr6:28313764	chr6:28170845~28172521:+
PRAD	cis	rs2638953	0.64	rs10843208	ENSG00000278733.1	RP11-425D17.1	-7.11	4.64e-12	1.67e-09	-0.38	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28572171	chr12:28185625~28186190:-
PRAD	cis	rs4713118	0.955	rs9468206	ENSG00000219392.1	RP1-265C24.5	-7.11	4.64e-12	1.67e-09	-0.4	-0.32	Parkinson's disease;	chr6:27722674	chr6:28115628~28116551:+
PRAD	cis	rs2427308	0.607	rs1741635	ENSG00000273619.1	RP5-908M14.9	7.11	4.65e-12	1.68e-09	0.24	0.32	Colorectal cancer;	chr20:62363141	chr20:62386303~62386970:-
PRAD	cis	rs1075232	1	rs72722861	ENSG00000215302.7	CTD-3092A11.1	-7.11	4.65e-12	1.68e-09	-0.71	-0.32	Survival in colorectal cancer (non-distant metastatic);	chr15:31412085	chr15:30470779~30507623:+
PRAD	cis	rs1075232	0.826	rs12438813	ENSG00000215302.7	CTD-3092A11.1	-7.11	4.65e-12	1.68e-09	-0.71	-0.32	Survival in colorectal cancer (non-distant metastatic);	chr15:31413710	chr15:30470779~30507623:+
PRAD	cis	rs1075232	1	rs34959140	ENSG00000215302.7	CTD-3092A11.1	-7.11	4.65e-12	1.68e-09	-0.71	-0.32	Survival in colorectal cancer (non-distant metastatic);	chr15:31433020	chr15:30470779~30507623:+
PRAD	cis	rs2638953	0.962	rs11049611	ENSG00000278733.1	RP11-425D17.1	-7.11	4.65e-12	1.68e-09	-0.39	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28447311	chr12:28185625~28186190:-
PRAD	cis	rs2243480	1	rs313820	ENSG00000273142.1	RP11-458F8.4	-7.11	4.65e-12	1.68e-09	-0.35	-0.32	Diabetic kidney disease;	chr7:66109479	chr7:66902857~66906297:+
PRAD	cis	rs858239	0.601	rs1558313	ENSG00000226816.2	AC005082.12	7.11	4.66e-12	1.68e-09	0.35	0.32	Cerebrospinal fluid biomarker levels;	chr7:23116460	chr7:23206013~23208045:+
PRAD	cis	rs858239	0.601	rs6962526	ENSG00000226816.2	AC005082.12	7.11	4.66e-12	1.68e-09	0.35	0.32	Cerebrospinal fluid biomarker levels;	chr7:23118614	chr7:23206013~23208045:+
PRAD	cis	rs858239	0.539	rs6971673	ENSG00000226816.2	AC005082.12	7.11	4.66e-12	1.68e-09	0.35	0.32	Cerebrospinal fluid biomarker levels;	chr7:23119904	chr7:23206013~23208045:+
PRAD	cis	rs2439831	0.867	rs12443102	ENSG00000205771.5	CATSPER2P1	-7.11	4.66e-12	1.68e-09	-0.5	-0.32	Lung cancer in ever smokers;	chr15:43639905	chr15:43726918~43747094:-
PRAD	cis	rs6847067	0.683	rs55871210	ENSG00000180769.7	WDFY3-AS2	7.11	4.66e-12	1.68e-09	0.35	0.32	Oropharynx cancer;	chr4:84942499	chr4:84965682~85011277:+
PRAD	cis	rs12612619	0.695	rs10207670	ENSG00000229122.1	AGBL5-IT1	-7.11	4.67e-12	1.68e-09	-0.36	-0.32	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27020133	chr2:27061038~27061815:+
PRAD	cis	rs9362426	0.608	rs56329400	ENSG00000218793.1	RP3-382I10.3	7.1	4.68e-12	1.68e-09	0.41	0.32	Depressive episodes in bipolar disorder;	chr6:87448994	chr6:87441165~87442146:-
PRAD	cis	rs1023500	0.552	rs133368	ENSG00000205702.9	CYP2D7	7.1	4.69e-12	1.69e-09	0.24	0.32	Schizophrenia;	chr22:42067685	chr22:42140203~42144577:-
PRAD	cis	rs964611	0.882	rs12148383	ENSG00000259488.2	RP11-154J22.1	7.1	4.69e-12	1.69e-09	0.31	0.32	Metabolite levels (Pyroglutamine);	chr15:48368235	chr15:48312353~48331856:-
PRAD	cis	rs964611	0.882	rs873661	ENSG00000259488.2	RP11-154J22.1	7.1	4.69e-12	1.69e-09	0.31	0.32	Metabolite levels (Pyroglutamine);	chr15:48368914	chr15:48312353~48331856:-
PRAD	cis	rs2638953	0.924	rs12368745	ENSG00000278733.1	RP11-425D17.1	-7.1	4.69e-12	1.69e-09	-0.4	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28396198	chr12:28185625~28186190:-
PRAD	cis	rs995000	0.931	rs10157265	ENSG00000235545.1	RP11-230B22.1	7.1	4.7e-12	1.69e-09	0.41	0.32	Triglyceride levels;	chr1:62627946	chr1:62688482~62710694:+
PRAD	cis	rs995000	0.931	rs2366638	ENSG00000235545.1	RP11-230B22.1	7.1	4.7e-12	1.69e-09	0.41	0.32	Triglyceride levels;	chr1:62633906	chr1:62688482~62710694:+
PRAD	cis	rs6951245	0.554	rs10270249	ENSG00000229043.2	AC091729.9	-7.1	4.71e-12	1.7e-09	-0.45	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1112250	chr7:1160374~1165267:+
PRAD	cis	rs6951245	0.529	rs76001997	ENSG00000229043.2	AC091729.9	-7.1	4.71e-12	1.7e-09	-0.45	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1112979	chr7:1160374~1165267:+
PRAD	cis	rs17711722	0.522	rs62469933	ENSG00000234585.5	CCT6P3	7.1	4.71e-12	1.7e-09	0.24	0.32	Calcium levels;	chr7:65800652	chr7:65038354~65074713:+
PRAD	cis	rs79349575	0.721	rs4794004	ENSG00000248278.1	SUMO2P17	7.1	4.71e-12	1.7e-09	0.36	0.32	Type 2 diabetes;	chr17:48961109	chr17:48874860~48908983:-
PRAD	cis	rs875971	0.577	rs35072105	ENSG00000236529.1	RP13-254B10.1	-7.1	4.71e-12	1.7e-09	-0.34	-0.32	Aortic root size;	chr7:66144830	chr7:65840212~65840596:+
PRAD	cis	rs1799949	0.965	rs8176161	ENSG00000267002.1	RP11-242D8.1	7.1	4.72e-12	1.7e-09	0.3	0.32	Menopause (age at onset);	chr17:43089373	chr17:43164183~43170403:-
PRAD	cis	rs1799949	0.894	rs8176160	ENSG00000267002.1	RP11-242D8.1	7.1	4.72e-12	1.7e-09	0.3	0.32	Menopause (age at onset);	chr17:43089486	chr17:43164183~43170403:-
PRAD	cis	rs2638953	0.853	rs10843180	ENSG00000278733.1	RP11-425D17.1	-7.1	4.72e-12	1.7e-09	-0.39	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28462221	chr12:28185625~28186190:-
PRAD	cis	rs2243480	0.764	rs2460423	ENSG00000273142.1	RP11-458F8.4	-7.1	4.73e-12	1.7e-09	-0.35	-0.32	Diabetic kidney disease;	chr7:66136229	chr7:66902857~66906297:+
PRAD	cis	rs2243480	0.908	rs313822	ENSG00000273142.1	RP11-458F8.4	-7.1	4.73e-12	1.7e-09	-0.35	-0.32	Diabetic kidney disease;	chr7:66108952	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs313824	ENSG00000273142.1	RP11-458F8.4	-7.1	4.73e-12	1.7e-09	-0.35	-0.32	Diabetic kidney disease;	chr7:66116220	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs186378	ENSG00000273142.1	RP11-458F8.4	-7.1	4.73e-12	1.7e-09	-0.35	-0.32	Diabetic kidney disease;	chr7:66117071	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs160637	ENSG00000273142.1	RP11-458F8.4	-7.1	4.73e-12	1.7e-09	-0.35	-0.32	Diabetic kidney disease;	chr7:66119331	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs422164	ENSG00000273142.1	RP11-458F8.4	-7.1	4.73e-12	1.7e-09	-0.35	-0.32	Diabetic kidney disease;	chr7:66121618	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs316313	ENSG00000273142.1	RP11-458F8.4	-7.1	4.73e-12	1.7e-09	-0.35	-0.32	Diabetic kidney disease;	chr7:66128561	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs316312	ENSG00000273142.1	RP11-458F8.4	-7.1	4.73e-12	1.7e-09	-0.35	-0.32	Diabetic kidney disease;	chr7:66131504	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs419603	ENSG00000273142.1	RP11-458F8.4	-7.1	4.73e-12	1.7e-09	-0.35	-0.32	Diabetic kidney disease;	chr7:66132354	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs387676	ENSG00000273142.1	RP11-458F8.4	-7.1	4.73e-12	1.7e-09	-0.35	-0.32	Diabetic kidney disease;	chr7:66133233	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs13310597	ENSG00000273142.1	RP11-458F8.4	-7.1	4.73e-12	1.7e-09	-0.35	-0.32	Diabetic kidney disease;	chr7:66133553	chr7:66902857~66906297:+
PRAD	cis	rs75422866	0.85	rs73111210	ENSG00000280054.1	RP1-197B17.7	7.1	4.74e-12	1.71e-09	0.84	0.32	Pneumonia;	chr12:47576949	chr12:47728151~47730598:-
PRAD	cis	rs12612619	0.732	rs920433	ENSG00000229122.1	AGBL5-IT1	7.1	4.74e-12	1.71e-09	0.32	0.32	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26989658	chr2:27061038~27061815:+
PRAD	cis	rs67180937	0.844	rs4846384	ENSG00000272750.1	RP11-378J18.8	-7.1	4.74e-12	1.71e-09	-0.42	-0.32	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222624272	chr1:222658867~222661512:-
PRAD	cis	rs4842666	0.915	rs73437358	ENSG00000258302.2	RP11-981P6.1	7.1	4.75e-12	1.71e-09	0.38	0.32	Blood pressure;	chr12:89678299	chr12:89561129~89594878:+
PRAD	cis	rs4842666	0.915	rs11105368	ENSG00000258302.2	RP11-981P6.1	7.1	4.75e-12	1.71e-09	0.38	0.32	Blood pressure;	chr12:89680664	chr12:89561129~89594878:+
PRAD	cis	rs4842666	0.765	rs4842675	ENSG00000258302.2	RP11-981P6.1	7.1	4.75e-12	1.71e-09	0.38	0.32	Blood pressure;	chr12:89681466	chr12:89561129~89594878:+
PRAD	cis	rs2243480	1	rs313814	ENSG00000273142.1	RP11-458F8.4	-7.1	4.75e-12	1.71e-09	-0.36	-0.32	Diabetic kidney disease;	chr7:66038306	chr7:66902857~66906297:+
PRAD	cis	rs2274273	0.638	rs3759667	ENSG00000258413.1	RP11-665C16.6	-7.1	4.75e-12	1.71e-09	-0.44	-0.32	Protein biomarker;	chr14:55191703	chr14:55262767~55272075:-
PRAD	cis	rs2676071	0.767	rs907953	ENSG00000259446.4	RP11-489D6.2	-7.1	4.77e-12	1.72e-09	-0.44	-0.32	Periodontitis (Mean PAL);	chr15:33318904	chr15:33303657~33310659:-
PRAD	cis	rs1355223	1	rs35365094	ENSG00000271369.1	RP11-350D17.3	-7.1	4.77e-12	1.72e-09	-0.37	-0.32	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34746243	chr11:34709600~34710161:+
PRAD	cis	rs17275866	1	rs17275866	ENSG00000248174.4	RP11-148L24.1	7.1	4.77e-12	1.72e-09	0.45	0.32	Chin dimples;	chr4:174150335	chr4:174094660~174220398:-
PRAD	cis	rs17275866	1	rs17354466	ENSG00000248174.4	RP11-148L24.1	7.1	4.77e-12	1.72e-09	0.45	0.32	Chin dimples;	chr4:174150380	chr4:174094660~174220398:-
PRAD	cis	rs41307935	0.908	rs60798877	ENSG00000260063.1	RP5-968P14.2	-7.1	4.8e-12	1.73e-09	-0.65	-0.32	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26781648	chr1:26692132~26694131:-
PRAD	cis	rs41307935	0.915	rs12685	ENSG00000260063.1	RP5-968P14.2	-7.1	4.8e-12	1.73e-09	-0.65	-0.32	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26781754	chr1:26692132~26694131:-
PRAD	cis	rs2033711	0.87	rs1051500	ENSG00000269473.1	CTD-2619J13.19	7.1	4.81e-12	1.73e-09	0.34	0.32	Uric acid clearance;	chr19:58433035	chr19:58440448~58445849:+
PRAD	cis	rs1020064	0.636	rs2576750	ENSG00000235319.1	AC012360.4	-7.1	4.81e-12	1.73e-09	-0.4	-0.32	AIDS;	chr2:105300178	chr2:105324210~105330529:+
PRAD	cis	rs1799949	1	rs1960605	ENSG00000267002.1	RP11-242D8.1	7.1	4.81e-12	1.73e-09	0.29	0.32	Menopause (age at onset);	chr17:43153380	chr17:43164183~43170403:-
PRAD	cis	rs1799949	1	rs2037076	ENSG00000267002.1	RP11-242D8.1	7.1	4.81e-12	1.73e-09	0.29	0.32	Menopause (age at onset);	chr17:43153866	chr17:43164183~43170403:-
PRAD	cis	rs995000	0.899	rs1748201	ENSG00000235545.1	RP11-230B22.1	-7.1	4.82e-12	1.73e-09	-0.41	-0.32	Triglyceride levels;	chr1:62579835	chr1:62688482~62710694:+
PRAD	cis	rs2638953	0.777	rs10843181	ENSG00000278733.1	RP11-425D17.1	-7.1	4.82e-12	1.74e-09	-0.39	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28462824	chr12:28185625~28186190:-
PRAD	cis	rs7560272	0.695	rs13022149	ENSG00000163016.8	ALMS1P	-7.1	4.83e-12	1.74e-09	-0.36	-0.32	Schizophrenia;	chr2:73414387	chr2:73644919~73685576:+
PRAD	cis	rs1799949	0.55	rs2343818	ENSG00000267002.1	RP11-242D8.1	7.1	4.83e-12	1.74e-09	0.3	0.32	Menopause (age at onset);	chr17:43332406	chr17:43164183~43170403:-
PRAD	cis	rs1799949	0.526	rs4352088	ENSG00000267002.1	RP11-242D8.1	7.1	4.83e-12	1.74e-09	0.3	0.32	Menopause (age at onset);	chr17:43337311	chr17:43164183~43170403:-
PRAD	cis	rs1799949	0.93	rs8176194	ENSG00000267002.1	RP11-242D8.1	7.1	4.84e-12	1.74e-09	0.3	0.32	Menopause (age at onset);	chr17:43079204	chr17:43164183~43170403:-
PRAD	cis	rs2638953	0.853	rs10506037	ENSG00000278733.1	RP11-425D17.1	-7.1	4.84e-12	1.74e-09	-0.39	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28498213	chr12:28185625~28186190:-
PRAD	cis	rs995000	0.965	rs4587594	ENSG00000235545.1	RP11-230B22.1	7.1	4.84e-12	1.74e-09	0.42	0.32	Triglyceride levels;	chr1:62668259	chr1:62688482~62710694:+
PRAD	cis	rs6991838	0.778	rs11779601	ENSG00000272010.1	CTD-3025N20.3	7.1	4.84e-12	1.74e-09	0.32	0.32	Intelligence (multi-trait analysis);	chr8:65550241	chr8:65591850~65592472:-
PRAD	cis	rs6452524	0.87	rs6452511	ENSG00000249664.1	CTD-2227C6.2	7.1	4.85e-12	1.74e-09	0.39	0.32	Hypertension (SNP x SNP interaction);	chr5:83127403	chr5:83012285~83013109:-
PRAD	cis	rs995000	0.931	rs1748200	ENSG00000235545.1	RP11-230B22.1	-7.1	4.86e-12	1.75e-09	-0.41	-0.32	Triglyceride levels;	chr1:62580368	chr1:62688482~62710694:+
PRAD	cis	rs995000	0.931	rs1629122	ENSG00000235545.1	RP11-230B22.1	-7.1	4.86e-12	1.75e-09	-0.41	-0.32	Triglyceride levels;	chr1:62580907	chr1:62688482~62710694:+
PRAD	cis	rs6496044	0.507	rs1471455	ENSG00000202081.1	RNU6-1280P	-7.1	4.86e-12	1.75e-09	-0.38	-0.32	Interstitial lung disease;	chr15:85611496	chr15:85651522~85651628:-
PRAD	cis	rs4664293	0.867	rs2303550	ENSG00000226266.5	AC009961.3	-7.1	4.86e-12	1.75e-09	-0.42	-0.32	Monocyte percentage of white cells;	chr2:159781110	chr2:159670708~159712435:-
PRAD	cis	rs7429990	0.965	rs4858880	ENSG00000229759.1	MRPS18AP1	-7.1	4.86e-12	1.75e-09	-0.32	-0.32	Educational attainment (years of education);	chr3:48062959	chr3:48256350~48256938:-
PRAD	cis	rs11976180	0.517	rs6949375	ENSG00000244198.4	RP4-545C24.1	-7.1	4.87e-12	1.75e-09	-0.52	-0.32	Obesity-related traits;	chr7:144076758	chr7:144194858~144280547:+
PRAD	cis	rs2033711	0.84	rs10423138	ENSG00000269473.1	CTD-2619J13.19	7.1	4.87e-12	1.75e-09	0.34	0.32	Uric acid clearance;	chr19:58416935	chr19:58440448~58445849:+
PRAD	cis	rs2033711	0.87	rs3764534	ENSG00000269473.1	CTD-2619J13.19	7.1	4.87e-12	1.75e-09	0.34	0.32	Uric acid clearance;	chr19:58417769	chr19:58440448~58445849:+
PRAD	cis	rs6569038	0.669	rs7764418	ENSG00000253194.1	RP11-351A11.1	7.1	4.87e-12	1.75e-09	0.41	0.32	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:119062817	chr6:118934785~119031541:+
PRAD	cis	rs964611	0.882	rs79379792	ENSG00000259488.2	RP11-154J22.1	-7.1	4.88e-12	1.75e-09	-0.34	-0.32	Metabolite levels (Pyroglutamine);	chr15:48351980	chr15:48312353~48331856:-
PRAD	cis	rs964611	0.882	rs13380180	ENSG00000259488.2	RP11-154J22.1	-7.1	4.88e-12	1.75e-09	-0.34	-0.32	Metabolite levels (Pyroglutamine);	chr15:48352572	chr15:48312353~48331856:-
PRAD	cis	rs964611	0.882	rs13379705	ENSG00000259488.2	RP11-154J22.1	-7.1	4.88e-12	1.75e-09	-0.34	-0.32	Metabolite levels (Pyroglutamine);	chr15:48352611	chr15:48312353~48331856:-
PRAD	cis	rs875971	0.545	rs2420456	ENSG00000226824.5	RP4-756H11.3	-7.1	4.88e-12	1.76e-09	-0.47	-0.32	Aortic root size;	chr7:66280619	chr7:66654538~66669855:+
PRAD	cis	rs1023500	0.552	rs5758566	ENSG00000205702.9	CYP2D7	7.1	4.88e-12	1.76e-09	0.25	0.32	Schizophrenia;	chr22:42058350	chr22:42140203~42144577:-
PRAD	cis	rs9326248	0.559	rs484646	ENSG00000280143.1	AP000892.6	7.1	4.88e-12	1.76e-09	0.24	0.32	Blood protein levels;	chr11:116862140	chr11:117204967~117210292:+
PRAD	cis	rs2276314	0.802	rs9963714	ENSG00000278986.1	RP11-723J4.3	-7.1	4.9e-12	1.76e-09	-0.39	-0.32	Endometriosis;Drug-induced torsades de pointes;	chr18:36012093	chr18:35972151~35973916:+
PRAD	cis	rs2276314	0.802	rs4799838	ENSG00000278986.1	RP11-723J4.3	-7.1	4.9e-12	1.76e-09	-0.39	-0.32	Endometriosis;Drug-induced torsades de pointes;	chr18:36017567	chr18:35972151~35973916:+
PRAD	cis	rs2276314	0.748	rs4799839	ENSG00000278986.1	RP11-723J4.3	-7.1	4.9e-12	1.76e-09	-0.39	-0.32	Endometriosis;Drug-induced torsades de pointes;	chr18:36017568	chr18:35972151~35973916:+
PRAD	cis	rs6903823	0.508	rs1150724	ENSG00000204709.4	LINC01556	7.1	4.91e-12	1.77e-09	0.4	0.32	Pulmonary function;	chr6:28282459	chr6:28943877~28944537:+
PRAD	cis	rs10208649	0.611	rs12616263	ENSG00000272156.1	RP11-477N3.1	7.1	4.91e-12	1.77e-09	0.5	0.32	Body mass index;	chr2:54039235	chr2:54082554~54085066:+
PRAD	cis	rs9309473	0.607	rs1522927	ENSG00000163016.8	ALMS1P	7.1	4.91e-12	1.77e-09	0.39	0.32	Metabolite levels;	chr2:73329027	chr2:73644919~73685576:+
PRAD	cis	rs6991838	0.778	rs11782837	ENSG00000272010.1	CTD-3025N20.3	7.1	4.91e-12	1.77e-09	0.32	0.32	Intelligence (multi-trait analysis);	chr8:65550328	chr8:65591850~65592472:-
PRAD	cis	rs2243480	1	rs431076	ENSG00000273142.1	RP11-458F8.4	-7.1	4.92e-12	1.77e-09	-0.35	-0.32	Diabetic kidney disease;	chr7:66135333	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs2460422	ENSG00000273142.1	RP11-458F8.4	-7.1	4.92e-12	1.77e-09	-0.35	-0.32	Diabetic kidney disease;	chr7:66136518	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs316334	ENSG00000273142.1	RP11-458F8.4	-7.1	4.92e-12	1.77e-09	-0.35	-0.32	Diabetic kidney disease;	chr7:66137139	chr7:66902857~66906297:+
PRAD	cis	rs12612619	0.704	rs6754356	ENSG00000272148.1	RP11-195B17.1	7.1	4.92e-12	1.77e-09	0.38	0.32	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27092153	chr2:27062428~27062907:-
PRAD	cis	rs9287719	0.601	rs13427815	ENSG00000243819.4	RN7SL832P	7.1	4.93e-12	1.77e-09	0.31	0.32	Prostate cancer;	chr2:10567859	chr2:10690344~10692099:+
PRAD	cis	rs9287719	0.601	rs10177062	ENSG00000243819.4	RN7SL832P	7.1	4.93e-12	1.77e-09	0.31	0.32	Prostate cancer;	chr2:10573572	chr2:10690344~10692099:+
PRAD	cis	rs9309473	0.519	rs1881246	ENSG00000163016.8	ALMS1P	-7.1	4.93e-12	1.77e-09	-0.36	-0.32	Metabolite levels;	chr2:73422994	chr2:73644919~73685576:+
PRAD	cis	rs75920871	0.588	rs7112111	ENSG00000254851.1	RP11-109L13.1	7.1	4.93e-12	1.77e-09	0.43	0.32	Subjective well-being;	chr11:117110142	chr11:117135528~117138582:+
PRAD	cis	rs287982	1	rs56154233	ENSG00000269973.1	RP11-95D17.1	-7.1	4.94e-12	1.78e-09	-0.31	-0.32	Nonsyndromic cleft lip with cleft palate;	chr2:9829098	chr2:9936360~9939590:+
PRAD	cis	rs35160687	0.712	rs2303359	ENSG00000273080.1	RP11-301O19.1	-7.1	4.95e-12	1.78e-09	-0.35	-0.32	Night sleep phenotypes;	chr2:86251547	chr2:86195590~86196049:+
PRAD	cis	rs4713118	0.786	rs200502	ENSG00000219392.1	RP1-265C24.5	-7.1	4.95e-12	1.78e-09	-0.4	-0.32	Parkinson's disease;	chr6:27820284	chr6:28115628~28116551:+
PRAD	cis	rs733592	0.894	rs886589	ENSG00000240399.1	RP1-228P16.1	-7.1	4.97e-12	1.78e-09	-0.26	-0.32	Plateletcrit;	chr12:48083414	chr12:48054813~48055591:-
PRAD	cis	rs858239	0.601	rs6971002	ENSG00000226816.2	AC005082.12	7.1	4.97e-12	1.79e-09	0.36	0.32	Cerebrospinal fluid biomarker levels;	chr7:23132685	chr7:23206013~23208045:+
PRAD	cis	rs7429990	0.965	rs9854454	ENSG00000229759.1	MRPS18AP1	-7.1	4.97e-12	1.79e-09	-0.32	-0.32	Educational attainment (years of education);	chr3:47971307	chr3:48256350~48256938:-
PRAD	cis	rs995000	0.524	rs61775962	ENSG00000235545.1	RP11-230B22.1	-7.1	4.98e-12	1.79e-09	-0.4	-0.32	Triglyceride levels;	chr1:62733679	chr1:62688482~62710694:+
PRAD	cis	rs13113518	0.683	rs9761521	ENSG00000249700.7	SRD5A3-AS1	7.1	4.98e-12	1.79e-09	0.41	0.32	Height;	chr4:55363436	chr4:55363971~55395847:-
PRAD	cis	rs2243480	1	rs781150	ENSG00000273142.1	RP11-458F8.4	-7.1	4.98e-12	1.79e-09	-0.36	-0.32	Diabetic kidney disease;	chr7:66015986	chr7:66902857~66906297:+
PRAD	cis	rs6449502	0.536	rs10471505	ENSG00000251279.1	CTC-436P18.1	7.1	4.98e-12	1.79e-09	0.53	0.32	Mean platelet volume;	chr5:61192023	chr5:61162070~61232040:+
PRAD	cis	rs4713118	0.869	rs4713121	ENSG00000219392.1	RP1-265C24.5	-7.09	4.99e-12	1.79e-09	-0.4	-0.32	Parkinson's disease;	chr6:27754285	chr6:28115628~28116551:+
PRAD	cis	rs7191700	0.712	rs7187741	ENSG00000263080.1	RP11-485G7.5	-7.09	5e-12	1.79e-09	-0.38	-0.32	Multiple sclerosis;	chr16:11339246	chr16:11341809~11345211:-
PRAD	cis	rs7829975	0.572	rs28446104	ENSG00000253893.2	FAM85B	7.09	5e-12	1.79e-09	0.39	0.32	Mood instability;	chr8:8938391	chr8:8167819~8226614:-
PRAD	cis	rs10129255	0.957	rs7493713	ENSG00000211970.3	IGHV4-61	-7.09	5e-12	1.8e-09	-0.29	-0.32	Kawasaki disease;	chr14:106783685	chr14:106639119~106639657:-
PRAD	cis	rs10129255	0.912	rs35468694	ENSG00000211970.3	IGHV4-61	-7.09	5e-12	1.8e-09	-0.29	-0.32	Kawasaki disease;	chr14:106784199	chr14:106639119~106639657:-
PRAD	cis	rs10129255	0.957	rs8019272	ENSG00000211970.3	IGHV4-61	-7.09	5e-12	1.8e-09	-0.29	-0.32	Kawasaki disease;	chr14:106784709	chr14:106639119~106639657:-
PRAD	cis	rs6565180	1	rs12930787	ENSG00000183604.13	SMG1P5	-7.09	5e-12	1.8e-09	-0.3	-0.32	Tonsillectomy;	chr16:30369982	chr16:30267553~30335374:-
PRAD	cis	rs2439831	0.85	rs12442297	ENSG00000249839.1	AC011330.5	-7.09	5e-12	1.8e-09	-0.57	-0.32	Lung cancer in ever smokers;	chr15:43876272	chr15:43663654~43684339:-
PRAD	cis	rs7131987	0.65	rs3782509	ENSG00000275476.1	RP11-996F15.4	-7.09	5e-12	1.8e-09	-0.33	-0.32	QT interval;	chr12:29300845	chr12:29277397~29277882:-
PRAD	cis	rs1799949	1	rs33926631	ENSG00000267002.1	RP11-242D8.1	7.09	5.01e-12	1.8e-09	0.29	0.32	Menopause (age at onset);	chr17:43152446	chr17:43164183~43170403:-
PRAD	cis	rs12612619	0.704	rs6742004	ENSG00000272148.1	RP11-195B17.1	7.09	5.03e-12	1.81e-09	0.38	0.32	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27086791	chr2:27062428~27062907:-
PRAD	cis	rs2681472	0.524	rs7314459	ENSG00000258302.2	RP11-981P6.1	7.09	5.04e-12	1.81e-09	0.38	0.32	Hypertension;Coronary artery disease;Myocardial infarction;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Systolic blood pressure;Diastolic blood pressure;	chr12:89562564	chr12:89561129~89594878:+
PRAD	cis	rs2836950	0.565	rs2836942	ENSG00000255568.3	BRWD1-AS2	-7.09	5.04e-12	1.81e-09	-0.26	-0.32	Menarche (age at onset);	chr21:39219455	chr21:39313935~39314962:+
PRAD	cis	rs79349575	0.756	rs2291726	ENSG00000248278.1	SUMO2P17	-7.09	5.05e-12	1.81e-09	-0.36	-0.32	Type 2 diabetes;	chr17:48961892	chr17:48874860~48908983:-
PRAD	cis	rs11846409	0.655	rs79296226	ENSG00000274576.2	IGHV2-70	7.09	5.05e-12	1.81e-09	0.33	0.32	Rheumatic heart disease;	chr14:106650436	chr14:106770577~106771020:-
PRAD	cis	rs7191700	0.644	rs12149160	ENSG00000263080.1	RP11-485G7.5	-7.09	5.06e-12	1.81e-09	-0.38	-0.32	Multiple sclerosis;	chr16:11345446	chr16:11341809~11345211:-
PRAD	cis	rs858239	0.601	rs10239760	ENSG00000226816.2	AC005082.12	7.09	5.06e-12	1.82e-09	0.36	0.32	Cerebrospinal fluid biomarker levels;	chr7:23110331	chr7:23206013~23208045:+
PRAD	cis	rs11098499	0.789	rs10212719	ENSG00000245958.5	RP11-33B1.1	-7.09	5.06e-12	1.82e-09	-0.3	-0.32	Corneal astigmatism;	chr4:119333282	chr4:119454791~119552025:+
PRAD	cis	rs875971	0.545	rs75577046	ENSG00000226824.5	RP4-756H11.3	-7.09	5.07e-12	1.82e-09	-0.47	-0.32	Aortic root size;	chr7:66493729	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.545	rs3735147	ENSG00000226824.5	RP4-756H11.3	-7.09	5.07e-12	1.82e-09	-0.47	-0.32	Aortic root size;	chr7:66505541	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.545	rs1638724	ENSG00000226824.5	RP4-756H11.3	7.09	5.07e-12	1.82e-09	0.47	0.32	Aortic root size;	chr7:66575494	chr7:66654538~66669855:+
PRAD	cis	rs77204473	0.744	rs6589606	ENSG00000254851.1	RP11-109L13.1	7.09	5.07e-12	1.82e-09	0.73	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117222170	chr11:117135528~117138582:+
PRAD	cis	rs1011728	0.531	rs10862975	ENSG00000258815.1	RP11-408B11.2	-7.09	5.07e-12	1.82e-09	-0.42	-0.32	Bone mineral density (Ward's triangle area);	chr12:85355620	chr12:85318060~85342912:+
PRAD	cis	rs9400467	0.528	rs465796	ENSG00000271789.1	RP5-1112D6.7	-7.09	5.08e-12	1.82e-09	-0.35	-0.32	Amino acid levels;Blood metabolite levels;	chr6:111298522	chr6:111297126~111298510:+
PRAD	cis	rs760794	0.764	rs6904518	ENSG00000228412.5	RP4-625H18.2	7.09	5.08e-12	1.82e-09	0.39	0.32	Endometriosis;	chr6:19798473	chr6:19802164~19804752:-
PRAD	cis	rs6860806	0.661	rs28472559	ENSG00000233006.5	AC034220.3	7.09	5.1e-12	1.83e-09	0.27	0.32	Breast cancer;	chr5:132245918	chr5:132311285~132369916:-
PRAD	cis	rs6903823	0.508	rs1150721	ENSG00000280107.1	AL022393.9	-7.09	5.11e-12	1.83e-09	-0.38	-0.32	Pulmonary function;	chr6:28287263	chr6:28170845~28172521:+
PRAD	cis	rs6903823	0.508	rs1150718	ENSG00000280107.1	AL022393.9	-7.09	5.11e-12	1.83e-09	-0.38	-0.32	Pulmonary function;	chr6:28289170	chr6:28170845~28172521:+
PRAD	cis	rs6903823	0.508	rs1233660	ENSG00000280107.1	AL022393.9	-7.09	5.11e-12	1.83e-09	-0.38	-0.32	Pulmonary function;	chr6:28292472	chr6:28170845~28172521:+
PRAD	cis	rs71636778	0.509	rs35617712	ENSG00000260063.1	RP5-968P14.2	-7.09	5.12e-12	1.84e-09	-0.64	-0.32	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26724732	chr1:26692132~26694131:-
PRAD	cis	rs2638953	0.853	rs11049693	ENSG00000278733.1	RP11-425D17.1	-7.09	5.13e-12	1.84e-09	-0.37	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28525011	chr12:28185625~28186190:-
PRAD	cis	rs2034650	0.563	rs2412523	ENSG00000223313.1	RNU6-516P	7.09	5.13e-12	1.84e-09	0.38	0.32	Interstitial lung disease;	chr15:40417487	chr15:40529570~40529673:+
PRAD	cis	rs2276314	0.857	rs28375959	ENSG00000278986.1	RP11-723J4.3	-7.09	5.14e-12	1.84e-09	-0.39	-0.32	Endometriosis;Drug-induced torsades de pointes;	chr18:36021571	chr18:35972151~35973916:+
PRAD	cis	rs6496044	0.507	rs2467096	ENSG00000202081.1	RNU6-1280P	-7.09	5.15e-12	1.85e-09	-0.38	-0.32	Interstitial lung disease;	chr15:85667447	chr15:85651522~85651628:-
PRAD	cis	rs2836950	0.501	rs4818019	ENSG00000255568.3	BRWD1-AS2	-7.09	5.18e-12	1.86e-09	-0.26	-0.32	Menarche (age at onset);	chr21:39322530	chr21:39313935~39314962:+
PRAD	cis	rs875971	0.502	rs6460311	ENSG00000226824.5	RP4-756H11.3	7.09	5.19e-12	1.86e-09	0.47	0.32	Aortic root size;	chr7:66646886	chr7:66654538~66669855:+
PRAD	cis	rs2638953	0.889	rs11049481	ENSG00000247934.4	RP11-967K21.1	-7.09	5.19e-12	1.86e-09	-0.33	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28252087	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.962	rs11049482	ENSG00000247934.4	RP11-967K21.1	-7.09	5.19e-12	1.86e-09	-0.33	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28252088	chr12:28163298~28190738:-
PRAD	cis	rs7515577	0.533	rs17578954	ENSG00000223787.2	RP4-593M8.1	7.09	5.2e-12	1.86e-09	0.74	0.32	Cholesterol, total;	chr1:92300508	chr1:92580476~92580821:-
PRAD	cis	rs3096299	0.967	rs2965935	ENSG00000261118.1	RP11-104N10.1	-7.09	5.2e-12	1.86e-09	-0.31	-0.32	Multiple myeloma (IgH translocation);	chr16:89414866	chr16:89492017~89504460:-
PRAD	cis	rs812925	0.537	rs778153	ENSG00000271889.1	RP11-493E12.1	-7.09	5.21e-12	1.87e-09	-0.35	-0.32	Immature fraction of reticulocytes;	chr2:61381517	chr2:61151433~61162105:-
PRAD	cis	rs7586673	0.578	rs6723840	ENSG00000227403.1	AC009299.3	-7.09	5.22e-12	1.87e-09	-0.44	-0.32	Intelligence (multi-trait analysis);	chr2:161023104	chr2:161244739~161249050:+
PRAD	cis	rs7586673	0.578	rs6723841	ENSG00000227403.1	AC009299.3	-7.09	5.22e-12	1.87e-09	-0.44	-0.32	Intelligence (multi-trait analysis);	chr2:161023105	chr2:161244739~161249050:+
PRAD	cis	rs1198430	0.852	rs909537	ENSG00000232482.2	RP4-654C18.1	-7.09	5.22e-12	1.87e-09	-0.52	-0.32	Total cholesterol levels;	chr1:23483570	chr1:23410832~23412146:+
PRAD	cis	rs2688482	0.512	rs3103953	ENSG00000224769.1	AC069213.1	-7.09	5.23e-12	1.87e-09	-0.51	-0.32	Lung disease severity in cystic fibrosis;	chr3:195793726	chr3:195614947~195620233:+
PRAD	cis	rs4842666	0.915	rs11105364	ENSG00000258302.2	RP11-981P6.1	7.09	5.23e-12	1.88e-09	0.38	0.32	Blood pressure;	chr12:89675499	chr12:89561129~89594878:+
PRAD	cis	rs10208649	0.656	rs12623097	ENSG00000272156.1	RP11-477N3.1	7.09	5.24e-12	1.88e-09	0.56	0.32	Body mass index;	chr2:54071182	chr2:54082554~54085066:+
PRAD	cis	rs2638953	0.861	rs11049685	ENSG00000278733.1	RP11-425D17.1	-7.09	5.24e-12	1.88e-09	-0.36	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28512775	chr12:28185625~28186190:-
PRAD	cis	rs10411161	1	rs10402988	ENSG00000269483.1	AC006272.1	7.09	5.26e-12	1.88e-09	0.47	0.32	Breast cancer;	chr19:51859851	chr19:51839924~51843324:-
PRAD	cis	rs10411161	1	rs2867318	ENSG00000269483.1	AC006272.1	7.09	5.26e-12	1.88e-09	0.47	0.32	Breast cancer;	chr19:51860219	chr19:51839924~51843324:-
PRAD	cis	rs10411161	1	rs6509581	ENSG00000269483.1	AC006272.1	7.09	5.26e-12	1.88e-09	0.47	0.32	Breast cancer;	chr19:51860629	chr19:51839924~51843324:-
PRAD	cis	rs1799949	1	rs3092994	ENSG00000267002.1	RP11-242D8.1	7.09	5.26e-12	1.89e-09	0.3	0.32	Menopause (age at onset);	chr17:43063808	chr17:43164183~43170403:-
PRAD	cis	rs2911132	1	rs2911130	ENSG00000248734.2	CTD-2260A17.1	7.09	5.27e-12	1.89e-09	0.34	0.32	Urate levels (BMI interaction);	chr5:96847724	chr5:96784777~96785999:+
PRAD	cis	rs875971	0.505	rs6955582	ENSG00000237310.1	GS1-124K5.4	7.09	5.28e-12	1.89e-09	0.27	0.32	Aortic root size;	chr7:65966699	chr7:66493706~66495474:+
PRAD	cis	rs9326248	0.559	rs476399	ENSG00000280143.1	AP000892.6	7.09	5.29e-12	1.89e-09	0.24	0.32	Blood protein levels;	chr11:116863012	chr11:117204967~117210292:+
PRAD	cis	rs763567	0.869	rs629234	ENSG00000271811.1	RP1-79C4.4	7.09	5.3e-12	1.9e-09	0.36	0.32	Tonsillectomy;	chr1:170662622	chr1:170667381~170669425:+
PRAD	cis	rs172166	0.694	rs203893	ENSG00000220721.1	OR1F12	7.09	5.3e-12	1.9e-09	0.36	0.32	Cardiac Troponin-T levels;	chr6:28094288	chr6:28073316~28074233:+
PRAD	cis	rs172166	0.652	rs476167	ENSG00000220721.1	OR1F12	7.09	5.3e-12	1.9e-09	0.36	0.32	Cardiac Troponin-T levels;	chr6:28098110	chr6:28073316~28074233:+
PRAD	cis	rs172166	0.694	rs203892	ENSG00000220721.1	OR1F12	7.09	5.3e-12	1.9e-09	0.36	0.32	Cardiac Troponin-T levels;	chr6:28099418	chr6:28073316~28074233:+
PRAD	cis	rs2439831	0.85	rs9944216	ENSG00000205771.5	CATSPER2P1	7.09	5.3e-12	1.9e-09	0.49	0.32	Lung cancer in ever smokers;	chr15:43868575	chr15:43726918~43747094:-
PRAD	cis	rs858239	0.6	rs9691762	ENSG00000226816.2	AC005082.12	7.09	5.31e-12	1.9e-09	0.35	0.32	Cerebrospinal fluid biomarker levels;	chr7:23086303	chr7:23206013~23208045:+
PRAD	cis	rs12612619	0.732	rs6547355	ENSG00000272148.1	RP11-195B17.1	7.09	5.32e-12	1.9e-09	0.37	0.32	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26987337	chr2:27062428~27062907:-
PRAD	cis	rs6547741	0.844	rs7382	ENSG00000234072.1	AC074117.10	-7.08	5.32e-12	1.91e-09	-0.24	-0.32	Oral cavity cancer;	chr2:27650548	chr2:27356246~27367622:+
PRAD	cis	rs1075232	1	rs12439239	ENSG00000215302.7	CTD-3092A11.1	-7.08	5.33e-12	1.91e-09	-0.71	-0.32	Survival in colorectal cancer (non-distant metastatic);	chr15:31359515	chr15:30470779~30507623:+
PRAD	cis	rs2243480	1	rs3885839	ENSG00000226824.5	RP4-756H11.3	-7.08	5.34e-12	1.91e-09	-0.62	-0.32	Diabetic kidney disease;	chr7:65825416	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs73142122	ENSG00000226824.5	RP4-756H11.3	-7.08	5.34e-12	1.91e-09	-0.62	-0.32	Diabetic kidney disease;	chr7:65846311	chr7:66654538~66669855:+
PRAD	cis	rs2243480	0.901	rs73142137	ENSG00000226824.5	RP4-756H11.3	-7.08	5.34e-12	1.91e-09	-0.62	-0.32	Diabetic kidney disease;	chr7:65878455	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs13247184	ENSG00000226824.5	RP4-756H11.3	-7.08	5.34e-12	1.91e-09	-0.62	-0.32	Diabetic kidney disease;	chr7:65893941	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs35283677	ENSG00000226824.5	RP4-756H11.3	-7.08	5.34e-12	1.91e-09	-0.62	-0.32	Diabetic kidney disease;	chr7:65894246	chr7:66654538~66669855:+
PRAD	cis	rs2243480	1	rs35421653	ENSG00000226824.5	RP4-756H11.3	-7.08	5.34e-12	1.91e-09	-0.62	-0.32	Diabetic kidney disease;	chr7:65898442	chr7:66654538~66669855:+
PRAD	cis	rs2243480	0.908	rs55876148	ENSG00000226824.5	RP4-756H11.3	-7.08	5.34e-12	1.91e-09	-0.62	-0.32	Diabetic kidney disease;	chr7:65914813	chr7:66654538~66669855:+
PRAD	cis	rs12612619	0.732	rs13032059	ENSG00000272148.1	RP11-195B17.1	7.08	5.34e-12	1.91e-09	0.37	0.32	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27010921	chr2:27062428~27062907:-
PRAD	cis	rs12612619	0.732	rs13032100	ENSG00000272148.1	RP11-195B17.1	7.08	5.34e-12	1.91e-09	0.37	0.32	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27010991	chr2:27062428~27062907:-
PRAD	cis	rs2638953	0.925	rs11049510	ENSG00000247934.4	RP11-967K21.1	-7.08	5.34e-12	1.91e-09	-0.34	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28290839	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.962	rs61922978	ENSG00000247934.4	RP11-967K21.1	-7.08	5.34e-12	1.91e-09	-0.34	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28292075	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.962	rs12372448	ENSG00000247934.4	RP11-967K21.1	-7.08	5.34e-12	1.91e-09	-0.34	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28293956	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.925	rs11049511	ENSG00000247934.4	RP11-967K21.1	-7.08	5.34e-12	1.91e-09	-0.34	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28294393	chr12:28163298~28190738:-
PRAD	cis	rs6547741	0.904	rs1528403	ENSG00000234072.1	AC074117.10	7.08	5.34e-12	1.91e-09	0.24	0.32	Oral cavity cancer;	chr2:27623778	chr2:27356246~27367622:+
PRAD	cis	rs4718428	1	rs1830070	ENSG00000232546.1	RP11-458F8.1	-7.08	5.34e-12	1.91e-09	-0.24	-0.32	Corneal structure;	chr7:66884684	chr7:66848496~66858136:+
PRAD	cis	rs172166	0.611	rs203883	ENSG00000220721.1	OR1F12	7.08	5.37e-12	1.92e-09	0.36	0.32	Cardiac Troponin-T levels;	chr6:28110578	chr6:28073316~28074233:+
PRAD	cis	rs4842666	0.915	rs11105376	ENSG00000258302.2	RP11-981P6.1	7.08	5.39e-12	1.93e-09	0.41	0.32	Blood pressure;	chr12:89694991	chr12:89561129~89594878:+
PRAD	cis	rs11098499	0.588	rs2389874	ENSG00000245958.5	RP11-33B1.1	7.08	5.39e-12	1.93e-09	0.29	0.32	Corneal astigmatism;	chr4:119633836	chr4:119454791~119552025:+
PRAD	cis	rs875971	0.54	rs736270	ENSG00000237310.1	GS1-124K5.4	7.08	5.39e-12	1.93e-09	0.27	0.32	Aortic root size;	chr7:65963835	chr7:66493706~66495474:+
PRAD	cis	rs1949733	0.585	rs2631768	ENSG00000205959.3	RP11-689P11.2	7.08	5.4e-12	1.93e-09	0.34	0.32	Response to antineoplastic agents;	chr4:8471323	chr4:8482270~8512610:+
PRAD	cis	rs875971	0.545	rs10261710	ENSG00000226824.5	RP4-756H11.3	-7.08	5.4e-12	1.93e-09	-0.48	-0.32	Aortic root size;	chr7:66249202	chr7:66654538~66669855:+
PRAD	cis	rs853679	0.607	rs13204012	ENSG00000280107.1	AL022393.9	-7.08	5.4e-12	1.93e-09	-0.63	-0.32	Depression;	chr6:28233753	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.607	rs13205211	ENSG00000280107.1	AL022393.9	-7.08	5.4e-12	1.93e-09	-0.63	-0.32	Depression;	chr6:28235278	chr6:28170845~28172521:+
PRAD	cis	rs9543976	0.858	rs9530447	ENSG00000261553.4	RP11-29G8.3	7.08	5.41e-12	1.94e-09	0.5	0.32	Diabetic retinopathy;	chr13:75592666	chr13:75549773~75807120:+
PRAD	cis	rs995000	0.899	rs4495740	ENSG00000235545.1	RP11-230B22.1	7.08	5.41e-12	1.94e-09	0.41	0.32	Triglyceride levels;	chr1:62658794	chr1:62688482~62710694:+
PRAD	cis	rs2439831	0.85	rs3742982	ENSG00000249839.1	AC011330.5	-7.08	5.42e-12	1.94e-09	-0.54	-0.32	Lung cancer in ever smokers;	chr15:43884483	chr15:43663654~43684339:-
PRAD	cis	rs453301	0.653	rs1045529	ENSG00000254340.1	RP11-10A14.3	-7.08	5.44e-12	1.95e-09	-0.38	-0.32	Joint mobility (Beighton score);	chr8:9032588	chr8:9141424~9145435:+
PRAD	cis	rs2276314	0.857	rs28396546	ENSG00000278986.1	RP11-723J4.3	-7.08	5.44e-12	1.95e-09	-0.39	-0.32	Endometriosis;Drug-induced torsades de pointes;	chr18:36059061	chr18:35972151~35973916:+
PRAD	cis	rs9287719	0.601	rs9287718	ENSG00000243819.4	RN7SL832P	-7.08	5.44e-12	1.95e-09	-0.31	-0.32	Prostate cancer;	chr2:10561503	chr2:10690344~10692099:+
PRAD	cis	rs11098499	0.562	rs13101722	ENSG00000245958.5	RP11-33B1.1	7.08	5.45e-12	1.95e-09	0.29	0.32	Corneal astigmatism;	chr4:119634820	chr4:119454791~119552025:+
PRAD	cis	rs2911132	1	rs2617433	ENSG00000248734.2	CTD-2260A17.1	7.08	5.45e-12	1.95e-09	0.34	0.32	Urate levels (BMI interaction);	chr5:96840738	chr5:96784777~96785999:+
PRAD	cis	rs1799949	0.965	rs9646418	ENSG00000267002.1	RP11-242D8.1	7.08	5.45e-12	1.95e-09	0.3	0.32	Menopause (age at onset);	chr17:43348533	chr17:43164183~43170403:-
PRAD	cis	rs1015362	0.54	rs2378026	ENSG00000276073.1	RP5-1125A11.7	-7.08	5.45e-12	1.95e-09	-0.39	-0.32	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:33921845	chr20:33985617~33988989:-
PRAD	cis	rs1858037	0.836	rs17475335	ENSG00000281920.1	RP11-418H16.1	7.08	5.45e-12	1.95e-09	0.39	0.32	Rheumatoid arthritis;	chr2:65378646	chr2:65623272~65628424:+
PRAD	cis	rs995000	0.868	rs1007205	ENSG00000235545.1	RP11-230B22.1	-7.08	5.46e-12	1.95e-09	-0.42	-0.32	Triglyceride levels;	chr1:62471241	chr1:62688482~62710694:+
PRAD	cis	rs1862618	0.627	rs744023	ENSG00000271828.1	CTD-2310F14.1	7.08	5.46e-12	1.95e-09	0.56	0.32	Initial pursuit acceleration;	chr5:56901251	chr5:56927874~56929573:+
PRAD	cis	rs172166	0.694	rs1631552	ENSG00000204709.4	LINC01556	7.08	5.46e-12	1.95e-09	0.41	0.32	Cardiac Troponin-T levels;	chr6:28121921	chr6:28943877~28944537:+
PRAD	cis	rs12612619	0.732	rs893790	ENSG00000272148.1	RP11-195B17.1	-7.08	5.47e-12	1.95e-09	-0.38	-0.32	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26978989	chr2:27062428~27062907:-
PRAD	cis	rs9287719	0.601	rs759401	ENSG00000243819.4	RN7SL832P	7.08	5.47e-12	1.95e-09	0.31	0.32	Prostate cancer;	chr2:10569796	chr2:10690344~10692099:+
PRAD	cis	rs6847067	0.683	rs1508670	ENSG00000180769.7	WDFY3-AS2	7.08	5.47e-12	1.96e-09	0.35	0.32	Oropharynx cancer;	chr4:84923506	chr4:84965682~85011277:+
PRAD	cis	rs6847067	0.683	rs72664957	ENSG00000180769.7	WDFY3-AS2	7.08	5.47e-12	1.96e-09	0.35	0.32	Oropharynx cancer;	chr4:84927520	chr4:84965682~85011277:+
PRAD	cis	rs1707322	0.686	rs1541131	ENSG00000280836.1	AL355480.1	7.08	5.48e-12	1.96e-09	0.4	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619262	chr1:45581219~45581321:-
PRAD	cis	rs1707322	0.686	rs3014239	ENSG00000280836.1	AL355480.1	7.08	5.48e-12	1.96e-09	0.4	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45624129	chr1:45581219~45581321:-
PRAD	cis	rs1707322	0.686	rs3014236	ENSG00000280836.1	AL355480.1	7.08	5.48e-12	1.96e-09	0.4	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45625633	chr1:45581219~45581321:-
PRAD	cis	rs2067615	0.579	rs4385986	ENSG00000260329.1	RP11-412D9.4	-7.08	5.49e-12	1.96e-09	-0.27	-0.32	Heart rate;	chr12:106739997	chr12:106954029~106955497:-
PRAD	cis	rs2243480	1	rs316307	ENSG00000273142.1	RP11-458F8.4	-7.08	5.49e-12	1.96e-09	-0.35	-0.32	Diabetic kidney disease;	chr7:66105184	chr7:66902857~66906297:+
PRAD	cis	rs2015599	0.623	rs3782510	ENSG00000275476.1	RP11-996F15.4	7.08	5.49e-12	1.96e-09	0.33	0.32	Platelet count;Mean platelet volume;	chr12:29301176	chr12:29277397~29277882:-
PRAD	cis	rs2638953	0.541	rs10843209	ENSG00000278733.1	RP11-425D17.1	-7.08	5.49e-12	1.96e-09	-0.36	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28573702	chr12:28185625~28186190:-
PRAD	cis	rs9810089	0.802	rs10935182	ENSG00000261758.1	RP11-102M11.2	7.08	5.5e-12	1.97e-09	0.36	0.32	Gestational age at birth (child effect);	chr3:136418580	chr3:136752630~136755780:+
PRAD	cis	rs34787248	1	rs34787248	ENSG00000226314.6	ZNF192P1	-7.08	5.51e-12	1.97e-09	-0.45	-0.32	Autism spectrum disorder or schizophrenia;	chr6:28230108	chr6:28161781~28169594:+
PRAD	cis	rs526231	0.578	rs1898672	ENSG00000175749.11	EIF3KP1	-7.08	5.51e-12	1.97e-09	-0.42	-0.31	Primary biliary cholangitis;	chr5:102958149	chr5:103032376~103033031:+
PRAD	cis	rs1799949	0.894	rs36062488	ENSG00000267002.1	RP11-242D8.1	-7.08	5.51e-12	1.97e-09	-0.29	-0.31	Menopause (age at onset);	chr17:43185455	chr17:43164183~43170403:-
PRAD	cis	rs2239557	0.5	rs7157723	ENSG00000259065.1	RP5-1021I20.1	7.08	5.52e-12	1.97e-09	0.39	0.31	Common traits (Other);	chr14:73999497	chr14:73787360~73803270:+
PRAD	cis	rs2599510	0.703	rs58852184	ENSG00000276334.1	AL133243.1	7.08	5.52e-12	1.97e-09	0.36	0.31	Interleukin-18 levels;	chr2:32504696	chr2:32521927~32523547:+
PRAD	cis	rs7429990	0.932	rs9862913	ENSG00000229759.1	MRPS18AP1	7.08	5.52e-12	1.97e-09	0.32	0.31	Educational attainment (years of education);	chr3:47974682	chr3:48256350~48256938:-
PRAD	cis	rs7429990	0.965	rs7426976	ENSG00000229759.1	MRPS18AP1	-7.08	5.52e-12	1.97e-09	-0.32	-0.31	Educational attainment (years of education);	chr3:47981083	chr3:48256350~48256938:-
PRAD	cis	rs7429990	0.965	rs1013431	ENSG00000229759.1	MRPS18AP1	-7.08	5.52e-12	1.97e-09	-0.32	-0.31	Educational attainment (years of education);	chr3:47987628	chr3:48256350~48256938:-
PRAD	cis	rs2638953	0.962	rs10506029	ENSG00000247934.4	RP11-967K21.1	-7.08	5.52e-12	1.97e-09	-0.34	-0.31	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28320302	chr12:28163298~28190738:-
PRAD	cis	rs2276314	1	rs1540042	ENSG00000278986.1	RP11-723J4.3	-7.08	5.54e-12	1.98e-09	-0.39	-0.31	Endometriosis;Drug-induced torsades de pointes;	chr18:35975273	chr18:35972151~35973916:+
PRAD	cis	rs6991838	0.806	rs13262793	ENSG00000272010.1	CTD-3025N20.3	7.08	5.54e-12	1.98e-09	0.31	0.31	Intelligence (multi-trait analysis);	chr8:65549662	chr8:65591850~65592472:-
PRAD	cis	rs58873874	0.737	rs75326191	ENSG00000251405.2	CTB-109A12.1	7.08	5.54e-12	1.98e-09	0.83	0.31	Bipolar disorder (body mass index interaction);	chr5:157445797	chr5:157362615~157460078:-
PRAD	cis	rs995000	0.931	rs6675401	ENSG00000235545.1	RP11-230B22.1	7.08	5.55e-12	1.98e-09	0.41	0.31	Triglyceride levels;	chr1:62608304	chr1:62688482~62710694:+
PRAD	cis	rs995000	0.931	rs6678483	ENSG00000235545.1	RP11-230B22.1	7.08	5.55e-12	1.98e-09	0.41	0.31	Triglyceride levels;	chr1:62608771	chr1:62688482~62710694:+
PRAD	cis	rs995000	0.931	rs10889347	ENSG00000235545.1	RP11-230B22.1	7.08	5.55e-12	1.98e-09	0.41	0.31	Triglyceride levels;	chr1:62610155	chr1:62688482~62710694:+
PRAD	cis	rs995000	0.931	rs10889349	ENSG00000235545.1	RP11-230B22.1	7.08	5.55e-12	1.98e-09	0.41	0.31	Triglyceride levels;	chr1:62616248	chr1:62688482~62710694:+
PRAD	cis	rs995000	0.931	rs61471917	ENSG00000235545.1	RP11-230B22.1	7.08	5.55e-12	1.98e-09	0.41	0.31	Triglyceride levels;	chr1:62618359	chr1:62688482~62710694:+
PRAD	cis	rs995000	0.931	rs10889350	ENSG00000235545.1	RP11-230B22.1	7.08	5.55e-12	1.98e-09	0.41	0.31	Triglyceride levels;	chr1:62619595	chr1:62688482~62710694:+
PRAD	cis	rs17772222	1	rs56987357	ENSG00000258983.2	RP11-507K2.2	7.08	5.55e-12	1.98e-09	0.45	0.31	Coronary artery calcification;	chr14:88358019	chr14:88499334~88515502:+
PRAD	cis	rs6847067	0.644	rs1484661	ENSG00000180769.7	WDFY3-AS2	7.08	5.55e-12	1.98e-09	0.35	0.31	Oropharynx cancer;	chr4:84861079	chr4:84965682~85011277:+
PRAD	cis	rs7131987	0.65	rs10843377	ENSG00000275476.1	RP11-996F15.4	7.08	5.56e-12	1.98e-09	0.34	0.31	QT interval;	chr12:29284120	chr12:29277397~29277882:-
PRAD	cis	rs1707322	0.721	rs12043945	ENSG00000280836.1	AL355480.1	-7.08	5.57e-12	1.99e-09	-0.39	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45641250	chr1:45581219~45581321:-
PRAD	cis	rs1707322	0.721	rs12091503	ENSG00000280836.1	AL355480.1	-7.08	5.57e-12	1.99e-09	-0.39	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45642196	chr1:45581219~45581321:-
PRAD	cis	rs875971	0.545	rs73142265	ENSG00000226824.5	RP4-756H11.3	-7.08	5.58e-12	1.99e-09	-0.47	-0.31	Aortic root size;	chr7:66234510	chr7:66654538~66669855:+
PRAD	cis	rs2427308	0.643	rs477859	ENSG00000273619.1	RP5-908M14.9	7.08	5.59e-12	1.99e-09	0.23	0.31	Colorectal cancer;	chr20:62362541	chr20:62386303~62386970:-
PRAD	cis	rs4664293	0.867	rs3771721	ENSG00000226266.5	AC009961.3	-7.08	5.59e-12	1.99e-09	-0.42	-0.31	Monocyte percentage of white cells;	chr2:159771644	chr2:159670708~159712435:-
PRAD	cis	rs4664293	0.867	rs11681245	ENSG00000226266.5	AC009961.3	-7.08	5.59e-12	1.99e-09	-0.42	-0.31	Monocyte percentage of white cells;	chr2:159772882	chr2:159670708~159712435:-
PRAD	cis	rs59482735	1	rs59482735	ENSG00000226752.6	PSMD5-AS1	-7.08	5.59e-12	2e-09	-0.38	-0.31	Prostate-specific antigen levels;	chr9:120881148	chr9:120824828~120854385:+
PRAD	cis	rs7739264	0.602	rs6456260	ENSG00000228412.5	RP4-625H18.2	7.08	5.6e-12	2e-09	0.38	0.31	Endometriosis;	chr6:19762721	chr6:19802164~19804752:-
PRAD	cis	rs539096	0.5	rs2367804	ENSG00000237950.1	RP11-7O11.3	7.08	5.6e-12	2e-09	0.34	0.31	Intelligence (multi-trait analysis);	chr1:43848594	chr1:43944370~43946551:-
PRAD	cis	rs2243480	1	rs906134	ENSG00000273142.1	RP11-458F8.4	-7.08	5.6e-12	2e-09	-0.36	-0.31	Diabetic kidney disease;	chr7:65979301	chr7:66902857~66906297:+
PRAD	cis	rs995000	0.899	rs1183260	ENSG00000235545.1	RP11-230B22.1	-7.08	5.62e-12	2e-09	-0.42	-0.31	Triglyceride levels;	chr1:62479747	chr1:62688482~62710694:+
PRAD	cis	rs995000	0.899	rs1305521	ENSG00000235545.1	RP11-230B22.1	-7.08	5.62e-12	2e-09	-0.42	-0.31	Triglyceride levels;	chr1:62483363	chr1:62688482~62710694:+
PRAD	cis	rs3020264	1	rs3020264	ENSG00000271743.1	CTD-2541M15.3	7.08	5.63e-12	2.01e-09	0.38	0.31	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks);	chr8:6631056	chr8:6615604~6617198:-
PRAD	cis	rs2638953	0.815	rs117066882	ENSG00000278733.1	RP11-425D17.1	-7.08	5.63e-12	2.01e-09	-0.39	-0.31	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28477287	chr12:28185625~28186190:-
PRAD	cis	rs11098499	0.604	rs2389886	ENSG00000245958.5	RP11-33B1.1	-7.08	5.64e-12	2.01e-09	-0.33	-0.31	Corneal astigmatism;	chr4:119649267	chr4:119454791~119552025:+
PRAD	cis	rs2299587	0.527	rs10112643	ENSG00000253671.1	RP11-806O11.1	-7.08	5.65e-12	2.01e-09	-0.31	-0.31	Economic and political preferences;	chr8:17868510	chr8:17808941~17820868:+
PRAD	cis	rs172166	0.694	rs188105	ENSG00000220721.1	OR1F12	7.08	5.65e-12	2.01e-09	0.37	0.31	Cardiac Troponin-T levels;	chr6:28103615	chr6:28073316~28074233:+
PRAD	cis	rs13068223	0.607	rs184695	ENSG00000243926.1	TIPARP-AS1	-7.08	5.67e-12	2.02e-09	-0.3	-0.31	Age-related hearing impairment (SNP x SNP interaction);	chr3:156679600	chr3:156671862~156674378:-
PRAD	cis	rs113835537	0.529	rs11821155	ENSG00000255517.5	CTD-3074O7.5	7.07	5.7e-12	2.03e-09	0.32	0.31	Airway imaging phenotypes;	chr11:66478866	chr11:66473490~66480233:-
PRAD	cis	rs6782228	1	rs11718130	ENSG00000242551.2	POU5F1P6	7.07	5.7e-12	2.03e-09	0.46	0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611184	chr3:128674735~128677005:-
PRAD	cis	rs6539247	0.509	rs4275717	ENSG00000257890.1	RP11-114F10.2	-7.07	5.72e-12	2.04e-09	-0.37	-0.31	Attention function in attention deficit hyperactive disorder;	chr12:106052074	chr12:106050961~106058254:-
PRAD	cis	rs4845570	1	rs17568246	ENSG00000268288.1	RP11-98D18.16	7.07	5.72e-12	2.04e-09	0.53	0.31	Coronary artery disease;	chr1:151763980	chr1:151766486~151767000:-
PRAD	cis	rs172166	0.611	rs203882	ENSG00000220721.1	OR1F12	7.07	5.72e-12	2.04e-09	0.37	0.31	Cardiac Troponin-T levels;	chr6:28110724	chr6:28073316~28074233:+
PRAD	cis	rs172166	0.694	rs1770131	ENSG00000220721.1	OR1F12	7.07	5.72e-12	2.04e-09	0.37	0.31	Cardiac Troponin-T levels;	chr6:28118635	chr6:28073316~28074233:+
PRAD	cis	rs6452524	0.904	rs10076056	ENSG00000249664.1	CTD-2227C6.2	-7.07	5.74e-12	2.05e-09	-0.38	-0.31	Hypertension (SNP x SNP interaction);	chr5:83161702	chr5:83012285~83013109:-
PRAD	cis	rs853679	0.607	rs56075693	ENSG00000280107.1	AL022393.9	-7.07	5.75e-12	2.05e-09	-0.63	-0.31	Depression;	chr6:28322551	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.607	rs34218844	ENSG00000280107.1	AL022393.9	-7.07	5.75e-12	2.05e-09	-0.63	-0.31	Depression;	chr6:28322870	chr6:28170845~28172521:+
PRAD	cis	rs1355223	1	rs11601923	ENSG00000271369.1	RP11-350D17.3	-7.07	5.75e-12	2.05e-09	-0.37	-0.31	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34742807	chr11:34709600~34710161:+
PRAD	cis	rs516805	0.597	rs666046	ENSG00000279453.1	RP3-425C14.4	-7.07	5.75e-12	2.05e-09	-0.31	-0.31	Lymphocyte counts;	chr6:122290427	chr6:122436789~122439223:-
PRAD	cis	rs2638953	0.853	rs11049636	ENSG00000278733.1	RP11-425D17.1	-7.07	5.75e-12	2.05e-09	-0.39	-0.31	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28465728	chr12:28185625~28186190:-
PRAD	cis	rs2067615	0.524	rs7959062	ENSG00000260329.1	RP11-412D9.4	-7.07	5.76e-12	2.05e-09	-0.27	-0.31	Heart rate;	chr12:106713556	chr12:106954029~106955497:-
PRAD	cis	rs2439831	0.85	rs61390361	ENSG00000205771.5	CATSPER2P1	-7.07	5.76e-12	2.05e-09	-0.5	-0.31	Lung cancer in ever smokers;	chr15:43867644	chr15:43726918~43747094:-
PRAD	cis	rs2439831	0.85	rs11856795	ENSG00000205771.5	CATSPER2P1	-7.07	5.76e-12	2.05e-09	-0.5	-0.31	Lung cancer in ever smokers;	chr15:43868384	chr15:43726918~43747094:-
PRAD	cis	rs995000	0.783	rs993013	ENSG00000235545.1	RP11-230B22.1	-7.07	5.77e-12	2.06e-09	-0.41	-0.31	Triglyceride levels;	chr1:62645398	chr1:62688482~62710694:+
PRAD	cis	rs10218795	1	rs10218795	ENSG00000233396.6	RP11-458D21.1	-7.07	5.77e-12	2.06e-09	-0.62	-0.31	Coronary heart disease (SNP X SNP interaction);	chr1:146018957	chr1:146052566~146061948:+
PRAD	cis	rs12091564	1	rs12091564	ENSG00000233396.6	RP11-458D21.1	7.07	5.77e-12	2.06e-09	0.62	0.31	Coronary heart disease (SNP X SNP interaction);	chr1:146039391	chr1:146052566~146061948:+
PRAD	cis	rs995000	0.931	rs11207997	ENSG00000235545.1	RP11-230B22.1	7.07	5.77e-12	2.06e-09	0.41	0.31	Triglyceride levels;	chr1:62596235	chr1:62688482~62710694:+
PRAD	cis	rs2274273	0.638	rs3825614	ENSG00000258413.1	RP11-665C16.6	-7.07	5.77e-12	2.06e-09	-0.44	-0.31	Protein biomarker;	chr14:55262669	chr14:55262767~55272075:-
PRAD	cis	rs2243480	1	rs2462569	ENSG00000273142.1	RP11-458F8.4	7.07	5.77e-12	2.06e-09	0.34	0.31	Diabetic kidney disease;	chr7:66009859	chr7:66902857~66906297:+
PRAD	cis	rs3096299	0.933	rs3096297	ENSG00000261118.1	RP11-104N10.1	7.07	5.78e-12	2.06e-09	0.31	0.31	Multiple myeloma (IgH translocation);	chr16:89386747	chr16:89492017~89504460:-
PRAD	cis	rs8040855	0.825	rs4843021	ENSG00000259295.5	CSPG4P12	-7.07	5.78e-12	2.06e-09	-0.43	-0.31	Bulimia nervosa;	chr15:85151317	chr15:85191438~85213905:+
PRAD	cis	rs875971	0.528	rs801213	ENSG00000226824.5	RP4-756H11.3	7.07	5.78e-12	2.06e-09	0.46	0.31	Aortic root size;	chr7:66549931	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.545	rs801212	ENSG00000226824.5	RP4-756H11.3	7.07	5.78e-12	2.06e-09	0.46	0.31	Aortic root size;	chr7:66550643	chr7:66654538~66669855:+
PRAD	cis	rs875971	0.545	rs1267814	ENSG00000226824.5	RP4-756H11.3	7.07	5.78e-12	2.06e-09	0.46	0.31	Aortic root size;	chr7:66579422	chr7:66654538~66669855:+
PRAD	cis	rs4938330	0.681	rs12271169	ENSG00000254851.1	RP11-109L13.1	7.07	5.79e-12	2.06e-09	0.43	0.31	Blood protein levels;	chr11:117109305	chr11:117135528~117138582:+
PRAD	cis	rs9368481	0.547	rs2093303	ENSG00000241549.7	GUSBP2	7.07	5.79e-12	2.06e-09	0.35	0.31	Autism spectrum disorder or schizophrenia;	chr6:26896627	chr6:26871484~26956554:-
PRAD	cis	rs2067615	0.56	rs1882542	ENSG00000260329.1	RP11-412D9.4	-7.07	5.79e-12	2.06e-09	-0.27	-0.31	Heart rate;	chr12:106676271	chr12:106954029~106955497:-
PRAD	cis	rs853679	0.55	rs1225598	ENSG00000204709.4	LINC01556	7.07	5.81e-12	2.07e-09	0.42	0.31	Depression;	chr6:28193021	chr6:28943877~28944537:+
PRAD	cis	rs853679	0.55	rs1150689	ENSG00000204709.4	LINC01556	7.07	5.81e-12	2.07e-09	0.42	0.31	Depression;	chr6:28197321	chr6:28943877~28944537:+
PRAD	cis	rs853679	0.55	rs1225599	ENSG00000204709.4	LINC01556	7.07	5.81e-12	2.07e-09	0.42	0.31	Depression;	chr6:28197412	chr6:28943877~28944537:+
PRAD	cis	rs853679	0.574	rs1233705	ENSG00000204709.4	LINC01556	7.07	5.81e-12	2.07e-09	0.42	0.31	Depression;	chr6:28198669	chr6:28943877~28944537:+
PRAD	cis	rs6860806	0.661	rs1588263	ENSG00000233006.5	AC034220.3	7.07	5.81e-12	2.07e-09	0.26	0.31	Breast cancer;	chr5:132241465	chr5:132311285~132369916:-
PRAD	cis	rs6860806	0.695	rs6867282	ENSG00000233006.5	AC034220.3	7.07	5.81e-12	2.07e-09	0.26	0.31	Breast cancer;	chr5:132247427	chr5:132311285~132369916:-
PRAD	cis	rs12432203	1	rs72622438	ENSG00000258479.4	LINC00640	7.07	5.82e-12	2.07e-09	0.56	0.31	Cancer;	chr14:51269185	chr14:51333393~51365557:+
PRAD	cis	rs853679	0.505	rs200992	ENSG00000280107.1	AL022393.9	-7.07	5.82e-12	2.07e-09	-0.57	-0.31	Depression;	chr6:27846899	chr6:28170845~28172521:+
PRAD	cis	rs853679	0.55	rs9295762	ENSG00000204709.4	LINC01556	-7.07	5.83e-12	2.08e-09	-0.42	-0.31	Depression;	chr6:28187640	chr6:28943877~28944537:+
PRAD	cis	rs8103278	0.507	rs4802275	ENSG00000267395.4	AC074212.6	-7.07	5.83e-12	2.08e-09	-0.28	-0.31	Coronary artery disease;	chr19:45757117	chr19:45767796~45772504:+
PRAD	cis	rs1799949	1	rs3950989	ENSG00000267002.1	RP11-242D8.1	7.07	5.83e-12	2.08e-09	0.3	0.31	Menopause (age at onset);	chr17:43085936	chr17:43164183~43170403:-
PRAD	cis	rs1799949	1	rs2070834	ENSG00000267002.1	RP11-242D8.1	7.07	5.83e-12	2.08e-09	0.3	0.31	Menopause (age at onset);	chr17:43090268	chr17:43164183~43170403:-
PRAD	cis	rs8103278	0.507	rs7260651	ENSG00000267395.4	AC074212.6	-7.07	5.84e-12	2.08e-09	-0.28	-0.31	Coronary artery disease;	chr19:45756987	chr19:45767796~45772504:+
PRAD	cis	rs897984	0.806	rs4889571	ENSG00000279196.1	RP11-1072A3.3	-7.07	5.85e-12	2.08e-09	-0.33	-0.31	Dementia with Lewy bodies;	chr16:30937726	chr16:30984630~30988270:-
PRAD	cis	rs897984	0.806	rs11640534	ENSG00000279196.1	RP11-1072A3.3	-7.07	5.85e-12	2.08e-09	-0.33	-0.31	Dementia with Lewy bodies;	chr16:30938194	chr16:30984630~30988270:-
PRAD	cis	rs897984	0.762	rs7206511	ENSG00000279196.1	RP11-1072A3.3	-7.07	5.85e-12	2.08e-09	-0.33	-0.31	Dementia with Lewy bodies;	chr16:30939031	chr16:30984630~30988270:-
PRAD	cis	rs853679	0.527	rs853693	ENSG00000204709.4	LINC01556	7.07	5.85e-12	2.08e-09	0.41	0.31	Depression;	chr6:28314871	chr6:28943877~28944537:+
PRAD	cis	rs412050	0.793	rs17821866	ENSG00000224086.5	LL22NC03-86G7.1	-7.07	5.85e-12	2.08e-09	-0.52	-0.31	Attention deficit hyperactivity disorder;	chr22:21988067	chr22:21938293~21977632:+
PRAD	cis	rs7727544	0.582	rs10052046	ENSG00000233006.5	AC034220.3	7.07	5.86e-12	2.09e-09	0.28	0.31	Blood metabolite levels;	chr5:132208773	chr5:132311285~132369916:-
PRAD	cis	rs995000	0.64	rs6679002	ENSG00000235545.1	RP11-230B22.1	-7.07	5.87e-12	2.09e-09	-0.4	-0.31	Triglyceride levels;	chr1:62734265	chr1:62688482~62710694:+
PRAD	cis	rs12439619	0.53	rs28883606	ENSG00000255769.6	GOLGA2P10	-7.07	5.87e-12	2.09e-09	-0.37	-0.31	Intelligence (multi-trait analysis);	chr15:82216713	chr15:82472993~82513950:-
PRAD	cis	rs526231	0.578	rs17154825	ENSG00000175749.11	EIF3KP1	7.07	5.87e-12	2.09e-09	0.43	0.31	Primary biliary cholangitis;	chr5:102910365	chr5:103032376~103033031:+
PRAD	cis	rs526231	0.578	rs35100629	ENSG00000175749.11	EIF3KP1	7.07	5.87e-12	2.09e-09	0.43	0.31	Primary biliary cholangitis;	chr5:102910381	chr5:103032376~103033031:+
PRAD	cis	rs6847067	1	rs13145705	ENSG00000180769.7	WDFY3-AS2	7.07	5.88e-12	2.09e-09	0.32	0.31	Oropharynx cancer;	chr4:84799214	chr4:84965682~85011277:+
PRAD	cis	rs2243480	1	rs1404147	ENSG00000228409.4	CCT6P1	7.07	5.89e-12	2.1e-09	0.34	0.31	Diabetic kidney disease;	chr7:65799537	chr7:65751142~65763354:+
PRAD	cis	rs7260598	0.685	rs73021420	ENSG00000268442.1	CTD-2027I19.2	7.07	5.89e-12	2.1e-09	0.54	0.31	Response to taxane treatment (placlitaxel);	chr19:24082833	chr19:24162370~24163425:-
PRAD	cis	rs2243480	1	rs313798	ENSG00000273142.1	RP11-458F8.4	-7.07	5.91e-12	2.1e-09	-0.36	-0.31	Diabetic kidney disease;	chr7:66028044	chr7:66902857~66906297:+
PRAD	cis	rs2243480	1	rs313809	ENSG00000273142.1	RP11-458F8.4	-7.07	5.91e-12	2.1e-09	-0.36	-0.31	Diabetic kidney disease;	chr7:66034996	chr7:66902857~66906297:+
PRAD	cis	rs2911132	1	rs2911132	ENSG00000248734.2	CTD-2260A17.1	7.07	5.92e-12	2.11e-09	0.34	0.31	Urate levels (BMI interaction);	chr5:96851285	chr5:96784777~96785999:+
PRAD	cis	rs4718428	1	rs12534637	ENSG00000232546.1	RP11-458F8.1	-7.07	5.92e-12	2.11e-09	-0.24	-0.31	Corneal structure;	chr7:66862667	chr7:66848496~66858136:+
PRAD	cis	rs1799949	0.965	rs7223952	ENSG00000267002.1	RP11-242D8.1	7.07	5.93e-12	2.11e-09	0.3	0.31	Menopause (age at onset);	chr17:43042868	chr17:43164183~43170403:-
PRAD	cis	rs1707322	0.721	rs6665808	ENSG00000280836.1	AL355480.1	-7.07	5.94e-12	2.11e-09	-0.39	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45696611	chr1:45581219~45581321:-
PRAD	cis	rs1707322	0.682	rs28508523	ENSG00000280836.1	AL355480.1	-7.07	5.94e-12	2.11e-09	-0.39	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723953	chr1:45581219~45581321:-
PRAD	cis	rs1707322	0.691	rs11211175	ENSG00000280836.1	AL355480.1	-7.07	5.94e-12	2.11e-09	-0.39	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755212	chr1:45581219~45581321:-
PRAD	cis	rs1707322	0.721	rs61784800	ENSG00000280836.1	AL355480.1	7.07	5.94e-12	2.11e-09	0.39	0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45712440	chr1:45581219~45581321:-
PRAD	cis	rs12612619	0.704	rs6754356	ENSG00000229122.1	AGBL5-IT1	7.07	5.94e-12	2.11e-09	0.32	0.31	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27092153	chr2:27061038~27061815:+
PRAD	cis	rs2299587	0.527	rs7818801	ENSG00000253671.1	RP11-806O11.1	-7.07	5.94e-12	2.11e-09	-0.32	-0.31	Economic and political preferences;	chr8:17865358	chr8:17808941~17820868:+
PRAD	cis	rs2522056	1	rs2522056	ENSG00000233006.5	AC034220.3	-7.07	5.94e-12	2.11e-09	-0.32	-0.31	Fibrinogen;Lymphocyte counts;	chr5:132466034	chr5:132311285~132369916:-
PRAD	cis	rs875971	0.619	rs12533585	ENSG00000237310.1	GS1-124K5.4	7.07	5.96e-12	2.12e-09	0.27	0.31	Aortic root size;	chr7:66519618	chr7:66493706~66495474:+
PRAD	cis	rs71636778	0.509	rs59715866	ENSG00000260063.1	RP5-968P14.2	-7.07	5.96e-12	2.12e-09	-0.64	-0.31	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26752685	chr1:26692132~26694131:-
PRAD	cis	rs71636778	0.509	rs12737946	ENSG00000260063.1	RP5-968P14.2	-7.07	5.96e-12	2.12e-09	-0.64	-0.31	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26753403	chr1:26692132~26694131:-
PRAD	cis	rs71636778	0.509	rs12742115	ENSG00000260063.1	RP5-968P14.2	-7.07	5.96e-12	2.12e-09	-0.64	-0.31	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26753440	chr1:26692132~26694131:-
PRAD	cis	rs71636778	0.57	rs71636776	ENSG00000260063.1	RP5-968P14.2	-7.07	5.96e-12	2.12e-09	-0.64	-0.31	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26756557	chr1:26692132~26694131:-
PRAD	cis	rs71636778	0.509	rs12731749	ENSG00000260063.1	RP5-968P14.2	-7.07	5.96e-12	2.12e-09	-0.64	-0.31	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26759071	chr1:26692132~26694131:-
PRAD	cis	rs71636778	0.509	rs34885854	ENSG00000260063.1	RP5-968P14.2	-7.07	5.96e-12	2.12e-09	-0.64	-0.31	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26759758	chr1:26692132~26694131:-
PRAD	cis	rs71636778	0.509	rs71636777	ENSG00000260063.1	RP5-968P14.2	-7.07	5.96e-12	2.12e-09	-0.64	-0.31	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26761777	chr1:26692132~26694131:-
PRAD	cis	rs71636778	0.509	rs34681611	ENSG00000260063.1	RP5-968P14.2	-7.07	5.96e-12	2.12e-09	-0.64	-0.31	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26762955	chr1:26692132~26694131:-
PRAD	cis	rs71636778	0.509	rs74825034	ENSG00000260063.1	RP5-968P14.2	-7.07	5.96e-12	2.12e-09	-0.64	-0.31	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26768641	chr1:26692132~26694131:-
PRAD	cis	rs71636778	0.73	rs34951175	ENSG00000260063.1	RP5-968P14.2	-7.07	5.96e-12	2.12e-09	-0.64	-0.31	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26778568	chr1:26692132~26694131:-
PRAD	cis	rs7690978	1	rs7690978	ENSG00000249717.1	RP11-44F21.3	7.07	5.96e-12	2.12e-09	0.42	0.31	Interferon gamma-induced protein 10 levels;	chr4:75066634	chr4:74955974~74970362:-
PRAD	cis	rs1707322	0.721	rs6429574	ENSG00000280836.1	AL355480.1	-7.07	5.97e-12	2.12e-09	-0.39	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668382	chr1:45581219~45581321:-
PRAD	cis	rs7429990	0.93	rs13075457	ENSG00000229759.1	MRPS18AP1	-7.07	5.97e-12	2.12e-09	-0.32	-0.31	Educational attainment (years of education);	chr3:48013063	chr3:48256350~48256938:-
PRAD	cis	rs7429990	0.93	rs11130152	ENSG00000229759.1	MRPS18AP1	-7.07	5.97e-12	2.12e-09	-0.32	-0.31	Educational attainment (years of education);	chr3:48014919	chr3:48256350~48256938:-
PRAD	cis	rs858239	0.601	rs11982002	ENSG00000226816.2	AC005082.12	7.07	5.98e-12	2.13e-09	0.35	0.31	Cerebrospinal fluid biomarker levels;	chr7:23123651	chr7:23206013~23208045:+
PRAD	cis	rs6547741	0.844	rs9941696	ENSG00000234072.1	AC074117.10	-7.07	5.98e-12	2.13e-09	-0.24	-0.31	Oral cavity cancer;	chr2:27697197	chr2:27356246~27367622:+
PRAD	cis	rs4664293	0.836	rs13032500	ENSG00000226266.5	AC009961.3	-7.07	5.99e-12	2.13e-09	-0.42	-0.31	Monocyte percentage of white cells;	chr2:159749740	chr2:159670708~159712435:-
PRAD	cis	rs875971	0.545	rs7783889	ENSG00000226824.5	RP4-756H11.3	-7.07	5.99e-12	2.13e-09	-0.47	-0.31	Aortic root size;	chr7:66283366	chr7:66654538~66669855:+
PRAD	cis	rs287982	1	rs287982	ENSG00000269973.1	RP11-95D17.1	7.07	5.99e-12	2.13e-09	0.31	0.31	Nonsyndromic cleft lip with cleft palate;	chr2:9832313	chr2:9936360~9939590:+
PRAD	cis	rs1707322	0.686	rs3014242	ENSG00000280836.1	AL355480.1	7.07	5.99e-12	2.13e-09	0.4	0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45621905	chr1:45581219~45581321:-
PRAD	cis	rs853679	1	rs853685	ENSG00000226314.6	ZNF192P1	-7.07	6e-12	2.13e-09	-0.5	-0.31	Depression;	chr6:28321008	chr6:28161781~28169594:+
PRAD	cis	rs2638953	0.815	rs11049658	ENSG00000278733.1	RP11-425D17.1	-7.07	6e-12	2.13e-09	-0.39	-0.31	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28481930	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.962	rs10843151	ENSG00000247934.4	RP11-967K21.1	-7.07	6e-12	2.14e-09	-0.34	-0.31	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28318386	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.962	rs10843152	ENSG00000247934.4	RP11-967K21.1	-7.07	6e-12	2.14e-09	-0.34	-0.31	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28319090	chr12:28163298~28190738:-
PRAD	cis	rs2599510	0.811	rs2710615	ENSG00000276334.1	AL133243.1	7.07	6.01e-12	2.14e-09	0.35	0.31	Interleukin-18 levels;	chr2:32566155	chr2:32521927~32523547:+
PRAD	cis	rs964611	0.882	rs12903327	ENSG00000259488.2	RP11-154J22.1	7.07	6.01e-12	2.14e-09	0.31	0.31	Metabolite levels (Pyroglutamine);	chr15:48355466	chr15:48312353~48331856:-
PRAD	cis	rs9595908	0.965	rs9595877	ENSG00000212293.1	SNORA16	7.07	6.02e-12	2.14e-09	0.4	0.31	Body mass index;	chr13:32589512	chr13:32420390~32420516:-
PRAD	cis	rs853679	0.607	rs35001169	ENSG00000225595.2	XXbac-BPG308K3.6	7.07	6.02e-12	2.14e-09	0.69	0.31	Depression;	chr6:28219854	chr6:28859625~28864630:-
PRAD	cis	rs1858037	0.867	rs876933	ENSG00000281920.1	RP11-418H16.1	7.07	6.03e-12	2.14e-09	0.39	0.31	Rheumatoid arthritis;	chr2:65382303	chr2:65623272~65628424:+
PRAD	cis	rs812925	0.537	rs10865324	ENSG00000271889.1	RP11-493E12.1	-7.07	6.04e-12	2.15e-09	-0.34	-0.31	Immature fraction of reticulocytes;	chr2:61394172	chr2:61151433~61162105:-
PRAD	cis	rs2638953	0.962	rs11049484	ENSG00000247934.4	RP11-967K21.1	-7.07	6.04e-12	2.15e-09	-0.33	-0.31	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28252254	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.962	rs11049485	ENSG00000247934.4	RP11-967K21.1	-7.07	6.04e-12	2.15e-09	-0.33	-0.31	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28252522	chr12:28163298~28190738:-
PRAD	cis	rs2638953	0.962	rs10843143	ENSG00000247934.4	RP11-967K21.1	-7.07	6.04e-12	2.15e-09	-0.33	-0.31	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28253484	chr12:28163298~28190738:-
PRAD	cis	rs7829975	0.54	rs2976909	ENSG00000254153.1	CTA-398F10.2	-7.07	6.04e-12	2.15e-09	-0.36	-0.31	Mood instability;	chr8:8489180	chr8:8456909~8461337:-
PRAD	cis	rs5760092	0.755	rs915589	ENSG00000206090.4	AP000350.7	-7.07	6.04e-12	2.15e-09	-0.48	-0.31	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23939998~23942798:+
PRAD	cis	rs2836950	0.545	rs2836940	ENSG00000255568.3	BRWD1-AS2	-7.07	6.05e-12	2.15e-09	-0.26	-0.31	Menarche (age at onset);	chr21:39216770	chr21:39313935~39314962:+
PRAD	cis	rs79349575	0.691	rs28528789	ENSG00000248278.1	SUMO2P17	-7.07	6.05e-12	2.15e-09	-0.35	-0.31	Type 2 diabetes;	chr17:48909254	chr17:48874860~48908983:-
PRAD	cis	rs79349575	0.715	rs999474	ENSG00000248278.1	SUMO2P17	-7.07	6.05e-12	2.15e-09	-0.35	-0.31	Type 2 diabetes;	chr17:48910303	chr17:48874860~48908983:-
PRAD	cis	rs2274273	1	rs10140857	ENSG00000258413.1	RP11-665C16.6	-7.07	6.05e-12	2.15e-09	-0.4	-0.31	Protein biomarker;	chr14:55152893	chr14:55262767~55272075:-
PRAD	cis	rs2274273	1	rs74617736	ENSG00000258413.1	RP11-665C16.6	-7.07	6.05e-12	2.15e-09	-0.4	-0.31	Protein biomarker;	chr14:55154201	chr14:55262767~55272075:-
PRAD	cis	rs8012947	1	rs10151828	ENSG00000279636.2	LINC00216	-7.06	6.06e-12	2.16e-09	-0.36	-0.31	Alcohol consumption in current drinkers;	chr14:58282711	chr14:58288033~58289158:+
PRAD	cis	rs2836950	0.545	rs2836952	ENSG00000255568.3	BRWD1-AS2	-7.06	6.08e-12	2.16e-09	-0.26	-0.31	Menarche (age at onset);	chr21:39244725	chr21:39313935~39314962:+
PRAD	cis	rs56114371	0.53	rs2056923	ENSG00000226314.6	ZNF192P1	-7.06	6.09e-12	2.16e-09	-0.46	-0.31	Breast cancer;	chr6:27722160	chr6:28161781~28169594:+
PRAD	cis	rs2243480	1	rs316329	ENSG00000273142.1	RP11-458F8.4	-7.06	6.09e-12	2.16e-09	-0.35	-0.31	Diabetic kidney disease;	chr7:66143429	chr7:66902857~66906297:+
PRAD	cis	rs12612619	0.732	rs11688708	ENSG00000229122.1	AGBL5-IT1	7.06	6.09e-12	2.17e-09	0.32	0.31	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26976740	chr2:27061038~27061815:+
PRAD	cis	rs6496932	0.802	rs56306166	ENSG00000218052.5	ADAMTS7P4	7.06	6.1e-12	2.17e-09	0.38	0.31	Central corneal thickness;Corneal structure;	chr15:85326848	chr15:85255369~85330334:-
PRAD	cis	rs3096299	0.606	rs4785573	ENSG00000261118.1	RP11-104N10.1	7.06	6.1e-12	2.17e-09	0.32	0.31	Multiple myeloma (IgH translocation);	chr16:89498995	chr16:89492017~89504460:-
PRAD	cis	rs2276314	0.857	rs3737474	ENSG00000278986.1	RP11-723J4.3	-7.06	6.1e-12	2.17e-09	-0.38	-0.31	Endometriosis;Drug-induced torsades de pointes;	chr18:36033632	chr18:35972151~35973916:+
PRAD	cis	rs2276314	0.802	rs58906216	ENSG00000278986.1	RP11-723J4.3	-7.06	6.1e-12	2.17e-09	-0.38	-0.31	Endometriosis;Drug-induced torsades de pointes;	chr18:36050334	chr18:35972151~35973916:+
PRAD	cis	rs2276314	0.857	rs6507157	ENSG00000278986.1	RP11-723J4.3	-7.06	6.1e-12	2.17e-09	-0.38	-0.31	Endometriosis;Drug-induced torsades de pointes;	chr18:36051740	chr18:35972151~35973916:+
PRAD	cis	rs12439619	0.693	rs28665836	ENSG00000255769.6	GOLGA2P10	-7.06	6.1e-12	2.17e-09	-0.37	-0.31	Intelligence (multi-trait analysis);	chr15:82218955	chr15:82472993~82513950:-
PRAD	cis	rs6449502	0.536	rs28409386	ENSG00000251279.1	CTC-436P18.1	7.06	6.11e-12	2.17e-09	0.53	0.31	Mean platelet volume;	chr5:61190761	chr5:61162070~61232040:+
PRAD	cis	rs73607972	0.935	rs6499628	ENSG00000275191.1	RP11-36I17.2	-7.06	6.12e-12	2.17e-09	-0.48	-0.31	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53570265	chr16:53628256~53628816:-
PRAD	cis	rs6847067	0.655	rs58074983	ENSG00000180769.7	WDFY3-AS2	7.06	6.13e-12	2.18e-09	0.35	0.31	Oropharynx cancer;	chr4:84964394	chr4:84965682~85011277:+
PRAD	cis	rs6847067	0.683	rs67624868	ENSG00000180769.7	WDFY3-AS2	7.06	6.13e-12	2.18e-09	0.35	0.31	Oropharynx cancer;	chr4:84965615	chr4:84965682~85011277:+
PRAD	cis	rs2337406	0.539	rs2583290	ENSG00000274576.2	IGHV2-70	7.06	6.13e-12	2.18e-09	0.32	0.31	Alzheimer's disease (late onset);	chr14:106650277	chr14:106770577~106771020:-
PRAD	cis	rs7626444	0.584	rs7633044	ENSG00000272359.1	U4	-7.06	6.14e-12	2.18e-09	-0.37	-0.31	Monocyte count;	chr3:196763772	chr3:196747192~196747324:-
PRAD	cis	rs2638953	0.924	rs11049575	ENSG00000278733.1	RP11-425D17.1	-7.06	6.14e-12	2.18e-09	-0.39	-0.31	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28411328	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.924	rs2348235	ENSG00000278733.1	RP11-425D17.1	-7.06	6.14e-12	2.18e-09	-0.39	-0.31	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28414019	chr12:28185625~28186190:-
PRAD	cis	rs2638953	0.886	rs11049577	ENSG00000278733.1	RP11-425D17.1	-7.06	6.14e-12	2.18e-09	-0.39	-0.31	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28414437	chr12:28185625~28186190:-
PRAD	cis	rs516805	0.748	rs511279	ENSG00000279453.1	RP3-425C14.4	-7.06	6.14e-12	2.18e-09	-0.29	-0.31	Lymphocyte counts;	chr6:122451385	chr6:122436789~122439223:-
PRAD	cis	rs875971	0.638	rs801205	ENSG00000237310.1	GS1-124K5.4	-7.06	6.14e-12	2.18e-09	-0.27	-0.31	Aortic root size;	chr7:66557157	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.617	rs810400	ENSG00000237310.1	GS1-124K5.4	-7.06	6.14e-12	2.18e-09	-0.27	-0.31	Aortic root size;	chr7:66557902	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.638	rs3898855	ENSG00000237310.1	GS1-124K5.4	-7.06	6.14e-12	2.18e-09	-0.27	-0.31	Aortic root size;	chr7:66571411	chr7:66493706~66495474:+
PRAD	cis	rs875971	0.638	rs10278816	ENSG00000237310.1	GS1-124K5.4	-7.06	6.14e-12	2.18e-09	-0.27	-0.31	Aortic root size;	chr7:66572000	chr7:66493706~66495474:+
PRAD	cis	rs6496044	0.507	rs8034676	ENSG00000202081.1	RNU6-1280P	7.06	6.14e-12	2.18e-09	0.38	0.31	Interstitial lung disease;	chr15:85616031	chr15:85651522~85651628:-
PRAD	cis	rs853679	0.55	rs1233701	ENSG00000204709.4	LINC01556	-7.06	6.16e-12	2.19e-09	-0.42	-0.31	Depression;	chr6:28200948	chr6:28943877~28944537:+
PRAD	cis	rs62355900	0.627	rs62358073	ENSG00000271828.1	CTD-2310F14.1	7.06	6.17e-12	2.19e-09	0.66	0.31	Endometriosis;	chr5:56831013	chr5:56927874~56929573:+
PRAD	cis	rs964611	0.935	rs7495591	ENSG00000259488.2	RP11-154J22.1	-7.06	6.17e-12	2.19e-09	-0.36	-0.31	Metabolite levels (Pyroglutamine);	chr15:48278571	chr15:48312353~48331856:-
PRAD	cis	rs2337406	0.587	rs10150642	ENSG00000274576.2	IGHV2-70	7.06	6.17e-12	2.19e-09	0.31	0.31	Alzheimer's disease (late onset);	chr14:106647269	chr14:106770577~106771020:-
PRAD	cis	rs71636778	0.509	rs71636773	ENSG00000260063.1	RP5-968P14.2	-7.06	6.18e-12	2.19e-09	-0.64	-0.31	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26724828	chr1:26692132~26694131:-
PRAD	cis	rs71636778	0.509	rs60401377	ENSG00000260063.1	RP5-968P14.2	-7.06	6.18e-12	2.19e-09	-0.64	-0.31	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26725756	chr1:26692132~26694131:-
PRAD	cis	rs41307935	0.818	rs35145624	ENSG00000260063.1	RP5-968P14.2	-7.06	6.18e-12	2.19e-09	-0.64	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26726121	chr1:26692132~26694131:-
PRAD	cis	rs71636778	0.509	rs35256560	ENSG00000260063.1	RP5-968P14.2	-7.06	6.18e-12	2.19e-09	-0.64	-0.31	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26727525	chr1:26692132~26694131:-
PRAD	cis	rs71636778	0.509	rs56932185	ENSG00000260063.1	RP5-968P14.2	-7.06	6.18e-12	2.19e-09	-0.64	-0.31	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26730152	chr1:26692132~26694131:-
PRAD	cis	rs71636778	0.509	rs34216334	ENSG00000260063.1	RP5-968P14.2	-7.06	6.18e-12	2.19e-09	-0.64	-0.31	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26736928	chr1:26692132~26694131:-
PRAD	cis	rs71636778	0.509	rs34026879	ENSG00000260063.1	RP5-968P14.2	-7.06	6.18e-12	2.19e-09	-0.64	-0.31	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26741747	chr1:26692132~26694131:-
PRAD	cis	rs71636778	0.509	rs34693293	ENSG00000260063.1	RP5-968P14.2	-7.06	6.18e-12	2.19e-09	-0.64	-0.31	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26742480	chr1:26692132~26694131:-
PRAD	cis	rs71636778	0.509	rs35560426	ENSG00000260063.1	RP5-968P14.2	-7.06	6.18e-12	2.19e-09	-0.64	-0.31	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26742678	chr1:26692132~26694131:-
PRAD	cis	rs71636778	0.509	rs58421016	ENSG00000260063.1	RP5-968P14.2	-7.06	6.18e-12	2.19e-09	-0.64	-0.31	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26744038	chr1:26692132~26694131:-
PRAD	cis	rs71636778	0.642	rs12752833	ENSG00000260063.1	RP5-968P14.2	-7.06	6.18e-12	2.19e-09	-0.64	-0.31	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26747433	chr1:26692132~26694131:-
PRAD	cis	rs71636778	0.509	rs115772301	ENSG00000260063.1	RP5-968P14.2	-7.06	6.18e-12	2.19e-09	-0.64	-0.31	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26749193	chr1:26692132~26694131:-
PRAD	cis	rs41307935	0.643	rs34909427	ENSG00000260063.1	RP5-968P14.2	-7.06	6.18e-12	2.19e-09	-0.64	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26750763	chr1:26692132~26694131:-
PRAD	cis	rs41307935	0.908	rs12735646	ENSG00000260063.1	RP5-968P14.2	-7.06	6.18e-12	2.19e-09	-0.64	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26751875	chr1:26692132~26694131:-
PRAD	cis	rs4713118	0.955	rs9368528	ENSG00000226314.6	ZNF192P1	-7.06	6.18e-12	2.19e-09	-0.42	-0.31	Parkinson's disease;	chr6:27716019	chr6:28161781~28169594:+
PRAD	cis	rs4713118	0.955	rs9368529	ENSG00000226314.6	ZNF192P1	-7.06	6.18e-12	2.19e-09	-0.42	-0.31	Parkinson's disease;	chr6:27716852	chr6:28161781~28169594:+
PRAD	cis	rs4713118	0.955	rs9380012	ENSG00000226314.6	ZNF192P1	-7.06	6.18e-12	2.19e-09	-0.42	-0.31	Parkinson's disease;	chr6:27716875	chr6:28161781~28169594:+
PRAD	cis	rs4713118	0.955	rs9468201	ENSG00000226314.6	ZNF192P1	-7.06	6.18e-12	2.19e-09	-0.42	-0.31	Parkinson's disease;	chr6:27719256	chr6:28161781~28169594:+
PRAD	cis	rs995000	0.965	rs10789112	ENSG00000235545.1	RP11-230B22.1	7.06	6.19e-12	2.2e-09	0.41	0.31	Triglyceride levels;	chr1:62492087	chr1:62688482~62710694:+
PRAD	cis	rs2836950	0.545	rs4818001	ENSG00000255568.3	BRWD1-AS2	-7.06	6.2e-12	2.2e-09	-0.26	-0.31	Menarche (age at onset);	chr21:39203162	chr21:39313935~39314962:+
PRAD	cis	rs240993	0.812	rs9487644	ENSG00000230177.1	RP5-1112D6.4	-7.06	6.2e-12	2.2e-09	-0.4	-0.31	Inflammatory skin disease;Psoriasis;	chr6:111443064	chr6:111277932~111278742:+
PRAD	cis	rs240993	0.761	rs9487645	ENSG00000230177.1	RP5-1112D6.4	-7.06	6.2e-12	2.2e-09	-0.4	-0.31	Inflammatory skin disease;Psoriasis;	chr6:111443065	chr6:111277932~111278742:+
PRAD	cis	rs2638953	0.853	rs10506038	ENSG00000278733.1	RP11-425D17.1	7.06	6.21e-12	2.2e-09	0.38	0.31	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28506239	chr12:28185625~28186190:-
PRAD	cis	rs42648	0.869	rs42614	ENSG00000227646.6	STEAP2-AS1	-7.06	6.21e-12	2.2e-09	-0.29	-0.31	Homocysteine levels;	chr7:90321049	chr7:89882353~90211635:-
PRAD	cis	rs964611	0.882	rs4775750	ENSG00000259488.2	RP11-154J22.1	7.06	6.21e-12	2.2e-09	0.31	0.31	Metabolite levels (Pyroglutamine);	chr15:48360567	chr15:48312353~48331856:-
PRAD	cis	rs964611	0.882	rs4775751	ENSG00000259488.2	RP11-154J22.1	7.06	6.21e-12	2.2e-09	0.31	0.31	Metabolite levels (Pyroglutamine);	chr15:48360910	chr15:48312353~48331856:-
PRAD	cis	rs1707322	0.686	rs11211179	ENSG00000280836.1	AL355480.1	-7.06	6.23e-12	2.21e-09	-0.39	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45762410	chr1:45581219~45581321:-
PRAD	cis	rs1707322	0.721	rs10157795	ENSG00000280836.1	AL355480.1	-7.06	6.23e-12	2.21e-09	-0.39	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45762520	chr1:45581219~45581321:-
PRAD	cis	rs11846409	0.629	rs76295389	ENSG00000274576.2	IGHV2-70	7.06	6.23e-12	2.21e-09	0.33	0.31	Rheumatic heart disease;	chr14:106650437	chr14:106770577~106771020:-
PRAD	cis	rs11846409	0.698	rs71419854	ENSG00000274576.2	IGHV2-70	7.06	6.23e-12	2.21e-09	0.33	0.31	Rheumatic heart disease;	chr14:106650440	chr14:106770577~106771020:-
PRAD	cis	rs2337406	0.5	rs71419855	ENSG00000274576.2	IGHV2-70	7.06	6.23e-12	2.21e-09	0.33	0.31	Alzheimer's disease (late onset);	chr14:106650444	chr14:106770577~106771020:-
PRAD	cis	rs4713118	0.513	rs149972	ENSG00000220721.1	OR1F12	7.06	6.24e-12	2.21e-09	0.36	0.31	Parkinson's disease;	chr6:28015449	chr6:28073316~28074233:+
PRAD	cis	rs67180937	0.582	rs71524942	ENSG00000272750.1	RP11-378J18.8	-7.06	6.24e-12	2.21e-09	-0.43	-0.31	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222689650	chr1:222658867~222661512:-
PRAD	cis	rs4927850	0.881	rs7624638	ENSG00000231464.1	AC024937.4	7.06	6.25e-12	2.22e-09	0.38	0.31	Pancreatic cancer;	chr3:196021858	chr3:195996738~195998233:+
PRAD	cis	rs4927850	1	rs10881564	ENSG00000231464.1	AC024937.4	7.06	6.25e-12	2.22e-09	0.38	0.31	Pancreatic cancer;	chr3:196023455	chr3:195996738~195998233:+
PRAD	cis	rs1707322	0.721	rs10890346	ENSG00000280836.1	AL355480.1	7.06	6.26e-12	2.22e-09	0.39	0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45758220	chr1:45581219~45581321:-
PRAD	cis	rs2638953	0.927	rs11049630	ENSG00000278733.1	RP11-425D17.1	-7.06	6.26e-12	2.22e-09	-0.38	-0.31	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference a